id|nct_id|group_type|title|description
9816687|NCT02075008|Experimental|QGE031 every 4 weeks (q4w)|QGE031 240 mg subcutaneously q4w
9816688|NCT02075047|Placebo Comparator|1|
9816689|NCT02075047|Experimental|ziprasidone|
10114637|NCT04458662||Eumenorrheic women|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~In both studies, eumenorrheic participants were evaluated at three specific moments of the menstrual cycle: Early-follicular phase (EFP), late-follicular phase (LFP) and mid-luteal phase (MLP);"
10182455|NCT03773679|No Intervention|Control Group|The preterm infants in the control group did not receive the daily exercise program, only the standard clinical routine.
9693910|NCT04794647|Experimental|cervical mobilization|'Rotation mobilization' was applied to the symptomatic segment / segments after the detailed evaluation (symptom localization tests, cervical region safety tests, joint play tests, pain provocation/alleviation tests) in accordance with the Kaltenborn-Evjenth system in cervical region. Five series of 45-s mobilizations were performed with 15 s of rest. Each patient received 6 treatment sessions over a period of 3 week.
9693911|NCT04794647|Placebo Comparator|placebo mobilization|Placebo mobilization was applied to the cervical region in the same position and the same grip with the mobilization group. The physiotherapist put her hand on a randomly selected faset without any pushing or pulling, The duration of placebo mobilization was the same as the duration of the other group. Each patient received 6 treatment sessions over a period of 3 week.
9519338|NCT03288090||Treated|
9693912|NCT04794738|Experimental|Treatment group A|
9693913|NCT04794738|Experimental|Treatment group B|
9693914|NCT04794738|Placebo Comparator|Treatment group C|
9693915|NCT04794738|Active Comparator|Treatment group D|
9693916|NCT04794556|Experimental|Group A|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
9693917|NCT04794556|Experimental|Group B|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
9693918|NCT04794556|Experimental|Group C|Participants were randomly assigned to groups A, B, and C to reduce learning effects according to the mask type
9693919|NCT04795037|Experimental|CU06-1004 for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
9693920|NCT04795037|Placebo Comparator|Placebo for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~2 of out 8 subjects per cohort will be randomized to receive placebo"
9693921|NCT04795037|Experimental|CU06-1004 for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
9693922|NCT04795037|Placebo Comparator|Placebo for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~2 of out 8 subjects per cohort will be randomized to receive placebo"
9693923|NCT04794712||Study group A|"Participants group: Group A : 20 participants with chronic venous insufficiency~3 months exercise pre surgery~Pre-surgery evaluation~Venous reflux assessment by ultrasound and PPG~Pain assessment by CHEPS,VAS QS MCGILL~3 months exercise post surgery~Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
9693924|NCT04794712||Study group B|"Participants group: Group B : 20 participants with chronic venous insufficiency~Pre-surgery evaluation~Venous reflux assessment by ultrasound and PPG~Pain assessment by CHEPS,VAS QS MCGILL~Post surgery evaluation by US, PPG, CHEPS and VAS QS MCGILL."
9693925|NCT04794712||Study Group C|"Participants group: Control Group C : 40 participants with chronic venous insufficiency SUBGROUP 1: WITHOUT EXERCISE 20 PARTICIPANTS~VENOUS ASSESSMENT TOOLS( U/S, PPG )~PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)~SUBGROUP 2: 3 MONTHS EXERCISE 20 PARTICIPANTS~VENOUS ASSESSMENT TOOLS ( U/S, PPG )~PAIN ASSESSMENT TOOLS (CHEPS VAS, MCGILL)"
9693926|NCT04794608|Experimental|HypnoVR Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
9693927|NCT04794608|No Intervention|Control Arm|During the three days of study in protector isolation, patients benefit from a 20-minute session of activity among those currently proposed in the service of hematology (reading, music, television).
9693928|NCT04794842|Active Comparator|Tetracaine|Patients will be positioned in supine position at this time 0.5% tetracaine drops will be used to fill the ear canal. Tetracaine will then be allowed to stay in place for approximately 10 to 15 minutes with the patient's head positioned with affected ear up. After this, using an operative microscope the drops will be removed from the ear canal with suction.
9693929|NCT04794842|Active Comparator|Phenol|Patients will be positioned in supine position and tympanic membrane visualized with operative microscope. Phenol applicator will be used to topically apply 90% phenol to the injection site (posterior/Inferior aspect of tympanic membrane).
9693930|NCT04794881|Experimental|24 hours|Newborn infants in this group will undergo repeat lumbar puncture at 24 hours after a traumatic lumbar puncture
9693931|NCT04794881|Active Comparator|48 hours|Newborn infants in this group will undergo repeat lumbar puncture at 48 hours after a traumatic lumbar puncture
9693932|NCT04794777|Experimental|Experimental arm|Individualised therapy based on results of the PSMA PET/CT.
9693933|NCT04794777|Active Comparator|Control arm|Standard salvage therapy. Results of PSMA PET/CT blinded.
9693934|NCT04794816||Observational (questionnaire administration)|Participants complete an online questionnaire over 5 minutes regarding information on patient demographics and preferences for receiving real-time appointment imaging results.
9693935|NCT04794673||Left damage|Have the brain damage and the location of the damage in the left brain
9693936|NCT04794673||Right damage|Have the brain damage and the location of the damage in the right brain
9693937|NCT04794673||Nomal control|Not have the brain damage
9519339|NCT03288090||Non-treated|
9519340|NCT03288077|Experimental|Triptophan beverage|Proprietary blend of nutritional interventions aimed at increasing sleepiness
9816690|NCT02075073|Experimental|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
9816691|NCT02075073|Active Comparator|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
9816692|NCT02075073|Active Comparator|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
9816693|NCT02075125|Experimental|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
9816694|NCT02075125|Experimental|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
9816695|NCT02075203|Experimental|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
9816696|NCT02075203|Active Comparator|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
9816697|NCT02075203|Placebo Comparator|Placebo|2 Doses on Study Days 0 and 56
9816698|NCT02075255|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
9816699|NCT02075255|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
9816700|NCT02075255|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks
9816701|NCT02075320|Experimental|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
9816702|NCT02075463|Experimental|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
9816703|NCT02075476|Active Comparator|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
9816704|NCT02075476|Experimental|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
9816705|NCT02075515|Experimental|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
9816706|NCT02075515|Experimental|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
9816707|NCT02075515|Experimental|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
9816708|NCT02075541|Experimental|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
9816709|NCT02075541|Placebo Comparator|Control group|Subjects in this group will receive placebo.
9816710|NCT02075554|Other|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
9816711|NCT02075606|Experimental|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
9816712|NCT02075632|Experimental|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
9816713|NCT02075658|Other|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
9816714|NCT02075658|Active Comparator|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
9816715|NCT02076022|Active Comparator|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
9816716|NCT02076022|Experimental|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
9816717|NCT02076100|Experimental|Part I GT3 Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
9816718|NCT02076100|Experimental|Part II GT1a Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
9519341|NCT03288064|Experimental|Corinthian currant supplementation|Corinthian currant supplementation: 1.5 g CHO/kg BW prior to exercise
9519342|NCT03288064|Experimental|Glucose supplementation|Glucose drink (Top Star 100, Esteriplas, Portugal) supplementation: 1.5 g CHO/kg BW prior to exercise
9816719|NCT02076100|Experimental|Part III GT2b Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
9816720|NCT02076113|Active Comparator|Ventral|Ventral Decompression with Fusion
9816721|NCT02076113|Active Comparator|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
9965672|NCT01017055||Voice and Swallowing Evaluations|
9667804|NCT02921776|Experimental|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.~Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
9667805|NCT02921776|Experimental|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.~Intervention is usability tasks with the VidaTalk app"
9667806|NCT02921776|Experimental|Aim 3 - VidaTalk tablet app|"Test the clinical efficacy of VidaTalk with MV patients by examining qualitative and quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.~Intervention will be receipt of VidaTalk tablet application."
9667807|NCT02921776|Other|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
9667808|NCT02921776|No Intervention|Aim 5-VidaTalk Efficacy in Family caregivers|"Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.~Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured .Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured."
9667809|NCT02920216|Experimental|eligible patient for a salvage surgery|
9965673|NCT01251874|Experimental|Treatment (veliparib, F 18 fluorothymidine, carboplatin)|Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
9965674|NCT01251939||Treatment with ibuprofen|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and echocardiographic evidence of hemodynamically significant PDA
9965675|NCT01251939||Controls|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and without significant PDA
9965676|NCT01251991|Experimental|Combinatorial treatment|
9965677|NCT01251991|Active Comparator|Single treatment: Psyllium husks|
9667815|NCT02912988|Experimental|Letrozole group|"Letrozole + standard treatment:~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
9667816|NCT02912988|No Intervention|Control group|"Standard treatment:~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
9667817|NCT02912078|Experimental|Pocket-warmed epidural medication|This arm will consist of pocket-warmed epidural medications to be administered per standard protocol to patients randomized to this group; this group is the pocket-warming group.
9667818|NCT02912078|Active Comparator|Room-temperature epidural medication|This arm will consist of room-temperature epidural medications to be administered per standard protocol to patients randomized to this group. This group has no experimental intervention; standard of care labor epidural.
9667819|NCT02909556|Experimental|ACURATE neo AS|
9667820|NCT02908048||Hepatocellular Carcinoma|Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
9667821|NCT02908048||Biliary Tract Cancer|Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
9667822|NCT02908048||Cirrhosis|Blood samples will be collected during regular intervals over a three year period.
9667823|NCT02908048||Chronic Liver Disease without Cirrhosis|A single blood sample will be collected at entry into the study
9667824|NCT02903667|Experimental|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
9667825|NCT02903667|Sham Comparator|natural healing|ridge modelling after multiple tooth extractions.
9965678|NCT01251991|Active Comparator|Single treatment: Isolated soy protein|
9965679|NCT01251991|Placebo Comparator|Control|
9816722|NCT02076152|Experimental|FMISO PET & MRI Group 1|"Bevacizumab:~-- Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~MRI -- Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
10114638|NCT04458662||Oral contraceptive users|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~Oral contraceptive users performed the trial at two moments: Withdrawal phase (WP) and active pill phase (APP)."
10114639|NCT04458662||Postmenopausal women|"he project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.~Postmenopausal women were tested only once, since their hormonal status does not fluctuate."
10114640|NCT04458246|Experimental|Intervention|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will receive an online home-based aerobic training, three times a week, during 3 months.
10114641|NCT04458246|No Intervention|Control|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will be advised to maintain their daily routine.
10114642|NCT04458090|Experimental|Intervention|Receive hospice patient decision aid
10114643|NCT04458090|No Intervention|Control|Does not receive hospice decision aid
10114644|NCT04458064|Active Comparator|i gel|I gel LMA was inserted for all patients
10114645|NCT04458064|Active Comparator|Air Q LMA|Air Q LMA was inserted for all patients
10114646|NCT04458233|Active Comparator|long axis|
10114647|NCT04458233|Active Comparator|short axis|
10114648|NCT04458142|Experimental|Single buccal infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine).~Injecting by a small amount of solution in the superficial mucosa. After a few seconds, the needle was slowly advanced in the mucobuccal fold toward the apex of the molar and 1.8 ml of 4% articaine using short 30-gauge needle was slowly given.~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed by inquiring about the area of numbness from the participant, no pain during pricking the palatal mucosa. The cases in which palatal anesthesia will not be reported by the patient will be given supplemental palatal infiltration with 0.2 to 0.3 mL articaine.~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
10114649|NCT04458142|Active Comparator|Buccal and intrapapillary infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine) Injecting a small amount of solution in the superficial mucosa,then needle will slowly advanced in the mucobuccal fold toward the apex of the molar and 1.5 ml of 4% articaine was slowly given. The remaining 0.3ml solution will be given equally into the distal, mesial intrapapillary and palatal sites respectively until blanching of the palate is observed extending more than halfway along the palatal gingival margin.~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed.~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
10114650|NCT04458168|Experimental|Recently completed treatment|25 women who have just completed treatment
10114651|NCT04458168|Experimental|No recurrence of ovarian cancer for at least one year|25 women who have not experienced a recurrence of their ovarian cancer at least one year after their initial diagnosis
10114652|NCT04458168|Experimental|Recurrence of ovarian cancer|25 women who have experienced a recurrence of their ovarian cancer after primary treatment
10114653|NCT04458025|Active Comparator|Standard rehabilitation program|Standard postoperative 4 weeks immobilization rehabilitation program with a sling in adduction and internal rotation
9667826|NCT02898259|Experimental|Lenalidomide + Ixazomib + Rituximab|Ixazomib will be orally administered with a starting dose of 2.0mg. Lenalidomide will be administered orally with a starting dose of 20mg. Rituximab will be administered intravenously at the standard dose of 375mg/m2. The study will use a standard 3 + 3 design for determination of MTD during cycle 1. There will be three dose levels for escalation, followed by two expansion cohorts of 12 patients each at the MTD, one cohort with follicular lymphoma and one cohort with non-follicular low-grade lymphoma (SLL, marginal zone, lymphoplasmacytic). Patients will be treated for 12 cycles of 4 week duration.
9696501|NCT04766190|Other|Group 2: The DISCO App|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see their oncologist. The app includes a short video and asks questions about the patient's financial concerns. The app will give the patient a list of questions the patient may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with the patient's oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting the oncologist, the patient will complete another brief survey. The questions will ask about how the meeting went and what the patient thought of the app. The meeting with the oncologist will not be delayed or changed in any way because of this study."
9816723|NCT02076152|Experimental|FMISO PET & MRI Group 2|"Bevacizumab + CCNU:~Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~CCNU will be administered at a dose of 110 mg/m2 every 42 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~-FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~- MRI~Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
9816724|NCT02076165|Experimental|ABC-I|"Participants completed a 5 session intervention, Acceptance and the Behavioral Changes to Treat Insomnia (ABC-I). This was considered the new treatment being studied."
9816725|NCT02076165|Active Comparator|CBT-I|"Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the standard care treatment."
9816726|NCT02076243|Experimental|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
9816727|NCT02076321|Other|Acetaminophen|control group
9816728|NCT02076321|Other|NSAID (Ibuprofen)|Study group
9816729|NCT02076334|Active Comparator|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
9816730|NCT02076334|Active Comparator|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
9816731|NCT02076334|Sham Comparator|Normal Garment + normal garment|Spandex during exercise + Spandex at night
9816732|NCT02076334|Active Comparator|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
9816733|NCT02076399|Experimental|Fostamatinib Disodium|Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
9816734|NCT02076399|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
9816735|NCT02076412|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
9816736|NCT02076412|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
10114654|NCT04458025|Experimental|Early rehabilitation program|Early rehabilitation program will start passive mobilization during second week after surgery, including controlled external rotation movements
10114655|NCT04458324|Experimental|NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
9816737|NCT02076425|Experimental|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
9816738|NCT02076425|No Intervention|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
9816739|NCT02076776|Active Comparator|Repetitive Task Practice (RTP)|This group focuses on RTP.
10114656|NCT04458324|Placebo Comparator|NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
9816740|NCT02076776|Experimental|Voluntary cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
9816741|NCT02076776|Experimental|Assisted cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
9816742|NCT02076919|Experimental|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
9816743|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
9816744|NCT02076919|Experimental|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
10114657|NCT04458324|Sham Comparator|sham NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
9816745|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
9816746|NCT02076997|Experimental|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
9816747|NCT02077140|Experimental|MDT-10013|Subjects will receive MDT-10013.
9816748|NCT02077140|Active Comparator|Standard of Care|Subjects will receive standard of care.
9816749|NCT02077374|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
9816750|NCT02077374|Placebo Comparator|Placebo|Placebo BID
10114658|NCT04458324|Active Comparator|sham NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
10182456|NCT03773822|Placebo Comparator|Placebo of hydrocortisone and placebo of fludrocortisone|Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days
9816751|NCT02077465|Experimental|Andecaliximab|Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
9816752|NCT02077465|Placebo Comparator|Placebo to match andecaliximab|Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
9816753|NCT02078102|Other|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
9667827|NCT02891564|Placebo Comparator|Control Arm (R 33)|a mobile 3D video game to be used as placebo.
9667828|NCT02891564|Experimental|Intervention Arm (R 33)|a mobile 3D video game (Band Together) that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
9667829|NCT02889926|Experimental|a swab according to the method of Levine|
9816754|NCT02078180|Active Comparator|generic bupropion IR75|One oral dose of generic bupropion IR75
9816755|NCT02078180|Active Comparator|generic bupropion IR100|One oral dose of generic bupropion IR100
9816756|NCT02078180|Active Comparator|generic bupropion SR100|One oral dose of generic bupropion SR100
9816757|NCT02078180|Active Comparator|generic bupropion SR150|One oral dose of generic bupropion SR150
9816758|NCT02078180|Active Comparator|generic bupropion XL150|One oral dose of generic bupropion XL150
9816759|NCT02078180|Active Comparator|generic bupropion XL300|One oral dose of generic bupropion XL300
9816760|NCT02078193|Experimental|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
9816761|NCT02078219|Experimental|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
9816762|NCT02078219|Experimental|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
9816763|NCT02078219|Experimental|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
9667830|NCT02889926|Experimental|Bacteriological referred to biopsy|
9667831|NCT02885896||Experimental period (active platform)|During the experimental period, the eligible calls will be transferred to the platform by SAMU regulator doctors, and callers will be subject to health advice by specially trained nurses. The nurse conduct the call by holding the conversation guide, giving advice for a home care, answering questions from the circle (caller, family,..) and ensuring the proper understanding of these tips. An information leaflet for the theme of the call will be sent in the days following the call to the caller of the experimental group having given their consent.
9816764|NCT02078219|Placebo Comparator|RDEA3170 4|RDEA3170 Placebo
9816765|NCT02078219|Other|Allopurinol|Allopurinol 200mg
9667832|NCT02885896||Control period (inactive platform)|During the control periods, the call center will not be active, eligible calls can not receive advice from nurses, but will be subject to the usual care: the regulator doctor will treat the call as its current practice.
10114659|NCT04458285|Experimental|Sacubitril/valsartan|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous angiotensin converting enzyme inhibitor(ACEI), ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
9816766|NCT02078284|Experimental|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
9816767|NCT02078284|Active Comparator|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
9816768|NCT02078284|Experimental|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
9816769|NCT02078284|Active Comparator|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
10114660|NCT04458285|Active Comparator|Valsartan|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
10114661|NCT04458506|Experimental|Rapid Maxillary Expander (RME)|36 patients will be treated with RME in order to correct their unilateral posterior cross bite
10114662|NCT04458506|Active Comparator|Quad Helix (QH)|36 patients will be treated with QH in order to correct their unilateral posterior cross bite
9816770|NCT02078284|Experimental|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
9816771|NCT02078284|Active Comparator|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
9816772|NCT02078284|Experimental|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
10114663|NCT04457986|Experimental|Erector spina plane block (ESP)|Patients will receive Erector spina plane block (ESP) with bupivacaine for postoperative analgesia
10114664|NCT04457986|Experimental|Modified thoracolumbar interfacial plane block (MTI)|Patients will receive Modified thoracolumbar interfacial plane block (MTI) with bupivacaine for postoperative analgesia
9816773|NCT02078284|Active Comparator|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
9816774|NCT02078492|Experimental|Group 1 - 10 mg of Ketorolac|Subjects will be administered 10 mg of Ketorolac for pain relief.
9816775|NCT02078492|Experimental|Group 2 - 15mg|Subjects will be administered 15mg of Ketorolac.
9816776|NCT02078492|Experimental|Group 3 - 30mg|Subject will receive 30mg of Ketorolac as a part of standard care.
9816777|NCT02078557|Experimental|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
9816778|NCT02078713|Experimental|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
9816779|NCT02078713|No Intervention|Usual Care (Control)|Patients in this arm will receive usual family planning care.
9816780|NCT02078726|Active Comparator|Glucagon|1 mg glucagon given during colonoscopy
9816781|NCT02078726|Placebo Comparator|Placebo|1 mL normal saline
9816782|NCT02078752|Experimental|Part 1|
10114665|NCT04457986|Active Comparator|Intravenous patient controlled analgesia (IV-PCA)|Patients will receive Intravenous patient controlled analgesia (IV-PCA) with tramadol for postoperative analgesia
9816783|NCT02078817|Experimental|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
9816784|NCT02078882|Experimental|Abatacept 125 mg weekly|Open label treatment with Abatacept
9816785|NCT02078960|Experimental|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
9816786|NCT02079025|Active Comparator|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
9816787|NCT02079025|Experimental|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
9816788|NCT02079038|Active Comparator|Totalis™ Direct Decompression Procedure|Totalis
9816789|NCT02079038|Active Comparator|Comparator Procedure|Comparator Surgical Procedure
9816790|NCT02079077|Other|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
9816791|NCT02079077|Other|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
9816792|NCT02079246|Experimental|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
9816793|NCT02079246|Experimental|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
9816794|NCT02079311|Experimental|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
10114666|NCT04457934||IBD patients|"Patients with IBD will undergo preparation for Standard endoscopy with PLENVU, since it is considered to be less affecting for patients. IBD patients have to undergo endoscopy often and mostly suffer from non-efficient preparation.~Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and will follow the Guidelines for preparation of endoscopy.~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
10114667|NCT04457934||Screening patients|"Screening patients will undergo Standard endoscopy to prevent colon Cancer. Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and nd will follow the Guidelines for preparation of endoscopy.~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
9816795|NCT02079311|Active Comparator|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
9816796|NCT02079519|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
9816797|NCT02079532|Experimental|MabThera (Rituximab)|
9816798|NCT02079610|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
9816799|NCT02079610|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
9816800|NCT02079636|Experimental|Abemaciclib + Pemetrexed|150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9816801|NCT02079636|Experimental|Abemaciclib + Gemcitabine|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9816802|NCT02079636|Experimental|Abemaciclib + Ramucirumab|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9965680|NCT01252004||TT Syndrome|Will be included over a period of one year, prospectively, all patients newly diagnosed
10114668|NCT04457999|Experimental|Lipiflow treatment|Lipiflow thermal pulsation prior to cataract surgery
10114669|NCT04457973|Experimental|Active tDCS|
10114670|NCT04457973|Placebo Comparator|Sham tDCS|
10114671|NCT04458116|Experimental|Tumeric Group|participants will receive capsules containing 1.5 grams of turmeric 95% curcumin
10114672|NCT04458116|Placebo Comparator|Placebo Group.|will receive capsules containing corn starch.
10114673|NCT04458129|Experimental|Polyethylene glycol treatment|Study participants will take a 3-month laxative treatment with polyethylene glycol for 3 months.
10114674|NCT04458038|Experimental|intervention arm|
9965681|NCT01252017|Experimental|Nilotinib|Single arm, open label study
10114675|NCT04457843||COPD patients|
10114676|NCT04458337||SARS-CoV-2 patients undergoing a surgical procedure|The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery.
9816803|NCT02079636|Experimental|Abemaciclib + LY3023414|100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9816804|NCT02079636|Experimental|Abemaciclib + Pembrolizumab|100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9816805|NCT02079649|Experimental|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
9816806|NCT02079649|Experimental|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
9816807|NCT02079649|Active Comparator|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
10114677|NCT04457856|Experimental|TJ003234|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
10114678|NCT04457856|Placebo Comparator|Placebo|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
9816808|NCT02079649|Placebo Comparator|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
9816809|NCT02079805|Experimental|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
9816810|NCT02079805|Active Comparator|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
9816811|NCT02079844|Experimental|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
9816812|NCT02079844|Experimental|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
9816813|NCT02079844|Experimental|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
9816814|NCT02079909|Experimental|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
9816815|NCT02079909|Experimental|T-817MA-L|224 mg T-817MA once daily
9816816|NCT02079909|Placebo Comparator|Placebo|Placebo once daily
9816817|NCT02079987|Experimental|ED-to-home care transition intervention|The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
9816818|NCT02079987|Experimental|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
10114679|NCT04457869|Experimental|Single arm|
10114680|NCT04457908|Other|intelligent|receive the neurological function assessment by artificial intelligence
10114681|NCT04457908|No Intervention|manual|receive the neurological function assessment by doctor
10114682|NCT04457726|Experimental|Recipients with severe COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have severe COVID-19.
10114683|NCT04457726|Experimental|Recipients with mild to moderate COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have mild to moderate COVID-19.
9816819|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
9826810|NCT02433080|Active Comparator|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
9965682|NCT01252030|Experimental|intervention|stimulation of physical activity by messages sent through e mail or SMS; in combination with monitoring of physical activity with physical activity monitors
9965683|NCT01252030|Placebo Comparator|control|no stimulation of physical activity
10114684|NCT04457570||exposed patients|"The exposed patients are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an exposed patient if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection."
9816820|NCT02080195|Experimental|Nonmyeloablative Conditioning and BMT|Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
9816821|NCT02080221|Experimental|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
9816822|NCT02080273|Placebo Comparator|Colgate Cavity Protection toothpaste|Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
9816823|NCT02080273|Active Comparator|Colgate Total toothpaste|Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
9816824|NCT02080273|Active Comparator|Parodontax|Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.
9816825|NCT02080312|Experimental|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
9816826|NCT02080364|Experimental|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
9816827|NCT02080364|Placebo Comparator|Placebo|Placebo orally once daily for 18 months
9816828|NCT02080403|Experimental|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
9816829|NCT02080403|No Intervention|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
9816830|NCT02080455|Experimental|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
9816831|NCT02080455|Experimental|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
9816832|NCT02080468|Experimental|Arm 1: Lomitapide & EE/Norgestimate - Taken Together|Lomitapide & EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)
9816833|NCT02080468|Experimental|Arm 2: Lomitapide & EE/Norgestimate - Taken 12 Hours Apart|Lomitapide & EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)
9816834|NCT02080481|Experimental|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
9816835|NCT02080481|Other|conventional block needle|ultrasound guidance with a conventional block needle
9816836|NCT02080507|Active Comparator|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
9816837|NCT02080507|Sham Comparator|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
9816838|NCT02080546|Active Comparator|Cut/Coag|
9816839|NCT02080546|Experimental|V-mode|
9816840|NCT02080637|Active Comparator|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
9816841|NCT02080637|Placebo Comparator|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
9816842|NCT02080780|Experimental|2% Diltiazem & Clarithromycin XL|"3 parts:~- Single Dose, Diltiazem (Day 1)~- Multiple Dose, Clarithromycin XL (Days 4-9)~- Single Dose, Diltiazem (Day 8)"
10114685|NCT04457570||control patients|"The control patients  are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection"
9816843|NCT02080819|No Intervention|Healthy Control|Non drug using healthy controls
9816844|NCT02080819|Placebo Comparator|Placebo|Placebo BID for 7 weeks
9816845|NCT02080819|Experimental|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
9816846|NCT02080832|Experimental|Medication (Citalopram 20mg)|Citalopram (20mg dose)
9816847|NCT02080832|Placebo Comparator|Placebo|
9816848|NCT02080832|Experimental|Medication (Citalopram 40mg)|Citalopram 40mg dose
9816849|NCT02080871|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
9816850|NCT02081001|Experimental|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
9816851|NCT02081001|Active Comparator|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
9816852|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
9816853|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
9816854|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
9816855|NCT02081079|Experimental|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
9816856|NCT02081079|Experimental|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
10114686|NCT04457921|Experimental|Deep tissue massage|deep tissue massage applied group
10114687|NCT04457921|No Intervention|Standard of care|group without deep tissue massage
10182457|NCT03773822|Experimental|Combination of hydrocortisone + fludrocortisone|Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days
9816857|NCT02081196|Experimental|CoolSculpting of the Flank With Alternate Treatment Parameters|Each subject served as their own control with 1 flank treated with CoolSculpting; the contralateral flank was untreated.
9816858|NCT02081248|Active Comparator|Standard Consent|This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
9816859|NCT02081248|Experimental|Easy-to-Read Informed Consent|This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
9816860|NCT02081365|Experimental|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
9816861|NCT02081365|No Intervention|High Anxiety Wailist Control|
9816862|NCT02081417|Other|Peer led|"Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
9816863|NCT02081417|Other|Clinician led|"Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
9816864|NCT02081443|Experimental|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
9816865|NCT02081443|Active Comparator|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
9816866|NCT02081456|Active Comparator|Therapeutic Ultrasound|Therapeutic ultrasound applied for a period of 5 minutes to the most painful region of the neck, then a second 5 minute dose at the most painful region of the upper extremity
9816867|NCT02081456|Experimental|Soft Tissue Mobilization|Passive soft tissue mobilization to the neck and upper extremity
9816868|NCT02081534|Experimental|1 mg bid|1 mg AZD1722 bid
9816869|NCT02081534|Experimental|3 mg bid|3 mg AZD1722 bid
9816870|NCT02081534|Experimental|10 mg bid|10 mg AZD1722 bid
9816871|NCT02081534|Experimental|30 mg bid|30 mg AZD1722 bid
9816872|NCT02081534|Experimental|3 mg od|3 mg AZD1722 od
9816873|NCT02081534|Experimental|30 mg od|30 mg AZD1722 od
9816874|NCT02081534|Placebo Comparator|Placebo|Placebo (double dummy technique)
9816875|NCT02081573|Experimental|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
9816876|NCT02081586|Experimental|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
9816877|NCT02081586|Experimental|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
9816878|NCT02081586|Experimental|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
9816879|NCT02081586|Active Comparator|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
9816880|NCT02081599|Experimental|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
9816881|NCT02081599|Placebo Comparator|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
9816882|NCT02081638|Active Comparator|Elite Controller|Elite controllers not on ART
9816883|NCT02081638|Active Comparator|Treated Progressors|HIV infected on ART
9816884|NCT02081677|Active Comparator|etafilcon A|Marketed control soft contact lens
9816885|NCT02081677|Experimental|Prototype E1|Investigational soft contact lens
9816886|NCT02081677|Experimental|Prototype E2|Investigational soft contact lens
9816887|NCT02081677|Experimental|Prototype E3|Investigational soft contact lens
9816888|NCT02081690|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
9816889|NCT02081807||Dabigatran|
9816890|NCT02081807||Warfarin|
9816891|NCT02081846|Experimental|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
9816892|NCT02081846|Active Comparator|Control|This arm will receive standard of care.
9816893|NCT02081859|Placebo Comparator|Conventional grading|Embryos will be scored based on conventional criteria.
9816894|NCT02081859|Active Comparator|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
9816895|NCT02081950|Experimental|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
9816896|NCT02081963|Experimental|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
9816897|NCT02081963|Other|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
9816898|NCT02082119|Experimental|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
9816899|NCT02082145|No Intervention|Control|Treated according to local protocol for diabetic peripheral neuropathy
9816900|NCT02082145|Experimental|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
9816901|NCT02082158|Active Comparator|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
9816902|NCT02082158|Active Comparator|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
10114688|NCT04457544||Retrospective patients|The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.
9816903|NCT02082158|Experimental|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
9816904|NCT02082158|Experimental|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
9816905|NCT02082158|Experimental|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
9816906|NCT02082158|Experimental|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
9816907|NCT02082184|Experimental|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
9816908|NCT02082184|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
9816909|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part A)|Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
9816910|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part B)|Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
9816911|NCT02082262|Experimental|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
9816912|NCT02082288|Experimental|Edessy ICSI Outcome Embryo Score|ICSI
9816913|NCT02082340|Experimental|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
9816914|NCT02082340|No Intervention|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
9816915|NCT02082392|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
9816916|NCT02082392|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
9816917|NCT02082392|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
9816918|NCT02082392|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
9816919|NCT02082483|Experimental|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
9816920|NCT02082483|No Intervention|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
9816921|NCT02082522|Experimental|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
9965684|NCT01252043||cohort|cholestatic children without esophageal variceal bleeding
10114689|NCT04457544||Prospective patients|Patients presenting at the hospital with newly diagnosed SCAD will be informed of the SwissSCAD study and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the prospective arm.
10114690|NCT04457609|Placebo Comparator|Control Group|Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin
9965685|NCT01252043||study|cholestatic children with esophageal variceal bleeding
10114691|NCT04457609|Experimental|Experiment Group|Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment
9816922|NCT02082522|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
10114692|NCT04457882|Experimental|Without Drainage Tube|No place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
10114693|NCT04457882|Active Comparator|With Drainage Tube|Place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
10114694|NCT04457674|Other|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.
10114695|NCT04457674|Other|Sleep Hygiene Education (SHE)|SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.
10114696|NCT04457804|Experimental|Online ACT workshop for Emotional Eating|All participants will be assigned to 2, 1.5 hour interventions using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
10114697|NCT04457388|Experimental|Tele-Yoga Therapy|Individualised Yoga therapy based on participant's clinical condition and personal needs. Twice a week sessions were carried out by trained and experienced Yoga therapist via video conference with each therapy for individualized based on each participant.
10114698|NCT04457791|Experimental|Intervention phase|From week 5-8, participants will receive the intervention, namely personalized dietary advice.
10114699|NCT04457791|No Intervention|Observational phase|From week 1-4, participants will not receive any intervention, but just will be observed, to form as their own control
10114700|NCT04457453|Active Comparator|control group|intubation with direct laryngoscope in sniffing position
10114701|NCT04457453|Experimental|direct laryngoscope in Trendelenburg and Sellick position|intubation with direct laryngoscope in Trendelenburg and Sellick position
10114702|NCT04457453|Experimental|video laryngoscope in Trendelenburg and Sellick position|intubation with video laryngoscope in Trendelenburg and Sellick position
10114703|NCT04457531|Experimental|LiuWeiLuoBi Group|Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.
10114704|NCT04457531|Other|Control Group|Patients will receive the standard medical treatment for 12 weeks.
10114705|NCT04457661|Experimental|TCI711 probiotic|Taking one capsule (containing 10^10 of Bacillus coagulans TCI711) daily for one month
10114706|NCT04457830|Experimental|Single arm|
10114707|NCT04457648|Placebo Comparator|Conventional|
10114708|NCT04457648|Active Comparator|Manuka Honey|
10114709|NCT04457765|Experimental|group 1|All participants will have PVP-I at 1.25% administered as an intranasal topical preparation prior undergoing rhinoplasty
10114710|NCT04457635|Experimental|Brief psychotherapy (brief PsT)|The focus was on normalizing, accepting and coping with their present mental health complaints and their hindrance for work participation. Primarily, there was no intention to process previous pathogenic experiences. The standard duration was set on six sessions.
10114711|NCT04457635|Active Comparator|Short psychotherapy (short-PsT)|With more extended focus, there was besides coping of mental health and challenges concerning WP, an emphasis on both an extensive anamnesis and possibility to establish a so-called central theme based on previous or current challenging issues such as trauma, difficult childhood conditions, and personality-related issues. Additional aims of the intervention could include reducing symptoms and problematic behaviour and an improvement of home situation, with deeper focus on cognitive maladaptive coping strategies or dynamic repetitions. The number of sessions was aimed to be 20 on average
10114712|NCT04457375||Healthy Adults|Healthy
10114713|NCT04457427|No Intervention|Tracheostomy, no DPS|5 patients undergoing tracheostomy for failure to wean will receive no additional intervention.
10114714|NCT04457427|Experimental|Trachesotomy with immediate DPS stimulation and monitoring|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate stimulation and monitoring.
10114715|NCT04457427|Active Comparator|Trachesotomy with DPS monitoring, stimulation on day 5|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate monitoring followed by stimulation on day 5 post-procedure.
10114716|NCT04457583|Experimental|Intervention|Procedure: Inspiratory muscle training with powerbreathe with a linear pressure resistance using an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, 30 exercises daily for 12 weeks.
10114717|NCT04457583|No Intervention|Control|Procedure: Training with the same equipment but without load-generating resistance.
10114718|NCT04457310|Experimental|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
10114719|NCT04457310|Experimental|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
10114720|NCT04457310|Experimental|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
9816923|NCT02082678|Active Comparator|Ondansetron|Ondansetron will be given 0.5 mg twice a day (BID). The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
9816924|NCT02082678|Placebo Comparator|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
9816925|NCT02082717|Experimental|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
9816926|NCT02082717|Active Comparator|Control|standard of practice potassium chloride replacement (with no additive)
9816927|NCT02082769|Experimental|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
9965686|NCT01252043||cholestatic children without EV|cholestatic children without esophageal variceal bleeding
9816928|NCT02082769|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
9816929|NCT02082769|Active Comparator|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
9816930|NCT02082912|Experimental|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
9816931|NCT02082912|Active Comparator|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
9816932|NCT02082977|Experimental|Part 1:GSK2816126 50 mg twice-weekly|Eligible subjects will receive GSK2816126 with a starting dose of 50 milligrams (mg) twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816933|NCT02082977|Experimental|Part 1:GSK2816126 100 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816934|NCT02082977|Experimental|Part 1:GSK2816126 200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816935|NCT02082977|Experimental|Part 1:GSK2816126 400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816936|NCT02082977|Experimental|Part 1:GSK2816126 800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816937|NCT02082977|Experimental|Part 1:GSK2816126 1200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816938|NCT02082977|Experimental|Part 1:GSK2816126 1800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816939|NCT02082977|Experimental|Part 1:GSK2816126 2400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816940|NCT02082977|Experimental|Part 1:GSK2816126 3000 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
9816941|NCT02082977|Experimental|Part 2: All subjects|Subjects with Germinal Center B-cell-like Diffuse Large B-cell Lymphoma (GCB-DLBCL)-mutant and wild type, Transformed Follicular Lymphoma (TFL)-mutant and wild type as well as with multiple myeloma (MM) will be enrolled in Part 2 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D).
9816942|NCT02083107|Experimental|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
9816943|NCT02083107|Placebo Comparator|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
9816944|NCT02083107|Experimental|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
9816945|NCT02083185|Experimental|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
9816946|NCT02083185|Experimental|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
9816947|NCT02083185|Active Comparator|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
9816948|NCT02083263|Experimental|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
9816949|NCT02083263|Active Comparator|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
9816950|NCT02083380|Experimental|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
9816951|NCT02083380|Experimental|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
9816952|NCT02083380|Experimental|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
9816953|NCT02083406|Experimental|Treatment A: OZ439 Prototype 1|800mg OZ439 prototype formulation 1 and 960mg PQP single doses
10182458|NCT03773744|Experimental|Arm 1: Intravenous Dosing|Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.
9816954|NCT02083406|Experimental|Treatment B: OZ439 Prototype 2|800mg OZ439 prototype formulation 2 and 960mg PQP single doses
9816955|NCT02083406|Experimental|Treatment C: OZ439 Prototype 3|800mg OZ439 prototype formulation 3 and 960mg PQP single doses
9965687|NCT01252056|No Intervention|Control|
9965688|NCT01252056|Active Comparator|Probucol|Probucol treatment
9965689|NCT01252056|Active Comparator|Combination|Probucol and Cilostazol
9816956|NCT02083653|Experimental|Arm A: Sym004 (12 mg/kg)|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
9816957|NCT02083653|Experimental|Arm B: Sym004 (9/6 mg/kg)|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
9816958|NCT02083653|Active Comparator|Arm C: Investigator's Choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
10114721|NCT04457310|Experimental|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
9816959|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
9816960|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
9816961|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
9816962|NCT02083679|Experimental|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
9816963|NCT02083783|Experimental|TRI102|Active, amphetamine extended-release oral suspension
9816964|NCT02083783|Placebo Comparator|Placebo|Placebo
9816965|NCT02083809|Placebo Comparator|Placebo|500ml saline or lactated ringer without oxytocin added
9816966|NCT02083809|Active Comparator|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
9816967|NCT02083861|Experimental|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
9816968|NCT02083861|Placebo Comparator|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
9816969|NCT02083926|Experimental|Ketamine infusion|A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
9816970|NCT02083926|Experimental|Saline infusion|A saline infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
9816971|NCT02083965|Experimental|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
9816972|NCT02083965|Experimental|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
9816973|NCT02084056|Experimental|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
9816974|NCT02084056|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
9816975|NCT02084056|Experimental|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
9816976|NCT02084056|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
9816977|NCT02084069|Active Comparator|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
9816978|NCT02084069|Placebo Comparator|Control|Placebo
9816979|NCT02084082|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
10182459|NCT03773744|Experimental|Arm 2: Intravenous followed by Intratumoral Dosing|A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).
9816980|NCT02084082|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
9816981|NCT02084082|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
9816982|NCT02084082|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
9816983|NCT02084134|Active Comparator|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
9816984|NCT02084134|No Intervention|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
9816985|NCT02084160||CLD from HIS-EX-408/PLT-BID-1108|"Chronic liver disease subjects from previous Exalenz trial HIS-EX-408 and PLT-BID1108"
9816986|NCT02084238|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
9816987|NCT02084511|Experimental|BI 1026706 low dose|BI 1026706 low dose
9816988|NCT02084511|Experimental|BI 1026706 high dose|BI 1026706 high dose
9816989|NCT02084511|Experimental|Placebo reference|Placebo reference
9816990|NCT02084511|Experimental|Celecoxib reference|Celecoxib capsule
9816991|NCT02084628|Experimental|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
9816992|NCT02084706|Active Comparator|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
9816993|NCT02084706|Experimental|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
9816994|NCT02084797|Experimental|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
9816995|NCT02085070|Experimental|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
9816996|NCT02085070|Other|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
9816997|NCT02085135|Experimental|Titration Schedule 1|
9816998|NCT02085135|Experimental|Titration Schedule 2|
9816999|NCT02085161|Placebo Comparator|placebo|patient will receive placebo once daily, 2 puffs in the morning
9817000|NCT02085161|Experimental|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
9817001|NCT02085161|Active Comparator|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
9817002|NCT02085161|Experimental|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
9817003|NCT02085252|Experimental|Leuprorelin 11.25 mg|Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
9817004|NCT02085252|No Intervention|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
9817005|NCT02085356|Experimental|Intervention women with partners|Women will enroll with male partners and both members of the couple will attend the Protect your Family intervention
9817006|NCT02085356|Experimental|Intervention women without partners|Women will enroll alone and will attend the Protect your Family Intervention without a partner
9817007|NCT02085356|No Intervention|Control women with partners|Women will enroll with male partners and both members of the couple will attend time-matched video sessions
9817008|NCT02085356|No Intervention|Control women alone|Women will enroll alone and will attend time-matched video sessions
9817009|NCT02085447|Experimental|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
9817010|NCT02085460|Placebo Comparator|Placebo|6 times daily
9817011|NCT02085460|Experimental|2% Rebamipide liquid|6 times daily
9817012|NCT02085460|Experimental|4% Rebamipide liquid|6 times daily
9817013|NCT02085473|Active Comparator|Cohort 1|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'W' mL/min.
10182460|NCT03773783|Active Comparator|Twin Block|Twin Block appliance
9817014|NCT02085473|Experimental|Cohort 2|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'X' mL/min.
10182461|NCT03773783|Experimental|Button and Bead|Button and Bead appliance
10182462|NCT03773562|Other|Erenumab|All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
9817015|NCT02085473|Experimental|Cohort 3|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Y' mL/min.
9817016|NCT02085473|Experimental|Cohort 4|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Z' mL/min.
9817017|NCT02085551|Experimental|Mechanical thrombectomy by the Indigo System|
9817018|NCT02085720|Experimental|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
9817019|NCT02085785|Experimental|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
9817020|NCT02085785|Active Comparator|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
9817021|NCT02085785|Other|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
9817022|NCT02085980|Experimental|Laser Treatment|Laser Treatment
9965690|NCT01252069|Experimental|A|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ended by a drug free period until return of menses.
9817023|NCT02086110|Active Comparator|Prebiotic only first, then synbiotic|This group will receive prebiotic only (bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the first five weeks, followed by a two week break with no treatment, and then will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the next five weeks.
9817024|NCT02086110|Active Comparator|Synbiotic first, then prebiotic only|This group will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the first five weeks, followed by a two week break with no treatment, and then will receive the prebiotic only (bovine milk oligosacharrides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the next five weeks.
9817025|NCT02086162|Experimental|Behavioral intervention|Web-based motivational decision support system
9817026|NCT02086162|Active Comparator|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
9817027|NCT02086331|Active Comparator|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
9817028|NCT02086331|Active Comparator|PAD|Symptomatic peripheral arterial disease
9817029|NCT02086331|Active Comparator|DM|Symptomatic diabetic peripheral neuropathy
9817030|NCT02086500|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during emergency medical transport
9817031|NCT02086500|Placebo Comparator|Control|Identical volume of saline during emergency medical transport
9817032|NCT02086565|Experimental|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
9817033|NCT02086565|Active Comparator|portal training|Participants are assured internet access and taught to use the patient portal
9519343|NCT03288064|Placebo Comparator|Water ingestion|Water ingestion: 7 ml/kg BW prior to exercise
9817034|NCT02086591|Experimental|Doxycycline|Doxycycline 200 mg twice daily
9817035|NCT02086682||General Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.
9817036|NCT02086682||Critical Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.
9817037|NCT02086708|Experimental|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
9817038|NCT02086786|Experimental|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
9817039|NCT02086786|Experimental|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
9817040|NCT02086968|Active Comparator|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
9817041|NCT02086968|Active Comparator|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
9817042|NCT02087046|Other|Stimulation|ANS Totally Implantable Deep Brain Stimulation System
9817043|NCT02087059|Experimental|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
9519344|NCT03288051|Active Comparator|Crystalloid group|
9519345|NCT03288051|Active Comparator|Colloid group|
9519346|NCT03288038|Experimental|RSV5mg + EZE 10mg|Rosuvastatin 5mg/Ezetimibe 10mg
9519347|NCT03288038|Active Comparator|RSV5mg|Rosuvastatin 5mg
9817044|NCT02087085|Experimental|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
9817045|NCT02087085|Sham Comparator|Sham|Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
9519348|NCT03288038|Experimental|RSV10mg + EZE10mg|Rosuvastatin 10mg/ Ezetimibe 10mg
9519349|NCT03288038|Active Comparator|RSV10mg|Rosuvastatin 10mg
9826811|NCT02433080|No Intervention|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
9826812|NCT02433288|Other|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
9826813|NCT02433288|Other|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
9519350|NCT03288038|Experimental|RSV20mg + EZE10mg|Rosuvastatin 20mg/Ezetimibe 10mg
9519351|NCT03288038|Active Comparator|RSV20mg|Rosuvastatin 20mg
9519352|NCT03287999||Haemophilia patients|Persons with haemophilia A or B - 240 to be recruited
9519353|NCT03287999||Healthy volunteers|Healthy volunteers - 10 to be recruited
9519354|NCT03287986||Suicide attempters|Depressed patients over 60 years of age with a personal history of suicide attempts scanned with MRI
9817046|NCT02087150|No Intervention|Medical management (MM)|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
9817047|NCT02087150|Experimental|Eustachian tube balloon catheter (ETBC) plus MM|Eustachian tube dilation with the ETBC plus medical management
9817048|NCT02087163|Experimental|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
9817049|NCT02087176|Experimental|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
9817050|NCT02087176|Placebo Comparator|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
9817051|NCT02087241|Experimental|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
9817052|NCT02087241|Experimental|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
9817053|NCT02087306|Experimental|Brincidofovir|"Subjects who weighed <50 kg received 2 mg/kg (not to exceed 100 mg) BCV twice weekly administered orally as the appropriate volume of 10-mg/mL liquid suspension.~Subjects who weighed ≥50 kg received 100 mg BCV twice weekly administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine)."
9817054|NCT02087514|Active Comparator|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
9817055|NCT02087514|Experimental|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
9817056|NCT02087514|Experimental|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
9817057|NCT02087514|Experimental|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
9817058|NCT02087514|Experimental|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
10114722|NCT04457310|Placebo Comparator|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Subjects will be randomized to the order of doses of CVL-562 (PF-06412562) (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
9817059|NCT02087514|Experimental|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
9817060|NCT02087670|Active Comparator|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
9817061|NCT02087670|Placebo Comparator|community based exercise|educational program and not supervises exercise program
9817062|NCT02087748|Active Comparator|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
9817063|NCT02087748|Placebo Comparator|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
9817064|NCT02087774|No Intervention|Control School|Control School received no intervention.
9817065|NCT02087774|Experimental|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
9817066|NCT02087904|Experimental|ABT-981 low dose|25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
9817067|NCT02087904|Experimental|ABT-981 medium dose|100 mg ABT-981 SC E2W
9817068|NCT02087904|Experimental|ABT-981 high dose|200 mg ABT-981 SC E2W
9817069|NCT02087904|Placebo Comparator|Placebo|Placebo
9817070|NCT02087943|Experimental|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
9817071|NCT02087943|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
9817072|NCT02087943|Experimental|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
9817073|NCT02087943|Experimental|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
9817074|NCT02087943|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
9817075|NCT02087956|Active Comparator|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
9817076|NCT02087956|Active Comparator|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
9817077|NCT02087995|Experimental|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
9817078|NCT02088034|Experimental|Promotora-led Intervention|The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
9826814|NCT02433340|Experimental|ABT-122 120 mg EOW|All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.
9826815|NCT02433366||Patients|
9826816|NCT02433366||Physicians|
9817079|NCT02088034|Active Comparator|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
9817080|NCT02088034|Active Comparator|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
9817081|NCT02088047|Experimental|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
10114723|NCT04457063|Experimental|penetrating keratoplasty|A prospective non-comparative non-randomized clinical study which was conducted on 12 eyes of 8 patients 4 males and 4 females who underwent PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction
10114724|NCT04457258|Experimental|Diagnostic (68Ga-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV, and then undergo PET/CT over 20-90 minutes.
10114725|NCT04457141|Other|first:shod ,second:minimalist shoes|"The first group will race with conventional shoes and then minimalist shoes. The group run 5 minutes for warming and then 30 seconds at 9km/h, 30 seconds at 11km/h and 30 seconds at 13km/h.~They have a washout period of 10 minutes between both interventions."
10114726|NCT04457141|Other|first:minimalist shoes ,second:shod|"The second group will race with minimalist shoes and then conventional shoes. The group run 5 minutes for warming and then 30 seconds at 9km/h, 30 seconds at 11km/h and 30 seconds at 13km/h.~They have a washout period of 10 minutes between both interventions."
10114727|NCT04457167|Experimental|Robotic surgery|Robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
10114728|NCT04457167|Active Comparator|Non robotic surgery|Non-robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
10114729|NCT04457050|Experimental|Non-Diabetic Hepatitis C infected patients|"clinical examination,~measurement of weight (Kg), height (meter), and waist circumference (cm).~Calculation of the body mass index.~Ultrasound abdominal examination.~Laboratory Investigations including Complete blood count, Serum aspartate and alanine aminotransferases, serum albumin, serum bilirubin, serum gamma-glutamyl transpeptidase, and international normalization ratio. HCV-RNA quantification before treatment and 12 weeks after the end of therapy.. Serum lipid profile, fasting and post-prandial blood sugar, glycated hemoglobin A1c also included.~Treatment of all patients with the available generic direct antivirals in Egypt (sofosbuvir/ledipasvir ± ribavirin or sofosbuvir plus daclatasvir ± ribavirin).~Evaluation of insulin resistance using the homeostasis model assessment of insulin resistance before and 12 weeks after end of treatment.~measurement of serum levels of resistin before and at 12 weeks after treatment."
10114730|NCT04457180|Experimental|Treament|"In phase A, subjects receiving a single dose of Repaglinid orally on day 1 , a single dose of Bupropion orally on day 2 and wash-out for 10 days, then apatinib once daily will be conducted on D5 through D16~# In addition, In phase B, subjects receiving a single dose of Repaglinid (in combination with apatinib) orally on day 12 , a single dose of Bupropion (in combination with apatinib) orally on day 13."
10114731|NCT04457232|Experimental|Basic Science (68Ga-FAPi-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT imaging over 20-50 minutes.
10114732|NCT04457193||post-ablation Barrett's patients|The patients with known prior diagnosis of histologically-confirmed Barrett's esophagus with or without dysplasia who have documentation of complete remission of Barrett's esophagus by endoscopy and histology after endoscopic ablation
10114733|NCT04456881|Experimental|anatomical reconstruction group of Patellofemoral ligament|
10114734|NCT04457102|Active Comparator|Arm N°1 - Standard treatment-Breast DIBH|Patients will be treated during spontaneous breath hold wich is considered as the gold-standard radiotherapy treatment for left breast cancer.
10114735|NCT04457102|Experimental|Arm N°2 - Interventional -Breast MANIV DIBH|Irradiation will take place during DIBH induced by MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 40-50 seconds to allow the complete delivery of a treatment beam.
10188013|NCT03720379|Placebo Comparator|PLACEBO|"- Placebo - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor.~APPLICATION OF PLACEBO will be performed AT BASELINE, after 3,6 months (control 1) and after 9 AND 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
9519355|NCT03287986||Patient controls|depressed patients over 60 years of age without a personal history of suicide attempt scanned with MRI
9667841|NCT02881814|Experimental|Lung ultrasound and clinical decision|Clinical assessment and choice of chest physiotherapy treatmetn performed by the clinical physiotherapist, followed by a comprehensive lung and diaphragm ultrasonography. After ultrasonography, the clinical physiotherapist is asked what CPT treatment he was going finally to implement, and explain the reasons for change, if any.
9667842|NCT02881814|Experimental|Mechanically ventilated patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
9817082|NCT02088047|No Intervention|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
9817083|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g three times daily|Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
9519356|NCT03287986||Healthy Controls|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts, scanned with MRI
9817084|NCT02088073|Placebo Comparator|Placebo once daily|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
9817085|NCT02088073|Experimental|Sodium zirconium cyclosilicate 5 g once daily|Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
9817086|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g once daily|Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
9817087|NCT02088073|Experimental|Sodium zirconium cyclosilicate 15 g once daily|Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
9817088|NCT02088177|Experimental|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
9817089|NCT02088216|Active Comparator|N-Acetylcysteine group|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
10182463|NCT03773536|Experimental|ASAQ + SLD Primaquine|Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).
9817090|NCT02088216|Other|Control group|Participants received as-needed therapy.
9817091|NCT02088385|Experimental|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
9817092|NCT02088385|Active Comparator|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
9817093|NCT02088541|Experimental|Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)|Participants under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m^2 (milligrams per square meter) (60 to 120 mg based on body surface area [BSA]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
9817094|NCT02088541|Experimental|Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)|Participants under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
9817095|NCT02088541|Experimental|Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
9817096|NCT02088541|Active Comparator|Physician's Choice 1 (PV <5)|Participants under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
9817097|NCT02088541|Active Comparator|Physician's Choice 2 (PV >=5)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
9817098|NCT02088697|Experimental|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
9817099|NCT02088697|Active Comparator|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
9817100|NCT02088788|Experimental|"Board (Rad Board)"|Radial artery catheterization is performed using radio-opaque armboard
9817101|NCT02088788|Active Comparator|No Board|Regular radio-penetrating armboard is used (the one normally used during non-study procedures) with a radio-opaque pelvic shield
9817102|NCT02088905|Experimental|Parent Child Interaction Therapy|Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
9817103|NCT02088905|No Intervention|Wait list control|Families will wait 18 weeks for treatment, serving as controls.
9817104|NCT02089113|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
9817105|NCT02089113|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
9817106|NCT02089191|Other|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
9817107|NCT02089191|Other|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
9817108|NCT02089230|Experimental|Phase I Cohort 1 - MEK 162|Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.
9817109|NCT02089230|Experimental|Phase I Cohort 2 - MEK 162|Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
9817110|NCT02089230|Experimental|Phase II Cohort 3 - MDK 162|Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
9817111|NCT02089334|Experimental|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
9817112|NCT02089347|Experimental|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
9817113|NCT02089347|Active Comparator|DT Group|Participants randomized to receive DT vaccine subcutaneously
9817114|NCT02089464|Active Comparator|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
9817115|NCT02089464|Sham Comparator|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
9817116|NCT02089659|Experimental|Part 1: Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
9817117|NCT02089659|Experimental|Part 1: Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
9817118|NCT02089659|Experimental|Part 2: Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
9817119|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
9817120|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
9817121|NCT02090075|Active Comparator|apixaban|apixaban 5 mg or 2.5 mg po bid
9817122|NCT02090075|Placebo Comparator|warfarin|warfarin with target INR of 2-3
9817123|NCT02090088||All Subjects|All Subjects
9817124|NCT02090283|Experimental|SD-101 Dermal Cream (6%)|All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
9817125|NCT02090374|Experimental|Poly ICLC dose escalation|Poly ICLC nasal challenge dose escalation 10ug, 100ug, 500ug
9817126|NCT02090374|Experimental|Poly ICLC highest dose|Poly ICLC nasal challenge single dose of 1000ug
9817127|NCT02090374|Experimental|Poly I:C single dose|Poly I:C nasal challenge single dose 500ug
9817128|NCT02090374|Experimental|R848 high dose|R848 nasal challenge 10ug
9817129|NCT02090374|Experimental|R848 low dose|R848 nasal challenge low dose 1-2ug (0.02ug/kg)
9817130|NCT02090374|Experimental|Grass pollen|Timothy grass pollen nasal challenge
9817131|NCT02090374|Experimental|Vitamin D supplementation|Vitamin D 4000U orally daily
9817132|NCT02090374|Experimental|Tuberculin|Tuberculin PPD nasal challenge
9817133|NCT02090413|Experimental|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
9817134|NCT02090413|Experimental|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
9817135|NCT02090413|Experimental|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
9817136|NCT02090426|No Intervention|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
10114736|NCT04457102|Experimental|Arm N°3 - Interventional -Liver/Lung MANIV DIBH|Irradiation will take place during DIBH induced by the MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 40-50 seconds to allow the complete delivery of a treatment beam [13]. Prior to treatment, a radio-opaque fiducial will be implanted in the tumor by an interventional radiologist, to facilitate the tumor position monitoring from onboard imaging. Residual tumor baseline shift and motion will thus be measured during beam delivery, and used to recompute the optimal safety margins that ensure an adequate dose coverage of at least 90% of tumors, according to literature recommendations [24]. We will also compare these safety margins computed under MANIV condition with those routinely applied in free-breathing condition (from a matched retrospective cohort) to estimate the gain in terms of margin reduction.
10188014|NCT03720353|Active Comparator|Active H|Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.
9817137|NCT02090426|Experimental|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
9817138|NCT02090634|Experimental|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
10188015|NCT03720353|Active Comparator|Active L|Participants will take SAS2094AL and SAS2094BL for 10 days
9817139|NCT02090634|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
9817140|NCT02090725|Experimental|3-4 Diaminopyridine (DAP)|
9817141|NCT02090764|Experimental|Ozenoxacin|ozenoxacin cream 1%
9817142|NCT02090764|Placebo Comparator|Placebo|Placebo cream
9817143|NCT02090777|Other|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
9817144|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
9817145|NCT02090894|Experimental|UV Light|
9817146|NCT02090959|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for up to 144 weeks.
9817147|NCT02091089|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
9817148|NCT02091102|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
9826817|NCT02433379|Experimental|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
9817149|NCT02091167|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
9817150|NCT02091167|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 30 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
9817151|NCT02091206|Experimental|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
9817152|NCT02091206|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
9817153|NCT02091206|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
9817154|NCT02091206|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
9817155|NCT02091284|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
9817156|NCT02091284|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
9817157|NCT02091362|Placebo Comparator|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
9817158|NCT02091362|Experimental|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
9817159|NCT02091375|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
9817160|NCT02091375|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
9817161|NCT02091414|Experimental|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
9519357|NCT03287973|Active Comparator|Lifestyle modification program group|Patients with apnea-hypopnea index (AHI) ≥ 15/hr on home sleep study will participate in a dietitian-led lifestyle modification program (LMP) for 6 months. Patients will attend dietary consultation weekly in the first 4 months, and then monthly in the following two months.
9817162|NCT02091440|Other|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
9817163|NCT02091466|Active Comparator|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
10114737|NCT04457102|Experimental|Arm N°4 - Interventional -Liver/Lung MANIV VC|Patients will be ventilated by VC mode during their treatment. For each fraction, the treatment time, the number of reconstructions of the tracking model and the correlation errors of the model will be collected. The same information will be extracted from a matched retrospective cohort treated by tracking in spontaneous breathing.
10114738|NCT04457102|Other|Arm N°5 -Liver/Lung MANIV DIBH for PT|Data on tumor position and its residual motion from patients included in the arm n°3 will be used to compute the planned and in silico delivered dose distribution with PBS PT. The MIRO lab (UCLouvain - IREC) has developed comprehensive tools for simulating treatment delivery on patients CT images using the Monte Carlo dose engine MCsquare [25], coupled with log-file acquisitions [26]. In this way, we will be able to validate our approach in silico in collaboration with IBA, as a first step before conducting prospective trials for the clinical validation of this approach.
9817164|NCT02091466|No Intervention|Control|Patients received no active warming before the anesthesia procedure in control groups
9817165|NCT02091531|Experimental|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
9817166|NCT02091726|Experimental|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
9817167|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (100 Units)|"Main period (1 treatment cycle): Subjects to receive 100 Units.~Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
9817168|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (75 Units)|"Main period (1 treatment cycle): Subjects to receive 75 Units.~Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
9817169|NCT02091739|Placebo Comparator|Placebo|"Main period (1 treatment cycle): Subjects to receive placebo injection.~Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
9817170|NCT02091778|Experimental|Fast Gelling Dressing|
9817171|NCT02091856|Experimental|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
9817172|NCT02091856|Experimental|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
9817173|NCT02091856|No Intervention|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
9817174|NCT02091869|Experimental|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
9817175|NCT02091869|Experimental|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
9817176|NCT02091882|Experimental|Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System|"Participants were placed a patch by the clinical staff prior to each ingestible event marker (IEM) tablet ingestion. Participants received one IEM tablet approximately every 2 hours, for a total of 4 ingestions on Day 1 at 0, 2, 4 and 6 hours.~Following placement of the patch by clinic staff, participants ingested one 10 mg aripiprazole-embedded IEM tablet without food at Hour 0, one placebo-embedded IEM tablet without food at approximately Hour 2, one placebo-embedded IEM tablet with a high fat meal at approximately Hour 4, and one placebo-embedded IEM tablet without food at approximately Hour 6. Clinic staff recorded the time of each ingestion of an IEM and the time detected by MIND1 System."
9519358|NCT03287973|Other|CPAP group|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
9817177|NCT02091921|Experimental|Experimental|All subjects will receive Ticagrelor.
9817178|NCT02091986|Active Comparator|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
9817179|NCT02091986|Active Comparator|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
9817180|NCT02091986|Active Comparator|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
9817181|NCT02092025||Azilsartan|Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.
9817182|NCT02092116|Other|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of ~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
9817183|NCT02092116|Other|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of ~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
9817184|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
9817185|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
9817186|NCT02092181|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 mg daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or, for those in the placebo arm, two placebo tablets.
9817187|NCT02092181|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
9817188|NCT02092220|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
9817189|NCT02092220|Active Comparator|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
9965691|NCT01252069|Experimental|B|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets) during 3 periods each ended by a drug free period until return of menses.
9965692|NCT01252082|Active Comparator|Scalig and Rootplaning|patients will receive scaling and root planing therapy
10114739|NCT04457128|Experimental|Secular Image|Secular Image
10114740|NCT04457128|Experimental|Non-secular image|non-secular images
10114741|NCT04457128|Experimental|Secular message|secular messages
9519359|NCT03287960|Experimental|setmelanotide|setmelanotide subcutaneous injection once daily
9519360|NCT03287960|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
9817190|NCT02092285|Experimental|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
9817191|NCT02092298|Experimental|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
9817192|NCT02092311|Experimental|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
9817193|NCT02092311|Active Comparator|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
9817194|NCT02092324|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
9817195|NCT02092350|Experimental|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
9817196|NCT02092350|Experimental|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
9817197|NCT02092350|Experimental|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
9817198|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine [AZA]/ 6-mercaptopurine [6-MP]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
9817199|NCT02092415|Experimental|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
9817200|NCT02092441|Active Comparator|Alcohol prep pad group|isopropyl alcohol prep pad
9817201|NCT02092441|Placebo Comparator|Normal Saline prep pad|normal saline prep pad
9817202|NCT02092467|Experimental|Treatment Arm 1|
9817203|NCT02092467|Experimental|Treatment Arm 2|
9817204|NCT02092467|Active Comparator|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
9817205|NCT02092610|Active Comparator|Standard Implant BI300|The product was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
9817206|NCT02092610|Experimental|Novel Implant BI300|The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
9817207|NCT02092649|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
9817208|NCT02092649|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
9817209|NCT02092662||Stroke|Stroke patients at the subacute phase
9817210|NCT02092662||Healthy controls|healthy age-matched voluntiers
9817211|NCT02092857|Active Comparator|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
10114742|NCT04457128|Experimental|Non-secular message|non-secular messages
9817212|NCT02092857|Active Comparator|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
9817213|NCT02092857|Placebo Comparator|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
9817214|NCT02092909|Experimental|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
9817215|NCT02092961|Experimental|Dosing Group A|Oral treatment and subcutaneous injection.
9817216|NCT02092961|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection.
9817217|NCT02092961|Placebo Comparator|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
9817218|NCT02092987|Experimental|NYU Caregiver Intervention|The New York University (NYU) caregiver intervention arm received the NYU caregiver intervention in addition to social work support and educational materials.
9817219|NCT02092987|Active Comparator|REACH OUT|The Resources for Enhancing Caregiver Health Offering Useful Treatments (REACH OUT) intervention arm received the REACH OUT caregiver intervention in addition to social work support and educational materials.
9817220|NCT02093026|Experimental|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first [Day 1] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints >=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
10114743|NCT04457037|Experimental|MSC|Patients with trophic ulcers received standard treatment and MSC
9817221|NCT02093221|Experimental|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
9817222|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
9817223|NCT02093221|Placebo Comparator|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
9817224|NCT02093221|Experimental|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
9817225|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
9817226|NCT02093221|Placebo Comparator|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
9667843|NCT02878798|Placebo Comparator|Placebo|An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
9817227|NCT02093234|Active Comparator|Mobile health care application|Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
9817228|NCT02093234|Active Comparator|Community Health Worker (CHW)|CHWs assist study patients in managing there health care in various ways.
9817229|NCT02093234|Experimental|CHWs and mobile health care application|Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
9817230|NCT02093351|Experimental|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
9817231|NCT02093351|Experimental|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
9817232|NCT02093351|Experimental|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
9817233|NCT02093390|Experimental|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
9817234|NCT02093390|Experimental|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
9817235|NCT02093520|Active Comparator|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
9817236|NCT02093520|Active Comparator|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
9817237|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
9817238|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
9817239|NCT02093702|Active Comparator|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
9826818|NCT02433483|Experimental|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).~Interventions:~Cycle 1: cytarabine, HPC-A donor infusion~Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
10114744|NCT04456985|Active Comparator|Intervention group|Before the operation, the patient took 20ml of brown sugar aqueous solution containing folic acid and VitB12 for 3 days (folic acid concentration is 0.4mg / d for 2 year old children + 1.2μg / d of VitB12, dissolved in 20ml brown sugar water once a day). Postoperatively, PAED scores were performed at the time of awakening, extubation and every 10min within 30min after extubation. 10 points is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
10114745|NCT04456985|Placebo Comparator|Placebo group|The patients in the placebo group took 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation. Postoperatively, PAED scores were performed at the time of recovery, extubation, and every 10 minutes within 30 minutes after extubation. The PAED scores of all children were measured by the same person. (The total score is 0-20, and the score ≥10 is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
10114746|NCT04456803|Experimental|Ferric citrate tablet|Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.
10114747|NCT04456803|Active Comparator|Sevelamer carbonate tablet|Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.
10114748|NCT04456907|Experimental|PPR group|Receive PRP injection
10114749|NCT04456907|Sham Comparator|Saline group|Receive saline injection
10114750|NCT04456751||No redo op|Patients with a single cardiac operation under extracorporeal bypass
10114751|NCT04456751||Redo op|Patients with a redo cardiac operation under extracorporeal bypass
10114752|NCT04456725|Active Comparator|Control|Usual care group
10114753|NCT04456725|Experimental|Intervention|Intensive management utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring.
10114754|NCT04457011|Experimental|High dose group|High dose Susu Xiao'er Zhike Granules, 1 bag, bid
10114755|NCT04457011|Experimental|Middle dose group|Middle dose Susu Xiao'er Zhike Granules, 1 bag, bid
10114756|NCT04457011|Placebo Comparator|Extremely-low dose group|Extremely-low dose Susu Xiao'er Zhike Granules, 1 bag, bid
10188016|NCT03720353|Placebo Comparator|Placebo|Participants will take placebo for 10 days.
9667844|NCT02878798|Experimental|Topiramate|Oral topiramate
9817240|NCT02093702|Experimental|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
9817241|NCT02093793|Experimental|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
9817242|NCT02093793|Active Comparator|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
9667845|NCT02870348|Experimental|Alpha-1 MP|Participants received IV infusion of 60 mg/kg Alpha-1 MP administered weekly for mean duration of 213 weeks.
9817243|NCT02093819|Experimental|BI 416970 single rising dose part|single rising dose given as tablet
9817244|NCT02093897|Experimental|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
9817245|NCT02093923|Experimental|DX-2930, Cohort 1|Participants will receive 30 milligram (mg) dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
9817246|NCT02093923|Experimental|DX-2930, Cohort 2|Participants will receive 100 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
9817247|NCT02093923|Experimental|DX-2930, Cohort 3|Participants will receive 300 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
9817248|NCT02093923|Experimental|DX-2930, Cohort 4|Participants will receive 400 mg dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
9817249|NCT02093923|Placebo Comparator|Placebo|Participants will receive placebo matched to 30, 100, 300 and 400 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
9817250|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
9667846|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
9817251|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
9817252|NCT02093962|Experimental|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
9817253|NCT02093962|Active Comparator|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
9817254|NCT02094118|Active Comparator|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
9817255|NCT02094118|Experimental|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
9826819|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
10114757|NCT04456738|Experimental|Parent Training|16 weeks of parent training in a group context with 5 to 10 relative and non-relative foster caregivers
10114758|NCT04456738|No Intervention|Services as Usual|Foster care services as usual
9826820|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
9826821|NCT02433665|Active Comparator|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
9826822|NCT02433665|Active Comparator|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
9826823|NCT02433678|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
9826824|NCT02433678|Active Comparator|Dapagliflozin|10 mg daily for the 12 weeks
9826825|NCT02433834|Experimental|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
9826826|NCT02433834|Experimental|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
9826827|NCT02433834|Experimental|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
9826828|NCT02433834|Experimental|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
9826829|NCT02433834|Experimental|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
9826830|NCT02433834|Placebo Comparator|Placebo|Placebo
9826831|NCT02433834|Active Comparator|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
9826832|NCT02433977|Experimental|Conjugated Linolenic Acid + NOx|"This is a single arm study~Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
9826833|NCT02434081|Experimental|Chemo-radiotherapy with concurrent nivolumab|4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.
10114759|NCT04456855||Locoregional surgery|
9817256|NCT02094300|Experimental|Endovascular|
9817257|NCT02094417|Experimental|AMG531 (Dose 1)|
9817258|NCT02094417|Experimental|AMG531 (Dose 2)|
9817259|NCT02094417|Experimental|AMG531 (Dose 3)|
9817260|NCT02094417|Experimental|AMG531 (Dose 4)|
9817261|NCT02094443|Experimental|Alisporivir 300 mg BID|Alisporivir (ALV) 300 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
9667847|NCT02841280|Experimental|Chlorthalidone|Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
9667848|NCT02841280|Placebo Comparator|Placebo|Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.
9817262|NCT02094443|Experimental|Alisporivir 400 mg BID|ALV 400 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
9817263|NCT02094534|Experimental|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
9817264|NCT02094534|Placebo Comparator|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
9817265|NCT02094573|Experimental|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).
9817266|NCT02094573|Experimental|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).
9817267|NCT02094586|Experimental|PXVX0200 Lot A|PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
9817268|NCT02094586|Experimental|PXVX0200 Lot B|PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
9817269|NCT02094586|Experimental|PXVX0200 Lot C|PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
9817270|NCT02094586|Placebo Comparator|Placebo|Placebo physiological saline
9817271|NCT02094612|Active Comparator|Usual Care|Usual clinic ADHD care
9817272|NCT02094612|Experimental|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
9817273|NCT02094664|No Intervention|Standard oxygen via nasal cannula|Standard therapy
9817274|NCT02094664|Active Comparator|Heated and humidified oxygen|Heated and humified oxygen
9817275|NCT02094677|Active Comparator|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
9817276|NCT02094677|Active Comparator|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
10114760|NCT04456855||No surgery|
9667849|NCT02838745|Experimental|Pemetrexed (300 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
10114761|NCT04456660|No Intervention|Control group|
9667850|NCT02838745|Experimental|Pemetrexed (400 mg/m2) and Cisplatin (175 mg/m2)|Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
9817277|NCT02094755||Single cohort|Single cohort will receive Blood draw only.
9817278|NCT02094872|Experimental|Arm I (molecularly targeted therapy)|Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
9817279|NCT02094885|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
9817280|NCT02094885|Other|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
9817281|NCT02094898|Experimental|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
9817282|NCT02094937|Experimental|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
10114762|NCT04456660|Active Comparator|sFlt-1 & Doppler group|
9817283|NCT02094937|Experimental|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
9817284|NCT02094937|Experimental|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
10188017|NCT03720340|Active Comparator|Recombinant human interleukin-11|Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.
9817285|NCT02094937|Experimental|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
9817286|NCT02095106|Other|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
9817287|NCT02095106|Other|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
10114763|NCT04456764|Experimental|SaFTiE|The SaFTiE intervention includes: [a] real-time text-message assessments of fatigue and sleep during and between scheduled shift work; [b] tailored text-message alerts that promote adopting evidence based strategies for mitigating fatigue when high levels of fatigue or sleepiness are reported; [c] a mobile app that delivers goal setting, summary data of sleep/fatigue indicators from all study participants, and video interviews of EMS clinicians focused on sleep and fatigue.
10114764|NCT04456764|Placebo Comparator|Attention Placebo Control|The attention placebo control includes: [a] real-time text-message assessments of teamwork during and between scheduled shift work; [b] text-message alerts that promote techniques for mitigating poor teamwork when episodes of poor teamwork are reported; [c] a mobile app that delivers goal setting, summary data of teamwork indicators from all study participants, and video interviews of EMS clinicians focused on teamwork.
9817288|NCT02095145|Experimental|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
9817289|NCT02095145|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
9817290|NCT02095158|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
9817291|NCT02095197|Other|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~No Catheter Delivery will be used to deliver the medication."
9817292|NCT02095197|Active Comparator|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~Catheter targeted delivery will be used to deliver the medication."
9817293|NCT02095223|Experimental|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
9817294|NCT02095223|Active Comparator|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
9817295|NCT02095340|Experimental|Positive Training|
9817296|NCT02095340|Sham Comparator|Neutral Training|
9817297|NCT02095535||Study group|All study participants
9817298|NCT02095561|Experimental|HPV Self testing|HPV self testing offered by CHWs during home visits
10114765|NCT04456829|Experimental|Resveratrol drink|
9667851|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).~No intervention but only observational."
10114766|NCT04456829|Placebo Comparator|Placebo drink|
9667852|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).~No intervention but only observational."
9817299|NCT02095561|No Intervention|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
9817300|NCT02095678|Experimental|HCC or metastatic Liver Lesions|Patients with HCC or metastatic liver lesions who are refered to the abdominal imaging and biopsy clinic will have a liver biopsy performed. 3-5 days after a clinical MRI indicating a cancerous lesion, patients will return for the free-breathing MRI and a liver biopsy. These images will be compared to the clinical MRI and to images of the benign lesions.
9817301|NCT02095678|Active Comparator|Benign Liver Lesion|Patients with benign liver lesions will be referred to the study team. 3-5 days after a clinical MRI an experimental, free-breathing MRI will be performed on these patients. The results will be compared to their clinical MRI images and to images of HCC or metastatic lesions
9817302|NCT02095691|Experimental|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
9817303|NCT02095873|Experimental|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
9817304|NCT02095873|Experimental|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
9817305|NCT02095951|Experimental|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
10114767|NCT04456777|Experimental|1group|patients with vortioxetine
9817306|NCT02095951|Active Comparator|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
9817307|NCT02096003|Active Comparator|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
9817308|NCT02096003|Experimental|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
9817309|NCT02096029|Experimental|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
9817310|NCT02096029|Active Comparator|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
10114768|NCT04456777|Placebo Comparator|2 group|patients without vortioxetine
9817311|NCT02096081|Experimental|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
9817312|NCT02096081|Active Comparator|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
9817313|NCT02096107|Active Comparator|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
9817314|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
9817315|NCT02096263|Experimental|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
9817316|NCT02096263|Active Comparator|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
9817317|NCT02096263|Active Comparator|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
9817318|NCT02096276||Exposure Group_Prospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and prospective (i.e., registration to registry is done before the outcome of the pregnancy is known)
9817319|NCT02096276||Exposure Group_Retrospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and retrospective (i.e., pregnancy outcome is already known at the time of registration to Registry)
9817320|NCT02096458|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
9817321|NCT02096471|Experimental|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (~8 months) will be considered treatment failures and taken off study.
9817322|NCT02096575|Experimental|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
9817323|NCT02096575|No Intervention|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
9817324|NCT02096588|Experimental|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.
9817325|NCT02096588|Active Comparator|No drug|Participant not randomized to simvastatin will participate in all aspects of the study, including planned doxorubicin/cyclophosphamide chemotherapy, with the exception of simvastatin administration.
9817326|NCT02096679|Experimental|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg [14C]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
9817327|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
9817328|NCT02096705|Experimental|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
9817329|NCT02096705|Placebo Comparator|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
9817330|NCT02096718|Experimental|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
10114769|NCT04456712|Experimental|ciprofloxacin for diabetic patients|50 diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
10114770|NCT04456712|Experimental|levofloxacin for diabetic patients|50 diabetic patients received intravenous levofloxacin 750mg/24 hours.
10114771|NCT04456712|Experimental|ciprofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
10114772|NCT04456712|Experimental|levofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous levofloxacin 750mg/24 hours.
10188018|NCT03720340|Placebo Comparator|Saline|Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.
10188019|NCT03720327|Active Comparator|Get FIT|The Get FIT intervention
9817331|NCT02096718|Experimental|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
10114773|NCT04456478|Active Comparator|pH 7.38 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.38 ± 0.02
10114774|NCT04456478|Experimental|pH 7.22 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.22 ± 0.02
9817332|NCT02096718|Other|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
9817333|NCT02096731||LABA + tiotropium|
10114775|NCT04456621|Experimental|PBT arm|
10114776|NCT04456816|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
9667853|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR < 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).~No intervention but only observational."
9817334|NCT02096731||LABA mono|
9817335|NCT02096731||neither tiotropium nor LABA|
9817336|NCT02096731||tiotropium + LABA|
9817337|NCT02096731||tiotropium mono|
9817338|NCT02096744|Experimental|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
9817339|NCT02096744|Experimental|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
9817340|NCT02096744|Experimental|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
9817341|NCT02096835|Experimental|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
9817342|NCT02096835|Active Comparator|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
9817343|NCT02096835|Sham Comparator|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
9817344|NCT02096861|Experimental|CT-P13 - CT-P13|CT-P13 followed by CT-P13 from Week 30
9965693|NCT01252082|No Intervention|control|patients in control group will not receive periodontal treatment in the time period of the study
10114777|NCT04456816|Experimental|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
10114778|NCT04456868|Active Comparator|Healthy volunteers|Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
10114779|NCT04456868|Experimental|Anhedonic drug-resistant bipolar depression patient|Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
10114780|NCT04456868|Active Comparator|Non-anhedonic drug-resistant bipolar depression Pat|Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
10114781|NCT04456868|Active Comparator|Mild to moderate Parkinson's disease patient|Adult patients at least 18 years of age with mild to moderate Parkinson's disease
10114782|NCT04456452|Experimental|Ampion|Ampion
9667854|NCT02831335||Group 1|normal 21-35 years old participants
9667855|NCT02831335||Group 2|normal 36-50 years old participants
10114783|NCT04456452|Other|Standard of Care|Standard of Care
9667856|NCT02831335||Group 3|normal 51-65 years old participants
9667857|NCT02831335||Group 4|normal 66- 80 years old participants
9667858|NCT02830958|Experimental|Kinesiotaping Group|applied next to the lymphatic system from the validated methods Kinesiotaping®.
9667859|NCT02830958|Placebo Comparator|Ordinary tape Group|Installation of an ordinary tape (not having the characteristics of Curetape®).
9667860|NCT02813668|Experimental|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
9817345|NCT02096861|Active Comparator|CT-P13 - Remicade|CT-P13 followed by Remicade from Week 30
9817346|NCT02096861|Active Comparator|Remicade - Remicade|Remicade followed by Remicade from Week 30
9817347|NCT02096861|Experimental|Remicade - CT-P13|Remicade followed by CT-P13 from Week 30
9817348|NCT02096900|Active Comparator|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
9817349|NCT02096900|Active Comparator|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
9817350|NCT02096952|Experimental|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
9817351|NCT02097030|Active Comparator|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
9817352|NCT02097030|Active Comparator|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
9817353|NCT02097030|Active Comparator|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
9817354|NCT02097056|Experimental|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
9817355|NCT02097108|Other|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
9965694|NCT01252108|Experimental|Treatment|All subjects receive SQ109
9965695|NCT01252121|Other|Systane, Hialid, Unisol|1 drop Systane in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
9817356|NCT02097238|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
9817357|NCT02097277|Placebo Comparator|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
9817358|NCT02097277|Experimental|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
9817359|NCT02097277|Experimental|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
9817360|NCT02097277|Experimental|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
9817361|NCT02097277|Experimental|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
9817362|NCT02097290|Experimental|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
9817363|NCT02097303|Other|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
9817364|NCT02097472|Experimental|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
9817365|NCT02097472|Placebo Comparator|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
9817366|NCT02097472|Experimental|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
9817367|NCT02097472|Placebo Comparator|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
9817368|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
9817369|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
9817370|NCT02097472|Active Comparator|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
9817371|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
9817372|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
9817373|NCT02097472|Active Comparator|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
9817374|NCT02097485|Active Comparator|Abametapir Lotion 0.74% w/w|Topically administered to hair and scalp for 10 minutes application.
9817375|NCT02097485|Placebo Comparator|Vehicle Lotion|Administered to scalp and hair for 10 minutes application.
9817376|NCT02097537|Experimental|Methacholine Chloride|children with bronchial asthma
9817377|NCT02097641|Experimental|Human Mesenchymal Stromal Cells (hMSCs)|A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
9817378|NCT02097641|Placebo Comparator|Plasma-Lyte A (placebo)|A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes.
9817379|NCT02097719|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
9817380|NCT02097719|Active Comparator|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
9817381|NCT02097732|Active Comparator|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
9817382|NCT02097732|Experimental|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
9817383|NCT02097745|Experimental|MabThera/Rituxan|
9817384|NCT02097823|Experimental|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
9826834|NCT02434328|Experimental|Brolucizumab 6 mg|Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
10114784|NCT04456530|Experimental|Testosterone Group|Participants receiving two IM Testosterone injections.
10114785|NCT04456530|Placebo Comparator|Control Group|Participants receiving two IM Normal Saline Injections.
9817385|NCT02097823|Experimental|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
10114786|NCT04456504|Experimental|Healthcare worker|Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.
9817386|NCT02097849|Active Comparator|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
9817387|NCT02097849|Experimental|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
9817388|NCT02097992|Experimental|SD placebo and MD roflumilast then MD placebo|Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.
9817389|NCT02097992|Experimental|SD placebo and MD placebo then MD roflumilast|Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
9817390|NCT02097992|Experimental|SD roflumilast and MD placebo then MD roflumilast.|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
9817391|NCT02097992|Experimental|SD roflumilast and MD roflumilast then MD placebo|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily
9817392|NCT02098109|Experimental|XM02 Filgrastim (Granix) and Plerixafor|"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
9817393|NCT02098109|Active Comparator|Filgrastim (Neupogen) and Plerixafor|"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
9817394|NCT02098304|Other|Sound and Unsound Molars|Imaging of unrestored sound molars (ICDAS 0), and third Molars (ICDAS 1,2 or 3) with the Calcivis Caries Activity Imaging System
9817395|NCT02098369|Other|Usual care|Written education material (basic)
10114787|NCT04456374||Under-12 (U12) players|
10114788|NCT04456374||Under-14 (U14) players|
10114789|NCT04456374||Under-16 (U16) players|
10114790|NCT04456374||Under-18 (U18) players|
10114791|NCT04456595|Experimental|Adult - Vaccine|Participants aging 18-59 years receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
9817396|NCT02098369|Experimental|Proactive|Written education material (basic) Additional education material PELICAN-Proactive [In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)]
10114792|NCT04456595|Experimental|Elderly - Vaccine|Participants aging 60 years or above receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
9817397|NCT02098369|Experimental|Reactive|Written education material (basic) Additional education material PELICAN-Reactive [In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)]
9817398|NCT02098395|Experimental|Liraglutide 1.8 mg + insulin|
10114793|NCT04456595|Placebo Comparator|Adult - Placebo|Participants aging 18-59 years receiving two doses with 14-days interval of placebo
10114794|NCT04456595|Placebo Comparator|Elderly - Placebo|Participants aging 60 years or above receiving two doses with 14-days interval of placebo
10114795|NCT04456543|Experimental|Pressure monitoring group|In the pressure monitoring group, garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg for 2 months. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
10114796|NCT04456543|Active Comparator|conventional treatment group|In the conventional treatment group, non-surgical standard treatment of burn scars except for pressure monitoring was performed in the same manner. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
10114797|NCT04456608|Experimental|Low and High n-3 PUFA|Individuals with low or high n-3 PUFA RBC concentration will be given aspirin (81 mg of aspirin once a day, for 6 days)
10114798|NCT04456387|Experimental|Arm 1-on demand treatment|Part A-Participants will receive on-demand treatment with Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection for 6 months.
9817399|NCT02098395|Experimental|Liraglutide 1.2 mg + insulin|
10114799|NCT04456387|Experimental|Arm 2- prophylaxis treatment|"Part B-Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.~12 Participants of them will receive PK assessment at ED1 and ED35(Participants will be tested for PK assessment at timepoints throughout the study based on exposure days (ED). One ED is equivalent to a 24 hours period in which drug is dosed.)，measured by one-stage assay, they would not be given prophylaxis treatment until the completion of PK blood collection."
10114800|NCT04456361|Experimental|COVID-19 patients|Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
10114801|NCT04456582|Experimental|Amyloidosis transthyretin with cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
10114802|NCT04456582|Experimental|Amyloidosis transthyretin without cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
10114803|NCT04456582|Placebo Comparator|Healthy subjects|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
10114804|NCT04456348||positive|Subjects have gait disorder according to intelligent gait assessment at baseline.
10114805|NCT04456348||negative|Subjects don't have gait disorder according to intelligent gait assessment at baseline.
10114806|NCT04456218|Experimental|Biliary stone|Participants who meet the criteria of biliary stone enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
10114807|NCT04456218|Experimental|Biliary stricture|Participants who meet the criteria of biliary neoplasm enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
10114808|NCT04456335||Caries-free|Caries-free children
10114809|NCT04456335||Early childhood caries|Children with early childhood caries
10114810|NCT04456257|Experimental|Fractional Picosecond 1,064 nm laser|The subjects with abdominal striae alba were treated with a fractional picosecond 1,064 nm laser
10114811|NCT04456049|Experimental|Enzalutamide (Xtandi®)|Interventional treatment
10114812|NCT04456049|Active Comparator|Standard of care (SOC)|Supportive treatment
10114813|NCT04456231||QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. In Addition, this Group will receive a health app for better preparation and more Information regarding preparation and endoscopy itself.
10114814|NCT04456231||no QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. This Group will have no app and will have to receive Information in traditional ways.
10114815|NCT04456114|Experimental|Acid etched brackets|Stainless steel bracket base etched with 10% Hydrofluoric acid for 1 minute
10114816|NCT04456114|Active Comparator|Sandblasted brackets|Stainless steel bracket sandblasted base
10114817|NCT04456309||Atrial fibrillation|stroke patients with atrial fibrillation
10114818|NCT04456309||Intracardiac thrombus|stroke patients with intracardiac thrombus
10114819|NCT04456062|Experimental|Caring Contacts Group|
10114820|NCT04456062|No Intervention|Standard Treatment Group|
10114821|NCT04456205||Dual Therapy|Dual Therapy (long-acting muscarinic antagonist [LAMA] + long-acting beta-agonist [LABA])
10114822|NCT04456205||Triple Therapy|Triple Therapy (inhaled corticosteroid [ICS]/ long-acting beta-agonist [LABA] + long-acting muscarinic antagonist [LAMA])
10114823|NCT04456010||Infertile couple|Infertile couple who had a fertility treatment prescribed during the past 9 months which was not completed yet.
10114824|NCT04455932|Experimental|HCC surveillance with US and aNC-MRI|
9817400|NCT02098395|Experimental|Liraglutide 0.6 mg + insulin|
10114825|NCT04455919|Experimental|Yoga|Yoga classes once a week for eight weeks
10114826|NCT04455919|Other|Wait-list control|The delayed intervention group was to benefit from the intervention after week 8.
10114827|NCT04456283||Incomplete pathological response with less than 12 LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
10114828|NCT04456283||Incomplete pathological response with 12 or more LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
9817401|NCT02098395|Placebo Comparator|Liraglutide placebo 0.3 ml + insulin|
10114829|NCT04456283||Complete pathological response with less than 12 LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
10114830|NCT04456283||Complete pathological response with 12 or more LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
10114831|NCT04456192|Experimental|Women with Obesity|23 healthy, obese (BMI ≥ 30 kg/m2; waist circumference > 80) women, aged 34-62, screened at the outpatient clinic of the Department of Internal Medicine, Metabolic Disorders, and Hypertension, University of Medical Sciences, Poznań, Poland were enrolled based on the inclusion criteria and the willingness to participate in the research.
10114832|NCT04456192|Active Comparator|Normal-weight Women|"8 healthy, normal-weight (≤ 24.9 and ≥ 18.5 kg/m2) women, aged 34-62 were enrolled to intervention from the announcement.~Random selection for groups was not applicable due to the planned body mass difference in the studied groups."
10114833|NCT04456101||Control group|healthy volunteers without COVID-19
10114834|NCT04456101||Severe/Critical COVID-19 rehabilitation group|Patients recovering from severe/critical COVID-19
10114835|NCT04456101||mild/moderate COVID-19 rehabilitation group|Patients recovering from mild/moderate COVID-19;
10114836|NCT04456101||asymptomatic COVID-19 rehabilitation group|Asymptomatic COVID-19 patients with laboratory test for SRARS-COV2 turning negative
9817402|NCT02098395|Placebo Comparator|Liraglutide placebo 0.2 ml + insulin|
9817403|NCT02098395|Placebo Comparator|Liraglutide placebo 0.1 ml + insulin|
9817404|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
9817405|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
10114837|NCT04455802|Active Comparator|Morphine|Infants randomized to the morphine arm will start at a dose of 0.06 mg/kg/dose every 4 hours. A buprenorphine placebo will also be given at the same frequency as a faux drug.
10114838|NCT04455802|Experimental|Buprenorphine|"Infants randomized to the buprenorphine arm will be started on a dose of 10 mg/kg/dose every 8 hours. A morphine placebo will also be given at the same frequency as a faux drug.~Patients can only be randomized to only one arm."
10114839|NCT04456088|Experimental|Phase 1- Nitric oxide treatment- 80ppm|
10114840|NCT04456088|Experimental|Phase 2- Group 1- Nitric oxide treatment- 150ppm|
9667861|NCT02809820|Active Comparator|Carvedilol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
9667862|NCT02809820|Active Comparator|Metoprolol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
9667863|NCT02804022|Experimental|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
10114841|NCT04456088|No Intervention|Phase 2- Group 2- control|Standard of Care
10114842|NCT04455945||Open|Patients with open surgery for rectal cancer planned in our department.
10114843|NCT04455945||Laparoscopic|Patients with laparoscopic surgery for rectal cancer planned in our department.
10114844|NCT04455984||Neoadjuvant chemoradiotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemoradiotherapy followed by curative-intent surgery
9667864|NCT02799602|Experimental|BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel|Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
9667865|NCT02799602|Placebo Comparator|Placebo + standard ADT + Docetaxel|Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel
9667866|NCT02799095|Experimental|ALKS 4230|
9667867|NCT02799095|Experimental|ALKS 4230 + pembrolizumab|
9667868|NCT02789956|Experimental|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
9667869|NCT02789956|Active Comparator|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
9667870|NCT02786498|Experimental|High Loading Dose|150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
9667871|NCT02786498|Experimental|High Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
9667872|NCT02786498|Experimental|Low Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
9667873|NCT02786498|Placebo Comparator|Control Group|Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
9667874|NCT02785016||Stress Urinary Incontinence|Females with stress urinary incontinence, who undergo a tension free surgical sling procedure.
9667875|NCT02782104|Experimental|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
9667876|NCT02775630|Experimental|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
9667877|NCT02775630|No Intervention|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
9667878|NCT02774538|Other|Experimental arm|
9667879|NCT02771275|Experimental|Harpoon Medical Device TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
9667880|NCT02768701|Experimental|Experimental: Single Arm|Subjects will receive a single dose (300 mg/m2) of cyclophosphamide given the day before cycle 1 of pembrolizumab (200 mg), which will be administered every 3 weeks.
9667881|NCT02763384|Experimental|Arm 1: BL-8040 and Nelarabine|"Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6~Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5~Treatment may be repeated every 21 days for up to 4 cycles"
9667882|NCT02748941|Experimental|symptomatic and asymptomatic patients|
9667883|NCT02744612|Experimental|Treatment (Ibrutinib and Brentuximab Vedotin)|Patients receive ibrutinib PO QD on days 1-21 and brentuximab vedotin IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9667884|NCT02742506|Experimental|Brain-damaged patients|Electroencephalography (EEG) will be performed in patients in coma, in a vegetative state or in a minimally conscious state to assess the P300 response after different auditive stimulations
9667885|NCT02742506|Active Comparator|Healthy volunteers|Electroencephalography (EEG) will be performed in healthy participants to assess the P300 response and medial prefrontal cortex activity after different auditive stimulations
9667886|NCT02741128|Experimental|CYD Dengue vaccine group|Subjects will receive 3 doses of CYD dengue vaccine at 0, 6, and 12 months
9667887|NCT02741128|Placebo Comparator|Placebo vaccine group|Subjects will receive 3 doses of placebo (NaCl, 0.9%) vaccine at 0, 6, and 12 months
9667888|NCT02737579|Other|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
9667889|NCT02729116|Experimental|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
9667890|NCT02729116|Active Comparator|Ertapenem group|Ertapenem 1 gm IV every 24 h
9667891|NCT02721134|Other|additional blood tubes|
9667892|NCT02705846||BRCA1 mutation carriers|Men with a known pathogenic germline BRCA1 mutation
9667893|NCT02705846||BRCA2 mutation carriers|Men with a known pathogenic germline BRCA2 mutation
9667894|NCT02705846||BRCA1 controls|Men known not to carry a pathogenic germline BRCA1 mutation
9667895|NCT02705846||BRCA2 controls|Men known not to carry a pathogenic germline BRCA2 mutation
9667896|NCT02683616|Experimental|OSA + T2DM|CPAP treatment
9667897|NCT02683616|Experimental|OSA no T2DM|CPAP treatment
9667898|NCT02683616|No Intervention|T2DM no OSA|Standard care
9667899|NCT02683616|No Intervention|Healthy controls no ÓSA|no intervention
9667900|NCT02676349|Experimental|Arm B|Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy
9667901|NCT02676349|Active Comparator|Arm A|Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy
9667902|NCT02675959|Experimental|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
9667903|NCT02675426|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive Upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will continue on Upadacitinib 15 mg once daily."
9667904|NCT02675426|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive Upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants will continue on Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
9667905|NCT02675426|Experimental|Placebo and Upadacitinib 15 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 15 mg once daily."
9667906|NCT02675426|Experimental|Placebo and Upadacitinib 30 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
9667907|NCT02646748|Experimental|pembrolizumab + itacitinib|"Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors."
9667908|NCT02646748|Experimental|pembrolizumab + INCB050465|"Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.~Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer."
9667909|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
9667910|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
9667911|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
9667912|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667913|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667914|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667915|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667916|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667917|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667918|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1.33 mg/kg)|Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667919|NCT02639546|Experimental|Phase II (Suspension) Cobimetinib (1 mg/kg)|Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
9667920|NCT02635672|Experimental|Dose escalation of VIP152 (BAY 1251152) / PART 1 (Completed)|Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL
9667921|NCT02635672|Experimental|Dose expansion of VIP152 (BAY 1251152) / PART 2|Investigating VIP152 (BAY 1251152) in a dose expansion cohort in patients with solid tumors and aggressive NHL
9667922|NCT02635672|Experimental|Dose escalation of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 3|Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose escalation cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.
9667923|NCT02635672|Experimental|Dose expansion of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 4|Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose expansion cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.
9667924|NCT02632448|Experimental|Part A: LY2880070|Multiple oral doses of LY2880070 during 21-day cycles
9667925|NCT02632448|Experimental|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles
9817406|NCT02098993|Experimental|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
9817407|NCT02098993|No Intervention|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
9817408|NCT02099006|Experimental|Medications|Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.
9817409|NCT02099006|Placebo Comparator|Placebo|The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.
9817410|NCT02099084|Experimental|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
9817411|NCT02099084|Placebo Comparator|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
9817412|NCT02099110|Experimental|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
9817413|NCT02099110|Experimental|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
9817414|NCT02099110|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
9817415|NCT02099110|Experimental|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
9817416|NCT02099110|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
9817417|NCT02099266|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
9817418|NCT02099461|Other|No treatment|Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
9817419|NCT02099461|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
9817420|NCT02099461|Experimental|Denosumab 120 mg|Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
9817421|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
9817422|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
9817423|NCT02099721|Active Comparator|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects receive an ICD/CRT-D implant."
9817424|NCT02099721|No Intervention|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects choose not to receive an ICD/CRT-D implant."
9817425|NCT02099721|Active Comparator|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects receive an ICD/CRT-D implant."
9817426|NCT02099721|No Intervention|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects choose not to receive an ICD/CRT-D implant."
9817427|NCT02099721|Other|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects receive an ICD/CRT-D implant."
9817428|NCT02099721|No Intervention|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects choose not to receive an ICD/CRT-D implant."
9965696|NCT01252121|Other|Systane, Unisol, Hialid|1 drop Systane in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
10114845|NCT04455984||Neoadjuvant chemotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemotherapy followed by curative-intent surgery
9817429|NCT02099786|Experimental|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
9817430|NCT02099786|Experimental|Usual Care|Hearing testing done according to Audiology Clinic protocol
9817431|NCT02099799|Active Comparator|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
9817432|NCT02099799|No Intervention|Usual Care|Verbal instructions and written materials about exercise.
10114846|NCT04456270||Primary care patients with current asthma|Male and female primary care patients aged ≥18 years of age with clinically diagnosed asthma.
9817433|NCT02099838|Experimental|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
9817434|NCT02099838|Placebo Comparator|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
9817435|NCT02099864|Experimental|Treatment (Enzalutamide)|Patients receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo a tumor biopsy of a metastatic site at study entry (prior to initiation of enzalutamide) and after the time of progression. Per the investigator, patients may continue treatment beyond progression.
9817436|NCT02100007|Experimental|ME-344|ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
9817437|NCT02100072|Experimental|Nd:YAG 1440 nm laser|
9667926|NCT02632448|Experimental|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
9667927|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Breast)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
9667928|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Colorectal)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
9817438|NCT02100124|Experimental|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
9817439|NCT02100124|Experimental|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
9817440|NCT02100124|Active Comparator|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
9817441|NCT02100189|Experimental|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
9817442|NCT02100228|Experimental|Apixaban|
9817443|NCT02100228|Active Comparator|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
9817444|NCT02100280|Experimental|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
10114847|NCT04455893|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
9667929|NCT02632448|Experimental|Part B:LY2880070 and Gemcitabine (Ovarian)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
9667930|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Endometrial)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
9667931|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
9817445|NCT02100280|No Intervention|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
9817446|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
9817447|NCT02100410|Experimental|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
9817448|NCT02100410|Experimental|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
9817449|NCT02100410|Experimental|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
9817450|NCT02100475|Experimental|Insulin degludec/liraglutide + Metformin|
9817451|NCT02100475|Active Comparator|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
9667932|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Pancreatic)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
9667933|NCT02631044|Experimental|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
9667934|NCT02631044|Experimental|JCAR017 2-dose schedule (no longer accruing)|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
10114848|NCT04455893|Experimental|Combined 2: Stratified only|Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
10114849|NCT04455672|Experimental|interventional group|patient using two types of splints (3d Anterior Rrepositioning Splint then printed stabilizing splint)
9817452|NCT02100514|Experimental|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
10114850|NCT04455672|Active Comparator|control group|patient using two types of splints (3d printed stabilizing splint then Anterior Rrepositioning Splint)
10114851|NCT04455867||UHN Toronto Rehab|Participants with prediabetes of T2DM undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as per the site's standard protocol (Diabetes Exercise and Healthy Lifestyle Program).
10114852|NCT04455867||Sunnybrook Health Sciences Centre|Participants with prediabetes or T2DM receiving care from an outpatient service at Sunnybrook Health Sciences Centre.
10114853|NCT04455698|Experimental|Remote Telegenetics: TELEPHONE (ARM A)|"Remote Phone Telegenetics:~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - TELEPHONE."
9667935|NCT02625480|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
9667936|NCT02617056||Observational group|Subjects with dementia
9667937|NCT02597660|Active Comparator|Drug: Somatropin|Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
9667938|NCT02597660|Placebo Comparator|Drug: Placebo|Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
9667939|NCT02595281|Experimental|Study arm|
9667940|NCT02592707|Experimental|177Lu-OPS201|177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
9667941|NCT02575339|Experimental|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
9667942|NCT02575339|Experimental|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
9667943|NCT02575339|Active Comparator|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
9667944|NCT02566668||Asthmatic|1 year observational follow-up
9667945|NCT02566668||Non-Asthmatic|1 year observational follow-up
9667946|NCT02543905||Family History Cohort|"Caucasian men with a family history of prostate cancer defined as:~Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years~Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years~Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
9667947|NCT02543905||Black African / Black Caribbean Cohort|"Men of black African or black Caribbean ancestry defined as:~Both parents and all 4 grandparents from that origin."
9667948|NCT02543905||High-risk gene mutation cohort|Men of any ethnicity who have been found to have inherited a gene mutation that increases risk of prostate cancer (gene mutation including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol).
9667949|NCT02542267|Other|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
9667950|NCT02537314|Active Comparator|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
9667951|NCT02537314|Placebo Comparator|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
9667952|NCT02535078|Experimental|Arm 1|Tebentafusp (IMCgp100) with durvalumab (MEDI4736)
9667953|NCT02535078|Experimental|Arm 2|Tebentafusp (IMCgp100) with tremelimumab
9667954|NCT02535078|Experimental|Arm 3|Tebentafusp (IMCgp100) with durvalumab (MEDI4736) and tremelimumab
9667955|NCT02535078|Experimental|Arm 4|Tebentafusp (IMCgp100) (single agent)
9667956|NCT02535078|Experimental|Arm 5|Tebentafusp (IMCgp100) (single agent) subcutaneous injection
9667957|NCT02530034|Experimental|Treatment (Hu8F4)|Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9667958|NCT02523248|Active Comparator|Tonsillectomy|Tonsillectomy with cold steel
9667959|NCT02523248|Active Comparator|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty; using cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
9667960|NCT02522637|Active Comparator|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
9667961|NCT02522637|Experimental|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
9667962|NCT02503527|Other|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
9667963|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
9667964|NCT02499003|Experimental|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
9667965|NCT02498444|Experimental|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
9667966|NCT02498444|Placebo Comparator|Saline|Saline administration via subcutaneous infusion
9667967|NCT02494063||Sentinel lymph node (SLN)|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
9817453|NCT02100514|Placebo Comparator|placebo|
9817454|NCT02100579|Active Comparator|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
9817455|NCT02100579|Placebo Comparator|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
9817456|NCT02100631|Experimental|PXVX0200 in Older Adults|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
9817457|NCT02100631|Placebo Comparator|Placebo in Older Adults|Placebo physiological saline
9817458|NCT02100631|Other|Historical Control: Adults Aged 18-45|This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
9817459|NCT02100644|Experimental|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
9817460|NCT02100657|Experimental|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
9817461|NCT02100670|Experimental|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
9817462|NCT02100670|Experimental|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
9817463|NCT02100670|Experimental|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
9817464|NCT02100670|Placebo Comparator|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
9817465|NCT02100696|Experimental|Cohort 1: Etrolizumab (Open-Label Induction (OLI) Phase)|Participants assigned to this arm will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) for 14 weeks during the induction phase.
9817466|NCT02100696|Placebo Comparator|Cohort 2: Placebo (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind placebo SC injection Q4W for 14 weeks during the induction phase.
9817467|NCT02100696|Experimental|Cohort 2: Etrolizumab (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind etrolizumab 105 mg SC injection Q4W for 14 weeks during the induction phase.
9817468|NCT02100696|Placebo Comparator|Placebo Responders: Placebo (Maintenance Phase)|Participants who received placebo during the induction phase, Cohort 2: Placebo (Double-Blind Induction Phase), and achieve a clinical response with placebo at Week 14 will continue to receive blinded placebo from Week 16 up to Week 66 during the maintenance phase.
9817469|NCT02100696|Placebo Comparator|Etrolizumab Responders: Placebo (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive placebo SC injection Q4W from Week 16 up to Week 66.
9817470|NCT02100696|Experimental|Etrolizumab Responders: Etrolizumab (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive etrolizumab 105 mg SC injection Q4W from Week 16 up to Week 66.
9817471|NCT02100748|Experimental|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
9519361|NCT03287934|Experimental|digital light processing stent|according to the allocation, the experimental group will receive a digital light processing stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
9519362|NCT03287934|Active Comparator|selective laser sintering|according to the allocation, the intervention for the control group will be a selective laser sintering stent after atraumatic extraction of the target tooth for immediately implant placement. the selective laser sintering stent will be adapted and drilling will be done through the stent.
9817472|NCT02100748|Experimental|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
9519363|NCT03287921||mono bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
9817473|NCT02100748|Experimental|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
9817474|NCT02100748|Experimental|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
9817475|NCT02100748|Active Comparator|Morphine|Morphine 4 mg IV Q4H x 48 h
9817476|NCT02100748|Placebo Comparator|Placebo|Placebo (D5W) IV Q4H x 48 h
9826835|NCT02434328|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
9826836|NCT02434471|No Intervention|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
9826837|NCT02434471|Active Comparator|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
9826838|NCT02434497|Experimental|Single Arm|One treatment period for all patients (<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
9826839|NCT02434523|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
9519364|NCT03287921||dual bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
9826840|NCT02434523|Placebo Comparator|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
9817477|NCT02100813|Other|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
9817478|NCT02100813|Active Comparator|Part 2: LEO 43204 x dose|X dose for 2 days treatment
9817479|NCT02100813|Active Comparator|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
9817480|NCT02100813|Placebo Comparator|Part 2: Placebo|Placebo for 2 days treatment
9817481|NCT02100826|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
9817482|NCT02100826|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
9817483|NCT02100839|Experimental|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
9817484|NCT02100839|Placebo Comparator|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
9817485|NCT02100930|Experimental|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
9817486|NCT02100969|Experimental|HIZENTRA ®|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive Hizentra in a minimum of one infusion per week and a maximum of 4 infusions per week. Dose and rate depend on the visit and how each participant tolerates the drug. Max cc per site is 50 cc per site per hour.
9817487|NCT02101008|Other|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
9817488|NCT02101021|Experimental|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
9817489|NCT02101021|Placebo Comparator|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
9817490|NCT02101034|Experimental|Phase I: Dose Level 1|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
9817491|NCT02101034|Experimental|Phase I: Dose Level 2|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
9817492|NCT02101034|Experimental|Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
9817493|NCT02101034|Experimental|Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
9817494|NCT02101034|Experimental|Phase II Arm 3:|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
9817495|NCT02101060|Experimental|exercise|16-week progressive aerobic and resistance exercise training
10114854|NCT04455698|Experimental|Remote Telegenetics: VIDEOCONFERENCING (ARM B)|"Remote Videoconferencing Telegenetics:~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - VIDEOCONFERENCING."
9817496|NCT02101060|No Intervention|control|usual care controls
9817497|NCT02101112|Experimental|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
9817498|NCT02101112|Experimental|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
9817499|NCT02101112|Experimental|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
9817500|NCT02101190|Experimental|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
9817501|NCT02101190|Experimental|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
9826841|NCT02434770|Experimental|BBIBP bOPV Lot 1|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
9817502|NCT02101281|Experimental|Group 1 - rhNGF 20 μg/mL|(first planned dose): drop (35 μL) corresponding to 0.70 μg of rhNGF (recombinant human Nerve Growth Factor) was instilled into each eye twice a day (b.i.d.) every 12±2 h for a total daily dose of 2.8 μg (both eyes), for 28 consecutive days. The total dose was 78.4 μg/28 days.
9817503|NCT02101281|Experimental|Group 2 - rhNGF 4 μg/mL|after completion of Group 1 treatment, one drop (35 μL) corresponding to 0.14 μg of rhNGF (recombinant human Nerve Growth Factor) instilled into each eye b.i.d. every 12±2 h for a total daily dose of 0.56 μg, for 28 consecutive days. Total dose was 15.68 μg/28 days.
9817504|NCT02101294|Experimental|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
9667968|NCT02494063||Control|Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
9817505|NCT02101359|Experimental|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
9817506|NCT02101359|Active Comparator|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~Topical Mydriatic treatments were instilled three times before surgery."
9817507|NCT02101411||clopidogrel|treated with cloopidogrel
9817508|NCT02101411||ticagrelor|treated with ticagrelor
9817509|NCT02101411||cilostazol|treated with clopidogrel+cilostazol
9817510|NCT02101437|Placebo Comparator|control|normal subjects.
9817511|NCT02101437|Active Comparator|clopidogrel|subjects received clopidogrel 75mg qd.
9817512|NCT02101437|Active Comparator|ticagrelor|subjects received ticagrelor 90mg qd.
9817513|NCT02101437|Active Comparator|cilostazol|subjects received cilostazol 100mg bid.
9817514|NCT02101515|Placebo Comparator|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
9817515|NCT02101515|Experimental|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural~Intervention: one additional hour for the second stage of labor~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
9817516|NCT02101554|Experimental|Embeda|One arm, open label, active
9817517|NCT02101918|Experimental|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
9817518|NCT02101983|Experimental|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
9817519|NCT02101983|Active Comparator|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
9817520|NCT02102100|Experimental|Menthol-Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
9826842|NCT02434770|Experimental|BBIBP bOPV Lot 2|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
9965697|NCT01252121|Other|Hialid, Systane, Unisol|1 drop Hialid in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
10114855|NCT04455698|Experimental|USUAL CARE (ARM C)|"Usual Care:~Participants will receive referrals to genetic counseling providers, initiating services on their own. At 6 months, if participants have not sought and received genetic counseling services, they will be offered randomization to ARM A/ARM B."
10114856|NCT04455763|Experimental|SVF|Thumb carpometacarpal injection with adipose-derived SVF combined with splinting
10114857|NCT04455763|Active Comparator|Splint|Thumb carpometacarpal osteoarthrosis treated with splinting only
10114858|NCT04455789|Experimental|conventional mechanical ventilation|routine mechanical ventilation will be adjusted based on conventional mechanical ventilation settings with tidal volume of 8 ml/kg and PEEP level of 5
10114859|NCT04455789|Experimental|mechanical ventilation adjusted according to driving pressure|routine mechanical ventilation adjusted based on driving pressure during lateral position. After patients are put to lateral position incremental increase in PEEP will be applied and the driving pressures will be recorded for each PEEP level and the patients will be ventilated with this PEEP during anesthesia. the other setting will be same with conventional group. tidal volume of 8 ml/kg
10114860|NCT04455880|Active Comparator|GDM with insulin therapy|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
10114861|NCT04455880|Active Comparator|GDM treated with only diet (without any medical therapy)|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
10114862|NCT04455880|Active Comparator|Non-diabetic Controls|Singleton non diabetic healthy pregnancies above 36 gestational weeks
10182464|NCT03773640|Experimental|The study group|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
10188020|NCT03720327|Experimental|Get FIT+|The Get FIT+ intervention, which includes push-only personalized text messages from a health coach.
9965698|NCT01252121|Other|Hialid, Unisol, Systane|1 drop Hialid in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
9817521|NCT02102100|Experimental|Non-Menthol Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
9817522|NCT02102204|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
9817523|NCT02102230|Experimental|CBT-I|Group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
9817524|NCT02102230|Active Comparator|CBT-I-MA|Group Cognitive-Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
9817525|NCT02102230|Placebo Comparator|PC|Desensitization Treatment for Insomnia (DTI)
9817526|NCT02102399|Experimental|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
9817527|NCT02102399|Experimental|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
9817528|NCT02102464|Experimental|LipiFlow|Single 12-minute LipiFlow treatment
9817529|NCT02102464|No Intervention|Untreated Control|Untreated Control (No Intervention)
9817530|NCT02102464|Experimental|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
9817531|NCT02102490|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
9817532|NCT02102724|Experimental|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
9817533|NCT02102724|Placebo Comparator|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
9817534|NCT02102932|Experimental|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
9817535|NCT02102932|Experimental|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
9817536|NCT02102932|Experimental|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
9817537|NCT02102932|Experimental|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
9817538|NCT02103062|Experimental|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
9817539|NCT02103114|Experimental|Anti-thrombin III|
9817540|NCT02103114|Placebo Comparator|Placebo|
9817541|NCT02103127|Experimental|755nm Alexandrite laser with lens array|
9817542|NCT02103153|Experimental|Picosure Laser System|
9817543|NCT02103218|Experimental|Risky sex prevention|education, activities, empowerment, racial pride building
9817544|NCT02103218|Active Comparator|Healthy behaviors|General health education, activities
9817545|NCT02103270|Placebo Comparator|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
9817546|NCT02103270|Active Comparator|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
9817547|NCT02103270|Active Comparator|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
9817548|NCT02103309|Other|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
9817549|NCT02103309|Other|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
9817550|NCT02103439|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
9817551|NCT02103439|Active Comparator|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
9826843|NCT02434770|Active Comparator|BioFarma bOPV|Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
10188021|NCT03720314||IBS|Irritable bowel syndrome patients
9817552|NCT02103478|Experimental|Phase 1 Dose Escalation|Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
9817553|NCT02103478|Experimental|Phase 2 Dose Confirmation|Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
9817554|NCT02103478|Experimental|Phase 2 Fixed-Dose Combination|Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
9817555|NCT02103608|Experimental|Percentage of hair reduction|This is an open label, prospective study to evaluate safety and efficiency of Silk'n Glide on the face. During the study, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment .
9817556|NCT02103816|Experimental|SmartLipo Triplex laser system along with the SideLaze800 hand|
9817557|NCT02103855|Experimental|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
9817558|NCT02104141||Operated Subjects|ROIA Interbody Cage with VerteBRIDGE plating
9817559|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
9817560|NCT02104414|Active Comparator|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
9817561|NCT02104414|Active Comparator|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
9817562|NCT02104414|Placebo Comparator|Normal Saline|30mL Normal Saline
9817563|NCT02104427|Experimental|TG-0054 combined with G-CSF|1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
9817564|NCT02104505|Active Comparator|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
9817565|NCT02104505|Placebo Comparator|Placebo|Safflower oil capsules
9817566|NCT02104557||prevention of pregnancy|Non intervention
9817567|NCT02104557||management of endometriosis-associated pain|Non intervention
9817568|NCT02104583|Experimental|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
9817569|NCT02104583|Experimental|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
9817570|NCT02104583|Placebo Comparator|Placebo|Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
9817571|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
9817572|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
9817573|NCT02104739|Placebo Comparator|Saxagliptin, then Exenatide, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
9817574|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
9817575|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
9817576|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
9817577|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
9817578|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
9817579|NCT02104739|Experimental|Saxagliptin, then Exenatide, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
10114863|NCT04455542||LMND-ALS|The main clinical manifestations were muscle weakness with atrophy and bundle fibrillation, the pyramidal tract sign was relatively mild, and extensive neurogenic damage with CMAP amplitude decreased could be seen in patients with electromyography.
10114864|NCT04455542||UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
10114865|NCT04455542||FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy
10114866|NCT04455711|Placebo Comparator|Remifentanil group|Emerge with continuous infusion of remifentanil 1.5 ng/ml
9817580|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
9817581|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
9817582|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
9817583|NCT02104752|Experimental|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
9817584|NCT02104752|Placebo Comparator|Sugar Pill|Matched placebo, 2 capsules twice daily.
9817585|NCT02104765|Experimental|5 mg LY2951742 Single Dose|5 mg LY2951742 given subcutaneously once
9817586|NCT02104765|Experimental|50 mg LY2951742 Single Dose|50 mg LY2951742 given subcutaneously once
9817587|NCT02104765|Experimental|120 mg LY2951742 Single Dose|120 mg LY2951742 given subcutaneously once
9817588|NCT02104765|Experimental|300 mg LY2951742 Single Dose|300 mg LY2951742 given subcutaneously once
10114867|NCT04455711|Experimental|Lidocaine group|Emerge with continuous infusion of remifentanil 1.5 ng/ml with IV bolus of lidocaine 1.5 mg/kg
9817589|NCT02104765|Experimental|300 mg LY2951742 Multiple Dose|300 mg LY2951742 given subcutaneously once every 4 weeks (Q4W)
9817590|NCT02104765|Placebo Comparator|Placebo Single Dose|Placebo given subcutaneously once
9817591|NCT02104765|Placebo Comparator|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks (Q4W)
9817592|NCT02104804|Experimental|Saxagliptin 5mg|Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
9817593|NCT02104804|Placebo Comparator|Placebo|Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
9817594|NCT02104817|Experimental|EPANOVA|Epanova + statin, once daily
9817595|NCT02104817|Active Comparator|Corn oil|Corn oil + Statin
9817596|NCT02104830|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
9817597|NCT02104830|Experimental|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
9817598|NCT02104830|Active Comparator|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
9817599|NCT02104895|Active Comparator|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
9817600|NCT02104895|Experimental|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
9817601|NCT02104947|Experimental|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
9817602|NCT02105012|Experimental|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
9817603|NCT02105012|Experimental|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
9817604|NCT02105012|Experimental|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
9667969|NCT02487134|Placebo Comparator|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
9817605|NCT02105012|Experimental|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
9817606|NCT02105012|Placebo Comparator|Placebo MDI|Placebo MDI administered as 2 inhalations BID
9817607|NCT02105246|Experimental|Home-based|Referral to a home-based cardiac rehabilitation program (intervention).
9817608|NCT02105246|Active Comparator|Center-based|Referral to a center-based cardiac rehabilitation program (standard of care).
9817609|NCT02105272|Experimental|OPC-1085EL ophthalmic solution|Once daily
9817610|NCT02105272|Active Comparator|Latanoprost ophthalmic solution|Once daily
9817611|NCT02105285|Experimental|OPC-1085EL ophthalmic solution|Once daily
9817612|NCT02105285|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
9817613|NCT02105324|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
9817614|NCT02105324|Experimental|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
9817615|NCT02105415|Active Comparator|Etomidate|weight based dose of 0.15mg/kg
9817616|NCT02105415|Experimental|Ketamine / Propofol Admixture|weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
9817617|NCT02105454|Experimental|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
9817618|NCT02105467|Experimental|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
10114868|NCT04455607|Experimental|experimental group|Random perturbation training
10114869|NCT04455607|Active Comparator|control group|Block perturbation training
10114870|NCT04455568||experimental group|Non-invasive Wearable Device, use ECG Wisdom bracelet
9817619|NCT02105467|Placebo Comparator|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
9817620|NCT02105558|Experimental|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
9817621|NCT02105558|Experimental|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
9817622|NCT02105662|Experimental|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
9817623|NCT02105688|Experimental|Immediate Treatment Arm: Grazoprevir/Elbasvir|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
9817624|NCT02105688|Placebo Comparator|Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir|In Part A, participants receive placebo to MK-5172A once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants received 12 weeks of open-label treatment with the MK-5172A FDC and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
9817625|NCT02105701|Experimental|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
9817626|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
9817627|NCT02105701|Experimental|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
9817628|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
9817629|NCT02105740|Experimental|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
9817630|NCT02105740|Active Comparator|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
9817631|NCT02105948|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
9817632|NCT02105948|Placebo Comparator|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
9817633|NCT02105961|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
9817634|NCT02105961|Experimental|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
9817635|NCT02105961|Experimental|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
9817636|NCT02105974|Experimental|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
9817637|NCT02105974|Experimental|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
9817638|NCT02105987|Experimental|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
9667970|NCT02487134|Active Comparator|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
9817639|NCT02105987|Active Comparator|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
9817640|NCT02106065|Experimental|In-person Education and Skill-Building Rehabilitation (ESBR-i) Condition|Education and Skill-Building Rehabilitation delivered in clinic
9817641|NCT02106065|Experimental|Education and Skill-Building Rehabilitation over Video (ESBR-V) Condition|Education and Skill-Building Rehabilitation delivered via video telehealth.
9817642|NCT02106065|Active Comparator|Usual Care Condition|Usual Care plus supplemental paper education materials
9965699|NCT01252121|Other|Unisol, Systane, Hialid|1 drop Unisol in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
9965700|NCT01252121|Other|Unisol, Hialid, Systane|1 drop Unisol in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
10114871|NCT04455737||Patients with indigo carmine stained specimen|Specimen which underwent pathologic work-up after ex vivo indigo carmine injection into the inferior mesenteric artery after transanal total mesorectal excision.
9817643|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
9817644|NCT02106325|Experimental|Ketamine|IV Ketamine .25mg/kg
9817645|NCT02106325|Placebo Comparator|Diphenhydramine|25mg Diphenhydramine
9817646|NCT02106351|Experimental|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
9817647|NCT02106351|Experimental|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
9817648|NCT02106351|Experimental|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
9817649|NCT02106390|Experimental|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
9817650|NCT02106390|Active Comparator|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
9817651|NCT02106390|Active Comparator|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
9817652|NCT02106403|Experimental|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
9817653|NCT02106403|Active Comparator|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
9817654|NCT02106403|Placebo Comparator|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
9817655|NCT02106442||Sodium Risedronate 75 mg|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking. Participants receive sodium risedronate 75 mg as part of routine medical care.
9817656|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
9817657|NCT02106494|Experimental|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
9817658|NCT02106494|Active Comparator|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
9817659|NCT02106728|Experimental|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
9817660|NCT02106728|Active Comparator|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
9817661|NCT02106832|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
9817662|NCT02106832|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
9817663|NCT02106832|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
9817664|NCT02106832|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
9817665|NCT02106884|Experimental|Arm A|Nab-paclitaxel - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
10114872|NCT04455737||Patients with unstained specimen|Specimen which underwent pathologic work-up after transanal total mesorectal excision without indigo carmine dyeing.
10114873|NCT04455490||Delayed wound healing|Patients with delayed wound healing after Achilles tendon suture who were treated at Peking University Third Hospital
9817666|NCT02106884|Active Comparator|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
9817667|NCT02106910|Experimental|Participants with Barrett's and No History of Ablation|Participants with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE.
10114874|NCT04455555|Experimental|rotigotine treatment group|rotigotine sustained release microspheres therapy by injection
9817668|NCT02106910|Experimental|Participants with Barrett's and a History of Ablation|Participants with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
9817669|NCT02106923|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
9817670|NCT02106923|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
9817671|NCT02106923|Experimental|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
9817672|NCT02106962|Experimental|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
10114875|NCT04455555|Placebo Comparator|placebo comparator|placebo comparator/null microspheres
10114876|NCT04455412|No Intervention|control group|Conventional ICSI procedure was done for first portion of sibling oocytes
10114877|NCT04455412|Experimental|Study group 1|Laser assisted drilling ICSI procedure was done for second portion of sibling oocytes
10188022|NCT03720314||control|healthy controls
9817673|NCT02106962|Experimental|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
9817674|NCT02106975|Active Comparator|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
9817675|NCT02106975|Placebo Comparator|5% Dextrose in Water|50ml every 6 hours for 96 hours
9817676|NCT02107014|Other|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
9817677|NCT02107092|Experimental|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
9817678|NCT02107131|Active Comparator|Monthly Intravitreal ranibizumab 0.3mg|Monthly Intravitreal ranibizumab 0.3mg injections.
9817679|NCT02107131|Active Comparator|PRN Intravitreal ranibizumab 0.3mg|PRN Intravitreal ranibizumab 0.3mg injections.
9817680|NCT02107157|Experimental|755nm Alexandrite laser with cap array|
9817681|NCT02107196|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
9817682|NCT02107196|Placebo Comparator|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
9817683|NCT02107274|Active Comparator|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
9817684|NCT02107274|Placebo Comparator|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
9817685|NCT02107300|Experimental|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
9817686|NCT02107300|Placebo Comparator|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
9817687|NCT02107313|Other|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
9817688|NCT02107313|Other|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
9817689|NCT02107339|Experimental|methadone group|Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
9817690|NCT02107339|Active Comparator|Hydromorphone group|Patients will receive hydromorphone 2 mg at the end of the surgical procedure
9817691|NCT02107443|Experimental|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
9817692|NCT02107443|Active Comparator|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
9817693|NCT02107482|Active Comparator|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
9817694|NCT02107482|Sham Comparator|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
9826844|NCT02434939|Experimental|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
9826845|NCT02434939|Active Comparator|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
9826846|NCT02435069|No Intervention|Pre-operative Baseline Phase|Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
9826847|NCT02435069|Experimental|Dose Response - NS and USP Glycerin - First Intervention|Initial flush used NS or USP Glycerin randomized to treatment sequence. The starting volume and administration frequency for NS was 10mL/kg and glycerin 20 mL administered every other day. The NS dose was titrated in 10 mL increments to achieve continence so as not to exceed 500 mL daily for a child under five years of age and 1000 mL daily for a child over 5 years of age. USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, NS was decreased by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. USP Glycerin was decreased in 5 mL increments to the lowest dose of 5 mL daily. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was be trialed on the alternate therapy and then dropped from the study.
10114878|NCT04455412|Experimental|Study group 2|Laser assisted thinning ICSI procedure was done for Third portion of sibling oocytes
10114879|NCT04455516||repair group|The first operation in these patients was meniscus repair
10114880|NCT04455516||nonfailure group|These patients had a successful first operation
10114881|NCT04455516||failure group|In these patients, the first meniscus repair operation failed
10114882|NCT04455373||orthopedic surgery group|Planned tumor resection
10114883|NCT04455373||traumatic surgery group|Patients with traumatic vascular injury
10114884|NCT04455659|Experimental|TENS + Conventional physical therapy exercise|
10114885|NCT04455659|Active Comparator|conventional physical therapy exercise|
10114886|NCT04455529||ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
10114887|NCT04455399|Other|Intravitreal injection guide|Single use, combination ocular surface caliper to determine point of intravitreal injection and set-depth injection guide to limit injection needle entry into the eye
10114888|NCT04455399|Other|Dual blade eyelid speculum|Dual blade eyelid speculum to open eyelids followed by Castroviejo surgical caliper to measure injection point 3.5 mm from limbus
10114889|NCT04455438|Experimental|SBRT Level 1|The starting dose level will be SBRT 30 Gy in 5 fractions (level 1 or L1).
10114890|NCT04455438|Experimental|SBRT Level 2|If the starting dose is tolerated in the first 5 patients, the next dose will be SBRT 40 Gy in 5 fractions (level 2 or L2)
10114891|NCT04455438|Experimental|SBRT Level 3|If the second dose is tolerated in the next 5 patients, the next dose will be SBRT 50 Gy in 5 fractions (level 3 or L3)
10114892|NCT04455386||stable|The anterior drawer test and/or talar tilt test are negative and the ankle joint is stable.
9664743|NCT05292326|Active Comparator|standard compression band/tourniquet|standard treatment with respect to preventing hemorrhagic complications and implantation site inflammation, the patients will be dressed with a standard compression device/sand bag
10114893|NCT04455386||slightly instable|The anterior drawer test and/or talar tilt test are slightly positive and the ankle joint is partially instable.
10114894|NCT04455386||obviously instable|The anterior drawer test and/or talar tilt test is significantly positive, with significantly instable. The ankle joint is completely instable and can featured with dimple sign.
10114895|NCT04455334|Other|healthy|year 1 study
10114896|NCT04455334|Other|stroke|year 1 study
10114897|NCT04455334|Active Comparator|active control group|year 2 study
9664744|NCT05290883|Experimental|Group A: Yoghurt drink (polar lipid) intervention|
9664745|NCT05288647|Experimental|Group A|Patients treated with four computer-guided sodium hyaluronate injections in superior TMJ space.
9664746|NCT05288647|Active Comparator|Group B|Patients treated with four conventional sodium hyaluronate injections in superior TMJ space.
9664747|NCT05287984|Experimental|ZFCR regimen|Patients aged 65 years or younger who can tolerate FCR： Patients in this group will receive zanubrutinib monotherapy for 12 months, then receive 4 cycles of zanubrutinib, fludarabine, cyclophosphamide and rituximab(ZFCR). Efficacy evaluation and MRD test of peripheral blood and bone marrow were performed at the 17th cycle after 16 cycles to obtain study end point data. Patients with CR/CRi and MRD negative could stop taking zanubrutinib, and other patients could stop taking zanubrutinib or continue treatment. Follow-up and efficacy assessment were conducted every three months.
9664748|NCT05287984|Experimental|ZBR regimen|For patients older than 65 years or who cannot tolerate FCR regimens: Patients in this group will receive zanubrutinib monotherapy for 12 months, then receive 4 cycles of bendamostine and rituximab(BR). Efficacy evaluation and MRD test of peripheral blood and bone marrow were performed at the 17th cycle after 16 cycles to obtain study end point data. Patients with CR/CRi and MRD negative could stop taking zanubrutinib and other patients could stop taking zanubrutinib or continue treatment.
9664749|NCT05287347||Prospective|Blood specimens will be obtained for the model-assigned high risk cohort at each collaborating HCO, over two years of recruitment period. Data of each participant will be electronically followed for observation of outcome measures for up to 3 years.
9664750|NCT05287308|Experimental|AC followed by albumin-bound paclitaxel|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by albumin-bound paclitaxel for 4 cycles.
9664751|NCT05287308|Active Comparator|AC followed by taxanes|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by paclitaxel or docetaxel for 4 cycles.
9664752|NCT05287009|Experimental|ILM nonpeeling|
9664753|NCT05287009|Other|ILM peeling|
9664754|NCT05286853|No Intervention|Cohort 1: Standard of Care Arm|Participants randomized to Cohort 1 will undergo institutional Standard of Care and will not be receiving REACT® . Participants will be followed 32 months at the same time intervals as Cohort 2.
9664755|NCT05286853|Experimental|Cohort 2: 2 REACT® Injections|Participants randomized to Cohort 2 will receive 2 REACT® injections into biopsied and non-biopsied contralateral kidneys 3 months apart (+30 days).
9664756|NCT05286567|Experimental|RGRN-305|1 tablet of 250mg RGRN-305 once daily for 16 weeks
9664757|NCT05286567|Placebo Comparator|Placebo|1 tablet of placebo once daily for 16 weeks
9664758|NCT05286151|Experimental|Children who stutter|Children who stutter
9664759|NCT05286151|Experimental|Children who do not stutter|Children who do not stutter
9664761|NCT05285826|Experimental|V503|Participants will receive a single 0.5 mL intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
9664762|NCT05285826|Placebo Comparator|Placebo|Participants will receive a single 0.5 mL IM injection of placebo at Day 1, Month 2, and Month 6.
9664763|NCT05285800|Experimental|Saddle group|After administration of 12mg of 0.5 % Hyperbaric Bupivacaine intrathecally, Patient is advised to remain in Sitting position for the next 5minutes and then take supine position
9664764|NCT05285800|Active Comparator|Spinal group|After administration of 12mg of 0.5% Hyperbaric Bupivacaine intrathecally, Patient is advised to take Supine position immediately.
9664765|NCT05285722|Other|dental anxiety group|"Children,~Aged 5-15 years~Having dental anxiety but not having negative experiences during dental treatment in childhood or adolescence~Without any systemical and mental diasabilities~Who volunteered to participate in the study and whose parental consent was obtained."
9664766|NCT05285371|Placebo Comparator|CONT Group|CONT group will receive standard traditional intravenous fluid of D50.45% NaCl + 20 mEq/L KCl at 2/3 maintenance rate.
9664767|NCT05285371|Experimental|BOL Group|BOL group will receive intravenous boluses of Lactated Ringer's three times daily at 2/3 maintenance rate.
9664768|NCT05285319|Experimental|Prostate Only (Arm A)|Hypofractionated Intensity modulated radiotherapy (IMRT) to the prostate only to a dose of 60Gy/20fractions (3 Gy per fraction)
9817695|NCT02107599|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
9817696|NCT02107703|Experimental|Abemaciclib + Fulvestrant|150 milligrams (mg) Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
9817697|NCT02107703|Placebo Comparator|Placebo + Fulvestrant|Placebo will be supplied as capsules administered orally every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
9817698|NCT02107703|Experimental|Abemaciclib + Fulvestrant (Endocrine Naïve Cohort)|150 milligrams mg Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
9817699|NCT02107859|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.
9817700|NCT02107898|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
9817701|NCT02107898|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.~≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)~≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
9817702|NCT02108171|Active Comparator|dexmedetomidine|intranasal dexmedetomidine
9817703|NCT02108171|Placebo Comparator|placebo|intranasal saline
9817704|NCT02108223|Active Comparator|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
9817705|NCT02108223|Active Comparator|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
9817706|NCT02108223|Active Comparator|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
9817707|NCT02108262|Experimental|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
9817708|NCT02108262|Experimental|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
9817709|NCT02108262|Placebo Comparator|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
9817710|NCT02108288|Experimental|OPC-1085EL ophthalmic solution|Once daily
9817711|NCT02108288|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
9817712|NCT02108288|Active Comparator|Latanoprost ophthalmic solution|Once daily
9817713|NCT02108457||Proton subjects|
9817714|NCT02108457||IMRT subjects|
9817715|NCT02108522|Experimental|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.~If after the first treatment there is persistent infection, there is an option to receive more treatments. These additional treatments might be with cells from the same donor or another donor whose cells are also thought to be a good match for the patient and effective against their virus. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
9817716|NCT02108600|No Intervention|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
10114898|NCT04455334|Experimental|Error-augmented treadmill training|year 2 study
9817717|NCT02108600|Experimental|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
9817718|NCT02108691|Experimental|Glycin max(L.) Merr. pell extract|
9817719|NCT02108691|Placebo Comparator|Placebo|
9817720|NCT02108821|Experimental|Fecal Microbiome Transplantation|Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour
9817721|NCT02108912|Experimental|Traditional outpatient|Traditional outpatient physical therapy
9817722|NCT02108912|Experimental|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
10114899|NCT04455334|Experimental|Error-augmented concept combined physical therapy group|year 3 study
10114900|NCT04455334|Active Comparator|conventional physical therapy group|year 3 study
10114901|NCT04455581|Experimental|Treatment group|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
9817723|NCT02108951|Experimental|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
9817724|NCT02108977|Experimental|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
9817725|NCT02108977|Active Comparator|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
9817726|NCT02109029|Experimental|Insulin Peglispro (LY2605541)|Part A Cohort 1: (low dose) priming dose (PD) of 2.00 units (U), 0.92 U/hour (U/h) constant infusion of insulin peglispro Part A Cohort 1: (high dose) PD of 8.00 U, 4.50 U/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 1) PD of 4.00 U, 1.84/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 2) PD of 6.0 U, 2.76 U/h constant IV infusion of insulin peglispro Part B Insulin Peglispro: PD of 6.00 U, 2.76 constant IV infusion of insulin peglispro and a constant infusion of 6 pico moles per kilogram per minute (pmol/kg/min). IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
9817727|NCT02109029|Active Comparator|Human Insulin|Constant IV infusion ( 6 pico moles per kilogram perminute [pmol/kg/min]) of human insulin for up to 36 hours. IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
9817728|NCT02109042|Experimental|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
9817729|NCT02109107|Experimental|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
9817730|NCT02109133|Experimental|Deep neuromuscular blockade|Deep neuromuscular blockade
9817731|NCT02109133|Active Comparator|moderate neuromuscular blockade|moderate neuromuscular blockade
9817732|NCT02109159|Experimental|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
9817733|NCT02109159|Active Comparator|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
9817734|NCT02109419||All participants|All participants, including control, mild cognitive impairment, and dementia.
9817735|NCT02109432|Other|Pedal Desk|"Participants will complete three 2-week conditions in the following order:~Self-directed Pedal Desk~Facilitated Pedal Desk~Facilitated Pedal Desk with Pedometer"
9817736|NCT02109445|Experimental|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
9817737|NCT02109445|Experimental|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
9817738|NCT02109445|Active Comparator|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
9817739|NCT02109458|Experimental|Assessing peripheral pulmonary nodules|To evaluate the feasibility and safety of a procedure path including convex Endobronchial Ultrasound (EBUS) lymph node sampling, navigation guided bronchoscopy (NB) and navigation guided transthoracic needle aspiration (N-TTNA).
9817740|NCT02109484|Experimental|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
9817741|NCT02109484|Placebo Comparator|Cohort A Placebo|Cohort A toddlers (24-35 mo)
10114902|NCT04455360|Experimental|EMDR R-TEP intervention|Participants will receive a minimum of 2 and a maximum of 8 online EMDR R-TEP sessions, starting within 3-months of hospital discharge. Sessions will be delivered online by experienced, suitably trained and registered psychological practitioners.
10114903|NCT04455360|No Intervention|Standard care|Patients will receive standard post-hospital discharge care.
10114904|NCT04455594|Experimental|Almonertinib|Almonertinib 110mg QD
10114905|NCT04455594|Active Comparator|Investigator-choice therapy (Erlotinib or Chemotherapy)|Erlotinib 150mg QD or Cisplatin(75mg/m2) or Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
9817742|NCT02109484|Experimental|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
9817743|NCT02109484|Experimental|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
9817744|NCT02109484|Placebo Comparator|Cohort B placebo|Cohort B infants aged 6 to < 8 weeks receiving placebo
9817745|NCT02109484|Experimental|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
9817746|NCT02109484|Experimental|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
9817747|NCT02109484|Experimental|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
9817748|NCT02109497|Other|Caffeine Dosing|Single dose of caffeine 100 mg administered
10114906|NCT04455256||recurrent pregnancy loss group|Women between the ages of 18 and 45 who had a history of miscarriage under 3 weeks and above 22 weeks were included in this group.
10114907|NCT04455256||women who had healthy birth|Women between the ages of 18-45 who have not had a history of pregnancy loss and who have had at least one healthy birth and no known chronic diseases are included in this group.
10114908|NCT04455191|Experimental|Thawing Embryos in Advance|Thawing embryos one day in advance (16:00), 18h before embryos transfer (10:00).
9817749|NCT02109562|Experimental|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
9817750|NCT02109562|Experimental|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
9817751|NCT02109562|Placebo Comparator|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
9817752|NCT02109640|Experimental|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
9817753|NCT02109640|Active Comparator|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
10114909|NCT04455191|Experimental|Thawing Embryos on the Day of Transfer|Thawing embryos on the day of transfer (8:00), 2h before embryos transfer (10:00).
10114910|NCT04455958|Experimental|Group I (lopinavir/ritonavir)|Patients receive lopinavir/ritonavir PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
9817754|NCT02109731|Experimental|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
9817755|NCT02109939|Active Comparator|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
9817756|NCT02109939|Placebo Comparator|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm until after week 12.
9817757|NCT02110095|Experimental|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
9817758|NCT02110108|Experimental|Revlite Laser System- Single Wavelength|Revlite Laser System- 1064nm wavelength will be used on half of the face.
9817759|NCT02110108|Experimental|Revlite Laser System- Dual Wavelength|Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.
9817760|NCT02110121|Experimental|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
9817761|NCT02110121|Experimental|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
9817762|NCT02110147|Experimental|Uridine Triacetate to Replace Uridine|Replacement therapy for oral uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. The starting dose of uridine triacetate will be 60 mg/kg/day which may be escalated to 300 mg/kg/day of oral uridine triacetate. The dose may be given once a day or as equally divided doses twice a day.
9817763|NCT02110225|Experimental|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
9817764|NCT02110225|Experimental|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
9817765|NCT02110225|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
9817766|NCT02110238|Active Comparator|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
9817767|NCT02110238|Experimental|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
9817768|NCT02110264|Experimental|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
9817769|NCT02110264|Experimental|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
9817770|NCT02110264|Active Comparator|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
9817771|NCT02110381|Active Comparator|Device Guided Breathing/Combination Therapy|Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
9817772|NCT02110381|Active Comparator|Isometric Hand Grip/Combination Therapy|Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
9817773|NCT02110485|Experimental|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
10114911|NCT04455958|Placebo Comparator|Group II (placebo)|Patients receive placebo PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
9664769|NCT05285319|Experimental|Prostate and Pelvic Lymph Nodes (Arm B)|Hypofractionated Intensity modulated radiotherapy (IMRT) with elective pelvic nodes irradiation up to 44Gy/20 fractions (2.2 Gy per fraction) with a Simultaneous Integrated Boost (SIB) to the prostate to a dose of 60Gy/20fractions (3 Gy per fraction)
9817774|NCT02110485|No Intervention|Standard Consultation|Patients and their caregivers will receive standard consultation alone
9817775|NCT02110693|Other|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
9817776|NCT02110706|Placebo Comparator|Placebo|The placebo group will receive a vehicle control infusion
9817777|NCT02110706|Experimental|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
9817778|NCT02110732|Active Comparator|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
9817779|NCT02110732|Placebo Comparator|Crystalline cellulose|Crystalline cellulose
9817780|NCT02110758||Pilot Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at pilot practice in southeastern Pennsylvania
9817781|NCT02110758||Comparison Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at comparison practice in southeastern Pennsylvania
9817782|NCT02110758||Pilot Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology pilot practice in southeastern Pennsylvania
9817783|NCT02110758||Comparison Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology comparison practice in southeastern Pennsylvania
9817784|NCT02110758||Pilot Practices Quality Measures Cohort|Patients with a new diagnosis of cancer in the past two years
9817785|NCT02110901|Active Comparator|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
9817786|NCT02110901|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
9817787|NCT02111083|Active Comparator|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).
9667971|NCT02487108|Placebo Comparator|Placebo|Participants will receive placebo matching to TV46763 (hydrocodone bitartrate/acetaminophen) immediate release (IR) tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
9667972|NCT02487108|Experimental|TV-46763 5.0 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 5.0 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
9667973|NCT02487108|Experimental|TV-46763 7.5 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 7.5 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
9667974|NCT02487108|Experimental|TV-46763 10.0 mg/325 mg|Participants will receive TV46763 (hydrocodone bitartrate/acetaminophen) 10.0 mg/325 mg IR tablets for 48 hours (every 4 to 6 hours) on Days 1, 2, and 3 during the inpatient treatment period. Participants will continue to take the same treatment daily, every 4 to 6 hours after discharge on Day 3, over a 10-day (±1 day) outpatient treatment period.
9667975|NCT02480374|Experimental|Single Arm|
9667976|NCT02467374|Active Comparator|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
9667977|NCT02467374|Active Comparator|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
9667978|NCT02455557|Experimental|Treatment (SurVaxM, temozolomide)|Patients receive the first priming dose of SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC within 7-28 days after completion of chemoradiation. Treatment repeats every 2 weeks for a total of 4 doses in the vaccine priming phase and then every 12 weeks during the adjuvant phase in the absence of disease progression or unacceptable toxicity. Patients also receive standard adjuvant temozolomide PO or IV on days 1-5. Treatment repeats every 28 days for 6 courses or more (at the discretion of the investigator) in the absence of disease progression or unacceptable toxicity. Patients may then receive maintenance SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC every 12 weeks in the absence of disease progression or unacceptable toxicity.
9667979|NCT02455479|Other|Cohort 1: 100µg|Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
9667980|NCT02455479|Other|Cohort 2: 316 µg|Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
9667981|NCT02455479|Other|Cohort 3: 1000µg|Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
9667982|NCT02455141|Active Comparator|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
9667983|NCT02455141|Experimental|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
9667984|NCT02447692|Active Comparator|PSV ventilation strategy|The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
9667985|NCT02447692|Active Comparator|PAV+ ventilation strategy|The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
9667986|NCT02441751||bleeding|intraoperative blood loss > 500 ml
9667987|NCT02441751||no bleeding|intraoperative blood loss < 500 ml
9667988|NCT02439385|Experimental|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
9667989|NCT02435849|Experimental|Single dose of CTL019|Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).
9667990|NCT02431091|Experimental|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.~Optical Coherence Tomography is performed in all definite cases"
9667991|NCT02431091|Active Comparator|Control|"Patients with normal response on both the screening questions and all the cognitive screening tests.~Optical Coherence Tomography is performed in matched control A patients"
9667992|NCT02419664|Experimental|Ga-68 DOTATOC PET in pituitary adenomas|"To give Ga-68 DOTATOC in pituitary patients doing PET/CT~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease."
9667993|NCT02405169|Experimental|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
9667994|NCT02405169|Active Comparator|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
9667995|NCT02402439|Experimental|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
9667996|NCT02401789|Experimental|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
9667997|NCT02401789|No Intervention|control- natural healing|
9817788|NCT02111083|Experimental|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).
9817789|NCT02111096|Experimental|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
9817790|NCT02111096|Active Comparator|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
9817791|NCT02111096|Placebo Comparator|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
9817792|NCT02111174|Experimental|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
9817793|NCT02111174|Sham Comparator|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
9817794|NCT02111187|Active Comparator|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
9817795|NCT02111187|No Intervention|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
9817796|NCT02111200|Active Comparator|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
9817797|NCT02111200|Active Comparator|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
9817798|NCT02111200|Active Comparator|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
9817799|NCT02111213|Active Comparator|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
9817800|NCT02111213|Experimental|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
9817801|NCT02111252|Experimental|TAK-850 0.5 mL|A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.
9817802|NCT02111369|Experimental|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
9817803|NCT02111447|Active Comparator|Sevoflurane, propofol, Nasal oxygen|After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
9817804|NCT02111447|Active Comparator|Sevoflurane, Propofol, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
9817805|NCT02111447|Active Comparator|Sevoflurane, sevoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
9817806|NCT02111447|Active Comparator|Sevoflurane, isoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
9817807|NCT02111564|Experimental|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
9817808|NCT02111564|Placebo Comparator|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
9817809|NCT02111577|Experimental|DCVAC/PCa with standard of care chemotherapy|Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)
9817810|NCT02111577|Placebo Comparator|Placebo with standard of care chemotherapy|Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator
9817811|NCT02111603|Other|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
9817812|NCT02111746|Experimental|Exparel®|Patients in this group will receive will receive the study drug [bupivacaine liposomal injectable suspension (Exparel®)] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
9817813|NCT02111746|Active Comparator|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
9667998|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
9667999|NCT02393690|Experimental|Arm I (selumetinib, iodine I-131)|Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.
9668000|NCT02393690|Active Comparator|Arm II (placebo, iodine I-131)|Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
9668001|NCT02387996|Experimental|Nivolumab|Nivolumab intravenous infusion as specified
9668002|NCT02386800|Experimental|ruxolitinib monotherapy|ruxolitinib monotherapy. Patients are to use the study treatment based on the parent protocol.
9668003|NCT02386800|Experimental|combination of ruxolitinib + panobinostat|combination of ruxolitinib and panobinostat. Patients are to use the study treatment based on the parent protocol.
9668004|NCT02369731||Translarna|Participants with nmDMD receiving Translarna will be followed for at least 5 years from their date of enrollment, or until participant withdrawal of consent or death, whichever occurs first.
9668005|NCT02363010|Active Comparator|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
9668006|NCT02363010|Experimental|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
9668007|NCT02363010|Experimental|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
9668008|NCT02362997|Experimental|Diffuse large B cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
9668009|NCT02362997|Experimental|Classical Hodgkin lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
9668010|NCT02362997|Experimental|Peripheral T cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
9668011|NCT02352129|Experimental|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
9668012|NCT02352129|Active Comparator|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
9668013|NCT02351856|Experimental|ARRY-371797|
9668014|NCT02349386|Experimental|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
9668015|NCT02349386|Experimental|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
9668016|NCT02349386|Experimental|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
9668017|NCT02349386|Placebo Comparator|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
9668018|NCT02337985|Experimental|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
9693938|NCT04794582|Active Comparator|ProGrip® Mesh reinforcement|Once the closure has been completed in 2 muscle-aponeurotic planes with continuous synthetic suture (Monomax® USP 0), the closure will be completed by placing the ProGrip® macroporous polypropylene monofilament mesh in supra-aponeurotic position using the surface with the polylactic acid microgrips, which act as Velcro, in direct contact with the superficial aponeurotic plane constituted by the aponeuroses of the greater oblique muscle and the crescentic line of the anterior rectus abdominis muscle. The polylactic acid microgrips provide immediate fixation, making additional fixation with stitches unnecessary, which makes the technique very easy to use and systematize among the different surgeons of the transplant team. The procedure is completed with the placement of a low caliber round Jackson-Pratt subcutaneous drain (10F) connected to a vacuum system that will be removed on post-transplant day 2 or 3
9693939|NCT04794582|No Intervention|Monomax® USP 0 2 planes closure|The control group will proceed according to standard clinical practice with closure using the technique in 2 muscle-aponeurotic planes with very long-term (3 months) absorbable synthetic continuous suture of poly(4-hydroxybutyrate), monofilament, elastic (Monomax® USP 0) according to the small-bites technique. In order to achieve masking of the participating subject, a small-bore (10F) Jackson-Pratt drain connected to a vacuum system will be placed in the subcutaneous space at the end of the procedure in a manner similar to the intervention group. In both treatment groups, the subcutaneous drain will be removed on post-transplant day 2 or 3.
9693940|NCT04794725|Other|Blood Sampling|blood samples from venepuncture (10mL)
9693941|NCT04794855||preganant women|observation from 6-8 weeks.
9693942|NCT04794634|Experimental|Alzheimer Disease|
9693943|NCT04794634|Experimental|Lewy body disease|
9693944|NCT04794634|Active Comparator|healthy patient|
9693945|NCT04794868||Culprit vessel of acute coronary syndrome|Culprit vessel of acute coronary syndrome
9693946|NCT04794868||Non-culprit vessel of acute coronary syndrome|Non-culprit vessel of acute coronary syndrome
9693947|NCT04794452|Active Comparator|Battery operated toothbrush|battery operated toothbrush
9668019|NCT02328014|Experimental|Dose Escalation and Expansion|"The acalabrutinib dose will be fixed and the ACP-319 dose will be escalated in each of three cohorts, and each cohort will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.~Expansion groups of up to 12 subjects for Germinal center B-cell (GCB) DLBCL and Non-GCB DLBCL to take a fixed dose of acalabrutinib and ACP-319. Each disease group will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals."
9668020|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
10114912|NCT04455165||RVAo MITAVA|Patient operated since 2009 for aortic valve replacement through right anterior minithoracotomy approch in Dijon Burgundy University Hospital
10114913|NCT04455971||OM Group|People who participate in the practice of orgasmic meditation (OM)
10114914|NCT04455321|Active Comparator|Vicryl|Single layer locked uterine closure with vicryl suture material
9668024|NCT02308241|Experimental|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
9668025|NCT02281500|Experimental|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
9668026|NCT02281175|No Intervention|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
9668027|NCT02281175|Active Comparator|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
9668028|NCT02281175|Experimental|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
9668029|NCT02274155|Experimental|Group 1|Anti-OX40 antibody administration 3 weeks prior to surgical resection
9668030|NCT02274155|Experimental|Group 2|Anti-OX40 antibody administration 2 weeks prior to surgical resection
9668031|NCT02274155|Experimental|Group 3|Anti-OX40 antibody administration 1 week prior to surgical resection
9668032|NCT02257580|Experimental|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
9668033|NCT02257580|Placebo Comparator|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
9668034|NCT02243020|Experimental|Vagus Nerve Stimulation (VNS) + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions.
9668035|NCT02243020|Active Comparator|Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
9668036|NCT02229344||Newly Diagnosed Moderate to Severe Ulcerative Colitis|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
9668037|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
9668038|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
9668039|NCT02188095||Excia T®|
9668040|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Follicular Lymphoma subjects
9668041|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive Follicular Lymphoma subjects
9668042|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
9668043|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
9668044|NCT02180711|Experimental|Part 3: acalabrutinib Regimen 1|acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
9668045|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
10114915|NCT04455321|Experimental|rapide vicryl|Single layer locked uterine closure with rapide vicryl suture material
10114916|NCT04455048|Experimental|Intervention Group|A single-session manipulation with a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied each week for two weeks.
9668048|NCT02163356|Experimental|Primary therapy|Fenretinide/LXS oral powder 1500 mg/m2/day for 7 days plus ketoconazole 6 mg/kg/day for 7 days plus single dose vincristine (dose escalating) given on day 3. Starting dose of vincristine is 0.75 mg/m2/dose. Followed by 14 days of rest.
9693948|NCT04794452|Active Comparator|Manual toothbrush|Manual toothbrush
9693949|NCT04794426|Active Comparator|control group|The group that have caries in primary molars and treat them with Hall Technique
10114917|NCT04455048|Sham Comparator|Control Group|A sham manipulation without a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied.
10114918|NCT04455074|Experimental|PD patients with motor fluctuations|FN scale is an autoquestionnaire consisting of 20 questions, to be answered in On-med and OFF-med condition
10114919|NCT04455126|Experimental|Preservative-free tafluprost|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
10114920|NCT04455230|Experimental|Participants who have received gene therapy vector (FLT190)|
10114921|NCT04455113||Normo-phosphatemia|238 patients included in this group. Phosphorus level >2.5 mg/dl
10114922|NCT04455113||Hypophosphatemia|79 patients included in this group. Phosphorus level <2.5 mg/dl
10114923|NCT04455308|Experimental|Subjects with chilblains|
10114924|NCT04455308|Active Comparator|Subjects without chilblains|
10114925|NCT04454983|Experimental|Lipiflow - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
10114926|NCT04454983|Experimental|iLux - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
10114927|NCT04455269|Experimental|Full-Mouth Erythritol Powder Air-polishing Therapy (FM-EPAPT)|"The quadrants allocated to FM-EPAPT underwent the following steps:~Decontamination of soft tissues with air-polishing and erythritol powder;~Supra-gingival removal biofilm with air-polishing and erythritol powder;~Sub-gingival removal of biofilm with air-polishing and erythritol;~Calculus removal with a piezoceramic scaler."
10114928|NCT04455269|Active Comparator|Ultrasonic debridement and abrasive paste (US+P)|"The quadrants allocated to US+P treatment underwent the following steps:~Full-mouth ultrasonic debridement with piezoceramic scaler;~Plaque removal and polishing with soft rubber cup and low-RDA polishing paste"
10114929|NCT04455035|Active Comparator|Retrospective Group(Control)|
10114930|NCT04455035|Experimental|Prospective Group|
10114931|NCT04455204||non-pregnant women (group 1)|20 non-pregnant women who serve as a control group (group 1)
10114932|NCT04455204||pregnant women (group 2)|20 pregnant women with normal pregnancy at their third trimesters (group 2)
10114933|NCT04455204||pregnant women with Preeclampsia (group 3)|20 pregnant women with Preeclampsia in their third trimester (group 3) will be screened to fit the inclusion and exclusion criteria.
10114934|NCT04454996|Experimental|Non-erosive reflux disease test group|
10114935|NCT04454996|Placebo Comparator|Non-erosive reflux disease control group|
10114936|NCT04454996|Experimental|Diarrhea-type irritable bowel syndrome test group|
10114937|NCT04454996|Placebo Comparator|Control group with diarrheal irritable bowel syndrome|
10114938|NCT04454996|No Intervention|Healthy control group|
10114939|NCT04455087||before intervention|1000 patients befor sensitization
10114940|NCT04454736|Experimental|SBGmentdis|Children and adolescents with mental disorders at the Department of Child and Adolescents Psychiatry in Salzburg, Austria
10114941|NCT04454736|Experimental|SBGhealthy|Healthy children and adolescents from schools in Salzburg, Austria
10114942|NCT04454736|Experimental|VIEhealthy|Members from the Vienna Boys Choir, Austria
10114943|NCT04454944|No Intervention|Control|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. Participants in the control arm will receive no other intervention.
9668049|NCT02146924|Experimental|Arm I (cellular immunotherapy closed to accrual January 2019)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
10114944|NCT04454944|Experimental|No subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm will receive an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
10114945|NCT04454944|Experimental|Subsidy, no distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas (LPG) purchases.
10114946|NCT04454944|Experimental|Subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas) (LPG) purchases an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
10114947|NCT04454710|Active Comparator|Real Pulsed Radiofrequency|The participant will receive real pulsed radiofrequency for 2 minutes at a frequency of 2 pulses per second (2Hz) while lie in the supine position with their leg of interest partially flexed about 45 degrees and externally rotated. The full procedure will take eight minutes, composed of four sessions of 2 minutes in which the temperature was maintained below 42°C.
10114948|NCT04454710|Sham Comparator|Sham Pulsed Radiofrequency|Identical to the real pulsed radiofrequency, except the participants will only receive the initial 2 seconds of ramp-up, after which the device will switch-off for the rest of the session and will turn-on again at the end of the session.
10114949|NCT04454762|Experimental|Cabozantinib|40 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 20 mg daily.
10114950|NCT04455243|Experimental|Intervention group|
9668050|NCT02146924|Active Comparator|Arm II (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells after 28 days.
9668051|NCT02138734|Experimental|N-803+BCG|(Phase Ib and IIb) for BCG-naive patients
9668052|NCT02138734|Active Comparator|BCG alone|(Phase IIb) for BCG-naive patients
9668053|NCT02114372||CogState Brief Battery|Enrolled participants will be randomized in a balanced manner to CogState brief battery in both the Main Study and the SubStudy. CogState consists of four tasks that respectively measure the functions of attention, processing speed, visual learning, and working memory. The CogState Brief Battery is an approximately 15 minute computerized battery with demonstrated reliability, validity, and short term stability, that was developed expressly for maximal sensitivity to detect change. CogState can be administered via the internet or on a stand-alone computer and is available in over 50 languages.
9693950|NCT04794426|Experimental|experimental group|The group that have caries in primary molars and treat them with Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC.
10114951|NCT04455243|Placebo Comparator|Control group|
10114952|NCT04455009|Experimental|100mg Caffeine Formula|10kcal drink containing a total of 100 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
9817814|NCT02111772|Experimental|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
9817815|NCT02111772|Active Comparator|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
9817816|NCT02111785|Active Comparator|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
9817817|NCT02111785|Experimental|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
9817818|NCT02111785|Other|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
9817819|NCT02111785|Other|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
9817820|NCT02111798|Placebo Comparator|Placebo/Abstinence Initiation|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
9817821|NCT02111798|Active Comparator|Bupropion XL/Abstinence Initiation|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
9817822|NCT02111798|Placebo Comparator|Placebo/Relapse Prevention|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
9817823|NCT02111798|Active Comparator|Bupropion XL/Relapse Prevention|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
9817824|NCT02111811|Experimental|Be Well At Work intervention + IC|CBT based intervention focused on work productivity plus integrated care as usual
9817825|NCT02111811|No Intervention|Integrated Care Only|usual care group (Behavioral Health lab care at the PVAMC)
9817826|NCT02111863|Experimental|Lymphocyte Depleting Prep Regimen|Patients will receive a lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of 4-1BB selected tumor infiltrating lymphocytes (TIL) plus IV aldesleukin.
9817827|NCT02111980|Experimental|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
9817828|NCT02111993|Active Comparator|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
9817829|NCT02111993|Active Comparator|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
9817830|NCT02112045|Experimental|Experimental: Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.~HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0"
9817831|NCT02112045|Active Comparator|Control: High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0."
9817832|NCT02112370|Placebo Comparator|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
9817833|NCT02112370|Experimental|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
9817834|NCT02112448|Active Comparator|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
10114953|NCT04455009|Experimental|140mg Caffeine Formula|10kcal drink containing a total of 140 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
10114954|NCT04455009|Placebo Comparator|Placebo Formula|non-caloric/non-caffeinated drink
9817835|NCT02112448|Active Comparator|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
9817836|NCT02112838|Active Comparator|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
9817837|NCT02112838|Active Comparator|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
10188023|NCT03720301|Experimental|Treatment|Study arm who will receive pre operative and intraoperative treatments intended to effect POST severity.
10188024|NCT03720301|Sham Comparator|Sham|Sham are who will receive a preoperative treatment not intended to effect POST outcomes.
9817838|NCT02112838|Placebo Comparator|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
9817839|NCT02112877|Experimental|VICI Stent Implantation - Feasibility|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
9817840|NCT02112877|Experimental|VICI Stent Implantation - Pivotal|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
9817841|NCT02112994|Experimental|Sebelipase Alfa|Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
9817842|NCT02113007|Experimental|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
9817843|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
9817844|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
9817845|NCT02113189|Experimental|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
9817846|NCT02113189|Experimental|Individualized walking program|This group will receive a customized walking program.
9817847|NCT02113189|Experimental|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
9817848|NCT02113241|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
9817849|NCT02113241|Placebo Comparator|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
9817850|NCT02113410|Experimental|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga attended twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
9817851|NCT02113410|Active Comparator|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
9817852|NCT02113436|Experimental|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
9817853|NCT02113436|Active Comparator|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
9817854|NCT02113449|Experimental|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
9817855|NCT02113579|Experimental|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
9817856|NCT02113579|Placebo Comparator|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
9817857|NCT02113956|Experimental|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
9817858|NCT02113956|No Intervention|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
9817859|NCT02114151|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
9817860|NCT02114164|Active Comparator|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
9817861|NCT02114164|Active Comparator|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
9817862|NCT02114177|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
9817863|NCT02114177|Experimental|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
9817864|NCT02114203|Experimental|cohort 1 PF-04447943|
9817865|NCT02114203|Experimental|cohort 2 PF-04447943|
9817866|NCT02114203|Placebo Comparator|placebo comparator|
9817867|NCT02114203|Experimental|optional cohort of PF-04447943|
9817868|NCT02114216|Sham Comparator|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
9817869|NCT02114216|Active Comparator|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
9817870|NCT02114216|Active Comparator|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
9817871|NCT02114268|Experimental|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
9817872|NCT02114268|Experimental|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
9817873|NCT02114268|Experimental|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
9817874|NCT02114268|Experimental|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
9817875|NCT02114268|Experimental|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
9817876|NCT02114268|Placebo Comparator|Placebo|Participants received placebo on Day 1.
9817877|NCT02114307|Active Comparator|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
9817878|NCT02114307|Sham Comparator|REVITIVE IX: sham device|Trial participants will receive a sham device
9817879|NCT02114385|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
9817880|NCT02114385|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
9817881|NCT02114515|Other|Usual Care|"Hospital usual care~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge."
9817882|NCT02114515|Experimental|Usual Care + PArTNER|"Navigator intervention: (Community health worker, peer-led telephone support line, usual care)~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge.~Community health worker: The community health worker provides social support, literacy appropriate education, and acts as a conduit between the patient and the patient's medical team~Peer-led telephone support line: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team."
9817883|NCT02114606|Experimental|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.
9817884|NCT02114684|Active Comparator|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
9817885|NCT02114684|Active Comparator|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
9817886|NCT02114814|Experimental|Intervention group|Diabetes self-management and family support
9817887|NCT02114814|Active Comparator|Attention control group|General health information
9817888|NCT02114879|Active Comparator|Standard of Care Rehabilitation|
9817889|NCT02114879|Experimental|Enhanced Medical Rehabilitation|
9817890|NCT02114892|Experimental|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
9817891|NCT02114892|Placebo Comparator|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
9817892|NCT02114931|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
10114955|NCT04454749||Stimulated cycles|Ovarian stimulation will be performed by standard protocols. Stimulation medication dosage will be individualised prior to stimulation start according to the ovarian reserve parameters and during ovarian stimulation according to the ovarian response and the measured levels of E2 and progesterone (P4), in order to avoid progesterone elevation during late follicular phase. Final oocyte maturation will be achieved by administration of either 10.000 IU of hCG, 0.3 mg of GnRH agonist (Triptorelin) or dual trigger (hCG and GnRH-analogue), as soon as ≥ 3 follicles ≥ 17 mm are present. Oocyte retrieval will be carried out 36 hours after administration of the trigger. Embryos will undergo PGT-A at blastocyst stage and be vitrified thereafter.
10182465|NCT03773640|Active Comparator|The control group|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
10188025|NCT03720288|Experimental|Acetazolamide|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the acetazolamide group, he / she will start using the adjuvant medication as acetazolamide drug capsule at the daily dose of 250 mg / day (oral) during the first three days of treatment.
9817893|NCT02115048|Active Comparator|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
9817894|NCT02115048|Experimental|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
9817895|NCT02115113|Experimental|Group A (Tacrolimus Elimination Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
9817896|NCT02115113|Active Comparator|Group B (Tacrolimus Minimization Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
9817897|NCT02115139|Experimental|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
9817898|NCT02115256|Active Comparator|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
9817899|NCT02115256|Active Comparator|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
9817900|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
9826848|NCT02435069|Experimental|NS and USP Glycerin - Effectiveness - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they achieved continence on optimal dosing with minimal side effects.This arm evaluated the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
9826849|NCT02435277|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
9826850|NCT02435277|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
9826851|NCT02435277|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
9826852|NCT02435277|Active Comparator|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
9826853|NCT02435381|Placebo Comparator|Placebo|Participants will receive placebo from days 2- 4.
9826854|NCT02435381|Active Comparator|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
9826855|NCT02435511|No Intervention|Control arm|The control group will receive usual care, no HealtheRx.
9826856|NCT02435511|Experimental|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
9826857|NCT02435524|Experimental|A&T Intervention Communes|
9826858|NCT02435524|No Intervention|Control Communes|
9826859|NCT02435680|Experimental|Arm 1: MCS110+carboplatin+gemcitabine|MCS110+carboplatin+gemcitabine
9826860|NCT02435680|Active Comparator|Arm 2: carboplatin+gemcitabine|carboplatin+gemcitabine
10188026|NCT03720288|Experimental|Placebo|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.
9693951|NCT04794309|Experimental|Experimental Group|The participants will receive circuit training exercise and dietary intervention.
9693952|NCT04794309|Active Comparator|Control group|The participants will be only involved in dietary intervention.
9693953|NCT04794348|Active Comparator|Fresh Frozen Plasma (FFP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL of fresh frozen plasma. After completion of warfarin dosing, approximately 810 mL of fresh frozen plasma will be intravenously administered to the subject.
9693954|NCT04794348|Experimental|Freeze Dried Plasma (FDP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL, that will be manufactured into freeze dried plasma units. After completion of warfarin dosing, approximately 810 mL of freeze dried plasma will be intravenously administered to the subject.
9693955|NCT04794244|Experimental|Experimental|group in which the experimental group training program is applied
9693956|NCT04794244|No Intervention|No Intervention|group without control group training program
9693957|NCT04794400|Experimental|Intervention|An additional oxygen mask was applied for 30 minutes, in patients with ongoing HFNC treatment.
9693958|NCT04794231|Active Comparator|Standard dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
9693959|NCT04794231|Active Comparator|Chlorhexidine gluconate -impregnated dressing group|Patients were randomly assigned to one of two dressings, both of which were being actively used as part of standard care.
9693960|NCT04794413|Experimental|Pimavanserin|All participants will receive pimavanserin 17mg once daily for 1 week and, if the tics are deemed to be inadequately controlled then increase to 34 mg once daily, taken orally as two 17 mg tablets once daily.
9693961|NCT04794504|Experimental|Botox Injection Group|Two weeks pre-operatively, patients in the Botox injection group will receive intramuscular injections of Botox totaling 100U bilaterally (50U/side). 10 U will be injected into the temporalis (over 5 sites) and 40 U will be injected into the masseter muscle (over 4 sites). Botox will be reconstituted from a powdered form in 2cc of 0.9% sterile saline, and appropriate volumes will be administered.
9693962|NCT04794504|Placebo Comparator|Saline Injection Group|Two weeks pre-operatively, patients in the saline injection group will receive intramuscular injections of Botox totaling the same volumes administered for Botox patients above, across the same number of sites in the temporalis and masseter muscles bilaterally.
10182466|NCT03773848|Experimental|A- hook plate|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with hook plate. X-ray was applied to check the grade of reduction before the operation is completed.
9693963|NCT04794010||Cohort 1|Participants with Metastatic Non-Small Cell Lung Cancer
9693964|NCT04794049|Experimental|Experiment cohort|4-6 hours before colonoscopy, patients in experiment cohort began to drink the first 150ml lactulose and half hour later, drink other 150ml lactulose dissolved in 1.5 L of water at a rate of 250ml every 15 minutes.
9693965|NCT04794049|Active Comparator|Control cohort|The participants in control cohort began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
9693966|NCT04793945|Active Comparator|light therapy twice weekly|15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light twice weekly and topical steroid twice daily the second patch will be treated by topical steroid twice daily. the third patch will be left as a control.
9693967|NCT04793945|Active Comparator|light therapy once weekly|"15 or half of the patients with three patches of Alopecia Areata on the scalp the first patch will be treated by 308nm Excimer light once weekly and topical steroid twice daily.~the second patch will be treated by topical steroid twice daily. the third patch will be left as a control."
9693968|NCT04794127|Experimental|Trabectedin in combination with Pioglitazone|Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and Pioglitazone given continuously at the daily dose of 45 mg by oral route. Since Trabectedin has no cumulative toxicities, and Pioglitazone as well, the combination will be administered until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician.
9693969|NCT04793997|Active Comparator|Verum Microbiome spray group|Daily use of microbiome spray for two weeks
9693970|NCT04793997|Placebo Comparator|Placebo spray group|Daily use of placebo spray for two weeks
9693971|NCT04793997|No Intervention|Household member group|No use of spray
9693972|NCT04794088|Active Comparator|Intravenous imatinib mesylate (Impentri®)|Patients receiving the active investigational medicinal product will be receiving imatinib 200mg b.i.d. (administered as an 8 mg/mL solution for i.v. infusion) for 7 days.
9693973|NCT04794088|Placebo Comparator|Placebo solution|Patients receiving the placebo comparator will be receiving the same amount of intravenous solution, however containing 0.01M acetate buffer with 1.9% glycerol.
9693974|NCT04794270|Experimental|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
9693975|NCT04794270|Experimental|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
9693976|NCT04794140|Experimental|one pass group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from a single pass for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
9693977|NCT04794140|Experimental|two passes group|We use the endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique to procure the specimens, and use the sample obtained from two passes for primary cell culture. EUS-FNB wet suction technique refer from Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.
9693978|NCT04793984|Experimental|Inhaleen|Iota-Carrageenan inhalation
9693979|NCT04793984|Placebo Comparator|Placebo|NaCl inhalation
9693980|NCT04794257|Active Comparator|i-IONM|In operations with i-IONM mode the IONM stimulator will be used to test vagal response at the beginning of surgery, map out and trace the RLNs during surgery by repetitive stimulations, and in case of loss of signal (LOS) it will be used to identify the type and site of neural injury (Type I vs. Type II). Final prognostication of postoperative neral function will be based on vagal stimulation at the end of each lobectomy.
9693981|NCT04794257|Experimental|NerveTrend|In operations with NerveTrend the IONM stimulator will be used in the same manner as in the i-IONM arm, but the EMG trending including amplitude and latency changes from initial vagal baseline will be evaluated using the NerveTrend mode at 3 - 5min intervals to assure almost real time EMG tracing and allow for modification of surgical maneuvers in case of occurrence of severe combined events (yellow zone) in order not to end up with the LOS (red zone).
9693982|NCT04794179|Other|Naida Link CROS device|Individuals 65+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
9693983|NCT04793971||postoperative cases|patients that underwent percutaneous release of the paratenon for chronic midportion Achilles tendinopathy
9693984|NCT04794439|Active Comparator|Toothpaste 1 with Stannous Fluoride|Toothpaste with Stannous Fluoride
9693985|NCT04794439|Active Comparator|Toothpaste 1 with Sodium Fluoride and sodium bicarbonate|Toothpaste with Sodium Fluoride and sodium bicarbonate
9693986|NCT04794439|Active Comparator|Toothpaste 2 with Stannous Fluoride|Toothpaste with Stannous Fluoride
9693987|NCT04794439|Active Comparator|Toothpaste 2 with sodium Fluoride and sodium bicarbonate|Toothpaste with sodium Fluoride and sodium bicarbonate
10114956|NCT04454749||Artificial (HRT) Cycles|"Start of estradiol valerate 4mg on day 2 of the cycle for three days. Increase E2 to 6mg on day 4 of E2 treatment. E2 dose may be increased according to clinician discretion based on endometrial thickness. Maximum time of E2 exposure will be 14 days. Transvaginally scan to monitor endometrial development and to exclude the presence of a dominant follicle. Serial measurements of serum LH, estradiol and progesterone levels. Commence the initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue estradiol administration 6mg (3 tablets daily).~Blastocyst transfer is scheduled on the 5th full day of progesterone administration, following the initial initiation of progesterone."
10114957|NCT04454749||Spontaneous natural cycles|"Ultrasound scans to monitor follicular growth and serial measurements of serum LH, estradiol and progesterone levels to determine the timing of ovulation. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter.~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/ml confirming ovulation (day 0). This is considered as day 0 with initiation of vaginal progesterone 100mg (vaginal suppository) at 2200H. The following day (day 1) increases progesterone administration to 100mg vaginally three times daily (8 hourly) and continues this regime until 7 weeks gestation as per clinic protocol.~Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
10114958|NCT04454775||group I|50 cases who received raloxifene and calcium therapy
10114959|NCT04454775||group II|30 cases who received only calcium therapy
9693988|NCT04794465||Asymptomatic IBD diagnosed during the colorectal cancer screening|
9693989|NCT04794101|Experimental|Deferred treatment from MGT-RPGR-021 4e11|Deferred treatment
9693990|NCT04794101|Active Comparator|Already treated in MGT-RPGR-021|Already treated
9693991|NCT04794101|Experimental|Deferred treatment from MGT-RPGR-021 2e11|Deferred treatment
9693992|NCT04793919|Active Comparator|Standard Risk (SR)|Patient with APL and WBC less than 10x10e9/L at presentation before start treatment
9693993|NCT04793919|Experimental|High Risk (HR)|Patient with APL, with the highest pre-treatment WBC count equal to or greater than 10x10e9/L at presentation
9693994|NCT04794153|Experimental|Pork|Locally sourced
9693995|NCT04794153|Experimental|Salmon|Locally sourced
9693996|NCT04794153|Experimental|Mycoprotein|Provided by Marlow Foods
9693997|NCT04794153|Experimental|Lentils|Red
9693998|NCT04794153|Experimental|Egg|Local supplier
9693999|NCT04794153|Active Comparator|Egg whites|Local Supplier
9694000|NCT04793932|Active Comparator|PAXG Arm A|cisplatin 30 mg/m2 every 2 weeks, nab-paclitaxel 150 mg/m2 every 2 weeks, gemcitabine 800 mg/m2 every 2 weeks, capecitabine 1250 mg/m2/day (for 28 consecutive days) in 28-day cycles administered for 4 cycles (4 months).
9694001|NCT04793932|Active Comparator|mFOLFIRINOX Arm B|irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, folinic acid at a fixed dose of 400 mg/m2, fluorouracil continuous IV infusion 2.4 g/m2 over 46 hours in 14-day cycles administered for 8 cycles (4 months).
9694002|NCT04793932|Active Comparator|short-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive immediate surgery followed by 2 further months of the same chemotherapy
9694003|NCT04793932|Active Comparator|long-course chemotherapy|Allocated by second randomization after 4 months of chemotherapy to receive 2 further months of the same chemotherapy followed by surgery
9694004|NCT04794114|Experimental|orthosis in hemiplegia|
9694005|NCT04793737|Experimental|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
9694006|NCT04793893|Experimental|Treatment of residual hypermetropia refraction after LASIK|"The main problem at young patients post - LASIK after one year is residual hypermetropic refractive errors (especially accommodation problem) The method used in Eye Hospital is treatment with implantation of human fresh corneal lenticule (min. -1.50D) taken from myopic patients in post - LASIK patients with residual hypermetropic refractive error (min. +1.0D).~The flap of LASIk is lifted,cleaned and then the lenticule gently inserted.The lenticule was positioned according the K2 values when is astigmatism residual refractive error.In cases where is not astigmatism the lenticule was positioned in central position under the flap."
9694007|NCT04793711|Experimental|EpiCeram|Open-Label, 3 (three) times per day, topical, to hands and face, for 28 days.
9694008|NCT04793529|Experimental|Cholecalciferol injection|
9694009|NCT04793841||General population|sexually experienced adults (aged 18 or above) of the randomly selected household
9694010|NCT04793841||men who have sex with men|men who have sex with men aged 18 or above and normally living in Hong Kong
9694011|NCT04793555|Experimental|Experimental_Arm|Assessment of behavior during day and night by unobtrusive sensors
9694012|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION + NONINVASIVE VENTILATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session with non-invasive ventilation.
9694013|NCT04793802||Patients benefiting from HIGH-FLOW OXYGENATION|Patients benefiting from high-flow oxygenation will have their physiotherapy session without non-invasive ventilation.
9694014|NCT04793750|Experimental|POC HIV VL Testing|Participants will receive the standard of care tests (DPP HIV-Syphilis Test System, OraQuick) plus the HIV POC VL test.
9694015|NCT04793750|Active Comparator|SOC HIV Testing|Participants will receive routine standard of care HIV testing.
9694016|NCT04793854||Case|Children with sickle cell anemia attending the centre of reference for sickle cell disease in Guadeloupe.
9694017|NCT04793854||Control|Control children without chronical disease
9694018|NCT04793581|Other|Single Arm|Single-arm study
9694019|NCT04793672||Patients with malignant tumors and healthy people|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
9694020|NCT04793594||Tele- Assessment Group|Balance Assessment
9817901|NCT02115282|Experimental|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
9817902|NCT02115282|Placebo Comparator|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
9817903|NCT02115308|Other|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
9817904|NCT02115321|Experimental|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
9817905|NCT02115321|Experimental|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
9817906|NCT02115321|Experimental|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
9817907|NCT02115321|Experimental|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
9817908|NCT02115347|Experimental|Ertugliflozin 15 mg - Moderate Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
9817909|NCT02115347|Other|Ertugliflozin 15 mg - Healthy Participants|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
9817910|NCT02115347|Experimental|Ertugliflozin 15 mg - Mild Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
9817911|NCT02115373|Experimental|Phase 1b: Tepotinib 300 mg|
9528157|NCT03213353|Experimental|Treatment sequence BA|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
9817912|NCT02115373|Experimental|Phase 1b: Tepotinib 500 mg|
9817913|NCT02115373|Experimental|Phase 2: Tepotinib 500 mg|
9817914|NCT02115386|Experimental|Nilotinib|Dosage was 300 mg BID daily taken orally without food.
9817915|NCT02115542|Experimental|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
9817916|NCT02115581|Experimental|Coenzyme Q10|"Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects."
9817917|NCT02115581|Placebo Comparator|Placebo|known cases of idiopathic dilated cardiomyopathy who received placebo
9817918|NCT02115607|Experimental|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
9817919|NCT02115633|Experimental|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
9817920|NCT02115633|Experimental|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
9817921|NCT02115646|Experimental|fractionated carbon dioxide laser|fractionated carbon dioxide laser
9817922|NCT02115750|Active Comparator|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
9817923|NCT02115750|Experimental|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
9817924|NCT02115815|Placebo Comparator|Placebo|Sterile saline for human use from commercial source, liquid
9817925|NCT02115815|Experimental|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
9817926|NCT02115815|Experimental|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
10182467|NCT03773848|Experimental|B- tightrope|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with tightrope. X-ray was applied to check the grade of reduction before the operation is completed.
9817927|NCT02115815|Experimental|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
9817928|NCT02115815|Experimental|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
9817929|NCT02115815|Experimental|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
9817930|NCT02115815|Experimental|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
9817931|NCT02115828|Experimental|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
9817932|NCT02115984|Experimental|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
9817933|NCT02115984|Placebo Comparator|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
10182468|NCT03773809|Placebo Comparator|Group A0|Vitamin D3 deficient ACO patients with placebo at day 0.
10182469|NCT03773809|Placebo Comparator|Group A90|Vitamin D3 deficient ACO patients with placebo at day 90.
10182470|NCT03773809|Active Comparator|Group B0|Vitamin D3 deficient ACO patients with vitamin D3 at day 0.
9668054|NCT02114372||Clinical Drug Research Assessment System (CDR-AS)|Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
9668055|NCT02114372||Delis Kaplan Executive Function System (DKEFS)|Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions that has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
9668056|NCT02114372||COGNITO|Enrolled participants will be randomized in a balanced manner to COGNITO at the other site of the SubStudy. COGNITO is an approximately 45 to 60 minute computerized neuropsychometric examination based on well-known cognitive tests designed for both cognition research and clinical assessment. COGNITO assesses reaction time, primary and working memory, visuospatial and verbal secondary memory, implicit learning, language skills, functional and semantic categorization of visual data, focused and divided attention, and crystallized intelligence. Responses are made via a tactile screen which permits the recording of response latency (deducting reaction time provides an estimation of information processing time).
9668057|NCT02114242||Parkinson's disease patients|Patients suffering from Parkinson desease
9668058|NCT02114242||multiple system atrophy patients|"Patients suffering from probable multiple system atrophy according to clinical consensus criteria and age > 30"
9668059|NCT02114242||progressive supranuclear palsy|Patients suffering from progressive supranuclear palsy and age > 40
9668060|NCT02108652|Experimental|Cohort 2: Participants With Second-line or Beyond Treatments|Participants with advanced disease who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
9668061|NCT02102477|Experimental|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
9668062|NCT02102477|Active Comparator|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
9668063|NCT02091999|Experimental|Part A enfortumab vedotin Dose Escalation (Dose Levels 1-4)|All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
9668064|NCT02091999|Experimental|Part B enfortumab vedotin Renal Insufficiency Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at a dose level below and escalated up to the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
9668065|NCT02091999|Experimental|Part B enfortumab vedotin NSCLC Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
9668066|NCT02091999|Experimental|Part B enfortumab vedotin Ovarian Cancer Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
9668067|NCT02091999|Experimental|Part C enfortumab vedotin CPI Treated Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15). A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of enfortumab vedotin, Investigator decision or consent withdrawal.
9668068|NCT02075697||New drugs|Cohort exposed to biologic therapy, apremilast or fumarates
9668069|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
9668070|NCT02059668||Biomarker analyses head & neck cancer tissue, blood specimen|Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.
9668071|NCT02053051|Experimental|MDI of insulin & ABC4D|Advanced Bolus Calculator for Type Diabetes (ABC4D)
9668072|NCT02053051|Active Comparator|MDI of insulin|Multiple daily injections(MDI) of insulin
9668073|NCT02051257|Experimental|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
9668074|NCT02051257|Experimental|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
9668075|NCT02022098|Experimental|Debio 1143|In addition to Cisplatin and Radiotherapy, Debio 1143 in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
9668076|NCT02022098|Placebo Comparator|Placebo|In addition to Cisplatin and Radiotherapy, matching placebo in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
9694021|NCT04793594||Face To Face (Clinic) Group|Balance Assessment
9694022|NCT04793815|Experimental|Cryo-activation and anti-PD-1 monotherapy combination|
9694023|NCT04793620|Experimental|TQL1055|TQL1055 + acellular pertussis vaccine
9694024|NCT04793620|Active Comparator|Acellular pertussis vaccine|Acellular pertussis vaccine
9817934|NCT02116205|Experimental|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
9817935|NCT02116205|Experimental|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
9817936|NCT02116205|Experimental|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
9817937|NCT02116205|Experimental|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
9817938|NCT02116309|Active Comparator|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
9817939|NCT02116309|Active Comparator|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
9817940|NCT02116322|Experimental|Pancreatic mass|Patients with pancreatic mass presenting for EUS-FNA
9817941|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
9817942|NCT02116361|Experimental|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
9817943|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
9817944|NCT02116361|Experimental|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
9817945|NCT02116530|Experimental|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
10114960|NCT04454814|Active Comparator|Rotary Engine-driven Instruments|The instrumentation protocol with Protaper Universal rotary files was began with an S1 file with a brushing movement to the two thirds of the working length and then an SX file was introduced to the two thirds of the working length with a brushing movement Afterwards, S1, S2, F1, F2 files in mesial roots and F4 files in distal roots were used to the working length, respectively. Protaper F2 instrument was then used to complete the canal preparation in mesial roots and Protaper F4 instrument was used to complete the canal preparation in distal roots.
9668077|NCT02021006|Active Comparator|ANTIBIOTIC PROPHYLAXIS|"Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.~The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
9668078|NCT02021006|Experimental|NO PROPHYLAXIS|Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years
9817946|NCT02116530|Active Comparator|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~placebo"
9817947|NCT02116582|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
9817948|NCT02116608|Active Comparator|Group 1: Betadine|Apply locally as needed.
9817949|NCT02116608|Active Comparator|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
9817950|NCT02116608|Active Comparator|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
9817951|NCT02116621|Experimental|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
9817952|NCT02116621|No Intervention|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
9817953|NCT02116660|Experimental|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
9817954|NCT02116660|Active Comparator|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
9817955|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 1|(Part A): Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9817956|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 2|(Part B): Relapse/Refractory EWS or PNET Patients receive MTD from Phase 1 portion of study. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9817957|NCT02116803|Experimental|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
9817958|NCT02116803|Experimental|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
9817959|NCT02116972|Experimental|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
9817960|NCT02116972|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
9817961|NCT02116972|Placebo Comparator|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
9817962|NCT02117024|Experimental|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
9668079|NCT02016924|Experimental|Part A, Cohort 1|Participants ages 12 to <18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR. The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
9668080|NCT02016924|Experimental|Cohort 2|Participants ages 6 to <12 years old will receive cobicistat 150 mg and emtricitabine/tenofovir alafenamide 200/25 mg with either ATV or DRV.
9817963|NCT02117024|Active Comparator|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
9817964|NCT02117193|Placebo Comparator|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
9817965|NCT02117193|Active Comparator|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
9817966|NCT02117310|Experimental|ICG|Angiography with administered ICG
9817967|NCT02117349|Experimental|Raplixa plus Gelfoam|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate target bleeding site (TBS). The treatment is topically applied using 1 of the following 3 methods:~A thin layer of Raplixa is sprinkled directly from the vial onto the TBS, followed by application of Gelfoam.~A thin layer of Raplixa is sprayed onto the TBS using the RaplixaSpray device, followed by application of Gelfoam.~Raplixa is applied onto moistened Gelfoam which is then applied to the TBS.~Manual pressure is applied over the treatments using sterile gauze. The amount of Raplixa and Gelfoam used is at the discretion of the investigator, within the maximum of two 1 gram (g) vials of Raplixa that are permitted for each participant.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute time-to-hemostasis (TTH) evaluation."
9817968|NCT02117349|Other|Gelfoam Only|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate TBS. Gelfoam is cut to the appropriate size and applied topically, according to the manufacturer's package insert, followed by manual pressure using sterile gauze.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute TTH evaluation, if necessary."
9817969|NCT02117414|Experimental|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
9817970|NCT02117414|Sham Comparator|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
9817971|NCT02117427|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
9817972|NCT02117427|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
9817973|NCT02117427|Experimental|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
9817974|NCT02117479|Experimental|Ruxolitinib plus capecitabine|
9817975|NCT02117479|Active Comparator|Placebo plus capecitabine|
9817976|NCT02117544|Other|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
9817977|NCT02117544|Other|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
9817978|NCT02117570|Experimental|High dose of C. difficile vaccine|
9817979|NCT02117570|Experimental|Low dose of C. difficile vaccine|
9817980|NCT02117570|Placebo Comparator|Placebo|
9817981|NCT02117648|Experimental|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
9817982|NCT02117648|Experimental|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
9817983|NCT02117648|Experimental|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
9817984|NCT02117687|Active Comparator|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
9817985|NCT02117687|Active Comparator|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
9817986|NCT02117713|Experimental|LUM001 (Maralixibat)|Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
9817987|NCT02117934|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
9817988|NCT02117934|Active Comparator|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
9817989|NCT02117999|Experimental|Cross-linking with iontophoresis|Transepithelial cross-linking by using iontophoresis to administer riboflavin into the corneal stroma
9817990|NCT02117999|Active Comparator|Standard corneal cross-linking|Standard corneal cross-linking includes de-epithelialization and stromal soaking by applying drops of riboflavin
10182471|NCT03773809|Active Comparator|Group B90|Vitamin D3 deficient ACO patients with vitamin D3 at day 90.
9817991|NCT02118012|Active Comparator|Chlorcyclizine and RBV|Chlorcyclizine HCl and Ribavirin
9817992|NCT02118012|Active Comparator|Chlorcyclizine HCl only|Chlorcyclizine HCl only
9817993|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 3 mg/kg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.
9817994|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
9817995|NCT02118337|Experimental|MEDI0680 0.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
9817996|NCT02118337|Experimental|MEDI0680 2.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
9817997|NCT02118337|Experimental|MEDI0680 10 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
9817998|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
9817999|NCT02118337|Experimental|MEDI0680 20 mg/kg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
9818000|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 750 mg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
9818001|NCT02118337|Active Comparator|Nivolumab 240 mg|Participants in dose-expansion phase will receive IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
9818002|NCT02118428|Experimental|Mirasol|Transfusions with Mirasol-treated whole blood
9818003|NCT02118428|Active Comparator|Control|Transfusions with untreated whole blood
9818004|NCT02118441|Active Comparator|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
9818005|NCT02118441|Active Comparator|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
9818006|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
9818007|NCT02118714|Experimental|Atrasentan|Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
9818008|NCT02118766|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
9818009|NCT02118766|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
9818010|NCT02118792|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
9818011|NCT02118792|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
9818012|NCT02118831|Active Comparator|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
9818013|NCT02118831|Active Comparator|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
9818014|NCT02118831|Active Comparator|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
9818015|NCT02118896|Experimental|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
9818016|NCT02118961|Experimental|BK1301|
9818017|NCT02118961|Active Comparator|DT toxoid|
10182472|NCT03773549||Body dysmorphic disorder|Meet DSM-5 criteria for principal body dysmorphic disorder, assessed via the Structured Clinical Interview for the DSM-V Axis I Disorders (SCID)
10182473|NCT03773549||Healthy control|Individuals who do not have a current psychiatric diagnosis, assessed via the Mini-International Neuropsychiatric Interview (MINI)
9818018|NCT02119026|Active Comparator|A: XELIRI + BEV Followed by XELOX + BEV|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
9818019|NCT02119026|Active Comparator|B: XELOX + BEV followed by XELIRI + BEV|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)~Arm B:~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
9818020|NCT02119104||Prevenar (13v)|
9818021|NCT02119156|Experimental|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
9818022|NCT02119156|Active Comparator|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
9818023|NCT02119156|No Intervention|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
9818024|NCT02119260|Experimental|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
9818025|NCT02119260|Experimental|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
9818026|NCT02119260|Experimental|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
9818027|NCT02119260|Experimental|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
9818028|NCT02119260|Experimental|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
9818029|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
9818030|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
9818031|NCT02119286|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
9818032|NCT02119299|Experimental|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
9818033|NCT02119325|Experimental|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
9818034|NCT02119325|Placebo Comparator|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
9818035|NCT02119442|Other|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
9818036|NCT02119455|Experimental|Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
9818037|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
9818038|NCT02119650|Experimental|Ruxolitinib plus Pemetrexed/Cisplatin|
9818039|NCT02119650|Active Comparator|Placebo plus Pemetrexed/Cisplatin|
9818040|NCT02119663|Experimental|Ruxolitinib plus capecitabine|
9818041|NCT02119663|Active Comparator|Placebo plus capecitabine|
9818042|NCT02119676|Experimental|Ruxolitinib plus regorafenib|
9818043|NCT02119676|Active Comparator|Placebo plus regorafenib|
9818044|NCT02119819|Experimental|10 mg LY2944876|"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
9818045|NCT02119819|Experimental|15 mg LY2944876|15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
9818046|NCT02119819|Experimental|30 mg LY2944876|30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
9818047|NCT02119819|Experimental|50 mg LY2944876|50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
9818048|NCT02119819|Experimental|Exenatide extended-release|2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
9818049|NCT02119819|Placebo Comparator|Placebo|"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
9818050|NCT02119871|Experimental|Bilateral Open Pleurae|Bilateral open pleurae and usage of right pulmonary vein drainage
9818051|NCT02119871|Active Comparator|Right pleura open|Opening of right pleura and usage of left ventricular apical drainage.
10114961|NCT04454814|Active Comparator|Reciprocal Engine-driven Instruments|The instrumentation of the root canal in the Reciproc Blue group began with a R25 instrument with a slow in-and-out pecking movement.According to the manufacturer instructions, a #10 K-file was inserted to the canal to check the canal is free to 1 mm beyond the prepared canal section. After each 3 pecks or when a resistance was encountered the instrument was pulled out of the canal. Afterward, the R25 instrument was inserted in to root canal until approximately two thirds of the working length.RB R25 instrument was then used to complete the canal preparation in mesial roots and RB R40 instrument was used to complete the canal preparation in distal roots.
10114962|NCT04454970|Experimental|Urethral catheterisation device (UCD)|First attempt of urethral catheterisation using the Urethrotech(R) Urethral catheterisation device (UCD)
10114963|NCT04454970|Active Comparator|Bardia Aquafil Foley catheter|First attempt of urethral catheterisation using the Bardia Aquafil Foley catheter
10114964|NCT04454892||Amyotrophic lateral sclerosis patients|Although previous studies have provided reference for the diagnosis and treatment of ALS, the etiology of ALS is still unknown, and the relevant clinical features and natural history of ALS still lack the verification of large samples. Therefore, the research on the natural history of ALS is of great significance to further increase the understanding of ALS and provide new evidence for the diagnosis and treatment of ALS
10114965|NCT04454840|Experimental|Biological+Riluzole|Plasma from healthy young people treatment + Riluzole
10114966|NCT04454840|Active Comparator|Riluzole|Riluzole
10114967|NCT04454866|Placebo Comparator|Control group|For patients in the control group, a dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron 10 mg, diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
10114968|NCT04454866|Experimental|Single injection group|For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
10182474|NCT03773601|Experimental|Athletes|Athletes will undergo a 4-days sleep monitoring with the use of the Sleep Profler. At the same time, they will fill the Total Quality of Recovery (TQR) scale and the Pittsburgh Sleep Quality Index (PSQI).
9668081|NCT02016924|Experimental|Cohort 3|Participants ages ≥ 3 will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.
9668082|NCT02016924|Experimental|Part B, Cohort 1|Participants ages 12 to <18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR. The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
9668083|NCT02013336|Experimental|MM-398 + cyclophosphamide|MM-398+cyclophosphamide
9668084|NCT02004080||TBI admitted to ICU|Intensive Care treatment
9668085|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
9818052|NCT02119936|Experimental|Heart Rate Variability Biofeedback Tool|Intervention: Participants will be taught how to use the Heart Rate Variability Biofeedback tool (emWave 2) as a mechanism to reduce stress and anxiety, then use the tool, coupled with deep breathing exercises, to visualize their stress reduction.
9818053|NCT02120001|Experimental|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
9668086|NCT01955356|Experimental|Scratching|induced endometrial injury
9668087|NCT01955356|No Intervention|No scratching|None intervention
9668088|NCT01950234|Experimental|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
9668089|NCT01950234|Placebo Comparator|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
9668090|NCT01921140|Other|Fasted|Olaparib tablets following no breakfast
9668091|NCT01921140|Other|High-fat meal|Olaparib tablets after high-fat breakfast
9668092|NCT01905384|Active Comparator|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
9818054|NCT02120001|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
9694025|NCT04793503|Active Comparator|conventional complete denture|the patients receive conventional complete denture constructed from heat cure acrylic resin
9694026|NCT04793503|Active Comparator|CADCAM 3D printed denture|the patients receiveCADCAM 3D printed denture constructed by using printing machine
9694027|NCT04793503|Active Comparator|CAD/CAM milled denture|the patients receiveCADCAM 3D printed denture constructed by using milling machine
9694028|NCT04793828|Experimental|Intervention (velibra)|Arm consisting of participants who receive velibra, an internet-based cognitive behavioral therapy program.
9694029|NCT04793542|No Intervention|Control|
9694030|NCT04793542|Sham Comparator|Lukewarm Water|
9694031|NCT04793542|Active Comparator|Hot Water|
9694032|NCT04793724|Experimental|Simeox first|Patients who will undergo Simeox intervention first. After three months cross-over to PARI O PEP intervention.
9694033|NCT04793724|Active Comparator|PARI O PEP first|Patients who will undergo PARI O PEP intervention first. After three months cross-over to Simeox intervention.
9694034|NCT04793763|Placebo Comparator|group A|"placebo Comparator Group A~: twenty patients were received traditional Physical Therapy agents"
9694035|NCT04793763|Experimental|group B|experimental Group B Group B: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and deep neck flexors exercises;
9694036|NCT04793763|Experimental|group C|"Experimental Group C~Group C: twenty patients were received traditional Physical Therapy agents plus isometric, stretching, scapulothoracic exercises and Mckenzie technique."
9694037|NCT04793477|Experimental|K files (Dentsply Caulk, Milfors, DE, USA)|Instrumentation with manual files shall be performed with balanced forces (Roane) technique consist of placing the instrument as apically as it can go and then turning it clockwise (less than 180º). This is followed by a counterclockwise rotation (of at least 120º) with slight apical pressure. This is repeated until the desired working length is obtained.
9694038|NCT04793477|Experimental|VDW.ROTATE (VDW, Munich, Germany).|Instrumentation with VDW.ROTATE files shall be performed with a glide path to WL using VDW.ROTATETM 15.04 until reaching working length (1.3cNm and 300-400 rpm), the next instrument in the sequence is VDW.ROTATETM 20.05 until reaching working length (2.1cNm and 300-400rpm). and finally instrument with VDW.ROTATETM 25.04 (2.3cNm and 300-400rpm)
9694039|NCT04793477|Experimental|Reciproc® blue (RCP, VDW, Munich, Germany)|Instrumentation with Reciproc blue files shall be performed with only one file and move it in a pecking motion (the amplitude will not exceed 3mm). All the instruments shall be cleaned after 3 pecks.
9694040|NCT04793282|Placebo Comparator|Control|Post-test satisfaction
9694041|NCT04793282|Experimental|Experimental|Treatment and satisfaction
9694042|NCT04793113|Experimental|Intervention|Low carbohydrate, high protein meals
9694043|NCT04793451|Experimental|Group A|Endurance training
9694044|NCT04793451|Experimental|Group B|Endurance-strength training
9694045|NCT04793256|Experimental|intervention|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
9694046|NCT04793256|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
9694047|NCT04793386|Experimental|Carotid ultrasound|When stopping chest compressions to check manual palpation every 2 minutes, an ultrasound scan of the carotid artery is performed. Whether or not return of spontaneous circulation is determined based on the compressibility and pulsatility of the carotid artery, and the time taken from the start of the ultrasound scan to the determination is recorded.
9694048|NCT04793178|Active Comparator|Oxygen Reserve Index Blinded Group|Aneshesist will be blinded for oxygen reserve index monitoring (ORI, Masimo Corporation), but he will be allowed to use pulse oxymetry and end-tidal carbon dioxide monitoring to manage the respiratory conditions and depth of sedation.
9694049|NCT04793178|Experimental|Oxygen Reserve Index Group|Aneshesist will be allowed to use pulse oxymetry, end-tidal carbon dioxide and oxygen reserve index (ORI) monitoring. He will manage the depth of sedation, respiaratory conditions.
9694050|NCT04793243|Experimental|Intervention group|Formed by 22 patients that received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
9694051|NCT04793243|No Intervention|Control group|Formed by 20 patients that did not receive supplementation
9694052|NCT04793347|Experimental|shock waves|group of patients with anal fissure will be treated with shock waves
9694053|NCT04793165|Experimental|Non-hybrid closed-loop system|"To compare two types of treatments:~During the first 3 days: Previous or conventional, with CSII plus CGM in open loop.~During the second 3 day period: AP with CSII plus CGM in a closed-loop system, through the ARG algorithm."
9694054|NCT04793399|Experimental|Bosutinib-Atezolizumab Combination|"Drugs to be administered:~Bosutinib 400 MG/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year"
9694055|NCT04793425|No Intervention|Standard care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI.
9694056|NCT04793425|Experimental|Mobile app care|Patients randomized to standard care arm will take part in the rehabilitation program according to regular schedule. Additionally every patient will have 2 cardiological visits: 1 and 6 months after the hospitalization due to MI. On top of that every patient will be given an access to mobile application, which will support rehab process. The application stands as a educational and coordination tool.
9694057|NCT04793308|Experimental|Group (1); (ProTaper Next, Rotary system).|Group I teeth were prepared with rotary instrumentation using ProTaper Next (Dentsply, Switzerland)
9694058|NCT04793308|Experimental|Group (2); K- files, Manual instruments.|Group II root canals were prepared by manual instrumentation using K type files Mani, Japan).
9694059|NCT04793373|Experimental|EpiFaith® group|Study subject will have the epidural placement with an EpiFaith® syringe.
9694060|NCT04793373|Active Comparator|Conventional group|Study subject will have the epidural placement with a conventional glass syringe.
9818055|NCT02120027|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
9818056|NCT02120027|Placebo Comparator|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
9818057|NCT02120157|Experimental|Haploidentical BMT with PTCy for acute leukemias and MDS|"Patients with AML and MDS:~Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV~For patients with ALL and lymphoblastic lymphoma:~Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV~Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days~All patients Day 0: Infuse unmanipulated bone marrow~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day~Day +30: Assess chimerism and disease status in bone marrow~Day +35: Discontinue MMF~Day +60: Assess chimerism and disease status in bone marrow~Day 180: Discontinue tacrolimus"
9818058|NCT02120261|Experimental|TPI with Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
9818059|NCT02120261|Active Comparator|TPI with Lidocaine & Triamcinolone Acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
9818060|NCT02120287|Experimental|BZ-SRS with Bevacizumab|"All patients will receive Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until progression.~One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS"
9818061|NCT02120300|Experimental|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
9818062|NCT02120300|Experimental|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
9818063|NCT02120300|Experimental|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
9818064|NCT02120352|Experimental|GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks (Q8W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subject will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subject will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 900 mg IM. Week 4 only - GSK744 LA 600 mg IM (second loading dose, no TMC278).Week 8 - GSK744 LA 600 mg IM + TMC278 LA 900 mg IM every 8 weeks for 96 weeks.
9818065|NCT02120352|Experimental|GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks (Q4W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 600 mg IM. Week 4 - GSK744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 weeks for 96 weeks
9818066|NCT02120352|Active Comparator|Oral Control Arm|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive an oral regimen of 30 mg of GSK744 and ABC/3TC once daily for 96 weeks (or 104 weeks if going on to the Extension Period)
9818067|NCT02120417|Experimental|Treatment A - Capecitabine and ruxolitinib|
9818068|NCT02120417|Active Comparator|Treatment B - Capecitabine and placebo|
9818069|NCT02120443|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.
9818070|NCT02120456|Experimental|LEO 43204|Open-label, dose-escalation, 2-day treatment
9818071|NCT02120456|Experimental|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
9818072|NCT02120456|Experimental|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
9818073|NCT02120456|Placebo Comparator|Placebo|Placebo once daily for two days
9818074|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
9818075|NCT02120664|Experimental|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
9826861|NCT02435706|Experimental|Flapless immediate implant placement group|Flapless placement of immediate implant and temporary crown
9826862|NCT02435706|Active Comparator|Flap assisted immediate implant placement group|Flap elevation prior to placement of immediate implant and temporary crown
10114969|NCT04454866|Experimental|Continuous infusion group|For patients in this group, a dose of penehyclidine (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
10114970|NCT04454788|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
10114971|NCT04454788|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
9818076|NCT02120664|Experimental|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
9818077|NCT02120716|Experimental|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
9818078|NCT02120716|No Intervention|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
9818079|NCT02120781|Experimental|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
9818080|NCT02120781|Placebo Comparator|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
9818081|NCT02120794|Experimental|530G insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
9818082|NCT02120833|Active Comparator|EPI|
9818083|NCT02120833|Experimental|NEE|
9818084|NCT02120898|Experimental|Generic Imiquimod Cream 2.5%|Generic imiquimod cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
9818085|NCT02120898|Active Comparator|Zyclara® (Imiquimod) Cream 2.5%|Zyclara® (imiquimod) cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
9818086|NCT02120898|Placebo Comparator|Vehicle Cream|Vehicle cream will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
9818087|NCT02120924|Active Comparator|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
9818088|NCT02120924|Experimental|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
9818089|NCT02120924|Placebo Comparator|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
9818090|NCT02120950|Experimental|Aflibercept + Sham PDT|Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
9818091|NCT02120950|Experimental|Aflibercept + Active PDT|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)
9818092|NCT02121002|Experimental|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
9818093|NCT02121002|Active Comparator|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
9818094|NCT02121002|Placebo Comparator|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
9818095|NCT02121041|No Intervention|Usual Care|Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
9818096|NCT02121041|Active Comparator|ABPM Guided|Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
9818097|NCT02121067|Experimental|LNG-IUS placed at 2 weeks postpartum|Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum
10114972|NCT04454697|Experimental|Intervention|Patient receive personalized 3D-printed GWR
9818098|NCT02121210|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
9818099|NCT02121210|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
10114973|NCT04454697|Active Comparator|Control|Patient receive standardized radiation protection tooth splints
9818100|NCT02121262|Other|Laser Photocoagulation|Laser photocoagulation was administered in the study eye on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
9818101|NCT02121262|Experimental|Dexamethasone|Dexamethasone 700 μg was administered as intravitreal injection in the study eye on Day 1, Months 5, and 10.
9818102|NCT02121301|Experimental|Low Dose SkQ1|Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
9818103|NCT02121301|Experimental|High Dose SkQ1|Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
9818104|NCT02121301|Placebo Comparator|Placebo (vehicle)|Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days
9818105|NCT02121392|Sham Comparator|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
9818106|NCT02121392|Experimental|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
10114974|NCT04454593||Lateral patellar compression syndrome|Patients diagnosed with lateral patellar compression syndrome between February 2016 and April 2019
10114975|NCT04454593||patellar dislocation|Patients diagnosed with patellar dislocation between February 2016 and April 2019
10114976|NCT04454593||meniscus tear|Patients diagnosed with meniscus tear between February 2016 and April 2019
10182475|NCT03773705|Active Comparator|Electrocautery group|Electrocautery used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
9818107|NCT02121418|Experimental|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
9818108|NCT02121483|Experimental|empagliflozin high dose|Patient to receive a high dose of empagliflozin
9818109|NCT02121483|Experimental|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
9818110|NCT02121483|Experimental|empagliflozin low dose|Patient to receive a low dose of empagliflozin
9818111|NCT02121509|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
9818112|NCT02121509|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
9818113|NCT02121509|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
9818114|NCT02121509|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
9818115|NCT02121522|Experimental|BI 144807|twice daily
9818116|NCT02121535|Experimental|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
9818117|NCT02121535|Active Comparator|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
9818118|NCT02121756|Experimental|Dipyridamole|ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
9818119|NCT02121756|Active Comparator|Placebo then Dipyridamole|ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
9818120|NCT02121795|Experimental|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
9818121|NCT02121795|Active Comparator|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
9826863|NCT02435836|Experimental|Aripiprazole|All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
9826864|NCT02435901|Experimental|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
9826865|NCT02435914|Experimental|AGN-223575 Dose A|1 drop of AGN-223575 Dose A ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose A ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
9826866|NCT02435914|Experimental|AGN-223575 Dose B|1 drop of AGN-223575 Dose B ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose B ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
9826867|NCT02435914|Experimental|AGN-223575 Dose C|1 drop of AGN-223575 Dose C ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose C ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
9826868|NCT02435914|Placebo Comparator|AGN-223575 Vehicle|1 drop of Vehicle to AGN-223575 ophthalmic solution administered in each eye twice daily for 14 day followed by 1 drop of vehicle to AGN-223575 ophthalmic solution in each eye once daily for 7 days.
9826869|NCT02435966|Experimental|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
9826870|NCT02435966|Other|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
9826871|NCT02435966|No Intervention|Untreated control|Natural history of the condition
9826872|NCT02435992|Experimental|RPC1063 (Ozanimod)|1mg, daily oral administration during Induction and Maintenance periods.
9826873|NCT02435992|Placebo Comparator|Placebo|Daily oral administration during Induction and Maintenance periods.
9668093|NCT01905384|Active Comparator|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
9826874|NCT02436005|Experimental|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
9826875|NCT02436005|Active Comparator|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
9826876|NCT02436031|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
9826877|NCT02436031|Experimental|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
9826878|NCT02436135|Experimental|Cohort A, Idelalisib + Ruxolitinib|Idelalisib 50 mg once daily in participants receiving ruxolitinib.
9826879|NCT02436135|Experimental|Cohort B, Idelalisib + Ruxolitinib|Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
9826880|NCT02436135|Experimental|Cohort C, Idelalisib + Ruxolitinib|Idelalisib 150 mg once daily in participants receiving ruxolitinib.
9818122|NCT02121808|Experimental|Supine|NIPPV and Tidal volume
10114977|NCT04454632|Experimental|Mirror therapy group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the mirror therapy group bilateral exercised with the affected arm behind the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation.
9818123|NCT02121808|Experimental|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
9818124|NCT02121808|Experimental|Proclive (Global 25 deg)|NIPPV and Tidal volume
9818125|NCT02121834|Experimental|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
9818126|NCT02121834|Placebo Comparator|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
9818127|NCT02121847|Experimental|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
9818128|NCT02121860|Experimental|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
9818129|NCT02121860|Experimental|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
9818130|NCT02121860|Experimental|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
9818131|NCT02121860|Experimental|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
9818132|NCT02121912|Experimental|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
9818133|NCT02121912|Active Comparator|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
9818134|NCT02122146|Experimental|PF-06664178|Experimental
9818135|NCT02122341|Experimental|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
9818136|NCT02122341|No Intervention|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
9818137|NCT02122380|Experimental|Sitagliptin, then Placebo|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
9818138|NCT02122380|Experimental|Placebo, then Sitagliptin|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
9818139|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
9818140|NCT02122445|Experimental|Low Back Pain|Lower body exercises before and after the application of Cramer Sports Motion tape
9818141|NCT02122471|Experimental|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
9818142|NCT02122471|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
9818143|NCT02122471|Experimental|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
9818144|NCT02122549|Experimental|HWD1000|Subjects using HWD1000
9818145|NCT02122770|Experimental|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
9818146|NCT02122770|Experimental|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A (safety lead-in step): MLN4924, 15mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A: MLN4924, 20mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
9818147|NCT02122783|Experimental|Conventional then Experimental brace resistance|Participants received the Default intervention for a period of a month, were evaluated in the lab and then the novel intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
9818148|NCT02122783|Experimental|Experimental then Conventional brace resistance|Participants received the the novel elastomer to provide brace support intervention for a period of a month, were evaluated in the lab and then the conventional intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
9818149|NCT02122796|Experimental|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
9818150|NCT02122796|No Intervention|Standard of Care|Standard of care post-mastectomy.
9818151|NCT02122887|No Intervention|control group|no intervention for 3 months
9818152|NCT02122887|Experimental|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
9818153|NCT02122952|Experimental|Cohort 1|6.7 X 10^13 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=3)
9818154|NCT02122952|Experimental|Cohort 2|2.0 X 10^14 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=12)
9818155|NCT02123017|Experimental|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses
10182476|NCT03773705|Active Comparator|Scalpel group|Scalpel used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
9818156|NCT02123017|Experimental|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses
9818157|NCT02123017|Experimental|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses
9818158|NCT02123134|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9818159|NCT02123134|Experimental|ATX-101 deoxycholic acid injection|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9818160|NCT02123251|Experimental|Financial Incentives Group|Participants (159) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
9818161|NCT02123251|No Intervention|Control Group|Participants (161) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
9818162|NCT02123329|Active Comparator|Control arm|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
9818163|NCT02123329|Experimental|Intervention arm|Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy. The sessions will be set at a date and time that is convenient for both the pharmacist and the participant. The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
9818164|NCT02123446|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
9818165|NCT02123446|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
9818166|NCT02123459|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
9818167|NCT02123459|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
9818168|NCT02123472|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
9818169|NCT02123472|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
9818170|NCT02123485|Experimental|low frequency rTMS|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
9818171|NCT02123485|Sham Comparator|Sham-rTMS|Sham right prefrontal rTMS 2 times a week
9818172|NCT02123511|Experimental|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
9818173|NCT02123511|Placebo Comparator|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
9818174|NCT02123576|Experimental|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy
9818175|NCT02123576|Placebo Comparator|Placebo|This is a standard placebo pill.
9818176|NCT02123745|Experimental|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
9818177|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
9818178|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages >800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
9818179|NCT02123797||Multidisciplinary Caregivers|Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
9818180|NCT02123797||Serial Care Caregivers|Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
9818181|NCT02123797||Clinical Providers|Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.
9818182|NCT02123849|Experimental|Arm I (continuous aspirin)|Participants receive aspirin PO QD for 12 weeks.
9818183|NCT02123849|Experimental|Arm II (intermittent aspirin)|Participants receive placebo PO QD during weeks 1, 3, 5, 7, 9, and 11 and aspirin PO QD during weeks 2, 4, 6, 8, 10, and 12.
9818184|NCT02123966|Experimental|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
9818185|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.~ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS"
9818186|NCT02124044|Experimental|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
9818187|NCT02124044|Experimental|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
9818188|NCT02124083|Experimental|Vorinostat|Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.
9818189|NCT02124122|Experimental|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
9818190|NCT02124122|Placebo Comparator|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
9818191|NCT02124161|Other|13vPnC+SIIV/Placebo|
9818192|NCT02124161|Other|Placebo+SIIV/13vPnC|
9818193|NCT02124265|Experimental|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
9818194|NCT02124304|Experimental|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
9818195|NCT02124304|Experimental|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
9818196|NCT02124460|No Intervention|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
9818197|NCT02124460|Experimental|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
9818198|NCT02124512|Experimental|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
9818199|NCT02124512|Placebo Comparator|Arm 2 Placebo|Placebo
9818200|NCT02124564|Experimental|Lacosamide|Open-label, single-arm
9818201|NCT02124603||single group|Patients undergone cataract surgery
9818202|NCT02124707|Experimental|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
9818203|NCT02124746|Experimental|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
10114978|NCT04454632|Experimental|Visual feedback group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the visual feedback group bilateral exercised by seeing both arms in the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
10114979|NCT04454632|No Intervention|Control group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the control group bilateral exercised without a mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
10114980|NCT04454541|Active Comparator|Greater occipital nerve block with ultrasound|A-Greater occipital nerve block The ultrasound-guided GONB was performed to more accurately locate the nerve. The patient was asked to lie prone on the table. To locate the nerve, we searched for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp was cleaned with iodine. After that, the skin was sterilized, and the probe was sheathed in a sterile plastic package GONB was performed by applying the injection to the medial of the artery. A 22-gauge needle was advanced beneath the lateral border of the probe using real-time ultrasound guidance and an in-plane technique. In all patients the occipital nerve was seen medial to the artery. The injected side was determined by the patients' clinical symptoms and according to the painful side reported in their headache diaries. The patients were required to lie down for 30 minutes after the injection to avoid dizziness.
10188027|NCT03720275|Experimental|patients with chronic neuropathy of unknown aetiology|For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
9818204|NCT02124746|Experimental|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
10188028|NCT03720249|Experimental|supplementation of compound nutrients|Betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc are provided as a 800mg tablet. And the tablet is orally taken once a day, four tablets at a time for 12 weeks.
10188029|NCT03720249|Placebo Comparator|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement.
10188030|NCT03720236|Experimental|Full preparation|Group A: the complete milling protocol indicated by the manufacturer for the 3.75x10 mm BLX implant will be performed.
9668094|NCT01904032|Experimental|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
9668095|NCT01904032|Active Comparator|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
9668096|NCT01894282|Active Comparator|Manual Therapy|Spinal Manipulative therapy (SMT) for the purpose of this study we will allow the use of other types of MT, including non-thrust spinal mobilization and flexion-distraction technique.
9668097|NCT01894282|Experimental|Mind Body Intervention (MBI)|"Mind Body Intervention will consist of a combination of the previously described manual therapy and Cognitive Behavioral Therapy for pain (CBT-p). Cognitive Behavioral Therapy for pain management has three basic components. The treatment rationale, coping skills training and application and maintenance of learned coping skills."
9818205|NCT02124746|Experimental|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
9818206|NCT02124746|Experimental|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
9818207|NCT02124759|Placebo Comparator|Placebo|Placebo: maltodextrin, 6 g three times a day
9818208|NCT02124759|Active Comparator|Sevelamer|Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day)
9818209|NCT02124759|Active Comparator|Synbiotic|Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet
9818210|NCT02124772|Experimental|Part A - TMT 0.0125 mg/kg/day|Participants treated with trametinib 0.0125 mg/kg/day
9818211|NCT02124772|Experimental|Part A - TMT 0.025 mg/kg/day|Participants treated with trametinib 0.025 mg/kg/day
9818212|NCT02124772|Experimental|Part A - TMT 0.032 mg/kg/day|Participants under 6 years of age treated with trametinib 0.032 mg/kg/day
9818213|NCT02124772|Experimental|Part A - TMT 0.04 mg/kg/day|Participants treated with trametinib 0.04 mg/kg/day
9818214|NCT02124772|Experimental|Part B - Neuroblastoma|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
9818215|NCT02124772|Experimental|Part B - LGG fusion|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
9818216|NCT02124772|Experimental|Part B - NF-1 with PN|Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day
9818217|NCT02124772|Experimental|Part B - BRAF V600 mutant solid tumor|Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day
9668098|NCT01876953|Experimental|Dasatinib 100mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
9668099|NCT01876953|Experimental|Dasatinib 140mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
9668100|NCT01850355|Experimental|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
9818218|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 50% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for <12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)
9818219|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 100% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
9818220|NCT02124772|Experimental|Part C - TMT 0.032 mg/kg/day + 100% DRB RP2D|Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)
9818221|NCT02124772|Experimental|Part D - LGG|Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
9818222|NCT02124772|Experimental|Part D - LCH|Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
9818223|NCT02124798|Experimental|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
9818224|NCT02124811|Experimental|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
9668101|NCT01827904|Experimental|Transcranial ExAblate|Transcranial ExAblate
9668102|NCT01827904|Sham Comparator|Sham Transcranial ExAblate|Sham Treatment with Transcranial ExAblate
9668103|NCT01799629|Experimental|Intervention|Intervention group will receive the glycerin suppository
9668104|NCT01799629|No Intervention|Control|Normal care
9668105|NCT01793805||Metastatic Colorectal Cancer Patients|
9818225|NCT02124811|Experimental|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
9818226|NCT02124863|Experimental|Intrapulmonary Percussive Ventilation|number of refluxes during 20 min of IPV ( rate : 300/min, p = 10cmH2O) at least 120 min after feeding
9818227|NCT02124889|Experimental|Weekly surveys|Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment.
9818228|NCT02124889|No Intervention|No Survey|Subjects will take the multivitamin.
9818229|NCT02125279|Experimental|Calcitriol ointment|
9818230|NCT02125292|Experimental|Mesalamine (Vanilla Yogurt)|One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
9818231|NCT02125292|Experimental|Mesalamine (Applesauce)|One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
9818232|NCT02125292|Experimental|Mesalamine (Dosing Cup)|One 500mg capsule contents emptied into a dosing cup and taken with water
9818233|NCT02125331||PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
9818234|NCT02125331||PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
9818235|NCT02125604|Experimental|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
9818236|NCT02125721|Experimental|CBTD Patients|Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period
9818237|NCT02125734|Experimental|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
9818238|NCT02125734|Experimental|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
9818239|NCT02125838|Active Comparator|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
9818240|NCT02125838|Experimental|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
9818241|NCT02125877|Active Comparator|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
9818242|NCT02125877|Experimental|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
9818243|NCT02126306|Placebo Comparator|Placebo|Normal saline administered orally daily as a placebo
9818244|NCT02126306|Active Comparator|Beta Glucosylceramide|Beta glucosylceramide administered orally daily
9818245|NCT02126319|Experimental|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
9818246|NCT02126319|Active Comparator|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
9818247|NCT02126670|Placebo Comparator|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
9818248|NCT02126670|Active Comparator|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
9818249|NCT02126670|Active Comparator|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
9668106|NCT01776398||1.1 HEALTHY SUBJECTS|Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
9818250|NCT02126670|Other|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
9818251|NCT02126748|Experimental|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
9818252|NCT02126748|Active Comparator|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
9818253|NCT02126748|No Intervention|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
9818254|NCT02126826|Placebo Comparator|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
9818255|NCT02126826|Experimental|BI 1026706|Multiple Rising Doses BI 1026706
9818256|NCT02126839|Placebo Comparator|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
9818257|NCT02126839|Experimental|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
9818258|NCT02126969|Experimental|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
9818259|NCT02126969|Active Comparator|Chemotherapy without Radiation|Chemotherapy only
9818260|NCT02127125|Placebo Comparator|Type2 Diabetes Mellitus - Placebo|Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
9818261|NCT02127125|Placebo Comparator|Obese with NGT - Placebo|Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
9818262|NCT02127125|Placebo Comparator|Lean with NGT -Placebo|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
9818263|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Synbiotic|Type 2 Diabetic subjects will receive synbiotic
9818264|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Sevelamer|Type 2 Diabetic subjects will receive sevelamer
9818265|NCT02127125|Active Comparator|Obese with NGT - Synbiotic|Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
9818266|NCT02127125|Active Comparator|Obese with NGT - Sevelamer|Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
9818267|NCT02127125|Active Comparator|Lean with NGT - Synbiotic|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
9818268|NCT02127125|Active Comparator|Lean with NGT - Sevelamer|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
9818269|NCT02127281|Active Comparator|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
9818270|NCT02127281|No Intervention|Control|A standard of care sterile wound dressing will be placed.
9818271|NCT02127567|Experimental|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
9818272|NCT02127567|Other|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
9818273|NCT02127632|Active Comparator|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
9818274|NCT02127632|Experimental|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
9818275|NCT02127710|Experimental|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
9818276|NCT02127723|Experimental|Macrolane|All subjects will receive hyaluronic acid injection (Macrolane VRF30)
9818277|NCT02127892|Other|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
9818278|NCT02127892|Other|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
9818279|NCT02127892|Other|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
9818280|NCT02127892|Other|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
9818281|NCT02127931|Experimental|ADHD group played Game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
9818282|NCT02127931|Active Comparator|Control group played game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
9818283|NCT02127970|Experimental|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
9818284|NCT02127970|Experimental|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
9818285|NCT02128074|Experimental|KRX-0502|KRX-0502 (ferric citrate)
9818286|NCT02128217|Experimental|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
9818287|NCT02128217|Experimental|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
10182477|NCT03773731|Experimental|High intensity interval training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test.~10 minutes with 30% of maximal power output."
10188031|NCT03720236|Experimental|Partial preparation|Group B: the partial / under milling protocol for the 3.75x10 mm implant, indicated by the manufacturer, will be carried out.
10188032|NCT03720236|Experimental|Deferred loading|Code 2: for implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. Impressions will be taken at 6 weeks to place the provisional prosthesis at 8 weeks. At 6 months the final impressions will be taken for the definitive load.
10114981|NCT04454541|Experimental|Multifidus cervicis plane block with ultrasound guided|Patients placed in a lateral position with their affected side upwards. Several gel cushions were placed under their head, neck, and arm to put the neck in a stable and slightly anterior flexion position spinal level was determined by identifying the transverse process of the seventh and sixth cervical vertebrae (C7 and C6). The seventh cervical transverse process (C7) differs from the levels above by having a rudimentary anterior tubercle and a prominent posterior tubercle. After aseptic preparation of the injection area, lidocaine 1% was used to anesthetize the skin. Under continuous ultrasound guidance, the needle (22-G, 0.7 mm × 60 mm, Plexufx, B-BRAUN, Tokyo, Japan) was introduced in-plane through the skin and advanced into the fascial plane between the multifidus cervicis and semispinalis cervicis muscles for the MCP block.
9818288|NCT02128230|Experimental|Total Therapy 5b|Induction, optional bridging, first transplant, optional bridging, inter-therapy, optional bridging, second transplant, optional bridging, consolidation, maintenance
9818289|NCT02128269|Experimental|ALXN1007- Open label study|ALXN1007
9818290|NCT02128490|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818291|NCT02128490|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818292|NCT02128490|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818293|NCT02128490|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818294|NCT02128490|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818295|NCT02128542|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
9818296|NCT02128724|Experimental|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral buparlisib. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with buparlisib for a total of fourteen days. One week after commencing buparlisib, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take buparlisib for 4 weeks at the MTD.
9818297|NCT02128763|Experimental|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
9818298|NCT02128763|Placebo Comparator|Placebo|Olive oil-5 gelcaps per day
9818299|NCT02128828|Experimental|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
9818300|NCT02128867|Experimental|Assisted Autogenic Drainage (AAD)|airway clearance technique for infants :Assisted Autogenic Drainage
9818301|NCT02128867|Experimental|bouncing and AAD|airway clearance technique for infants : bouncing combined with AAD
9818302|NCT02128867|Experimental|bouncing|bouncing . intervention to relax the infant
9818303|NCT02128919|Experimental|Active tDCS|tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
9818304|NCT02128919|Sham Comparator|Sham tDCS|tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
9818305|NCT02128932|Experimental|Semaglutide 0.5 mg/week|
9818306|NCT02128932|Experimental|Semaglutide 1.0 mg/week|
9818307|NCT02128932|Active Comparator|Insulin glargine|
9818308|NCT02128997|Experimental|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
9818309|NCT02128997|No Intervention|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
9818310|NCT02129062|Experimental|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9818311|NCT02129075|Experimental|Arm I (CDX-301, CDX-1401, poly-ICLC)|Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401 SC or ID on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
9818312|NCT02129075|Active Comparator|Arm II (CDX-1401, poly-ICLC)|Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
9818313|NCT02129192|Experimental|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
9818314|NCT02129192|Active Comparator|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
9818315|NCT02129205|Experimental|PF-06650808|
9818316|NCT02129426|Experimental|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
9818317|NCT02129426|Active Comparator|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
9818318|NCT02129478|Experimental|Olanzapine|
9818319|NCT02129556|Experimental|MK-3475 with trastuzumab (single arm)|"Phase Ib: MK-3475 at dose of 2 mg/kg or 10 mg/kg (i.v.), or a fall-back dose of 1 mg/kg, together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
9818320|NCT02129608|Active Comparator|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
9818321|NCT02129608|Active Comparator|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
9818322|NCT02129608|Active Comparator|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
9818323|NCT02129660|Experimental|Dose 1 of glycopyrrolate, 2.0% QD|glycopyrrolate Topical Wipes
9818324|NCT02129660|Experimental|Dose 2 of glycopyrrolate, 3.0% QD|glycopyrrolate Topical Wipes
9818325|NCT02129660|Active Comparator|Dose 1 of glycopyrronium, 2.5% QD|glycopyrronium Topical Wipes
9818326|NCT02129660|Active Comparator|Dose 2 of glycopyrronium, 3.75% QD|glycopyrronium Topical Wipes
9818327|NCT02129660|Placebo Comparator|Vehicle|Vehicle Topical Wipes
9818328|NCT02129725|Experimental|sildenafil citrate|In the parent study, subjects are randomized to sildenafil 25 mg tid.
9818329|NCT02129725|Placebo Comparator|placebo oral capsule|In the parent study, subjects are randomized to matching placebo
9818330|NCT02129777|Experimental|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
9818331|NCT02129777|Experimental|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
9818332|NCT02129777|Experimental|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
9818333|NCT02129777|Experimental|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
9818334|NCT02129777|Placebo Comparator|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
9818335|NCT02129777|Experimental|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
9818336|NCT02129777|Experimental|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
9826881|NCT02436135|Experimental|Cohort D, Idelalisib + Ruxolitinib|Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
10114982|NCT04454619|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
9826882|NCT02436200|Experimental|Intervention|Patients receiving neuromuscular electrical stimulation.
9826883|NCT02436239|Experimental|Vilazodone|
9826884|NCT02436304|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
9826885|NCT02436304|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
9826886|NCT02436304|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
9826887|NCT02436330|Experimental|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
9826888|NCT02436330|Active Comparator|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
9826889|NCT02436356|Active Comparator|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
9826890|NCT02436356|Active Comparator|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
9826891|NCT02436356|Active Comparator|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
9826892|NCT02436408|Experimental|Vismodegib|150mg taken orally once daily
9826893|NCT02436577|Experimental|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
9826894|NCT02436577|Experimental|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
9826895|NCT02436577|Experimental|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
9826896|NCT02436577|Experimental|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
9826897|NCT02436577|Experimental|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
9826898|NCT02436577|Experimental|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
9826899|NCT02436668|Active Comparator|Ibrutinib|"Ibrutinib daily in combination with:~Nab-paclitaxel and gemcitabine"
9826900|NCT02436668|Placebo Comparator|Placebo|"Placebo daily in combination with:~Nab-paclitaxel and gemcitabine"
9826901|NCT02436681|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
9826902|NCT02436759|Experimental|RVL-1201|RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks
9826903|NCT02436759|Placebo Comparator|RVL-1201 Vehicle Placebo|RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks
9826904|NCT02436811|Experimental|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
10114983|NCT04454619|Experimental|Hand antisepsis with Clorhexidina and solution|chlorhexidine gluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate.
9818337|NCT02129803|Experimental|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
9818338|NCT02129803|Placebo Comparator|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
9818339|NCT02130024|Experimental|Ranibizumab 0.5 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
9818340|NCT02130024|Active Comparator|Aflibercept 2.0 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
9818341|NCT02130063|Experimental|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
9818342|NCT02130063|Active Comparator|iron sucrose (Venofer®)|iron sucrose (Venofer®)
9818343|NCT02130193|Experimental|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
9818344|NCT02130193|Experimental|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
9818345|NCT02130258|Other|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
9818346|NCT02130258|Other|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
9818347|NCT02130284|Experimental|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
9818348|NCT02130297|Active Comparator|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
9818349|NCT02130297|Active Comparator|Group 2 - day 14|Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.
9818350|NCT02130297|Active Comparator|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
9818351|NCT02130427|Other|Lung Imaging|Weekly 3D/4D CT scans during radiation therapy. MRI may be used in addition to or instead of CT depending on the location of the tumor and the decision of the treating physician.
9818352|NCT02130557|Experimental|Bosutinib|Bosutinib, 400 mg, oral administration once a day
9818353|NCT02130557|Active Comparator|Imatinib|Imatinib, 400 mg, oral administration once a day
9818354|NCT02130570|Experimental|Multi-Model Intensive Discharge Program|Multi-Model Intensive Discharge Program
9818355|NCT02130570|No Intervention|Usual Care|Usual Care
9818356|NCT02130583|Experimental|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
9818357|NCT02130583|Active Comparator|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
9818358|NCT02130635|Experimental|Part A: GSK2269557 1000 MCG|Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
9818359|NCT02130635|Placebo Comparator|Part A: PLACEBO|Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days
9818360|NCT02130635|Experimental|Part B: GSK2269557 100 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
9818361|NCT02130635|Experimental|Part B: GSK2269557 200 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
9818362|NCT02130635|Experimental|Part B: GSK2269557 500 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days
9818363|NCT02130635|Experimental|Part B: GSK2269557 700 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
9818364|NCT02130635|Experimental|Part B: GSK2269557 1000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
9818365|NCT02130635|Experimental|Part B: GSK2269557 2000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
9818366|NCT02130635|Placebo Comparator|Part B: PLACEBO|Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days
9818367|NCT02130765|No Intervention|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
10114984|NCT04454398|Experimental|COVI-GUARD|COVI-GUARD (STI-1499) administered via a single IV push injection at a dose of 10 mg, 30 mg, 100 mg, or 200 mg, in addition to standard of care
10114985|NCT04454398|Placebo Comparator|Placebo|Placebo administered via a single IV push injection, in addition to standard of care
9818368|NCT02130765|Active Comparator|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
9818369|NCT02130986|Experimental|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
9818370|NCT02130986|Active Comparator|Usual Care group|Telephone Visit at Day 15 and Day 30
9818371|NCT02130999|Experimental|Sequence A|"Single oral dose of tasimelteon 20 mg on Day 1~Single I.V. dose of tasimelteon 2 mg on Day 6"
9818372|NCT02130999|Experimental|Sequence B|"Single I.V. dose of tasimelteon 2 mg on Day 1~Single oral dose of tasimelteon 20 mg on Day 6"
9818373|NCT02131064|Active Comparator|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
9818374|NCT02131064|Experimental|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
9818375|NCT02131129|Experimental|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
9818376|NCT02131129|Sham Comparator|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
9818377|NCT02131233|Experimental|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
9818378|NCT02131233|Active Comparator|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
9818379|NCT02131259||Afatinib|
9818380|NCT02131272|Experimental|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
10114986|NCT04454502|Experimental|Experimental|"In the first stage of data collection, the information in the Mother-Preterm Introductory Information Form study and control groups before colostrum administration, and the information in Preterm Follow-up Form including questions related to physiological parameters, body measurements and nutrition will be obtained. In the second stage, oral colostrum, will be administered once every 3 hours and for at least 5 days until the newborn begins oral feeding. In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered in approximately 1 minute for infants weighing between 1001-1500 g. The third stage, the effectiveness of the first breastfeeding will be evaluated by the observers in experimental group using the Bristol Breastfeeding Assessment Tool. In the last stage, one week after the first breastfeeding sucking / breastfeeding experience will be evaluated again."
10114987|NCT04454502|No Intervention|Control Groups|The infants in the control group will be followed up by oral care with sterile physiological saline in routine care of the service
10114988|NCT04454606|Experimental|Fit test|All the subjects will be tested for fit test
10114989|NCT04454580||treated patients|hypomethylating agent (azacitidine or decitabine) in combination with venetoclax
10114990|NCT04454853||Lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in lung cancer.
10114991|NCT04454853||Lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in lung cancer.
10114992|NCT04454853||Suspected lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in suspected lung cancer.
10114993|NCT04454853||Suspected lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in suspected lung cancer.
10114994|NCT04454359|Experimental|EXP|EXP group will ingest a supplement consisting of 1) flavored whey protein isolate with added pure leucine (3 g) diluted in water, twice daily, before breakfast and before bedtime; doses are adjusted per body weight as follows: 20 g, 25 g or 30 g per category of <65 kg, 65-75 kg and >75 kg of body weight respectively. 2) fish oil containing vitamin D, provided as 7.5 mL liquid oil providing 1500 IU vitamin D3 + 1125 mg EPA + 750 mg DHA, to be ingested once daily.
10114995|NCT04454359|Placebo Comparator|CTR|Control will ingest an isocaloric placebo consisting of 1) 30 g maltodextrin, twice daily, following the same schedule, and 2) 7.5 mL corn oil, once daily.
10114996|NCT04454294|Experimental|Control|The first method; There is no application in maintaining the drain opening, but if there are necessary medical indications such as clot formation, blood accumulation in the drainage connections, lack of drainage, this group is intervened by milking method. In our study, this group will be taken as a control group, there will be a situation that requires intervention in the first 6 hours, and if the milking method is used, it will be excluded from the sample.
10114997|NCT04454294|Experimental|Experimental Group (Absorption Group)|The second method used to maintain the drain opening is the suction method. In this study, this group will be taken as the first experimental group. The suction method is a continuous use until the patient's drainage requirement and the physician's request is terminated by ensuring that the pressure is between 5 and 15 kPa (kilopascals) or 10-20 cm H20 after the appropriate negative pressure tracking system of the patient, who is accepted with intensive care under water drainage system, is established. system.
10188033|NCT03720236|Experimental|Immediate load|The code 1: to the implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. The impression will be made in the same surgery and the placement of the provisional prosthesis before 7 days. At 6 months the final impressions will be taken for the definitive load.
9818381|NCT02131272|Active Comparator|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
9818382|NCT02131311|Experimental|pessary|disposable, single-use pessary
9818383|NCT02131324|Active Comparator|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
9818384|NCT02131324|Experimental|DFD06 Cream|applied twice a day for 15 days
9818385|NCT02131402|Experimental|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
9818386|NCT02131402|Active Comparator|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
9818387|NCT02131402|Active Comparator|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
9818388|NCT02131532|Experimental|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
9818389|NCT02131636|Experimental|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
9818390|NCT02131636|Placebo Comparator|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
9818391|NCT02131662|Experimental|VPR 4 mg|
9818392|NCT02131662|Experimental|VPR 2 mg|
9818393|NCT02131662|Experimental|VPR 1 mg|
9818394|NCT02131662|Experimental|VPR 0.5 mg|
9818395|NCT02131662|Placebo Comparator|Placebo|
9818396|NCT02131766|Experimental|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM.~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
9818397|NCT02131766|Placebo Comparator|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week.
9818398|NCT02132117|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
9818399|NCT02132117|Placebo Comparator|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
9818400|NCT02132130|Experimental|CGF166 dose 20 uL|single dose volume #1
9818401|NCT02132130|Experimental|CGF166 dose 30 and 40 uL|single dose volume #2
9818402|NCT02132130|Experimental|CGF166 dose 40 uL|single dose volume #3
9818403|NCT02132130|Experimental|CGF166 dose 60 uL|single dose volume #4
9818404|NCT02132130|Experimental|CFG166 dose 30 uL|Single dose volume #5
9818405|NCT02132169|Experimental|AC-170 0.24%|
10182478|NCT03773731|Active Comparator|Moderate intensity continuous training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output~10 minutes with 30% of maximal power output."
9818406|NCT02132169|Placebo Comparator|AC-170 0%|
9818407|NCT02132195|Active Comparator|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
9818408|NCT02132195|No Intervention|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study.
9818409|NCT02132195|Active Comparator|Rescue therapy|There is an option for the patient in no-treatment arm to elect to be placed in the active treatment arm of the trial (rescue therapy).
9818410|NCT02132247|Experimental|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
9818411|NCT02132312|Experimental|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
9818412|NCT02132312|Active Comparator|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
9818413|NCT02132468|Experimental|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
9818414|NCT02132520|No Intervention|Control|Subjects receiving standard-of-care physical therapy only.
9818415|NCT02132520|Sham Comparator|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
9818416|NCT02132520|Active Comparator|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
9818417|NCT02132533|Experimental|Nifedipine|Women with preterm labor will receive nifedipine.
9818418|NCT02132533|Experimental|Placebo|Women with preterm labor will receive placebo.
9818419|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
9818420|NCT02132598|Experimental|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.~Treatment cycles are 4 weeks in duration"
9818421|NCT02132637|Experimental|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
9818422|NCT02132637|Experimental|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
9818423|NCT02132650|Experimental|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
9818424|NCT02132650|Active Comparator|SS|Rehabilitation of walking using typical steady state (SS) walking
9818425|NCT02132676||Active treatment|All those scheduled for a Shared Medical Appointment (SMA), regardless of whether the Peer to Peer (P2P) program was offered.
9818426|NCT02132676||Usual Care|The randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
9818427|NCT02132754|Experimental|MK-4166 0.0015 mg|Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818428|NCT02132754|Experimental|MK-4166 0.0045 mg|Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818429|NCT02132754|Experimental|MK-4166 0.014 mg|Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818430|NCT02132754|Experimental|MK-4166 0.04 mg|Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818431|NCT02132754|Experimental|MK-4166 0.12 mg|Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9668107|NCT01776398||1.2 SUBJECTS WITH LUNG DISEASE|Defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population)
9818432|NCT02132754|Experimental|MK-4166 0.37 mg|Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818433|NCT02132754|Experimental|MK-4166 1.1 mg|Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818434|NCT02132754|Experimental|MK-4166 3.3 mg|Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818435|NCT02132754|Experimental|MK-4166 10 mg|Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818436|NCT02132754|Experimental|MK-4166 30 mg|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818437|NCT02132754|Experimental|MK-4166 42 mg|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818438|NCT02132754|Experimental|MK-4166 59 mg|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818439|NCT02132754|Experimental|MK-4166 82 mg|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818440|NCT02132754|Experimental|MK-4166 120 mg|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818441|NCT02132754|Experimental|MK-4166 170 mg|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818442|NCT02132754|Experimental|MK-4166 240 mg|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818443|NCT02132754|Experimental|MK-4166 340 mg|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818444|NCT02132754|Experimental|MK-4166 480 mg|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
10182479|NCT03773588|Active Comparator|Closed-Loop propofol Target control infusion|Closed loop target controlled infusion(TCI) TIVA with propofol using BD TCI pumps guided by entropy and SPI
9818445|NCT02132754|Experimental|MK-4166 670 mg|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818446|NCT02132754|Experimental|MK-4166 900 mg|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
9818447|NCT02132754|Experimental|MK-4166 1.1 mg + Pembro|Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818448|NCT02132754|Experimental|MK-4166 3.3 mg + Pembro|Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818449|NCT02132754|Experimental|MK-4166 10 mg + Pembro|Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818450|NCT02132754|Experimental|MK-4166 30 mg + Pembro|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818451|NCT02132754|Experimental|MK-4166 42 mg + Pembro|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818452|NCT02132754|Experimental|MK-4166 59 mg + Pembro|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818453|NCT02132754|Experimental|MK-4166 82 mg + Pembro|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818454|NCT02132754|Experimental|MK-4166 120 mg + Pembro|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818455|NCT02132754|Experimental|MK-4166 170 mg + Pembro|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818456|NCT02132754|Experimental|MK-4166 240 mg + Pembro|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818457|NCT02132754|Experimental|MK-4166 340 mg + Pembro|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818458|NCT02132754|Experimental|MK-4166 480 mg + Pembro|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818459|NCT02132754|Experimental|MK-4166 670 mg + Pembro|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818460|NCT02132754|Experimental|MK-4166 900 mg + Pembro|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
9818461|NCT02132767|Active Comparator|Rhythm control|"Rhythm Control in post-operative AF~Amiodarone and/or DC-cardioversion~Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
9818462|NCT02132767|Active Comparator|Rate control|"Rate Control in post-operative AF~Beta-blocker and/or Calcium channel blockers and/or Digoxin~Dose, frequency and duration determined by medical professional as medically needed"
9818463|NCT02132832|Experimental|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
9818464|NCT02132832|Placebo Comparator|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
9818465|NCT02132910|Experimental|RESTORE Intervention|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.~For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.~For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.~At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
9818466|NCT02132910|No Intervention|Control Group 2|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.~You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.~At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
9818467|NCT02132936|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
9818468|NCT02132936|Placebo Comparator|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
9818469|NCT02132936|Active Comparator|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
9818470|NCT02132936|Placebo Comparator|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
9818471|NCT02132949|Experimental|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams [mg] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram [mg/kg] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
9818472|NCT02132949|Experimental|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m^2 intravenously (IV) q3w, epirubicin 100mg/m^2 IV q3w, and cyclophosphamide 600mg/m^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m^2 in Cycle 5, then 100mg/m^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
9818473|NCT02133001|Experimental|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
9818474|NCT02133001|Placebo Comparator|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
9818475|NCT02133066|Active Comparator|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
9818476|NCT02133066|Placebo Comparator|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
9818477|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
9818478|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
9818479|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
9818480|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
9818481|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
9818482|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
9818483|NCT02133131|Experimental|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
9818484|NCT02133235|Active Comparator|conventional|insertion of endobronchial blocker and auscultation, fiberoptic confirmation and reposition
9818485|NCT02133235|Experimental|auscultation|insertion endobronchial blocker by auscultation without conventional bronchoscopic reposition
9818486|NCT02133352|Experimental|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
9818487|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
9818488|NCT02133664|Experimental|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
9818489|NCT02133664|Placebo Comparator|placebo|placebo oil and placebo lipoic acid
9818490|NCT02133742|Experimental|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
9818491|NCT02133781|Experimental|Age 8-17 years (identical twins )|Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula
9818492|NCT02133781|Experimental|Age 18-30 years (non-twins)|Participants will be receive Fluzone® 2009-2010 Formula
9818493|NCT02133781|Experimental|Age >70 years (non-twins)|Participants will receive Fluzone® 2009-2010 Formula
9818494|NCT02134015|Experimental|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
9818495|NCT02134015|Experimental|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
9519365|NCT03287895|Experimental|Intervention - Decision Support|In addition to the regular conversation about CPR that a patient's physician may have with them, participants will be given a two-part intervention. First, the participant will receive a values clarification tool which helps them rate and understand which relevant values are most important to them. There are two forms of this tool, a full and simplified version. All participants in this arm will receive both, in randomized order. The second aspect of the intervention is an educational video about the potential risks and benefits of CPR, which all participants in this arm will receive.
9668108|NCT01776398||2. WCMC/NYPH CLINICAL PATIENTS|"Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit.~WCMC/NYPH clinical patients will not undergo any additional procedures listed in this protocol as part of this research study."
9818496|NCT02134119|Experimental|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
9818497|NCT02134119|Placebo Comparator|Sugar pill|Placebo given 8,000mg/day by mouth
9818498|NCT02134184|Experimental|CMV negative group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
9818499|NCT02134184|Experimental|CMV positive group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
9818500|NCT02134184|Experimental|Recent CMV Converters|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
9818501|NCT02134210|Active Comparator|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
9818502|NCT02134210|Experimental|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
9818503|NCT02134314|Experimental|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
9818504|NCT02134314|Placebo Comparator|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
9818505|NCT02134353|Experimental|Experimental arm A|Active treatment. Inhaled Mannitol
9818506|NCT02134353|Placebo Comparator|Arm B - Control|Arm B
9818507|NCT02134522|Experimental|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
9818508|NCT02134587|Other|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
9818509|NCT02134756|Experimental|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
9818510|NCT02134756|Placebo Comparator|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
9818511|NCT02134951|Experimental|ketamine|IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
9818512|NCT02134951|Placebo Comparator|Placebo|Placebo group will receive normal saline
9818513|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
9818514|NCT02135016|Experimental|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
9818515|NCT02135016|Experimental|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
9818516|NCT02135016|Placebo Comparator|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
9818517|NCT02135094|Experimental|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
9818518|NCT02135094|Placebo Comparator|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
9818519|NCT02135107|Experimental|Arm A|
9818520|NCT02135107|Experimental|Arm B|
9818521|NCT02135107|Experimental|Arm C|
9818522|NCT02135107|Experimental|Arm D|
9818523|NCT02135146|Active Comparator|Plasmalyte 3ml/kg/hr group|
9818524|NCT02135146|Active Comparator|Plasmalyte 6ml/kg/hr group|
9818525|NCT02135432|Experimental|Ivacaftor (VX-770)|twice a day administration of Ivacaftor: 150mg
9818526|NCT02135432|Placebo Comparator|Placebo|matching placebo
9818527|NCT02135445|Experimental|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
9818528|NCT02135445|Active Comparator|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
9818529|NCT02135614|Experimental|Presatovir|Participants will receive a single dose of presatovir.
9818530|NCT02135614|Placebo Comparator|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
9818531|NCT02135653||Feasibility Phase: Eischens Yoga Group|
9818532|NCT02135653||Phase II: Eischens Yoga Group|
9818533|NCT02135692|Experimental|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
9818534|NCT02135848|Experimental|GSK1278863|Study Drug
9818535|NCT02135848|Placebo Comparator|Placebo|Placebo
9818536|NCT02135861|Experimental|Healthy volunteers|All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
9818537|NCT02135861|Experimental|Heart failure patients|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
9818538|NCT02135861|Experimental|Acute decompensated heart failure|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
9818539|NCT02135900|Experimental|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
9818540|NCT02136004|Experimental|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
9818541|NCT02136238|Active Comparator|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
9818542|NCT02136238|Active Comparator|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
9818543|NCT02136238|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
9818544|NCT02136420|Experimental|Tilt perception, Training, placebo|placebo
9818545|NCT02136420|Placebo Comparator|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
9818546|NCT02136420|Experimental|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
9818547|NCT02136420|Experimental|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
9818548|NCT02136420|Experimental|Manual Control, Training, placebo|placebo
9818549|NCT02136420|Placebo Comparator|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
9818550|NCT02136420|Experimental|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
9818551|NCT02136420|Experimental|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
9818552|NCT02136420|Experimental|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
9818553|NCT02136420|Experimental|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
9818554|NCT02136498|Active Comparator|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
9818555|NCT02136498|Experimental|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects & secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
9818556|NCT02136576|Active Comparator|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
9818557|NCT02136576|Active Comparator|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
9818558|NCT02136576|Active Comparator|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
9818559|NCT02136680|Active Comparator|Patients at Intervention Site|Staff receives CASA Education
9818560|NCT02136680|No Intervention|Patients at CONTROL site|Staff does not receive CASA Education
9818561|NCT02136914|Experimental|ADS-5102|ADS-5102 (amantadine HCl extended release)
9818562|NCT02136914|Placebo Comparator|Placebo|Placebo
10114998|NCT04454294|Experimental|Experimental Group (Milking Group)|The third method is milking. In our study, this group will be taken as the 2nd experimental group. In the milking method, the process starts from the area close to the drain entry point. The latex tube is folded into 12 cm long pieces and gripped with two hands. The nurse repeats the process 3 times by compressing the parts gripped by the hand. This process is then used at intervals every hour to repeat the distal part.
10114999|NCT04454164|Experimental|PRP group|Intraarticular 5 ml single PRP injection
10115000|NCT04454164|Placebo Comparator|Saline group|Intraarticular 5 ml single saline injection
10115001|NCT04454164|Experimental|Multiple PRP group|Intraarticular 3 dose of 5 ml PRP injection (0, 1, 3 month injection)
10115002|NCT04454164|Placebo Comparator|Multiple saline group|Intraarticular 3 dose of 5 ml saline injection (0, 1, 3 month injection)
10115003|NCT04454307|Experimental|Tramadol|tramadol 100 mg twice daily for 10 days
10115004|NCT04454307|Active Comparator|standard care|standard care plus (placebo twice daily for 10 days).
10115005|NCT04454177||SMART watch|Medical records from patients aged 18 years or older undergoing Transcatheter Aortic Valve Replacement
10115006|NCT04454190||Glaucoma - Slow progressors|Rates of MD change slower than -0.50 dB/year Rates of global RNFL thickness change slower than -1.0 µm/year
10115007|NCT04454190||Glaucoma - Fast progressors|Rates of MD change faster -0.50 to -2.00 dB/year Rates of global RNFL thickness change -1.0 to -4.0 µm/year
10115008|NCT04454190||Glaucoma - Catastrophic progressors|Rates of MD change faster than -2.00 dB/year Rates of global RNFL thickness change faster than -4.0 µm/year
10115009|NCT04454034||Group1|The refractory elbow RA who undergo arthroscopic synovectomy
10115010|NCT04454099||Fecal Occult Blood Test|People in this group will use four kind of fecal occult blood test, including quantitative and qualitative method, to detect Hb in stool before colonoscopy.
10115011|NCT04454125|Active Comparator|Routine Care|
10115012|NCT04454125|Experimental|AQI Intervention|
10115013|NCT04454060||Extracapsular method group|consecutive 43 patients who received extracapsular method treatment for refractory tennis elbow
10115014|NCT04454086|Experimental|Supportive care (exercise program, counseling)|Patients undergo aerobic exercise over 10-30 minutes and resistance exercise comprising 1-3 sets of 8-12 repetitions of 10 different exercises over 1 hour for 24 weeks. Patients also receive behavioral activity counseling once a week and nutritional counseling over 30 minutes for 10 sessions after center-based exercise sessions during months 1-2.
9668109|NCT01776398||3. PCNY CLINICAL PATIENTS|Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit. Clinical patients seen at the Pulmonary Consultants of New York will only undergo the nasal sample collection and may be asked to have a blood draw of about 2 teaspoons (9ml).
9668110|NCT01772472|Active Comparator|Trastuzumab|
9668111|NCT01772472|Experimental|Trastuzumab emtansine|
9818563|NCT02137226|Experimental|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
10115015|NCT04454151|Experimental|Azithromycin|1x250
10115016|NCT04454047||Extracapsular method group|50 patients with refractory tennis elbow who received extracapsular arthroscopic surgery.
10115017|NCT04453956|Sham Comparator|Control group|Patients will receive colonoscopy without assistance of EndoAngel's any function.
10115018|NCT04453956|Experimental|Polyp detection function group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection function.
10115019|NCT04453956|Experimental|Quality monitoring function group|Patients will receive colonoscopy with the assistance of EndoAngel's quality monitoring function.
10115020|NCT04453956|Experimental|Polyp detection plus quality monitoring functions group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection plus quality monitoring function.
10115021|NCT04454281|Experimental|Naloxone HCl Low dose: 0.02 mg|This arm will receive 0.02 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
10115022|NCT04454281|Experimental|Naloxone HCl High dose: 0.08 mg|This arm will receive 0.08 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
10115023|NCT04453943|Experimental|Group A - SCI|Ten individuals with SCI at the T1-T10 level will be recruited (Group A). These individuals can have incomplete or complete paraplegia.
10115024|NCT04453943|Experimental|Group B - Subjects without disability|Twenty individuals without disability will be recruited (Group B). Individuals with SCI who have experience in using some kind of walking assistive devices in the recent past will be preferably recruited.
10115025|NCT04453930|Experimental|Camrelizumab+Irinotecan+Platinum→Camrelizumab+apatinib|Participants received intravenous infusions of Camrelizumab 200 mg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) or Cisplatin 30 milligrams per square meter (mg/m^2) followed by Irinotecan 65 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4/5/6). On Days 8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6), Cisplatin 30 mg/m^2 and Irinotecan 65 mg/m^2 was administered. Thereafter, participants received maintenance (Cycle onward) Camrelizumab 200 mg on Day 1 of every 21-day cycle with Apatinib 250mg until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
10115026|NCT04453904|Experimental|"sequential radiochemotherapy in a sanwich mode"|Two courses of TC regimen chemotherapy (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) will be given first, followed by external pelvic radiation (± vaginal brachytherapy), and then four courses of the same regime consolidation chemotherapy.
10182480|NCT03773588|Active Comparator|Open-loop propofol target control infusion|Open-loop target controlled infusion of propofol using BD TCI pumps based on Schnider effect site algorithm
9818564|NCT02137226|Active Comparator|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
9818565|NCT02137369|Active Comparator|SSRI|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks or Sertraline, pill form, 50 - 150 mg, daily for 12 weeks
9818566|NCT02137369|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
9818567|NCT02137382|Experimental|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
9818568|NCT02137382|Experimental|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
9818569|NCT02137447|Experimental|Negative Pressure Wound Therapy|"After the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg.~For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7"
9818570|NCT02137486||sequential ballooning|include BMS or DES
9818571|NCT02137486||final kissing ballooning|include BMS or DES
9818572|NCT02137499|Active Comparator|Healthy subjects|Healthy subjects, free from vascular disease
9818573|NCT02137499|Experimental|Superficial venous insufficiency|Clinically symptomatic and ultrasound evidence of superficial venous insufficiency
9668112|NCT01764711|Experimental|Low Salt Diet POTS|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
9818574|NCT02137499|Experimental|Deep venous insufficiency|Clinically symptomatic and ultrasound evidence of deep venous insufficiency
9818575|NCT02137499|Experimental|Deep venous obstruction|Clinically symptomatic and ultrasound evidence of deep venous obstruction
9818576|NCT02137512|Experimental|Closed-Loop Control System|Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
9818577|NCT02137512|Active Comparator|Sensor-Augmented Pump (SAP)|Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump
9818578|NCT02137538|Active Comparator|Letrozole|Letrozole 2.5 mg daily
9818579|NCT02137538|Active Comparator|Anastrozole|Anastrozole 1 mg daily
9519366|NCT03287895|No Intervention|Control|Participants in this arm will receive usual care, the regular conversation about CPR that their physician may have with them.
9818580|NCT02137603|Experimental|Fast track|Patients discharged home the same day following appendectomy
9818581|NCT02137603|No Intervention|Admission|Patients are admitted to the inpatient unit following appendectomy for suppurative appendicitis and treated per the current standard of care.
9818582|NCT02137772|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
9818583|NCT02137772|Placebo Comparator|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
9818584|NCT02137785|Experimental|ALA|
9818585|NCT02137785|Placebo Comparator|Vehicle|
9818586|NCT02137837|Placebo Comparator|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
9818587|NCT02137837|Experimental|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
9818588|NCT02137837|Experimental|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
10182481|NCT03773692|Experimental|Passive feedback and JITAI|"Passive feedback and JITAI~Second Phase - PA Level Feedback Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)"
9818589|NCT02138006|Experimental|Intensive insulin treatment|Intensive insulin treatment
9818590|NCT02138006|Active Comparator|Standard insulin treatment|Standard insulin treatment
9826905|NCT02436811|Experimental|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
9826906|NCT02436811|Experimental|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
9826907|NCT02436876|Experimental|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
9826908|NCT02436876|Experimental|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
9818591|NCT02138097||Glitazones|
9818592|NCT02138097||Linagliptin|
9818593|NCT02138097||Meglitinides|
9818594|NCT02138097||Metformin|
9818595|NCT02138097||Non-insulin injectables|
9818596|NCT02138097||Saxagliptin|
9818597|NCT02138097||Sitagliptin|
9818598|NCT02138097||Sulfonylurea|
9818599|NCT02138110|Experimental|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
9818600|NCT02138136|Experimental|Lubiprostone|"Participants receive lubiprostone twice daily~Participants must have completed the entire 12-week treatment period during the preceding study. Those who received 12 mcg twice daily (BID) continued to receive 12 mcg, those who received 24 mcg BID continued with that dose.Those of the placebo arm in the previous study weighing less than 50 kg received 12 mcg BID and over 50 kg received 24 mcg BID during this study."
9818601|NCT02138214|Experimental|Arm I (no CND)|Patients undergo total thyroidectomy alone.
9818602|NCT02138214|Experimental|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
9818603|NCT02138214|Active Comparator|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
9818604|NCT02138227|Active Comparator|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills.
9818605|NCT02138227|Active Comparator|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
9818606|NCT02138240|Experimental|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
9519367|NCT03287882|No Intervention|Standard of care|"Preconception period: none~Pregnancy period: daily iron (60 mg) and folic acid (400 µg) supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily iron and folic acid supplementation to 6 months postpartum"
9818607|NCT02138253|Experimental|IDN-6556|IDN-6556 25 mg BID
9818608|NCT02138253|Placebo Comparator|Placebo|Placebo BID
9818609|NCT02138461||bimatoprost|These patients take bimatoprost topically for glaucoma.
9818610|NCT02138461||latanoprost group|These patients take latanoprost topically for glaucoma.
9818611|NCT02138578|Experimental|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
9818612|NCT02138578|Active Comparator|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
9818613|NCT02138578|Active Comparator|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
9818614|NCT02138747|Experimental|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
9818615|NCT02138747|Experimental|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
9818616|NCT02138747|Experimental|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
9818617|NCT02138747|Experimental|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
9818618|NCT02138786|Experimental|selinexor|"oral tablets~10 mg & 25 mg (bottled); or~20 mg (blister pack)"
9818619|NCT02138825|Experimental|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
9826909|NCT02436876|Experimental|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
10188034|NCT03720223|Experimental|Liposomal Bupivacaine|20ml Liposomal Bupivacaine 1.3% (13.3mg/mL), injected to the buccal mucosal graft harvest site.
9818620|NCT02138825|Placebo Comparator|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
9818621|NCT02138838|Active Comparator|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
9818622|NCT02138838|Experimental|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
9818623|NCT02138890|Experimental|APS injection|Autologous Protein Solution
9818624|NCT02138890|Placebo Comparator|Control|Saline
9818625|NCT02138916|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
9818626|NCT02138916|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
9818627|NCT02138916|Placebo Comparator|Placebo|Placebo administered subcutaneously
9818628|NCT02139007|Active Comparator|Continuation Arm|Alendronate continuation arm
9818629|NCT02139007|Active Comparator|Discontinuation Arm|Alendronate discontinuation arm
9818630|NCT02139046|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818631|NCT02139046|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818632|NCT02139046|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818633|NCT02139046|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818634|NCT02139046|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
9818635|NCT02139124|Placebo Comparator|Placebo|Placebo Arm
9818636|NCT02139124|Experimental|PRC-063 25 mg|PRC-063 25 mg
9818637|NCT02139124|Active Comparator|PRC-063 45 mg|PRC-063 45 mg
9818638|NCT02139124|Active Comparator|PRC-063 70 mg|PRC-063 70 mg
9818639|NCT02139124|Active Comparator|PRC-063 100 mg|PRC-063 100 mg
9818640|NCT02139137|Experimental|High Interference Control Condition|Computerized training program requiring participants to repeatedly practice controlling interference on a cognitive task
9818641|NCT02139137|Active Comparator|Low Interference Control Condition|Computerized training program requiring participants to minimally practice controlling interference on a cognitive task
9818642|NCT02139176|Active Comparator|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
9818643|NCT02139176|Experimental|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
9818644|NCT02139228|Experimental|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
9818645|NCT02139228|Active Comparator|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
9818646|NCT02139280|Active Comparator|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
10182482|NCT03773510|Active Comparator|Trabectedin continuation|All the patients who will complete 6 cycles of trabectedin without disease progression, will continue trabectedin until progressive disease, unacceptable toxicity, patient or investigator decision
9818647|NCT02139280|Experimental|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
9818648|NCT02139306|Experimental|Ataluren (PTC124®)|Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
9818649|NCT02139306|Placebo Comparator|Placebo|Participants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.
9818650|NCT02139358|Experimental|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
9818651|NCT02139540|Other|N2O/Placebo|First session: Nitrous oxide Second session: placebo
9818652|NCT02139540|Other|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
9818653|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
9818654|NCT02139644|Experimental|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9818655|NCT02139644|Experimental|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9818656|NCT02139644|Experimental|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9818657|NCT02139644|Experimental|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9818658|NCT02139644|Placebo Comparator|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9818659|NCT02139800|Active Comparator|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
9818660|NCT02139800|Experimental|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
10115027|NCT04453904|Active Comparator|concurrent chemoradiotherapy followed by chemotherapy|External pelvic radiation (± vaginal brachytherapy) will be given after operation. On the first day and the 29th day of radiotherapy, concurrent intravenous cisplatin (50mg/m2) will be given. After the concurrent radiochemotherapy, four courses of TC regimen (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) chemotherapy will be given.
10115028|NCT04454008|Experimental|Intervention|The intervention group will receive 12 sessions of executive function family training, including executive function training for children and parenting guidance for parents.
9818661|NCT02139826|Experimental|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
9818662|NCT02139826|Experimental|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
9818663|NCT02139826|Experimental|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
9818664|NCT02139878|Experimental|Wild blueberry juice|240 ml wild blueberry juice
9818665|NCT02139878|Placebo Comparator|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
9818666|NCT02139943|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
9818667|NCT02139943|Experimental|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
9818668|NCT02139943|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks
10115029|NCT04454008|Active Comparator|waiting|The waiting group will receive routine clinical intervention, including health education, family support and guidance from outpatient clinic.
9818669|NCT02139969||GreenLight XPS Laser System|Treatment of BPH in men using the GreenLight XPS Laser System and the MoXy fiber
9818670|NCT02139982|Other|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
9818671|NCT02139982|Other|group UL( phase 1)|specific nerve block:ulnar nerve block
9818672|NCT02139982|Other|group RA (phase 1)|specific nerve block:radial nerve block
9818673|NCT02139982|Other|group ME (phase 1)|specific nerve block:median nerve block
9818674|NCT02139982|Experimental|group A(phase 2)|30ml ropivacaine 0.125%
9818675|NCT02139982|Experimental|group B(phase 2)|30ml ropivacaine 0.2%
9818676|NCT02139982|Experimental|group C(phase 2)|30ml ropivacaine 0.25%
9818677|NCT02139982|Experimental|group D(phase 2)|30ml ropivacaine 0.375%
9818678|NCT02139982|Experimental|group E(phase 2)|30ml ropivacaine 0.5%
9818679|NCT02139982|Experimental|group F(phase 2)|30ml ropivacaine 0.75%
9818680|NCT02140060|Experimental|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
9818681|NCT02140060|Experimental|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
9818682|NCT02140060|Experimental|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
9818683|NCT02140060|Active Comparator|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
9818684|NCT02140060|Active Comparator|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
9818685|NCT02140060|Active Comparator|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
9818686|NCT02140164|Experimental|Minocycline|Oral administration of minocycline
9818687|NCT02140372|Experimental|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
9818688|NCT02140411|Experimental|Ranibizumab|Ranibizumab treatment
9519368|NCT03287882|Experimental|MMN supplementation and life skills education|"Preconception period: twice-weekly MMN supplementation and bi-monthly group session including life skill based education materials~Pregnancy period: daily MMN supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily MMN supplementation to 6 months postpartum"
9818689|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
9818690|NCT02140593|Placebo Comparator|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
9818691|NCT02140593|Active Comparator|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
9818692|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
9818693|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
9818694|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
9818695|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
9818696|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
9818697|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
9818698|NCT02140762|Experimental|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
9818699|NCT02140762|Active Comparator|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
9818700|NCT02140775|Experimental|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
9818701|NCT02140775|Active Comparator|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
9818702|NCT02140957|Experimental|Educational Intervention|Parents in this arm received a 5 minute educational intervention on bottle cessation plus standard nutritional counseling.
9818703|NCT02140957|Placebo Comparator|Control|Parents in this arm received a placebo which consisted of standard nutritional counseling alone.
9818704|NCT02140970|Experimental|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
9818705|NCT02140970|Placebo Comparator|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
9818706|NCT02141204|Experimental|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination, who received two oral doses of Liquid Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
9818707|NCT02141204|Active Comparator|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who received two oral doses of Lyophilized Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
10182483|NCT03773510|Experimental|Trabectedin discontinuation|"All the patients who will complete 6 cycles of trabectedin without disease progression , will discontinue trabectedin.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
9818708|NCT02141217|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
9818709|NCT02141217|Active Comparator|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
9818710|NCT02141295|Experimental|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m^2) as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
9818711|NCT02141295|Experimental|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
9818712|NCT02141295|Active Comparator|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
9818713|NCT02141295|Experimental|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
9818714|NCT02141295|Active Comparator|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
9818715|NCT02141295|Experimental|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
9818716|NCT02141360|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
9818717|NCT02141360|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
9818718|NCT02141399|Experimental|ALKS 5461|
9818719|NCT02141451|Experimental|INCB7839 100 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
9818720|NCT02141451|Experimental|INCB7839 200 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
9818721|NCT02141451|Experimental|INCB7839 300 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
9818722|NCT02141451|Experimental|INCB7839 (Phase II)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
9818723|NCT02141490|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|Ferumoxytol +MRI
9818724|NCT02141516|Experimental|Group A|Complement deficiency
9818725|NCT02141516|Experimental|Group B|asplenia/splenic dysfunction
9818726|NCT02141516|Active Comparator|Group C|age-matched healthy controls
9818727|NCT02141555|Active Comparator|Vaginal misoprostol|Participants will insert four misoprostol tablets (total of 800 micrograms) deeply into the vagina with their fingers.
9818728|NCT02141555|Experimental|Buccal Misoprostol|Participants will place two tablets of misoprostol between their gum and cheek on each side (total 800 micrograms), then swish and swallow the remnants after 30 minutes.
9818729|NCT02141581|Experimental|Group A Fluzone® (IM)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)~2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study"
9818730|NCT02141581|Experimental|Group B Fluzone® Intradermal (ID)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)~2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study"
9519369|NCT03287856|Experimental|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
9818731|NCT02141581|Experimental|Group C 2011-2012 FluMist®|"Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.~FluMist was only used in the first year of study."
9818732|NCT02141620|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo.
9818733|NCT02141620|Experimental|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
9818734|NCT02141633|Experimental|smokers|participants with smoking history ( > 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
9818735|NCT02141633|Experimental|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
9818736|NCT02141659|Experimental|Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
9818737|NCT02141659|Experimental|Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
9818738|NCT02141659|Experimental|Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
9818739|NCT02141659|Experimental|Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg|TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
9818740|NCT02141659|Experimental|Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
9818741|NCT02141659|Experimental|Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
9668113|NCT01764711|Experimental|Low Sodium Diet Controls|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
9818742|NCT02141672|Experimental|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
9818743|NCT02141672|Experimental|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
9818744|NCT02141672|Placebo Comparator|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
9818745|NCT02141854|Experimental|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
9818746|NCT02141854|Experimental|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
10115030|NCT04453865|Experimental|Project EMPOWER|"Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, & Mullarkey, 2020) and existing interventions targeting accommodation (Lebowitz & Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
10115031|NCT04453865|Other|Online Resources and Referrals (ORR)|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
10115032|NCT04453826|Experimental|Camrelizumab plus chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy with concurrent and adjuvant camrelizumab therapy.
10115033|NCT04453826|Active Comparator|Chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy.
10115034|NCT04453605||Patients with neo-diagnosed type 2 diabetes|Patients referring for the first time to the outpatient diabetes clinic in the department of Internal Medicine between January 2008 and December 2015 and matching the inclusion criteria.
10115035|NCT04453631|Experimental|active tDCS + CBT-UP|Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
10115036|NCT04453631|Active Comparator|sham tDCS + CBT-UP|Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
10115037|NCT04453631|Active Comparator|active tDCS + Psychoeducation|Active tDCS combined with psychoeducation (control condition for CBT-UP).
10115038|NCT04453631|Placebo Comparator|sham tDCS + Psychoeducation|Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).
10115039|NCT04453644|Experimental|Group A (Hamstrings)|Hamstring stretching would be done then isometric strength would be measured.
10115040|NCT04453644|Experimental|Group B (Calf)|Calf stretching would be done then isometric strength would be measured.
10115041|NCT04453670||COVID-19 non-survivors|ICU adults who died from severe COVID-19 and in whom autopsy could be performed
9668114|NCT01742026||High Risk Oncohematological Patients|Detection Aspergillus PCR technique and Aspergillus AGA technique
9668115|NCT01737255||TP53 mutation carriers|Carriers of TP53 mutation not known to be low penetrance
9818747|NCT02141854|Experimental|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
9818748|NCT02141854|Experimental|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
9818749|NCT02141854|Placebo Comparator|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
9818750|NCT02141867||Noncardiac surgical patients|Noncardiac surgery patients 16 years or older undergoing inpatient surgery
9818751|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
9818752|NCT02141997|Active Comparator|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
9818753|NCT02141997|Experimental|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
9818754|NCT02141997|Experimental|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
9818755|NCT02141997|Experimental|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
9818756|NCT02142049|Experimental|Part 1: Dose Level 1|Ibrutinib 560 mg PO + DA-EPOCH-R
9818757|NCT02142049|Experimental|Part 1: Dose Level 2|Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
9818758|NCT02142049|Experimental|Part 1: Dose Level 3|Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
10115042|NCT04453813|Experimental|Toripalimab plus concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy plus concurrent and adjuvant toripalimab.
10115043|NCT04453813|Active Comparator|Concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy alone.
10115044|NCT04453774|Experimental|Covi19 patients receiving intervention|We will collect self-reported symptoms via a questionnaire, temperature and oxygen saturation will be entered by the patient and passive near continuous sensing of heart rate, audio for cough detection, respiratory rate, cough and physical activity from a smart watch. The smart watch then transmits this sensor data to the paired smartphone.
10115045|NCT04453748||COVID-19 convalescents|People who recovered from COVID-19: have no symptoms and no SARS-Cov2 RNA in PCR
10115046|NCT04453696||Communication before operation|Communication was established before the operation.
9818759|NCT02142049|Experimental|Part 1: Dose Level 4|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
9818760|NCT02142049|Experimental|Part 2: RP2D|Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
9818761|NCT02142153|Experimental|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
9818762|NCT02142153|Placebo Comparator|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
9818763|NCT02142153|Experimental|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
9818764|NCT02142153|Placebo Comparator|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
9818765|NCT02142153|Experimental|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
9818766|NCT02142153|Placebo Comparator|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
9818767|NCT02142153|Experimental|F901318 mg/kg|Single intravenous infusion over 4 hours
9818768|NCT02142153|Placebo Comparator|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
9818769|NCT02142153|Experimental|F901318 5 mg/kg|Single intravenous infusion over 4 hours
9818770|NCT02142153|Placebo Comparator|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
9818771|NCT02142283|Experimental|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
9818772|NCT02142283|Active Comparator|Medical Management|Medical Management
9818773|NCT02142361|Active Comparator|Omafilcon A/Enfilcon A|Subject's habitual hydrogel toric lenses Omafilcon A will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
9818774|NCT02142361|Active Comparator|Ocufilcon D/Enfilcon A|Subject's habitual hydrogel toric lenses Ocufilcon D will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
9818775|NCT02142361|Active Comparator|Methafilcon B/ Enfilcon A|Subject's habitual hydrogel toric lenses Methafilcon B will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
9818776|NCT02142387|Active Comparator|New DA-BLS training program|A one-hour training course that includes a 30-minute video-based self-instruction (VSI) training session, a short role-play, and a debriefing. The video consists of a bystander CPR simulation with dispatcher instructions using the trainee's own phone and practice session following demonstration by a simulated layperson. After watching the video clip, all trainees are divided into two groups and conduct a role-play as dispatchers and laypersons for 15 minutes. Finally, there is a 15-minute debriefing session with several assignments. The HEROS program focuses on cooperation with a dispatcher, from recognition of cardiac arrest to performing DA-CPR, with hands-on practice so that laypersons can provide bystander CPR immediately in a real situation. Moreover, the HEROS program emphasizes practice for providing the correct address of the scene and switching to speakerphone mode, especially for the elderly.
9818777|NCT02142387|No Intervention|Current Basic Life Support (BLS) training program|A one-hour training program that was developed by the Korea Center for Disease Control and Prevention (CDC) and it was based on the American Heart Association (AHA) guideline (http://www.cdc.go.kr/board.es?mid=a20503050000&bid=0021&tag=&act=view&list_no=127655). The program consists of a 30-minute VSI, and a 30-minute practice debriefing session. It focuses on detailed techniques for performing high-quality chest compressions including the correct hands and body position of the bystanders.
9818778|NCT02142504|Experimental|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
9818779|NCT02142504|Experimental|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
9818780|NCT02142504|Placebo Comparator|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
9818781|NCT02142608|Experimental|BR55|All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
9818782|NCT02142712|Active Comparator|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
9818783|NCT02142712|Active Comparator|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
9818784|NCT02142712|Experimental|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
9818785|NCT02142712|Experimental|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
9818786|NCT02142738|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
9818787|NCT02142738|Active Comparator|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
9826910|NCT02436889|Experimental|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
10115047|NCT04453696||Communication after operation|Communication was established after the operation.
9519370|NCT03287830|Experimental|Intervention|Text message influenza vaccine reminders
9818788|NCT02142738|Active Comparator|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
9818789|NCT02142738|Active Comparator|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
9818790|NCT02142738|Active Comparator|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
9818791|NCT02142738|Active Comparator|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
9818792|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
9818793|NCT02143024|Experimental|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
9818794|NCT02143024|Active Comparator|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
9818795|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
9818796|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
9818797|NCT02143141|Active Comparator|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
9818798|NCT02143141|Experimental|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
9818799|NCT02143310|Experimental|EVP|Subject who use the EVP for up to 2 years
9818800|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
9818801|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
9818802|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
9818803|NCT02143648|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
9818804|NCT02143648|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
9818805|NCT02143648|Placebo Comparator|Sugar pill|Placebo tablets BID
9818806|NCT02143713|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
9818807|NCT02143713|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
9818808|NCT02143778|Experimental|Compensated cirrhotic patients|A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
10115048|NCT04453696||Communication before and after operation|Communication took place both before and after the operation.
9818809|NCT02143843|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new 13 mg Bimatoprost Ocular Insert and used continuously for another 6 months.
9818810|NCT02143947|Experimental|Full Contact Orthosis|Full Contact Orthosis
9818811|NCT02143947|Experimental|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
9818812|NCT02143973|Experimental|nalbuphine HCl ER|nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.
9818813|NCT02144012|Experimental|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
9818814|NCT02144012|Active Comparator|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
9818815|NCT02144077|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
9818816|NCT02144077|Active Comparator|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
9818817|NCT02144220|Experimental|Virtual care visit|One-time virtual care visit for Parkinson disease.
9818818|NCT02144233|Experimental|Occlusal adjustment therapy|Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter lateral guidance on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
10115049|NCT04453696||No communication|No communication.
10115050|NCT04453735|Active Comparator|Intervention|Atorvastatin mylan 40 mg once daily
10115051|NCT04453735|No Intervention|Control|No statin therapy
9818819|NCT02144233|Placebo Comparator|Placebo occlusal adjustment therapy|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
9818820|NCT02144259|Active Comparator|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
9818821|NCT02144259|Active Comparator|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
9818822|NCT02144259|No Intervention|Control group|Subjects selecting their own method of contraception or no contraception.
9818823|NCT02144285|Experimental|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
9818824|NCT02144285|Placebo Comparator|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
9818825|NCT02144285|Experimental|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
9818826|NCT02144285|Placebo Comparator|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
9818827|NCT02144285|Experimental|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
9818828|NCT02144285|Placebo Comparator|Placebo IV (Part B)|Single dose of placebo matching LY3113593 administered IV
9818829|NCT02144337|Experimental|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
9818830|NCT02144337|No Intervention|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
9818831|NCT02144519|Experimental|Immediate Intervention|Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
9818832|NCT02144519|Experimental|Delayed Intervention|Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.
9818833|NCT02144597|Active Comparator|2-week LCD and Roux-en-Y gastric bypass (RYGB)|A 2-week liquid formula low-calorie diet (LCD) will be administered for 2 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
9818834|NCT02144597|Active Comparator|6-week LCD|A 6-week liquid formula low-calorie diet (LCD) will be administered for 6 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
9818835|NCT02144597|Other|Control diet|1000 calorie diet
9818836|NCT02144610|Experimental|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular (IM) injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
9818837|NCT02144610|Placebo Comparator|Placebo|Randomized subjects will receive 4 sets of intramuscular (IM) injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
9818838|NCT02144675|Experimental|Arm I (choline magnesium trisalicylate and chemotherapy)|Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
9818839|NCT02144675|Active Comparator|Arm II (chemotherapy)|Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
9818840|NCT02144701|Experimental|Lactobacillus rhamnosus GG|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
9818841|NCT02144701|No Intervention|No intervention|Patients receive no intervention.
9818842|NCT02144714|Experimental|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
9818843|NCT02144714|Active Comparator|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
9818844|NCT02144714|Active Comparator|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
9818845|NCT02145026|Experimental|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (</=) 10 g/dL; if the hemoglobin level increases less than (<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases >/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
9818846|NCT02145039|Experimental|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
9818847|NCT02145078|Experimental|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
10115052|NCT04453800|Experimental|Group A ：low dose sofadil|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
10188035|NCT03720223|No Intervention|Control|No local anesthetics injected to the buccal mucosal graft harvest site
10188036|NCT03720197||Participants aged less than 14 years old|
9818848|NCT02145156|Experimental|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
9818849|NCT02145156|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
9818850|NCT02145156|Other|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
9826911|NCT02436889|Active Comparator|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
9826912|NCT02436915|Experimental|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA."
9826913|NCT02436915|Sham Comparator|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session."
9826914|NCT02437084|Other|Individuals without diabetes eligible to receive statin therapy|Eligible participants will receive 40 mg of atorvastatin
9826915|NCT02437162|Placebo Comparator|Group 1 (Placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
9826916|NCT02437162|Experimental|Group 2 (Ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
9826917|NCT02437162|Experimental|Group 3 (Ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
9826918|NCT02437188|Experimental|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
9826919|NCT02437188|No Intervention|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
9826920|NCT02437253|Experimental|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
9826921|NCT02437253|Experimental|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
9826922|NCT02437305|Experimental|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
9826923|NCT02437305|Active Comparator|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
9826924|NCT02437344|Experimental|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
9826925|NCT02437383|Active Comparator|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
9826926|NCT02437383|Placebo Comparator|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
9826927|NCT02437487|Experimental|SER-109|SER 109 (1 × 108 SporQs)
9826928|NCT02437487|Placebo Comparator|Placebo|Placebo
10188037|NCT03720197||Participants aged 14 years old and older|
9818851|NCT02145182|Experimental|Active|Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours [h] later).
9818852|NCT02145182|Placebo Comparator|Placebo|Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
9818853|NCT02145247|Active Comparator|Normal adult women|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
9818854|NCT02145247|Active Comparator|Women with PCOS|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
9818855|NCT02145299|Experimental|TruePath CTO Device|"The TruePath™ CTO Device (Boston Scientific Corporation, Natick, MA) is a new solution for intraluminal treatment of chronic total occlusions (CTO). It is the longest available crossing device (165 cm), and has a diamond-coated distal tip that can rotate at 13,000 rpm. Its profile is similar to a 0.018 guidewire, and includes a shapeable distal tip allowing 1:1 torque response. In addition, it provides audio and visual navigation during CTO crossing."
9818856|NCT02145299|Active Comparator|CROSSER CTO Device|"The CrosserTM CTO Recanalization Catheter (Crosser system) (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing."
9818857|NCT02145429|Experimental|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
9818858|NCT02145429|No Intervention|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
9818859|NCT02145468|Experimental|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
9818860|NCT02145468|Placebo Comparator|Placebo|Placebo twice daily oral tablet
9818861|NCT02145676|Experimental|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
9818862|NCT02145676|Experimental|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
9818863|NCT02145676|Placebo Comparator|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
9818864|NCT02145754|Active Comparator|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
9818865|NCT02146001|Active Comparator|Moderate-to-vigorous activity group|This group will target achieving the current recommendations for physical activity in older adults. This is 150 minutes of moderate-to-vigorous activity per week.
9818866|NCT02146001|Experimental|Reducing sedentary behavior group|This group will target a 60 minute per day reduction in sedentary behavior using an objective activity monitor.
9818867|NCT02146105|Experimental|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
9818868|NCT02146131|Active Comparator|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
9818869|NCT02146131|Active Comparator|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
9818870|NCT02146248|Experimental|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
9818871|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
9818872|NCT02146326|Active Comparator|Motivational Interviewing-Mental Health Staff|
9818873|NCT02146326|Active Comparator|BREATHE-Mental Health Staff|
9818874|NCT02146326|Active Comparator|Motivational Interviewing-Clients|
9818875|NCT02146326|Active Comparator|BREATHE-Clients|
9818876|NCT02146352|Experimental|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
9818877|NCT02146365||PATH-wSP 300 µg + Booster|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
9818878|NCT02146365||PATH-wSP 300 µg Only|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
9818879|NCT02146365||PATH-wSP 600 µg + Booster|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
9818880|NCT02146365||PATH-wSP 600 µg Only|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
9818881|NCT02146365||Booster Only (300 µg)|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
9818882|NCT02146365||Booster Only (600 µg)|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
9818883|NCT02146365||No Intervention (300 µg)|Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
9818884|NCT02146365||No Intervention (600 µg)|Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
9818885|NCT02146430|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
9818886|NCT02146430|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
9818887|NCT02146430|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
9818888|NCT02146430|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
9818889|NCT02146482|No Intervention|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
9818890|NCT02146482|Experimental|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
9818891|NCT02146599||Pseudophakic|
9818892|NCT02146833|Experimental|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
9818893|NCT02146833|Experimental|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
9818894|NCT02146833|Experimental|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
9818895|NCT02147067|Experimental|Ranolazine|Ranolazine 1,000 mg twice daily
9818896|NCT02147067|Placebo Comparator|Placebo|Placebo twice daily
9818897|NCT02147093|Other|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
9818898|NCT02147093|Other|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
9818899|NCT02147132|Experimental|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
9818900|NCT02147132|Experimental|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
9818901|NCT02147132|Experimental|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
9818902|NCT02147132|Experimental|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
9818903|NCT02147158|Experimental|UPA 5 mg:Placebo|Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
9818904|NCT02147158|Experimental|UPA 10 mg:Placebo|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
9818905|NCT02147158|Experimental|UPA 5 mg:UPA 5 mg|UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
9818906|NCT02147158|Experimental|UPA 10 mg:UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
9818907|NCT02147158|Experimental|Placebo:UPA 5 mg|Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
9818908|NCT02147158|Experimental|Placebo:UPA 10 mg|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
9818909|NCT02147197|Experimental|UPA 5 mg|Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
9818910|NCT02147197|Experimental|UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
9818911|NCT02147197|Placebo Comparator|Placebo|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.
10115053|NCT04453800|Experimental|Group B: Medium dose group|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
10115054|NCT04453800|Experimental|Group C: high dose group|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
10115055|NCT04453800|Placebo Comparator|Group D: placebo group|Saline was administered intravenously
10115056|NCT04453683|Active Comparator|Group I ( Air Q)|nsertion of proper size Air-Q. ILA
10115057|NCT04453683|Active Comparator|Group II (ILMA)|nsertion of proper size ILMA
10115058|NCT04453657|Experimental|Intervention|There is only one arm in this study. All recruited and consented participants will fill out a pre-survey, engage with the digital toolkit for 15 weeks, then fill out a post-survey.
10115059|NCT04453761|Experimental|Drugs Group|Thiamine IV
10115060|NCT04453761|Placebo Comparator|Placebo|NaCl IV
10182484|NCT03773497|Other|Common snack combination|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of a combination of common snack foods (pretzels, potato chips, and popcorn).
10182485|NCT03773497|Other|Cheese broccoli|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli.
10182486|NCT03773497|Other|Cheese broccoli with Daikon radish powder|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder.
10182487|NCT03773497|Other|Uncooked broccoli with ranch-type dip|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of uncooked, freeze-dried broccoli with ranch-type dip.
10182488|NCT03773432|Other|Men|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
10182489|NCT03773432|Other|Women|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
10182490|NCT03773484|Experimental|Clinical Decision Support nudges|"Clinical decision support nudges within the electronic health record to discourage unnecessary opioid prescribing through the application of behavioral insights-empirically-tested social and psychological interventions that affect choice. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart."
10182491|NCT03773458|Other|Eligible patients for AI test.|Device: An artificial system for the screening of scoliosis
10182492|NCT03773198|Experimental|ERCS Group|
10182493|NCT03773198|Placebo Comparator|Control Group|
10182494|NCT03773146|No Intervention|Control|No airtime incentive was given for completing the survey
10182495|NCT03773146|Experimental|1X Incentive|1X Airtime Incentive
10182496|NCT03773146|Experimental|Lottery|Lottery Airtime Incentive
10182497|NCT03773406|Active Comparator|Offline tDCS-before therapy|Participants will receive 20 minutes of tDCS prior to the 40 minute speech-language therapy session.
10182498|NCT03773406|Active Comparator|Offline tDCS-after therapy|Participants will receive 20 minutes of tDCS after the 40 minute speech-language therapy session.
10182499|NCT03773406|Active Comparator|Online tDCS|tDCS will be applied at the beginning of the 40 minute speech-language therapy session and will last for 20 minutes.
10182500|NCT03773406|Sham Comparator|Sham tDCS|Sham tDCS will be applied at the beginning of the 40 minute speech-language therapy session.
10182501|NCT03773367|Experimental|Treatment with chemotherapy pre- and postoperative.|
10182502|NCT03773211|Experimental|Renaparin|Solution administered once to kidney ex-vivo
10182503|NCT03773211|Placebo Comparator|Placebo|Placebo administered once to kidney ex-vivo
10182504|NCT03773172|Placebo Comparator|Placebo Control Group|Subjects will receive placebo treatment to mimic active treatment.
10182505|NCT03773172|Active Comparator|Active treatment|IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
10182506|NCT03773315|Experimental|UMH group|This group takes UMH extract for 12 weeks
10182507|NCT03773315|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
9818912|NCT02147288|Experimental|Breast Recon with acellular dermal matrix (ADM) on NPWT|
9818913|NCT02147288|Experimental|Lipoabdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
9818914|NCT02147288|Experimental|Abdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
9818915|NCT02147288|Experimental|Ventral Hernia Repair (VHR) on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
9818916|NCT02147288|Experimental|Panniculectomy on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
9818917|NCT02147288|No Intervention|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
9818918|NCT02147288|No Intervention|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
9818919|NCT02147288|No Intervention|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
9818920|NCT02147288|No Intervention|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
9818921|NCT02147288|No Intervention|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
9818922|NCT02147301|Experimental|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
9818923|NCT02147353|Active Comparator|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
9818924|NCT02147353|Placebo Comparator|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
9818925|NCT02147522|Experimental|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
9818926|NCT02147522|No Intervention|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
9818927|NCT02147561|Experimental|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
9818928|NCT02147587|Experimental|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
9818929|NCT02147587|Placebo Comparator|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
9818930|NCT02147613|Experimental|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
9818931|NCT02147613|Active Comparator|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
9818932|NCT02147626|Active Comparator|Information and Screening Group|Intervention: The patient website will include the American Heart Association (AHA) Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) Dietary Approaches to Stop Hypertension (DASH) website, and the NIH smoking cessation website
9818933|NCT02147626|Experimental|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
9818934|NCT02147691|Experimental|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%~Azelaic acid 15% to the face each PM"
9818935|NCT02147691|Active Comparator|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
9818936|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
9818937|NCT02147899|Experimental|SYM-1219 Low Dose|Administered orally
9818938|NCT02147899|Experimental|SYM-1219 High Dose|Administered orally
9818939|NCT02147899|Placebo Comparator|Placebo|Administered orally
9818940|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (625mg BID)|Starting dose of 625mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
9818941|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (500mg BID)|Starting dose of 500mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
9818942|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M -ve (500mg BID)|Starting dose of 500mg rociletinib, taken twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
9818943|NCT02148107|Experimental|BI 691751 Dose 1|multiple dose given over 14 days
9818944|NCT02148107|Experimental|BI 691751 Dose 2|multiple dose given over 14 days
9818945|NCT02148107|Experimental|BI 691751 Dose 3|multiple dose given over 14 days
9818946|NCT02148107|Experimental|BI 691751 Dose 4|multiple dose given over 14 days
9818947|NCT02148107|Experimental|BI 691751 Dose 5|multiple dose given over 14 days
9818948|NCT02148107|Experimental|BI 691751 Dose 6|multiple dose given over 14 days
9818949|NCT02148107|Placebo Comparator|Placebo|Placebo
9818950|NCT02148211||Exposed cohort|Pregnant women, vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccine(s) (GSK sIIVs): Fluarix/ FluLaval/Fluarix Quadrivalent /FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
10115061|NCT04453618|Experimental|Food effect|Healthy subjects receive a single dose of SYHA1402 (100mg) in either a fasted state or with a meal.
9818951|NCT02148250|Experimental|100 Syringe Units, then 200|Participants randomized to first receive 100 syringe units of U-500 regular insulin, then 200 units
9818952|NCT02148250|Experimental|200 Syringe Units, then 100|Participants randomized to first receive 200 syringe units of U-500 regular insulin, then 100 units
9818953|NCT02148302|Experimental|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.~A run-in period of two weeks followed by twelve weeks of active treatment"
9818954|NCT02148302|No Intervention|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
9818955|NCT02148445|Active Comparator|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
9818956|NCT02148445|Experimental|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
9818957|NCT02148523|Experimental|Weekly Adherence Report|Adherence report to subject every 7 days.
10115062|NCT04453618|Experimental|Multiple doses 25mg|Healthy subjects receive multiple doses of SYHA1402 (25mg) or Placebo(25mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
9818958|NCT02148523|Experimental|Weekly Adherence Peer-Comparison Report|Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
9818959|NCT02148523|Other|Usual Care|Usual care with GlowCap.
9818960|NCT02148588|Experimental|Pain testing|"Completion of NPSI questionnaire~Sensory mapping of the affected limb~Quantitative Sensory Testing~Patients will have a peripheral nerve blockade"
9818961|NCT02148718|Experimental|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
9818962|NCT02148809|Experimental|Blood Volume Analysis, Fluid|Preop I-131 is given and the BVA is performed, 6 hours after surgery the same procedure will be done to compare the TBV at both points
9818963|NCT02148835|Active Comparator|Triomeg|Sausage: Triomeg
9818964|NCT02148835|Placebo Comparator|Control sausage|Sausage: Control
9818965|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
9818966|NCT02148952|Experimental|Intervention Health Facility|WHO Safe Childbirth Checklist Program
9818967|NCT02148952|No Intervention|Control Health Facility|Matched control facilities providing comparison for intervention facilities
9818968|NCT02149108|Experimental|Nintedanib (BIBF 1120) + BSC|
9818969|NCT02149108|Placebo Comparator|Placebo + BSC|
9818970|NCT02149173|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
9818971|NCT02149199|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
9818972|NCT02149199|Active Comparator|"terbutaline as needed+placebo Pulmicort bid"|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
9818973|NCT02149199|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
10115063|NCT04453618|Experimental|Multiple doses 50mg|Healthy subjects receive multiple doses of SYHA1402 (50mg) or Placebo (50mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
10115064|NCT04453618|Experimental|Multiple doses 150mg|Healthy subjects receive multiple doses of SYHA1402 (150mg) or Placebo (150mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
9818974|NCT02149264|Experimental|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses [69 mg]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
9818975|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
9818976|NCT02149303||Dabigatran|
9818977|NCT02149342|Experimental|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
9818978|NCT02149420|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
9818979|NCT02149420|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg
9818980|NCT02149420|Placebo Comparator|Placebo|single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
9818981|NCT02149524|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
9818982|NCT02149524|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
9818983|NCT02149810|Experimental|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
9818984|NCT02149810|No Intervention|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
9818985|NCT02149836|Experimental|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
9818986|NCT02149875|Experimental|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
9818987|NCT02149875|Experimental|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
9818988|NCT02149875|Placebo Comparator|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
9818989|NCT02150044|Experimental|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
9818990|NCT02150057|No Intervention|Control Group|This group receives no experimental bracing intervention in the study.
9818991|NCT02150057|Active Comparator|Experimental Group|This group will receive the Breg Fusion Osteoarthritis Knee Unloading Brace to wear for a determined amount of time per study protocol for the treatment of osteoarthritis pain.
9818992|NCT02150109|Experimental|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
9818993|NCT02150109|Experimental|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
9818994|NCT02150213|Experimental|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to > 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
10115065|NCT04453566||Elite Athletes|Elite Athletes
10115066|NCT04454528|Active Comparator|Arm 1|Arm 1 will receive radiotherapy on day -14 and pembrolizumab on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
9818995|NCT02150343|Experimental|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
9818996|NCT02150343|Experimental|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
9818997|NCT02150343|Experimental|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
9818998|NCT02150343|Placebo Comparator|Placebo|8 x placebo 4 weeks apart
9818999|NCT02150460|Experimental|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
9668116|NCT01737255||Population controls|Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
9819000|NCT02150460|Active Comparator|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
9819001|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
9819002|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
9819003|NCT02150759|Experimental|Dexmedetomidine-ketamine|Dexmedetomidine-ketamine group
10115067|NCT04454528|Active Comparator|Arm 2|Arm 2 will receive pembrolizumab on day -14 and radiotherapy on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
10115068|NCT04454528|Active Comparator|Arm 3|Arm 3 will receive pembrolizumab on day -14. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
9819004|NCT02150759|Active Comparator|Dexmedetomidine-fentanyl|Dexmedetomidine-fentanyl group
9819005|NCT02150837||5 & 2 & 2 Plan|MWCC members who used the Medifast 5 & 2 & 2 Meal Replacement Plan for weight loss.
9819006|NCT02150837||4 & 2 & 1 Plan|MWCC members who used the Medifast 4 & 2 & 1 Meal Replacement Plan for weight loss.
9819007|NCT02150954|Active Comparator|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
9819008|NCT02150954|Active Comparator|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
9819009|NCT02151058|Other|Negative Control, 035000513007|Colgate® Regular Cavity Protection
9819010|NCT02151058|Experimental|Experimental Mouth Rinse, 19545-118|
9819011|NCT02151058|Active Comparator|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
9819012|NCT02151110|Placebo Comparator|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
9819013|NCT02151110|Experimental|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
9819014|NCT02151110|Experimental|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
9668117|NCT01682278||Amalgam cohort|Patients with medically unexplained physical symptoms attributed to dental amalgam restorations which the patient wish to have removed.
9668118|NCT01682278||MUPS-cohort|Patients with medically unexplained physical symptoms without attribution to amalgam and no explicit wish to remove amalgam.
9668119|NCT01682278||Dental cohort|Healthy comparison group: Subjectively healthy without diagnosed chronic disease or prescribed medication.
9819015|NCT02151110|Experimental|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
9819016|NCT02151110|Experimental|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
9819017|NCT02151110|Experimental|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
9819018|NCT02151110|Experimental|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
9819019|NCT02151110|Experimental|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
9819020|NCT02151149|Other|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
9819021|NCT02151149|Other|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
9819022|NCT02151253|Experimental|Armodafinil First, Then Placebo|"During double-blind treatment subjects took armodafinil for 4 weeks before crossing over to placebo for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
9819023|NCT02151253|Placebo Comparator|Placebo First, Then Armodafinil|"During double-blind treatment subjects took placebo for 4 weeks before crossing over to armodafinil for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
9819024|NCT02151266|Experimental|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
9819025|NCT02151266|Experimental|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
9819026|NCT02151266|Sham Comparator|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
9819027|NCT02151331|Experimental|REP + EF|Replication Effective Programs (REP) augmented with External Facilitation (EF)
9819028|NCT02151331|Experimental|REP + EF/IF|Replicating Effective Programs (REP) augmented with External and Internal Facilitation (EF + IF)
9819029|NCT02151448|Experimental|vaccine + chemokine modulatory regimen|Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before & after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days & CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed & Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
9819030|NCT02151461|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
9819031|NCT02151461|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
9819032|NCT02151461|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
9819033|NCT02151461|Experimental|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
9819034|NCT02151487||Ropivacaine|Ropivacaine 0.5% 25 ml alone for supraclavicular block
9819035|NCT02151487||Ropivacaine and dexamethasone|25 ml 0.5% ropivacaine + 4 mg dexamethasone
9819036|NCT02151487||Ropivacaine and clonidine|25 ml 0.5% ropivacaine + 100 mcg clonidine
9819037|NCT02151487||Ropivacaine, dexamethasone and clonidine|25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
9819038|NCT02151591|Experimental|Integrated Counseling for Tobacco and Alcohol (INT)|Integrated counseling for smoking and alcohol entails weekly counseling for 12-weeks targeting both behaviors. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
9819039|NCT02151591|Other|Standard Care for Primary Presenting Concern (SC)|Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
9819040|NCT02151643|Experimental|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
9819041|NCT02151643|Experimental|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
9668120|NCT01644669|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
10115069|NCT04454528|Other|Arm 4|Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.
9668121|NCT01632878||Post Myocardial Infarction|One single cohort of Index post Myocardial Infarction patients
9668122|NCT01627821|Active Comparator|Jarvik 2000 Treatment|Jarvik 2000 VAS, Post-Auricular Cable
9668123|NCT01627821|Active Comparator|HeartMate II Control|HeartMate II VAS Control
9668124|NCT01556139|Experimental|Spirotiger|Patients belonging to this group perform 20 sessions of usual training (cyclette and calisthenic exercises) and additional 20 sessions of a specific training for respiratory muscles with Spirotiger
9819042|NCT02151643|Experimental|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
9819043|NCT02151643|Experimental|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
9819044|NCT02151643|Placebo Comparator|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
9819045|NCT02151682|Active Comparator|Morphine prolonged-release (Part 1)|"10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 200 mg per day."
9819046|NCT02151682|Experimental|Tapentadol prolonged-release (Part 1)|"25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 500 mg per day."
9819047|NCT02151682|Experimental|Tapentadol in Part 2 after Tapentadol or Morphine in Part 1|Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily.
9819048|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 1|Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed).
9819049|NCT02151682|No Intervention|Observation Period after Morphine in Part 1|Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed).
9819050|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 2|Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2.
9819051|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
9819052|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
9819053|NCT02151851|Experimental|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
9819054|NCT02151851|Placebo Comparator|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
9819055|NCT02151877|Experimental|Nitric oxide on CPB|neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
9819056|NCT02151877|Placebo Comparator|control|neonates not receiving inhaled NO into the cardiopulmonary bypass
9819057|NCT02151903|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
9819058|NCT02151903|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
9819059|NCT02151994|Experimental|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
9819060|NCT02151994|Placebo Comparator|Placebo|tablets, visually matching active medication
9819061|NCT02152007|Experimental|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
10115070|NCT04453579||116 patients completed a survey|116 patients were assessed during the Italian lockdown by means of a telephone interview performed by a trained researcher. The interview was composed of socio-demographic items (e.g. employed before and during the lockdown, own accommodation during lockdown etc.) and questions about physical and mental health in relation to the COVID-19 emergency
9819062|NCT02152085|Experimental|Narrow pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 0.4 ms.
9819063|NCT02152085|Experimental|Wide pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 1 ms.
9819064|NCT02152137|Experimental|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10115071|NCT04454112|Experimental|24-hour esophageal pH monitoring|24-hour esophageal pH monitoring was conducted using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands). This system consists of a portable data logger (MMS Investigation and Diagnostic Software®) and a disposable catheter which contains two pH electrodes (Unisensor, Attikon, Switzerland). Before recording, the pH electrode was calibrated in the special buffer solutions at pH values of 1 and 2.
9668125|NCT01556139|No Intervention|Control|Control group with a placebo device
9819065|NCT02152163|Active Comparator|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
9819066|NCT02152163|Placebo Comparator|IV Saline|IV Saline
9819067|NCT02152345|Experimental|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
9819068|NCT02152345|Active Comparator|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
9819069|NCT02152371|Experimental|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
9819070|NCT02152371|Placebo Comparator|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
9819071|NCT02152384|Experimental|Insulin peglispro (LY2605541, with Insulin Lispro)|Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
9819072|NCT02152384|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
9819073|NCT02152540|Experimental|ACTIVE rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
9668126|NCT01553071|Experimental|Investigational|Fenretinide (4-HPR) plus Intravenous Safingol
9819074|NCT02152540|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
9819075|NCT02152605|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
9819076|NCT02152605|Placebo Comparator|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
9819077|NCT02152631|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
9819078|NCT02152631|Active Comparator|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
9819079|NCT02152696|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
9819080|NCT02152696|Active Comparator|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
9819081|NCT02152696|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
9819082|NCT02152761|Experimental|bimagrumab 700 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
9819083|NCT02152761|Experimental|bimagrumab 210 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
9819084|NCT02152761|Placebo Comparator|placebo|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
9819085|NCT02152761|Experimental|Bimagrumab 70 mg|Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
9826929|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
9668127|NCT01551472||3DKnee™ with e-plus Insert|Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
9668128|NCT01506973|Experimental|Gemcitabine/Abraxane/Hydroxychloroquine|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15 Hydroxychloroquine: 1200 mg/day PO daily (600mg BID) Daily from D1
9668129|NCT01506973|Experimental|Gemcitabine/Abraxane|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15
9819086|NCT02152826|Experimental|potassium oxalate gel|Professional application
9819087|NCT02152826|Active Comparator|Potassium oxalate liquid|Professional application
9819088|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
9819089|NCT02153086||Ramelteon 8 mg Tablets|
9819090|NCT02153099|Experimental|Cohort 1: TAK-058 15 mg|TAK-058 15 mg, 100 mL oral solution, once on Day 1.
9819091|NCT02153099|Experimental|Cohort 2: TAK-058 30 mg|TAK-058 30 mg, 100 mL oral solution, once on Day 1.
9819092|NCT02153099|Experimental|Cohort 3: TAK-058 45 mg|TAK-058 45 mg, 100 mL oral solution, once on Day 1.
9819093|NCT02153099|Experimental|Cohort 4: TAK-058 5 mg|TAK-058 5 mg, 100 mL oral solution, once on Day 1.
9819094|NCT02153099|Experimental|Cohort 5: TAK-058 75 mg|TAK-058 75 mg, 100 mL oral solution, once on Day 1.
9819095|NCT02153099|Experimental|Cohort 6: TAK-058 150 mg|TAK-058 150 mg, 100 mL oral solution, once on Day 1.
9819096|NCT02153099|Placebo Comparator|Cohort 1-6: Placebo|TAK-058 placebo-matching, 100 mL oral solution, once on Day 1.
9819097|NCT02153112|Experimental|Cohort 1, Group 1: 1 Dose|Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.
9819098|NCT02153112|Experimental|Cohort 1, Group 1: 2 Doses|Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.
9819099|NCT02153112|Experimental|Cohort 1, Group 2: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.
9819100|NCT02153112|Experimental|Cohort 1, Group 2: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
9819101|NCT02153112|Experimental|Cohort 1, Group 2a: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
9819102|NCT02153112|Experimental|Cohort 1, Group 2a: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
9819103|NCT02153112|Experimental|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
9819104|NCT02153112|Experimental|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to <1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
9819105|NCT02153112|Experimental|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.
9819106|NCT02153112|Experimental|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.
9819107|NCT02153346|Other|Arm 1|Intervention 1 & 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
9819108|NCT02153359|Experimental|Air cleaner then sham air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the experimental arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the sham comparator arm.
9826930|NCT02437669|Experimental|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
9826931|NCT02437864|No Intervention|Baseline Group|Airway management (intubation) undertaken immediately after anesthetic induction, without simultaneous supplemental oxygen via nasal cannula.
9819109|NCT02153359|Sham Comparator|Sham air cleaner then air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the sham comparator arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the experimental arm.
9819110|NCT02153398|Experimental|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: <20 kg
9819111|NCT02153398|Experimental|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
9819112|NCT02153398|Experimental|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
9819113|NCT02153398|Experimental|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
10115072|NCT04453787|Experimental|Arch support orthoses with forefoot medial wedge|The intervention of this group include orthoses with arch support and added forefoot medial wedge.
9819114|NCT02153398|Experimental|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
9819115|NCT02153476|Experimental|2.0mg of ALG-1001|2.0mg of ALG-1001
9819116|NCT02153476|Placebo Comparator|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
9819117|NCT02153489|Experimental|Aclidinium bromide|Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
9819118|NCT02153489|Placebo Comparator|Placebo|Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
9819119|NCT02153528|Active Comparator|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
9819120|NCT02153528|Experimental|double rimfampicin|2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
9819121|NCT02153671|Experimental|Primed with H5N2|Subjects who received A(H5N1) inactivated influenza vaccine as well as primed with H5N2 live attenuated influenza vaccine approximately 1.5 years before
9819122|NCT02153671|Active Comparator|Did not receive A(H5N2)|Subjects who received A(H5N1) inactivated influenza vaccine and did not receive A(H5N2) live attenuated influenza vaccine in a previous study.
9819123|NCT02153710|Experimental|Phonomotor therapy|Experimental group
9819124|NCT02153710|Active Comparator|Semantic Feature Analysis therapy|Current standard of care therapy
9819125|NCT02153723|Experimental|Copaxone|"Dose escalation:~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection."
9819126|NCT02153736|No Intervention|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
10115073|NCT04453787|Experimental|Arch support orthoses|The intervention of this group include orthoses with arch support.
9819127|NCT02153736|Experimental|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
9819128|NCT02153788|Active Comparator|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
9819129|NCT02153788|Placebo Comparator|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
9819130|NCT02153827|Experimental|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
9819131|NCT02153827|Sham Comparator|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
9819132|NCT02153905|Experimental|Phase 1 - Dose Escalation/De-Escalation|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
9819133|NCT02153905|Experimental|Phase II - Maximum Tolerated Dose|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
9819134|NCT02153918|Experimental|Vaccine Plus Booster Shots|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectomy or off therapy PROSTVAC
9819135|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Placebo|Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation
10115074|NCT04453787|Sham Comparator|Flat insole|This group will wear a flat insole. It is made from ethylene-vinyl acetate copolymer with 4mm thickness. It only provide shock absorbtion.
10115075|NCT04454268|Other|hydatid cyst|
10115076|NCT04453553|Active Comparator|Standard of care|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
10115077|NCT04453553|Experimental|Near Patient Testing|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system
9819136|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Colchicine|Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation
9819137|NCT02153983|Experimental|Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine|Participants with Diet-controlled Type 2 Diabetes who were assigned to Open-label treatment with colchicine. These participants were not randomized and were not part of the randomized controlled trial.
9819138|NCT02153983|No Intervention|Evaluation Only Non-obese Adults|Participants without obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
9819139|NCT02153983|No Intervention|Evaluation Only Obese Adults Not Randomized|Participants with obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort. These participants were found not eligible for randomization.
9819140|NCT02153983|No Intervention|Evaluation Only Adults with Type 2 Diabetes|Participants with Diet-controlled Type 2 Diabetes seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
9819141|NCT02154048|Active Comparator|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
9819142|NCT02154048|Placebo Comparator|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
9819143|NCT02154048|Active Comparator|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
9819144|NCT02154061|Experimental|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
9819145|NCT02154061|Active Comparator|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
9819146|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
9819147|NCT02154243|Experimental|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV<15 will be given oral midodrine, 10 mg, once.
9819148|NCT02154243|Experimental|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
9819149|NCT02154243|No Intervention|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
10115078|NCT04453280||Cohort 1 - Prague and Central Bohemian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - Prague and Central Bohemian Region population
10115079|NCT04453280||Cohort 2 - South Moravian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - South Moravian Region population.
9819150|NCT02154347|Experimental|KAD-1229/KAD-1229|Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
9819151|NCT02154347|Other|Placebo/KAD-1229|Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
9819152|NCT02154386|Experimental|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
9819153|NCT02154386|Active Comparator|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
9819154|NCT02154425|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
9819155|NCT02154477|Active Comparator|diabetes|All patient will receive insulin at one visit and saline at another visit
9819156|NCT02154477|Active Comparator|control|All patient will receive insulin at one visit and saline at another visit
9819157|NCT02154581|Active Comparator|Type 1 implant and thin biotype|In this group, immediate implant placement (SLActive implant) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
9819158|NCT02154581|Active Comparator|Type 1 implant and thick biotype|In this group, immediate implant placement (SLActive implant) is performed including bone grafting of the void between the implant and the fresh extraction socket.
9819159|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
9819160|NCT02154763|Placebo Comparator|Intraperitoneal Normal Saline|Intraperitoneal Normal Saline: 100mL (Milliliter) normal saline administered as in intervention arm
10115080|NCT04453358|Active Comparator|Interactive coaching|Airway clearance therapy using goal setting and interactive feedback.
10115081|NCT04453358|Active Comparator|Standard of care coaching|Standard of care airway clearance therapy.
10115082|NCT04453501||Azithromycin or non-azithromycin group|Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
9819161|NCT02154763|Experimental|Intraperitoneal ropivacaine|The abdomen will be entered and trocars placed in the usual manner. Using a standard suction/irrigation device and tubing, 200mg of Ropivacaine (0.2% Ropivacaine in 100mL Normal Saline) will be instilled into the abdomen at the start of the case, prior to dissection as follows. Under direct visualization, 50mL (Milliliter) (of the 100mL) will be infused over the esophageal hiatus. The remaining 50mL will be infused throughout the abdomen. The infusion line will then be flushed with 30mL (Milliliter) of Normal Saline to ensure the entire treatment dose is delivered, and no Ropivacaine remains in the tubing. The remainder of the surgery will proceed as usual.
9819162|NCT02154906|Active Comparator|DFDBA|DFDBA used to graft intrabony defect
9819163|NCT02154906|Experimental|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
9819164|NCT02155010|Experimental|Dexmedetomidine|IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
9819165|NCT02155010|Active Comparator|Dexmedetomidine with heavy bupivacaine|IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
9819166|NCT02155101|Active Comparator|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
9819167|NCT02155101|Experimental|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
9819168|NCT02155257|Active Comparator|Modafinil|Modafinil 200 mg will be administered orally one time
9819169|NCT02155257|Placebo Comparator|Placebo|A placebo will be administered orally one time
9819170|NCT02155257|Active Comparator|Gabapentin|Gabapentin 900 mg will be administered orally one time
9819171|NCT02155283|Other|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
9819172|NCT02155309|Experimental|Scopolamine|0.2 mg intranasal scopolamine, single dose
9819173|NCT02155309|Placebo Comparator|Placebo|placebo intranasal (0.1 mg per nostril), single dose
9819174|NCT02155322|Experimental|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
9819175|NCT02155335|Experimental|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
9819176|NCT02155335|Experimental|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
9819177|NCT02155465|Experimental|Ruxolitinib and Erlotinib|"Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.~Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily."
9819178|NCT02155543|Experimental|Cohort 1: AGN-223575 Form A/Vehicle|One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days.
9819179|NCT02155543|Experimental|Cohort 2: AGN-223575 Formulation A BID|One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15.
9819180|NCT02155543|Experimental|Cohort 3: AGN-223575 Formulation B BID|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
9819181|NCT02155543|Experimental|Cohort 4: AGN-223575 Formulation C BID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
9819182|NCT02155543|Placebo Comparator|AGN-223575 Vehicle BID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
9819183|NCT02155543|Experimental|Cohort 5: AGN-223575 Formulation C TID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C three times daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
9819184|NCT02155543|Placebo Comparator|AGN-223575 Vehicle TID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle three times daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
9819185|NCT02155608|Experimental|Active eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
9819186|NCT02155608|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
9819187|NCT02155647|Experimental|Part A: Avelumab|Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
9819188|NCT02155647|Experimental|Part B: Avelumab|Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
9819189|NCT02155660|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
9819190|NCT02155660|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
9819191|NCT02155660|Experimental|Benralizumab Arm C|Benralizumab administered subcutaneously
9819192|NCT02155660|Placebo Comparator|Placebo|Placebo administered subcutaneously
9819193|NCT02155712|Active Comparator|Triathlon Tritanium Knee|Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
9819194|NCT02155712|Active Comparator|Triathlon Knee|Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
9819195|NCT02155725|Experimental|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
9819196|NCT02155725|Placebo Comparator|Placebo|2 vials (200ml)
9819197|NCT02155738|Placebo Comparator|Placebo|100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
9819198|NCT02155738|Experimental|IV Acetaminophen|100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
9819199|NCT02155829|Experimental|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
9819200|NCT02155829|Placebo Comparator|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
9819201|NCT02155881|Experimental|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
9819202|NCT02155881|Placebo Comparator|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
9819203|NCT02155985|Active Comparator|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
9819204|NCT02155985|Active Comparator|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
9819205|NCT02155985|Placebo Comparator|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
9819206|NCT02156076|Placebo Comparator|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
9819207|NCT02156076|Experimental|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
9819208|NCT02156076|Experimental|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
9819209|NCT02156076|Experimental|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
9819210|NCT02156154|Placebo Comparator|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
9819211|NCT02156154|Experimental|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
9819212|NCT02156167|Experimental|CP810 and Codacs™Test System|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
9819213|NCT02156258||Diagnostic Cases|Collection of cases that were scheduled for biopsy (BI-RADS 4 or 5) using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
9819214|NCT02156258||Recall Cases|Collection of Imaging Recall Cases (were scheduled for additional imaging due an assessment of BI-RADS 0) using FFDM Mammography and DBT Mammography
9819215|NCT02156258||Screening Cases|Collection of cases who underwent routine screening mammography using FFDM Mammography and DBT Mammography
9819216|NCT02156271|Active Comparator|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
9819217|NCT02156271|Placebo Comparator|placebo|15 subjects will be randomized to receive the placebo
9819218|NCT02156466|Experimental|MSB0010841 30 mg|
9819219|NCT02156466|Experimental|MSB0010841 60 mg|
9819220|NCT02156466|Experimental|MSB0010841 120 mg|
9819221|NCT02156466|Experimental|MSB0010841 240 mg|
9819222|NCT02156466|Placebo Comparator|Placebo|
9819223|NCT02156492|Experimental|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
9819224|NCT02156492|Experimental|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
9819225|NCT02156492|Active Comparator|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
9819226|NCT02156492|Experimental|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
9819227|NCT02156492|Active Comparator|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
9819228|NCT02156492|Experimental|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
9819229|NCT02156674|Experimental|Naglazyme®|weekly Naglazyme® infusion for 2 years
9819230|NCT02156687|Active Comparator|Cololast, Inc. Restorell Y mesh|Y mesh
9819231|NCT02156687|Active Comparator|Coloplast, Inc. Restorelle Dual flat mesh|Dual flat mesh
9819232|NCT02156804|Experimental|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
9819233|NCT02156908|Experimental|D-serine|D-serine
9819234|NCT02157103|Experimental|Bevacizumab|Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
9819235|NCT02157168|No Intervention|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
9819236|NCT02157168|Other|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
9819237|NCT02157298|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
9819238|NCT02157298|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo
9819239|NCT02157376|Experimental|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
9819240|NCT02157376|Active Comparator|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
9819241|NCT02157506|Experimental|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
9819242|NCT02157506|Experimental|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
9819243|NCT02157506|Experimental|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
9819244|NCT02157506|Experimental|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
9819245|NCT02157506|Experimental|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
9819246|NCT02157506|Experimental|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
9819247|NCT02157506|Placebo Comparator|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
9819248|NCT02157519|Experimental|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
9819249|NCT02157519|No Intervention|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
9819250|NCT02157623|Experimental|Red Light PDT and Blue Light PDT|The tumor clearance with one side treated with Levulan and Red light PDT, and the contralateral side treated with Blue light PDT.
9819251|NCT02157779|Experimental|Cognitive Behavioral Intervention (CBI)|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
9819252|NCT02157779|Active Comparator|Supportive Intervention (SI)|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
9819253|NCT02157909|Experimental|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
9819254|NCT02157909|Active Comparator|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
9819255|NCT02157935|Active Comparator|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
9819256|NCT02157935|Active Comparator|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
9819257|NCT02157948|Active Comparator|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
9819258|NCT02157948|Experimental|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
9826932|NCT02437864|Experimental|With-Cannula Group|Airway management (intubation) undertaken immediately after anesthetic induction, with simultaneous supplemental oxygen via nasal cannula.
10115083|NCT04453488|Experimental|RUTI® vaccine|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
10115084|NCT04453488|Placebo Comparator|Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
10115085|NCT04453319|Experimental|Application of the device (PICO)|PICO® is a disposable, single-use pump without a canister that generates an effective, non-adjustable, negative pressure of -80 mmHg and that can be used for up to 7 days.(-1113) It incorporates leak detection and low battery indicators and is connected to a 4-layer absorbent dressing that primarily removes wound exudates through evaporative loss. The mechanism of action has been postulated to occur because of the combined effects of a reduction in the frequency of dressing changes, a reduction in stress concentration in the tissue surrounding the incision, and an enhancement in the appositional strength of the incision line, thus reducing dead space and minimizing the risk of wound contamination.(14) PICO® has also been demonstrated to enhance lymphatic clearance and decrease the risk of hematomas or seromas
10115086|NCT04453319|No Intervention|Conventional Dressing of the femoral wound|Conventional Dressing of the femoral wound
10115087|NCT04453423|Other|First-line Treatment|
10115088|NCT04453423|Experimental|Maintenance Treatment A|
10115089|NCT04453423|Experimental|Maintenance Treatment B|
10115090|NCT04453423|Experimental|Maintenance Treatment C|
10115091|NCT04453306|Placebo Comparator|placebo|"Patients with the same characteristics as the intervention group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
10115092|NCT04453306|Experimental|intervention|"Patients with the same characteristics as the placebo group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
10115093|NCT04453371|Experimental|Study group|Thrombolysis
10115094|NCT04453371|Placebo Comparator|Control group|Ringer's solution infusion
10115095|NCT04453514|Experimental|Trauma-informed yoga video recording|Participants will complete a single trauma-informed yoga practice using a 45-minute guided video recording.
10115096|NCT04453345|Experimental|TPM regimen|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
10115097|NCT04453436||Virologic failure|Viral load above detection limits at window period
10115098|NCT04453436||Virologic Success|Viral load bellow detection limits at window period
10115099|NCT04453332|Active Comparator|Oral hormone therapy|Estradiol 1mg and micronized natural progesterone 200mg 14 days a month (oral)
10115100|NCT04453332|Active Comparator|Non-oral hormone therapy|Percutaneous estradiol gel 1.5mg and micronized progesterone 200mg vaginal 14 days a month (non-oral)
10115101|NCT04453462|Active Comparator|Local direct median nerve block|
10115102|NCT04453462|Active Comparator|Brachial plexus block|
10115103|NCT04453228||2017-2018 snow season|Injured skiers in the 2017-2018 snow season
10115104|NCT04453228||2018-2019 snow season|Injured skiers in the 2018-2019 snow season
10115105|NCT04453241|Experimental|NBP615|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
10115106|NCT04453241|Active Comparator|GARDASIL|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
10115107|NCT04453176||"operating block admission on foot"|Patient going to the oparating block on foot
10115108|NCT04453176||standard operating block admission|Patient going to the operating room in a conventional way (stretcher)
10115109|NCT04453254|Active Comparator|Whole Food Meal|A whole meal consisting of 1 cup 2% milk, 1 cup Kashi Go Lean Original cereal, ¼ cup of almonds, ¼ cup of strawberries, and ¼ cup of raspberries.
10115110|NCT04453254|Active Comparator|Supplement Food Meal|A supplemental meal equivalent consisting of 1 cup 2% milk, 20 g whey protein, ½ EAS Myoplex bar, and ½ Balance bar.
10115111|NCT04453189|Experimental|Treatment Sequence: AB(Part 1) followed by C(Part 2-Optional)|Participants will received Treatment A (single dose of JNJ-64417184 in fed condition on Day 1) in period 1 followed by Treatment B (lansoprazole on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5) in period 2 of part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
10115112|NCT04453189|Experimental|Treatment Sequence: BA(Part 1) followed by C(Part 2-Optional)|Participants will receive Treatment B in period 1 followed by Treatment A in period 2, Part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
10115113|NCT04453124|No Intervention|Soap and Water|Standard of care using soap and water
10115114|NCT04453124|Experimental|Ficus Septica Sap|Ficus Septica Sap, topical cream, 50ul, daily, for 2 days
10115115|NCT04453124|Active Comparator|Chlorhexidine (Topical)|Chlorhexidine, topical solution, 50ul, daily, for 2 days
10115116|NCT04453020|Experimental|LHA DBS|Subjects will receive bilateral DBS of the LHA
10115117|NCT04452760|Active Comparator|Control group|Only testing sessions
10115118|NCT04452760|Experimental|Progressive resistance training group|10-weeks of progressive resistance training group. Leg press, leg extension, calf raises, hip extension exercises.
9819259|NCT02158039|Experimental|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
9819260|NCT02158247||Conventional group, Touch and Read group|
9819261|NCT02158273|Active Comparator|TRICOR (fenofibrate)|
9819262|NCT02158273|Placebo Comparator|Sugar Pill|
9819263|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
9819264|NCT02158442|Experimental|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
9819265|NCT02158442|Active Comparator|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
9819266|NCT02158494|Experimental|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
9819267|NCT02158494|Sham Comparator|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation (sham device). 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
9819268|NCT02158520|Experimental|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
10115119|NCT04452773|Experimental|Manremyc|Participants will receive daily oral administration of a capsule of Manremyc for 14 days in the morning with breakfast
9819269|NCT02158520|Experimental|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
9819270|NCT02158533|Experimental|High Dose|
9819271|NCT02158533|Experimental|Low Dose|
9819272|NCT02158533|Placebo Comparator|Placebo|
9819273|NCT02158546|Experimental|ALKS 5461|
9819274|NCT02158546|Placebo Comparator|Placebo|
9819275|NCT02158572|Experimental|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
9819276|NCT02158663|Active Comparator|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
9819277|NCT02158663|Active Comparator|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
9819278|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study [NIPS]).~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
9819279|NCT02158806|Experimental|Aspirin|150 mg capsule once daily for up to 24 weeks
9819280|NCT02158806|Placebo Comparator|Inert capsule|Matching capsule once daily for up to 24 weeks
9819281|NCT02158884|Other|IDEO brace|IDEO brace
9819282|NCT02158936|Experimental|Eltrombopag|Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
9819283|NCT02158936|Placebo Comparator|Placebo|Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
9819284|NCT02158949|Experimental|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
9819285|NCT02158949|No Intervention|Usual Care|Usual care in ED
9819286|NCT02158975|Experimental|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
9819287|NCT02159053|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
10115120|NCT04452773|Placebo Comparator|Placebo|Participants will receive daily oral administration of a capsule of Placebo for 14 days in the morning with breakfast
10115121|NCT04452851|Experimental|Treadmill test with BREATHE|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with the prototype BREATHE system until they are fully recovered (Borg: 0).
9819288|NCT02159053|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
9819289|NCT02159053|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
9819290|NCT02159079|No Intervention|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
9819291|NCT02159079|Experimental|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
9819292|NCT02159118|Active Comparator|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
9819293|NCT02159118|Active Comparator|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
9819294|NCT02159183|Experimental|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
9819295|NCT02159183|Active Comparator|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
9819296|NCT02159352|Experimental|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
9819297|NCT02159352|Experimental|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
9819298|NCT02159365|Experimental|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
9819299|NCT02159469|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
9819300|NCT02159482|Experimental|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
9819301|NCT02159521|Experimental|EkoSonic® Endovascular System|Thrombolytic infusion (Alteplase), at an infusion rate of 0.5-1.0 milligrams/hour (mg/hr) will be delivered to the participants with chronic lower extremity venous obstruction after DVT and PTS through the EkoSonic® Endovascular System for at least 12 hours and overnight as needed up to a maximum of 48 hrs. The alteplase dose could be adjusted per investigator discretion, but not to be exceeded 1 mg/hr or a total dose of 48 mg.
9819302|NCT02159547|Active Comparator|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
9819303|NCT02159547|Placebo Comparator|normal slaline|50 ml normal saline
9819304|NCT02159703|Experimental|Single Arm Phase 2|
9826933|NCT02437890|Placebo Comparator|Placebo|"Two s.c. injections with placebo every 2 weeks (q2w).~***~Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
9826934|NCT02437890|Experimental|ALX-0061 75 mg q4w|"ALX-0061 75 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46."
9826935|NCT02437890|Experimental|ALX-0061 150 mg q4w|"ALX-0061 150 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
9826936|NCT02437890|Experimental|ALX-0061 150 mg q2w|"ALX-0061 150 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
9826937|NCT02437890|Experimental|ALX-0061 225 mg q2w|"ALX-0061 225 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46."
10115122|NCT04452851|Active Comparator|Treadmill test with BiPAP|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a standard BiPAP machine until they are fully recovered (Borg: 0).
9819305|NCT02159729|Placebo Comparator|Placebo|Participants treated with placebo in previous ATX-101 studies
9819306|NCT02159729|Experimental|ATX-101 (1 mg/cm^2)|Participants treated with ATX-101 (1 mg/cm^2) in previous phase 2 studies
9819307|NCT02159729|Experimental|ATX-101 (2 mg/cm^2)|Participants treated with ATX-101 (2 mg/cm^2) in previous phase 2 studies
9819308|NCT02159729|Experimental|ATX-101 (4 mg/cm^2)|Participants treated with ATX-101 (4 mg/cm^2) in previous phase 2 studies
9819309|NCT02159768|Experimental|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
9819310|NCT02159807|Active Comparator|1.25 mg Bupivacaine|1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
9819311|NCT02159807|Active Comparator|1.66 mg Bupivacaine|1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
9819312|NCT02159807|Active Comparator|2.5 mg Bupivacaine|2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
9819313|NCT02159859|Experimental|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
9819314|NCT02159872|Experimental|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
9819315|NCT02159898|Experimental|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
9819316|NCT02159898|Active Comparator|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
9819317|NCT02159950|Experimental|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
9819318|NCT02159950|Experimental|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
9819319|NCT02159976|Active Comparator|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
9819320|NCT02159976|Experimental|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
9819321|NCT02160002|Active Comparator|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
9819322|NCT02160002|Active Comparator|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
9819323|NCT02160041|Experimental|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
9819324|NCT02160145|Experimental|Tolvaptan|Tolvaptan (OPC-41061)
9819325|NCT02160145|Placebo Comparator|Placebo|Placebo
9819326|NCT02160288|Active Comparator|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
9819327|NCT02160288|Placebo Comparator|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
9819328|NCT02160314|Placebo Comparator|pad|absorbent pad control
9819329|NCT02160314|Experimental|pessary|disposable, single-use pessary
9819330|NCT02160535|Experimental|Treatment with OnabotulinumtoxinA|OnabotulinumtoxinA
9668130|NCT01347970|Experimental|Arm I (beta-adrenergic/alpha-1 adrenergic blocker)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
9819331|NCT02160626|Placebo Comparator|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
9819332|NCT02160626|Active Comparator|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
9819333|NCT02160626|Active Comparator|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
9819334|NCT02160730|Experimental|R-roscovitine|• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
9819335|NCT02160782|Experimental|LUM001 (Maralixibat)|"LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid [sBA] level and ItchRO[Obs] score) and safety assessment.~Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat."
9819336|NCT02160782|Placebo Comparator|Placebo|Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
9819337|NCT02160808|Active Comparator|Secretin|Stimulate pancreatic secretion
9819338|NCT02160808|Placebo Comparator|Saline|Placebo should not stimulate the pancreas to release its fluids
9819339|NCT02160847|Experimental|DRIVE program|Participants in the experimental group will receive the DRIVE curriculum (15 sessions) via weekly sessions conducted in their home by a DRIVE provider.
9819340|NCT02160847|No Intervention|Control Group|"The parents in the control group will be mailed information on nutrition, physical activity, and parent-child interactions. Information on nutrition will include guidelines provided by the MyPlate website (http://www.choosemyplate.gov/preschoolers.html) in addition to information on proper nutrition and suggest levels of physical activity for preschoolers. Lastly, parents will be provided with the free publication, Adventures in Parenting: How responding, Preventing, Monitoring, Mentoring, and Modeling Can Help You Be A Successful Parent, authored by National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. Information covered in this document includes effective parenting strategies for children at specific ages."
9819341|NCT02160873|Experimental|chocolate milk|In this arm, subjects receive chocolate milk
9819342|NCT02160873|Placebo Comparator|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
9819343|NCT02160899|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
9819344|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
9819345|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
9819346|NCT02160899|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
9668131|NCT01347970|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
9819347|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
9819348|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
9819349|NCT02160977|Experimental|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
9819350|NCT02160977|Active Comparator|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
9819351|NCT02160990|Experimental|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
9819352|NCT02160990|Placebo Comparator|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
9819353|NCT02161133|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
9819354|NCT02161133|Active Comparator|Health Education|Health education provides didactic information about Gulf War Illness
9819355|NCT02161146|Experimental|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
9819356|NCT02161146|Placebo Comparator|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
10115123|NCT04452851|Placebo Comparator|Treadmill test with placebo inhaler|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a placebo inhaler until they are fully recovered (Borg: 0).
9819357|NCT02161146|Active Comparator|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
9819358|NCT02161146|Other|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
9819359|NCT02161146|Other|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
9819360|NCT02161185|Other|USL261|
9819361|NCT02161406|Active Comparator|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
9819362|NCT02161406|Placebo Comparator|Placebo|125mg Placebo
9819363|NCT02161458|Experimental|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
9819364|NCT02161458|Placebo Comparator|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
9819365|NCT02161458|Experimental|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
9819366|NCT02161458|Experimental|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
9819367|NCT02161484|Experimental|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
9819368|NCT02161484|Active Comparator|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
9819369|NCT02161536|Experimental|Motus CleanC System|Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
9819370|NCT02161536|Experimental|Motus Cleansing System Rev 2.5|Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
9819371|NCT02161536|Experimental|Motus Cleansing System Rev 3.0|Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
9819372|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
9819373|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
9819374|NCT02161562|Experimental|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
9819375|NCT02161562|Experimental|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
9819376|NCT02161575|Experimental|Ranibizumab|All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
9819377|NCT02161705|Experimental|Ropivacaine Group|Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
9819378|NCT02161705|Placebo Comparator|Saline Group|Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.
9819379|NCT02161718|Experimental|Samidorphan + olanzapine (ALKS 3831)|Active study drug
9819380|NCT02161718|Placebo Comparator|Placebo + olanzapine|
9819381|NCT02161731|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
9519371|NCT03287830|No Intervention|Usual care|"Season 2017-18: Usual care has no text message~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
9819382|NCT02161731|Experimental|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17
9819383|NCT02161757|Experimental|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
9819384|NCT02161757|Placebo Comparator|Placebo Dose Regimen 1|Placebo subcutaneous injection
9819385|NCT02161757|Experimental|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
9819386|NCT02161757|Placebo Comparator|Placebo Dose Regimen 2|Placebo subcutaneous injection
9819387|NCT02162433|Active Comparator|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
9819388|NCT02162433|Placebo Comparator|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
9819389|NCT02162433|Active Comparator|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
9819390|NCT02162433|Placebo Comparator|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
9819391|NCT02162446|Experimental|68Ga-OPS202|Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
9819392|NCT02162576|Other|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
9819393|NCT02162667|Experimental|CT-P6|
9819394|NCT02162667|Active Comparator|Trastuzumab|
9819395|NCT02162680|Active Comparator|lidocaine|1% lidocaine intradermal injection
9819396|NCT02162680|Active Comparator|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
9819397|NCT02162680|No Intervention|no local anesthetic|usual care practice of no local anesthetic administration
9819398|NCT02162719|Experimental|Ipatasertib + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
9819399|NCT02162719|Placebo Comparator|Placebo + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
9819400|NCT02162758|Experimental|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
9819401|NCT02162758|Experimental|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
9819402|NCT02162771|Experimental|CT-P10|"Patient treated with CT-P10 (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with CT-P10 (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
9819403|NCT02162771|Active Comparator|Rituxan|"Patient treated with Rituxan (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with Rituxan (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
9819404|NCT02162862|Other|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
9819405|NCT02162862|Other|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
9819406|NCT02162862|No Intervention|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
9819407|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
9819408|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
9819409|NCT02163057|Other|Cohort 1: Surgery Cohort|Participants received up to two doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart before surgery and up to three doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart after surgery for a total of no more than four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device.
9668132|NCT01322581||observational cohort|This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal
9819410|NCT02163057|Other|Cohort 2: Chemoradiation|Participants received four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device 3 weeks (± 3 days) apart beginning approximately 2 to 6 months after chemoradiation therapy.
9819411|NCT02163226|Experimental|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
9819412|NCT02163226|Active Comparator|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
9819413|NCT02163395|Other|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm
9819414|NCT02163421|Experimental|Vedolizumab SC 54 mg|Vedolizumab SC, once on Day 1.
9819415|NCT02163421|Experimental|Vedolizumab SC 108 mg|Vedolizumab SC, once on Day 1.
9819416|NCT02163421|Experimental|Vedolizumab SC 160 mg|Vedolizumab SC, once on Day 1.
9819417|NCT02163421|Active Comparator|Vedolizumab IV 300 mg|Vedolizumab IV, once on Day 1.
9819418|NCT02163434|Experimental|gabapentin|1800-2400mg/day divided tid or qid, orally.
9819419|NCT02163434|Experimental|metoclopramide|45-60mg/day divided tid or qid, orally
9819420|NCT02163447|Active Comparator|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
9826938|NCT02437903|Other|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
9668133|NCT01294020|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B of the study.
10188038|NCT03720184|Experimental|HAR group|Treated group is exposed to an haematic antegrade autologous repriming of the MiECC CLass IV circuit, reducing the haemodilution related to CPB initiation to a fix amount of 300ml
10188039|NCT03720184|No Intervention|Control Group|Control group is not exposed to HAR. The extracorporeal circuit is a MiECC primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit
10188040|NCT03720171|Experimental|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb.
10188041|NCT03720158|Experimental|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
9668134|NCT01275846|Experimental|Health Guide using AHA protocols|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
9668135|NCT01187810|Experimental|Combination of Fenretinide, Cytarabine, and Methotrexate|IV for 7 days for each 21 day cycle
10188042|NCT03720158|Placebo Comparator|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
9668136|NCT01169194||Affected|Patients with IBD
9668137|NCT01169194||Unaffected|Individuals who do not have IBD
10188043|NCT03720145|Experimental|Treatment Group|lifestyle medicine group
10188044|NCT03720145|No Intervention|CAU group|Care-As-Usual group
9668138|NCT01137123|Active Comparator|standard two field +follow-up|
9668139|NCT01137123|Experimental|standard two field +adjuvant chemotherapy|
9668140|NCT01137123|Experimental|total two field+follow-up|
9668141|NCT01137123|Experimental|total two field+adjuvant chemotherapy|
9819421|NCT02163447|Active Comparator|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
9819422|NCT02163447|Active Comparator|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
9819423|NCT02163447|Active Comparator|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
9819424|NCT02163447|Active Comparator|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
9819425|NCT02163486|Active Comparator|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
9819426|NCT02163486|Experimental|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
9819427|NCT02163499|Experimental|Sodium Zirconium Cyclosilicate|
9819428|NCT02163538|Active Comparator|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
9819429|NCT02163538|Active Comparator|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
9819430|NCT02163577|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W). Dose was determined by the participant's weight and prescribed dose by their study doctor.
9819431|NCT02163577|Experimental|Burosumab Q4W Then Q2W|Burosumab SC injections every 4 weeks (Q4W). Dose was determined by the participant's weight and prescribed dose by their study doctor. Participants in Q4W were to switch to Q2W beginning with Week 64 dosing.
9819432|NCT02163759|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
10115124|NCT04452851|Experimental|Activity of Daily Living with BREATHE|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
10115125|NCT04452851|Experimental|Activity of Daily Living with BREATHE during recovery|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
10115126|NCT04452851|No Intervention|Activity of Daily Living|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system will NOT be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
10115127|NCT04452799|Experimental|expermintal|1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days
10115128|NCT04452799|Active Comparator|standard|standard care therapy in quarantine hospitals
10115129|NCT04453111|Experimental|Hyaluronic Acid (HA) + P-MMSCs|Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
10115130|NCT04453111|Experimental|Hyaluronic Acid (HA) + BM-MMSCs|Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
10115131|NCT04453111|Active Comparator|Hyaluronic Acid (HA)|Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients
10115132|NCT04453098|Experimental|Re group|high-Resistance-moderate-endurance, participants performed 10 repetitions at 70% of one maximal repetition in resistance and 30% of VO2-peak for endurance training
10115133|NCT04453098|Experimental|rE group|moderate-resistance (30%) - high-Endurance (70%)
10115134|NCT04453098|Experimental|re group|moderate-resistance (30%) - moderate-endurance (30%).
10115135|NCT04453098|No Intervention|control group|no intervention
9519372|NCT03287765||Experimental 18F-AV-1451|
9668142|NCT01137123|Experimental|three field+follow-up|
9668143|NCT01137123|Experimental|three field+adjuvant chemotherapy|
9668144|NCT01124942|Experimental|MGuard|MGuard net protective stent, investigational device
9668145|NCT01124942|Active Comparator|BMS plus thrombectomy|Bare-metal stent plus manual thrombectomy device
9668146|NCT01097005||Klaricid|Those with an exposure
9668147|NCT01093612|Experimental|Arm I|PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.
9668148|NCT01072682|Experimental|SCD|Selective Cytopheretic Device
9668149|NCT00999011|Active Comparator|One 20 minute period of activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
9668150|NCT00999011|Active Comparator|Two periods of 20 minute activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
9668151|NCT00985400|Experimental|Exercise Program|Arm I (exercise program): Oncologist advice; Resistance bands & pedometer with written/DVD instructions for resistance exercise twice a week for 16 weeks. Brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day. Monthly newsletters; Telephone counseling weekly for 4 weeks then monthly for 12 weeks; and tailored message telephone prompts once every 2 weeks during last 12 weeks of the study intervention.
9668152|NCT00985400|Experimental|Relaxation Intervention|Arm II (relaxation program): Oncologist advice; Written/CD audio instructions on diaphragmatic breathing and guided imagery. Practice relaxation techniques for 15 minutes/day, 5-7 days/week, for 16 weeks. Monthly newsletters, telephone counseling, and tailored-message telephone prompts as in arm I.
9668153|NCT00931255|Active Comparator|Tacrolimus|Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
9668154|NCT00931255|Active Comparator|Sirolimus|5 mg, PO , daily
9668155|NCT00918112||Parkinson's Disease|Meets criteria for definite Parkinson's Disease
9668156|NCT00918112||Healthy Controls|- Must be in good health
9668157|NCT00779168|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive white button mushroom extract PO twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
9668158|NCT00730678||All Participants|All participants enrolled on this study will have blood drawn for genetic testing.
9668159|NCT00706420|Experimental|1|Islet cell transplantation alone
9668160|NCT00669669|Experimental|Treatment (chemotherapy, autologous stem cell transplant)|See Detailed Description
9668161|NCT00608023|Experimental|Tesamorelin 12 months (T-T)|Tesamorelin 2 mg/day for 12 months
9668162|NCT00608023|Experimental|Tesamorelin-Placebo (T-P)|Tesamorelin 2 mg/day for 6 months - Placebo for 6 months
9668163|NCT00608023|Experimental|Placebo-Tesamorelin (P-T)|Placebo 6 months - Tesamorelin 2 mg/day for 6 months
9965701|NCT01004952||screening questionnaire|This study will involve two phases. Guided by EDTM, we will first build models of decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing)using in-home ethnographic interviews with 25 melanoma FDRs (Phase I). In Phase II, we will test the validity of each composite model. This will be completed using EMA data collection with 60 different melanoma FDRs from Phase I who will report on their sunscreen use, shade-seeking, use of hat, and use of UVR protective clothing and decision-making regarding these outcomes via interactive voice response (IVR) system and audio narrative diaries (using a digital voice recorder). We will examine the validity of each model and examine the influence of theory-driven affective and cognitive predictors of UVR protection maintenance across time.
9965702|NCT01252160|Experimental|QUTENZA|Cutaneous patch
9668166|NCT00540995|Experimental|Arm I: 1200cGy|"1200cGy = 150cGy x 8 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate."
9668167|NCT00540995|Experimental|Arm II: 1350cGy|1350cGy = 150cGy x 9 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.
9965703|NCT01252199|Experimental|cαStx1/cαStx2|
9965704|NCT01252199|Placebo Comparator|Control|
9965705|NCT01252212|Experimental|Receiving SMS alerts|The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
10115136|NCT04452968|Experimental|intermittent fasting|"Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.~Women were told about timed restricted feeding. They were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours."
9668174|NCT00484471|Experimental|1|
9668175|NCT00484471|Placebo Comparator|2|
9668176|NCT00418301|Experimental|Precision Spinal Cord Stimulation and PET Scan|Positron emission tomography (PET) scan imaging procedures to assess Spinal Cord Stimulation.
9694061|NCT04793152|Experimental|Vancomycin continuous infusion|A loading dose of 15-20mg/kg will be given followed by continuous infusion dose of 30mg/kg over 24 hours if normal renal function. Dose will be adjusted based on creatinine clearance. A random vancomycin level will be done with routine morning blood work until target level have been achieved. The dose is adjusted to target of 17-21mg/L based on target area under the curve of 400-500.
9819433|NCT02163759|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
9819434|NCT02163759|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
10115137|NCT04452968|Active Comparator|caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
9819435|NCT02163811|Experimental|VETPALS|VETPALS is a five session course utilizing adult learning methods to teach self-management for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA Puget Sound clinician in conjunction with a peer facilitator (Veteran with limb loss).
9819436|NCT02163811|Active Comparator|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
9819437|NCT02163824|Active Comparator|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
9819438|NCT02163824|Active Comparator|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
9819439|NCT02163824|Placebo Comparator|Vehicle of KPI-121 0.25%|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
9819440|NCT02163824|Placebo Comparator|Vehicle of KPI-121 1.0%|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
9819441|NCT02163837|Experimental|rifaximine|
9819442|NCT02163902|Experimental|ATX-101|Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
9819443|NCT02163902|Placebo Comparator|Placebo|Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
9819444|NCT02163915|Experimental|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
9819445|NCT02163915|Experimental|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
9819446|NCT02163915|Experimental|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
9819447|NCT02163915|Experimental|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
9819448|NCT02163915|Experimental|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
9819449|NCT02163915|Experimental|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
9819450|NCT02163967|Other|Dose sequence: Sham, Low, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -1 milliamp stimulation intensity, Day 3 - 2milliamp stimulation intensity
9819451|NCT02163967|Other|Dose sequence: Sham, High, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -2 milliamp stimulation intensity, Day 3 - 1milliamp stimulation intensity
9819452|NCT02163967|Other|Dose sequence: Low, Sham, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 -Sham stimulation; Day 3 - 2milliamp stimulation intensity
9819453|NCT02163967|Other|Dose sequence: Low, High, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 - 2milliamp stimulation intensity; Day 3 - Sham stimulation
9819454|NCT02163967|Other|Dose sequence: High, Sham, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - Sham stimulation; Day 3 - 1 milliamp stimulation intensity
9819455|NCT02163967|Other|Dose sequence: High, Low, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - 1 milliamp stimulation intensity; Day 3 - Sham stimulation
9819456|NCT02163993|Experimental|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
9819457|NCT02163993|Experimental|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
9819458|NCT02163993|Experimental|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
9819459|NCT02163993|Experimental|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
9819460|NCT02163993|Placebo Comparator|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
9819461|NCT02164240|Experimental|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
9819462|NCT02164318|No Intervention|Control group|Standard of care
9819463|NCT02164318|Experimental|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
9819464|NCT02164318|Experimental|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
10115138|NCT04452864|Experimental|Study Intervention|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by AD. This training will be performed for three months (each day for 20 minutes). After three months this group will continue the training at home for six months and meet monthly for group sessions (i.e. booster sessions) on site.
9819465|NCT02164318|Experimental|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
9819466|NCT02164383|Experimental|Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
9819467|NCT02164383|Experimental|No Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention:~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
9819468|NCT02164396|Active Comparator|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
9819469|NCT02164396|Active Comparator|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
9819470|NCT02164396|Experimental|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
9819471|NCT02164422|Experimental|Guanfacine 3mg/day|Guanfacine 3mg/day
9819472|NCT02164422|Experimental|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
9819473|NCT02164422|Placebo Comparator|Placebo|Placebo
9819474|NCT02164513|Experimental|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
9819475|NCT02164513|Experimental|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
9819476|NCT02164513|Experimental|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
9819477|NCT02164539|Experimental|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
9819478|NCT02164539|Experimental|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
9819479|NCT02164539|Experimental|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
9819480|NCT02164721|Other|CRT-D (Defibrillator)|Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
9819481|NCT02164864|Experimental|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
9819482|NCT02164864|Experimental|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
9819483|NCT02164864|Active Comparator|Warfarin|Warfarin doses to maintain INR
9819484|NCT02164916|Active Comparator|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
9819485|NCT02164916|Experimental|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9819486|NCT02164929|Active Comparator|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
9819487|NCT02164929|Active Comparator|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
9819488|NCT02164929|Active Comparator|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
9519373|NCT03287739||Single-group study|Assessment of behavioral biometric impairments
9519374|NCT03287726|Experimental|probiotics|
9819489|NCT02164929|Active Comparator|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
9819490|NCT02164981|Active Comparator|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
9819491|NCT02164981|Other|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
9819492|NCT02164981|Placebo Comparator|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
9819493|NCT02165111|Experimental|Onabotulinumtoxin A|"One hand of each patient will be randomly selected for injection of Botulinum Toxin A (Onabotulinumtoxin A, 20 units/mL).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (10 units each=0.5mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (5 units each= 0.25mL each). Total treatment dose of Botulinum Toxin A will not exceed 50 units per hand."
9819494|NCT02165111|Placebo Comparator|Placebo|"One hand of each patient will be randomly selected for injection of sterile saline solution (placebo).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (0.5 mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (0.25 mL each)."
9819495|NCT02165124|Experimental|Intervention/Bariatric Embolization|
9819496|NCT02165202|Active Comparator|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
9819497|NCT02165202|Placebo Comparator|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
10115139|NCT04452864|Active Comparator|Active Control Group|This control study arm will watch documentaries at home for three months (each day for 20 minutes) , instead of performing the CCT and serve as active control group. This group will also train with the CCT tasks after these three months.
10115140|NCT04452864|Other|Wait-List Control|This control study arm will start with the CCT with a delay of three months and serve as wait-list control group.
10115141|NCT04452890|Experimental|Sonourethrography|Ultrasound of the urethra (Sonourethrography - SUG): In this procedure, a Foley catheter is inserted into the top of the urethra and physiological serum is instilled into the urethra while a linear 7.5 MHz ultrasound probe is placed sagitally on the course of the urethra to detect a narrowing of the urethra.
9819498|NCT02165384|Experimental|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
9819499|NCT02165397|Experimental|Randomized Study (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
9819500|NCT02165397|Experimental|Randomized Study (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
9819501|NCT02165397|Experimental|Open-Label Substudy (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
9819502|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
9965706|NCT01252212|Active Comparator|No SMS messages|The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
10115142|NCT04452838|Other|Cohort 1 Sequence 1 (Part A)|Treatment Sequence A,B,C and D
10115143|NCT04452838|Other|Cohort 1 Sequence 2 (Part A)|Treatment Sequence B, A,C and D
10115144|NCT04452838|Other|Cohort 2 Sequence 1 (Part B)|Treatment Sequence E, F, G, and H
10115145|NCT04452838|Other|Cohort 2 Sequence 2 (Part B)|Treatment Sequence E, F, H and G
9965707|NCT01252225|Active Comparator|Nebulised Lidocaine followed by Placebo throat spray|
9965708|NCT01252225|Active Comparator|Nebulised Placebo followoed by Lidocaine Throat Spray|
10115146|NCT04452838|Other|Cohort 2 Sequence 3 (Part B)|Treatment Sequence F, E, G, and H
10115147|NCT04452838|Other|Cohort 2 Sequence 4 (Part B)|Treatment sequence F, E, H, and G
10115148|NCT04452786|Other|Endoscopic sleeve gastroplasity operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
10115149|NCT04452786|Other|Laparoscopic sleeve gastrectomy operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
10115150|NCT04453046|Experimental|Hemopurifier and Pembrolizumab|In this clinical trial, the exosome-depleting device, the Hemopurifier, will be combined with standard of care therapy, Pembrolizumab. The purpose of the combination is to more effectively reduce immune suppression and provide a combined benefit of immune restoration for patients with recurrent/metastatic HNSCC. Therapy with the Hemopurifier will be initiated on the same day as and prior to Pembrolizumab infusion. The Hemopurifier treatment will be 4h. The subject treated with the Hemopurifier will remain in the Hemopurifier treatment area for the duration of the treatment. Pembrolizumab infusion will take place shortly after Hemopurifier treatment and may take place through the next day if needed.
9819503|NCT02165605|Experimental|HylaCare|HylaCare cream Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily, but not within 4 hours prior to radiation treatment.
9819504|NCT02165605|Placebo Comparator|Placebo|The patient is her own control.
9819505|NCT02165722|Experimental|Intervention: Toolkit|4 Pillars Toolkit
9819506|NCT02165722|No Intervention|No Intervention: Standard practice|11 Clinical Practices [control sites]
9819507|NCT02165735|Experimental|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification patient concerns and patient behavioral rehearsal for asking about these concerns.
9819508|NCT02165735|Experimental|Usual Care|Usual care for HIV
9819509|NCT02165761|Active Comparator|GORE® Hybrid Vascular Graft|GORE® Hybrid Vascular Graft
9819510|NCT02165761|Other|Non-heparin bonded synthetic graft|Non-heparin bonded synthetic graft
9819511|NCT02165826|Experimental|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
9819512|NCT02165826|Experimental|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
9819513|NCT02165826|Experimental|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
9819514|NCT02165839|Active Comparator|Healthy Eating Education Learning (HEAL)|Control group.
9819515|NCT02165839|Experimental|Brief Behavioral Therapy for Insomnia (BBT-I)|
9819516|NCT02165904|Experimental|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
9819517|NCT02166047|Placebo Comparator|Placebo 4 Weeks (Cohort A)|Placebo tablet once a week for 4 weeks
9819518|NCT02166047|Experimental|Vesatolimod 1 mg 4 Weeks (Cohort A)|Vesatolimod 1 mg tablet once a week for 4 weeks
9819519|NCT02166047|Experimental|Vesatolimod 2 mg 4 Weeks (Cohort A)|Vesatolimod 2 mg tablet once a week for 4 weeks
9819520|NCT02166047|Experimental|Vesatolimod 4 mg 4 Weeks (Cohort A)|Vesatolimod 4 mg tablet once a week for 4 weeks
9819521|NCT02166047|Placebo Comparator|Placebo 8 Weeks (Cohort B)|Placebo tablet once a week for 8 weeks
9819522|NCT02166047|Experimental|Vesatolimod 1 mg 8 Weeks (Cohort B)|Vesatolimod 1 mg tablet once a week for 8 weeks
9519375|NCT03287726|Placebo Comparator|placebo|
9819523|NCT02166047|Experimental|Vesatolimod 2 mg 8 Weeks (Cohort B)|Vesatolimod 2 mg tablet once a week for 8 weeks
9819524|NCT02166047|Experimental|Vesatolimod 4 mg 8 Weeks (Cohort B)|Vesatolimod 4 mg tablet once a week for 8 weeks
9819525|NCT02166047|Placebo Comparator|Placebo 12 Weeks (Cohort C)|Placebo tablet once a week for 12 weeks
9819526|NCT02166047|Experimental|Vesatolimod 1 mg 12 Weeks (Cohort C)|Vesatolimod 1 mg tablet once a week for 12 weeks
9819527|NCT02166047|Experimental|Vesatolimod 2 mg 12 Weeks (Cohort C)|Vesatolimod 2 mg tablet once a week for 12 weeks
9819528|NCT02166047|Experimental|Vesatolimod 4 mg 12 Weeks (Cohort C)|Vesatolimod 4 mg tablet once a week for 12 weeks
9819529|NCT02166333|Active Comparator|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
9819530|NCT02166333|Active Comparator|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
9819531|NCT02166333|Active Comparator|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
9819532|NCT02166333|Active Comparator|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
9819533|NCT02166346|Experimental|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
9819534|NCT02166346|Experimental|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
9819535|NCT02166476|Experimental|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams [g] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
9819536|NCT02166476|Active Comparator|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
9819537|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
9819538|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
9819539|NCT02167035|Active Comparator|Combigan Two Times Daily (BID)|Combigan 0.2%/0.5% one drop Two Times Daily (BID)
9819540|NCT02167035|Active Comparator|Simbrinza Three Times Daily (TID)|Simbrinza 1/0.2% one drop Three Times Daily (TID)
9819541|NCT02167074|Active Comparator|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
9819542|NCT02167074|Active Comparator|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
9819543|NCT02167139|Experimental|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
9819544|NCT02167139|Active Comparator|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
9826939|NCT02438137|Active Comparator|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
9826940|NCT02438137|Placebo Comparator|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
9826941|NCT02438280|Experimental|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
9826942|NCT02438280|Active Comparator|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
9826943|NCT02438371|Active Comparator|Nifedipine|Participants will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours.
9826944|NCT02438371|Active Comparator|Nifedipine plus Indomethacin|Participants will receive will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours, as well as indomethacin 100 mg orally, then indomethacin 50 mg orally every 6 hours for a total of 48 hours.
9827617|NCT02462057|Active Comparator|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:~Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths~No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
9827618|NCT02462070|Experimental|IDP-118 Lotion|Lotion
9827619|NCT02462070|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
9827620|NCT02462083|Experimental|IDP-118 Lotion|IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.
9827621|NCT02462122|Experimental|IDP-118 Lotion|Lotion
9827622|NCT02462122|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
9827623|NCT02462148|Experimental|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
9827624|NCT02462148|Experimental|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
9827625|NCT02462148|Placebo Comparator|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
9827626|NCT02462291|Experimental|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
9827627|NCT02462291|No Intervention|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
9827628|NCT02462382|Active Comparator|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
9827629|NCT02462382|Placebo Comparator|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
9827630|NCT02462473|Experimental|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
9827631|NCT02462473|Experimental|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
9827632|NCT02462473|Experimental|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
9819545|NCT02167204|Experimental|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
9819546|NCT02167217|Experimental|Oral Prednisolone|Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast
9819547|NCT02167256|Experimental|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
9819548|NCT02167256|Placebo Comparator|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
9819549|NCT02167451|Experimental|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
9819550|NCT02167594|Experimental|PSP Subjects|Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
9819551|NCT02167594|Experimental|CBD subjects|Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
9819552|NCT02167594|Experimental|Healthy volunteers|Healthy volunteers receiving a flortaucipir PET scan at baseline.
9819553|NCT02167815|Active Comparator|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
9819554|NCT02167815|Experimental|Intervention ( Mepilex XT)|
10115151|NCT04452903|Experimental|Reassurance intervention|The physiotherapist in the intervention group (n=15) will participate in a 3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
10115152|NCT04452903|No Intervention|Control|The physiotherapist in the control group (n=15) receives no training.
10115153|NCT04452812|Experimental|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
10115154|NCT04452812|Placebo Comparator|Best available treatment|"Best available treatment + Placebo (0.9% saline solution)~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Placebo will consist on 2 doses of 200 ml of 0.9% saline solution separated on a 12 hour interval."
10115155|NCT04452721||Retrospective cohort|340 to 400 patients
10115156|NCT04452721||Validation cohort|120 patients
10115157|NCT04452734|Active Comparator|Control Group|
10115158|NCT04452734|Experimental|Study Group|
10115159|NCT04452929|Active Comparator|Randomized treatment phase: Erenumab|Erenumab 140 mg single subcutaneous injection at baseline
10115160|NCT04452929|Placebo Comparator|Randomized treatment phase: Placebo|Saline placebo single subcutaneous injection at baseline
10115161|NCT04452929|Other|Open-label extension treatment phase: Erenumab|Erenumab 140 mg monthly subcutaneous injection for six months after completion of the randomized, double-blinded, placebo-controlled study phase during the open-label extension
9819555|NCT02167867|Experimental|Lay End Users|Employees of the test sites (that were fitness centers or spas) who were provided with a User's Manual to operate the ZERONA Z6 to administer 6 40-minute evenly spaced treatments over 2 consecutive weeks to the front and back of the waist, hips and thighs of one Treatment Subject.
9819556|NCT02167867|Experimental|Treatment Subject Group|Treatment subjects received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
9819557|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
9819558|NCT02168062|Active Comparator|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
9819559|NCT02168062|Experimental|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
9819560|NCT02168101|Experimental|MLN9708 - 2.3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 2.3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
9819561|NCT02168101|Experimental|MLN9708 - 3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
10115162|NCT04452695||Intervention arm|Patients presenting to the emergency department are triaged using a novel robotic telehealth triage system. Once triage is complete, patients complete a quantitative assessment to measure their acceptance and willingness to interact with the robotic telehealth system.
10115163|NCT04452708||HFNC at 30-60L/min|HFNC at 50-60L/min with humidification at 37C (Airvo 2, Fisher & Paykel, Auckland, New Zealand) will be applied for patients with moderate type 1 respiratory failure
10115164|NCT04452708||NIV|NIV (Respironics V60) via oronasal mask (Quattro, ResMed) will be reserved for patients with type 2 respiratory failure
9819562|NCT02168101|Experimental|MLN9708 - 4 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
9819563|NCT02168153|Active Comparator|Chiropractic Manipulative Therapy|Participants will complete questionnaires and biomechanical assessments, and additionally receive CMT treatment.
9819564|NCT02168153|Placebo Comparator|Wait-List Control Group|Participants will complete questionnaires and biomechanical assessments
9819565|NCT02168309|Other|Labetalol|Labetalol 200mg PO BID starting dose
9819566|NCT02168309|Other|Nifedipine|Nifedpine XL starting at dose 30mg PO daily
9819567|NCT02168361|Active Comparator|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
9819568|NCT02168361|Experimental|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
9819569|NCT02168387|Active Comparator|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
9819570|NCT02168387|Active Comparator|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
9819571|NCT02168439|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
9819572|NCT02168439|Experimental|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
9819573|NCT02168478|Experimental|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
9819574|NCT02168491|Experimental|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
9819575|NCT02168660|Active Comparator|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OHD level.
9819576|NCT02168660|Experimental|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
9819577|NCT02168660|Experimental|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, D3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
9819578|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
9819579|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
9819580|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
9819581|NCT02168803|Experimental|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
9819582|NCT02168803|Experimental|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
9819583|NCT02168803|Experimental|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
9819584|NCT02168803|Experimental|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
9819585|NCT02168816|Active Comparator|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
10115165|NCT04452708||Conventional nasal oxygen|Oxygen 1-5 L/min via nasal cannula for those with mild type 1 respiratory failure
9819586|NCT02168816|Active Comparator|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
9819587|NCT02168816|Active Comparator|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
9819588|NCT02168842|Active Comparator|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
9819589|NCT02168842|Placebo Comparator|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
9819590|NCT02168855|Active Comparator|Active nicotine gum|
9819591|NCT02168855|Placebo Comparator|Inactive gum|
9819592|NCT02168933|Experimental|active excimer laser|308 nm excimer laser treatment: treatment with the laser by a dose protocol with increasing output.
9819593|NCT02168933|Sham Comparator|Sham excimer laser|Sham 308 nm excimer laser treatment: laser dose was administered with a cap that blocks all active UV passing through the device, therefore is a placebo, but because the procedure is the same, maintains a blind.
9819594|NCT02168946|Experimental|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
9819595|NCT02168946|Active Comparator|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
9819596|NCT02169115|Experimental|Omalizumab 150mg|
9819597|NCT02169115|Experimental|Omalizumab 300mg|
9819598|NCT02169115|Placebo Comparator|Placebo|
9819599|NCT02169219|Experimental|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
9819600|NCT02169271|Experimental|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
9819601|NCT02169271|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
9819602|NCT02169284|Experimental|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
9819603|NCT02169284|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
9819604|NCT02169336|Experimental|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
9819605|NCT02169336|Experimental|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
9819606|NCT02169336|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
9819607|NCT02169414|Experimental|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
9819608|NCT02169414|Experimental|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
9819609|NCT02169414|Experimental|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
9819610|NCT02169414|Placebo Comparator|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
9819611|NCT02169427|Experimental|Opicapone (OPC)|100 mg OPC
9819612|NCT02169440|Experimental|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
9819613|NCT02169440|Active Comparator|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
9819614|NCT02169453|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
9819615|NCT02169453|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
9819616|NCT02169453|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
9819617|NCT02169453|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
9819618|NCT02169466|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
9819619|NCT02169466|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
9819620|NCT02169466|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
9819621|NCT02169466|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
9819622|NCT02169479|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
9819623|NCT02169479|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
9819624|NCT02169479|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
9819625|NCT02169479|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
9819626|NCT02169505|Experimental|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
9819627|NCT02169674|Active Comparator|10-11 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
9819628|NCT02169674|Active Comparator|15-16 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
9819629|NCT02169739|No Intervention|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
9826945|NCT02438384|No Intervention|Usual care|Pts will receive education and follow-up based on judgment of emergency provider.
9826946|NCT02438384|Experimental|Video|Patients will watch 10 minute educational video
9965709|NCT01252225|Placebo Comparator|Nebulised placebo followed by placebo throat spray|
9965710|NCT01252264||Individuals with craniofacial anomalies|Individuals who have a craniofacial anomaly (head, face, or eye disorder)
9965711|NCT01252264||Control Subjects|Family members of individuals with a craniofacial anomaly
9965712|NCT01252303|Experimental|Nutrisystem|Group will receive Nutrisystem meals in addition to the behavioral weight loss program.
9819630|NCT02169739|Active Comparator|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
9819631|NCT02169791|Experimental|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
9819632|NCT02169869|Experimental|Immediate postplacental IUD insertion|Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
10115166|NCT04452682||Era of COVID 19|Total number of cases admitted during first six months of 2020
10115167|NCT04452682||Era of Non COVID 19|Total number of cases admitted the first six months of 2019
9819633|NCT02169869|Active Comparator|6 weeks postpartum IUD insertion|Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.
9819634|NCT02169895|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~Every period with concomitant single oral administration of Prolopa® 100-25"
9819635|NCT02169895|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
9819636|NCT02169895|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
9819637|NCT02169895|Active Comparator|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
9819638|NCT02170025|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
9819639|NCT02170025|Experimental|Placebo|Participants received matching placebo tid.
9819640|NCT02170051|Experimental|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
9819641|NCT02170051|Active Comparator|Goal-focused supportive contact|Goal-focused supportive contact
9819642|NCT02170064|Experimental|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
9819643|NCT02170064|Experimental|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
9819644|NCT02170064|Experimental|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
9819645|NCT02170077|Experimental|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
9819646|NCT02170077|Experimental|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
9819647|NCT02170077|Placebo Comparator|PLG - placebo group|placebo
9819648|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
9819649|NCT02170220|Experimental|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
9819650|NCT02170220|Experimental|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
9965713|NCT01252303|Active Comparator|Control|Group will receive a behavioral weight loss program only.
10115168|NCT04452643|Active Comparator|Bacmune (MV130)|Subject included in the active group will receive Bacmune. The dose consists on 2 spray puff every 12 hours for 45 days.
10115169|NCT04452643|Placebo Comparator|Placebo|Subject included in the placebo group will receive placebo. The dose consists on 2 spray puff every 12 hours for 45 days.
10115170|NCT04452539||Paediatric cardiac surgery patients|All patients undergoing paediatric cardiac surgery
9819651|NCT02170363|Experimental|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
9819652|NCT02170376|Experimental|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
9819653|NCT02170376|Experimental|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
9819654|NCT02170376|Experimental|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
9819655|NCT02170376|Experimental|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
9819656|NCT02170376|Placebo Comparator|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
9819657|NCT02170389|Experimental|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
9819658|NCT02170519|Experimental|Phase 2: Inhaled Iloprost continuous|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy."
9819659|NCT02170519|Experimental|Phase 1: Inhaled Iloprost 3 doses|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose."
9819660|NCT02170532|Active Comparator|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
9819661|NCT02170532|Active Comparator|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
9819662|NCT02170532|Active Comparator|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
9819663|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
9819664|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
9819665|NCT02170649|Experimental|Single Group|the volunteers received a single 800 mg BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period
9819666|NCT02170662|Active Comparator|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
9819667|NCT02170662|Active Comparator|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
9819668|NCT02170688|Active Comparator|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
9819669|NCT02170688|Active Comparator|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
9819670|NCT02170688|Active Comparator|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
9819671|NCT02170688|Active Comparator|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
9819672|NCT02170688|Active Comparator|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
9819673|NCT02170727|Experimental|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
9819674|NCT02170779|Experimental|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
9819675|NCT02170779|Other|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
10115171|NCT04452669|Experimental|Study Treatment|Up to 10 days of inhaled epoprostenol delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
9819676|NCT02170870|Experimental|Healthy Controls Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
9819677|NCT02170870|Placebo Comparator|Healthy Controls Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
9819678|NCT02170870|Experimental|Diabetics Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
9819679|NCT02170870|Placebo Comparator|Diabetics Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
9819680|NCT02170870|Experimental|Functional Dyspepsia Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
9819681|NCT02170870|Placebo Comparator|Functional Dyspepsia Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
9819682|NCT02171065|Sham Comparator|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
9819683|NCT02171065|Active Comparator|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
9819684|NCT02171130|Experimental|Nasal glucagon|3 mg nasal glucagon powder delivered using a nasal powder dosing device.
9819685|NCT02171195|Experimental|Group 1 (20 mg)|
9819686|NCT02171195|Experimental|Group 2 (50 mg)|
9819687|NCT02171195|Experimental|Group 3 (100 mg)|
9819688|NCT02171195|Experimental|Group 4 (200 mg)|
9819689|NCT02171195|Experimental|Group 5 (400 mg)|
9819690|NCT02171195|Experimental|Group 6 (600 mg)|
9819691|NCT02171195|Experimental|Group 7 (900 mg)|
9819692|NCT02171195|Experimental|Group 8 (1200 mg)|
9819693|NCT02171234|Experimental|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
9819694|NCT02171234|Experimental|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
9819695|NCT02171234|Experimental|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
9819696|NCT02171234|Experimental|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
9819697|NCT02171247|Active Comparator|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
9819698|NCT02171247|Active Comparator|Visipaque 320|Standard protocol is Visipaque 320.
9819699|NCT02171260|Experimental|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 milligram per square meter (mg/m^2) (Dose Level 1), which is approximately 80% of the adult MTD, and will be escalated up to no more than 2.2 mg/m^2.
9819700|NCT02171429|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
9819701|NCT02171429|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
9819702|NCT02171429|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
9819703|NCT02171611|Experimental|Dabigatran etexilate pellets|
10115172|NCT04452669|Placebo Comparator|Placebo Control|Up to 10 days of inhaled 0.9% sodium chloride solution delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
9819704|NCT02171611|Experimental|Dabigatran etexilate powder|
9819705|NCT02171611|Active Comparator|Dabigatran etexilate capsule|
9819706|NCT02171819|Experimental|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose
9819707|NCT02171819|Experimental|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose.
9819708|NCT02171819|Placebo Comparator|Placebo|Phosphate buffered saline
9819709|NCT02172040|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
9819710|NCT02172040|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
9819711|NCT02172040|Placebo Comparator|Placebo+Celecoxib|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
9819712|NCT02172040|Sham Comparator|Placebo+Placebo|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
9819713|NCT02172625|Placebo Comparator|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
9819714|NCT02172625|Experimental|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
9819715|NCT02172664|Active Comparator|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
9819716|NCT02172664|Experimental|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
9819717|NCT02172742|Experimental|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
9819718|NCT02172742|Placebo Comparator|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
9819719|NCT02172755|Experimental|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
9819720|NCT02172755|Experimental|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
9819721|NCT02172820|Experimental|Financial incentives|Participants receive financial incentives for completing exercise sessions.
9819722|NCT02172820|No Intervention|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
9819723|NCT02172911|Experimental|Cohort I: INO-3112: Curative Intent|Cohort I included participants with biopsy-proven, stage IB-IVB inoperable, newly diagnosed invasive cervical carcinoma associated with HPV-16 and/or HPV-18 treated with standard chemoradiation therapy with curative intent. Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
9819724|NCT02172911|Experimental|Cohort II: INO-3112: Salvage Therapy|Cohort II included participants with persistent and/or recurrent cervical carcinoma associated with HPV-16 and/or HPV-18 who had been treated with salvage therapy (chemotherapy and/or radiation therapy). Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
9819725|NCT02172950|Experimental|Previously treated patients (PTPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
9819726|NCT02172950|Experimental|Previously untreated patients (PUPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
9819727|NCT02173054|Placebo Comparator|Adapalene gel|"Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face"
9819728|NCT02173054|Placebo Comparator|Adapalene gel with placebo moisturizer|"Morning~Wash face by prepared facial foam and dry their face~Apply placebo cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply placebo cream all over the face"
9819729|NCT02173054|Active Comparator|Adapalene gel with Eucerin|"Morning~Wash face by prepared facial foam and dry their face~Apply Eucerin cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply Eucerin cream all over the face"
9819730|NCT02173158|Experimental|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
9819731|NCT02173392|Experimental|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
9819732|NCT02173392|Experimental|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
9819733|NCT02173522|Experimental|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
9819734|NCT02173522|No Intervention|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
9819735|NCT02173535|Experimental|etafilcon test contact lens Variant AP|
9819736|NCT02173535|Experimental|etafilcon test contact lens Variant JG|
9819737|NCT02173535|Experimental|etafilcon test contact lens Variant CS|
9819738|NCT02173535|Experimental|etafilcon test contact lens Variant VC|
9819739|NCT02173535|Experimental|etafilcon test contact lens Variant LA|
9819740|NCT02173548|Active Comparator|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
9819741|NCT02173548|Placebo Comparator|Placebo|Matching Placebo
9819742|NCT02173704|Experimental|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
9819743|NCT02173704|Active Comparator|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
9819744|NCT02173769||Adults with COPD|
9819745|NCT02174198|Experimental|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
9819746|NCT02174198|No Intervention|No Bone Graft|No placement of BioOss at the time of implant placement
9819747|NCT02174276|Active Comparator|TDF 48 weeks|Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
9819748|NCT02174276|Experimental|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
9819749|NCT02174276|Experimental|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
9819750|NCT02174276|Experimental|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
9819751|NCT02174419|Experimental|nalbuphine HCl ER 90mg|nalbuphine HCl ER tablets 90 mg BID
9819752|NCT02174419|Experimental|nalbuphine HCl ER 180 mg|nalbuphine HCl ER tablets 180 mg BID
9819753|NCT02174419|Placebo Comparator|Sugar pill|Placebo tablets BID
9819754|NCT02174432|Experimental|nalbuphine HCl ER|nalbuphine HCl ER
9819755|NCT02174510|Experimental|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
10115173|NCT04452370|Experimental|oral Etoposide+Anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
10115174|NCT04452279|Experimental|Ocular Surface Disease post-stenting|Eyes will undergo phacoemulsification cataract surgery combined with iStent or iStent inject implantation according to standard clinical practice. From baseline through 3 months postoperatively, participants will complete subjective and objective assessments of ocular surface disease.
10115175|NCT04452227||eumenorrheic healthy women|women with a regular menstrual cycle for three months, predictable, and a period between 24-38 days that lasts less than 8 days.
10115176|NCT04452396|Experimental|patients|patients undergoing CGM monitoring
10115177|NCT04452552|Experimental|ultra-sound cavitation|cavitation40 KHz applied for 30 min, once time weekly for 8 weeks.
10115178|NCT04452552|Experimental|radiofrequency|radiofrequency multi-polar 5MHZ applied for 30 min, once time weekly for 8 weeks
10115179|NCT04452487||Patient 2019|Patients hospitalized in selected centers during march and june 2019
10115180|NCT04452487||Patient 2020|Patients hospitalized in selected centers during march and june 2020 (during COVID-19 pandemia)
10115181|NCT04452487||Patient 2021|Patients hospitalized in selected centers during march and june 2021
10115182|NCT04452409|Active Comparator|study (low level laser plus Mediterranean diet)|Active infra -red laser in addition to diet
10115183|NCT04452409|Other|control (Mediterranean diet only)|diet
10115184|NCT04452448|Experimental|Laser in situ keratomileusis|A prospective clinical study including 20 eyes of 10 cases undergoing laser in situ keratomileusis (LASIK)
10115185|NCT04452357|Experimental|PLDR Chemoradiation|"Patients will receive pulse-low-dose rate radiation, along with gemcitabine chemotherapy.~6 patients each will be accrued at two dose levels. PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows: Dose level 1: 56 Gy; Dose level 2: 66 Gy"
10115186|NCT04452461|Other|Single Arm Intervention|"Chemotherapy: 6 cycles (three months) of IV combination chemotherapy with mFOLFIRINOX on day 1 followed by one week of rest (14-day cycle). Alternatively, patients will receive three months of gemcitabine / nab-paclitaxel.~Re-staging CT scan with Carbohydrate Antigen (CA) 19-9 serum test.~Radiation therapy with SBRT for 5 days.~Re-staging CT scan with CA 19-9 serum test one week following the last day of SBRT . Staging laparoscopy to rule out occult metastatic disease is optional based on surgeon's preference.~Pancreatectomy 4 weeks following the last day of SBRT as per standard of care.~Adjuvant chemotherapy: as per standard of care.~Clinical assessment and CT scan with CA 19-9 serum test at 4-month intervals until identification of cancer recurrence.~Follow up of patients after 2 years every six months for up to 5 years following the initiation of treatment will be performed off-protocol as per standard of care."
10115187|NCT04452331|Experimental|OAA Intervention|Visit recorded, both patient and provider aware, both patient and provider have access to audio post-visit
10115188|NCT04452331|Sham Comparator|OAA Physician Aware Control|Visit recorded, both patient and provider aware, neither patient nor provider have access to audio post-visit
10115189|NCT04452331|Placebo Comparator|OAA Physician Unaware Control|Visit recorded, patient aware but provider unaware, neither patient nor provider have access to audio post-visit
10115190|NCT04452630||Covid 19 Patients|patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered.
10115191|NCT04452123|Experimental|Argon plasma|Patients with endometrioma treated with laparoscopic argon plasma energy.
10115192|NCT04452123|Experimental|Stripping and suture/coagulation|Patients with endometrioma treated with laparoscopic excision with suture or gentle coagulation of the rest of ovary.
10115193|NCT04452175|Experimental|HIGH 5%|
10115194|NCT04452175|Active Comparator|LOW 1.7%|
10115195|NCT04452253|Active Comparator|PS128|"The PS128, which belongs to Lactobacillus plantarum subsp. plantarum, 2 caps daily use.~Sub-project 2 (Open label) for IT specialists also take the same probiotics."
10115196|NCT04452253|Active Comparator|PS23 live|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
10115197|NCT04452253|Active Comparator|PS23 heat-treated|PS23 heat-treated, 2 caps daily use.
10115198|NCT04452253|Placebo Comparator|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
10115199|NCT04452266||case group|Women with Lynch Syndrome and endometrial Cancer matched on age of endometrial cancer diagnosis
10115200|NCT04452266||control group|Women with Lynch Syndrome, without Cancer at Lynch Syndrome Diagnostic matched on their age at Lynch Diagnostic
10115201|NCT04452214|Experimental|CAN04 and pembrolizumab|Subjects will receive weekly doses of CAN04 in combination with pembrolizumab given as standard regimen
10115202|NCT04452318|Experimental|REGN10933 + REGN10987|
10115203|NCT04452318|Placebo Comparator|Placebo|
10115204|NCT04452201|Experimental|Guided Participation (GP)|A GP intervention is participatory formal and informal education to support learning of a practice beyond what could occur as efficiently and effectively without guidance. GP uses strategies for teaching-learning that make best use of the family's situation and opportunities, tailored to the parents' needs. The overall goal of the GP intervention is to support parent couples in effectively communicating for parenting work, including care-giving and maintaining the couple's relationship
9819756|NCT02174510|Experimental|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
9819757|NCT02174510|Experimental|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
9819758|NCT02174523|Experimental|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
9819759|NCT02174523|Placebo Comparator|placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
9819760|NCT02174562|Experimental|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
9819761|NCT02174562|Placebo Comparator|Enhanced Usual Care|Usual care enhanced with education and controls for attention
9819762|NCT02174627|Experimental|Roxadustat|
9819763|NCT02174627|Placebo Comparator|Placebo|
9819764|NCT02174731|Experimental|Roxadustat|
9819765|NCT02174731|Active Comparator|Epoetin alfa|
9819766|NCT02174848|Experimental|Deferiprone|All patients will receive deferiprone oral solution.
9819767|NCT02174861|Experimental|Erenumab|Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.
9819768|NCT02174913|Active Comparator|bispectral index/TCI propofol/fentanyl|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
9819769|NCT02174913|Placebo Comparator|clinical signs/TCI propofol/fentanyl|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
9819770|NCT02175121|Placebo Comparator|Treatment A- Placebo|
9819771|NCT02175121|Experimental|Treatment B- PF-06291874|
9819772|NCT02175121|Experimental|Treatment C- PF-06291874|
9819773|NCT02175121|Experimental|Treatment D- PF-06291874|
9819774|NCT02175121|Experimental|Treatment E- PF-06291874|
9819775|NCT02175199|Experimental|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
9819776|NCT02175199|Active Comparator|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
9819777|NCT02175212|Experimental|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
9819778|NCT02175212|Active Comparator|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy"
9819779|NCT02175225|Experimental|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
9819780|NCT02175225|Placebo Comparator|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
9826947|NCT02438384|Experimental|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
9826948|NCT02438423|Experimental|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
9826949|NCT02438423|Active Comparator|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
9826950|NCT02438423|Experimental|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
9826951|NCT02438423|Placebo Comparator|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
9826952|NCT02438475|Active Comparator|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
9826953|NCT02438475|Other|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
9826954|NCT02438540|Experimental|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
9826955|NCT02438540|Placebo Comparator|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
9826956|NCT02438722|Experimental|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9826957|NCT02438722|Active Comparator|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9826958|NCT02438787|Placebo Comparator|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
10115205|NCT04452201|No Intervention|Usual Care (UC)|The UC group will receive standard of care
9965714|NCT01252316|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
9819781|NCT02175277|Experimental|Darbepoetin Alfa|Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.
9819782|NCT02175368|Experimental|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
9819783|NCT02175472|Active Comparator|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
9819784|NCT02175472|Sham Comparator|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
9819785|NCT02175641|Experimental|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
9819786|NCT02175641|Active Comparator|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
9819787|NCT02175745|Experimental|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
9819788|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 12 to < 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
9819789|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 12 to < 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
9819790|NCT02175758|Experimental|6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 6 to < 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
9819791|NCT02175758|Experimental|6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 6 to < 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
9819792|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
9819793|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
9819794|NCT02175771|Experimental|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819795|NCT02175771|Active Comparator|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819796|NCT02175771|Experimental|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819797|NCT02175771|Active Comparator|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819798|NCT02175771|Experimental|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819799|NCT02175771|Active Comparator|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819800|NCT02175771|Experimental|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819801|NCT02175771|Active Comparator|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
9819802|NCT02175966|Experimental|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
9819803|NCT02175966|Experimental|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
9819804|NCT02175966|Experimental|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
9819805|NCT02175966|Other|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
9819806|NCT02175979|Placebo Comparator|standard|standard of care
9819807|NCT02175979|Experimental|enriched enteral nutrition|enriched enteral tube feeding 1.5ml/ minute perioperative
9819808|NCT02176005|Active Comparator|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
9819809|NCT02176005|Experimental|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
9819810|NCT02176005|Experimental|DAV132|DAV132 oral, 7.5g x3/day for 7 days
9819811|NCT02176005|Placebo Comparator|Negative control|Negative control: 7.5g x3/day for 7 days
9819812|NCT02176018|Active Comparator|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
9819813|NCT02176018|Placebo Comparator|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
9819814|NCT02176031|Experimental|Natalizumab|"Natalizumab-~(Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion~At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab.~If participants have no response after one dose, they will be not be given a second dose.~Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered.~Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365.~Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert"
10115206|NCT04452110||Group I|In volunteers in Group 1, values obtained using a linear probe will be compared.
9819815|NCT02176083|Experimental|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
9819816|NCT02176083|No Intervention|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
9819817|NCT02176226|Experimental|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
9819818|NCT02176291|Experimental|Buprenorphine|Buprenorphine
9819819|NCT02176291|Placebo Comparator|Placebo|Placebo
9819820|NCT02176343|Experimental|ReSTOR Toric +2.5|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
9819821|NCT02176356|Other|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
9819822|NCT02176382|Active Comparator|Standard dose teriparatide|teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
9819823|NCT02176382|Active Comparator|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
9819824|NCT02176408|Experimental|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
9819825|NCT02176408|Active Comparator|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
9819826|NCT02176421|Experimental|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
9819827|NCT02176486|Experimental|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
9819828|NCT02176486|Experimental|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
9819829|NCT02176486|Experimental|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
10115207|NCT04452110||Group II|In volunteers in Group 2, values obtained using a hockey stick probe will be compared.
10115208|NCT04452097|Experimental|Phase 1 Low-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.
10115209|NCT04452097|Experimental|Phase 1 Middle-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.
10115210|NCT04452097|Experimental|Phase 1 High-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.
9819830|NCT02176486|Experimental|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
9819831|NCT02176486|Placebo Comparator|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in 28-day cycle, Cycles 1 through 3.
9819832|NCT02176525|Experimental|BI 207127 in patients with cirrhosis|multiple rising doses
9819833|NCT02176525|Experimental|BI 207127 in patients without cirrhosis|multiple rising doses
9819834|NCT02176525|Placebo Comparator|Placebo in patients without cirrhosis|
9819835|NCT02176642|Active Comparator|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
9819836|NCT02176642|Placebo Comparator|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
9819837|NCT02176655|Active Comparator|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
9819838|NCT02176655|Placebo Comparator|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
9819839|NCT02176837|Experimental|Sodium Nitrite|One dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).
9819840|NCT02176928|Active Comparator|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
9819841|NCT02176928|Sham Comparator|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
9819842|NCT02177032|Experimental|4-sites, 1-week without HRIG|"PCEC rabies vaccine, administered ID according to the 4-sites, 1-week regimen"
9819843|NCT02177032|Experimental|4-sites, 1-week with HRIG|"PCEC rabies vaccine, administered ID to adults, according to the 4-sites, 1-week regimen plus HRIG"
9819844|NCT02177032|Active Comparator|2-sites, TRC without HRIG|"PCEC rabies vaccine, administered ID according to the 2-sites, TRC regimen"
9819845|NCT02177032|Active Comparator|2-sites, TRC with HRIG|"PCEC rabies vaccine, administered ID to adults , according to the 2-sites, TRC regimen plus HRIG"
9819846|NCT02177123|Experimental|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in the anterior chamber of the eye on patients with primary open angle glaucoma after am antiproliferative treatment of mitomycin C (MMC)
9819847|NCT02177136|Experimental|1.5 mg OCA titrating to 3 mg OCA|Participants randomized to 1.5 mg OCA took 1.5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 3 mg OCA daily for an additional 12 weeks.
9819848|NCT02177136|Experimental|5 mg OCA titrating to 10 mg OCA|Participants randomized to 5 mg OCA took 5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 10 mg OCA daily for an additional 12 weeks.
9819849|NCT02177136|Experimental|Placebo|Participants randomized to placebo took placebo for 24 weeks during the DB phase.
9819850|NCT02177136|Experimental|LTSE OCA Total|Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the LTSE phase (planned as a further 24 months) beginning at 5 or 10 mg OCA, based on the last treatment received during the DB phase. Doses up to 10 mg daily were evaluated. All participants received open-label OCA during the LTSE phase of the study.
9819851|NCT02177201|Sham Comparator|Group 1|intravenous administration of 10 ml/kg/h 0.9% saline solution
9819852|NCT02177201|Active Comparator|Group 2|intravenous administration of 20 ml/kg/h 0.9% saline solution
9819853|NCT02177786|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
9819854|NCT02177786|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
9819855|NCT02177786|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
9819856|NCT02177786|Placebo Comparator|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
9819857|NCT02177812|Experimental|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
9819858|NCT02177812|Experimental|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
9819859|NCT02177838|Experimental|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
9819860|NCT02177942|Experimental|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
9819861|NCT02177942|Active Comparator|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
9819862|NCT02178059|Experimental|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
9819863|NCT02178059|Active Comparator|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
9819864|NCT02178241|Experimental|Treatment (eribulin mesylate and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9819865|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
9819866|NCT02178540|Other|Open label|one dose (4 capsules) of placebo
9819867|NCT02178553|Active Comparator|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
9819868|NCT02178553|Active Comparator|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
9819869|NCT02178592|Experimental|Dolutegravir|Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
9819870|NCT02178592|Active Comparator|Efavirenz|Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
9819871|NCT02178696|Experimental|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
9819872|NCT02178696|Experimental|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
9819873|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
9819874|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
9819875|NCT02178800|Experimental|Group 1: GSK1265744|Participants in Cohorts 1 and 2 will receive one GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
9819876|NCT02178800|Placebo Comparator|Group 2: Placebo|Participants in Cohorts 1 and 2 will receive one placebo tablet orally every day from study entry through Week 4. They will then receive an injection of placebo-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
9819877|NCT02178995|No Intervention|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
9819878|NCT02178995|Experimental|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
9819879|NCT02178995|Experimental|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
9819880|NCT02178995|Experimental|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
9819881|NCT02178995|Experimental|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
9819882|NCT02178995|Experimental|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
9819883|NCT02178995|Experimental|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
9819884|NCT02178995|Experimental|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
9819885|NCT02178995|Experimental|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
9819886|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
9819887|NCT02179047||placebo|healthy subject
9819888|NCT02179177|Active Comparator|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
9819889|NCT02179177|Placebo Comparator|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
9819890|NCT02179190|Experimental|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
9819891|NCT02179398|Experimental|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.~(WBC and band counts blinded to the physician in charge of the patient)"
9819892|NCT02179398|Active Comparator|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
9819893|NCT02179424|Experimental|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
9819894|NCT02179424|Experimental|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
9819895|NCT02179424|Experimental|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
9819896|NCT02179424|Experimental|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
9819897|NCT02179515|Experimental|modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine|Three cohorts will receive modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
9819898|NCT02179671|Experimental|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
9819899|NCT02179671|Experimental|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
9819900|NCT02179671|Experimental|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
9819901|NCT02179671|Experimental|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
9819902|NCT02179788|Experimental|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
9819903|NCT02179788|Placebo Comparator|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
10115211|NCT04452097|Experimental|Phase 2a Treatment Group|Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.
10115212|NCT04452097|Placebo Comparator|Phase 2a Control Group|Eligible subjects will receive a single infusion of placebo control and standard of care treatment.
10115213|NCT04452084|Active Comparator|Control|
10115214|NCT04452084|Experimental|Experimental Procedure|
10115215|NCT04452071||prepubertal|patients born in 2012-2011
9965715|NCT01252316|Active Comparator|Recruitment with Volunteers|UPHS volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
10115216|NCT04452071||pubertal|patients born in 2010-2009-2008-2007
10115217|NCT04452071||postpubertal|patients born in 2006-2005-2004-2003
9694062|NCT04793152|Active Comparator|Vancomycin intermittent dosing|A loading dose of 25mg/kg (maximum 2g) will be given to severely ill patients at the discretion of physician and pharmacist. The intermittent dose will be 15mg/kg every 12 hours if normal renal function. The frequency of dosing will be adjusted based on creatinine clearance. Trough level will be done before the fourth dose and adjusted to target trough level of 15-20mg/L.
9694063|NCT04793269||Long COVID|Patients with long COVID syndrome
9694064|NCT04793321|Other|healty nulliparous females|"each participant did three conditions:~holding nothing (unloaded).~holding an infant mannequin in arms(arms).~holding an infant mannequin in the baby carrier(carriers)."
9694065|NCT04793048|Active Comparator|Active group received an active device and a scaling and root planing (SRP) at baseline|
9694066|NCT04793048|Sham Comparator|Sham group received a sham device and a scaling and root planing (SRP) at baseline|
9694067|NCT04793074|Experimental|Transforming nanoparticle dressing|Patients in the treatment group (n=30) had transforming nanoparticle dressing
9694068|NCT04793074|Active Comparator|Conventional compression dressing|The control group (n=30) received conventional compression dressing.
9694069|NCT04793360||LiverCare Surveillance|Participants undergoing orthotopic liver transplant (de-novo or re-transplant) will be considered for this study
9694070|NCT04793438|Experimental|Intervention group|Motive-specific intervention; three appointments within two weeks, 30-45 minutes per session.
9694071|NCT04793438|Active Comparator|Control group|Supportive conversations; three appointments within two weeks; 30-45 minutes per session.
9694072|NCT04793022|Experimental|TIVA-Propofol|Intravenous anesthesia with Propofol
9694073|NCT04793022|Active Comparator|Inhaled Anesthesia|General Inhaled Anesthesia
9694074|NCT04793009||mesh group|patients undergoing abdominoperineal resection with end colostomy and implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
9694075|NCT04793009||no-mesh group|patients undergoing abdominoperineal resection with end colostomy without implantation of a prophylactic, funnel-shaped, intraperitoneal mesh
9694076|NCT04792593|Experimental|Senl-h19 CAR-T|Patients will be treated with Senl-h19 CAR-T cells
9694077|NCT04792775|Experimental|Prolonged Exposure + Emotion Regulation Skills Training|Twelve, 90-minute sessions of Prolonged Exposure (PE) with Dialectical Behavior Therapy (DBT) Emotion Regulation Skills Training.
9694078|NCT04792931|Other|Adult Autoimmune Myopathies|It is a description Autoimmune Myopathie cohort
9694079|NCT04792723|Experimental|Healthy volunteer|Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks
9694080|NCT04792996||Gilbert´s Syndrome|Subjects with mild hyperbilirubinaemia and a plasma level of unconjugated bilirubin of 17.1 µmol.
9694081|NCT04792996||Control group|Healthy controls with lower plasma level of unconjugated bilirubin of 17.1 µmol, aen and gender matched.
9694082|NCT04792645|Placebo Comparator|Placebo|10mg once daily of placebo for two weeks, then 20mg for the remaining six weeks
9694083|NCT04792645|Experimental|Memantine|10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks
9694084|NCT04792671||Perinatal group|females who are pregnancy
9694085|NCT04792671||postpartum group|female who get delivery(from day 1 up to 1 year)
9694086|NCT04792762|Experimental|GIP(1-42)|
9694087|NCT04792762|Experimental|GIP(1-30)NH2|
9694088|NCT04792762|Placebo Comparator|Placebo|
9694089|NCT04792944||No treatment|Those are the patients that do not receive any treatment for the aneurysm, neither endovascular nor surgical
9694090|NCT04792944||External ventricular drain only with neither embolization nor clipping|These patients will be treated with an external ventricular drain only with neither embolization nor clipping
9694091|NCT04792944||Embolization|These patients will be treated endovascularly
9694092|NCT04792944||Programmed surgical clipping|These patients will be treated no on an emergency basis with surgical clipping of an aneurysm that has bled
9694093|NCT04792944||Emergency surgical clipping with cisternal urokinase administration|These patients with undergo emergency surgical clipping with cisternal urokinase administration
9694094|NCT04792944||Patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping|This group will include patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping
9694095|NCT04792619|Experimental|Control|
9694096|NCT04792619|Active Comparator|Study|
9694097|NCT04792697|Experimental|Advance/Extend Manipulation|"For ~2 weeks, Advance/Extend participants will advance bedtime and regularize wake time. The first night of the manipulation will be conducted in the lab under tightly-controlled experimental conditions. Participants will then go home and for the next 12 days will be instructed to:~Sleep scheduling-- advance bedtime by 1.5 hours ( + sleep duration)~Decrease evening blue light exposure via blue blocker goggles (2 hrs before bed)~Increase morning bright light exposure via bright light goggles (30 min after rise)~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
9694098|NCT04792697|Active Comparator|Control|Control participants will complete the baseline laboratory study, then maintain their habitual sleep schedules over the next 13 days at home, with no instruction on sleep timing or light exposure. Control participants will complete smartphone-and text-based assessments, thereby controlling for effort.
9694099|NCT04792827||analgosedation group|analgosedation concept
9694100|NCT04792827||historical group|standard historical concept
9819904|NCT02179892|Active Comparator|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
9819905|NCT02179892|Active Comparator|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
9819906|NCT02179918|Experimental|PF-05082566 +MK-3475|PF-05082566 +MK-3475
9819907|NCT02180061|Experimental|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
9819908|NCT02180061|Experimental|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
9819909|NCT02180100|Experimental|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
9819910|NCT02180100|Active Comparator|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
9819911|NCT02180165|Experimental|Cohort 1: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
9819912|NCT02180165|Active Comparator|Cohort 1: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
9819913|NCT02180165|Experimental|Cohort 2: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
9819914|NCT02180165|Active Comparator|Cohort 2: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
9819915|NCT02180230|Other|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
9819916|NCT02180438|Experimental|Open label prospective single arm study of Stribild|
9819917|NCT02180646|Active Comparator|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
9819918|NCT02180646|Active Comparator|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
9819919|NCT02180659|Experimental|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
9819920|NCT02180659|Active Comparator|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
9819921|NCT02180672|Active Comparator|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
9819922|NCT02180672|Placebo Comparator|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
9819923|NCT02180828|Experimental|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
9819924|NCT02180828|Active Comparator|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
9819925|NCT02180893|Experimental|Paravertebral block|Patient receiving a PVB prior to robotic mitral valve surgery
9819926|NCT02180893|Placebo Comparator|No block|Patients who did not receive PVB
9819927|NCT02181075|Experimental|Part I|"All participants in Part I received:~Pre-LTLD Biopsy of Target Liver Tumour ThermoDox® (LTLD) Post-LTLD Biopsy of Target Liver Tumour Focused Ultrasound of Target Liver Tumour Thermometry of Target Tumour Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour~Part I of the study was designed to identify optimal focused ultrasound (FUS) exposure parameters for a range of tumour locations within the liver, using real-time thermometry data from an implanted thermometry device (a thermistor or thermocouple). Plasma and biopsy samples of the target liver tumour were taken pre-LTLD, post-LTLD and post-LTLD+FUS."
10115218|NCT04451941|Experimental|RecoveriX with individual EEG calibration|RecoveriX applied functional electrical stimulation (FES) according to individual brainwave by individual EEG calibration for 4 weeks
9819928|NCT02181075|Experimental|Part II|"All participants in Part II received:~ThermoDox® (LTLD) Focused Ultrasound of Target Liver Tumour Post-LTLD Biopsy of Target Liver Tumour~Following a minimum of 5 Part I cases, and subject to Trial Management Group approval, Part II of the study was opened to run in parallel to Part I. Part II did not require implantation of a thermometry device, and instead used predictions from Part I data to set the FUS parameters. Targeted drug delivery in Part II thus proceeded completely non-invasively, and this part of the study was designed to more closely reflect how the therapy might be implemented in routine clinical practice. Plasma samples were taken pre-LTLD, post-LTLD and post-LTLD+FUS. Biopsy samples of the target liver tumour were taken only post-LTLD+FUS."
9819929|NCT02181127|Active Comparator|Glucagon-only Bionic Pancreas (active)|Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.
9819930|NCT02181127|Placebo Comparator|Glucagon-only Bionic Pancreas (placebo)|Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.
10115219|NCT04451941|Sham Comparator|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 4 weeks
9819931|NCT02181140|Other|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
9819932|NCT02181231|Experimental|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
9819933|NCT02181231|Placebo Comparator|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
9819934|NCT02181296|Active Comparator|High concentration group|0.2% ropivacaine
10115220|NCT04452019|Active Comparator|Standing frame|Use of standard standing frame
10115221|NCT04452019|Experimental|Innowalk|Use of a new Device; Innowalk Pro
9694101|NCT04792814||MAT-RAP group|MAT and RAP
9819935|NCT02181296|Active Comparator|Lower concentration group|0.1% ropivacaine
9819936|NCT02181387|Active Comparator|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
9694102|NCT04792814||historical group|standard procedure
9819937|NCT02181387|Placebo Comparator|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
9819938|NCT02181400|Active Comparator|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
9819939|NCT02181400|Active Comparator|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
9819940|NCT02181400|Active Comparator|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
9819941|NCT02181413|Experimental|Ixazomib Citrate|Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.
9819942|NCT02181413|Placebo Comparator|Placebo|Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons.
10115222|NCT04451746|Other|Tableted hormonal drugs for contraception|Tableted hormonal drugs for contraception, 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
10115223|NCT04451915|Experimental|Early management GDM group|defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
10115224|NCT04451915|Experimental|Late management GDM group|early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.
10115225|NCT04451980||HIV+ non-diabetics|HIV-infected participants with hemoglobin A1c (HbA1c) <5.7% or fasting glucose <100 mg/dl.
10115226|NCT04451980||HIV+ pre-diabetics|HIV-infected participants with HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dl.
10115227|NCT04451980||HIV+ diabetics|HIV-infected participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
10115228|NCT04451980||HIV-negative diabetics|HIV-negative participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
10115229|NCT04451759|Active Comparator|healthy controls|
10115230|NCT04451759|Experimental|Anorexia|
10115231|NCT04451759|Experimental|Obesity|
10182508|NCT03773354|Experimental|Intervention|There is no control group for this study, and all participants receive the intervention. Although a few participants will be asked to give additional information during the intake and after the study concludes for quality improvement purposes. Effects of these additional interview questions will be considered during analysis
9694106|NCT04792606||"Natural History or watchful waiting"|
9694107|NCT04792606||Serial botulinum toxin injections|
9694108|NCT04792606||Adductor (+/- psoas) muscle releases alone|
9694109|NCT04792606||Hip reconstructive surgery|
9694110|NCT04792606||Salvage hip surgery|
9694111|NCT04792749|Experimental|Metformin treatment|Patients who receive metformin in addition to progestin therapy
9694112|NCT04792749|No Intervention|Conventional treatment|Patients who receive progestin therapy only
9694113|NCT04792710|Experimental|Intervention arm|This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose
9694114|NCT04792710|Placebo Comparator|Control arm|This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose
9694115|NCT04792983||Older (≥ 65 years of age)|Older surgical patients presenting for elective spine surgery.
9694116|NCT04792736||Survivors|Patients discharged alive from intensive care unit
9694117|NCT04792736||non survivors|Patients who succumbed during their ICU stay
9694118|NCT04792632||Intervention|Intervention is the use of Veye Lung Nodules during the reading of the CT scans
9694119|NCT04792918||NEC/LOS preterm infants|Collection of biological samples (stool, stomach fluid, blood) and health-related data over the first few weeks of life, additional stool samples after onset of NEC/LOS
9694120|NCT04792918||Preterm infants not developing NEC/LOS|Collection of biological samples (stool, stomach fluid, blood) and health-related data over the first few weeks of life
9694121|NCT04792918||Family members of preterm infants|Collection of biological samples (stool, breastmilk, vaginal swab) and health-related data at one timepoint after the birth of the preterm infant from members of the family (mother, father)
9694124|NCT04792541|Placebo Comparator|control group|saline solution
9694125|NCT04792541|Experimental|test group|HY containing gel; GUM® Afta Clear Gel, Sunstar
9694126|NCT04792554||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
9694127|NCT04792528|Experimental|One training period|One training period of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
9694128|NCT04792528|Experimental|Two training periods|Two training periods of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
9694129|NCT04792528|Active Comparator|Active control|The generalized brain training group (Active control) will play solitaire 30 minutes daily for 25 sessions
9819943|NCT02181426|Placebo Comparator|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
9819944|NCT02181426|Active Comparator|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
9819945|NCT02181426|Active Comparator|15 mg Ketorolac|participant receives 15 mg of Ketorolac
9819946|NCT02181426|Active Comparator|30 mg Ketorolac|participant receives 30mg of Ketorolac
9819947|NCT02181504|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
9819948|NCT02181504|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
9819949|NCT02181504|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
9819950|NCT02181517|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
9819951|NCT02181517|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
9819952|NCT02181517|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
9819953|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
9819954|NCT02181556|Experimental|FOLFIRI + Aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
9819955|NCT02181634|Experimental|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel 125 mg/m² IV and Gemcitabine 1000 mg/m² on days 1, 8 and 15 every 28 days until progression or unacceptable toxicity.
9819956|NCT02181673|Placebo Comparator|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
9819957|NCT02181673|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
9819958|NCT02181738|Experimental|Nivolumab (Cohort A, B, C and D)|"Cohort (A, B, C): Nivolumab: Specified dose on specified days~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days"
9819959|NCT02181803|Experimental|Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic|Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability
9819960|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability
9819961|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability
9819962|NCT02181803|Experimental|Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy|Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability
9819963|NCT02181803|Placebo Comparator|Part 1 Panel A & B Placebo Monotherapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy
9819964|NCT02181803|Placebo Comparator|Part 2 Panel C Placebo Add-on Therapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy
9819965|NCT02181803|Placebo Comparator|Part 3 Panel D Placebo Monotherapy: Healthy|Healthy participants will receive dose-matched placebo to MK-8189 monotherapy
9819966|NCT02181816||Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
9819967|NCT02181829|Experimental|Whole Lung IMRT|This is a single institution study involving patients with synovial sarcoma who have completed all standard therapy (e.g. surgery +/- radiation to the primary site) +/- any adjuvant chemotherapy. The sequence and types of therapy offered prior to WLI will likely vary based on primary tumor site, tumor resectability, extent of metastatic disease, performance status, and comorbidity. Each patient's therapy will be determined by the disease management team irrespective of participation on this protocol.
9819968|NCT02181842||Pioglitazone|Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
9819969|NCT02182115|Active Comparator|standard of care|Surgeon's routine for preoperative showering.
9819970|NCT02182115|Experimental|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.~Chlorhexidine gluconate soap applied for bathing daily.~Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.~Nasal mupirocin to applied inside nostrils twice daily."
9819971|NCT02182440|Placebo Comparator|Placebo|1 hour IV infusion once daily for 3 days
9819972|NCT02182440|Experimental|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
9819973|NCT02182440|Experimental|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
9819974|NCT02182440|Experimental|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
9819975|NCT02182492|Experimental|Glucocorticoid|Fluticasone propionate nasal spray
9819976|NCT02182492|Experimental|Clarithromycin|Clarithromycin tablet
9819977|NCT02182804|Experimental|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
9819978|NCT02182830|Experimental|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
9819979|NCT02182830|Placebo Comparator|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
9819980|NCT02182843|Experimental|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
9819981|NCT02182895|Experimental|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
10115232|NCT04451889|Experimental|Confocal laser endomicroscopy diagnostic study|"Cohort 1: COVID-19 patients. Cohort 2: patients with lung diseases unrelated to COVID-19.~All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special Alveoflex miniprobe during the hospitalisation period. Records will be done and analysed prospectively with the included software for the endomicroscopic system.~Using Alveoflex is a minimally invasive intervention."
9819982|NCT02182895|No Intervention|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
9819983|NCT02182947|Experimental|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
9819984|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
9819985|NCT02182999|Placebo Comparator|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
9819986|NCT02182999|Active Comparator|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
9819987|NCT02183519|Experimental|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
9819988|NCT02183519|Experimental|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
9819989|NCT02183675|Experimental|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
9819990|NCT02183675|Active Comparator|T/A|Telmisartan/Amlodipine fixed-dose combination
9819991|NCT02183675|Active Comparator|T/H|Telmisartan/HCTZ fixed-dose combination
9819992|NCT02183792|Experimental|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
9819993|NCT02183792|Active Comparator|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
9819994|NCT02184143|Experimental|CBPT intervention|CBPT program consisting of weekly phone calls.
9819995|NCT02184143|Active Comparator|Education intervention|Education program consisting of weekly phone calls.
9819996|NCT02184169|Experimental|HLHS|Patients undergoing palliative repair.
9819997|NCT02184169|Active Comparator|TGA|Surgical repair of TGA.
9819998|NCT02184208||Device utlization following extubation|
9819999|NCT02184208||Pulmonary mechanics|
9826959|NCT02438787|Experimental|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
9826960|NCT02438787|Experimental|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
9826961|NCT02438813||All Enrolled Participants|All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.
9826962|NCT02438826|Experimental|Galcanezumab 300 mg|"Double-Blind Treatment Phase: Participants received galcanezumab 300 mg once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
9826963|NCT02438826|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
9826964|NCT02439138|Experimental|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
9694130|NCT04792151||PHP Youth|Youth ages 6-17 receiving standard of care treatment (i.e., transdiagnostic intervention for emotional disorders) in a partial hospitalization program
9965716|NCT01252316|Active Comparator|Recruitment with Nurses|UPHS Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
10182509|NCT03773328|Experimental|CK0801, 50ml|"All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one 50mL intravenous dose of CK0801 (Treg cells) on study Day 0. A total of three cohorts will be evaluated.~Cohort dosing will be as follows:~Dose level 1 = 1x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 2 = 3x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 3 = 1x10e7/kg Treg cells per kg recipient ideal body weight (IBW)."
9694131|NCT04792125|Experimental|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed external electrical stimulation (EES) added to pelvic floor muscle training (PFMT).
9694132|NCT04792125|Other|External electrical stimulation (EES) group|This arm is going to include the patients who are performed external electrical stimulation (EES).
9694133|NCT04792125|Active Comparator|Pelvic floor muscle training (PFMT) group|This arm is going to include the patients who are performed pelvic floor muscle training (PFMT).
9694134|NCT04792294||Lung transplant recipients with chronic lung allograft dysfunction|Lung transplant recipients with chronic lung allograft dysfunction, who underwent extracorporeal photopheresis
9694135|NCT04792281||Patients with suspected native valve endocarditis|
9694136|NCT04792398|Experimental|Sleep Bruxism Subjects|"Ultrasound guided BTX-A injection: 25 units (divided in two injections) in each masseter muscle.~One-time intervention. Effect observation by measuring various biosignals (EMG, EOG, EEG), bite force, chewing efficiency, psychometric assessments."
9694137|NCT04792333|Experimental|Treatment|500 mg (2 capsules of 250 mg)
9694138|NCT04792450||ED Patients|Patients presenting in Emergency Department
9694139|NCT04792450||ED Staff|Staff working within the Emergency Department
9694140|NCT04792242|Active Comparator|goal directed therapy|svo2,haematocrite value,urine output,mean arterial pressure and central venous pressure
9694141|NCT04792242|Active Comparator|PCO2 gap algorithm|PCO2 gap,haematocrite value,Spo2,cardiac index
9694142|NCT04792229|Experimental|Experimental Group|"Standing on WBV device (frequency of 40 Hz); 3 Minute vibration with 3 minute rest.~Three times repetition . Total 18-minute vibrational therapy protocol. 3 days session per week"
9694143|NCT04792229|Active Comparator|Control Group|"Stretching exercise (hip adductors ,plantar flexors, external rotators of hip & knee flexors).~Active and passive ROMS to lower extremities. Strengthening exercises (hip and knee extensors, ankle dorsiflexes) 3 Repetitions into 3 day session per week"
9694144|NCT04792489|Experimental|Single, open label|
9694145|NCT04792385|Experimental|E4/DRSP 15/3 mg|Single treatment arm will receive E4/DRSP 15/3 mg
9694146|NCT04792359|Experimental|Equinometer|Measurement with Equinometer
9694147|NCT04792437||glioma patients|glioma patients with routine surgery
9694148|NCT04792255|Experimental|Group A: Reduced contrast media dose group|"Reduced contrast media protocol: extracranial carotid artery intervention (2-4 fps with institutional protocol).~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 3 ml iodined contrast media with a 3 ml/s flow rate.~DSA and DVA images will be calculated; DVA images will be used for diagnosis and interventions."
9694149|NCT04792255|Active Comparator|Group B: Standard contrast media dose group|"Standard contrast media protocol: extracranial carotid artery intervention (2-4 fps with institutional protocol).~Contrast administration with an automatic contrast injector: angiographic image acquisitions will be performed with 6 ml iodined contrast media with a 3 ml/s flow rate.~DSA and DVA images will be calculated; DSA images will be used for diagnosis and interventions."
9694150|NCT04792411|Experimental|Prehabilitation group|This arm will be subject to at least 6 weeks of a tailored prehabilitation programme
9694151|NCT04792320|Experimental|Active bamboo charcoal|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The participants will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
9694152|NCT04792320|Experimental|Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
9694153|NCT04792320|Experimental|Active bamboo charcoal+Probiotics|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
9694154|NCT04792320|No Intervention|No invervention|"Eligible 120 participants (group I),The other 60 eligible controls (group II) will be also randomized into ABC-treatment (A) or no-treatment (B) with a 1:1 ratio. The patients will receive CharXenPlus 4g particles ( containing ABC 2g) thrice daily for 6 months in subgroups IA and IIA.~While the patients in subgroups IB and IIB will not receive any ABC. The subgroups IA and IB will be further randomly subdivided into IAa, IAb, IBa, and IBb subsubgroups.~All the patients will receive probiotics APL-MIX2 (CharXprob) 0.8 g powder once a day in the last 3 months except those in subsubgroups IAb and IBb."
9820000|NCT02184442|Experimental|TAVR - SAPIEN XT|TAVR (transaortic valve replacement) with SAPIEN XT
10182510|NCT03773263|Experimental|sequential oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. COCs were removed from aspirated follicular fluid and transferred into HEPES-buffered collection medium. The immature oocytes will be cultured in sequential IVM medium 1 for 6 hours (37℃, 5% CO2), and removed into sequential IVM medium 2 for further cultivation. After 24 and 40 hours cultivation, the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle.
9820001|NCT02184442|Active Comparator|TAVR - SAPIEN|TAVR (transaortic valve replacement) with SAPIEN is the control arm
9820002|NCT02184455|Experimental|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
9820003|NCT02184494|Experimental|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
9820004|NCT02184494|Experimental|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
9820005|NCT02184494|Experimental|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
9820006|NCT02184572|Experimental|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
9820007|NCT02184572|Active Comparator|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
9820008|NCT02184611|Experimental|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
9820009|NCT02184611|Placebo Comparator|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
9820010|NCT02184624|Experimental|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
9820011|NCT02184624|Experimental|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
9820012|NCT02184624|Experimental|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
9820013|NCT02184624|Experimental|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
9820014|NCT02184624|Experimental|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
9820015|NCT02184988|Experimental|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
9820016|NCT02185014|Other|Adalimumab|Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
9820017|NCT02185040|Experimental|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
9820018|NCT02185040|Experimental|CC-220 0.3mg Every Day (QD)|"Part 1: CC-220 0.3mg capsules by mouth every day (QD)~ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
9820019|NCT02185040|Experimental|CC-220 0.6mg/0.3mg alternating dose QD|"Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days~ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
9820020|NCT02185040|Experimental|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
9820021|NCT02185040|Placebo Comparator|Placebo QD|Part 1: Identically matching placebo capsules PO QD
9820022|NCT02185053|Experimental|CPC-201|
9820023|NCT02185105|Experimental|comfilcon A MTO|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
9820024|NCT02185105|Active Comparator|comfilcon A|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
9820025|NCT02185131|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
9820026|NCT02185131|Active Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
9820027|NCT02185183|Experimental|AlequelTM|AlequelTM
9820028|NCT02185339|Experimental|dNMB group|For patients randomized to the dNMB group, intravenous infusion of 0.6 mg/kg/h rocuronium will be administered 10 minutes after the administration of intubation dose or after the return of post-tetanic count (PTC), whichever comes first. Then, the infusion rate will be titrated according to PTC (target to keep PTC between 1 to 2). Infusion rate will be increased or be reduced at a rate of 0.1 mg/kg/h if PTC is > or < than 1-2 to maintain deep muscle relaxation throughout the surgery. Neuromuscular monitoring will be carried out by monitoring the adductor pollicis muscle in response to ulnar nerve stimulation. A dose of sugammadex (4 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
9820029|NCT02185339|Active Comparator|mNMB group|For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count >2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is > or < than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
9820030|NCT02185404|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
9820031|NCT02185521|Experimental|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
9820032|NCT02185534|Experimental|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
9820033|NCT02185534|Active Comparator|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
10115233|NCT04452032|Experimental|Single arm|"The first phase of the study will consist of an evaluation of the initial dental state of each subject based on stomatological examination, orthopantomogram, bitewing radiographs, evaluation of potential risks of caries and fractures. Dental decalcification, dental care and/or avulsion if necessary, and afterwards, a dental splint will be performed before the start of RT treatment.Based on our predictive model, every tooth which potentially will receive more than 40 Gy and for which long term survival is compromised will be avulsed at least 2 weeks before the start of RT.~After RT, the subject will have clinical follow-up with dental evaluation every 6 months for 36 months in order to identify possible dental events. At each consultation, a stomatological examination will be performed as well as bitewing radiographs. Orthopantomogram will be done once a year. Periapical X-rays will be performed if there is a dental complain or to refine a lesion visible on orthopantomogram."
10115234|NCT04451824|Experimental|Intervention with Routine Use of Red Light|Routine Use of red light (635nm) for 30 minutes on patients is to be observed in relation to its effect(s) in achieving circumferential reduction of the thighs, hips and waist of the patient, and a contour reduction of any protrusion of fat.
10115235|NCT04451967||Transfer after thrombolysis|
10115236|NCT04451967||Transfer after DAPT|
10115237|NCT04451967||Direct transfer|
10115238|NCT04451694||Covid-19 unit outgoing patients|nutritional evaluation and intervention
10115239|NCT04451928||Preterm delivery|Pregnant women who give birth before 37th gestational week
10115240|NCT04451928||Term delivery|Pregnant women who will give birth 37th and after gestational week
10115241|NCT04451811|Experimental|OPL-002 SDD 20 mg|20 mg SDD formulation of OPL-002
10115242|NCT04451811|Experimental|OPL-002 5 mg Tablet|5 mg tablet formulation of OPL-002
10115243|NCT04451811|Experimental|OPL-002 20 mg Tablet|20 mg tablet formulation of OPL-002
10115244|NCT04452006|Experimental|Part A (SAD) - A1, ACT-541478 10 mg fasted|SAD = single ascending dose
10115245|NCT04452006|Experimental|Part A (SAD) - A2, ACT-541478 30 mg fasted|SAD = single ascending dose
10115246|NCT04452006|Experimental|Part A (SAD) - A3 (Period 1), ACT-541478 100 mg fasted|SAD = single ascending dose
10115247|NCT04452006|Experimental|Part A (SAD) - A3 (Period 2), ACT-541478 100 mg fed|SAD = single ascending dose
10115248|NCT04452006|Experimental|Part A (SAD) - A4, ACT-541478 300 mg fasted|SAD = single ascending dose
10115249|NCT04452006|Experimental|Part A (SAD) - A5, ACT-541478 1000 mg fasted|SAD = single ascending dose
10115250|NCT04452006|Experimental|Part B - B1-3, ACT-541478 low or high dose|
10115251|NCT04452006|Experimental|Part C (MAD) - C1, ACT-541478 30 mg, fasted|MAD = multiple ascending dose
10115252|NCT04452006|Experimental|Part C (MAD) - C2, ACT-541478 100 mg, fasted|MAD = multiple ascending dose
10115253|NCT04452006|Experimental|Part C (MAD) - C3, ACT-541478 300 mg, fasted|MAD = multiple ascending dose
10115254|NCT04452006|Experimental|Part C (Elderly) E1, ACT-541478, fasted|
10115255|NCT04452058||Internal cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to December 31,2019. Patients with single pulmonary lesion underwent preoperative chest CT scan and histologically confirmed precancerous lesions or early stage lung adenocarcinoma after thoracic surgery was included.
10115256|NCT04452058||External cohort 1|The same inclusion/exclusion criteria were applied for another independent centers, Sun Yat-sen Memorial Hospital ,Guangdong Province, China, forming an external validation cohort of 73 patients
10115257|NCT04452058||External cohort 2|The same inclusion/exclusion criteria were applied for another independent centers, Zhoushan Lung Cancer Institution, Zhejiang Province, China, forming second external validation cohort of 30 patients
10115258|NCT04452058||Immune Cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to May 31,2020. Patients with advanced lung cancer underwent preoperative chest CT scan and histologically confirmed NSCLC before receiving immunotherapy was included.
10115259|NCT04451642||Peripheral nerve block Group|Every patient scheduled during 2011-2019 for the surgery needed a peripheral nerve block were enrolled.
10115260|NCT04451629|Experimental|Exercises group|intervention group çalışma grubundaki kadın öğrencilere 8 hafta süresince haftada 4 kez 40 dakika boyunca pelvik taban ve core egzersizleri uygulatılacak
10115261|NCT04451629|No Intervention|control group|students will be watched without any intervention
10115262|NCT04451486|Experimental|Treatment dose 1|1x10*5 CD61-Lin- cells /0.25mL DPBS
10115263|NCT04451486|Experimental|Treatment dose 2|1x10*6 CD61-Lin- cells /0.25mL DPBS
10115264|NCT04451486|Experimental|Treatment dose 3|1x10*7 CD61-Lin- cells /0.25mL DPBS
9820034|NCT02185534|Active Comparator|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
9820035|NCT02185729|Active Comparator|Healthy Volunteer|Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat)
9820036|NCT02185794|Placebo Comparator|Placebo (GT 1a, Cohort 1)|Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
9820037|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
9820038|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
9820039|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
9820040|NCT02185794|Placebo Comparator|Placebo (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
9820041|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
9820042|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
9820043|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
9820044|NCT02185794|Placebo Comparator|Placebo (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
9820045|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
9820046|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 4, Cohort 4)|Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
9820047|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1b, Cohort 5)|Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
9820048|NCT02185794|Experimental|Voxilaprevir 100 mg Fed (GT 3a, Cohort 6)|Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
9820049|NCT02185794|Experimental|Voxilaprevir 600 mg (Cohorts 7-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
9820050|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
9820051|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.
9820052|NCT02186015|Experimental|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
9820053|NCT02186015|No Intervention|Vitamin D sufficient|All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.
9820054|NCT02186171|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
9820055|NCT02186171|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months.
9820056|NCT02186210|Experimental|prewarming|prewarming during induction of anesthesia
9820057|NCT02186210|No Intervention|control|no prewarming during induction of anesthesia
9820058|NCT02186223|Experimental|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
9820059|NCT02186301|Active Comparator|Erlotinib Mono-Therapy|
9820060|NCT02186301|Experimental|Rociletinib Mono-Therapy|
9820061|NCT02186509|Experimental|Alisertib, fractionated stereotactic radiosurgery|"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.~MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
9820062|NCT02186561|Experimental|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
9820063|NCT02186587|Other|ConforMIS|Subjects who receive a ConforMIS custom total knee implant.
9820064|NCT02186652|Other|Pantoprazole|
9820065|NCT02186665|Experimental|calcitriol ointment|calcitriol 3 mcg/g ointment
9820066|NCT02186665|Placebo Comparator|placebo|placebo comparator
9820067|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
9820068|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
9820069|NCT02186808|Other|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
9820070|NCT02186821|Experimental|Ceritinib 750 mg|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
9820071|NCT02186847|Active Comparator|Chemoradiation|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
10115265|NCT04451655|Experimental|Interventional|
9519376|NCT03287713|Active Comparator|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
9694155|NCT04792177|Experimental|Intervention group|Emotion regulation skills training group
10182511|NCT03773263|Active Comparator|traditional oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. On the day of ovulation, COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed and the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle. If biochemical pregnancy is not achieved, thawed blastocysts transfer will be performed.
9519377|NCT03287713|Active Comparator|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
9694156|NCT04792177|No Intervention|waitlist control group|The control group will not receive any intervention during the trial but will be offered the same treatment at the end of the six-months follow-up assessment.
9694157|NCT04792138||Men suspected of Prostate Cancer|
9694158|NCT04792424|Experimental|No monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.~Citrate dose start at 4 mmol/L and no adjustment of citrate dose. Post-filter ionized calcium result will blind for physician.~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
9694159|NCT04792424|Placebo Comparator|Monitoring of post filter ionized calcium|"Starting dialysis with continuous renal replacement therapy with regional citrate anticoagulation.~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate.~Citrate dose start at 4 mmol/L with adjustment of citrate dose to acheive post-filter ionized calcium at 0.25-0.35 mmol/L.~Other laboratory such as pre-filter ionized calcium, electrolyte, ABG, calcium, the ratio of total calcium to systemic ionized calcium will monitor every 8 hour."
9694160|NCT04792112|Experimental|Guideline + decision support tool|A decision support tool summarizing harms and benefits of late preterm antenatal corticosteroids will be integrated into the clinical practice guideline available to clinicians in the hospitals in the experimental arm.
9694161|NCT04792112|No Intervention|Guideline only|Clinicians in the hospitals in the 'no-intervention' arm will have access to the standard guideline only (without the integrated decision support tool).
9694162|NCT04792216|Experimental|Wild Salmon|Wild salmon fillets in a raw form
9694163|NCT04792216|Experimental|Farmed Salmon|Farmed salmon fillets in a raw form
9694164|NCT04792463||Patients with personal and/or family history suggestive of hereditary BAP1|Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, CM, mesothelioma, RCC, cholangiocarcinoma, hepatocellular carcinoma and meningioma
9694165|NCT04792463||Pathogenic, likely pathogenic variants in BAP1 and variants of uncertain significance|"Affected and unaffected individuals with pathogenic or likely pathogenic variant in BAP1 and their family members~Patients with personal family history of any of the BAP1 associated cancer and a variant of uncertain significance of BAP1"
9694166|NCT04792476|Active Comparator|Active Comparator: Experimental group|The experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
9694167|NCT04792476|No Intervention|No Intervention: Control group|"The control group will only receive the conventional treatment offered in the clinical program. For 12 weeks, parients will attend 8 visits with mental health specialist nurse, where they will receive information, oral and written, to comply with the recommendations for physical exercise: 150-300 min/week of moderate physical activity or 75-150 min/week of vigorous physical activity.~In both groups (experimental and control), patients will be informed of the risk of weight gain, and they will be advised, regardless of the group assigned, to watch their diet and increase physical exercise until they meet the weekly recommendations."
9694168|NCT04792099|Experimental|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) with blended oxygen delivered by binasal prongs or nasal mask.
9694169|NCT04792099|Active Comparator|Nasal Cannula|Blended oxygen delivered by nasal cannula (NC).
9694170|NCT04792515|Experimental|treatment group|Patients were treated with camrelizumab combined with SOX/ or apatinib
9694171|NCT04792307|Other|Neuromuscular electrical stimulation (NMES) to one leg|"NMES left leg, no high protein ice cream supplementation~NMES right leg, no high protein ice cream supplementation"
9694172|NCT04792307|Other|High protein ice cream supplementation|"NMES left leg, high protein ice cream supplementation~NMES right leg, high protein ice cream supplementation"
9694173|NCT04792086||Inhabitants in Nord-Trøndelag 70 years of age and older|All inhabitants in Nord-Trøndelag 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
9694174|NCT04792086||Inhabitants in one area in Trondheim, 70 years of age and older|All inhabitants one area in Trondheim, 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
9694175|NCT04792047||Lesions with perivasular FAI greater than ≥-70.1|
9694176|NCT04792047||Lesions with perivasular FAI greater than <-70.1|
9694177|NCT04792060|Experimental|adult patients with distal ulna fractures|adult patients with distal ulna fractures
9694178|NCT04792034|Experimental|Active|Active: FDA Approved Golprelto (Cocaine Hydrochloride Topical Solution)
10115266|NCT04451395|Experimental|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet..The supplement is provided within the parent trial.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
10115267|NCT04451395|No Intervention|Standard of care|Daily iron and folic acid supplementation provided through the existing public health system.
9694181|NCT04791826|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of HF in diabetes and the lack of an active order for SGLT2i therapy.
9694182|NCT04791826|No Intervention|No Alert|The CDS will not issue an on-screen alert.
9694183|NCT04791917|Experimental|Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session designed to induce delayed onset muscle soreness in the biceps
9694184|NCT04791917|Sham Comparator|Sham Delayed Onset Muscle Soreness Induction|Participants will complete an exercise session that is unlikely to induce delayed onset muscle soreness in the biceps
9694185|NCT04791943|Experimental|Experimental Treatment - Melatonin|Premedication for three nights with 10mg melatonin
9694186|NCT04791943|Placebo Comparator|Control Treatment - Lactose|Premedication for three nights with lactose capsules
9694187|NCT04791956|Experimental|Prebiotic|Inulin-type fructans
9694188|NCT04791956|Placebo Comparator|Placebo|Maltodextrin
9694189|NCT04791774|Active Comparator|Protein group|Patients receive 20 grams of Intrinsically labelled milk protein.
9694190|NCT04791774|Experimental|Free amino acid group|Patients receive 20 grams of free amino acids equivalent to the milk protein labelled with 13C-Phenylalanine
9694191|NCT04791605|Experimental|Gait analysis of cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to cemented stem
9694192|NCT04791605|Experimental|Gait analysis of non-cemented total hip|Gait analysis of acute collum femoris fracture patient randomized to non-cemented stem
9694193|NCT04791683|No Intervention|Control|Infertile couples in the control group were selected by randomization, routine protocols in the clinic were applied
9694194|NCT04791683|Experimental|Experimental|"st interview: Application of data collection tools~nd meeting: Sexual counseling (1 week after the first interview)~rd interview: Sexual counseling (1 week after the first session)~th meeting: Sexual counseling (1 week after the second session)~th interview: Telephone interview (2 months after the first assessment)~th interview: re-application of data collection tools, including the final evaluation"
9694195|NCT04791982|Experimental|Experimental group|
9694196|NCT04791982|No Intervention|Control group|
9694197|NCT04791865|Active Comparator|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
9694198|NCT04791865|Experimental|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
9694199|NCT04791618|Active Comparator|Health360x only (High tech)|"Access to Health360x technology only for 6 months Behavioral: Health360x Participants will receive Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self- management skills. Every participant will view an orientation video which will include information on how to access Health360 from home and other internet connected devices; how to use activity monitors provided by the study and sphygmomanometer. They will receive an introduction to heart health curriculum, quizzes and discussion forums. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the Helath360x application will be available online and by phone.~The Health360x application will send messages to participants in this arm reminding them to perform study related activities."
9694200|NCT04791618|Experimental|Health360x plus Coach (High tech High touch)|"Health360x technology plus health coach Behavioral: Health360x plus health coach Participants will receive all of the resources in Arm A and Health coach interactions.~The Health coach will send messages to participants in this arm reminding them to perform study related activities. The coach interactions will be focused on helping with attainment of self- management behaviors"
9694201|NCT04791657||Patients without complications|Patients with uneventful recovery
9694202|NCT04791657||Patients with complications|Patients experiencing complications within 30 days postoperatively
9694203|NCT04791501||Hypoxemic Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more and FiO2 of 0.3 or more.
9694204|NCT04791592|Active Comparator|Group PIFB|PIF block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
9694205|NCT04791592|Active Comparator|Group TTMPB|TTMP block (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline) + IV morphine-PCA
9694206|NCT04791397|Experimental|Group trial|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
9694207|NCT04791397|Experimental|Group control|Included 30 patients, with metabolic syndrome, aged 24-71 year old.
9694208|NCT04791423|Experimental|Single dose of GRAd-COV2|1 single IM dose of GRAd-COV2 2 x 10^11 vp plus 1 dose of saline placebo after 21 days
9694209|NCT04791423|Experimental|Double dose of GRAd-COV2|2 repeated (21 days apart) IM dose of GRAd-COV2 1 x 10^11
9820072|NCT02186847|Experimental|Metformin + Chemoradiation|Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
9820073|NCT02186873|Experimental|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
9820074|NCT02186873|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
9820075|NCT02186938|No Intervention|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
9820076|NCT02186938|Experimental|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
9820077|NCT02187016|Experimental|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
9820078|NCT02187016|Experimental|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
9820079|NCT02187016|Experimental|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
9820080|NCT02187016|Active Comparator|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
9820081|NCT02187029|Experimental|PF-06743649 dose level 1 (Cohort 1)|
9820082|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 1)|
9820083|NCT02187029|Experimental|PF-06743649 dose level 2 (Cohort 2)|
9820084|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 2)|
9820085|NCT02187042||All patients|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
9820086|NCT02187055|Experimental|Tofacitinib 5 mg twice daily with methotrexate|
9820087|NCT02187055|Experimental|Tofacitinib 5 mg twice daily monotherapy|
9820088|NCT02187055|Active Comparator|Adalimumab with methotrexate|
9820089|NCT02187159|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
9820090|NCT02187159|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
9820091|NCT02187159|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
9820092|NCT02187159|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
9820093|NCT02187172|Active Comparator|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter. Patient will receive total of 52 weeks of ustekinumab (12 weeks during RCT phase, 40 weeks post RCT phase). The end of study is at Week 52 for this arm.
9820094|NCT02187172|Placebo Comparator|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator until week 12 (end of RCT phase). At week 12, ustekinumab will be administered according according to the same injection schedule as the active comparator arm for 52 weeks. Patient will receive total of 52 weeks of ustekinumab (0 weeks during RCT phase, 52 weeks post RCT phase). The end of study is at Week 64 for this arm.
9820095|NCT02187471|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
9820096|NCT02187471|Other|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
9820097|NCT02187471|Experimental|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
9820098|NCT02187471|Experimental|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
9820099|NCT02187744|Experimental|PF-05280014|
9820100|NCT02187744|Active Comparator|Herceptin®|
9965717|NCT01252316|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
9965718|NCT01252329|Active Comparator|Elective lymph node treatment arm|Patients entering this arm will undergo selective nodal dissection of the draining lymph nodes with subsequent radiation and/or chemotherapy if indicated.
9820101|NCT02187783|Experimental|LEE011|LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
9820102|NCT02187809|Experimental|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
9826965|NCT02439164|Experimental|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
9826966|NCT02439164|Active Comparator|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
10115268|NCT04451369|No Intervention|Control group|Group without prehabilitation program before surgery
9820103|NCT02187861|Experimental|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
9820104|NCT02187861|Experimental|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
9820105|NCT02187861|Experimental|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
9820106|NCT02187861|Active Comparator|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
9820107|NCT02187887|Experimental|Personalized normative feedback|Intervention participants receive feedback correcting their misperceptions of the drinking behavior and attitudes of fellow veterans
9820108|NCT02187887|No Intervention|Control|Control participants receive feedback correcting their misperceptions of the video game playing behavior and attitudes of fellow veterans
9820109|NCT02188160|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
9820110|NCT02188160|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
9820111|NCT02188303|Placebo Comparator|Placebo (Single Dose, Cohorts 1-3)|Single dose of placebo matching LY2944876 administered subcutaneous (SC) on Day 1
9820112|NCT02188303|Experimental|LY2944876 (Single Dose, Cohorts 1-3)|Single dose of 10 milligrams (mg) of LY2944876 administered SC on Day 1
9820113|NCT02188303|Placebo Comparator|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1-7
9820114|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 4)|40 mg LY2944876 administered once daily SC on Days 1-7
9820115|NCT02188303|Placebo Comparator|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
9820116|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses of 15 mg on Day 1, 30 mg on Day 4, up to 60 mg on Day 6, and up to 80 mg on Days 8, 10 and 12 administered once daily SC
9820117|NCT02188459|Active Comparator|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
9820118|NCT02188459|Placebo Comparator|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
9820119|NCT02188485|Experimental|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
9820120|NCT02188485|No Intervention|Care-as-Usual|Care as usual in primary care with study assessments.
9820121|NCT02188576|Experimental|high dose TXA|"High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion"
9820122|NCT02188576|Experimental|Low Dose TXA|"Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion"
9820123|NCT02188589|Experimental|Nasal implant group|Bilateral or unilateral INEX nasal implants
9820124|NCT02188719|Experimental|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
9820125|NCT02188719|Experimental|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
9820126|NCT02188719|Experimental|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
9820127|NCT02188719|Experimental|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
10115269|NCT04451369|Experimental|Prehabilitation group|Group will follows a prehabilitation program before surgery
10115270|NCT04451421|Experimental|Standing Angle|Assist the electric hospital bed to conduct different Angle standing training, starting from 20 degrees, every five minutes to rise 5 degrees, the maximum rise to 80 degrees
10115271|NCT04451434|Experimental|Danicopan 200 mg Fasted|Fasting participants will receive a single dose of 200 mg danicopan.
9694210|NCT04791423|Placebo Comparator|Placebo|Two doses of saline placebo on day 1 and day 22
9694211|NCT04791345|Experimental|Methylprednisone single-dose|Subjects receive a single dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
9694212|NCT04791345|Experimental|Methylprednisone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 7 days after administration in 20 fractions.
9694213|NCT04791345|Experimental|Deflazacort single-dose|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration in 10 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h post-administration. Blood samples will be collected until 6 days after administration in 5 fractions: pre-administration and 24h, 48h, 72h and 120h post-administration.
9820128|NCT02188784|Active Comparator|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
9820129|NCT02188784|Placebo Comparator|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
9820130|NCT02188849|Experimental|Creatine|Creatine 5 g/ day
9820131|NCT02188849|Placebo Comparator|Placebo|Maltodextrin 5 g/day to be dissolved in water
9820132|NCT02189122|Active Comparator|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
9820133|NCT02189122|Active Comparator|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
9820134|NCT02189161|Experimental|Radiofrequency Ablation|circumferential radiofrequency ablation (RFA) to the anal canal
9820135|NCT02189213|Active Comparator|Sertraline|Sertraline will be administered PO to treat anxiety disorders in children and adolescents. he following dosing schedules will be used: Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks. The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration.
9820136|NCT02189213|No Intervention|Control|There will be no intervention in this arm.
9820137|NCT02189252|Active Comparator|E4:L4|Crossover Sequence
9820138|NCT02189252|Active Comparator|L4:E4|Crossover Sequence
9820139|NCT02189252|Active Comparator|E2:L4|Crossover Sequence
9820140|NCT02189252|Active Comparator|L4:E2|Crossover Sequence
9820141|NCT02189317|Experimental|Exparel|This arm will receive Exparel
9820142|NCT02189317|No Intervention|Control|
9965719|NCT01252329|No Intervention|Clinical observation arm|Patients who enter into this arm will undergo regular, periodic clinical nodal observation with subsequent evaluation and treatment if indicated upon discovery of a palpable lymph node.
9965720|NCT01252342|Experimental|Intramyometrial oxytocin|
9965721|NCT01252342|Placebo Comparator|Intramyometrial Saline|
10115272|NCT04451434|Experimental|Danicopan 200 mg Fed|Fed participants will receive a single dose of 200 mg danicopan.
9820143|NCT02189382|Experimental|Potassium Oxalate Gel|Self Applied
10115273|NCT04451434|Experimental|Danicopan 400 mg Fed|Fed participants will receive a single dose of 400 mg danicopan.
9820144|NCT02189382|Other|Water|Self Applied
9820145|NCT02189473|Experimental|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
9820146|NCT02189473|Active Comparator|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
9820147|NCT02189629|Experimental|CD5789 (trifarotene) cream|
9820148|NCT02189668|Experimental|Non-operative Management|Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
9820149|NCT02189668|No Intervention|Surgery|Usual care with urgent appendectomy
9820150|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
9820151|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
9820152|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
9820153|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
9820154|NCT02189837|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
9820155|NCT02189837|Active Comparator|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
9820156|NCT02189837|Experimental|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
9820157|NCT02189837|Experimental|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
9820158|NCT02189850|Experimental|BLI800 - Dose 1|BLI800 oral solution
9820159|NCT02189850|Experimental|BLI800 - Dose 2|BLI800 oral solution
9965722|NCT01252368||RAS active drugs|ACE inhibitors and sartanes
9965723|NCT01252368||healthy participants|
9965724|NCT01252381|Active Comparator|Vitamin D|
9965725|NCT01252381|Placebo Comparator|Calcium tablet|
9965726|NCT01252394||Hemodialysis patients|
9965727|NCT01252407|Experimental|tens|
9965728|NCT01252433|Experimental|Entree energy density 100%|100% energy density
9965729|NCT01252433|Experimental|Entree energy density 85%|85% energy density
9820160|NCT02189863|Other|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
9820161|NCT02189863|Other|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
9820162|NCT02189889|Active Comparator|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
9820163|NCT02189889|No Intervention|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
9820164|NCT02189915|Experimental|Creatine monohydrate|
10115274|NCT04451447|Experimental|white test arm|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
10115275|NCT04451447|Other|Saline test arm|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
10115276|NCT04451538|Experimental|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g [12 spoon, 500 kcal]/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g [12 spoon, 440 kcal]/day, twice a day).
10115277|NCT04451538|Placebo Comparator|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
10115278|NCT04451603||Surgical resection|
10115279|NCT04451603||Y-90 therapy|
10115280|NCT04451603||Systemic Therapy|
10115281|NCT04451590|Experimental|VR-based Simulation (Intervention)|Students will receive training on traumatic airway management using VR-based simulation.
10115282|NCT04451590|Other|Mannequin-based Simulation (Control)|Students will receive training on traumatic airway management using mannequin-based simulation.
10115283|NCT04451577||EMPLOYEES WITHOUT COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.~Negativity to COVOD-19 will be tested by peripheral blood samples every month for 6 months (or until seroconversion). If they are positive for anti- covid 19 antibodies, a test for positivity of the virus will be carried out. T"
10115284|NCT04451577||EMPLOYEES WITH COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.~employees that are Sars-Cov-2 positive both symptomatic and asymptomatic, there will be at least 2 peripheral blood samples (5 and 3 ml) at every control visit until ascertained negativity. They will also undergo a pharyngeal swab for viral titers and microbiota analysis at enrollment and at negativity. In addition, a sample of saliva/sputum will be collected for most of the employees at positivity and at every control visit.~For employees hospitalized but not requiring intensive care the following samples will be collected:~an aliquot of samples from the respiratory tract (e.g., bronchial aspirate, bronchoalveolar lavage) residual from the normal clinical practice~saliva/sputum~pharyngeal swab not used for diagnosis both at admission and at the first check up~blood sample in EDTA for plasma and peripheral blood mononuclear cell (PBMC)"
10115285|NCT04451473|Experimental|ERAS- Group|Patients underwent surgery for lung cancer accepted the enhanced recovery after surgery (ERAS).
10115286|NCT04451473|Other|Control- Group|Patients underwent surgery for lung cancer without enhanced recovery after surgery (ERAS).
10115287|NCT04451564|Experimental|MORE Mindfulness oriented recovery enhancement group|MORE Mindfulness oriented recovery enhancement group
10115288|NCT04451564|No Intervention|Control|wait-list
10115289|NCT04451200|Experimental|busulfan treatment|Personalized BU administration
10115290|NCT04451343||Patients|Patients with a diagnosis of colorectal cancer before 65 years.
10115291|NCT04451343||Family|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
10115292|NCT04451239|Other|COVID-19 keratoconjunctivitis|cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
10115293|NCT04451382||OnabotulinumtoxinA (BoNTA)|DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
10115294|NCT04451382||Percutaneous tibial nerve stimulation (PTNS)|DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.
10115295|NCT04451616||Group A - study group - patients with metabolic syndrome|"Patients with metabolic syndrome will be included.~Procedures:~blood sample collection~hair sample collection~urine sample collection~body composition analysis~questionnaires~blood pressure, pulse and blood oxygen saturation measurement"
10115296|NCT04451616||Group B - control group - patients without metabolic syndrome|"Patients without metabolic syndrome will be included.~blood sample collection~hair sample collection~urine sample collection~body composition analysis~questionnaires~blood pressure, pulse and blood oxygen saturation measurement"
10115297|NCT04451135|Experimental|Patients with Treatment-Resistant Depression|
9820165|NCT02189941|Experimental|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
9820166|NCT02189941|Experimental|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
9820167|NCT02189941|Active Comparator|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
9820168|NCT02189954|Active Comparator|Group Routine Care|The placement according to the manufacturer's instructions.
9820169|NCT02189954|Experimental|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
9820170|NCT02190045|Experimental|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
9820171|NCT02190045|Placebo Comparator|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
9820172|NCT02190279|Experimental|Suspected Localized Prostate Cancer|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
9820173|NCT02190279|Experimental|Biochemical Recurrence|Patients with biochemical prostate cancer relapse after definitive treatment
9820174|NCT02190279|Experimental|Known Metastatic Disease|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
9820175|NCT02190435|Experimental|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
9820176|NCT02190435|Active Comparator|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
9820177|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
9820178|NCT02190591|No Intervention|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
9820179|NCT02190591|Experimental|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
9820180|NCT02190604|Experimental|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820181|NCT02190604|Experimental|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820182|NCT02190604|Experimental|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820183|NCT02190604|Experimental|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820184|NCT02190604|Experimental|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820185|NCT02190604|Experimental|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820186|NCT02190604|Experimental|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820187|NCT02190604|Experimental|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820188|NCT02190604|Experimental|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820189|NCT02190604|Placebo Comparator|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
9820190|NCT02190604|Experimental|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
9820191|NCT02190604|Experimental|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
9820192|NCT02190604|Experimental|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
9820193|NCT02190604|Experimental|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
9820194|NCT02190604|Experimental|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
9820195|NCT02190604|Placebo Comparator|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
9820196|NCT02190604|Experimental|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
9826967|NCT02439281|Active Comparator|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
9965730|NCT01252433|Experimental|Entree energy density 75%|75% energy density
9820197|NCT02190604|Experimental|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
9820198|NCT02190604|Experimental|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
9820199|NCT02190604|Placebo Comparator|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
9820200|NCT02190747|Experimental|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
9820201|NCT02190747|Experimental|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
9820202|NCT02190747|Experimental|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
9820203|NCT02190747|Placebo Comparator|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
9820204|NCT02190903|Active Comparator|General endotracheal anesthesia|Standard care general endotracheal anesthesia
9820205|NCT02190903|Active Comparator|Regional (spinal) anesthesia|Standard care spinal anesthesia
9820206|NCT02191033|Experimental|Text messaging|Smoking counseling, nicotine patch, text messaging
9820207|NCT02191033|Active Comparator|Standard of care|Smoking counseling, nicotine patch
9820208|NCT02191046|Active Comparator|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
9820209|NCT02191046|Experimental|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
9820210|NCT02191137|Experimental|Riociguat 0.5mg to 2.5 mg|Single arm, open label
9820211|NCT02191267|Experimental|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
9820212|NCT02191267|Experimental|Control Group|Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
9820213|NCT02191267|Experimental|AD Dementia Group|Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
9820214|NCT02191397|Experimental|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
9820215|NCT02191397|Active Comparator|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
9820216|NCT02191579|Active Comparator|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
9820217|NCT02191579|Active Comparator|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
9820218|NCT02191605|Experimental|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
9820219|NCT02191605|Experimental|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
9820220|NCT02191605|Experimental|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
9820221|NCT02191605|No Intervention|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
9820222|NCT02191605|No Intervention|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
9820223|NCT02191618|Other|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
9820224|NCT02191865|Experimental|Mild liver impairment|Patients with mild hepatic impaired function (Child-Pugh A)
9820225|NCT02191865|Experimental|Moderate liver impairment|Patients with moderate hepatic impaired function (Child-Pugh B)
9820226|NCT02191865|Experimental|Healthy volunteers|Healthy control subjects
9820227|NCT02192099|Experimental|Rapastinel (225 mg/450 mg IV administration) prefilled syringe|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
9820228|NCT02192190|Placebo Comparator|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
9820229|NCT02192190|Active Comparator|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
9820230|NCT02192190|Experimental|LY2951742 5 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
9820231|NCT02192190|Experimental|LY2951742 50 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
9820232|NCT02192190|Experimental|LY2951742 120 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
9820233|NCT02192190|Experimental|LY2951742 300 mg + Placebo|Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
9820234|NCT02192307|Experimental|potassium oxalate gel|Professional application
9820235|NCT02192307|Active Comparator|Potassium oxalate liquid|Professional application
10115298|NCT04451330|Experimental|Trifarotene (CD5789) Cream + Doxycycline|Participants will apply trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.
9820236|NCT02192541|Experimental|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
9820237|NCT02192606|Active Comparator|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
9820238|NCT02192606|Active Comparator|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
9820239|NCT02192684|Active Comparator|pioglitazone|pioglitazone 45 mg, oral, daily
9820240|NCT02192684|Placebo Comparator|placebo|Placebo, one pill daily
9820241|NCT02192814|Experimental|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
9820242|NCT02192879|Active Comparator|Thoracic Epidural|
9820243|NCT02192879|Active Comparator|Continuous Paravertebral Catheter|
9820244|NCT02192879|Active Comparator|Patient-Controlled Analgesia|
9820245|NCT02192905|Experimental|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
9826968|NCT02439281|Experimental|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
9826969|NCT02439320|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
9826970|NCT02439320|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
9826971|NCT02439320|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
9826972|NCT02439749|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
9826973|NCT02439749|Sham Comparator|Sham Procedure|Renal angiography
9826974|NCT02439814|Experimental|Pregnenolone|
9826975|NCT02439814|Placebo Comparator|Placebo|
9826976|NCT02439879|Active Comparator|alpha lipoic acid treatment|After a decrease in the total symptoms score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
9826977|NCT02439879|No Intervention|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
9826978|NCT02440022|Experimental|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
9826979|NCT02440022|Active Comparator|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
9820246|NCT02192970|Experimental|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
9820247|NCT02192970|No Intervention|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
9820248|NCT02193074|Experimental|nusinersen|
9820249|NCT02193074|Sham Comparator|Sham procedure|
9820250|NCT02193087|Active Comparator|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
9820251|NCT02193087|Active Comparator|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
9820252|NCT02193087|Experimental|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
9820253|NCT02193087|Experimental|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
9820254|NCT02193152|Experimental|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.~One cycle of pazopanib is 28 days."
9820255|NCT02193165|Active Comparator|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
9820256|NCT02193165|Active Comparator|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
9820257|NCT02193165|Placebo Comparator|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
9820258|NCT02193178|Experimental|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
9820259|NCT02193347|Experimental|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
9820260|NCT02193490|Active Comparator|DNase|DNase 0.1% eye drops four times a day for 8 weeks
9820261|NCT02193490|Placebo Comparator|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
9820262|NCT02193776|Experimental|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
9820263|NCT02193776|Experimental|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
9820264|NCT02193776|Experimental|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
9820265|NCT02193776|Active Comparator|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
9820266|NCT02193815|Experimental|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
9820267|NCT02193828|Experimental|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
9820268|NCT02193828|Experimental|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
9820269|NCT02193828|Experimental|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
9820270|NCT02193828|Placebo Comparator|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
9820271|NCT02193880|Other|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
9820272|NCT02194062|Active Comparator|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
9820273|NCT02194062|Active Comparator|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
9820274|NCT02194062|Active Comparator|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
9820275|NCT02194088|Experimental|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
9820276|NCT02194088|Placebo Comparator|placebo|Placebo capsules will be delivered in same number as the medication
9820277|NCT02194439||hematopoietic stem cell transplant|procedure
9820278|NCT02194465|Experimental|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
9820279|NCT02194465|Experimental|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
9820280|NCT02194465|Experimental|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
9820281|NCT02194465|Experimental|13 mg LY2623091 + 20 mg tadalafil|13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
9820282|NCT02194465|Experimental|20 mg tadalafil|20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
9820283|NCT02194465|Active Comparator|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
9820284|NCT02194465|Placebo Comparator|Placebo|Placebo for blinding administered orally once daily for 4 weeks.
9820285|NCT02194621|Experimental|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
9820286|NCT02194621|Experimental|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
9820287|NCT02194621|Placebo Comparator|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
9820288|NCT02194699|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
9820289|NCT02194699|Placebo Comparator|Placebo|Placebo subcutaneous injection
9820290|NCT02194933|Experimental|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
9820291|NCT02194933|Experimental|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
9820292|NCT02194985|Experimental|Migalastat HCl 150 mg|Migalastat HCl 150 milligram (mg).
9820293|NCT02194998|Experimental|Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
9820294|NCT02194998|Experimental|Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
9820295|NCT02194998|Experimental|Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
9820296|NCT02194998|Experimental|Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
9820297|NCT02195011|Experimental|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
9820298|NCT02195011|Experimental|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
9820299|NCT02195232|Experimental|Cohort A - Isoquercetin|"-- Cohort A: 500 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
9820300|NCT02195232|Experimental|Cohort B - Isoquercetin|"--Cohort B: 1000 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
9820301|NCT02195310|Experimental|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
9820302|NCT02195310|Active Comparator|Conventional sterile wound dressings|Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
9820303|NCT02195349|Experimental|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
9820304|NCT02195349|Experimental|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
9820305|NCT02195349|Experimental|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
9820306|NCT02195414|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
9820307|NCT02195427|Experimental|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
9820308|NCT02195427|Experimental|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
9820309|NCT02195518|Experimental|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
9820310|NCT02195531|Active Comparator|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
9820311|NCT02195531|Active Comparator|Control Group|Participants will receive education inconsistent with their profile.
9820312|NCT02195531|No Intervention|Standard of care|Participants will not receive education or feedback.
10115299|NCT04451330|Placebo Comparator|Trifarotene Vehicle + Doxycycline Placebo|Participants will apply vehicle trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of placebo doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.
10115300|NCT04451291|Experimental|Decidual Stromal Cells (DSC)|Participants will receive one dose of DSC at 1x10^6/kg. A second dose may be given sometime between Day 5 and Day 8 if the participant's condition improves.
10115301|NCT04451174|Experimental|Treatment|Prednisone 40 mg days 1 to 4. Then Prednisone 20 mg days 5 to 8.
10115302|NCT04451174|No Intervention|Control|
10115303|NCT04451148||Obese subjects|Subjects with obesity
10115304|NCT04451148||Obese plus metabolic syndrome subjects|Subjects with obesity and metabolic syndrome
10115305|NCT04451148||Healthy controls|Otherwise healthy subjects
10115306|NCT04451005||Elderly patients with sarcopenia|Elderly patients with sarcopenia
10115307|NCT04451031|Experimental|LiFT Program|LiFT is a two-module curriculum workshop for youth and their parenting adults. Topics for youth include communication skills, condom use, and skill building to access sexual healthcare resources. For parenting adults, topics include building a climate of trust and open communication with youth about sexual health. Trained and certified facilitators deliver each 2.5 hour module over one or two sessions. Youth and parents participated in simultaneous but separate programming in community locations such as schools or health care settings. They received participant guides that encourage communication between them. They could opt-in to receive 12 weekly texts that offered additional resources. Parenting adults received a phone call from the facilitator a month after the workshop to reinforce the skills learned during the program.
10115308|NCT04451031|No Intervention|Comparison Group|The comparison group received business as usual. The youth and parents enrolled in the study could receive the existing services available within the broader community, which may have included sexual education delivered in the local school system. Study staff collected data throughout the study to track access to other TPP programming offered at the study sites.
10115309|NCT04451499|Experimental|Intervention group -smartphone app|"All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.~All the participants will get access to our study's smartphone app site."
10115310|NCT04451499|No Intervention|Control group|All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.
10115311|NCT04451070||Family Medicine resident physicians|Family Medicine resident physicians at David Grant Medical Center who started their Family Medicine residency at David Grant Medical Center between June 2018 - June 2019 and are scheduled to graduate from Family Medicine residency between June 2021 - June 2022.
10115312|NCT04451057|Experimental|high flow nasal nasal cannula|Patients allocated for this arm are received high flow nasal cannula therapy after extubation.
10115313|NCT04451057|Active Comparator|low flow nasal cannula|Patients allocated for this arm are received conventional oxygen therapy after extubation.
10115314|NCT04451122|Other|Treatment of ocular demodicosis|
10115315|NCT04451096|Active Comparator|Probiotic with prebiotic|Drug: Probiotic sachet containing granulated multiple strains of Lactobacillus and Bifidobacterium, granulated fermented milk, lactose, fructo-oligosaccharide (FOS) with orange flavouring.
10115316|NCT04451096|Placebo Comparator|Placebo|Drug : Placebo sachet of granulated milk, lactose and orange flavouring, without FOS or microbial cells which appeared similar to the probiotics
10115317|NCT04450940|Experimental|PACV|The PACV arm received the PACV survey at baseline in order to assess the impact of administration on vaccine hesitancy. All participants received the PACV at 6-month follow up.
10115318|NCT04450940|Sham Comparator|Placebo|The placebo arm received a placebo survey on general childhood health topics at baseline. All participants received the PACV at 6-month follow up.
10115319|NCT04451083|Experimental|FOY-305|
10115320|NCT04450849|Experimental|collagen membrane associated to anorganic bone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio) associated to anorganic bovine bone matrix + collagen (Bio-Oss® Collagen) . The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
10115321|NCT04450849|Active Comparator|collagen membrane alone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio). The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
10115322|NCT04451109||Cases in which Dilapan-S was used for cervical ripening.|Every participating site will select 50 cases of pregnant women who underwent cervical ripening by Dilapan-S prior to induction of labor. These cases has to fulfill inclusion/exclusion criteria defined in the protocol.
9820313|NCT02195583|Experimental|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
9820314|NCT02195583|Experimental|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
9820315|NCT02195583|Experimental|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
9820316|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
9820317|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
9820318|NCT02195583|Placebo Comparator|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
9820319|NCT02195622|Other|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
9820320|NCT02195622|Other|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
9820321|NCT02195687|Experimental|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
9820322|NCT02195687|Placebo Comparator|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
9820323|NCT02195700|Experimental|SD-809|SD-809 tablets taken twice daily for 12 weeks.
9820324|NCT02195700|Placebo Comparator|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
9820325|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
9820326|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
9820327|NCT02195869|Experimental|Phase 1b: Dose Level 1|Subjects receive daily dose of 420 mg of Ibrutinib capsules
9820328|NCT02195869|Experimental|Phase 1b: Dose Level 2|Subjects receive daily dose of 280 mg of Ibrutinib capsules
9820329|NCT02195869|Experimental|Phase 1b: Dose Level 3|Subjects receive daily dose of 140 mg of Ibrutinib capsules
9820330|NCT02195869|Experimental|Phase 2|Subjects receive daily dose of recommended phase 2 dose
9820331|NCT02195895|Experimental|Alendronate, Calcium, Vitamin D|"Drug: Weekly oral alendronate 70 mg for 12 months~Supplements: 1000 mg Calcium and 1000 IU Vitamin D daily for 12 months"
9820332|NCT02195921|Experimental|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
9820333|NCT02195921|Experimental|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
9820334|NCT02195921|Experimental|ST36+CV12 acupoints|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
9820335|NCT02195921|Active Comparator|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
9820336|NCT02196038|Other|Attention Control|Usual care group with bi-weekly contact from study staff
9820337|NCT02196038|Active Comparator|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
9820338|NCT02196077|Experimental|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
9820339|NCT02196077|Experimental|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
9820340|NCT02196077|Experimental|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
9820341|NCT02196077|Experimental|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
9820342|NCT02196077|Experimental|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
9820343|NCT02196168|Experimental|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
9820344|NCT02196168|Active Comparator|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
9820345|NCT02196259|Experimental|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
9820346|NCT02196259|Experimental|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
9820347|NCT02196259|Experimental|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
9820348|NCT02196324|Active Comparator|serlopitant 5 mg tablets|serlopitant 5 mg tablets
9820349|NCT02196324|Placebo Comparator|Placebo tablets|Placebo tablets
9820350|NCT02196506|Experimental|Brexpiprazole + ADT|Brexpiprazole + ADT
9820351|NCT02196506|Placebo Comparator|Placebo + ADT|Placebo + ADT
9820352|NCT02196558|Experimental|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
9820353|NCT02196558|Experimental|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
9820354|NCT02196558|Experimental|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
9820355|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
9820356|NCT02196688|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
9820357|NCT02196688|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
9820358|NCT02196701|Experimental|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
9820359|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
9820360|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
9820361|NCT02196714|Experimental|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
9820362|NCT02196714|Experimental|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
9820363|NCT02196766|Active Comparator|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
9820364|NCT02196766|Active Comparator|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
9820365|NCT02196831|Experimental|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
9820366|NCT02196831|Placebo Comparator|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
9820367|NCT02196857|Experimental|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
9820368|NCT02196922|Active Comparator|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
9820369|NCT02196922|Experimental|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
9820370|NCT02197065|Experimental|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
9820371|NCT02197065|Placebo Comparator|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
9820372|NCT02197078||Glitazones|
9820373|NCT02197078||Linagliptin|
9820374|NCT02197078||Sulfonylurea|
9820375|NCT02197078||Within-class comparators|
9820376|NCT02197130|Experimental|20 mg PF-02545920 BID|20 mg PF-02545920 BID
9820377|NCT02197130|Experimental|5 mg PF-02545920 BID|5 mg PF-02545920 BID
9820378|NCT02197130|Placebo Comparator|Placebo BID|Matching placebo
9820379|NCT02197247|Experimental|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
9826980|NCT02440139|No Intervention|Arm 1|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
9965731|NCT01252446||ADHD|The sample of 187 children and adolescent in the age of 6 to 17 years referred to the Child and Adolescent Clinic, Haugesund, Norway during the period of one year and diagnosed in ICD 10 system as ADHD.
10115323|NCT04450836|Experimental|Arm A (R-TT)|Regorafenib followed by trifluridine-tipiracil.
9820380|NCT02197273|Active Comparator|Standard of care analgesia|"Total Hip Arthroplasty (THA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine~Injection into capsular tissue after placement of the acetabular component:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Knee Arthroplasty (TKA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc~Injection into posterior capsule of the knee:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Shoulder Arthroplasty (TSA):~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
9820381|NCT02197273|Experimental|Liposomal bupivacaine|"THA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue~TKA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue~TSA:~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
9820382|NCT02197377|Active Comparator|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
9820383|NCT02197377|Experimental|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
9820384|NCT02197416|Experimental|dabigatran etexilate|
9820385|NCT02197455|Experimental|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
9820386|NCT02197481|Active Comparator|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
9820387|NCT02197481|Experimental|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
9820388|NCT02197520|Experimental|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
9820389|NCT02197520|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
9820390|NCT02197572|Experimental|Sapanisertib|Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
9820391|NCT02197767|Experimental|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
9820392|NCT02197806|Experimental|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
9820393|NCT02197806|Experimental|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
9820394|NCT02197806|Experimental|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
9820395|NCT02197806|Experimental|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
9820396|NCT02197897|Experimental|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
9820397|NCT02198040|Experimental|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
9820398|NCT02198040|Experimental|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
9820399|NCT02198040|No Intervention|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
9820400|NCT02198235|Active Comparator|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
9820401|NCT02198235|Active Comparator|Control NB + IV Dex|IV Dexamethasone (4 mg)
9820402|NCT02198235|Experimental|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
9820403|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
9820404|NCT02198430||Control group|Children without hemophilia
9820405|NCT02198651|Experimental|Adalimumab 40 mg eow|40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
10115324|NCT04450836|Experimental|Arm B (TT-R)|Trifluridine-tipiracil followed by Regorafenib.
9820406|NCT02198651|Active Comparator|Adalimumab Tapering|40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
9820407|NCT02198651|Placebo Comparator|Adalimumab Withdrawal Arm|Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
9820408|NCT02198651|Experimental|Adalimumab 40 mg eow Rescue Arm|40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
9820409|NCT02198664|Experimental|ARC001 placebo group|Subjects who received placebo in study ARC001.
9820410|NCT02198664|Experimental|ARC001 AR101 group|Subjects who received AR101 and tolerated up to 300 mg peanut protein (443 mg cumulative) in the DBPCFC at the end of study ARC001.
9820411|NCT02198963|Experimental|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
9820412|NCT02198963|Active Comparator|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
9820413|NCT02198963|Placebo Comparator|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
9820414|NCT02199028|Experimental|Hyaluronidase, Then Control|"Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.~On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.~On weeks 2 and 4 (control weeks) no Hyaluronidase was administered."
9820415|NCT02199028|Experimental|Control, Then Hyaluronidase|"Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.~On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.~On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear."
9820416|NCT02199041|Experimental|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.~Cells for infusion are prepared using the CliniMACS System."
9820417|NCT02199080|Other|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
9820418|NCT02199197|Experimental|Radium Ra 223 Dichloride and Enzalutamide|Radium Ra 223 Dichloride and Enzalutamide administered concurrently for 6 28-day cycles.
9820419|NCT02199197|Active Comparator|Enzalutamide alone|Enzalutamide administered as a single agent for 6 28-day cycles.
9820420|NCT02199314|Experimental|desflurane MEP's|Transcranial motor evoked potentials are obtained under total intravenous anesthesia (TIVA) and again after desflurane at 3%, for at least 5 minutes.at two different time points. Each subject is his/her own control
9820421|NCT02199496|Experimental|Cohort 1: Ustekinumab-Single-dose Phase 1, Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously then re-enrolled into the multi-dose phase. In multi-dose phase, subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
9820422|NCT02199496|Experimental|Cohort 2: Ustekinumab-Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
9820423|NCT02199574|Experimental|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
9820424|NCT02199652|Placebo Comparator|placebo|placebo pill
9820425|NCT02199652|Experimental|prazosin|prazosin pill
9820426|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
9820427|NCT02199743|Active Comparator|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
9820428|NCT02199743|Active Comparator|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
9820429|NCT02199743|Active Comparator|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
9820430|NCT02199795|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
9820431|NCT02199795|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
9820432|NCT02199964|Experimental|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
9820433|NCT02199964|Active Comparator|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
9820434|NCT02200055|Experimental|Bioimpedance Assessment|"The only group will be those patients having major intra-abdominal surgical procedures.~Each patient involved in the study will be evaluated with a bioimpedance monitor ('Bodystat Quadscan 4000') to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
9820435|NCT02200211|Experimental|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
9820436|NCT02200211|Active Comparator|Patching Treatment|Patching 2 hours per day, 7 days per week
9826981|NCT02440139|Active Comparator|Arm 2|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
9820437|NCT02200445|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 0.3x10^6 IU/m^2/day.~Cohort 2: 1.0x10^6 IU/m^2/day.~Cohort 3: 1.5x10^6 IU/m^2/day.~Up to 6 subjects will be recruited to each dose cohort.~Once the maximum tolerated dose has been identified, a further 10 subjects will receive IL-2 at the maximum tolerated dose."
9820438|NCT02200458|Experimental|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
9820439|NCT02200510|Other|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
9820440|NCT02200510|Other|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
9820441|NCT02200523|Experimental|SARA electrode|new electrode
9820442|NCT02200523|Active Comparator|Gold cup|gold standard
9820443|NCT02200536|Experimental|Test|Infant oral health promotion package
9820444|NCT02200536|Active Comparator|Control 1|Infant oral health pamphlet
9820445|NCT02200536|No Intervention|Control 2|
9820446|NCT02200614|Experimental|Darolutamide (BAY1841788)|Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
9820447|NCT02200614|Placebo Comparator|Placebo|Participants received matching placebo 2 tablets twice daily with food.
9820448|NCT02201056|Experimental|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
9820449|NCT02201056|Experimental|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
9820450|NCT02201056|Experimental|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
9820451|NCT02201056|Experimental|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
9820452|NCT02201056|Experimental|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
9820453|NCT02201056|Experimental|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
9820454|NCT02201056|Placebo Comparator|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
9820455|NCT02201108|Placebo Comparator|Placebo|Matching placebo tablets
9820456|NCT02201108|Experimental|Teriflunomide|Teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent
9820457|NCT02201212|Experimental|Everolimus|"Everolimus~Fixed doses orally once a day per each 28 day cycle~Participants will stay on study as long as they do not progress for a maximum of 24 months.~Tumor assessments will be performed after every 2 cycles for as long as they are on study."
9820458|NCT02201251|Experimental|Topiramate|Topiramate weight based dosing for participants 2 to less than (<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
9820459|NCT02201251|Active Comparator|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
9820460|NCT02201277|Experimental|Denali|Denali IVC Filter
9820461|NCT02201277|Experimental|Option|Option Elite IVC Filter
9820462|NCT02201290|Experimental|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of < 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
9820463|NCT02201329|Experimental|A|Volasertib escalating doses + azacitidine
9826982|NCT02440178|Experimental|micafungin prophylaxis|Patients received 50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to recovery of neutrophil count (absolute neutrophil count > 500/μg for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity.
9826983|NCT02440204|Active Comparator|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
10115325|NCT04450862|Experimental|Intervention arm|Participants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky & Mooney, 1990).
9826984|NCT02440204|Active Comparator|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
9826985|NCT02440204|Active Comparator|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
9826986|NCT02440308|Experimental|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
9826987|NCT02440334|Experimental|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
9826988|NCT02440451|Experimental|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
9827633|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
10115326|NCT04450862|No Intervention|Control arm|A waiting-list will be used as a control condition. If the self-management intervention is found to be acceptable and not associated with any risk, then participants in the control condition will receive the intervention.
9820464|NCT02201394|Experimental|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
9820465|NCT02201394|Experimental|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
9820466|NCT02201420|Experimental|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
9820467|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
9820468|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
9820469|NCT02201524|Experimental|Cohort 1|200mg of PF-04965842 twice daily
9820470|NCT02201524|Experimental|Cohort 2|400mg of PF-04965842 once daily
9820471|NCT02201524|Experimental|Cohort 3|200mg of PF-04965842 once daily
9820472|NCT02201524|Placebo Comparator|Cohort 4|Placebo comparator daily
9820473|NCT02201771|Active Comparator|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
9820474|NCT02201771|Experimental|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
9820475|NCT02201771|Experimental|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
9820476|NCT02201784|Active Comparator|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
9820477|NCT02201784|Active Comparator|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
9820478|NCT02201901|Experimental|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
9820479|NCT02201901|Experimental|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
9820480|NCT02201901|Experimental|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
9820481|NCT02201940|Experimental|SOF/VEL|SOF/VEL for 12 weeks
9820482|NCT02201940|Placebo Comparator|Placebo|SOF/VEL placebo for 12 weeks
9820483|NCT02201953|Experimental|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
9820484|NCT02201953|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
9820485|NCT02202031|Experimental|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
9820486|NCT02202031|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
9820487|NCT02202109|Active Comparator|CHWs facilitated Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
9820488|NCT02202109|Active Comparator|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
9820489|NCT02202135|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
9820490|NCT02202135|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
9820491|NCT02202161|Experimental|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
9820492|NCT02202161|Experimental|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
9820493|NCT02202161|Experimental|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
9820494|NCT02202161|Experimental|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
9820495|NCT02202161|Placebo Comparator|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
9820496|NCT02202161|Active Comparator|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
9820497|NCT02202252|Experimental|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
9820498|NCT02202252|Experimental|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
9820499|NCT02202317|Experimental|Y90 Based PET/CT Scan|
9827634|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
9820500|NCT02202499|Active Comparator|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
9820501|NCT02202499|Active Comparator|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
10115327|NCT04450511|Active Comparator|Group 1: Bladder Training (BT)|BT, consisting of four stages, did not contain any PFM training programs in all groups. In these stages, including urgency suppression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women were encouraged to pause/stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
9820502|NCT02202499|Active Comparator|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
9820503|NCT02202538|Experimental|Indego|Indego
9820504|NCT02202551|Experimental|ADS-5102|amantadine HCl extended release
9820505|NCT02202616|Other|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
9820506|NCT02202746|Experimental|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
9820507|NCT02202746|Experimental|Cohort B: Lucitanib (CO-3810) 15 mg daily|15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
9820508|NCT02202746|Experimental|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
9820509|NCT02202759|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
9820510|NCT02202785|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
9820511|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
9820512|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
9820513|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
9820514|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
9820515|NCT02202980|Experimental|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
9820516|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
9820517|NCT02202980|Experimental|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
9820518|NCT02202980|Experimental|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
9820519|NCT02202980|Experimental|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
9820520|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
9820521|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
9820522|NCT02202980|Experimental|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
9820523|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
9820524|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
9820525|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
9820526|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
9820527|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
9820528|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
9820529|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
9820530|NCT02203019|Active Comparator|Propofol|Propofol will be administered for sedation.
9820531|NCT02203019|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered for sedation
10115328|NCT04450511|Experimental|Group 2: Bladder Training+Magnetic Stimulation|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is inserted by this magnetic ﬁeld, an eddy current ﬂow is generated. This eddy current stimulates nerve or muscle of the pelvic ﬂoor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
10115329|NCT04450589|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
10115330|NCT04450589|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
10115331|NCT04450758||resection|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with acute resection.
10115332|NCT04450758||bridge to sugery|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with bridge to surgery i.e. either stent or stoma and resection later on.
10115333|NCT04450563|Active Comparator|Placebo + closed-loop insulin system|
10115334|NCT04450563|Experimental|Empagliflozin 2.5 mg + closed-loop insulin system|
10115335|NCT04450563|Experimental|Empagliflozin 5 mg + closed-loop insulin system|
10115336|NCT04450875|Experimental|Experimental group (with diet)|It consisted in the administration of nutritional therapy with foods high in methionine according to the National Nutrient Database For Standard Reference (USDA) and adapted to the consumption and usual cost in the Mexican diet.
10115337|NCT04450875|No Intervention|Control|The control group continued with their usual diet for the same period of 3 months as the experimental group.
10115338|NCT04450602|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR (Patent Pending) active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
10115339|NCT04450602|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
10115340|NCT04450524|Experimental|Hypnosis|Hypnosis formed from hypnotic induction (an adapted version from Harvard Group Scale of Hypnotic Susceptibility) together with hypnotic suggestions about a future where they will control their eating behaviors by choosing the low-calorie food instead of dense calorie one.
10115341|NCT04450524|Experimental|Food Inhibition Training|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press or not a button when the pictures are framed in a bold frame (dense calorie food).
10115342|NCT04450524|Placebo Comparator|Control|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press the button to indicate the position of the picture - left or right.
10115343|NCT04450810||Control|Evaluation of serum and salivary NLRP3
10115344|NCT04450810||Periodontitis|Evaluation of serum and salivary NLRP3
10115345|NCT04450810||Diabetes|Evaluation of serum and salivary NLRP3
10115346|NCT04450810||Periodontitis + diabetes|Evaluation of serum and salivary NLRP3
10115347|NCT04450641|Experimental|Treatment|Treatment group used GuessWhat during the 4 week intervention period.
10115348|NCT04450641|Other|Control|Participants in control group received standard treatment as usual.
10115349|NCT04450784||Secondary Acute Myeloid Leukemias (AML) of the child|
9820532|NCT02203032|Experimental|Open-label ustekinumab|
9820533|NCT02203032|Experimental|Double-blind guselkumab|
9820534|NCT02203032|Experimental|Double-blind ustekinumab|
9820535|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
10115350|NCT04450901|Experimental|Cohort A1 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 0.5 mg/kg
10115351|NCT04450901|Experimental|Cohort A2 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 2 mg/kg
10115352|NCT04450901|Experimental|Cohort A3 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 5 mg/kg
10115353|NCT04450901|Experimental|Cohort A4 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 10 mg/kg
9820536|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
9820537|NCT02203149|Experimental|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
9820538|NCT02203149|Experimental|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
9820539|NCT02203149|Experimental|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
9820540|NCT02203149|Placebo Comparator|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
9820541|NCT02203149|Experimental|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
9820542|NCT02203162|Experimental|cough reflex sensitivity|electronic cigarette exposure
9820543|NCT02203331|Placebo Comparator|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
9820544|NCT02203331|Experimental|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
9820545|NCT02203331|Experimental|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
9820546|NCT02203331|Experimental|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
9820547|NCT02203331|Experimental|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
9820548|NCT02203331|Active Comparator|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
9820549|NCT02203357|Active Comparator|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
9820550|NCT02203357|Experimental|60μg, 0-1|112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
9820551|NCT02203357|Experimental|60μg, 0-2|125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
9820552|NCT02203565|Experimental|Supportive care (Dakin's solution, radiation therapy)|Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.
9820553|NCT02203578|Experimental|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9820554|NCT02203591|Experimental|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
9820555|NCT02203591|Experimental|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
9820556|NCT02203591|Active Comparator|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
9820557|NCT02203591|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
9820558|NCT02203630|Active Comparator|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
9820559|NCT02203630|Active Comparator|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
9820560|NCT02203721|Experimental|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
9820561|NCT02203721|Active Comparator|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
9820562|NCT02203747||Pseudophakic implanted with toric IOL|Subjects bilaterally implanted with toric IOL
9820563|NCT02203747||Pseudophakic implanted with non-toric IOL|Subjects bilaterally implanted with non-toric IOL
9820564|NCT02203786|Active Comparator|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
9820565|NCT02203786|Active Comparator|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
9820566|NCT02203838|Experimental|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.
9827635|NCT02462486|Active Comparator|Ranibizumab (rQ4)|Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
9965732|NCT01252459|Experimental|Arm A: AA-PET based target volume delineation|Experimental intervention (Arm A): High-precision re-irradiation. Target volume delineation based on AA-PET.
9965733|NCT01252459|Active Comparator|Arm B: T1Gd-MRI based target volume delineation|Control intervention (Arm B): High-precision re-irradiation. Target volume delineation based on T1Gd-MRI.
9965734|NCT01252472||Flomax|Male patients scheduled for cataract surgery with current or past use of Flomax
9694214|NCT04791345|Experimental|Dexamethasone single-dose|"Subjects receive a single-dose treatment. Urine samples will be collected until 13 days after administration in 11 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-72h, 72-96h, 96-120h, 120-144h post-administration.~Blood samples will be collected until 9 days after administration in 6 fractions: pre-administration and 24h, 48h, 72h, 120h and 192h post-administration."
9694215|NCT04791345|Experimental|Dexamethasone multiple-dose|Subjects receive a multiple dose treatment. Urine samples will be collected until 10 days after administration in 34 fractions. Blood samples will be collected until 13 days after the first administration.
9694216|NCT04791332|Experimental|Single Dose Cohort: Cohort 1 and 2|Participants will receive a single oral dose of JNJ-67953964 or a matching placebo on Day 1.
9694217|NCT04791332|Experimental|Multiple Dose Cohort: Cohort 3|Participants will receive multiple oral dose of JNJ-67953964 once daily or a matching placebo up to Day 14.
9694218|NCT04791293||Group 1|Patients with postoperative complications
9694219|NCT04791293||Group 2|Patients without postoperative complications
9694220|NCT04791579|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
9694221|NCT04791579|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
9694222|NCT04791410||Experimental group|patients who met the inclusion criteria were treated with RVLM decompression at the same time of facial nerve decompression.
9694223|NCT04791410||control group|Patients who met the inclusion criteria were followed up for 3 months before surgery
9694224|NCT04791449|Experimental|Treatment-as-usual plus medically-supervised exercise (TAU-EX)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. Coincident with these appointments, ideally, they will also attend a medically-supervised exercise program supervised by the exercise physiologists of the Cardiac Rehabilitation facility. The exercise sessions will last no more than 1-hr per session. The maximum number of sessions possibly attended over the 12-wk intervention period is 36. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
9694225|NCT04791449|No Intervention|Treat-as-usual (TAU)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
9694226|NCT04791267|Experimental|Intervention|Community health navigator program for six months
9694227|NCT04791267|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program
9694228|NCT04791566|Active Comparator|Intestinal obstruction, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
9694229|NCT04791566|Placebo Comparator|Intestinal obstruction, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
9694230|NCT04791566|Active Comparator|Perforated viscus, Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered preoperatively as an i.v. infusion over 10-15 minutes
9694231|NCT04791566|Placebo Comparator|Perforated viscus, PLACEBO|Physiologic saline, administered preoperatively as an i.v. infusion over 10-15 minutes
9694232|NCT04791306|Experimental|Exercise Training|All participants should increase their physical activity level to at least 150 min per week, guided with once a week supervised in-house training as well as an application for planning and documentation for home-based physical activity
9694233|NCT04791254||A - main study cohort|"This is the main study cohort. All patients with upper gastrointestinal (gastric, oesophageal and gastro-oesophageal) cancers attending the medical oncology clinic and commencing systemic therapy will be invited to participate.~They will receive dietician support as part of their standard treatment. They will undergo assessments of body composition as part of this assessment"
9694234|NCT04791254||Sub-cohort B|This sub-cohort will be invited to undergo more detailed fitness testing in the form of cardio-pulmonary exercise testing in addition to their routine care in the main cohort
9694235|NCT04791254||sub-cohort C|This sub-cohort will be invited to undergo an assessment of gut hormone and cytokine levels in addition to their routine care in the main cohort
9694236|NCT04791254||Cohort D|This is a cohort of healthy volunteers invited to act as a control to cohort C and undergo the gut hormone assessment
9694237|NCT04791475|Experimental|Dexmedetomidne with 0.5% bupivacaine|1mcg/kg dexmedetomidine as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
9694238|NCT04791475|Active Comparator|Dexamethasone with 0.5% bupivacaine|4mg dexamethasone as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
9694239|NCT04791280||patients with systemic sclerosis|"On the day of inclusion, the faeces collection will be carried out by the patient using adapted equipment, either at the hospital or at home. In the case of a home collection, it will be carried out on the day of a planned hospital and preserved using equipment provided and tested to maintain the quality of the collection before storage.~6 months after inclusion (+/- 2 months) a follow-up visit will be carried out and the patient will perform a second faecal sample.~At the inclusion visit and at M6 the UCLA SCTC GIT 2.0 questionnaire will be completed by the patient."
9694240|NCT04791202|Experimental|Dextrose Group|Injection for Group A: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 15% dextrose mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
9820567|NCT02203851|Experimental|Risankizumab 90 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 continued to receive open-label (OL) risankizumab 90 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
9820568|NCT02203851|Experimental|Risankizumab 180 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved <90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 switched to open-label (OL) risankizumab 180 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
9820569|NCT02203916|Experimental|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
9820570|NCT02203916|Experimental|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
9820571|NCT02203916|Placebo Comparator|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
9820572|NCT02204007|Experimental|3D imaging, surrogate bone model|3D imaging & surrogate bone model
9820573|NCT02204007|No Intervention|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
9820574|NCT02204124|Active Comparator|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
9820575|NCT02204124|Experimental|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
9820576|NCT02204150|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
9820577|NCT02204176|Sham Comparator|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
9820578|NCT02204176|Experimental|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
9820579|NCT02204176|Experimental|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
9820580|NCT02204293|Experimental|Canakinumab|Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
9820581|NCT02204293|Placebo Comparator|Placebo|Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
9820582|NCT02204319|Experimental|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
9820583|NCT02204371|Experimental|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
9820584|NCT02204371|Experimental|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
9965735|NCT01252472||Control|Male adult patients scheduled for cataract surgery with no history of Flomax use
9965736|NCT01252498||Radiotherapy|Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
10115354|NCT04450901|Experimental|Cohort B1|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
9820585|NCT02204410|Experimental|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
9820586|NCT02204449|Experimental|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
9820587|NCT02204449|No Intervention|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
9820588|NCT02204566|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
9820589|NCT02204579|Experimental|NPSP795|intravenous
9820590|NCT02204657|Active Comparator|Continuous Glucose Monitoring System|Patients in this arm will receive Continuous Glucose Monitoring System (CGMS) at 28,32 and 36 weeks of gestation and their insulin titrated according to the CGMS results.
9820591|NCT02204657|No Intervention|Control|Patients in this arm will not receive any Continuous Glucose Monitoring System( CGMS) and the insulin titration will be made based on their fingerstick sugar readings.
9820592|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
9820593|NCT02204761|Experimental|Treatment|Proton beam radiation therapy
9820594|NCT02204917|Experimental|Comparative performance of ceVUS & VCUG|Contrast enhanced Voiding Urosonography (ceVUS) will be performed with the intravesical administration of 0.1%-0.5% OPTISON / normal saline solution. The exact OPTISON dose (ml) that will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. Voiding Cystourethrography (VCUG) exam will be subsequently performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
9820595|NCT02204982|Experimental|Duvelisib + Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
9820596|NCT02204982|Placebo Comparator|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
9820597|NCT02205177|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
9820598|NCT02205177|Experimental|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
9820599|NCT02205307|Experimental|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
9820600|NCT02205307|No Intervention|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
9820601|NCT02205333|Experimental|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
9820602|NCT02205333|Experimental|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
9820603|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
9820604|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
9820605|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
9820606|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
9820607|NCT02205333|Experimental|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
9820608|NCT02205333|Experimental|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
9965737|NCT01252511|Active Comparator|long biliopancreatic limb, 75 cm|
10115355|NCT04450901|Experimental|Cohort B2|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 3 weeks (Q3W). Dose: 300 mg"
10115356|NCT04450901|Experimental|Cohort B2 reserve|"Tumor type: Advanced Solid tumor (unresectable, locally advanced, or metastatic and have progressed following all standard treatments or are not suitable for standard treatments).~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 300 mg"
10115357|NCT04450901|Experimental|Cohort B3|"Tumor type: Metastatic NSCLC (Non-small-cell lung carcinoma), unresectable or metastatic, MSI-H (microsatellite instability-high) or dMMR (Deficient MisMatch Repair), recurrent or metastatic HNSCC (Head and neck squamous cell carcinoma), non-clear cell RCC (renal cell carcinoma), aSCC (anal squamous cell carcinoma), uterine cervical cancer, cSCC (cutaneous squamous cell carcinoma of the skin), uterine endometrial carcinoma, TMB-H (high tumor mutation burden) tumors, epithelial tumor of the penis (squamous cell carcinoma or adenocarcinoma), neuroendocrine tumor (any origin, pancreatic or non-pancreatic), and nasopharyngeal cancer.~YBL-006 will be administered once every 2 weeks (Q2W). Dose: 200 mg"
10115358|NCT04450771|Experimental|Family-based Treatment for ARFID(FBT-ARFID)|FBT-ARFID is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior. Early sessions focus on inciting parents to make changes and include a family meal that allows therapists to observe & consult directly to mealtime behaviors. FBT-ARFID for children 12 and under is manualized and consists of 2 phases. The first phase is focused on parents taking charge & changing the eating behaviors of their child that are maintaining ARFID. The second phase focuses on the child taking up in an age-appropriate way managing their eating consistent with the changes the parents have employed in phase 1. Fourteen 1-hour sessions will be conducted approximately weekly over 4 months. Throughout medical monitoring and weekly dietary consultation are available to the family.
10115359|NCT04450771|Active Comparator|Manualized Non-Specific Usual Care for ARFID(NSC)|A manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model that has been used in other RCTs with eating disorders as a comparison. NSC consists of sessions with the child alone and 5 parent-only meetings. Sessions are 1-hour. NSC matches FBT-ARFID for time and therapist attention. The focus of the NSC intervention is psychoeducation about health & social impacts of restrictive eating and supporting parent & child exploration of motivation to change eating patterns & choices they make about changes to eating. The therapist does not initiate behavioral or cognitive interventions. Feelings about eating and making changes are explored in both the child and parent sessions. Medical and dietary advice are provided weekly.
10115360|NCT04450615|Experimental|Training group|"The first part of the program aims in pelvic and hip mobility and includes the following exercises, glute bridge, single-leg glute bridge, side-lying clam, side plank and side plank with hip abduction, on stable surface.~The second part consists of exercises for deep and superficial trunk muscles. In the first exercise the participants learn to activate the transversus abdominis muscle from the crook-lying position, by performing abdominal hollow. Other exercises include the front plank, trunk curl-up, trunk curl-up on stable surface and curl-up on unstable surface (Swiss ball).~The third part of the program consists of exercises for strengthening the lumbar multifidus muscle. The participants will perform prone trunk extension, superman exercise, quadruped diagonal arm and leg lift, single leg supine bridge and supine bridge on unstable surface (Swiss ball)."
10115361|NCT04450615|No Intervention|Control group|The participants of this group will follow their typical daily routine
10115362|NCT04450537|Experimental|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
10115363|NCT04450537|No Intervention|Sun Safety Control|Participants will be exposed 10 sun safety messages
10115364|NCT04450485|Active Comparator|Medial para-patellar approach|Fast track protocol applied total knee arthroplasty patients operated by using medial para-patellar approach
10115365|NCT04450485|Active Comparator|Mini mid-vastus approach|Fast track protocol applied total knee arthroplasty patients operated by using mini mid-vastus approach
9694241|NCT04791202|Active Comparator|Methylprednisolone Acetate Group|Injection for Group B: A 27-gauge needle to be inserted in the 1st CMC joint, at which time 0.5 ml of 40mg methylprednisolone acetate mixed with 0.5 ml of 1% lidocaine solution is injected into intra and peri-articular area.
9965738|NCT01252511|Active Comparator|long Roux limb, 150 cm|
10115366|NCT04450446||cerebral hemorrhage|
10115367|NCT04450446||thromboembolism|
10115368|NCT04450446||no thromboembolism and cerebral hemorrhage|
10115369|NCT04450251||Pregnant women, at least 24 weeks gestation|
10115370|NCT04450160|Placebo Comparator|Standard of Care|Current GBM Treatment of surgery, radiation and chemotherapy with temozolomide.
10115371|NCT04450160|Experimental|AEO with Standard of Care|Anhydrous Enol-Oxaloacetate added to the Standard of Care (surgery, radiation and chemotherapy with temozolomide).
10115372|NCT04450134|Placebo Comparator|Placebo|6 weeks high-intensity interval training + placebo intake
10115373|NCT04450134|Experimental|Blockade|6 weeks high-intensity interval training + histamine H1/H2 receptor blockade
10115374|NCT04450433||Baseline table of patients|
10115375|NCT04450433||Differential metabolites of two groups of control patients|
10115376|NCT04450433||Functional verification of differential metabolites|
10115377|NCT04450056||Mother-infant pairs|Mothers with a term-born (>37 weeks gestation) infant whom they are exclusively or predominantly breastfeeding at 1 month postpartum. Mothers must be enrolled in the MaPPS Trial (ClinicalTrials.gov Identifier: NCT03287882).
10115378|NCT04450030||Intravenous methyl prednisolone|Patients receiving an additional course of intravenous methyl prednisolone for treatment of a steroid-refractory MS relapse
10115379|NCT04450030||Immunoadsorption|Patients receiving 6 courses of immunadsorption treatment for treatment of a steroid-refractory MS relapse
10188045|NCT03720132|Experimental|Patients with port catheter: flushing|In patients with a catheter-related blood stream infection (CRBSI) and a port catheter, being treated with vancomycin intravenously, we will flush the catheter with 30 ml of sodium chloride 0.9 % prior to blood sampling to determine vancomycin concentrations, in order to decrease residuel vancomycin in the port.
10188046|NCT03720106|Other|treatment arm|In this arm the GOAL therapy plan is used.
9965739|NCT01252524|Placebo Comparator|Placebo|A placebo tablet PO TID before each meal with 8 oz of water for 6 months.
9965740|NCT01252524|Experimental|Calcium polycarbophil|Calcium polycarbophil 625 mg PO TID before each meal with 8 oz of water for 6 months
9694242|NCT04791241|Experimental|check-list with ultrasound|check-list including lung ultrasound for the management of patients with acute respiratory failure at the emergency department during the COVID-19 era
10115380|NCT04450420|Experimental|Simulation based curriculum|"Three phases:~Self-study of an eBook - Participating trainees will be required to learn material pertaining to tunnel construction and general surgical principles during SICS from an eBook that has been developed by HelpMeSee.~Instructor led teaching - didactic training, lab activities to gain familiarity with instruments, simulator based training through deliberate practice, and debriefing with instructor.~Instructor supervised performance of surgery on patients in the operating room."
10115381|NCT04450420|Active Comparator|Standard training|Current standard curriculum for resident training.
10115382|NCT04450212|Experimental|Phase I, Buccal Swab Collection for DNA Isolation|Approximately 200 healthy volunteers recruited. They complete a brief demographic survey and a undergo one-time buccal swab for collection of cheek cells for DNA analysis.
10115383|NCT04450212|Experimental|Phase II, Vitamin K (Vitacost) Supplementation|Subjects from Phase I with a homozygous CYP4F2*1 (n=14) or CYP4F2*3 (n=14) genotype are selected to receive daily vitamin K supplementation, for 10-days. Blood and urine samples are collected sequentially, at baseline, and during the supplementation period.
9694243|NCT04790981|Active Comparator|selected physical therapy program group|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
9694244|NCT04790981|Active Comparator|motor imaginary training and selected physical therapy program group|"The study group received the selected physical therapy program for one hour, three times weekly for three successive months in addition to motor imagery program for 30 minutes as the following.~Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise"
9694247|NCT04790838||Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
9694248|NCT04790838||Reference Product|ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK
9694249|NCT04791020|Active Comparator|Lidocaine + paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
9694250|NCT04791020|Experimental|Lidocaine|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied.
9694251|NCT04790942|Experimental|berberine hydrochloride group|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets
9694252|NCT04790942|Placebo Comparator|lifestyle intervention group|Lifestyle intervention group (CON) refers to healthy lifestyle education
9694253|NCT04790825|Experimental|Intensive periodontal treatment|Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia.
9694254|NCT04790825|Active Comparator|Community-based periodontal care|Standard cycle of supragingival mechanical scaling and polishing.
9694255|NCT04791007|Experimental|Single dose administration (Part 1)|the dose of the drug (4g OB-002H (8.0 mg/g)) administrated once vaginally or rectally
9694256|NCT04791007|Experimental|Multidose administration (Part 2)|the dose of the drug (4g OB-002H (8.0 mg/g)) or placebo administered vaginally through five consecutive days
9694257|NCT04791163|Experimental|Sub-ischial socket|Start using the sub-ischial socket for four weeks and be tested with this socket.
9694258|NCT04791163|Active Comparator|Ischial containment socket|Start using the ischial containment socket for four weeks and be tested with this socket.
9694259|NCT04790877|Active Comparator|First sub-study: Glucose beverage|This intervention entails the intake of a beverage including 25 g of glucose.
9694260|NCT04790877|Experimental|First sub-study: Regular alcohol-free beer|This intervention entails the intake of regular alcohol-free beer including 25 of carbohydrates.
9694261|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (isomaltulose + maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 25 g of carbohydrates.
9694262|NCT04790877|Experimental|First sub-study: Alcohol-free beer with modified composition (++ maltodextrin)|This intervention entails the intake of an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 25 g of carbohydrates.
9694263|NCT04790877|Active Comparator|Second sub-study: White bread + Water|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and water.
9694264|NCT04790877|Experimental|Second sub-study: White bread + Regular alcohol-free beer|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and regular alcohol-free beer (providing 14.3 g of carbohydrates).
9694265|NCT04790877|Experimental|Second sub-study: White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin)|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched with isomaltulose (2.5 g/100 mL) and a resistant maltodextrin (0.8 g/100 mL) (IMB). This beverage included 14.3 g of carbohydrates.
9694266|NCT04790877|Experimental|Second sub-study: White bread + Alcohol-free beer enriched with ++ maltodextrin|This intervention entails the intake of white bread (providing 50 g of carbohydrates) and an alcohol-free beer with modified composition in which the maltose has been almost completely eliminated and enriched a resistant maltodextrin (2.0 g/100 mL) (MB). This beverage included 14.3 g of carbohydrates.
9965741|NCT01252537||Initiation of antituberculosis therapy|Patients initiating treatment for tuberculosis with and without HIV co-infection in primary health care centres in Ethiopia
9519378|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
10115384|NCT04450368||Cases with Air Trapping|20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
10115385|NCT04450368||Cases without Air Trapping|20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
10115386|NCT04450368||Healthy Controls|Non COPD patients and non-smokers
10115387|NCT04450264|Other|Breast Cancer Education Program|
10115388|NCT04450017||Clinical Features of Severe Patients With COVID-19|Critical ill patients with COVID-19 admitted to the ICU. The demographic, clinical data, laboratory data, and Instrumental data will be analysed.
10115389|NCT04450082||One anastomosis gastric bypass|One anastomosis gastric bypass in Sleeve Gastrectomy failure
10115390|NCT04450303|Experimental|Telehealth Therapy|
10115391|NCT04450095|Active Comparator|Treated group|Tab. Volibris 10mg given once a day for 5 days, starting 48 hours before surgery (in addition for the standard treatment for partial nephrectomy)
9668194|NCT00358943||Patients in ICGG Gaucher Registry|No experimental intervention is given. A patient with Gaucher Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
9668195|NCT00358943||Pregnant women with confirmed diagnosis of Gaucher disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Gaucher disease who are participating in the ICGG Gaucher Registry and consented to participate in the Gaucher Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy and irrespective of the commercial product with which she may be treated.
9668196|NCT00261456||BRCA1/2 carriers|Carriers of a BRCA1 or BRCA2 mutation.
9668197|NCT00261456||BRCA1/2/non Carriers|Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.
9668198|NCT00080756|Experimental|Group 1 (planned risk reduction mastectomy)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 6 months. Patients then undergo planned risk reduction mastectomy.
9668199|NCT00080756|Active Comparator|Group 2 (continued survaillance)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 10 months. Patients then undergo continued surveillance through 10 months.
9668200|NCT05120856|Experimental|Active AAT-App|Participants will receive the active AAT-App.
9668201|NCT05120856|Sham Comparator|Minimal AAT-App|Participants will receive the minimal version of AAT-App.
9668202|NCT05117385|Experimental|Acerola|"dietary supplement : acerola extract self administrated by mouth for 28 days~1 capsule per day"
9668203|NCT05117385|Experimental|Panax ginseng extract|"dietary supplement : panax ginseng extract self administrated by mouth for 28 days~1 capsule per day"
9668204|NCT05117385|Experimental|Echinacea extract|"dietary supplement : echinacea extract self administrated by mouth for 28 days~1 capsule per day"
9668205|NCT05117385|Experimental|Quillaja extract|"dietary supplement : quillaja extract self administrated by mouth for 28 days~1 capsule per day"
9668206|NCT05117385|Placebo Comparator|Maltodextrin|"dietary supplement : maltodextrin supplement self administrated by mouth for 28 days~1 capsule per day"
9668207|NCT05108974|Experimental|3 months choline bitartrate|Over the 9-month study, participants will receive a total of 3 months of choline bitartrate (19 mg/kg) and a total of 6 months of placebo
9668208|NCT05108974|Experimental|6 months choline bitartrate|Over the 9-month study, participants will receive a total of 6 months of choline bitartrate (19 mg/kg) and a total of 3 months of placebo
9668209|NCT05105139||A1: Allantoin / Coal Tar / Clioquinol (Sebryl®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 5.0 g/ 3.0 g Administration way: For scalp use
10115392|NCT04450095|No Intervention|Control group|Treated with the standard treatment for partial nephrectomy
10115393|NCT04450316|Active Comparator|Low-dose naltrexone|4.5mg of naltrexone to be taken one hour prior to bedtime nightly for 8 weeks.
10115394|NCT04450316|Placebo Comparator|Placebo|Placebo tablet (sugar-pill) to be taken one hour prior to bedtime nightly for 8 weeks.
10115395|NCT04450121|Active Comparator|GA (n =22)|Patients will be intubated using Air-Q airway
10115396|NCT04450121|Active Comparator|GF (n =22)|Patients will be intubated using Fekry airway
10115397|NCT04450290|Experimental|single arm - treatment|All subjects will be implanted with the investigational device.
10115398|NCT04450186|Experimental|EEG/fMRI neurofeedback|Healthy volunteers
10115399|NCT04449965|Experimental|PVP-I sinus rinses and throat gargles|Participants will dilute 7 mL of 10% PVP-I into 300 mL of saline for a final concentration of 0.23% available iodine. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
10115400|NCT04449965|Placebo Comparator|Placebo sinus rinses and throat gargles|Participants will dilute 7 mL of PVP-I placebo into 300 mL of saline. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
10115401|NCT04449965|Experimental|PVP-I gel forming nasal spray|0.6% PVP-I gel forming nasal spray will come prepared and ready for participants to use. They will be instructed to use two sprays to each nostril each time they administer the spray.
10115402|NCT04449991|Experimental|Intervention arm: Repeat kidney biopsy at M12|Patients will undergo repeat kidney biopsy at month 12 from baseline.
10115403|NCT04449991|No Intervention|Control arm: No repeat kidney biopsy|Patients will not undergo repeat kidney biopsy at month 12 from baseline.
10115404|NCT04450342|Experimental|ARCR augmented with REGENETEN™ Bioinductive Implant|During the ARCR procedure, the REGENETEN™ Bioinductive Implant is covering the tendon and attached to the bone and the tendon with small anchors.
10115405|NCT04450342|Sham Comparator|ARCR alone|The rotator cuff is repaired during arthoscopic standard procedure. No product is added for healing
10115406|NCT04450342|Other|ARCR revision group|ARCR revision group allows treatment of subjects having recurrent tears, ARCR supplemented with REGENETEN
9820609|NCT02205333|Experimental|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
9820610|NCT02205476|Experimental|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
9820611|NCT02205476|Experimental|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
9820612|NCT02205801|Active Comparator|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
9820613|NCT02205801|Placebo Comparator|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
9820614|NCT02205801|Active Comparator|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
9820615|NCT02205801|Placebo Comparator|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
9820616|NCT02205814|Experimental|Fasitibant low dose|Drug: solution for intra-articular injection
9820617|NCT02205814|Experimental|Fasitibant intermediate dose|Drug: solution for intra-articular injection
9820618|NCT02205814|Experimental|Fasitibant high dose|Drug: solution for intra-articular injection
9820619|NCT02205814|Placebo Comparator|PLACEBO|Drug: solution for intra-articular injection
9820620|NCT02205983|Experimental|2 mg hydromophone|Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
9820621|NCT02205983|Experimental|4 mg hydromphone|Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
9820622|NCT02205983|Experimental|1000 mg acetaminophen|Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
9820623|NCT02205983|Placebo Comparator|Dextrose|Healthy adult volunteers will recieve Dextrose (placebo).
9820624|NCT02206061|Experimental|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
9820625|NCT02206061|Active Comparator|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
9820626|NCT02206061|Active Comparator|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
9820627|NCT02206152|Placebo Comparator|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
9820628|NCT02206152|Experimental|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
9820629|NCT02206217|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
9820630|NCT02206217|Experimental|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
9820631|NCT02206607|Experimental|PF-04937319 IR MST|Reference formulation
9820632|NCT02206607|Experimental|PF-04937319 MR 1|Test MR #1
9820633|NCT02206607|Experimental|PF-04937319 MR 2|Test MR #2
9820634|NCT02206607|Experimental|PF-04937319 MR 3|Test MR #3
9820635|NCT02206620|Experimental|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
9820636|NCT02206620|Placebo Comparator|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
9820637|NCT02206685|Active Comparator|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
9820638|NCT02206685|Placebo Comparator|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
9820639|NCT02206776|Placebo Comparator|Midazolam|A single dose of intranasal midazolam up to 4 mg
9820640|NCT02206776|Experimental|Ketamine|A single dose of intranasal ketamine up to 50 mg
9820641|NCT02206828||1 GROUP|Only 1 group not predetermined
9820642|NCT02207088|Experimental|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily [QD] and dasabuvir 250 mg twice daily [BID]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
9820643|NCT02207231|Experimental|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
9820644|NCT02207231|Placebo Comparator|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
9820645|NCT02207231|Active Comparator|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
9820646|NCT02207244|Experimental|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab [two 0.8 milliliter (mL) injections] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
9820647|NCT02207244|Placebo Comparator|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
9820648|NCT02207244|Active Comparator|Group III|Participants will receive adalimumab 80 mg (two 40 mg [0.8 mL] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
9820649|NCT02207322|No Intervention|Standard transplant care|"Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)~-- Complete baseline data collection, and registration~Patient Randomization~Standard transplant oncology care~-- Palliative care consults only upon request~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
9820650|NCT02207322|Experimental|transplant with early palliative care|"Standard transplant oncology care with early palliative care~Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)~--Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
9820651|NCT02207374|Experimental|Semaglutide 0.5 mg|
9820652|NCT02207374|Experimental|Semaglutide 1.0 mg|
9820653|NCT02207374|Active Comparator|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
9820654|NCT02207400|Experimental|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
9820655|NCT02207400|Active Comparator|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
9820656|NCT02207413|Experimental|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
9820657|NCT02207413|Active Comparator|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
9820658|NCT02207413|Experimental|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
10115407|NCT04449952|Experimental|AFEO-Containing Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive AFEO-containing mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 milliliter (mL) of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
9668210|NCT05105139||A2: Allantoin/ Coal Tar/ Clioquinol/ Triclosan (Sebryl Plus®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 3.0 g/ 3.0 g/ 0.3 g Administration way: For scalp use
9519379|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
9668211|NCT05103215|Experimental|lidocaine group|Patients in the lidocaine group receive an intravenous injection of 1.5 mg/kg Lidocaine HCl 2% at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
10115408|NCT04449952|Experimental|Listerine Cool Mint Mouth Rinse (Marketed product)|Participants with Diabetes (Type 1 and 2) will be randomized to receive Listerine cool mint mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
10115409|NCT04449952|Experimental|5 Percent (%) Hydroalcohol Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive 5% Hydroalcohol mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
9668212|NCT05103215|Placebo Comparator|control group|Patients in control group receive the same volume of saline injection.
9694267|NCT04790877|Active Comparator|Second sub-study: Extra-White bread + Water|This intervention entails the intake of white bread which provides 64.3 g (50 g + 14.3 g) of carbohydrates and water. This intervention would be the comparator in carbohydrates-equally conditions.
9694268|NCT04791072|Experimental|Telecoaching group|They will be given breathing exercise training and will be asked to do it every day for 8 weeks. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. They will be called by phone once a week and encouraging speeches will be made.
9694269|NCT04791072|Active Comparator|Control Group|They will be given breathing exercise training and will be asked to do it every day. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. There will be no interviews in the control group.
9694270|NCT04791098|Experimental|Stronger pre-transplant check-up|routine patient management + specific infectious diseases consultation
9694271|NCT04791098|No Intervention|Standard pre-transplant check-up|routine patient management + letter sent to nephrologist
9694272|NCT04791085||general surgeons|General surgeons who work at general or private hospitals in Greece
9694273|NCT04790812|Placebo Comparator|Celecoxib plus Placebo|Single oral dose of celecoxib 200 mg with placebo 30 to 60 minutes prior to the dental procedure
9694274|NCT04790812|Active Comparator|Celecoxib plus Acetaminophen|Single oral dose of celecoxib 200 mg in combination with acetaminophen 1000 mg 30 to 60 minutes prior to the dental procedure.
9694275|NCT04791150|Experimental|Patient with cancer immunotherapy treatment|All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment.
9694276|NCT04790929|Experimental|Regular Muse Meditation System - No Coaching|Participants will join a 1.5-hour virtual onboarding session where they will complete their first Muse session. Participants will then be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks. If they wish to use the system more frequently within the 6 weeks, they will be encouraged to do so and will be able to choose between all the styles of meditation available in the Muse Meditation System (Mind, Heart, Breath, Body, Guided or Sleep Journeys). For any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
9694277|NCT04790929|Experimental|Regular Muse Meditation System - Additional Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 8 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
9694278|NCT04790929|No Intervention|Controls|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery, plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness, anxiety and depression and sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
9694279|NCT04791124||Typical Developing Subjects|EEG evaluation of typical developing subjects
9694280|NCT04791124||Down Syndrome Subjects|EEG evaluation of DS subjects
9694281|NCT04790799|Experimental|Intervention group|Treatment in a hospital setting at Gentofte Hospital skin department with patient education, glove counselling, personal product screening by a chemistry engineer, extended allergy testing and the standard treatment of hand eczema.
9694282|NCT04790799|No Intervention|Control group|Treatment as usual (at a dermatologist office).
9694283|NCT04791189||Patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Major male or female patient [18 to 45 years of age] with juvenile idiopathic arthritis reported before the age of 16.~- Able to understand and complete the questionnaire online (speaking and reading French, with an internet connection for completion via RedCap°). ¬~- Able to give informed consent to participate~- Involving one's parents in the survey is not a prerequisite for inclusion."
9694284|NCT04791189||Parents of patients with juvenile rheumatoid arthritis aged from 18 to 45 years|"Parents of adult patients with JIA~- Parents able to understand and complete the questionnaire online (speaking and reading French, having an internet connection for completion via Red Cap°).~- Able to give informed consent to participate~- The parents must have been in charge of the patient as a teenager."
9694285|NCT04791046||By CDSS (MedicBK) Analysis|
9820659|NCT02207413|Active Comparator|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
9820660|NCT02207413|Experimental|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
9820661|NCT02207413|Active Comparator|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
9965742|NCT01252550|Active Comparator|Activia®|Activia® (125g/pot)
9965743|NCT01252550|Placebo Comparator|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
10115410|NCT04449887|Experimental|The treatment group|The subjects in this group were treated with Xiangsha Liujunzi granule for 4 weeks
10115411|NCT04449939|Experimental|Group 1|Single dose of KY1005 by i.v. infusion
10115412|NCT04449939|Experimental|Group 2|Single lower dose KY1005 by s.c. injection
10115413|NCT04449939|Experimental|Group 3|Single higher dose KY1005 by s.c. injections
10115414|NCT04449757|Experimental|bicarbonated ringer's solution|We apply bicarbonated ringer's solution as resuscitation fluid to patients with septic shock.
10115415|NCT04449757|Experimental|lactated ringer's solution|We apply lactated ringer's solution as resuscitation fluid to patients with septic shock.
10115416|NCT04449848|Experimental|Sitting after intra tympanic injection|Patients with Sudden hearing loss sitting after intra tympanic injection of steroids
9694286|NCT04791046||General practice|
9694287|NCT04790760|Experimental|Continuous Glucose Monitoring|Participants will wear a CGM device on the back of both their left and right arm for 6 weeks.
9694288|NCT04790747|Experimental|radiotherapy and CAR-T therapy|sequential radiotherapy and CAR-T cell therapy
9694289|NCT04790734|Experimental|Remimazolam Besylate|"Remimazolam continuous infusion of 0.1 to 0.2 mg/kg/h to reach a RASS score of -3 to 0.~remifentanil continuous infusion of 4 to 9 ug/kg/h to reach a CPOT score of 0 to 2.~The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician."
9694290|NCT04790734|Active Comparator|Propofol|"Propofol continuous infusion of 0.5 to 4 mg/kg/h to reach a RASS score of -3 to 0.~remifentanil continuous infusion of 4 to 9 ug/kg/h to reach a CPOT score of 0 to 2.~The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician."
9694291|NCT04790500|Active Comparator|Group A|mobilization technique
9694292|NCT04790500|Experimental|Group B|muscle energy technique
9694293|NCT04790383|Experimental|Advanced Self-Adhesive resin composite hybrid restorations|(Surefil one (Dentsply Sirona)).
9694294|NCT04790383|Active Comparator|Conventional resin composite restoration.|Sphere Tec, (Dentsply Sirona)
9694295|NCT04790461|Experimental|1. experimental group: face to face education+PMR exercise|The education and PMR exercises prepared in line with the face-to-face Roy adaptation model will be applied. In groups of 8-10 people, the first 4 sessions in rehabilitation centers will last for the first 4 sessions, and then PMR exercises will be taught and applied (between the 2nd and the 5th weeks, they will be encouraged to do PGE twice at home). The next 4 weeks will be provided with PMR consultancy (3 times a week application / total 24 sessions of PMR application). PMR exercises will be given a follow-up schedule and the caregivers will be followed up by the caregivers themselves and the researchers.
9694296|NCT04790461|Experimental|2. experimental group: mobile health education + PMR exercise|Access to mobile applications will be provided for 8 weeks, including the Roy adaptation model-based training and PMR exercises, which include video and training presentations prepared by the consultant and researcher, as a power point presentation. PMR exercises will be uploaded to the system by uploading a follow-up schedule to the system, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers can follow the participants.
9694297|NCT04790461|Experimental|3rd experimental group: face to face and mobile health education + PMR exercise|4 sessions prepared in line with the Roy adaptation model face to face and held in rehabilitation centers, training in groups of 8-10 people, teaching PMR exercises and installing phone applications that can be accessed for 8 weeks), 8-week intervention including training (enabling them to do progressive relaxation exercises and access to training content) will be provided. . The PMR exercises will be uploaded to the system / given as a printout according to the caregiver's preference, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers watch the participant.
9694298|NCT04790461|Other|Control group|Without applying any intervention, the post-test YBYKA, ASÖ and SBÇYA scales will be applied in the 10th week of the study. After all the tests for the study are measured and finished, they will be provided with training and relaxation exercises.
9694299|NCT04790422|Experimental|Dietary fiber 1|
9694300|NCT04790422|Experimental|Dietary fiber 2|
9694301|NCT04790422|Experimental|dietary fiber 3|
9694302|NCT04790422|Experimental|caseine protein hydrolisate|
9694303|NCT04790422|Placebo Comparator|Maltodextrine|
9820662|NCT02207478|Experimental|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
9820663|NCT02207478|Active Comparator|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
9820664|NCT02207491|Experimental|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
9820665|NCT02207491|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
9820666|NCT02207530|Experimental|MEDI4736|MEDI4736 monotherapy
9820667|NCT02207556|Experimental|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
9820668|NCT02207569|Experimental|CoreValve Evolut R TAVR system|"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:~Evolut R Transcatheter Aortic Valve (TAV)~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~EnVeo R Loading System (LS)"
9820669|NCT02207608|Active Comparator|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
9820670|NCT02207608|Experimental|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
9820671|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
9820672|NCT02207621|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
10115417|NCT04449822|Active Comparator|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
10115418|NCT04449822|Active Comparator|Colonic stenting|The colonic stent placement
10115419|NCT04449718|Experimental|Experimental|Patients will receive 200,000 IU of vitamin D3 on admission + conventional care
10115420|NCT04449718|Placebo Comparator|Placebo|Patients will receive an equivalent amount of a placebo solution on admission + conventional care
10115421|NCT04449809|Experimental|Exercise|Exercise program
10115422|NCT04449783||study patients|Patients undergoing elective cancer surgery, who will receive pre-operative screening including reporting symptoms and nose and throat swabbing 48 hours prior to surgery
9820673|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
9820674|NCT02207634|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
10115423|NCT04449601||Group 1 (with hypertension )|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
10115424|NCT04449601||Group 2( without hypertension)|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
10115425|NCT04449666||Experimental group|Patients undergoing neurological rehabilitation after aneurysmal subarachnoid hemorrhage
10115426|NCT04449666||Control group|Healthy adults controlled for age, gender and educational status
10115427|NCT04449692|Experimental|80 µg s.c. dasiglucagon|80 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
10115428|NCT04449692|Experimental|120 µg s.c. dasiglucagon|120 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
10115429|NCT04449692|Active Comparator|15 g oral carbohydrate (dextrose tablets)|15 g of oral carbohydrate (dextrose tablets) will be administered when plasma glucose levels reach 4.5 mmol/l
10115430|NCT04450147|Experimental|Tai Chi and Qigong|50mins x 12 weeks of virtually-delivered group tai chi/qigong
10115431|NCT04450147|Active Comparator|Walking and Stretching|50mins x 12 weeks of virtually-delivered group walking and stretching
10115432|NCT04450199|Active Comparator|Vitamin D|12 over encapsulated 50,000 IU Vitamin D2
10115433|NCT04450199|Placebo Comparator|Placebo|12 over encapsulated placebo tablets
10115434|NCT04450355|Experimental|Nefopam group|At the end of induction, the nefopam group will receive intravenous nefopam 20mg mixed with 50ml of normal saline, and at the end of surgery, this group will receive intravenous nefopam 60mg mixed with 50ml of normal saline at a rate of 2ml/hr.
10115435|NCT04450355|Placebo Comparator|Control group|The control group will receive intravenous normal saline 50ml at the end of induction and receive intravenous normal saline 50ml at a rate of 2ml/hr at the end of surgery.
10115436|NCT04449900||The exudative CCH group|Treatment naïve patients with exudative CCH which caused subfoveal retinal detachment and/or intraretinal fluid
10115437|NCT04449900||The healthy eye control group|In the healthy eye control group, all eyes should have no ocular diseases and the best-corrected visual acuity (BCVA) should be 20/20 or better.
10115438|NCT04449640||Uterine rupture|Women who had uterine rupture during pregnancy.
10188047|NCT03720080||670G/OpenAPS|Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.
9694304|NCT04790708|Experimental|Midgut NETs|75 patients affected by non-functional and functional NETs arising from: stomach, duodenum, jejunum, ileum, colon and rectum.
9694305|NCT04790708|Experimental|Pancreatic NETs|75 patients affected by non-functional and functional NETs arising from Pancreas.
9694306|NCT04790708|Experimental|Bronchial NETs|25 patients affected by non-functional and functional Bronchial NETs.
9694307|NCT04790708|Experimental|Sympathetic-Adrenergic axis NEts|25 patients affected by non-functional and functional: Pheochromocytoma, Paraganglioma and Neuroblastoma
9694308|NCT04790708|Experimental|Other Nets|25 patients affected by non-functional and functional NETs arising from Skin, Thyroid (medullary thyroid and anaplastic cancer) and Parathyroids.
10115439|NCT04449653||Lupus Cases|Individuals who are diagnosed with System Lupus Erythematosus and consent to the study will be placed in this cohort. Upon enrollment they will be given the opportunity to invite a non-SLE-diagnosed friend to enroll in the study as a healthy control. These individuals will answer weekly questions and receive a smartwatch to measure their physical activity.
9820675|NCT02207634|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
9820676|NCT02207725|Experimental|Andexanet|Andexanet (antidote)
9820677|NCT02207725|Placebo Comparator|Placebo|Placebo
9820678|NCT02207803|Experimental|Intervention|Experimental Transition Assistance Program
10115440|NCT04449497||Bereaved caregivers|Caregivers who, in the past two years,have lost a family member or close friend after a brief or extended period of illness or injury
10115441|NCT04449497||Country experts|Qualified individuals (providers, palliative care experts, policy makers) from countries across the globe with knowledge of the phenomenon of interest-end-of-life care.
9820679|NCT02207803|No Intervention|Control|Control
9820680|NCT02207816|Experimental|GSK257049 Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
9820681|NCT02207816|Active Comparator|GSK257049 Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
9820682|NCT02207816|Active Comparator|VeroRab/Menjugate Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
9820683|NCT02207829|Experimental|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
9820684|NCT02207829|Active Comparator|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
9820685|NCT02207907|Experimental|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
9820686|NCT02207907|Active Comparator|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
9820687|NCT02207946|Experimental|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
9820688|NCT02207946|Placebo Comparator|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
9820689|NCT02207972|Active Comparator|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
9820690|NCT02207972|Active Comparator|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
9820691|NCT02208037|Experimental|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
9820692|NCT02208037|Experimental|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
10115442|NCT04449419||very severe COPD|Patients diagnosed with COPD and FEV1 less than 30
10115443|NCT04449419||Severe COPD|Patients diagnosed with COPD and FEV1 less than 50
10115444|NCT04449419||Moderate COPD|Patients diagnosed with COPD and FEV1 less than 80
10115445|NCT04449419||Mild COPD|Patients diagnosed with COPD and FEV1 80 or more.
9820693|NCT02208037|Experimental|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
9820694|NCT02208050|Other|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
9820695|NCT02208050|Other|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
9820696|NCT02208063|Experimental|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
10115446|NCT04449419||CONTROL|Non-copd control group
10115447|NCT04449419||Exacerbated Patients|Patients 48 hours after hospital admission for COPD exacerbation.
9820697|NCT02208063|Active Comparator|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
9820698|NCT02208089|Experimental|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
9820699|NCT02208089|Active Comparator|CXL only|Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
9820700|NCT02208297|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
9820701|NCT02208297|Placebo Comparator|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
9826989|NCT02440568|Experimental|Cohort 1: Omacetaxine at Dose level at 0.625mg/m^2|Patients will receive Omacetaxine at Dose level 0.625mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
9826990|NCT02440568|Experimental|Cohort 2: Omacetaxine at Dose level at 1.25mg/m^|Patients will receive Omacetaxine at Dose level 1.25mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
9826991|NCT02440568|Experimental|Cohort 3: Omacetaxine at Dose level at 2.0mg/m^|Patients will receive Omacetaxine at Dose level 2.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
9826992|NCT02440568|Experimental|Cohort 4: Omacetaxine at Dose level at 3.0mg/m^|Patients will receive Omacetaxine at Dose level 3.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
9826993|NCT02440594|Experimental|Enhanced Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
9826994|NCT02440594|Active Comparator|Standard Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
9826995|NCT02440594|Experimental|Enhanced Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Enhanced BHL Program Services, which for this group include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Monitoring via a one-time BHP follow-up call with the enrollee after 6 weeks to discuss continuing versus discontinuing the medication.
9826996|NCT02440594|Active Comparator|Standard Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
9827636|NCT02462720|Experimental|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
9965744|NCT01252576||women with and without sexual dysfunction|women with and without female sexual dysfunction
9820702|NCT02208310|Active Comparator|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. <-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
9820703|NCT02208310|Experimental|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. <-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if <50 ng/ml, a 30 day course will be administered.
9820704|NCT02208349|Experimental|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
9820705|NCT02208349|Active Comparator|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
9820706|NCT02208466|Experimental|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
9820707|NCT02208466|Experimental|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
9820708|NCT02208466|Experimental|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
9820709|NCT02208843|Experimental|Afatinib|Afatinib tablet once daily until progression
9820710|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
9820711|NCT02209064|Other|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
9820712|NCT02209181|Experimental|JNJ-10450232 250 mg|
9820713|NCT02209181|Experimental|JNJ-10450232 1000 mg|
9820714|NCT02209181|Placebo Comparator|Placebo|
9820715|NCT02209181|Active Comparator|Acetaminophen 1000 mg|
9820716|NCT02209259|Experimental|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
9820717|NCT02209259|Experimental|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
9820718|NCT02209259|Experimental|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
9820719|NCT02209272|Experimental|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
9820720|NCT02209272|Active Comparator|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
9820721|NCT02209454|Other|Enantyum® oral solution|25mg DKP.TRIS oral solution
9820722|NCT02209454|Other|Keral® tablet|25mg DKP.TRIS tablet
9820723|NCT02209506|Experimental|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
9820724|NCT02209506|Experimental|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
9820725|NCT02209506|Experimental|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
9820726|NCT02209506|Experimental|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
9820727|NCT02209506|Experimental|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
9820728|NCT02209506|Experimental|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
9820729|NCT02209506|Experimental|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
9965745|NCT01252589||Adults with CML|Adult patients (18 years of age or older) with confirmed diagnosis of CML
9820730|NCT02209506|Experimental|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
9820731|NCT02209506|Experimental|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
9820732|NCT02209506|Experimental|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
9820733|NCT02209519|Experimental|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
9820734|NCT02209519|Placebo Comparator|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
9820735|NCT02209532|Active Comparator|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
9519380|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
9820736|NCT02209532|Active Comparator|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
9820737|NCT02209597|Experimental|StudyArm|"Subjects will be studied for 28 weeks in a sequential cross-over study: a~Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
9820738|NCT02209610|Other|Patients With Heart Failure: Neuromuscular Abnormalities|Patients with Heart Failure
9820739|NCT02209610|Other|Health Control Subjects and Neuromuscular Function|Health Control Subjects
9820740|NCT02209766|Experimental|D5884|D5884 capsule, Per oral(po)
9820741|NCT02209766|Placebo Comparator|Placebo|Placebo capsule, po
9820742|NCT02209948|Experimental|Temozolomide|Those patients will take 6 additional Temozolomide cycles
9820743|NCT02209948|No Intervention|Without treatment|
9820744|NCT02210000|Placebo Comparator|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
9820745|NCT02210000|Experimental|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
9820746|NCT02210039|Experimental|SECM Probe Imaging|SECM probe will be guided to a pre-determined length in the esophagus and spiral imaging will be performed using the SECM Imaging System.
9820747|NCT02210052|Experimental|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
9820748|NCT02210065|Experimental|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
9820749|NCT02210091|Experimental|<6 years old|
9519381|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
9519382|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
9519383|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
9519384|NCT03287661|Experimental|Treatment Condition|An Online 8-week Acceptance-based Behavioural Therapy for chronic pain.
9519385|NCT03287661|No Intervention|Wait-list Control Condition|Wait-list Control group (8-weeks)
9519386|NCT03287609|Active Comparator|Evolocumab|Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
9519387|NCT03287609|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
9668213|NCT05094258|Active Comparator|mobile insert|Unicondylar knee arthroplasty with mobile insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
9820750|NCT02210091|Experimental|≥6 to <12 years|
9820751|NCT02210195|Active Comparator|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
9820752|NCT02210195|Placebo Comparator|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
9820753|NCT02210208|Experimental|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
9820754|NCT02210208|Experimental|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
9820755|NCT02210247|Active Comparator|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
9820756|NCT02210247|Active Comparator|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
9820757|NCT02210247|Active Comparator|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
9820758|NCT02210247|Active Comparator|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
9820759|NCT02210247|Active Comparator|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
9820760|NCT02210286|Experimental|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
9820761|NCT02210689|Experimental|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
9820762|NCT02210689|Active Comparator|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
9820763|NCT02210689|Placebo Comparator|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
9820764|NCT02210780|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
9820765|NCT02210780|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
9820766|NCT02211014|Experimental|Cohort 1|Acalabrutinib 100 mg twice daily (bid) continuously
9820767|NCT02211014|Experimental|Cohort 2|Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
9820768|NCT02211261|Experimental|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
9820769|NCT02211261|Experimental|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
9820770|NCT02211261|Experimental|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
9820771|NCT02211261|Experimental|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
9820772|NCT02211261|Experimental|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
9820773|NCT02211261|Experimental|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
9820774|NCT02211261|Experimental|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
9820775|NCT02211261|Experimental|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
9820776|NCT02211261|Experimental|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
9820777|NCT02211313|Active Comparator|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
9820778|NCT02211313|Active Comparator|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
9820779|NCT02211456|Experimental|Participants|Having an ablation procedure with access to the left side of the heart
9820780|NCT02211495|Active Comparator|No device|Treated with best medical therapy
9820781|NCT02211495|Experimental|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
9820782|NCT02211534|Active Comparator|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
9820783|NCT02211534|Sham Comparator|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
9820784|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
9820785|NCT02212028|Experimental|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
9820786|NCT02212028|Active Comparator|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
9820787|NCT02212106|Experimental|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
9820788|NCT02212106|Active Comparator|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
9820789|NCT02212197|Experimental|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
9820790|NCT02212197|Experimental|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
9820791|NCT02212197|Active Comparator|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
9820792|NCT02212301|Active Comparator|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
9820793|NCT02212301|Active Comparator|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
9820794|NCT02212379|Experimental|raltegravir and etravirine|
9820795|NCT02212457|Experimental|rMenB_0_2 Group|Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
9820796|NCT02212457|Experimental|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
9820797|NCT02212457|Experimental|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
9965746|NCT01252602||Prenatally depressed|Women who tested positive for prenatal depression with a score of > 12 on the Edinburgh Postnatal Depression Scale
9820798|NCT02212457|Experimental|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
9820799|NCT02212457|Experimental|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
9820800|NCT02212457|Experimental|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
9820801|NCT02212587|Experimental|TOBI Podhaler|
9820802|NCT02212678|Experimental|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
9820803|NCT02212730|Experimental|Neoadjuvant Pembrolizumab + RCC Resection|Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
9820804|NCT02212730|Experimental|RCC Resection|Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.
9820805|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
9820806|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
9820807|NCT02212977|Active Comparator|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
9820808|NCT02212977|Experimental|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
9820809|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
9820810|NCT02213042|Active Comparator|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.
9820811|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
9820812|NCT02213055|Experimental|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
9820813|NCT02213055|Active Comparator|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
9820814|NCT02213068|Experimental|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 40-60% of the previous dose Day 21 (~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue~MPA: administered according to SOC"
9820815|NCT02213068|Active Comparator|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 10% of the previous dose Day 21 (~ 3 weeks into study): 20% of the previous dose Day 30 (~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
9820816|NCT02213068|Other|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
9820817|NCT02213094|Experimental|Nicotinamide 500 mg|Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
9820818|NCT02213094|Experimental|Nicotinamide 1000 mg|Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
9965747|NCT01252602||Not Prenatally Depressed|Women who tested not depressed on the prenatal depression scale with a score < 13
10115448|NCT04449679|Experimental|Health Services Research (RT-CAMSS)|Patients receive RT-CAMSS over 2 months or until chemotherapy is discontinued, whichever is earlier. RT-CAMSS consists of text messages addressing knowledge about specific cancer type and chemotherapy, side-effect prevention, suggestions of lifestyle behavioral changes and emotional support, and preparation for surgery. Patients then record their symptoms through answering a series of questionnaires and receive tailored feedback according to their answers, including a consultation with a nurse.
10115449|NCT04449614||1|"Inclusion criteria: All consenting Infants and children who have had A Congenital Pulmonary Airway Malformation (CPAM) surgically removed by thoracoscopy over a 10 year period (2008-2017) in a regional centre.~Exclusion criteria: Non consenting participants"
10115450|NCT04449627||Naturalistic cohort|Patients who were hospitalised between March and June from Covid19, who did not require treatment in intensive care, who at 8 weeks post discharge have symptoms of anxiety or depression. All patients are offered access to an audio based self help programme based on applied relaxation and mindfulness based cognitive therapy.
10115451|NCT04449536|Experimental|Mesna|Administration of a single oral dose of 400 mg, 800 mg, 1200 mg or 1600 mg
9519388|NCT03287570|Experimental|Cettum (Electric moxibustion)|The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
9668214|NCT05094258|Active Comparator|fixed insert|Unicondylar knee arthroplasty with fixed insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
9668215|NCT05089396|Active Comparator|conventional dentally anchored maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch). a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
9668216|NCT05089396|Experimental|skeletally anchored maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in addition, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
9668217|NCT05086341|Experimental|My COPD|In addition to usual care, participants in the intervention group will receive a 12-week, twice a week, physiotherapist-supported individualized exercise program and physical activity plan via the eHealth tool My COPD.
9668218|NCT05086341|No Intervention|Usual care|Participants in the control group will receive usual care only. Usual care is recommended to include, but not restricted to, long-acting anticholinergics and long-acting ß2-antagonists with 24-hour duration and support for smoking cessation, PA and exercise, self-management and nutrition.
9668219|NCT05076994|Experimental|Patient Education Tool|
9668220|NCT05076994|Active Comparator|Standard Care|
9668221|NCT05075005|Active Comparator|Treatment Cohort|Treatment Cohort: Will utilize a minimalist shoe (Vibram® Fivefingers) and follow the training protocol described below for training on natural terrain.
9668222|NCT05075005|Experimental|Control Cohort|Control Cohort: Will utilize the same minimalist shoe and follow the same training schedule as the treatment group, with the modification of training on hardscapes.
9668223|NCT05060874||single group|gripwise or jamar will be randomly assessed first
9668224|NCT05047783|Experimental|Masitinib 3.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo (all patients will receive Best Supportive Care)
9668225|NCT05047783|Experimental|Masitinib 4.5 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding placebo (all patients will receive Best Supportive Care)
9668226|NCT05047783|Experimental|Masitinib 6.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for 6 days versus corresponding placebo (all patients will receive Best Supportive Care)
9668227|NCT05047783|Placebo Comparator|Placebo|Placebo arms associated with the three Experimental arms (all patients will receive Best Supportive Care) which will be pooled for analysis
9668228|NCT05042700|Experimental|Melatonin-Placebo sequence|50% of the included patients will receive 4 weeks of treatment with melatonin, followed by a 4 week wash out period, and then 4 weeks of treatment with placebo. The treatments are blinded.
9668229|NCT05042700|Experimental|Placebo-Melatonin sequence|50% of the included patients will receive 4 weeks of treatment with placebo, followed by a 4 week wash out period, and then 4 weeks of treatment with melatonin. The treatments are blinded.
9668230|NCT05036928||HIV infection group|
9668231|NCT05033483|Experimental|Iron Supplement|65.7 mg of iron as ferrous fumarate
9668232|NCT05033483|Active Comparator|Placebo|0 mg of iron
9668233|NCT05032755|Experimental|VLNC Group|Participants in this condition will be provided with Spectrum NRC102/103 (nonmenthol/menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco with reported nicotine yield (ISO) of 0.03 +/- 0.01 mg and a tar yield of 9 +/- 1.5. Participants will be asked to smoke only study cigarettes for 4 weeks.
9668234|NCT05032755|Active Comparator|NNC Group|Participants in this condition will be provided with Spectrum NRC600/601 (non-menthol/menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco with reported nicotine yield (ISO) of 0.8 +/- 0.15 mg and a tar yield of 10.5 +/- 1.5.
9668235|NCT05030896|Experimental|Experimental group|Participants will receive EPM and they will perform exercise program during 1 month.
9668236|NCT05030896|Experimental|Control group|Participants will receive needling puncture and they will perform exercise program during 1 month.
9668237|NCT05021328|Experimental|Anlotinib combined with SBRT|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Toripalimab 240mg iv drip D1 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
9668238|NCT05021328|Experimental|Anlotinib combined with SBRT and Toripalimab|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
9668239|NCT05015608|Experimental|Savolitinib + Osimertinib|Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks)
9668240|NCT05015608|Active Comparator|Pemetrexed combined with platinum|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
9668241|NCT05009836|Experimental|Savolitinib|Savolitinib 600 mg or 400 mg QD orally +Osimertinib 80 mg QD orally ( every 3 weeks)
9965748|NCT01252615|Experimental|patient only|Patient with the ICD is involved in the intervention
10115452|NCT04449198|Experimental|Individuals with type 1 diabetes|Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)
10115453|NCT04449198|No Intervention|Healthy Controls|Healthy individuals who participate will receive no intervention and serve as controls.
10115454|NCT04449224||RA patients who start bDMARD|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a biologic disease modifying antirheumatic drug (bDMARD) including Adalimuab, Etanercept, Tocilizumab or Abatacept after shared-decision making.
10115455|NCT04449224||RA patients who start small molecule inhibitor|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a small molecular inhibitor including Tofacitinib or Baricitinib after shared-decision making.
10115456|NCT04449159|Placebo Comparator|Placebo|
10115457|NCT04449159|Experimental|Vinh Wellness Collagen|
10115458|NCT04449575||Health care workers with hand eczema|Swabs will be taken from eczema lesions on dominating hand (if possible) and nostril
10115459|NCT04449575||controls (health care workers without hand eczema)|swabs will be taken from healthy skin on dominating hand and nostril
10115460|NCT04449107|Experimental|Intervention Arm|The intervention arm in addition to the standard counselling will include receiving text messages, voice messages, pictorial messages and video messages regarding vaccination once a week till the child turns 14 weeks
10115461|NCT04449107|No Intervention|Control Arm|The control group will receive one-time standard verbal counselling at the time of initial visit for on-time EPI vaccines at 10 and 14 weeks of age as recommended by EPI, government of Pakistan.
10115462|NCT04449146|Experimental|shoulder localizer ultrasound|The localizer ultrasound of the shoulder is performed on an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer. The Protocol plans to acquire different landmarks on the scapula: lower angle, coracoid, scapula spine and bilateral acromioclavicular joint (definition of the coronal plan). These acquisitions are carried out by the probe connected to a Tablet (Microsoft surface Pro 3) which allows to locate the probe and by extension of the probe the location of the points selected by ultrasound.
10115463|NCT04449120|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one-month. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
10115464|NCT04449120|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group received the written nutrition educational information as well as four online cooking classes (one cooking class per week) during the one-month intervention period. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected.~Participants will attend 4 culinary workshops between visit 2 and 3. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
10115465|NCT04449315|Experimental|Peppermint and Lavender Essential Oil|Young Living Essential oil of Peppermint and Lavender will be used to patients who meet the inclusion criteria.
10115466|NCT04449237|Other|volunteer|40 volunteer will not accept any treatment
10115467|NCT04449237|Placebo Comparator|patients with unmodified music group|40 participants in this group will listen to music without any modification
10115468|NCT04449237|Experimental|patients with modified tinnitus relieving music|40 participants in this group will listen to the music modified according to the matched dominant tinnitus pitch
10115469|NCT04449289|Active Comparator|Intravenous lidocaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+intravenous lidocaine infusion for the first 48 hours postoperative
10115470|NCT04449289|Active Comparator|Epidural ropivacaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+epidural ropivacaine infusion for the first 48 hours postoperatively
10115471|NCT04449471|Experimental|Naproxen Tablet|Subjects will received a single 220-mg dose of naproxen sodium (Aleve) by mouth.
9668242|NCT05009836|Placebo Comparator|placebo|placebo 600 mg or 400 mg QD orally+ Osimertinib 80 mg QD orally ( every 3 weeks)
9668243|NCT05002257|Experimental|Experimental Arm|
9668244|NCT05002257|Active Comparator|Control arm|
9668245|NCT05001815|Experimental|Continuous subcutaneous insulin infusion (CSII)|Patients with indications will receive continuous subcutaneous insulin infusion (CSII) treatment achieved by patch insulin pump devices.
9668246|NCT05001815|Active Comparator|Multiple daily insulin injection (MDI)|Patients with indications will receive traditional multiple daily insulin injection (MDI) treatment.
10115472|NCT04449445|Other|Standard enteral tube feeds|Patients will be instructed to continue a normal diet before surgery. Post-operatively, patients will receive standard of care isocaloric and iso-nitrogenous standard enteral tube feeds
10188048|NCT03720067|Active Comparator|Phase 1: Propranolol (PPL)|Hepatic venous pressure gradient (HVPG) will be measured before and after 120 minutes of a loading dose of Propranolol (PPL) 80 mg PO. Thereafter, patients will receive maintenance therapy with Propranolol (40 to 320 mg / day) adjusted according to blood pressure and heart rate. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
9668247|NCT05001555|Experimental|Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)|"Group A:~Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days."
9668248|NCT05001555|Active Comparator|Group B: Dexketoprofen|Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.
9694309|NCT04790708|Experimental|Cancers of Unknown Primary Origin (CUP) NETs|25 patients affected by non-functional and functional unknown primary NETs
9519389|NCT03287570|Active Comparator|Traditional indirect moxibustion|The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
9519390|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
9519391|NCT03287544|Experimental|Combined rehabilitation|Linguistic training as well as communication training.
9668249|NCT04999514|Experimental|Mindful Parenting Program|The Mindful Parenting program as developed by Bögels and Restifo (2013), is selected as one of the parenting intervention programs in this study. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in parenting context.
9668250|NCT04999514|Experimental|Tuning in to Kids Program|The Tuning in to Kids program as developed by Havighurst and colleagues (2010), is selected as one of the parenting intervention programs in this study. It will be extended to 8-week program that aims at equipping parents with emotion coaching skills.
9668251|NCT04999514|No Intervention|Waitlist Control Group|The waitlist control group will not receive any intervention until the intervention arms complete their training. Depending on the availability of the program instructor, either the Mindful Parenting or Tuning in to Kids program will be offered to this group.
9668252|NCT04975555|Experimental|Siltuximab|Patients who experience CRS/ICANS will receive this treatment
9668253|NCT04972565|Experimental|Usual Care plus Inspiratory Muscle Training (IMT)|"Participants will attend the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network. The program consists of i) an individualized home-based rehabilitation and exercise program (twelve weeks of aerobic, neuromotor, and resistance-based exercises), ii) a self-management education intervention, and iii) a community resource engagement plan. Furthermore, patients attend four on-site sessions (a baseline assessment and three follow-up visits).~Participants in this group will also be provided with a personalized prescription for an IMT program for eight weeks to be performed in the home environment (two daily IMT sessions of 30 breaths, five days per week). Participants will be virtually supervised by the study team weekly with any adverse events closely monitored. Participants will receive instructions and feedback on how to optimize their home training efforts with direct observation of their IMT practice."
9668254|NCT04972565|No Intervention|Usual Care|Participants will participate in the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network.
9668255|NCT04968158|Experimental|Group A: Etoricoxib/Tramadol|Administered orally, one packet of etoricoxib / tramadol granules diluted in 100 ml of water, every 24 hours for 7 days.
9668256|NCT04968158|Active Comparator|Group B: Acetaminophen / Tramadol|Administered orally, one tablet, every 8 hours, for 7 days.
9668257|NCT04964453|Experimental|Dose group 1|
9668258|NCT04964453|Experimental|Dose group 2|
9668259|NCT04964453|Experimental|Dose group 3|
9668260|NCT04964453|Experimental|Dose group 4|
9668261|NCT04964453|Placebo Comparator|Placebo|
9668262|NCT04945109|Experimental|Mankai beverage first|Two weeks of Mankai supplementation followed by two weeks of water supplement
9668263|NCT04945109|Experimental|Mankai beverage last|Two weeks of water supplementation followed by two weeks of Mankai supplement
9668264|NCT04941560||Algorithm training and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to training and validate the algorithm for CAD detection based on facial photos.
9965749|NCT01252615|Experimental|patient and partner|patient with the ICD and intimate partner are involved in the intervention
9668266|NCT04924699|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
9668267|NCT04909567|Experimental|Intervention arm|"Optimisation:~Diet, organised exercise, psychosocial support"
9668268|NCT04909567|No Intervention|Control arm|Current standard preparation before surgery
9965750|NCT01252654||1 IntraLase flaps|Patients who have undergone flap creation with IntraLase laser
9965751|NCT01252654||2 Visumax flaps|Patients who have undergone flaps created with Visumax laser
9668271|NCT04896749|Experimental|Group A/ Nerve mobilization group|In this group, patients will receive nerve mobilization exercises along with routine physical therapy. Patients will also be given home plan for cervical isometric exercises.
9668272|NCT04896749|Active Comparator|Group B/ Conventional physical therapy group|In this group, patients will receive routine physical therapy and also given home plan for cervical isometric exercises
9668273|NCT04895098||combination therapy group|750 Subjects in the statin and ezetimibe combination therapy group
9668274|NCT04895098||monotherapy group|250 Subjects in the statin monotherapy group
9668275|NCT04891315||Pregnant women|Women aged 16+ in early pregnancy (before 20 weeks of gestation).
9668276|NCT04890821|Experimental|CI Percutaneous Ring Annuloplasty System|Patients treated with the CI Percutaneous Ring Annuloplasty System
9668277|NCT04889066|Active Comparator|Durvalumab and standard fSRT|Fractionated stereotactic radiotherapy (fSRT) will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 fractions total, delivered every other day (~2 times/week) with first cycle of Durvalumab.
9668278|NCT04889066|Experimental|Durvalumab and PULSAR|"Personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR), will be delivered to all previously untreated brain metastases noted at the time of treatment (up to 10 max). All brain metastases will be treated concurrently, 3 pulses of radiation total, delivered one pulse monthly with each cycle of Durvalumab."
9668279|NCT04888611|Experimental|Neoadjuvant PD-1 inhibitor plus DC vaccine|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, DC vaccines and further PD-1 inhibitor treatment until toxicity or progression.
9668280|NCT04888611|Active Comparator|Neoadjuvant PD-1 inhibitor plus Placebo|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, placebo and further PD-1 inhibitor treatment until toxicity or progression.
9668281|NCT04865783|Active Comparator|Cryospray|Cryospray will be sprayed from a distance of 20-30 cm to the back of one hand.
9965752|NCT01252680|Experimental|Group 1: Healive+Healive|75 subjects to receive two doses of Healive 6 months apart
10188049|NCT03720067|Active Comparator|Phase 1: Carvedilol (CVD)|HVPG will be measured before and after 120 minutes of a loading dose of Carvedilol (CVD) 12.5 mg PO. Thereafter, patients will receive maintenance therapy with Carvedilol (6.25 - 25 mg / day) adjusted according to blood pressure. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
9668282|NCT04865783|Placebo Comparator|Placebo|A saline solution will be sprayed from a distance of 20-30 cm to the back of the hand.
9668283|NCT04861220|Experimental|Pre-habilitation group + neoadjuvant treatment|The patients in the Pre-habilitation group + neoadjuvant treatment (Group A), will undergo neoadjuvant cancer therapy and be instructed to practice physical exercises at home 03 times a week, during neoadjuvant therapy, until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
9668284|NCT04861220|Experimental|Prehabilitation Program + immediate surgical treatment|The patients in the Pre-habilitation group + immediate surgical treatment (Group B), will be instructed to practice physical exercises at home 03 times a week until the date of surgery. The pre-habilitation program (intervention) will consist of prescription of physical exercises and guidance on its importance, through a booklet and practice practice diary. The intervention group will be accompanied weekly by a call to encourage the performance of the exercises, and in case of doubts, new explanations regarding the performance of these exercises.
9668285|NCT04861220|No Intervention|Usual activities + neoadjuvant treatment|Patients allocated to this group (Group C) will not participate in the pre-habilitation program and will be instructed to continue their usual activities during the neoadjuvant cancer therapy, until the date of surgery.
9668286|NCT04861220|No Intervention|Usual activities + immediate surgical treatment|Patients allocated to this group (Group D) will not participate in the pre-habilitation program and will be instructed to continue their usual activities until the date of surgery.
9668287|NCT04859088|Experimental|Partial Enteral Nutrition|Patients allocated to Partial Enteral Nutrition study arm will be asked to replace 50% of their daily energy requirements with a proprietary formula (Modulen IBD, Nestle) for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
9668288|NCT04859088|No Intervention|Unrestricted diet|Patients allocated to unrestricted diet study arm will be asked to follow their normal diet for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
9668289|NCT04855799|Experimental|Aquamin®|
9668290|NCT04848454|Experimental|Experimental group|"Drug:~Vinorelbine i.v. 25 mg/m2, d1, d8 or p.o. 60-80 mg/m2 d1, d8; q3w; for 6 cycles.~Cisplatin i.v. 75 mg/m2，d1, d2; q3w; for 6 cycles. Camrelizumab i.v. 200mg, q3w; for 17cycles (1 year)."
9668291|NCT04828239|Experimental|Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
9668292|NCT04828239|Active Comparator|Manual Acupuncture Group|Acupuncture point: PC-6 and PC-7 Responses elicited: de qi sensation Manual: twirling with lifting-thrusting method stimulation Needles retained for 30 min Needle type: C&G, gauge and size: 0.25x40mm
9668293|NCT04828239|Sham Comparator|Sham Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 Sham laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
9668294|NCT04819386|Experimental|Active group|18 half-hour in-office active vision therapy sessions with the NEIVATECH system
9668295|NCT04819386|Placebo Comparator|Control group|2 hours of conventional patching per day at home
9668296|NCT04810351||Younger 1|young patients ( 18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than one week but less than three weeks of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
9668297|NCT04810351||Older 1|old patients ( > 70 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than one week but less than three weeks out of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever
9668298|NCT04810351||Young 2|young patients (18-69 years old) with oral or rectal fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during more than 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever.
9668299|NCT04810351||Older 2|old patients ( > 70 years old) with oral or rectal fever fever > 37°8 or tympanic fever > 37°2 or CRP > 30 mg/dl during 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever13 .
9668300|NCT04803812|Experimental|Receive weekly SMS containing wellness stories shared by other Ontario physicians|
9668301|NCT04803812|Experimental|Receive weekly SMS containing aim wellness resources/strategies.|
9668302|NCT04803812|Experimental|Receive weekly SMS combining wellness stories & resources/strategies|
9668303|NCT04799236|Active Comparator|Group 1: Oral Miltefosine|Miltefosine will be administered per os at 150 mg/day [50 mg tid] for 28 days. This is the standard regimen of miltefosine for persons >45 kg.
9668304|NCT04799236|Active Comparator|Group 2: Intravenous pentavalent antimony|IV pentavalent antimony (meglumine antimoniate) will be administrated at 20 mg x kg x d during 20 consecutive days. Antimony will be diluted in 10 times its volume in 5%Dextrose in destilled water and injected IV in 20 minutes
9668305|NCT04799236|Experimental|Group 3: Intravenous liposomal amphotericin B|LAMB will be administered IV at 3 ampules [150 mg] on each of days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Three ampules is the individual dose suggested by Aronson et al [2016] and equals 2.5 mg/kg/dose for a 60 kg person. 15 doses of 3 ampules (total of 2250 mg) equals 37.5 mg/kg for a 60 kg person.
9668306|NCT04785326|Experimental|DMB-3115|Patients randomized to receive DMB-3115 at the beginning of the study will continue to receive the same treatment
9668307|NCT04785326|Active Comparator|Stelara|Patients randomized to receive Stelara at the beginning of the study will be re-randomized at Week 28 in a 1:1 ratio to either continue on Stelara or will be transitioned to receive DMB-3115
9668308|NCT04778501|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
9820819|NCT02213133|Experimental|Cohort 1: Head and Neck-SCC|Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than [<] 100*10^9 per litre [/L]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
9820820|NCT02213133|Experimental|Cohort 2: Lungs-SCC|Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
9820821|NCT02213133|Experimental|Cohort 3: Esophagus-SCC|Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
9820822|NCT02213198|Experimental|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
9820823|NCT02213198|Active Comparator|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
9820824|NCT02213250|Experimental|BeneFIX|
9820825|NCT02213263|Experimental|PF-05280586|
9820826|NCT02213263|Active Comparator|MabThera®|
9820827|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)|"For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:~Immuno-oncology included PD-L1 IHC combined positivity score >10, high microsatellite instability, tumor mutation burden >15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab."
9820828|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (HER2 amplified)|HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
9820829|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EFGR amplified)|EGFR amplified. These patients received ABT-806.
9820830|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)|FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
9820831|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)|MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
9820832|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EGFR expressing)|EGFR expressing. These patients received standard cytotherapy plus ABT 806.
9820833|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (All negative)|All negative. These patients received standard cytotherapy plus Ramucirumab.
9820834|NCT02213289|Other|Non-ITT: Standard Therapy|Patients without monoclonal antibodies available received standard cytotherapy.
9820835|NCT02213380|Other|group GA|General anesthesia
9820836|NCT02213380|Other|group RA|Regional anesthesia
9820837|NCT02213458|Experimental|Navigated Care|Comprehensive longitudinal continuing care program
10188050|NCT03720067|Active Comparator|Phase 2: PPL non-responders/rosuvastatin|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
10188051|NCT03720067|Placebo Comparator|Phase 2: PPL non-responders/placebo|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
9820838|NCT02213458|No Intervention|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
9820839|NCT02213510|Experimental|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
9820840|NCT02213510|Active Comparator|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
9820841|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
9820842|NCT02213900|Experimental|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
9820843|NCT02213900|Placebo Comparator|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
9820844|NCT02214017|Active Comparator|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
9820845|NCT02214017|Experimental|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
9820846|NCT02214121|Other|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
9820847|NCT02214121|Other|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
9820848|NCT02214147|Experimental|Alisertib: Normal Hepatic Function|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN.
9820849|NCT02214147|Experimental|Alisertib: Moderate Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin > 1.5-3 x ULN and any ALT level.
9820850|NCT02214147|Experimental|Alisertib: Severe Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin > 3 x ULN and any ALT level.
9820851|NCT02214186|No Intervention|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
9820852|NCT02214186|Active Comparator|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
9820853|NCT02214212|Active Comparator|Red Light (RL)|"Intervention/Device:~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
9820854|NCT02214212|Experimental|Bright White Light (BWL)|"Intervention/Device:~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
9820855|NCT02214225|Experimental|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
9820856|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
9820857|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
9820858|NCT02214238|Active Comparator|Market released PAP device|Use of a market released PAP device
9820859|NCT02214238|Experimental|Modified PAP device|Us of the modified PAP device
9820860|NCT02214277|Experimental|Test Arm|
9820861|NCT02214277|Active Comparator|Control Arm|
9820862|NCT02214277|Other|Safety Arm|
9820863|NCT02214290|Active Comparator|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
9820864|NCT02214290|Placebo Comparator|Placebo|Placebo pill produced by NOW FOODS, USA
9820865|NCT02214290|Experimental|L-citrulline|L-citrulline capsule (750 mg) provided by NOW FOODS
9820866|NCT02214420|Active Comparator|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
9820867|NCT02214420|Active Comparator|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
9820868|NCT02214615|Active Comparator|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
9820869|NCT02214615|Placebo Comparator|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
9820870|NCT02214628|Experimental|Fovista® plus anti-VEGF Simultaneous|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Simultaneous regimen followed by quarterly administration."
9820871|NCT02214628|Experimental|Fovista® plus anti-VEGF Pre-Treatment|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment regimen followed by quarterly administration."
9820872|NCT02215070|Experimental|Pasireotide + Preparatory Regimen|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
9820873|NCT02215161|Experimental|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9965753|NCT01252680|Experimental|Group 2: Healive+Havrix|75 subjects to receive one dose of Healive and another dose of Havrix 6 months apart
10188052|NCT03720067|Active Comparator|Phase 2: CVD non-responders/rosuvastatin|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
9820874|NCT02215200|Experimental|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
9820875|NCT02215200|Experimental|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
9820876|NCT02215200|Placebo Comparator|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
9820877|NCT02215252|Experimental|PF-05089771|
9820878|NCT02215252|Experimental|Placebo|
9820879|NCT02215252|Experimental|Pregabalin|
9820880|NCT02215252|Experimental|PF-05089771 + Pregabalin|
9820881|NCT02215369|Experimental|VenaCure EVLT 400 µm fiber Procedure Kit|Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to the study schedule.
9820882|NCT02215616|Placebo Comparator|Placebo|Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.
9820883|NCT02215616|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.
9820884|NCT02215616|Experimental|Laquinimod 1.0 mg|Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.
9820885|NCT02215616|Experimental|Laquinimod 1.5 mg|"Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily.~Note: The treatment of this high dose arm was discontinued as of 10 January 2016."
9820886|NCT02215954|Experimental|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
9820887|NCT02215954|Experimental|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
9820888|NCT02215954|Active Comparator|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
9820889|NCT02215967|Experimental|Multiple Myeloma|Dose Escalation with 5 dose levels based on the patients actual bodyweight
9519392|NCT03287544|Active Comparator|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
9519393|NCT03287531|Experimental|conventional therapy (group I)|"Exercise therapy.~For muscles around TMJ :~Masetter Lateral Pterygoid Medial Pterygoid Temporalis Digastric~Pulsed ultrasound at 0.3 to 0.6 watts per sq cm over the lateral poles of the temporomandibular joint condyles with a small sound head for 2 to 3 minutes per side"
9820890|NCT02216071|Active Comparator|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
9820891|NCT02216071|Experimental|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
9820892|NCT02216097|Experimental|Treatment|
9820893|NCT02216097|Placebo Comparator|Placebo|
9820894|NCT02216123|Experimental|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
9820895|NCT02216123|Experimental|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
9820896|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
10188053|NCT03720067|Placebo Comparator|Phase 2: CVD non-responders/placebo|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
9668309|NCT04771637|Placebo Comparator|control with normal saline|
9820897|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
9820898|NCT02216136||Mastectomy Only Cohort|Mastectomy Only Cohort: This group will have mastectomy without reconstruction. They may or may not require chemotherapy and radiation.
9820899|NCT02216214|Placebo Comparator|Placebo|Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
9827637|NCT02462720|Active Comparator|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
9827638|NCT02462759|Experimental|Nusinersen|Administered by intrathecal injection.
9820900|NCT02216214|Experimental|Mirabegron|Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
9820901|NCT02216357|Active Comparator|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
9820902|NCT02216357|Placebo Comparator|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
9820903|NCT02216422|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
9820904|NCT02216526|Experimental|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
9820905|NCT02216526|Experimental|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
9820906|NCT02216526|No Intervention|Standard skin care|Usual skin care routine of the nursing home resident
9820907|NCT02216591|Experimental|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
9820908|NCT02216591|Sham Comparator|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
9820909|NCT02216773|Active Comparator|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
9820910|NCT02216773|Experimental|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
9820911|NCT02216812|Experimental|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
9820912|NCT02216812|Placebo Comparator|Placebo|Arm will take 1 placebo pill per day for 6 weeks
9820913|NCT02216851|Experimental|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
9820914|NCT02216851|No Intervention|No-treatment control|No-treatment control group do not receive any treatment during the main study period
9820915|NCT02217280|Experimental|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
9820916|NCT02217332|Experimental|dexpramipexole|dexpramipexole 150 mg BID
9820917|NCT02217410|Experimental|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
9820918|NCT02217410|Experimental|Regimen B|CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
9820919|NCT02217410|Active Comparator|Regimen C|Standard of care (SoC) [concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction]
9820920|NCT02217436|Experimental|iPad|iPad with age-appropriate applications, videos, and music
9820921|NCT02217436|Active Comparator|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
9820922|NCT02217475|Experimental|Cenicriviroc (CVC) 150mg/CVC 150 mg|CVC 150 mg tablet in Years 1 and 2.
9820923|NCT02217475|Experimental|Placebo/CVC 150 mg|Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2.
9820924|NCT02217475|Placebo Comparator|Placebo/Placebo|Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.
9820925|NCT02217501|Experimental|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
9519394|NCT03287531|Experimental|low level laser therapy (groupII)|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
9820926|NCT02217501|Active Comparator|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
9827639|NCT02462759|Sham Comparator|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
9965754|NCT01252680|Experimental|Group 3: Havrix+Havrix|75 subjects to receive two doses of Havrix 6 months apart
9820927|NCT02217527|Experimental|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
9820928|NCT02217527|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
9820929|NCT02217566|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
9820930|NCT02217618|Experimental|LY2409021|Single oral dose of 20 milligrams (mg) LY2409021.
9820931|NCT02217800|Other|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
9820932|NCT02217878|Active Comparator|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
9820933|NCT02217878|Placebo Comparator|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
9820934|NCT02217904|Experimental|Islatravir 1 mg|Single oral dose of islatravir 1 mg
9820935|NCT02217904|Experimental|Islatravir 2 mg|Single oral dose of islatravir 2 mg
10115473|NCT04449445|Experimental|Nestle IMPACT AR|Patients will be encouraged to continue their regular diet until their surgery day. In addition, beginning 5 days before surgery, subjects will be instructed to drink three, 6 ounce cartons of Nestle IMPACT AR each day until their surgery. Post operatively patients who are able to eat orally, will be given three, 6 ounce cartons of Nestle IMPACT AR to drink each day for 5 days. Patients who are not able to tolerate an oral diet will be given Nestle IMPACT via a continuous tube feeding for 5 days through a temporary nasogastric feeding tube placed per standard post-operative care. Dosing of the tube feeding will be based on weight at a rate of approximately 70-75 cc/hour.
10115474|NCT04449302|Experimental|Immediate molar implant with customized healing abutment|Patients will receive an immediate mandibular molar implant with customized healing abutment
10115475|NCT04449302|Active Comparator|Immediate molar implant with submerged healing|Patients will receive an immediate mandibular molar implant with submerged healing
10115476|NCT04449367||Randomized and Single-Arm Trials|a sham comparator (no intervention)
10115477|NCT04449185|Experimental|HP eradication group|"HP eradication group~Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days"
10115478|NCT04449354|Other|Quality of Life assessment|HidraWear AX Garment
10115479|NCT04449458|Experimental|Positively Me|Positively Me is a 12-session (8 [1.5] hour main sessions plus four booster sessions) intervention guided by Social Cognitive Theory to promote smoking cessation in people with certain health conditions.
10115480|NCT04449458|Sham Comparator|Positively Living|Positively Living is a modified updated version of a healthy living intervention based on Social Cognitive Theory that is designed for people with certain health conditions and attention-matched to the experimental condition (8 [1.5] hour main sessions plus four booster sessions).
10115481|NCT04449380|Experimental|IFNβ 1a|
10115482|NCT04449380|Active Comparator|Standard care|
10115483|NCT04449133|Experimental|Treatment Group 1|AD128 for 7 days, then, after a wash-out period of 7-10 days, placebo for 7 days
10115484|NCT04449133|Experimental|Treatment Group 2|Placebo for 7 days, then, after a wash-out period of 7-10 days, AD128 for 7 days
10115485|NCT04449068||Evaluation of patients with Tourette's Gilles Syndrome|Neurological and neuropsychological evaluations of patients with Tourette's Gilles syndrome treated with high frequency bilateral stimulation of the anterior part of the internal pallid globus
10115486|NCT04449016|Experimental|Caucasian|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
10115487|NCT04449016|Experimental|Hispanic|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
10115488|NCT04448912||Non-trauma damge control surgery|Patients with non-traumatic abdominal emergencies undergoing damage control surgery.
9519395|NCT03287518|Active Comparator|Verum|WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
9668310|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.25 µg/kg/h|
10115489|NCT04448912||Non-trauma conventional surgery|Patients with non-traumatic abdominal emergencies undergoing conventional surgery with primary abdominal closure.
10115490|NCT04448925|Experimental|Recovery duration 15 seconds|Resting for 15 sec
10115491|NCT04448925|Experimental|Recovery duration 30 seconds|Resting for 30 sec
10115492|NCT04448925|Experimental|Recovery duration 45 seconds|Resting for 45 sec
10115493|NCT04448873|Active Comparator|Maintenance treatment group|After at least 2 years of remission of KHE, the participant receives sirolimus as usual. The serum concentration is supposed to be 5-7 ng/ml. If the effect or side effects of sirolimus require discontinuation, it is allowed to modify intervention, and if so, the patient stays in the maintenance group.
9820936|NCT02217904|Experimental|Islatravir 10 mg|Single oral dose of islatravir 10 mg
9820937|NCT02217904|Experimental|Islatravir 30 mg|Single oral dose of islatravir 30 mg
9820938|NCT02217904|Experimental|Islatravir 0.5 mg|Single oral dose of islatravir 0.5 mg
9820939|NCT02217904|Experimental|Islatravir 0.25 mg|Single oral dose of islatravir 0.25 mg
9820940|NCT02217904|Experimental|Islatravir 30 mg Extended Observation|Single oral dose of 30 mg islatravir administered following >8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
9965755|NCT01252680|Experimental|Group 4: Havrix+Healive|75 subjects to receive one dose of Havrix and another dose of Healive 6 months apart
10115494|NCT04448873|Experimental|Guided discontinuation group|"After at least 2 years of remission of KHE, the discontinuation measurement should be guided by the clinician with the following principles:~10% monthly reduction of the previous dose at most.~At least 5 half-lives between each reduction (2 weeks).~Blood concentration should be monitored monthly. Adjustment can be suggested according to the linear relationship between the dose and the blood concentration.~At least 6 months for the duration of guided discontinuation.~Regular assessments and evaluations should be done.~If the condition relapses or worsens during this process, dose of sirolimus should be adjusted to the previously effective dose. After a 3-month stabilization phase, 5% monthly reduction of the previous dose could be considered."
10115495|NCT04448808|Experimental|BX-1 (dronabinol)|BX-1
9820941|NCT02217982|No Intervention|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS >6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
9820942|NCT02217982|Active Comparator|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
9820943|NCT02218008|Experimental|High Dose|
9820944|NCT02218008|Experimental|Low Dose|
9820945|NCT02218008|Placebo Comparator|Placebo|
9820946|NCT02218164|Experimental|Capecitabine or 5-FU with Pegylated Interferon alpha-2b|"Participants will start the Capecitabine pills on day 1 thru day 14 and be off for 7 days (day 15-day 21).~Participants will receive 5-FU days 1-4 of each 21 day cycle.~Participants will receive the Interferon alpha-2b injection weekly every week. The three week period is referred to as one cycle.~After three cycles, new imaging studies will be performed that will measure how the disease is responding to treatment. Participants whose disease is stable or improved will undergo an additional 3 cycles of therapy and the imaging studies will be repeated. Again, participants whose disease is stable or improved will undergo a final 3 cycles of treatment (a total 27 weeks of treatment)."
9820947|NCT02218190|Experimental|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
9820948|NCT02218190|Placebo Comparator|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
9820949|NCT02218203|Placebo Comparator|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
10115496|NCT04448808|Placebo Comparator|Placebo|Placebo of BX-1
10115497|NCT04448756|Experimental|M5049 50 mg|
10115498|NCT04448756|Experimental|M5049 100 mg|
9820950|NCT02218203|Experimental|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
9519396|NCT03287518|Placebo Comparator|Placebo|"The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.~One (1) ml IP should be taken with breakfast and one (1) ml with supper every day."
9668311|NCT04771637|Experimental|dexmedetomidine loading dose 0.5 µg/kg + maintenance dose 0.5 µg/kg/h|
9820951|NCT02218203|Experimental|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
9820952|NCT02218203|Experimental|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
9820953|NCT02218203|Experimental|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
9820954|NCT02218203|Experimental|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
9820955|NCT02218203|Experimental|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
9820956|NCT02218203|Experimental|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
10115499|NCT04448756|Placebo Comparator|Placebo|
10115500|NCT04448730||Group 1 (normal weight with PCOS )|35 cases
10115501|NCT04448730||overweight PCOS|38 cases
10115502|NCT04448821|Experimental|Sequence A|Period 1: metformin; Period 2: metformin + nilotinib
10115503|NCT04448821|Experimental|Sequence B|Period 1: metformin + nilotinib; Period 2: metformin
10115504|NCT04448860|Experimental|Retinitis Pigmentosa patients|Patients with Retinitis Pigmentosa (RP) at different stages of impairment of the visual field, acuity and sensitivity to contrasts 15 patients will be included in phase 1 versus 36 in phase 2 (15 in step 1 and 21 in step 2).
10115505|NCT04448860|Other|healthy volunteers patients|36 patients will be included just in phase 2 (15 in step 1 and 21 in step 2).
9820957|NCT02218203|Experimental|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
9820958|NCT02218203|Experimental|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
9820959|NCT02218203|Experimental|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
9820960|NCT02218203|Experimental|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
9820961|NCT02218203|Experimental|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
9820962|NCT02218203|Experimental|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
9820963|NCT02218203|Experimental|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
9820964|NCT02218203|Experimental|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
9965756|NCT01252719|Experimental|Single-Dose IV Oritavancin Diphosphate|
9965757|NCT01252719|Active Comparator|IV Vancomycin|
9965758|NCT00927719||ACAM2000® vaccinia vaccine Cohort|Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.
9965759|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 1|
9820965|NCT02218216|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
9820966|NCT02218216|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
9820967|NCT02218242|Experimental|Ultrasound|Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
9820968|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
9820969|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
9820970|NCT02218307|Active Comparator|Mupirocin|topical antibiotic
9820971|NCT02218307|Placebo Comparator|Placebo|Placebo control for mupirocin
9820972|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
9820973|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
9820974|NCT02218372|Experimental|Fidaxomicin|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
9820975|NCT02218372|Active Comparator|Vancomycin|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
9820976|NCT02218424|Experimental|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
9965760|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 2|
10115506|NCT04448509|Other|Healthy donor|Healthy donor
9519397|NCT03287505|Experimental|Abilify IM Depot 300mg by once|300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;
9519398|NCT03287505|Experimental|Abilify IM Depot 400mg by once|400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.
9519399|NCT03287479|Experimental|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
9519400|NCT03287479|Active Comparator|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
9519401|NCT03287466|Experimental|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
9519402|NCT03287466|Active Comparator|Current best practice|The control group will have no specific SpO2 targets. Clinicians will be able to target SpO2 according to parameters they feel are suitable for the patient, according to standard UK practice.
9519403|NCT03287453|Experimental|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
9519404|NCT03287440|Active Comparator|COPD Wellness With Health Advocate|This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.
9519405|NCT03287440|Active Comparator|COPD Wellness|This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.
9519406|NCT03287427|Experimental|TetMYB Vaccine & BGB-A317|
9668312|NCT04771637|Experimental|dexmedetomidine loading dose 1 µg/kg + maintenance dose 0.5 µg/kg/h|
9965761|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 3|
9965762|NCT01252758|Placebo Comparator|placebo|
9965763|NCT01252758|Active Comparator|Ventolin HFA dose 1|
9965764|NCT01252758|Active Comparator|Ventolin HFA dose 2|
9965765|NCT01252771|Experimental|PKM report and algorithm|Phosphate kinetic modeling was performed and displayed in graphical form laboratory results and an estimated phophorus protein ratio
10115507|NCT04448691|Other|CCTA|Suspected coronary disease patients enrolled in EVINCI trial with CCTA where recalled for follow up CCTA and blood sampling
9820977|NCT02218424|Placebo Comparator|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
9820978|NCT02218463|Active Comparator|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
9668313|NCT04768777|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
9668314|NCT04768777|No Intervention|waitlist control condition|Participants will have 16-weeks of no intervention or interaction.
9668315|NCT04766697|Experimental|Receive Intervention|All 20 couples will receive the 8-session adapted intervention.
9668316|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Quality of Life|mindfulness stress reduction program reduces menopausal complaints.
9668317|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Menopausal Symptoms|mindfulness stress reduction program improves the quality of life of women in the menopausal period.
9668318|NCT04751591|Experimental|Endoscopic resection|The endoscopist will perform endoscopic resection for patients enrolled in this group.
9668319|NCT04751591|Other|Laparoscopic partial gastrectomy|The endoscopist will perform laparoscopic partial gastrectomy for patients enrolled in this group.
9668320|NCT04743310|Experimental|Tozuleristide with Canvas imaging system|
9668321|NCT04737343|Active Comparator|Azathioprine treatment arm|Patients will be treated with Azathioprine 100mg QD for 18 months combined with rednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period.All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intoleran.t
9668322|NCT04737343|Experimental|Leflunomide treatment arm|Patient will be treated with Leflunomide 30mg QD for 18 months combined with prednisone. The dosage of prednisone is tapered in the study period but will be maintained at 7.5mg/d to the end of the study period. All included patients will be treated with TMPco 2 tablets everyday during the study period if not contraindicated or intolerant.
9668323|NCT04731389|Experimental|internet CBT|Intervention with remote and self-applicable cognitive behavioral therapy, during 4 weeks.
9668324|NCT04731389|Active Comparator|Quality of life promotion|Control intervention, during 4 weeks.
9668325|NCT04724512|Active Comparator|polypropylene|patients randomised to receive polypropylene sutures.
9668326|NCT04724512|Active Comparator|polyglactin|patients randomised to receive polyglactin sutures.
9668327|NCT04710979|Experimental|Yoga Intervention Group|
9668328|NCT04710979|No Intervention|Control Group|Control participants will receive no guidance from the research staff to change their behavior.
9668329|NCT04695041|Experimental|Cohort A: 1200 mg PBI-4050|
9668330|NCT04695041|Experimental|Cohort B: 1600 mg PBI-4050|
9668331|NCT04695041|Experimental|Cohort C: 2000 mg PBI-4050|
9668332|NCT04695041|Experimental|Cohort D: 2400 mg PBI-4050|
9668333|NCT04695041|Experimental|Cohort E: 2400 mg PBI-4050|
9668334|NCT04695041|Experimental|Cohort F (Supplemental): 1600 mg PBI-4050|
9668335|NCT04645264|Experimental|Indwelling Foley|Indwelling Foley placed during surgery
9668336|NCT04645264|Active Comparator|Straight Catheter|straight catheterization (in-and-out straight catheterization) will take place at the end of the surgery
9668337|NCT04645264|No Intervention|No Catheter|Patient is not catheterized
9668338|NCT04639258|Experimental|Medtronic Evolut™ PRO+ System|All study subjects will be treated with the Medtronic Evolut™ PRO+ TAVR System.
9668339|NCT04638881|Experimental|Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
9668340|NCT04638881|Placebo Comparator|Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
9668341|NCT04633356|Experimental|EUS-portal pressure gradient measurement (PPGM)|All patients would receive measurement of PPGM using the study device
9668342|NCT04629703|Active Comparator|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care
9668343|NCT04629703|Placebo Comparator|Placebo (twice daily for 14 days) + Standard of Care|Placebo (twice daily for 14 days) + Standard of Care
9668344|NCT04626869|Active Comparator|Interscalene block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) to detect the brachial plexus. At the cervical level 5-6, the posterior brachial plexus will be approached as in-plane from the posterior with the needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed with stimulation in the upper extremity muscles with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
9668345|NCT04626869|Active Comparator|Anterior suprascapular nerve block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) will be placed in the suprascapular region in a coronal oblique manner. The omohyoid muscle, under it the suprascapular nerve, the brachial plexus and the subclavian artery will be identified. The suprascapular nerve will be approached from the posterior as in-plane with a needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed by stimulation in the supraspinous muscle with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
9668346|NCT04602000|Experimental|CT-P59 Arm 1 & CT-P59 Arm 2|
9668347|NCT04602000|Placebo Comparator|Placebo|
9668348|NCT04601558|No Intervention|Control group|The first group of participants was control group. The number of participant was 70, and the participants in this group after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
9668349|NCT04601558|Sham Comparator|Passive-intervention group|The second group of participant was passive-intervention group. There were 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, they were receiving remainder on their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
9519407|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
9820979|NCT02218463|Active Comparator|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
9820980|NCT02218489|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
9820981|NCT02218489|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
9820982|NCT02218541|Other|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
9820983|NCT02218541|Other|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
9820984|NCT02218736|Experimental|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
9820985|NCT02218736|Placebo Comparator|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
9820986|NCT02219009|Experimental|MIND1 System|
9820987|NCT02219048|Placebo Comparator|Placebo|Matched blinded placebo
9820988|NCT02219048|Experimental|PF-03715455|PF-03715455
9820989|NCT02219087|Experimental|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
9820990|NCT02219087|Active Comparator|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
9820991|NCT02219256|Experimental|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
9820992|NCT02219256|Experimental|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
9820993|NCT02219256|Placebo Comparator|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
9820994|NCT02219282|Active Comparator|Group Dentulous|Laryngeal Mask Unique insertion
9820995|NCT02219282|Experimental|Group Edentulous|Laryngeal Mask Unique insertion
9820996|NCT02219308|Experimental|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
9820997|NCT02219308|Sham Comparator|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
9519408|NCT03287388|Experimental|No Rocuronium|Phase 1: no neuromuscular blockade
9519409|NCT03287388|Experimental|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
9519410|NCT03287388|Experimental|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
9820998|NCT02219321|Active Comparator|Lidocaine infusion|A continuous intravenous infusion of lidocaine
9820999|NCT02219321|Placebo Comparator|Saline infusion|A continuous intravenous infusion of saline
9821000|NCT02219334|Experimental|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
9821001|NCT02219334|No Intervention|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
9821002|NCT02219438|Experimental|RIGHT side BOLUS and left side basal|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours
9821003|NCT02219438|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours. For the left catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours.
9821004|NCT02219464|Active Comparator|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
9821005|NCT02219464|Other|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
9821006|NCT02219477|Experimental|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
9821007|NCT02219477|Experimental|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
9821008|NCT02219477|Experimental|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
9821009|NCT02219503|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
9821010|NCT02219516|Experimental|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
9821011|NCT02219516|Experimental|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
9821012|NCT02219516|Experimental|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
9821013|NCT02219516|Experimental|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
9821014|NCT02219685|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
9821015|NCT02219685|Placebo Comparator|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
9821016|NCT02219685|Experimental|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
9821017|NCT02219815|No Intervention|Standard Care|Patients in the standard care group will receive care as is currently delivered to patients awaiting cardiac surgery at each site. At present, patients are advised to rest and participate in very light intensity physical activity while awaiting surgery. At 1-2 weeks prior to their scheduled surgical date, the patient attends a single three hour cardiac pre-assessment with a nurse practitioner and cardiac anesthesiologist. In addition, a cardiac nurse counsels each patient on healthy behaviors (e.g. smoking cessation, diet, exercise).
9821018|NCT02219815|Experimental|Prehab Intervention|Patients in the Prehab group will receive, in addition to the standard of care, an eight-week comprehensive exercise therapy and education program at a community-based CR facility. Patients will be asked to complete at least two sessions of supervised, structured exercise class plus have the option to attend one additional exercise class per week for eight-weeks, with progression to a moderate to high-intensity interval program based on the supervised assessment of the patient's capabilities. Prehab participants will also attend four education sessions on topics such as risk factor reduction, medication use, cardiovascular physiology, smoking cessation, healthy eating, exercise, and stress management and promotion of self-managed care.
9821019|NCT02219932|Experimental|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
9821020|NCT02219932|Placebo Comparator|Placebo|Matched placebo 10 mg BID for up to 24 weeks
9821021|NCT02219997|Experimental|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
9821022|NCT02219997|Active Comparator|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
9821023|NCT02220205|Active Comparator|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
10115508|NCT04448899|Active Comparator|Ivabradine|"Patients administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.~Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study."
9821024|NCT02220205|Placebo Comparator|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
9821025|NCT02220712|Experimental|Drug: OPC-14597 IMD|
9821026|NCT02220725|Experimental|Andexanet 800mg bolus (Part I)|Andexanet (antidote) - 800 mg bolus
9821027|NCT02220725|Experimental|Andexanet 800mg + 960mg (Part II)|800 mg bolus + 960 mg infusion (8 mg/min)
9821028|NCT02220764|Experimental|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
9821029|NCT02220764|Active Comparator|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
9821030|NCT02220907|Experimental|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
9821031|NCT02220920|Experimental|Canagliflozin (TA-7284) ＋insulin|
9821032|NCT02220920|Placebo Comparator|Placebo＋insulin|
9821033|NCT02220998|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
9821034|NCT02220998|Experimental|SOF+RBV|SOF+RBV for 12 weeks
9821035|NCT02221219|Placebo Comparator|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
9821036|NCT02221219|Experimental|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
9821037|NCT02221219|Active Comparator|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
9821038|NCT02221219|Experimental|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
9821039|NCT02221284||Alogliptin|Alogliptin 25 milligram (mg), tablets, orally, once daily, up to 12 months, along with an insulin preparations, with a rapid-acting insulin secretagogue (Glinide), with a SGLT-2 inhibitor, or the other diabetic drugs within 3 months prior to the start of alogliptin treatment or during the alogliptin treatment period in routine medical care.
9821040|NCT02221349|Other|oxalate liquid & gel plus SnF2 paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied
9821041|NCT02221349|Other|oxalate liquid & gel plus NaF paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied
9821042|NCT02221557|Experimental|New alloplastic bone graft material|
10115509|NCT04448899|Placebo Comparator|Control|Patients administered a placebo twice daily. Patients were followed up after 1 week of initiation of the study then monthly till the end of the study.
10115510|NCT04448522|Experimental|Reduced dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 63.6 Gy
9821043|NCT02221648|Placebo Comparator|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
10115511|NCT04448522|Active Comparator|Conventional dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 69.96 Gy
9821044|NCT02221648|Active Comparator|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
9821045|NCT02221674|Experimental|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
9821046|NCT02221739|Experimental|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
9821047|NCT02221869|Experimental|Xyrem|Active Xyrem at a dose ≤9 g/night
9821048|NCT02221869|Placebo Comparator|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
9821049|NCT02221882|Experimental|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
9821050|NCT02221947|Active Comparator|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
9821051|NCT02221947|Placebo Comparator|placebo|single dose of placebo, intravenous infusion over 1 hour
9821052|NCT02222129|Active Comparator|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
10115512|NCT04448652||+NSAIDs|Patients undergoing elective colorectal cancer resection before april 1st 2016 were treated with paracetamol tablets 1000 mg and ibuprofen tablets 400 mg four times a day from the day of the operation and until discharge.
10115513|NCT04448652||-NSAIDs|Patients undergoing elective colorectal cancer resection from april 1st 2016 were only treated with paracetamol tablets 1000 mg four times a day from the day of the operation and until discharge.
10115514|NCT04448847|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
10115515|NCT04448847|Experimental|Bif195 arm|Active trial product with minimum 100 billion CFU daily dose
10115516|NCT04448665||patients with suspected infection|The hospitalized patients in whom, based on clinical signs and symptoms, an infection is suspected, and an administration of antimicrobial agents as empiric therapy is necessary.
10115517|NCT04448964|Experimental|Part 1: Treatment Sequence ABC|Participants will receive a single dose of JNJ-70033093 spray-dried dispersion (SDD) tablet under fasted conditions (Treatment A) in Treatment Period 1, followed by JNJ-70033093 SDD tablet in fed conditions (Treatment B) in Treatment Period 2, and then JNJ-70033093 SDD granule capsule under fasted conditions (Treatment C) in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
10115518|NCT04448964|Experimental|Part 1: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
10115519|NCT04448964|Experimental|Part 1: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
10115520|NCT04448964|Experimental|Part 1: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
9821053|NCT02222129|Experimental|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
9821054|NCT02222181|Experimental|Pharmacotherapy follow-up|patients with Alzheimer's disease
9821055|NCT02222207|Experimental|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
9821056|NCT02222207|Experimental|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
9821057|NCT02222207|Experimental|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
10115521|NCT04448964|Experimental|Part 1: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment C in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
10115522|NCT04448964|Experimental|Part 1: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
10115523|NCT04448964|Experimental|Part 2: Treatment Sequence DE|Participants will receive Treatment D (single dose of JNJ-70033093 SDD tablet in fed conditions) in Treatment Period 1, and then Treatment E (single dose of JNJ-70033093 SDD granule capsule under fasted conditions) in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
10115524|NCT04448964|Experimental|Part 2: Treatment Sequence ED|Participants will receive Treatment E in Treatment Period 1, and then Treatment D in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
10115525|NCT04448977||Multiple Sclerosis group 1|Individuals with Multiple Sclerosis who are going to be starting Ocrevus as determined by Neurologist as part of clinical care.
9821058|NCT02222207|Experimental|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
9821059|NCT02222207|Experimental|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
9821060|NCT02222207|Experimental|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
9821061|NCT02222207|Experimental|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
9821062|NCT02222207|Active Comparator|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
9821063|NCT02222246|Experimental|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
9821064|NCT02222246|Active Comparator|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
9821065|NCT02222337|Active Comparator|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
9821066|NCT02222337|No Intervention|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
9821067|NCT02222493|Experimental|PF-06438179|
9821068|NCT02222493|Active Comparator|Infliximab|
9821069|NCT02222558|Experimental|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
9821070|NCT02222558|Experimental|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
9821071|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
9821072|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
9821073|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
9821074|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
9519411|NCT03287375|Experimental|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 5 weeks interval.
9519412|NCT03287362|Experimental|ST-arm|one-third of the patients is randomized to schema therapy
9821075|NCT02222610|Experimental|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.~Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on spectral domain (SD)-optical coherence tomography (OCT). The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
9827640|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
10115526|NCT04448977||Multiple Sclerosis group 2|Individuals with Multiple Sclerosis who are going to be starting Copaxone as determined by Neurologist as part of clinical care.
10115527|NCT04448977||Healthy Controls|Healthy individuals who are age, gender and education matched to the other groups.
9519413|NCT03287362|Active Comparator|CBT-arm|one-third of the patients is randomized to cognitive behavioral therapy
9519414|NCT03287362|Placebo Comparator|IST-arm|one-third of the patients is randomized to individualized supportive therapy
9519415|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
10115528|NCT04448990|Experimental|tVNS|Stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) bilaterally at the cymba conchae of the auricles for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
9821076|NCT02222610|Experimental|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
9821077|NCT02222610|Experimental|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
9821078|NCT02222688|Experimental|Cirmtuzumab 0.015 - 0.03 mg/kg|Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
9821079|NCT02222688|Experimental|Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg|Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
9821080|NCT02222688|Experimental|Cirmtuzumab 0.5 - 1.0 mg/kg|Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
9821081|NCT02222688|Experimental|Cirmtuzumab 2.0 - 4.0 mg/kg|Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
9821082|NCT02222688|Experimental|Cirmtuzumab 8 mg/kg|Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
9821083|NCT02222688|Experimental|Cirmtuzumab 16 mg/kg|Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
10115529|NCT04448990|Sham Comparator|Sham|Same stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) to bilaterally to the earlobes for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
9668350|NCT04601558|Active Comparator|Active-intervention group|The third group of participant was active-intervention group. There were also 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, active-intervention group were receiving Cochrane abstracts in the form of blog-shots.
10115530|NCT04448535|Experimental|Gingko Biloba|oral intake of gingko biloba for 4 weeks
9821084|NCT02222688|Experimental|Cirmtuzumab 20 mg/kg|Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
10115531|NCT04448769|Other|Anti-SARS-CoV-2 IgT seropositivity|Analysis of the serology result: The ELISA method allows semi-quantitative detection of total IgT antibodies. A positive sample will be defined by a ratio ≥ 1.0.
10115532|NCT04448639||STEMI|Patients with ST-elevation myocardial Infarction (STEMI) (TS) who undergo urgent coronary angiography within 12 hours of symptom onset.
9519416|NCT03287336|Experimental|Cohort 1|Dose of Tranexamic acid 5mg/kg will be administered.
9519417|NCT03287336|Experimental|Cohort 2|Dose of Tranexamic acid 10 mg/kg will be administered.
10115533|NCT04448639||TS|Patients with Takotsubo Syndrome (TS) who undergo urgent coronary angiography within 12 hours ofsymptom onset.
10115534|NCT04448587|Experimental|Sitagliptin|
9821085|NCT02222714|Active Comparator|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
9821086|NCT02222714|Active Comparator|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
9821087|NCT02222714|Active Comparator|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
9519418|NCT03287336|Experimental|Cohort 3|Dose of Tranexamic acid 15 mg/kg will be administered.
9668351|NCT04572165||semaglutide|New users of Ozempic® or Rybelsus®
9821088|NCT02222714|Active Comparator|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
9965766|NCT01252797|Active Comparator|Stereotactic Radiosurgery (15 Gy)|Group A: If the tumor which will be surgically removed is at least 2 cm and up to 4 cm in maximum diameter, then this group will receive Dose Level II (15 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
9668352|NCT04572165||Active comparator|First-time ever users of an active comparator drug
9668353|NCT04569123|Active Comparator|Vibration|The device will deliver imperceptible vibration for the treatment group.
9668354|NCT04569123|Sham Comparator|No Vibration|The device will deliver no vibration for the control group.
9821089|NCT02222714|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
9821090|NCT02222818|Other|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
9821091|NCT02222818|Other|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
9821092|NCT02222870|Experimental|Fluzone Study Group 1|Participants at 6 months to < 36 months age at enrollment
9821093|NCT02222870|Experimental|Fluzone Study Group 2|Participants at 3 years to < 9 years of age at enrollment
9821094|NCT02222896|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
9821095|NCT02222896|Placebo Comparator|Vehicle Cloth|Excipients on cloth
9821096|NCT02222896|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
9821097|NCT02222922|Experimental|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
9821098|NCT02222922|Experimental|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
9821099|NCT02222922|Experimental|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
9821100|NCT02222922|Experimental|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
9821101|NCT02223065|Experimental|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
9821102|NCT02223065|Experimental|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
9821103|NCT02223260|Experimental|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
9821104|NCT02223338|Active Comparator|Ciprofloxacin|"Ciprofloxacin:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
9821105|NCT02223338|Active Comparator|Standard Aseptic Technique|"Standard Aseptic Technique:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
9821106|NCT02223351|Other|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir
9821107|NCT02223351|Other|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir
9821108|NCT02223364|Active Comparator|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
9821109|NCT02223364|Active Comparator|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
9821110|NCT02223364|Active Comparator|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
9821111|NCT02223390|Experimental|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
9821112|NCT02223390|No Intervention|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
9821113|NCT02223429|Experimental|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
9821114|NCT02223429|Experimental|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
9821115|NCT02223455|Placebo Comparator|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
9668355|NCT04568031|Active Comparator|Part I|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
9821116|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Monthly|Intervention: Hand Hygiene Signs Changed Monthly Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
9821117|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Weekly|Intervention: Hand Hygiene Signs Changed Weekly Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
9821118|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
9821119|NCT02223637||Exposure group|"Pregnant women who were exposed to~≥1 dose of Menveo vaccine within 28 days prior to conception or at any time during pregnancy were included."
9821120|NCT02223650|Experimental|Overminus Treatment|2.50D overminus spectacles
9821121|NCT02223650|Active Comparator|Non-overminus Treatment|spectacles without overminus or no spectacles
9668356|NCT04568031|Placebo Comparator|Part II|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
9821122|NCT02223689|Experimental|Skin Affix|Surgical adhesive
9821123|NCT02223702|Active Comparator|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
9668357|NCT04563338|Experimental|Arm A (Liver Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
9668358|NCT04563338|Experimental|Arm B (Lung Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
9668359|NCT04563338|Experimental|Arm C (Lung Cancer)|Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
9668360|NCT04560439|Experimental|Treatment (METFIT program)|Patients undergo METFIT program for 16 sessions over 6 months.
9668361|NCT04557501|Active Comparator|Control - SOC Treatment|Participants to receive surgery or radiotherapy (+/- hormone therapy) as planned per SOC.
9668362|NCT04557501|Experimental|Experimental - PSMAiTx|Participants undergo PSMA PET/CT prior to treatment, and treated intensified based on image findings.
9668363|NCT04552262|Experimental|BAY2327949 / Placebo|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
9668364|NCT04552262|Experimental|Placebo / BAY2327949|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
9668365|NCT04537741|Experimental|NSTEMI scheduled for angiography|
9668366|NCT04519203|Active Comparator|SPI group|Group of patients where opioid consumption will be guided using SPI target
9668367|NCT04519203|Active Comparator|Control Group|Group of patients where only standard monitoring and patient reaction will be used to guide opioid administration during intraoperative period
9668368|NCT04498273|Active Comparator|Apixaban 2.5mg|Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
9668369|NCT04498273|Active Comparator|Apixaban 5mg|Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
9668370|NCT04498273|Active Comparator|Aspirin|Antiplatelet agent: low dose aspirin 81mg po qd
9668371|NCT04498273|Placebo Comparator|Placebo|Placebo
9668372|NCT04498208|Experimental|Personalized prehabilitation|Patients will participate in a personalized health optimization program combining one-on-one coaching, tailored to each patient's physical, nutritional, well-being and cognitive status baseline. Prehabilitation will last from a minimum of 14 days to a maximum of 42 days before surgery
9668373|NCT04498208|No Intervention|Standard prehabilitation|Patients in the control group will be provided with standard instructions in a hard-copy form specific to prehabilitation before surgery associating physical, nutritional, stress-reduction and cognitive recommendations without any personalized coaching for at least 14 days prior to surgery.
9668374|NCT04489771|Experimental|Dose A (standard dose)|Participants receive Dose A (standard dose) of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.
9668375|NCT04489771|Experimental|Dose B (higher dose)|Participants receive Dose B (higher dose) of belzutifan by oral administration, QD, until disease progression or discontinuation.
9668376|NCT04484974|Experimental|Pecan snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted roasted pecan nuts will be administered.
9668377|NCT04484974|Active Comparator|Tortilla chip snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted pretzels will be administered.
9668378|NCT04476654|No Intervention|Fact Sheet Arm|Komen print materials about genetic counseling and testing will be given to women.
9668379|NCT04476654|Active Comparator|YouTube Video Arm|Participants in this arm will receive the culturally tailored video either via a Youtube link or a DVD.
9668380|NCT04475055||Community sample|Participants will take part in the DIPS-interview and in an online survey.
9668381|NCT04463251|Experimental|RPH-104 80 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of placebo on different administration sites
9668382|NCT04463251|Experimental|RPH-104 160 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of (80 mg) of RPH-104 on different administration sites
9668383|NCT04463251|Placebo Comparator|Placebo|subjects will receive subcutaneous single injection of 2 mL of placebo and 2 mL of placebo on different administration sites
9668384|NCT04450953|Experimental|Eplerenone group A (cross over design)|Patient will receive eplerenone 50mg/day taken orally for 6 months, followed by a 2-month wash-out period, then a 6-month period without eplerenone, until the end of the study.
9668385|NCT04450953|Active Comparator|Eplerenone group B (cross over design)|Eplerenone-free for 6 months, followed by a 2-month wash-out period, then a 6-month period in which patients will receive eplerenone 50 mg/day as a single dose taken orally.
9668386|NCT04450238||Study Group|"All participants are inpatients at the clinic Stillachhaus in Germany. They are receiving treatment for a variety of psychological disoders, mostly depressive disoders."
9668387|NCT04440475|Experimental|Tap Block|"TAP block at the end of the surgery, in addition to conventional postoperative oral medication as needed~postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours"
9668388|NCT04440475|No Intervention|Conventional postoperative oral medication|postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours
9668389|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on warfarin|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used warfarin as a secondary stroke/TIA prevention.
9668390|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on apixaban|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used apixaban as a secondary stroke/TIA prevention.
9694310|NCT04790552|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
9821124|NCT02223702|Experimental|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
9821125|NCT02223715||CDI|
9821126|NCT02223754|Active Comparator|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
9821127|NCT02223754|Experimental|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
9821128|NCT02223793|Experimental|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
9821129|NCT02223793|Experimental|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
9821130|NCT02223793|Experimental|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
9821131|NCT02223858|Experimental|Positive Activities (PA)|Positive Activities (PA) Program
9821132|NCT02223858|Active Comparator|Attention Control (AC)|Attention Control (AC) Program
9821133|NCT02223871|Experimental|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
9821134|NCT02224053|Experimental|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
9821135|NCT02224157|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
9821136|NCT02224157|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
9821137|NCT02224274|Active Comparator|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
9821138|NCT02224274|Experimental|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
9821139|NCT02224313|No Intervention|1.Premenopausal women|No treatment
9821140|NCT02224313|Experimental|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
9821141|NCT02224404|Experimental|Fast Gelling Dressing|
9821142|NCT02224482|No Intervention|Control|Print materials
9821143|NCT02224482|Active Comparator|Intervention Group|PROGRESS
9821144|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
9821145|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
9821146|NCT02224560|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
9821147|NCT02224560|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
9821148|NCT02224560|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
9821149|NCT02224612|Active Comparator|Children 4-5 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
9821150|NCT02224612|Active Comparator|Children 6-9 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
9821151|NCT02224612|Active Comparator|Children 10-12 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
9821152|NCT02224625|Experimental|2% CHG Cloth|Chlorhexidine Gluconate 2%
10115535|NCT04448678|Experimental|HIEP intervention|Participants will be randomized to receive the insurance navigation intervention from patient navigators, which includes four, one hour long, educational learning sessions. Randomization will be done by age at diagnosis and site.
10115536|NCT04448678|Active Comparator|Usual Care|"Participants will be randomized to receive standard navigation provided by patient navigators (usual care)."
9821153|NCT02224625|Placebo Comparator|Vehicle Cloth|Excipients on cloth
9821154|NCT02224625|Active Comparator|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
9821155|NCT02224625|Sham Comparator|Saline|0.9% sodium chloride
9821156|NCT02224625|Active Comparator|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
9821157|NCT02224638|Active Comparator|TheraHoney HD|Honey product
9821158|NCT02224638|Active Comparator|SkinTegrity|Skin moisturizer
9821159|NCT02224664|Experimental|Cohort 3|Titration of PF-06649751 up to 5 mg QD
9821160|NCT02224664|Experimental|Cohort 4|Titration of PF-06649751 up to 15 mg QD
9821161|NCT02224664|Experimental|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
9821162|NCT02224664|Experimental|Cohort 6|Titration of PF-0649751 up to 25 mg QD
9826997|NCT02440594|Experimental|Enhanced Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
10115537|NCT04448496|Experimental|Arms|Diabetic macular edema Dexamethasone 0.7mg is injected into the vitreous cavity. Center-involved macular edema secondary to diabetic retinopathy for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
10115538|NCT04448743||Covid-19 patients|
10115539|NCT04448743||patients with coronary artery disease|
10115540|NCT04448743||healthy volunteers|
10115541|NCT04448470||patients with a clinical suspicion of sleep apnea (n=150)|patients with a clinical suspicion of sleep apnea
10115542|NCT04448470||healthy subjects (n=10)|healthy subjects
10115543|NCT04448457|Experimental|SSTS group|Patients received sufentanil nanotab patient controlled analgesia (PCA) system (Zalviso) 15 mcg with 20 min of lockout interval during 48 hours postoperatively
10115544|NCT04448457|Active Comparator|Oxycodone group|Patients received oxycodone extended-release tablet (OxyContin) 10 mg every 12 hours systematically plus Oxycodone 5 mg every 6 hours if numeric rating scale is above 3 during the 48 hours postoperatively
10115545|NCT04448249|Experimental|Interventional group|After inclusion, eligible patients are randomly assigned to one of the following groups: the control group of patients keeps a traditional follow-up (AH then consultation with a MD within approximately two to six months) and the interventional group meets an APN between the AH and the MD consultation, within one to three months
10115546|NCT04448249|No Intervention|Control group|After inclusion, eligible patients are randomly assigned to one of the following groups: the control group of patients keeps a traditional follow-up (AH then consultation with a MD within approximately two to six months) and the interventional group meets an APN between the AH and the MD consultation, within one to three months
10115547|NCT04448093|Experimental|Treatment group|Treated group (53) that answered quality of life questionnaires before, after and with 45 days of treatment.
10115548|NCT04448093|No Intervention|Group control|Untreated group (68) that answered quality of life questionnaires before, after and with 45 days of treatment.
9826998|NCT02440594|Active Comparator|Standard Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
9826999|NCT02440594|Experimental|Caregiver TEP Intervention|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Enhanced BHL Program Services which include: 1) a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services, and 2) the Telehealth Education Program (TEP) - BHPs provide manual and workbook-guided psychoeducation, support, and skills training.
9827000|NCT02440594|Active Comparator|Caregiver Control|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Standard BHL Program Services, which include a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services
9827001|NCT02440633|Experimental|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
9827002|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
10115549|NCT04448106|Experimental|Phase 2 Arm 1 - OA Knee|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
10115550|NCT04448106|Active Comparator|Phase 2 Arm 2 OA Knee|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
10115551|NCT04448106|Experimental|Phase 2 Arm 3 - OA Hip|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
10115552|NCT04448106|Active Comparator|Phase 2 Arm 4 - OA Hip|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
9821163|NCT02224690|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
9821164|NCT02224690|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
9821165|NCT02224703|Experimental|10 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/milliliter [mL] cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
9821166|NCT02224703|Experimental|20 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
9821167|NCT02224703|Placebo Comparator|Placebo Control|Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
9821168|NCT02224729|Experimental|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
9821169|NCT02224755|Experimental|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
9821170|NCT02224755|Active Comparator|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
9821171|NCT02224820|Experimental|Intravenous IdeS|One or two doses of IdeS in ascending doses
9821172|NCT02224846|Experimental|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
9821173|NCT02224846|Experimental|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
9821174|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
9821175|NCT02225106|Experimental|Open label methylphenidate treatment|Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily.
9821176|NCT02225132|Experimental|1|This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
9821177|NCT02225223|Other|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
9821178|NCT02225223|Other|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
9821179|NCT02225353|Experimental|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
9821180|NCT02225353|Experimental|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
9821181|NCT02225353|Active Comparator|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
9821182|NCT02225587|Experimental|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
9821183|NCT02225587|Placebo Comparator|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
9821184|NCT02225665|Experimental|Cohort 1|
9821185|NCT02225665|Experimental|Cohort 2|
9821186|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
9821187|NCT02225860|Active Comparator|Diet and Water adjustment|Reduction in dietary salt and protein intake
9821188|NCT02225860|No Intervention|Control|Continue with usual diet
9821189|NCT02225925|Experimental|Dynamic dosimetry brachytherapy|Cohort treated with dynamic dosimetry brachytherapy
9821190|NCT02226003|Experimental|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
9821191|NCT02226003|Experimental|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
9821192|NCT02226003|Placebo Comparator|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
9821193|NCT02226120|Experimental|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
9821194|NCT02226159|Active Comparator|Lidocaine|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
9821195|NCT02226159|Experimental|Lidocaine with Dexamethasone|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
9821196|NCT02226172|Experimental|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
9821197|NCT02226172|Placebo Comparator|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
9821198|NCT02226198|Active Comparator|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
9821199|NCT02226198|Placebo Comparator|Placebo|6 weeks treatment during crossover
9821200|NCT02226549|Experimental|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
9821201|NCT02226549|Experimental|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
9821202|NCT02226562|Experimental|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
9821203|NCT02226562|Other|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
9821204|NCT02226653|Experimental|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
9821205|NCT02226653|Experimental|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
9821206|NCT02226796|Active Comparator|Prime Condition|The primed (PRIME) condition is an intervention that will consist of presentation of a-tDCS for 20 minutes to the dorsolateral prefrontal cortex prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
9821207|NCT02226796|Active Comparator|Non-Prime Condition/Control|The non-primed (NON-PRIME) condition, or sham controlled, is an intervention that will consist of presentation of sham tDCS to the dorsolateral prefrontal cortex for 20 minutes prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
9821208|NCT02226965|Experimental|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
9821209|NCT02227108|Experimental|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
9821210|NCT02227121|Experimental|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
9821211|NCT02227316|Experimental|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
9821212|NCT02227316|Experimental|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
9821213|NCT02227316|Experimental|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
9821214|NCT02227316|Active Comparator|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
9821215|NCT02227329|Experimental|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
9821216|NCT02227329|Active Comparator|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
9821217|NCT02227368|Experimental|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
9821218|NCT02227368|Active Comparator|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
9821219|NCT02227446|Experimental|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
9821220|NCT02227446|No Intervention|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
9821221|NCT02227485|Active Comparator|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
9821222|NCT02227485|Experimental|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
9821223|NCT02227667|Experimental|Patients with Advanced Colorectal Cancer|This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD (with or without confirmation according to RECIST 1.1) during the monitoring period, administration of MEDI4736 may resume at the Q2W schedule, for up to another 12 months. The same treatment guidelines followed during the initial 12-month treatment period will be followed during the retreatment period, including the same dose and frequency of treatments and the same schedule of assessments.
9821224|NCT02227693|Experimental|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
9821225|NCT02227693|Experimental|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
9821226|NCT02227693|Experimental|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
9821227|NCT02227693|Placebo Comparator|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
9821228|NCT02227706|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
9519419|NCT03287323|No Intervention|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
9821229|NCT02227706|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
9821230|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
9821231|NCT02227784|Experimental|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
9821232|NCT02227784|Active Comparator|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
9821233|NCT02227784|Active Comparator|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
10115553|NCT04448106|Experimental|Phase 2 Arm 5 - OA Shoulder|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
9821234|NCT02227784|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
9821235|NCT02227810|Experimental|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
9821236|NCT02227810|Sham Comparator|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
9821237|NCT02227836|Experimental|Allergy Patch Testing APT|"Patient will undergo APT testing per the following protocol:~2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.~Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits~The patches will be removed at 48 hours, and results read at 72 and 120 hours after application~Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
9821238|NCT02227849|Experimental|Canagliflozin (TA-7284) ＋GLP-1 analogue|
9821239|NCT02228096|Experimental|tisagenlecleucel (CTL019)|Pediatric patients with relapsed/refractory B-cell ALL
9821240|NCT02228174|Experimental|Subjects Treated with Sonata|Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System or the Sonata, which is a sonography guided transcervical ablation device intended for treatment of symptomatic uterine fibroids. Subjects with symptomatic uterine fibroids and heavy menstrual bleeding who met the study population selection criteria received treatment with Sonata.
9821241|NCT02228395|Experimental|Cohort 1|Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
9821242|NCT02228395|Experimental|Cohort 2|Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
9821243|NCT02228395|Experimental|Cohort 3|Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
9821244|NCT02228408|Experimental|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
10115554|NCT04448106|Active Comparator|Phase 2 Arm 6 - OA Shoulder|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
10115555|NCT04448288|Experimental|Hamstring Group|Pretest-posttest experimental design. Subjects participated in three experimental trials on three different days. On day-I for static-stretching for 2 minutes (SS2), day-II for 4 minutes (SS4), and day-III for 8 minutes (SS8). Testing was conducted before (pre), immediately after (post), and at 10 and 20 min post stretching. MVCF was measured using strain gauze as main outcome measure. The SS trials involved varied repetitions of 30-s static-stretches and 20-s relax period. MVC force was assessed.
10115556|NCT04448080|Experimental|Topical Anesthesia|topical tetracaine eye drops (3 times, given in 1 minute intervals) followed by topical Xylocaine 2% Gel (alcohol-free formulation), given in 1 minute intervals for a total of 5 minutes
9519420|NCT03287323|Other|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
9519421|NCT03287284|Active Comparator|LLLT Group|Active Low Level Laser Therapy application with a dose of 240 Joules before resistance training
9519422|NCT03287284|Placebo Comparator|Placebo Group|Placebo Low Level Laser Therapy application before resistance training
9519423|NCT03287271|Experimental|Defactinib (VS-6063) +Carboplatin/Paclitaxel|
9821245|NCT02228408|Active Comparator|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
9821246|NCT02228460|Experimental|GZ/SAR402671|GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.
10115557|NCT04448080|Active Comparator|Analgosedation|Remifentanil 1mg i.v., and, Thiopental i.v., adapted to patients' weight, age, and hepatic and renal function; usually, a bolus of 150-250mg
10115558|NCT04448275|Experimental|study group|received conventional selected exercise program and in addition to Neurodynamics Nerve flossing for femoral nerve
9821247|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
9821248|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
9821249|NCT02228564|Experimental|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
9821250|NCT02228590|Other|APL-130277|open label baseline comparison
9821251|NCT02228681|Experimental|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
9821252|NCT02228681|Active Comparator|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
9821253|NCT02228720|Experimental|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
9821254|NCT02228824|Experimental|Very low nicotine content cigarettes|
9821255|NCT02228824|Active Comparator|Normal nicotine content cigarettes|
9821256|NCT02228967|No Intervention|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
9821257|NCT02228967|Active Comparator|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:~Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.~Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.~Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
9821258|NCT02228980|Experimental|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
9821259|NCT02228980|Experimental|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
9821260|NCT02228980|Experimental|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
9821261|NCT02228980|Experimental|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
9821262|NCT02229214|Experimental|VI-0521 (Qsymia)|"Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
9821263|NCT02229214|Placebo Comparator|Sugar pill|Days 1-28: Placebo
9821264|NCT02229227|Experimental|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
9821265|NCT02229227|Experimental|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
9821266|NCT02229318|Experimental|FruitiVits|Daily administration of FruitiVits dietary supplement
9821267|NCT02229383|Experimental|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
9821268|NCT02229383|Placebo Comparator|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
9821269|NCT02229396|Experimental|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
9821270|NCT02229396|Experimental|Exenatide Once Weekly 2 mg Alone|
9821271|NCT02229396|Active Comparator|Dapagliflozin Once Daily 10 mg Alone|
9821272|NCT02229461|Experimental|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
9821273|NCT02229461|Experimental|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
9821274|NCT02229461|Experimental|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
9821275|NCT02229461|Active Comparator|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
9827003|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
9827004|NCT02440789|Experimental|Sirolimus|
9821276|NCT02229461|Experimental|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
9821277|NCT02229461|Experimental|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
9821278|NCT02229474|Experimental|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
9821279|NCT02229474|No Intervention|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
10115559|NCT04448275|Experimental|control group|received conventional selected exercise program in form of: Ultrasound therapy The flexibility exercises for iliopsoas & quadriceps in heamophilic patient The iliopsoas & quadriceps muscles strength exercise
9821280|NCT02229487|Active Comparator|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
9821281|NCT02229487|Experimental|Short Sleepers|Prediabetes patients with short sleep duration (<6 hours/night) as measured objectively
9821282|NCT02229513|No Intervention|Control|Normal cesarean technique.
9821283|NCT02229513|Experimental|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
9821284|NCT02229539|Experimental|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
9821285|NCT02229539|Active Comparator|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.~Patients will complete the Oral Symptoms booklet per the protocol."
9821286|NCT02229539|Placebo Comparator|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
9821287|NCT02229552|Other|Baseline Cohort|Children completed body weight and other measures at baseline, 1-year follow up and 2-year follow up measurement periods.
9821288|NCT02229851|Experimental|NNC0195-0092 (somapacitan)|
9821289|NCT02229851|Active Comparator|Daily hGH|
9821290|NCT02229851|Placebo Comparator|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
9821291|NCT02229864|Experimental|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
9821292|NCT02230085||CPAP therapy|
9821293|NCT02230306|Experimental|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
9821294|NCT02230332|Experimental|Alendronate|Alendronate in 10mg capsules taken once daily
9821295|NCT02230332|Placebo Comparator|Placebo|Placebo capsule taken once daily
9821296|NCT02230384|Experimental|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
9821297|NCT02230384|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
9821298|NCT02230527|Active Comparator|Clopidogrel|Clopidogrel 75mg by mouth daily
10115560|NCT04448366|Experimental|Cognitive behavioral therapy group|Patients in this group will undergo a total of 7 sessions of CBT in 5 months in addition to usual care.
10115561|NCT04448366|No Intervention|Usual care|Patients in this group will undergo usual care only.
9821299|NCT02230527|Experimental|Ticagrelor|Ticagrelor 90mg by mouth twice daily
9821300|NCT02230540|Experimental|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
9821301|NCT02230540|Experimental|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.~Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
9821302|NCT02230566|Experimental|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
10115562|NCT04448379|Experimental|Dose Escalation Cohort|"Two dose levels of JMT101 combined with afatinib or osimertinib will be tested according to the 3 + 3 dose-escalation design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
10115563|NCT04448379|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
10115564|NCT04448353||Development / training|Selected by stratified partitioning
10115565|NCT04448353||Sequestered / test|Selected by stratified partitioning
10115566|NCT04448158||5 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 5 years
10115567|NCT04448158||10 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 10 years
10115568|NCT04448392|Other|Neonatal HSV disease requiring suppressive therapy|All subjects enrolled in the study will receive 2 (up to 7) days of valacyclovir 20 mg/kg every 8 hours after completion of standard of care treatment course with acyclovir.
10115569|NCT04448223|Experimental|CKD-351|CKD-351
10115570|NCT04448223|Active Comparator|Latanoprost+Dorzolamide|Latanoprost(50ul/ml) Dorzolmamide(20mg/ml)
10115571|NCT04448405||Patients followed by the CRIAVS|Patients followed by the CRIAVS (resource center for workers working with authors of sexual violence) in CHU Motpellier from June to October 2020
10115572|NCT04448132|Experimental|IPV-Al AJV|One dose of 0.5 mL of IPV-Al AJV injected intramuscularly perpendicular to the skin in the RIGHT deltoid muscle.
10115573|NCT04448236|Experimental|BFR-RE intervention group|"The participants will have the standardised 2 week resistance training with BFR-device with details as follows:~Cuff size: medium~Restriction time: 5- 10 mins (stop after finishing 4 sets of training or terminating by Physiotherapists)~Applied location: alternate quadriceps in consecutive day~Applied pressure: 80% limb occlusion pressure (LOP)"
10115574|NCT04448236|No Intervention|Control group|"Same standardized 2-week in-patient rehabilitation and same amount of the above-mentioned resistance training without the BFR device."
10115575|NCT04448340||Parkinson Disease Dementia|the PDD group comprised of 58 patients fulfilling the Criteria for probable PDD of the Movement Disorders Society
10115576|NCT04448340||Dementia with Lewy Bodies|the DLB group comprised of 40 patients, according to the recent revised criteria for probable DLB
10115577|NCT04448444|Experimental|Motor Program Activating Therapy (MPAT)|The MPAT was chosen for our clinical experience - it was developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centred. Then somatosensory (manual and verbal) stimuli are applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when the patient is lying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to use the acquired motor skills automatically in daily life.
10115578|NCT04448444|Experimental|Vojta Reflex Locomotion (VRL)|VRL was developed by prof. Vojta and is standardly used in the Czech Republic. In this therapy, patients should be set up into the precisely given initial position with defined angular setting of extremities. In each position (supine, prone, lying on the side, and low kneeling position), activation points (zones) are stimulated with precise localization and pressure direction. Such stimulation activates one of the global movement patterns (reflex turning and reflex creeping) corresponding to the initial position. In addition to motor involuntarily reaction, also sensory and autonomic response is activated.
10115579|NCT04448444|No Intervention|healthy controls|sex and age matched healthy controls
10115580|NCT04448041||Ghana|
10115581|NCT04448041||India|
10115582|NCT04448041||Philippines|
10115583|NCT04448041||Zambia|
10115584|NCT04448119|Experimental|Chemoprophylaxis|Participants of LTCH units allocated to the chemoprophylaxis arm receive favipiravir for 25 days. Residents in the LTCH unit diagnosed with COVID- 19 at enrollment will be offered treatment with favipiravir for 14 days.
10115585|NCT04448119|Placebo Comparator|Placebo|Participants of LTCH units allocated to the control arm receive placebo for 25 days. Residents in the LTCH unit diagnosed with COVID-19 at enrollment will be offered treatment with placebo for 14 days.
9821303|NCT02230566|Experimental|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
10115586|NCT04447976||Patients undergoing ERCP by formally trained Endoscopists|No intervention has been used and this is an observational study of evaluation of a TIP duodenoscope performance overall.
10115587|NCT04448015|Experimental|Enhanced Perinatal Care|Pregnant women enrolled in the study will receive enhanced perinatal care from community healthcare providers that have participated in the perinatal OUD education curriculum.
10115588|NCT04448067|Experimental|LOW Lentil Intake|Consumption of meals containing 60 g of lentils 5 out of 7 days per week for 8 weeks.
10115589|NCT04448067|Experimental|HIGH Lentil Intake|Consumption of meals containing 120 g of lentils 5 out of 7 days per week for 8 weeks
10115590|NCT04448067|Sham Comparator|CONTROL|Consumption of meals matched in total energy and protein to the lentil meals but containing 0 g of lentils 5 out 7 days per week for 8 weeks
10115591|NCT04447989|Active Comparator|Cohort 1, sildenafil|Sildenafil (0.5 mg/kg IV or 1 mg/kg enteral) every 8 hours for 28 days
10115592|NCT04447989|Placebo Comparator|Cohort 1, placebo|Placebo (IV or enteral) every 8 hours for 28 days
9821304|NCT02230566|Experimental|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
9821305|NCT02230566|Experimental|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
10115593|NCT04447989|Active Comparator|Cohort 2, sildenafil|Sildenafil (1 mg/kg IV or 2 mg/kg enteral) every 8 hours for 28 days
10115594|NCT04447989|Placebo Comparator|Cohort 2, placebo|Placebo (IV or enteral) every 8 hours for 28 days
9821306|NCT02230579|Experimental|Cohort SAD1 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
9821307|NCT02230579|Experimental|Cohort SAD2 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
9821308|NCT02230579|Experimental|Cohort SAD3 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
9821309|NCT02230579|Experimental|Cohort SAD4 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
9821310|NCT02230579|Experimental|Cohort SAD5 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
9821311|NCT02230579|Experimental|Cohort SAD6 Fed|Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
9821312|NCT02230670|Experimental|IDN-6556|25 mg BID of IDN-6556
9821313|NCT02230670|Placebo Comparator|Placebo|Placebo BID
9821314|NCT02230683|Experimental|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
9821315|NCT02230683|Experimental|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
9821316|NCT02230683|Experimental|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
9821317|NCT02230696|Experimental|Test Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Perrigo
9821318|NCT02230696|Active Comparator|Reference Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Meda
9821319|NCT02230696|Placebo Comparator|Placebo Product|Placebo nasal spray
9821320|NCT02230761|Experimental|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
9821321|NCT02230761|Placebo Comparator|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
9821322|NCT02230904|Experimental|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
10115595|NCT04447989|Active Comparator|Cohort 3, sildenafil|Sildenafil (2 mg/kg IV or 4 mg/kg enteral) every 8 hours for 28 days
10115596|NCT04447989|Placebo Comparator|Cohort 3, placebo|Placebo (IV or enteral) every 8 hours for 28 days
10115597|NCT04448002|Experimental|AIM2ACT|AIM2ACT is the experimental arm for the trial. AIM2ACT is a dyadic mHealth intervention designed to sustain caregiver involvement and monitoring as well as guide dyads through collaborative asthma management.
10115598|NCT04448002|Active Comparator|mHealth Attention Control Condition|The mHealth attention control condition is the active comparator arm in the trial that accounts for staff attention and novelty of technology based asthma management intervention.
9821323|NCT02230904|Experimental|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
9821324|NCT02230956|Experimental|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
9821325|NCT02230956|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
9821326|NCT02230956|Placebo Comparator|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
9821327|NCT02230995|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
9821328|NCT02230995|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
9821329|NCT02231086|Active Comparator|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
9821330|NCT02231086|Experimental|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
9821331|NCT02231164|Placebo Comparator|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
9821332|NCT02231164|Experimental|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
9821333|NCT02231177|Experimental|BI 1744 CL/Tiotropium FDC|
9821334|NCT02231177|Active Comparator|BI 1744 CL|
9821335|NCT02231177|Active Comparator|Tiotropium|
9821336|NCT02231580|Experimental|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
9821337|NCT02231580|Placebo Comparator|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
9821338|NCT02231749|Experimental|Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg|Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9827005|NCT02441062|Other|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
9821339|NCT02231749|Active Comparator|Arm B: Sunitinib 50 mg|"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks"
9821340|NCT02231918|Experimental|MIRAPEX® - low|
9821341|NCT02231918|Experimental|MIRAPEX® - medium|
9821342|NCT02231918|Experimental|MIRAPEX® - high|
9821343|NCT02232009|Other|3.0 T Neonatal Scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
9821344|NCT02232022|Experimental|NonCryptogenic Ischemic Stroke Patients|Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset
9821345|NCT02232061|Experimental|Fingolimod|Fingolimod 0.5mg/day tablets taken orally.
9821346|NCT02232074|Experimental|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
9821347|NCT02232074|No Intervention|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
9821348|NCT02232087|Experimental|test product A|salmeterol and fluticasone propionate, 2 puffs
9821349|NCT02232087|Active Comparator|reference product D|salmeterol and fluticasone propionate, 2 puffs
9821350|NCT02232087|Experimental|test product B|salmeterol and fluticasone propionate, 6 puffs
9821351|NCT02232087|Active Comparator|reference product E|salmeterol and fluticasone propionate, 6 puffs
9821352|NCT02232087|Experimental|test product C|salmeterol and fluticasone propionate, 12 puffs
9821353|NCT02232087|Active Comparator|reference product F|salmeterol and fluticasone propionate, 12 puffs
9821354|NCT02232126|No Intervention|Usual Care|
9821355|NCT02232126|Experimental|Intervention|
9821356|NCT02232178|Experimental|2 100mg Xaracoll implants|Bupivacaine HCl implant
9821357|NCT02232178|Experimental|3 100mg Xaracoll implants|Bupivacaine HCl implant
9821358|NCT02232178|Active Comparator|150mg Bupivacaine HCl injection|Bupivacaine HCl
9821359|NCT02232243|Experimental|Initial: Hydroxychloroquine 400mg HCQ|These initial 3 patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
9821360|NCT02232243|Experimental|Secondary: Hydroxychloroquine 800mg HCQ|Based on data analysis from the initial patients, these patients received 400mg hydroxychloroquine (HCQ) twice daily (800mg/day total) for 14 days prior to surgery.
9821361|NCT02232243|Experimental|Tertiary: Hydroxychloroquine 400mg HCQ|Based on data from the primary and secondary groups, patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
9821362|NCT02232425|Experimental|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
9821363|NCT02232425|Placebo Comparator|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
9821364|NCT02232698|Experimental|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
9821365|NCT02232698|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
9821366|NCT02232802|Experimental|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
9821367|NCT02232802|Experimental|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
10115599|NCT04447833|Experimental|Mesenchymal Stromal Stem Cell Treatment|Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg.
9821368|NCT02232893|Experimental|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID (15g/day)
9821369|NCT02232893|Placebo Comparator|Placebo|Placebo TID
9827006|NCT02441114|Experimental|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.~The periods were separated with a washout period of 14 days."
9827007|NCT02441179|Experimental|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
9827008|NCT02441179|Placebo Comparator|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
9827009|NCT02441218|Experimental|Ivabradine|
9827010|NCT02441218|Placebo Comparator|Placebo|
9827011|NCT02441283|No Intervention|HCV-infected Participants|Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.
9827012|NCT02441309|Experimental|A. Mifamurtide only|"Treatment Weeks 1-6 (post 1st biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 13-36:~Mifamurtide 2mg/m2, IV infusion, once/week."
9827641|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
9821370|NCT02232984||All study patients|All study patients will be implanted with a Boston Scientific (BSC) quadripolar Cardiac Resynchronization Therapy (CRT-D) and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
9821371|NCT02233101|Active Comparator|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
9821372|NCT02233101|Active Comparator|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
9821373|NCT02233296|Experimental|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
9821374|NCT02233296|Experimental|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
9821375|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
9821376|NCT02233413|Sham Comparator|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
9821377|NCT02233413|Active Comparator|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
9821378|NCT02233478|Active Comparator|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
9821379|NCT02233478|Active Comparator|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
9821380|NCT02233478|Active Comparator|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
9821381|NCT02233517|Experimental|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
9821382|NCT02233517|Active Comparator|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
9821383|NCT02233530|Experimental|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
9821384|NCT02233543|Experimental|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
9821385|NCT02233543|Experimental|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
9821386|NCT02233647|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
9821387|NCT02233647|Experimental|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.~Placebo will be administered acutely during low dose phendimetrazine maintenance."
9821388|NCT02233647|Experimental|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
9821389|NCT02233647|Experimental|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.~Placebo will be administered acutely during high dose phendimetrazine maintenance."
9821390|NCT02233738|Experimental|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
9821391|NCT02233738|Active Comparator|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
9821392|NCT02233751|Experimental|Testosterone enanthate auto-injector - 50 mg|Testosterone enanthate auto-injector - 50 mg (SC injection)
9821393|NCT02233751|Experimental|Testosterone enanthate auto-injector - 200 mg|Testosterone enanthate auto-injector- 200 mg (SC injection)
9821394|NCT02233803|Experimental|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
9821395|NCT02233803|Experimental|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
9821396|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
9821397|NCT02233946|Experimental|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
9821398|NCT02233946|No Intervention|Screening with Treatment as Usual|Screening with Treatment as Usual
9821399|NCT02233985|Active Comparator|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
9821400|NCT02233985|Experimental|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
9821401|NCT02233998|Active Comparator|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
9821402|NCT02233998|Active Comparator|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
10115600|NCT04447781|Experimental|Group 1 (Part A)|"Number of Subjects: 20 subjects~ID Injection of INO-4800 1mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
10115601|NCT04447781|Experimental|Group 2 (Part A)|"Number of Subjects: 20 subjects~ID Injection of INO-4800 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
10115602|NCT04447781|Experimental|Group 3 (Part B)|"Number of Subjects: 90 subjects~ID Injection of INO-4800 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
10115603|NCT04447781|Placebo Comparator|Group 4 (Part B, Placebo)|"Number of Subjects: 30 subjects~ID Injection of Placebo (SSC) 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
10115604|NCT04447859|Active Comparator|label recommended titration|eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy)
10115605|NCT04447859|Experimental|Slow semaglutide titration|A slower 16-week titration regimen (initiate treatment at 0.0675mg/week and increase the dose by 0.0675mg weekly until a dose of 1mg/week is reached)
10115606|NCT04447937||Multiple Sclerosis and Related Diseases|Individuals with one or more immunoglobulin level results and medical histories available for data collection will be included. Subjects will be 18 years of age or older at the time of data collection.
10115607|NCT04447703|Experimental|Aim I (Interview)|Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinical for 2 weeks. After 2 weeks, provides discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.
9821403|NCT02233998|Placebo Comparator|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
9821404|NCT02234063|Experimental|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
9821405|NCT02234063|No Intervention|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
9821406|NCT02234115|Experimental|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
9821407|NCT02234128|Experimental|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
9821408|NCT02234128|Experimental|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
9821409|NCT02234128|No Intervention|Control Group|Those patients receiving a single or double lung via conventional transplant.
9821410|NCT02234141|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 milligrams (mg) for 24 weeks and may continue on this dose during the long-term treatment phase.
9821411|NCT02234141|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
9821412|NCT02234141|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
9821413|NCT02234141|Experimental|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
9821414|NCT02234180|Experimental|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9821415|NCT02234180|Placebo Comparator|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9821416|NCT02234284|Experimental|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
9821417|NCT02234284|No Intervention|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
9821418|NCT02234362|Experimental|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
9821419|NCT02234427|Experimental|Aspirin|
9821420|NCT02234479|Active Comparator|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
9821421|NCT02234479|Experimental|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
9821422|NCT02234570|Experimental|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
9821423|NCT02234570|Experimental|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
9821424|NCT02234570|Experimental|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
9821425|NCT02234570|Experimental|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
9821426|NCT02234570|Experimental|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
9821427|NCT02234570|Experimental|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
9821428|NCT02234570|Experimental|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
9821429|NCT02234583|Experimental|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
9821430|NCT02234596|Experimental|Nintedanib|
9821431|NCT02234622|Experimental|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
9821432|NCT02234622|Active Comparator|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
9827642|NCT02462928|Active Comparator|Ranibizumab 0.5 mg (rQ4)|Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.
9821433|NCT02234713|Experimental|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
9821434|NCT02234713|Active Comparator|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
9821435|NCT02234752|Experimental|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS & Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS & Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS & Memantine XR 21 mg HS
9821436|NCT02235064|Experimental|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
9821437|NCT02235064|Placebo Comparator|Placebo|Identical appearing capsule daily containing color-matched cellulose only
9821438|NCT02235077|Active Comparator|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
9821439|NCT02235077|Placebo Comparator|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
9821440|NCT02235285|Experimental|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
9821441|NCT02235298|Experimental|Dapagliflozin and Metformin Group|Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.
9821442|NCT02235298|Active Comparator|Metformin and Placebo Group|Participants in this group will receive Metformin and Placebo for 6 months.
9821443|NCT02235311|Active Comparator|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
9821444|NCT02235311|Active Comparator|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
9821445|NCT02235454|Other|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
10115608|NCT04447703|Active Comparator|Aim II: Arm I (Genetic Counseling, Genetic Testing)|Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.
10115609|NCT04447703|Experimental|Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)|Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.
10115610|NCT04447794|Active Comparator|Step Away App|Participants randomly assigned to this arm will access the Step Away smartphone-based mobile application immediately upon enrollment.
10115611|NCT04447794|Experimental|Step Away Chatbot|Participants randomly assigned to this arm will access the Step Away mobile, text-based, interactive AI chatbot immediately upon enrollment.
10115612|NCT04447794|No Intervention|Step Away App Delay|Participants randomly assigned to this arm will be provided access to the Step Away smartphone-based mobile application three months after enrollment.
10115613|NCT04448028|Placebo Comparator|Intervention group|Patients randomized to the intervention group discontinue their pre-existing PPI treatment and replace it with placebo (day 15 to 360). During the first 14 days (dose tapering phase) patients in the intervention group will receive placebo on day 1, 3, 5, 7, 9, 10, 12, 13 and esomeprazole 20mg on day 2, 4, 6, 8, 11, 14, to minimize the risk for gastric acid rebound symptoms.
10115614|NCT04448028|Active Comparator|Control group|Patients randomized to the control group continue their pre-existing PPI therapy with esomeprazole 20mg/day (day 15 to 360). During the first 14 days (dose tapering phase) patients in the control group receive esomeprazole 20mg/day on day 1 to 14.
10115615|NCT04447807|Experimental|Group A: Metacognitive Training Intervention|"Participants of this group will under go Metacognitive Training (MCT) in group format for the duration of 8 weeks. The intervention will be helf once a week, with an estimate duration of 1-2 hours. The MCT intervention focuses on rehabilitating Social Cognition and teaching skills of inter-personal relations, as well as functional remediation aspects.~We estimate a total of 45 participants in this group."
10115616|NCT04447807|Experimental|Group B: Treatment as Usual|Participants of this group will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School, although they will not be part taking in any group rehabilitation format We estimate a total of 45 participants in this group.
10115617|NCT04447911|Experimental|Empagliflozin|Empagliflozin (Jardiance)® 25mg per os once daily for 30 days
10115618|NCT04447911|Placebo Comparator|Placebo|Placebo (Lactose tablet) per os once daily for 30 days
10115619|NCT04447950|Experimental|Study group|Posterior QL block with 20-40 cc of Bupivocaine in posterior border of Quadratum Lumborum muscle at the end of the operation.
10115620|NCT04447950|Placebo Comparator|Placebo group|Posterior QL block with 40 cc of Saline in posterior border of Quadratum Lumborum muscle at the end of the operation.
9519424|NCT03287258|Active Comparator|three program|200 patients are subjected to educational Pelvic floor dysfunction prevention program with perineal massage and Pelvic floor muscle exercise.
9519425|NCT03287258|Active Comparator|one program|200 patients are subjected to educational Pelvic floor dysfunction prevention program
9821446|NCT02235493||Retrospective Case Only|
9821447|NCT02235831|Experimental|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
9821448|NCT02235831|Active Comparator|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
9668391|NCT04435301|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator(NeuroConn, Germany). Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3), respectively. 40Hz acoustic stimuli and 40Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
9668392|NCT04435301|Experimental|Beta modulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the middle and lower part of the face to stimulate the maxillary nerve (V2) and the mandibular nerve (V3). 28Hz acoustic stimuli and 28Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
9668393|NCT04435301|Sham Comparator|Sham modulation group|Sham stimulation was identical to the 40Hz stimulation, except that the acoustic and electric stimulation were ramped down after 0.5 min to remain turned off for the remaining 39.5 min. Sham stimuli are applied for 40min/day, for a total of 5 days.
9668394|NCT04428554|No Intervention|Control arm|Standard of care
9668395|NCT04428554|Experimental|Experimental arm|
9694311|NCT04790552|Experimental|Night Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will consume a Fast Bar 3 hours after the dinner and then fast overnight. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
9694312|NCT04790552|Experimental|Bar + Coffee Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with coffee on day 2.
9694313|NCT04790552|Experimental|Bar + Tea Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar with tea on day 2.
9694314|NCT04790617|Experimental|Intervention|Community health navigator program for six months.
9694315|NCT04790617|No Intervention|Control|Usual health care.
9694316|NCT04790643||Stage 1 - Development of the new cardiac risk stratification protocol|This will be a prospective cohort study, in which individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables that will be used to guide the elaboration of the cardiac risk stratification protocol. After this initial evaluation, the volunteers will be followed for 2 months during their habitual cardiac rehabilitation routine for the evaluation and registry of the occurrence of minor adverse events, defined as signs and symptoms (arrhythmias, blood pressure alterations, tachypnea, pallor, chest pain, cramps, muscle pain, fatigue, and nausea). The cardiac rehabilitation program in which the volunteers will be recruited is based on moderate-intensity aerobic exercise.
9694317|NCT04790643||Stage 2 - Reproducibility and efficiency of the new protocol|"This will be a prospective cohort study, in which a new sample of individuals attending cardiac rehabilitation programs will be assessed by clinical and physical variables and stratified in one of the three following risk classes: low risk, moderate risk, and high risk accordingly to the new risk stratification protocol. After that, the sample will be followed for 2 months of rehabilitation to the evaluation of the occurrence of signs and symptoms. The cardiac rehabilitation program from where the volunteers will be recruited is based on moderate-intensity aerobic exercise and resistance training. With these data, the reproducibility and efficiency of the protocol will be evaluated."
9694318|NCT04790643||Stage 3 - Protocols´ agreement between evaluators|This will be a cross-sectional observational study in which a new sample of participants will be evaluated by two independent physiotherapists for clinical and physical variables, and based on these data will be stratified by the new protocol by the same evaluators independently. After these procedures, the protocol´s agreement between evaluators will be analyzed.
9694319|NCT04790630|Experimental|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|
9694320|NCT04790630|Active Comparator|Active Control|
9694321|NCT04790656|Active Comparator|Conventional Therapy|The control program will consist of progressive exercises according to each postoperative day. Two daily sessions with an average duration of 25 min will be performed. In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
9694322|NCT04790656|Experimental|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days
9694323|NCT04790487|Experimental|Chlorpheniramine|Chlorpheniramine (CPM)
9694324|NCT04790487|Placebo Comparator|Control|Saline
9694325|NCT04790604|Experimental|Intervention|Community health navigator program for six months.
9694326|NCT04790604|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program.
9694327|NCT04790565|Experimental|Fecal microbiota transplantation (FMT)|Patients will be given capsulized FMT, 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Patients will continue fasting for 2 hours after the intervention. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
9694328|NCT04790682|Experimental|NSCLC patient in a metastatic stage eligible for 1st-line TT with immune checkpoint inhibitor.|
9694329|NCT04790591|Active Comparator|Age <80 yrs. and ASA class <3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
9694330|NCT04790591|Active Comparator|Age ≥80 yrs. and/or ASA class ≥3|To follow a same-day surgery protocol when undergoing a partial knee replacement procedure.
9694331|NCT04790669|Experimental|Daily adjustable progressive resistance exercises (DAPRE)|DAPRE technique, hot pack, stretching exercises.
9694332|NCT04790669|Experimental|Close kinetic chain exercises (CKC).|CKC exercises, hot pack, stretching exercises
9694333|NCT04790448|Experimental|VIC regimen|"Patients will receive VIC regimen every 2 weeks:~Cetuximab 500mg/m2 IV on Day 1; Irinotecan 180mg/m2 IV on Day 1 (If patient carries UGT*28 7/7 or UGT*6 A/A or UGT*28 6/7 and UGT*6 A/G variants, use Irinotecan IV 150mg/m2 instead); Vemurafenib PO BID on Days 1 to 14 (Dosage: 480mg; 720mg; 960mg, determined by the maximum tolerated dose (MTD) in Phase Ia trial)."
9827643|NCT02462967|Active Comparator|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
9821449|NCT02235831|Active Comparator|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
9821450|NCT02235870|Active Comparator|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
9821451|NCT02235870|Sham Comparator|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
9821452|NCT02235987|Other|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
9821453|NCT02236130|Active Comparator|General|General Anesthesia only
9821454|NCT02236130|Experimental|Regional|General Anesthesia combined with regional block
9821455|NCT02236338|Active Comparator|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
9821456|NCT02236338|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
9821457|NCT02236520|Active Comparator|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
9821458|NCT02236520|Active Comparator|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
9821459|NCT02236520|Active Comparator|Diet|diet of 6 g salt per day for 8 weeks
9821460|NCT02236520|Placebo Comparator|Placebo|placebo capsule administered orally 1 per day for 8 weeks
9821461|NCT02236559|Active Comparator|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
9821462|NCT02236559|Experimental|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%."
9821463|NCT02236598|Experimental|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
9821464|NCT02236598|Experimental|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months~Subjects will be instructed to take the pills"
9821465|NCT02236611|Experimental|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
9821466|NCT02236611|Experimental|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
9821467|NCT02236767|Experimental|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
9821468|NCT02236988|Experimental|Group 1|"Participants received the following 4 treatments, given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) B) A single oral dose 75 mg apremilast tablet prototype MR 1 C) A single oral dose 75 mg apremilast tablet prototype MR 2 D) A single oral dose 75 mg apremilast capsule prototype MR 3"
9821469|NCT02236988|Experimental|Group 2|"Participants received the following 4 treatments, given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) E) A single oral dose 75 mg apremilast capsule prototype MR 4 F) A single oral dose 75 mg apremilast capsule prototype MR 5 G) A single oral dose 75 mg apremilast capsule prototype MR 6"
9821470|NCT02236988|Experimental|Group 3|"Participants received the following 3 treatments, given in 6 possible sequences (AIJ, IJA, JAI, AJI, IAJ, or JIA) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) I) A single oral dose 80 mg apremilast capsule prototype MR 8 J) A single oral dose 80 mg apremilast capsule prototype MR 9"
9827644|NCT02462967|Active Comparator|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
9827645|NCT02462967|Placebo Comparator|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
10115621|NCT04447612|Experimental|Durvalumab arm|"Induction phase: Durvalumab 1500mg via intravenous infusion every 4 weeks, with chemotherapy gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.~Concurrent phase: Durvalumab 1500mg via intravenous infusion every 4 weeks for 2 cycles, with cisplatin 100mg/m2 via intravenous infusion every 3 weeks for 3 cycles.~Maintenance phase: Durvalumab 1500mg daily via intravenous infusion every 4 weeks for 8 cycles."
9668396|NCT04423874|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while listening to vocalisations. Physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
9668397|NCT04417595|Experimental|Fish Oil|Participants allocated to n-3 LCPUFA supplementation will be instructed to take four 1000 mg n-3 LCPUFA capsules (Metagenics™) daily. This will provide a total daily dose of 4000 mg n-3 LCPUFAs (2840 EPA and 1160 DHA).
9668398|NCT04417595|Placebo Comparator|Olive Oil|Oleic acid (olive oil) capsules have a similar texture, size, color, and consistency to EPA capsules. Participant will be instructed to take four 100mg olive oil capsules
9668399|NCT04409470||Indication for blood gas sampling|To be eligible, patients will need to be classified as critically ill and there has to be a clear clinical indication for an arterial blood gas sampling. Enrollment will be performed in a consecutive manner at all hours.
9668400|NCT04405076|Experimental|mRNA-1273: Dose 50 microgram (ug) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 18-54 years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
9668401|NCT04405076|Experimental|mRNA-1273: Dose 50 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
9668402|NCT04405076|Experimental|mRNA-1273: Dose 100 ug - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 18-54 years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
9668403|NCT04405076|Experimental|mRNA-1273: Dose 100 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
9668404|NCT04405076|Placebo Comparator|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.~Part B: Participants aged 18-54 who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
9668405|NCT04405076|Placebo Comparator|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
9668406|NCT04405076|Experimental|mRNA 1273.351 20 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1.
9668407|NCT04405076|Experimental|mRNA 1273.351 50 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA 1273.351 on Day 1.
9668408|NCT04405076|Experimental|mRNA-1273/mRNA-1273.351 mixture (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA-1273/mRNA-1273.351 mixture on Day 1.
9668409|NCT04376424|Experimental|Ultra Sound Guided Therapy Group|Hand carried ultrasound will be used in this group to measure IVCd, collapsibility along with internal jugular vein collapsibility. The results of the ultrasound will be unblinded to the treating team.
9668410|NCT04376424|No Intervention|Conventional Therapy Group|Conventional therapy will occur the use of hand carried ultrasound. The results will be blinded to the treating team. The managing team will analyze the data at the end of the study.
9668411|NCT04375722|Experimental|tACS 10 Hz low frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 10-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
9668412|NCT04375722|Experimental|tACS 40 Hz high frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 40-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
9668413|NCT04375722|Sham Comparator|tACS sham|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups.
9668414|NCT04372914|Experimental|BRB Lozenges|Oral lozenges that contain 1 gram of BRB freeze-dried powder
9668415|NCT04371432||Sample Group 1 (NIHCC)|Existing NIH Clinical Center patients/participants tested positive for SARS-CoV-2 invited to participate by their NIH study team
9668416|NCT04371432||Sample Group 2 (OMS &amp; Field)|Recruited through NIH OMS, referred by collaborators or who self-refer, tested positive for SARS-CoV-2 (and selected relatives of participants irrespective of infection status)
9821471|NCT02236988|Experimental|Group 4|"Participants received the following 5 treatments, given in 10 possible sequences (ALOMN, LMANO, MNLOA, NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, or MLNAO) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) L) A single oral dose 80 mg apremilast capsule prototype MR 11 M) A single oral dose 80 mg apremilast capsule prototype MR 12 N) A single oral dose 80 mg apremilast capsule prototype MR 13 O) A single oral dose 80 mg apremilast capsule prototype MR 14"
9821472|NCT02237001|Experimental|Treatment|Suture-based meniscal repair
9821473|NCT02237092|Experimental|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
9821474|NCT02237118|Active Comparator|Mepitel One|Pain on dressing removal, by VAS
9821475|NCT02237118|Active Comparator|UrgoTul|Pain on removal by VAS
9821476|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 1)|Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
9821477|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 2)|Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
9821478|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 3)|Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
9821479|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 4)|Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose
9821480|NCT02237196|Experimental|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.~Cat immunotherapy will be administered weekly."
9821481|NCT02237196|Active Comparator|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.~Cat immunotherapy will be administered weekly."
9821482|NCT02237196|Experimental|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.~Placebo for Cat immunotherapy will be administered weekly."
9821483|NCT02237196|Placebo Comparator|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.~Placebo for cat immunotherapy will be administered weekly."
9821484|NCT02237417|Other|Healthy Control|
9821485|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group A)|
9821486|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group B)|
9821487|NCT02237898|Experimental|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application & Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
9821488|NCT02237898|Active Comparator|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
9821489|NCT02237911|Experimental|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
9821490|NCT02237911|Active Comparator|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
9821491|NCT02237911|No Intervention|Wait-listed usual medical care|Wait-listed usual medical care - no intervention provided by study.
9821492|NCT02237950|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
9821493|NCT02237950|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
9821494|NCT02237989|Active Comparator|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
9821495|NCT02237989|Experimental|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
9821496|NCT02238028|Experimental|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
9821497|NCT02238028|No Intervention|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
9821498|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
9821499|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
9821500|NCT02238379|Experimental|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
9821501|NCT02238379|Placebo Comparator|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
9821502|NCT02238483|Experimental|AZD7624|Active treatment
9821503|NCT02238483|Placebo Comparator|Placebo|Placebo Comparator
9821504|NCT02238626|Placebo Comparator|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets plus 50 mg riluzole by mouth twice daily for 6 months.
9821505|NCT02238626|Experimental|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day plus 50 mg riluzole 2 times a day by mouth for 6 months.
9821506|NCT02238782|Experimental|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
9821507|NCT02238847|Active Comparator|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
9821508|NCT02238847|Active Comparator|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
9821509|NCT02238925|Experimental|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
9821510|NCT02238977|Active Comparator|Fluoxetine|Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
9821511|NCT02238977|Experimental|Bupropion|Bupropion sustained release (SR) 150 mg orally twice per week
9519426|NCT03287180|Experimental|Experimental group|Participants in the experimental group will attend one individual assessment with the study physician for combination of buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
9821512|NCT02239094|Other|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
9821513|NCT02239120|Experimental|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
10115622|NCT04447612|Active Comparator|Standard of care arm|"Induction phase: Chemotherapy with gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.~Concurrent phase: Cisplatin 100mg/m2 on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles."
10115623|NCT04447664|Experimental|Telemedicine arm|
9821514|NCT02239120|Active Comparator|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
9821515|NCT02239224|Experimental|Cohort 1: ATYR1940 0.3 mg/kg|Participants will receive ATYR1940 0.3 milligrams/kilograms (mg/kg) intravenous (IV) infusion once weekly for 4 weeks.
9821516|NCT02239224|Experimental|Cohort 2: ATYR1940 1.0 mg/kg|Participants will receive ATYR1940 1.0 mg/kg IV infusion once weekly for 4 weeks.
9821517|NCT02239224|Experimental|Cohort 3: ATYR1940 3.0 mg/kg|Participants will receive ATYR1940 3.0 mg/kg IV infusion once weekly for 12 weeks.
9821518|NCT02239224|Placebo Comparator|Placebo|Participants will receive placebo matched to ATYR1940 IV infusion once weekly for 4 weeks in Cohorts 1 and 2 and for 12 weeks in Cohort 3.
9821519|NCT02239263|Experimental|N6 Input Processing Features|
9821520|NCT02239289|Experimental|Biofeedback|Subjects will be provided with four sessions of supervised biofeedback training
9821521|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
9821522|NCT02239380|Experimental|Lorazepam|Lorazepam intravenous formulation
9821523|NCT02239510|Active Comparator|Senna|1 capsule (50 mg) Senna daily for 12 weeks
9821524|NCT02239510|Active Comparator|Linzess|1 capsule (145 mcg) once daily for 12 weeks
9821525|NCT02239536|Experimental|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
9821526|NCT02239536|Experimental|Hot snare polypectomy(saline injection)|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
9821527|NCT02239562|Experimental|SAD sPIF 0.1|single ascending dose (SAD) 3 patients with normal liver function tests (LFTs) and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1
9821528|NCT02239562|Experimental|SAD sPIF 0.5|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: single SQ dose 0.5 mg/kg sPIF or Placebo Day 1
9821529|NCT02239562|Experimental|SAD sPIF 1.0|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Cohort 3: single SQ dose 1.0 mg/kg sPIF or Placebo Day 1
9821530|NCT02239562|Experimental|MAD sPIF 0.1|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ (one time) 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.1 mg/kg sPIF or Placebo Days 1-5
9821531|NCT02239562|Experimental|MAD sPIF 0.5|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.5 mg/kg sPIF or Placebo Days 1-5
9821532|NCT02239562|Experimental|MAD sPIF 1.0|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 1.0 mg/kg sPIF or Placebo Days 1-5
10115624|NCT04447664|No Intervention|Control arm|
9821533|NCT02239601|Experimental|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
9821534|NCT02239640||Medtronic NV market-released device|Patients experiencing an acute ischemic stroke due to a large vessel occlusion treated with a Medtronic Neurovascular market-released neurothrombectomy device.
9821535|NCT02239679|Experimental|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
9821536|NCT02239679|Placebo Comparator|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
9821537|NCT02239679|Experimental|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
9821538|NCT02239692|Active Comparator|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
9821539|NCT02239692|Experimental|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
9821540|NCT02239744|Experimental|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
9821541|NCT02239744|Sham Comparator|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
9821542|NCT02239770|Placebo Comparator|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
9821543|NCT02239770|Experimental|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
10115625|NCT04447885|Experimental|Experimental blanket|This blanket is the weight being tested which cannot be disclosed without unblinding participants.
10115626|NCT04447885|Active Comparator|Control blanket|This blanket is the control weight which cannot be disclosed without unblinding participants.
10115627|NCT04447599|Experimental|Photographs|Photographs
10115628|NCT04447352|Active Comparator|Arm A - FLOT|"Patients randomized to treatment Arm A already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
10115629|NCT04447352|Experimental|Arm B - FLOT/HIPEC|"Patients randomized to treatment Arm B already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery including Intraoperative Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) during gastric-/ esophagogastric resection using Cisplatin 75mg/m². Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
10115630|NCT04447586|Active Comparator|Patients following Command A and B|This group of patients followed the Commands A and B with this specific order, and performed 3 exhalation attempts for each command.
10115631|NCT04447586|Active Comparator|Patients following Command B and A|This group of patients followed the Commands B and A with this specific order, and performed 3 exhalation attempts for each command.
10115632|NCT04447586|Active Comparator|intervention group|"Intervention group was requested to exhale as indicated by the right command, performing 3 sets of 10 repetitions."
10115633|NCT04447586|No Intervention|control group|"Did not perform exhalation attempts by the right command."
10182512|NCT03773250|Experimental|Behavioral Intervention|Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
10182513|NCT03773250|No Intervention|Control|No intervention will be provided.
10182514|NCT03773094|Experimental|Guava leaves extract|A natural product that is prepared as a mouthwash
10182515|NCT03773094|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
10182516|NCT03773224|Active Comparator|Irrigation|Layer by layer irrigation of the surgical wound with gentamicin-saline solution
10182517|NCT03773224|No Intervention|Control|The surgical wound is closed layer by layer without irrigation
10182518|NCT03773159||Patients|Patients with von Willebrand disease or major constitutional thrombopathy or patients on antiplatelet drugs
10182519|NCT03773159||Controls|Blood donors at the French blood establishment in Burgundy Franche-Comté
10182520|NCT03773068|Experimental|Group 1 - BAY1817080 Dose 1|Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
10182521|NCT03773068|Experimental|Group 2 - BAY1817080 Dose 2|Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg [13C715N]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
10182522|NCT03773068|Experimental|Group 3 - BAY1817080 Dose 3|Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence
10182523|NCT03773055|Active Comparator|NPC-06 (High dosage)|18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage
9821544|NCT02239770|Experimental|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
9821545|NCT02239770|Placebo Comparator|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
9821546|NCT02239770|Experimental|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
9827646|NCT02463032|Experimental|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
9519427|NCT03287180|Active Comparator|Control group|Participants in the control condition will attend weekly individual medical management sessions with the MD who will also provide a prescription for a combination of buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
9668417|NCT04347226|Experimental|BMS-986253|BMS-986253 2400mg IV
9668418|NCT04347226|No Intervention|Standard of Care treatment|Usual treatment of COVID-19 per study physician discretion
9668419|NCT04334980|Experimental|bacTRL-Spike|"Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);~Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;~Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;~Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older.~Group 5 (n=12): DSMB-defined prime and boost doses of bacTRL-Spike delivered with a 28-day intervening interval."
9668420|NCT04333108|Experimental|Masitinib & BSC|"Experimental Arm:~Masitinib (titration to 6.0 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC).~Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control."
9668421|NCT04333108|Placebo Comparator|Placebo & BSC|"Placebo Comparator:~Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)"
9668422|NCT04268550|Experimental|Treatment (selpercatinib)|Patients receive selpercatinib orally PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9668423|NCT04268498|Experimental|Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)|Participants in this group will receive Bortezomib, Lenalidomide and Dexamethasone on a 21 day treatment cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
9668424|NCT04268498|Experimental|Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)|Participants in this group will receive Carfilzomib, Lenalidomide and Dexamethasone on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
9668425|NCT04268498|Experimental|Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)|Participants in this group will receive Carfilzomib, Lenalidomide, Dexamethasone with Daratumumab, Acetaminophen, Diphenhydramine and Montelukast on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
9668426|NCT04250194|Experimental|Navigation Bronchoscopy (NB) with F-Nav|
9668427|NCT04250194|Experimental|CT-guided Biopsy|
9668428|NCT04248465|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
9668429|NCT04248465|Placebo Comparator|Placebo|Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.
9668430|NCT05245383|Other|Single arm|
9668431|NCT05245370|Active Comparator|Control group 1: Control video|
9668432|NCT05245370|Active Comparator|Control group 2: Rationale video + control video|
9668433|NCT05245370|Experimental|Rationale video + clinician testimonial|
9668434|NCT05245370|Experimental|Rationale video + patient testimonial|
9668435|NCT05245370|Experimental|Rationale video + clinician testimonial + patient testimonial|
9668436|NCT05245344||Patients with RRMS (untreated)|"Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria;~EDSS score ≤ 5.5;~Age between 18 and 55 years (exclusive);~no disease modifying therapies for at least 3 months or treatment naïve;~no corticosteroid administration in the previous month;~disease duration <10 years;~Ability to provide written informed consent."
9668437|NCT05245344||Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)|"Main inclusion criteria of NMOSD patients (Wingerchuk et al., 2015):~Positive test for Aquaporin 4 IgG;~Age between 18 and 55 years (exclusive);~no immunosuppressive therapies for at least 3 months or treatment naïve.~no corticosteroid administration in the previous month~disease duration <10 years~Ability to provide written informed consent"
9668438|NCT05245344||Healthy subjects (HD)|"Age between 18 and 55 years (exclusive), matched by gender, age and ethnicity towards the MS groups.~Ability to provide written informed consent."
9668439|NCT05245331|Active Comparator|High-volume TAI|This group will be instructed on High-volume TAI to be perform daily or every 2 days for 2 months. After 1 months of wash-out they will switch to Low-TAI treatment for 2 months.
9668440|NCT05245331|Active Comparator|Low volume - TAI|This group will be instructed on Low-volume TAI to be perform daily or every 2 days for 2 months. After 1 months of wash-out they will switch to the Low-TAI treatment for 2 months.
9668441|NCT05245318|Active Comparator|Standard clinical care control group|Standard physiotherapy program of 12 weeks (1 treatment session /week)
9668442|NCT05245318|Experimental|Experimental blended physiotherapy program group|Blended physiotherapy program of 12 weeks with exercises and counselling provided through a smartphone application and 6 face-to-face treatment sessions (1 physiotherapy treatment session every 2 weeks)
10115634|NCT04447547|Experimental|SL1904B CAR-T|Patients will be treated with CD19 CAR-T cells
9668443|NCT05245305|Experimental|MBSR Intervention|The intervention group will take part in mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. The MBSR program was structured as 11 weeks, taking into account the characteristics of the participants.
9668444|NCT05245305|No Intervention|Control|No intervention was applied to the control group. Data will be collected from the control group simultaneously with the study group.
9668445|NCT05245279|Experimental|Normal placenta-entitle|The 3-DPD indices was measured in the entire placenta volume.
9668446|NCT05245279|Experimental|Normal placenta-sonobyopsy|The 3-DPD indices was measured at cord insertion in placenta by sonobiopsy
9668447|NCT05245266|Other|Analysis of blood samples from healthy pregnant women|"Analysis of blood samples from healthy pregnant women. A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.~Control samples for comparison will also be recruited from healthy males and non-pregnant females from populations over 18 years of age. Luna genetics personnel will enroll and consent the subject at Luna Genetics in Houston. A certified phlebotomist will collect the blood samples. Sample identifiers will be removed .No information will go back to patients or their physicians."
9668448|NCT05245240|Experimental|Severe OSA group|Dietary and physical activity intervention
9668449|NCT05245240|Experimental|Mild OSA group|Dietary and physical activity intervention
9668450|NCT05245227|Active Comparator|Intravenous Oxytocin only|Patients will receive standard postpartum Oxytocin IV per protocol
9668451|NCT05245227|Experimental|Misoprostol plus intravenous Oxytocin|Patients will receive standard postpartum Oxytocin IV per protocol and also be given Misoprostol 400 mcg sublingual
9668452|NCT05245201|Active Comparator|Arm 1 - Standard of care|Standard of care
9668453|NCT05245201|Active Comparator|Arm 2 - Clinical decision support for PrEP|EHR-based decision support tools to support PrEP discussions and prescribing for patients who have increased predicted HIV risk
9668454|NCT05245188|Experimental|Experimental Product 1|Consumption of 200 ml of product 1. Subjects will take this amount only on the day of the visit that they are to consume this product.
9668455|NCT05245188|Experimental|Experimental Product 2|Consumption of 200 ml of product 2. Subjects will take this amount only on the day of the visit that they are to consume this product.
9668456|NCT05245188|Experimental|Experimental Product 3|Consumption of 200 ml of product 3. Subjects will take this amount only on the day of the visit that they are to consume this product.
9668457|NCT05245188|Experimental|Experimental Product 4|Consumption of 200 ml of product 4. Subjects will take this amount only on the day of the visit that they are to consume this product.
9668458|NCT05245175|Experimental|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
9668459|NCT05245175|Experimental|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
9668460|NCT05245175|Placebo Comparator|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
9668461|NCT05245175|Experimental|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
9668462|NCT05245175|Experimental|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
9668463|NCT05245162||Participants|Study participants with breast cancer
9668464|NCT05245162||Participants partner|Study participants partner
9668465|NCT05245149||Prospective Cohort|Patients with a clinical indication for coronary CT angiography will undergo this scan on a photon counting detector CT (PCD-CT).
9668466|NCT05245149||Retrospective Cohort|For comparison, a matched retrospective cohort will be created of patients who had undergone coronary CT angiography on prior CT scanner generations (with energy-integrating detector CT, EID-CT)
9668467|NCT05245110|Experimental|experimental group|received a tele-exercise training program
9668468|NCT05245110|No Intervention|control group|usual care only
9668469|NCT05245084|Experimental|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~Period 3: D013, D326, D337- A single oral dose of 3tablet s under fasting condition~Period 4: CKD-386(2)- A single oral dose of 1 tablet under fasting condition"
9668470|NCT05245084|Experimental|Sequence 2|"Period 1: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386(2)- A single oral dose of 1 tablet under fasting condition~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
9668471|NCT05245045|Experimental|Shengtaibufen Photodynamic Therapy(STBF-PDT)|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 0.5mg/ml Shengtaibufen solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
9668472|NCT05245045|Placebo Comparator|Red light|The Shengtaibufen photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying normal saline solution for 45min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
9668473|NCT05245032||Feasibility testing|During the screening visit, blood and/or a bone marrow sample will be obtained for the patient's standard clinical evaluation. An aliquot of the blood and/or marrow sample will be obtained for ex vivo drug sensitivity assay
9668474|NCT05245019|Experimental|cardamom group|the pH of saliva will be checked first then they r required to chew cardamom nd after 15 minutes again pH will be checked
9668475|NCT05245019|Experimental|fennel group|the pH of saliva will be checked first then they r required to chew fennel and after 15 minutes again pH will be checked
10115635|NCT04447573|Experimental|BCMA CAR-T cells|Patients will be treated with BCMA CAR-T cells
10182524|NCT03773055|Active Comparator|NPC-06 (Low dosage)|15 mg (iv) in Day 1 as an induction dosage and 6 mg (iv) in Day 2 - 7 as a maintenance dosage
10182525|NCT03773055|Placebo Comparator|Placebo|Saline will be administered intravenously
9668478|NCT05244954|Experimental|Intermittent Screening and Treatment (IST)|Students will be screened for infection using a higher sensitivity malaria rapid diagnostic test and treated if positive. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
9668479|NCT05244954|Experimental|Intermittent Preventive Treatment (IPT)|All students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
9668480|NCT05244954|No Intervention|Control|Students will not receive preventive treatment.
9668481|NCT05244941||Cross site-case study|Qualitative methods: semi-structured interviews for patients, front line clinical practitioners, and health system stakeholders, case study building across sites
9668482|NCT05244928|Experimental|Cluster 1.|The clusters will be formed from two ambulance stations (Approximately 50 participants).
9668483|NCT05244928|Experimental|Cluster 2.|The clusters will be formed from five ambulance stations (Approximately 70 participants).
9668484|NCT05244915|Experimental|Experimental|Participants will receive a geriatric assessment which consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on participant responses, tailored recommendations will be provided.
9668485|NCT05244889|Experimental|Digital CBT-I|After assignment to dCBT-I, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session dCBT-I programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of dCBT-I. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
9668486|NCT05244889|Active Comparator|Sleep Hygiene Education (SHE)|After assignment to SHE, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session SHE programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of SHE. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
9668487|NCT05244863||One group|Geriatric individuals
9668488|NCT05244850||One group|Stroke patients
9668489|NCT05244837|Experimental|Arm A:Resectable Stage IIB-IIIA Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 3-4 cycles before surgical resection, followed by adjuvant intravenous tislelizumab monotherapy for 1 year ( 200 mg every 3 weeks for 2 cycles, followed by 200 mg every 4 weeks for 12 cycles).
9668490|NCT05244837|Experimental|Arm B：Unresectable Stage IIIA/IIIB/IIIC or IV Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 4-6 cycles , followed by adjuvant intravenous tislelizumab monotherapy ( 200 mg every 3 weeks )，until disease progression or intolerable toxicity If surgery is not possible；If surgery is possible after assessment, subsequent treatment at the discretion of the investigator
9668491|NCT05244824||Rheumatoid Arthritis|To translate the EDAQ, which determines the difficulties experienced by individuals with rheumatoid arthritis in daily life, into Turkish.
9668492|NCT05244811|Placebo Comparator|use of placebo in treatment of functional ovarian cyst|trial the effect of placebo in treatment of functional ovarian cyst
9668493|NCT05244811|Active Comparator|use of cocs in treatment of functional ovarian cyst|trial of the effectiveness of cocs in the treatment of functional ovarian cyst
9668494|NCT05244811|Active Comparator|use of progesterone in treatment of functional ovarian cyst|comparison between the effect of progesterone in the treatment of functional ovarian cyst with the effect of cocs
9668495|NCT05244798|Experimental|Group of Tislelizumab combined with neoadjuvant chemotherapy|Tislelizumab (D1 administration) was given in combination with chemotherapy (TP regimen: albumin-paclitaxel + cisplatin, D1 administration) for 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. For postoperative assistance, the researchers selected postoperative treatment according to the guidelines for the diagnosis and treatment of esophageal cancer. The researchers chose their own postoperative treatment according to the guidelines for the diagnosis and treatment of esophageal cancer.
9668496|NCT05244798|Experimental|Group of Tislelizumab combined with neoadjuvant chemoradiotherapy|Tislelizumab (D1) was administered in combination with concurrent chemoradiotherapy. Chemotherapy regimen: TP regimen: albumin paclitaxel + cisplatin, D1 administration, 2 cycles. Every 3 weeks, there was a dosing cycle (Q3W). Radiotherapy regimen: according to IMRT treatment plan, the total dose was 40Gy, divided into 20 times, 5 days a week. Surgery was performed 6-8 weeks after completion of neoadjuvant therapy. The researchers chose their own postoperative treatment according to the guidelines for the diagnosis and treatment of esophageal cancer.
9668497|NCT05244772|Experimental|Remote monitoring|At discharge, patients in the remote monitoring group receive verbal and paper care- and recovery instructions from a day care ward nurse and in adittion they will have a monitoring application installed on theirpersonal smartphone. Once they are back home, they can start recording pain and nausea and ask questions about their recovery with the application and report back the anaesthesia backoffice.
9668498|NCT05244772|No Intervention|Standard care|At discharge, patients in the standard care group receive verbal and paper care- and recovery instructions from a day care ward nurse.
9668499|NCT05244759|Experimental|Arm 1|Single oral dose of [14C]-BLU-5937
10182526|NCT03773042|Experimental|HSK3486|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg
9821547|NCT02239770|Experimental|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
9821548|NCT02239939|Experimental|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for >10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
9821549|NCT02239939|Active Comparator|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
9821550|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
9821551|NCT02239978||Control|Age-matched healthy adults
9821552|NCT02240030|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
9821553|NCT02240030|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
9821554|NCT02240030|Placebo Comparator|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
9821555|NCT02240108|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
9821556|NCT02240108|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
9821557|NCT02240121|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
9821558|NCT02240121|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
9821559|NCT02240186|Experimental|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
9821560|NCT02240329|Other|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
9821561|NCT02240368||Group 1|Children age between 1 month to 12 months
9821562|NCT02240368||Group 2|Children age between 13 months and 36 months
9821563|NCT02240368||Group 3|Children age between 37 months to 144 months
9821564|NCT02240589|Experimental|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
9821565|NCT02240589|Placebo Comparator|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
9821566|NCT02240628|Active Comparator|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
9821567|NCT02240628|Placebo Comparator|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
9821568|NCT02240654||Dabigatran etexilate|
9821569|NCT02240667||Subjects with atrial fibrillation|
9821570|NCT02240680|Experimental|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
10182527|NCT03773042|Active Comparator|Propofol|1.0mg/kg, 2.0mg/kg
9821571|NCT02240680|Placebo Comparator|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
9668500|NCT05244746|Active Comparator|Rectus sheath block|
9668501|NCT05244746|Placebo Comparator|Control|
9821572|NCT02240693|Experimental|BI 409306 dose 1|
9821573|NCT02240693|Experimental|BI 409306 dose 2|
9821574|NCT02240693|Experimental|BI 409306 dose 3|
9821575|NCT02240693|Experimental|BI 409306 dose 4|
9821576|NCT02240693|Placebo Comparator|Placebo|
9827013|NCT02441309|Experimental|B. Ifosfamide (Followed by Mifamurtide)|"Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
9827014|NCT02441309|Experimental|C. Ifosfamide + Mifamurtide|"Treatment Weeks 1-6:~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, each given at least 3 days apart, for 6 weeks.~Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, given at least 3 days apart, for 6 weeks. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
9827015|NCT02441517|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
9827016|NCT02441946|Experimental|Abemaciclib + Anastrozole|"Abemaciclib (150 milligrams [mg]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
9827647|NCT02463032|Experimental|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
10182528|NCT03773081|Other|Magmaris implantation|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice.
10182529|NCT03773029|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 capsules)
9668502|NCT05244733|Experimental|Social Engage (S-ENGAGE)|S-ENGAGE is a skills-based psychotherapy that focuses on helping patients engage in meaningful rewarding social activities. Subjects will receive 10 one-hour individual sessions of S-ENGAGE over 10 weeks.
9668503|NCT05244733|Placebo Comparator|The Healthy Lifestyles Education Program|The healthy lifestyles education program consists of a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources. Study staff meet with participants once, individually, for 1 hour to review each section and answer questions participants might have.
9668504|NCT05244720|Experimental|Intervention|"Baseline questionnaire filled out at recruitment. Invited to an examination of the liver, by fibroscan and blood samples, shortly after recruitment.~Follow-up by phone after 6 months."
9668505|NCT05244720|Other|Control|Baseline questionnaire filled out at recruitment. Follow-up by phone after 6 months. Invited to an optional examination of the liver, by fibroscan and blood samples, after 6 months.
9668506|NCT05244707|Experimental|Mediterranean style diet|Mediterranean style diet.
9668507|NCT05244707|Active Comparator|Standard of care|Standard of care.
9668508|NCT05244694|Experimental|Insulin|Participants will complete a 60 minute hyperinsulinemic-euglycemic infusion.
9668509|NCT05244642|Experimental|Group A (Penpulimab)|Participants receive Penpulimab 200mg intravenously (IV) on Day 1, Q2W for 24 months.
9668510|NCT05244642|Active Comparator|Group B (Chemotherapy)|Participants receive investigator's choice of chemotherapy Q2W or Q3W for up to 4 or 6 cycles.
9668511|NCT05244629|Active Comparator|Bare Metal Stent|
9668512|NCT05244629|Active Comparator|Covered Stent|
9668513|NCT05244603|Experimental|Normal Hearing|Listeners with normal hearing
9668514|NCT05244603|Experimental|Hearing Impaired|Listeners with hearing loss
9668515|NCT05244590|Experimental|Intervention|"GPs' eligibility criteria~Working in the centre health care region in Portugal.~Authorisation of the coordinator of each GP health care unit to integrate the study.~Patients' eligibility criteria~Inclusion criteria~Belonging to the list of patients of the recruited GPs.~18 years or older.~Diagnosis of advanced stage neoplasm (ASN), Chronic Obstructive Pulmonary Disease (COPD) Gold III/IV, Congestive Heart Failure (CHF) NYHA III/IV, Chronic Kidney Disease (CKD) stage IV/V.~Exclusion Criteria~Refusal, at any time, to participate in the study.~Level of understanding or execution that compromises taking part in the study and answering the IPOS patient version (evaluated using Mini Mental State Examination score).~Level of disease severity requiring urgent intervention (GP clinical judgement)."
9668516|NCT05244577|Experimental|Olanzapine|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Olanzapine 5mg Po D1-7
9668517|NCT05244577|Placebo Comparator|Placebo|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Placebo 5mg Po D1-7
9668518|NCT05244564|Experimental|3MDR delivered via Augmented Reality Head Mounted Display|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
9668519|NCT05244564|Active Comparator|3MDR delivered in the Computer Assisted Rehabilitation Environment (CAREN)|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
9668520|NCT05244525|Experimental|Treatment|
9668521|NCT05244525|Active Comparator|Control Group|
9668522|NCT05244512|Experimental|Evidence-based leadership training|The training course will take 6 months. It is divided into seven online modules. Participants join the course based on pre-structured schedule. The progress of the training course will follow specific steps to improve participants' evidence-based leadership competencies. First, each participant identifies one leadership problem on daily practice. Second, organisational data will be collected and analysed to increase the understanding of the key problem. Third, scientific literature will be searched, identified and critically appraised to find solutions. Fourth, the views of stakeholders (patients, clinicians, family members, etc.) are considered together with ethical implications. And last, all sources of information are critically appraised, new solution will be designed and implemented into the practice, and evaluated in real world context. Each module includes specific learning material. Trained tutors are responsible for mentoring each module.
9668523|NCT05244512|Active Comparator|Conventional training|The participants will join a training course with the same structure, topics, and timing as the experimental group. However, training in this group is based on independent learning methods. The participants have access to the separate learning platform, which includes reading material to be read independently. No group discussions with peers, self-reflection, assignments, or support from tutors will be offered.
9668524|NCT05244499|Experimental|Evidence-based leadership training|The training course will take 6 months. It is divided into seven online modules. Participants join the course based on pre-structured schedule. The progress of the training course will follow specific steps to improve participants' evidence-based leadership competencies. First, each participant identifies one leadership problem on daily practice. Second, organisational data will be collected and analysed to increase the understanding of the key problem. Third, scientific literature will be searched, identified and critically appraised to find solutions. Fourth, the views of stakeholders (patients, clinicians, family members, etc.) are considered together with ethical implications. And last, all sources of information are critically appraised, new solution will be designed and implemented into the practice, and evaluated in real world context. Each module includes specific learning material. Trained tutors are responsible for mentoring each module.
9668525|NCT05244499|Active Comparator|Conventional training|The participants will join a training course with the same structure, topics, and timing as the experimental group. However, training in this group is based on independent learning methods. The participants have access to the separate learning platform, which includes reading material to be read independently. No group discussions with peers, self-reflection, assignments, or support from tutors will be offered.
9821577|NCT02240706|Active Comparator|Arm B|Best Supportive Care Alone
10182530|NCT03773029|Placebo Comparator|control|2 capsules of placebo
9821578|NCT02240706|Experimental|Arm A|BI 836858 plus Best Supportive Care
9821579|NCT02240810||PLATINUM Diversity (Overall)|PLATINUM Diversity (Overall) population. Test device is Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (CSS)
10115636|NCT04447326|Experimental|IC＋CCRT＋Toripalimab＋Endostar|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w; Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles; Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles.
10115637|NCT04447326|Active Comparator|IC＋CCRT|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w.
10115638|NCT04447274|Experimental|Camrelizumab and Apatinib|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
10115639|NCT04447209||Child Health Clinic (CHC)|"Children attending CHC for routine vaccinations and follow-up in a tertiary center Parents will be counselled on food groups based on Infant and Young Children feeding practices.~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
10182531|NCT03772665|Experimental|Emixustat|10 mg
9668526|NCT05244460|Experimental|Intervention|Patients who receive droperidol 2.5mg intravenous once and diphenhydramine 25mg intravenous once
10182532|NCT03772665|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
10182533|NCT03772756|Experimental|EUS-RFA group|Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy
10182534|NCT03772756|Active Comparator|control group|the control group will receive chemoradiotherapy only
10182535|NCT03772769|Experimental|Subjects with advanced deep space odontogenic infection|Subjects will be diagnosed via two methods: 1. Target Enriched Multiplex PCR (TEM- PCR) and 2. Standard microbial culture.
9668527|NCT05244434|Experimental|Prospective cohort (SOC treatment, biopsy, blood collection)|Patients receive SOC treatment consisting of ribociclib or palbociclib plus AI. Patients undergo biopsy of tumor tissue at baseline and post-treatment. Patients also undergo collection of blood samples at baseline, on day 1 of SOC treatment cycles 2, 4, and 6, every 6 cycles thereafter, and at post-treatment.
9668528|NCT05244434|Experimental|Retrospective cohort|Patients' tumor tissue collected during previous SOC treatment (ribociclib or palbociclib plus AI) is used for analysis.
9668529|NCT05244421|Experimental|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
9668530|NCT05244408||SCI Subjects|"Patients who suffer a traumatic spinal cord injury who meet the following inclusion criteria are eligible for admission into the study as SCI subjects:"
9668531|NCT05244408||Non-SCI Spine Trauma Control Subjects.|"Patients who suffer a fracture or dislocation of their spinal column but without neurologic injury are eligible for admission into the study as Non-SCI Spine Trauma Control Subjects"
9668532|NCT05244382|Experimental|Overcome group|Three-month multimodal program. Aerobic exercise will be combined with the use of TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy.
9668533|NCT05244382|No Intervention|Usual treatment|Usual medical treatment for the same period of time
9668534|NCT05244369|Active Comparator|Acupuncture+TENS group|Acupuncture application twice a week - a total of 8 sessions, and rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes for 5 days a week for 4 weeks, current frequency 60-100 Hz to stump tip, impulse duration 100 microseconds transcutaneous electrical nerve stimulation (TENS) will be applied.
9668535|NCT05244369|Other|Only TENS group|A rehabilitation program consisting of joint range of motion, stretching, and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and transcutaneous electrical nerve stimulation (TENS) with a current frequency of 60-100 Hz and an impulse duration of 100 microseconds will be applied.
9668536|NCT05244356|Experimental|Descriptive Norm (70%)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing that about 70% of Malaysians have expressed acceptance for the COVID-19 vaccine.~Rally slogan: It's safe and effective!"
9821580|NCT02241486|Experimental|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
10182536|NCT03772860||Healthy volunteers|Healthy volunteers will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
10182537|NCT03772860||Left headache|Migraine patients with mostly left sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
10182538|NCT03772860||Right headache|Migraine patients with mostly right sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
10182539|NCT03772860||Bilateral headache|Migraine patients without a dominant side headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
10182540|NCT03772834|Experimental|Group I (methylphenidate, resistance training, walking)|Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.
10182541|NCT03772834|Active Comparator|Group II (placebo, resistance training, stretching)|Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.
10182542|NCT03772834|Active Comparator|Group III (methylphenidate, stretching)|Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.
10182543|NCT03772834|Active Comparator|Group IV (placebo, stretching)|Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.
9821581|NCT02241512|Experimental|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
9821582|NCT02241512|Placebo Comparator|Placebo|Single dose IV normal saline
9821583|NCT02241655|Experimental|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
9821584|NCT02241655|No Intervention|Control Arm|Participants will have the standard anesthetic protocol.
9821585|NCT02241720|Experimental|Regorafenib treatment|
9821586|NCT02241733|Active Comparator|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
9821587|NCT02241733|Experimental|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
9821588|NCT02241785|Experimental|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
9821589|NCT02241889|Active Comparator|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
9821590|NCT02241889|Experimental|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
9821591|NCT02241889|Experimental|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
9821592|NCT02241967|Experimental|tDCS Full Dose|4 active treatments
9821593|NCT02241967|Experimental|tDCS Half Dose|2 active treatments
9821594|NCT02241967|Experimental|tDCS Minimal dose|1 active treatment
10115640|NCT04447209||Community Children|"Children of urban poor families living in low-cost flats around Kuala Lumpur. Parents will be counselled on food groups based on Infant and Young Children feeding practices.~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
10115641|NCT04447430|Experimental|bright light group|treat patients with bright light (10000 lux)
9821595|NCT02241967|Sham Comparator|Sham tDCS|no active treatments
9821596|NCT02242019|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
10115642|NCT04447430|Placebo Comparator|dim red light group|treat patients with dim red light (100 lux)
10115643|NCT04447456||Surgery|
10115644|NCT04447456||Radiotherapy|
10115645|NCT04447443|Experimental|Prebiotic Fiber|
10115646|NCT04447443|Placebo Comparator|Maltodextrin|
10115647|NCT04447300|Active Comparator|Standard power application|
10115648|NCT04447300|Active Comparator|High power application|
10115649|NCT04447482|Experimental|Treatment Group|4D electromagnetic navigation bronchoscopy (4D-ENB) for lung biopsy. Guidance based on tip tracked surgical tools and images calculated from CT.
10115650|NCT04447482|Active Comparator|Control Group|Bronchoscopic lung biopsy taken while using X-ray fluoroscopy.
10115651|NCT04447235|Placebo Comparator|ARM A: Placebo|Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
10115652|NCT04447235|Experimental|ARM B: Ivermectin plus losartan|Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days
9821597|NCT02242045|Experimental|Idelalisib|Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.
9821598|NCT02242201|Active Comparator|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
10115653|NCT04447391|Experimental|Exercise group|Exercise group who performed a combined exercise and 300 kcal/day deficit diet during 12 weeks.
10115654|NCT04447391|Placebo Comparator|Control group|Control group who performed 300 kcal/day deficit diet during 12 weeks.
10115655|NCT04447924|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
10115656|NCT04447924|Experimental|Bif195 arm|Active trial product with minimum 15 billion CFU daily dose
10115657|NCT04447079||'Before' and 'After' Arm|"Before Arm - This refers to the rate of Emergency Department visits in the pre-intervention period (12 months).~After Arm - This refers to the rate of Emergency Department visits in the post-intervention period (12 months) following the START of intervention."
10182544|NCT03772847|Experimental|ginkgolide group|ginkgolide plus alteplase
9821599|NCT02242201|Active Comparator|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
9821600|NCT02242201|Active Comparator|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
9821601|NCT02242305|Experimental|Hyoscine Butylbromide - Tablet|
9821602|NCT02242305|Active Comparator|Hyoscine Butylbromide - Capsule|
9821603|NCT02242487|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
9821604|NCT02242487|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
9821605|NCT02242630|Active Comparator|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
9821606|NCT02242630|Active Comparator|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
9821607|NCT02242630|Active Comparator|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
9821608|NCT02242630|Active Comparator|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
10182545|NCT03772847|No Intervention|control|alteplase
9821609|NCT02242643|Experimental|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
10115658|NCT04447560|Experimental|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol before and after the plane block and two researchers will measure the radius and area of those vessels separately.
10115659|NCT04447092|Experimental|Gemcitabine/Nab-paclitaxel|Gemcitabine/Nab-paclitaxel + pembrolizumab
10115660|NCT04447092|Experimental|FOLFIRINOX|FOLFIRINOX + pembrolizumab
10115661|NCT04447378|Experimental|Fondaparinux|Subcutaneous injection of fondaparinux 2.5 mg once daily would be given over 10 days for post partum thromboprophylaxis
10115662|NCT04447508|Experimental|Exercise class and motivational interviewing|Patients receiving the intervention will be enrolled in an online instructor led group exercise class and five online one on one motivational interviewing sessions.
9821610|NCT02242643|Active Comparator|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
10115663|NCT04447508|No Intervention|Usual care|Participants in the control group will receive an exercise booklet and educated on the benefits of exercise for low back pain. They will be advised to exercise for the duration of the study
10115664|NCT04447625|Active Comparator|CE patients receiving OAA|Patients diagnosed with CE receiving the gold standard treatment of oral antibiotic administration (OAA)
10115665|NCT04447625|Experimental|CE patients receiving OAA and IAI|Patients diagnosed with CE receiving a combination of the gold standard treatment of oral antibiotic administration (OAA) and intrauterine antibiotic infusion (IAI)
10115666|NCT04447105|Experimental|TIVA group|Patients receiving total intravenous anesthesia with propofol.
10115667|NCT04447105|Active Comparator|Desflurane group|Patients receiving inhalation anesthesia with desflurane.
10115668|NCT04447261|Experimental|BI 1356225|
10115669|NCT04447261|Placebo Comparator|Placebo|
10115670|NCT04447196||CCHS|20 patients presenting with central hypoventilation syndrome during spontaneous breathing and with Non Invasive Ventilation
10115671|NCT04447404|Experimental|DUR-928|
10115672|NCT04447404|Placebo Comparator|Placebo|
10115673|NCT04447066||Patients hospitalized at the rehabilitation department|
10115674|NCT04447144||COVID-19 mild severity|"Definition of mild cases according to MOH:~Age < 60~Temperature <38.5~arterial oxygen saturation (SaO2) >92%~Heart Rate <110~Respiratory Rate <25 /min.~Neutrophil / lymphocyte ratio on complete blood count (CBC) < 3.1~No co-morbidities that necessitates hospital admission: Pregnancy, severe uncontrolled Diabetes, Chronic lung disease, Chronic kidney disease, Chronic liver disease, Serious heart diseases (arrythmia, Ischemic heart disease, uncontrolled hypertension), immunocompromised: prolonged use of corticosteroids and other immunosuppressive drugs/ organ transplantation/ HIV/ Immunodeficiency, Obesity (BMI > 40)"
10115675|NCT04447144||COVID-19 moderate severity|Any patient not fulfilling the above mild criteria is considered having moderate disease as well as any positive pulmonary imaging findings
10115676|NCT04447417|Experimental|Dupilumab|Double dose on Day 1 and followed by single dose every 14 ±2 or 3 days through week 14. - Type: Experimental
10115677|NCT04447417|No Intervention|Healthy volunteers|Healthy volunteers are matched by age, gender, body location and study site to AD patients. They will receive no treatment with dupilumab but will be monitored in the same way as atopic dermatitis patients during the study.
10115678|NCT04446923|Experimental|Hand antisepsis by scrub|Hand antisepsis by scrub using propan-ol-1 60%
10115679|NCT04446923|Active Comparator|Hand antisepsis by rub|Hand antisepsis by rub using propan-ol-1 60%
10115680|NCT04446897|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
10115681|NCT04446897|Active Comparator|standard treatment|standard treatment according to clinical protocols
10115682|NCT04446949||Undocumented migrants|
10115683|NCT04446949||Immigrants with Norwegian ID|
10115684|NCT04446949||Norwegian residents|
10115685|NCT04446858||With TIPS|Prospective cohort that received TIPS
10115686|NCT04446858||Without TIPS|Prospective cohort that did not receive TIPS
10115687|NCT04446910|Experimental|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to encourage attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
10115688|NCT04446910|Active Comparator|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
10115689|NCT04446741||Acute Myeloid Leukemia (AML)|Newly diagnosed or relapsed/resistant AML
9821611|NCT02242903|Experimental|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
10115690|NCT04446832||Liver transplantation candidates|
10115691|NCT04446936||Propeller flaps|Patients who undergone propeller flap surgery
10115692|NCT04446936||Random flaps|Patients who undergone random flap surgery
10115693|NCT04446728|Active Comparator|Strategy I.Training|Sites randomized to Strategy I will receive a three hour training webinar in preparing for implementation of the PAT in their center.
10115694|NCT04446728|Active Comparator|Strategy II.Training+Implementation Enhanced Resources (TIER)|Sites randomized to Strategy II will identify a Champion for screening and will participate in a monthly consultation call in addition to completing the three hour training webinar for implementing the PAT in their center.
10115695|NCT04446975|No Intervention|BPA Off|No BPA message is displayed to providers.
10115696|NCT04446975|Experimental|BPA On|BPA message is displayed to providers based on patient opioid intake as reported in the EHR.
10115697|NCT04447001|Experimental|Tai Chi Prime (TCP)-session 1|This arm will receive Tai chi prime as an intervention. TCP is a combination of two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
9821612|NCT02242903|Placebo Comparator|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
9821613|NCT02242981|Experimental|LY2623091|Single oral dose of LY2623091
9821614|NCT02242994|Experimental|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
9821615|NCT02243007|Experimental|Folfirinox-ARM A|"Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel~Treatment will be administered on an outpatient basis and will include intravenous administration of the FOLFIRINOX regimen on predetermined days.~After completion of FOLFIRINOX all patients without progressive disease will proceed with radiation therapy with the standard dose of capecitabine.~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
9821616|NCT02243007|Experimental|Gemcitabine/nab-Paclitaxel- Arm B|"Treatment will be administered on an outpatient basis. Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel).~Intravenous administration of the Gemcitabine/Nab-paclitaxel regimen on predetermined days of each 28 day treatment cycle (unless a delay is mandated by toxicity criteria). A cycle of Gemcitabine/Nab-paclitaxel will constitute a 28 day treatment period.~After Gemcitabine/Nab-paclitaxel, all patients without progressive disease will proceed to radiation therapy with the standard dose of capecitabine~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
9821617|NCT02243046|Placebo Comparator|Control toothpaste|1450 ppm Fluoride toothpaste
9821618|NCT02243046|Experimental|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
9821619|NCT02243046|Active Comparator|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
9821620|NCT02243176|Experimental|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
9821621|NCT02243176|Active Comparator|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
9821622|NCT02243202|Experimental|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
9821623|NCT02243202|Experimental|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
9821624|NCT02243202|Experimental|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
9821625|NCT02243202|Placebo Comparator|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
9821626|NCT02243280|Experimental|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
9821627|NCT02243280|Experimental|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
9821628|NCT02243280|Experimental|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
9821629|NCT02243280|Experimental|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
9821630|NCT02243280|Experimental|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
9821631|NCT02243280|Experimental|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
9821632|NCT02243280|Experimental|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
9821633|NCT02243280|Experimental|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
9821634|NCT02243280|Experimental|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
9821635|NCT02243280|Experimental|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
9821636|NCT02243280|Experimental|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
9821637|NCT02243293|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
9821638|NCT02243293|Experimental|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821639|NCT02243293|Experimental|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821640|NCT02243293|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
9821641|NCT02243293|Experimental|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821642|NCT02243293|Experimental|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821643|NCT02243293|Experimental|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821644|NCT02243293|Experimental|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821645|NCT02243293|Experimental|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821646|NCT02243293|Experimental|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821647|NCT02243293|Experimental|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
9821648|NCT02243293|Experimental|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
9821649|NCT02243293|Experimental|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
9821650|NCT02243293|Experimental|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
9821651|NCT02243293|Experimental|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
9821652|NCT02243293|Experimental|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
9821653|NCT02243293|Experimental|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
9821654|NCT02243293|Experimental|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
9821655|NCT02243293|Experimental|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
9821656|NCT02243293|Experimental|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
9821657|NCT02243293|Experimental|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
9821658|NCT02243293|Experimental|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
9821659|NCT02243371|Experimental|Arm A: CY/ GVAX/ CRS-207/ nivolumab|
9821660|NCT02243371|Experimental|Arm B: CY/ GVAX/ CRS-207|
9821661|NCT02243527|Experimental|Inspiratory Muscle Training|
9821662|NCT02243527|Sham Comparator|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
9821663|NCT02243579|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
9821664|NCT02243605|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9821665|NCT02243865|Experimental|Chordate S200 + control module (CT100), active|Chordate System S200 giving Kinetic Oscillation Stimulation Treatment for 15 minutes in each nostril
9821666|NCT02243865|Placebo Comparator|Chordate S200 + control module (CT100), placebo|Chordate System S200 giving Kinetic Oscillation Stimulation in placebo mode. Non-inflated and non-vibrating treatment
9821667|NCT02243943|Experimental|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
9821668|NCT02243943|Active Comparator|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
9821669|NCT02244424|Experimental|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
9821670|NCT02244424|No Intervention|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
10115698|NCT04447001|No Intervention|Wait list control-session 2|Wait-list group will be receiving Tai-chi prime intervention after 8 weeks wait time. At week 7, pre-test measures from wait-list group will be used as a control and compared with the post intervention measures of the experimental group.
9821671|NCT02244580|Experimental|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
9827648|NCT02463071|Experimental|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
9827649|NCT02463071|Experimental|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
10182546|NCT03772886|Experimental|Peanut Ball Arm|Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
9668537|NCT05244356|Experimental|Descriptive Norm|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing that the COVID-19 vaccine has been widely tested including with the elderly and people with existing health conditions, while subsequently highlighting that the vaccine was already received by millions worldwide.~Rally slogan: It's safe and effective!"
9668538|NCT05244356|Experimental|Healthcare worker (HCW) recommendation|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content highlights recommendation from Malaysian healthcare workers to get the vaccine, since majority of them has already received it, including the Malaysian Health Director General~Rally slogan: It's safe and effective!"
9668539|NCT05244356|Experimental|Negative attribute framing|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing the rate of side effects occurring with COVID-19 vaccination in a negative frame.~Rally slogan: It's safe and effective!"
9668540|NCT05244356|Experimental|Positive attribute framing|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing the rate of side effects occurring with COVID-19 vaccination in a positive frame.~Rally slogan: It's safe and effective!"
9668541|NCT05244356|Experimental|Risky choice framing (Safety)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing a risky choice frame which compares the death rates occurring with COVID-19 vaccination versus contracting the virus itself.~Rally slogan: It's safe and effective!"
9668542|NCT05244356|Experimental|Risky choice framing (Side effects)|"Intervention in the form of a message likened to a social media post. Composed of 3 parts:~Opening tag line highlighting the main concern that Malaysians have about the COVID-19 vaccine (safety and side effects)~Message content describing a risky choice frame that compares the incidence rates of blood clots occurring with COVID-19 vaccination versus contracting COVID-19.~Rally slogan: It's safe and effective!"
9668543|NCT05244356|Experimental|Control message|"Control message containing only rally slogan: It's safe and effective!"
9668544|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Descriptive Norm|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
9668545|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + HCW recommendation|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
9668546|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Negative attribute framing|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
9668547|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Positive attribute framing|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
9668548|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Risky choice framing (Safety)|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
9668549|NCT05244356|Experimental|Combination message: Descriptive Norm (70%) + Risky choice framing (Side effects)|Participants received 2 messages which were exposed one at a time. Sequence of message appearing randomly rotated.
9668550|NCT05244330||Partial vaccination|One dose of vaccine received at least 7 days prior to study enrollment
9668551|NCT05244330||Full vaccination|Two doses of COVID-19 vaccine received at least 7 days prior to study enrollment
9668552|NCT05244330||Unvaccinated|No dose of COVID-19 vaccine for at least 7 days prior to study enrollment
9668553|NCT05244317|Placebo Comparator|cast group|treatment of the participant of this group will be by the standard method which is by casting
9668554|NCT05244317|Experimental|splint group|treatment of the participant of this group will be by the removable splint
9668555|NCT05244239|Experimental|Treatment (lurbinectedin and palliative radiation therapy)|Patients undergo palliative RT over 5 or 10 treatment fractions at the discretion of the treating physician daily for 21 days. Patients also receive lurbinectedin IV over 1 hour on day 1 of each cycle. Cycles of lurbinectedin repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9668556|NCT05244200|No Intervention|Non-Intervention Group|Patients in the non-intervention group will be followed for the therapeutic outcomes and detection of DTPs without tempting to resolve them
9668557|NCT05244200|Experimental|Intervention Group|A strict protocol developed by IDC for insulin prescription is going to be implement and patients will be assessed for the therapeutic outcomes along with the detection and resolution of drug therapy problems throughout the course
9668558|NCT05244174|Active Comparator|Biliary stent|Biliary stent by ERCP is indicated both in palliative treatment, because of biliary duct decompression improves patient comfort by decreasing itching and jaundice, as in the treatment of the disease itself, because of it lets reach non-toxic levels of bilirubin which is necessary for chemotherapeutic treatment.
9694334|NCT04790526|Experimental|Group A|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
10182547|NCT03772886|No Intervention|Control Arm|Study participants randomized to the Control Arm will labor without the peanut ball.
9821672|NCT02244619|Active Comparator|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
9821673|NCT02244619|Active Comparator|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
9821674|NCT02244840|Experimental|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
9821675|NCT02244918|Active Comparator|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
9821676|NCT02244918|Experimental|Counseling Plus NRT|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy(NRT) (like the patch, gum or lozenge) of their choice.
9821677|NCT02244957|Active Comparator|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
9821678|NCT02244957|Active Comparator|Nocturnal oxygen|Nocturnal oxygen
9821679|NCT02244996|Experimental|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
9821680|NCT02244996|Placebo Comparator|Placebo|Placebo
9821681|NCT02245217|Experimental|PET/CT Imaging arm|
9821682|NCT02245360|Experimental|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
9821683|NCT02245360|Placebo Comparator|Placebo|Placebo
9821684|NCT02245412|Experimental|ALXN1007 10 mg/kg once weekly|Cohort 1, the first dosing cohort, received 10 mg/kg ALXN1007 IV once weekly for 8 weeks.
9821685|NCT02245412|Experimental|ALXN1007 20 mg/kg once weekly|Cohort 2 received 20 mg/kg ALXN1007 IV once weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
9821686|NCT02245412|Experimental|ALXN1007 20 mg/kg twice weekly|Cohort 3 received 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
9821687|NCT02245516|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
9821688|NCT02245516|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
9821689|NCT02245568|Experimental|LMTM|
9821690|NCT02245620|Experimental|Elamipretide|Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
9821691|NCT02245620|Placebo Comparator|Placebo|Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
9821692|NCT02245737|Experimental|Lanabecestat 20 milligrams (mg)|Lanabecestat 20 mg given orally once daily for 104 weeks.
9821693|NCT02245737|Experimental|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
9821694|NCT02245737|Placebo Comparator|Placebo|Placebo given orally once daily for 104 weeks.
9821695|NCT02245815|Experimental|use probiotics boucardii|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
9821696|NCT02245815|Experimental|use probiotics Multi-species|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
9821697|NCT02246010|Experimental|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
9821698|NCT02246010|No Intervention|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
9821699|NCT02246062|No Intervention|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
9821700|NCT02246062|Active Comparator|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
9821701|NCT02246062|Active Comparator|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
9821702|NCT02246062|Active Comparator|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
9821703|NCT02246166|Experimental|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
9821704|NCT02246166|Placebo Comparator|Placebo|Matching placebo tablet
9821705|NCT02246218|Experimental|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
10182548|NCT03772808|Experimental|Lycocomfort|The once-daily supplement LycoComfort™ is a combination of lycopene and beta-sitosterol, a chemically defined extract of phytosterols with beta-sitosterol as the main component,
10182549|NCT03773016|Experimental|Art apps - Group 1 (A-B)|Cross-over use of two different visual art apps on touchscreen tablets (App A and App B)
9821706|NCT02246309|Experimental|Embryoscope Time Lapse System|All embryos from patients randomized to this arm will be cultured in the Embryoscope culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
9821707|NCT02246309|Active Comparator|Standard Embryo Culture|All embryos from patients randomized to this arm will be cultured in the standard embryo culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
9821708|NCT02246413|Experimental|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
9821709|NCT02246413|No Intervention|Usual Care|Usual Care.
9821710|NCT02246439|Experimental|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
9821711|NCT02246439|Placebo Comparator|Placebo|Placebo
9821712|NCT02246478|Placebo Comparator|Placebo|
9821713|NCT02246478|Active Comparator|TAS-205 low dose|
9821714|NCT02246478|Active Comparator|TAS-205 middle dose|
9821715|NCT02246478|Active Comparator|TAS-205 high dose|
9821716|NCT02246582|Other|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
9821717|NCT02246582|Other|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
9821718|NCT02246608|Active Comparator|Routine NPWT Standard of Care|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, standard of care dressing will be placed.
9821719|NCT02246608|Experimental|NPWT Standard of Care plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied in addition to standard of care dressing.
9821720|NCT02246647||Healthy volunteers|Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
9821721|NCT02246647||IBS-C|Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
9821722|NCT02246660|Active Comparator|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
9821723|NCT02246660|Active Comparator|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
9821724|NCT02246660|Placebo Comparator|Placebo|Placebo will be taken orally for 6 months.
9821725|NCT02246673|Experimental|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
9821726|NCT02246673|Experimental|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
9821727|NCT02246673|Experimental|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
9821728|NCT02246673|Experimental|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
9821729|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
9821730|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
9821731|NCT02246764|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
9821732|NCT02246777|Experimental|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
9821733|NCT02246998|Experimental|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
9821734|NCT02246998|Experimental|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
9821735|NCT02246998|Experimental|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
9821736|NCT02246998|Experimental|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
9821737|NCT02247011|Other|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
9821738|NCT02247011|Other|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
9821739|NCT02247063|Sham Comparator|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
9821740|NCT02247063|Experimental|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
9821741|NCT02247193|Experimental|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
9821742|NCT02247193|Placebo Comparator|Saline|Injection of normal saline into cleft lip at time of surgical repair.
9821743|NCT02247245|Placebo Comparator|Placebo|Subjects are given a placebo capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
9821744|NCT02247245|Active Comparator|Ivabradine|Subjects are given an ivabradine capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
9821745|NCT02247245|Experimental|Atrial fibrillation|Subjects are (double blind) randomised to either a low base pacing rate (30) or a standard base rate (60), with rate adaptive algortithms switched on.
9821746|NCT02247336|Experimental|Immediate|Patients will complete a family health history platform at enrollment
9821747|NCT02247336|Active Comparator|Delayed|Patients will complete a family health history platform 12 months following enrollment
9821748|NCT02247401|Active Comparator|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
9821749|NCT02247401|Active Comparator|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
9821750|NCT02247401|Active Comparator|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
9821751|NCT02247440|Experimental|PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week~Ribavirin initial dosing in the morning and in the evening:~For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).~For genotypes 1, 4, 5 and 6:~800 mg/day, if bodyweight <65 kg,~1000 mg/day, if bodyweight between 66-80 kg,~1200 mg/day, if bodyweight between 81-105 kg,~1400 mg/day, if bodyweight >105 kg.~Duration: 48 weeks"
9821752|NCT02247466|Active Comparator|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
9821753|NCT02247466|Active Comparator|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
9821754|NCT02247479|Experimental|Lampalizumab Once in Every 4 Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
9821755|NCT02247479|Experimental|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
9821756|NCT02247479|Sham Comparator|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
9821757|NCT02247531|Experimental|Lampalizumab once in every 4 weeks (Q4W)|Participants will receive 10 mg (milligrams) dose of lampalizumab by intravitreal injection, Q4W, starting at the Day 1 visit for approximately 92 weeks.
9821758|NCT02247531|Experimental|Lampalizumab once in every 6 weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab by intravitreal injection, Q6W, starting at the Day 1 visit for approximately 90 weeks.
9821759|NCT02247531|Sham Comparator|Sham Comparator|Participants will receive sham comparator, Q4W, starting at the Day 1 visit for approximately 92 weeks or Q6W, starting at the Day 1 visit for approximately 90 weeks.
9821760|NCT02247739|Experimental|rhC1INH twice weekly|rhC1INH administered twice weekly
9821761|NCT02247739|Experimental|rhC1INH once weekly|rhC1INH administered once weekly
9965767|NCT01252797|Experimental|Stereotactic Radiosurgery (12Gy)|Group B: If the tumor which will be surgically removed is larger than 4 cm and up to 6 cm in diameter, then this group will receive Dose Level I (12 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
10115699|NCT04446585|No Intervention|Control sites|"For all 1-1-2 calls with suspected cardiac arrest to the emergency dispatch center will activate a two-tiered response consisting of dispatch of an ambulance with an emergency medical technician, a physician-staffed mobile emergency care unit, and citizen first responders through the Heart Runner app.~The medical dispatcher offers telephone assisted cardiopulmonary resuscitation (CPR) to bystanders. Furthermore, if more than two bystanders are present and an AED is accessible within 1½ minute travel distance (depending on the type of terrain), then one bystander is guided to localize and retrieve the AED."
10115700|NCT04446585|Experimental|Intervention sites|"As a supplement to the standard care as described in the control arm, the following will be supplied:~Strategical deployment of AEDs with 24:7 availability and 1½ minute walking distance to every residence within the area. The AEDs will be registered with the AED network and thus linked to the emergency dispatch center.~The emergency dispatch center will retrieve data from used AEDs.~For each interventional area, approximately 120 residents will receive a course in CPR and AED use and subsequently be recruited as citizen responders so that they can be activated through the HeartRunner app in case of a nearby cardiac arrest."
10115701|NCT04446988|Experimental|Ultrasound(US)|Sacroiliac joint injection using ultrasound
9965768|NCT01252823|Experimental|Implantable loop recorder (ILR) in hemodialysis patients|implantation of loop recorder in hemodialysis patients
9821762|NCT02247739|Placebo Comparator|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
9821763|NCT02247765|Experimental|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
9821764|NCT02247765|Experimental|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
9821765|NCT02247804|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
9821766|NCT02247804|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
9821767|NCT02247804|Active Comparator|Timolol 0.5%|Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
9821768|NCT02247960|Active Comparator|Ciprofloxacin|Antibiotic
9821769|NCT02247960|No Intervention|No Antibiotic|No Antibiotic
9821770|NCT02248103|Experimental|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
9821771|NCT02248103|Active Comparator|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
9821772|NCT02248246|Other|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
9821773|NCT02248285|Experimental|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
9821774|NCT02248285|No Intervention|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
9821775|NCT02248480|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
9821776|NCT02248480|Placebo Comparator|Placebo|Placebo administered orally once a day for 15 weeks.
9821777|NCT02248558|Active Comparator|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
9821778|NCT02248558|Experimental|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
9821779|NCT02248636|Experimental|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
9821780|NCT02248636|Sham Comparator|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
9821781|NCT02248649|Experimental|Physical Activity|Structured walking program
10115702|NCT04446988|Experimental|Fluoroscopy(FL)|Sacroiliac joint injection using fluoroscopy
9821782|NCT02248649|Active Comparator|Control|Health education attention control
9821783|NCT02248662||Surveillance, Epidemiology, and End Results (SEER) Database|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER) with a diagnosis of ductal carcinoma in situ (DCIS) between 1990 and 2011 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
9821784|NCT02248662||Surveillance, Epidemiology, and End Results (SEER)-Medicare|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER)-Medicare with a ductal carcinoma in situ (DCIS) diagnosis between 1991 and 2009 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
9821785|NCT02248675|Experimental|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
9821786|NCT02248675|Active Comparator|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
9821787|NCT02248714|Experimental|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
9821788|NCT02248714|No Intervention|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
9821789|NCT02248727|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
9821790|NCT02248727|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
9821791|NCT02248766|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
9821792|NCT02248766|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
9821793|NCT02248818|Experimental|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
9821794|NCT02248818|Placebo Comparator|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
9821795|NCT02248857|No Intervention|Usual Care|Employ the current standard of care. No intervention.
9827017|NCT02441946|Experimental|Abemaciclib|"Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
9827650|NCT02463071|Placebo Comparator|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
9827651|NCT02463097|Experimental|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
9965769|NCT01252836|Placebo Comparator|Control|Treatment with Tegaderm
9965770|NCT01252836|Experimental|AWBAT-D|Application of AWBAT-D on donor site.
10115703|NCT04446884|Experimental|mesenchymal stem cells|Patients with Stress urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
10115704|NCT04446884|Active Comparator|control|Patients with Stress urinary incontinence receiving standard treatment
9965771|NCT01252849|Experimental|First Arm: One iStent, medication|Device: One iStent, medication
9821796|NCT02248857|Experimental|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.~Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.~A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
9821797|NCT02248857|Experimental|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
9821798|NCT02248922|Experimental|Tobramycin ALL|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off
9821799|NCT02248961|Experimental|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
9821800|NCT02248961|Active Comparator|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
9821801|NCT02248974|Active Comparator|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
9821802|NCT02248974|No Intervention|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
9821803|NCT02249052|Active Comparator|AA4500|single injection of 0.58 mg study drug
9821804|NCT02249052|Placebo Comparator|Placebo|single injection of placebo
9821805|NCT02249065|Experimental|Mirvaso Gel|Brimonidine topical gel, 0.33%
9821806|NCT02249091|Experimental|Cohort 1 / Selinexor 40 mg/m^2 in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a dose of 40 mg/m^2 twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
9821807|NCT02249091|Experimental|Cohort 2 / Selinexor 60 mg flat dose in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m^2 continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a flat dose of 60 mg twice weekly orally in weeks 1-3 of a 4-week cycle starting on day 2 (total of 6 doses per induction cycle)."
9821808|NCT02249104|Experimental|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily~Cetaphil Acne Regimen:~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
9821809|NCT02249143|Active Comparator|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
9821810|NCT02249143|No Intervention|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
9827018|NCT02441946|Active Comparator|Anastrozole|"Anastrozole (1 mg) is given orally QD for 2 weeks.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
9827019|NCT02442206|Experimental|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
9827020|NCT02442206|Experimental|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
9827021|NCT02442271|Experimental|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
9827022|NCT02442284|Experimental|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
9827023|NCT02442310|Experimental|Delayed release, fed conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
9965772|NCT01252849|Experimental|Second Arm: Two iStents, medication|Device: Two iStent devices, medication
9965773|NCT01252849|Experimental|Third Arm: Three iStents, medication|Device: Three iStent devices, medication
9827024|NCT02442310|Experimental|Delayed release, fasting conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
9827025|NCT02442310|Experimental|Delayed release half-tablets|A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
9965774|NCT01252862|Experimental|Two iStents devices|Two iStents devices will be implanted
9821811|NCT02249182|Experimental|12 to < 18 Years Old|"Participants between 12 to < 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
9821812|NCT02249182|Experimental|6 to < 12 Years Old|"Participants between 6 to < 12 years of age weighing ≥ 17 kg and < 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
9821813|NCT02249182|Experimental|3 to < 6 Years Old|"Participants between 3 to < 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing < 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
9821814|NCT02249585|Experimental|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
9821815|NCT02249585|Experimental|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
9821816|NCT02249585|Experimental|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
9821817|NCT02249728|Experimental|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
9821818|NCT02249728|Experimental|Radiolabelled AME|oral 14C PBT2
9821819|NCT02249767|Active Comparator|Generic Tretinoin|Treatment of acne once daily over 12 weeks
9821820|NCT02249767|Active Comparator|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
9821821|NCT02249767|Placebo Comparator|Placebo Vehicle|Treatment of acne once daily over 12 weeks
9821822|NCT02249793||Study group|Healthy volunteers
9821823|NCT02249819|Experimental|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
9821824|NCT02249819|Experimental|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
9821825|NCT02249832|Experimental|seated robot-assisted ankle therapy|All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (>0.8m/sec) functioning.
9821826|NCT02249949|Experimental|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9821827|NCT02250092|Active Comparator|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
9821828|NCT02250092|Placebo Comparator|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
9821829|NCT02250183|Other|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
9821830|NCT02250274|Other|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
9821831|NCT02250274|Other|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
9821832|NCT02250417|Experimental|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
9827026|NCT02442310|Active Comparator|Oral solution, fasting conditions|A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
9821833|NCT02250417|Experimental|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
9821834|NCT02250443|Experimental|BYM338|BYM338 Group
9821835|NCT02250521|Experimental|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The liquid crystal display (LCD) monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
9821836|NCT02250612|Experimental|SYL040012 (bamosiran) 0.375% eye drops|1 drop in each eye once daily for 28 consecutive days
9821837|NCT02250612|Experimental|SYL040012 (bamosiran) 0.750% eye drops|1 drop in each eye once daily for 28 consecutive days
9821838|NCT02250612|Experimental|SYL040012 (bamosiran) 1.125% eye drops|1 drop in each eye once daily for 28 consecutive days
9821839|NCT02250612|Experimental|SYL040012 (bamosiran) 1.5% eye drops|1 drop in each eye once daily for 28 consecutive days
9965775|NCT01252875|Other|LDL-C to100 mg/dL (+/-10 mg/dL)|"Target : 100 mg/dL (+/-10 mg/dL):~Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of 100 mg/dL(+/-10 mg/dL)."
9821840|NCT02250612|Active Comparator|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
9821841|NCT02250651|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
9821842|NCT02250651|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
9821843|NCT02250651|Active Comparator|Timolol 0.5%: Comparator|Both Eyes: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
9821844|NCT02250703|Active Comparator|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
9821845|NCT02250703|Experimental|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
9821846|NCT02250807|Experimental|Simeprevir and Sofosbuvir|Subjects will receive oral capsule of Simeprevir 150 milligram (mg) along with oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
9821847|NCT02251236|Other|Stribild Arm|Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
9821848|NCT02251236|Other|Genvoya Arm|Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
9821849|NCT02251236|Other|Untreated Arm|Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
9821850|NCT02251275|Experimental|Tolvaptan|"Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:~Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.~Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.~Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability."
9821851|NCT02251379|Experimental|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
9821852|NCT02251379|Active Comparator|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
9821853|NCT02251496|Active Comparator|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
9821854|NCT02251496|Active Comparator|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
9821855|NCT02251561|Experimental|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
9821856|NCT02251561|Active Comparator|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
9821857|NCT02251613|Experimental|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
9965776|NCT01252875|Other|LDL-C < 70 mg/dL|70 mg/dL: Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of less than 70 mg/dL.
9821858|NCT02251613|Active Comparator|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
9668559|NCT05244174|Experimental|Biliary and pancreatic stent|During ERCP, the cannulation of the main pancreatic duct may be performed for the placement of a pancreatic duct stent, which is performed routinely as a prophylaxis of post-ERCP acute pancreatitis in patients at risk. In patients with pancreatic cancer, the placement of a pancreatic stent could improve pancreatic secretion by clearing the main pancreatic duct and thus it could improve fat digestion and nutritional status of patients, avoiding the need for PERT
9821859|NCT02251652|Active Comparator|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
9821860|NCT02251652|Active Comparator|Cryotherapy Alone|Cryotherapy only
9821861|NCT02251717|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
9821862|NCT02251717|Experimental|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
9821863|NCT02251743|Experimental|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
9821864|NCT02251743|Placebo Comparator|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
9821865|NCT02251886|Active Comparator|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
9821866|NCT02251886|Active Comparator|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
9821867|NCT02251886|No Intervention|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
9821868|NCT02251886|No Intervention|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
9821869|NCT02251912|Experimental|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
9821870|NCT02251912|Placebo Comparator|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
9821871|NCT02251938|Experimental|DE-109 Sirolimus|DE-109 440 μg
9821872|NCT02251990|Experimental|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
9821873|NCT02251990|Placebo Comparator|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
9821874|NCT02252016|Experimental|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
9821875|NCT02252016|Placebo Comparator|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
9821876|NCT02252042|Experimental|Pembroliziumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
9821877|NCT02252042|Active Comparator|Active Comparator|Participants receive methotrexate 40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
9821878|NCT02252068|Other|I-CBT feasibility pilot|Open trial of I-CBT
9821879|NCT02252068|Experimental|I-CBT randomized trial|I-CBT in randomized trial.
9821880|NCT02252068|Active Comparator|IDC randomized trial|Comparison condition (Individualized Drug Counseling) in randomized trial.
9821881|NCT02252081|Active Comparator|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
9821882|NCT02252081|Placebo Comparator|Placebo|placebo pill(s) orally per day for 16 weeks
9821883|NCT02252133|Other|DT1, then 1DAVTE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
9821884|NCT02252133|Other|1DAVTE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
9821885|NCT02252146|Experimental|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
9821886|NCT02252211|Experimental|DS-8895a|Patients received infusions with DS-8895a on Days 1, 8, 22, and 36. Infusions on Days 1 and 36 were trace labelled with ^89Zr (^89Zr-Df-DS-8895a). The Day 1 dose was 0.2 mg/kg, followed by subsequent doses calculated based on individual patient body weight and dosing cohort assignment.
9821887|NCT02252354|Experimental|Part 1: [14C]-TAK-385|[14C]-TAK-385 80 mg, solution, orally, once on Day 1.
9821888|NCT02252354|Experimental|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and [14C]-TAK-385 80 μg, infusion, intravenous once on Day 1.
9821889|NCT02252406|Experimental|Ranolazine|Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
9821890|NCT02252406|Placebo Comparator|Placebo|Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.
9668560|NCT05244161|No Intervention|Radio messaging (RM)|Radio messaging only (RM)
9821891|NCT02252445|Active Comparator|Propofol|Propofol will be administered as the anesthetic maintenance agent.
9821892|NCT02252445|Experimental|Sevoflurane|Sevoflurane will be administered as the anesthetic maintenance agent.
9821893|NCT02252536|Placebo Comparator|Sugar Pill|Matching placebo, sugar pill
9821894|NCT02252536|Active Comparator|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
9821895|NCT02252562|No Intervention|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
9821896|NCT02252562|Experimental|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system [(SAGE Products Inc., Cary, Il),
9821897|NCT02252588|Experimental|Chlorhexidine|Oral Rinse
9821898|NCT02252588|Placebo Comparator|Placebo|Oral Rinse
9821899|NCT02252666|Experimental|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
9821900|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
9821901|NCT02252939|Experimental|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
9821902|NCT02252965|Active Comparator|Metformin IR|
10115705|NCT04446819|Other|Cohort|Patients diagnosed with solid tumors who are about to received albumin-binding paclitaxel monotherapy are recruited. Dominant hands and non-dominant hands are treated with small-size compression gloves and suitable-size compression gloves, respectively, during the administration of albumin-binding paclitaxel.
9821903|NCT02252965|Experimental|Metformin XR|
9821904|NCT02253147|Experimental|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
9821905|NCT02253147|Experimental|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
9821906|NCT02253160|Experimental|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
9821907|NCT02253160|Experimental|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
9821908|NCT02253173|Experimental|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
9821909|NCT02253173|Experimental|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
9821910|NCT02253173|Experimental|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
9821911|NCT02253173|Placebo Comparator|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
9821912|NCT02253433|Experimental|Enhanced Clinic Care|This arm receives enhanced in-clinic care only.
9821913|NCT02253433|Experimental|Enhanced Clinic Care + Home Intervention|This arm receives the enhanced in-clinic care intervention, as well as a home-based intervention.
9821914|NCT02253537||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
9821915|NCT02253654|Experimental|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
9821916|NCT02253654|Active Comparator|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
10115706|NCT04446871|Placebo Comparator|Standard care|Placebo
10115707|NCT04446871|Experimental|Methylene blue|Methylene blue
10115708|NCT04446559|Experimental|Sitting in a chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
9821917|NCT02253992|Experimental|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
9965777|NCT01252888|Experimental|Two iStent devices and medication|Implantation of two iStents through small temporal clear corneal incision
10182550|NCT03773016|Experimental|Art apps - Group 2 (B-A)|Cross-over use of two different visual art apps on touchscreen tablets (App B and App A)
9821918|NCT02254252|Active Comparator|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
9821919|NCT02254252|Active Comparator|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
9821920|NCT02254265|Experimental|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
9821921|NCT02254265|Experimental|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
9821922|NCT02254265|Placebo Comparator|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
9821923|NCT02254291|Experimental|Semaglutide 0.5 mg|
9821924|NCT02254291|Experimental|Semaglutide 1.0 mg|
9821925|NCT02254291|Active Comparator|Sitagliptin 100 mg|
9821926|NCT02254304|Experimental|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
9821927|NCT02254304|Experimental|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
9821928|NCT02254408|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
9821929|NCT02254408|Placebo Comparator|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
9821930|NCT02254421|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
9821931|NCT02254421|Placebo Comparator|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
9821932|NCT02254460|Experimental|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
9821933|NCT02254460|Placebo Comparator|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
9821934|NCT02254473|Experimental|Wedge Insert|Patients will receive a wedge insert
9821935|NCT02254473|Placebo Comparator|Flat insert|Patients will receive a flat insert
9821936|NCT02254486|Experimental|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
9821937|NCT02254486|Active Comparator|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
9821938|NCT02254551|Experimental|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
9821939|NCT02254681|Experimental|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m^2) and cisplatin (25 mg/m^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
9821940|NCT02254772|Experimental|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
9821941|NCT02255032|Experimental|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
9821942|NCT02255032|Experimental|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
9821943|NCT02255097|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
9821944|NCT02255110|Experimental|TH-302 and doxorubicin|
9965778|NCT01252914|Experimental|One iStent Supra Stent and medication|The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma
9821945|NCT02255149|Experimental|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
9821946|NCT02255175|Experimental|Perimenopausal women, depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
9821947|NCT02255175|Active Comparator|Perimenopausal women, non-depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
9821948|NCT02255279|Experimental|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
9821949|NCT02255279|Active Comparator|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
9821950|NCT02255357|Placebo Comparator|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
9821951|NCT02255357|Active Comparator|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
9821952|NCT02255422|Experimental|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
9821953|NCT02255422|Experimental|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
9821954|NCT02255422|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
9821955|NCT02255422|Experimental|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
9821956|NCT02255422|Experimental|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
9821957|NCT02255422|Experimental|omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
9821958|NCT02255422|Experimental|omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
9821959|NCT02255461|Experimental|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
9821960|NCT02255474|Active Comparator|Biofinity|Soft spherical contact lens
9821961|NCT02255474|Experimental|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
9821962|NCT02255474|Experimental|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
9821963|NCT02255500|Experimental|Bupivacaine FNB + EXPAREL Infiltration|Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
9821964|NCT02255513|Experimental|HLD200|"HLD200 (methylphenidate hydrochloride) 20, 40, 60, 80, or 100 mg capsules~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to continue their HLD200 treatment over an one week double-blind, placebo-controlled phase. HLD200 was administered orally, once daily each evening."
9821965|NCT02255513|Placebo Comparator|Placebo|"Placebo capsules (dose matched to HLD200 capsules)~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to receive placebo treatment over a one week double-blind, placebo-controlled phase. Treatments were administered orally, once daily each evening."
9821966|NCT02255552|Experimental|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
9821967|NCT02255552|No Intervention|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
9821968|NCT02255565|Experimental|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
9821969|NCT02255565|Experimental|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
9821970|NCT02255565|Experimental|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
10115709|NCT04446559|No Intervention|Semi-recumbent in bed position|The patient will benefit from conventional positioning techniques in the ICU bed. With the help of the medical monitoring software present in the wards, we will note the different nursing care given to the patient during the 3 hours following the morning arterial gasometry.
10182551|NCT03772795|Active Comparator|Group 1- Alignment with fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Uniteks, 0.022 Roth prescription brackets.Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
9821971|NCT02255604|Active Comparator|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
9821972|NCT02255604|Placebo Comparator|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
9821973|NCT02255604|Sham Comparator|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
9821974|NCT02255760|Experimental|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
9821975|NCT02255760|Experimental|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
9821976|NCT02255760|Experimental|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
9821977|NCT02255760|Experimental|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
9821978|NCT02255760|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
9821979|NCT02255981|Experimental|Acupuncture group|"Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months~."
9821980|NCT02256072|Experimental|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
9821981|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
9821982|NCT02256111|Experimental|ENZ+ADT+Usual care|The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
9821983|NCT02256111|Experimental|ENZ+ADT+Exercise|The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
9821984|NCT02256189|Other|Sitagliptin first, then placebo|Sitagliptin treatment for four weeks, then washout for four weeks, then placebo for four weeks
9821985|NCT02256189|Other|Placebo first, then sitagliptin|Placebo for four weeks, then washout for four weeks, then sitagliptin for four weeks
9821986|NCT02256267|Experimental|LY2835219|Single oral dose of LY2835219
9821987|NCT02256267|Experimental|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
9821988|NCT02256345|Active Comparator|KNO3 active comparator|KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
9821989|NCT02256345|Placebo Comparator|KCl placebo comparator|KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
9821990|NCT02256358|Active Comparator|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
9821991|NCT02256358|Experimental|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
9821992|NCT02256384|Experimental|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
9821993|NCT02256436|Active Comparator|Control|Participants receive paclitaxel 175 mg/m^2 intravenously (IV) or docetaxel 75 mg/m^2 IV or vinflunine 320 mg/m^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experience disease progression may be able to switch over to receive pembrolizumab 200 mg Q3W for up to 35 treatment administrations (up to approximately 2 years).
9821994|NCT02256436|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg IV on Day 1 Q3W. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to approximately 1 additional year).
9821995|NCT02256488|Experimental|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
9821996|NCT02256488|Experimental|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
9821997|NCT02256488|Experimental|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
9821998|NCT02256488|Active Comparator|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
9821999|NCT02256540|Placebo Comparator|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
9822000|NCT02256540|Experimental|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
9822001|NCT02256540|Active Comparator|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
9822002|NCT02256553|Experimental|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
9822003|NCT02256839||non TB infection|Group tested with CST_001
9822004|NCT02256839||low exposure risk|Group tested with CST_001
9822005|NCT02256891|Experimental|Double Row|Double Row
9822006|NCT02256891|Experimental|Double Row with PRFM|Double Row with PRFM
9822007|NCT02256917|Experimental|Human-cl rhFVIII|
9822008|NCT02256969|Other|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
9822009|NCT02256969|Other|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
9822010|NCT02256969|Active Comparator|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
9827027|NCT02442336|Experimental|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
9827028|NCT02442622|Active Comparator|Occupational therapy|Traditional therapy for de Quervain's Tenosynovitis
9827029|NCT02442622|Experimental|Occupational therapy with ASTYM|Traditional therapy for de Quervain's Tenosynovitis plus ASTYM
9827030|NCT02442687|Active Comparator|A|JKB 121, 5 mg twice daily
9827031|NCT02442687|Active Comparator|B|JKB 121, 10 mg twice daily
9827032|NCT02442687|Placebo Comparator|C|Identical appearing placebo
9827033|NCT02442700|Experimental|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
9827034|NCT02442700|Experimental|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
9827035|NCT02442804|Experimental|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
9827036|NCT02442804|Placebo Comparator|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
9827652|NCT02463227|Experimental|VRC01|Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
9822011|NCT02256982|Experimental|Resectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~-- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to surgery~Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
9822012|NCT02256982|Experimental|Unresectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to radiation therapy with protons or photons, determined by available resources~Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
9822013|NCT02257177|Active Comparator|0.15 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 0.15mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
9822014|NCT02257177|Active Comparator|1.5 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 1.5mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
9822015|NCT02257177|Active Comparator|3 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 3mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
9822016|NCT02257177|Active Comparator|10 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 10mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
9822017|NCT02257177|Active Comparator|20 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 20mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
9822018|NCT02257177|Active Comparator|50 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 50mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
9822019|NCT02257177|Placebo Comparator|Placebo Part 1|12 Healthy Subjects are administered placebo inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
9822020|NCT02257177|Active Comparator|0.3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 0.3mg TD139 once daily for 14 days inhaled as a dry powder.
9822021|NCT02257177|Active Comparator|3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 3mg TD139 once daily for 14 days inhaled as a dry powder.
9822022|NCT02257177|Active Comparator|10 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 10mg TD139 once daily for 14 days inhaled as a dry powder.
9822023|NCT02257177|Placebo Comparator|Placebo Part 2|9 Patients with IPF are administered placebo inhaled as a dry powder.
9822024|NCT02257372|Experimental|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
9822025|NCT02257372|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
9822026|NCT02257385|Experimental|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
9822027|NCT02257385|Placebo Comparator|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
9822028|NCT02257489|Experimental|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
9822029|NCT02257489|Experimental|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
9822030|NCT02257489|Experimental|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
9822031|NCT02257489|Experimental|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
9822032|NCT02257489|Experimental|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
9822033|NCT02257489|Experimental|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
9822034|NCT02257489|Experimental|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
9827037|NCT02442830|Experimental|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
9822035|NCT02257541|Experimental|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
9822036|NCT02257632|Experimental|Group 1|6 monthly intravitreal injections of 0.5 mg ranibizumab
9822037|NCT02257632|Experimental|Group 2|3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
9822038|NCT02257684|Experimental|Pegcrisantaspase|
10182552|NCT03772795|Experimental|Group 2- Alignment with clear aligners|Clear aligner orthodontic appliance (EON, Eon Dental NV, Belgium). Teeth alignment with clear aligners.
10182553|NCT03772678|Placebo Comparator|Placebo|0.9% Saline For SAD and MAD arms.
9822039|NCT02257957|Experimental|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
9822040|NCT02257957|Active Comparator|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
9822041|NCT02257970|Experimental|Part 1: Exploratory Group|"Ketoprofen 225-300 mgs daily, taken orally~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months"
9822042|NCT02257970|Experimental|Part 2: Open-label Group|"Ketoprofen 225 mg daily, taken orally~Open-label group: 75 mgs, three times daily, for four months"
9822043|NCT02257970|Placebo Comparator|Part 3: Placebo Group|"Participants randomized to receive placebo: placebo, three times daily, taken orally~Placebo: 1 capsule, three times daily, for four months"
9822044|NCT02257970|Active Comparator|Part 3: Ketoprofen Group|"Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally~Ketoprofen: 1 capsule, three times daily, for four months"
9822045|NCT02258074|Experimental|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
9822046|NCT02258074|Placebo Comparator|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
9822047|NCT02258074|Active Comparator|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
9822048|NCT02258074|Placebo Comparator|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
10182554|NCT03772678|Experimental|Single Ascending Dose - Low Dose|LSALT peptide (1mg/mL in 0.9% saline) Single escalating dose - 0.01mg, 0.1mg, 0.3mg, 0.5mg intravenously Escalation to 2.5mg and 5mg doses in next cohorts if no adverse effects are seen after 10-14 days.
9822049|NCT02258139|Experimental|Study Group 1|1st overnight visit with no contact lens; 2nd overnight visit randomized to either left or right eye for B&L Investigational Contact Lens
9822050|NCT02258152|Placebo Comparator|Placebo|
9822051|NCT02258152|Experimental|SYN120|
9822052|NCT02258217|Experimental|Single arm|Acthar 80 units subcutaneously for five consecutive days.
9822053|NCT02258256|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
9822054|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
9822055|NCT02258334|Experimental|Fluzone® Intradermal vaccine Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
9822056|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
9822057|NCT02258334|Experimental|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
9822058|NCT02258373|Experimental|CGM Only|"Participants will be instructed to check the blood glucose with the standard study BGM for calibration of the CGM and for specific circumstances that are specified in the protocol. This group will make management decisions based on the CGM glucose value without a BGM confirmation measurement as long as the participant is confident that the CGM glucose value is not erroneous.~In addition, participants will be instructed to make a BGM measurement on the blinded study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia and a standard BGM measurement has not been made. The participant may be asked to make post-prandial blinded BGM measurements at selected times."
9822059|NCT02258373|Active Comparator|CGM+BGM|Participants will be instructed to perform BGM measurements for sensor calibration according to Dexcom specifications and measure the blood glucose whenever a diabetes management decision is made. A BGM measurement is to be made on the study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia. Additional BGM measurements can be made on the study BGM at any time that the participant desires.
9822060|NCT02258412|Active Comparator|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
9822061|NCT02258412|Active Comparator|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
9822062|NCT02258464|Experimental|Radium 223 dichloride|Participants treated with a single hormonal agent as background therapy received 50 kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) of Radium 223 dichloride intravenously for a maximum of 6 cycles at intervals of 4 weeks
9822063|NCT02258464|Placebo Comparator|Placebo|Participants treated with a single hormonal agent as background therapy received isotonic saline (0.9% sodium chloride solution for injection) intravenously for a maximum of 6 cycles at intervals of 4 weeks
9822064|NCT02258477|Active Comparator|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
9822065|NCT02258477|Active Comparator|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
9822066|NCT02258477|Active Comparator|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
9822067|NCT02258477|Active Comparator|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
9822068|NCT02258529|Experimental|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
9822069|NCT02259010|Experimental|Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg|All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
9822070|NCT02259088|Experimental|Ranibizumab (RFB002)|3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
9822071|NCT02259088|Active Comparator|Laser|Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
9822072|NCT02259114|Experimental|Continuous Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
9822073|NCT02259114|Experimental|Days 1-7 Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
9822074|NCT02259231|Experimental|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
9822075|NCT02259231|Experimental|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
9822076|NCT02259231|Experimental|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
9822077|NCT02259231|Experimental|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
9822078|NCT02259231|Experimental|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
9822079|NCT02259231|Experimental|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
9822080|NCT02259231|Experimental|Omaveloxolone 150 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
9822081|NCT02259348|Experimental|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
9822082|NCT02259400|Active Comparator|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
9822083|NCT02259400|Active Comparator|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
9822084|NCT02259582|Placebo Comparator|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
9822085|NCT02259582|Active Comparator|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
9822086|NCT02259582|Active Comparator|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
9822087|NCT02259608|Experimental|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
9827653|NCT02463331|Active Comparator|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
9822088|NCT02259699|Experimental|Decision Aid (PCOA)|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
9822089|NCT02259699|No Intervention|UC (Standard care)|Standard pamphlets will be given to patients to educate them about IV and IV/IP therapies.
9822090|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
9822091|NCT02260180|Active Comparator|A-101 40%|A-101 40% Topical Solution
9822092|NCT02260180|Active Comparator|A-101 32.5%|A-101 32.5% Topical Solution
10115710|NCT04446494|Experimental|Axillary dissection with DEPART technique|In the experimental group, 1 ml (2.5 mg) indocyanine green (ICG) and methylene blue (MB) was intradermally injected into the internal bicipital sulcus of ipsilateral arm. During axillary dissection, the identified arm sentinel nodes were carefully injected with 0.1 ml methylene blue (MB) using a 1-cc syringe with a 32-gauge needle. MB could then flow from the nodes along several lymphatic channels toward the infraclavicular nodes. Subsequent-echelon nodes and lymphatics were identified. Sentinel lymph nodes (SLNs) were removed after the identification of the arm sentinel nodes and the procedure of MB injection. When patients harbored positive SLNs, axillary lymph node dissection (ALND) was performed subsequently. All discernible arm lymphatics and lymph nodes were preserved, except that gross arm lymph nodes (major axis larger than 10 mm or node firm on palpation) were sent for immediate partial frozen section (pFS) to determine their resection during ALND.
10115711|NCT04446494|No Intervention|Standard axillary dissection|In the control group (no intervention), ALND was performed with complete resection of at least Berg's levels I and II. Resection of level III was performed only in cases with gross disease in level II and/or III
10115712|NCT04446663|Experimental|Toripalimab+induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT .~Toripalimab 240mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy"
10115713|NCT04446663|Active Comparator|induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT ."
10115714|NCT04446520|Experimental|autogenic drainage and traditional physiotherapy|autogenic drainage technique plus traditional physiotherapy (localized breathing exercise, diaphragmatic breathing and splinted coughing)
10115715|NCT04446520|Active Comparator|traditional physiotherapy|traditional physiotherapy (localized breathing exercise, diaphragmatic breathing, and splinted coughing)
10115716|NCT04446715|Experimental|Sufentanil Group|Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia
10115717|NCT04446715|Experimental|Meperidine Group|Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia
10115718|NCT04446780||Women who underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery with mediolateral episiotomy
10115719|NCT04446780||Women who did not underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery without mediolateral episiotomy
10115720|NCT04446767|Experimental|Bioptron light therapy and medical care|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks plus medical care in the form of Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
10115721|NCT04446767|Active Comparator|medical care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
10115722|NCT04446572|Experimental|Repetitive Abortion (RA) group|Starting at day 0, women of the RA (n=21) group consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
10115723|NCT04446572|Experimental|Infertility (INF) group|Starting at day 0, women of the INF group (n=23) consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
9822093|NCT02260180|Placebo Comparator|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
9822094|NCT02260258|Experimental|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous intravenous (IV) infusion as per standard intensive care unit practice.~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
9822095|NCT02260258|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
9822096|NCT02260388|Experimental|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
9822097|NCT02260388|Experimental|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
9822098|NCT02260388|Experimental|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
9822099|NCT02260388|Experimental|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
9827654|NCT02463331|Experimental|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
9822100|NCT02260401|Experimental|Individualized report|Each patient in this group will receive an individualized report with their own outcome data (pain and function) during the first year of the LESS trial. They will receive these reports at 18 months.
9822101|NCT02260401|No Intervention|Individualized Reports after 24 months|Patients in this group will receive the individualized report, but will not receive it until after the conclusion of the study at 24 months. They will serve as the control group.
9822102|NCT02260440|Experimental|Pembrolizumab and Azacitidine Arm|"9 cycles~Pembrolizumab will be given at 200 mg every 21 days.~Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
9822103|NCT02260492|Experimental|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
9822104|NCT02260492|Active Comparator|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
9822105|NCT02260492|Placebo Comparator|Placebo|Placebo (twice daily inhalation throughout the study)
9822106|NCT02260531|Experimental|Cohort 1 - Cabozantinib, Trastuzumab for HER2+|"HER2-positive~Cabozantinib- orally administered daily per treatment cycle, 60 mg per day~Trastuzumab- IV administered once per cycle, 8 mg/kg IV loading dose followed by 6 mg/kg IV Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
9822107|NCT02260531|Experimental|Cohort 2 - Cabozantinib for ER+ and/or PR+|"Hormone receptor-positive (ER+ and/or PR+)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
9822108|NCT02260531|Experimental|Cohort 3 - Cabozantinib for ER-, PR-, HER2-|"Triple negative (ER-, PR-, HER2-)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
9822109|NCT02260622|Active Comparator|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
9822110|NCT02260622|Experimental|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
9822111|NCT02260635|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
9822112|NCT02260635|Placebo Comparator|Placebo|Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.
9822113|NCT02260648|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered PO once a day for 12 weeks.
9822114|NCT02260648|Active Comparator|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered PO once a day for 12 weeks as a reference arm.
9822115|NCT02260648|Placebo Comparator|Placebo|Placebo and 10 mg atorvastatin administered PO once a day for 12 weeks.
9822116|NCT02260791|Experimental|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
9822117|NCT02260791|Active Comparator|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
9822118|NCT02260804|Experimental|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
9822119|NCT02260804|Active Comparator|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
9822120|NCT02260817|Experimental|Expanded Access for 11C-Choline|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
9822121|NCT02260817|Experimental|11C-Choline Comparison of Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
9822122|NCT02260882|Experimental|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
9822123|NCT02260882|Experimental|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
9822124|NCT02260921|Experimental|iovera° Treatment|Treatment with the iovera° device administered by a trained investigator to treat knee pain.
9822125|NCT02260921|Sham Comparator|Sham Treatment|Sham Treatment (similar device with no active therapeutic treatment) administered by a trained investigator to treat knee pain.
9822126|NCT02260934|Active Comparator|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
9822127|NCT02260934|Experimental|Rituximab/Cyclophosphamide/Belimumab (RCB)|"Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.~Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
9822128|NCT02260986|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
9822129|NCT02260986|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
9822130|NCT02260986|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
9827655|NCT02463357|Experimental|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
9822131|NCT02261428|Experimental|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
9822132|NCT02261428|Active Comparator|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
9822133|NCT02261467|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
9822134|NCT02261467|Placebo Comparator|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
9822135|NCT02261493|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
9822136|NCT02261493|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
9822137|NCT02261493|Placebo Comparator|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
9822138|NCT02261597||Insomnia Disorder|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among participants with a clinical diagnosis of insomnia disorder.
9822139|NCT02261597||Healthy Control|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among healthy participants without a diagnosis of insomnia disorder.
9822140|NCT02261714|Experimental|TG01/GM-CSF and Gemcitabine|
9822141|NCT02261727|Placebo Comparator|Placebo|Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily
9822142|NCT02261727|Active Comparator|Low-dose theophylline arm|Theophylline 100 mg twice daily
9822143|NCT02261727|Active Comparator|Theophylline and Prednisone arm|Theophylline 100 mg twice daily plus prednisone 5 mg once daily
9822144|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 1|Ganetespib 100 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
9822145|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 2|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
9822146|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase II Expansion|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
9822147|NCT02261818|Other|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
10115724|NCT04446572|No Intervention|Control group|The control group (n = 14) included fertile women having at least two children after uncomplicated term pregnancies.
10115725|NCT04446546||Cold Stored Allograft Vascular Access|
9822148|NCT02261948|Active Comparator|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
9822149|NCT02261948|Placebo Comparator|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
9822150|NCT02261961|Experimental|Nutritional Supplement|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
9822151|NCT02261961|Placebo Comparator|Placebo|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
9822152|NCT02261974|Active Comparator|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
9822153|NCT02261974|Placebo Comparator|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
10115726|NCT04446598|Experimental|Laser group|In the laser group, the patients received two sessions of Er:YAG intraurethral laser in non-ablative SMOOTH™ mode, with 1 month interval between sessions.
10115727|NCT04446598|Active Comparator|Tadalafil group|The tadalafil group was treated with daily oral administration of tadalafil, at a dose of 5 mg/day, which lasted consecutively for two months.
10182555|NCT03772678|Experimental|Single Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Single dose - 1mg intravenously over 2h Escalation to next dose in next participant every 72h if no adverse effects are seen.
9822154|NCT02262039|Active Comparator|Conventional Pressure|Conventional Insufflation with 15mmHg target pressure
9822155|NCT02262039|Experimental|Low Pressure (VTI)|Valveless recirculating insufflation (VTI) with 10mmHg target pressure
9822156|NCT02262078|Placebo Comparator|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
9822157|NCT02262078|Experimental|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
9822158|NCT02262130|Experimental|Omalizumab|Omalizumab 300 mg W0, W4 and W8
9822159|NCT02262260|Experimental|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
9822160|NCT02262260|Experimental|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
9822161|NCT02262364|Experimental|NStride APS|Subjects will receive an intra-articular injection of APS.
9822162|NCT02262377|Experimental|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
9822163|NCT02262377|No Intervention|Standard of Care|primary care visits, which include medications and advice
9822164|NCT02262507|Experimental|Device wearing|All subjects who meet the study criteria and volunteer to participate will be included in the study. Subjects will undergo repeat oto-acoustic measures both wearing the device and not wearing the device. The intervention will be the auto-acoustic measurement - taken while wearing the collar and then again when not wearing the collar.
9822165|NCT02262728|Experimental|Panel 1|Participants with Child-Pugh score <7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
9822166|NCT02262728|Experimental|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
9822167|NCT02262754|Experimental|PF-06372865|Daily BID dosing for 4 weeks
9822168|NCT02262754|Placebo Comparator|Placebo|Daily BID dosing for 4 weeks
9822169|NCT02262754|Active Comparator|Naproxen|Daily BID dosing for 4 weeks
9822170|NCT02263014||Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide to have contralateral prophylactic mastectomy (CPM) along with scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after the surgery is completed.
9822171|NCT02263014||No Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide not to have contralateral prophylactic mastectomy (CPM) performed during scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after unilateral mastectomy or breast conserving surgery is completed.
9822172|NCT02263040|Experimental|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5 mL containing 60μg hemagglutinin per virus strain
9822173|NCT02263040|Active Comparator|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5 mL containing 15μg hemagglutinin per virus strain for adults
9822174|NCT02263079|Experimental|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
9822175|NCT02263079|No Intervention|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
9822176|NCT02263079|Experimental|Peg-INF-Alfa-2A Monotherapy|Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
9822177|NCT02263118|Experimental|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
9822178|NCT02263118|Experimental|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
9822179|NCT02263118|Experimental|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
9822180|NCT02263118|Experimental|Control group|Individuals were given a feature phone (simple mobile phone)
9822181|NCT02263131|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
9822182|NCT02263131|Active Comparator|TIV PFS|VAXIGRIP Prefilled Syringe INJ.
9822183|NCT02263326|Experimental|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
9822184|NCT02263326|Active Comparator|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
9822185|NCT02263547|Other|teriflunomide elimination with colestipol|
9822186|NCT02263833||Overall Participants|Participants not previously on erythropoietin-stimulating agent (ESA) therapy and participants on ESA therapy who were switched to Mircera
9822187|NCT02263911|Experimental|Baricitinib Test Treatment 1 (T1)|Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
9822188|NCT02263911|Experimental|Baricitinib Reference Treatment 1 (R1)|Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
9822189|NCT02263911|Experimental|Baricitinib Test Treatment 2 (T2)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
9822190|NCT02263911|Experimental|Baricitinib Reference Treatment 2 (R2)|Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
9822191|NCT02263911|Experimental|Baricitinib Test Treatment 2 with Meal (T2F)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.
9822192|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
9822193|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
9822194|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
9822195|NCT02264353|Experimental|Donepezil|Sleep data with Donepezil given
9822196|NCT02264353|Placebo Comparator|Placebo|Sleep data with Placebo given
9822197|NCT02264574|Experimental|IBR + OB|Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.
9822198|NCT02264574|Experimental|CLB + OB|"Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.~Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity."
9822199|NCT02264639|Experimental|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
9822200|NCT02264639|Experimental|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
9822201|NCT02264639|Experimental|Cohort 3|Repeated Dose 180 mg/day
9822202|NCT02264639|Experimental|Cohort 4|Repeated Dose 270 mg/day
9822203|NCT02264821|Experimental|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
9822204|NCT02264821|Experimental|rachi morphine|100 µg intrathecal morphine and saline infiltration
9822205|NCT02264821|Placebo Comparator|placebo|intrathecal saline and saline infiltration
9822206|NCT02264990|Experimental|Veliparib + Carboplatin + Paclitaxel|"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
9822207|NCT02264990|Active Comparator|Investigator's Choice Chemotherapy|"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:~Carboplatin AUC 6 mg/mL*min + paclitaxel 200 mg/m²~Cisplatin 75 mg/m² + pemetrexed 500 mg/m²~Carboplatin AUC 6 or AUC 5 mg/mL*min + pemetrexed 500 mg/m²~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
9822208|NCT02265224|Experimental|Test - Reference|N-acetylcysteine (NAC) 600 mg uncoated tablet (single dose) followed by NAC 600 mg film-coated tablet (single dose)
9822209|NCT02265224|Active Comparator|Reference - Test|N-acetylcysteine (NAC) 600 mg film-coated tablet (single dose) followed by NAC 600 mg uncoated tablet (single dose)
9822210|NCT02265237|Experimental|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
9822211|NCT02265237|Experimental|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
9822212|NCT02265237|Experimental|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
9822213|NCT02265237|Experimental|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
9822214|NCT02265341|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9822215|NCT02265510|Experimental|Phase 1a: INCB052793 Monotherapy|
9822216|NCT02265510|Experimental|Phase 1b: INCB052793 Combination Therapy|
9822217|NCT02265510|Experimental|Phase 2: INCB052793 and itacitinib Combination Therapy|
9822218|NCT02265705|Experimental|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
9822219|NCT02265705|Placebo Comparator|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52.~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
9822220|NCT02265744|Experimental|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
10182556|NCT03772678|Experimental|Multiple Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Dose will be determined based on results of SAD arm. LSALT will be administered intravenously once or twice daily for 3 days.
9822221|NCT02265744|Experimental|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
9822222|NCT02265744|Experimental|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
9822223|NCT02265744|Experimental|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
9822224|NCT02265744|Placebo Comparator|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
9822225|NCT02265783|Other|Nellcor USB Pulse Oximeter Monitor Interface Cable Sensor Test|
9822226|NCT02265796|Active Comparator|Ranolazine|"Ranolazine 500 mg tablets~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
9822227|NCT02265796|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
10115728|NCT04446533|Experimental|Hydrogen Peroxide and Hyaluronic acid (BMG0703)|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
10115729|NCT04446533|Active Comparator|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
9822228|NCT02265848|Active Comparator|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
9822229|NCT02265848|Active Comparator|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
9822230|NCT02265913|Experimental|Test Product|acyclovir cream
9822231|NCT02265913|Active Comparator|Reference Product|acyclovir cream
9822232|NCT02265913|Placebo Comparator|Placebo Product|Placebo cream
10115730|NCT04446533|Placebo Comparator|Placebo product|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
10182557|NCT03772639|Experimental|Experimental group|The experimental group received a standard medical and pharmacological care in a daily format and shared decision making (SDM). The general framework of SDM was developed focusing on self-management goals which include education that addresses continuous use of medication, behavioral change, breathing training, learning to interpret changes in the disease and its consequences, and use of medical and community resources.
9822233|NCT02265952|Experimental|Open-label|Open-label REGN1500
9822234|NCT02265965|Experimental|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
9822235|NCT02265965|No Intervention|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
9822236|NCT02266004|Experimental|tDCS+ LT|Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.
9822237|NCT02266108|Experimental|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
9822238|NCT02266108|Other|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
9822239|NCT02266147|Experimental|SD-101 in combination with low-dose radiation|"PART 1~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29~PART 2~Cycle 1: Required~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29~Cycle 2: Optional~Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181~COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209~COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
9822240|NCT02266225|Experimental|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
9827038|NCT02442830|No Intervention|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
9519428|NCT03287167|Experimental|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
9827039|NCT02442856|Experimental|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
10115731|NCT04446689|Active Comparator|Biofeedback|The intervention group will develop an activity with self-monitoring called Cardiovascular Biofeedback or Cardiac Frequency Variability (CFV). This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph. This photoplethysmograph verifies blood flow alterations through an optical method. Cardiac frequency oscillations may be estimated both by the quantity of blood infrared lights absorbed or reflected, and by variations in blood volume and pressure. Captured physiological signs will be recorded during ten minutes by the Software Emwave Pro Plus®, which is adapted to biofeedback training.
10182558|NCT03772639|No Intervention|Control Group|The control group received standard care and pharmacological care including systemic steroids, antibiotics, inhaled bronchodilators, and oxygen therapy.
10182559|NCT03772938|Active Comparator|Stem/progenitor cells transplantation|Intervention: A single intravitreal injection of autologous bone marrow-derived stem/progenitor cells will be performed.
10182560|NCT03772938|Sham Comparator|Standard treatment of degenerative disease of retina|Symptomatic treatment of degenerative disease of retina without biologic cell-based treatment
9827040|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 CAMS|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
9827041|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 DBT|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
9827042|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Additional Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
9827043|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 DBT|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
9827044|NCT02443103|Experimental|Guanabenz|
9827045|NCT02443155|Experimental|NNC0114-0006 + Liraglutide|
9827046|NCT02443155|Experimental|NNC0114-0006 + Placebo|
9827047|NCT02443155|Active Comparator|Liraglutide + Placebo|
9827048|NCT02443155|Placebo Comparator|Placebo|
9827049|NCT02443298|Experimental|Risankizumab|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
9827050|NCT02443298|Placebo Comparator|Placebo|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
9827051|NCT02443337|Experimental|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
9827052|NCT02443402|Experimental|Sitagliptin|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take sitagliptin. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
9827053|NCT02443402|Placebo Comparator|Placebo|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take a placebo. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
9827656|NCT02463357|Experimental|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
9827657|NCT02463357|Experimental|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
9519429|NCT03287167|Active Comparator|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
9519430|NCT03287141|Sham Comparator|First intervention|The subjects did a shuttle walk test without any previous intervention.
9822241|NCT02266277|Active Comparator|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
9822242|NCT02266277|Active Comparator|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
9822243|NCT02266277|Active Comparator|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
9822244|NCT02266277|No Intervention|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
9822245|NCT02266277|Active Comparator|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
9822246|NCT02266277|No Intervention|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
9822247|NCT02266381|Other|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
9822248|NCT02266381|Other|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
9822249|NCT02266381|Other|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
9822250|NCT02266433|Active Comparator|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
9822251|NCT02266433|Experimental|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
9822252|NCT02266472|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
9822253|NCT02266472|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
9822254|NCT02266576|Active Comparator|Standard Diabetes Prevention Program (DPP)|Participants receive Standard DPP over the course of 20 weeks.
9822255|NCT02266576|Experimental|Enhanced DPP|Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.
9822256|NCT02266706|Experimental|Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC|Participants ≥12 to <18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
9822257|NCT02266706|Experimental|Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg|Participants ≥7 to <12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
9822258|NCT02266706|Experimental|Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥2 to <7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
9822259|NCT02266706|Experimental|Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥3 months to <2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
9822260|NCT02266706|Experimental|Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg|Participants from birth (>32 weeks gestation, 7 days postnatal) to <3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
9822261|NCT02266706|Experimental|Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg|Participants from birth (≤32 weeks gestation, 7 days postnatal) to <3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m^2.
9822262|NCT02266810|Experimental|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
10182561|NCT03772912||Total Knee Arthroplasty Patients|Patients undergoing primary or revision total knee arthroplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
9822263|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
9822264|NCT02266810|Experimental|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
9822265|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
9822266|NCT02266875|Experimental|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
9822267|NCT02266875|Active Comparator|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
9822268|NCT02266888|Experimental|Rituximab Induction|Rituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
9822269|NCT02266888|Placebo Comparator|Placebo Induction|Placebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
9822270|NCT02267083|Experimental|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
9822271|NCT02267135|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
9827658|NCT02463357|Placebo Comparator|Placebo|Sugar pill manufactured to look like all other investigational products
10115732|NCT04446689|No Intervention|activity without self monitoring|"The placebo group will develop an activity without self monitoring. In order to keep blindness between the groups the activities will be processed by an electronic device - the on line app Jigsaw Puzzles. This app consists of a puzzle with different levels of difficulties, and is played in a tablet.~Each participant will be performing in the study during four weeks, with two encounters each week (total: four weeks). While the participant will be performing its activity he/she will be monitored by the researchers through CFV (Cardiac Frequency Variability) - with no visualization of the computer monitor.~The control group will answer the research protocol in two moments (D1 and D8), to evaluate"
10115733|NCT04446637|Experimental|Ipratropium/Levosalbutamol|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
10115734|NCT04446637|Active Comparator|Salbutamol + Ipratropium|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
10115735|NCT04446624|No Intervention|Treatment as usual (TAU)|Patients in the TAU group will receive the treatment routinely offered to patients undergoing RT for breast cancer.
10115736|NCT04446624|Experimental|Music therapy intervention (PSY)|Patients in the PSY group will participate to a short-term group psychotherapy with elements of music therapy; meetings will be 1 / week, for a total of 6 weeks. Beginning of psychotherapy intervention will be 1-2 weeks after recruitment at T0 and will therefore cover the entire duration of the RT cycle.
10115737|NCT04446416|Experimental|Bevacizumab plus NaviFUS System|"Device: NaviFUS System BBB Disruption by FUS in recurrent GBM Microbubbles (MB) (SonoVue®) 0.1 mL/kg and optimal ultrasound exposure doses (based on the acoustic emission feedback FUS power control algorithm) generated from the NaviFUS System every 2 weeks to transiently open the BBB.~Drug: Bevacizumab 10 mg/kg every 2 weeks for up to 36 weeks or until evidence of progressive disease, unacceptable toxicity, non-compliance with study follow-up, or withdrawal of consent."
10115738|NCT04446455|Experimental|Functional Power + Cognitive Training|Training sessions began with approximately 30 minutes of cognitive training using a desktop computer followed by 40 minutes of functional power training.
10115739|NCT04446455|Active Comparator|Functional Power Training|Training sessions began with 40 minutes of functional power training.
10115740|NCT04446403|Experimental|circumflex|patients will undergo ultrasound guided SSN+circumflex
10115741|NCT04446403|Experimental|posterior cord|patients will undergo ultrasound guided SSN+circumflex
10115742|NCT04446338||Healthcare Worker|Staff of the Department of Ophthalmology, University Tuebingen, Germany
10115743|NCT04446299|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
10115744|NCT04446299|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
10115745|NCT04446195|No Intervention|Control group|The control group received routine intestinal preparation education.
10115746|NCT04446195|Active Comparator|Experimental group|The experimental group was treated with routine intestinal preparation education and individualized intervention.
10115747|NCT04446312|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
10115748|NCT04446312|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
10115749|NCT04446364|Experimental|Aloe vera group|Gel cavity disinfection
10115750|NCT04446364|Active Comparator|Chlorohexidine group|2% cavity disinfection
9827659|NCT02463357|Experimental|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
9827660|NCT02463409|Experimental|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
10115751|NCT04445922|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
10115752|NCT04445922|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
9965779|NCT01252927|Experimental|ASIST intervention|The gatekeeper training intervention group received the Applied Suicide Intervention Skills Training (ASIST) 10.0 in addition to TAU. ASIST is a two-day (fourteen hour), intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The intervention was offered to students on a weekend and was conducted by three senior ASIST trainers and one junior trainer, with two trainers assigned to each training group.
10115753|NCT04446026|Experimental|teneligliptin|
10115754|NCT04446026|Placebo Comparator|placebo|
10115755|NCT04445974|Active Comparator|Expand Your Horizons: More than my skin|Participants allocated to the intervention condition will be asked to follow the adapted instructions for 'Expand Your Horizon'. Participants will be asked to complete three 15 min writing exercises over approximately six days. Participants who complete the first exercise on Qualtrics will be sent links to and asked to complete the second and third writing exercises.
10115756|NCT04445974|Experimental|Control writing activity|Participants in the control condition will be asked to complete three 15 minute creative writing exercises online via Qualtucs over approximately six days. Participants completing the first writing exercise will be sent links to the second and third writing exercises.
10115757|NCT04446377|Experimental|LAM-002A|LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days
10115758|NCT04446377|Placebo Comparator|Placebo|(microcrystalline cellulose) in 5 capsules BID for 10 days
10115759|NCT04446169||SARS-CoV 2 Patients|Patients with previous nasopharyngeal swab positive for SARS-CoV-2, subsequently negativeized in two detections
10115760|NCT04446234|Experimental|Risperidone|Risperidone tablet
10115761|NCT04446234|Experimental|Aripiprazole|Aripiprazole tablet
10115762|NCT04446234|Experimental|Ziprasidone|Ziprasidone tablet
10115763|NCT04446234|Experimental|Amisulpride|Amisulpride tablet
10115764|NCT04446234|Experimental|Quetiapine|Quetiapine tablet
10182562|NCT03772613|Active Comparator|Low ACT Target|ACT target range of 225 to 275 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
9822272|NCT02267135|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
9822273|NCT02267187|Experimental|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
9822274|NCT02267226|Experimental|Octafibrin|
9822275|NCT02267278|Experimental|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
9822276|NCT02267317|Active Comparator|Obese Group-D5W|Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
9822277|NCT02267317|Active Comparator|Obese Group - Eritoran|Obese subjects receive IV administration of Eritoran 12 mg every 12 hours
9822278|NCT02267317|Active Comparator|Diabetes (T2DM) Group - D5W|T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
9822279|NCT02267317|Active Comparator|Diabetes (T2DM) Group - Eritoran|T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours
9519431|NCT03287141|Experimental|Second intervention|Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
9519432|NCT03287141|Experimental|Third intervention|Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
9822280|NCT02267356|Experimental|Low dose 12-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
9822281|NCT02267356|Experimental|Low dose 24-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
9822282|NCT02267356|Experimental|High dose 12-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
9822283|NCT02267356|Experimental|High dose 24-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
9822284|NCT02267356|Placebo Comparator|Placebo|4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
9822285|NCT02267382|Experimental|VT-1161 Low-dose 3-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
9822286|NCT02267382|Experimental|VT-1161 Low-dose 6-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
9822287|NCT02267382|Experimental|VT-1161 High-dose 3-month|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
9822288|NCT02267382|Experimental|VT-1161 High-dose 24-week|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
9822289|NCT02267382|Placebo Comparator|Placebo|2 placebo tablets once daily for 7 days, then once weekly for 23 weeks
9822290|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
9822291|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
9822292|NCT02267538|Experimental|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
9822293|NCT02267538|Placebo Comparator|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
9822294|NCT02267577|Experimental|Healthy Adults Volunteers|Men and women over the age of 18 will have their blood pressure measured with both the Sphygmo: Automatic Blood Pressure Monitor device and the GE Dinamap ProCare automatic blood pressure monitor.
9822295|NCT02267629|Experimental|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
10115765|NCT04446065|Experimental|Previfenon®|Participants will receive coded non-transparent bottles of Previfenon®, each containing 90 EGCG capsules (250 mg per capsule plus excipients) The total EGCG dose per patient will be 750 mg/day (3 capsules) for 40 consecutive days as minimum or a maximum variable time between 60 to 70 days. It will be divided into three daily intakes of one capsule of Previfenon® every 8 hours.
9519433|NCT03287115|Experimental|Broccoli|Subjects will consume a dose of broccoli on day 11
9822296|NCT02267746|Active Comparator|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
10115766|NCT04446065|Placebo Comparator|Placebo|Participants will receive coded non-transparent bottles of placebo, each containing 90 starch capsules (250 mg plus excipients) under the same dosage, frequency and duration that Previfenon@ arm.
9519434|NCT03287102|Other|Temporal inverted ILM peeling group|The internal limiting membrane is peeled from the temporal side of the fovea only
9519435|NCT03287102|Other|Complete ILM peeling group|The internal limiting membrane is completely removed around the fovea
9519436|NCT03287076|Experimental|Active|Patients will receive exenatide injections
9519437|NCT03287076|No Intervention|Standard Care|Standard care for stroke as per hospital protocol
9668561|NCT05244161|Active Comparator|RM, Video job aids, Early Childhood Development program (RMV-ECD)|Radio messaging, short video job aids primarily for CHW use, and the UNICEF Care for Childhood Development program (RMV-ECD)
9822297|NCT02267746|Experimental|Tazarotene|Tazarotene 0/1% foam (Actavis)
9822298|NCT02267746|Placebo Comparator|Vehicle foam|Foam vehicle of the test product (Actavis)
9822299|NCT02267772|Experimental|IV Acetaminophen|IV acetaminophen for pain control
9822300|NCT02267772|Active Comparator|IV morphine|IV morphine for pain control
9822301|NCT02267811|Experimental|Fixed Orthodontic Treatment with OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
10182563|NCT03772613|Active Comparator|Medium ACT Target|ACT target range of 275 to 325 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
9822302|NCT02267811|Experimental|Fixed Orthodontic Treatment|Subjects assigned to this group receive orthodontic treatment with no OrthoPulse™ treatment.
9822303|NCT02267824|Experimental|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
9822304|NCT02267824|Other|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
9822305|NCT02267837|Experimental|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
9822306|NCT02267837|No Intervention|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
9822307|NCT02267850|Experimental|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
9822308|NCT02267850|Sham Comparator|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
9822309|NCT02268045|Experimental|RTXM83|Active Ingredient: Rituximab (Biosimilar)
9822310|NCT02268045|Active Comparator|MabThera|Active Ingredient: Rituximab
9822311|NCT02268058|Active Comparator|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
9822312|NCT02268058|Active Comparator|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
9822313|NCT02268058|Active Comparator|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency Department."
9822314|NCT02268058|No Intervention|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
9822315|NCT02268084|Sham Comparator|Sham Stimulation|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
9822316|NCT02268084|Active Comparator|Active sTMS|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase) and 2 additional weeks for all subjects (open label) with Synchronized Transcranial Magnetic Stimulation (sTMS), using an active device.
9822317|NCT02268214|Experimental|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
9822318|NCT02268214|Experimental|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
9822319|NCT02268214|Placebo Comparator|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
9822320|NCT02268396|Experimental|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
9822321|NCT02268500|Active Comparator|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
9822322|NCT02268500|Active Comparator|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
9965780|NCT01252927|No Intervention|Control group: training as usual|Training as usual consisted of didactic teaching and a tutorial with case-based examples around suicide risk factors in their first year of medical school. Third- and fourth-year students may also have the opportunity to practice their skills with real patients during their clerkship rotations or in the emergency department.
9965781|NCT01252979|Experimental|Medium Chain Triglyceride|
9822323|NCT02268526|Experimental|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
9822324|NCT02268526|Experimental|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
9822325|NCT02268526|Placebo Comparator|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
9822326|NCT02268786|Experimental|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
9822327|NCT02268786|No Intervention|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
9822328|NCT02268812||Ziconotide|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.~IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
9822329|NCT02268851|Experimental|CLL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
9822330|NCT02268851|Experimental|MCL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
9822331|NCT02268864|Experimental|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
9822332|NCT02268877|Experimental|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
9822333|NCT02268877|Active Comparator|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
9822334|NCT02268942|Experimental|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
9822335|NCT02268955|Placebo Comparator|Control Group: Adults age 18-55 years|Saline-only control group
9822336|NCT02268955|Active Comparator|IV Ibuprofen: Adults age 18-55 years|Patients receiving intravenous ibuprofen therapy
9822337|NCT02268994|Experimental|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
9822338|NCT02268994|Placebo Comparator|Placebo|Matching Placebo
9822339|NCT02269098|Experimental|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
9822340|NCT02269098|No Intervention|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
9822341|NCT02269124|No Intervention|Conventional Measures Only|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
9822342|NCT02269124|Experimental|Conventional Measures + Hearing Aid|In arm 2, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by an audiologist. The subject will be instructed to wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals. No washout period will take place between the two arms. Subjects will be randomized to complete one arm first for 3 months, followed immediately by 3 months in the opposite arm.
9822343|NCT02269163|Active Comparator|Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period|Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.
9822344|NCT02269163|Experimental|Prometic IGIV 10% Treatment Period|Subjects will receive Prometic Immune Globulin Intravenous 10%
9822345|NCT02269241|Experimental|LF111 (drospirenone)|single treatment arm receives LF111
10115767|NCT04446273|Experimental|PRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The PRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist).
9822346|NCT02269423|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
9822347|NCT02269423|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
9822348|NCT02269423|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
9822349|NCT02269423|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
9822350|NCT02269475|Experimental|MEDI3250|MEDI3250 Nasal Spray
9822351|NCT02269475|Placebo Comparator|Placebo|Placebo Nasal spray
9822352|NCT02269488|Experimental|MEDI3250|MEDI3250 Nasal spray
9822353|NCT02269631|Experimental|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
9965782|NCT01252992||1:paradoxical reaction negative (RP-)|control group with tuberculosis but without paradoxical reaction
9965783|NCT01252992||1:paradoxical reaction negative (RP+)|group with tuberculosis and paradoxical reaction
9965784|NCT01253031||Group 1|young normal hearing
9965785|NCT01253031||Group 2|older normal hearing
9822354|NCT02269631|Active Comparator|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
9822355|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
9822356|NCT02269709|Experimental|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
9822357|NCT02269787|Experimental|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
9822358|NCT02269787|No Intervention|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
9822359|NCT02269943|Experimental|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
9822360|NCT02270060|Experimental|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
9822361|NCT02270060|Active Comparator|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
9822362|NCT02270060|No Intervention|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
9822363|NCT02270242|Active Comparator|Aspirin + Ticagrelor|enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
9822364|NCT02270242|Placebo Comparator|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months
9822365|NCT02270255|Sham Comparator|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
9822366|NCT02270255|Experimental|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
9822367|NCT02270515|Experimental|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
9822368|NCT02270645|Experimental|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
9822369|NCT02270645|No Intervention|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
9822370|NCT02270671|Placebo Comparator|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
9822371|NCT02270671|Experimental|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
9822372|NCT02270736|Experimental|Double-blind MP: Placebo (Age 6 to 17 Years)|Participants will receive placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.
9822373|NCT02270736|Experimental|Double-blind, MP: NT 201 (Age 6 to 17 Years)|Participants will receive NT 201 (up to 2.5 Units per kilogram [U/kg] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
9827661|NCT02463487|Active Comparator|Cardinal Pro + Irrigation (NPWTi)|Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation
10115768|NCT04446273|Active Comparator|DRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The DRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).
9822374|NCT02270736|Experimental|Open-label, MP: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
9822375|NCT02270736|Experimental|OLEX: NT 201 (Age 6 to 17 Years)|"Participants will receive NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm will consist of participants who will participate in MP arms Double-blind, MP: placebo (age 6 to 17 years) and Double-blind, MP: NT 201 (age 6 to 17 years)."
9822376|NCT02270736|Experimental|OLEX: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).
9822377|NCT02270944|Experimental|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
9822378|NCT02270944|Active Comparator|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
9822379|NCT02270983|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
9822380|NCT02270983|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
9822381|NCT02270983|Experimental|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
9822382|NCT02271217|Placebo Comparator|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
9822383|NCT02271217|Active Comparator|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
9822384|NCT02271217|Active Comparator|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
9822385|NCT02271386|Experimental|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
9822386|NCT02271386|Other|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
10115769|NCT04446078|Experimental|PEEK - All-on-4|Patients rehabilitated with a PEEK-acrylic resin prosthesis supported by immediate function dental implants inserted through the All-on-4 concept
10115770|NCT04446013|Experimental|Group General Anesthesia|C-Section under general anesthesia
9822387|NCT02271425|Experimental|Evacetrapib Tablet + Evacetrapib Intravenous|A single oral dose of 130 milligrams (mg) evacetrapib tablet + a single intravenous (IV) dose of 175 micrograms (μg)[¹³C₈] evacetrapib administered over a 4 hour infusion.
9965786|NCT01253031||Group 3|older hearing impaired
9822388|NCT02271451|Experimental|Q collar|subjects wearing the q collar
9822389|NCT02271451|No Intervention|Control|subjects not wearing the Q collar
9822390|NCT02271477|No Intervention|Wild-Type|The setting is standard spinal anesthesia and corresponds to our first arm of the study, used as the control sample and statistical reference. During the induction phase, the patient is fitted with non-invasive blood pressure monitoring, three-lead ECG, pulse-oximetry and peripheral intravenous device. Data and vital signs are recorded and an infusion of crystalloid (NaCl 0.9% or Ringer's acetate) is given during the procedure until the beginning of the operation. Total amount of fluid is also recorded before and after the spinal anesthesia.
9827662|NCT02463487|Active Comparator|Cardinal Pro (NPWT) Therapy|Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation
10115771|NCT04446013|Experimental|Grup Spinal Anesthesia|C-Section under spinal anesthesia
10115772|NCT04445948|Active Comparator|Triple Therapy|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days.
10115773|NCT04445948|Active Comparator|Sequential Therapy|Received the sequential therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 g tablets twice daily for 5 days, then esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus metronidazole 500 milligrams tablets twice daily plus clarithromycin 500 milligrams tablets twice daily after meal for another 10 days.
10115774|NCT04445948|Active Comparator|Triple Therapy plus Lactoferrin|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days. in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner for 14 days.
10182564|NCT03772613|Active Comparator|High ACT Target|ACT target range of 325 to 375 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
9827663|NCT02463799|Experimental|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
9965787|NCT01253057||Experimental Group|
9965788|NCT01253057||Control Group|
10115775|NCT04445948|Active Comparator|Sequential Therapy plus Lactoferrin|Received the sequential therapy in the form of esomeprazole 40 milligrams once daily 30 minutes before breakfast plus amoxicillin 1 gram twice daily for 5 days, then esomeprazole 40 mg once daily 30 minutes before breakfast plus metronidazole 500 milligrams twice daily plus clarithromycin 500 milligrams twice daily after meal for another 10 days in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner throughout the 15 days.
9822391|NCT02271477|Experimental|Echocardiography|In addition to the current clinical standard, a Trans-Thoracic Echocardiography is performed before spinal anesthesia, with the aim of assessing the patient's volume status; the exam is performed to assess size and collapsing of the Inferior Vena Cava during breathing cycle. According to different pre-established parameters13, the patient is defined as fluid-responsive or unresponsive. If the patient is not responsive, investigators proceed to spinal anesthesia; otherwise they proceed to administration of crystalloid bolus (500 ml of NaCl 0.9% or Hartmann's solution). The patient may receive another bolus so as to reach a non-responsive pattern for echocardiographic evaluation.
9822392|NCT02271529|Experimental|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
9822393|NCT02271698|Active Comparator|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
9822394|NCT02271698|Active Comparator|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
9822395|NCT02271698|Active Comparator|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
10115776|NCT04446039||1. Escitalopram Cohort|
9822396|NCT02271698|Placebo Comparator|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
9822397|NCT02271854|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
9822398|NCT02271854|Placebo Comparator|Placebo|Placebo gel applied four times daily
9822399|NCT02271880|Active Comparator|Medication as usual|Medication as typically prescribed by physician.
9822400|NCT02271880|Active Comparator|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
9822401|NCT02271906|Experimental|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
9822402|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
9822403|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
9822404|NCT02271984|Experimental|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
9822405|NCT02271984|Experimental|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
9822406|NCT02271984|Experimental|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
9822407|NCT02271984|Experimental|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
9822408|NCT02271984|Experimental|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
9822409|NCT02272244|Active Comparator|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
9822410|NCT02272244|Experimental|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
9822411|NCT02272413|Experimental|BI 695502|
9822412|NCT02272413|Active Comparator|Avastin|
9822413|NCT02272634|Experimental|Treatment A|Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
9822414|NCT02272634|Experimental|Treatment B|Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
9822415|NCT02272634|Placebo Comparator|Treatment C|Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days.
10115777|NCT04446039||2. Paroxetine Cohort|
10115778|NCT04446039||3. Fluoxetine Cohort|
10115779|NCT04446039||4. Mirtazapine Cohort|
10115780|NCT04446039||5. Duloxetine Cohort|
10115781|NCT04446039||6. Sertraline Cohort|
10115782|NCT04446039||7. Venlafaxine Cohort|
9822416|NCT02272686|Experimental|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
9822417|NCT02272725|Placebo Comparator|Placebo|tasteless and inert tablets
9822418|NCT02272725|Active Comparator|Ibuprofen|Each tablet containing 400mg of ibuprofen
10115783|NCT04446039||8. Tianeptine Cohort|
9822419|NCT02272777|Active Comparator|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.
10115784|NCT04446039||9. Vortioxetine Cohort|
10115785|NCT04446039||10. Desvenlafaxine Cohort|
10115786|NCT04446039||11. Bupropion Cohort|
10115787|NCT04446091|Experimental|Two-drug group|Camrelizumab:200mg,iv,Q2W; Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
10115788|NCT04446091|Experimental|Three-drug group|Camrelizumab:200mg,iv,Q3W; Irinotecan:150mg/m2,iv 30~90min,d1,Q3W Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
10115789|NCT04446052|Placebo Comparator|Placebo|
10115790|NCT04446052|Active Comparator|GM-CSF priming|
10115791|NCT04446104|Experimental|Hydroxychloroquine|Participants will receive hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
10115792|NCT04446104|Experimental|Ivermectin|Participants will receive ivermectin tablet 12mg single dose
10115793|NCT04446104|Experimental|Zinc/ Vitamin C|Participants will receive zinc tablet 80 mg/vitamin C 500mg daily for 42 days
9822420|NCT02272777|Experimental|Nilotinib|Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.
9822421|NCT02272816|Experimental|Carboplatin AUC-10|
9822422|NCT02272842|Experimental|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
9822423|NCT02272842|Placebo Comparator|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
9822424|NCT02272985|Other|CBF change during hemodialysis|[15O]H2O PET-CT scan and NIRS (Invos)
9822425|NCT02273037|Placebo Comparator|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
9965789|NCT01253096|Experimental|L19IL2|
10115794|NCT04446104|Experimental|Povidone-iodine throat spray|Participants will receive povidone-iodine throat spray (3 times daily) for 42 days
10115795|NCT04446104|Active Comparator|Vitamin C|Participants will receive vitamin C tablet 500mg daily for 42 days
10115796|NCT04445909||VA-ECMO patients|VA-ECMO support because of low cardiac output.
10115797|NCT04445935|Active Comparator|Standard treatment|"In this arm the patients will be treated according to our standard anticoagulation protocol.~The patients will not be treated with Bivalirudin (the investigational drug)."
10115798|NCT04445935|Experimental|Bivalirudin arm|The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.
10115799|NCT04446130|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed T-ALL/LBL and T/M-MPAL patients.
10115800|NCT04445883|Experimental|Study Group A|Study group A will include patients from the medical unit on 6S100 in addition to the Rehab units on 6N400/500. Participants in Study Group A will be receiving mealtime assistance from volunteers via the Eating Matters Program.
10115801|NCT04445883|No Intervention|Control Group B|Control Group B will include participants from the Rehab Unit on 4N400 and the Medical unit on 6S200.
10115802|NCT04445857|Active Comparator|Group 1|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 100 IU salmon calcitonin(1ml) intrathecally and injection of 10 ml normal saline (NS) slowly intravenously (IV) over 5 min.
10115803|NCT04445857|Active Comparator|Group 2|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 100 IU salmon calcitonin (1ml) diluted in 9 ml NS slowly IV over 5 min.
10115804|NCT04445857|Placebo Comparator|Group 3 (control group)|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 10 ml NS slowly IV over 5 min.
10115805|NCT04445727|Experimental|vitamin c|daily dose of 1000 mg vitamin c in order to regenerate collagen
10115806|NCT04445727|Experimental|spinal manipulation|Spinal manipulation in cervical and dorsal with high speed and short amplitude techniques
10115807|NCT04445727|Experimental|Transcutaneous electrical nerve stimulation (TENS)|electrotherapy for an analgesic purpose
10115808|NCT04445727|Experimental|manual therapy|manual muscle treatment for epicondyl musculature
10115809|NCT04445779|Experimental|CoQ10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in the form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before the surgical procedure.
10115810|NCT04445779|Placebo Comparator|Placebo|Patients will receive per-orally placebo in three divided doses.
10115811|NCT04445831|Placebo Comparator|Placebo|Placebo administered at predefined time points over a 48-week period.
10115812|NCT04445831|Experimental|ACI-35.030 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
10115813|NCT04445831|Experimental|ACI-35.030 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
10115814|NCT04445831|Experimental|ACI-35.030 - High dose|Active vaccine administered at predefined time points over a 48-week period.
10115815|NCT04445831|Experimental|JACI-35.054 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
10115816|NCT04445831|Experimental|JACI-35.054 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
10182565|NCT03772990|Experimental|Calcium chloride|Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass
9822426|NCT02273037|Experimental|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
9822427|NCT02273050|Experimental|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
9822428|NCT02273050|Active Comparator|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
9822429|NCT02273050|Active Comparator|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
9822430|NCT02273063|Experimental|Transcranial Magnetic Stimulation|Stimulation at pulse frequency of 5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000/session. Sessions delivered once/day on weekdays for up to 40 sessions.
9822431|NCT02273115|Active Comparator|Nulliparous - Foley only|Nulliparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
9822432|NCT02273115|Active Comparator|Nulliparous - Foley and oxytocin|Nulliparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
9822433|NCT02273115|Active Comparator|Multi(primi)parous - Foley only|Multiparous and primiparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
9822434|NCT02273115|Active Comparator|Multi(primi)parous - Foley and oxytocin|Multiparous and primiparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
9822435|NCT02273141|Experimental|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
9822436|NCT02273141|Active Comparator|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
9822437|NCT02273167|Experimental|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
10182566|NCT03772990|Placebo Comparator|0,9% Sodium Chloride|Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass
10182567|NCT03773003|Active Comparator|Arm 1: Tumor disease w/o fatigue|Group receiving probiotics.
10182568|NCT03773003|Placebo Comparator|Arm 2: Tumor disease w/o fatigue|Group receiving placebo (corn starch)
9822438|NCT02273167|Experimental|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
9822439|NCT02273167|Active Comparator|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
9822440|NCT02273180|Experimental|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
9822441|NCT02273180|Active Comparator|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
9822442|NCT02273206|Active Comparator|Prevention Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
9822443|NCT02273206|Experimental|Prevention Care Management for Depression and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
9822444|NCT02273310|Experimental|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
9822445|NCT02273310|No Intervention|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
9822446|NCT02273323|Experimental|Tea|Black tea
9822447|NCT02273323|Placebo Comparator|Placebo|Placebo
9827664|NCT02463799|Active Comparator|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
9965790|NCT01253109||SENSIMED Triggerfish|
9965791|NCT01253122|Experimental|TRx0037|
9822448|NCT02273596|Experimental|ALXN1840|"Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period."
9822449|NCT02273726|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).
9822450|NCT02273726|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert [USPI] or Summary of Product Characteristics [SmPC]) or local SOC.
9822451|NCT02273739|Experimental|Enasidenib|During the dose escalation phase, consented eligible participants will be enrolled into sequential cohorts of increasing doses of enasidenib.The starting dose for this study is 100 mg administered every 24 hours,
9822452|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
9822453|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
9822454|NCT02273960|Experimental|Arm A: BMS-986004|BMS-986004 solution intravenously (IV) as specified
9822455|NCT02273960|Experimental|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
9822456|NCT02273960|Experimental|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
9822457|NCT02273960|Experimental|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
9822458|NCT02273973|Placebo Comparator|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
9822459|NCT02273973|Experimental|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
9827054|NCT02443519|Experimental|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
9827055|NCT02443519|No Intervention|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
9827056|NCT02443688|Experimental|50 mg CTX-4430|Once daily oral capsule for 48 weeks
9827057|NCT02443688|Experimental|100 mg CTX-4430|Once daily oral capsule for 48 weeks
9827058|NCT02443688|Placebo Comparator|Matching Placebo|Once daily oral capsule for 48 weeks
9827059|NCT02443740|Experimental|Single Ascending Dose-1 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
9827060|NCT02443740|Experimental|Single Ascending Dose-2 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
9827061|NCT02443740|Experimental|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of BIIB118 administered to healthy volunteers to assess the PK of BIIB118 in CSF
9827062|NCT02443792|Experimental|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
9827063|NCT02443792|Active Comparator|Open Surgical|Open surgical circumcision under local anesthetic with suturing
9827064|NCT02443805|Active Comparator|300 IR|300 IR tablet of HDM Allergen Extracts
9827065|NCT02443805|Placebo Comparator|Placebo|Placebo tablet
9827066|NCT02443883|Experimental|Ramucirumab Regimen 1|Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
9827067|NCT02443883|Experimental|Ramucirumab Regimen 2|Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
9827068|NCT02443883|Experimental|Ramucirumab Regimen 3|Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
9827069|NCT02443883|Experimental|Ramucirumab Regimen 4|Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
9827070|NCT02444143|Active Comparator|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
9827071|NCT02444143|Experimental|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
10182569|NCT03773003|Active Comparator|Arm 3: Healthy control group|Group receiving probiotics
9965792|NCT01253122|Active Comparator|TRx0014|
9965793|NCT01253213|Experimental|BR55|
9822460|NCT02274038|Experimental|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
9822461|NCT02274311|Experimental|Clomiphene citrate|Patients receiving clomiphene citrate
9822462|NCT02274493|Experimental|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
9822463|NCT02274558|Experimental|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
9822464|NCT02274558|Experimental|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
9822465|NCT02274558|Experimental|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
9822466|NCT02274649|Experimental|Intervention|Intervention group receiving one-to-one peer mentoring
9822467|NCT02274649|Active Comparator|Control|Control group receiving general peer support
9822468|NCT02274675|Experimental|Robot group|Receive 0.5 hour of robot-assisted therapy for wrist and forearm and 1.5 hours of daily standard rehabilitation therapy
9822469|NCT02274688|No Intervention|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
9822470|NCT02274688|Experimental|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.~Randomized and will be blindly assessed."
9822471|NCT02274766|Experimental|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
9822472|NCT02274766|Placebo Comparator|Placebo|Placebo
9822473|NCT02274792|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
9822474|NCT02274844|Experimental|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
9822475|NCT02274844|No Intervention|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
9822476|NCT02274857|Active Comparator|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
9822477|NCT02274857|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
9822478|NCT02274870|Experimental|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
9822479|NCT02274870|Active Comparator|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
9822480|NCT02274948|Active Comparator|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
9822481|NCT02274948|Placebo Comparator|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
9822482|NCT02275026|Experimental|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
9822483|NCT02275052|Experimental|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
9822484|NCT02275052|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
9822485|NCT02275065|Experimental|Bictegravir 5 mg|Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
9822486|NCT02275065|Experimental|Bictegravir 25 mg|Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
9822487|NCT02275065|Experimental|Bictegravir 50 mg|Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
10115817|NCT04445675|Experimental|Experimental|The support for breastfeeding and the feeding of infants' with breast milk will be conducted in one stage for the experimental group. (1) breastfeeding support education. The content of the support for breastfeeding and the feeding of infants' with breast milk and the materials used were determined by the researchers in accordance with the literature. The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding. Breastfeeding support will be provided in the postpartum service and lactation outpatient clinic of the relevant hospital.
9822488|NCT02275065|Experimental|Bictegravir 100 mg|Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
10115818|NCT04445675|No Intervention|Control Groups|The infants in the control group will be followed up in routine service. No intervention will be made.
9822489|NCT02275065|Placebo Comparator|Placebo|Placebo matched to bictegravir tablet for 10 days
9822490|NCT02275117|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
9822491|NCT02275117|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
9822492|NCT02275117|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
9822493|NCT02275117|Experimental|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
9822494|NCT02275117|Placebo Comparator|Placebo|Placebo (IV)
9822495|NCT02275156|Experimental|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
9822496|NCT02275338|Experimental|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
9822497|NCT02275364|Experimental|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
9822498|NCT02275364|Placebo Comparator|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
9822499|NCT02275611|Active Comparator|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
9822500|NCT02275611|Placebo Comparator|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
9822501|NCT02275767|Experimental|Combination 50% cortical/50% cancellous FDBA|Ridge preservation with Combination 50% cortical/50% cancellous freeze-dried bone allograft (FDBA)
9822502|NCT02275767|Active Comparator|100% cortical FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
9822503|NCT02275767|Active Comparator|100% cancellous FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
9822504|NCT02275780|Experimental|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
9822505|NCT02275780|Active Comparator|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
9822506|NCT02275819|No Intervention|control|Will not receive intervention with exercise
9822507|NCT02275819|Active Comparator|Intervention group|2 groups will receive 2 different types of therapy (exercise or Inspiratory Muscle Therapy)
9822508|NCT02275923|Experimental|Diagnostic|'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
9822509|NCT02276027|Experimental|BYL719 350 mg QD|Patient's tumor must have molecular alteration of the PIK3CA gene.
9822510|NCT02276027|Experimental|INC280 400 mg BID tab/600 mg BID cap|Patient's tumor must have molecular alteration of the c-MET gene.
9822511|NCT02276027|Experimental|LDK378 750 mg QD|Patient's tumor must have ALK or ROS1 gene rearrangement.
9822512|NCT02276027|Experimental|MEK162 45 mg BID|Patient's tumor must have KRAS, NRAS or BRAF mutation.
9822513|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
10115819|NCT04445467|Experimental|Favipiravir|1800 mg Favipiravir twice daily on Day 1 followed by 800 mg Favipiravir twice daily for the next 13 days.
10115820|NCT04445467|Placebo Comparator|Placebo|Matched Placebo
9822514|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
9822515|NCT02276222|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
9822516|NCT02276222|Active Comparator|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
9822517|NCT02276274|Experimental|Fasted dosing followed by fed dosing|Oral administration
9822518|NCT02276274|Experimental|Fed dosing followed by fasted dosing|Oral administration
9822519|NCT02276482|Experimental|Tedizolid Phosphate|Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
9822520|NCT02276482|Active Comparator|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
9822521|NCT02276612|Experimental|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
9822522|NCT02276638||18-28 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
9822523|NCT02276638||29-80 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
9822524|NCT02276638||29-80 years old pathological|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
10115821|NCT04445571|Active Comparator|INSURE|Surfactant administration by Intubation-surfactant-extubation to CPAP according to standard protocol including premedication with analgesia and sedation.
9822525|NCT02276807|Experimental|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
9822526|NCT02276807|Active Comparator|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
9822527|NCT02276872|Experimental|Cohort 1 (Transitioning from Parental)|Transitioned from IV or SC Remodulin to oral treprostinil
9822528|NCT02276872|Experimental|Cohort 2 (Transitioning from Inhaled)|Transitioned from inhaled prostacyclin to oral treprostinil
9822529|NCT02276872|Experimental|Cohort 3 (Add-on to Current PAH Therapy)|Treated with oral treprostinil as a de novo add-on to current PAH therapy
9822530|NCT02276963|Experimental|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
9822531|NCT02277054|Experimental|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
9822532|NCT02277093|Experimental|Pacritinib|"Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID)~Pacritinib should be take at approximately the same times every day with a glass of water, with or without food"
9822533|NCT02277249|Other|Transvaginal digoxin|Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
9822534|NCT02277249|Other|Transabdominal digoxin|Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
9822535|NCT02277548|Experimental|Lyrica at 300 mg per day|
9822536|NCT02277548|Placebo Comparator|Placebo|
9822537|NCT02277626|Experimental|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
9822538|NCT02277626|Experimental|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
9822539|NCT02277639|Experimental|Bone Marrow Failure Syndrome|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
9822540|NCT02277639|Experimental|Immunodeficiency / Dysregulation|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
9822541|NCT02277665|Active Comparator|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
9822542|NCT02277665|Experimental|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
9822543|NCT02277691|Experimental|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
10115822|NCT04445571|Active Comparator|LISA|Surfactant administration by thin catheter during spontaneous breathing and continued CPAP according to set protocol including premedication with analgesia.
10182570|NCT03773003|Placebo Comparator|Arm 4: Healthy control group|Group receiving placebo (corn starch)
10182571|NCT03772496|Experimental|circulating tumor cells|circulating tumor cells test and FNAB will be performed at the same time
10182572|NCT03772600|Experimental|Dexcom G6|Use a Dexcom G6 CGM for 36 months
9822544|NCT02277743|Experimental|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
9822545|NCT02277743|Experimental|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
9822546|NCT02277743|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
9822547|NCT02277769|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
9822548|NCT02277769|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
9822549|NCT02277769|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
9822550|NCT02277925|Active Comparator|Gore-Tex permanent suture|Participants in this arm will receive Gore-Tex permanent suture
9822551|NCT02277925|Experimental|PDS delayed absorbable suture|Participants in this arm will receive 2-0 PDS delayed absorbable suture
9822552|NCT02277990|Active Comparator|TYRX™ envelope|The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
9822553|NCT02277990|No Intervention|Control|No TYRX™ envelope, bare CIED
9827072|NCT02444182|Experimental|Probiotics|participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
9827073|NCT02444182|Placebo Comparator|Control - No probiotics|Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)
9822554|NCT02278003|Experimental|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.~measure the amnesic effects of propofol."
9822555|NCT02278003|Active Comparator|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
9822556|NCT02278146|Experimental|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
9822557|NCT02278146|Experimental|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
9822558|NCT02278237|Experimental|VME Group|Pre and post VME education group. The Intervention is the use of the virtual education module rather than the interpersonal educational strategy.
9822559|NCT02278263|Placebo Comparator|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
9822560|NCT02278263|Experimental|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
9822561|NCT02278263|Experimental|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
9822562|NCT02278289|Active Comparator|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
9822563|NCT02278289|Active Comparator|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
9822564|NCT02278328|Experimental|A. Placebo then 15mg then 30mg|"Subjects will receive a single dose of placebo on week 1, 15 mg of STX209 on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
9822565|NCT02278328|Experimental|B. 15mg then placebo then 30mg|"Subjects will receive a single dose of 15 mg of STX209 on week 1, placebo on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
9822566|NCT02278328|Experimental|C. 15mg then 30mg then placebo|"Subjects will receive a single dose of 15 mg of STX209 on week 1, 30 mg of STX209 on week 2 and placebo on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
9822567|NCT02278341|Experimental|Roxadustat|Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
9822568|NCT02278341|Active Comparator|ESA (Erythropoiesis Stimulating Agent) treatment|Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.
9822569|NCT02278354|Experimental|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
9822570|NCT02278354|Experimental|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
9822571|NCT02278367|Experimental|Flortaucipir PET Scans|
9822572|NCT02278471|No Intervention|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
9822573|NCT02278471|Experimental|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily."
9822574|NCT02278484|Other|Balloon Sinus Dilation|
9822575|NCT02278562|Active Comparator|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
9965794|NCT01253239||TECNIS/ReZoom|Patients who received a TECNIS multifocal IOL in one eye and a ReZoom multifocal IOL in the opposite eye.
9822576|NCT02278562|Active Comparator|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
9827074|NCT02444234|Experimental|Tedizolid PO|Tedizolid phophate 200mg tablet
10182573|NCT03772600|No Intervention|FreeStyle Libre|"Keep using their FreeStyle Libre for 6 months. Before the 6 month time point is reached, patients will wear a blinded Dexcom G6 for 28 days, together with their FreeStyle Libre.~Cross-over to Dexcom G6 for 30 months."
9965795|NCT01253239||TECNIS/TECNIS|Patients who received TECNIS multifocal IOLs in both eyes
9965796|NCT01253252|Experimental|Specific procedure|"A [18F] Fluorodeoxyglucose PET Scan Imaging will be added to their conventional follow up (CT scan, usual blood sampling, ECG…) i.e. within one month before endovascular surgery (inclusion visit), at one month and 6 month of follow-up.~Furthermore, blood sampling for biological investigations (biological markers of the inflammation, proteolysis and coagulation potentially related to morphology and evolution of AAA) will be done."
9965797|NCT01253278|Experimental|20 mg LY2393910|
9822577|NCT02278562|Placebo Comparator|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
9822578|NCT02278614|Experimental|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
9822579|NCT02278614|Active Comparator|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
9822580|NCT02278640|Other|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
9822581|NCT02278783|Experimental|Regorafenib Treatment arm, all patients|
9822582|NCT02278939|Experimental|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
9822583|NCT02278939|Active Comparator|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
9822584|NCT02279043|Experimental|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of Interaction with users of IUC and non-IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
9822585|NCT02279043|Placebo Comparator|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will have interaction with non-IUC users only. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
9822586|NCT02279043|No Intervention|IUC users|IUC users will be recruited to populate intervention groups. Interaction with IUC users will be the intervention for non-IUC users randomized to the intervention arm. IUC users will receive no intervention.
9822587|NCT02279082|Experimental|DFN-02|DFN-02 to be taken during migraine attack
9965798|NCT01253278|Experimental|60 mg LY2393910|
9965799|NCT01253278|Experimental|150 mg LY2393910|
10115823|NCT04445818|Experimental|More Appreciation|"A 6-minute engaging video will be shown, illustrating examples where a mother initially withholds her appreciation for her son's effort in school and later express it. The video will also capture the effect on the child and the family. Attributional discussion questions will follow to elicit positive outcomes of expressing appreciation and the negative outcomes of withholding appreciation (e.g., What may be the long-term effects of showing appreciation on your child, family, or on yourself?). Key points will be summarised and reinforced to enhance behavioural intention (Schwarzer & Luszczynska, 2008). Then the participants will be asked to plan by indicating when (e.g., Saturday afternoon), what (e.g., child helping a younger sibling prepare for a dictation test), and how (e.g., I can see that you gave up your leisure time to help your sister with the spelling. Thank you!) they would express appreciation to their children."
10115824|NCT04445818|Experimental|Less Criticism|"Participants will watch a 6-minute video showing examples of a father criticising his son, which will be replaced by positive communication later, and the different reactions evoked in the child and the family. Then, participants will have an attributional discussion on the negative effects of criticism (e.g., negative effect on self-worth and motivation) and positive outcomes of using constructive feedback (e.g., promptly identifying undesirable behaviours without relating to personal traits or abilities). In small groups, they will work out alternatives (i.e., constructive feedback; termed positive reminder in the intervention) to criticism, and each plan and write down when (e.g., after school), what (e.g., low test marks), and how (e.g., How do you prepare for the tests?)"
10115825|NCT04445818|Experimental|Fruit and Vegetable|This workshop will emphasise the importance of consuming at least 5 portions of fruit and vegetable daily for a healthy diet, and aim to boost participants' self-efficacy in achieving this. Participants will be presented with examples of one portion of fruit or vegetable, and then create their own recipes. They will also consider how to overcome obstacles of consuming more portions. Each participant will set goals and write down plans on when, where, what, and how they would increase their fruit and vegetable intake of their children and family as a whole.
10115826|NCT04445597|Other|COVID-19 positive or negative patients|Hospitalised patients with or without COVID-19 (with or without olfactory dysfunctions)
10115827|NCT04445649||ICU patients|Patients with impaired consciousness admitted to intensive care unit after severe brain injury
10182574|NCT03772535|No Intervention|Control Group|Subjects in this arm will receive the standard postoperative pain prescription protocol.
9822588|NCT02279108|Experimental|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
9822589|NCT02279108|Active Comparator|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
9822590|NCT02279160|Experimental|APD811|Multiple dose titration to maximum tolerated dose.
9965800|NCT01253278|Experimental|450 mg LY2393910|
9822591|NCT02279160|Placebo Comparator|Placebo|Multiple dose titration to maximum tolerated dose.
9822592|NCT02279173|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.
9965801|NCT01253278|Placebo Comparator|Placebo|
9822593|NCT02279407|Placebo Comparator|placebo|
9822594|NCT02279407|Experimental|Omega-3 carboxylic acids 4g / day|
9822595|NCT02279407|Experimental|Dapagliflozin, 10mg / day|
9822596|NCT02279407|Experimental|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
9822597|NCT02279420|Other|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
9822598|NCT02279498|Experimental|Liprotamase|Individually-optimized dose to be administered orally
9822599|NCT02279498|Active Comparator|porcine (pig) PERT|Individually-optimized dose to be administered orally
9822600|NCT02279524|Experimental|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
9822601|NCT02279524|Experimental|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
9822602|NCT02279524|Placebo Comparator|Placebo|Two tablet of Aramchol matching placebo.
9822603|NCT02279641|Experimental|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
9822604|NCT02279641|Experimental|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
9965802|NCT01253330|No Intervention|Comparison 1st|Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
9822605|NCT02279667|Experimental|Group A|"st period - 16 mL oral suspension 50 mg/mL~nd period - Four 200 mg tablets~rd period - One 800 mg tablet"
9822606|NCT02279667|Experimental|Group B|"st period - One 800 mg tablet~nd period - 16 mL oral suspension 50 mg/mL~rd period - Four 200 mg tablets"
9822607|NCT02279667|Experimental|Group C|"st period - Four 200 mg tablets~nd period - One 800 mg tablet~rd period - 16 mL oral suspension 50 mg/mL"
9822608|NCT02279732|Experimental|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
9822609|NCT02279732|Experimental|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
9822610|NCT02279862|Experimental|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
9822611|NCT02279862|Experimental|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
9822612|NCT02280044|Experimental|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
9822613|NCT02280044|Placebo Comparator|placebo|Subjects receiving placebo will be challenged with C. jejuni
9822614|NCT02280096|Active Comparator|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
9822615|NCT02280096|Placebo Comparator|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
9822616|NCT02280122||gen. mod. to sev. chronic periodontitis|"Sites with probing pocket depths (PPD) ≥ 3.5 mm~Attachment loss (PAL-V) ≥ 3 mm > 30% of sites~no Intervention provided"
9822617|NCT02280122||periodontally healthy|"PPD ≤ 3 mm~PAL-V ≤ 2 mm at < 30% of sites~BOP < 20%~No radiographically detectable bone loss: distance cemento-enamel junction to provided~no Intervention but aMMP-8 test"
9822618|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
9822619|NCT02280200|Experimental|AFO to improve outcomes|Patients completed graded treadmill testing, followed by 12 weeks of unstructured community-based walking using the AFO ad libitum
9822620|NCT02280200|No Intervention|Historical Controls|Historical PAD control group (n = 10) received upfront advice to walk at home with no intervention
9822621|NCT02280226|Experimental|Deliberate Apnea Group|Subjects undergo maximum apnea.
9822622|NCT02280291|Active Comparator|Ankle Single Shot Block (SSB)|
9822623|NCT02280291|Experimental|Ankle OnQ (Continuos Sedation OnQ Pump)|
9822624|NCT02280291|Experimental|DR SSB|
9822625|NCT02280291|Experimental|DR OnQ|
9822626|NCT02280304|Experimental|Inner Resources for Veterans (IRV) mindfulness and mantra|Complete a mindfulness and mantra therapy
9822627|NCT02280304|Active Comparator|Essential Skills therapy|Learn symptoms of mTBI and PTSD, coping skills
9822628|NCT02280317|Experimental|Cohort 1: 0.5 mg/kg|VAL201-001 Sub-cutaneous injection. 0.5 mg/kg
9822629|NCT02280317|Experimental|Cohort 2: 1 mg/kg|VAL201-001 Sub-cutaneous injection. 1.0 mg/kg
9822630|NCT02280317|Experimental|Cohort 3: 2 mg/kg|VAL201-001 Sub-cutaneous injection. 2.0 mg/kg
9822631|NCT02280317|Experimental|Cohort 4: 4 mg/kg|VAL201-001 Sub-cutaneous injection. 4.0 mg/kg
9827075|NCT02444234|Experimental|Tedizolid IV|Tedizolid phophate 200mg IV
9822632|NCT02280317|Experimental|Cohort 5: up to 8 mg/kg|VAL201-001 Sub-cutaneous injection. 8.0 mg/kg; potential to escalate to 16 mg/kg after 3 cycles according to clinician decision Flexibility of dosing enabled under protocol.
9822633|NCT02280408|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0 and Day 28.
9822634|NCT02280408|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0 and Day 28.
9822635|NCT02280408|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0 and Day 28.
9822636|NCT02280408|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
9822637|NCT02280421|Other|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
9822638|NCT02280421|Other|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
9822639|NCT02280473|Experimental|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
9822640|NCT02280473|Active Comparator|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
9822641|NCT02280655|Active Comparator|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
9822642|NCT02280655|Active Comparator|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
9822643|NCT02280811|Experimental|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
9822644|NCT02280863|Experimental|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
9822645|NCT02280863|Experimental|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
9822646|NCT02281136|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
9822647|NCT02281318|Experimental|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
9822648|NCT02281318|Placebo Comparator|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
9822649|NCT02281344|Experimental|Cohort 1|Cohort 1 will receive a single dose of 20mg MMV390048.
9822650|NCT02281357|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
9822651|NCT02281357|Placebo Comparator|Placebo|Placebo subcutaneous injection
9822652|NCT02281409|Experimental|Phase I: Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin.
9822653|NCT02281409|Experimental|Phase II: Mogamulizumab (KW-0761)|Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
9822654|NCT02281422|Other|Group 1 normal renal function|normal renal function (creatinine clearance > 80 mL/min)
9822655|NCT02281422|Other|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
9822656|NCT02281422|Other|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
9822657|NCT02281422|Other|Group 4 severe renal impairment|severe renal impairment (creatinine clearance <30 mL/min)
10115828|NCT04445636|Experimental|Dexmedetomidine group|A group which will receive dexamedetomidine as an adjunct to bupivacaine used in caudal anesthesia.
9822658|NCT02281422|Other|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
9827076|NCT02444533|Active Comparator|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
9827077|NCT02444533|No Intervention|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
9827078|NCT02444663|Active Comparator|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
9827079|NCT02444663|Active Comparator|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
9827080|NCT02444663|Experimental|Device Valgus - 0 Newton force|Device performed fluoroscopic valgus stress X-rays - 0 Newton force
9827081|NCT02444663|Experimental|Device Valgus - 10 Newton force|Device performed fluoroscopic valgus stress X-rays - 10 Newton force
9827082|NCT02444663|Experimental|Device Valgus - 20 Newton force|Device performed fluoroscopic valgus stress X-rays - 20 Newton force
9827083|NCT02444663|Experimental|Device Valgus - 30 Newton force|Device performed fluoroscopic valgus stress X-rays - 30 Newton force
9827084|NCT02444663|Experimental|Device Varus - 0 Newton force|Device performed fluoroscopic varus stress X-rays - 0 Newton force
9827085|NCT02444663|Experimental|Device Varus - 10 Newton force|Device performed fluoroscopic varus stress X-rays - 10 Newton force
9827086|NCT02444663|Experimental|Device Varus - 20 Newton force|Device performed fluoroscopic varus stress X-rays - 20 Newton force
9827087|NCT02444663|Experimental|Device Varus - 30 Newton force|Device performed fluoroscopic varus stress X-rays - 30 Newton force
9827088|NCT02444715|Active Comparator|Standard care (SC)|
9827089|NCT02444715|Experimental|Interventional care (IC)|
10115829|NCT04445636|Experimental|Morphine group|A group which will receive morphine as an adjunct to bupivacaine used in caudal anesthesia.
9822659|NCT02281448|Other|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
9822660|NCT02281448|Other|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
9822661|NCT02281526|Other|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
9822662|NCT02281526|Other|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
9822663|NCT02281552|Experimental|tofacitinib modified release tablet|
9822664|NCT02281552|Active Comparator|tofacitinib immediate release tablet|
9822665|NCT02281591|Experimental|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
9822666|NCT02281591|Active Comparator|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
10115830|NCT04445740|Experimental|Intervention|Participants will receive an intervention and will participate in assessments
10115831|NCT04445740|No Intervention|Control|Participants will not receive an intervention, but will participate in assessments
10182575|NCT03772535|Active Comparator|Pharmacogenomics Guided Group|Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.
10182576|NCT03772418|Placebo Comparator|Cream base|A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.
10182577|NCT03772418|Active Comparator|Pomegrante and Ginkgo biloba group|A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.
10182578|NCT03772548||Patients with spinal cord injury|
10182579|NCT03772548||Healthy subjects|
10182580|NCT03772275|Active Comparator|New york Heart Association Class II-IV|New york Heart Association Class II-IV heart failure
10182581|NCT03772275|Active Comparator|New york Heart Association Class I|New york Heart Association Class I with no heart failure
9528158|NCT03213249|Active Comparator|Arm 1: Intraoperative pocket irrigation with NS|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
9822667|NCT02281591|Active Comparator|S-licarbazepine|450 mg of S-licarbazepine
9822668|NCT02281591|Active Comparator|R-licarbazepine|450 mg of Rlicarbazepine
9822669|NCT02281760|Experimental|Combination therapy with dabrafenib and trametinib in patients with ECD|Patients with Erdheim Chester Disease (ECD) and BRAFV600E mutation received combination therapy with dabrafenib, a BRAFV600E inhibitor 150mg orally every twelve hours, and trametinib, an inhibitor of MEK, downstream of BRAF, 2mg orally daily.
9822670|NCT02281773|Experimental|dose 1|
9822671|NCT02281773|Experimental|dose 2|
10182582|NCT03772574|Experimental|THRIVE|THRIVE preoxygenation (tidal volume breathing with the OptiFlow system applied at 100% oxygen).
10182583|NCT03772574|Active Comparator|Facemask|Facemask preoxygenation (tidal volume breathing via a face mask set at 100% oxygen).
10182584|NCT03772483|Active Comparator|Control group|Local anesthesia with conventional syringe
10182585|NCT03772483|Active Comparator|Virtual reality group|Local anesthesia with conventional syringe + VR device
10182586|NCT03772366||Warfarine|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Warfarine
10182587|NCT03772366||Fluindione|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Fluindione
10182588|NCT03772366||Rivaroxaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Rivaroxaban
9822672|NCT02281773|Experimental|dose 3|
9822673|NCT02281773|Experimental|dose 4|
9822674|NCT02281773|Placebo Comparator|placebo|
9822675|NCT02281851||Supplemented|The group consists of well-trained cyclists who habitually consume vitamin/antioxidant supplements for a period longer than 6 months
9822676|NCT02281851||Non-supplemented|The group consists of well-trained cyclists who do not consume vitamin/antioxidant supplements
9822677|NCT02282111|Active Comparator|EUS-CNB|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that the procedure terminated.
9822678|NCT02282111|Active Comparator|SINK|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
9822679|NCT02282163|Experimental|Lumason|All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.
9822680|NCT02282293|Active Comparator|Daily TS + Monthly DP pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
9822681|NCT02282293|Placebo Comparator|Daily TS + DP Placebo pregnancy|Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
9827090|NCT02444793|Experimental|PF-05082566 + KW-0761|During Parts 1 & 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
9822682|NCT02282514|Experimental|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
9822683|NCT02282527|Other|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
9822684|NCT02282527|Other|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
10182589|NCT03772366||Apixaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Apixaban
9822685|NCT02282605|Experimental|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
9822686|NCT02282605|Experimental|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
9822687|NCT02282605|Placebo Comparator|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
9822688|NCT02282631|Experimental|Intervention group school|School where the incentive scheme will be run.
9822689|NCT02282631|No Intervention|Control group school|School with no intervention; ongoing advice on active school travel.
9822690|NCT02282722|Active Comparator|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
9822691|NCT02282722|Experimental|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
9822692|NCT02282813|Experimental|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
9822693|NCT02282813|Experimental|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
9822694|NCT02282813|Experimental|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
9822695|NCT02282813|Experimental|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
9822696|NCT02282904|Experimental|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
9822697|NCT02282930|Experimental|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
9822698|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
9822699|NCT02283268|Experimental|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
9822700|NCT02283294|Experimental|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
9822701|NCT02283294|Active Comparator|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
9822702|NCT02283333|Experimental|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
9822703|NCT02283333|Active Comparator|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
9822704|NCT02283411|Other|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
9822705|NCT02283528|Experimental|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
9822706|NCT02283528|Active Comparator|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
9822707|NCT02283658|Experimental|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9822708|NCT02283749|Experimental|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
9822709|NCT02283762|Experimental|Riociguat|Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
9822710|NCT02283762|Placebo Comparator|Placebo|Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
9822711|NCT02283788|Experimental|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
9822712|NCT02283788|Experimental|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
9827091|NCT02444936|Active Comparator|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
10182590|NCT03772366||Control|Women in childbearing age with superficial venous insufficiency without treatment oral anticoagulant or antiplatelet.
9822713|NCT02283788|Experimental|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
9822714|NCT02283788|Experimental|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
9822715|NCT02283814|Experimental|Group A BIA 2-093 + Topamax|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days~Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
9822716|NCT02283814|Experimental|Group B BIA 2-093 + Topamax|"Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;~Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;~Treatment: 200 mg once daily dose of TPM administered for four consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
9822717|NCT02283827|Experimental|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
9822718|NCT02283827|Experimental|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
9822719|NCT02283840|Experimental|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
9822720|NCT02283840|Experimental|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
9822721|NCT02283840|Experimental|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
9822722|NCT02283840|Experimental|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
9822723|NCT02283840|Experimental|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
9822724|NCT02283840|Experimental|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
9822725|NCT02284009|Experimental|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
9822726|NCT02284009|Experimental|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
9822727|NCT02284126|Experimental|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
9822728|NCT02284126|No Intervention|Standard of Care|Control group, receive standard of care only
9822729|NCT02284178|Experimental|Enhanced oral suction|Deep oropharyngeal suction with catheter
9822730|NCT02284178|Sham Comparator|Usual Care Oral Suction|Oropharyngeal suction with suction swab
9822731|NCT02284243|Experimental|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
9822732|NCT02284243|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours.
9965803|NCT01253330|Experimental|Participant 1st|Enrollment in the CMSText website text messaging system during first 3 months of study participation.
10115832|NCT04445753|Experimental|Tai Chi program|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
10115833|NCT04445753|Other|Control group|Individuals in the control group will be trained on heart failure. The only attempt to be made to the control group will be education.
10115834|NCT04445480|Experimental|Popliteal block group|
10115835|NCT04445480|Active Comparator|Control group|
9822733|NCT02284347|Experimental|NuVent™|Revision patients treated with NuVent™
9822734|NCT02284386|Experimental|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
9822735|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
9965804|NCT01253356|No Intervention|No IABP|Standard of care and no IABP
10115836|NCT04445506||SARS-CoV2 patients that received dexamethasone|
9822736|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
9822737|NCT02284464|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
9827092|NCT02444936|No Intervention|Control|There is no drug given in this arm.
9822738|NCT02284464|Experimental|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
9822739|NCT02284516|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
9822740|NCT02284516|Placebo Comparator|Placebo|Placebo to match active treatment, BID for 84 days
9822741|NCT02284555|Experimental|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
9528159|NCT03213249|Active Comparator|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
9822742|NCT02284828|Experimental|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
9822743|NCT02284854|Experimental|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
9822744|NCT02284854|Experimental|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
9822745|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
9822746|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
9822747|NCT02284880|Experimental|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
9822748|NCT02284880|Experimental|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
9822749|NCT02284893|Experimental|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
9822750|NCT02284893|Experimental|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
10115837|NCT04445623|Active Comparator|prasugrel hydrochloride|film-coated tablets of prasugrel hydrochloride (10 mg daily dose after loading dose of 60 mg)
10115838|NCT04445623|Placebo Comparator|placebo|film-coated tablets of placebo (10 mg daily dose after loading dose of 60 mg)
10115839|NCT04445402||Heme/Non-Sickle Cell Disease|Subjects with a diagnosis of hemoglobinapathy except Sickle Cell Disease
10115840|NCT04445402||Heme/Sickle Cell Disease|Subjects with a diagnosis of Sickle Cell Disease
10115841|NCT04445402||Neuro-Oncological Disease|Oncology diagnosis with involvement of the neurological system
10115842|NCT04445402||Oncology/Non-Neuro-Oncological|Subjects with any oncology diagnosis except those that involve the neurological system.
9822751|NCT02285010|Placebo Comparator|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
9822752|NCT02285010|Active Comparator|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
9822753|NCT02285023||CU-Q2oL|"Evaluation by the Urticaria Activity Score (UAS7)~Fill the DLQI and CU-Q2oL questionnaire"
9822754|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to < 18 years of age and ≥ 35 kg in body weight will switch their current 2-NRTI containing regimen to F/TAF (200/25 mg for unboosted 3rd agent and 200/10 mg for boosted 3rd agent) while continuing on their 3rd ARV agent for 48 weeks.
9822755|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to < 12 years of age and ≥ 25 kg in body weight must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF 200/25 mg while continuing on their boosted PI for 48 weeks.
9822756|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to < 12 years of age and between 17 kg to < 25 kg in body weight must be on a boosted protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF 120/15 mg while continuing their 3rd ARV agent for 48 weeks.
9822757|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
9822758|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
9822759|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
10115843|NCT04445402||Transplant patients|Subjects who have received or are intending to have a stem cell transplant for treatment of disease.
10115844|NCT04445532||hepatobiliary tumor patients|benign or malignant hepatobiliary tumors patients
10115845|NCT04445532||Benign Hepatobiliary Disease|chronic hepatitis, cirrhosis, and healthy control
10115846|NCT04445376|Experimental|Intervention Group (Ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
10115847|NCT04445376|Experimental|Intervention (Non ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
9822760|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
10115848|NCT04445298||Pregnant women with expected delivery in the fall or winter|We will enroll up to 40 women who are expected to deliver in the fall (September, October, November) and winter (December, January, February). We will then follow their infant offspring.
9822761|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
9822762|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
9822763|NCT02285114|Experimental|FTC/TAF +3rd ARV agent (Extension Phase)|After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) the participant turns 18 and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or, b) F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or, c) Gilead Sciences elects to terminate development of F/TAF in the applicable country.
9822764|NCT02285153|Experimental|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
9822765|NCT02285153|Placebo Comparator|0.9% sodium-chloride solution|0.9% sodium-chloride solution
9822766|NCT02285283|Placebo Comparator|Placebo|2 capsules by mouth twice a day for 24 weeks
9822767|NCT02285283|Active Comparator|Itraconazole|Two 100mg capsules by mouth twice a day for 24 weeks
9822768|NCT02285361||GIOTRIF|
9822769|NCT02285634|Experimental|Oxymetazoline 0.05%|Oxymetazoline 0.05%
9822770|NCT02285634|Experimental|Phenylephrine 0.25%|Phenylephrine 0.25%
9965805|NCT01253356|Active Comparator|Intra-Aortic Balloon Pump (IABP)|Standard of care, IABP inserted < or = 3 hours before noncardiac surgery, maintained for > or = 12-24 hours after surgery
10115849|NCT04445298||Pregnant women with expected delivery in the spring or summer|We will enroll up to 40 women who are expected to deliver in the spring (March, April, May) and summer (June, July, August). We will then follow their infant offspring.
10115850|NCT04445298||Infants born in the fall or winter|The infants born to the enrolled mothers will be followed. These are infants born in the fall (September, October, November) or winter (December, January, February).
10115851|NCT04445298||Infants born in the spring or summer|The infants born to the enrolled mothers will be followed. These are infants born in the spring (March, April, May) or summer (June, July, August).
10115852|NCT04445272|Experimental|Tocilizumab|"Patients will receive IV tocilizumab as per clinical practice and at the discretion of treating investigator, following the posology indicated in the SmPC, or the recommendations proposed by the Spanish Ministry of Health:~The recommended posology by the SmPC is 8 mg per kg in patients weighing greater than or equal to 30 kg or 12 mg per kg in patients weighing less than 30 kg. If no clinical improvement in the signs and symptoms up to 3 additional doses of tocilizumab may be administered. The interval between consecutive doses should be at least 8 hours.~The recommendations of the Spanish Ministry of Health:~Patients more than 80 kg: first dose 600 mg; second dose 600 mg. Patients less than 80 kg: first dose 600 mg; second dose 400 mg.~A third dose might be considered 16 to 24 hours after if: fever persists or a worsening of the laboratory parameters~Given the exceptionality of the situation modification of doses according to the physician experience will be allowed."
10115853|NCT04445259||Critically Ill Patients with COVID-19|We plan to recruit patients who are admitted to intensive care units with COVID-19 diagnosis.
10115854|NCT04445311|Experimental|Ivermectin group|group that will receive ivermectin plus standard of care ttt
10115855|NCT04445311|No Intervention|Control group|group that will receive standard of care ttt
10115856|NCT04445285|Experimental|Treatment Arm|Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
10115857|NCT04445285|Placebo Comparator|Placebo Arm 0.9% sodium chloride|Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
10115858|NCT04445805|Active Comparator|CBTI Treatment Group|Telemedicine Cognitive Behavioral Therapy for Insomnia (CBTI)
10115859|NCT04445805|Experimental|Perinatal-enhanced behavioral therapy for insomnia|Telemedicine Mindfulness Based Therapy for Insomnia (MBTI)
10115860|NCT04445805|Placebo Comparator|Attention Control Treatment Group|Minimal intervention control
10115861|NCT04445363|Experimental|Cohort 1,0.5% Bid|Jacatinib hydrochloride cream 0.5% concentration, twice daily
10115862|NCT04445363|Experimental|Cohort 1,1.5% Bid|Jacatinib hydrochloride cream 1.5% concentration, twice daily
10115863|NCT04445363|Experimental|Cohort 1,2.5% Qd|Jacatinib hydrochloride cream 2.5% concentration, once daily
10115864|NCT04445363|Experimental|Cohort 1,2.5% Bid|Jacatinib hydrochloride cream 2.5% concentration, twice daily
9822771|NCT02285634|Experimental|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
9822772|NCT02285634|Placebo Comparator|Bacteriostatic 0.9% sodium chloride (NaCL)|Bacteriostatic 0.9% NaCL
9822773|NCT02285777|Experimental|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
9822774|NCT02285777|Active Comparator|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
9822775|NCT02285855|Experimental|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
9822776|NCT02285855|Placebo Comparator|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
9965806|NCT01253382|Active Comparator|ecallantide|
9965807|NCT01253382|Placebo Comparator|placebo|phosphate buffered saline
9965808|NCT01253395|Experimental|Strength training|Supervised strength training.
9965809|NCT01253395|Active Comparator|Aerobic exercise|Supervised aerobic exercise.
10115865|NCT04445363|Placebo Comparator|Dose extension: Placebo|Placebo, twice daily
10115866|NCT04445363|Experimental|Dose extension: 1.5% Bid|Jacatinib hydrochloride cream 1.5% concentration, twice daily
9822777|NCT02285907|Experimental|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
9822778|NCT02285907|Experimental|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
9822779|NCT02285907|Experimental|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
9822780|NCT02285907|Experimental|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
9822781|NCT02285920|Active Comparator|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
9822782|NCT02285920|Active Comparator|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
9822783|NCT02285920|Active Comparator|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
10115867|NCT04445363|Experimental|Dose extension: 2.5% Bid|Jacatinib hydrochloride cream 2.5% concentration, twice daily
10115868|NCT04444999|Experimental|Endovascular abdominal aortic aneurysm repair|a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA).
9822784|NCT02285920|Placebo Comparator|Placebo|Participants will be treated with placebo for 36 weeks.
9822785|NCT02285998|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
9822786|NCT02285998|Active Comparator|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
9822787|NCT02286102|Experimental|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
9822788|NCT02286102|Active Comparator|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
9822789|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
9822790|NCT02286466|Active Comparator|Health Education Program|The presence and usage of Health Education Program.
9822791|NCT02286466|Experimental|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
9965810|NCT00839137||no exercise program group|group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit
10115869|NCT04444973||Invasive RV assessment|RV conductance catheter assessment of RV performance
10115870|NCT04445181||Patients with T2D|Active patients (defined as patients seen by an LMC endocrinologist between January 1, 2019 and December 31, 2019) with T2D (Type 2 Diabetes). Among the patients with T2D, those identified with CKD will be included in the renal registry.
10115871|NCT04445181||Healthcare providers|Healthcare providers caring for patients with CKD and T2D.
10115872|NCT04445064|Experimental|IO102 vaccine|
10115873|NCT04445064|No Intervention|Control group|
10115874|NCT04445077|Experimental|Intervention group|The education will be delivered weekly with 60-90 minutes per lecture for eight lectures. Multiple teaching methods will be used, including lectures, structured handouts, video, role play, case study and discussion. During the study period, the research team will provide ongoing support and consultation through electronic communication and bimonthly field visits.
10115875|NCT04445077|Other|Control group|Printed materials will be given to the participants in the control group for their self-study.
10115876|NCT04445012||Aortic Valve Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
9822792|NCT02286518|Experimental|Cohort 1A: TAK-114 10 mg|Orally, once only.
9822793|NCT02286518|Experimental|Cohort 1B: TAK-114 10 mg|Orally, once
9822794|NCT02286518|Experimental|Cohort 2A: TAK-114 20 mg|Orally, once
9822795|NCT02286518|Experimental|Cohort 2B: TAK-114 20 mg|Orally, once
9822796|NCT02286518|Experimental|Cohort 3A: TAK-114 50 mg|Orally, once
9822797|NCT02286518|Experimental|Cohort 3B: TAK-114 50 mg|Orally, once
9822798|NCT02286518|Experimental|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
9822799|NCT02286518|Experimental|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
9822800|NCT02286518|Experimental|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
9822801|NCT02286518|Experimental|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
9822802|NCT02286518|Experimental|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
9822803|NCT02286518|Experimental|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
9822804|NCT02286518|Placebo Comparator|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
9822805|NCT02286518|Placebo Comparator|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
9822806|NCT02286518|Placebo Comparator|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
9822807|NCT02286713|Active Comparator|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
9822808|NCT02286713|Active Comparator|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
9822809|NCT02286726|Experimental|Arm I (lower-dose (50 units/m^2) CPX-351)|Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5 of a 28-day course. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
9822810|NCT02286726|Experimental|Arm II (intermediate-dose (75 units/m^2) CPX-351)|Patients receive intermediate-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
9822811|NCT02286726|Experimental|Arm III (standard-dose (100 units/m^2) CPX-351)|Patients receive standard-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
9822812|NCT02286843|Experimental|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
9822813|NCT02286895|Active Comparator|Group A (without rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).
9822814|NCT02286895|Experimental|Group B (with rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).
9822815|NCT02286921|Experimental|Arm A: Testosterone cypionate or testosterone enanthate|Patients on BAT will receive testosterone cypionate or testosterone enanthate administered as an intramuscular injection. A dose of 400 mg of either agent will be injected intramuscularly (IM) every 28 days.
9822816|NCT02286921|Experimental|Arm B: Enzalutamide|Patients randomized to enzalutamide will be prescribed enzalutamide 40 mg tablets and instructed to take 4 tablets per day orally for 28 days/cycle.
9822817|NCT02286947|Experimental|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
9822818|NCT02286960|Active Comparator|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
9822819|NCT02286960|Placebo Comparator|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
9822820|NCT02287038|Active Comparator|Atomoxetine 80mg|Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
9822821|NCT02287038|Placebo Comparator|Placebo|A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.
10115877|NCT04445012||Mitral Valve Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
10115878|NCT04445012||Aortic Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe aortic regurgitation, using the BSE gradings [Wharton 2014].
9668562|NCT05244135|Experimental|Pulmonary rehabilitation in VR (VR group)|"The VR group will perform the endurance exercise training using the Virtual Park, developed by CNR-STIIMA. The system includes a COSMED cycle-ergometer, a virtual environment and a physiological sensor-either a HR band or a pulse-oximeter depending on the target patient's needs. The virtual environment represents a ride in a park, enriched with realistic elements and sound effects, in order to simulate a daily life situation.~In the VR group, the VR Tier One device (Stolgraf®) will be used as a VR source. Thanks to using a head mounted display and the phenomenon of total immersion, VR therapy provides an intense visual, auditory and kinaesthetic stimulation. The aim of the software was to calm and improve the mood, while motivating and cognitively activating the patient."
9668563|NCT05244135|Active Comparator|Traditional Pulmonary Rehabilitation (TPR)|"In the TPR group, exercise training will be performed on the bicycle. The training will be conducted on cycle ergometers with the use of the Peloton™ system, which ensures the monitoring of performance parameters.~In the TPR group, Schultz Autogenous Training will be performed. Schultz Autogenic Training has been shown to be effective in treating these pathologies. In both groups the relaxation training will be carried out once a day and will last about 20 minutes."
9822822|NCT02287350|Experimental|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
9822823|NCT02287376|Experimental|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
9965811|NCT00839137||exercise group|will meet three times a week for 12 weeks, following specific exercise program
9668564|NCT05244122|Experimental|Experimental|Observers could choose to participate in each of four experiments on each of six days
9668565|NCT05244109|Experimental|NSAIDs|Patients responding to any class of NSAIDs and unlikely to initiate biotherapy
9822824|NCT02287402|Experimental|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
9822825|NCT02287415|Experimental|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
9965812|NCT01253434|Experimental|1|
9965813|NCT01253434|Experimental|2|
9822826|NCT02287467|Experimental|Arm A: hIVIG|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
9822827|NCT02287467|Placebo Comparator|Arm B: Placebo|Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
9822828|NCT02287623|Experimental|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
9822829|NCT02287623|Active Comparator|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
9822830|NCT02287675|Active Comparator|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
9822831|NCT02287675|Active Comparator|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:~In adults, to assist in the:~localization of lymph nodes draining a primary tumor in patients with~breast cancer or malignant melanoma when used with a hand-held gamma counter.~evaluation of peritoneovenous (LeVeen) shunt patency in adults."
9822832|NCT02287688||Exposure group|Subjects aged 2-23 months who received at least one dose of the MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
9822833|NCT02287779|Experimental|SHP626|9/12 subjects -1x daily dose of 20mg for 12 days 9/12 subjects-1x daily dose of 40mg for 12 days 9/12 subjects-1x daily dose of 80mg for 12 days 9/12 subjects-1x daily dose of 120mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-1x daily dose of 160mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD) for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD; lower or higher than cohort 6) for 12 days 9/12 subjects-1x or 2x daily dose of SHP626 in an escalating titration (doses TBD). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days 9/12 subjects will take a 1x or 2x daily dose of SHP626 in escalating titration (doses TBD; lower or higher dose than cohort 8). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days
9822834|NCT02287779|Placebo Comparator|Placebo|Three subjects per cohort will take a matched placebo
9822835|NCT02287818|Placebo Comparator|Placebo|Placebo plus Febuxostat
9822836|NCT02287818|Experimental|AC-201|AC-201 CR tablet plus Febuxostat
9822837|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
9822838|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
9822839|NCT02287896|Experimental|Roledumab Open-label IM|"- Planned antenatal prophylaxis: A single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IM anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IM postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
9822840|NCT02287896|Experimental|Roledumab Open-label IV|"- Planned antenatal prophylaxis: A single dose of 300 µg IV of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
9822841|NCT02287909|Experimental|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
10115879|NCT04445012||Mitral Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral stenosis, using the BSE gradings [Wharton 2014].
10115880|NCT04445012||Mixed Valve Disease (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mixed valve disease. Overall classification based on the most severe disease using the BSE gradings [Wharton 2014].
10115881|NCT04445012||Ventricular Septal Defects (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe ventricular septal defects, using gradings from [Samaan 1970].
10115882|NCT04445012||Aortic Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe aortic stenosis
10115883|NCT04445012||Pulmonary Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe pulmonary stenosis.
9827093|NCT02444988|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
9965814|NCT01253434|Experimental|3|
9965815|NCT01253434|Experimental|4|
9965816|NCT01253434|Experimental|5|
9965817|NCT01253473|Active Comparator|ipratropium/albuterol|1 puff 4 times daily
9822842|NCT02287909|Experimental|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
9822843|NCT02287909|Experimental|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
9822844|NCT02287909|Active Comparator|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
9822845|NCT02287922|Experimental|ALX-0061 150 mg q4w|ALX-0061 150 mg every 4 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
9822846|NCT02287922|Experimental|ALX-0061 150 mg q2w|ALX-0061 150 mg every 2 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
9822847|NCT02287922|Experimental|ALX-0061 225 mg q2w|ALX-0061 225 mg every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
9822848|NCT02287922|Active Comparator|TCZ 162 mg q1w or q2w|Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
9822849|NCT02288091|Experimental|Open-label|Subjects will receive oral inosine daily.
9822850|NCT02288156|Active Comparator|0.1mM|
9822851|NCT02288156|Experimental|0.01mM|
9822852|NCT02288156|Experimental|0.001mM|
10115884|NCT04445012||Patent Ductus Arteriosus (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe patent ductus arteriosus, graded using ductal size [Arlettaz 2017].
9528160|NCT03213314|Experimental|Main cohort|Patients undergoing liver resection
9822853|NCT02288156|Placebo Comparator|Placebo|
9822854|NCT02288182|Experimental|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of > 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and < 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
9822855|NCT02288182|Active Comparator|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
9822856|NCT02288273|Experimental|Bydureon|Once weekly injected exenatide
9822857|NCT02288273|Placebo Comparator|Placebo|Placebo comparator
9822858|NCT02288312|Experimental|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
9822859|NCT02288312|Experimental|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
9822860|NCT02288312|Experimental|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
9822861|NCT02288325|Experimental|Open-Label FETZIMA®|FETZIMA® (levomilnacipran extended release [ER]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
9822862|NCT02288325|Placebo Comparator|Double-Blind Placebo|Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
9822863|NCT02288325|Experimental|Double-Blind FETZIMA®|FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
9822864|NCT02288364|Active Comparator|1% Lidocaine|1% Lidocaine alone.
9822865|NCT02288364|Active Comparator|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
9822866|NCT02288377|Experimental|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
9822867|NCT02288377|Placebo Comparator|placebo|In this arm, patients will receive placebo every 28 days until disease progression
9822868|NCT02288559|Experimental|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
9822869|NCT02288559|Experimental|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
9822870|NCT02288559|Experimental|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
9822871|NCT02288559|Sham Comparator|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
9822872|NCT02288819|Experimental|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
9822873|NCT02289079|Experimental|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
9822874|NCT02289079|Active Comparator|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
10115885|NCT04445012||No Disease (Paediatric Patients)|264 paediatric patients with no heart disease. Note that we are only taking recordings from those who have been referred for an echocardiogram with a suspected heart condition but are subsequently found to have no heart disease.
9528161|NCT03213314|Experimental|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
9965818|NCT01253473|Experimental|Budesonide|budesonide 180 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
10115886|NCT04445129||Narcolepsy Type 1 Participants|Participants with NT1 on stable wake-promoting medications and exclusive of any sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
10115887|NCT04445129||Healthy Participants|Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
10115888|NCT04445142||epiretinal membrane group|Patients developed secondary fovea epiretinal membrane
9822875|NCT02289105|Experimental|Mandatory active choice|The mandatory active choice group will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
9822876|NCT02289105|No Intervention|Control|Participants in the control group will be presented an AD form only and will be encouraged to complete, and submit the form without having to declare the choice of completing or declining the AD.
9822877|NCT02289157|Experimental|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
9822878|NCT02289157|No Intervention|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
9822879|NCT02289222|Experimental|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
9827094|NCT02444988|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
9827095|NCT02445014|Experimental|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
9827096|NCT02445027|Experimental|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
9827097|NCT02445196|Experimental|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
9827098|NCT02445196|Active Comparator|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
9827099|NCT02445287|Experimental|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
9827100|NCT02445287|Experimental|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
9827101|NCT02445326|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
9827102|NCT02445326|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
9827103|NCT02445573|Active Comparator|EA group|
9827104|NCT02445573|Placebo Comparator|Sham EA group|
9827105|NCT02445586|Experimental|Pertuzumab in Combination with Trastuzumab and Docetaxel|Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
9827106|NCT02445625|Experimental|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
9827107|NCT02445794|Experimental|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
9827108|NCT02445794|Experimental|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
9827109|NCT02445807|Experimental|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
9827110|NCT02445807|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
9827111|NCT02445859|Active Comparator|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
9827112|NCT02445859|Experimental|Interventional regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
9827113|NCT02445911|Experimental|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
9827114|NCT02445911|Experimental|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
9827115|NCT02445911|Experimental|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
9827116|NCT02445911|Placebo Comparator|Placebo|Multiple ascending doses matching KQ-791 dose
9827117|NCT02445963|Active Comparator|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
9827118|NCT02445963|Active Comparator|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
9827119|NCT02445963|Active Comparator|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
9827120|NCT02445963|Active Comparator|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
9827121|NCT02446015|Experimental|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
9827122|NCT02446015|Active Comparator|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
9827123|NCT02446171|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
9827124|NCT02446171|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
10115889|NCT04445337|Experimental|Open Label SGB|Initial perineural bolus injection - clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml will be used for SGB block.
9822880|NCT02289352|Experimental|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
9822881|NCT02289352|Active Comparator|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
9822882|NCT02289352|Placebo Comparator|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
9822883|NCT02289417|Experimental|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks:~Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)~Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
9822884|NCT02289417|Experimental|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
9822885|NCT02289417|Placebo Comparator|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)~After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
9822886|NCT02289456|Experimental|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle~• Carboplatin AUC = 5 mg*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
9822887|NCT02289469|Experimental|PictureRx|PictureRx medication history platform
9822888|NCT02289469|No Intervention|Usual care|Usual medication history process
9822889|NCT02289690|Experimental|Phase 1: Veliparib + Carboplatin + Etoposide|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of veliparib in combination with carboplatin/etoposide for up to four 21-day cycles.~Participants without evidence of disease progression will continue on veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity."
9822890|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Veliparib|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity.
9822891|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Placebo|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
9822892|NCT02289690|Active Comparator|Phase 2: Placebo + Carboplatin + Etoposide -> Placebo|Participants will receive placebo in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
9822893|NCT02289729||All Participants|Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.
9822894|NCT02289742|Other|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
9822895|NCT02289742|Other|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
9822896|NCT02289755|Experimental|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
9822897|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
9822898|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
9822899|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
9822900|NCT02289820|Experimental|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
9822901|NCT02289820|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
9822902|NCT02289833|Experimental|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
9822903|NCT02289833|Experimental|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
9822904|NCT02289898|Experimental|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
9528162|NCT03213314|Experimental|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
9822905|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
9822906|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
9822907|NCT02289950|Experimental|Farletuzumab|All participants will receive a loading dose for the first 2 weeks of 10 milligram per kilogram (mg/kg) farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV).
9822908|NCT02289950|Placebo Comparator|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
10115890|NCT04445168|No Intervention|Usual Care|Participants assigned to usual care may receive advice from their primary care physician to increase their physical activity. They will receive handouts about every 6 weeks on general health topics.
10115891|NCT04445168|Experimental|Intervention|Participants assigned to the intervention arm will receive telephone-based motivational interviews with trained interventionists to encourage increases in physical activity.
10115892|NCT04445038|Experimental|610 group|Participants will be administered with 0.03mg/kg, 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg of 610 by subcutaneous injection. Subjects will be followed for 84 days.
10115893|NCT04445038|Placebo Comparator|controll group|Participants will be administered with 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg placebo once by subcutaneous injection. Subjects will be followed for 84 days.
10115894|NCT04445155|Experimental|Modified DECIDE|DECIDE has two primary components: 1) three parent training sessions designed to help patients effectively ask questions and participate in decisions about care: and 2) a 12-hour workshop and up to 4 individual coaching sessions for providers to improve perspective-taking, reduce attributional errors, and increase receptivity to parent participation
10115895|NCT04445155|No Intervention|Usual Care|Usual Care consists of standard outpatient mental health care, including individual treatment for the adolescent (i.e., therapy, and/or medication) or family treatment for adolescents and parents, delivered in a variety of settings (e.g., clinics, schools, homes).
10115896|NCT04445194|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
10115897|NCT04445194|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
9668566|NCT05244109|Experimental|Anti-TNF antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-TNF treatment arm
10115898|NCT04445194|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
10115899|NCT04445116|Experimental|Endeavor group|25 participants will fill out questionnaires and complete a neuropsychological evaluation. During study participation, participants will target using Endeavor™ action video game to complete 25-30 minutes at-home sessions 5 days a week for a total of 8 weeks via an iOS application.
10115900|NCT04445025|Experimental|Test group|Subjects will receive the medication elagolix
10115901|NCT04445025|Active Comparator|Control group|Subjects will receive leuprolide acetate
10115902|NCT04445350|Experimental|External focus of attention training program|The intervention group receives a strength and neuromuscular training program. The training instructions have an external focus of attention.
9668567|NCT05244109|Experimental|Anti-IL17 antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-IL-17 treatment arm
9822909|NCT02289963|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
10115903|NCT04445350|Active Comparator|Internal focus of attention training program|The control group receives a strength and neuromuscular training program. The training instructions have an internal focus of attention.
10115904|NCT04445051|Active Comparator|Standard of care|SpeediCath® standard Male and Female
10115905|NCT04445051|Experimental|New intermittent catheter variation 1 for male and female|New intermittent catheter variation 1 for male and female
10115906|NCT04445051|Experimental|New intermittent catheter variation 2 for male and female|New intermittent catheter variation 2 for male and female
10115907|NCT04444986|Experimental|FAVIR then AVIGAN|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
9668568|NCT05244096||COVID+|COVID + positive individuals from March 15 2020 to Nov 30, 2021
9668569|NCT05244083|Experimental|Experimental Group|The experimental group will perform a 5-week motor program consisting of 4 bimanual exercises with mirror therapy, to be done at home 30 minutes a day, 5 days a week.
9668570|NCT05244083|Active Comparator|Control Group|The control group will perform a 5-week motor program consisting of 4 bimanual exercises without mirror therapy, to be done at home 30 minutes a day, 5 days a week.
9668571|NCT05244070|Experimental|BMS-986403 + Fludarabine + Cyclophosphamide|
9822910|NCT02289963|Placebo Comparator|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
9822911|NCT02289989|Active Comparator|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
9822912|NCT02289989|Experimental|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
9822913|NCT02290028|Other|Sentus QP left ventricular lead|Subjects consented and implanted with a Sentus QP left ventricular lead.
9822914|NCT02290106|Experimental|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
9822915|NCT02290106|Placebo Comparator|Placebo|Identical placebo 4mg by mouth daily for 6 months
9822916|NCT02290184|Experimental|Intervention - PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
9822917|NCT02290184|Active Comparator|Active control - pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
9822918|NCT02290223|Experimental|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
9822919|NCT02290223|No Intervention|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
9822920|NCT02290340|Placebo Comparator|Placebo|Participants will receive placebo intramuscularly.
9822921|NCT02290340|Experimental|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
9822922|NCT02290340|Experimental|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
9822923|NCT02290340|Experimental|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
9822924|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score > 14 on the Insomnia Severity Index, report insomnia for > 3 months, have sleep difficulties > 3 nights per week, score < 3 on the Epworth Sleepiness Scale (ESS), score > 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
9822925|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score < 10 on the ESS, score < 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
9822926|NCT02290444|Experimental|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
9822927|NCT02290444|No Intervention|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
9822928|NCT02290509|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
10115908|NCT04444986|Experimental|AVIGAN then FAVIR|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
9822929|NCT02290509|Active Comparator|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
9822930|NCT02290574|Experimental|Thermo-radio-chemotherapy arm|Hyperthermia with concurrent chemo-radiation therapy
9822931|NCT02290613|Experimental|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
9822932|NCT02290613|Placebo Comparator|Placebo|Placebo tablet
9822933|NCT02290691|Experimental|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
9822934|NCT02290691|Active Comparator|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
9822935|NCT02290821|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1%
9822936|NCT02290821|Placebo Comparator|Placebo|Placebo
9822937|NCT02290873|Experimental|Remimazolam|"Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
9822938|NCT02290873|Placebo Comparator|Placebo|"Inactive control arm~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
9822939|NCT02290873|Active Comparator|Midazolam|"Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.~*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
9822940|NCT02290925|Experimental|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
9822941|NCT02290925|Placebo Comparator|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
9822942|NCT02291016|Active Comparator|Formoterol via DPI then Formoterol via nebulizer|"Group A: Received Formoterol 12 µg via DPI and placebo via nebulizer at treatment visit #1, and Formoterol 20 µg (solution form) via nebulizer and placebo via DPI at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
9827125|NCT02446171|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
9827126|NCT02446171|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
9827127|NCT02446223|Experimental|Active|
9822943|NCT02291016|Active Comparator|Formoterol via nebulizer then Formoterol via DPI|"Group B: Received Formoterol 20 µg (solution form) via nebulizer and placebo via a DPI at treatment visit #1, and Formoterol 12 µg via a DPI with placebo via nebulizer at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
9822944|NCT02291029|Experimental|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
9822945|NCT02291029|Placebo Comparator|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
9822946|NCT02291029|Experimental|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
9822947|NCT02291029|Placebo Comparator|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
9822948|NCT02291029|Experimental|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
9822949|NCT02291029|Experimental|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
9822950|NCT02291133|Experimental|Electrochemotherapy treatment|
9822951|NCT02291237|Experimental|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
9822952|NCT02291237|Experimental|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
9822953|NCT02291289|Experimental|Cohort 1: 5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
9822954|NCT02291289|Experimental|Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
9822955|NCT02291289|Experimental|Cohort 3: capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
9822956|NCT02291289|Experimental|Cohort 4: Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
9822957|NCT02291289|Active Comparator|Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
9822958|NCT02291289|Active Comparator|Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
9822959|NCT02291289|Active Comparator|Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
9822960|NCT02291289|Active Comparator|Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
9822961|NCT02291289|Other|Cohort 1: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
9822962|NCT02291289|Other|Cohort 2: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
9822963|NCT02291289|Other|Cohort 3: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
9822964|NCT02291289|Other|Cohort 4: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
9822965|NCT02291302|Active Comparator|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
9822966|NCT02291302|Placebo Comparator|Sham and Control (control)|Sham air purifiers and no school integrated pest management environmental intervention
9822967|NCT02291302|Placebo Comparator|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
9822968|NCT02291302|Sham Comparator|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
9822969|NCT02291419|Experimental|ticagrelor|ticagrelor 90mg bid
9822970|NCT02291419|Active Comparator|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
9822971|NCT02291432|Experimental|AMDC-USR|Cell treatment
9822972|NCT02291510|Experimental|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
9822973|NCT02291510|Experimental|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
9822974|NCT02291510|Active Comparator|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
9822975|NCT02291510|Active Comparator|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
9822976|NCT02291549|Experimental|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
9822977|NCT02291549|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
9822978|NCT02291601|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
9822979|NCT02291601|Placebo Comparator|Vehicle Cloth|Excipients on cloth
9822980|NCT02291601|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
9822981|NCT02291614|Experimental|AMG 211 200 μg/day for 7/14 Days|In cycle 1 participants receive 200 µg/day AMG 211 administered as a continuous intravenous infusion (cIV) infusion at a constant flow rate for 7 days followed by a 3-week treatment-free interval. In cycle 2 and thereafter, participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
9822982|NCT02291614|Experimental|AMG 211 200 μg/day for 14 Days|Participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
9822983|NCT02291614|Experimental|AMG 211 400 μg/day for 14 Days|Participants receive 400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
9822984|NCT02291614|Experimental|AMG 211 800 μg/day for 14 Days|Participants receive 800 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
9822985|NCT02291614|Experimental|AMG 211 1600 μg/day for 14 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
9822986|NCT02291614|Experimental|AMG 211 1600 µg/day for 28 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
9822987|NCT02291614|Experimental|AMG 211 3200 µg/day for 14 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
9822988|NCT02291614|Experimental|AMG 211 3200 µg/day for 28 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
9822989|NCT02291614|Experimental|AMG 211 6400 µg/day for 14 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
9822990|NCT02291614|Experimental|AMG 211 6400 µg/day for 28 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
9822991|NCT02291614|Experimental|AMG 211 12,800 µg/day for 28 Days|Participants receive 12,800 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
9822992|NCT02291679|Experimental|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
9822993|NCT02291679|Experimental|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
9822994|NCT02291679|Placebo Comparator|Placebo|matching placebo, once daily for 12 weeks
9822995|NCT02291718|Active Comparator|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
9822996|NCT02291718|Active Comparator|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
9822997|NCT02291718|Active Comparator|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
9822998|NCT02291861|Placebo Comparator|Placebo|Placebo tablets taken twice daily for 12 weeks.
9822999|NCT02291861|Experimental|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
9823000|NCT02291861|Experimental|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
9823001|NCT02291861|Experimental|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
9823002|NCT02291913|Experimental|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
9823003|NCT02292082|Active Comparator|Peri-Articular Injections only|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Surgeon will perform the periarticular injections:~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine~Intravenous sedation with midazolam and propofol."
9827128|NCT02446314|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
9827129|NCT02446314|Experimental|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
9827130|NCT02446314|Experimental|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
9668572|NCT05244057|Experimental|Hepalatide + TAF + PEG-IFN|Patients will receive 4.2mg Hepalatide +25mg Tenofovir alafenamide+ 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
9668573|NCT05244057|Placebo Comparator|Placebo+ TAF + PEG-IFN|Patients will receive Placebo +25mg Tenofovir alafenamide + 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
9823004|NCT02292082|Experimental|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Adductor canal block technique:~Supine position, after IV sedation~Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches~Femoral artery will be identified in the adductor canal deep to the Sartorius muscle~15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone~Local anesthetic will be delivered periarterial between 12 and 6 o'clock~Intravenous sedation with midazolam and propofol.~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
9823005|NCT02292186|Experimental|Revusiran (ALN-TTRSC)|
9823006|NCT02292212|Experimental|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
9823007|NCT02292433|Experimental|PF-04937319|PF-04937319 Split dose
9823008|NCT02292433|Placebo Comparator|Placebo|Placebo split dose
9823009|NCT02292446|Experimental|All patients|All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
9823010|NCT02292537|Experimental|Nusinersen|Nusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.
9823011|NCT02292537|Sham Comparator|Sham procedure|Sham comparator on Days 1, 29, 85 and 274.
9823012|NCT02292719|Experimental|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
9823013|NCT02292719|Experimental|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.
9823014|NCT02292719|Experimental|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
9823015|NCT02292719|Experimental|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
9823016|NCT02292719|Experimental|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
9823017|NCT02292719|Experimental|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
9823018|NCT02292771|Experimental|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
9823019|NCT02292771|Active Comparator|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
9823020|NCT02292784|Placebo Comparator|Placebo (200719 study)|All infants and children born to women who received the placebo (0.9 percent sodium chloride infusion matched for retosiban volume, intravenous [IV] loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment) in 200719 study. Current study will not require any medical interventions or study visits to an investigational site.
9823021|NCT02292784|Experimental|Retosiban (200719 and 200721 study)|All infants and children born to women who received retosiban (6 milligram [mg] IV loading dose of retosiban over 5 minutes followed by a 6 mg per hour continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg per hour continuous infusion for remainder of 48-hour treatment period) in 200719 study or 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
9823022|NCT02292784|Active Comparator|Atosiban (200721 study)|All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter [mL] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
9823023|NCT02292849|Experimental|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
9823024|NCT02292849|Active Comparator|Referral|These individuals will receive a standard mental health referral to a community agency.
9823025|NCT02292927|No Intervention|Pre-intervention|Patients treated as standard before intervention
9823026|NCT02292927|Active Comparator|Post-intervention arm = Prehabilitation|Introduction of rehabilitation program
9823027|NCT02293044|Experimental|Crest® Sensi-Stop™ Strips|Self Applied
9827131|NCT02446314|Experimental|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
9827132|NCT02446418|Experimental|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
9965819|NCT01253473|Experimental|budesonide/formoterol|budesonide/formoterol 160/4.5 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
9823028|NCT02293096|Experimental|Metoprolol succinate, CYP2D6 Genotyping, CYP2D6 Phenotyping|"The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol. The following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.~metoprolol succinate~Genotyping: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete.~CYP2D6 Phenotyping: Phenotype can be discordant from what is predicted by genotype. CYP2D6 henotyping using dextromethorphan will be used. Investigators will be blind to the patient blood pressure outcome for this intervention."
9823029|NCT02293395|Active Comparator|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
9823030|NCT02293395|Experimental|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
9823031|NCT02293395|Active Comparator|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
9823032|NCT02293395|Experimental|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
9823033|NCT02293460|Experimental|I10E Arm|
9823034|NCT02293499|Active Comparator|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
9823035|NCT02293499|Active Comparator|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
9823036|NCT02293512|Experimental|Coping Effectiveness Training|Coping Effectiveness Training (CET) is provided in a 3-session intervention to facilitate coping strategies among individuals with tinnitus. The CET psychoeducational intervention teaches coping skills to increase understanding of stress and coping with tinnitus, and to help individuals better know how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
9823037|NCT02293512|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy (CBT) is provided in a 3-session psychoeducational intervention to reduce negative affectivity triggered by tinnitus. CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
10182591|NCT03772561|Experimental|AZD5363+Olaparib+Durvalumab|"A traditional 3+3 design will be used during the dose escalation part of the study.~Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities."
9823038|NCT02293512|Active Comparator|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is provided in a 3-session psychoeducational intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
9823039|NCT02293512|No Intervention|Wait-list control group|Wait-list control group involves no intervention. This is a 'usual care' group.
9823040|NCT02293538|Experimental|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
9823041|NCT02293538|Active Comparator|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
9823042|NCT02293798|Experimental|SERI|Subjects receiving SERI for mastopexy
9823043|NCT02293837|Experimental|Tocilizumab (TCZ) + SOC|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight <30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
9823044|NCT02293837|Placebo Comparator|Tocilizumab Placebo Group + SOC|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
9823045|NCT02293863|Experimental|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
9823046|NCT02293863|Experimental|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
9823047|NCT02293863|Placebo Comparator|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
9827133|NCT02446418|Active Comparator|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
9823048|NCT02293902|Experimental|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either tender joint count [TJC] or swollen joint count [SJC], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
9823049|NCT02293902|Experimental|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
9823050|NCT02293902|Placebo Comparator|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
9823051|NCT02293902|Placebo Comparator|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
9823052|NCT02293993|Experimental|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
9823053|NCT02293993|Experimental|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
9823054|NCT02293993|Experimental|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
9823055|NCT02293993|Experimental|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
9823056|NCT02294019|Experimental|Ibuprofen caplet arm|
9823057|NCT02294058|Active Comparator|Interferon beta-1a|Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
9823058|NCT02294058|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
9823059|NCT02294058|Experimental|Ozanimod 1 mg|Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
9823060|NCT02294175|Active Comparator|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
9823061|NCT02294175|Active Comparator|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
9823062|NCT02294227|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
10115909|NCT04445324|Experimental|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
10115910|NCT04445324|Active Comparator|Control Group (pharmacotherapy and/or psychotherapy N=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
10182592|NCT03772470|No Intervention|Control|No airtime incentive was given for completing the survey
10182593|NCT03772470|Experimental|1X Incentive|1X airtime incentive
10182594|NCT03772470|Experimental|2X incentive|2X airtime incentive
9823063|NCT02294227|Experimental|Secukinumab 150 mg No load|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
9823064|NCT02294227|Placebo Comparator|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
9823065|NCT02294253|Experimental|Buprenorphine/naloxone stabilization|Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
9823066|NCT02294318|Active Comparator|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
9823067|NCT02294318|Experimental|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
9823068|NCT02294396|Experimental|Mirabegron + Solifenacin|Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.
9823069|NCT02294396|Experimental|Mirabegron + Propiverine|Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
9823070|NCT02294396|Experimental|Mirabegron + Imidafenacin|Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
9823071|NCT02294396|Experimental|Mirabegron + Tolterodine|Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.
9823072|NCT02294474|Experimental|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
9823073|NCT02294474|Active Comparator|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
9823074|NCT02294604|Experimental|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
9823075|NCT02294604|Active Comparator|Group I|Traditional scrub formation with 10 % povidone-iodine
9823076|NCT02294604|Active Comparator|Group C|Traditional scrub formation with 4% chlorhexidine
9823077|NCT02294630|Active Comparator|Dose Schedule I|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
9823078|NCT02294630|Active Comparator|Dose Schedule II|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
9823079|NCT02294630|Active Comparator|Dose Schedule III|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
9823080|NCT02294630|Active Comparator|Dose Schedule IV|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2
9823081|NCT02294682|Experimental|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
9823082|NCT02294682|Experimental|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
9823083|NCT02294734|Experimental|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
9823084|NCT02294734|Placebo Comparator|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
9823085|NCT02294773|Active Comparator|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
9823086|NCT02294773|Active Comparator|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
10115911|NCT04444843|Other|Mycophenolate Mofetil Capsules|The dosage of mycophenolate mofetil (CellCept) will be decided by the investigator and should be adjusted according to clinical response or therapeutic drug monitoring. It is not allowed to switch to other MPAs. When MMF is discontinued but is not switched to other MPA, the patients will be followed until the end of study.
9528163|NCT03213314|Experimental|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
10115912|NCT04444934||Patients with not-surely pathologic diaphragmatic peritoneum|The definition of not-surely pathologic diaphragmatic peritoneum was given in association with the presence of flat dyschromic areas.
10115913|NCT04444934||Patients with certainly pathologic diaphragmatic peritoneum|The definition of certainly pathological diaphragmatic peritoneum was given when isolated or confluent thick nodules were visualized at the intra-operative inspection.
10115914|NCT04444687||SARS-CoV-2-positive 01|SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
9823087|NCT02294786|Experimental|Octreotide treatment|Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
9823088|NCT02294786|Experimental|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
9823089|NCT02295020|Active Comparator|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
9823090|NCT02295020|Experimental|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
9823091|NCT02295280|Active Comparator|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
9823092|NCT02295280|Active Comparator|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
9823093|NCT02295553|Experimental|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
9823094|NCT02295553|Experimental|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
9823095|NCT02295553|Experimental|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
9823096|NCT02295553|Experimental|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
9823097|NCT02295644|Experimental|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
9519438|NCT03287037|Experimental|tDCS over DLPFC|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.
9519439|NCT03287024|Experimental|BeGrow Stent System|All enrolled subjects will receive the BeGrow Stent System
9823098|NCT02295644|Experimental|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
9823099|NCT02295644|Experimental|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
9823100|NCT02295644|Experimental|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
9823101|NCT02295735|Experimental|Mepilex® Border|If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
9823102|NCT02295735|No Intervention|Control|Standard pressure ulcer prevention according to hospital standard
9823103|NCT02295774|Placebo Comparator|Group A|Biopsy samples collected during standard white light colonoscopy.
9823104|NCT02295774|Active Comparator|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
9823105|NCT02295995|Experimental|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
9823106|NCT02295995|No Intervention|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the Veterans Health Administration (VHA) for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
9827134|NCT02446483|Experimental|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
10115915|NCT04444687||SARS-CoV-2-positive 02|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
10115916|NCT04444687||SARS-CoV-2-positive 03|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
10115917|NCT04444687||Control|Control patients, SARS-CoV-2-negative
9519440|NCT03287011|Active Comparator|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
10115918|NCT04444596|Other|Swab|Conjunctival swab and nasopharyngeal swab for SARS-COV 2
10115919|NCT04444960||Intracoronary physiology and imaging-guided group|
10115920|NCT04444960||Angiography-guided group|
10115921|NCT04444674|Experimental|Group 1- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
9519441|NCT03287011|Experimental|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
9823107|NCT02296099|Experimental|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
9823108|NCT02296099|Placebo Comparator|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
9823109|NCT02296112|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9823110|NCT02296138|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
9823111|NCT02296138|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
9823112|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
9823113|NCT02296190|Experimental|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
9823114|NCT02296190|Placebo Comparator|Placebo|1 dose of placebo via 4 intranasal applications at time 0
9823115|NCT02296242|Experimental|BVD-523|
9823116|NCT02296320|Active Comparator|MEDI4893 5000 mg|Participants will receive a single intravenous (IV) dose of MEDI4893 5000 milligrams (mg) on Day 1 of the study.
9823117|NCT02296320|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
9823118|NCT02296320|Active Comparator|MEDI4893 2000 mg|Participants will receive a single IV dose of MEDI4893 2000 mg on Day 1 of the study.
9823119|NCT02296346|Active Comparator|Corticosteroid arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
9823120|NCT02296346|Experimental|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:~ECP will be administered according to the following schedule:~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
9823121|NCT02296424|Experimental|Canakinumab Dose Reduction|All patients received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab was administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continued to maintain inactive disease for 24 additional weeks, canakinumab was administered at 1mg/kg every 4 weeks. If the patient continued to maintain inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
9823122|NCT02296424|Experimental|Canakinumab Dose Interval Prolongation|All participants received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval was prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continued to be stable with inactive disease for 24 additional weeks, canakinumab dose interval was prolonged to a regimen of 4mg/kg every 12 weeks. If the patient was clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
9823123|NCT02296476|Experimental|Birabresib 80 mg|Participants received 80 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
9823124|NCT02296476|Experimental|Birabresib 120 mg|Participants received 120 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
9823125|NCT02296476|Experimental|Birabresib 160 mg|Participants received 160 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
9823126|NCT02296502||Autism Spectrum Disorder (DSM IV & 5)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in both DSM-IV and DSM-5
9823127|NCT02296502||Autism Spectrum Disorder (DSM 5 only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-5 but not DSM-IV
9823128|NCT02296502||Autism Spectrum Disorder (DSM IV only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-IV but not DSM-5
9823129|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who do not meet diagnostic criteria for ASD.
9827135|NCT02446483|Experimental|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
10115922|NCT04444674|Placebo Comparator|Group 1- placebo|Participants (HIV-negative) will receive two doses of Normal saline (0.9%) in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
9823130|NCT02296775|Experimental|DRL_RI|
9823131|NCT02296775|Active Comparator|Rituxan|
9519442|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
9519443|NCT03286985||General ICU patients|No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay >72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
9823132|NCT02296775|Active Comparator|MabThera|
9823133|NCT02296840|Experimental|Ibuprofen|After undergoing adenotonsillectomy, patients who are randomized into the test intervention arm will receive ibuprofen (10mg/kg/day every 6-8 hours) after surgery.
9823134|NCT02296840|Active Comparator|Hydrocodone-acetaminophen (Control)|After undergoing adenotonsillectomy, patients who are randomized into the control intervention will receive hydrocodone-acetaminophen (0.15mg/kg/day every 4-6 hours).
9823135|NCT02296853|Experimental|Severe Hepatic Impairment Group|Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.
9823136|NCT02296853|Active Comparator|Matched Normal Hepatic Function Group|Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.
9823137|NCT02296892|Experimental|Remimazolam|"Double-blind Remimazolam arm: 5 mg iv for sedation induction, and 2.5 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
9823138|NCT02296892|Placebo Comparator|Placebo|"Double-blind placebo arm as inactive control~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
9823139|NCT02296892|Active Comparator|Midazolam|"Open-label Midazolam arm: 1.75 mg* iv for sedation induction and 1.0 mg* iv for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
9823140|NCT02296931|Active Comparator|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
9823141|NCT02296931|Experimental|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
9823142|NCT02297100|Experimental|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
9823143|NCT02297100|Active Comparator|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
10115923|NCT04444674|Experimental|Group 2a- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
10115924|NCT04444674|Placebo Comparator|Group 2a- placebo|Participants (HIV-negative) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
9823144|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
9823145|NCT02297503|Experimental|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
9823146|NCT02297503|Experimental|Filler alone as single treatment|HA filler alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
9823147|NCT02297516|Experimental|Azzalure/Dysport as single treatment|Azzalure/Dysport as single treatment at initial treatment
9823148|NCT02297516|Experimental|Filler as single treatment|Filler as single treatment at initial treatment
10115925|NCT04444674|Experimental|Group 2b- IP|Participants will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
9823149|NCT02297815||Broad-spectrum antibiotics|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
9823150|NCT02297815||Narrow-spectrum|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.
9823151|NCT02297841|Experimental|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
9823152|NCT02298023|Experimental|Mesenchymal stem cell group|Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.
9823153|NCT02298023|Active Comparator|Active control (fibrin glue) group|Received fibrin glue and normal saline.
9823154|NCT02298023|Placebo Comparator|Control (normal saline )group|Received only normal saline.
9823155|NCT02298179|Experimental|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with no adjuvant.
9823156|NCT02298179|Experimental|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with aluminum hydroxide adjuvant.
9823157|NCT02298179|Experimental|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with MF59 adjuvant.
9823158|NCT02298179|Placebo Comparator|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 1.
9823159|NCT02298179|Experimental|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with no adjuvant.
9823160|NCT02298179|Experimental|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with aluminum hydroxide adjuvant.
9823161|NCT02298179|Experimental|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with MF59 adjuvant.
9823162|NCT02298179|Placebo Comparator|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 2.
9823163|NCT02298179|Experimental|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with no adjuvant.
9823164|NCT02298179|Experimental|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with aluminum hydroxide adjuvant.
9823165|NCT02298179|Experimental|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with MF59 adjuvant.
9823166|NCT02298179|Placebo Comparator|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 3.
9823167|NCT02298192|Experimental|Once weekly titration|
9823168|NCT02298192|Experimental|Twice weekly titration|
9823169|NCT02298322|Experimental|CoolSculpting Treatment|The intervention is the CoolSculpting System.
9823170|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
9823171|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
9823172|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
9823173|NCT02298491|Experimental|H.P. Acthar Gel|
9823174|NCT02298803|Other|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
9823175|NCT02298842|Active Comparator|Platelets Stored in Plasma|Platelets stored in Plasma
9823176|NCT02298842|Experimental|Test Platelets Stored in InterSol|Platelets stored in InterSol
9823177|NCT02298868|Experimental|Treatment|All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
9823178|NCT02298933|Experimental|Eculizumab|1200 mg IV infusion over 30-40 min
9823179|NCT02298946|Experimental|DL1 - CTX, SBRTx1 day, & AMP-224|Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0. Stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days for a total of 6 doses
9823180|NCT02298946|Experimental|DL2 - CTX, SBRTx3 days, and AMP-224|Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.
9823181|NCT02299050|Other|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day~Other Names:~Bromocriptine Mesylate Quick Release"
9823182|NCT02299076|Other|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
9823183|NCT02299076|Active Comparator|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
9823184|NCT02299089|Experimental|CAM2029 10 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
9823185|NCT02299089|Experimental|CAM2029 20 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
9823186|NCT02299089|Experimental|CAM2029 10 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
9823187|NCT02299089|Experimental|CAM2029 20 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
10182595|NCT03772470|Experimental|Lottery Incentive|Lottery airtime incentive given to one in 20 participants
9823188|NCT02299141|Experimental|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle
9823189|NCT02299167|Experimental|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
9823190|NCT02299258|Active Comparator|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
9823191|NCT02299258|Experimental|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
9823192|NCT02299297|Experimental|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
9823193|NCT02299336|Other|PRN (pro re nata)|2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks
9823194|NCT02299349|Experimental|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
9823195|NCT02299349|Active Comparator|concentrated multi drug injection|concentrated multi drug periarticular injection
9823196|NCT02299375|Experimental|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
9823197|NCT02299375|Experimental|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
9823198|NCT02299388|Active Comparator|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
9823199|NCT02299388|Placebo Comparator|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
9823200|NCT02299427|Experimental|dog safety|2 weeks of regular use of website on child dog safety developed for this research
9823201|NCT02299427|Active Comparator|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
9823202|NCT02299479|Experimental|Intervention|Volunteers will wear a Dexcom G4 Platinum CGM device as well as an activity monitor. Data will be uploaded to study investigators on a regular basis, and recommendations will be made to adjust insulin dosing based upon analysis of these data.
9823203|NCT02299570|Active Comparator|Group A|Two enemas of RBX2660 (microbiota suspension) administered 7 days apart
9823204|NCT02299570|Placebo Comparator|Group B|Two enemas of placebo administered 7 days apart
9823205|NCT02299570|Active Comparator|Group C|1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo administered 7 days apart
9823206|NCT02299635|Experimental|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
9823207|NCT02299791|Active Comparator|Early Intervention|6 study clinics received the ALL intervention starting 6/1/11
9823208|NCT02299791|Active Comparator|Late implementation|5 study clinics received the ALL intervention starting 6/1/12
9823209|NCT02299869|Other|Group 1 - Verde (Competitor-control) vs. Green (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
9823210|NCT02299869|Other|Group 2 - Cinza (Competitor-control) vs. Grey (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
9823211|NCT02299869|Other|Group 3 - Esmeralda (Competitor-control) vs. Jade (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
9823212|NCT02299869|Other|Group 4 - Azul (Competitor-control) vs. Blue (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
9823213|NCT02300025|Experimental|Cohort 1: Normal function|
9823214|NCT02300025|Experimental|Cohort 2: Mild Hepatic Impairment|
9823215|NCT02300025|Experimental|Cohort 3: Moderate Hepatic Impairment|
9823216|NCT02300025|Experimental|Cohort 4: Severe Hepatic Impairment|
9823217|NCT02300077|Active Comparator|Control|Control (Intra-operative administration of opioids, other than methadone)
9823218|NCT02300077|Active Comparator|Treatment methadone 0.1 mg/kg|methadone 0.1 mg/kg
9823219|NCT02300077|Active Comparator|Treatment methadone 0.15 mg/kg|
9823220|NCT02300103|Experimental|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
9823221|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
9823222|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
9823223|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
9823224|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
9823225|NCT02300220|Active Comparator|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
9823226|NCT02300220|Placebo Comparator|Placebo|one capsule, twice daily for 1 week.
9823227|NCT02300259|Experimental|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
9823228|NCT02300259|Experimental|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
9823229|NCT02300259|Experimental|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
9823230|NCT02300259|Experimental|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
9823231|NCT02300259|Experimental|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
9823232|NCT02300259|Experimental|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
9823233|NCT02300259|Experimental|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
9823234|NCT02300259|Experimental|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
9823235|NCT02300285|Experimental|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
9823236|NCT02300285|Placebo Comparator|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
9823237|NCT02300298|Experimental|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
9823238|NCT02300311|Experimental|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
9823239|NCT02300311|Placebo Comparator|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
9823240|NCT02300545|Experimental|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
9823241|NCT02300558|Experimental|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
9823242|NCT02300558|Experimental|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
9823243|NCT02300610|Experimental|Dose Escalation|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).
9823244|NCT02300610|Experimental|Dose Expansion|Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
9823245|NCT02300727|Active Comparator|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
9823246|NCT02300727|Experimental|Curcumin|Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
10115926|NCT04444674|Placebo Comparator|Group 2b- placebo|Participants will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
10182596|NCT03772314|Active Comparator|Modafinil|Participants in this study arm will take modafinil.
9823247|NCT02300727|Other|Curcumin-MTD|"Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)"
9823248|NCT02300987|Active Comparator|LEE011|600 mg daily dosing days 1-21 of a 28 day cycle
9823249|NCT02300987|Placebo Comparator|Placebo Arm|600 mg daily dosing days 1-21 of a 28 day cycle
9965820|NCT01253486|Experimental|Disease-related expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period
9823250|NCT02301039|Experimental|Soft tissue sarcoma|Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
9823251|NCT02301039|Experimental|Bone sarcoma|Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]. Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
9823252|NCT02301039|Experimental|Expansion|Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
9823253|NCT02301143|Experimental|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.~Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR~Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR~Surgical intervention"
9823254|NCT02301169|Active Comparator|T4P1001|
9823255|NCT02301169|Sham Comparator|Placebo|
9823256|NCT02301299||Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
9823257|NCT02301364|Experimental|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
9823258|NCT02301377|Active Comparator|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
9823259|NCT02301377|No Intervention|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
9823260|NCT02301390|Active Comparator|Amiodarone only|The control group will receive amiodarone only.
9823261|NCT02301390|Experimental|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
10182597|NCT03772314|Experimental|Amphetamine-dextroamphetamine|Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).
9823262|NCT02301403|Active Comparator|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
9823263|NCT02301403|Experimental|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
9823264|NCT02301416|Experimental|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
9823265|NCT02301416|No Intervention|Historical Control|Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment
9823266|NCT02301429|Experimental|Model 20105|Receiving the model 20105 Lead
9823267|NCT02301546|Experimental|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
9823268|NCT02301546|Active Comparator|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
9823269|NCT02301624|Experimental|Eculizumab/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams [mg]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
9823270|NCT02301624|Experimental|Placebo/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
9823271|NCT02301793|Experimental|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.~Intervention: Nurse education in contemporary format"
9823272|NCT02301793|Active Comparator|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.~Intervention: Nurse education in traditional format"
9668576|NCT05243927|Experimental|Aerobic exercise group|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes, 3 days a week for 8 weeks.
9823273|NCT02301897|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
9823274|NCT02301897|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
9823275|NCT02301897|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
9823276|NCT02301936|Experimental|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
9823277|NCT02301936|Experimental|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
9823278|NCT02301975|Experimental|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
9823279|NCT02301975|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
9823280|NCT02301975|Experimental|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
9823281|NCT02301988|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
9823282|NCT02301988|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
9823283|NCT02302066|Experimental|Group 1 (TDV 2-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 91. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 365.
9823284|NCT02302066|Experimental|Group 2 (TDV 1-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Day 1. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 91 and 365.
9823285|NCT02302066|Experimental|Group 3 (TDV 1-Dose + Booster)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 365. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 91.
9823286|NCT02302066|Placebo Comparator|Group 4 (Placebo Control)|Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 1, 91 and 365.
9823287|NCT02302092|Experimental|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
9823288|NCT02302092|Active Comparator|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
9823289|NCT02302157|Experimental|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
9823290|NCT02302222|Active Comparator|Standard of Care|dry sterile dressing/gauze and steristrips
9823291|NCT02302222|Experimental|Customizable|Prevena Customizable Dressing with ActiV.A.C. Therapy Unit
9823292|NCT02302339|Experimental|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
9823293|NCT02302339|Experimental|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
9823294|NCT02302339|Experimental|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
9823295|NCT02302339|Experimental|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
9823296|NCT02302716|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
9528271|NCT03212547|Experimental|Experimental group|"Verbal interventions made on infants (accompanied by their mothers) who presents sustained social withdrawal detected on the child consultations (at 2, 6 and 12 months of corrected gestational age), made by neonatologists certifieds in the assess of Alarm Distress Baby Scale. Theintervention is described in a guide for Promotion of verbal interventions for interaction , and will be supplemented with a written guideline for parents."
9827665|NCT02464033|Experimental|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
10182598|NCT03772431|Experimental|Male Informational|Male voice, informational introduction
10182599|NCT03772431|Experimental|Male Motivational|Male voice, motivational introduction
9668577|NCT05243927|Active Comparator|Stabilization exercise group|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes, 3 days a week for 8 weeks.
9823297|NCT02302716|Active Comparator|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
9823298|NCT02302807|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
9823299|NCT02302807|Active Comparator|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
9823300|NCT02302846|Experimental|Ixazomib|Participants receive 4 mg oral dose of Ixazomib on Days 1, 8 and 15 of each 28-day cycle.
9823301|NCT02303041|Experimental|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
9823302|NCT02303041|Experimental|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
9823303|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
9823304|NCT02303093||Panzyga|Patient receiving panzyga
9823305|NCT02303184|Experimental|4 mg CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
9823306|NCT02303184|Active Comparator|sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
9823307|NCT02303262|Experimental|Mocetinostat and gemcitabine|For each 21-day cycle, gemcitabine is administered on days 5 and 12 and mocetinostat is administered 3 days a week.
9823308|NCT02303574|Experimental|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
9823309|NCT02303574|Placebo Comparator|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
9823310|NCT02303704|Active Comparator|multiport antegrade cardioplegia|Patients who received multiport antegrade cardioplegia and continuous controlled warm blood perfusion through vein grafts.
9823311|NCT02303704|Active Comparator|Aortic root antegrade cardioplegia|Patients who underwent routine conventional CABG with antegrade aortic root cardioplegia without warm blood perfusion
9823312|NCT02303743|Active Comparator|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
9528272|NCT03212547|No Intervention|Control group|Control group: infants will assist at child consultations (at 2, 6 and 12 months of corrected gestational age) whit non trained neonatologists. However, these group will receive a development stimulation guide adapted of the ministerial guides for the stimulation of development of the Ministry of Health of Chile.
9823313|NCT02303743|Active Comparator|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
9823314|NCT02303977|Experimental|Gemcitabine + Paciltaxel|All patients were treated intravenously with albumin-bound paclitaxel at 100 mg/m2 plus gemcitabine at 1000 mg/m2 on days 1 and 8 of each three-week cycle.
9823315|NCT02303990|Experimental|Single arm|Hypofractionated RT and Pembro
9823316|NCT02304159|Experimental|Group A - 16 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks
9823317|NCT02304159|Active Comparator|Group B - 24 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks
9823318|NCT02304432|Experimental|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
9823319|NCT02304432|Experimental|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
9823320|NCT02304432|Experimental|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
9823321|NCT02304484|Experimental|Evolocumab|Participants received 420 mg evolocumab once a month for up to 2 years.
9823322|NCT02304705|Placebo Comparator|Placebo|Placebo three times per day, orally
9823323|NCT02304705|Active Comparator|Sildenafil|Sildenafil 20 mg three times per day, orally
9823324|NCT02304757|Experimental|99Tc-MDP|15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.
9823325|NCT02304757|Active Comparator|Fosamax|70mg po every week for 12 months.
9823326|NCT02304926|Experimental|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
9823327|NCT02304926|Experimental|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
9823328|NCT02305017|Experimental|Period 1 OPC + Paracetamol; Period 2 OPC|Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
9823329|NCT02305017|Experimental|Period 1 OPC; Period 2 OPC+ Paracetamol|Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
9823330|NCT02305238|Experimental|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
9823331|NCT02305238|Experimental|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
9823332|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
9823333|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
9823334|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
9823335|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
9823336|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
9823337|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
9827136|NCT02446496|Experimental|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
9827137|NCT02446496|Experimental|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
9827138|NCT02446613|Other|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
9827139|NCT02446691|Experimental|MenACWY Group|Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
9827140|NCT02446717|Experimental|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
9827141|NCT02446717|Experimental|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
9827142|NCT02446717|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
9827143|NCT02446717|Experimental|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
9827144|NCT02446717|Experimental|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
9827145|NCT02446743|Experimental|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
9827146|NCT02446743|Active Comparator|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
9528273|NCT03212235|Experimental|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
9827147|NCT02446769|Experimental|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
9827666|NCT02464059|Experimental|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
9823338|NCT02305316|Experimental|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
9823339|NCT02305316|Experimental|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
9823340|NCT02305329|Experimental|Group 1 BIA 9-1067 25 mg|Period 1 - 5x5 mg OPC Period 2 - 1x25 mg OPC
9823341|NCT02305329|Experimental|Group 2 BIA 9-1067 25 mg|Period 1 - 1x25 mg OPC Period 2 - 5x5 mg OPC
9823342|NCT02305329|Experimental|Group 1 BIA 9-1067 50 mg|Period 1 - 2x25 mg OPC Period 2 - 1x50 mg OPC
9823343|NCT02305329|Experimental|Group 2 BIA 9-1067 50 mg|Period 1 - 1x50 mg OPC Period 2 - 2x25 mg OPC
9823344|NCT02305381|Experimental|Semaglutide 0.5 mg/Week|
9823345|NCT02305381|Experimental|Semaglutide 1.0 mg/Week|
9823346|NCT02305381|Placebo Comparator|Semaglutide Placebo 0.5 mg/Week|
9823347|NCT02305381|Placebo Comparator|Semaglutide Placebo 1.0 mg/Week|
9823348|NCT02305446|Experimental|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
9823349|NCT02305563|Experimental|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
9823350|NCT02305563|Experimental|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
9823351|NCT02305563|Experimental|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
9823352|NCT02305563|Other|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
9823353|NCT02305758|Experimental|Veliparib + modified FOLFIRI ± bevacizumab|Dosing of oral veliparib (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Modified FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle.
9823354|NCT02305758|Placebo Comparator|Placebo + FOLFIRI ± bevacizumab|Dosing of oral placebo (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Standard FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) on Day 1 of each 14-day cycle.
9823355|NCT02305797|Experimental|EDG004|EDG004 - Extended release lorazepam capsules
9668578|NCT05243888|No Intervention|control|The control arm corresponds to women receive a conventional invitation letter sent by post to the home address of eligible women recommending them to make an appointment to a doctor or a midwife for the collection of a cervical specimen.
9823356|NCT02305797|Placebo Comparator|Placebo|Placebo
9823357|NCT02305849|Experimental|Peficitinib 100 mg|Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
9965821|NCT01253486|Active Comparator|Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
9528274|NCT03212157|Experimental|GT1|Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
9668579|NCT05243888|Experimental|vaginal self-sampling|eligible women receive at their home address a vaginal self-sampling kit in addition to the conventional invitation letter
9668580|NCT05243888|Experimental|urinary self-sampling|eligible women receive at their home address a urine collection kit in addition to the conventional invitation letter
9823358|NCT02305849|Experimental|Peficitinib 150 mg|Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
9823359|NCT02305849|Placebo Comparator|Placebo|Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.
9823360|NCT02305888|Experimental|LEO 43204, 0.018% once daily for 3 days|
9823361|NCT02305888|Experimental|LEO 43204, 0.037% once daily for 3 days|
9823362|NCT02305888|Experimental|LEO 43204, 0.1% once daily for 3 days|
9823363|NCT02306265|Other|DBT and FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental).
9823364|NCT02306694|Experimental|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
9823365|NCT02306759|Experimental|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
9823366|NCT02306759|Placebo Comparator|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
9823367|NCT02306850|Experimental|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
9823368|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
9823369|NCT02307123||HEMS treated patients|Patients whose airways were secured by the HEMS physician.
9823370|NCT02307266|Experimental|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
9823371|NCT02307266|Experimental|Standard of care|Subjects will receive standard-of-care instructions only.
10182600|NCT03772431|Experimental|Female Informational|Female voice, informational introduction
9823372|NCT02307266|Experimental|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
9823373|NCT02307318|Other|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
9823374|NCT02307370|Experimental|Turbo-Elite Atherectomy|
9823375|NCT02307513|Experimental|Placebo / Apremilast|Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
9823376|NCT02307513|Experimental|Apremilast|Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
9823377|NCT02307526|Experimental|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
9823378|NCT02307552|Experimental|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
9823379|NCT02307682|Experimental|Brolucizumab 3 mg|Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
9823380|NCT02307682|Experimental|Brolucizumab 6 mg|Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
9823381|NCT02307682|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
9823382|NCT02307838|Other|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
9823383|NCT02307916|Experimental|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
10115927|NCT04444674|Experimental|Group 3- IP|Participants (HIV-positive) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
10115928|NCT04444674|Placebo Comparator|Group 3- placebo|Participants (HIV-positive) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
10115929|NCT04444856||NovoSeven|Women with severe postpartum haemorrhage treated with NovoSeven
10115930|NCT04444856||Standard of care|Women with severe postpartum haemorrhage treated with standard of care
10115931|NCT04444648||One groupe without distinction of age, sexe, and pathology.|"Patients with strok in coma, with or without wake up, and with disorder of consciousness. No limit in age (maybe give the younger age).~We obtain this data from medical record. Every assessment was made of clinical purposes.~We use the Glasgow coma recovery scale for assessment of behavior to check the variation of wakefulness. The scale was performed by the nursing staff every 2 to 8 hours depending on the severity of the medical condition.~The continuous analysis of neurophysiologic data was based on EEG with a bipolar montage composed of the less noisy electrodes per recording period.~The EEG features will include: spectral analysis (relative and absolute power in 4 canonical bands: Delta/Theta/Alpha/Beta) and complexity analysis (DFA, determinism, SVD entropy and permutation entropy).~The patient outcome at the ICU and hospital discharges were collected from the medical files."
10115932|NCT04444765||Patients with bicarbonate-based intermittent dialysis|Dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid).
10115933|NCT04444765||Patients with acetate free biofiltration dialysis|Acetate free biofiltration (AFB-K)is a technique that does not require dialysate acidification
10115934|NCT04444635|Active Comparator|Serratus Anterior Plan block plus fentanyl infusion|The patients will receive serratus anterior block in addition to continous intraoperative fentanyl infusion.
10115935|NCT04444635|Active Comparator|Fentanyl infusion only|The patient will receive fentanyl infusion only.
9527662|NCT03218033|No Intervention|Control|Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules for 8 weeks. At the end of each module there were questions pertaining to the subject of each module. The control group answered the questions in provided journals and these were sent back to the investigator. All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies.
9823384|NCT02307916|Placebo Comparator|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
9823385|NCT02308007|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
9823386|NCT02308007|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
9823387|NCT02308007|Active Comparator|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
9965822|NCT01253486|Sham Comparator|Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
10115936|NCT04444479|Experimental|PICC catheter placement|Study subjects in whom placement of the PICC catheter is indicated
10115937|NCT04444466|Experimental|UCB8600|Study participants randomized to this arm will receive various single doses and multiple doses of UCB8600 administered to various cohorts.
10115938|NCT04444466|Placebo Comparator|Placebo|Study participants randomized to this arm will receive various single doses and multiple doses of Placebo administered to various cohorts.
9823388|NCT02308020|Experimental|Part A Abemaciclib: HR+, HER2+ Breast Cancer|Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9823389|NCT02308020|Experimental|Part B Abemaciclib: HR+, HER2- Breast Cancer|"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET).~Participants may continue to receive treatment until discontinuation criteria are met."
9823390|NCT02308020|Experimental|Part C Abemaciclib: Surgical Resection|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9823391|NCT02308020|Experimental|Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9823392|NCT02308020|Experimental|Part E Abemaciclib: Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9823393|NCT02308020|Experimental|Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9823394|NCT02308033|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
9823395|NCT02308033|Placebo Comparator|Gel vehicle|One applicator full at bedtime
9823396|NCT02308046|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
9823397|NCT02308046|Placebo Comparator|Gel vehicle|One applicator full at bedtime
9823398|NCT02308124|Experimental|Midodrine|Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
9823399|NCT02308124|Experimental|Pyridostigmine|Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
9823400|NCT02308124|Experimental|Midodrine + Pyridostigmine|Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
9823401|NCT02308163|Placebo Comparator|Placebo|Participants were assigned to receive placebo to peficitinib once a day until week 12.
9823402|NCT02308163|Experimental|Peficitinib 100 mg|Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.
9823403|NCT02308163|Experimental|Peficitinib 150 mg|Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.
9965823|NCT01253486|No Intervention|Control condition|Participants in the control condition do not receive any intervention and complete only the assessments
9823404|NCT02308163|Active Comparator|Etanercept|Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.
9823405|NCT02308189|Active Comparator|Exercise|Low load resistance exercise training
9823406|NCT02308189|Experimental|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
9823407|NCT02308228|Experimental|Metformin|Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.
9823408|NCT02308228|Placebo Comparator|Placebo, Sugar Pill|Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.
9823409|NCT02308371|Experimental|Prospective|Patients in this arm will have fluid given based on standard clinical data (blood pressure, heart rate, lactate level, urine output) in addition to information provided by automated pulse pressure variation (PPV). PPV will be followed for first 48 hours after recruitment to the study. Fluid (normal saline, albumin 5%, hetastarch per the clinician preference) will be given in 5cc/kg increments for PPV> 13 (in addition to standard clinical data) until PPV < 13.
9823410|NCT02308371|No Intervention|Retrospective|Patients in this arm were previously admitted to the PICU and were given fluid based on standard clinical data. PPV was not used to guide therapy in this group of patients.
9823411|NCT02308501|Active Comparator|Lastacaft ®|One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
9823412|NCT02308501|Placebo Comparator|Tears Naturale ®|One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
9823413|NCT02308540|Experimental|Adult SIILPCV10|Single dose of SIILPCV10 on day 0
9823414|NCT02308540|Active Comparator|Adult Pneumovax 23|Single dose of Pneumovax 23 on day 0
9823415|NCT02308540|Experimental|Toddler SIILPCV10|Single dose of SIILPCV10 on day 0
9823416|NCT02308540|Active Comparator|Toddler Prevenar 13|Single dose of Prevenar 13 on day 0
9823417|NCT02308540|Experimental|Infants SIIL PCV10|A three-dose series of SIILPCV10 on day 0, day 28, and day 56
9823418|NCT02308540|Active Comparator|Infants Prevenar 13|A three-dose series of Prevenar 13 on day 0, day 28, and day 56
9823419|NCT02308540|Experimental|Infant Booster Dose SIILPCV 10|One dose of SIILPCV 10 at 9 months of age
9823420|NCT02308540|Active Comparator|Infant Booster Dose Prevenar 13|One dose of SIILPCV 10 at 9 months of age
9823421|NCT02308696|Experimental|Peer-to-peer support (non-randomized)|225 older adults that are currently receiving peer-to-peer support
9823422|NCT02308696|Active Comparator|Standard Services (non-randomized)|225 older adults will continue receiving standard community services
9823423|NCT02308748|Active Comparator|Dofetilide|Dofetilide alone arm
9823424|NCT02308748|Active Comparator|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
9823425|NCT02308748|Active Comparator|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
9823426|NCT02308748|Active Comparator|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
9823427|NCT02308748|Placebo Comparator|Placebo|Placebo (#2 gelcap and intravenous saline)
9823428|NCT02309099|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
9823429|NCT02309112|Experimental|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
9823430|NCT02309112|Experimental|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
9823431|NCT02309112|Experimental|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
9823432|NCT02309138|Active Comparator|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of >130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
9823433|NCT02309138|Active Comparator|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
9823434|NCT02309294|Experimental|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
9823435|NCT02309359|Placebo Comparator|Placebo q2w + MTX|Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
9823436|NCT02309359|Experimental|ALX-0061 75 mg q4w + MTX|ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
9823437|NCT02309359|Experimental|ALX-0061 150 mg q4w + MTX|ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
9823438|NCT02309359|Experimental|ALX-0061 150 mg q2w + MTX|ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
9823439|NCT02309359|Experimental|ALX-0061 225 mg q2w + MTX|"ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.~The last study drug administration was at the Week 22 visit."
9823440|NCT02309372|Experimental|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
9823441|NCT02309372|No Intervention|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
10115939|NCT04444726|Experimental|"Phototherapy PUVA +traditional medical treatmentn"|"patient sock his hands in a bath containing water with the constitution of psoralen meladinine  capsule for 20 minutes then irradiated at the UVA device for 3 sessions per week for 8 weeks Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
9823442|NCT02309411|Experimental|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
9823443|NCT02309489|Experimental|Intervention|"Receive standard maternity care~Woman and partner attend one extra couple counselling session during pregnancy (A)~Partner attends one group education session for men (B)~Partner participates in pre-discharge consultation (C)"
10115940|NCT04444726|Experimental|Tap Water Iontophoresis + Traditional medical treatment|"Tap-water iontophoresis was given 3 times weekly for 10 min The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30mA. Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
9823444|NCT02309489|No Intervention|Control|"Receive standard maternity care~No active encouragement of partner involvement, no extra sessions offered"
9823445|NCT02309515|Experimental|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
9823446|NCT02309515|Active Comparator|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
9823447|NCT02309723|Experimental|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
9823448|NCT02309723|Experimental|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
9823449|NCT02309723|No Intervention|No beta amyloid information|
9823450|NCT02309944|Active Comparator|Standard Wound Closure|Standard surgical closure of the fascia and skin.
9823451|NCT02309944|Experimental|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
9823452|NCT02310100|Experimental|TactiCath Quartz|TactiCath Quartz treatment
9823453|NCT02310126|Active Comparator|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
9823454|NCT02310126|Active Comparator|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
9823455|NCT02310568|Experimental|PF 06372865 2.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
9823456|NCT02310568|Experimental|PF 06372865 7.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
9823457|NCT02310568|Experimental|Placebo then PF 06372865 2.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
9823458|NCT02310568|Experimental|Placebo then PF 06372865 7.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
9823459|NCT02310568|Placebo Comparator|Placebo followed by placebo.|Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
9823460|NCT02310581|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
9823461|NCT02310581|Experimental|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
9823462|NCT02310581|Experimental|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
9823463|NCT02310581|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
9823464|NCT02310646|Active Comparator|Treatment group 1|Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
10182601|NCT03772431|Experimental|Female Motivational|Female voice, motivational introduction
9823465|NCT02310646|Active Comparator|Treatment group 2|Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
9823466|NCT02310672|Experimental|Macitentan|All patients take open-label macitentan 10mg o.d.
9823467|NCT02310750|Experimental|PF-06700841 Oral Solution/Suspension|
9823468|NCT02310750|Experimental|PF-06700841 Tablet|
9823469|NCT02310750|Placebo Comparator|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
9823470|NCT02310763|Experimental|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
9823471|NCT02310763|Placebo Comparator|Placebo|Matching Placebo
9823472|NCT02310776|Other|Automated & Handheld breast US exams|"Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.~Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
9823473|NCT02310789|Experimental|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
9823474|NCT02310906|Experimental|Part 1: SRP-4053|Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
9823475|NCT02310906|Placebo Comparator|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
9823476|NCT02310906|Experimental|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
9823477|NCT02310906|No Intervention|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
9823478|NCT02311153|Active Comparator|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
9823479|NCT02311153|Experimental|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
10115941|NCT04444726|Active Comparator|traditional medical treatment|"Traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
9668581|NCT05243875|Experimental|Vaccine Concierge|The experimental group will be offered the intervention, involving COVID-19 education, testing and vaccination information, as well as scheduling appointments and arranging transportation for testing/vaccination.
9668582|NCT05243875|Other|Wait-List Control|The wait-list control group will only receive brief COVID-19 education and information about clinical guidelines for testing and the benefits of vaccination. Control group participants who have not been tested/vaccinated at 1-month follow-up will be asked about their interest in the experimental intervention.
9694335|NCT04790526|Experimental|Group B|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
9694336|NCT04790526|Experimental|Group C|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
9694337|NCT04790526|Experimental|Group D|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
9694338|NCT04790292|Active Comparator|group M|group M 10mg morphine +0.25% bupivacaine
9694339|NCT04790292|Active Comparator|group MD|group MD 10mg morphine + 8mg dexamethasone +0.25% bupivacaine
9694340|NCT04790539|Experimental|SHR-1210+Paclitaxel-albumin+Carboplatin|SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first day of each cycle, with intravenous drip.
9694341|NCT04790357|Other|Reference strategy|correspond to the reference techniques according to the current guidelines in the etiological work up of ischemic strokes and TIA
9694342|NCT04790357|Other|Evaluated strategy|correspond to perform the cci-MR: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
9694343|NCT04790331|Experimental|verapamil group|verapamil group who will receive verapamil 80 mg PO 3 hours preoperative
9694344|NCT04790331|Experimental|Ditiazim|Diltiazim group will receive Diltiazim 90mg PO 3 hours preoperative
9694345|NCT04790331|Experimental|placebo group|Placebo oral tablet
9694346|NCT04790318|Active Comparator|General Anesthesia +TiQLB|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume limited to 20 ml
9694347|NCT04790318|Active Comparator|General Anesthesia+ Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
9694348|NCT04790253|Active Comparator|PCI followed by brain MR surveillance|"Prophylactic cranial irradiation will be delivered at the dose of 25 Gy in 10 fractions to the whole brain.~Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 months.~Extracranial imaging is recommended and will be performed per institutional standards at the discretion of the treating physician."
9694349|NCT04790253|No Intervention|MRI Active Surveillance|Patients must have a brain MRI performed within 28 days before randomisation and at 3, 6, 9, 12, 18 and 24 month. Clinical evaluation will be performed every 3 months.
9694350|NCT04790162|Active Comparator|Meditation Intervention|Heartfulness meditation
9694351|NCT04790162|No Intervention|Control|Wait listed control group
9694352|NCT04790149|Sham Comparator|Conventional Group|Conventional usual Rehabilitation is administered to a group of patients without any effect on their recovery
9694353|NCT04790149|Experimental|NEUROM|participants received the new protocol of a method called NEUROM consisting of 3 phases of treatment : Motor Imagery training, active rehabilitation and functional rehabilitation
9694354|NCT04790149|Experimental|NEUROM combined with tDCS|same as the second arm of NEUROM combined with transcranial direct stimulation
9694355|NCT04790110||Studie A ESO - monitoring|Patients that present themselves at the clinic through referral from their dentist with tooth wear, who have no request for help, receive a non-restorative 'counseling & monitoring' strategy , in which appropriate preventive measures are recommended and wear and tear is monitored and recorded by periodically taking intra-oral photographs and 3D scans
9694356|NCT04790136|Experimental|GLA-015|GLA-015 (Glatt Pharmaceutical Services GmbH & Co. KG, Germany); 5.051 g granules containing 1500 mg cannabidiol to be dispersed in water; oral multiple dose administration twice daily over 7 consecutive days after a light meal
9694357|NCT04790136|Active Comparator|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|"DAC C-052 Cannabidiol / NRF 22.10 Ölige Cannabidiol-Lösung 100 mg/ml (Oily cannabidiol solution 100 mg/ml) (Glatt Pharmaceutical Services GmbH & Co. KG, Germany; according to DAC/NRF specifications); 15 ml solution containing 1500 mg cannabidiol; oral multiple dose administration twice daily over 7 consecutive days after a light meal"
9694358|NCT04790279|Experimental|Amlodipine|
9694359|NCT04790279|Active Comparator|Nifedipine ER|
9694360|NCT04790006|Experimental|TG103|TG103 will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
9694361|NCT04790006|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
9694362|NCT04790097|Experimental|Simultaneous In-Field Boost on FET-PET positive target volumes|
9694363|NCT04790084||Healthy-Myopia-CSC|Cross-sectional study, no intervention, only collecting OCT,OCTA images and other eye parameters of patients.
9694364|NCT04789967|Active Comparator|Guided Imagery (GI)|A 8 minute audio that focuses on evoking mental images in reducing the abdominal bloating sensation in patients
10182602|NCT03772249|Experimental|Cohort A1 DCR-HBVS|Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
9528275|NCT03212157|Experimental|GT2|Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
9668583|NCT05243862|Experimental|PolyPEPI1018 plus Atezolizumab|Participants receive every 3 weeks PolyPEPI1018 CRC Vaccine (Emulsified solution, 0.2 mg/peptide, 6 peptides total, and Montanide™ ISA51VG adjuvant), by SC injection in combination with Atezolizumab (Injectable solution,1200mg/20mL) by IV injection.
9668584|NCT05243849||Ischemic Stroke|The diagnosis of ischemic stroke was obtained from previous diagnostic reports or electronic medical records, according to the diagnostic criteria from the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
9668585|NCT05243849||Control|Inclusion criteria for healthy controls were no history of ischemic stroke or other neurological and ocular diseases.
9668586|NCT05243810|Experimental|Intervention|A prospective, single-arm, repeated measures study pilot study will be coordinated on the use of EPC Silver Wound Gel in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection classification, wound ecology, and immunological biomarkers, as well as to clarify parameters for a potential future study.
9668587|NCT05243797|Experimental|Arm A: Teclistamab-Lenalidomide (Tec-Len)|
9668588|NCT05243797|Active Comparator|Arm B Lenalidomide Alone (Len)|Lenalidomide orally.
9668589|NCT05243784|Experimental|Intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of 8 weeks and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
9668590|NCT05243784|No Intervention|Control|Students in the control group (CG) will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT program once the interventions are completed.
9668591|NCT05243771||Rectal resection with diverting stoma|Patients operated for rectal cancer with rectal resection and diverting stoma.
9668592|NCT05243771||Rectal resection without diverting stoma|Patients operated for rectal cancer with rectal resection without diverting stoma.
9668593|NCT05243771||Rectal resection with primary colostomy|Patients operated for rectal cancer with rectal resection with primary colostomy.
9668594|NCT05243758|Active Comparator|Group video fiberscope of experienced practitioner|More experienced physician: endotracheal intubation with video fiberscope Assoc. Dr. The group in which Ersin Köksal performed endotracheal intubation using a video fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
9668595|NCT05243758|Active Comparator|Group video laryngoscope of experienced practitioner|More experienced physician: Endotracheal intubation with DCI video laryngoscopeThe group in which Assoc. Dr. Ersin Köksal performed endotracheal intubation using a DCI video laryngoscope(Storz DCI Video Laryngoscope (Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
9668596|NCT05243758|Active Comparator|Group video fiberscope of less experienced practitioner|Endotracheal intubation with video fiberscope: The group in which DrHalil Cebeci applied endotracheal intubation using a video fiberscope( Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients. Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
9668597|NCT05243758|Active Comparator|Group video laryngoscope of less experienced practitioner|Endotracheal intubation with DCI video laryngoscope:The group in which Dr.Halil Cebeci applied endotracheal intubation using a DCI video laryngoscope(Karl Storz GmbH &Co. KG, Tuttlingen, Germany) consisted of 15 patients.Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
9668598|NCT05243706|No Intervention|Control group|30 patients will receive Vincristine 1.5 mg/m2 (maximum: 2 mg) or Vinblastine 6 mg/m2 according to treatment protocol.
9668599|NCT05243706|Experimental|Loratadine group|30 patients will receive One tablet 10 mg orally once daily starting with vincristine or vinblastine administration for three cycles
9668600|NCT05243706|Experimental|diosmin 450mg / hesperidin 50 mg group|30 patients will receive 50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet orally twice daily starting with vincristine or vinblastine administration for three cycles
9668601|NCT05243693|Experimental|Brentuximab vedotin and DHAP|A clinical study of safety and efficacy of treatment with Brentuximab vedotin and DHAP in patients with relapsed/refractory Hodgkin lymphoma
9668602|NCT05243680|Experimental|Participants diagnosed with asthma receiving GSK3511294 (Depemokimab)|
9668603|NCT05243654|Experimental|Metformin 1000mg extended release (XR) once daily + standard-of-care MDT|Metformin hydrochloride 500mg XR tablets once daily by mouth for 2 weeks, escalating to a target dose of 1000mg XR once daily for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
9668604|NCT05243654|Placebo Comparator|Placebo + MDT|Matching metformin placebo tablets once daily by mouth for 2 weeks, escalating to two tablets for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
9694365|NCT04789967|Active Comparator|Progressive Muscle Relaxation (PMR)|A 8 minute audio that focuses on contracting certain muscle groups and relaxing it progressively in reducing the abdominal bloating sensation in patients
10115942|NCT04444830|No Intervention|Standard|"To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed a standard postoperative regimen of Acetaminophen 650 mg PO q 6-8 hours + Ibuprofen 600 mg PO q 6-8 hours + rescue narcotics (Oxycodone 5-10 mg PO q 4-6 hours or if allergic to Oxycodone, Norco 5-10mg/325mg PO q 4-6 hours) for breakthrough pain"
10182603|NCT03772249|Placebo Comparator|Cohort A1 Placebo|Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
9668605|NCT05243641|Experimental|Part 1b (dose escalation)|This portion of the study will enroll a maximum of 27 patients in the dose-finding trial including the possibility of adding up to 6 additional ER+ patients in a safety assessment of aromatic inhibitor treatment
9668606|NCT05243641|Experimental|Part 2 (dose expansion)|This portion of the study will enroll a maximum of 29 patients
9668607|NCT05243602|Experimental|Switch to B/F/TAF|Participants in this arm will switch from their current ARV regimen to the study drug B/F/TAF. This is an oral drug administered once daily for the duration of the study.
9668608|NCT05243602|Active Comparator|Continue current regimen|Participants in this arm will be maintained on their pre-enrollment ARV regimen for the duration of the study.
9668609|NCT05243589|Experimental|group A/ routine physical therapy and proprioceptive training|Routine physical therapy and proprioceptive training is performed
9668610|NCT05243589|Active Comparator|Group B/ routine physical therapy|Routine physical therapy
9668611|NCT05243576||incomplete SCI|"1) Be motor incomplete; 2) Be AIS classified as C or D; 3) have a neurological level of injury from C6 - T6; 4) Have LEMS score > 10; 5) Have Modified Ashworth Scale ≤ 3 for spasticity.~Additional - 1) Be able to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions; 3) Have been diagnosed with a spinal cord injury by a physician."
9668612|NCT05243576||complete SCI|"1) Be chronic (≥ 1-year post injury); 2) AIS classified as A or B motor-complete;~Additional - 1) Be able to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions; 3) Have been diagnosed with a spinal cord injury by a physician."
9668613|NCT05243576||Able-bodied|1) Be able and willing to tolerate electrical stimulation; 2) Be able and willing to comply with study requirements, procedures and verbal instructions.
9668614|NCT05243537||QTc time interval in former preterm neonates, or term born healthy controls|former preterms and healthy term controls are defined as described in the cohort as previously published (Salaets et al, Pediatr Res 2021; Gervais et al, Pediatr Res 2020; Bassareo et al, J Matern Fetal Neonatal Med 2011). This includes both the perinatal characteristics as well as the characteristics collected at assessment (pediatric age or young adulthood) In all cases, an ECG was collected at rest, and these individual values (preterm or healthy term controls will be pooled.
9668615|NCT05243524|Experimental|MVP-S + CPA|All subjects will receive two doses of maveropepimut-S (q3w) followed by up to six doses (q8w) plus low-dose cyclophosphamide on a repeating cycle of one week on/one week off.
9668616|NCT05243511|Active Comparator|Digital Acceptance and Commitment Therapy (ACT) Arm|
9668617|NCT05243511|Active Comparator|Digital Symptom Tracker|
9668618|NCT05243498||no acute GVH, no chronic GVH|
9668619|NCT05243498||acute GVH without chronic GVH|
9668620|NCT05243498||chronic GVH without acute GVH|
9668621|NCT05243498||acute and chronic GVH|
9668622|NCT05243485||Cohort 1 (reference group)|500 patients will be included as an observatory control group and as a reference group to the second cohort. The PreHEART score is calculated without further consequences for triage in the ambulance and are transferred to the ED of the nearest hospital for standard care.
9668623|NCT05243485||Cohort 2 (intervention group)|500 patients will be included in the interventional cohort. The calculated PreHEART score has consequences for triage in the ambulance. If the PreHEART score is ≥ 5, the patient is classified as a high-risk patient for having NSTE-ACS. These patients are immediately transferred to the ED of the nearest PCI center for further diagnostic examination and to rule out other life-threatening pathologies. When the PreHEART score is ≤ 4, the patient is classified as a low-risk patient for having NSTE-ACS and is transferred to the ED of the nearest hospital without PCI facilities (non-PCI center) for further diagnostic work-up
9668624|NCT05243459|Experimental|Gaze-Contingent Feedback Training|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the veteran will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracking technology, the veteran will be instructed to view the matrices of faces as he chooses, as described above in the assessment task. The music chosen by the veteran will play only when s/he is looking at neutral faces and it will stop when s/he looks at threatening faces.
9668625|NCT05243459|Active Comparator|RT-Based Attention Bias Modification|"The task consists of 160 trials. Each trial begins with a centrally-presented fixation cross (+), on which the participant is asked to focus for 500ms. When it disappears, two stimuli will be presented 1.5cm above and below the previous fixation cross for 500ms. After the stimuli disappear, a target probe (right- or left-pointing arrowhead) will appear in place of one of the stimuli, and the participant will be asked to indicate which target probe is presented by pressing the respective key. The target probe will remain on the screen until the participant's response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the neutral face location. Thus, over multiple trials, learning occurs that the threatening face predicts the location of the target probe, thereby achieving the desiring change in attention patterns."
9668626|NCT05243459|Placebo Comparator|Non-Contingent Feedback Training|This condition is based on the aforementioned eye-tracking task with a fundamental change - The music chosen by the veteran will play continuously without any reinforcement for looking at threat or neutral faces.
9668627|NCT05243446||Study group|Hypotensive treatment including Losartan
9668628|NCT05243446||Control group|Hypotensive treatment without renin-angiotensin-aldosteron system blockers.
9823480|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration > 8 g/dL.
9823481|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration < 8 g/dL.
9823482|NCT02311361|Experimental|Durvalumab + 8 Gray (Gy) in 1 fraction|Cohort 1/Dose Level A1 Durvalumab + 8 Gray (Gy) in 1 fraction
9823483|NCT02311361|Experimental|Durvalumab +5 Gy in 5 fractions|Cohort 2/Dose Level A2 Durvalumab +5 Gy in 5 fractions
9823484|NCT02311361|Experimental|Tremelimumab + 8 Gy in 1 fraction|Cohort 3/Dose Level B1 (was removed with Amendment A) Tremelimumab + 8 Gy in 1 fraction
9823485|NCT02311361|Experimental|Tremelimumab + 5 Gy in 5 fractions|Cohort 4/Dose Level B2 (was removed with Amendment A) Tremelimumab + 5 Gy in 5 fractions
9823486|NCT02311361|Experimental|Durvalumab +Tremelimumab + 8 Gy in 1 fraction|Cohort C/ Dose Level C1 Durvalumab +Tremelimumab + 8 Gy in 1 fraction
9823487|NCT02311361|Experimental|Durvalumab +Tremelimumab +5 Gy in 5 fractions|Cohort C/Dose Level C2 Durvalumab +Tremelimumab +5 Gy in 5 fractions
9823488|NCT02311478|Experimental|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
9823489|NCT02311881|Experimental|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
9823490|NCT02311881|Active Comparator|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
9823491|NCT02311881|Placebo Comparator|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
9823492|NCT02311894|Experimental|Somatropin|Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
9823493|NCT02311907|Experimental|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
9823494|NCT02311907|Placebo Comparator|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
9823495|NCT02311933|Experimental|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9823496|NCT02311933|Experimental|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
9823497|NCT02311972|Active Comparator|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
9823498|NCT02311972|Active Comparator|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
9823499|NCT02312063|Experimental|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
9823500|NCT02312063|Active Comparator|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
9823501|NCT02312154|Experimental|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.~(We performed split face study)"
9823502|NCT02312154|No Intervention|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
9823503|NCT02312206|Experimental|NEOD001|24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
9823504|NCT02312206|Placebo Comparator|Placebo|Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
9823505|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
9823506|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
9694366|NCT04789967|Placebo Comparator|Audiobook|A 8 minute audio that focuses on providing educational information regarding functional gastrointestinal disorders and related knowledge.
9694367|NCT04790019|Experimental|Low energy availability|Intervention involves three of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day.
9694368|NCT04790019|Experimental|Low energy availability and high impact jumping|Intervention involves three days of dietary energy restriction providing 15 kilo-calories per kilogram of fat-free mass per day and brief high impact jumping exercise performed daily in the morning and in the evening.
9694369|NCT04789980||Patients|Patients with locally advanced or metastatic pancreatic cancer who plan to receive palliative chemotherapy
9694370|NCT04789941|Experimental|Single arm of patients with locally advanced cancer cervix|"Single arm study to assess the efficacy and safety of use of neoadjuvant cisplatin and irinotecan in treatment of patients with locally advanced cancer cervix.~A combined regimen of intravenous infusion of cisplatin 80mg/m2 on day 1 with irinotecan 60mg/m2 on day 1 and day 8 of every 21- day cycle for 3 cycles.~Then, MRI pelvis will be used for assessment of disease response. According to RECIST criteria, patients who will develop at least stable disease, will be sent for radical hysterectomy. Afterwards, 6 weeks after the surgery, another 3 cycles of the same regimen will be given to the participants as adjuvant treatment."
9694371|NCT04790214|Experimental|Stable CHF patients|Stable CHF patients on stage II/III based on the New York Heart Failure classification
9694372|NCT04790123|Sham Comparator|Control group|
9694373|NCT04790123|Experimental|Experimental group|
9694374|NCT04789902|Experimental|Hospital site 1|This site will provide usual ED care during the control period which will last for the first six months of the study. After six months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
9694375|NCT04789902|Experimental|Hospital site 2|This site will provide usual ED care during the control period which will last for the first 12 months of the study. After 12 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
9694376|NCT04789902|Experimental|Hospital site 3|This site will provide usual ED care during the control period which will last for the first 18 months of the study. After 18 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
9694377|NCT04789902|Experimental|Hospital site 4|This site will provide usual ED care during the control period which will last for the first 24 months of the study. After 24 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
9694378|NCT04789746|Experimental|Running group|Participants that will join the running program.
9694379|NCT04789798|Experimental|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~Electronic transmission of capillary blood glucose measurement results~Electronic transmission of blood pressure measurements~Synchronized video-conferencing, secure messaging~Access to clinical data from patient files when necessary~Reminding of routine follow-up tests and examinations~Providing web-based educational materials to patients."
9694380|NCT04789798|Active Comparator|Usual Care|usual diabetes care, as provided by primary care providers in the hospital
9694381|NCT04789694|No Intervention|A|Patients will be provided with a basic information and standard of care support.
9694382|NCT04789694|Experimental|B|Active prehabilitation will be provided, composed of i) three physical activity-related interventions provided by a physical and rehabilitation medicine (PRM) specialist; iii) three 30 min consultations regarding nutritional status with physician or nutrition specialist; ii) three sessions with psychologist.
9694383|NCT04790071|Active Comparator|Conventional therapy|It covers the classical physical therapy modalities that patients will take for shoulder pain.
9694384|NCT04790071|Active Comparator|Conventional therapy plus dry needling|It covers the classical physical therapy modalities that patients will take for shoulder pain. It also refers to the dry needling treatment to be applied.
9694385|NCT04789824|Experimental|Investigation group|Eye Hygiene (warm compress, eyelid massage, and eyelid cleaning)
9694386|NCT04789824|No Intervention|Control Group|No intervention
9694387|NCT04789759|Experimental|Socket Preservation Alloplastic Material|"10 Consecutive Patients with hopeless teeth and 1/3 or more buccal bone resorption will be placed in a therapy go bone regeneration called socket preservation technique.~The surgery will include placement of 2/3 biphasic calcium sulfate cement matrix's with hydroxyapatite (HA granules) to fill the alveolar defects, and place a resorbable membrane sutured to adjacent tissue, to avoid material leakage.~No flap retraction. 3 Month later an implant will be placed, and a bone biopsy of the healed socket harvested. 2 Month later a final Zirconia ceramic crown screw retained to the osseointegrated implant.~Primary (T0) and Secondary (T1) stability measured with ISQ values.~Intraoral Scanner and an STL File will be taken at T0 , T1 and T2 for volumetric alteration evaluation."
9694388|NCT04789759|Active Comparator|Extraction Socket Spontaneous Healing|10 Consecutive patients with a tooth extraction without the aim of placing a future implant and without Biomaterial filler placed in the socket. Spontaneous healing
9694389|NCT04789733|Experimental|Tight pressure management|"Patients assigned to tight blood pressure control angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.~Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication.~The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days."
9694390|NCT04789733|Other|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
9823507|NCT02312310|Placebo Comparator|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
9823508|NCT02312310|Active Comparator|F 260 mg|"daily consumption of capsules containing 260 mg* cocoa flavanol for 12 weeks~*see note in Record Log regarding the change in the method of assessment of cocoa flavanol content of the capsules"
9823509|NCT02312310|Active Comparator|F 510 mg|daily consumption of capsules containing 510 mg cocoa flavanol for 12 weeks
9528164|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
9823510|NCT02312310|Active Comparator|F 770 mg|daily consumption of capsules containing 770 mg cocoa flavanol for 12 weeks
9823511|NCT02312622|Experimental|Cohort A - Pegylated Irinotecan to treat NSCLC|Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
9823512|NCT02312622|Experimental|Cohort B - Pegylated Irinotecan to treat SCLC|Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
9823513|NCT02312622|Experimental|Cohort C - Pegylated Irinotecan to treat mBC|Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
9823514|NCT02312687|Experimental|KRN23|KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.
9823515|NCT02312713|Active Comparator|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
9823516|NCT02312713|Experimental|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
9823517|NCT02312713|No Intervention|Wait list control|no intervention
9823518|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
9823519|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
9823520|NCT02312739|Active Comparator|Vicodin, Lorazepam and Oxygen|"Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
9823521|NCT02312739|Experimental|Placebo pills and Nitrous Oxide|"Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
9823522|NCT02312765|Experimental|Intervention|Study participants will receive a tablet computer with the AirCare system.
9823523|NCT02312765|No Intervention|Control|Standard care
9823524|NCT02312856|Experimental|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
9823525|NCT02312882|Experimental|Tofacitinib|Participants will receive tofacitinib for 3 months.
9823526|NCT02312934|Experimental|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
10182604|NCT03772249|Experimental|Cohort A2 DCR-HBVS|Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
9823527|NCT02312934|Placebo Comparator|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
9823528|NCT02312986|Experimental|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
9823529|NCT02313155|Experimental|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
9823530|NCT02313155|Experimental|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
9823531|NCT02313233|Experimental|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
9823532|NCT02313233|Placebo Comparator|Placebo|Cornstarch.
9823533|NCT02313454|Experimental|Intranasal Application|Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
9823534|NCT02313454|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
10182605|NCT03772249|Placebo Comparator|Cohort A2 Placebo|Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
9823535|NCT02313506|Active Comparator|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
9668629|NCT05243394|Experimental|Gamified virtual reality environtment + tDCS + treadmill gait training|The first group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill. They will also receive tDCS for the first 20 minutes of each session.
9668630|NCT05243394|Experimental|Gamified virtual reality environtment + treadmill gait training|The second group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last. They will be immersed in a gamified virtual reality environment in which they will interact with the in-game ambient by having their feet represented on the screen and move as their own on the treadmill.
9668631|NCT05243394|Active Comparator|Treadmill gait training|The third group will follow an 18-session gait training protocol for 6 weeks. Duration of the sessions will progressively increase from 20 to 45 minutes from first session to last.
9668632|NCT05243381|Other|Immune non-responder patients|"HIV viral load < 50 copies/ml in the past 2 years~CD4+ T-cell count < 350 cells/mm3 on the last two tests"
9668633|NCT05243381|Other|Immune responder patients|"HIV viral load < 50 copies/ml in the past 2 years~CD4+ T-cell count > 500 cells/mm3 on the last two tests"
9668634|NCT05243368|Experimental|Nutritional Intervention (NI)|In addition to the usual treatment, will receive dietary advice and a nutritional supplement, according to the results of their evaluation in the Endocrinology Service
9668635|NCT05243368|No Intervention|Control (C)|Who will continue with their usual treatments in the Diabetic Foot Unit and they will receive dietary advice
9668636|NCT05243355|Experimental|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w. Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles. Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total.
9668637|NCT05243316|Active Comparator|Patients with clamping of the chest tube|Patients with 6hour clamping prior to removal
9668638|NCT05243316|Sham Comparator|Patients without clamping of the chest tube|Patients will have chest tube removed immediately
9668639|NCT05243303|Experimental|Active taVNS|These patients will self-administer transcutaneous auricular vagus nerve stimulation (taVNS).
9668640|NCT05243303|Sham Comparator|Sham taVNS|These patients will self-administer a sham procedure mimicking the active taVNS procedure.
9668641|NCT05243290|Active Comparator|Study Supplement: NR|26 subjects will take the supplement (nicotinamide riboside) during the first phase of the study. 300mg will be taken once a day for the 10-week period in phase one.
9668642|NCT05243290|Placebo Comparator|Control|26 subjects will take the placebo during the first phase of the study (10 weeks).
9668643|NCT05243238|Active Comparator|Hesperidin group|
9668644|NCT05243238|Active Comparator|Diosmin|
9668645|NCT05243238|Active Comparator|Hesperidin and diosmin|
9668646|NCT05243238|No Intervention|control group|
9668647|NCT05243225||laparoscopic management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, trocars are inserted in the abdomen, insufflation by CO2 adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram then according to the site and the size of the injury repair will done. If the injury is small simple repair or repair on T-tube will be done. If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done. Intra-abdominal drains insertion
9668648|NCT05243225||open surgical management of post cholecystectomy bile duct injury.|Under general intubation anaesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the bile duct. Evaluation by intraoperative cholangiogram according to the site and the size of the injury repair will be done. If the injury is small simple repair or repair on T-tube will be done . If the injury is large repair on T-tube or hepaticojejunostomy will be done .If it is a distal injury repair on T-tube or biloenteric shunt will be done .If the injury is proximal biloenteric shunt will be done .Intra-abdominal drains insertion.
9668649|NCT05239533|Experimental|Safety lead-in Phase: Participants with Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. The protocol will start with a safety-lead in phase using a 3+3 design to establish the maximal tolerated dose (MTD) of 177Lu-labeled-girentuximab in combination with standard-dose nivolumab. The initial starting dose of 177Lu-labeled-girentuximab is 1804 MBq/m2 which is 75% of the single agent dose established in prior studies and will proceed as shown in the schema below. Once the MTD is established, a Simon two-stage optimal design will commence. 10 patients will be enrolled in the first stage and if no responses are observed, the study will be terminated. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
9668650|NCT05239533|Experimental|Phase 2 Participants|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
9694391|NCT04789915|Active Comparator|Memantine + amisulpride|"Tablet memantine or placebo will be initiated at 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. The tablets will be identical and be provided in 10mg tablets or 20 mg tablets. (12 weeks of treatment).~Tablet amisulpride will be administered in doses starting at 50-100mg/day. Doses will be increased slowly according to effect and side effects up to 800mg/day."
9823536|NCT02313506|Placebo Comparator|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
9823537|NCT02313558|Experimental|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
9823538|NCT02313558|Placebo Comparator|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
9823539|NCT02313597|Placebo Comparator|SETON|Silk suture will be used as SETON
9823540|NCT02313597|Experimental|VAAFT|Video assisted anal fistula treatment
9823541|NCT02313675|Experimental|IV tylenol|One time intra-operative IV acetaminophen administration
9823542|NCT02313675|Experimental|IV toradol|One time intra-operative IV ketorolac thromethamine administration
9823543|NCT02313675|Experimental|IV tylenol/toradol combination|One time intra-operative IV combination of acetaminophen/ketorolac administration
9823544|NCT02313675|Placebo Comparator|saline|One time intra-operative 50ml IV normal saline administration
9823545|NCT02313766|No Intervention|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.~End of preoxygenation FEO2=90%"
9823546|NCT02313766|Experimental|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
9823547|NCT02313766|Experimental|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
9823548|NCT02313909|Experimental|Rivaroxaban|Rivaroxaban 15 mg orally once daily
9823549|NCT02313909|Active Comparator|Aspirin|Aspirin 100 mg orally once daily
9823550|NCT02314000|Active Comparator|SCS starting with supra-perception|Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS
9823551|NCT02314000|Experimental|SCS starting with sub-perception amplitude|Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS
9823552|NCT02314026|Experimental|Suspected NASH|13C-Octanoate, 13C-Methacetin
9823553|NCT02314052|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
9823554|NCT02314104|Active Comparator|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
9823555|NCT02314104|Active Comparator|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
9823556|NCT02314104|Active Comparator|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
9823557|NCT02314117|Experimental|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
9823558|NCT02314117|Active Comparator|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
9827148|NCT02446769|No Intervention|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
9827149|NCT02446847|Experimental|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
10115943|NCT04444830|Experimental|Sprix|To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed regimen of Sprix 30.5mg Intranasal q 6-8 hour up to 4 times daily + Acetaminophen 650 mg PO q 6- 8 hours + rescue narcotics (as above) for breakthrough pain during the day of surgery and the following 4 postoperative days.
9827150|NCT02446847|Experimental|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
9827151|NCT02446886|Active Comparator|One Time Treatment|"MS patients enrolled in this study will be randomized into:~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
9827152|NCT02446886|Experimental|Monthly Treatments|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
9827153|NCT02446899|Experimental|Anifrolumab|Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
9965824|NCT01253499|Experimental|TRx0037|Double blind placebo controlled study of TRx0037 in healthy elderly volunteers to assess safety, tolerability, bioavailability and pharmacokinetics
9965825|NCT01253512|Experimental|THR-18 0.25mg/kg|Treatment with combination with Tissue Plasminogen Activator (tPA) treatment
9694392|NCT04789915|Placebo Comparator|Placebo + amisulpride|"Coated placebo tablets will be provided to match memantine. Placebo equivalent of 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. (12 weeks of treatment).~Tablet amisulpride will be administered in doses starting at 50-100mg/day. Doses will be increased slowly according to effect and side effects up to 800mg/day."
9694393|NCT04789772|Experimental|Laser acupuncture group|Laser acupuncture group receive laser acupuncture treatment with cognitive behavioral therapy.
9694394|NCT04789525|Experimental|Group A (high-intensity aerobic training with high protein diet )|
9694395|NCT04789525|Experimental|Group B(regular physical activities and taken regular diet)|
9694396|NCT04789538||Monofocal IOL|
9694397|NCT04789460||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT in two tertier hospital in Istanbul
9694398|NCT04789668|Experimental|Treatment (bintrafusp alfa, pimasertib)|Patients receive bintrafusp alfa IV over 1 hour every 2 weeks and pimasertib PO BID on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9694399|NCT04789629|Active Comparator|low level laser , physiotherapy|Instrumentation Diode laser device will use for biostimulation of the muscle fiber . The device has a wavelength of 808 nm and a power output 0-250 mW. parameters of laser : Wavelength 808 nm Power output 100 mW Spot size 0.0314 cm2 Power density 3,18 W/cm2 Treatment time per point 40 s Energy density per point 4,77 J/cm2 Energy per point 4 J 12 sessions for one month with traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training .)
9694400|NCT04789629|Active Comparator|physiotherapy|traditional physiotherapy ( stretching , strenghthing exercises , trunk control , balance training , standing exercises , gait training ) for one hour
9694401|NCT04789512||Covid-19 players|Female volleyball players with Covid-19
9694402|NCT04789512||non-Covid-19 players|Female volleyball players with non Covid-19
9694403|NCT04789447||COVID-19 patients in hospital|All patients aged 18 years and over, positive for SARS-CoV-2 PCR test and / or Covid-19 treatment with signs of Covid-19 disease on CT
9694404|NCT04789876|Experimental|App Intervention Group (AIG)|Phosphate mobile app for 12 weeks.
9694405|NCT04789876|Active Comparator|Dietitian Intervention Group (DIG)|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study.
9694406|NCT04789707||KERATOCONUS group|"All workers with keratoconus all stages followed at the service of ophthalmology in CHU Gabriel Montpied, Clermont-Ferrand, Auvergne.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
9694407|NCT04789707||CONTROL group|"workers with good visual acuity consulting in ophthalmology service of Clermont-Ferrand.~The investigators only assessed data from usual routine practice. Patients answer the auto questionnaire in last minutes of consultation."
9694408|NCT04789720|Experimental|SyMon-SAYS Intervention (Group A)|Group A participants will receive the SyMon-SAYS intervention every week for 16 weeks.
9694409|NCT04789720|Other|SyMon-SAYS Waitlist Control (Group B)|The waitlist control group participants (Group B) will receive their usual care during weeks 1-8 and will receive the SyMon-SAYS intervention every week during weeks 9-16.
9694410|NCT04789382|Other|Sequence 1|LID018869+RepleniSH in the right eye and Biofinity+RepleniSH in the left eye (first wear period), followed by PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
9694411|NCT04789382|Other|Sequence 2|Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (first wear period), followed by LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
9694412|NCT04789382|Other|Sequence 3|LID018869+Biotrue in the right eye and PV+Biotrue in the left eye (first wear period), followed by Biofinity+RepleniSH in the right eye and LID018869+RepleniSH in the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
9694413|NCT04789382|Other|Sequence 4|PV+Biotrue in the right eye and LID018869+Biotrue in the left eye (first wear period), followed by LID018869+RepleniSH in the right eye and Biofinity+RepleniSH the left eye (second wear period). Each wear period will be 2 hours (-15 min/+1 hour) with a washout between periods.
9694414|NCT04789837|Experimental|Cilostazol|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
9694415|NCT04789837|Placebo Comparator|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
9694416|NCT04789811|Experimental|Exercise Group|It describes the exercise protocol that the patients will do.
9694417|NCT04789811|Experimental|Exercise plus Dry Needling Group|It describes the exercise protocol to be performed by the patients and the methodology of dry needling to be applied.
9694418|NCT04789343|Experimental|hand files with lateral condensation technique|Previously done root canal filling removed by hand files (Hedstrom file,VDW, Munich,Germany ) and shaped with the same files and after instrumentation, all canals were filled by AH Plus sealer (Dentsply De Tray, Costanz, Germany) and lateral condensation technique of gutta-percha.
9694419|NCT04789343|Experimental|Reciproc instrument with lateral condensation technique|Previous root canal filling removed by Reciproc instrument (VDW ,Munich, Germany )using Endomotor (VDW, Munich, Germany). After removal, root canal instrumented with the same instrument and obturated using AHPlus sealer with lateral condensation technique of gutta-percha.
9694420|NCT04789343|Experimental|Reciporoc instrument with continuous warmed condensation technique|Previous root canal removed by Reciproc instrument using Endomotor, shaped and obturated by AhPlus sealer with continuous gutta-percha technique (Diadent Dia-Duo (Diadent, Chongju, Korea).
9694421|NCT04789642|Experimental|study group|A social group will be created on whatsapp for subjects of the intervention group and they will receive education about blood pressure measurement guidelines in 24 sessions, once per day in the form of text, image and video clips. In addition to British and Irish Hypertension Society (BIHS) blood pressure measurement auscultatory tutorials.
9694422|NCT04789642|No Intervention|control group|The control group will not receive any intervention only their routine education that is provided by the continuous staff development team of the hospital.
9823559|NCT02314143|Experimental|Dabrafenib followed by combination therapy|Eligible subjects will receive dabrafenib 150 milligrams (mg) twice a day (BID) continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
9823560|NCT02314143|Experimental|Trametinib followed by combination therapy|Eligible subjects will receive trametinib 2 mg per day continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
9823561|NCT02314143|Experimental|Combination therapy|Eligible subjects will receive trametinib 2 mg per day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
9823562|NCT02314247|Experimental|Selinexor|60 mg dose (equivalent to ~35 mg/m²)
9823563|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length &, Modified bishop score calculation, then induction of labour at our hospital.
9823564|NCT02314403|Experimental|Combined Bone Marrow and Kidney Transplantation|Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.
9823565|NCT02314520|Active Comparator|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
9823566|NCT02314520|Active Comparator|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
9823567|NCT02314546|Placebo Comparator|Saline placebo|saline placebo
9823568|NCT02314546|Active Comparator|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
9823569|NCT02314546|Active Comparator|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
9823570|NCT02314598||No treatment|
9823571|NCT02314637|Experimental|Teneligliptin|Teneligliptin for 52 weeks
9823572|NCT02314637|Experimental|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
9823573|NCT02314689|Experimental|IV citrulline|IV citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
9823574|NCT02314728|Active Comparator|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
10115944|NCT04444778|Active Comparator|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
9823575|NCT02314728|Active Comparator|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
9823576|NCT02314780|Experimental|Heme arginate (high dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
9823577|NCT02314780|Experimental|Heme arginate (low dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
9823578|NCT02314780|Placebo Comparator|Placebo|24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.
9823579|NCT02314936|Experimental|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
9823580|NCT02314936|Experimental|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
9823581|NCT02314936|Experimental|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
9823582|NCT02314936|Placebo Comparator|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
9823583|NCT02315170|Experimental|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
9823584|NCT02315170|Active Comparator|standard lid speculum|Standard wire eyelid speculum
9823585|NCT02315352|Experimental|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
9823586|NCT02315352|Experimental|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
9823587|NCT02315430|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9823588|NCT02315560|Experimental|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
10115945|NCT04444778|No Intervention|Conservative treatment|Diet and general life style recommendations.
9823589|NCT02315625|Experimental|1/ Arm 1 Sunitinib|Sunitinib
9823590|NCT02315625|Experimental|2/ Arm 2 Everolimus|Everolimus
10182606|NCT03772249|Experimental|Cohort A3 DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
9823591|NCT02315664|Experimental|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
9823592|NCT02315664|Experimental|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
9823593|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
9823594|NCT02315872|Experimental|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
9823595|NCT02315872|Placebo Comparator|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
9823596|NCT02315989|Other|safety|proton therapy
9823597|NCT02316171|Experimental|CVA21|CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
9823598|NCT02316171|Experimental|CVA21/Mitomycin C|Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
9823599|NCT02316223|Experimental|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
9823600|NCT02316223|Active Comparator|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
9823601|NCT02316223|No Intervention|Usual care|Clinician-centric strategy and EMR-based clinician decision support
9823602|NCT02316353|Experimental|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
10115946|NCT04444817||Tacrolimus-based immunosuppression|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started.
10115947|NCT04444609||COVID -19 with chronic lung disease|"Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
10115948|NCT04444609||COVID-19 without chronic lung disease|"Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)~Mild/Moderate ( n =30) (absence of severe criteria)"
10115949|NCT04444609||Chronic Lung disease|"Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)~Asthma (defined as severe) - (n=20)~CF (FEV1% predicted baseline <50%) - (n=20)~COPD (FEV1% predicted baseline <50%) - (n=20)~Idiopathic Pulmonary Fibrosis (n=20)"
9519444|NCT03286972||PET/MRI|"All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner."
9519445|NCT03286959|Active Comparator|PCR WITH CALCIUM HYDROXIDE|PCR WITH CALCIUM HYDROXIDE : A layer of dycal (dentsply) was placed adjacent to pulpal or axial wall after mixing as per manufacturer recommendations followed by etching and restoration with composite using incremental technique.
9519446|NCT03286959|Active Comparator|PCR WITH RMGIC|PCR WITH RMGIC: A layer of resin modified liner ( GC Fuji II ) was placed adjacent to pulpal or axial wall and light cured for 40 sec. afterwards the cavity was restored with composite as in other groups.
9519447|NCT03286959|Active Comparator|PCR WITH DIRECT COMPOSITE|PCR WITH DIRECT COMPOSITE: After partial caries excavation , etching and bonding was done directly without using any liner and cavity was restored with composite as in other groups
9519448|NCT03286946|Experimental|Blunt-type block needle|block with Blunt-type block needle.
9519449|NCT03286946|Active Comparator|Sharp-type block needle|block with Sharp-type block needle.
9519450|NCT03286933|Experimental|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
9519451|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
10115950|NCT04444609||Healthy volunteers|Healthy subjects with no COVID-19 (n=30)
10182607|NCT03772249|Placebo Comparator|Cohort A3 Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
9823603|NCT02316353|Experimental|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
9823604|NCT02316366|Experimental|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
9823605|NCT02316366|No Intervention|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
9823606|NCT02316470|Active Comparator|VLA84 75 mcg (microgram) w/o Alum|VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
9823607|NCT02316470|Active Comparator|VLA84 200 mcg w/o Alum|VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
9823608|NCT02316470|Active Comparator|VLA84 200 mcg with Alum|VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
9823609|NCT02316470|Placebo Comparator|Placebo|Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
9823610|NCT02316548|No Intervention|No Radiation Therapy|Patients do not receive radiation therapy (RT).
9823611|NCT02316548|Experimental|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
9823612|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
9823613|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
9823614|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
9823615|NCT02316717|Experimental|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
9823616|NCT02316717|Experimental|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
9823617|NCT02316717|Placebo Comparator|Treatment Arm C|Matching placebo, three times daily, orally
9823618|NCT02316769|Active Comparator|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
9823619|NCT02316769|Active Comparator|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
9823620|NCT02316847|Experimental|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
9823621|NCT02316847|Experimental|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
9823622|NCT02317016|Experimental|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
9823623|NCT02317042|Active Comparator|Standard ST Mode|"Participants underwent the first PSG study (Titration Night 1) on ST Mode ( prior to going on AutoEPAP iVAPS or Fixed EPAP iVAPS) whilst receiving their standard NIV therapy through the clinical trial device Juno. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy."
9519452|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
10182608|NCT03772249|Experimental|Cohort A4 DCR-HBVS|Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
9823624|NCT02317042|Experimental|AutoEPAP iVAPS|"Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
9823625|NCT02317042|Active Comparator|Fixed EPAP iVAPS|"Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
9823626|NCT02317432|Experimental|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
10182609|NCT03772249|Placebo Comparator|Cohort A4 Placebo|Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
9694425|NCT04789278|Experimental|Notification|"Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or postal mail that will inform them of the CAC identified on their previous chest CT. It will provide an overview of CAC, an image of their chest CT, and a recommendation that they discuss this finding with their clinician. These clinicians will be notified of these findings via an earlier EHR message. Any treatment decisions will be made by the patient and their clinician.~Patients randomized to notification who are not prescribed a statin medication and do not have a documented discussion regarding statin therapy within three months will be sent a second message at that time. Their primary care providers will receive a second EHR message concurrently."
9823627|NCT02317432|Active Comparator|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
9823628|NCT02317510|Active Comparator|group 1|Laparoscopic cholecystectomy in General Anesthesia
9823629|NCT02317510|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
9823630|NCT02317549|Experimental|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
9823631|NCT02317549|Placebo Comparator|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
9823632|NCT02317562|Experimental|I10E Arm|
9823633|NCT02317575|Experimental|Part A: LY900014 Test A|Test Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
9823634|NCT02317575|Experimental|Part A:Insulin Lispro|Reference formulation. 15 U insulin lispro administered SC in one of five periods.
9823635|NCT02317575|Experimental|Part A: LY900014 Test B|Test Formulation B. Single dose LY900014 administered subcutaneously (SC) in one of five periods.
9823636|NCT02317575|Experimental|Part A: LY900014 Test C|Test Formulation C. Single dose LY900014administered subcutaneously (SC) in one of five periods.
9823637|NCT02317575|Experimental|Part A: LY900014 Test D|Test Formulation D. Single dose LY900014administered subcutaneously (SC) in one of five periods.
9823638|NCT02317575|Experimental|Part B: LY900014|Test formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
9823639|NCT02317614|Experimental|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
9823640|NCT02317614|No Intervention|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
9823641|NCT02317627|Experimental|Cohort 1|KD025 400 mg QD PO for 12 weeks
9823642|NCT02317627|Experimental|Cohort 2|KD025 200 mg BID PO for 12 weeks
9823643|NCT02317627|Experimental|Cohort 3|KD025 400 mg BID PO for 12 weeks
9823644|NCT02317692|Active Comparator|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
9823645|NCT02317692|Experimental|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
9823646|NCT02317744|Experimental|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
9823647|NCT02317744|Placebo Comparator|Pill placebo|Daily placebo medication for 3 months
9823648|NCT02317809|Experimental|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
9823649|NCT02317809|Experimental|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
9823650|NCT02318095|Other|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
9823651|NCT02318134|Experimental|FMT group|In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.
9823652|NCT02318134|Placebo Comparator|Control group|In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.
9823653|NCT02318303|Placebo Comparator|GSP 301 Placebo NS|
9823654|NCT02318303|Experimental|GSP 301-1 NS (QD)|
9823655|NCT02318303|Experimental|GSP 301-2 NS (BID)|
9823656|NCT02318303|Active Comparator|Olopatadine HCl-1 NS (QD)|
9823657|NCT02318303|Active Comparator|Olopatadine HCl-2 NS (BID)|
9823658|NCT02318303|Active Comparator|Mometasone Furoate-1 NS (QD)|
9823659|NCT02318303|Active Comparator|Mometasone Furoate-2 NS (BID)|
9823660|NCT02318368|Experimental|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
9823661|NCT02318368|Active Comparator|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
9823662|NCT02318602|Experimental|Infants|"Participants 1 to<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
9823663|NCT02318602|Experimental|Children|"Participants 2 to <12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
9823664|NCT02318602|Experimental|Adolescents|"Participants 12 to <17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
9823665|NCT02318667|Experimental|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
9823666|NCT02318693|Experimental|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
9823667|NCT02318693|Active Comparator|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
9823668|NCT02318706|Placebo Comparator|placebo|placebo group (14 weeks)
9827154|NCT02446899|Placebo Comparator|Placebo|Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
9823669|NCT02318706|Experimental|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
9823670|NCT02318706|Experimental|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
9823671|NCT02318706|Experimental|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
9823672|NCT02318719|Placebo Comparator|Placebo|Placebo (14-weeks)
9823673|NCT02318719|Experimental|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
9823674|NCT02318719|Experimental|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
9823675|NCT02318719|Experimental|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
9823676|NCT02318797|Active Comparator|Patient Self-Directed Care|See intervention description
9823677|NCT02318797|Active Comparator|Provider-Supported Integrated Care|See intervention description
9823678|NCT02318940|Other|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.~access will be through the femoral vein only"
9965826|NCT01253512|Placebo Comparator|Placebo treatment|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
9823679|NCT02318940|Active Comparator|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
9823680|NCT02318979|Experimental|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
9823681|NCT02318979|Experimental|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
9823682|NCT02318992|Active Comparator|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% sodium chloride (NaCl) in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
9823683|NCT02318992|Active Comparator|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80 degrees Celsius (C) freezer labeled with identity (ID) and expiration date which was 6 months after preparation day (Frozen).
9823684|NCT02318992|Active Comparator|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4 degrees celsius (C) and were used within 6 months after preparation day.
9823685|NCT02319031|Active Comparator|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
9823686|NCT02319031|Active Comparator|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
9823687|NCT02319044|Experimental|MEDI4736|MEDI4736 monotherapy
9823688|NCT02319044|Experimental|Tremelimumab|Tremelimumab monotherapy
9823689|NCT02319044|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
9823690|NCT02319148|Experimental|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
9823691|NCT02319148|Experimental|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
9823692|NCT02319148|Experimental|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
9823693|NCT02319174|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
9823694|NCT02319304|Other|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:~FOLFOX: combination of drugs administered in a specific sequence as prescribed below.~Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours~Leucovorin: 200 mg/m2 IV bolus over 2 hours~5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours~Part II:~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
9519453|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
9823695|NCT02319317|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
9823696|NCT02319317|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
9519454|NCT03286907|Experimental|Online videos|Participants will watch two online videos, complete a self-administered online tutorial, and receive reminders at Month 1, 2, 4, 6 & 8
9823697|NCT02319369|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
9827155|NCT02446912|Experimental|Anifrolumab - higher dose|Anifrolumab
9965827|NCT01253512|Experimental|THR-18 0.5mg/kg|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
10182610|NCT03772249|Experimental|Cohort A5 DCR-HBVS|Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
9823698|NCT02319369|Experimental|Part 1A, Milademetan with 5-azacytidine (AZA)|Participants receive milademetan in combination with 5-azacytidine (AZA), with different dose schedules
9823699|NCT02319369|Experimental|Part 2, Cohort 1|Participants with refractory or relapsed acute myelogenous leukemia (AML) receive the recommended dose for Part 2 of milademetan or milademetan with5-azacytidine (AZA)
9823700|NCT02319369|Experimental|Part 2, Cohort 2|Participants with newly diagnosed acute myelogenous leukemia (AML) unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
9823701|NCT02319369|Experimental|Part 2, Cohort 3|Participants with high-risk myelodysplastic syndrome (MDS) receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
9823702|NCT02319486|Experimental|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
9823703|NCT02319525|Experimental|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
9823704|NCT02319525|Active Comparator|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology [ACR])
9823705|NCT02319642|Experimental|Certolizumab Pegol (CZP)|"Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.~Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
9823706|NCT02319668|Experimental|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
9823707|NCT02319668|Placebo Comparator|Control|Sodium fluoride toothpaste (Aquafresh Mild & Minty)
9823708|NCT02319759|Experimental|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
9823709|NCT02319759|Experimental|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
9823710|NCT02319824|Experimental|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
9823711|NCT02319967|No Intervention|Enhanced usual care|Inhaler technique education and distribution of spacers to all participants.
9823712|NCT02319967|Experimental|ED-only|Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
9823713|NCT02319967|Experimental|ED-plus-home|"Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.~Home visits by a community health worker (CHW)."
9823714|NCT02320058|Experimental|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously~Maintenance Phase: Nivolumab infusion intravenously"
9823715|NCT02320123|Experimental|Patients - intervention|For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
10182611|NCT03772249|Placebo Comparator|Cohort A5 Placebo|Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
9823716|NCT02320123|No Intervention|Patients - Control|Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
9823717|NCT02320149|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
9823718|NCT02320149|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
9823719|NCT02320175|No Intervention|Pre-intervention|Before implementation of Patient and Family Centered I-PASS.
9823720|NCT02320175|Experimental|Post-intervention|After implementation of Patient and Family Centered I-PASS.
9823721|NCT02320214|Experimental|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
9823722|NCT02320227|Experimental|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
9823723|NCT02320253|Active Comparator|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
9827156|NCT02446912|Placebo Comparator|Placebo|Placebo
9827157|NCT02446912|Experimental|Anifrolumab - lower dose|Anifrolumab
9827158|NCT02446990|Experimental|Ivabradine|
9827159|NCT02446990|Placebo Comparator|Placebo|
9965828|NCT01253551|Experimental|001|Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
10182612|NCT03772249|Experimental|Cohort B DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
10182613|NCT03772249|Placebo Comparator|Cohort B Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
9823724|NCT02320253|Experimental|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
9823725|NCT02320253|Experimental|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
9823726|NCT02320487|Experimental|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
9823727|NCT02320695|Placebo Comparator|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
9823728|NCT02320695|Placebo Comparator|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
9823729|NCT02320695|Experimental|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
9823730|NCT02320695|Experimental|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
9823731|NCT02320695|Experimental|Original Ointment|Neosporin® Original Ointment (0.3 cc)
9823732|NCT02320695|Experimental|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
9823733|NCT02320721|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
9823734|NCT02320721|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
9823735|NCT02320812|Experimental|Treated subjects|human retinal progenitor cells
9823736|NCT02320838|Experimental|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
9823737|NCT02320838|Experimental|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
9823738|NCT02320838|Sham Comparator|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
9823739|NCT02320903|Experimental|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
9823740|NCT02321098|Experimental|Investigator blinded Loceryl NL+ Cosmetic varnish|Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
9823741|NCT02321098|Experimental|Investigator blinded Loceryl NL alone|Loceryl NL once/week for 12 weeks on right or left foot toenails
9823742|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Saline|IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour
9823743|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Intralipid|IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour
9823744|NCT02321111|Active Comparator|Eritoran + Intralipid|IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour
9823745|NCT02321319|Experimental|Hydromorphone HCl ER Tablets|Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)
9823746|NCT02321436|Active Comparator|Treatment group|Dysport® 500U intramuscular injection
9823747|NCT02321436|Placebo Comparator|Placebo Group|Placebo intramuscular injection
9823748|NCT02321462|Experimental|Eziclen|
9823749|NCT02321462|Active Comparator|Fortrans®|
9823750|NCT02321527|Experimental|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™). Ultrasound images and videos of tumor and lymph nodes in underarm area taken. Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery. Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
9823751|NCT02321748|Other|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
9823752|NCT02321748|Other|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
9823753|NCT02321800|Experimental|Cefiderocol|Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
9823754|NCT02321800|Active Comparator|Imipenem/cilastatin|Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
9823755|NCT02321930|Other|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
9823756|NCT02322021|Experimental|MCI/Prodromal Cohort: Low Dose|A low dose of E2609 will be assessed.
9823757|NCT02322021|Experimental|MCI/Prodromal Cohort: Middle Dose|A middle dose of E2609 will be assessed.
9823758|NCT02322021|Experimental|MCI/Prodromal Cohort: High Dose|A high dose of E2609 will be assessed.
9823759|NCT02322021|Placebo Comparator|MCI/Prodromal Cohort: Placebo|
9823760|NCT02322021|Experimental|Mild to Moderate AD Cohort: Low Dose|A low dose of E2609 will be assessed.
9823761|NCT02322021|Experimental|Mild to Moderate AD Cohort: High Dose|A high dose of E2609 will be assessed.
9823762|NCT02322021|Placebo Comparator|Mild to Moderate AD Cohort: Placebo|
9823763|NCT02322021|Experimental|Mild to Moderate AD cohort: Middle Dose|A middle dose of E2609 will be assessed.
9823764|NCT02322047|Experimental|Praz/Nal|"Prazosin and Naltrexone.~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
9823765|NCT02322047|Active Comparator|Praz/Pl|"Prazosin and Placebo (Naltrexone)~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
9823766|NCT02322047|Active Comparator|Nal/Pl|"Naltrexone and Placebo (Prazosin)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
9823767|NCT02322047|Placebo Comparator|Pl/Pl|"Placebo (Prazosin) and Placebo (Naltrexone)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
9823768|NCT02322125|Experimental|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
9823769|NCT02322190|No Intervention|Investigator chosen second line therapy|Investigator chosen second line therapy
9823770|NCT02322190|Experimental|Second line therapy + Extracorporeal Photopheresis|Second line therapy in addition to Extracorporeal Photopheresis (ECP)
9823771|NCT02322216|Experimental|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
9823772|NCT02322216|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
9827160|NCT02447003|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants will be administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
9827161|NCT02447003|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants will be administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
9827162|NCT02447029|Experimental|Active Comparator|Drug: vaginal 2% Xylocaine
9827163|NCT02447029|Other|standard lidocaine paracervical block|standard lidocaine paracervical block
9827164|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
9827165|NCT02447172|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
9827166|NCT02447172|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
9827167|NCT02447172|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
9827168|NCT02447250|Experimental|Single Arm: varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning after 14 days of age and at 28w0d to 33w6d corrected gestational age. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a single dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
9827169|NCT02447302|Experimental|Etrasimod Low Dose|Oral, low dose, daily for 12 Weeks
9827170|NCT02447302|Experimental|Etrasimod High Dose|Oral, high dose, daily for 12 weeks
9827171|NCT02447302|Placebo Comparator|Placebo|Oral, placebo, daily for 12 weeks.
9827172|NCT02447328|Experimental|Single Arm|Faslodex treated in the study
9827173|NCT02447432|Experimental|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
9827174|NCT02447432|Active Comparator|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
9827175|NCT02447458|Experimental|Cohort 1: MLN3126 300 mg|MLN3126 300 mg tablets, orally, fasting, once on Day 1.
9827176|NCT02447458|Experimental|Cohort 2: MLN3126 600 mg|MLN3126 600 mg tablets, orally, fasting, once on Day 1.
9827177|NCT02447458|Experimental|Cohort 3: MLN3126 1000 mg|MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.
9827178|NCT02447458|Experimental|Cohort 4: MLN3126 1500 mg|MLN3126 1500 mg administered orally as tablets, once on Day 1.
9827179|NCT02447458|Experimental|Cohort 5: MLN3126 2000 mg|MLN3126 2000 mg tablets, orally, fasting, once on Day 1.
9827180|NCT02447458|Experimental|Cohort 6|Did not take place due to termination of the study.
9823773|NCT02322229|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
9823774|NCT02322242|Active Comparator|Perineural Dexamethasone|ISB performed with local anesthetic (ropivacaine 0.5%) and perinerual dexamethasone (4mg)
9823775|NCT02322242|Other|Systemic Dexamethasone|ISB with local anesthetic alone (ropivacaine 0.5%) alone and intravenous dexamethasone (4mg)
9823776|NCT02322281|Experimental|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
9823777|NCT02322281|Experimental|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
9823778|NCT02322281|Active Comparator|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.~Gemcitabine~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.~Docetaxel~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.~Paclitaxel~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
9823779|NCT02322320|Active Comparator|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
9823780|NCT02322320|Active Comparator|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
9823781|NCT02322320|Active Comparator|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
9823782|NCT02322333|Active Comparator|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
9823783|NCT02322333|Placebo Comparator|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
9823784|NCT02322411|Active Comparator|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
9823785|NCT02322411|Experimental|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
9823786|NCT02322528|Other|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
9823787|NCT02322749|Experimental|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
9823788|NCT02322749|Experimental|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
9823789|NCT02322749|Experimental|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate [TPGS] variant) administered orally
9823790|NCT02322775|Experimental|Arm A|Benralizumab administered subcutaneously every 4 weeks
9823791|NCT02322775|Experimental|Arm B|Placebo administered subcutaneously every 4 weeks
10115951|NCT04444622|Experimental|AlloStim|"AlloStim is administered in three cycles:~Cycle 1 Day 0: 0.5ml ID AlloStim® Day 7: 0.5ml ID AlloStim® Day 14: 0.5ml ID AlloStim® Day 21: 0.5ml ID AlloStim® Day 28: 0.5ml ID AlloStim®~Cycle 2 Day 42: 0.5ml ID AlloStim® Day 49: 0.5ml ID AlloStim® Day 56: 0.5ml ID AlloStim® Day 63: 0.5ml ID AlloStim® Day 70: 0.5ml ID AlloStim® + 3ml IV AlloStim®~Cycle 3 Day 84: 0.5ml ID AlloStim® Day 91: 0.5ml ID AlloStim® Day 98: 0.5ml ID AlloStim® Day 105: 0.5ml ID AlloStim® Day 112: 0.5ml ID AlloStim® + 3ml IV AlloStim®"
10115952|NCT04444570||Control group|14 days before the date of the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom)
10115953|NCT04444570||Study group|Right after the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
10115954|NCT04444375||obese, non-obese|obese and non-obese diabetic patients
10115955|NCT04444557||Turkish hemodialysis patients|Turkish patients undergoing in-center hemodialysis
10115956|NCT04444557||Temporarily protected Syrian hemodialysis patients|Temporarily protected Syrian patients undergoing in-center hemodialysis
10115957|NCT04444219|Other|Breakfast meal_1|100 g white bread, 40 g yellow cheese and Κing Oyster mushrooms (test meal)
10115958|NCT04444219|Other|Breakfast meal_2|100 g white bread, 40 g yellow cheese and 6-7 cherry tomatoes (control meal)
10115959|NCT04444167|Experimental|AK104 and Lenvatinib|AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
9823792|NCT02322788|Active Comparator|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
9823793|NCT02322788|Active Comparator|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
9823794|NCT02322788|Placebo Comparator|Turbuhaler M2, Placebo|Placebo powder for inhalation
9823795|NCT02322788|Placebo Comparator|Turbuhaler M3, Placebo|Placebo powder for inhalation
9823796|NCT02322814|Experimental|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
9823797|NCT02322814|Placebo Comparator|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
9823798|NCT02322814|Experimental|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
9823799|NCT02322814|Experimental|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
9823800|NCT02322866|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
10115960|NCT04444271|Experimental|Mesenchymal stem cells|10 patients will be given mesenchymal stem cells at dose 2x10^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
10115961|NCT04444271|Placebo Comparator|Placebo|Only supportive care will be given to 10 patients
10115962|NCT04444349|Experimental|Coenzyme Q10 group|Participants in the experimental group will be given 10mg of Coenzyme Q10 each time (3 times a day).
10115963|NCT04444349|Sham Comparator|Control|Participants in the experimental group will be given 10mg of placebo each time (3 times a day).
10115964|NCT04444284|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1.
10115965|NCT04444284|Placebo Comparator|Dosage Group 1: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
10115966|NCT04444284|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2.
10115967|NCT04444284|Placebo Comparator|Dosage Group 2: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
10115968|NCT04444284|Experimental|Dosage Group 3: RSV Vaccine Dosage 3|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3.
10115969|NCT04444232|Experimental|Health services research (educational video, survey)|Participants view an educational video on cancer and cancer screening options over 12 minutes. Participants also complete a phone survey over 10-15 minutes before attending the video session and 2 months after the video session.
10115970|NCT04444297|Active Comparator|2D telemedicine|2D telemedicine first, followed by crossover to 3D telemedicine with no washout period
10115971|NCT04444297|Experimental|3D Telemedicine|3D telemedicine first, followed by crossover to 2D telemedicine with no washout period
10115972|NCT04444258|Experimental|Experimental I Group|After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
10115973|NCT04444258|No Intervention|Control Group|FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
10115974|NCT04444063|Experimental|NIPSA technique with Allograft plus PRF|Non-incised papilla preservation technique to treat intraosseous bony defects with the addition of Allograft plus PRF
10115975|NCT04444063|Active Comparator|NIPSA technique|Non-incised papilla preservation technique to treat intraosseous bony defects without the addition of Allograft plus PRF
10115976|NCT04444440|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
10115977|NCT04444440|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
10115978|NCT04444102|No Intervention|Control group (CG)|Those subjects randomized to the CG will be offered reading options that do not evoke high emotional distress. They will spend an hour reading.
10182614|NCT03772249|Experimental|Cohort C1 DCR-HBVS|4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
10182615|NCT03772249|Placebo Comparator|Cohort C1 Placebo|4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
9823801|NCT02322866|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
9823802|NCT02322879|Experimental|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.~The total study time is 6 weeks."
9823803|NCT02322879|Experimental|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.~The total study time is 6 weeks."
9823804|NCT02322892|Placebo Comparator|Control Arm|50 mL normal saline solution
9823805|NCT02322892|Experimental|Thiamine|200 mg thiamine in 50 mL normal saline solution
9827181|NCT02447458|Placebo Comparator|Placebo: Cohort 1-6|Placebo-matching MLN3126 tablets, orally, once on Day 1.
10182616|NCT03772249|Experimental|Cohort C2 DCR-HBVS|4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
10182617|NCT03772249|Placebo Comparator|Cohort C2 Placebo|4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
9823806|NCT02323048|Experimental|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
9823807|NCT02323048|Experimental|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
9823808|NCT02323048|Experimental|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
9823809|NCT02323048|Experimental|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
9823810|NCT02323048|Experimental|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
9823811|NCT02323113|Experimental|Phase 1b: TAK-659|TAK-659 tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage of TAK-659 may increase in 20 mg increments using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
9823812|NCT02323113|Experimental|Phase 2: TAK-659|TAK-659, tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage for this phase will be determined from results of Phase 1b MTD/RP2D.
9823813|NCT02323204|Experimental|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
9823814|NCT02323204|Active Comparator|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
9823815|NCT02323217|Experimental|Healthy Volunteers|
9823816|NCT02323334|Placebo Comparator|Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg|"Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626."
9823817|NCT02323334|Experimental|Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626."
9823818|NCT02323334|Experimental|Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO."
9823819|NCT02323334|Experimental|Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole."
9823820|NCT02323334|Experimental|Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
9823821|NCT02323334|Experimental|Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra|"Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
9823822|NCT02323334|Experimental|Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.
9823823|NCT02323334|Experimental|Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.
9823824|NCT02323334|Experimental|Part B Cohort 4: 1.6mg|Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.
9823825|NCT02323334|Experimental|Part B Cohort 5: 10mg|Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.
9823826|NCT02323334|Experimental|Part B Cohort 6: 26mg|Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.
9823827|NCT02323334|Placebo Comparator|Part B Cohort 4, 5, 6: Placebo Comparator|Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.
9823828|NCT02323334|Experimental|Part C Cohort 7: 1mg|Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.
9823829|NCT02323334|Experimental|Part C Cohort 8: 6mg|Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
9823830|NCT02323334|Experimental|Part C Cohort 9: 26mg|Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
9823831|NCT02323334|Placebo Comparator|Part C Cohort 7, 8 ,9: Placebo Comparator|Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.
9823832|NCT02323334|Experimental|Part D Cohort 10: 6mg|Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
9823833|NCT02323646|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
10115979|NCT04444102|Experimental|Stretching protocol 1, Mild Stretching Group (MSG)|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 50% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch and then corrected to 50%. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 50% with some feedback from the instructor.
10115980|NCT04444102|Experimental|Stretching protocol 2, Intense Stretching Group (ISG):|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 100% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 100% with some feedback from the instructor.
9823834|NCT02323646|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
9823835|NCT02323646|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
9823836|NCT02323854|Other|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
9823837|NCT02324049|Experimental|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
9823838|NCT02324075|Experimental|Behavior change|Behavior change messaging with facilitating hardware
9823839|NCT02324075|No Intervention|Control Arm|Standard habits and practices
9823840|NCT02324153|Experimental|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
10115981|NCT04444245|Experimental|ARM 1 Platelet Rich Plasma|Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. (Emcyte II Pure PRP) Endovaginal ultrasound guided intra-ovarian placement into ovarian parenchyma, preferably both if accessible.
9823841|NCT02324153|Placebo Comparator|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
9823842|NCT02324205|Experimental|DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.
9823843|NCT02324270|Active Comparator|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
9823844|NCT02324270|Experimental|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
9823845|NCT02324270|Placebo Comparator|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
9823846|NCT02324335|Placebo Comparator|Placebo Comparator Oral Rinse|Water for Injection
9823847|NCT02324335|Active Comparator|Active Comparator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
9823848|NCT02324361|Experimental|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
9823849|NCT02324361|Experimental|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
9823850|NCT02324465|Active Comparator|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL
10115982|NCT04444245|Experimental|ARM 2 emulsified tSVF and PRP|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue into tSVF (Tulip Nanofat device). Blending of Nanofat with PRP at a 3:1 ratio.~Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible."
9823851|NCT02324465|Active Comparator|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL
9823852|NCT02324504|Experimental|Placement with C3 Wave Tip System|Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
9823853|NCT02324543|Experimental|Dose level 1 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/twice daily (BID)~Cisplatin - 15 mg/m^2~Irinotecan - 20 mg/m^2"
9823854|NCT02324543|Experimental|Dose Level 2 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 40 mg/m^2"
9823855|NCT02324543|Experimental|Dose Level 3 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 60 mg/m^2"
9823856|NCT02324543|Experimental|Dose Level 1a - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
9823857|NCT02324543|Experimental|Dose level 1b - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 40 mg/m^2"
9823858|NCT02324543|Experimental|Phase 2|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
9823859|NCT02324569|Experimental|Treatment Group I|One tablet of SYR-472 100 mg orally once weekly before breakfast
9823860|NCT02324569|Experimental|Treatment Group II|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
9823861|NCT02324660|Other|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
9823862|NCT02324673|Experimental|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
9823863|NCT02324673|Experimental|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose [20 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
9823864|NCT02324673|Experimental|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose [40 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
9823865|NCT02324699|Experimental|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
9823866|NCT02324699|Placebo Comparator|Placebo|Identical placebo taper
9823867|NCT02324842|Active Comparator|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
9823868|NCT02324842|Active Comparator|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
9823869|NCT02324842|Active Comparator|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
9823870|NCT02324920|Experimental|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
10182618|NCT03772249|Experimental|Cohort C3 DCR-HBVS|4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
10182619|NCT03772249|Placebo Comparator|Cohort C3 Placebo|4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
10182620|NCT03772249|Experimental|Cohort 4C DCR-HBVS|"1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)"
9823871|NCT02324920|Placebo Comparator|ODO|The pacemaker will be programmed in ODO mode.
9823872|NCT02324972|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
9823873|NCT02324972|Placebo Comparator|Placebo|1 x placebo capsule daily
9823874|NCT02325219|Experimental|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
9823875|NCT02325219|Experimental|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
9823876|NCT02325219|Experimental|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
9823877|NCT02325401|Experimental|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
9823878|NCT02325414|Experimental|Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
9823879|NCT02325414|Experimental|Placebo|Intravenous infusion of placebo at baseline.
9823880|NCT02325518|Experimental|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
9823881|NCT02325518|Active Comparator|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
9823882|NCT02325687|Experimental|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
9823883|NCT02325687|Experimental|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
9823884|NCT02325687|Experimental|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score <3 are considered to have minimal risk for OSA and will be included in the control group.~Intervention: Lumbar Puncture (Standard-of-Care)"
9823885|NCT02325713|Experimental|Sequence A-B-C1-D1|
9823886|NCT02325713|Experimental|Sequence A-B-C1-D2|
9823887|NCT02325713|Experimental|Sequence A-B-C2-D1|
9823888|NCT02325713|Experimental|Sequence A-B-C2-D2|
9823889|NCT02325713|Experimental|Sequence A-B-D1-C1|
9823890|NCT02325713|Experimental|Sequence A-B-D2-C1|
9823891|NCT02325713|Experimental|Sequence A-B-D1-C2|
9823892|NCT02325713|Experimental|Sequence A-B-D2-C2|
9823893|NCT02325713|Experimental|Sequence B-A-C1-D1|
9823894|NCT02325713|Experimental|Sequence B-A-C1-D2|
9823895|NCT02325713|Experimental|Sequence B-A-C2-D1|
9823896|NCT02325713|Experimental|Sequence B-A-C2-D2|
9823897|NCT02325713|Experimental|Sequence B-A-D1-C1|
9823898|NCT02325713|Experimental|Sequence B-A-D2-C1|
9823899|NCT02325713|Experimental|Sequence B-A-D1-C2|
9823900|NCT02325713|Experimental|Sequence B-A-D2-C2|
9823901|NCT02325739|Experimental|Phase I: FGF401 50 mg fasted|Participants received single agent FGF401 50 mg while fasted
9823902|NCT02325739|Experimental|Phase I: FGF401 80 mg fasted|Participants received single agent FGF401 80 mg while fasted
9823903|NCT02325739|Experimental|Phase I: FGF401 80 mg fed|Participants received single agent FGF401 80 mg while fed
9823904|NCT02325739|Experimental|Phase I: FGF401 120 mg fasted|Participants received single agent FGF401 120 mg while fasted
9823905|NCT02325739|Experimental|Phase I: FGF401 120 mg fed|Participants received single agent FGF401 120 mg while fed
9823906|NCT02325739|Experimental|Phase I: FGF401 150 mg fasted|Participants received single agent FGF401 150 mg while fasted
9823907|NCT02325739|Experimental|Phase I: FGF401 80 mg + PDR001 300 mg|Participants received FGF401 80 mg in combination with PDR001 300 mg while fasted
9823908|NCT02325739|Experimental|Phase I: FGF401 120 mg + PDR001 300 mg|Participants received FGF401 120 mg in combination with PDR001 300 mg while fasted
9823909|NCT02325739|Experimental|Phase II: Group 1 - FGF401 120 mg QD|Group 1 was comprised of HCC participants from Asian countries who received single agent FGF401 120 mg QD while fasted
9823910|NCT02325739|Experimental|Phase II: Group 2 - FGF401 120 mg QD|Group 2 was comprised of HCC participants from non-Asian countries who took single agent FGF401 120 mg QD while fasted
9823911|NCT02325739|Experimental|Phase II: Group 3 - FGF401 120 mg QD|Group 3 was comprised of participants with other solid malignancies regardless of geography who took single agent FGF401 120 mg QD while fasted
9823912|NCT02325791|Experimental|Part A: Suptavumab 30 mg/kg|
9823913|NCT02325791|Experimental|Part B: Placebo Matched to Suptavumab|
9823914|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg- 1 Dose|
9823915|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg - 2 Doses|
9823916|NCT02325856|Active Comparator|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
9823917|NCT02325856|Placebo Comparator|Control group|Dry weight determined by clinical symptoms
9823918|NCT02326025|Experimental|Part A|"Doxorubicin Alone: On Cycle 1, Day 1, participants received 75 milligram/square meter (mg/m2) of doxorubicin intravenously (IV).~Olaratumab Alone: On Cycle 1, Day 10, participants received 15 milligram/kilogram (mg/kg) of olaratumab IV.~Olaratumab + Doxorubicin: For Cycles 2 to 8, participants received 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, IV and 75 mg/m2 of doxorubicin IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onward, until discontinuation criteria are met."
9823919|NCT02326025|Experimental|Part B|"Doxorubicin Alone: On Cycle 1, Day 1, participants received doxorubicin 75 mg/m2 IV~Olaratumab Alone: On Cycle 1, Day 10, participants received 20 mg/kg of olaratumab IV.~Olaratumab + Doxorubicin:~For Cycle 2, participants received 20 mg of olaratumab on Days 1 and 8 of each 21-day cycle, IV. On Day 1 of Cycle 2, doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~For Cycles 3 - 8, Day 1 and 8, olaratumab 15 mg/kg was administered and on Day 1 doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onwards, until discontinuation criteria are met."
9823920|NCT02326220|Experimental|Placebo Q2W (Double Blind Period)|Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
9823921|NCT02326220|Experimental|Alirocumab 150 mg Q2W (Double Blind Period)|Alirocumab 150 mg SC injection Q2W up to Week 16.
9823922|NCT02326220|Experimental|Alirocumab 150 Q2W (Open Label Treatment Period)|Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
9823923|NCT02326233|Experimental|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
9823924|NCT02326233|Active Comparator|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
9827182|NCT02447497|Experimental|3M CHG/IPA - Abdominal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
9827183|NCT02447497|Placebo Comparator|Normal Saline - Abdominal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
9827184|NCT02447497|Experimental|3M CHG/IPA - Inguinal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
9827185|NCT02447497|Placebo Comparator|Normal Saline - Inguinal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
9827667|NCT02464163|Experimental|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
9823925|NCT02326272|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
9823926|NCT02326272|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
9823927|NCT02326272|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
9823928|NCT02326298|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
9823929|NCT02326298|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
9823930|NCT02326298|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
9823931|NCT02326363|Experimental|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
9827186|NCT02447575|Other|MDI use Evaluation|"All subjects took 2 or more puffs of the placebo metered dose inhaler (MDI), attaching the Cognita electronic flowmeter to show measurements during the MDI use.~The inhaler technique is also evaluated by study staff prior to an education demonstration."
10182621|NCT03772249|Experimental|Cohort 5C1 DCR-HBVS|4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
10182622|NCT03772249|Experimental|Cohort 5C2 DCR-HBVS|2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
10182623|NCT03772249|Experimental|Cohort 5C3 DCR-HBVS|2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)
10182624|NCT03772444|Active Comparator|Beetroot juice|
10182625|NCT03772444|Placebo Comparator|Control group 1|
10182626|NCT03772444|Sham Comparator|Control group 2|
9823932|NCT02326363|Active Comparator|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery. The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
9823933|NCT02326467|Experimental|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
9823934|NCT02326597|Active Comparator|Standard Practice|Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
9823935|NCT02326597|Experimental|Standard Practice + Decision Aid|Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
9823936|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
9823937|NCT02326805|Experimental|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
9823938|NCT02326805|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
9823939|NCT02326844|Experimental|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
9823940|NCT02326883|Experimental|Care Management|The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
9823941|NCT02326883|Experimental|Skills Training|The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
9823942|NCT02326883|Active Comparator|Usual Care|Those assigned to the Usual Care group will not be approached or contacted.
9823943|NCT02327013|Experimental|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
9823944|NCT02327013|Experimental|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
9823945|NCT02327013|Placebo Comparator|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
9823946|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
9823947|NCT02327117|Experimental|Tranexamic acid|
9823948|NCT02327117|Placebo Comparator|Normal Saline|
9823949|NCT02327130|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
9823950|NCT02327143|Experimental|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
9823951|NCT02327143|Experimental|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
9823952|NCT02327169|Experimental|MLN2480 + MLN0128|Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
9823953|NCT02327169|Experimental|MLN2480 + Alisertib|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
9823954|NCT02327169|Experimental|MLN2480 + Paclitaxel|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
10182627|NCT03772262|Experimental|Control|Study subjects will be administered a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one rosuvastatin tablet (10 mg) by mouth. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
9823955|NCT02327169|Experimental|MLN2480 + Cetuximab|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m^2 (cycle 1 Day 1), then at 250 mg/m^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
9823956|NCT02327169|Experimental|ML2480 + Irinotecan|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
9823957|NCT02327169|Experimental|MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)|Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
9823958|NCT02327260|Experimental|Video + MI for CR|This group receives the educational video and an MI session for CR participation.
9823959|NCT02327260|Experimental|MI for medication adherence|This group receives an MI session for taking prescribed cardioprotective medications.
9823960|NCT02327260|No Intervention|Control group (standard care)|The control group receives standard care while hospitalized.
9823961|NCT02327325|Experimental|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
9823962|NCT02327325|Experimental|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
9823963|NCT02327325|No Intervention|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
9823964|NCT02327351|Experimental|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
9823965|NCT02327429|Experimental|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
9823966|NCT02327741|Experimental|plavix long term|taking plavix more than 12 months
9823967|NCT02327741|Active Comparator|plavix short term|taking plavix less than 12 months
9823968|NCT02328027|Experimental|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
9823969|NCT02328040|Placebo Comparator|Part A|Placebo and Insulin monotherapy via CL
9823970|NCT02328040|Active Comparator|Part B|Sitagliptin and insulin/novolog via CL
9823971|NCT02328326|Experimental|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients' primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
9823972|NCT02328326|Active Comparator|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
9823973|NCT02328404|Active Comparator|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
9823974|NCT02328404|Placebo Comparator|placebo|Placebo tablet given orally once weekly for 3 months
9823975|NCT02328547|Experimental|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
9823976|NCT02328547|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
9823977|NCT02328755|Experimental|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
9823978|NCT02328807|Experimental|Radio-Frequency Ablation (RFA)|Focal Prostate Radio-Frequency Ablation (RFA). Focal bipolar RFA followed by clinical follow-up visits at 6 weeks, 3 months and 6 months.
9823979|NCT02328937|Active Comparator|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
9823980|NCT02328937|Active Comparator|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
9823981|NCT02328937|Active Comparator|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
9823982|NCT02328937|Active Comparator|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
9823983|NCT02328937|Active Comparator|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
9823984|NCT02328937|Active Comparator|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
9823985|NCT02329015|Experimental|Health and Wellness program|Behavioral intervention
9823986|NCT02329015|Active Comparator|Physical Education Class|Behavioral intervention
9519455|NCT03286907|Experimental|Online videos and MI|Participants will watch two online videos, complete a self-administered online tutorial, received motivational interviewing (MI), and receive reminders at Month 1, 2, 4, 6 & 8
9694426|NCT04789278|No Intervention|Usual Care|Both arms have previously had their CT scans reported according to standard clinical practice. This may include notification of the CAC in the imaging report. The usual care arm will not receive any additional notification beyond this standard of care during the project.
9519456|NCT03286907|Active Comparator|Control group|Participants will receive online messages about mental health problems and stress reduction exercises
9519457|NCT03286894||1264 healthy schoolchildren|There is only one study group consisting of 1264 children recruited at school.
9694427|NCT04789239|Experimental|SZC + MRA treated heart failure patients|"Optimal dose of SZC, which is an approved drug for hyperkalemia in Sweden.~The subject is treat with 5 mg daily however it can be reduced to once every second day, or inreased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with a mineralcorticoid receptor antagonist (spironolacton or eplerenon), 25 mg or 50 mg depending on what dose they could tolerate."
9519458|NCT03286881|Experimental|Group 1|
9519459|NCT03286881|Experimental|Group 2|
9694428|NCT04789239|Placebo Comparator|Placebo + MRA treated heart failure patients|The subject is treat with placebo drug, 5 mg once daily, however it can be reduced to once every second day, or increased to as much as as 10 mg daily, depending on measured potassium levels. This is combined with the dose of mineralcorticoid receptor antagonist (spironolacton or eplerenon) 25 mg or 50 mg depending on what dose they could tolerate.
9694429|NCT04789187|Active Comparator|Arm A: Exercise intervention arm|
9694430|NCT04789187|Placebo Comparator|Arm B: Control arm|
9694431|NCT04789031|Experimental|Intervention group|Patients received oral nutritional supplementation and standard nutritional counseling for 6 months.
9694432|NCT04789031|No Intervention|Control group|Patients received standard nutritional counseling for 6 months.
9694433|NCT04789291|Experimental|Fed state (Test, T) - Fasted state (Reference, R)|
9694434|NCT04789291|Experimental|Fasted state (Reference, R) - Fed state (Test, T)|
9694435|NCT04789421|Active Comparator|Arm 1 (interventional)|Patients with equivocal skin lesions suspicious for melanoma, randomised to adjunctive RCM evaluation, following clinical and dermoscopy evaluation.
9694436|NCT04789421|Placebo Comparator|Arm 2 (control)|Patients with equivocal skin lesions suspicious for melanoma, randomised to clinical and dermoscopy evaluation only; adjunctive RCM evaluation refused.
9694437|NCT04789265|Experimental|Combined Therapy (Instrumented Soft Tissue Mobilization)|
9694438|NCT04789265|No Intervention|Control Group (Exercise Therapy)|
9694439|NCT04789603|Active Comparator|Without Mask Group|Patients who will perform the 6-min walk test without mask
9694440|NCT04789603|Active Comparator|Surgical Mask|Patients who will perform the 6-min walk test with surgical mask
9694441|NCT04789603|Experimental|Fpp2 Mask|Patients who will perform the 6-min walk test with Fpp2 mask
9694442|NCT04789252||Patients with NSCLC or with colon cancer|"The subjects are men or women with aged more than 18 years suffering from colon or lung cancer; The lesions are more than 1 cm. They are also able to give informed consent.~The pathologist will sample the material and select the tissue that can be used for the experiment after having taken all that is needed for diagnostic purposes. The research sample will be placed in test tubes and kept on ice.~It will then be sent to University of Milano-Bicocca laboratory whrere It will analyze approximately 60 patients for immunofluorescence studies and 4 patients for single cell transcriptomic analyzes"
9694443|NCT04789317||Stable CAD or stabilized NSTEMI (ACS) with significant epicardial lesions defined as FFR≤0.80.|The PPG Global Registry an investigator-initiated, observational, multicenter study of patients with an indication for PCI based on coronary angiography and FFR ≤0.80. After confirmation of intention to treat with PCI, a manual pullback with PPG analysis will be performed. A second level of decision making is then performed concerning PCI, coronary artery bypass grafting (CABG) or medical therapy (OMT). Patients will undergo PCI at operator discretion and post-PCI FFR will be measured. Clinical follow-up will be performed at 1, 2 and 3 years.
9694444|NCT04789018||Observational (survey, virtual genetic board, interview)|Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
9694445|NCT04789473||Control Normal Glycemic Pregnancy|Cohort of control adults who are currently pregnant or have been pregnant within the last year, but were not diagnosed with gestational diabetes.
9694446|NCT04789473||Gestational Diabetic Cohort|Cohort of adults who are currently pregnant or have been pregnant within the last year, but were diagnosed with gestational diabetes.
9694447|NCT04789356|Active Comparator|High-risk individuals (with comorbidities)|Public safety and security (police officers and law enforcement, fire department), and high school and college/university professionals of the state government public education network who present at least one of the comorbidities included in the National Plan for the Operationalization of Vaccination Against COVID-19 will be invited to receive the CoronaVac vaccine
9694448|NCT04789356|No Intervention|Low-risk individuals (without comorbidities)|Participants with low risk (without comorbidities as a risk factor for severe COVID-19 according to the national plan for the implementation of vaccination against COVID-19) will not receive the vaccine within the scope of the research project.
9694449|NCT04789044|Experimental|PEG fusion mediated repair|NTX-001 will be administered topically via isolation chamber medical device. Dose Unit: 2.5 mL NTX-001 is a single use surgical product intended for use as adjunct treatment in the repair of severed peripheral nerves in patients requiring standard suture neurorrhaphy.
9694450|NCT04789044|Experimental|PEG mediated reconstruction|NTX-001 will be administered topically via isolation chamber medical device. Dose Unit: 2.5 mL NTX-001 is a single use surgical product intended for use as adjunct treatment in the repair of severed peripheral nerves in patients requiring standard suture neurorrhaphy.
9823987|NCT02329223|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
9823988|NCT02329223|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
9823989|NCT02329223|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
9823990|NCT02329431|Experimental|activation curriculum|Psycho-social curriculum teaching activation skills
9823991|NCT02329431|Active Comparator|support group|Parent-directed support group
9823992|NCT02329587|Experimental|ERP plus tDCS|ERP plus anodal tDCS of right inferior frontal gyrus
9823993|NCT02329587|Active Comparator|ERP plus sham tDCS|ERP plus sham tDCS of right inferior frontal gyrus
9823994|NCT02329600|No Intervention|control subjects|10 systemically healthy control subjects taking no medication.
9823995|NCT02329600|Active Comparator|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
9823996|NCT02329600|Experimental|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
9823997|NCT02329730|Experimental|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
9823998|NCT02329730|Experimental|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
9823999|NCT02329730|Experimental|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
9824000|NCT02329743|Experimental|RX-10045 0.05% nanomicellar solution|topical eye drops
9824001|NCT02329743|Experimental|RX-10045 0.1% nanomicellar solution|topical eye drops
9824002|NCT02329743|Placebo Comparator|Vehicle|topical eye drops
9824003|NCT02329964|Experimental|R-S group|"Rocuronium-Sugammadex group~Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent : Rocuronium 1mg/kg~After endotracheal intubation : normal saline(0.025 ml/kg)~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg~Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
9824004|NCT02329964|Active Comparator|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group~Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent :Succinylcholine 1mg/kg~After endotracheal intubation : Cisatracurium 0.08mg/kg~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg~Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
9824005|NCT02330055|Active Comparator|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
9824006|NCT02330055|Placebo Comparator|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
9824007|NCT02330081|Experimental|Mirasol|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subjects untreated fresh whole blood."
9965829|NCT01253551|Experimental|002|Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
9965830|NCT01253590||post op cancer patients experiencing atrial fibrillation|This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
9965831|NCT01253616|Experimental|VNS plus tones|
9965832|NCT01253655|Experimental|PF-05212365|
9519460|NCT03286881|Experimental|Group 3|
9668651|NCT05237414|Experimental|Binge Drinkers with Combined Intervention (active CT + active tDCS)|Subjects will perform a variation of the TNTA task (Anderson & Green, 2001; López-Caneda et al., 2019) to enhance the suppression of alcohol-related memories. The Learning phase will be composed of 2 blocks of 12-image pairs (as there is no a baseline block), and in the TNT phase, all the stimuli to be inhibited will be alcohol-related images. After the Learning Phase, active neuromodulation will be performed using tDCS. Twenty minutes of 2 mA direct current will be applied on the scalp using a saline-soaked pair of 35 cm2 surface sponge electrodes, through an Eldith DC Stimulator Plus (Neuroconn, Germany). To stimulate the right DLPFC, the anodal electrode will be placed over F4 according to the 10-20 international system for EEG electrode placement. The cathode electrode will be over the contralateral supraorbital area. The current fade in for 15 seconds, is constant at 2 mA for 20 minutes, and then fade out for 15 seconds.
9824008|NCT02330094|Experimental|Gabapentin|Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
9824009|NCT02330094|Placebo Comparator|Control|Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
9824010|NCT02330172|Active Comparator|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.~When the end of operation, a injection of neostigmine or sugammadex will be administered."
9824011|NCT02330172|Active Comparator|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.~When the end of operation,, a injection of neostigmine or sugammadex be administered."
9824012|NCT02330276|Experimental|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
9824013|NCT02330276|Experimental|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
9824014|NCT02330276|Experimental|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
9824015|NCT02330341|Experimental|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
9824016|NCT02330341|Placebo Comparator|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
9519461|NCT03286881|Experimental|Group 4|
9519462|NCT03286881|Active Comparator|Group 5|
9824017|NCT02330523|Active Comparator|allograft + x-link collagen membrane|Demineralized freeze-dried allograft + x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
9824018|NCT02330523|Active Comparator|xenograft + non-x-link collagen|Xenograft + non-x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
9824019|NCT02330549|Experimental|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food for up to 24 weeks.
9824020|NCT02330549|Placebo Comparator|Placebo|Placebo-matching CVC, administered orally once daily and taken every morning with food for up to 24 weeks.
9824021|NCT02330588|Experimental|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
9824022|NCT02330588|Experimental|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
9824023|NCT02330588|Experimental|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
9824024|NCT02330588|Experimental|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
9824025|NCT02330588|Placebo Comparator|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
9824026|NCT02330627|Experimental|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
9824027|NCT02330627|No Intervention|Delayed Treatment (Waitlist)|
9824028|NCT02330978|Experimental|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
9824029|NCT02331095|Active Comparator|Anticoagulation|Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
9824030|NCT02331095|Experimental|Atorvastatin + anticoagulation|In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment
9824031|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
9824032|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
9824033|NCT02331108|Active Comparator|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
9824034|NCT02331108|Active Comparator|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
9824035|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age >55.
9824036|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age >55.
9824037|NCT02331368|Experimental|Anti-PD-1 (MK-3475)|"Standard Treatment:~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.~Study Treatment:~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
9827187|NCT02447718|Active Comparator|Experimental|Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
9827188|NCT02447718|No Intervention|Healthy Control|Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.
9827189|NCT02447744|Experimental|Mindfulness group|This arm receives an 8-week mindfulness based behavioral intervention program.
9827190|NCT02447744|Other|Waitlist control group|This arm waits while the mindfulness group receives their intervention, and then receives the mindfulness based intervention after their waiting period.
9827191|NCT02447848|Experimental|sufentanil sublingual tablet 30 mcg|Patients may be administered one tablet every 60 minutes as needed during the study period
9827192|NCT02447926|Other|Leaukapheresis of End Stage Liver Disease Patients|Leukapheresis. All subjects will receive the same treatment arm.
9827193|NCT02447952|Experimental|Pilot and Core Study Phase|During Pilot phase,subjects will attend clinic at least once to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (home monitoring). During 48 week Core Study, subjects will attend 5 clinic visits to perform gold standard measures of function (ALS Functional Rating Scale-Revised and Forced Vital Capacity) and perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visits (home monitoring). In between clinic visits, subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period
9827194|NCT02447991|Placebo Comparator|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
9827195|NCT02447991|Experimental|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
9827196|NCT02448043|Other|Right Hand Bimatoprost 0.01% drops, Left Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the right hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the left hand digits two times per day for 30 days."
9827197|NCT02448043|Other|Left Hand Bimatoprost 0.01% drops, Right Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the left hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the right hand digits two times per day for 30 days."
9827198|NCT02448303|Experimental|Arm 1|pembrolizumab
9827199|NCT02448303|Experimental|Arm 2|acalabrutinib plus pembrolizumab
9827200|NCT02448368|Experimental|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
9827201|NCT02448368|Experimental|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
9827202|NCT02448368|Experimental|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
9827203|NCT02448368|Experimental|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
9827204|NCT02448368|Experimental|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
9827205|NCT02448368|Experimental|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
9827206|NCT02448368|Experimental|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
9827207|NCT02448368|Experimental|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
9827208|NCT02448446|Active Comparator|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
9827209|NCT02448446|Active Comparator|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
9827210|NCT02448537|Experimental|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.~PM01183 predetermined dose daily via IV per cycle~Doxorubicin predetermined dose daily via IV per cycle"
9827211|NCT02448537|Experimental|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure~PM01183 predetermined dose given twice via IV per cycle~Gemcitabine predetermined dose given twice via IV per cycle"
9827212|NCT02448537|Experimental|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine~-PM01183 predetermined dose once via IV per cycle"
9827213|NCT02448563|Experimental|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
9827214|NCT02448563|No Intervention|Control|Standard of care - one counseling visit with a study dietitian
9827215|NCT02448641|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
9827216|NCT02448641|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
9827217|NCT02448641|Sham Comparator|Sham Control|Sham surgery
9827218|NCT02448654|Active Comparator|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
9827219|NCT02448654|Placebo Comparator|Sugar Pill|Sugar pill
9827220|NCT02448706|Active Comparator|Hearing Aid Fitting Order A|High level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
9694451|NCT04789044|No Intervention|conventional nerve repair|Standard nerve repair
9694452|NCT04789044|No Intervention|conventional nerve reconstruction|standard nerve reconstruction
9694453|NCT04788810|Experimental|Oral route|Volunteers receiving d12-Cl2BPA via oral route
9694454|NCT04788810|Experimental|Dermal route|Volunteers receiving d12-Cl2BPA via oral route
9694455|NCT04789135|Experimental|Ozone Therapy|Administration of intravesical ozone gas in patients with Interstitial cystitis/bladder pain sydrome
9694456|NCT04788797|Active Comparator|Prolyl Endopeptidase|Patients blinded-receive active AN-PEP at a dose of 2 capsules/breakfast, lunch and dinner during 8 weeks (study arm)
9694457|NCT04788797|Placebo Comparator|Placebo|Patients blinded-receive 2 capsules of a placebo (specially designed and prepared for the study) at breakfast, lunch and dinner during 8 weeks (Placebo arm).
9694458|NCT04789005|Active Comparator|Phenylephrine group|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
9694459|NCT04789005|Experimental|Norepinephrine group|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
9694460|NCT04788706|Active Comparator|Group I|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
9694461|NCT04788706|Placebo Comparator|Group II|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
9694462|NCT04788706|Active Comparator|Group III|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
9694463|NCT04788706|Placebo Comparator|Group IV|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
9694464|NCT04788758|Experimental|Health Services Research (G8 screening tool, referral)|"PHASE I: Registered Nurses receive training on how to administer the G8 screening tool utilizing an Epic flowsheet to patients using a self-directed education module and by direct assessment by a geriatrician.~PHASE II: Patients complete the G8 screening tool questionnaire over 10 minutes as part of their standard initial assessment, and their answers are entered into their EHR flowsheet. Patients who score =< 14 on the G8 are referred for a CGA at SAOC, and these patients and their medical oncologists are made aware. Within 2 weeks of the initial screening, the results are communicated with the patient and medical oncologist at a 2-hour SAOC visit. Patients with a score of > 15 on the G8 are made aware of their results without any referral generated."
9694465|NCT04788940||AMI patients treated with PCI|Acute myocardial infarction patients who underwent percutaneous coronary intervention and cardiac magnetic resonance imaging
9694466|NCT04788680|Experimental|Experimental: Beverage 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
9694467|NCT04788680|Experimental|Experimental: Beverage 2|Participants receive a beverage with a defined amount of non-nutritive sweetener.
9694468|NCT04788680|Experimental|Experimental: Beverage 3|Participants receive a beverage with a defined amount of monosaccharide.
9694469|NCT04788680|Experimental|Experimental: Beverage 4|Participants receive a beverage with a defined amount of disaccharide.
9694470|NCT04788641|Experimental|Cohort 1|Subjects in Cohort 1 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: tacrolimus alone (treatment A) followed by the combination treatment of tacrolimus and SZC (treatment B) or vice versa.
9694471|NCT04788641|Experimental|Cohort 2|Subjects in Cohort 2 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: cyclosporin alone (treatment C) followed by the combination treatment of cyclosporin and SZC (treatment D) or vice versa.
9694472|NCT04788823|No Intervention|Control|Group 1 will represent controls and will not receive prednisone in the 3-year post-op period.
9694473|NCT04788823|Experimental|Prednisone Monthly - Scheduled|Group 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered.
9694474|NCT04788823|Experimental|Prednisone Monthly - As Needed|Group 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered.
9694475|NCT04788823|Experimental|Prednisone Every Other Week|Group 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks
9694476|NCT04788836||Surgery Group|60 (minimum) to 150 (maximum) adults with class II-III obesity (BMI≥35kg/m2) planned for bariatric surgery or who had bariatric surgery in the last six months.
9694477|NCT04788836||Control Group|Comparison of food purchase behaviour with control subjects will be performed using an already existing cohort from a previous study. This does not required recruiting control subjects.
9694478|NCT04788914|Other|Active bamboo charcoal|In this proposal, investigators aim to determine the therapeutic impact of a carbonaceous oral adsorbent made of activated bamboo charcoal (ABC) with/without probiotics on the endothelial/vascular function, CV outcome and mortality in CKD patients with PAD. In addition, investigators hypothesize that circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota. Investigators also hypothesize that the administration of ABC could normalize the dysbiosis of gut microbiota, dysregulated circulating lncRNAs and metabolome that are linked to adverse CV/limb outcomes in CKD patients with PAD.
9694479|NCT04788914|Other|Probiotics|The therapeutic impact of probiotics on circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota.
9694480|NCT04788654|Active Comparator|Pharmacological group|Pharmacological analgesia will be performed
9824038|NCT02331394|Experimental|Chinese herbs formula: Shu Yu Wan|All participants will be offered the choice of taking the CH formula in capsules or sachets in addition to standard care. This study will use the Shu Yu Wan formula which comprises 23 different herbs and is based on the best evidence in the literature of use of CH in lung cancer.
9824039|NCT02331407|Experimental|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
9824040|NCT02331446|No Intervention|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
9824041|NCT02331446|Experimental|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
9824042|NCT02331446|Experimental|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
9824043|NCT02331446|Experimental|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
9824044|NCT02331589|Active Comparator|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
9824045|NCT02331589|Placebo Comparator|Placebo (for KRG)|placebo (for KRG) for 3 weeks
9824046|NCT02331680|Experimental|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
9824047|NCT02331680|Experimental|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
9824048|NCT02331680|Placebo Comparator|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
9824049|NCT02331940|Active Comparator|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
9824050|NCT02331940|Active Comparator|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
9827221|NCT02448706|Active Comparator|Hearing Aid Fitting Order B|Low level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
10115983|NCT04444245|Experimental|ARM 3 emulsified tSVF and PRP, enriched with cSVF|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP tSVF preparation: Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue (Tulip Nanofat device).~cSVF preparation: lipoaspiration as above. Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocol. Quantification of viable nucleated cell count with flow cytometry. Addition of pellet of viable nucleated cells to tSVF.~Blending of tSVF/cSVF emulsion with PRP at a 3:1 ratio. Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible.~Intervention:"
10115984|NCT04444245|Experimental|ARM 4 Intra-ovarian guided placement|Specifically designed 23 gauge modified oocyte harvester needle for ultrasound guided placement
10115985|NCT04444154|Active Comparator|Control group|oral hygiene advice given orally
10115986|NCT04444154|Active Comparator|Group with active participation|oral hygiene advice given orally and demonstration of brushing methods in the sink with active participation
9668652|NCT05237414|Experimental|Binge Drinkers with Cognitive Intervention (active CT + sham tDCS)|Subjects perform the variation of the TNTA task for active CT. After the Learning Phase, sham neuromodulation is performed using the same montage of the active tDCS. However, the electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds. There is no current for the rest of the time.
10115987|NCT04444154|Experimental|Group with video and quizz|oral hygiene advice given orally and an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
10115988|NCT04444414|Experimental|Manual Therapy group|Bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
10115989|NCT04444414|Other|Control group|They received no treatment, they just went to the evaluations.
10115990|NCT04444180||Clinical high risk for psychosis (CHR)|No intervention. Just use virtual hand illusion (VHI) paradigm to observe the outcome of individuals with CHR at one-year follow-up node and analyze the predictive role of self-representation in transition into psychosis.
10115991|NCT04444180||First episode of schizophrenia (FES)|In contrast to FES, it is anticipated to observe CHR individuals with similar behavioral performance to FES may presented higher risk of transition.
10115992|NCT04444180||Healthy control (HC)|In contrast to HC, it is anticipated to observe CHR individuals with similar behavioral performance to HC may presented lower risk of transition.
10115993|NCT04444193|Experimental|Durvalumab and Lenvatinib|Combination therapy of Lenvatinib 80-120mg daily orally and durvalumab 1500mg by IV infusion every 4 weeks
10115994|NCT04444492|Experimental|Ranibizumab+Laser-arm|Ranibizumab injections and additional targeted laser
10115995|NCT04444492|Active Comparator|Ranibizumab-arm|Only Ranibizumab injections
10115996|NCT04444141|Experimental|AK104|AK104 450mg IV every 2 weeks (Q2W)
10115997|NCT04444388|Experimental|Cocoa group|5 g/day of flavonoid-rich defatted cocoa for 10 weeks
10115998|NCT04444388|Placebo Comparator|Placebo group|5 g/day of maltodextrin for 10 weeks
9694481|NCT04788654|Experimental|Pharmacologican and surgical group|Pharmacological and surgical analgesia will be performed.
9694482|NCT04788849||Women referred to colposcopy|Three sample types (urine, vaginal and cervical) will be collected from all enrolled women.
9824051|NCT02331992|Experimental|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
9824052|NCT02332239|Experimental|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored CBT-based text-message program"
9824053|NCT02332239|Placebo Comparator|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
10115999|NCT04444206|Experimental|CL and CCI screening|The Cervical lenght (CL) and the Consistence Cervix Index (CCI) will be evaluated by transvaginal ultrasound. CL and CCI measurements will be expected in the first trimester, between 11 and 13 weeks + 6 days, in the second trimester, between 19 and 22 weeks and in the third trimester between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy, in accordance with current national guidelines.
10116000|NCT04444206|No Intervention|No CL and CCI screening|The investigators collect data of these pregnant women without any additional ultrasound examination
10116001|NCT04444089|Experimental|conventional group, CG|receives Ringer's lactate solution at a rate of 4 ml/kg/h for the first-10 kg of body weight, 2 ml/kg/h for the second-10 kg of body weight, and 1 ml/kg/h for each further kg of body weight. The deficit volume is calculated as the maintenance volume multiplied by fasting hours and given as follows: 50% of the volume in the first hour, 25% of the volume in the second hour, and 25% of the volume in the third hour, in addition to the aforementioned maintenance volume
10116002|NCT04444089|Experimental|restricted group, RG|Patients in the RG receives Ringer's lactate solution at a rate of 3 ml/kg/h from the start to the end of surgery.
10116003|NCT04443920|Active Comparator|Tranexamic acid (TXA)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of 15 mg/kg of Tranexamic acid (TXA) before the release of the tourniquet. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
10116004|NCT04443920|Placebo Comparator|Placebo Normal Saline (NS)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of placebo (Normal Saline) in the volume calculated to be equal to the volume of 15 mg/kg of TXA. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
10116005|NCT04444037||OCT-guided PCI|PCI procedure was done with intra-coronary imaging OCT.
10116006|NCT04444037||Angiography-guided PCI|PCI procedure was done without any intra-coronary imaging assistance, guided by angiography alone
10116007|NCT04443829|Experimental|CD19CAR T-cells|Treatment with the ATIMP: CD19CAR T-cells
10116008|NCT04443946|Active Comparator|Group-P|Group-P: (Propofol group): 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
10116009|NCT04443946|Experimental|Group-PAS|Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 2.5 mg kg-1 h-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
10116010|NCT04443946|Experimental|Group-PS|Group-PS: (Propofol and Sevoflurane group): 2.5 mg kg-1 h-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time.
10116011|NCT04443946|Experimental|Group-S|Group-S: (Sevoflurane group): 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
10116012|NCT04443946|Experimental|Group-PSu|Group-PSu: (Propofol and Sufentanil group): 5 mg kg-1 h-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
10116013|NCT04443894|Active Comparator|PECS block|
10116014|NCT04443894|Active Comparator|local infiltration|
9694483|NCT04788537|Experimental|Intervention Group|
10116015|NCT04443998|Experimental|Bone reduction forceps|
10116016|NCT04443933||Cerebral Small Vessel Disease|In this group, patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI.
10116017|NCT04443933||non-Cerebral Small Vessel Disease|In this group, cerebral small vessel disease is ruled out by preoperative multimodal MRI.
10116018|NCT04443725|Experimental|Hydroxychloroquine plus Sofosbuvir/Daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days, Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days
10116019|NCT04443725|Active Comparator|Standard of care|Hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days
10116020|NCT04443790|Active Comparator|Obesecure Capsules (Test Group)|A dose of 500mg capsule twice daily of Polyherbal formulation Obesecure was given in the test group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
10116021|NCT04443790|Placebo Comparator|Plasicure (Control Group)|A dose of 500mg capsule twice daily of Placebo as Plasicure was given in the control group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
10116022|NCT04443842|Experimental|Intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentive, social incentives and weekly feedback on performance for 6 months.
9694484|NCT04788537|No Intervention|Nonintervention Group|
9694485|NCT04788719|Experimental|Preoperative|Gait analysis kinematics and kinetics
9694486|NCT04788719|Experimental|Postoperative|Gait analysis kinematics and kinetics
9694487|NCT04788732||1-Inhalation Anesthesia|patients in this group will be anesthetized only with an inhaled anesthetic ( Sevoflurane ).
9694488|NCT04788732||2-Total Intravenous Anesthesia|the patients in this group will be anesthetized with only intravenous drugs such as benzodiazepícos (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not to relaxing neuromuscular (nondepolarizing/depolarizing), and adjuvant drugs such as dextrocetamina, dexmedetomidine, lidocaine, and magnesium sulfate.
9824054|NCT02332291|Active Comparator|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
9824055|NCT02332291|Placebo Comparator|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
9824056|NCT02332707|Experimental|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
9824057|NCT02332707|Experimental|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
9824058|NCT02332707|Experimental|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
9824059|NCT02332707|Experimental|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
9824060|NCT02332707|Experimental|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
9824061|NCT02332707|Experimental|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
9824062|NCT02332707|Experimental|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
9824063|NCT02332707|Experimental|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
9824064|NCT02332707|Experimental|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
9824065|NCT02332707|Experimental|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
9824066|NCT02332707|Experimental|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
9824067|NCT02332707|Experimental|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
9824068|NCT02332707|Experimental|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
9824069|NCT02332707|Experimental|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
9824070|NCT02332707|Experimental|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
9824071|NCT02332707|Experimental|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
9824072|NCT02332707|Experimental|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
9824073|NCT02332707|Experimental|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
9824074|NCT02332720|Experimental|A1: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
9824075|NCT02332720|Experimental|A2: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
9824076|NCT02332720|Experimental|A3: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
9824077|NCT02332720|Experimental|A4/B4: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|Participants will be randomized to either Part A or Part B. In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
9824078|NCT02332720|Experimental|B5: GT3 NC TN MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
9824079|NCT02332720|Experimental|B6: GT3 NC TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
9824080|NCT02332720|Experimental|B7: GT3 NC TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
9824081|NCT02332720|Experimental|B8: GT3 NC TE MK-3682B (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
9824082|NCT02332720|Experimental|B9: GT3 NC TE MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
9824083|NCT02332720|Experimental|B10: GT3 NC TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
9824084|NCT02332720|Experimental|B11: GT3 NC TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682 FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
9824085|NCT02332720|Experimental|B12: GT3 NC TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
9824086|NCT02332720|Experimental|B13: GT3 C TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
9824087|NCT02332720|Experimental|B14: GT3 C TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
9824088|NCT02332720|Experimental|B15: GT3 C TN MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
9824089|NCT02332720|Experimental|B16: GT3 C TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
9824090|NCT02332720|Experimental|B17: GT3 C TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
9824091|NCT02332720|Experimental|B18: GT3 C TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
9824092|NCT02332720|Experimental|B19: GT3 C TE MK-3682B + RBV (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.
9824093|NCT02332720|Experimental|B20: GT4 NC TN MK-3682B (8 weeks)|In Part B, HCV GT4-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
9824094|NCT02332720|Experimental|B21: GT5 NC TN MK-3682B (12 weeks)|In Part B, HCV GT5-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
9824095|NCT02332720|Experimental|B22: GT6 NC TN MK-3682B (12 weeks)|In Part B, HCV GT6-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
9824096|NCT02332798|Experimental|PF-04958242 0.25 mg|All participants who received PF-04958242 0.25 milligram (mg) twice daily (BID) for 14 consecutive days with the last dose occurring in the morning on Day 14.
9824097|NCT02332798|Experimental|PF-04958242 0.475 mg|All participants who received PF-04958242 0.475 mg BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
9824098|NCT02332798|Placebo Comparator|Matching Placebo|All participants who received placebo BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
9824099|NCT02332824|Placebo Comparator|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
9824100|NCT02332824|Experimental|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
9824101|NCT02332824|Experimental|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
9824102|NCT02332824|Experimental|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
9824103|NCT02332824|Experimental|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
9824104|NCT02332824|Active Comparator|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
9824105|NCT02332863|Active Comparator|Back-loaded needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G back-loaded needle. CRFs will be used to record data for primary and secondary endpoints.
9824106|NCT02332863|Experimental|Preloaded Needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G preloaded needle. CRFs will be used to record data for primary and secondary endpoints.
9824107|NCT02332876|Experimental|Exercise Intervention|This arm will receive a 12-week individually tailored phone and email-based exercise program.
9824108|NCT02332876|Active Comparator|Wellness Waitlist Control|This arm will receive emails on the same schedule as the exercise arm, that cover a variety of health and wellness topics. At the end of the 12 weeks, participants will be able to start the exercise program.
9824109|NCT02332889|Experimental|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
9824110|NCT02332902|Experimental|Intervention|This is a single arm intervention using Everolimus
9824111|NCT02332915|Experimental|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
9824112|NCT02332915|Experimental|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
9824113|NCT02333045|Experimental|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
9824114|NCT02333045|Experimental|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
9824115|NCT02333071|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
9824116|NCT02333071|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
9519463|NCT03286868|Placebo Comparator|Standard of Care TKA|Standard of Care Total Knee Arthroplasty (TKA): No data from the Verasense sensor will be used to influence the surgery
9824117|NCT02333331|Experimental|BYM338 70 mg|BYM338 70 mg intravenous infusion
9824118|NCT02333331|Experimental|BYM338 210 mg|BYM338 210 mg intravenous infusion
9824119|NCT02333331|Experimental|BYM338 700 mg|BYM338 700 mg intravenous infusion
9824120|NCT02333331|Placebo Comparator|Placebo|Placebo intravenous infusion
9824121|NCT02333383||Participants with Ankylosing Spondylitis|Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks
9824122|NCT02333487|Experimental|Lu AF35700 (Group D1)|Up to 3 PET scans, besides baseline scan, using [11C]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
9824123|NCT02333487|Experimental|Lu AF35700 (Group D2)|Up to 3 PET scans, besides baseline scan, using [11C]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
9824124|NCT02333487|Experimental|Lu AF35700 (Group 5-HT6)|Up to 3 PET scans, besides baseline scan, using [11C]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700
9824125|NCT02333630|Experimental|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
9824126|NCT02333630|Active Comparator|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
9824127|NCT02334059|Active Comparator|Ketamine|Ketamine: 0.5 mg/kg IV dose
9824128|NCT02334059|Active Comparator|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
9824129|NCT02334059|Placebo Comparator|Placebo|Placebo (normal saline)
9824130|NCT02334215|Experimental|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
9824131|NCT02334215|Experimental|Methadone|Participants will begin methadone during detention.
9824132|NCT02334215|Active Comparator|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
9824133|NCT02334267|Active Comparator|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
9824134|NCT02334267|Active Comparator|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
9824135|NCT02334306|Experimental|MEDI5872 210 mg|Participants will receive a fixed SC dose of 210 mg MEDI5872 every week (QW) from Days 1 to 15 and then every 2 weeks (Q2W) from Days 29 to 85 in double-blind period. In open-label period, participants will continue dosing of MEDI5872 210mg Q2W from Days 99 to 183 and will receive an additional dose of blinded placebo on Day 106.
9824136|NCT02334306|Placebo Comparator|Placebo/MEDI5872 210 mg|Participants will receive a SC dose of placebo matching with MEDI5872 QW on Days 1, 8, and 15 and then Q2W from Days 29 to 85 in double-blind period. In open-label period, participants will receive a fixed SC dose of 210 mg MEDI5872 QW (Days 99 to 113) and Q2W (Days 127 to 183) in open-label period.
9824137|NCT02334358||YVOIRE Classic s|Treatment with YVOIRE Classic s
9824138|NCT02334384|Experimental|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
10116023|NCT04443842|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
9824139|NCT02334384|No Intervention|Standard of care - standard wound packing|In this control arm the subject will receive standard of care with standard wound packing. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
9824140|NCT02334423|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
9824141|NCT02334423|Placebo Comparator|Placebo|0.9 % sterile, unpreserved saline
9824142|NCT02334436|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
9824143|NCT02334436|Placebo Comparator|Placebo|0.9% sterile, unpreserved saline
9824144|NCT02334527|Other|Palbociclib Single Arm trial|Palbociclib
9824145|NCT02334683|Experimental|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
9824146|NCT02334683|Active Comparator|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
9824147|NCT02334748|Experimental|canakinumab|Patients will continue the same dose as their last dose administered in the study CACZ885G2301E1, CACZ885N2301 or CACZ885G2306. For all indications, the maximum canakinumab dose is 4 mg/kg or 300 mg for patients ≥ 40 kg. Ilaris® dosage may be adjusted (or interrupted) according to the clinical response and to investigators judgment.
9824148|NCT02334787|Experimental|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
9824149|NCT02334787|Experimental|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
9824150|NCT02334787|Experimental|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
9824151|NCT02334787|Placebo Comparator|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
9824152|NCT02334787|Experimental|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
9824153|NCT02334787|Experimental|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
9824154|NCT02334787|Experimental|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
9824155|NCT02334787|Experimental|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
9824156|NCT02334800|Experimental|Healthy Volunteers|Cohort of Healthy Volunteers
9824157|NCT02334800|Experimental|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
9824158|NCT02334800|Experimental|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
9824159|NCT02334800|Experimental|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
9824160|NCT02334813|Active Comparator|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to <25 mg/d by week 14 and <7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
9824161|NCT02334813|Active Comparator|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
9824162|NCT02334982|Experimental|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
9824163|NCT02334982|Experimental|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
9824164|NCT02334982|Experimental|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
9824165|NCT02334982|Experimental|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
9824166|NCT02334982|Experimental|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
9824167|NCT02334982|Experimental|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
9824168|NCT02334982|Placebo Comparator|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
9824169|NCT02335125|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
9824170|NCT02335125|No Intervention|Usual Care|Only standard care practices will be administered to this arm.
9824171|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
9824172|NCT02335229||Axium DRG Neurostimulator|All eligible subjects recruited and treated with the Axium Neurostimulator
9824173|NCT02335294|Experimental|TRV130|
9824174|NCT02335294|Active Comparator|Morphine|
9824175|NCT02335294|Placebo Comparator|Placebo|
9824176|NCT02335346|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
9824177|NCT02335450|Experimental|Single Arm|All five participants in the study will receive this intervention. The participants will be visited in their homes by a physical therapist once a week. The physical therapist will use a coaching technique called motivational interviewing to help the participant develop personal physical activity goals. The participant will discuss their physical activity challenges, and with the help of the physical therapist the participant will set up personal physical activity goals for the following week. The participant will be given a wristband physical activity monitor to wear during the day for four weeks to track their progress in meeting their activity goals.
9824178|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
9824179|NCT02335502||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
9824180|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith & Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
9824181|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
9824182|NCT02335905|Experimental|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
9824183|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 56 mg/m²|"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
9824184|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
9824185|NCT02335983|Experimental|RRMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
9824186|NCT02335983|Experimental|NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²|"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
9824187|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
9824188|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 56 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
10116024|NCT04443959|Experimental|MBTI Treatment|Telemedicine-assisted digital mindfulness-based therapy for insomnia (MBTI).
10116025|NCT04443868|Experimental|Nitric Oxide Releasing Solution|Daily nasal irrigation (240mL) 14.4ppm
9824189|NCT02336074|Active Comparator|Control|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)
9824190|NCT02336074|Experimental|Intervention|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).
9824191|NCT02336165|Experimental|Cohort A|Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
10116026|NCT04443868|Placebo Comparator|Placebo Isotonic Saline|Daily nasal irrigation (240mL) 0.9% saline
10116027|NCT04444024||NTC/-HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to normal TC/ none hypertension(NTC/-HTN) group.
10116028|NCT04444024||NTC/+HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to normal TC/ hypertension(NTC/+HTN) group.
9824192|NCT02336165|Experimental|Cohort B|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
9824193|NCT02336165|Experimental|Cohort B2|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
9824194|NCT02336165|Experimental|Cohort B3|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
9824195|NCT02336165|Experimental|Cohort C|Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
9824196|NCT02336178|Experimental|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
9824197|NCT02336282|Active Comparator|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
9824198|NCT02336282|Active Comparator|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
9824199|NCT02336360|Experimental|Urine Analysis|Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
9824200|NCT02336373|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
9824201|NCT02336438|No Intervention|Baseline Phase (Control)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours."
9824202|NCT02336438|Experimental|Treatment Phase (Glucomannan)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals."
9824203|NCT02336451|Experimental|Arm 1 (PrALKi=Y, PrBRad=Y)|Participants with metastases in the brain without evidence of leptomeningeal carcinomatosis (LC), previously treated with radiation to the brain and with prior exposure to an Anaplastic lymphoma kinase inhibitor (ALK-I). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
9824204|NCT02336451|Experimental|Arm 2 (PrALKi=Y, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
9824205|NCT02336451|Experimental|Arm 3 (PrALKi=N, PrBRad=Y)|Participants with metastases in the brain without evidence of LC, previously treated with radiation to the brain but with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
9824206|NCT02336451|Experimental|Arm 4 (PrALKi=N, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain and with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
9824207|NCT02336451|Experimental|Arm 5 (LepDis)|Participants had LC with or without evidence of active lesion at the baseline Gadolinium-enhanced brain magnetic resonance imaging (MRI). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3.
9824208|NCT02336555|Experimental|MK-8291 → Placebo|In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
9827222|NCT02448719|Experimental|Cohort 1-active|Single oral administration of TAK-792 30 milligram (mg) in Japanese participants
9827223|NCT02448719|Placebo Comparator|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
10116029|NCT04444024||BHTC/-HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to borderline-high TC/ none hypertension (BHTC/-HTN) group.
10116030|NCT04444024||BHTC/+HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to borderline-high TC/ hypertension (BHTC/+HTN) group.
9668653|NCT05237414|Sham Comparator|Binge Drinkers with Control Intervention (sham CT + sham tDCS)|"Subjects will perform a variation of the TNTA task, where the Learning phase also have only two blocks of 12-image pairs. However, in this case the TNT phase is replaced by a Forced-Choice Reaction Time (FCRT) task, during which the participants only must categorize alcoholic and non-alcoholic images answering to the question What type of beverage was there in the image? (answer: Alcoholic drink or Non-alcoholic drink); thus, they do not have to inhibit the memories related to the alcoholic images. During this phase, sham neuromodulation will be performed using the same montage of the active tDCS. The electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds, while a sham memory inhibition CT is performed."
9668654|NCT05237414|No Intervention|Non/Low-Drinkers|No intervention.
9668655|NCT05234008|Experimental|home therapy group|one group of 15 participants (i.e. persons with CLBP) performing a six-week HIT exercise intervention with a total of 12 rehabilitation sessions (two sessions per week).
9824209|NCT02336555|Experimental|Placebo → MK-8291|In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
9824210|NCT02336594|Experimental|Sequence ABCD|2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.
9824211|NCT02336594|Experimental|Sequence BACD|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat
9824212|NCT02336594|Experimental|Sequence ABDC|2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
9824213|NCT02336594|Experimental|Sequence BADC|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
9824214|NCT02336607|Experimental|Felodipine tablet (Plendil)|
9824215|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
9824216|NCT02336607|Active Comparator|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
9824217|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Hydrochlorothiazide|
9824218|NCT02336737|Experimental|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
9965833|NCT01253681|Experimental|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
9668656|NCT05231382|Experimental|Experimental group SALOX regimen|The therapeutic scheme was SLAOX regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), Raltitrexed (3mg/m2 infusion for 30-60 minutes on day 1)
9824219|NCT02336815|Experimental|Part 1|Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).
9824220|NCT02336815|Experimental|Part 2|Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).
9824221|NCT02336958|Active Comparator|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
9824222|NCT02336958|Placebo Comparator|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
9824223|NCT02337062|Experimental|APD421 + standard anti-emetic|Single dose of IV APD421
9824224|NCT02337062|Placebo Comparator|Placebo + standard anti-emetic|Single dose of IV placebo
9824225|NCT02337218|Active Comparator|SENSUS Pain Management System|Electrical stimulation device worn on the leg delivering a dose of 50 volts.
9824226|NCT02337218|Sham Comparator|SENSUS Pain Management System - Sham|Electrical stimulation device worn on the leg and programmed to deliver no stimulation.
9824227|NCT02337361|Experimental|e-SBI|Single session, Electronic SBI for risky alcohol use
9824228|NCT02337361|No Intervention|Control|Treatment as usual with only assessment
9824229|NCT02337387|Experimental|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
10116031|NCT04444024||HTC/-HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to high TC/ none hypertension(HTC/-HTN) group.
9668657|NCT05231382|Active Comparator|Control group FOLFOX regimen|The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours).
9668658|NCT05224453|Other|Physical training and high protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d).
9824230|NCT02337387|Experimental|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
9824231|NCT02337387|Placebo Comparator|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
9824232|NCT02337387|Experimental|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
9824233|NCT02337465|Experimental|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
9824234|NCT02337478|Experimental|Treatment (vincristine sulfate liposome)|Patients receive vincristine sulfate liposome via injection on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9824235|NCT02337491|Experimental|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
9824236|NCT02337491|Experimental|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
10116032|NCT04444024||HTC/+HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 80 mmHg belong to high TC/ hypertension(HTC/+HTN) group.
10116033|NCT04443556|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|Standart postoperative analgesia + Continue Rhomboid Intercostal and Subserratus Plane Block
10116034|NCT04443556|Other|Control Group|Standart postoperative analgesia
10116035|NCT04443777|Active Comparator|Sulphonylurea Group|Gliclazide 60 mg (Diamicron® MR) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
10116036|NCT04443777|Placebo Comparator|Placebo Group|Placebo (starch, sodium lauryl sulfate and Aerosil) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
10116037|NCT04443634|Experimental|Adductor 20|Ultrasound guided adductor canal block will be performed with injection of 20 ml bupivacaine
10116038|NCT04443634|Experimental|Adductor 30|Ultrasound guided adductor canal block will be performed with injection of 30ml bupivacaine
10116039|NCT04443634|Experimental|Adductor /Saphenous|Ultrasound guided adductor canal block will be performed by injection of 20 ml bupivacaine , combined with ultrasound guided saphenous nerve block at the distal third of the thigh in the intermuscular plane between Vastus Medialis and Sartorius muscle with injection of 10ml bupivacaine 0.5%.
10116040|NCT04443972|Experimental|PD VitalOs cement® alone|class II furcation defects that will be treated with PD VitalOs cement® alone
10116041|NCT04443972|Experimental|PD VitalOs cement® plus Bone graft and membrane|PD VitalOs cement® and Hydroxyapatite bone graft and biodegradable collagen membrane in the treatment of class II furcation defects.
10116042|NCT04443452||Prevalent Central Sensitisation|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
10116043|NCT04443452||Non-prevalent Central Sensitisation|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
10116044|NCT04443673|Experimental|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
10116045|NCT04443673|No Intervention|Control|Participants will receive the habitual treatment for their severe condition.
10116046|NCT04443517|Experimental|Maintenance-Alpha Optimization / Wake from Propofol|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive individualized titration of anesthetic gas and opioid. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
10116047|NCT04443517|Active Comparator|Maintenance-Alpha Optimization / Wake from Volatile|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive real-time monitoring of alpha recordings and individualized titration of desflurane and opioid. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
10116048|NCT04443517|Active Comparator|Maintenance-Routine Care / Wake from Propofol|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
9824237|NCT02337491|Experimental|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
9824238|NCT02337517|Experimental|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
9824239|NCT02337530|Active Comparator|Arm A|"Selumetinib: 75mg/ bid PO given on days 2-19 Pemetrexed: 500mg/m^2 & Cisplatin or Carboplatin*: AUC6: 75mg/m^2 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
9827224|NCT02448719|Experimental|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
9827225|NCT02448719|Placebo Comparator|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
9824240|NCT02337530|Active Comparator|Arm B|"Selumetinib: 75mg/ bid PO given on days 1-21 (continuous) Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC 6 given on day 1 Schedule = q 21 days~**Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
9824241|NCT02337530|Active Comparator|Arm C|"Selumetinib: NOT GIVEN Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC6 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
9824242|NCT02337907|Placebo Comparator|Placebo comparator|
9824243|NCT02337907|Experimental|BI 409306 dose 1|
10116049|NCT04443517|No Intervention|Maintenance-Routine Care / Wake from Volatile|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
10182628|NCT03772262|Experimental|Treatment|Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
10182629|NCT03772379|Experimental|tooth borne hyrax expander group|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars .
9824244|NCT02337907|Experimental|BI 409306 dose 2|
9824245|NCT02337907|Experimental|BI 409306 dose 3|
9824246|NCT02337907|Active Comparator|Active Comparator Donepezil|
9824247|NCT02337907|Experimental|BI 409306 dose 4|
9824248|NCT02337933|Experimental|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
9824249|NCT02337933|Placebo Comparator|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
9824250|NCT02337946|Active Comparator|Group A|Panitumumab (Pmab) 6 mg/kg, intravenous drip infusion (DIV), at Day 1, oxaliplatin (OXA) 85 mg/m^2, DIV, at Day 1, levofolinate (l LV) 200 mg/m^2, DIV, at Day 1, fluorouracil (5-FU) 400 mg/m^2, intravenous (IV) at Day 1, 5-FU 2400 mg/m^2, continuous intravenous infusion (CIV), at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
9824251|NCT02337946|Experimental|Group B|Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
9824252|NCT02337959|Experimental|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
9824253|NCT02337959|Experimental|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
9824254|NCT02337959|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
9824255|NCT02338076|Experimental|Interventional arm|petrolatum application under occlusion
9824256|NCT02338193|Experimental|DAPA/MET Extended Release (XR)|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
9824257|NCT02338193|Active Comparator|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
9824258|NCT02338193|Active Comparator|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
9824259|NCT02338336|Placebo Comparator|Placebo|Placebo
9824260|NCT02338336|Experimental|Nowarta110 3 drops|Nowarta110 3 drops administration
9824261|NCT02338336|Experimental|Nowarta110 6 drops|Nowarta110 6 drops administration
9824262|NCT02338336|Experimental|Nowarta110 10 drops|Nowarta110 10 drops administration
9824263|NCT02338362|Active Comparator|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
9824264|NCT02338362|Placebo Comparator|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
9824265|NCT02338492|Experimental|Photodynamic Bone Stabilization System|Photodynamic Bone Stabilization System (PBSS) is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone
9824266|NCT02338713|Experimental|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
9824267|NCT02338843|Experimental|LJPC-501 (angiotensin II)|Treatment arm
9824268|NCT02338843|Placebo Comparator|Placebo (0.9% sodium chloride solution)|Placebo arm
9824269|NCT02338882|Experimental|Bi flex M multifocal intraocular lens|Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
9824270|NCT02338882|Active Comparator|Bi flex 1.8 monofocal intraocular|Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
9827226|NCT02448719|Experimental|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
9827227|NCT02448719|Placebo Comparator|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
9824271|NCT02338960|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
9824272|NCT02338960|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
9824273|NCT02338973|Experimental|Interferon Gamma-1b|Topical interferon (IFN) gamma-1b, 112 µg dose, administered in study eye daily for two weeks
9824274|NCT02338999|Experimental|Pioglitazone, then placebo|Treatment with pioglitazone up to 45 mg orally daily for three months. Followed by a two-month washout period before cross over to placebo orally daily for three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
9824275|NCT02338999|Experimental|Placebo, then Pioglitazone|Treatment with placebo orally daily for three months. Followed by a two-month washout period before cross over to pioglitazone up to 45 mg daily orally for an additional three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
9824276|NCT02339038|Other|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
9824277|NCT02339155|Experimental|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
9824278|NCT02339155|Experimental|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
9824279|NCT02339246|Active Comparator|Prograf vs Envarsus XR vs Astagraf XL|Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
9824280|NCT02339246|Active Comparator|Prograf vs Astagraf XL vs Envarsus XR|Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
9824281|NCT02339285|Experimental|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
9824282|NCT02339285|Experimental|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
9824283|NCT02339285|Sham Comparator|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
9824284|NCT02339389||ventilation during labor analgesia|We are simply measuring ventilation changes that occur following labor analgesia.
9824285|NCT02339415|Active Comparator|Treatment|Edoxaban 30mg daily
9824286|NCT02339415|Placebo Comparator|Placebo|Matching Placebo
9824287|NCT02339506|Active Comparator|Cosyntropin|Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
9824288|NCT02339506|Placebo Comparator|Normal saline (Placebo)|Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
9824289|NCT02339545||All Enrolled Subjects|All subjects will receive Coronary Flow Reserve (CFR) measurements post successful orbital atherectomy treatment and stenting.
10116050|NCT04443621||participants with early stage dementia|Subjects with diagnosed any type of dementia at an early phase (MMSE score 20 - 25 points) - for longitudinal study (three phasis).
9824290|NCT02339558|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9824291|NCT02339584|Experimental|Brinz/Brim|Vehicle solution, 1 drop, followed by Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) twice daily (BID) for 3 months
9824292|NCT02339584|Active Comparator|Brinz+Brim|Brimonidine 2 mg/mL eye drops, solution, 1 drop, followed by Brinzolamide 10 mg/mL eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) BID for 3 months
9824293|NCT02339831|Active Comparator|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
9824294|NCT02339831|Active Comparator|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
9827228|NCT02448719|Experimental|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
9827229|NCT02448719|Placebo Comparator|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
9827230|NCT02448719|Experimental|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
9827231|NCT02448719|Placebo Comparator|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
9827232|NCT02448719|Experimental|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
9827233|NCT02448719|Placebo Comparator|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
10116051|NCT04443621||participants without dementia|Subjects without dementia with MMSE score 26 - 30 points (for validation of ACE-III).
10116052|NCT04443595|Experimental|Experimental|Treatment of Acute Severe Pancreatitis with DPN
10116053|NCT04443413|Experimental|Arm I (x-ray therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo x-ray therapy over 25 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may then receive a 4-fraction boost of x-ray therapy.
9824295|NCT02339909|Active Comparator|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
9824296|NCT02339909|Experimental|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
9824297|NCT02339909|Experimental|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
9824298|NCT02340000|Active Comparator|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
9824299|NCT02340000|Experimental|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
9824300|NCT02340078|Active Comparator|HA IDF II|cross-linked HA filler
9824301|NCT02340078|Experimental|HA IDF II plus|cross-linked HA filler with lidocaine
9824302|NCT02340091|Experimental|HA IDF plus|cross-linked HA filler with lidocaine
9824303|NCT02340091|Active Comparator|HA IDF|cross-linked HA filler without lidocaine
9824304|NCT02340104|Experimental|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
9824305|NCT02340156|Experimental|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
9824306|NCT02340299|Experimental|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
9824307|NCT02340299|Active Comparator|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
9824308|NCT02340338|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
9824309|NCT02340338|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
9824310|NCT02340338|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
9824311|NCT02340338|Experimental|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
9824312|NCT02340338|Experimental|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
9824313|NCT02340338|Experimental|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
9824314|NCT02340338|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
9824315|NCT02340520|Experimental|thophylline and roflumilast|Theophylline for one week, followed by the addition of Roflumilast for a further one week.
9824316|NCT02340663|Experimental|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
10182630|NCT03772379|Experimental|tooth borne hyrax expander with microosteoperforation|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars and microosteoperforation .
9824317|NCT02340663|Active Comparator|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
9824318|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
9824319|NCT02340767|No Intervention|No Device Clinicians|The clinicians will not receive any additional training.
9824320|NCT02340767|Experimental|Spectra Device Clinicians|The clinicians in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
9827234|NCT02448771|Experimental|Palbociclib in Combination with Bazedoxifene|"Palbociclib 125 mg Oral on days 1-21 per cycle Bazedoxifene 40 mg Oral on days 1-28 per cycle~One cycle is 28 days."
9824321|NCT02340767|Experimental|DIAGNOdent Device Practitioners|The clinicians in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
9824322|NCT02340780|Experimental|Buparlisib|100mg daily orally every 28 days
9824323|NCT02340806|Experimental|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
9824324|NCT02340806|Experimental|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
9824325|NCT02340819|Experimental|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
9824326|NCT02340949|Experimental|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
9824327|NCT02340949|Active Comparator|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
9824328|NCT02340962|Experimental|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
9824329|NCT02340962|Experimental|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
9824330|NCT02340975|Experimental|Phase 1b-M20 mg/kg (Q4W) + T 1 mg/kg (Q4W) Fw M10 mg/kg (Q2W)|Participants in second-line therapy with gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive intravenous (IV) infusion of 20 mg/kg MEDI4736 every 4 weeks (Q4W) for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
9824331|NCT02340975|Experimental|Phase 2 Arm A-(M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
9824332|NCT02340975|Experimental|Phase 2 Arm B-M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg MEDI4736 Q2W for 12 months (up to 26 doses).
9824333|NCT02340975|Experimental|Phase 2 Arm C-T10 mg/kg (Q4W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg tremelimumab Q4W for 7 doses and then Q12W for 2 doses for 12 months (for a total of up to 9 doses).
9824334|NCT02340975|Experimental|Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
9824335|NCT02340975|Experimental|Phase 2 Arm E-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second and third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma and a positive IFN-γ gene expression signature will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
9824336|NCT02341144|Active Comparator|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
9824337|NCT02341144|Active Comparator|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
9824338|NCT02341417|Experimental|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received > 14 days before day 1 of this study.~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
9824339|NCT02341456|Experimental|AZD1775|AZD1775 will be administered orally as a single dose on Day 1 Cycle 0. Following a 5±2 days washout period, AZD1775 (5 doses BID over 2.5 days) will be taken in combination with paclitaxel and carboplatin in each 21-day cycle for 6 cycles. Following 6 cycles of combination treatment, patients may continue on AZD1775 monotherapy (5 doses BID Day 1 to Day 2.5 in each 21-day cycle) at the investigator's discretion.
10116054|NCT04443413|Experimental|Arm II (proton beam radiation therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 days since the last chemotherapy, patients undergo proton beam radiation therapy over 5 fractions in the absence of disease progression or unacceptable toxicity. Optionally, patients may receive a concurrent 5-fraction boost of proton beam radiation therapy.
10116055|NCT04443608|Active Comparator|Veltassa|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
9824340|NCT02341456|Experimental|Paclitaxel|Commercially available paclitaxel will be administered at a dosage of 175 mg/m2 as a 3-hour IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles.
9824341|NCT02341456|Experimental|Carboplatin|Following the paclitaxel infusion, carboplatin will be administered at a dose of AUC 5 as an IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles. According to the Cancer Therapy Evaluation Program Information Letter Regarding the AUC Based Dosing of Carboplatin, the maximum carboplatin dose should not exceed the target AUC (mg*min/mL)*150 mL/min, but it may be less (Ivy et al 2010). For this study, the maximum dose of carboplatin cannot exceed a total dose of 750 mg.
9824342|NCT02341482|Experimental|PF-04958242 and itraconazole|"PF-04958242 will be provided in a capsule. Participants will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.~Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17)."
9824343|NCT02341599|Experimental|Group A: Healthy|Healthy participants with normal renal function (Stage 1: eGFR ≥90 mL/min/1.73m^2).
9824344|NCT02341599|Experimental|Group B: Mild RI|Participants with mild RI (Stage 2: eGFR ≥60 to <90 mL/min/1.73m^2).
9824345|NCT02341599|Experimental|Group C: Moderate RI|Participants with moderate RI (Stage 3: eGFR ≥30 to <60 mL/min/1.73m^2).
9824346|NCT02341599|Experimental|Group D: Severe RI|Participants with severe RI (Stage 4: eGFR <30 mL/min/1.73m^2) not receiving HD.
9824347|NCT02341599|Experimental|Group E: ESRD-HD|Participants with ESRD who are receiving HD for at least 3 months preceding the initial dose in this study (Stage 5).
9824348|NCT02341859|Active Comparator|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
9824349|NCT02341859|Active Comparator|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
9824350|NCT02342015|Experimental|Atorvastatin|Atorvastatin 40 mg/day for three months
9824351|NCT02342171|Experimental|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children <45kg
9824352|NCT02342171|No Intervention|standard care|The control arm will consist of historical controls having being treated with standard of care
9824353|NCT02342197|Active Comparator|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
9824354|NCT02342197|Active Comparator|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
9824355|NCT02342223|Experimental|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
9824356|NCT02342288|Experimental|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
9824357|NCT02342288|Active Comparator|Head in neutral position|Head in neutral position
9824358|NCT02342314|Experimental|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
9824359|NCT02342314|Experimental|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
10116056|NCT04443608|Placebo Comparator|Placebo|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
10116057|NCT04443439||No related neurological symptoms and transient ischemic attack|Mild stenosis group: CTA suggested carotid stenosis < 30%; Moderate stenosis group: CTA suggested carotid stenosis of 30-69%; Severe stenosis group: CTA indicated carotid stenosis ≥70%;
9824360|NCT02342314|Placebo Comparator|Placebo (Part A)|Single SC injection of normal saline on Day 1
9824361|NCT02342314|Active Comparator|rGlucagon (Part B)|Single SC injection on Day 1
9824362|NCT02342314|Placebo Comparator|Placebo (Part B)|Single SC injection of normal saline on Day 1
9824363|NCT02342327|Other|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
9824364|NCT02342327|Other|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
9824365|NCT02342379|Experimental|Bevacizumab and TH-302|Patients will be treated with combination of bevacizumab and TH-302.
9824366|NCT02342418|Active Comparator|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
9824367|NCT02342418|Active Comparator|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
9824368|NCT02342535|Other|Physical activity intervention|"Participants will attend bi weekly exercise classes for a total of 16 weeks, led by certified, and trained instructors.~The participant's children between the ages of 6 and 14 years will participate in the martial arts class with the mothers."
9824369|NCT02342548|Experimental|20 mg BID PF-02545920 non-titrated|Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920
9824370|NCT02342548|Experimental|20mg BID PF-02545920 titrated|Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)
9824371|NCT02342561|Experimental|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
9824372|NCT02342561|No Intervention|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
9824373|NCT02342639|Experimental|Rifaximin|Participants will receive a 10-day course of Rifaximin.
9824374|NCT02342639|Placebo Comparator|Placebo|Participants will receive a 10-day course of placebo.
9824375|NCT02342678|Experimental|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
10116058|NCT04444011|Experimental|Anaprazole Sodium enteric-coated tablet|Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), one tablet each time.
10116059|NCT04444011|Experimental|Amoxicillin capsules|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 capsules each time."
10116060|NCT04444011|Experimental|Clarithromycin tablet|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 tablets each time."
10116061|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin|"Cohort 1: Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods ( only once on the morning of D5 of treatment periods).~Cohort 2: Administered orally on an empty stomach once on the morning of D1 of treatment periods"
10116062|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin+Bismuth|Administered orally on an empty stomach once on the morning of D1 of treatment periods in cohort 2
10116063|NCT04443647|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
10116064|NCT04443647|Placebo Comparator|Placebo|Saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
10116065|NCT04443881|Experimental|Anakinra Arm|Standard of care plus Anakinra (100mg) administered as 4-times daily i.v. infusions for a maximun of 15 days
10116066|NCT04443881|No Intervention|Control Arm|Standard of care
10116067|NCT04443387|Active Comparator|Asthmatic low vitamin D on treatment|asthmatic patient low vitamin D level received treatment for Vitamin D 50000IU weekly
10116068|NCT04443387|Placebo Comparator|Asthmatic low vitamin D on placepo|asthmatic patient low vitamin D level received placepo
10116069|NCT04443543|Experimental|Arm 1|"Arm 1 includes patients with MSS/pMMR. In this arm, patients receive consolidation chemotherapy after neoadjuvant chemoradiation (nCRT). The chemotherapy regimens either XELIRI or FOLFIRINOX, and the cycles of chemotherapy depend on patient tumor responses. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
10116070|NCT04443543|Experimental|Arm 2|"Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
10116071|NCT04443127|Experimental|Game-Based Rehabilitation|
9824376|NCT02342678|Experimental|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
9824377|NCT02342704|Experimental|natalizumab|Open-label natalizumab 300 mg IV every 4 weeks (Q4W)
9824378|NCT02342704|Active Comparator|fingolimod|Open-label fingolimod 0.5 mg once daily orally
9824379|NCT02342743|Experimental|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
9824380|NCT02342886|Experimental|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
9824381|NCT02342886|Active Comparator|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:~HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight~HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
9824382|NCT02342886|Experimental|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
10116072|NCT04443127|Placebo Comparator|Conventional Rehabilitation|
10116073|NCT04443270|Experimental|Chloroquine phosphate prophylactic group|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
10116074|NCT04443270|No Intervention|Control group|Health personnel who want to be included voluntary in the study and meet the inclusion criteria without Chloroquine use.
10116075|NCT04443322|Experimental|Durvalumab and Lenvatinib|"Participants receive intravenous (IV) durvalumab at 1500mg on Day 1 of each 28-day cycle. Number of cycles: until unacceptable toxicity develops or >42 days before liver transplantation (If patients with locally advanced HCC would undergo liver transplant).~Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation(If patients with locally advanced HCC would undergo liver transplant)."
10116076|NCT04443036|Experimental|Albumin-bound Paclitaxel Combined With Toripalimab|"Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W~Toripalimab：240 mg，IV d1，Q3W~until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months"
10116077|NCT04443075||exposed group|The exposed group consists of the frontline medical workers who take part in the medical team to support Wuhan.
10116078|NCT04443075||non-exposed group|This group includs medical workers who didn't join in the medical team to support Wuhan.
10116079|NCT04443101||Group（SN6CWS）|Group（SN6CWS）：Implant SN6CWS intraocular lens
9824383|NCT02342886|Experimental|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
9824384|NCT02342886|Experimental|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
9824385|NCT02343003|Experimental|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
9824386|NCT02343003|Active Comparator|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
9824387|NCT02343081|Active Comparator|Temodal|Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
9824388|NCT02343081|Experimental|Dralitem|Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
9824389|NCT02343276|Placebo Comparator|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
9824390|NCT02343276|Experimental|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
9824391|NCT02343380|Experimental|morning-first|calorimetric exam after a standard meal
9824392|NCT02343380|Experimental|evening-first|calorimetric exam after a standard meal
9824393|NCT02343406|Experimental|ABT-414/temozolomide|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks in combination with temozolomide (TMZ) to adult participants
9824394|NCT02343406|Experimental|ABT-414_adult|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to adult participants
9824395|NCT02343406|Active Comparator|Control_lomustine|Adult participants relapsing during temozolomide (TMZ) treatment or within the first 16 weeks after the first day of the last TMZ cycle received lomustine on Day 1 of every 42-day treatment period until one of the treatment withdrawal criteria was met, up to a maximum of 1 year.
9824396|NCT02343406|Active Comparator|Control_ temozolomide|Adult participants relapsing 16 weeks or more after the first day of the last temozolomide (TMZ) cycle received TMZ on Day 1 to Day 5 for the first 28-day cycle, with dose escalation in subsequent cycles in case of adequate tolerance and treatment continuing until one of the treatment withdrawal criteria was met.
9824397|NCT02343406|Experimental|ABT-414_ pediatric|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to pediatric participants. Temozolomide (TMZ) was only allowed for pediatric participants if its use was in accordance with local clinical practice, and was not considered an investigational product for the study (unless this was a local requirement).
9824398|NCT02343458|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
9824399|NCT02343458|Experimental|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
9824400|NCT02343458|Experimental|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
9824401|NCT02343458|Placebo Comparator|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
9824402|NCT02343575|Experimental|Valproic Acid|"Start:~VPA PO/NGT 500 mg BID~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
9824403|NCT02343575|Placebo Comparator|Placebo|"Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN"
9824404|NCT02343627|Experimental|NVXT Solution|NVXT Solution once daily for 60 days
9824405|NCT02343627|Placebo Comparator|Vehicle of test product|Vehicle of test product, once daily for 60 days
9824406|NCT02343939|Experimental|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
9824407|NCT02343939|Experimental|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
9824408|NCT02343939|Experimental|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
9824409|NCT02344004|No Intervention|Multi-drug Regimen|Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] Guidelines)
9824410|NCT02344004|Experimental|LAI + Multi-drug Regimen|"Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes"
9824411|NCT02344225|Active Comparator|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
9827235|NCT02448810|Experimental|Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)|Subjects stratified according to their mutation status.
10116080|NCT04443101||Group（MI60）|Group（MI60）：Implant MI60 intraocular lens
10116081|NCT04443101||Group（Aspira-aA）|Group（Aspira-aA）：Implant Aspira-aA intraocular lens
9824412|NCT02344225|Experimental|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
9824413|NCT02344225|Experimental|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
9824414|NCT02344238|Other|Standard Capsules|Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.
9824415|NCT02344238|Other|ID Capsules without Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
9824416|NCT02344238|Other|ID Capsules with Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
9824417|NCT02344251|Other|Group 1|Adherence measured by MEMS Cap
9824418|NCT02344251|Other|Group 2|Adherence measured by ID-Cap technology.
9824419|NCT02344316|Active Comparator|Melatonin|Group randomized to melatonin 3 mg orally nightly
9824420|NCT02344316|Placebo Comparator|Placebo|Group randomized to placebo orally nightly
9824421|NCT02344342|Experimental|Health Buddy Web Management system|Patients randomized to the telemonitoring intervention will be assigned to use the Bosch Health Buddy Web management system.
9824422|NCT02344342|Experimental|Flexible Diuretic Regimen|Patients randomized into the Flexible Diuretic Regimen intervention will have a diuretic regimen specified by specific weight ranges.
9824423|NCT02344407|Experimental|2|ChAd3-EBO Z
9824424|NCT02344407|Experimental|3|VSVG-ZEBOV
9824425|NCT02344407|Placebo Comparator|1|Placebo (Saline)
9824426|NCT02344576|No Intervention|Control: Usual Care|Patients and caregivers will receive the current usual education and consent process for DT LVAD at each hospital. This often means viewing consent forms and industry materials.
9824427|NCT02344576|Experimental|DT LVAD Decision Support Intervention|In the intervention phase of the study, patients and caregivers will receive the new decision support intervention, which consists primarily of decision aid materials about DT LVAD. The standard consent process will also still take place, but will be supplemented with additional decision support.
9824428|NCT02344628|Active Comparator|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
9824429|NCT02344628|Experimental|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
9824430|NCT02344745|Placebo Comparator|Control|Distilled water
9824431|NCT02344745|Experimental|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
9824432|NCT02345031|Active Comparator|AUT00063 (600 mg capsules)|3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
9824433|NCT02345031|Placebo Comparator|(AUT00063 placebo capsules)|3 capsules of placebo, to take orally once daily with food for 4 weeks
9824434|NCT02345161|Experimental|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
9824435|NCT02345161|Experimental|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
9824436|NCT02345226|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks.
9824437|NCT02345226|Active Comparator|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
9824438|NCT02345226|Experimental|Open Label Extension Phase|After the Week 96 visit, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead elects to discontinue the study, whichever occurs first.
9824439|NCT02345252|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
9824440|NCT02345252|Active Comparator|FTC/RPV/TDF|FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
9824441|NCT02345252|Experimental|Open Label Extension Phase|After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
9824442|NCT02345330|Experimental|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
9824443|NCT02345434|No Intervention|No informative letter|This is the control arm and it involves no contact with the prescriber
9824444|NCT02345434|Experimental|Informative letter|This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)
9824445|NCT02345486|Active Comparator|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
10116082|NCT04443049|Active Comparator|Lenvatinib +Placebo|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
9827236|NCT02448810|Experimental|Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)|Subjects stratified according to their mutation status.
9824446|NCT02345486|Active Comparator|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
9824447|NCT02345512|Other|Falls|Wearing of Lycra splinting garment
9824448|NCT02345642|Active Comparator|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
9824449|NCT02345642|Experimental|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
9824450|NCT02345720|Experimental|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
9824451|NCT02345811|Experimental|Sapphire|Participants were randomized to wear the Sapphire lens pair for two weeks during the cross over study.
9824452|NCT02345811|Active Comparator|senofilcon A|Participants were randomized to wear the senofilcon A lens pair for two weeks during the cross over study.
9824453|NCT02345889|Active Comparator|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
9824454|NCT02345889|Active Comparator|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
9824455|NCT02345889|Active Comparator|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
9824456|NCT02345889|Active Comparator|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
9824457|NCT02346136|Experimental|Tai Chi|This arm will receive a 6-month Tai Chi training intervention. Tai Chi training will include gentle dynamic stretching and strengthening, slow integrated movements, efficient posture, heightened body awareness and inner focus, active relaxation of body and mind, mindful diaphragmatic breathing, and healing imagery and intention. Participants will be asked to complete two formal group classes each week for at least 6 months, led by senior Tai Chi instructors. Additionally, participants will be given practice Digital Versatile Disc (DVD), DVD players if necessary, and instructions for daily home practice a minimum of 20 minutes on 3 non-class days each week.
9824458|NCT02346136|Active Comparator|Educational Control|This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
9824459|NCT02346240|Experimental|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
10116083|NCT04443049|Experimental|Lenvatinib and mebendazole|Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
10116084|NCT04443166|Experimental|Group A|At the beginning of the study (T0), group A will receive one course of PRP+HA program and group B will receive one HA course (a single HA injection (Hyajoint) weekly for 3 weeks). The PRP+HA program includes 3 HA injections and a single PRP injection (Arthrex double syringe system).
10116085|NCT04443166|Active Comparator|Group B|In the 6th month, alternately, group B will receive one PRP+HA program and group A will receive one HA course.
10116086|NCT04443205||no macrosomy|pregnant women whose child is not macrosomal
10116087|NCT04443205||screened macrosomy|pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy
10116088|NCT04443205||no screened macrosomy|pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy
10116089|NCT04443283||LTBI Group|IGRA(+)
10116090|NCT04443283||No LTBI Group|IGRA(+)
10116091|NCT04442919|Experimental|Ticagrelor followed with methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
10116092|NCT04442919|Active Comparator|Ticagrelor followed with morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
10116093|NCT04442919|Active Comparator|Ticagrelor|patients who received ticagrelor without any analgesia due to unstable angina
10116094|NCT04443179||Infants a family history of ASD/ADHD|
10116095|NCT04443179||Infants without a family history of ASD/ADHD|
10116096|NCT04442932||Interventions|Per test, a minimum of 40 atopic subjects for a given allergy and a total of at least 100 non-atopic subjects. To ensure that sufficient subjects with valid results are enrolled, the atopic enrollment goal per allergy is approximately 50 subjects. For each allergen, approximately 20% of the samples must be in the range of 0.70 to 3.5 IUA/mL and the remainder must cover a measuring range that is representative of the target population. Results from a single positive subject can be used in the analyses of more than one allergen if the subject is sensitized for more than one allergen.
10116097|NCT04442841|Experimental|Single arm (vaccine)|No further description
10116098|NCT04442802|Experimental|Long time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 6 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
10116099|NCT04442802|Active Comparator|Short time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 3 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
9824460|NCT02346240|Experimental|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
9824461|NCT02346240|Active Comparator|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
9824462|NCT02346240|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
9824463|NCT02346370|Experimental|PEGPH20 + Docetaxel|PEGylated recombinant human hyaluronidase PH20 (PEGPH20) (1.6, 3.0, or 2.2 micrograms per kilogram (ug/kg)) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m^2)) was administered on Day 2 of each 21-day cycle.
9824464|NCT02346383|Active Comparator|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
9824465|NCT02346383|Active Comparator|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
9824466|NCT02346383|Active Comparator|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
9824467|NCT02346461|Active Comparator|Cohort A|6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
9824468|NCT02346461|Active Comparator|Cohort B|6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.
9824469|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
9824470|NCT02346708|Experimental|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
9824471|NCT02346708|Sham Comparator|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
9824472|NCT02346721|Experimental|SOF/VEL|SOF/VEL for 12 weeks
9824473|NCT02346903|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. The patients will be asked follow-up questions concerning their experiences with chest pain in the past and their tolerance of spicy foods. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion."
9824474|NCT02346916|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
9824475|NCT02347072|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
9824476|NCT02347072|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
9824477|NCT02347072|Active Comparator|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
9827237|NCT02448810|Experimental|Part 2: Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
9824478|NCT02347085|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
9824479|NCT02347085|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
9519464|NCT03286868|Experimental|TKA with Verasense sensor|Total Knee Arthroplasty (TKA) with Verasense sensor for Intraoperative Balancing: Surgeon will attempt to optimize the intraoperative pressures using the data from the Verasense sensor
9824480|NCT02347098|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
9824481|NCT02347098|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
9824482|NCT02347124|Active Comparator|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
9824483|NCT02347124|Experimental|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
9824484|NCT02347176|Placebo Comparator|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
9824485|NCT02347176|Experimental|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
9824486|NCT02347176|Experimental|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
9824487|NCT02347176|Experimental|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
9824488|NCT02347189|Other|Melody TPV PB1016|
9824489|NCT02347332|Experimental|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
9824490|NCT02347332|Active Comparator|Methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
9824491|NCT02347345|Active Comparator|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
9824492|NCT02347345|Active Comparator|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
9824493|NCT02347345|No Intervention|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
9824494|NCT02347410|Other|Investigation Group|This is a single-arm investigation. All subjects were treated with the SIFS device filled with bone graft. Posterior fixation required.
9824495|NCT02347488|Experimental|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
9824496|NCT02347605|Experimental|Nicotine lozenge 4 mg prior to cue exposure|Nicotine lozenge is used 15 minutes prior to smoking cue exposure
9824497|NCT02347605|Placebo Comparator|Placebo lozenge prior to cue exposure|Placebo lozenge is used 15 minutes prior to smoking cue exposure
9824498|NCT02347605|Other|Control condition: Lozenge after cue exposure|Lozenge is used immediately after smoking cue exposure
9824499|NCT02347631|Experimental|Alcon DAILIES TOTAL1, and ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
9824500|NCT02347631|Active Comparator|ACUVUE TruEye and Alcon Dailies Total 1|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm & 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
9824501|NCT02347657|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
9824502|NCT02347657|Experimental|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
9824503|NCT02347761|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
9824504|NCT02347761|Experimental|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
9519465|NCT03286855|Experimental|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
9519466|NCT03286855|Active Comparator|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
9824505|NCT02347761|Placebo Comparator|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
9824506|NCT02347774|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg Twice Daily (BID) via e-Flow (R) Closed System (CS) nebulizer
9824507|NCT02347774|Experimental|SUN-101 25 mcg BID e-Flow (CS) nebulizer|SUN-101 25 mcg (BID) via e-Flow (R) Closed System (CS) nebulizer
9824508|NCT02347774|Placebo Comparator|Placebo BID Eflow (CS) nebulizer|Placebo (BID) via e-Flow (R) Closed System (CS) nebulizer
9824509|NCT02347787|Placebo Comparator|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
9824510|NCT02347787|Experimental|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
9824511|NCT02347813|Other|Delayed Intervention|After enrollment, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
9824512|NCT02347813|Other|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
9827238|NCT02448810|Experimental|Part 2: Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.
9827239|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
9827240|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
9827241|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
9827242|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
9827243|NCT02448875|Active Comparator|CyPass|CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
9827244|NCT02448875|Experimental|CyPass30|CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
9827245|NCT02448875|Experimental|CyPass60|CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
9827246|NCT02448914|Experimental|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
9827247|NCT02448914|Experimental|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
9827248|NCT02449018|Experimental|QBW251|QBW251 will be provided to participants during 70 days
9827249|NCT02449018|Placebo Comparator|Placebo|Placebo will be provided to participants during 70 days
9827250|NCT02449044|Experimental|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
9827251|NCT02449174|Active Comparator|Frozen Microbiota|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
9827252|NCT02449174|Active Comparator|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
9519467|NCT03286816|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
9827253|NCT02449291|Experimental|APD421 standard|Single (standard) dose IV APD421
9827254|NCT02449291|Experimental|APD421 high|Single (high) dose IV APD421
9827255|NCT02449291|Placebo Comparator|Placebo|Single IV placebo
9827256|NCT02449356|Experimental|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
9827257|NCT02449356|No Intervention|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
9827258|NCT02449434||Severe Tooth Wear|"Severe tooth wear with a BEWE score of 12 and at least one score of 3 in three quadrants Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
9827259|NCT02449434||Without Tooth Wear|"BEWE score of 10 or lower and no score of 3 on any surface of any tooth (clinically classified as no or mild erosive tooth wear) Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
9827260|NCT02449473|Experimental|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
9827261|NCT02449473|Placebo Comparator|Placebo Dose Regimen|Placebo Subcutaneous Injection
9824513|NCT02348008|Experimental|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
9824514|NCT02348008|Other|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
9824515|NCT02348203|Experimental|Arm I (aspirin, zileuton)|Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
9824516|NCT02348203|Placebo Comparator|Arm II (double placebo)|Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
9824517|NCT02348216|Experimental|Axicabtagene Ciloleucel|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, axicabtagene ciloleucel.
9824518|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
9824519|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
9824520|NCT02348489|Experimental|SGI-110 (guadecitabine)|Guadecitabine 60 mg/m^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.
9824521|NCT02348489|Active Comparator|Treatment Choice|One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.
9824522|NCT02348593|Active Comparator|75 mg of JZP-110|Once Daily Dosing
9824523|NCT02348593|Active Comparator|150 mg JZP-110|Once Daily Dosing
9824524|NCT02348593|Active Comparator|300 mg of JZP-110|Once Daily Dosing
9824525|NCT02348593|Placebo Comparator|Placebo|Once Daily Dosing
9824526|NCT02348606|Active Comparator|37.5 mg of JZP-110|Once Daily Dosing
9824527|NCT02348606|Active Comparator|75 mg of JZP-110|Once Daily Dosing
9824528|NCT02348606|Active Comparator|150 mg of JZP-110|Once Daily Dosing
9824529|NCT02348606|Active Comparator|300 mg of JZP-110|Once Daily Dosing
9824530|NCT02348606|Active Comparator|Placebo|Once Daily Dosing
9824531|NCT02348619|Active Comparator|75, 150, 300 mg of JZP-110|Once Daily Dosing
9824532|NCT02348619|Active Comparator|Placebo|Once Daily Dosing
9824533|NCT02348632|Other|75 mg - 300 mg of JZP-110|Once Daily Dosing
9824534|NCT02348658|Other|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
9824535|NCT02348658|Other|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
9824536|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
9824537|NCT02348723|Experimental|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
10116100|NCT04442750|Experimental|A (0.5%) group|patients will receive a single shot erector spinae block with 30 ml 0.5% bupivacaine followed by general anesthesia
10116101|NCT04442750|Experimental|B (0.375%) group|patients will receive a single shot erector spinae block with 30 ml 0.375% bupivacaine followed by general anesthesia
9824538|NCT02348723|Active Comparator|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
9824539|NCT02348775|Experimental|GlyNAC|HIV infected subjects will be studied before and after taking oral glycine and n-acetylcysteine for 3 months
10116102|NCT04442750|Experimental|C (0.25%) group|patients will receive a single shot erector spinae block with 30 ml 0.25% bupivacaine followed by general anesthesia
9824540|NCT02348840|Experimental|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
9824541|NCT02348840|Active Comparator|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
9824542|NCT02348840|Active Comparator|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
9824543|NCT02348918|Active Comparator|Luminate 1.0mg group|Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
9824544|NCT02348918|Active Comparator|Luminate 2.0mg group|Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
9824545|NCT02348918|Active Comparator|Luminate 3.0mg group|Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
9824546|NCT02348918|Active Comparator|Avastin® group|Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
9824547|NCT02348918|Active Comparator|Avastin then Luminate 1.0 mg IVT + sham injection|Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
10116103|NCT04442828||Primary mitral regurgitation|Patients with mitral regurgitation due to mitral valve disease
9824548|NCT02348918|Active Comparator|Avastin then Luminate 0.5 mg IVT + sham injection|Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
9824549|NCT02348918|Active Comparator|Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
9824550|NCT02348918|Active Comparator|Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT|Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
9824551|NCT02348918|Active Comparator|Avastin 1.25 mg + Sham IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
9824552|NCT02349048|Experimental|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
9824553|NCT02349048|Experimental|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
9824554|NCT02349061|Experimental|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
9824555|NCT02349061|Experimental|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
9824556|NCT02349152|Experimental|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
9824557|NCT02349152|Active Comparator|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
9824558|NCT02349178|Experimental|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
9824559|NCT02349295|Experimental|Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)|Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
9824560|NCT02349295|Experimental|Ixekizumab 80 mg Q4W|Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
9824561|NCT02349295|Placebo Comparator|Placebo|Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
9824562|NCT02349360|Active Comparator|Probiotic|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
9824563|NCT02349360|Placebo Comparator|Placebo|Encapsulated starch placebo administered for 8 weeks
9824564|NCT02349412|Experimental|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
9824565|NCT02349412|Experimental|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
9965834|NCT01253694|Experimental|Patients with 3-5 consecutive Avastin injections|These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
9965835|NCT01253694|Experimental|Patients with 6 or more consecutive injections of Bevacizumab|Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
9824566|NCT02349425|Experimental|Cohort 1: Gefapixant>Placebo|50, 100, 150, and 200 mg gefapixant twice daily (BID) for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
9824567|NCT02349425|Experimental|Cohort 1: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 50, 100, 150, and 200 mg BID for 4 days each in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
9824568|NCT02349425|Experimental|Cohort 2: Gefapixant>Placebo|Gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
9824569|NCT02349425|Experimental|Cohort 2: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
9824570|NCT02349438|Experimental|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
9824571|NCT02349438|Active Comparator|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
9824572|NCT02349451|Active Comparator|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
9824573|NCT02349451|Placebo Comparator|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
9824574|NCT02349451|Experimental|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
9824575|NCT02349451|Experimental|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
9824576|NCT02349477|Experimental|Gabapentin|Gabapentin up to 1200 mg per day in 3 divided doses
9824577|NCT02349477|Placebo Comparator|placebo|matching placebo
9824578|NCT02349542|Experimental|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
9824579|NCT02349633|Experimental|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
9824580|NCT02349633|Experimental|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
9824581|NCT02349633|Experimental|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
9824582|NCT02349633|Experimental|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
9824583|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
9824584|NCT02349685|Experimental|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
9824585|NCT02349685|Experimental|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
9824586|NCT02349685|Active Comparator|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
9824587|NCT02349711|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
9824588|NCT02349711|Experimental|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
9824589|NCT02350127|Experimental|Immediate Start|The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
9824590|NCT02350127|Active Comparator|Delayed Start|Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
9824591|NCT02350309|Experimental|Lemborexant 5 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 5 mg within 5 minutes before bedtime.
9824592|NCT02350309|Experimental|Lemborexant 10 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 10 mg within 5 minutes before bedtime.
9824593|NCT02350309|Placebo Comparator|Lemborexant-matched Placebo|Participants will receive a single, oral tablet formulation dose of lemborexant-matched placebo within 5 minutes before bedtime.
9824594|NCT02350309|Active Comparator|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
9824595|NCT02350478|Active Comparator|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
9824596|NCT02350478|Placebo Comparator|Placebo|The subjects will receive placebo.
9824597|NCT02350569|Experimental|LDV/SOF|Participants with genotype 1 or 4 HCV who are undergoing liver transplant will receive one dose of LDV/SOF prior to the transplant and then will receive LDV/SOF once daily for 4 weeks following the transplant.
9824598|NCT02350647|Experimental|HEALICOIL Regenesorb|Suture anchor for rotator cuff repair
9824599|NCT02350647|Active Comparator|Twinfix Ultra HA|Suture anchor for rotator cuff repair
9824600|NCT02350660|Experimental|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
9824601|NCT02350660|Experimental|Peanut powder|peanut oral immunotherapy
9827262|NCT02449798|Experimental|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
9824602|NCT02350816|Active Comparator|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).~HGT-SAN-093 = NCT02060526"
9824603|NCT02350816|Active Comparator|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
9824604|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
9824605|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
9824606|NCT02350998|Experimental|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
9824607|NCT02351037|Experimental|Ibrutinib Monotherapy Cohort|Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.
9824608|NCT02351037|Experimental|Ibrutinib + LD-AraC Combination Cohort|Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
9824609|NCT02351037|Experimental|Ibrutinib+Azacitidine Combination Cohort|Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).
9824610|NCT02351115|Experimental|Sequence BEADC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
9824611|NCT02351115|Experimental|Sequence CDAEB|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
9824612|NCT02351115|Experimental|Sequence DEBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
9824613|NCT02351115|Experimental|Sequence EDBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
9824614|NCT02351115|Experimental|Sequence CABED|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
9824615|NCT02351167|Active Comparator|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
9824616|NCT02351167|Active Comparator|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
9824617|NCT02351167|Placebo Comparator|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
9824618|NCT02351258|Experimental|Usual Care only, then Usual Care + 70% Isopropyl Alcohol|Usual care for central line while patients are at home and then switch to usual care plus 70% isopropyl alcohol after washout.
9824619|NCT02351258|Experimental|Usual Care + 70% Isopropyl Alcohol, then Usual Care only|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting and then switch to usual care only after washout.
9824620|NCT02351271|Experimental|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
9824621|NCT02351271|Active Comparator|Manual capsulorhexis&lens fragmentation|The Conventional group acts as a control group with conventional capsulorhexis and ultrasound phacoemulsification
9824622|NCT02351349|Experimental|multidisciplinary intervention|Due to the problem of randomization, the study became a before and after assessment in the one group that completed the 12 week exercise program and received nutritional support
9824623|NCT02351349|No Intervention|Non adherence|Those who were offered the program but did not complete the prescription
9824624|NCT02351505|Experimental|Treatment (selinexor)|Patients receive selinexor PO twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9824625|NCT02351700|Active Comparator|IV Caldolor (ibuprofen)|Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
9827263|NCT02449889|Experimental|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
9827264|NCT02449889|Experimental|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
9827265|NCT02449889|Active Comparator|rhCG|recombinant human chorionic gonadotropin
9827266|NCT02449902|Active Comparator|Treatment 1|Estradiol 10 μg vaginal softgel capsule
9519468|NCT03286816|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
9824626|NCT02351700|Placebo Comparator|standard treatment group|IV placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
9824627|NCT02351739|Other|Pembrolizumab|Arm 1: pembrolizumab monotherapy
9824628|NCT02351739|Other|ACP-196 in combination with pembrolizumab|Arm 2: ACP-196 in combination with pembrolizumab
9824629|NCT02351817|Experimental|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
9824630|NCT02351817|Experimental|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
9824631|NCT02351934|Experimental|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
9824632|NCT02351934|Active Comparator|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
9824633|NCT02351960|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
9824634|NCT02351960|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
9824635|NCT02352259|Experimental|Electrochemotherapy|
9824636|NCT02352298|Experimental|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
9824637|NCT02352298|Active Comparator|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
9824638|NCT02352363|Experimental|CVT-301|Capsules of Levodopa Inhalational Powder (LIP) used up to 5 times per day for OFF episodes, for up to 54 weeks duration.
9824639|NCT02352363|Other|Observational Cohort|Standard of care. Patients in both the CVT-301 treatment group and the observational cohort will be managed with their standard PD treatment throughout the study.
9824640|NCT02352493|Active Comparator|ALN-CC5|
9824641|NCT02352493|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
9824642|NCT02352779|Experimental|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
10116104|NCT04442828||Secondary mitral regurgitation|Patients with mitral regurgitation due to ventricular or atrial disease
10116105|NCT04442893|Experimental|Experimental group|The experimental group would be provided with a 6- session RFCBT program for 12 weeks (60-90 mins, once every two weeks).
9824643|NCT02352779|Experimental|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
9824644|NCT02352779|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
9824645|NCT02352831|Experimental|Phase I (tosedostat + capecitabine)|"The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion.~Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat.~Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle~Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain."
9824646|NCT02352831|Experimental|Phase II (tosedostat + capecitabine)|"Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle~Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
9824647|NCT02352844|Experimental|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
9824648|NCT02352922|Experimental|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
9824649|NCT02352922|Active Comparator|Bupivacaine HCl|short-acting bupivacaine
9824650|NCT02352974|Experimental|GAD-Alum+Vitamin D|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
10116106|NCT04442893|Other|Control group|The control group would receive a 6- session Health Education program for 12 weeks (60-90 mins, once every two weeks)
10116107|NCT04442984|Active Comparator|FOLFOX6|5FU 400mg/m2 iv bolus d1, 5-FU 2400 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
9824651|NCT02353091|No Intervention|APD Control Group|Comprised 13 children diagnosed with APD and acts as a control without using any form of intervention.
9824652|NCT02353091|Experimental|APD Intervention Group|Comprised 13 children diagnosed with APD and received the Remote Microphone Hearing AId intervention at the start of the study, after baseline testing, and used for 6 months.
10116108|NCT04442984|Experimental|mFOLFIRINOX|Irinotecan 180mg/m2 d1, 5FU 250mg/m2 iv bolus d1, 5-FU 2200 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
9824653|NCT02353169|Experimental|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
9824654|NCT02353169|Experimental|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
9824655|NCT02353169|Experimental|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
9824656|NCT02353169|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
9824657|NCT02353299|Active Comparator|Silenor 6 mg (DXP-4H)|Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
9824658|NCT02353299|Placebo Comparator|Placebo (PBO-4H)|placebo single nightime dose -4 hour post dose arousability and cognitive assessments
9824659|NCT02353299|Active Comparator|Zolpidem 10 mg (ZOL-1.5H)|zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
9824660|NCT02353299|Placebo Comparator|Placebo (PBO-1.5H)|placebo single nightime dose -1.5 hour arousability and cognitive assessments
9824661|NCT02353442|Placebo Comparator|Control group|"This group will perform during 4 weeks:~placebo ultrasound during 5min ;~scapular squeezing in the sitting position (3x10repetitions);~upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
9824662|NCT02353442|Active Comparator|Experimental group|"This group will perform during 4 weeks:~posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);~external rotators strengthening in sidelying positions with load (3x10repetitions);~posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
9824663|NCT02353754|Active Comparator|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
9824664|NCT02353754|Experimental|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
9824665|NCT02353780|Active Comparator|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
9824666|NCT02353780|Active Comparator|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
9824667|NCT02353780|Active Comparator|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
9824668|NCT02353806|Experimental|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
9824669|NCT02353871|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
9824670|NCT02353871|Placebo Comparator|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
9824671|NCT02354092|Sham Comparator|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~Sham Paracervical Block done with capped spinal needle~osmotic dilators placed in the usual fashion~postprocedural assessment"
9824672|NCT02354092|Experimental|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~18 ml 1% buffered lidocaine Paracervical Block~osmotic dilators placed in the usual fashion~postprocedural assessment"
9824673|NCT02354144|Experimental|Carrageenan-based gel|"The intervention to be administered is:~a commercially available gel that contains carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
9824674|NCT02354144|Placebo Comparator|Control gel|"The intervention to be administered is:~a commercially available gel that does not contain carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
9824675|NCT02354222|Experimental|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
9824676|NCT02354222|Placebo Comparator|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
9824677|NCT02354235|Experimental|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
9824678|NCT02354235|Placebo Comparator|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
9824679|NCT02354339|Experimental|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
9824680|NCT02354339|Placebo Comparator|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
9827267|NCT02449902|Placebo Comparator|Treatment 2|Placebo vaginal softgel capsule
9824681|NCT02354352|Active Comparator|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
9824682|NCT02354352|Active Comparator|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
9824683|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
9824684|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
9824685|NCT02354417|Experimental|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:~For subjects > 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to ~1 hour."
9824686|NCT02354443|Experimental|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
9824687|NCT02354482||Diverse, high-risk patient populations|
10116109|NCT04442958|Experimental|Convalescent Plasma Therapy Group|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
10116110|NCT04442958|No Intervention|Non-Plasma Therapy Group|Standart critical care treatment group
10116111|NCT04442971|Experimental|Music Stimulation|Patients preferred music is presented via headphones.
10116112|NCT04442971|Active Comparator|Alternative Auditory Stimulation|An audio book is presented via headphones.
10116113|NCT04442971|Sham Comparator|No Auditory Stimulation|Silence is presented via headphones.
10116114|NCT04442906|Active Comparator|group B|IGroup B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline
10116115|NCT04442906|Active Comparator|group BD|. Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
9824688|NCT02354508|Experimental|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
9824689|NCT02354534|Experimental|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
9824690|NCT02354534|Experimental|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
9824691|NCT02354534|Experimental|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
9824692|NCT02354534|Experimental|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
9824693|NCT02354586|Experimental|Niraparib|
9824694|NCT02354599|Experimental|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
9824695|NCT02354599|Placebo Comparator|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
9824696|NCT02354599|Experimental|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
10116116|NCT04442906|Active Comparator|group BF|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug).
10116117|NCT04442854|Experimental|cognitive behavioral group therapy|A cognitive behavioral group prevention program An 8-session, cognitive behavioral group prevention program, featuring cultural appropriateness. One session per week, 3 hours for each session. The program contents include psychoeducation, cognitive skills training to identify and challenge maladaptive cognitions, and behavioral skills training. Each session contains mood check and homework. Participants' own examples are used in the group to demonstrate the CBT skills.
10116118|NCT04442854|No Intervention|Wait-list control group|No immediate intervention No intervention was provided when the experimental group was receiving services, but the same cognitive behavioral group prevention program was delivered to the wait-list control group after that.
10116119|NCT04443114|Other|Early Arm|The early arm will receive the experimental organ donation workshop first, followed by the control workshop on end-of-life care.
10116120|NCT04443114|Other|Late Arm|The late arm will receive the control workshop on end-of-life care first, followed by the experimental organ donation workshop.
10116121|NCT04443023|Active Comparator|Sapien|Patients randomized to treatment
10116122|NCT04443023|Active Comparator|Myval|Patients randomized to treatment
10116123|NCT04442776|Experimental|Intervention group|The intervention group will complete the Dual Integrated Attention Program (D-AIP) The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made.
10116124|NCT04442776|No Intervention|Control group|The control group will complete the usual treatment. One session per day voluntary during admission and discharge, nursing consultations only to put injectable medication
9519469|NCT03286803|Experimental|Arm A|Inactivated Poliovirus vaccine
9824697|NCT02354599|Placebo Comparator|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
9824698|NCT02354599|Experimental|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
9824699|NCT02354599|Placebo Comparator|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
9824700|NCT02354599|Experimental|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
9824701|NCT02354599|Placebo Comparator|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
9824702|NCT02354690|Experimental|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
9824703|NCT02354781|Experimental|Experimental|The vector will be delivered to both limbs via multiple, direct intramuscular injections of rAAV1.CMV.huFollistin344; the number of injections per muscle will depend on the size of the patient. A total dose of 2.4E12 vg/kg (1.2E12vg/kg/limb) will be delivered to the lower limbs of 6 DMD subjects
9824704|NCT02354833|Experimental|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
9824705|NCT02354833|Experimental|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
9824706|NCT02354859|Active Comparator|5 day of infusion of gallium nitrate|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device () using an ambulatory infusion pump infused over 24 hours for 5 sequential days.
9824707|NCT02354859|Placebo Comparator|5 day of infusion of normal saline|Placebo with be dispensed as 1,000 milliliters of 0.9% sodium chloride to match the reconstitution volume of the IV Ga
9824708|NCT02354924|Experimental|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
9824709|NCT02354924|Active Comparator|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
9824710|NCT02354976|Placebo Comparator|Placebo|
9824711|NCT02354976|Experimental|Omega-3 carboxylic acids 4g / day|
9824712|NCT02354976|Active Comparator|Fenofibrate 200mg|
9824713|NCT02355028|Experimental|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
9824714|NCT02355028|Placebo Comparator|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
9824715|NCT02355067|Experimental|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
9824716|NCT02355067|Active Comparator|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
9824717|NCT02355158|Experimental|Active|Clonidine hydrochloride topical gel, 0.1%
9824718|NCT02355210|Placebo Comparator|Placebo|5 g lactose given as a placebo
9824719|NCT02355210|Experimental|Probiotic 1|Bifidobacteria adolescentis BD1, 10^9
9824720|NCT02355210|Experimental|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10^9
9824721|NCT02355210|Experimental|Prebiotic|galactooligosaccaride, 5 g
9824722|NCT02355210|Experimental|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)
9824723|NCT02355210|Experimental|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)
9824724|NCT02355275|Experimental|Home Exercise Program|
10116125|NCT04443309|Experimental|Lenvatinib plus Camrelizumab|"Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
10116126|NCT04442698||Diabetic MGB post op patients|Diabetic MGB post op patients
10116127|NCT04442529|No Intervention|Control|Pregnant women will receive prenatal care as usual.
9824725|NCT02355665|Experimental|Nicotine|Nicotine Spray
9824726|NCT02355665|Placebo Comparator|Placebo|Placebo to match Nicotine spray
9824727|NCT02355691|Experimental|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
9824728|NCT02355691|No Intervention|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
10116128|NCT04442529|Experimental|Intervention|Pregnant women will receive the 12-session Mothers and Babies intervention
9519470|NCT03286803|Active Comparator|Arm B|fractional dose inactivated poliovirus vaccine
9824729|NCT02355743|Experimental|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
9824730|NCT02355821|Experimental|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
9824731|NCT02355821|Active Comparator|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
9824732|NCT02355886|Experimental|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
9824733|NCT02355886|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
9827668|NCT02464163|Experimental|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
9824734|NCT02355977|Active Comparator|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
9824735|NCT02355977|Active Comparator|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
9824736|NCT02355977|Experimental|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
9824737|NCT02356003|Experimental|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
9824738|NCT02356107|Experimental|Open label treatment with 5-HTP and Creatine|
9668659|NCT05224453|Other|Physical training and low protein diet|Subjects in this group underwent integrated physical training for 8 weeks. In addition to the integrated physical training exercises, group B received a low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (<1 g/kg aBW/d)
9824739|NCT02356198|Active Comparator|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
9668660|NCT05221398||Immune checkpoint inhibitors based adjuvant therapy|Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
9519471|NCT03286803|Experimental|Arm C|inactivated poliovirus vaccine
9824740|NCT02356198|Active Comparator|Intrathecal opioid (IT)|single injection intrathecal hydromorphone analgesia given preoperatively
9824741|NCT02356211|Experimental|Treatment|Geriatric Multifactorial Falls Assessment Clinic
9824742|NCT02356211|No Intervention|Control|Geriatric Evaluation and Management Service (GEM)
9824743|NCT02356471|Experimental|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
9824744|NCT02356484||Major abdominal surgery cohort|In this surgical cohort, 4 inflammatory markers were measured: albumin, procalcitonin, CRP and lactate levels
9824745|NCT02356562|Experimental|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily [QD] and dasabuvir twice daily [BID]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
9824746|NCT02356575|Active Comparator|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
9824747|NCT02356575|Active Comparator|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
9824748|NCT02356588|Experimental|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
9824749|NCT02356588|Placebo Comparator|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
9519472|NCT03286803|Active Comparator|Arm D|fractional dose inactivated poliovirus vaccine
9668661|NCT05221398||Without adjuvant therapy|Patients in this arm will not receive any adjuvant therapy.
9668662|NCT05220878|Experimental|GNR-069|Main group (80 patients) - multiple weekly subcutaneous injections of GNR-069, doses are calculated individually.
9668663|NCT05220878|Active Comparator|Nplate|Control group (80 patients) - multiple weekly subcutaneous injections of Nplate, doses are calculated individually.
9824750|NCT02356692|Experimental|enfilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
9668664|NCT05219305|Experimental|Freeze-Dried Bone Allograft|edentulous site grafted with FDBA in previous study.
9824751|NCT02356692|Active Comparator|senofilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
9519473|NCT03286777|Placebo Comparator|Placebo|Mannitol and silicon dioxide
9519474|NCT03286777|Experimental|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
9668665|NCT05219305|Experimental|Partially-demineralized tooth graft|edentulous site grafted with partially-demineralized tooth graft in the previous study.
9668666|NCT05219305|Experimental|mineralized tooth graft|edentulous site grafted with mineralized tooth graft in the previous study.
9519475|NCT03286777|Experimental|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
9519476|NCT03286764|Placebo Comparator|Placebo|Distilled water spray as a placebo during Colonoscopy
9519477|NCT03286764|Experimental|Peppermint Oil|Peppermint Oil spray during Colonoscopy
9668667|NCT05218837||First vaginal birth|The first vaginal birth in nulliparous women
9668668|NCT05218837||Vaginal birth after cesarean section (VBAC)|The first vaginal birth after one or more prior cesarean sections (VBAC)
9668669|NCT05218837||Second vaginal delivery|The second vaginal delivery
9824752|NCT02356783|Other|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
9965836|NCT01253707|Experimental|Dose Escalation|
9824753|NCT02356783|Other|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
9824754|NCT02356887|Experimental|sitting position|The volunteers were kept comfortable in the sitting position. The cricoid cartilage (representing the C6 level) was used as a landmark. A horizontal straight line drawn across the volunteer's neck at the cricoid level and intersecting the IJV on both sides of the neck marked the initial scanning points. The second scanning point was along the IJV at the highest accessible point on the neck. Internal jugular vein cross-sectional area and blood velocity were measured using 2D ultrasound and Doppler (Philips CX50, Andover, MA, USA), respectively, with a 12-3 MHz transducer (Philips L12-3, Andover, MA, USA)
9824755|NCT02356900|Experimental|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
9824756|NCT02356900|Sham Comparator|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
9824757|NCT02357043|Experimental|Dario Blood Glucose Monitoring System|Subject will be requested to follow the device instructions and perform his/her own finger-stick test using the Dario Glucose Monitoring System (BGMS).
9824758|NCT02357134|Experimental|Arm I (high-flow oxygen)|Patients receive high-flow oxygen via nasal prongs during a structured stationary bicycle exercise session.
9824759|NCT02357134|Experimental|Arm II (high-flow air)|Patients receive high-flow air via nasal prongs during a structured stationary bicycle exercise session
9824760|NCT02357134|Active Comparator|Arm III (low-flow oxygen)|Patients receive low-flow oxygen via a nasal cannula during a structured stationary bicycle exercise session.
9824761|NCT02357134|Active Comparator|Arm IV (low-flow air)|Patients receive low-flow air via a nasal cannula during a structured stationary bicycle exercise session.
9824762|NCT02357147|Experimental|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin~Maintenance Phase - Amatuximab"
9824763|NCT02357147|Experimental|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin~Maintenance Phase - Placebo"
9824764|NCT02357173|Active Comparator|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
9824765|NCT02357173|Experimental|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
9824766|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
9824767|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
9824768|NCT02357290|Experimental|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
9824769|NCT02357342|Experimental|Sirolimus|Intravitreal Sirolimus
9824770|NCT02357342|Active Comparator|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
9824771|NCT02357368|Experimental|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.
9824772|NCT02357368|Experimental|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
9824773|NCT02357368|Experimental|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
9824774|NCT02357368|Experimental|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
9824775|NCT02357394|Experimental|Device: Arabin Pessary|Participants randomized to this group will receive the pessary.
9824776|NCT02357394|No Intervention|Standard of Care|Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.
9824777|NCT02357420|Experimental|Relamorelin 10 μg|Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
9824778|NCT02357420|Experimental|Relamorelin 30 μg|Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
9824779|NCT02357420|Experimental|Relamorelin 100 μg|Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
9824780|NCT02357420|Placebo Comparator|Placebo|Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.
9824781|NCT02357459|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
9824782|NCT02357459|Placebo Comparator|Normal Saline|Single 5 mL intra-articular (IA) injection
9824783|NCT02357459|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
9824784|NCT02357485|Experimental|Treatment arm|Single injection of ADSC
9824785|NCT02357576|Experimental|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
9824786|NCT02357576|Active Comparator|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
9824787|NCT02357706|Active Comparator|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
9824788|NCT02357706|Active Comparator|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
9824789|NCT02357758|Active Comparator|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
9824790|NCT02357758|No Intervention|Healthy Population|Healthy population
9824791|NCT02357758|No Intervention|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
9824792|NCT02357836|Other|Itraconazole|600 mg twice daily for 10-14 days
9824793|NCT02357901|Experimental|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.~In addition, participants received individual drug counseling (IDC) at least once a week."
9824794|NCT02357901|Experimental|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
9824795|NCT02357901|Placebo Comparator|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).~In addition, participants received individual drug counseling (IDC) at least once a week."
9824796|NCT02357901|Placebo Comparator|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
9824797|NCT02357940|Experimental|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
9824798|NCT02357940|Experimental|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
9824799|NCT02357979|Experimental|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
9824800|NCT02357979|Active Comparator|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
9824801|NCT02358044|Experimental|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
9824802|NCT02358044|Active Comparator|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
9824803|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
9824804|NCT02358135|Experimental|CCH Model|The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes. Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
9824805|NCT02358343|Active Comparator|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
9824806|NCT02358343|No Intervention|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
9827268|NCT02449915|Experimental|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
10116129|NCT04442568|Active Comparator|ERAS|all patients in this group will be performed LSG under a specified anesthesia protocol. This protocol includes non-opioid analgesia and sedation. Also short-acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the second hour postoperatively, also will be started oral intake between second and fourth hours.
9824807|NCT02358343|Active Comparator|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
9824808|NCT02358343|Active Comparator|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
9824809|NCT02358343|No Intervention|Observational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
9824810|NCT02358369|Experimental|13 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye (OU) for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops to each eye twice a day (BID) for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
9824811|NCT02358369|Experimental|2.2 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 2.2 mg Bimatoprost Ocular Insert in each eye for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops in each eye twice a day for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
9824812|NCT02358369|Active Comparator|Timolol 0.5%|"Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 0.5% timolol ophthalmic solution in each eye for 6 weeks. Note: participants simultaneously wore placebo ocular inserts for 12 weeks.~After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks."
9824813|NCT02358473|Experimental|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
9824814|NCT02358603|Experimental|Case group|At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
9824815|NCT02358603|Placebo Comparator|Control group|Each subject of the control group will do the same test and examination with the subjects in the case group.
9824816|NCT02358668|Experimental|BTI320 4 grams|three times daily, oral for 16 weeks
9824817|NCT02358668|Experimental|BTI320 8 grams|three times daily, oral for 16 weeks
9824818|NCT02358668|Placebo Comparator|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
9824819|NCT02358863|Experimental|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
9824820|NCT02358889|Experimental|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
9824821|NCT02358889|Experimental|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
9824822|NCT02358889|Active Comparator|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
9824823|NCT02359006|Active Comparator|minocycline|200mg minocycline
9824824|NCT02359006|Placebo Comparator|Placebo|Sugar pill
9824825|NCT02359019|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
9824826|NCT02359045|Experimental|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
9824827|NCT02359045|Experimental|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
9824828|NCT02359058|Other|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
9824829|NCT02359058|Other|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
9824830|NCT02359058|Other|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9824831|NCT02359110|Experimental|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
9824832|NCT02359110|Placebo Comparator|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
9824833|NCT02359305||IV Acetaminophen|Acetaminophen administered by intravenous infusion.
10116130|NCT04442568|No Intervention|no ERAS|all patients in this group will be performed LSG under a conventional anesthesia protocol which is depended on the anesthesiologist . This protocol includes opioid analgesia and sedation. Also short and long acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the fourth hour postoperatively, also will be started oral intake in the next day morning after surgery.
10116131|NCT04442594|Experimental|personalized video|Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).
9668670|NCT05215691||Group I (n=45, TAPA)|The patients who received TAPA block for postoperative analgesia are named as a Group I ( n=45). The TAPA block is performed at the rib margin where the 9th and 10th ribs meet. A linear transducer is placed at the costochondral angle in the sagittal plane. It is carried out by injecting 20 ml of Bupivacaine %0.200 between the upper and lower surface of the chondrium. All patients receive IV PCA with morphine 0.5 mg/ml.
9824834|NCT02359305||Rectal Acetaminophen|Acetaminophen administered by rectal suppository.
9824835|NCT02359435|Experimental|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
9824836|NCT02359435|Active Comparator|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
9824837|NCT02359552|Placebo Comparator|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
9824838|NCT02359552|Active Comparator|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
9824839|NCT02359851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
9824840|NCT02359877|Experimental|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
9824841|NCT02359877|Active Comparator|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
9824842|NCT02359877|Active Comparator|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
9824843|NCT02359890|Experimental|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
9824844|NCT02359903|Experimental|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
9824845|NCT02359903|Active Comparator|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
9824846|NCT02359916||A|Snacks sold under equal pricing, no delays
9824847|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
9824848|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
9824849|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
9824850|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
9824851|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
9824852|NCT02359916||G|Snacks sold under equal pricing, no delays
10116132|NCT04442594|Active Comparator|generic vidéo|The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.)
9824853|NCT02359955|Experimental|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
9824854|NCT02359955|Experimental|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
9824855|NCT02360124|Placebo Comparator|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
9824856|NCT02360124|Experimental|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
9824857|NCT02360124|Active Comparator|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
9824858|NCT02360215|Experimental|WBRT + Memantine|Whole brain radiation therapy (WBRT) and memantine
9824859|NCT02360215|Experimental|HA-WBRT/IMRT+ Memantine|Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) using intensity modulated radiation therapy (IMRT) and memantine
9824860|NCT02360228|Experimental|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
9824861|NCT02360228|Experimental|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
10116133|NCT04442620|Experimental|1st group: Physical Activity and Mediterranean Diet (PA-MD)|"A first group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 35-40% fat, 20% proteins, and 40-45% carbohydrates. Healthy fats (a maximum of 8-10% from saturated fats, >20% from monounsaturated fats, >10% from polyunsaturated fats and <300 mg/day of cholesterol) and low glycaemic index foods rich in fibre (not less than 30-35g /day) are strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Such diet reflects the traditional Mediterranean Diet described in the PREDIMED (Primary Prevention of Cardiovascular Disease with a Mediterranean Diet)-Plus study.~As for physical activity, patients the participants will be recommended a 35 minutes interval training session three times a week. Physical activity sessions of 35 minutes will consist of 5 minutes warm-up, 20 minutes interval training, and 10 minutes breathing and stretching."
10116134|NCT04442620|Experimental|2nd group: High Meal Frequency of Mediterranean Diet (HMF-MD)|A second group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30-35% fat, 25% proteins, and 40-45% carbohydrates. Healthy fats and low glycaemic index foods will be strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Participants will be advised to consume 7 meals a day, gradually reducing the caloric content at each main meal, and to walk 10.000 steps a day.
10116135|NCT04442620|Active Comparator|3rd group: Control diet (CD)|A third group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30% fat, 15% proteins, and 55% carbohydrates, and maintain an adequate fibre (25g/day) and cholesterol (<250mg/day) intake. Meal frequency will be of 3-5 meals a day. Moreover, the participants will be advised to walk 10.000 steps a day.
10116136|NCT04442516||Adults receiving Cisplatin as part of their cancer therapy|
10116137|NCT04442516||Children receiving Cisplatin as part of their cancer therapy|
10116138|NCT04442451|Experimental|Control Exercise|Low-load knee extension resistance training (20% of 1-RM) without blood flow restriction. A 10-cm wide inflatable cuff will be placed around the upper portion of the thigh but not inflated.
10116139|NCT04442451|Experimental|Blood Flow Restriction Exercise|Low-load knee extension resistance training (20% of 1-RM) with blood flow restriction using a 10-cm wide inflatable cuff placed around the most proximal part of the exercising thigh. Blood flow will be restricted in the BFR leg at above the limb occlusion pressure of the and this will be determined prior to the exercise while the participant is seated in the knee extensor machine. The cuff pressure during the BFR protocol will be 10 mmHg above limb occlusion pressure.
10116140|NCT04442672|Experimental|compartment syndrome model group(CSM group)|
9528165|NCT03213158|Experimental|Highly sensitized kidney transplant candidates|The study population will include all highly sensitized kidney transplant candidates on the waitlist for more than 24 months at University of Wisconsin.
10116141|NCT04442672|Sham Comparator|sham group|
10116142|NCT04442607|Experimental|AI arm|Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis
10116143|NCT04442230|Experimental|NasoVAX|Participants will receive a single intranasal dose of NasoVAX on Day 1 (enrollment).
10116144|NCT04442230|Placebo Comparator|Placebo|Participants will receive a single intranasal dose of placebo on Day 1 (enrollment).
10116145|NCT04442126|Experimental|NM21-1480 Treatment arm|
10116146|NCT04442542|Experimental|Respiratory exercises plus method JaPer|Respiratory exercises plus the new intervention protocol with an inspirometer (JaPer Method)
10116147|NCT04442542|Active Comparator|Protocol of use of inspirometer in a conventional way|Respiratory exercises plus conventional use of the inspirometer.
10116148|NCT04442464|Experimental|Study Eye|One eye will be randomly selected to wear the scleral lenses to be worn during study measurements
10116149|NCT04442464|No Intervention|Control Eye|Non-lens wearing eye
10116150|NCT04442412|Experimental|Arm B (Experimental):|"Patients randomized to Arm B will receive a prephase with oral prednisone and a prephase therapy with VitD according to the below reported schedule followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~Schedule for VitD supplementation: 25,000 U/day starting on day -6:~daily loading dose for 7 days if 25 VitD baseline level 20-40 ng/ml daily loading dose for 14 days if 25 VitD baseline level < 20 ng/ml followed by weekly maintenance supplementation of 25,000 U for the entire duration of immunochemotherapy (6 courses every 21 days - 18 weeks), regardless of the baseline level of 25 VitD."
10116151|NCT04442412|Other|Arm A (Standard arm)|"Patients randomized to Arm A will receive a prephase with oral prednisone followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~If patients randomized to arm A are already on VitD, they are allowed to continue receiving VitD supplementation at a dose that can be considered part of the standard of care and does not exceed the maximum standard VitD dose recommended for general adult and elderly population , up to 10,000 U/week VitD"
10116152|NCT04442321|Active Comparator|PENS plus exercise group|Experimental: PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently . It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
10116153|NCT04442321|Sham Comparator|Sham PENS plus exercise group|Sham Comparator: Sham PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently. It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
9528166|NCT03213327|Other|Case management|Case management program Utilization of the StayOk web application
9528167|NCT03213093|Other|Diabetic patients with a risk of diabetic foot ulcer|
9824862|NCT02360228|Sham Comparator|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
9824863|NCT02360280|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
9824864|NCT02360280|Active Comparator|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
9824865|NCT02360293|Experimental|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
9824866|NCT02360293|Active Comparator|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
9824867|NCT02360319|Active Comparator|Clinician's Choice|Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
9824868|NCT02360319|Experimental|Aripiprazole Once Monthly|Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years
9824869|NCT02360371|Placebo Comparator|Placebo (oral)|Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.
9824870|NCT02360371|Experimental|Hydromorphone (oral) 2mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
9824871|NCT02360371|Experimental|Hydromorphone (oral) 4mg|Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.
9824872|NCT02360371|Experimental|Hydromorphone (oral) 8mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
9824873|NCT02360397|Experimental|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
9824874|NCT02360475|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
9824875|NCT02360475|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
9824876|NCT02360475|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
9824877|NCT02360475|Active Comparator|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
9824878|NCT02360488|Experimental|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
10116154|NCT04442438|Experimental|Intensive care unit 1|Receives of intervention consisting of monthly moral case deliberation (ethical decision-making) meetings, planned and set up by ICU professionals which have received the task of being more attentive to ethical situations during work.
9528168|NCT03213171|No Intervention|Usual care|Usual care / Standard of care No intervention implemented
9528169|NCT03213171|Experimental|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
9528170|NCT03213236|Experimental|OSA Homemonitoring|Homemonitoring diagnostic system
9824879|NCT02360488|Active Comparator|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
9824880|NCT02360605|Active Comparator|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
9824881|NCT02360605|Active Comparator|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
9824882|NCT02360631|Experimental|Chantix (varenicline)|Participants will receive 1mg pills to take twice a day for 12 weeks.
9824883|NCT02360631|Placebo Comparator|Placebo|Participants will receive a placebo pill to take twice a day for 12 weeks.
9824884|NCT02360774|Experimental|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
9824885|NCT02360774|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
9824886|NCT02360995|Active Comparator|Total Toothpaste|Triclosan/fluoride toothpaste
9824887|NCT02360995|Active Comparator|Toothpaste + Mouthwash|Stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash
9824888|NCT02360995|Placebo Comparator|Control group|fluoride toothpaste +fluoride mouthwash
9824889|NCT02361216|Experimental|Ingenol mebutate gel|Treatment once daily for 3 days
9824890|NCT02361216|Placebo Comparator|Vehicle|Treatment once daily for 3 days
9824891|NCT02361307|Placebo Comparator|conventional ADL training|The control group receive the conventional ADL training programme
9824892|NCT02361307|Active Comparator|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
9824893|NCT02361476|Experimental|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
9824894|NCT02361476|Placebo Comparator|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
9824895|NCT02361736|Sham Comparator|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
9824896|NCT02361736|Experimental|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
9824897|NCT02361762|Experimental|Training|Computerized executive control training
9824898|NCT02361762|No Intervention|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
9824899|NCT02362048|Experimental|Experimental: Arm 1|ACP-196 alone
9824900|NCT02362048|Experimental|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
9824901|NCT02362191|Experimental|Single Session tACS Across Menstrual Cycle|Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.
9824902|NCT02362269|Active Comparator|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
9824903|NCT02362269|Experimental|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
9824904|NCT02362282|Active Comparator|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
9824905|NCT02362282|Active Comparator|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
9824906|NCT02362321|Experimental|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
9824907|NCT02362321|Placebo Comparator|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
9824908|NCT02362360|Experimental|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
9824909|NCT02362360|Experimental|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
9824910|NCT02362373|Other|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
9824911|NCT02362412|Experimental|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
9824912|NCT02362412|Experimental|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
9824913|NCT02362425|Active Comparator|RYR1-RM Patients Administered N-acetylcysteine|N-acetylcysteine
9824914|NCT02362425|Placebo Comparator|RYR1-RM Patients Administered Placebo|Placebo
9824915|NCT02362425|No Intervention|Healthy Volunteers|Healthy volunteers who had physical exam, study biomarker, Near Infrared Spectroscopy (NIRS) testing and muscle ultrasound only, in one visit.
9824916|NCT02362594|Experimental|Pembrolizumab|In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.
9824917|NCT02362594|Placebo Comparator|Placebo|In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.
10116155|NCT04442438|Other|Intensive care unit 2|First non-intervention, then flips to experimental arm type after six months.
10116156|NCT04442438|Other|Intensive care unit 3|First non-intervention, then flips to experimental arm type after six months.
10116157|NCT04442438|Other|Intensive care unit 4|First non-intervention, then flips to experimental arm type after twelve months.
10116158|NCT04442438|Other|Intensive care unit 5|First non-intervention, then flips to experimental arm type after twelve months.
9824918|NCT02362646|Experimental|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
9824919|NCT02362646|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
10116159|NCT04442438|Other|Intensive care unit 6|First non-intervention, then flips to experimental arm type after Eighteen months.
10116160|NCT04442399|Experimental|Intervention|The intervention was based on the WHO-endorsed manual entitled Positive Connections: Leading Information and Support Groups for Adolescents Living with HIV. For Family Connections, a caregiver companion guide was developed. In brief, adolescent/caregiver pairs attended 10 intervention sessions held every other Saturday at their HIV clinic over a six-month period.
10116161|NCT04442399|No Intervention|Comparison|The comparison arm consisted of standard of care for adolescents as offered at the HIV clinics.
9528171|NCT03213106|Experimental|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
9824920|NCT02362672|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
9824921|NCT02362672|Placebo Comparator|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
9824922|NCT02362724|Experimental|Sapphire|Subjects randomized to the experimental contact lens over the study duration
9824923|NCT02362724|Active Comparator|Pearl|Subjects randomized to the active comparator contact lens over the study duration
9824924|NCT02362789|Experimental|Secukinumab|300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
9824925|NCT02362789|Placebo Comparator|Placebo|Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28
9824926|NCT02363270|Active Comparator|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
9824927|NCT02363270|Active Comparator|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
9824928|NCT02363283|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
9824929|NCT02363322|Active Comparator|A/Current Standard of Care Alone|A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
9528172|NCT03213106|Sham Comparator|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
9528173|NCT03213145|Experimental|Part 1|
9824930|NCT02363322|Experimental|B/Current Standard of Care Plus ZMapp|"B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.~ZMapp 50mg/kg IV administered every third day for 3 infusions."
9824931|NCT02363439|Experimental|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
9824932|NCT02363478|Experimental|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
9824933|NCT02363621|Active Comparator|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
9824934|NCT02363621|Active Comparator|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
9824935|NCT02363686|Other|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
9824936|NCT02363738|Experimental|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
9824937|NCT02363738|Placebo Comparator|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
9827269|NCT02449915|Placebo Comparator|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
9827270|NCT02450383|Active Comparator|Control|Autologous subepithelial connective tissue graft
9827271|NCT02450383|Experimental|Experimental|Acellular Dermal Matrix
9827272|NCT02450487|Experimental|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
9827273|NCT02450526|Experimental|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
9827274|NCT02450526|Active Comparator|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
9827275|NCT02450526|Placebo Comparator|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
9827276|NCT02450526|Placebo Comparator|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
9827277|NCT02450539|Experimental|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9827278|NCT02450539|Active Comparator|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9827279|NCT02450552|Experimental|Oral ezogabine 600 mg/day|
9827280|NCT02450552|Experimental|Oral ezogabine 900 mg/day|
9528174|NCT03213145|Experimental|Part 2|
9528175|NCT03213197|Experimental|CPR video|Patient watches a short CPR video
9827281|NCT02450552|Placebo Comparator|Placebo|
9827282|NCT02450578|Experimental|Cohort 1a: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0
9827283|NCT02450578|Active Comparator|Cohort 1b: Malarone, sporozoite inoculum|Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0
9827284|NCT02450578|Experimental|Cohort 2: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0
9827285|NCT02450578|Experimental|Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)|DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0
9827286|NCT02450747|Experimental|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
9827287|NCT02450799|Experimental|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
9827288|NCT02450799|Active Comparator|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
9827289|NCT02450799|Active Comparator|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
9827290|NCT02450903|Experimental|LDK378 (Ceritinib)|Participants who received LDK378 750mg once daily on a 28 day cycle.
9827291|NCT02451007|Experimental|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
9827292|NCT02451124|Experimental|Screening: non-endoscopic inflatable balloon for the esophagus|Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
9827293|NCT02451137|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 units per millilitre [U/mL]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
9827294|NCT02451137|Active Comparator|Standard of Care|Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
9827295|NCT02451150|Experimental|Azilsartan 5 mg|Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
9824938|NCT02363803|Placebo Comparator|Normal saline infusion then lidocaine infusion|Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
9824939|NCT02363803|Active Comparator|Lidocaine infusion, then normal saline infusion|Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.
9824940|NCT02363933|Experimental|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
9824941|NCT02363946|Experimental|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
9824942|NCT02363946|Experimental|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
9824943|NCT02363946|Experimental|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
9824944|NCT02363946|Experimental|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
9824945|NCT02363946|Experimental|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
9824946|NCT02363946|Experimental|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
9824947|NCT02363946|Experimental|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
9824948|NCT02363946|Experimental|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
9824949|NCT02363946|Experimental|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
9824950|NCT02363946|Placebo Comparator|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
9824951|NCT02363946|Experimental|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
9824952|NCT02363946|Experimental|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
9824953|NCT02363946|Experimental|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
9824954|NCT02363946|Experimental|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
9824955|NCT02363946|Placebo Comparator|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
9824956|NCT02363959|Experimental|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
9824957|NCT02363959|Other|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
9824958|NCT02363972|Experimental|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
9824959|NCT02364037|Other|Phase 1: Enhanced Care|Women in Phase 1 of the prospective study will receive the CHOICE Project structured contraceptive counseling in addition to usual care by their health care provider. Contraceptive coverage will be by the usual mechanism such as insurance or financial assistance programs.
9824960|NCT02364037|Other|Phase 2: Complete CHOICE|Women in Phase 2 of the prospective study (Complete CHOICE) will receive the CHOICE Project structured contraceptive counseling. Immediately prior to the start of Phase 2, health care providers in participating health centers will undergo a contraceptive education session with a focus on evidence-based guideline for LARC provision and same-day insertion. Participating women will receive cost support for IUDs and implants if she chooses either as her contraceptive method and does not have appropriate insurance coverage.
9824961|NCT02364076|Experimental|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
9824962|NCT02364180|Other|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
9824963|NCT02364271||Not low risk for MACE in 30 days|"Patients with not low risk of major adverse cardiac events within 30 days Patients with TIMI>0 or mHEART>2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
9824964|NCT02364271||Low risk for MACE in 30 days|"Patients with low risk of major adverse cardiac events within 30 days~Patients with TIMI=0 and mHEART<=2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
9824965|NCT02364336|Experimental|HBeAg positive|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg and HBeAg positivity
9824966|NCT02364336|Experimental|HBeAg negative|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg positivity and HBeAg negativity
9824967|NCT02364388|Active Comparator|Imagio IUS gray-scale ultrasound|Imagio gray-scale ultrasound
9824968|NCT02364388|Other|Imagio OA/US|Imagio OA/US (opto-acoustic+gray-scale ultrasound)
9827296|NCT02451150|Experimental|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
10116162|NCT04442334||The LITMUS Study Cohort|Prospectively recruited NAFLD patients, recruited according to The European NAFLD Registry study protocol.
9824969|NCT02364570|Active Comparator|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
9824970|NCT02364570|Experimental|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
9824971|NCT02364570|Experimental|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
9824972|NCT02364570|Experimental|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
9824973|NCT02364700|Experimental|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
9824974|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
9824975|NCT02364947|Experimental|Nalmefene hydrochloride 10 mg|
9824976|NCT02364947|Experimental|Nalmefene hydrochloride 20 mg|
9824977|NCT02364947|Placebo Comparator|Placebo|
9824978|NCT02364999|Experimental|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
9824979|NCT02364999|Active Comparator|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
9824980|NCT02365064|Active Comparator|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
9824981|NCT02365064|Experimental|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
9824982|NCT02365285|Experimental|Galantamine 16 mg then placebo|Galantamine 16 mg po one time dose then placebo on 2nd visit
9824983|NCT02365285|Placebo Comparator|Placebo then Galantamine 16 mg|Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
9824984|NCT02365298|Experimental|etafilcon A|Worn in a daily disposable modality
9824985|NCT02365298|Active Comparator|nelfilcon A|Worn in a daily disposable modality
9824986|NCT02365480|Experimental|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
10116163|NCT04442334||The LITMUS Metacohort|Collated data and biological samples on patients with histologically characterised NAFLD prospectively recruited at contributing academic centres across Europe.
10116164|NCT04442334||EFPIA Clinical Trial Cohort|Collated data and biological samples on patients with histologically characterised NAFLD that have participated in phase 2 and phase 3 trials of IMPs for NAFLD.
9824987|NCT02365480|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
9824988|NCT02365506|Experimental|Eleclazine 24 mg + Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1 and 4, eleclazine 24 mg on Day 2 and eleclazine 48 mg on Day 3.
9824989|NCT02365506|Experimental|Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1, 2 and 4, and eleclazine 48 mg on Day 3.
10116165|NCT04442139||Mini-Gastric Bypass|Patients reported completing survey following Mini-Gastric Bypass
9824990|NCT02365506|Placebo Comparator|Placebo|Participants will receive placebo to match eleclazine on Days 1 to 4.
9824991|NCT02365519|Experimental|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
10116166|NCT04442191|Experimental|Convalescent plasma|This study will utilize convalescent plasma from donors recovered from infection with SARS-CoV-2 (which causes COVID-19) with neutralizing antibody titers >1:64.
10116167|NCT04442191|Placebo Comparator|Placebo|Placebo utilized in this study will include Fresh Frozen Plasma collected before the COVID-19 pandemic began. As an extra control, some of this plasma will be saved and tested for COVID-19 antibodies to ensure they are not present.
10116168|NCT04442633|Active Comparator|conventional therapy|topical corticosteroid plus antifungal
9824992|NCT02365519|Placebo Comparator|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
9824993|NCT02365558|Experimental|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
9824994|NCT02365558|Experimental|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.~Evacetrapib will be co-administered once, orally on Day 14."
9824995|NCT02365584|Experimental|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
9824996|NCT02365584|No Intervention|Standard care|Standard care according to site clinical practice.
9824997|NCT02365636|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
9824998|NCT02365636|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
9824999|NCT02365636|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
9825000|NCT02365714|Other|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
9825001|NCT02365870|Active Comparator|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
9825002|NCT02365870|Placebo Comparator|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
9825003|NCT02365961|Experimental|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine [per 60 mL] and epinephrine 1:400,000)
9825004|NCT02365961|Active Comparator|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
10116169|NCT04442633|Experimental|Glutamine with a topical corticosteroid plus antifungal|Glutamine therapy in combination with a topical corticosteroid plus antifungal
10116170|NCT04442113|Active Comparator|Control group|Pulmonary vein isolation alone (by catheter ablation)
9825005|NCT02366091|Experimental|Methotrexate|Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
9825006|NCT02366091|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily
9825007|NCT02366091|Experimental|Methotrexate & Colchicine|Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily
9825008|NCT02366091|Experimental|Placebo|Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
9825009|NCT02366130|Experimental|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
9825010|NCT02366143|Experimental|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
9825011|NCT02366143|Experimental|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
10116171|NCT04442113|Experimental|STAR guided ablation group|Pulmonary vein isolation plus ablation guided by STAR MappingTM
9825012|NCT02366143|Active Comparator|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
9825013|NCT02366195|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter. Participants were treated with talimogene laherparepvec until they achieved a complete response, all injectable tumors had disappeared, clinically significant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of treatment, per modified World Health Organization (WHO) response criteria, or intolerance of study treatment, whichever occurred first.
9825014|NCT02366312|Experimental|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
9825015|NCT02366403|Experimental|SKY|a standardized meditation program
9825016|NCT02366403|Active Comparator|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
10116172|NCT04442035|Experimental|The teatment group|5-element misic therapy
10116173|NCT04442035|Experimental|The control group|health education
10116174|NCT04442100|Experimental|bioprosthesis|"prosthetics of heart valves with dentures MedEng-Bio"
9825017|NCT02366468|Experimental|Discretion of the investigator (DI)|ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
9825018|NCT02366468|Active Comparator|Pro re nata (PRN)|ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
10116175|NCT04441970|Active Comparator|Neutral position|General anesthesia will be induced and nasotracheal tube will be placed through the patient's nose. After 30 seconds, the cuff pressure will be measured using a cuff manometer. Inspiratory tidal volume, expiratory tidal volume, peak inspiratory pressure, and end-tidal carbon dioxide waveform will be recorded three times according to breathing. Whether ventilation is not adequate and air is leaking will be recorded.
10116176|NCT04441970|Experimental|Head extension position|After changing the posture of the head and neck into head extension, cuff pressure will be recorded.
9825019|NCT02366611|Experimental|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
9825020|NCT02366611|No Intervention|Chemoradiotherapy Standard of Care|The control group will consist of patients receiving the Standard of care and no neuromodulation.
9825021|NCT02366637|Placebo Comparator|Placebo|Double blind placebo for PF-03715455
9825022|NCT02366637|Experimental|PF-03715455|
9825023|NCT02366663|Experimental|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
9825024|NCT02366663|Active Comparator|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
9825025|NCT02366689|Active Comparator|Toothpaste|Triclosan/fluoride toothpaste
9825026|NCT02366689|Active Comparator|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
9825027|NCT02366689|Placebo Comparator|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
9825028|NCT02366767|Experimental|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
10116177|NCT04441970|Experimental|Head flexion position|After changing the posture of the head and neck into head flexion, cuff pressure will be recorded.
10116178|NCT04441970|Experimental|Head rotation position|After changing the posture of the head and neck into head rotation, cuff pressure will be recorded.
10116179|NCT04441723|Active Comparator|lag screw with dynamic mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
10116180|NCT04441723|Active Comparator|lag screw with static mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
10116181|NCT04441684|Experimental|PCR+ group|This group includes any symptomatic person with a positive COVID result, with a RT-PCR test carried out at least 10 days before inclusion.
10116182|NCT04441684|Experimental|PCR- group|This group includes any symptomatic person with a negative RT-PCR COVID 19 test carried out at least 10 days before inclusion.
10116183|NCT04441684|Experimental|No PCR|This group includes any person, for which no COVID 19 RT- PCR testing was performed.
10116184|NCT04441801|Experimental|15 seconds|Stretching of the hamstring muscles will be performed by the primary researcher. A straight-leg-raising technique will be used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible, each subject's knee will be maintained in extension with the ankle at 90 degrees without medial (internal) or lateral (external) rotation of the lower extremity, and the extremity was raised until the subject reported discomfort. The subject was asked to relax the lower extremity in an effort to prevent contracting muscles from affecting the stretch and to allow for a slow stretch. stretching will continue for 15 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
10116185|NCT04441801|Experimental|30 seconds|the same stretching technique will continue for 30 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
10116186|NCT04441801|Experimental|60 seconds|the same stretching technique will continue for 60 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
10116187|NCT04441801|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end.
10116188|NCT04441827|No Intervention|Control|Usual care
10116189|NCT04441827|Experimental|Pranayama|Pranayama breathing exercise
10116190|NCT04441827|Experimental|Deep breathing exercise|Deep breathing exercise
10116191|NCT04441853|Experimental|YouTube video group|The intervention group attended five sessions of weekly-based tutorial, by watching YouTube videos on older people's and their caregivers' lived experience. On each session, they would joined post-video group discussion.
10116192|NCT04441853|Active Comparator|No YouTube video group|The control group were offered for five sessions of tutorial with same content without YouTube or other audio-visual tools. They also needed to join for group discussion in each tutorial.
10116193|NCT04441658|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75*10^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.
9825029|NCT02366767|Active Comparator|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
9825030|NCT02366845|Active Comparator|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.~INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
9825031|NCT02366845|Experimental|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.~A pre-transfusion INR (before transfusion) and a target post-transfusion INR (after transfusion) will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
9825032|NCT02366871|Experimental|Oral apixaban|Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
9825033|NCT02366871|Active Comparator|Subcutaneous enoxaparin|Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
9825034|NCT02366910|Experimental|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
9825035|NCT02366910|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
9825036|NCT02366923|Experimental|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
9825037|NCT02366923|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
9825038|NCT02366936|Experimental|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
9825039|NCT02367014|Experimental|Low Dose|elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
9825040|NCT02367014|Experimental|Intermediate dose|elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
9825041|NCT02367014|Experimental|High dose|elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
9825042|NCT02367014|Placebo Comparator|Placebo|In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
9825043|NCT02367066|Experimental|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
9825044|NCT02367066|Placebo Comparator|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
9825045|NCT02367131||Jardiance|
9825046|NCT02367352|Experimental|Cohort 1 (Dose Escalation Phase)|Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).
9825047|NCT02367352|Experimental|Cohort 2 (Dose Escalation Phase)|Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
9825048|NCT02367352|Experimental|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
9825049|NCT02367391|Experimental|Motivational Text Messages|
9825050|NCT02367391|Sham Comparator|Control|
9825051|NCT02367430|Experimental|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
9825052|NCT02367521|Experimental|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
9825053|NCT02367521|Placebo Comparator|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
9825054|NCT02367599|Active Comparator|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
9825055|NCT02367599|No Intervention|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
9825056|NCT02367729|Experimental|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
9825057|NCT02367729|Sham Comparator|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
9825058|NCT02367781|Experimental|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
9827669|NCT02464163|Experimental|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
10116194|NCT04441658|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
9825059|NCT02367781|Active Comparator|Arm B (Nab-Paclitaxel+Carboplatin)|Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression.
9825060|NCT02367820|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
9825061|NCT02367833|Experimental|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
9825062|NCT02367833|Experimental|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
9825063|NCT02367833|Experimental|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
9825064|NCT02367833|No Intervention|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
9825065|NCT02367859|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
9825066|NCT02367872|Active Comparator|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
9825067|NCT02367872|Experimental|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
9825068|NCT02367872|Experimental|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
9825069|NCT02367872|Experimental|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
9825070|NCT02367872|Experimental|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
9825071|NCT02367872|Active Comparator|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
9825072|NCT02367872|Experimental|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
9825073|NCT02367872|Experimental|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
9825074|NCT02367885|Experimental|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
9825075|NCT02367885|Experimental|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
9825076|NCT02367885|Experimental|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
9825077|NCT02367911|Experimental|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
9825078|NCT02367911|Placebo Comparator|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
10116195|NCT04441788|Experimental|ION-827359|Single-dose of ION-827359 will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks
10116196|NCT04441788|Placebo Comparator|Placebo|Single-dose of placebo will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks
9825079|NCT02368093|Experimental|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
9825080|NCT02368093|Placebo Comparator|Placebo|placebo pills with the same appearance as Detosiv tablets.
9825081|NCT02368210|Experimental|122-0551 Foam|122-0511 Foam, topically applied twice daily
9825082|NCT02368210|Placebo Comparator|Vehicle Foam|Vehicle Foam, topically applied twice daily
9825083|NCT02368314|Experimental|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
9825084|NCT02368314|Active Comparator|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
9825085|NCT02368431|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
9825086|NCT02368431|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
9825087|NCT02368457|Experimental|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
9825088|NCT02368457|No Intervention|CONTROL|No drug treatment
9825089|NCT02368691|Experimental|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
9825090|NCT02369068|Experimental|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
9825091|NCT02369068|Active Comparator|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
9825092|NCT02369159|Experimental|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.~Subjects ≥12 years will receive a dose of 600 mg.~Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).~Subjects < 6 months will receive a dose of 8 mg/kg."
9825093|NCT02369159|Active Comparator|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.~Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).~Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
9825094|NCT02369172|Other|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
9825095|NCT02369211|Experimental|Intravenous acetaminophen|Patient receives 1g intravenous acetaminophen after the incision
9825096|NCT02369211|Placebo Comparator|Placebo|Patient receives saline injection instead of the study drug
9825097|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
9825098|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged >60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
9825099|NCT02369484|Other|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
9825100|NCT02369510|Experimental|Low-dose epinephrine|100micrograms of epinephrine group
9825101|NCT02369510|Experimental|High-dose epinephrine|200micrograms of epinephrine group
9825102|NCT02369510|Placebo Comparator|No epinephrine|0.2ml saline
9825103|NCT02369796|Experimental|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
9825104|NCT02369796|Experimental|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
9825105|NCT02369796|Experimental|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
9825106|NCT02369796|Experimental|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
9825107|NCT02369796|Experimental|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
9825108|NCT02369835|Experimental|Arm I (modified Dakin's solution)|Participants apply modified Dakin's solution (0.005% to 0.010%) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
9825109|NCT02369835|Placebo Comparator|Arm II (placebo)|Participants apply placebo solution (saline) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
9825110|NCT02369848|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
9825111|NCT02369874|Experimental|MEDI4736|MEDI4736 monotherapy
10116197|NCT04441710||Caregivers|Staff of university hospitals
9825112|NCT02369874|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
9825113|NCT02369874|Active Comparator|Standard of Care|Standard of Care
9825114|NCT02369900|Active Comparator|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
9825115|NCT02369900|Placebo Comparator|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
9825116|NCT02370004|Experimental|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
9825117|NCT02370043|Experimental|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
9825118|NCT02370043|Experimental|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
9825119|NCT02370043|Placebo Comparator|Placebo|Single dose of placebo matching KQ-791 dose
9825120|NCT02370056|Experimental|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
10116198|NCT04441710||Primary care caregivers|Population of professional caregivers such as general practitioner or freelance nurse.
10116199|NCT04441710||Patients|
9825121|NCT02370056|Active Comparator|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
9825122|NCT02370095|Active Comparator|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
9825123|NCT02370095|Placebo Comparator|Placebo|Placebo administration will be administered as above for the active arm
9825124|NCT02370121|Placebo Comparator|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
9825125|NCT02370121|Experimental|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
9825126|NCT02370160|Experimental|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
9825127|NCT02370238|Experimental|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.~continuing from D 1 to Day 21 of 28-day cycle"
9825128|NCT02370238|Active Comparator|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
9825129|NCT02370251|Experimental|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
9825130|NCT02370368|Experimental|Dance Group|"Training: participants will engage in dance training with the Xbox Kinect 360 using the Just Dance 2014 disc.~Duration : 45 minutes per session. Frequency: three times per week for six weeks."
9825131|NCT02370368|Active Comparator|Ladder Drills|Intervention: Agility ladder drill training. Duration: 45 minutes per session. Frequency: three times per week for six weeks
9825132|NCT02370394|Experimental|ROSE Program|Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
9825133|NCT02370394|No Intervention|Control Condition|Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
9825134|NCT02370407|Experimental|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
9825135|NCT02370407|Experimental|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
9825136|NCT02370420|Experimental|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
9825137|NCT02370420|Active Comparator|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
9825138|NCT02370498|Experimental|Pembrolizumab|Participants receive 200 mg intravenous (IV) pembrolizumab on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years).
9825139|NCT02370498|Active Comparator|Paclitaxel|Participants receive 80 mg/m^2 IV paclitaxel on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
9825140|NCT02370511|Experimental|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
9825141|NCT02370511|Experimental|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
9825142|NCT02370511|Experimental|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
9825143|NCT02370537|Experimental|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
9825144|NCT02370537|Experimental|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
9825145|NCT02370602|Experimental|Pilot Cohort: [^11C]T-773 + TAK-063|[^11C]T-773 <8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
9825146|NCT02370602|Experimental|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 <8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
10116200|NCT04441918|Experimental|Test group|
9825147|NCT02370615|Experimental|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
9825148|NCT02370615|Experimental|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
10116201|NCT04441918|Experimental|Control group|
10116202|NCT04441866|Active Comparator|Automated algorithms|Automated 3D techniques in measuring fetal biometry and reconstructing standard anatomical planes
10116203|NCT04441866|Placebo Comparator|Standard technique|Standard 2D assessment
9825149|NCT02370641|Active Comparator|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
9825150|NCT02370641|Active Comparator|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
9827297|NCT02451202|Experimental|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
9827298|NCT02451202|Active Comparator|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections]will be administered at least reappearance of T2."
9827299|NCT02451488|Experimental|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
9827300|NCT02451488|Other|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
9827301|NCT02451514|Experimental|MenABCWY+OMV Group|Subjects who received 2 doses of MenABCWY+OMV vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received a booster dose of MenABCWY+OMV vaccine in the current study at Day 1.
9827302|NCT02451514|Experimental|MenACWY Group|Subjects who received MenACWY vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received 2 doses of MenABCWY+OMV vaccine, one month apart (Day 1 and Day 31), in the current study.
9827303|NCT02451514|Experimental|Naive Group|Subjects similar in age to subjects in the MenABCWY+OMV and MenACWY groups, who had not previously received any meningococcal vaccine and who received 2 doses of MenABCWY+OMV vaccine, 1 month apart (Day 1 and Day 31), in the current study.
9827304|NCT02451670|Experimental|Prioritized Clinical Decision Support|Patients receiving care in clinics randomized to the intervention arm of the study and their primary care providers were presented with patient-specific written advice as to prioritized treatment and lifestyle changes that could reduce their cardiovascular risk, prompted by an electronic health record-based alert during their primary care visit.
9827305|NCT02451670|No Intervention|Usual Care|Patients receiving care in clinics randomized to the usual care arm of the study and their providers were not presented with the prioritized clinical decision support.
9827306|NCT02451696|Experimental|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
9827307|NCT02451696|No Intervention|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
10116204|NCT04441944||Telemedicine Cases|Patients presenting to rural emergency departments who had real-time provider-to-provider telemedicine used to supplement their emergency department care.
9827308|NCT02451839||Crohn's Disease|Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
9827309|NCT02451839||Rheumatoid Arthritis|Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
9827310|NCT02451839||Psoriasis|Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
9827311|NCT02451917|Experimental|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
9827312|NCT02451917|Active Comparator|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
9827313|NCT02451930|Experimental|Necitumumab + Pembrolizumab|"Part A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies).~Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology.~Part C were Japan participants. Part C were Japan participants."
10116205|NCT04441944||Non-Telemedicine Cases|Patients presenting to rural emergency departments who did not have real-time provider-to-provider telemedicine used to supplement their emergency department care.
9825151|NCT02370667|Experimental|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
9825152|NCT02370667|Active Comparator|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
9668671|NCT05215691||Group II (n=45, IV opioid)|The patients who did not prefer the block and preferred intravenous patient-controlled analgesia (PCA) are named as Group II (n=45). IV PCA is prepared with morphine 0.5 mg/ml.
9825153|NCT02370667|Other|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
9825154|NCT02370693|Active Comparator|bortezomib plus mycophenolate mofetil|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
9825155|NCT02370693|Placebo Comparator|Placebo plus mycophenolate mofetil|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
9825156|NCT02370784|Active Comparator|Active Drug|atorvastatin 40 mg once daily for sixteen weeks
9825157|NCT02370784|Placebo Comparator|Placebo control|receive a placebo of similar appearance once daily for sixteen weeks
9825158|NCT02370810|Experimental|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
9825159|NCT02370810|Other|weekly check-in group with delayed treatment|will complete weekly measures and commence the treatment once the experimental group completes the intervention
9825160|NCT02370914|Experimental|Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a SCAT test.
9825161|NCT02370914|Experimental|Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a SCAT test.
9825162|NCT02371187|Experimental|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
9825163|NCT02371187|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
9825164|NCT02371252|No Intervention|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
9825165|NCT02371252|Active Comparator|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
9825166|NCT02371356||Depressed, Medication only|Screen positive for depression and use only antidepressants during pregnancy
9825167|NCT02371356||Depressed, Psychotherapy only|Screen positive for depression and receive psychotherapy only.
9825168|NCT02371356||Depressed, Medication & Psychotherapy|Screen positive for depression and receive both antidepressants and psychotherapy.
9825169|NCT02371356||Depressed, untreated|Screen positive for depression and receive no treatment.
9825170|NCT02371356||Not depressed|Screen negative for depression and receive no treatment.
9825171|NCT02371369|Experimental|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
10116206|NCT04441645|Experimental|the acupoint-on-head group|pressing acupoints only on head
10116207|NCT04441645|Experimental|the acupoint-on-body group|pressing acupoints only on body
9668672|NCT05214443|Experimental|POEM + F arm|This arm will receive the POEM + F procedure
9668673|NCT05213650|No Intervention|Invisalign control patients (liquid soap)|Patients who clean their plaques only with liquid soap and toothbrush
9668674|NCT05213650|Experimental|Invisalign non-abrasive toothpaste patients|Patients who clean their plaque with non-abrasive toothpaste and toothbrush
9668675|NCT05213650|Experimental|Invisalign abrasive toothpaste patients|Patients who clean their plaque with abrasive toothpaste and toothbrush
10116208|NCT04441645|Experimental|the acupoint-on-head-and-body group|pressing acupoints on head and body
9825172|NCT02371369|Placebo Comparator|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
9825173|NCT02371369|Experimental|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
9825174|NCT02371369|Experimental|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
9825175|NCT02371616|Experimental|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
9825176|NCT02371616|Active Comparator|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
10116209|NCT04441645|No Intervention|the control group|routine care
9825177|NCT02371629|Experimental|NVA237 Twice daily|Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
9825178|NCT02371629|Experimental|NVA237 Once daily|Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
9825179|NCT02371668|Placebo Comparator|Placebo|Placebo, 5% dextrose (D-glucose) water
9825180|NCT02371668|Experimental|CR6261|CR6261, Investigational monoclonal antibody against influenza A viruses
10116210|NCT04441879|Experimental|Blended Be a Mom|Women will receive a blended intervention (integrating face-to-face and online sessions) for the treatment of postpartum depression.
10116211|NCT04441879|Active Comparator|Control (treatment as usual)|Women will receive intervention provided by primary healthcare units (treatment as usual).
10116212|NCT04441619|Active Comparator|Repeated exposure|Participants will complete four exercise sessions designed to induce delayed onset muscle soreness in the biceps
10116213|NCT04441619|Active Comparator|Single exposure|Participants will complete one exercise session designed to induce delayed onset muscle soreness
10116214|NCT04441619|No Intervention|Natural history|Participants will complete all sensory testing and imaging but not perform any exercise sessions.
10116215|NCT04441606|Experimental|Different types of cancer|"The study population will include up to 50 patients with disease in whom a diagnostic challenge is met, including but not limited to:~Inconclusive findings on 18F-FDG PET/CT or other imaging modalities.~Better delineation of tumor extent prior to therapy~Malignancies known to show variable avidity to FDG and at times, no uptake at all (e.g. Exocrine Pancreatic cancer, Gastric carcinoma, Mucin-producing or Signet-ring carcinoma).~Patients unable to optimally comply with the required preparation for FDG imaging.~The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff."
10116216|NCT04441580|Experimental|Artificial intelligence arm|Patients undergoing colonoscopy with artificial intelligence.
10116217|NCT04441580|Active Comparator|standard colonoscopy arm|Patients undergoing colonoscopy with standard colonscopy
10116218|NCT04441632|Other|Positive feedback|Participants in the study will provide consistent positive feedback to the colleagues they work with in the medical ICU (MICU) over a 4 week duration.
10116219|NCT04441463|Experimental|cohort|Mother-child couple
10116220|NCT04441593|Experimental|Intervention|Videoconferencing Intervention for Heavy Drinking and Chronic Pain
10116221|NCT04441593|Active Comparator|Control|Treatment as Usual
10116222|NCT04441697||continuous apomorphine delivery|apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day
10116223|NCT04441697||continous levodopa/carbidopa delivery|levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day
10116224|NCT04441697||deep brain stimulation|bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings
9668676|NCT05213650|Experimental|Invisalign Efferdent patients|Patients who clean their plaques with liquid soap and use Efferdent antibacterial cleaning tablet once a week
10116225|NCT04441736|Active Comparator|High flow nasal cannula|A device og high flow nasal cannula giving 60 litres / min
10116226|NCT04441736|Placebo Comparator|Conventional oxygen|Nasal cannula giving oxygen up to 10 litres / minute
10116227|NCT04441242|Placebo Comparator|Retrospective: Low lighting during screening colonoscopy|Screening colonoscopies performed with low lighting conditions.
10116228|NCT04441242|Active Comparator|Prospective: Ambient lighting during screening colonoscopy|Screening colonoscopies performed with ambient lighting conditions.
9825181|NCT02371746|Experimental|Cohort 1|ENV515-1 and ENV515-3 implants in Study Eye for 28 days
9825182|NCT02371746|Experimental|Cohort 2|Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
9825183|NCT02371746|Experimental|Cohort 3|One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)
10116229|NCT04441671|Experimental|Open label|Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00
10116230|NCT04441333|Experimental|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum.
9668677|NCT05213650|Experimental|Invisalign Cleaning Crystals patients|Patients who clean their plaques with liquid soap and use Invisalign Cleaning Crystals tablet once a week
9668678|NCT05211193||eTNM arm|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1- 42.
9825184|NCT02371759|Experimental|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
9825185|NCT02371759|Experimental|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
9825186|NCT02371759|Active Comparator|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
9825187|NCT02371759|Active Comparator|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
9825188|NCT02371759|Experimental|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
9668679|NCT05206331|Experimental|contrast enhanced mammography|Women who have been recently diagnosed with a suspicious abnormality for which they have scheduled a breast biopsy and meet inclusion criteria will be invited to have a contrast enhanced mammography before their scheduled biopsy procedure.
9825189|NCT02371759|Experimental|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
9825190|NCT02371759|Active Comparator|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
9825191|NCT02371759|Active Comparator|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
9825192|NCT02371785|Experimental|CorPath 200 System|CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
9825193|NCT02371850|Experimental|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
9825194|NCT02371876|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
9825195|NCT02371980|Experimental|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
9825196|NCT02371980|Placebo Comparator|Double-blind: Placebo|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
9825197|NCT02371980|Experimental|Double-blind: Vortioxetine 5 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
9825198|NCT02371980|Experimental|Double-blind: Vortioxetine 10 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
9825199|NCT02371980|Placebo Comparator|Double-blind: Vortioxetine 20 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
9825200|NCT02372006|Experimental|afatinib|dose escalation
9825201|NCT02372058|Other|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
10116231|NCT04441294|Experimental|ACE-Plus|"ACE-Plus is a one-on-one dual-session intervention for males aged 16 to 20 within foster care or preventive services settings which promotes condom use and knowledge of dual methods of contraception. The goal of ACE-Plus is to promote correct and consistent condom use of male latex condoms during penile-vaginal sex and to promote male engagement (e.g., discussion, decision-making) with their female partners in the use of female-centered contraception methods.~Session one focuses on correct and consistent condom use for purposes of HIV/STD prevention including information and activities that address teen pregnancy prevention. Session two, which occurs within 10 to 14 days of the first session, promotes dual-method contraceptive use. Both sessions are one hour."
10116232|NCT04441294|No Intervention|On Track|On Track was the alternative program provided to males randomly assigned to the control group. On Track seeks to assist participants in identifying their aptitudes and preferences regarding their careers and their values associated with employment, and to provide tools to prepare them for the work setting and future job interviews. Participants learn how to identify attitudes, values, preferences, and challenges surrounding a career path, receive an understanding of the documents required for employment, and develop an initial employment strategy and action plan. Trained foster care agency staff deliver the curriculum to participating youth in two one-on-one sessions at agencies. Each session is one hour in length. Session two occurs 10 to 14 days after session one.
10116233|NCT04441450|Experimental|[14C]ICP-022|Subjects will take a single of 150mg 100μCi of [14C]ICP-022.
10116234|NCT04441385|Experimental|Test arm|100 subjects will be randomly assigned to this arm. Patients in the test group will receive 300 mg of maraviroc BID for 14 days (added to standard care).
9825202|NCT02372071|Other|BiliCare|Two measurements with the BiliCare device
9825203|NCT02372097|Experimental|Group A|Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
9825204|NCT02372097|Experimental|Group B|Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
9825205|NCT02372136|Experimental|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
9825206|NCT02372136|Other|Optimized Nutrition|Optimized nutrition
9825207|NCT02372253|Experimental|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
9827314|NCT02451995|Experimental|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
9825208|NCT02372253|Placebo Comparator|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
9825209|NCT02372344|Experimental|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
9825210|NCT02372344|Experimental|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
9825211|NCT02372344|Experimental|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
9825212|NCT02372383|Experimental|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
9825213|NCT02372383|Experimental|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
9825214|NCT02372383|Active Comparator|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
9825215|NCT02372396|Experimental|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
9825216|NCT02372396|Active Comparator|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
9825217|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
9825218|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
9825219|NCT02372799|Experimental|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
9825220|NCT02372799|Placebo Comparator|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
9825221|NCT02372799|Active Comparator|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
9825222|NCT02373098|Experimental|FTY720|
9825223|NCT02373098|No Intervention|Healthy volunteers|Healthy volunteers with no intervention or drug administered.
9825224|NCT02373124|Experimental|open-label|52 minute infusion of NMDA antagonist
9825225|NCT02373137|Other|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
10116235|NCT04441385|Other|Control arm|100 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health has issued detailed guidelines for the management of COVID-19. Local Institutional Guidelines and Protocols for supportive management will also be implemented.
10116236|NCT04441359|Experimental|supplemented formula|Standard formula supplemented with prebiotic inulin-type fructans
10116237|NCT04441359|Placebo Comparator|standard formula|Standard Formula not supplemented with prebiotic inulin-type fructans
10116238|NCT04441216|No Intervention|Consultation only|Review by Chinese Medicine practitioner only
9825226|NCT02373137|Other|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
9825227|NCT02373202|Experimental|Sarilumab 150 mg q2w + DMARDs|Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
9825228|NCT02373202|Experimental|Sarilumab 200 mg q2w + DMARDs|Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
9825229|NCT02373202|Experimental|Sarilumab 150 mg q2w|Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
9825230|NCT02373202|Experimental|Sarilumab 200 mg q2w|Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
9825231|NCT02373371|Experimental|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
9825232|NCT02373371|Active Comparator|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
9827315|NCT02451995|Active Comparator|Local activation Time Mapping AT Ablation|Standard activation mapping will be used to guide ablation.
9825233|NCT02373813|Experimental|Open Label Run-In: Etanercept plus Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
9825234|NCT02373813|Experimental|Double-Blind Treatment: Methotrexate Monotherapy|"Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
9825235|NCT02373813|Experimental|Double-Blind Treatment: Etanercept Monotherapy|"Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
9825236|NCT02373813|Experimental|Double-Blind Treatment: Etanercept plus Methotrexate|"Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment)."
9825237|NCT02374060|Active Comparator|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
9825238|NCT02374060|Active Comparator|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
9825239|NCT02374060|Active Comparator|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0~Second injection permitted at Week 12 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
9825240|NCT02374099|Experimental|CC-486 and fulvestrant|CC-486 300 mg by mouth (PO) daily on days 1-21 of each 28 day cycle and fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
9825241|NCT02374099|Experimental|Fulvestrant|Fulvestrant will be administered by intramuscular injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
9825242|NCT02374138|Active Comparator|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
9825243|NCT02374138|Experimental|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
9825244|NCT02374164|Experimental|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
9825245|NCT02374164|Experimental|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
9825246|NCT02374164|Experimental|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
9825247|NCT02374255|Experimental|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
9825248|NCT02374255|No Intervention|Usual Care|
9825249|NCT02374307|Experimental|Exercise and education|This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
9825250|NCT02374307|No Intervention|Control|The control group performs activities as usual.
9825251|NCT02374398|Active Comparator|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
9825252|NCT02374398|Active Comparator|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
10116239|NCT04441216|Active Comparator|JinQi JiangTang Fang|JinQi JiangTang Fang (Rhizoma Coptidis, Radix Astragali and Flos Lonicerae)
10116240|NCT04441216|Active Comparator|JM-ELD|JQJT plus extra low dose Ophiopogonis Radix
10116241|NCT04441216|Active Comparator|JM-LD|JQJT plus low doses Ophiopogonis Radix
10116242|NCT04441346||patients with recent hemodialysis(less than 6 month|
10116243|NCT04441346||patients on hemodialysis more than 6 months and l|
10116244|NCT04441346||patients on hemodialysis more than 5 years|
9825253|NCT02374398|Active Comparator|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
9825254|NCT02374398|Placebo Comparator|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
9825255|NCT02374463|Experimental|Multimodality Balance Intervention (MMBI)|Multimodality Balance Intervention (MMBI)
9825256|NCT02374463|Active Comparator|Tai Chi|Tai Chi Intervention
9825257|NCT02374593|Experimental|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
9825258|NCT02374671|Experimental|Implantation-Non-Randomized|Subjects are not participants in the randomized sub-study. VisAbility micro inserts surgically implanted in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
9825259|NCT02374671|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. VisAbility micro inserts surgically implanted in the eyes. Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
9825260|NCT02374671|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
9825261|NCT02374918|Experimental|mTBI wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
9825262|NCT02374918|Placebo Comparator|mTBI wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
9825263|NCT02374918|Experimental|HC wavelength-1 bright light|30 minutes of light exposure
9825264|NCT02374918|Placebo Comparator|HC wavelength-2 bright light|30 minutes of light exposure
9825265|NCT02374957|Active Comparator|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
9825266|NCT02374957|No Intervention|Control|No Cilostazol
9825267|NCT02375347|Experimental|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
9825268|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
9825269|NCT02375698|Experimental|Gr 1 H56:IC31 5/500|5ug H56 + 500 ug IC31
9825270|NCT02375698|Placebo Comparator|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
9825271|NCT02375724|Experimental|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
9825272|NCT02375724|Placebo Comparator|Placebo|placebo twice daily by inhalation
9825273|NCT02375971|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
9825274|NCT02375971|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
9825275|NCT02375971|Active Comparator|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
9825276|NCT02375984|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
10116245|NCT04441424|Experimental|Convalescent plasma group|21 critically-ill COVID-19 patients were given convalescent plasma: 400 ml of convalescent plasma from COVID-19 recovered subjects. The plasma infusion lasts for one hour.
10116246|NCT04441424|Other|Control group|"This group is 28 critically-ill COVID-19 patients who are at the same disease stage to those of experimental group that were treated with conventional therapy without taking convalescent plasma.~The conventional therapy: 400 mg once PO Hydroxychloroquine/day with 250mg once PO Azithromycin."
9825277|NCT02376010|Active Comparator|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
9825278|NCT02376010|Active Comparator|warfarin|warfarin orally once a day, titrated to INR of 2-3
9825279|NCT02376166|Experimental|Metformin|850 mg PO once daily for 4 weeks
9825280|NCT02376179||Cuffed ETT|Pediatric patients intubated with a cuffed endotracheal tube for adenotonsillectomy.
9825281|NCT02376257|Active Comparator|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
9825282|NCT02376257|Active Comparator|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
9825283|NCT02376257|Placebo Comparator|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
9825284|NCT02376283|Other|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
9825285|NCT02376283|Other|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
9825286|NCT02376283|Other|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
9825287|NCT02376283|Other|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
9825288|NCT02376283|Other|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
9825289|NCT02376283|Other|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
9825290|NCT02376361|Active Comparator|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
9825291|NCT02376361|No Intervention|Control Group|Control group will receive standard monitoring (standard care).
9825292|NCT02376530|No Intervention|Usual shopping|No change in condition.
9825293|NCT02376530|Experimental|Nutrient profiling|Nutrient profiling system will be present during shopping session.
9825294|NCT02376530|Experimental|Price change|Price changes will be present during shopping session.
9825295|NCT02376530|Experimental|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
9825296|NCT02376790|Active Comparator|Methotrexate Monotherapy|Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
9825297|NCT02376790|Experimental|Etanercept Monotherapy|Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
9825298|NCT02376790|Experimental|Methotrexate + Etanercept|Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.
9825299|NCT02376998|Experimental|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
9825300|NCT02377063|Other|pressed juice 6 bottles|Subjects will consume pressed juice daily for 3 days.
9825301|NCT02377349|Experimental|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
9825302|NCT02377349|Placebo Comparator|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
9825303|NCT02377362|Experimental|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
9825304|NCT02377362|Placebo Comparator|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
9825305|NCT02377362|Experimental|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
9825306|NCT02377362|Placebo Comparator|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
9825307|NCT02377362|Experimental|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
9825308|NCT02377362|Placebo Comparator|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
9825309|NCT02377427|Experimental|Mepolizumab 40 mg in Part A and B|Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
9825310|NCT02377427|Experimental|Mepolizumab 100 mg in Part A and B|Participants with bodyweight >= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
9825311|NCT02377466|Experimental|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
9825312|NCT02377466|Placebo Comparator|Placebo|The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
9825313|NCT02377674|Experimental|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
9825314|NCT02377700|Experimental|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
9825315|NCT02377752|Experimental|Part A cohort 1: Olaratumab+Doxorubicin|"15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met~."
9825316|NCT02377752|Experimental|Part A cohort 2: Olaratumab+Doxorubicin|15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
9827316|NCT02452034|Experimental|3.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
9825317|NCT02377752|Experimental|Part A cohort 3 Olaratumab + Doxorubicin|20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
9825318|NCT02377752|Experimental|Part B: Olaratumab|15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
9825319|NCT02377817|Experimental|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
9825320|NCT02377817|Sham Comparator|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
9825321|NCT02377921|Experimental|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
9825322|NCT02377921|Placebo Comparator|Placebo|Matching placebo TID for 48 weeks.
9825323|NCT02377947||Patients with cirrhosis (grade 3 & 4 per west haven cr.)|Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema
9825324|NCT02377986|Experimental|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
9825325|NCT02378025|Experimental|Yoga Group|Postures, meditation, breathing exercises
9825326|NCT02378025|Active Comparator|Pain Management Wellness Group|Behavioral medicine
9825327|NCT02378038|Experimental|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
9825328|NCT02378207|Experimental|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
9825329|NCT02378207|Experimental|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
9825330|NCT02378207|Active Comparator|Group 3 BCG (2-8 x 105 CFU)|Administered IM as 0.1 mL in either deltoid muscle at Day 0.
9825331|NCT02378207|Placebo Comparator|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
10116247|NCT04441515|Experimental|Music|music supplied by ipod
10116248|NCT04441515|Active Comparator|oral books|Listening to books on ipod
10116249|NCT04441515|Placebo Comparator|usual care|Usual care
10116250|NCT04441411|Other|NEMOST-AIS|This study is designed as a cohort study.
10116251|NCT04441177|Experimental|Study group|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
10116252|NCT04441177|No Intervention|Control group|Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays.
10116253|NCT04441541|Experimental|Treadmill with auditory feedback group|
10116254|NCT04441541|Experimental|Treadmill with visual feedback group|
10116255|NCT04441541|Experimental|Treadmill with auditory and visual feedback group|
10116256|NCT04441541|Active Comparator|Treadmill training group|
10116257|NCT04441476||ICU staff|
10116258|NCT04441398|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
10116259|NCT04441398|Placebo Comparator|Placebo|Subjects will receive placebo TID.
9825332|NCT02378220|No Intervention|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
9825333|NCT02378220|Active Comparator|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
9825334|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
10116260|NCT04441567|No Intervention|Phase 1|Participants in phase 1 will be observed and data about their recovery time will be collected from which recovery curves will be calculated for Phase 2
10116261|NCT04441567|Experimental|Phase 2|Participants in Phase 2 will have their clinic visits potentially revised based on the phase 1 recovery curves which may increase or decrease the number of clinic visits they receive based on the PROMs reported.
10116262|NCT04441203|No Intervention|Control|Heart failure clinic follow up
10116263|NCT04441203|Active Comparator|CardioMems|The treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.
10116264|NCT04441151|Experimental|Experimental group|Pulmonary rehabilitation therapy
10116265|NCT04441151|No Intervention|Control group|Routine medical treatment
10116266|NCT04441437|Experimental|Splint Group|1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
10116267|NCT04441437|Placebo Comparator|No-Splint Group|1-hour task-oriented training without wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
10116268|NCT04441320|Experimental|CMUS group|Coated metal ureteral stent is indwelled.
10116269|NCT04441320|Other|DJS group|Double-J stent is indwelled
10116270|NCT04441164|Experimental|Observation of Virtual Actions (steps 1 and 3)|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
9825335|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
9825336|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
9825337|NCT02378480|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
9825338|NCT02378480|Active Comparator|Linezolid|Linezolid IV; Linezolid tablets
9825339|NCT02378506|Experimental|ETN 50mg QW|
9825340|NCT02378662|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
9825341|NCT02378662|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
9825342|NCT02378714|Placebo Comparator|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
9825343|NCT02378714|Experimental|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
9825344|NCT02378714|Active Comparator|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
9825345|NCT02378714|Experimental|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
9825346|NCT02378753|Experimental|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
9825347|NCT02378753|Experimental|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
9825348|NCT02378844|Active Comparator|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
9825349|NCT02378844|Sham Comparator|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
9825350|NCT02378883|Other|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
9825351|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
9825352|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
9825353|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
9825354|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
10116271|NCT04441164|Placebo Comparator|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
10116272|NCT04441164|Other|Patients|It will be offered to patients hospitalized in these 2 services and presenting post-resuscitation ICU-weakness, especially in the aftermath of COVID infection, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
9825355|NCT02378935|Experimental|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
9825356|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
9825357|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
9825358|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
9825359|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
9668680|NCT05205174|Other|Feasibility|This is a preliminary, prospective interventional study to investigate the feasibility of using depth electrodes in conjunction with novel analytical algorithms to detect CSDs in TBI patients.
9825360|NCT02378935|Experimental|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
9825361|NCT02378961|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
9825362|NCT02378961|Experimental|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
9825363|NCT02378961|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
9825364|NCT02378961|Experimental|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
9825365|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
9825366|NCT02378961|Experimental|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
9825367|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
9825368|NCT02379052|Experimental|Dupilumab 300 mg QW|Participants received SC dupilumab 300 mg during the 12-week double-blind treatment phase. Participants received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
9825369|NCT02379052|Experimental|Placebo|Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.
9825370|NCT02379078|Experimental|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
9825371|NCT02379078|Placebo Comparator|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
9825372|NCT02379091|Placebo Comparator|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
9825373|NCT02379091|Experimental|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
9825374|NCT02379091|Experimental|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
9825375|NCT02379091|Experimental|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant was discontinued from the study. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
9825376|NCT02379117||Crohn's Disease Patients|Patients with a diagnosis of Crohn's disease fitting the studies inclusion & exclusion criteria.
9825377|NCT02379117||Healthy Volunteers|For healthy volunteers the studies exclusion criteria apply.
9668681|NCT05204537||Patients who developed in-hospital COVID-19 thoracic complications, surgically managed.|"The study population consists of patients who have been surgically treated for COVID-19 thoracic complications.~Thoracic complications have been defined as any condition involving the thorax, directly or indirectly consequence of COVID-19, including either pathologies strictly related to the infection, or iatrogenic effects of therapeutic attempts to treat it. Since the wide span of diagnosis, the novelty of this pathology and the different protocols adopted by participating centers, it is not possible to identify common criteria for surgical indications. A wide variety of pleuro/parenchimal surgical procedures are included. Patients undergone chest tube placement alone are not included in the study."
9825378|NCT02379195|Experimental|A|"All patients receive the same treatment.~All patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy are administered on day 0 to day 5.~Interleukin-2 are administered in an i.v. continuous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days~Subcutaneous injections of peginterferon alpha 2b are administered three time (day -2, day 7 and day 14)"
9825379|NCT02379221|Experimental|Injectable / Topical|Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.
9825380|NCT02379247|Experimental|Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 250mg daily on day 1-28~Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
9825381|NCT02379247|Experimental|Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 300mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
9825382|NCT02379247|Experimental|Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 350mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
9825383|NCT02379247|Experimental|BYL-719 (alpelisib) Dose Expansion|"BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
9825384|NCT02379273|Experimental|Hybrid L24 pivotal study subjects|Subjects implanted with the Nucleus Hybrid L24 Implant as part of the pivotal IDE study and who still have the device implanted will continue to be followed for 5 years post activation
9825385|NCT02379442|Experimental|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
9827317|NCT02452034|Experimental|4.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
9827318|NCT02452034|Experimental|3.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
9825386|NCT02379637|Experimental|A N-acetylcysteine|N-acetylcysteine
9825387|NCT02379637|Placebo Comparator|B Placebo|Placebo
9668682|NCT05203445|Experimental|Olaparib in Combination with Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks in conjunction with olaparib (for the first 12 weeks) and cytotoxic chemotherapy (after olaparib has been completed) if administered prior to surgery and if the patient is not deemed to have tumor growth.
9825388|NCT02379728|Experimental|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
9825389|NCT02379728|Experimental|PrenaBelt with Body Position Sensor|"Participants will be instructed to use the PrenaBelt (with integrated body position sensor (BPS)) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
9825390|NCT02379728|Sham Comparator|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
9825391|NCT02379728|Sham Comparator|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
9825392|NCT02379858|Experimental|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
9825393|NCT02379858|Placebo Comparator|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
9825394|NCT02379923|Experimental|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
9825395|NCT02380183|Experimental|Intervention|Civco needle guidance device will be used while the nerve block is performed.
9825396|NCT02380183|No Intervention|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
9825397|NCT02380248|Experimental|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
9825398|NCT02380261|Experimental|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
9825399|NCT02380287|Experimental|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
9825400|NCT02380287|Experimental|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
9825401|NCT02380287|Experimental|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
9825402|NCT02380287|Experimental|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
9827670|NCT02464163|Experimental|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
9668683|NCT05201612|Experimental|Pembrolizumab plus olaparib|"Treatment cycles will be 21 days in length. All participants will receive treatment as follows:~Olaparib 300 mg, orally (po), twice a day (BID) continuously. Pembrolizumab 200 mg, intravenously (IV), every 21 days. Treatment will be continued in the absence of disease progression, unacceptable toxicity, withdrawal of consent or death. Pembrolizumab will be administered up to a maximum of 2 years (35 cycles)."
9668684|NCT05200351|Experimental|EAT Intervention|15 sessions of EAT
9668685|NCT05200052|Active Comparator|Colchicine 0.5 mg oral tablet|100 patients presented with anterior Myocardial infarction undergoing primary Percutaneous coronary intervention will receive colchicine tablet 1mg loading dose and colchicine 0.5 mg maintance dose for 6 months and will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
9668686|NCT05200052|No Intervention|Standard anti ischemic treatment|100 patients presented with anterior myocardial infarction undergoing primary percutaneous coronary intervention will do longitudinal strain pattern echocardiography to asses left ventricles systolic function
9825403|NCT02380287|Experimental|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
9825404|NCT02380287|Experimental|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
9825405|NCT02380287|Experimental|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
9825406|NCT02380287|Experimental|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
9825407|NCT02380612|Experimental|All Participants (within patient control)|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
9825408|NCT02380677|Experimental|Schedule 1 Cohort 1|CRLX301 7.5 mg/m2 IV given every 3 weeks
9825409|NCT02380677|Experimental|Schedule 1 Cohort 2|CRLX301 15 mg/m2 IV given every 3 weeks
9825410|NCT02380677|Experimental|Schedule 1 Cohort 3|CRLX301 30 mg/m2 IV given every 3 weeks
9825411|NCT02380677|Experimental|Schedule 1 Cohort 4|CRLX301 60 mg/m2 IV given every 3 weeks
9825412|NCT02380677|Experimental|Schedule 1 Cohort 5|CRLX301 75 mg/m2 IV given every 3 weeks
9825413|NCT02380677|Experimental|Schedule 1 Cohort 6|CRLX301 90 mg/m2 IV given every 3 weeks
9825414|NCT02380677|Experimental|Schedule 2 Cohort 1|CRLX301 25 mg/m2 IV given weekly
9825415|NCT02380677|Experimental|Schedule 2 Cohort 2|CRLX301 35 mg/m2 IV given weekly
9825416|NCT02380677|Experimental|Schedule 2 Cohort 3|CRLX301 45 mg/m2 IV given weekly
9825417|NCT02380677|Experimental|Schedule 2 Cohort 4|CRLX301 54 mg/m2 IV given weekly
9825418|NCT02380677|Experimental|Schedule 2 Cohort 5|CRLX301 54 mg/m2 given weekly for 3 weeks with 1 week off
9825419|NCT02380677|Experimental|Phase 2a expansion cohort|CRLX301 75mg/m2 IV given every 3 weeks
9825420|NCT02380690|Experimental|Peer Coach Assignment|Veteran participants will be assigned to a peer coach, who delivered self-management instruction one-on-one over a 6-month period.
10116273|NCT04441164|Other|Caregivers|It will be offered to caregivers of the ICU of the Rennes University Hospital, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
10116274|NCT04441164|Experimental|Relaxation (step 3)|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
10116275|NCT04441164|Experimental|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
9668687|NCT05198804|Experimental|ZN-c3 and Niraparib|ZN-c3 in combination with Niraparib
9668688|NCT05196945|Experimental|VA-dual|"14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
9668689|NCT05196945|Active Comparator|EACP - quadruple|14days(Esomeprazole 20mg/ time, 2 times/day, oral+Amoxicillin 1g/ time, 2 times/day, oral+Clarithromycin 0.5g/ time, 2 times/day, oral+Bismuth potassium citrate 220mg/ time, twice a day, orally)
9668690|NCT05193708|Active Comparator|Digital Indirect bonding|An indirect bonding tray will be fabricated from a 3D printed model
9825421|NCT02380690|No Intervention|Control|"Veteran participants will attend a 2-hour class in pain basics and pain self-management. Veterans will aso be given a set of pamphlets related to pain self-management."
9827319|NCT02452034|Experimental|4.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
9825422|NCT02380703|Experimental|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
9825423|NCT02380703|Placebo Comparator|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
9825424|NCT02380742|Experimental|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
9825425|NCT02380742|Placebo Comparator|Placebo|4 mL of placebo cream
9825426|NCT02380859|Active Comparator|Prism adaptation|Patients will undergo twice daily adaptation to upward shifts in vision. Participants will be provided with goggles fitted with prismatic lenses that shift vision upward by 25 dioptres (about 17 degrees). While wearing the lenses, participants point to two 10cm-diameter visual targets positioned one above the other (about 20cm apart) on a wall, returning their pointing arm to their chest between each pointing movement. Participants make 50 pointing movements, as fast and as accurately as possible. Such a procedure induces a downward sensorimotor adaptation of pointing movements. Participants undergo this training twice a day (morning and evening) for two weeks in a self-guided fashion.
9825427|NCT02380859|Sham Comparator|Sham adaptation|Participants undergo the same treatment protocol as described in the active comparator arm, with the exception that they wear goggles fitted with neutral lenses that do not induce sensorimotor adaptation.
9825428|NCT02381015|Experimental|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
9825429|NCT02381015|Experimental|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
9825430|NCT02381015|Experimental|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
9825431|NCT02381015|Experimental|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
10116276|NCT04441164|Placebo Comparator|Observation of Virtual Actions|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
10116277|NCT04441164|Experimental|Haptic stimulation|Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
9519478|NCT03286712|Experimental|Incident Peritoneal Dialysis|After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.
9519479|NCT03286686|Experimental|Experience 1|
9825432|NCT02381288|Experimental|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
9825433|NCT02381288|Experimental|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
9825434|NCT02381288|Experimental|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
9825435|NCT02381288|Placebo Comparator|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
9825436|NCT02381392|Experimental|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
9825437|NCT02381392|No Intervention|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
9825438|NCT02381418|Experimental|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
9825439|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
10116278|NCT04441164|Placebo Comparator|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
9519480|NCT03286686|Experimental|Experience 2|
9519481|NCT03286686|Experimental|Experience 3|
9668691|NCT05193708|Experimental|Windowed Bonding technique|3D printed guide with windows for positioning the bracket
9519482|NCT03286686|Experimental|Experience 4|
9825440|NCT02381795|Experimental|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
9825441|NCT02382016|Experimental|Investigational treatment|Macitentan film-coated tablet 10 mg once daily.
9825442|NCT02382016|Placebo Comparator|Placebo|Matching placebo tablet once daily.
9825443|NCT02382133|Other|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
9825444|NCT02382276|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
9825445|NCT02382640|Experimental|Sequence 1: ABDC|Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
9825446|NCT02382640|Experimental|Sequence 2: DACB|Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
9825447|NCT02382640|Experimental|Sequence 3: CDBA|Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
9519483|NCT03286686|Experimental|Experience 5|
9519484|NCT03286686|Experimental|Experience 6|
9825448|NCT02382640|Experimental|Sequence 4: BCAD|Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
9825449|NCT02382744|Experimental|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
9825450|NCT02382744|Experimental|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
9825451|NCT02382796|Experimental|Dacomitinib|3 dose strengths (45 mg, 30 mg, and 15 mg), continuous oral daily dosing
9519485|NCT03286673|Experimental|calcium phosphate|Pentacalcium hydroxy-triphosphate (Ca5(PO4)3OH) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
9519486|NCT03286673|Experimental|Tricalcium Phosphate|β-tricalcium phosphate (Ca3(PO4)2) as incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
9519487|NCT03286673|Experimental|Calcium carbonate|Calcium carbonate (CaCO3) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
9519488|NCT03286673|Active Comparator|Placebo|Wholemeal and crispy wafer bread without additional calcium additive.
9519489|NCT03286660|Other|COPD patients|"All convenient COPD patients admitted in real life for a rehabilitation program were included.~Exercises consist on a Chair Rise Tests and short questionnaire were added to the usual tools for the evaluation."
9519490|NCT03286647|Experimental|NORMALGRIEF|Oral hygiene instruction
9519491|NCT03286647|Experimental|COMPLICATEDGRIEF|Oral hygiene instruction
9519492|NCT03286647|Active Comparator|CONTROLS|Oral hygiene instruction
9519493|NCT03286634|Experimental|SR|"Standard Risk (SR) :~CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD <0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%~SR strategy:~All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.~During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval."
9519494|NCT03286634|Experimental|LR|"Low Risk (LR):~Time-point #1 (Day 15 induction) Flow MRD <1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) <0.01% AND CNS 1 only~LR strategy:~For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.~Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients."
9519495|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
9519496|NCT03286621||Typically Developing Children|Typically developing children
9825452|NCT02382848|Active Comparator|Prazosin, Then Placebo|Participants first received Prazosin. A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily. After a washout period, they then receive Placebo
9825453|NCT02382848|Placebo Comparator|Placebo, Then Prazosin|Participants first received Placebo (matching Prazosin) for a 3 consecutive week period during the 7 week study period. After a washout period, they then received Prazosin. The starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
9825454|NCT02382913|Experimental|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
9825455|NCT02382913|Experimental|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
9825456|NCT02382913|Experimental|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
9825457|NCT02382913|Experimental|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
9825458|NCT02382913|Experimental|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9825459|NCT02382913|Experimental|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9668692|NCT05186974|Experimental|Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A)|Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
9825460|NCT02382913|Experimental|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9825461|NCT02382913|Experimental|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
9825462|NCT02382913|Experimental|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9825463|NCT02382913|Active Comparator|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
9825464|NCT02382939|Experimental|somapacitan|
9825465|NCT02382939|Active Comparator|hGH (somatropin)|
9668693|NCT05186974|Experimental|SG + Pembrolizumab (Cohort B)|Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.
9825466|NCT02382991|Other|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
9825467|NCT02382991|Other|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
10116279|NCT04441060|Experimental|distress intervention subject group|Distress intervention program will be developed, and applied to the subject group, and they will be assessed before and after the intervention program with several tools.
10116280|NCT04441060|No Intervention|distress intervention control group|No intervention will be applied to the control group. They will be assessed before and after the intervention program with same tools with subject group.
10116281|NCT04441528|Experimental|Lid wipes containing terpinen-4-ol and sodium hyaluronate|The lid wipes will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
10116282|NCT04441528|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
10116283|NCT04440891|Experimental|TMS-Stimulation with X-Torp task|TMS with VR 1 experimental arm
10116284|NCT04440891|Experimental|TMS-Stimulation with MindMotion Go|TMS with VR 2 experimental arm
10116285|NCT04440891|Sham Comparator|TMS-Sham with X-Torp task|TMS sham control with VR 1
10116286|NCT04440891|Sham Comparator|TMS-Sham with MindMotion Go|TMS sham control with sham VR 2
10116287|NCT04440826|Active Comparator|Whole Food Meal|Whole foods meal - grilled cheese and drink meal
10116288|NCT04440826|Experimental|Processed Food Meal|Highly processed foods - grilled cheese and drink meal
10116289|NCT04440826|Experimental|Gluten-Free and Lactose-Free Meal|Gluten-free and lactose-free foods - grilled cheese and drink meal
10116290|NCT04440800||Study participants|All patients will receive the intervention
10116291|NCT04441112|Experimental|Ketorolac Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with ketorolac.
9825468|NCT02383017|Experimental|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
9825469|NCT02383017|Placebo Comparator|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
9825470|NCT02383043|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
9825471|NCT02383043|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
9825472|NCT02383056|Sham Comparator|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
9825473|NCT02383056|Experimental|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
9825474|NCT02383173|Active Comparator|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
9825475|NCT02383173|Experimental|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
9825476|NCT02383355|Experimental|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
9825477|NCT02383355|Active Comparator|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
9825478|NCT02383420|Experimental|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
9825479|NCT02383420|Experimental|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
9825480|NCT02383420|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
9825481|NCT02383472|Experimental|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
9825482|NCT02383472|Placebo Comparator|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
9825483|NCT02383576||Bevacizumab|Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
9825484|NCT02383576||Bevacizumab and Capecitabine|Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
9825485|NCT02383589|Active Comparator|Mycophenolate Mofetil (MMF)|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
9825486|NCT02383589|Experimental|Rituximab (RTX)|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally twice daily Q12H from Day 1 to Week 52.
9519497|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
9825487|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
9825488|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
9825489|NCT02383719|Experimental|Oro-nasal mask|All patients are included in this arm. Patients in this group receive the experimental oro-nasal mask during non-invasive ventilation
9825490|NCT02383758|Experimental|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
10116292|NCT04441112|Active Comparator|Triamcinolone Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with triamcinolone.
9827320|NCT02452034|Experimental|6 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
10116293|NCT04441112|Experimental|Ketorolac Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with ketorolac.
9825491|NCT02383758|Active Comparator|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
9825492|NCT02383862|Experimental|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
9825493|NCT02383862|No Intervention|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
9825494|NCT02383940|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
9825495|NCT02383940|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.
9825496|NCT02383966|Experimental|Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil|
9825497|NCT02383966|Active Comparator|Cisplatin/Carboplatin + 5-Flurouracil|
9825498|NCT02384044|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
9825499|NCT02384044|Active Comparator|Colgate® Sensitivity Relief Pen|Professionally Applied
9825500|NCT02384070|Experimental|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
9825501|NCT02384070|Active Comparator|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
9825502|NCT02384070|Experimental|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
9825503|NCT02384096|Active Comparator|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
9825504|NCT02384096|Active Comparator|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
9825505|NCT02384200|Experimental|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
9825506|NCT02384200|Active Comparator|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
9825507|NCT02384382|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
9825508|NCT02384395|Experimental|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
9825509|NCT02384460|Experimental|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
9825510|NCT02384460|Placebo Comparator|Placebo (SD-101-0.0) cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
9825511|NCT02384538|Placebo Comparator|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
9825512|NCT02384538|Experimental|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
9825513|NCT02384941|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
9825514|NCT02384941|Experimental|Sotagliflozin 200 milligrams (mg)|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
9825515|NCT02384941|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.
9825516|NCT02385084|Experimental|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
9825517|NCT02385084|Experimental|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
9825518|NCT02385084|Experimental|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
9825519|NCT02385084|Experimental|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
9825520|NCT02385084|Experimental|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
9825521|NCT02385097|Experimental|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
9825522|NCT02385097|Active Comparator|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
9825523|NCT02385240|Experimental|Test product|Brimonidine Topical Gel, 0.33 percent
9825524|NCT02385240|Active Comparator|Reference Product|Brimonidine Topical Gel, 0.33 percent (Reference)
9825525|NCT02385240|Placebo Comparator|Placebo gel|Placebo
9825526|NCT02385318|Experimental|Test Product|Ingenol Mebutate
9825527|NCT02385318|Active Comparator|Reference product|Ingenol Mebutate
9825528|NCT02385318|Placebo Comparator|Placebo product|Placebo gel
9825529|NCT02385526||Group A|Vagus Nerve Stimulation Therapy Standard Titration
9825530|NCT02385526||Group B|Vagus Nerve Stimulation Therapy Alternate Titration 1
9825531|NCT02385526||Group C|Vagus Nerve Stimulation Therapy Alternate Titration 2
9825532|NCT02385669|Experimental|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
9825533|NCT02385708|Active Comparator|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
9825534|NCT02385708|Active Comparator|Treatment Arm|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
9825535|NCT02385799|Placebo Comparator|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
9825536|NCT02385799|Active Comparator|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
9825537|NCT02386098|Experimental|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
9825538|NCT02386098|Other|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
9825539|NCT02386098|Experimental|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
9825540|NCT02386098|Experimental|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
9825541|NCT02386098|Other|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
9825542|NCT02386189|No Intervention|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
9825543|NCT02386189|Active Comparator|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
9825544|NCT02386319|Active Comparator|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
9825545|NCT02386319|Placebo Comparator|Placebo|Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
9825546|NCT02386605|Experimental|Treatment|Motivational Interviewing Treatment group
9825547|NCT02386605|Active Comparator|Control|Relaxation Skills Training group
9825548|NCT02386995||BIS and Entropy monitoring|Depth of anesthesia monitoring (BIS and entropy) are compared with standard clinical monitoring in patients with deep brain stimulators inserted at internalization whilst they are having a general anesthesia.
9825549|NCT02387008|Active Comparator|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
9825550|NCT02387008|Active Comparator|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
9825551|NCT02387008|Active Comparator|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
9825552|NCT02387164|Experimental|Alum-GAD, Vitamin D3|Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.
9825553|NCT02387164|Placebo Comparator|Placebo, Vitamin D3|Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years
9825554|NCT02387216|Experimental|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
9825555|NCT02387216|Active Comparator|Arm B: Comparator Arm|Docetaxel alone
9825556|NCT02387268|Experimental|CleanC|Standard colonoscopy procedure using the CleanC system
9825557|NCT02387294|Experimental|Age group 1: children (3-11 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly."
9825558|NCT02387294|Experimental|Age group 2: adolescents (12-18 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
9825559|NCT02387359|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
9825560|NCT02387359|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
9825561|NCT02387359|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
9827671|NCT02464176|Experimental|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
9825562|NCT02387372|Experimental|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~Those with Creatinine clearance (CLCR) > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
9825563|NCT02387372|Experimental|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
9825564|NCT02387476|Experimental|FRESCA mask first night|"FRESCA mask first night (experimental device) | CPAP second night (active comparator)"
9825565|NCT02387476|Experimental|CPAP Mask first night|"CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)"
9825566|NCT02387502|Experimental|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
9825567|NCT02387502|Active Comparator|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
9825568|NCT02387502|Active Comparator|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
9825569|NCT02387554|Experimental|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
9825570|NCT02387554|Active Comparator|HGP0904|amlodipine
9825571|NCT02387554|Active Comparator|HGP0608|losartan
9825572|NCT02387554|Active Comparator|HGP1405|chlorthalidone
9825573|NCT02387580|Active Comparator|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
9825574|NCT02387580|Experimental|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
9825575|NCT02387580|Experimental|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
9825576|NCT02387580|Active Comparator|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
9825577|NCT02387580|Experimental|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
9825578|NCT02387580|Experimental|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
9825579|NCT02387710|Active Comparator|Tiagabine|Tiagabine PO 12 mg before sleep
9825580|NCT02387710|Placebo Comparator|Placebo|Placebo PO before sleep
9825581|NCT02387749|Experimental|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
9825582|NCT02387762|Experimental|ACP-196 + Methotrexate|Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
9825583|NCT02387762|Placebo Comparator|Placebo + Methotrexate|Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
9825584|NCT02387801|Experimental|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
9825585|NCT02387801|Experimental|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
10116294|NCT04441112|Active Comparator|Triamcinolone Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with triamcinolone.
9825586|NCT02387814|Experimental|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
9825587|NCT02387814|Experimental|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
9825588|NCT02387814|Experimental|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
9825589|NCT02387814|Experimental|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
9825590|NCT02387840|Experimental|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
9825591|NCT02387840|Experimental|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
9825592|NCT02387840|Experimental|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
9825593|NCT02387840|Experimental|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
10116295|NCT04440878|Experimental|Static stretching|Static stretching will be administered to the hamstring muscles in the first group.
10116296|NCT04440878|Experimental|Mulligan TSLR technique|The Mulligan TSLR technique will be administered on the same muscle in the second group.
10116297|NCT04440852|Experimental|TEACCH intervention|TEACCH intervention for ASD
9668694|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin Safety Run-in|Participants will receive SG (de-escalating dose levels: 10.0 mg/kg, 7.5 mg/kg, or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.
10116298|NCT04440852|No Intervention|conventional rehabilitation group|Other conventional interventions
10116299|NCT04440865|Active Comparator|Arm 1- Standard colonoscopy|Standard colonoscopy is performed
9668695|NCT05186974|Experimental|SG + Pembrolizumab + Cisplatin Safety Run-in (Optional)|Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m^2 on Day 1 of a 21-day cycle.
9668696|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C)|Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
9668697|NCT05186974|Experimental|SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D)|Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.
9668698|NCT05184413|Experimental|Multimodal treatment|Therapeutic Exercise plus Pain Neuroscience Education
9668699|NCT05184413|Active Comparator|Unimodal treatment|Therapeutic Exercise
9668700|NCT05183321|No Intervention|Control Group|Group will not receive treatment: periodontal therapy
9668701|NCT05183321|Experimental|Periodontal therapy|Group will receive treatment: periodontal therapy
9668702|NCT05183126|Active Comparator|Normal SMA (>7310 mm^2)|Standard paclitaxel infusion time.
9668703|NCT05183126|Experimental|Low SMA (5120 - 7310 mm^2) and Sarcopenic SMA (<5120 mm^2)|Adjusted paclitaxel infusion time during only one dose; standard paclitaxel infusion time for all other doses.
9668704|NCT05178355|Experimental|Part A - KVD824 - 10 mg|6 participants were administered10 mg of KVD824 in capsule form (1 x 10 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
9668705|NCT05178355|Experimental|Part A - KVD824 - 20 mg|6 participants were administered 20mg of KVD824 in capsule form ( 2 x 10 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
9668706|NCT05178355|Experimental|Part A - KVD824 - 40 mg|6 participants were administered 40mg of KVD824 in capsule form (1 x 40 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
9668707|NCT05178355|Experimental|Part A - KVD824 - 80 mg|6 participants were administered 80mg of KVD824 in capsule form (2 x 40 mg capsules) on one occasion on Day 1. 2 participants received matching placebo.
9668708|NCT05178355|Experimental|Part A - KVD824 - 160mg|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
9668709|NCT05178355|Experimental|Part A - KVD824 - 320 mg|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
9668710|NCT05178355|Experimental|Part A - KVD824 - 640 mg|6 participants were administered 640 mg of KVD824 in capsule form (2 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
9668711|NCT05178355|Experimental|Part A - KVD824 - 1280 mg|6 participants were administered 1280 mg of KVD824 in capsule form (4 x 320 mg capsule) on one occasion on Day 1. 2 participants received matching placebo.
9668712|NCT05178355|Experimental|Part B - KVD824 - 80 mg Multi-Dose|6 participants were administered 80 mg of KVD824 in capsule form (2 x 40 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
9668713|NCT05178355|Experimental|Part B - KVD824 - 160 mg Multi-Dose|6 participants were administered 160mg of KVD824 in capsule form (1 x 160 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
9668714|NCT05178355|Experimental|Part B - KVD824 - 320 mg Multi-Dose|6 participants were administered 320mg of KVD824 in capsule form (1 x 320 mg capsule) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
9668715|NCT05178355|Experimental|Part B - KVD824 - 640 mg Multi-Dose|6 participants were administered 640mg of KVD824 in capsule form (2 x 320 mg capsules) in multiple doses over a period of 5 days (twice a day on Days 1-4 and once in morning of Day 5; the first dose on each day was administered fasted). 2 participants received matching placebo.
9668716|NCT05178355|Experimental|Part C - KVD824 - 320 mg Fasted|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 in a fasted state.
9668717|NCT05178355|Experimental|Part C - KVD824 - 320 mg High fat breakfast|12 participants were administered 320 mg of KVD824 in capsule form (1 x 320 mg capsule) on one occasion on Day 1 following consumption of a high fat breakfast.
9668718|NCT05167500||Experimental : Lorlatinib inn ALK Or ROS1 Metastatic NSCLC patient|Patients with metastatic non-small cell lung cancer treated with lorlatinib who were included in the compassionate use program in Spain between November 2016 and February 2019 for those with an ALK alteration, and between November 2016 to March 2021 for those with ROS1 alteration.
9668719|NCT05167331|Active Comparator|Virtual Reality|"(T1) after fitting the headset to the child's face, the assistant starts the VR program chosen by the child.~(T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~(T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~(T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~(T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
10116300|NCT04440865|Active Comparator|Arm 2- Colonoscopy assisted by Genius|Colonoscopy assisted by Genius artificial intelligence system is performed
9668720|NCT05167331|Active Comparator|Nitrous oxide sedation|"(T1) With the nitrous oxide/oxygen inhalation system titrated to 50%/50% whose flow rate is adapted to the child's respiratory flow. The assistant is responsible for controlling the sedation. Verbal encouragement is always present to reassure the child.~(T2) Five minutes after induction, local anesthesia with the QUICKSLEEPER device is performed. The injection of a cartridge of anesthetic Articaïne SEPTANEST 1/200 000 is administered intraosseously.~(T3) After placing the rubber dam, the investigator performs restorative +/- endodontic care of the selected temporary molar.~(T4) Once the treatment is finished, the sedation is stopped and the patient rests in the chair for 5 minutes.~(T5) As soon as the investigator considers that the child is back to normal state, he can leave the office with his parents."
9668721|NCT05166512|Active Comparator|Standard DPP|Standard DPP (over 12 months)
9668722|NCT05166512|Experimental|DPP Cooks|Standard DPP plus DPP Cooks (over 12 months, with 6 active cooking sessions during the first 4 months)
9668723|NCT05166265|Experimental|Sentio system|Prospective, open label, single-arm multi-centre investigation following clinical practice for bone conduction devices.
9668724|NCT05162846|Active Comparator|Arm 1 - Usual care (UC)|Participants are provided with a link to the Michigan Department of Health and Human Services (MDHHS) informational website and are instructed to follow up with their oncology provider about genetic testing.
9668725|NCT05162846|Experimental|Arm 2 - Virtual genetics navigator|Participants receive access to an online genetics tool, the virtual genetics navigator, to help learn why and how to seek out genetic testing for hereditary cancer syndromes.
9668726|NCT05162846|Experimental|Arm 3 - Motivational interviewing (MI)|Participants receive up to 2 phone calls from trained genetics health coaches who provide information about genetic testing and use motivational interviewing to encourage participants to seek out clinical genetic testing.
9668727|NCT05160597|Experimental|Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)|"SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 IV and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.~IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care TRUS."
9668728|NCT05159999|Experimental|Home Systolic Blood Pressure <140 mmHg|Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <140 mmHg.
9668729|NCT05159999|Active Comparator|Pre-Dialysis Systolic Blood Pressure <140 mmHg|Participants will have their blood pressure taken by an automated blood pressure device by dialysis unit staff using regular dialysis unit equipment according to usual clinical care. Pre-dialysis blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a pre-dialysis systolic blood pressure target of <140 mmHg.
9668730|NCT05159999|Other|Home Systolic Blood Pressure <130 mmHg|This will be an optional, exploratory 2 month study at the end of the primary 10-month trial. Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <130 mmHg.
9668731|NCT05155007|Experimental|Treatment Sequence ABC|Participants will receive a single oral dose of rilematovir (Treatment A) in Treatment Period 1, followed by a single oral dose of ciclosporin (Treatment B) in Treatment Period 2 and then single oral dose of ciclosporin plus single oral dose of rilematovir (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
9668732|NCT05155007|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
9668733|NCT05155007|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
9668734|NCT05155007|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
9668735|NCT05155007|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
9668736|NCT05155007|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
9668737|NCT05154903|Active Comparator|Citicoline|the Citicoline group will receive citicoline in continuous Iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks
9668738|NCT05154903|No Intervention|control|the control group will not receive citicoline
9668739|NCT05153330|Experimental|Dose Escalation Phase|"Experimental: ARM A:~Study participants who are not receiving a moderate or strong CYP3A4 inhibitor.~Dose Escalation Phase:~Cohort 1: participants with acute leukemia~Cohort 2: participants with diffuse large B-cell lymphoma~Cohort 3: participants with multiple myeloma~Participants will receive 100 mg BMF-219 orally once per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose)~Dose Expansion Phase:~Cohorts 1, 2, and 3 will receive BMF-219 at the OPD/RP2D to further assess the safety/efficacy of the investigational drug."
9668740|NCT05153330|Experimental|Dose Expansion|"Experimental: ARM B:~Study participants who are receiving a moderate or strong CYP3A4 inhibitor.~Dose Escalation Phase:~• Cohort 1: participants with acute leukemia will receive 25 mg BMF-219 orally once per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).~Dose Expansion Phase:~Cohort 1 will receive BMF-219 at the OBD/RP2D to further assess the safety and efficacy of the investigational drug."
9825594|NCT02387840|Experimental|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
9825595|NCT02387840|Experimental|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
9825596|NCT02387853|Experimental|LEO 90100|
9825597|NCT02387957|Experimental|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
9825598|NCT02387957|Experimental|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
9668741|NCT05150028|Experimental|Intervention - Pediatric parent/caregiver|Questionnaires along with instructional video for the use of Medication Event Monitoring System (MEMS)
9668742|NCT05150028|Experimental|Clinicians|Will complete pre and post survey about medication education practices
9825599|NCT02387957|Experimental|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
9825600|NCT02387970|Active Comparator|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
9825601|NCT02387970|Active Comparator|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
9825602|NCT02387983|Experimental|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
9825603|NCT02388074|Experimental|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
9825604|NCT02388165|Active Comparator|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
9825605|NCT02388165|Placebo Comparator|Placebo|Diluent (sterile water) for Placebo
9825606|NCT02388191|Experimental|Naproxen sodium|550 mg naproxen sodium
9825607|NCT02388191|Placebo Comparator|Placebo|Placebo
9825608|NCT02388269|Active Comparator|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
9668743|NCT05148858||Cases|Patients affected by COVID-19 infection
9668744|NCT05148858||Control|Normal subjects not affected by COVID-19 infection
9668745|NCT05141695|Experimental|therapeutic group|therapeutic repetitive peripheral magnetic stimulation
9668746|NCT05141695|Sham Comparator|sham group|sham repetitive peripheral magnetic stimulation
9668747|NCT05140044|No Intervention|Control|Older adults who are not given a 4-week balance intervention program
9668748|NCT05140044|Experimental|Home Intervention|Older adults who are given a 4-week home-based balance exercise program. Performed 3days/week for 30min/day over the course of a 4-week period using participants' smartphones.
9668749|NCT05129475|Experimental|Treatment A|Single oral dose of ritonavir at -12 hours prior to PF-07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
9668750|NCT05129475|Experimental|Treatment B|Single oral dose of ritonavir at -12 hours prior to PF 07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
9668751|NCT05127226|Experimental|Cohort A: Dose 1|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
9668752|NCT05127226|Experimental|Cohort B: Dose 2|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
9668753|NCT05127226|Experimental|Cohort C: Dose 3|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
9825609|NCT02388269|Sham Comparator|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
9825610|NCT02388295|Experimental|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
9825611|NCT02388295|Placebo Comparator|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
9825612|NCT02388321|Experimental|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
9825613|NCT02388321|Active Comparator|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
9825614|NCT02388347|Placebo Comparator|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
9825615|NCT02388347|Experimental|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
9825616|NCT02388347|Experimental|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
9825617|NCT02388347|Experimental|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
9825618|NCT02388347|Experimental|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
9825619|NCT02388386|Experimental|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
9827321|NCT02452034|Experimental|6 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
9827322|NCT02452047|Experimental|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
9827323|NCT02452047|Active Comparator|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
9827324|NCT02452047|Experimental|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
9827325|NCT02452060|Placebo Comparator|treatment/placebo|saline infusion
9827326|NCT02452060|Experimental|treatment|ketamine (0.4mg/kg)
9827327|NCT02452190|Experimental|Reslizumab|Reslizumab
9827328|NCT02452190|Placebo Comparator|Placebo|Matching Placebo
9827329|NCT02452320|Placebo Comparator|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
9827330|NCT02452320|Active Comparator|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
9827331|NCT02452346|Experimental|All Patients|Tosedostat 120 mg PO once daily will be administered.
9827332|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 1)|"Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.~(Enrollment complete- 33 enrolled)"
9827333|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 2)|"Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors~(Enrollment Complete- 45 enrolled)"
9827334|NCT02452463|Experimental|Arm I (nintedanib)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9827335|NCT02452463|Placebo Comparator|Arm II (placebo)|Beginning 4-8 weeks after completion of radiation therapy, patients receive placebo capsules PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9827336|NCT02452463|Experimental|Arm III (nintedanib, durvalumab)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28 and standard of care durvalumab IV over 60 minutes on days 1 and 15. Treatment with nintedanib repeats every 28 days for up to 6 cycles and treatment with durvalumab repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
9827337|NCT02452476|Experimental|CHF5633|Single dose within 24 hours from birth
9827338|NCT02452476|Active Comparator|Poractant alfa|Single dose within 24 hours from birth
9827339|NCT02452528|Experimental|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
9827672|NCT02464176|Experimental|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
10116301|NCT04440904||Characteristic of aortic length and body surface mark|The diameters and lengths of blood vessels and the distances on the body surface were measured by three-dimensional reconstruction using related Software on CT Workstation
10116302|NCT04440956|Experimental|Intervention|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection."
10116303|NCT04440813|Active Comparator|Clinician Training|Traditional healers randomized to the control arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by trained medical personnel.
10116304|NCT04440813|Experimental|Healer + Clinician Training|Traditional healers randomized to the intervention arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by both healers who already use PPE regularly and trained medical personnel.
10116305|NCT04440917|Experimental|Study group|Inductive therapy with Camrelizumab and Apatinib
9825620|NCT02388568|Active Comparator|Lorcaserin plus Lifestyle Modification|
9825621|NCT02388568|Placebo Comparator|Placebo plus Lifestyle Modification|
9825622|NCT02388633||Plasmapharesis|Patients undergoing apheresis for elevated LDL. Patients will undergo contrast ultrasound perfusion imaging at rest and during forearm exercise at before and immediately after apheresis.
9825623|NCT02388646|Active Comparator|Exercise Only|Home exercise program.
9825624|NCT02388646|Active Comparator|Brace Only|Reaction Web brace.
9825625|NCT02388646|Active Comparator|Bracing + Exercises|Reaction Web brace and home exercises.
9825626|NCT02388724|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
9825627|NCT02388724|Active Comparator|Lansoprazole 30 mg|Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
9825628|NCT02388737|Experimental|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
9825629|NCT02388737|Experimental|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
9825630|NCT02388737|Active Comparator|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
9825631|NCT02388763|Other|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
9825632|NCT02388763|Other|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
9825633|NCT02388815|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
9825634|NCT02388880|Experimental|ITPR|Use of the ITPR for 240 minutes.
10116306|NCT04440969|Experimental|Intervention|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks. (Week 1 - 24)
9825635|NCT02388932|Experimental|Treatment (SBRT)|"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.~Three dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.~The dosing strategy for the 2nd (45Gy) cohort will be identical to the first."
9825636|NCT02388997|Active Comparator|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
9825637|NCT02388997|Placebo Comparator|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
9825638|NCT02389088|No Intervention|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
9825639|NCT02389088|Active Comparator|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
9825640|NCT02389101|Experimental|Lymphoma|Newly diagnosed lymphoma, all subtypes allowed
9825641|NCT02389361|Experimental|Group Z|Postoperative Analgesia with Zaldiar
9825642|NCT02389361|Active Comparator|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
9825643|NCT02389374|Other|chloroquine primaquine 14days|P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
10116307|NCT04440969|Experimental|Wait-list control|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks after Intervention Group has completed intervention. (Week 25 - 48)
10116308|NCT04441138|Experimental|Concurrent, Split Course Chemoradiation Followed by Durvalumab|Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
10116309|NCT04441021||Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
9825644|NCT02389374|Other|artemether-lumefantrine primaquine 1day|P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
10116310|NCT04440787||Three point cuff palpation and Blck mark line technique|"In Three point cuff palpation technique the cuff will be palpated just below the cricothyroid membrane,at the level of suprasternal notch and below the suprasternal notchand the tube is re-positioned in case of any discrepancy between the black mark line technique and three point cuff at three different over the trachea."
9668754|NCT05127226|Experimental|Cohort D: Dose TBD|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
9668755|NCT05127226|Experimental|Cohort E: Dose TBD|ION582 will be administered as IT injection of over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
9668756|NCT05119686|Experimental|Group 1|AR882 Dose 1 x 12 weeks
9668757|NCT05119686|Experimental|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks
9668758|NCT05119686|Placebo Comparator|Group 3|AR882 matching placebo x 12 weeks
9668759|NCT05119296|Experimental|Pembrolizumab 200 mg|Participants will receive pembrolizumab (Keytruda) 200 mg administered by IV infusion every 3 weeks. Participants will remain on study and receive pembrolizumab for the nominal duration of treatment (35 cycles, approximately 2 years) or until there is evidence of disease progression by RECIST, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason.
9668760|NCT05098132|Experimental|Part A: STK-012 monotherapy dose escalation|STK-012 will be administered in sequential ascending doses as monotherapy subcutaneously weekly until unacceptable toxicity, disease progression, or withdrawal of consent.
9668761|NCT05098132|Experimental|Part B: STK-012 + pembrolizumab combination dose escalation|STK-012 will be administered in sequential ascending doses subcutaneously weekly in combination with a fixed dose of pembrolizumab intravenously every 3 weeks until unacceptable toxicity, disease progression, or withdrawal of consent.
9668762|NCT05098132|Experimental|Part C: STK-012 + pembrolizumab combination dose expansion|STK-012 will be administered at the recommended phase 2 dose subcutaneously weekly in combination with a fixed dose of pembrolizumab intravenously every 3 weeks until unacceptable toxicity, disease progression, or withdrawal of consent.
9668763|NCT05097144|Experimental|Lens A (Test)|Subjects will be randomized to wear test lenses (Lens A) for one month and then cross-over to wear to control lens B for one month.
9668764|NCT05097144|Active Comparator|Lens B (Control)|Subjects will be randomized to wear control lenses (Lens B) for one month and then cross-over to wear Test lens A for one month.
9668765|NCT05093335|Experimental|[68Ga]-Pentixafor|An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of [68Ga]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. [68Ga]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). [68Ga]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.
9668766|NCT05084508|Experimental|VNS_Low Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of low potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.
9668767|NCT05084508|Experimental|VNS_Med Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of medium potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.
9668768|NCT05084508|Experimental|VNS_High Group|Healthy children aged 12 to 15 months of age receive 1 dose of an investigational varicella vaccine (VNS) of high potency, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and 1 dose a 13-valent pneumococcal conjugate vaccine on Day 1.
9668769|NCT05084508|Active Comparator|VV_Lot1 Group|Healthy children aged 12 to 15 months of age receive 1 dose of a marketed varicella vaccine (VV) of Lot 1, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and a 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.
9668770|NCT05084508|Active Comparator|VV_Lot2 Group|Healthy children aged 12 to 15 months of age receive 1 dose of a marketed varicella vaccine (VV) of Lot 2, 1 dose of a measles, mumps, and rubella vaccine, 1 dose of a hepatitis A vaccine, and a 1 dose of a 13-valent pneumococcal conjugate vaccine on Day 1.
9668771|NCT05083845|Active Comparator|Erector Spinae Plane Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area.
9668772|NCT05083845|Active Comparator|Erector Spinae Plane Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine was injected into the area.
9668773|NCT05061537|Experimental|Monotherapy dose escalation (Part 1A)|Participants will receive PF-07263689 once a week for 4 doses
9668774|NCT05061537|Experimental|Combination dose escalation (Part 1B)|Participants will receive PF-07263689 intravenous (IV) once week for 4 doses in combination with sasanlimab subcutaneous (SC) once every 4 weeks
9668775|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm A|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
9668776|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm B|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
9825645|NCT02389374|Other|artemether-lumefantrine primaquine 14days|mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
9668777|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm C|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
9668778|NCT05058469||Tracheotomy without antiplatelet therapy+technique 1|
9668779|NCT05058469||Tracheotomy under antiplatelet therapy+technique 1|
9668780|NCT05058469||Tracheotomy without antiplatelet therapy+technique 2|
9668781|NCT05058469||Tracheotomy under antiplatelet therapy+technique 2|
9668782|NCT05057390|Experimental|New Human Milk Fortifier|From the Baseline (start of intervention) each patient will receive the case study product for at least 4 weeks (28 days), with at least 1-week administration in the community.
9668783|NCT05055011||Observational (survey, medical record review)|Parents complete survey over 20 minutes. Patients' medical records are reviewed.
9668784|NCT05052554|Experimental|30 µg cohort|Open label single dose cohort: Dose level 1
9668785|NCT05052554|Experimental|60 µg cohort|Open label single dose cohort: Dose level 2
9668786|NCT05048043|Experimental|Computer-assisted Behavior Intervention|A serious game paired with teacher consultation to address common needs related to ADHD in the classroom.
9668787|NCT05048043|Active Comparator|Challenging Horizons Program, School Consultation|An established teacher consultation program to help teachers address ADHD in the classroom.
9668788|NCT05035511|Experimental|Responders vs Non-responders|After the tDCS outcome recorded immediately after tDCS treatment, participants will be categorized into responders and non-responders based on the percentage of change in the total SRS score (primary outcome). Participants that show reductions of at least 10% in the total SRS scores as compared to baseline scores will be considered responders.
9668789|NCT05023655|Experimental|Tazemetostat|tazemetostat 800 mg po twice daily in continuous 28- day cycles
9668790|NCT05002387|Experimental|Unicompartmental OA or equivocal findings in XR|After obtaining informed consent, patients will undergo needle arthroscopy, performed in the operating room prior to undergoing arthroplasty
9668791|NCT04990427|Experimental|CLBS201|CLBS201 will be administered in an open-label fashion via intra-renal-arterial infusion in 6 subjects followed by 6 months of observation.
9668792|NCT04986852|Experimental|Olinvacimab (TTAC-0001) 16 mg/kg and Pembrolizumab (Keytruda®) 200 mg|"Olinvacimab (TTAC-0001) 16 mg/kg on D1, D8 and D15~Pembrolizumab (Keytruda®) 200 mg on D1 Cycle: 3 weeks (21 days per cycle)"
9694489|NCT04788732||3-Balanced anesthesia|the patients in this group will be anesthetized with blends of anesthetic inhaled (Sevoflurane) and intravenous drugs such as benzodiazepine (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not with neuromuscular relaxants (nonpolarizing/depolarizing) and adjuvant drugs such as dextrocetamine, dexmedetomidine, lidocaine, and magnesium sulfate.
9694490|NCT04789057|Experimental|Statins|Atorvastatin 40 mg treatment, p.o., QD
9694491|NCT04789057|Placebo Comparator|Placebo|Placebo tablet, p.o., QD
9694492|NCT04788745|Experimental|Experimental|Trimetazidine 35mg
9694493|NCT04788433||ROCCO-A (A-symptomatic)|Patients with documented COVID-19 infection and NO symptoms
9694494|NCT04788433||ROCCO-P (Pauci-symptomatic)|Patients with documented COVID-19 infection and mild symptoms but NO oxygen support)
9694495|NCT04788433||ROCCO-L (mild)|Patients with documented COVID-19 infection and mild severity - requiring OXIGEN SUPPORT
9694496|NCT04788433||ROCCO-M (moderate)|Patients with documented COVID-19 infection and moderate severity - requiring OXIGEN SUPPORT by NON-INVASIVE modalities
9694497|NCT04788433||ROCCO-S(severe)|Patients with documented COVID-19 infection and severe disease requiring INVASIVE VENTILATION OR EXTRACORPOREAL MEMBRANE OXYGENATION
9694498|NCT04788693|Experimental|Motor imagery and gait training group|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise. In an interspersed way, motor imagery exercises will be carried out where participants must rehearse or simulate mentally each gait exercise that will be developed in the session."
9694499|NCT04788693|Active Comparator|Gait training group without motor imagery|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise. In the periods that the experimental group performs the motor imagery exercises, the control group will take breaks."
9694500|NCT04788355|Active Comparator|Control Group standard treatment|Patients will be treated only with standard hospital treatment
9694501|NCT04788355|Experimental|Group Hydroxychloroquine|Patients will be treated with Hydroxychloroquine associated with standard hospital treatment
9694502|NCT04788355|Experimental|Group Hydroxychloroquine e Apixaban|Patients will be treated with Hydroxychloroquine associated with apixaban and standard hospital treatment
9694503|NCT04788355|Experimental|Group Apixabana|Patients will be treated with apixaban associated with standard hospital treatment
9694504|NCT04788381||Participants with CRC or lung cancer was performed unexpected operation|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
9694505|NCT04788368||Patients treated with TEM - transanala microsurgery|Early rectal cancer treated with TEM - full thickness resection
9694506|NCT04788368||Patients treated with ESD|Early rectal cancer treated with the endoscopic treatment ESD - endoscopic submucosal resection
9694507|NCT04788368||Patients treated with EMR|Early rectal cancer treated with the endoscopic treatment EMR - endoscopic mucosal resection
9694508|NCT04788290||Single group(No interventional)|Other Name: Observational Rabone D®, Once daily administered per the locally approved product information
9825646|NCT02389452|Experimental|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore [measurement of pain while walking on flat surface] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
9825647|NCT02389621|Experimental|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
9825648|NCT02389621|Placebo Comparator|Placebo|Placebo once daily for up to 7 days.
9825649|NCT02389725|Active Comparator|disposable elastic tourniquet|
9825650|NCT02389725|Active Comparator|manual blood pressure cuff|manual blood pressure cuff inflated to 150 milliliters mercury (mmHg)
9825651|NCT02389738|Experimental|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
9825652|NCT02389764|Experimental|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
9825653|NCT02389816|Placebo Comparator|Placebo|Placebo tablets, orally, once daily for up to Week 8
9825654|NCT02389816|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 8
9825655|NCT02389816|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8
9825656|NCT02389829|Active Comparator|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
9668793|NCT04986085||GEP NET|GEP NET patients in Spain
9825657|NCT02389829|Active Comparator|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour."
9825658|NCT02389881|Experimental|Cohort 1 Non-elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
9825659|NCT02389881|Experimental|Cohort 2 Non-elderly Healthy: TAK-058 75 mg|TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
9825660|NCT02389881|Experimental|Cohort 3 Non-elderly Healthy: TAK-058 150 mg|TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
9825661|NCT02389881|Experimental|Cohort 4 Elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.
9825662|NCT02389881|Placebo Comparator|Cohort 5 Non-elderly Healthy: TAK-058 300 mg|TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.
9825663|NCT02389881|Placebo Comparator|Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.
9668794|NCT04984629|Experimental|HYDRAFIL Implant|Polymer Implant of HYDRAFIL into a one or two lumbar intervertebral discs
9825664|NCT02389881|Placebo Comparator|Cohort 4 Elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
9825665|NCT02389894|Active Comparator|Embol-X Embolic Protection Device|The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
9825666|NCT02389894|Active Comparator|CardioGard Cannula|The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
9668795|NCT04982445|Experimental|Participants receiving CABENUVA|
9668796|NCT04973436|Experimental|Dialectical Behavioral Therapy Skills Training|The DBT-MLC intervention will teach participants dialectical behavioral therapy-based skills to reduce psychological distress through improved physical symptom management, emotion regulation, and tolerance of uncertainty. The DBT-MLC intervention will consist of 8-10 weekly sessions that will last approximately 60 minutes each.
9668797|NCT04961879|Active Comparator|Reversed Cross Finger Flap group 1|
9668798|NCT04961879|Active Comparator|Reversed island Homo-digital Flap group 2|
9825667|NCT02389894|No Intervention|Standard Cannula|Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
10116311|NCT04440748|Experimental|Experimental Group|Participants in the experimental group will perform additional high-intensity therapy on the T-Chair 2.0, which is a newly developed non-CE-marked prototype to train trunk control and sitting balance. This they will do in addition to their normal rehabilitation program.
9825670|NCT02389959|Experimental|Bevacizumab|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
9827340|NCT02452528|Placebo Comparator|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
9827341|NCT02452762|Experimental|Enteral Loading Arm|Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)
9827342|NCT02452762|Placebo Comparator|Placebo Arm|Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.
9827343|NCT02452866|Experimental|SYM-1219|All pateints recieved single dose SYM-1219 Containing 2 Grams of Secnidazole
10116312|NCT04440748|Active Comparator|Control Group|Participants in the control group will execute their normal rehabilitation program.
9694509|NCT04788420||Sorafenib group|Patients assigned to this group received sorafenib post-transplantation.
9694510|NCT04788420||Control group|Patients assigned to this group did not receive sorafenib or any other FLT3 inhibitor post-transplantation until reaching the primary outcome.
9694511|NCT04788407|Experimental|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID.
9694512|NCT04788407|Placebo Comparator|Placebo|Subjects will receive placebo TID.
9694513|NCT04788160|Experimental|Cervical SNAGs along with conventional therapy|patient will receive Cervical SNAGs along with conventional therapy (Group A)
9694514|NCT04788160|Other|Conventional Therapy|patient will receive only conventional therapy (Group B)
9694515|NCT04788212|Experimental|GBAT|10-week behavioral activation treatment group.
9694516|NCT04788862|Experimental|Group 1: High prior P. falciparum exposure|6 participants with high previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
9694517|NCT04788862|Experimental|Group 2: Low prior P. falciparum exposure|6 participants with no or low previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
9694518|NCT04788485|Active Comparator|Neonates before adding smectite|neonates will receive diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
9694519|NCT04788485|Active Comparator|neonates after adding smectite|neonates after they received diosmectite for treating of gastroesophageal reflux in neonates after MII-ph
9694520|NCT04788199||Non-closure group|Group in which mesenteric defects were not closed after laparoscopic Roux-en-Y gastric bypass.
9694521|NCT04788199||Closure group|Group in which mesenteric defects were closed using cyano-acrylate glue after laparoscopic Roux-en-Y gastric bypass.
9694522|NCT04788277||Diagnostic (biospecimen collection)|Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.
9694523|NCT04788446|Experimental|Mini-flipped Game-based Learning|"20 minutes for the Mediterranean food table game, 20 minutes for the Mediterranean diet nutrition course.~1 time a week (40 mins/ each time)~Lasts for 8 weeks"
9694524|NCT04788446|Placebo Comparator|Balanced diet|"Given a balanced diet nutrition health education manual for the aged.~Lasts for 8 weeks"
9694525|NCT04788472|Experimental|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
9694526|NCT04788342||Patients with and without left ventricular systolic dysfunction|Patients with different pathologies of the cardiovascular system (coronary artery disease, hypertension, valvular heart disease, heart failure) will be performed pulse wave recording using a CardioQvark cardiomonitor and echocardiography.
9694527|NCT04788316|Experimental|Intervention|A computerized brief intervention (CBI) followed by six months of personalized text messaging
9694528|NCT04788316|No Intervention|Control|Treatment as usual
9694529|NCT04788264|Experimental|Arm I (exercise training, behavior modification)|Beginning 1 week prior to start of intervention, patients receive a Fitbit to monitor physical activity for 13 weeks. Patients receive consultation and personalized exercise prescription from a physical therapist at baseline, and attend exercise training sessions with a physical therapist during weeks 1, 3, 6, 9, and 12. Patients also attend behavior modification sessions with a behavioral therapist that focus on goal setting and healthy behavior changes during weeks 2, 4, 5, 7, 8, 10, and 11.
9694530|NCT04788264|Active Comparator|Arm II (Fitbit, consultation)|Patients receive a Fitbit to monitor physical activity for 12 weeks. Patients also receive consultation from a physical therapist to assess physical performance at weeks 1, 6, and 12.
9694531|NCT04788069|Active Comparator|Wholemeal bread|Treatment with wholemeal bread
9694532|NCT04788069|Active Comparator|Sourdough bread|Treatment with sourdough bread
9694533|NCT04788069|Active Comparator|Bread with sourdough|Treatment with bread with sourdough
9694534|NCT04788030||Digital nerve reconstruction with muscle-in-vein conduits|
9694535|NCT04788043|Experimental|Magrolimab (Hu5F9 G4) and pembrolizumab|All subjects will have a baseline PET CT and excisional or core needle biopsy within 1 month of study enrollment and baseline electrocardiogram and laboratory studies within 1 week of study enrollment. All subjects will receive treatment with magrolimab and pembrolizumab according to the dosing schedule. Magrolimab IV given on cycle 1, 2 and 3. Pembrolizumab 200 mg IV given on Cycle 1, 2 and 3. Patients may continue to receive treatment on the study for a maximum of 24 months or until progression of disease, unacceptable toxicity, or bridge to stem cell transplantation (SCT).
9694537|NCT04788121|Active Comparator|Treatment/Tranexamic Acid Group|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS.
9694538|NCT04788121|Placebo Comparator|Control Group|The control group will receive injection 100 ml NS over 15 minutes infusion, followed by injection 500 ml NS over 12 hours infusion.
9694539|NCT04787952||Group 1= healthy subjects|"Inclusion criteria to the group 1 (healthy males) N=20:~BMI <25 kg/m2;~RR<140/90mmHg;~age 21-43 years~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;~no chronic disease"
9694540|NCT04787952||Group 2 = overweight/obese subjects|"Inclusion criteria to the group 2 ( overweight/obese males ) N=20:~Blood pressure < 140/90 mmHg (well controlled by inh ACE; no beta-blockers)~No chronic disease~BMI > 25 <35kg/m²~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;~age 21-43 years"
9694541|NCT04788186|No Intervention|Continue beta blocker therapy|Participants in this arm will continue their beta blocker therapy as per their usual clinical care
9694542|NCT04788186|Experimental|De-prescribe beta blocker therapy|Beta blocker therapy will be de-prescribed in this arm
10116313|NCT04440722||Transgender individuals|All transgender individuals referred to center of gender identity Odense
10116314|NCT04440709|Experimental|Brain/neural hand exoskeleton (B/NHE)|
10116315|NCT04440371|Active Comparator|Tacrolimus|Phototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
10116316|NCT04440371|Active Comparator|calcipotriol / betamethasone|Phototherapy NBUVB will be given 3 times per week and calcipotriol & betamethasone containing cream will be applied once a day
10116317|NCT04440488|Experimental|ARALAST NP 120 mg/kg|Participants will receive 120 mg/kg BW of ARALAST NP intravenous (IV) infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
10116318|NCT04440488|Experimental|ARALAST NP 60 mg/kg|Participants will receive 60 mg/kg BW of ARALAST NP IV infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
9519498|NCT03286595|Experimental|Early Psychosis (EP)|EP participants will be individuals who are either a) at clinical high risk (CHR) for developing psychosis and/or bipolar disorder, or b) First Episode Psychosis (FEP) participants meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder.
9519499|NCT03286595|Experimental|Clinicians|Clinicians/treatment team members who are providing treatment services to the EP participants at one of the three early psychosis clinics.
9519500|NCT03286582|Experimental|AC-203|
9668799|NCT04954287|Experimental|Young adult cohort (age 18-55), low dose, no prior COVID vaccine or infection|CVXGA1 administered as a single dose of 1 x 10^6 PFU by intranasal route on Day 1
9668800|NCT04954287|Experimental|Young adult cohort (age 18-55), high dose, no prior COVID vaccine or infection|CVXGA1 administered as a single dose of 1 x 10^7 PFU by intranasal route on Day 1
9668801|NCT04954287|Experimental|Young adult cohort (age 18-55), high dose, receipt of prior COVID Pfizer vaccine|CVXGA1 administered as a single dose of 1 x 10^7 PFU by intranasal route on Day 1, Pfizer Comirnaty® primary two dose regimen
9668802|NCT04938765|Experimental|Magnesium sulfate arm|MgSo4 diluted to 20% will be administered at 40 mg/kg dosed to ideal body weight over 10min to the study arm followed by 10mg/kg/hr infusion.
9668803|NCT04938765|Placebo Comparator|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
9668804|NCT04938180|Experimental|Cohort A|Low-Dose AMB-05X Each subject will receive a low dose of AMB-05X every 2 weeks, for a total of 6 doses over the 12-week treatment period.
9668805|NCT04937075||Before period without multiplex PCR identification|
9668806|NCT04937075||After period with multiplex PCR identification|
9668807|NCT04935359|Experimental|Safety run-in part: NIS793+gemcitabine+nab-paclitaxel|In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel.
9668808|NCT04935359|Experimental|Randomized part: NIS793+gemcitabine+nab-paclitaxel|Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel
9668809|NCT04935359|Placebo Comparator|Randomized part: placebo+gemcitabine+nab-paclitaxel|Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel
9668810|NCT04928742|Experimental|Treatment (9-week online CBT group)|Participants assigned to the treatment group will participate in a 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. All participants in the treatment group will be mailed a hardcopy of the program manual.
9668811|NCT04928742|No Intervention|Control (treatment as usual)|The control group will receive standard postnatal care from Niagara Region Public Health, their obstetrician, midwife, and/or family physician.
9668812|NCT04927572|Experimental|FMX114|
9668813|NCT04927572|Placebo Comparator|Vehicle|
9668814|NCT04923321||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
9668815|NCT04923321||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
9668816|NCT04923321||Non exposure|Non-pharmacological treatment (psychotherapy)
9668817|NCT04920344|Active Comparator|GROUP I - Low Risk Recurrence (transoral surgery, clinical observation))|After standard of care transoral surgery, patients whose small tumor was removed completely and have only one lymph node involved will undergo clinical observation.
9668818|NCT04920344|Experimental|GROUP II - Medium Risk Recurrence (transoral surgery, EBRT 50Gy)|Patients whose tumor was removed completely but has certain features that make it more likely to come back such as growth around the nerves or into the vessels, or has more than one lymph nodes involved, will undergo external body radiation therapy (EBRT) RT 50Gy for 5 weeks in the absence of disease progression or unacceptable toxicity.
9668819|NCT04920344|Experimental|GROUP III - High Risk Recurrence (transoral surgery, EBRT 60Gy, cisplatin 30 mg/m2)|"Patients whose tumor has a positive margin, which means the tumor could not be removed with healthy tissue around it or tumor grows significantly outside the lymph node will undergo EBRT RT 60 Gy for 6 weeks and receive cisplatin intravenously (IV) weekly 30mg/m2 for 6 weeks in the absence of disease progression or unacceptable toxicity."
9668820|NCT04914975|Experimental|NMES Group|Participants will receive neuromuscular electrical stimulation of the abdominal wall before defaecation for 30 minutes over the course of 16 weeks.
9668821|NCT04912115|Experimental|Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.1 mg/kg/hr to 0.30 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).
9668822|NCT04912115|Active Comparator|Midazolam|Midazolam will be administered as intravenous infusions with infusion rates ranging from 0.009 mg/kg/hr to 0.027 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).
10116319|NCT04440423|Experimental|Clotiazepam Test Product|
10116320|NCT04440423|Active Comparator|Clotiazepam Reference Product|
10116321|NCT04440540|Experimental|lifestyle modification program group|
9825671|NCT02389959|Placebo Comparator|Saline Control|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. The saline control placebo will be mixed by the Stanford Hospital Pharmacy to a total dose of 4mL in order to be identical in quantity and appearance to the mixed doses of bevacizumab, and 2mL will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
9825672|NCT02389998|Experimental|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
9825673|NCT02389998|Other|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
9825674|NCT02390050|Active Comparator|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
9825675|NCT02390050|Active Comparator|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
9825676|NCT02390050|Active Comparator|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
9825677|NCT02390050|Placebo Comparator|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
9825678|NCT02390076|Active Comparator|Left active LLLT|Active LLLT targeting the left forehead Attention Bias Modification Left low level light therapy
9825679|NCT02390076|Active Comparator|Right active LLLT|Active LLLT targeting the right forehead Attention Bias Modification Right low level light therapy
9825680|NCT02390076|Sham Comparator|Sham LLLT|Sham LLLT targeting the right forehead Attention Bias Modification Sham low level light therapy
9825681|NCT02390167|Experimental|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
9825682|NCT02390219|Experimental|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
9825683|NCT02390557|No Intervention|Control - Standard Practice|Standard measures of quality at baseline. No intervention reports sent to providers
9825684|NCT02390557|Experimental|Survey|Persons with Disabilities Quality Survey.PDQS Survey Reports Intervention.reports sent to providers of OneCare enrollees
9825685|NCT02390557|Experimental|YESHealth|Arm 3: YESHealth Reports and PDQS Survey Reports sent to providers of OneCare enrollees
9825686|NCT02390791|Experimental|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
9825687|NCT02390791|Active Comparator|treatment as usual standard portal|Standard version of myADHDportal.com web software
9825688|NCT02390908|Experimental|Site 1 Immediate PLUS intervention|Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
9825689|NCT02390908|Active Comparator|Wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
9825690|NCT02390908|Experimental|Site 2 Immediate PLUS intervention|Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
9825691|NCT02390908|Experimental|Site 3 Immediate PLUS intervention|Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
9825692|NCT02391038|Experimental|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
9825693|NCT02391116|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
10116322|NCT04440540|Experimental|usual care group (control)|
10116323|NCT04440605||cI|clincal TNM stage I
10116324|NCT04440605||cII|clinical TNM stage II
9825694|NCT02391311|Active Comparator|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
9825695|NCT02391311|Experimental|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
9825696|NCT02391337|Active Comparator|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
9827344|NCT02452892|Sham Comparator|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
10116325|NCT04440605||cIII|clinical TNM stage III
10116326|NCT04440683||Antler plate group|Antler plate group
9825697|NCT02391337|Active Comparator|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
9825698|NCT02391350|Active Comparator|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
9825699|NCT02391350|Experimental|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
9825700|NCT02391363|Experimental|Calmer Life|Cognitive behavior treatment for anxiety
9825701|NCT02391363|Active Comparator|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
9825702|NCT02391545|Experimental|Duvelisib and Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
9825703|NCT02391545|Experimental|Duvelisib and Obinutuzumab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
9825704|NCT02391584|Experimental|XprESS|Balloon dilation of the Eustachian tube
9825705|NCT02391584|Other|Control|Continued medical management
9825706|NCT02391701|Experimental|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
9825707|NCT02391701|No Intervention|Control|No intervention
9825708|NCT02391714|Placebo Comparator|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
9825709|NCT02391714|Experimental|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
9825710|NCT02391961|Experimental|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
9825711|NCT02391961|Placebo Comparator|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
9825712|NCT02391987|Active Comparator|Tele-Monitoring|Tele-monitoring and health coaching in addition to standard health care
9519501|NCT03286582|Active Comparator|Clobetasol|
9825713|NCT02391987|No Intervention|Standard Care|Standard care is defined as Heart Failure (HF) care based on current American College of Cardiology (ACC) and American Heart Association (AHA) HF guidelines implemented and orchestrated by a cardiologist and support staff at the participating institution.
9825714|NCT02392000|Experimental|WatchPAT and CBT-i Coach mobile app|Individuals use the WatchPAT sleep monitor and the CBT-i Coach app to self-manage insomnia
9825715|NCT02392104|Experimental|Intervention Arm|All patients in the study will be in the intervention arm.
9825716|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are </= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
9825717|NCT02392208|Other|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
9825718|NCT02392208|Other|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
9825719|NCT02392234|Experimental|VX-661/Ivacaftor combination|
9825720|NCT02392234|Experimental|Ivacaftor monotherapy|
9825721|NCT02392234|Placebo Comparator|Placebo|
9825722|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
9825723|NCT02392286|Active Comparator|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
9825724|NCT02392286|Active Comparator|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
9825725|NCT02392351|Experimental|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
9825726|NCT02392351|Sham Comparator|Masked Procedure|Percutaneous renal angiography
9825727|NCT02392403|Experimental|Nucleus CI532 cochlear implant|
9825728|NCT02392481||Healthy subjects|
9825729|NCT02392481||Mild asthma|
9825730|NCT02392481||Moderate asthma|
9825731|NCT02392481||Severe asthma|
9825732|NCT02392494|Experimental|MK-1075 100 mg (Panel A)|HCV-infected participants receive a single 100 mg dose of MK-1075.
9825733|NCT02392494|Experimental|MK-1075 200 mg (Panel B)|HCV-infected participants receive a single 200 mg dose of MK-1075.
9825734|NCT02392494|Experimental|MK-1075 400 mg (Panel C)|HCV-infected participants receive a single 400 mg dose of MK-1075.
9825735|NCT02392494|Experimental|MK-1075 800 mg (Panel D)|HCV-infected participants receive a single 800 mg dose of MK-1075.
9825736|NCT02392507|Experimental|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.~Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).~Participants may continue to receive treatment until discontinuation criteria are met."
9825737|NCT02392559|Placebo Comparator|Placebo|Matching subcutaneous injection every 4 weeks (QM)
9825738|NCT02392559|Experimental|EvoMab 420 mg QM|Evolocumab subcutaneous injection QM
9825739|NCT02392611|Experimental|Monotherapy: Alobresib 0.6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 0.6 mg to determine the MTD.
9825740|NCT02392611|Experimental|Monotherapy: Alobresib 1.4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 1.4 mg to determine the MTD.
9825741|NCT02392611|Experimental|Monotherapy: Alobresib 2 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 2 mg to determine the MTD.
9825742|NCT02392611|Experimental|Monotherapy: Alobresib 3 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 3 mg to determine the MTD.
9825743|NCT02392611|Experimental|Monotherapy: Alobresib 4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 4 mg to determine the MTD.
9825744|NCT02392611|Experimental|Monotherapy: Alobresib 6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 6 mg to determine the MTD.
9825745|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Exemestane|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with exemestane 25 mg.
9825746|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with fulvestrant 500 mg.
10116327|NCT04440696|Experimental|group 1:dose 1.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
9825747|NCT02392611|Experimental|Combination Therapy: Alobresib 3 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 3 mg in combination with fulvestrant 500 mg.
9825748|NCT02392624|Experimental|Omalizumab|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive omalizumab treatment at 300 mg SC Q4W for next 24 weeks (up to Week 48). Participants randomized to omalizumab may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
9825749|NCT02392624|Placebo Comparator|Placebo|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
9825750|NCT02392767|Active Comparator|Verum|2 times 2 tablets a day for 4 weeks.
10116328|NCT04440696|Experimental|group 2:dose 3g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
10116329|NCT04440696|Experimental|group 3:dose 4.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
9825751|NCT02392767|Placebo Comparator|Placebo|2 times 2 tablets a day which cornstarch. Tablets look identical like verum tablets.
9825752|NCT02392806|Active Comparator|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B&B Bubbler device for 24 hours
9825753|NCT02392806|Active Comparator|B&B Bubbler, B&B medical Technologies|Infants randomized to the B&B Bubbler device will be extubated to B&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
9825754|NCT02393209|Experimental|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
9825755|NCT02393209|Experimental|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
9825756|NCT02393209|Experimental|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m^2 IV infusion on Days 1 and 8 of a 21-day cycle.
9825757|NCT02393209|Experimental|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
9825758|NCT02393339|Active Comparator|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
10116330|NCT04440696|Experimental|group 4:dose 6g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
10116331|NCT04440579|Active Comparator|Standard Cystoscopy|Patients will undergo a standard of care cystoscopy
9825759|NCT02393339|Placebo Comparator|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
9825760|NCT02393378|Experimental|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
9825761|NCT02393378|Active Comparator|Namilumab 150 mg|Namilumab 150*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
9825762|NCT02393417|Experimental|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
9825763|NCT02393417|Experimental|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
9825764|NCT02393417|Experimental|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
9825765|NCT02393417|Placebo Comparator|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
9825766|NCT02393547|Experimental|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
9825767|NCT02393677|Placebo Comparator|Ropivacaine|amide local anesthetic
9825768|NCT02393677|Active Comparator|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
9825769|NCT02393755|Experimental|Treatment (capecitabine, nintedanib)|Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
9825770|NCT02393755|Experimental|Treatment (capecitabine , nintendanib)|Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
9825771|NCT02393950|Experimental|Drug: ODM-106|Oral capsules dosage 2-800mg once daily for one day
9825772|NCT02393950|Placebo Comparator|Drug: Placebo|Oral capsules given once daily for one day
9825773|NCT02394275|Experimental|Single arm:|Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
9825774|NCT02394340|Experimental|Luliconazole Cream 1%|Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.
9825775|NCT02394457|Experimental|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
9825776|NCT02394457|Active Comparator|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
10116332|NCT04440579|Experimental|PTNS and Cystoscopy|Patients will undergo PTNS while undergoing cystoscopy
10116333|NCT04440579|Sham Comparator|Sham PTN and Cystoscopy|Patients will undergo a sham PTNS procedure while undergoing cystoscopy
10116334|NCT04440293|Experimental|Group BBAT / CT|Group BBAT / CT started treatment with BBAT and received 2 days a week for 6 weeks. After the interval of 5-week, group BBAT / CT was treated with CT twice a week for 6 weeks.
10116335|NCT04440293|Experimental|Group CT / BBAT|Group CT / BBAT started treatment with CT and received 2 days a week for 6 weeks. After the interval of 5-week, group CT / BBAT was treated with BBAT twice a week for 6 weeks.
9825777|NCT02394561|Experimental|Cw6-positive AIN457 300 mg|Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
9825778|NCT02394561|Experimental|Cw6-negative AIN457 300 mg|Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
9825779|NCT02394600|Experimental|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
9825780|NCT02394600|Placebo Comparator|Placebo|48 participants will receive placebo once per day for 120 days.
9668823|NCT04907656|Experimental|dCBT Condition|The dCBT used in this study (Daylight) was selected due to its noted efficacy in treating GAD. 25 interventions will be provided in four modules, with an average duration of 20 minutes. Sessions are unlocked weekly, and completion of an initial assessment drives an algorithm to personalize the program. Individuals may progress through treatment at a slower pace than weekly sessions; 10 weeks is allowed for treatment completion. Treatment is based on principles of applied relaxation, stimulus control, cognitive restructuring, and imaginal exposure. Participants schedule a time for each session and receive prompts if they miss the appointment. All interventions are aided by the use of an animated therapist.
9825781|NCT02394730|Experimental|vorapaxar|2.5mg of vorapaxar po qd
9825782|NCT02394730|Placebo Comparator|Placebo|sugar pill po qd
9825783|NCT02394756|Experimental|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
9825784|NCT02394756|Active Comparator|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
9825785|NCT02394756|Active Comparator|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
9825786|NCT02394769|Placebo Comparator|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
9825787|NCT02394769|Active Comparator|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
9825788|NCT02394769|Active Comparator|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
9825789|NCT02394808|Experimental|Test Lens 1|senofilcon A (Approved contact lens material)
9825790|NCT02394808|Active Comparator|Test Lens 2|lotrafilcon B (Approved contact lens material)
9825791|NCT02394912|Experimental|Single-arm|
9825792|NCT02394925|Experimental|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
9825793|NCT02394951|Experimental|Pregabalin|Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
9825794|NCT02394951|Placebo Comparator|Placebo|Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
9825795|NCT02395042|Placebo Comparator|LiRIS Placebo, LiRIS Placebo (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period (Tx 1): Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 10 and then removed and a second matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 14 and removed on Day 28. Treatment 2 Period (Tx 2): optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and removed on Day 14.
10116336|NCT04440215|Other|Control|Usual rehabilitation care (no telerehabilitation, interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals)
9825796|NCT02395042|Experimental|LiRIS®, LiRIS® (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period: LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 then removed and a second LiRIS® 400 mg inserted into the bladder on Day 14 and removed on Day 28. Treatment 2 Period: optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and then removed on Day 14.
9825797|NCT02395042|Experimental|LiRIS Placebo, LiRIS® (Tx 1)/ LiRIS® (Tx 2)|Treatment 1 Period: Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 0 and then removed and LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 14 then removed on Day 28. Treatment 2 Period: optional LiRIS® 400 mg inserted into the bladder by cystoscopy on Day 0 then removed on Day 14.
9825798|NCT02395055|Experimental|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
9825799|NCT02395055|Active Comparator|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
9668824|NCT04907656|No Intervention|Waitlist (control) Condition|Participants allocated to the waitlist (control) condition will not receive an active intervention during the study. Participants will still complete all scheduled study assessments. They will receive access to the dCBT after completion of all study assessments.
9825800|NCT02395081|Placebo Comparator|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
9825801|NCT02395081|Experimental|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
9825802|NCT02395081|Experimental|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
9825803|NCT02395133|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
9825804|NCT02395133|Experimental|Dupilumab 300 mg Q8W|Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
9825805|NCT02395133|Experimental|Dupilumab 300 mg Q4W|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
9519502|NCT03286569|Active Comparator|Active upper Wilson appliance|Active upper arch Wilson quadhelex appliance
9668825|NCT04907357|Active Comparator|rTMS|Participants will receive up to 30 rTMS sessions within the 8-week treatment period.
10116337|NCT04440215|Experimental|Telerehabilitation|A mix of home or rehabilitation center visits, telerehabilitation and interprofessional shared decision making process.
9825806|NCT02395133|Experimental|Dupilumab 300 mg Q2W/QW|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
9825807|NCT02395172|Experimental|Avelumab|
9825808|NCT02395172|Active Comparator|Docetaxel|
9825809|NCT02395185|Experimental|Milk|Milk bottle administration
9825810|NCT02395185|Experimental|Water|Water bottle administration
9825811|NCT02395185|Experimental|Sucrose|Sucrose bottle administration
9825812|NCT02395302|Experimental|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
9825813|NCT02395471|Experimental|Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
9825814|NCT02395471|Experimental|Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
9825815|NCT02395536|Experimental|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
10116338|NCT04440280|Active Comparator|NAC 10% group|Subjects in this group will be treated with eye drops containing a 10% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
10116339|NCT04440280|Active Comparator|NAC 20% group|Subjects in this group will be treated with eye drops containing a 20% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
10116340|NCT04440280|Placebo Comparator|Placebo group|Subjects in this group will be treated with a placebo (Visine Tears Dry Eye Relief artificial tears ophthalmic solution.)
10116341|NCT04440267|Experimental|single arm|Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) in CR. Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors.
10116342|NCT04440241|Experimental|Test group|submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
10116343|NCT04440241|Experimental|Control group|non submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
10116344|NCT04440254|Other|ONE|One single group of patients
10116345|NCT04440631||Antibiotic therapy including rifampicin|
10116346|NCT04440631||Non-rifampicin antibiotic therapy|
10116347|NCT04440631||Control group (healthy volunteers)|
9825816|NCT02395536|Other|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
9825817|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
9825818|NCT02395627|Experimental|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
9825819|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
10116348|NCT04440345|Experimental|IBI362|"Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses."
10116349|NCT04440345|Placebo Comparator|placebo|Participants received matching placebo dose regiments by subcutaneous injection
10116350|NCT04440553|Active Comparator|Uniform random|In this arm the types of messages were sent out randomly, i.e. with a uniform random distribution.
10116351|NCT04440553|Experimental|Reinforcement learning|In this arm the types of messages were chosen by a reinforcement learning algorithm. The decision about which message to send was based on several contextual variables, including data for the pedometer app, and consecutive days since messages from different categories were sent.
10116352|NCT04440020|Experimental|Beverage of Olive Oil Leaves|50 patients Beverage of Olive Oil Leaves
9825820|NCT02395653|Experimental|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
9825821|NCT02395692|Experimental|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10116353|NCT04440020|Active Comparator|Mediterranean dietary protocol Intervention|50 patients Dietary Supplement: Dietary Supplement:Mediterranean Diet
10116354|NCT04440228|Experimental|Schools implementing TeamSTEPPS|Select schools will take a participatory approach to collaboratively identify solutions to challenges in collocated school-based mental health services based upon the feedback of stakeholders and use TeamSTEPPS to support mental health team-school collaboration.
9825822|NCT02395822|Experimental|Preparative Regimen and SubQ rHuIL-15|"Preparative Regimen of Fludarabine and Cyclophosphamide~IL-15 Activation of Donor NK Cells:~IL-15 to Facilitate NK Cell Survival and Expansion"
9825823|NCT02395978|Experimental|Part I: 1 PDC-1421 Capsule|1 PDC-1421 Capsule TID, p.o. after meal for 28 days
9825824|NCT02395978|Experimental|Part I: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
9825825|NCT02395978|Experimental|Part II: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 42 days
9825826|NCT02395978|Experimental|Part II: 1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
9825827|NCT02395978|Placebo Comparator|Part II: 2 placebo|2 placebo TID, p.o. after meal for 42 days
10116355|NCT04440046|Experimental|Real manual therapy|Real manual therapy directed to the thoracic spine and glenohumeral joint added to a therapeutic exercise program
9668826|NCT04907357|Sham Comparator|Sham (Placebo)|Participants will receive up to 30 sham rTMS sessions within the 8-week treatment period.
9668827|NCT04906564||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:~1. Written informed consent is obtained; 2. Patients with age between 4-60 years; 3. Cerebral digital subtraction contrast angiography (DSA) reveal severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'.~Exclusion Criteria:~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
9668828|NCT04905693|Experimental|Inhaled Treprostinil|Treprostinil inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated to a target of 15 breaths QID or until the subject reaches their maximum clinically tolerated dose.
9668829|NCT04902781|Experimental|Experimental: AT-007|AT-007 The starting dose in Part A will be 5 mg/kg for all age groups. For each age group, Part B of the study will not start until the optimum dose evaluated in Part A has been identified
9668830|NCT04902781|Placebo Comparator|Placebo|Placebo given orally
9668831|NCT04902625|Active Comparator|Naltrexone-Bupropion combination|The patients in this arm will receive 2 tablets of naltrexone-bupropion 8/90mg 2 times daily in combination with the Back On Track module.
9668832|NCT04902625|No Intervention|Control|The patients is this arm will only participate in the Back On Track module and will not receive any investigational or placebo product.
10116356|NCT04440046|Sham Comparator|Sham thoracic manual therapy|Sham manual therapy directed to the thoracic spine with real manual therapy directed to the glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
9668834|NCT04899856|Other|Control / Crossover to TransAeris Therapy|"The Control group will be treated per standard hospital policy following electrode implant. If the participant is not liberated from mechanical ventilation after 120 hours (5 days), the participant will begin using TransAeris therapy. The participant will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
9668835|NCT04899856|Experimental|Treatment with TransAeris Therapy|"The Treatment group will start TranAeris therapy shortly after arrival in the Intensive Care Unit (ICU). Participants will use the study device in the ICU until liberated from the ventilator but no longer than 30 days after implant surgery."
9668836|NCT04893811|Experimental|Single Arm|Bivalent recombinant lipoprotein 2086 vaccine
9668837|NCT04891822||E (ERAS protocol)|receive ERAS protocol 8 hours of fasting and ingestion of oral carbohydrate 2 hour before surgery TIVA(Total intra-venous anesthesia) TAP(transversus abdominis plane) block IV-PCA using NSAIDs after surgery Resuming oral intake 2 hours after surgery.
9668838|NCT04891822||C (Control)|receive standard perioperative care 8 hours of fasting before surgery Inhalation anesthesia IV-PCA using NSAIDs Resuming oral intake 6 hours after surgery.
9668839|NCT04882644|Experimental|Aerobic Exercise Intervention Group|The subjects receive an intensive aerobic exercise for 3 months and a health education content for 12 months.
9668840|NCT04882644|No Intervention|Control Group|The subjects do not change their physical activity routine and receive a health education content for 12 months.
9668841|NCT04881708|No Intervention|Current Care Group|The current care group will receive the standard of care currently in place within the subspecialty practices in the Department of Surgery, Mayo Clinic Rochester. This includes postoperative inpatient care directed by the surgical team, including timing of discharge and follow-up.
9668842|NCT04881708|Active Comparator|Remote Care Group|Patients randomized to the remote monitoring arm will engage in a Connected Care Remote Patient Monitoring (RPM) Complex Care program. RPM Complex Care programs utilize established and standardized equipment, logistics/reverse logistic, engagement methods, and nursing clinical practice. Use of RPM Complex Care programs in this manner, is considered standard practice. Patients will be monitored for 30 days by the Connected Care nursing team as is standard for surgical RPM Complex Care programs.
9668843|NCT04860713|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
9668844|NCT04860713|Active Comparator|Nurtec (Rimegepant) Group|Drug: 75 mg of ODT
9668845|NCT04847271|Experimental|Physical activity on prescription|Physical activity on prescription is a behaviour change intervention comprising 3 components: a person-centred pre-intervention dialogue, a written prescription for individually tailored physical activity, and a structured follow-up.
9668846|NCT04825132|Experimental|Bacteremia and/or acute respiratory infection|Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards…) for with bacteraemia and/or acute respiratory infection
9668847|NCT04825132|Active Comparator|Without suspicion of infection|The control patient will undergo the exact same procedures as the case patient described before except for the blood and respiratory sample part. • The typical control patient will be of the same age (+/- 3 years, but aged above 65 years), same sex, without suspicion of infection and hospitalized during the past or upcoming month in the same centre. There will be 2 controls for one case.
9668848|NCT04805632||Dialysis|Patients on hemodialysis or peritoneal dialysis who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
9668849|NCT04805632||Healthy|Medical staff who received 2 administrations of Gam-COVID-Vac (Sputnik V) vaccine against SARS-CoV-2 infection
9668850|NCT04799015|Experimental|Dexamethasone|Dexamethasone 10mg IV + metoclopramide 10mg IV
9668851|NCT04799015|Placebo Comparator|Placebo|Placebo IV + metoclopramide 10mg IV
9668852|NCT04796584||MS subjects who are being treated with ocrelizumab|Ocrelizumab's immunomodulating mechanisms of action is B-cell lytic. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
9825828|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
9825829|NCT02396147|Experimental|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
9825830|NCT02396147|Experimental|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
9825831|NCT02396160|Active Comparator|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
9825832|NCT02396160|Placebo Comparator|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
9827345|NCT02452892|Active Comparator|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
9827346|NCT02452892|Active Comparator|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
9827347|NCT02452892|Other|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
9827348|NCT02452931|Experimental|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
9827349|NCT02452944|Experimental|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
9827350|NCT02452944|Active Comparator|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
9827351|NCT02453048|Experimental|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
9827352|NCT02453048|Experimental|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
9827353|NCT02453048|Experimental|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
9827354|NCT02453048|Experimental|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
9827355|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
9827356|NCT02453191|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy~Talimogene Laherparepvec Dose Levels:~• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL"
9827357|NCT02453256|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
9827358|NCT02453256|Experimental|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
9827359|NCT02453282|Experimental|Monotherapy|PD-L1 monoclonal Antibody monotherapy.
9827360|NCT02453282|Experimental|Combination Therapy|PD-L1+Tremelimumab combination therapy
9827361|NCT02453282|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
9827362|NCT02453321|Active Comparator|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
9827363|NCT02453321|Experimental|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
9827364|NCT02453321|Experimental|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
9519503|NCT03286569|Placebo Comparator|Non active upper expansion appliance|Non-Active upper arch Wilson quadhelex appliance
9668853|NCT04796584||MS subjects who are being treated with fingolimod|Fingolimod's immunomodulating mechanisms of action is to prevent mobilization of B and T cells from peripheral lymphoid organs. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
9825833|NCT02396212|Experimental|Canakinumab|All patients received canakinumab (ACZ885) as open-label study medication. Patients were administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed was 300 mg.
10116357|NCT04440046|Sham Comparator|Sham manual therapy|Sham manual therapy directed to the thoracic spine and glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
10116358|NCT04440059|Experimental|ICP-022|Subjects will take ICP-022 150mg once daily (QD).
9519504|NCT03286530|Experimental|Ruxolitinib|Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
9668854|NCT04796584||MS subjects who are being treated with natalizumab|Natalizumab's immunomodulating mechanisms of action is to block transmigration of monocytes, and lymphocytes into the central nervous system. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
9668855|NCT04796584||MS subjects who are being treated with dimethyl fumarate/diroximel fumarate|Dimethyl Fumarate's immunomodulating mechanisms of action is to reduce inflammation-induced oxidative stress. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
9668856|NCT04791553|Experimental|Normal Hepatic Function|Group 1 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to Matching healthy subjects with normal hepatic function
9668857|NCT04791553|Experimental|Hepatic Impairment|Group 2 single oral dose of 200 mg (2 x 100 mg tablet) cenobamate given to subjects with severe hepatic impairment
9668858|NCT04788901|Experimental|Online therapeutic game|Participants in this group will have access to the evaluation module of the REThink game.
9668859|NCT04761055|Experimental|Screening Visits for Breast Cancer|Consenting patients will receive their already scheduled standard CBE and mammogram and in addition will receive a breast exam utilizing the iBreast Exam (iBE).
9668860|NCT04758741|Experimental|Acceptance and commitment treatment|The members of the intervention group receive one session of acceptance and commitment treatment per week according to Hayes (2006) approach in groups of 10 in 8 sessions of 90 minutes by a trained counselor (researcher) in Mashhadalkoubeh Health Center.
9668861|NCT04758741|Sham Comparator|Health Education|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience.
9668862|NCT04750252|Experimental|Subjects with moderate to severe OA of the Knee|
9668863|NCT04749355|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m^2/d or 2.3 g/m^2/d, for 6 days
9668864|NCT04733053|Experimental|Diet plus exercise|The initial physiotherapy consultation for participants in this group will last 75 minutes, with 30 minutes for the exercise component and 45 minutes for the diet component. Thereafter, consultations will last 50 minutes, with 20 minutes for the exercise component and 30 minutes for the diet component. The exercise component will be the same as that described for the exercise alone group.
9668865|NCT04733053|Active Comparator|Exercise|Physiotherapy consultations for participants in this group will last 30 minutes initially and then 20 minutes thereafter, consistent with clinical practice. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate and a personalised physical activity plan.
9668866|NCT04732715|Experimental|CaRE Course|Black American caregivers of PLWD will participate in the CaRE Course.
9668867|NCT04727983|No Intervention|Pelvic Floor Muscle Function|Pelvic floor muscle function will be evulated with the Modified Oxford Scale
9668868|NCT04727983|No Intervention|Bladder function|Bladder function will be evulated with the urinary diary for 3 days
9668869|NCT04727983|No Intervention|Incontinence Symptoms|Incontinence Symptoms will be evulated with The International Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) and the Coital Incontinence Score (CIS)
9668870|NCT04727983|No Intervention|Quality of Life|Quality of life will be evulated with the King Health Questionnaire (KHQ)
9668871|NCT04727983|No Intervention|Sexual Function|Sexual Function will be evaluated with Pelvic Organ Prolapse / Urinary Incontinence Sexual Questionnaire (PISQ-12).
9668872|NCT04727983|Experimental|NMES group|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS)
9668873|NCT04727983|Sham Comparator|SHAM ES group|The second group will be given sham NMES in addition to LSS
9668874|NCT04727983|No Intervention|End of Treatment Special Evaluations|Subjective perception of improvement and treatment satisfaction of the patients will be questioned
9668875|NCT04724902|Experimental|Compression Group|The volunteer must remain supine on a stretcher, with both legs extended and relaxed. The intervention will be performed with elastic bandages (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity). The bandage will involve the knee from the distal to the proximal, respecting the blood flow of the venous return. The level of compression was defined according to recommendations in the literature on compression interventions in lymphedema and venous changes, and should be kept between 30 mmHg and 60 mmHg. Variations on stipulated values may be interfered according to the volunteer's self-report, which should indicate a level of moderate, comfortable and pain-free compression. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days.
9825834|NCT02396251|Experimental|HA experimental|HA experimental only
9825835|NCT02396251|Active Comparator|HA comparator|HA experimental + HA comparator
9825836|NCT02396316|Experimental|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
9694543|NCT04787978|Experimental|AAMWI-OSU Intervention|In this single-arm pilot program, 100 African American male participants will be enrolled who have poor or average cardiovascular health (< 4 life's simple 7 metrics in the ideal range) to a physical activity, education and patient activation intervention.
9694544|NCT04788498|Experimental|Laparoendoscpoic single site surgery LESS|35 patients undergoing laparoscopic ovarian cystectomy A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
9825837|NCT02396316|Sham Comparator|Sham Injection|Sham injection group
9825838|NCT02396381|Experimental|THS 2.2|Ad libitum use of THS 2.2
9825839|NCT02396381|Active Comparator|CC|Ad libitum use of CC
9825840|NCT02396420|Experimental|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
9825841|NCT02396511|Experimental|TRC105 and Bevacizumab|TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion
9825842|NCT02396537|Experimental|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
9825843|NCT02396537|Placebo Comparator|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
9825844|NCT02396732|Experimental|Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)|Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
9825845|NCT02396732|Active Comparator|Low Molecular Weight Heparin (LMWH) Alone|Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.
9825846|NCT02396745|Experimental|TECR & ECM|Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)
9825847|NCT02396758|Experimental|APT/2 Hours-r-tPA/2 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 2 mg/hour [hr]/catheter) will be delivered through Ekosonic® Endovascular Device (EKOS) ultrasonic infusion catheter for 2 hrs.
9825848|NCT02396758|Experimental|APT/4 Hours-r-tPA/1 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 4 hrs.
9825849|NCT02396758|Experimental|APT/6 Hours-r-tPA/1 mg/hr/Catheter|A total of 6 or 12 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
9825850|NCT02396758|Experimental|APT/6 Hours-r-tPA/2 mg/hr/Catheter|A total of 12 or 24 mg r-tPA (as 2 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
9825851|NCT02396849|Experimental|Continuous Positive Airway Pressure (CPAP)|Use of a CPAP machine for at least 5 days per week for 28 days
9825852|NCT02396849|Sham Comparator|Continuous Positive Airway Pressure (CPAP) Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
9825853|NCT02396953|Experimental|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
9825854|NCT02397057|Active Comparator|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
9825855|NCT02397057|Placebo Comparator|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
9965837|NCT01253720|Experimental|PACE CALL/Fit4Life|"Fit4Life intervention activities:~Website: Provides weekly nutrition, physical activity, and weight loss information.~Counseling Calls: Participants and their parents will get phone calls from their Health Coach to assess progress & problems.~Health Coach Question & Answer: Participants will be assigned a Health Coach that they can contact at any time to ask questions or express any concerns.~Text & Picture Messages: Participants will receive daily text messages to help remind them of being healthy. Messages will relate to the weekly topics and general checking in questions.~Parent Materials: Parents will receive a packet of printed materials that relate to parenting skills regarding being a healthy role model for their child and healthy eating and exercise tips."
9694545|NCT04788498|Active Comparator|Conventional multiport laparoscopy|35 patients undergoing laparoscopic ovarian cystectomy It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
9694546|NCT04788082|No Intervention|Control|Standard of care (not involving 3D printing)
9694547|NCT04788082|Experimental|3D Model|3D printed models (at least one rigid blood volume model and one flexible shell model) will be used for surgical planning.
9694548|NCT04787926||Duralock-C 4%|DuraLock-C 4.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 40 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
9694549|NCT04787926||Duralock-C 30%|DuraLock-C 30.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 300 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
9694550|NCT04787926||Duralock-C 46.7%|DuraLock-C 46.7%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 467 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
9694551|NCT04787913|No Intervention|controlgeneric|No intervention provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
9694552|NCT04787913|No Intervention|controlmeasles|No intervention provided. Participant answers outcome questions about measles. English and French.
9694553|NCT04787913|No Intervention|controlpertussis|No intervention provided. Participant answers outcome questions about pertussis. English and French.
9694554|NCT04787913|No Intervention|controlflu|No intervention provided. Participant answers outcome questions about flu. English and French.
9694555|NCT04787913|Experimental|herdimmgeneric|Web-based application (main intervention) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.
9694556|NCT04787913|Experimental|herdimmmeasles|Web-based application (main intervention) provided. Participant answers outcome questions about measles. English and French.
9694557|NCT04787913|Experimental|herdimmpertussis|Web-based application (main intervention) provided. Participant answers outcome questions about pertussis. English and French.
9827365|NCT02453334|Experimental|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
9827366|NCT02453334|Placebo Comparator|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
9825856|NCT02397096|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
9825857|NCT02397096|Active Comparator|Delayed Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
9825858|NCT02397122|Experimental|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
9825859|NCT02397122|Active Comparator|CAF+CTG|coronally advanced flap + connective tissue graft
9825860|NCT02397265|Experimental|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
9825861|NCT02397265|Active Comparator|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
9825862|NCT02397265|Placebo Comparator|Insulin only|Insulin only closed loop
9965838|NCT01253720|No Intervention|Control|The Control group will receive monthly mailings on basic nutrition and physical activity information.
9825863|NCT02397278|Active Comparator|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
9825864|NCT02397278|No Intervention|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
9825865|NCT02397291|Placebo Comparator|Part 1: Measurements of maternal and fetal concentrations|"At the time of the elective cesarean section, a blood sample of 0.5 ml will be obtained from a maternal heated hand vein at the time the umbilical cord is clamped. Then, the umbilical cord will be doubly clamped to isolate a segment. The umbilical artery and vein will be sampled for 0.5 ml of blood. There are no stable isotopes infused. Heating the maternal hand vein allows it to be arterialized. These patients are separate from those required for the stable isotope studies listed below."
9825866|NCT02397291|Active Comparator|Part 2: Stable Isotope Studies|Prior to the elective cesarean section, 2 samples from the patient's heated hand vein are obtained to establish a baseline for the compounds. Next, a primed constant infusion containing the stable isotopes of mannose and myoinositol is begun in a peripheral IV of the mother. This is continued approximately 2 hours until the Cesarean section is complete and the umbilical cord samples are obtained. An additional 3 samples are obtained from the patient's heated hand vein: 1 at the start of the cesarean section, 1 at the time the fetus is delivered, and 1 at the time the umbilical cord samples are obtained.
9825867|NCT02397408|Experimental|Diagnostic 11C- and 18F-choline PET/MR imaging|Patients are given 370 megabecquerel (MBq) 11C-Choline (11C) intravenously and 3 MBq/kg 18F-Choline (18F) intravenously prior to a whole-body PET/MR imaging
9825868|NCT02397447|Experimental|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
9825869|NCT02397447|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
9825870|NCT02397460|Experimental|Gefapixant 50 mg|Gefapixant 50 mg (1 tablet) administered as a single dose
9825871|NCT02397460|Experimental|Gefapixant 300 mg|Gefapixant 300 mg (6 tablets) administered as a single dose
9825872|NCT02397460|Placebo Comparator|Placebo|Placebo-matching tablets administered as a single dose
9825873|NCT02397473|Experimental|Galcanezumab 300mg|Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
9825874|NCT02397473|Placebo Comparator|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
9825875|NCT02397564|Experimental|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
9825876|NCT02397694|Experimental|BIC + F/TAF|"Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
9825877|NCT02397694|Active Comparator|DTG + F/TAF|"Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
9965839|NCT01253733|Experimental|SMS and Internet|The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
9965840|NCT01253733|No Intervention|Control|The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
9827367|NCT02453347|Experimental|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
9965841|NCT01253759||1|Combined treatment of Transpupillary Thermotherapy and ICG-based photodynamic therapy (PDT)
9965842|NCT01253798|Active Comparator|Group training on land|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
9965843|NCT01253798|Active Comparator|Group training in water|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip
10116359|NCT04440527|Experimental|Microshunt|Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).
10116360|NCT04440527|Active Comparator|Trabeculectomy|Patients will be treated with trabeculectomy.
10116361|NCT04440436|Experimental|IM19 CAR-T cells|IM19 CAR-T cells be administrated in two dose level
10116362|NCT04440111|Active Comparator|Control group|One year basic life support training
10116363|NCT04440111|Sham Comparator|Experimental group|Two years basic life support training
9694558|NCT04787913|Experimental|herdimmflu|Web-based application (main intervention) provided. Participant answers outcome questions about flu. English and French.
9694559|NCT04787913|Active Comparator|robertkochgeneric|Web-based application (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
9694560|NCT04787913|Active Comparator|sbsnewsgeneric|Video (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.
9694561|NCT04787913|Active Comparator|guardianmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
9694562|NCT04787913|Active Comparator|theotheredmundmeasles|Video (comparator) provided. Participant answers outcome questions about measles. English only.
9694563|NCT04787913|Active Comparator|publichealthagencycanadaflu|Video (comparator) provided. Participant answers outcome questions about flu. English and French.
9694564|NCT04787796|Experimental|The Self-built-in M-ECG recorders have passed the electrical.|We shall conduct this prospective clinical study to define the specific patterns of multichannel ECG change in adults with suspected CAD or ACS. For multichannel ECG (M-ECG) examination, the signal will be recorded with a Self-built-in ECG recorder.
9694565|NCT04787887|Active Comparator|Abcertin|Abcertin 60IU/kg
9694566|NCT04787887|Active Comparator|Cerezyme|EU-sourced Cerezyme
9694567|NCT04787900|Experimental|iPhone measurement application|For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
9694568|NCT04787900|Active Comparator|Bubble inclinometer|measurement will be done by the same method. For the measurement, the participant was asked to lie on his side and flex the knee to 90 degrees. The examiner stabilized the patient from the pelvis with one hand, and with the other hand brought the flexed leg of the participant to abduction and extension. The Examiner 3 recorded the result by placing the device to be measured on the lateral projection of the midpoint of the femur.
9694569|NCT04788225||Patients with ATFL repair by arthroscopic method|Patients who have passed at least 1 year after the operation Unilateral arthroscopic ATFL repair Between the ages of 18-65 Volunteer to participate in the study Without any orthopedic conditions, neuromuscular disease, balance disorder, cognitive disorder No history of fracture and surgical operation of the lower extremity
9694570|NCT04788225||Control group|Between the ages of 18-65 Volunteer to participate in the study Healthy individuals with no disease
9694571|NCT04787848|Experimental|HIV negative without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
9694572|NCT04787848|Experimental|HIV negative with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
9694573|NCT04787848|Experimental|HIV positive without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
9694574|NCT04787848|Experimental|HIV positive with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
9694575|NCT04787861|Active Comparator|Control group|Control group treatment is identical to treatment of the study group but without a motorized movement device.Childen in this group received chest physical therapy program including positioning, breathing exercises, and postural drainage in addition to incentive spirometer training for 20 minutes, 3 times/week for 12 weeks.
9694576|NCT04787861|Experimental|study group|This group received the same program given to the control group in addition to an aerobic training regimen for 25 minutes 3 times/week for 12 weeks using a motorized movement device.
9694577|NCT04788056|Experimental|Bupivacaine|PSPB catheters will be placed with 60mL of 0.2% bupivacaine and continue to infuse bupivacaine 0.125% at 10mL/hr through the catheter
9694578|NCT04788056|Placebo Comparator|Saline|PSPB catheters will be placed with 60mL of saline and continue to infuse saline through the catheters.
9694579|NCT04787770||diabetes without complications|diabetes without complications
9694580|NCT04787770||diabetes with Peripheral Arterial Disease|diabetes with Peripheral Arterial Disease
9694581|NCT04787770||diabetic foot group|diabetic foot group
9965844|NCT01253837|Experimental|L19TNFa|"Phase I: Prospective, open-label, dose escalation study.~Phase II: Prospective, single-arm, open-label study, equivalent to the stage 1 of the Simon two-stage phase II design."
9965845|NCT01253863|Other|determining damaged tissue|
10116364|NCT04440150|Other|Complicated Acute Appendicitis|The patients were assigned to the complicated acute appendicitis group (Group C) based on the preoperative imaging findings (periappendiceal abscess formation or significant periappendiceal fat tissue contamination in ultrasonography and computed tomography), intraoperative exploration findings (presence of gangrenous appendicitis, perforation or abscess formation), and pathological examination findings (acute phlegmonous appendicitis, acute gangrenous appendicitis or acute perforated appendicitis).
10116365|NCT04440150|Other|Uncomplicated Acute Appendicitis|The patients were assigned to the uncomplicated acute appendicitis group (Group UC) based on the increased diameter and wall thickness of the appendix and detection of minimal contamination in the surrounding fat tissue in the imaging tests; the presence of edema and the absence of gangrene, perforation or abscess in the the exploratory surgery of appendix, and confirmation of the diagnosis of acute appendicitis by the pathological examination findings
10116366|NCT04440085|Active Comparator|Intervention group|Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
10116367|NCT04440085|Placebo Comparator|Control group|By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
10116368|NCT04440137|No Intervention|Control Group|Mother of children will receive a brochure with a standard of care info (with only essential information regarding the harmful effect of bottle feeding) and kid toothbrush and toothpaste (1000ppm of fluoride).
10116369|NCT04440137|Experimental|Intervention group|Mother of the children will be provided with intervention brochure (which include detailed information regarding the harmful effect of bottle feeding), kid toothbrush and toothpaste (1000ppm of fluoride) and a sippy cup.
10116370|NCT04439903|Experimental|Web-based Simulation Tool (WST)|
10116371|NCT04439929|Experimental|Adalimumab-TUR01|
10116372|NCT04439929|Active Comparator|Adalimumab-EU|
10116373|NCT04439955|Experimental|CBD|At the end of the one month run-in period, all trial subjects will continue on individual Standard of case plus increasing doses of CBD during the first six weeks of the study. Dosage of CBD will start at 25 mg twice a day and will be increased once every 14 days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day CBD respectively. Treatment will be given with food. If the 300 mg CBD dose level is deemed safe for two weeks patients will continue receiving 300 mg CBD +for an additional follow-up period of three months
10116374|NCT04439981|Placebo Comparator|Control Group|treated by ice cream without any Curcuma extract supplementation
10116375|NCT04439981|Experimental|Treatment Group|treated by ice cream supplemented by Curcuma extract
10116376|NCT04439968|Active Comparator|Targeted Csats|Subjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.
10116377|NCT04439968|No Intervention|Non-targeted Csats|Subjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.
10116378|NCT04439890|Experimental|Anlotinib hydrochloride capsule + chemotherapy|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
10116379|NCT04439890|Placebo Comparator|Placebo + chemotherapy|Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
10116380|NCT04439617||sepsis patient|
10116381|NCT04439617||Sepsis-free patient|
10116382|NCT04439721|Experimental|γδT|γδT,Infusion,iv,0.5×10^6-8×10^7γδT /kg,once.
10116383|NCT04439695|Experimental|Low Dose KBP-V001|Subjects in this group will receive the low dose of KBP-V001.
10116384|NCT04439695|Experimental|Intermediate KBP-V001|Subjects in this group will receive the intermediate dose of KBP-V001.
9965846|NCT01253876|Experimental|Soy milk|
9965847|NCT01253876|Experimental|Caw's milk|
10116385|NCT04439695|Experimental|High Dose KBP-V001|Subjects in this group will receive the high dose of KBP-V001.
10116386|NCT04439695|Placebo Comparator|Placebo|Subjects in this group will receive placebo
10116387|NCT04439591|Experimental|Intervention group|Intervention group undergoes computerised brain training programme first.
10116388|NCT04439591|Other|Control group|Waitlist control group: control group undergoes programme after intervention group has completed it in a crossover design.
10116389|NCT04439708||Group 1|Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy
10116390|NCT04439708||Group 2|Control group : patients without choroidal neovascularization
10116391|NCT04439838|Experimental|Treatment group|
10116392|NCT04439838|Placebo Comparator|Placebo group|
10116393|NCT04439786|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
10116394|NCT04439786|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
10116395|NCT04439799|Active Comparator|Testosterone Cypionate Group|Participants in this group will receive the intramuscular Testosterone Cypionate intervention for four months
10116396|NCT04439799|Active Comparator|Natesto Group|Participants in this group will receive the intranasal testosterone (Natesto) intervention for four months.
10116397|NCT04439604||patient undergoing surgery under general anaesthesia|
10116398|NCT04439669|Active Comparator|Starts with active stimulation|"Active nrTMS is given to S2 at the right side (10 sessions in a three week period). Thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to M1 contralateral to the side of pain. After 5 stimulation sessions the response is evaluated. If pain is still ≥510, the investigators change the target to the S2 on the left side for five sessions. If there is response with pain relief, a maintenance therapy with this target is offered for 6 months with gradually reducing stimulation sessions."
10116399|NCT04439669|Placebo Comparator|Starts with sham stimulation|"Sham nrTMS will be targeted to the S2 on the right side, but using a sham box/coil. Stimulation period is similar than for the active comparator. Similarly, thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to S2 at the right side. After 5 stimulation sessions the response is evaluated. If pain is still ≥5/10, the investigators change the target to M1 on the contralateral side of the pain and furthermore to S2 at the left side after 5 stimulation sessions, if pain is still ≥5/10."
10116400|NCT04439825|Active Comparator|Botox|
10116401|NCT04439825|Placebo Comparator|Placebo|
10116402|NCT04439747||Control|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, neutrophil- gelatinase assosiated lipocalin-2 (NGAL), adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, antibodies to thyroid peroxidase (Ab-TPO), Ab--R-TSH, Ab-Tg, parathyroid hormone (PTH), vitamin D, osteocalcin, b-cross-laps, prolactin)
10116403|NCT04439747||CKD 1-2|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps, prolactin)
10116404|NCT04439747||CKD 3-5|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps,prolactin)
10116405|NCT04439500|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
10116406|NCT04439500|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
10116407|NCT04439760|No Intervention|control study.|No intervention
10116408|NCT04439760|Active Comparator|superior cervical block.|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
10116409|NCT04439682|Experimental|Study group|Aerobic exercise will be performed for a single session
10116410|NCT04439682|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
10116411|NCT04439864|Experimental|MyIDEA|Research Participants interacted with MyIDEA program both in the hospital and in the follow up cardiology appointment.
10116412|NCT04439864|No Intervention|Treatment as normal|The research participants were given the chance to play games on the tablet and received normal clinical education.
10116413|NCT04439773|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
10116414|NCT04439773|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
10116415|NCT04439812||R=0|Patients without positive margins after gastrectomy for gastric cancer
9825878|NCT02397694|Experimental|Open Label Extension Phase|After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.
9825879|NCT02397707|Experimental|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
10116416|NCT04439812||R=1|Patients with positive margins after gastrectomy for gastric cancer
10116417|NCT04439630|Sham Comparator|reference|Test product without the active components
10116418|NCT04439630|Experimental|Nopal fraction 1|Fraction one out of two possible
10116419|NCT04439630|Experimental|Nopal fraction 2|Fraction two out of two possible
10116420|NCT04439474|Experimental|Patients with vitamin D deficiency|This group receives 50,000 units of vitamin D3 daily for up to 8 days until the serum level of vitamin D reaches above 30 ng/ml.
10116421|NCT04439474|Active Comparator|Patients without vitamin D deficiency|Participants in this group receive only their usual treatments
10116422|NCT04439422|Experimental|SAINT|
10116423|NCT04439422|Active Comparator|Self-help material|
10116424|NCT04439305|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10182631|NCT03772405|Experimental|Nascum Plus and ACC|In a cross-over design, patients are exposed to pollen in the ACC twice for 4 hours each 3 weeks apart. Subjects will receive treatment with Nascum Plus either 5 minutes before the first or the second 4 hour pollen challenge.
10182632|NCT03772340|Experimental|Tradipitant|
10182633|NCT03772340|Placebo Comparator|Placebo|
10116425|NCT04439487||Obese patients requiring general anesthesia|Group consists of consecutive, adult, obese patients undergoing elective surgical procedures requiring general anaesthesia, direct laryngoscopy and intubation. All patients undergo general anesthesia according to a standardised protocol. They are preoxygenated with 100% oxygen breathed through a face mask for 3-5 minutes. Induction of general anaesthesia is achieved with propofol 1,5-2 mg·kg-1 (of Ideal Body Weight) and 0,1mg fentanyl or sufentanil 10µg. Muscle relaxation is accomplished with rocuronium 0.6 mg ·kg-1 (of Ideal Body Weight). Depth of muscular blockade is monitored using Train of Four (TOF) method. The first laryngoscopy attempt is performed at TOF 0. The patient is placed in an optimal, sniffing or ramped position as appropriate and a #3 or #4 Macintosh blade is used. Successful intubation is confirmed with bilateral auscultation and capnography.
10116426|NCT04439396|Placebo Comparator|Control|Saline injection administered during surgical procedure
10116427|NCT04439396|Experimental|Low Dose (15mg) Toradol|15mg ketorolac (toradol) administered during surgery
10116428|NCT04439396|Experimental|High Dose (30mg) Toradol|30mg ketorolac (toradol) administered during surgery
10116429|NCT04439097|Experimental|Experimental Group|"Patients allocated to the intervention group will perform a MPEP during 6 months, with a frequency of 3 sessions per week, and approximately 45-50 minutes of duration each session. In addition, they will have a Mediterranean Diet.~The patients in the MPEP will be carried out in small groups of 5-8 people. Structure of sessions: 3 different parts: an initial warm-up, a main part and a final cool-down and relaxation."
10116430|NCT04439097|Active Comparator|Control Group|Participants allocated to the control group will receive usual care and continue with their life normally, without participating in a standardized exercise program. They will be instructed to maintain their current physical activity level.
10182634|NCT03772288|Experimental|Dose Escalation: TAK-659 + NKTR-214|TAK-659 tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 in a 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participant. The dose escalation phase will determine the MTD or RP2D of TAK-659. Dose escalation of TAK-659 will be based on available safety and tolerability data.
10182635|NCT03772288|Experimental|Safety Expansion: TAK-659 + NKTR-214|TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
10182636|NCT03772132|Experimental|Chemotherapy|The patients wil receive conventional chemotherapy FORFIRINOX
10182637|NCT03772223|Experimental|Treatment sequence 1 (ABC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027) , Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
10182638|NCT03772223|Experimental|Treatment sequence 2 (BCA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
10182639|NCT03772223|Experimental|Treatment sequence 3 (CBA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
10182640|NCT03772223|Experimental|Treatment sequence 4 (ACB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
10182641|NCT03772223|Experimental|Treatment sequence 5 (BAC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
10182642|NCT03772223|Experimental|Treatment sequence 6 (CAB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
10182643|NCT03772119||Surgical treatment of hemivertebra|cohort of children with a vertebral malformation treated by surgical resection
10182644|NCT03772210|Active Comparator|Current Intensity 1 mA|tDCS will be administered at an intensity of 1 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
10182645|NCT03772210|Sham Comparator|Sham 1 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1 mA tDCS.
10182646|NCT03772210|Active Comparator|Current Intensity 1.5 mA|tDCS will be administered at an intensity of 1.5 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
10182647|NCT03772210|Sham Comparator|Sham 1.5 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1.5 mA tDCS.
10182648|NCT03772210|Active Comparator|Current Intensity 2 mA|tDCS will be administered at an intensity of 2 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
9519505|NCT03286517|Experimental|Tanner Stage I|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
10116431|NCT04439370||Aim 1: Postmenopausal Women|Participants in this group are postmenopausal women.
10116432|NCT04439370||Aim 1: Premenopausal Women|Participants in this group are premenopausal women.
10116433|NCT04439370||Aim 2: Premature/Early Menopause|Participants in this group women who experienced premature or early menopause.
10116434|NCT04439370||Aim 2: Typical-Age Menopause|Participants in this group are women who experienced menopause at a typical age.
10116435|NCT04439162|Experimental|group A|antegrade cardioplegia
10116436|NCT04439084||Chronic Liver Disease Group|COVID-19 patients with Chronic Liver Disease.
10116437|NCT04439084||Control Group|COVID-19 patients without Chronic Liver Disease.
10116438|NCT04439448||HIV+ non-obese|HIV+ adults on antiretroviral therapy with a body mass index <30 kg/m2
10116439|NCT04439448||HIV+ obese|HIV+ adults on antiretroviral therapy with a body mass index >=30 kg/m2
10116440|NCT04439448||HIV-negative obese|HIV-negative adults on antiretroviral therapy with a body mass index >=30 kg/m2
10116441|NCT04439058|Active Comparator|Bupivacaine+lignocaine|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with10 ml of bupivacaine 0,25%+ 5ml lignocaine 1%(20 patients).~Under complete aseptic precautions an ultrasound guided left stellate ganglion block (paratracheal technique ) The patient placed in the supine position with the head in the neutral position and slightly extended.~The US probe placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia anterior to the C6 vertebral body and deep to the carotid artery. skin infiltration with local anesthetic, the needle inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
10116442|NCT04439058|Other|Normal saline|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with 15 ml of normal saline (20 patients).~US machine Mindray M5 (Shenzhen Mindray Bio-Medical Electronics Co., LTD. Shenzhen, China.) with a linear 38-mm high frequency 10-12 MHz transducer), with an imaging depth of 4 cm. A 50-mm short bevel 22-gauge insulated stimulating needle (PAJUNK® GmbH Medizin technologie, Deutschland"
10116443|NCT04438889||AML|Patients with WHO 2016 diagnosis of AML
10116444|NCT04438889||MDS|Patients with WHO 2016 diagnosis of MDS
10116445|NCT04438889||CMML|Patients with WHO 2016 diagnosis of CMML
10116446|NCT04438889||PMF|Patients with WHO 2016 diagnosis of PMF
10116447|NCT04438980|Experimental|Methylprednisolone Arm|Standard of care plus Methylprednisolone
10116448|NCT04438980|Placebo Comparator|Placebo Arm|Standard of care plus placebo
10116449|NCT04438655|Experimental|Oral + Parenteral prophylaxis|"Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.~Systemic antibiotic drugs:~Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
10116450|NCT04438655|Sham Comparator|Only parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
10116451|NCT04438837|No Intervention|control group|no intervention
10116452|NCT04438837|Active Comparator|intervention group|participants will recieve hydroxychloroquine in a dosage regimen of 400mg BID in the first day followed by 200mg BID for overall 10 days.
10116453|NCT04438876|Experimental|Function power training|12-week structured FPT program, conducted by a certified trainer from a community service provider. Sessions were held twice weekly at the respective community senior activity centers, each lasting 60 minutes in duration.
10116454|NCT04438876|Active Comparator|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
10116455|NCT04439019|Experimental|All patients referred to the Alberta Hip and Knee Clinic|All patients who are diagnosed with severe osteoarthritis undergoing total hip/knee replacement surgery and show interest to be part of the study.
10116456|NCT04438902|Experimental|osimertinib combined with anlotinib|
10116457|NCT04438759|Experimental|investigational group|Virtual Reality
10116458|NCT04438759|No Intervention|reference group|standard of care
10116459|NCT04438798|Placebo Comparator|face mask group|Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
10116460|NCT04438798|Active Comparator|THRIVE group|High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
10116461|NCT04438915|No Intervention|Average weight .control group|Average weight BMI (18.5_25)
10116462|NCT04438915|Active Comparator|Overweight|Overweight BMI ( 25_30 )
10116463|NCT04438915|Active Comparator|Mild obese|Mild obese BMI (30_35 )
10116464|NCT04438733|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
10116465|NCT04438733|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
10116466|NCT04438811|Other|Consultant Anesthetist|Patients who are randomized to this arm will receive their spinal anesthesia froma consultant anesthetist
10116467|NCT04438811|Other|Medical Officer|Patients randomized to this arm will receive their spinal anesthetic from a medical officer. There will be a consultant anesthetist immediately available if needed but they will not be a direct participant in this arm. Any involvement by the consultant will result in the label of failure for this patient.
10116468|NCT04438850|Experimental|I_600|ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo
10116469|NCT04438850|Experimental|I_1200|ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
10116470|NCT04438850|Placebo Comparator|Placebo|placebo
10116471|NCT04438707|Experimental|Experimental group|
10116472|NCT04438707|Active Comparator|Control group|
10182649|NCT03772210|Sham Comparator|Sham 2 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 2 mA tDCS.
10116473|NCT04438928|Experimental|Healthy pregnant women - Supplement|"Supplementation with micronutrients plus docosahexaenoic acid (DHA) preparation (Multimicronutrients and docosahexaenoic acid (MMS) soft gel capsules) during 2nd and 3rd trimesters of pregnancy.~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
10116474|NCT04438928|Other|Healthy pregnant women - Non-Supplement|"Control study group~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
10116475|NCT04438720|Active Comparator|Extended Release Nifedipine Tablets（Adalat® GITS）|Extended Release Nifedipine reference formulation at a single dose of 30 mg
10116476|NCT04438720|Experimental|Extended Release Nifedipine Tablets|Extended Release Nifedipine test formulation at a single dose of 30 mg
10116477|NCT04438642|Other|conventional ceramic onlay with shoulder finishline|tooth that need ceramic onlay restoration, a conventional cavity will be prepared with shoulder finishline.
10116478|NCT04438642|Experimental|conservative ceramic onlay preparation buttjoint with bevel|tooth that need ceramic onlay restoration, a conservative cavity will be prepared with butt joint with bevel finishline.
10116479|NCT04438629||Mild disease|COVID-19 hospitalized patients
10116480|NCT04438629||Severe disease|COVID-19 hospitalized patients in intensive care unit
10116481|NCT04438629||paucisymptomatic syndrome|Mild symptomatic patients in home quarantine
10116482|NCT04438772|Experimental|LPEC|
10116483|NCT04438772|Sham Comparator|Sham procedure|
10116484|NCT04438616|Active Comparator|dome magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor~We connect magnetic attachment(dome) for each groups on complete denture by pick up procedure at day of implant installation"
10116485|NCT04438616|Active Comparator|flat magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor~We connect magnetic attachment(flat) for each groups on complete denture by pick up procedure at day of implant installation"
10116486|NCT04438694|Active Comparator|STANDARD OF COARE|Receiving SOC
10116487|NCT04438694|Experimental|STANDARD CP DOSE Adm (Two infusions)|Two infusions 48 hours apart
10116488|NCT04438746|Experimental|Group receiving CBAT|
10116489|NCT04438746|Placebo Comparator|Group receiving general emotion training|
10116490|NCT04438564|Other|cancer of breast, colorectal, ovarian and endometrial|Patient who diagnostic of Breast cancer, Colorectal cancer, cancer of Ovary, and cancer of Endometrial are can recruit.
10116491|NCT04438499|Experimental|Subjects Indicated for a UDS study|The investigational device, i.e. the eSense catheter will be used in all the subjects to assess primary and exploratory objectives. It is a single arm study with no comparative, placebo, sham or control arm.
10116492|NCT04438486|Active Comparator|dietary advice|
10116493|NCT04438486|Experimental|dietary advice+ Barely Green|
10116494|NCT04438343|Experimental|experimental group|
9825880|NCT02397707|Experimental|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
10116495|NCT04438343|Active Comparator|control group|
10116496|NCT04438603||IgAN patients at low risk of disease progression|n = 30, incipient disease
10116497|NCT04438603||IgAN patients at high risk of disease progression|n = 60, incipient disease
10116498|NCT04438603||Long-term stable patients|n = 30, follow-up for at least 15 years
10116499|NCT04438603||Progressive IgAN patients|n = 30
10116500|NCT04438603||Healthy control|n = 30
10116501|NCT04438291|Experimental|Intervention schools|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
10116502|NCT04438291|Other|Control schools|Control and usual care
10116503|NCT04438356|Experimental|M-health|After the acute myocardial infarction, patients will be randomly assigned to the intervention group. Give the intervention group mobile health care programs and given Garmin monitoring hands ring. In order to give patients clear walking goals and exercise intensity, the intervention group will use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
10116504|NCT04438356|Experimental|wait list control|wait list control for 3 months and then use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
10116505|NCT04438200||Adolescents|Individuals aged 10-19 years
10116506|NCT04438200||Young Adults|Individuals aged 20-39 years
10116507|NCT04438200||Elderly Adults|Individuals aged 40+ years
10116508|NCT04438252|Experimental|Cariescan pro|device for early caries detection
10116509|NCT04438252|Experimental|ICDAS II|Index for caries detection
10116510|NCT04438239||Covid-19 discharged|Patients affected by COVID-19 and discharged from hospital wards of the Azienda USL- IRCCS Of Reggio Emilia (Italy).
10182650|NCT03772210|Experimental|Structural, Diffusion and MREIT Imaging|"Structural and High angular resolution diffusion weighted imaging will be performed.~Magnetic Resonance Electrical Impedance Tomography imaging will be performed using electrode locations F3-F4."
10116511|NCT04438317|Active Comparator|Seldinger Technique|Small bore chest tubes inserted by Seldinger technique. A needle is inserted into the intercostal space, and the aspiration of a fluid allows the confirmation the correct position, possibly after ultrasound tracking. A metal guidewire is inserted through the needle, which is then removed. A dilator is then inserted on the metal guidewire to dilate the skin and the subcutaneous tissues. The chest tube is finally inserted on the guide, which is finally removed, and the chest tube is connected to the aspiration system after fixation to the chest wall.
9825881|NCT02397785|Experimental|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
10116512|NCT04438317|Active Comparator|Surgical-like Technique|Large bore chest tube inserted by surgical-like technique. Progressive chest wall dissection is conducted with appropriate instruments (scissors, scalpel, clamps…) by a non-surgeon physician. Large bore drain with rigid introductor is blindly inserted in the pleural cavity, secured to the chest wall with suture fixation and further connection to the aspiration system.
10116513|NCT04438395||Enrolled AFL and AF Patients|All subjects that are enrolled are group one, as there is only one group of subjects in this study
10116514|NCT04438213|Experimental|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
10116515|NCT04438213|Experimental|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
10116516|NCT04438213|Placebo Comparator|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
10116517|NCT04438473|Experimental|Pectin|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
10116518|NCT04438473|Placebo Comparator|Control|standard formula enteral nutrition feeding without pectin for 7 days
10116519|NCT04438460|Experimental|Patient group|150 children aged 1 month to 12 years with multi-visceral failure syndrome within 48 hours of hospitalization in pediatric resuscitation will be included in this study
10116520|NCT04438460|Other|Control group|60 children aged 1 month to 12 years hospitalized for simple elective surgery will be included in this study
10116521|NCT04438551|Active Comparator|Standard dietary counseling|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection.
10116522|NCT04438551|Experimental|Standard dietary counseling plus mobile app|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection. Subjects will use a mobile app to build their shopping lists prior to grocery shopping.
10116523|NCT04438408||severe asthma patient|Adult patients (≥ 18 years) with diagnosis of severe asthma for at least 12 months
10116524|NCT04438421|Experimental|BMG0703|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
10116525|NCT04438421|Active Comparator|Chlorhexidine 0.2%|Subjects will then be given a 0.2% Chlorhexidine product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
10116526|NCT04438421|Placebo Comparator|Placebo Product|Subjects will then be given a placebo product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
10116527|NCT04438577|Experimental|Efficacy of Lidocaine mucilage-ICG|Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
10116528|NCT04438447|Experimental|ERAS plus artificial nutrition|"Patients randomised in the treatment arm will be treated with a full ERAS protocol that establishes oral food at will plus parenteral nutrition (PN) from postoperative day 1. A 3-bag compartment peripheral parenteral solution (mOsm < 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation. In case of the occurrence of any complication impairing the full or partial recovery of oral food, the treatment will be continued until clinically indicated"
10116529|NCT04438447|Active Comparator|Enhanced recovery protocol|"Patients randomised in the control arm will be treated with a full ERAS protocol that establishes oral food at will. In case of the occurrence of any complication impairing the full recovery of oral food within postoperative day 7, patients will receive parenteral nutrition as in the treated arm until clinically indicated"
10116530|NCT04438187|Other|Aggressive Arm|If an intubated patient is suspected of having an ICU-acquired HAP/VAP during the aggressive period, antimicrobials should be initiated immediately after quantitative or semi-quantitative endobronchial cultures are sent regardless of clinical status. This will include patients who, as determined by the attending intensivist, are in sepsis or septic shock. If, after 72 hours, cultures and other clinical data do not point to a pneumonia, the antimicrobials should be stopped in the absence of another source of infection.
10182651|NCT03772106|Experimental|Group P|Group P : Propolipid 1% dose : variable to keep BIS between 40 and 60
10182652|NCT03772106|Experimental|Group S|Group S : Sevoflurane dose : variable to keep BIS between 40 and 60
10182653|NCT03772509|Experimental|CATI|Introduction and consent via computer assisted telephone interview
10182654|NCT03772509|No Intervention|IVR|Introduction and consent via interactive voice response
10182655|NCT03772054|Active Comparator|Propofol|After spinal anesthesia, patients in this arm will receive an intravenous target controlled infusion to site effect (TCI/Ce) infusion of propofol to achieve hypnosis guided to a bispectral index (BIS) level of 40-60 during surgery.
10182656|NCT03772054|Experimental|Sevoflurane|After spinal anesthesia, patients in this arm will receive an inhalation induction with sevoflurane to achieve hypnosis guided to 0.7-0.9 minimum alveolar concentration (MAC) during surgery.
10116531|NCT04438187|Other|Conservative Arm|If a patient is suspected of having an ICU-acquired HAP/VAP during the conservative period, quantitative or semi-quantitative endobronchial cultures should be sent. If the patient is in septic shock persistent hypotension requiring vasoactive medications to maintain mean arterial pressure (MAP) ≥65 mm HG or persistent lactic acidosis (>2 mmol/L) despite adequate resuscitation) antimicrobials will be initiated immediately. If the patient has new onset organ dysfunction that is presumed to be due to infection (sepsis) then antimicrobials will be initiated at the discretion of the attending intensivist. In the absence of septic shock or sepsis (intensivist discretion), antimicrobials will not be initiated unless objective evidence of pneumonia is present or another documented source of infection is identified mandating treatment with antimicrobials.
10116532|NCT04438434|Experimental|Hydrogen Peroxide and Hyaluronic acid mouthwash (BMG0703)|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
10116533|NCT04438434|Active Comparator|Chlorhexidine 0.2% mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
10116534|NCT04438434|Placebo Comparator|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
10116535|NCT04437914||Group 1 - Smartwatch - single lead (D1)|To obtain the automatic electrocardiographic diagnosis of the clock, two ECG tracings of 30 seconds will be obtained, in a calm environment, with the patient at rest, in the horizontal supine position. The device will be attached to the wrist on the left side with the use of the fingers of the right hand on the sensor button of the watch to complete the electrocardiographic DI derivation following the Einthoven triangle derivation criteria. The automatic diagnosis obtained must be the same in both plots to be validated. The specific results of the automatic diagnosis obtained by the watch will be: low beats with FC≤40 beats per minute (bpm); high beats with HR≥120bpm; sinus rhythm when interpreted as normal by the clock, atrial fibrillation, inconclusive and does not allow analysis due to poor technical quality and did not allow tracing.
10116536|NCT04437914||Group 2 - conventional ECG|The conventional ECG tracing will be obtained in the 12 leads of the frontal plane (DI, DII, DIII, aVR, AVL, AVF) and the horizontal plane (V1 to V6) and a 30-second rhythm trace in the DI lead. The diagnostic results of conventional ECG tracings will be: normal or abnormal; sinus rhythm, AF, atrial flutter or other non-sinus rhythm; intraventricular conduction disorder: left bundle branch block (BRE), right bundle branch block (BRD), right posteroinferior lower block (BDPI or left anterior superior (BDAS), isolated or associated; normal electrical axis, shifted to the right or shifted to the right) left, inconclusive and does not allow analysis due to poor technical quality.
10116537|NCT04437901||COVID-19 patients|Patients admitted at one of the participating centres with highly suspected/confirmed infection with SARS-CoV-2.
10116538|NCT04437823|Experimental|Group 1 : Treatment|Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10^5 UCMSCs per Kg body weight delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).
10116539|NCT04437823|No Intervention|Group 2: standard care|Five (5) subjects will be treated under Standard of Care (SOC) .
10116540|NCT04437836|Experimental|Control arm|Participants will receive standard treatment of rifampicin
10116541|NCT04437836|Experimental|First High dose|Participants will receive 30mg per kg body weight of rifampicin
10116542|NCT04437836|Experimental|Second high dose|Particpants will receive 40mg per kg body weight of rifampicin
10116543|NCT04437953|Experimental|Avatrombopag|Patients will receive an initial dose of Avatrombopag 60 mg on Day 1.Starting on Day 2, the dose will be Avatrombopag 20 mg daily.
10116544|NCT04438005|Experimental|ICP-022|
10116545|NCT04437992||Pregnant women|"Pregnant women resident in the Emilia Romagna region who access the combined test at regional counseling centers and hospital prenatal clinics.~Women able to understand the information, participate in pre-test counseling and provide informed consent."
10116546|NCT04438122|Active Comparator|Red Wine group|Participants of this group consumed 200ml of red wine along with a meal (lunch or dinner) every day for 8 weeks.
10116547|NCT04438122|Active Comparator|Ethanol group|Participants of this group consumed 69mL of tsipouro along with a meal (lunch or dinner) every day for 8 weeks.
10116548|NCT04438122|No Intervention|Control group|Participants of this group consumed no alcohol along with a meal (lunch or dinner) every day for 8 weeks
10116549|NCT04437849|Experimental|Telemonitoring|
10116550|NCT04437849|No Intervention|Usual Care|
10116551|NCT04437875|Experimental|Component 1|rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene.
10116552|NCT04437875|Experimental|Component 2|rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
10116553|NCT04437875|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
10116554|NCT04438044|Experimental|ICP-022|150mg,QD
10116555|NCT04438070|Placebo Comparator|Daily active screening only|
10116556|NCT04438070|Experimental|Daily active screening and self-collected nasal swab|
10116557|NCT04438070|Experimental|Daily active screening and self-collected oral-nasal swab|
10116558|NCT04438070|Experimental|Daily active screening and nurse collected nasopharyngeal swab|
10116559|NCT04437784|Active Comparator|Laparoscopic Trans-Abdominal Pre-Peritoneal (Lap TAPP group))|Both hernias were treated by laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
10116560|NCT04437784|Active Comparator|Open Pre-Peritoneal Repair ( Open PP group)|Both hernias were treated by open pre-peritoneal single mesh repair with suture fixation
10116561|NCT04437784|Active Comparator|Bilateral Lichtenstein repair (LICHT group)|treated by bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
10116562|NCT04437797|Experimental|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
10116563|NCT04437797|Active Comparator|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
10116564|NCT04437771||Subjects with Fanconi Anaemia Subtype A (FA-A)|Subjects treated with ex vivo lentiviral gene therapy product in FANCOLEN-I trial and agree to participate in this long-term follow-up (LTFU) study
10116565|NCT04437758|Experimental|Hydrolyzed collagen and Vitamin C powder mix|20 g hydrolyzed collagen + 50 mg vitamin C (ascorbic acid) pre-packed powder diluted in 250 ml (8 oz) of water
10116566|NCT04437758|Placebo Comparator|Maltodextrin powder|20 g maltodextrin pre-packed powder diluted in 250 ml (8 oz) of water
10116567|NCT04437459|Experimental|Abbreviated Fat Tolerance Test|
10116568|NCT04437459|Active Comparator|Oral Glucose Tolerance Test|
10116569|NCT04438096|Experimental|100 mg|
10116570|NCT04438096|Experimental|200 mg|
10116571|NCT04438096|Experimental|300 mg|
10116572|NCT04438096|Placebo Comparator|Placebo|
10116573|NCT04437940||Covid-19 positive women|Women with nasofarangeal Covid-19 PCR test is positive
10116574|NCT04437446|Experimental|Case Group|"The Case group corresponds to patients with glaucoma following the clinical criteria for glaucoma:~papilla excavation> 5/10 with altered ISNT rule, or neuro-retinal rhyme characteristic of glaucoma, or fiber alterations characteristic of glaucoma.~OCT with typical alterations (loss of the layer of nerve fibers or loss of these ganglion cells), loss of fibers typical of glaucoma.~Humphrey 24: 2 visual fields produced, reliable and typical of glaucoma.~The assignment to the Cas group will be carried out by an ophthalmologist specializing in glaucoma according to the following criteria:~- The intraocular pressure must be increased before the start of treatment (21 mmHg or more), except in cases of normal pressure glaucoma.~The additional examination corresponds to an OCTA alone leading to an extension of the duration of the consultation by 5 minutes."
10116575|NCT04437446|Experimental|Control Groupe|"The Control group corresponds to patients with no glaucoma, no suspicion or history of glaucoma, ocular hypertension, or alterations detected during the ophthalmological consultation.~Witnesses will be matched to cases by age (+/- 5 years) and gender.~For patients in this group, the additional examinations correspond to a visual field, an OCT and an OCTA leading to an extension of the duration of the consultation by 35 minutes."
10116576|NCT04437966|Experimental|Self-management Group|"The intervention consists of three levels - (1) chronic disease self-management workshops, (2) distribution of and teaching on the use of medication pill boxes and (3) use of social media (WhatsApp version 2.0) to encourage medication adherence.~We combine the Stanford Chronic Disease Self-Management Curriculum, add medication adherence tools and social media use to develop a novel intervention aimed at better blood pressure control. The CDSMP focuses on enhancing skills through problem solving and brainstorming activities. In the workshop we discuss: blood pressure control, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control. Pill boxes will be distributed to all individuals in the intervention group. Post workshop, participants will be sent twice weekly reminders to use their high blood pressure medications via the social media tool WhatsApp. These will be sent for one month."
10116577|NCT04437966|No Intervention|Usual care group|Controls will receive educational material at baseline and one didactic session (on importance of medication adherence to hypertension control) lasting 1 hour delivered by a health care professional.
10116578|NCT04437693|Experimental|Hydroxychloroquine|400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks.
10116579|NCT04437693|Placebo Comparator|Placebo|2 tablets (Placebo White tablets) twice daily on day 1 followed by 2 tablets weekly for 7 weeks
9694582|NCT04787783|Experimental|Web based assessment|Participants will be leaded through preoperative period on a web based application. Participants will be addressed to either virtual or traditional face to face outpatient consultation on the basis of the information registered in the web based preoperative questionnaire that the application incorporates. Virtual assessment will be the performed by evaluating both the filled web based questionnaire together with participants´ electronic records. Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records.
10116580|NCT04437745|Experimental|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
10116581|NCT04437745|No Intervention|Control|No Intervention
10116582|NCT04437355|Active Comparator|Control Group|Young and healthy Group of People (18-50 years) without any pathology of the lower limb
10116583|NCT04437355|Active Comparator|Ankle Fracture Type Weber B|Young and healthy patients with an operative treated fracture of the ankle (type Weber B)
10116584|NCT04437355|Active Comparator|Ankle Fracture Weber C and complex|Young and healthy patients with an operative treated fracture of the ankle (type Weber C or complex fracture)
10116585|NCT04437433|Experimental|Atogepant 60 mg|Taken once daily
10116586|NCT04437316|Active Comparator|Low Level Laser|therapeutic laser
10116587|NCT04437316|Placebo Comparator|Placebo Low Level Laser|non-therapeutic laser
10116588|NCT04437550|Experimental|high-intensity|
10116589|NCT04437550|Experimental|low-intensity|
10116590|NCT04437524|Active Comparator|balance-proprioception exercises group|balance-proprioception exercises group
10116591|NCT04437524|Active Comparator|aerobic exercises group|aerobic exercises group
10116592|NCT04437472||CareSignal|-Participants will undergo a single training session on how to use the CareSignal software no more than 4 weeks before starting standard of care therapy. After the training session, patients will be encouraged by the treatment team to complete the baseline symptom report once they receive the questions via SMS prior to starting any therapy and to complete the weekly reports during therapy and in follow up.
10116593|NCT04437394||Study group|Study group was performed on 30 patients who were diagnosed with ankylosing spondylitis using modified New York criterion.
10116594|NCT04437394||Control group|Control group was performed on 30 participants who were healthy.
10116595|NCT04437407|Other|Control|The first night will be a control night with infrared video recording where only the Ajuvia sleep monitor is worn in passive mode so that each participant can act as her own control for comparison of treatment effect on outcomes.
10116596|NCT04437407|Experimental|PB2-1|During this night, the PB2-1 prototype will be worn with the Ajuvia in passive mode.
10116597|NCT04437407|Experimental|PB2-2|During this night, the PB2-2 prototype will be worn with the Ajuvia in passive mode.
10116598|NCT04437407|Experimental|PB2-3|During this night, the PB2-3 prototype will be worn with the Ajuvia in passive mode.
10116599|NCT04437407|Experimental|PB2-4|During this night, the PB2-4 prototype will be worn with the Ajuvia in passive mode.
10116600|NCT04437407|Experimental|PB2-5|During this night, the PB2-5 prototype will be worn with the Ajuvia in active mode.
10116601|NCT04437251|Experimental|Brain stimulation-induced improvements in leg skill learning|"To examine the degree of stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group. Up to date, most studies have investigated the effects of brain stimulation on hand skill improvements in healthy young adults; little is known about stimulation-induced improvement in the leg skill improvement in stroke survivors as well as in older healthy adults. The investigators will answer the question: Do stroke survivors improve leg skill learning at a comparable rate as healthy young and older adults after brain stimulation transcranial direct current stimulation (tDCS)?"
10116602|NCT04437251|Experimental|Effects of brain stimulation on functional improvements|"To determine the effect of brain stimulation (tDCS) on functional improvements in stroke survivors. Specifically, the investigators will compare stepping reaction time, cortical neuronal activity, peripheral nerve activity, and walking function in the stroke survivors before and after tDCS, and also compared these findings with results from healthy adults. The investigators will answer the question: Do stroke survivors shorten stepping reaction time and improve leg muscle activation and gait performance after tDCS, and these improvements are at a similar rate as compared to data collected from healthy young and older adults?"
10116603|NCT04437251|Sham Comparator|Effects of brain stimulation combined with stepping training|After enrolling to the study, participants with chronic stroke will be randomly assigned to one of two groups: anodal tDCS or sham tDCS groups. All subjects will then undergo a total of twelve training sessions over four weeks in which subjects will learn a novel visuomotor stepping task immediately after visuomotor learning training while 20-minute tDCS (anodal or sham stimulation) is delivered over the leg area of primary motor cortex.The investigators will measure changes in brain neuronal activity, peripheral nerve activity, and walking performance before and after a 12-session training program, and will follow up one week later.
10116604|NCT04437654|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
10116605|NCT04437654|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
10116606|NCT04437329|Experimental|DNF-N|"Induction chemotherapy:~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~Concurrent chemoradiotherapy:~three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~Radiotherapy: radical intense modulated radiation therapy"
10116607|NCT04437329|Active Comparator|DPF-P|"Induction chemotherapy:~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous cisplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~Concurrent chemoradiotherapy:~three cycles of 100 mg/m² cisplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~Radiotherapy: radical intense modulated radiation therapy"
10116608|NCT04437225|Experimental|Constant Infusion of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 5:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 7:30 am for the carbon 13 glycolate infusion which will occur at a constant rate for 10 hours, following a priming dose. From 7:30 am to 5:30 pm, urine collections will occur hourly, and from 8:30 am to 5:30 pm, IV blood collections will occur every half hour. Subjects will receive a meal at 5:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
10116609|NCT04437225|Experimental|Single Intravenous Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 8:30 am for a single dose of carbon-13 glycolate to be administered. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, IV blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
10116610|NCT04437225|Experimental|Single Oral Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. At 8:30 am, subjects will ingest the carbon-13 glycolate, dissolved in to 50 ml (about 1/4 cup) of water. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, intravenous (IV) blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
10116611|NCT04437420||T-ALL|
10116612|NCT04437420||B-ALL|
10116613|NCT04437082||Normal|no pre-existing conditions
10116614|NCT04437082||Glaucoma|diagnosis of glaucoma
10116615|NCT04437082||Retina|diagnosis of retina pathology
10116616|NCT04437082||Cornea|diagnosis of corneal condition
10116617|NCT04437121||Parents of children aged 2-18 years|Parents of children aged 2-18 years during the lockdown due to the COVID-19 pandemic, following their informed consent form prior to their participation to the study.
10116618|NCT04437030|Active Comparator|Patient|Patient with Head and neck cancer
10116619|NCT04437030|Other|Healthy subjects|Healty subjects with not history of Tumor disease in the Head and neck region
10116620|NCT04437017|Experimental|Olanzapine+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists(a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
10116621|NCT04437017|Active Comparator|Dexamethasone+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists (a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administered, and on day 2-4, the given dose of dexamethasone is 8 mg.
10116622|NCT04437095|Experimental|PSBPS Audiorecording|Thirty minute daily administration of audio recording containing messages of psychological support based on positive suggestion delivered via headphones
10116623|NCT04437095|No Intervention|Control|Standard of care
10116624|NCT04437160|Experimental|Adjuvant chemotherapy|"Adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.~Adjuvant chemotherapy regiments: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV + Cyclophosphamide 600mg/m2 IV, q21d*4cycles."
10116625|NCT04437160|No Intervention|Observation|No adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.
10116626|NCT04437290||Alzheimer disease|The group is composed of individuals with a consensus diagnosis of amnestic mild cognitive impairment (MCI) or amnestic multimodal MCI or dementia primarily attributed to Alzheimer's disease (AD), as determined by the UW ADRC Clinical Core. They will have age of presentation > 55 years, sporadic onset, CDR (Clinical Dementia Rating Scale) score 0.5-1.0, and sufficient English competency to complete a standardized cognitive testing battery. All will have no contraindication to MRI and will have had an MRI scan in the UW ADRC Imaging and Biomarker Core. These participants will undergo PET scanning with the investigational tau tracer [18F] MK6240
10116627|NCT04437212|Experimental|Toripalimab Group|All patients will receive radiation therapy scheme: 41.4Gy in 23 fractions over 5 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 45mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22,29 and 2 cycles of toripalimab 240 mg every 3 weeks after chemoradiotherapy. Esophagectomy is performed 6-8 weeks after CRT completion and after operation patients received 4 cycles of toripalimab 240 mg every 3 weeks for adjuvant treatment.
10116628|NCT04437069|No Intervention|Standard Care (Control)|Participants will receive standard care and will not view either the Decision Aid or the Values Clarification Exercise
10116629|NCT04437069|Experimental|Decision Aid|Participants view the Decision Aid only
10116630|NCT04437069|Experimental|Decision Aid & Values Clarification Exercise|Participants view both the Decision Aid and the Values Clarification Exercise
10116631|NCT04437147|Placebo Comparator|Placebo|a) Control placebo (P1) Component Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
10116632|NCT04437147|Active Comparator|3 Billion CFU strains of probiotics|b) 3 Billion CFU (P2) Component Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
10116633|NCT04437147|Active Comparator|8 Billion CFU strains of probiotics|c) 8 Billion UFC (P3) Component Lactobacillus paracasei LPC 00 ID 1076 1 billion CFU;Bifidobacterium longum BL 03 ID 1152 1 billion CFU; Bifidobacterium lactis BS 01 ID 1195 1 billion CFU;Lactobacillus casei LC 03 ID 1872 1 billion CFU; Bifidobacterium animalis LMG 10508 1 billion CFU; Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
10182657|NCT03771820|Experimental|NC-6004 +pembrolizumab|"NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.~In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion."
10182658|NCT03771820|Active Comparator|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
10182659|NCT03771833|Other|Main MARIA scan visit|For Arm 1, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 1 participants will receive study information that they will be sent home with and informed that they will be approached via a telephone call in 2-3 days (or the closest working day to that date) to enquire if they would like to schedule an appointment for the study visit. If so, this will be scheduled to occur around 7 days from the date of the phone call.
10182660|NCT03771833|Other|Same-day MARIA scan visit|"For Arm 2, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 2 participants will receive study information and as much time as possible to consider their involvement with the study (at least 1 hour). If the patient agrees to participate, they will be scheduled to have their MARIA scans at a time that suits their commitments that day.~This arm also includes the 2b group, who can optionally consent to a dielectric constant reading of their routinely-aspirated cyst fluid before this is disposed of as per usual site process."
10182661|NCT03771846|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin
10182662|NCT03771846|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and oxaliplatin
10182663|NCT03771911|Other|AED guided|"Laypeople will be guided by an Automatic External Defibrillator's (AED) voice instructions during the cardiopulmonary resuscitation.~No other help is available."
10182664|NCT03771911|Other|Telephone guided|"Laypeople will be guided by telephone assistance (from an Emergency Call Center) during the cardiopulmonary resuscitation.~AED voice instructions are also available."
10182665|NCT03771755|Active Comparator|Ibuprofen group|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
10182666|NCT03771755|Placebo Comparator|Acetaminophen group|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
10182667|NCT03771950|Experimental|Intervention group|Early team based neuro-rehabilitation after Traumatic Brain Injury
10182668|NCT03771950|No Intervention|Control group|Treatment as usual.
10182669|NCT03771742|Active Comparator|transverse TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
10182670|NCT03771742|Experimental|paramedian sagittal TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the para-sagittal scan, in-plain, caudal to cephalic approach.0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
10182671|NCT03771729|Experimental|LCZ696 treatment|LCZ696 200mg twice daily
10182672|NCT03771976||Over 35 years of age|Primiparous women over 35 years of age.
10182673|NCT03771976||Between 20-34 years of age|Primiparous women between 20 and 34 years of age.
10182674|NCT03771937|Experimental|Intervention|Intervention group received a telephone follow-up intervention, which consisted of a pre-discharge education program and three telephone follow-up sessions based on the RAM.
10182675|NCT03771937|No Intervention|Control group|the control group received routine care.
10182676|NCT03772067|Experimental|MBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will contain 38 g protein mostly from milk and dairy products.
10182677|NCT03772067|Active Comparator|OBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will 38 g protein without milk or dairy products mostly from other proteins, i.e. eggs, tuna, soy, oatmeal. Milk product will be avoided in this diet also in other meals along the day.
10182678|NCT03771794|Active Comparator|Active Comparator: ReguRate RR2 active|Device: ReguRate neurostimulation device
10182679|NCT03771794|Sham Comparator|Sham Comparator: ReguRate RR2 sham.|Device: Sham ReguRate neurostimulation - mock sham stimulation mode
10116634|NCT04437043|Other|Laparoscopic ventral hernia repair with closure of the defect|In laparoscopic intraperitoneal onlay mesh or IPOM repair, the mesh is inserted intra-abdominally and fixed to the peritoneum / abdominal wall. The general steps include safe entry into the peritoneum, insufflation and placement of the trocars to gain access and visibility (via laparoscope) of the defect. Careful adhesiolysis is performed, which is the removal of scar tissue connecting tissues and organs. The content of the hernia, which may include intestine and fatty tissue, is returned into the abdominal cavity. After closure of the hernia defect, a wide intraperitoneal mesh is fixed over the defect. Desufflation releases the gas from the abdomen. The trocars will be removed and the incisions are closed.
10182680|NCT03771807|Placebo Comparator|Placebo & facial cleansing|"Maltodextrin and food coloring~Subjects will clean the right side of their face with a cosmetic instrument daily"
9965848|NCT01253889|Active Comparator|Oral Glucose with soother|Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
9965849|NCT01253889|Placebo Comparator|Oral water with soother|Oral water first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
9965850|NCT01253889|Active Comparator|Oral glucose with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
9965851|NCT01253889|Placebo Comparator|Oral water with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
9965852|NCT01253915|Experimental|Carbon Dioxide|
9965853|NCT01253915|Placebo Comparator|Placebo|
9965854|NCT00773773|Experimental|Patients undergoing prostatic biopsy|This study will enroll two groups of 250 patients who are to undergo prostatic biopsy as part of their routine medical care because of suspicion of prostate cancer (elevated PSA between 2 and 10 ng/ml, abnormal rectal examination, or both). The first group will contain 250 patients of African-American descent and the second will contain 250 Caucasian men.
9965855|NCT01253928|Active Comparator|Pioglitazone 45mg per day|Pioglitazone 45mg qd will be added to the current treatment
9965856|NCT01253928|Placebo Comparator|placebo|placebo qd will be added to current treatment
9965857|NCT01253941|Experimental|Mud Bath therapy|
9965858|NCT01253941|No Intervention|no Mud Bath Therapy|
9965859|NCT01253954||ICU patients with IFI|1
9976381|NCT01350882|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
9976382|NCT01350882|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
9976383|NCT01350895||Experimental Group|
9976384|NCT01350895||Control Group|
9976385|NCT01350908|Other|Blood sampling|
9976386|NCT01350960|Placebo Comparator|saline 0.9%|
9976387|NCT01350960|Experimental|Cohort 1|0.5 mg/kg in Healthy Subjects
9976388|NCT01350960|Experimental|Cohort 2|1.5 mg/kg in Healthy subjects
9976389|NCT01350960|Experimental|Cohort 3|5.0 mg/kg in Healthy subjects
9976390|NCT01350960|Experimental|Cohort 4|10 mg/kg in Healthy subjects
9976391|NCT01350960|Experimental|Cohort 5|TBD mg/kg in FH subjects
9976392|NCT01350986|Experimental|Directive|
9976393|NCT01350986|Active Comparator|Non-Directive|
9976394|NCT01351012|Placebo Comparator|Corn and safflower oil|
9976395|NCT01351012|Active Comparator|Canola oil|
9976396|NCT01351012|Active Comparator|High oleic acid canola oil|
9976397|NCT01351012|Active Comparator|DHA enriched high oleic acid canola oil|
9976398|NCT01351012|Active Comparator|Flax and safflower oil|
9976399|NCT01351038|Experimental|treatment|3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1
9976400|NCT01351051||No endometriosis|
9976401|NCT01351051||Superficial endometriosis|
9976402|NCT01351051||Endometrioma|
10116635|NCT04437043|Other|Open ventral hernia repair with closure of the defect|An open retromuscular ventral hernia repair involves an incision through the abdominal wall. Adhesiolysis is performed and the content of the hernia is returned into the abdominal cavity. The posterior rectus sheath is separated from the rectus muscle and closed, which closes the abdominal cavity. The mesh is then placed behind the muscle and anterior to the re-approximated posterior rectus sheath. Preperitoneal mesh extension is allowed via transversus abdominis release (TAR). The anterior rectus sheath is closed over the mesh, which closes the hernia.
9825882|NCT02397785|Sham Comparator|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
10182681|NCT03771807|Active Comparator|Beauty From Within & facial cleansing|"Study Product contains collagen hydrolysate, ceramide wheat extract oil and lutein~Subjects will clean the right side of their face with a cosmetic instrument daily"
9825883|NCT02397837|Experimental|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
9825884|NCT02397837|Placebo Comparator|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
9825885|NCT02397889|Experimental|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
9825886|NCT02397889|Active Comparator|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
9825887|NCT02397915|Experimental|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
9825888|NCT02397915|Experimental|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
9825889|NCT02397954|Experimental|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
9825890|NCT02398188|Experimental|LIPO-202|Experimental arm
9825891|NCT02398188|Placebo Comparator|Placebo|Placebo comparator
9825892|NCT02398227|Experimental|HOPE|Cognitive Behavioral Treatment Program for PTSD
9825893|NCT02398227|Active Comparator|PCT|Present Centered Therapy for PTSD
9825894|NCT02398409|Experimental|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
9825895|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
9825896|NCT02399085|Experimental|Treatment (MOR00208, lenalidomide)|"MOR00208 Fc-Optimized Anti-CD19 Antibody, intravenous Infusion, weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), 4 week cycles, until disease progression or unacceptable toxicity or discontinuation due to any other reason.~Lenalidomide (Revlimid®), PO, daily, 4 week cycles, lenalidomide is used 3 of the 4 weeks. Up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9825897|NCT02399163|Experimental|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
9825898|NCT02399163|Placebo Comparator|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
9825899|NCT02399163|Active Comparator|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
9825900|NCT02399163|Experimental|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
9825901|NCT02399228|Experimental|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
9825902|NCT02399254||Pulmonary Rehabilitation|Chronic Obstructive Pulmonary Disease (COPD) patients following pulmonary rehabilitation
9825903|NCT02399345|Experimental|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
9825904|NCT02399475|Experimental|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
9825905|NCT02399475|Experimental|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
9825906|NCT02399917|Experimental|Phase 1b Lead-in Cohort 1|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 1.0 mg/kg"
9825907|NCT02399917|Experimental|Phase 1b Lead-in Cohort 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
9825908|NCT02399917|Experimental|Phase 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
9825909|NCT02400073|Experimental|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
9825910|NCT02400307|Experimental|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
10116636|NCT04437043|Other|Robotic ventral hernia repair with closure of the defect|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar closure of the hernia defect and similar retromuscular mesh placement as for the open approach. Preperitoneal mesh extension is allowed via TAR. The da Vinci System is a robotic-assisted surgical device that allows the surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of the abdominal cavity. Rather than one long incision with open repair, four to six small incisions are made along the outer part of the abdomen between the rib cage and the hip.
10116637|NCT04437641||Experimental|A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.
10116638|NCT04437173|Experimental|Virtual Reality Arm|Patients undergo interventional pain procedure with virtual reality distraction
10116639|NCT04437173|No Intervention|No Intervention Arm|Patients undergo interventional pain procedure without virtual reality distraction
10116640|NCT04437342||Maternal Group|Pregnant women in labour (vaginal delivery or caesarean section) that are admitted to the hospital. Pre-labour 3 different questionnaires are administered to evaluate depression, general anxiety disorder and the association to the covid-19 pandemic. 40 days post delivery via telephone contact 2 questionnaires are administered, one in order to assess the postpartum disorder the other to assess depression.
10116641|NCT04437186|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
10116642|NCT04437186|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
10116643|NCT04437134||On-line exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-line. Patients attend both the exercise and educational sessions by logging on to virtual rooms using links sent out by e-mail. The sessions are led and supervised by GLA:D certified physiotherapists.
10116644|NCT04437134||On-site exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-site. Patients attend both the exercise and educational sessions at physiotherapy clinics in Denmark. The sessions are led and supervised by GLA:D certified physiotherapists.
10116645|NCT04436978|Active Comparator|First month DAPT|
10116646|NCT04436978|Active Comparator|First month standard therapy|
10116647|NCT04436952|Experimental|H7 coil only|patients undergoing DTMS treatment using the H7 coil
10116648|NCT04436952|Active Comparator|Cool D-B80 coil only|20 patients undergoing rTMS treatment using the cool D-B80 coil
10116649|NCT04436952|Active Comparator|DTMS treatment using the H7 coil + ERP|20 patients undergoing DTMS treatment using the H7 coil + ERP
10116650|NCT04436952|Active Comparator|rTMS treatment using the cool D-B80 coil + ERP|20 patients undergoing rTMS treatment using the cool D-B80 coil + ERP
10116651|NCT04436952|Active Comparator|ERP only|20 patients undergoing ERP only
10116652|NCT04436939|Experimental|PEEK healing abutment|Healing abutment made of polyetheretherketone (PEEK)
10116653|NCT04436939|Active Comparator|Ti healing abutment|Healing abutment made of titanium (Ti)
10116654|NCT04436835|Experimental|Supportive care (ART)|Patients undergo ART over 60-90 minutes once a week for up to 5 sessions.
10116655|NCT04436770|Active Comparator|Control Group|Standard physiotherapy and OT
10116656|NCT04436770|Experimental|Experimental|Virtual Reality Therapy and OT
10116657|NCT04436848||PD patients positive for LRRK2 G2385R|
10116658|NCT04436848||PD patients negative for LRRK2 G2385R|
10116659|NCT04436848||Non-PD controls negative for LRRK2 G2385R|
10116660|NCT04436809|Other|SNB only|"cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have disease-free sentinel nodes (pN0) after primary chemotherapy, are directed to SNB only: i.e. no further treatment to the axilla."
10116661|NCT04436809|Other|SNB + AD|cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have metastatic sentinel nodes (pN1) on sentinel node biopsy (SNB) will undergo axillary dissection (AD) i.e. surgical removal of most axillary lymph nodes.
9825911|NCT02400307|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
9825912|NCT02400307|Experimental|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
9825913|NCT02400333|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
10116662|NCT04436783|Experimental|Virtual Reality Epley Maneuver System - VREMS|Patients in the VREMS cohort will be provided with the VREMS device, which will help guide them through the Epley maneuver in a virtual reality environment. All participants will be asked to rate the severity of their symptoms before undergoing the Epley maneuver. Subsequently, patients will be supervised as they perform the Epley maneuver - VREMS assisted. In both groups, once the patient has performed the Epley maneuver (whether with VREMS assistance or with the IH), they will be asked to rate their symptom severity after undergoing the Epley maneuver
9976403|NCT01351051||Deep infiltrating endometriosis|
10116663|NCT04436783|Active Comparator|Instructional Handout (IH)|Those in the control cohort will be provided an instructional handout (IH) to help them perform the Epley maneuver. They will be given a chance to review the IH, and then they will have a chance to perform the Epley maneuver.
10116664|NCT04436796|Experimental|Artificial Pancreas|Subjects will be provided the Interoperable Artificial Pancreas System (iAPS) which includes the iAPS phone platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This iAPS is designed to help control blood sugar in people living with type 1 diabetes.
10182682|NCT03771677|Active Comparator|Active Comparator:NAs group|"Active Comparator:nucleotide analogues(NAs)~patients continue to use NAs"
10116665|NCT04436796|Active Comparator|Sensor Augmented Pump/Predictive Low Glucose Suspend|Subjects will continue use of home insulin pump with a study continuous glucose monitor (CGM) and study glucometer. Subject may use home pump in PLGS mode if this is supported and compatible with the study sensor.
10116666|NCT04436705|Experimental|Progressive Muscle Relaxation (PMR) technique|Participants in intervention group continued Progressive Muscle Relaxation (PMR) technique daily for 20 minutes for a total of four weeks addition to usual care. The usual care consists of pharmacological interventions to manage Cancer-related pain.
10116667|NCT04436705|No Intervention|control|control group received only usual care for their pain during the study period. The usual care consists of pharmacological interventions to manage Cancer-related pain.
10116668|NCT04436926|Experimental|opioid approach bias training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of opioid approach bias modification taking place over two weeks.
10116669|NCT04436926|Sham Comparator|sham training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of sham training taking place over two weeks.
10116670|NCT04436601|Active Comparator|Lactulose|90 ml of Lactulose dissolved in 750 ml of water administered orally by mouth or nasogastric tube (three doses within 24 hrs) continued up to 72 hours or until patient discharge, whichever comes first.
10116671|NCT04436601|Experimental|PEG: Polyethylene Glycol|Three or four sachet of Movicol(PEG) will be dissolved in 750 ml of water and will be given over 24 hrs as 3 doses orally by mouth or Nasogastric tube and will continue up to 72 hours or until patient discharge, whichever comes first
10116672|NCT04436588||DDX3X|DDX3X
10116673|NCT04436653|Experimental|Tricuspid Valve Replacement System|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system will be included in this arm.
10116674|NCT04436874|Experimental|Han ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Han ethnic by endoscopy
10116675|NCT04436874|Experimental|Han ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Han ethnic by endoscopy
10116676|NCT04436874|Experimental|Dai ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Dai ethnic by endoscopy
10116677|NCT04436874|Experimental|Dai ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Dai ethnic by endoscopy
10116678|NCT04436562|Experimental|Poziotinib|A single oral dose of 8 mg poziotinib as a capsule formulation (as the hydrochloride salt) containing approximately 100 μCi of [14C]-poziotinib
10116679|NCT04436419|Placebo Comparator|Placebo|Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.
9519506|NCT03286517|Experimental|Tanner Stage II|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
9519507|NCT03286517|Experimental|Tanner Stage III|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
9519508|NCT03286517|Experimental|Tanner Stage IV|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
9519509|NCT03286517|Experimental|Tanner stage V|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
9519510|NCT03286517|Experimental|Adult Group|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.
9965860|NCT01253967||Group A|Subjects who are hospitalised for acute gastroenteritis
10116680|NCT04436419|Active Comparator|ALA|Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.
10116681|NCT04436627|Experimental|Mild severity:|Brunnstrom stage of distal part: 5-6
10116682|NCT04436627|Experimental|Moderate severity:|Brunnstrom stage of distal part: 4
10116683|NCT04436627|Experimental|severe severity:|Brunnstrom stage of distal part: 2-3
10116684|NCT04436718|Experimental|Daily POCUS|Patients are assessed by facility experts with daily chest ultrasound and findings of interstitial syndrome and IVC measurement are reported to primary care providers.
10116685|NCT04436718|No Intervention|Usual care|Patients are assessed daily by primary care providers per usual care.
10116686|NCT04436614|Experimental|Aloe Vera and Crocus|50 patients Aloe Vera and Crocus (saffron) 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle Intervention: Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle 1L, per 15 days.
10116687|NCT04436614|Placebo Comparator|Aloe Vera|50 patients Aloe Vera (simple) in a glass bottle 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera (simple) in a glass bottle Intervention: Dietary Supplement: Aloe Vera (simple) in a glass bottle in a glass bottle 1L, per 15 days.
10116688|NCT04436614|Other|Mediterranean Diet|50 patients Mediterranean dietary protocol Intervention:mediterranean diet
10116689|NCT04436445|Active Comparator|dry cupping|Dry cupping is considered to be a noninvasive and inexpensive technique, used worldwide to treating patients with pain syndromes It is in fact a type of physical therapy which is applied by the specialists of acupuncture or other individuals. It improves the subcutaneous blood flow and, as a result, stimulates the autonomic nervous system and reduces the pai
10182683|NCT03771677|Experimental|Experimental:PEG-IFN group|"Experimental: peg-interferon alfa-2a~patients switch to sequential peg-interferon α-2a"
10182684|NCT03771690|No Intervention|Control 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
10116690|NCT04436445|Active Comparator|Life style modification|"lifestyle modifications in the form of dietary recommendations, exercises and sleep quality improvement for 8 weeks.The life style modification followed in the treatment: Avoid consumption of all kinds of alcohol beverages. Avoid consumption of spicy foods, pepper, chili and coffee Follow a correct diet assuming each day 50% carbohydrates,30% fats and 20% proteins Increase your intake of fruits, vegetables and foods rich of natural fibers (dark bred, vegetables, spinaches).~8 hour sleep at night 40 minutes of walking 3time per week."
10116691|NCT04436666|Experimental|Ice Application|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
10116692|NCT04436666|Experimental|Virtual Reality|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
10116693|NCT04436666|No Intervention|control|No Intervention
10116694|NCT04436887|No Intervention|Primary closure|Primary closure of midline laparotomy
10116695|NCT04436887|Experimental|Mesh closure|Sub-lay permanent mesh supported the closure
10116696|NCT04436471|Experimental|Component 1|"rAd26 Component, 1 vaccination~Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene"
10116697|NCT04436471|Experimental|Component 2|"rAd5 Component, 1 vaccination~Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene."
10116698|NCT04436471|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
10116699|NCT04436536|Experimental|training with random speed changes|Walking training on treadmill with random speed changes, that is, random sequence of several different walking speeds
10116700|NCT04436536|Active Comparator|training with blocked speed changes|Walking training on treadmill with blocked speed changes, that is a steady progression of faster walking speed.
10116701|NCT04436549||Patients with varicose veins|Patients with varicose veins and eligible to receive open surgery (stab avulsion of varicose veins) as routinely care.
10116702|NCT04436406|Other|Arm 1: Non-small cell lung cancer|"Participants with non-small cell lung cancer as per inclusion/exclusion criteria undergo baseline and PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PDL1 single-domain antibody SPECT imaging at 0 and 9 weeks.~FDG-PET/CT is also performed at baseline (0) and first follow-up (9) weeks scans, in addition to standard CT clinical imaging at 0, 9 and 18 weeks."
10116703|NCT04436406|Other|Arm 2: Melanoma|"Participants with malignant melanoma as per inclusion/exclusion criteria undergo baseline and PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PDL1 single-domain antibody SPECT imaging at 0 and 12 weeks.~FDG-PET/CT is also performed as standard clinical imaging at baseline (0), first follow-up (12) weeks and 24 weeks."
10116704|NCT04436900|Experimental|Intervention group|20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
10116705|NCT04436341||Patients with Alzheimer's disease|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
10116706|NCT04436341||Patients with Lewy body dementia|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
10116707|NCT04436341||Healthy controls|No treatment interventions. Investigations: physical examination, ear-EEG cranial MR, cognitive tests, blood samples
10116708|NCT04436237|Experimental|Non-visual exproprioception training|The training requires the participant to place the foot at a target without visual cues of the foot in virtual environment.
10116709|NCT04436237|Active Comparator|Visual exproprioception group|The training requires the participant to place the foot at a target with visual cues of the foot in virtual environment.
10116710|NCT04436263|Experimental|Supplement|Ethanol-water extract of winery by-products
10116711|NCT04436263|Placebo Comparator|Placebo|Maltodextrin-based placebo
10116712|NCT04436172|No Intervention|pre intervention|Before intervention
10116713|NCT04436172|Experimental|post intervention|Received soinal anesthesia
10116714|NCT04436328|Experimental|Surgical treatment|Surgical treatment of native vertebral osteomyelitis followed by antimicrobial therapy
10116715|NCT04436328|Active Comparator|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only
10116716|NCT04436250|Active Comparator|Placebo|Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg
10116717|NCT04436250|Experimental|S-Ketamine Low dose|S-Ketamine at a dose of 0.2 mg/kg
10116718|NCT04436250|Experimental|S-ketamine High dose|S-ketamine at a dose of 0.4 mg/kg
10116719|NCT04436211||TKA (mechanical alignment)|
10116720|NCT04436211||TKA (kinematic alignment)|
10116721|NCT04436107|Experimental|Part 1 : Zanubrutinib + Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide on Days 1 - 21 of each 28-Day cycle for up to 48 months"
10116722|NCT04436107|Experimental|Part 2 : Zanubrutinib+Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide at the RP2D dose determined from Part 1 administered on Days 1 - 21 of each 28-Day cycle for up to 48 months"
10116723|NCT04436302|Experimental|Intervention|Dividat senso exergame device
10116724|NCT04436302|Active Comparator|Control|Listening to music
10116725|NCT04436315|Experimental|Intervention|Exergame intervention
10116726|NCT04436315|Sham Comparator|Control|Active control condition
10116727|NCT04436185|No Intervention|Characteristics of newborns included|Characteristics of newborns included in the randomized controll
10116728|NCT04436185|Experimental|Intraclass Correlation between the NIPS Score of Parent, Nurse|Intraclass Correlation between the NIPS Score of Parent, Nurse
10116729|NCT04436185|Experimental|Comparisons of procedural pain scores among groups|Comparisons of procedural pain scores among groups
10182685|NCT03771690|No Intervention|Control 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
10116730|NCT04435899|Experimental|EFFECTS OF A CHAIR-YOGA EXERCISES ON STRESS HORMONE LEVELS.|assess the changes mediated by exercise on activities of daily life and falls (autonomy), physical fitness, salivary cortisol and alpha amylase in older adults living in social care givers centers. Methods: 35 women (83.81 ± 6.6 years old) were divided into two groups: chair-yoga exercises (CY, n=20) and control group (CG, n=15). All subjects were evaluated before and after 14-weeks of intervention. CY was involved in classes two times per week, while the GC did not participate in any exercise.
10116731|NCT04435899|Experimental|Physical fralty and health outcomes of fitness, sex hormones.|The study aimed to investigate the association of frailty with diverse geriatric health characteristics and how the latter might contribute to the former. Cross-sectional data of 140 women aged over 75 years were analyzed. Fried's definition of physical frailty, psychological, sex hormones, disability and physical fitness outcomes were examined. Prevalence of frailty was 40%. Frail women had lower scores in cognitive and physical fitness, and high scores for depression and comorbidities. Significant correlations emerged between frailty and disability, fear of falling, aerobic resistance and cognition showed that only aerobic resistance and cognition. A trend towards lower systolic blood pressure in the frail group may reflect being less physically active and/or having more systemic comorbidity. Using simple functional fitness and cognitive measures rather than using less reliable self-report assessments can better identify those with physical frailty.
10116732|NCT04435899|Experimental|physical fitness and frailty syndrome institutionalized older|"This study analyzed the relationship between old physical frailty syndrome (PF) and PhFi indicators and assessed how the latter might predict the former. Participants were 119 elderly women (81.96 ±7.89 years) recruited from four social and healthcare centers. PhFi was assessed through muscle strength tests of upper and lower limbs, endurance, agility-dynamic balance, flexibility and body composition.~The following PF indicators were assessed: weight loss, exhaustion, weakness, slowness and low physical activity level."
10116733|NCT04435899|Experimental|THE RELATIONSHIP BETWEEN FUNCTIONAL DISABILITY OUTCOMES|The associations between functional disability activities of life activities and frailty have already been explored. The contribution of each component of physical frailty and their contribution to understanding the early physical decline of older individuals are poorly explored. The relationships between PF and functional disability and to identify the independent components of frailty that most influence on disability in older women. A cross-sectional study of 119 (81,96±7,89) older women aged 75 and over. Functional disability was assessed through Agility-dynamic and Static balance tests, Activities of daily life and Falls risk screen outcomes.
10116734|NCT04435977|Experimental|Cabozantinib|Drug: Cabozantinib Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).
10116735|NCT04435912|No Intervention|PS alone group|Patients received only Protamine Sulfate for reversal of Heparin
10116736|NCT04435912|Experimental|PS and HC group|Patients received Hydrocortisone pre-treatment then Protamine Sulfate for the reversal of Heparine
10116737|NCT04435925|Active Comparator|Remifentanil|Patients assigned to this group will receive IV Remifentanil as an opioid for general anesthesia.
10116738|NCT04435925|Placebo Comparator|Fentanyl|Patients assigned to this group will receive IV Fentanyl as an opioid for general anesthesia.
10116739|NCT04435951||Group 1 (with TMJD)|Group 1, consists of 60 patients diagnosed with Temporomandibular Joint Dysfunction (TMJD) according to the Research Diagnostic Criteria for Temporomandibular Disorders by a specialist and experienced dentist in TMJD.
10116740|NCT04435951||Group 2 (without TMJD)|Group 2, consists of 60 individuals who did not exhibit TMJD symptoms and have not TMJD diagnosis.
10116741|NCT04436393||Advanced Breast Cancer|Patients with diagnosis of advanced breast cancer
10116742|NCT04436120|Other|Tumor biopsy and blood draw|Tumor biopsy and blood draw
9965861|NCT01253967||Group B|Subjects who visit an emergency room for acute gastroenteritis
9965862|NCT01253967||Group C|Subjects who have rotavirus positive laboratory results and developed acute gastroenteritis at least 48 hours after hospitalisation.
10116743|NCT04436055||All participants|All participants including cannabis users, other drug users, and non-drug users.
9965863|NCT01254058||Glaucoma Group|
9965864|NCT01254058||Age-Matched Controls|
9965865|NCT01254071|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
9965866|NCT01254084|Placebo Comparator|Placebo tea|Dietary Supplement: Placebo tea 3 gram twice daily, orally
9965867|NCT01254084|Active Comparator|Gynostemma pentaphyllum Tea|Gynostemma Pentaphyllum tea 3 grams twice daily, orally
9965868|NCT01254097|Placebo Comparator|Probiotic|Participants are provided in double blinded fashion, probiotic given to take with antibiotics prescribed by their provider.
9965869|NCT01254097|Placebo Comparator|Placebo|Participants are provided in double blinded fashion, Look alike placebo given to take with antibiotics prescribed by their provider.
9965870|NCT01254110||1|Enterally fed with leucine
9965871|NCT01254110||2|Enterally fed with glutamine
9965872|NCT01254110||3|Enterally fed with protein powder
9965873|NCT01254123|Active Comparator|Exenatide|
9965874|NCT01254123|Placebo Comparator|Placebo|
9965875|NCT01254162|Experimental|Placebo Gel|
9965876|NCT01254175|Experimental|rHPIV3cp45 Vaccine|Participants will receive one dose of the rHPIV3cp45 vaccine at baseline and a second dose at Month 6.
9965877|NCT01254175|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of the placebo vaccine at baseline and a second dose at Month 6.
9965878|NCT01254201||Dry Eye|Female patients over the age of 18 years with ocular complaints of dryness, grittiness, irritation, or related symptoms, without any identifiable cause.
9965879|NCT01254201||Fibromyalgia|Female patients over the age of 18 years diagnosed with Fibromyalgia.
9965880|NCT01254201||Healthy Control|Female patients over the age of 18 years with no symptoms of dry eyes and with no known diagnosis of Fibromyalgia.
9976404|NCT01351116|Experimental|EBR plus HDRIB|External Beam Radiation (EBR) plus High Dose Rate Intraluminal Brachytherapy (HDRIB)
9976405|NCT01351116|Active Comparator|EBR|External Beam Radiation (EBR)
10116744|NCT04436094|Experimental|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
10116745|NCT04436094|Active Comparator|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
10116746|NCT04436029|Experimental|Descartes 11|
10116747|NCT04436003|Experimental|Muscle and Articulation chains GDS method treatment|"Participants in the intervention Group are examined and treated according to the principles of Muscle and Articulation Chains GDS Method. They receive GDS treatment individually, up to 8 sessions of 1 hour."
10116748|NCT04436003|No Intervention|Control (treatment as usual)|The Control Group receives standard treatment from their RGP/ doctor. Some are prescribed physiotherapy or chiropractor treatment, or they choose their own alternatives.
10116749|NCT04436159|Active Comparator|Nissen fundoplication|Addition of 360 fundoplication after crural closure
9825914|NCT02400333|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
9965881|NCT01254240|Experimental|UVA/B phototherapy treatment|UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
9965882|NCT01254240|Active Comparator|UVB phototherapy treatment|UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
10116750|NCT04436159|Active Comparator|Toupet fundoplication|Addition of 180 posterior fundoplication after crural closure
10116751|NCT04435938|Experimental|Stereotactic Body Radiotherapy (SBRT)|The dose prescribed in the study will be 45Gy in 5 fractions, delivered once every 3-4 days, such that treatment is completed within 15 days. (e.g. treatment given on Monday/Thursday/Mon/Thurs/Mon) (Exceptions: treatment duration of up to 18 days will be allowed to account for cancer centre closures and unforeseen patient issues.)
10116752|NCT04436354|Experimental|vaginoscopic office hysteroscopy in the trendelenburg position|
9825915|NCT02400333|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
9825916|NCT02400333|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
9965883|NCT01254253|Experimental|Group a|no severe cardiac perfusion defects
9965884|NCT01254253|Experimental|Gooup b|reversible cardiac perfusion defects
9965885|NCT01254253|Experimental|Group c|irreversible cardiac perfusion defects
9965886|NCT01254266|Experimental|conservative treatment|conservative weight reduction treatment in an inpatient unit.
9965887|NCT01254266|Experimental|bariatric surgery|inpatient program as a pre- and post- operational 'envelope' for bariatric surgeries.
9965888|NCT01254279|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
9965889|NCT01254357||YA Burned Subjects|Any person between the years of 19-30 years old treated for a burn injury, having incurred within past 12 months.
9965890|NCT01254383|Active Comparator|Treatment A|Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
9965891|NCT01254383|Experimental|Treatment B|Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
9965892|NCT01254383|Experimental|Treatment C|Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.
9965893|NCT01254435|Active Comparator|'Free' positioning withdrawal|Withdrawal of the colonoscope with the patient positioned at the discretion of the endoscopist
9965894|NCT01254435|Experimental|'Fixed' position withdrawal|Patient positioned in the left lateral position to visualise the caecum, ascending colon and hepatic flexure; supine to visualise the transverse colon; and in the right lateral position to visualise the splenic flexure, descending colon and the sigmoid colon
9965895|NCT01254448|Placebo Comparator|Placebo|Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).
9965896|NCT01254448|Experimental|TC-5619|Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).
9965897|NCT01254461|Experimental|A|
9965898|NCT01254461|Experimental|B|
9965899|NCT00701207|No Intervention|2.|control group-no intervention
9965900|NCT00701207|No Intervention|3|Healthy control group-blood and sputum samples
9965901|NCT00701207|Experimental|1.|nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
9965902|NCT01254500||patients with brain lesions|
9965903|NCT01254500||young normal controls|
9965904|NCT01254500||old normal controls|
9965905|NCT01254513|Experimental|Arm A - Docetaxel every 3 weeks + Prednisone|"Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks~Prednisone 10 mg/day continuously"
10116753|NCT04436354|Experimental|vaginoscopic office hysteroscopy in lithotomy position|
10116754|NCT04435847|Experimental|HST 001|HST 001 (also known as hair stimulating complex [HSC]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges.
10116755|NCT04435847|Placebo Comparator|Placebo - Phosphate Buffered Saline|Phosphate Buffered Saline
10116756|NCT04435886|Experimental|Probiotic group|A multi-strain probiotic
10116757|NCT04435886|Placebo Comparator|Placebo group|Identical placebo
10116758|NCT04435821|Experimental|Pediatric Chronic Pain Patients|Individuals 11-18 years old, with chronic pain (lasting at least 2 months).
10116759|NCT04435860||Ankylosing Spondylitis|Patients with ankylosing spondylitis meeting the inclusion and exclusion criteria
10116760|NCT04435860||Healthy Controls|Healthy individuals meeting the exclusion criteria
10116761|NCT04435730||Group 1|45 patients with cutaneous psoriasis with no musculoskeletal manifestations.
10116762|NCT04435730||Group 2|45 patients with psoriatic arthritis fulfilling CASPAR criteria of PsA
10116763|NCT04435730||Group 3|45 patients with subclinical psoriatic arthritis (patients with cutaneous psoriasis and musculoskeletal manifestations but not fulfilling CASPARcriteria of PsA).
10116764|NCT04435730||Group 4|45 sex and age matched healthy controls
10116765|NCT04435665|Experimental|NFX-179 Gel Low|NFX-179 Gel for topical administration, once daily for 28 days
10116766|NCT04435665|Experimental|NFX-179 Gel Mid|NFX-179 Gel for topical administration, once daily for 28 days
10116767|NCT04435665|Experimental|NFX-179 Gel High|NFX-179 Gel for topical administration, once daily for 28 days
10116768|NCT04435665|Placebo Comparator|Vehicle Arm|Vehicle Gel, for topical administration, once daily for 28 days
10116769|NCT04435743||DLBCL|Treatment-naive or relapsed/refractory CD20+ diffuse large B-cell lymphoma patients who receive induction therapy containing lenalidomide.
10116770|NCT04435743||FL/MCL/MZL|Treatment-naive or relapsed/refractory CD20+ follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma patients who receive induction therapy containing lenalidomide.
10116771|NCT04435743||Maintenance|B-cell non-Hodgkin lymphoma patients who achieve complete or partial remission after induction therapy and receive maintenance therapy containing lenalidomide.
10116772|NCT04435639|Experimental|MLD + Adjustable Compression Sleeve.|Manual lymph drainage + Adjustable Compression Sleeve.
10116773|NCT04435639|Active Comparator|MLD + Coban Compression Bandage.|Manual lymphatic drainage + Coban compression bandaging.
10116774|NCT04435704|Experimental|Oxytocin|Oxytocin will be administered at increasing and decreasing rates
10116775|NCT04435717|Experimental|TCZ 8 mg / kg one dose|TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment
10116776|NCT04435717|Experimental|TCZ 8 mg / kg in two|TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment
10116777|NCT04435717|No Intervention|standard care treatment|Usual / standard care treatment
10116778|NCT04435587|Experimental|ivermectin|"Combination of~oral ivermectin 600 mcg/kg/day once daily for 3 days~Zinc sulfate (100mg/tab) 2 tab every 12 hours for 3 days"
10116779|NCT04435587|Active Comparator|ART/hydroxychloroquine|"Combination of~Day1 hydroxychloroquine 400mg bid, then 200mg bid on Day 2-5~Darunavir/ritonavir (400/100mg) every 12 hours for 5 days~Zinc sulfate (100/tab) 2 tab every 12 hours for 5 days"
10116780|NCT04435652|Experimental|Experimental: Cohort A|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
10116781|NCT04435652|Experimental|Experimental: Cohort B-arm1|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
10116782|NCT04435652|Experimental|Experimental: Cohort B-arm2|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
10116783|NCT04435613|Other|protective mechanical ventilation|Ten patients with moderate to severe ARDS were subjected to a nearly ultra-protective ventilation strategy generating a reduction in minute ventilation (Tidal volume of 5 ml/kg of predicted body weight together with a 20% reduction in respiratory rate). In addition to end-inspiratory pause, prolongation was set to avoid hypercapnia. Protocol phases: Baseline conditions: Tidal volume of 7 ml/kg. I: Tidal volume of 6 ml/kg. II: Tidal volume of 5 ml/kg. III: Increase end-inspiratory pause until achieving an I:E ratio equal to 1. IV: Respiratory rate reduction until 20% of the basal condition keeping constant I:E ratio equal to 1
10116784|NCT04435483|Experimental|Treatment Sequence 1|Participants will receive Treatment A (100 mg acalabrutinib suspension via NG administration plus 20 mg rabeprazole) in Period 1, Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 2, and Treatment C (100 mg acalabrutinib capsule) in Period 3.
10116785|NCT04435483|Experimental|Treatment Sequence 2|Participants will receive Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 1, Treatment C (100 mg acalabrutinib capsule) in Period 2, and Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 3.
10116786|NCT04435535|Other|Positive expiratory pressure (PEP)|PEP 10 cmH2O 15 min
10116787|NCT04435561|Experimental|Standard physiotherapy rehabilitation and dry needling|"In addition to the usual therapy, the experimental group will receive the application of dry needling technique in the hemiparetic limbs.~Dry needling intervention will take place over a period of one and a half months (6 weeks), with a total of 6 sessions. Each session will be performed once a week, where a single puncture will be made in each muscle to be treated, using Hong´s technique and lasting 60 seconds per muscle (or until the muscle is release).~The muscles that will receive dry needling are the following ones:~Upper limb: infraspinatus, teres minor, pectoralis major, deltoid.~Lower limb: gastrocnemius, soleus and anterior tibial muscles."
10116788|NCT04435561|Other|Standard physiotherapy rehabilitation|The control group will receive the usual therapy and treatment.
10116789|NCT04435509|Experimental|Greek Mountain Tea|50 patients Greek Mountain Tea 50 grams one per 30 days. Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams Intervention:Greek Mountain Tea in a plastic bag.
10116790|NCT04435509|Placebo Comparator|Mediterranean Diet|50 patients same dietary habits and a Mediterranean dietary protocol Intervention: Mediterranean diet.
10116791|NCT04435522|Experimental|Maraviroc Treatment|Maraviroc 300 mg Twice Daily
10116792|NCT04435496|Other|GYN-CS insertion|GYN-CS device will be inserted in women during their c-section. The study patient can chose between a lifespan of 3 years (GYN-CS 3) and a lifespan of 10 years (GYN-CS 10) of the device.
10116793|NCT04435574|Experimental|Group A|group A is lactoferrin group, receiving 100mg sachet of lactoferrin once daily.
10116794|NCT04435574|Active Comparator|Group b|group B is the ferrous sulfate group, receiving 6mg/kg/ day single dose of ferrous sulfate.
10116795|NCT04435171||Open renal transplantation|Patients who were performed open renal transplantation due to end stage renal disease.
10116796|NCT04435171||robot assisted renal transplantation|Patients who were performed robot assisted renal transplantation due to end stage renal disease
10116797|NCT04435275|Active Comparator|Donning PPE using VA then doffing PPE using HC|Study subjects will receive VA guidance for donning first, then guidance from a human coach (HC) for doffing.
10116798|NCT04435275|Active Comparator|Donning PPE using HC then doffing PPE using VA|Study subjects will receive HC guidance for donning first, then VA guidance for doffing.
10116799|NCT04435275|Active Comparator|Intubation using VA then extubation using HC;|Study subjects will receive VA guidance for the intubation first , then HC guidance for extubation procedure
10116800|NCT04435275|Active Comparator|Intubation using HC then extubation using VA|Study subjects will receive HC guidance for the intubation first , then VA guidance for extubation procedure
10116801|NCT04435236|Active Comparator|Cervical ESP block group|Cervical ESP block will be performed as described by Elsharkawy at al. (7).
10116802|NCT04435236|Sham Comparator|ISB Block group|ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
10116803|NCT04435223||COVID-19 severe pneumonia|
10116804|NCT04435223||Severe pneumonia due to other pathogene|
10116805|NCT04435314|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
10116806|NCT04435314|Placebo Comparator|Placebo|Subjects will receive placebo TID.
10116807|NCT04435353|Active Comparator|Time-day of respiratory fail|Objective data
10116808|NCT04435353|Active Comparator|Oxygen status|Facultative data
10116809|NCT04435353|Active Comparator|Oxugen support|FiO2
10116810|NCT04435353|Active Comparator|Adverse outcomes|Complication
10116811|NCT04435132|Experimental|PCNL with the aid of the robotic device|Patients will undergo prone PCNL under fluoroscopic guidance and with the aid of the robotic device.
10116812|NCT04435145|Experimental|Intervention|Sugar-sweetened beverage warning label
10116813|NCT04435145|No Intervention|Control|No label
10116814|NCT04435327||Oxygen therapy|Patients who were hospitalised due to COVID-19 pneumonia and received only oxygen support therapy.
10116815|NCT04435327||Non invasive ventilation (NIV/CPAP)|Patients who were hospitalised due to COVID-19 pneumonia and received non invasive ventilation (NIV/CPAP) as maximum support therapy
10116816|NCT04435327||Invasive ventilation|Patients who were hospitalised due to COVID-19 pneumonia and received invasive mechanical ventilation (IMV)
10116817|NCT04435366|Experimental|Zimura Treatment Group|Monthly Zimura 2mg Intravitreal Injections, followed by monthly injections or every other month injections from Month 12 to Month 23
10116818|NCT04435366|Sham Comparator|Sham Treatment Group|Monthly Sham Administration until Month 23
10116819|NCT04435340|Other|Retrospective|All patients in the retrospective cohort are contacted at least 1 year after surgery and/or 3 years after surgery via phone call or letter, informed about the study and asked to participate. In case of informed consent, they are invited to the study site. They are asked to complete the questionnaires and they undergo a Sonography of the ventral abdomen.
10116820|NCT04435340|Other|Prospective|All patients in the prospective cohort are informed about the study and asked to participate in the outpatient clinic before surgery. In case of informed consent, they are invited to the study site at least one year and three years, respectively, after surgery. They are asked to complete the questionnaires and they undergo an ultrasound of the ventral abdomen.
10116821|NCT04435405||Video microanalisys|Video footage analysis of group and individual behavioral processes.
9976406|NCT01351129|Experimental|Formulation 1|
10116822|NCT04435262||ILR Group followed with RM|Patients with unexplained syncope underwent ILR monitoring and followed with RM
10116823|NCT04435262||ILR Group followed with in-hospital visits|Patients with unexplained syncope underwent ILR monitoring and followed with in-hospital visits
10116824|NCT04435197|Experimental|Arm A|"Arm 1:~A: Pembrolizumab 200mg(100mg if weight less than 50kg) IV on days 1 and 22 B: Carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~D: Ivor-Lewis or McKeown esophagectomy~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
10116825|NCT04435106||Opaganib + Standard of Care|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
10116826|NCT04435106||Standard of Care|Study participants received Standard of Care
10116827|NCT04435093||MFM completion|
10116828|NCT04435015|Experimental|Camostat mesylate 200 mg|Participants will be given Camostat mesylate three times daily.
10116829|NCT04435015|Placebo Comparator|Microcrystalline Cellulose|Participants will be given placebo three times daily.
10116830|NCT04435002|Experimental|Intervention Group|For 9 different points acupressure technique applied to this group for 4 weeks
10116831|NCT04435002|No Intervention|Control Group|
10182686|NCT03771690|Experimental|Standardised meal 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
10182687|NCT03771690|Experimental|Standardised meal 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
9965906|NCT01254513|Experimental|Arm B - Docetaxel weekly + Prednisone|"Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)~Prednisone 10 mg/day continuously"
10116832|NCT04434989|Experimental|Stereotactic Body Radiation Therapy|SBRT is defined as a special radiotherapy technique. The high dose of radiotherapy is accurately injected into the tumor lesion in one to several times using external irradiation technique. Then the tumor is exposed to high dose and the surrounding normal tissue to low dose.
10116833|NCT04434989|Active Comparator|Radiofrequency Ablation|Percutaneous radiofrequency ablation to the tumor
10116834|NCT04434885||Psoriatic arthritis|Patients diagnosed with PsA and fulfilling the classification criteria for PsA with symptom duration of up to 10 years and not receiving biological or targeted synthetic disease modifying antirheumatic drugs (b or tsDMARDs).
10116835|NCT04435028||control group|55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen)
10116836|NCT04435028||ketotifen group|Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment
10116837|NCT04434950|Experimental|Intervention|Intervention group
10116838|NCT04435210|Experimental|Nifedipine arm|Participants in this arm will be pregnant women with severe hypertension who will receive nifedipine
10116839|NCT04435210|Experimental|Hydralazine|Participants in this arm will be pregnant women with severe hypertension who will receive hydralazine
10116840|NCT04435054|Other|Non invasive tests|
10116841|NCT04434742|Experimental|Intervention group|The subjects in this group receive complex interventions, including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team.
10116842|NCT04434742|Other|Control group|The control group received usual discharge care and community resources that were made available to them as appropriate. A monthly social call was made to each client in the control group in order to exclude social effects. The contents of the social call, such as asking about entertainment and clients' hobbies, were set in the protocol.
10116843|NCT04434859||Patients with tinnitus|Patients (over 18 years old) seen at the medical center due to tinnitus, lasting at least 3 months.
10116844|NCT04435067||Cohort A|patients in whom lung metastasis were resected for therapeutic purposes
10116845|NCT04435067||Cohort B|patients in whom lung metastasis were removed for diagnostic purposes only
10116846|NCT04434612|Experimental|OXSIGHT smart glasses|Wearing OXSIGHT smart glasses
10116847|NCT04434716|Other|Feasibility of Wearing a Readiband|"Participants will wear the Fatigue Science Readiband for 42 consecutive day. On day one, every seventh day and at the end of the study each participant will complete the Dyspnea-Characteristic scale, BRICS NINR PROMIS Fatigue Short Form6a scale , Modified Pulmonary Functional Status, Dyspnea Questionnaire and the BRICS NINR PROMIS SF v1.0-Sleep Disturbance 6a scale.The Minnesota Living with Heart Failure Questionnaire and Self-Care of Heart Failure Index will be completed on day one and day 60. The purpose of this intervention is to assess the Feasibility of Wearing a Readiband.~Semi-structured Interview will be conducted at the end of 42 days to assess patient comfort and challenges with wearing the Readiband."
10116848|NCT04434690|Experimental|Simultaneous|2 surgeons will perform simultaneous total knee arthroplasty in this group.
10116849|NCT04434690|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
10116850|NCT04434872|Active Comparator|FMT from a healthy donor|"Patients will undergo FMT 4 times during the study:~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
10116851|NCT04434872|Placebo Comparator|FMT from a self donated stool sample|"Patients will undergo FMT 4 times during the study:~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
10116852|NCT04434820|No Intervention|standard dressing group|patients will receive sterile wound dressing of gauze and tape for 4 days.
10116853|NCT04434820|Active Comparator|External negative pressure dressing system group|patients will receive placement of a sterile dressing of gauze and occlusive adhesive over the closed incision. The dressing's tubing will then be attached to a compact, portable negative-pressure therapy unit (Yuwell 7E-A portable suction unit) that will deliver -80 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
10116854|NCT04434794|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
10116855|NCT04434794|Active Comparator|control|standard treatment according to clinical protocols
10116856|NCT04434833||Extra nodal diseases|Patients with both lymph node and extra nodal involvement.
10116857|NCT04434833||Target drugs|Patients enrolled in clinical trials of novel target drugs.
9965907|NCT01254526|Experimental|A|
10116858|NCT04434833||Relapse|Patients with high risk of relapse.
10116859|NCT04434573||french-speaking digestive surgeons|french-speaking digestive surgeons are visceral and digestive surgeons that have a general surgical activity too. They can have or not an expertise on hernia pathology. They are questioned by survey on decisions about different patient asymptomatic hernia clinical situations.
10116860|NCT04434482|Experimental|IMP4297 and temozolomide|"IMP4297 and temozolomide~The dose levels will be escalated following a modified 3+3 dose escalation scheme."
10116861|NCT04434534|Experimental|Hipocaloric Diet with Açaí Juçara|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories, including 200g of Açaí Juçara (2 pulps).
10116862|NCT04434534|Active Comparator|Hipocaloric Diet|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories.
10116863|NCT04434586|Sham Comparator|angiography 2D|Control group: an arteriography will be performed on the entire treated segment to assess the quality of the result, the application or not an active balloon will be left to the discretion of the operator. In case of application of the active balloon, a new arteriography before decision or not the use of stenting will be practiced. In case of stenting, an arteriographic final is performed.
10116864|NCT04434586|Experimental|angiography 2D with OCT|Experimental group: an arteriography and OCT acquisition on the entire treated segment to ensure the quality of the result, the application or not of an active ball will be left. In case of application of the active balloon, a new arteriography and OCT acquisition before decision or not the use of stenting will be practiced. In case of stenting, a final arteriography and then OCT acquisition are performed.
10116865|NCT04434560|Experimental|Neoadjuvant Immunotherapy|Patients will receive a single dose of neoadjuvant nivolumab and ipilimumab 7 days (± 3 days) prior to surgical resection.
10116866|NCT04434443|Experimental|trunk exercise on unstable surface|trunk exercise training in supine and sitting positions, with unstable surfaces
10116867|NCT04434443|Sham Comparator|upper limb range of motion exercise|upper limb range of motion exercise in sitting with back fully supported
10116868|NCT04434651|Experimental|Block group (A)|"26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using 2 % lidocaine before induction of anesthesia.~The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes."
10116869|NCT04434651|Sham Comparator|control sham group (B)|26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using normal saline.The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes
10116870|NCT04434677|Active Comparator|Hypofractionation|Control arm:patients who will receive standard 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
10116871|NCT04434677|Experimental|Ultrahypofractionation|Experimental arm: Patients who will receive 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
10116872|NCT04434703|Active Comparator|Platelet rich fibrin (PRF)|Platelet rich fibrin is the secoond generation of platelet concentrates which is an autogenous biomaterial that is prepared from the patient's own blood
10116873|NCT04434703|Experimental|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin is the last modification of PRF which is expected to contain a relatively greater number of white blood cellsand growth factors
10116874|NCT04434703|Placebo Comparator|blood clot|normal healing of the wound without adding any biomaterial
10116875|NCT04434378|Placebo Comparator|Placebo|Patients undergoing laparoscopic inguinal hernia repair will randomized to one dose of placebo in the preoperative holding area 2 hours before surgery.
10116876|NCT04434378|Experimental|Interventional|Patients undergoing laparoscopic inguinal hernia repair will be randomized to one dose of 0.4 mg tamsulosin in the preoperative holding area 2 hours before surgery.
10116877|NCT04434495|Experimental|PRP group|mock embryo transfer and PRP injection
10116878|NCT04434495|No Intervention|control group|only mock embryo transfer
10116879|NCT04434755||health care professionals in palliative care|health care professionals in palliative care
10116880|NCT04434755||health care professionals in neurorehabiliation|health care professionals in neurorehabiliation
10116881|NCT04434547|Experimental|PRP group|In the PRP group autologous platelets rich plasma was prepared from the blood using the two step centifuge process .Under ultrasound guidance and complete aseptic procedure , 1 ml of PRP was infused inside the uterus while performing the mock embryo transfer
10116882|NCT04434547|No Intervention|Control group|In the control group mock embryo transfer was performed without injecting anything inside the uterus.
10116883|NCT04434391||QF-PCR for GBS screening|QF-PCR for vaginal-rectal samples in pregnant women
10116884|NCT04434508|Active Comparator|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
10116885|NCT04434508|Active Comparator|open right hemicolectomy with CME and central v|open right hemicolectomy with CME and central v
10116886|NCT04434625|No Intervention|control group|Colonoscopy was performed in the control group directly.
10116887|NCT04434625|Experimental|model-based interference group|Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group colonoscopy directly.
10116888|NCT04434456||CGuard stenting (interventional)|CGuard implantation in the carotid artery with aneurysm requiring intervention
10116889|NCT04434638|Experimental|Transitions of Care Coordinator Group|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
10116890|NCT04434638|Active Comparator|Usual Care Group|Patients in the usual care group, which served as the control, received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
9965908|NCT01254526|Experimental|B|
10116891|NCT04434664|Active Comparator|Amlodipine besylate|Initial dose 5mg (1 capsule) daily, titrated up to 10mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
10116892|NCT04434664|Active Comparator|Metoprolol succinate|Initial dose 100mg (1 capsule) daily, titrated up to 200mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
10116893|NCT04434404|Placebo Comparator|control group|33, patients in the control group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 without cardioprotective agents
10116894|NCT04434404|Active Comparator|L-carnitine group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine
10116895|NCT04434404|Active Comparator|Silymarin group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin140 mg
10116896|NCT04434313|Experimental|Delivery of iStride™ device gait treatment using telemedicine|"Treatment with the gait device will be adapted to remote delivery using the telemedicine platform. Participants and caregivers will be guided through an adapted treatment protocol remotely by physical therapists. Training will include platform navigation, device instruction, treatment guidelines, safety precautions, and assessment performance. Understanding will be verified through a caregiver quiz.~Gait patterns will be monitored before, during, and after treatment using gait sensors and outcome measures. Assessments include the 10-Meter Walk Test, Six Minute Walk Test, Timed Up and Go Test, Geriatric Depression Scale, Activities-Specific Balance Confidence Scale, and Stroke Impact Scale-16. Treatment will consist of 12 sessions of walking on the device for a goal of 30 minutes per session. Assessments will be repeated one-week, one-month, three-months, six-months, and 12-months after treatment. Feasibility and safety of the delivery method will be measured throughout the trial."
10116897|NCT04434430|Active Comparator|Gabapentin|Patient will receive preemptive oral gabapentin 600 mg
10116898|NCT04434430|Placebo Comparator|Placebo|Patient will receive oral placebo
10116899|NCT04434365|Experimental|Berberine+standard therapy Arm|In the Berberine Arm, patients will receive berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
10116900|NCT04434365|Active Comparator|Standard therapy Arm|In the Control Arm, patients will receive standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
10116901|NCT04434339|Experimental|group 1|"ESP block group ,Patients received preoperative US guided ESP block on BOTH sides to be operated upon 30 minutes before being transferred to the OR"
10116902|NCT04434339|Experimental|group 2|"TAB group ,Patients received bilateral lower TAB 30 min before being transferred to the OR"
10116903|NCT04434339|No Intervention|group 3|"the control group, Patients will not receive any block."
10116904|NCT04434183|Active Comparator|isokinetic exercise|The group (isokinetic exercise group, n = 25) was given isokinetic exercise.
10116905|NCT04434183|Active Comparator|home exercise|The group(home exercise group, n=25) was given home exercise program.
10116906|NCT04434248|Experimental|Favipiravir, lower dose (pilot stage)|1600mg BID on the 1st day followed by 600mg BID for 13 days
10116907|NCT04434248|Experimental|Favipiravir, higher dose (pilot stage)|1800mg BID on the 1st day followed by 800mg BID for 13 days
10116908|NCT04434248|Active Comparator|Standard of care (pilot stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
10116909|NCT04434248|Experimental|Favipiravir, selected dose (pivotal stage)|The dose will be selected based on pilot study results.
10116910|NCT04434248|Active Comparator|Standard of care (pivotal stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
10116911|NCT04434261||Patients tested for SARS-CoV-2|Patients who underwent the preoperative screening program for SARS-CoV-2
10116912|NCT04434014||males from 20 to above 65 y|will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
10116913|NCT04434014||female from 20 to above 65 y|will be sub divided into 4 groups according to age will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
10116914|NCT04433936||Thyroid Gland Dysfunction|Patients with a recent diagnosis of TGD (the study group) were recruited from endocrinology outpatient clinic of Specialized Medical Hospital, Mansoura University. Diagnosis of TGD was based on précised history, clinical examination and laboratory investigations. In order to avoid bias, patients with history of intake of any thyroid-related medications (antithyroid medications or thyroxine replacement), radioactive iodine or thyroidectomy were excluded from the study.
10116915|NCT04433936||Control|fifty age and gender matched healthy subjects without known personal or family history of thyroid disease or any autoimmune diseases were recruited from candidates of refractive surgery referred to the outpatient clinic of Mansoura Ophthalmology Center for pentacam assessment and who were proved to have normal corneal pentacam parameters. They were further examined by the endocrinologist to exclude thyroid dysfunction; this was supported by normal thyroid function profile (serum TSH and free T4) and negative anti-TPO and antithyroglobulin antibodies.
10116916|NCT04433910|Experimental|Convalescent plasma|Convalescent plasma transfusion on day 1, 3 and 5.
10116917|NCT04433910|No Intervention|Best supportive care|Best supportive care, cross over for patients with progressive disease on day 14 with convalescent plasma transfusion on day 15, 17 and 19.
9825917|NCT02400346|Experimental|Adjunct brexpiprazole|All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition
9976407|NCT01351129|Experimental|Formulation 2|
9976408|NCT01351129|Experimental|Formulation 3|
10116918|NCT04434235||Dynamic cervical stability|"The participant is asked to move the head in 6 directions in a sitting position and 30° leaning backward sitting position; lateral flexion (left / right), flexion, extension, and rotation (left / right). Results are to be taken for each direction and random at each axial load-level (0 kg, 1kg, 2 kg, and 3 kg). In total 24 measurements.~The duration of all measurement will be 60 minutes."
10116919|NCT04434235||Cervical Stiffness|The participant is asked to move the head in 4 directions; flexion, extension, and rotation (left / right). Joint-Position Error measurements will be executed in neutral sitting position. Additionally, stiffness will be measured in neutral sitting position and neutral sitting position with 45° cervical flexion. All measurements will be performed with 0 kg and 3 kg axal loading. In total 18 measurements.The duration of all measurement will be 60 minutes.
10116920|NCT04434053|Experimental|MIETHKE M.blue®|
10116921|NCT04434053|Active Comparator|MIETHKE proGAV 2.0® (with SA 2.0®)|
10116922|NCT04433923|Active Comparator|GROUP1|Phototherapy with aluminum foil
10116923|NCT04433923|Placebo Comparator|GROUP2|Phototherapy without aluminum foil
10116924|NCT04434105|Experimental|PRP group|patients received ultrasound-guided injection of 2 mL PRP into the affected carpal tunnel.patients will be injected twice with 2 weeks intervals
10116925|NCT04434105|Active Comparator|Steroid group|patients received ultrasound-guided injection of 2 mL steroids (40 mg triamcinolone acetonide). into the affected carpal tunnel. patients will be injected twice with 2 weeks intervals
10116926|NCT04434105|Placebo Comparator|Control group|patients received ultrasound-guided injection of 2 mL saline patients will be injected twice with 2 weeks intervals
10116927|NCT04434118||Rheumatoid Arthritis with COVID-19|
10116928|NCT04434118||Rheumatoid Arthritis without COVID-19|
10116929|NCT04433884|Experimental|Conventional MAC Laryngoscope|Patients in this group will undergo intubation using conventional macintosh laryngoscope
10116930|NCT04433884|Experimental|C-MAC Video laryngoscope|Patients in this group will undergo intubation using video C-Mac laryngoscope
10116931|NCT04434131|Experimental|Single Arm|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Vitalant from local and national donors following national blood donation guidelines. All subjects receive the convalescent plasma.
10116932|NCT04434144||Group A:|Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10days
10116933|NCT04434144||Group B|Hydroxychloroquine 400mg first day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days.
10116934|NCT04434170||Heart failure|outpatients with heart failure with reduced ejection fraction in treatment with sacubitril/valsartan according to guidelines
10116935|NCT04433962|Active Comparator|conventional rehabilitation group|the conventional rehabilitation group completed hip joint range of motion and muscle strengthening exercises
10116936|NCT04433962|Experimental|conventional rehabilitation + balance training group|The conventional rehabilitation + balance training group completed hip joint range of motion and muscle strengthening exercises and 12 balance exercises.
10116937|NCT04434079||Included individuals|Adult patients consecutively admitted to the ICU from June to October 2018 are eligible if expected length of stay is superior to 24 hours and no oral nutritional has been offered.
10116938|NCT04434066|Experimental|Abdominal Morcellation|Abdominal morcellation will occur following completion of the hysterectomy. Route of incision will be either suprapubic or umbilical incision - based on surgeon preferences. All steps and instruments have been standardized for abdominal morcellation.
10116939|NCT04434066|Experimental|Vaginal Morcellation|Vaginal morcellation will occur following completion of the hysterectomy. All steps and instruments have been standardized for vaginal morcellation.
10116940|NCT04433949|Active Comparator|Arm I (physician choice)|Patients get best supportive care + physician choice of treatment
10116941|NCT04433949|Experimental|Arm II (LDRT)|Patients receive best supportive care + low dose RT (whole lung)
10116942|NCT04433819||Cushing syndrome|Male and female patients diagnosed as Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
10116943|NCT04433819||Controls|Healthy controls matched for age, gender, and body mass index
10116944|NCT04433754||patients with pancreatic injury|patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
9965909|NCT01254539|Experimental|Autologous bone marrow stem cells intraspinal transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
10116945|NCT04433754||patients without pancreatic injury|patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
10116946|NCT04433897||Oral estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + IUD
10116947|NCT04433897||Oral estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + hysterectomy.
10116948|NCT04433897||Oral estrogen + oral progesterone|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + oral progesterone.
10116949|NCT04433897||Transdermal estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + IUD.
10116950|NCT04433897||Transdermal estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + hysterectomy.
10116951|NCT04433897||Transdermal estrogen + oral progesteron|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + oral progesteron
10116952|NCT04433897||SERM|Women who opt to be treated for their postmenopausal symptoms using SERM's
10116953|NCT04433897||Aromatase inhibitor|Women who opt to be treated for their postmenopausal symptoms using aromatase inhibitor.
10116954|NCT04433897||Duavive|Women who opt to be treated for their postmenopausal symptoms using duavive.
10116955|NCT04433897||No treatment|Women who opt not to be treated for their postmenopausal symptoms.
10116956|NCT04433676||Patients with surgical procedures|Adult patients undergoing surgical procedures under general or regional anesthesia and with an admission to a recovery unit for the initial postoperative care.
10116957|NCT04433715||patients with UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
10116958|NCT04433715||patients without UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
10116959|NCT04433793|Experimental|Yoga group|Patients in the yoga group will receive yoga therapy, one hour every week for eight weeks.
10116960|NCT04433793|No Intervention|Waitlist-control group|Patients in the waitlist-control group will receive no intervention at first, but nine weeks after IG, they will get the opportunity to also receive yoga therapy for 8 weeks.
10116961|NCT04433533|Active Comparator|Rosuvastatin 20mg (Group 1)|
10116962|NCT04433533|Experimental|Rosuvamibe 10/10mg (Group 2)|
10116963|NCT04433624|Active Comparator|Group (B)|will receive The bilateral ESP blocks before surgery
10116964|NCT04433624|Active Comparator|Group B MG|will receive bilateral ESP blocks performed by each side) before surgery
10116965|NCT04433780|Experimental|Delstrigo|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
10116966|NCT04433689||Pregnant women|Pregnant woman, age 18 to 38 yo, with uncomplicated singleton pregnancy and no ocular diseases.
10116967|NCT04433611|Experimental|'lidocaine flushing' group|intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy
10116968|NCT04433611|Placebo Comparator|Placebo group|intrauterine infusion of 0.9 % normal saline (placebo group) just prior to HyFoSy.
10116969|NCT04433481|Experimental|DABIGATRAN|150mg BD for 12 months
10116970|NCT04433481|Placebo Comparator|Placebo|Placebo
10116971|NCT04433663|Experimental|Mentalization-based Intervention|Participants in the intervention group, received mentalization-based psychotherapy with the developed ECOSA axis. Therapist received mentalization-based supervision.
10116972|NCT04433663|Active Comparator|IPT-Inter Personal Therapy|The control group's participants received IPT - interpersonal psychotherapy that focused on resolving interpersonal problems and symptomatic recovery. The control group's therapist received regular supervision - with no emphasis on mentalization or tool's usage.
10116973|NCT04433598|Experimental|Nutrition Education Intervention|the participants the intervention group under went to Nutrition Education Intervention program were received the developed educational materials (pamphlets).
10116974|NCT04433598|No Intervention|Treatment as usual|the participants in the control group were received the usual medical care at their respective Center.The developed educational materials (pamphlets) were distributed at the end of the study.
10116975|NCT04433468|Active Comparator|RIPC|
10116976|NCT04433468|No Intervention|Control|
10116977|NCT04433702|Experimental|Experimental Eye|10 mmHg of negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that only one goggle receives negative pressure.
10116978|NCT04433702|Placebo Comparator|Control Eye|The opposing eye serves as the intrasubject control for each participant. No negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that the other goggle does not receive negative pressure.
10116979|NCT04433650|Experimental|Group 1|"The child will firstly undergo phase A without the digital reporting and communication tool.~The child will secondly undergo phase B with the digital reporting and communication tool (i.e., A, B)."
10116980|NCT04433650|Experimental|Group 2|"The child will firstly undergo phase B with the digital reporting and communication tool.~The child will secondly undergo phase A without the digital reporting and communication tool (i.e., B, A)."
10116981|NCT04433494|Experimental|TY-302 ; TY-302 combine with Tamoxifen|"TY-302~Find the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D) of TY-302, given orally.~Increased dose cohorts from low dose to MTD, starting at 25mg daily.~TY-302 combine withTamoxifen in dose-escalation stage~TY-302: RP2D-1to RP2D daily for 28 days of each 28 day cycle.~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle.~TY-302 combine withTamoxifen in dose-expansion stage~TY-302: RP2D daily for 28 days of each 28 day cycle.~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle."
10116982|NCT04433429||RYR plus CoQ|333 mg of red yeast rice (RYR, equivalent to 10 mg of Monacolin K) plus 30 mg of Coenzyme Q10 (CoQ10) in a single pill once daily
10116983|NCT04433741|Other|Oxytocin First, then Placebo|Oxytocin administered intravenously for the first half of the study and then will receive intravenous placebo for the second half.
10116984|NCT04433741|Other|Placebo, Then Oxytocin|Placebo administered intravenously for the first half of the study and then will receive intravenous oxytocin for the second half.
10116985|NCT04433572|Active Comparator|Temsirolimus|Temsirolimus delivered to adventitia and perivascular tissue after primary revascularization
10116986|NCT04433572|Placebo Comparator|Placebo|Saline placebo delivered to adventitia and perivascular tissue after primary revascularization
10116987|NCT04433546|Experimental|High Dose (100 mg) Group|High: Pemziviptadil (PB1046) 100 mg subcutaneous (SC) weekly for 4 weeks or until hospital discharge
10116988|NCT04433546|Experimental|Middle Dose (40 mg) Group|Middle: Pemziviptadil (PB1046) 40 mg SC weekly for 4 weeks or until hospital discharge
10116989|NCT04433546|Placebo Comparator|Low Dose (10 mg) Control Group|Low Control: Pemziviptadil (PB1046) 10 mg SC weekly for 4 weeks or until hospital discharge
10116990|NCT04433507|Active Comparator|Sleeve Gastrectomy group|This group will receive a Sleeve Gastrectomy only, a mainly restrictive procedure which consists in creating a narrow tube-like stomach based on its lesser curvature.
10116991|NCT04433507|Experimental|Sleeve Gastrectomy + Hiatal Hernia repair group|This group will receive a Sleeve Gastrectomy combined with hiatal hernia repair. Hiatal Hernia repair consists of a peri-esophageal dissection proximal to the diaphragmatic crura to achieve an intra-abdominal esophageal length of 2-3 cm. The pillars will then be closed anteriorly and posteriorly using nonabsorbable sutures.
10116992|NCT04433559|Active Comparator|Group Active Tadalafile|One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.
10116993|NCT04433559|Placebo Comparator|Group Placebo|One oral tablet of placebo daily for 14 weeks of treatment.
10116994|NCT04433637|Experimental|Nutrition Group|Pregnant women in the first experimental group were provided to consume cake and fruit juice 30 minutes before the NST procedure.
10116995|NCT04433637|Experimental|Video Group|The video, which contains information about the developments and changes occurring in the mother and the fetus during pregnancy, was watched for 15-20 minutes during the NST procedure, accompanied by music that provided relaxation.
10116996|NCT04433637|No Intervention|Control Group|No intervention was applied to the pregnant women in the control group.
10116997|NCT04433377|Experimental|Suprascapular nerve block group|"Suprascapular nerve block will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the suprascapular fossa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 22 gauge 90-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
10116998|NCT04433377|Experimental|Subacromial injection group|"Subacromial injection will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the subacromial bursa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 21 gauge 38-mm injector.~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
10116999|NCT04433208|Experimental|Cohort 1 (PPI + probiotic)|Subjects in Cohort 1 will take a PPI and a probiotic orally once daily on Days 1-7. Subjects will mix the probiotic in an aqueous diluent supplied by the pharmacy and ingest between 1-2 hours after taking a PPI.
10117000|NCT04433208|Experimental|Cohort 2 (Complex oligosaccharide + PPI)|Subjects in Cohort 2 will take the complex oligosaccharide orally twice daily on Days 1-14. On Days 1-7, the first dose of the complex oligosaccharide will be taken between 1-2 hours after taking a PPI. On Days 8-14, subjects will not take a PPI prior to the complex oligosaccharide.
10117001|NCT04433208|Experimental|Cohort 3-6 (Complex oligosaccharide + PPI +probiotic)|Subjects in Cohort 3, 4, and 6 will take a complex oligosaccharide orally twice daily (doses will vary per cohort) on Days 1-14 in combination with a probiotic orally once daily on Days 1-7. Cohort 5 will undergo the same dosing regimen a second time on days 29-43
10117002|NCT04433364||Screening group|"a general population of women giving birth, called screening group included at routine antenatal visits, their partners, and children"
10117003|NCT04433364||COVID-19 group|"group of women testing positive for SARS-CoV-2 or falling ill with COVID-19, called COVID-19 group, their partners, and children"
10117004|NCT04433169|Experimental|Experimental group|ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1.
10117005|NCT04433169|Active Comparator|Control group|The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy).
10117006|NCT04433416||hypertension|After admission, two or more of the three blood pressure measurements under the same period of calm state that met hypertension, and the patient reported that he had a history of hypertension and that the blood pressure reached the standard of hypertension in the previous non-medication state was included in the hypertension group
10117007|NCT04433416||non-hypertension|Patients who denied the history of hypertension and were not taking antihypertensive drugs after admission and had normal blood pressure measurements were included in the non-hypertensive group
10117008|NCT04433351|Experimental|SE cohort|Patients in the SE cohort will carry out first the simple rehabilitation protocol (S, 4 weeks) followed by enriched rehabilitation (E, 4 weeks).
10117009|NCT04433351|Experimental|ES cohort|Patients in the ES cohort will carry out first the enriched rehabilitation protocol (E, 4 weeks) followed by simple rehabilitation (S, 4 weeks).
10117010|NCT04433247|Experimental|Peer Led Group Intervention|In the virtual peer-led group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
10117011|NCT04433247|No Intervention|Wait-List Control|Participants will be placed on a wait list for four weeks, an equal span of time of participants in the peer led group intervention. At four weeks, participants will complete their post-test assessment, then receive the intervention.
10117012|NCT04433156|Experimental|VR-CAP|Rituximab, 375 mg/m2, Intravenous administration on day 0, Bortezomib, 1.3 mg/m2 hypodermic injection on day 1 and 4, combined with regimen: Cyclophosphamide, Epirubicin, and Prednisone: repeated every 3 weeks, up to 6 cycles.
10117013|NCT04433325||Patients transferred|Patients transferred from Paris's Intensive Care Units
10117014|NCT04433325||Patients not transferred|Patients admitted in Intensive Care Units with no transfer from Paris
10182688|NCT03772015||Study|"Patients who had the operation of laparoscopic lateral mesh suspension for apical prolapse will have magnetic resonance imaging preoperatively and at postoperative 6th month"
10182689|NCT03772015||Control|Multiparous, sexually active participants who have grade 0 or 1 (asymptomatic if exists) prolapse will have magnetic resonance imaging as a control group
10182690|NCT03772028|No Intervention|conventional surgery|Primary cytoreductive surgery without HIPEC
10182691|NCT03772028|Experimental|HIPEC|Primary cytoreductive surgery with HIPEC with cisplatin
10182692|NCT03772002|Experimental|HCV screening|
10182693|NCT03771924|Experimental|inorganic phosphate|"Experimental intervention:~Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling"
10182694|NCT03771924|Placebo Comparator|Placebo|Single dose of Sodium chloride in combination with a standardized meal and blood sampling
10182695|NCT03771781|Other|Empagliflozin Tablets|The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
10182696|NCT03771781|Other|Empagliflozin Tab 25 MG|The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
10182697|NCT03771768|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.
10182698|NCT03771768|Experimental|Diode laser|Diode laser 980 nm & 100mWatt.
10182699|NCT03772080|Experimental|Early counseling of prematurity in high-risk pregnancies|
10117015|NCT04433117|Other|Control Group|Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
10117016|NCT04433117|Experimental|Test Group|The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
10117017|NCT04433221|Experimental|Multiple sarcoma-specific CAR-T cells|Patients who have confirmed surface antigens including GD2, PSMA, Her2, CD276 or other markers
10117018|NCT04433143|Experimental|oral medication|just oral minocycline hydrochloride capsules (100mg/ time, once per day),
10117019|NCT04433143|Experimental|Intense Pulsed Light single filter|Intense pulsed Acne filter
10117020|NCT04433143|Experimental|Intense Pulsed Light two filters|Intense pulsed light Acne filter and another filter (560nm, 590nm or 640nm filter)
10117021|NCT04433078|Experimental|Doxycycline|Participants receive 100 MG BID for 21 days
10117022|NCT04433078|Placebo Comparator|Placebo|Participants receive Placebo BID for 21 days
10117023|NCT04433104|Experimental|Treatment (UC-MSC trasnplatation)|1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure
10117024|NCT04433104|Other|control arm|drug therapy according to Vietnamese MOHS procedure
10117025|NCT04432896|Experimental|New dietary protocol|Exclusion of food containing nickel (duration: 4 weeks) + gradual weekly reintroduction of food containing nickel (duration: 4 weeks) under the supervision of a trained dietician who monitors symptoms related to systemic nickel allergy syndrome.
10117026|NCT04432896|Active Comparator|Traditional dietary protocol|Exclusion of foods containing nickel without monitoring for symptoms related to systemic nickel allergy syndrome by a trained dietician.
10117027|NCT04432714|Experimental|R2-DA-EPOCH|
10117028|NCT04432805|Experimental|Pregnant women|Pregnant women suspected of COVID-19
10117029|NCT04432818|Experimental|Pack Health's digital life coaching (DLC)|Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up
10117030|NCT04432883|Active Comparator|Experimental: Active cathodal tDCS + Speech-language training|In this arm, 25 patients with stroke induced Aphasia will undergo 15 sessions of active tDCS (x 30 minutes of stimulation) combined with 1 hour simultaneous speech-language training on consecutive weekdays.
10117031|NCT04432883|Sham Comparator|Comparator: Placebo cathodal tDCS + Speech-language training|In this arm, 25 patients with stroke induced Aphasia will undergo 15 sessions of sham tDCS (x 30 minutes sham) combined with 1 hour simultaneous speech-language training on consecutive weekdays..
10117032|NCT04432948||Maternal Group|Pregnant women administered into a maternity public hospital in labour (vaginal delivery, caesarean section)
10117033|NCT04432974|Experimental|ACTIVA|ACTIVA closed-loop anesthesia control system
10117034|NCT04433091|Active Comparator|2-HOBA|2-Hydroxybenzylamine(2-HOBA) 250 mg three tabs TID (po) for seven days prior to ablation and 28 days post ablation.
10117035|NCT04433091|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for seven days prior to ablation and 28 days post-ablation
10117036|NCT04432688||Latuda®|Chinese schizophrenia patients who are receiving Latuda® in the real world
10117037|NCT04432753|Experimental|Decision aid with incidental findings information|Participants in this arm will view a video decision aid that include information on incidental findings in lung cancer screening.
10117038|NCT04432753|Active Comparator|Decision aid without incidental findings information|Participants in this arm will view a video decision aid that does not include information on incidental findings in lung cancer screening.
10117039|NCT04432740|Active Comparator|Below Arm Cast Group|All the patients were prepared in the supine position at the emergency department. For analgesia, we used the hematoma block technique with 3 cc of 2% prilocaine hydrochloride®. In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, the standard below arm cast was applied. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
10117040|NCT04432740|Active Comparator|Reverse Sugar Tong Group|In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, sugar tong splint made of 12 layers of plaster was performed by one person. The reverse sugar tong splint succeeds as a classic sugar tong splint by stabilizing the volar and dorsal aspects of the wrist and forearm, maintaining the same degree of immobilization. The splint fold is located distally at the first web space of the hand, which does not immobilize the elbow. In all the groups, the wrist immobilization position was the same; pronated forearm, 15-20° wrist flexion, ulnar deviation, and care was taken not to immobilize the metacarpophalangeal joints. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
10117041|NCT04432987|Experimental|Newly Diagnosed Patient Group (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
10117042|NCT04432987|Experimental|Patient Group Monitored by Mechanical Ventilation (n=30)|"I. Dornase Alpha treated group (n=15)~ii. Control group (n=15)"
10117043|NCT04433052|Experimental|Personalised prevention program (PPP)|Participants will be invited to return to the study site six times over a three year period to receive lifestyle coaching and exercise prescriptions. Eupropean Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications. Participants will also receive pharmaceutical treatment according to the ESC guideline for chronic coronary syndromes.
10117044|NCT04433052|No Intervention|Usual care (UC)|"Participants will be referred back to usual care provided by their treating physicians. It is anticipated that physicians will treat these participants according to local usual medical practices. Patients randomized to UC group will not receive any treatment recommendations nor restrictions by the study investigators or nurses.~Randomized UC patients are invited to site visits twice over a three year period."
10117045|NCT04432779||Women tested positive to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~Follow up end at 1 month post delivery."
10117046|NCT04432779||Women tested negative to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.~No follow up after delivery."
10117047|NCT04432779||Newborns from women tested positive|"Newborns born to mothers who had a positive nasal swab or a positive serology during pregnancy or at delivery and who consented the follow up study.~Follow up end at 3 years of age."
10117048|NCT04432779||Newborns from women tested negative|"Newborns born to mothers who had no COVID-19 infection during pregnancy or at delivery and who consented the follow up study. These control children will be matched with children from the other group for gestational age and ethnicity.~Follow up end at 3 years of age."
10117049|NCT04432909||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UroCAD analysis, the result will be compared with cytology and FISH test.
10117050|NCT04432909||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD analysis.
10117051|NCT04432675|Experimental|hydroxyethl starch group|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
10117052|NCT04432675|Active Comparator|The control group|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
10117053|NCT04432766|Experimental|Low dose|
10117054|NCT04432766|Experimental|Medium dose|
10117055|NCT04432766|Experimental|High dose|
10117056|NCT04432662|Active Comparator|Erythropoietin|Administration of Erythropoietin (1000 U/kg) IV once a day x 5 doses along with cooling therapy
10117057|NCT04432662|Active Comparator|Darbepoetin Alpha|Administration of Darbepoetin Alpha (10 mcg/kg) IV single dose given less than 24 hours of age along with cooling therapy
10117058|NCT04432662|No Intervention|Standard of care|Standard of care: Cooling only
10117059|NCT04432571|Active Comparator|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC)
10117060|NCT04432571|Experimental|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT)
10117061|NCT04432571|Experimental|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV)
10117062|NCT04432571|Experimental|E-NAV/SOC-OIC|Electronic Navigation/SOC-OIC
10117063|NCT04432571|Experimental|E-NAV/CCT|E-Nav/Conditional cash transfer
10117064|NCT04432571|Experimental|E-NAV/IP-NAV|E-Nav/In-Person Peer Navigation
10117065|NCT04432519|Experimental|Group CA|Customized healing abutment inserted in immediate implant placement.
10117066|NCT04432519|Active Comparator|Group CM|Resorbable Collagen Membrane for socket closure in immediate implant placement.
10117067|NCT04432506|Experimental|Treatment (cyclophosphamide, fludarabine, axi-cel, anakinra)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra SC on days 0-6 in the absence of disease progression or unacceptable toxicity.
10117068|NCT04432454|Experimental|Treatment|Women who have locally advanced or metastatic ER+/HER2- breast cancer and disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation
10117069|NCT04432480||Children|0-15 years old children undergoing surgery under general anesthesia
10117070|NCT04432649|Experimental|Effectiveness of 4SCAR-276 T cells|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
10117071|NCT04432389|Experimental|ALLOB|Single injection of ALLOB at fracture site (4 ml)
10117072|NCT04432389|Placebo Comparator|placebo|Single injection of Placebo at fracture site (4 ml)
10117073|NCT04432363|Active Comparator|M1 stimulation|A 20 minutes 1mA direct current stimulation over left M1.
10117074|NCT04432363|Active Comparator|M1+DLPFC stimulation|A 20 minutes 1mA direct current stimulation over left M1 and 1mA direct current stimulation over left DLPFC.
10117075|NCT04432363|Sham Comparator|Sham stimulation|A 20 minutes sham stimulation where the device only is working first 30s and last 30s of the intervention and have a 10 seconds fade out in intensity at each ramp.
10117076|NCT04432415|Experimental|Group Silver Diamine Fluoride|Participants receive Annual applications of 38% SDF solution and semestral applications of artificial saliva and a personalized dental health education program.
10117077|NCT04432415|Experimental|Group Sodium Fluoride Varnish|Participants receive semestral applications of Sodium Varnish Fluoride and a personalized dental health education program.
10117078|NCT04432415|Placebo Comparator|Placebo|Participants receive semestral apllications of artificial saliva and a personalized dental health education program.
10117079|NCT04432636|Other|Prospective French population based cohort|"Data collection of environmental factors at the recruitment~Collection of maternal feces~Collection of infant feces:~A food questionnaire completed by the mother the week after delivery, a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year and a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years~A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day~The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up"
10117080|NCT04432558||Preoperative anxiety level|
10117081|NCT04432558||Postoperative pain and analgesic consumption|
10117082|NCT04432402|Experimental|Lenalidomide in Combination With R-GemOx|Lenalidomide 10mg、15mg、20mg、25mg qd PO d1-7 Rituximab 375mg/m2 ivd d0 Gemcitabine 1g/m2 ivd d1 Oxaliplatin 100mg/m2 ivd d1 every14 days as a cycle
10117083|NCT04432428|Experimental|sufentanil sublingual tablet|sufentanil sublingual 15µg tablets
10117084|NCT04432324|Experimental|Intravenous Immune Globulin + Standard Medical Treatment|Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
10117085|NCT04432324|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29
10117086|NCT04432181||Group 1, astigmatic patients with amblyopia|astigmatic children with amblyopia
10117087|NCT04432181||Group 2, astigmatic patients without amblyopia|astigmatic children without amblyopia
10117088|NCT04432194|No Intervention|Control group|The subjects in this group will receive the usual care, which includes the non-pharmacology recommendations by the European Society of Cardiologists 2006 (1) and COPD guides for treatment (6), both founded in the sodium and liquids restriction.
10117089|NCT04432194|Active Comparator|Pulmonary Rehabilitation Group|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months.
10117090|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus HMB (4g)|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
10117091|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus citrulline (3g)|Patients in this group will receive pulmonary rehabilitation specified by the doctor specialized in rehabilitation according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
10117092|NCT04432220|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
10117093|NCT04432220|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
10117094|NCT04432129|Experimental|IBBIS II|Integrated Mental Health Care and Vocational Rehabilitation
10117095|NCT04432129|Active Comparator|Service As Usual|Standard vocational rehabilitation and treatment
10117096|NCT04432142||Proton|Patients receiving proton therapy
10117097|NCT04432142||Photon|Patients receiving photon therapy in 4 fractions or less
10117098|NCT04432116|Experimental|virtual reality 1|the subject is in a virtual room and is asked to emit a retrospective time duration judgement at the end of the session
10117099|NCT04432116|Experimental|virtual reality 2|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible while the background of the virtual environment is a starfield with standard speed vs. self-determined speed vs. static stars
10117100|NCT04432116|Experimental|virtual reality 3|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible.Asynchronous distracters vs. synchronous distracters, vs no distracters are displayed while the subjects wait for the target
10117101|NCT04432168|Experimental|Fetoscopic Laser Surgery|fetoscopic laser coagulation of the vascular anastomoses at the placental surface
10117102|NCT04432168|Other|Standard Treatment|Expectant management, IUT (with or without PET), preterm delivery
10117103|NCT04432259|Experimental|Arm B: Oral Dexamethasone|Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days
10117104|NCT04432259|Placebo Comparator|Arm A: Placebo|Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days
10117105|NCT04432233|Experimental|Intravenous therapy|Subjected enrolled will receive (a) a 10-day intravenous triple therapy containing esomeprazole 40 mg thrice a day, metronidazole 500 mg twice a day and levofloxacin 500 mg once a day and (b) esomeprazole 20 mg twice a day taken orally for 8 weeks.
10117106|NCT04432337|Experimental|Type 2 diabetes patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for TD2 patients after cardiac surgery with extracorporeal circulation .
10117107|NCT04432337|Active Comparator|Non-diabetic type 2 patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for non-diabetic type 2 patients after cardiac surgery with extracorporeal circulation
10117108|NCT04432103|Experimental|Severe COVID-19 pneumonia|Hospitalized patients with SARS-CoV 2 severe infection will receive an anti SARS-CoV 2 Convalescent Plasma
10117109|NCT04432103|Experimental|Critical COVID- 19 pneumonia|Hospitalized patients with SARS-CoV 2 critical infection will receive an anti SARS-CoV 2 Convalescent Plasma
10117110|NCT04432155|Experimental|NBTX-001|Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
10117111|NCT04432155|Placebo Comparator|Placebo|Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume.
10117112|NCT04432246|Experimental|bilateral SMA|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
10117113|NCT04432298|Experimental|Pamrevlumab|Pamrevlumab: 35 milligrams/kilogram (mg/kg) on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
10117114|NCT04432298|Experimental|Placebo|Pamrevlumab-matching placebo on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
10117115|NCT04432012|Experimental|arm-A Intra-venous dexamethasone|9 mg of Intra-venous dexamethasone
10117116|NCT04432012|Experimental|arm-B intra-articular dexamethasone|9 mg of intra-articular dexamethasone
10117117|NCT04432012|No Intervention|arm-C routine|No steroid supplementation or other drugs will be added to the routinely performed anaesthesia protocol in the control group
10117118|NCT04431895|Experimental|tofacitinib 5mg twice a day|
10117119|NCT04432064|Experimental|Phase 3 Active TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation. Participants will receive stimulation for 60 minutes on one day.
10117120|NCT04432064|Sham Comparator|Phase 3 Sham TI-NDBS|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds.
10117121|NCT04432064|Active Comparator|Phase 4 Traditional tDCS|Participants assigned to this condition will receive traditional transcranial direct current stimulation for 60 minutes for 5 days.
10117122|NCT04432064|Experimental|Phase 4 TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation for 60 minutes for 5 days and will be compared to sham stimulation and tDCS.
10117123|NCT04432064|Sham Comparator|Phase 4 Sham stimulation|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds. Participants will be in the scanner for 60 minutes for 5 days. This will be used as the control condition and compared with TI-NDBS and tDCS.
10117124|NCT04432025|Active Comparator|Control|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
10117125|NCT04432025|Experimental|Intervention|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
10117126|NCT04432051|Placebo Comparator|GRUP Control|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis.
10117127|NCT04432051|Active Comparator|GRUP Ultrasonography|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis. However, the lung of the patient will be evaluated by ultrasound and the position to use the lung capacity most appropriately will be given.
9668876|NCT04724902|Sham Comparator|Sham Group|For Sham application, the volunteer must remain supine on a stretcher, with both lower limbs extended and relaxed. Elastic bandages will be used (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity) . The bandage will involve the knee from the distal (tibial tuberosity) to the proximal (femoral condyles), respecting the blood flow of the venous return. However, in this group, no compression force will be performed, maintaining the pressure at 00 mmHg according to a previous reliability study. The procedure will be carried out for 20 minutes, once a day, for 4 consecutive days.
10117128|NCT04431648|Experimental|MRg-FUS MB Treatment|Patients with head and neck cancer will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
10117129|NCT04431843|Experimental|Spirulina maxima extract|Spirulina maxima extract for 1.5 g/day
10117130|NCT04431843|Placebo Comparator|Placebo|Spirulina maxima extract for 0 g/day
10117131|NCT04431713|Experimental|Exenatide|
10117132|NCT04431713|No Intervention|Standard of care|
10117133|NCT04431960|Active Comparator|low-BC Group|consume: 1) one tablet containing 392 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
10117134|NCT04431960|Active Comparator|high-BC Group|consume: 1) two capsules containing 392 mg BC extract per tablet (total 784 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
10117135|NCT04431960|Placebo Comparator|Control Group|consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
10117136|NCT04431986||NuAge participants|All Individuals of the NuAge study who agreed to be part of the NuAge Database for future research purposes
10117137|NCT04431921||Lung cancer patients|Lung cancer survivors who had stable conditions and routine follow-up at Hacettepe University Oncology Hospital
10117138|NCT04431921||Healthy subjects|No health problems related or affect outcome measure parameters examined in this study.
10117139|NCT04431856|Experimental|Immediate Condition|Participants in the Immediate Condition group will receive a total of 4 sessions of Unified Protocol for COVID-19 Parenting Stress (UP-COVID) intervention
10117140|NCT04431856|Active Comparator|Delayed Condition|Participants in the Delayed Condition group will receive the Self Help Guide (SHG) by the National Child Traumatic Stress Network (NCTSN). They will then receive the UP-COVID intervention following their week 6 assessment
10117141|NCT04431791||Regorafenib|
10117142|NCT04431791||Fruquintinib|
10117143|NCT04431817||Left transtibial|Left below knee amputation- 25
10117144|NCT04431817||Right transtibial|Right below knee amputation- 25
10117145|NCT04431817||Left transfemoral|Left above knee amputation- 25
10117146|NCT04431817||Right transfemoral|Right above knee amputation- 25
9668877|NCT04724902|No Intervention|Control Group|The Control group will be composed of individuals with knee osteoarthritis, who make up the study's waiting list and will carry out evaluations at the same time intervals as the other groups, but will not receive any type of intervention and will be instructed not to start another treatment during their participation.
9668878|NCT04716387||Chlorfenapyr ITN|These study districts will receive Interceptor G2 ITNs during the mass distribution campaign.
9668879|NCT04716387||Piperonyl butoxide ITN|This study district will receive piperonyl butoxide ITN during the mass distribution campaign.
9668880|NCT04716387||Standard LLIN|These study districts will receive standard ITNs during the mass distribution campaign.
10117147|NCT04431817||Provider|Provider- 15
10117148|NCT04431973|Experimental|Shoulder prothesis|Evaluate the performance of the Medacta Shoulder System total reverse shoulder prothesis
10117149|NCT04432038||General population of adults from about 30 countries|Data will be collected in general population of adults from about 30 countries. Questionnaires contain also questions about the occurrence of chronic illnesses, being a professional athlete, etc. to control all such aspects.
10117150|NCT04432038||General population of adults from Poland|
10117151|NCT04432038||General population of adults from Germany|
10117152|NCT04432038||General population of adults from China|
10117153|NCT04432038||General population of adults from Vietnam|
10117154|NCT04432038||General population of adults from Spain|
10117155|NCT04432038||General population of adults from Brazil|
10117156|NCT04432038||General population of adults from Croatia|
10117157|NCT04432038||General population of adults from Ethiopia|
10117158|NCT04432038||General population of adults from France|
10117159|NCT04432038||General population of adults from Indonesia|
10117160|NCT04432038||General population of adults from Iran|
10117161|NCT04432038||General population of adults from Sri Lanka|
10117162|NCT04432038||General population of adults from USA|
9668881|NCT04716387||Pyriproxyfen ITN|This study district will receive Royal Guard ITNs during the mass distribution campaign.
10117163|NCT04432038||General population of adults from Italy|
10117164|NCT04432038||General population of adults from South Africa|
10117165|NCT04432038||General population of adults from Portugal|
10117166|NCT04432038||General population of adults from Norway|
10117167|NCT04432038||General population of adults from Lithuania|
10117168|NCT04432038||General population of adults from Romania|
10117169|NCT04432038||General population of adults from Pakistan|
10117170|NCT04432038||General population of adults from Ukraine|
10117171|NCT04432038||General population of adults from India|
10117172|NCT04432038||General population of adults from Japan|
10117173|NCT04432038||General population of adults from Russia|
10117174|NCT04432038||General population of adults from Bangladesh|
10117175|NCT04432038||General population of adults from Nigeria|
10117176|NCT04432038||General population of adults from Egypt|
9965910|NCT01254539|Experimental|Intrathecal infusion of autologous bone marrow stem cells|Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
9965911|NCT01254539|Placebo Comparator|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
9965912|NCT01254578|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo blood and bone marrow biopsies and aspirate collection at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies. Buccal swab samples are also collected at baseline and analyzed for genetic polymorphisms."
10117177|NCT04431674|Experimental|MRg-FUS MB Treatment|Patients with locally advanced breast cancer (LABC) and chest wall tumours will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
10117178|NCT04431934|No Intervention|CONTROL|No intervention arm
10117179|NCT04431934|Active Comparator|PROBIOTIC|
10117180|NCT04431934|Active Comparator|FMT REGIMEN|
10117181|NCT04431882|Experimental|optic nerve sheath fenestration|Leukemic patients mainly those suffering from acute lymphoblastic leukemia.
10117182|NCT04431765|Active Comparator|Patient for Eye Movement desensitization Reprocessing therapy|Patient with post-traumatic Stress Disorder will receive Eye Movement Desensitization reprocessing therapy
10117183|NCT04431765|Placebo Comparator|patients for Trauma-Centred Cognitive and Behavioural Therapy|Patients with post-traumatic Stress Disorder will receive Trauma-Centred Cognitive and Behavioural Therapy
10117184|NCT04431570|Experimental|rTMS over M1 region|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is M1 region.
10117185|NCT04431570|Experimental|rTMS over supplementary motor area (SMA)|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is SMA region.
10117186|NCT04431570|Sham Comparator|sham stimulation|
10117187|NCT04431687|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
10117188|NCT04431687|Experimental|Sequence 2|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days"
10117189|NCT04431687|Experimental|Sequence 3|"Period 1: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
10117190|NCT04431687|Experimental|Sequence 4|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).~Period 2: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets)."
10117191|NCT04431622|Experimental|Effects of hearing aid algorithms|Neural processing and cognitive effort will be assessed in individuals who listen to stimuli generated with linear and fast-acting compression hearing aid algorithms and with actual hearing aids.
10117192|NCT04431401|Experimental|rTMS treatment group|The participants will be divided into the rTMS treatment group and the sham treatment group by means of randomized methods.The protocol of the treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
10117193|NCT04431401|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
10117194|NCT04431596|Active Comparator|Cooling|Participants will be actively cooled during rest breaks.
10117195|NCT04431596|No Intervention|No Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
10117196|NCT04431492||coronary artery bypass|
10117197|NCT04431492||thoracic surgery|
10182700|NCT03772080|No Intervention|Standard counseling of prematurity in high-risk pregnancies|
10182701|NCT03771872|Experimental|Virtual Prism Adaptation Therapy|This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
10117198|NCT04431323|Experimental|biopsychosocial intervention|"Young adults with MS will receive an intervention (group setting) composed of physical activities (duration: 10-12 weeks; either dancing or walking) and psychosocial interventions (6-8 encounters).~[The intervention will start as soon as 8-10 patients will have been enrolled. A waiting list will be then created and patients contacted when the subsequent group starts. This waiting list does not serve as control group.~One or more groups, respectively for the psychological intervention and the physical activities, may start at the same time but on different days, considering also the results of the co-creation phase.]"
10117199|NCT04431440||Methicillin resistant staphylococcus aureus|
10117200|NCT04431440||vancomycin resistent staphylococcus aureus|
10117201|NCT04431128||study group|Adenoid hypertrophy
10117202|NCT04431128||Control group|UTI, GE, vomiting, diarrhea
10117203|NCT04431284||Obese patients with binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
10117204|NCT04431284||Obese patients without binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
10117205|NCT04431349||ticagrelor|The patient with acute myocardial infarction received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
10117206|NCT04431349||clopidogrel|The patient with acute myocardial infarction received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
10117207|NCT04431583||2008-2012 Participants|Participants who underwent bariatric surgery between 2008 and 2012 (inclusive).
10117208|NCT04431583||2013-2016 Participants|Participants who underwent bariatric surgery between 2013 and 2016 (inclusive).
10117209|NCT04431583||2017- 2018 Participants|Participants who underwent bariatric surgery between 2017 and 2018 (inclusive).
10117210|NCT04431388||SIPB (block)|Patients undergone nephectomy and who received SIPB as analgesia
10117211|NCT04431388||QL block|Patients undergone nephectomy and who received QL as analgesia
10117212|NCT04431232|Experimental|Band Ligation|Band ligation of gastric body for weight loss
10117213|NCT04431336||younger aortic dissection or aneurysm patients|this is an observation cohort study about younger aortic dissection or aneurysm patients without intervention.
10117214|NCT04431531|Active Comparator|yogatherapy-EMDR|one of the two groups will have yogatherapy treatment and Eye movement desensibilization reprocessing (EMDR)
10117215|NCT04431531|Active Comparator|waiting list and EMDR|The other group will have Eye movement desensibilization reprocessing
10117216|NCT04431167|Experimental|Living well with Lupus Group|A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
10117217|NCT04431167|No Intervention|Usual Care Group|This group will receive all regular medical care and advice healthy
10117218|NCT04431310||Serial seroconversion measurements in hospital employees|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
10117219|NCT04431427|Active Comparator|Partially Covered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
10117220|NCT04431427|Active Comparator|Uncovered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
10117221|NCT04431609||CAROtid WEB associated with cerebral infarction|french multicentric cohort that collects retrospectively and prospectively purely observational data on patients with cerebral infarction associated with a carotid web. Diagnostic, therapeutic or follow-up strategies will be at the discretion of the Stroke Unit taking care of the patient.
10117222|NCT04431271||Robot-assisted laparoscopy|Patients who underwent robot-assisted groin hernia repair
10117223|NCT04431271||Conventional laparoscopy|Patients who underwent conventional laparoscopic groin hernia repair
10117224|NCT04431193|Experimental|Oxytocin 4 picogram/millilitre|Oxytocin infused to maintain serum concentration of 4 picogram/millilitre
10117225|NCT04431193|Experimental|Oxytocin 16 picogram/millilitre|Oxytocin infused to maintain serum concentration of 16 picogram/millilitre
10117226|NCT04431193|Experimental|Oxytocin 64 picogram/millilitre|Oxytocin infused to maintain serum concentration of 64 picogram/millilitre
10117227|NCT04431193|Experimental|Oxytocin 256 picogram/millilitre|Oxytocin infused to maintain serum concentration of 256 picogram/millilitre
10117228|NCT04431245||Stop antiviral|HBeAg-negative non-cirrhotic CHB patients on long-term NA ≥3 years will be identified. Only those who have undetectable serum HBV DNA by the conventional assay (Cobas Taqman, Roche Diagnostics, Branchburg, NJ) which has a lower limit of detection (LLOD) of 10 IU/mL will be recruited. CHB patients were treated with potent oral NA (i.e. tenofovir or entecavir). All recruited patients will have written informed consent for participation of study. Patients with HCC, cirrhosis, history of liver transplantation, or on immunosuppressants, will be excluded.
10182702|NCT03771872|Sham Comparator|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
10182703|NCT03771599|Active Comparator|Control group|"Routine physical therapy~[Time Frame: Twelve weeks]"
10182704|NCT03771599|Experimental|Intervention group|"Traditional massage + Routine physical therapy~[Time Frame: Twelve weeks]"
10182705|NCT03772093|Active Comparator|Patients with manual massage therapy|30 patients were randomly assigned to massage therapy. The procedures were performed for ten days, with weekend break. Manual massage of lumbar area was performed by certified massage therapist with the typical course of the procedure. The technique was consisted of stroking, kneading, grinding, patting and shaking. The procedure lasted twenty minutes.
10117229|NCT04431297|Other|Health Care Workers|Voluntary participation in the virtual presentations
10117230|NCT04431362|No Intervention|Baseline|Participants will not listen to music for 5 to 15 days based on the baseline duration they were assigned.
10117231|NCT04431362|Experimental|Intervention|Participants will listen to music for 3 weeks.
10117232|NCT04431206|Experimental|Oxytocin|Oxytocin administered by IV infusion
10117233|NCT04431115||Stakeholders|"Academic experts, Politicians and officials of state ministries of health and education and teachers.~Interviews will be conducted for academic experts, politicians and officials of state ministries of health and education.~Headteachers and physical education teachers will be administered questionnaires."
10117234|NCT04431115||Parents|Parents of the primary school children to be recruited for the study. Focus group discussion in a group of 3 of ten in each group.
10117235|NCT04431115||Primary school children aged 6-12 yrs.|"A cross sectional survey of the biographical data, socio economic status, physical activity level through appropriate questionnaires will be done.~A pedometer will be attached to the waist of each of the participants for a consecutive 7 days to objectively determine the level of their physical activity."
10117236|NCT04431154|No Intervention|Experimental: Usual care|Participants randomized to this arm will receive the standard of care (SOC) following the STAR program protocol in various sites in Johannesburg. This will include provision of an HIV self-screening test kit, the standard linkage officer follow-up call following report of a positive HIVSS test and an invitation to i) participate in study visit 1 to have their positive HIVSS result confirmed and complete blood collection for viral load PCR testing and to ii) participate in study visit 2 at 6 months for Viral Load PCR. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
10117237|NCT04431154|Experimental|Experimental: Incentives and linkage promotion|Participants randomized to this arm will receive the same standard HIV self-screen test kit and linkage officer follow-up call including the invitation to i) participate in study visit 1 and ii) study visit 2. In addition, they will receive a financial incentive if they complete a confirmatory HIV test at visit 1 and if they demonstrate viral suppression at study visit 2, approximately 6 months after positive HIVSS result. They will also receive monthly reminders and incentives to pick up HIV medication. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
10117238|NCT04431180|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors'life saving donation during 2019-nCoV epidemic.
10117239|NCT04431180|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
10117240|NCT04431180|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
10117241|NCT04431180|Placebo Comparator|SMS with blood donor day greeting|SMS content in this group will be about SMS with blood donor day greeting.
10117242|NCT04431050||Suspected influenza or other respiratory viral infection.|"Any adult presenting to the Accident & Emergency department with influenza like illness or a febrile illness associated with symptoms such as cough, sore throat or rhinorrhoea, and for whom a respiratory viral screen is clinically indicated.~For the purposes of this study one nasal swab will be taken from consenting adults."
10117243|NCT04430790|Experimental|Doxapram|Blinded doxapram (2mg/ml, in glucose 5%) loading dose of 2.0 to 2.5 mg/kg administered in 5 to 10 minutes, followed by a continuous infusion of 0.5 - 1.0 mg/kg/hr ('www.kinderformularium.nl') as long as needed. Therapy is down titrated or stopped based on the patients' respiratory condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons.
10117244|NCT04430790|Placebo Comparator|Placebo|Placebo (glucose 5%) will also be administered with a loading dose and continuous infusion (in equal amounts of fluid as in experimental arm) by intravenous or gastro-intestinal infusion. The treatment protocol will be equal to the protocol in the doxapram arm.
10117245|NCT04430777|Placebo Comparator|Placebo group|No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
10117246|NCT04430777|Experimental|Intravenous group|A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
10117247|NCT04430777|Experimental|Subcutaneous group|"A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow:~4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine.~6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine."
10117248|NCT04431089|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
10117249|NCT04430907||Vaccine Accepting|This group will receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
10117250|NCT04430907||Vaccine Rejecting|This group will not receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
9668882|NCT04713657|Active Comparator|Propranolol|The target dose of Propranolol hydrochloride for this study target dose for this study will be 4 mg/kg/day divided in 4 doses. The concentration of propranolol solution is 20 mg/5 mL. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with propranolol will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
9965913|NCT01254617|Experimental|Treatment (lenalidomide and cetuximab)|Patients receive lenalidomide PO QD on days 1-21 and cetuximab IV over 1-2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10182706|NCT03772093|Active Comparator|Patients with Trabert current therapy|30 patients were randomly assigned to Trabert current therapy. The Trabert current was administered by 143 frequency, time of 2 ms impulse, time of break 5 ms. The current was generated by Pulsotronic ST-6D device (ZAMED©). The electric pads were placed on the lumbar area, in the middle part of spine. The anode in the lower part, near to buttocks. The intensity of current was regulated between 15-25 mA. The time of procedure lasted fifteen minutes.
10117251|NCT04431102|Experimental|PILATES METHOD|"It was intended the Pilates program were low supervision and easily realizable by all patients, which implied flexibility in the schedule. In this sense the sessions of Pilates was adjusted to these assumptions and the Pilates monitor offered several schedules on diferent days of the week.~The pregnant women assigned to the intervention group were supervised by the midwifery of reference and trained by a Pilates monitor who explained the training program. The women received eight sessions of Pilates, given with a frequency of two classes per week and one hour of duration during a period of four weeks. The exercises for each session were determined beforehand. In addition, the participants maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~The therapeutic control were carried out by telephone call and clinical history review between the eighth and tenth day postpartum."
10117252|NCT04431102|No Intervention|MATERNAL EDUCATION|"The control group maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~Therapeutic control was carried out by phone call and review of the clinical history between the eighth and tenth day postpartum."
10117253|NCT04430764|Experimental|smoker|
10117254|NCT04430764|Active Comparator|non-smoker|
10117255|NCT04430920|Active Comparator|Intensive intraoperative blood pressure management|
10117256|NCT04430920|Placebo Comparator|Conventional intraoperative blood pressure management|
10117257|NCT04430868|Experimental|LRP group|The participants in LRP group receive lifestyle redesign program plus treatment as usual. The LRP intervention consisted of one 90-minute session each week for 10 weeks
10117258|NCT04430868|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as LRP group.
10117259|NCT04431037|Experimental|Early oral feeding group(A)|Patients admitted in the HDU postoperatively.NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
10117260|NCT04431037|No Intervention|Traditional postoperative care group(B)|Patients in this group were managed traditionally
10117261|NCT04430933|Experimental|NC318 + Pemetrexed/Carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin
10117262|NCT04430933|Experimental|NC318 + Nab-paclitaxel/carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin
10117263|NCT04430933|Experimental|NC318 + Docetaxel|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel
10117264|NCT04430816|Active Comparator|modified chevrel technique|22 participant with large midline incisional hernia underwent repair by double mesh modification of chevrel's technique
10117265|NCT04430816|Active Comparator|ON LAY mesh hernioplasty|21 participant with large midline incisional hernia underwent repair by online mesh hernioplasty
10117266|NCT04430751|Active Comparator|Immediate start|
10117267|NCT04430751|Active Comparator|wait time control|
10117268|NCT04430803|Experimental|Hydrogen-rich water|"Hydrogen-rich water (Rejuvenation, HRW Natural Health Products Inc.)~8 ppm of hydrogen~Administered one dose two times per day on an empty stomach in the morning and at the evening"
10117269|NCT04430803|Placebo Comparator|Control water|"Tap water~0 ppm of hydrogen~Administered one dose two times per day on an empty stomach in the morning and at the evening"
10117270|NCT04430946|Experimental|Lean patients with type 1 diabetes|Test meal consumed within 10 minutes
10117271|NCT04430946|Experimental|Obese patients with type 1 diabetes|Test meal consumed within 10 minutes
10117272|NCT04430946|Active Comparator|Lean healthy control subjects|Test meal consumed within 10 minutes
10117273|NCT04430946|Active Comparator|Obese healthy control subjects|Test meal consumed within 10 minutes
10117274|NCT04430998|Experimental|Zinc L-Carnosine mouth rinse|Using undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 60 seconds, 3 times daily
10117275|NCT04430998|Active Comparator|Chlorhexidine|Using undiluted 10 ml of Chlorhexidine mouth rinse, retain for 60 seconds, 3 times daily
10117276|NCT04430998|Placebo Comparator|Water|Mouth rinsing with 10 ml of water, retain for 60 seconds, 3 times daily
10117277|NCT04430647|Experimental|phaco-UCP|Under peribulbar anesthesia, UCP was performed first, followed by phacoemulsification. UCP was performed using the same technique described before [18]. For all treatments, 2nd generation probe was used (EyeOP1, Eye Tech care; France) with the same parameters; Operating frequency was 21 MHz. Number of sectors activated was 6. Acoustic power was 2.45 W; duration of each shot was 8s; and the time between shots was 20s. The probe diameter (11, 12 or 13 mm) was determined according to the eye's biometric readings. The coupling cone was centered on the eye and kept in place with low vacuum suction, followed by introduction of the treatment probe inside the cone, then activation of the transducers by constantly pressing the foot switch. Once UCP treatment was finished, phacoemulsification was commenced
10117278|NCT04430647|Active Comparator|Phaco alone|A standard phacoemulsification was performed with 2.2 mm clear corneal incision, continuous curvilinear capsulorhexis, phacoemulsification and intrabagal implantation of foldable acrylic intraocular lens (AcrySof® IQ SN60WF monofocal; Alcon Laboratories Inc, Fort Worth, TX, USA) for all patients. Irrigation-aspiration was performed for at least 30 seconds to remove any viscoelastic from the anterior chamber. Reformation of the anterior chamber was done with balanced saline solution (BSS), followed by hydration of the corneal wound and side port.
10117279|NCT04430621|Experimental|FSH|FSH, 300 IU s.c.
9965914|NCT00660673|Experimental|1|Levodopa-carbidopa intestinal gel
10117280|NCT04430621|Placebo Comparator|Control|Placebo, s.c.
10117281|NCT04430673|Experimental|Home-School based VR trial|The VR system will be provided to each participant for a 2-week home- or school- based trial. No additional interventions.
10182707|NCT03771638|Experimental|DOT Diary Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
9965915|NCT01254682|Active Comparator|Hyaluronic acid sodium salt (1%, 20mg/2ml)|
9965916|NCT01254682|Other|Standard arthroscopic procedure|
10117282|NCT04430725||Observational (microwave ablation, wedge excision, CT)|Patients undergo standard care microwave ablation or wedge resection followed by contrast-enhanced CT imaging at 1, 6, 12, 18 and 24 months. Patients also complete questionnaires over 10-15 minutes at baseline up to 9 months.
10117283|NCT04431063|Experimental|Sutured Stump|The group consist of subject with distal stump suturing of perobeus longus agains peroneus brevis in ACL Reconstruction Case
9668883|NCT04713657|Placebo Comparator|Placebo|Placebo will be given in a volume that corresponds to the patient's weight. Additionally, labeled syringes will be provided to families for accurate weight-based dosing. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age. There is no current standard of care for pharmacologic therapy for infants with ToF. As such, there are no alternative treatments, and the placebo group is standard of care.
9668884|NCT04702568|Experimental|BCX9930|Intervention: Drug: BCX9930
9965917|NCT01254695|Active Comparator|Standard settings|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 210 μsec
10117284|NCT04431063|No Intervention|Unsutured Stump|The group consist of subject without distal stump suturing of peroneus longus agains peroneus brevis in ACL Reconstruction Case
10117285|NCT04430556|Other|Volumetric changes in response to sertraline or escitalopram|
10117286|NCT04430608|Other|Fingerprick glucose|Standard care with fingerprick glucose + blinded CGM stratification on COVID-19 status
10117287|NCT04430608|Experimental|Open continous glucose monitoring (CGM)|Standard care with fingerprick glucose + un-blinded CGM stratification on COVID-19 status
10117288|NCT04430660|Other|Arm 1|Participants will have there glial acetate metabolism assessed via 13C MRS at baseline and then again 14 days later. Participants will wear blinded continuous glucose monitoring devices for ~4 weeks.
10117289|NCT04430413|No Intervention|Group A|50 Participants who underwent a total excision of the pilonidal sinus and the wound remained open for secondary healing.
10117290|NCT04430413|Active Comparator|Group B|50 Participants who underwent the same operation with secondary healing intention but on postoperative days 4 and 12 the platelet rich plasma was injected to the surgical wound.
10117291|NCT04430595|Experimental|Multiple 4SCAR T cells to treat breast cancer|Multiple 4SCAR T cells to treat breast cancer
10117292|NCT04430439|Experimental|Psychosocial stress|Participants will complete the Trier Social Stress Test (TSST) immediately following consumption of their assigned meal type (low or high GI).
10117293|NCT04430439|Active Comparator|Control non-stress|Participants will complete a non-stress relaxed task immediately following consumption of their assigned meal type (low or high GI).
10117294|NCT04430361|Experimental|Megestrol|Palonosetron 2.5mg, Dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, Megestrol acetates 160mg orally every morning on the day of the beginning of chemotherapy for 10 days.
10117295|NCT04430361|Other|Control|Palonosetron 2.5mg, Dexamethasone12mg on the first day, 8mg on the 2nd-4th day
10117296|NCT04430491||Training dataset|No interventions
9965918|NCT01254695|Experimental|Experimental Setting 1|Amplitude: Sensory threshold Frequency:6.9 Hz Pulse width 210 μsec
9965919|NCT01254695|Experimental|Experimental setting 2|Amplitude: Sensory threshold Frequency:31 Hz Pulse width 210 μsec
9965920|NCT01254695|Experimental|Experimental setting 3|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 330 μsec
9965921|NCT01254695|Experimental|Experimental setting 4|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 90 μsec
9965922|NCT01254708|Active Comparator|Control|Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
10117297|NCT04430491||Validation dataset|No interventions
10117298|NCT04430270||Comparison of Perceptions of X-ray, CT and 3D Model|The study group consisted of 11 orthopaedic residents of University Hospital. Selection criteria for the 4 cases was the involved patients who required orthopaedic surgery. 4 cases for orthopaedic procedures were determined with the consensus of experts. As data collection tool was used to evaluate the perceptions of each of these imaging methods in terms of their usefulness in seeing the surgical problem, their efficiency in differential diagnosis and presurgical planning. CT images were converted into in the 3D model was prepared. The survey utilized by our group, addressed the issues in understanding bone anatomy, seeing pathology, and preparation for unexpected events. A multi-item survey was prepared to assess fellow's perception of residency training. Residents who completed their examination in the stations answered the questions on a scale of 10. Descriptive statistics and Friedman test were used for comparison analysis using IBM SPSS Statistics, version 24.
10117299|NCT04430244|Experimental|DALK using Dehydrated Corneas|Corneal transplantation of anterior lamellar grafts from dehydrated corneas.
10117300|NCT04430244|Active Comparator|DALK using Standard Organ Culture Stored Corneas|Corneal transplantation of anterior lamellar grafts from standard organ culture stored corneas.
10117301|NCT04430504|Experimental|Telerehabilitation (TR)|Multidisciplinary, weekly video meetings, self-exercises at home, digital diary recordings, follow-up assessments
10182708|NCT03771638|Other|DOT Diary Control|Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
9965923|NCT01254708|Experimental|liposomal amphotericin B (AmBisome ®)|Inhaled Liposomal preparation of Amphotericin B.
9965924|NCT01254734|Experimental|Arm I|Patients undergo transoral robotic microsurgery.
9965925|NCT01254786|Active Comparator|CPAP2 - HFPPV group|the non-dependent lung will be ventilated with CPAP of 2 cm H2O for 30 min followed with HFPPV for min.
9965926|NCT01254786|Active Comparator|HFPPV-CPAP2 group|the non-dependent lung will be ventilated with HFPPV for 30 min followed with CPAP of 2 cm H2O for 30 min.
9965927|NCT01254799|Placebo Comparator|Placebo|Women in this arm will receive identical Placebo capsules twice daily for 5 days
9965928|NCT01254799|Active Comparator|Doxycycline|Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
9965929|NCT01254812||Bilateral dual TAP-block|
9965930|NCT01254812||Placebo Bilateral dual TAP-block|
9965931|NCT01254825|Experimental|Adductor-Canal-Block, Ropivacain|Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients
9965932|NCT01254825|Placebo Comparator|Adductor-Canal-Block (ACB) - Saline|Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.
10117302|NCT04430530|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20 infusion|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
10117303|NCT04430231||Wait list time 0-2 weeks|Wait list time 0-2 weeks
10117304|NCT04430231||Wait list time 2-4 weeks|Wait list time 2-4 weeks
10117305|NCT04430231||Wait list time 4-6 weeks|Wait list time 4-6 weeks
10117306|NCT04430231||Wait list time > 6 weeks|Wait list time > 6 weeks
10117307|NCT04430309|Experimental|Baduanjin exercise group|"The intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements.~The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks"
10117308|NCT04430309|Active Comparator|Control group|The control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
10117309|NCT04430257|Experimental|PrEP for health|Participants in the PrEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.
10117310|NCT04430257|Active Comparator|Standard of care|Participants in the standard of care arm will receive PrEP information and referrals.
10117311|NCT04430296|Active Comparator|High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU)|
10117312|NCT04430296|Active Comparator|MicroPulse cyclophotocoagulation (MP-CPC)|
10117313|NCT04430296|Active Comparator|Continuous Wave cyclophotocoagulation (CW-CPC)|
10117314|NCT04430127||Colorectal adenocarcinoma|patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal DECT for initial staging
10117315|NCT04430465|Experimental|High wholegrain then low wholegrain|Starting with high wholegrain intervention followed by low wholegrain intervention
10117316|NCT04430465|Experimental|Low wholegrain then high wholegrain|Starting with low wholegrain intervention followed by high wholegrain intervention
10117317|NCT04430166|Experimental|PD-1 monoclonal antibody|
10117318|NCT04430478|Experimental|Volume flow group|Consecutive patients undergoing sequential volume flow measurements using percutaneous DUS
10117319|NCT04430543|Experimental|CBM Group|This group will receive Cognitive Bias Modification training
10117320|NCT04430543|Sham Comparator|Control Group|This group will receive Sham (control) training
10117321|NCT04429945|Experimental|Immersive Virtual Reality|A Virtual Reality headset will be used for 30 minutes twice per day outside of usual therapy times while in bed with bedrails raised. Virtual Reality games will be selected that will help with relaxation, pain, and arm and hand recovery after a stroke.
10117322|NCT04430049||no visitation group|relatives cannot visit ICU patient during Covid pandemic period in France
10117323|NCT04430049||restrictive visitation group|relatives have restriction to visit ICU patient during Covid pandemic period in France
10117324|NCT04430049||open visitation group|relatives can visit ICU patient during no Covid period in France
10117325|NCT04429815||Active smokers.|Active smokers since October 2019.
10117326|NCT04429815||Smokers undergoing smoking cessation|Smokers undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019.
10117327|NCT04429815||Non-smoking.|Person who's never smoked before.
10117328|NCT04429984||Velaglucerase alfa (VPRIV)|Participants with Gaucher disease will receive VPRIV therapy according to the investigator's judgment for 12 months.
10117329|NCT04429841||D1 Gastrectomy|Patients are managed by radical gastrectomy with D1 lymphadenectomy
10117330|NCT04429841||D2 Gastrectomy|Patients are managed by radical gastrectomy with D2 lymphadenectomy
10117331|NCT04429906||test group|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
10117332|NCT04429906||control group A|Pulse oximetry monitor/desktop ECG monitor with a medical device registration certificate was selected as reference device A. The mean value of qualified pulse oximetry measured by pulse oximetry monitor/desktop ECG monitor within 2 minutes of each successive measurement of the Huami Smart Wearable Device was used as control group A measurement.
10117333|NCT04429906||control group B|A carbon monoxide blood gas analyzer (CO-oximeter) was selected as reference device B. Arterial blood was sampled and arterial oxygen saturation (SaO2) was obtained from the blood gas analyzer as a control group B measurement.
10117334|NCT04430062||Covid-19 patients operated (February 21st -April 10th)|
10117335|NCT04429958||GDM|125 mothers with a history of GDM in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
10117336|NCT04429958||abnormal GCT group|125 mothers with an abnormal glucose challange test (GCT of 130mg/dl or more) in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
10117337|NCT04429958||normal group|125 mothers with both a normal GCT and OGT in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
10117338|NCT04430088|Experimental|VVZ-149 Injections|
10117339|NCT04430088|Placebo Comparator|Placebo|
10117340|NCT04429763|Experimental|Experimental|Usual tratment for COVID-19 plus MSC
10117341|NCT04429763|Placebo Comparator|Control|Usual treatment for COVID-19
10117342|NCT04429867|Experimental|Hydroxychloroquine|
10117343|NCT04429867|Placebo Comparator|Placebo|
10117344|NCT04429789|Experimental|Active-Alert Hypnosis|
10117345|NCT04429789|Experimental|Traditional Hypnosis|
10117346|NCT04429789|No Intervention|Wait-List Control|Participants in this arm will continue their usual care for fatigue. The therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their fatigue. The study therapist will emphasize the importance of completing the outcome assessments. Following the completion of their final assessment (3 month follow-up); these individuals will be offered their choice of the two hypnosis treatments.
10117347|NCT04430114|Experimental|TAAA spinal loop graft|
10117348|NCT04430192|Experimental|177Lu-PSMA-617 followed by prostatectomy|177Lu-PSMA-617 followed by prostatectomy
10117349|NCT04429997|Experimental|Removal of fibrosynovial tissue|Removal of fibrosynovial tissue in patellar non-resurfacing TKA
10117350|NCT04429997|Experimental|Non-removal of fibrosynovial tissue|Non-removal of fibrosynovial tissue in patellar non-resurfacing TKA
10117351|NCT04430179|Active Comparator|Active drug|Dupilumab 300 mg every other week for 24 weeks
10117352|NCT04430179|Placebo Comparator|Placebo|Placebo
10117353|NCT04429828|Experimental|e-package: psychological wellbeing for healthcare workers|A COVID-19 educational package on psychological wellbeing for healthcare workers, accessible to all healthcare students.
10117354|NCT04430153||Low match|A group with both low observed and perceived upper limb ability.
10117355|NCT04430153||Good match|A group with both good observed and perceived upper limb ability.
10117356|NCT04430153||Mismatch|A group with good observed but low perceived function.
10117357|NCT04429750|Active Comparator|Immediate umbilical cord clamping|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH management procedure as described in the French national CDH management guidelines (Programme National de Soins).The resuscitation maneuvers are started after the umbilical cord is clamped."
10117358|NCT04429750|Experimental|Intact cord resuscitation|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH resuscitation maneuvers as described in the French national CDH management guidelines (Programme National de Soins) before the umbilical cord is clamped. The resuscitation maneuvers are started at birth while the umbilical cord still bridges mother and child."
10117359|NCT04429776|Experimental|Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results fed back to recruiting clinical team who can choose to use these to influence their tapering decisions.
10117360|NCT04429776|Active Comparator|No Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results not fed back to recruiting clinical team.
10117361|NCT04429724|Experimental|health workers at hospital|Three blood samples will be taken at day 1, month 3 and month 6. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
10117362|NCT04429737|Experimental|Experimental|The prediabetes patients in this arm will receive Clam protein capsules or Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months.
10117363|NCT04429737|Placebo Comparator|placebo|The prediabetes patients in this arm will receive placebo with similar appearance of Clam protein capsules or Clam peptide plus Chlorella capsules.
10117364|NCT04429711|Placebo Comparator|IVERMECTIN|
10117365|NCT04429711|Active Comparator|PLACEBO|
10117366|NCT04429646|Experimental|LAMax left atrial appendage occluder|Intervention device, LAMax left atrial appendage closure system
10117367|NCT04429646|Active Comparator|Watchman (control)|Intervention device, Watchman® LAA Closure Device
10117368|NCT04429633|Active Comparator|Conventional Cardiac intervention|Starting candesartan in patients with left ventricular ejection fraction (LVEF) between 45% and 50% by echocardiogram.
10117369|NCT04429633|Active Comparator|Early Cardiac intervention|Starting candesartan in patients with decreased myocardial strain below 18% regardless of LVEF by echocardiogram.
10117370|NCT04429698|Other|POCUS group|Patients in this group underwent POCUS after primary clinical evaluation with the knowledge of their primary physician. This procedure was performed in the first hour after the patients' primary clinical evaluations to evaluate the predetermined parameters in the study form for the heart, lungs, hepatobiliary, aortic and deep veins.
10117371|NCT04429698|No Intervention|Control group|All processes and results were followed without any intervention in the processes related to the patients in this group and the results were recorded in the study form
10117372|NCT04429672|Experimental|Experimental Group (EG)|"The participants of the Experimental Group receive as treatment the intervention called The Right to your Sexual Health, which is socio-educational and is composed of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Conduct and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of the opening, development and closing phase established in a manual for the facilitator, it should be noted that the intervention is applied by a multidisciplinary team in which the areas of medicine, nursing and psychology participate. In addition, Information and Communication Technologies (ICTs) are used through a Moodle platform that has available to participants digital support material as digital presentations on each of the thematic axes, as well as audiovisual material through the Podcast format of conversations concerning each of the axes."
10117373|NCT04429672|Active Comparator|Control Group (CG)|The participants of the Control Group receive the usual sexual health intervention applied by Secretary of Health consisting of six sessions (one a week) lasting 50 minutes each using illustrative material through rotating official secretary of health folios on reproductive health, sexually transmitted diseases and sexual violence.
10117374|NCT04429529|Experimental|TY027 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
10117375|NCT04429529|Placebo Comparator|Placebo 0.5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10117376|NCT04429529|Experimental|TY027 5mg/kg|Subject will be administered with 5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
10117377|NCT04429529|Placebo Comparator|Placebo 5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10117378|NCT04429529|Experimental|TY027 10 mg/kg|Subject will be administered with 10 mg/kg of TY027 via IV infusion over a period of 30 minutes.
9668885|NCT04701593|No Intervention|Control|No additional drug given
10117379|NCT04429529|Placebo Comparator|Placebo 10 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10117380|NCT04429529|Experimental|TY027 20 mg/kg|Subject will be administered with 20 mg/kg of TY027 via IV infusion over a period of 30 minutes.
10117381|NCT04429529|Placebo Comparator|Placebo 20 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10117382|NCT04429529|Experimental|TY027 30 mg/kg|Subject will be administered with 30 mg/kg of TY027 via IV infusion over a period of 30 minutes.
10117383|NCT04429529|Placebo Comparator|Placebo 30 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10117384|NCT04429516|Experimental|Morphine Sulfate|
10117385|NCT04429516|Placebo Comparator|Placebo|
10117386|NCT04429503|Experimental|aflibercept Q8|Administered every 8 weeks after a loading phase
10117387|NCT04429503|Experimental|High-Dose aflibercept Q12|Administered every 12 weeks after a loading phase
10117388|NCT04429503|Experimental|High-Dose aflibercept Q16|Administered every 16 weeks after a loading phase
10117389|NCT04429412|Experimental|Metacognitive Training (MCT+)|"MCT+ combines the process-oriented approach of metacognitive group training with elements of individual cognitive-behavioral therapy.~The metacognitive training program is comprised of 10 modules targeting common cognitive errors in schizophrenia. (Moritz et al, 2013).~The modules are: 1:Therapeutic alliance, 2: Introducyion to MCT+, 3:Disease model, 4: Attributional style, 5: Decision making, 6: Changing beliefs, 7: Empathizing, 8: Memory, 9: Depression and self-steem, 10: Relapse prevention.~The treatment consist of 10 weekly sessions of 45-60 minutes."
10117390|NCT04429412|No Intervention|TAU|Treatment as usual.
10117391|NCT04429425|Other|EA group|patients with colorectal surgery that willl be performed epidural anesthesia
10117392|NCT04429425|No Intervention|non -EA group|patients with colorectal surgery that willl be performed only general anesthesia
10117393|NCT04429490|Experimental|"Group Cases"|patients with pancreatic adenocarcinoma
10117394|NCT04429490|Other|"Group Controls"|patients without pancreatic adenocarcinoma
10117395|NCT04429594|Other|volonteers|
10117396|NCT04429282|Experimental|ibuprofen( 400mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 400 mg .
10117397|NCT04429282|Experimental|ibuprofen( 800mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 800 mg.
10117398|NCT04429282|Placebo Comparator|placebo group|Patients were randomly divided into the group received respectively IV placebo,.
10117399|NCT04429217|Experimental|Arm-A|experimental post-operative rehabilitation intervention consisting in immediate weight-bearing
10117400|NCT04429217|Active Comparator|Arm-B|control post-operative rehabilitation intervention consisting in delayed weight-bearing
10117401|NCT04429230|Active Comparator|Real tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
10117402|NCT04429230|Sham Comparator|Sham tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
10117403|NCT04429373|Experimental|Implant installation with PRF|PRF membrane over the buccal aspect of implant site
10117404|NCT04429373|Active Comparator|Implant installation without PRF|Implant installation contralateral to the the experimental implant, without PRF membrane
10117405|NCT04429568|Other|Smoked Cannabis, Vaped Cannabis, or Tobacco Cigarette|"Abstinence from any product night before hospital admission~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~6-hr abstinence and blood draws (PK)~2 hr Free use session w/ video monitoring~Free use of assigned product~12-hr cardiovascular (CV) monitoring~Circadian blood draws~12-hr urine collection"
10117406|NCT04429568|Other|Either of the 2 remaining products|"Abstinence from any product night before hospital admission~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~6-hr abstinence and blood draws (PK)~2 hr Free use session w/ video monitoring~Free use of assigned product~12-hr CV monitoring~Circadian blood draws~12-hr urine collection"
10117407|NCT04429568|Other|Remaining product|"Abstinence from any product night before hospital admission~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~6-hr abstinence and blood draws (PK)~2 hr Free use session w/ video monitoring~Free use of assigned product~12-hr CV monitoring~Circadian blood draws~12-hr urine collection"
10117408|NCT04429295|Experimental|Group A - Intervention regimen|SHAN6™ + routine pediatric vaccines pneumococcal 13-valent conjugate vaccine [PCV] [Prevnar 13®] and oral rotavirus vaccine [ORV-1] [Rotarix™] at age of 2, 4 months; SHAN6™ + Prevnar 13® at age of 6 months; SHAN6™ administered alone as a booster dose at age of 15-18 months
10117409|NCT04429295|Active Comparator|Group B - Control regimen|SHAN5™ + bivalent oral polio vaccine (bOPV), co-administered with Prevnar 13® and Rotarix™ at 2, 4 months of age and with inactivated polio vaccine [IPV] at 4 months of age; SHAN5™ + bOPV, co-administered with Prevnar 13® at 6 months of age SHAN6™ administered alone as a booster dose at 15-18 months of age
10117410|NCT04429620||Positive group|Subjects are diagnosed with SARS-CoV2 by qPCR assay.
10117411|NCT04429620||Negative group|Subject were 2 times proved negative SARS-CoV2 by qPCR assay.
10117412|NCT04429451|Experimental|4SCAR-PSMA Cell Therapy for PSMA positive tumor|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
10117413|NCT04429438|Experimental|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after chemotherapy will be treated with a combination of 4SCAR gene-engineered T cells.
10117414|NCT04429347|Experimental|Tizanidine 2mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
10117415|NCT04429347|Experimental|Gabapentin 300mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
10117416|NCT04429347|Placebo Comparator|Placebo|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
10117417|NCT04429269||mammography and ultrasound|mammography and ultrasound screening
10117418|NCT04429334|Experimental|nangibotide|
10117419|NCT04429334|Placebo Comparator|placebo|
10117420|NCT04429204|Experimental|Basic science (cryoablation, tissue collection)|At the time of standard of care pleural biopsy, patients undergo cryoablation over 30 minutes, then a sample of tissue from the ablated region and a non-ablated (tumor negative control) region are collected.
10117421|NCT04429191|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|"The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.~The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose."
10117422|NCT04429165||ACL reconstruction|ACL reconstruction using an autologous hamstring tendon
10117423|NCT04429165||control group|knee-healthy, age-matched subjects as a control group
10117424|NCT04429152|Experimental|Doravirine|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
10117425|NCT04428762|Experimental|I-Port use arm|
10117426|NCT04428762|No Intervention|Regular injection arm|
10117427|NCT04428840|Experimental|on-day|Use of the self-measurement kiosk: measurement of vital signs + completion of short questionnaire
10117428|NCT04428840|No Intervention|Off-day|No use of the self-measurement kiosk
10117429|NCT04428892|Experimental|Clinical Simulation|The group denominated SP received a teaching strategy based on a class session with simulated practice for decision-making in clinical skills when caring for a person with LBP. Each session lasted approximately 120 minutes, and the clinical case used for the SP sessions was subjected to face validity with experts in the area of study.
10117430|NCT04428892|Active Comparator|Conventional Pedagogical strategy|"received a class session based on a role playing simulation strategy, structured for the same purpose established in the SP group. This session lasted approximately 120 minutes, and the learning environment was the classroom in which students assumed different roles to act out; some of them acted as people with LBP and others as physiotherapists"
10117431|NCT04428970||TBI patients with ICP monitoring|Patients with severe TBI (GCS<9 on arrival) receiving invasive ICP monitoring
10117432|NCT04429035|Experimental|Vitamin K2|Participants receive Vitamin K2 (Menaquinone) 100mcg tablet orally 3 times daily for 12 months.
10117433|NCT04429035|Placebo Comparator|Placebo|Participants receive Vitamin K2 (Menaquinone) placebo tablet matching Vitamin K2 (Menaquinone) orally 3 times daily for 12 months.
10117434|NCT04428827||Surgery|Patients treated with surgery
10117435|NCT04428827||Medications|Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism
10117436|NCT04428944|Active Comparator|PV antral isolation alone (PVAI)|PV antral isolation alone (PVAI)
10117437|NCT04428944|Active Comparator|PV antral isolation plus ablation of drivers|PV antral isolation plus ablation of drivers (PVAI+drivers)
10117438|NCT04428944|Active Comparator|PV antral isolation plus isolation of posterior wall|PV antral isolation plus isolation of LA posterior wall (PVAI+Box)
10117439|NCT04428957|Experimental|Telemonitoring group|3 months home-based telemonitoring
10117440|NCT04428957|No Intervention|Control group|3 months standard care
10117441|NCT04429061|No Intervention|SOC Arm|Standard of care (SOC): the sexual reproductive curriculum which is implemented by the schools as part of mandatory SRH education.
10117442|NCT04429061|Active Comparator|Enhanced Arm|The SKILLZ-Girl Curriculum, plus the graduation event (including HIVST + access to family planning) and home based delivery of commodities with subsequent encouragement to be involved with SKILLZ-Clubs at their school
10117443|NCT04428983|Experimental|Hericium erinaceus mycelium|Hericium erinaceus capsules 1 table tid orally per day for 24 months
10117444|NCT04428983|Placebo Comparator|placebo|placebo capsules 1 table tid orally per day for 24 months
10117445|NCT04429113||G1 or Early Group|Patients treated before age 7 (Quad Helix on decidual second molars)
10117446|NCT04429113||G2 or Late Group|Patients treated between 7 and 13 years old (Quad Helix on first permanent molars)
10117447|NCT04429074||Group 1 (Registrar)|Group 1 (Registrar): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a registrar (young specialist surgeon)
10117448|NCT04429074||Group 2 (Consultant)|Group 2 (Consultant): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a consultant (expert)
10117449|NCT04429009|Experimental|Active Study Group|"Participants in this group will be prescribed to use the ZEPHYRx RT device for incentive spectrometer once every hour during waking hours to perform a series of 10 deep breaths. The novel ZEPHYRx RT system consists three components:~The Spirobank Smart Spirometer, which is a non-significant risk, FDA-cleared diagnostic spirometer made by Medical International Research (MIR) that connects via bluetooth to an Android tablet.~A Samsung 10-inch tablet provided by Pad-in-Motion Inc. that will be connected to the hospital GuestWiFi network.~The ZEPHYRx Respiratory Therapy video game application installed on the tablet. This application consists of seven games that have been created to combine traditional IS techniques with playing a breath controlled video game. The application will record data while playing the video games including date/time of use, game played, inhalation duration, and inhalation volume."
10117450|NCT04429009|Active Comparator|Control Group|Participants in this group will be prescribed to routine respiratory care, Routine respiratory care involves the use of a standard incentive spirometer that is not a digital device and does not include any built-in reminder. As per routine care, the nurse or respiratory therapist will remind the subjects to perform a series of at least 10 deep breaths every hour.
10117451|NCT04428879|Experimental|Phase I single arm trial|
10117452|NCT04428814|Experimental|CT-P43 (Part 1)|45mg single dose administration
10117453|NCT04428814|Active Comparator|EU-approved Stelara (Part 1)|45mg single dose administration
10117454|NCT04428814|Experimental|CT-P43 (Part 2)|45mg single dose administration
10117455|NCT04428814|Active Comparator|EU-approved Stelara (Part 2)|45mg single dose administration
10117456|NCT04428814|Active Comparator|US-licensed Stelara (Part 2)|45mg single dose administration
10117457|NCT04428996|Experimental|Arm AB|"A means SCIT program, and B means treatment as usual. Arm AB will receive a 60-minutes manual-guide SCIT session each week for 20 times first, then receive treatment as usual.~Before the SCIT session, after the SCIT session and after 20 weeks treatment as usual, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
10117458|NCT04428996|Experimental|Arm BA|"A means SCIT program, and B means treatment as usual. Arm BA will first receive treatment as usual, then a 60-minutes manual-guide SCIT session each week for 20 times.~At the first week, before and after the SCIT session, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
10117459|NCT04428801|Experimental|Phase 2 AdMSC group|"Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days~Other Names: Celltex-AdMSCs Celltex-AdMSCs"
10117460|NCT04428801|Placebo Comparator|Phase 2 Placebo group|The control group- receive three doses of placebo via intravenously infusion every three days.
10117461|NCT04428437||Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by lenvatinib.
10117462|NCT04428437||Non-Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by non-lenvatinib.
10117463|NCT04428606|Experimental|Metabolic Rheostat™|Participants will take 6 capsules of Rheostat daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
10117464|NCT04428606|Experimental|Butyrate Ultra|Participants will take 6 capsules Butyrate Ultra daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
10117465|NCT04428606|Placebo Comparator|Placebo|Participants will take 6 capsules of placebo daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
10117466|NCT04428593|Experimental|Treamid 5 mg|Cohort 1 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 5 mg (4 subjects) or placebo (1 subject, see placebo arm).
10117467|NCT04428593|Experimental|Treamid 15 mg|Cohort 2 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 15 mg (4 subjects) or placebo (1 subject, see placebo arm).
10117468|NCT04428593|Experimental|Treamid 50 mg|Cohort 3 - 5 subjects were randomized in a 8:2 ratio to be treated either Treamid 50 mg (8 subjects) or placebo (2 subjects, see placebo arm).
10117469|NCT04428593|Placebo Comparator|Placebo|Placebo comparator arm consists of 4 subjects (1 subject from Сohorts 1 and 2, 2 subjects from Cohort 3).
10117470|NCT04428671|Experimental|Treatment (cemiplimab)|"NEOADJUVANT PHASE: Prior to standard of care surgery, patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~ADJUVANT PHASE: Within 2-6 weeks after standard of care radiation therapy (or surgery if no radiation therapy), patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity."
10117471|NCT04428697|Experimental|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm. After identifying both the internal and external sphincters completely, under direct vision, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. This section was preserved during the operation in a standard fashion for all patients . Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter bundle was elevated with a right angle clamp, then cut with cautery . The operation was completed with meticulous hemostasis and additional suturing (3/0 absorbable suture) of the proximally dissected mucosal flap underlying the muscularis layer
10117472|NCT04428697|Active Comparator|Closed Lateral Internal Sphincterotomy|The sphincterotomy was performed through a new incision, guided by the surgeon's finger, as described by Boulos et al Boulos PB, Araujo JG. Adequate internal sphincterotomy for chronic anal fissure: subcutaneous or open technique? The British journal of surgery 1984;71:360-2.
10117473|NCT04428580|Experimental|Online Training|10 lectures that are self-paced with a maximum of three months to complete with each lecture bundle comprising of 5-8 short (about 4 minutes in length), didactic videos that discuss the treatment model and provide mock therapy session video clips (modeling FBT with a typical adolescent AN case), as well as supplementary readings and videotaped role-plays. Enrollees complete each lecture bundle and complete the assignments as they move through the training at their own pace, but to have completed all within the 3-month time frame. When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
10117474|NCT04428580|Active Comparator|Webinar Training|1-hour weekly webinar lectures that essentially is the FBT training that is conducted in person, just recorded. There will be lectures discussing the scientific evidence supporting FBT, how therapists set up treatment for FBT, main interventions used in FBT during each phase, and recorded role-plays illustrating interventions throughout the 3 phases. Enrollees watch each webinar video as it is released weekly over a 12 week (3 month period). When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
10117475|NCT04428710||patients admitted to cancer genetic counseling test|Participants were recruited from all consecutive patients referred to the Cancer Genetic Program at the Hospital Universitari i Politècnic la Fe.
10117476|NCT04428463|Active Comparator|tympanoplasty using fascia and cartilage|tympanoplasty under general anesthesia using fascia and cartilage witch is the gold standard for treating tympanic membrane perforations.
10117477|NCT04428463|Experimental|Tachosil|repair of tympanic perforations under local anesthesia using Tachosil patch.
10117478|NCT04428515||Radiotherapy Response Monitoring|
10117479|NCT04428684|Experimental|Pepti 3.6 treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
10117480|NCT04428684|Active Comparator|Zoladex 3.6 mg treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
10117481|NCT04428619|Active Comparator|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|The PENFS device has a battery activated generator and wire harness. Four leads are attached to the generator, each with a sterile 2 mm, titanium needle. The patient's ear is trans-illuminated to identify neurovascular bundles that are avoided during needle placement. The generator is attached with adhesive to the skin behind the patient's ear. Needles are inserted into the dorsal and ventral aspects of the ear, within 1-1.5 mm of the vascular branches to create a field effect. The device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The device is worn for 5 days/week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will be asked to wear a SmartWatch during the study to monitor heart rate.
10117482|NCT04428619|Sham Comparator|Sham Device|The sham devices will be identical to the active devices but will not administer electrical charges. Per manufacturer design and patient anecdotal experience from previous studies, both active stimulation and sham are below detectable sensation threshold. Per report from previous studies, some patients may experience a sensation around the ear after percutaneous needle placement; however, this sensation can occur with equal likelihood in the active or sham device. The device is worn for 5 days a week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will also be asked to wear a SmartWatch as above.
10117483|NCT04428450|Experimental|Deprexis (unguided)|web-based self-help program without any support from a therapist during the 10-week treatment period
10117484|NCT04428450|Experimental|Deprexis (guided, with therapist)|web-based self-help program plus scheduled e-mail contact with a therapist during the 10-week treatment period
10117485|NCT04428450|No Intervention|Wait-list|Wait-list group (subjects receive access to Deprexis after 10 weeks)
10117486|NCT04428528||Neoadjuvant Chemotherapy Monitoring|
10117487|NCT04428528||Breast Mass Characterization|
10117488|NCT04428372|Experimental|Mannitol|intravenous 20% mannitol, 0.25g/kg/hour (maximum 25g/hour; maximum 75g per session; maximum volume 375mL/session) as a continuous infusion during dialysis
10117489|NCT04428372|Placebo Comparator|Placebo|0.9% saline at a rate of 1.25mL/kg/hour (maximum volume 375mL) as a continuous infusion during dialysis
10117490|NCT04428255|Experimental|HBM9161 Dose A|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
10117491|NCT04428255|Experimental|HBM9161 Dose B|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
10117492|NCT04428255|Placebo Comparator|Placebo|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
10117493|NCT04428099|Experimental|Intervention|Lifestyle change promotion program
10117494|NCT04428099|Active Comparator|Control 1|MBCT program
10117495|NCT04428099|Placebo Comparator|Control 2|Usual care
10117496|NCT04428242||Group 1|Subjects with normal macular thickness in one or both eyes.
10117497|NCT04428242||Group 2|Subjects with center-involving macular edema due to w/AMD in one or both eyes.
10117498|NCT04428242||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes.
10117499|NCT04428268|Active Comparator|Chloroquine|Patients will receive chloroquine phosphate 450 mg every 12 hours orally
10117500|NCT04428268|Experimental|Chloroquine plus losartan|Patients will receive Chloroquine phosphate 450mg orally every 12hrs plus Losartan 25mg orally every 12hrs
10117501|NCT04428320|Experimental|Bupivicaine pelvic floor muscle injection|Five injections at pre-specified locations at pelvic floor muscle bilaterally after induction of general anesthesia for vaginal pelvic prolapse surgery
10117502|NCT04428320|No Intervention|Standard of care (no injection) preoperatively|No injection - standard analgesia
10117503|NCT04428086|Experimental|Assess PK effects of Apatinib on Rosuvastatin|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 7 and Apatinib at a dose of 250 mg once daily from Day 4 until Day 9.
10117504|NCT04428086|Experimental|Assess PK effects of Apatinib on Metformin|Participant will be administered a single oral dose of metformin 500 milligram (mg) on Day 1 and Day 6 and Apatinib at a dose of 250 mg once daily from Day 3 until Day 7.
10117505|NCT04428177|Experimental|Intrvascular Lithotripsy|Calcified coronary lesions will be treated with intrvascular lithotripsy
10117506|NCT04428177|Active Comparator|Standard therapy|Standard treatment of calcified coronary lesions: cutting, scoring or non-compliant balloon predilatation or rotational atherectomy
10117507|NCT04428138||Patients with Inguinal hernia|Patients presenting with inguinal hernia will undergo vascular in-office visit and echo duplex of aorta, carotid arteries and lower limb arteries in order to detect any abnormalities related to arterial disease (aneurysm, stenosis, flow alteration).
10117508|NCT04428073|Experimental|Low dose group|Subjects will receive 1.0 mL of low dose vaccine at week 0 and 2.
10117509|NCT04428073|Experimental|High dose group|Subjects will receive 1.0 mL of high dose vaccine at week 0 and 2.
10117510|NCT04429139|Experimental|PDT treatment group|All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.
10117511|NCT04428125||Healthy sporty subjects|Healthy sporty subjects that participate in the following sports: baseball, tennis, swimming, rowing, volleyball, rugby football, weightlifting.
10117512|NCT04428125||Healthy non-sporty subjects|Healthy subjects that do not partecipate in sport activities.
10117513|NCT04429048|Experimental|acupressure group|The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day.
10117514|NCT04429048|Sham Comparator|control group|The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints.
10117515|NCT04427683|Experimental|Brief mindful parenting program|The program will consist of a four-session and last for eight hours integrating mindfulness skills and psychoeducation in managing stress under social unrest and promoting strategies for emotion regulation, conflict management, and self-care.
10117516|NCT04427683|Other|Wait-list control group|A four-minute educational video will be distributed to the participants who accept the randomisation. It includes brief information on mental health. After the participants from experimental group complete the intervention, those in wait-list control group will receive the same intervention.
10117517|NCT04427774|Experimental|Surufatinib plus Sintilimab|
10117518|NCT04427709|Other|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®) first then placebo injection.
10117519|NCT04427709|Other|Placebo, Then Oxytocin|Subjects in this arm will receive Intramuscular placebo injection first then oxytocin injection
9965933|NCT00660218|Experimental|Radiation therapy, cetuximab, paclitaxel poliglumex|Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
10117520|NCT04427852|Experimental|30 day Beef consumption|One serving of beef is consumed each day for 30 days.
10117521|NCT04427852|Placebo Comparator|30 day Veggie Patty consumption|One serving (1 patty) of a vegetable based protein source is consumed each day for 30 days. The weight of the food, total calories, grams of protein, and total fat are the same as the beef serving.
10117522|NCT04427826|Experimental|Patient admitted for acute Exacerbation of Chronic Obstructive|Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and required NIV
10117523|NCT04427969||EPP|patients who applied early awake prone position for treatment with conventional oxygen supply
10117524|NCT04427969||non-EPP|patient who only get conventional oxygen therapy as respiratory supply
10117525|NCT04427878|Experimental|patients with Covid-19|
10117526|NCT04427995||Oen Angle Glaucoma|• Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma with IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy. Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.
10117527|NCT04428021|Active Comparator|Standard therapy protocol (STP)|STP is defined as the best evidence based therapy approved for treatment of COVID-19 patients by Regional Health System emergency committee. STP could be updated during the trial.
10117528|NCT04428021|Experimental|STP + Standard Plasma (SP)|STP + 3 units on day 1-3-5 of Standard Plasma collected in pre-COVID era (January-September 2019)
10117529|NCT04428021|Experimental|STP + COVID-19 Convalescent Plasma (CP)|STP + 3 units on day 1-3-5 of COVID-19 Convalescent Plasma containing neutralizing SARS-Cov-2 antibodies
10117530|NCT04427865|Experimental|Lactoferrin prophylaxis|200 mg oral lactoferrin daily
10117531|NCT04427865|No Intervention|Control group|
10117532|NCT04427917|Experimental|PF-06835919|
10117533|NCT04427917|Placebo Comparator|Placebo|
10117534|NCT04427943||RIKA cohort|patients with periprosthetic knee joint infection scheduled for revision knee arthroplasty surgery
10117535|NCT04427787|Experimental|Cabozantinib+lanreotide|Cabozantinib will be administered orally at a dose of 60 mg/day continuously in combination with Lanreotide 120 mg injection every 28 days. Both treatments will start the same day
10117536|NCT04427670|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group.
10117537|NCT04427670|Other|Group intervention|Group intervention will be provided to the experimental group.
10117538|NCT04427696|Active Comparator|Aerobic walking|The participants in this arm were obligated to carry out one hour aerobic walking (goal setting walking) daily. The goal of aerobic walking: 1. at least 60 steps per minute; 2. continuously walking for 10 minutes.
10117539|NCT04427696|Placebo Comparator|No aerobic walking|The participants in this arm were requested to maintain sedentary life, without joining other physical exercise programmes.
10117540|NCT04427930|Experimental|JOINTSTEM|Long Term Follow-up after Jointstem Transplantation
10117541|NCT04427930|Placebo Comparator|Saline|
10117542|NCT04427735||before COVID-19|Patients with myocardial infarction from January 24, 2019 to June 24, 2019
10117543|NCT04427735||after COVID-19|Patients with myocardial infarction from January 24, 2020 to June 24, 2020
10117544|NCT04427657|Active Comparator|Controls|39 patients with knee osteoarthritis undergoing arthroscopic debridement
10117545|NCT04427657|Experimental|Cases|39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
10117546|NCT04427553|Experimental|Percutaneous Peripheral Nerve Stimulation|"Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve. We will apply a biphasic compensated electrical current at a frequency of 10 Hz, a pulse width of 240 µs and intensity allowed over a pain-free motor threshold (muscle contraction). Each participant will receive 10 repetitions of 10 seconds each one with 10 seconds rest- period between series (total treatment session 1.40 min).~After that participants will walk during 3 minutes."
10117547|NCT04427553|Placebo Comparator|Control|Participants in the control group will walk during 5 minutes, without receiving any intervention
10117548|NCT04427566|Experimental|Radiation Arm|Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
9965934|NCT01254916||Patients with chronic rhinosinusitis|
10117549|NCT04427618|Experimental|Intervention group|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision, and Intravenous oxytocin 5 units post delivery of the baby.
10117550|NCT04427618|Placebo Comparator|Control group|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision, and intravenous oxytocin 5 units post delivery of the baby
10117551|NCT04427423|Experimental|Positional Distraction plus Stabilization Exercise group|The treatment group will receive positional distraction with stabilization exercises
10117552|NCT04427423|Active Comparator|Stabilization Exercise group|control group will be treated with stabilization exercises only.
10117553|NCT04427176||Nurses|"Nursing staff working 8 or 12 hours a day for 2 consecutive days in a COVID unit at the hospital of Saint Etienne will be included.~They will be wear ARFC mask."
10117554|NCT04427163||Genomic, transcriptomic, proteomic, metabolomic profiles|Determination of genomic, transcriptomic, proteomic, metabolomic profiles in subjects.
10117555|NCT04427215|Experimental|A - Music Therapy|Two section a week of music therapy
10117556|NCT04427215|Experimental|B - Art Therapy|Two section a week of Art therapy
10117557|NCT04427215|Experimental|C - Dance-Movement Therapy|Two section a week of Dance-Movement Therapy
10117558|NCT04427215|Experimental|D - Bibliotherapy|Two section a week of Bibliotherapy
10117559|NCT04427215|Experimental|E - Physical Activity|Two section a week of systematized physical activity
10117560|NCT04427228|Experimental|Arm A|
10117561|NCT04427228|Active Comparator|ARM B|
10117562|NCT04427631|Experimental|Single arm study|The family will complete questionnaires before and after each childs intervention. Therefore each child will act as their own control.
10117563|NCT04427449|Experimental|Experimental: Single arm 4SCAR-CD44v6 T cells to treat cancer|
10117564|NCT04427644||Complication positive|Patients with perioeprative complications after laparascopic sleeve gastrectomy before discharge (wound complications, thromboembolic events, staple line leakage, splenic infarction proven by imaging modalities, bleeding detected due to low hemoglobin and hematocrit values during follow-up, acute renal failure due to deterioration in biochemical parameters)
10117565|NCT04427644||Complication negative|Patients without perioeprative complications after laparascopic sleeve gastrectomy before discharge
10117566|NCT04427644||BMI 40 - 45 kg/m2|Operated patients preoperative BMI values between 40 - 45 kg/m2
10117567|NCT04427644||BMI 45 - 50 kg/m2|Operated patients preoperative BMI values between 45 - 50 kg/m2
10117568|NCT04427644||BMI over 50 kg/m2|Operated patients preoperative BMI values 45 - 50 kg/m2
10117569|NCT04427644||Clavien Dindo Major Complications|"Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy This grade also includes wound infections opened at the bedside~Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions, antibiotics and total parenteral nutrition are also included"
10117570|NCT04427644||Clavien Dindo Minor Complciations|3. Requiring surgical, endoscopic or radiological intervention 3a Intervention under regional/local anaesthesia 3b Intervention under general anaesthesia 4. Life-threatening complication requiring intensive care/intensive care unit management 4a Single-organ dysfunction 4b Multi-organ dysfunction 5. Patient demise
10117571|NCT04427293|Experimental|Open Label|All participants will receive one 21-day cycle of therapy prior to surgery, consisting of lenvatinib 12 mg daily, days 1 through 14, and pembrolizumab 200 mg IV on day 1
10117572|NCT04427241|Active Comparator|Amantadine plus cerebrolysin|
10117573|NCT04427241|Active Comparator|Amantadine only|
10117574|NCT04427241|Active Comparator|Cerebrolysin only|
10117575|NCT04427436||Patients|Mild Cognitive Impairment (clinical determination)
10117576|NCT04427436||Control|Healthy Elderly
10117577|NCT04427332||Covid19 infection related patients|"All subjects that had access to the nasopharyngeal swabs service of the hospital for the detection of the Sars-CoV-2 virus, both hospitalized and discharged from the hospital and not hospitalized, from mid-May to the end of June 2020, will be consecutively enrolled. It is assumed that 500 people will be recruited."
10117578|NCT04427514|Experimental|CAPD group|Standard CAPD therapy wtih telemedicine system
10117579|NCT04427267||Health workers|
10117580|NCT04427384||GammaTile|Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.
10117581|NCT04427319|Experimental|Experimental group|Product: β-Alanine Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
10117582|NCT04427319|Placebo Comparator|Placebo group|Product: wheat semolina Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
10117583|NCT04427345||Covid19 infection related patients|Patients admitted to COVID wards of the S. Gerardo Hospital of Monza, including Intensive Care wards.
10117584|NCT04427527|Experimental|Multi-level Intervention|Receives the project intervention first
10117585|NCT04427527|No Intervention|Delayed Multi-level Intervention|Offered the intervention later in the project
10117586|NCT04427540|Experimental|Oxytocin|Single IM injection Oxytocin 17 micrograms
10117587|NCT04427475|Other|pabolizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
10117588|NCT04427475|Other|nafulizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
10117589|NCT04427410||pregnancy|
10117590|NCT04427410||postpartum|
10117591|NCT04427371||survivors|Improve or under treatment
10117592|NCT04427371||nonsurvivors|all-cause 28-day mortality
10117593|NCT04427254|Experimental|Neurological biological samples|
10117594|NCT04426903|Experimental|LLM Care|LLM Care training Participants use the webFitForAll exergaming computer platform as the physical training component (PT); Participants use the language adapted version of the BrainHQ Program as the cognitive training component (CT)
10117595|NCT04426903|Experimental|Physical Training (PT)|Physical training only. Participants use the webFitForAll exergaming computer platform as the physical training component (PT).
10117596|NCT04426903|Experimental|Cognitive Training (CT)|Cognitive training only. Participants use the language adapted Version of the BrainHQ Program as the cognitive training component (CT).
10117597|NCT04426877|Experimental|Experimental group|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
10117598|NCT04426877|Experimental|Control Group|The control group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
10117599|NCT04426799|No Intervention|Control group|no application
10117600|NCT04426799|Experimental|Experimental group|application is done
10117601|NCT04427111||Mild-moderate OSA patients for MAD treatment|Patients are classified as mild Obstructive Sleep Apnea (OSA) if they have between 5-15 Apnea-Hypopnea Index, moderate if they have between 15-30, and severe if they have >30, as measured by Polysomnography (Epstein LJ, Kristo D, Strollo PJ, et al. 2009). The principal treatment methodology for OSA patients is positive airway pressure. In patients with mild to moderate OSA, oral appliances such as mandibular advancement devices (MAD) is alternately indicated (Ramar K, Dort LC, Katz SG, et al. 2015) The American Academy of Dental Sleep Medicine (Ramar K, Dort LC, Katz SG, et al. 2015) recommended titratable-customized MADs for patient comfort and the ability to permit modifications in the amount of mandibular protrusion for treatment efficacy. However, Aarab et al (Aarab G, Lobbezoo F, Hamburger HL, Naeije M. 2010) demonstrated similar therapeutic efficiency of non-titratable-customized MADs in the treatment of OSA
10182709|NCT03771404|Other|Operable (stages I-IIIA) NSCLC|For Operable (stages I-IIIA) NSCLC Patients, blood sampling and tissue samples of the primary tumor as well as the regional involved lymph nodes and, in selected patients, from biopsies from metastasis
10182710|NCT03771443|Experimental|gluten free toothpaste|experimental gluten free toothpaste with natural ingredients prepared for the study to be used 3 times per day for six months
10182711|NCT03771482|Active Comparator|Opioid module first then fluid|The providers in this arm will first receive daily information and questions related to opioid use for eight weeks and then daily information and questions related to intravenous fluid prescribing for five weeks.
10182712|NCT03771482|Active Comparator|Fluid module first then opioid|The providers in this arm will first receive daily information and questions related to intravenous fluid prescribing for five weeks and then daily information and questions related to opioid use for eight weeks.
10182713|NCT03771378|Experimental|Effective of rhTPO|After enrollment, all subjects receive rhTPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
9519511|NCT03286504|No Intervention|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
9965935|NCT01254929||F-18 PET bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo an F-18 PET bone scan for diagnostic imaging.
9965936|NCT01254929||Tc-99m MDP bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo a Tc-99m MDP bone scan for diagnostic imaging.
10182714|NCT03771378|Active Comparator|Effective of eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
10182715|NCT03771430|Experimental|Non-surgical group|Osteoarthritis education, exercise and eCBT
10182716|NCT03771430|Experimental|Combined group|Total knee arthroplasty + osteoarthritis education, exercise and eCBT
10182717|NCT03771430|Active Comparator|Surgery only (standard care)|Total knee arthroplasty + standard physiotherapy
9519512|NCT03286504|Experimental|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take ~ 2 hours.
10182718|NCT03771365||Standard-PCNL|Perform PCNL with ≥24 Fr access tract for the treatment of ≥2 renal stones
10182719|NCT03771365||Mini-PCNL|Perform PCNL with 12-20 Fr access tract for the treatment of ≥2 renal stones
10182720|NCT03771365||Super-mini PCNL|Perform SMP for the treatment of ≥2 renal stones
10182721|NCT03771547||More 80|The first group included ERCP patients aged 80 and above.
10182722|NCT03771547||Less 80|The second group included those ERCP patients younger than 80.
10182723|NCT03771573|Experimental|Home based intervention|will be submitted to a total of 24 sessions of an unsupervised Cardiovascular Physical Therapy protocol, composed of the following steps: warm up, proper training (aerobic training + muscle training for upper and lower limbs with theraband in 5 series with 10 repetitions) often three times a week for eight weeks.
10182724|NCT03771573|Placebo Comparator|Control group|Will not be submitted to the Cardiovascular Physiotherapy Rehabilitation protocol for unsupervised domiciliary, only monitorization of cardiovascular variables.
9965937|NCT01254942|Active Comparator|Usual Care|Usual care following hip fracture
10117602|NCT04426890|Experimental|Arm 1|300 mg of CT-P39 as SC injections via PFS
10117603|NCT04426890|Active Comparator|Arm 2|300 mg of EU-approved Xolair as SC injections via PFS
10117604|NCT04426890|Experimental|Arm 2-1|300 mg of CT-P39 as SC injections via PFS
10117605|NCT04426890|Active Comparator|Arm 2-2|300 mg of EU-approved Xolair as SC injections via PFS
10117606|NCT04426890|Experimental|Arm 3|"Treatment period 1: 150 mg of CT-P39~Treatment period 2: 300 mg of CT-P39"
10117607|NCT04426890|Active Comparator|Arm 4|"Treatment period 1: 150 mg of EU-approved Xolair~Treatment period 2: 300 mg of EU-approved Xolair"
10117608|NCT04426773|Experimental|tDCS treatment|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
10117609|NCT04426864|Active Comparator|Supervised Aerobic Plus Stretching Exercises Group|The participants were instructed to perform the walking exercise at their target HR on a treadmill and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
10117610|NCT04426864|Experimental|Supervised Resistance Plus Stretching Exercises Group|The participants were instructed to perform resistance exercises using weight machines and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
10117611|NCT04426864|Experimental|Home-based Stretching Exercises Group|The participants were instructed to perform the stretching exercises at home.
10117612|NCT04426838|Experimental|PLwD Cognitive Behavioral Therapy for Insomnia (CBTi)|Persons living with dementia in a dyad receiving the CBTi intervention in a videoconferencing format.
10117613|NCT04426838|Experimental|Caregiver Cognitive Behavioral Therapy for Insomnia (CBTi)|Caregivers in a dyad receiving the CBTi intervention in a videoconferencing format.
10117614|NCT04427085|Experimental|Obese group|body mass index≥ 30 kg/m2
10117615|NCT04427085|Active Comparator|Non-obese group|BMI < 30 kg/m2
10117616|NCT04426851|Experimental|Part 2: BI 1358894 (Test 2-Reference 2)|BI 1358894
10117617|NCT04426851|Experimental|Part 2: BI 1358894 (Reference 2-Test 2)|BI 1358894
10117618|NCT04426851|Experimental|Part 1: BI 1358894 (Test 1-Reference 1)|BI 1358894
10117619|NCT04427020|Experimental|Milk Protein + Probiotic|25 gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
10117620|NCT04427020|Active Comparator|Milk Protein|25 gram dose of milk protein concentrate
10117621|NCT04426760||Women with submucosal leiomyoma(s)|Women with submucosal leimyomas undergoing hysteroscopical removal of the leiomyoma
10117622|NCT04426760||Women with intramural leiomyomas|Women with intramural leiomyomas undergoing myomectomy
10117623|NCT04426760||Infertility patients|Patients treated at the Department for Reproductive Medicine at the Oslo University hospital failing to conceive after 3 or more embryo transfers with good quality embryos.
10117624|NCT04426760||Fertile women|Healthy, volunteering women with proved fertility with 1 or more deliveries and no history of infertility
10117625|NCT04426916||normal lumbar spine|Patient without spondylolisthesis or significant spinal anatomic deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
10117626|NCT04426916||spondylolisthesis|Spondylolisthesis patients, with whom the deformity is at just one level. The patients should not have any other significant spinal deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
10117627|NCT04426994||Case|Patients admitted with hypomagnesemia are evaluated for proton pump inhibitor use and likelihood of hypomagnesemia due to proton pump inhibitor use
10117628|NCT04426994||Control|Patients on long-term proton pump inhibitor without documented hypomagnesemia
10117629|NCT04427124||Prospective|Patients admitted into the hospital will receive care based on a multidisciplinary team approach and Institutional critical limb ischemia protocol.
10117630|NCT04427124||Retrospective|A retrospective analysis of all patients with CLI admitted to the hospital from 2017-2019 will serve as a baseline comparator for overall CLI care and long-term mortality out to 2 years will be analyzed in the retrospective cohort using the national death index. Patients will be identified by the following ICD codes: 440.22 (ASVD of extremities with rest pain), 440.23 (ulceration), and 440.24 (gangrene).
10117631|NCT04426942||Spontaneous pregnancy|
10117632|NCT04426942||Assisted reproduction pregnancy|
10117633|NCT04427059|Experimental|Arm A - laparoscopic assisted TAP block|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (TPA).
10117634|NCT04427059|Active Comparator|Arm B - PSI|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.25%) is then injected for postoperative pain control according to the allocated procedure (PSI).
10117635|NCT04427007|Experimental|Experimental Prosthetic Liner|Participants will test the experimental liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
10117636|NCT04427007|Other|Control Prosthetic Liner|Participants will test the control liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
10117637|NCT04427098|Active Comparator|a phase II single-arm interventional prospective study|"Patients included in the interventional study will receive subcutaneous enoxaparin in a single daily dose of:~60 mg once daily in case of body weight of 45 to 60 kg~80 mg per day in case of weight from 61 to 100 kg or~100 mg once daily in case of bodyweight >100 kg~Enoxaparin will be started on the first day of COVID19 diagnosis and continued for 14 days."
10117638|NCT04427098|Experimental|observational cohort study|Patients included in the observational cohort will will receive standard thrombo-prophylaxis with subcutaneous enoxaparin 40 mg/die
10117639|NCT04426734|Experimental|Dextenza|"Sustained Released 0.4 mg Dexamethasone intracanalicular insert in both upper and lower punctum.~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
10182725|NCT03771573|Active Comparator|Professional seupervision based|eight weeks of supervised activities by professional. Each day and for 20 days (20 sessions), volunteers will undergo exercises on cycle ergometer during 30 minutes for upper and lower limbs
10182726|NCT03771534|Experimental|Oxygen gas|10-15 L/min of oxygen by face mask for up to 45 minutes for the MRI and up to 30 minutes for the echocardiogram.
10117640|NCT04426734|Active Comparator|Topical Pred Forte 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
10117641|NCT04426682||post-operative urinary incontinents|In patients who have previously had incontinence surgery due to stress incontinence, symptoms may return in the following years, and the patient may reapply with urinary incontinence. The first group will consist of postoperative urinary incontinence recurrent patients. Patients whose urodynamics are reperformed due to recurrence are the study group.
10117642|NCT04426682||without postoperative urinary incontinence|Patients who previously had incontinence surgery due to stress incontinence and who did not have postopertive urinary incontinence but whose urodynamics were repeated during the routine controls will constitute the control group.
10117643|NCT04426721|Experimental|Ozone|Participant will receive an intraarticular injection of oxygen-ozone, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
10117644|NCT04426721|Active Comparator|Hyaluronic acid|Participant will receive an intraarticular injection of hyaluronic acid, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
10117645|NCT04426552|Experimental|Dexmedetomidine|have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
10117646|NCT04426552|Active Comparator|Sevoflurane|(sevoflurane) will be preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
10117647|NCT04426578|Experimental|Perhexiline|
10117648|NCT04426578|Placebo Comparator|Placebo|
10117649|NCT04426617|Experimental|fentanyle|: patients will receive US guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & fentanyl).
10117650|NCT04426617|Experimental|Midazolam|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & midazolam).
10117651|NCT04426617|Placebo Comparator|control|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25%).
10117652|NCT04426643|Experimental|mesenchymal stem cells|Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
10117653|NCT04426643|Active Comparator|control|Patients with Urinary incontinence receiving standard treatment
10117654|NCT04426708|Experimental|Mild hepatic impaired subjects (A)|Mild hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
10117655|NCT04426708|Experimental|Moderate hepatic impaired subjects (B)|Moderate hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
10117656|NCT04426708|Experimental|Healthy volunteers (C)|Matched healthy volunteers: to receive a single dose of HMS5552 ( 25mg ) tablet orally
10117657|NCT04426669|Experimental|CISH CRISPR TIL / Phase I Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin
10117658|NCT04426669|Experimental|CISH CRISPR TIL / Phase II Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of CISH inactivated TIL
10117659|NCT04426331|No Intervention|No Voucher|"Individuals being referred from screening events randomized to no intervention received the standard approach to offering free follow-up examinations (patient education, standard counseling, appointment information packet, reminder phone calls)."
10117660|NCT04426331|Experimental|Voucher Without Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher Without Value Information received a personal voucher."
10117661|NCT04426331|Experimental|Voucher With Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher With Value Information received a personal voucher, which differed from the voucher in the second arm since it included a statement of value."
10117662|NCT04426357|Experimental|Group 1 (Participants with Renal impairment): JNJ-64417184|Participants with varying degrees of impaired renal impairment function (moderate renal impairment [optional], severe renal impairment, and end stage renal disease [ESRD] not requiring hemodialysis) will be enrolled and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
10117663|NCT04426357|Active Comparator|Group 2 (Healthy Participants): Control Group|Participants with normal renal function will be enrolled in controlled group and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
10117664|NCT04426422|Experimental|metformin group|all the patients were treated with metformin 1500-2000mg daily for 3 months.
10117665|NCT04426474|Experimental|LY3502970|LY3502970 administered orally.
10117666|NCT04426474|Placebo Comparator|Placebo|Placebo administered orally.
10117667|NCT04426513|Active Comparator|Only kinesiotherapy|Patients have only kinesiotherapy of hand without steroid anti-inflammatory drugs and magnetotherapy.
10117668|NCT04426513|Experimental|Kinesiotherapy with bipolar magnetic field|Patients have kinesiotherapy of hand and bipolar magnetic field. All patients without steroid anti-inflammatory drugs.
10117669|NCT04426513|Experimental|Kinesiotherapy with unipolar magnetic field|Patients have kinesiotherapy of hand and unipolar magnetic field. All patients without steroid anti-inflammatory drugs.
9965938|NCT01254942|Experimental|Intervention|Follow-up Fracture Clinic
10117670|NCT04426604|Experimental|Light induced fluorescence intraoral camera|
10117671|NCT04426604|Experimental|Laser-induced fluorescence device|
10117672|NCT04426604|Active Comparator|Visual-tactile assessment method according to FDI criteria|
10117673|NCT04426448|Experimental|Intervention group|Participants will receive the BREATHE intervention for three weeks
10117674|NCT04426448|No Intervention|Control group|The participants will receive treatment as usual
10117675|NCT04426500|Placebo Comparator|Placebo/Local Anesthesia|Direct injection of 0.25% bupivacaine into surgical wounds
10117676|NCT04426500|Active Comparator|Ultrasound-guided transversus abdominus plane (UTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
10117677|NCT04426500|Experimental|Laparoscopic-guided transversus abdominus plane (LTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using laparoscopic guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
10117678|NCT04426409|No Intervention|control group|
10117679|NCT04426409|Experimental|ointment group|Ointment group should apply a nasal ointment to both noses using a cotton swab the night before surgery and the morning of surgery.
10117680|NCT04426370||Case|100 rheumatoid arthritis patients (age from 20 to 70 years)
10117681|NCT04426370||Control|95 healthy volunteer
10117682|NCT04426487|Placebo Comparator|Control|Receiving conventional management for traumatic subarachinoid hemorrhage
10117683|NCT04426487|Active Comparator|progesterone group|Intramusculer progesterone therapy before and after craniotomy
10117684|NCT04426305|Experimental|Intervention arm|psychosocial support
10117685|NCT04426305|Active Comparator|control arm|care as usual
10117686|NCT04426526|Experimental|Biceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of biceps brachii.
10117687|NCT04426526|Experimental|Triceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of triceps brachii.
10117688|NCT04426526|Experimental|Lower limb circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of muscles in lower limbs.
10117689|NCT04426526|Experimental|Oblique muscles toning|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of oblique muscles.
10117690|NCT04426214|Experimental|Active tDCS|
10117691|NCT04426214|Placebo Comparator|Sham tDCS|
10117692|NCT04426344|Experimental|Group A - core warming|Patients randomized to Group A will have core warming with the ensoETM device initiated in the ICU or other clinical environment in which they are being treated. The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).
10117693|NCT04426344|No Intervention|Group B - Control Group|Group B is serving as the control group who will not have the ensoETM device used.Control group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature < 36°C) or antipyretic therapy for febrile patients, as requested by the treating physician.
10117694|NCT04426565|Other|the motivational enhancement interview|The motivational enhancement interview is a counseling approach developed in part by clinical psychologists William R. Miller and Stephen Rollnick. It is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.
10117695|NCT04426565|Other|the individual psychotherapy|The individual psychotherapy is the use of psychological methods, particularly when based on regular personal interaction with adults, to help a person change behavior and overcome problems in desired ways. Psychotherapy aims to improve an individual's well-being and mental health, to resolve or mitigate troublesome behaviors, beliefs, compulsions, thoughts, or emotions, and to improve relationships and social skills.
10117696|NCT04426565|Other|the group psychotherapy|The group psychotherapy is a form of psychotherapy in which one or more therapists treat a small group of clients together as a group. The term can legitimately refer to any form of psychotherapy when delivered in a group format, including Art therapy, cognitive behavioural therapy or interpersonal therapy, but it is usually applied to psychodynamic group therapy where the group context and group process is explicitly utilised as a mechanism of change by developing, exploring and examining interpersonal relationships within the group.
10117697|NCT04426565|Other|the family therapy|The family therapy is is a branch of psychotherapy that works with families and couples in intimate relationships to nurture change and development. It tends to view change in terms of the systems of interaction between family members.
10117698|NCT04426227|Experimental|Group Gaze|The gaze-trained group will be shown a video, derived from the eye tracker, of an expert's visual control whilst performing the ultrasound task. Participants will be made aware of the target-focused gaze strategy (lengthy and stable fixations on the needling target), and the manner in which the gaze shifted from target to tools (hands, needle and transducer) in a fast, smooth fashion. They will then be advised to try to mimic the gaze strategy of the expert while undertaking the needling task as their first training task. After completion of this training task, participants will be shown their own video data, as captured by the eye tracker. Participants will be asked to comment on differences between their own video and the expert video they had previously seen. This feedback process will be replicated a further four training task attempts. Participants in this group will therefore undergo a total of five training attempts of the needling task.
10117699|NCT04426227|Active Comparator|Group Discovery|The discovery learning group will be given no video feedback and will be instructed to perform five training attempts at the needling task without further training or feedback.
10117700|NCT04426162|Experimental|Memory Boot Camp Participants|All subjects undergo a 12-week control period, followed by a multi-domain 12-week memory program.
10117701|NCT04426097|Experimental|Cervical Vagal Blockade|
10117702|NCT04426097|Placebo Comparator|Without Blockade|
10117703|NCT04425993|Experimental|Rectal indomethacin and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
10117704|NCT04425993|Active Comparator|Rectal indomethacin and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
10117705|NCT04425993|Active Comparator|Rectal placebo and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
10117706|NCT04425993|Placebo Comparator|Rectal placebo and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
10117707|NCT04425889||exposed Healthcare workers|Healthcare workers working for 8 weeks in a COVID-19 area
10117708|NCT04426435|Experimental|Intervention|Group A: patients receiving HB syrup, 10 cc three times daily
10117709|NCT04426435|Placebo Comparator|Placebo|Group B: patients receiving placebo, 10 cc three times daily
10117710|NCT04426955|Experimental|Arm A|Camrelizumb + Paclitaxel + Cisplatin + Radiotherapy.
10117711|NCT04426955|Placebo Comparator|Arm B|Placebo + Paclitaxel + Cisplatin + Radiotherapy.
10117712|NCT04426019|Experimental|CLS intervention|
10117713|NCT04426019|Active Comparator|No CLS intervention|
10117714|NCT04425967|Active Comparator|25x2Gy|the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week OTT
10117715|NCT04425967|Experimental|14x3Gy|the study schedule of 14 x 3 Gy, once daily fractionation in a three-week overall treatment time
10117716|NCT04426045|Experimental|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
10117717|NCT04426045|Active Comparator|Supra-inguinal fascia iliaca compartment block|Participants receiving supra-inguinal fascia iliaca compartment block
10117718|NCT04425902|Experimental|Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254|Participants will be administered a single dose of probe substrate drugs: caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg (2.5 milliliter [mL]), digoxin 0.25 mg, and pravastatin 40 mg on Day 1; followed by washout of 10 days. On Days 11 to 20, participants will be administered once daily doses of GSK3640254 200 mg followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.
10117719|NCT04426136||1. WLE group|patients in this group receiving WLE merely
10117720|NCT04426136||2. other method group|patients in this group receiving any other surgical procedures except WLE
10117721|NCT04426175|Experimental|2D LASIK|With the 2D method, the flap resection is created in a planar mode (xy-plane), without vertical cut, at the requested depth.
10117722|NCT04426175|Experimental|3D LASIK|With the 3D method, the flap resection is done in a three-dimensional mode, at the requested depth, with the requested diameter and the desired border (side cut) angle
10117723|NCT04425980|Experimental|Modified Constraint-Induced Movement Therapy (test treatments)|A list of fine and motor activities consisted of the functional tasks or play activities such as school-education and sports activities, manipulative games, arts, and crafts, etc. to elicit the maximum capacity of the more affected upper limb was created according to the procedure of modified constraint-induced movement therapy (Gordon et al., 2005) and Bimanual training. In addition, specific activities were also chosen in terms of deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request. In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook a role as a dominant hand
10117724|NCT04425980|Active Comparator|Bimanual training|For the Bimanual training, skilled, repetitive, and structured bimanual activities (part or whole task practice) were used to promote bimanual hand use and improve movement deficits determined before the intervention. All targeted deficits of interest were addressed within the context of the selected activity. Specifically, symmetrical bilateral movements were utilized to augment neural input from both sides. Also, meaningful activities such as buttoning and zipping-up trousers, etc. were used to ensure a transition from structured setting to real-life activities
10117725|NCT04426240|Active Comparator|Cyclosporine|Subject who use cyclosporine and hyaluronate artificial tear 1 month before cataract surgery
10117726|NCT04426240|No Intervention|non-Cyclosporine|Subject who use only hyaluronate eye drop 1 month before cataract surgery
10117727|NCT04426032||Patients with RRI between 0.6 and 0.7|Normal renal resistive index
10117728|NCT04426032||Patients with RRI more than 0.7|High renal resistive index
10117729|NCT04425928|Active Comparator|activity group|Participants received an activity-based home program that was performed for 4 weeks.
10117730|NCT04425928|Experimental|exercise group|Participants received an exercise-based home program was performed that was performed for 4 weeks.
10117731|NCT04425928|No Intervention|control group|No intervention
10117732|NCT04426123|Active Comparator|Botulinum toxin|Botulinum toxin type A
10117733|NCT04426123|Placebo Comparator|Saline solution|NaCl
10117734|NCT04426149|Experimental|interventional|supplement: trehalose
10117735|NCT04425876|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib combined with FOLFIRINOX followed by maintenance Fluzoparib monotherapy
10117736|NCT04426188|Sham Comparator|Without mouthguard|Heading series without mouthguard from machine-projected soccer balls at standardized speeds
10117737|NCT04426188|Experimental|With mouthguard|Heading series with mouthguard from machine-projected soccer balls at standardized speeds
10117738|NCT04425837|Active Comparator|Standard care alone|
10117739|NCT04425837|Experimental|SARS-CoV-2 convalescent plasma treatment plus standard care|
10117740|NCT04425564|Active Comparator|Classic (A)|patients recieving classic XELOX (oxaliplatin 130mg/m2 and capecitabine 1000mg/m2 bid)
10117741|NCT04425564|Experimental|metronomic (B)|patients recieving low dose capecitabine (2000mg daily divided in two doses for 8 weeks) and oxaliplatin (30mg/m2 weekly for eight weeks) followed by 2 weeks rest.
10182727|NCT03771287|Experimental|OpenSound Navigator (OSN) Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
10117742|NCT04425551|Active Comparator|Treated|"The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias.~The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn.~After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes."
10117743|NCT04425551|No Intervention|Untreated|The lateral eye was observed as control.
10117744|NCT04425590|Experimental|Experimental Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
10117745|NCT04425590|Active Comparator|Control Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
10117746|NCT04425655|Experimental|Fludarabine and CPX351|"Induction 1:~Fludarabine 30 mg/m2/day IV on days 1-5 for 5 doses Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3, 5 (given 4 hours after fludarabine infusion) for 3 doses~Induction 2 (residual leukemia after Induction 1):~Fludarabine 30 mg/m2/day IV on days 1-3 for 3 doses~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3 (given 4 hours after fludarabine infusion) for 2 doses~Optional consolidation, up to 2 cycles:~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 29 mg/m2/day and cytarabine 65 mg/m2/day IV on days 1, 3 for 2 doses"
10117747|NCT04425460|Experimental|Favipiravir|Favipiravir Tablets, 200 mg/tablet Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
10117748|NCT04425460|Placebo Comparator|Placebo|Placebo control group Favipiravir combined with supportive care recommended in the current National/Local guidelines
10117749|NCT04425642|Experimental|Glucose/Amino acids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose and amino acids according age and weight
10117750|NCT04425642|Experimental|Glucose/Amino acids/Lipids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose, amino acids and lipid emulsions according age and weight
10117751|NCT04425668|Active Comparator|Control Group|
10117752|NCT04425668|Experimental|Academic detailing intervention|
10117753|NCT04425512|Active Comparator|Thyroid Malignancy|Thyroidectomy
10117754|NCT04425512|Sham Comparator|Benign Thyroidal Goitor|Thyroidectomy
10117755|NCT04425512|Other|Control Group|Selective lichtenstein procedure for inguinal hernia
10117756|NCT04425811|No Intervention|No tape applied|Walking parameters were evaluated without any intervention.
10117757|NCT04425811|Experimental|Kinesiological Tape|Walking parameters were evaluated after kinesiological taping on the tibialis anterior muscle
10117758|NCT04425811|Sham Comparator|Sham taping|Walking parameters were evaluated after sham taping on the tibialis anterior muscle
10117759|NCT04425694||F3B ward staff|The e-EWS system will be implemented in a selected surgical ward (F3B ward) in Tuen Mun Hospital. All F3B ward staff will use the system and evaluate its effectiveness.
10117760|NCT04425616|Experimental|Universal Interventions|"The delivery of nutrition, exercise and psychological interventions delivered in the following structure:~Month 1: Up to three times per week~Months 2-3: Once per week~Months 4 - 6: One session per month for the last 3 months"
10117761|NCT04425681|Experimental|Osimertinib With Bevacizumab group|Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks
10117762|NCT04425499|Placebo Comparator|Control group|On GEN (Gamified Educational Network), each student will view individually eight videos of an expert performing a running subcuticular suture correctly. The OSATS (Objective Structured Assessment of Technical Skills) Global Rating Scale (GRS) and Subcuticular Suture Checklist will be available beside each video and students will be required to fill them out for each video. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, students will view the same eight videos of an expert performing a running subcuticular suture, however, the videos will be shuffled in a different order. The order of the videos will be the same for all students.
10117763|NCT04425499|Experimental|Self-learning|Each student will view eight videos individually and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. The errors will be technical mistakes in the execution of a running subcuticular suture. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, all students will repeat this activity. However, the same videos will be shuffled in a different order. The order of the videos will be the same for all students.
10117764|NCT04425499|Experimental|Peer-learning|Each student will view eight videos and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. After this initial test, students will interact with other medical students in their group on the GEN platform anonymously for three days. We will display distinct videos on GEN. Comments will be allowed in an interactive way to encourage exchanges. Students will be required to participate in the discussion of at least two videos. Students will not be able to modify their answers on the initial test. On the third day, students in this group will perform a post-test individually with the same eight initial videos but shuffled. The order of the videos will be the same for all students.
10117765|NCT04425499|Experimental|Peer-learning with expert feedback|"Same as group 3, the only difference is that an expert will actively participate in the discussion by commenting on each video on GEN, enhancing students' educational experience. Although anonymous, students will be able to identify the expert as the name expert will be used. The expert will answer any question and comment on the discussion in order to guide the students."
10117766|NCT04425707|Experimental|A ivermectin alone|ivermectin will be administarted alone to COVID 19 patients
10117767|NCT04425707|Experimental|B standard care alone|standard care will be administarted alone
9965939|NCT01254955||organ transplant patients|
9965940|NCT01254955||healthy controls|
9965941|NCT01254968||examining group|20 healthy subjects (11 men, 9 women, average age 23.94)
9965942|NCT01254968||control group|6 healthy subjects (3 men, 3 women, average age 23.6)
9965943|NCT01254981|Experimental|Nobori|Percutaneous coronary intervention with implantation of coronary stent (Nobori)
9965944|NCT01254981|Experimental|Cypher|Percutaneous coronary intervention with implantation of coronary stent (Cypher)
9965945|NCT01254994|Active Comparator|Control group|The patients were prescribed the tradition comprehensive medical treatment without entecavir.
9965946|NCT01254994|Experimental|ETV group|All the patients were prescribed the tradition comprehensive medical treatment with entecavir. Entecavir was supplied by the Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Patients took 0.5 mg entecavir following oral fasting one time per day.
9965947|NCT01255007|Experimental|Post chemotherapy group|The first group consists of patients with colorectal liver metastases who have had treatment with chemotherapy and are now awaiting surgery. This group would have had Multidetector Liver CT (MDCT) imaging prior to the chemotherapy, and will now undergo post chemotherapy MDCT as part of standard clinical care in addition to Gd-EOB-DTPA enhanced liver MRI and Diffusion Weighted MRI (DW-MRI). The MRI will be performed as an additional imaging investigation after obtaining informed consent.
9965948|NCT01255007|Experimental|Pre and Post Chemotherapy Group|The second group consists of patients with colorectal liver metastases who are due to receive neoadjuvant chemotherapy. This group will be imaged prior to receiving and after receiving chemotherapy. This will all be done prior to surgical resection of their colorectal liver metastases.
9965949|NCT01255020|Active Comparator|α-Keto Acid plus restricted protein diet|Participants randomized to this group will receive 12 months treatment of α-Keto Acid. The dose of α-Keto Acid is 100mg/kg per day and will divided into three times per day, and the α-Keto Acid will be asked to be taken during the meal. In addition, the participants will be asked to restrict the protein intake. The protein intake is restricted as 1g/kg/d.
9965950|NCT01255020|Placebo Comparator|Placebo plus restricted protein diet|All participants will receive 12 months treatment of placebo, at the same time they will be asked to restrict the protein intake.The dose of placebo is 100mg/kg per day, and the protein intake is restricted as 1g/kg/d.
9965951|NCT01255033||Pulmonary surgical patients|Patients submitted for scheduled lung surgery requiring one-lung ventilation
9965952|NCT01255046|Active Comparator|Donepezil plus STA-1|
9965953|NCT01255046|Placebo Comparator|Donepezil plus placebo|
9965954|NCT01255059||Female lung cancer group|Female, non-smoker, non-small cell lung cancer
9965955|NCT01255059||Health control|Female, non-smokers, no lung cancer or other types of cancers' healthy population
9965956|NCT01255072|Active Comparator|Active rTMS + placebo|Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
9965957|NCT01255072|Sham Comparator|SHAM|Patients, free from medication at least for one week (washout of 3 weeks for fluoxetine users)receiving 20 sessions of Sham TMS delivered to the left dordolateral prefrontal cortex, at the same time this washed out of antidepressives patients start taking Citalopram 20mg/day, for 60 days.
9965958|NCT01255085|Experimental|10 g of yellow pea fiber|
9965959|NCT01255085|Experimental|20 g of yellow pea fiber|
9965960|NCT01255085|Experimental|10 g of yellow pea protein|
9965961|NCT01255085|Experimental|20 g of yellow pea protein|
9965962|NCT01255085|Experimental|Control Tomato Soup|
9965963|NCT01255098||Experimental Group|
9965964|NCT01255098||Control Group|
9965965|NCT01255124||Health infants (ClinicalTrials.gov ID: NCT01183611)|The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
9965966|NCT01255176|No Intervention|placebo group|not receive physical therapy intervention, there will only support the achievement of a handbook on the abdomen of the baby.
9965967|NCT01255176|No Intervention|control group|not receive any type of intervention, and infants remain at rest
9965968|NCT01255176|Experimental|Thoracoabdominal rebalancing|infants who receive physical therapy through the application of the handlings of the RTA.
9965969|NCT01255189|Experimental|Device: near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements
10117768|NCT04425707|Active Comparator|C ivermectin added to standard of care|ivermectin will be administarted in adition to standard care
9965970|NCT01255202||twin preganacies|
9965971|NCT00605982|Experimental|1|Women with core biopsy proven DCIS with or without microinvasion seen for surgical consultation at Memorial Sloan-Kettering Cancer Center and for whom operative intervention is planned.
9965972|NCT01255215|Experimental|Inhaled Nitric Oxide|iNO, a gaseous molecule, will be administered by inhalational route over a maximum period of 72 hours.
9965973|NCT01255215|Placebo Comparator|Room air|Room air will be delivered by air compressor through an indistinguishable mask system.
9965974|NCT01255228|Experimental|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
9965975|NCT01255228|Experimental|diet intervention|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
9965976|NCT01255241||othopaedic surgical intervention|children with lower limbs deformities
9965977|NCT01255254|Experimental|A: Scaling group|The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
10117769|NCT04425824|Experimental|Toripalimab combine with Rituximab|"Experimental: Toripalimab combine with Rituximab~Induction period:~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Maintenance:~Toripalimab 240mg administered intravenously (IV) and Rituximab 375mg/m² on Day 1 of each 56-day cycle for 6 cycles."
10117770|NCT04425772|Experimental|Experimental Group|FNC+Standard of Care
10117771|NCT04425772|Placebo Comparator|Control Group|FNC dummy tablet+ Standard of Care
10117772|NCT04425785|Experimental|Physical Exercise Group|A structured exercise program for 12 weeks
10117773|NCT04425785|Experimental|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy for 12 weeks
10117774|NCT04425785|No Intervention|Standard Clinical Care|Standard Clinical Care
10117775|NCT04425733|Experimental|Panel A MK-5475 180 µg|Participants receive 180 µg of MK-5475 once daily (QD) via inhalation from Days 1-7.
10117776|NCT04425733|Placebo Comparator|Panel A Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
10117777|NCT04425733|Experimental|Panel B MK-5475 360 µg|Participants receive 360 µg of MK-5475 QD via inhalation from Days 1-7.
10117778|NCT04425733|Placebo Comparator|Panel B Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
10117779|NCT04425733|Experimental|Panel C MK-5475 ≤360 µg|Participants receive ≤360 µg of MK-5475 QD via inhalation from Days 1-7.
10117780|NCT04425733|Placebo Comparator|Panel C Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
10117781|NCT04425798||Patients with LEV application|LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.
10117782|NCT04425798||Patients without LEV application|LGG patients with GRE do not take any medicine or receive any treatment preoperatively.
10117783|NCT04425265|Experimental|Plasma radiofrequency ablation arm|Plasma radiofrequency ablation at low temperature for localized recurrent nasopharyngeal carcinoma
10117784|NCT04425265|Active Comparator|Electrocautery block resection arm|Electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma
10117785|NCT04425369|No Intervention|inner side approaches for iliac crest bone graft|An anterior approach was used to expose the inner table of the ilium.
10117786|NCT04425369|Experimental|two-sided approaches for iliac crest bone graft|both sides of the ilium were totally exposed of the ilium.
10117787|NCT04425408|Experimental|Positional pillow followed by vibrating belt|26 patients with positional sleep apnea will be randomized to spend 3 nights using a positional pillow followed by a vibrating belt. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
10117788|NCT04425408|Experimental|Vibrating belt followed by positional pillow|26 patients with positional sleep apnea will be randomized to spend 3 nights using a vibrating belt followed by a positional pillow. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
10117789|NCT04425187|Active Comparator|gefitinib|
10117790|NCT04425187|Experimental|gefitinib&bevacizumab|
10117791|NCT04425304|Active Comparator|Group counseling|
10117792|NCT04425304|Experimental|Group counseling + persuasive ICT support|
10117793|NCT04425304|Active Comparator|Intensive group counseling|
10117794|NCT04425304|Experimental|Intensive group counseling + persuasive ICT support|
10117795|NCT04425109|Experimental|tempeh steak|The subjects were received the tempeh steak meal with isocal diet containing energy 307.4Kcal
10117796|NCT04425109|Experimental|soybean steak|The subjects were received the soybean steak meal with isocal diet containing energy 307.4Kcal
10117797|NCT04425473|Experimental|Esketamine|
10117798|NCT04425473|Placebo Comparator|Placebo|
10117799|NCT04425382||Darunavir/Cobicistat|Patients received Darunavir/Cobicistat (Rezolsta®) as part of the treatment regimen for COVID-19 pneumonia
10117800|NCT04425382||Lopinavir/Ritonavir|Patient received Lopinavir/Ritonavir (Kaletra®) as part of the treatment regimen for COVID-19 pneumonia
10117801|NCT04425343|Experimental|Periodontitis, Adult|Plaque samples were taken from subgingival pocket and send to the lab for metagenomic analysis
10117802|NCT04425343|Experimental|Metgenomic analysis|Analysis for whole bacterial count
10117803|NCT04425330|Experimental|physiotherapy exercises + PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The irradiation will be with LED with a wavelength of 850 nm, energy per point of 25 J, 50 seconds per point and power of 200 mW.~Treatment will be performed in 24 sessions 2 times a week"
10117804|NCT04425330|Sham Comparator|physiotherapy exercises + SHAM PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The same LED device will be used in groups. However, in the placebo group (Sham), the device does not emit light.~Treatment will be performed in 24 sessions 2 times a week"
10117805|NCT04425135|Experimental|Camrelizumab +apatinib mesylate+Pemetrixed + Carboplatin|Camrelizumab combined with apatinib mesylate,Pemetrixed and Carboplatin in the treatment（4-6 cycle）of effective (CR, PR, SD) patients continued to be treated with Camrelizumab combined with apadine mesylate until PD, toxicity intolerance, and other reasons that the researcher thinks need to stop the research treatment.
10117806|NCT04424992||Covid19 infection related patients|The patients enrolled in the study are all patients with clinical and microbiological diagnosis of COVID-19 infection hospitalized since February 23, 2020 at San Gerardo Hospital (ASST-Monza).
10117807|NCT04425161||VO2 ≥15 %|This group is classified based on increased oxygen consumption (VO2) ≥15 % by volume expansion in fluid responders
10117808|NCT04425161||VO2 <15 %|This group is classified based on increased oxygen consumption (VO2) < 15 % by volume expansion in fluid responders
10117809|NCT04425044||AiM Covid|Self Monitoring of symptoms in AiM Covid App
10117810|NCT04425278|Active Comparator|Real Stimulation|The Real Stimulation of tDCS lasted 20 mins.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
10117811|NCT04425278|Sham Comparator|Sham Stimulation|The Sham Stimulation of tDCS lasted 20 minutes with no current. In particular, the current went up for the first 30 seconds and went down for the last 30 seconds.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
10117812|NCT04425278|No Intervention|Control|Behavior and ERPs dataset should be acquired before and after 14 days.
10117813|NCT04425005|No Intervention|Control group|
9965978|NCT01255254|No Intervention|B: Control group|The control group will receive no periodontal treatment during the study. After completion of the study, these patients will be given oral hygiene instruction and a full mouth scaling.
9965979|NCT01255267||Acute coronary syndrome patients|
10117814|NCT04425005|Experimental|Exercise training group|
10182728|NCT03771287|Active Comparator|omni-directional Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the Omni-directional microphone system enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
10182729|NCT03771248|Active Comparator|Co-cr telescopic partial denture|A removable partial denture, that gains retention from a telescopic crown made of cobalt chromium
10182730|NCT03771248|Experimental|PEEK telescopic partial denture|A removable partial denture, its attachment is a telescopic crown made of PEEK
10182731|NCT03771300|Experimental|Mindfulness condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
10182732|NCT03771300|Experimental|Mindfulness condition complemented by VR|This condition is equivalent to the mindfulness condition (group sessions, held once a week over a space of 6 weeks and offered as an extra-curricular activity), unlike the time of each session, which is reduced from 90 to 75 minutes of duration.
10182733|NCT03771300|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extra-curricular activity.
10182734|NCT03771222|Experimental|Prophylactic DLI|The scheduled time of the first prophylactic DLI was +30 ~ +60 days after transplantation for HLA-matched sibling donors (MSD)-PBSCT recipients and +60 ~ +90 days after transplantation for HLA-haploidentical sibling donors (HID)-PBSCT recipients.
10182735|NCT03771222|No Intervention|No prophylactic DLI|
10182736|NCT03771339|Active Comparator|Continuous Epidural Analgesia|Continuous epidural analgesia using ropivacaine 0.375% 3 mL boluses followed by ropivacaine 0.2% with rate 6 mL per hour for 24 hours
10182737|NCT03771339|Experimental|Bilateral Quadratus Lumborum Block|Bilateral Quadratus lumborum block using ropivacaine 0.2% 20 mL each injection after surgery
10182738|NCT03771170|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
10182739|NCT03771170|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
10182740|NCT03771105|Experimental|Patients with hereditary hypophosphatemic rickets with HHRH|Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
10182741|NCT03771105|Active Comparator|Patients with X-linked Hypophosphatemia|Patients with X-linked hypophosphatemia
10182742|NCT03771105|Active Comparator|15 Patients with X-linked Hypophosphatemia|15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
9965980|NCT01255267||Chronic coronary artery disease patients|
9965981|NCT01255267||Healthy control|
10182743|NCT03771105|Active Comparator|15 Patients Hereditary hypophosphatemic rickets with HHRH|15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
10182744|NCT03771235|Experimental|Mindfulness-based Intervention for Tics|8-week group-based mindfulness-based program
10182745|NCT03771235|Active Comparator|Tic Information and Coping Strategies|8-week group-based educational and supportive therapy program
10182746|NCT03770988|Experimental|poziotinib single arm study|Single Arm study
10182747|NCT03770897|Experimental|3D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed with 3d technology device by young surgeons, tutored by an expert assistant.
10182748|NCT03770897|Active Comparator|2D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed by young surgeons (tutored by an expert assistant) with the standard 2D viewing method.
10182749|NCT03771144|Experimental|Experimental|
10182750|NCT03771131|Experimental|Experimental group|Group receiving the multi-domain cognitive training
10182751|NCT03771131|No Intervention|Control group|Passive control group
10182752|NCT03771196|Experimental|Bioactive-Restorative material|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
9976409|NCT01351155|Active Comparator|polyurethane foam (Allewyn adesive)|Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
9976410|NCT01351155|Active Comparator|polyurethane film (Tegaderm)|The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
10117815|NCT04425356|Experimental|Intervention Group|This group will receive the LifeXT program
10117816|NCT04425356|No Intervention|Control Group|Wait-list control group that receives the LifeXT program after the conclusion of the study
10117817|NCT04425083||Polycystic Ovary Syndrome|Polycystic Ovary Syndrome women
10117818|NCT04425083||control|non- Polycystic Ovary Syndrome women
10117819|NCT04424953|Active Comparator|McGrath videolaryngoscope|Anesthetists randomized to this group will intubate patients using the McGrath videolaryngoscope
10117820|NCT04424953|Active Comparator|Direct laryngoscope|Anesthetists randomized to this group will intubate patients using the direct laryngoscope
10117821|NCT04425057|Experimental|Interval training|Physiotherapy program during two months: Interval training at a high intensity, inlcuding a warm-up and a cool-down. Aerobic exercises, resistance exercises, stretching
10117822|NCT04425057|No Intervention|Control group|No physiotherapy
10117823|NCT04425070|Experimental|ATG-010 + ICE|ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11
10117824|NCT04425070|Experimental|ATG-010 + GEMOX|ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9
10117825|NCT04425122||Esophageal cancer|Patients with esophageal cancer (SCC)
10117826|NCT04425122||Non-cancer group|Non-cancer patients scheduled for upper endoscopy
10117827|NCT04425226|Experimental|Pembrolizumab plus Lenvatinib|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle. Number of cycles: until >42 days before liver transplantation or unacceptable toxicity develops. Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation.
10117828|NCT04425226|No Intervention|Comparator|Participants are advised to stay as healthy as possible and wait regularly
10117829|NCT04424901|No Intervention|Standard Care|"Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
10117830|NCT04424901|Experimental|Standard Care with Dipyridamole|"For this arm, Dipyridamole 100 mg, tid is given for 7 days. Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
10117831|NCT04424888|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 2 weeks
10117832|NCT04424888|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 2 weeks
10117833|NCT04424836||H GROUP|patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.
10117834|NCT04424836||C GROUP|patients get the oxygen supply with conventional methods. In group C 6-15 L/min oxygen delivered to patients by conventional methods and targeted to maintain the oxygen saturation %90 or over.
10117835|NCT04424758|Experimental|Intervention group|Receives information about mammography screening through a video. The video was developed with the goal of informing about mammography screening in a societal perspective using best available evidence.
10117836|NCT04424758|Placebo Comparator|Control group|Receives information about energy systems through a video. The video does not contain any information related to mammography screening.
10117837|NCT04424784|No Intervention|20% O2|In the control group, oocyte pickup will be performed in atmospheric oxygen environment (20% oxygen, 89% nitrogen, 6% carbon dioxide).
10117838|NCT04424784|Experimental|5% O2|In the experimental group, oocyte pickup will be performed in a low oxygen tension environment (5% oxygen, 89% nitrogen, 6% carbon dioxide). If time lapse embryo culture system is used, fertilization check and embryo grading will also be conducted under the low oxygen tension environment.
10117839|NCT04424771||Health workers|They include doctors, nurses, techinicians, biologists and other non technical inhospital workers
10117840|NCT04424810|Experimental|Video group|Patients selected to be in the intervention group will be asked to watch a high-quality, physician created video describing their condition and the operative treatment they are about to undergo.
10117841|NCT04424810|Placebo Comparator|Control group|Patients selected to be in the control group will not be asked to watch a video prior to surgery.
10117842|NCT04424680|No Intervention|Control|"Patients will be followed in heart failure outpatients units according to the usual established protocol. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.~Treatment for heart failure will be the same in both groups."
10117843|NCT04424680|Experimental|Intervention|"Patients will participate in the Advanced Care Planning Program. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.~Treatment for heart failure will be the same in both groups."
10117844|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 28|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 28 will receive a placebo injection at week 36. Subject will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
10117845|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 36|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 36 will receive a placebo injection at week 28. Subjects will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
10117846|NCT04424706||Normal people|No diabetes and atherosclerosis
10117847|NCT04424706||type 2 diabetes mellitus without atherosclerosis|Newly diagnosed type 2 diabetes without atherosclerosis
10117848|NCT04424706||type 2 diabetes mellitus with atherosclerosis|Newly diagnosed type 2 diabetes with atherosclerosis
10117849|NCT04424875|Experimental|study arm|patients will undergo surgery to remove impacted lower third molar and receive Melatonin (3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%) in the socket following removal of the impacted third molar
10117850|NCT04424875|Placebo Comparator|controlled arm|patients will undergo surgery to remove impacted lower third molar and patients will receive no melatonin (2 ml of hydroxyethyl cellulose gel 2 %).
10117851|NCT04424719|Other|Patients with uveal melanoma|
10117852|NCT04424407|Other|CBT-I|
10117853|NCT04424732|Other|Stereotactic Body Radiotherapy for Breast Bony oligometastases|Newly diagnosed bone only oligometastatic breast cancers with 1-3 bone metastases will be enrolled in this protocol. Patients will receive SBRT to all metastatic sites.
10117854|NCT04424420|Experimental|Paracetamol|Study phase 1 (single dosing): 1000 mg once. Study phase 2 (multiple dosing): 1000 mg twice daily for a minimum of 12 and a maximum of 14 days.
10117855|NCT04424420|Active Comparator|Ibuprofen|Study phase 1 (single dosing): 800 mg once.
10117856|NCT04424420|Placebo Comparator|Placebo|Study phase 1 (single dosing): Once. Study phase 2 (multiple dosing): Twice daily for a minimum of 12 and a maximum of 14 days.
10117857|NCT04424823|Experimental|LED|LED photobiomodulation therapy for the non-specific LBP working nurse
10117858|NCT04424823|Sham Comparator|Sham|Shame group. The all procedure was same as the LED group but the LED ped was upside down without direct treatment.
10117859|NCT04424433|Other|Normoxaemia First|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second.
10117860|NCT04424433|Other|Hyperoxia First|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second.
10117861|NCT04424576||Regular Menstrual Cycles|22 adolescents with regular menstrual cycles (i.e., once every 4-6 weeks) will be enrolled within 11 months of menarche.
10117862|NCT04424576||Irregular Menstrual Cycles|26 adolescents with irregular menstrual cycles (i.e., < 4 weeks or > 6 weeks between periods) will be enrolled within 11 months of menarche.
10117863|NCT04424472|Experimental|Ultrasonography|Patient will be scheduled to undergo an additional US by a blinded sonographer within 4 weeks of their most recent cross-sectional imaging that indicated a recurrence
10117864|NCT04424667|Active Comparator|Holder pasteurization|Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
10117865|NCT04424667|Experimental|HTST pasteurization|Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
10117866|NCT04424511|Placebo Comparator|Control|"Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml / kg child weight~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture."
10117867|NCT04424511|Active Comparator|Azithromycin-biannually (Azi-biannual)|"Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml / kg child weight~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug.~Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg."
10117868|NCT04424511|Active Comparator|Azithromycin-quarterly|"Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age:~Single-dose of 0.5 ml (20 mg) / kg child weight.~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin."
10117869|NCT04424563||Group A|Patients of group A include 40 patients, received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
10117870|NCT04424563||Group B|While patients of group B include 40 patients, received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed.
10117871|NCT04424485|Active Comparator|Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy|"Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC)~Standard TT+CLND procedure only"
10117872|NCT04424485|Experimental|Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node|"Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND).~TT+CLND with NIR fluorescence ICG"
10117873|NCT04424459||Patients included from 10/01/19 to 12/31/19.|Patients included from 10/01/19 to 12/31/19. (the study will be extended to a larger number of patients according to the first results), continued according to the first results. DCNC patients treated at the Montpellier Pain Assessment and Treatment Center hospitalized during the period from 10/01/19 to 12/31/19, for misuse of opioid treatment.
10117874|NCT04424628|Active Comparator|Radiotherapy 3 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (0.5 Gy in 6 fractions alternating days).~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be randomized to 3 or 6 Gy again"
10117875|NCT04424628|Active Comparator|Radiotherapy 6 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (1 Gy in 6 fractions alternating days).~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be treated with 6 Gy again"
10117876|NCT04424849||COVID-19 patients|Patient tested positive for COVID-19 who had a CT scan
10117877|NCT04424381|Active Comparator|Rivaroxaban 20 MG Oral Tablet [Xarelto]|rivaroxaban oral tablet [Xarelto] at a single oral dose of 20 mg
10117878|NCT04424381|Experimental|Rivaroxaban 20 MG Oral Tablet|rivaroxaban oral tablet at a single oral dose of 20 mg
10117879|NCT04424394|Experimental|DualStim Therapy with Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of umbilical cord-derived Wharton's Jelly formulation.
10117880|NCT04424394|Active Comparator|DualStim Therapy without Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of normal saline.
10117881|NCT04424589|Experimental|Myofascial release|"Myofascial release or induction (MFR) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. Manual therapists often use their hands using their knuckles, elbows, or other instrumental tools to slowly penetrate the layers of the fascia, using applied pressure with a few kilograms of force that can strain the restricted fascia, this implies a guided gentle stretch.~The experimental group will receive 1 examination session and 6 myofascial release sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for the spinal at the level of the quadratus lumborum, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks."
10117882|NCT04424589|Sham Comparator|Sham Therapy|The control group will receive 1 examination session and 6 simulated myofascial releasesessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial release, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
10117883|NCT04424264|Experimental|Tenofovir Alafenamide|TAF 25 mg once-daily administered with RIF/INH 600*/300mg
10117884|NCT04424329|Experimental|Nutrition intervention|Ingestion of fibers and probiotics daily for 22 days
10117885|NCT04424329|No Intervention|No intervention|No intervention
10117886|NCT04424303||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).
10117887|NCT04423991|Experimental|Exposed group|All patients were exposed to the algorithm and were characterized as being likely responders to hydroxychloroquine treatment. Treatment decisions regarding the administration of hydroxychloroquine were made independently by care providers.
10117888|NCT04423926|Experimental|Lenalidomide+CHOP|
10117889|NCT04423965|Experimental|mFOLFOXIRI|Patients receive 6 cycles of mFOLFOXIRI
10117890|NCT04423965|Experimental|Chemoradiotherapy(CRT)|Patients receive standard chemoradiotherapy
10117891|NCT04424095||Pediatric patients|Recruited pediatric patients will undergo an in-office vascular visit and an echo duplex scan of lower limbs, in order to detect any symptoms or signs related to chronic venous disease.
10117892|NCT04424186|Experimental|'Rehabilitation for Life'|Vital sign measurement and rehabilitation
10117893|NCT04424186|Active Comparator|Usual care and rehabilitation|Usual care and rehabilitation provided in primary and secondary sectors
10117894|NCT04424056|Experimental|Anakinra +/- Ruxolitinib|"Anakinra +/- Ruxolitinib~According to clinical stage (gradual strategy):~Stage 2b or 3 : Anakinra +/- ruxolitinib depending of evolution; Advanced stage 3 : Anakinra and Ruxolitinib"
10117895|NCT04424056|Experimental|Tocilizumab +/- Ruxolitinib|"Tocilizumab +/- Ruxolitinib~According to clinical stage (gradual strategy):~Stage 2b or 3 : Tocilizumab +/- ruxolitinib depending of evolution; Advanced stage 3: Tocilizumab +ruxolitinib"
10117896|NCT04424056|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
10117897|NCT04424017||Healthcare workers (HCWs)|
10117898|NCT04424017||Healthy blood donors and healthy subjects in blood bank|
10117899|NCT04424017||Convalescents|
10117900|NCT04424043|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
10117901|NCT04424043|Active Comparator|surgery alone|hepatic resection remove the liver tumors
10117902|NCT04423913|Experimental|Patients undergoing transarterial embolization of the prostate|Three patients will undergo transarterial embolization of the prostate using unloaded beads.
10117903|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 2.5 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 2.5 mg of doxorubicin.
10117904|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 5.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 5.0 mg of doxorubicin.
10117905|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 10.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 10.0 mg of doxorubicin.
10117906|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing|Participants will be approached and randomized to receive standard care plus ECG-stress testing
10117907|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing and CACS|Participants will be approached and randomized to receive standard care plus ECG-stress testing and coronary artery calcium scoring
10117908|NCT04424121|Active Comparator|Standard of care plus CCTA|Participants will be approached and randomized to receive standard care plus ≥ 64 multidetector coronary computed tomography angiography
10117909|NCT04424251|Experimental|HSK21542 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg
10117910|NCT04424251|Experimental|HSK21542 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg
9519513|NCT03286491||Patients presenting with acute coronary syndrome|Patients presenting to emergency department with acute coronary syndrome
10117911|NCT04424251|Experimental|HSK21542 2 μg/kg|Preoperative:2 μg/kg Postoperative:1 μg/kg
10117912|NCT04424251|Experimental|HSK21542|Preoperative:2 μg/kg Postoperative:1 μg/kg
10117913|NCT04424251|Placebo Comparator|Placebo 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg
10117914|NCT04424251|Placebo Comparator|Placebo 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg
10117915|NCT04424251|Placebo Comparator|Placebo 2 μg/kg|Preoperative:2 μg/kg Postoperative:1 μg/kg
10117916|NCT04424251|Placebo Comparator|Placebo|Preoperative:2 μg/kg Postoperative:1 μg/kg
10117917|NCT04424069|Active Comparator|LASIK group|Patients will do excimer laser LASIK operation for correction of myopia with flap creation by mechanical keratome
9825918|NCT02400437|Experimental|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity~Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.~Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase~Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase~Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
10117918|NCT04424069|Active Comparator|SMILE group|Patients will do Femtosecond laser assisted corneal refractive surgery for correction of myopia
10117919|NCT04424069|Active Comparator|Photorefractive keratectomy group|Patients that will undergo photorefractive keratectomy for correction of myopia
10117920|NCT04424069|Active Comparator|Refractive lens exchange|Include eyes that will undergo refractive lens exchange
10117921|NCT04424069|No Intervention|Control group|Myopic control eyes with no surgical intervention
10117922|NCT04424147|Experimental|HVA treatment|All patients with rrAML are treated with HVA regimen
10117923|NCT04424082|Other|dead space removal|external dead space will be removed and Vcap parameters (VCO2, PaCO2 and alveolar dead space) recorded before and after.
10117924|NCT04424238|No Intervention|Standard Clinic Prenatal Care (Control Group)|pregnancy's prenatal care appointment would be changed to once every two weeks when diagnosed with GDM. Doctors generally ask GDM women record their daily diet, exercise, weight, BG and blood pressure for at least three days between two visits and give lifestyle guidance according to the records. If they fail to show diaries, doctors would ask them come back with record next week. If BG control is poor, medicine intervention would be considered.
10117925|NCT04424238|Experimental|m-health group (Intervention Group)|participants were managed continuously through WeChat group chat.
10117926|NCT04424160|Experimental|Endometrial PRP|Patients in whom endometrial PRP was performed
10117927|NCT04424134|Experimental|Bromhexine And Spironolactone|
10117928|NCT04424134|Active Comparator|Base therapy|
10117929|NCT04423952||Patients with chronic otitis media|Patients aged 7 to 15 years with chronic otitis media.
10117930|NCT04423952||Controls|Minors aged 7 to 15 years, with no and no history of chronic otitis.
9825919|NCT02400463|Experimental|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
10117931|NCT04424355||Patients with suspected pneumonia COVID-19|"Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
10117932|NCT04424355||Patients with suspected pneumonia with COVID -19|"Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
10117933|NCT04423900|Experimental|Plantar Fasciitis App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
10117934|NCT04423900|Experimental|Achilles Tendinopathy App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
10117935|NCT04423900|Experimental|Plantar Fasciitis Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
10117936|NCT04423900|Experimental|Achilles Tendinopathy Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
10117937|NCT04423900|Experimental|Plantar Fasciitis Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
10117938|NCT04423900|Experimental|Achilles Tendinopathy Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
10117939|NCT04423887|Active Comparator|Control|
9825920|NCT02400580|Experimental|Intravenous IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
9825921|NCT02400580|Placebo Comparator|Normal Saline|The patients in the placebo arm will receive normal saline.
10117940|NCT04423887|Experimental|Creatine Supplementation|
10117941|NCT04423835||lateral closing osteotomy for cubitus varus deformity|The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs.
10117942|NCT04423770||U.S. dentists|Dentists in the United States
10117943|NCT04423692||pregnant women with abnormal labs|Mothers who have abnormal labs during pregnancy with abnormal coagulation profile
10117944|NCT04423562||Durable LVAD recipient with post implant VO2|
10117945|NCT04423627|Experimental|Clonidine|0.2 mg/day oral
10117946|NCT04423627|Active Comparator|Hydrochlorothiazide|37.5 mg/day oral
10117947|NCT04423627|Placebo Comparator|Placebo|Placebo
10117948|NCT04423653|Experimental|Tele-coaching group|This group will receive exercises videos, 2 sessions a week to be done on participant's own and the 3rd session will be live video conference session for training, supervision, and consultation purposes.
10117949|NCT04423653|Active Comparator|Self-monitored group|This group will receive exercises videos, 3 sessions a week to be done on participant's own with out any supervision.
10117950|NCT04423861|Experimental|nitazoxanide BID|Patients will receive nitazoxanide 600 mg BID for 7 days.
10117951|NCT04423861|Placebo Comparator|Placebo|Patients will receive matching placebo BID for 7 days.
10117952|NCT04423679||CIN2+|Cases of cervical precancer will include women diagnosed with cervical intraepithelial grades 2 or 3 (CIN2/3) or adenocarcinoma in situ (AIS). If any women are diagnosed with cancer in the study, they will be included in this group.
10117953|NCT04423679||< CIN2|Non-cases will include those with <CIN2 on colposcopy/biopsy and women who did not have an indication for colposcopy (because of a negative screening test).
10117954|NCT04423536||tested group|
10117955|NCT04423536||controlled group|
10117956|NCT04423809||caregivers of adult patients hospitalized in psychiatry|a face-to-face interview with a nurse and self-assessment scales.
10117957|NCT04423666|Experimental|Intervention|"Will receive:~education~a wireless pedometer with set up~nurse coaching via text message, email or telephone based on participant preference and at frequency determined by the participant"
10117958|NCT04423666|Experimental|Control|"Will receive:~education~a wireless pedometer with set up"
10117959|NCT04423549||tested group|
10117960|NCT04423549||controlled group|
10117961|NCT04423848|Experimental|Home Hospital for Lymphoma|The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
10117962|NCT04423510||Recurrent pilonidal sinus|Postoperative recurrent pilonidal sinus disease
10117963|NCT04423640||COVID Patients|Diagnosed patients with COVID-19 by PCR
10117964|NCT04423328|Experimental|acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Shenmen→Neiguan→Hegu acupoints.
10117965|NCT04423328|Sham Comparator|sham acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Waiguan→Liangqiu→Tiaokou→ Chengshan acupoints
10117966|NCT04423354|Experimental|Research group|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy.
10117967|NCT04423107|Active Comparator|No opioid|Acetaminophen every 6 hours and Ibuprofen every 6 hours
10117968|NCT04423107|Active Comparator|Opioid|Acetaminophen every 6 hours, Ibuprofen every 6 hours, and Oxycodone every 6 hours as needed for breakthrough pain for 10 doses.
10117969|NCT04423224|Active Comparator|Control group|Control group Management of the hemodynamic status in the control group will be performed in the discretion of the attending anesthesiologist, with the aim of keeping mean arterial pressure (MAP) > 65mmHg. The type and amount of delivered fluids, and vasoactive or inotropic drugs will be recorded.
10117970|NCT04423224|Active Comparator|GDFM|Goal-directed fluid management group (GDFM). . Baseline SV will be measured after the patients will be turned to left/right position & before implementation of regional anesthesia. Fluid challenges of 250 ml will be repeated until SV fails to increase by 10%. At this point, preload is considered optimized and SV optimum is defined. SV trigger is defined as SV opt - 10%. N/S 250ml boluses will be administered when SV is below SV trigger. Inotropic drugs will be administered (dobutamine infusion at 0.2-10mcg/kg/min) if CO is below 3.5 L/min and vasopressors (phenylephrine bolus doses of 50-100mcg) if SV and CO are within the target range but MAP is below 65mmHg. Patients will be reassessed during the intraoperative period every 10 minutes . Except from the fluid boluses, all patients will be administered Ringer's lactate solution at an infusion rate of 2ml/kg/h.
10117971|NCT04423198||Target Condition|Subjects presenting to the Emergency Department (ED) or Urgent Care (UC) with a blunt head trauma
10117972|NCT04423198||Trauma Control|Subjects presenting to the ED or UC requiring an Xray but do not have a head trauma
10117973|NCT04423198||Healthy Control|Subjects that are healthy and not taking any prescription medications
10117974|NCT04423263|Experimental|Intervention|Receives bilateral internal iliac artery occlusion
10117975|NCT04423263|Active Comparator|Control|Does not receive bilateral internal iliac artery occlusion
10117976|NCT04423276|Placebo Comparator|Control|
10117977|NCT04423276|Experimental|Donepezil|
10117978|NCT04423432|Active Comparator|Control|
10117979|NCT04423432|Experimental|Creatine Supplementation|
10117980|NCT04423432|Experimental|Glucoseamine/ Chondritin Sulfate Supplementation|
10117981|NCT04423185|Experimental|Almonertinib-EGFR mutation|Administration: 110 mg oral qd, to disease progression or intolerable adverse effects.
10117982|NCT04423185|Experimental|Dacomitinib-EGFR mutation|Administration: 45 mg oral qd, to disease progression or intolerable adverse effects.
10117983|NCT04423185|Experimental|Alectinib-ALK fusion|Administration: 600 mg oral qd, to disease progression or intolerable adverse effects.
10117984|NCT04423185|Experimental|Crizotinib-ALK fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
10117985|NCT04423185|Experimental|Vemurafenib-BRAF mutation|Administration: 960 mg oral bid, to disease progression or intolerable adverse effects.
9965982|NCT01255280|Active Comparator|Information, Motivation, Behavioral skills|The comparison condition will only receive the two IMB risk reduction sessions. The intervention will begin with modules that focus directly with sexual risk reduction practices. It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits. This session will also involve a Q&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information). The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
9965983|NCT01255280|Experimental|Behavioral Activation Therapy and Risk Reduction Counseling|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions-1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention. Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
9965984|NCT01255293|Active Comparator|1000 centistoke silicone oil|
9965985|NCT01255293|Active Comparator|5000 centistoke silicone oil|
9965986|NCT01255332||C13-urea breath test: positive|lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days
9965987|NCT01255345||Adult females with CPP living in Denmark|
9965988|NCT01255358|Experimental|Ery-Dex|Patients treated with monthly treatment of Ery-Dex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
9965989|NCT01255371|Active Comparator|Arm A : Lopinavir|"Emtricitabine/tenofovir :~TDF300mg.FTC200mg (Fixed Dose Combination)~1 tablet per day~Lopinavir/ritonavir :~LPV200mg/RTV50mg~2 tablets twice a day"
9965990|NCT01255371|Experimental|Arm B : Atazanavir|"Lamivudine/tenofovir :~3TC300mg/TDF300mg (Fixed Dose Combination)~1 tablet per day~Atazanavir/ritonavir :~ATV300mg/RTV100mg~2 tablets once a day"
9965991|NCT01255384||Non Diabetic-Controls|Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
9965992|NCT01255384||Diabetic Pregnancy|Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
9965993|NCT01255397|Experimental|Male Infertility Protocol|
9965994|NCT01255410|Experimental|Healthy Adults (Group 1)|Healthy adults will receive a single dose of 10^6 plaque forming unit (PFU) rHMPV-Pa vaccine intranasally.
9965995|NCT01255410|Experimental|Seropositive Children-Vaccine (Group 2)|Seropositive children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
9965996|NCT01255410|Placebo Comparator|Seropositive Children-Placebo (Group 2)|Seropositive children will receive a single dose of placebo vaccine intranasally.
9965997|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^5) (Group 3)|Seronegative infants and children will receive a single dose of 10^5 PFU rHMPV-Pa vaccine intranasally.
9965998|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 3)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
9965999|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^6) (Group 4)|Seronegative infants and children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
9966000|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 4)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
9966001|NCT01255462|Experimental|LFG316 0.15mg|
9966002|NCT01255462|Experimental|LFG316 0.5mg|
9966003|NCT01255462|Experimental|LFG316 1.5mg|
9966004|NCT01255462|Experimental|LFG316 5mg|
9966005|NCT01255475|Experimental|Intervention|
9966006|NCT01255475|Placebo Comparator|Control|
9966007|NCT01255488|Experimental|EBN-Search (without full-text manuscripts)|In the intervention arm research subjects will be provided access to EBN-Search (a fictitious search engine) with nine abstracts relating to the clinical case but no full-text manuscripts.
9966008|NCT01255488|Active Comparator|EBN-Search (with full text manuscripts)|Research subjects will be exposed to 9 abstracts and corresponding full-text manuscripts related to the simulated clinical encounter.
9519514|NCT03286478|Experimental|Mindfulness|Mindfulness-based body image intervention
9966009|NCT01255501|Experimental|NI-0701|
9966010|NCT01255501|Placebo Comparator|Placebo|
9966011|NCT01255514|Experimental|VAD|VAD : high dose dexamethasone -> response(CR, PR)-> VAD chemotherapy(vincristine + doxorubicin + dexamethasone)-> PBSC -> aSCT
9966012|NCT01255514|Experimental|PAD|PAD : high dose dexamethasone -> response(MR,NC,PD)-> PAD chemotherapy(bortezomib + doxorubicin + dexamethasone)-> PBSC -> aSCT
9966013|NCT01255527|Active Comparator|Busulfan|
9966014|NCT01255527|Active Comparator|Melphalan|
9966015|NCT01255566||Medical therapy cohort|For patients electing continued medical therapy, medication was prescribed based on the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
9966016|NCT01255566||Surgical cohort|For patients electing ESS, surgery was performed by the enrolling rhinologist. In addition, medical management was administered in the perioperative and postoperative periods as dictated by the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
9966017|NCT01255579|Active Comparator|SF|Extrafine Fluticasone/Salmeterol
9966018|NCT01255579|Active Comparator|FB|Extrafine Formoterol and beclometasone HFA
9966019|NCT01255618||study group, control group|
9966020|NCT01255644|Experimental|Antiviral drug|
9966021|NCT01255657|Experimental|ABT-806 Arm|
9966022|NCT01255683||Chronic rhinosinusitis|
9966023|NCT01255735||Vocal nodules|Two groups of children who are hoarse and have vocal nodules will be examined to see whether voice therapy is effective as a treatment strategy
9966024|NCT01255774|Experimental|Ranibizumab|Open Label use of Ranibizumab for wet age related macular degeneration
9966025|NCT01255800|Experimental|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.~Starting on Day 15 of the first cycle, Patients will take the study drug by mouth every day."
9966026|NCT01255813|Placebo Comparator|Placebo|
9966027|NCT01255813|Experimental|Sub-perception|
9966028|NCT01255813|Experimental|Full Stimulation|
9976411|NCT01351155|Active Comparator|Hydrocolloid (Duoderm)|Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
9976412|NCT01351155|No Intervention|Control|In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
9976413|NCT01351168|Placebo Comparator|Sugar pill|
9976414|NCT01351168|Active Comparator|Levodopa|
9976415|NCT01351168|Experimental|Zolpidam second dose|
9976416|NCT01351168|Experimental|Zolpidam first dose|
9976417|NCT01351181|Experimental|Exercise advice|Behavioural
9976418|NCT01351181|Other|Normal Care|Normal care
9976419|NCT01351194|Experimental|RFA group|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
9976420|NCT01351194|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
9976421|NCT01351207|Active Comparator|pork sausages and hash brown potatoes plus eggs|
9976422|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes plus egg-free pudding|
9976423|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes|
9976424|NCT01351220|Active Comparator|Basic dissemination|
9976425|NCT01351220|Active Comparator|Organizational dissemination|
9976426|NCT01351246|Experimental|Intervention|
9976427|NCT01351259|Experimental|Pneumatic device, tapered cuff|Intervention: continuous control of cuff pressure using a pneumatic device, tapered polyurethane cuff
9976428|NCT01351259|Experimental|Pneumatic device, cylindrical cuff|Continuous control of cuff pressure using a pneumatic device in patients intubated with cylindrical polyurethane cuffed tracheal tubes
9976429|NCT01351259|Active Comparator|Routine care, tapered cuff|Routine care of cuff pressure using a manometer, tapered polyurethane cuff
9976430|NCT01351259|Active Comparator|Routine care, cylindrical cuff|Routine care of cuff pressure using a manometer, cylindrical polyurethane tracheal cuff
9976431|NCT01351272|Experimental|methylphenidate, non-retard|
9976432|NCT01351285|Experimental|Sevo group|undergoing sevoflurane-remifentanil anesthesia
9976433|NCT01351285|Active Comparator|Des group|undergoing desflurane-remifentanil anesthesia
9976434|NCT01351285|Active Comparator|Pro group|undergoing propofol-remifentanil anesthesia
9976435|NCT01351298|Placebo Comparator|Saline spray|
9976436|NCT01351298|Experimental|Decongestant|
9976437|NCT01351298|Experimental|Decongestant and local anesthetic|
9976438|NCT01351311|Experimental|Exercise Group|Resistance exercise with swiss ball and drug treatment
9519515|NCT03286478|Experimental|Dissonance|Cognitive dissonance-based body image intervention
9976439|NCT01351311|Other|Control Group|Drug treatment
9976440|NCT01351324|Experimental|SFA|Oral dose of palmitic acid (SFA) given as a chocolate-flavoured drink every 30 min (0-390 min) with a continuous infusion of heparin (60-390 min).
9976441|NCT01351324|Experimental|SFA + LC n-3 PUFA|Oral dose of palmitic acid and DHA-rich fish oil (SFA + LC n-3 PUFA) given as a chocolate-flavoured drink every 30 min (0-390 min) together with a continuous infusion of heparin (60-390 min).
9976442|NCT01351363|Experimental|Electrical pain threshold measrement patients|
9976443|NCT01351389|Active Comparator|Brief Motivational Intervention (BMI)|
9976444|NCT01351389|Active Comparator|Brief Advice|
9976445|NCT01351428|Experimental|NICOM group|Vasodilator therapy begins when SVR increases by 20% or greater than baseline. Therapy is titrated according to hemodynamic profile and clinical signs and symptoms.
9976446|NCT01351441|Other|Age 65 years or over AND at least 5 chronic medications|
9976447|NCT01351454|Active Comparator|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
9976448|NCT01351454|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
9976449|NCT01351467||Parkinson's disease patients|People diagnosed with Parkinson's disease by a physician
9976450|NCT01351493|Active Comparator|Nitric oxide gel|
9976451|NCT01351493|Placebo Comparator|placebo|
9976452|NCT01351519|Experimental|Aminolevulinic Acid (AL)|
9976453|NCT01351532|Experimental|Lifestyle counseling, smoking cessation drug|
9976454|NCT01351532|Active Comparator|Lifestyle counseling|
9976455|NCT01351558|No Intervention|Control|No intervention for 12 weeks
9976456|NCT01351558|Active Comparator|Knee muscle strengthening exercises|
9519516|NCT03286478|Experimental|Confident Me|Dove Confident Me body image intervention
9966029|NCT01255826|Active Comparator|Sustained lung inflation followed by CPAP|"Sustained pressure-controlled inflation using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel, Auckland, New Zealand).~This will be followed by early CPAP."
9966030|NCT01255826|Active Comparator|Conventional self inflating bag and mask ventilation|Intermittent bag and mask ventilation using a self-inflating bag with an oxygen reservoir.
9966031|NCT01255839|Active Comparator|Double-balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
9966032|NCT01255839|Active Comparator|Prostglandin E2|The prostaglandin 2 minprostin (3mg) was applied vaginally
9966033|NCT01255852|Experimental|Atorvastatin group|Patients in atorvastatin group will received 40 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
9966034|NCT01255852|No Intervention|Control group|Patients in control group will receive 20mg atorvastatin daily treatment.
9966035|NCT01255878|Experimental|stabilization splint|
9966036|NCT01255878|Experimental|Gabapentine|
9966037|NCT01255891|Other|Adjuvant|Adjuvant suppression plus radiation therapy
9966038|NCT01255917||Chronic pancreatitis|
9966039|NCT01255956|Experimental|Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100)
9966040|NCT01255956|Experimental|Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100)
9966041|NCT01255969|No Intervention|Control|
9966042|NCT01255969|Experimental|Exercise|Patients in this arm will undergo to personalized exercise program.
9966043|NCT01255982||1|Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion
9966044|NCT01255995||Control Patients|Controls without PXF who require cataract surgery
9966045|NCT01255995||Pseudo Exfoliation patients|PXF subjects with or without glaucoma who require cataract surgery
9966046|NCT01256021|Experimental|Treatment Group 1|Meditoxin
9966047|NCT01256047|Active Comparator|group A|preoperative immunonutrition
9966048|NCT01256047|No Intervention|group B|ordinary diet
9966049|NCT01256073|Experimental|IPH2101|
9966050|NCT01256099|Experimental|Guided Internet-CBT for insomnia|
9966051|NCT01256099|Placebo Comparator|Control treatment|
9966052|NCT01256099|Experimental|Guided Internet-CBT for insomnia (9)|(9 weeks instead of 8)
9966053|NCT01256099|Active Comparator|Guided Internet-CBT for depression|
9966054|NCT01256112|Experimental|NAE + Behavioral Intervention|Parents of participants receive training in behavioral support at home, in addition to a standard nutrition and physical activity education (NAE) program.
9966055|NCT01256112|Active Comparator|Nutrition/Activity Education|Parents and participants receive a standard nutrition and physical activity education (NAE) program.
9966056|NCT01256125||Allogene MSCs transplantation|Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
9966057|NCT01256125||control|only medical treatments were performed in patients with chronic liver diseases.
9966058|NCT01256138||transplantation|
9966059|NCT01256138||control|
9966060|NCT01256151|Active Comparator|Alprazolam conventional tablet|Alprazolam conventional tablet
9966061|NCT01256151|Experimental|Alprazolam sublingual tablet|Alprazolam sublingual tablet
9966062|NCT01256203|Experimental|Sunscreen|Solar Protection Formula SPF® 60 will be applied on the skin of each subject. Applications will be followed by photobiological testings to assess skin protection.
9966063|NCT01256216|Other|Signature Custom Cutting Guides|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Signature Cutting Guides Surgical Technique.
9966064|NCT01256216|Other|CAS (Computer Assisted Surgery)|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Computer Assisted Surgery Technique.
9966065|NCT01256229|Experimental|Developmentally delayed - Hearing aids|This arm contains deaf children that have developmental delays and are randomized to be treated with the conventional therapy, hearing aids.
9966066|NCT01256229|Experimental|Developmentally Delayed - Cochlear implant|This arm contains deaf children that have developmental delays and are randomized to be treated with cochlear implantation.
9966067|NCT01256229|Active Comparator|Not developmentally delayed|This control arm contains deaf children that do not have developmental delays and will be treated with cochlear implantation.
9966068|NCT01256242|Experimental|Group 1|Standard Suture Repair + Augment Rotator Cuff
9966069|NCT01256242|Active Comparator|Group 2|Standard Suture Repair
9966070|NCT01256255||influenza infection|Patients with the diagnosis of influenza infection by standard laboratory technique
9966071|NCT01256268|Experimental|Endometrial Cancer|Phase 1A + Cohort 1B - Recurrent or Metastatic Endometrial Cancer. Patients with recurrent or metastatic endometrial cancer with up to 1 prior chemotherapy. Ridaforolimus at the Phase 1A MTD and schedule will be administered with paclitaxel at the Phase 1A MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
9966072|NCT01256268|Experimental|Ovarian Cancer|Phase 1 A + Cohort 1B - Recurrent or Metastatic Ovarian Cancer. Patients with platinum-sensitive, recurrent ovarian cancer with up to 2 prior chemotherapy regimens. Ridaforolimus at the phase 1A MTD and schedule will be administered with paclitaxel at the phase 1 MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
9966073|NCT01256307|Experimental|training group|training and educational program
9966074|NCT01256307|Other|control group|
9966075|NCT01256320|No Intervention|Control Group|no shell egg consumption and usual dietary practices
9966076|NCT01256320|Active Comparator|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
10117986|NCT04423185|Experimental|Niraparib-BRCA mutation or HRD|Administration: 200/300 mg oral qd, to disease progression or intolerable adverse effects.
10117987|NCT04423185|Experimental|Pyrotinib-HER-2 overexpression/amplification|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
10117988|NCT04423185|Experimental|Imatinib-CKIT mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
10117989|NCT04423185|Experimental|Palbociclib-CDKN2A mutation|Administration: 125 mg oral qd for 21 days q28d, to disease progression or intolerable adverse effects.
10117990|NCT04423185|Experimental|Crizotinib-ROS-1 fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
10117991|NCT04423185|Experimental|Crizotinib-C-MET amplification|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
10117992|NCT04423185|Experimental|Crizotinib-C-MET mutation|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
10117993|NCT04423185|Experimental|Pyrotinib-HER-2 mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
10117994|NCT04423185|Experimental|Sintilimab-PD-1|Administration: 200mg q21d, to disease progression or intolerable adverse effects.
10117995|NCT04423185|Experimental|Combination ARM-Niraparib & Sintilimab|Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
10117996|NCT04423185|Experimental|Combination ARM-Vemurafenib & Atezolizumab|Vemurafenib (960 mg oral bid) & Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
10117997|NCT04423185|Experimental|Combination ARM-Palbociclib & Atezolizumab|Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
10117998|NCT04423133|Experimental|Online Family Literacy Program|The Ready and Healthy for Kindergarten program is a bilingual family literacy program that uses anticipatory guidance on health routines (e.g., physical activity) to introduce language and literacy skills to children and their families delivered via an online video conference format.
10117999|NCT04423289|Experimental|Farmalarm|Farmalarm app for the follow-up
10118000|NCT04423289|No Intervention|Control|Regular primary care follow-up
10118001|NCT04423367|Experimental|bortezomib/dexamethasone|Enrolled patients will receive the combination therapy of bortezomib and dexamethasone.
10118002|NCT04423445|Experimental|Laser acupuncture combined with acupressure (LAA)|A 4-week LAA intervention included low-level laser acupuncture and auricular acupressure. Six acupuncture points were selected, and three auricular points. Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. After five days, the seed was removed, and a new seed was taped on the other ear.
10118003|NCT04423445|No Intervention|Control group|Control participants received a similar intervention, but without laser energy output or acupressure.
10118004|NCT04423380|Experimental|SH3051 capsules treatment|Oral Twice Daily Administration of SH3051
10118005|NCT04422938||Manuel compression|Manuel chest compressions will be handled by clinicians
10118006|NCT04422938||Mechanical compression|Mechanical chest compressions will be handled via mechanical chest compression device
10118007|NCT04423172|Experimental|Using the New Tissue Containment System group|using the new tissue containment system during Laparoscopic Hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
10118008|NCT04423172|No Intervention|Open group|Without using any procteciton system during Laprascopic Hysterectomy.
10118009|NCT04423159|Experimental|OCV vaccine|Shanchol 1.5mL to be administered orally. Each dose contains V.cholerae O1 Inaba El Tor Strain, Inaba classical strain, ogawa classical strain and O139 strain. As well as Thiomersal and a buffer
10118010|NCT04423042|Experimental|Tocilizumab Arm|Tocilizumab 8 mg/kg IV up to a maximum of 800 mg with possible repetition of the same dosage within 28 hours (the optional second dose after 12 hours but before 28 hours following the first dose), based on the clinical judgement of the attending physician in consultation with the COVID-inflammation team.
9519517|NCT03286478|No Intervention|Control|Classes as usual, assessment-only control group.
10118011|NCT04423042|No Intervention|No Intervention Arm|No intervention arm patients will be identified from medical records, as being COVID-19 positive patients with hyperinflammation who did not receive any interleukin antagonist treatment.
10118012|NCT04423419|Other|A|will undergo Peri -articular nerve group block for hip joint under ultrasound guide as analgesia post operative after hip arthroscopy
10118013|NCT04423419|Other|B|will undergo ultrasound guided fascia iliaca block as postoperative analgesia after hip arthroscopy
10118014|NCT04423419|Other|C|will receive ordinary IV analgesia during operation hip arthroscopy
10182753|NCT03771196|Active Comparator|Resin Modified Glass Ionomer (RMGI)|Fuji II Lc, fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics a wear-resistant, self-adhesive, light-cured resin coating.
9668886|NCT04701593|Experimental|Experimental (Triamcinolone Acetonide)|receives a sub-tenon irrigation of 1 cc 40mg/mL triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation
10182754|NCT03770910|Placebo Comparator|Placebo+placebo|Saline infusions
10182755|NCT03770910|Active Comparator|GIP+placebo|GIP(1-42), receptor agonist
10182756|NCT03770910|Experimental|GIP+dose 1|GIP(1-42) and lowest dose of GIP(3-30)NH2
10182757|NCT03770910|Experimental|GIP+dose 2|GIP(1-42) and dose of GIP(3-30)NH2
10182758|NCT03770910|Experimental|GIP+dose 3|GIP(1-42) and dose of GIP(3-30)NH2
10182759|NCT03770910|Experimental|GIP+dose4|GIP(1-42) and highest dose of GIP(3-30)NH2
10182760|NCT03770962|Experimental|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will observe the birth or give any assistance needed."
10118015|NCT04422977|Other|CoVID exposure|
10118016|NCT04422951|Experimental|Wise interventions plus online behavioral Rx|Wise social psychological interventions (growth mindset and values self-affirmation) plus a usual care online behavioral intervention for weight control.
10118017|NCT04422951|Active Comparator|Online behavioral Rx|Usual care online behavioral intervention for weight control.
10118018|NCT04422639|Experimental|Arm I (pre-operative SRS/SRT)|Patients undergo SRS or SRT within 15 days of randomization followed by surgery within 15 days of radiation completion. Patients may undergo additional SRS or SRT if disease returns after treatment.
10118019|NCT04422639|Active Comparator|Arm II (post-operative SRS/SRT)|Patients undergo surgery within 15 days of randomization followed by standard-of-care SRS or SRT within 30 days of surgery. Patients may undergo additional SRS or SRT if disease returns after treatment.
10118020|NCT04422678|Experimental|Imatinib Standard Dose|"Imatinib 400 mg oral tablet once daily for 21 days~In addition for the treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
10118021|NCT04422678|Experimental|Imatinib Low Dose|"Imatinib 200 mg oral tablet once daily for 21 days.~In addition to the treatment for COVID-19 Pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
10118022|NCT04422678|Active Comparator|Control|Treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH).
10118023|NCT04422665|Experimental|Single Exercise|Subjects allocated to this group will perform a single bout of one-legged resistance exercise. This bout will take place 1 day prior to the start of the bed rest. The resistance exercise will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
10118024|NCT04422665|Experimental|Multi Exercise|Subjects allocated to this group will perform 4 bouts of one-legged resistance exercise. These bouts will take place on alternate days the week leading up to the bed rest. Each resistance exercise bout will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
10118025|NCT04422652|Active Comparator|Strategy 1|Strategy 1: Single-blind Behavioral Activation Therapy plus placebo for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind bupropion (Phase 2) for another 8 weeks.
10118026|NCT04422652|Active Comparator|Strategy 2|Strategy 2: Double-blind bupropion plus single-blind Clinical Management (CM) attention control for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind BAT (Phase 2) for another 8 weeks.
10118027|NCT04422652|Placebo Comparator|Control|Control: Clinical management attention control plus placebo for 16 weeks
10118028|NCT04422899|Experimental|AIV007 Treatment Dose 1|Intravitreal, Dose 1
10118029|NCT04422899|Experimental|AIV007 Treatment Dose 2|Intravitreal, Dose 2
10118030|NCT04422899|Experimental|AIV007 Treatment Dose 3|Intravitreal, Dose 3
10118031|NCT04422834|Experimental|Health Professional Students|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
10118032|NCT04422821|Experimental|FreeStyle Libre™|FreeStyle Libre™ will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will receive subcutaneous sensor for glucose monitoring (FreeStyle Libre™; Abbott Diabetes Care, Alameda, CA) for 4 weeks.
10118033|NCT04422821|Active Comparator|iXell®|iXell® will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will monitor glycemia through use of standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) for 4 weeks.
10118034|NCT04422704|Experimental|Retired people|People who are either ordinarily or early retired and who have previously held a paid employment.
10118035|NCT04422886|Experimental|Physio+tDCS|Receives 20 minutes of active tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
10118036|NCT04422886|Sham Comparator|Physio+sham|Receives 20 minutes of sham tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
10118037|NCT04422691||Covid-19 suspected|Emergency department patients with suspected or diagnosed COVID-19 disease. All patients will be screened at triage and put into isolation if suspected disease. Ultrasound of the patients lungs will be performed after patient consent and findings will be recorded and categorized (Soldati et al., 2020). The use of ultrasound and registration of data will not affect the regular patient evaluation, treatment or logistics.
10118038|NCT04422782|Other|Single Arm|Single Arm
10118039|NCT04422860|Experimental|Gum Arabic varnish|Gum arabic (Acacia senegal) is an exudate obtained from Acacia senegal stems and roots, and other similar African Acacia species. It consists mainly of high molecular weight polysaccharides high concentrations of calcium, magnesium, and potassium salts which can potentially increase tooth remineralization.
10118040|NCT04422860|Active Comparator|Sodium Fluoride varnish|The gold standard remineralizing agent recommended by the guidelines.
10118041|NCT04422860|Active Comparator|10% w/v CPP-ACP, 5% sodium fluoride varnish|CPP-ACP is the most studied non fluoride remineralizing agent.
10118042|NCT04422457|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans
10118043|NCT04422600||Mothers who report use of THC with or without CBD|Mothers who report THC and CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
10182761|NCT03770962|No Intervention|One midwife|This is standard care. One midwife is responsible for the care of the woman and her unborn baby during labor and birth.
10182762|NCT03771014|Experimental|Early mobility|Patients will receive standard physiotherapy regimen plus 2 x 30 minute rehabilitation sessions 5 days per week.
10182763|NCT03771014|No Intervention|Standard care|Patients will receive standard physiotherapy regimen
10182764|NCT03771066|Experimental|Diet plus bisphenol A|Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.
10182765|NCT03771066|Placebo Comparator|Placebo|Participants will receive a 4-day diet plus no bisphenol A.
10118044|NCT04422600||Mothers who report use of CBD only|Mothers who report CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
10118045|NCT04422600||Control Mothers|Recruitment of pregnant women who do not use THC or CBD will be conducted using the Epic MyChart research participant recruitment tool
10118046|NCT04422509|Experimental|lanadelumab|20 Patients will receive an intravenous dose of 300 mg lanadelumab on day 1, followed by a second dose of lanadelumab 300mg iv on day 4 (if needed).
10118047|NCT04422509|Other|controls|20 patients will received standard of care In additiona, for every index patient we will match one historical controls. Controls will be matched based on age, bodyweight and gender.
10118048|NCT04422496|Experimental|HEC96719 tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B: There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
10118049|NCT04422496|Placebo Comparator|placebo tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B:There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
10118050|NCT04422483||Service Model Level Case Studies|Realist Interviews. MONTHS 9-30 (N=6-8 sites, 12 people per site, 96 interviewees)
10118051|NCT04422483||Individual/family level interviews|Child Interviews. MONTHS 9-30 (N=6-8 sites, 6 people per site, max. 48 interviewees)
10118052|NCT04422483||Individual child/family Level Case Studies:|MONTHS 10-30 (N=6-8 sites, 78 people per model (x4), 312 participants, 156 per NU/SCFT depending on distribution of sites)
10118053|NCT04422483||Focus groups:|MONTHS 9-30 (N=6-8 sites, 6-8 focus groups of up to 8 parents) N= 64
10118054|NCT04422548|Active Comparator|AI-assisted Group|
10118055|NCT04422548|Active Comparator|Standard|
10118056|NCT04422275|Active Comparator|Budesonide & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
10118057|NCT04422275|Active Comparator|Placebo & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
10118058|NCT04422275|Active Comparator|Budesonide & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
10118059|NCT04422275|Placebo Comparator|Placebo & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
10118060|NCT04422587||RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
10118061|NCT04422236||Obese patients eligible for laparoscopic bariatric surgery|
10118062|NCT04422327|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
10118063|NCT04422353|Experimental|video Dance classes|"The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm.~Classes will be divided into four stages: Joint warm-up and stretching on the chairs; strengthening, balance, and rhythm exercises with the support of the chair; exercises inspired by the samba and forró (Brazilian ballroom dance) basic steps; and Final cool down. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.~The video Dance classes will happen in the period of self-isolation and social distance during the Covid-19 pandemic."
10118064|NCT04422353|Active Comparator|Unsupervised physical activities|The unsupervised physical activity programs will happen in the period of self-isolation and social distance during the Covid-19 pandemic. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
10118065|NCT04422353|No Intervention|control group|The control group will be people with PD, engaged, before the Covid-19 pandemic, in the Dance, the Nordic Walk and the Aquatic Jogging extension projects at Federal University of Rio Grande do Sul but did not do any type of physical activity during the Covid-19 pandemic.
10118066|NCT04422535||Critical care patients|Patients admitted to critical care units for COVID-19, where ECG records and relevant clinical information are available to assess the impact of the disease and its concomitant treatment on electrocardiographic parameters of ventricular repolarization
10118067|NCT04422405|Experimental|Patients undergoing OAGB|
10118068|NCT04422197|Active Comparator|Patients with ultrasound-guided botox injection|Effect of Botox injection on lateral abdominal wall muscles after major open abdominal surgery
10118069|NCT04422197|Active Comparator|Patients with no botox injection|Patients with major abdominal surgery without botox injection
10118070|NCT04422392|Experimental|Neoadjuvant PD-1 antibody puls chemotherapy|"Neoadjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3) Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of combinded adjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will be administered. Thirteen cycles of PD-1 antibody will start within day 21-24 days from day 1 of adjuvant cycle 2."
9966077|NCT01256320|Active Comparator|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
9966078|NCT01256346||Babies|Preterm newborn infants thought to be 24-32 weeks gestational age.
9668887|NCT04700722||Parkinson's disease|Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
10118071|NCT04422392|Active Comparator|Neoadjuvant chemotherapy|"Neoadjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3).~Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of adjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will be administered."
10118072|NCT04422119|Experimental|Multi-layer foam dressing|Patients in experimental group will receive the application of a multi-layer foam dressing with Safetac in surgical wound
10118073|NCT04422119|Active Comparator|Usual care|Patients in control group will receive standard treatment with povidone-iodine and a gauze dressing with plaster.
10118074|NCT04422132|Active Comparator|ARM 1 - 2 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 32.5 Gy in 5 fractions. Patients receiving 32.5 Gy in 5 fractions cannot be treated on consecutive days.
10118075|NCT04422132|Active Comparator|ARM 2 - 4 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 55 Gy in 20 fractions.
10118076|NCT04422067||Case group (Retrognatism)|All pregnant patients with one or more fetuses suffering from a microretrognathia, diagnosed prenatally and integrated into a Pierre Robin Sequence, were included. All cases were confirmed postnatally, either by a pediatric examination or by a fetopathological examination in the case of a medical termination of the pregnancy. We had 21 cases.
10118077|NCT04422067||Control group|47 pregnant patients with fetus without facial abnormalities
10118078|NCT04422028|Experimental|Desogestrel Test Product|Participants received two tablets of the test formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
10118079|NCT04422028|Active Comparator|Desogestrel Reference Product|Participants received two tablets of the marketed reference formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
10118080|NCT04422301|Experimental|High intensity eccentric training|"High intensity eccentric training high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.~eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction."
10118081|NCT04422301|Experimental|High intensity eccentric training with blood flow restriction|High intensity eccentric training with blood flow restriction high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction
10118082|NCT04422301|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
10118083|NCT04422301|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
10118084|NCT04422184|Experimental|SEN GROUP|Sensodyne Repair and Protect - NOVAMIN technology
10118085|NCT04422184|Experimental|REG GROUP|Dentalclean Daily Regenerator - REFIX technology
10118086|NCT04422184|Experimental|REGK GROUP|Dentalclean Daily Regenerator - REFIX technology + potassium citrate
10118087|NCT04422158|Experimental|Nuun Single strength|3 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
10118088|NCT04422158|Experimental|Nuun Double strength|6 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
10118089|NCT04422158|Placebo Comparator|Control|Subjects will drink one liter of water over 30 min (250 mL every 7.5 min)
10118090|NCT04422223||Cohort|Patients newly diagnosed with liver cirrhosis form the Gastro Unit, Amager Hvidovre Hospital, Denmark. All patients with clinically verified diagnosis, irrepsective of disease stage and etiology is included.
10118091|NCT04421989|Experimental|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
10118092|NCT04421989|Active Comparator|Support Group|Participants randomized to FBT + Support parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The parent support group facilitates parent discussion and support around a variety of topics central to treatment for pediatric AN including: understanding medical co-morbidities, levels of care for treatment, understanding expected body weight, navigating FMLA, and medications. The facilitator introduces each topic weekly and opens up discussion between parents. The facilitator's role is to ensure the group remains on topic and on time.
10118093|NCT04421976|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
10118094|NCT04421976|Experimental|Driving pressure (DP) guided-PEEP|PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
10118095|NCT04422054||Open Surgery Repair Group|In the open surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications, in the postoperative period, during follow up.
10118096|NCT04422054||Endovascular Repair Group|In the endovascular surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications in the postoperative period, during follow up.
9966079|NCT01256359|Experimental|Docetaxel and AZD6244|Docetaxel with AZD6244
9966080|NCT01256359|Experimental|Docetaxel and Placebo|Docetaxel without AZD6244
10118097|NCT04422145|Active Comparator|Interventional/intensive|Participants received a structured nurse led education programme surrounding hypoglycaemia. They were encouraged to use self monitoring of blood glucose (SMBG) and had their diabetes medications adjusted according to this. They also received information on how to avoid hypoglycaemia (including the effects of diet, exercise, alcohol and their medications) and how to treat hypoglycaemia should it occur.
10118098|NCT04422145|Placebo Comparator|Standard|Participants returned to their standard diabetes care provider with no intervention.
10118099|NCT04422145|No Intervention|Observational|Participants were happy to have baseline characteristics collected and be followed up using electronic records in a longitudinal fashion but did not wish to be randomized. The observational and standard groups therefore received the same diabetes care.
10118100|NCT04421846|Other|Group 1 : Status epilepticus|
10118101|NCT04421846|Other|Group 2 : Dysimmune encephalitis|
10118102|NCT04421846|Other|Group 3 : Control patients|
10118103|NCT04422041|Active Comparator|Early discharge|Discharge between 24 and 48 hours
10118104|NCT04422041|Experimental|Very early discharge|Discharge in less than 24 hours
10118105|NCT04421729|Active Comparator|Savvy Caregiver Program|Savvy Caregiver Program, 6 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
10118106|NCT04421729|Active Comparator|Savvy Express|Savvy Express, 3 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
10118107|NCT04421833|Active Comparator|group starting with TOVERTAFEL activities|Participants will benefit from TOVERTAFEL activities for 6 weeks then the usual animation techniques for 6 weeks with a week of wash-out between the two periods.
10118108|NCT04421833|Sham Comparator|group ending with TOVERTAFEL activities|Participants will benefit from the usual animation techniques for 6 weeks then from TOVERTAFEL activities for 6 weeks with a week of wash-out between the two periods.
10118109|NCT04421612|Experimental|Intensive|This group recieve access to a new module every 3rd day.
10118110|NCT04421612|Experimental|Ordinary|This group recieve access to a new module every 5th day.
10118111|NCT04421651|Experimental|Treatment group|The participants in the treatment group were offered 20 Dance movement therapy sessions in addition to standard care.
10118112|NCT04421651|No Intervention|Control group|Participants in the control group continued treatment as usual in the health services.
10118113|NCT04421820|Experimental|Gastric Cancer|
10118114|NCT04421820|Experimental|Pancreatic Cancer|
10118115|NCT04421820|Experimental|Colorectal Cancer|
10118116|NCT04421820|Experimental|Cholangiocarcinoma|
10118117|NCT04421781||Salvage HIFU for local recurrence after prostatectomy and EBRT|Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
10118118|NCT04421872|Experimental|General anesthesia Group|
10118119|NCT04421872|No Intervention|Healthy control group|
10118120|NCT04421885|Experimental|A: TBPM-PI-HBr (Reference - fasted)|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
10118121|NCT04421885|Experimental|B: TBPM-PI-HBr (Test - fasted)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
10118122|NCT04421885|Experimental|C: TBPM-PI-HBr (Test - fed)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions.
10118123|NCT04421573|Experimental|BCPHD-D5W with usual care|"Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, 6 and 8 weeks.~All helpful treatment methods already underway are continued. Other new treatment methods are discouraged."
10118124|NCT04421573|Active Comparator|Waiting period with usual care|All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
10118125|NCT04421716|Experimental|Ursolic Acid|Administration of Ursolic Acid twice a day for 2 weeks
10118126|NCT04421716|Experimental|Curcumin|Administration of Curcumin twice a day for 2 weeks
9528176|NCT03213028|Other|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
9966081|NCT01256372|Experimental|AP214; dose-level 1|AP214; dose-level 1
10118127|NCT04421716|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin. If subjects from Cohort 1 or 2 wish to continue in the study, they will undergo a washout period of at least 4 weeks before participating in Cohort 3
10118128|NCT04421911|Experimental|ketoprofen|
10118129|NCT04421911|Active Comparator|Diclofenac|
10118130|NCT04421859|Experimental|EyeCU App|"Augmented reality mobile application called EyeCU which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes."
9966082|NCT01256372|Experimental|AP214; dose-level 2|AP214; dose-level 2
9966083|NCT01256372|Placebo Comparator|Placebo to AP214|Placebo
9966084|NCT01256437|Experimental|ointment Threolone|Treatment with topical application of combined anti inflammatory and anti bacterial agent.
9966085|NCT01256437|Active Comparator|ointment Synthomycine|ointment once daily for 1 month
9966086|NCT01256437|Placebo Comparator|Aqua cream|
9966087|NCT01256463|No Intervention|Comparison|
9966088|NCT01256463|Experimental|HIV prevention intervention|The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (including physicians, clinical officers, and nurses) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction during clinic visits. Health care providers will also assess and treat sexually transmitted infections (STIs), and provide basic contraceptives and brief safer pregnancy counseling.
9966089|NCT01256489|Other|Infliximab|Every patient enrolled in the study will receive monthly infusions of Infliximab throughout the term of the study. Infliximab will be administered intravenously.
9966090|NCT01256515|Experimental|Health Education Training Group 1|One form of health education training
9966091|NCT01256515|Active Comparator|Health Education Training Group 2|Another form of health education training
9966092|NCT01256528|Experimental|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
9966093|NCT01256541|Experimental|Kristalose|Kristalose as Bowel Evacuant
9966094|NCT01256554|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
9966095|NCT01256580|Active Comparator|Monotherapy|Bevacizumab (Avastin; Genentech, Inc.)1.25 mg by intravitreal injection on day 0 and then prn (as-needed) based on ophthalmic examination and OCT findings
9966096|NCT01256580|Active Comparator|Combination therapy|Intravitreal injection of bevacizumab 1.25 mg (Avastin; Genentech, Inc.) combined with reduced fluence PDT(Visudyne®; Novartis,) and 200 ug of intravitreal dexamethasone(4mg/ml, American regent, Inc) on Day 0 and then monthly retreatment with bevacizumab as-needed and triple therapy every 3 months as-needed.
9966097|NCT01256606||Positive for fetal aneuploidy|
9966098|NCT01256606||Negative for fetal aneuploidy|
9966099|NCT01256619|Active Comparator|marvelon|
9966100|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD with PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, with Posterior Vitreous Detachment (PVD Positive). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
9966101|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD w/o PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, without Posterior Vitreous Detachment (PVD Negative). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed basis, based on predefined criteria.
9966102|NCT01256645|No Intervention|restrictive transfusion|No transfusion given to correct anemia unless vital indication is given
9966103|NCT01256645|Experimental|liberal transfusion|transfusions are given in single units until Hb is > 12 mg/dl
9966104|NCT01256697|Experimental|Alga Dunaliella Bardawil|
9966105|NCT01256697|Placebo Comparator|Sugar pill|
9966106|NCT01256710||Trifecta Valve Group|
9966107|NCT01256723||J-LESSON Central committee|
9966108|NCT01256736|Experimental|Tocilizumab 8mg/kg + DMARDs|
9966109|NCT01256775|Placebo Comparator|NCX4016 placebo|NCX4016 placebo b.i.d for 6 months
9966110|NCT01256775|Active Comparator|NCX4016|ncx4016,800 mg b.i.d., on top of aspirin 100 mg o.d.
9966111|NCT01256801||cytokine|The patients are randomized to receive the cytokine infusion in the pleural cavity
9966112|NCT01256814|Experimental|Behaviorial Intervention|SystemCHANGE-HIV is a 10-week, small-group intervention that will promote behavior changes to improve the following: physical activity, sleep behaviors and mental wellness. S
9966113|NCT01256814|Active Comparator|Control|"The control group will receive the manual Symptom Management Manual: Strategies for People Living with HIV/AIDS."
9528177|NCT03213301|Experimental|Lurbinectedin|Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
9966114|NCT01256827||ranibizumab in MARINA/ANCHOR|Exudative AMD patients previously enrolled in the ranibizumab treatment arms of the MARINA or ANCHOR studies with subsequent enrollment into the HORIZON extension study.
9966115|NCT01256853|Experimental|MVA Vaccine|
9966116|NCT01256866|Active Comparator|DEXMEDETOMIDINE, SEDATION|
9966117|NCT01256866|Active Comparator|Midazolam, sedation,|
9966118|NCT01256905|Experimental|Armodafinil|
9966119|NCT01256931||organ transplant patients|
9966120|NCT01256931||healthy controls|
9966121|NCT01256957|Active Comparator|Indoor air HEPA filtration|HEPA filters operating in the participant's bedroom and living room.
9966122|NCT01256957|No Intervention|Control|Control
9966123|NCT01256970||Polycystic Ovary Syndrome.|Polycystic ovary syndrome was diagnosed according to the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria: PCOM, chronic anovulation and hyperandrogenism.
9966124|NCT01256970||Normal Control|Normal control women were women who did not present with any of three PCOS criteria.
9966125|NCT01256996|Experimental|Low-abrasive powder|
9976457|NCT01351558|Active Comparator|Upper extremity strengthening exercises|
9668888|NCT04700722||Multiple System Atrophy|Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
9966126|NCT01257009|Other|1|Arm 1: cessation of any statin therapy for at least 6 weeks, then the first sympathetic activity measurement will be done.Subsequently, atorvastatin 20mg is added for 6 weeks. Then the second sympathetic measurement will be performed.
9966127|NCT01257009|Other|2|Patients will receive atorvastatin for 6 weeks, then the first sympathetic measurement will be done. Then atorvastatin will be stopped and 6 weeks the second measurement will be done
9966128|NCT01257022|Experimental|Family Function Intervention|Familias Unidas Intervention Program
9966129|NCT01257022|No Intervention|Treatment as Usual|Control
9966130|NCT01257035||18F-FAZA-PET/CT|
9966131|NCT01257048|Placebo Comparator|1|Single Dose evaluation placebo (V5)
9966132|NCT01257048|Active Comparator|2|Single Dose evaluation formoterol (V5)
9966133|NCT01257061|Experimental|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g
9966134|NCT01257061|Active Comparator|Group 2|Dexchlorpheniramine maleate 10 mg/g
9966135|NCT01257074|Experimental|Drug 1|Penciclovir 10mg/g
9966136|NCT01257074|Active Comparator|Drug 2|Acyclovir 50mg/g
9966137|NCT01257100||Cases with NPC|Cases with NPC
9966138|NCT01257100||Hospital based controls|Hospital based controls
9966139|NCT01257113|Experimental|supervised exercise|The group gets 10 supervised exerciseclasses at the physiotherapy clinic in addition to homebased exercises
9966140|NCT01257113|Experimental|homebased exercises|The group gets 1 supervised exerciseclass before they do all their exercises at home
9966141|NCT01257126|Experimental|diclofenac potassium|
9966142|NCT01257126|Active Comparator|nimesulide|
9966143|NCT01257139|No Intervention|dual-agent therapy or docetaxel alone|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, according to PS or age
9966144|NCT01257139|Experimental|dual-agent therapy or docetaxel or best supportive care|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, or best supportive care, allocated on the basis of a simplified geriatric scale, plus a more thorough geriatric evaluation if necessary
9966145|NCT01257165|Experimental|Zopiclone 5 mg|Zopiclone 5 mg pill + placebo pill + placebo drink
9966146|NCT01257165|Experimental|Zopiclone 10 mg|2 x zopiclone 5 mg pills + placebo drink
9966147|NCT01257165|Active Comparator|Ethanol 0.8 g/L|2 x placebo pills + ethanol 50 g/70 kg
9966148|NCT01257165|Placebo Comparator|Placebo|2 x placebo pills + placebo drink
9966149|NCT01257178|Experimental|Normal hepatic function|6mg, oral, once on day 1
9966150|NCT01257178|Experimental|Mild hepatic impairment|6 mg, oral, once on day 1
9966151|NCT01257178|Experimental|Moderate hepatic impairment|6 mg, oral, once on day 1
9966152|NCT01257178|Experimental|Severe hepatic impairment|6 mg, oral, once on day 1
9966153|NCT01257191|Experimental|Carbon Black|
9966154|NCT01257191|Experimental|Diesel Exhaust Particles|
9966155|NCT01257191|Experimental|Fine Concentrated Ambient Particles|
9966156|NCT01257191|Experimental|Ultrafine Concentrated Ambient Particles|
9966157|NCT01257191|Placebo Comparator|Placebo|
9966158|NCT01257243|Experimental|DRUG 1|Syrup of oxomemazine, guaifenesin and potassium iodate
9966159|NCT01257243|Active Comparator|DRUG 2|Syrup of guaifenesin
9966160|NCT01257256||infertile patients|male infertile patients(ICD-9:606),female infertile patients(ICD-9:628)
9966161|NCT01257269||1|Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
9966162|NCT01257269||2|Family members of patients with confirmed hereditary TTP
9966163|NCT01257295|Placebo Comparator|control|No additions of fiber to a breakfast meal
9966164|NCT01257295|Active Comparator|low viscous, low gelling|low viscous, low gelling fibre added to breakfast meal
9966165|NCT01257295|Active Comparator|high viscous, low gelling|high viscous, low gelling fibre added to breakfast meal
9966166|NCT01257295|Active Comparator|low viscous, high gelling|low viscous, high gelling fibre added to breakfast meal
9966167|NCT01257295|Active Comparator|high viscous, high gelling|high viscous, high gelling fibre added to breakfast meal
9966168|NCT01257295|Active Comparator|fibre supplement|high viscous, high gelling fibre is added, not to the breakfast meal, but as supplement
9966169|NCT01257321||post tonsillectomy|children
9966170|NCT01257334|Experimental|Treatment Group|BI 10773 10 mg, 25 mg administered once daily
9966171|NCT01257334|Placebo Comparator|Control Group|Placebo administered once daily
9966172|NCT01257373||patiens with Firebird 2 stent|The group of 1300 patients, in which only Fireibrd2 stent is implanted, will be collected. All inclusive patients should be definitely diagnosed type 2 diabetic mellitus （DM）, either before or during the present hospitalization and with complex coronary lesion.
9966173|NCT01257386|Experimental|Asacol®|Import Mesalazine
9966174|NCT01257386|Active Comparator|Mesalazine|Marketed Mesalazine
9966175|NCT01257399|Experimental|Asacol®|Import Mesalazine
9966176|NCT01257399|Active Comparator|Mesalazine|Marketed Mesalazine
9966177|NCT01257412|Experimental|1|
9966178|NCT01257412|Experimental|2|
9966179|NCT01257412|Placebo Comparator|3|
9966180|NCT01257451|Experimental|Vildagliptin|
9966181|NCT01257451|Placebo Comparator|Placebo|
9966182|NCT01257464|Active Comparator|Sitagliptin|
9966183|NCT01257464|Placebo Comparator|Placebo|
9966184|NCT01257490|Experimental|Intensive counseling|4 sessions of intensive counseling plus bupropion
9966185|NCT01257490|Active Comparator|Brief Counseling|Brief physician advice to quit plus bupropion
9966186|NCT01257516|Other|Pregabalin immediate release, 300 mg|Reference Treatment
9966187|NCT01257516|Experimental|Pregabalin controlled release, 330 mg|
9966188|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, low-fat|
9966189|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, medium-fat|
9966190|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, high-fat|
10118131|NCT04421586|Experimental|Pregnant women receiving VISTA counseling|Up to 30 pregnant women are screened and counseled for vaccine concerns using VISTA
10118132|NCT04421586|No Intervention|Pregnant women receiving usual care|Up to 30 pregnant women receiving usual care
10118133|NCT04421755|Experimental|Produce Only|Receives weekly home delivery of fresh fruits and vegetables
10118134|NCT04421755|Experimental|Produce + Cooking Classes|Receives weekly home delivery of fresh fruits and vegetables plus invitation to participate in a series of three small group culinary medicine cooking classes
10118135|NCT04421755|No Intervention|Control|Control group with no cooking classes or groceries
10118136|NCT04421768|Experimental|systematic cervical exam training--retrospective measures|Effects of systematic cervical exam training on Labor and Delivery Care The total number of exams per hour of labor or triage stay and exam discrepancy between 2 examiners who performed exams less than 30 minutes apart will be compared between the 6 month time period before the unit wide training and 6 months after completing training
10118137|NCT04421768|Experimental|systematic cervical exam training--prospective measures|Effects of systematic cervical exam training on Labor and Delivery care Patient will be approached to obtain consent for them to have 2 cervical exams performed one after the other when an exam is clinically indicated. The discrepancy between the 2 examiners will be compared between the 6 month time period before the unit wide training and 6 months after completion of the training.
10118138|NCT04421898||group 1|group 1 : infants with congenital muscular torticollis
10118139|NCT04421898||group 2|group 2 : healthy , without congenital muscular torticollis
10118140|NCT04421794|Experimental|NMES group|For the NMES group one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will deliver NEMS (15 min; 75 EMS contractions completed during the training session; rise time = 0.25 s and descending time = 0.75 s). In order to maximize muscle tension without accompanying detrimental effects on fatigue onset, biphasic symmetric regular-wave pulsed currents (85 Hz) lasting 400 μs will be delivered. Each 4-s steady tetanic stimulation will be followed by pause lasting 8-s, during which subjects will be submaximally stimulated at 4 Hz on the medial arch muscles. According to the recommendations, the two electrodes are placed behind the head of the first metatarsal to stimulate the medial arch intrinsic muscles. The goal is to attain the highest tolerable level of muscle contraction without discomfort during the 15 minutes and to provide a full tetanic contraction of the intrinsic foot muscles during the contraction time.
10118141|NCT04421794|Placebo Comparator|Control group|For the control group the one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will be used to apply a stimulation of 15 minutes considered by TENS at the lowest intensity detectable by the participant in order to not influence the outcomes of interest. Our aim is to strengthen IFM which is not the role of TENS. The two electrodes will be placed on the dominant foot, at the same place than those for the NMES group.
9966191|NCT01257529|Other|Pregabalin immediate release, 300 mg|Reference Treatment
10118142|NCT04421924|Experimental|Thrombelastogram (TEG)|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.
10118143|NCT04421924|Experimental|Standard of Care (SOC)|In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
10118144|NCT04421599|Experimental|Experimental Group A|Experimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.
10118145|NCT04421599|No Intervention|Control Group|Control Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.
10118146|NCT04421599|Experimental|Experimental Group B|Experimental Group B who were not administered aspiration during IM injection.
10118147|NCT04421807|Experimental|Exercise+Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
10118148|NCT04421807|Active Comparator|Only Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
10118149|NCT04421742||43 COPD|COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks
10118150|NCT04421677|Experimental|Phenylbutyrate|Open-label phenylbutyrate
10118151|NCT04422002||Surgical treatment|
10118152|NCT04422002||Palliative treatment|
10118153|NCT04421547|Experimental|Letrozole|Letrozole 1 tablet (2,5 mg) orally once a day
9966192|NCT01257555||Treatment Group|
10118154|NCT04421547|Active Comparator|Standard Chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
10118155|NCT04421339|Experimental|Melatonin|
10118156|NCT04421339|Placebo Comparator|Placebo|
10118157|NCT04421534|Experimental|Standard of care in addition to 400 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 400 mg oral lactoferrin daily [two sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
10118158|NCT04421534|Experimental|Standard of care in addition to 600 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 600 mg oral lactoferrin daily [three sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
10118159|NCT04421534|Active Comparator|Standard of care only|Standard of care treatment; as per MOHP protocol
10118160|NCT04421625|Experimental|Diagnostic test for SARS-Cov2 for patients and health staff|"Blood test (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens)~Nasal swab test (only if the patient has symptoms)~Questionnaires"
10118161|NCT04421508|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 125 mcg/kg IBW/hour
10118162|NCT04421508|Sham Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
10118163|NCT04421248||Attention Deficit Hyperactivity Disorder (ADHD)|8 to 12 year old children diagnosed with ADHD
10118164|NCT04421248||Typically developing controls (TDC)|Typically developing controls - 8 to 12 year old children
10118165|NCT04421287|Experimental|Zhenyuan capsule|
10118166|NCT04421287|Placebo Comparator|Zhenyuan capsule placebo|
10118167|NCT04421430|Experimental|Distraction cards group|Distraction cards was applied to the children in this group during the venipuncture procedure.
10118168|NCT04421430|Experimental|Virtual reality group|Virtual reality intervention was applied to the children in this group during the venipuncture procedure.
10118169|NCT04421430|Experimental|Buzzy® group|Buzzy® was applied to the children in this group during the venipuncture procedure.
10118170|NCT04421430|No Intervention|Control group|The control group received the routine venipuncture procedure and did not receive any other non-pharmacological intervention.
10118171|NCT04421521|Experimental|Acupuncture Group|
10118172|NCT04421521|No Intervention|Standard Therapy Group|
10118173|NCT04421443|Active Comparator|3 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 3 days.
10118174|NCT04421443|Active Comparator|5 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 5 days.
10118175|NCT04421443|Active Comparator|8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
10118176|NCT04421469|Experimental|Comprehensive treatment|Patients with multiple metastatic NPC were given Triprilimab(JS001) and chemotherapy combined with local treatment.
10118177|NCT04421222|Experimental|Cohort 1|200 mg EPI-7386
10118178|NCT04421222|Experimental|Cohort 2|400 mg EPI-7386
10118179|NCT04421222|Experimental|Cohort 3|600 mg EPI-7386
10118180|NCT04421222|Experimental|Cohort 4|800 mg EPI-7386
10118181|NCT04421222|Experimental|Cohort 5|1000 mg EPI-7386
10118182|NCT04421222|Experimental|Cohort 6|800 mg EPI-7386
10118183|NCT04421261||Air-Q Self Pressurized Airway Device with Blocker|
10118184|NCT04421261||I-Gel|
10118185|NCT04421183||1|preeclampsia
9966193|NCT01257594|Experimental|No cytoreductive surgery planned|Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial. They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
9976458|NCT01351558|Active Comparator|Cardiovascular fitness exercises|
10118186|NCT04421183||4|normal pregnancy without complication
10118187|NCT04421183||2|hellp
10118188|NCT04421183||3|eclampsia
10118189|NCT04421274|Experimental|BM-MSCs group|Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )
10118190|NCT04421274|Sham Comparator|Control group|Receive the best medication, percutaneous coronary intervention
10118191|NCT04421300|Experimental|smile exercise|smile exercise, 4 times a day，8 weeks
10118192|NCT04421300|Active Comparator|0.1% Sodium Hyaluronate Eye Drops|0.1% sodium hyaluronate, 4 times a day, 8 weeks.
10118193|NCT04421209|Experimental|Propranolol treatment|"Subjects randomized to the propranolol treatment arm will be administered propranolol 40mg BID for three days prior to surgery, 40mg BID the day of surgery and on post-operative days 1 and 2. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid usend pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
10118194|NCT04421209|Placebo Comparator|Placebo|"Subjects randomized to the placebo treatment arm will be administered placebo tablets with the same schedule as propranolol in the experimental arm. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.~Patients will be evaluated for opioid use and pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers compared to placebo, and if this correlates to decreased opioid use and pain scores post-operatively.~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
10118195|NCT04421326||Patients with acute ischemic stroke|Patients undergoing Mechanical Thrombectomy for large vessel occclusion with acute ischemic stroke
10118196|NCT04421157|Experimental|Schroth group|The Schroth group received Schroth exercises in addition to traditional rehabilitation.
10118197|NCT04421157|Experimental|Stabilization group|The stabilization group received core stabilization in addition to traditional rehabilitation.
10118198|NCT04421391|Experimental|Treatment Arm|Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks
10118199|NCT04421144|Experimental|study group|using CAD/CAM surgical cutting guides for maxilla and mandible and customized titanium plates to guide all osteotomies and fixation of both arches.
10118200|NCT04421079|Placebo Comparator|Placebo|Comparable placebos
10118201|NCT04421079|Active Comparator|Low Dose BDPP|8 oz. Concord grape juice + 450 mg Grape seed polyphenol extract + 150 mg Trans-resveratrol
10118202|NCT04421079|Active Comparator|Medium Dose BDPP|16 oz. Concord grape juice + 900 mg Grape seed polyphenol extract + 300 mg Trans-resveratrol
10118203|NCT04421079|Active Comparator|High Dose BDPP|24 oz. Concord grape juice + 1200mg Grape seed polyphenol extract + 450mg Trans-resveratrol
10118204|NCT04421066||Peri-implantitis|Patients with at least one dental implant diagnosed with peri-implantitis undergoing treatment for peri-implantitis as their standard of care will be included in this study.
10118205|NCT04421066||Healthy|Patients with general good health and health gingiva undergoing extraction of wisdom tooth will be included in this study group.
10118206|NCT04421105|Experimental|Group 1 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
10118207|NCT04421105|Experimental|Group 2 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
10118208|NCT04421105|Experimental|Group 3 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
10118209|NCT04421105|Placebo Comparator|Group 4 N=12|6 doses 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
10118210|NCT04420949|Experimental|Healthy|Healthy adults with visually-induced dizziness with undergo the testing and treatment.
10118211|NCT04420949|Experimental|Vestibular-impaired|Adults with unilateral or bilateral, peripheral vestibular loss who also have visually-induced dizziness with undergo the testing and treatment.
10118212|NCT04420884|Experimental|Monotherapy Dose Escalation Phase: TAK-676 SA|"Safety Lead-in: TAK-676 0.1 milligram (mg), infusion, intravenously, once weekly, on Days 1, 8 and 15 in 21-day treatment Cycles.~TAK-676 SA Dose Escalation: TAK-676 SA, infusion, intravenously, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the TAK-676 SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in Phase."
10118213|NCT04420884|Experimental|Combination Dose Escalation Phase: TAK-676 + Pembrolizumab|"TAK-676, infusion, intravenously, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above) plus pembrolizumab 200 mg, infusion, intravenously, once on Day 1 in each 21-day treatment cycles.~The dosing will be initiated based on the available safety and tolerability data from the initial TAK-676 SA cohorts."
10118214|NCT04420975|Experimental|Treatment (BO-112, nivolumab)|Patients receive BO-112 intratumorally on days 1, 8, and 15 and nivolumab IV over 30-60 minutes on days 8 and 22 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.
10118215|NCT04420832|Active Comparator|Surgical treatment|Patients with a distance of 5 mm or more between tendon ends will be treated surgically and with physiotherapy
10118216|NCT04420832|Other|Non-surgical treatment|Patients with a distance of less than 5 mm between tendon ends will be treated non-surgically and with physiotherapy
10118217|NCT04420962||Microbial Keratitis|Presence of a bacteria or fungal keratitis with ≥ 2mm stromal infiltrate
10118218|NCT04420962||Viral or Inflammatory Keratitis|Non-infectious inflammatory, Viral, Acanthamoeba, or other forms of keratitis
10182766|NCT03771092|Experimental|Patients with non-severe anemia treated with SunActive®Fe|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized
10182767|NCT03771092|Experimental|Patients with non-severe anemia treated with Lipofer®|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®
10182768|NCT03771092|Experimental|Patients with severe anemia with Lipofer®|Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®
10182769|NCT03771092|Experimental|Patients with severe anemia with SunActive®Fe|Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized
10182770|NCT03771092|Experimental|Patients with severe anemia with intravenous ferric gluconate|Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
10182771|NCT03771326|Experimental|obese men|To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
10182772|NCT03771326|Experimental|Normal men|To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
10182773|NCT03771001|Other|Convenience sample participants|In this feasibility study all participants will receive the intervention.
10182774|NCT03771209|Experimental|ultrasound assessment|The aim of this study is the creation of a five-step ultrasound examination to evaluate and monitor HF patients during hospitalization and short follow-up.
10182775|NCT03771495|Experimental|Hip Joint Mobilization|passive accessory movement on femur in anterior/posterior direction, grade III for four minutes and passive physiological movement of the most restricted hip joint movement, grade III for one minute (without pain), and a verbal education of hypothesized underlying effect mechanisms.
9976459|NCT01351571||Cohort|
10182776|NCT03771495|Sham Comparator|Laying on of Hands|grade I, very small amplitude without encountering any tissue resistance for five minutes, thus effectively a Laying on of Hands, with a verbal education of hypothesized underlying effect mechanisms.
10182777|NCT03770923|No Intervention|No intervention|No intervention
10182778|NCT03770923|Active Comparator|Rupatadine|Rupatadine 10 mg once daily.
10182779|NCT03770923|Active Comparator|Montelukast|Montelukast 10 mg daily
10182780|NCT03770819|Placebo Comparator|Placebo group|Application of placebo gel followed by sham Photodynamic therapy
10182781|NCT03770819|Active Comparator|Zinc oxide gel group|Application of Zinc oxide gel followed by sham Photodynamic therapy.
10182782|NCT03770819|Experimental|PDT group|Application of placebo gel followed by Photodynamic therapy.
10182783|NCT03770819|Experimental|Zinc oxide and PDT group|Application of Zinc oxide gel followed by Photodynamic therapy.
10182784|NCT03770975|Active Comparator|Delayed implant placement with immediate provisionalization|Single delayed implant placement in the esthetic zone with placing an immediate temporary crown placed within 48 hours after the surgery
10182785|NCT03770975|Experimental|Implant with immediate temporization and soft tissue graft|Single delayed implant placement in the esthetic zone with placing a subepithelial connective tissue graft buccal to the implant and immediate temporary crown within 48 hours after the surgery
10182786|NCT03771625||single-group studies|All the patients received chemotherapy and radiotherapy.
10118219|NCT04420897||Normoxy: PaO2 = 80-120 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
10118220|NCT04420897||Moderate hyperoxemia: PaO2 =120-200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
10118221|NCT04420897||Severe hyperoxemia: PaO2 >200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
10118222|NCT04420780|Experimental|Xyl Group|Children will receive sugar-free gums containing 100% Xylitol as sweetener
10118223|NCT04420780|Active Comparator|Pol Group|Children will receive sugar-free gums containing a polyols mixture plus a low amount of Xylitol (22%).
10118224|NCT04420910||Parkinson's disease group|being diagnosed with PD by a neurologist, being in Hoehn & Yahr Stage 1-3
10118225|NCT04420910||Healthy group|20 healthy volunteers with matching ages and genders.
10118226|NCT04420806|Active Comparator|HIT-exercise|13 months of high intensity endurance and resistance exercise - 3 months of exercise break
10118227|NCT04420806|Sham Comparator|control|no exercise intervention that affect the present study outcomes
10118228|NCT04420858|Other|Control|The control arm will receive standard education about cell-free DNA screening that would typically be presented during a prenatal visit.
10118229|NCT04420858|Experimental|Experimental|The experimental arm will receive additional education about federal legislation that protects the privacy of genetic information (Genetic Information Nondiscrimination Act, GINA).
10118230|NCT04420936|Experimental|Lifestyle coaching|
10118231|NCT04420936|Active Comparator|Control tracking|
10118232|NCT04420871|Active Comparator|capecitabine reference formulation at a single dose of 150 mg|150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
10118233|NCT04420871|Experimental|capecitabine test formulation at a single dose of 150 mg|The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.
10118234|NCT04420728|Experimental|Early auto-mode enabled|Auto mode continuous glucose monitoring enabled 2-10 days post-partum
10118235|NCT04420728|Active Comparator|Delayed auto mode enabled|Auto mode continuous glucose monitoring enabled 12 weeks post-partum
10118236|NCT04420793||ECT and Voice Recorded Group|This is an add-on study of voice samples to be gathered during ECT clinical treatments. The ONLY research procedures are four tasks on an online form, one text task and three voice recording tasks. These voice recordings will take place in a private room on the 5th floor of the Institute of Psychiatry on the same day of a patient's ECT treatment. The questionnaire will take less than 10 minutes.
10118237|NCT04420650|Active Comparator|Anodal tDCS|Anodal tDCS of the hypothalamus-cognitive network
10118238|NCT04420650|Active Comparator|Cathodal tDCS|Cathodal tDCS of the hypothalamus-cognitive network
10118239|NCT04420650|Sham Comparator|Sham Stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
10118240|NCT04420585|Experimental|Treatment Group|Desmopressin 0.2mg tablets, dose titrated to effect
10118241|NCT04420923|Experimental|Observe-and-Plan|Patients will follow the same protocol as described by dr. Mantel et al. (2014) in the first Observe-and-Plan study conducted in Lausanne.
10118242|NCT04420923|Active Comparator|Treat-and-Extend|Patients will follow the standard treatment protocol for Treat-and-Extend, used for several years in the participating clinics.
10118243|NCT04421001|Experimental|I-Port™*(Medtronic) use Arm|Patients will administer insulin via iport system. I-Port™* (Medtronic), infusion set, dedicated for insulin deliery for 72 hours.
10118244|NCT04421001|Active Comparator|Insulin Pen Injections|Patients will administer insulin via injections as usual
10118245|NCT04420767|Experimental|tDCS and Go-No Go task|"Certain randomly assigned participants will receive tDCS to the DLPFC for 8 daily 20-minute sessions, with a TDCS amplitude of 2 mAmps.~During the tDCS session, individuals will perform a 10-min computerized Go-No Go task"
10182787|NCT03770871|Active Comparator|IPT using Dycal (TM )|Indirect pulp treatment; IPT using Dycal (TM ); (2 paste system) by partial caries removal
10182788|NCT03770871|Experimental|IPT using Vitrebond (TM )|Indirect pulp treatment; IPT using Vitrebond (TM );(powder and liquid) by partial caries removal
9966194|NCT01257594|Experimental|Cytoreductive surgery planned|"Patients scheduled for salvage resection as part of their routine care will be considered for this cohort. They will receive 1 pre-operative dose of 2000 mg erlotinib. Resection will occur ≤ 3 hours after the pre-operative dose. After recovery from surgery, patients will resume pulsatile erlotinib dosing."
9966195|NCT01257620|Placebo Comparator|Placebo|Placebo
9966196|NCT01257620|Experimental|Probiotic|Life Start Two
9966197|NCT01257633||The study population|Laryngeal cancer patients requiring surgical tumor resection.
9966198|NCT01257646||Recent stroke group|These patients have hemiplegia following a stroke within the last 6 months
9966199|NCT01257646||Old stroke group|The patients have hemiplegia following a stroke that took place at least a year ago
9966200|NCT01257659|Experimental|STARR arm|In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
9966201|NCT01257659|Active Comparator|Elevate arm|In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.
9976460|NCT01351597|Experimental|docetaxel/ oxaliplatin|All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
9976461|NCT01351610|Experimental|Group B|
9976462|NCT01351610|Experimental|Group A|
9976463|NCT01351636|Experimental|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride
9976464|NCT01351636|Placebo Comparator|Non arotinolol group|Antihypertensive medications without arotinolol hydrochloride
9976465|NCT01351649|Other|attention control|Sessions with school nurse to discuss health-promoting topics and after-school health-promoting workshop. Physical activity and healthy eating were not addressed.
9976466|NCT01351649|Experimental|physical activity|
9976467|NCT01351662|Experimental|Self management program|"The Arthritis Self-Management Program (ASMP) will be administered to 15 African American lupus patients participating in an ongoing SLE Clinic Database Project at the Medical University of South Carolina (MUSC). Fifteen other patients will serve as controls and receive usual care."
9976468|NCT01351688|Experimental|AZD3514|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
9976469|NCT01351714|Other|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
9976470|NCT01351727||Seniors with Seizures|Seniors aged 65 or older with newly diagnosed seizures (consistent with epilepsy) or epilepsy as of October, 2010.
9976471|NCT01351779||Progressive glaucoma|Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
9976472|NCT01351792|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
9976473|NCT01351792|Active Comparator|Symbicort® Turbohaler®|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
9976474|NCT01351818||Growth hormone|Patients with a condition
9976475|NCT01351831|Experimental|Rehabilitation with strength training|
9976476|NCT01351831|Active Comparator|Rehabilitation without strength training|
9976477|NCT01351844|Active Comparator|Education and exercise intervention|"The intervention module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises."
9976478|NCT01351844|Placebo Comparator|Education and general exercise|"The control module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises."
9976479|NCT01351857|Other|Transition Coordinator|A Transition Coordinator, a Certified Diabetes Educator, will provide transition support and the link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
9976480|NCT01351857|No Intervention|Current Standard of Care|Subjects in the control group will transition to adult care equal to the intervention group and will differ only by exclusion of Transition Coordinator. Control group will receive the current standard of diabetes care otherwise unchanged. Three months following randomization, subjects in the control group will be referred to the adult endocrinologist in the same way as subjects in the intervention group
9976481|NCT01351870|Active Comparator|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
9976482|NCT01351870|Experimental|Hyperfractionated radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
9976483|NCT01351883|No Intervention|Standard enteral nutrition supplement|regular standard enteral nutrition(SEN) was made by hospital for patient
10182789|NCT03770936|No Intervention|Control group|No intervention
9668889|NCT04700722||Dementia with Lewy bodies|Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
9976484|NCT01351922||A|
9976485|NCT01351935|Experimental|AVL-292|
9976486|NCT01351948|Experimental|Group 1|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
9976487|NCT01351948|Experimental|Group 2|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
9976488|NCT01351948|Experimental|Group 3|AdCh63 AMA1 + AMA1-C1/Alhydrogel®
9976489|NCT01351948|Experimental|Group 4|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
9976490|NCT01351948|Experimental|Group 5|AdCh63 AMA1 + MVA AMA1
9976491|NCT01351961|Other|Elderly hypertensive patients with mnemonic subjective|"Elderly hypertensive patients with mnemonic subjective without dementia. Interventions :~blood sampling brain MRI Assessment of cognitive functions brain MRI and TEP cerebral Electrocardiogram and blood pressure Pulse wave velocity Quality of life questionnaire Urine sample Vascular explorations"
9976492|NCT01352000|Active Comparator|Usual Care (UC)|Receive Quitline services
9976493|NCT01352000|Active Comparator|Repeated Mailings (RM)|Receive the 8 Forever Free booklets sent by mail at regular intervals over a period of 12 months
10182790|NCT03770936|Active Comparator|Candesartan|Candesartan 8 mg/day
9668890|NCT04700722||Pure Autonomic Failure|Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
9966202|NCT01257672|Experimental|ondansetron|ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose
9966203|NCT01257672|Active Comparator|domperidon|domperidone, syrup, 0,5 mg/Kg of body weight, one dose
9966204|NCT01257672|Placebo Comparator|placebo|placebo, syrup, one dose
9966205|NCT01257685||Control Group|Normal group
9966206|NCT01257685||NAFLD Group|NAFLD in the present study was defined a value of LAI <5 HU using an unenhaned CT.
9966207|NCT01257711|Other|Billroth II reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Billroth II reconstruction.
9966208|NCT01257711|Other|Roux-en-Y reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Roux-en-Y reconstruction.
9966209|NCT01257724|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
9966210|NCT01257724|Active Comparator|Self-serve evidence service|Organizations allocated to the control group will only be provided website access to a listing of systematic reviews that are organized by year of publication with links to the record on PubMed (or another publicly available source when not available on PubMed) and access to worksheets that help community-based organizations find and use research evidence.
9966211|NCT00077285|Experimental|pts with intermediate- and high-risk rhabdomyosarcoma|
9966212|NCT01257776|Active Comparator|Mesenchymal stem cells 0,5 million * weight (kg)|Group of low dose of Mesenchymal stem cells.
9966213|NCT01257776|Active Comparator|Mesenchymal stem cells 1 million * weight (kg)|Group of mid dose of mesenchymal stem cells
9966214|NCT01257776|No Intervention|Controlled group|Controlled group with no intervention
9966215|NCT01257789||gastric bypass patients|Consecutive series of 300 patients undergoing laparoscopic gastric bypass
9966216|NCT01257815|Experimental|Ranibizumab 0.5mg|
9966217|NCT01257828|Placebo Comparator|Placebo|Placebo medication and decompressive cervical spine surgery
9966218|NCT01257828|Experimental|Riluzole|Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery
9966219|NCT01257841|Placebo Comparator|Fasting alone|
9966220|NCT01257841|Active Comparator|Fasting plus leptin|
9966221|NCT01257854||Busulfan, pharmacogenetic, pharmacokinetic, children|Children who receive Busulfan IV and have a pharmacokinetic of Busulfan
9966222|NCT01257867|Experimental|Lithia spring water|Lithia water (active) for 4 weeks then placebo water for 4 weeks
9966223|NCT01257867|Placebo Comparator|Natural spring water|Placebo water for 4 weeks then lithia water (active) for 4 weeks
9966224|NCT01257893|Experimental|Aspirin 81 mg|Subjects will take 81 mg aspirin per day for 10-14 consecutive days
9966225|NCT01257893|Placebo Comparator|Placebo|Subjects will take matching placebo capsule (excipient: methylcellulose) for 10-14 consecutive days.
9966226|NCT01257906|Experimental|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel Test Product
9966227|NCT01257906|Active Comparator|ZIANA®|Topical Gel Reference Product
9966228|NCT01257906|Placebo Comparator|Vehicle Control|Topical Gel Placebo
9966229|NCT01257919|Experimental|Azelaic Acid Foam 15%|Dermal application of Azelaic Acid Foam 15%
9966230|NCT01257919|Active Comparator|Azelaic Acid Gel 15%|Dermal application of Azelaic Acid Gel 15%
9966231|NCT01257932||Diagnostic Tool|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
9966232|NCT01257945|Experimental|Flexibility & Function|Subjects take part in an exercise program based on flexibility and function.
9966233|NCT01257945|Experimental|Aerobic Exercise|Subjects will take part in an aerobic exercise program
9966234|NCT01257945|Other|Home exercise|Standard of care home exercise program
9966235|NCT01257958|Experimental|19 nor vitamin d|
9966236|NCT01257971||1|Patients with hypercholesterolaemia
9966237|NCT01257984|Experimental|Arm 1|
9966238|NCT01257984|Experimental|Arm 2|
9966239|NCT01257997||Healthy subjects|18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
9966240|NCT01258010|Experimental|Tranexamic acid|Study subjects will be randomized to receive a bolus dose of 30 mg/kg of tranexamic acid administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of tranexamic acid of 16 mg/kg/h administered up to 6 hours after surgery.
9966241|NCT01258010|Placebo Comparator|Normal saline (NaCl 0.9%)|Study subjects will be randomized to receive a bolus dose of normal saline (NaCl 0.9%) of equivalent volume administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
9966242|NCT01258023|Experimental|transplant recipients|Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation
9966243|NCT01258036||Fractured Mothers|Fractured Mothers and their daughters
9966244|NCT01258036||Non fractured mothers|Mothers non fractured and their daughters
9966245|NCT01258062|Experimental|of GelVac™ nasal powder H5N1 influenza vaccine.|
9966246|NCT01258062|Placebo Comparator|Placebo|
9966247|NCT01258088|Active Comparator|Cohort 1: AN2728 Ointment|
9966248|NCT01258088|Placebo Comparator|Cohort 1: AN2728 Vehicle|
9966249|NCT01258088|Active Comparator|Cohort 3: AN2728 Ointment|
9966250|NCT01258088|Placebo Comparator|Cohort 3: AN2728 Vehicle|
9976494|NCT01352000|Active Comparator|Massed Mailings (MM)|Receive all 8 booklets in a single mailing
9976495|NCT01352013|Placebo Comparator|Colored olive oil|
10118246|NCT04420767|Sham Comparator|Sham brain stimulation and Go-No Go task|"Certain randomly assigned participants will receive Sham Stimulation to the DLPFC for 8 daily 20-min sessions. The Sham stimulation is an inactive form of stimulation.~During the sham brain stimulation session, individuals will perform a 10-min computerized Go-No Go task"
10118247|NCT04420559|Experimental|Virtual Reality|
9966251|NCT01258114|Active Comparator|SPA treatment (ST)|"Drug : spa treatment during 18 days soon after randomization the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises) ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
10118248|NCT04420559|Experimental|Distraction Card|
10118249|NCT04420559|No Intervention|Control|
9966252|NCT01258114|Sham Comparator|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
10118250|NCT04420390|Experimental|Radiotherapy|
10118251|NCT04420377|Placebo Comparator|Placebo Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
10118252|NCT04420377|Experimental|Experimental Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a treatment condition (Carnipure™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
10118253|NCT04420715|Experimental|Less-experienced group|The participant who has completed the number of PCI less than 200 before recruiting
10118254|NCT04420715|Experimental|Experienced group|The participant who has completed the number of PCI more than 200 before recruiting
10118255|NCT04420260|Experimental|Treatment oropharyngeal spray + immunostimulant emulsion|Active principle oropharyngeal spray + Active principle immunostimulant taken PO.
10118256|NCT04420260|Placebo Comparator|Placebo|Placebo oropharyngeal spray + Placebo emulsion was taken PO.
10118257|NCT04420234|Experimental|Pharmacokinetics study of single and multiple administration|During the study session, 30 healthy subjects will be administered a single and multiple dose of narfurine hydrochloride orally disintegrating tablets 5 µg (2.5 µg/table) to evaluate the pharmacokinetic parameters and the safety profile.
10118258|NCT04420429||Cohort|All patients
10118259|NCT04420468||Possible COVID-19 infection and acute myocarditis|"Children presented with an acute myocarditis, fever and shock with a possible COVID-19 infection cared between April 2020 till the end of the main SARS-Cov-2 outbreak in 4 AP-HP Parisian hospitals :~Necker-Enfants Malades~Armand Trousseau~Robert Debré~Kremlin Bicêtre"
9668891|NCT04700722||Healthy Controls|No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
9976496|NCT01352013|Active Comparator|Omega-3 (oil)|
9976497|NCT01352026|Experimental|Metformin|
9976498|NCT01352039|Experimental|Heparin Sodium - Eurofarma|
9668894|NCT04696094||Healthy volunteers|"Health volunteers' inclusion criteria:~Age between 4-60; Male or female;~Exclusion criteria:~Exclude the volunteers with history of cerebrovascular disease."
10118260|NCT04420442|Active Comparator|Intervention Group|In addition to the comparison between arm 1 and 2, there will be an intraindividual comparison within arm 1.
10118261|NCT04420442|No Intervention|Control Group|No Intervention.
10118262|NCT04420481|Active Comparator|Growth hormon group|A 12 month study, consisting of a 9 months growth hormone treatment phase followed by a 3 month growth hormone treatment-free period.
10118263|NCT04420481|Placebo Comparator|Control group|A 12 month study, consisting of a 9 month placebo treatment phase followed by a 3 month treatment-free period.
9694583|NCT04787783|No Intervention|Traditional face to face assessment|"Participants will be leaded through preoperative period following traditional institutional standards of care.~Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records."
9694584|NCT04787679||Osteoporotic patients|Osteoporotic patients, age > 18 years old
9694585|NCT04787679||Non osteoporotic patients|Non osteoporotic patients, age > 18 years old
10118264|NCT04420533|Active Comparator|Behavior therapy alone|Behavior therapy alone
10118265|NCT04420533|Experimental|Behavior therapy plus mirabegron 50mg|Behavior therapy plus Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
10118266|NCT04420065|Active Comparator|Classical biventricular pacing|Commercially available LV-pacing capable CRT devices and quadripolar leads will be implanted. Right ventricular (RV) and right atrial (RA) leads will be placed according to standard practice. The LV lead will also be placed according to standard practice, targeting to a lateral, posterolateral, or anterolateral branch of the coronary sinus (CS). Interventricular delay programmed will be determined based on stroke volume maximization, and will be used as a criterion for BVP optimization. Atrioventricular delay optimization shall be automatically performed by the device.
10118267|NCT04420065|Experimental|Preferential left ventricular pacing|In G2 patients, an algorithm for preferential left ventricular pacing will be activated. Following selection of the dipole maximizing stroke volume during simultaneous LV-RV pacing, subsequent V-V delay optimization shall be delegated to the algorithm. Based on previous studies, a subgroup analysis of G2 will be performed, comparing those receiving ≥50% with those receiving <50% preferential LV pacing evaluated over the total duration of the study (12 months).
10118268|NCT04420169||PRE implementation communication protocol|
10118269|NCT04420169||POST implementation communication protocol|
10118270|NCT04419948|Experimental|Control|100g white bread plus 40ml butter
10118271|NCT04419948|Experimental|Positive control|100g white bread plus 40ml butter and 400mg ibuprofen
10118272|NCT04419948|Experimental|Refined olive oil|100g white bread plus 40ml refined olive oil
10182791|NCT03770936|Active Comparator|Ramipril|Ramipril 1.25 mg/day
10118273|NCT04419948|Experimental|EVOO with moderate concentration of oleocanthal|100g white bread plus 40ml EVOO containing 250 mg/kg oleocanthal
10118274|NCT04419948|Experimental|EVOO with high concentration of oleocanthal|100g white bread plus 40ml EVOO containing 500 mg/kg oleocanthal
10118275|NCT04420299|Experimental|Experimental - therapeutic bemiparin dose|Sub-cutaneous dose of bemiparin at therapeutic dose for 10 days
10118276|NCT04420299|Experimental|Control - prophylactic bemiparin dose|Sub-cutaneous dose of bemiparin at prophilactic dose for 10 days
10118277|NCT04420494|Experimental|Patients treated with umbilical cord blood|
10118278|NCT04420195|Experimental|Envarsus XR|Envarsus XR to be initiated once patient is tolerating oral medications
10118279|NCT04420195|Experimental|IR tacrolimus (historical control)|Historical cohort of patients maintained on IR tacrolimus following transplant
10118280|NCT04420351|Experimental|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
10118281|NCT04420351|Other|Antiplatelet treatment|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018
10118282|NCT04419974||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
10118283|NCT04419974||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
10118284|NCT04419974||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
10118285|NCT04420364|Experimental|Maintenance of Immunosuppression|Maintenance of immunosuppression (defined as no change to pre-admission immunosuppression, or reduction in anti-metabolite by up to 50% (to a minimum of MMF 500 mg per day or azathioprine 50 mg per day)
10118286|NCT04420364|Active Comparator|Reduction of Immunosuppression|Reduction of immunosuppression (defined as anti-metabolite withdrawal plus reduction of tacrolimus or cyclosporin, to a minimum target trough concentration of 3 ng/mL for tacrolimus and 50 ng/mL for cyclosporin).
10118287|NCT04420039||1- Single biliary LAMS|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent after failed ERCP cannulation or inaccessible papilla.
10118288|NCT04420039||2- Biliary LAMS plus Doublu-Pigtail plastic Etent|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent (plus double-pigtail plastic stent) after failed ERCP cannulation or inaccessible papilla.
10118289|NCT04420338|Experimental|Chronic hemodialysis patients|
10118290|NCT04420338|Experimental|Caregivers of chronic hemodialysis patients|
10118291|NCT04419987|Experimental|constitutional platelet patholog|Patient and relatives having a constitutional platelet pathology
10118292|NCT04420052|Experimental|OMT group|
10118293|NCT04420052|Placebo Comparator|Placebo group|
10118294|NCT04420247|Experimental|Intervention|"Treatment with either Chloroquine or Hydroxychloroquine according to what was available in the hospital:~Chloroquine - 900mg on the first day, followed by 450mg in the next 4 days. Hydroxychloroquine - 800mg on the first day, followed by 450mg in the next 4 days.~+~Standard treatment available and recomended by the Brazilian Guidelines for COVID-19."
10118295|NCT04420247|Active Comparator|Control|Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.
10118296|NCT04420000|Experimental|Interventional group|Patients having a Mindfulness program
10118297|NCT04420000|Placebo Comparator|Control group|Patients having a routinary managment
10118298|NCT04419922||Smartphone Contingency Management Arm|100 participants will be voluntarily recruited at BrightView's Colerain outpatient treatment center to participate in the Smartphone Contingency Management Intervention.
10118299|NCT04420026|Experimental|Experimental Arm|Hepatocellular tumours
10118300|NCT04419961|No Intervention|Control|Routine care.
10118301|NCT04419961|Experimental|Intervention|Routine care plus participation in an educational program including a group discussion and a booklet.
10118302|NCT04420130|Experimental|Camrelizumab combined with ablation and chemotherapy|First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.
10118303|NCT04420091|Experimental|Cartidyss|
10118304|NCT04420104|Experimental|esp block group|
10118305|NCT04420104|Active Comparator|control group|
10118306|NCT04419766|Experimental|intervention|Community of Tambai: Indoors and outdoors spraying with IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester)
10118307|NCT04419766|No Intervention|Control|Community of Micheu 1: Without spraying.
10118308|NCT04419792||Narcolepsy|
10118309|NCT04419662|Experimental|All patients included|
10118310|NCT04419753|Active Comparator|No Attention Focus Walking Group (NAFWG)|In each training session, the NAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway without attention focus instruction (20 minutes) and cool down (5 minutes).
10118311|NCT04419753|Experimental|External Attention Focus Walking Group (EAFWG)|In each training session, the EAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with external attention focus instructions (20 minutes) and cool down (5 minutes).
10118312|NCT04419753|Experimental|Internal Attention Focus Walking Group (IAFWG)|In each training session, the IAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with internal attention focus instructions (20 minutes) and cool down (5 minutes).
9528178|NCT03213067||Mitochondrial Disease Patients|"Male and Females >18 years at the time of screening~Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A>G mutation.~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
9966253|NCT01258127||Pemetrexed and Carboplatin|For patients in arm pemetrexed/carboplatin, folic acid (350-1000 μg) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 μg) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day before, the day of, and the day after each dose of pemetrexed, for rash prophylaxis unless medically contraindicated. Patients must receive pemetrexed at day 1 at the dose of 500 mg/m2 as an IV infusion over approximately 10 minutes, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
9966254|NCT01258127||Vinorelbine and Carboplatin|Patients in arm vinorelbine and carboplatin follow the regimen: The scheduled infusion time is 6-10 minutes for IV vinorelbine at the dose of 25 mg/m2 d1,8, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
9966255|NCT01258140|Active Comparator|1|Patients examined with normal-dose Computed tomography pulmonary angiography
9966256|NCT01258140|Active Comparator|2|Patients examined with low-dose Computed tomography pulmonary angiography
9966257|NCT01258166||Tramuatic ulnar translocation|Patients who suffered a traumatic ulnar translocation following injury.
9966258|NCT01258179||Sepsis Group|Patients suffering from sepsis in the postoperative course after major abdominal surgery
9966259|NCT01258179||Control Group|Patients without suffering sepsis during postoperative follow up after major abdominal surgery
9966260|NCT01258192|Experimental|nab-paclitaxel plus cisplatin|
9966261|NCT01258205|Experimental|Part B|One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.
9966262|NCT01258205|Experimental|Part A|Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.
9966263|NCT01258218||Accent MRI Group|
9966264|NCT01258231||Cardiac surgery|Adult patients undergoing cardiac surgery
9966265|NCT01258244||Audiovisual feedback on CPR|EMS technicians will receive audiovisual feedback from the ZOLL device on depth, frequency, and interruptions to cardiac compressions
9966266|NCT01258257|Active Comparator|Lumbar drain (LD) / Tuohy drain|Intervention: Insertion of a lumbar drain All patients in the LD group receives a lumbar drain during anesthesia required for aneurysm treatment. Drainage of CSF is started after the post-procedural CT scan on day one after aneurysm securement.
9966267|NCT01258257|No Intervention|No Lumbar drain (NoLD)|Patients randomized to the control group should not receive a lumbar drain before the planned control angiography to be performed on day 7 to 10 after SAH. If the patient develops hydrocephalus, and no EVD was placed initially for CSF drainage, a lumbar drain may be installed at the discretion of the local investigator. These patients are analyzed in the intention-to-treat analysis, but are not suitable for per-protocol analysis.
9966268|NCT01258270|Active Comparator|(AQUACEL® Ag Surgical Dressing|
9966269|NCT01258270|Active Comparator|Standard island gauze and tape dressing|A standard island dressing consists of adhesive tape and gauze.
9966270|NCT01258283||The study population|See inclusion and exclusion criteria.
9966271|NCT01258296|Active Comparator|Active fentanyl patch|25 mcg/hr fentanyl patch
9966272|NCT01258296|Placebo Comparator|Placebo patch|Inactive patch that resembles treatment patch but contains no drug
9966273|NCT01258309|Experimental|1|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
9966274|NCT01258309|Active Comparator|2|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
9966275|NCT01258322|Experimental|pioglitazone|
9966276|NCT01258335|Active Comparator|Omega 3 Fatty acids|"II. Study arms:~a. Participants in the dry AMD study group will be randomized into two arms with a 4:1 ratio: i. Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)"
9966277|NCT01258335|Placebo Comparator|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
9966278|NCT01258361||The study population|Patients will be recruited during anesthesia consultations carried out before programmed pelvic or visceral surgeries.
9966279|NCT01258413|Experimental|Laparoscopic Radical Hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
9966280|NCT01258413|Active Comparator|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
9966281|NCT01258426||Normal, IGT, T2DM|
9966282|NCT01258439|Active Comparator|1.Raltegravir plus truvada|Raltegravir 400mg twice daily plus truvada 300mg/200mg once daily for 24 weeks
9966283|NCT01258439|Active Comparator|2. ritonavir boosted darunavir plus truvada|Darunavir 800mg with ritonavir 100mg plus truvada 300mg/200mg once daily for 24 weeks
9966284|NCT01258452|Experimental|CHF 5074 (fed group)|oral tablet, single dose
9966285|NCT01258452|Experimental|CHF 5074 (fasting group)|oral tablet, single dose
9966286|NCT01258465|Active Comparator|Pivotal Response Training|A naturalistic behavioral intervention designed to facilitate verbal communication.
9966287|NCT01258465|Active Comparator|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to facilitate communication via picture icons.
9966288|NCT01258478|Experimental|rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
9966289|NCT01258478|Sham Comparator|usual care|Usual care before surgery is provided
9966290|NCT01258517||group 1, group 2, group 3, group 4|administration of beractant with single lumen ET tube administration of poractant with single lumen ET tube administration of beractant with double lumen ET tube administration of poractant with double lumen ET tube
9528179|NCT03213067||Healthy Control Group|"Male and Females >18 years at the time of screening~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
9528180|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
9966291|NCT01258530|Experimental|Treatment A|Over-encapsulated oseltamivir 75 mg (1 capsule)
9966292|NCT01258530|Experimental|Treatment B|oseltamivir 75 mg (1 capsule)
9966293|NCT01258543||Non-specific back pain|
9966294|NCT01258556|Experimental|Probiotic yogurt|
9966295|NCT01258556|Placebo Comparator|Placebo yogurt.|
9966296|NCT01258569|Active Comparator|Entereg|
9966297|NCT01258569|Placebo Comparator|Placebo|
9966298|NCT01258621|Experimental|Laparoscopic Distal Pancreatectomy|
9966299|NCT01258634|Other|Pre-op treatment|
9966300|NCT01258647|Experimental|Feeding group|The feeding group will include 20 mother/infant dyads. The infants will be between 8 and 10 months of age.
9966301|NCT01258673|Experimental|Fimasartan/HCTZ combination group|
9966302|NCT01258673|Active Comparator|Fimasartan group|
9966303|NCT01258686|Experimental|silymarin, treatment|
9966304|NCT01258686|Placebo Comparator|placebo|
9966305|NCT01258699|Experimental|3|BK-C-0701 480mg
9966306|NCT01258699|Experimental|2|BK-C-0701 320mg
9966307|NCT01258699|Active Comparator|1|Thioctacid HR tab 600mg
9966308|NCT01258712|Experimental|1|
9966309|NCT01258712|Placebo Comparator|2|
9966310|NCT01258725|Experimental|amnioinfusion|The investigators propose an open trial comparing baseline Doppler waveforms in the uteroplacental and fetal pulmonary circulation in patients presenting with severe, idiopathic olighydramnios (AFI<5, no apparent ethiopathology), managed either with single or with serial amnioinfusions. The patients will be followed up weekly in the fetomaternal unit, Dept. of ObGyn for measuring AFI repeatedly to assess the need for further infusions. These will be carried out when the AFI falls below 5cm again
9966311|NCT01258751|Experimental|PF-05212377|
9966312|NCT01258764|Active Comparator|Lisinopril|
9966313|NCT01258764|Active Comparator|Hydrochlorothiazide|
9966314|NCT01258777|Experimental|001|200 mg golimumab or placebo Single dose of 200 mg subcutaneously
10118313|NCT04419610|Experimental|Patients with confirmed/suspected C19 given intervention|Intravenous infusion of either placebo or TRV027 at 12mg/hr. Treatment will continue until discharge or for 7 days (whichever is sooner).
9966315|NCT01258777|Experimental|002|400 mg golimumab or placebo Single dose of 400 mg subcutaneously
9966316|NCT01258829|Experimental|Non-invasive haemodynamic optimisation|Optimization of pressure production by the heart, as measured by systolic blood pressure in the systemic circulation
9966317|NCT01258829|Active Comparator|ECHO optimisation|Optimization of AV/VV delay using the guideline recommendations
10118314|NCT04419610|Placebo Comparator|Patients with confirmed/suspected C19 given no intervention|Saline infusion.
9528181|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
9966318|NCT01258842|Experimental|B. lactis HN019|
9966319|NCT01258842|Placebo Comparator|Placebo|
9966320|NCT01258868|Experimental|1|Celebrex+ tumor cell vaccine
9966321|NCT01258920|Experimental|Paliperidone palmitate|Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
9966322|NCT01258933|Experimental|Ofatumumab|Ofatumumab 300 mg dose 1, then 1,000 mg weekly * 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.
9966323|NCT01258959||Ophthalmic surgery patients|Patients (men and women) of at least 18 years of age undergoing an ophthalmic procedure on the posterior section of the eye under local anaesthesia, i.e. with a peribulbar block. Inclusion and exclusion criteria for the study are the same as for the peribulbar anaesthesia.
9966324|NCT01258972|Active Comparator|Angioplasty POBA|Side Branch balloon angioplasty with main branch DES
9966325|NCT01258972|Experimental|Tryton Side Branch Stent|Side Branch treated with Tryton Side Branch Stent with main branch DES
9966326|NCT01259050|Experimental|Zinc and Copper|
9966327|NCT01259076||Group 1|Participants who are eligible for and have opted to undergo gastric bypass surgery
9966328|NCT01259076||Group 2|Participants who are eligible for but decided not to undergo gastric bypass surgery.
9966329|NCT01259141|Experimental|Moxifloxacin|
9966330|NCT01259141|Experimental|Cephalosporins and azithromycin|
9966331|NCT01259154||RFITT+UPPP|
9966332|NCT01259154||UPPP|
9966333|NCT01259167||BACK group|training with a traditional protocol of Therapeutic Physical Exercise
9966334|NCT01259167||"Group C."|Control group with sedentary people undergoing usual care.
9966335|NCT01259167||JOBA group|training with JOBA® Core Trainer
9966336|NCT01259180|Experimental|Acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
9966337|NCT01259180|Sham Comparator|Sham acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
9966338|NCT01259180|No Intervention|Control group|observation.
9966339|NCT01259193|Experimental|Sorafenib and Zoledronic Acid|
9966340|NCT01259206||diabetic patients|
9966341|NCT01259206||diabetic patients and healty controls|there are two groups in this study. One group is obese type 2 diabetic patiens and other group is healty controls.
9966342|NCT01259219|Experimental|Rifabutin (Mycobutin)|Rifabutin is a red-violet powder souble in chloroform and methanol, sparingly souluble in ethanol, and very slightly soluble in water. Mycobutin capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. Mycobutin capsules for oral administered contain 150mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose magenesium stearate, red iron oxide3, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.
9966343|NCT01259232||schizophrenia patients,untreated|
9966344|NCT01259232||schizophrenia relatives|
9966345|NCT01259232||controls|
9966346|NCT01259258|Active Comparator|varicocelectomy with dye|subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation
9966347|NCT01259258|Active Comparator|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
9966348|NCT01259271|Experimental|Supra-threshold|Supra-threshold is defined as the nerve stimulation amplitude at which a subject can tolerate sensory responses (like tingling, tapping in the thumb, index or middle fingers) but will not cause pain or duress to the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers and they feel the paresthesia or tingling sensation.
9966349|NCT01259271|Experimental|Sub-threshold|Sub-threshold is defined as the nerve stimulation amplitude just below the sensory perception of the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers. Subjects do not feel the paresthesia or tingling sensation despite there being a signal transmitted..
9966350|NCT01259271|Sham Comparator|Sham Control|All subjects in the sham arm will go through the same process / experimental setup as in each of the active stimulation arms; however there will be no stimulation signal during the sham stimulation (output set and SNS box locked at 0 V). As this is the Sham control, there is no intervention but rather the intevention (TAMS device) setup (Tyco electrodes, wires and stimulator) are sent with the subject as if it were on (and just like Subthreshold arm the subjects cannot feel the stimulation). Audible alerts (to signify that the box is unplugged) will be disabled throughout the duration of the study. This sham arm will be used to assess the placebo effect caused by the stimulation and hence isolate the true effect of stimulation.
9966351|NCT01259310||Women with epilepsy|Women with epilepsy, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
9966352|NCT01259310||Women without epilepsy|Healthy women, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
9966353|NCT01259323|Experimental|Cohort 1|
9966354|NCT01259323|Experimental|Cohort 2|
9966355|NCT01259323|Experimental|Cohort 3|
9966356|NCT01259336|Active Comparator|Itraconazole|Role of itraconazole in CCPA
9966357|NCT01259336|Experimental|treatment in cavitary pulmonary aspergillosis|Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
9966358|NCT01259349|Experimental|one percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
9966359|NCT01259349|Active Comparator|40 percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
9966360|NCT01259362|Active Comparator|Transcranial Magnetic Stimulation|Cocaine addicted will receive a 20 day TMSr to right dorsolateral prefrontal cortex.
9966361|NCT01259362|Sham Comparator|Transcranial Magnetic Stimlation|cocaine addicted will receive a 20 day sham TMSr to right dorsolateral prefrontal cortex
9966362|NCT01259414|Experimental|group1|Chemoembolization with solvent with specific gravity less than lipiodol
9966363|NCT01259414|Experimental|group2|Chemoembolization with Solvent with specific gravity equivalent to lipiodol
9966364|NCT01259453|Active Comparator|Standard vaccination schedule|Standard dosing at 0, 1, and 6 months
9966365|NCT01259453|Active Comparator|Accelerated Schedule|Accelerated dosing at 0, 1, and 2 months
10118315|NCT04419623|Experimental|Dose Finding - 200mg BID|200mg TL-895 orally BID taken continuously in 7-day cycles for 2 - 4 cycles with SAT for COVID-19 (14 - 28 days of treatment).
9966366|NCT01259479|Experimental|1|Dose escalation, continuous treatment without DLTs
9976499|NCT01352039|Active Comparator|Heparin Sodium - APP Pharmaceuticals|
9976500|NCT01352052|No Intervention|waiting list assignment|6 months waiting list assignment followed by the 2-week interdisciplinary rehabilitation programme
9976501|NCT01352052|Active Comparator|Intervention: interdisciplinary rehabilitation programme|A two-weeks non-residential, group-based, psycho-educative treatment course conducted by an interdisciplinary team.
9976502|NCT01352065|Experimental|BOSENTAN|
9976503|NCT01352065|Experimental|AMBRISENTAN|
9976504|NCT01352065|Placebo Comparator|PLACEBO|
9976505|NCT01352091|Experimental|Switch to Zoladex + AI for 3-2 years|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
9976506|NCT01352091|Experimental|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
9976507|NCT01352104|Experimental|waiting-intervention-course|
9976508|NCT01352130|Active Comparator|Ondansetron|Patients given Ondansetron
9976509|NCT01352130|Active Comparator|Granisetron|Patients given Granisetron
9976510|NCT01352208|Experimental|ASP9521|
9976511|NCT01352234|Experimental|Group A|Acetylsalicylic Acid 160mg administered at bedtime
9976512|NCT01352234|Active Comparator|Group B|Acetylsalicylic Acid 80mg administered at bedtime
9976513|NCT01352247|Experimental|Unicompartmental Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure."
10118316|NCT04419883||Anesthesia Providers|Anesthesia providers from 15 different health care facilities in the United States.
10118317|NCT04419857|Experimental|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
10118318|NCT04419857|No Intervention|Standard calorie formula|Infant randomly assigned to standard-calorie formula for 14 days
10118319|NCT04419844|Active Comparator|TAR with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect Botox injection .
10118320|NCT04419844|Active Comparator|TAR without Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect without Botox injection .
10118321|NCT04419636|Experimental|Part A Single doses|Lu AG06466 in fast and fed state
10118322|NCT04419636|Experimental|Part B Repeated doses|Lu AG06466 after light meal
10118323|NCT04419493|Experimental|Part B: Test treatment (T)|
10118324|NCT04419493|Active Comparator|Part B: Reference treatment (R)|
10118325|NCT04419493|Experimental|Part A: Test|Open-label
10118326|NCT04419584|Experimental|Modified Qing-Ying Decoction|Herbal granules, twice per day for 12 weeks
10118327|NCT04419584|Placebo Comparator|Identical looking placebo|Placebo granules, twice per day for 12 weeks
10118328|NCT04419545||interstitial pneumonia cases|Chest x-ray diagnosis
10118329|NCT04419545||Negative controls|Chest x-ray Negative for pneumonia
10118330|NCT04419701|Experimental|periarticular infiltration group|will receive intraoperative periarticular infitration consisting of 89.5 mL of normal saline, 20 mL of 5% bupivacaine and 0.5 mL of adrenaline (4.5 ugm/ml) with a concentration 1:220000 (total volume: 110 mL)
10118331|NCT04419701|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% with adrenaline 2.5 µg/ml with a concentration 1:400000 in the immediate postoperative period.
10118332|NCT04419740|Experimental|Mindfulness based psychological intervention|"Patients allocated to the intervention group will receive an email with a link to a video and a pdf document. The video and the pdf document will introduce them to the principles and the practice of mindfulness. They will also receive an access code to an e-tool valid for 1 month. On this e-tool the patient will have access to short guided meditations both general and specific to infertility. They will be instructed to follow the découverte (discovery) program of 8 meditations of 10 minutes and then the program désir de parentalité (wish to become a parent) of 13 minutes 15 meditations of 13 minutes each. Patients will be given access to all other meditations programs of PetitBambou and instructed to meditate with the program for at least 10-15 minutes on a daily basis."
10118333|NCT04419740|No Intervention|Standard care|The control group will have no additional intervention and will receive standard care in the institution. Women in all 3 study sites have access to counselling/psychological support with a trained professional before treatment initiation. During that consultation coping and stress reduction strategies are discussed.
10118334|NCT04419571||Suspected or Confirmed COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) with clinically or radiologically suspected COVID-19, or with viral PCR confirmation; diagnosis made 7-days before and 30-days after date of surgery in accordance with the COVIDsurg study criteria (3).
10118335|NCT04419571||Negative or non-suspected COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) without clinically or radiologically suspected COVID-19, or without viral PCR (Polymerase Chain Reaction) confirmation.
10118336|NCT04419805|Experimental|Single Palatal TAD|Single Palatal TAD for orthodontic molar intrusion
10118337|NCT04419805|Experimental|Two buccal TADs|Two buccal TADs for orthodontic molar intrusion
10118338|NCT04419415|Experimental|Skipping breakfast and maintain habitual physical activity|Subject will skip breakfast and maintain habitual physical activity.
10118339|NCT04419415|Experimental|High protein breakfast and maintain habitual physical activity|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and maintain habitual physical activity.
10118340|NCT04419415|Experimental|Skipping breakfast and exercising three times per week|Subject will skip breakfast and participate in organized exercise-training three times per week (and maintain habitual physical activity)
10118341|NCT04419415|Experimental|High protein breakfast and exercising three times per week|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
10118342|NCT04419441||treated patients|patients with relapsed/refractory Hodgkin lymphoma who received a treatment with the combination of radiotherapy and an immune checkpoint inhibitor
10118343|NCT04419116|Experimental|tibial preservation bone cut|tibial preservation bone cut following mobile bearing UKA
10118344|NCT04419116|Experimental|tibial conventional bone cut|tibial conventional bone cut following mobilebearing UKA
10118345|NCT04419090|Experimental|Monogenic positive FH, direct contact|
10118346|NCT04419090|No Intervention|Monogenic positive FH, usual care|
10118347|NCT04419090|Experimental|Monogenic negative FH, direct contact|
10118348|NCT04419090|No Intervention|Monogenic negative FH, usual care|
10118349|NCT04419181|Experimental|Pathologic complete response (pCR)|Participants will receive four cycles of TCHP [docetaxel (Taxotere®), carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who achieve pathologic complete response will receive infusions of trastuzumab every 3 weeks for a total of 12 cycles/infusions.
10118350|NCT04419181|Experimental|Residual Disease|Participants will receive four cycles of TCHP [docetaxel (Taxotere®, carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who have residual disease may be offered two more cycles of TCHP in the adjuvant settings (optional) per treating oncologist's discretion and then will receive infusion of Trastuzumab Emtansine (TDM1) plus pertuzumab every three weeks for a total of 12 cycles/infusions.
10118351|NCT04419259|Experimental|Erenumab|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
10118352|NCT04419077|Other|Virtual reality exposure|Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)
10118353|NCT04419142|Experimental|Total infrapatellar fat pad excision group|Infrapatellar fat pad was totally excised during total knee arthroplasty in patients randomized to this group.
10118354|NCT04419142|Experimental|Partial infrapatellar fat pad excision group|Infrapatellar fat pad was partially excised during total knee arthroplasty in patients randomized to this group.
10118355|NCT04419285|Experimental|Retinitis Pigmentosa patients|50 patients with very severe Retinitis Pigmentosa
10118356|NCT04419389|Experimental|Safety Lead-In Cohort 1|APR-246 + Acalabrutinib in Subjects with R/R CLL.
10118357|NCT04419389|Experimental|Safety Lead-In Cohort 2|APR-246 + Venetoclax + Rituximab in Subjects with R/R CLL.
10118358|NCT04419389|Experimental|Expansion Cohorts|APR-246 + (Acalabrutinib, OR, (Ven+R)) in Subjects with R/R TP53-mutant CLL, and/or MCL, and/or RT
10118359|NCT04419389|Experimental|Safety Lead-In Cohort 3|APR-246 + Venetoclax + Rituximab in Subjects with RT
10118360|NCT04419233||All Participants|Participants with 5q SMA and who were prescribed with nusinersen sodium injection in China according to the local marketing authorization.
10118361|NCT04419129|Active Comparator|Mobile bearing unicompartmental knee arthroplasty|50 mobile bearing UKA
10118362|NCT04419129|Active Comparator|posterior stabilized fixed bearing total knee arthroplasty|50 posterior stabilized fixed bearing cemented total knee arthroplasty
10118363|NCT04419298||Acute CO poisoning with myocardial injury|"A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin >5% (>10% in smokers).~Myocardial injury was defined as elevated high-sensitivity TnI level above the upper limit (> 0.046 ng/mL) when measured in the emergency department (ED) or repeatedly within 24 hours after ED arrival."
10118364|NCT04419324|Other|esophago-gastroscopy endoscopy with narrow band imaging|a transoral flexible endoscope with magnifying narrow band imaging in nasopharyngeal examination
10118365|NCT04419220||Observational|Doppler Ultrasound will be performed in all subjects.
10118366|NCT04419246|Active Comparator|Group I|interscalene block + General anesthesia
10118367|NCT04419246|Active Comparator|Group T|Tranexamic acid +General anesthesia
10118368|NCT04419246|Sham Comparator|Group S|General anesthesia
10118369|NCT04419350|Experimental|treatment|microneedling.
10118370|NCT04419350|No Intervention|No treatment|No treatment will be done to these hypopigmented lesions
10118371|NCT04419272|Experimental|Methylphenidate|Subjects who will receive methylphenidate in the double-blinded period; when assigned to the active drug, the dosage of MPH will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 3 weeks.
10118372|NCT04419272|Placebo Comparator|Placebo|Subjects who will receive placebo in the double-blinded period; when assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 4 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
10118373|NCT04419363|Experimental|The whole cohort|Children affected with X-linked hypophosphatemia of average age of 9.8 years were switch from conventional therapy to burosumab
10118374|NCT04419038|Active Comparator|conjunctival autografting with MMC|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
10118375|NCT04419038|Active Comparator|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
10118376|NCT04419376||Patients with pARDS|Within 7 days of known clinical insult Respiratory failure not fully explained by cardiac failure or fluid overload chest imaging findings of new infiltrate(s) consistent with acute pulmonary parenchymal disease patients with an oxygenation index (OI) ([FIO2 × mean airway pressure × 100]/PaO2) above 4
10118377|NCT04419376||Patients with non-pARDS|non-pARDS patients who received mechanical ventilation support due to respiratory failure.
10118378|NCT04418999|Experimental|Dexamethasone insert|Per participant, one eye will be randomized to receive the intracanalicular dexamethasone insert at the baseline visit (study eye). DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus at the day 1 visit by pulling the lower lid taught and using a forceps to insert the medication into the lower canaliculus through the lower punctum.
10118379|NCT04418999|Active Comparator|Loteprednol etabonate ophthalmic gel 0.38%|Per participant, one eye will be randomized to receive the standard of care topical lotemax etabonate ophthalmic gel 0.38% (control eye). Patients will be prescribed a loteprednol etabonate ophthalmic gel 0.38% and will instill one drop into the eye following a 4x/day,3x/day,2x/day,1/xday weekly taper
10118380|NCT04419012||Patients with AF treated with VKA|
10118381|NCT04419012||Patients with AF treated with NOAC|
10118382|NCT04419025|Active Comparator|NAC|Patients receiving N-acetylcysteine (NAC)
10118383|NCT04419025|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
10118384|NCT04418921|Experimental|Experimental Group|"Intervention on self-regulation will be carried out through a non-immersive virtual reality platform, SR-Mrehab: Un colegio emocionante in which students must conduct a series of activities designed specifically for this purpose. These activities will be performed by the children using mainly their hands to manage the virtual objects showed in the screen. To do this, our system make use of a Kinect motion sensor connected to the computer to control the body movements of the children. Moreover, our system records some relevant data of the execution of these activities for further analysis of the children's performance.The exercises will be divided into two blocks, emotional regulation (ER) and cognitive regulation (CR), in a total of 10 sessions, once a week, performing an exercise of each block per session. Each session will consists of 60 minutes. ."
10118385|NCT04418921|Active Comparator|Control group|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom (5, 49). Each session will last 50 minutes, just like in the experimental group. The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation. The activities are similar for the experimental group, but the virtual reality system will not be used. It will be held in parallel in another room of the school, on the same day and time, carried out by occupational therapists and students from the students in the last year of occupational therapy degree.
10118386|NCT04418778||BEAR intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma
10118387|NCT04418778||BEAR LifeMoves intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma who are currently living in transitional housing at LifeMoves
10118388|NCT04418778||Control Condition|Treatment as usual group, women participating in individual or group therapy but not taking the BEAR group
10118389|NCT04418986|Sham Comparator|Control (CCI Group)|The Participants will undergo phacoemulsification with on-axis incision
10118390|NCT04418986|Active Comparator|Study (OCCI Group)|The Participants will undergo phacoemulsification with opposite clear corneal incisions
10118391|NCT04418908|Active Comparator|GnRHant + E2|Participants in this arm received GnRHant and a transdermal estradiol patch (0.075 mg/day) for a period of 1 week.
10118392|NCT04418908|Placebo Comparator|GnRHant + PL|Participants in this arm received GnRHant and a placebo patch for a period of 1 week.
10182792|NCT03770806|Experimental|Femoral Nerve Block|Standard Ultrasound-guided femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
10182793|NCT03770806|Experimental|Adductor Canal Nerve Block|Standard Ultrasound-guided adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
10182794|NCT03770806|Experimental|No Block|For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
10182795|NCT03770754|Experimental|Control group|"Control Group (n= 15): the root canals were prepared manually with K-files (Dentsply-Maillefer, Ballaigues, Switzerland) and step back technique up to size #35."
10182796|NCT03770754|Experimental|Group 1|Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
10182797|NCT03770754|Experimental|Group 2|Group 2 (n= 15): root canals were instrumented with ProTaper Next (Dentsply Maillefer, Ballaigues, Switzerland) using X1, X2 to X3. 0.5% NaOCl was used for irrigation.
10182798|NCT03771027|Experimental|Low FODMAP diet group|four weeks of the low FODMAP diet based on Monash University low FODMAP diet App.
10182799|NCT03771027|Active Comparator|Control group|four weeks of the diet based on NICE guidelines and contained products with different FODMAP content
10182800|NCT03771053|Experimental|Ezetimibe with simvastatin group|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
10182801|NCT03771053|Active Comparator|Simvastatin group|simvastatin 40mg everyday for 12 months after PCI
10182802|NCT03770793|Experimental|Lung-sono guided|Before starting one-lung ventilation, alveolar recruitment is performed under the examination with ultrasound. Find the minimal airway pressure that actually starts to resolve the observed atelectasis. Repeat alveolar recruitment with the minimal pressure untill the atlelectasis is not visible.
10182803|NCT03770793|No Intervention|Conventional|Before starting one-lung ventilation, alveolar recruitment is performed with the pressure of 30mmHg for 10 seconds which is a conventional method.
10182804|NCT03770429|Experimental|AZD6738|Patients will receive AZD6738 orally on a 28-day cycle
10182805|NCT03770416|Experimental|Cohort A|Patients receive ibrutinib PO daily on days 1-28. Beginning course 1, patients also receive nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
10182806|NCT03770416|Experimental|Cohort B|Patients receive ibrutinib PO daily on days 1-28 and nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
10182807|NCT03770702|No Intervention|Control group|No intervention
10182808|NCT03770702|Active Comparator|Angiotensin receptor blockers|ARB ( Angiotensin receptor blockers) + Traditional therpy.
10182809|NCT03770702|Active Comparator|Statins|Statin + Traditional therapy.
10182810|NCT03770572|Experimental|Open-label, single-dose, dose-escalation study of AT-GTX-502|"Cohort 1: AT-GTX-502 Low-Dose~Cohort 2: AT-GTX-502 High-Dose"
10182811|NCT03770520|Experimental|QFR-guided|This group will be performed a CABG surgery based on CAG and QFR, whether graft the moderate stenosis vessels will be based on the result of QFR.
10182812|NCT03770520|Active Comparator|Angio-guided|This group will be performed a CABG surgery only based on CAG, the final surgery strategy will be decided after the discussion of heart team.
10182813|NCT03770403|Experimental|ARGX-113|
9528182|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
10182814|NCT03770559|Active Comparator|Open-RAMPS|Patients with pancreatic cancer treated by traditional open surgery
10182815|NCT03770559|Experimental|MI-RAMPS|Patients with pancreatic cancer treated by laparoscopic surgery
10182816|NCT03770585|Active Comparator|Group 1(Fluoroscopy guided group)|IN Fluoroscopy guided group, with x-ray beam, after cleaning and drapping and administration of local anesthesia, a22-g spinal needle is inserted in line till bony contact is felt under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.
10182817|NCT03770585|Active Comparator|Group2 (Ultrasound guided group)|In Ultrasound guided group, with Ultrasound guidance, , a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml(20mg) methylprednisolone acetate is administered intra-articular (until resistance was encountered) and injected around the posterior facet joint capsule.
10182818|NCT03770481|Experimental|Assess the NLCS' feasibility|"Hypothesis: No significant differences will be observed in recruitment and attrition between NLCS intervention and control groups.~Approach: Determine rates of enrollment and drop-outs between groups."
10118393|NCT04418570|Experimental|Cognitive remediation|"Computerized cognitive remediation through Neuropersonal Trainer software, 1.5 h per session twice a week for 12 weeks (36 h of total duration).~Participants will also attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled."
10118394|NCT04418570|Other|Treatment as usual|Participants will attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled.
10118395|NCT04418726|Experimental|Intensive Monitoring and Preemptive Intervention|In this group patients receive intensive monitoring and preemptive intervention. AVF surveillance refers to using non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa every month. Clinical assessment refers to monitoring for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V. Preemptive intervention is performed as long as problems are recognized, including health education and timely surgery.
10118396|NCT04418726|No Intervention|Traditional Monitoring and Intervention|In this group patient receive traditional AVF monitoring, includes clinical assessment for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V.
9694586|NCT04787601|Experimental|Cognitive training|Cognitive-based neuromuscular exercises will be applied to the experimental group for a total of 8 weeks.
9694587|NCT04787601|Other|Control|The control group will only do the classic training.
10118397|NCT04418687|Active Comparator|Physiotherapy only|Standard treatment post Total Knee Arthroplasty
10118398|NCT04418687|Experimental|Physiotherapy + Orthoglide intervention|Standard treatment post TKA, with additional Orthoglide device provided.
10118399|NCT04418648|Experimental|Toripalimab Consolidation|Patients in experimental group will receive toripalimab consolidation (240 mg) via iv infusion Q3W.
10118400|NCT04418648|No Intervention|Observation|Patients in this group will receive observation.
10118401|NCT04418752|Other|Psychological therapy|Narrative Exposure Therapy will be delivered to all participants in the study except carer participants recruited to complete informant measures.
10118402|NCT04418791|Experimental|MIF-regular|MIF-regular will start with modified intermittent fasting. After 12 weeks, this arm will return to regular diet with no fasting intervention.
10118403|NCT04418791|Experimental|Regular-MIF|Regular-MIF will start with regular diet with no fasting. After 12 weeks, this arm will start with modified intermittent fasting.
10118404|NCT04418635|Experimental|Tamsulosin and Prosta-OK® Neo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo 707mg 2 tablets twice daily for 85 days
10118405|NCT04418635|Placebo Comparator|Tamsulosin and Prosta-OK® Neo-matched placebo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days
10118406|NCT04418804|Experimental|Healthy|Participants without an active diagnosis of pleural disease.
10118407|NCT04418804|Experimental|Pneumothorax|Participants diagnosed with pneumothorax during the past 24 hours.
10118408|NCT04418804|Experimental|Pleural effusion|Participants diagnosed with current pleural effusion during the past 48 hours.
10118409|NCT04418700|Experimental|Breath Stacking technique|"The intervention group will receive routine physical therapy associated with the Breath Stacking technique in 2 daily sessions of up to 20 minutes.~The technique consists of an Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes."
10118410|NCT04418700|No Intervention|Routine physical therapy|The control group will receive only routine physical therapy. Routine physiotherapy consists of breathing exercises, using techniques bronchial hygiene and pulmonary reexpansion, and motor physiotherapy through exercise passive, active-assisted or active mobilization, stretching, training activities of daily living, positioning and removal of the bed and guidelines for post-discharge.
10118411|NCT04418583|Experimental|Three-dimensional imaging|Participants receive a three-dimensional image of their chest, just prior to and after application of the Crane technique.
10118412|NCT04418856|Experimental|Experimental light: Breast cancer surgery and chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
10118413|NCT04418856|Active Comparator|Comparison Light:Breast cancer surgery and chemotherapy|Exposed to comparison systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
10118414|NCT04418856|Experimental|Experimental light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
10118415|NCT04418856|Active Comparator|Comparison light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
10118416|NCT04418973|Experimental|A - load/apnea|Threshold inspiratory load then apnea
10118417|NCT04418973|Experimental|B- apnea/load|apnea than threshold inspiratory load
10118418|NCT04418843|Experimental|Standard Endoscopic Mucosal Resection|Standard Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
10118419|NCT04418843|Experimental|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
10118420|NCT04418557||Pregnant women without COVID-19 Infection|Women who are tested for COVID-19 at the time of admission for labor and delivery and test negative
9694588|NCT04787432|Experimental|Intervention|"Experimental: SAFRAPP Intervention~Participants in this group will receive a 6-week SAFRAPP intervention, comprising of laughter yoga, health education and case management. SAFRAPP will be conducted on social media (Facebook and WhatsApp)."
9694589|NCT04787432|No Intervention|Control Grup|The control group will not receive any intervention during the study. Participants in the control group will take the same program after the study is completed.
10118421|NCT04418557||Pregnant women with a history of COVID-19 infection|Women who are tested for COVID-19 at any point during their pregnancy, including at the time of admission for labor and delivery, and test positive
10118422|NCT04418557||Pregnant women vaccinated for COVID-19|Women who are vaccinated against COVID-19 at any point during their pregnancy
10118423|NCT04418674|Experimental|Ketamine|Patient will be given Ketamine 0.3mg/kg intravenously before sitting positioning for subarachnoid block.
10118424|NCT04418674|Active Comparator|Fentanyl|Patient will be given Fentanyl 1.5mcg/kg intravenously before sitting position for subarachnoid block.
10118425|NCT04418544||Control|Do not test positive for COVID
10118426|NCT04418544||COVID-19 Positive|Test positive for Covid using swab test.
10118427|NCT04418596||Elite Soccer Players|Adolescent male aged 12-16 years old elite athletes that are recruited from special sport school in Leuven-Belgium and play football at a high level.
10118428|NCT04418596||Recreational Soccer players (control)|Adolescent male aged 12-16 years old recruited from ordinary school in Flanders Belgium that play soccer or any other sport recreationally with no high intensity training
10118429|NCT04418869|Experimental|Exercise|All subject will perform three different exercise bouts and one control session.
10118430|NCT04418531|Experimental|Experimental antibodies (immunoglobulins) infusion|Anti-coronavirus obtained with double-filtration plasmapheresis (DFPP) from convalescent patients
10118431|NCT04418713|Experimental|exercise group with active video-games|exergaming exercise: A combination of traditional exercise and exercise through active video games performed 3 days a week for one hour during 7 months. As well, it will be including some session about nutritional advice.
10118432|NCT04418713|No Intervention|control group|no physical intevention will be provided, but it will be included some sessions on nutritional advice.
10118433|NCT04418505|No Intervention|Standard of Care|This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.
10118434|NCT04418505|Experimental|Standard of Care + Vielight RX Plus Treatment|The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.
10118435|NCT04418492|Experimental|SAFE intervention|The single group received the SAFE intervention for 10 weeks.
10118436|NCT04418310|Active Comparator|Lay open and curettage|Lay open and curettage in Pilonidal sinus
10118437|NCT04418310|Active Comparator|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method in the treatment of sacrococcygeal pilonidal sinus disease
10118438|NCT04418934|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext One device.
10118439|NCT04418934|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
10118440|NCT04418323|Active Comparator|Video-assisted anal fistula treatment (VAAFT|Video-assisted anal fistula treatment (VAAFT) in the Management of anal fistula
10118441|NCT04418323|Active Comparator|Fistula-tract Laser Closure (filac)|Fistula-tract Laser Closure (filac)in the Management of anal fistula
10118442|NCT04418323|Active Comparator|Conventional seton|Conventional seton in the Management of anal fistula
10118443|NCT04418440|No Intervention|Control|Routine NHS care following traumatic brain injury
10118444|NCT04418440|Experimental|Treatment|Routine NHS care following traumatic brain injury plus daily dose of test compound (oral nutritional supplement)
10118445|NCT04418388|Experimental|A|
10118446|NCT04418388|Experimental|B|
10118447|NCT04418388|Experimental|C|
10118448|NCT04418154|Experimental|EC-ABX/PD-1|Patients who are treated with epirubicin hydrochloride andcyclophosphamide followed by nanoparticlealbumin-bound paclitaxel and Toripalimab
10118449|NCT04418336|Active Comparator|Endoscopic Pilonidal sinus treatment (EPSIT)|Endoscopic Pilonidal sinus treatment (EPSIT)
10118450|NCT04418336|Active Comparator|Sinus Laser Closure (SiLaC)|Sinus Laser Closure (SiLaC)
10118451|NCT04418336|Active Comparator|lay open technique|lay open technique
10118452|NCT04418245||Patients positive for SARS-CoV-2|
10118453|NCT04418180|Active Comparator|GROUP1|group receiving single dose fenofibrate
10118454|NCT04418180|Active Comparator|GROUP2|group receiving double dose fenofibrate
10118455|NCT04418180|Placebo Comparator|GROUP3|photo therapy only
10118456|NCT04418219|Experimental|Treatment (SV-BR-1GM, pembrolizumab)|Patients receive cyclophosphamide IV over 1-2 hours on day 1, SV-BR-1-GM ID on day 3, pembrolizumab IV over 30 minutes on day 5, and interferon-alpha-2b ID on days 5 and 7. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10118457|NCT04418414|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|G-CSF/Plerixafor mobilization and apheresis will be used for collection of hematopoietic stem cells and subjects will receive transplantation of autologous CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector encoding the human factor VIII gene.
10118458|NCT04418284||Veterinary Medical students|Veterinary Medical students who are studying anatomy during COVID-19 pandemic lockdown
10118459|NCT04418037|Experimental|Single arm using the Digital Health Feedback System|This protocol is designed to evaluate a novel technology that employs an ingestible sensor to detect medication ingestion for use by persons initiating or restarting antiretroviral (ARV) treatment for HIV infection during a hospital admission.
10118460|NCT04418128|No Intervention|Conventional therapy|The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
10182819|NCT03770481|Experimental|Assess the NLCS' acceptability|"Hypothesis: More surrogates agree that the NLCS is suitable, appropriate, effective and willing to adhere versus treatment as usual (TAU) communication.~Approach: Assess outcome using the validated instrument, Client Satisfaction Questionnaire (CSQ-8)."
10118461|NCT04418128|Experimental|Conventional therapy + Nafamostat mesylate|"The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).~Nafamostat mesylate injection day), taking into account the severity and underlying disease of the clinical trial patient.~Method of administration: Nafamostat injection is mixed with 1,000 ml of 5% DW infusion, followed by continuous infusion over 24 hours.~Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient."
10118462|NCT04417959|Other|Phaco-DSAEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's stripping automated endothelial keratoplasty.
10118463|NCT04417959|Other|Phaco-DMEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's membrane endothelial keratoplasty.
10118464|NCT04417920|Active Comparator|group I (Express implant)|conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva
10118465|NCT04417920|Active Comparator|group II (trabeculectomy)|"Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.~conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of sclerectomy and peripheral iridectomy and closed scleral flab and conjunctiva by nylon 10/0 sutures"
10118466|NCT04417972|Experimental|SHR7280 dose 1|oral administration for 21days,Phase I
10118467|NCT04417972|Experimental|SHR7280 dose 2|oral administration for 21days,Phase I
10118468|NCT04417972|Experimental|SHR7280 dose 3|oral administration for 21days,Phase I
10118469|NCT04417972|Experimental|SHR7280 dose 4|oral administration for 21days,Phase I
10118470|NCT04417972|Active Comparator|SHR7280 low dose|oral administration for 84days,Phase II
10118471|NCT04417972|Active Comparator|SHR7280 high dose|oral administration for 84days, Phase II
10118472|NCT04417972|Placebo Comparator|Placebo|oral administration for 84days, Phase II
10118473|NCT04417998|Active Comparator|Motion Correction|Aim 1 involves the prospective data collection of subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system (hereafter referred to as the V600-R1) in the PET/CT Molecular Imaging Research Center on Charlton 6 of Mayo Clinic Rochester. The purpose of this arm is to evaluate the effectiveness of motion correction software.
10118474|NCT04417998|Active Comparator|Parametric Imaging|Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this arm is to evaluate the data acquisition and image processing workflow.
10118475|NCT04418102|Experimental|Palmitic acid rich interesterified fat|Snacks (muffins) and spread containing palmitic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
10118476|NCT04418102|Active Comparator|Stearic acid rich interesterified fat|Snacks (muffins) and spread containing stearic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
10118477|NCT04418011|Active Comparator|Active 10 Hz rTMS|Active treatment will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered at 10 Hz according to conventional FDA-approved parameters (4 s on and 26 s off; 3000 pulses per session; total duration 37.5 mins) .
10118478|NCT04418011|Active Comparator|Active iTBS|Active iTBS will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered in triplet 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds.
10118479|NCT04418011|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters as either 10 Hz rTMS or iTBS.~For both active and sham stimulation, TMS coil positioning for each individual will be optimized by combining participant fMRI data, meta-analytic functional analysis, electric field modelling, and real-time neuronavigation."
10118480|NCT04418024|Experimental|AG10 800 mg|TTR stabilizer administered orally twice daily (BID)
10118481|NCT04418024|Placebo Comparator|Placebo|Placebo administered orally twice daily (BID)
10118482|NCT04417751|Experimental|Intervention Group|Intervention group will receive 47 sessions of individual CS and participate in 3 evaluation sessions. The CS program will last 1 year and each individual CS session will last approximately 45 minutes.
10118483|NCT04417751|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
10118484|NCT04417946|Experimental|PrEP Messages|The peer leaders and the study staff will post PrEP related health messages
10118485|NCT04417946|Active Comparator|Health messages|The peer leaders and study staff will post general health messages that are not related to sexual health.
10118486|NCT04417699|Experimental|TAS102 plus Oxaliplatin|Oxaliplatin 85mg/m2 IV over 2 hours and TAS-102 (35 mg/m2/dose) orally BID
10118487|NCT04417738|Active Comparator|Active|Patients will receive the active treatment.
10118488|NCT04417738|Sham Comparator|Sham|Patients will receive the sham treatment (the identical LED covered by aluminum foil).
10118489|NCT04417686|Experimental|patient|
10118490|NCT04417881||patients with acurate heart failure|
10118491|NCT04417829||Only one arm (intervention=TAVI)|There is not control group/arm for comparison.
10118492|NCT04417933|Experimental|Tumor Electric Fields Treatment System|Patients have a histologically confirmed diagnosis of supratentorial glioblastoma that is recurrent. All patients will receive Tumor Electric Fields Treatment System.
10118493|NCT04417855||LDH|Group of symptomatic individuals with LDH confirmed in MRI.
10118494|NCT04417855||Control|Group of asymptomatic individuals with no LDH.
10118495|NCT04418076|Experimental|No feedback|For participants in the control group (Group A), no feedback from the TowerView Health® smart pill box or clinical nurse will be given.
10118496|NCT04418076|Experimental|Automated feedback|For participants in Group B (automated feedback), automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages.
10118497|NCT04418076|Experimental|Automated feedback + Clinician feedback|For participants in Group C, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, clinical nurse will also send personalized feedback and suggestions to the participants in this group.
10118498|NCT04418076|Experimental|Automated feedback + Social Network feedback|For participants in Group D, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, a weekly text reminder will be sent to each participant from a social network designee chosen by the participant.
10118499|NCT04417985|Experimental|18F-FDG PET/CT with MRI and blood sampling|"The enrolled subjects received 18F-FDG PET/CT and MRI before, during, and after the primary definitive treatment.~The blood sample was collected on the same day of PET/CT scan."
10118500|NCT04417816|Experimental|Exercise training + adipose tissue cavitation|
10118501|NCT04417816|Sham Comparator|Exercise training + sham procedure|
10118502|NCT04418089|Experimental|Simvastatin|The group received standard treatment with the oral administration of Simvastatin
10118503|NCT04418089|Experimental|Placebo|The group received standard treatment with the oral administration of Placebo
10118504|NCT04417790||Study population|Children under 12 years of age, Undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease, Aristotle score ≤9, Giving prior written informed consent.
10118505|NCT04417647|Experimental|Group 1|Proximal wound SoC treatment - Distal wound VZ application
10118506|NCT04417647|Experimental|Group 2|Distal wound SoC treatment - Proximal wound VZ application
10118507|NCT04417764|Experimental|TACE combined PD-1 knockout T cell treatment|
10118508|NCT04417582||life syte modification only|obese patients followed with life style modification
10118509|NCT04417582||medical teatment with antiobesity drugs|patients prescribed antiobesity drugs
10118510|NCT04417582||bariatric surgery|patients undergone bariatric surgery
10118511|NCT04417452||Mothers / children after diabetes in pregnancy|The study collective is composed of mother-child pairs after gestational diabetes, which were supervised in the Competence Center for Diabetes and Pregnancy at the University Hospital of Jena. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
10118512|NCT04417452||Controls|The control collective is composed of mother-child pairs who were cared for at the same time as the study collective at the University Hospital Jena. This collective is status post singleton pregnancy and term birth. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
10118513|NCT04417439||flame burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
10118514|NCT04417439||scald burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
10118515|NCT04417439||electrical burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
10118516|NCT04417335|Experimental|Treatment|BCG vaccine (Danish strain 1331, SSI, Denmark)
10118517|NCT04417335|Placebo Comparator|Placebo|0.9% NaCl
10118518|NCT04417556|Experimental|Sleep Measurement|Sleep Measurement arm, sleep are simultaneously measured using polosomgraphy, actigraphy and Thai-version Richards Campbell Sleep Questionnaire.
10118519|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2019|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2019
10118520|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2020|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2020
10118521|NCT04417322||Control|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
10118522|NCT04417322||Periodontitis|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
10118523|NCT04417192|Experimental|Olaparib or Olaparib Plus Pembrolizumab|Cohort 1 : Olaparib will be administered for 6 weeks before surgery. Cohort 2 : Olaparib and Pembrolizumab will be administered simultaneously for 2 cycles(6 weeks) before surgery.
10118524|NCT04417491|Experimental|Dry Needling|The intervention group will receive real dry needling (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
10118525|NCT04417491|Sham Comparator|Sham Needling|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
10118526|NCT04417400|Experimental|Intervention|Patients who received MUR at visit 1
10118527|NCT04417400|No Intervention|Control|Patients received standard care and MUR after visit 2 (upon completion of the study)
10118528|NCT04417114|Experimental|Single-Arm Open label|This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.
10118529|NCT04417504|Experimental|MobFood breakfast kit|
10118530|NCT04417504|Experimental|Control isocaloric breakfast|
9694590|NCT04787458|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
10118531|NCT04417205|Active Comparator|Carbohydrate rich breakfast|Participants will be provided with 28-days worth of pre-weighed carbohydrate rich breakfast materials to consume before 1000h daily.
10118532|NCT04417205|Experimental|Whey protein enriched breakfast|Participants will be provided with 28-days worth of pre-weighed whey protein enriched rich breakfast materials to consume before 1000h daily.
10118533|NCT04417205|No Intervention|Extended morning fast|Participants will be asked to remain fasted (i.e. to not consume breakfast) until 1200h daily for 28-days.
10118534|NCT04417517|Experimental|evorpacept (ALX148) + azacitidine|"Phase 1: Participants will receive escalating doses of evorpacept (ALX148) in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle~Phase 2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle"
10118535|NCT04417517|Active Comparator|azacitidine|Phase 2 only: Participants will receive azacitidine 75 mg/m2 IV or subcutaneous daily for 7 days of a 28-day cycle
10118536|NCT04417153||Mindfulness based intervention, Non Emergency (MBI-NE)|"4 week Mindfulness foundation course face to face (MF-NE) or~8 week Mindfulness Based stress reduction face to face (MBSR-NE)~The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions. Participants will be provided handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together"
10118537|NCT04417153||Mindfulness based intervention, DORSCON Orange (MBI-Orange))|"4 week Mindfulness foundation course face to face (MF-Orange) or~8 week Mindfulness Based stress reduction face to face (MBSR-Orange)~The content of these courses are the same as in the non emergency ones, and consist of four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together."
10118538|NCT04417153||Mindfulness based intervention, Partial lockdown (MBI-Covid)|"4 week Mindfulness foundation course online (MF-Covid) or~8 week Mindfulness Based stress reduction online, partial lockdown situation (MBSR-Covid)~The content of these courses are the same as in the non emergency ones. Participants will also be provided with the same handouts for the information covered during these talks and discussions.~During the partial lockdown, classes can only be held online, using platform as zoom with the teacher and up to around 17 participants together."
10118539|NCT04417478|Active Comparator|Normal weight|Patients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2.
10118540|NCT04417478|Experimental|class I Obesity|Patients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2.
10118541|NCT04417478|Experimental|class II Obesity|Patients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2.
10118542|NCT04417296||nonlaboring term singleton pregnancies|"All patients had an uncomplicated pregnancy and to define a pregnancy uncomplicated we adopted Chappell's definition: a normotensive pregnancy, delivered at >37 weeks, ending in a live-born baby who was not small for gestational age and did not have any other notable pregnancy complications"
10118543|NCT04417270|Other|Freestyle Libre 14-day CGM|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
10118544|NCT04417270|Other|Accuchek Inform II meter|ACCU-CHEK INFORM II system quantitatively measures glucose in fresh venous, arterial, neonatal heel stick and capillary whole blood from the finger and is used as an aid in monitoring the effectiveness of glucose control
10118545|NCT04417309|Experimental|Moderate Intensity Exercise|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
9694591|NCT04787458|No Intervention|Control group|subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
9694592|NCT04787588||Hospitalized patients|100 patients hospitalized with Covid-19, and 100 hospitalized controls without Covid-19
9694593|NCT04787588||Mild/Moderate asthma and health controls|20 asthmatic patients, 10 patients with asthma and allergic rhinitis, and 5 healthy controls.
9694594|NCT04787718|Experimental|Almond|Participants will consume 2.0 oz of raw, shelled, unsalted almonds.
9694595|NCT04787718|Active Comparator|Control group|an isocaloric (2.0 oz raw almonds) amount of unsalted pretzels daily.
9694596|NCT04787575|Experimental|Arm A|Oxygen-ozone therapy plus antibiotic therapy
9694597|NCT04787575|Other|Arm B|Antibiotic therapy
9694598|NCT04787341|Active Comparator|Panitumumab followed by Regorafenib|
9694599|NCT04787341|Experimental|Regorafenib followed by Panitumumab|
9694600|NCT04787497|Experimental|Experimental Group|
9694601|NCT04787497|No Intervention|Control Group|
9694602|NCT04787471|Active Comparator|30 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes
10118546|NCT04417309|Active Comparator|Control|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
10118547|NCT04417348|Active Comparator|Retinoic Acid|patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter
10118548|NCT04417348|Placebo Comparator|Sunscreen|patients with melasma treated with UV-Visible light filter alone
10118549|NCT04417075|Experimental|Impacto|This is the mobile app to be developed and evaluated in this project.
10118550|NCT04417075|Active Comparator|Dejar de Fumar Asistente|This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto.
10118551|NCT04417465|Experimental|ABBV-CLS-579 Monotherapy|Participants will receive escalating doses of ABBV-CLS-579
10118552|NCT04417465|Experimental|ABBV-CLS-579 And Programmed Cell Death-1 (PD-1) Inhibitor|Participants will receive escalating doses of ABBV-CLS-579 and PD-1 inhibitor.
10118553|NCT04417543|Active Comparator|Memantine hydrochloride group|included 50 patients who received memantine
10118554|NCT04417543|Placebo Comparator|Placebo group|included 50 patients who received placebo
10118555|NCT04417218|Experimental|Normal Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the normal lysine diet, participants will be asked to adhere to a specific diet for 1 week. Each study subject will receive 3 meals and 1-2 snacks per day during the study period.
10118556|NCT04417218|Experimental|High Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the high lysine diet, participants will be asked to consume the same foods as in the normal lysine diet, but with the addition of lysine supplements (5g/day).
10118557|NCT04416971||mature AVF|Patients initiate HD with mature AVF.
10118558|NCT04416971||immature AVF|Patients initiate HD with immature AVF.
10118559|NCT04417140|Experimental|Treatment Arm-dHACM|Patients enrolled in this arm will have a thin sheet of dHACM placed as an overlay over the length of the closed incisions. dHACM is Dehydrated Human Amniotic-Chorion Membrane. It is a FDA registered healing adjunct that has been applied in a broad range of diseases including wounds, plantar fasciitis and burns.
10118560|NCT04417140|No Intervention|Control Arm|Patients enrolled in this arm will have routine closure.
10118561|NCT04416945|Experimental|RACD|Reactive case detection led by VMWs in response to cases in study area HCCA, with follow up testing with HS-RDTs/RDTs in both villages and forest workers; referrals for qualitative G6PD testing for P. vivax cases and 14-day PQ for G6PD non-deficient
10118562|NCT04416945|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMWs; village-based RACD conducted by district staff in some areas
10118563|NCT04416828||Suspected ganglion cyst of the wrist or hand|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging AND cart-based ultrasound imaging before surgery.
10118564|NCT04416802|Experimental|PRP and Li-ESWT treatment|Participants diagnosed with erectile dysfunction will receive the combined treatment of platelet-rich plasma and low-intensity extracorporeal shockwave therapy.
10118565|NCT04417101|Experimental|JBT treatment|The participants will be instructed to take their Chinese herbal medicine formula (CHM), which named Juan Bi Tang, and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
10118566|NCT04417101|No Intervention|No treatment|Participants in the non-treatment period will receive conventional self-care management for myofascial pain syndrome.
10118567|NCT04416750|Experimental|Treatment|Open label; Imatinib tablets administered once daily; Dosage: in the range of 100mg-400mg; Group evaluated: adults with PAH
10118568|NCT04416932||Post-operative patients who had total shoulder arthroplasty|Patients who have had a total shoulder replacement will be scheduled for an ultrasound at Duke Radiology. An ultrasound will be completed on the shoulder that has been replaced, which takes no more than an hour. This ends all study involvement.
10118569|NCT04416893||Children under 15 years of age in a community|Children under 15 years of age in a community : kindergarten, school, college, holiday center, etc.
10118570|NCT04416724|Experimental|Phacoemulsification|Main study intervention will be Phacoemulsification
10118571|NCT04416724|Experimental|SLT|Main study intervention will be Selective Laser Trabeculoplasty
10182820|NCT03770481|Experimental|Assess the NLCS' preliminary effects|Hypothesis: NLCS improves communication and decreases surrogates' psychological distress (e.g., anxiety and depression) Approach: Compare pre- and post-intervention scores of the Quality of Communication (QOC) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Decisional Conflict Scale (DCS) between intervention and control groups.
10182821|NCT03770533|Other|MR-proADM guided|
10182822|NCT03770533|No Intervention|Standard Care|
10182823|NCT03770663|Experimental|European strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day"
10182824|NCT03770663|Experimental|American strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL."
10182825|NCT03770442|Experimental|Cycling with FES|"Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.~Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.~These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all)."
10182826|NCT03770442|Active Comparator|Control - routine physiotherapy|Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
10182827|NCT03770611|Active Comparator|Probiotic|Subjects receiving probiotic supplementation: 2x108 CFU probiotic bacteria + prebiotic placebo per day during 3 months
10182828|NCT03770611|Active Comparator|Prebiotic|Subjects receiving prebiotic supplementation: 20 g of prebiotic fiber + probiotic placebo per day during 3 months
10118572|NCT04416841|Experimental|Tai Chi Chuan Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour Tai Chi Chuan training per week for 24 weeks and standard diabetic care education.
10118573|NCT04416841|Active Comparator|Fitness Walking Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour fitness walking training per week for 24 weeks and standard diabetic care education
10118574|NCT04416841|Other|Control group|In addition to conventional medical treatment, participants will receive standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
10118575|NCT04416997||Rheumatoid arthritis patients|Blood and serum samples
10118576|NCT04416685|Other|Level 1|Those tumors located superior to the portal confluence were classified as Level I,
10118577|NCT04416685|Other|Level II|those tumors located on the confluence (involving the confluence) located on the portal confluence
10118578|NCT04416685|Other|Level III|those tumors located inferior to the portal confluence
10118579|NCT04416698||Youth smokers|Participants of Youth Quitline
10118580|NCT04416776||Eligible patients for AI test|Device: strabismus diagnostic system.
10118581|NCT04416854|Experimental|Chemotherapy plus surgery|Chemotherapy plus surgery: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to surgery group. Patients receive palliative resection of Primary tumor. Then the rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
10118582|NCT04416854|Active Comparator|Chemotherapy alone|Chemotherapy alone: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to chemotherapy group. The rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
10118583|NCT04416815|No Intervention|Usual care|The participants allocated to the control group received no intervention. However, they could, on their own initiative, approach the usual range of community or health services (e.g., home help services, rehabilitation, or medical care).
10118584|NCT04416815|Experimental|eHealth|The intervention will be delivered for 6 months on top of usual care.
10118585|NCT04416919|Other|Assembled Mask|Participant will be fitted with a full-face mask that covers the mouth and nose or a Whole face mask that covers the eyes, nose, and mouth depending on participant's preferences. The Fitted Mask will be attached to a bacterial/viral filter for fit testing. After completing the Fit test, the mask will be placed on the face for 15 minutes while the participant performs various activities to document the ability to tolerate the respirator. Participants oxygen and carbon dioxide level will be measured in the beginning and at the end of the 15 minutes. The individuals will be able to remove the Mask anytime if they experience significant discomfort or claustrophobia. At the end, the mask will be removed.
10118586|NCT04416880|Experimental|Press Tack Needle Acupuncture|Patients in this group were given seirin pyonex press tack needle treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
10118587|NCT04416880|Sham Comparator|Sham Control Press Tack Needle Acupuncture|Patients in this group were given sham treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
10118588|NCT04416568|Experimental|Solid Tumor (Stratum 1)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle~Patients with INI1-negative relapsed or refractory extracranial solid tumors"
10118589|NCT04416568|Experimental|CNS (Stratum 2)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle~Patients with INI1-negative relapsed or refractory CNS tumors"
10118590|NCT04416425||Enrolled Cohort|200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year.
10118591|NCT04416620|Active Comparator|The active group of Syria|"Participants in the active group received the 'pharmacist standard counseling' plus the 'pharmaceutical care service' designed by the research group. Both services were delivered by one female clinical pharmacist who has a Master's degree in pharmaceutical sciences, 5-year work experience in community pharmacies, and comprehensive knowledge of PCOS. The time it took to deliver the counseling and education to each participant in the active group was formally assessed. This time assessment excluded data collection and questionnaire filling time (which was planned to take around 15 min).~Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise."
10118592|NCT04416620|No Intervention|The control group of Syria|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
10118593|NCT04416620|Active Comparator|The active group of Jordan|Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise.
10118594|NCT04416620|No Intervention|The control group of Jordan|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
10118595|NCT04416334|Experimental|Colchicine plus symptomatic treatment (paracetamol).|"Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.~All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice."
10118596|NCT04416334|Active Comparator|Symptomatic treatment|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
10118597|NCT04416256||France|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118598|NCT04416256||Spain|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118599|NCT04416256||Portugal|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118600|NCT04416256||Croatia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118601|NCT04416256||Germany|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118602|NCT04416256||Italy|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118603|NCT04416256||Netherlands|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118604|NCT04416256||Austria|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118605|NCT04416256||US|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118606|NCT04416256||Canada|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118607|NCT04416256||Mexico|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118608|NCT04416256||Brazil|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118609|NCT04416256||Uruguay|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118610|NCT04416256||Argentina|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118611|NCT04416256||Chile|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118612|NCT04416256||Australia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118613|NCT04416256||Belgium|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118614|NCT04416256||Finland|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
10118615|NCT04416399|Experimental|Inhaled budesonide|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
10118616|NCT04416399|No Intervention|Standard of care|Standard of care
10118617|NCT04416529|Experimental|Intervention (tele-MBCT) group|"Tele-MBCT was an 8-week program delivered to participants online via a videoconferencing program called Zoom by a tele-MBCT instructor. Tele-MBCT was delivered in three, 8-week rounds. Each round consisted of 8 weekly, 2-hour group sessions with 4-6 participants on Wednesdays from 2:00 to 4:00 pm. Participants were trained in mindfulness concepts and techniques including mindful eating, body scan, sitting meditation, breathing awareness, mindful walking and mindful movements. Participants were given a mindfulness a book called The Mindful Way Workbook and a practice log. The book was a guide for their daily practice at home and the practice log was a simple log for self-recording daily practices (number of minutes of daily MBCT practice) and a note pad for recording the reasons/obstacles for not practicing."
10118618|NCT04416529|No Intervention|Control Group|Participants in the control group continued their usual caregiving activities.
10118619|NCT04416308|Other|Seroprevalence survey|NG Test + short self-questionnaire (except validation survey and detailed survey)
10118620|NCT04416308|Other|Validation test of the NG test survey|Blood test + NG test + detailed self-questionnaire
10118621|NCT04416308|Other|Detailed Survey|NG test + self-questionnaire complementary to the short questionnaire
10118622|NCT04416308|Other|Prevalence monitoring (2 population samples)|"Participants having presented a certain or probable COVID: acts of the validation test survey, + follow-up questionnaire,+ blood test + NG test, on D30 and D90~Others Participants : drawn by lot: acts of the seroprevalence survey, + follow-up questionnaire + NG test, on D90"
10118623|NCT04416347||Workstream 1|Adult patients admitted to SGHFT (St. Georges Hospital Foundation Trust) with or without laboratory confirmed SARS- CoV-2.
10118624|NCT04416347||Workstream 2|Adult patients admitted to to SGHFT (St. Georges Hospital Foundation Trust) ITU with respiratory failure.
10118625|NCT04416503|Experimental|Intervention group|Foot reflexology was performed for 12 week in the intervention group, whereas the control group continued their routine treatment and follow-up.
10118626|NCT04416503|No Intervention|Control group|Usual follow-up was done to the control group.
10118627|NCT04416542|No Intervention|Control|Subjects in this group will be implanted with the Inspire UAS system and will undergo a standard in-lab PSG titration study at approximately 3 months post-activation and a 2-night HST at approximately 6 months post-activation
10118628|NCT04416542|Active Comparator|Home Monitoring|Subjects who have undergone implant of the Inspire UAS System and are randomized to this group will undergo a 2-night HST at 3 months post-activation. Depending on the results of the 2-night HST, the subject will either (a) undergo a PSG titration at 5 months post-activation and a 2-night HST at 6 months post-activation OR (b) undergo only a 2-night HST at approximately 6 months post-activation
10118629|NCT04416321|Other|Device|All subjects who are entered into this trial will receive the Keos Lumbar Interbody Fusion Device.
10118630|NCT04416464||Pneumonia due to SARS-CoV-2 infection|Adult hospitalized patients with pneumonia due to proven or suspected SARS-Cov-2 infection.
10118631|NCT04416594||Factor XIII deficiency|Patients admitted to hospital with FXIII levels below 70% during their hospital stay
10118632|NCT04416607|Experimental|corifollitropin alpha|Ovarian stimulation protocol is performed with a single dose of 100 μg (<60 kg) or 150 μg (≥60 kg) of corifollitropin alpha (Elonva, Schering-Plough, Brazil), plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
10118633|NCT04416607|Active Comparator|menotropin|150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3, according to age, AMH level and AFC, plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
10118634|NCT04416191|Experimental|Limb immobilization|Participants will undergo a 2-week leg immobilization period
10118635|NCT04416243|Experimental|Recumbent Stepping, High-Intensity Interval Training|
10118636|NCT04416139|Active Comparator|Treated group|Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.
10118637|NCT04416139|No Intervention|Control Group|The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables.
10118638|NCT04416295|Active Comparator|Standard COPD care and a digital COPD support system|Device: LifePod The intervention group is testing LifePod on a digital communication platform between patient and healthcare provide
10118639|NCT04416295|Other|Control group Standard COPD Care|
10118640|NCT04416230|Experimental|Massage|Infants randomized to the massage intervention received a 30 minute massage daily for the 7 day study.
10118641|NCT04416230|Active Comparator|Quiet Time|Infants randomized to the Quiet Time intervention experienced a 30 minute time during which non-essential clinical caregiving tasks were restricted.
10118642|NCT04416074|Experimental|Group psychotherapy group|Students will be intervened by an online 5-week professional identity group psychotherapy.
10118643|NCT04416074|Other|Controlled message push group|Students will receive online messages of self-care knowledge forward by researchers.
10118644|NCT04416269|Experimental|Oral Anti-diabetes Drugs (OADs) alone|OADs will be continued at same outpatient dosage unless contraindicated
10118645|NCT04416269|Active Comparator|Basal bolus insulin|Basal insulin with glargine or detemir and rapid-acting insulin (lispro/aspart) will be used as per the hospital formulary. OADs and non-insulin injectable antidiabetic medication will be discontinued on admission.
10118646|NCT04416204|Experimental|Type 2 diabetes|
10118647|NCT04416204|Experimental|Participants without diabetes|
10118648|NCT04416165|Experimental|Experimental: 68Ga-DOTA-FAPI-04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
10118649|NCT04415814|Experimental|Group 1 (Unilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed unilaterally, which means on one side of the spinous processes. The system will be fixed with standard rod and blockers.
10118650|NCT04415814|Active Comparator|Group 2 (Bilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed bilaterally, which means on the both sides of the spinous processes. The system will be fixed with standard rods and blockers.
10118651|NCT04415827|Experimental|Athletes with community-acquired pneumonia|man and women, athletes, age 17-25, patients with community-acquired pneumonia
10118652|NCT04415827|Experimental|Untrained people with community-acquired pneumonia|man and women, untrained people, age 17-25, patients with community-acquired pneumonia
10118653|NCT04415827|Experimental|Athletes with bronchitis|man and women, athletes, age 17-25, patients with bronchitis
10118654|NCT04415827|Experimental|Untrained people with bronchitis|man and women, untrained people, age 17-25, patients with bronchitis
10118655|NCT04415827|Experimental|Athletes with chronic obstructive pulmonary disease|man and women, athletes, age 17-25, patients with with chronic obstructive pulmonary disease
10118656|NCT04415827|Experimental|Untrained people with chronic obstructive pulmonary disease|man and women, untrained people, age 17-25, patients with with chronic obstructive pulmonary disease
10118657|NCT04415827|Experimental|Athletes with acute respiratory infections|man and women, athletes, age 17-25, patients with acute respiratory infections
10118658|NCT04415827|Experimental|Untrained people with acute respiratory infections|man and women, untrained people, age 17-25, patients with acute respiratory infections
10118659|NCT04416061||Subjects underwent COVID-19 test|Subjects who underwent COVID-19 test in HKSH during the study period
10118660|NCT04415944|Experimental|Second Look Laparoscopy and HIPEC with Carboplatin|Laparoscopic assessment of disease status of the peritoneal cavity with lysis of adhesions as necessary noting either no gross residual disease or minimal residual disease prior to or after resection. This is performed prior to establishment of a peritoneal perfusion circuit and hyperthermic intraperitoneal chemotherapy.
10118661|NCT04415775|Experimental|Dual-task walking Intervention|
10118662|NCT04415775|Active Comparator|Conventional Gait Rehabilitation|
10118663|NCT04415775|No Intervention|Healthy Controls|
10118664|NCT04416126|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
10118665|NCT04416126|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
10118666|NCT04415957|Experimental|Elastic Tape Group (ETG)|The ET will be placed in the patient chest wall and abdomen for as long of 2 consecutive weeks.
10118667|NCT04415957|No Intervention|Control Group (CG)|The CG will be an education program in COPD and physical activity recommendations. Besides, after study ends they will be invited to place the ET.
10118668|NCT04415879|Active Comparator|No Mask|Individuals will perform a Modified Balke Treadmill test with no mask and their estimated VO2 peak will be calculated based off of peak workload.
10118669|NCT04415879|Experimental|N-95 Respirator|Individuals will perform a Modified Balke Treadmill test while wearing a N-95 Respirator and their estimated VO2 peak will be calculated based off of peak workload.
10118670|NCT04415879|Experimental|Cloth Mask|Individuals will perform a Modified Balke Treadmill test while wearing a cloth mask and their estimated VO2 peak will be calculated based off of peak workload.
10118671|NCT04415970|Experimental|Flotation Therapy|Participants will utilize flotation sensory deprivation tanks.
10118672|NCT04415970|Active Comparator|Sleep Pod|Participants will utilize sleep pods with partial sensory deprivation (no light and silence).
10118673|NCT04415892|Other|High-Low-Vehicle|Volunteers in group A will receive a high dose, low dose and vehicle solution of each compound on digit 2, 3 and 4, respectively.
10118674|NCT04415892|Other|Vehicle-High-Low|Volunteers in group B will receive a high dose, low dose and vehicle solution of each compound on digit 3, 4 and 2, respectively.
10118675|NCT04415892|Other|Low-Vehicle-High|Volunteers in group C will receive a high dose, low dose and vehicle solution of each compound on digit 4, 2 and 3, respectively.
10118676|NCT04415892|Other|Paclitaxel Patients|Group of patients after treatment with paclitaxel.
10118677|NCT04415892|Other|Paclitaxel Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Paclitaxel Patients.
10118678|NCT04415892|Other|Oxaliplatin Patients|Group of patients after treatment with oxaliplatin.
10118679|NCT04415892|Other|Oxaliplatin Controls|Group of healthy volunteers, matched for sex, age and BMI with the group of Oxaliplatin Patients.
10118680|NCT04415905|Experimental|group P|The participants in the group P are anesthetized with propofol.
10118681|NCT04415905|Active Comparator|group S|The participants in the group S are anesthetized with sevoflurane.
10118682|NCT04416009||mild pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the ward
10118683|NCT04416009||severe pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the intensive care unit
10118684|NCT04416035|Experimental|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle，carboplatin will be administered at an AUC 6 mg/mL/ min by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
10118685|NCT04416035|Active Comparator|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle and carboplatin will be administered at an AUC 6 mg/mL/min (the maximum dose capped at 900 mg) by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
10118686|NCT04415983|Experimental|Nitazoxanide group|Clarithromycin, Nitazoxanide and Proton pump inhibitor
10118687|NCT04415983|Active Comparator|Traditional group|Clarithromycin, Metronidazole and Proton pump inhibitor
10118688|NCT04415801|Experimental|Implant abutments|implant abutments
10118689|NCT04415918|Experimental|Intervention group|Recruited patient according inclusion/exclusion criteria
10118690|NCT04415918|No Intervention|Historical control|Cohort of historical patients matched to study population to serve as control
10118691|NCT04416360|Experimental|Interview by psychologists|Children and adolescent interview Parents interview Referring caregiver interview
10118692|NCT04415853|Experimental|Lerotinib Arm|350 mg,qd, orally about half an hour after a meal, continuous administration, every 21 days for a treatment cycle.
10118693|NCT04415853|Active Comparator|Active Comparator Arm|"Irinotecan: Intravenously administered at a dose of 180 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.~Tegafur: 40-60mg po bid(d1-d14),every 21 days as a cycle, continuous drug administration from 1 to 14 days of each cycle, and then stopped 7 days."
10118694|NCT04415749|Experimental|NasoShield One Dose in Position 1|NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
10118695|NCT04415749|Placebo Comparator|Placebo in Position 1|Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
10118696|NCT04415749|Experimental|NasoShield Two Doses in Position 2|NasoShield on Day 1 and Day 29 in position 2 (Group 2)
10118697|NCT04415749|Placebo Comparator|Placebo in Position 2|Saline placebo on Day 1 and Day 29 in position 2 (Group 2)
10118698|NCT04415749|Experimental|NasoShield Two Doses in Position 3|NasoShield on Day 1 and Day 29 in position 3 (Group 3)
10118699|NCT04415749|Placebo Comparator|Placebo in Position 3|Saline placebo on Day 1 and Day 29 in position 3 (Group 3)
10118700|NCT04415723|Experimental|intervention group|supportive care management programme
10118701|NCT04415723|No Intervention|control group|receive the usual care provided by the health care system of Cyprus
10118702|NCT04415788|Experimental|Test of Incremental Respiratory Endurance - IMT|Training will consist of six levels (A-F) with six inspirations at each level for up to 36 breaths per session. TIRE data will be stored in the tablet and automatically synced to account on cloud-based online platform for subsequent interrogation and data retrieval. Before every training session, subjects will be required to complete one maximal and sustained inspiratory effort from which the training is based on for that day.
10118703|NCT04415788|Experimental|Threshold - IMT|Subjects assigned to the Standard training regimen will receive a commonly used Threshold inspiratory muscle trainer. This device features a one-way spring-loaded valve at one end and a mouthpiece on the other through which subjects will be required to breathe in hard enough to overcome the resistance provided by the spring-loaded valve, allowing correct inspiration to happen. In other words, air flow is blocked until subjects generate sufficient inspiratory pressure to exceed the device pre-set pressure in cmH2O. The resistance will be set using the device's adjustable pressure setting which is fixed at 50% of the subject's MIP at the time of enrollment. The resistance will be readjusted as needed at week 4 to still reflect 50% of their inspiratory muscle strength at that time. Subjects will be coached to perform up to 36 breaths daily using the device. They will be also instructed to complete the training session within a 30-minute period.
10118704|NCT04415788|Sham Comparator|Sham IMT (Low resistence)|The Sham (Low Resistance) training regimen will use the same methods described above for the Standard IMT, except for the amount of resistance applied within the device. Subjects will receive a Threshold which has been set to its minimal resistance, which is 9 cmH2O. Again, subjects will be instructed to perform up to 36 breaths daily using the device within a 30-minute period.
10118705|NCT04416087|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
10118706|NCT04416113|Active Comparator|photobiomodulation group|"Laser watch Patients will be subjected to low-level laser (diode laser 980nm) for 30 minutes, the recommended dose based on the previous study is 20 J for 3 to 7 days.~The laser device:~Laser watched applied at the wrist on the radial artery.~Laser acupuncture"
10118707|NCT04416113|Active Comparator|photodynamic group|"Methylene blue injection USP 1% will be used as a photosensitizer in PDT.~0.1 to 0.2 mL of 1% solution per kilogram of body weight Methylene Blue (methylene blue injection) will be injected intravenously very slowly over a period of several minutes to~After one hour apply Light dose: 100 - 200 J/cm2 50-100 mW/cm2. (50 mW/cm2 increased the phototoxic response as well as the fractionated light application).~The session will be done twice per week~Laser watched applied at the wrist on the radial artery."
10118708|NCT04416113|Active Comparator|positive control|This group will include patients who are subjected to conventional treatment
10118709|NCT04415645|Experimental|VVZ-149 Injections|
10118710|NCT04415567||lenvatinib|high-risk patients with HBV-related HCC who took lenvatinib as adjuvant therapy after liver transplantation
10118711|NCT04415567||control|high-risk patients with HBV-related HCC who received routine treatment and follow-up after liver transplantation
10118712|NCT04415736||Delayed cerebral ischemia|Patients with subarachnoid hemorrhage that develop delayed cerebral ischemia
10118713|NCT04415736||Non delayed cerebral ischemia|Patients with subarachnoid hemorrhage that do not develop subarachnoid hemorrhage
10118714|NCT04415697||Responders|Those who present complete response, partial response, or stable disease, according to RECIST 1.1.
10118715|NCT04415697||Not responders|Those who present progression disease according to RECIST 1.1.
10118716|NCT04415463|Experimental|FC-SEMS|Placement of multisegmented fully covered self-expandable metal stent
10118717|NCT04415580|Experimental|Vestibular Rehabilitation Group|
10118718|NCT04415580|Active Comparator|Conventional rehabilitation Group|
10118719|NCT04415593|Experimental|high dose of peanut|20 patients
10118720|NCT04415593|Active Comparator|low dose of peanuts|20 patients
10118721|NCT04415554||exposure to aminoglicosides|preterm receiving aminoglycosides
10118722|NCT04415554||non exposure to aminoglycosides|preterm not receiving aminoglycosides
10118723|NCT04415346|Experimental|HU-014 Inj(Phase 1|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
10118724|NCT04415411|No Intervention|Control group|Routine nursing care
10118725|NCT04415411|Experimental|Intervention group|Nursing care based on the Theory of Human Caring
10118726|NCT04415671|Experimental|Part A- AD-214 SAD in Healthy Volunteers|
10118727|NCT04415671|Placebo Comparator|Part A-Placebo SAD in Healthy Volunteers|
10118728|NCT04415671|Experimental|Part B-AD-214 MAD in Healthy Volunteers|
10118729|NCT04415671|Placebo Comparator|Part B-Placebo MAD in Healthy Volunteers|
10118730|NCT04415320|Experimental|X-396(Ensartinib) Capsule|
10118731|NCT04415268|Experimental|Multitreatment|"Pharmacological treatment per standard of care (whole study length, starting on week 1).~Supervised exercise protocol (phase 1, 8 weeks starting on week 9). Unsupervised exercise protocol (phase 2, 8 weeks starting on week 17)."
10118732|NCT04415307|Experimental|Acupuncture|Acupuncture over acupoints.
10118733|NCT04415307|Experimental|Far-Infrared|Far-Infrared heat-patch attachment over acupoints.
10118734|NCT04415307|Experimental|Combination of Acupuncture and Far-Infrared|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
10118735|NCT04415307|Placebo Comparator|Placebo (no Acupuncture nor Far-Infrared)|Far-Infrared heat-patch attachment over acupoints without electric current passing.
10118736|NCT04415606|Experimental|QuikClot Control+|QuikClot Control+
10118737|NCT04415606|Placebo Comparator|Standard gauze|Standard gauze per standard of care
10182829|NCT03770611|Experimental|Symbiotic|Subjects receiving probiotic and prebiotic supplementation: 2x108 CFU probiotic bacteria + 20 g of prebiotic fiber per day during 3 months
10182830|NCT03770611|Placebo Comparator|Placebo|Subjects receiving placebo of probiotic and prebiotic per day during 3 months
10118738|NCT04415281|Experimental|Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
10118739|NCT04415281|Sham Comparator|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
10118740|NCT04415398|Experimental|Delivery of automated external defibrillators using drones|"Three drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating feasibility in:~Operational feasibility (Legislation, Weather conditions, conflict in airspace)~Participant feasibility (Failure to respond; Dispatcher, Drone-pilot, Air traffic controller)~Technological feasibility (Drone technology, software, winch-system , 4G network, radio communication"
10118741|NCT04415385|Experimental|Camrelizumab + Apatinib|Participants receive Camrelizumab 200mg intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
10118742|NCT04415476|Other|Sirolimus and Tacrolimus and prednisone|Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)
10118743|NCT04415476|Experimental|Standard of Care|"Arm1:) sirolimus and tacrolimus and prednisone group:~Tacrolimus, The patient will receive 0.1-0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 5-12 ng/ml.~Mycophenolate mofetil (NA )Stopped upon sirolimus initiation Sirolimus:1-5 mg/day PO if >40 kg / 1 mg/m²/day if <40 kg trough blood levels 5-12 ng/ml Prednisone:20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effects.~Arm 2) Standard Therapy Tacrolimus:0.1 to 0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 8-12 ng/ml Mycophenolate mofetil:750-1250 mg bid PO and adjust to tolerance (WBCs and GI side effects Sirolimus: NA Prednisone: Prednisone dose 20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effect"
10118744|NCT04415632|Experimental|LGI Diet|low glycemic index diet
10118745|NCT04415632|Other|HGI Diet|High glycemic index diet
10118746|NCT04415450|Experimental|Nutrition Education Group|The experimental group is the group who received the intervention which is the nutrition education and counseling. Phase I of the data collection from the experimental group which is the pregnant women (baseline assessment) using a questionnaire immediately before receiving nutrition counseling from their ANC providers first took place. Health professionals then started providing nutrition education to pregnant women preselected and assessed before the intervention. Immediate post education evaluation of the pregnant women was done by the same questionnaire used to assess in the pretest. Phase II or post intervention data collection of pregnant women was done after the client was appointed for 6 weeks after the counseling session.
10118747|NCT04415619|Experimental|Intervention group|10 patients will have immediate implant placement with buccal pad of fat free tissue
10118748|NCT04415242|Active Comparator|suspension group|Arm on the side operated at 90 ° abduction, 90 ° anti-drive, resting on an arm support.
10118749|NCT04415242|Experimental|supported group|Arm on the operated side at 0 ° abduction, 90 ° anti-pulsation, resting on an adjustable support arm support located opposite the patient's head.
10118750|NCT04415255|Experimental|EPABI & IABPI|extrapleural autologous blood injection (EPABI) along with intraparenchymal autologous blood patch injection (IABPI)
10118751|NCT04415255|Active Comparator|IABPI-alone|intraparenchymal autologous blood patch injection (IABPI)
10118752|NCT04415216||ISR PCI with thin-DES|
10118753|NCT04415216||ISR PCI with DEB|
10118754|NCT04415203|Experimental|TAES plus usual care|TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); Usual Care: usual medicine treatment for PVCs.
10118755|NCT04415203|Placebo Comparator|Sham-TAES plus usual care|"Sham-TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); the same acupoints as the treatment group without any current.~Usual Care: usual medicine treatment for PVCs."
10118756|NCT04415073|Active Comparator|Axatilimab (SNDX-6352)|Axatilimab on Days 1 and 15, IV + SOC
10118757|NCT04415073|Placebo Comparator|Placebo|Matching placebo on Days 1 and 15 + SOC
10118758|NCT04414865||single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
10118759|NCT04414878|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System
10118760|NCT04415125|Experimental|elite male ice hockey players|The subjects were 50 elite men's ice hockey players playing in the super league from Turkish clubs subject to Turkey Ice Hockey Federation. All ice hockey players had practicing training programs after warming up for 10 minutes for at least 3 days a week and 1 hour in a day during the season. They also played a match at least 1 day a week. The inclusion criteria were; being a member of Turkish Ice Hockey Federation and to be subject to any of the licensed athletes who played in the super league team, to be over 18, to be male. Exclusion criteria were; being under the age of 18, being a woman, having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.
10118761|NCT04414839|Active Comparator|Digital Intubation (Two-finger)|
10118762|NCT04414839|Active Comparator|Video Laryngoscopy|
10118763|NCT04414995|Experimental|Paracetamol+Ibuprofen|Patients in Group 1 will receive a combination of 1000 mg IV paracetamol and 800 mg IV ibuprofen at the end of operation following by 1000 mg IV paracetamol and 800 mg IV ibuprofen every 6 hours up to 72 hours.
10118764|NCT04414995|Experimental|Paracetamol+normal saline|Patients in Group 2 will receive 1000 mg IV paracetamol and 100 ml IV normal salines at the end of operation following by 1000 mg IV paracetamol and 100 ml IV normal salines every 6 hours up to 72 hours.
10118765|NCT04414995|Experimental|Ibuprofen+normal saline|Patients in Group 3 will receive 800 mg IV ibuprofen and 100 ml IV normal salines at the end of operation following by 800 mg IV ibuprofen and 100 ml IV normal salines every 6 hours up to 72 hours.
9966367|NCT01259505|Experimental|Safety|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9966368|NCT01259518|Experimental|Once monthly administration of TRIN2755|
10118766|NCT04414904||Case group|"Men 18-50 years of age~Already attending hospital for another reason~High risk of prior COVID-19 infection:~EITHER Prior positive COVID-19 PCR test result~OR history suggestive of COVID-19 illness"
10118767|NCT04414904||Control Group|"Men 18-50 years of age~Already attending hospital for another reason~Low risk of prior COVID-19 infection:~EITHER Negative positive COVID-19 PCR test result within last 4 weeks~OR no history suggestive of COVID-19 illness"
10118768|NCT04415190||cholangiocarcinoma with early palliative care|
10118769|NCT04415190||cholangiocarcinoma without early palliative care|
10118770|NCT04414852|Experimental|mild renal impairment|
10118771|NCT04414852|Experimental|moderate remal impairment|
10118772|NCT04414852|Active Comparator|normal renal impairment|
10118773|NCT04415008|Experimental|treatment arm|prospective, open-label, multicenter,single arm
9668895|NCT04696094||Moyamoya disease patients|"Moyamoya disease patients' inclusion Criteria:~1.written informed consent had been obtained; 2. more than 4 years old and less than 60 years old; 3. cerebral digital subtraction contrast angiography (DSA) revealed severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals'; 4. received surgical revascularization;~Exclusion Criteria:~1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases."
10118774|NCT04414982|Experimental|Intervention Values Affirmation|Compare the effects of the values-affirmation exercise with a control exercise in AI/AN patients with hypertension.
10118775|NCT04414982|Active Comparator|Control Values Affirmation|Compare the effects of the values-affirmation exercise in AI/AN patients with its effects in white patients.
10118776|NCT04414813|Experimental|hAESCs treatment|hAESCs of 50 million transplant to Parkinson's disease participants.
10182831|NCT03770624|Experimental|200 mg QD|Tablet QL-007 will be administered orally daily (200 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
10182832|NCT03770624|Experimental|400 mg QD|Tablet QL-007 will be administered orally daily (400 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
10182833|NCT03770624|Experimental|600 mg QD|Tablet QL-007 will be administered orally daily (600 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
10182834|NCT03770624|Experimental|100 mg BID|Tablet QL-007 will be administered orally daily (100 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
10182835|NCT03770624|Experimental|200 mg BID|Tablet QL-007 will be administered orally daily (200 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
10182836|NCT03770624|Active Comparator|TDF 300 mg QD|TDF will be administered orally daily (300 mg QD) over the 28 days not request fast .
10182837|NCT03770637|Experimental|Glucagon RTU (glucagon injection)|Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon)
10182838|NCT03770637|Placebo Comparator|Placebo|Non-active vehicle for Glucagon RTU; 60 μL injection
9668896|NCT04690478|Experimental|Remote blood pressure management group|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
10182839|NCT03770767|Experimental|Intervention with insulin Fiasp|Women randomized to insulin Fiasp
10182840|NCT03770767|Active Comparator|Control (insulin Novorapid)|Women randomized to insulin NovoRapid
10182841|NCT03770377|Experimental|Stroke without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
10182842|NCT03770377|Experimental|Stroke with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
10182843|NCT03770377|Experimental|SCA6 without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
10182844|NCT03770377|Experimental|SCA6 with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
10182845|NCT03770377|Active Comparator|Age-Matched Controls|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
10182846|NCT03770507|Experimental|Treadmill Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
10182847|NCT03770507|Experimental|Cyclo Ergometer Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
10182848|NCT03770338|No Intervention|Control|Recruitment for fusion surgery as usual
10182849|NCT03770338|Experimental|Teriparatide|Preoperative 1 month use of teriparatide, before lumbar fusion surgery
10182850|NCT03770221|Experimental|Financial Incentive|"Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.~Additionally, participants in this arm will receive $20 for every week they maintain contact with CATCH service providers, as required by their care plan. Contact can be by phone, text, email, or in person with CATCH service providers over 6 months of follow up, or until they are successfully transitioned to longer-term supports (for up to $80/month per participant)."
10118777|NCT04414969|Experimental|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1; PEG-ASP 2500U/m2 im d1; Chidamide, 30mg, PO, on d1，d5，d8，d12，d15，d19; repeat every 3 weeks.
10118778|NCT04415060|Experimental|Inhaled - volatile anesthetic|The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
10118779|NCT04415060|No Intervention|Standard Care|The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
10118780|NCT04415060|No Intervention|Non-randomized|In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
10118781|NCT04414826|Active Comparator|Mindfulness + Compassion (MC) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching both mindfulness and compassion skills.
10118782|NCT04414826|Active Comparator|Mindfulness Alone (MO) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching mindfulness skills alone.
10118783|NCT04414826|Placebo Comparator|Waitlist Control (WL)|Those in the wait-list control condition will wait one week and complete a one-week follow-up assessment before being randomized to one of the two intervention conditions.
10118784|NCT04415034||Pediculosis capitis|Subjects with pediculosis capitis based on the findings of eggs, larva, or an adult parasite on the scalp or in the hair
10118785|NCT04414956|Other|Surveillance|All participants will be examined with three biomarker tests and sonography every six months and contrast-enhanced CT annually.
10118786|NCT04415112|Active Comparator|Mediterranean Diet|The MD diet is rich in plant based foods including vegetables, whole cereal and fruit with the main added fat being extra virgin olive oil. In addition, the diet emphasises, while consumption of legumes, nuts and fish is high, consumption of red meat and home-made desserts is low, and consumption of fermented milk and poultry is moderate. The MD diet had a target macronutrient composition of 35-40% fat (with <10% of energy as saturated fat), 40-44% carbohydrate and 20% protein.
10118787|NCT04415112|Active Comparator|Low Fat Diet|The Low Fat diet had a target macronutrient composition of 55% of energy from carbohydrate, 20-25% from fat (with <10% of energy as saturated fat) and 20-25% from protein. Nutrition education focused on choosing foods containing ≤3 grams of fat/serving, limiting added fats, and using low-fat meal preparation strategies. Parents were instructed to offer their children ample amounts of grains, vegetables, fruits, lean meats, low-fat dairy products and limit high-fat foods
10118788|NCT04415138||Robotic-assisted Group|
10118789|NCT04415138||Video-assisted Group|
10118790|NCT04414774|Experimental|using app first|The experimental group will immediately start using the GGSI app, for a period of 15 days (T1). After 15 days (T2) the experimental group ceases its use of the app. The end of this period is marked T3. The research team will contact the experimental group on T1, T2 and T3 in order to fill out questionnaires regarding suicide ideation and related risk factors.
10118791|NCT04414774|Active Comparator|waiting list|During the first 15 days, the control group is inactive (T1). After 15 days (T2) the control group will start using GGSI app for additional 15 days (T3). Participants will fill questionnaires about suicide ideation and related risk factors three time during the study on: T1, T2 and T3.
10118792|NCT04414891|Experimental|NAVA arm|"Delivery of NIV-NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~Subjects randomised to this arm will undergo placement of Edi catheter and will be initiated on NIV. Appropriate NAVA level will be selected based on the scalars corresponding to stable ventilation in pressure support mode. During NAVA, the NAVA level would be increased in multiples of 0.2 cm H2O/µV to attain favourable response (tidal volume 6-8mL/kg RR ≤25). Once the patient's clinical condition stabilises, and the Edi maximum starts declining or remains unchanged with stable tidal volumes, NAVA level will be decreased in steps of 0.2 cm H2O/μV every 2 hours. If response to new settings is not favourable earlier settings will be restored. If favourable response is attained the weaning is continued until peak pressure is <12cm H20 and PEEP requirement is <5cm H2O. NIV will be replaced by a venture mask to titrate SpO2 between 88-92%"
10118793|NCT04414891|Active Comparator|ASV arm|Patients randomised to the ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland). The patients will be ventilated with an initial setting of 100%-minute volume (MV%). Increments of 10% will be made every 15 minutes to achieve clinical response (relief of dyspnea, RR<30, and tidal volume 6-8mL/kg). The expiratory trigger sensitivity will be set at 35% and adjusted accordingly. PEEP will be commenced at 3-4 cm H2O and increased by 1 cm of H2O to achieve SpO2 between 89-92% and maximum PEEP of 10 cm of H2O. Weaning would be performed by reducing the MV% gradually in decrements of 10%/hour to a MV% of 60% after the peak inspiratory pressure decreases to <8 cm of H2O, and the respiratory rate is < 28 breaths per minute and patient is able to maintain SpO2 > 90% at FiO2< 30%. Once the patient is comfortable on these settings, NIV will be replaced with oxygen supplementation using a venturi mask to maintain SpO2 between 89 and 92%.
10118794|NCT04414800|Placebo Comparator|Control (Placebo+ Standard of Care))|
10118795|NCT04414800|Active Comparator|Ketamine + Standard of Care|
10118796|NCT04414800|Active Comparator|Fentanyl + Standard of Care|
10118797|NCT04414709|Experimental|Two short implants|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
10118798|NCT04414709|Active Comparator|Single short implant|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
10118799|NCT04415099|Experimental|One group|Only one group was assessed before and after performing muscle fatigue protocol.
10118800|NCT04415164|Experimental|Xueshuantong|Patients will receive intravenously administered Xueshuantong, combined with guidelines-based standard care.
10118801|NCT04415164|Placebo Comparator|Placebo|Patients will receive intravenously administered Xueshuantong placebo, combined with guidelines-based standard care.
10118802|NCT04414943|Experimental|S-katamine group|For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
10118803|NCT04414943|Placebo Comparator|Placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
10118804|NCT04414540|Experimental|Arm 1: Metformin before Pembrolizumab|Metformin ER 1000mg daily D-14 to D-7. Metformin ER 2000mg daily D-7 to D1. D1 Begin Pembrolizumab 200mg every 3 weeks, while continuing Metformin ER 2000mg daily.
9668897|NCT04690478|Other|Non-remote blood pressure management group|Non-remote blood pressure management group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
9825922|NCT02400710|Experimental|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
10118805|NCT04414540|Experimental|Arm 2: Metformin after Pembrolizumab|D-21 Begin Pembrolizumab 200mg. D-7 begin Metformin ER 1000mg daily. D1 begin Metformin ER 2000mg daily. Continue Pembrolizumab 200mg every 3 weeks.
10118806|NCT04414553|Experimental|Community-AHF|Participants in this arm will receive the 10 month Community Active and Healthy Families Intervention
10118807|NCT04414553|No Intervention|Wait List|Participants in this arm will receive routine primary care follow up for childhood overweight/obesity. After the 10 month experimental period they will be offered the Community Active and Healthy Families Intervention but participation is not required.
10118808|NCT04414592|Experimental|Human Umbilical Cord Mesenchymal Stem Cells|Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc
10118809|NCT04414436|Experimental|GYNEA- digital coping program|Participants randomized to this arm will receive active treatment after the inclusion
10118810|NCT04414436|No Intervention|Waiting list|6 weeks waiting list before crossing over to GYNEA- digital coping program
10118811|NCT04414293|Experimental|Treatment|All the patients will be treated with low dose lung radiation
10118812|NCT04414462|Experimental|Group I|Group I will receive following exergaming training: heading, tightrope tension,snowboard slalom and table tilt game
10118813|NCT04414462|Active Comparator|Group II|Group II will receive Habituation,wobble board exercises,double leg,single leg and tandem stance training.
10118814|NCT04414501|Active Comparator|Tablet study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
10118815|NCT04414501|Active Comparator|VR study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
10118816|NCT04414605|Experimental|Chinese herbal medicine in combination with secukinumab|Oral Chinese herbal medicine (Gu Ben Hua Yu Fang decoction) and secukinumab will be used concurrently. The treatment duration for both secukinumab and oral Chinese herbal medicine is up to 16 weeks. Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg). Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice a day. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
10118817|NCT04414215|Experimental|Cognitive training|Emotional working memory training
10118818|NCT04414215|Placebo Comparator|Placebo training|Placebo working memory training
10118819|NCT04414566|Experimental|IC plus RT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m^2) every three weeks for three cycles during radiotherapy.
10118820|NCT04414566|Active Comparator|IC plus CCRT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy.
10118821|NCT04414579|No Intervention|No Intervention: Conventional Insulin Aspart (NovoLog®)|In the aspart group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
10182851|NCT03770221|Active Comparator|Usual Care|Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
10182852|NCT03770143||Group 1|Infants feeding predominantly with palm olein free formula if presence in addition to breast milk for 8 weeks of life
9966369|NCT01259518|Experimental|Once weekly administration of TRIN2755|
10118822|NCT04414579|Active Comparator|Faster Insulin Aspart (Fiasp®)|In the Fiasp group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Fiasp is put into their pump and delivered to their body through a small tube placed under their skin. In this Fiasp treatment group, the subject will take fiasp with each meal while their pump also gives them a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
10118823|NCT04414228|Active Comparator|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
10118824|NCT04414228|Active Comparator|ProAQT in guiding goal-directed hemodynamic therapy|Subjects randomized to the GDT group will be managed according to the ERAS algorithm utilizing ProAQT variables (mean arterial pressure, stroke volume variation and cardiac index) If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If mean arterial pressure is < 70 mmHg and/or cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of < 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
10118825|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 670G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 670G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
10118826|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 780G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 780G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
10118827|NCT04414280||type 1 diabetes patients using Tandem Control-IQ|Patients with type 1 diabetes, aged 6 years or older, who start with the Tandem Control-IQ system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
10118828|NCT04414397|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM VOLUMA® XC injectable gel in temple. Participants are eligible for touch up treatment.
10118829|NCT04414397|No Intervention|Control- No treatment|No treatment is administered. Optional treatment at month 3.
10118830|NCT04414488||Patient controlled analgesia|General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
10182853|NCT03770143||Group 2|Infants feeding with other formulas including palm olein if presence in addition to breast milk for 8 weeks of life
9668898|NCT04690478|Other|Routine blood pressure management group|Routine blood pressure management group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
9668899|NCT04666467|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
9668900|NCT04665713||Normal|children whose BMI are in the normal range(From P5 to P85)
9668901|NCT04665713||Overweight|children whose BMI are above the normal range(over P85)
9668902|NCT04653454|Experimental|CGM Patients|Patients with diabetes mellitus admitted to the hospital and using a CGM will be encouraged to continue to use these devices in inpatient setting. The device alarms of high or low glucose levels will be communicated to the nursing staff.
9668903|NCT04647227|Other|Hemophilia A and B Cases|SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.
9668904|NCT04644003|Experimental|STP1 Low Dose|1 capsule and 1 tablet per intake
9668905|NCT04644003|Experimental|STP1 High Dose|1 capsule and 1 tablet per intake
9668906|NCT04644003|Placebo Comparator|Placebo|1 placebo capsule and 1 placebo tablet per intake
9668907|NCT04640987|Experimental|Experimental: Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. The participant's cells will then be manipulated via a T-allo10 cell addback. Participants will be followed for outcomes for two years.
9668908|NCT04611529|Experimental|Oral ibuprofen + topical diclofenac|Oral ibuprofen 400mg Topical diclofenac 2gm
9668909|NCT04611529|Active Comparator|Oral ibuprofen + topical placebo|Oral ibuprofen 400mg Topical placebo
9668910|NCT04611529|Active Comparator|Oral placebo + topical diclofenac|Oral placebo Topical diclofenac 2gm
9668911|NCT04601337||Brachial plexus and/or nerve transfer surgery patients|Patients set to undergo brachial plexus reconstruction or nerve transfer surgery that are 18 years or older.
10118831|NCT04414488||Thoracic paravertebral block and patient controlled analgesia|Before induction of general anesthesia thoracic paravertebral block was performed. General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
10118832|NCT04414644|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
10118833|NCT04414644|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
10118834|NCT04414371|Experimental|Group 1 - Yoga Group|Learn online yoga practices and practice daily for 12-weeks
10118835|NCT04414371|Other|Group 2 - Control Group|waist-list control for 4-week, cross-over to yoga practice for 8-week
10118836|NCT04414254|Experimental|conference-Cefprozil for Suspension®|"Cefprozil for Suspension® (125mg/5ml, 50ml/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.)"
10118837|NCT04414254|Experimental|test-cefprozil granule|cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd)
10118838|NCT04414267|Experimental|BCG vaccine|One intradermal injection of 0.1ml of BCG (BCG vaccine Moscow strain 361-1; Serum Institute of India Pvt. Ltd)
10118839|NCT04414267|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
10118840|NCT04414072|Active Comparator|laparoscopic sleeve gastrectomy|
10118841|NCT04414072|Active Comparator|mini gastric bypass|
10118842|NCT04414072|Active Comparator|sleeve gastrectomy with loop bipartition|
10118843|NCT04414046|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
10118844|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|
10118845|NCT04414124|Other|Self Supportive Care (SSC) Alone|
10118846|NCT04414150|Experimental|SHR-1802|
10118847|NCT04414163|Experimental|IMC-001|Single Dose level (IMC-001 20mg/kg, every 2 weeks)
10118848|NCT04414176||Case|Patients with coronary artery stenosis more than 75% (or left-main stenosis more than 50%) are defined as case group
10118849|NCT04414176||Control|Patients with normal angiography are considered as control group.
10118850|NCT04413734|Experimental|Triprilumab in combination with chemotherapy of GP|Triprilumab, 240 mg, every 3 weeks (Q3W), Day 1 of each 3 week cycle PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity .
10118851|NCT04413734|Active Comparator|Mono-chemotherapy of GP|Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity.
10118852|NCT04413747|Experimental|Yoga-based breathing support|Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
10118853|NCT04413903|Active Comparator|Pressure controlled ventilation, Volum controlled ventilation|Undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled ventilation settings were adjusted to be 50% O2- 50% air, 8ml / kg TV (tidal volume) and PEEP 5.
10118854|NCT04413903|Active Comparator|Optic Nerve Sheath Diameter|In optic nerve diameter measurements; A layer of water-soluble sterile gel was applied to the closed upper eyelid. The linear 10-5 MHz ultrasound probe was carefully placed on the upper eyelid over the gel. The entrance of the optic nerve to the orbital globe in 2D mode was displayed on the monitor without applying too much pressure. After finding the optimal contrast between the retrobulbar echogenic fat tissue and vertical hypoechoic band 23, the diameter of the optic nerve sheath was measured 3 mm behind the optic disc using an electronic caliper.
9668912|NCT04599166|Experimental|Participant arm|Participants will be recruited to complete the WWYC intervention.
9668913|NCT04584853|Active Comparator|Endocrine Therapy only|
9668914|NCT04584853|Experimental|Endocrine Therapy with abemaciclib|
10118855|NCT04413994|Active Comparator|Randomized study product group|"receiving study product (human milk fortifier Humavant) until a gestational age of 36 weeks"
10118856|NCT04413994|Active Comparator|Randomized control group|receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation
10118857|NCT04413994|No Intervention|Term control group|Term-born controls as a reference group for outcome parameters
10118858|NCT04413968|Experimental|Interventional|nasopharyngeal and blood sample
10118859|NCT04413838|Experimental|NIVOLUMAB on top of routine standard of care|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND aspartate aminotransferase (AST) > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a NIVOLUMAB treatment and routine standard of care for COVID-19 infection at the time of study inclusion
10182854|NCT03770143||Group 3|Having similar demographical properties with infants feeding with breast milk (gender, age, weight, height)
10182855|NCT03770156||Subjects who contacted CUMP by phone|Subjects who contacted CUMP (Medical Psychological Emergency Cell) by phone from Paris November 13th, 2015, London 11th,2017 ; Barcelone 17-18th, 2017 ; Strasbourg 11th, 2018.
10118860|NCT04413838|Other|Standard of care for COVID-19 infection|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND AST > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a routine standard of care for COVID-19 infection at the time of study inclusion
10118861|NCT04414007|Experimental|Internet+ home-based cardiac rehabilitation group|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
10118862|NCT04414007|Active Comparator|conventional care group|The UC-assigned patients will maintain standard of care.The conventional rehabilitation group received routine medical care and traditional home-based cardiac rehabilitation based on the rehabilitation manual and exercise diary, followed up by telephone and outpatient.
10118863|NCT04413864|Other|SARS-CoV-2 (Covid-19 positive)|Patients hospitalized in intensive care unit (ICU), infected with SARS-CoV-2
10118864|NCT04413942|Active Comparator|FB825|FB825
9966370|NCT01259531|Experimental|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
10118865|NCT04413942|Placebo Comparator|Placebo|Formulation buffer
10118866|NCT04414020|No Intervention|Control|Control group receiving conventional treatment without progesterone
10118867|NCT04414020|Active Comparator|progesterone group|1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface
10118868|NCT04414137||Eosinophilic pneumonia on daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia
10118869|NCT04413890|Active Comparator|Classical administration|One prostaglandin vaginal gel every 24 hours
10118870|NCT04413890|Experimental|Experimental administration|One prostaglandin vaginal gel every 12 hours
10118871|NCT04413708|Experimental|P3-T PrEP adherence app|"Intended app use includes, at a minimum, participant completion of selected app activities (medication tracking, daily quest, social wall post) each day for the 3 month intervention period.~Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit."
10118872|NCT04413708|No Intervention|Standard of Care|Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit.
10118873|NCT04413721|Experimental|Short-term storage RBCs (stored for ≤ 14 days)|patients in this group were transfused with short-term storage RBCs (stored for ≤ 14 days).
10118874|NCT04413721|Active Comparator|Longer-term storage RBCs (stored for ≥21 days)|patients in this group were transfused with longer-term storage RBCs (stored for ≥21 days).
10118875|NCT04413565|Experimental|Two surgeon bilateral TKA group|2 surgeons will perform simultaneous total knee arthroplasty in this group.
10118876|NCT04413565|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
10118877|NCT04413552|Experimental|Part I-Active arm|Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort
10118878|NCT04413552|Placebo Comparator|Part II-Placebo arm|Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort
10118879|NCT04413552|Experimental|Part II-Active arm-fed|Study medication will be administered after a high fat meal. Dose to be determine based on a well-tolerated dose studied in Part I.
9694603|NCT04787471|Active Comparator|10 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes
9966371|NCT01259544|Active Comparator|Di -petide breath tests and ePFT secretin induced|Di peptide breath tests will be performed on subjects with known chronic pancreatitis
10118880|NCT04413552|Experimental|Part II-Active arm-fasting|Study medication will be administered under fasted conditions. Dose to be determine based on a well-tolerated dose studied in Part I.
10118881|NCT04413656|Experimental|ablation group|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ). Meanwhile, post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
10118882|NCT04413656|Experimental|surgery group|Patients with stage IA operable peripheral lung tumor will be performed surgery. cfDNA methylation would be monitored at different time(before surgery , after surgery 1month, 3month). Post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
10118883|NCT04413578|Experimental|Dexcom G6 (Intervention Group)|• Intervention group: CGM using a Dexcom G6 to measure glycosylated hemoglobin levels every five minutes. Patients will be asked to download the Dexcom G6 and Clarity applications (to have access to their real-time data) and be given a link to complete an exit survey in REDCap near the end of their study participation. Data will be sent via Bluetooth and then exported by the Intermountain research team into a Tableau (or similar) dashboard for data analysis/comparison
10118884|NCT04413578|Placebo Comparator|Contour NextOne (Standard of Care) Glucometer|• Control group: A standard finger-prick protocol that will require patients to continue with their daily fingerprick regimen established by their physician. This group will be given a Contour Next One meter to ensure that each patient is receiving the same level of accuracy by the same device. A review by Ekhlaspour et al of 17 glucose meters demonstrated wide variability, with only two devices achieving the 2013 ISO standard (with the most accurate being the Contour Next). Patients in the control group will be asked to download the Contour Next application which will send data via Bluetooth similar to above. Data will be aggregated, and protected health information removed prior to analysis (by Intermountain Healthcare and Savvysherpa). At the end of the study, patients will be asked to complete a short survey in REDCap about their willingness to participate in future studies.
10118885|NCT04413669|Experimental|white light bronchoscopy and autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out for people at high risk for lung cancer with heavy smoking (smoking history> 400 years).Biopsy was taken for abnormal bronchial mucosa.
10118886|NCT04413591|Experimental|Intervention Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
10118887|NCT04413591|No Intervention|Control Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
10118888|NCT04413682|Experimental|Supervised Exercise Group|One session per day, 3 days per week over a 12-weeks structured exercise program under supervision of a physical therapist.
10118889|NCT04413682|Experimental|Telerehabilitation Group|One session per day, 3 days per week over a 12-weeks structured exercise program through Telerehabilitation
10118890|NCT04413630|Experimental|Study group|family workshop
10118891|NCT04413396||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
10118892|NCT04413422||propofol|Those patients planned for general surgery, who received propofol as an induction agent for general anesthesia.
10118893|NCT04413422||etomidate|Those patients planned for general surgery, who received etomidate as an induction agent for general anesthesia.
10118894|NCT04413422||thiopental|Those patients planned for general surgery, who received thiopental as an induction agent for general anesthesia.
10118895|NCT04413812|Experimental|Experimental Group|The experimental group will participate in a 3-months training programme focusing on health competence related outcomes.
10118896|NCT04413812|No Intervention|Control Group|The control group does not participate in the exercise programme but undergoes identical outcome assessments.
10118897|NCT04413383|Active Comparator|Traditional Curved Iris Scissors|The traditional curved Iris scissors are used to during the dermatologic surgery. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
10118898|NCT04413383|Experimental|Modified Curved Iris Scissors|"The Wuennenberg modified curved Iris scissors are used during the dermatologic surgery.~Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure."
10118899|NCT04413383|Other|Comparative Experience|Both the traditional and modified curved Iris scissors are used and patients are asked which they prefer. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
10118900|NCT04413305|Experimental|WGS-based screen and control group|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
9966372|NCT01259544|Active Comparator|c13 di peptide breath tests|Healthy volunteers to compare breath tests results to subjects with chronic pancreatitis
10118901|NCT04413305|No Intervention|Non-intervention|Non-intervention
10118902|NCT04413643|Experimental|Noninvasive Ventilation|Subjects will be introduced to NIV and educated on sleep disordered breathing. NIV will be initiated during hospitalization following resolution of acute respiratory failure. NIV settings will be based on inspiratory and expiratory positive airway pressures (IPAP, EPAP), rates, and tidal volumes tolerated during the acute phase of treatment. Initial settings will be set with goals of tolerance and acceptance of therapy. Minimum pressure difference between IPAP and EPAP settings will be 5cmH20. Volume assured pressure support mode with a target tidal volume (Vt) of 8ml/kg ideal body weight will be used. Final device settings and patient parameters will be documented after 10 minutes of acclimation to the device. Data from the device will be reviewed the following day. Tolerance, mask comfort, and acceptance of therapy will be assessed. Changes to settings, mask interface, or other comfort features will be performed at this initial reassessment period.
10118903|NCT04413500|Experimental|adaptive intervention|The patients will receive various adaptive digital interventions through mobile app.
10118904|NCT04413292||Group A|21 patients with lung cancer
10118905|NCT04413292||Group B|21 patients with various benign lung diseases
10118906|NCT04413292||Group C|Healthy controls
10118907|NCT04413292||Group D|15 patients with malignant pleural mesothelioma (MPM)
10118908|NCT04413292||Group E|16 patients having various benign pleural diseases
10118909|NCT04413214|Experimental|Test Group|The 3x3 dose escalation design will be adopted, including 200mg, 400mg and 600mg of Carrimycin; and three subjects at each dose level initially. If there is no DLT in the dose level of 200mg, the dose level of 400mg will be followed; if there is one DLT in the dose level of 200mg, another three patients will be added in the dose level of 200mg; if there is no DLT occurs in the another three patients, the dose level of 400mg will also be followed; if there is one DLT in the another three patients, the trial will be closed. The same condition to the dose level of 400mg and 600mg.
10118910|NCT04413227|Experimental|PEG-ENDO+Docetaxel|PEG-ENDO( 1 mg/kg or 2mg/kg or 4mg/kg or 6mg/kg or 8mg/kg）+Docetaxel 75 mg/m2，once every 3 weeks at day 1
10118911|NCT04413240|Experimental|Telerehabilitation group|"Patients in this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain telerehabilitation (motor, speech and/or cognitive) with VRRS, K-Wand and Khymu connected to a workstation (Telecockpit)."
10118912|NCT04413240|Active Comparator|Conventional rehabilitation group|"The patients assigned to this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain rehabilitation (motor, speech and/or cognitive). It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated."
10118913|NCT04413175|Experimental|a music group|Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.
9966373|NCT01259557|Experimental|Botulinum toxin type A(Meditoxin®)|
10118914|NCT04413175|No Intervention|control group|control group
10118915|NCT04413409|Experimental|surgical group|The metastatic sites are firstly treated by surgery then followed by systemic treatment
10118916|NCT04413409|No Intervention|systemic group|After confirmation of puncture, receive systemic treatment
10118917|NCT04413188|Experimental|A warm foot bath group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
10118918|NCT04413188|No Intervention|Control group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
10118919|NCT04413513|Experimental|Integrated Attention Training Program|"The intervention group (I) will receive integrated attention training program (IATP) on a variety of structured attention tasks by an intervention instructor. It is considered to be simple and safe but effective enough for cognitive health promotion."
10118920|NCT04413513|Placebo Comparator|Health Education|The control group (C) will receive health educational sessions on health concerns and physical diseases commonly found in old age during the invention period.
10118921|NCT04413435||Confirmed COVID-19 cases|Patients with PCR test positive were considered as the confirmed COVID-19 cases.
10118922|NCT04413435||Suspected COVID-19 cases|The suspected COVID-19 cases were defined as follows: those who were interpreted in favor of the suspected covid-19 on c-CT by radiologists in addition to the typical symptoms of the novel coronavirus disease such as cough, high fever (>38,5 °C), or dyspnea, and those with a history of contact with another confirmed COVID-19 patient in addition to typical symptoms.
10118923|NCT04413136|Experimental|Web-ORLA|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.~The participant is presented with 3-5 word (level 1) or 8-10 word (level 2) sentences, depending upon the severity of the aphasia. Each sentence is chosen by the software program at random from a group of 150 sentences. The participant is instructed to look, listen, and point to words spoken by the virtual therapist, read highlighted words aloud, and then read the sentence aloud, both chorally with the virtual therapist and independently."
10118924|NCT04413136|Placebo Comparator|Control|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.~A commercially available game, Bejeweled 2, by PopCap. Participants use loaned 13-in laptop computers to access the Bejeweled interface, which displays an 8 X 8 grid of gems of varying shapes and colors. The objective is to match three gems of the same color and shape to score points and advance to more difficult levels."
10118925|NCT04412811||Patients with hematological disease|Adult and children allogenic Hematopoietic stem cell transplantation recipients
10118926|NCT04413019||Group (D): Planned domiciliary care.|Patients within this group will be counseled for home care with self-monitoring for any symptoms suggestive of preterm labor, maternal or fetal distress.
10118927|NCT04413019||Group (H): Planned hospital care.|Patients within this group will be admitted at hospital for close monitoring of maternal & fetal wellbeing & finally the neonatal outcome
10118928|NCT04412876|Experimental|Duloxetine|Receive Duloxetine 30 mg treatment per day
10118929|NCT04412876|Active Comparator|Imipramine|Receive Imipramine 25 mg treatment per day
10118930|NCT04412889|Experimental|CAR-T treatment group|The patients will receive BCMA/CD19 dual-target CAR-T cell treatment. BCMA/CD19 dual-target CAR-T cell dosage ranges from 2×10^5 to 1×10^6 CAR+T/Kg.
10118931|NCT04413045||C Group|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
10118932|NCT04413071||Health care workers|Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.
10118933|NCT04413032|Experimental|Patients with MS|30 Patients with MS will use the DreaMS App over a study duration of 6 weeks.
10118934|NCT04413032|Experimental|Healthy Volunteers|30 Healthy Volunteers will use the DreaMS App over a study duration of 6 weeks.
10118935|NCT04412772|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen.
10118936|NCT04412772|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
10118937|NCT04412954|Experimental|Intervention|Health coach with Smartphone application for diet and physical activity
10118938|NCT04412954|No Intervention|Control|No intervention, using a Smartphone application for sleep monitoring
10118939|NCT04413084|Experimental|Gaze stability exercises|Group I will receive Gaze stability exercises.
10118940|NCT04413084|Experimental|Brandt-Daroff Exercises|Group II will receive Brandt-Daroff Exercises.
10118941|NCT04412798|Other|group 1|orange juice concentrate
10118942|NCT04412798|Other|Group 2|Sugar-sweetened orange-flavoured beverage
10118943|NCT04412798|Other|Group 3|Whole orange juice with skin removed
10118944|NCT04412850|Experimental|Control group|Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.
10118945|NCT04412850|Placebo Comparator|placebo group|Normal Saline in equal volume as the control group.
10118946|NCT04413006|Experimental|Treatment Arm|Participants who will receive the 6-session Group-Based Virtual Self-Compassion for Chronic Pain treatment
10118947|NCT04412733|Experimental|Pulsed Ultrasound Group|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2 ) 5-min daily session, 5 days per weeks, for a total of 15 sessions.
9966374|NCT01259570|Active Comparator|Skimmilk enriched with VD encapsulated in CM|
10118948|NCT04412733|Sham Comparator|Sham Group|Control group received sham ultrasound with the same protocol.
10118949|NCT04413110||Non-subjective cognitive impaired|Cases of migraine and non-subjective cognitive impaired
10118950|NCT04413110||Subjective cognitive impaired|Cases of migraine and subjective cognitive impaired
10118951|NCT04413110||Control group|Age and sex matched healthy controls
10118952|NCT04412759|No Intervention|Porcine xenograft|porcine xenograft derived from dermal porcine skin. Standard of care treatement for partila thickness burn at the specfic centre
9668915|NCT04570332|Experimental|Single Arm|Patients will be treated with the combination of BO-112 and pembrolizumab. IT administration of BO-112 will be performed once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV. The order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles.
10118953|NCT04412759|Experimental|Microbial cellulose|Novel dressing consisting of a biopolymer spun by the bacteria Acetobacter xylinum (later removed).
10118954|NCT04412967|Active Comparator|Standard Technique PVC placement|Standard PVC placement technique
10118955|NCT04412967|Experimental|DUST|Dynamic ultrasound-guided short-axis needle tip navigation (DUST)
10118956|NCT04412577|Experimental|TQB3473 tablets|TQB3473 tablets administered once daily in 28-day cycle .
10118957|NCT04412590|Experimental|Vermont Family Based Approach|"The VFBA group was offered a variety of supports and services to help them achieve and maintain wellness and address emotional behavioral challenges.~All families partnered with a Family Wellness Coach (FWC) to design and implement a comprehensive program of family health and wellness with an emphasis on nutrition, exercise, music training, mindfulness, decreasing screen time, and positive parenting.~Families with a child or parent experiencing significant emotional and behavioral problems were also partnered with Focused Family Coaches (FFCs) and Family Based Psychiatrists (FBPs). FFCs and FBPs respectively provided evidence-based psychotherapy and psychiatric care from the family perspective.~Families also were also offered health promotion programs, including music lessons for all family members, behavioral parent training, yoga and mindfulness training, and nutrition coaching."
10118958|NCT04412590|Active Comparator|Control|The Control Group received pediatric care as usual.
10118959|NCT04412603|Experimental|Conventional Mirror Therapy group|"Therapy:~-With the affected upper limb into the mirror box, perform the exercise with the non-affected extremity which is reflected in the mirror box. -The affected side must perform the corresponding movement within its possibilities, according to the exercise that is being performed with the healthy arm. - It is very important to look at the mirror at all times, which reflects the non-affected side while doing the exercises."
10118960|NCT04412603|Experimental|Mirror Therapy Virtual Reality group|"Therapy:~-Perform the exercises with the non-affected limb, which must be watched constantly with virtual reality glasses, to interpret that this limb corresponds to the affected side. - The affected side accompanies the movement within its possibilities (out of sight of the patient, it can be covered with a handkerchief). - It is very important to look at the non-affected side. The affected side should be out of the visual field to avoid confusion."
10118961|NCT04412538|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
10118962|NCT04412538|Experimental|Low dosage vaccine on a 0- and 14-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
9668916|NCT04567693|Experimental|Early 1|Advance to spaced-out appointments at month 6 after a single viral load is measured.
9668917|NCT04567693|Experimental|Early 2|Advance to spaced-out appointments at month 6 after two viral loads are measured.
9668918|NCT04567693|No Intervention|Usual Care|Do not advance to spaced-out appointments during study period
9668919|NCT04562610|Active Comparator|Group A: All oral pre-operative analgesics|"Group A patients will be administered the following medications in the preoperative holding area:~Acetaminophen 1,000 mg by mouth prior to operation~Celecoxib 200mg by mouth prior to operation~Tranexamic acid 2 grams by mouth prior to operation~Gabapentin 600mg by mouth prior to operation"
9668920|NCT04562610|Active Comparator|Group B: Intravenous agents|"Group B patients will receive:~Acetaminophen (Ofirmev) 1,000mg intravenous prior to operation~Celecoxib 200mg by mouth prior to operation~Tranexamic acid 2grams intravenous at start of operation~Gabapentin 600 mg by mouth prior to operation"
10118963|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
10118964|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 14-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
10118965|NCT04412538|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
10118966|NCT04412538|Experimental|High dosage vaccine on a 0- and 14-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
10118967|NCT04412538|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
10118968|NCT04412538|Placebo Comparator|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0, 14
10118969|NCT04412382||covid-19|Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION.
10118970|NCT04412382||control|Control group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer.
10118971|NCT04412668|Experimental|ATYR1923 1 mg/kg|Single dose of ATYR1923 1 mg/kg
10118972|NCT04412668|Experimental|ATYR1923 3 mg/kg|Single dose of ATYR1923 3 mg/kg
10118973|NCT04412668|Placebo Comparator|Placebo|Single dose of Placebo
10118974|NCT04412564|Experimental|TQ-B3101 capsules|TQ-B3101 capsules 300mg bid administered orally in 28-day cycle.
10118975|NCT04412642|Other|methoxyflurane|methoxyflurane
10118976|NCT04412720|Experimental|Aerobic and Breathing Exercises|The experimental intervention will be aerobic and breathing exercises.
10118977|NCT04412720|Active Comparator|Aerobic and Stretching Exercises|The active comparative intervention will be aerobic and stretching exercises.
10118978|NCT04412434|Other|patients with acute ischemic stroke|This open-label prospective study will be conducted in the single medical center (RAMBAM Medical Center) and will include at least 200 patients with acute ischemic stroke resulted from MCA or ICA occlusion.
10118979|NCT04412447|Experimental|Subjects|"Phase V1: 1 month of home-based FES-training using isometric contractions of quadriceps and hamstring muscles (3 times a week).~Phase V2: 2 months of home-based FES-training on an ergo-cycle with arm support (3 times a week)~Phase V3: 1 month of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting.~Optional (only for selected pilot):~Phase V4: 2-4 months of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting. This phase is focussing on optimizing the performance of the pilot and improving the mechanical efficiency of the tricycle.~Phase V5: Participation on Cybathlon 2020"
10118980|NCT04412655||STEMI patients treated in March April 2019|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
10118981|NCT04412655||STEMI patients treated in March April 2020|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
10118982|NCT04412304||thrombose prophylaxis|The dose used to prevent thromboembolic complication in critically ill
10118983|NCT04412304||double thrombose prophylaxis|Double the dose used to prevent thromboembolic complication in critically ill
10118984|NCT04412304||full dose anticoagulant|Dose used to treat thromboembolic event
10118985|NCT04412408|Experimental|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
10118986|NCT04412291|Active Comparator|Standard-of-care Treatment (SOC)|"SOC according to local recommendations at the Karolinska University Hospital:~Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep or Klexane or new oral anticoagulants incl. dabigatran, apixaban or rivaroxaban).~Steroids (Betapred)"
10118987|NCT04412291|Active Comparator|Anakinra + SOC|"Anakinra: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.~SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.."
10118988|NCT04412291|Active Comparator|Tocilizumab + SOC.|Tocilizumab: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep) Steroids (Betapred) Prophylactic broad spectrum antibiotics for seven days.
10118989|NCT04412681|Experimental|PE Enhanced Screening|"The PE screening program entails the following for all participants:~provision of additional demographic and risk factors~provision of mean arterial pressure~standard nuchal translucency scan as part of their first trimester screening (FTS) with the addition of the measurement of the uterine artery Doppler by a certified sonographer~standard blood sample (as part of the FTS)~results of the PE screening (in the format of a screening report) will be provided to the study team and participant's healthcare provider"
10118990|NCT04412512|Experimental|VATS approach|patients treated by VATS technique.
10118991|NCT04412512|Active Comparator|Thoracotomy approach|patients treated by Thoracotomy technique
10118992|NCT04412343|Experimental|Virtual group exercise|Individuals in the (virtual) group-based exercise program, will have the opportunity to take part in (virtual) group exercise classes, delivered via videoconferencing, by experienced older adult exercise instructors. Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group. Classes will be offered multiple days a week at 9am PST (12 noon EST), and will last approximately 50 minutes. Classes include a warm-up component, moderate intensity exercises as the core component of the class, and a cool-down. At the end of classes participants will have the opportunity to connect in small groups (videoconferencing breakout groups) to socially connect over a beverage (coffee, water) from their own homes. Participants in the group condition will also be sent, by mail, a program t-shirt to foster a sense of distinctiveness.
10118993|NCT04412343|Experimental|Personal exercise|Each of the older adult instructors described above will also contribute to delivering pre-recorded exercise classes (involving the same exercises, intensity, music, and so forth as those described above for the group condition). However, in this instance, instructors will deliver those classes to each participant by referring to themselves as each participant's personal trainer/coach, with language directed to the individual and not the group. That is, no sense of 'groupness' or 'shared social identities/connectivity' will be primed. Also, participants in this condition will not have the opportunity to interact with other older adults after classes have ended and will not receive the same program t-shirts designed to foster a sense of group distinctiveness.
10118994|NCT04412343|No Intervention|Wait-list control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 12-week trial. They will be asked to complete the same questionnaires (and will be remunerated in the same way as those in the other two conditions via $10 per questionnaire completion). At the end of the 12-week trial, participants in this condition will have access to the personal exercise programming.
10118995|NCT04412317||Children < 15 years old|Patients under 15 years old who consults a physician on an outpatient basis or in the emergency room and who requires a Sars-CoV-2 RT- PCR (nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction) diagnostic
10118996|NCT04412356|Experimental|Early tracheotomy|Tracheotomy within 7 days after intubation.
10118997|NCT04412356|Active Comparator|Late tracheotomy|Tracheotomy after at least 10 days after intubation.
10118998|NCT04412148|Active Comparator|Intralesional Steroids|
10118999|NCT04412148|Placebo Comparator|Control|
10119000|NCT04412278||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
9668921|NCT04561986|Active Comparator|Arm A: Standard of care (SOC) + tocilizumab (TCZ)|SOC, as below + TCZ (162 mg every week, subcuataneous administration)
9668922|NCT04561986|No Intervention|Arm B: SOC|Tacrolimus (target concentration 6 ±1 µg/L) + MPA (1.5-2 g/day as tolerated) + prednisolone (not less than 5 mg/day), all oral administration
9668923|NCT04557748||Prospective Observational Cohort Study|Men and women with lower urinary tract symptoms.
9668924|NCT04557748||Prospective Observational Cohort Study Controls|Men and women who do not have urinary dysfunction.
9966375|NCT01259570|Active Comparator|VD will be dissolved in milkfat and homogenized into skimmilk|VD will be dissolved in milkfat and homogenized into skimmilk
9966376|NCT01259570|Active Comparator|3% fat milk wherein the VD will be in CM|3% fat milk wherein the VD will be in CM
10119001|NCT04412083|Other|PPA Tele-Savvy Pilot Intervention|The Tele-Savvy program is comprised of weekly, two-hour interactive classes, over seven consecutive weeks, the same duration as the proposed intervention. Tele-Savvy consists of educational instruction, video and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of contented involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
10119002|NCT04412200|Experimental|Hyperbaric oxygen chamber Arm|Patients will be randomized at a ratio of 2:1, to hyperbaric chamber (100% oxygen at 2 ATA)
10119003|NCT04412200|Sham Comparator|Sham hyperbaric chamber Arm|Patients will be randomized at a ratio of 2:1, to Sham chamber (21% oxygen at 1 ATA)
10119004|NCT04412005||Manhiça|Pregnant women attending the Manhiça District Hospital
10119005|NCT04412005||Ilha Josina|Pregnant women attending the Ilha Josina Health Center
10119006|NCT04412005||Magude|Pregnant women attending the Magude Health Center
10119007|NCT04412330|Experimental|ICU followup + physical therapy|Patients surviving ICU admission for Covid-19 will receive ICU follow-up care in an ICU Recovery Clinic plus 8 weeks of physical therapy interventions. ICU Recovery Clinic is standard of care for patients surviving medical ICU admission at University of Kentucky with potential to attend in person or complete through telemedicine up to 5 appointments in the first year after hospital discharge. Physical therapy interventions completed at an outpatient pulmonary rehabilitation center or through telemedicine is not currently standard of care for patients in the short-term recovery phase (1-6 months after hospital discharge) after critical illness.
10119008|NCT04412161||Extra-Malatya|Liver transplant patients with MTD>6 cm of HCC
10119009|NCT04411953|Active Comparator|Reference Product (Treatment A)|"Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
10119010|NCT04411953|Experimental|Test Product (Treatment B)|"Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
10119011|NCT04412070||Patient with Non-Muscle invasive Bladder Cancer|Patients in this group will be enrolled before the start of their treatment with BCG. This will start within 4 weeks after the transurethral bladder resection, in accordance with the guidelines
10119012|NCT04412070||Patient with Muscle Invasive Bladder Cancer|Patients in this group will be enrolled in the study before surgical treatment by radical cystectomy
10119013|NCT04411927||control group|this group included 25 typically developed children
10119014|NCT04411927||on-heamodialysis group|this group included children with CKD on-heamodialysis treatment
10119015|NCT04411927||non-dialysis group|this group included children with CKD who don't require dialysis
10119016|NCT04412213||children of possitive family history of stuttering|
10119017|NCT04412213||children of negative family history of stuttering|
10119018|NCT04411940|Active Comparator|Reference Product (Treatment A)|Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
10119019|NCT04411940|Experimental|Test Product (Treatment B)|Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
10119020|NCT04412109|Active Comparator|injection of low volume of saline|low volume (5 cc) saline injection during thoracic epidural catheterization
9966377|NCT01259570|Active Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
10119021|NCT04412109|Active Comparator|injection of intermediate volume of saline|intermediate volume (10 cc) saline injection during thoracic epidural catheterization
10119022|NCT04412109|Active Comparator|injection of high volume of saline|high volume (20 cc) saline injection during thoracic epidural catheterization
10119023|NCT04412252|Experimental|Tofacitinib|Participants will receive tofacitinib 10 mg twice per day for 14 days and standard of care therapy.
10119024|NCT04412252|Placebo Comparator|Placebo|Participants will receive tofacitinib-matching placebo twice per day for 14 days and standard of care therapy.
10119025|NCT04411992|Experimental|Allocated to Vibration intervention (1) A|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
10119026|NCT04411992|No Intervention|Allocated to Control intervention (1) B|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
10182856|NCT03770195||Abdominoplasty Patients|Patients undergoing full abdominoplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
9966378|NCT01259583|Experimental|CO2|CO2 insufflation instead air insufflation in unsedated colonoscopy
9966379|NCT01259583|Experimental|Warm Water irrigation|warm water irrigation during the insertion phase of colonoscopy
9966380|NCT01259609|Experimental|Diabetic Macular Edema Group|
9966381|NCT01259609|Active Comparator|Epiretinal Membrane Group|
10119027|NCT04411992|Experimental|Allocated to Vibration intervention (2) B|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
10119028|NCT04411992|No Intervention|Allocated to Control intervention (1) A|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
10119029|NCT04411875|Active Comparator|Amlodipine|amlodipine reference formulation at a single dose of 10 mg
10119030|NCT04411875|Experimental|Levamlodipine|levamlodipine test formulation at a single dose of 5 mg
10119031|NCT04411966|Experimental|18F-fluorothymidine PET|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
10119032|NCT04412174|Experimental|GC022F|The patients will receive GC022F CAR-T treatment. GC022F dosage ranges from 3×10^5 to 1×10^6 CAR+T/Kg.
10119033|NCT04412239|Experimental|Telephone Consultation in TB Patients|The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective.
10119034|NCT04411615|Experimental|Omega|Omega-3 re-esterified triglyceride form
10119035|NCT04411589|Experimental|Magnifying endoscopy with optical enhancement system group|Patients in this group go through gastroscopy under the magnifying endoscopy with optical enhancement system.
10119036|NCT04411589|Active Comparator|white light endoscopy group|Patients in this group go through gastroscopy under white light endoscopy.
10119037|NCT04411602|Experimental|Treatment with Convalescent Plasma|SARS-CoV-2 convalescent plasma from approved donors will be transfused into severely ill patients with confirmed COVID-19 severe respiratory distress. Plasma will be administered on days 0, 2,4, 6 and 8.
10119038|NCT04411732||patients with neuromuscular disorder|cohort of patients with neuromuscular disorder
10119039|NCT04411732||healthy controls|cohort of healthy controls
10119040|NCT04411810|Experimental|Participants with skin lesions|Participants who have up to 3 concerning skin lesions will be evaluated by both an in-person dermatologist and a team of three teledermatologists(board-certified dermatologists). The teledermatoogy team will deliver a consensus recommendation. If either the in-person dermatologist or teledermatologists are concerned that the skin spot(s) may be a skin cancer, a biopsy will be recommended and can be performed at no charge. Or if both agree that the spot(s) are not concerning for skin cancer, no biopsy will be needed.
10119041|NCT04411693|Active Comparator|Group A: Intravitreal Dexamethasone Implant|Subjects in this arm will be given intravitreal Dexamethasone implant injection at month 0. PRN intravitreal Dexamethasone implant injections will be given for persistent edema, if it has been 10 weeks or more since last implant injection. If it has been less than 10 weeks since last implant injection, subjects will receive PRN intravitreal Aflibercept for persistent edema.
10119042|NCT04411693|Active Comparator|Group B: Intravitreal Aflibercept|Subjects in this arm will be given Intravitreal aflibercept at month 0. PRN intravitreal Aflibercept will be given at months 1-6 for persistent edema.
10119043|NCT04411823|Experimental|Intervention arm|Undergo an upper endoscopy with EndoFLIP at baseline before sleeve gastrectomy
10119044|NCT04411745||Parturition|Healthy women who are carrying a healthy singleton pregnancy, but have not yet gone to labor at 40 weeks of gestation or who are at term and admitted to hospital for any sign of labor.
10119045|NCT04412044|Experimental|Asthmatics|Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment
10119046|NCT04411979|No Intervention|treatment-as-usual|
10119047|NCT04411979|Experimental|treatment-as-usual plus aerobic walking|
10119048|NCT04411706|Experimental|Sintilimab+Apatinib+Capecitabine|=Drug: Sintilimab（i.v）+apatinib（p.o）+capecitabine（p.o）
9528183|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
9966382|NCT01259609|No Intervention|Healthy Control|
9966383|NCT01259622|Placebo Comparator|placebo|
9966384|NCT01259622|Experimental|K201|intravenous K201
10119049|NCT04411524|Experimental|Treatment Arm|A total of 50 MSI-H LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
10119050|NCT04411550|Experimental|HLX11 group|HLX11 are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
10119051|NCT04411550|Active Comparator|CN-Perjeta group|CN-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
10119052|NCT04411550|Active Comparator|EU-Perjeta group|EU-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
10119053|NCT04411550|Active Comparator|US-Perjeta group|US-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
9966385|NCT01259635|Experimental|Bio feedback for freezing|When ever freezing occures, a metronom sound will be heard
9966386|NCT01259661|Experimental|Experimental Group|
9966387|NCT01259661|Active Comparator|Control Group|
9966388|NCT01259674|Experimental|AboMeg-B-09 syrup|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
9966389|NCT01259674|Placebo Comparator|Placebo|Placebo syrup
10119054|NCT04411862|Experimental|Intervention Group|50 Participants with NAFLD that receive lifestyle modification by Clinical Pharmacist plus Phosphatidylcholine two soft capsules 3 times daily(2.1 g per day) for 6 month
10119055|NCT04411862|Active Comparator|Control Group|50 Participants with NAFLD that receive only lifestyle modification by Clinical Pharmacist
10119056|NCT04411758|Other|Control Group|The control group will not receive any intervention in those first two months, and then the groups will be crossed and will receive the same amount of propolis as the first group.
10119057|NCT04411758|Experimental|Propolis Group|The propolis will be instructed to use 20 drops of standardized green propolis alcohol extract (16% w / v) diluted in 1 glass of water, daily for 2 months before to sleep, and then the groups will be crossed and will not receive any intervention
9966390|NCT01259687||Study group|
9966391|NCT01259700|Experimental|High risk management|
9966392|NCT01259700|Experimental|Salt reduction|
10119058|NCT04412122|Experimental|Kinesio Taping|Kinesio taping is thought to remove the barriers that slow the healing process, activate neurological suppression and reduce pain (El-Refayea, El Nahasa & Ghareebb, 2016; Kamali, Sinaei & Taherkhan, 2018). Kinesio tape stimulates cutaneous mechanoreceptors. Mechanoreceptors decrease sympathetic nervous system activity and increase parasympathetic activity, which can improve intestinal control (Azam, 2017; Szczegielniak, Krajczy, Bogacz, Luniewski & Sliwinski, 2007). Kinesio taping changes skin contours and accelerates blood flow. Increased blood flow brings more oxygen and nutrients to the area. This phenomenon contributes to the natural healing process (Kafa et al., 2015).
10119059|NCT04412122|Experimental|Breathing Exercise|Breathing exercise is accepted as a key to relaxation or cooling down (El-Refayea et al., 2016). It is stated that breathing exercises reduce anxiety by preventing the transmission of pain messages to the spinal cord (Rejeh et al., 2013), reducing the catecholamine response (Rakel & Herr, 2004) and muscle tension by distracting subjects (Kelle, Güzel & Sakallı, 2016).
10119060|NCT04412122|Experimental|Kinesio Taping and Breathing Exercise|According to the application protocols, two applications were made together.
10119061|NCT04412122|Other|Control Group|No intervention was performed to reduce pain in the control group.
10119062|NCT04411719|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
10119063|NCT04411719|Experimental|Electric stimulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
10119064|NCT04411719|No Intervention|No treatment group|No electric stimulation is applied.
10119065|NCT04411537|Experimental|Treatment Arm|A total of 50 MSS LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
10119066|NCT04411901|Experimental|vitamin D 3|oral vitamin D3 drops and tablets
10119067|NCT04411563||Group I-Mild|The patients who have these mild symptoms are low-grade fever (not more than 38 degrees celsius), dry cough, fatigue, sore throat, headache, the new loss of taste, and smell. Patients with normal or mild pneumonia findings of radiological imaging and blood lymphocyte count ≥800 / µl and serum CRP≤40 mg /l, ferritin ≤500ng/ml, D-Dimer ≤1000 ng/ml will be included in group I.
10119068|NCT04411563||Group II-Moderate|The patients who have these moderate symptoms are fever of about 38,5-39 degrees celsius, chills, deep cough, fatigue and body aches, muscle pain, the general feeling of being unwell. Patients with bilateral diffuse pneumonia findings of radiological imaging or blood lymphocyte count <800 / µl or serum CRP> 40 mg / l or ferritin> 500ng / ml or D-Dimer> 1000 ng / ml will be included in group II.
10119069|NCT04411563||Group III-Severe|The patients who have these severe symptoms are all the common symptoms mentioned above along with shortness of breath, chest discomfort, confusion/unresponsiveness, bluish face/lips, possible gastrointestinal issues, like diarrhea or nausea. Patients with ICU (intensive care unit) admission criteria, such as confusion or tachycardia (> 125 / min) or respiratory distress or tachypnea (> 22 / min) or hypotension <90/60 mmHg or SPO2 <93%will be included in group III. Also, patients with the central nervous system and heart involvement will be directly included in the severe case group
10119070|NCT04411355|No Intervention|control group patients|non intervention. only rutin care
10119071|NCT04411355|Experimental|intervention group patients|The intervention group was trained and monitored by a professional team in line with the components of the model. Life quality scale, hypertension information questions and chronic care assessment scale were applied to both groups at the beginning and in the sixth month of the study.
10119072|NCT04411316|Experimental|Pharmacomechanical thrombolysis plus anticoagulation|"This group of patients will receive Pharmacomechanical catheter-directed thrombolysis (PCDT) plus Anticoagulation.~PCDT will be AngioJet along with alteplase. Anticoagulation will be heparin only"
10119073|NCT04411316|Active Comparator|Anticoagulation|This group of patients will receive standard anticoagulation only. Anticoagulation will be Heparin only
10119074|NCT04411394||Healthy Participants|There is no intervention
10119075|NCT04411394||Anxiety Participants|There is no intervention
9528184|NCT03213119|Sham Comparator|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
9668925|NCT04557748||Central Sensitization Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
9966393|NCT01259700|Experimental|high risk management and salt reduction|
9966394|NCT01259700|No Intervention|Usual care|
9966395|NCT01259739|Experimental|Flavanol rich cocoa|(596 mg), dissolved in water, twice daily intervention
10119076|NCT04411173|Active Comparator|Rice Protein|Rice Protein - 24 grams, chocolate, powder
10119077|NCT04411173|Active Comparator|Whey Protein|Whey Protein - 24 grams, chocolate, powder
10119078|NCT04411277||T2DM Elderly on Insulin CGM|70 patients with type 2 diabetes > 65 years of age taking insulin as treatment. The sample size was calculated to estimate the minimal number of patients necessary to describe the mean TIR (minutes/day).
10119079|NCT04411381|Active Comparator|Telemedicine-based model of care|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
9825923|NCT02400710|Active Comparator|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
9825924|NCT02400749|Experimental|Apremilast|Patients will receive Apremilast until week 32.
9528185|NCT03213054|Experimental|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
10119080|NCT04411381|No Intervention|Traditional model of care|Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation
10119081|NCT04411251|Experimental|Outdoor|Nature-centered therapy in a near-natural area
10119082|NCT04411251|Active Comparator|Indoor|Conventional therapy in rooms mainly in a hospital building
10119083|NCT04411407|Other|Group WT|PROM registration via the DANBIO WebApp and thereafter the outpatient touchscreen
10119084|NCT04411407|Other|Group TW|PROM registration via the outpatient touchscreen and thereafter the DANBIO WebApp
10119085|NCT04411303|Experimental|Reducing interlimb asymmetry with biofeedback post-stroke|We will use a randomized crossover design to determine the performance and retention effects following single-day training sessions with biofeedback of three different gait variables (i.e., step length, propulsive force, and interlimb asymmetry) in 25 individuals with chronic stroke.
10119086|NCT04411303|Experimental|Evaluating capacity for biofeedback use at varied intensities|We will use a within-session randomized crossover design to test the capacity of persons post-stroke (second cohort; n=25) to reduce their interlimb asymmetry using the biofeedback variable found to be the most effective for the group in Aim 1 while walking in three aerobic intensity zones: low, moderate, and vigorous (30-40%, 50-60%, and 70-80% of heart rate reserve, respectively).
10119087|NCT04411433|Experimental|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
10119088|NCT04411433|Experimental|Favipiravir (3600 mg + 1600 mg)|"Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
10119089|NCT04411433|Experimental|Favipiravir combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
10119090|NCT04411433|Experimental|Favipiravir combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
10119091|NCT04411433|Active Comparator|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
10119092|NCT04411433|Active Comparator|Hydroxychloroquine combined with Azithromycin|"Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
10119093|NCT04411446|Experimental|Vitamin D|5 capsules containing 100.000 UI of vitamin D each. The intervention will be 5 capsules given in one-time oral intake.
10119094|NCT04411446|Placebo Comparator|Placebo|5 capsules containing placebo. The intervention will be 5 capsules given in one-time oral intake.
10119095|NCT04411290||Total Thyroidectomy (TT)-indicated patients|Patients with presumably benign thyroid disease (multinodular goitre, solitary thyroid nodule, toxic goitre, etc.) Patients with thyroid carcinoma (biopsy-proved) Total thyroidectomy preference by the primary surgeon
10119096|NCT04411264|No Intervention|Classic protocol for pain management|classic protocol for pain management during chronic wound dressing
10119097|NCT04411264|Experimental|Virtual reality for pain management|protocol associating virtual reality with the classic protocol for pain management during the treatment of chronic wound dressings
10119098|NCT04411238||Patients|
10119099|NCT04411238||Caregivers|
10119100|NCT04411238||Home help|
10119101|NCT04411342||patients with type 2 diabetes|patients with type 2 diabetes and have normal range of albumine in urine and decline in renal functions
10119102|NCT04411329|Active Comparator|group A|patients will receive 30 ml of 0.125% bupivacaine with 8 mg dexamethasone (20 ml before skin incision and 10 ml at end of surgery
10119103|NCT04411329|Active Comparator|group B|we will add 50µg dexmedetomidine to the previous mixture given to group A (20 ml before skin incision and 10 ml at end of surgery
10119104|NCT04411329|Active Comparator|group c|we will add 1500 IU hyalurodinase to the mixture given to group A. (20 ml before skin incision and 10 ml at end of surgery
9528186|NCT03213288|Active Comparator|Delphinidin type anthocyanins|Bilberry extract
10119105|NCT04411134|Experimental|Arm 1|Approximately 3x10^8 or 1.5x10^9 E7 TCR T cells will be injected on day 0 and 1.5x10^9 E7 TCR T cells on day 31 (2 escalating dose levels)
10119106|NCT04411134|Experimental|Arm 2|The MTD from among dose level 1 and dose level 2
10119107|NCT04411225|Experimental|Cannabidiol Augmentation|The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
10119108|NCT04411225|Placebo Comparator|Placebo Augmentation|Placebo will appear identical to the cannabidiol solution
10119109|NCT04411160||Group A|Patients of group A received inhalation of nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose.
10119110|NCT04411160||Group B|While patients of group B received 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
9668926|NCT04557748||Central Sensitization Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
9668927|NCT04557748||Physical Activity and Sleep Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
10119111|NCT04411498||Group of Systemic Sclerosis|Patients who were followed-up with the diagnosis of diffuse systemic sclerosis in the Hospital of Rheumatology Clinic were evaluated in terms of inclusion criteria. 44 female patients who met the inclusion criteria were included in the study. All patients were evaluated by a rheumatologist with detailed history and physical examination. Scleroderma patient group was evaluated for the presence of other rheumatic diseases that may accompany.
10119112|NCT04411498||Group of control|The healthy control group (96 female ) was evaluated for rheumatic diseases [undiagnosed connective tissue diseases and additional rheumatological diseases] that may accompany secondary FMS exclusion.
10119113|NCT04411095|Experimental|Stretching of intrathoracic fascia|A technique will be used to stretch the intrathoracic fascia. The subject lies in his/her back, and a flexion of the upper cervical spine is combined with a retraction movement of the lower cervical and upper thoracic spine, this in combination with inspiration.
10119114|NCT04411095|Placebo Comparator|Test without stretching|A placebo technique is performed by positioning the hands of the therapist on the thorax without pressure or performing a technique. Similar as the stretching technique, a deep inspiration is performed by the patient, for each of the intrathoracic cilinders. This without performing a retraction of the lower cervical and upper thoracic spine.
10119115|NCT04411459||COVID-19 pneumonia patients|Patients needing intubation and mechanical ventilation for COVID-19 related pneumonia without other primary causes of ICU admission
10119116|NCT04411108|Active Comparator|Exercise Instruction by PT and written handout|
10119117|NCT04411108|Experimental|Exercise Instruction by Motion Coach Technology|
10119118|NCT04411212|Active Comparator|Granulocyte colony-stimulating factor and platelet-rich plasma|
10119119|NCT04411212|Other|Control group|
10119120|NCT04411485||Group of Ankylosing Spondylitis|Patient with ankylosing spondylitis diagnosed by a rheumatologist
10119121|NCT04411485||Group of control|Healthy volunteers of the same age and gender as patients
10119122|NCT04411069|No Intervention|Patients without previous CINV|Patients who didn't have chemotherapy or that didn´t have any nausea and/or vomiting induced by chemotherapy (CINV) before surgery
10119123|NCT04411069|Other|Patients with previous CINV|Patients who had previous nausea and vomiting induced by chemoterapy.
10119124|NCT04411056|Experimental|Barrier box|Participants will have a barrier box placed during intubation
10119125|NCT04411056|No Intervention|No Barrier box|Participants will have routine intubation with no barrier box
10119126|NCT04410926|Placebo Comparator|control group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).~Neuromuscular electrical stimulation The control group received placebo NMES with no current stimulation. In another words, the current intensity was set at 0mA while standing on both feet for 30 minutes."
10119127|NCT04410926|Experimental|intervention group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).~Neuromuscular electrical stimulation~The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles. High-voltage pulsed current was set at frequency of 85 Hz with 5 seconds contraction time and 12 seconds rest time while the ramp-up and ramp-down time were 0.3 and 0.7 respectively. The current intensity was adjusted based on the individual tolerance without reporting pain or discomfort while standing on both feet. The stimulation time lasted each session for 30 minutes."
10119128|NCT04410835||Psychiatric patients|Psychiatric patients with ICD-10 (International Statistical Classification of Diseases and Related Health Problems) F2/F3/F4 diagnosis
9668928|NCT04557748||Physical Activity and Sleep Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
9668929|NCT04557748||Organ-Based Study|Women enrolled in the Prospective Observational Cohort Study with urinary urgency, with and without urgency incontinence.
9668930|NCT04557748||Organ-Based Study Controls|Women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency pr urgency incontinence.
9668931|NCT04557748||Qualitative Assessment of Patients with Urinary Urgency Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency who have treatment plans prescribed at the baseline visit.
9668932|NCT04554927|Experimental|WEB-application|
9668933|NCT04554927|Active Comparator|Standard accompaniment|
10119129|NCT04410835||Healthy Controls|Participants who do not have a psychiatric disorder or a first degree relative with psychiatric disorder.
10119130|NCT04410874|Experimental|Imvamune|Imvamune vaccine to be administered intratumorally at one of three doses on Days 0 and 4 of the study
10119131|NCT04410848||All patient with suspicion of choledocholithiasis|Patient with the suspect of common biliary duct stone for pain type colic in the right upper quadrant abdomen, the elevation of bilirubin, alkaline phosphatase, pancreatitis, dilated common bile duct and cholangitis. According to the criteria to assign the risk of choledocholithiasis. We are going to validate a scale based on intelligence artificial compared to the clinical predictor.
10119132|NCT04410887|Experimental|PISOXO|"st cycle of PIPAC during 1st laparoscopic exploration Three cycles of SOX~nd cycle of PIPAC during 2nd laparoscopic exploration Surgery Three cycles of SOX +/-OLAPARIB~PIPAC Intraperitoneal chemotherapy for PIPAC is Docetaxel Neoadjuvant Chemotherapy Patients will receive three cycles of a standard dose of Tegafur gimeracil oteracil potassium capsule (TGO) plus oxaliplatin (SOX) +Olaparib prior to curative gastrectomy.~Adjuvant chemotherapy Three cycles of SOX +/- OLAPARIB will be given as postoperative chemotherapy.~Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg oral twice a day"
10119133|NCT04410861|Active Comparator|Minimal Micropulse Arm|"Wavelength 810 577 Power 0.75 W 0.15 W DC 5% 5% Spot size 125um 100um Duration 0.3 sec 0.3 sec Number of spots 100-120 100-120~."
10119134|NCT04410861|Experimental|Panmacular Micropulse Arm|Wavelength 810 577 Power 1.7 W 0.425 W DC 5% 5% Spot size 500um 500um Duration 0.3 sec 0.3 sec Number of spots 400-450 400-450
10182857|NCT03770247|Experimental|intraoperative group (IOCPN group)|Intraoperative celiac plexus neurolysis Before closure of the abdomen the surgeon will expose the aorta at the level of the celiac trunk.With the stomach retracted inferiorly, the index and second finger of the surgeon's left hand straddle the aorta with the index finger placed on the splenic artery and the second finger on the common hepatic artery. we will use of a 20- gauge spinal needle (in contrast to the usual short intravenous needle) allows better visualization and access to this area, especially in deep patients, while a 10 ml syringe permits the surgeon to control the injection with the right hand alone.(10) Twenty ml of 90 % alcohol, five ml lidocaine 2%, five mg dexamethasone will be injected in each side of the aorta after aspiration to exclude intravascular or subarachnoid injection.
9966396|NCT01259739|Experimental|flavanol poor cocoa drink|( 13mg) dissolved in water, twice daily intervention
9966397|NCT01259752|Experimental|compression stockings|
9966398|NCT01259752|Placebo Comparator|standard non compressive stockings|
9966399|NCT01259765|Active Comparator|VHH|"The active substance is VHH batch 203027."
10182858|NCT03770247|Active Comparator|CT group (CTCPN group)|CT guided celiac plexus neurolysis After one week of the operation and the patient completely awake, the patient will be transferred to CT lab. The procedure will be done after attachment of basic monitors and transfusion of 500 ml saline in 20 G cannula before starting the procedure and the patient will be given 5 mg midazolam as a sedation. The procedure will be done by anesthetist and radiologist who had a good experience in celiac plexus neurolysis. In our study we will use the classic posterior bilateral approach. The patient will be in the prone position. After sterilization of the back by chlorohixidine 10 % , subcutaneous injection of 5 ml lidocaine as a local anaesthesia until a wheel will be formed then the procedure will be done. We will use 20 G Chiba needle under guidance of CT. Twenty ml of 95% alcohol , five ml lidocaine 2 % and five mg dexamethasone in each side of the aorta after aspiaration to exclude intravascular injection and subarachnoid injection
10182859|NCT03770234|Experimental|Treatment A: Transtec patch application for 96 hours|Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.
10182860|NCT03770234|Experimental|Treatment B: Transtec patch application for 72 hours|Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.
10182861|NCT03770117||Prehabilitation|"In this arm of the study, participants will undergo prehabilitation prior to surgery. This is intended to increase the participants overall health prior to surgery to try and increase their general well-being during and after surgery.~Prehabilitation is multimodal therapy comprising:~Assessment for malnutrition and nutritional support dependent on the outcome~Optimisation of management of pancreatic exocrine insufficiency~Assessment of muscle mass and strength~Individually tailored, goal directed exercise regimen under the care of physiotherapy"
10182862|NCT03770117||Standard Procedure|In this arm, participants will not receive any Rehabilitation prior to the surgery. This is the current standard care and will act as the control data for this study.
10182863|NCT03770208|Placebo Comparator|Control: Standard Care + Placebo|"Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV placebo (Lactated Ringers). Lactated Ringers will be delivered as a initial bolus and then run as a continuous infusion to mimic the volume (as per Kg) of study drug for 72-96 hours. Standard care will be determined by the care team with no limitations introduced by the research team. Medications utilized and dosing regimes will be recorded after the intervention."
10182864|NCT03770208|Experimental|Intervention: Lidocaine|Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV lidocaine. IV lidocaine will be administered as a bolus dose of 2 mg/kg (maximum dose 100 mg) followed by a 2 mg/kg/hr infusion for 72-96 hrs.
10182865|NCT03770065||Group A|
10182866|NCT03770065||Group B|
10182867|NCT03770325|Experimental|Berberine|berberine (500 mg orally twice a day)
10182868|NCT03770325|Placebo Comparator|Placebo|placebo (500 mg orally twice a day)
10182869|NCT03770000|Experimental|Tenalisib+Romidepsin|Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15
10182870|NCT03770312|Active Comparator|Low intensity statin group|Taking low intensity statin
10182871|NCT03770312|Active Comparator|Moderate intensity statin group|Taking moderate intensity statin
10182872|NCT03770104|Experimental|Intervention Group (5.5 plus weight)|ETT insertion depth using Spanish recommendations Patients included in the intervention group arm who are included in the study will be intubated using Spanish recommendations (5.5 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
9966400|NCT01259765|Placebo Comparator|Placebo|Placebo product
10119135|NCT04410770|Active Comparator|Active intervention|Participants assigned to the active treatment arm are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 6 week outcome. The participant is encouraged to continue completing the self-ratings, but does not receive any more support calls. After 6 more weeks, the 12 week outcome is assessed the participant's involvement with the study ends.
10119136|NCT04410770|No Intervention|Wait list|Wait list participants have no study activities for 6 weeks after completing the baseline assessment. After 6 weeks, list participants complete the 6 week assessment. After completing the assessment. wait list participants are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 12 week outcome and the participant's involvement with the study ends.
10119137|NCT04410809|Placebo Comparator|Placebo|The same composition as the active medication but without the active substance TA-46
10119138|NCT04410809|Experimental|TA-46|Decoy protein of the fibroblast growth factor receptor 3
10119139|NCT04411017|Active Comparator|1L PEG|
10119140|NCT04411017|Active Comparator|2L PEG|
9825925|NCT02400749|Placebo Comparator|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
10119141|NCT04411017|Active Comparator|2L sodium picosulfate|
10119142|NCT04410705|Experimental|Tendinopathy patients|Patients with tendinopathy will be administered ESWT
10119143|NCT04410692|No Intervention|Control|Participants' COVID-19 predictions are elicited via a survey
10119144|NCT04410692|Experimental|Treatment|Participants' COVID-19 predictions are elicited via a prediction market
10119145|NCT04411030|Experimental|Part 1|Oral administration of ASTX660 and itraconazole at specific time points.
10119146|NCT04411030|Experimental|Part 2|Oral administration of ASTX660 and midazolam at specific time points.
10119147|NCT04410731|Experimental|BM-MSC injections for low back pain|Single bilateral intra-articular injections of allogeneic BM-MSCs for lumbar facet joint arthropathy
10119148|NCT04410718||The intensive care unit cohort|Patients (with or without diabetes) with COVID-19 admitted to the intensive care unit
10119149|NCT04410718||The hospitalisation cohort|Patients with diabetes and COVID-19 admitted to the medical ward
9668934|NCT04552847|Experimental|Patients|"In the main part of the trial (part A) 75 patients with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/CT scan.~In part B of the trial 10 up to 20 patients with with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/MR scan."
9668935|NCT04550676|Experimental|High intensity interval training|
10119150|NCT04411004||Women who underwent shaving for rectal endometriosis|
10119151|NCT04410666|Experimental|GREEN TEA MOUTH WASH|an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C.
9528187|NCT03213288|Active Comparator|Cyanidin type anthocyanins|Black rice extract
9825926|NCT02400905|Experimental|BioMimics 3D Vascular Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Vascular Stent System
9966401|NCT01259791|Experimental|Statin|Individual-specific statin causing myopathy - i.e., Patients will receive the specific statin previously associated with myopathic symptoms in them (can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously).
9966402|NCT01259791|Placebo Comparator|Placebo|Identical placebo to patient-specific statin
10119152|NCT04410666|Placebo Comparator|Placebo|distilled water, in sterile glass containers.
10119153|NCT04410679|Experimental|injectabl PRF for treatment of internal root resorption|
10119154|NCT04410588|No Intervention|saline|saline for pain for nasal packing
9528188|NCT03213288|Placebo Comparator|Placebo|No anthocyanins
9966403|NCT01259804|Experimental|Peanut immunotherapy|Peanut flour
10119155|NCT04410588|Active Comparator|levobupivacaine|levobupivacaine for pain of nasal packing
10119156|NCT04410588|Active Comparator|fentanyl +levobupivacaine|fentanyle with levobupivacaine for pain of nasal packing
10119157|NCT04410601|Active Comparator|No dysphagia (after total thyroidectomy-TT)|"Patients s/p post-thyroidectomy without complication~*will NOT be enrolled to standard dysphagia-rehabilitation treatment"
10119158|NCT04410601|Experimental|Dysphagia (with at least one more complication of TT)|"Patients s/p post-thyroidectomy with both dysphagia and other documented TT complication such as vocal cord paralysis/hypocalcemia/surgical site infection etc.~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
10119159|NCT04410601|Experimental|Dysphagia (the only complication after TT)|"Patients s/p post-thyroidectomy dysphagia only.~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
10119160|NCT04410497|Experimental|Porcine xenograft|Conformité Européenne/European Conformity (CE)-marked dressing product used in clinical practise (Standard of care).
10119161|NCT04410497|Active Comparator|Silver foam|Conformité Européenne/European Conformity (CE)- marked dressing product used in clinical practise
10119162|NCT04410354|Active Comparator|MMPD + remdesivir|Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
10119163|NCT04410354|Placebo Comparator|Placebo + remdesivir|Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
10119164|NCT04410315||Tumorcraniotomy patients|
10119165|NCT04410393||sacrocolpopexy patients|Patients who underwent sacrocolpopexy for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
10119166|NCT04410393||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
10119167|NCT04410419|No Intervention|Standard Care|Standard care for patients with diabetes pre-operatively .
10119168|NCT04410419|Experimental|Carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
10119169|NCT04410471||Liver transplant patient after having Covid19|Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
10119170|NCT04410471||No immunosuppressed patient with previous Covid19|Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June
10119171|NCT04410510|Placebo Comparator|Control group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days Placebo capsule equivalent to 250mg of excipient every 12 hours for 14 days
10119172|NCT04410510|Experimental|Intervention group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days
10119173|NCT04410458|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic.
10119174|NCT04410458|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
10119175|NCT04410458|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
10119176|NCT04410458|Placebo Comparator|SMS with thank-you note|SMS content in this group will be thank-you note for their previous donation(s) .
10119177|NCT04410536|Other|Symptomatic drugs - bridge theray - mindfu|"abrupt withdrawal of overuse symptomatic drugs, with possibility to use indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide i.m. injection in case of vomiting;~oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day);~mindfulness practice daily with standard sessions by smartphone 6 minutes per day."
10119178|NCT04410614|Experimental|Free epithelial graft|Free epithelial graft at implant and teeth sites to increase the band of keratinized mucosa
10119179|NCT04410575|Experimental|Intervention Group (Pharmacist Interventions)|Participants enrolled in the intervention group will receive pharmacist interventions, in addition to standard care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians), at enrollment (month 0) and at months 1, 3, and 6
10119180|NCT04410575|Active Comparator|Control Group (Standard Pharmacist Care)|Patients randomized to the usual care groups will receive standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians) and physician care with no specific interventions for the duration of 6 months
10119181|NCT04410289|Experimental|Intervention Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the intervention group were positioned using props horizontally aligning the external auditory meatus (EAM) with the sternal notch (SN) and the chin with the sinciput. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
10119182|NCT04410289|Active Comparator|Control Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the control group were positioned freely according to the provider's preference. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
10119183|NCT04410276||Patients with enterococcal bloodstream infections|Adult patients (≥ 18 years of age) with ≥ 1 positive blood cultures with Enterococcus during hospitalization and who have repeat blood culture(s) within 7 days from the first positive culture will be included.
10119184|NCT04410302||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue samples during standard of care tumor biopsy or surgical resection to establish PDXs. Patients may also undergo collection of blood, saliva, and urine samples to compare DNA abnormalities to noncancer cells in order to determine if they were present before the cancer started or developed with it.
10119185|NCT04410263||COVID-positive ICU patients|The collective of COVID-positive patients on the ICU
10119186|NCT04410250|Active Comparator|Oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 1 will be instructed to clean the child's oral cavity by massaging the gingival rods with gauze and filtered water once a day at night.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
9966404|NCT01259817|Experimental|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
9966405|NCT01259817|Active Comparator|Aspirin|81 or 100 mg daily.
10119187|NCT04410250|Experimental|Absence of oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 2 will be advised not to perform any type of oral cavity cleaning of the newborn.~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
10119188|NCT04410432||Patient|Patient hospitalized with SARS-Cov2 infection proven by virological sampling.
10119189|NCT04410146|Experimental|Embolization|Middle Meningeal Artery (MMA) embolization
10119190|NCT04410146|Active Comparator|No Embolization|Standard Management
10119191|NCT04410068|Experimental|Electrical heating pad|"Electrical heating pad (WARMTAC device). Patients will be randomized to one arm.~In this arm, the WARMTAC device will be conected and warmed to 41 degrees before patients lay down."
10119192|NCT04410068|Experimental|forced-air warming device|Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down.
10119193|NCT04409925|Experimental|rhDNase1 (Pulmozyme, Roche/Genentech)|Single Arm: rhDNase1 (Pulmozyme, Roche/Genentech) 2.5 mg inhaled nebulisations BID, for a maximum of 14 consecutive days.
10119194|NCT04410016|Experimental|Staff Wellbeing Centre|Wellbeing Centres are rooms where staff employed at the hospital trust can go for a break, rest, relaxation, quiet time out, advice support or signposting. They are manned by Wellbeing Buddies who are support workers who offer advice and signposting services. The Centres are accessible to all staff at the Trust.
10119195|NCT04409899||Urological surgical patients during COVID-19 pandemic|During the COVID-19 pandemic, the urological patients in the need of a surgical intervention have been screened on the basis of the underline conditions, the priority of surgery, and risk-benefit assessment. A pre-surgical work-out was performed in the selected patients, with some of them being detected of COVID-19 at RT-PCR or suspected for it according to the risk-assessment survey. Enhanced blood tests and X-rays of the thorax were performed as baseline assessments. In case of development of post-surgical unspecific symptoms, clinical and laboratory work-out were performed before to expedite a new RT-PCR, which would have required preventive isolation of a patient in a COVID-19 ward. We evaluated the impact of COVID-19 in this selected cohort and the complications eventually associated with the viral infection.
10119196|NCT04409847||COVID+ PCR|Subjects who are SARS-CoV-2 PCR+ve and/or have diagnostic CXR or CT chest features of COVID -19
10119197|NCT04409847||COVID- PCR|subjects admitted with COVID-19 like symptoms but are SARS-CoV-2 PCR-ve and have CXR or CT chest that show low probability of COVID-19 will form the control group
10119198|NCT04409990|Other|Shear Wave Elastography|SWE value measurement will be added during the ERUS examination.
10119199|NCT04409912|Experimental|Sirolimus coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the vessel wall by inflating the sirolimus coated balloons at 2 minutes at rated burst pressure (typically 12 to 14ATM). All the lesions within the dialysis circuit with sirolimus coated balloon.
10119200|NCT04409912|Placebo Comparator|Plain balloon|The plain balloon or placebo will not be coated. The plain balloon will be inflated at 2 minutes at rated burst pressure (typically 12 to 14 ATM). Plain balloon will be applied to all the narrowed segment of the dialysis circuit
10119201|NCT04409977||Patient group|Patients suffering from cluster headache will be included in this group. When analysing the data, the investigators will distinguish those in the in-bout period from those in the out-bout period. People in this group may participate twice: once in the in-bout and once in the out-bout period.
10119202|NCT04409977||Control group|Participants not suffering from cluster headache will be included in this group.
10119203|NCT04410029|Experimental|Intervention|Standard counseling + Healthwise Decision Aid
10119204|NCT04410029|Active Comparator|Control|Standard counseling + a control informational handout.
10119205|NCT04410055|Active Comparator|Sitting|Three hours of sitting condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
10119206|NCT04410055|Active Comparator|Static standing|Four hours of static standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
10119207|NCT04410055|Active Comparator|Dynamic standing|Four hours of dynamic standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
10119208|NCT04409938|Experimental|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention.
10119209|NCT04409938|Experimental|Progressive Muscle Relaxation with Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds.
10119210|NCT04409938|No Intervention|Standard Practice|The standard practice of the lab was made.
10119211|NCT04409821|Experimental|Tele-delivered psychological intervention|Weekly tele-delivered psychological intervention
10119212|NCT04410003|Placebo Comparator|Placebo|Cellulose capsules, cloxacillin, electrolyte purgative (Peglyte)
10119213|NCT04410003|Active Comparator|Active|Capsules of stool from Protected donors, cloxacillin, electrolyte purgative (Peglyte)
10119214|NCT04410185|Experimental|MEDITATION|Meditation sessions will take place over 12 weekly sessions of 1.5 hours. A retreat (3 hours) will be realized after the 9th session
10119215|NCT04410120||Asthma with recent (<4/52) asthma attack|
10119216|NCT04409873|Placebo Comparator|Control (Distilled Water)|Over the counter: Distilled water
10119217|NCT04409873|Experimental|Oral-B Mouth Sore (H2O2) mouthwash|Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)
10119218|NCT04409873|Experimental|Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash|Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)
9668936|NCT04550676|Active Comparator|Continuous moderate intensity exercise|
10119219|NCT04409873|Experimental|CloSYS (ClO2) mouthwash|Over the counter: CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)
10119220|NCT04409873|Experimental|Listerine Mouthwash|Over the counter: Listerine Zero (Alcohol-Free)(Johnson and Johnson, USA) (C30H52O3)
10119221|NCT04410081|Experimental|14C-lazertinib|Participants will receive a single oral dose of 14C-lazertinib on Day 1.
10119222|NCT04410094|Experimental|Cohort 1: Lazertinib plus Itraconazole|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by itraconazole capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
10119223|NCT04410094|Experimental|Cohort 2: Lazertinib plus Rifampin|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by rifampin capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
10119224|NCT04410211|Active Comparator|Group S (inhalational Sevoflurane sedation)|"The inhalational anaesthetic agent and oxygen will be delivered via an anaesthetic circuit with a vaporizer (Sevotec 3, Ohmeda, Streeton UK) with a nasal mask.~Patients who are allocated for Sevoflurane will be given initial oxygen flow of 8L/min and then Sevoflurane was introduced at a concentration of 0.2% and was increased stepwise by 02% for every 30s up to a maximum of 1.0 minimum alveolar concentration (MAC; 2.05% end tidal). Patient's deepest sedation was recorded and adjusted to achieve optimal Observer's Assessment of Alertness/ Sedation Scale (OAAS) score of 3.~Inadequate or over sedation was treated by reducing or increasing the Sevoflurane concentration dial by 0.2 - 0.6% until the desired effect is reached.~Full vital signs monitoring are done for every participant"
10119225|NCT04410211|Active Comparator|Group M (Intravenous Midazolam sedation)|"Patients who are allocated for Midazolam will be given the similar nasal mask delivering 8L/min oxygen. However, Sevoflurane will not be introduced to these patients.~Midazolam is titrated slowly to achieve OAAS score of 3 but no more than 2.5mg is to be given within 2 minutes period to patients selected to be in Midazolam group.~Inadequate sedation is treated by giving slow titration of the medication based on the unblinded observer's judgement. Over sedation is treated by withholding the midazolam and continuing oxygen supplementation until the patient returned to the desired sedation level. No other sedative agents are allowed to be given to the patient or else patient will be excluded from this study."
10119226|NCT04410107||Severe Pneumonia|"Presence of fever or suspected lower respiratory infection, plus one of the following criteria:~1) respiratory rate> 30 movements / min; 2) severe respiratory distress 3) Pulse oximetry (SpO2) ≤93% in room air; and/or 3) Pulmonary infiltrates> 50% on chest imaging within 24-48hrs of symptom onset."
10119227|NCT04410107||Acute respiratory distress syndrome (ARDS)|"Onset: acute, i.e. within 1 week of known clinical insult or new or worsening respiratory symptoms; and~Chest imaging (e.g. X-ray or CT scan): bilateral opacities, not fully explained by effusions, lobar/lung collapse or nodules; and~Origin of pulmonary edema: respiratory failure not fully explained by cardiac failure or fluid overload; and~Degree of hypoxemia: arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg with positive end-expiratory pressure ≥ 5 cm H2O."
10119228|NCT04409808|Experimental|IRIS vitrectomy device|all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device
10119229|NCT04409535||Rural Living Community Member|Adult residents of a New Mexico rural county (as federally designated)
10119230|NCT04409535||Urban/Suburban Living Community Member|Comparison group: adult resident of a New Mexico urban/suburban city or town (as federally designated)
10119231|NCT04409717||Patients treated for type II endoleaks|Patients treated for type II endoleaks between the 01 January 2008 and the 31 March 2018 in the Cardiovascular and Thoracic Surgery Unit of Dijon Burgundy University Hospital
10119232|NCT04409522|Experimental|Test Group|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
10119233|NCT04409522|Active Comparator|Control Group|Participants in this group will receive the usual treatment of COVID-19
10119234|NCT04409626||Cases|
10119235|NCT04409626||Controls|Matched (5 controls per case) by date of birth +/- 180 days.
10119236|NCT04409444||Data (main study)|This study group is for any individual that attends and has a lung health check. The data collected for this study group is to evaluate the uptake and performance of a community-based lung health check / lung screening programme.
10119237|NCT04409444||Biomarker (sub-study)|This sub-study is for participants that are determined to require a CT scan through their lung health check and have also signed up to the data part of the study. This part of the study is to evaluate the potential for biomarkers to improve the early detection of lung cancer.
10119238|NCT04409431|Experimental|Adrenal Artery Ablation|Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol.
10119239|NCT04409431|No Intervention|Spironolactone|Patients in this group will be treated with aldosterone 20-80mg daily according to blood pressure
10119240|NCT04409691|Active Comparator|prednison group|
10119241|NCT04409691|Experimental|prednison+sirolimus group|
10119242|NCT04409704|Experimental|10 Hz|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 4-6 weeks
10119243|NCT04409600|Active Comparator|Home Based Gait Retraining + Saline Injection|
10119244|NCT04409600|Experimental|Home Based Gait Retraining + Botulinum Toxin Injection|
10119245|NCT04409600|Active Comparator|Supervised Gait Retraining + Saline Injection|
10119246|NCT04409600|Experimental|Supervised Gait Retraining + Botulinum Toxin Injection|
10119247|NCT04409587|No Intervention|NovoLog®-only|In the aspart-Only group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
10119248|NCT04409587|Active Comparator|Novolog® and Tresiba® Group|This study population will have an expertise in diabetes self-management with their insulin pump and Dexcom CGM. In the Novolog® and Tresiba® group, the subject will still take aspart via their pump for meals and correction boluses, but they will reduce the slow trickle (basal insulin) programmed in their pump to almost zero. Instead of receiving their normal basal insulin via CSII, the subject will injected degludec once or twice daily from an insulin pen for your basal insulin.
10119249|NCT04409756|Other|postassessment of the SRQ-T test|the SRQ -T will be obtained to all patients three days after the first assessment
10119250|NCT04409782|Experimental|Arm 1|Registered attendees of a group educational class events will have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
10119251|NCT04409782|Experimental|Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via a geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
10119252|NCT04409678|Experimental|activity|
10119253|NCT04409678|No Intervention|bed rest|
10119254|NCT04409730|Experimental|Children with Cerebral Palsy|"Aged 5-12 years, diagnosed as spastic diplegia or hemiplegia , having a level of I, II, III according to GMFCS"
10119255|NCT04409379||acute leukemia group|300 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
10119256|NCT04409613|Active Comparator|Clinical pharmacist-provided services+standard care group|that receive clinical pharmacist-provided services at the Warfarin Counseling Clinic plus standard medical care
10119257|NCT04409613|No Intervention|Standard care group|that will receive standard medical care
10119258|NCT04409769||Description of use of ceftaroline and ceftobiprole|description of patients and their PJI/BJI,conditions of use, adverse event
10119259|NCT04409548|Active Comparator|Lumbar Disc Hernaition Group|The number of participants in this group is anticipated to be 154. The pain intensity of the patients was recorded by a Visual Analog Scale (VAS) immediately before performing the analysis. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
10119260|NCT04409548|Active Comparator|Healthy Control Group|The number of participants in this group is anticipated to be 54. The participants were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
10119261|NCT04409548|Active Comparator|Preoperative and Postoperative Group|The number of participants in this group is anticipated to be 60. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day, before and 15 days after surgery.
10119262|NCT04409210|Experimental|Intervention Group|The intervention group will receive establishment of individual health records, cardiovascular risk assessment, popularization of medical knowledge, personalized reminders and routine treatment.
10119263|NCT04409210|Other|Control Group|The control group just receive routine treatment and routine management.
10119264|NCT04409223|Experimental|Famitinib|
10119265|NCT04409223|Active Comparator|Sunitinib|
10119266|NCT04409483|Active Comparator|Standard Care|Standard care for COVID-19 according to the national guidelines of Niger
10119267|NCT04409483|Experimental|Standard Care plus lopinavir/ritonavir|Standard care for COVID-19 according to the national guidelines of Niger plus lopinavir/ritonavir
10119268|NCT04409288|Experimental|Group A|Apalutamide followed by Enzalutamide Study participants will receive 12 weeks of oral apalutamide (240mg) daily, followed by five weeks of washout period, and then 12 weeks of oral enzalutamide (160mg) daily.
10119269|NCT04409288|Experimental|Group B|Enzalutamide followed by Apalutamide Study participants will receive 12 weeks of oral enzalutamide (160mg) daily, followed by five weeks of washout period, and then 12 weeks of oral apalutamide (240mg) daily.
10119270|NCT04409366|Active Comparator|Conventional Crown Lengthening; CCL|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days.
10119271|NCT04409366|Experimental|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan
10119272|NCT04409496|Experimental|Intervention group|Chat-based instant messaging support + Self-help booklet
10119273|NCT04409496|Active Comparator|Control group|SMS message support + Self-help booklet
10119274|NCT04409392||Prothestic joint infection due to Staphylococcus lugdunensis|Patients having had a prosthetic joint infection with Staphylococcus lugdunensis
10119275|NCT04409327|Experimental|10 mg daily RTB101|TORC1 inhibitor
10119276|NCT04409327|Placebo Comparator|Placebo|Placebo
10119277|NCT04409119|Experimental|HIS/LBB pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS, to correct the LBBB or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead. If that is not possible either, a left ventricular (LV) lead is implanted.
10119278|NCT04409119|Active Comparator|LV pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.
10119279|NCT04409067||TMD-pain group|The TMD-pain group consisted of 30 children aged between 7.1 and 12.3 with a pain-related TMD diagnosis. All the patients in the TMD-pain group had myogenous or arthrogenous TMD according to the RDC/TMD protocol.
10119280|NCT04409067||pain-free TMD group|The pain-free TMD group consisted of 30 children between 7.3 and 12.6 years of age. To be included in the pain-free TMD group the participants had to meet Axis I of the RDC/TMD criteria for a pain-free diagnosis.
10119281|NCT04409067||non-TMD group|The non-TMD group comprised 30 children aged between 7.2 and 12.5 without any recognised TMD based on RDC/TMD, Axis I.
10119282|NCT04409132|Experimental|Triferic AVNU infusion pre-dialyzer|Patients will receive one (1) 6.75 mg Fe dose of Triferic AVNU by continuous infusion over 3 hours into the predialyzer blood line.
10119283|NCT04409132|Experimental|Triferic AVNU for injection at T=0 and T= 3 hours|Patients will receive two (2) doses of Triferic AVNU 3.4 mg IV (2.25 mL) at T=0 and T=3 hours of hemodialysis into the venous drip chamber.
10119284|NCT04409132|Experimental|Triferic AVNU for injection at T=0|Patients will receive one (1) dose of Triferic AVNU 0.08 mg/kg IV, up to 6.75 mg Fe, at T=0 of hemodialysis into the venous drip chamber.
10119285|NCT04409132|Experimental|Triferic AVNU for injection at T=0, T=1.5 and T= 3 hours|Patients will receive three (3) doses of Triferic AVNU 2.25 mg Fe (1.5 mL) at T=0, T=1.5 and T=3.0 hours of hemodialysis into the venous drip chamber.
10119286|NCT04409145|Experimental|VT30|VT30 is a PI3K-inhibitor prodrug, formulated as a topical gel and dispensed from a metered dose pump; administration is once or twice daily, applied to target-treatment area(s) on the skin. One pump action dispenses 250 µL of gel, intended to treat an area of 140 cm2.
10119287|NCT04409028|Active Comparator|indirect restoration|
10119288|NCT04409028|Active Comparator|direct restoration|
10119289|NCT04408781|Experimental|Ridge expansion by osseodensifcation|Ridge expansion and osteotomy drilling by osseodensifcation in conjunction with simultaneous implant placement in narrow ridges
10119290|NCT04408781|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
10119291|NCT04408872|Active Comparator|EGD|SUBJECT WILL UNDERGO ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)
10119292|NCT04408872|Experimental|EUS|SUBJECT WILL UNDERGO ENDOSCOPIC ULTRASOUND (EUS)
10119293|NCT04408716|Experimental|Ablation Index Guided High-Power Short-Duration Group|For patients assigned to undergo AF ablation with ablation index guided high-power short-duration strategy, point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
10119294|NCT04408716|Active Comparator|Standard Radiofrequency Ablation Group|For patients assigned to undergo AF ablation with standard radiofrequency ablation group, point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
10119295|NCT04408690|Experimental|Rehabilitation and optional delayed ACL reconstruction|
10119296|NCT04408690|Active Comparator|Immediate ACL reconstruction + rehabilitation|
10119297|NCT04408859||NACS|The patients with advanced gastric cancer who received neoadjuvant chemotherapy followed by surgery（NACS）.
10119298|NCT04408859||SA|The patients with advanced gastric cancer who received surgery alone.
10119299|NCT04408742||females with Multiple Sclerosis|patients with a confirmed diagnosis of MS according to the McDonald criteria, physician-administered Expanded Disability Status Scale (EDSS) range of 1-3.5, having regular menstrual cycle (between 21-35 days), and cognitive levels to give history and following the instructions
10119300|NCT04408586|Active Comparator|Phentermine - Topiramate Extended Release group|
10119301|NCT04408586|Placebo Comparator|Placebo Group|
10119302|NCT04408703||Ulcerative colitis in clinical remission|Clinical remission with SCCAI <3 at baseline and stable remission for the last 3 months
10119303|NCT04408846|Other|Minimally invasive lumbar fusion|
10119304|NCT04408846|Other|Open posterior lumbar fusion|
10119305|NCT04408989|Experimental|MB02-SP (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
10119306|NCT04408989|Experimental|MB02-DM (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
10119307|NCT04408989|Active Comparator|US licenced Avastin®|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
10119308|NCT04408768||Normal RBS|Normal RBS on ICU admission and controlled blood sugar within 24 hours
10119309|NCT04408768||High RBS|High RBS on ICU admission and uncontrolled blood sugar during first 24 hours
10119310|NCT04409171||PD|pancreaticoduodenectomy
10119311|NCT04409171||DP|distal pancreatectomy
10119312|NCT04408911||Midazolam|Critically ill intensive care unit patients receiving midazolam
10119313|NCT04408911||Lormetazepam|Critically ill intensive care unit patients receiving lormetazepam
10119314|NCT04408534|Active Comparator|continuous positive airway pressure|Patients receive continuous positive airway pressure as a mode of noninvasive ventilation
10119315|NCT04408534|Experimental|bilevel positive airway pressure|Patients receive bilevel positive airway pressure as a mode of noninvasive ventilation
10119316|NCT04408599|Experimental|NC410|NC410 for IV infusion of various dose strengths administered in 14 day dosing cycles
10119317|NCT04408547||soft catheter|Patients who underwent embryo transfer with a soft catheter
10119318|NCT04408547||stiff catheter|Patients who underwent embryo transfer with a stiff catheter because soft couldn't pass
10119319|NCT04408612||Dyspnea in stable coronary artery disease|Stable patients with dyspnea and coronary artery disease
10119320|NCT04408573|No Intervention|Regular Continuous High Frequency|Patient remains 2 weeks in the currently chosen stimulation protocol.
10119321|NCT04408573|Experimental|Cycling High Frequency|Patient is stimulated with the same polarity, voltage/current, pulse width and frequency as the currently chosen stimulation protocol, but with cycling stimulation: 40sec On - 02 sec OFF
10119322|NCT04408573|Experimental|Continuous Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz). Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
9966406|NCT01259830|Experimental|Arcoxia® 120 mg|
10119323|NCT04408573|Experimental|Cycling Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz) and cycling stimulation: 40sec On - 02 sec OFF. Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
10119324|NCT04408521|Experimental|NEUROFEEDBACK|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. Self-regulation of alpha rhythm is reflected in the dynamically varying opacity of the video replay window, i.e. the window would turn lighter/darker and reveal/obscure video content during episodes of low/high alpha amplitude, respectively.
10119325|NCT04408521|Placebo Comparator|CONTROL|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. The recording is passive without real-time EEG neurofeedback (i.e. constant brightness and volume).
10119326|NCT04408495|Experimental|Intervention group_MRA|Recruitment maneuvers and high PEEP
10119327|NCT04408495|Active Comparator|Control group|No recruitment maneuvers and low PEEP
10119328|NCT04408365||COVID-19 patients|Adult COVID-19 patients admitted to intensive care units
10119329|NCT04408352|Active Comparator|RF Trigone Ablation Treatment Arm|A compatible standard cystoscopy lens (30°) will be inserted into the Hologic trigone RF Device. The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Ablations at the trigone will be created using the Hologic trigone RF ablation device together with the compatible standard commercially available RF cannula and generator. It is expected that a subject would receive between 4-6 ablations to completely treat the appropriate area of the trigone. At the completion of the procedure, 200 ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge.
10119330|NCT04408352|Sham Comparator|RF Trigone Ablation Sham Arm|"The sham procedure will mimic the Hologic trigone RF ablation device procedure to maintain subject blinding and provide the most accurate assessment of control data while minimizing risk to the subject.~The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Suction will be applied to the bladder wall and the cannulas (needles) will be introduced into the bladder wall. Energy will not be delivered to the tissue when each sham ablation is started. In order to maintain blinding of the subject, the typical sounds that Hologic trigone RF ablation device makes during actual ablation/fulguration will be replicated. The simulated ablation procedure will be repeated as many times as necessary to cover the area of the trigone. 4 to 6 sham ablations would be required. At the completion of the procedure, 200ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge."
10119331|NCT04408378||mild pneumonia|The patients who has followed in the ward
10119332|NCT04408378||severe pneumonia|The patiens who has followed in the intensive care unit
10119333|NCT04408378||control group|patients who has not covid 19 pneumonia
10119334|NCT04408651|Experimental|Acceptance and Commitment Therapy|
10119335|NCT04408651|Experimental|Compassion-Focused Therapy|
10119336|NCT04408469|Experimental|Online EQuIP|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
10119337|NCT04408469|Placebo Comparator|Self-Monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
10119338|NCT04408456|Active Comparator|Post Exposure Prophylaxis (PEP) Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene Plus Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
10119339|NCT04408456|Other|Control Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
10119340|NCT04408391||COVID-19 patients with anosmia|Patients reporting loss of smell and scoring < 30 on a VAS 0-100 for ability to detect n-Butanol diluted 1/1000
10119341|NCT04408391||COVID-19 patients without anosmia|Patients reporting no loss of smell and scoring > 80 on a VAS 0-100 for ability to detect n-Butanol diluted 1/16000
10119342|NCT04408274|Experimental|Computerized Tests|
10119343|NCT04408274|Placebo Comparator|Placebo Control|
10119344|NCT04408404||Type A aortic dissection|Patient operated for type A acute aortic dissection between 01 January 2007 and 31 December 2017 in Dijon Burgundy University Hospital
10119345|NCT04408313|Experimental|XR-B|Extended-release buprenorphine
10119346|NCT04408313|Active Comparator|XR-NTX|Extended-release naltrexone
9966407|NCT01259830|Placebo Comparator|Sugar pill|
10119347|NCT04408261|Experimental|Buqitongluo Granule|Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
10119348|NCT04408261|Placebo Comparator|Placebo|Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.
10119349|NCT04408326||Angiotensin II|Patients with COVID-19 and acute respiratory distress syndrome who received angiotensin II as an add-on vasopressor will be collected
10119350|NCT04408326||Anakinra|Patients with COVID-19 and acute respiratory distress syndrome who received Anakinra (interleukin 1 receptor antagonist) will be collected
10119351|NCT04408326||Angiotensin II control|Patients with COVID-19 and acute respiratory distress syndrome who also received vasopressor support will be matched to angiotensin II group by date of intensive care unit admission, age, history of hypertension, history of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, respiratory support
10119352|NCT04408326||Anakinra control|Patients with COVID-19 and acute respiratory distress syndrome will be matched to Anakinra group by matching age and date of intensive unit care admission
10119353|NCT04408287|Experimental|Intervention|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
10119354|NCT04408144|Experimental|StudyGroup|Patients will receive an addition of dydrogesterone (Duphaston) to the standard treatment for luteal phase support
10119355|NCT04408144|No Intervention|Control Group|Patients will receive the standard treatment for luteal phase support without Dydrogesterone
10119356|NCT04408443|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
10119357|NCT04408443|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
10119358|NCT04408209|Experimental|Convalescent Plasma|Convalescent Plasma - early treatment of patients with severe COVID-19
10119359|NCT04408053|Experimental|Preventive fixation of the contralateral femoral neck|Mini-invasive preventive fixation of the contralateral femoral neck : 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
10119360|NCT04408053|No Intervention|No fixation|
10119361|NCT04408157|Experimental|Self-management booklet|Self-management booklet: developed drawing on existing evidence and work conducted by researchers at the Health Psychology section at KCL, tailored to the current circumstances in response to the COVID-19 pandemic.
10119362|NCT04408157|No Intervention|Education only (waiting-list)|Participants allocated to the waiting-list control arm will receive a link via email to educational materials related to COVID produced by King's College London for an online event and will be provided with the self-management booklet after completing the T2 assessment and qualitative interview. The topics covered in the online event are the same as the ones included in the self-management booklet, without structured guidance and behaviour change techniques to facilitate behaviour change.
10119363|NCT04408027|Experimental|Virtual-Care Cognitive Behavioural Therapy|
10119364|NCT04408235|Active Comparator|Low-Dose LMWH|Enoxaparin 4000 IU daily
10119365|NCT04408235|Experimental|High-Dose LMWH|Enoxaparin 70 IU/kg twice daily
10119366|NCT04407975|Experimental|Betamethasone|Patients will receive 14 mg (2 ml) intramuscular betamethasone
10119367|NCT04407975|Placebo Comparator|Placebo|Patients will receive an equivalent volume of normal saline
10119368|NCT04408079|Experimental|TQB3558 Tablets|TQB3558 tablets administered orally once. Then TQB3558 tablet administered orally, once daily in 28-day cycle after 4 days of first administration.
10119369|NCT04407728|Experimental|precocious EchoMorpho-T1|Women whose fetus is at high risk of congenital heart disease after the 1st trimester screening echo (EchoT1), will benefit from an early morphological ultrasound centered on the heart (EchoMorpho-T1) by a sonographer referent between 11 and 14 weeks +/- of an early fetal heart ultrasound (EchoCoeur-T1) between 11 and 15 weeks by a cardio-pediatrician in the event of an abnormality with the EchoMorpho-T1.
10119370|NCT04408066|Experimental|Arm A:Suspected COVID-19 patients|Arm A: Suspected COVID-19 Patients - SARS-CoV-2 viral antigen test swab and blood sample for SARS-CoV-2 IgG/IgM
10119371|NCT04408066|Experimental|Arm B: Previously positive COVID-19 patients|Arm B: Previously Positive COVID-19 patients - SARS-CoV-2 IgG/IgM blood sample. Capillary fingerstick samples will additionally be collected in Stage 2.
10119372|NCT04407949|Other|event detection|
10119373|NCT04408001||Symptomatic individuals|"Hospital staff identified by the COVID-19 case census cell :~who have been infected (confirmed by a positive RT-PCR result on a nasopharyngeal swab)~OR who have displayed clinical signs compatible with COVID-19 despite a negative RT-PCR result."
10119374|NCT04408001||Asymptomatic individuals|Hospital staff who have not been identified by the COVID-19 case census cell.
10119375|NCT04408014||HC-USP|Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
10119376|NCT04408014||CORAS|Refugees living in the city of São Paulo
10119377|NCT04408014||Hemocenter|Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
10119378|NCT04408014||CPP - Butantan Penitentiary Progression Center|Participants of the CPP - Butantan Penitentiary Progression Center
10119379|NCT04408014||CHSP - Penitentiary System Hospital Center|Participants of the CHSP - Penitentiary System Hospital Center
10119380|NCT04408014||SABE (Health, Wellness and Aging)|Participants of the SABE Project (Health, Wellness and Aging)
10119381|NCT04408014||ILPI - Long-Term Care Institution for the Elderly|Residents of the Long-Term Care Institution for the Elderly of Botucatu
10119382|NCT04408014||ICR-USP - Children's Institute of HCFMUSP|Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
10119383|NCT04407741|Experimental|SHR2554+ SHR1701|Drug: SHR2554 recommended dose from phase Ⅰstudy, PO, twice a day, every 3 weeks SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
10119384|NCT04407741|Experimental|SHR1701|Drug: SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
10119385|NCT04407754|Placebo Comparator|Control Arm|This group will receive placebo powder twice daily.
10119386|NCT04407754|Active Comparator|Inositol Arm|This group will receive myo-inositol (2,000mg) plus d-chiro-inositol (50mg) supplement powder twice daily.
10119387|NCT04408170||Work Stream A|Patients that are recruited in hospital with either query COVID-19 or who have tested positive for COVID-19.
10119388|NCT04408170||Work Stream B|Known COVID-positive and/or COVID-negative community testing
10119389|NCT04408170||Work Stream C|Undifferentiated community testing
10119390|NCT04407793||Diverticulitis Group|Patients with acute diverticulitis episode
10119391|NCT04407793||Diverticulosis group|Patients diagnosed with diverticulosis without any acute diverticulitis episode
10119392|NCT04407793||Non-diverticulosis|Patients without diverticulosis
10119393|NCT04407871|Experimental|acupuncture and CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after embryo transfer (ET). They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
10119394|NCT04407871|Placebo Comparator|acupuncture and placebo CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
10119395|NCT04407871|Placebo Comparator|control acupuncture and CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
10119396|NCT04407871|Placebo Comparator|control acupuncture and placebo CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
10119397|NCT04407832|Active Comparator|low dose PPI|40 mg esomeprazole IV for three days followed by esomeprazole 40 mg po daily for two months
10119398|NCT04407832|Active Comparator|high dose PPI|40 mg esomeprazole IV every 6 hr for 3 days followed by 40 mg po daily for two months
10119399|NCT04408131|Experimental|Homeless people|Blood sample
10119400|NCT04407884|Experimental|study arm|Subjects will receive an active study device.
10119401|NCT04407650|Active Comparator|Metformin|Oral 1000 mg BD
10119402|NCT04407650|Experimental|Ursodeoxycholic acid|Oral 500 mg BD
10119403|NCT04407910|Experimental|Air-powder polishing device|
10119404|NCT04407910|Experimental|Rubber-cup+paste|
10119405|NCT04408118|Experimental|Atezolizumab + Paclitaxel + Bevacizumab (Avastin®)|"All eligible patients will be treated with atezolizumab (840 mg) intravenously on days 1 and 15, Paclitaxel (90 mg/m2) on days 1, 8 and 15 via IV infusion and Bevacizumab (Avastin® 10mg/kg) intravenously on days 1 and 15.~Treatment cycles and patient visits are organized in scheduled cycles of 28 days."
10119406|NCT04407819||diabetes mellitus type 2|36 patients with diabetes mellitus type 2, aged 20-80 years, attending endocrinology outpatient clinics were studied for the assessment of muscle mass and function compared to controls.
10119407|NCT04407819||CONTROLS|14 community people who visited the endocrinology outpatient hospital clinic for a routine checkup, or with a non-related to diabetes disease.
10119408|NCT04407559||Groupe 1|Group 1: Rheumatoid arthritis seropositive for RF (+)
10119409|NCT04407559||Groupe 2|Group 2: Rheumatoid arthritis seronegative for RF (-)
10119410|NCT04407702|Experimental|Control Group|The volunteers in this group will receive the same hygiene instructions as the other groups and will undergo both treatments, except that water will be used instead of the sealant and the laser device will be set to a power of 0 W. In other words, the same irradiation procedure will be performed but without the emission of light.
10119411|NCT04407702|Experimental|Sealant Group|The volunteers in this group will receive treatment with sealant (Permaseal - Ultradent), which is a photopolymerizable methacrylate-based resin.
10119412|NCT04407702|Experimental|Low-Level Laser Group|The volunteers in this group will receive irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation.
10119413|NCT04407702|Experimental|Low Level Laser + Sealant Group|The volunteers in this group will receive the same irradiation administered to Low-level Laser Group. During the last session, these volunteers will also receive the same sealant applied in Sealant Group.
10119414|NCT04407663||Bariatric Patient|Inclusion criteria were as follows: obese adults (> 18 years of age, BMI> 40 or > 35 with comorbidities) older than 18 years; patients undergoing bariatric surgery within 6 months; patients who required clinical and instrumental control; presence of a caregiver in case of subject with cognitive impairment; patients with a history of bariatric surgery who requested a first outpatients access or established patients who requested an outpatients' visit for an emerging problem.
10119415|NCT04407715|Placebo Comparator|High Flow Anesthesia, Low Flow Anesthesia|. The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow. Group 1 (n = 40) was operated under high flow anesthesia with 50% O2 - 50% air at 2 L/min and desflurane at 1.1 MAC for the duration of the surgery. For anesthesia maintenance, Group 2 (n=40) was administered 50% oxygen - 50% air at 2 L/min and desflurane for 10-15 minutes. After reaching 1.1 MAC, it was switched to minimal flow with 50-60% oxygen- 40-50% air at 0.5 L/min and desflurane. 10 minutes before the end of the surgery, it was switched to high flow with 50% oxygen -50% air at 2 L/min.
10119416|NCT04407715|Active Comparator|Peroperetive Optic Nerve Sheath Diameter|Optic nerve sheath diameter measurements were performed by an experienced and the same anesthetist. In the measurements, the GE Healthcare Logiq e series USG device and 12-MHz linear probe were used. Longitudinal and transverse axis images were obtained on both eyelids while the patient was in the supine position. Measurements were taken 3 mm behind the optic nerve head
10119417|NCT04407624|Experimental|Intermittent Exercise Group|Warm-up, loading (walking, squat, sitting down on a chair, limb movements with weights, stepping on steps, walking on different floors), cooling and relaxation exercises
10119418|NCT04407624|Active Comparator|Control Group|Warm-up, loading (brisk walking at 60-85% of maximum heart rate), cooling and relaxation exercises
10119419|NCT04408040|Other|Critical Patients|
10119420|NCT04408040|Other|Severe Patients|
10119421|NCT04408040|Other|High Risk|
10119422|NCT04408040|Other|Health Care Providers|
10119423|NCT04407520||Adult patients with intellectual and/or physical disabilities|Adult patients with intellectual and/or physical disabilities requiring dental treatment under general anesthesia
10119424|NCT04407429||Health care workers|Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
10119425|NCT04407429||Patients|Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples.
10119426|NCT04407416|Active Comparator|Healthy subjects|The breath of all patients with positive FIT (fecal immunochemical test) but negative colonoscopy will be sampled using a breath sampler
10119427|NCT04407416|Active Comparator|Colorectal Cancer patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colorectal cancer detected by colonoscopy will be sampled using a breath sampler
10119428|NCT04407416|Active Comparator|Colonic Polyps patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colonic polyp detected by colonoscopy will be sampled using a breath sampler
10119429|NCT04407468||COVID|Patients with or without prone position
10119430|NCT04407182|Experimental|Viusid Plus Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.~A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care.~Treatment duration: 21 days."
10119431|NCT04407182|No Intervention|Control|"A total of 60 subjects will be randomized 2: 1 in this study. 20 Control patients will be assigned to standard of care.~Treatment duration: 21 days."
10119432|NCT04407273||with statins|Covid-19 infected patients with statins
10119433|NCT04407273||without statins|Covid-19 infected patients without statins
10119434|NCT04407338|Experimental|B-DYN Device|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
10119435|NCT04407338|Active Comparator|Conventional bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
10119436|NCT04407455||Children with cerebral palsy|Children who will be referred to pediatric dentistry above the age of 2 years.
10119437|NCT04407455||Children with typical development|Children who will be referred to pediatric dentistry above the age of 2 years.
10119438|NCT04407364||Intervention Cohort|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
10119439|NCT04407364||Historical Cohort|Primary and Revision total hip arthroplasty patients between 18-85 years of age
10119440|NCT04407442|Experimental|Treatment (azacitidine, dexamethasone, daratumumab)|"PRE-INDUCTION (CYCLE 0): Patients receive azacitidine IV on days -7 to -3 in absence of disease progression or unacceptable toxicity.~INDUCTION (CYCLES 1-2): Patients receive azacitidine IV on days 22-26, dexamethasone IV or orally (PO), and daratumumab subcutaneously (SC) over 3-5 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 3-6): Patients receive azacitidine IV on days 22-26 of cycle 3 and on days 1-5 of cycles 5-6, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity~MAINTENANCE (CYCLES 7+): Patients receive azacitidine IV on days 1-5, dexamethasone IV or PO, and daratumumab SC over 3-5 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity"
10119441|NCT04407260||Intervention|Patients on oxygen hoods who have fail conventional high-flow oxygen delivery systems.
10119442|NCT04407260||Control|Patients maintained on conventional high-flow oxygen delivery systems (such as non-rebreather masks, high-flow nasal cannula, BiPAP, CPAP) or who have failed on these conventional symptoms and were subsequently mechanically ventilated.
10119443|NCT04407195||Healthcare Providers|Healthcare workers (physicians and nurses) who have interacted with patients with known or suspected COVID-19.
10119444|NCT04407494||COVID-19|Healthcare workers and adult outpatients attending the COVID-19 screening center of the University Hospital of Montpellier, France.
10119445|NCT04407169||Patients without chronic respiratory disease|All patients hospitalized for severe CoVid-19 without chronic respiratory disease
10119446|NCT04407169||Patients with chronic respiratory diseas|Patients hospitalized for severe CoVid-19 with one chronic respiratory disease
9528276|NCT03212157|Experimental|GT3|Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.
9966408|NCT01259843||Acute Aortic Syndrome|Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of acute aortic syndrome whose diagnosis was subsequently confirmed in due course of hospitalization by further investigations.
9966409|NCT01259882|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Cohort 1
9966410|NCT01259882|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Cohort 2
9966411|NCT01259882|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Cohort 3
9966412|NCT01259882|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Cohort 4
9966413|NCT01259882|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Cohort 5
9966414|NCT01259882|Experimental|Cohort 6: Experimental intervention: PF-05089771 or placebo|Cohort 6
9966415|NCT01259895||Obesity|BMI > 30kg/m2
9966416|NCT01259895||Normal weight|BMI between 19 and 24,9kg/m2
9966417|NCT01259908||Laparoscopic vs open Ygraft|Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
9966418|NCT01259921|Experimental|Neurofeedback T4-P4|40 sessions of SMR neurofeedback training using T4-P4 placement administered twice weekly
9966419|NCT01259921|Active Comparator|Neurofeedback T3-T4|40 sessions of SMR neurofeedback using T3-T4 placement training administered twice weekly
9966420|NCT01259934|No Intervention|Arm A|Observation only - no therapy
9966421|NCT01259934|Experimental|Arm B Interferon 1 year|Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months
9966422|NCT01259934|Experimental|Arm C Interferon 2 years|"Two year arm Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months"
9966423|NCT01259947|Experimental|Lippia alba|
9966424|NCT01259960||BMI < 25|Body Mass Index (BMI) according to WHO definition. BMI < 25 is defined as 'normal weight'.
9966425|NCT01259960||25 <= BMI < 30|Body Mass Index (BMI) according to WHO definition. BMI >= 25 and < 30 is defined as 'overweight'.
9966426|NCT01259960||BMI >= 30|Body Mass Index (BMI) according to WHO definition. BMI >= 30 is defined as 'obese'.
9966427|NCT01259973|Experimental|Risperidone|
9966428|NCT01259973|Placebo Comparator|Placebo|
9966429|NCT01259973|Experimental|Haloperidol|
9966430|NCT01259986|Experimental|Laser treatment|
9966431|NCT01259999|Experimental|Energy dense formula|
9966432|NCT01260012|Experimental|praziquantel+antioxidant|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In additions, antioxidant suppliment will be given daily for a period of one year
9966433|NCT01260012|Active Comparator|Praziquantel +placebo 2mths then antioxidant for 10 months|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
9966434|NCT01260012|No Intervention|Praziquantel therapy with placebo supplement|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for a period of one year.
9966435|NCT01260025|Experimental|PEDylated Recombinant Human Endostatin|PEDylated Recombinant Human Endostatin
9966436|NCT01260064|Active Comparator|Open appendectomy|The subjects will have open appendectomy procedure.
9966437|NCT01260064|Active Comparator|Metal endoclip|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
9966438|NCT01260064|Active Comparator|Intracorporeal suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
9966439|NCT01260077||Experimental group|The sample was composed of 78 individuals (156 ears), 40 females (80 ears) and 38 males (76 ears).
9966440|NCT01260090|Experimental|Vagus Nerve Stimulation|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
9966441|NCT01260090|Sham Comparator|No Stimulation|
9966442|NCT01260103|Active Comparator|Temozolomide (TMZ)|Study subjects receive TMZ for 13 cycles
9966443|NCT01260103|Experimental|ANP Therapy|Escalating doses of ANP therapy are given daily for 52 weeks.
9966444|NCT01260116||1|Ziprasidone,Zeldox capsule
9966445|NCT01260129|Experimental|Silodosin 8 mg|
9966446|NCT01260129|Experimental|Silodosin 4 mg|
9966447|NCT01260155|Experimental|Treatment A Fasted|
9966448|NCT01260155|Experimental|Treatment B Fasted|
9966449|NCT01260155|Experimental|Treatment C Food Effect|
9966450|NCT01260168||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.
10119447|NCT04407403|Experimental|Tai Chi tailored for lowering blood pressure (PRESSURE)|During the 12-week Tai Chi intervention, participants in the PRESSURE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the PRESSURE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
10119448|NCT04407403|Experimental|Tai Chi tailored for improving balance (BALANCE)|During the 12-week Tai Chi intervention, participants in the BALANCE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the BALANCE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
10119449|NCT04407403|No Intervention|control group (CONTROL)|During the 12-week Tai Chi intervention, participants in the CONTROL group performed their regular daily activities. In addition, participants in the CONTROL group were instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed. Of note, both PRESSURE and BALANCE were offered to participants assigned in the CONTROL group after data collection was completed.
10119450|NCT04407312|Experimental|CILO group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~For the CILO group, cilostazol-SR 200 mg daily was added to dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Cilostazol-SR, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
10119451|NCT04407312|Placebo Comparator|Placebo group|"Intervention:~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.~In the Placebo group, placebo tablet was administered on top of dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.~Drug:~Placebo, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
10119452|NCT04407247|Active Comparator|Arm I (infliximab)|Patients receive infliximab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
10119453|NCT04407247|Experimental|Arm II (vedolizumab)|Patients receive vedolizumab IV over 1 hour at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
10119454|NCT04407208|Experimental|Convalescent plasma recipient|Recipients receive 3 times of each 100 ml convalescent plasma on day 0, 3, and 6
10119455|NCT04407234|Experimental|Tirzepatide + Acetaminophen|Tirzepatide administered subcutaneously (SC) and acetaminophen administered orally.
10119456|NCT04407351|Other|Arm Green LED light - Red LED light|Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks, the rest of the time indoors is not limited by light. Then crossover to red light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks.
10119457|NCT04407351|Other|Arm Red LED light - Green LED light|Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks, and the rest of the time indoors is not restricted by light. Then crossover to green light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks.
10119458|NCT04407130|Active Comparator|Tab Ivermectin +Cap Doxycycline|"200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~+ Placebo one tablet D2-5"
10119459|NCT04407130|Active Comparator|Tab Ivermectin|"Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5~+ Placebo two tablets D1 followed by Placebo one tablet D2-5"
10119460|NCT04407130|Placebo Comparator|Placebo|"Drug: Placebo~3 Placebo tablets D1 followed by 2 tablets D2-5"
10119461|NCT04407299||1|180 patients diagnosed with autoimmune rheumatic disease. Patients are RA SLE Rhupus AS Behcet Sjogren Vasculitis FM Polymyalgia APA Sarcoidosis IBD Scleroderma DM PSA Mixed
10119462|NCT04407299||2|control group composed of 180 healthy individuals (matched for age and sex)
10119463|NCT04407325|Experimental|AeoNose|the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
10119464|NCT04407078|Experimental|Sugammadex group|Sugammadex group receives the intravenous sugammadex of 2 mg/kg.
10119465|NCT04407078|Placebo Comparator|Neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
10119466|NCT04407390|Placebo Comparator|Control|Patients receiving placebo.
10119467|NCT04407390|Experimental|NR|Patients receiving nicotinamide riboside (NR-E)
10119468|NCT04407091|Experimental|[14C]AZD4831 Oral Solution|One 10 mg dose of [14C]AZD4831 Oral Solution
10119469|NCT04407013|Experimental|A|Experimental group with application of the standardized care pathways and symptom management education
10119470|NCT04407013|Other|B|Control group with usual care (symptom monitoring only)
10119471|NCT04407065|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
10119472|NCT04407065|Active Comparator|HCG|HCG is used to trigger ovulation
10119473|NCT04406714|Experimental|Mailed FIT|Patients randomized to this arm will receive mailed FIT plus up to two reminder letters to complete and return the FIT. Patients with a positive (abnormal) FIT result will be offered patient navigation to facilitate follow-up colonoscopy.
10119474|NCT04406714|No Intervention|Usual Care|Patients randomized to this arm will receive usual care. Current usual care at the participating community health centers consists of a visit-based FIT distribution approach.
10119475|NCT04407052|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
10119476|NCT04407052|Active Comparator|HCG|HCG is used to trigger ovulation
10119477|NCT04406779||Patients with breast cancer|Patients with breast cancer
10119478|NCT04406779||Control|Healthy patients without breast cancer
10119479|NCT04406870|Experimental|Intervention|patients with propranolol-resistant IHHE are given propranolol combined with sirolimus
10119480|NCT04406909|Experimental|Training|Access to training at membership training facility
10119481|NCT04406909|No Intervention|No training|No access to training at membership training facility
10119482|NCT04406727|Experimental|UB-421|"2-arm Comparison Phase: UB-421(25 mg/kg, every 2 weeks) in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
10119483|NCT04406727|Active Comparator|Placebo|"2-arm Comparison Phase: Placebo in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
10119484|NCT04406922|Experimental|Intervention group|Cold exposure in the morning and evening.
10119485|NCT04406935|Active Comparator|475 KHz|NuEra device treatment using 475 KHz
10119486|NCT04406935|Active Comparator|1 MHz|Arm 2: NuEra device treatment using 1 MHz
10119487|NCT04406935|Active Comparator|2 MHz|NuEra device treatment using 2 MHz
10119488|NCT04407039||Glioma molecular subtype: G-CIMP-low|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
10119489|NCT04407039||Glioma molecular subtype: G-CIMP-high|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
10119490|NCT04407039||Glioma molecular subtype: codel|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
10119491|NCT04407039||Glioma molecular subtype: classic-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
10119492|NCT04407039||Glioma molecular subtype: mesenchymal-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
10119493|NCT04407039||Glioma molecular subtype: LGM6-GBM|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
10119494|NCT04407039||Glioma molecular subtype: PA-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
10119495|NCT04406805||Severe aortic stenosis|Patients will be enrolled among those who will be (i) aged from 18 to 99 years, (ii) admitted to the hospital due to severe aortic stenosis, and (iii) qualified for treatment with either surgical aortic valve replacement or transcatheter aortic valve implantation
10119496|NCT04407000|Experimental|Test Drug|Loqular 200 mg Film Tablet containing 200 mg favipiravir (World Medicine İlaç-Turkey)
10119497|NCT04407000|Active Comparator|Reference drug|Avigan 200 mg Film Tablet containing 200 mg favipiravir (Toyama Chemical Industry Co.Ltd./Japan)
10119498|NCT04406883|Active Comparator|A (Simavastatin 10 mg with gelatin sponge graft)|A group: After atraumatic extraction, filled the tooth socket with Simvastatin10 mg solution impregnated gelatin sponge.
10119499|NCT04406883|Active Comparator|B(Gelatin sponge graft )|B group: Following atraumatic extraction, put in the tooth socket with gelatin sponge.
10119500|NCT04406753|Experimental|Manual Therapy + Exercise Group|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
10119501|NCT04406753|Active Comparator|Exercise Group|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
9528277|NCT03212222|Experimental|Peek Acuity Screening|Cell phone application to be used for visual acuity screening.
10119502|NCT04406896|Experimental|Participants with mild hepatic impairment (Group 1)|Participant with Child-Pugh Grade A Score of 5-6.
10119503|NCT04406896|Experimental|Participants with moderate hepatic impairment (Group 2)|Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.
10119504|NCT04406896|Experimental|Healthy participants (Group 3)|
10119505|NCT04406766|Experimental|Connected nutrition pump system|
10182873|NCT03770104|Experimental|Control Group (6 plus weight)|ETT insertion depth using international recommendations Patients included in the intervention group arm who are included in the study will be intubated using international recommendations (6 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
10182874|NCT03770078|Experimental|Study period|First the subjects will use the comparator (SenSura Mio) and then the test products (Test Product A)
10182875|NCT03770039|Experimental|2-period, fixed sequence|fixed sequence with 2 treatment period
10119506|NCT04406831||New Unresectable Pancreatic Cancer|Individuals with biopsy-proven adenocarcinoma of the pancreas, classified as locally advanced or metastatic disease
10119507|NCT04406831||Control|Healthy individuals without cancer diagnoses to provide reference microRNA
10119508|NCT04407026||Healthy|Healthy control group (n=25) consisted of the volunteers having clinically healthy gingiva, PD≤3 mm, BOP<10% and no sign of clinical attachment loss and radiographic alveolar bone destruction.
10119509|NCT04407026||Gingivitis|Gingivitis group (n=25) had PD≤3 mm with BOP>50% in the entire mouth, and no clinical attachment loss or alveolar bone loss.
10119510|NCT04407026||Stage 3 periodontitis|Stage 3 periodontitis group included the patients exhibiting PD ≥6 mm and interdental CAL ≥5 mm at %30 or more teeth. They had no more than four teeth loss.
10119511|NCT04406675|Other|Patients Amyotrophic Lateral Sclerosis|
10119512|NCT04406675|Other|Control subjects|
10119513|NCT04406597|Experimental|the New Tissue Containment System group|Using the New Tissue Containment System during Laparoscopic Ovarian Cystectomy
10119514|NCT04406597|No Intervention|Open group|Without any protection system during Laparoscopic Ovarian Cystectomy
10119515|NCT04406298|Experimental|Small Quantity Paracentesis|Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
10119516|NCT04406298|Active Comparator|Large Volume Paracentesis|Large Volume Paracentesis > 5 litres
10119517|NCT04406272|Experimental|Before and After Surgery|"VB-111 will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
10119518|NCT04406272|Experimental|After Surgery|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
10119519|NCT04406272|Experimental|After Surgery Standard of Care|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovery from surgery, participants will receive standard of care treatment every 6 weeks until tumor growth is evidenced a two consecutive time points."
10119520|NCT04406610|Experimental|GD2 CAR-T|Treated by GD2 CAR-T therapy intravenously
10119521|NCT04406610|No Intervention|Control|With no medical intervention
10119522|NCT04406337|Experimental|Low intensity pulsed ultrasound|Participants in this arm will receive low intensity pulsed ultrasound therapy on the affected knees for 20 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
10119523|NCT04406337|Active Comparator|High intensity continuous ultrasound|Participants in this arm will receive high intensity continuous ultrasound therapy on the affected knees for 10 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
10119524|NCT04406324||SARS-CoV-2 patients|Patients infected by SARS-CoV-2
10119525|NCT04406428|Experimental|NKI followed by EBD|
10119526|NCT04406428|No Intervention|Standard EBD|
10119527|NCT04406220|Active Comparator|Small clog size|
10119528|NCT04406220|Active Comparator|Large clog size|
10119529|NCT04406454||Heathy volunteers|Patients has healthy skin at 5 anatomical locations including face, back, dorsal forearm, volar forearm, calf and at least a nevus without superficial scales and crusting.
10119530|NCT04406402|Experimental|Acute glucose tolerance test|A standard oral glucose tolerance test (75 grams of dextrose in 180 cc of water)
10119531|NCT04406402|Experimental|Acute protein load test|A protein-rich, vanilla-flavored powder (Pro-gym, Telpharma, Is
10119532|NCT04406402|Experimental|Acute fat load test|a 100-gram portion of sweet cream containing 300 Kacls, of which 94% of the ingested calories were fat
10119533|NCT04406402|Experimental|Acute alcohol load test|Vodka (100 cc, 40% alcohol)
10119534|NCT04406402|Experimental|Acute exercise|30 minutes of supervised graded walking on a treadmill according to each subject's individual ability. A goal heart rate was calculated as 70% of the age-adjusted maximal allowable heart rate.
10119535|NCT04406402|Experimental|Lifestyle modification program - 12 weeks|12 weeks of weight-loss dietary program constructed according to the guidelines of the American Diabetes Association. Based on weight, gender, and age, daily dietary allowance varied at 1200-1800 Kcal, 50% carbohydrates, 20% protein, and 30% fat. Participants were also asked to engage in moderate physical activity comprised of a 40-minute walk three times a week. A weekly clinic visit alternating with a weekly telephone contact was also required.
10119536|NCT04406389|Active Comparator|Intermediate Dose Prophylaxis|"Subjects will receive one of the following interventions, at their physician's discretion:~Enoxaparin 0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min~Enoxaparin 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 mL/min~If patient develops acute kidney injury: unfractionated heparin 7,500 units subcutaneously every 8 hours.~Fondaparinux (if history of heparin-inducted thrombocytopenia [HIT]) 2.5 mg daily subcutaneously"
10119537|NCT04406389|Experimental|Therapeutic Dose Anticoagulation|"Subjects will receive one of the following interventions, at their physician's discretion:~Unfractionated heparin (UFH) to target anti-Xa level 0.3 -0.7 IU/mL or activated partial thromboplastin time (aPTT) (according to institutional protocol).~Enoxaparin 1 mg/kg subcutaneously every 12 hours~Argatroban (if heparin-induced thrombocytopenia [HIT]), dosed according to institutional protocol.~Fondaparinux (if HIT and creatinine clearance greater than or equal to 50 ml/min) dosed by weight:~≥100 kg: 10 mg daily~<100 kg but ≥50 kg: 7.5 mg daily~<50 kg: 5 mg daily"
10119538|NCT04406376|Active Comparator|Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days, 40 mg for 2 days, 20 mg for 2 days (Total 11 days)
9528278|NCT03212222|Active Comparator|Standard Visual Screening|Standard visual acuity screening administered at Duke University Eye Center regarded as the gold standard.
10119539|NCT04406376|Active Comparator|No Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days (Total 7 days)
10119540|NCT04406246|Experimental|Nitazoxanide early treatment|Health workers with symptoms of COVID-19 not requiring hospitalization will receive an early treatment with nitazoxanide.
10119541|NCT04406350|Experimental|Study group - MRI CO2 and O2 stress test|Pilot Study of Feasibility of tight control of end-tidal respiratory gases during conduct of anesthesia
10119542|NCT04406480|Other|90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)|
10119543|NCT04406506||Group A|Group A received nasogastric feeding (NG), insure through ngt pump
10119544|NCT04406506||Group B|"receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~Patients were placed in right lateral position"
10119545|NCT04406493|Experimental|COVID 19 patients|"COVID 19 patients are admitted to the Infectious Diseases Unit, will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization each patient will undergo this examination twice a day until discharged.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation The time between lung impedance started to decrease (expression of the lung fluids accumulation) and the need for mechanical ventilation will be measured."
10119546|NCT04406571||"pancreatic adenocarcinoma before COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 16/03/2020.
10119547|NCT04406571||"pancreatic adenocarcinoma after COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 17/03/2020 and 31/10/2020.
10119548|NCT04406532|Experimental|PT-Pal|Participants randomized to the 14-day intervention arm will receive exercise instructions via PT-Pal. The Pt-Pal is a mobile health technology used to facilitate communication between the Care Team and patients, by allowing the team to send from their web-portal, exercise routines, surveys and educational material to the patient's mobile device. The PT-Pal app then captures the patient activity adherence, and reports those results back to the team including a graphical summary about patients' condition and activity. Clinicians can send/receive HIPAA-secure messages with patients. The app was designed to work with intermittent data connectivity typically found in mobile networks by switching between store-and-forward and real-time mode of connectivity to ensure data delivery.
10119549|NCT04406532|Active Comparator|Self-guided exercises|Participants randomized to the 14-day control arm will be instructed by research staff on how to use the exercise manual provided at the time of their screening.
10119550|NCT04406207||Patients|Patients relapsing or not after hematopoietic stem cell transplantation.
10119551|NCT04406259|Other|Verapamil|administration of verapamil to treat cluster headache
10119552|NCT04406285|Active Comparator|Leukemia Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
10119553|NCT04406285|Experimental|Leukemia Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
10119554|NCT04406285|Active Comparator|Lymphoma Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
10119555|NCT04406285|Experimental|Lymphoma Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
10119556|NCT04406181|Other|operation deferred|Adult patients whose operation date has been deferred due to the pandemic
10119557|NCT04406181|Other|no operation date|Patients who did not have had an operation date and who were told to need cardiac surgery before the pandemic started
10119558|NCT04406181|Other|postoperative consultation deferred|Patients who have been operating on during the month before the pandemic
10119559|NCT04406012|Active Comparator|block group|Paravertebral group at Thoracic 9-10 vertebrae level with an in-plane technique advanced ultrasound guided 10 ml bupivacaine hydrochloride (Marcaine 0.5%, Astra Zeneca) in 20 ml volume was enjected in the paravertebral area with real-time visualisation It was observed that the local anesthetic drug spread on the pleura and the pleura was pushed. All blocks were performed by the same experienced anaesthesiologist.
10119560|NCT04406012|No Intervention|Control group|Conventional analgesia methods were applied to the control group. Control group was relieved by dexketoprofen 50mg intravenously. If the patient was not relieved with dexketoprofen and VAS score >4, tramadol 1 mg kg-1 was administered intravenously.
10119561|NCT04406025||participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have attended a Regional Anesthesia Seminar taking place once a year
10119562|NCT04406025||no participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have not attended a Regional Anesthesia Seminar taking place once a year
10119563|NCT04405895|Experimental|Breakfast Diet (3Mdiet)|The Breakfast Diet (3Mdiet) will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
10119564|NCT04405895|Active Comparator|Allday Diet (6Mdiet)|The Allday Diet (6Mdiet) will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% in each of the three snacks.
10119565|NCT04405973||COVID-19 ARDS, vv-ECMO|All patients in the study centers with diagnosed COVID-19 infection (PCR proven) and treatment with vv-ECMO
10119566|NCT04406051|Active Comparator|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive colloid preloading (5 mL/kg)
10119567|NCT04406051|Active Comparator|norepinephrine infusion and crystalloid co-loading (NOR-CRYS)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive crystalloid co-loading (10 mL/kg)
10119568|NCT04405986|Experimental|Electrophysiological procedure|Brainstem reflexes and neural conduction will be explored using Auditory Evoked Potentials (AEP) and blink and Masseter Inhibitory Reflex (MIR) in hospitalised patients with COVID infection
10119569|NCT04405960|Experimental|Intervention group|Individuals in intervention group were given oral Vitamin D supplements (Alphacalcidol 1 µg) once daily
10119570|NCT04405960|Placebo Comparator|Control Group|Individuals in control group were given placebo once daily
10119571|NCT04405804|Experimental|Ivabradine|Eligible patients will be given treatment with ivabradine during a titration period which will last from a minimum of 3 days to a maximum of 15 days. This will be followed by a maintenance period of another 14 days. At the end of maintenance period, primary endpoint will be assessed. After maintenance period, the patient will continue ivabradine at the same dosage during a follow-up period that will last 4 months.
10119572|NCT04405843|Experimental|Ivermectin|Ivermectin, 300 micrograms / kg, once daily for 5 days
10119573|NCT04405843|Placebo Comparator|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
10119574|NCT04406155||Patients with suspicion of rectosigmoid endometriosis|
10119575|NCT04406116|Experimental|patients receiving microwave therapy using the HS1 Instrument|
10119576|NCT04405947|Other|deltopectoral|deltopectoral surgical approach
10119577|NCT04405947|Other|antero-superior|antero-superior approach
10119578|NCT04405921|Experimental|Hydroxychloroquine associated to azithromycin|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. Azithromycin: 500 mg at day 1 then 250 mg/day for 4 days. with standard of care in association to treatments.
10119579|NCT04405921|Active Comparator|Hydroxychloroquine with placebo|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. with standard of care in association to treatments.
10119580|NCT04406064|Experimental|Viral Specific T-cells (VSTs)|
10119581|NCT04406077|Experimental|Intervention|Patients suffering from hydrocele, underwent treatment using Ligasure device.
10119582|NCT04405752||12-mm diameter metallic billiary stent|
10119583|NCT04405752||10-mm diameter metallic billiary stent|
10119584|NCT04405531|Experimental|task-oriented training(TOT)|The first phase of the TOT, functional activity analysis, was performed for the activities, for which performance problem was determined by Canadian Occupational Performance Measure (COPM) and Functional Independence Measure for Children (WeeFIM). In the second phase, the occupational performance, fatigue and functional independence levels that prevent the realization of the activity were determined by functional activity analysis. These designated occupational performance, fatigue and functional independence levels constitute the task of this study, as we aim to improve children's functionality. In the third phase, various functional activities including these tasks were executed. The TOT was practiced by following the above mentioned steps for each performance area. All the activities were designed for the inpatient settings of children.
10119585|NCT04405531|Experimental|conventional occupational therapy (COT)|The treatment efficacy determined by the therapist was provided by considering the functional level in order to achieve the desired goal by the participant. The COT included functional activities based on the client-centered principles of the neuro-developmental approach. All the sessions started with relaxation training combined with breathing exercises. At the end of approximately 10 minutes of application time, individualized functional activities were implemented.
10119586|NCT04405453|Active Comparator|Trapezius Muscle İnjection (TMI) group|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
10119587|NCT04405453|Active Comparator|Erector Spina Plane Block (ESPB) group|ESPB group in the 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
10119588|NCT04405440||Healthy controls|The healthy control group will perform a well-validated avoidance (behavioral) task and will fill in some questionnaires about eating behaviors, emotions, and feelings.
10119589|NCT04405440||Anorexia Nervosa patients|As the healthy controls, the participants of the anorexia nervosa group will perform the same behavioral task and will fill in the same questionnaires
10119590|NCT04405596|Experimental|Ambroxol|Participants randomized to the 1350 mg/day group will begin with a dose of 450 mg, increasing bi-weekly to a dose of 1350 mg/day.
10119591|NCT04405596|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
10119592|NCT04405700||Cohort 1 (C1)|Prospective recruitment of pregnant women enrolling in ANC at the site. All HIV+ pregnant women and a 1:1 systematic sample of HIV- pregnant women enrolling in antenatal clinic at the site will be prospectively enrolled in the study. In addition, medical record data for the mother and infant will be collected at the time of delivery for all women who deliver at the site and as such will contribute to a subset of C2 (below). Women enrolled in C1 who do not deliver at the site will be contacted by phone and through field follow-up to ascertain their pregnancy and infant outcomes. Infants born to women enrolled in this component who are suspected of having CAs will be enrolled as outlined in C3 (below) if their mothers deliver at the site. If their mothers do not deliver at the site these infants will be enrolled in the field. Photos/videos of infants with CAs will also be taken for review and classification by a panel of experts (see C3 below).
10119593|NCT04405700||Cohort 2 (C2)|Cross-sectional data collection for deliveries at the site. Data will be collected retrospectively from medical records for all women who deliver at the site (including the women enrolled in C1 above), as well from the medical records of all newborn infants and stillbirths delivered at the site. Missing or incomplete information in the woman or her infant's medical record will be clarified by contacting the woman to provide this information.
10119594|NCT04405700||Cohort 3 (C3)|Photos/videos of infants with CAs. All newborn infants and stillbirths ≥ 24 weeks gestational age delivered at the site, as well as all infants born to women enrolled in C1, will be assessed by surface exam for the presence of CAs. Video and photographs will be taken of CAs identified on surface exam. These images will be reviewed and classified by panel of experts in genetics, dysmorphology and teratology. Mothers of infants with major CAs will be contacted by phone at 1, 6, and 12 months post-delivery to ascertain their infants' vital status and care engagement status.
10119595|NCT04406129|Experimental|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
10119596|NCT04406129|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
10119597|NCT04405609|Experimental|ArmAssist group|"The post-stroke patients who participate in the study, are classified in differents stages (3 patients in each stage).~Group 1: subacute, between 2 - 6 months Group 2: chronic of short evolution, between 6 - 12 months Group 3: long-term chronic, more than 12 months.~The system is tested in a clinical (training) and patients' home setting. The ArmAssist system includes the ArmAsist 2.0 device (without motors), the tele rehabilitation platform based on serious games and Antari's HomeCare tele-care platform for the clinicians."
10119598|NCT04405713|Active Comparator|from the onset of symptoms within the first 3 days (group 1)|ELC for ACC from the onset of symptoms within the first 3 days (group 1)
10119599|NCT04405713|Active Comparator|from the onset of symptoms within the 4-7 days|ELC for ACC from the onset of symptoms within the4-7 days (group II)
10119600|NCT04405713|Active Comparator|from the onset of symptoms beyond 7 days|ELC for ACC from the onset of symptoms beyond 7 days (group III)
10119601|NCT04405622|Experimental|Toripalimab plus gemcitabin arm|Subjects receive gemcitabine and toripalimab.
10119602|NCT04405492|Experimental|Population 1 : Patients|Hospitalized patients, positive or suspected of SARS-CoV-2 infection
10119603|NCT04405492|Experimental|Population 2 : Hospital caregivers exposed to SARS-CoV-2|Longitudinal study of a hospital caregiver cohort
10119604|NCT04405492|Experimental|Population 3 : Lay users|Suitability of rapid test in view of its intended purpose for self-testing
10119605|NCT04405687||Severe head and face deformity|
10119606|NCT04405505|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
10119607|NCT04405505|Active Comparator|Paclitaxel for injection (albumin bound)|Paclitaxel for Injection (albumin bound) 100mg / m2 administered intravenously (IV) on Day 1, 8, 15 in 28-day cycle.
10119608|NCT04405466||Group 1|Workers working within a production area
10119609|NCT04405466||Group 2|Workers working within a laboratory area
10119610|NCT04405466||Group 3|Workers working within other areas
10119611|NCT04405765|Active Comparator|Lyopreserved Stravix|Treated with NPWT and lyopreserved Stravix
10119612|NCT04405765|Active Comparator|Cryopreserved Stravix|Treated with NPWT and cryopreserved Stravix
10119613|NCT04405544|Other|Main|patients with COVID-19 and Acute Encephalopathy
10119614|NCT04405544|Other|Control|patients with COVID-19 without Acute Encephalopathy
10119615|NCT04405388|Other|Spermidine first|First treatment period (8 weeks) will be 4 mg spermidine per day orally. Afterwards 4 weeks of wash-out followed by 8 weeks of placebo treatment.
10119616|NCT04405388|Other|Placebo first|First treatment period (8 weeks) will be placebo. Afterwards 4 weeks of wash-out followed by 8 weeks of 4 mg spermidine per day orally.
10119617|NCT04405427|Experimental|head acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the head
10119618|NCT04405427|Active Comparator|body acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the body
10119619|NCT04405375|Experimental|treatment arm|gemcitabine 1.25g/㎡ d1, pegaspargase 2500IU/㎡ d1 (max dose =<3750IU) etoposide 75mg/㎡ d1-3 dexamethasone 20mg d1-4 repeated every 21 days, up to 6 cycles.
10119620|NCT04405050|Active Comparator|Restrata|Treated with Restrata
10119621|NCT04405050|Active Comparator|NPWT|Treated with NPWT (Negative Pressure Wound Therapy)
10119622|NCT04405024|Other|Hepatitis C testing|"If the patient is included in the study, HCV serology (2 x 5 ml tubes) will be taken at the time of admission as part of the routine entry assessment.~These two tubes will be used for HCV screening. The patient is informed of the HCV serology result during hospitalization by an investigator."
10119623|NCT04405206||Group A:Clinical complete response (cCR)|Group A:Clinical complete response (cCR) Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
10119624|NCT04405206||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
10119625|NCT04405206||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation
10119626|NCT04405336|Active Comparator|giving tab block|giving patients tab block
10119627|NCT04405336|Active Comparator|giving PCA|Giving PCA to patients
10119628|NCT04405336|No Intervention|Patients who will not receive PCA or tab block|No tab block or PCA
10119629|NCT04405193|Experimental|Treatment|2 capsules, each containing 600 mg N-acetylcysteine administered once daily every morning.
10119630|NCT04405193|Placebo Comparator|Placebo|2 capsules of matching placebo administered once daily every morning
10119631|NCT04405180|Experimental|20 mg Sodium Nitrite TID Arm|Subject is to receive active study drug three times per day during treatment (12 weeks +/- 5 days) period and then after the treatment period (up to 16 weeks total).
10119632|NCT04405180|Placebo Comparator|Placebo Control Arm|Subject is to receive placebo three times per day during treatment period (12 weeks +/- 5 days) and then after the treatment testing period (up to 16 weeks total).
10119633|NCT04405271|Experimental|FTC/TAF|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks.
9668937|NCT04546698||Multiple Sclerosis patients with an acute relapse|Multiple Sclerosis diagnosed according to Mc Donald's criteria with an acute relapse
10119634|NCT04405271|Placebo Comparator|Placebo|Identical tablets to the active experimental tablets with the same characteristics and packaging. A dose of 1 tablet per day will be administered for a total of 12 weeks
10119635|NCT04405154|Experimental|Investigational Arm|Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.
10119636|NCT04405089|Experimental|Active tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over right frontal cortex, cathode over left frontal cortex; 2 mAmps for 26 minutes).
10119637|NCT04405089|Sham Comparator|Sham tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
10119638|NCT04405245|Experimental|AKB-9778 QD + Latanoprost|• AKB-9778 QD (AM) and placebo for AKB-9778 ophthalmic solution QD (PM) plus latanoprost QD (PM) for 28 days
10119639|NCT04405245|Experimental|AKB-9778 BID + Latanoprost|• AKB-9778 BID (AM & PM) plus latanoprost QD (PM) for 28 days
10119640|NCT04405245|Placebo Comparator|Placebo BID + Latanoprost|• Placebo for AKB-9778 ophthalmic solution BID (AM & PM) plus latanoprost QD (PM) for 28 days
10119641|NCT04405037|Experimental|Alvimopan Group|"Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan doses will be given if there is no return of bowel function or if symptoms of distension and/or nausea persist despite some return of bowel function.~All patients will follow a standard ERAS pathway after surgery, with early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol."
10119642|NCT04405037|No Intervention|Control Group|Control patients will follow a standard ERAS pathway after surgery, including NPO status, IV fluid rehydration, and nasogastric decompression, early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol.
10119643|NCT04405011|Experimental|Entecavir 0.5mg daily for 24 weeks|Entecavir will be delivered for 24-week and will be the experimental arm
10119644|NCT04405011|Active Comparator|Entecavir 0.5mg daily for 12 weeks|12-week entecavir will be served as active comparator
10119645|NCT04405011|No Intervention|Control|Control group does not receive prophylactic ETV
10119646|NCT04405310|Experimental|EXP-PC-F2|Patients with Pneumonia due to SARS-COV-2 phase 2 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
10119647|NCT04405310|Placebo Comparator|EXP-NONPC-F2|20 Patients with Pneumonia due to SARS-COV-2 phase 2 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
10119648|NCT04405310|Experimental|EXP-PC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
10119649|NCT04405310|Placebo Comparator|EXP-NONPC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
10119650|NCT04405258|Active Comparator|PVI alone|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
10119651|NCT04405258|Active Comparator|PVI and PWI|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
10119652|NCT04405219|Sham Comparator|smokers (S)|
10119653|NCT04405219|Active Comparator|non smokers (NS)|
10119654|NCT04405323|Experimental|Lu AG06466 - Sequence 1|Dosing on Days 1 and 8 will be following an overnight fast, and dosing on Days 3 and 10 will be following a standard high-fat breakfast.
10119655|NCT04405323|Experimental|Lu AG06466 - Sequence 2|Dosing on Days 1 and 8 will be following, a standard high-fat breakfast and dosing on Days 3 and 10 will be following an overnight fast.
10119656|NCT04404894||Prolaris tested patients with Prostate Cancer|Recently diagnosed patients with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites who have undergone Prolaris testing.
10119657|NCT04404946|Active Comparator|phenylephrine infusion|fixed-rate phenylephrine infusion
10119658|NCT04404946|Active Comparator|norepinephrine infusion|fixed-rate norepinephrine infusion
10119659|NCT04404946|Placebo Comparator|placebo infusion|normal saline infusion
10119660|NCT04404868||Enrolled patients|"Each patient (whether hospitalized or outpatient) included in the study underwent to a baseline evaluation in which near and remote pathological history were recorded (main concomitant pathologies, drug therapy in progress, previous major surgery) and the following evaluation scales were administered: modified Ashworth scale (MAS), MI (motricity index), FMA (Fughl Meyer assessment) and Modified Rankin' scale (MRS).~Each patient will subsequently undergo to a follow-up evaluation at 4, 12 and 24 weeks after the date of inoculation through the execution of a specialist visit (physiatric/neurological) and the administration of the following evaluation scales: MAS, MI, FMA and MRS. For the duration of the study, each patient may undergo integrated rehabilitation treatment at the discretion of each of the investigators of each centre involved in the study according to the guidelines and common clinical practice."
10119661|NCT04404881|Experimental|Bevacizumab|"The research study procedures include: screening for eligibility, pretreatment period, study treatment, end-of-study visit, and follow-up visit. Each period consists of 12 weeks, for a total of 36 weeks.~Pretreatment Period:Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~Induction Period (first 3 months of bevacizumab treatment):~Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.~Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~Maintenance Period (second 3 months of bevacizumab treatment):~Hematologic Support: Iron transfusions and red cell transfusions as determined by study doctor.~Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
10119662|NCT04404855|Other|Intervention Group (NGS + Antibiotic Recommendation)|Next Generation Sequencing results along with Infectious Disease Pharmacist will be shared with clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
10119663|NCT04404855|Other|Control Group|NGS results will not be shared with the clinical provider at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
10119664|NCT04404764||Treated with nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III treated with nusinersen in the Brazilian Unified Public Health System
10119665|NCT04404764||With indication to receive nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III with indication, but not yet receiving nusinersen treatment in the Brazilian Unified Public Health System
10119666|NCT04404959|Active Comparator|fascia iliaca compartment block with ropivacaine|in this arm, the fascia iliaca compartment block will be performed with 40 mL ropivacaine 0.25%
10119667|NCT04404959|Placebo Comparator|fascia iliaca compartment block with placebo|in this arm, the fascia iliaca compartment block will be performed with 40 mL normal saline
10119668|NCT04404738|Experimental|MicroPort® Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using MicroPort® surgical system
10119669|NCT04404738|Active Comparator|da Vinci Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using da Vinci surgical system
10119670|NCT04404751|Active Comparator|Arm 1|
10119671|NCT04404751|Active Comparator|Arm 2|
10119672|NCT04404751|Sham Comparator|Arm 3|
10119673|NCT04404829|Experimental|Informational Manual Therapy|It is an integral no orthopedic and very soft manual therapy
10119674|NCT04404790|Experimental|Anfibatide 5 IU/60kg|Ten subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes.
10119675|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
10119676|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
10119677|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
10119678|NCT04404790|Experimental|Anfibatide 7 IU/60kg|Ten subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes.
10119679|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
10119680|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
10119681|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
10182876|NCT03770026|Active Comparator|Clomiphene citrate only|Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
10182877|NCT03770026|Experimental|Platelet-rich plasma plus Clomiphene|Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.
10182878|NCT03770013|Active Comparator|bupivacaine 0.25% and Dexmedetomidine|bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.)
10182879|NCT03770013|Active Comparator|bupivacaine and clonidine|20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP
10182880|NCT03770013|Placebo Comparator|bupivacaine and placebo|bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP
10182881|NCT03769974|Experimental|Motor imagery|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-person kinesthetic motor imagery training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of motor imagery will be 2 series of 30 seconds for each of the 12 manual positions to remember
10182882|NCT03769974|Experimental|Action observation|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-personaction observation training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of action observation will be 2 series of 30 seconds for each of the 12 manual positions to remember in video format.
10182883|NCT03769974|Placebo Comparator|Placebo group|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which an imagery training and placebo observation, inspired by a rural landscape, will be given for four consecutive days. This group will carry out the observation and imagination of a landscape during 2 series of 30 seconds for each manual motor sequence to remember.
10182884|NCT03769961||ET (DBS-, Ataxia+)|Essential Tremor without DBS with Ataxia on examination
10182885|NCT03769961||ET (DBS-, Ataxia-)|Essential Tremor without DBS and without Ataxia on examination
10182886|NCT03769961||ET (DBS+, Ataxia+)|Essential Tremor with DBS with Ataxia on examination
10182887|NCT03769961||ET (DBS+, Ataxia-)|Essential Tremor with DBS without Ataxia
10182888|NCT03769935|Experimental|experimental arm|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
10182889|NCT03769935|Active Comparator|active comparator|cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
10182890|NCT03769922|Experimental|Extensive mesenteric resection|Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
10182891|NCT03769922|Active Comparator|Limited mesenteric excision|"Mesentery is retained, i.e. Close shave or 3 cm from the border of bowel (using whatever approach - clips, or haemostatic vessel sealing device)."
10119682|NCT04404647|Experimental|Intervention|Selected patients who choose to participate will undergo ablation of the target lesion using irreversible electroporation.
10119683|NCT04404556|Experimental|Diabetes Journey|Diabetes Journey is a web-based intervention to address key adherence barriers. Participants randomized to this arm will first receive the mandatory Introduction and Problem-Solving Module. Based on their elevations on the Barriers to Diabetes Adherence measure, participants will receive up to 7 modules in total. Participants will navigate through the web-based theme park map and complete modules independently and then will have accompanying Zoom telehealth sessions with a therapist.
10119684|NCT04404556|Active Comparator|Enhanced Standard of Care|Participants randomized to Enhanced Standard of Care will receive general education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) from each site across 12-weeks. Content to address adherence barriers were modified and or newly developed for the Enhanced Standard of Care group via the T1DToolkit website.
10119685|NCT04404816|Experimental|Group 1|premature infants born < 33 G.A. enrolled in the first 72 hours after birth, with respiratory distress syndrome, requiring non-invasive ventilation with FiO2 <0.4
10119686|NCT04404816|Experimental|Group 2|premature infants born < 33 G.A. with respiratory insufficiency requiring mechanical ventilation, after more than 1 failed extubation attempt
10119687|NCT04404777||Patients with local recurrence|
10119688|NCT04404842||EvidenceQ Cohort|Adult subjects, aged over 18 years, male and female.
10119689|NCT04404348|Experimental|Intervention|Three times per week for four weeks, participants will complete a computerized cognitive training session (approximately 30 minutes long).
10119690|NCT04404348|Placebo Comparator|Control|Three times per week for four weeks, participants will complete a computerized session (approximately 30 minutes long) that consists of inert computer games.
10119691|NCT04404686|Experimental|Indomethacin group|Group of patients receiving Indomethacin for preterm labor treatment.
10119692|NCT04404686|Active Comparator|Nifedipine group|Group of patients receiving Nifedipine for preterm labor treatment.
10119693|NCT04404621|Experimental|Cross-Over Sequence A|Participants in this arm will be randomized to receive the 18 week program first and be in treatment as usual comparison condition in the following 18 weeks.
10119694|NCT04404621|Experimental|Cross-Over Sequence B|Participants in this arm will be randomized to remain in treatment as usual during the first 18 week period and then receive the 18 week program during the following 18 weeks.
10119695|NCT04404673||Open rectal resection|
10119696|NCT04404673||Laparoscopic rectal resection|
10119697|NCT04404673||Robotic rectal resection|
10119698|NCT04404673||Trans-anal TME (Ta-TME)|
10119699|NCT04404374|Active Comparator|A-PRF|Advanced Platelet-Rich Fibrin
10119700|NCT04404374|Active Comparator|EMD|Enamel Matrix Derivatives
10119701|NCT04404530||Palynziq Therapy for PKU|Participants with PKU who are starting Palynziq therapy.
10119702|NCT04404335||Healthy (control group)|"This group will include a total of 30 patients free of periodontitis Samples of crevicular fluid to quantity levels of antimicrobial peptide LL-37 will be taken at baseline~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
10119703|NCT04404335||Periodontitis (test group)|"60 Periodontal patients (subdivided in 2 groups of 30, depending of the severity of their disease):~30 patients with Stage I-II periodontitis (mild/moderate)~30 patients with Stage III-IV periodontitis (severe).~Two sets of samples of crevicular fluid will be obtained before and after receiving a course of routine basic periodontal treatment (root scaling and planing).~A reevaluation visit to re-assess clinical periodontal parameters will take place at 4-6 weeks after treatment. New samples of crevicular fluid will then be taken at this stage to compare the level of LL-37 before and after the treatment.~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
10119704|NCT04404517|Active Comparator|40mg1w|Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks
10119705|NCT04404517|Active Comparator|80mg2w|Adalimumab at an administration of 80 mg every two weeks
10119706|NCT04404309||Population 1|Any patient admitted to a psychiatric ward with a clinical diagnosis of (unipolar) major depression
10119707|NCT04404309||Population 2|Any patient with a clinical diagnosis of a moderate or severe unipolar depressive disorder with suicidal tendencies that persist for at least 48 hours after admission
10119708|NCT04404309||Population 3|Patients with moderate or severe unipolar depressive episodes validated by research interviews and suicidal tendencies that persist for at least 48 hours after admission who will be followed up for 6 months
10119709|NCT04404322|Experimental|IPT A SCI|The IPT-A SCI follows the intervention protocol, which includes an intensive phase of 5 weekly 50-minute sessions and 3 follow up personal emails.
10119710|NCT04404322|Active Comparator|Treatment as usual|TAU patients receive an integrative combination of psychodynamic, supportive and cognitive behavioural therapy, usually lasting between 10-30 weeks.
10119711|NCT04404322|No Intervention|wait list|WL patients are monitored by a trained clinician during their waiting period and complete the study questionnaire battery at the parallel time intervals.
10119712|NCT04404491|Active Comparator|PD-1 and Concurrent chemoradiotherapy|Camrelizumab: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
10119713|NCT04404491|Placebo Comparator|placebo and Concurrent chemoradiotherapy|placebo: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
10119714|NCT04404439|Experimental|Nortriptyline + topiramate|Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
10119715|NCT04404439|Experimental|Verapamil + paroxetine|Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
10119716|NCT04404439|Placebo Comparator|Placebo|Placebo pill.
10119717|NCT04404608||Asymptomatic or mild symptoms patients patients|Patients with no or mild symptoms and need no respiratory support.
10119718|NCT04404608||Severe symptoms patients|Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.
9668938|NCT04546698||Multiple sclerosis pataients treated with Natalizumab|Multiple Sclerosis patients diagnosed according to Mc Donald's criteria and treated with Natalizumab since 6 cures
9668939|NCT04546698||Healthy people|
10119719|NCT04404608||Critically ill patients|Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients
10119720|NCT04404426|Experimental|L-citrulline|Administration of citrulline enterally for 7 days
10119721|NCT04404426|Placebo Comparator|Placebo|Administration of placeboenterally for 7 days
10119722|NCT04404296|Other|25-gauge 20000 PPV|Eyes will undergo pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
10119723|NCT04404361|Experimental|Pacritinib and SOC|Pacritinib 400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC
10119724|NCT04404361|Placebo Comparator|Placebo and SOC|4 capsules once daily [QD] on Day 1, then 2 capsules twice daily [BID] from Day 2 to Day 14) + SOC
10119725|NCT04404543|Experimental|Escalation Cohort|"Five dose levels will be tested according to the 3 + 3 dose-escalation design.~The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1807 to the end of the first cycle (28 days)."
10119726|NCT04404543|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 12~40 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D.
10119727|NCT04404413|Experimental|PARTICIPANTS|A single-group crossover design was used to compare the effects of 2x8 weeks of high-intensity interval training without (HIIT) or with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake) on body composition and performance. There were two weeks in the middle of both phases in which they did not carry out programmed activity, in order not to alter the experimental phase.
10119728|NCT04404387|Experimental|Experimental arm|vitamin C 50 mg/kg every 6 hours for 96 hours.
10119729|NCT04404387|Placebo Comparator|Control arm|Placebo administration
10119730|NCT04404478|Experimental|B-SWELL|Participants in the B-SWELL intervention will receive information about stress and goal setting in addition to healthy lifestyle behaviors. The intervention will take place weekly for eight weeks in groups of 11 to 13 midlife Black women for peer support. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
10119731|NCT04404478|Active Comparator|WE|The attention control group (WE), will include education about healthy lifestyle behaviors and peer support. The attention control groups will also have weekly sessions for eight weeks in groups of 11 to 13 midlife Black women. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
10119732|NCT04404218|Experimental|Açaí palm berry extract|Açaí palm berry extract is a powerful antioxidant with no known side-effects and is widely consumed in Brazil. Açaí palm berry chemical composition has been established and includes several antioxidants - gallic acid, catechin, chlorogenic acid, caffeic acid, p-coumaric acid, epicatechin, orientin, cyanidin-3-0-glucoside, luteolin and apigenin. Orientin is the most concentrated compound (7,96mg/g) and this compound is able to modulate the NLRP3 inflammasome.
9668940|NCT04545671||Patients already implanted with study lens|No intervention as patients are already implanted.
10119733|NCT04404218|Placebo Comparator|Placebo arm|This study will be double-blinded and placebo-controlled. To ensure double-blinding, placebo and active compound capsules will be over-encapsulated with DBCAPS® capsules, which were developed with a tamper-evident design to address the clinical trial challenges of testing without bias. These capsules are made of gelatin and have no interaction with bioavailability.
10119734|NCT04404231|Sham Comparator|No infrared light therapy|This arm does not receive any phototherapy
10119735|NCT04404231|Active Comparator|810 nm|Many clinical studies have used 810nm twice a week for 4 weeks. This is the standard.
10119736|NCT04404231|Experimental|945nm|This wavelength has been chosen as a comparison to 810, to see if it works better.
10119737|NCT04404231|Experimental|random frequency|A wavelength between 650-1100nm which is picked at random
10119738|NCT04403867||Endometrial cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
10119739|NCT04403867||Cervical cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
10119740|NCT04403815||right radial access|"diagnostic coronary angiography and/or PCI performed through right wrist and distal (snuffbox) radial access"
10119741|NCT04403815||left distal radial access|"diagnostic coronary angiography and/or PCI performed through left distal (snuffbox) radial access"
10119742|NCT04404036|Experimental|SinuSonic Device|"Aim 1: SinuSonic device used once a day over a 2 day period.~Aim 2: SinuSonic device used twice daily for 3 minutes in the home setting for 6 weeks.~Aim 3: SinuSonic device used twice daily for 3 minutes in the home setting for 4 weeks."
9668941|NCT04544124|Experimental|Contingency management for treatment attendance|Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.
10119743|NCT04403997|Active Comparator|Chromoendoscopy with methylene blue 0.1%|Once the cecum is reached, a spray catheter is introduced through the working channel and the dye, a 0.1% methylene blue solution, is applied.
10119744|NCT04403997|Experimental|Virtual Chromoendoscopy with NBI with HQ190 endoscopes|Intubation is done with normal white light. Once the cecum is reached, the removal will be done in NBI mode
9668942|NCT04544124|No Intervention|Treatment-as-usual|Participants who solely receive their usual care (treatment-as-usual) and do not receive contingency management.
9668943|NCT04540588|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
10119745|NCT04404179||CASE|59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL.
10119746|NCT04404062||Trial Participants|Male and female participants aged 5-70 years
10119747|NCT04404205||Adult patient with cochlear implant|Adult patients who had cochlear implant surgery before will be included. We will call patients from our cochlear implant list.
10119748|NCT04403906|Experimental|PCL Rapid Antigen Test arm|Single arm trial design. Only patients undergoing standard clinical testing (SARS-CoV-2 PCR test) and consenting for additional testing with the PCL rapid antigen test will be included
10119749|NCT04404049|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
10119750|NCT04404049|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
10119751|NCT04404049|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
10119752|NCT04404075||Group 1 patients|"Age 18 and above~Eczema Area and Severity Index (EASI) score ≥ 10~Investigator Global Assessment (IGA) ≥ 3"
10119753|NCT04404075||Group 2 patients|"Age 18 and above~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10~Investigator Global Assessment (IGA) 1 or 2"
10119754|NCT04404075||Group 3 patients|"Age 12 to 17~Eczema Area and Severity Index (EASI) score ≥ 10~Investigator Global Assessment (IGA) ≥ 3"
10119755|NCT04404075||Group 4 patients|"Age 12 to 17~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10~Investigator Global Assessment (IGA) 1 or 2"
10119756|NCT04404023|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
9966451|NCT01260207|Experimental|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
9966452|NCT01260207|No Intervention|Usual care|Patients in this arm will not receive IVR follow-up. One year after discharge, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
10119757|NCT04404023|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
10119758|NCT04404023|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
10119759|NCT04404023|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
10119760|NCT04404023|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
9966453|NCT01260220|Active Comparator|Circumferential|Completing a complete circle of RF lesions around the left and right pulmonary veins
9966454|NCT01260220|Experimental|Segmental|Isolating the left and right pulmonary veins through RF lesions with a segmental antral approach.
9966455|NCT01260233|No Intervention|Control|No intervention. Patients will receive standard of care.
9966456|NCT01260233|Experimental|Smoking cessation program|Receives smoking cessation program
10119761|NCT04404127|Placebo Comparator|No induction Arm|
10119762|NCT04404127|Active Comparator|Induction with basiliximab|
10119763|NCT04403945||Group 1|healthy volunteers with normal fasting blood glucose and HbA1c, without hypertension, kidney diseases, or taking drugs that affects microcirculation
10119764|NCT04403945||Group 2|type 2 diabetic patients without microvascular complications like Diabetic nephropathy, diabetic retinopathy, diabetic foot or diabetic peripheral neuropathy
10119765|NCT04403945||Group 3|type 2 diabetic patients with diabetic nephropathy diagnosed by clinic or pathology.
10119766|NCT04404114||Normal renal function|Normal renal function
10119767|NCT04404114||Acute kidney injury in normal kidney|Acute kidney injury in normal kidney
10119768|NCT04404114||Acute kidney injury in chronic kidney disease|Acute kidney injury in chronic kidney disease
10119769|NCT04404114||Chronic kidney disease|Chronic kidney disease
10119770|NCT04403854||ME/CFS patients|Patients diagnosed according to Canada Criteria 2003
10119771|NCT04403854||Healthy Controls|Age and sex matched healthy controls
10119772|NCT04403958|Experimental|PRC|Total wrist arthrodesis with PRC and dorsal plate
10119773|NCT04403958|Active Comparator|TWA|Total wrist arthrodesis with dorsal plate
10119774|NCT04403789|Experimental|Intervention Group|During the intervention period they will receive 2 hours per week of group exercise sessions during working hours for 12 weeks. However, after the intervention period, there will be no change in working hours
10119775|NCT04403789|Active Comparator|Delayed Intervention Group (Control group)|During the intervention period there will be no change in working hours. However, after the intervention period they will receive 2 hours of exercise time during working hours per week for 4 weeks
10119776|NCT04403841|Other|Intervention|The intervention of group education on type 2 diabetes, including, in addition to usual diabetes care
10119777|NCT04403841|Other|Control|Patients meeting the inclusion criteria assigned to usual diabetes care alone
10119778|NCT04403776|Experimental|Treatment A, separated washout phase, followed Treatment B.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
10119779|NCT04403776|Experimental|Treatment B, separated washout phase, followed Treatment A.|"Treatment A:~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~Washout phase: no later than 72 hours~Treatment B:~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
10119780|NCT04403672||COVID-19 positive|ideSHi (CRO) investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.
10119781|NCT04403672||COVID-19 Negative|"ideSHi investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.~In addition, 60 fresh specimens which will be tested at IEDCR will also be tested at ideSHi using RealDetect on a real time basis. These samples will also be blinded by IEDCR and sent to the testing laboratory (ideSHi). Of these 60 samples, 30 will be COVID-19 positive and 30 COVID- 19 negative samples. These fresh samples will be provided to ideSHi for testing and analysis for performance evaluation of RealDetect COVID-19 RT-PCR kit."
10119782|NCT04403685|Experimental|Tocilizumab|Single-dose tocilizumab of 8 mg/kg (maximum dose of 800mg). Best supportive care.
10119783|NCT04403685|No Intervention|Control arm|Best supportive care.
10119784|NCT04403503|Active Comparator|Gelatine Sponge|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA)
10119785|NCT04403503|Active Comparator|Gelatine sponge +Cyanoacrylate|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group)
10119786|NCT04403477|No Intervention|Standard treatment|Standard supportive treatment (Oxygen, Enoxaparine, antibiotic, fluid, immune modulator (Steroid) and or antiviral (favipiravir or ramdesivir or lopinavir + ritonavir)
10119787|NCT04403477|Experimental|Standard treatment + 200 ml plasma|Standard supportive treatment + 200 ml apheretic convalescent plasma single transfusion
10119788|NCT04403477|Experimental|Standard treatment + 400 ml plasma|Standard supportive treatment + 400 ml apheretic convalescent plasma single transfusion
10119789|NCT04403438||patients with behçet's or fmf|
10119790|NCT04403750|Experimental|Combined laser-surgical technology|"Combined laser-surgical technology includes 3 steps:~Nd-YAG laser excision of the vitreoretinal traction zone~Pneumatic retinopexy (10% C3F8)~Barrier laser photocoagulation around retinal break after retinal attachment."
10119791|NCT04403490|Experimental|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
10119792|NCT04403490|Active Comparator|Conventional intervention|Conventional physical and occupational therapy
10119793|NCT04403464|Experimental|HABIT-ILE with REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities with an interactive device
10119794|NCT04403464|Active Comparator|HABIT-ILE without REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
10119795|NCT04403659|Experimental|Intervention|Use of a telemonitoring/telemedicine suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care
10119796|NCT04403659|No Intervention|Control|Routine clinical care, following European Society of Cardiology 2016 Guidelines on Heart failure and Good Clinical Practice guidelines
10119797|NCT04403451|Experimental|Phase 1/Cohort 1|True North Love Notes, Financial Stability, Jobs
10119798|NCT04403451|Experimental|Phase 2/Cohort 2|True North Love Notes, Financial Stability, Jobs
10119799|NCT04403451|Experimental|Phase 3/Cohort 3|True North Love Notes, Financial Stability, Jobs
10119800|NCT04403724|Active Comparator|premixed injection|will receive an intrathecal injection of 2.4 ml hyperbaric bupivacaine 0.5%, 20 µg fentanyl, and 100 µg preservative-free morphine mixed together.
10119801|NCT04403724|Active Comparator|sequential injections|will receive an intrathecal injection of 2,4 ml hyperbaric bupivacaine 0.5% followed immediately by the opioid mixture by two separate syringes.
10119802|NCT04403529|Experimental|Traditional Chinese Medicine|"60 days of oral Traditional Chinese Medicine (prescription for breast cancer Traditional Chinese Medicine formulation)"
10119803|NCT04403529|Placebo Comparator|Placebo|"60 days of oral placebo (placebo contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler)"
10119804|NCT04403646|Experimental|TREATED|"Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy.~Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
10119805|NCT04403646|Placebo Comparator|CONTROL|"Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product.~Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
10119806|NCT04403568|Experimental|Ursolic Acid|Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy
10119807|NCT04403568|Experimental|Curcumin|Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy
10119808|NCT04403568|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy
10119809|NCT04403555|Experimental|Ivermectin|Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
10119810|NCT04403555|No Intervention|Standard of care|Standard of care treatment
10119811|NCT04403711|Active Comparator|local anesthetic and dexmedetomidine|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL dexmedetomidine
10119812|NCT04403711|Placebo Comparator|local anesthetic and placebo|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL normal saline
10119813|NCT04403594||MS with spasticity of one lower extremity|A person diagnosed with Multiple Sclerosis and spasticty of one lower extremity. The person must be able to walk 25 feet and cannot have had Botox in the lower extremity on the last 6 months.
10119814|NCT04403373|Placebo Comparator|Waitlist control group|Participants in this group receive no intervention during the 12-week period.
10119815|NCT04403373|Experimental|Moderate-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a moderate intensity (~3.5 METs). The training will be conducted outdoors. Each training session lasts for 50 minutes.
10119816|NCT04403373|Experimental|Vigorous-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a vigorous intensity (~7 METs). The training will be conducted outdoors. Each training session lasts for 25 minutes.
10119817|NCT04403412|Experimental|Left atrial appendage closure group|
10119818|NCT04403412|Experimental|Radiofrequency ablation group|
10119819|NCT04403412|Experimental|LAAC combined with radiofrequency ablation group|
10119820|NCT04403360|Experimental|Erector Spinae plane Block (ESPB) group|The ultrasound-guided ESPB was realized at T12 level (levo bupivacaine 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)after the induction of anesthesia but before the start of the surgery.
10119821|NCT04403360|Active Comparator|Local anesthesia infiltration by the surgeon|The surgeon infiltrates the surgical site after skin incision with local anesthetics (Levo Bupivacaïne 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)
10119822|NCT04403347|Experimental|Innovative Dietary Formulation|In addition to regular diets and usual care of hypertension, additional innovative dietary formulation will be orally taken 3 times per day.
10119823|NCT04403347|Active Comparator|Antihypertensive Medication|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
10119824|NCT04403347|No Intervention|Usual Care|Usual Care (Guideline-based patient education and lifestyle recommendations)
10119825|NCT04403126|Experimental|Forgiveness curriculum for 5th grade|"Classrooms randomly assigned to the experimental group will receive the forgiveness intervention. The forgiveness intervention will follow the curriculum - The Journey Toward Forgiveness -A Guided Curriculum for Children Ages 10-12 (Grade 5 in the US). The Forgiveness Curriculum Guide consists 14 lessons over 12 weeks. Each class meets weekly for 40 to 60 minutes to complete one lesson (in two of the weeks, there will be two lessons)."
10119826|NCT04403126|No Intervention|Regular school instruction|Classrooms randomly assigned to the control group will have instruction as usual.
10119827|NCT04403074||Chronic Pancreatitis Patients|Patients that have Chronic Pancreatitis and the current treatment with Celiac Plexus Blocks (CPB) are providing minimal relief of pain (CPB provide less than one month of pain relief). These patient will then receive a Celiac Plexus Neurolysis.
10119828|NCT04403087|Experimental|Trimebutine add group|Addition of Trimebutine on the Bismuth-containing quadruple regimen
10119829|NCT04403087|No Intervention|Control group|Bismuth-containing quadruple regimen
10119830|NCT04403035||ID NOW vs. Acccula arm|Each patient serves as his or her own control. The ID NOW test is the one that is being currently used (i.e. the control) and the Accula test is the newer test being evaluated.
10119831|NCT04403334|Experimental|Intracameral levofloxacin|0.5% unpreserved solution
10119832|NCT04403334|Experimental|Intracameral moxifloxacin|0.5% unpreserved solution
10119833|NCT04403152|Experimental|Rehabilitation group|This is the study group in whom post-operative rehabilitation was provided for 5 days.
10119834|NCT04403152|Active Comparator|Mobilization group|This is the control group in whom post-operative mobilization was provided for 5 days.
10119835|NCT04403178||Children who develops hip displacement|Patient group 1 includes children who developed a Migration Percentage of > 40 % in either hip over a follow-up period of three years.
10119836|NCT04403178||Children who do not develops hip displacement|Patient group 2 includes children who did not develop a Migration Percentage of > 40 % on either hip over a follow-up period of three years
10119837|NCT04403100|Active Comparator|Hydroxychloroquine Sulfate|Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
10119838|NCT04403100|Active Comparator|Lopinavir/ Ritonavir|Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
10119839|NCT04403100|Active Comparator|Hydroxychloroquine plus Lopinavir/ Ritonavir|"Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days~Plus~Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days"
9966457|NCT01260246|Experimental|sitagliptin|sitagliptin 100mg/daily for 6 months
10119840|NCT04403100|Placebo Comparator|Placebo|"Placebo~Twice a day from day 1 through day 10."
10119841|NCT04403243|Experimental|1. Colchicine|30 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
10119842|NCT04403243|Experimental|2. Ruxolitinib|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
10119843|NCT04403243|Experimental|3.Secukinumab|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
10119844|NCT04403243|Active Comparator|4.Standard treatment|-30 patients Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
10119845|NCT04403282|Active Comparator|Paired(right and left neck) comparison group eflornithine|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
10119846|NCT04403282|Placebo Comparator|Paired(right and left neck) comparison group placebo|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
10119847|NCT04403230|Experimental|Clinical behaviour on teeth prepared without finish line|Evaluate the clinical behavior of restorations placed on teeth prepared without finish line, monitoring periodontal status as well as the prostheses to assess stability and treatment predictability.
10119848|NCT04403191||Group A|received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours
10119849|NCT04403191||Group B|received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours
10119850|NCT04403191||Group C|received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours.
10119851|NCT04403269|Experimental|IgIV|The experimental arm is human immunoglobulins. 2 infusion at D1 and D2. (0.8 g / kg by IV infusion)
10119852|NCT04402957|Placebo Comparator|Placebo|100 mL drug-free IV saline infusion over 2 hours daily
10119853|NCT04402957|Experimental|LSALT|100 mL of 5 mg IV LSALT peptide infusion over 2 hours daily
10119854|NCT04403009||the nonsevere Coronavirus Disease 2019 Patients|
10119855|NCT04403009||the severe Coronavirus Disease 2019 Patients|
10119856|NCT04403321|Placebo Comparator|Eltrombopag|Eltrombopag and the placebo would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day.
10119857|NCT04403321|Experimental|Eltrombopag + Tacrolimus|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. Tacrolimus will be given at 1mg bid with the target concentration to be 5-10 ng/ml throughout the study.
10119858|NCT04403321|Experimental|Eltrombopag + Cyclosporin A|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. Cyclosporin A will be given started with 100mg bid with the target concentration to be 100-150 ng/ml throughout the study.
10119859|NCT04403217|Experimental|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
10119860|NCT04402983|Experimental|Telerehabilitation Group|Physiotherapy will be carried out by conducting online conference method. Program content; Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
10119861|NCT04402983|No Intervention|Control group|Information and exercise brochure will be provided
10119862|NCT04402879|Experimental|Prone Positioning (PP)|The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day.
10119863|NCT04402879|No Intervention|Control - usual management|The control group will consist of standard medical care with no instructions or prompts to change positioning to staff or patients.
10119864|NCT04402931|Other|Transcatheter Valve-in-Valve Intervention|Transcatheter Valve-in-Valve Intervention
10119865|NCT04402931|Other|Redo Surgery|Surgical Mitral valve replacement
10119866|NCT04403048|Active Comparator|Patients in which standard provisional approach is preformed|Detailed technique is described in the Detailed study description paragraph
10119867|NCT04403048|Experimental|Patients in which provisional DCB approach is preformed|Detailed technique is described in the Detailed study description paragraph
9966458|NCT01260246|Placebo Comparator|placebo|placebo match for 6 months
10119868|NCT04402892|Active Comparator|Patients hospitalized for SARS-CoV-2|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
10119869|NCT04402892|Active Comparator|Patients who have recovered from CoV-2-SARS|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
10119870|NCT04402840|Experimental|Stellate Ganglion Block (SGB)|Clinical Stellate ganglion block
10119871|NCT04402762|Experimental|TR treatment sequence|Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma. Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France.
10119872|NCT04402762|Active Comparator|RT treatment sequence|Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France. Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma.
10119873|NCT04402853||COVID 19 Patients|hospitalized patients with COVID 19
10119874|NCT04402710|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Action-Coping Planning and Monitoring Physical Activity Session 4: Goal re-visitation and adjustment and building self-efficacy. Session 5: Physical Activity Enjoyment and Barriers/Solutions. Session 6: Relapse prevention and commitment to exercise. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, antibiotic use, oral health, osteoporosis and vitamin D).
10119875|NCT04402710|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Learn about fear of self-compassion and the benefits of self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Dealing with difficult emotions, loving Kindness and Self-Compassionate motivation. Session 6: Living deeply, self-appreciation and stages of progress.
10119876|NCT04402814||Arm A (positive for COVID-19)|"One or two samples of your blood that were previously collected for routine care will be obtained from the hospital laboratory and will be tested for the antibodies against COVID-19 virus.~First blood sample obtained: 7 to 12 days following onset of symptoms; and/or~Second blood sample obtained: 12 to 40 days following the onset of symptoms."
10119877|NCT04402814||Arm B (negative for COVID-19)|One sample of blood that was collected for routine care at any point during hospitalization will be obtained from the hospital laboratory and will be tested for the antibodies.
10119878|NCT04402580|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells)~How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~Where: in Hospital~When and how much: once; diluted in 1000 ml of normal saline."
10119879|NCT04402580|Active Comparator|Mycophenolate Mofetil|"Drug Name: Mycophenolate Mofetil (MMF)~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis~Procedures: MMF 1,200 mg/1,73 sqm orally divided in 2 daily doses"
10119880|NCT04402671|Active Comparator|non-crosslinked collagen membrane group|2 patients (1 male, 1 female)
9668944|NCT04537078|Active Comparator|the progestin primed double stimulation group|luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Duphaston at 20 mg/day will be started from the first day of the ovulation induction.Decapeptyl in a dose of 2 ampules of 0.2 mg will be administered when leading follicle >18 mm in diameter for triggering.Then, Controlled ovarian hyper-stimulation the next day after the previous oocyte pickup simultaneously with Duphaston. Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate (Cyclo-Progynova (white tablets) daily.When endometrial thickness ≥ 7 mm.Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.
9668945|NCT04537078|Active Comparator|the flexible GnRh antagonist|This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle >18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle >18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.
9668946|NCT04534933|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualisation will be established by compliance guided end-expiratory and peak pressure setting during double lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
10119881|NCT04402671|Active Comparator|glutaraldehyde cross-linked collagen membrane|2 patients (2 females)
10182892|NCT03769883|Experimental|Dietary control (DCON)|The macro-nutrient distributions are in line with the current guidelines from the national Diabetes Association and Canadian guidelines, where individualization in macronutrient distribution should lie within the range of 45-60E% carbohydrate, 15-20E% protein and 20-35E% fat. The dietary plan will aim at reducing saturated fat intake <7E% aiming at a caloric deficit of 500 kilo calories/day
10182893|NCT03769883|Experimental|Moderate Exercise Dose (MED)|Two aerobic training sessions per week of 45-60 min duration and one session per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
10182894|NCT03769883|Experimental|High Exercise Dose (HED)|Four aerobic training sessions per week of 45-60 min duration and two sessions per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
10182895|NCT03769883|No Intervention|Control|No intervention
10187606|NCT03724539|Experimental|STRIPA intervention|"GPs in the intervention group will perform a STRIPA analysis for each of their 8-10 patients after the recruitment of the patient into the OPTICA trial, so that the results can be discussed in the next consultation and a shared decision-making can be performed.~STRIPA is a structured method to perform pharmacotherapy optimization. The STRIPA intervention in the OPTICA trial consists of 4 steps:~recording medication and diagnoses in STRIPA (upload from data from the 'Family medicine ICPC Research using Electronic medical records' (FIRE) database)~structured drug review through the GP based on the STRIPA with the integrated STOPP/START criteria~shared decision-making between GP and patient with possible adaptation of the recommendation~follow-up through study team"
10187607|NCT03724539|Sham Comparator|Sham intervention|Patients in the control group will receive a sham intervention, which consists of a usual medication review by their GP as well as a shared decision making of the latter.
10187608|NCT03724487|Experimental|Coachman|The first study condition, A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN) will be exposed to three Technology-based Interventions (TBI) accessible via smartphone and counseling from a local community nurse organization for hypertension self-management support.
10187609|NCT03724487|Experimental|Enhanced Usual Care|The second study condition, Enhanced Usual Care (EUC) will be exposed to routine and standard hypertension education materials and one session on self-monitoring blood pressure.
10119882|NCT04402918|Other|pregnancy patients diagnosed with SARS Cov2 during pregnancy|Delivery day biological samples from the mother and the newborn will be performed
10119883|NCT04402606|Experimental|Evaluation on skin toxicities|This evaluation consists on a clinical examination of the skin and the realization of the cutaneous measurements of reference on 4 sites frequently exposed to the cutaneous toxicities: face, neckline, palms of the hands and soles of the feet.
10119884|NCT04402723|Experimental|Donafenib, 0.2g|Donafenib,0.2g,bid,Combination with Cytarabine and Daunorubicin.
10119885|NCT04402723|Experimental|Donafenib,0.3g|Donafenib,0.3g,bid,Combination with Cytarabine and Daunorubicin
10119886|NCT04402736|Experimental|Modified Barthel Index-based rehabilitation nursing program|Patients received the Modified Barthel Index based rehabilitation nursing from qualified nurses.
10119887|NCT04402736|Other|Usual care|Patients received the usual care.
10119888|NCT04402320||Control group|extubated and weaning from the ventilator and followed our routine protocol of management post extubation without mechanical ventilation or BIPAP machine
10119889|NCT04402320||Invasive ventilation group|reconnected to mechanical ventilator before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use of NIV.
10119890|NCT04402320||non invasive ventilation group|following the same previous protocol done after extubation with immediate connection to NIV with BIPAP mode for 1 hour and repeated every 12hours for 48 hours, BIPAP adjusted in our study by FIO2 40%, PEEP 8 cmH2O, Pressure support of 15 cmH2O.
10119891|NCT04402697|No Intervention|Normal-weight (NW)|Individuals with BMI<25 kg/m2
10119892|NCT04402697|Experimental|Overweight-Obese (OW-OB)|Individuals with BMI>25 kg/m2, submitted to a nutritional intervention (hypocaloric balanced diet) during 6 months and prescription of physical activity to achieve weigh loss
10119893|NCT04402697|Experimental|Metabolically obese normal-weight (MONW)|Individuals with BMI<25 kg/m2, with metabolic alterations related to obesity (hypertriglyceridemia, hypercholesterolemia, hyperglycaemia, hypertension or high waist-hip ratio), submitted to an intervention to improve dietary habits and physical activity in order to achieve a better body composition and metabolic health. Mediterranean diet will be and aerobic and strength exercises will be advised to these individuals.
10119894|NCT04402359||Group A|Patients of Group A received meropenem one gram slowly IV infusion every 8 hours for 14 days and gentamicin 7 milligram (mg)/ Kilogram body weight per day slowly IV infusion once daily only for one week after ventilator for 2 weeks
10119895|NCT04402359||Group B|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution). The solution for injection should be administered over 120 minutes.after ventilator for 2 weeks
10119896|NCT04402411|Active Comparator|Control Group|Patients will receive general anesthesia with intravenous opioid
10119897|NCT04402411|Experimental|Quadratus lumborum|Patients will receive bilateral quadratus lumborum block
10119898|NCT04402411|Experimental|Transversus abdominis plane|Patients will receive bilateral transversus abdominis plane block
10119899|NCT04402450|Active Comparator|suprainguinal fascia iliaca block|Forty mL of levobupivacaine 0.25% with epinephrine 5 ug/mL will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
10119900|NCT04402450|Experimental|Pericapsular nerve group block|Twenty mL of levobupivacaine 0.5% with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle.
10119901|NCT04402619|Experimental|Online CBT|Ten modules with minimum therapist guidance
10119902|NCT04402476|Experimental|Device and Control|"Device:~Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, Tested for use with Chemotherapy Drugs.~Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive Control:~0.4% Sodium Lauryl Sulfate (SLS) Dose. 0.2 ml"
10119903|NCT04402775|No Intervention|Vascular clamps|Patients randomized to the use of vascular clamps to obtain a bloodless field during arteriovenous fistula surgery (standard protocol).
9966459|NCT01260259|Experimental|Remote Ischemic Preconditioning (RIPC)|
9966460|NCT01260259|Sham Comparator|Control|
9966461|NCT01260285|Experimental|Vardenafil|
10119904|NCT04402775|Experimental|Tourniquet|Patients randomized to the use of a tourniquet to obtain a bloodless field during arteriovenous fistula surgery.
10119905|NCT04402268||Low risk|Low risk of sudden cardiac death according to HCM Risk-SCD Calculator
10119906|NCT04402268||Intermediate risk|Intermediate risk of sudden cardiac death according to HCM Risk-SCD Calculator
10119907|NCT04402268||High risk|High risk of sudden cardiac death according to HCM Risk-SCD Calculator
10119908|NCT04402346|Experimental|Radiofrequency-assisted|
10119909|NCT04402346|Active Comparator|Stapler|
10119910|NCT04402502|Experimental|Healthy Population|Healthy Individuals with no presence of neurological disorders, rheumatoid arthritis or comorbid health conditions, and are not pregnant.
10119911|NCT04402424||Two-Week Rule Colorectal Patients|Patients that the GP has referred to two-week rule colorectal clinics at Royal Surrey County Hospital with bowel symptoms or found to be anaemic
10119912|NCT04402437|Active Comparator|Receives LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
10182896|NCT03769870|Other|Teneligliptin|
10182897|NCT03769870|Other|Atorvastatin|
10182898|NCT03769870|Other|Teneligliptin + Atorvastatin|
10119913|NCT04402437|Active Comparator|Receives QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
10119914|NCT04402372||Group 1|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F bidirectional (BiflowTM, LivaNova, Italy) for femoral artery cannulation
10119915|NCT04402372||Group 2|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F conventional (HLS, Maquet, Germany cannula with downstream line (6F) for femoral artery cannulation
10119916|NCT04402541|Experimental|CB-5339|Orally administered CB-5339
10119917|NCT04402333||Robotic interval debulking surgery|Surgery will commence with an initial assessment with a camera inserted though the belly button. This visual assessment will be used to determine whether it is feasible to proceed with surgery robotically or whether full debulking surgery to zero macroscopic residual disease would be best carried out through an open surgical approach. If an open surgical approach is considered the optimum treatment for the patient and they have consented for this, then this will be done. If there is disease that cannot be removed Robotically after starting by this route, but can be removed via an open incision the surgery will be converted to an open procedure if it is safe to do so. If there are any complications, we may also need to convert to open surgery. The aim of the surgery whether by robotic or open is to remove all visible disease safely.
10119918|NCT04402333||Open interval debulking surgery|Standard Care. Following initial laparoscopic assessment patients not deemed suitable for minimally invasive robotic surgery will proceed with standard open interval debulking surgery through an extended midline incision. These patients will also be followed up to assess recovery, complication rate and quality of life.
10119919|NCT04402528|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will use the mehealth for ADHD web-based software and have access to a module that allows parents and teachers/childcare providers to develop and implement behavioral interventions such as daily report cards online.
10119920|NCT04402255|Experimental|behcet group|this group includes 16 patients with behçet
10119921|NCT04402255|Experimental|fmf group|this group includes 16 patients with fmf
10119922|NCT04402255|Active Comparator|healty control|this group includes 16 healthy control
10119923|NCT04402203|Experimental|Favipiravir + Standard Treatment|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
10119924|NCT04402203|Placebo Comparator|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
10119925|NCT04402047|Experimental|Electroacupuncture group|
9966462|NCT01260298||MC1 Ultrasonic Device|
10119926|NCT04402047|Active Comparator|Topical DSG group|
10119927|NCT04402086||Biorepository|Participants with rheumatic diseases who contributed biospecimen samples (blood, saliva, urine, stool, tissue).
10119928|NCT04402021|Experimental|Aerobic Exercise|Participants randomized to the aerobic exercise group will complete 30 minutes of outdoor walking at a moderate intensity, defined as 50% heart rate reserve from the American College of Sports Medicine (ACSM) exercise prescription recommendations. A 5-minute warm-up and cool-down will occur before and after the 30-minute bout. A Polar H10 heart rate monitor will continuously monitor exercise intensity during the session. Ratings of Perceived Exertion (RPE) will be assessed using the Borg scale (i.e., 6-20 rating system) to indicate perceived exercise effort every 5 minutes during the exercise session. Each session will last approximately 50 minutes.
10119929|NCT04402021|Other|Quiet Rest|Participants randomized to this condition will be instructed to watch a nature documentary void of topics related to sleep or exercise. A Polar H10 heart rate monitor will continuously monitor heart rate during the session to mimic the aerobic exercise condition. Participants will not be permitted to complete homework or work during the allotted time to reduce the chance of unintended stimuli. The quiet rest sessions will be 50 minutes in length.
10119930|NCT04401917|Other|HIV positive (HIV+) subjects with Opioid Use Disorder (OUD)|
10119931|NCT04401917|Other|HIV negative (HIV-) subjects with OUD|
10119932|NCT04401917|Other|HIV Positive (HIV+) subjects with OUD negative|HIV+ subjects who may have been opioid-exposed but do not have current or past OUD
10119933|NCT04401917|Other|Healthy volunteer|HIV-, OUD- healthy controls who have been opioid-exposed but do not have current or past OUD
10119934|NCT04402138|Experimental|Acalabrutinib|Acalabrutinib will be self-administered orally for up to approximately 2 years post-BMT.
10119935|NCT04401878|Experimental|the treatment group (A)|Patients who have PDPH are manged by SPGB, they are assessed by NRS before the block, at 30 mins, 2h, 4h, 6h, 12h, and 24hours after block. The patients are also examined by TCD before and after the block.
10119936|NCT04401878|Experimental|control group (B)|The control group (B) of 60 patients with no PDPH were examined by TCD
9966463|NCT01260337|Active Comparator|Diabetes Support and Education (DSE)|
9966464|NCT01260337|Experimental|Portion controlled diet (PCD)|behavior modification
10119937|NCT04402216|No Intervention|Current standard of care, no formal preparation|Participants in this group will receive the standard of care with no formal preparation. MRI technologist will meet patient prior to scan introducing role of patient, role of MRI technician, and give verbal discussion of MRI process. MRI technologist will offer opportunity for patient to watch a movie as alternative focus/distraction during MRI scan. The child life specialist will not meet with the caregiver or child during their visit.
10119938|NCT04402216|Experimental|Child Life-led preparation|Participants will meet with a child life specialist who will provide psychological preparation utilizing photos, MRI sounds, verbal discussion of MRI process, and discuss various coping strategies such as deep breathing or stress ball and option to watch a movie for alternative focus/distraction during the scan.
9966465|NCT01260363|Active Comparator|Naropin, Adrenalin, applicationsite|
9966466|NCT01260363|Active Comparator|Femoral nerve block|
9966467|NCT01260376|Experimental|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
9966468|NCT01260376|No Intervention|Placebo|Placebo tablets will be administered 4 times previous to and during the investigation day
9966469|NCT01260389|No Intervention|control group|Usual pharmacist care in patients with Chronic Obstructive Pulmonary Disease (COPD).
9966470|NCT01260389|Experimental|pharmaceutical care intervention|A pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
9966471|NCT01260415|Experimental|Folfox/Folfiri, Panitumumab|Eligible patients will recieved chemotherapy/panitumumab for 2 months (4 cycles) pre-operatively and 4 months post-operatively, plus a further 6 months of pantimumab post-chemotherapy
9966472|NCT01260428||healthy active subjects|with and without high altitude intolerance
9966473|NCT01260441|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected over various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
9966474|NCT01260441|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
9966475|NCT01260480|Experimental|[18F]-ML-10|
9966476|NCT01260506|Experimental|VB-111|Antiangiogenic and vascular disruptive agent
9966477|NCT01260519|Experimental|active arm: heparin|
9966478|NCT01260532||Graves' disease|no intervention
9966479|NCT01260532||Hashimoto's thyroiditis|no intervention
9966480|NCT01260532||Healthy subjects|no intervention
9966481|NCT01260545|Experimental|Infusion|A standard 3+3 design will be employed to determine maximum tolerated dose
9966482|NCT01260558|Active Comparator|Arm 1|Sirolimus-Permanent-Polymer Eluting Stent
9966483|NCT01260558|Active Comparator|Arm 2|Sirolimus-Polymer-free Eluting Stent
9966484|NCT01260571|Experimental|Benzoyl Peroxide and Sulfur|Topical Medications containing benzoyl peroxide and sulfur
9966485|NCT01260597|Experimental|Life Style Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report not being quit and are randomized to the intervention condition, tailored messages are delivered via the IVR system. The automated calls would include an assessment of the individual's interest in another quit attempt and deliver brief, tailored messages to perceived barriers for re-engaging into treatment. The system is programmed to transfer the caller to a live quit line counselor if the individual is willing to re-engage in cessation treatment.
9966486|NCT01260597|Active Comparator|Life Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report still smoking the IVR will thank them for their time and the call will end.
9966487|NCT01260610|Active Comparator|Tenofovir|
9966488|NCT01260610|Active Comparator|Telbivudine|
9966489|NCT01260610|Experimental|Tenofovir plus Telbivudine|
9966490|NCT01260636|Experimental|MultiHance contrast agent|MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)
9966491|NCT01260636|Active Comparator|Magnevist|Magnevist administered at a dose of 0.2 mmol/kg
9966492|NCT01260675||NanoBUP Capsules|Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
9966493|NCT01260675||Suboxone Sublingual Tablets|Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
9966494|NCT01260714|Experimental|Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)|Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
9966495|NCT01260727|Experimental|Group 1|Participants will receive PENNVAX-G vaccine administered by intramuscular injection (IM) via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
9966496|NCT01260727|Experimental|Group 2|Participants will receive PENNVAX-G vaccine administered via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
9966497|NCT01260727|Experimental|Group 3: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
9966498|NCT01260727|Placebo Comparator|Group 3: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via Biojector 2000 needless device in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
9966499|NCT01260727|Experimental|Group 4: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
9966500|NCT01260727|Placebo Comparator|Group 4: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
9966501|NCT01260753|Experimental|UR-63325|
9966502|NCT01260753|Active Comparator|Fluticasone propionate nasal spray|
9966503|NCT01260753|Placebo Comparator|Placebo|
9966504|NCT01260766|Active Comparator|Active Comparator: Oplon Active Patch|
9966505|NCT01260766|Placebo Comparator|Placebo Comparator: Placebo patch|
9966506|NCT01260792||Children|Children between 5 and 18 years old.
9966507|NCT01260792||Adults|Parents of children between 5 and 18 years old
9966508|NCT01260805|Active Comparator|Reference Drug|
10119939|NCT04402216|Experimental|MRI preparation video|Participants will be shown an MRI preparation video by the research coordinator in the MRI dressing room prior to MRI scan. The MRI preparation video will walk the patient through the MRI experience with a mock patient explaining all the steps of MRI process from check in to discharge. The child life specialist will not meet with the caregiver or child during their visit.
10119940|NCT04402216|Experimental|Child Life preparation with VR|Participants will be provided MRI preparation with a child life specialist using the Kind VR device. The VR (virtual reality) session will consist of an audio and visual MRI experience designed to serve as an opportunity for the patient to practice their scan prior to MRI. The VR session will take place once during the Radiology admission and will be approximately 15 minutes in duration. The VR software was developed by Kind VR and was designed specifically for the purpose of preparation for brain MRI. The interactive VR experience walks patients through each step of an MRI. Patients can practice holding still for the MRI and will get feedback from the VR headset when they are moving their head. Along with VR practice session CCLS will discuss various coping strategies such as deep breathing and/or stress ball and option to watch a movie for alternative focus/distraction during the scan.
10119941|NCT04402177|Experimental|Hypersensitivity Pneumonitis patients showing lung fibrosis|hypersensitivity Pneumonitis patients that shows lung fibrosis after CT scan ( fibrotic patients ) methyl prednisolone 0.5mg/kg /day orally for 8 weeks
10119942|NCT04402177|Active Comparator|hypersensitivity Pneumonitis patients without lung fibrosis|hypersensitivity Pneumonitis patients that doesn't show lung fibrosis after CT ( non-fibrotic patients ) will be given also methyl prednisolone 0.5mg/kg /day orally for 8 weeks
10119943|NCT04401943|Experimental|Fatigue intervention|the Fatigue intervention is a 6 week intervention delivered using video teleconferencing
10119944|NCT04402073|Other|standard arms|"Criteria: Adult SHH (p53wt) M0-1, adult WNT M0-1, adult Group 4 M0-1.~Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.~Criteria: Post pubertal < 18 y SHH (p53wt) M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy."
10119945|NCT04402073|Experimental|experimental arms|"Radiotherapy Criteria: Adult and post-pubertal SHH (p53wt) M0; adult WNT M0, adult Group 4 M0.~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy.~SMO-inhibitor Criteria: Adult and post-pubertal SHH (p53wt) M0.~Sonidegib 200 mg/day (daily) from first day of radio-chemotherapy until end of maintenance chemotherapy, including 6w chemotherapy break."
10119946|NCT04401787|Active Comparator|laparoscopic anterior resection (LAR)|LAR group included 88 patients, 17 patients converted to open
10119947|NCT04401787|Active Comparator|open anterior resection|Open anterior resection for 56 patients
10119948|NCT04402034|Experimental|Application of tele-rehabilitation|Individuals that will perform the protocol of virtual reality intervention.
10119949|NCT04401852|Active Comparator|MgSO4 group|will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose
10119950|NCT04401852|Placebo Comparator|placebo group|will receive an equal volume of isotonic 0.9% saline over 15-20 minutes
10119951|NCT04401722|Active Comparator|PD in normal altitude|PD underwent in the area at the level of the sea, normal altitude region
10119952|NCT04401722|Active Comparator|PD in high altitude region.|PD underwent in high altitude region.
10119953|NCT04401839|Active Comparator|Control group|153 patients received Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
10119954|NCT04401839|Active Comparator|Study group|156 patients received Oxytocin 10 IU I.V shot at the time of delivery of the of the anterior shoulder of the baby according to the WHO recommendation .Then oxytocin is stopped and cervical traction (Amr maneuver )is applied.
10119955|NCT04401709|Experimental|Gemcitabine/Capecitabine|gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21
10119956|NCT04401709|Active Comparator|Capecitabine|capecitabine 2,500 mg/m2 D1-14
10119957|NCT04401670|Other|Triage with different options|"Self-Collection: hrHPV and Biomarkers Testing (among hrHPV+)~ThinPrep Specimen: Liquid-Based Cytology (LBC), hrHPV Testing, and Biomarker Testing (among hrHPV+)~Visual Inspection after Acetic Acid (VIA)"
10119958|NCT04401631||Interventions|"A minimum of 20 subjects with targeted levels of total IgE are needed to participate in the Operator-to-Operator whole blood study.~A minimum of 20 subjects with targeted levels of allergen-specific and total IgE are needed to participate in the capillary whole blood between-run imprecision study in the POL environment.~A minimum of 40 subjects with targeted levels of Fel d 1-specific IgE and total IgE are needed to participate in the sample type comparison study. These subjects will be recruited, and their samples analyzed at 1 POL.~A minimum of 300 subjects (approximately 100 subjects enrolled and evaluated at each of three sites) and with targeted levels of total IgE are needed to participate in the method comparison study."
10119959|NCT04402164|Active Comparator|Dentally anchored Herbst group|Herbst appliance will be anchored on the mandibular dentition
10119960|NCT04402164|Active Comparator|Skeletally anchored Herst group|Herbst appliance will be anchored on mini-plates placed in the para symphesial areas
10119961|NCT04401527|Active Comparator|Sodium Nitrite|Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.
10119962|NCT04401527|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.
9966509|NCT01260805|Active Comparator|Test Drug|
10182899|NCT03769857|Experimental|NEM® + BIOCURC®|"NEM® + BIOCURC®~NEM, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS BIOCURC, 350 mg, #10 oval softgel, once daily orally for 2 weeks"
10119963|NCT04401566|Experimental|Internal Myofascial Release Group|Internal myofascial trigger point release therapy consists of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial release techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point. Releasing pelvic muscle tension includes applying varying amounts of pressure, sometimes gradually stroking and strumming the muscle region while systematically contracting and relaxing the affected muscles to aid in a trigger point release.
10119964|NCT04401566|Experimental|External Myofascial Release Group|Eksternal myofascial trigger point release therapy consists of 30 minutes massage to the abdominal wall, gluteal area and abductors, and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and the lower extremity of the muscle.
10119965|NCT04401566|Other|Control Group|The Control group will have a video about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breathing, pelvic floor muscle stretching, and releasing.
10119966|NCT04401683|Experimental|Digital Rehabilitation|Standard medical treatment + Fully remote rehabilitation program with a digital therapist
10119967|NCT04401683|Active Comparator|Conventional Rehabilitation|Standard medical treatment + Home-based rehabilitation program
10119968|NCT04401774|Experimental|Nivolumab Maintenance|All patients will undergo cerebrospinal fluid (CSF) and blood collection as well as MRI imaging as standard of care prior to (- 21 days) first-line treatment initiation, during first-line therapy (before initiation of the 5th methotrexate dose (+/- 7 days)), at completion of first-line chemotherapy therapy (+/- 7 days) as well as 60, 180, and 360 days after enrollment into maintenance or observation (+/- 7 days). Those patients with persistent cfDNA in the CSF after completion of first-line chemotherapy and either complete or partial response on imaging will be enrolled into the nivolumab maintenance treatment arm. All other patients (no persistent cfDNA in the CSF and either complete or partial response on imaging) are followed with observation. Patients who do not respond to first-line therapy are not eligible for nivolumab maintenance and will no longer be followed in the biospecimen and clinical data collection cohort.
10119969|NCT04401605|Experimental|Fermented Food-Supplemented Diet|Patients in this arm will supplement their regular diet by an increasing number of daily servings of fermented food over a period of 10 weeks.
10119970|NCT04401605|Placebo Comparator|Regular Diet Control Arm|Patients in this arm will continue their regular diet throughout the 10 weeks of study with a maximum of 1 serving of fermented foods per day.
10119971|NCT04401475|Experimental|Stage 1|Stage 1 (Phase II Study) For 80% power (β = 0.20), at a significance level of 5% (α =0.05) and a 1:1 randomization ratio, a total of 316 (EB05: 158, SOC: 158) evaluable patients will be required. Allowing for 20% attrition a total of 396 patients will be recruited.
10119972|NCT04401475|Experimental|Stage 2|Stage 2 (Phase III Study - Canada) For a 1:1 ratio of patients treated with EB05 vs. Placebo, 80% power, and a two-sided alpha of 0.05 (equivalent to one sided test with an alpha of 0.025) to detect an Odds Ratio of 1.50, a total of 884 evaluable patients will be required for Stage 2 (Phase III study). Allowing for 20% attrition, a total of 1,105 patients will be enrolled in this Stage.
10119973|NCT04401618||Class V RMGI Restorations|Resin-modified glass ionomer (RMGI - Fuji 2 LC) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
10119974|NCT04401618||Class V Glass ionomer - GIC Restorations|Glass ionomer (GI - Fuji 9) Class V restorations performed by by 3rd and 4th-year dental students in adult patients of Schulich dental clinic over the last three years will be evaluated using mirrors and probes.
10119975|NCT04401644|Experimental|primary arm|There will only be one set of participants with each participants samples and results as the comparator groups. There will be within group comparison of methods of detection of virus by two test methodologies. Post hoc validation of test performance against reference set.
10119976|NCT04401735|Experimental|Polydeoxyribonucleotide|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml
10119977|NCT04401735|Experimental|Polydeoxyribonucleotide, Placebo|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml Placebo (Normal saline)
10119978|NCT04401735|Placebo Comparator|Placebo|Placebo (Normal saline)
10119979|NCT04401813|Experimental|IBI310|An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
10119980|NCT04401696|Experimental|Group A|Use of Bubble CPAP for management of respiratory distress
10119981|NCT04401696|Active Comparator|Group B|Use of Oxygen via nasal cannula for respiratory distress
10119982|NCT04401657|Experimental|FFR Measurement|Myocardia ischemia evaluation during adenosine stress testing
10119983|NCT04401501|Experimental|Manual Therapy + Exercise Group|Combination of manual therapy and exercises for cervicogenic headache
9966510|NCT01260818|Experimental|Tranexamic Acid|
10119984|NCT04401501|Active Comparator|Exercise Group|Only exercises for cervicogenic headache
10119985|NCT04401462|Active Comparator|Operative group|tension band wiring or plate fixation
10119986|NCT04401462|Active Comparator|Non-operative group|conservative treatment
9966511|NCT01260818|Placebo Comparator|control group|
9966512|NCT01260831|Experimental|Intervention Hospitals|hospitals randomized to implement bedsidePEWS documentation system (vital sign assessment record)
10119987|NCT04401189||Breast cancer patients|
10119988|NCT04401189||Healthy controls|
10119989|NCT04401137|Placebo Comparator|Placebo|
10119990|NCT04401137|Experimental|QDX 25|
10119991|NCT04401137|Experimental|QDX 50|
10119992|NCT04401137|Experimental|QDX 100|
10119993|NCT04401137|Experimental|QDX 200|
10119994|NCT04401124||patients treated at surgical emergency rooms|
10119995|NCT04401124||patients receiving surgeries (both elected and emergency)|
10119996|NCT04401514|Experimental|Experiemntal intervention|The experimental intervention is a 20 min. long rocking chair with music therapy.
10119997|NCT04401514|Active Comparator|Control intervention|Control intervention is also transferred to the rocking chair, but the therapy program will not be turned on.
10119998|NCT04401319|Sham Comparator|Sham Stimulation Group for Crossover Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the crossover study.
10119999|NCT04401319|Active Comparator|DLPFC Stimulation Group for Crossover Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the crossover study.
10120000|NCT04401319|Active Comparator|AG Stimulation Group for Crossover Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the crossover study.
10120001|NCT04401319|Sham Comparator|Sham Stimulation Group for Parallel Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the parallel study.
10120002|NCT04401319|Active Comparator|DLPFC Stimulation Group for Parallel Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the parallel study.
10120003|NCT04401319|Active Comparator|AG Stimulation Group for Parallel Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the parallel study.
10120004|NCT04401176|Active Comparator|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
10120005|NCT04401176|Active Comparator|Intradetrusor Onabotulinumtoxin A Injection|100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone.
10120006|NCT04401397|Experimental|Early mobilization group|Immediately after ICU extubation, enrolled patients will receive an intensive 30-45 minutes, implemented twice a day early mobilization protocol containing psychological empowerment, detailed informative education of patients and close relatives, close monitoring of the recovery course, frequent parameter protocol configuration, high intensity active progressive pulmonary and musculoskeletal exercises and mobility techniques, close monitoring for early identification and measures for prevention and treatment of complications.
10120007|NCT04401397|Active Comparator|Standard care group|Enrolled patients will receive the standard hospital mobilization protocol after their admission to the ward, containing standardized basic pulmonary and mobilization techniques of 15 minutes, once a day.
10120008|NCT04401215|Other|Technology Augmented Treatment group|Intervention Group
10120009|NCT04401215|No Intervention|Control group|After the baseline visit the control arm participants will receive no additional follow-up beyond usual care until the 30 days' end. Surveys at the end of 30 days.
10120010|NCT04401228||covid ICU patients|
10120011|NCT04401228||covid conventionnal ward|
10120012|NCT04401345|Experimental|Experimental Group (GP)|Patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated at 25mcg/min.
10120013|NCT04401345|Placebo Comparator|Placebo Group(NS)|patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated at 25 mcg/min
10120014|NCT04401085||Population area cohort - Control Cohort|A population cohort of asymptomatic individuals (only adults). This is a representative sample of the population, which are part of the research project of Institute for Clinical and Experimental Medicine and Czech Academy of Sciences. The second subsample included individuals from the official household survey of Czech Statistical Office. This cohort allowed better comparative analysis of other population cohorts from specific geographical areas.
10120015|NCT04401085||Population cohort from specific geographical areas|"This cohort is based on epidemiologically defined demographic parameters. These are populations from the following geographical areas:~Brno and the South Moravian Region; Praha; Olomouc; Litoměřice; Litovel and Uničov."
10120016|NCT04401085||Chronically ill patients cohort|A cohort of chronically ill people enrolled by Institute for Clinical and Experimental Medicine with chronic cardiovascular problems, hypertension, or diabetes.
10120017|NCT04401306|Experimental|Self-regulated simulation training|
10120018|NCT04401306|Active Comparator|Instructor-regulated simulation training|
10120019|NCT04401423|Experimental|TXA127|Participants will receive one 3-hour dosage (0.74 mg/kg), intravenously, for 10 days consecutively.
10120020|NCT04401423|Placebo Comparator|Placebo|Participants will receive one 3-hour dosage (0.74 mg/kg), intravenously, for 10 days consecutively.
10120021|NCT04401111||Survivors of Intensive care unit patients|Survivors of severe COVID-19 pneumonia after intensive care unit
10120022|NCT04401046|Experimental|Post traumatic stress and anxiety evaluation|
10120023|NCT04401033||Endoscopic cohort|Endoscopic examinations: They will be carried out according to the recommendations of the Spanish society for digestive endoscopy (SEED). In summary, the patient will perform a hand wash with hydroalcoholic solution before entering the endoscopy room, and will put on a surgical mask and gloves. Personnel close to the patient will wear an FFP2 mask, exceptionally a surgical mask, a gown (waterproof in high-risk examinations as established in the SEED guidelines), a cap, nitrile gloves and face shield or safety glasses (reusable) and shoe covers. The examinations will be performed by endoscopist-guided sedation in accordance with current clinical guidelines.
10120024|NCT04401033||Ultrasonography cohort|Abdominal ultrasound: They will be carried out according to international clinical guidelines (12). The explorer will wear an FFP2 mask, exceptionally a surgical mask, a gown, a hat, nitrile gloves, and a face shield or safety glasses (reusable) and shoe covers. The gel bottle, transducer, and stretcher will be washed prior to each scan with low-level disinfectant
10120025|NCT04401033||Telephonic cohort|The patient will be telephonically contacted for a medical visit.
10120026|NCT04401007|Experimental|Group 20/30|Two different local anesthetic volumes will be investigated: 20 mL of 1.5% lidocaine (300 mg lidocaine) at one study visit and 30 mL of 1.5% lidocaine (450 mg lidocaine) at the other study visit. Volunteers will be randomized to one of two intervention groups: (1) Group 20/30: A unilateral ESP block with 20 mL of local anesthetic at the first visit, and 30 mL of local anesthetic at the second visit
9966513|NCT01260831|Active Comparator|Control Hospitals|hospitals randomized to continue with their pre existing documentation system (vital sign assessment record)
10120027|NCT04401007|Experimental|Group 30/20|(2) Group 30/20: a unilateral ESP block with 30 mL of 1.5% lidocaine with 1/200,000 epinephrine at the first visit, and 20 mL of the same local anesthetic solution at the second visit. This crossover design allows subjects to serve as their own control.
10120028|NCT04400825|Experimental|Dry needling|Dry needling of 3 active MTrPs at most.
10120029|NCT04400825|Active Comparator|Stretching|Stretching of the main hip flexors (rectus femoris, iliopsoas and tensor fasciae latae)
10120030|NCT04400747|Experimental|weekly treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 50,000 IU of vitamin D weekly for 8 weeks.
10120031|NCT04400747|Experimental|daily treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 6,000 IU of vitamin D daily for 8 weeks.
10120032|NCT04400747|No Intervention|control group|20 patients with high calcium (Ca) values in blood tests, patients with kidney and urinary stones, as well as patients who refuse to use vitamin D supplements will be included in the control group
10120033|NCT04400760|Other|DAPA Tx|This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.
10120034|NCT04400773|Experimental|Plyometric Group|This group will receive a 6-week upper body plyometric exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
10120035|NCT04400773|Experimental|Strength Group|This group will receive a 6-week upper body strength exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
10120036|NCT04400851|Experimental|Sintilimab in advanced childhood cancer patients|
10120037|NCT04400721|No Intervention|PCIA arm|Standard post-operative treatment with patient-controlled intravenous analgesia (Piritramide bolus = 2mg, bolus interval = 7 minutes, max 4 hour dose = 30mg)
10120038|NCT04400721|Active Comparator|ESP block arm|ultrasound guided Erector spinae block (Single shot of 30ml of 0.5% solution of Naropin [Ropivacaine])
10120039|NCT04400721|Active Comparator|IC block arm|3 ml of 0.5% solution of Naropin [Ropivacaine] per intercostal space, up to a maximum of 30ml
10120040|NCT04400708|Sham Comparator|control group|normal saline injection
10120041|NCT04400708|Experimental|test group|0.5% ropivacaine injection
10120042|NCT04400786|Experimental|On-demand treatment|This group of 98 ankylosing spondylitis patients is prescribed with intermittent Imrecoxib (100mg.prn.po) according to the feeling of pain till 24 weeks. The sulfasalazine (500mg.tid.po) is used.
10120043|NCT04400786|Active Comparator|Continuous treatment|This group of 98 ankylosing spondylitis patients is prescribed with continuous Imrecoxib (100mg.bid.po) for 24 weeks. The sulfasalazine (500mg.tid.po) is used.
10120044|NCT04400669|Experimental|Mechanical Bowel Preparation|Patients will have only clear liquids after a normal breakfast and lunch on the day before surgery and subsequently fasten for 7-9 hours prior to surgery. Patients will ingest first dose of 45 ml oral sodium phosphate (NaP) enema (BT ORAL SOLUSYON 45 ML®, Yenisehir Lab. Tic. San. Ltd. Sti, Turkey) at 4 p.m. and a second dose at 8 p.m. in the evening before the scheduled surgery.
10120045|NCT04400669|Active Comparator|Low fibre diet|Patients will be given detailed instructions about the pre-operative diet (total daily Fibre intake inferior to 10 g) to be used for 3 days prior to surgery.
10120046|NCT04400669|Active Comparator|MBP plus low fibre diet|This group will receive both mechanical bowel preparation and 3-days low fibre diet.
10120047|NCT04400669|No Intervention|Control|Control subjects will receive no instructions about the pre-operative diet (free diet).
10120048|NCT04400864|Experimental|Mediterranean Diet|Nutritional guidelines based on the principals of the Mediterranean Diet
10120049|NCT04400864|Experimental|Paleolithic Diet|Nutritional guidelines based on the principals of thePaleolithic Diet
10120050|NCT04400994|Active Comparator|Rituximab only|"Rituximab infusion 375mg/m2 body surface area (BSA) weekly for 4 weeks from baseline (week 0, 1, 2, 3)~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 24 (week 24, 25, 26, 27)~Rituximab infusion 375mg/m2 BSA weekly for 2 weeks at week 52 (week 52, 53)~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 76 (week 76, 77)~A total of 12 doses of rituximab will be given in 55 weeks"
10120051|NCT04400994|Experimental|Rituximab and IVIG|"Rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 1, 2, 3);~Week 4: Rituximab + IVIG 2g per kg~Week 5, 6, 7: Above treatment repeated for 2nd cycle, infusion of rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 5, 6, 7);~Week 8: Rituximab + IVIG 2g/kg~In months 3, 4, 5, 6, patients received a single infusion of rituximab (375 mg/m2 BSA) plus infusion of 2g/kg IVIG~Thus in 6-month period patients received a total of 12 infusions of rituximab and 7 infusions of IVIG~If a patient was clinically free of disease at end of 6 months, additional infusions of IVIG will be given at week 30, 38, 48, 60 and 76~A total of 12 doses of rituximab and 12 cycles of IVIG will be given"
10120052|NCT04400942||Women with uterine myomas undergoing hysteroscopic myomectomy|
10120053|NCT04400968|Experimental|Auricular therapy group|The auricular therapy group received an intervention based on the bilateral application of 7 adhesive tapes with vaccaria seeds. The points were located with a retractable 250 gr. pressure palpator (Sedatelec®). An experienced health professional trained on acupuncture techniques applied the vaccaria seeds.
10120054|NCT04400968|Sham Comparator|Auricular therapy Placebo group|The auricular therapy placebo group had adhesive tapes without seeds displaced from the treatment points.
10120055|NCT04400968|Experimental|Kinesio tape group|The kinesio tape group received an intervention that consisted on the standard application of three elastic bandages. An experienced kinesio tape certified physical therapist applied the taping.
10120056|NCT04400968|Sham Comparator|kinesio tape Placebo group|The kinesio tape placebo group had the application of three elastic bandages that were shorter than the used in the kinesio tape group. In addition, the tape was adhered with no tension and not place in the treatment area.
10120057|NCT04400968|No Intervention|Control group|The control group did not receive any treatment. The participants continued with their routine medical treatment. However, the controls completed all the questionnaires to collect the information regarding their symptoms in order to observe their progress with no intervention.
10120058|NCT04400916|Experimental|Topical tranexamic acid|
10120059|NCT04400916|Placebo Comparator|Topical BSS|
10120060|NCT04400929|Experimental|Group A: Treatment Group|Day 1 - 5: Receive study medication Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
10120061|NCT04400929|Placebo Comparator|Group B: Placebo Group|Day 1 - 5: Receive normal saline 0.9% daily (via infusion into the vein) in addition to standard of care treatments
10120062|NCT04400929|Experimental|Group C|Day 6 - 10: Subjects in Group A who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
10120063|NCT04400929|Experimental|Group D|Day 6 - 10: Subjects from Group B to receive study medication (based on the treating physician's assessment), Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
10120064|NCT04400929|Experimental|Group E|Day 11 - 15: Subjects in Group D who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
10120065|NCT04400981|Experimental|Intervention arm: RIC plus standard medical therapy|"Remote ischemic conditioning (RIC) will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.~Patients randomized to remote ischemic conditioning will also receive standard medical therapy"
10120066|NCT04400981|Active Comparator|Control arm: Standard medical therapy alone|"Standard medical therapy will be administered immediately after randomization in the Emergency Department. Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
10120067|NCT04400630|No Intervention|Control (TAU)|patients without any intervention + treatment as usual (TAU)
10120068|NCT04400630|Experimental|PE intervention+TAU|Physical exercise (PE) intervention + treatment as usual (TAU)
10120069|NCT04400890|Active Comparator|Resveratrol with Vitamin D3|Resveratrol 1000mg four times per day for 15 days. Vitamin D3 100,000 IU on day 1
10120070|NCT04400890|Placebo Comparator|Placebo with Vitamin D3|Placebo capsules 4 times per day for 15 days. Vitamin D3 100,000 IU on day 1
10182900|NCT03769857|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS Placebo, 350 mg, #10 oval softgel, once daily orally for 2 weeks
10182901|NCT03769831|Experimental|SHR2285|Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
10182902|NCT03769831|Experimental|Placebo|Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.
10182903|NCT03769818|Active Comparator|bupivacaine and dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
10182904|NCT03769818|Active Comparator|bupivacaine and placebo to dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
10182905|NCT03769818|Placebo Comparator|control group|Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
10182906|NCT03769805|Experimental|Anlotinib Arm|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
10182907|NCT03769792|Experimental|Impedance spectroscopy|"24 women will be included in the study and divided into two subgroups.~12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.~Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.~The planned interventions are:~Blood and faeces tests~Impedance spectroscopy test~Full gynecological and proctological examination~Transanal ultrasonography~Anorectal manometry"
10182908|NCT03769779|Experimental|Treatment|Lutein (FloraGLO™) in safflower oil
9966514|NCT01260844|Experimental|single dose of briakinumab|single dose briakinumab cocktail of CYP substrates
9966515|NCT01260909||Real-time kV/MV Prostate Imaging|
9966516|NCT01260935|Active Comparator|Arm A|Laparoscopic Hill
9966517|NCT01260935|Active Comparator|Arm B|Laparoscopic Nissen
10182909|NCT03769779|Placebo Comparator|Placebo|safflower oil
10182910|NCT03769753|Experimental|intraoperative use of IRE|Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.
10182911|NCT03769740||CPR Group|
9966518|NCT01260974|Experimental|Caspofungin|Study group
9966519|NCT01260987|Active Comparator|AK split-face treatment|Split-face treatment of two symmetrical areas with moderate to severe actinic keratoses. One area is treated with conventional PDT the other with fractional laser assisted PDT.
9966520|NCT01260987|Active Comparator|Fractional laser assisted PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is pretreated with fractional CO2 laser followed by methyl-aminolevulinate PDT.
9966521|NCT01260987|Active Comparator|Konventional PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is treated with methyl-aminolevulinate PDT.
9966522|NCT01261013||keratoconus stage I in whom KeraRing ICRS were implanted|
10120071|NCT04400617||Assisted-living residents|The target population will be inactive men and women residents of the Brenda Strafford Foundation (> 50 yrs. old). We expect the participants to be classified as inactivity, which will be defined as an engagement in < 3 sessions/week of 20 min or more of vigorous exercise. Participants should be able to move independently without the assistance of a wheelchair.
10120072|NCT04400617||Control group|Volunteers from the Brain in Motion II (BIM II) study (NCT03035851). The BIM II study aims to examine the mechanisms whereby exercise may improve sleep and cognition in men and women aged 50 to 80 years old. As the baseline measurements of the BIM II study are similar to the assessments proposed in this study, the assisted living residents will be matched with older individuals of the same age and cognitive performance who live independently to answer the last research question.
10120073|NCT04400526|Other|Phase 1: A video competition for anti-drug abuse|Phase 1 aims to increase the public awareness of hazardous effects of drug abuses and existing resources available for drug abusers through a video competition. We will co-organize a video competition for anti-drug abuse with C.H.O.I.C.E. The competition will appeal to the participation of all children (aged 13-18) living in the four targeted districts.
10120074|NCT04400526|Other|Phase 2: Developing a community-based network|Phase 2 aims to develop a community-based network through training anti-drug ambassadors (ADAs). We target to recruit a total of 150 children aged 13 - 18 as ADAs through secondary schools and community centres in the four targeted districts by sending invitation letters. The content of the workshop will be designed by our expert panel. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
9966523|NCT01261013||keratoconus stage II in whom KeraRing ICRS were implanted|
10120075|NCT04400526|Other|Phase 3: A mass promotional campaign|Phase 3 aims to engage the public to join the community-based network through anti-drug activities organized by anti-drug ambassadors. They are encouraged to design their own promotional activities for community members in the targeted districts.Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites.
10120076|NCT04400292|Experimental|SLN mapping by NIR with ICG|Patients will undergo ICG injection and NIR imaging for lymphatic mapping. Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy. The SLN biopsy procedure will be performed as described below. Although NIR with ICG is used to assess conduit perfusion in all esophagectomies performed at MSK, its use for lymphatic mapping is considered experimental in esophageal cancer.
10120077|NCT04400513||Aortic Stenosis|Subjects with echo-confirmed AS graded moderate-to-severe or worse
10120078|NCT04400513||Mitral Regurgitation|Subjects with echo-confirmed MR graded moderate-to-severe or worse
10120079|NCT04400513||Tricuspid Regurgitation|Subjects with echo-confirmed TR graded moderate-to-severe or worse
10120080|NCT04400513||Innocent Murmur|Subjects with echo-confirmed trace/trivial valve disease severity
10120081|NCT04400513||Diastolic Murmur|Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS)
10120082|NCT04400513||Continuous Murmur|Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA)
10120083|NCT04400396||target HM fortification|Contemporary cohort fed HM with target fortification
9668947|NCT04534933|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during thoracic surgery. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure in double lung ventilation and 6ml/kg PBW in one lung ventilation. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
9668948|NCT04534127|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
9668949|NCT04533399|Experimental|Cohort 1 (HIV negative) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
10120084|NCT04400396||standard HM fortification|Historical cohort fed HM with standard fortification
10120085|NCT04400565|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
10120086|NCT04400565|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
10120087|NCT04400422|Experimental|Lipano MCT formula|Kanso Lipano will be consumed daily for 3 months each to assess tolerability and compliance
10120088|NCT04400344||Survey Respondents|Respondents are members of the American Association of Diabetes Educators recruited via an introductory email sent out by the AADE on behalf of Podimetrics.
10120089|NCT04400240|Experimental|Intervention|complete questionnaires and phone sessions
10120090|NCT04400240|No Intervention|Control|complete questionnaires only
10120091|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op|Oral nutrition supplementation (ONS) pre-operatively and post-operatively up to being discharged from hospital
9668950|NCT04533399|Placebo Comparator|Cohort 1 (HIV negative) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
9668951|NCT04533399|Experimental|Cohort 2 (HIV positive) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
9668952|NCT04533399|Placebo Comparator|Cohort 2 (HIV positive) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
9966524|NCT01261013||keratoconus stage III in whom KeraRing ICRS were implanted|
9966525|NCT01261026||Ectopic pregnancy, extra-uterine pregnancy|Ectopic pregnancy, control
10120092|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Oral nutrition supplementation (ONS) pre-operatively, post-operatively up to being discharged from hospital and an extended oral nutrition supplementation post-operatively up to 3 months
10120093|NCT04400552|Active Comparator|Usual intake Pre-op + ONS Post-op|Follow a meal plan of 2000 kcal / day using conventional foods and oral nutrition supplementation (ONS) post-operatively up to being discharged from hospital
10120094|NCT04400253|Experimental|Intervention group|The intervention group will receive a 18-week in-person program. The program includes the following components: multi family group counseling, group exercise classes, mother group discussion, daughter group discussion and Fitbit.
10120095|NCT04400253|No Intervention|Control group|The group group will receive print materials about physical activity.
10120096|NCT04400409|Active Comparator|Intervention A + site 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.~6-Minute Walk Test (6MWT) will be administered by site staff."
10120097|NCT04400409|Active Comparator|Intervention B + site 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.~6-Minute Walk Test (6MWT) will be administered by site staff."
10120098|NCT04400409|Active Comparator|Intervention A + CPC EQuIP 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
10120099|NCT04400409|Active Comparator|Intervention B + CPC EQuIP 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
10120100|NCT04400370||Pediatric patients undergoing lung resection|
10120101|NCT04400357|Experimental|Robotic pancreaticoduodenectomy|Patients randomized in this arm will undergo a robotic pancreaticoduodenectomy.
10120102|NCT04400357|Active Comparator|Open pancreaticoduodenectomy|Patients randomized in this arm will undergo a routine open pancreaticoduodenectomy.
10120103|NCT04400266|Experimental|Buspirone and Melatonin|Buspirone 15mg and Melatonin 3mg
10120104|NCT04400214|Experimental|Food Allergy Superheroes Training (FAST) Program|Participants enrolled in this arm of the study will receive 5, 20 minutes skills training sessions designed to promote adherence to food allergy safety guidelines. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
10120105|NCT04400214|Active Comparator|Food Allergy Knowledge (FAK) Intervention|Participants enrolled in this arm of the study will receive 5, 20 minutes educational training sessions designed to increase knowledge pertaining to food allergies. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
10120106|NCT04400201|Experimental|Remimazolam Tosilate|
10120107|NCT04400201|Active Comparator|Propofol|
10120108|NCT04400175|Experimental|B-ESP|B-ESP group will be fed with a feeding system with a valved ergonomic teat.
10120109|NCT04400175|Sham Comparator|B-STD|B-STD will be fed with a standard feeding system.
10120110|NCT04400188|Experimental|Experimental A (part 1) : Fluzoparib + temozolomide|
10120111|NCT04400188|Experimental|Experimental B (part 2) : Fluzoparib + temozolomide + SHR-1316|
10120112|NCT04400279|Experimental|Yoga Exercise group|Using the Down Dog app, this group will be given access to an at-home personalized yoga practice, unique every time the participants complete it. Asked to complete yoga practice 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
10120113|NCT04400279|Experimental|High Intensity Interval Training group|Using the Down Dog app, this group will be given access to at-home bodyweight high intensity interval training (HIIT) workouts. Asked to complete these HIIT workouts 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
10120114|NCT04400279|Experimental|Combination Yoga & HIIT group|Using the Down Dog app, this group will be given access to both the unique yoga practice and bodyweight HIIT workouts. Asked to complete 2 yoga and 2 HIIT workouts per week. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
10120115|NCT04400279|No Intervention|Control group|This group will be maintaining their pre-study activity levels for the first 6 weeks of the study. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. Then the participants will be given access to all the Down Dog apps (both yoga and HIIT included) to use as the participants please for the following 6 weeks. A final wellbeing and health survey at the end of the second 6 weeks will be administered.
10120116|NCT04400162|Active Comparator|CCT (standard)|This arm consists of the CCT in a standard variant that provides the basic training experience without any added gaming elements.
10120117|NCT04400162|Experimental|CCT (game)|This arm consists of the same CCT as the standard version, however pre-defined gaming elements that are thought to increase usability as well as interest in the intervention have been added.
10120118|NCT04400045|Experimental|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0
10120119|NCT04400084||Pregnant mothers|Pregnant mothers who have a normal pregnancy
10120120|NCT04400097|Experimental|hidden-knot group|
10120121|NCT04400097|Active Comparator|two-knot group|
10120122|NCT04400097|Active Comparator|multi-knot group|
10120123|NCT04400032|Experimental|Panel 1|25 million cells/unit dose (cumulative dose: 75 million MSCs)
10120124|NCT04400032|Experimental|Panel 2|50 million cells/unit dose (cumulative dose: 150 million MSCs)
10120125|NCT04400032|Experimental|Panel 3|up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)
10120126|NCT04400071|Experimental|Active Music Engagement|See intervention description.
10120127|NCT04400071|Active Comparator|Audio Storybooks|See intervention description.
10120128|NCT04399759|Experimental|A-IADL Group|Approach-Instrumental Activities of Daily Living in home
10120129|NCT04399759|Active Comparator|Control group|Home health education
10120130|NCT04400019|No Intervention|Tracking control|"According to the randomization process described, those nursing homes assigned to the control arm of the trial will receive the same treatment as those assigned to the intervention group, except for the medication, which will be a masked placebo.~The study is triple blind, so neither the professionals who carry out the follow-up, nor the patients, nor the person in charge of analyzing the data, know to which group each nursing home belongs."
10120131|NCT04400019|Experimental|Intervention|The dose to be used as chemoprophylaxis will be 800mg of Hydroxychloroquine (HCQ) on the first day and 400mg during the subsequent four days. Participating subjects will be followed up at 6, 14 and 28 days.
10120132|NCT04399785|Experimental|Arm 1|
10120133|NCT04399876|Experimental|Surgery Cohort|"Participant eligibility for intervention and selection of lesion for device placement~- Surgery Cohort will undergo percutaneous placement of several microdevices in a selected tumor(s) prior to surgery. The microdevice in the surgery cohort will dwell in the tumor tissue for approximately 48 hours to allow time for tissue effects of the drugs in the microdevice reservoirs.~Placement of at least 1, and up to 6, microdevices depending on the number of lesions, size and accessibility~Extirpative surgery will proceed according to standard-of-care procedures. The microdevice(s) will be removed surgically along with surrounding tumor tissue.~Standard of care treatment and follow-up of clinical course"
10120134|NCT04399876|Experimental|Ex-Vivo Cohort|"Each participant will undergo a screening process to determine their eligibility for microdevice placement, consisting of the following items:~Routine standard of care for radical prostatectomy.~Placement of implantable microdevice with multiple miniature drug reservoirs but no drug in prostate that have been removed~Ex vivo image guided removal using retrieval device~Standard of Care Treatment and follow-up of clinical course"
10120135|NCT04399902|Experimental|Study blanket|Two standard warmed hospital blankets will be placed on top of the patient and the study blanket on top of the standard warmed blankets, covering as much of the patient as possible, at the discretion of the care team. At all times, clinicians should ensure that the study blanket does not touch the patient's bare skin.The blanket will remain on the patient through their path of care, and removed from the patient at arrival to the ICU/final phase of care, or if the patient temperature exceeds 38˚C at any point.
10120136|NCT04399915||Hyperoxalemia/Hyperuricemia Group|
10120137|NCT04399915||Hyperoxalemia/Hyperuricemia-free Group|
10120138|NCT04399915||Healthy Subjects|
10120139|NCT04399824|Experimental|Arm I (SBRT)|Patients undergo SBRT in 5 fractions over 14 days in the absence of disease progression or unacceptable toxicity.
10120140|NCT04399824|Experimental|Arm II (HDR brachytherapy)|Patients undergo HDR brachytherapy on day 1 and a second fraction within 14 days in the absence of disease progression or unacceptable toxicity.
10120141|NCT04400136|No Intervention|GROUP A - no PPI|no PPI treatment (control group)
10120142|NCT04400136|Experimental|GROUP B PPI 1/day for 6 months|(standard dose-long term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months
10120143|NCT04400136|Experimental|GROUP C PPI 1/day for 3 months|(standard dose-short term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months
10120144|NCT04399941|Experimental|IVUS and venography group|Participants in the this group will receive venography/fistulogram, intravascular ultrasound (IVUS), and image processing.
10120145|NCT04399720||BPS group|patients under Bisphosphonate therapy for at least 24 months
10120146|NCT04399720||healthy patients|healthy patients not assuming with no previous Bisphosphonate assumption
10120147|NCT04399707|Active Comparator|Active TENS Unit|
10120148|NCT04399707|Placebo Comparator|Placebo TENS Unit|
10120149|NCT04399707|No Intervention|No TENS Unit|
10120150|NCT04399798|Experimental|Baricitinib active treatment|Baricitinib 4 mg/day
10120151|NCT04399850|Experimental|Patients who receive hypnosis|Patients who receive hypnosis during procedure by experiment physician
9966526|NCT01261026||Abnormal intrauterine pregnancy|
10120152|NCT04399850|No Intervention|Control arm|Patient with conventional pain management
10120153|NCT04399642|Active Comparator|Standard|Patients receiving single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision
10120154|NCT04399642|Experimental|Vanco|Patients receiving a single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision + a single dose of intra-articular vancomycin powder (1 gram) before articulation (hip or knee) closure
10120155|NCT04399603||COVID critically unwell patients|
10120156|NCT04399603||Non-Covid critically unwell Patietns|
10120157|NCT04399512|Active Comparator|Patients with liver cirrhosis|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in MELD(model for end stage liver disease) will be checked after treatment.
10120158|NCT04399512|Active Comparator|Normal healthy patients|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis
10120159|NCT04399564|Active Comparator|temporary hemodialysis catheters|one arm-temporary hemodialysis catheter
10120160|NCT04399564|Experimental|long-term hemodialysis catheters|another arm-long term hemodialysis catheter
10182912|NCT03769714|Active Comparator|Saline Solution for Injection|Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
10120161|NCT04399616|Experimental|Experimental|"The intervention consists of the availability in the patient's medical history of the visual risk map. The patients in the intervention group will have a risk map in their medical history similar to the one presented in image (annex 2), and any care provider will have immediate access to this map which we think will help them to prioritize the implementation of the relevant practices. safe (in relation to the areas that appear in red).~Areas of risk:~Other independent variables will be the areas of risk:~Identification of the patient~Functional autonomy and quality of life~Caregiver~Safe management and use of medicines~Risk of falls~Risk of injuries and pressure ulcers~Symptom control~Risk of infection associated with health care~Patient and family values and beliefs~Social risk~Unplanned hospital admissions / proactive monitoring~Continuity of care 7X24 h~Transfers (between care levels)~Safety culture~Nursing work environment"
10120162|NCT04399616|No Intervention|No intervention|The patients in the control group will have in their medical records the usual records of the comprehensive geriatric assessment.
10120163|NCT04399629|Active Comparator|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
10120164|NCT04399629|Experimental|Parenting Wisely|Online parenting training
10120165|NCT04399681|Other|Suspected COVID-19 Group|Patients who admitted to emergency department with suspicion of COVID 19 pneumonia will be evaluated with POCUS/ bedside lung ultrasound.
10120166|NCT04399278|Other|Group A|The EEO test will be applied first over 15 seconds and secondly over 30 seconds (each EEO test separated by 1 minute wash-out period)
10120167|NCT04399278|Other|Group B|The EEO test will be applied first over 30 seconds and secondly over 15 seconds (each EEO test separated by 1 minute wash-out period)
10120168|NCT04399304||Simultaneous|One-stage bilateral high tibial osteotomy
10120169|NCT04399304||Staged|Two-stage bilateral high tibial osteotomy
10120170|NCT04399317|Experimental|Group A|This is the treatment group. Patients will be ventilated using the new device (Evone) applying flow controlled ventilation for 48 hours. Ventilation parameters will be assessed every 6-8 hours. All other treatment will be unchanged and according to institutional standards.
10120171|NCT04399317|No Intervention|Group B|These patients will be treated according to institutional standards. Only data will be collected. This is the control group.
10120172|NCT04399187|Experimental|scaling and root planing, Sodium hypochlorite gel application|Periodontal pockets > 5 mm in patients of test group were treated by scaling and root planing and Sodium hypochlorite gel application
10120173|NCT04399187|Placebo Comparator|scaling and root planing alone|scaling and root planing alone was performed
10120174|NCT04399200||Sleep-disordered breathing group|Sleep-disordered breathing (SDB) patients (AHI>15/h, measured by polysomnography performed 3 months after stroke)
10120175|NCT04399200||Control group|Control patients with no SDB (AHI<15/h, measured by polysomnography performed 3 months after stroke)
10120176|NCT04399213|Experimental|Group A|From cubital fossae to wrist: 50 - 15 - 5 µg histamine dihydrochloride
10120177|NCT04399213|Experimental|Group B|From cubital fossae to wrist: 15 - 5 - 50 µg histamine dihydrochloride
10120178|NCT04399213|Experimental|Group C|From cubital fossae to wrist: 5 - 50 - 15 µg histamine dihydrochloride
10120179|NCT04399369|Experimental|SDF|38% silver diamine fluoride solution
10120180|NCT04399369|Active Comparator|NaF|5% sodium fluoride varnish
10120181|NCT04399395|Active Comparator|Lifestyle and naltrexone/bupropion|
10120182|NCT04399395|Other|Lifestyle|
10120183|NCT04399434||normal pregnancy|pregnancy with a normal fetal size
10120184|NCT04399434||fetal growth restriction|fetal birth weight is below two standard deviations of the average weight for the same gestational age, or below the 10th percentile of normal weight for the same age
10120185|NCT04399434||fetal macrosomia|fetal birth weight ≥ 4000g
10120186|NCT04399525|Experimental|Sequence 1|Desloratadine 5 mg Levocetirizine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
10120187|NCT04399525|Experimental|Sequence 2|Desloratadine 5 mg Levocetirizine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
10120188|NCT04399525|Experimental|Sequence 3|Levocetirizine 5 mg Desloratadine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
10120189|NCT04399525|Experimental|Sequence 4|Levocetirizine 5 mg Desloratadine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
10120190|NCT04399265|Experimental|Trehalose|Trehalose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
10120191|NCT04399265|Placebo Comparator|Maltose placebo|Isocaloric maltose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
10120192|NCT04399577|Experimental|Wart Patients|Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
10120193|NCT04399408|Experimental|Study group|Device users
10120194|NCT04399447||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
10120195|NCT04399447||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
10120196|NCT04399447||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
10120197|NCT04399447||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
10120198|NCT04399447||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
10120199|NCT04399447||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
10120200|NCT04399343|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
10120201|NCT04399343|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
10120202|NCT04399148|Experimental|Sequence 1|Desloratadine - Aprepitant - Ketotifen
10120203|NCT04399148|Experimental|Sequence 2|Aprepitant - Ketotifen - Desloratadine
10120204|NCT04399148|Experimental|Sequence 3|Ketotifen - Desloratadine - Aprepitant
10120205|NCT04399135|Active Comparator|Normal Patients|All patients admitted to Qassim dental clinics, who need root canal treatment would be screened for possible involvement in this study
10120206|NCT04399135|Active Comparator|Periodontitis Patients|All patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. the periodontitis patients would be categorized according to the new periodontitis classification 2017 world workshop.
10120207|NCT04398875|Experimental|ASC|Traditional manual acupuncture with standard care (ASC) will be provided. Subjects in the ASC group will receive 9 sessions of acupuncture and standard care for 3 weeks. A semi-standardized acupuncture treatment protocol (combined fixed acupoints with additional acupoints by symptom differentiation) will be employed. The fixed acupuncture points including, Guanyuan (CV4), Xuanzhong(GB39), Sanyinjiao (SP6), Yinlingquan (SP9), Zusanli (ST36), Yingtang (EX-HN3), Baihui (GV20), and Qihai (CV6) will be used in every session.
10120208|NCT04398875|Sham Comparator|SSC|Sham acupuncture plus standard care (SSC) will be provided. Subjects in the SSC group will receive 9 sessions of sham acupuncture and standard care for 3 weeks. The Streitberger sham acupuncture will be employed. The selection of acupoints is the same as ASC.
10120209|NCT04398875|Placebo Comparator|SC|Standard care alone (SC) will be provided. Subjects in the SC group will standard care for 3 weeks.
10120210|NCT04398888|Experimental|BXD|"Participants will be diagnosed and treated by Chinese medicine practitioners (CMPs) with at least 5 years of clinical experience. CMPs will differentiate syndrome and prescript herbs in a semi-standardized protocol, which consists of a base Chinese medicine decoction, BXD, and the additional syndrome-specific herbs.~The modified decoction will be prepared in a conventional decocting method at the Chinese medicine pharmacy in the clinic (HKBA-HKU CMCTR) and will be packaged into bags by the auto-decocting machines. Participants will take the decoction twice per day, 5 days per week, for 3 weeks."
10120211|NCT04398888|No Intervention|Waitlist|Participants in the waiting list control group will be observed for a three-week waiting period. Rescue medication is not restricted.
10120212|NCT04398940|Experimental|TQ-B3139 capsules|TQ-B3139 capsules administered orally.
10120213|NCT04398901||Colombia ZIKV-exposed|Seventy children in Colombia were previously enrolled as part of a fetal-neonatal neuroimaging study in 2016-2017 and were from Department of Atlantico, Colombia on the Caribbean coast. Eligible children had prior normal fetal MRI and fetal US, normal birth head circumference, normal clinical exam, no more than mild non-specific postnatal imaging findings, and are thus without findings of CZS.
10120214|NCT04398901||Colombia Non-ZIKV exposed control|The investigators will enroll 70 non-ZIKV exposed children, age 4 to 5 years, in Department of Atlántico, Colombia with birth dates prior to March 31, 2016. Based on the arrival of ZIKV to Colombia in November 2015, this date would ensure a control cohort without congenital ZIKV exposure in the first half of gestation and unlikely during any of the pregnancy.
10120215|NCT04398901||United States ZIKV-exposed|The US cohort either presented during pregnancy or after birth and sought clinical care with the Children's National Congenital Zika Program in Washington, DC and were ZIKV-exposed.
10120216|NCT04398901||United States Non-ZIKV exposed control|The investigators will enroll 32 non-ZIKV exposed children, age 4 years, in Washington, DC.
10120217|NCT04398810|Experimental|the low-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~Cholelithiasis~Chronic cholecystitis~Gallbladder polyps~Gallbladder adenoma~Porcelain gallbladder~The experimental group controls the CO2 flow that is injected into the abdominal cavity during surgery and maintains the pressure in the abdominal cavity at a low level of 5 mmHg to perform the surgery."
9966527|NCT01261039|Active Comparator|Solar bed UV-radiation|Solar bed UV-radiation
10120218|NCT04398810|Experimental|the standard-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery~Cholelithiasis~Chronic cholecystitis~Gallbladder polyps~Gallbladder adenoma~Porcelain gallbladder~In the case of the control group, surgery is performed while maintaining the pressure in the abdominal cavity at 12 mmHg as generally performed during surgery."
10120219|NCT04399096||General population|The general public attending exhibitions of the artworks who wish to complete the on-line questionnaire and feedback
10120220|NCT04398966|Experimental|PAE Procedure|This will be a single arm, uncontrolled, non-blinded study of PAE using HydroPearl Beads in a small population of 30 subjects with benign prostate hyperplasia (BPH)
10120221|NCT04399005|Experimental|daily room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
10120222|NCT04399005|Experimental|after-each-case room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. After-each-case room disinfection was defined as after completing each case.
10120223|NCT04398823|Active Comparator|Foam sclerotherapy,FS|Participants in this arm will receive the enteroscopic treatment with the sclerosing foam of lauromacrogol.
10120224|NCT04398823|Placebo Comparator|Liquid sclerotherapy,Ls|Participants in this arm will receive the enteroscopic treatment with the liquid of lauromacrogol.
10120225|NCT04398953|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
10120226|NCT04398849||14-19 year olds residing in the Northern Territory|All consenting 14-19 year olds residing in the Northern Territory in 2020-2021
10120227|NCT04399070|Placebo Comparator|Propofol group|patients were treated with propofol 1 mg/kg and saline bolus infusion before ECT
10120228|NCT04399070|Active Comparator|Ketamine group|patients were treated with propofol 1 mg/kg and ketamine 0.5 mg/kg bolus infusion before ECT
10120229|NCT04399070|Experimental|S-ketamine group|patients were treated with propofol 1 mg/kg and S-ketamine 0.25 mg/kg bolus infusion before ECT
10120230|NCT04399044|No Intervention|Group 1: No flap|Participants will undergo the scheduled vascular surgery procedure without involvement of the plastic surgery team and use of muscle flaps for graft coverage.
10120231|NCT04399044|Experimental|Group 2: Prophylactic muscle flap|Participants will undergo the scheduled vascular surgery procedure and then a muscle flap will be used to cover the vascular graft by a plastic surgeon in the same setting.
10120232|NCT04399057||andrological patients|shear wave elastosonography of the corpora cavernosa was performed to all patients who went to our clinic for andrological problems. in addition, the International Index of Erectile Function short form (IIEF5) questionnaire and the Erectile Hardness Score (EHS) questionnaire were administered.
10120233|NCT04399109|Active Comparator|TCC-COVID mHealth solution|TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms, connected to a back-end clinical database with inbuilt data analytics.
10120234|NCT04399109|No Intervention|Control|Propensity matched and synthetic control groups will be utilised from another local health district not participating in the ReCOVER study. The control group will not be actively recruited at the same time as the intervention. The control group will be matched via data linkage at the completion of the trial. However, it is not a historical control, as the control standard of care treatment will be provided simultaneously as our intervention
10120235|NCT04398927|Experimental|Folfirinox plus PD1|Patients treated with systemic chemotherapy(regimen: Folfirinox) plus PD1
10120236|NCT04398693|No Intervention|Normotensive Patients|40 normotensive patients with systolic BP (SBP) < 140 mmHg and diastolic BP (DBP) < 90 mmHg at the office, without the use of antihypertensive drugs and evaluated through ambulatory blood pressure monitoring (ABPM) to confirm normotension (BP < 130/80 mmHg) and the exclusion of possible masked hypertension.
10120237|NCT04398693|No Intervention|Controlled Hypertensive Patients|40 controlled hypertensive patients using up to three antihypertensive drugs with SBP < 130 mmHg and DBP < 80 mmHg evaluated through 24 hours ambulatory blood pressure monitoring (ABPM).
10120238|NCT04398693|Active Comparator|Resistant Hypertensive Patients|The study will be double-blinded, randomized, placebo-controlled crossover Initially, 20 individuals of the resistant hypertensive group will take prebiotic for 4 weeks, while other 20 individuals this group will use placebo. After a washout period of 4 weeks, the study protocol will be repeated in the other arm.
10120239|NCT04399083|Experimental|Single Arm|
10120240|NCT04399031|Experimental|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
10120241|NCT04399031|Experimental|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
10120242|NCT04399031|Experimental|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
10120243|NCT04399031|Experimental|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
10120244|NCT04399031|Experimental|E-cigarette e-liquid 5|Participants will self-administer an e-cigarette e-liquid.
10120245|NCT04399031|Experimental|E-cigarette e-liquid 6|Participants will self-administer an e-cigarette e-liquid.
10120246|NCT04399031|Experimental|E-cigarette e-liquid 7|Participants will self-administer an e-cigarette e-liquid.
10120247|NCT04399031|Experimental|E-cigarette e-liquid 8|Participants will self-administer an e-cigarette e-liquid.
10120248|NCT04399031|Experimental|E-cigarette e-liquid 9|Participants will self-administer an e-cigarette e-liquid.
9694604|NCT04787731|Active Comparator|Lidocaine|Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent. It exists in liquid form in cartridges. Lidocaine is a FDA approved marketed anesthetic drug.
10120249|NCT04399031|Experimental|E-cigarette e-liquid 10|Participants will self-administer an e-cigarette e-liquid.
10120250|NCT04399031|Experimental|E-cigarette e-liquid 11|Participants will self-administer an e-cigarette e-liquid.
10120251|NCT04399031|Experimental|E-cigarette e-liquid 12|Participants will self-administer an e-cigarette e-liquid.
10120252|NCT04399031|Experimental|E-cigarette e-liquid 13|Participants will self-administer an e-cigarette e-liquid.
10120253|NCT04399031|Experimental|E-cigarette e-liquid 14|Participants will self-administer an e-cigarette e-liquid.
10120254|NCT04399031|Experimental|E-cigarette e-liquid 15|Participants will self-administer an e-cigarette e-liquid.
10120255|NCT04399031|Experimental|E-cigarette e-liquid 16|Participants will self-administer an e-cigarette e-liquid.
10120256|NCT04399031|Experimental|E-cigarette e-liquid 17|Participants will self-administer an e-cigarette e-liquid.
10120257|NCT04399031|Experimental|E-cigarette e-liquid 18|Participants will self-administer an e-cigarette e-liquid.
10120258|NCT04399031|Experimental|E-cigarette e-liquid 19|Participants will self-administer an e-cigarette e-liquid.
10120259|NCT04399031|Experimental|E-cigarette e-liquid 20|Participants will self-administer an e-cigarette e-liquid.
10120260|NCT04398784|Other|1-Blueberry First/Placebo First|Participants will be randomly assigned into either blueberry-first treatment or placebo-first group.
10120261|NCT04398784|Other|2-Crossover|Participants who received blueberry treatment will switch to placebo and vice versa.
10120262|NCT04398797|Experimental|Intervention|Use of notification algorithm and nurse follow-up
10120263|NCT04398797|No Intervention|Control|Standard regime (usual care)
10120264|NCT04398836|Active Comparator|Malnourished patients - EEN|patiens will receive EEN for 4 week prior surgery
10120265|NCT04398836|Other|Malnourished patients - enriched diet|patiens will receive an enriched high energy and protein diet.
10120266|NCT04398836|Other|Well nourished patients|Patient will receive a standard nutrition
10182913|NCT03769714|Experimental|Exparel|Group B (study, n=26) to receive 20ml of liposomal bupivacaine (EXPAREL) into the stroma of the cervix at the 4 and 8 o'clock positions (innervation insertion points of the cervix).
10120267|NCT04398576|No Intervention|Support as usual|"There will be no interventions, only support as usual. All GPs receive an information package by post or via e-mail containing:~Belgian guidelines on the management of hazardous and harmful alcohol use~A summary card about EIBI for hazardous and harmful alcohol consumption.~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider."
10120268|NCT04398576|Active Comparator|Training and support|"All GPs receive an information package by post or via e-mail containing:~Belgian guidelines on the management of hazardous and harmful alcohol use~A summary card about EIBI for hazardous and harmful alcohol consumption.~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider.~There shall be tailored training and support for the general practioners. At the start of the study, this group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months."
10120269|NCT04398576|Active Comparator|Training and support and community actions|In this group, GPs receive the same training and support as in the second arm (training and support). There will also be embedded community-based actions within a local strategy.
10120270|NCT04398758|Experimental|Treatment group|"Children of the treatment group receive the cream SanaCutan Basiscreme. The cream's main ingredients are white soft paraffin and liquid paraffin and it is already approved for the treatment of several skin diseases due to its skin care effect."
10120271|NCT04398758|No Intervention|Control group|Children of the control group should avoid regular skincare applications. Skincare is not prohibited, however, it is recommended to use products only in urgent cases.
10120272|NCT04398680|Experimental|Part 1, Group 1: Participants with normal hepatic function|Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase [AST] less than or equal to [<=] Upper limit of normal [ULN]) will be administered with Belantamab mafodotin
10120273|NCT04398680|Experimental|Part 1, Group 2: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Serum bilirubin greater than >1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin
10120274|NCT04398680|Experimental|Part 2,Group 3: Participants with severe hepatic impairment|Participants with severe hepatic impairment (Serum bilirubin >3 times ULN and any AST) will be administered with Belantamab mafodotin
10120275|NCT04398537|Experimental|5mm retraction of clip deployment apparatus|The participants in this group will have clip placement 5mm in front of the biopsy site site.
10120276|NCT04398537|Active Comparator|no retraction of clip deployment apparatus|These participants will the clip delivered at the biopsy site.
10120277|NCT04398719|Active Comparator|CBD|
10120278|NCT04398719|Placebo Comparator|Placebo|
10120279|NCT04398771||Treatment|Rovatitan 5/80mg (Rosuvastatin 5mg/Valsartan 80mg) Rovatitan 5/160mg (Rosuvastatin 5mg/Valsartan 160mg) Rovatitan 10/80mg (Rosuvastatin 10mg/Valsartan 80mg) Rovatitan 10/160mg (Rosuvastatin 10mg/Valsartan 160mg) Rovatitan 20/80mg (Rosuvastatin 20mg/Valsartan 80mg) Rovatitan 20/160mg (Rosuvastatin 20mg/Valsartan 160mg)
10120280|NCT04398615|Experimental|Intervention|Single arm, receiving the experimental device
10120281|NCT04398641||Nerve and vessel sparing segmental resection (NVSSR)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of nerve and vessel sparing segmental resection (NVSSR)
10120282|NCT04398641||Transanal disc excision (TADE)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of transanal disc excision (TADE)
10120283|NCT04398420|Active Comparator|TVERP|
10120284|NCT04398420|Active Comparator|TURis|
10120285|NCT04398420|Active Comparator|HoLEP|
10120286|NCT04398498||Cohort A: Clinical Practice|Subjects more than 60 days post-transplant
10120287|NCT04398498||Cohort B: Long Term Follow-Up|Subjects who are at least 2 years post transplant up to 5 years post-transplant
10182914|NCT03769675|Experimental|Spinal Cord Stimulator Implant|Spinal Cord Stimulator implant
10182915|NCT03769662|Experimental|High dose from study XT-150-1-0201|Open label administration of the highest dose in the earlier study, in which all doses were well tolerated
10182916|NCT03769623|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter
10182917|NCT03769623|Active Comparator|Powerline|Balloon dilated catheter
10182918|NCT03769610|Active Comparator|Inpatient Foley catheter|Subjects will be admitted to a room on labor and delivery and will be monitored with the external fetal monitor (EFM) and tocometer (a device to monitor contractions). If she is contracting less than every 2 minutes, intravenous (IV) Pitocin will be started at 2 milliunits/minute and increased per hospital protocol. While on pitocin, she will remain on continuous EFM and tocometer. She will also be kept on a clear liquid diet with intravenous fluids per standard protocol. If the Foley catheter has not been expulsed in 24 hours, it will be removed. After expulsion or removal of the Foley catheter, induction may proceed as deemed clinically appropriate by the managing physician. No further cervical ripening will be performed after the Foley catheter is expulsed/removed, or after 24 hours.
10182919|NCT03769610|Experimental|Outpatient Foley catheter|Subjects are asked to return to the hospital ~12 hours after placement. Subjects are to return to the hospital if they develop heavy vaginal bleeding, decreased fetal movement, rupture of membranes, or increasingly painful or frequent contractions requiring an epidural or pain relief. Once admitted, subjects will be evaluated for expulsion of the catheter. If the catheter is in place IV Pitocin will be started. If the catheter has been expulsed, the induction will proceed as deemed clinically appropriate. After 24 hours, if the Foley catheter is still in the cervix it will be removed and the induction will proceed as deemed clinically appropriate.
9966528|NCT01261039|Sham Comparator|Solar bed with UV filter|Solar bed with UV filter
9966529|NCT01261078|Placebo Comparator|Placebo|8 mg bupivacaine only
10120288|NCT04398459|Experimental|IBRIAN|
10120289|NCT04398472|Active Comparator|Challenge|"Participants in the challenge will be asked to complete four activities over the next four weeks to address loneliness and social isolation in their communities.~The activities will involve doing an activity with people in their neighbourhood. These activities have been selected based on being positive, engaging and feasible to the average individuals. An example of the type of activities is having a conversation with a neighbour on the phone or via video chat and safely checking in on someone who is elderly or living alone. All activities will adhere to the relevant country or states health department's safety recommendations and laws during COVID-19.~Hypothesis 1 (H1). There will be a reduction in the primary outcome, loneliness in participants assigned to the Nextdoor KIND Challenge groups compared to the waitlist control group post the 4-week intervention"
10120290|NCT04398472|No Intervention|Waitlist|
10120291|NCT04398589|Experimental|SSNB and ANB c DEX|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for SSNB and ANB.
10120292|NCT04398589|Placebo Comparator|SSNB and ANB c saline|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for SSNB and ANB.
10120293|NCT04398238||Pre-PBM|patients screened for surgery before the implementation of PBM program: pre-operative evaluation and treatment according to usual care
10120294|NCT04398238||post-PBM|patients screened for surgery after the implementation of PBM program (3 months allowed for training/optimization): all patients with pre-operative hemoglobin < 13g/dl undergo screening for causes and treatment as needed.
10120295|NCT04398225|Experimental|Cohort 1 (9-12 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
10120296|NCT04398225|Experimental|Cohort 2 (9-12 y)|Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days
10120297|NCT04398225|Experimental|Cohort 3 (9-12 y)|Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days
10120298|NCT04398225|Experimental|Cohort 4 (6-8 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
10120299|NCT04398225|Experimental|Cohort 5 (4-5 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
10120300|NCT04398251|Experimental|Uric acid drug control group|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week
10120301|NCT04398251|Active Comparator|Non-drug control group|They are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.
10120302|NCT04398173||Group A (previous negative biopsy)|Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI
10120303|NCT04398173||Group B (biopsy naive)|Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI
10120304|NCT04398095|Experimental|Radiotherapy with hyperthermia in resectable sarcomas|12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery
10120305|NCT04398095|Experimental|Radiotherapy with hyperthermia in non-resectable sarcomas|12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)
10120306|NCT04398147|Experimental|phase ⅠLow single dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
10120307|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (18-<55)|6 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
10120308|NCT04398147|Experimental|phase ⅠLow 2 dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
10120309|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (18-<55)|6 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
10120310|NCT04398147|Experimental|phase ⅠLow single dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
10120311|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
10120312|NCT04398147|Experimental|phase ⅠLow 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
10120313|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
10120314|NCT04398147|Experimental|phase ⅠMedium single dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
9827673|NCT02464176|Placebo Comparator|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
10120315|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
10120316|NCT04398147|Experimental|phase ⅠMedium 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
10120317|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
10120318|NCT04398147|Experimental|Phase II Low single dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
10120319|NCT04398147|Placebo Comparator|Phase II placebo low single dose (18-<55)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
10120320|NCT04398147|Experimental|Phase II Low 2 dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
10120321|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (18-<55)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
10120322|NCT04398147|Experimental|Phase II Low single dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
10120323|NCT04398147|Placebo Comparator|Phase II placebo low single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
10120324|NCT04398147|Experimental|Phase II Low 2 dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
10120325|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
10120326|NCT04398147|Experimental|Phase II medium single dose (55-<85)|50 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
10120327|NCT04398147|Placebo Comparator|Phase II placebo medium single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
10120328|NCT04398147|Experimental|Phase II medium 2 dose (55-<85)|50 subjects，Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
10120329|NCT04398147|Placebo Comparator|Phase II placebo medium 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
10120330|NCT04398147|Experimental|Phase II Low 1 or 2 dose (18-<55)|100 subjects，Ad5-nCoV containing 5E10 vp, 1or2 dose, Intramuscular administration ，according to the Previous trial results
10120331|NCT04398147|Placebo Comparator|Phase II placebo 1 or 2 dose (18-<55)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
10120332|NCT04398147|Experimental|Phase II Low or medium dosage 1 or 2 dose (55-<85)|100 subjects，Ad5-nCoV containing 5E10 vp or 10E10vp, 1or2 dose, Intramuscular administration，according to the Previous trial results
10120333|NCT04398147|Placebo Comparator|Phase II placebo Low or medium,1 or 2 dose (55-<85)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
10120334|NCT04398394|Experimental|Group 1|Individuals with healthy retina, 18 to 50 years old.
10120335|NCT04398394|Experimental|Group 2|Individuals with healthy retina and presenting with myopia, 18 to 50 years old.
10120336|NCT04398394|Experimental|Group 3|Individuals with healthy retina, over the age of 50.
10120337|NCT04398394|Experimental|Group 4|Patients with early and intermediate AMD, over the age of 50.
10120338|NCT04398394|Experimental|Group 5|Patients with other retinopathies than AMD, over the age of 18.
10120339|NCT04398212|Placebo Comparator|Non-complaining group|the students in this group are not complaining of CVS symptoms but will be examined to diagnose CVS or exclude it
10120340|NCT04398212|Experimental|Complaining group|the students in this group are complaining of CVS symptoms but will be examined to document their complains and correlate to clinical findings
10120341|NCT04398186||Study group 1|Hiperandrogenism + ultrasonographic PCO
10120342|NCT04398186||Study group 2|Menstruel cycle irregular + ultrasonographic PCO
10120343|NCT04398186||Study group 3|Menstruel cycle irregular + ultrasonographic PCO + hyperandrogenism
10120344|NCT04398186||Control group|Do not have PCOS
10120345|NCT04398108|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to choose one of the 3 chemotherapies based on patient conditions.
10120346|NCT04398303|Experimental|ACT-20-MSC in ACT-20-CM|Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
10120347|NCT04398303|Experimental|ACT-20-CM|Conventional treatment plus ACT-20-CM administered intravenously
9966530|NCT01261078|Active Comparator|Epi 25|8 mg of bupivacaine mixed with 25 mcg of epinephrine
9966531|NCT01261078|Active Comparator|Epi 50|8 mg of bupivacaine mixed with 50 mcg of epinephrine
10120348|NCT04398303|Placebo Comparator|Placebo|Conventional treatment plus placebo (MEM-α) administered intravenously
10120349|NCT04398290|Experimental|iNOpulse Treatment Group|Participants in this group will receive iNO delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days.
10120350|NCT04398290|Active Comparator|Placebo Group|Participants in this group will receive nitrogen gas delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days
10120351|NCT04398511|Experimental|L brevis|Lactobacillus brevis CD2 in lozenges containing 4 billion CFU. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
10120352|NCT04398511|Placebo Comparator|Placebo|Placebo in lozenges, identical to those of L brevis. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
10120353|NCT04398277|Active Comparator|Initial Low dose|Participants will receive only one daily positive emotion prompt in the first seven days of the toolkit use.
10120354|NCT04398277|Active Comparator|Initial high dose|Participants will receive two daily positive emotion prompts in the first seven days of use.
10120355|NCT04398056|Experimental|Chemotherapy plus radiotherapy and Toripalimab|Patients were treated with PF chemotherapy for a maximum of six cycles followed by loco-regional radiotherapy combined with toripalimab.
10120356|NCT04398316|Experimental|Intravenous Lidocaine|Administered at a dose of 2 mg/kg over 5 minutes
10120357|NCT04398316|Active Comparator|Intravenous Hydromorphone|Administered at a dose of 1 mg over 5 minutes
10120358|NCT04398069|No Intervention|Standard Group|standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure > or equal to 65 mmHg and diastolic arterial pressure > ou equal to 50 mmHg within the first 60 minutes.
10120359|NCT04398069|Experimental|personalized hemodynamic goals Group|Personalized hemodynamic goals and catecholamin infusion to achieve normal cerebral perfusion assessed by transcranial doppler: PI < 1,2.
10120360|NCT04398017|Active Comparator|Standard support|
10120361|NCT04398017|Experimental|Hypnosis|
10120362|NCT04398004|Experimental|Clarithromycin arm|Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.
10120363|NCT04397926|Experimental|neoantigen vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
10120364|NCT04397666|Experimental|1|
10120365|NCT04397640|Other|Sonovue|ICU patients with sepsis and septic shock who are eligible for myocardial contrast echocardiography with sulphur hexafluoride microbubbles contrast Sonovue (Bracco, Milan, Italy) injection.
9825927|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
9825928|NCT02401022|Active Comparator|AZD8529 low dose|1.5 mg
9825929|NCT02401022|Active Comparator|AZD8529 high dose|40mg
10120366|NCT04397744|Experimental|Unidas por Vida y Salud prevention program|Unidas por Vida y Salud (United for Life and Health) prevention program
10120367|NCT04397744|No Intervention|No intervention control|The control arm will not receive the Unidas por Vida y Salud (United for Life and Health) prevention program during the study analysis period (though, the control arm will receive the intervention after study has been completed).
10120368|NCT04397770|Experimental|Camre+Apa+TMZ|
9966532|NCT01261078|Active Comparator|Epi 100|8 mg of bupivacaine mixed with 0.1 mg of epinephrine
10120369|NCT04397887|Experimental|Men with Azoospermia and varicocele|In this single arm study, TEX 101 is measured in the seminal fluid of all participants, and it will be used as a predictor for appearance of sperms in the ejaculate in 3 and 6 moths follow-up periods
10120370|NCT04397601||A|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
10120371|NCT04397601||B|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
10120372|NCT04397991|Experimental|Furosemide|Patients will receive nebulised furosemide
10120373|NCT04397991|Placebo Comparator|Placebo|Patients will receive nebulised 0.9% saline
10120374|NCT04397705|Experimental|Ambulatory monitoring|Participants will be asked to wear the sensors (heart rate, respiratory rate, temperature, and pulse oximetry) for three weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care.
10120375|NCT04397653|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
10120376|NCT04397653|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
10120377|NCT04397822||COVID-19 GROUP Intensive care unit|Patients suffering from COVID-19 hospitalized in intensive care unit
10120378|NCT04397822||COVID-19 GROUP Standard care unit|Patients suffering from COVID-19 hospitalized in standard care unit.
10120379|NCT04397679|Experimental|Treatment (radiation therapy, temozolomide, chloroquine, TTF)|"Patients undergo 30 fractions of 3D CRT or Intensity-modulated radiation therapy (IMRT) and receive temozolomide by mouth (PO) and chloroquine PO daily from day 1 for the duration of radiation therapy up to day 49. Treatment continues in the absence of disease progression or unacceptable toxicity.~ADJUVANT TREATMENT: Beginning 4 weeks after the last day of radiation therapy, patients receive temozolomide PO QD on days 1-5 and chloroquine PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients demonstrating continued benefit may continue to receive temozolomide and chloroquine for up to 12 cycles. Patients also undergo TTF therapy over 18 hours or longer per day."
10120380|NCT04397965|Experimental|Experimental: Continuous Monitoring|Intervention: Device: Cascade Continuous Glucose Monitoring System
10120381|NCT04397692|Experimental|Inhaled NO delivered using LungFit™ in addition to SST|Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
10120382|NCT04397692|No Intervention|Standard of care|Control - Standard of care
10120383|NCT04397783|No Intervention|Cruciate incision|the classic cruciate incision in the colostomy construction
10120384|NCT04397783|Experimental|longitudinal incision|longitudinal incision with two proline sutures
10120385|NCT04397913||Treatment(paracetamol or ibuprofen)|Paracetamol and ibuprofen are administered at standard dose for children with PDA.
10120386|NCT04397718|Placebo Comparator|Placebo + BSC|No active, only placebo (2 - prefilled syringes containing 3 ml of 0.9% saline) plus best supportive care.
10120387|NCT04397718|Experimental|Degarelix + BSC|Active Degarelix (2 - prefilled syringes containing 3 ml of reconstituted Degarelix concentrated to 40mg/ml) plus best supportive care.
10120388|NCT04397497|Experimental|Mavrilimumab|Single dose of IV Mavrilimumab
10120389|NCT04397497|Placebo Comparator|Placebo|Single dose of matching IV placebo
10120390|NCT04397523|Other|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
9966533|NCT01261078|Active Comparator|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
9966534|NCT01261091|Experimental|Early Tracheostomy|Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 3 days from intubation.
10120391|NCT04397380||ED Patients|Patients Presenting in Emergency Department
10120392|NCT04397341|Experimental|biweekly TPF induction|Docetaxel: 50 mg/m2 Cisplatin : 50 mg/m2 5-fluorouracil : 2,500 mg/m2 for 40-48 hrs Leucovorin: 250 mg/m2
10120393|NCT04397458|Sham Comparator|Sham Control|20 milliliters (mL) 0.9% saline on each side
10120394|NCT04397458|Experimental|Quadratus Lumborum Block|20 mL solution with 0.25% bupivacaine (50 milligrams (mg)) and 3mg preservative-free dexamethasone on each side
10120395|NCT04397510|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
10120396|NCT04397510|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days
10120397|NCT04397315|Active Comparator|Complete Pulpotomy|In case of complete pulpotomy procedure the exposed pulp tissue will be amputated using sterile bur in high speed hand piece to the level of canal orifices.
10120398|NCT04397315|Active Comparator|Partial Pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece to a depth of 2-3 mm.
10120399|NCT04397393||non-camel milk consumption|non-camel milk consumption over life time
10120400|NCT04397393||camel milk consumption|camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).
10120401|NCT04397211|Active Comparator|Angiography-derived FFR-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by Angiography-derived FFR-guided strategy
10120402|NCT04397211|Active Comparator|IVUS-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by IVUS-guided strategy
10120403|NCT04397250|Experimental|High-intensity interval training|Participants will be asked to perform four 30 minutes bouts of high-intensity interval exercise per week.
10120404|NCT04397250|No Intervention|Control|Participants will be asked to continue their habitual lifestyle
10120405|NCT04397133|Experimental|intervention 1|in this group patients will get 4 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
10120406|NCT04397133|Experimental|intervention 2|in this group patients will get 8 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
10120407|NCT04397133|Sham Comparator|control group|this group will get sham intervention with 0 to 5 cmH2O resistance
10120408|NCT04397146|Experimental|Single-blind sensory and satiety evaluation|In total 8 different ONS products are consumed and evaluated, each product on a separate test day. The order of products is randomized between study participants.
10120409|NCT04397471||Healthy Volunteer|A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests.
9825930|NCT02401048|Experimental|Phase 1b/ 2: Follicular lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
10120410|NCT04397289|Experimental|Heparin group|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT/INR was kept at 1.25-1.5.
10120411|NCT04397289|Experimental|Rivaroxaban group|Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.
10120412|NCT04397289|Sham Comparator|Control group|No preventive intervention measures.
10120413|NCT04397224||CRT responder|
10120414|NCT04397224||CRT non-responder|
10120415|NCT04397549|Active Comparator|Block group|Cervical Erector Spinae Plane Block administered group
10120416|NCT04397549|Sham Comparator|Control group|Control group
10120417|NCT04397198||HIBRIDH-SG 01|Study subjects with documented ST segment Elevation Myocardial Infarction
10120418|NCT04397328|Experimental|Hydroxychloroquine 200mg|Regular Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg twice a day for 4 consecutive days (5 days in total) Modified Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
10120419|NCT04397328|Placebo Comparator|Placebo Arm|The placebo arm will be matched to study drug to maintain the study blind. Regular Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab twice a day for 4 consecutive days (5 days in total) Modified Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
10120420|NCT04396990|Experimental|Group A Dextenza|
10120421|NCT04396990|Active Comparator|Group B Topical Prednisolone|
10120422|NCT04397029|Experimental|Subjects without messes|Subjects who are believed to be free of masses.
10120423|NCT04397029|Experimental|Subjects with known masses|Subjects with known masses.
10120424|NCT04397081||Control Group|Control group was defined as healthy patients between the ages of 30-65 without allergic complaints.Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
10120425|NCT04397081||Study group|"Study group was defined as patients between the ages of 30-65 with allergic complaints complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed atopic disease (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.~Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded."
10120426|NCT04397068|Other|macular pucker wherefore vitrectomy|one eye phaco-vitrectomy and other eye only phaco. No other involvement of drug or device. Standard of care procedure
10120427|NCT04396834|Experimental|Lorcaserin|Lorcaserin (10mg BID)
10120428|NCT04396834|Placebo Comparator|Placebo|Placebo pill (BID)
10120429|NCT04396678|No Intervention|PrEP Standard of Care|PrEP standard of care, administered through the Baltimore City Health Department
10120430|NCT04396678|Experimental|PrEP standard of care+behavioral intervention|PrEP standard of care, administered through the Baltimore City Health Department, and the behavioral intervention.
10120431|NCT04396899|Other|EHM Implantation|All patients will receive EHM implant
10120432|NCT04396951|No Intervention|Passive external overheating|"Passive external overheating in the environmental temperature control adjusted to thermal comfort.~Measure during 6 hours with indirect calorimetry"
10120433|NCT04396951|Active Comparator|Active external overheating with heating plate|Combination of passive and active external heating with heating plate Measure during 6 hours with indirect calorimetry
10120434|NCT04396951|Active Comparator|Active external overheating with air blanket|Combination of passive and active external heating with convective air blanket Measure during 6 hours with indirect calorimetry
10120435|NCT04396821|Experimental|Part A Q2W|Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, 5 dose levels will be tested.
10120436|NCT04396821|Experimental|Part A Q3W|Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg,, and 4 dose levels will be tested.
10120437|NCT04396821|Experimental|Part B Cohort 1|Participants with gastric or gastroesophageal junction cancers CLDN18.2 expression, dosed Q2W IV with the Part A Q2W recommended dose.
10120438|NCT04396821|Experimental|Part B Cohort 2|Participants with solid tumors other than gastric or gastroesophageal junction cancers with CLDN18.2 expression dosed Q2W IV with TST001 as above.
10120439|NCT04396821|Experimental|Part B Cohort 3|Participants with any kind of advanced or metastatic solid tumors with CLDN 18.2 expression, dosed Q3W with the Part A Q3W recommended dose of TST001
10120440|NCT04396795|Experimental|PRP group|Participants in this group will receive 2 sessions of autologous PRP penile injection, each administered 1 month apart ± 7 days
10120441|NCT04396795|Placebo Comparator|Placebo group|Participants in this group will receive 2 sessions of placebo injection, each administered 1 month apart ± 7 days.
10120442|NCT04396938|Experimental|Lamotrigine|Single dose of Lamotrigine (300mg - capsule). In healthy volunteers.
10120443|NCT04396938|Placebo Comparator|Placebo|Placebo capsule: identical appearance to experimental capsule. In healthy volunteers.
10120444|NCT04396847|Experimental|Lorcaserin|Lorcaserin (10mg BID)
10120445|NCT04396847|Placebo Comparator|Placebo|Placebo pill (BID)
10120446|NCT04396730|Placebo Comparator|Placebo followed by cannabidiol|Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily for cycle 1. During cycle 3, cannabidiol will be taken once daily along with OCPs.
10120447|NCT04396730|Experimental|Cannabidiol follow Placebo|Oral contraceptives will be taken daily for 24 days along with Cannabidiol 400mg once daily for cycle 1. During cycle 3. placebo will be taken once daily along with OCPs.
10120448|NCT04397055|Experimental|Cottonseed Oil|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance
10120449|NCT04397055|Active Comparator|Olive Oil|Participants are given foods enriched with olive oil and instructed on how to substitute study foods into their diet to maintain caloric balance
10120450|NCT04396743|Active Comparator|Periapical surgery with placement of prf high clots|Patients will undergo periapical surgery and PRF-high clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
10120451|NCT04396743|Active Comparator|Periapical surgery with placement of prf medium clots|Patients will undergo periapical surgery and PRF-medium clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
10120452|NCT04396886|Experimental|Bintrafusp Alfa|Single group assignment of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) nonkeratinizing nasopharyngeal carcinoma (NPC)
10120453|NCT04396769|Experimental|FLOW-PA|Participants received the physical activity component of FLOW five days a week during participants' 45-minute long physical education (PE) class period for six months. Intervention activities were designed to promote moderate-vigorous physical activity through circuit-based stations with both aerobic and strength exercises. Trained research staff partnered with PE teachers to facilitate lessons and undergraduate college students were trained to complete activities with participants.
10120454|NCT04396769|Active Comparator|PE class as usual|Participants had PE class as usual 5 days a week for 45 minutes.
10120455|NCT04396912||Control, s/p TT, without complication|Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)
10120456|NCT04396912||Experimental, s/p TT with only VCP|Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)
10120457|NCT04396912||Experimental, s/p TT with only H|Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)
10120458|NCT04396912||Experimental, s/p TT with both VCP+H|"Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H);~Subgroups:~4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent)~Please answer:~Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?)~Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?"
10120459|NCT04396782|Experimental|physiotherapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
10120460|NCT04396782|Active Comparator|standard physiotherapy rehabilitation|static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.
10120461|NCT04396977|Other|Histamine and placebo skin pricks|Each subject will receive the same histamine (10 mg/ml) and control (saline) skin prick on the right and left forearm on both study visits, to allow an intra-individual comparison
10120462|NCT04396600||Healthcare Workers Already Starting Peer Support Program|
10120463|NCT04396600||Healthcare Workers Starting Peer Support Program Later|
10120464|NCT04396470|Experimental|tVNS treatment|
10120465|NCT04396470|Sham Comparator|tVNS sham treatment|
10120466|NCT04396301|Active Comparator|Fydrane group|Fydrane is injected intracamerally at the beginning of cataract surgery after the first incision, at a dose of 0.2 ml of solution, in only one injection. Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). No preoperative topical eye drops are used.
10120467|NCT04396301|No Intervention|Reference group:|not injected with intracameral Fydrane. Pupillary dilatation in this group is achieved using preoperative topical eye drops: cyclopentolate hydrochloride 1% and tropicamide 1 % one drop every 15 min for 1 hour preoperatively.
10120468|NCT04396249|Experimental|Active tVNS group|The active tVNS group will be stimulated with 10 sessions of active transcutaneous vagal nerve stimulation (tVNS)
10120469|NCT04396249|Sham Comparator|Sham tVNS group|The sham tVNS group will be stimulated with 10 sessions of sham transcutaneous vagal nerve stimulation (tVNS)
10120470|NCT04396314|Experimental|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources, is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits. BBAT consists of a broad scope of movements in the following positions: lying, sitting, standing and walking. Relational movements are practiced in therapy with components such as rhythm, form, elasticity, flow, intention and voice
10120471|NCT04396314|Active Comparator|Control|The control group will be treatment for usual for PTSD. Pharmacological treatment is based in fluoxetine, paroxetine, sertraline and venlafaxine. Regarding non-pharmacological treatment the strongly recommendations are cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
10120472|NCT04396262|Experimental|HTD-blueberry beverage with white bread|The beverage prepared using hydro-thermodynamic processing of whole wild blueberries.
10120473|NCT04396262|Experimental|Sweetened water (control) with white bread|The water control of the same volume and with the same amount of available carbohydrate as HTD-blueberry beverage.
10120474|NCT04396509||women giving birth by normal vaginal delivery|100 women delivered vaginally. . They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
10120475|NCT04396509||women giving birth by c-section|100 delivered with cesarean section. They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
10120476|NCT04396392|Experimental|VR-based training|receiving only VR intervention
10120477|NCT04396392|Active Comparator|text-based training|receiving only text-based intervention
10120478|NCT04396392|Experimental|VR- and text-based training|receiving both VR intervention and text-based intervention
10120479|NCT04396392|No Intervention|waiting list|waiting list in phase 1 and text-based training after 3 weeks
9966535|NCT01261091|Active Comparator|Prolonged Intubation|Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy between days 7 to 14 from intubation.
9966536|NCT01261104||Hearing impaired elderly|
10120480|NCT04396431|Other|2|The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy.
10120481|NCT04396327|Active Comparator|Active Comparator: 2-Drug Combination|50 mg diphenhydramine and 0.5 mg lorazepam
10120482|NCT04396327|Experimental|Active Treatment: SM-1 3-Drug Combination|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
10120483|NCT04396457|Experimental|Pembrolizumab+Pemetrexed|"200 mg of pembrolizumab is intravenously infused over 30 minutes and more on day 1.~500 mg/m^2 of pemetrexed is intravenously infused over 10 minutes and more on day 1.~*Administration of folic acid and vitamin B12 is started 1 week before the start of treatment with pemetrexed.~And repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the pembrolizumab administration is 35 cycles, and the pemetrexed administration will continue until the treatment cessation criteria are met."
10120484|NCT04396418|Experimental|Intervention arm|A 16-week blended learning programme targeting stroke prevention and rhythm control therapy at the healthcare professional level, with controlled assessments, a commitment to change plan, and reinforcement actions
10120485|NCT04396418|Other|Control arm|No added education of healthcare professionals
10120486|NCT04396496|Experimental|Daratumumab Injection|"Up to 12 four-week cycles of Daratumumab (DARA), in combination with the immunomodulatory drug (IMiD) lenalidomide.~DARA is injected. Dosage calculated by weight.On Cycles 1 and 2, DARA is given on Days 1, 8,15 and 22. On Cycles 3-6,DARA is given on Days 1 and 15. On Cycles 7-12, DARA is given on Day 1.~Lenalidomide is taken by mouth. 15 mg on Days 1-21 of each cycle."
10120487|NCT04396561|Experimental|Paravertebral group (group P):|After induction of general anesthesia and stabilization of the patients, they were positioned in lateral decubitus position with the side to be blocked uppermost.
10120488|NCT04396561|Experimental|Control group (group C):|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia (IV fentanyl 2 μcg/kg at induction and 1 gm of IV paracetamol).
10120489|NCT04396548|Active Comparator|Group A (midodrine group)|Midodrine will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
10120490|NCT04396548|Placebo Comparator|Group B (placebo group):|Inert tablet containing sugar (placebo) will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
10182920|NCT03769597|Experimental|Iohexol administration|After injecting a loading dose of 5ml of Iohexol Inj 300 MG/ML bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
10182921|NCT03769571|Other|parental coaching program at ESDM (P-ESDM)|
10182922|NCT03769571|No Intervention|CONTROL|
10182923|NCT03769558||JIA patients prescribed abatacept|
10182924|NCT03769506|Active Comparator|ASP-1929 Photoimmunotherapy|Use of ASP1929 PIT therapy
10182925|NCT03769506|Active Comparator|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
10182926|NCT03769493|Experimental|Mobile After-Care Support (MACS) app|All participants will download the MACS app to their mobile phone (or a study provided phone, as needed). The app runs through the third-party platform, mEMA, designed by Ilumivu. It is designed to prompt engagement through questions and tailored responses at multiple times throughout the day and provide brief interventions.
10182927|NCT03769480||Study Group|Study Group=Athletes with Disability
10182928|NCT03769480||Control Group|Control Group=Healthy Athletes
10182929|NCT03769467|Experimental|tabelecleucel in combination with pembrolizumab|Tabelecleucel will be administered initially to 12 subjects at a dose of 2 x 10^6 cells/kg intravenously (IV) on Day 1, Day 8, and 15 of a 21-day cycle. For Cohort 1, if there is a dose-limiting toxicity, the dose of tabelecleucel will be reduced to 1 x 10^6 cells/kg. Pembrolizumab will be administered to adult subjects at 200 mg or to pediatric subjects (12 to < 18 years of age) at 2 mg/kg IV every 3 weeks.
10182930|NCT03769454|Experimental|PP-001 low dose group|
10182931|NCT03769454|Placebo Comparator|Placebo low dose group|
10182932|NCT03769454|Experimental|PP-001 mid dose group|
10182933|NCT03769454|Placebo Comparator|Placebo mid dose group|
10182934|NCT03769454|Experimental|PP-001 high dose group|
10182935|NCT03769454|Placebo Comparator|Placebo high dose group|
10120491|NCT04396223|Experimental|Avelumab combined with methotrexate and folinic acid|Avelumab administration at 800 mg every 2 weeks and methotrexate administration at 1mg/kg/day during 4 months ½ (median)
10120492|NCT04396353||Physically active|Those who receive regular amounts of physical activity. Those who participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen as recommended by the health organizations. Additionally, a person who spend less time sitting (i.e. watching television, surfing the web, playing video games).
10120493|NCT04396353||Sedentary|Those who do not receive regular amounts of physical activity. Where physical inactivity is considered the failure to meet the recommendations of the health organizations, stating that an individual should participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen. Sitting about 70-85% of the time (i.e. watching television, surfing the web, playing video games) is also considered a person living a sedentary lifestyle.
10120494|NCT04396275|Experimental|Cooked whole navy beans|A meal consisting of cooked navy beans
10120495|NCT04396275|Experimental|Cooked whole yellow split peas|A meal consisting of cooked yellow peas
10120496|NCT04396275|Experimental|Cooked rice (control)|A meal consisting of cooked rice
10120497|NCT04396379|Experimental|Device Implantation|To epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy) using an epicardial implant.
10120498|NCT04396132|Experimental|Virtual SVV|The subjects will be tested by virtual SVV. The deviation angle will be measured at 15, 30 and 45-degree head tilt to the left and right side while they are standing
10120499|NCT04396054|Active Comparator|Lag Screws|Group 1: underwent open reduction and internal fixation using two lag screws.
10120500|NCT04396054|Active Comparator|Double Y-shaped plates|Group 2: underwent open reduction and internal fixation using double Y-shaped plates.
10120501|NCT04396067|Active Comparator|Aerosolized 13 cis retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
10120502|NCT04396067|Active Comparator|All trans retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 14 days
10120503|NCT04396067|Placebo Comparator|Placebo Comparator|4 Placebo tablets twice daily by mouth for 2 weeks
10120504|NCT04396197||COVID-19|Observations taken of standard physiotherapy practice. All patients are assessed daily and receive respiratory care and rehabilitation as deemed appropriate by the treating therapist
10120505|NCT04396184|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 288 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once every two weeks for 3 times.
10120506|NCT04396184|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
10120507|NCT04395820||Cystic Fibrosis|
10120508|NCT04395820||Healthy|
10120509|NCT04395742||Coffee:1,3,7-trimethylxanthine|
10120510|NCT04395742||Tea and hot chocolate with milk|
10120511|NCT04395807|Active Comparator|Helmet CPAP|Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
10120512|NCT04395807|Active Comparator|HFNC|High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)
9966537|NCT01261104||Hearing impaired adults|
10120513|NCT04395872||COVID-19|Among patients who were confirmed as COVID-19 and admitted to the COVID-19 management ward of Daegu Catholic University Hospital, patients who were consulted by the Department of psychiatry was selected as participants. Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R). were collected from participants. It evaluates whether there is a difference in the psychological scale according to the difference in participants' sociodemographic status and medical severity, and evaluates the effectiveness of psychiatric counseling by comparing clinical psychological measures before and after referral to department of psychiatry.
10120514|NCT04395911|Other|SCD|Cytopheretic device
10120515|NCT04395781||Control cases|Children who suspected COVID-19 cases but tested negative for COVID-19
10120516|NCT04395781||Confirmed cases|Children who tested positive for COVID-19
10120517|NCT04395924||Pregnant women COVID-19 positive by RT-PCR|Pregnant women COVID-19 positive by RT-PCR on nasopharyngeal swabs and/or by serology or with previous history of SARS-Cov-2 positive during the pregnancy coming to the maternity to deliver
10120518|NCT04395768|Experimental|Vitamin C|"Participants will receive vitamin C in addition to active comparator treatment:~Inpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;~Plus Active Comparator treatment:~Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days"
10120519|NCT04395768|Active Comparator|Control|Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days
10120520|NCT04395716|Experimental|Treatment Group|This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.
10120521|NCT04395976|No Intervention|Control Group|Participants randomised into the control group receive conventional standard care given by recommended guideline.
10120522|NCT04395976|Experimental|Ayurveda|Treatment includes a tailored combination of herbs based on individual constitution (based on Ayurveda) nutritional advice, specific consideration of selected food items, specific lifestyle advice, yoga advice along with standard recommendations.
10120523|NCT04396015|Placebo Comparator|medium chain triglyceride (MCT) vs placebo|MCT or placebo (olive oil) for 4 months. Crossover at 4 months
10120524|NCT04396015|Other|open label extension|6 months of MCT oil.
10120525|NCT04395794||Medical Employees|Asymptomatic medical employees in high-volume cardiovascular center.
10120526|NCT04396158|Experimental|intervention|
10120527|NCT04395950|Active Comparator|PF-0522130|PF-05221304 10 mg daily (two 5mg tablets daily in the morning).
10120528|NCT04395950|Placebo Comparator|Placebo|Placebo (two tablets daily in the morning).
10120529|NCT04396002||Primary Open-Angle Glaucoma|Patients diagnosed with primary open-angle glaucoma.
10120530|NCT04396002||Control|Participants with healthy eyes.
10120531|NCT04396080|Experimental|Onlays behaviour depending on materials|Patients who require it as treatment option will be treated with posterior partial restorations, and will have clinical follow-up to obtain a comparison of the behavior of subsequent restorations based on the material.
10120532|NCT04395885||study group|health care staff, regardless of gender, who is actively working during the outbreak
10120533|NCT04395885||control group|age matched group of non-health worker individuals.
10120534|NCT04395989|Experimental|LAR-HER2+|If patients were LAR subtype with HER2 gene activated mutation
10120535|NCT04395989|Experimental|LAR-PAM+|If patients were LAR subtype without HER2 gene activated mutation, but had PI3K/AKT/mTOR pathway mutation
10120536|NCT04395989|Experimental|IM|If patients were IM subtype (CD8 positive T cell more than 20%)
10120537|NCT04395989|Experimental|BLIS|If patients were BLIS subtype or MES subtype and without PI3K/AKT/mTOR pathway activation
10120538|NCT04395989|Experimental|MES-PAM+|If patients were MES subtype and had PI3K/AKT/mTOR pathway activation
10120539|NCT04395937|Active Comparator|respiratory physiotherapy|exercises to improve the way of breathing
10120540|NCT04395937|Experimental|respiratory physiotherapy and physical exercises|intensity determined by the VO2max measured during ergospirometric measure
10120541|NCT04396483|Experimental|"Tubal sterilization Pomeroy's method"|
10120542|NCT04396483|Active Comparator|Salpingectomy|
10120543|NCT04395456|Experimental|AMY-101|
10120544|NCT04395456|Placebo Comparator|Placebo|
10120545|NCT04395690|Active Comparator|Inferior Alveolar Block Nerve (IABN)|Inferior Alveolar Block Nerve (IABN) anesthesia technique before posterior mandibular implant placement.
10120546|NCT04395690|Experimental|Infiltration (INF)|Infiltration (INF) anesthesia technique before posterior mandibular implant placement.
9528279|NCT03212053|Other|Patients with Essential Thrombocythemia|"patients who come in consultation at diagnosis or during the follow-up for an Essential Thrombocythemia.~They will have biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)"
10120547|NCT04395677|Experimental|AB-106 （DS-6051b）|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106
10120548|NCT04395521|Experimental|Facebook group arm|Access to a diabetic foot self-management support program via a Facebook group platform for three months plus the standard care.
10120549|NCT04395521|No Intervention|Standard care arm|Carry on with the routine diabetes care offered to the participants in their health facilities.
10120550|NCT04395482||covid-19 pneumonia related patients|The study aims to collect the highest number possible of lung CT scan images performed in patients with COVID-19, in order to obtain a large sample size that will allow us to characterize the extent of lung injury, the presence of specific patterns of lung alteration, and their potential association with the outcome of patients - in view of assisting the medical staff in better understanding the grade of the severity impairment in these patients which might be potentially candidates to more intensive therapeutic strategies.
10120551|NCT04395430|Active Comparator|Information Group|Subjects randomized to the Information Group will receive standard care and age appropriate reading books.
10120552|NCT04395430|Experimental|Intervention Group|Subjects randomized to the Intervention Group will receive standard care plus invitation to participate in the online KKH Sports Singapore programme.
10120553|NCT04395625|Experimental|Group 1|Patients had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding.
10120554|NCT04395625|Experimental|Group 2|Patients had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
10120555|NCT04395443|Experimental|patients admitted to emergency department|the intervention is the medication reconciliation
10120556|NCT04395547|Placebo Comparator|Placebo|
10120557|NCT04395547|Experimental|JointAlive™|
10120558|NCT04395612|Experimental|Treatment arm1|niraparib 200mg/day and brivanib 400mg/day
10120559|NCT04395612|Experimental|Treatment arm2|niraparib 200mg/day and toripalimab 240mg/21 days
10120560|NCT04395638|Experimental|Weekly Vitamin D group|
10120561|NCT04395638|Experimental|Daily Vitamin D group|
10120562|NCT04395495||Neurofibromatosis 1 (NF1)|Individuals with a confirmed or suspected diagnosis of Neurofibromatosis Type 1 (NF1). Diagnosis may be made clinically and/or confirmed through genetic testing. Clinical (non-genetic) diagnosis requires that individuals meet the National Institute of Health's (NIH) clinical diagnostic criteria for NF1.
10120563|NCT04395495||Noonan Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
10120564|NCT04395495||Noonan Syndrome with Multiple Lentigines|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome with Multiple Lentigines. Diagnosis may be made clinically and/or confirmed through genetic testing.
10120565|NCT04395495||Noonan Neurofibromatosis Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Neurofibromatosis Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
10120566|NCT04395495||Cardiofaciocutaneous Syndrome|Individuals with a confirmed or suspected diagnosis of Cardiofaciocutaneous Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
10120567|NCT04395495||Costello Syndrome|Individuals with a confirmed or suspected diagnosis of Costello Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
10120568|NCT04395495||Legius Syndrome|Individuals with a confirmed or suspected diagnosis of Legius Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
10120569|NCT04395495||Smith-Kingsmore Syndrome|Individuals with a confirmed or suspected diagnosis of Smith-Kingsmore Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
10120570|NCT04395495||GATOR-1 Mutation|Individuals with a suspected or known mutation of GATOR-1.
10120571|NCT04395495||SYNGAP1-Related Intellectual Disability|Individuals with a suspected or known mutation of SYNGAP1.
10120572|NCT04395495||DLG4 Mutation|Individuals with a suspected or known mutation of DLG4.
10120573|NCT04395495||MAPK1 Gene Mutation|Individuals with a suspected or known mutation of MAPK1.
10120574|NCT04395495||MTOR Gene Mutation|"Individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway."
10120575|NCT04395495||RAS Mutation|"Individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway."
10120576|NCT04395352||Pre-ECV|Patients having undergone colonoscopy prior to the introduction of ECV (November 1 2018 to April 30 2019).
10120577|NCT04395352||ECV|Patients having undergone colonoscopy after the introduction of ECV (June 1 2019 to November 30 2019).
10120578|NCT04395404|Experimental|Single arm|
10120579|NCT04395378||Flying pilots|Flying pilots holding class 1 and class 2 certificates
10120580|NCT04395417|Experimental|Hyaluronic acid injection group|This is the study group in whom Hyaluronic acid injection was injected at lateral epicondylitis site.
10120581|NCT04395417|Active Comparator|Prolotherapy injection group|This is the control group in whom prolotherapy injection was given at lateral epicondyle site.
10120582|NCT04395365|Experimental|Co-trimoxazole|Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 18 months
10120583|NCT04395365|Placebo Comparator|Placebo|Placebo, 960mg capsule oral tablet, to be taken daily for 18 months
10120584|NCT04395326||24 months follow-up|"Single-group study Patients have been included for up to 4 weeks after the initiation of Second Generation Antipsychotic (SGA) treatment (baseline)~Patients under 18 years of age, previously naïve of antipsychotics, starting an SGA or who started an SGA treatment for less than 4 weeks, followed longitudinally at one of the selected recruiting centers, regardless of the diagnosis that motivated the prescription. Comedications and combination of APs are allowed, as this is an observational study.~The exclusion criteria are the following: participants diagnosed before or at the baseline with diabetes, dyslipidemia, high blood pressure, thyroid dysfunction, hepatic disease, a disorder that can lead to hyperprolactinemia or another disorder that may interfere with the development of the side effects studied in this research, participants taking a drug intended to treat one of the conditions mentioned above before starting the SGA treatment, and pregnancy."
10120585|NCT04395183|Active Comparator|5-HTP + Placebo|5-hydroxytryptophan 100mg PO BID plus placebo matched to creatine monohydrate
10120586|NCT04395183|Active Comparator|Creatine + Placebo|Creatine 5g PO qday plus placebo matched to 5-HTP
10120587|NCT04395183|Active Comparator|Creatine + 5-HTP|Creatine 5g PO qday plus 5-hydroxytryptophan 100mg PO BID
10120588|NCT04395183|Placebo Comparator|Double Placebo|Creatine-matched placebo and 5-HTP-matched placebo
10120589|NCT04395261||Group 0|Patients were divided into groups according to observation in surgery Empty ear in operation
10120590|NCT04395261||Group 1|Patients were divided into groups according to observation in surgery Serous fluid in operation
9966538|NCT01261117|Active Comparator|intravenous ibuprofen|Extremely low birth weight patients receiving iv ibuprofen
10120591|NCT04395261||Group 2|Patients were divided into groups according to observation in surgery Mucoid fluid in operation
10120592|NCT04395261||Group 3|Patients were divided into groups according to observation in surgery Adhesive tympanic membrane in operation
10120593|NCT04395261||Group 4|Control group. Subjects with no otitis media with effusion
10120594|NCT04395040||Patients|Elderly patients with digestive cancer or breast cancer.
10120595|NCT04395105|Experimental|High dose Dexamethasone|Intravenous Dexamethasone 16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
10120596|NCT04395105|No Intervention|Usual care - low dose Dexamethasone|Intravenous Dexamethasone 6 mg qd for 10 days based on RECOVERY trial
10120597|NCT04395248|Active Comparator|Risk factors of difficult intubation|Appearance anpalpationpalpationpalpationd ultrasound features for predicting difficult laryngoscopy intubation
10120598|NCT04395248|Active Comparator|Radial artery cannulation using ultrasound or blind palpation|In the ultrasound group, a linear vascular probe in the frequencies 5 to 13 MHz (GE 12L-RS, GE Healthcare, Chicago, IL, USA) of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image.
10120599|NCT04395248|Active Comparator|Preoxygenation using high-flow nasal cannula or facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher & Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs.
10120600|NCT04395248|Active Comparator|Type of volatile anesthetics and M-Entropy guidance|Patients will be randomized by a computer-generated list into one of the four groups, desflurane with usual care (N=20), desflurane with M-Entropy guidance (N=20), sevoflurane with usual care (N=20), and sevoflurane with M-Entropy guidance (N=20).
10120601|NCT04395053|Experimental|Treatment group TR|Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.
10120602|NCT04395053|Experimental|Treatment group RT|Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation.
10120603|NCT04395092|Experimental|K-NK002|
10120604|NCT04395235|Experimental|Targeted Surgical Therapy Plan|This study pointed out that 3D surgico-anatomical models lead to more precise anatomical understanding compared to CT images in terms of detail perception. The 3D models of vascular patterns proves to be the optimal design according to the experts' evaluation with its teaching effects on surgical residents. The demonstration of the hepatic source vascular anatomy and corresponding vascular patterns may provide practically useful guides in decision making related to vascular detail during living donor liver transplantation.Model CT's were measured in order to verify 1:1 modelling and the printing the process was carried out with 3D printers of Mass Portal Pharaoh xd 20 with Eryone PLA 3D printer flament (2.2LBS)/Spool, White). Measurements of the anatomical structures were compared between the original CT images, and the CT images of the 3D model. The morphometric values such as inter-arterial distances, inter-venous distances and the distance between artery and vein were noted.
10120605|NCT04395131|Other|Clearum HF Dialysis Subjects|All subjects enrolled in the study and treated with the Clearum HF hemodialyzer
10120606|NCT04394962|No Intervention|Control group|Patients who will be randomized to the control group will be waiting for the ET procedure without any intervention and without any deviation from the standard of care
10120607|NCT04394962|Experimental|Study group|Exposure to virtual reality environment exposure
10120608|NCT04395144|Experimental|Awake prone positioning|Prone positioning of patients on nasal high-flow oxygen therapy
10120609|NCT04395144|Active Comparator|Standard care|Standard decubitus positioning of patients on nasal high-flow oxygen therapy
10120610|NCT04395209|Experimental|stroke individuals|
10120611|NCT04395209|Active Comparator|healthy individuals|
10120612|NCT04395118|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
10120613|NCT04395118|Active Comparator|Mailed Outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in patients with elevated LFTs and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody test. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will call to this potential subject. Patients will also receive centralized patient navigation to facilitate screening completion and appropriate test follow-up. He/she will help patients schedule HCV antibody testing and will assume responsibility for tracking results. Patients referred to the Hepatitis C clinic for treatment evaluation will receive reminder calls from trained and credentialed study staff 5-7 business days for scheduled appointments.
10120614|NCT04394975|Experimental|Test group|Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orraly twice daily.
10120615|NCT04394975|Active Comparator|Control group|Sunitinib will be administered 50mg QD orally according to label recommendation (4 consecutive weeks followed by a 2-week off-treatment period,or 2 consecutive weeks followed by a 1-week off-treatment period), until treatment criteria are met.
10120616|NCT04395300||Healthcare workers|Physicians, Nurses, Laboratory workers, radiology technicians
10120617|NCT04395287||Preschool children|Attending public preschools in Svendborg, Denmark, at the time of recruitment
10120618|NCT04395170|Experimental|Convalescent plasma|Plasma from patients recovering from COVID-19.
10120619|NCT04395170|Experimental|Anti-COVID-19 human immunoglobulin|Anti-COVID-19 human immunoglobulin to be administered intravenously.
10120620|NCT04395170|Active Comparator|Standard (specific) therapy|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
10120621|NCT04395027|No Intervention|Usual care|These patients will not have their iatrogenic septal defect closed.
10120622|NCT04395027|Experimental|Device|These patients will have their iatrogenic septal defect closed after the mitral intervention is completed.
10120623|NCT04395079|Experimental|Arm I (durvalumab, brachytherapy)|Patients receive durvalumab IV on day 1. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
10120624|NCT04395079|Experimental|Arm II (tremelimumab, brachytherapy)|Patients receive tremelimumab IV on day 1. Treatment repeats every 28 days for 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
10120625|NCT04395274||Current E-Cigarette Users|Monitoring current e-cigarette users
10120626|NCT04395274||Never E-Cigarette / Tobacco Users|Monitoring never users of any tobacco or e-cigarette products.
10120627|NCT04394936|Experimental|Guselkumab|Guselkumab 100 mg/ml in prefilled syringe, subcutaneous injection, administered on day 0, 28 and 84.
10120628|NCT04394936|Placebo Comparator|Placebo|Sodiumchloride 0,9% solution for injection, subcutaneous injection, administered on day 0, 28 and 84.
10120629|NCT04394936|No Intervention|Healthy volunteers|Healthy volunteer cohort (observational)
10120630|NCT04394702|Experimental|One Shape Single-file rotary system|
10120631|NCT04394702|Active Comparator|Manual stainless steel K-file|
10120632|NCT04394910|Experimental|Pomegranate Juice|Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.
10120633|NCT04394910|Placebo Comparator|Placebo Juice|Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.
10120634|NCT04394897||TIVA|TIVA either with remifentanil and propofol infusions separately
10120635|NCT04394897||MIXTIVA 2/1000|MIXTIVA infusion that had remifentanil/propofol proportion 2/1000
10120636|NCT04394897||MIXTIVA 3/1000|MIXTIVA infusion that had remifentanil/propofol proportion 3/1000
10120637|NCT04394676|Experimental|Reduction in Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
10120638|NCT04394676|Active Comparator|Standard Amount of Pressure|This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
10120639|NCT04394520|No Intervention|Control|No change will be made to the introduction content or the consent mode (active opt-in and active opt-out) from other related trials
10120640|NCT04394520|Experimental|Modified Intro, Standard Consent|Modified introductory language will be used, but the consent structure (active opt-in and active opt-out) will remain the same.
10120641|NCT04394520|Experimental|Modified Intro, Active Opt-in|Modified introductory language will be used, and the consent mode will be changed to active opt-in only.
10120642|NCT04394520|Experimental|Modified Intro, Active Opt-out|Modified introductory language will be used, and the consent mode will be changed to active opt-out only.
10120643|NCT04394520|Experimental|Modified Intro, Passive Opt-in|Modified introductory language will be used, and the consent mode will be changed to passive opt-in only.
10120644|NCT04394598|Experimental|CRT with Dendrobium Huoshanense|"Dendrobium Huoshanense Granules: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
10120645|NCT04394598|Placebo Comparator|CRT with Placebo|"Placebo: 3g tid per day for 5weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
10120646|NCT04394572||colorectal cancer|Patients with and without colorectal cancer
10120647|NCT04394741|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
9519518|NCT03286413|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
10120648|NCT04394741|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
10120649|NCT04394611||Fetal Growth Restriction (FGR)|FGR will be defined as an estimated fetal weight (grams) less than the 10th percentile for gestational age. Hadlock I formula will be used to calculating estimated fetal weight percentiles
10120650|NCT04394611||Control|healthy pregnancies will be selected for the control group.
10120651|NCT04394832|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.~In the intervention phase the participant was offered around five intervention sessions with a researcher. Each session the participant chose which intrusive memory they would like to focus on and the cognitive task was completed. The intervention included a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants were given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary."
10120652|NCT04394819||experimental and control groups|"Task-oriented EMG-triggered ES treatment will be applied to the experimental group 2 days a week for 5 weeks and will continue with conventional physiotherapy.~The control group will only continue conventional physiotherapy treatment."
10120653|NCT04394780|No Intervention|Peritoneal dialysis at 37 C|Patients underwent peritoneal dialysis with the standard temperature.
10120654|NCT04394780|Active Comparator|Peritoneal dialysis at 32 C|Patients started on continuous ambulatory peritoneal dialysis using a peritoneal dialysate cooled to between 32-33 degrees centigrade, at a pre-determined and precisely controlled temperature for the 4 hour duration treatment.
10120655|NCT04394533|Experimental|Prilocaine (Intervention) Group|Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
10120656|NCT04394533|Active Comparator|Bupivacaine (Control) Group|Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
10120657|NCT04394793|Experimental|Study Arm|
10120658|NCT04394559|No Intervention|Usual care|inpatient pharmacists as available; standard discharge orders; standard follow up visit.
10120659|NCT04394559|Experimental|Intervention|Discharge counseling; discharge opioid order set; post-discharge pain management follow up; patient pain management app.
10120660|NCT04394507||Fontan Patients|Fontan patients operated at the two centres between 1991 and 2014.
10120661|NCT04394507||Control Group|Age, gender and weight matched healthy controls.
10182936|NCT03769441|Active Comparator|Ferric(III) carboxymaltose|The intervention group will be treated with four dosages of 500 mg iron in the form of 10 mL ferric(III) carboxymaltose dissolved in 240 mL of NaCl 0.9%, with interval periods of six weeks.
10120662|NCT04394494|Experimental|Motor Imagery|Patients are instructed in a motor imagery protocol of imaging extension exercises (similar to the CG), without doing the actual extension exercises. Patients will be instructed in visualizing them moving into extension and back as well as common sensations they may experience (as if doing the actual exercise). They will repeat the visualization process 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 visualization exercises.
10120663|NCT04394494|Active Comparator|Control|Patients are instructed in extension exercises and actually, physically doing the actual extension exercises. Patients will physically repeat the extension exercises 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 exercises.
10120664|NCT04394715|Experimental|Intervention|Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.
10120665|NCT04394715|No Intervention|Control|Providers will not see an electronic alert for any patients and will provide usual care. Silent alerts will be generated that will be sent to study team members.
10120666|NCT04394468|Other|patient group|Data is collected from women (18-45y) with endometriosis (superficial and / or deep infiltrating endometriosis) where the preferred treatment is a laparoscopic intervention at UZ Gent.
10120667|NCT04394234||Treatment Group|Participants data who are new users of rivaroxaban, apixaban and dabigatran with prior Non-valvular atrial fibrillation/Venous thromboembolism/Total hip replacement (NVAF/VTE/THR) or Total knee replacement (TKR) in a nationally representative population of insured participants in the United States (US) will be compared pairwise.
10120668|NCT04394234||Comparator Group|Participants data who are new users of warfarin, apixaban, and dabigatran with prior NVAF/VTE/THR or TKR in a nationally representative population of insured participants in the US will be compared pairwise.
10120669|NCT04394286|Experimental|Cohort 1|Cohort 1 participants will receive a single intravenous (IV) infusion of SHP648 on the day of dosing (Day 0).
10120670|NCT04394286|Experimental|Cohort 2|Cohort 2 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 1 on the day of dosing (Day 0).
9668953|NCT04509401|Active Comparator|Interventional|High dose of Vitamin B6 with Magnesium. Vitamin B6 will be given orally 150 mg for ages 2-3 years, 200 mg for ages 4-6 years,300 mg for ages 7-8 years and Magnesium will be given orally 50 mg for 2-3 years, 100 mg for ages 7-8 years for three months.
10120671|NCT04394286|Experimental|Cohort 3|Cohort 3 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 2 on the day of dosing (Day 0).
10120672|NCT04394455|Experimental|Brief cognitive behavioral therapy|Medical staff (medical doctors and residents) who will receive brief cognitive behavioral therapy through telepsychiatry.
10120673|NCT04394455|Active Comparator|Crisis intervention therapy|Medical staff (medical doctors and residents) who will receive 3 sessions of crisis intervention therapy through telepsychiatry.
10120674|NCT04394312|Experimental|Intervention|Participants will attended a 75 minute physical literacy workshop (Parent PLAYSHOP). A questionnaire will be completed at the beginning of the workshop and the end of the workshop to measure if there is a difference in parent's knowledge and confidence levels in regard to engaging in meaningful physical activity with their children.
10120675|NCT04394312|No Intervention|Control|Participants will complete the 2 questionnaires online, one week or more apart. Once questionnaires are completed they will be invited to attended the 75 minute physical literacy workshop. The workshop content and delivery will be the same as the intervention group but will not include questionnaires.
10120676|NCT04394156|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.~In the intervention phase the participant will be offered around five intervention sessions with a researcher. Each session the participant will choose which intrusive memory they would like to focus on and the cognitive task will be completed. The intervention includes a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants will be given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary."
10120677|NCT04394195||patients with COVID-19 infection|patients with COVID-19 infection
10182937|NCT03769441|Placebo Comparator|Placebo|The placebo-controlled group will receive four dosages of 250 mL of NaCl 0.9% solution with interval periods of six weeks.
10182938|NCT03769428|Active Comparator|group B:ESP block|"Patients in the experimental arm will receive an erector spinae plane block prior to induction of general anesthetic :- 150 mg of Ropivacaine : 40cc of Ropivacaine (3.75mg/cc)~An intravenous patient controlled analgesia device will be given to the patients postoperatively"
10182939|NCT03769428|Placebo Comparator|group P: Sham ESP block|"Patients allocated to the placebo-control arm will receive a sham erector spinae plane block .they will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block:- 40 cc of normal saline will be injected~-An intravenous patient controlled analgesia device will be given to the patients postoperatively"
10182940|NCT03769402|Active Comparator|Citric acid|Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft
10182941|NCT03769402|Placebo Comparator|Control|Control test
10182942|NCT03769389|Experimental|assessing the GI + GL of Birhi + YEO 0% fat yoghurt|47g of total carbohydrate in which contains 43.6g of Freeze-dried of Birhi powder+ 150g of 0% fat yoghurt
9668954|NCT04509401|Placebo Comparator|Control|Control group will receive oral placebo in the same manner, schedule and time frame.
9668955|NCT04503551|Experimental|PDS Arm|Participants randomized to the PDS arm will receive two intravitreal ranibizumab injections and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 36-weeks (Q36W) thereafter
9966539|NCT01261117|Active Comparator|Oral ibuprofen|Extremely low birth weight patients receiving oral ibuprofen
9668956|NCT04503551|Other|Comparator Arm|Participants randomized to the comparator arm will undergo study visits every 4 weeks (Q4W) for comprehensive clinical monitoring until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q36W thereafter. Participants will be eligible to receive intravitreal ranibizumab 0.5 mg injections if treatment eligibility criteria are met.
9668957|NCT04498221|Experimental|Imaging Phase|During routine examination under anaesthetic 4 x peritumoural injection of Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
10120678|NCT04394104||COVID-19 Survey Group|Group of individuals participating in the survey via self-selection. There is not intervention being administered. The group is simply answering questions on their health behaviors before COVID-19 and their health behaviors in the past 7-30 days, during the COVID-19 outbreak in the United States.
10120679|NCT04394338|Active Comparator|plastic sheath covering|plastic sheath was prepared with the standard 9 cmx15cm self-gripping mesh. Then the meshe were folded and unfolded over or under the plastic sheaths in different directions.
10120680|NCT04394338|No Intervention|mesh placement without plastic sheath|self-gripping mesh were placed without plastic sheath.
10120681|NCT04394403|Experimental|immediate guided self-help|In this condition, individuals will be given access to material and exercises based on CBT to reduce their stress
10120682|NCT04394403|No Intervention|waitlist|Individuals in this condition will wait 6 weeks before they are provided access to the guided self-help program
10120683|NCT04394208|Placebo Comparator|Group 1|Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo
10120684|NCT04394208|Experimental|Group 2|patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses
10120685|NCT04394442|Experimental|Hydroxycholoroquine group|
10120686|NCT04394442|No Intervention|Control group|
10120687|NCT04394273||Long- Term Exercise Group|They will exercise one an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).In this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
10120688|NCT04394273||Short-Term Exercise Group|They will exercise half an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).n this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
10120689|NCT04394273||Home Program|Pregnant women who choose the home program group are told to continue their home program until the 32nd week, which includes posture and body mechanics training, increase their physical activity levels and be as active as possible and take daily walks.
10120690|NCT04394416|Experimental|Imatinib|Imatinib oral 400 mg daily for 14 days.
10120691|NCT04394416|Active Comparator|Placebo|Placebo oral for 14 days
10120692|NCT04394377|Other|Group 1|"The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral):~Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin);~Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation)."
10120693|NCT04394377|Other|Group 2|Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.
10120694|NCT04394091||PET CT and ultrasensitive PET CT|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .
10120695|NCT04394364||BIS monitor group|Patients under monitoring of BIS
10120696|NCT04394143|Experimental|AD128|The study specific intervention includes per oral administration of two capsules of AD128, once daily, just before lights out, for 7 days.
10120697|NCT04394143|Placebo Comparator|placebo|Two placebo capsules (Mannitol) will be administered for the control intervention once daily, just before light outs, for one week.
10120698|NCT04394078||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
10120699|NCT04393870|Experimental|Maryam's Flower Group|Maryam's flower was placed in a bowl of water and left in the room of the pregnant women who were at 1 cm cervical dilatation and in the first phase of the labor. It was explained to the pregnant women that the leaves of the plant would open up in the water, and they were asked to imagine that the birth canal would simultaneously open up. In effect, they were told to focus on the opening of these leaves during the course of the labor
10120700|NCT04393870|No Intervention|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
10120701|NCT04394052||Soft-tissue tumors|Benign and malignant soft tissue masses
10120702|NCT04394052||Bone tumors|Benign and malignant bone focal bone lesions
10120703|NCT04393844|Placebo Comparator|with obturator|A group using an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
9966540|NCT01261130|Experimental|Part I-A: 10μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation A
10120704|NCT04393844|Experimental|without obturator|A group that does not use an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
10120705|NCT04393883|Experimental|Standard maintenance programme group|pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
10120706|NCT04393883|Experimental|Improvement maintenance programme group,|pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
10120707|NCT04393831|Active Comparator|Retzius sparing|Using the Retzius technique, the surgeon will remove the prostate in a way that preserves a portion of the nerves and tissue structures that are typically removed during the conventional technique.
10120708|NCT04393831|No Intervention|Conventional (non-Retzius) nerve sparing|A non-Retzius nerve sparing technique will be performed, according to surgeon's preference--nerve sparing during radical prostatectomy is performed with significant variation and there is an absence of universally agreed upon steps or techniques.
10120709|NCT04393909|Active Comparator|Control group|Patients do not have access to the Patient Dx Questionnaire.
10120710|NCT04393909|Active Comparator|Patient Dx Questionnaire User group|Patient enrollees will be randomized to receive the Patient Dx Questionnaire administered by the research staff at the bedside.
10120711|NCT04393922|Experimental|Aim 1|"To accomplish this aim, we will conduct one experiment in two sessions separated by 2- 3 days using a crossover design. Participants will be assigned into one of three groups: spastic SCI, non-spastic SCI, and controls. We expect that people enrolled in Aim 1 will complete 2 visits within 1 week.~Visit 1 Measurements:~MVCs~MEP Recruitment Curves~iMEPs~StartReact~Visit 2 Measurements:~Participant Reported Spasticity~MAS~PSAD~KINARM~MRI of brain and spinal cord"
10120712|NCT04393922|Experimental|Aim 2|"To accomplish this aim, we will use a randomized crossover design study with spastic SCI participants receiving a single intervention combining non-invasive acoustic stimuli (Startle) or sham-Startle with motor training to enhance cortico- and reticulo-spinal contribution, separated by ~2 weeks.~Visit 1 and Visit 2~Single intervention of:~Startle + exercise training OR sham-Startle + exercise training~Pre and post measurements:~MVCs~MEP recruitment curves~iMEPs~StartReact~Participant reported spasticity~MAS~PSAD~KINARM~Neuromechanical hand and/or leg testing~GRASSP~TRI-HFT~10-meter walk test~Pendulum Test"
10120713|NCT04393961|Other|Past Positive COVID-19 confirmed|Invited participants who Radish Health has completed a positive COVID-19 test who have recovered from all symptoms for more than 14 days.
10120714|NCT04393961|Other|Physician Diagnosed: Not Tested|Individuals who self report that a medical professional has told them they likely have COVID-19 (and have since recovered), but did not get a confirmatory test.
10120715|NCT04393961|Other|Self-Diagnosed Not Tested|Participant suspects they contracted (and have since recovered) from COVID-19, but they do not have a medical diagnosis or confirmatory test.
10120716|NCT04393961|Other|Likely Exposed, No Symptoms. Not Tested|Participant suspects that they've been exposed to COVID-19, but have not shown symptoms and wonder if they have antibodies so they may return to some normalcy.
10120717|NCT04393805||MED-Cohort|Patients hospitalized for SARS-COVID-2 infection in a medical ward
10120718|NCT04393805||ICU-Cohort|Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
10120719|NCT04394000||Before or control group|All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
10120720|NCT04394000||After or intervention group|On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
10120721|NCT04393818|Experimental|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep), work environment, and social support.
10120722|NCT04393818|Sham Comparator|Control App|Participants allocated to the control App will receive access to a a fully operational mobile phone App with limited contents about management and prevention of mental health problems. Although this group will also receive psychoeducation, the content will be reduced to general, written recommendations.
10120723|NCT04393792|Active Comparator|Povidone-Iodine|0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
10120724|NCT04393792|Placebo Comparator|Normal Saline|sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
10120725|NCT04394065||uEXPLORER total-body PET/CT|Newly diagnosed NPC patients will undergo a one-hour total-body dynamic PET/CT examination and subsequently followed by a conventional PET/CT scan within 30 minutes
10120726|NCT04394013|Experimental|Mindfulness Arm|The content of the approximately 20 minutes video is recorded in advance of the intervention by a certified teacher with teaching experience. The 20 minutes session consists of a series of body stretching exercises (around 17 different gentle and simple stretches from head to toe) with the incorporation of breathing technique (i.e. when to breathe in and breathe out). The whole body stretching exercise is performed with a sitting position, ideally on an exercise mat. As mentioned above, the participants are required to conduct the stretching exercise by following the guidance video for at least 5 days weekly for at least 2 weeks duration. The video will be uploaded onto a webpage which requires participants to log in and view the video. The webpage and video will be accessible through computers and mobile phones.
10120727|NCT04394013|Active Comparator|Non-mindfulness Arm|In this study, for control group, the participants are instructed with a similar video content as the intervention group, minus the incorporation of breathing technique, as breathing technique is hypothesised to be a key component of mindfulness.
10120728|NCT04394039|Experimental|public sp exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
10182943|NCT03769389|Experimental|assessing the GI + GL of Khassab + YEO 0% fat yoghurt|47g of total carbohydrate in which contains34.6g of freeze-dried Khassab powder+ 150g of 0% fat yoghurt
9668958|NCT04498221|Experimental|Surgical Phase|Excision of contralateral nodes identified on imaging *(fhSPECT or SPECT/CT*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
9668959|NCT04496674|Experimental|Treatment with bispecific Ab CC-1|administration of bispecific PSAMxCD3 Ab CC-1.
9668960|NCT04486742|Experimental|Itch CBT Arm|Participants randomized to the Itch CBT Arm will participate in 4 weekly telehealth sessions with a therapist to address common areas of anxiety related to atopic dermatitis.
9966541|NCT01261130|Experimental|Part I-B: 30μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation B
9668961|NCT04486742|No Intervention|Usual Care Arm|Participants randomized to the Usual Care Arm of the study will receive standard of care eczema educational materials that are typically provided by their health care provider after a clinic (or telehealth) visit.
9668962|NCT04486352|Experimental|Atezolizumab and Bevacizumab Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with no specified gene signatures will be enrolled in this cohort. Twenty patients will be enrolled. Once twenty patientsare enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
9966542|NCT01261130|Experimental|Part I-C: 100μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation C
9966543|NCT01261130|Experimental|Part I-D: 10μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation D
9966544|NCT01261130|Experimental|Part I-E: 30μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation E
9966545|NCT01261130|Experimental|Part I-F: 100μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation F
9966546|NCT01261130|Experimental|Part II-A: 10μgNaGST1/Alhydrogel|Part II (endemic area), Formulation A
9966547|NCT01261130|Experimental|Part II-B: 30μgNaGST1/Alhydrogel|Part II (endemic area), Formulation B
9966548|NCT01261130|Experimental|Part II-C: 100μgNaGST1/Alhydrogel|Part II (endemic), Formulation C
9966549|NCT01261130|Experimental|Part II-D: 10μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation D
9966550|NCT01261130|Experimental|Part II-E: 30μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation E
9966551|NCT01261130|Experimental|Part II-F: 100μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation F
9966552|NCT01261130|Active Comparator|Part II-G: Butang® hepatitis B vaccine|Part II (endemic), HepB comparator
9966553|NCT01261143|Experimental|BK-C-0701, diabetic neuropathy|
9966554|NCT01261143|Active Comparator|alpha lipoic acid, diabetic neuropathy, capsule|
10120729|NCT04393896|Experimental|intervention group|Participants in the intervention group will receive the usual financial benefits of the Reward Policy as well as the WIFI program which will include three key components: psycho-education through WOA publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call.
10120730|NCT04393896|No Intervention|control group|Participants in the control group will receive the usual financial benefits of the Reward Policy and receive payment from the Changsha psychiatric hospital. However, they will not have access to the WIFI program since they cannot scan the WeChat barcode for the research.
9694605|NCT04787731|Active Comparator|Bupivacaine|Bupivacaine HCI (1.8mL) 5% concentration, with epinephrine (1:200,000) is the investigational product. It exists in liquid form in cartridges. Bupivacaine is a FDA approved marketed anesthetic drug and meets IND Exemption.
9966555|NCT01261156|Experimental|Study Arm 1|
9966556|NCT01261156|Experimental|Study Arm 2|
9966557|NCT01261169||Myfortic|
9966558|NCT01261182|Experimental|In School Feeding|
9966559|NCT01261182|Experimental|Take Home Rations|
9966560|NCT01261182|No Intervention|Control|
9976514|NCT01352247|Experimental|Total Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position."
9976515|NCT01352260||Cardiac Disease|Total Aortic Arch Replacement
9976516|NCT01352273|Experimental|MEK162 + RAF265|
9976517|NCT01352299|Active Comparator|Macintosh|Laryngoscopy performed with Macintosh Laryngoscope
9976518|NCT01352299|Active Comparator|McCoy|Laryngoscopy performed with MacCoy Laryngoscope
9976519|NCT01352299|Active Comparator|Miller|Laryngoscopy performed with Miller Laryngoscope
9976520|NCT01352299|Active Comparator|TrueView|Laryngoscopy performed with TrueView Laryngoscope
9976521|NCT01352312|Experimental|Treatment (pentostatin, bendamustine, ofatumumab)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, pentostatin IV on day 1, and ofatumumab IV on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9976522|NCT01352325|Experimental|system constellations seminar (exp. group)|Study participants randomized to this group receive the intervention (system constellation seminar) 4 months prior to the control group
9976523|NCT01352325|Experimental|system constellations seminar (control group)|Study participants randomized to this group receive the intervention (system constellations seminar) 4 months after the experimental group.
9976524|NCT01352338|Experimental|lenalidomide, endoxan, prednisone|"lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone"
9976525|NCT01352351|Experimental|Breastfeeding promotion intervention|"Intervention:~Group breastfeeding counseling during monthly microcredit borrower group meetings~Weekly cell phone messages about breastfeeding"
9976526|NCT01352351|No Intervention|No intervention|The no intervention group will participate in their regular microcredit borrower group meetings, but will not receive breastfeeding counseling or cell phone messages.
9976527|NCT01352364|Experimental|deaf children|
10120731|NCT04393987|Experimental|Arms|Treatment Compliance Training The treatment compliance training consists of five sessions in total and was given individually. Each session of the treatment compliance training given once a week took 45 minutes on average.
10120732|NCT04393987|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
10120733|NCT04393727|Experimental|Intervention|Patients in the intervention group will receive 200 cc of convalescent plasma
10120734|NCT04393727|No Intervention|Control|Patients will continue to receive standard therapy
10120735|NCT04393714|Experimental|autogenous dentin graft treated with nitric acid|
10120736|NCT04393714|Active Comparator|autogenous dentin graft treated with hydrochloric acid|
10120737|NCT04393636|No Intervention|Control arm|Participants will receive at the different time intervals through our custom-made Digital Cardiac Counselling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes.Additional to known risk factors a Covid-19 module will be used as well.
10120738|NCT04393636|Active Comparator|Intervention arm|All participants will receive at the different time intervals through our custom-made Digital Cardiac Counseling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes. Additional to above participants in the intervention group will receive through the Digital Cardiac Counseling platform different modules with E-counseling for risk factors evaluated in the questionnaires. Additional to known risk factors a Covid-19 module will be used as well.
10120739|NCT04393610|Active Comparator|Group (L)|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group)
9966561|NCT01261234|Experimental|Cilostazol group|Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)
10120740|NCT04393610|Active Comparator|Group M|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
10120741|NCT04393610|Active Comparator|Group F|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
10120742|NCT04393623|Experimental|Cognitive Reappraisal Microintervention|"The CR microintervention (session 1) is drawn from Barlow & colleagues empirically supported treatment for emotional disorders (the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders). The microintervention consist of four sections: (1) Introduction to cognitive appraisal; (2) Introducing the idea of thinking traps that prevent reappraisal and maintain negative emotion; (3) Describing cognitive reappraisal as a strategy that can help the participant get out of such thinking traps; (4) Providing an example of this process (situation> negative appraisal > negative emotion > thinking trap > opportunity for cognitive reappraisal) and have participants provide a personalized example."
10120743|NCT04393623|Active Comparator|Psychoeducation (Control)|The manualized psychoeducational control module, serving as an attentional control, is derived from two sources: 1. The first session of the Women's Health Education Manual, which provides psychoeducation about the basic body systems and their function, with focus on components of the immune system and 2. Fact sheets published by the American College of Obstetricians and Gynecologists(ACOG), providing female-specific facts about cancer and heart health. None of this psychoeducation discusses potential relevancy of alcohol use, nor will any behavior changes be suggested during the control microintervention.
10120744|NCT04393675|Active Comparator|LT5001|Administered twice daily (maximum 6 g per time, morning and evening respectively)
10120745|NCT04393675|Placebo Comparator|Placebo|Administered twice daily (maximum 6 g per time, morning and evening respectively)
10120746|NCT04393688|Experimental|Experimental: Tri-wire Peripheral Balloon Dilatation Catheter|Percutaneous transluminal angiography (PTA) will be performed using the Tri-wire Peripheral Balloon Dilatation Catheter. Interventions: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter; Procedure: Percutaneous Transluminal Angiography.
10120747|NCT04393688|Active Comparator|Active Comparator: OHICHO Ⅱ PTA Balloon Catheter.|Percutaneous transluminal angiography (PTA) will be performed using OHICHO Ⅱ PTA Balloon Catheter, a commercially available high-pressure PTA balloon. Multiple balloons, inflations and/or prolonged inflation may be used. Interventions: Device: OHICHO Ⅱ PTA Balloon Catheter. Procedure: Percutaneous Transluminal Angiography.
10120748|NCT04393389||non-CLI group|Rutherford Clinical Category (RCC) 2-3
10120749|NCT04393389||CLI group|critical limb ischemia，Rutherford Clinical Category (RCC) 4-6
10120750|NCT04393415|Active Comparator|patients receiving LGF|
10120751|NCT04393415|No Intervention|patients not receiving LGF nor PRP|
10120752|NCT04393415|Active Comparator|patients receiving Platelet rich plasma|
10120753|NCT04393480|Active Comparator|Robotic therapy|Robotic rehabilitation and conventional rehabilitation
10120754|NCT04393480|Sham Comparator|Conventional therapy|Conventional rehabilitation
10120755|NCT04393324||Transferred patients|A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds
10120756|NCT04393324||Matched Non-transferred patients|A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables
10120757|NCT04393662||Tenodesis group|Tenodesis as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
10120758|NCT04393662||Tenotomy group|Tenotomy as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
10120759|NCT04393506|Other|Inductive therapy|Inductive therapy with Camrelizumab and Apatinib, followed by radical surgery and post-operative radiotherapy/chemoradiotherapy.
10120760|NCT04393454|Experimental|Sirolimus|Participants will be instructed to take 2 mg every day for 28 days (1 cycle). They will be evaluated in the oncology clinic every 2 weeks to make sure they are tolerating the medication well.
10120761|NCT04393545|Active Comparator|HV night splint (SP) group|
10120762|NCT04393545|Active Comparator|exercise (EX) group|
10120763|NCT04393545|Active Comparator|high-voltage galvanic stimulation (EL) group|
10120764|NCT04393519||Prospective|Prospective cohort that received TIPS from 05/12/2020 onwards
10120765|NCT04393402||Patients with Covid-19 and admitted in critical care unit|
10120766|NCT04393428||COVID-19 patients with urinary samples|COVID-19 patients with urinary samples
10120767|NCT04393584|Experimental|FOLFIRINOX|Irinotecan 180mg/m2 d1, d1-2 5-FU 2450 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
10120768|NCT04393584|Active Comparator|FLOT|d1 Docetaxel 50mg/m2, d1-2 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m² every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
10120769|NCT04393441|Active Comparator|Systane Ultra Multidose|Participants will administer 1 to 2 drops in each eye 3 times daily
10120770|NCT04393441|Experimental|New Artificial Tear Formulation|Participants will administer 1 to 2 drops in each eye 3 times daily
10120771|NCT04393597|Experimental|Group 1|Subjects take DWJ1458 on a fasted condition, and after wash-out period, take DWJ1458 with a high-fat diet.
10120772|NCT04393597|Experimental|Group 2|Subjects take DWJ1458 with a high-fat diet, and after wash-out period, take DWJ1458 on a fasted condition.
10120773|NCT04393467|Experimental|real tSMS|tSMS will be delivered by a magnet applied to M1, bilaterally (120 min daily, for 6 months). Magnet will be kept in position by a plastic helmet.
10120774|NCT04393467|Sham Comparator|sham tSMS|A non-magnetic steel cylinder, with same size, weight and appearance of the magnet, will be used for sham stimulation.
10120775|NCT04393649||Older patients / community dwellers|"The inclusion criteria are:~Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria~Living and staying at home because of physical and social distancing~Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.)~Agree to participate in the study~The exclusion criteria are:~A concomitant participation to another medical trial~Living in semi-autonomous residence or CHSLD"
10120776|NCT04393220|Experimental|Bevacizumab and anti-PD-1 therapy|
10120777|NCT04393220|Active Comparator|Bevacizumab|
10120778|NCT04393220|Active Comparator|anti-PD-1|
10120779|NCT04393259||Participants|Women attending an antenatal service using the Rainbow Clinic model of care.
10120780|NCT04393571|Experimental|conventional follow up patients|
10120781|NCT04393571|Experimental|Mobile app follow up patients|
10120782|NCT04393246|Active Comparator|Standard of care|Standard of care
10120783|NCT04393246|Experimental|EDP1815|1.6 x 10^11 cells dosage-in-capsule orally twice per day for up to 7 days (with the option to extend up to 14 days), on top of standard of care
10120784|NCT04393246|Experimental|Dapagliflozin and Ambrisentan|Ambrisentan 5mg tablet orally once per day for up to a maximum of 14 days and Dapagliflozin 10mg tablet orally once per day for up to a maximum of 14 days, on top of standard of care
10120785|NCT04393558||COVID-19|Individuals experiencing COVID-19 like symptoms.
10120786|NCT04393558||Healthy Controls|Individuals without any known significant health problems
10120787|NCT04393207|Sham Comparator|Control group|Patient will receive intrathecal morphine and a Sham TAP block.
10120788|NCT04393207|Experimental|Liposomal Bupivacaine|Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
10120789|NCT04393207|Active Comparator|Bupivacaine|Patient will receive intrathecal morphine + TAP block with only bupivacaine.
10120790|NCT04393077|No Intervention|Control|Participants will complete the pre-tests of the introductory features form, SUD, STAI-I, and burnout scales sent via Survey Monkey. The participants (n=40) will be given 15 minutes of free time and asked to be in a position where the individuals were comfortable, in the quietest and most tranquil environment possible. At the end of this period, post-test SUD, STAI-I, and burnout scales will be sent to the participants and they will be asked to fill in the scores.
10120791|NCT04393077|Experimental|Intervention|Firstly, people in the entire group fill out the introductory features form on the online questionnaire form. The time of the meeting will be determined by collaborating with the participants in the experimental group. During the interview, they will be asked to be in a position that was comfortable for the individuals, in the quietest and calm environment possible. At the beginning of the meeting, they will be asked to fill in the pre-test SUD, STAI-I, and burnout scales sent via SurveyMonkey. Then, the EFT session (20 minutes) will be conducted once mutually with the researcher, who is an expert in their field. At the end of the session, they will be filled the post-test SUD, STAI-I and burnout scales
10120792|NCT04392908||Patients|Pediatric patients from 12 to 17 with cancer diagnosis only taken by Meyer Children's Hospital prior consent. Knowledge of fluent Italian language is required
10120793|NCT04392908||Parents|Parents of pediatric patients prior consent. Knowledge of fluent Italian language is required
10120794|NCT04392908||Medical Staff|Medical staff including doctor, psychologist and nurse
10120795|NCT04392869|Experimental|CRAFT group|This arm will instruct the students on an adapted and extended version of the CRAFT program. This is a mindfulness based program which is a systematic combination of practices derived from ancient philosophies, such as yoga and Buddhism, in conjunction with more recent disciplines such as mindfulness, emotional intelligence and positive psychology. The contents are structured along in five consecutive modules aimed at cultivating and enhancing consciousness, relaxation and regulation, attention, bliss and transcendence.
10120796|NCT04392869|Experimental|MBSR group|This arm will instruct the students on an adapted and extended version of the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
10120797|NCT04392869|No Intervention|No intervention group|This group does not receive any instruction. The aim of this arm is to determine if there are any differences in outcomes between the two groups that receive intervention and this one.
10120798|NCT04392934|Experimental|flat shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
10120799|NCT04392934|Experimental|curved shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
10120800|NCT04392934|Experimental|hooked shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
10120801|NCT04392960|Experimental|18F-florbetaben PET-CT scans|
10120802|NCT04393025|Other|Intracranial Stenting|25 Patients presented with recurrent Ischemic CVS with Large ICSD received ICS
10120803|NCT04393025|Active Comparator|Aspirin+Clopidogrel|25 Patients presented with recurrent Ischemic CVS with Large ICSD received optimal medical treatment
10120804|NCT04393038|Experimental|ABX464|ABX464 - Capsules + Standard of Care (SOC)
10120805|NCT04393038|Placebo Comparator|Placebo|Placebo - Capsules + Standard of Care (SOC)
10120806|NCT04393064|Other|full term and preterm|75 preterm and 75 fullterm will be recruited in this study; all will be hemodynamically stable on discharge doing FEES
10120807|NCT04392973|Experimental|Intervention|Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)
9966562|NCT01261234|Active Comparator|Non-Cilostazol group|Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)
9966563|NCT01261260|Placebo Comparator|Uridine|1g BID
9966564|NCT01261273||Stable angina|Patient admitted with stable angina
9966565|NCT01261273||Acute Coronary Syndrome|Patients admitted with Acute Coronary Syndrome
10120808|NCT04392973|No Intervention|Control|Standard of Care Treatment for COVID-19 Infection
10120809|NCT04392986|No Intervention|Baseline|Baseline measurement
10120810|NCT04392986|Experimental|Intervention|Sunlight intervention
10120811|NCT04392843|Other|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
10120812|NCT04392843|Active Comparator|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
10120813|NCT04392947|Active Comparator|combined iTBS/cTBS|"Combined theta burst stimulation (TBS) of the left (intermittent TBS, iTBS) and right (continuous TBS, cTBS) dorsolateral prefrontal cortex (dlPFC; F3 and F4 according to EEG10/20 system). Each stimulation session will comprise 2 trains of 600 stimuli each applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s. In the same session, stimulation with cTBS will be applied continuously for 40 s. Intensity of iTBS/cTBS will be standardized at 80 % of the resting motor threshold (rMT).~Additionally, patients receive an electrical co-stimulation of the forehead. One electrode is fixed to FZ and the 2nd one is either fixed to the left forehead (iTBS) or the right forehead (cTBS), rectangular aligned to the upper edge of the FZ-electrode with a distance of 0.5 cm. Intensity of the co-stimulation is applied with 50% of TBS-intensity."
10120814|NCT04392947|Sham Comparator|sham stimulation|Setup is identical to combined active iTBS/cTBS but TBS is not actively delivered
10120815|NCT04393012|Experimental|Noddle Group|Patients who received noddle to allow access to the nurse call system.
10120816|NCT04393155||COVID-19+|Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
10120817|NCT04393194|Experimental|Vaginal estrogen cream|subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
10120818|NCT04393194|Placebo Comparator|vaginal placebo cream|Subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
10120819|NCT04393168|Experimental|Patients with unilateral arm or leg lymphedema|
10120820|NCT04392895||Patients with locally advanced cervical cancer|Patients with locally advanced cervical cancer, who had undergone a PAL
10120821|NCT04392882|Experimental|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
10120822|NCT04392882|No Intervention|Usual diet group|"Maintaining usual diet~Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~Regular 30-min walk after dinner each day"
10120823|NCT04392830|Experimental|ALZ002 DS|"SAD: 6 cohorts of subjects are planned to be orally dosed, ranging from 15 mg - 800 mg.~MAD: 3 cohorts of subjects are planned to be orally dosed once or twice daily for 7 consecutive days, ranging from 300 mg - 600 mg."
10120824|NCT04392830|Placebo Comparator|Placebo|Placebo
10120825|NCT04393051|Experimental|BAR group|"Patients who will be assigned (after a computerized randomization) to the BAR group will. receive baricitinib as adjunctive therapy.~Baricitinib will be administered at 4 mg daily via oral route for 14 days as add-on therapy or 2 mg daily via oral route (eGFR between 30 and 60 ml/min and for patients with age >75 years old) for 14 days as add-on therapy"
10120826|NCT04393051|No Intervention|Control group|Patients in the control group will continue to receive standard therapy.
10120827|NCT04392817|Experimental|the participating group in the intervention|patient complaining of seppch rerrors due t ovelopharyngeal insufficiency and underwent the intervention
10120828|NCT04392791|Active Comparator|Treated group|The participants received thermal water therapy
10120829|NCT04392791|No Intervention|Control group|The participants haven't received thermal water therapy
10120830|NCT04392778|No Intervention|Untreated|Group 1: patients that are not on a ventilator (n=10) No extra intervention will be done.
10120831|NCT04392778|Sham Comparator|Saline Control|Group 2: patients that are on a ventilator and will receive saline injections (n=10) as control for MSC transplantation group (3).
10120832|NCT04392778|Experimental|Experimental UC-MSCs|Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)
10120833|NCT04392388||SAPRIS-SERO|SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.
10120834|NCT04392596|Experimental|patients|40
10120835|NCT04392661||Laparoscopic Sleeve Gastrectomy (group I)|111 morbid obese females underwent LSG (group I). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
10120836|NCT04392661||Laparoscopic Roux-en-Y Gastric Bypass (group II)|86 morbid obese females underwent LRYGB (group II). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
10120837|NCT04392635|Experimental|Trocar Placement Assist Device (TPAD)|Participants will receive investigational TPAD device during laparoscopic surgery
10120838|NCT04392427|Active Comparator|INTERVENTION|"*Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :"
10120839|NCT04392427|No Intervention|CONTROL|"B) Control group: will not receive nothing~Data collection will include: sociodemographic data, clinical history, results of follow up (daily or according to clinical situation )~Follow-up: to record any side effects of drugs, swab will be taken for PCR"
10120840|NCT04392700|Experimental|group A|drugs：tenofovir disoproxil fumarate, dose：300mg/d
10120841|NCT04392700|Active Comparator|group B|drugs：entecavir dose： 0.5 mg/d
10120842|NCT04392414|Experimental|COVID-19 convalescent hyperimmune plasma|Moderately and severely ill COVID-19 patients treated with convalescent hyperimmune plasma. Patients will be infused with two units of 300 ml
10182944|NCT03769389|Experimental|assessing the GI + GL of 50g of Glucose in 100 ml of water|50g of pure glucose dissolved in 100ml of water
9694606|NCT04787120||Individuals with arterial abdominopelvic bleeding|Arterial abdominopelvic bleeding or imminent risk of bleeding
9966566|NCT01261273||Female|Participant female patients
9966567|NCT01261273||Bifurcation|One or more lesions treated during the baseline in bifurcation
9966568|NCT01261273||Insulin Dependent Diabetes Mellitus|Patients that were insulin-dependent diabetes mellitus at admission
9966569|NCT01261273||Non-Insulin Dependent Diabetes Mellitus|Patients that were non-insulin-dependent diabetes mellitus at admission
9966570|NCT01261273||Small Vessels|vessels smaller or equal to 2.75mm
9966571|NCT01261273||NOBORI Long Lesions|Lesions longer or equal to 20mm
9966572|NCT01261273||Renal Insufficiency|Patients that at admission had renal insufficiency (> 2.0 mg/dL - 176 µmol/mL) at admission
9966573|NCT01261273||Elderly|Patients more or equal 80 years old
9966574|NCT01261273||Restenosis|One or more lesions treated during the baseline in were restenotic lesions
9966575|NCT01261273||Multivessel Treatment|Patients who underwent the treatment of more than 1 vessel during the index procedure
9966576|NCT01261273||Complex Lesions|Patients who underwent a PCI on the Left Main Trunk, on a Chronic Total Occluded lesion or located on a Saphenous Vein Graft
9966577|NCT01261273||Overall|Total Population
9966578|NCT01261299|Experimental|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
9966579|NCT01261364|Active Comparator|Treatment as Usual|
9966580|NCT01261364|Experimental|Pharmacogenetic guided treatment|
9966581|NCT01261377|Active Comparator|Bi-level positive airway pressure (BPAP)|bi-level will be titrated to optimize oxygenation and ventilation.
9966582|NCT01261377|Active Comparator|Nocturnal oxygen|oxygen will be provided as per standard of care.
9966583|NCT01261377|Active Comparator|Continuous positive airway pressure|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
9966584|NCT01261416||Infants with seizures|
9966585|NCT01261429|Experimental|Nilotinib|
9694607|NCT04787315|Active Comparator|Intensive rehabilitation without workstation|
9694608|NCT04787315|Experimental|Intensive rehabilitation with workstations|
9694609|NCT04787367|Experimental|Early-operative TAP block|The TAP block will be administered after the placement of the camera port.
9694610|NCT04787367|Experimental|Late-operative TAP block|The TAP block will be administered at the completion of the case just before removing the camera port.
9694611|NCT04787263|Experimental|CD19-CAR_Lenti|Following lymphodepletion with chemotherapy (fludarabine + cyclophosphamide), patients will be treated with 1.0 to 3.0 x 10^6/kg CD19-Chimeric Antigen Receptor (CAR)_Lenti positive cells as a single dose. The product will be infused fresh, at the end of manufacturing.
9694612|NCT04787406|Active Comparator|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
9694613|NCT04787406|Active Comparator|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
9694614|NCT04787406|Sham Comparator|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
9966586|NCT01261442||Diabetic patients with DSPN|
9966587|NCT01261442||Diabetic patients without DSPN|
9966588|NCT01261455|Active Comparator|Superior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from superior conjunctival tissue.
9966589|NCT01261455|Experimental|Inferior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from inferior conjunctival tissue.
9966590|NCT01261468|Active Comparator|Active SCS|
9966591|NCT01261468|Sham Comparator|Inactive SCS|
9966592|NCT01261481|Experimental|Tolvaptan Intact Tablet Orally|
9966593|NCT01261481|Experimental|Tolvaptan via Nasogastric Tube|
9966594|NCT01261494|Experimental|GFT505 80mg|
9966595|NCT01261494|Placebo Comparator|Matching placebo|
9966596|NCT01261520|Other|Culturally-tailored video|The culturally-tailored video was designed to focus on Chinese women's cultural health beliefs and align with Chinese customs, norms, and values, which includes two segments: 1) a soap-opera and 2) recommendation from a Chinese female physician.
9966597|NCT01261533|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
9966598|NCT01261546|Experimental|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
9966599|NCT01261546|Placebo Comparator|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
9966600|NCT01261572|Experimental|High dose group|ASP3350 high dose
9966601|NCT01261572|Experimental|Low dose group|ASP3350 low dose
9966602|NCT01261598|Other|1|Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy
9966603|NCT01261598|Other|2|Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment
9966604|NCT01261637|Experimental|0.25% Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
9966605|NCT01261637|Placebo Comparator|Placebo|20ml saline
9966606|NCT01261650|Active Comparator|transcranial direct current stimulation|transcranial direct current stimulation of the primary motor cortex
9966607|NCT01261650|Sham Comparator|sham treatment|
10120843|NCT04392414|Placebo Comparator|Non-convalescent fresh frozen plasma (Standard plasma)|Moderately and severely ill COVID-19 patients treated with non-convalescent fresh frozen plasma (standard plasma). Patients will be infused with two units of 300 ml
10120844|NCT04392739|Other|TPOXX|TPOXX 600 mg BID x 7 days
10120845|NCT04392492||Patients undergoing transfemoral TAVI with MANTA closure|Patients undergoing transfemoral transcatheter aortic valve replacement with femoral access site closure using the novel plug-based vascular closure device (MANTA, Teleflex/Essential Medical Inc., Malvern, Pennsylvania, USA).
10182945|NCT03769350|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
10182946|NCT03769350|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
10182947|NCT03769337||Infected|Serum biomarkers in patients with diagnosis of prosthetic joint infection
10182948|NCT03769337||Not Infected|Serum biomarkers in patients with implant failure not caused by infection
10182949|NCT03769324||Normal Eye Group|Normal eye receiving Osmolarity Test
10182950|NCT03769324||DED Group|Dry Eye Disease receiving Osmolarity Test
10182951|NCT03769272||Echocardiographic targeting|
10182952|NCT03769272||Electrogram targeting|
10182953|NCT03769259|Experimental|Brief Cognitive Behavioral Therapy|
10182954|NCT03769259|Active Comparator|Present-Centered Therapy|
10182955|NCT03769246|Experimental|Upright Go Device Group|"Patients receiving the Upright device will have a brief training on the use of the device and proper posture. They will be asked to download the Upright app on their phone from the Playstore.~Patients will wear the device once daily for training. They will attach the device applying an adhesive on their upper back, as instructed, and the device will be attached to the adhesive by velcro. Once completed they should remove adhesive."
10182956|NCT03769246|Active Comparator|Control Group|The control group will receive a 15-20 minute instruction on proper posture by the physician and will receive an ergonomic handout.
10182957|NCT03769233|Experimental|Mindfulness-based Intervention|5 week, manual-based group MBI treatment for depressive and anxious symptoms
10182958|NCT03769168|Experimental|Group 1 - Secukinumab 75 mg|Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
10182959|NCT03769168|Experimental|Group 2 - Secukinumab 150 mg|Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
10182960|NCT03769129|Experimental|Microwave ablation|Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
9966608|NCT01261663||NOS intake either at end of meals or as snackings.|
10182961|NCT03769129|Other|Pembrolizumab|Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
10182962|NCT03769103|Active Comparator|SRS + Osimertinib|Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.
10182963|NCT03769103|Experimental|Osimertinib alone|Osimertinib 80mg PO daily
10182964|NCT03769077|Experimental|Exergaming (Case) Group|"Participants assigned to the exergame condition will play the exergames for 30 minutes, 5 days a week for 3 weeks (15 exergame sessions). Outcomes will be acquired at baseline (before intervention), and at the end of every week during the 3 week intervention phase. Participants will also receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
9966609|NCT01261676||Caesarean section|
10182965|NCT03769077|No Intervention|Comparison Group|"Participants will receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital and will complete questionnaires and assessments at the same time points during study participation.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
10182966|NCT03769064|Experimental|Qualification Phase (Part A)|Placebo/Methylphenidate (60 mg) on days 1 and 3
10182967|NCT03769064|Experimental|Qualification Phase (Part B)|Methylphenidate (60 mg)/Placebo on days 1 and 3
10182968|NCT03769064|Experimental|Treatment Phase Sequence 4213|Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg
10182969|NCT03769064|Experimental|Treatment Phase Sequence 2134|Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg
10182970|NCT03769064|Experimental|Treatment Phase Sequence 1342|Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo
10182971|NCT03769064|Experimental|Treatment Phase Sequence 3421|Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo
9966610|NCT01261676||Vaginal birth (control)|
9966611|NCT01261689|Active Comparator|Epidural analgesia|Women will be allocated to the EA group. In the EA group, women are given an EA as soon as they are in labour.
10182972|NCT03769038|Other|Chronic Total Occlusion and Restenosis|contemporary antegrade or retrograde dissection and re-entry (ADR or RDR) to open CTO
10182973|NCT03769012|Experimental|Treatment|Beta-Glucan
10182974|NCT03769012|Placebo Comparator|Placebo|Placebo
10182975|NCT03768986|Active Comparator|Treatment Group A|Standard referral for HIV testing and online HIV risk reduction training
10182976|NCT03768986|Experimental|Treatment Group B|Standard referral for HIV testing and online HIV risk reduction training plus reinforcement
10182977|NCT03768973||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
10120846|NCT04392570||Fasting group|patients with type 2 diabetes who prefer to fast during Ramadan
10120847|NCT04392570||Non-fasting group|patients with type 2 diabetes who are otherwise healthy and have no contraindications for fasting but prefer not to fast
10120848|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Bortezomib+Dexamethasone|TAK-573 0.1 to 1.5 milligram per kilogram (mg/kg), infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 milligram per square meter (mg/m^2), injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 milligram (mg) (20 mg if aged more than 75 years), tablets, orally on Days 1, 8, and 15 in each 21-days treatment cycle from Cycle 1 through Cycle 8. For participants who continue beyond Cycle 8, TAK-573 will be given as an infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle with dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally from Cycle 9 through Cycle 17.
10120849|NCT04392648|Experimental|Escalation:TAK-573 0.05-0.75mg/kg+Pomalidomide+Dexamethasone|TAK-573 0.05 to 0.75 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
10120850|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Cyclophosphamide+Dexamethasone|TAK-573 0.1 to 1.5 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
10120851|NCT04392648|Experimental|Expansion: TAK-573 + Bortezomib + Dexamethasone|TAK-573, infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 mg/m^2, injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, and 15 in each 21-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and recommended dose for expansion (RAD) determined in the previous Dose Escalation Phase.
9966612|NCT01261689|Other|Care as-usual pain treatment|Women will be allocated to the care-as-usual group. In this care-as-usual(restrictive) group, women receive pain relief only on their explicit request. If necessary epidural analgesia.
10120852|NCT04392648|Experimental|Expansion: TAK-573 + Pomalidomide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
10120853|NCT04392648|Experimental|Expansion: TAK-573 + Cyclophosphamide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
10120854|NCT04392518|Active Comparator|Hospital based rehabilitation group|This group will perform the exercises in the hospital under the supervision of a physiotherapist
10120855|NCT04392518|Active Comparator|Telerehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection
10120856|NCT04392752|Experimental|Participants|The participants are recruited via the University of Jyväskylä and Finnish Fitness Sports Association web page and social media channels. An online pre-study questionnaire are sent to randomly chosen athletes and control group candidates who claim to fulfill the inclusion criteria and volunteer for the study. The participants selected for the study filled an additional questionnaire which is subsequently reviewed by the physician of the study to confirm that they will meet inclusion criteria relating to health.
10120857|NCT04392752|No Intervention|Control|The target is 15 male ja 15 female participants for both the control and intervention groups. To be included, participants need to be with two or more years of resistance training experience, similar to our previous study in females (Hulmi et al. 2017). If more than 15+15 control participants sign up for the study, the final group will be matched to the intervention group based on age, height, weight, and training experience reported on the pre-study questionnaire. The control group maintain their normal nutrition and training during the study.
10120858|NCT04392479|Active Comparator|Aflibercept-FOLFIRI (arm 1)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~Irinotecan (D1) H+1: 180mg/m² IV infusion over 60min (+ 2-minute window),~5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min (+ 2-minute window),~5-fluorouracile (D1 to D3): H+3.5: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~H+49.5: End of treatment administration"
10120859|NCT04392479|Experimental|Aflibercept-mFOLFIRI3 (arm 2)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~Irinotecan (D1 and D3) H+1 and H+49: 75mg/m² IV infusion over 60min (+ 2-minute window) on cycles 1 and 2, then 90mg/m² at cycle 3 and furthers in absence of AEs grade ≥2,~5-fluorouracile (D1 to D3) H+3: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~H+50: End of treatment administration"
10120860|NCT04392557|Active Comparator|metformin/alogliptin|metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months
10120861|NCT04392557|Active Comparator|metformin/pioglitazone|metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months
10120862|NCT04392557|Active Comparator|triple therapy|metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months
10120863|NCT04392466||Transtibial amputees|People who use transtibial prosthesis.
10120864|NCT04392466||Transfemoral amputees|People who use transfemoral prosthesis.
10120865|NCT04392466||Healty individuals|Healty individuals
10120866|NCT04392713|Active Comparator|Ivermectin arm|Participants will be administered Ivermectin with standard chloroquine regimen
10120867|NCT04392713|No Intervention|Control arm|This arm will only receive chloroquine as per existing policy of hospital
10120868|NCT04392375|Active Comparator|Nifedipine 30MG|Oral administration of 30mg Nifedipine XL q24 hours until delivery
10120869|NCT04392375|Placebo Comparator|Placebo|Matching placebo group q24hrs until delivery
10120870|NCT04392674|Experimental|using the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
10120871|NCT04392349|Other|NORMAL|Normal group includes eyes with healthy cornea.
10120872|NCT04392349|Other|IRREGULAR|Irregular goup includes eyes with irregular astigmatism or corneal scarring.
10120873|NCT04392583||Device: ENTACT Septal Staple|Septoplasty
10120874|NCT04392531|Active Comparator|Group A (control)|The control group will consist on the standard treatment that patients will receive according to hospital standard of care protocol.
10120875|NCT04392531|Experimental|Group B (experimental)|The experimental group will consist on cyclosporine added to the standard treatment that patients will receive according to hospital standard of care protocol.
10120876|NCT04392024|Other|Triumf|Subjects who have cataract surgery with Triumf IOL
10120877|NCT04392284|Experimental|Diet Counseling|Delivery of nutrition counseling intervention to improve diet quality.
10120878|NCT04392284|Experimental|Exercise Counseling|Delivery of exercise counseling intervention to increase engagement in physical activity..
10120879|NCT04391985|Active Comparator|Cirrhotic Participants|The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
10120880|NCT04391985|Active Comparator|Non-cirrhotic Participants|The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.
10120881|NCT04392258||Status post resuscitation|Patients or dataset that underwent resuscitation
10120882|NCT04392193|Experimental|Proton Particle Therapy for Cardiac Arrhythmia|Subjects who have an ICD with recurrent VT, VF, or VT storm who have failed one prior standard catheter-based ablation after device implantation, will subsequently undergo particle-based extracorporeal ablation.
10120883|NCT04392076||Radiofrequency Ablation (RFA) of RCC|Patients following image guided radiofrequency ablation (RFA) of renal cell carcinoma (RCC)
10120884|NCT04392076||Microwave Ablation (MWA) of RCC|Patients following image guided microwave ablation (MWA) of renal cell carcinoma (RCC)
10120885|NCT04392076||Cryoablation (CRYO) of RCC|Patients following image guided cryoablation (CRYO) of renal cell carcinoma (RCC)
10120886|NCT04392102|Experimental|ZL-2306(Niraparib)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
10120887|NCT04391907|Active Comparator|IPL group|Subject who have intense pulsed light (IPL) laser 2 twice 1-6 weeks before cataract surgery
10120888|NCT04391907|No Intervention|Non-IPL group|Subject who do not have intense pulsed light (IPL) laser before cataract surgery
10120889|NCT04392063|Other|Cerebral palsy|Not included
10120890|NCT04392128|Experimental|Treatment arm|Patients enrolled in the experimental arm will receive hydroxychloroquine (200mgx3 tablets per day during 10 days) and azithromycine (500 mg at day 1 (2 capsules taken at the same time) then 250mg per day (1 capsule per day) during 4 days).
10120891|NCT04392128|Placebo Comparator|Control arm|Patients enrolled in the control arm will receive a placebo of hydroxychloroquine (3 tablets per day during 10 days) and a placebo of azithromycine (2 capsules taken at the same time at day 1, then 1 capsule per day during 4 days)
10120892|NCT04392089||COVID-19|Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time of intubation
10120893|NCT04391959|Experimental|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to twice weekly.
10120894|NCT04391959|Experimental|AZR-MD-001 Active|AZR-MD-001 Active will be dosed up to twice weekly.
10120895|NCT04392297||Patients with CMV infection|
9966613|NCT01261702|Placebo Comparator|Placebo|Normal saline IV
10120896|NCT04392206|Experimental|Adipose Derived Mesenchymal Stem Cells|Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment.
10120897|NCT04392037|Experimental|Iberdomide plus low-dose cyclophosphamide and dexamethasone|"Iberdomide 1.6mg on days 1-21~Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle~Dexamethasone 40 mg once weekly (20 mg in patients aged > 75 years)"
10120898|NCT04392115|Experimental|Exercise Group|"The home-based exercise program called the PREPARE program.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
10120899|NCT04392115|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
10120900|NCT04391972|Other|SAV multifocal IOL|Subjects who have cataract surgery with SAV multifocal IOL
10120901|NCT04392271|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later.
10120902|NCT04391933|Other|MRI colon cancer|MRI scan of patients with colon cancer
10120903|NCT04391998|Active Comparator|Anemia without parasitic infection|women with anemia without parasitic infection will receive iron treatment
10120904|NCT04391998|Active Comparator|parasitic infection treated with iron|women with anemia with parasitic infection will receive oral iron treatment
10120905|NCT04391998|Active Comparator|parasitic infection treated with iron and antihelmemsic|women with anemia with parasitic infection will receive oral iron treatment and antihelminsic treatment in the form of metronidazole 500mg tab twice daily for 5 days in cases with Entamoeba or Giardia or albendazol 200mg tab
10120906|NCT04391868|Active Comparator|Viagra tablet|Subjects receive a single dose of 50 mg Viagra tablet followed by plasma sampling for 14 hours.
10120907|NCT04391868|Experimental|Sildenafil citrate ODF without water|Subjects receive a single dose of 50 mg sildenafil ODF without water followed by plasma sampling for 14 hours.
10120908|NCT04391868|Experimental|Sildenafil citrate ODF with water|Subjects receive a single dose of 50 mg sildenafil ODF with water followed by plasma sampling for 14 hours.
10120909|NCT04391738||BMI SARS-CoV-2|Patients admitted to Intensive Care Unit with SARS-CoV-2
10120910|NCT04391582|Experimental|Test - Tilapia Skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage.
10120911|NCT04391582|Active Comparator|Control - Silver sulfadiazine|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and band
10120912|NCT04391621|Experimental|Adipose Derived Stem Cell(ADSC) arm|In this arm, the participant selected keloid will receive a single dose intra-lesional Adipose derived Stem cells infiltration. This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6).
10120913|NCT04391621|Active Comparator|Triamcinolone Acetanoide (TAC) arm|"This arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid.~This will be a single dose infiltration of 40mg/cubic centimetres."
10120914|NCT04391829|Experimental|SARS-CoV-2 positive men|Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.
10120915|NCT04391426||Patients who will undergo ERCP (case group)|
10120916|NCT04391426||Living liver transplantation donors (control group)|
10120917|NCT04391725|Experimental|Periapical surgery with guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and the defect is filled with mixture of iPRF and type 1 collagen granules before flap closure.
10120918|NCT04391725|Active Comparator|Periapical surgery without any guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and flap closure done.
10120919|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution|
10120920|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution and 70% ethanol|
10120921|NCT04391517|Experimental|Study Population|Included patients will be evaluated by an anaesthesiologist according to national and international guidelines as it is routine at the pre-operative clinic. In addition, all included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
10120922|NCT04391465|Experimental|Patients Scheduled for Elective Electrophysiological Study|"High right atrial pacing will occur at the following rates for 60 seconds each, with a rest period of at least 60 seconds between pacing runs:~600 msec (100 bpm)~500 msec (120 bpm)~400 msec (150 bpm)~350 msec (171 bpm)"
10120923|NCT04391712|Experimental|Experimental|Participants will receive MLS laser treatment along with regular inpatient medical care.
10120924|NCT04391712|Active Comparator|Control Group|Participants will receive regular inpatient medical care.
10120925|NCT04391634|Other|Mechanical ventilation|Preterm infants on mechanical ventilation
10120926|NCT04391491||Heart failure with preserved ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFpEF (Symptoms of HF (NYHA II-IV); LVEF >50%; Elevated levels of natriuretic peptides (NT-pro BNP > 300 pg/ml in sinus rhythm, >600 pg/ml in AF);Relevant structural heart disease (Left ventricle hypertrophy (LVH) and/or Left atrium enlargement (LAE); left atrial volume index (LAVI) >34 mL/m2 or a left ventricular mass index (LVMI) =115 g/m2 for males and =95 g/m2 for females)
10120927|NCT04391491||Microvascular angina|Patients of both sexes and > 18 years with a confirmed diagnosis of MVA (Angina-like chest pain: signs of exercise-induced ischemia (ST-depression on exercise ECG (>1 mm down-sloping or rectilinear ST-segment depression in >2 leads)); No fixed stenosis (>50%) in epicardial coronary arteries or branches at baseline coronary arteriography)
10120928|NCT04391491||Pulmonary hypertension|Patients of both sexes and > 18 years with a confirmed diagnosis of secondary PH due to left heart disease (Left ventricular systolic dysfunction, left ventricular diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow obstruction and congenital cardiomyopathies) or chronic thromboembolic pulmonary hypertension defined by echo when peak tricuspid regurgitation velocity =2.8 m/s and presence of other echo 'PH signs'
10120929|NCT04391491||Heart failure with redused ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFrEF (Symptomatic HF (NYHA class II-IV), left ventricular ejection fraction ≤ 35% (at any time in the past))
10120930|NCT04391647||HPV vaccinated group|"Women (18-25 years old) whom are previously fully vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
10120931|NCT04391647||HPV unvaccinated group|"Women (18-25 years old) whom are not previously vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
10120932|NCT04391699|Experimental|CPAP + Heated humidification|CPAP + Heated humidification
10120933|NCT04391699|No Intervention|CPAP alone|CPAP
10120934|NCT04391530|Experimental|emotional freedom technique group|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
10120935|NCT04391530|Experimental|Breathin therapy group|Breathing therapy: the basic recipe After applying pre-test forms to students, the hall will be quiet and dim. In this study, breathing exercise application will be performed in three stages as (1) relax, (2) deep breath and (3) feel yourself.
10120936|NCT04391530|No Intervention|Control group|No intervention was made to the students in the control group.
10120937|NCT04391764|Experimental|Naltrexone|Naltrexone at a dose of 50 mg per day.
10120938|NCT04391764|Placebo Comparator|Placebo|Placebo tablets will be identical in size, colour, shape, and taste and will be given in a similar manner.
10120939|NCT04391569|Placebo Comparator|IV Placebo|Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
10120940|NCT04391569|Experimental|IV ganaxolone active|Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
10120941|NCT04391790|Active Comparator|Control|Study subject will cohere to current national guidlines with a cystectomy and standard urinary conduit ad modum Bricker
10120942|NCT04391790|Experimental|Intervention|Subject in the interventional arm, will be treated with a cystectomy and modified retrosigmoid conduit
10120943|NCT04391751|Experimental|Single incision|Carpal tunnel release and basal joint arthroplasty through a single radial approach
10120944|NCT04391751|Active Comparator|Double incision|Double approach: carpal tunnel release through palmar approach and basal joint arthroplasty through radial approach
10120945|NCT04391543|Experimental|Experimental Arm|"4 experimental session (baseline, after treatment, 6 month post treatment and 12 months post treatment) with :~comprehensive interview~cognitive tests~anthropometric measures~postural balance test~critical force test~Astrand-Ryhming test~self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~actimetry~clinical and biological characteristics~determination of inflammatory markers~skeletal muscle index"
10120946|NCT04391504|Experimental|transesophageal echocardiography guidance|
10120947|NCT04391504|Experimental|intracardiac echocardiography guidance|
10120948|NCT04391478|Active Comparator|milrinone|Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
10120949|NCT04391478|Active Comparator|sildenafil|Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.
10120950|NCT04391361|Experimental|trial group|
10120951|NCT04391361|Placebo Comparator|control group|
10120952|NCT04391413|Experimental|OCT group|"OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data:~Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification.~Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel.~After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment."
10120953|NCT04391413|No Intervention|Control group|Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.
10120954|NCT04391387|Active Comparator|16-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour after prone position
10120955|NCT04391387|Experimental|24-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour, 24- hour after prone position
10120956|NCT04391374||Conservative treatment|Subjects with atherosclerotic peripheral artery disease (PAD) who undergo standard of care conservative treatment according to the current PAD guidelines.
10120957|NCT04391374||Peripheral artery bypass grafting|Subjects with atherosclerotic peripheral artery disease who undergo an open bypass grafting with synthetic prosthesis in aorto-iliac or femoro-popliteal position
10120958|NCT04391374||Peripheral artery balloon angioplasty and stenting|Subjects with atherosclerotic peripheral artery disease who undergo endovascular balloon angioplasty and stenting with bare-metal stents in aorto-iliac or femoro-popliteal position
10120959|NCT04391348|Experimental|PET-TDM|PET-TDM with 18F-FDG and PET-TDM with 18F-fluorocholine
10120960|NCT04391231|Experimental|Pentoxifylline Arm|Pentoxifylline (in suspension with SyrSpend SF)
10120961|NCT04391231|Placebo Comparator|Placebo Arm|Placebo (SyrSpend SF only)
10120962|NCT04391140|Experimental|Experimental|Combination of prone position and HFNC
10120963|NCT04391140|No Intervention|Control|Standard care: HFNC set for a SpO2 90-95% if unless indication for intubation is present.
10120964|NCT04391088||hospitalized people living with diabetes|hospitalized people living with diabetes
10120965|NCT04391062|Experimental|intraoperative PDT 400J/cm²|
10120966|NCT04391062|Experimental|intraoperative PDT 600J/cm²|
10120967|NCT04391062|Experimental|intraoperative PDT 800J/cm²|
10120968|NCT04391192|Experimental|Participants|All participants will be given the phone number and encouraged to call any time they plan to use substances alone
10120969|NCT04391257|Other|Main|gekoTM neuromuscular electrostimulation device (NMES) briefly used on patients with cardiac pacemakers to check if pacemakers detect the gekoTM electrical pulses as interference.
10120970|NCT04391153|Active Comparator|conventional samplig|"Patients with biliary strictures udergo ERCP or EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods.~Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology."
10120971|NCT04391153|Active Comparator|Fluorescence in situ Hybridization (FISH)|Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
10120972|NCT04391023|Sham Comparator|Sham tDCS|The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.
10182978|NCT03768973||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
10182979|NCT03768934|No Intervention|Control|No airtime incentive for completing the survey
10182980|NCT03768934|Experimental|1X Incentive|1X airtime incentive
10182981|NCT03768934|Experimental|2X incentive|2X airtime incentive
10120973|NCT04391023|Experimental|2 mA tDCS|The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
10120974|NCT04391023|Experimental|4 mA tDCS|The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
10120975|NCT04391075||Exposed|Pudendal nerve block provided
10120976|NCT04391075||Not exposed|Pudendal nerve block is NOT provided
10120977|NCT04391218|Experimental|Multidisciplinary Approach Group|Multidisciplinary medication review and reconciliation during hospitalization involving geriatricians, nurses, pharmacists and supported by a Clinical Decision Support System, followed by an end-user App to support patients/caregivers in the correct drug intake after discharge.
10120978|NCT04391218|No Intervention|Control Group|Medication review and reconciliation will be performed by geriatricians according to Good Clinical Practice and usual habits, that might also include digital and printed supports for medication appropriateness and drug interaction. Drug therapy will be listed and explained to the patient/caregiver at discharge. Patients/caregivers will be allowed to use any tools to support medication adherence, according to their habits and preferences (i.e. calendars, alarms, pill boxes).
10120979|NCT04391296|Experimental|I (Prepectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
10120980|NCT04391296|Active Comparator|II (Subpectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
10120981|NCT04391127|Experimental|Hospitalized patients with COVID-19 QTc < 500 mseg|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc < 500 ms could be randomized to hydroxychloroquine, ivermectin or placebo.
10120982|NCT04391127|Experimental|Hospitalized patients with COVID-19 infection with QTc >500ms|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc > 500 ms could be randomized to ivermectin or placebo.
10120983|NCT04390789|Experimental|single visit retreatment|nonsurgical root canal retreatment will be carried out in single visit.
10120984|NCT04390789|Active Comparator|multi visit retreatment|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
10120985|NCT04390828|Experimental|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
10120986|NCT04390828|No Intervention|Usual care|usual care
10120987|NCT04390776|Experimental|Treatment Sequence 1|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2), and followed by Capsules (fed, Period 3).
10120988|NCT04390776|Experimental|Treatment Sequence 2|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2), and followed by Capsules (fed, Period 3).
10120989|NCT04390776|Experimental|Treatment Sequence 3|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2).
10120990|NCT04390776|Experimental|Treatment Sequence 4|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2).
10120991|NCT04390841|Experimental|Single Arm ( Qubic Stim Cardiac Stimulator )|There is only one Arm in this trial, the subjects who meet the inclusion and exclusion criteria will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
10120992|NCT04390724||Patient Group 1: Y90 Standard-of-Care|The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care
10120993|NCT04390724||Patient Group 2: Y90 Dose determined by results from Group 1|The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1
10120994|NCT04390711||Healthy subjects|We included 40 age- and gender-matched healthy subjects to serve as the control group, who had normal blood pressure, serum fasting glucose, lipid profile, and renal function.
10120995|NCT04390711||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. All patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
10120996|NCT04390711||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association.T2DM without CAD was diagnosed if no luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
10120997|NCT04391010|Other|Health care providers with beard|
10120998|NCT04391010|Other|Health care providers without beard|
10120999|NCT04390906||All participants|Participants will receive standard of care partial brain radiation therapy at discretion of their radiation oncologist
9966614|NCT01261702|Experimental|Magnesium sulphate|Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
9966615|NCT01261715|Active Comparator|Woman with previous ceasarean section - staples|
9966616|NCT01261741|Experimental|Memantine|
9966617|NCT01261741|Placebo Comparator|Placebo|
9966618|NCT01261754|Active Comparator|Metastatic prostate adenocarcinoma|
9966619|NCT01261754|Active Comparator|Healthy Volunteers|
9966620|NCT01261754|Active Comparator|Newly Diagnosed, High-Risk Prosate Cancer Patients|
9966621|NCT01261767|Experimental|Anti-IL-20|
9966622|NCT01261767|Placebo Comparator|Placebo|
9966623|NCT01261806|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up: 10 session intervention in foster families' homes designed to enhance parental nurturance, synchrony, and provide skills such that parents can help children calm down when overwhelmed.
9966624|NCT01261806|Active Comparator|Developmental Education for Families|10 session intervention in foster families' homes that targets cognitive and motor skills of children
9966625|NCT01261832|Experimental|Dual antiplatelet therapy for 1 year|Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
9966626|NCT01261832|Experimental|Triple antiplatelet therapy for 1 month|Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
9966627|NCT01261832|Experimental|Triple antiplatelet therapy for 6 months|Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol
9966628|NCT01261858|Experimental|Stainless steel and Kryptonite|Sternal closure with stainless steel and kryptonite
9966629|NCT01261858|Active Comparator|Stainless steel|Sternal closure with only stainless steel
9966630|NCT01261871||Robotic laparoscopic prostatectomy|Patients who are undergoing primary surgical treatment for a diagnosis of prostate operatively will be enrolled. IOP will be measured throughout the case to assess for change. The various techniques employed for a radical prostatectomy will be compared. Patients undergoing RRP (open surgery) will act as controls. Those undergoing LRP (minimally invasive surgery) will be compared with the control group to assess for differences in IOP that may result from the different approaches. three arms will be used for the comparison: open, laparoscopic intraperitoneal approach), and laparoscopic (extraperitoneal approach).
9966631|NCT01261884|No Intervention|Routine prenatal care|
9966632|NCT01261884|Experimental|Exercise support|
9966633|NCT01261884|Experimental|Exercise intervention|
9966634|NCT01261897|Active Comparator|Adductor-Canal-Blockade with Ropivacaine|
9966635|NCT01261897|Placebo Comparator|Adductor-Canal-blockade with saline|
9966636|NCT01261910|No Intervention|Usual education (standard care)|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant.
9966637|NCT01261910|Experimental|Intensive initial education|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant. In addition, participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
9966638|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency|metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency
9966639|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency Controls|metabolism of 30 mg alitretinoin single dose in 8 healthy controls.
9966640|NCT01261936||women with a diagnosis of CBD|women in the fertile age, with an ascertained diagnosis of CBD, followed up for heavy periods and needing a specific treatment.
9966641|NCT01261949|Experimental|Combined frontal and temporal rTMS|Combined low frequency frontal and temporal transcranial magnetic stimulation of auditory cortex and right DLPFC
10121000|NCT04390919||high group|high group: monocyte count≥0.445×10*9 cells/L
9966642|NCT01261949|Experimental|Temporal low frequency rTMS|temporal low frequency rTMS of auditory cortex
9966643|NCT01261962|Experimental|Chemotherapy and zinc|Patients in adjuvant chemotherapy supplemented with zinc
9966644|NCT01261962|Placebo Comparator|Chemotherapy placebo|Patients in adjuvant chemotherapy with placebo
9966645|NCT01261962|Other|Control and zinc|Healthy patients supplemented with zinc
9966646|NCT01261962|Other|Control Placebo|Healthy volunteers received placebo
9966647|NCT01262014|Experimental|Experimental single arm|Single arm of pazopanib 800 mg (2x400mg) given as a single agent.
9966648|NCT01262040|Experimental|pts having a thorascopic, laparoscopic or robotic procedure|The procedure will begin with washings (peritoneal) and two assessments of the extent of peritoneal disease. First, a four quadrant inspection of the peritoneal cavity under white light, this is the standard of care assessment. Then, a repeat four quadrant inspection of the peritoneal cavity under NBI will be done, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI. For those patients scheduled for thorascopic procedures: The procedure will begin with sampling of pleural effusions when clinically indicated. Then there will be two assessments of the pleural surfaces. First, an inspection of the pleural cavity under white light, this is the standard of care assessment. Then, a repeat inspection under NBI, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI.
10121001|NCT04390919||low group|low group: monocyte count<0.445×10*9 cells/L;
9966649|NCT01262053|Experimental|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated.
9966650|NCT01262053|Experimental|Active Intervention|The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders.
9966651|NCT01262053|Active Comparator|Control|Parallel control with no intervention
9966652|NCT01262066|Experimental|LifeSkills workshop intervention|Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
9966653|NCT01262066|No Intervention|Enhanced usual care|The Usual Care group received a self-help brochure on BP control developed by the National Heart, Lung, and Blood Institute (NHLBI). In addition, with the participants' permission, their BP readings were sent to their listed physicians, along with the 1-page JNC-7 express summary for the management of high BP.
9966654|NCT01262079||Group 1: 6-15 years old|
9966655|NCT01262079||Group 2: 16-25 years old|
9966656|NCT01262079||Group 3: 26-35 years old|
9966657|NCT01262079||Group 4: 36-45 years old|
9966658|NCT01262079||Group 5: 46-55 years old|
9966659|NCT01262079||Group 6: 56-65 years old|
9966660|NCT01262079||Group 7: 66-75 years old|
9966661|NCT01262079||Group 8: 76-85 years old|
9966662|NCT01262079||Group 9: > 85 years old|
9966663|NCT01262144||Case group|
9966664|NCT01262157|Sham Comparator|placebo|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
9966665|NCT01262157|Active Comparator|Shock wave therapy|12 treatment sessions twice a week during 9 weeks with an interim of 3 weeks no treatment
9966666|NCT01262170|Experimental|CigRx Lozenge|CigRx Lozenge
9966667|NCT01262170|Active Comparator|Tobacco Lozenge|Tobacco Lozenge
9966668|NCT01262183|Experimental|Concurrent chemoradiation therapy with panitumumab|
9966669|NCT01262183|Active Comparator|Concurrent chemoradiation therapy without panitumumab|
9966670|NCT01262196|Experimental|MP4OX|250-mL dose
9966671|NCT01262196|Placebo Comparator|Control|250-mL of normal saline solution
9966672|NCT01262209|Experimental|Low Vision Aids|"All patients will receive:~A low vision examination:~Low vision refraction~Distance best corrected visual acuity~Near best corrected visual acuity~Contrast Sensitivity~Quality of life questionnaire~Low vision therapy: to teach strategies for more effective use of remaining vision and use of low-vision devices~Prescribed low vision devices including binocular telescope (2.1x or 3.5x), monocular telescope, 6x telemicroscopes, microscopes, magnifiers, portable CCTV and absorptive filters."
9966673|NCT01262222||pts undergoing major surg procedure referred to cardiology|Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
9966674|NCT01262248||patients with colorectal polyps|
9966675|NCT01262274|Active Comparator|ANA|
9966676|NCT01262274|Experimental|ANA+UFT|
9966677|NCT01262300|Experimental|VZV vaccine|"Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection~All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels."
9966678|NCT01262313|Sham Comparator|Control Group|"The Control group will have an hour-long meeting of instruction by a registered dietitian on using the provided A Healthier You: Everyday Healthy Eating and Physical Activity for Life book, based on the Dietary Guidelines for Americans 2005."
9966679|NCT01262313|Experimental|lifestyle counseling intervention|"This group will participate in the weekly Healthy Creations classes for 8 weeks presented by a Registered Dietitian and a certified fitness trainer. This is a community based lifestyle intervention program."
9966680|NCT01262326|Experimental|Low Carbohydrate Diet|Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate.
9966681|NCT01262326|Active Comparator|Low Calorie Diet|Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively).
9966682|NCT01262378|Other|Harmonic knife|surgery using the Harmonic knife
9966683|NCT01262378|Active Comparator|HF knife|
9966684|NCT01262391|Experimental|AD-PED 2.5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 2.5 mg of solifenacin succinate.
9966685|NCT01262391|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 5 mg of solifenacin succinate.
9966686|NCT01262391|Experimental|AD-PED 10 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 10 mg of solifenacin succinate.
9966687|NCT01262391|Experimental|CH-PED 2.5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 2.5 mg of solifenacin succinate.
9966688|NCT01262391|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
9966689|NCT01262391|Experimental|CH-PED 10 mg|Male and female children aged 5 to less than 12 years old who receive PED of 10 mg of solifenacin succinate.
9966690|NCT01262404||HealthEd,Minfdulness,Compassion|HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation.
9966691|NCT01262417|Experimental|- Seprafilm group|patients receiving resorbable barrier membrane during the first surgery
9966692|NCT01262417|Other|- No-treatment control group|patients without seprafilm barrier during the first surgery
9966693|NCT01262430|Active Comparator|OtisMed|
9966694|NCT01262430|Active Comparator|Computer Assisted Surgery (CAS)|
10121002|NCT04390984|Experimental|1|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
10121003|NCT04390893|Experimental|ultrasound positioning group|
10121004|NCT04390893|Active Comparator|leak test positioning group|
10121005|NCT04390854|Active Comparator|Induced blood clot scaffold|
10121006|NCT04390854|Experimental|Induced blood clot scaffold combined with Platelet rich fibrin|
10121007|NCT04390932|Experimental|Enhanced TA|Therapeutic exercise protocol accompanied by an enhanced TA.
10121008|NCT04390932|Active Comparator|Neutral therapeutic alliance|Therapeutic exercise protocol accompanied by an limited TA
10121009|NCT04390880|Experimental|PEt/CT arm|Subjects receive a PET/CT scan.
10121010|NCT04390815|Experimental|Intervention|"Before starting the therapeutic procedure, all wounds will be fully washed with normal saline.~Group A patients will receive 10 units (0.1 mL) of regular insulin (manufactured by novo nordisk) in solution with 1 cc of normal saline 0.9% for each 10 cm of wound. The solution will be sprayed on the wound surface with an insulin syringe needle, once daily.~The patients in this arm will receive conventional therapy."
10121011|NCT04390815|Placebo Comparator|Control|Before starting the therapeutic procedure, all wounds will be fully washed with normal saline Group B patients will receive conventional topical application without insulin
10121012|NCT04390997|No Intervention|Periodontally Healthy|20 participants with bleeding on probing less than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
10121013|NCT04390997|No Intervention|Gingivitis|20 participants with bleeding on probing greater than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
10121014|NCT04390997|Other|Periodontitis|20 participants with bleeding on probing greater than or equal to 30%, probing depths greater than or equal to 5mm at least non-adjacent two teeth in each quadrant of the dentition, and clinical attachment loss greater than or equal to 4mm which was measured by six sites per tooth, and radiographic bone loss on the coronal third of root or severe (vertical/ horizontal) bone loss.
10121015|NCT04391101|Experimental|Intervention group|Administration of two units of fresh frozen plasma (between 400 and 500 ml) obtained from convalescent patients from infection by SARS-CoV-2. Convalescent plasma is defined as the plasma of patients who had PCR confirmed SARS-CoV-2 infection, who have recovered clinically, and who have positive antibodies against SARS-CoV-2.
10121016|NCT04391101|No Intervention|Control group|Subjects assigned to the control group will receive support treatment in the intensive care unit based on institutional management guidelines. The use of antiviral, antimalarial or anti-inflammatory drugs is allowed in both groups according to the ICU protocols.
10121017|NCT04390464|Active Comparator|Standard of care|Standard of care
10121018|NCT04390464|Experimental|Ravulizumab + Standard of care|Ravulizumab IV (adjusted to weight, Day 1 only)
10121019|NCT04390464|Experimental|Baricitinib + Standard of care|Baricitinib PO OD (4mg, Days 1-14)
10121020|NCT04390438|Experimental|High-Intensity short time percutaneous electrolysis|Application of a 0,66uA galvanic current in the active TrP through a needle during 10 seconds. During the 20 seconds left necessary to blind the patient and the examiner, the needle was inside but with no electrical current
10121021|NCT04390438|Experimental|Low-Intensity long time percutaneous electrolysis|Application of a 0,22uA galvanic current in the active TrP through a needle during 30 seconds
10121022|NCT04390438|Active Comparator|Dry needling|One acupuncture needle was placed in the active TrP to produce a local twitch response during 30 seconds
10121023|NCT04390542|Experimental|Psychoeducation intervention|Psychoeducatoinal intervention
10121024|NCT04390542|No Intervention|Usual care|Information from healthcare providers
10121025|NCT04390685|Experimental|Tacrolimus ointment|Apply whole arm, in a thin layer, once daily for one year
10121026|NCT04390685|No Intervention|Control|
10182982|NCT03768934|Experimental|Lottery Incentive|Lottery airtime incentive where odds of winning lottery are 1 out of 20
10187610|NCT03724474|Experimental|Be SMART Condition|"Subjects randomly assigned to the Be SMART condition (n=30) will first meet with a credentialed health coach to help create personally relevant weekly, short-term (6-weeks) and long-term (12-weeks) PA and sleep goals, and an initial action and coping plan. At 6- weeks (study mid-point), Be SMART subjects will complete a short telephonic booster session with the health coach. Throughout the 12-week intervention, our agent-based feedback system will communicate weekly messages via short message service (SMS) based on their weekly goal achievement, informed by the continuous collection of their Fitbit data. In addition, subjects in the Be SMART condition will also take their morning blood pressure using a blue-tooth enabled device that wirelessly sends this data to the Be SMART server."
10187611|NCT03724474|Active Comparator|Fitbit Only Condition|Subjects who are randomly assigned to the active control condition (n=30) will receive a Fitbit device and wireless blood pressure monitor (same as Be SMART condition). However, subjects in the Fitbit Only condition will not meet with a health coach for establishing SMART goals and creating an action/coping plan, nor will Fitbit Only subjects receive any feedback messages or prompts from the Be SMART server, although data from their Fitbit devices will be continuously collected throughout the q12 week intervention.
10187612|NCT03724461|Active Comparator|High intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg is established as control.
10187613|NCT03724461|Active Comparator|Light intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes light-moderate intensity resistance training (12 weeks) and the other leg is established as control.
10187614|NCT03724461|Experimental|High vs Light intensity (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg undergoes light-moderate intensity resistance training.
10187615|NCT03724461|Experimental|High intensity (Acute)|Analysis of the effects of one High Intensity resistance training session, with a crossover design.
10187616|NCT03724461|Experimental|Light intensity (Acute)|Analysis of the effects of one Light-moderate Intensity resistance training session, with a crossover design.
9966695|NCT01262443|Experimental|Therapy Cool Flex catheter group|Therapy Cool Flex Catheter . No more available data
9528280|NCT03211949|Experimental|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
9966696|NCT01262469|Experimental|Lapatinib + Capecitabine|lapatinib 1250 mg/day (once daily) Capecitabine 2x850 mg/m2/day, days 1-14 during the first cycle and 2x1000 mg/m2/day, days 1-14, every 21 days for following cycles ( if no unacceptable toxicity is observed).
9966697|NCT01262482|Experimental|Oxaliplatin + Sorafenib|
9966698|NCT01262495|Other|orchidectomy|as specified in the summary
9966699|NCT01262508||Risk Population|Patients being suspected to be at risk of hemodynamic instability due to medical history
9966700|NCT01262521|Experimental|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
9966701|NCT01262521|Placebo Comparator|Water|150 ml Chapelle mineral water
9966702|NCT01262534||1|Clinical profile of patients Comorbidities and associated type of treatments will be collected.
9966703|NCT01262534||2|Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
9966704|NCT01262534||3|Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
9966705|NCT01262586|Experimental|Vildagliptin|
9966706|NCT01262586|Active Comparator|Glimepiride|
9966707|NCT01262612|Active Comparator|immediate treatment with cediranib|8 patients with ascites and 8 patients with pleural effusion will start immediate treatment with cediranib
9966708|NCT01262612|Active Comparator|start cediranib after 28 days BSC|patients in group B will start with cediranib after one month best supportive care.
9966709|NCT01262625|Experimental|Group A: CCTA Diagnostic|Participants randomized to diagnostic evaluation using CCTA to determine therapeutic course of action.
9966710|NCT01262625|Active Comparator|Group B: SPECT MPI/ICA Diagnostic|Standard-of-care diagnostic assessment using SPECT MPI, possibly followed by diagnostic ICA dependent on SPECT MPI results.
9966711|NCT01262664|Experimental|Prohibitin-TP01|Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
9966712|NCT01262690|Experimental|Dose|6 treated, 3 placebos
9966713|NCT01262703|Experimental|REVA Medical ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
9966714|NCT01262729|Experimental|Xenon-Arm|Patients in Xenon-Arm will be inhalated with xenon within 2 hours additionally to therapeutical hypothermia after successful cardiopulmonary resuscitation.
9966715|NCT01262729|Active Comparator|MTH|Patients after successful cardiopulmonary resuscitation will be treated only with therapeutical hypothermia
9966716|NCT01262742|Active Comparator|Carbetocin 80mcg|
9966717|NCT01262742|Active Comparator|Carbetocin 90mcg|
9966718|NCT01262742|Active Comparator|Carbetocin 100mcg|
9966719|NCT01262742|Active Comparator|Carbetocin 110mcg|
9966720|NCT01262742|Active Comparator|Carbetocin 120mcg|
9966721|NCT01262768|Experimental|2D Portion Size Measurment Aids (PSMAs)|The 2D PSMAs are life-size photographs of the 3D PSMAs.
9966722|NCT01262768|Experimental|3D Portion Size Measurement Aids (PSMAs)|The 3D PSMAs include foam rubber replicas of a golf ball, a hockey puck, a tennis ball and a baseball.
9966723|NCT01262794|Experimental|CDP6038 0.3 mg/kg|
9966724|NCT01262794|Experimental|CDP6038 1 mg/kg|
9966725|NCT01262794|Experimental|CDP6038 3 mg/kg|
9966726|NCT01262794|Experimental|CDP6038 6 mg/kg|
9966727|NCT01262794|Placebo Comparator|Placebo|
9966728|NCT01262807|Experimental|Exercise|This group will receive instructions on specific exercises to perform after randomization.
9966729|NCT01262807|No Intervention|Standard Care|This group will receive standard care
9966730|NCT01262833||Cases|Patients with erectile dysfunction by ILEF questionnaire
9966731|NCT01262833||Controls|Patients without erectile dysfunction by ILEF questionnaire
9966732|NCT01262859|Experimental|Study Intervention|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
9966733|NCT01262885|Experimental|Part A Cohort 1|GSK2251052 500 mg (6 subjects), Placebo (1 subject)
9966734|NCT01262885|Experimental|Part A Cohort 2|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
9966735|NCT01262885|Experimental|Part A Cohort 3|GSK2251052 2000 mg (6 subjects), Placebo (1 subject)
9966736|NCT01262885|Experimental|Part A Cohort 2 - fed|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
9966737|NCT01262885|Experimental|Part B Cohort 1|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
9966738|NCT01262885|Experimental|Part B Cohort 2|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
9966739|NCT01262885|Experimental|Part B Cohort 3|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
9966740|NCT01262885|Experimental|Part A Cohort 4|Placebo (1 subject), GSK2251052 (6 subjects) dose to be determined
9966741|NCT01262911|Active Comparator|1.0 g SRT2379|Single dose of 1.0g of SRT2379
9966742|NCT01262911|Placebo Comparator|1.0 g Placebo|Single dose of 1.0g of placebo
9966743|NCT01262924|Experimental|Group A|dTPa vaccine
9966744|NCT01262924|Experimental|Group B|Pa vaccine
9966745|NCT01262924|Active Comparator|Group C|Tedivax-Adult™/ Td-Rix™
9966746|NCT01262937||Biliary Confocal Imaging|
9966747|NCT01262937||Esophageal Confocal Imaging|
9966748|NCT01262963|Experimental|Study Medication|GSK2118436 suspension
9966749|NCT01263041|Experimental|glutamine, PT, sepsis|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
9966750|NCT01263041|No Intervention|Control|after been allocated, will receive nothing and observed for the same outcomes
10121027|NCT04390607||Subjects undergoing revision joint surgery|
10121028|NCT04390516|Other|COViage|Machine learning intervention
10121029|NCT04390490|No Intervention|control|Automatic chemiluminescence analyzer will be used for dectecting the concentration of cardiac troponin I as control group.
10121030|NCT04390490|Experimental|Photoelectrochemical immunosensor|Photoelectrochemical immunosensor will be used for dectecting the concentration of cardiac troponin I as test group.
10121031|NCT04391439||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
10121032|NCT04390503|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Participants randomized to the experimental arm will receive 2 units (approximately 200 to 250 mL per unit, total 400-500mL) of convalescent plasma that was collected from a volunteer who recovered from COVID-19 disease.
10121033|NCT04390503|Active Comparator|Control (albumin 5%)|Participants randomized to the control arm will receive 2 units of 250 mL (500mL total) of albumin (human) 5% infusion. The albumin will be prepared in bags that are identical to the bags used for plasma. The similar appearance of albumin and plasma will facilitate maintaining the blinded status of subjects and most of the study staff.
10121034|NCT04390737|Experimental|HH2853 administered on a BID schedule in continuous 28-day treatment cycles|HH2853 is supplied as tables with dosage strength of 25mg and 200mg. HH2853 is administered orally on a continuous BID schedule in 28-day treatment cycles. Patients in accelerated titration part (ATD) should be administered a single dose on the first day in order to evaluate the PK of a single dose administration. Dosing is twice daily from the second day thereafter.
10121035|NCT04390360|Other|Protective ventilation with HME|Protective ventilation + HME
10121036|NCT04390360|Other|Protective ventilation with Heated humidifier|Protective ventilation + HH
10121037|NCT04390360|Other|Implementation of protective ventilation|Protective ventilation implementation
10121038|NCT04390360|Other|Tidal Volume reduction|Tidal volume reduction
9668963|NCT04486352|Experimental|Atezolizumab and Ipatasertib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with PIK3CA/AKT1/PTEN-altered tumors will be enrolled in this cohort. Twenty patients will be enrolled. Once twenty patients are enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
9694615|NCT04787419|Experimental|probiotics|"2 sachets per day for 4 weeks.~1 sachet of probiotics (1gram) contains: Viable Counts 1 x 107 CFU/g living bacteria in dual pH dependent release coated (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus), Vitamin C 10 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Niacin 2 mg."
10121039|NCT04390412|Experimental|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA fashion
10121040|NCT04390334|Experimental|Treatment A: Daridorexant|Single dose of 50 mg daridorexant
10121041|NCT04390334|Experimental|Treatment B: Famotidine & daridorexant|Single dose of 40 mg famotidine followed 3 h later by a single dose of 50 mg daridorexant
10121042|NCT04390334|Experimental|Treatment C: Efavirenz|600 mg efavirenz once daily in the evening from Day 5 to Day 14
10121043|NCT04390334|Experimental|Treatment D: Daridorexant & efavirenz|Single dose of 50 mg daridorexant in the morning of Day 15 followed by a single dose of 600 mg efavirenz in the evening of Days 15 and 16
10121044|NCT04390425|No Intervention|Control - Standard pneumatic tourniquet pressure|This group receives the standard pneumatic tourniquet pressure during surgery like they would during standard of care.
10121045|NCT04390425|Experimental|Experimental - Limb occlusion pressure|This group receives a slightly lower tourniquet pressure than they would during standard of care. This lowered limb occlusion pressure is determined by the tourniquet device.
10121046|NCT04390594|No Intervention|Standard of Care|The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
10121047|NCT04390594|Experimental|Standard of Care + Nafamostat mesilate|"The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.~Nafamostat mesilate"
10121048|NCT04390568|Experimental|Dose group 1|
10121049|NCT04390568|Experimental|Dose group 2|
10121050|NCT04390568|Experimental|Dose group 3|
9528281|NCT03212027||Patients with low-risk thymomas|low-risk thymomas include types A, AB, and B1 thymomas
9825931|NCT02401048|Experimental|Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
9528282|NCT03212027||Patients with high-risk thymomas|high-risk thymomas include types B2 and B3 thymomas
10121051|NCT04390568|Experimental|Dose group 4|
10121052|NCT04390568|Experimental|Dose group 5|
10121053|NCT04390321|Experimental|Down Syndrome LLMcare|Individuals with Down Syndrome which are able to execute the LLMcare physical and cognitive training intervention
10121054|NCT04390347|Experimental|Intervention|The intervention product (Yakult) (supplied as fermented milk) and placebo will be delivered in sealed pots of 65 mL with date stamped expiry. Yakult contains Lactobacillus casei Shirota (a minimum of 6.5 × 109 live cells of Lactobacillus casei Shirota are contained in each pot).
10121055|NCT04390347|Placebo Comparator|Placebo|The placebo will be indistinguishable (identical in taste and colour but will not contain Lactobacillus casei Shirota) to both participants and trial investigators. It will be stored and provided in exactly the same manner as the intervention product.
10121056|NCT04390295|Experimental|SHR3824+Metformin, Placebo+Metformin|once daily for SHR3824 and placebo, three times daily for metformin, 24 weeks
10121057|NCT04390295|Experimental|SHR3824 5 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
10121058|NCT04390295|Experimental|SHR3824 10 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
10121059|NCT04390269||Infected group|The infected group will be classified according to the severity whether mild ,moderate or severe
10121060|NCT04390269||susceptible (non infected|This group either exposed and not infected .
10121061|NCT04390269||control group|normal control subject
10121062|NCT04390035|No Intervention|Control|Participants in the control arm will follow the standard-of-care treatment exercises for the 6 months following ACL reconstruction surgery.
10121063|NCT04390035|Experimental|Test (BFRT)|Participants in the test arm will follow the identical physical therapy exercises as the control arm but will perform the exercises with BFRT during the first 16 weeks post-surgery. After reaching the 16-week mark, participants will complete the identical standard-of-care rehabilitation between weeks 16-24.
10121064|NCT04390009|Other|Siemens Biograph Vision PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
10121065|NCT04390009|Other|United Imaging uEXPLORER PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
10121066|NCT04389931|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
10121067|NCT04389931|Experimental|Periodontal treatment, Omega 3|Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.
10121068|NCT04389983|Active Comparator|Healthy, under 65 years|Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter (All MCT doses administered as a single dose at time 0)
10121069|NCT04389983|Active Comparator|Healthy, over 65 years|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
10121070|NCT04389983|Active Comparator|Alzheimer's Disease subjects|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
10121071|NCT04390243|Experimental|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
10121072|NCT04389879|Experimental|CAD/CAM|CAD/CAM custom-cut Nickel Titanium (NiTi) FR
10121073|NCT04389879|Active Comparator|Conventional multistranded|Conventional multistranded Stainless Steel (SS) FR
10121074|NCT04390217|Experimental|LB1148|LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
10121075|NCT04390217|Placebo Comparator|Placebo|Placebo contains polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Placebo will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Placebo is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
10121076|NCT04389996||Patients with cancer|Survey
10121077|NCT04389892|Experimental|study participants|After a careful endoscopic ultrasound examination in B mode of the entire pancreas, contrast enhancement was administrated to the participants. The uptake and the wash-out of the agent were followed and then a morphological diagnose was established. EUS-fine needle aspiration of the cyst wall, septa or solid components was guided by the enhancing pattern.
10121078|NCT04390061|Experimental|tofacitinib+HYQ|Tofacitinib 10mg cp twice a day + Hydroxychloroquine 200mg cp three times a day, both for 14 days
10121079|NCT04390061|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200mg cp three times a day for 14 days
10121080|NCT04389944|Experimental|convalescent plasma treatment|"After confirmation of negative SARS-CoV-2 polymerase chain reaction (PCR) in two consecutive nasal swabs or 28 days after resolution of symptoms, donor check is performed and plasma donation occurs by apheresis. The plasma is photochemically pathogen reduced using the INTERCEPT Blood System.~In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up."
10121081|NCT04390204|Experimental|Experimental|Motor control exercises are performed on foam mats. The physiotherapist instructs them, and gives a description on paper, as well as a USB key allowing to view the exercises on video. A supervised home self-rehabilitation program on foam mats is implemented.
10121082|NCT04390204|No Intervention|control|According to the recommendations of learned societies, patients are offered voluntary MPP contraction work, in strength and endurance, in increasing complexity, under manual endocavitary control and under biofeedback. A supervised program of self-rehabilitation at home by voluntary contraction of MPP is set up.
10121083|NCT04390126||Register of haematological malignancies|
10121084|NCT04390126||Idiopathic Pulmonary Fibrosis and PAH Cohort|
10121085|NCT04390126||Giant Cell Arteritis Cohort|
9966751|NCT01263041|Experimental|L-arginine,NEC, PT|enteral or via NG tube dose of 260 mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
9966752|NCT01263067|Experimental|Lifespan Integration Therapy (LI)|
10121086|NCT04390126||AMD and Macular Edema Cohort|
10121087|NCT04390126||Multiple Sclerosis Cohort|
10121088|NCT04390126||Myocardial Infarction Observatory RICO|
10121089|NCT04390126||Heart Failure Cohort|
10121090|NCT04390126||Hemophilia Cohort|
10121091|NCT04390074||COVID-19|Patients with COVID-19 who have received or are receiving Intensive Care in Sweden. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
10121092|NCT04390074||Control|Age- and sex-matched controls are drawn from all residents of Sweden by Statistics Sweden.
10121093|NCT04389905|Experimental|Motivational Interviewing Oral Health Education Group|The intervention group focused on the mothers from before birth until their child reached the age of 3 years. They received repeated questionnaires and repeated oral health education using the Motivational Interviewing (MI) technique.
10121094|NCT04389905|No Intervention|Local Control Group|The local control group included other mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
10121095|NCT04389905|No Intervention|Similar Socio-economics Control Group|This control group is from a Public Dental Clinic with similar socioeconomics (among the families in the catchment area of the clinic) as in the intervention group. This control group included mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
10121096|NCT04389866|Experimental|Both Jawline and Lateral (Zygomatic) Cheek Area Injections|JUVÉDERM VOLUMA™ XC 1-3 syringes (each syringe is 1 cc) will be injected into the lateral cheek (zygomatic) area plus JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation)
10121097|NCT04389866|Experimental|Jawline Injections|JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation)
10121098|NCT04390152|Experimental|Mesenchymal stem cell|WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
10121099|NCT04390152|Active Comparator|Control group|Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo
10121100|NCT04390230||Patient with peniale implantation|All patients who underwent implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France.
10121101|NCT04389970|Experimental|Time Restricted Feeding|Participants will be asked to follow a time-restricted meal pattern (8:16 protocol)
10121102|NCT04390191|Experimental|Continuous Positive Airway Pressure (CPAP)|Patients will be given CPAP at fixed pressure of 8-10 cm water pressure for 72 hours continuously
10121103|NCT04390191|No Intervention|Control|Patients in this arm will be not be given any intervention and will be monitored for 72 hours continuously, and then daily for a total of 14 days.
10121104|NCT04390100|Active Comparator|PRF|PRF membrane is placed in the area where the free gingival graft was taken from the palate
10121105|NCT04390100|Active Comparator|hyaluronic acid|hyaluronic acid gel is placed in the area where the free gingival graft was taken from the palate and the patient is instructed to place the gel 3 times per day
10121106|NCT04390100|Active Comparator|Gel foam|Gel foam is placed in the area where the free gingival graft was taken from the palate
10121107|NCT04389853|Active Comparator|Flexible ureteroscopy (fURS)|Retrograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
10121108|NCT04389853|Active Comparator|Mini-percutaneous nephrolithotomy (mini-PCNL)|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs)4
10121109|NCT04390165||Malaysian COVID-19 Cohort|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
10121110|NCT04390256|Active Comparator|Egg shell powder nanoparticles|
10121111|NCT04390256|Experimental|Clove water extract|
10121112|NCT04390256|Experimental|Carbopol|
10121113|NCT04390256|Experimental|Carboxymethyle cellulose|
10121114|NCT04390087|Experimental|Exercise|Upper-body rowing performed up to 30 min, 3 times per week with moderate-to-vigorous intensity
10121115|NCT04390087|No Intervention|Control|The participants allocated to the control group will be asked to maintain their normal lifestyle throughout the intervention period
10121116|NCT04389840|Experimental|Dociparstat sodium (DSTAT)|Dociparstat 4 mg/kg IV bolus on Day 1, followed by Dociparstat by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])
10121117|NCT04389840|Placebo Comparator|Placebo|Placebo IV bolus on Day 1, followed by Placebo by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])
9528283|NCT03212027||Patients with thymic carcinomas|thymic carcinomas also called types C thymomas
10121118|NCT04389554||Control Group|Healthy pregnant women
10121119|NCT04389554||Study Group|Pregnant women with COVID-19
10121120|NCT04389528|Experimental|tDCS active arm|
10121121|NCT04389528|Placebo Comparator|tDCS placebo|
10121122|NCT04389476||Medical staff in high contact with patients|
10121123|NCT04389476||Other personnel in low contact with patients|
10121124|NCT04389476||Patients|
10121125|NCT04389476||Community residents|
10121126|NCT04389736|Experimental|SIT|Sitting
10121127|NCT04389736|Experimental|STAND|Standing
10121128|NCT04389736|Experimental|NMES|Self-selected maximal intensity of neuromuscular electrical stimulation
10121129|NCT04389710|Experimental|Intervention Group|Participants included in the experimental group will receive 200-600 milliliters of convalescent plasma, administered at a rate of 100-250 mL/hr
10121130|NCT04389606|Experimental|Study Formula (SF)|New infant formula for term infants
10121131|NCT04389606|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
10121132|NCT04389606|No Intervention|Human Milk Reference Group|Human milk
10121133|NCT04389762|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
10121134|NCT04389502|Experimental|CaPtyVa app group|Those assigned to the CaPtyVa app group will receive a tutorial video describing its operation and will have to complete 10-item clinical vignette quiz according to the app recommendations based on local current CRC screening and surveillance guidelines on every question. Physicians in this group will download a free of charge application (CaPtyVa CCR APP, Digital Means, Argentina) on their iOs or Android device.
10121135|NCT04389502|Active Comparator|Control group|The ones assigned to the control group will be asked to complete the 10-item clinical vignette quiz according to their current knowledge on local current CRC screening and surveillance guidelines
10121136|NCT04389619|Experimental|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
10121137|NCT04389619|Active Comparator|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
10121138|NCT04389749|Experimental|CPM|The experimental group will have a CPM applied in the PACU immediately post-op and it will be utilized while the patient is awake in bed for 2 hours on and 2 hours off, when not mobilizing with Physical Therapy (PT). The experimental group will also have traditional PT, including sessions 1 to 3 times a week.
10121139|NCT04389749|No Intervention|No CPM|The control group will have typical care, including working with physical therapy 1 to 3 times a week.
10121140|NCT04389697|Experimental|Intervention arm|Clear fluids and food up to up to 1 hour before the procedure
10121141|NCT04389697|No Intervention|Control arm|Fasting for solids for up to 6 hours and fluids up to 2 hours before the procedure
10121142|NCT04389788|Active Comparator|Rt Eye|The right eye of the patients received carboxy therapy for 6 sessions every 2 weeks. The used device is locally manufactured by a national company for esthetic and dermatological devices. Carbon dioxide gas was subcutaneously injected at the lateral one-third of each eye lid (5 cc gas in each puff according to standardized flowmetry) using insulin syringe. Compression of the injected area will be avoided to prevent rapid leakage of the gas.
10121143|NCT04389788|Active Comparator|Lt Eye|The left eye of the same patients received microneedling with topical glutathione for 6 sessions every 2 weeks. Microneedling was done with Derma pen which is automatic and rechargeable device (vibrating frequency : 6500-10000 r/m , vibration speed level 5 , model :Ultima A6 , company : Dr ,pen and country : Korea). Needle length is adjustable from 0.25 mm to 0,5 mm.Needles number : 36 .Then, Patient was subjected to topical glutathione about 0.25 ml (vial : 600mg/5ml).
10121144|NCT04389567||Patients with COVID-19 taking Famotidine|Use of any dose of oral Famotidine during period of COVID-19
10121145|NCT04389801|Experimental|Desferal|An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours
10121146|NCT04389801|Placebo Comparator|control group|Will receive glucose 5% over 4 hrs infusion
10121147|NCT04389580|Active Comparator|13 cis retinoic acid doses orally plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
10121148|NCT04389580|Active Comparator|13 cis retinoic acid doses Aerosolized plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of tamoxifen therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
10121149|NCT04389580|No Intervention|No Intervention:|No study treatment Arm No Isotretinoin or Tamoxofien treatment
10121150|NCT04389463||Cardiac or thoracic surgery in COVID-19 positive patients|
10121151|NCT04389463||Cardiac/thoracic surgery in COVID-19 negative patients|
10121152|NCT04389723|Other|Placebo→ Qualia Mind|Subjects are first administered the placebo then crossover to the investigational product
10121153|NCT04389723|Other|Qualia Mind→ Placebo|Subjects are first administered the investigational product then crossover to the placebo
10121154|NCT04389437|Experimental|NCD patients (case)|Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.
10121155|NCT04389437|Other|Control patients with memory complaint|Normal neuropsychological evaluation during assessment
10121156|NCT04389437|Other|Control patients without memory complaint|MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint
10121157|NCT04389424||Anastrozole|Breast cancer women with anastrozole treatment
10121158|NCT04389424||Tamoxifen|Breast cancer women with tamoxifen treatment
10121159|NCT04389424||Exemestane|Breast cancer women with exemestane treatment
10121160|NCT04389424||Basal|Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)
10121161|NCT04389424||Recurrence|Breast cancer women luminal type with recurrence of disease during endocrine therapy
10121162|NCT04389346|Active Comparator|Periapical surgery with PRF group|Autologous platelet aggregate (PRF) will be placed over the denuded root surface, following apicoectomy and before flap repositioning.
10121163|NCT04389346|Placebo Comparator|Control group without PRF|Flap will be repositioned following apicoectomy without placement of any autologous platelet aggregate.
10121164|NCT04389359|Experimental|HCQ group (dialysis)|"Dialysis patients will receive Hydroxychloroquine sulfate 200 mg capsules or tablets (oral administration), as 600mg weekly in divided doses, given as 200mg after each dialysis session.~Non-dialysis patients will receive Hydroxychloroquine sulfate, 400mg twice daily for two days, then 400mg weekly.~Maximum treatment duration will be 26 weeks (6 months)."
10121165|NCT04389359|No Intervention|Control|Patients will continue with their usual medicines and clinical care without additional HCQ.
10121166|NCT04389398|Experimental|Pocket compression fixation belt|Pocket compression belt is used to compress the bleeding vessels and reduce bleeding after implantation.
10121167|NCT04389398|Active Comparator|Sand bag compression|Sand bag compression is used to compress the bleeding vessels and reduce bleeding after implantation.
10121168|NCT04389164|Experimental|Tissue engineering method|The thickness of scar tissue in the middle of the dermis is removed by a roller cutter with a thickness of about 0.01 -- 0.02mm. After cleaning, the dermis can be used for punching and mesh drawing in the dermal rolling machine.Autologous epidermal basal cell suspension was prepared according to the description of autologous epidermal basal cell extraction box.The size of the remaining skin should be the same as the wound surface. After washing with normal saline, the wet yarn should be wrapped for later use.The autogenous scar dermal scaffold was prepared and transplanted onto the wound surface. The autoepidermal basal cells prepared were sprayed or coated between the mesh and the dermal scaffold. Autologous skin slices were transplanted onto the wound surface and fixed with pressure bandaging.
10121169|NCT04389164|Active Comparator|Conventional therapy|Autologous skin was grafted onto the wound surface and fixed with pressure bandage
10121170|NCT04389112|Experimental|Patients with actinic keratoses|
10121171|NCT04389112|Experimental|patients with squamous cell carcinoma in situ|
10121172|NCT04389112|Experimental|patients with squamous cell carcinomas|
10121173|NCT04389112|Experimental|patient with invasive metastates|
10121174|NCT04389268||HCV patients|Patients with uncomplicated newly diagnosed hepatitis C virus
10121175|NCT04389268||Control group|Age and sex matched with patients
10121176|NCT04389411|Experimental|Montelukast|10mg Oral Montelukast once daily for 60 days
10121177|NCT04389411|Placebo Comparator|Placebo|Placebo.
10121178|NCT04389320||Rheumatoid patients receiving hydroxychloroquine|immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics
10121179|NCT04389372|Experimental|Mindfulness by Smartphone|mindfulness therapy by smart phone
10121180|NCT04389190|Active Comparator|Standard Protocol|This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.
10121181|NCT04389190|Experimental|Low frame rate protocol|This will have fluoroscopy and cine image acquisition at 7.5 FPS at 8-inch mode with all other settings on factory default. Virtual collimation and LIH will be used as needed. This protocol will be implemented for 6 weeks as well.
10121182|NCT04389190|Experimental|Customized Protocol|This will have varying settings based on three weight based groups. Small (<60 kg), medium (60-85 kg), large (>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.
10121183|NCT04389138|No Intervention|Comparison|In this arm participants will attend 3 study visits to complete study questionnaire and assessments. In between these visits, participants will be asked to wear an activity monitor and record an activity diary for one week. Other than this, participants will continue to receive only standard of care treatment.
10121184|NCT04389138|Experimental|Intervention arm|In this arm participants will attend the same 3 study visits to complete study questionnaires and assessments. Participants will be asked to wear an acitvity monitor and record an activity diary for one week after the study visits. In between baseline and 6 month follow up, intervention arm participants will receive study physiotherapy. This will consist of an individual assessment and 4 additional sessions of physiotherapy.
10121185|NCT04388969||Gaucher disease patients|Patients with type 1,2,3 Gaucher disease.
10121186|NCT04388969||GBA carriers with Parkinson disease|Patients with Parkinson disease GBA related (carriers)
10121187|NCT04389151|Other|The experimental group|
10121188|NCT04389099||Healthy placenta (control)|Pregnant women without preeclampsia and/or fetal growth restriction
10121189|NCT04389099||Pathological placenta|Pregnant women with preeclampsia and/or fetal growth restriction divided into two subgroups : preeclampsia without fetal growth restriction ; fetal growth restriction without preeclampsia.
10121190|NCT04389060|Active Comparator|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing
10121191|NCT04389060|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 2 hours prior to testing
10121192|NCT04389086|Experimental|Induction chemotherapy + chemoradiotherapy + surgery|Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
10121193|NCT04389086|Active Comparator|Neoadjuvant chemotherapy + surgery|Neoadjuvant chemoradiotherapy followed by surgery
10121194|NCT04388930||Kidney transplant live-donor|Participants that will be a planned live renal transplant donor
10121195|NCT04388930||Kidney transplant recipient|Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant
10121196|NCT04389229|Experimental|UTIL-01|Single dose autologous unmodified tumour infiltrating lymphocytes
10121197|NCT04389229|Experimental|CoTIL-01|Single dose autologous gene modified tumour infiltrating lymphocytes
10121198|NCT04389125|Experimental|Improvement of Blood Flow group|One packet once a day, after breakfast (1.5 g/day, 1.5 g/day as an Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures)
10121199|NCT04389125|Placebo Comparator|Placebo group|One packet once a day, after breakfast (1.5 g/day)
10121200|NCT04389385|Experimental|COVID-19 STCs -Exo therapy|"In addition to the best available treatment, participants will receive inhaler COVID-19 STCs -Exo therapy *.~Biological: Inhaler CSTH-Exo treatment will be applied daily x 5 times (2.0 x 108 nano vesicle / 3 ml; on day 1 to day 5).~* If the improvement contribution is observed in the parameters, this application period could be extended"
10121201|NCT04389216|Experimental|Radiofrequency|Radiofrequency Ablation of breast cancer tumour by Cool-tip electrode.
10121202|NCT04389021|Experimental|VR|The intervention group will receive VR support upon the standard of care during the procedure.
10121203|NCT04389021|No Intervention|Control|The control group will have standard care without the VR support.
10121204|NCT04389255||Healthy people|65 people will be included.
10121205|NCT04389034||Adults|Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy
10121206|NCT04388995|Experimental|observed patients|
10121207|NCT04389008||Postoperative death|
10121208|NCT04389008||Postoperative non-death|
10121209|NCT04388943||1|
10121210|NCT04388774|Experimental|Ketamine|Total dose administration or 0.5 mg/kg of ketamine
10121211|NCT04388917||Clip Group|Use of Hemo-lock hemostatic clips during tumor resection to prevent bleeding
10121212|NCT04388917||No Clip group|No Hemo-lock hemostatic clips used during tumor resection
10121213|NCT04389307|Other|Group 1: Bladder Training - Control group|Specific goals are to correct faulty habit patterns of frequent urination, improve control over bladder urgency, prolong voiding intervals, increase bladder capacity, reduce incontinence episodes and restore patient confidence in controlling bladder function
10121214|NCT04389307|Active Comparator|Group 2: Bladder Training+Intra Vaginal Electrical Stimulation|IVES was performed in lithotomy position via Enraf Nonius Myomed 632 device with a vaginal probe. IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24-session treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback
10121215|NCT04388735||Newly Diagnosed MM 1st Line and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~Both patients with or without identified caregivers will complete a one time series of questionnaires.~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete."
10121216|NCT04388735||MM receiving 1-3 prior lines of therapy and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~Both patients with or without identified caregivers will complete a one time series of questionnaires.~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
10121217|NCT04388735||MM patients receiving ≥ 4 lines of therapy and Cargivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~Both patients with or without identified caregivers will complete a one time series of questionnaires.~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
10121218|NCT04388982|Experimental|MSCs-Exos Dosage 1|MSCs-Exos. low-dose group
10121219|NCT04388982|Experimental|MSCs-Exos Dosage 2|MSCs-Exos mid-dose group
10121220|NCT04388982|Experimental|MSCs-Exos Dosage 3|MSCs-Exos high-dose group
10182983|NCT03768921|Experimental|PEEP Titriation|patients with respiratory distress syndrome will undergo alveolar recruitment in the mechanical ventilator and will have their final positive mechanical ventilator pressure determined by ventilator evaluation by the electrical impedance tomograph. The increase of the peep in the mechanical ventilator to perform the alveolar recruitment will be of 2 in 2 cmH2O every 2 minutes until the pressure reaches 25 cmH20, after the pressure was reduced in the same way being evaluated in the tomograph what will be the point with greater alveolar recruitment, having greater ventilation, without alveolar hyperdistension or alveolar collapse.
10182984|NCT03768908|Active Comparator|Treatment with artesunate + amodiaquine|Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.
10182985|NCT03768908|Active Comparator|Treatment with artemether-lumefantrine (Coartem®)|Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose.
9825932|NCT02401230|Active Comparator|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
9825933|NCT02401230|Active Comparator|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
9966753|NCT01263067|Active Comparator|Waitlist Control- Lifespan Integration|
9966754|NCT01263080|Active Comparator|mirtazapine+folic acid|mirtazapine 30mg QD, folic acid 0.4mg QD
9966755|NCT01263080|Active Comparator|mirtazapine+folic acid placebo|mirtazapine 30mg QD, folic acid placebo 1 tablet QD
9966756|NCT01263080|Active Comparator|mirtazapine placebo+folic acid|mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD
9966757|NCT01263080|Placebo Comparator|mirtazapine placebo+folic acid placebo|mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD
9976528|NCT01352390|Active Comparator|Control Condition|A basic reminder mailing will prompt each subject to receive a health test as specified on the mailing
9976529|NCT01352390|Experimental|Artwork Prompt Condition|A basic reminder mailing will prompt each subject to give their child a reminder postcard to color
9976530|NCT01352403|Other|intensive life style intrvention|intensive life style intervention over 18 months including movement, psychological meetings and change in food intake
9976531|NCT01352403|Other|gastric bypass|
9976532|NCT01352429||Phase 1 Feasibility|
9976533|NCT01352429||Phase 2 Registration|
9976534|NCT01352455|Experimental|5 days per week hemodialysis|5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session
9976535|NCT01352481|Experimental|Intervention group|
9976536|NCT01352481|No Intervention|Control group|
9976537|NCT01352494|Experimental|docetaxel/gemcitabine|All the patients are locally advanced breast cancer. Patients with a measurable lesion at chest CT. (at least 1 measurable lesion)
9976538|NCT01352559|Experimental|responders|50 ≤ Decrease rate(%) of HAM-D score
9976539|NCT01352559|Active Comparator|non-responders|nonresponders is a patients having 50 > Decrease rate(%) of HAM-D score
9976540|NCT01352572|Experimental|antidepressant response|antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
9976541|NCT01352572|Active Comparator|antidepressant non-response|antidepressant non-response are refered the patients having a 50 > Decrease rate(%) of HAM-D score
9976542|NCT01352611|Experimental|baclofen, intrathecal|A single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
9976543|NCT01352624|Experimental|Experimental|$teps for Achieving Financial Empowerment ($AFE)
9976544|NCT01352624|No Intervention|Usual Care|Veterans in control arm will receive usual care at VA
9976545|NCT01352650|Active Comparator|Cohort 1A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5
9976546|NCT01352650|Active Comparator|Cohort 1B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
9976547|NCT01352650|Active Comparator|Cohort 2A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5
10121221|NCT04388631||Exposed group|Male patient discharged with COVID-19
10121222|NCT04388631||Control group|Healthy male volunteers without COVID-19
10121223|NCT04388618||covid19 positive patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested positive
10121224|NCT04388618||covid19 negative patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested negative
9976548|NCT01352650|Active Comparator|Cohort 2B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 2 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 4 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
9976549|NCT01352650|Active Comparator|Cohort 3A|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5
9976550|NCT01352650|Active Comparator|Cohort 3B|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10
9976551|NCT01352663|Experimental|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
9976552|NCT01352663|Active Comparator|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
9976553|NCT01352689|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
9976554|NCT01352689|Experimental|Free combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
9976555|NCT01352702|Experimental|Arm 1|Dabigatran Therapy
9976556|NCT01352702|Active Comparator|Arm 2|Phenprocoumon Therapy
9976557|NCT01352728|Experimental|TACE+Axitinib|
9976558|NCT01352767|Experimental|InsuPad Device|Use of the InsuPad which heats the injection site.
9976559|NCT01352767|No Intervention|CONTROL|no treatment
9976560|NCT01352780|No Intervention|usual care|Motivational interviewing
9976561|NCT01352806|Experimental|fluoroscopy, palpation, ultrasound|in the same subject we will compare the accuracy of identifying the intralaminar space by three technique, fluoroscopy, ultrasound, palpation.
10121225|NCT04388488|Experimental|CONNECT TF|Trans-femoral amputees currently using a conventional handmade socket will be fitted with the CONNECT TF adaptable socket system for 6 weeks and their current existing conventional socket for 6 weeks, data collection on both sockets will be performed and outcomes compared.
10121226|NCT04388592|Experimental|Nurse practitioner (NP)-led care arm|The patient randomized to the NP intervention arm will be contacted by the NP to be scheduled for an NP appointment within 4 to 6 weeks from the date of the referral. The NP consultation will include patient history, physical examination, symptomatic management strategies as appropriate (eg: bladder and bowel management strategies, fatigue management, depression, anxiety, spasticity etc), discussion of mental and physical health resources for symptomatic treatment, support, physical and mental health resources to optimize functioning (eg: home care, physical/occupational therapy referral) and quality of life. There will be NP followup, in person or by phone or videoconferencing at 3 months, and 6 months. The NP will be using the electronic medical record offered by Alberta Health Services.
9825934|NCT02401230|Active Comparator|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
9966758|NCT01263145|Experimental|Treatment (Akt inhibitor MK2206 and paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 PO QD on days 2, 9, and 16. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10121227|NCT04388592|No Intervention|Usual Care Arm|Those patients randomized to the usual care arm (community neurologist and registered nurses) will be contacted by the NP to be scheduled for an NP appointment in 6 months, so that every participant is given the opportunity to meet with the NP, after their involvement in the study has concluded. During the six-month period, patients randomized to the control group will receive usual care from community neurologists and MS registered nurses or family physicians. The care will be delivered according to standard practices, and follow-up visits will be conducted according to the various neurologists' or family physicians' practices.
10121228|NCT04388423|Experimental|Group S|
10121229|NCT04388423|Experimental|Group C|
10121230|NCT04388397|Experimental|Immediate-access Arteriovenous Grafts|Immediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients
10121231|NCT04388397|Active Comparator|Standard Arteriovenous Grafts|Standard Arteriovenous Grafts as a vascular access for hemodialysis patients
10121232|NCT04388709|Experimental|Peginterferon lambda-1a|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
10121233|NCT04388709|No Intervention|Best supportive care|Best supportive care
10121234|NCT04388410|Experimental|convalescent plasma|Convalescent plasma obtained from volunteers who have recovered from COVID 19. Enclosed with a similar material as the control
10121235|NCT04388410|Placebo Comparator|Normal saline|Normal saline solution in 200 ml plasma bags enclosed with with a similar material as the plasma
10121236|NCT04388371|Experimental|Prior to subject taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
10121237|NCT04388371|Experimental|subjects taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
10121238|NCT04388176|Experimental|C21 followed by placebo|
10121239|NCT04388176|Experimental|Placebo followed by C21|
10121240|NCT04388306||Study Group|Thirty-two participants with undergone arthroscopic Rotator Cuff repair
10121241|NCT04388306||Control Group|Thirty-two healthy participants
10121242|NCT04388137||infants aged 0-3|No intervention.
10121243|NCT04388137||children aged 4-18|No intervention.
10121244|NCT04388904|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
10121245|NCT04388267||Septic shock|Patients with septic shock, according to the Sepsis 3 definition, regardless of the origin
10121246|NCT04388267||Major vascular surgery|Patients who underwent elective or emergent major vascular surgery abdominal aortic surgery (open or endovascular surgery)
10121247|NCT04388514|Experimental|Blood ozonization|Blood ozonization plus BAT
10121248|NCT04388514|No Intervention|Standard of Care|"BAT only~To note that the BAT are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days."
10121249|NCT04388280|Other|Imaging|Echocardiography combined with coronary flow reserve (CFR) and strain imaging, or computed tomography (CT) angiography with direct visualization of coronary arteries.
10121250|NCT04388280|No Intervention|Observation|No imaging for the estimation of coronary artery disease
10121251|NCT04388202|Experimental|Sertraline|Sertraline 100-200 mg daily for 8 weeks
10121252|NCT04388202|Active Comparator|Escitalopram|Escitalopram 10-20 mg daily for 8 weeks
10121253|NCT04388215|Experimental|Treatment group|"Drug: CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg~- CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
10121254|NCT04388215|Active Comparator|Comparator group 1|"Drug: CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D013(placebo) 80mg~- CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D337(placebo) 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
10121255|NCT04388215|Active Comparator|Comparator group 2|"Drug: CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg~- CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg, orally, 1 tablet once a day for 8 weeks"
10121256|NCT04388124|Placebo Comparator|Placebo|Patient will receive placebo for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
10121257|NCT04388124|Experimental|Bosentan|Patient will receive Bosentan for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
10121258|NCT04388527|Experimental|Treatment|Penn COVID-19 convalescent plasma
10121259|NCT04388696|Experimental|Sisterhood 2.0|"Sisterhood 2.0 used a group format with activities that explore respect, nonviolence, healthy relationships, and sexuality, through 8 sessions (3 hours/session) over an 8 week period.~Sessions focus on gender, consider harmful messages around femininity and their image, healthy sexuality, healthy relationships and connections, understanding sexual abuse and assault, and self care."
10121260|NCT04388696|Active Comparator|Job Skills Training|The curriculum used for this program is an intensive 18-24 hour job readiness training curriculum distributed across 3 weeks, or up to 2 months.
10121261|NCT04388462||locked plating with predicted distribution of loc|
10121262|NCT04388462||unlocked plating with predicted distribution of loc|
10121263|NCT04388462||Interlocking nail +/- blocking screws|
10121264|NCT04388189|Experimental|Duloxetine|Duloxetine 60 mg daily for 8 weeks
10121265|NCT04388189|Active Comparator|Bupropion|Bupropion 150-450 mg daily for 8 weeks
10121266|NCT04388111|No Intervention|Control Group|Patient receives an intraosseous injection of antibiotics into the tibia as per the standard of care for primary total knee arthroplasty under the study providers.
10121267|NCT04388111|Experimental|Intarosseous Morphine|Patient receives an intraosseous injection of antibiotics + 10mg of morphine into the tibia during their total knee arthroplasty.
10121268|NCT04388722|No Intervention|Control Arm|
10121269|NCT04388722|Experimental|Investigational Arm|
10121270|NCT04388657||Covid Intensive arm|Patients included in intensive care admission by one of the principal investigators from the 3 selectioned centers.
10121271|NCT04388358|Other|mixed Chinese herb formula|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
10121272|NCT04388098||Asthmatic children|Asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
10121273|NCT04388098||Non-asthmatic children|Non-asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
10121274|NCT04388254|Experimental|Simufilam 100 mg oral tablets throughout|Simufilam 100 mg oral tablets administered twice daily (BID) for the full 24 months (including the randomized period Month 12 to Month 18)
10121275|NCT04388254|Placebo Comparator|Simufilam 100 mg oral tablets / Placebo / Simufilam 100 mg oral tablets|This placebo arm is only for Month 12 to Month 18. Day 1 to Month 12, as well as Month 18 to Month 24 are open-label treatment periods of simufilam 100 mg b.i.d. for all subjects.
10121276|NCT04388059||Transection at 2 cm from the pylorus|the effect of transection at 2 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
10121277|NCT04388059||Transection at 5 cm from the pylorus|the effect of transection at 5 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
10121278|NCT04388046|Experimental|skeletal class 2 malocclusion|10 patients treated with type IV Herbst appliance. The appliance was connected directly to the mandible by a bilateral reconstruction bone plates to provide a skeletal anchorage and avoid any mandibular teeth involvement
10121279|NCT04387838||Anti-SARS-CoV2 serological status|"At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.~For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60.~For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped."
10121280|NCT04387864|Experimental|Whole-body Vibration Exercise Group|"The patients in the WBV exercise group underwent WBV exercise sessions 2 days a week (72 hours in between) for a total of 6 weeks. Each exercise session was performed under the supervision of a physician.~The patients received support from both hands on the WBV platform and both knees were positioned statically at 40-60 degree flexion (high squat position). All patients stood on the platform with sports socks (without shoes) to avoid the shoes absorbing vibration. Vibration was given by a Power Plate® device where a three-plane oscillation occurs (most vertical, Z axis). In all vibrations, 30 Hz frequency and 2 mm amplitude (low amplitude) were used. The vibration time was set to be 30 seconds in the first two weeks, 45 seconds in the next two weeks and 60 seconds in the last two weeks. The repetition of vibration was increased by 1 repetition every week, starting with 5, and 10 repetitions were given in the last week. A 1-minute rest period was given between each repetition."
10121281|NCT04387864|No Intervention|Home Exercise Group|The home program, which included isometric and isotonic exercises, was followed at home for 6 weeks. Three sets of quadriceps setting as 5 repetitions, 5-second contractions, and three sets of isotonic quadriceps exercise in seating position with weights as 12 repetitions were administered to be performed two days a week. While the patients included in the study group came for TVT exercise two days a week, the patients in the control group performed quadriceps setting exercises also on those days. The patients were invited to the physician follow-up on Wednesday every week for motivation and follow-up. The patients were asked to write their complaints during and after the exercise, if any. In addition, they were asked to note the number of repetitions and sets of their exercises on exercise booklets prepared for the patient.
10121282|NCT04387799||Negative PCR Covid associated Pneumonia|Patients with pneumonia who test negative to RT-PCR
10121283|NCT04387799||Positive PCR Covid associated Pneumonia|Patients with pneumonia from Covid 19
10121284|NCT04387812|Experimental|Xtrodes home PSG system|Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .
10187617|NCT03724448|Experimental|ALEOZEN group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
10121285|NCT04387825|Experimental|Experimental group|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
10121286|NCT04387825|No Intervention|Control|Evolution and medical therapy effects were observed in the control group.
10121287|NCT04387929||IgG negative|No intervantion. Only antibody mesurment from blood sample
10121288|NCT04387929||IgG positive, viral load negative|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
10121289|NCT04387929||IgG positive, viral load positive|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
10121290|NCT04387903||Reoperation group|The group of patients who underwent pancreaticduodenectomy for management of periampullary tumors and required surgical reintervention afterwards for management of procedure-related complications as pancreatic fistula, bleeding, abdominal collection, biliary fistula, gastric fistula.
10121291|NCT04387903||No reoperation group|The group of patients who underwent pancreaticoduodenectomy for management of periampullary tumors and did not require surgical reintervention.
10121292|NCT04387916|Experimental|KC1036|Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
10121293|NCT04387968||agents in contact with the public|patients working with children, policemen, desk office
10121294|NCT04387968||agents with no contact with the public|administrative workers
10121295|NCT04387981|Experimental|[14C]-orvepitant|[14C]-orvepitant administered as 30mg single dose in oral solution
10121296|NCT04387890||Serologic Screening|Participants will be screened for IgM and IgG SARS-CoV-2 antibodies at baseline and every 2 weeks. Participants showing symptoms compatible with COVID-19 will undergo nasopharyngeal swab for PCR testing for diagnosis. Participants recovered from COVID-19 will have to have 2 negative and consecutive nasopharyngeal swab PCR tests in order to return to work.
9966759|NCT01263158|Experimental|Expectant group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Expectancy of standard oxytocin treatment for 3 hours.
9966760|NCT01263158|No Intervention|Early oxytocin group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Oxytocin treatment started within 20 minutes.
10121297|NCT04387695|Experimental|SBRT + TACE + Sorafenib|SBRT sequential TACE combined with Sorafenib
10121298|NCT04387695|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
10121299|NCT04387721||Trifocal IOL(Finevision IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted First group: FineVision
10121300|NCT04387721||Trifocal toric IOL (Finevision Toric IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted: Second group: FineVisionToric
10121301|NCT04387734|Experimental|Ocrevus|
10121302|NCT04387734|Active Comparator|Platform therapies|Platform therapies consist of the following injectable disease modification treatments: IFNb-1a, IFNb-1b, and glatiramer acetate.
10121303|NCT04387682|Other|OSCC subjects with β-glucan supplement|Oral squamous cell carcinoma subjects with pre-surgical administration of whole glucan particle β-glucan
9966761|NCT01263171|Other|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy prior to short course pre-operative radiotherapy followed by adjuvant chemotherapy.
9966762|NCT01263184||sportive wheelchair users|
9966763|NCT01263184||sportive non disabled|
9966764|NCT01263184||non sportive wheelchair users|
9966765|NCT01263210|Active Comparator|Pneumococcal vaccine|Half of the children were randomized to receive heptavalent pneumococcal conjugate vaccine (before this vaccine was included in the national immunization programme).
9966766|NCT01263210|No Intervention|Control|Half of the children were randomized to no vaccination and functioned as controls.
9966767|NCT01263236|Experimental|LY2940094 - single dose|Single oral dose of 2-800 milligram (mg) LY2940094
10121304|NCT04387682|No Intervention|Healthy donors|healthy donors without pre-surgical administration of whole glucan particle β-glucan
10121305|NCT04387682|No Intervention|OSCC subjects without β-glucan supplement|Oral squamous cell carcinoma subjects without pre-surgical administration of whole glucan particle β-glucan
10121306|NCT04387877|Experimental|Graston Group|Graston technique will be applied on the lateral and posterior myofascial chain area tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
10121307|NCT04387877|Sham Comparator|Sham Group|"Sham graston technique will be applied on lateral and posterior myofascial chain area (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied to the patient by partially touching the muscle or fascia region via ultrasound gel with the flat part of the Graston tool so as not to provide the activity of the fascia)"
10121308|NCT04388033|Experimental|Safety Evaluation Group|"Basic treatment phase:~The patients have surgery followed by concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days).~Immunotherapy phase:~Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle. Fusion cells will be suspended in 0.5 mL normal saline and then injected intradermally close to a cervical lymph node. IL-12 will be injected subcutaneously at the same side at dose of 6ug twice for interval of one hour."
10121309|NCT04387409|Active Comparator|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
10121310|NCT04387409|Placebo Comparator|Placebo|Physiological saline 0.1ml
10121311|NCT04387617|Experimental|CBD Oil Group|
10121312|NCT04387617|Placebo Comparator|Control Group|
10121313|NCT04387604||non vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
10121314|NCT04387604||vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
10121315|NCT04387487|Experimental|Video Group|"Video Group~multimedia video information of 4.5 mins regarding procedure, indication and complications related to spinal anesthesia will be shown to patients in intervention group , patient will be allowed to ask questions."
10121316|NCT04387487|No Intervention|non video group|patients in control group will be given verbal information regarding procedure, indication and complication, patient will be allowed to ask questions.
10121317|NCT04387305|Experimental|Tranexamic acid 15 mg/kg bolus|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 30 minutes followed by a 2 mg/kg/h infusion over 8 hours. This represents 31 mg/kg total dose of TXA.
10121318|NCT04387305|Experimental|Tranexamic acid 30 mg/kg bolus|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 30 minutes followed by a 4 mg/kg/h infusion over 8 hours. This represents 62 mg/kg total dose of TXA.
10121319|NCT04387305|Experimental|Tranexamic acid 45 mg/kg bolus|Subjects will receive a 45 mg/kg bolus of tranexamic acid over 30 minutes followed by a 6 mg/kg/h infusion over 8 hours. This represents 91 mg/kg total dose of TXA. This dosing arm will only open if a dose-effect is determined based on accumulating data.
10121320|NCT04387305|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours
10121321|NCT04387578|Experimental|Group A singlestrand NiTi arch wires|in which 10 patients (5 males and 5 females) were treated with round singlestrand NiTi arch wires in a sequence of 0.012, 0.014, and 0.016 inch.
10121322|NCT04387578|Experimental|Group B Gummetal arch wires|in which 10patients (6 males and 4 females) were treated with niobium-titanium-tantalum-Zirconium arch wires (Gummetal arch wires) in a sequence of 0.014, 0.016, and 0.018 inch.
10121323|NCT04387578|Experimental|Group C multistrand NiTi arch wires|in which 10 patients (4males and 6females) were treated with multistrand NiTi arch wires in a sequence of 0.016, 0.018, and 0.020 inch.
10121324|NCT04387539|Active Comparator|Non-Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian non-cirrhotic experienced HCV GT4 participants for 12 weeks
10121325|NCT04387539|Active Comparator|Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian cirrhotic experienced HCV GT4 participants for 12 weeks
10121326|NCT04387591|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
10121327|NCT04387591|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
10121328|NCT04387383|Experimental|Acupuncture group|Electro-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
10121329|NCT04387383|Placebo Comparator|sham-acupuncture group|Sham-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
10121330|NCT04387318|Experimental|Multimodal training|"IMT + NMES + Pulmonary Rehabilitation~IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
10121331|NCT04387318|Experimental|IMT + Pulmonary Rehabilitation|"IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
10121332|NCT04387318|Experimental|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
10121333|NCT04387318|Placebo Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise.
10121334|NCT04387357||Control|Neurologically healthy older adults above the age of 50
10121335|NCT04387357||Experimental|Older adults above the age of 50 with Mild Cognitive Impairment or Dementia
10121336|NCT04387422|Experimental|150 mg/dL|Hyperglycemia target of 150 mg/dL
10121337|NCT04387422|Experimental|225 mg/dL|Hyperglycemia target of 225 mg/dL
10121338|NCT04387422|Experimental|300 mg/dL|Hyperglycemia target of 300 mg/dL
10121339|NCT04387565||Preeclampsia|The diagnosis of LOPE, as will be defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will be established based on the presence of proteinuria and a blood pressure level of ≥140/90 mmHg that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure ≥ 160/110 mm Hg, it will be accepted as mild; and in case these values exceeded this level, it will be accepted as severe.
10121340|NCT04387565||control pregnant group|These participants with normal healthy pregnancies at the third trimester (before birth)
10121341|NCT04387565||control non-pregnant group|A volunteer group of healthy women who visited the gynaecology clinic for routine examinations and women who were admitted for pre-pregnancy tests were invited randomly to this research as a control group.
10121342|NCT04387526|Active Comparator|SOF/DCV|"Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.~This arm included non-cirrhotic treatment-naïve patients"
10121343|NCT04387526|Active Comparator|SOF/DCV/RBV + Cirrhosis|This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
10121344|NCT04387526|Active Comparator|SOF/DCV/RBV + Non-Cirrhosis|This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
10121345|NCT04387500|Experimental|Sintilimab injection combined with Inlyta|"Sintilimab injection 10ml: 100mg, 200mg intravenously, once every three weeks. Course of treatment: discontinue medication when the disease progresses clinically or radiologically.~Inlyta 5mg orally, twice a day. Course of treatment: continue treatment as long as a clinical benefit is observed, or until an unacceptable toxicity is present that cannot be controlled by combination or dose adjustment.~In the whole research process, if the disease progresses, the attending doctor has the right to carefully choose other anti-tumor methods, including radiotherapy, chemotherapy and other targeted drugs."
10121346|NCT04387630|Experimental|metformin group|"metformin 850 mg once daily increased within 3 weeks to a maximum dose of 2550 mg on three divided daily doses.~Neoadjuvant cytotoxic chemotherapy as per MDT (multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization."
10121347|NCT04387630|Placebo Comparator|Placebo group|placebo. Neoadjuvant cytotoxic chemotherapy as per MDT(multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.
10121348|NCT04387292|Experimental|Ophthalmologic exam|
10121349|NCT04387474|Experimental|Experimental group|brain-computer interface rehabilitation training and traditional rehabilitation training.
10121350|NCT04387474|Other|Control group|traditional rehabilitation training.
10121351|NCT04387266||Modified reduce-volume target IMRT|Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
10121352|NCT04387396|Experimental|Physiotherapy|Exercise intervention will be applied to this arm.
10121353|NCT04387396|No Intervention|Control|No intervention will be made to this arm, only evaluations will be made.
10121354|NCT04387279||Inflammatory bowel disease|Patients with inflammatory bowel disease who live in COVID-19 hyperemic area
10121355|NCT04387149||CSA-AKI|Patients that developed cardiac surgery-associated Acute Kidney Injury
10121356|NCT04387149||non CSA-AKI|Patients that did not developed cardiac surgery-associated Acute Kidney Injury
10121357|NCT04387058|Other|patients with cirrhosis and and portal hypertension|All major patients under 70 years of age with cirrhosis and portal hypertension justifying a treatment with TIPS. These patients must be affiliated to a social security and able to sign a free, informed and written consent.
10121358|NCT04387175|Experimental|Carriere Motion 3D Class III Appliance|
10121359|NCT04387175|Active Comparator|Facial mask|
10121360|NCT04387240|Experimental|intervention group|this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days
10121361|NCT04387240|Placebo Comparator|placibo|this group will receive a placebo of the same shape and picture of the study drug
10121362|NCT04387214||Veterinary students and researchers|
10121363|NCT04387201|Experimental|Dulaglutide, then Cyanocobalamin|Dulaglutide is experimental, cyanocobalamin is inactive placebo comparator
10121364|NCT04387201|Experimental|Cyanocobalamin, then Dulaglutide|Cyanocobalamin is inactive placebo comparator, dulaglutide is experimental
10121365|NCT04386967|Experimental|Dose expansion|Dose expansion trial comprises of 2 cohorts. In cohort 1, OH2 injection will be administered at 1x10e7CCID50/mL . In cohort 2, OH2 injection will be administered at 1x10e7CCID50/mL in combination with Keytruda injection, an anti-PD-1 antibody, and the first doses of the two anti-tumor agents will be administered on the same day.
10121366|NCT04387136|Experimental|Sublingual Sufentanil|Participants in this arm will receive the intervention.
10121367|NCT04387136|No Intervention|Control|Participants in this arm will not receive an intervention.
10121368|NCT04387006|Experimental|Osteopatic Manipulative Treatment (OMT)|
10121369|NCT04387006|Placebo Comparator|Manual Placebo (MP)|
10121370|NCT04386772|Experimental|PVE with coils plus TAGM|PVE with coils proximally plus TAGM distally and subsequent major hepatectomy
10121371|NCT04386772|Active Comparator|PVE with multiple coils|PVE with multiple coils and subsequent major hepatectomy
10121372|NCT04386876|Experimental|Orvical-Kaletra-Orvical-Kaletra|In first and third periods of the study, participants received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. In second and fourth periods, they received Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. All periods were performed under fasting state.
10121373|NCT04386876|Experimental|Kaletra-Orvical-Kaletra-Orvical|In first and third periods of the study, participants received Kaletra 200 mg/50 mg Film Coated Tablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. In second and fourth periods, they received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. All periods were performed under fasting state.
10121374|NCT04387084|Experimental|Treatment (STF, PD-1/PD-L1 inhibitor)|Patients undergo STF for 47-48 hours prior to immunotherapy and for 24 hours after immunotherapy with standard of care pembrolizumab given IV over 30 minutes, nivolumab IV over 30 minutes, cemiplimab IV over 30 minutes, avelumab IV over 60 minutes, atezolizumab IV over 60 minutes, or durvalumab IV over 60 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
10121375|NCT04386733||Cancelled|all adult patients whose surgery was cancelled on the day of the planned procedure
10121376|NCT04386733||Non-cancelled|all adult patients whose surgery was not cancelled on the day of the planned procedure
10121377|NCT04387019||I|30 with uncontrolled type 2 DM patients
10121378|NCT04387019||II|30 controlled type 2 DM patients
9966768|NCT01263236|Experimental|LY2940094 - multiple dose|Daily oral dose of 2-200 mg LY2940094 for 14 days
9966769|NCT01263236|Experimental|Placebo|Single oral dose or daily oral dose for 14 days
9966770|NCT01263249|Active Comparator|Catheter Anterior to Femoral Nerve|Each subject will have one lower extremity (Right or Left) randomized to receive a perinural catheter, placed anterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
9966771|NCT01263249|Active Comparator|Catheter Posterior to Femoral Nerve|Each subject will have the opposite lower extremity (Right or Left) randomized to receive a perinural catheter, placed posterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
9966772|NCT01263275|Experimental|Active tDCS|
10121379|NCT04387019||III|30 healthy subjects as a control group
10121380|NCT04386824||Behçet's disease|Male patients who arediagnosed as Behçet's disease according to International Study Group Classification Criteria
10121381|NCT04387032|Experimental|Experimental group|Experimental group (students with hypomobile SIJs)
10121382|NCT04387032|Sham Comparator|Control group|control group (students without hypomobile SIJs)
10121383|NCT04386889|Other|SLE Vasculitis|20 SLE Female patients will subjected to study of the all vasculitic pattern that may occur.
10121384|NCT04387123|Active Comparator|Conventional vaginoscopy|Vaginoscopy without vulvar tightness
10121385|NCT04387123|Active Comparator|Tight vaginoscopy|Vaginoscopy via Darwish sheet
10121386|NCT04387045|Experimental|Guilty feelings|Write for 20 minutes about a situation that in the participant's past life has caused feelings of guilt.
10121387|NCT04387045|Placebo Comparator|Neutral feelings|Write for 20 minutes about a situation that in the participant's past life has caused neutral feelings.
10121388|NCT04386850|Experimental|Treatment|Infected patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or with a COVID-19 positive test by the polymerase chain reaction (PCR)
10121389|NCT04386850|Experimental|Prevention|This arm of study includes the health care providers and hospital workers with a negative test for COVID-19 and a close patient relative with a negative test for COVID-19 who lives with the infected patients.
10182986|NCT03768895||MRI group|The criteria for patient inclusion were: Age > 18 years old, who had realised a pelvis MRI for any cause at MRI Center. Exclusion criteria included age < 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
10182987|NCT03768882|Experimental|Paracetamol|Experimental: Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 102 patients
10182988|NCT03768882|Experimental|dexketoprofen|Dexketoprofen Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay-Menarini,Turkey) intravenous (IV) was given 98 patients
10182989|NCT03768869|Experimental|Low Risk: Oupatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
10182990|NCT03768869|Active Comparator|Low Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
10182991|NCT03768869|Active Comparator|High Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
10182992|NCT03768843|Other|traumatic odontoid fracture|C1 C2 fusion screws
10182993|NCT03768830|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
10182994|NCT03768830|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
10182995|NCT03768830|Experimental|Healthy Exercise|Healthy individuals that will exercise-group (HE). Intervention is exercise training.
10182996|NCT03768830|No Intervention|Healthy Control (no-Exercise)|Healthy individuals that will not exercise (HC).
9694616|NCT04787419|Placebo Comparator|placebo|"2 sachets per day for 4 weeks.~1 sachet of placebo (1gram) contains: saccharum lactis"
9694617|NCT04787536||Study cohort|Patients aged 65 years or greater; scheduled to perform noncardiac elective surgery expected to require at least an overnight stay in hospital after surgery; surgery deferred, with a known or probable surgery date in ≥6 weeks
10182997|NCT03768817||Patients treated with triheptanoin|Patients with LC-FAOD treated with triheptanoin before 01 September 2018 under eIND
10182998|NCT03768804|Other|SyncAV algorithm on|"Device randomised to have SyncAV on, with delta programmed to the value which gives the narrowest QRS duration at rest and pseudo left ventricular (LV) only pacing"
10182999|NCT03768804|Other|SyncAV algorithm off|"Device randomised to have SyncAV off, with a fixed sensed atrioventricular (AV) delay of 120ms or shorter if necessary to prevent fusion, and biventricular (BiV) pacing"
10183000|NCT03768791|Experimental|SCS off|
10183001|NCT03768791|Experimental|SCS on|
10183002|NCT03768778|Other|Debridement|
10183003|NCT03768765||Long Term Medication Usage|Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
10183004|NCT03768765||Short Term Medication Usage|Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)
10183005|NCT03768739||CICU extubated patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
10183006|NCT03768713|Experimental|Drug (Suvorexant)|20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)
10183007|NCT03768713|Placebo Comparator|Placebo|20 mg of Placebo daily (taken orally ~1 hour before bedtime)
10183008|NCT03768700||Cohort|Hospitalization in a Post-Resuscitation Rehabilitation Care Units (SRPR)
10183009|NCT03768674||Inpatient cohort (Target group)|"Inpatient at mental health centre/ psychiatric hospital due to severe self-harm. Duration > 4 weeks and/or > five admissions last year.~Assessment of diagnoses, functioning and health services"
10183010|NCT03768674||Outpatient comparison cohort|"Admitted to treatment within Norwegian Network of personality-focused treatment during 2017-2018.~Assessment of diagnoses, functioning and health services"
10183011|NCT03768661||SILC Group|patients with symptomatic cholelithiasis submitted to a single-incision laparoscopic cholecystectomy
10121390|NCT04386915|Experimental|Single-dose experimental group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2 and Day4. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
10121391|NCT04386915|Placebo Comparator|Single-dose control group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
10121392|NCT04386915|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
10121393|NCT04386915|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
10121394|NCT04386915|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
10121395|NCT04386915|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
10121396|NCT04386668|Experimental|LIO-C|Participants receive LIO-C writing intervention
10121397|NCT04386668|Placebo Comparator|Neutral writing control|Participants receive neutral writing control intervention
10121398|NCT04386694|Experimental|PBMT/sMF|"Active PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with PBMT/sMF.~PBMT/sMF will be applied using MR5™ ACTIV PRO LaserShower, manufactured by Multi Radiance Medical (Solon, OH, USA). This device has 4 diodes of 905 nm (1.25 mW each diode, 0.32 cm2 each), 8 diodes of 633 nm (25 mW each diode, 0.85 cm2 - each), and 8 diodes of 850 nm (40 mW each diode, 0.56 cm2 - each). The static magnetic field is 110 mT."
10121399|NCT04386694|Placebo Comparator|Placebo PBMT/sMF|"Placebo PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with placebo PBMT/sMF.~The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The static magnetic field will be also turned off. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator."
10121400|NCT04386681|Experimental|RCBI|Receiving RCBI intervention, including BICS, ICAN, and RF.
10121401|NCT04386681|No Intervention|Treatment as usual- Control group|Not receiving the RCBI intervention
10121402|NCT04386746|Experimental|Intravesical Gemcitabine/Docetaxel|
10121403|NCT04387097||gradual withdrawal following by drip-infusion of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated. Following by drip-infusion of remifentanil for 30 minutes was administered immediately after tracheal extubation.
10121404|NCT04387097||gradual withdrawal of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated.
10121405|NCT04386707|Experimental|Experimental Vaccine-lot 1|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
10121406|NCT04386707|Experimental|Experimental Vaccine-lot 2|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
10121407|NCT04386707|Experimental|Experimental Vaccine-lot 3|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
9966773|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 400 IU|
10121408|NCT04386707|Active Comparator|Control Vaccine|Wild strain IPV (wIPV）manufactured by Sanofi Pasteur S.A.
10121409|NCT04386473||Left Bundle Branch Pacing|
10121410|NCT04386473||Right Ventricular Outflow Tract Septal Pacing|
10121411|NCT04386525|Experimental|Omega-3|Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly
9966774|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 1000 IU|
9966775|NCT01263288|Placebo Comparator|Placebo|
10121412|NCT04386525|No Intervention|Controle|for comparison with interventional arm
10121413|NCT04386486|Experimental|bathe group|The patients were divided into two equal groups randomly first group is BATHE anamnesis group.
10121414|NCT04386486|Sham Comparator|standart anamnesis group|The patients were divided into two equal groups randomly second group is standart anamnesis group.
9966776|NCT01263327|Experimental|HPV 16/18|Participants in this arm would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
9966777|NCT01263340||People with COPD|
10121415|NCT04386499|Experimental|Resveratrol|A nutraceutical formulation (trade mark Genante) composed of resveratrol, REVIFAST, folic acid, Vitamin D
10121416|NCT04386499|Active Comparator|Folic acid|Folic Acid 400 ug
10121417|NCT04386642|Experimental|Experiment group|Each ampule contains TXA 250 mg. TXA preparation is 2000 mg dilute in normal saline 50 ml to get the concentration of 40 mg/ml. TXA will be administered 20 mg/kg loading over 20 min before skin incision followed by a maintenance infusion of 0.025 ml/kg/h (1 mg/kg/h) until the end of operation.
10121418|NCT04386642|Placebo Comparator|Control group|Normal saline solution 50 ml is prepared in a clear 50 ml syringe similar to the experiment group.
10121419|NCT04386655|Experimental|Telemedicine Group|BICS-T is the intervention that will take place over telemedicine software on the iPad provided to participants
10121420|NCT04386655|Active Comparator|In-Person Group|Participants a part of the in-person BICS group will then come to the NRC for the following BICS sessions. This group is the traditional, in-person, BICS group
10121421|NCT04386356|No Intervention|Orotracheal intubation with macintosh laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Macintosh laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
10121422|NCT04386356|Active Comparator|Orotracheal intubation with Airtraq Video Laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
10121423|NCT04386382|Experimental|ridge splitting flapless technique using interchangeable guide|"Fabrication of interchangeable surgical guide stent:~Optical scanning of the dental casts was done using Ceramill map 400~The treatment plan and the surgical stent were designed using Mimics Innovation Suite 19 ™ software~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique."
10121424|NCT04386369||Airway Pressure Release Ventilation|Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.
9966778|NCT01263353|Experimental|Functional tumors, pre-treated|
10121425|NCT04386408|Experimental|Combination of plant extracts (BSL_EP027)|Volunteers will dissolve in water a sachet per day with the Combination of plant extracts (BSL_EP027), and maltodextrin.
10121426|NCT04386408|Placebo Comparator|Placebo|Volunteers will dissolve in water a sachet per day with maltodextrin.
10121427|NCT04386577|Active Comparator|Vitamin D + fish oil|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Each capsule contains 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA).
10121428|NCT04386577|Active Comparator|Vitamin D + fish oil placebo|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary supplement: Fish oil placebo
10121429|NCT04386577|Active Comparator|Vitamin D placebo + fish oil|Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Dietary supplement: Vitamin D3 placebo
10121430|NCT04386577|Placebo Comparator|Vitamin D placebo + fish oil placebo|Dietary supplement: Vitamin D3 placebo Dietary supplement: Fish oil placebo
10121431|NCT04386291|Active Comparator|Anxiety Reduction Training (A.R.T.)|Participants will received biweekly on-line lessons that provide education and strategies to reduce stress and disturbing thoughts and improve healthy coping and sleep. .
10121432|NCT04386291|Experimental|ART and Kundalini Yoga|This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
10121433|NCT04386291|Experimental|ART and Meditation|This combines ART with a daily 15 minute meditation with stress reduction techniques and guided breathing.
10121434|NCT04386161|Experimental|Children with dyslexia|Children, aged between 8 and 11 years, with clinical dyslexia diagnosed by a child and adolescent psychiatrist
10121435|NCT04386239|Experimental|Covid-19|Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and <4 will be requested consent to the study.
10121436|NCT04386226|Experimental|2 grams Ambrotose LIFE|2 grams daily for 8 weeks
10121437|NCT04386226|Experimental|4 grams Ambrotose LIFE|4 grams daily for 8 weeks
10121438|NCT04386226|Active Comparator|2 grams Advanced Ambrotose|2 grams daily for 8 weeks
10121439|NCT04386226|Active Comparator|4 grams Advanced Ambrotose|4 grams daily for 8 weeks
10121440|NCT04386226|Placebo Comparator|Placebo|4 grams Maltodextrin daily for 8 weeks
10121441|NCT04386070|No Intervention|Control (normal practice)|Treatment without the trial intervention. Patients will be treated as per hospital routine practice. The control arm may change over the course of the trial and will be monitored by the TMG and DMC
10183012|NCT03768661||Laparoscopy Group|patients with symptomatic cholelithiasis submitted to a standard three trocar laparoscopic cholecystectomy
10183013|NCT03768635||Necrotizing external otitis|description of necrotizing external otitis
10121442|NCT04386070|Experimental|RESP301|RESP301 is administered quickly (8-10 minutes) via an easy-to-use, vibrating mesh nebuliser. The recommended nebulisers used to administer this intervention are available in all participating countries. The intervention will be administered using a nebuliser according to standard local practice; where permitted for patients to self-administer, a member of the clinical team will ensure that the patient has viewed the intervention administration training video, and will also oversee the patient for the first trial dose to ensure proper administration.
10121443|NCT04386083||COVID-19 patients with neurologic manifestations|Patients with confirmed COVID-19 disease who presented with neurological symptoms or new-onset neurological disorders/complications
10121444|NCT04386083||COVID-19 patients without neurologic manifestations|Patients with confirmed COVID-19 disease who did not present with neurological symptoms or new-onset neurological disorders/complications
10121445|NCT04386434|Experimental|Active for Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
10121446|NCT04386213|Experimental|Paclitaxel Drug-coated Balloon|
10121447|NCT04386213|Active Comparator|SeQuent® Please Paclitaxel Drug-coated Balloon|
10121448|NCT04386564||Mild COVID-19|Pneumonia without respiratory failure
10121449|NCT04386564||Moderate COVID-19 up to 60 years|Respiratory frequency ≥30/minute, blood oxygen saturation≤93%
10121450|NCT04386564||Moderate COVID-19 over 60 years old and severe COVID-19|Pneumonia with respiratory distress syndrome
10121451|NCT04386343|Placebo Comparator|50% dose level arm - Phase I|4 healthy volunteer will use 50% dose level for Phase I in the left hand side and use placebo in the right hand side
10121452|NCT04386343|Placebo Comparator|100% dose level arm - Phase I|4 healthy volunteer will use 100% dose level for Phase I in the left hand side and use placebo in the right hand side
10121453|NCT04386343|Active Comparator|167% dose level arm - Phase I|4 healthy volunteer will use 167% dose level for Phase I in the left hand side and use placebo in the right hand side
10121454|NCT04386343|Placebo Comparator|Placebo arm - Phase II|20 Breast cancer patients will use Placebo in the radiation affected area right after radiation
10121455|NCT04386343|Placebo Comparator|50% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 50% of the expected dose level in the radiation affected area right after radiation
10121456|NCT04386343|Placebo Comparator|100% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 100% of the expected dose level in the radiation affected area right after radiation
10121457|NCT04386343|Placebo Comparator|167% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 167% of the expected dose level in the radiation affected area right after radiation
10121458|NCT04386148||laparoscopic colorectal surgery|Patients undergoing laparoscopic colorectal surgery with use of Obsidian ASG® during primary anastomosis.
10121459|NCT04386200|Experimental|WEB GROUP|Traditional approach integrated with web-based technologies.
10121460|NCT04386200|Other|TRADITIONAL GROUP|Traditional educational approach
10121461|NCT04386278|Experimental|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
10121462|NCT04386278|Experimental|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
10121463|NCT04386278|Experimental|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
10121464|NCT04386278|Experimental|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
10121465|NCT04386278|Experimental|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
10121466|NCT04386278|Experimental|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
10121467|NCT04386278|Experimental|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
10121468|NCT04386278|Experimental|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
10121469|NCT04386109||Neonates COVID-19 positive|1. Neonatal COVID-19 in babies (<29 days old) in neonatal units, paediatric intensive care units and other in-patient locations.
10121470|NCT04386109||Neonates born to COVID-19 positive mothers|2. Neonates (<29 days old) born to COVID-19 positive mothers requiring neonatal care
10121471|NCT04386122|Experimental|FABALOFEN 60|Subjects will receive a single dose of 1 FABALOFEN 60 tablet under fed condition
10121472|NCT04386122|Active Comparator|JAPROLOX TABLET|Subjects will receive a single dose of 1 JAPROLOX® TABLETS tablet under fed condition
10121473|NCT04386005|Experimental|Continuous Glucose Monitoring|All participants will have the continuous glucose monitoring device placed.
10121474|NCT04386421|Experimental|video group|Group A: A 3 minute video will be shown providing information regarding the care of the dentition during Fixed Appliance Treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions. Participants in this group will also receive the same video graphic educational material through their Whats app once weekly for a total duration of 3 months.
10121475|NCT04386421|Experimental|Plaque disclosing tablet|Group B: Plaque-disclosing tablets will be taken by patients on chair-side showing the location of the biofilm. The patients will be given plaque disclosing tablets to be used once weekly for 3 months to evaluate their oral hygiene at home. They will be given written information in the form of leaflets on importance of cooperation and compliance. Participants in this group will receive a reminder log fill, and tablets that are not used will be asked to return to the investigator by the participants to check the compliance.
10121476|NCT04386421|No Intervention|Control. verbal instructions|Control Group C: Controls will be given only routine verbal OHI and will be briefed on the importance of cooperation and compliance at every orthodontic visit for a period of 3 months study. They will receive a reminder log that they will return at the end of the study to check compliance.
10121477|NCT04386031||group with antifungal drug|
10121478|NCT04386031||A control group|A control group will be taken ,patients undergoing thyroidectomy or parotidectomy
10121479|NCT04386447|Experimental|Oxytocin 40 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
10121480|NCT04386447|Experimental|Oxytocin 25 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
10121481|NCT04386447|Other|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~Oxygen supply or non-invasive ventilation to target peripheral blood saturation > 94%~Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~Prophylaxis for deep vein thrombosis~Steroids are not routinely recommended but may be considered in selected patients."
10121482|NCT04385940|Experimental|High dose vitamin D|Ddrops® products,Vitamin D3, 50,000 IU, Oral
10121483|NCT04385940|Active Comparator|Low dose vitamin D|Vitamin D3 1000IU
10121484|NCT04385719|Experimental|Study A Sequence 1|"Single dose remdesivir 150mg IV on Day 1~Wash out period Day 2-7~TDF/3TC 300/300mg tablets OD from Day 8-14 single dose remdesivir 150mg IV on Day 14"
10121485|NCT04385719|Experimental|Study A Sequence 2|"TDF/3TC 300/300mg tablets OD from Day 1-7 single dose remdesivir 150mg IV on Day 7~Wash out period Day 8-14~Single dose remdesivir 150mg IV on Day 15"
10121486|NCT04385719|Experimental|Study B|TDF/3TC/ATV/r 300/300/300/100mg tablets OD from Day 1-7 single dose remdesivir 150mg IV infusion on Day 7
10121487|NCT04385615|Experimental|FMD Group|Participants will be requested to follow a Fasting Mimicking Diet, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
10121488|NCT04385615|No Intervention|Control Group|Participants will be requested to continue with their habitual eating habits, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
10121489|NCT04385979|Active Comparator|Curcumin|%2 Curcumin gel
10121490|NCT04385979|Active Comparator|Nanocurcumin|%1 NanoCurcumin gel
10121491|NCT04385628||Relatives of patients hospitalized in the intensive care unit|Demographic data of the relative of the patient (age, proximity, educational background, patient co-existence, ethnicity, marital status, number of children, history of psychological treatment and the presence of an intensive care treatment history of any family member before) will be recorded. After the 3rd, 10th, and 30th days of patient admission, and once a month, the patient satisfaction survey will be filled face to face during informing the patient's relative. These three main data (Demographic data of the patient relatives, the most recent satisfaction questionnaire and emotional reactions observed while reporting death) will be evaluated and interpreted.
10121492|NCT04385966|Active Comparator|Standard Volume Dose|24 patients will be included in the Standard Volume Dose arm. 20 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
10121493|NCT04385966|Experimental|Low Volume Dose|24 patients will be included in the Low Volume Dose arm. 10 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
10121494|NCT04385602|Placebo Comparator|CON group|placebo
10121495|NCT04385602|Active Comparator|DT group|Intratracheal dexmedetomidine
10121496|NCT04385784|Experimental|Sedentary Intervention Group (SIG)|Group of sedentary older adults who perform the intervention and a home-based exercise program.
10121497|NCT04385784|Experimental|Active Intervention Group (AIG)|Group of active older adults who perform the intervention and a home-based exercise program.
9966779|NCT01263353|Experimental|Functional tumors, treatment naïve|
9966780|NCT01263353|Experimental|Nonfunctional tumors, pretreated 1|
10121498|NCT04385784|Active Comparator|Control Group (CG)|Group of sedentary older adults who perform a home-based exercise program.
10121499|NCT04385771|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
10121500|NCT04385771|Other|vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
10121501|NCT04385693|Experimental|Pulpotomy|Group A: The patient will benefit from an experimental treatment: a Pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
10121502|NCT04385693|Active Comparator|Control Group|Group B: Extracted teeth will serve as controls, and information regarding the need or not of space maintenance, and the impact on the occlusion and eruption of the succedaneous permanent tooth will be noted.
10121503|NCT04385745|Experimental|Elastic Stable Intramedullary Nailing|BIN (biodegradable intramedullary nailing) method will be compared with the ESIN (elastic stable intramedullary nailing)
10121504|NCT04385745|Experimental|Biodegradable intramedullary nailing|BIN method will be compared with the ESIN.
10121505|NCT04385849|Experimental|Experimental Arm|N-803 Recombinant human super agonist interleukin-15 (IL-15) complex
10121506|NCT04385849|Placebo Comparator|Placebo Arm|Sterile saline solution
10121507|NCT04385836|Active Comparator|alpha one antitrypsin group|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) add to 2cm of normal saline solution as nebulizer every 12 hours for 5 days
9827674|NCT02464449|Experimental|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
10121508|NCT04385836|Placebo Comparator|placebo group|we will give 8 ml of normal saline as nebulizer every 12 hours for 5 days
10121509|NCT04385654|Experimental|Neoadjuvant toripalimab plus axitinib|Toripalimab (240 mg,ivgtt,q3w) combined with Axitinib (5 mg,po,bid) was treated for 6 weeks and underwent surgery within 2-4 weeks
10121510|NCT04385524|Other|Vaccination|"Heplisav B vaccine will be administered to subjects demonstrating completion of two prior series of standard 3-dose Hepatitis B vaccine but still without evidence of seroconversion.~One dose (20 mcg) of vaccine will be administered intramuscularly followed by Hepatitis B quantitative antibody titer 30-60 days later.~If still Hepatitis B antibody negative, a second dose (20 mcg) of vaccine will be administered intramuscularly followed by a Hepatitis B quantitative titer 30-60 days later.~If still no evidence of Hepatitis B immunity (10iU antibody or greater), will be deemed a non-responder to this vaccine"
10121511|NCT04385459||Patients without coronary artery disease|No prior coronary intervention and no significant stenosis noted during coronary angiography.
10121512|NCT04385459||Patients with coronary artery disease|"Our definition of coronary artery disease is:~Prior coronary artery bypass grafting or percutaneous coronary intervention~Significant stenosis or occlusion noted during coronary angiography"
10121513|NCT04385485|Experimental|Active rehabilitation|The patient see an occupational therapist 1-3 days after surgery. A splint is made to immobilise the wrist and work as a extension block for the MCP-joints. This splint has to be worn day and night for 4 weeks. Another splint that immobilise the DIP- and PIP-joints are worn whenever the patient is not exercising. During active exercise the patient follows a strict protocol with both active and passive training and increasing number of repetitions. The rehabilitation is proceeding for 3 months.
10121514|NCT04385485|Active Comparator|Passive rehabilitation|1-3 days after surgery the patient gets a new plaster that immobilise the wrist and work as an extension block for the MCP-joints. The occupational therapist attach rubberbands to the nails of all the fingers and the training is done passively with active hold according to a strict protocol. The training with rubberbands is done during 4 weeks. After that the rehabilitation is active. The rehabilitation is proceeding for 3 months.
10121515|NCT04385342|Active Comparator|FSH then HP-hMG|Women will receive 225 IU FSH alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm, the 150 IU HP-hMG will substitute FSH and continued to the day of triggering
10121516|NCT04385342|Active Comparator|FSH + HP-hMG|Women will receive 150 IU FSH plus 75IU HP-hMG from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm 150 IU HP-HMG till day of triggering
10121517|NCT04385563|Experimental|TQ-B211 + docetaxel|Participants will be administered TQ-B211 plus docetaxel once every three weeks(Q3W) in cycles up to cycle 8.
10121518|NCT04385563|Active Comparator|Herceptin®+docetaxel|Participants will be administered Herceptin® plus docetaxel Q3W in cycles up to cycle 8.
10121519|NCT04385576|Active Comparator|Aerosol Box|Intubation using the Taiwan model Aerosol Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
10121520|NCT04385576|Active Comparator|Intubation Box|Intubation using the UMMC model Intubation Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
10121521|NCT04385953||Trauma patients|Subject experiencing major trauma
10121522|NCT04385953||Obstetric patients|Obstetric patient with postpartum hemorrhage
10121523|NCT04385914||COVID positive patients|
10121524|NCT04385914||COVID negative patients|
10121525|NCT04385810|Experimental|Ophthalmologic exam|
10121526|NCT04385901|No Intervention|Standard of Care|These are patients who were diagnosed with COVID19 and recovered with usual care prior to implementation of the rehabilitation program developed by MUHC therapists. These patients will be selected in such a way as to match the approximate demographics that exist within the treatment group. These patients received education and supportive care only.
10121527|NCT04385901|Experimental|Rehabilitation Group|These are patients who were diagnosed with COVID19 and participated in the physical and pulmonary rehabilitation program developed at MU Healthcare as described in the study design.
10121528|NCT04385797||Dyads|Community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers
10121529|NCT04385641|Experimental|Dose-finding (Group A)|"In this study, the dose was explored according to the 3+3 mode, in which group A was divided into three dose groups: 1.5*10＾9 group, 2*10＾9 group and 3*10＾9 group. If DLT occurs in one of the first three subjects in each dose group within four weeks after cell infusion, three subjects will continue to be included. If more than 1/6 cases of DLT appear in 6 subjects with 1.5*10＾9 dose, the dose level and/or cell infusion frequency and method will be reduced after discussion between the investigator, the collaborator and DMC. If DLT did not occur in the first 3 subjects within 4 weeks after receiving 1.5*10＾9 cell infusion，another three subjects were enrolled into the group received 2*10＾9 cell infusion. DLT did not occur within 4 weeks after cell infusion, it will increase to 3*10＾9 dose group. That is to say, the first three subjects were included for observation for 4 weeks in the 3*10＾9 dose group, if DLT did not occur, there will be another 3 cases, reaching to 6 subjects."
10121530|NCT04385641|Experimental|Extended research (Group B)|If DLT≤1/6, the dose will not be increased. This dose will also be used as the treatment dose of group B. If DLT is more than 1/6 in the 3*10＾9 dose group, three subjects will be added in 2*10＾9 dose group. If DLT ≤1/6 in 4-week observation, the 2*10＾9 will be the maximum tolerable dose, and will be used as the treatment dose of group B. The subjects in group A were enrolled first, after at least 4 weeks of observation for all subjects, six subjects will be included in group B.
10121531|NCT04385550|Experimental|Anlotinib hydrochloride capsule + AK105 injection|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
10121532|NCT04385550|Active Comparator|Standard Second-line Chemotherapy|Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.
10121533|NCT04385888|Experimental|Low-calorie sweetener restriction|Participants will be instructed to avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners, and to instead consume unsweetened alternatives, such as plain or sparkling water for 12 weeks.
10121534|NCT04385888|No Intervention|Usual consumption/control|Participants will continue low-calorie sweetener consumption, as usual.
10121535|NCT04385511|Experimental|supraglottic jet ventilation group|Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will put the Wei NASAL JET（WNJ）into one's nose to give the supraglottic jet ventilation with the driving pressure 0.01-0.03 megapascal (MPa), respiratory rate 15 beats per minute（BPM）, inspiratory/expiratory rate 1-1. 5.Check blood gas,stomach-ultrasound after 3 min, then do the tracheal intubation guided by visual laryngoscope.Stop jet ventilation during intubation.
10121536|NCT04385511|No Intervention|mask pressurized ventilation group|"Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will give them 1 min mask pressure respiration, by pressure control V - E technique after muscle relaxant. Check blood gas,stomach-ultrasound after 2 min, then do the tracheal intubation guided by visual laryngoscope."
10121537|NCT04385186|Experimental|Convalescent plasma+Support treatment selected by the hospital|Participants will receive two doses of ABO - Rh compatible inactivated convalescent plasma, each one of 200 mililiters (mL), with a 24-hour interval via transfusion, for a final volume of 400 mL, meanwhile they continue to receive the supportive treatment chosen by the hospitals, according to each institutional protocol.
10121538|NCT04385186|Active Comparator|Support treatment selected by the hospital|The best support treatment selected by the hospital, according to each institutional protocol. Due to the ongoing development of knowledge of pathophysiology and scientific evidence of the available alternatives, it will be selected at the time of treatment.
10121539|NCT04385225|Other|Healthy controls|Age-matched controls with normal hearing or mild sensorineural hearing loss: 40 decibel or less in better hearing ear, and normal vestibular function
10121540|NCT04385225|Other|Moderate Sensorineural hearing loss|Moderate Sensorineural hearing loss: 41-60 decibel in the better hearing ear
10121541|NCT04385225|Other|Severe Sensorineural hearing loss|Severe Sensorineural hearing loss: 61-80 decibel in the better hearing ear
10121542|NCT04385225|Other|Bilateral Vestibulopathy|Bilateral vestibulopathy: half with normal hearing, half with severe to profound sensorineural hearing loss
10121543|NCT04385225|Other|Mild Cognitive Impairment|Mild Cognitive Impairment
10121544|NCT04385225|Other|Alzheimer's Disease|Alzheimer's Disease
10121545|NCT04385199|Experimental|Intervention|Convalescent plasma 200mL transfusion
10121546|NCT04385199|No Intervention|Control|Standard therapy for COVID-19 disease as defined by institutional protocols
10121547|NCT04385290|Experimental|MODULE trial: dose escalation|Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m^2 i.v. on days 1 to 3).
10121548|NCT04385290|Experimental|MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin|Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
10121549|NCT04385290|Placebo Comparator|MAGNOLIA-trial: conventional chemotherapy+GO and placebo|Phase II (Trial part MAGNOLIA): placebo is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
10121550|NCT04385290|Experimental|MAGMA-trial: conventional chemotherapy+midostaurin and GO|Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML
10121551|NCT04385290|Active Comparator|MAGMA-trial: conventional chemotherapy+midostaurin|Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v plus midostaurin). No additional GO is given.
10121552|NCT04385173|Experimental|B7-H3 CAR-T|Patients will received regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval. 3 infusions of B7-H3 CAR-T with 1-2 weeks of interval will be used in between cycles of Temozolomide treatment. Temozolomide treatment during B7-H3 CAR-T infusions will be stopped and resumed after CAR-T infusion.
10121553|NCT04385147||ERCP|Patients who will have endoscopic retrograde cholangiopancreatography
10121554|NCT04385147||EUS|Patients who will have endoscopic ultrasound
10121555|NCT04385420|Experimental|ATR-002 100 mg (SAD)|100 mg ATR-002 once (morning)
10121556|NCT04385420|Experimental|ATR-002 300 mg (SAD)|300 mg ATR-002 once (morning)
10121557|NCT04385420|Experimental|ATR-002 600 mg (SAD)|600 mg ATR-002 once (morning)
10121558|NCT04385420|Experimental|ATR-002 900 mg (SAD)|900 mg ATR-002 once (morning)
10121559|NCT04385420|Placebo Comparator|Placebo (SAD)|Placebo once (morning)
10121560|NCT04385420|Experimental|ATR-002 100 mg (MAD)|100 mg ATR-002 once daily (morning) for 7 days
10121561|NCT04385420|Experimental|ATR-002 300 mg (MAD)|300 mg ATR-002 once daily (morning) for 7 days
10121562|NCT04385420|Experimental|ATR-002 600 mg (MAD)|600 mg ATR-002 once daily (morning) for 7 days
10121563|NCT04385420|Placebo Comparator|Placebo (MAD)|Placebo once daily (morning) for 7 days
10121564|NCT04385264|Placebo Comparator|Placebo|Placebo (Mannitol), oral capsules Day 0: 4 capsules PO OD Days 1-5: 2 capsules PO OD
10121565|NCT04385264|Experimental|Hydroxychloroquine|Hydroxychloroquine 200mg (HCQ, Plaquenil), oral capsules Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
10121566|NCT04385381|Experimental|URECA CTO device|investigate the safety and efficacy of the URECA CTO device in facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature.
10121567|NCT04385134||General parturient|Observe the enterovirus infection in general parturients and their neonates.
10121568|NCT04385134||Puerpera with fever|Observe the enterovirus infection in puerpera with fever and their neonates.
10121569|NCT04385134||Febrile newborns|Observe the enterovirus infection in neonates
10121570|NCT04385355|Other|Control Group|Control group will receive an intermediate transmucosal abutment with conventional diameter and 3mm height, once the implants are placed.
10121571|NCT04385355|Experimental|Test Group|Test group will receive an intermediate transmucosal abutment with a TCP design, narrower than the conventional one, of 3mm height, once the implants are placed
10121572|NCT04385407|Active Comparator|SOF + RBV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
10121573|NCT04385407|Active Comparator|SOF + RBV (Experienced)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
10121574|NCT04385407|Active Comparator|SOF + SMV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
10121575|NCT04385407|Active Comparator|SOF + SMV (Expereined)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
10121576|NCT04385537|No Intervention|Control|Participants in this group avoid all nuts for 4-weeks
10121577|NCT04385537|Experimental|PECAN|Participants in this group consume 68 g of pecans/d with no other changes to their habitual diet and avoid all other nuts.
10121578|NCT04385316||Gastric Cancer|
10121579|NCT04385316||Colorectal Cancer|
10121580|NCT04385316||Bladder Cancer|
10121581|NCT04385329|Experimental|Experimental group:shock waves extended to gastrocnemius TrP|Focused shock wave therapy was extended from the plantar fascia to the gastrocnemius-soleus trigger points.
10121582|NCT04385329|Active Comparator|Control group: shock waves not extended to gastrocnemius TrP|A standard focused shock wave therapy exclusively targeted at the plantar fascia
10121583|NCT04385095|Active Comparator|SNG001|inhalation using the I-neb device.
10121584|NCT04385095|Placebo Comparator|Placebo|inhalation using the I-neb device.
10121585|NCT04385446|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material in the area where the pterygium tissue was removed during the surgery.
10121586|NCT04385446|No Intervention|conjnctival autograft.|Conjunctival autograft was used as a covering material in the area where the pterygium tissue was removed during the surgery.
10121587|NCT04385082|Placebo Comparator|Placebo|Smoked Cannabis (~0% THC)
10121588|NCT04385082|Experimental|Low strength cannabis|Smoked Cannabis (~4% THC)
10121589|NCT04385082|Experimental|Higher strength cannabis|Smoked Cannabis (~10% THC)
10121590|NCT04384861|Experimental|ACTIVE|The ACTIVE arm of the project received the Mayo Clinic SMART training (1 two-hour in-person workshop) and access to the Mayo Clinic's SMART eLearning Support study modules (4 x 45 minute modules in weeks 1-4; 20 x 10 minute modules weeks 5-24)
9827675|NCT02464449|Active Comparator|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
10121591|NCT04384861|No Intervention|CONTROL|The CONTROL did not receive any interventions.
9966781|NCT01263353|Experimental|Nonfunctional tumors, pretreated 2|
10121592|NCT04384835||Mild to moderate asthma|low or medium dose of inhaled steroids according to GINA guidelines
9966782|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 1|
9966783|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 2|
10121593|NCT04384835||Severe asthma|criteria described by the ATS / ERS guidelines (for the recruitment of severe patients)
10121594|NCT04384757|Active Comparator|Open distal gastrectomy|An incision of 15~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth II method was used for gastric reconstruction for most cases
10121595|NCT04384757|Experimental|Laparoscopic distal gastrectomy|"5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.~The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6.~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.~The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7.~The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3.~As a general rule, Billroth II method was used for gastric reconstruction for most cases"
10121596|NCT04384744||GH-POR|Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
10121597|NCT04384744||NGH-POR|Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
10121598|NCT04384744||NGH-NOR|Participants with normal ovarian reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
10121599|NCT04384783||GH group|GH group: Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
10121600|NCT04384783||NGH group|NGH (non-GH) group: Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
9966784|NCT01263366|Experimental|Norepinephrine|
9966785|NCT01263379|Experimental|LEAES treatment|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
9966786|NCT01263392|Active Comparator|Polyvinyl Chloride Catheter|Re-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
9966787|NCT01263392|Active Comparator|Hydrophilic catheter|Use hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
9966788|NCT01263405||Normal|normal volunteers without sarcoma
9966789|NCT01263405||Sarcoma|Sarcoma
9966790|NCT01263418|Experimental|Ofatumumab|
9966791|NCT01263431|Active Comparator|Hemorrhoidectomy|Excision of hemorrhoid cushions
9966792|NCT01263431|Experimental|Hemorrhoidal dearterialization|Ligation of therminbal branches oh hemorrhoid arteries
9966793|NCT01263522|Experimental|Endurance training|
9966794|NCT01263522|Experimental|interval training|
9966795|NCT01263522|Experimental|strength endurance training|
9966796|NCT01263522|Placebo Comparator|control|
9966797|NCT01263535|Experimental|SENSIMED Triggerfish|
9966798|NCT01263548||Vyvanse|This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.
9966799|NCT01263574|Placebo Comparator|Heparinized Saline|This group will maintain their central lines patent with heparinized saline.
9966800|NCT01263574|Experimental|Ethanol lock solution group|Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
9966801|NCT01263613|Other|Biopsy|biopsy
9966802|NCT01263626||Cough as Primary Complaint|"Male and female volunteers 18 years of age and older~Cough as chief complaint~Referred to the GI clinic to evaluate if reflux is the cause of their chief complaint~pH testing for standard of care purposes"
9966803|NCT01263626||Healthy Volunteers|"Male and female volunteers 18 years of age and older~No history of chronic or acute cough and throat clearing~Ability to read a 5th grade script written in English for approximately 20 minutes"
9966804|NCT01263652|Active Comparator|IMmed|Patients receiving intra-muscular medication and oral placebo
9966805|NCT01263652|Active Comparator|POmed|Patients receiving intra-muscular placebo and oral medication
9966806|NCT01263678|Other|Non-Coaching|Usual care for patients with a diagnosis of spinal stenosis after viewing a DA and completing a survey.
9966807|NCT01263678|Other|Coaching|Patients randomized to coaching group will receive one week post viewing of Decisional Aid.
10121601|NCT04385017|Other|DNA from monocytes|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
10121602|NCT04385056|Experimental|Low Dose MSCTC-0010|Participants will receive low-dose cell administration
10121603|NCT04385056|Experimental|Medium Dose MSCTC-0010|Participants will receive medium-dose cell administration
10121604|NCT04385056|Experimental|High Dose MSCTC-0010|Participants will receive high-dose cell administration
10121605|NCT04384809|Experimental|Leukocyte rich platelet rich plasma injection|Patients will be injected with leukocyte rich platelet rich plasma in their common extensor tendon
10121606|NCT04384809|Experimental|Percutaneous tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
10121607|NCT04384874|Active Comparator|Silbernagel combined concentric-eccentric program|A graduated rehabilitation program using exercises with concentric and eccentric contractions and progressing to plyometric training. The exercises are performed daily with progression guided by pain symptoms. There is no specificity in prescribed exercise loading.
10121608|NCT04384874|Experimental|SSC6|A multi-stage rehabilitation program with focus on strength and reactive strength targets, as well as running gait re-training. These exercises will be initially carried out 3 days per week for the first 6 weeks with specific load targets prescribed.
9966808|NCT01263730|Active Comparator|Tai Chi Training|The active group will be given 12 weeks of tai chi training
9966809|NCT01263730|No Intervention|Waitlist control group|There is a waitlist control group that will receive the training following a 12 week no treatment period of time
9966810|NCT01263743|Experimental|This is a single arm study|Relaxation Response training will be given to all participants
9966811|NCT01263756||ASD group|Adolescents and adults with Autism Spectrum Disorders (ASDs).
9966812|NCT01263808|Experimental|Indacaterol 150 µg|Indacaterol 150 µg
9966813|NCT01263808|Experimental|Indacaterol 300 µg|Indacaterol 300 µg
9966814|NCT01263808|Experimental|Indacaterol 600 µg|Indacaterol 600 µg
9966815|NCT01263808|Placebo Comparator|Placebo|Placebo
9966816|NCT01263808|Active Comparator|Placebo/moxifloxacin|Placebo/moxifloxacin
9966817|NCT01263821|Experimental|Arm I|Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.
9966818|NCT01263834|Active Comparator|Mitomycin c|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
9966819|NCT01263834|Experimental|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
9966820|NCT01263847|Placebo Comparator|No Galactooligosaccharide|0 g galactooligosaccharide added to calcium-containing yogurt beverage
9966821|NCT01263847|Active Comparator|5 g Galactooligosaccharide|5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
9966822|NCT01263847|Active Comparator|10 g Galactooligosaccharide|10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
9966823|NCT01263860|Experimental|24-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
9966824|NCT01263860|Active Comparator|48-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
9966825|NCT01263899|Experimental|SB1518|
9966826|NCT01263912|Active Comparator|LCPUFA Supplement|DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
9966827|NCT01263912|Placebo Comparator|A Placebo|400 mg/day corn oil
9966828|NCT01263951|Experimental|Everolimus and sorafenib|All patients will receive everolimus and sorafenib daily.
9966829|NCT01263964||stroke, troponin elevation|Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
9966830|NCT01263964||non-stemi (controll group)|Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
9966831|NCT01263977|Experimental|Thermodilution controlled volume management|Volume management based on parameters: GEDI, ELWI, CI
9966832|NCT01263977|Active Comparator|Volume management based on surviving sepsis campaign|volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2
9966833|NCT01263990|No Intervention|Nexfin|Nexfin is used in all patients
9966834|NCT01264003|Active Comparator|1|Antibiotic prohylaxis / Lichtenstein repair
9966835|NCT01264029|Experimental|Group A|Movement meditation for 2 hours
9966836|NCT01264029|Active Comparator|Group B|Non-moving sitting meditation for 2 hours
9966837|NCT01264029|Active Comparator|Group C|Mall Walking for 2 hours
9966838|NCT01264029|Active Comparator|Group D|Weekly Discussion
9966839|NCT01264042|Experimental|FeSo4|
9966840|NCT01264068|No Intervention|Insomnia control|
9966841|NCT01264068|Experimental|Suan Tsao Jen Tang|
9966842|NCT01264068|Experimental|Jia-Wey Shiau-Yau San|
9966843|NCT01264120|Experimental|Health Psychology Intervention|A 50 minute health psychology behavioural intervention with sessions pre-surgery, post-surgery and at 3 month follow up.
9966844|NCT01264120|No Intervention|Control Group|The control group receive usual care through the bariatric surgery process.
9966845|NCT01264146|Active Comparator|calcaneal plating HBOT|Open reduction and internal fixation of calcaneal fracture + HBOT
9966846|NCT01264146|Placebo Comparator|calcaneal plating|Open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
10121609|NCT04384900|Experimental|Accelerated prone position|Prone position ventilation initiated as soon as possible following intubation. The patients are maintained in a prone position for 12-16 hrs daily for 5 days, unless one of the following criteria are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption. Following the five day intervention period, prone position ventilation will be continued according to the intervention in the control group
9694618|NCT04787289|Active Comparator|Higher Standard dosing as per standard regimen|bevacizumab 15mg/kg + chemotherapy
9966847|NCT01264159|Placebo Comparator|Control|
9966848|NCT01264159|Active Comparator|Lung impedence-guided treatment|
9966849|NCT01264172|Active Comparator|PCCP, Proximal femur fracture|Patients, who received a minimal-invasive surgical treatment with the PCCP-plate
9966850|NCT01264172|Active Comparator|Osteosythesis with nails, prox. femur frac.|Patients, who received a minimal-invasive surgical treatment including a osteosynthesis with nails
9966851|NCT01264172|Active Comparator|DHS, proximal femur fracture|Patients, who received a conventional surgical treatment with the dynamic hip screw (DHS)
9966852|NCT01264185||Asia--Thailand; S. America--Brazil|
9966853|NCT01264185||Africa--Zambia|
9966854|NCT01264198|Sham Comparator|Stretching Exercises|The patients will perform twice weekly home based static stretching workout.
9966855|NCT01264198|Experimental|Resistance Training|The patients will perform twice weekly supervised RT for 3 months
9966856|NCT01264211|Experimental|Diacerein|
9966857|NCT01264211|Placebo Comparator|Placebo|
9966858|NCT01264224|Experimental|PAC-14028|
9966859|NCT01264237|Experimental|Etoricoxib|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.
9966860|NCT01264237|Placebo Comparator|Placebo|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib, followed by a 4-week randomized, double-blind, placebo-controlled treatment phase, during which subjects will receive either etoricoxib or placebo.
9966861|NCT01264250|Experimental|1|
9966862|NCT01264250|Placebo Comparator|2|
9966863|NCT01264263||1|
9966864|NCT01264289|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
9966865|NCT01264289|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
9966866|NCT01264302|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
9966867|NCT01264302|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
9966868|NCT01264315|Other|Lenalidomide in maintenance|
9966869|NCT01264328|Experimental|Panitumumab + Paclitaxel|Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.
9966870|NCT01264341|Experimental|Bevacizumab combined with temsirolimus|Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly
9966871|NCT01264354|Experimental|1|Clevudine 30mg
9966872|NCT01264354|Experimental|2|Clevudine 20mg+Adefovir dipivoxil 10mg
9966873|NCT01264354|Experimental|3|Clevudine 20mg
9966874|NCT01264367|Experimental|1|Clevudine 30mg
9694619|NCT04787289|Experimental|Lower standard dosing bevacizumab plus chemotherapy|bevacizumab 7.5mg/kg + chemotherapy
9966875|NCT01264367|Active Comparator|2|Clevudine 30mg + peg-interferon 180mcg
9966876|NCT01264393|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an internet-based weight loss program, and the option of attending face-to-face group sessions
9966877|NCT01264393|Active Comparator|Shape Up Rhode Island + Online Weight Loss Program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention in addition to an internet-based weight loss program
9966878|NCT01264393|Active Comparator|Shape Up Rhode Island + Internet Resources|Participants in this arm will receive the Standard Shape Up Rhode Island statewide intervention plus access to internet resources
9966879|NCT01264406||Exercise Group (20 KKW)|Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session.
9966880|NCT01264406||Exercise Group (8 KKW)|One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per wee, which will result in each session lasting approximately 30 minutes
9966881|NCT01264406||Control group|This group will be instructed to maintain their baseline level of exercise.
9966882|NCT01264432|Experimental|Treatment (veliparib, LDRWAR)|Patients receive veliparib PO BID on days 1-21 (days 5-21 of course 1). Patients undergo LDFWAR in BID on days 1 and 5 of weeks 1-3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
9966883|NCT01264445|Experimental|Group A|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
9966884|NCT01264445|Experimental|Group B|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
9966885|NCT01264445|Experimental|Group C|Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
9966886|NCT01264445|Experimental|Group D|Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
9966887|NCT01264458||Traumatic Injury|Trauma patients arriving at Saint Mary's Emergency Department
9966888|NCT01264458||Control group|
9966889|NCT01264471||Gulf War Syndrome patients|Gulf War veterans who have been diagnosed with Gulf War Syndrome.
9966890|NCT01264484||Advantage prosthetic heart valve|All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.
9966891|NCT01264510|Other|patients implanted with a Bone-anchored hearing aid(Baha)|
9966892|NCT01264536|Experimental|Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
9966893|NCT01264536|Placebo Comparator|maltodextrin|Maltodextrin is an inert sugar.
9827676|NCT02464540|Active Comparator|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
9966894|NCT01264562||Chemotherapy group|Breast cancer patients treated with chemotherapy
9966895|NCT01264562||Non-chemotherapy group|Breast cancer patients not treated with chemotherapy
9966896|NCT01264562||Healthy controls|Women without a cancer diagnosis, matched for age and education
9966897|NCT01264575|Experimental|BPV6E1|
9966898|NCT01264575|Experimental|BPV7E1|
9966899|NCT01264575|Experimental|BPV8E1|
9966900|NCT01264575|Experimental|BPV9E1|
9966901|NCT01264575|Experimental|BPV10E1|
9966902|NCT01264575|Experimental|BPV11E1|
9966903|NCT01264575|Experimental|BPV6E2|
9966904|NCT01264575|Experimental|BPV7E2|
9966905|NCT01264575|Experimental|BPV8E2|
9966906|NCT01264575|Experimental|BPV9E2|
9966907|NCT01264575|Experimental|BPV10E2|
9966908|NCT01264575|Experimental|BPV11E2|
9966909|NCT01264588|Active Comparator|topical calcium glycerophosphate lotion|
9966910|NCT01264588|No Intervention|standard-of-care|
9966911|NCT01264627|Experimental|Mindful Breathing (MB)|"The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. No other intervention is included. No FDA drug or device is involved."
9966912|NCT01264627|Other|Usual Care (UC)|Usual Care consists of the standard care made available to participants through their primary physician. No intervention is included. No FDA drug or device is involved.
9966913|NCT01264640|Experimental|A|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
9966914|NCT01264653|Experimental|experimental group,control group|Intraocular adrenalin,topical mydriatics, experimental group: Intervention: Procedure:refractive cataract surgery with Intraocular adrenalin, control group:refractive cataract surgery with topical mydriatics
9966915|NCT01264666|Experimental|Chinese tea flavor liquor|
9966916|NCT01264666|Placebo Comparator|Water|Water combined with meal as control.
9966917|NCT01264666|Placebo Comparator|Chinese Meijiao Liquor|
9966918|NCT01264692|Experimental|Treatment A|ACT-280778
9966919|NCT01264692|Placebo Comparator|Treatment B|Placebo
10121610|NCT04384900|Active Comparator|Standard prone position|Standard of care: Prone position applied according to standard indications (severe ARDS not improving with 12-24 hours of mechanical ventilation with PaO2-to-FiO2 ratio (PAF) < 150 mmHg with FiO2 of ≥0.6, a positive end-expiratory pressure (PEEP) of ≥5 cm of water, and a tidal volume of about 6 ml per kilogram of predicted body weight). Until one of the following are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption.
10121611|NCT04384848||Chronic myeloid leukemia (CML) patients|CML patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy
10183014|NCT03768609|Experimental|Group 1: Sequence AB|Participants will receive Treatment A (pimodivir 600 milligram [mg] orally as two tablets of 300 mg each) on Day 1 in Period 1 followed by Treatment B (pimodivir 600 mg as two tablets of 300 mg each plus cyclosporine 400 mg orally as four capsules of 100 mg each) on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
10183015|NCT03768609|Experimental|Group 2: Sequence BA|Participants will receive Treatment B on Day 1 in Period 1 followed by Treatment A on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
10183016|NCT03768596|Experimental|Nudge|receiving nudge and form
10183017|NCT03768596|Active Comparator|No nudge|receiving the same form without nudge (only questions about their opinion/attitudes about vaccination)
10183018|NCT03768596|No Intervention|No intervention|receiving no nudge nor form
10183019|NCT03768583|Experimental|Group TSM ICT sneakers|"ICT with sneaker~five weeks~twice a week~half hour."
10183020|NCT03768583|Experimental|Group TSM ICT barefoot|"ICT barefoot~five weeks~twice a week~half hour."
10183021|NCT03768583|Experimental|Group TSM health barefoot|"Health with sneaker~five weeks~twice a week~half hour."
10183022|NCT03768583|Experimental|Group TSM health sneakers|"Health barefoot~five weeks~twice a week~half hour."
10183023|NCT03768557|Experimental|Minocycline|single dose of minocycline (200mg)
10183024|NCT03768557|Placebo Comparator|Placebo|lactose pills (400mg)
10183025|NCT03768531|Experimental|Arm A: Nivolumab|
10183026|NCT03768531|Experimental|Arm B: Nivolumab and Cabrilizumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes, a 30 minute rest, followed by cabiralizumab every 2 weeks. (Cycle length 2 weeks).
10183027|NCT03768479|Experimental|FES-Fulvestrant|Patients with ER positive breast cancer receive Fulvestrant as the first line treatment enrolled in the study would receive 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant.
10183028|NCT03768466|Experimental|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
10183029|NCT03768427|Experimental|EZ 10 mg/Ator 10 mg|Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
10183030|NCT03768427|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg tablets administered orally, QD for 84 days
10183031|NCT03768427|Experimental|EZ 10 mg/Ator 20 mg|Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
10183032|NCT03768427|Active Comparator|Atorvastatin 40 mg|2 atorvastatin 20 mg tablets administered orally, QD for 84 days
10183033|NCT03768401|Experimental|Educational Seminars and Wellness Clinics|"I. Community outreach educational seminars about wellness and exercise while living with a neurological physical disability and measurement of the effects of these seminars for training individuals with neurological physical disabilities and their care givers (family, therapists, community personal trainers and community funders such as Lions or Rotary Clubs) about how to create a safe cost-effective exercise program .~II. Creation and measurement of the effects of a wellness clinic for those with a neurological physical disability."
10183034|NCT03768388|Other|Fasting State|A single 600 mg dose of levoketoconazole administered in a fasting state.
10183035|NCT03768388|Other|Fed State|A single 600 mg dose of levoketoconazole administered in a fed state.
10183036|NCT03768375|Experimental|target therap|The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
10183037|NCT03768375|Experimental|FORFIRINOX|The patients wil receive conventional chemotherapy(FORFIRINOX)
10183038|NCT03768362|Experimental|Undergoing plication strabismus surgery|
10183039|NCT03768362|Active Comparator|Undergoing resection strabismus surgery|
10183040|NCT03768323|No Intervention|Control|No airtime incentive was given for completing the survey
10183041|NCT03768323|Experimental|1X incentive|1X airtime incentive
10183042|NCT03768323|Experimental|2X incentive|2X airtime incentive
10183043|NCT03768297|Experimental|immediate implant with dual zone therapeutic concept|
10183044|NCT03768297|Active Comparator|immediate implant with buccal bone fill|
10183045|NCT03768245|Experimental|Behaviour|Physical activity and the Health Education programs are applied.
10183046|NCT03768245|Active Comparator|Nutrition|In this Arm, the the Physical activity, the Health education and Nutrition program are applied.
10183047|NCT03768219|Experimental|Stage 1 (SAD) Cohort 1|6 subjects will receive 2 mcg/kg of APVO210 2 subjects will receive placebo
10183048|NCT03768219|Experimental|Stage 1 (SAD) Cohort 2|6 subjects will receive 5 mcg/kg of APVO210 2 subjects will receive placebo
10183049|NCT03768219|Experimental|Stage 1 (SAD) Cohort 3|6 subjects will receive 10 mcg/kg of APVO210 2 subjects will receive placebo
10183050|NCT03768219|Experimental|Stage 1 (SAD) Cohort 4|6 subjects will receive 20 mcg/kg of APVO210 2 subjects will receive placebo
10183051|NCT03768219|Experimental|Stage 1 (SAD) Cohort 5|6 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
10183052|NCT03768219|Experimental|Stage 1 (SAD) Cohort 6|6 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
10183053|NCT03768219|Experimental|Stage 1 (SAD) Cohort 7|6 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
10183054|NCT03768219|Experimental|Stage 1 (SAD) Cohort 8|6 subjects will receive 320 mcg/kg of APVO210 2 subjects will receive placebo
10183055|NCT03768219|Experimental|Stage 2 (MAD) Cohort 9|8 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
10121612|NCT04384991|Experimental|HU007 Eye drop|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
10121613|NCT04384991|Active Comparator|Restasis Eye drop 0.05% (Cyclosporine)|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
10121614|NCT04384679|Experimental|Hydrophilic polymer and potassium ferrate powder|Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved
10121615|NCT04384679|No Intervention|Direct pressure with sterile gauze|Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved
10121616|NCT04384926||Cohort 1|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery completed during the COVID-19 pandemic
10121617|NCT04384926||Cohort 2|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery delayed or cancelled during the COVID-19 pandemic
10121618|NCT04385030|Active Comparator|ETCC Active associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
10121619|NCT04385030|Sham Comparator|ETCC simulated associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
10121620|NCT04385043|Experimental|plasma-hyperimmune|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with plasma hyperimmune add on to the standard therapy
9668964|NCT04486352|Experimental|Atezolizumab and Talazoparib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with tumors that have a ≥16%genomic loss of heterozygosity (LOH) will be assigned to this cohort. Twenty patients will be enrolled. Once twenty patients are enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
10121621|NCT04385043|Active Comparator|standard therapy|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with the standard therapy
10121622|NCT04384718||Medea Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at IRCCS Medea
10121623|NCT04384718||Asur Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at Asur Marche
10121624|NCT04384718||Waiting list Group|Group of children with Developmental Dyslexia on a waiting list for treatment with Tachidino protocol at IRCCS Medea or Asur Marche
10121625|NCT04384640||Patients seated after Intra-Tympanic injection|
10121626|NCT04384666|Experimental|LY03003|LY03003 28 mg
10121627|NCT04384666|Active Comparator|Neupro 4Mg/24Hr Transdermal Patch|Neupro 4 mg / 24 Hr. Transdermal Patch
10121628|NCT04384562|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 20 mg methylphenidate 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
10121629|NCT04384562|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 4 mg reboxetine 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
10121630|NCT04384562|Experimental|Cholinergic receptor agonist|Participants in the cholinergic receptor agonist group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a gum with 2 mg of nicotine.
10121631|NCT04384562|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
10121632|NCT04384588|Experimental|Cancer patients with COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
10121633|NCT04384588|Experimental|Cancer patients with COVID 19 infection and risk factors|All patients will be treated with 1 or more convalescent plasma units
10121634|NCT04384588|Experimental|Non-Cancer patients COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
10121635|NCT04384588|Experimental|Non-cancer patients COVID 19 (+) and risk factors|All patients will be treated with 1 or more convalescent plasma units
10121636|NCT04384549|Experimental|BCG Arm|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
10121637|NCT04384549|Placebo Comparator|PLACEBO Arm|One intradermal placebo injection.
10121638|NCT04384614||COVID (+)|Patients COVID19(+) confirmed by PCR
10121639|NCT04384614||COVID (-)|Patients COVID19 (-) who had been in contact with COVID-19 (+) confirmed by PCR
10121640|NCT04384536|Experimental|Neural therapy group|Neural therapy group underwent local anesthetics injections by the same physician. Local injections, segmental injections and injection of trigger points of the forearm are done. The patients are evaluated at the beginning of the study and after 4 weeks of follow-up. Pre and post-treatment visual analog scale and Duruöz Hand Index scores are obtained.
10121641|NCT04384536|No Intervention|Control group|Control group used thumb spica splint and had rest
10121642|NCT04384380|Experimental|HCQ in adult Patients with COVID-19|The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
10121643|NCT04384380|No Intervention|standard of care treatment (SOC)|The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.
10121644|NCT04384432|Experimental|Routine Physical Therapy with Thoracic mobility exercise|Combination of Routine Physical Therapy with Thoracic mobility exercise.
9966920|NCT01264692|Other|Treatment C|Amlodipine
10121645|NCT04384432|Active Comparator|Routine Physical Therapy|Routine Physical Therapy exercise
10121646|NCT04384653|Experimental|Treatment A|Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 1 and IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 2
10121647|NCT04384653|Experimental|Treatment B|IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 1 and Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 2
10121648|NCT04384315||EVRF|Patients that have undergone Endovenous Radio Frequency® (EVRF®) from F Care Systems (Belgian) for the treatment of primary great and short saphenous vein reflux.
10121649|NCT04384367|Experimental|Rizatriptan 10mg+ Naproxen 550mg|Rizatriptan 10mg+ Naproxen 550mg
10121650|NCT04384367|Active Comparator|Maxalt 10mg|Rizatriptan10mg
10121651|NCT04384367|Active Comparator|Flanax 550mg|Naproxen 550mg
10121652|NCT04384367|Placebo Comparator|Placebo|Placebo
10121653|NCT04384731|Experimental|Surfactant arm|patient receiving the surfactant
10121654|NCT04384731|No Intervention|Control arm|patient not receiving the surfactant
10121655|NCT04384328|Experimental|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
10121656|NCT04384328|No Intervention|Standard Care|Standard follow-up within the RPSOF-ASNR network, without systematic speech therapy sessions.
10121657|NCT04384289|No Intervention|''Standard Care''|''Standard Care'' group were given standard care services.
10121658|NCT04384289|Experimental|"Transitional Care Model"|"Transitional Care Model group were given care based on the Transitional Care Model until the post discharge 9th week starting from date of hospitalization."
10121659|NCT04384471||People living with Type 1 Diabetes|People from all ages living with type 1 diabetes in the Province of Quebec
10121660|NCT04384510||Patients with placenta accreta spectrum (PAS)|This cohort presents patients who were suspected or diagnosed either antenatal or intrapartum with placenta accreta spectrum
10121661|NCT04384601|Experimental|SOX Chemotherapy|"Three preoperative and three postoperative cycles of SOX chemotherapy~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
10121662|NCT04384601|Active Comparator|FLOT Chemotherapy|"Four preoperative and four postoperative cycles of FLOT chemotherapy~A cycle consist of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
10121663|NCT04384458|Active Comparator|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with with 20 milligrams twice on day of active zinc for 45 consecutive days
10121664|NCT04384458|Active Comparator|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
10121665|NCT04384263|Experimental|Tai Chi group|"During the 12-week online Tai Chi intervention, participants in the Tai Chi group will attend live online Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 45 minutes/session for 12 weeks. The participants will also practice Tai Chi offline between sessions using instructional videos that will be shared with them at the end of each live online Tai Chi session.~Participants in the Tai Chi group will be instructed: 1) to maintain their regular level of physical activity outside of the live online Tai Chi exercise sessions and offline Tai Chi exercise, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
10121666|NCT04384263|No Intervention|control|"Participants in the control group will perform only their regular habitual daily activities throughout the 12 weeks of intervention period.~Participants in the control group will be instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
10121667|NCT04384211||Radiologists|A computer search of CT scans (2010.01.01-2018.09.30) was performed in Wan Fang Hospital. These CT images were retrospectively reviewed by an experienced radiologist who classified and marked with annotations of vertebral fractures by the Genant's semiquantitative method.
10121668|NCT04384211||Smart Bone|The same CT images were separately reviewed and processed by the artificial intelligence system (Smart Bone) by Quanta for compression fractures. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
10121669|NCT04384081|Experimental|Dose group 1|
10121670|NCT04384081|Experimental|Dose group 2|
10121671|NCT04384081|Experimental|Dose group 3|
10121672|NCT04384081|Placebo Comparator|Placebo group|
10121673|NCT04384003|Active Comparator|Shear Wave Ultrasound Elastography|Shear Wave Ultrasound Elastography (SWUE, AplioTM 300 Platinum, Toshiba Medical System Corp, Japan, 6I) to examine the morphology and mechanical properties (μ = ρVs2, μ is the shear modulus of the tissue, ρ is the density of muscle (1000 kg m-3), Young's modulus )
10121674|NCT04384003|Active Comparator|The 3-D Motion Analysis|
10121675|NCT04384003|Active Comparator|EMG acquisition system|
10121676|NCT04384003|Active Comparator|Foot intrinsic muscle assessment and training device|"Schematic diagram of the novel modified foot intrinsic muscle (FIM) assessment and training device, which consists of one controller unit (signal generators, amplifier and A/D converter; signal generators provide noise-enhanced vibration to facilitate the muscle activation), 2 voice coil motor & server, 2 optical rulers, 2 rail scale, and 7 load cells.~The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing and kicking."
9694620|NCT04787224||infected sockets|Signs of infection were periapical radiolucency only in 3 sites (2 patients), fistula in 2 sites (2 patients), sinus in 11 sites (7 patients) and finally swelling in 3 sites (2 patients)
10121677|NCT04384237|Experimental|Er,Cr:YSGG laser-aided CSF|Experimental: Er, Cr: YSGG laser-aided Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment of the orthodontic treatment by inserting the laser tip at an angle of 10-15º to the radicular surface
10121678|NCT04384237|Active Comparator|Conventional CSF|Fiberotomy comparator: this arm is going to receive a blade conventional Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment by inserting a surgical blade into the gingival sulcus at an angle like that in the laser-aided CSF.
10121679|NCT04384042||Malaysian COVID-19 Cohort (Cases)|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
10121680|NCT04384042||Healthy Volunteers (Controls)|A cohort of age and sex-matched healthy volunteers will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
10121681|NCT04384133|Other|COPD group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. To assess symptom control in patients with COPD, a dyspnea scale of mMRC will be administered. The COPD assessment test (CAT) will be applied to measure the quality of life. All participants will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for COPD.
10121682|NCT04384133|Other|Healthy control group with a history of smoking|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
10121683|NCT04384133|Other|Healthy control group with no smoking history|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
10121684|NCT04384120|Experimental|Rotator Cuff Rehabilitation Using BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation using blood flow restriction cuffs.~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy using blood flow restriction cuffs.~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy using blood flow restriction cuffs."
10121685|NCT04384120|Active Comparator|Rotator Cuff Rehabilitation Without BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation without using blood flow restriction cuffs.~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy without using blood flow restriction cuffs.~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy without using blood flow restriction cuffs."
10121686|NCT04383990|Active Comparator|Early Glargine|To take insulin Glargine at 6-7 pm
10121687|NCT04383990|Active Comparator|Late Glargine|To take insulin Glargine at 10-12 pm
10121688|NCT04383964|Experimental|Transport distraction osteogenesis|"Locally made and designed submerged monodirectional in the vertical (Y) axis distractor was used.~A transport disc is created at the remaining stump of the RCU with an L shaped osteotomy.~The prepared disc is to be wide enough to fit the upper portion of the distrcator.~The submerged distractor will be placed in a position to guide the transport disc moving up and backwards toward the glenoid fossa.~The length of the distractor is determined according to the amount of distraction planned to reach the glenoid fossa."
10121689|NCT04384016|Experimental|Evaluating the Safety of Skyvaricella Inj.|"The main target:~• Evaluating the safety of Live Attenuated Varicella Vaccine SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection"
10121690|NCT04384016|Experimental|Evaluating the Immunogenicity of Skyvaricella Inj.|"Secondary target~• Evaluating the immunogenicity of Live Attenuated Varicella Vaccine SKYVaricella injection in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
10121691|NCT04384185|Experimental|Group A: Exercise therapy|Group A: will perform an exercise protocol to improve the stability of the spine muscle of low-back
10121692|NCT04384185|Experimental|Group B. Manual therapy and exercises|Group B: Will be treated with manual therapy in the diaphragm muscle and the same protocol of therapeutic exercise applied in group A
10121693|NCT04384224|Placebo Comparator|sham acupuncture + placebo tablet group|sham acupuncture point + placebo tablet
10121694|NCT04384224|Experimental|true acupuncture + placebo tablet group|true acupuncture point + placebo tablet
10121695|NCT04384224|Experimental|true acupuncture + antihistamine group|true acupuncture point + Dexchlorpheniramine (4 mg)
10121696|NCT04384224|Sham Comparator|sham acupuncture + antihistamine group|sham acupuncture point + Dexchlorpheniramine (4 mg)
10121697|NCT04384094||Test subjects|Test subjects according to the inclusion / exclusion criterias.
10121698|NCT04383977|Experimental|Apatinib-Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
10121699|NCT04383977|Active Comparator|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
10121700|NCT04384068||Chinese RA patients|Chinese RA patients who used tocilizumab in real world clinical practice
10121701|NCT04384198|Experimental|Sonolysis group|Cerebral hemisphere with sonolysis during MitraClip implantation.
10121702|NCT04384198|No Intervention|Control group|Cerebral hemisphere without sonolysis during MitraClip implantation.
10121703|NCT04383912|Experimental|onabotulinum toxin A group (brow)|"Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC~Description: The side randomized to treatment will receive an injection of 20 units of onabotulinum toxin A as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
10121704|NCT04383912|Placebo Comparator|placebo group (brow)|"Product name: normal saline~Description: The side randomized to placebo will receive an injection of normal saline as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
10121705|NCT04383860|Experimental|5-0 suture|5-0 suture administration during surgery
10121706|NCT04383860|Active Comparator|4-0 suture|4-0 suture administration during surgery
10121707|NCT04383899||Case patient|Patients from the cohort with severe coronavirus infection necessitating intensive care (artificial ventilation) with ulterior recovery or fatal outcome.
10121708|NCT04383899||Control patient|All patients from the cohort with non-severe coronavirus infection, who were not admitted to hospital or who were admitted to hospital but without the need for intensive care, and who recovered.
10121709|NCT04383886||Emergency department staff|
10121710|NCT04383795||Graves' disease patients|First diagnosed Graves' disease patients volunteered for stool collection
10121711|NCT04383925|Experimental|BCG-Japan|Infants randomized to receive BCG-Japan at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Japan (Tokyo BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination.
10121712|NCT04383925|Active Comparator|BCG-Russia|Infants randomized to receive BCG-Russia at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
10121713|NCT04383782|Active Comparator|Expectancy Challenge|The expectancy challenge intervention will involve two brief videotaped testimonials in which former smokers discuss their experiences with smoking-related health conditions. Participants will be encouraged to reflect back on the content of each video once per week leading up to the follow-up assessment.
10121714|NCT04383782|Experimental|Expectancy Challenge + Behavioral Activation|In addition to the expectancy challenge intervention (see Expectancy Challenge condition), participants in the Expectancy Challenge + Behavioral Activation group will also receive a novel behavioral activation intervention. Participants will be presented with brief psychoeducation about behavioral activation, several examples of possible functions of cigarette smoking, and several suggestions of behavioral strategies. All participants will receive the same information, but they will be encouraged to apply the information to their personal circumstances and to consider additional examples of rewarding activities they may engage in over the next four weeks. Participants will also be encouraged to engage in at least one behavioral activation activity each week leading up to the follow-up assessment.
9668965|NCT04486352|Experimental|Atezolizumab and Trastuzumab emtansine (TDM-1) Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with tumors that with an amplification of ERBB2/HER2 will be assigned to this cohort. Twenty patients will be enrolled. Once twenty patients are enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
9668966|NCT04486352|Experimental|Atezolizumab and Tiragolumab Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with tumor type MSI-H and/or tTMB >=10 mut/mb will be assigned to this cohort. Twenty patients will be enrolled initially. Once twenty patients are enrolled, the cohort may be expanded if a positive signal is shown. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
9668967|NCT04482751||Infertile women|the group consists of 80 infertile patients undergoing IVF
9694621|NCT04787224||Non infected sockets|This is ensured by the absence of any clinical signs and symptoms of infection in addition to negative radiographic findings
10121715|NCT04383782|Placebo Comparator|Neutral Reading|The control group will receive neutral reading materials related to the components and structure of a cigarette. The content will be strictly curated so as to avoid inadvertently encouraging or discouraging smoking among participants.
10121716|NCT04383678||COVID-19 positive patients|
10121717|NCT04383691|Experimental|Lurasidone|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
10121718|NCT04383691|Placebo Comparator|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
10121719|NCT04383535|Experimental|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma, in addition to standard care.
10121720|NCT04383535|Placebo Comparator|Placebo|Single infusion of saline solution, in addition to standard care.
10121721|NCT04383769||5,000 participants:|"2,500 are PLHIV receiving standard care in the hospital and 2,500 are PLHIV receiving care in DSD-ART model~Inclusion criteria:~Thai citizenship~Age ≥ 18~HIV positive~Received ART for at least 6 months at a participating hospital (Except for After hour ART clinic model that will allow participants who receive ART less than 6 months into service)~One of the following:~Accept DSD-ART, OR~Already receiving DSD-ART, OR~Decline DSD-ART and will continue standard ART service at the hospital."
10121722|NCT04383613|Experimental|PRONE POSITIONING|Patients in this arm will be instructed to lie on their stomach while they are in bed for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for >24 hours or study outcome.
10121723|NCT04383613|No Intervention|STANDARD OF CARE|Patients in this arm are not specifically instructed to lie on their stomach while they are in bed.
10121724|NCT04383730||Usual practice of intravenous sedation|The choice of the intravenous sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center
10121725|NCT04383730||Usual practice of inhaled sedation|The choice of the inhaled sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center.
10121726|NCT04383717|Active Comparator|Proposed treatment group|Levamisole and isoprinosine
10121727|NCT04383717|Active Comparator|Control group|hydroxychloroquine and azithromycin
10121728|NCT04383405|Experimental|Sequential Preparotory Approach|
10121729|NCT04383405|Active Comparator|Conventional|
10121730|NCT04383600|No Intervention|Conventional side|Canine retraction was commenced without micro-osteoperforations.
10121731|NCT04383600|Experimental|Mops side|Canine retraction was commenced with micro-osteoperforations.
10183056|NCT03768219|Experimental|Stage 2 (MAD) Cohort 10|8 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
9966921|NCT01264731|Active Comparator|peptide vaccine plus imiquimod|Peptide Vaccine: Days 1, 8, 15, 36, 57, 78 Imiquimod: Applied daily on days 1-85.
10121732|NCT04383704|Experimental|calorie-restricted modified MIND diet|This arm received instruction in modifying the content of their diet to meet MIND pattern guidelines.
10121733|NCT04383704|Active Comparator|calorie-restricted standard control diet|They instructed to calorie-restricted diet alone.
10121734|NCT04383483||CoVID patients admitted to ICU|Patients admitted to the intensive care unit with the diagnosis of COVID
10121735|NCT04383561|Active Comparator|stage 3 periodontitis|GCF and serum samples were collected before and after treatment from periodontitis patients.
10121736|NCT04383561|Placebo Comparator|Periodontally healthy controls|GCF and serum samples were collected from periodontally healthy controls at baseline for once.
9827677|NCT02464540|Active Comparator|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
9966922|NCT01264731|Active Comparator|Imiquimod|Imiquimod: Applied daily on days 1-85.
10121737|NCT04383652||Adult cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~Age 16 years or older~Have provided informed consent~Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
10121738|NCT04383652||Paediatric cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)~Age less than 16 years~Parent or caregiver has provided informed consent Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
10121739|NCT04383236|Experimental|ChocBalls|(L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
10121740|NCT04383236|Active Comparator|Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt)|"Each 100 g contains:~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g."
10121741|NCT04383366||Patients with keratoconus|
10121742|NCT04383496|Experimental|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
10121743|NCT04383470||General population, during COVID pandemic|General population during COVID-19 pandemic. Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
10121744|NCT04383470||General population, 6 months after COVID pandemic|General population, 6 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
10121745|NCT04383470||General population, 12 months after COVID pandemic|General population, 12 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
10121746|NCT04383223|No Intervention|YLH Historical Control Group|"Participants in this group will have the following phases:~Screening~Single visit assessment"
10121747|NCT04383223|Experimental|YLH iTransition Intervention Group|"Participants in this group will have the following phases:~Screening~Baseline Visit~Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3 and 9 month"
10121748|NCT04383223|Experimental|Provider Group|"Participants in this group will have the following phases:~Screening~Baseline Visit~Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3, 9 and 15 month"
10121749|NCT04383223|Experimental|Transition Champion Group|"Participants in this group will have the following phases:~Screening~Baseline Visit and Follow-Up visits at 6, 12 and 18 month~Interview visits for selected YLH around 3, 9 and 15 month"
10121750|NCT04383418|Experimental|High dose group|In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.
10121751|NCT04383418|Experimental|Low dose group|In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.
10121752|NCT04383418|Placebo Comparator|Placebo group|In the placebo group，36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
10121753|NCT04383548|Experimental|Hyper immunoglobulins have anti-Corona VS2 immunoglobulin|safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients
10121754|NCT04383353||Cancer arm|Participants with new diagnosis of cancer, from whom a blood sample and contemporaneous tissue samples will be collected.
10121755|NCT04383353||Benign disease arm|Participants with benign diseases corresponding to the tumor types in the cancer arm, from whom a blood sample and contemporaneous tissue samples will be collected.
10121756|NCT04383353||Non-tumor arm (Healthy)|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
10121757|NCT04383301|Active Comparator|Intra corneal ring segment|Intra corneal ring segment implantation for moderate keratoconus patients
10121758|NCT04383301|Active Comparator|Corneal Wavefront-guided TPRK and ACXL|Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking following intracorneal ring segment by at least three months
10121759|NCT04383158|Active Comparator|PRGF extraction sockets (Test)|Immediately after dental extraction, the socket will be filled with Plasma Rich in Growth Factors (ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16))
10121760|NCT04383158|No Intervention|Unassisted extraction sockets (Control)|Dental extraction sockets to be left to heal spontaneously unassisted.
10121761|NCT04383392|Experimental|Rate adaptive pacing|Turn on Rate adaptive pacing
10121762|NCT04383392|Active Comparator|No Rate adaptive pacing|Turn off Rate adaptive pacing
10121763|NCT04383184||TRACHEAL FORMING GROUP|Left pulmonary artery transplantation and slide tracheoplasty
10121764|NCT04383184||NON-TRACHEAL FORMING GROUP|only Left pulmonary artery transplantation
10121765|NCT04383197|Experimental|Semaglutide treatment|3 months of therapeutic semaglutide treatment
10121766|NCT04383197|Experimental|Semaglutide and Endurance exercise|12 weeks of endurance exercise concomitant to semaglutide treatment
10121767|NCT04383197|Experimental|Endurance exercise|12 weeks of endurance exercise
10121768|NCT04383054|Experimental|Long PA intervention group|The long PA intervention will be a MI (motivational interview) exploring the participant's knowledge and concerns about PA. An MI involves a semi-structured discussion between an investigator and the participant. The MI initially explores the participant's knowledge of the benefits of PA and their concerns about PA. The MI will then explore the participant's confidence in increasing their PAL, help the participant come up with a plan to increase their PAL and finally the participant will be signposted to further support and local opportunities for PA. The investigator will use a Moving Medicine 'more minutes' conversation tool of a chronic health condition that the patient has to facilitate every MI. Where possible the investigator will discuss the chronic condition that most relates to the participant's current admission to hospital. For patients with no health conditions the primary prevention section will be used.
10121769|NCT04383054|Active Comparator|Short PA intervention group|The short PA intervention will involve a short (1 min) discussion between an investigator and a participant. A Moving Medicine 'one minute' intervention appropriate to the participant's health conditions will be used to guide every short intervention. The short intervention will firstly involve the investigator asking whether the participant knew that doing PA was beneficial for their health. The investigator would then explain to be more PA they could try to build more PA into their daily routine and that this was often enough to meet the current PA recommendations. The investigator will also offer the participant a patient information sheet about PA.
10121770|NCT04383093||Combination Therapy|"Patients initial assessment included age, waist circumference, blood pressure, clinical laboratory parameters, digital rectal examination. LUTS were evaluated with total IPSS, focusing also on storage, voiding IPSS sub-scores, and IPSS QoL, and Overactive Bladder questionnaire (OAB-q), while ED with IIEF-515. Each patient underwent uroﬂowmetry and postvoid residual volume (PVR) was measured with abdominal ultrasound immediately after voiding. All patients reporting any intake of therapies for LUTS or ED underwent a 4 weeks treatment-free washout period.~All subjects were treated with tadalafil 5 mg/die plus tamsulosin 0.4 mg/die for 12 weeks. The medications were self-administered every day at the same time, before the night rest, without any limitations or variations of sexual activity timing or food intake. Patients were re-evaluated after 12 weeks of treatment with Uroflowmetry and PVR, IPSS, IPSS QoL, OAB-q and IIEF-5"
10121771|NCT04383249||Pathology result|Pathology result of the hernia sac
10121772|NCT04382742|Experimental|Exercise|
10121773|NCT04382781||COVID-19 infection|Consecutive patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who showed clinical and analytical data suggestive of macrophage activation syndrome during admission until March 30, 2020 .
10121774|NCT04382768|Experimental|Luarprofen|Inhaled Hypertonic ibuprofen 50 mg tid
10121775|NCT04382716||PANS participants|
10121776|NCT04383275|Experimental|IRIS-A|
10121777|NCT04383275|Experimental|IRIS-B|
10121778|NCT04383080|Experimental|Low-level laser therapy|Low-level laser irradiation on specific acupuncture points
10121779|NCT04383080|Active Comparator|Acupuncture therapy|Dry needle inserting specific acupuncture points
10121780|NCT04383080|Placebo Comparator|Placebo low level laser therapy|Low-level laser irradiation on specific acupuncture points for placebo control
10121781|NCT04382794||DMT2 COVID19 positive patients treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
10121782|NCT04382794||DMT2 COVID19 positive patients not treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes not treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
10121783|NCT04382846|Experimental|Nitazoxanide|Nitazoxanide with standard protocol of treatment
10121784|NCT04382846|No Intervention|Control group|Standard protocol alone
10121785|NCT04383067|Experimental|Tumor Infiltrating Lymphocytes (TIL)|
10121786|NCT04383041||Patients with Type 2 Diabetes|Patients with Metformin containing prescription drugs will be eligible for participation and consecutively invited to study participation in their pharmacy.
10121787|NCT04382989||Mothers of extremely preterm infants|(gestational age < 28 weeks)
10121788|NCT04382989||Mothers of very preterm infants|(gestational age 28 - 31 weeks)
10121789|NCT04382989||Mothers of moderate and late preterm infants|(gestational age 32 - 36 weeks)
10121790|NCT04382989||Mothers of term infants|(gestational age ≥ 37 weeks)
10121791|NCT04382950|Experimental|Experimental: rbACE2 group plus Aerosolized Isotretinoin|rbACE2 0.4 mg/kg IV BID for 7 days (unblinded) plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
10121792|NCT04382950|No Intervention|No Intervention: Control group|Standard of care; no placebo
10121793|NCT04382703|Experimental|Intervention|Given the associated questionnaire which has the embedded self-affirmation exercise.
10121794|NCT04382703|Active Comparator|Control|Given the associated questionnaire without the embedded self-affirmation exercise.
10121795|NCT04382859|Active Comparator|TAP block with liposomal bupivacaine|Active comparator
10121796|NCT04382859|Other|TAP block with 0.25% bupivacaine|Standard comparator
10121797|NCT04382833|Experimental|HOT APPLICATION GROUP|Thermoforming, one of the dry hot application methods, was performed on the sacral (S1-S4) vertebrae region of pregnant women in the hot application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). Thermoforming was applied by wrapping it with a towel to protect pregnant women from the direct effect of its hot surface. The mean water temperature used in thermoforming was 50C. The water temperature was measured using a liquid thermometer. When 50°C water was subjected to hot application, the surface temperature reached around 40°C. The hot application was carried out continuously for 20 min.20 The body temperature of the pregnant women was evaluated before the application.
9966923|NCT01264757|Active Comparator|Education|Educational brochure about physical activity provided.
10121798|NCT04382833|Experimental|MASSAGE GROUP|Massage using effleurage and friction techniques was applied to the 4-5 cm right and left lateral parts of the midline on the sacral (S1-S4) vertebrae region of pregnant women in the massage application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). The massage application was carried out continuously for only 10 min because it was thought to cause irritation to the area where it was practiced.
10121799|NCT04382833|No Intervention|CONTROL GROUP|
10121800|NCT04382677|Experimental|Promoting First Relationships|The PFR program designed for birth families being reunited after foster care placement consists of a manualized 12-session intervention delivered in the home by trained providers.
10121801|NCT04382677|Other|Resource & Referral|The service consists of a needs assessment conducted by phone, followed by a personalized resource packet and referrals, and 3 monthly check-in phone calls.
10121802|NCT04382560|Experimental|Intervention group|The intervention group will receive a Deep Breathing Training and a Compassion Intervention. Deep Breathing Training and Compassion Intervention will be administered once, on two consecutive days, and will last for 30 minutes.
9966924|NCT01264757|Experimental|Pedometer|A pedometer was provided in addition to educational materials.
10121803|NCT04382560|No Intervention|Wait-list control group|The waiting list group will receive the intervention at the end of the study.
10183057|NCT03768219|Experimental|Stage 2 (MAD) Cohort 11|8 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
10183058|NCT03768219|Experimental|Stage 2 (MAD) Cohort 12|8 subjects will receive 360 mcg/kg of APVO210 2 subjects will receive placebo
10183059|NCT03768219|Experimental|Expansion Cohort (Psoriasis)|"12 subjects will receive the starting dose for the Psoriasis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
10183060|NCT03768219|Experimental|Expansion Cohort (Ulcerative Colitis)|"12 Subjects will receive the starting dose for the Ulcerative Colitis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
10183061|NCT03768193|Experimental|Deep serratus anterior plane block|Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
10183062|NCT03768193|Active Comparator|Surgically-placed paravertebral block|Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
10183063|NCT03768167|Other|patients with metastatic spinal lesions|corpectomy
10183064|NCT03768154|Experimental|study arm|all patients will receive all four intervention in the same sequential method
10183065|NCT03768141||Liver surgery|Any type of liver surgery
10183066|NCT03768050|Active Comparator|Advanced care for frail elderly|Integrated care program for frail elderly covering Home Hospitalization/Early Discharge; geriatric residences and; home-based case management done by dedicated teams specialised in geriatric medicine
10183067|NCT03768050|No Intervention|Standard care|Usual care at the community and geriatric residences by primary care physicians
9966925|NCT01264783|Experimental|RNS60|RNS60
10183068|NCT03768037|Experimental|Anlotinib plus Pemetrexed|Anlotinib plus Pemetrexed
10183069|NCT03768037|Other|Pemetrexed|Pemetrexed
10183070|NCT03768024|Experimental|Treatment A: GRT0151Y 100 mg|Treatment A: GRT0151Y 100 mg free base: 2 × GRT0151Y 50 mg capsules and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
10183071|NCT03768024|Experimental|Treatment B: GRT0151Y 200 mg|Treatment B: GRT0151Y 200 mg free base: 4 × GRT0151Y 50 mg capsules and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
10183072|NCT03768024|Experimental|Treatment C: GRT0151Y 400 mg|Treatment C: GRT0151Y 400 mg free base: 8 × GRT0151Y 50 mg capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
10183073|NCT03768024|Experimental|Treatment D: Matching placebo|Treatment D: Matching placebo to GRT0151Y and hydromorphone IR: 8 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
10183074|NCT03768024|Experimental|Treatment E: Hydromorphone IR 4 mg|Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
10183075|NCT03768024|Experimental|Treatment F: Hydromorphone IR 8 mg|Treatment F: Hydromorphone IR 8 mg: 2 × hydromorphone IR 4 mg tablet (encapsulated) and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
10183076|NCT03768024|Experimental|Treatment G: Hydromorphone IR 16 mg|Treatment G: Hydromorphone IR 16 mg: 4 × hydromorphone IR 4 mg tablet (encapsulated) and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
10187618|NCT03724448|Placebo Comparator|placebo group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
9966926|NCT01264783|Placebo Comparator|Placebo|Placebo
9966927|NCT01264796|Experimental|behavioral intervention, counseling|2hr group education for 6 weeks
9966928|NCT01264796|No Intervention|delyed intervention|control group
9966929|NCT01264809|Experimental|A : immediate physical activity counseling|Participants randomized in the experimental group (group A) will receive physical activity counseling during a one-to-one consultation at both baseline and 3 months.
9966930|NCT01264809|Active Comparator|B : later physical activity counseling|Exercise consultation will be realised only at 3 months in the control group(group B). Furthermore, patients of group B will not received any physical activity counseling at baseline.
9966931|NCT01264822||Treatment Arm 1 Rabeprazole Sodium|
9668968|NCT04478019|Other|Control > Active Intervention|Treatment is 3 weeks of standard personal protective equipment without any povidone-iodine (PI) or chlorhexidine gluconate (CHG) intervention (control), followed by a 2 weeks washout period, and 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures.
9966932|NCT01264848|Experimental|Balloon angioplasty and/or stenting|Balloon angioplasty and/or stenting of stenosed internal jugular vein and/or azygous vein and/or brachiocephalic vein
9966933|NCT01264861|Experimental|Arm 1:|Arm 1: Eligible subjects will receive escalating doses of safinamide for the 6-week duration of treatment. Each dose level will be last 10-14 days. Doses 200mg and 300mg will have a 3 day intermediate step up dose, 150mg and 250mg dose.
9966934|NCT01264874|Experimental|Vitamin D3|Vitamin D3 administration
9966935|NCT01264874|Placebo Comparator|placebo|matched placebo
9966936|NCT01264900|Experimental|Cognitive Behavioral Therapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment
9966937|NCT01264900|Active Comparator|Supportive Psychotherapy|Twelve weekly 50-minute sessions of individual supportive (client-centered) psychotherapy
9976562|NCT01352832|Experimental|Interactive DVD|"Patients randomized to this arm will receive a DVD DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
9976563|NCT01352832|Placebo Comparator|Usual Care|Patients randomized to this arm receive their usual care.
9976564|NCT01352858|Experimental|TolDC|Experimental arm - TolDC administered arthroscopically
9976565|NCT01352858|Placebo Comparator|Control|Arthroscopy & saline irrigation alone
9976566|NCT01352871||Concentration / meditation|The subject will try to influence the innate immune response by concentration / meditation in advance of and during endotoxemia
9976567|NCT01352884|Experimental|Stage 1|Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
9976568|NCT01352884|Experimental|Stage 2|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood specimens will be evaluated for pharmacodynamic markers/activity at specified timepoints throughout the study.
9976569|NCT01352910|Experimental|effective rTMS|
9976570|NCT01352910|Sham Comparator|Sham rTMS|
10121804|NCT04382729|Experimental|NMES Group|
9976571|NCT01352923|Experimental|peripheral blood|healthy voluntary donors
9976572|NCT01352936||Experimental Group|
9976573|NCT01352936||Control Group|
9976574|NCT01352988|Experimental|Fumaric acid esters|
9976575|NCT01353001|Experimental|Diet Only|
9976576|NCT01353001|Experimental|Diet plus Aerobic Training|
9976577|NCT01353001|Experimental|Diet plus Resistance Training|
9976578|NCT01353014|Experimental|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genetic information.
9976579|NCT01353014|Active Comparator|General dietary recommendations|This group will receive general dietary recommendations for caffeine, vitamin C, sugar and sodium from recognized health institutions (caffeine: Health Canada; sugar: the World Health Organization; vitamin C and sodium: the Institute of Medicine).
9976580|NCT01353027|Placebo Comparator|Placebo|
9976581|NCT01353027|Experimental|AVI-6002|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
9976582|NCT01353040|Experimental|AVI-6003|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
9976583|NCT01353040|Placebo Comparator|Placebo|Normal saline
9976584|NCT01353053||Tacrolimus, Everolimus|Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.
9976585|NCT01353066|Active Comparator|Intensive Medical Treatment|
9976586|NCT01353066|Experimental|Intensive medical treatment (IMM)+RYGBP|
9976587|NCT01353092|Experimental|Active PEMF twice daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
9976588|NCT01353092|Active Comparator|Active PEMF once daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
9976589|NCT01353105|Experimental|Ex vivo lung transplantation|single-group studies
9976590|NCT01353131||ECG Screening|1000 patients with moderate to high risk determined by stratification algorithm based on the electronic analysis of 69,088 routine 12-lead ECGs performed in a large medical institution during a 6 month period by combining previously established indices of abnormal repolarization (wide QRS-T angle) with validated measures of myocardial damage (Selvester QRS score) excluding those > 70 years of age or with LV ejection fraction ≤ 35%, or at a high risk of dying within 3 years from cancer, end stage cardiac, pulmonary, renal, immunologic or neurologic diseases excluded on clinical data obtained through medical record.
9976591|NCT01353157||patients with elective cardiac surgery|
9976592|NCT01353170|Experimental|Prevalent hd patients|Patients undergoing three consecutive cross-over hd session with 3 different dialysate calcium concentrations
9976593|NCT01353183|Experimental|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
9976594|NCT01353209|Experimental|Letrozole|
9976595|NCT01353209|Placebo Comparator|Placebo|
9976596|NCT01353235|Sham Comparator|usual care|
10121805|NCT04382729|Active Comparator|Control Group|
10121806|NCT04382547|Experimental|mesenchymal stem cells|Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
10121807|NCT04382547|Active Comparator|control|Patients with Covid-19 associated pneumonia receiving standard treatment
10121808|NCT04382690||India|People residing in India
10121809|NCT04382690||United Kingdom|People residing in the United Kingdom
9668969|NCT04478019|Other|Active Intervention > Control|Treatment is 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures, followed by 2 weeks of washout, and 3 weeks of standard personal protective equipment without any PI or CHG intervention (control).
9966938|NCT01264913||Shift Workers|
9966939|NCT01264913||Day Workers|
9966940|NCT01264926||rotator cuff tear, pain|
9966941|NCT01264978|Experimental|repetitive neuromuscular stimulation|repetitive neuromuscular stimulation of the quadriceps arm are patients actively stimulated at increasing intensity to afford maximal contraction during training sessions
9966942|NCT01264991|Experimental|APM group|
9966943|NCT01264991|Placebo Comparator|Sham group|
9966944|NCT01265004||Stitches, rupture of achilles tendon|Patients, in who the achilles tendon rupture was treated with tendon surgery including a special way of stitching to preserve the sliding ability of the tendon.
9966945|NCT01265004||Fibrin-glue, rupture of achilles tendon|Patients, who received a surgical treatment including a fixing of the tendon with fibrin-glue.
9966946|NCT01265004||Stiches and Fibrin-glue|Patients, in who the achilles rupture was treated with stitches and fibrin-glue.
9966947|NCT01265017|Experimental|Active Treatment|"interventions include Estradiol, medroxyprogesterone, hydrocortisone, GH as follows~Estradiol 1mg every 8 hours administered orally~Medroxyprogesterone 2.5 mg every 24 hours administered orally~Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~Growth hormone 2 mg once a day administered by subcutaneous injection"
9966948|NCT01265017|Placebo Comparator|Placebo|Matching placebo
9966949|NCT01265030|Experimental|Sirolimus|"Preoperative sirolimus:~loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligram)~starting 24 hours after the initial loading dose, subjects will receive a dose of 4 milligram/meters2 daily; Per Os (PO), by mouth days 2 through 28"
9966950|NCT01265043|Experimental|OHI|Patients provided with oral hygiene instruction and electric toothbrush
9966951|NCT01265043|Experimental|OHI + CHX mouthrinse|Patients provided with oral hygiene instruction and Corsodyl mouthrinse
9966952|NCT01265043|Experimental|OHI + CHX mouthrinse + assisted brushing|Oral hygiene instruction, Corsodyl mouthrinse, and assisted brushing
9966953|NCT01265069|Active Comparator|high dose dual therapy|Group A - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
9966954|NCT01265069|Experimental|concomitant therapy|Group B - concomitant therapy (rabeprazole 20 mg, amoxicillin 1000 mg, metronidazole 500 mg, clarithromycin 500 mg, bid for 10 days).
9966955|NCT01265082||Patients in remission with pruritus|
9966956|NCT01265082||Patients in remission without pruritus|
9966957|NCT01265095||VRE bacteremia|VRE bacteremia patients
9966958|NCT01265108|Experimental|Intravenous iron sucrose|Infusion of 200 mg iron sucrose (Venofer) in 100 ml normal (0.9%) saline.
9966959|NCT01265108|Placebo Comparator|Intravenous normal saline|Infusion of 100 ml normal (0.9%) saline.
9966960|NCT01265121|Experimental|CPAP treatment|This acromegalic patients is going to have sleep apnea treated for 3 months with a with a continuous positive air pressure device (CPAP)
9966961|NCT01265121|Placebo Comparator|Nasal adhesive|This acromegalic patients will be treated will an external nasal dilator adhesive intended to serve as a placebo treatment
9966962|NCT01265134||Experimental Group|the healthy elders
9966963|NCT01265134||Control Group|the elders who have fallen once
9966964|NCT01265147|Active Comparator|Cisplatin|cisplatin combine with IMRT
9966965|NCT01265147|Experimental|Nedaplatin|Nedaplatin combine with IMRT
9966966|NCT01265160||the group of Jiangzhuo prescription|
9966967|NCT01265160||the group of fenofibrate|
9966968|NCT01265160||the group of placebo|
9966969|NCT01265173|Active Comparator|Cefotaxime|iv 2G q 8hrs for general, dose titration if needed (eg.CKD)
9966970|NCT01265173|Experimental|Ceftriaxone|iv 2G q 24hrs
9966971|NCT01265173|Experimental|Ciprofloxacine|iv 400mg q 12hrs for general, dose titration if needed (eg.CKD)
9966972|NCT01265186||Ventilated term newborns|Ventilated newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
9966973|NCT01265186||Control group: healthy term newborns|Control group: healthy newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
9966974|NCT01265251||Test-retest|Forty-four healthy elderly 60-82 years old
9966975|NCT01265251||Validity|Twenty six patients with various diseases and various ages
9966976|NCT01265251||Feasibility|Twenty seven patients under the preoperative investigation for INPH
9966977|NCT01265277||at home|Infants 0-3 months who will stay at home with a parent
9966978|NCT01265277||child care|Infant 0-3 months who will attend a licensed child care center
9966979|NCT01265290|Experimental|Telemetric ECG monitoring|Telemetric Full Disclosure ECG monitoring
9966980|NCT01265290|Experimental|24 hours standard Holter monitoring|
9966981|NCT01265303|Other|Catheter ablation|
9966982|NCT01265303|Other|Pacemaker implantation|
9966983|NCT01265303|Other|Pharmacotherapy|
9966984|NCT01265329|No Intervention|Control|No sperm selection
9966985|NCT01265329|Experimental|Annexine V negative|Sperm selection with Annexine V protein
9966986|NCT01265342|Placebo Comparator|Placebo|
9966987|NCT01265342|Experimental|Beclomethasone|Beclometasone suspension 400 mcg will be administered through a nebuliser twice a day, in the morning and in the evening, for 10 days
9966988|NCT01265355|Experimental|Anti-rotavirus protein|
9966989|NCT01265355|Placebo Comparator|Maltodextrin|
9966990|NCT01265368|Experimental|Study medication|
9966991|NCT01265381||Cohort of Chernobyl Cleanup Workers in Ukraine|Thyroid cancer cases and matched controls in the cohort
9976597|NCT01353235|Active Comparator|Prednisolone|1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
10121810|NCT04382690||China|People residing in China
10121811|NCT04382690||Australia|People residing in Australia
9966992|NCT01265433|Experimental|WT-1-vaccine Montanide + GM-CSF|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
9966993|NCT01265433|Active Comparator|Montanide adjuvant + GM-CSF (This arm is closed)|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
10121812|NCT04382690||South Africa|People residing in South Africa
9966994|NCT01265485|Experimental|treatment|
9966995|NCT01265576|Placebo Comparator|Sorafenib with placebo|Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
9966996|NCT01265576|Experimental|Sorafenib plus VT-122|
9966997|NCT01265589|Placebo Comparator|I=surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
9966998|NCT01265589|Experimental|II=surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
9966999|NCT01265602|Experimental|LAS41007|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
9967000|NCT01265602|Active Comparator|LASW1510|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
9967001|NCT01265602|Placebo Comparator|vehicle|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
9967002|NCT01265628||Glaucoma|
9967003|NCT01265628||Retinitis pigmentosa (RP)|
9967004|NCT01265628||Anterior Ischemic Optic Neuropathy (AION)|
9967005|NCT01265641|Experimental|1|
9967006|NCT01265641|Experimental|2|
9967007|NCT01265641|Experimental|3|
9967008|NCT01265641|Placebo Comparator|4|
9967009|NCT01265654||All patients|Patients with ABC and two lines of hormonal treatment
9967010|NCT01265680|Experimental|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital
9967011|NCT01265680|No Intervention|Control|No added administration other than our standard of care.
9967012|NCT01265732|Active Comparator|oral single dose dispersion 100mg|Subjects receive a single dose of PF-04191834 as a dispersion
9967013|NCT01265732|Active Comparator|oral wet milled suspension 100mg|Subjects receive a single dose of PF-04191834 as a suspension
9967014|NCT01265732|Active Comparator|oral wet milled suspension 300mg|Subjects receive a single dose of PF-04191834 as a suspension
9967015|NCT01265745|Active Comparator|Valortim|Valortim 1mg,5mg,10mg
9967016|NCT01265745|Placebo Comparator|Placebo|Saline solution will be used as the placebo
9967017|NCT01265758|Experimental|Telemetric ECG monitoring|Telemetric 14-days Full Disclosure ECG recording.
9967018|NCT01265758|Active Comparator|Standard 24-hours Holter ECG recording|Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
9967019|NCT01265771|Experimental|Telemetry ordered by a Cardiologist|
9967020|NCT01265771|Experimental|24 hours standard Holter monitoring|
9967021|NCT01265771|Experimental|Telemetry ordered by a Pediatrician|
9967022|NCT01265810|Other|sodium chloride -> supersaturated calcium-phosphate|Patients in this arm start first with sodium chloride 0.9% mouth rinses and go crossover to supersaturated calcium-phosphate mouth rinses.
9967023|NCT01265810|Other|supersaturated calcium-phosphate -> sodium chloride|Patients in this arm start first with supersaturated calcium-phosphate mouth rinses and go crossover to sodium chloride 0.9% mouth rinses.
9967024|NCT01265836||1|
9967025|NCT01265849|Experimental|LI + CIZ + SOC|LI plus CIZ (cyclophosphamide, indomethacin and zinc) is given as adjuvant therapy prior to standard of care (SOC).
9967026|NCT01265849|Active Comparator|Standard of Care (SOC)|SOC for previously untreated SCCHN patients is currently surgery followed by either radiotherapy or combined radiochemotherapy depending the patient's risk status for relapse determined at surgery.
9967027|NCT01265849|Experimental|LI + SOC|LI is administered without CIZ to determine the contribution of CIZ to the effects of LI.
9967028|NCT01265862|Active Comparator|LMA-Fastrach® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach®, establishment of ventilation~Evaluation of glottic view through LMA-Fastrach® using fibrescope~Tracheal intubation with the GlideRite® tube through the LMA-Fastrach®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
9976598|NCT01353261||Elective Cases|Patients with stable CAD undergoing PCI
9976599|NCT01353261||AMI Cases treated with clopidogrel|Patient with AMI undergoing PCI
9976600|NCT01353261||AMI Cases treated with prasugrel|Patients with AMI undergoing PCI
9976601|NCT01353287||TAVI live case or video-taped transmission|
9976602|NCT01353287||TAVI without transmission|
10121813|NCT04382690||Indonesia|People residing in Indonesia
10121814|NCT04382690||Saudi Arabia|People residing in Saudi Arabia
10121815|NCT04383015|Other|Carbohydrate (CHO)-only|Carbohydrate dose of 0.3g/kg/hr given every 30 minutes of exercise if blood glucose is in range with usual basal insulin infusion
10121816|NCT04383015|Other|50 Percent Basal Rate Reduction (BRR)|A 50 percent basal rate reduction set 90-minutes pre-exercise and throughout exercise
10121817|NCT04383015|Other|Combo|The combination of a 50 percent basal rate reduction and carbohydrate dose of 0.3g/kg/hr (given every 30 minutes) both at exercise onset
10121818|NCT04382456|Experimental|acacia gum|
10121819|NCT04382404|Experimental|Sofosbuvir-Velpatasvir|Sofosbuvir-Velpatasvir
9976603|NCT01353326|Active Comparator|Cementless Hip Resurfacing|Patients randomized into the Cementless Hip Resurfacing Group will have their hip resurfaced with the cementless Cormet / Corin Hip Resurfacing System.
10121820|NCT04382599|Experimental|Added sugar warning message|"Message displayed on warning labels is: WARNING: High in added sugar."
10121821|NCT04382599|Experimental|Weight gain warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to weight gain."
10121822|NCT04382599|Experimental|Type 2 diabetes warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to type 2 diabetes."
10121823|NCT04382599|Experimental|Heart damage warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to heart damage."
10121824|NCT04382599|Active Comparator|Neutral message|"Message displayed on control label is: Please refrain from littering."
10121825|NCT04382625|Experimental|Hydroxychloroquine (HCQ)|Initial dose: HCQ 400mg x 2 (800mg) then 200mg by mouth, three times per day (600mg/24hr period) starting 8 hours after the initial dose for a total of 14 doses over 5 days Plus Usual Care (See below for full description)
10121826|NCT04382625|No Intervention|Usual Care|The care of hospitalized patients with covid-19 is evolving with hospital guidelines arising across the U.S. with several commonalities. Patients receive clinical assessment, chest x-ray, covid-19 testing, basic labs (WBC, CMP), and additional labs based on protocol or clinical judgment (ABG, CRP, LDH), antibiotics for possible bacterial pneumonia, acetaminophen for fever, supplemental O2, and consideration for mechanical ventilation. Early intubation over escalating noninvasive support. Low tidal volume ventilation and prone positioning are lung protective strategies used in critically ill covid-19 patients that are based on management of acute respiratory distress syndrome generally. Conservative fluid replacement is used to avoid worsening oxygenation.
10121827|NCT04382443|Experimental|Oral Colchicine +BMS implantation|This group will receive after BMS and Colchicine, at the time of PCI, 0,5 mg twice a day during the first three months after stent implantation
10121828|NCT04382443|No Intervention|Second generation Drug eluting stent (DES)|"This group will receive DES at the moment of randomization and will be treated as standard of care.~All second generation DES should be approved by ANMAT for clinical use."
10121829|NCT04382170|Active Comparator|20 mcg|Participants randomized to the 20mcg group will receive 20mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 80mcg.
10121830|NCT04382170|Experimental|60 mcg|Participants randomized to the 60mcg group will receive 60mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 240mcg.
10121831|NCT04382378|No Intervention|control group|Group that will receive a standard care from physiotherapy staff not involved in delivering the intervention whenever feasible.
10121832|NCT04382378|Experimental|50 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 50 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
10121833|NCT04382378|Experimental|100 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 100 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
10121834|NCT04382417||Covid-19|Patients with verified or highly suggestive Covid-19 diagnosis and Intensive Care treatment.
10121835|NCT04382079|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
10121836|NCT04382079|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
10121837|NCT04382079|No Intervention|control|Routine care to encourage oral care three times a day.
10121838|NCT04382352|Experimental|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection|Registration number: CTR20181455 Indications: HER2-positive recurrent or metastatic breast cancer Experimental popular topic: Phase Ia clinical study of recombinant anti-HER2 humanized monoclonal antibody composition
10121839|NCT04382209|Active Comparator|Erector Spinae plane block group|Erector spinae plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively.
10121840|NCT04382209|Sham Comparator|Control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
10121841|NCT04382573||CDK13|CDK13 intragenic pathogenic variant
10121842|NCT04382092|Experimental|Intervention COVID-19|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
10187619|NCT03724422|No Intervention|Control|This group will receive the standard of care treatment for their distal humerus fracture only.
10121843|NCT04382365|Other|Internet-Based Insomnia Intervention|"2 weeks of online sleep diaries. Participants will also wear an Actiwatch at night, which records measurements of movements of a limb, providing an estimation of sleep duration, sleep pattern and disturbed sleep.~9 week interveition period, subjects complete the internet based CBT-I program, consisting of six Cores (Getting Ready, Sleep Scheduling, Sleep Practices, Thinking Differently, Sleep Hygiene, and Moving On).Each Core takes approximately 45-60 minutes to review online, and most participants spend an additional 30-45 minutes per week on recommended exercises.~Participant will then be instructed to complete a post-Assessment, consisting of one online questionnaire and two weeks of Daily Sleep Diaries. The Actiwatch is worn as before during this two week period."
10121844|NCT04382131|Experimental|Hypertonic saline nasal irrigation and gargling|Participants in the intervention arm will be asked to perform hypertonic saline nasal irrigation and gargling up to 12 times daily for a maximum of 14 days or until they report that they feel well.
10121845|NCT04382131|No Intervention|Standard Care|Participants in the control arm will be given standard NHS guidance for the management of their symptoms and household hygiene.
10121846|NCT04382274|Experimental|Quadratus Lumborum Block|the transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized, leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial then placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
10121847|NCT04382274|Experimental|Dual block|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
10121848|NCT04382261|Placebo Comparator|Periodontitis quadrant|Patients undergo non surgical quadrant scaling and root planing
10121849|NCT04382261|Active Comparator|Periodontitis full mouth|Patients undergo non surgical full mouth scaling and root planing
10121850|NCT04382196||Health care workers|Health care workers at university hospital
10121851|NCT04382287|Experimental|REMIN paste|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
10187620|NCT03724422|Experimental|Intervention|This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.
10187621|NCT03724383|No Intervention|Control|Participants in the control arm will receive standard care.
9827368|NCT02453360|Experimental|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
9967029|NCT01265862|Experimental|I-gel® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel®, establishment of ventilation~Evaluation of glottic view through I-gel® using fibrescope~Tracheal intubation with the GlideRite® endotracheal tube through the I-gel®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
9967030|NCT01265888|Experimental|Dosing Group 1|1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)
9967031|NCT01265888|Experimental|Dosing Group 2|2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm
9967032|NCT01265888|Experimental|Dosing Group 3|4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm
9967033|NCT01265914|Placebo Comparator|placebo|
9967034|NCT01265914|Experimental|FP-01.1|
9967035|NCT01265927|Experimental|GRN163L + Trastuzumab|
9967036|NCT01265940|Experimental|Pazopanib + Vinflunine|
9967037|NCT01265979||GIST treated with regorafenib/placebo|patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
9967038|NCT01266005|Experimental|1|Clevudine 30mg
9967039|NCT01266005|Active Comparator|2|Entecavir 0.5mg
9967040|NCT01266031|Experimental|Bevacizumab|10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.
9967041|NCT01266031|Experimental|Vorinostat and Bevacizumab|"Vorinostat: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.~Bevacizumab: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle."
9967042|NCT01266057|Experimental|Hydroxychloroquine + Sirolimus|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Sirolimus starting dose of 2 mg by mouth every day for a 21 day cycle.
9967043|NCT01266057|Experimental|Hydroxychloroquine + Vorinostat|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Vorinostat starting dose of 200 mg by mouth per day for a 21 day cycle.
10121852|NCT04382287|Experimental|MI PASTE PLUS|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
10121853|NCT04382287|Active Comparator|COLGATE Total|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
10121854|NCT04382339|Active Comparator|Treatment-naive|"Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
10121855|NCT04382339|Active Comparator|Treatment-experienced|"Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
10121856|NCT04382300|Experimental|Treatment arm|pyrotinib 400mg p.o. qd, combined with thalidomide 200mg p.o. qd
10121857|NCT04382521|Experimental|Text Message Intervention (TMI)|Participants in the TMI condition will receive daily text messages through an adaptive algorithm plus separate twice-weekly tailored messages focused on a specific health goal.
10121858|NCT04382521|Other|Wait-list Control Group (WLC)|Waitlist Control group participants will begin to receive the full 12-week Text Message Intervention (with all components, e.g., phone check-ins) after completing follow-up assessments at Weeks 12 and 24. Participants in this group will receive no text messages or other study-specific interventions during the first 24 weeks of the study.
10121859|NCT04382534||Rehabilitation guidance group|1 to 2 times of rehabilitation instruction according to the rehabilitation instruction program, either online or in person.According to the rehabilitation instruction, the patient performed self-rehabilitation exercises in the isolation point.
9967044|NCT01266083|Experimental|WT1 peptide vaccine|This is a Phase II study evaluating the safety and efficacy of the WT1 peptide vaccine in patients who are in CR from Acute Myeloid Leukemia (AML).
10121860|NCT04382534||Systematic rehabilitation treatment|According to the systematic rehabilitation treatment program, the rehabilitation therapist entered the home for one-to-one rehabilitation treatment, once a day, for a total of 10 days.
10121861|NCT04382157|Experimental|Mablet|Mablet 360 mg. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
10121862|NCT04382157|Placebo Comparator|Placebo|Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
10121863|NCT04382105||Control|observation of salivary IL-6 levels
10121864|NCT04382105||Periodontitis|observation of salivary IL-6 levels
10121865|NCT04382040|Experimental|ArtemiC|Active study treatment + Standard care
10121866|NCT04382040|Placebo Comparator|PLACEBO|Placebo + Standard care
10121867|NCT04382027|Experimental|Monoacylglycerol|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in monoacylglycerol form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
10121868|NCT04382027|Active Comparator|Ethyl ester|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in ethyl ester form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
10121869|NCT04381884|Experimental|IVERMECTIN (IVER P®)|Patients in this group will receive Ivermectin (IVER P®) 600 µg / kg / once daily plus standard care.
10121870|NCT04381884|No Intervention|CONTROL|Patients in this group will receive standard care.
10121871|NCT04381975|Experimental|Move in Mind Program|The Move in Mind Program is a 6-week Rolfing®-based intervention program shortened from ten to six sessions and adapted to a group setting by Rolfing® instructor Monica Canducci.
10121872|NCT04381975|Other|6 Week Waitlist Control|Participants will be crossed over to the Move in Mind program following the 6-week waitlist control. Participants of the waitlist control group will be asked to complete follow-up questionnaires both at the same time as the intervention group (after week six) as well as after their own program.
10121873|NCT04381754||AVG/AVF Treated with Passeo-18 Lux|Patients with failing dialysis access, treated lesions located between the anastomosis to the axillary-subclavian vein junction.
10121874|NCT04381962|Experimental|Azithromycin|Azithromycin 2x250mg capsules to be taken orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
10121875|NCT04381962|No Intervention|Usual standard care|Standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
10121876|NCT04381910|Experimental|LY01610|LY01610(Irinotecan Hydrochloride Liposome Injection),Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted. Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance. If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
10121877|NCT04381676||Flipped Classroom|Residents in the flipped classroom were assigned a pre-class video lecture prior to completing the flipped classroom in-class case-based activity in groups of 2-3 each.
10121878|NCT04381676||Traditional Classroom|Residents in the traditional classroom were assigned a pre-class reading assignment followed by a 44-minute lecture that was delivered in-person using PowerPoint.
10121879|NCT04381689|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
10121880|NCT04381689|Active Comparator|GSK PFS|Fluarix Tetra Pre-filled Syringe
10121881|NCT04381949|No Intervention|Standard extubation Arm|
10121882|NCT04381949|Experimental|Positive pressure extubation arm|
10121883|NCT04381637|Experimental|NIPE|
10121884|NCT04381741|Experimental|CD19-7×19 CAR-T plus PD1 monoclonal antibody|
10121885|NCT04381780|Experimental|Assessing clinical outcomes|Nutritional support with Recovery Factors
10121886|NCT04381767||Concussion Evaluation|Adult athletes receiving a clinical evaluation for a suspected concussion after head injury
10121887|NCT04381520|Experimental|Heat-sensitive moxibustion plus antihypertensive drugs|
10121888|NCT04381520|Active Comparator|Antihypertensive drugs|
10121889|NCT04381806|Experimental|5-ALA|orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)
10121890|NCT04381845|Other|psychiatric patient|patients who are hospitalized in psychiatric department
10121891|NCT04381702||Patients with an open approach|Patients requiring pancreatoduodenectomy and operated with an open approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology before the first laparoscopic pancreaticoduodenectomy.
10121892|NCT04381702||Patients with a laparoscopic approach|Patients requiring pancreatoduodenectomy and operated with a laparoscopic approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology operated with a laparoscopic approach.
10121893|NCT04381663||conservative treatment|In study A this group will be treated conservatively (stenosis). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
10121894|NCT04381663||surgical treatment (stenosis and myelopathy).|In study A this group that will be treated surgically (stenosis and myelopathy). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
10121895|NCT04381611||Primary Glaucoma|
10121896|NCT04381611||Glaucoma Surgery|
10121897|NCT04381611||Glaucoma Laser|
10121898|NCT04381611||Glaucoma Surgery Combined|
10121899|NCT04381611||Glaucoma treatment|
10121900|NCT04381611||Glaucoma imaging|
10121901|NCT04381611||Glaucoma co-morbidity|
10121902|NCT04381611||Glaucoma untreated|
10121903|NCT04381611||Glaucoma Suspect|
10121904|NCT04381611||Secondary Glaucoma|
10121905|NCT04381871|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
10121906|NCT04381871|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose
10121907|NCT04381585|Experimental|Distraction osteogenesis using mini distractor|"A mini distractor will be used to move bone. Distraction osteogenesis originally developed for the severe craniofacial malformations has been adapted to correct vertical defects of the oral bone to improve bone volume for dental procedures.~However, the design of the distractor~has not evolved to adapt to a much smaller surgical site such as bone ridge in the oral cavity which necessitates a smaller screw.~are bulky, cumbersome to place, and cause significant discomfort to the patient.~has an extraoral component jutting out of the mouth to which a key (blue object) is attached to turn the screw to move bone fragments. Our Solution and the Innovation is to remove the extra-oral component by reducing the size and permitting an atraumatic placement of the screw under the gingiva (gum) thereby lessening irritation for the patient."
10121908|NCT04381624|Experimental|Transcutaneous Vagal Stimulation|TVS will be applied through a portable electrostimulation equipment during the whole session in each of the treatment sessions. The electrodes will be placed in the left ear, specifically in the auricular concha. The device will be programmed with a biphasic square current at an intensity that produces a clear tingling sensation that is neither uncomfortable nor painful, with pulses of 300 microseconds, at 25 Hertz, the stimulus will be present for 30 seconds and will be followed by a 30-second rest period repeating this for approximately one hour.
10121909|NCT04381624|Placebo Comparator|Placebo Transcutaneous Vagal Stimulation|In the application of this placebo, the device will be configured with the same parameters and intensity of the real TVS. However the device will be located in the left ear lobe.
10121910|NCT04381598|Experimental|stevia rebaudiana bertoni|Randomly in all subjects one quadrant will be allotted as test site for placing stevia gel in the gingival sulcus having probing depth ≥ 5mm after performing thorough scaling and root planing.
10121911|NCT04381598|Placebo Comparator|placebo|Other quadrant will be allotted as a control site for placing placebo in the gingival sulcus having PD≥ 5mm after performing thorough scaling and root planing.
10121912|NCT04382144|Active Comparator|Levobupivacaine arm|Patients will receive a single injection of 10 mL of 0.5% (5 mg/mL) levobupivacaine into the common extensor origin.
10121913|NCT04382144|Experimental|Liposomal Bupivacaine arm|Patients will receive a single injection of 10 mL (133mg) of liposomal bupivacaine into the common extensor origin.
10121914|NCT04382430|Experimental|US Guided Axillary venous access|Physician/ provider will perform 2 unassisted & 10 solo Ultrasound (US) guided venous access and pocket creation cardiac device implant. First 2 device implant will be done to educate physicians about ultrasound guided venous access. Subsequent subject will be randomized to 2:1 in ultrasound vs. conventional technique.
10121915|NCT04382430|Active Comparator|Conventional technique|Physician/ provider will perform 5 cardiac device implant using conventional technique for venous access and pocket creation.
10121916|NCT04381546|Experimental|FES in patients with hemiplegia|Patients will be equipped with 5 inertial measurement units. Two wireless bluetooth pressure insoles will be connected to the Raspberry. Electrical stimulation will be delivered via a wireless stimulator to the quadriceps and hamstrings via surface electrodes. Insoles will be used to online analyze Paretic Foot Support to discriminate between stance and swing phases. Stimulation will also be delivered just before initial contact at the end of swing phase. In stance phase, stimulation will be triggered either to quadriceps or hamstrings, depending on the paretic knee angle estimation relatively to the knee angle setpoint defined by the practitioner as the optimal flexion during stance phase (around 5°).
10121917|NCT04381572||High fidelity simulation training|Group consisting of medical students scheduled to undergo high fidelity medical simulation as a part of standard scholastic program.
10121918|NCT04381715||YY1|YY1 intragenic pathogenic variant
10121919|NCT04381416|Experimental|Cohort I: SEAD treatment|Following the first SEAD™ treatment, women who experience a sub-optimal treatment response (at least 3 months after the first treatment) will be eligible to receive a second SEAD™ treatment (see re-treatment criteria below), which will be performed during the first 1-3 days following the cessation of their menses immediately following decision to retreat.
10121920|NCT04381416|Experimental|Cohort II: Repeted SEAD treatment 1m post op|Following the first SEAD™ treatment, women will undergo a second SEAD™ treatment during the first 1-3 days following the cessation of their next menses.
10121921|NCT04382014|Experimental|MAG fish oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1,5 g MAG fish oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
10121922|NCT04382014|Active Comparator|Rice bran oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of rice bran oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
10121923|NCT04382014|Active Comparator|Curcumin extract|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
10121924|NCT04381858|Experimental|Severe pneumonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]~Requiring invasive mechanical ventilation."
9976604|NCT01353326|Active Comparator|Cemented Hip Resurfacing|Patients randomized into the Cemented Hip Resurfacing Group will have their hip resurfaced with the cemented Conserve Plus Total Resurfacing Hip System.
10121925|NCT04381858|Active Comparator|Severe pnemonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]~Requiring invasive mechanical ventilation."
10121926|NCT04381403|Experimental|Bio-descaling D-Tart toothpaste|Bio-descaling D -Tart is a bio-descaler toothpaste that is manufactured at Du-Var laboratories (1460 Graham Bell, Boucherville, Québec, Canada J4B 6H5)
10121927|NCT04381403|Active Comparator|Crest®|anti-tartar toothpaste, Complete Whitening plus Scope, tartar control produced by Procter & Gamble, Cincinnati, OH),
10121928|NCT04381793|Experimental|Assessing clinical efficacy|Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum. Pre-and post FIQ-R and VA symptom score will be assessed as well as overall well-being. In a subgroup, pre-and post antibody levels will also be checked. Phase 1 will be a group of 60 subjects
10121929|NCT04381390|Experimental|Whole egg consumption|This arm involved whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
10121930|NCT04381390|Experimental|Egg whites consumption|This arm involved egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
10121931|NCT04381377|Experimental|Polyoxidonium|Polyoxidonium will be administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
10121932|NCT04381377|Placebo Comparator|Placebo|Placebo will be administered (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
9976605|NCT01353339|Placebo Comparator|sugar pill|
9976606|NCT01353339|Active Comparator|levofloxacin|
10121933|NCT04381442|Experimental|Buccal &palatal low level laser therapy|In group I,low level laser therapy was delivered at 10 points; 5 from buccal and 5 from palatal aspects with a total dose of 8 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
10121934|NCT04381442|Active Comparator|Buccal low level laser therapy|In group II, low level laser therapy was delivered at 5 points; from buccal palatal aspects only with a total dose of 4 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
10121935|NCT04381338|Experimental|Rehabilitation in COVID-19 patients in ICU|"Every person admitted to ICU for ARDS with a confirmed diagnosis of COVID-19 Motor program~Intubated patient GCS >8: passive mobilization; postural positioning GCS< 8: passive and active-assist mobilization; postural positioning~Extubated patient~If strength < 3 MRC: passive and/or active-assist; functional retraining~If strength ≥3 MRC: active-assist and active; strength training; functional retraining Pulmonary Rehabilitation~Intubated patient GCS >8: postural positioning GCS< 8: postural positioning, cautious inspiratory muscle training~Extubated patient~If strength < 3 MRC: postural positioning, positive pressure expiration exercise,inspiratory muscle training~If strength ≥3 MRC: postural positioning, positive pressure expiration exercise, inspiratory muscle training The intensity of exercise will prescribed based on the results of the PFIT. and modified Borg Scale.~Frequency of sessions: 3×15 min/day"
9967045|NCT01266096|Experimental|newly diagnosed or recurrent head/neck melanoma|This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.
9967046|NCT01266109|Experimental|CM-FAM|
10121936|NCT04381338|No Intervention|COVID-19 in ICU without Rehabilitation|Standard of care without rehabilitation in ICU
10121937|NCT04381182|Other|Biostrap/Apollo Device Use|Participants wear a Biostrap wearable device which measures steps, heart rate, heart rate variability, sleep metrics, and quantitative data in typical day-to-day activities of residents. Participants then again wear Biostrap except now also with the Apollo device which is worn around the ankle and is suggested to modulate heart rate variability and perceived stress of participants.
10121938|NCT04381234|Experimental|ATA plus citrate|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan) in combination with citrate (1 mM) containing dialysate
10121939|NCT04381234|Active Comparator|ATA plus predilution hemodiafiltration|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan), in combination with high volume predilution hemodiafiltration
10121940|NCT04381013|Experimental|Phase 1: Routine surgery|As part of routine cardio-thoracic surgery, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 1 minute.
10121941|NCT04381013|Experimental|Phase 2: ECHO treatment|During care with Extracorporeal Membrane Oxygenation (ECMO) for non-SARS-CoV-2, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 24 hours.
10121942|NCT04381013|Experimental|Phase 3: COVID-19 treatment|Endotracheal tubes split from ventilator delivering oxygen independently to two patients with COVID-19 disease for up to 1 hour.
10121943|NCT04381000|No Intervention|Control Group|The control group will not participate in any exercise program.
10121944|NCT04381000|Experimental|Intervention|The intervention group will participate in an exercise program for 6 weeks/ 2 sessions per week, for a total of 12 sessions of 30-45 minutes each.
10121945|NCT04380974|Experimental|OCTA plus OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization, OCTA and OCT in the extension treatment period.
10121946|NCT04380974|Active Comparator|OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization and OCT in the extension treatment period.
10121947|NCT04380961|Experimental|Sirukumab|Participants will receive single intravenously (IV) dose infusion of sirukumab on Day 1 along with standard of care treatment.
10121948|NCT04380961|Placebo Comparator|Placebo|Participants will receive IV single dose infusion of placebo on Day 1 along with standard of care treatment.
10121949|NCT04380935|Experimental|convalescent plasma and standard of care|
10121950|NCT04380935|Active Comparator|standard of care|
10121951|NCT04380909|Experimental|Internet-based self-help|The self-help program consists of six text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
10121952|NCT04380909|Other|Waiting control group|Access to internet-based intervention after 3 weeks.
10121953|NCT04381195||Aim 1|"Item Drafting and Revising (Aim 1). Together with a stakeholder panel of adults with ASD and parents/caregivers, the study investigators will generate an item pool based on the conceptual model. The measure will utilize the capability scale response options from the PROMIS preferred response sets (4 = without any difficulty, 3 = with a little difficulty, 2 = with some difficulty, 1 = with much difficulty, 0 = unable to do). To increase the reliability of ratings, a visual response scale with objective benchmarks and anchors will be developed for each response option.~Cognitive Interviews (Aim 1). A battery of assessments will be completed to describe the sample. The investigators will monitor these results to ensure that the sample is representative of the range of functioning in ASD, and will enrich the sample as needed. The assessment battery will be the same as the battery for the calibration sample (see battery in Aim 2)."
9668970|NCT04474054|Experimental|FARAPULSE Ablation System Plus|Ablation using the FARAPULSE Ablation System Plus
10121954|NCT04381195||Aim 2|"Item Calibration (Aim 2). Measures will be completed online. To be conscious of participant burden, the minimum needed measures were selected to describe the sample, enable differential item functioning (DIF) analyses, and support IRT co-calibration.~The battery will include:~measures to characterize the sample (demographics, medical/psychiatric history, treatment and education, history, employment, parent- and self-reported IQ/verbal ability, 2) the online version of the Wide Range Achievement Test- Reading;~measures related to functional outcomes for IRT co-calibration (Vineland Scale of Adaptive Behavior -3; Wisconsin Activities of Daily Living, Specific Levels of Functioning Scale, PROMIS Social Participation, PROMIS Emotional Support, World Health Organization Quality of Life); and~symptom measures (Emotion Dysregulation Inventory, Adult Behavior Checklist/Adult Self-Report of psychiatric symptoms, and Social Responsiveness Scale - 2 of ASD symptoms)."
10121955|NCT04381026|Placebo Comparator|Placebo Group|Pill of 500 mg containing filler agent, two pills daily for eight weeks.
10121956|NCT04381026|Experimental|Treatment Group with botanical extracts|Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.
10121957|NCT04380922||Active IBD|"Active Inflammatory Bowel Diseases defined as :~For Crohn's disease :~Harvey Bradshaw Index ≥ 4~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis~Partial Mayo score ≥ 2~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months"
10121958|NCT04380922||Non-active IBD|Non-active Inflammatory Bowel Diseases
10121959|NCT04381130|Experimental|EF-009|In both the Phase I and Phase IIa portions of the study, subjects will be evaluated for response every 8 weeks after EF-009 wafer implantation for up to 2 years, by CT, PET/CT or MRI (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be assessed based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST v1.1). The total study duration for each subject consists of screening, treatment, and extended follow-up period and survival follow-up period.
10121960|NCT04380844|Active Comparator|Beprevent|10 will become part of the intervention group. Each of the participants in the intervention group is selected. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
10121961|NCT04380844|No Intervention|patients only evaluated|10 will be included in the control group. During the period of the study, we will pass the same questionnaires in the participants assigned to the control group, also leaving a time interval of two weeks, and no device will be installed, nor will any monitoring be carried out in their homes.
10121962|NCT04381065|Experimental|PKG+ Group|For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is in the target range or out of the target range based on scores provided by the PKG.
10121963|NCT04381065|Placebo Comparator|PKG- Group|For subjects in the PKG- Group, participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
10121964|NCT04381117||No Treatment|Subjects who participated in and completed study EN3835-201 and had composite improvement of at least 2-levels on both the Clinician Reported-Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported-Photonumeric Cellulite Severity Scale (PR-PCSS) in EN3835-201 study will be eligible for this study. The study will consist of a single day evaluation approximately 4 years after the first dose of the study drug was received in the EN3835-201 study.
10121965|NCT04381104|Active Comparator|Paracetamol|Capsule Paracetamol 1000 mg 1 hour before the mammography procedure
10121966|NCT04381104|Placebo Comparator|Placebo|The control arm will receive 2 capsules of placebo.
9825935|NCT02401256|Experimental|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.~Included drugs:~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
10121967|NCT04381208||Sacroiliac joint pain|Patients diagnosed with sacroiliac joint pain on the basis of history, physical examination and diagnostic sacroiliac joint block
10121968|NCT04381208||Lumbar pain|Patients diagnosed with other chronic lumbar pathologies on the basis of history, physical examination and radiographic studies
10121969|NCT04380870||Chinese Herbal Medicine|Chinese Herbal Medicine for suspected COVID-19 symptoms.
10121970|NCT04380597||Patients with nail psoriasis|Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
10121971|NCT04380883|Experimental|InnoSEAL+TRB|InnoSEAL is a hemostatic patch which will be applied along with TRB to control bleeding from access site
10121972|NCT04380883|Active Comparator|TRB alone|
9668971|NCT04469712||SASI Bipartition|Subjects submitted to SASI Bipartition
9825936|NCT02401412|Other|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
9825937|NCT02401412|Other|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
10121973|NCT04380896||SARS-CoV-2 Seropositive Cases|"It will be formed of approximately N= 200 to 350 staff members~Core Group of PCR Confirmed Cases N ~ 150 to 250:~A) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive N ~ 150 to 250 OR~Other SARS-CoV-2 Sero-positives N ~ 50 to 100:~B) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases. OR C) No symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases"
10121974|NCT04380896||SARS-CoV-2 Seronegative Comparison Group|"It will be formed of approximately N= 800 to 900 staff members~Core Comparison Group N ~ 800 A) Have not had clinical symptoms consistent with SARS-CoV-2 infection OR~Other Seronegatives N ~ 100 B) Have had sympoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days"
10121975|NCT04380623|Experimental|Mobile Phone-Based Web-Page: HPV vaccine|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit, tailored education information on the HPV vaccine via a text message with a website link.
10121976|NCT04380623|Active Comparator|Mobile Phone-Based Web-Page: Healthy Lifestyles|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit education information on an unrelated topic (e.g., healthy eating and physical activity) via a text message with a website link.
10121977|NCT04380818|Active Comparator|Control group|a control group only receive pharmacological treatment
10121978|NCT04380818|Experimental|Experimental group|an experimental group will receive low-dose lung irradiation
10121979|NCT04380857|Experimental|Dexamethazone ophthalmic insert 0.4 mg|Dexamethazone ophthalmic insert 0.4 mg
10121980|NCT04380857|Experimental|topical prednisolone acetate ophthalmic drops|topical prednisolone acetate ophthalmic drops
10121981|NCT04380766||Pre-COVID|All patients with pancreatic cancer diagnosis before COVID-19 pandemic
10121982|NCT04380766||COVID|All patients with pancreatic cancer diagnosis during COVID-19 pandemic
10121983|NCT04380558||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
10121984|NCT04380675|Active Comparator|Music during ESWL|Patients listen to music during ESWL
10121985|NCT04380675|No Intervention|ESWL without music|Patients don't listen to music during ESWL
10121986|NCT04380584||I|30 patients with type 2 DM with nephropathy
10121987|NCT04380584||II|30 type 2 DM without nephropathy
10121988|NCT04380584||III|30 non DM as control group
10121989|NCT04380662||COVID+ patients WITH worsening of the disease|COVID+ patients WITH worsening of the disease (case group)
10121990|NCT04380662||COVID+ patients WITHOUT worsening of the disease|COVID+ patients WITHOUT worsening of the disease (control group)
9668972|NCT04469712||Roux-en-Y gastric bypass|Subjects submitted to gastric bypass
10183077|NCT03767998|Experimental|IMST group|Interventions: Respiratory muscle training for IMST. Inspiratory muscle training for patients with inspiratory muscle weakness (MIP less than 70% of normal range). IMT will commence from 30% to 60 % of MIP and then adjust one level of training loading according to the tolerance of continuously breathing through a respiratory trainer for two sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week.
10183078|NCT03767998|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
10183079|NCT03767998|Experimental|EMST group|Intervention: Respiratory muscle training for EMST. For patients with only swallowing disturbance. Training resistance will be adjusted accordingly. The loading will be performed with the previous resistance setting or even lower if training load is not tolerated or not completed.
10183080|NCT03767985|Active Comparator|Occlusion therapy|Participants are prescribed 2 hours of occlusion therapy per day, 7 days a week.
10183081|NCT03767985|Experimental|Dichoptic video game therapy|Participants receive dichoptic video game therapy: 1 hour per week at the out-patient clinic under direct supervision.
10183082|NCT03767972|Experimental|Rejuvenation|Adults requiring rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will receive energy-based treatment (Fraxel Restore, Helios III, PicoWay, Halo, ThermiVa or DiVa) based on the investigators' assessment and discretion. The treating physician will decide which energy-based device is best-suited to addressing the patients' aging concerns; although patient preference will be taken into account, ultimately the treating physician will be responsible for the correct assessment of patients' rejuvenation needs and use of appropriate energy-based devices for the final treatment.
9967047|NCT01266109|Active Comparator|US|
10183083|NCT03767959|Experimental|Chen's U-Suture|Patients in this group will treated by Chen's U-suture technique in pancreaticojejunostomy.
10183084|NCT03767959|Active Comparator|Classic pancreatic duct to mucosa|Patients in this group will treated by classic pancreatic duct to mucosa technique in pancreaticojejunostomy.
10183085|NCT03767946||Group 1|"Children both genders according to age:~*1-year old children (12 months -1/+4 months); n=125 at the date of recruitment."
10183086|NCT03767946||Group 2|"Children both genders according to age:~*2-year-old children (24 months -1/+4 months); n=125 at the date of recruitment."
10183087|NCT03767946||Group 3|"Children both genders according to age:~*5-year old children (60 months +/- 6 months); n=125 at the date of recruitment."
10183088|NCT03767946||Group 4|"Children both genders according to age:~*12-years old children (12 years old +/- 6 months); n=125 at the date of recruitment."
10183089|NCT03767920|Active Comparator|bupivacaine and dexamethasone|Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
10183090|NCT03767920|Active Comparator|bupivacaine and placebo to dexamethasone|BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
10183091|NCT03767855|Experimental|CK-3773274 for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274
10183092|NCT03767855|Placebo Comparator|Placebo for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo
10183093|NCT03767855|Experimental|CK-3773274 for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274
10121991|NCT04380532|Experimental|V-SARS recipients|Single arm having at least 20 volunteers administered once-per-day pill of V-SARS
10121992|NCT04380571|Experimental|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
10121993|NCT04380571|Experimental|Electrical Stimulation|Bilateral (TPTNS); was applied with an electrode above the medial malleolus A second electrode) was applied just below the same malleolus. Electrical stimulation with a low-frequency current (10 Hz), and adjustable intensity. The procedure was done for 20-30 minutes, three times per week for 3 months together with the conventional maneuvers applied in the control group.
10121994|NCT04380571|Active Comparator|Control group|were managed by conventional methods through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
10121995|NCT04380415|Active Comparator|Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist. ECG will be collected from a single lead ambulatory ECG patch worn on the chest. The data from both the commercial wrist-worn device and the ECG patch are not analyzed real-time.
10121996|NCT04380415|No Intervention|Non Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist.
9967048|NCT01266174|Experimental|Eltoprazine|eltoprazine pill 2.5mg bid, eltoprazine pill 5mg bid, eltoprazine 7.5mg bid
9967049|NCT01266174|Placebo Comparator|Placebo|placebo pill 2.5mg bid, placebo pill 5mg bid, placebo 7.5mg bid
9967050|NCT01266187|Experimental|Arm B|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
9967051|NCT01266187|Active Comparator|Arm A|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
10121997|NCT04380428||Cross section of the student body.|Matriculated students at Portuguese medical and dental faculties.
10121998|NCT04380402|Experimental|Treatment|40 mg
10121999|NCT04380402|No Intervention|Control|Standard care
10122000|NCT04380467|Experimental|Vitamin D Group|Six doses of cholecalciferol 100,000units (5x aviticol 20,000units capsules) administered monthly over 20 weeks.
10122001|NCT04380467|No Intervention|Control|No vitamin D given
10122002|NCT04380454|Experimental|Fast treadmill walking with functional electrical stimulation|Fast treadmill walking with functional electrical stimulation (FastFES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. FES is delivered only to the paretic ankle muscles, enhancing afferent ascending as well as descending corticomotor drive. Increased corticomotor drive in lesioned corticomotor circuits in turn promotes improved timing and intensity of muscle activation in the paretic plantar- and dorsi-flexor muscles, increasing plantarflexor moment and propulsion from the paretic ankle.
10122003|NCT04380454|Active Comparator|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention that provides similar structure, dose, and intensity of stepping practice as FastFES, but does not include FES, and no specific instructions are provided to target practice to the paretic leg or specific ankle deficits
10122004|NCT04380506|Experimental|Drain removal|Patients that fulfill criteria for surgical drains removal
10122005|NCT04380363|Experimental|Honda Walk Assist (HWA) Group|Participants utilize HWA device at home for 2 months according to prescribed settings.
10122006|NCT04380363|Active Comparator|Control Group|Participants complete prescribed exercise program at the Shirley Ryan AbilityLab gym for 2 months.
10122007|NCT04380324|Experimental|LY3471851|Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.
10122008|NCT04380324|Placebo Comparator|Placebo|Healthy participants in each cohort will receive the placebo comparator.
10122009|NCT04380272||Brodsky tonsil staging system|An oropharynx examination of all participants will be performed and tonsil size will be evaluated according to the Brodsky staging system. According to this staging system, tonsil sizes will be classified as stage I when the tonsils fill less than 25% of the transverse oropharyngeal space measured between the anterior tonsillar pillars; stage II when they fill between 25% and 50%, stage III when they fill between 50% and 75%, and stage IV when they fill more than 75%.
10122010|NCT04380272||The ultrasonographic data|The submental ultrasonography will be performed on all participants. Ultrasonographic examinations will be performed blinded to the physical examination results. All measurements will be performed by the same radiologist with experience in the field of ultrasonography. A GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) device will be used in the ultrasonography examination. The participants will be viewed using a 2-9 MHz linear probe from the submental region. The examination will be performed while the patient was lying in a supine position with a support placed under the neck.
10122011|NCT04380389|Other|profound hypoxia|
10122012|NCT04380220||Relapsing MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in relapse, untreated or treated with only immunomodulatory therapy.
10122013|NCT04380220||Remitting MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in remission, untreated or treated with only immunomodulatory therapy.
10122014|NCT04380220||Healthy controls|Age- and sex-matched healthy control subjects.
10122015|NCT04380285|Active Comparator|Group 1. Custom heel pads and modified soft molded orthotics|Modified soft custom orthotics supported in the medial longitudinal arches and medial shock absorbing heel pads with customized cutout at the point corresponding to the heel pain
10122016|NCT04380285|Active Comparator|Group 2. Custom hard orthotics|Custom hard orthotics made from a positive mold of a foot in neutral position, with arch support and medial heel postings.
10122017|NCT04380480|Experimental|Experiment|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
10122018|NCT04380376|Experimental|Melphalan inhalations|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 7-10 consequent days
10122019|NCT04380376|Other|Standard of care group|Patients assigned to the standard of care group will not receive any additional therapy.
10122020|NCT04380246||Clinicians|"Clinicians who care for pediatric patients >50% of their time, who treat pediatric patients who are in acute pain and between 0 and 3 years of age. May include physicians, clinical pharmacists, nurse practitioners, physician assistants, and/or nurses.~This cohort will complete a qualitative interview about pain and distress in infants and young children."
10122021|NCT04380155|Experimental|Participants|All participants will perform three moderate intensity cycling trials of different duration (30, 60 and 120 min) in an energy replete state.
10122022|NCT04380181||Dobutamine|Weaning from cardiopulmonary bypass using dobutamine as inotrope.
10122023|NCT04380181||Milrinone-epinephrine|Weaning from cardiopulmonary bypass using milrinone and epinephrine as inotropes.
10122024|NCT04380311|Experimental|Precision Tacrolimus|Participants in this arm of the study will have their tacrolimus dose determined using a precision medicine decision support software tool. The participant's transplant physician will consider the recommended dose from the decision support tool in combination with the physician's expertise and experience to determine the proper tacrolimus dose for the participant.
10122025|NCT04380298|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
10122026|NCT04380298|Active Comparator|The control group|In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
10122027|NCT04380259|Experimental|MBTR-R (Mindfulness-Based Trauma Recovery for Refugees)|Mindfulness-based group intervention consisting of nine 2.5-hour weekly sessions.
10122028|NCT04380259|No Intervention|Waitlist-Control|Following the 9-week waitlist period and 1-week post-intervention assessment, participants randomized to waitlist-control were offered an equivalent group intervention (i.e., 22.5 total hours, group instructor and cultural mediator, psychoeducation and low-intensity cognitive behavior therapy skill training, relaxation techniques).
10122029|NCT04380116|Experimental|Sb+Aware|Patients will access to the Soberlink device and receive treatment with Aware Recovery Care
10122030|NCT04380116|No Intervention|Aware|Patients will only have access to Aware Recovery Care
10122031|NCT04380103|Experimental|XELOXIRI/Bevacizumab|drugs: Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7, administered every 2 week for 12 cycles, after 12 cycles, administer bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy.
10122032|NCT04379947||FFR-CABG|Patients with at least one intermediate stenosis that received a preoperative FFR evaluation before being referred for CABG
10122033|NCT04379947||Angio-CABG|Patients with at least one intermediate stenosis that did not received a preoperative FFR evaluation before being referred for CABG
10122034|NCT04380194||victims|thirteen patients affected by lightning in collective fulguration
9827369|NCT02453360|Experimental|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
10122035|NCT04380194||healthy witnesses|fourteen healthy witnesses who have never been in contact with lightning, matched on age and sex
10122036|NCT04380129|Experimental|Μusic therapy-conversation sessions|
10122037|NCT04380129|Active Comparator|Discussion sessions|
10122038|NCT04379960||Peptides|PBMCs will be incubated with peptides.
10122039|NCT04379960||W/o peptides|PBMCs will be incubated without peptides.
10122040|NCT04379882|Experimental|Digital sedation|30 minutes Silva module
10122041|NCT04379973|Experimental|Tubal flush with Lipiodol Ultra Fluide® after Hyfosy|
10122042|NCT04379973|No Intervention|No tubal flush after Hyfosy|
10122043|NCT04379895|Active Comparator|Heated RF ablation|Patients with OA that will undergo heated RF of the genicular nerves
10122044|NCT04379895|Active Comparator|Pulsed RF ablation|Patients with OA that will undergo pulsed RF of the genicular nerves
10122045|NCT04379921|No Intervention|Control|Participants will receive standard care.
10122046|NCT04379921|Experimental|Apple Watch and App|Participants will receive standard care, and an Apple Watch to record activity through the App.
10122047|NCT04380012|Experimental|Single drug group|Pyrotinib: 400 mg, po, qd, 21d for a treatment cycle
10122048|NCT04380012|Experimental|Dual-targeted drug group|Pyrotinib: 400 mg, po, qd, 21d for one treatment cycle; Trastuzumab: first dose 8 mg/kg, then 6 mg/kg, iv, q3w, 21d for one treatment cycle
10122049|NCT04379869|Experimental|NNZ-2591 Single dose Cohort 1|Single dose of oral NNZ-2591 in healthy volunteers
10122050|NCT04379869|Experimental|NNZ-2591 Single dose Cohort 2|Single dose of oral NNZ-2591 in healthy volunteers
10122051|NCT04379869|Experimental|NNZ-2591 MAD Cohort 1|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
10122052|NCT04379869|Experimental|NNZ-2591 MAD Cohort 2|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
10122053|NCT04380168|Active Comparator|Modified pec 11 trunk block using ketamine additive|Ultasound guided modified pec 11 trunk block using ketamie hydrochoride 1mg/kg in 2ml volume added to 30ml bupivacaine 0.25% for trunk analgesia
10122054|NCT04380168|Active Comparator|Modified pec 11trunk block using dexmedetomidine additive|Ultasound guided modified pec 11 trunk block using dexmedetomidine 1ug/kg in 2ml volume added to 30ml bupivacaine 0.25%
10122055|NCT04380168|Active Comparator|Modified pec 11trunk block without additive|Ultasound guided modified pec 11 trunk block using bupivacaine 0.25% added to 2ml saline
10122056|NCT04379765||Grup 1: Exercise and physical therapy programme|30 patients with lumbar spinal stenosis will receive hot pack, transcutaneous electrical nerve stimulation and deep warming as a physical therapy modality , and lumber flexion and strengthening exercises were performed for 7 times/week for 3 weeks.
10122057|NCT04379765||Grup 2: Surgical procedure programme|30 patients with lumbar spinal stenosis underwent decompression operation of the relevant level.
10122058|NCT04379934|Other|Heart failure|Ejection fraction < 45%
10122059|NCT04379934|Other|Non-heart failure|Ejection fraction > 45%
10122060|NCT04379856|Experimental|Dose 1|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
10122061|NCT04379856|Experimental|Dose 2|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
10122062|NCT04379856|Experimental|Dose 3|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
10122063|NCT04379544||COVID-19 Positive Patients Receiving CPUS|Adult patients (18 years) presenting to the ED or ICU with highly suspected diagnosis or confirmed diagnosis of COVID-19 in whom the clinician deems a CPUS (cardiopulmonary ultrasound) is indicated.
10122064|NCT04379778|Experimental|Aerobic exercise|Moderate to high intensity aerobic exercise for 24 weeks.
9827370|NCT02453360|Experimental|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
10122065|NCT04379778|No Intervention|Standard care|Habitual lifestyle including standard care.
10122066|NCT04379531|Active Comparator|Standard Chest CT|
10122067|NCT04379531|Experimental|Low-dose Chest CT|
10122068|NCT04379648|Other|Posttraumatic stress disorder|cohort of patients with Posttraumatic stress disorder PTSD
10122069|NCT04379674|Experimental|Grup 1- Facilitation|It consists of cases that start with the taping of the facilitation.
10122070|NCT04379674|Experimental|Grup 2- İnhibition|It consists of cases that start with the taping of the inhibition.
10122071|NCT04379674|Placebo Comparator|Grup 3- Plasebo|It consists of cases that start with the taping of the placebo.
10122072|NCT04379583||Subjects|Female subjects providing DNA saliva sample
10122073|NCT04379726||patients with CFRD|Patients with diagnosis of CFRD, after OGTT
10122074|NCT04379726||patients without CFRD|Patients without diagnosis of CFRD, after OGTT
10122075|NCT04379804|Active Comparator|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery. The tissue between the carotid artery and the trachea was dissected gently parallel to the direction of the nerve until the nerve is identified visually and,or by hand held stimulation probe. After the identification of RLN, the vessels of inferior thyroid lobe was ligated. The nerve was dissected along its course to the entry point, and then the thyroid lobe was totally dissected from the trachea and the lobectomy was completed. If adverse EMG changes were encountered during lateral approach, traction was released immediately and waited for recovery.
10122076|NCT04379804|Active Comparator|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN nerve was identified at the point of entry both visually and with hand held stimulation probe. The RLN dissection was proceeded craniocaudally by the division of the suspensory ligaments of the berry through the level of inferior thyroid artery. After the identification and visualitzation of the RLN through its whole course, the medial and inferior vessels of the thyroid gland were dissected and ligated. Then, the lobe was dissected from the trachea and lobectomy was completed.
10122077|NCT04379830|Experimental|Very Low Energy Diet|VLED in its entirety is composed of the following for 3-weeks preoperatively: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
10122078|NCT04379557|Experimental|High power ablation|Ablation Index guided high power ablation (radio frequency energy: Left atrium anterior segment and roof: 40W, Left atrium inferior/posterior: 30W, near esophagus: 25W)
10122079|NCT04379557|Active Comparator|Conventional ablation|Conventional ablation applying 30-35W strategy for Left atrium anterior segments.
10122080|NCT04380025|Experimental|Mirtogenol|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) the experimental group will also take Mirtogenol. Mirtogenol is a dietary supplement composed of bilberry and pycnogenol which are botanical compounds with antioxidant properties. The active components of bilberry are flavonoid anthocyanosides (anthocyanins). Anthocyanosides are the only flavonoids able to reach the eye as a target organ in experimental animals. Unchanged anthocyanosides demonstrated after oral administration that it is absorbed and distributed into ocular tissues, showing its ability to pass through the blood-aqueous and blood retinal barriers.6
10122081|NCT04380025|Placebo Comparator|Lactose based Placebo|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) this control group will also take an identical placebo. This placebo is a inactive lactose based product of the same color and size capsule.
10122082|NCT04379453|Experimental|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses
10122083|NCT04379661|Experimental|Online support group|Online weekly 1-hour moderated support group sessions for 12-weeks; participants complete surveys at baseline and 12-week follow-up
10122084|NCT04379661|No Intervention|Treatment as usual|Inactive control group of participants who complete surveys at baseline and 12-weeks later
10122085|NCT04379609||Employees and students|The control group was selected from among the employees and students of the faculty of dentistry to represent the general population without any temporomandibular disorder (TMD).
10122086|NCT04379609||Patients|Patients who were referred to the Ondokuz Mayıs University Faculty of Dentistry Department of Prosthodontics with a complaint of pain in the chewing muscles were enrolled in this study.
10183094|NCT03767855|Placebo Comparator|Placebo for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo
10183095|NCT03767855|Experimental|CK-3773274 for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274
10122087|NCT04379739|Experimental|camrelizumab + apatinib|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; apatinib 250 mg, qd, p.o. 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
10122088|NCT04379739|Experimental|camrelizumab + platinum-based chemotherapy|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (squamous: carboplatin AUC5, gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
10122089|NCT04379401|Other|Biventricular Pacing deactivated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
10122090|NCT04379401|Other|Biventricular Pacing activated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
10122091|NCT04379375|Active Comparator|Inertia|"Participants simply receive and subsequently have default access (i.e., readily and immediately available) to handwashing (HW) materials. This condition will functionally serve as a control comparison. As the term implies, inertia capitalizes on minimizing effort necessary (e.g., going to the grocery store) to engage in HW behavior in one's personal environment."
10122092|NCT04379375|Experimental|Anchoring|"Involves once again providing default access to HW materials as above, but adds an explicit written cue to wash hands at a rate of (15) times per day, which is placed directly on the soap dispenser. The stimulus is intended to deliberately prime participant thinking (and subsequent behavior) towards a higher reference point that overshoots a desired target rate of 10+ daily HWs."
10122093|NCT04379479|Experimental|Dialyzable Leukocyte Extract|"Oral administration 2 mg/5 mL every 24 hours for 14 days, following by 2 mg/5 mL twice a week for 3 weeks.~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
10122094|NCT04379479|Placebo Comparator|Placebo|"Oral administration 5 mL every 24 hours for 14 days, following by 5 mL twice a week for 3 weeks.~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
10122095|NCT04379492|Experimental|Arm A - hydroxycholoroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
10122096|NCT04379492|Placebo Comparator|Arm B - placebo|Participants will receive placebo
10122097|NCT04379427|Experimental|Optimization and control 1|The first study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
10122098|NCT04379427|Experimental|Optimization and control 2|The second study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
10122099|NCT04379427|Other|Precision and accuracy|During the third study part with enrolment of 36 patients, the precision and accuracy of the final Sanmina biosensor algorithm will be demonstrated.
10122100|NCT04379388|Experimental|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
10122101|NCT04379388|No Intervention|Usual care control|Participants will receive referral to a quit smoking hotline
10122102|NCT04379362|Experimental|Low or intermediate grade prostate cancer|
10122103|NCT04379193|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
10122104|NCT04379193|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
10122105|NCT04379180||Treatment(bosentan, sildenafil and tadalafil)|
10122106|NCT04379167|Experimental|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma.
10122107|NCT04379349|Experimental|Active SMS|Weekly interactive SMS text messaging check-ins.
10122108|NCT04379349|Sham Comparator|Sham SMS|Weekly minimally interactive SMS text messages.
10122109|NCT04379271|Experimental|IMU-838|twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)
10122110|NCT04379271|Placebo Comparator|Placebo|twice-daily (BID) oral placebo (+ SoC)
10122111|NCT04379219|Active Comparator|surgery|"Valid consent~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )~Laparotomy transverse incision (pfannenstiel incision)~Exploration of the abdominal cavity~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.~Surgical repair of the uterine incision, and the abdomen"
10183096|NCT03767855|Placebo Comparator|Placebo for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo
10183097|NCT03767855|Experimental|Food Effect|Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion
10122112|NCT04379219|Active Comparator|methotrexate before surgery|"Valid consent~patient will receive 50 mgm /m2 of methtrexate after full investigation ( CBC, serum creatinie, AlT, AST), 1 week before surgery.~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )~Laparotomy transverse incision (pfannenstiel incision)~Exploration of the abdominal cavity~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.~Surgical repair of the uterine incision, and the abdomen"
10122113|NCT04379323|Experimental|YuWell YE900 and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE900 Electronic Sphygmomanometer (YuWell YE900) and with Desk Mercury Sphygmomanometer.
10122114|NCT04379310||covid-19 pneumonia|diagnosed with covid-19 by using PCR and computed tomography scans
10122115|NCT04378972||TREATED GROUP|25 portions of vitreous samples from 25 eyes of patients operated on vitrectomy for complications from diabetic retinopathy, incubated with curcumin, homotaurine and vitamin D3. The substances will be used individually and in triple association, to evaluate a possible synergistic effect on the expression of inflammatory cytokines and endothelial growth factors.
10122116|NCT04378972||CONTROL GROUP|The same fractions of vitreous samples (n = 25) evaluated for the expression of oxidative biomarkers, inflammatory cytokines and metalloproteinases, without prior incubation with the substances of the treated group.
10122117|NCT04378946|Experimental|Experimental - Error Augmented feedback (Restricted area)|Error augmented feedback. Random targets always INSIDE of workspace area.
9668973|NCT04460937|Experimental|Treatment (radiation therapy, adavosertib)|Patients undergo radiation therapy QD 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive adavosertib PO QD for 2-5 days (depending on dose level) during weeks 1 and 3 of radiation therapy in the absence of disease progression or unacceptable toxicity.
10122118|NCT04378946|Active Comparator|Control - General feedback (Full area)|General feedback about task success. Random target INSIDE or OUTSIDE of workspace area.
10122119|NCT04378816|Experimental|QPL intervention group|Using shared decision making support tool(Question Prompt List) for intervention
10122120|NCT04378816|No Intervention|Usual care group|No intervention, just continue using usual care
10122121|NCT04379102||IUD patients|80 patients who matched the inclusion criteria and received IUDs
10122122|NCT04379128||patients with epilepsy|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
10122123|NCT04379128||Normal controls|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
10122124|NCT04378894|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
10122125|NCT04378894|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Families in the wait-listed control group will participate in a special awareness program but not MOCEP. Although the families in the wait-listed control group will start as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
10122126|NCT04378998|Experimental|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Ying Tang were used.
10122127|NCT04378998|No Intervention|Usual care|
10122128|NCT04379037|Experimental|Intervention Arm|Adults over 18 years of age hospitalized because of COVID-19 infection will be treated with transcutaneous auricular vagus nerve stimulation (taVNS).
10122129|NCT04378829||ambulatory follow-up|
10122130|NCT04378829||hospital follow-up|
10122131|NCT04378829||intensive care unit follow-up|
10122132|NCT04378803|Experimental|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session. Then, 4 weeks of no-training interval followed by a testing session.
10122133|NCT04378803|Experimental|Wait-list control (WLC) group|Receives 4 weeks of no-training interval followed by a testing session. Then, 4 weeks of mindfulness training followed by a testing session.
10122134|NCT04378985|Experimental|Wearing a wearable device (the smart watch) for 8 weeks|The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.
9668974|NCT04457596|Active Comparator|Arm I (trastuzumab emtansine, placebo)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
10122135|NCT04378868|Active Comparator|Surgery within 8 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
10122136|NCT04378868|Experimental|Surgery within 24 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
10122137|NCT04378868|Experimental|Surgery within 8 hours, antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
10122138|NCT04378868|Experimental|Surgery within 24 hours, antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
10122139|NCT04378725|No Intervention|Control School|"When a student is screened as a smoker. The student will only be receiving Brief Intervention Advice from the dentist.~Brief Intervention advice: delivered to all schoolchildren regardless of smoking status by the dentist. Brief information of dangers of smoking was embedded in the generic lecture of Dental Health Education given to the whole school in large group."
10122140|NCT04378725|Experimental|Intervention School|The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
10122141|NCT04378777||Surveillance cohort|Cohort descriptive data will include demographic variables (e.g. age, sex, race, ethnicity), clinical information on enrollment and key aspects of medical history (e.g. concomitant medications, for example). Patients will be longitudinally followed, up to 12 months.
10122142|NCT04378634|Experimental|ME/CFS Exercise|Patients undergoing the physical stress test (aerobic power index)
10122143|NCT04378634|Experimental|Patients Stress|Patients undergoing the mental stress task (MIST)
10122144|NCT04378634|Active Comparator|Healthy Exercise|Healthy controls undergoing the physical stress test (aerobic power index)
10122145|NCT04378634|Active Comparator|Healthy Stress|Healthy controls undergoing the mental stress task (MIST)
10122146|NCT04378543|Experimental|ART252-L|local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion
10122147|NCT04378686||ESKD|Patients with ESKD and on treatment with any form of dialysis
10122148|NCT04378712|Experimental|Intervention Group|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
10122149|NCT04378712|Other|Control Group|Usual care referred to the standard-of-care (including oxygen therapy) recommended by Chinese National Health Commission.
10122150|NCT04378608|Other|2 DAA (OBV/PTV/r) ± ribavirin (RBV)|Administering Ombitasvir/Paritaprevir/Ritonavir/ tablets plus RBV tablets to HCV GT4 in the treatment of Egyptian naïve patients
10122151|NCT04378673||parental involvement group|n=46
10122152|NCT04378673||parental presence group|n=42
10122153|NCT04378673||parental absence group|control group, n=32
10122154|NCT04378465||ERP group|A prospective series of consecutive patients undergoing elective colorectal surgery completing a standardized Enhanced Recovery Program (ERP) protocol at the S. Anna University Hospital in Ferrara (Italy) in 2013-2015
10122155|NCT04378465||Non-ERP group|A retrospective series of consecutive patients operated at the same hospital (S. Anna University Hospital in Ferrara), in the same period of time (2013-2015), but with a traditional perioperative care protocol.
10122156|NCT04378660|Experimental|Intervention arm|Colonoscopy with AI
10122157|NCT04378595||During Pandemic|During Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. If a positive response is given, the investigators will ask if the food insecurity began or worsened during the pandemic in the past 1 to 2 months.
10122158|NCT04378595||Post-Pandemic|Post-Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. The investigators will assess if food insecurity has stopped or lessened after the pandemic.
10122159|NCT04378621|Experimental|Pharmacological anti-inflammatory treatment|Use of anti-rheumatic treatment with TNF-α inhibitor (subcutaneous injection given once or twice a week) or JAK inhibitor (per oral tablet once or twice a day)
10122160|NCT04378621|Experimental|Physical hand training|Physical hand training 10 min twice daily while on stable treatment
10122161|NCT04378556|Other|Nutrition|All participants received diet coaching, nutrition education and a per-meal protein prescription.
10122162|NCT04378738|Other|Cohort|the healthy people who accepted to participate in the study
10122163|NCT04378530|Experimental|Personalized Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be asked to select a cue to use to remember to meditate.
10122164|NCT04378530|Active Comparator|Study control|Participants in the control group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive non-anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day.
10122165|NCT04378530|Experimental|Fixed Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be given a specific cue (i.e. leaving the bathroom in the morning) to use to remember to meditate.
10122166|NCT04378452||COM-COVID cohort|Individuals of >16 years old evaluated during the COVID-19 outbreak by an anonymous survey and willing to respond. Expected timeframe for the collection of completed surveys: March 31th, 2020-September 30th, 2020]
10183098|NCT03767855|Experimental|Relative Bioavailability|Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.
9967052|NCT01266200|Active Comparator|Minimal-invasive treatment (Mantis)|Patients, who received a minimal-invasive surgery and the fracture was fixed by a system called Mantis
10183099|NCT03767829|Experimental|Part A: SAD: ALN-AAT02|Participants will be administered a single dose of ALN-AAT02.
10183100|NCT03767829|Placebo Comparator|Part A: SAD: Placebo|Participants will be administered a single dose of matching placebo.
10183101|NCT03767829|Experimental|Part B: MAD: ALN-AAT02|Participants will be administered multiple doses of ALN-AAT02.
10183102|NCT03767829|Placebo Comparator|Part B: MAD: Placebo|Participants will be administered multiple doses of matching placebo.
10183103|NCT03767816|Experimental|Group R : Rectus sheath block group|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision
10122167|NCT04378322|Active Comparator|Nutrition and food purchasing tool + telenutrition|Participants will use an online nutrition and food purchasing tool in addition to telenutrition.
10122168|NCT04378322|Active Comparator|Nutrition and food purchasing tool|Participants will use an online nutrition and food purchasing tool.
10122169|NCT04378322|Active Comparator|Nutrition education tool|Participants will be exposed to an online nutrition education materials.
10122170|NCT04378218|Experimental|HIIT Intervention|
10122171|NCT04378101||Anorexia Nervosa Case|Participants in this group have a life-time history of anorexia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
10122172|NCT04378101||Bulimia Nervosa Case|Participants in this group have a life-time history of bulimia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa.
10122173|NCT04378101||Binge-Eating Disorder Case|Participants in this group have a life-time history of binge-eating disorder as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa or bulimia nervosa.
10122174|NCT04378101||Control|Participants in this group have no history of disordered eating behaviors as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
10122175|NCT04378374|Experimental|Baked food made of lentil flour|Food prepared with 100% lentil flour
10122176|NCT04378374|Experimental|Baked food made of lentil flour and wheat flour|Food prepared with a mixture of lentil flour and wheat flour
10122177|NCT04378374|Experimental|Baked food made of wheat flour|Food prepared with 100% wheat flour
10122178|NCT04378374|Experimental|Water|Potable water (energy and carbohydrate-free control)
10122179|NCT04378413|Experimental|The Effect of Aquatic Exercises on Pain, quality of life|Water-based exercise program was conducted in the second group of 15 patients in an indoor swimming pool. Temperature of mineral water was 36 °C. The program included warming up by walking forwards, sideways and backwards through the water in the pool; active range of motion of the joints of the lower extremities; stretching lower extremities; strengthening exercises for hips, knees, arms, elbows and wrists; and cooling down (slow walking, squatting and standing).
10122180|NCT04378413|Experimental|The Effect of Land Exercises on Pain, Quality of life|Land-based exercise program included abdominal and back strengthening exercises.
10122181|NCT04378647|Active Comparator|Induction ESHAP|3 Cycles ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4]
10122182|NCT04378647|Experimental|Induction BV-ESHAP|3 Cycles of Brentuximab VEedotin + ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4] Brentuximab Vedotin [1.8 mg/kg IV, D1]
10122183|NCT04378205|Experimental|0.014/0.018 NiTi arch wire|0.014-inch NiTi on one side /0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
10122184|NCT04378205|Experimental|0.016/0.018 NiTi arch wire|0.016-inch NiTi on one side / 0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
10122185|NCT04378335|Experimental|one arm|oral disorder
10122186|NCT04378244|Experimental|DeltaRex-G|"Escalating doses of DeltaRex-G i.v daily for 7 days as follows:~Dose Level I: 3-6 patients will receive 1 x 10e11 cfu/dose Dose Level II: 3-6 patients will receive 2 x 10e11 cfu/ dose Dose Level III: 3-6 patients will receive 3 x 10e11 cfu/dose"
10122187|NCT04378582||COVID-19 confirmed|Patients with confirmed COVID-19 by RT-PCR or serological test
10122188|NCT04378582||COVID-19 suspected|Patients suspected COVID-19, as defined by clinical history and course, who have negative RT-PCR or serological test but where treated and cared for as COVID-19 patients
10122189|NCT04378127|Experimental|educational program + traditional medical care|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
10122190|NCT04378127|No Intervention|traditional medical care|traditional medical care
10122191|NCT04378062|Active Comparator|Traction Neurectomy|Traction neurectomy - of digital sensory nerves at the time of amputation.
10122192|NCT04378062|Experimental|Targeted Muscle Reinnervation|Targeted Muscle Reinnervation - of digital sensory nerves at the time of amputation
10122193|NCT04378062|Experimental|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface - of digital sensory nerves at the time of amputation
10122194|NCT04378296|Experimental|Teledermatology|The 221 patients who are included in this group will be monitored from the Primary Care centers.
10122195|NCT04378296|No Intervention|Conventional monitoring|The 221 patients included in this group will have to visit the dermatologist at the hospital.
10122196|NCT04378348|Experimental|Motivational Interview|
10122197|NCT04378348|Experimental|Participatory Group Activity|
10122198|NCT04378348|Placebo Comparator|Control Condition|
10122199|NCT04378231|Experimental|high-dose group|patients take dry suspension of amoxicillin clavulanate potassium 45 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
10122200|NCT04378231|Experimental|standard dose group|patients take dry suspension of amoxicillin clavulanate potassium 30 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
10122201|NCT04378166|Experimental|Smart glasses|Application of smart glasses for ultrasound-guided central venous catheterization
10122202|NCT04378166|No Intervention|Control|Conventional ultrasound-guided central venous catheterization
10122203|NCT04378517|Other|ADHD FAM-SOTC support: A Pilot Study|"Phase-I, a pilot study to evaluate the feasibility of offering a 5-week intervention for families of adolescents diagnosed with ADHD at BUGL. The outcome helps to determining the feasibility of subjecting the intervention to a more rigour and a more expensive and time-consuming RCT.~Phase-II and III are an RCTs to determine the benefit of a FAM-SOTC intervention: Is there a significant difference in the impact of FAM-SOTC intervention:~From caregiver's perspective (phase II) on the experience of support for, family functioning, believes, coping patterns, general well-being, parental adaptation and parental assessment of ADHD symptoms and adolescent developmental disruptive behaviour, compared to caregivers receiving delayed treatment?~From adolescents' perspective (Phase-III) in the assessment of adolescents own self-awareness and self-esteem, after their parents receive FAM-SOTC intervention, compared to a group of adolescents where caregivers receive delayed treatment?"
10122204|NCT04378309|Experimental|ePrep|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
10122205|NCT04378257|Experimental|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform. The sessions will be conducted in the Arabic or English languages.~Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~Acknowledging emotions and normalizing current stress~Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~Behavioral Activation Acceptance and Commitment Therapy (ACT)~Grounding, Breathing, Acceptance of emotions, and de-fusion"
10122206|NCT04378257|Active Comparator|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice.
10122207|NCT04378036|Active Comparator|Neurodevelopmental Therapy Group|The number of participants in this group is 30. All participants were included in the rehabilitation program using only the Neurodevelopmental Therapy approach for 16 sessions (8 weeks x 2 days x 45 minutes).
10122208|NCT04378036|Active Comparator|Hippotherapy Simulator Group|The same participants were taken into a rehabilitation program in which 16 sessions (8 weeks x 2 days a week) the Hippotherapy Simulator device (30 minutes) and Neurodevelopmental Therapy (NDT) (15 minutes) (HS + NDT method) were used together.
10122209|NCT04378088||Group 1 - experts|"Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
10122210|NCT04378088||Group 2 - mix experts/trainee|"If intra and interobserver rates in group 1 are >0.7 proceed to group 2 evaluation with the same intervention.~Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
10122211|NCT04377906|Experimental|High Protein-Fiber and Exercise|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day and exercise : aerobic and resistance training for 5x/week, 45 minute each sesion
10122212|NCT04377906|Experimental|High Protein-Fiber|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day
10122213|NCT04377906|Experimental|Exercise|aerobic and resistance training for 5x/week, 45 minute each sesion
10122214|NCT04377906|No Intervention|control|regular diet
10122215|NCT04378192|Active Comparator|Face mask ventilation|Use of face mask ventilation technique after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
10122216|NCT04378192|Active Comparator|Laryngeal mask ventilation|Use of laryngeal mask airway LMA for ventilation after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
10122217|NCT04378283|Experimental|LET as topical anesthetic for wound repair.|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%) is a topical anesthetic that is routinely used before laceration repair.
10122218|NCT04378283|Active Comparator|EMLA plus infiltration as anesthetic for wound repair.|"EMLA (eutectic mixture of local anesthetics) with subsequent lidocaine infiltration. EMLA is a mixture of lidocaine (2.5%) and prilocaine (2.5%) in a cream base."
10122219|NCT04377841||Facial Demodicosis|"Clinical presentation of facial skin matches any of the followings:~Pityriasis folliculorum.~Papulopustular lesion.~Rosacea.~Demodex infestation detected by direct microscopic examination ≥ 5 mites/cm2."
10122220|NCT04377841||Ocular Demodicosis|"Clinical presentation of ocular region matches any of the followings:~Chronic blepharitis.~Eyelash abnormalities: trichiasis, distichiasis, madarosis.~Meibomian gland dysfunction.~Recurrent chalazion.~Ocular rosacea.~Demodex infestation detected by cilia epilation test ≥ 1 mite/eyelid."
10122221|NCT04377867||LRBA deficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
10122222|NCT04377867||CTLA4 haploinsufficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
10122223|NCT04377867||Control group|Age matched healthy control group will be used during the study to determine the reference values of the immunological assays.
10122224|NCT04377828|Experimental|Laser intervention|1 to 2 sessions of pigment laser1
10122225|NCT04377893|Experimental|Treatment arm|Participants will receive eye-gaze AT intervention
10122226|NCT04377958|Other|Asthmatics|Asthmatic group from which serum samples will be collected for analysis
10122227|NCT04377789|No Intervention|non-quercetin group|Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
10122228|NCT04377789|Active Comparator|quercetin prophylaxis group|Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
10122229|NCT04377789|Active Comparator|quercetin treatment group|Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
10122230|NCT04377815||General Public cohort|General Public
10122231|NCT04377815||Hospital cohort|Medical records of patients hospitalised due to COVID-19
10122232|NCT04378010|Experimental|EDP-305 1.5 mg|Once a day orally for 72 weeks
10122233|NCT04378010|Experimental|EDP-305 2 mg|Once a day orally for 72 weeks
10122234|NCT04378010|Placebo Comparator|Placebo|Once a day orally for 72 weeks
10122235|NCT04377776||Transplanted patients|Transplanted Kidney, Pancreas or Pancreatic Islet patients at MedicineTransplant Unit - San Raffaele Scientific Istitute
10122236|NCT04377854||MCS recipients|All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.
10122237|NCT04377854||Recipient of cardiac transplant|All recipients of cardiac transplantation(s) will be followed up on a yearly basis with collection of clinical data for 25 years.
10122238|NCT04377854||Watchful waiting at Rigshospitalet|Patients referred for evaluation for treatment with advanced treatment (LVAD/HTX) but -for whatever reason- these pts will be on watchful waiting at the Rigshospitalet.
10122239|NCT04377971|Experimental|Ask-tell-ask method|Study team will provide participant education using the ask-tell-ask method. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
10122240|NCT04377971|Active Comparator|Standard of Care (SOC)|Participants will receive SOC education from the researcher. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
10122241|NCT04377750|Experimental|Tocilizumab treatment group|Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.
10122242|NCT04377750|Placebo Comparator|Placebo group|Placebo. intravenous administration of 100 ml of normal saline.
10122243|NCT04377698|Active Comparator|Platelet Rich Fibrin group(PRF)|Following apicoectomy PRF gel was prepared and placed in the osseous defect followed by placement of PRF membrane
10122244|NCT04377698|Active Comparator|Freezed Dried Bone Allograft group(FDBA)|Following apicoectomy FDBA graft were prepared and placed in the osseous defect followed by placement of PRF membrane
10122245|NCT04377568|Experimental|Convalescent Plasma + Standard of Care (C19-CP + SoC)|Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.
10122246|NCT04377568|No Intervention|Standard of Care (SoC)|Participants will receive standard of care while being hospitalized for COVID-19.
9827371|NCT02453386|Experimental|Tozadenant 60 mg BID|"During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
10122247|NCT04377737|Other|RT-PCR Covid-19|
10122248|NCT04378049|Active Comparator|Standard total knee arthroplasty|Participants who are randomized to the control group will undergo TKA according to local standard of care. The choice of implant and use of bone cement will be recorded but left to the surgeon's discretion according to their standard practice.
10122249|NCT04378049|Experimental|Robot-assisted partial knee arthroplasty|Participants with isolated medial or isolated lateral compartment OA who are randomized to the intervention group and have one affected knee compartment will receive a robot-assisted unicompartmental knee arthroplasty (UKA). If the patient has medial or lateral OA plus patellofemoral OA they will receive a bicompartmental knee arthroplasty (BiKA) consisting of a two simultaneous UKAs. The partial knee replacement procedures will be performed using the Mako RIO robotic arm (Stryker) according to the manufacturer's instructions. The choice of implant and use of bone cement will be recorded but will be left to the surgeon's discretion. Surgeons will resurface the patella if the patellar cartilage meets Outerbridge grade 3 or 4 criteria
10122250|NCT04377633|Sham Comparator|Pre-intervention|Anesthesia handover during surgery will be performed as usual, i.e., a verbal exchange of pertinent clinical information.
10122251|NCT04377633|Experimental|Post-intervention|Anesthesia handover during surgery will be performed according to a structured checklist.
10122252|NCT04377529|Experimental|Back Skills Training Champion|In additional to access to the online provider Back Skills Training course, participants in clusters randomised to this arm will receive additional support from a local champion. The local champion will have received additional training and support on the implementation of the Back Skills Training intervention from the study team.
10122253|NCT04377529|Active Comparator|No Champion|Participants in clusters randomised to this arm will not receive any additional training or support beyond access to the online provider Back Skills Training course.
10122254|NCT04378023|Other|Study group|Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
10122255|NCT04377646|Active Comparator|Hydroxychloroquine & Zinc|"Will receive:~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~Zinc 15 mg at daily dose up to 2 months"
10122256|NCT04377646|Active Comparator|Hydroxychloroquine|"Will receive:~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.~Placebo of Zinc"
10122257|NCT04377646|Placebo Comparator|Placebo|Will receive a double placebo (Hydroxychloroquine and Zinc) up to 2 months
10122258|NCT04377516|Experimental|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
10122259|NCT04377516|Active Comparator|Exercise group|pelvic floor muscle training
10122260|NCT04377516|Placebo Comparator|Control group|pelvic girdle education
10122261|NCT04377516|Other|Health group|pelvic girdle education
10122262|NCT04377607||Group OP|outpatients with asymptomatic or uncomplicated or mild pneumonia
10122263|NCT04377607||Group H|hospitalized patients
10122264|NCT04377607||Group IC|patients admitted to intensive care unit
10122265|NCT04377555|Experimental|All Participants|Main study participants will be evaluated at baseline, monitored and followed for a 1 year period with the option to participate in a 1 year extension. Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.
10122266|NCT04377282|Experimental|Buckwheat|Cooked buckwheat
10122267|NCT04377282|Experimental|Couscous|Cooked couscous
10122268|NCT04377282|Experimental|Water|Potable water
10122269|NCT04377178|Experimental|Dentin chips group from automated mill|Dentin particles prepared from dentin grinder will be placed in extraction socket immediately after extraction
10122270|NCT04377178|Active Comparator|Manually milled Dentin chips|Dentin particles prepared from bone mill will be placed in extraction socket immediately after extraction.
10122271|NCT04377594|Experimental|Pulmonary vein isolation plus substrate modification|Pulmonary vein isolation plus ablation of low voltage areas in the left atrium
10122272|NCT04377594|Active Comparator|Pulmonary vein isolation|Pulmonary vein isolation
10122273|NCT04377386|Experimental|Intervention group: 1000 IU DV|The 75 participants assigned to the intervention group will take 1 DV capsule of 1000 IU daily for 15 weeks.
10122274|NCT04377386|Placebo Comparator|Control group: 200 IU DV|The 75 participants of the control group will take 1 DV capsule of 200 IU daily for 15 weeks, this dose being the minimum recommended for children. The above, considering that it is ethical for the control group to receive a minimum dose of supplementation.
10122275|NCT04377347||Confirmed spontaneous subarachnoid haemorrhage|"Patients, minimum 18 years of age, identified with the diagnosis in the Danish National Patient Register. The diagnosis is verified by medical record review.~All patients were initially admitted to a hospital in the Capital Region of Denmark.~In a national labour marked register and the civil registration register the patients are then followed for four years."
10122276|NCT04377230|Experimental|Biliopancreatic limb 60cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
10122277|NCT04377230|Active Comparator|Biliopancreatic limb 100cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
10122278|NCT04377425||Patients with acute neurological symptoms|Consecutive patients with acute neurological disease admitted at the Neurology departments will be tested with a nasopharyngeal swap for SARS-COVID-19 RNA according to standard operating procedures at the department (if estimated hospital stay is >24hours). Medical and clinical characteristics will be collected
10122279|NCT04377425||Stroke patients|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
10122280|NCT04377425||Seizure/epilepsy|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
10122281|NCT04377542|Active Comparator|LIFT|Ligation of intersphincteric fistula tract
10122282|NCT04377542|Active Comparator|Parks|Modified Parks technique
10122283|NCT04377542|Active Comparator|Seton|Two-stage seton placement
10122284|NCT04377256|Experimental|Radiological assessement|Two CBCTs were recorded and compared, one at the baseline and the other at 4 months post-op. The bone resorption was quantified and analyzed using ITK-SNAP software
10122285|NCT04377256|Experimental|Histomorphometric analysis|During implant placement (4 months after the bone grafting), a bone biopsy is collected and stained with several colorants to analyze the biological bone healing
10122286|NCT04377126|Active Comparator|Unacylated ghrelin|Participants randomized to unacylated ghrelin will self-administer 20 ug/kg unacylated ghrelin daily. Study drug is dispensed in syringes labeled with the participant's name, date of birth, expiration date, and instructions for administration. Syringes will NOT be labeled with the group assignment, ensuring that both the research team collecting data and study participants are blinded to group assignment (i.e. double blinded status). Study drug is stored and handled according to the University of Chicago Research Pharmacy Standard Operating Procedure (SOP).
10122287|NCT04377126|Placebo Comparator|Placebo|Participants randomized to placebo will self-administer an identical-appearing solution of bacteriostatic saline daily.
10122288|NCT04377399|Active Comparator|high dose|vitamin D (40,000 IU weekly) for 24 weeks
10122289|NCT04377399|Active Comparator|Low dose|vitamin D (5,000 IU weekly) for 24 weeks
10122290|NCT04377412||Albania|
10122291|NCT04377412||Australia|
10122292|NCT04377412||Czech Republic|
10122293|NCT04377412||France|
10122294|NCT04377412||Germany|
10122295|NCT04377412||Hong Kong|
10122296|NCT04377412||Israel|
10122297|NCT04377412||Italy|
10122298|NCT04377412||Lebanon|
10122299|NCT04377412||Norway|
10122300|NCT04377412||Poland|
10122301|NCT04377412||Russia|
10122302|NCT04377412||Spain|
10122303|NCT04377412||Sweden|
10122304|NCT04377412||Taiwan|
10122305|NCT04377412||Ukraine|
10122306|NCT04377412||United States|
10122307|NCT04377321||group 1 on cochicine|The first group patients received colchicine 0.5 twice daily for 6 months
10122308|NCT04377321||group 2 on glucophage 1 gm twice daily|second group received glucophage 1gm twice daily for 6 months
10122309|NCT04377321||group 3 control|the third group patients were on diet only for 6 months
10122310|NCT04377464||COVID-19 Survivors|Patients following-up at the PWH outpatient clinics will be enrolled for further evaluation via telephone follow-up at one, three, and six months after hospital discharge. SF12, EQ-5D-5L and work status standardized quantitative assessments of quality of life will be implemented via telephone follow-up at these time-points.
10122311|NCT04377269|Experimental|Taping Group|33 participants, received ankle taping
10122312|NCT04377269|Experimental|Bandaging|33 participants, received ankle bandaging
10122313|NCT04377269|Placebo Comparator|Placebo Taping (Control) Group|34 participants, received ankle placebo taping
10122314|NCT04377087|Experimental|Olaparib|Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.
10122315|NCT04377243|Experimental|V8 850 mg|Arm 1: Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of V8
10122316|NCT04377243|Placebo Comparator|Placebo 850 mg|Arm: 2 Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of placebo
10122317|NCT04377139||Prophylaxis|Those LTR receiving prophylaxis against CMV
10122318|NCT04377139||Preemptive therapy|Those LTR receiving preemptive therapy against CMV
10122319|NCT04377191|Experimental|VR 1 Group|In this group, participants received standard exercise and exergame training with Microsoft Xbox 360 Kinect for 2 days per week for 6 weeks.
10122320|NCT04377191|Experimental|VR 2 Group|In this group, participants received standard exercise and exergame training with ALDA balance gear for 2 days per week for 6 weeks.
10122321|NCT04377191|Active Comparator|Control Group|In this group, participants received only standard exercise for 2 days per week for 6 weeks.
10122322|NCT04377308|No Intervention|Treatment As Usual|Participants may choose to not take fluoxetine and remain in the study
10122323|NCT04377308|Active Comparator|Fluoxetine|Participants will take fluoxetine 20 mg initially, increasing as tolerated to a maximum of 60 mg until symptoms abate, then will be tapered by 20 mg per week off the fluoxetine Participants will be on fluoxetine for 2 weeks to 2 months depending on symptom duration
10122324|NCT04376931|Experimental|Iscador®P as intravenous infusion|"Investigational therapy will be administered in six Dose Groups (DG):~10 mg, 20 mg, 40 mg, 90 mg, 140 mg and 200 mg Iscador®P. The initial dose group of the study is set to 40 mg Iscador®P. The two lower dose groups (20 or 10 mg) will only be used in case of intolerance at 40 mg Iscador®P. Once per week patients receive intravenous infusions of Iscador®P dissolved in 250 ml of sodium chloride solution (0.9 %). After the 4-week period of the MTD estimation phase each subject will immediately be included into a follow up observation in which he/she receives the last well tolerated dosage they had or the next lower dosage than the currently investigated DG in the running phase Ib study depending on the current estimate of the MTD at that time."
10122325|NCT04377022|No Intervention|Conventional Therapy|In this group, Patients receive Conventional Therapy for 40 minutes daily and 5 days in a week. The training period was 5 week after the recruitment of patients.
10122326|NCT04377022|Experimental|Combined Therapy|In this group, Patients receive Aerobic exercise training in addition to conventional Physical Therapy. Patients undergoes Aerobic exercise training for 25 minutes and 3 days in a week. A total of 15 session of aerobic exercise training session was given to patient.
10122327|NCT04376957|Active Comparator|Counselled with Current Standard Care|Standard of care consists of standard counselling and written materials provided by the oncologist or pharmacy (e.g. instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered).
10122328|NCT04376957|Experimental|Counselled with MASCC Oral agent Teaching Tool (MOATT)|This group will receive counselling using the MASCC Oral Agent Teaching Tool and be compared with the standard of care counselling.
10122329|NCT04377217|Experimental|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months.
10122330|NCT04377477|Experimental|Lung low dose radiotherapy|Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
10122331|NCT04376970|Active Comparator|Fluorometholone group|This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
10122332|NCT04376970|Active Comparator|Cyclosporine A group|This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
10122333|NCT04376840|Experimental|adults with severe SARS-CoV2 pneumonia|adult with severe SARS-CoV2 pneumonia
10122334|NCT04377165|Active Comparator|Newsfeed|This will provide you with reliable accurate information on the pandemic.
10122335|NCT04377165|Experimental|Gamification|The gamification function will allow users to earn points for actions completed. The gamification function has links to resources for infection control, watching or completing tasks or playing games to earn points. Points can be viewed at a facility level, state level or national level.
10122336|NCT04376697|Experimental|Active rTMS|Treatment will be delivered daily (weekdays) rTMS treatments, for up to 10 daily sessions and up to 75 sessions in total.
10122337|NCT04376671||temporal lobe epilepsy|Group of patients with temporal lobe epilepsy
10122338|NCT04376671||Extra-temporal lobe epilepsy|Group of patients with extra-temporal lobe epilepsy
10122339|NCT04376658||Cohort 1|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with up to 4L/minute oxygen supply through nasal catheter.
10122340|NCT04376658||Cohort 2|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection needing oxygen supplementation > 4L/min on nasal catheter or HFNC or NIV or MV or ECMO.
10122341|NCT04376658||Cohort 3|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with moderate or severe ARDS according to the Berlin definition
10122342|NCT04376736|No Intervention|Control arm|Patients are reminded about their appointments
10122343|NCT04376736|Experimental|Intervention arm|Patients are offered a one-time home visit by providers in lieu of their upcoming in-person visit
10122344|NCT04377048|Experimental|Nivolumab/GS|"Part-1: GS Induction~Patients will receive GS for 1 cycle.~S-1: 60/80/100 mg per day (based on body surface area, BSA); D1-12; 3 weeks per cycle~BSA < 1.25 m2: 60 mg/day; 1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day; BSA ≥ 1.5 m2: 100 mg/day~Gemcitabine: 850 mg/m2; D1, 8; 3 weeks per cycle~After GS, patients fulfilling the pre-defined CA 19-9 criteria will enter the Add-On part.~Part-2: Nivolumab Add-On~Nivolumab: 3 mg/kg every 2 weeks, 6 weeks per cycle~S-1: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~Gemcitabine: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle~The treatment will be continued until disease progression, intolerance to study treatment or death."
10122345|NCT04376853||COVID-19|Patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
10122346|NCT04376775||Transplant patient|This study will involve all the transplant centres in France. The investigator will use patient-completed surveys for all participants. Wait Listed Transplant Candidates and Transplant Recipients (liver, kidney, pancreas, heart, lung) will be contacted by the all French transplant centres and patient's associations.
10122347|NCT04376632|No Intervention|Control|Participants in this group avoid all nuts for 8 weeks.
10122348|NCT04376632|Experimental|Pecan ADD|Participants in this group consume 68 g of pecans/d with no additional dietary instructions and avoid all other nuts.
10122349|NCT04376632|Experimental|Pecan SUB|Participants in this group consume 68 g of pecans/d with instructions to substitute pecans with isocaloric foods in the habitual diet. They are also instructed to avoid all other nuts.
10122350|NCT04376866|Experimental|Toripalimab+CCRT|"Toripalimab 240mg, and Cisplatin 100mg/m2 (every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT), followed by Toripalimab 240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy.~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
10122351|NCT04376866|No Intervention|CCRT alone|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT).~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
10122352|NCT04376892||Group 1|Exercise capacity under 149 meter
10122353|NCT04376892||Group 2|Exercise capacity between 150 and 249 meter
10122354|NCT04376892||Group 3|Exercise capacity between 250 and 349 meter
10122355|NCT04376892||Group 4|Exercise capacity above 340
10122356|NCT04376879||Step 1: creation of the score|Cohort for the creation of clinical-biological score to predict the risk of intubation in COVID-19
10122357|NCT04376879||Step 2: validation of the score|Cohort for the validation of clinical-biological score to predict the risk of intubation in COVID-19
10122358|NCT04376944||Exposed group|Caregivers and agents working directly in COVID units compared to those living.
10122359|NCT04376944||Control group|caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection
10122360|NCT04376788|Experimental|Exchange transfusion|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
10122361|NCT04376788|Experimental|Methylene blue with plasma|Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
10122362|NCT04376788|Experimental|Exchange transfusion and methylene blue with plasma|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
10122363|NCT04376645|Experimental|Group 1|Group 1: - Class III patients with increased vertical relationship These patients were scheduled for bimaxillary surgical procedures (Maxillary advancement and mandibular setback with posterior maxillary impaction) to correct the antero-posterior and vertical skeletal discrepancies.
10122364|NCT04376645|Experimental|Group 2|Group 2: - Class III subjects with normal vertical relationship These patients were scheduled for mandibular setback surgical procedure (with no posterior maxillary impaction) to correct the antero-posterior skeletal discrepancy.
10122365|NCT04376996||General cohort|General population cohort aged 0-100 years from Slovenia
10122366|NCT04376710||Surgeons|
10122367|NCT04376710||Patients|
10122368|NCT04376606|Experimental|Left atrial appendage closure group|
10122369|NCT04376606|Experimental|Radiofrequency ablation group|
10122370|NCT04376606|Experimental|LAAC combined with radiofrequency ablation group|
10122371|NCT04376723|Experimental|Assisted self-guidance|Participants will be asked to use the app for five weeks and will be contacted via telephone once a week by a researcher to provide a rationale for using the app, or to offer any information about the app itself. This will not be used to provide therapeutic intervention.
10122372|NCT04376372||TD_lefthanders|Typical developing lefthanded children and adolescents Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
10122373|NCT04376372||F_lefthanders|Forced left handed NBPP children Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
10183104|NCT03767816|Active Comparator|Group RE: Rectus sheath block and erector spinae plane block|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision and ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml
10187622|NCT03724383|Experimental|Intervention|Participants in the intervention group will receive risk factor management consultations and take part in 1-hour biweekly diet classes and stress management classes for the first 3 months. This will be followed by 3 months of 1-hour biweekly high intensity interval training exercise classes. At the 6-month time point, participants will be prescribed a home based exercise program and will have the option of participating in weekly group walking sessions. During the final 6 months, participants will use a step/activity tracker to track their steps and heart rate.
10187623|NCT03724370|Experimental|TES+ VHA-SRM|Telehealth monitoring system (TES) will be added to the VA suicide risk management system (VHA-SRM)
10187624|NCT03724370|Active Comparator|VHA-SRM|VHA-SRM will be active comparator
10187625|NCT03724344||Dimensions with Behavioral and psychological symptoms|
9825938|NCT02401464|Experimental|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter [mL]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
9825939|NCT02401464|Experimental|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
9825940|NCT02401464|Experimental|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
9825941|NCT02401464|Experimental|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
9825942|NCT02401529|Experimental|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
9825943|NCT02401529|Active Comparator|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
9825944|NCT02401542|Active Comparator|Vofatamab plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor."
9825945|NCT02401542|Placebo Comparator|Placebo plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.~One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor"
9825946|NCT02401542|Experimental|Vofatamab|"IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination."
9825947|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
9825948|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
9825949|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
9825950|NCT02401672|Active Comparator|Active TMS|Repetitive TMS pulse stimulation
9825951|NCT02401672|Sham Comparator|Sham TMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
9825952|NCT02402062|Experimental|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
9825953|NCT02402127|Other|TruEye, MyDay, clariti 1day|Narafilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 1 day (16 hours).
9825954|NCT02402127|Other|TruEye, clariti 1day, MyDay|Narafilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
9825955|NCT02402127|Other|MyDay, TruEye, clariti 1day|Stenfilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
9825956|NCT02402127|Other|MyDay, clariti 1day, TruEye|Stenfilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
9825957|NCT02402127|Other|Clariti 1day, TruEye, MyDay|Somofilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
9825958|NCT02402127|Other|Clariti 1day, MyDay, TruEye|Somofilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
9825959|NCT02402153|Other|Sydvestjysk Hospital|Investigation of EEG recording with the Hyposafe device
9825960|NCT02402166|Experimental|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
10122374|NCT04376528|Experimental|Cyclosporin A|
10122375|NCT04376528|Active Comparator|Mycophenolate Mofetil|
10122376|NCT04376463|Experimental|Mood state and aminoacids supplementation|The aim of this study was to analyse the isolated and combined effects of BCAA supplementation and exercise on physical frailty status and mood states in pre-frail institutionalized older women.
10122377|NCT04376463|Experimental|Physical Tests|Through the combination of bcaa supplementation and physical exercise is able to improve the functional capacity of the elderly, through the SPPB test battery, short performance physical battery.
10122378|NCT04376463|Experimental|Psychometrics evaluated|Through the combination of bcaa supplementation and physical exercise, it is able to improve moods and cognition of the elderly.
10122379|NCT04376463|Experimental|Fried Scale Phenotype|Primary outcomes include Physical Frailty evaluated according to Fried's Frailty Phenotype2): Shrinking assessed by self-report of unintentional weight loss of four kilograms or more in the last six months; Self-reported exhaustion evaluated by concordance of two questions (7 and 20) of the Center for Epidemiology-Depression (CES-D) scale; Weakness analyzed using the handgrip strength test; Slowness measured by the 4.6 meters walking test; levels of Physical Activity assessed by the (IPAQ).
10122380|NCT04376411||patients with Behcet disease|Flow-cytometric assay Detailed 2 Di mention Echocardiographic analysis Two-Dimensional speckle tracking echocardiography
10122381|NCT04376411||Healthy control subjects|Flow-cytometric assay
10122382|NCT04376515|Experimental|HOPE Intervention|HOPE peer-led intervention
10122383|NCT04376515|No Intervention|Control|Control group- online community without peer leaders
10122384|NCT04376814|Experimental|Test Group|In this group, Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days, plus 200mg of Hydroxychloroquine two times per day will be given to patients for 7 days.
10122385|NCT04376814|Active Comparator|Control Group|In this group, Patients will be given a stat dose of 400mg Hydroxychloroquine tablets plus 200/50 mg of Lopinavir/Ritonavirtwo times per day for seven days.
10122386|NCT04376450|Experimental|Nonincised Papillae Surgical Approach|Nonincised papillae surgical approach is a papillae preservation technique, where an apical approach is carried out, without incisions or disinsertion of tissues at the level of the papillae or marginal tissues.
10122387|NCT04376450|Active Comparator|Entire Papilla Preservation Technique|Entire Papilla preservation technique is a tunnel-like procedure to preserve the defect associated papilla
10122388|NCT04376489|Experimental|Brief cognitive/behavioral strategies|
9825961|NCT02402218|Active Comparator|Usual Care|Participants receive standard of care for Hepatitis C in the clinic.
9825962|NCT02402218|Experimental|Usual care plus peer-mentors|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection.
10122389|NCT04376489|Experimental|Effortful self-regulatory activities|
10122390|NCT04376489|No Intervention|No activities|
10122391|NCT04376567|Active Comparator|One stage BBAVF|comparison
10122392|NCT04376567|Active Comparator|Two Stage BBAVF|comparison
10122393|NCT04376554|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.
10122394|NCT04376554|Active Comparator|amoxicillin-clavulanate|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or for 10 days.
10122395|NCT04376541||early extubation|the patients extubated in O.R or within 2 hours in the ICU
10122396|NCT04376541||late extubation|the patients extubated after 2 hours from O.R
10122397|NCT04376346|Experimental|Intervention Arm|Participants in the intervention arm will complete the AIY-C curriculum that has been translated for mHealth delivery. This includes completing various activities such as completing their own risk assessment when it comes to AEP and setting goals for themselves.
10122398|NCT04376346|No Intervention|Control Arm|Participants in the control arm will complete activities that are carefully designed under different topics than the intervention arm. In this regard, participants will complete various activities such as quizzes, interactive games and videos. The investigators will ensure that participants in both arms will spend similar time on completing the activities.
10122399|NCT04376359|Experimental|hyperbaric oxygen therapy|Patients with stroke will receive the hyperbaric oxygen therapy (HBOT) for 40 times, which were completed on 40 business days over a 2-month period and each session lasted 90 minutes at 100% oxygen concentration and 2 atmospheres.
10122400|NCT04376359|No Intervention|Control|Stroke patients were not treated with HBOT except for the same routine treatment as the experimental group.
9825963|NCT02402218|Experimental|Usual care plus incentives|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain goals during the course of the study.
9825964|NCT02402296|Active Comparator|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
9825965|NCT02402296|Placebo Comparator|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
10122401|NCT04376294|Experimental|Study group|This group received Extracorporeal Shockwave Therapy(ESWT) + conservative Physical Therapy Treatment (eccentric training + stretching exercise)
10122402|NCT04376294|Active Comparator|Control group|This group received conservative physical therapy treatment(eccentric training + stretching exercise) only.
10122403|NCT04376307|Experimental|minimal flow anesthesia|the patiennts who have thoracic sugery with one lung ventilaiton
10122404|NCT04376164|No Intervention|control group|was treated without laser intervention
10122405|NCT04376164|Experimental|laser group|received low level laser therapy
10122406|NCT04376008|Experimental|PI-RADS 1-2|Standard prostate biopsy
10122407|NCT04376008|Experimental|PI-RADS 3-5|Targeted and standard prostate biopsy
10122408|NCT04376073|Experimental|Treatment group|"Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh <77 kg) po QD day1~21, Anlotinib 12mg po QD day1~14.~Starting dose of anlotinib changed to 10mg from 2020-11-13."
10122409|NCT04376047|Experimental|Reverse Trendelenburg position group|Obese critically ill patients who are positioned in reverse Trendelenburg position
10122410|NCT04376047|Active Comparator|Semi-recumbent position group|Obese critically ill patients who are positioned in semi-recumbent position which is the routine ICU position
10122411|NCT04375917|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
10122412|NCT04375917|No Intervention|control|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
10122413|NCT04375930|Experimental|Experimental|The patient will be trained with STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION. The patient will be follow up at 2nd, 6th and 12th weeks.
10122414|NCT04375930|Active Comparator|control|The patient will be trained only skills and discharge education. The patient will be follow up at 2nd, 6th and 12th weeks.
10122415|NCT04376125|Experimental|Suboccipital inhibition in tension headache|"Two groups of patients suffering from tension headache associated with cervicalgia are selected.~The control group performs conventional therapy. The experimental group performs conventional therapy plus the technique of suboccipital inhibition"
10122416|NCT04376125|Active Comparator|study of results|We compared data from both groups
10122417|NCT04376320|Active Comparator|Group 1(ceramic membrane)|using customized ceramic membranes for augmentation of vertical mandibular ridge defects in preparation for implant placement
10122418|NCT04376320|Active Comparator|Group 2 (modified sausage technique)|using tenting titanium screws in conjunction with particulate bone graft and collagen membrane (modified sausage technique) for augmentation of vertical mandibular ridge defects in preparation for implant placement
10122419|NCT04376138|Experimental|Motor Imagery|A Brain-Computer Interaction (BCI) based intervention while receiving conventional therapy. Use of motor imagery training, allied with brain-computer interaction, as a solution to promote motor and cognitive gains in stroke survivors.
10122420|NCT04376138|Active Comparator|Conventional Therapy|Extra Occupational Therapy sessions while receiving conventional therapy. Use of conventional therapy techniques and tools for motor rehabilitation, following the original therapeutic intervention plan of the participants.
10122421|NCT04376255|Experimental|Mixed Reality Simulation (Phase 2)|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
10122422|NCT04376255|Active Comparator|Conventional Simulation (Phase 2)|Participants in the control arm will be introduced to workplace training modules using standard in person training.
10122423|NCT04376255|Active Comparator|Remote Mixed Reality Simulation (Phase 1)|During the initial phase of the study, up to 40 participants will enroll in mixed reality simulation remotely for a qualitative assessment of simulation transcripts
10122424|NCT04375969|Experimental|whole body cryostimulation treatment|WBC will be performed at the Pomeranian Rheumatologic Centre in Sopot. The centre is equipped with an electric cryochamber Zimmer Medicine System, Cryochamber ELECPOL, located in a temperature- and humidity-controlled room. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
10122425|NCT04375969|Experimental|Connection WBC treatment and HIIT training|This group will perform HIIT protocol and WBC sessions . HIIT will be performed after 1h WBC.
9668975|NCT04457596|Experimental|Arm II (trastuzumab emtansine, tucatinib)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
9668976|NCT04453722||Oxalert in monitor only mode|Randomization will be to Oxalert in monitor-only mode
9825966|NCT02402322|Active Comparator|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
9825967|NCT02402322|Experimental|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
10122426|NCT04375969|Active Comparator|Control Group|Control group who will be investigated (meanwhile at baseline and after the interventions)
9825968|NCT02402322|No Intervention|Waiting list|Participants in a waiting list.
10122427|NCT04375969|Experimental|HIIT training group|This group will perform only HIIT protocol without cryo-sessions
10122428|NCT04376151|Experimental|Intervention|Participants will work through an Acceptance and Commitment Therapy informed self-help bibliotherapy over a period of eight weeks. The bibliotherapy is called 'Get Out of Your Life and Into your Mind' written by Steve. C. Hayes.
9668977|NCT04453722||Oxalert in monitor in normal mode|Randomization will be to Oxalert in monitor normal mode which provides progressive audible and tactile alerts for hypoxemia.
9668978|NCT04448184|No Intervention|Prophylactic Platelet Transfusion|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109/L.
9825969|NCT02402452|Experimental|Normal Renal Function|Participants will receive a single dose of voxilaprevir on Day 1.
10122429|NCT04376099||Exercise oximetry|Patients complaining claudication and referred for exercise diagnostic oximetry. Exercise oximetry are performed on treadmill (3.2km/h, 10% slope)
10122430|NCT04376034|Other|Mild Severity|Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.
10122431|NCT04376034|Active Comparator|Moderate Severity|"Adult patients will be treated with 1 unit (200mL) of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma."
10122432|NCT04376034|Active Comparator|Severe or Critical Severity|"Adult patients will be treated with up to 2 units of convalescent plasma~Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma."
10122433|NCT04376021|Experimental|Physical Contact|Baby carrier (and education) provided to mother to increase physical contact with baby
10122434|NCT04376021|No Intervention|Control|No intervention
10122435|NCT04376086|Active Comparator|General anesthesia|Patients will receive general anesthesia
10122436|NCT04376086|Experimental|Epidural anesthesia|Patients will receive epidural anesthesia
10122437|NCT04376216|No Intervention|Control|No treatment
10122438|NCT04376216|Active Comparator|Prednisone|Oral prednisone. Starting dose of 60 mg with tapering for 2 months
10122439|NCT04376203||Control|any patient with indications for thyroidectomy other than confirmed preoperative cancer
10122440|NCT04376203||Thyroid microcarcinoma|either preoperative detection or random finding after thyroidectomy of another indication.
10122441|NCT04376177||Patients with Thoracic outlet syndrome|Patients referred to the University Hospital of Angers for the diagnostis or follow-up of thoracic outlet syndrome
10122442|NCT04375995|Other|Asthma group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed to all asthmatic patients.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. Asthma control test (ACT) and asthma quality of life scale (AQLQ) will be applied. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for asthma.
10122443|NCT04375995|Other|Healthy control group|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
10122444|NCT04376190|No Intervention|control group|12 patients treated with twin block functional appliance without low-level laser application for 9 month
10122445|NCT04376190|Experimental|laser group|12 patients treated with twin block functional appliance with low-level laser application with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. The laser was applied at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points. Laser application was repeated weekly for three months according to a standard protocol
10122446|NCT04375943||diabetic HF-pEF patients|It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (>45%).
10122447|NCT04375943||diabetic HF-rEF patients|It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).
10122448|NCT04376229||Cancer patients receiving proton radiation therapy|Registry of cancer patients who receive proton radiation therapy to track disease and toxicity outcomes.
10122449|NCT04375891|Other|Radiotherapy|Radiotherapy alone
10122450|NCT04375891|Other|Radiotherapy plus radiofrequency ablation|Radiotherapy plus radiofrequency ablation / vertebral augmentation(Combination therapy)
10122451|NCT04375852|Experimental|1|consecutive cases diagnosed with APS-1associated keratitis
10122452|NCT04375865|Experimental|Treatment A|Period1: Celecoxib 200mg Period2: Tramadol 150mg Period3: Celecoxib 200mg + Tramadol 150mg
10122453|NCT04375865|Experimental|Treatment B|Period1: Celecoxib 200mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Tramadol 150mg
10122454|NCT04375865|Experimental|Treatment C|Period1: Tramadol 150mg Period2: Celecoxib 200mg Period3: Celecoxib 200mg + Tramadol 150mg
10122455|NCT04375865|Experimental|Treatment D|Period1: Tramadol 150mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Celecoxib 200mg
10122456|NCT04375865|Experimental|Treatment E|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Celecoxib 200mg Period3: Tramadol 150mg
10122457|NCT04375865|Active Comparator|Treatment F|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Tramadol 150mg Period3: Celecoxib 200mg
10122458|NCT04375774|Other|FFP2|
10122459|NCT04375774|Other|Facial mask|
10122460|NCT04375774|Other|Modified full-face snorkeling|
10122461|NCT04375839|Experimental|Main treatment group|Zirconia implants will be placed in a prosthetically guided position in horizontally deficient ridges in main treatment group.
10122462|NCT04375839|Active Comparator|Control group|Titanium implants will be placed in a prosthetically guided position in horizontally deficient ridges in control group.
10122463|NCT04375826|Active Comparator|Epidural analgesia|Only Epidural analgesia is used for this group
10122464|NCT04375826|Active Comparator|Preperitoneal analgesia and IV-PCA|This group is given with both preperitoneal analgesia and Intravenous Patient Controlled Analgesia (IV-PCA)
10122465|NCT04375748||Patients treated for symptoms of acute myocarditis.|Patients treated in intensive coronary care unit (ICCU) or intensive care unit (ICU), in one of the participating hospitals, for symptoms of acute myocarditis confirmed by a myocardial MRI and/or a CT scan and/or a myocardial biopsy.
10122466|NCT04375657|Experimental|TRIIM Treatment|
10122467|NCT04375657|Active Comparator|Active Control|
9825970|NCT02402452|Experimental|Severe Renal Impairment|Participants will receive a single dose of voxilaprevir on Day 1.
10122468|NCT04375501||COVID-19 positive|All patients admitted with fractured neck of femur during specified time period testing POSITIVE for COVID-19
10122469|NCT04375501||COVID-19 negative|All patients admitted with fractured neck of femur during specified time period testing NEGATIVE for COVID-19
10122470|NCT04375475|Experimental|Bright Changyou probiotic flavored yogurt|Bright Changyou probiotic flavored yogurt contains 5.0×10^8cfu/g of probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum ST-Ⅲ (7mg/kg), and 1.5% of inulin
10122471|NCT04375475|Active Comparator|Bright Changyou lactobacillus flavored yogurt|Bright Changyou flavored yogurt contains probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum ST-Ⅲ (7mg/kg)
10122472|NCT04375475|Active Comparator|Bright flavored yogurt|Bright flavored yogurt contains Lactobacillus bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus casei LC2W (0.1 mg/kg)
10122473|NCT04375397|Experimental|Ibrutinib|Participants will receive Ibrutinib along with supportive care.
10122474|NCT04375397|Placebo Comparator|Placebo|Participants will receive Placebo along with supportive care.
10183105|NCT03767803||Positive Preeclampsia group|A group with diagnosis of preeclampsia within 24 hours of testing and pre-term delivery
10122475|NCT04375761||SARS-CoV-2 Surveillance: Total Group|"Participants either currently or in the past, enrolled in National Institutes of Health (NIH)-funded cohort studies, and their families (household contacts).~Active surveillance for detection of SARS-CoV-2 for 6 months, beginning with enrollment. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed at the time that biological samples are collected."
10122476|NCT04375540|Experimental|Upper first premolars extraction|Included 24 patients (7 males,17 females) with a mean age of 21.56±3.19years who were treated with fixed orthodontic appliance for 2.22±0.31years.
10122477|NCT04375540|Experimental|Upper second premolars extraction|Included 26 patients (8 males,18 females) with a mean age of 22.16±3.59years who were treated with fixed orthodontic appliance for 2.25±0.30 years.
10122478|NCT04375540|No Intervention|No intervention|Included 26 subjects (10 males, 16 females) with a mean age of 20.45±3.29years.This group was included to observe any changes in the vertical gingival display over the 2 years' observation period (1.65±0.17 years).
10122479|NCT04375449|Active Comparator|Pep2dia- dosage 1|700mg of whey protein hydrolysates single dose
10122480|NCT04375449|Active Comparator|Pep2Dia - dosage 2|1400mg of whey protein hydrolysates single dose
10122481|NCT04375449|Placebo Comparator|Placebo|maltodextrin single dose
10122482|NCT04375436|Active Comparator|NTRX-07-SDD|NTRX-07-SDD at 0.3-8mg/kg; single dose
9967053|NCT01266200|Active Comparator|Conventional technique (XIA)|Patients who received a surgical treatment including one long cut (conventional operation technique) and the fracture was fixed by a conventional system called XIA
10122483|NCT04375436|Placebo Comparator|Control|Placebo control
10122484|NCT04375566||IT specialist|20 IT Specialist will evaluate the usability and patient-friendliness of the tool
10122485|NCT04375566||Doctors|13 doctors will evaluate the information in the tool
10122486|NCT04375566||Patients|10-20 patients will evaluate the utility and the contribution of the tool in decision making proces.
10122487|NCT04375618|Experimental|EGF impregnated in collagen membrane|EGF impregnated in collagen membrane is placed in gingival recession defects
10122488|NCT04375618|Active Comparator|plain collagen membrane|plain collagen membrane is placed in gingival recession defects
10122489|NCT04375488|Experimental|Resistance Exercise Training Group|Resistance exercise training for 8 major muscle groups and 150 min per week walking suggestions were given
10122490|NCT04375488|Experimental|Inspiratory Muscle Training Group|Resistance exercise training for 8 major muscle groups and inspiratory muscle strength training and 150 min per week walking suggestions were given
10122491|NCT04375488|No Intervention|Control Group|150 min per week walking suggestions were given.
10122492|NCT04375527|Experimental|Treatment (binimetinib, nivolumab)|Patients receive binimetinib PO BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
10122493|NCT04375423|Experimental|Intervention|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. In response to the behaviors they report, they receive messages on their smartphones supporting ongoing healthy behaviors or suggesting alternative behaviors to limit risks. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
10122494|NCT04375423|Active Comparator|Control|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
10122495|NCT04375605|Active Comparator|Arm A (control arm)|Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, folinc acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).
10122496|NCT04375605|Experimental|Arm B (experimental arm)|Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, folinic acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).
10122497|NCT04375371|Active Comparator|Obese patients who have received a bariatric surgery|Obese patients who have undergone a bariaric surgery as part of routine clinical management within the indication of this intervention.
10122498|NCT04375371|No Intervention|Obese patients without a bariatric surgery|Obese patients who have not undergone bariaric surgery.
10122499|NCT04375111|Active Comparator|SAP block for management of post-mastectomy pain|the patients in this group shall undergo Serraturs anterior plane block for management of post-mastectomy pain.
10122500|NCT04375111|Active Comparator|TTP block combined with SAP block for post-mastectomy pain|the patients in this group shall undergo combined Serraturs anterior plane block, and Transversus thoracic plane block for management of post-mastectomy pain.
9967054|NCT01266213|Experimental|Fulvestrant plus Goserelin|
9967055|NCT01266213|Experimental|Anastrozole plus Goserelin|
9967056|NCT01266213|Active Comparator|Goserelin alone|
9967057|NCT01266226|Experimental|ACP treated|The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
9967058|NCT01266226|Placebo Comparator|Control group|The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
9967059|NCT01266239|Active Comparator|SES-KB|Sirolimus-eluting stent (SES) is deployed in the main vessel (MV)and subsequent kissing balloon inflation is performed in the bifurcation.
10122501|NCT04375319|Experimental|OCT guided 3-month follow-up group|OCT guided the operation, and OCT reexamined 3 months after the operation to evaluate the vascular repair
10122502|NCT04375319|No Intervention|3-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 3 months after operation to evaluate vascular repair
10122503|NCT04375319|No Intervention|6-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 6 months after operation to evaluate vascular repair
10122504|NCT04375098|Experimental|Early COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 at admission after confirmation of eligibility
10122505|NCT04375098|Experimental|COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 only if worsening of respiratory function or persistence of COVID symptoms for >7 days after enrolment
10122506|NCT04375306|Active Comparator|angiography guided CABG|angiography guided CABG
10122507|NCT04375306|Experimental|RFR guided CABG|RFR guided CABG
10122508|NCT04375150||Patients with advanced renal cell carcinoma (RCC)|
10122509|NCT04374981|Experimental|Celecoxib|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of celecoxib tablets (100mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
9825971|NCT02402764|Experimental|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
9825972|NCT02402881|Experimental|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
9825973|NCT02402881|No Intervention|Control|Patients will receive only the standard practices of care
9825974|NCT02402907|Experimental|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
10122510|NCT04374981|Experimental|Montelukast|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of Montelukast tablets (10mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
10122511|NCT04375059|Active Comparator|Study group|3 months of interactive attention training programs, 2 times per week, 15 min per session, a total of 24 sessions, with conventional rehabilitation programs
10122512|NCT04375059|No Intervention|Control group|3 months of conventional rehabilitation programs without interactive attention training programs
10122513|NCT04375163|Experimental|Massage group (ME)|A sport massage was applied between the sets of an intense isokinetic exercise protocol for knee extensor muscles
10122514|NCT04375163|Active Comparator|Control|the break between the sets of an intense isokinetic exercise protocol for knee extensor muscles was passive
10122515|NCT04375189|No Intervention|Standard Care|
10122516|NCT04375189|Experimental|Complex Clinic Arm|
10122517|NCT04375176||Tested positive for SARS-CoV-2|"Patients, tested positive for SARS-CoV-2, will be recruited in E.R. of the Ospedale Di Circolo - ASST Settelaghi Teaching Hospital in Varese."
10122518|NCT04374955|Experimental|İnfantile colic|Mothers of babies diagnosed with infantile colic in the intervention group will receive routine care and start taking probiotic products after the first stool of the babies and blood is taken for intestinal permeability and will continue for 15 days.
10122519|NCT04374955|Other|Control|Mothers of babies diagnosed with infantile colic in the control group will receive routine care for 15 days after blood is taken for the first stool and intestinal permeability of the babies.
10122520|NCT04375254||Intervention group|Medical students during psychiatry clerkship who received NbN psychopharmacology training
10122521|NCT04375254||Control group|Medical students during psychiatry clerkship who received standard psychopharmacology training
10122522|NCT04375215|Active Comparator|Selective caries removal to soft dentin (one step)|In selective caries removal to soft dentine, after caries excavation application of liner will be done on pulpal floor. Teeth will then be filled with composite resin material.
10122523|NCT04375215|Active Comparator|Stepwise caries removal (two step)|The stepwise caries removal is a two step procedure. The first step is similar to selective caries removal to soft dentin group. In the second step, after 6 months lesion will be re-entered to remove remaining carious tissue till firm dentin is encountered. Once all the caries is removed from floor of cavity a liner followed by final restoration with composite will be performed.
10122524|NCT04375137||Severe COVID|patients with positive PCR or compatible CT admitted in ICU or intubated
9825975|NCT02402907|Placebo Comparator|Placebo cloth|A fragrance free cleansing cloth
9825976|NCT02402933|Experimental|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
9967060|NCT01266239|Active Comparator|SES-NK|SES is deployed in the MV without kissing balloon inflation.
10122525|NCT04375137||Non-severe COVID-19|patients with positive PCR or compatible CT admitted in ward without hypoxia
10122526|NCT04375137||Healthy Controls|Healthy controls with negative IgM/IgG for COVID-19
10122527|NCT04374968|Experimental|BFR Treatment|Patients will be recruited following ACL tear and medical screening for history of DVT/PE. Patients allocated to the BFR intervention group will undergo physical therapy with the use of a blood flow restriction cuff. Rehabilitation will consist of a structured home exercise program prior to surgery. We will instruct patients on how to perform home BFR and test them in the office to ensure competence. Following surgery patients will immediately be started in physical therapy. Therapy will consist of a structured program progressing from range of motion, to strength training and then functional tests. Both arms will use the same protocol with the only difference being use of BFR.
9825977|NCT02403180|Other|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
10122528|NCT04374968|No Intervention|Control|The control arm will undergo the same pre and post operative physical therapy as the BFR group. They will undergo a structure home therapy program prior to surgery and an outpatient physical therapy program under the guidance of a therapist following surgery.
10122529|NCT04375046|Experimental|Experimental: rbACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
10122530|NCT04375046|No Intervention|No Intervention: Control group|Standard of care; no placebo
10122531|NCT04375267|Experimental|177Lu-DOTA-TATE and olaparib|
10122532|NCT04374994|Active Comparator|intervention group|Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks
10122533|NCT04374994|Placebo Comparator|control group|Males with sexual dysfunction who received daily placebo tablets for four weeks
10122534|NCT04375020||group1 on GABA|The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.
10122535|NCT04375020||group 2 on just insulin|The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.
10122536|NCT04375280|Experimental|Cohort 1|Participants will be involved in a long-term evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 5 years with evaluations taking place at inclusion, 6 months, at 1, 2 and 5 years
10122537|NCT04375241||Screening with Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
10122538|NCT04375202|Experimental|Colchicine plus current care|Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
10122539|NCT04375202|No Intervention|Current care alone|Current care
10122540|NCT04375293|Experimental|AERD|Patients suffering from AERD
10122541|NCT04375293|Sham Comparator|Healthy|Healthy Controls
10122542|NCT04375293|Active Comparator|CRSwNP|Patients suffering from CRS with nasal polyps
10122543|NCT04375293|Active Comparator|CRSsNP|Patients suffering from CRS without nasal polyps
10122544|NCT04374929|Active Comparator|Negative Pressure Wound Therapy|
10122545|NCT04374929|Active Comparator|Anti-Inflammatory Glucocorticoid|
10122546|NCT04374929|Active Comparator|Increased Electrode Spacing|
10122547|NCT04374929|Other|Control|
10122548|NCT04374942|Experimental|Study drug arm|50% of participants will be randomized to the study drug arm, and will take 400mg hydroxychloroquine orally once a day for three months (Day 1-90).
10122549|NCT04374942|Placebo Comparator|Placebo arm|50% of participants will be randomized to the placebo arm, and will take placebo orally once a day for three months (Day 1-90).
10122550|NCT04374786|Experimental|Intervention Group|"Will receive a 30-day are trial of the mobile meditation app Calm on study day 0"
10122551|NCT04374890|Experimental|Experimental|
10122552|NCT04374864|Experimental|Trilaglibtin 50 mg|Samples from 6 healthy, adult, male, Egyptian volunteers (age: 25-39 years, average weight: 89.8 kg, average body mass index (BMI): 34.2) were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144 and 168 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one Zafatek® tablet nominally containing 50 mg trilagliptin. Blood samples (1 mL of each sample) were centrifuged at 3000 rpm for 5 min.
10122553|NCT04374721|Experimental|Patients with Adrenal Insufficiency|Patients with Adrenal Insufficiency established or newly diagnosed, under glucocorticoid replacement therapy.
10122554|NCT04374721|Experimental|Patients with Cushing's Syndrome|patients with adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent Cushing's Syndrome diagnosis during active disease (new diagnosis or recidivating) at enrollment.
10122555|NCT04374721|Experimental|Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by Adrenal Insufficiency or Cushing's Syndrome.
10122556|NCT04374760|No Intervention|in-person control|Usual care, initial screening measures conducted in-person in the Emergency Department.
10122557|NCT04374760|No Intervention|Self-Administered Control|Usual care, initial screening measures conducted on their own via an iPad.
10122558|NCT04374760|Experimental|In-person Treatment|Treatment group (receives text messages), initial screening measures conducted in-person in the Emergency Department.
10122559|NCT04374760|Experimental|Self-Administered Treatment|Treatment group (receives text messages), initial screening measures conducted on their own via an iPad.
10122560|NCT04374825|Experimental|Acceptance and Commitment Therapy (ACT)|Weekly video conference groups led by a trained facilitator introducing key concepts of ACT
10122561|NCT04374825|Active Comparator|Cognitive Behavioral Stress Management (CBSM)|Weekly video conference groups led by a trained facilitator introducing key concepts of CBSM
10122562|NCT04374825|No Intervention|Usual care|Patients' usual health care as received over the duration of the pilot trial
10122563|NCT04374643||Confined patients|General population
10122564|NCT04374916|Experimental|Partosure® test + Premaquick® test|All patients will have the same 2 tests.
10122565|NCT04374708||trans men|fMRI: body morph test and neurocognitive testing
10122566|NCT04374708||trans women|fMRI: body morph test and neurocognitive testing
10122567|NCT04374708||homosexual cisgender men|fMRI: body morph test and neurocognitive testing
10122568|NCT04374708||homosexual cisgender women|fMRI: body morph test and neurocognitive testing
10122569|NCT04374708||cisgender women|fMRI: body morph test and neurocognitive testing
10122570|NCT04374708||cisgender men|fMRI: body morph test and neurocognitive testing
10122571|NCT04374591|Other|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
10122572|NCT04374591|Placebo Comparator|Control|placebo
10122573|NCT04374851|Experimental|New Device|The new Hearing aid is essentially the same as the current device (i.e., hardware, use) but with an improved digital signal processing (DSP).
10122574|NCT04374851|Active Comparator|Current Device|The current device is the Hearing aid that is currently sold on the market. It is used as a normal Hearing aid that is worn daily to amplify sounds for Hearing-impaired people.
10183106|NCT03767803||Study Cohort|A group without diagnosis of preeclampsia. Also includes a group without diagnosis of preeclampsia within 24 hours of testing, but who have subsequent worsening or re-emergence of signs and symptoms of preeclampsia, and are later diagnosed with preeclampsia and have pre-term delivery.
10183107|NCT03767790|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting. During AID use, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
10183108|NCT03767790|No Intervention|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting. During these 2 weeks, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
10183109|NCT03767777|Experimental|Intervention arm|Participants will be treated with Artery Stent Graft System Intervention: Device: Artery Stent Graft System
10183110|NCT03767764||HCC|Patients with diagnosis of Hepatocellular carcinoma
10183111|NCT03767764||Cirrhosis|Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC
10183112|NCT03767764||Chronic liver diseases|Patients with the diagnosis of Chronic liver diseases without cirrhosis
10183113|NCT03767764||Control|Normal human serum from donors without liver disease
10183114|NCT03767725|Experimental|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART19 cells.
10183115|NCT03767673|Experimental|Patients after esophageal atresia|Patients older than 12 years following surgical repair of congenital esophageal atresia will be included after written informed consent. Patients will be subjected to spirometry to determine their age, weight (determined by Kilogram (kg) on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
10183116|NCT03767673|Active Comparator|Control group|Age and sex matched adolescents will be recruited as control group and will be included after written informed consent. Adolescents will be subjected to spirometry to determine their age, weight (determined by Kilogram on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
10183117|NCT03767660|Experimental|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
10183118|NCT03767647|Experimental|Intervention group|Receives 6 lessons in 6 different weeks on Emotional Intelligence
10183119|NCT03767647|No Intervention|Control group|Receives no intervention.
10183120|NCT03767621||Patients with intermediate lesions.|Patients with intermediate lesions (stenosis in angiography between 25% and 60%) in LMCA.
10183121|NCT03767569|Experimental|Myo-inositol|Pretreatment with Gynositol (Myo-Inositol 4mg + Folic Acid 0.4mg) daily during 12 weeks before start of ART (Assisted Reproductive Technology)
10183122|NCT03767569|Other|Folic acid|Folic acid 0.4 mg daily during 12 weeks before start of ART
10183123|NCT03767556|No Intervention|Control|This group will not receive intervention
10183124|NCT03767556|Experimental|Inspiratory Muscle Training|This group, for inspiratory muscle training, will use the Powerbreathe® K5 device. This device will be adjusted with a load of 55% of previously assessed MIP. The volunteer will be instructed to inhale with sufficient force to overcome the resistance of the equipment and subsequently perform a normal expiration. During the 4-week period of respiratory muscle training volunteers will be instructed to perform 2 sets with 30 inspiratory efforts, 5 days a week. The training load will be readjusted on the first day of training each week, after a new reassessment of the PIMax in order to guarantee the overload during inspiratory muscle training.
10183125|NCT03767530|Experimental|Mibo Thermoflo (thermal device)|3 sessions at 2 weeks interval (basal, week 2, week 4)of 11 minutes per eye of thermal therapy with Mibo Thermoflo.
10183126|NCT03767530|Active Comparator|Warm compresses and eyelid massage|2 times per day, 11 minutes per eye.
10183127|NCT03767504|Experimental|Musclin|Thymol based dietary supplement
10183128|NCT03767491|Experimental|Smartphone-delivered CBT for OCD|12-week Smartphone delivered CBT for OCD.
10183129|NCT03767491|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
10183130|NCT03767478|Sham Comparator|Control group|Best Medical Therapy + Sham Revitive Medic Coach Neuromuscular Electrical Stimulation Device for 6 months
10183131|NCT03767478|Active Comparator|Intervention group|Best Medical Therapy + Revitive Medic Coach Neuromuscular Electrical Stimulation Device for 6 months
10183132|NCT03767452|Experimental|Single-Arm|Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
10183133|NCT03767439|Experimental|Nivolumab, Vismodegib, Ipilimumab|"Patients will receive a two week run-in of Vismodegib 150 mg PO daily followed by concurrent Nivolumab 480 mg IV every 4 weeks and Vismodegib 150 mg PO daily.~In an exploratory fashion, patients will have the option to receive combination Ipilimumab 1 mg/kg IV every 6 weeks and Nivolumab 360 mg IV every 3 weeks at the time of disease progression."
10183134|NCT03767426|No Intervention|Overnight sleep|Subjects are permitted a night of polysomnograph-recorded sleep before participating in training and testing sessions the next day
10122575|NCT04374604||Paturients with preeclampisia|The participants will be pregnant women with late-onset pre-eclampsia
10122576|NCT04374747|Experimental|Dietary Intervention|Intensive dietary counseling and fruit and vegetable box delivery.
10122577|NCT04374747|No Intervention|Information|Control condition of information on healthy eating during breastfeeding
10122578|NCT04374448|Other|Sinus Tumor Resection|Those who are undergoing endoscopic sinonasal surgery for benign and malignant tumor removal.
10122579|NCT04374448|Other|Skull Base Surgery|Those who are receiving Endoscopic Skull Base Surgery (ESBS) for minimally-invasive access for removal of skull base tumors, most commonly for ones of pituitary origin.
10122580|NCT04374448|Other|Endoscopic Sinus Surgery|Individuals with chronic rhinosinusitis (CRS) with or without polyposis that are to have endoscopic sinus surgery, a minimally invasive procedure to open the sinuses.
10122581|NCT04374448|Other|Epistaxis Management|Those who have severe nose bleeds and requires going into the operating room for management.
10122582|NCT04374396|Sham Comparator|Group 1|patients in this group will receive sham ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery without injection of local anesthetics
10122583|NCT04374396|Experimental|Group 2|patients in this group will receive real ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery with injection of 0.3 ml/kg of 0.25% of plain bupivacaine.
10122584|NCT04374487|Experimental|Test Arm|50 subjects will be randomized in this arm. Patients in the test group will receive convalescent plasma.
10122585|NCT04374487|Other|Control Arm|50 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health and Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity. For the management of ARDS or sepsis, the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented.
10122586|NCT04374318|Active Comparator|IT intrathecal|administration of intrathecal dexmedetomidine in addition to bupivacaine for lower limb surgeries
10122587|NCT04374318|Active Comparator|IV intravenous|administration of intravenous dexmedetomidine in addition to spinal anaesthesia for lower limb surgeries
10122588|NCT04374383|Experimental|main treatment group|LASER assisted SRP followed by antimicrobial photodynamic therapy with a novel photosensitizer dye Phthalocyanine
10122589|NCT04374383|Placebo Comparator|control group|LASER assisted SRP
10122590|NCT04374409|Experimental|High-flavanol Cocoa powder|Dietary supplement: single serving of a high-flavanol cocoa powder containing 150 mg of (-)-epicatechin and 35.5 mg of (+)-catechin
10122591|NCT04374409|Active Comparator|Low-flavanol Cocoa powder|Dietary supplement: single serving of a low-flavanol cocoa powder intervention containing < 4 mg of (-)-epicatechin and (+)-catechin and matched as best as possible for macronutrients and micronutrients, such as caffeine and theobromine.
10122592|NCT04374474|Sham Comparator|Control Group|The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.
10122593|NCT04374474|Experimental|Olfactory Retraining Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.
10122594|NCT04374474|Experimental|Olfactory Retraining_Budesonide Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.
10122595|NCT04374344||Medical professionals|Medical professionals including cardiologists and cardiology residents.
10122596|NCT04374669||patients with lumbar spinal stenosis|Patients with lumbar spinal stenosis will be scheduled for neuroplasty.
10122597|NCT04374773|Experimental|Estradiol|1 week treatment with 0.3 mg/24 hr transdermal estradiol
10122598|NCT04374773|Experimental|Cortisol|1 week treatment with 30 mg hydrocortisone daily, administered in 2 divided doses
10122599|NCT04374331|Experimental|Video-Assisted Training Group|The patients in the VAT group watch a training video in the patient rooms before RCR in addition to the routine treatment and care in the unit.
10122600|NCT04374331|No Intervention|control group|The control group received the routine treatment and care in the unit. The routine treatment and care of the unit includes verbal briefing by physicians and nurses about the surgical procedure before RCR, cold application and analgesic application for pain control after RCR, using arm sling, verbal discharge training (e.g., drug use, exercises, follow-up time, etc.) and discharge on the first post-operative day in the absence of complications. In addition, patients are invited to weekly controls to explain how to do the exercises and, if necessary, they are referred to physiotherapy.
10122601|NCT04374305|Experimental|Brigatinib Sub-Study|Subjects treated in this arm will receive brigatinib 90 mg by mouth daily for 7 days and then increased to 180 mg by mouth daily if the drug is tolerated.
10122602|NCT04374422||1|study group pre-pandemic time interval
10122603|NCT04374422||2|same population during pandemic
10122604|NCT04374461|Experimental|mechanically ventilated &/or managed in a critical-care|"This arm is closed to accrual as of September 2020. Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm A:~Transfer out of the critical-care unit~Extubation~Toxicity~Death"
10122605|NCT04374461|Experimental|non-mechanically ventilated, non-critical-care|"Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm B:~Discharge from hospital~Admission to a critical-care unit~Intubation~Toxicity~Death"
10183135|NCT03767426|Active Comparator|Sleep deprivation|Subjects sleep deprived before participating in training and testing sessions the next day
10183136|NCT03767426|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
10122606|NCT04374292|Experimental|Intervention group|"Intervention group mothers (n = 90) attended six weekly group sessions, which were led by nutritionists and lasted 90 minutes.~The key message was that healthy dietary habits and health risks are acquired at home and that opportunities for change can be identified in the processes that surround meal times. It begins with selecting and purchasing food, followed by preparation and consumption behaviors. Mothers were encouraged to participate in the sessions which involved the use of food models, videos, slides, and, in some cases, real food. Upon completing each session, mothers were given printed material to add to a home consultation manual.~Upon concluding consultations and group sessions, mother/child pairs from both groups were asked to return for monthly follow-ups over the next three months."
10122607|NCT04374292|Active Comparator|Control group|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. Similarly, CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
10122608|NCT04374799|Active Comparator|Low dose heparin|heparin (25 IU/Kg -maximal dose 3,000 IU)
10122609|NCT04374799|Active Comparator|High dose heparin|heparin 50 IU/kg -maximal dose 5,000 IU
10122610|NCT04374799|Placebo Comparator|Placebo|Normal saline 0.9%.
10122611|NCT04374526|Experimental|Convalescent plasma|Patients receive COVID-19 Convalescent Plasma (CCP) in addition to standard therapy
9967061|NCT01266239|Active Comparator|EES-KB|Everolimus-eluting stent (EES) is deployed in the MV and subsequent kissing balloon inflation is performed in the bifurcation.
10122612|NCT04374526|No Intervention|Standard therapy|Patients receive standard therapy alone
10122613|NCT04374435|Experimental|MKTP with Surgical Blade|The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.
10122614|NCT04374435|Experimental|MKTP with Negative Pressure Instrument|Blister grafting technique with dissociation of the cells was performed in the second arm of the study.
10122615|NCT04374435|Experimental|Suction blister grafting without cell dissociation|In this arm, transplanting the blisters without dissociation of the cells will be conducted.
10122616|NCT04374279|Active Comparator|Standard of care and bicalutamide|Randomized participants receive bicalutamide 150mg oral for 7 days, plus standard of care
10122617|NCT04374279|No Intervention|Standard of care only|Randomized participants receive standard of care only.
10122618|NCT04374552|Experimental|Hydroxychloroquine & Azithromycin|Hydroxychloroquine sulfate 400 mg po BID for day one and then 400 mg QD for 4 days Azithromycin 500 mg po on day one, followed by 250 mg po QD X 4 days
10122619|NCT04374552|Placebo Comparator|Placebo|Placebo for Hydroxychloroquine sulfate (2 pills bid day one and then 2 tablets QD for 4 days) Placebo for Azithromycin (2 pills on day one and followed by 1 pill po QD x 4 days)
10122620|NCT04374617||Venous thromboembolism|Patients at risk of venous thromboembolism (deep venous thrombosis and/or pulmonary embolism)
10122621|NCT04374110||Hospitalized patients with COVID-19|Hospitalized patients with COVID-19 will be included in the study in centers around Poland.
10122622|NCT04374110||Infected SARS-CoV-2 patients|patients with SARS-CoV-2 infection not requiring hospitalization
10122623|NCT04374110||Controls|structure-matched and co-existing disease matched control group from the general population.
10122624|NCT04374227|Experimental|Treatment Group|The treatment group received three osteopathic manipulative treatments once a week for three weeks. The osteopathic manipulative treatment was a full body treatment based upon Dr. Zink's model of a common compensatory pattern.
10122625|NCT04374227|No Intervention|Control Group|This group received an osteopathic structural exam once a week for three weeks without any treatment performed.
10122626|NCT04374058||Two Times|The treatment group consists of selected patients that, based on their mean ultrafiltration rate, are switched from thrice-weekly to twice-weekly hemodialysis sessions
10122627|NCT04374058||Three times|Usual thrice-weekly hemodialysis schedule
10122628|NCT04374071||Pre-Corticosteroid protocol|Patients with moderate or severe disease who presented to HFHS within the first week of the COVID epidemic in Detroit were initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases Physicians and Pharmacists. The institutional guidelines were developed by consensus, and based on the available literature, experience from Wuhan, China and other centers around the world affected by COVID-19 before Michigan. Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated patients. On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the COVID-19 institutional protocol.
10122629|NCT04374071||Corticosteroid Protocol|"As a result of observed poor outcomes, clinical rationale based upon immunology, clinical course of COVID-19, and more recently best available evidence, the HFHS corticosteroid protocol was developed. We hypothesized that early corticosteroids would combat the inflammatory cascade leading to respiratory failure, ICU escalation of care, and mechanical ventilation. The corticosteroid protocol became the institutional standard on March 20, 2020. Patients with confirmed influenza infection were not recommended to receive corticosteroids.~Patients with moderate COVID-19 who required 4 liters or more of oxygen per minute on admission, or who had escalating oxygen requirements from baseline, were recommended to receive IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days. Patients who required ICU admission were recommended to receive the above regimen of hydroxychloroquine and IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 to 7 days."
10122630|NCT04374162|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
10122631|NCT04374162|Experimental|Driving pressure (DP) guided-PEEP|"DP is calculated as plateau pressure - PEEP. 10 min after pneumoperitoneum， PEEP is increased from 5 to 15 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
10122632|NCT04374136|Experimental|AL001|AL001 every 4 weeks
10122633|NCT04374136|Placebo Comparator|Placebo|Placebo every 4 weeks
10122634|NCT04374136|Experimental|Open label - AL001|AL001 every 4 weeks
9967062|NCT01266239|Active Comparator|EES-NK|EES is deployed in the MV without kissing balloon inflation.
9967063|NCT01266252|Experimental|Dexmedetomidine|
10122635|NCT04374214|Active Comparator|Complete Pulpotomy using mineral trioxide aggregate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Mineral Trioxide Aggregate.
10122636|NCT04374214|Active Comparator|Complete Pulpotomy using Simvastatin-alphatricalcium phosphate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Simvastatin -alphatricalcium phospahte.
10122637|NCT04374201||2 zirconia FDPs|11 patients received 2 zirconia fixed dental prostheses
10122638|NCT04374201||1 zirconia FDP|26 patients received 1 zirconia FDP
10122639|NCT04373798||Suspected COVID-19|Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.
10122640|NCT04373824|Experimental|Group I- Ivermectin|First group with 25 confirmed cases of COVID 19 shall be treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with standard treatment of the hospital protocol
10122641|NCT04373824|No Intervention|Group II- standard treatment|The second group with 25 confirmed cases of COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19.
10122642|NCT04373850|Experimental|Home visit group|Will receive a home visit after discharge in addition to the standard discharge planning.
10122643|NCT04373850|No Intervention|Control group|Will receive only the standard discharge planning.
10122644|NCT04373980|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
10122645|NCT04373980|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
10122646|NCT04373980|No Intervention|Control group|
10122647|NCT04374175||Adenocarcinoma group|Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
10122648|NCT04374175||Control group|Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.
10122649|NCT04373928|Experimental|Drug guided by Mini-PDX/PDX|Procedure: The tumor tissue is used for drug sensitivity test by Mini-PDX, building PC PDX, and acquiring the genetic information by the second genetic sequence or RNA-sequence. PC patients will accept personalized treatment guided by the experimental results of mini-PDX and sequencing.
10122650|NCT04373928|No Intervention|Drug according to guideline|The drugs (gemcitabine, Nab-paclitaxel, S-1) are used ccording to NCCN pancreatic cancer guideline。
10122651|NCT04374045||Patients with SARS-CoV-2|patients having a continuous recording of the heart rhythm during their hospitalization
10122652|NCT04374006|Experimental|propolis 50|we do sonde everyday to the rat that given treatment of 50mg/kg propolis for 2, 4, and 6 weeks
10122653|NCT04374006|Experimental|propolis 100|we do sonde everyday to the rat that given treatment of 100mg/kg propolis for 2, 4, and 6 weeks
10122654|NCT04374006|Active Comparator|dienogest|we do sonde everyday to the rat that given treatment of 25mg/kg dienogest for 2, 4, and 6 weeks
10122655|NCT04374006|Placebo Comparator|water|we do sonde everyday to the rat that given 0,2 ml water placebo for 2, 4, and 6 weeks
10122656|NCT04374006|Sham Comparator|sham group|after the 2nd laparotomy, we do nothing about sonde, just giving food and drink everyday
10122657|NCT04374188|Active Comparator|ciprofloxacin|ciprofloxacin tablets
10122658|NCT04374188|Active Comparator|levofloxacin|levofloxacin tablets
10122659|NCT04374032|Experimental|ENKORTEN|
10122660|NCT04374032|Other|The standard of care treatment|The usual therapeutically established protocol for the treatment of patients with moderate to severe COVID-19 infection
10122661|NCT04373993||Nordlandssykehuset HF|
10122662|NCT04373993||Akershus universitetsssykehus|
10122663|NCT04373993||Helgelandssykehuset|
10122664|NCT04373993||Basel University Hospital|
10122665|NCT04373967|Experimental|TQZ2451+metformin hydrochloride|TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
10122666|NCT04373967|Active Comparator|Victoza®+metformin hydrochloride|Victoza® (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
10122667|NCT04373941|Experimental|Kasai GCSF|The Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously by day 3 post Kasai surgery
10122668|NCT04373941|No Intervention|Kasai no GCSF|The no GCSF group will not receive GCSF and receives the standard of care
10122669|NCT04373941|Experimental|No Kasai GCSF|The No Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously once the diagnosis of BA is established
10122670|NCT04373941|No Intervention|No Kasai No GCSF|The No Kasai No GCSF group will receive the standard of care and will not receive GCSF
10122671|NCT04373772|Experimental|abdominal massage group|the abdominal massage group received a total of 30 minutes of massage, 15 minutes every morning and evening, until the first defecation.
10122672|NCT04373772|No Intervention|control group|Routine care for the control group
10122673|NCT04373694|Active Comparator|Standard hysteroscopy|morcellation hysteroscopy with intravenous sedation and paracervical bloc
10122674|NCT04373694|Experimental|Vaginoscopy|morcellation hysteroscopy with only intravenous sedation
10122675|NCT04373499|Experimental|Virtual Teach-to-Goal (V-TTG)|"The RA will show the patient how to use the tablet to access the education module and be available for questions about the technology / tablet but not about the content. Within the module, the child will:~answer questions about how to use the inhaler as part of a pre-video assessment.~watch a video about how to correctly use a Metered Dose Inhaler (MDI) and spacer.~answer questions on the tablet to assess how well they understand how to use the inhaler.~If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions."
10122676|NCT04373499|Active Comparator|Brief Intervention (BI)|The RA will give the patient a handout about inhaler technique and read the steps to the child.
10122677|NCT04373551|Experimental|Cultural adaptation of a patient-provider communication tool|Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.
10122678|NCT04373512|Experimental|Low Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermitent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
10122679|NCT04373512|Experimental|High Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
10122680|NCT04373473|Experimental|Patients with UC will receive FMT capsules|Patients with ulcerative colitis will receive fecal microbiota capsules from 3 healthy donors
10122681|NCT04373473|Placebo Comparator|Patients with UC will receive placebo|Patients with ulcerative colitis will receive matching placebo capsules. Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
10122682|NCT04373590|Experimental|Decision aid (DA)|a one-page DA for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics.
10122683|NCT04373590|No Intervention|Treatment as usual (TAU)|Treatment as usual without the DA
10122684|NCT04373408||ACL rupture without indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL only
10122685|NCT04373408||ACL rupture with indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL and the ALL
10122686|NCT04373291|Active Comparator|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
10122687|NCT04373291|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine.
10122688|NCT04373278||description of infection of free fibula flap reconstruction|
10122689|NCT04373668|No Intervention|Control, optimised usual care|Treatment delivered as usual in the care home
10122690|NCT04373668|Experimental|Hypnotic Drug Review|Care homes to receive the Hypnotic Drug Review intervention
10122691|NCT04373668|Experimental|Structured Sleep Hygiene|Care homes to receive the Structured Sleep Hygiene intervention
9967064|NCT01266278|Experimental|Kinesiotape|Kinesiotape will be applied to the correct shoulder position of the participants.
10122692|NCT04373668|Experimental|Night Time Care Activities Programme (NightCAP)|Care homes to receive the Night Time Care Activities Programme (NightCAP) intervention
10122693|NCT04373668|Experimental|Hypnotic Drug Review and Structured Sleep Hygiene|Care homes to receive the Hypnotic Drug Review and Structured Sleep Hygiene interventions
10122694|NCT04373668|Experimental|Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP|Care homes to receive all three interventions: Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP interventions
10122695|NCT04373668|Experimental|Hypnotic Drug Review and NightCAP|Care homes to receive the Hypnotic Drug Review and NightCAP interventions
10122696|NCT04373668|Experimental|Structured Sleep Hygiene and NightCAP|Care home to receive the Structured Sleep Hygiene and NightCAP interventions
10122697|NCT04373538|Experimental|Memory Support Intervention|
10122698|NCT04373577|Experimental|ESP group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected beneath the erector spinae muscle sheath at the level of the transverse process of the second lumbar vertebrae
10122699|NCT04373577|Experimental|PENG group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected as the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
10122700|NCT04373447|Active Comparator|fundus-calot laparoscopic cholecystectomy|use laparoscopic fundus first then calot dissection cholecystectomy
10122701|NCT04373447|Active Comparator|open cholecystectomy|open cholecystectomy
10122702|NCT04373356|Experimental|Resin Infiltration|The interproximal surface with initial dental caries that are selected for this group will be treated using the resin infiltration ICON (DMG, Germany) and 5% Sodium Fluoride Varnish
10122703|NCT04373356|Active Comparator|Sodium Fluoride Varnish|The interproximal surface with initial dental caries that are selected for this group will be treated using topical application of 5% Sodium Fluoride Varnish.
10122704|NCT04373395|Experimental|D-CLAG|Administration of D-CLAG regimen (Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor)
10122705|NCT04373382|Experimental|Peer Resilience Champion Support|The clusters that receive this intervention will receive support from a Peer Resilience Champion.
10122706|NCT04373382|No Intervention|No Peer Resilience Champion Support|The clusters in this arm of the study will not receive the Peer Resilience Champion support until they cross-over into the Peer Resilience Champion support arm.
10122707|NCT04373382|Experimental|Enriched Feedback|This arm of the study encompasses individuals who will receive feedback from the survey that will hopefully help provoke self-reflection.
10122708|NCT04373382|No Intervention|Express Feedback|This arm of the study encompasses individuals who will not receive feedback from the survey.
10122709|NCT04373213||Pleth variability index|Patients undergoing fluid management with Pleth variability index
10122710|NCT04373213||hemodynamic|Patients undergoing fluid management with hemodynamic findings
10122711|NCT04373187|Experimental|CC-93538, 180mg/mL|26 healthy subjects will receive one injection of 2mL, 180mg/mL CC-93538
10122712|NCT04373187|Experimental|CC-93538, 150mg/mL|26 healthy subjects will receive 2 injections of 1.2mL, 150mg/mL CC-93538
10122713|NCT04373304|Experimental|low FODMAP diet|
10122714|NCT04373239||Women in BC conceiving by ART|All women in BC registered in the Perinatal Services BC database having undergone Assisted Reproductive Technology. Assisted Reproductive Technology will consist of in vitro fertilization (+/-ICSI). Data from April 1, 2008 to March 31 2018 will be analyzed for live birth rate.
10122715|NCT04373239||Women in BC conceiving spontaneously|he comparison group will be all women in BC registered in the Perinatal Services BC database with spontaneously conceived pregnancies between April 1, 2008 to March 31 2018.
9825978|NCT02403180|Other|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
10122716|NCT04373109||Single-group study|Assessment of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
10122717|NCT04373252|Experimental|Fecal Microbiota Transplant|All participants will receive two fecal microbiota transplants one week apart. The transplant will occur via antegrade enema and the enema transplant material will be provided by OpenBiome, the product used is FMT Lower Delivery (FMP 30).
10122718|NCT04373161|Experimental|Suspected COVID-19 patients being discharged to home|Patients will be given a portable, fingertip pulse oximeter to take home. Patients will monitor their resting home oxygen saturation three times per day.
10122719|NCT04373135|Experimental|Experimental|Subjects will be provided a brief educational intervention prior to completing follow up survey about SRA attitudes and knowledge
10122720|NCT04373135|No Intervention|Control|Subjects will not be provided any prior to completing follow up survey about SRA attitudes and knowledge
10122721|NCT04373174|Active Comparator|Group E|Thoracic Epidural block + Regional oximetry probe will be placed in the frontal area of the head
10122722|NCT04373174|Sham Comparator|Group P|Regional oximetry probe will be placed in the frontal area of the head
10122723|NCT04373096|Active Comparator|Group C (Control)|Will use current IPAC-UHN PPE as described under assigned intervention:
10122724|NCT04373096|Experimental|Group H (enhanced PPE group )|Will use modified IPAC-UHN PPE including the prototype hood as described under assigned intervention:
10122725|NCT04373005||Nasopharyngeal (NP) swabs|"NP swabs:~At the time of consent~3-6 weeks after starting cancer treatment (for patients whose treatment has yet not started) or 3-6 weeks after first swab (for patients already on treatment)~3 months after second swab~6 months after second swab~12 months after second swab"
10122726|NCT04373200|Experimental|COVID-19 patients with associated ARDS|
10122727|NCT04373200|Active Comparator|COVID-19 patients without associated ARDS|
10122728|NCT04373200|Active Comparator|Patients with ARDS from other causes|
10122729|NCT04372992|Experimental|Early stoma closure|Ileostomy closure between 30 and 40 day after rectal resection
10122730|NCT04372992|Active Comparator|Delayed stoma closure|Ileostomy closure 15 days from the end of adjuvant therapy (up to 60 days)
9825979|NCT02403206|Experimental|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
9825980|NCT02403206|Active Comparator|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
10122731|NCT04372810|Experimental|Intervention Group|Intervention group, assessed on day 1, then underwent manual manipulation intervention and were reevaluated post-intervention and again evaluated on the 7th post-treatment day and received preventive guidance at the end of the experiment (follow-up).
10122732|NCT04372810|Sham Comparator|Sham Group|Sham group, evaluated on day 1 and day 7, and received preventive diabetes guidance at the end of the experiment (follow-up).
10122733|NCT04372875|Experimental|SHS-derived CDS|All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.
10122734|NCT04372875|No Intervention|Usual care|All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.
10183137|NCT03767413|Active Comparator|PNF group|It will be consisted of 15 -25 healthy subjects receiving only proprioceptive nueromuscular facilitation training for 5 weeks with 17 days follow up after completion of program.
9827372|NCT02453386|Experimental|Tozadenant 120 mg BID|"During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
10183138|NCT03767413|Experimental|PNFMP|It will be consisted of 15 -25 healthy subjects receiving proprioceptive nueromuscular facilitation training and mental practice technique for 5 weeks with 17 days follow up after completion of program.
10183139|NCT03767400||Group A - Young skin (18 - 30 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
10183140|NCT03767400||Group B - Aged skin (55 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
10122735|NCT04373070|Experimental|chatbot-based intervention programme (intervention)|"Participants randomised to the intervention group will receive a CAir desk and a chatbot-based intervention programme for a period of 12 weeks. The CAir desk is supplied to assess HrQoL, physical activity, and spirometry data. The first week is equal to the procedure in the control group (for details see paragraph below) and serves for baseline measurements of daily physical activity. Starting in week 2 of the study duration, participants receive feedback on their daily physical activity through the CAir chatbot application and aim to increase their daily step count by 15% from baseline. Furthermore, the CAir chatbot provides several components of the Living well with COPD programme (e.g. educational content, information on exercise training) to the patient."
10122736|NCT04373070|Other|Usual care group (control)|Participants randomised to the control group receive usual care and a CAir desk for a period of 12 weeks. The CAir desk is supplied to assess daily symptom burden, physical activity, and spirometry data. In contrast to the intervention group, participants do not receive feedback or scores of the daily reported CAT and daily physical activity.
10122737|NCT04372667|Experimental|Post intervention|Community score card approach
10122738|NCT04372641|Experimental|Treatment (p97 inhibitor CB-5339 tosylate)|Patients receive p97 inhibitor CB-5339 tosylate PO QD 4 days on and 3 days off. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10122739|NCT04373083|Experimental|Concomitant treatment|Treatment Group A
10122740|NCT04373083|Experimental|Sequential treatment|Treatment Group B
10122741|NCT04372849|Active Comparator|Nasal insulin spray|
10122742|NCT04372849|Placebo Comparator|Placebo spray|
10122743|NCT04372836|No Intervention|Control arm|During laparoscopic enucleation of unilateral endometrial cyst, no intervention is added to subjects allocated to control arm.
10122744|NCT04372836|Experimental|Study arm (with vasopressin injection)|During laparoscopic enucleation of unilateral endometrial cyst, diluted vasopressin is injected into the interface between endometrioma and ovarian parenchyma of patients allocated to study arm.
10122745|NCT04372680|Experimental|CTUS strategy group|CTUS examination will be performed until the day of patient extubation. CTUS examination will consist on a fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
10122746|NCT04372680|No Intervention|standard strategy group|from the day of patient's inclusion and beyond every day, the clinical team in charge of patients will decide to perform or not an SBT following current recommendations2. These criteria are mainly based on clinical data and do not include any specific ultrasound assessment.
10122747|NCT04372797|Experimental|Mild Traumatic Brain Injury Participants|Males and females from 18-50 years of age who present to a recruitment site within 10 days of injury with a diagnosed concussion that meets all of the following criteria: 1) clear mechanism of injury (i.e., direct or indirect impact to head), 2) Glasgow Coma Scale= 13-15, 3) observed or reported signs (e.g., loss of consciousness, amnesia, or confusion) or symptoms (e.g., headache, dizziness, nausea), and 3) neurosensory symptoms.
10122748|NCT04372797|Active Comparator|Control Participants|Age- and sex-matched control subjects with minor, non-surgical injuries (e.g., sprains, strains) not requiring hospital admission and no history of mild traumatic brain injury will be recruited from the same study sites.
10122749|NCT04373044|Placebo Comparator|Arm II (placebo, antiviral therapy)|Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
10122750|NCT04373044|Experimental|Treatment (baricitinib, antiviral therapy)|Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
10122751|NCT04372784|Active Comparator|EGD with Balloon Dilatation|Esophagogastroduodenoscopy with balloon dilatation
10122752|NCT04372784|Experimental|EGD with Balloon Dilatation and Cryotherapy|Esophagogastroduodenoscopy with balloon dilatation and cryotherapy
10122753|NCT04372966|Active Comparator|Cemented|This group will receive a cemented Exeter stem and contemporary acetabular component (Stryker).
10122754|NCT04372966|Active Comparator|Uncemented|This group will receive an uncemented Corail stem and uncemented acetabular component (Depuy).
10122755|NCT04372823||Comparison|Comparison children within family child care homes not exposed to policy/program
10122756|NCT04372823||Intervention|Intervention children within family child care homes exposed to policy/program
10122757|NCT04372654|Experimental|Radial group|Use of Electroducer Sleeve on radial route
10122758|NCT04372654|Experimental|femoral group|Use of Electroducer Sleeve on femoral route
10122759|NCT04372901|Experimental|digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
10122760|NCT04372901|Active Comparator|digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement
10122761|NCT04372888|Other|rare genetic disease|Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)
10122762|NCT04372888|Other|common genetic disease|Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)
10122763|NCT04372771|No Intervention|Control|No diet or exercise intervention
10122764|NCT04372771|Experimental|Curves Program|The Curves group will follow the high protein/low fat diet (30% carbohydrate, 45% protein, 25% fat) for 7-days at 1,200 kcals/day and then 1,500 kcals/day for the remaining 21-days of the 30-day diet period. The participants will then consume a normal maintenance diet (2,200 kcals/d; 45% carbohydrate, 30% protein, 25% fat) for 30-days. During the maintenance period, participants will diet for 2-days at 1,200 kcals/day if they gain 3 pounds of weight.
10122765|NCT04372771|Experimental|Weight Watchers Momentum Program|"This program is based on the Weight Watchers four pillar approach (food, exercise, behavior and support). The Momentum Program uses POINTS values to help keep track of what you eat. A POINTS budget will be personalized for you at the weekly meetings."
10122766|NCT04373018|Active Comparator|Sodium hypochlorite|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Sodium hypochlorite during biomechanical preparation.
10122767|NCT04373018|Active Comparator|Chlorhexidine|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Chlorhexidine during biomechanical preparation.
10122768|NCT04373018|Experimental|Chlorhexidine + Hydrogen peroxide|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using a combination of Chlorhexidine + Hydrogen peroxide during biomechanical preparation.
10122769|NCT04372719|Experimental|H3N2 10EXP5 TCID50/mL|A/Belgium/4217/2015 (H3N2) (SGS Code: SGS 421-7), Wild-type, influenza A (H3N2) human challenge strain
10183141|NCT03767400||Group C - Atrophic acne scars (18 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
10183142|NCT03767387|Active Comparator|Prehabilitation + standard care|Trimodal Prehabilitation consisting on motivation, personalisation and supervision of physical activity before major surgery
9825981|NCT02403271|Experimental|Phase 1b|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
9825982|NCT02403271|Experimental|Phase 2|Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.
9825983|NCT02403479|Experimental|Saline then Silver Colloid|Each participant uses 6 weeks of Saline first (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks)
10183143|NCT03767387|No Intervention|Standard care|Standard care before major surgery
10183144|NCT03767374||Main study group (HIV-negative)|"2000 HIV-negative individuals seeking care at the STI clinic of Saint-Antoine Hospital~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
10183145|NCT03767374||Exposure-matched group (HIV-positive)|"500 HIV-positive men who have sex with men from the Infectious Diseases Unit of Saint- Antoine Hospital. These individuals will be compared to 500 HIV-negative MSM from the main study group, matching on age (+/-5 years).~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
10183146|NCT03767361|Active Comparator|Fresh PRBCs|Neonates will receive fresh packed red blood cells transfusion within 7 days of donation
10183147|NCT03767361|Active Comparator|Old PRBCs|Neonates will receive fresh packed red blood cells transfusion older than 7 days yet within the standard range accepted universally will be transfused to this group.
10183148|NCT03767335|Experimental|MEN1611|MEN1611 + Trastuzumab +/- Fulvestrant
10183149|NCT03767322|Active Comparator|Allopurinol group|The intervention group will receive 300 mg of allopurinol 12 hours before and 12 hours after the coronary intervention.
10183150|NCT03767322|Placebo Comparator|Placebo group|The placebo group will receive 300 mg of placebo 12 hours before and 12 hours after the coronary intervention.
10183151|NCT03767322|Active Comparator|Febuxostat group|The intervention group will receive 80 mg of febuxostat 12 hours before and 12 hours after the coronary intervention
10183152|NCT03767309|Experimental|Test group|SCTG will be harvested from the palate in the intervention group (coronally advanced flap and abrasively de-epithelialized free gingival graft)
10183153|NCT03767309|Active Comparator|Control group|SCTG will be harvested from the palate using Zucchilli's technique (zucchelli, 2010) in the control group (coronally advanced flap and conventionally de-epithelialized free gingival graft)
10183154|NCT03767296|Experimental|Dose Bolus of E-P-E|Ephedrine Hydrochloride 3 MG/ML- Phenylephrine - Ephedrine Hydrochloride 3 MG/ML
10183155|NCT03767296|Experimental|Dose Bolus P-E-P|Phenylephrine- Ephedrine Hydrochloride 3 MG/ML - Phenylephrine
10183156|NCT03767296|Experimental|Dose Bolus E-E-E|Ephedrine Hydrochloride 3 MG/ML- Ephedrine Hydrochloride 3 MG/ML - Ephedrine Hydrochloride 3 MG/ML
10183157|NCT03767296|Experimental|Dose Bolus P-P-P|Phenylephrine-Phenylephrine-Phenylephrine
10183158|NCT03767270|Experimental|MRT5201|Single Ascending Low, Mid, and High doses of MRT5201
10183159|NCT03767270|Placebo Comparator|Placebo|Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
10183160|NCT03767257|Experimental|Participants with Myeloma|Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea
10183161|NCT03767231|Experimental|HCV POC VL Group|This group will receive the POC HCV viral load testing via fingerstick using the novel Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
10183162|NCT03767231|No Intervention|Reference Group|This group will receive the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing only. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
10183163|NCT03767218|Experimental|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 12 of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
10183164|NCT03767218|Active Comparator|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
10122770|NCT04372862|Active Comparator|Serratus anterior plane block|Serratus anterior plane block was performed in the supine position placing the ipsilateral upper limb in abduction 90 degrees position. Aiming to find the serratus anterior muscle the investigator identified the fifth rib in the mid-axillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) were detected using ultrasound. The investigator penetrated the serratus anterior muscle by a 25 GA, 90 mm spinal needle in-plane concerning the ultrasound probe from superoanterior to posteroinferior to inject deep to it.
10122771|NCT04372862|Active Comparator|Erector spinae plane block|Erector spinae plane block was performed at lateral decubitus with the operation site up, the vertebrae were counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe was placed vertically 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle.
10122772|NCT04372732||Study group|All participants will be detected for antoantibodies and then treated with PD-1 blockade.
10122773|NCT04372693|Experimental|group of students who are learning by Online Distance|"The following principals implemented while online learning will be processing;~Address and consider the students' differences in online learning application as a new experience.~Allow for Individual Locus of Control.~Motivate the student:~Avoid information overload,~Create A real-life context,~Encourage social interaction,~Provide hands-on activities,~Encourage student reflection."
10122774|NCT04372693|No Intervention|students who were learned by Traditional Classroom-Based|
10122775|NCT04372290|Experimental|Product usage order ABECD|Subjects will use each of the 5 products sequentially (ABECD) during an evaluation period, followed by a 6 hour Test Session.
10122776|NCT04372290|Experimental|Product usage order BCADE|Subjects will use each of the 5 products sequentially (BCADE) during an evaluation period, followed by a 6 hour Test Session.
10122777|NCT04372290|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products sequentially (CDBEA) during an evaluation period, followed by a 6 hour Test Session.
10122778|NCT04372290|Experimental|Product usage order DECAB|Subjects will use each of the 5 products sequentially (DECAB) during an evaluation period, followed by a 6 hour Test Session.
10122779|NCT04372290|Experimental|Product usage order EADBC|Subjects will use each of the 5 products sequentially (EADBC) during an evaluation period, followed by a 6 hour Test Session.
10122780|NCT04372290|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products sequentially (DCEBA) during an evaluation period, followed by a 6 hour Test Session.
10122781|NCT04372290|Experimental|Product usage order EDACB|Subjects will use each of the 5 products sequentially (EDACB) during an evaluation period, followed by a 6 hour Test Session.
10122782|NCT04372290|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products sequentially (AEBDC) during an evaluation period, followed by a 6 hour Test Session.
10122783|NCT04372290|Experimental|Product usage order BACED|Subjects will use each of the 5 products sequentially (BACED) during an evaluation period, followed by a 6 hour Test Session.
10122784|NCT04372290|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products sequentially (CBDAE) during an evaluation period, followed by a 6 hour Test Session.
10122785|NCT04372589|Experimental|Investigational arm|Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen >24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also acceptable, as available) if no contraindication is present; alternatively, intravenous unfractionated heparin infusion may be used.
10122786|NCT04372589|No Intervention|Control arm|Participants will receive usual care of thromboprophylactic dose anticoagulation according to local practice.
10122787|NCT04372303|Experimental|Short-term Compassion Fatigue Resiliency Program|Experimental I received a short-term program (five hours per day for two days, ten hours in total).
10122788|NCT04372303|Experimental|Long-term Compassion Fatigue Resiliency Program|Experimental II received a long-term program (five weeks, two hours per week, ten hours in total).
10122789|NCT04372303|No Intervention|Control|No intervention was applied to the control group.
10122790|NCT04372342|Experimental|nalbuphine|
10122791|NCT04372342|Placebo Comparator|remifentanil|
10122792|NCT04372264|Experimental|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
10122793|NCT04372264|Experimental|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
10122794|NCT04372264|Experimental|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
10122795|NCT04372212|Active Comparator|Inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
10122796|NCT04372212|Active Comparator|Inversion and Ligation|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
9825984|NCT02403479|Experimental|Silver Colloid then Saline|Each participant uses 6 weeks of Silver Colloid first (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of saline (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks).
9827373|NCT02453386|Placebo Comparator|Placebo BID|"During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
9967065|NCT01266304||community members|Pittsburgh area community members, including people who attend an integrative medicine clinic and people who attend a conventional medicine clinic.
9967066|NCT01266330|Active Comparator|Low Dairy|<0.5 standard dairy servings/day
9967067|NCT01266330|Experimental|Adequate dairy|3.5 standard dairy servings per day
9967068|NCT01266343||Experimental Group|
9967069|NCT01266343||Control Group|
9967070|NCT01266356||Experimental Group|
9967071|NCT01266356||Control Group|
9967072|NCT01266369|Experimental|masitinib 3 mg/kg/day|masitinib 3 mg/kg/day
9967073|NCT01266369|Experimental|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
9967074|NCT01266408||DRSP/EE/metafolin|Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin
9967075|NCT01266408||Other OC users|Women using oral contraceptives containing other estrogen/progestogen combinations
9967076|NCT01266421||Dienogest (DNG)|Women using DNG) for the treatment of endometriosis
9967077|NCT01266421||Other approved endometriosis drugs (OAED)|Women using hormonal medications approved for endometriosis treatment in all particiapting countries other than DNG.
9967078|NCT01266421||Non-approved endometriosis drugs (NAED)|Women using hormonal medications not approved for endometriosis treatment in all particiapting countries.
9967079|NCT01266434|Experimental|simvastatin|
9967080|NCT01266434|Placebo Comparator|B1-6-12|
9967081|NCT01266473|Experimental|Physiotherapy techniques|Cough Technique vs Forced Expiration Technique
9967082|NCT01266486|Experimental|Metformin|
9967083|NCT01266499|Active Comparator|Group 1: will receive PO Garamycin 80mg x 4/d|will receive PO Garamycin 80mg x 4/d
9967084|NCT01266499|Active Comparator|Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d|
9967085|NCT01266499|Active Comparator|Group 3: will receive both medications|
10183165|NCT03767205|Experimental|stroke patients|All participants perform overground walking and treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot).
9827374|NCT02453555|Active Comparator|Linagliptin|patient to receive 5 mg linagliptin once daily
9967086|NCT01266499|Placebo Comparator|Group 4: will not receive PO treatment|
9967087|NCT01266512|Experimental|IMRT & docetaxel-cisplatin|"Concurrent chemo-RT:~Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -~Resting period: 2 weeks -~Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 -~Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration"
9967088|NCT01266538||IBD patients|Patients diagnosed with Inflammatory Bowel Disease (IBD)
9967089|NCT01266538||patients after a Large Bowel Resection|Patients after a Large Bowel Resection, with or without a pouch.
9967090|NCT01266538||Control group|Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
9967091|NCT01266551|No Intervention|lifestyle counseling|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring. In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
9967092|NCT01266564||Cohort|
9967093|NCT01266616|Experimental|Cohort 1: Vaccine alone IM/EP|HIV MAG pDNA alone IM/EP
9967094|NCT01266616|Placebo Comparator|Cohort 1: Placebo|Placebo given as an injection in each upper arm
9967095|NCT01266616|Experimental|Cohort 2: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 50 mcg of IL-12 pDNA IM/EP
9967096|NCT01266616|Placebo Comparator|Cohort 2: Placebo|Placebo given as an injection in each upper arm
9967097|NCT01266616|Experimental|Cohort 3: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 250 mcg of IL-12 pDNA IM/EP
9967098|NCT01266616|Placebo Comparator|Cohort 3: Placebo|Placebo given as an injection in each upper arm
9967099|NCT01266616|Experimental|Cohort 4: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 1,000 mcg of IL-12 pDNA IM/EP
9967100|NCT01266616|Placebo Comparator|Cohort 4: Placebo|Placebo given as an injection in each upper arm
9967101|NCT01266616|Experimental|Cohort 5: Vaccine plus IL-12 IM|HIV MAG pDNA plus 1,000 mcg (or highest dose reached) IL-12 pDNA IM
9967102|NCT01266616|Placebo Comparator|Cohort 5: Placebo|Placebo given as an injection in each upper arm
9967103|NCT01266629||capsule patients|All patients that will undergo endoscopic capsule
9967104|NCT01266655|Experimental|Baclofen|
9967105|NCT01266655|Placebo Comparator|Placebo|
9967106|NCT01266668||Primary breast DLBCL|Primary breast DLBCL was defined as that involving single extranodal organ (i.e. breast) regardless of the status of nodal disease.
9967107|NCT01266668||Nodal DLBCL|The disease was only limited to the lymph nodes or lymphoid organs without extranodal organ involvements.
9967108|NCT01266681|Active Comparator|Amiodarone|this group will be given Amiodarone to maintain sinus rhythm powst cardioversion.
9967109|NCT01266681|Active Comparator|Dronedarone|this group will be given dronedarone to maintain sinus rhythm post DC cardioversion
9967110|NCT01266694|Experimental|Cochicine|Colchicine arm: patient receiving 1 mg per day for 14 days
9967111|NCT01266694|Placebo Comparator|Placebo|patients placebo controlled
9967112|NCT01266707|Experimental|Vaccine|VEGRF1, VEGFR2
9967113|NCT01266720|Experimental|Phase 1 study|"Interventions:~Biological: VEGFR1, VEGFR2 Drug: Gemcitabine"
9967114|NCT01266733|Experimental|Interdisciplinary treatment|
9967115|NCT01266733|No Intervention|Usual treatment|
10122797|NCT04372537|Experimental|Hypnosis|"Patients will benefit from formal hypnosis (trance induction, hypno analgesia, comfort suggestions) and/or conversational hypnosis (confusion, distraction, use of chosen words, goodwill using verbal and non verbal languages).~They will also get to be informed of the proceedings of the performed examination as the standard procedure group."
10122798|NCT04372537|Active Comparator|Standard procedure group.|"Patients will be informed of the proceedings of the performed examination, without using any hypnosis technique.~This corresponds to the standard clinical procedures used while performing an electroneuromyogram."
10122799|NCT04372225||477 patients|the biological tests of 477 patients undergoing total thyroidectomy were analyzed
10122800|NCT04372238|Experimental|RAPIDS intervention|Participants randomized to receive the RAPIDS intervention will receive a fentanyl specific behavioral intervention and a brief behavioral intervention to increase willingness to use fentanyl test strips and engage in overdose risk reduction behaviors, in addition to standard OEND.
10122801|NCT04372238|Active Comparator|Standard OEND|In the control arm participants will receive standard overdose education and naloxone distribution (OEND).
9668979|NCT04448184|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.
10122802|NCT04372459|Experimental|Online integrated and stepped psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the online integrated and stepped psychosocial care group
10122803|NCT04372459|Experimental|Usual psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the usual psychosocial care group
10122804|NCT04372511|Experimental|Binaural Beats|Group A : use of stereo headphones that generate sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
10122805|NCT04372511|No Intervention|No sounds|Group B : use of stereo headphones with a white background noise
10122806|NCT04372420|Active Comparator|RhBMP-2|RhBMP-2 belongs to TGF-β super family with osteoinductive property which is capable of promoting bone formation
10122807|NCT04372420|Placebo Comparator|PLATELET RICH FIBRIN|Platelet rich fibrin(PRF) is a healing biomaterial with a great potential for bone and soft tissue regeneration, without any inflammatory reactions
10122808|NCT04372316|Active Comparator|methylcobalamin injection|
10122809|NCT04372316|Active Comparator|methylcobalamin tablet|
10122810|NCT04372277|Experimental|Enstilar|Enstilar foam
10122811|NCT04372381|Active Comparator|Supra-Annular transcatheter heart valve|Medtronic Evolut Pro Valve implantation
10122812|NCT04372381|Active Comparator|Annular transcatheter heart valve|Edwards Sapien 3 Ultra implantation
10122813|NCT04372407|Experimental|Treatment Crossover Arm|All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2
10122814|NCT04372355|Experimental|Chlorite-based drug WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five
9967116|NCT01266746||Macular hole|The patients of idiopathic macular hole enrolled in the study
9668980|NCT04440176|Experimental|Group 1 (MenABCWY 0-, 12-months)|MenABCWY administered at Month 0 and Month 12
9825985|NCT02403622|Experimental|Intervention: Fecal Microbiota Preparation|"Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.~Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor"
9825986|NCT02403635|Other|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
9825987|NCT02403674|Experimental|Doravirine, Tenofovir, Lamivudine|Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
9825988|NCT02403674|Active Comparator|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
9967117|NCT01266746||Macular hole retinal detachment|The patients of macular hole retinal detachment enrolled in the study
10122815|NCT04372485|Other|mHealth|Adolescents enrolled in this arm will receive treatment-related text messages.
10122816|NCT04372485|No Intervention|Usual care|Adolescents in this arm will receive usual care.
10122817|NCT04372433|Experimental|Dose Escalation|Dose cohorts treated with intravenous (IV) IO-202 monotherapy, in ascending doses Q2wks.
10122818|NCT04372433|Experimental|Dose Expansion|IV IO-202 monotherapy at the recommended Phase 2 dose and frequency
10122819|NCT04372394|Experimental|Fed/Fasted|surufatinib with food on Day 1 and surufatinib without food on Day 8
10122820|NCT04372394|Experimental|Fasted/Fed|surufatinib without food on Day 1 and surufatinib with food on Day 8
10122821|NCT04372550|Active Comparator|Standard of Care|"Standard of care treatment:~- including passive / assisted / active movements, stretching, functional exercise, scar treatment~Duration: 6-12 weeks"
10122822|NCT04372550|Experimental|Exercise|"Standard of care + added exercises~Exercise type: resistance and aerobic exercise~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)~Duration: 6-12 weeks"
9668981|NCT04440176|Experimental|Group 2 (MenABCWY 0-, 36-months)|MenABCWY administered at Month 0 and Month 36
10122823|NCT04372160||Younger school age children|Equal ratio of boys and girls, age range 7-13 years (68 subjects)
10122824|NCT04372160||Older school age children|Equal ratio of boys and girls), age range 14-17 years (68 subjects)
10122825|NCT04372160||Adults|Equal ratio of adult men and women, age range 18-65 years (68 subjects).
10122826|NCT04371939|Experimental|I (Romiplostim)|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
10122827|NCT04371939|Experimental|II (Eltrombopag)|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
9825989|NCT02403778|Active Comparator|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
9825990|NCT02403778|Experimental|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
10122828|NCT04371874|No Intervention|Control|Hypertension of patients in the control group was managed with the original protocol including lifestyle by doctors in village clinic.
10122829|NCT04371874|Experimental|Treatment with Ten Dollars Project (TDP)|"Hypertension of patients in the TDP group were managed with the protocol of Ten Dollars Project (TDP) by doctors in village clinic."
10122830|NCT04372004|Active Comparator|Viral RNA test using nasopharyngeal swab|
10122831|NCT04372004|Active Comparator|Viral RNA test using sputum|
10122832|NCT04372004|Active Comparator|Serology test using blood|
10122833|NCT04372043||Lebanese population|"The Sleep Hygiene Index with other demographic questions will be applied to the Lebanese population."
10122834|NCT04371965|Experimental|Decolonization|1% Povidone iodine mouthwash (95 mL), gargle, and nasal spray (2,5 mL by nostril), and 10% nasal gel (one drop). All four time a day for five days.
10122835|NCT04371965|No Intervention|Control|Absence of local decolonization
10122836|NCT04372082|Placebo Comparator|standard of care (SOC)|
10122837|NCT04372082|Experimental|SOC + Hydroxychloroquine|
10122838|NCT04372082|Experimental|SOC + Diltiazem-Niclosamide|
10122839|NCT04372095||group 1: Exposed to CPA + Meningioma|"Meningioma diagnosed in women by medical imaging examination and confirmed histologically if surgery is performed.~Cyproterone acetate taken for at least 6 months."
10122840|NCT04372095||group 2: Exposed to CPA without Meningioma|Women exposed to Cyproterone acetate without developing any meningioma Absence of meningioma assessed by a normal cerebral MRI . Cyproterone acetate taken for at least 5 years.
9825991|NCT02403817|Experimental|Eye Movement Game Control|Cognitive Training Eye Motor Training
9825992|NCT02403817|Active Comparator|Hand Movement Game Control|Cognitive Training Hand Motor Training
10122841|NCT04372095||group 3: Not exposed to CPA, Meningioma diagnosed|"Meningioma in women not exposed to cyproterone acetate. Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery was necessary.~Never exposed to cyproterone acetate."
10122842|NCT04372095||group 4: General population|Subjects (women) never diagnosed with meningioma and not exposed to cyproterone acetate.
10122843|NCT04372147|Experimental|intervention group|MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
10122844|NCT04372147|No Intervention|control group|standard medical care
10122845|NCT04371796|Experimental|Sintilimab injection|"Drugs: Eligible patients received two doses of intravenous sintilimab (200 mg) every 3 weeks (Q3W). Each infusion time is 30-60min.~Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 6-8 weeks after the first dose."
10122846|NCT04371991||Group 1|Ectopic pregnancy
10122847|NCT04371991||Group 2|Early viable pregnancy
10122848|NCT04371991||Group 3|incomplete miscarriage
10122849|NCT04371991||Group 4|Healthy women
10122850|NCT04372134|Active Comparator|real rTMS group|motor incomplete traumatic SCI patients receiving real repetitive transcranial magnetic stimulation therapy
10122851|NCT04372134|Sham Comparator|sham r TMS|motor incomplete traumatic SCI patients receiving sham repetitive transcranial magnetic stimulation therapy
10122852|NCT04372030|Other|General population|There is only one arm wishing to participate
9827375|NCT02453555|Experimental|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
10122853|NCT04371978|Experimental|DPP-4 inhibition|Participants in the Dipeptidyl Peptidase-4 (DPP-4) inhibition group will receive linagliptin in addition to standard of care insulin regimen as per hospital protocol during their entire hospitalization.
10122854|NCT04371978|No Intervention|Control|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during their entire hospitalization.
10122855|NCT04371926|Active Comparator|HCQ arm|"COVID-19 positive cases will receive receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff randomized to this group will receive HCQ sulfate 400 mg/week for 4 weeks"
10122856|NCT04371926|No Intervention|No-HCQ arm|Will receive standard treatment as needed, but no HCQ
10122857|NCT04371913|Other|Radiation Therapy|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT).
10183166|NCT03767192|Experimental|Active Stimulation|Device: The Ischemic Stroke System SPG stimulation and standard of care
10183167|NCT03767192|Sham Comparator|Sham Stimulation|Device: Sham control Sham stimulation and standard of care
10183168|NCT03767179||Study Group|The study group consisted of 30 fertile, under 35 years old women who were included in the study for the first time missed abortus diagnosis.
10183169|NCT03767179||Control Group|30 cases with the same trimester, fertile, and under 35 years old who were referred to Obstetrics clinic, who had no systemic disease, were included in the study.
10183170|NCT03767140|Experimental|Verum acupucnture|Real acupuncture treatment
10183171|NCT03767140|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
10122858|NCT04371614|Active Comparator|Prime Time Sister Circle Intervention|The women in this arm participate in a Prime Time Sister Circle (PTSC). The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group. PTSC addresses three key modifiable health risk factors for chronic disease: unmanaged stress, physical inactivity, and unhealthy nutritional choices. It also addresses additional risk factors that contribute to unhealthy lifestyles: lack of knowledge or misinformation about major illnesses-cardiovascular disease (CVD), hypertension, diabetes, cancer, stress and depression-and the failure of African American women to prioritize their health and take proactive steps to manage their health and health outcomes. PTSC gives African American women the information, motivation, tools, skills, and consultative support they need to improve and maintain their health.
10122859|NCT04371614|No Intervention|Usual Care|The women in the arm do not receive the intervention but provide data at baseline, 3 months, 9 months and 15 months.
10122860|NCT04371692||High-risk|staff working in a unit specifically for patients infected or suspected of being infected with SARS-Cov2
10122861|NCT04371692||Medium- risk|staff working in a unit that can accommodate patients infected or suspected of being infected with SARS-Cov2, i.e., all care services that do not fall into the high-risk group.
10122862|NCT04371692||Low-risk|off-patient staff
10122863|NCT04371705|Experimental|ESPB group|31 patients Will undergo ultrasound guided ESP block with 40 ml bupivacaine 0.25% (20 ml on each side).
10122864|NCT04371705|Placebo Comparator|control group|31 patients anesthetized with the protocol followed by Minia University Hospital
10122865|NCT04371757|Experimental|Aerobic exercise session|The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end.
10122866|NCT04371757|Experimental|Resistance exercise session|The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
10122867|NCT04371757|Experimental|Combined exercise session|The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
10122868|NCT04371588||Deep neuro-muscular blockade|
10122869|NCT04371588||Moderate neuro-muscular blockade|
9967118|NCT01266746||Myopic traction maculopathy|The patients of macular hole with myopic traction maculopathy enrolled in the study
9967119|NCT01266759|Experimental|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
9967120|NCT01266759|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
10122870|NCT04371601|Active Comparator|Control group|conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies
10122871|NCT04371601|Experimental|Experimental group|On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106/Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission
10122872|NCT04371549|Active Comparator|Glue|Skin closure after cesarean section using glue
10122873|NCT04371549|Active Comparator|Monocryl|Skin closure after cesarean section using running subcuticular sutures using synthetic monofilament
10122874|NCT04371653|Experimental|Active group|Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors
10122875|NCT04371653|Placebo Comparator|Placebo group|Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria
10122876|NCT04371731|Experimental|Active Arm|Active cohort will use the Care4today platform to help manage their heart failure
10122877|NCT04371731|No Intervention|Control arm|Control arm will contain standard of care heart failure treatment
10122878|NCT04371718|Experimental|JKB-122 Low dose|JKB-122 5 mg daily for 104 weeks
10122879|NCT04371718|Experimental|JKB-122 Medium dose|JKB-122, 15 mg daily for 104 weeks
10122880|NCT04371718|Experimental|JKB-122 High dose|JKB-122 35 mg daily for 104 weeks
9668982|NCT04430426|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days and be administered an intravenous (IV) load of glycolate. Participants will provide urine and blood samples both before the glycolate load to establish baseline levels and after the glycolate load to measure oxalate levels afterwards.
10122881|NCT04371718|Placebo Comparator|Placebo|Matched placebo, daily for 104 weeks
10122882|NCT04371536|Active Comparator|Arm A: Oral iron therapy|Arm A is standard oral iron therapy for 3 months.
9967121|NCT01266772|Active Comparator|montelukast group|Children with asthma treated with montelukast and budesonide.
10122883|NCT04371536|Experimental|Arm B: Oral iron therapy plus IRONCHILD web-based intervention|Oral iron therapy as per Arm A plus the IRONCHILD web-based intervention aimed at promoting oral iron adherence. This web-based intervention was developed specifically for caregivers of young children with nutritional iron deficiency anemia to promote oral iron adherence.
10122884|NCT04371523|Experimental|Intervention - Hydroxychloroquine|
10122885|NCT04371523|Placebo Comparator|Control|
10183172|NCT03767114|Experimental|cases of psoriasis|group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR
10122886|NCT04371315||Positive COVID-19|"Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected~Monthly follow-up until Covid-19 is negative: Respiratory and Whole Blood Samples Collected"
10122887|NCT04371315||Negative COVID-19|Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
10122888|NCT04371822|Active Comparator|5 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days
10122889|NCT04371822|Active Comparator|7mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days
10122890|NCT04371822|Active Comparator|9 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days
10122891|NCT04371822|Active Comparator|5mg TPPS dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days
10122892|NCT04371822|Placebo Comparator|placebo|No intervention
10122893|NCT04371510|Other|Covid-19 patients with moderate symptoms|Whole blood, culture supernatant, serum
10122894|NCT04371302||Intensive Care Unit nurses|Nurses working in the Intensive care Unit of an exclusive Covid-19 hospital in Malaysia, during the Covid-19 pandemic
10122895|NCT04371458|Experimental|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
10122896|NCT04371224|Experimental|NaliCap|nal-IRI/Capecitabine
10122897|NCT04371224|Active Comparator|NAPOLI|nal-IRI/5-FU/LV
10122898|NCT04371341|Experimental|E1|will receive erector spinae block with 0.25% bupivacaine volume of 2.5 ml/segment
10122899|NCT04371341|Experimental|E2|will receive erector spinae block 0.25% bupivacaine with volume of 3.4ml/segment
10122900|NCT04371341|Experimental|E3|will erector spinae block receive 0.25% bupivacaine with volume of 6.6 ml/segment
10122901|NCT04371341|No Intervention|C|will not receive erector spinae block
10122902|NCT04371237|Experimental|Intermittent pneumatic compression|IPC sleeve device on leg
10122903|NCT04371237|Experimental|Heat therapy|Custom water-circulating garment on leg
10122904|NCT04371367|Experimental|avdoralimab|"Biological/Vaccine: avdoralimab intravenous administration of avdoralimab~Other Names:~• IPH5401"
10122905|NCT04371367|Placebo Comparator|Placebo|intravenous administration of Placebo
10122906|NCT04371484||children from 0 to 5 years old, hospitalized|
10122907|NCT04371094|Active Comparator|stylet|The stylet is a device that is put inside the endotracheal tube to facilitate its insertion into the trachea
10122908|NCT04371094|Active Comparator|bougie|The bougie is a device that is inserted into the trachea and an endotracheal tube is loaded over it and is slide into the trachea
10122909|NCT04371068||Patients suspected of low-grade PJIs|Adult patients suspected of low-grade PJIs, who have a scheduled prosthesis removal or change and who meet the inclusion criteria
9668983|NCT04428333|Experimental|Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy|
10122910|NCT04371159|Experimental|Velieve U.S.|Each participant will test their urine sample using the Velieve U.S. device
10122911|NCT04371081||Amplatzer Piccolo Occluder|Amplatzer Piccolo Occluder device implant
10122912|NCT04371016|Experimental|Verticalization group|"After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed :~insertion of an esophageal balloon catheter (Nutrivent®, Sidam)~installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger)~insertion of a Swan-Ganz catheter~continuous recording of digital and analogic data~After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected."
10122913|NCT04371406|Experimental|Experimental Arm|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
10122914|NCT04371406|Sham Comparator|Control Arm|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
10122915|NCT04371185|Experimental|BAT2206 injection|45mg; subcutaneous injection
10122916|NCT04371185|Active Comparator|Stelara(US-licensed)|45mg; subcutaneous injection
10122917|NCT04371185|Active Comparator|Stelara(EU-licensed)|45mg; subcutaneous injection
9668984|NCT04428333|Placebo Comparator|Placebo + Pembrolizumab + 5-FU-platinum chemotherapy|
10122918|NCT04370938|Experimental|Coping strategies video|Individuals will be asked to watch a 1 hour long video that discusses strategies helpful in coping with stress during the COVID-19 pandemic.
10122919|NCT04370938|No Intervention|Control|No additional requests will be made of individuals in the control arm.
10122920|NCT04370886|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic
10122921|NCT04370886|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation
10122922|NCT04370886|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation
10122923|NCT04370886|Placebo Comparator|SMS with holiday greeting|SMS content in this group will be about holiday greeting of Labour Day.
10122924|NCT04370990|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
10122925|NCT04370990|No Intervention|controle|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
10122926|NCT04371146|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 35 mg methylphenidate 1.5 hours before performing the tasks.
10122927|NCT04371146|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 8 mg reboxetine 1.5 hours before performing the tasks.
10122928|NCT04371146|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before performing the tasks.
10122929|NCT04371133||Endometrioma|Endometrioma (n=23)
10122930|NCT04371133||Healthy controls|Healthy controls Healthy volunteers n=25
10122931|NCT04370769||Women with Kidney Disease|Women with kidney disease
10122932|NCT04370743||Group 1|
10122933|NCT04370977|Active Comparator|Artemether-Lumefantrine|4 sites, namely Massinga, Mopeia, Moatize and Montepuez
10122934|NCT04370977|Active Comparator|Amodiaquine-Artesunate|3 sites, namely Massinga, Mopeia and Montepuez
10122935|NCT04370782|Experimental|Experimental Arm 1|"Hydroxychloroquine~Azithromycin~Zinc sulfate"
10122936|NCT04370782|Experimental|Experimental Arm 2|"Hydroxychloroquine~Doxycycline~Zinc sulfate"
10122937|NCT04370899||Familial hypercholesterolaemia children|FH diagnostic criteria were as follows: a positive genetic test or, if no genetic test results were available, LDL-C >160 mg/dL and one parent with a DLCN score >8.
10122938|NCT04370899||Unaffected children|The children evaluated for suspected FH who did not meet the FH criteria were included in the non-FH control group
10122939|NCT04370691||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
10122940|NCT04370691||Limb Ischemia|Patients presenting with limb ischemia
10122941|NCT04370691||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
10122942|NCT04370691||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than deep vein thrombosis, limb ischemia or thrombosed hemodialysis access for treatment
10122943|NCT04370951|Active Comparator|Erector Spinae Plane Block|Patients will receive a ESP block with 20mls 0.25% Levobupivicaine bilaterally, pre incision plus standardised multimodal analgesia
10122944|NCT04370951|No Intervention|Control|no ESP block, standardised multimodal analgesia
10122945|NCT04370925|Active Comparator|Matched control|Patients undergo radical resection of primary colorectal cancer and receive standard adjuvant systemic chemotherapy
10122946|NCT04370925|Experimental|HIPEC|Patients undergo radical resection of colorectal cancer and HIPEC simultaneously or within 2 days after primary tumor resection. Followed by standard adjuvant systemic chemotherapy
10122947|NCT04370964|Other|Family with young aged people|The family will be evaluated in two stages via the standardized situations LTP (parents and patient) and LFP (family) as well as self-assessments
10122948|NCT04371029|Experimental|Experimental|A Polysomnography (PSG) will be performed in all patient the night before extubation, the day prior discharge and 3 month after. Recording will consist in EEG, EOG et EMG of the chin. We will record NIM EMG. We will also performed an actimetry during hospitalization in the post ICU ward. A quality of sleep questionnaire (Pittsburgh questionnaire) will be completed by the patients during the visit at 3 month.
10122949|NCT04371107|Experimental|azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
10122950|NCT04371107|Active Comparator|symptomatic treatment|continuation of symptomatic treatment
9967122|NCT01266772|Placebo Comparator|Placebo group|Children with asthma treated with placebo tablet and budesonide.
9976607|NCT01353352|Other|Cervical spine injury|We enrolled consecutive alert adults who were in stable condition and who presented with potential cervical spine injury after acute blunt trauma, including patients with posterior neck pain and those presenting by ambulance with immobilization of the cervical spine.
9976608|NCT01353378|Experimental|dexmedetomidine|intravenously injecting 0.125microgram/kg and 0.25microgram/kg within 10 minutes as soon as the operation begins respectively.
9976609|NCT01353391|Active Comparator|Metformin|
9976610|NCT01353391|Placebo Comparator|Placebo|
9976611|NCT01353404|Experimental|fenofibrate 65mg, fed condition, per oral|
9976612|NCT01353404|Experimental|fenofibrate 65mg, fasting condition, per oral|
10122951|NCT04370808||Mild to severe disease|Mild to severe disease (admission to isolation room)
10122952|NCT04370808||Critical patients|Critical patients (admission to ICU)
10122953|NCT04370483|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9976613|NCT01353404|Active Comparator|fenofibrate 160mg, fed condition, per oral|
10122954|NCT04370405|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
10122955|NCT04370496|Experimental|SOLUTION group|Patients enrolled in this clinical trial will undergo radical hysterectomy through minimally invasive surgery using an endoscopic stapler which both cuts and simultaneously sutures the open vaginal stump.
10122956|NCT04370626|Active Comparator|Screw Fixation|Patients with a clinically diagnosed purely ligamentous perilunate injury requiring an isolated repair to the scapholunate ligament. These subjects will be treated with open reduction and internal fixation using a Kirschner-wire (k-wire).
10122957|NCT04370626|Active Comparator|K-Wire Fixation|Patients with a clinically diagnosed purely ligamentous perilunate injury requiring an isolated repair to the scapholunate ligament. These subjects will be treated with open reduction and internal fixation using a stainless steel smooth shafted headless compression screw.
10122958|NCT04370600|Active Comparator|Group A|These patients will receive ketone supplementation between visits 1 and 2 and will receive placebo drink between visits 2 and 3 (after the washout period).
10122959|NCT04370600|Active Comparator|Group B|These patients will receive ketone supplementation between visits 2 and 3 (after the washout period) and will receive placebo drink between visits 1 and 2
10122960|NCT04370431|Experimental|PartA: TTYP01 single ascending doses|In Part A: a single-ascending-dose (SAD) escalation study with four consecutive cohorts, single ascending doses of TTYP01 (60, 120, 180 and 240 mg) will be orally administrated.
10122961|NCT04370431|Placebo Comparator|Part A: Placebo|Placebo control for Part A of the study
10122962|NCT04370431|Experimental|Part B: TTYP01 (oral edaravone) first then IV edaravone|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 60 mg oral edaravone tablet (TTYP01); Period 2: 30 mg IV edaravone (Radicut® ampoule), Period 3: 120 mg oral edaravone tablet (TTYP01); Period 4: 60 mg IV edaravone (Radicut® bag). Each dose will be spearated by a minimum of 7 days washout period.
10122963|NCT04370431|Experimental|Part B: IV edaravone first then TTYP01 (oral edaravone)|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 30 mg IV edaravone (Radicut® ampoule); Period 2: 60 mg oral edaravone tablet (TTYP01); Period 3: 60 mg IV edaravone (Radicut® bag); Period 4: 120 mg oral edaravone tablet (TTYP01). Each dose will be spearated by a minimum of 7 days washout period.
10122964|NCT04370431|Experimental|Part C: TTYP01: fasted dosing first then fed dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fasted condition; Period 2: under fed condition. Each dose will be spearated by a minimum of 7 days washout period.
10122965|NCT04370431|Experimental|Part C: TTYP01: fed dosing first then fasted dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fed condition; Period 2: under fasted condition. Each dose will be spearated by a minimum of 7 days washout period.
10183173|NCT03767114|Experimental|normal controls|group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR
10183174|NCT03767088|Active Comparator|WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
10183175|NCT03767088|Active Comparator|partial WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
10183176|NCT03767088|Sham Comparator|control|active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns
10183177|NCT03767075|Experimental|Module 1 Arm 1 - atezolizumab|"Genomically selected populations will all receive the same drug (6 groups of mutation will be evaluated)~Arm 1A: BRCA1 or BRCA2 mutations~Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations~Arm 1C: tumors with POLE mutation, POLD1 mutation.~Arm 1D: hypermutated tumors~Arm 1E: tumors with other mutations in DNA-repair genes.~Arm 1F: tumors with amplified PDL1~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 100 patients in part B of module 1."
10183178|NCT03767049||Lung transplant patients readmitted in ICU|
10183179|NCT03767036|Active Comparator|Tramadol|Each participant received an oral dose of tramadol hydrochloride 25 mg (A1, one capsule) under fasting conditions with 250 milliliters (mL) of water.
10183180|NCT03767036|Active Comparator|Ketorolac|Each participant received an oral dose of ketorolac 10 mg (A2, one tablet) under fasting conditions with 250 mL of water.
10183181|NCT03767036|Experimental|Tramadol and ketorolac|Each participant received an oral dose of tramadol hydrochloride 25 mg and ketorolac 10 mg simultaneously (A3 = one capsule of A1 + one tablet of A2, test medication) under fasting conditions with 250 mL of water.
10183182|NCT03767023||Stable AAA|"= patients with a small abdominal aortic aneursym diameter < 55 mm "
10183183|NCT03767023||instable AAA|"=patients with a large abdominal aortic aneursym diameter > 55 mm and/or AAA with rapid growth who needs open surgery or EndoVascular Aneurysm Repair EVAR"
10183184|NCT03767010|Experimental|Control (no PLM)|Control: Pre, post, delayed test Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
10183185|NCT03767010|Experimental|Experimental (PLM)|Experimental: PLM group (pre, post, delayed test, PLM) Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
10183186|NCT03766997|Experimental|local injection|Compound betamethasone injection (Each injection contains betamethasone dipropionate at 5 mg for betamethasone and betamethasone sodium phosphate at 2 mg for betamethasone) was local injected to the breast by the patient once a week for one to four times followed by Hydrocortisone butyrate cream(0.1%) topical use twice a day until the termination of treatment.
10183187|NCT03766997|Active Comparator|topical|Hydrocortisone butyrate 0.1% cream was applied to the breast by the patient twice a day until the termination of treatment.
10183188|NCT03766984|Experimental|Diclofenac 25 mg|Participants receive 1 tablet of diclofenac sodium 25 mg with 250 milliliters of purified water.
10183189|NCT03766984|Experimental|Tramadol 25 mg|Participants receive 1 tablet of tramadol hydrochloride 25 mg with 250 milliliters of purified water.
10183190|NCT03766984|Experimental|Diclofenac/Tramadol 25 mg/25 mg FDC|Participants receive 1 fixed-dose combination tablet of diclofenac sodium 25 mg/tramadol hydrochloride 25 mg with 250 milliliters of purified water.
10183191|NCT03766932||Blood culture candida positive group|
10183192|NCT03766932||Tracheal aspiration candida culture positive group|
10183193|NCT03766932||Urine candida culture positive group|
9668985|NCT04425317|Other|Diagnostic arm|Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells
10183194|NCT03766932||Other aseptic humoral candida positive group|
10183195|NCT03766919|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead)
10183196|NCT03766906|Experimental|Talk STEM Familia App|This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.
10122966|NCT04370314|Experimental|Zirconia implant-supported crown|Full zirconia implant-supported crown
10122967|NCT04370587|Experimental|Phase 1|T3011 single agent dose escalation in participants with solid tumors
10122968|NCT04370587|Experimental|Phase 2a Part 1 Arm A|RP2D T3011 single agent in participants with melanoma
10122969|NCT04370587|Experimental|Phase 2a Part 1 Arm B|RP2D T3011 single agent in participants with other solid tumors
10122970|NCT04370587|Experimental|Phase 2a Part 2|RP2D T3011 + pembrolizumab in participants with NSCLC
10122971|NCT04370587|Experimental|Rollover Arm|RP2D T3011 + pembrolizumab in participants who have progressed on T3011 single agent
10122972|NCT04370262|Active Comparator|SOC/Famotidine|Subjects in this study arm will receive a combination of Standard of Care (SOC) treatment and intravenous famotidine. Famotidine Injection, 10mg/mL mixed with Normal Saline is given intravenously at 120mg (30% of 400 mg oral dose). The total daily dose proposed is 360mg/day famotidine IV for a maximum of 14 days, or hospital discharge, whichever comes first. SOC will be administered as per the current clinical protocol for COVID-19.
10122973|NCT04370262|Placebo Comparator|SOC/Placebo|Subjects in this arm will receive the current Standard of Care treatment for COVID-19; plus placebo infusion three times daily.
10122974|NCT04370561|Active Comparator|1/3 tubular plate|"Standard care according to AO guidelines using the Implant 1/3 tubular plate"
10122975|NCT04370561|Active Comparator|Active ankle plate|"Actual care using the new implant using the Implant Active ankle plate"
10122976|NCT04370639|Experimental|AccuFlow Sensor|These 50 patients will wear the AccuFlow sensor device during their surgery, and will complete the post-procedural survey. The data will be reviewed after 25 patients, and the pilot study may be stopped at that point if it is felt that the device feasibility and tolerability have been adequately established.
10122977|NCT04370327|Active Comparator|Pain Free Exercise (PF)|Patients will be randomised to twice weekly for 24 weeks of pain free exercise in a supervised exercise programme
10122978|NCT04370327|Active Comparator|Moderate Claudication Pain Exercise (MOD-P)|Patients will be randomised to twice weekly for 24 weeks of moderate claudication pain exercise in a supervised exercise programme
10122979|NCT04370327|Active Comparator|Maximal Claudication Pain Exercise (MAX-P)|Patients will be randomised to twice weekly for 24 weeks of maximal claudication pain exercise in a supervised exercise programme
10122980|NCT04370340|No Intervention|control|
10122981|NCT04370340|Active Comparator|intervention|
9967123|NCT01266798|Experimental|Portal arm|
10122982|NCT04370223|Experimental|Ozone auto-hemotherapy plus standard treatment|Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days.
10122983|NCT04370223|No Intervention|Standard treatment alone|Standard treatment will be the one used in each hospital participating in the trial.
10122984|NCT04370444|Experimental|Experimental (PLR)|Participants will be given the OhNut Phallus Length Reducer (PLR) for use during the study period.
10122985|NCT04370444|Other|Control (Waitlist)|Participants will not have a PLR during the study period. They will be placed on a waitlist to receive the PLR at the end of the study period.
10122986|NCT04370457|Experimental|Experimental arm|Administration of the MyPal ePRO system
10122987|NCT04370457|No Intervention|Standard care arm|No further intervention besides standard palliative care approach if needed
10122988|NCT04370353|Placebo Comparator|Placebo|Placebo supplement, each capsule containing: 0mg total flavanols, matched for caffeine and theobromine content as experimental supplement (2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM after mixed meal for 7 days.
10122989|NCT04370353|Experimental|Cocoa Flavanols|Experimental supplement, each capsule containing: 316 mg CocoActiv (Naturex, Netherlands: 100mg total cocoa flavanols, 2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM) for 7 days.
10122990|NCT04369976|Experimental|SHORT ARM HUMAN CENTRIFUGE|SHORT ARM HUMAN CENTRIFUGE IN COMBINATION WITH EXERCISE INTERMITTENT CENTRIFUGATION TOTAL TIME 30 MINUTES
10122991|NCT04370210||Child without follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
10122992|NCT04370210||Child with follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
10122993|NCT04370093|Experimental|Pioglitazone Drug (including Placebo)|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
10122994|NCT04370093|Experimental|Weight Loss, Behavioral|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
10122995|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone 45 mg/day + Weight Loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
10122996|NCT04370106|No Intervention|Control|Usual care for participants with existing VLU in the CG is defined as visiting the outpatient wound clinic/visits by the community care nurse as prescribed by the physician. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses.
10122997|NCT04370106|Other|Social leg Program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
10122998|NCT04369872|Experimental|Microwave Ablation|Study participants will receive percutaneous microwave ablation of their malignant lung neoplasm.
10122999|NCT04370171||Group TC: Diabetic patients followed by Teleconsultation|Teleconsultation group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients.
10123000|NCT04370171||Group P: Diabetic patients with conventional follow-up|Conventional group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was differed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients and not available
10123001|NCT04370015|Experimental|Treatment group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
10123002|NCT04370015|Placebo Comparator|Control group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
10123003|NCT04369911|Experimental|Low Dose|Acupuncture treatment once per week for 5 weeks. Five total acupuncture treatments completed.
10123004|NCT04369911|Experimental|High Dose|Acupuncture treatment twice per week for 5 weeks. Ten total acupuncture treatments completed.
10123005|NCT04369989||Hydroxychloroquine - NO|Did not receive / are not receiving any Hydroxychloroquine
10123006|NCT04369989||Hydroxychloroquine - YES - started before|Hydroxychloroquine date started was before the date recorded for signs of respiratory distress
10123007|NCT04369989||Hydroxychloroquine - YES - started same|Hydroxychloroquine date started was the same as the date recorded for signs of respiratory distress
10123008|NCT04369989||Hydroxychloroquine - YES - started after|Hydroxychloroquine date started was after the date recorded for signs of respiratory distress
10123009|NCT04370288|No Intervention|Control group|Covid-19 patients treated with standard medical therapy (supportive therapy).
10123010|NCT04370288|Experimental|Intervention group|Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).
10123011|NCT04369794|Active Comparator|BCG vaccine|BCG Group (n = 200): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
10123012|NCT04369794|Placebo Comparator|Placebo|Placebo group (n = 200): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
10123013|NCT04369937|Experimental|IMRT + Pembrolizumab + Cisplatin + ISA101b|"IMRT (Intensity Modulated Radiotherapy) of 70 Gy in 35 fractions over 7 weeks (5 fractions per week).~Pembrolizumab will be administered at 200 mg (fixed dose) IV every 3 weeks (+/- 3 days), beginning beginning one week (week -1) prior to concurrent cisplatin-IMRT.~Cisplatin will be administered at 100 mg/m2 IV on days 1(Week 0) and 22 (Week 3).~ISA101b will be administered as three rounds of vaccination 3-4 weeks apart via two SC injections per vaccination round at 100ug/peptide, before pembrolizumab treatment. Vaccination #1 will be administered 1 week before pembrolizumab."
9668986|NCT04425252|Other|Standard of Care|Subjects are hospitalized for COVID-19 and will receive all supportive/interventional care per institutional guidelines.
10123014|NCT04369833||continuous glucose monitoring group|all participants wearing a continuous glucose monitoring device
9668987|NCT04425252|Experimental|Brequinar|Subjects will receive standard of care plus brequinar 100 mg daily (Study Days 1-5).
9668988|NCT04424862|Experimental|Multitarget Therapy|The combined therapy with prednisone, ciclosporin and mycophenolate mofetil.
9668989|NCT04424862|Active Comparator|Control|Ponticelli Regimen
9668990|NCT04411511||Lean children|Children between 4-18 years, living in the Netherlands.
10123015|NCT04369950|Active Comparator|2 percent Lidocaine with epinephrine and epidural morphine|
10123016|NCT04369950|Experimental|3 percent 2-Chloroprocaine and epidural morphine|
10123017|NCT04369716|Active Comparator|Whole fruit 1|Oranges
10123018|NCT04369716|Active Comparator|Whole fruit 2|Apples
10123019|NCT04369716|Experimental|Juice 1 + pomace|Orange Juice + orange pomace
10123020|NCT04369716|Experimental|Juice 2 + pomace|Apple Juice + apple pomace
10123021|NCT04369716|Active Comparator|Juice 1 alone|Orange Juice
10123022|NCT04369716|Active Comparator|Juice 2 alone|Apple Juice
10123023|NCT04369820|Experimental|COVID-19 PATIENTS|"Two blood samples (40mL) at 2 different points in time:~Within the first 72 hours of medical care in resuscitation unit or department.~Between the 5th and the 10th day of medical care (ideally at the end of the first week) or on the day of discharge of patient if it is earlier, or of death if it takes place earlier."
10123024|NCT04369625|Experimental|CHIMPS-T|(Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents. CHIMPS-T is based on a theory model, needs analyses and the pioneering studies of Williams Beardslee. The CHIMPS approach was tested, evaluated and manualized in an initial project (2007-2011).
10123025|NCT04369625|Experimental|CHIMPS-P-single|"CHIMPS-P-single is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention. The sessions will be carried out by a social worker (based on the Finnish model Let's talk about children (Solantaus), but in a family setting Let's talk WITH children)."
10123026|NCT04369625|Experimental|The CHIMPS-P-group|The CHIMPS-P-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families: preliminary talk, one additional session with the family (if needed), multifamily group with three to six other families, concluding session.
10183197|NCT03766893|Experimental|Pharmacy based opioid use disorder care|A single-arm pilot study to test the collaborative pharmacy practice agreement for MAT (using the medications buprenorphine or injectable naltrexone) care model with up to 12 patients with opioid use disorder, assessing feasibility of medication dispensing, administration, and monitoring in the pharmacy, and determining patient acceptability of this model.
10123027|NCT04369625|Experimental|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included. Overall, 8 consecutive online modules as well as elective modules will be included. These modules (e.g., dealing with difficult situations, emotion regulation, taboos and shame, self-worth) will be provided based on the specific constellation of children and adolescents of mentally ill parents. iCHIMPS will be completed by 2 booster session within a six months follow-up.
10123028|NCT04369625|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
10123029|NCT04369781||Suspected critical limb ischemia|Patients referred for transcutaneous oxygen pressure measurements due to a clinical suspicion of critical limb ischemia
10123030|NCT04369768|Active Comparator|direct composite restorations|
10123031|NCT04369768|Active Comparator|preformed metal crowns|
10123032|NCT04369495||Cyclophosphamide|Patients with induction therapy for lupus nephritis with cyclophosphamide
10123033|NCT04369495||Mycophenolate|Patients with induction therapy for lupus nephritis with mycophenolate
10123034|NCT04369534|Active Comparator|First group|The patients randomized into the first group will be given the newer P2Y12 receptor inhibitor ticagrelor during the 12 months.
10123035|NCT04369534|Active Comparator|Second group|The second group of patients will be given ticagrelor initially, and after the first 30 days it will be replaced with clopidogrel, that will be given for the remaining time period (up to 12 months). Clopidogrel dosing will be modified according to the results of the aggregometry using the ADP test.
10123036|NCT04369482|Active Comparator|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
10123037|NCT04369482|Active Comparator|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
10123038|NCT04369430|Experimental|AKST4290|Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.
10123039|NCT04369430|Placebo Comparator|Placebo|Subjects will receive placebo, twice daily, for 12 weeks.
10123040|NCT04369521|Experimental|Intervention|low free sugar diet with nutrition and exercise recommendation
10123041|NCT04369521|No Intervention|control|regular diet with nutrition and exercise recommendation
10123042|NCT04369586|Experimental|meplazumab dose 1|0.06mg/kg for single dose
10123043|NCT04369586|Experimental|meplazumab dose 2|0.12mg/kg for single dose
10123044|NCT04369586|Experimental|meplazumab dose 3|0.2mg/kg for single dose
10123045|NCT04369586|Experimental|meplazumab dose 4|0.3mg/kg for single dose
10123046|NCT04369586|Experimental|meplazumab dose 5|0.42mg/kg for single dose
9825993|NCT02403830|Experimental|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
9967124|NCT01266798|No Intervention|Treatment as usal|
10123047|NCT04369586|Experimental|meplazumab dose 6|0.56mg/kg for single dose
10123048|NCT04369586|Experimental|meplazumab multiple dose|0.3mg/kg for double doses, 1 dose/week
10123049|NCT04369456|Other|Covid-19 kidney transplant patients with moderate symptoms|
10123050|NCT04369469|Experimental|Ravulizumab plus Best Supportive Care|
10123051|NCT04369469|Other|Best Supportive Care|
10123052|NCT04369443|No Intervention|MANH|
10123053|NCT04369443|Experimental|LANH|
10123054|NCT04369404|No Intervention|Usual care|In the usual care group, the providers do not have access to the decision aids.
10123055|NCT04369404|Experimental|Patient Decision Aid|Providers have access to patient decision aids to review and discuss during the visit.
10123056|NCT04370249||Patient with suspected COVID-19 infection|Patients admitted and managed in an emergency department under suspicion of COVID-19 infection who received a pleuro-pulmonary ultrasound on admission
10123057|NCT04370080|Experimental|Silver Diamine Fluoride|Topical application of one drop of silver diamine fluoride 38% to active untreated roof surface caries, lesions at the furcation, or lesions at crown margins. Application was repeated once each six months.
10123058|NCT04370392|Active Comparator|control group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
10123059|NCT04370392|Experimental|IV dexmedetomidine group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline containing dexmedetomidine 1 ug/kg over 10 minutes.
10123060|NCT04370392|Experimental|IP dexmedetomidine group|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25% with dexmedetomidine 1 ug/kg) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
10123061|NCT04369391|Experimental|SEP363856 150 mg|SEP363856 tablet 150 mg
10123062|NCT04369391|Placebo Comparator|Placebo|matched placebo
10123063|NCT04369391|Active Comparator|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
10123064|NCT04369378|Experimental|Meditation app group|Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
10183198|NCT03766880|Experimental|Single arm study|Participants will receive MR imaging, transjugular HVPG measurement, and analysis per protocol.
10183199|NCT03766867|Experimental|Vortioxetine|
10183200|NCT03766867|Placebo Comparator|Placebo|
10123065|NCT04369378|No Intervention|Control group|Participants will be in the no intervention period for 30 days. Two days before the end of the 30 day no intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. After this 30 day no intervention period, participants are invited to use the Insight Timer app if they so choose. Two months after the conclusion of the 30 day no intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
10123066|NCT04369287||IDH1-mutated AML|Patients affected with AML and carryng IDH1 mutations
10123067|NCT04369287||IDH2-mutated AML|Patients affected with AML and carryng IDH2 mutations
10123068|NCT04369287||IDH1/2 unmutated AML|Patients affected with AML without IDH1/2 mutations
10123069|NCT04370535|Placebo Comparator|Control group + cellulose (Group A)|healthy subjects (control group) receive placebo (cellulose) as powder
10123070|NCT04370535|Active Comparator|Control group + PMA-zeolite(Group B)|healthy subjects (control group) receive PMA-zeolite as powder
10123071|NCT04370535|Placebo Comparator|UCD-group + Cellulose (Group C)|subjects with uncontrolled Crohn disease (UCD group) receive placebo (cellulose) as powder
10123072|NCT04370535|Active Comparator|UCD-group + PMA-zeolite (Group D)|subjects with uncontrolled Crohn disease receive PMA-zeolite as powder
10123073|NCT04369313|Experimental|delayed cord clamping|clamping the cord at least 30s at birth
10123074|NCT04369313|Other|early cord clamping|umbilical cord clamping before 15 seconds
10123075|NCT04369326|Experimental|Community-Based TPT Initiation|All TB index patients who agree to participate will have a home visit by clinic staff who will perform: (1) contact enumeration (2) TB symptom screening of all children <15 years (3) Initiation of TPT for all asymptomatic children and (4) Referral of all symptomatic children less than 15 years, including those living with HIV. HIV testing will be offered to all child contacts 12 months of age and older. Those children less than 12 months will be referred to the clinic for HIV testing, if indicated by local guidelines. In South Africa, these home visits will occur by a combination of community health workers and professional nurses. In Ethiopia, home visits will occur by health extension workers supported by nurses.
10123076|NCT04369326|No Intervention|Facility-Based TPT Initiation|Children less than 15 years living in the home of TB index patients who agree to participate in the study will be referred to clinic for TB symptom screening and initiation of TPT for all asymptomatic child contacts. Symptomatic child contacts will be referred to a physician for evaluation, as is currently the standard of care. Additionally, child contacts identified in any maternal and child health program will be referred to the TB clinic for TB symptom screening. HIV testing will be offered at the clinic for all child contacts and will be performed according to local guideline.
10123077|NCT04369248||Control group|30 healthy women with BMI < 30 between 18 and 35 years old
10123078|NCT04369248||Non-obese PCOS|2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score >8 and/ or hyperandrogenemia defining the testosterone level > 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level > 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume >10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI < 30 between age of 18 and 35.
10123079|NCT04369248||Obese PCOS|Obese group are the women with BMI > 30 between age of 18 and 35.
10123080|NCT04369092|Other|without swallowing problem|patients without swallowing problem
10123081|NCT04369092|Other|mild swallowing problem|patients with mild swallowing problem
10123082|NCT04369092|Other|severe swallowing problem|patients with severe swallowing problem
10123083|NCT04369170|Other|Group A - Control Group|Control group where an intermediate abutment is placed in between the CAD-CAM dental prostheses an the dental implant.
10123084|NCT04369170|Experimental|Group B - Test Group|Test group where the CAD-CAM dental prostheses is connected directly to the dental implant
10123085|NCT04369144|Experimental|Intervention group|The dynamic scapular recognition exercise + rigid taping with 50%-75% tension.
10123086|NCT04369144|Placebo Comparator|Control|The dynamic scapular recognition exercise + placebo taping
10123087|NCT04369235|Experimental|tCES & upper extremity rehabilitation|The experiment group will receive tCES combined with upper extremity rehabilitation of affected side.
10123088|NCT04369235|Sham Comparator|Sham tCES & upper extremity rehabilitation|The sham control group will receive sham tCES combined with upper extremity rehabilitation of affected side.
10123089|NCT04369274|Experimental|Interventional|All subjects will briefly be placed on the automated BVM compressor device. Measurements obtained while on this device will be compared to those obtained in the same subject prior to mechanical ventilation and while on a conventional ventilator.
10123090|NCT04369222||Controls|Children born from mothers with no consumption of mild analgesics 3 months before or during pregnancy
10123091|NCT04369222||Exposed|Children born from mothers with consumption of mild analgesics 3 months before or during pregnancy
10123092|NCT04368962||MMF group|Post-transplant patients accept immunosuppression protocol based on MMF for at least 12 months.
10123093|NCT04368884||Healthcare workers|The healthcare workers who are being tested for COVID-19 would be included in this group
10123094|NCT04368884||OPD patients|Individuals outside from the hospital who are coming for the COVID-19 testing will be included in this group
10123095|NCT04368884||IPD COVID-19 cases|Admitted positive cases of COVID-19 in the hospital will be included in this group
10183201|NCT03766854|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
10123096|NCT04369001|Experimental|Intervention Group|(Program ACTIVE n=20) Participants randomized into the Program ACTIVE group will receive a gym membership to a local, Detroit-based community recreation facility where they will complete 150 minutes of exercise per week for 12 weeks and will receive 10 sessions (once weekly) of CBT therapy sessions. Exercise per week will be documented using exercise logs. Exercise logs will be given to research staff at the end of the 12-week timeframe; all exercise logs will be kept organized respective to the participant identification number and related documents (questionnaires and surveys). To ensure treatment fidelity, three CBT and three physical activity sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
10123097|NCT04369001|No Intervention|Enhanced Usual Care|(EUC n=20) Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Participants will not be required to report any use of resources offered or change their course of treatment in any way. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, gym access and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
10123098|NCT04369118|Experimental|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up and wear the selective chest wall restriction belt in parallel. Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
10123099|NCT04369118|Active Comparator|conventional postoperative follow-up|Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
10123100|NCT04369157||Elective surgery group|Patients undergoing hip/knee replacements or colorectal surgery will be recruited and tested on 3 occasions: pre-op, post-op and at follow-up. POCD status will be determined at post-op and follow up. Cognitive function, zinc status, POCD biomarkers and inflammatory markers will be measured on all 3 occasions.
10123101|NCT04369027||preload responders|patients who increase their delta VTI by more than 10% during PLR
10123102|NCT04369027||preload unresponders|patients who do not increase their delta VTI by more than 10% during PLR
10123103|NCT04368793||Discharged COVID-19 patient cohort|All enrolled participants will be given 8 weeks (online 2 weeks + offline 6 weeks) pulmonary rehabilitation intervention, and will be followed up for at least one year, to assess their adherence and efficacy of the rehabilitation program.
10123104|NCT04369079|Experimental|TREATMENT GROUP|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side. The exact sequence and number of procedures differed in each patient according to need as determined by prior functional examination. Before or after every of the treatment procedure treatment group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
10123105|NCT04369079|Other|CONTROL GROUP|Treatment duration was a mean of 4 weeks. Therapy was performed daily excluding weekends and consisted of 45 minutes of individual work with an oncological physiotherapist. The control group underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area. Before or after every of the treatment procedure control group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
9967125|NCT01266811|Experimental|001|Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
10123106|NCT04369339|Experimental|Other High Risk HPV Positivity|Colposcopy performed to women with High risk HPV positive ,negative for intraepithelial lesions or malignancy cytology
10123107|NCT04369339|Active Comparator|HPV16/18|Colposcopy performed to women with HPV 16/18 positive ,negative for intraepithelial lesions or malignancy cytology
10123108|NCT04368741|Experimental|Experimental group|SANZ®KINGWILL
10123109|NCT04368741|Other|Control group|GLUCERNA SR®
10123110|NCT04368923|Experimental|Oxygen Therapy Group|
10123111|NCT04368923|Experimental|Physical Therapy Group|
9825994|NCT02403830|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
10123112|NCT04368819|Active Comparator|Allopurinol|Allopurinol 300mg P.O. once daily for four weeks followed by allopurinol 300mg P.O. twice daily for 12 weeks.
10123113|NCT04368819|Placebo Comparator|Placebo|Placebo pills indistinguishable from the active comparator given P.O. once daily for four weeks, followed by twice daily for 12 weeks.
10123114|NCT04368949|Experimental|Stepping-Up Group|Participants will attend one 2-hour virtual session (1-hour exercise and 1-hour SM) per week. Each class of 6-8 participants is supervised by a Physiotherapist (PT) and kinesiologist who will individually tailor the exercises for each participant.
10123115|NCT04368949|Active Comparator|TELE Group|The initial telephone session will be 20-30 minutes, with subsequent weekly calls will be approximately 10 minutes.
10123116|NCT04368949|Placebo Comparator|Chair-Based Yoga Group|Participants will attend two 1-hour virtual sessions per week to ensure this group is matched for attention to STEPPING-UP.
10123117|NCT04368611|Active Comparator|fundus first cholecystectomy|start with fundus dissection then complete the dissection
10123118|NCT04368611|Active Comparator|Calot first dissection|start and complete the dissection by dissection of Calot triangle
10123119|NCT04368624||Participants with PKU|"Patients with classical PKU phenotype (serum phenylalanine concentration > 10 mg/dL on a normal diet at diagnosis) # ~25~Patients with hyperphenylalaninemia (serum phenylalanine concentration < 10 mg/dL on a normal diet at diagnosis) # ~15~Patients with PKU on therapy with Kuvan # ~10"
10123120|NCT04368624||Non-PKU Control|Study Controls: Up to 50 children and adults without a known metabolic disorder.
10123121|NCT04368585|Experimental|TBPM-PI-HBr Alone (Period 1)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.
10123122|NCT04368585|Experimental|TBPM-PI-HBr and Antacid (Period 2)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.
10123123|NCT04368585|Experimental|TBPM-PI-HBr and Omeprazole (Period 3)|40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.
10123124|NCT04368546||Patients|Metastatic cell carcinoma patients before sunitinib treatment, after 4 week on, after 2 week off and finally again 4 week on medication.
10123125|NCT04368546||Healthy controls|Age-matched subjects without known disease.
10123126|NCT04368598|Experimental|High-dose Dexamethasone plus Acetylcysteine|For all patients in this arm, DXM was administered intravenously at 40 mg daily for 4 consecutive days and then stopped. If platelet count remained below 30×10^9/L or there were bleeding symptoms by day 10 to 14, an additional 4-day course of DXM (40 mg daily) was given. Besides, all patients received Acetylcysteine orally at 0.4g three times a day for 4 consecutive weeks in the first month.
10123127|NCT04368520|Placebo Comparator|Placebo|
10123128|NCT04368520|Experimental|Low dose vitamin D3|
10123129|NCT04368520|Experimental|High dose vitamin D3|
10123130|NCT04368572|Experimental|lumbar puncture under hypnosis|Hypnosis is the only act added by protocol to patients receiving a lumbar puncture as part of the etiological assessment of cognitive disorders
10123131|NCT04368572|Active Comparator|lumbar puncture without hypnosis|Lumbar puncture is performed by a physician assisted by a nurse or a psychologist who reassure the patient during the installation and the procedure.
10123132|NCT04368650|Experimental|Main treatment group|The in situ BMP-2 gel was prepared to a concentration of approximately 0.5 μg/ml and were stored at 4oC. The gel was then dispensed at site of interest in the study.
10123133|NCT04368650|Active Comparator|Control|In patients selected for control group, after degranulation, sticky bone was used to fill the defect. The surgical site was protected and covered using a periodontal dressing.
10123134|NCT04368663|Active Comparator|TJ-134 group|The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to（TJ-134, 7.5g/day), which consists of a mixture of a compound of peony root (6 g), cinnamon bark (4 g), jujube (4 g), glycyrrhiza (2 g), rhubarb (2 g), and ginger (1 g) is administered to enrolled patients for 8 weeks.
10123135|NCT04368663|Placebo Comparator|Lactomin group|Lactomin (3g/day) is administered to enrolled patients for 8 weeks.
10123136|NCT04368806|Experimental|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)
10123137|NCT04368806|Placebo Comparator|Placebo|Normal Saline with Autologous Serum
10123138|NCT04368507|Experimental|YYB101+Irinotecan|"b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks~a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks"
10123139|NCT04368702|Experimental|Phase I - Gastric Cancer|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
10123140|NCT04368702|Experimental|Phase I - Breast Cancer|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
10123141|NCT04368702|Experimental|Phase I - Mantle Cell Lymphoma|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
10123142|NCT04368702|Experimental|Phase I - Larynx|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
10123143|NCT04368702|Experimental|Phase I - Bladder|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
10123144|NCT04368715|Experimental|2780 nm Er:Cr;YSGG laser treated group|Patients treated with Er:Cr;YSGG laser for labial frenectomy
10123145|NCT04368715|Experimental|940 nm Diode laser treated group|Patients treated with 940 nm Diode laser for labial frenectomy
10123146|NCT04368767|No Intervention|Usual Care: Incubator|The infant will remain in the incubator and stress biomarkers will be collected per protocol
10123147|NCT04368767|Experimental|Intervention: Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, 30 minutes after feeding. SSC will usually occur in the afternoon between 11:30-12:30 pm or 14:30-15:30pm. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. The room will be monitored to maintain a temperature of 72-77 degrees Fahrenheit during SSC. Stress biomarkers will be collected per protocol.
10123148|NCT04368689|Experimental|Floating|Participants have 3 Floatation sessions that last up to 90 minutes. Each spaced about a week apart.
10183202|NCT03766854|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.~After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling."
9825995|NCT02403895|Experimental|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
10123149|NCT04368377|Experimental|Tirofiban|"Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0.15 microgram/kg/minute for 48 hours.~Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75 mg daily for 30 days.~Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75 mg daily for 30 days~Patents will receive concurrent fondaparinux 2.5 mg s/c per day for the duration of the hospital stay"
10123150|NCT04368312||Health care providers/hospital staff|The targeted group are doctors and nurses (hospital stuff) of a large university hospital directly confronted with patients with Cov-19
10123151|NCT04368403|Experimental|KHK4827|
10123152|NCT04368273|Experimental|treatment|PD-1 antibody combined CCRT for patients with local advanced cervical cancer.
10123153|NCT04368325||Study group|Total of 46 patients with low serum creatinine levels whose values were obtained from the central laboratory with inclusion criteria (< 40mmol/L)
9967126|NCT01266811|Other|002|Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
10123154|NCT04368325||Control group|A total of 61 consecutive patients were obtained who were treated in ICU CHC Osijek, according to the date of admission.
10123155|NCT04368286|Experimental|Rehabilitation group|To conduct a comprehensive pulmonary rehabilitation assessment and treatment
10123156|NCT04368286|No Intervention|Conventional medical group|Conventional medical treatment
10123157|NCT04368117|Active Comparator|Standard Therapy (ST)|Patients randomized to the ST group will receive standard of care, routine burn physical therapy.
10123158|NCT04368117|Experimental|Active Therapy (STAT)|Patients randomized to the STAT group will receive an intensive, quantifiable, activity-based physical therapy prescription emphasizing four of the most active components of therapy: mobilization, strength training, aerobic training and functional training.
10123159|NCT04368078|Experimental|Toripalimab plus Lenvatinib|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.~Toripalimab is a recombinant anti-human PD-1 monoclonal antibody."
10123160|NCT04367948|Experimental|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
10123161|NCT04367948|Experimental|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
10123162|NCT04368234||COVID-19 Patients|Any Duke patient that is being treated for COVID-19.
10123163|NCT04368026||Group 1|"Responders currently working in a COVID-19-dedicated hospital, which was transformed by Polish Ministry of Health during SARS-CoV-2 pandemic into institution designated only for SARS-CoV-2 patients, including those developing symptoms and quarantined."
10123164|NCT04368026||Group 2|"Responders currently working in non-COVID-19-dedicated hospital."
10123165|NCT04368000|Experimental|Prone Positioning|
10123166|NCT04368000|Active Comparator|Usual care|
10123167|NCT04368169|Experimental|Aromatic Extract|Participants receive the aromatic botanical extract orally every 4-6 waking hours for 3 days.
10123168|NCT04368169|Placebo Comparator|Placebo|Participants receive the placebo matching the botanical extract orally every 4-6 waking hours for 3 days.
10123169|NCT04368182|Experimental|Treatment group|Autologous C-TCR055 administered by intravenous (IV) infusion
10123170|NCT04368104||Group A|women using any form of minipills
10123171|NCT04368104||Group B|women subjected to office hysteroscopy for different indications but not using any form of hormones or systemic or local hormonal contraception.
10123172|NCT04368247||Nevi undergoing biopsy per SOC|Subjects with Nevi who will as part of their standard of care, will undergo biopsy.
10123173|NCT04368351||Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
10123174|NCT04368351||bacteriotherapy|Dietary Supplement: SivoMixx (200 billion) plus Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), and hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
10123175|NCT04367935|Active Comparator|Intervention|Pentoxifylline tablets 400mg three times daily for 2 months
10123176|NCT04367935|No Intervention|Control|Control Group receiving placebo tablets three times daily for 2 months
9668991|NCT04411511||Children with overweight or obesity|Children between 4-18 years, living in the Netherlands. Besides inclusion from the general population, childhood expertise centres will contact their patients to pay attention to this study.
9668992|NCT04409405||Cured population|• Age ≥ 5 year old
10123177|NCT04368364|Active Comparator|Group 1 (Control group)|
10123178|NCT04368364|Experimental|Group 2(Bupivacaine hydrochloride group)|
10123179|NCT04368364|Experimental|Group 3 (ropivacaine hydrochloride group)|
10123180|NCT04368013|Experimental|Experimental|The difference from the standard of care is extended sample collection and study related procedures during the study.
10123181|NCT04368052|Other|Observation|preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
10123182|NCT04367727|Experimental|5 minutes before 1|Light emitting diode applied 5 minutes before fatiguing task
10123183|NCT04367727|Placebo Comparator|5 minutes before 2|Light emitting diode applied 5 minutes before fatiguing task
10123184|NCT04367727|Experimental|1 hour before 1|Light emitting diode applied 1 hour before fatiguing task
10123185|NCT04367727|Placebo Comparator|1 hour before 2|Light emitting diode applied 1 hour before fatiguing task
10123186|NCT04367727|Experimental|5 hours before 1|Light emitting diode applied 5 hours before fatiguing task
10123187|NCT04367727|Placebo Comparator|5 hours before 2|Light emitting diode applied 5 hours before fatiguing task
10123188|NCT04367649|Experimental|Hall technique|
10123189|NCT04367649|Active Comparator|Atraumatic restorative treatment|
10123190|NCT04367649|Sham Comparator|Conventional restorative treatment|
10123191|NCT04367623|Active Comparator|Control|Patients receiving conventional hand therapy, time matched to the duration of total intervention in the Active group
10123192|NCT04367623|Active Comparator|Active|Patients receiving BCI FES prior to the conventional therapy
10123193|NCT04367662|Experimental|Patient with COVID-19 infection|Patient with COVID-19 infection hospitalized in a COVID unit
10123194|NCT04367753||Fulfilled contract|The contract before the epiphysiodesis has been fulfilled with the wanted limb length at the final analysis
10123195|NCT04367753||Failed contract|The contract before the epiphysiodesis hasn't been fulfilled with the wanted limb length at the final analysis
10123196|NCT04367636|Active Comparator|Active Comparator: PSE + OCAT-sham|Psycho-education video + an active placebo training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected scrambled sentences task with online contingent feedback.
10123197|NCT04367636|Experimental|Experimental: PSE + OCAT|Psycho-education video + an attention training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback.
10123198|NCT04367701||Thalassemia group|"16 pediatric patients with thalassemia major undergoing surgery for repair of congenital heart disease.~Authors measure hemolysis by free plasma hemoglobin concentration."
10123199|NCT04367701||Control group|"25 pediatric patients with demographic data related to those in thalassemia group, undergoing surgery for repair of congenital heart disease.~Authors measure hemolysis by free plasma hemoglobin concentration"
10123200|NCT04367558|Experimental|Interventional|Patient suffering from OSA, and found to suffer from obstruction of one or more of the following areas - Lower turbines, Soft Palate, Tonsils, Base-of-tongue.
10123201|NCT04367597|Experimental|Active NMES|
10123202|NCT04367597|Sham Comparator|Modified NMES sham|
10123203|NCT04367506|Experimental|BecomeAnEX|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital.
10123204|NCT04367506|Active Comparator|Usual Care|Brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
10123205|NCT04367571|Experimental|Osteopathic Manipulative Treatment|
10123206|NCT04367571|Placebo Comparator|Manual Placebo|
10123207|NCT04367584||Subjects with inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
10123208|NCT04367584||Subjects with non inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
10123209|NCT04367766|Active Comparator|Immediate Implant Placement|prosthetically driven immediate implant placement (WinSix, Biosafin) with bone substitute (BioOss Collagen, Geistlich) filling the gap between the buccal socket wall and the implant surface and a collagen matrix (Fibrogide, Geistlich) positioning at the vestibular aspect to increase soft tissue volume, with immediate (non occlusal loading) prosthetic provisionalization.
10123210|NCT04367766|Active Comparator|Alveolar Ridge Preservation (ARP) + Delayed Implant Placement:|ARP performed with bone substitute (BioOss Collagen, Geistlich) and a collagen matrix placed to seal the socket entrance (Mucograft Seal, Geistlich). After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm
10123211|NCT04367766|Active Comparator|Spontaneous Healing + Delayed Implant Placement|extraction socket will be left to heal spontaneously. After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm, and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm .
10123212|NCT04367532|Experimental|Foam rolling|Foam rolling of cuff muscles.
10123213|NCT04367532|Experimental|Tissue flossing|Tissue flossing of cuff muscles.
10123214|NCT04367532|No Intervention|Control group|Without any intervention.
10123215|NCT04367831|Experimental|Intervention arm: intermediate-dose anticoagulation|"If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily or unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1-0.3 U/mL.~If eGFR <30 mL/min or acute kidney injury or CRRT: Unfractionated heparin infusion at 10 units/kg/hour (minimum 500 units/hour if CRRT) with goal anti-Xa 0.1-0.3 U/mL"
10123216|NCT04367831|Active Comparator|Control arm: prophylaxis|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~BMI < 40 kg/m2: Enoxaparin 40 mg SC daily~BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~BMI > 50 kg/m2: Enoxaparin 60 mg SC q12h~If eGFR < 30 mL/min or acute kidney injury:~50-120 kg: Unfractionated heparin 5000 units SC q8h~>120 kg: Unfractionated heparin 7500 units SC q8h~If CRRT: Unfractionated heparin infusion pre-filter at 500 units/hour"
10123217|NCT04367493|Experimental|1. Group 55% cocoa intervention|55% cocoa intervention
10123218|NCT04367493|Experimental|2. Group White Chocolate|White chocolate
10123219|NCT04367493|No Intervention|3. Control Group|Control Group
10123220|NCT04367818|Active Comparator|Peri-anal local anaesthetic infiltration|Patients in this group will receive the prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline) in a syringe will be connected to 22_ gauge short, beveled needle. The technique of the block will be done guided by Nystrom et al.
10123221|NCT04367818|Active Comparator|caudal anaesthesia|Patients in this group will receive caudal block using 22_gauge short, beveled cannula or needle, The prepared anesthetic mixture (bupivacaine 0.25% in dose of 1ml\kg plus dexametomidine 2ug\kg diluted in 0.5ml of normal saline).
10123222|NCT04367779||A : High Grade Sarcoma|Pediatric and adult patients with High Grade Sarcoma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
10123223|NCT04367779||B : Brain tumors|Pediatric and adult patients with Brain Tumors treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
10123224|NCT04367779||C : Meningioma|Pediatric and adult patients with Meningioma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
10123225|NCT04367376|Experimental|manual therapy|The control group will receive central postero-anterior grade III mobilization through the pisiform grip method at the level of pain in the lumbar spine.
10123226|NCT04367376|Experimental|instrumental manual therapy|the intervention groub rcieved central postero-anterior mobilization with a force of 20-30 N through physiotherapy instrument mobilization at the level of pain in the lumbar spine.
10123227|NCT04367389|Experimental|Intervention|Participants receive a physical activity promotion intervention as well as an individualized exercise plan.
10123228|NCT04367389|No Intervention|Control|
10123229|NCT04367545|Experimental|Patient with COVID-19 infection suspicion|Patient with COVID-19 infection suspicion are tested using standard diagnosis method
10123230|NCT04367454|Experimental|Personal Protective Equipment|"Wearing: Tyvek pro-tech® C gear (Bonetti, Milano, Italy), a full visor SGE 400 mask (EN 136:98 CL3) connected to an A2B2E2K2-P3 R filter (Spasciani, Milano, Italy), and well-fitting, non-sterile Mapa Ultranitril 480 gloves (Mapa SAS, Colombes, France)."
10123231|NCT04367454|No Intervention|NO-Personal Protective Equipment|only wearing well-fitting, medical examination nitrile gloves.
10123232|NCT04367441|Experimental|608|8mg, 20mg, 40mg, 80mg, 120mg, 160mg, 200mg
10123233|NCT04367441|Placebo Comparator|Placebo|20mg, 40mg, 80mg, 120mg, 160mg, 200mg
10123234|NCT04367155|Active Comparator|tranexamic acid local|tranexamic acid inside the irrigation fluid
10123235|NCT04367155|Active Comparator|tranexamic acid IV|tranexamic acid injection
10123236|NCT04367103|Active Comparator|NEP group|Norepinephrine infusion of 0.025 µg/kg/min and 6 µg bolus will be used if BP is reduced 20 % below baseline.
10123237|NCT04367103|Placebo Comparator|PHE group|Phenylephrine will be started at 25µg/min immediately after the intrathecal local anaesthetic injection and titrated according to blood pressure and pulse rate.
10123238|NCT04367051|Experimental|Withdrawal group|Spironolactone will be discontinued in patients who were receiving optimal medical therapy including angiotensin-converting enzyme or angiotensin receptor blocker or angiotensin receptor neprilysin, beta-blocker, and spironolactone.
10123239|NCT04367051|Active Comparator|Continuation group|Spironolactone will be continued during the study period with other medical therapy in combination.
10123240|NCT04367402||Symptomatic Patients|Patients who had symptoms related to COVID-19 infection
10123241|NCT04367402||Health people|Healthy people who never had syntomps related to COVID-19 infection
10123242|NCT04367402||Asyntomatic Individuals|Asyntomatic people to recruit after the restriction have ended
10123243|NCT04367259|Active Comparator|Single puncture arthrocentesis (SPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with single puncture arthrocentesis
10123244|NCT04367259|Active Comparator|Double puncture arthrocentesis (DPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with double puncture arthrocentesis
10123245|NCT04367324||Low level laser therapy|Applied the low-level laser irradiation
9976614|NCT01353417||Renal allograft|
10123246|NCT04367324||Control|No low-level laser application
10123247|NCT04367415||Normal uterine cavity on office hysteroscopy|If the uterine cavity is normal the patient will be allocated as group A.
10123248|NCT04367415||uterine cavity shown one or more polyps on office hysteroscopy|If there is one or more polyp(s) the patient will be allocated as group B. Localization and size estimation of the polyp(s) is mandatory.
10123249|NCT04367428|Experimental|Probiotics|Patients will receive the previously mentioned combination of probiotics pre- and postoperatively
10123250|NCT04367428|No Intervention|No probiotics|Patients will not receive probiotics
10123251|NCT04367272|Active Comparator|First Knee|The first knee is the knee where the surgery will begin to be applied.
10123252|NCT04367272|Experimental|Second Knee|The second knee is the knee where the surgeon will apply secondly.
10123253|NCT04367194|Experimental|BPPV intervention|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
10123254|NCT04367194|Experimental|BPPV Epley|Only Epley training.
10123255|NCT04367194|Experimental|BPPV Optocinetic|Only Optocinetic training.
10123256|NCT04367363||Community sample|We plan to recruit a representative sample of the Singapore population.
10123257|NCT04367207||Adult patients with COVID-19 referred to intensive care|Prospective observational cohort study of adult (≥18 years) patients referred to intensive care or high-care units in Africa with suspected or known COVID-19 infection in Africa
10123258|NCT04367181|Experimental|ELGA group|"*Less than 29 weeks Gestational Age (GA) preemies (100)~DCS monitoring will be performed for up to 72 hours starting within 2 days after birth. In a subgroup of infants, we will also perform additional measurements with aEEG and FDNIRS. At a second stage we will add Transcranial Doppler Ultrasound (TCD)"
10123259|NCT04367220||Patients with known or suspected cardiovascular disease|All patients with known or suspected cardiovascular disease are studied with a-priori stratification of specific disease-based cohorts.
10123260|NCT04367337||Poland|Adults, general population, N = 400
10123261|NCT04367337||Australia|Adults, general population, N = 400
10123262|NCT04367337||Canada|Adults, general population, N = 400
10123263|NCT04367337||China|Adults, general population, N = 400
10123264|NCT04367337||France|Adults, general population, N = 400
10123265|NCT04367337||Gambia|Adults, general population, N = 400
10123266|NCT04367337||Germany|Adults, general population, N = 400
10123267|NCT04367337||Israel|Adults, general population, N = 400
10123268|NCT04367337||Italy|Adults, general population, N = 400
10123269|NCT04367337||Malaysia|Adults, general population, N = 400
10123270|NCT04367337||Portugal|Adults, general population, N = 400
10123271|NCT04367337||Romania|Adults, general population, N = 400
10123272|NCT04367337||Singapore|Adults, general population, N = 400
10123273|NCT04367337||Switzerland|Adults, general population, N = 400
10123274|NCT04367025|Active Comparator|SOX|SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 2-4 cycles
10123275|NCT04367025|Experimental|Camrelizumab+ SOX|Camrelizumab:200mg,iv drip for 1h,d1,q3w SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy+ Camrelizumab for 2-4 cycles, adjuvant chemotherapy + Camrelizumab for 2-4 cycles.
10123276|NCT04367298||Chronoprevention in hospital falls|Implementation of a hospital preventive measures program: adjusted to the identification of temporal patterns of falls and relative risk factors of falls.
10123277|NCT04367168|Active Comparator|Colchicine|Colchicine PO
10123278|NCT04367168|Placebo Comparator|Placebo|Placebo PO
10123279|NCT04367038|Experimental|Warm Acupressure Procedure Group|"Latent phase Visual Analog Scale and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first warm acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second warm acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
10123280|NCT04367038|Experimental|Cold Acupressure Procedure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first cold acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second cold acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
10123281|NCT04367038|Experimental|Conventional Acupressure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase Conventional acupressure was performed for 30 minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated twice more at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second conventional acupressure procedure was performed twice at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
10123282|NCT04367038|No Intervention|Control Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous sample taken Active phase~No procedure other than the routine clinical practices were carried out. Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase No procedure other than the normal clinical routines was conducted Visual Analog Scale III and Verbal Category Scale III were performed. Second venous blood sample taken"
10123283|NCT04367285|Experimental|Sensor-based Training|
10123284|NCT04367285|Active Comparator|Upper limb motor training|
10123285|NCT04367077|Experimental|MultiStem|
10123286|NCT04367077|Placebo Comparator|Placebo|
10123287|NCT04366999||LSG|In this group, the bariatric procedure is laparoscopic sleeve gastrectomy (LSG), all operations follow the same standard operating procedure.
10123288|NCT04366999||LRYGB|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass (LRYGB), all operations follow the same standard operating procedure.
10123289|NCT04366999||OAGB-MGB|In this group, the bariatric procedure is one anastomosis gastric bypass-mini gastric bypass(OAGB-MGB), all operations follow the same standard operating procedure.
10123290|NCT04367012||group 1 NAFLD and group 2 Non NAFLD|study from 20-60 years old.Subjects will be evaluated clinically by abdominal examination for evaluation of fatty liver and grades it into 3 grades .evaluation of fatty pancreas and grade it into 3 grades ,measuring blood pressure and physically by calculating body mass index (BMI) weight/height2
10123291|NCT04367012||Group1 NAFLD & Group 2 Non NAFLD|As the study is randomized cross sectional , all subjects whom have fatty liver by abdominal ultrasound included in group 1 NAFLD , and whom do not have fatty liver by abdominal ultrasound included in group 2.both groups was age and sex matched
10123292|NCT04366986||Pregnant Women|Women who are currently pregnant
9668993|NCT04409405||Contact population|"Age ≥ 5 year old~Contact of a participant included in cured-population cohort~Not diagnosed with EVD"
10123293|NCT04366986||Post-partum women|Women who have been pregnant in the past 6 months
10123294|NCT04366817|Experimental|women in postpartum period|
10123295|NCT04366609||ADHD patients|Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.
10123296|NCT04366661|Experimental|screening|Participants undergo low dose CT of the chest
10123297|NCT04366700|Active Comparator|Bone replacement substitute and membrane|periapical surgery will be done and defect will be filled with a mixture of autograft and prf and over the defect and denuded root surface collagen membrane will be placed before closure of flap
10123298|NCT04366700|Active Comparator|membrane|periapical surgery will be done and defect will be filled with blood clot and over the defect and denuded root surface collagen membrane will be placed before closure of flap
10123299|NCT04366674|Active Comparator|Langerbeck's repair|Langerbeck's repair of cleft palate,without specific restoration of levator veli palatini or tensor veli palatini. Incisions along the margins of the cleft at the junction of oral and nasal mucosa. Lateral relaxing incisions were performed and the mucoperiosteal flap of hard palate were elevated on both sides except the ones with only soft palate cleft. The anterior end of the mucoperiosteal flap may be cut off for the purpose of tension relieving and would be resutured to the anterior area during closing. In the soft palate, the division was made between the oral mucous layer and the palatal musculature layer. Hamulus were broken for closing the cleft without tension. Closing was done by two seperated layers, one layer of nasal mucosa-palatal muscle, and one layer of oral mucosa.
10123300|NCT04366674|Active Comparator|restoration of levator veli palatini|The incision was made similar to Langerbeck's repair. During disection, the levator veli palatini was identified after the elevation of flap. The levator veli palatini was separate from the oral and nasal mucosa. During closing, the anterior end of levator veli palatini was rotated towards the midline and the two muscle bundle from the two sides were sutured in the midline. In this process, the tensor veli palatini was not intentionally identified or dissected.
10123301|NCT04366674|Experimental|mordified restoration of tensor veli palatini|Incision was made similar to Langerbeck's repair. During disection, the tensor veli palatini was identified after flap elevation. Its tendinous fibers was released from but still connected to the pterygoid process without breaking the hamulus or cutting off the tendinous fibers. If the tension is too strong during suturing, the tensor tendon could be partly dissected laterally meanwhile be kept continuity medially so that the tensor veli palatini could be rotated more medially. The levator veli palatini, tensor veli palatini, together with the palatine aponeurosis and the nasal mucosa from two sides were sutured in the middle line. The tensor veli palatini may not be jointed to the contralateral one directly.
10123302|NCT04366622|Experimental|Riociguat, Child Pugh A|Participants with liver cirrhosis and mild hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123303|NCT04366622|Experimental|Riociguat, Child Pugh B|Participants with liver cirrhosis and moderate hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123304|NCT04366622|Experimental|Riociguat, control A|Healthy age-, weight-, and gender- matched participants to Child Pugh A group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123305|NCT04366622|Experimental|Riociguat, control B|Healthy age-, weight-, and gender- matched participants to Child Pugh B group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123306|NCT04366778||patients hospitalized for Covid-19|Patients with Covid-19 infection hospitalized in Lyon University Hospitals
10123307|NCT04366778||patients hospitalized for Covid-19 who present thrombosis|Patients with Covid-19 infection hospitalized in Lyon University Hospitals who present thrombosis during hospitalization
10123308|NCT04366596|Experimental|DEB group|angioplasty with paclitaxel eluting balloon
10123309|NCT04366596|Placebo Comparator|POB group|Angioplasty with plain old balloon
10123310|NCT04366739|Experimental|CHLORPROMAZINE (CPZ)|Standard of Care (SOC) plus CHLORPROMAZINE (CPZ)
10123311|NCT04366739|Active Comparator|standard of care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparator arm"
10123312|NCT04366895|Experimental|control|Participants in control group (Group-A) received conventional manufactured implant overdenture
10123313|NCT04366895|Experimental|intervention|participants in intervention group (Group-B) received CAD-CAM manufactured implant overdenture.
10123314|NCT04366804||Patients with neuropsychiatric fluctuations|PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)
10123315|NCT04366804||Patients without neuropsychiatric fluctuations|PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)
10123316|NCT04366869|Active Comparator|control|traditional approach of removing denture at night
10123317|NCT04366869|Experimental|intervention 1|occlusal splint
10123318|NCT04366869|Experimental|intervention 2|Botox
10123319|NCT04366726|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide.
10123320|NCT04366635|Experimental|Mineralised Plasmatic Matrix Group|Mineralized Plasmatic Matrix (MPM) is a product of mixing of two phases: the mineral phase and the plasma phase. After centrifugation, the white blood cells are recovered and mixed with the mineral phase of bone graft that can be autogenic, allogeneic bone, or a bone substitute like Xenogeneic Bone Synthetic. We will use Beta-tricalcium phosphate as a graft material. The result of this mixture is a homogeneous single component, which is compact and stable, containing the graft, the dense fibrin network, and the promoting healing. And then we are planning to place MPM material to extraction socket of impacted third molar tooth to improve periodontal healing at the distal aspect of second molar tooth. Additional after MPM places to extraction socket, Once the MPM has been placed, it will be covered with a Platelet Rich Fibrin (PRF) membrane and sutured as a primer.
10123321|NCT04366635|Experimental|Beta-tricalcium phosphate Group|Beta-tricalcium phosphate graft will place in the extraction socket and cover with a PRF membrane.
10123322|NCT04366635|Active Comparator|Control Group|In the control group, after removal of impacted third molar tooth no material will be placed on the extraction socket. Only the extraction socket was primarily closed with non-resorbable sutures.
10123323|NCT04366843|Experimental|The chair massage group|chair massage 15 min,, 2 x week; measurement before and after each treatment
10123324|NCT04366843|Experimental|The exercise program group|excercises 15 min., 2 x week; measurement before and after each treatment
10123325|NCT04366843|No Intervention|The control group|control 2 measurements, 4 weeks apart
10123326|NCT04366687|Active Comparator|PAT-AU|Parents randomized to this arm (i.e., group) receive Parents as Teachers (PAT) services as usual (AU).
10123327|NCT04366687|Experimental|PAT+CSA|Parents randomized to this arm (i.e., group) receive the added CSA-focused session (Smart Parents - Safe and Healthy Kids) added to typical Parents as Teachers (PAT).
10123328|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin o.d.|Effects of 40 mg subcutaneous enoxaparin o.d.
9825996|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (three)|Treatment with three initial sessions
10123329|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin b.i.d|Effects of 40 mg subcutaneous enoxaparin b.i.d
10123330|NCT04366570||The 1st group|(n=511; 36,45%) included patients with extra-articular injury of the proximal humerus (rotator cuff tear, anatomical and surgical neck fracture)
10123331|NCT04366570||The 2nd group|(n=309; 22,04%) included patients with intra-articular injury of the proximal humerus (contracture of the shoulder joint and shoulder instability, humeral head fracture, including Hill-Sachs lesion)
10123332|NCT04366570||The 3rd group|(n=582; 41,51%) - patients with injury of subacromial (suprahumeral) space (soft tissue injury, acromioclavicular and sternoclavicular joint injury, diaphyseal and distal end clavicle fracture)
10123333|NCT04366947|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
10123334|NCT04366947|Experimental|Experimental: IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
10123335|NCT04366557|Experimental|Body posture correction|Subjects from study group had an education about pelvic floor and additional a six week body posture therapy.
10123336|NCT04366557|Other|Without correction of body posture|Subjects form control group had only an education about pelvic floor.
10123337|NCT04366934||COVID-19 patients|Subject consulting in the Lariboisière hospital (Paris) in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection
10123338|NCT04366934||Control subjects|Subject consulting in the ear, nose and throat department at the Lariboisière hospital (Paris) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia
10183203|NCT03766841|Experimental|Facilitated Enrollment|Patients will be aided in the account creation and usage of a consumer informatics tool to collect and report patient-contextual data within the electronic health record
10183204|NCT03766841|No Intervention|Usual Care|Patients will be invited to use the patient contextual data tool as per usual care, but will not receive additional assistance in account creation and usage.
10183205|NCT03766828||inside-out-access technique with inside-out access device|
10183206|NCT03766828||access technique including Sharp recanalization|
10183207|NCT03766815|Placebo Comparator|Placebo|Fiber supplement mixed with jelly will be ingested for 18 days with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
10183208|NCT03766815|Experimental|BCAA 200mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (200mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
10183209|NCT03766815|Experimental|BCAA 400mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (400mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
10183210|NCT03766802|Active Comparator|Wearable watch training group.|"Aerobic exercises Strengthening exercises Stretching exercises Balance exercises Dose was increased as person is able to tolerate. Form:intervention is trackable and notifiable if patients don't exercise with smartwatch.~Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
10183211|NCT03766802|Active Comparator|Mobile application training group.|"Aerobic exercises Strengthening exercises Stretching exercises~Balance exercises Form:intervention is trackable and notifiable if patients don't exercise with smartphone Dose was increased as person is able to tolerate. Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
10183212|NCT03766802|Sham Comparator|Supervised exercise training group|Aerobic exercises Strengthening exercises Stretching exercises supervised by a physical therapist
9967127|NCT01266837|Other|single arm|Treatment with Everolimus
10183213|NCT03766789|Active Comparator|Intervention|They will receive the cell phone application, as reminder of medications time and dose.
10183214|NCT03766789|No Intervention|Control|Patients will receive standard of care recommendations.
9825997|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (two)|Treatment with two initial sessions
9825998|NCT02403999|Experimental|Test shampoo|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
9967128|NCT01266863|Experimental|E test method|
9967129|NCT01266889||study group, control group|
9967130|NCT01266915||Control group|Normal disease free (non lupus) subjects
9967131|NCT01266915||Diseased Control|
10183215|NCT03766776|Experimental|Anlotinib Arm|
10183216|NCT03766763|Experimental|ARM A VENETOCLAX|VENETOCLAX
10183217|NCT03766750|Experimental|LIMA|
10183218|NCT03766750|Active Comparator|Tradjenta®|
10183219|NCT03766750|Active Comparator|Forxiga®|
10183220|NCT03766737|Other|Eligible patients for AI test.|Device: An intelligent visual acuity diagnostic system for children. An artificial intelligence to evaluate children's vision.
10183221|NCT03766724|Experimental|Group A|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
10183222|NCT03766724|Experimental|Group B|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
10183223|NCT03766724|Experimental|Group C|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
10183224|NCT03766724|Experimental|Group D|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
10183225|NCT03766711|Experimental|Actual - Augmented|Reaching task as a physical therapy intervention. First with 1:1 visual feedback, then with augmented forward symmetry.
10183226|NCT03766711|Experimental|Augmented - Actual|Reaching task as a physical therapy intervention. First with augmented forward symmetry, then with 1:1 visual feedback.
10183227|NCT03766659|Other|MOSE|EUS-FNB with MOSE
10183228|NCT03766659|Other|ROSE|EUS-FNA with ROSE
10183229|NCT03766633||Living liver donors|This is a group of living liver donors that underwent a CT prior to donating their partial liver to a recipient.
10123339|NCT04366297|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
10123340|NCT04366297|Experimental|IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
10123341|NCT04366375||TLH+BSO|Total Laparoscopic Hysterectomy + Bilateral Salpingo-Oophorectomy N=20
10123342|NCT04366375||TAH + BSO|Total Abdominal Hysterectomy + BSO N=20
10123343|NCT04366180|Experimental|Probiotic|Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day).
10123344|NCT04366180|Placebo Comparator|Control|Control group who will receive a daily placebo capsule consisting of maltodextrin
10123345|NCT04366466|Other|suicide attempt patient who will receive sanitory supervision|The control group will establish the health monitoring
10123346|NCT04366466|Experimental|Suicide attempt patient who will participate to PEPS Program|The intervention group will test the program of Promotion of Commitment to Care for the Prevention of Suicidal Recidivism.
10123347|NCT04366141|Experimental|COVID-19 barrier box intervention group|Attending anesthesiologists will use a COVID-19 barrier box for intubating the patient participants of this group.
10123348|NCT04366141|No Intervention|Control group|Attending anesthesiologists will use standard intubation procedures.
9967132|NCT01266915||Diseased group 1|Those subjects with systemic lupus erythematosus.
10123349|NCT04366453|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
10123350|NCT04366284|Active Comparator|NOCTEM only (NOCTEM)|No external or internal facilitation
10123351|NCT04366284|Active Comparator|External Facilitation (NOCTEM+EF)|External facilitation only
10123352|NCT04366284|Active Comparator|External and Internal Facilitation (NOCTEM+EF/IF)|External and internal facilitation
10123353|NCT04366505|Experimental|NFB + (MBRP)|Neurofeedback (NFB) from target region or control region plus Mindfulness-based relapse prevention (for some)
10123354|NCT04366505|Active Comparator|TAU and sham NFB|TAU + Neurofeedback (NFB) from control region
10123355|NCT04366154||Patients|
10123356|NCT04366154||Caregivers|
10123357|NCT04366206||Patients exposed to the study variable|Depending on the studied variable (treatment or risk factor)
10123358|NCT04366206||Patients not exposed to the study variable|Depending on the studied variable (treatment or risk factor)
10123359|NCT04366232|Experimental|Anakinra +/- Ruxolitinib|"According to clinical stage (gradual strategy):~Stage 2b or 3 : Anakinra 300 mg IV~Overcome stage 3 : Anakinra 300 mg IV and Ruxolitinib 5 mg x 2"
10123360|NCT04366232|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
10123361|NCT04366479|Experimental|intervention group|The study lasted for 5 weeks (1 month 7 days). During the research process, we monitor closely, especially the training schedule, implementation, and evaluation, directly and indirectly. Directly assisting participants to do endurance training activities, not directly monitoring via telephone or WhatsApp.
10123362|NCT04366414|Active Comparator|hook breathing removing nose-clip|"It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.~During that training, only this group will perform an experimental breathing protocol consisted of removing nose-clip previous to surface and then perform hook breathing during 20 seconds. This protocol was applied at the end of each of the 8 submaximes-dynamic apnoeas and after the maximal-dynamic apnoea"
10123363|NCT04366414|Active Comparator|usual breathing (UB)|It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
10123364|NCT04366258|Experimental|t-PBM at High, Middle, Low Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 300 mW/cm2, then 50 mW/cm2, and then 0 mW/cm2.
10123365|NCT04366258|Experimental|t-PBM at High, Middle Irradiance, Sham, Low Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 300 mW/cm2, then 0 mW/cm2, and then 50 mW/cm2.
10123366|NCT04366258|Experimental|t-PBM at High, Low, Middle Irradiance Sham|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 50 mW/cm2, then 300 mW/cm2, and then 0 mW/cm2
10123367|NCT04366258|Experimental|t-PBM at High, Low Irradiance, Sham, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 50 mW/cm2, then 0 mW/cm2 and then 300 mW/cm2
10123368|NCT04366258|Experimental|t-PBM at High Irradiance, Sham, Middle, Low Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 0 mW/cm2, then 300 mW/cm2, and then 50 mW/cm2
10123369|NCT04366258|Experimental|t-PBM at High Irradiance, Sham, Low, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 0 mW/cm2, then 50 mW/cm2, and then 300 mW/cm2
10123370|NCT04366258|Experimental|t-PBM at Middle, High, Low Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 770 mW/cm2, then 50 mW/cm2, and then 0 mW/cm2
10123371|NCT04366258|Experimental|t-PBM at Middle, High Irradiance, Sham, Low Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 770 mW/cm2, then 0 mW/cm2, and then 50 mW/cm2
10123372|NCT04366258|Experimental|t-PBM at Middle, Low, High Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 50 mW/cm2, then 770 mW/cm2, and then 0 mW/cm2
10123373|NCT04366258|Experimental|t-PBM at Middle, Low Irradiance, Sham, High Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 50 mW/cm2, then 0 mW/cm2, and then 770 mW/cm2
9967133|NCT01266915||Diseased group 2|Subjects diagnosed with cutaneous lupus.
9976615|NCT01353430||VCP families|Patients with a personal or family history of VCP associated disease.
10123374|NCT04366258|Experimental|t-PBM at Middle Irradiance Sham High Irradiance Low Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 0 mW/cm2, then 770 mW/cm2, and then 50 mW/cm2
10123375|NCT04366258|Experimental|t-PBM at Middle Irradiance, Sham Low, High Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 0 mW/cm2, then 50 mW/cm2, and then 770 mW/cm2,
10123376|NCT04366258|Experimental|t-PBM at Low High Middle Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 770 mW/cm2, then 300 mW/cm2, and then 0 mW/cm2
10123377|NCT04366258|Experimental|t-PBM at Low, High Irradiance, Sham Middle Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 770 mW/cm2, then 0 mW/cm2, and then 300 mW/cm2
10123378|NCT04366258|Experimental|t-PBM at Low, Middle, High Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 300 mW/cm2, then 770 mW/cm2, and then 0 mW/cm2
10123379|NCT04366258|Experimental|t-PBM at Low, Middle Irradiance, Sham High Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 300 mW/cm2, then 0 mW/cm2, and then 770 mW/cm2
10123380|NCT04366258|Experimental|t-PBM at Low Irradiance, Sham High, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 0 mW/cm2, then 770 mW/cm2, and then 300 mW/cm2
10123381|NCT04366258|Experimental|t-PBM at Low Irradiance, Sham Middle, High Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 0 mW/cm2, then 300 mW/cm2, and then 770 mW/cm2
10123382|NCT04366258|Experimental|t-PBM at Sham, High, Middle, Low Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 770 mW/cm2, then 300 mW/cm2, and then 50 mW/cm2
10123383|NCT04366258|Experimental|t-PBM at Sham, High, Low, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 770 mW/cm2, then 50 mW/cm2, and then 300 mW/cm2
10123384|NCT04366258|Experimental|t-PBM at Sham, Middle, High, Low Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 300 mW/cm2, then 770 mW/cm2, and then 50 mW/cm2
10123385|NCT04366258|Experimental|t-PBM at Sham Middle, Low, High Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 300 mW/cm2, then 50 mW/cm2, and then 770 mW/cm2
10123386|NCT04366258|Experimental|t-PBM at Sham Low, High, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 50 mW/cm2, then 770 mW/cm2, and then 300 mW/cm2
10123387|NCT04366258|Experimental|t-PBM at Sham Low, Middle, High Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 50 mW/cm2, then 300 mW/cm2, and then 770 mW/cm2
10123388|NCT04366440|Other|Order set review and modification|The antimicrobial stewardship program will review and change order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
10123389|NCT04366440|Other|Order Set review and Modification plus facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
10123390|NCT04366128|Experimental|CAPA indution immunotherapy|CAPA regimen, repeat every 3 week for 4 cycles.
10123391|NCT04366427|Experimental|Low-pressure hyperbaric oxygenation (L-HBO)|Low-pressure hyperbaric oxygen administration at 1.45 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 sessions (3-4 per week).
10123392|NCT04366427|Experimental|Standard-pressure hyperbaric oxygenation (HBO)|Standard pressure hyperbaric oxygen administration at 2.5 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 non-consecutive sessions (3-4 per week).
10123393|NCT04366427|No Intervention|Control|Control group of athletes, no intervention.
10123394|NCT04366427|Experimental|30% O2|Administration of air mixture with 30% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
10123395|NCT04366427|Experimental|50% O2|Administration of air mixture with 50% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
10123396|NCT04366388||Frail hospitalized old adults|Over than 65-years of age Admitted into Acute Unit Nonambulatory
10123397|NCT04366089|Active Comparator|Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
10123398|NCT04366089|Experimental|Oxygen-ozone and probiotic|"Oxygen-ozone therapy, probiotic supplementation plus standard of care~Oxygen-ozone therapy: systemic autohemotherapy (twice a day).~Probiotic supplementation: SivoMixx 200 billion (six sachets twice a day)."
10123399|NCT04366076||nonlaboring term singleton pregnancies|A total of 51 nonlaboring term singleton pregnancies were enrolled.
10123400|NCT04366271|Experimental|Mesenchymal cells|Undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
10123401|NCT04366271|Active Comparator|Standard of care|Standard of care
10123402|NCT04366492|Other|persons in prison|
10123403|NCT04366037|Experimental|Control group|This group performed their routine training
10123404|NCT04366037|Experimental|Experimental 1|This group performed their routine training plus proprioceptive exercises in the warm-up.
10123405|NCT04366037|Experimental|Experimental 2|This group performed their routine training plus proprioceptive exercises in the cool-down
10123406|NCT04366063|Experimental|Two MSC infusion|Intervention Group1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) intravenously plus Conventional treatment.
10123407|NCT04366063|Experimental|Two MSC infusion Plus two EVs infusion|Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), intravenously plus two doses of EVs plus Conventional treatment
10123408|NCT04366063|No Intervention|Control|Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control.
10123409|NCT04365842|Experimental|Digital exercise group|"After the 6-week digital intervention, 1) qualitative interviews have done with 6-15 patients from intervention group to assess the feasibility of digital intervention.~2) The primary outcomes are hand pain and function and exercise adherence will be evaluated for all participants"
10123410|NCT04365842|Active Comparator|Waiting list conrol|A hand rehabilitation home program will be given to the patients in the group through the telephone messages with brochures.
10123411|NCT04365972|Experimental|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 5 sessions using a variant of the dot-probe task in which the target probe always replaces neutral rather than threat (health-related) stimuli to induce diversion of attention away from threat.
10123412|NCT04366050|Experimental|Ramipril 2.5mg orally daily|"Total 2.5 mg Ramipril per day once a day orally for 14 days~Intervention: Ramipril"
10123413|NCT04366050|Placebo Comparator|Placebo|Placebo in the form of a capsule, taken orally for 14 days
10123414|NCT04365751|Experimental|Percutaneous microwave ablation group|MWA (Microwave) is an ultrasound-guided, minimally invasive technique that implants ablation electrodes into target tissue to rapidly generate high temperatures and rapidly develop coagulative necrosis in tumor tissue, thereby achieving the goal of local tumor treatment.
10123415|NCT04365751|Other|Laparoscopic hepatectomy|Laparoscopic hepatectomy is a widely used surgical technique in the treatment of benign (malignant) liver diseases
10123416|NCT04365946||Complete type|Patients with complete-type intestinal metaplasia
10123417|NCT04365946||Incomplete type|Patients with incomplete-type intestinal metaplasia
10123418|NCT04365946||Controls|Healthy subjects
10123419|NCT04365829|Experimental|Virtual reality|
10123420|NCT04365933|Experimental|Arm 1|EYP001a Dose A QD + ETV 0.5 mg QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
10123421|NCT04365933|Experimental|Arm 2|EYP001a Dose A QD + peg-IFN dosed per body surface area (180 µg, 135 µg or 90 µg) QW
10123422|NCT04366011|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is a twelve-week therapeutic intervention based on the theory that maladaptive thoughts contribute to symptom development and maintenance of PD/A.
10123423|NCT04366011|Experimental|Capnometry Assisted Respiratory Training (CART)|Capnometry-assisted respiratory therapy is a five-week treatment based on the theory that hyperventilation causes or maintains panic disorder.
10123424|NCT04365894|No Intervention|Control|The study was applied in 2nd grade nursing students' disability health course. The control group was taught with the traditional method.
10123425|NCT04365894|Experimental|Intervention|The intervention group with learning activities based on the transformative learning theory.
10123426|NCT04365764||Exposed to the treatment|Exposure variable will be studied treatment
10123427|NCT04365764||Not exposer to the treatment (control group)|
10123428|NCT04365686|Active Comparator|Group K|Ketofol group
10123429|NCT04365686|Active Comparator|Group P|propofol group
10123430|NCT04365907|Experimental|Omarigliptin 12.5 mg|Drug: Omarigliptin 12.5 mg Once weekly new anti-diabetic drug approved only in Japan Other Name: Zafatek tablets
10123431|NCT04365712|Active Comparator|Oscillating saw|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by common oscillating saw
10123432|NCT04365712|Experimental|Piezoelectric tool|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by piezoelectric tool
10123433|NCT04365816||Prospective cohort University Hospital, Grenoble|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
10123434|NCT04365816||Prospective cohort University Hospital, Toulouse|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
10123435|NCT04365816||Prospective cohort University Hospital, Nancy|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
10123436|NCT04365816||Prospective cohort University Hospital, Rennes|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
10123437|NCT04365816||Prospective cohort Hospices Civils de Lyon|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
10123438|NCT04365816||Prospective cohort Assistance Publique Hôpitaux de Paris|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
10123439|NCT04365816||Prospective cohort University Hospital, Rouen|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
10123440|NCT04365621|Other|ultra-high risk of psychosis patient|patient with ultra -high risk of psychosis will be enrolled to the study
10123441|NCT04365738|Experimental|Pulmonary Rehabilitation|The patients who applied pulmonary rehabilitation were checked, motivated and followed-up regularly with video calls every day. Pulmonary rehabilitation program consists of patient education, breathing, in-house mobilization and range of motion exercises.
10123442|NCT04365738|Placebo Comparator|Control|As a patient education, information was given about the disease and treatment process, listening to the patient during this process and getting regular sleep, balanced nutrition and taking a break from smokers.
10123443|NCT04366024||Observed group|COVID-19 disease patients who were detected by RT-PCR and CT imaging.
10123444|NCT04365595||SARS-CoV-2 associated respiratory failure|Participants will receive a daily HrQoL questionnaire on their personal smartphone using the docdok health application during 3 months. A selection of participants will furthermore receive a custom-built home disease monitoring device during 1 month. Both procedures start at least 4 weeks after hospital discharge.
10123445|NCT04365556|Experimental|TASC Intervention|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
10123446|NCT04365556|No Intervention|Treatment as Usual|Participants will not receive any intervention.
10123447|NCT04365608|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy. The standard intubation procedure is to use a styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the guidelines on difficult airway management.
10123448|NCT04365608|Active Comparator|Vie Scope laryngoscopy|Intubation will be done using Vie Scope laryngoscopy
10183230|NCT03766607|Experimental|Trastuzumab with Ramucirumab and Paclitaxel|Single arm study of trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) every 21 days + ramucirumab (8 mg/kg) on days 1 & 15 every 28 days + paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days
10123449|NCT04365517|Active Comparator|Treatment group|patients will be treated with sitagliptin add on to nutritional therapy with o without insulin treatment. The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
10123450|NCT04365517|No Intervention|Control group|Patients who will be prescribed nutritional therapy with or without insulin treatment
10123451|NCT04365582|Experimental|Azithromycin|Azithromycin
10123452|NCT04365582|Experimental|Hydroxychlororquine|Hydroxychlororquine
10123453|NCT04365582|Experimental|Lopinavir/Ritonavir|Lopinavir/Ritonavir
10123454|NCT04365582|No Intervention|standards of care|SoC
10123455|NCT04365270|Experimental|Chitosan Glass ionomer|"purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan.~will be placed in the prepared cavity over the last layer of caries"
10123456|NCT04365270|Experimental|Chitosan/Titanium dioxide nanoparticles Glass ionomer|"The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid.~The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries"
10123457|NCT04365270|Active Comparator|Chlorhexidine glass ionomer|Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v
10123458|NCT04365270|Placebo Comparator|Glass ionomer|Stock powder and liquid Fuji IX from GC japan
9967134|NCT01266928|Active Comparator|vitaminCE|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
10123459|NCT04365439|Experimental|Convalescent plasma|Convalescent plasma from patients after COVID-19
10123460|NCT04365179|Experimental|NEROFE|"Dose Level - Nerofe Dose~-1 - 6mg/m2~- 12 mg/m2~- 24 mg/m2~- 48 mg/m2~- 96 mg/m2~- 150mg/m2"
10123461|NCT04365543|Experimental|UP-C/A for Misophonia|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.
10123462|NCT04365543|Experimental|Psychoeducation and Relaxation Therapy|Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.
10123463|NCT04365400|Experimental|DS102 2000mg|Participants in this group will receive 1000mg DS102 capsules twice daily.
10123464|NCT04365400|Experimental|DS102 4000mg|Participants in this group will receive 2000mg DS102 capsules twice daily.
10123465|NCT04365400|Placebo Comparator|Placebo|Participants in this group will receive placebo capsules twice daily.
10123466|NCT04365283|Experimental|New Bioactive Restorative Material|ACTIVA Presto restorative material
10123467|NCT04365283|Active Comparator|High Viscosity Glass Hybrid Reinforced Glass Ionomer|EQUIA Forte restorative material
10123468|NCT04365296|Experimental|Aerobic group|This group will include 30 burned patients who will receive aerobic exercises 8 weeks (3times/week) in form of treadmill exercise in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
10123469|NCT04365296|Experimental|Resistance group|This group will include 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
10123470|NCT04365452|Experimental|Invia Motion Arm|
10123471|NCT04365374|Experimental|Surgical Resection and GammaTile Therapy|Surgical Resection and GammaTile Therapy
10123472|NCT04365374|Active Comparator|Surgical Resection and Stereotactic Radiation Therapy|Surgical Resection and Stereotactic Radiation Therapy
10123473|NCT04365465|Experimental|Active device|Participants in this arm will receive an active NSS-Bridge device placed immediately following their cesarean section.
10123474|NCT04365465|Sham Comparator|Placebo device|Participants in this arm will receive an inactive (sham) NSS-Bridge device placed immediately following their cesarean section.
10123475|NCT04365465|Active Comparator|Active Control|Participants in this arm will receive no device, only the standard postpartum pain control.
10123476|NCT04365504||Osteoporotic|Post menopausal females with Lumbar T score <-2.5 as determined by dual energy X ray absorbitometry
10123477|NCT04365504||Osteopenic|Post menopausal females with Lumbar T score -1 to -2.5 as determined by dual energy X ray absorbitometry
10123478|NCT04365504||Normal|Post menopausal females with T score >-1 as determined by dual energy X ray absorbitometry
10123479|NCT04365322||Severe COVID-19 infection|
10123480|NCT04365322||Light to moderate COVID-19 infection|
10123481|NCT04365322||Cancer patients with COVID-19 infection|
10123482|NCT04365127|Experimental|Progesterone plus SOC|Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care
10123483|NCT04365127|No Intervention|SOC only|Subjects will receive institutional standard of care only
10123484|NCT04365309|No Intervention|the NCP standard treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment).
10123485|NCT04365309|Experimental|the NCP aspirin treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). Patients in the NCP aspirin group were given aspirin 100 mg/d orally after admission and aspirin for 14 days after discharge.
10123486|NCT04365231|Experimental|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
10123487|NCT04365231|Active Comparator|conventional management of patients|Regular management of patients
10123488|NCT04365192||I-gel|
10123489|NCT04365192||Self-pressurized air-Q|
10123490|NCT04365413|Experimental|Imaging of Tumor or Lymph node|"Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery.~The temperature of their skin prior to and after MSOT imaging will also be measured."
10123491|NCT04365426|Experimental|Oral contraceptive (OC)|Oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
10123492|NCT04365426|Experimental|No oral contraceptive (No OC)|No oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
10123493|NCT04365101|Experimental|Phase I|CYNK-001 infusions on Days 1, 4, and 7
10123494|NCT04365101|Active Comparator|Phase II|Randomized, open label; CYNK-001 infusions on Days 1, 4, and 7 compared to Control Group: Best Supportive Care
10123495|NCT04364880|Experimental|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
9825999|NCT02403999|Experimental|Test bath foam|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
10123496|NCT04364880|Sham Comparator|Sham controlled intervention|The sham-TBS coil produced a similar sound without a magnetic pulse.
10123497|NCT04365075|Experimental|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
10123498|NCT04365075|Active Comparator|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
10123499|NCT04364893|Other|Group 1|Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
10123500|NCT04364893|Other|Group 2|Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
10123501|NCT04364906|Active Comparator|Quadratus Lumborum Block 2|Quadratus Lumborum Block 2 (QLB 2) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
10123502|NCT04364906|Active Comparator|Quadratus Lumborum Block 3|Quadratus Lumborum Block 3 (QLB 3) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
10123503|NCT04364815|Experimental|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine oral loading dose of 400mg two times per day on Day 1 then 400 mg once a day for Day 2-10 plus standard preventive measures as defined by PGH Hospital Infection Control Unit (HICU)
10123504|NCT04364815|Placebo Comparator|Placebo plus standard preventive measure|Placebo tablet plus standard preventive measures as defined by PGH-HICU
10123505|NCT04364828|Other|Host Genome Analysis|For 150 patients from the extreme phenotypes - complementary to Whole Genome Analysis of each patient also Whole Transcriptome will performed Analysis; DNA methylation analysis using EPIC arrays will be performed in the pilot study (phase 1). Identically, in phase 2 starting from month 4, will be generated WGS, Whole transcriptome sequencing (WTS), and methylation data of the 500 patients. Epigenetic changes are likely to occur upon Corona infection. Subsequently, genome and epigenome data with RNA expression pattern will be correlated.
10123506|NCT04364828|Other|Host Response to SARS-CoV-2 Infection|Focus on longitudinal analysis of TCR repertoire of CD4+ and CD8+ T cells from blood samples (PBMCs) from clinically characterized patients (n = 24). The bulk- T-cell receptor (TCR) sequencing will be performed at different time points during the course of disease progression and recovery.
10123507|NCT04364828|Other|Viral Sequence Composition|The Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) viral composition is determined by Next Generation sequencing (different protocols for enrichment are available, and are currently being tested to successfully analyse the virus from different isolates). It is known that SARS-CoV-2 sequence is changing at least one position every second passing from person to person. Numerous variants have been described deriving from 3 different ancestral viruses (named A, B, and C) reflecting different distributions in East Asia, Europeans and Americans. At it is anticipated that other (super)infections may add to the severity of the infection and disease course, the entire metagenome of the throat is being sequenced and analyzed as well.
10123508|NCT04365049||Treatment|Patients in treatment group will receive anti-PD-1 antibody intravenously every three weeks and apatinib 250mg per day until disease progression, unacceptable toxicity, death or withdrawal. Concurrent external beam radiation will be initiated after one course of anti-PD-1 treatment. The total radiation dose is over 40Gy without damaging organic function. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed.
10123509|NCT04365049||Gemcitabine+cisplatin|Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
10123510|NCT04365062|Experimental|Intervention: Excimer laser and drug coated balloon|Intervention: Excimer laser and drug coated balloon group
10123511|NCT04365062|Active Comparator|Excimer laser and plain balloon|Excimer laser and plain balloon group
10123512|NCT04365062|Active Comparator|plain balloon and drug coated balloon|plain balloon and drug coated balloon group
10123513|NCT04364945|Placebo Comparator|Control group|General anesthesia is maintained using sevoflurane only. Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
10123514|NCT04364945|Experimental|Dexmedetomidine-remifentanil(DEX-R) group|General anesthesia is maintained using sevoflurane, dexmedetomidine (1 mcg/kg/hr) and remifentanil (0.1-0.2 mcg/kg/min). Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
9826000|NCT02403999|Experimental|Test head to toe Wash|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
9967135|NCT01266928|No Intervention|no drug|no drug
10123515|NCT04364919|Experimental|aerobic exercise intervention|The intervention group received a DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercise program requires twenty minutes to complete. Women were instructed to use the DVD 3 times a week for 3 months.
10123516|NCT04364919|No Intervention|control group|The control group received routine prenatal care only.
10123517|NCT04364802|No Intervention|Healthcare Workers - Control|Front-line healthcare workers (FLCHW) who are negative for COVID will receive standard PPE and a pre- and post-study test for COVID-19.
10123518|NCT04364802|Experimental|Healthcare Workers - PVP-I|Front-line healthcare workers (FLCHW) who are negative for COVID-19 will receive standard PPE and a pre- and post-study test for COVID-19. Additionally, they will receive PVP-I spray and gargle.
10123519|NCT04364802|No Intervention|Inpatients - Control|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test.
10123520|NCT04364802|Experimental|Inpatients - PVP-I|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays that will be applied shortly after admission or perioperatively.
10123521|NCT04364802|No Intervention|Community - Control|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test.
10123522|NCT04364802|Experimental|Community - PVP-I|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays.
10123523|NCT04365010|Experimental|Sodium Bicarbonate Ringer's Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
10123524|NCT04365010|Active Comparator|0.9% Sodium Chloride Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
10123525|NCT04364685|Active Comparator|Normal Walking|The participants performed 30 minutes on levelled surface on the track and field ground. Participants performed moderate intensity walking, self paced.
10123526|NCT04364685|Experimental|Sand Walking|The participants performed supervised walking on sand on the 20 meters pathway containing soft sand.The walking on sand for 30 minutes.
9827376|NCT02453555|Experimental|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
10123527|NCT04364620|Experimental|Arm AB-16B5 and Docetaxel|AB-16B5 at a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks on Day 1.
10123528|NCT04364724||Study group|"All patients referred to the Hematology clinic for diagnosis and treatment of active multiple myeloma will be asked to participate in the study and undergo 3 consecutive low-dose CT scans over a period of 12 months. For non-consenting patients only minimal demographic data will be documented.~Eligible consenting patients will sign informed consent."
9827377|NCT02453555|Placebo Comparator|Linagliptin placebo|
9827378|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin high dose placebo|
10123529|NCT04364971|Experimental|singleradius|Single Radius(SR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Single Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
10123530|NCT04364971|Experimental|Multiradius|Multi Radius(MR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Multi Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
10123531|NCT04365036|Experimental|toripalimab with P-GemOx|Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
10123532|NCT04365036|Active Comparator|P-GemOx|Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.
10123533|NCT04364659|Experimental|Food-specific ICT + TAU|Participants in the Food-specific ICT + TAU group will be encouraged to complete the FoodT phone app (a food-specific go/no-go task) and a food diary daily for four weeks. After four weeks, they will be asked to complete a post-intervention questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
10123534|NCT04364659|No Intervention|TAU|Participants in the TAU group will not receive the Food-specific ICT. After four weeks, they will be asked to complete a 'post-intervention' questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
10123535|NCT04364542|Experimental|Suprascapular nerve block (SSNB)|Single shot using the blind block technique with 10 ml 0.75% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
10123536|NCT04364542|Active Comparator|Interscalene Nerve Block (ISB)|Single shot using US-guided interscalene brachial plexus block with 15 ml 0.5% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
10123537|NCT04364672|Experimental|Women with stage 1-4 newly diagnosed breast cancer|
10123538|NCT04365023||1|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive first line platinum based chemotherapy
9827379|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin low dose placebo|
9827380|NCT02453581|Experimental|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
9827381|NCT02453581|Experimental|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
10123539|NCT04365023||2|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive receiving first line non-platinum chemotherapy
10123540|NCT04364490|Experimental|Experimental VF group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform advanced gait training sessions by the computerized BWS system without visual feedback; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
10123541|NCT04364490|Experimental|Experimental VF+ group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform the same advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
10123542|NCT04364490|Active Comparator|Control group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
10123543|NCT04364607|Active Comparator|Neostigmine group|After surgery, in the postoperative care unit, participants will receive 0.5 mg IM neostigmine
10123544|NCT04364607|Placebo Comparator|Placebo group|After surgery, in the postoperative care unit, participants will receive IM NaCl 0.9% as a placebo
10123545|NCT04364399|Experimental|Experimental group|Mumps vaccine, one dose
10123546|NCT04364399|Active Comparator|Control group|measles, mumps and rubella combined vaccine, live, one dose
10123547|NCT04364594|Experimental|affected individual|Patients affected by Coronavirus 19 admitted to the hospital setting
10123548|NCT04364243|Experimental|Patients exercise|Low back pain patients Next to basic medical physical training therapy group A receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
10123549|NCT04364243|No Intervention|Patients control|Low back pain patients Group B will receive basic medical physical training therapy
10123550|NCT04364243|Experimental|Non-patients exercise|non-patients Groups C will receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
9967136|NCT01266941|Experimental|Mild Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
10123551|NCT04364243|No Intervention|Non-patients control|non-patients Group D will receive no intervention
10123552|NCT04364334||Knee registry patients|
10123553|NCT04364191|Experimental|Intervention Arm|Meaningful activity protocol during the day and Assistive Relaxation Therapy (ART) at night; includes 1) Sleep Hygiene Education; 2) Meaningful Activity Modules a) Physical Activity b) Cognitive Activity and c) Social engagement; 3) ART, a breath-based relaxation intervention that is coupled with a physical anchoring task. Participants will complete a daily sleep diary, use the activity modules daily as pre-determined times personalized to the participant, use the ART software when they get in bed to help with insomnia symptoms, and wear an actiwatch for a four-week period. Participants will have biweekly phone consultation with the research nurse.
10123554|NCT04364191|Active Comparator|Control Arm|Study participants in the control group will also receive a tablet and watch, but the meaningful activity modules and ART software will not be accessible to them. The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education. This approach provides staff and technology interaction/attention that is comparable to the intervention arm, and thereby promotes adherence; it has been used as a placebo comparator for many insomnia treatment studies and has low attrition rates. Control subjects will also be asked to complete electronic sleep diaries and wear the actiwatch on the non-dominant wrist to monitor sleep/wake patterns. For both arms, participants will be asked to complete baseline assessments, 1 month (post-intervention) and follow-up (3 month).
10183231|NCT03766594|Active Comparator|Sildenafil group|Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
10183232|NCT03766594|Active Comparator|Control group|Includes 45 women who received placebo oral tablets (apparently identical to Respatio(R) 25mg tablets, four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
10183233|NCT03766568|Experimental|Diagnostic with JGG endoscope|
10183234|NCT03766555|Experimental|Microwave Ablation|Microwave ablation (MWA) will be performed in patients randomized to this arm.
10183235|NCT03766555|Active Comparator|Liver Resection|Liver resection will be performed in patients randomized to this arm.
10183236|NCT03766542|Active Comparator|CPAP|Oronasal CPAP therapy applied as per current international guidelines
10183237|NCT03766542|Experimental|Bi-level|Oronasal Bi-level therapy + supplemental oxygen (if necessary) applied as per current international guidelines
10187626|NCT03724331|Experimental|Light Physical Activity 1|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
9967137|NCT01266941|Experimental|Moderate Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
10123555|NCT04364204|Experimental|Kangaroo mother care with bracelet|
10123556|NCT04364204|Active Comparator|Kangaroo mother care|
10123557|NCT04364477|Active Comparator|Tap block Group|Tap Block group :(Group 1) After General anestehesia At the end of the operation, TAP blocks were placed to the 1st group patients.
10123558|NCT04364477|Placebo Comparator|Control Group|No block applied. only General anesthesia was applied.
10123559|NCT04364360|Experimental|Sulforaphane supplementation|Daily (2 capsules) consumption of BroccoMax (Jarrow Formulas Los Angeles, CA) for 3-weeks.
10123560|NCT04364464|Experimental|Riociguat, healthy participants|Participants with creatinine clearance (CLCR) >80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123561|NCT04364464|Experimental|Riociguat, mild renal impairment|Participants with CLCR 50-80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123562|NCT04364464|Experimental|Riociguat, moderate renal impairment|Participants with CLCR 30-<50 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123563|NCT04364464|Experimental|Riociguat, severe renal impairment|Participants with CLCR <30 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
10123564|NCT04364568|Experimental|Symptomatic group at three month|"Rivermead Post-Concussion Syndrome >= 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
10123565|NCT04364568|Experimental|Asymptomatic group at three month|"Rivermead Post-Concussion Syndrome < 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
10123566|NCT04364425|Experimental|low dose steroid|patient received ultrasound-guided 40mg triamcinolone + 4cc xylocaine + 12cc NS
10123567|NCT04364425|Active Comparator|high dose steroid|patient received ultrasound-guided 10mg triamcinolone + 4cc xylocaine + 15cc NS
10123568|NCT04364373|Active Comparator|D2 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232 and 231 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 will be removed.~For tumours in the rectosigmoid junction 251, 252 groups of the lymph node will be removed."
10123569|NCT04364373|Experimental|D3 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232, 231 and 253 will be removed.~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and 253 and partially 241, 242 (considering variation of the feeding artery) will be removed.~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 and 253 will be removed.~For tumours in the rectosigmoid junction 251, 252 and 253 groups of the lymph node will be removed."
10123570|NCT04364438|No Intervention|Control Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises
10123571|NCT04364438|Experimental|EMS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Electric Muscle Stimulation (EMS)
10123572|NCT04364438|Experimental|TENS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Transcutaneous Electric Nerve Stimulation (TENS)
10123573|NCT04364217|Other|Treatment|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz
10123574|NCT04364321|Experimental|Single dose Clonazepam|Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)
10123575|NCT04364321|Active Comparator|Intermittent oral diazepam|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.
10123576|NCT04364386|Experimental|InPress|Treatment with InPress Device for Postpartum Hemorrhage
10123577|NCT04364282||Parent-Child Dyads Taking Part in Weight-Management Programs|Participants in this study will be children and their parents taking part in existing pediatric weight-management programs at participating sites. All participants will be seen at baseline and 6-months for data collection visits.
10123578|NCT04364139|Experimental|Lower BP goal and Ramipril|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Ramipril 2.5 to 10 mg/d
10123579|NCT04364139|Experimental|Usual BP goal and Ramipril|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and participants assigned to Receive Ramipril 2.5 to 10 mg/d
10123580|NCT04364139|Experimental|Lower BP goal and Amlodipine|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
10123581|NCT04364139|Experimental|Usual BP goal and Amlodipine|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
10123582|NCT04364139|Experimental|Lower BP goal and Metoprolol|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
10123583|NCT04364139|Experimental|Usual BP goal and Metoprolol|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
10123584|NCT04364581|Active Comparator|Letrozole group|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
10123585|NCT04364581|Placebo Comparator|Placebo group|Women will be treated with placebo for 10 days before hysteroscopic intervention
9519519|NCT03286413|Active Comparator|cryoablation|Clinically, cryosurgery is accomplished by placing a cryoprobe(up to 3.5 mm) through a stab incision into the tumor under ultrasound guidance.Liquid nitrogen is utilized under low operating pressure as cryogen which is controlled by the computer modulated cryogen regulator. The cryoprobe achieves rapid freezing by means of an active freeze zone at its distal tip.
9827382|NCT02453581|Experimental|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
10123586|NCT04364178|Experimental|Viral Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
10123587|NCT04363996|Experimental|New Bioactive Restorative Material|Activa Presto Bioactive restorative material
10123588|NCT04363996|Active Comparator|Resin Modified Glass Ionomer|Fuji II
10123589|NCT04364009|Active Comparator|Optimized Standard of Care (oSOC)|The control group will receive optimized standard of care alone, including all treatments authorized for COVID-19 by the French Health Ministry and/or the center COVID-19 therapeutic committees at inclusion and during the follow-up.
10123590|NCT04364009|Experimental|Anakinra plus Optimized Standard of Care (oSOC)|The experimental group will receive Anakinra plus optimized Standard of Care. The patients will receive Intravenous injection (IV) of Anakinra 400mg/day (100mg IV every 6 hours) at Day 1, 2 and 3. From Day 4 to Day 10, the patient will receive IV injection of Anakinra 200mg/day (100mg every 12 hours). The total duration of Anakinra is 10 Days
10123591|NCT04364295||Implanted with SeaSpine spinal or orthobiologics product|
10123592|NCT04363892|Experimental|Receiving optical and infrared imaging|This is the only arm of the study. All patients will have optical and infrared images acquired of skin on the treated and contralateral sides.
10123593|NCT04363918|Active Comparator|intervention (IG1)|
10123594|NCT04363918|Active Comparator|intervention (MyoStim group)|
10123595|NCT04363918|Sham Comparator|control (CG)|
10123596|NCT04363970||group A- early catheter removal)|in group A, we will remove the catheter after 24 h.
10123597|NCT04363970||Group B- delayed catheter removal|In group B, we will remove the catheter after 48 h.
10123598|NCT04363944|Experimental|mRehab|Use of mRehab in a home program
10123599|NCT04363983|Active Comparator|Located/resected colorectal cancer|
10123600|NCT04363983|Active Comparator|Advanced colorectal cancer|
10123601|NCT04363983|Active Comparator|Located/resected pancreatic cancer|
10123602|NCT04363983|Active Comparator|Advanced pancreatic cancer|
10123603|NCT04363983|Active Comparator|Located/resected biliary tract cancer|
10123604|NCT04363983|Active Comparator|Advanced biliary tract cancer|
10123605|NCT04363983|Active Comparator|Located/resected gastroesophageal cancer|
10123606|NCT04363983|Active Comparator|Advanced gastroesophageal cancer|
10123607|NCT04363983|Active Comparator|Located/resected neuroendocrine cancer|
10123608|NCT04363983|Active Comparator|Advanced neuroendocrine cancer|
10123609|NCT04363827|Experimental|Group 1: Hydroxychloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1, followed by a weekly dose of Hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, covering a total of 1 month of treatment.
10123610|NCT04363827|No Intervention|Group 1: Observation|observation only
10123611|NCT04363827|Experimental|Group 2: Hydroxycloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1 followed by 200 mg twice daily for a total of at least 5-7 days according to clinical evolution.
10123612|NCT04363827|No Intervention|Group 2: Observation|Observation only
10123613|NCT04364113|Active Comparator|Study A Usual Protein Usual Pressure|Study A Usual Protein and Usual Pressure
10123614|NCT04364113|Experimental|Study A Usual Protein Low Pressure|Study A Usual Protein and Low Pressure
10123615|NCT04364113|Experimental|Study A Low Protein Usual Pressure|Study A Low Protein and Usual Pressure
10123616|NCT04364113|Experimental|Study A Low Protein Low Pressure|Study A Low Protein and Low Pressure
10123617|NCT04364113|Active Comparator|Study B Low Protein Usual Pressure|Study B Low Protein and Usual Pressure
10123618|NCT04364113|Experimental|Study B Low Protein Low Pressure|Study B Low Protein and Low Pressure
10123619|NCT04364113|Experimental|Study B Very Low Protein Usual Pressure|Study B Very Low Protein and Usual Pressure
10123620|NCT04364113|Experimental|Study B Very Low Protein Low Pressure|Study B Very Low Protein and Low Pressure
10123621|NCT04364022|Active Comparator|Lopinavir/Ritonavir|
10123622|NCT04364022|No Intervention|Active surveillance|
10123623|NCT04363957|Other|Standard Consent|Patients only receive the standard brachytherapy consent process
10123624|NCT04363957|Experimental|Standard Consent and Video Intervention|Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
9519520|NCT03286374|Other|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
10123625|NCT04364074|Experimental|GoodBelly Probiotic|Subjects randomized to this arm consume one serving of the Goodbelly lactobacillus plantarum 299v probiotic
10123626|NCT04364074|Placebo Comparator|Placebo|Subjects randomized to this arm consume one serving of the Goodbelly that does not contain lactobacillus plantarum 299v
10123627|NCT04364061|Experimental|Women with overweight or obesity|
10123628|NCT04364035|Experimental|CCMM+GS-9620|ChAdOx1.HTI 2 doses, MVA.HTI 2 doses, GS-9620 10 doses.
10123629|NCT04364035|Placebo Comparator|PLACEBO|ChAdOx1.HTI placebo 2 doses, MVA.HTI placebo 2 doses, GS-9620, placebo 10 doses.
10123630|NCT04364165|Experimental|Standard of care messaging|Participants randomized into this arm will receive standard invitation cards distributed at the Tutu Tester containing basic information encouraging HIV testing. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the standard invitation card and share a brief script including the standard Tutu Tester message that free HIV testing is available at the Tutu Tester, with no further information or motivation to test.
10183238|NCT03766503|Other|Intervention|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
10183239|NCT03766490|Experimental|Anlotinib Hydrochloride plus gefitinib or icotinib|
10123631|NCT04364165|Experimental|U=U messaging|Participants randomized into this arm will receive the U=U invitation cards distributed at the Tutu Tester that will seek to assuage the fears of testing HIV positive by conveying the message that HIV treatment makes it possible for HIV positive people to be untransmittable and to live normal lives. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the U=U invitation card and share a brief script asking people if they knew they could control HIV and that pills exist that can keep them healthy and ensure they don't transmit the virus to their sex partners, and that free HIV testing is available at the Tutu Tester.
10123632|NCT04363710|Experimental|Intervention group|Participants in this arm were advised intervention of Low Calorie Diet (800-1000 Kcal/day) for 8 weeks without any anti diabetic medication
10123633|NCT04363710|No Intervention|Control Group|Participants in this arm were kept on their standard medical treatment
10123634|NCT04363749|Experimental|15 COVID positive patients|dyspnea rating to various dyspneic stimulus
10123635|NCT04363749|Active Comparator|15 healthy controls|dyspnea rating to various dyspneic stimulus
10123636|NCT04363723||patients with an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that developed an acute exacerbation during a pulmonary Rehabilitation program but continued the Rehabilitation program
10123637|NCT04363723||patients without an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that did not develop an acute exacerbation during a pulmonary Rehabilitation program and completed the Rehabilitation program regularly.
10123638|NCT04363541|Experimental|Thermotherapy|"Electric heat pad applied in the thorax for 90 minutes, twice daily, for 5 days.~+ Usual in-hospital care"
10123639|NCT04363541|No Intervention|Control|Usual in-hospital care
10123640|NCT04363645|Experimental|Multicontext approach (Intervention) Arm|Participants received 30-minute sessions of strategy and self-monitoring practice within the context of everyday activities. These sessions were delivered either daily or twice a day. The total number of sessions varied depending on the participant's length of stay in acute rehabilitation.
10123641|NCT04363580||Patients|Children consulting for an assessment of central auditory skills
10123642|NCT04363866|Experimental|Hydroxychloroquine|400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
10123643|NCT04363866|Placebo Comparator|Placebo|Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
10123644|NCT04363775|Experimental|Regurgitation|intubation in regurgitation condition
10123645|NCT04363775|Experimental|Tongue edema|intubation in Tongue edema condition
10123646|NCT04363593|Other|prospective group COVID|New patients consulting for suspected or diagnosed COVID(+)
10123647|NCT04363593|Other|retrospective group COVID|Patients already diagnosed with COVID(+) or with a suspicion of unconfirmed COVID or at a date before the apparition of the COVID infection (April-March 2019)
10123648|NCT04363593|Other|Hospital staff|All hospital staff including those already diagnosed at COVID(+)
10123649|NCT04363853|Experimental|Tocilizumab tratment|
10123650|NCT04363502|Experimental|clazakizumab at a dose of 25 mg|A first dose of 25 mg of clazakizumab will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25mg clazakizumab (an identical dose to the day 1 dose) will be given no later than day 3
10123651|NCT04363502|Placebo Comparator|placebo|A first dose of placebo will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo (an identical dose to the day 1 dose) will be given no later than day 3
10123652|NCT04363931|Experimental|Manual Therapy|Manual Therapy is a widely used physiotherapy modality which is known to be effective in the management of musculoskeletal problems . Manual Therapy is a passive, therapeutic approach used to target a variety of anatomical structures with the intent to create beneficial changes in the amount of pain a patient experiences. Manual Therapy includes joint mobilization, manipulation, or treatment of the soft tissues and is widely used to break fibrous adhesions, restore normal range of motion, reduce local ischemia, stimulate synovial fluid production, and reduce pain .
10123653|NCT04363931|Experimental|Kinesio Taping|Kinesio tape is a type of elastic therapeutic tape that was developed which is used in many different situations with various aims. Advocates of Kinesio Tape state that it may promote different therapeutic objectives such as; improved circulation and lymphatic drainage, pain inhibition, reduction of delayed onset of muscle soreness or improvement in performance and coordination .
10123654|NCT04363515|No Intervention|Usual Pre-Transplant Counseling Intervention|Subjects in the control arm will undergo usual pre-transplant counseling as per the standard of care.
10123655|NCT04363515|Experimental|Social Support Network Counseling Intervention|Subjects in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks between 2-12 weeks after their initial transplant evaluation and counseling
10123656|NCT04363762|Experimental|Internet-based multimodal pain program|The iMPP is based on CBT and self-management principles that help patient cope with chronic TMD pain. The iMPP translates a face-to-face therapy to a software platform program.
10123657|NCT04363762|Active Comparator|Occlusal splint|Participants randomized to active control received a hard Michigan-type stabilization splint placed in the upper jaw by one of two calibrated general dentists {Ramfjord, 1994 #276}. The occlusal splint was chosen as the control treatment because it is a conventional and reversible treatment of TMD pain, and it has a known moderate efficacy {Welfare, 2011 #266}.
10123658|NCT04363788||Cardiopulmonary resuscitation|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
10123659|NCT04363554|Other|Urine dilution test|Urine dilution test
10123660|NCT04363554|Other|Urine concentration test|Urine concentration test
10123661|NCT04363528|Other|Doppler Echo|patients will have a Doppler Echo when they enter ICU (within 48 hours) and a second Doppler Echo 7 days later
10123662|NCT04363476|Experimental|Intervention|8-week exercise and education intervention. Two 60-minute physiotherapist-lead group exercise classes with education incorporated will be delivered weekly for 8 weeks (16 classes). In addition, participants will complete a 30-minute home exercise session once a week for 8-weeks (8 sessions). After the intervention, the group will enter a 16-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
10123663|NCT04363476|Other|Control|The control group will not receive an intervention during the first 8-weeks of the study. Being a step-wedge design, this group will receive the same 8-week exercise and education intervention later, after the intervention group has completed the intervention and the post-intervention testing. After the control group has completed the 8-week intervention, they will enter an 8-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
10123664|NCT04363450|Experimental|Hydroxychloroquine|Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.
10123665|NCT04363450|Placebo Comparator|Placebo|An identical placebo will be administered on an identical dosing interval and frequency.
10123666|NCT04363242|Experimental|Part A|Dose escalation of SYN125. Each dose level (low, medium, high) will be tested in a cohort of 3 patients. If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next SYN125 dose level.
10123667|NCT04363242|Experimental|Part B|Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated). Once cohorts with low and medium dose levels in Part A are completed and no DLTs are observed per cohort, Part B with the SYN125 low dose level + SYN004 will start and run in parallel with Part A. The high dose of SYN125 in a cohort in Part A will begin along with Part B.
10123668|NCT04363320|Experimental|High-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~4-hour onsite visit (NIATx Training)~11 monthly (one-hour) NIATx coaching calls~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
10123669|NCT04363320|Experimental|Low-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~One-hour conference call with Executive Sponsor~Two-hour NIATx webinar training with Change Leader/Team~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
10123670|NCT04363320|Experimental|High-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~4-hour onsite visit~11 monthly (one-hour) NIATx coaching calls"
10123671|NCT04363320|Experimental|Low-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches~One-hour conference call with Executive Sponsor~Two-hour NIATx webinar training with Change Leader/Team~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team"
10123672|NCT04363333||High Probability of OSA|Based on a sleep questionnaire
10123673|NCT04363333||Low Probability of OSA|Based on a sleep questionnaire
10123674|NCT04363190||Cases|
10123675|NCT04363190||Controls|
10123676|NCT04363411|Experimental|drug use|
10123677|NCT04363294|Other|Participants|Patients who had TAVR and underwent evaluation for ATTR with PYP scan
10123678|NCT04363203|Active Comparator|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg capsule in the AM and 200 mg in the PM on Days 2-5
10123679|NCT04363203|Active Comparator|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM followed by 250mg PO every day on days 2-5
10123680|NCT04363203|Placebo Comparator|Placebo|The pills packs for the 3 arms are identical.
10123681|NCT04363151||Hydatid cyst patients|patients who underwent surgery for liver hydatid cyst from 2004 to 2018 in two major university-affiliated hospitals in Fars Province, southern Iran
10123682|NCT04363086|Experimental|TAU|
10123683|NCT04363086|Experimental|iFD|
10123684|NCT04363086|Experimental|iFD + weekly phone calls|
10123685|NCT04363307||Adult participants|Adult participants ages 18 and older with AF
10123686|NCT04363255|Experimental|Maintenance group|After 4-6 cycles of EP/EC chemotherapy regiment, maintenance therapy with toripalimab and anlotinib was followed and continued until disease progression.
10123687|NCT04363359|Experimental|Quadrivalent influenza vaccine HD|Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
10123688|NCT04363359|Experimental|Quadrivalent influenza vaccine LD|Participants randomized to receive two injections of 0.25 mL quadrivalent influenza vaccine at Day 0 and 28.
10123689|NCT04363359|Active Comparator|Trivalent influenza vaccine Victoria|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Victoria strain at Day 0 and 28.
10123690|NCT04363359|Active Comparator|Trivalent influenza vaccine Yamagata|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Yamagata strain at Day 0 and 28.
10123691|NCT04363216|Experimental|Treatment|Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) will be added to each liter of sterile wate,r plus 1 g/L magnesium chloride to reduce burning sensation, and given parenterally over a 2-hour period. On the day of enrollment (Day 0), 0.3 g/kg will be given; Day 1 - 0.6 g/kg; Day 2 - 0.9 g/kg; Day 3 - 0.9 g/kg; Day 4 - 0.9 g/kg; Day 5 - 0.9 g/kg. After the first dose, each subsequent dose will be given 24 +/- 4 hours following the previous dose.
10123692|NCT04363216|No Intervention|Routine care|These subject will follow routine care and their clinical courses will be recorded only.
10123693|NCT04363424||Validation cohort|Patients with alcoholic cirrhosis with reliable self-reported alcohol use.
10123694|NCT04363424||Clinical application cohort|Patients with alcoholic cirrhosis who deny moderate or excessive alcohol use in the previous 3 months.
10123695|NCT04363372|Experimental|MRx-4DP0004|Patients receiving standard of care will add MRx-4DP0004 to their treatment. MRx-4DP0004 is taken as 2 capsules, twice a day for 14 days. Daily dose is 4 x 10^9 to 4 x10^10 colony forming units.
9519521|NCT03286361|Experimental|BeGraft Peripheral + Stent Graft System|Patients treated with the BeGraft Peripheral Plus Stent Graft System
10123696|NCT04363372|Placebo Comparator|Placebo|Patients receiving standard of care will also take 2 placebo capsules, twice a day for 14 days.
10123697|NCT04363398|Experimental|Comprehensive|Coaches from schools randomized to the comprehensive follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a trained research team member will monitor the team weekly for injuries, participation, and adherence, and provide support to the school coaches regarding the warm-up.
10123698|NCT04363398|Active Comparator|Standard|Coaches from schools randomized to the standard follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a research team member will monitor the team weekly for injuries, participation, and adherence, however will not provide support to the school coaches regarding the warm-up.
10123699|NCT04363073|Experimental|Anaabella|Milk will be expressed using Annabella breast pump.
10123700|NCT04363073|Active Comparator|Control pump|Milk will be expressed using a control breast pump.
10123701|NCT04363047||Healthy Volunteers|"These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
10123702|NCT04363047||Rheumatoid Arthritis|"These people will have already provided at least one sample as part of the BRAGGSS Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
10123703|NCT04363099||outpatients COVID 19 positive|
10123704|NCT04363385|Other|Collection of blood sample|
10123705|NCT04363060|Experimental|Azithromycin with amoxicillin/clavulanate|Combination of azithromycin during 4 days with amoxicillin/clavulanate during 7 days.
10123706|NCT04363060|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/clavulanate every day during 7 days.
10123707|NCT04363021||cases|Cases will be defined as women with systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis) and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
10123708|NCT04363021||controls|Controls will be defined as women with systemic sclerosis, no specific vascular complication and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
10123709|NCT04362904|Experimental|acupressure|In accordance with the acupressure protocol, each day for four weeks, taking into account the awakening and sleep periods of the individuals, acupressure applied for a total of 3 min to the each acupuncture points (one session 18 minutes) twice a day between 07:00 and 10:00 and 19:00 to 22:00 in the morning patients were asked to perform acupressure by their caregivers or on their own.
10123710|NCT04362904|No Intervention|control|No intervention was applied to the control group.
10123711|NCT04362787||High pressure _ low pressure non-invasive ventilation|"In the high-pressure NIV,52 patients will undergo pressure-limited NPPV at a higher IPAP level. IPAP is initially set at 20 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (up to 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 15 mL/kg of IBW.~2- EPAP for patients with COPD will be started at EPAP 5 and will be increased till 7 and for the patients with hypoventilation syndrome will be increased up to EPAP 8.~3-Respiratory rate 10-12 b/min."
10123712|NCT04362631||Adults|Adults 18 years or older
10123713|NCT04362995||SARS-CoV-2 Infection|St. Jude Children's Research Hospital employees with SARS-CoV-2 infection
10123714|NCT04362995||Controls|St. Jude Children's Research Hospital employees uninfected with SARS-CoV-2 infection
10123715|NCT04362982|Experimental|ADHD|In the first part of the clinical trials, ADHD cohorts are going to undergo a neuropsychological assessement. Moreover, they will interact with the serious game twice (30-45 minutes/each time). In the second part, participants will interact with game two or three times per week (30-45 minutes/each time). Finally, a neuropsychological assessment will be administered following the procedures of the first one.
10123716|NCT04362982|Active Comparator|non-ADHD|Non-ADHD group will follow the same procedures as the experimental one.
10123717|NCT04362592|Experimental|Percutaneous Technique|The percutaneous technique uses endoscopic scopes through the maternal skin and uterus to perform the surgery.
10123718|NCT04362592|Experimental|Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique consists of performing a laparotomy (incision into the abdominal cavity), exteriorizing the uterus, and using endoscopic scopes through the uterus to perform the correction.
10123719|NCT04362943||Complete sample|"Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 in the Perpetuo Socorro Hospital of Albacete (Spain)"
10123720|NCT04362943||Baricitinib|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Baricitinib.
10123721|NCT04362943||Anakinra|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Anakinra.
10123722|NCT04362930||Neurological and psychiatric impact of COVID-19|Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection
10123723|NCT04362930||Impact of Covid-19 in patients with neurological pathology|patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection
10123724|NCT04362683||High Power Atrial Fibrillation Ablation|"In our center, routine medical care for atrial fibrillation ablation includes:~Multidirectional high-density mapping~High power - short duration settings~Contact force sensing ablation catheter"
10183240|NCT03766425|Experimental|Aflibercept|Aflibercept applied intraoperatively as a subconjunctival injection at a dose of 0.05 ml (40 mg / ml) and one week after the operation at the same dose, also subconjunctival.
10183241|NCT03766425|Active Comparator|Mitomycin|Mitomycin applied during a surgery at a concentration of 0.3mg / ml for 3 min. on a soaked sponge.
9827383|NCT02453672|Experimental|SB8|SB8, single dose of 3 mg/kg, IV infusion
10123725|NCT04362917||FDR-|"Adults with a first degree relative with T1D, who have tested negative for islet autoantibodies.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
10123726|NCT04362917||FDR+|"Adolescents and adults with a first or second degree relative with T1D, who has tested positive for at least one islet autoantibody.~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
10123727|NCT04362917||Control|"Adults with no family history of Type 1 Diabetes, who have tested negative for islet autoantibodies~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
10123728|NCT04362735||Study group|All patients using vedolizumab for Crohn's disease as first biologic agent (all patients naive to previous biological therapy)
10123729|NCT04362605|Experimental|intervenional group|ENPT
10123730|NCT04362501|Experimental|dupilumab treatment group|dupilumab treatment group
10123731|NCT04362501|Placebo Comparator|placebo group|placebo group
10123732|NCT04362514|Experimental|IG|Intervention Group
10123733|NCT04362514|Active Comparator|aCG|Control Group
10123734|NCT04362540||Pregnant women with GDM|Ultrasound liver scan in addition to routine foetal assessment (antenatal) Metabolic profile blood tests, Oral Glucose Tolerance Test, ELF blood test, repeat liver ultrasound scan and MRI scan (post partum)
9668994|NCT04404140|Experimental|Ipatasertib + Atezolizumab + Docetaxel|"Part A (Safety Run-In): 12 Participants will be administered Ipatasertib orally once a day [QD] from Day 1 to Day 14 in combination with Atezolizumab administered by intravenous (IV infusion) every 3 weeks (Q3W) on Day 1 of each cycle (a cycle being 21 days) and Docetaxel administered by IV infusion (Q3W) on Day 1 of each cycle. Docetaxel will be administered for a maximum of 10 cycles (approximately 7 months), after which Atezolizumab and Ipatasertib will be administered as a doublet until disease progression. During Part A, a staggered recruitment will be applied to the first and potentially first 6 participants to enrol a participant only once the former one has safely overcome the safety time window (Cycle 1).~Part B (Expansion): 38 Participants will be administered Ipatasertib, Atezolizumab and Docetaxel as described above, though without a staggered enrolment or safety assessment window."
10123735|NCT04362527|Experimental|Milrinone|The patients randomized to this arm will have Milrinone (Laboratoires STRAGEN, France)
10123736|NCT04362527|Placebo Comparator|Placebo|The patients randomized to this arm will have Saline solution
10123737|NCT04362488|Experimental|Patients with chronic post-traumatic lateral ankle instability|"The study population consists in patients affected by chronic post-traumatic lateral ankle instability who must undergo surgical intervention of ankle external ligament reconstruction.~The patients will be analyzed pre and postoperatively using differents tests, questionnaires, instrument and clinical evaluation:~Delos system (computerized oscillating platform)~Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
10123738|NCT04362553||Adults|Adults scheduled to receive a TTE (Trans-esophogeal echocardiogram)
10183242|NCT03766412||School start time 8:30 AM or later|These are high schoolers with migraine who attend a school that begins at 8:30 AM or later (i.e. follows AAP recommendation re: high school start time).
10183243|NCT03766412||School start time earlier than 8:30|These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
10183244|NCT03766399|Experimental|Part 1a (SAD) Cohort 1|6 participants will receive inhaled dose 1 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
10183245|NCT03766399|Experimental|Part 1a (SAD) Cohort 2|6 participants will receive inhaled dose 2 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
10183246|NCT03766399|Experimental|Part 1a (SAD) Cohort 3|6 participants will receive inhaled dose 3 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
10183247|NCT03766399|Experimental|Part 1a (SAD) Cohort 4|6 participants will receive inhaled dose 4 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
10183248|NCT03766399|Placebo Comparator|Part 1a (SAD) Cohort 5|6 participants will receive inhaled dose 5 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
10183249|NCT03766399|Experimental|Part 1a (SAD) Cohort 6|6 participants will receive inhaled dose 6 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
10183250|NCT03766399|Experimental|Part 1b (IV cohort 1)|All 6 participants will receive single IV dose of AZD0449 solution.
10183251|NCT03766399|Experimental|Part 2a (MAD) Cohort 1|6 participants will receive inhaled dose 7 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
10183252|NCT03766399|Experimental|Part 2a (MAD) Cohort 2|6 participants will receive inhaled dose 8 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
10183253|NCT03766399|Experimental|Part 2b (MAD/healthy volunteers) Cohort 3|18 healthy volunteers will receive inhaled dose 9 of AZD0449 nebulized suspension and 12 healthy volunteers will receive inhaled placebo.
10183254|NCT03766399|Experimental|Part 3a (DPI/PoM)|18 participants will receive inhaled dose 10 of AZD0449 DPI and 6 participants will receive inhaled placebo.
10183255|NCT03766399|Experimental|Part 1b (IV cohort 2)|6 healthy volunteers will receive single IV dose of AZD0449 solution.
10183256|NCT03766399|Experimental|Part 3b (DPI/healthy volunteers)|Part 3b is optional. 8 healthy volunteers; 6 volunteers will receive AZD0449 DPI and 2 volunteers will recieve placebo.
10123739|NCT04362384|Experimental|Vitamin E ovules|Endoanal Vitamin E ovules will be prescriped during 14 days
10123740|NCT04362384|Active Comparator|Prednisolone ointment|Endoanal Prednisolone ointment will be prescriped during 14 days
10123741|NCT04362449|Experimental|Shortened hydration time with dispensary of Akynzeo|ABC-02 regime - gemcitabine and cisplatin with a shortened hydration time and administration of a newer antiemetic
10123742|NCT04362449|Active Comparator|Standard of care|ABC-02 regime - gemcitabine and cisplatin with currently approved hydration time and administration of the current choice of antiemetic
10123743|NCT04362397|Experimental|A (first group to receive the intervention)|This arm will receive the attention, care, and self-care training first.
10123744|NCT04362397|Experimental|B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive it after this period.
10123745|NCT04362423||propofol+fNIRS|During data collection, only propofol is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
10123746|NCT04362423||sevoflurane+fNIRS|During data collection, only sevoflurane is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
10123747|NCT04362423||neuro-stimulator+fNIRS|During data collection, we use neuro-stimulator to give the stimulation.
10123748|NCT04362241|Experimental|Dextenza|Sustained release Dexamethasone 0.4mg
10123749|NCT04362241|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate Ophthalmic drops
10123750|NCT04362358|Experimental|7 sessions of the online CBT programme|
10123751|NCT04362358|Active Comparator|Bibliotherapy|
10123752|NCT04362059|Experimental|Treatment Arm|Patients will be administered surfactant via COVSurf Drug Delivery System
10123753|NCT04362059|Active Comparator|Control Arm|Patients shall receive regular Standard of Care treatment
10123754|NCT04362280|Experimental|ReCHARGE|intervention intensity is increased through: the creation of family groups, greater involvement of school staff, separate lessons for females, health screeners will be home and families are invited to a nutrition counseling session with a registered dietitian.
10123755|NCT04362280|Active Comparator|Treatment as Usual (TAU)|PE class as usual which consisted of choice time.
10123756|NCT04361981||Cases|COVID-19 infection patients with a Deep Venous Disease event
10123757|NCT04362215||High AA group|Group 1 consisted of those having an AA level of 3.57-4.16 D (high AA group; those who had near clear vision between 24-28 cm). .
10123758|NCT04362215||Low AA group|Group 2 consisted of those having an AA level of 3.44-3.03 D (low AA group; those who had near clear vision between 29-33 cm)
10123759|NCT04362293|Experimental|Matched Sibling Donor (MSD)|Patients with a suitable HLA matched sibling donor (MSD) will be enrolled on the MSD arm.
10123760|NCT04362293|Experimental|Haploidentical (HAPLO)|Patients without an eligible MSD who have a suitable haploidentical (HAPLO) donor available will be enrolled on the HAPLO arm of the study.
10123761|NCT04362202|Experimental|experimental|8 individual experimental rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
10123762|NCT04362202|Active Comparator|control|8 individual of standard aquatic rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
10123763|NCT04362020|Experimental|Group-1|No anticoagulation
10123764|NCT04362020|Active Comparator|Group-2|ACT-guided anticoagulation
10123765|NCT04362319||Anaesthesiology clinicians|Including Consultants, Specialists and Medical officers serving in the Department of Anaesthesiology and Intensive Care
10123766|NCT04362332|Active Comparator|chloroquine|1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
10123767|NCT04362332|Active Comparator|hydroxychloroquine|2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
10123768|NCT04362332|No Intervention|Supportive care only|3. Supportive care only.
10123769|NCT04362371|Experimental|Ainara|"Ainara is a class II medical device, already marketed in several EU countries. The product is a mucoadhesive moisturising gel for vulvovaginal use, indicated for the relief of symptoms of vaginal atrophy and dryness, and related discomfort. In each packaging there is a tube containing the gel (sterile and viscous with about 87% water) and a syringe-like plastic applicator with cannula and plunger.~Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration)."
10123770|NCT04362033|Experimental|PLR group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PLR arm, patients will be submitted to the PLR maneuver (patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grade) firstly, then PEEP increment maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
10123771|NCT04362033|Experimental|PEEP group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PEEP arm, patients will be submitted to the PEEP maneuver (consisted in increase the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position) firstly, then PLR maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
10123772|NCT04362124|Experimental|vaccine BCG|"A single dose intradermal application of 0.1 ml of between 1 x 105 to 33 x 105 CFU of BCG, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
10123773|NCT04362124|Placebo Comparator|Placebo|"A single dose intradermal application of 0.1ml of normal saline solution, in the deltoid of the non-dominant arm.~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
10123774|NCT04362098|Experimental|Nurse home visits|Nurse home visits biweekly.
10123775|NCT04362098|No Intervention|Usual care|Usual care.
10123776|NCT04362410|Experimental|Tezepelumab: Low dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
10123777|NCT04362410|Experimental|Tezepelumab: Medium dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
10123778|NCT04362410|Experimental|Tezepelumab: High dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
10123779|NCT04362410|Placebo Comparator|Placebo|Placebo single dose subcutaneously injection.
10123780|NCT04361968|Experimental|Animal-assisted placebo condition|Participants receive verbal information that they are receiving an analgesic cream. Additionally, and before getting the dog, participants will get a therapeutic rationale for the presence of the dog.
10123781|NCT04361968|Experimental|Placebo condition|Participants receive verbal information that they are receiving an analgesic cream.
10123782|NCT04361968|Experimental|Dog only condition|Before meeting the dog, participants will get a therapeutic rationale for the presence of the dog.
10123783|NCT04361968|Other|Control condition|Participants in this condition will receive no intervention.
10123784|NCT04361942|Experimental|Experimental|Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline
10123785|NCT04361942|Placebo Comparator|Placebo|Intravenous injection of 100 ml of saline containing no cells
10123786|NCT04361916|Experimental|home care with active monitoring|home care with active monitoring conducted by health workers with daily visit to patients.
10123787|NCT04361773|Active Comparator|Photobiomodulation group|In this group, PBM will be applied daily using LED devices until the lesion presents healthy granulation tissue, absence of necrosis and purulent secretion and, therefore, is suitable for primary closure, closure by flap or graft or for healing by second intention. At this point, the protocol will be finalized.
10123788|NCT04361773|Sham Comparator|Sham group|Sham group participants will receive the application of the disconnected device, for the same period. The characteristic sound of the device will be activated by means of recording.
10123789|NCT04361760|Experimental|Healthy younger participants (20-30y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
10123790|NCT04361760|Experimental|Healthy older participants (65-75y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
10123791|NCT04361825|Experimental|Durvalumab(MEDI4736) and AZD6738 combination|
10123792|NCT04361734||Juvenile onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
10123793|NCT04361734||Adult onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
10123794|NCT04361734||Matching healthy volunteers|Healthy volunteers, matched by age and gender, will be used as a control group
10123795|NCT04361708|Experimental|High Risk UGT1A1 genotype|
10123796|NCT04361708|Experimental|Intermediate Risk UGT1A1 genotype|
10123797|NCT04361708|Experimental|Low Risk UGT1A1 genotype|
10123798|NCT04361695|Active Comparator|Ketoprophenum|A tablet with 10 mg Ketoprophenum is taken per os 2 hours before surgery
10123799|NCT04361695|Placebo Comparator|Placebo|A tablet containing starch is taken per os 2 hours before surgery
10123800|NCT04361552|Experimental|Arm I (tocilizumab, standard of care)|Patients receive tocilizumab IV every 12 hours for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care.
10123801|NCT04361552|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
10123802|NCT04361721||Chronic migraine patients|Three monthly administration of erenumab 70 mg subcutaneously.
10123803|NCT04361747|Experimental|nursing counseling intervention|The nursing counseling intervention was implemented by a maternity nursing instructor. During the 12-week prenatal genetic testing evaluation period, experimental-group participants received three nursing consultation sessions plus regular care, while their control-group peers received regular care only. The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
10123804|NCT04361747|No Intervention|control group|control group participants received regular care only
10123805|NCT04361526|No Intervention|Control|standard intensive care alone
10123806|NCT04361526|Experimental|Cytokine Adsorption|cytokine adsorption plus standard intensive care
10123807|NCT04361630|Experimental|Main treatment group|Collagen membranes incorporating 10ng/ml human recombinant basic fibroblast growth factor (FGF-2/bFGF) will be placed in the sites.
10123808|NCT04361604||250 Patients co infected HIV and SRAS-CoV2|Cohort of Patient co infected HIV AND SRAS-CoV2
10123809|NCT04361604||20 patients infected HIV without COVID-19|Group of 20 comparative patients PLWHIV without COVID-19. This group will realise only the interview of the research.
10123810|NCT04361578||Patients|All patients enrolled in the study will be in this group.
10123811|NCT04361903||Patients treated with ruxolutinib|SARS-CoV-2 COVID-19 patients with rapid worsening of respiratory parameters in the last 12 hours treated with ruxolutinib, dosage of at least 20 mg x 2 / day in the first 48 hours.
10123812|NCT04361812|Experimental|HS632|HS632 150mg for a single subcutaneous injection
10123813|NCT04361812|Active Comparator|Omalizumab (Xolair®)|Omalizumab 150mg for a single subcutaneous injection
10123814|NCT04361643|Experimental|Experimental|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
10123815|NCT04361643|Placebo Comparator|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3, and 5.
10123816|NCT04361513|Active Comparator|Nerve block group|3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.
10123817|NCT04361513|Other|intra-articular steroid injection|1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.
10123818|NCT04361890|Other|Women with predominant SUI|All women with predominant SUI will be referred to a physiotherapist for PFMT as usually. They will have an ultrasound evaluation before and after the session
10123819|NCT04361591||COVID-19|Liver Transplant recipients
10123820|NCT04361448|Other|Health Care Workers with Covid-19 symptoms|3 samples (2 nasopharyngeasl swabs, 1 oropharyngeal swab) willl be taken from each volunteer
10123821|NCT04361487||Horizontal Cleavage Meniscal Tear|Participants with horizontal cleavage meniscal tears
10123822|NCT04361487||Complex Meniscal Tear|Participants with complex meniscal tears
10123823|NCT04361500||COVID-19 patients with Seraph 100 therapy|
10123824|NCT04361110||Acute intestinal ischaemia|Abdominal CT scan within 48 hours preoperative.
10123825|NCT04361110||Controls|Abdominal CT scan within 48 hours preoperative.
10123826|NCT04361175|Experimental|letrozole group|letrozole group, Patients will receive 5 mg of letrozole oral tablets daily from day 2 of the cycle for 5 days for three successive cycles
10123827|NCT04361175|Experimental|Clomiphene Citrate group|Clomiphene Citrate group, Patients will receive 100 mg : Clomiphene Citrate daily starting on cycle day 2 for 5 days for three successive cycles
10123828|NCT04361461|Experimental|Group 1|Hydroxychloroquine (400 mg)
10123829|NCT04361461|Experimental|Group 2|Hydroxychloroquine (400 mg) + azithromycin (500 mg)
10123830|NCT04361279|Experimental|SIBP-02|"Biological: SIBP-02, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.~Treatment cycle: 6 cycles, each cycle is 3 weeks."
10123831|NCT04361279|Active Comparator|Rituximab|"Biological: Rituximab, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.~Treatment cycle: 6 cycles, each cycle is 3 weeks."
10123832|NCT04361188|Experimental|MAC anesthesia group|Parkinson's disease patients receiving deep brain stimulation under MAC anesthesia.
10123833|NCT04361188|Active Comparator|AAA anesthesia group|Parkinson's disease patients receiving deep brain stimulation under AAA anesthesia.
10123834|NCT04361084|Active Comparator|traditional training|Participants will undertake the Community simulation using traditional methods, physical items to recreate the community environment. Training will be in pairs and will play the role of their own profession when undertaking simulated scenarios. Medium to low fidelity traditional simulation techniques involving scenarios played out using actors as (standardised patients) to participants. Following a briefing, the participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results and are anonymous. They will also complete their pre-questionnaire which will anonymous. Afterwards participants undertake a post-questionnaire and then asked if they wish to take part in a semi-structured interview.
10123835|NCT04361084|Experimental|mixed reality simulation training|Participants will undertake a mixed reality (MR) simulation training session set in two home situations; involving immersive virtual reality equipment. Participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results. The participants will then undertake the simulation watched via live camera by the simulation technician, simulation fellow and a community specialist. Participants will undertake a post simulation questionnaire and then asked if they wish to take part in a semi-structured interview (optional).
10123836|NCT04361435|Other|NIOD first|In this arm, we will apply for NIOD first which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses. This arm of patients will receive standard CPT at least 3 hours after the NIOD intervention.
10123837|NCT04361435|Other|CPT first|In this arm, we will apply for CPT first which will be performed by physiotherapists. This arm of patients will receive NIOD procedures which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses at least 3 hours after the CPT intervention.
9827384|NCT02453672|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
10123838|NCT04361422|Active Comparator|Isotretinoin|13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally for one month
10123839|NCT04361422|Sham Comparator|Standard COVID-19 therapy|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases
10123840|NCT04361422|Active Comparator|Standard COVID-19 therapy+ isotretinoin|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) plus 13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally forone month.
10123841|NCT04361201||Ligament plastic surgery ankle|Patient treated priorly by ligament plastic surgery of lateral ankle plane under arthroscopy
10123842|NCT04361201||Control group|Controlateral ankle
10123843|NCT04361097|Experimental|Faecal microbiota transplant|This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
10123844|NCT04361097|Placebo Comparator|Placebo|This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
10123845|NCT04361292|Active Comparator|Group A: one day abstinence period|Patients allocated into group A had an ejaculatory abstinence period of one day
10123846|NCT04361292|Active Comparator|Group B: three days abstinence period|Patients allocated into group B had an ejaculatory abstinence period of three days
10123847|NCT04361331|Other|Toripalimab combined with lenvatinib|"Toripalimab: 240 mg, intravenous infusion, Q3W;~Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd;"
10123848|NCT04361331|Other|Lenvatinib combined with gemox|"Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd~Gemox chemotherapy D1: Oxaliplatin 85mg / m2, Gemcitabine 1g / m2 D8: Gemcitabine 1g / m2 Three weeks are a course, a total of 6-8 courses"
10123849|NCT04361214|Experimental|Leflunomide|"Leflunomide 300 mg once daily administered for three days followed by 30 mg once daily administered for two days or until fevers abate (maximum ten days of treatment allowed).~If patients report symptoms attributed to the medication, the dose will be administered at 50 mg once daily for the loading dose followed by 20 mg once daily."
10123850|NCT04361305|Experimental|tadalafil combined with dapoxetine|
10123851|NCT04361305|Active Comparator|tadalafil mono group|
10123852|NCT04361383|Placebo Comparator|Control group|patients will be operated under general anesthesia.
10123853|NCT04361383|Active Comparator|QLB group|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
10123854|NCT04361383|Active Comparator|ESPB group|patients will receive ultrasound-guided erector spinae plane block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
10123855|NCT04361071|Active Comparator|Stent|Stent group
10123856|NCT04361071|Active Comparator|Atherectomy|Atherectomy group
10123857|NCT04361370|Experimental|Treatment group|BRCA mutation wild type, non-mucinous , platinum-sensitive recurrent ovarian cancer
10123858|NCT04361318|Experimental|Hydroxychloroquine plus Nitazoxanide|200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days
10123859|NCT04361318|Active Comparator|Standard care|Standard care delivered in the COVID-19 isolation hospitals.
10123860|NCT04361149|Placebo Comparator|Placebo Topical|The cream was a lipobase cream, applied topically to the participants upper back, on their left side.
10123861|NCT04361149|Active Comparator|Capsaicin Topical|Capsaicin Cream (0.075%), applied topically to the participants upper back, on their left side.
10123862|NCT04361357|Experimental|Experimental group|whey protein powder was added on the basis of standardized enteral nutrition preparation.
10123863|NCT04361357|No Intervention|Control group|standardized enteral nutrition preparation only.
10123864|NCT04361253|Experimental|Arm A|Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.
10123865|NCT04361253|Placebo Comparator|Arm B|Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)
10123866|NCT04361136|Experimental|Delgocitinib cream 1 mg/g|Single topical occlusive administration
10123867|NCT04361136|Experimental|Delgocitinib cream 3 mg/g|Single topical occlusive administration
10123868|NCT04361136|Experimental|Delgocitinib cream 8 mg/g|Single topical occlusive administration
10123869|NCT04361136|Experimental|Delgocitinib cream 20 mg/g|Single topical occlusive administration
10123870|NCT04361136|Placebo Comparator|Delgocitinib cream vehicle|Single topical occlusive administration
10123871|NCT04361474|Experimental|Experimental group|Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
10123872|NCT04361474|Placebo Comparator|Control group|Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory re-education twice a day.
10123873|NCT04361058|Experimental|Arm A - HLA-matched unrelated donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with an HLA-matched unrelated donor will be separated into Arm A and treated with Nivolumab post-SCT
10123874|NCT04361058|Experimental|Arm B - HLA-haploidentical donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with a HLA-haploidentical donor will be separated into Arm B and treated with Nivolumab post-SCT
10123875|NCT04360915|Experimental|ASK120067 in fast condition|Take ASK120067 tablets orally once in the first day at 160mg in fast condition.
10123876|NCT04360915|Experimental|ASK120067 in fed condition|Take ASK120067 tablets orally once in the first day at 160mg in fed condition.
10123877|NCT04360746|Active Comparator|Clinical pharmacist intervention group|"all hip fractured patients admitted to D1 subunit in Beit rivka geriatric rehabilitation center. This group will get a clinical pharmacist review of their medication and a pharmaceutical counseling to the medical staff in the first few days of admission (1-5 days post admission)"
10123878|NCT04360746|Other|control group|"The control group will include all hip fractured patients admitted to D2 subunit in Beit rivka geriatric rehabilitation center. This group will not receive any pharmacist intervention during their rehabilitation."
10123879|NCT04360733||asymptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR but no clinical symptoms
10123880|NCT04360733||symptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR and light clinical symptoms
10123881|NCT04360733||severe Covid-19|Patients with confirmed SARS-CoV2 PCR and severe clinical symptoms with ICU admission
10123882|NCT04360733||healthy controls|Persons with negative SARS-CoV2 PCR
10123883|NCT04361409|Experimental|Rituximab plus chemotherapy|"Drug:Rituximab~Drug:Cisplatin~Drug:Gemcitabine"
10123884|NCT04360902|No Intervention|Standard of Care Group|Subjects in the standard of care group will continue to receive anemia management in the same way they normally do as part of their routine dialysis care. For the purposes of this study, this means the use of the clinic's established Mircera® anemia management algorithm. Participation in this study will not affect the anemia management of subjects in the control group.
10123885|NCT04360902|Experimental|Intervention Group|"For subjects randomized into the intervention group, our erythropoiesis model will be used to identify each subject's individual values for several physiological determinants of erythropoiesis based on his/her sex, body height and history of body weights, Hgb concentrations and Mircera® administrations over the preceding 150 to 180 days.~For subjects in the intervention group, their current method of anemia management will be discontinued. From this point on, Mircera® dose recommendations will be generated by the Anemia Controller software based on our erythropoiesis model and each subject for the duration of their 26-week participation in this study. The Anemia Controller computes the Mircera® doses required to attain the target Hgb level of 10.5 g/dL. Controller-generated Mircera® recommendations will be communicated to the respective clinics' anemia managers on a standardized report."
10123886|NCT04361162|Experimental|Nivolumab + Ipilimumab + Radiation|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, (Study cycles are 6 weeks.)~Nivolumab via iv, at predetermined dose every 2 weeks for duration of study.~Ipilimumab via iv at a predetermined dose on day 1 of 4 study cycles.~Radiation treatments will be administered every other weekday or 2 days during week 1 of cycle 1."
10123887|NCT04360759|Experimental|Arm 1: Chloroquine or hydroxychloroquine|Loading dose of 4 tablets (150 mg chloroquine base per chloroquine salt tablet; 155 mg chloroquine base per hydroxychloroquine tablet) at time 0 and 6 hours, followed by a maintenance dose of 2 tablets at time 12 hours, and then twice daily for a total of 7 days.
10123888|NCT04360759|No Intervention|Arm 2: Standard of care|This does not include specific therapy under current guidelines.
10123889|NCT04360954||Acute COVID infection|Active infection with positive RT-PCR
10123890|NCT04360954||Convalescent COVID|Recent documented infection. Now asymptomatic and RT-PCR negative.
10123891|NCT04360954||US Controls|Human samples pre-COVID.
10123892|NCT04360954||LMIC Controls|Samples from LMIC pre-COVID.
10123893|NCT04361032|Experimental|Tocilizumab|ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)
10123894|NCT04361032|Active Comparator|Deferoxamine|DESFERAL: 500 mg, powder, and solvent for IV solution
10123895|NCT04360967|Experimental|Randomized Standard Formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
10123896|NCT04360967|Experimental|Randomized Nutrient-enriched formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
10123897|NCT04360967|No Intervention|Non-randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
10123898|NCT04360967|No Intervention|Non-Randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
10123899|NCT04360993||Patients underwent PET/CT & PET/MRI|Patients with head and neck cancer were underwent PET/CT and PET/MRI for staging, assessment and follow up
10123900|NCT04360941|Experimental|Two-part phase 1b trial of induction palbociclib with avelumab|"Recruitment to Part A will be conducted at the Royal Marsden Hospital only. Up to 18 patients will be recruited for dose escalation of palbociclib in combination with fixed dose avelumab.~Part B will recruit at up to 8 high volume centres. Up to 27 patients will be recruited to treatment with the maximum tolerated dose and schedule established in part A. In Part B of the study, additional selection by triple negative histology and positive androgen receptor status will define the study population."
10123901|NCT04360694|Experimental|Incremental hemodialysis|Procedure: Incremental hemodialysis. It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
10123902|NCT04360694|Active Comparator|Conventional hemodialysis|Procedure: Conventional hemodialysis. It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
10123903|NCT04360824|Active Comparator|Standard of Care|1) Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30kg/m2).
10123904|NCT04360824|Other|Interventional|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
9967138|NCT01266941|Experimental|Matched healthy volunteers|Once a moderate subject has been recruited, a healthy control subject should be recruited (matched to the moderate subject on gender, ethnicity, body mass index +/-15%, age +/-5 years). In total there will be 9 matched healthy volunteers 1 for each subject with moderate hepatic impairment.
10123905|NCT04360863||Youth smokers|Participants of Youth Quitline
10123906|NCT04360889|Experimental|Tocopherol|patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days
10123907|NCT04360889|Experimental|Micronised purified flavonoid fraction|patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days
10123908|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema who will be treated with elastic compression - 90 days
10123909|NCT04360889|No Intervention|Healthy volunteers|healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days
10123910|NCT04360798|Experimental|Unilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will only be applied to the affected lower extremities of the participants.
9519522|NCT03286335|Experimental|Proton Radiation|"Radiation therapy will be delivered typically five (5) days per week on weekdays~Proton Radiation dose be determine by histology"
9519523|NCT03286322|Experimental|manual therapy cervical spine|
10123911|NCT04360798|Experimental|Bilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will be applied to the both lower extremities of the participants.
10123912|NCT04361006|Active Comparator|Radiofrequency (RF)|Twenty patients will be allocated to this group, which will be treated using radiofrequency (RF) ablation technique.
10123913|NCT04361006|Active Comparator|Cryotherapy (CRYO)|Twenty patients will be allocated to this group, which will be treated using Cryotherapy (CRYO) ablation technique.
10123914|NCT04360668|Experimental|Muscle Energy Technique combined with Trigger Point Therapy|For this group of participants, combined therapy (Muscle Energy Technique with Trigger Point Therapy) will be used
10123915|NCT04360668|Active Comparator|Muscle Energy Technique|For this group of participants, a single method (Muscle Energy Technique) will be used
10123916|NCT04360668|Active Comparator|Trigger Point Therapy|For this group of participants, a single method (Trigger Point Therapy) will be used
10123917|NCT04360785|Experimental|Methotrexate + Adalimumab|Experimental group : patients will receive 2 subcutaneous injections of methotrexate in addition of the usual adalimumab
10123918|NCT04360785|No Intervention|Adalimumab|Reference group : patient will receive adalimumab as usual to treat spondyloarthritis
10123919|NCT04360655|Active Comparator|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
10123920|NCT04360655|Experimental|combined with bronchoscopic microwave intervention|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
10123921|NCT04360642|Other|singing arm|"Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.~Lung function, frailty and health-related quality of life will be assessed by Spirometry, CRQ (chronic respiratory questionnaire), MRC breathlessness scale, Rockwood frailty and Warwick-Edinburgh Mental Well-being Scale (WEMWBS). Participants will be assessed at baseline and then again at completion of the 12-week course.~Written feedback from participants to capture qualitative experience using narrative and Patient Reported Outcome Measures (PROMs). The attrition and attendance rate will also be recorded for later review."
10123922|NCT04360577|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
10123923|NCT04360577|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
10123924|NCT04360577|No Intervention|Usual care|Chemotherapy without acupuncture
10123925|NCT04360603|Experimental|27 gauge system|study group, using 27G vitrectomy system
10123926|NCT04360603|Active Comparator|25 gauge system|control group, using 25G vitrectomy system
10123927|NCT04360564||Recurrent pregnancy loss|All women with >/=2 pregnancy loss before 20 weeks gestational age
10123928|NCT04360564||Primary recurrent pregnancy loss|Primary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age before the first birth
10123929|NCT04360564||Secondary recurrent pregnancy loss|Secondary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age occurring after the first birth
10123930|NCT04360564||No history of recurrent pregnancy loss|Those with 0 or 1 previous spontaneous pregnancy loss.
10183257|NCT03766386||Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are currently alive (including patients who may or may not have undergone heart transplantation).
10183258|NCT03766386||Deceased Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are deceased (including patients who may or may not have undergone heart transplantation).
10183259|NCT03766360|Experimental|FAP Intervention Group|All of the clients in the FAP intervention group will begin treatment at the same time and complete 3 assessments.
9967139|NCT01266941|Experimental|Severe Hepatic Impairment|Severe subjects will not be enrolled into the study until 9 moderate subjects and their matched control subjects have completed the study and the safety and PK data have been reviewed.
9967140|NCT01266954|Experimental|Stage 1|Three to six patients on a medium dose of GSK2141795 for four weeks
9967141|NCT01266954|Experimental|Stage 2|Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks
10183260|NCT03766360|No Intervention|Control Group|The clients in the control group will take their assessments at the same time as those in the FAP intervention group.
10183261|NCT03766334|Experimental|Diabetes Diet+Highland Barley Diet|Diabetes Diet+Highland Barley Diet(20g, thrice-daily)
10183262|NCT03766334|No Intervention|Diabetes Diet|only Diabetes Diet
10183263|NCT03766308|Experimental|Highland barley diet|highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)
10183264|NCT03766308|Active Comparator|ADA diet|ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)
10183265|NCT03766282||Animal study|Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.
10183266|NCT03766282||Clinical study|To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.
10183267|NCT03766269|Other|Baseline Opioid|One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
10183268|NCT03766256|Experimental|Shared decision-making with pharmacists|Pharmacist-coordinated shared decision making about treatment for history of gestational diabetes mellitus (lifestyle change and/or metformin), using a decision tool
10183269|NCT03766243|Experimental|Brochure and DVD plus nursing training|"In addition to the control intervention, see below, the experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. The nurse provided theoretical explanations on the exercises, watched the explanatory DVD with the patients, answering questions and commenting relevant points, and then had the patients repeat the exercises in front of a mirror under direct observation, so that any errors could be pointed out and corrected."
10123931|NCT04360343|Experimental|LC51-0255 film-coated tablet|Drug: LC51-0255
10123932|NCT04360343|Active Comparator|LC51-0255 uncoated tablet|Drug: LC51-0255
10123933|NCT04360317|Experimental|Experimental group|
10123934|NCT04360408|Experimental|Intervention|Participant of the cluster randomised to the intervention group will receive both the usual care from their healthcare providers and EVEREST delivered by the researcher who is a nurse.
10123935|NCT04360408|No Intervention|Control|Participants of the cluster randomised to the control group will receive usual care (standard care with no formalised, structured or tailored interventional to reduce symptom/s) from their healthcare providers
10123936|NCT04360525||Elderly patients|Elderly patients (60≤ age) with sigmoid volvulus
10123937|NCT04360525||Young patients|Young patients (<60 age) with sigmoid volvulus
10123938|NCT04360291||Healthy volunteers|Healthy volunteers
10123939|NCT04360291||Retinopathy pigment|Patients with retinopathy pigment
10123940|NCT04360551|Experimental|Telmisartan|Telmisartan 40 mg po daily x 21 days
10123941|NCT04360551|Placebo Comparator|Placebo|Placebo
10123942|NCT04360421|Experimental|Intraoperative liposomal bupivacaine field block|Patients will receive the maximum dosage of liposomal bupivacaine allowed for their body weight or the full vial, whichever is less. Injected once, along the incision before closure of the skin.
10123943|NCT04360538||COVID19 positive|ICU patients coronavirus positive
10123944|NCT04360538||non-COVID19|ICU patients without coronavirus
10123945|NCT04360304|Experimental|Study group|
10123946|NCT04360382||Enhanced recovery|"Part I: Preoperative evaluation and preparation:~Part II: Postoperative daily intervention:~Part III: Expected daily outcome :~Phase three: Implementing enhanced recovery program:~The established pathway will implement on the study group by researcher from admission till discharge as conventional care group assessment in phase one.~Phase four: Evaluating enhanced recovery program outcomes:~The efficacy of enhanced recovery program will be determined by comparing outcomes for patients of both control and study groups"
10123947|NCT04360382||Regular care|usual care for all cases of cesarean section at our hospital.
10123948|NCT04360447|Experimental|Reformer pilates group|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
10123949|NCT04360447|Active Comparator|Home exercise group|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
10123950|NCT04360512|Experimental|One session|One session of talus posteriorization
10123951|NCT04360512|Experimental|Two sessions|Two sessions of talus posteriorization
10123952|NCT04360512|Experimental|Three sessions|Three sessions of talus posteriorization
10123953|NCT04360512|Experimental|Four sessions|Four sessions of talus posteriorization
10123954|NCT04360239|Experimental|Fish Oil|Fish-Oil naïve subjects will be started on fish oil 4 weeks prior to surgery and continued until the 6 week follow up. Subjects already taking fish oil will be switched to the study fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
10123955|NCT04360239|No Intervention|Control|No fish oil supplementation
10123956|NCT04360200||Normal Aging|Normal Aging with normal cognitive function
10123957|NCT04360200||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
10123958|NCT04359914||NCoV-A-COVID|"adult patients of every age~admission to hospital with suspected COVID-19 disease~confirmed SARS-CoV-2 infection within 48 hours after admission"
10123959|NCT04359914||NCoV-A-CONTROL|"adult patients of every age~admission to hospital with suspected COVID-19 disease~exclusion of SARS-CoV-2 infection within 48 hours after admission"
10123960|NCT04359914||NCoV-P-COVID|"pediatric patients~admission to hospital with suspected COVID-19 disease~confirmed SARS-CoV-2 infection within 48 hours after admission"
10123961|NCT04359914||NCoV-P-CONTROL|"pediatric patient~admission to hospital with suspected COVID-19 disease~exclusion of SARS-CoV-2 infection within 48 hours after admission"
10123962|NCT04359875|Experimental|Management by a student/general practitioner tandem|Patients will receive a phone call from the medical student who will inquire about their health. The medical student will then transmit this information to the general practitioner who will decide on the most suitable management for the patient.
10123963|NCT04359875|No Intervention|Usual care|"Usual care, i.e. patients will call their general practitioner when needed, up to 1 month, which corresponds to the estimated time for the intervention to be delivered to all patients in the intervention group.~At the end of the intervention at 1 month, patients in the usual care group will also receive a phone-call from the medical student/general practitioner tandem."
10123964|NCT04360057|Other|Hand Hygiene education|
10123965|NCT04360083||Overweight and obese children|Overweight and obese children included in RéPPOP care programs between 2007 and 2010.
10123966|NCT04359927||SARS-CoV2/Covid-19 (cases)|Patients with detectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
10123967|NCT04359927||No SARS-CoV2/Covid-19 (controls)|Patients with undetectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
10123968|NCT04359901|Active Comparator|Standard of care plus subcutaneous sarilumab|Standard of care as directed by the treating clinicians, plus sarilumab 400 mg subcutaneous injection. Sarilumab is provided in prefilled syringes/pens containing 200 mg each as is used clinically, and both injections will be given as soon as is convenient after the patient has decided to enroll.
10123969|NCT04359901|No Intervention|Standard of care|Standard of care as directed by the treating clinicians.
10123970|NCT04359979|Experimental|tamsulosin treatment|patients will receive 0.4mg/day of Tamsulosin tablet for 3 months
10123971|NCT04359953|Experimental|Hydroxychloroquine|Patient will take 200mg of Hydroxychloroquine twice a day during 14 days
10123972|NCT04359953|Experimental|Azithromycin|Patient will take 250mg of Azithromycin twice a day during 14 days
10123973|NCT04359953|Experimental|Telmisartan|Patient will take 40mg of Telmisartan twice a day during 14 days
10123974|NCT04359953|No Intervention|Usual Care|No intervention
10123975|NCT04360161|Experimental|Healthy participants|Swept-source optical coherence tomography A device testing TM/SC and Lens morphology
10123976|NCT04359940||Repaired Tetralogy of Fallot|Patients undergoing routine clinical aand CMR surveillance
10123977|NCT04360174|Experimental|OTX-TIC-Cohort 1|15 µg (formulation1) implant
9967142|NCT01266980|Experimental|Severe Renal Imparement|Nine subjects with severe renal impairment (as defined by a Clcr<30mL/min) will be recruited for this study. they will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
9967143|NCT01266980|Experimental|Matched healthy volunteers|For each of the 9 renally impaired subjects a healthy control subject (as defined by a Clcr>80mL/min matched to the severe subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)) will be recuited. They will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
9967144|NCT01267006|Placebo Comparator|Placebo|Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule.
9967145|NCT01267006|Experimental|GSK1325756 200 mg|Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
9967146|NCT01267006|Experimental|GSK1325756 50 mg|Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
9967147|NCT01267006|Experimental|GSK1325756 100 mg|Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule.
9967148|NCT01267032|Experimental|Arm 1|Integrated Care + Cognitive-Behavioral Treatment for Insomnia
9967149|NCT01267032|Sham Comparator|Arm 2|Integrated Care + Desensitization Treatment for Insomnia
9967150|NCT01267058|Experimental|Group A|Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
9967151|NCT01267058|Active Comparator|Group B|Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
9967152|NCT01267058|Active Comparator|Group C|Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
9967153|NCT01267071|Experimental|A|GSK962040 (50 mg, SD, oral)
9967154|NCT01267071|Experimental|B|14C GSK962040 (100 μg, SD, iv)
9967155|NCT01267084|Experimental|Part 1|Patients will receive trabectedin+ketoconazole followed by trabectedin alone. Each cycle will be will be separated by 21 days. Patients will receive 6 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
9967156|NCT01267084|Experimental|Part 2|Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole. Each cycle will be separated by 21 days. Patients will receive 15 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
9967157|NCT01267097|Experimental|Cognitive Behavioural Therapy (CBT)|Group-based lifestyle counseling for parents
9967158|NCT01267097|Experimental|Psycho-Education Program (PEP)|Group-based lifestyle counseling for parents
9967159|NCT01267110|Experimental|Intervention|
9967160|NCT01267110|Active Comparator|Control|
9967161|NCT01267123|Experimental|Trendelenburg position|The endoscopist places the patient in 15° Trendelenberg position immediately prior to the initiation of the colonoscopy.
9967162|NCT01267123|Other|Standard care|The patient will have colonoscopy in the standard horizontal position
10123978|NCT04360174|Experimental|OTX-TIC-Cohort 2|26 µg (formulation1) implant
10123979|NCT04360174|Experimental|OTX-TIC-Cohort 3|15 µg (formulation 2) implant
9967163|NCT01267162||TDF Treatment|
9967164|NCT01267188|Experimental|NBI-98854|Open-label, dose titration of active drug
9967165|NCT01267214|Experimental|Osteotomy plus Hyalgan|Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
9967166|NCT01267214|Other|Osteotomy alone|
9967167|NCT01267305|Active Comparator|lung lmwh1|use LMWH once daily after lung resection
9967168|NCT01267305|Experimental|lung lmwh2|use LMWH twice daily after lung resection
9967169|NCT01267305|Experimental|lung Fondaparinux|use Fondaparinux once daily after lung resection
9967170|NCT01267305|Active Comparator|eso lmwh1|use LMWH once daily after esophagectomy
9967171|NCT01267305|Experimental|eso lmwh2|use LMWH twice daily after esophagectomy
9967172|NCT01267305|Experimental|eso Fondaparinux|use Fondaparinux once daily after esophagectomy
9967173|NCT01267331|Experimental|stem cells injection|Direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG
9967174|NCT01267331|Placebo Comparator|palcebo intramyocardial injection|Direct intramyocardial injection of placebo containing saline and 5% human serum albumin during CABG.
9967175|NCT01267344|Active Comparator|GEMOX|Intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks.
9967176|NCT01267344|Experimental|E-GEMOX|Arm A will receive E-GEMOX with additional intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above.
9967177|NCT01267357||Serous papillary endometrial ca patients|30 patients diagnosed with SP endometrial ca
9967178|NCT01267357||Endometrioid endometrial ca|32 patients diagnosed with Endometrioid endometrial ca
9967179|NCT01267370|Active Comparator|Soy polysaccharide fiber|Dietary fiber for treatment of chronic constipation in children
9967180|NCT01267370|Placebo Comparator|purified soy extract, with no fiber)|blinded control group
9967181|NCT01267383|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
9967182|NCT01267383|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
9967183|NCT01267396|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
9967184|NCT01267396|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
9967185|NCT01267435|Other|determining correct tunnel positions|
10123980|NCT04360174|Experimental|OTX-TIC-Cohort 4|5 µg (formulation 3) implant
10123981|NCT04359966|Active Comparator|First line therapy for H pylori infection|Tripple 14 day first line therapy Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID 14 days
10123982|NCT04359966|Experimental|First line therapy for H pylori infection second arm|"Bismuth quadruple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
10123983|NCT04359966|Active Comparator|Second line therapy for H pylori infection|"Bismuth quadruple second line therapy for those treated with Tripple first line therapy~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
10123984|NCT04359966|Experimental|Second line therapy for H pylori infection second arm|"Tripple second line therapy~Esomeprazol 40 mg BID Amoxicillin 1000 mg BID, Levofloxacin 500 mg OID, 14 days or"
10123985|NCT04360148|Experimental|Very-low-calorie-ketogenic-diet|Very-low-calorie-ketogenic-diet (VLCKD) for 12 weeks; hypocaloric-balanced-diet (HBD)
10123986|NCT04360148|Active Comparator|Hypocaloric-balanced-diet|Hypocaloric-balanced-diet (HBD)
10123987|NCT04360187|Experimental|Crisaborole ointment|Crisaborole ointment application twice daily for 28 days
10123988|NCT04360187|Placebo Comparator|Crisaborole Placebo Vehicle|Vehicle Ointment application twice daily for 28 days
10123989|NCT04359862|Experimental|SEVOFLURANE Group|
10123990|NCT04359862|Active Comparator|PROPOFOL Group|
10123991|NCT04360031||Tacrolimus / Mycophenolate Mofetil|All patients receive maintenance immunosuppressive treatment of tacrolimus in combination with Mycophenolate Mofetil.
10123992|NCT04360122|Active Comparator|Levamisole|Oral Levamisole 150 mg/day for two days per week for two months
10123993|NCT04360122|Active Comparator|Isoprinosine|Oral Isoprinosine 1 g 3 times per day daily for two months
10123994|NCT04360122|Active Comparator|Levamisole and Isoprinosine|Oral Levamisole 150 mg/day for two days per week and Oral Isoprinosine 1 g 3 times per day daily for two months
10123995|NCT04360122|No Intervention|Non-interventional group|No-intervention
10123996|NCT04360135|Experimental|Preemptive acetominophen|Acetaminophen 975mg BID the day before surgery and again 30-60 minutes preoperatively
10123997|NCT04360135|Placebo Comparator|Standard of care|Placebo the day before surgery and acetaminophen 30-60 minutes preoperatively
10123998|NCT04361045|Experimental|Intervention Condition|Participants in this condition were delivered 8 weeks of online intervention modules and then were invited to complete a posttest survey.
10123999|NCT04361045|No Intervention|Waitlist Condition|Participants in this condition received no intervention content nor communications for 8 weeks and then were invited to complete a posttest survey.
10124000|NCT04360356|Experimental|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
10124001|NCT04360356|Active Comparator|Standard care|Oxygen via ventilators
10124002|NCT04360499|Experimental|Low-weight-high-repetitions training|Low-weight-high-repetitions (LWHR) refer to a specific form of resistance exercise which utilizes low weights and very high repetitions. Participants will be exercised 3 times per week for 3 months in small groups.
10124003|NCT04360499|Active Comparator|Pilates Training|Pilates exercises focused on breathing, concentration, control and precision. Participants will be exercised 3 times per week for 3 months in small groups
10124004|NCT04360876|Experimental|Dexamethasone|Patients assigned to the dexamethasone arm will receive an intravenous dose of 20 mg once daily from day 1 to day 5 which will be reduced to 10mg once daily from day 6 to day 10. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The time from randomization to time for first medication administration will be 4 hours or less. All infusions - dexamethasone and placebo - will be manufactured by the investigational pharmacy at the University of Colorado.
10124005|NCT04360876|Placebo Comparator|Placebo|Participants randomized to the control group will received placebo intravenously for 10 days, one dose per day. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The placebo infusion bags will be as similar as possible to the dexamethasone infusion bags to ensure blinding.
10124006|NCT04359589||Acute myocardial infarction (AMI) group|"700 patients with AMI;several demographics, clinical and analytical parameters were collected, and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cardiovascular disease of different severity. Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute ischemic cardiovascular diseases."
10124007|NCT04359589||Acute ischemic stroke group|"500 patients with acute ischemic; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cerebrovascular disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
10124008|NCT04359589||Acute lower limb ischemia group|"500 patients with acute lower limb ischemia; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in lower limb ischemia disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of lower limb ischemia disease with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
10124009|NCT04359589||Control group|200 healthy volunteers were included as controls
10124010|NCT04359628||BOA|Patients with osteoarthritis registered in the Better BOA register
10124011|NCT04359628||Swedankle|Patients who underwent ankle replacement, fusion or osteotomies and registered in the Swedish ankle registry
10124012|NCT04359628||xBase|Patients with cruciate ligament injuries who received surgical treatment and were registered in the Anterior Cruciate Ligament Register
10124013|NCT04359628||SFR|Patients who received treatment in the Swedish Fracture Register
10124014|NCT04359628||SHAR|Patients who underwent hip replacement therapy and registered in the Swedish Hip Arthroplasty Register
10124015|NCT04359628||SKAR|Patients with knee osteoarthritis and other diagnoses who underwent knee replacement or osteotomies and were registered in the Swedish Knee Arthroplasty Register
10124016|NCT04359628||Bipolär|Patients with Bipolar disorder receiving treatment and were registered in the Swedish National Register for Bipolar Disorder
10124017|NCT04359628||Swedevox|Patients with respiratory failure receiving technical respiratory assistance and were registered in the Swedish National Registry for Respiratory Failure
10124018|NCT04359628||PsoReg|Patients receiving systemic treatment for psoriasis and were registered in the Swedish Registry for Systematic Psoriasis Treatment
10124019|NCT04359628||SRQ|Patients with rheumatic disease receiving medical treatment and rehabilitation and were registered in the Swedish Rheumatology Quality Register
10124020|NCT04359628||SwedeHF|Patients who received treatments of different types in the Swedish Heart Failure Registry
10124021|NCT04359628||Swespine|Patients with spinal stenosis, disc hernia and related diagnoses receiving surgical spine treatment and were registered in the Swedish Spine Register
10124022|NCT04359628||Population health survey|Data of members of the general population who answered population surveys using the EQ-5D-3L instrument
10124023|NCT04359680|Active Comparator|Nitazoxanide|Two NTZ 300 mg tablets orally twice daily for 6 weeks.
10124024|NCT04359680|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks.
10124025|NCT04359615|Experimental|Favipiravir|
10124026|NCT04359615|Active Comparator|Control|
10124027|NCT04359823|Experimental|Statin/Cholesterol Combination Group|This arm will utilize 2% cholesterol and 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
10124028|NCT04359823|Experimental|Statin Alone Group|This arm will utilize 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
10124029|NCT04359836||General Population|The general population will have their microbiome sequenced from stool samples provided.
10124030|NCT04359576||FET|Estrogen/progesterone substituted and natural cycles
10124031|NCT04359667||tocilizumab|one infusion of TCZ 8 mg/kg i.v., with a maximum dose of 800 mg, and SOC treatment according to local guidelines (hydroxychloroquine or/and lopinavir/ritonavir or/and remdesivir).
10124032|NCT04359706||Covid-19 group|Critically ill patients with SARS-CoV-2 infection
10124033|NCT04359706||control group|Historical critically ill patients with no SARS-CoV-2 infection
10124034|NCT04359537|Experimental|Arm 1|Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks
10124035|NCT04359537|Experimental|Arm 2|Hydroxychloroquine Sulphate will be admoinistered at a dose of 400 mg on day 1 followed by 400mg once every 3 weeks for at total of 12 weeks
10124036|NCT04359537|Experimental|Arm 3|Hydroxychloroquine Sulphate will be administered at a dose of 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks
10124037|NCT04359537|Placebo Comparator|Arm 4|Control group will recieve Placebo 200mg on day 1 followed by Placebo 200mg every three weeks for 12 weeks
10124038|NCT04359485|Experimental|glycolic acid peel|
10124039|NCT04359485|Placebo Comparator|Saline|
10124040|NCT04359810|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent plasma (1 unit; ~200-250 mL) collected from a volunteer who recovered from COVID-19 disease
10124041|NCT04359810|Active Comparator|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (1 unit; ~200-250 mL) of standard plasma collected prior to December 2019
10124042|NCT04359563|Experimental|Mindfulness-Based Intervention|The MBI programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on the investigator's ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
10124043|NCT04359641|Experimental|CoMET Display|Display of Continuous Monitoring of Event Trajectories (CoMET) predictive monitoring score, with standard CoMET device training.Risk scores will also be presented daily during rounds to members of the care team.
10124044|NCT04359641|No Intervention|No Display|Standard CoMET device training but no display or presentation of predictive monitoring score.
10124045|NCT04359732|Other|Hybrid PET/MRI|For the purposes of the study, in addition to standard imaging (EUS and CT scan), a fully integrated hybrid PET/MRI (PET/MRI) study with FDG will replace the Standard PET (pre-surgical evaluation) used for evaluating distant metastases and will be considered as the add-on procedure at three time points. The additional evaluation for patients is that during nCRT treatment.
10124046|NCT04359511|Experimental|corticosteroid + Optimized Standard of Care|"prednisone 0.7 mg/kg/day for 10 days, administered orally, once a day, or~hydrocortisone hemisuccinate 3.5 mg/kg/day by continuous infusion for 10 days, administered by IV route if the patient cannot take drugs by oral route,~standard of care"
10124047|NCT04359511|No Intervention|Optimized Standard of Care|standard of care
10124048|NCT04359550|Experimental|treatment group|ZKAB001 injection 10mg/kg once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
10124049|NCT04359550|Placebo Comparator|control group|placebo will given in the same way for once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
10124050|NCT04359524|Active Comparator|Intervention|Received vitamin D3 capsules (1200 IU/30µg).
10124051|NCT04359524|Placebo Comparator|Control|Received placebo (oil capsules).
10124052|NCT04359264|Experimental|Cash transfer|
10124053|NCT04359264|No Intervention|Control|
10124054|NCT04359199||Radiotherapy with chemotherapy|Patients treated with definitive RT and chemotherapy (cisplatin) or targeted therapy (cetuximab)
10124055|NCT04359199||Radiotherapy with immunotherapy|Patients treated with definitive RT and immunotherapy (pembrolizumab, nivolumab, or durvalumab)
10124056|NCT04359472|Other|Treatment Arm|Collection and reapplication of amniotic fluid.
10124057|NCT04359095|Active Comparator|I1 Emtricitabine + Tenofovir|Intervention 1: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days
10124058|NCT04359095|Active Comparator|I2 Colchicine + rosuvatatine|Intervention 2: Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
10124059|NCT04359095|Active Comparator|I3 Emtricitabine/ tenofobir + colchicine+ rosuvastatin|Intervention 3: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days + Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
10124060|NCT04359095|Other|I4 Standard Treatment|Intervention 4: Standard treatment. It is defined as treatment aimed to control symptoms including fever and pain, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient, might include Dexamethasone. No viral therapies are included.
10124061|NCT04359381|Experimental|kinesiotaping|by kinesiotaping during menstruation for 3 successive menstruation
10124062|NCT04359381|Experimental|pilate exercises|pilate exercises, 3 sessions per week for 3 months
10124063|NCT04359303|No Intervention|CONTROL|Base WHO recommended treatment.
10124064|NCT04359303|Experimental|TREATMENT|Base WHO recommended treatment + Systemic indirect endovenous ozone therapy
10124065|NCT04359121||Physicians|Questionnaires
10124066|NCT04359121||Medical staff|Questionnaires
10124067|NCT04359121||General public|Questionnaires
10124068|NCT04359121||Patients with psychiatric disorders|Questionnaires
10124069|NCT04359082|Placebo Comparator|Placebo|Placebo for 8 straight days
10124070|NCT04359082|Experimental|Bioflavanol|Bioflavanol supplementation for 8 days at 900 mg flavanol per day
10124071|NCT04359212||Medical|subject with a confirmed infection for COVID-19 and needing admission to a medical division for a non-severe clinical disease
10124072|NCT04359212||Intensive|subject with a confirmed infection for COVID-19 and needing admission to an Intensive Cure Unit for a severe to critical disease
10124073|NCT04359316|Experimental|Azithromycin|
10124074|NCT04359316|Active Comparator|Hydroxychloroquine|
10124075|NCT04359355||Artificial Intelligence|
10124076|NCT04359290|Experimental|Ruxolitinib treatment|Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days
10124077|NCT04359238|Active Comparator|Intervention group with motivation messages|There are 100 patients in the intervention group with automated or observer initiated motivation messages. They receive an individualized training program with regular notifications about their training status via their SmartWatch.
10124078|NCT04359238|Active Comparator|Intervention group without motivation messages|There are 100 patients in the intervention group without automated or observer initiated motivation messages. They receive an individualized training program without regular notifications about their training status via their SmartWatch.
10124079|NCT04359238|No Intervention|Control group|100 patients are in the control group without an individualized training program.
10124080|NCT04359342|Experimental|HIIT + protein|High-intensity interval training (HIIT) combined with protein supplementation
10124081|NCT04359342|Placebo Comparator|HIIT + placebo|High-intensity interval training (HIIT) combined with placebo
10124082|NCT04359342|Experimental|HIIT and resistance training + protein|High-intensity interval training (HIIT) and resistance training combined with protein supplementation
10124083|NCT04359342|Placebo Comparator|HIIT and resistance training + placebo|High-intensity interval training (HIIT) and resistance training combined with placebo
10124084|NCT04359225|Active Comparator|3D telemedicine|3D telemedicine system
10124085|NCT04359225|Placebo Comparator|2D telemedicine|2D telemedicine system (standard care)
10124086|NCT04359160|Experimental|Mobile-app follow-up|The mobile app follow-up group will receive an email, to connect into a secure website. They will answer to periodical questions about their condition. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative. All of this information is submitted via the mobile application (Orthense, Digikare Inc. Blagnac, France).The surgeon will have an access to the answer of the patient in real time, and if the patient didn't answer.
10124087|NCT04359160|Active Comparator|Conventional follow-up|Patients in the conventional, questionnaire follow-up group will have the same periodical questions but on paper. They will have to stick personally with the schedule without any reminders. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative where they have to bring the questionnaire.
10124088|NCT04359368||patients with hypersensitivity reactions to NDIPs|Patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer)
10124089|NCT04359108|Experimental|Navigation system for users of a visual prosthesis|This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition. The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis. Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems. Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
10124090|NCT04359069|Experimental|Urinary catheter removal on postoperative day 1|
10124091|NCT04359069|Active Comparator|Urinary catheter removal on postoperative day 3|
10124092|NCT04359251|Experimental|Optimizing oxygenation|Best oxygenation during PEEP titration
10124093|NCT04359251|Experimental|Optimizing compliance|Best compliance during PEEP titration
10124094|NCT04359251|Experimental|ARDSnet|PEEP settings according to ARDSnet table
10124095|NCT04359056|No Intervention|control|patients for the observational phase. This corresponds to usual cares where no clinical pharmacy activities will be performed
10124096|NCT04359056|Experimental|Interventional|patients for the interventional phase where clinical pharmacy activities will be performed at each step of the care pathway: from hospitalization to home care.
10124097|NCT04359043|Experimental|Mediational Intervention for Sensitizing Caregivers|Half of the child participants and the careworkers in the Community-based Organization taking care of them, received the Mediational Intervention for Sensitizing Caregivers.
10124098|NCT04359043|Other|Treatment as Usual|The other half of child participants and the careworkers in the Community-based Organization taking care of them, received Treatment as Usual which consists of the usual services delivered to children at the CBO: food, help with homework, registrations for birth certificates.
10124099|NCT04358978|Active Comparator|posterior mesh no attachment|laparoscopic sacral colpopexy with no fixation of posterior mesh
10124100|NCT04358978|Active Comparator|posterior mesh attachment|laparoscopic sacral colpopexy with fixation of posterior mesh by suture
10124101|NCT04358952||COVID + patients|Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR
10124102|NCT04358939|Experimental|Prone decubitus group|Prone positioning of patients on nasal high-flow oxygen therapy with usual care
10124103|NCT04358939|No Intervention|Control group|Patients on nasal high-flow oxygen therapy with usual care and positioned in supine
10124104|NCT04358965|Experimental|intravenous tranexamic acid|patients were given a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision plus one vaginal placebo tablet 1 hour before skin incision
10124105|NCT04358965|Active Comparator|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
10124106|NCT04358965|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
10124107|NCT04358614|Active Comparator|Case patients|Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day
10124108|NCT04358614|Other|Controls|Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.
10124109|NCT04358705|Experimental|Young Cigarillo User (YCU) Sample|"Aim 1: Online survey. 392 participants from the full YCU sample~Supplemental Aim 1: A sample of 196 heterosexual females from the Aim 1 survey will be compared to the SGM females~Aim 2: Eye tracking activity - A total of 152 participants divided between current/past cigarillo users and non-cigarillo users. These 76 cigarillo users will be accrued from YCU sample participants who participated in Aim 1 and live in the Cleveland, Ohio~Aim 3: (A total of 162 participants from Aim 1 survey). Consists of the Online Electronic Tobacco Marketplace (ETM) and the aim 3 survey components in the following order:~Demographic screener questions~Tobacco product withdrawal scale~ETM~Quality Assurance Question~Tobacco product withdrawal scale~Survey (nicotine dependence & flavor preferences)~A sample of 88 heterosexual females from the 162 Aim 3 participants will be compared with 88 SGM participants from supplemental Aim 1"
10124110|NCT04358705|Experimental|Sexual and Gender Minority (SGM) Female Cigarillo Users|"Supplemental Aim 1: An online convenience sample of 196 SGM females will complete the Aim 1 online survey and will be compared to sample of 196 heterosexual females from the YCU sample~Supplemental Aim 3: (88 SGM females who participated in the Supplemental Aim 1 survey). Consists of the ETM and the aim 3 survey components in the following order:~Demographic screener questions~Tobacco product withdrawal scale~ETM~Quality Assurance Question~Tobacco product withdrawal scale~Survey (nicotine dependence & flavor preferences)"
10124111|NCT04358705|Experimental|Aim 2 - Non-cigarillo users|"Aim 2: (Eye tracking activity)~A total of 152 participants divided between current/past cigarillo users and non-cigarillo users. These 76 non-cigarillo users will be accrued by means of social media posts and flyers at places that youth most likely frequent"
10124112|NCT04358705|Other|Cognitive interview|Separate population of participants (n=29) who were a mix of cigarillo users, dual e-cigarette and cigarillo users, e-cigarette users, and non-users. The cognitive interviews informed the Aim 1 survey
10124113|NCT04358796|Experimental|HBOT environment|Cognitive testing in 2ATA, 100% oxygen in breathing-masks
10124114|NCT04358796|Sham Comparator|Control environment|Cognitive testing in 1ATA, air in breathing-masks
10124115|NCT04358679|Active Comparator|Conventional Treatment|Conventional Treatment: Deep breathing, Assisted coughing, Sustained stretching, Splinting, Bracing and Functional mobility
10124116|NCT04358679|Experimental|Upper Limb ergometer training|Conventional Treatment + Upper Limb (UL) ergo-meter exercise
10124117|NCT04358653|Experimental|fall prevention exercise program|The experimental group was designed to undergo supervised exercise 2 days a week for 8 consecutive weeks for 45-50 min/session. The intervention program was implemented at the nursing home facilities.
10124118|NCT04358653|No Intervention|Control Group|The control group did not receive any intervention during that period and were instructed to pursue their habitual daily life activities.
10124119|NCT04358627||DEXMEDETOMIDINE|Patients receiving dexmedetomidine continuous infusion since their admittance to ICU. Continuous checking of the primary and secondary outcomes
10124120|NCT04358627||No-DEXMEDETOMIDINE|Historical Control patients matched for ICU admittance diagnosis, age, and concomitant disease and medication state. No Dexmedetomidine. CONtinuous checking of primary outcomes
10124121|NCT04358718|Active Comparator|general anesthesia|Patients in this group will receive general anesthesia with intraoperative and postoperative intravenous opioid-based analgesia.
10124122|NCT04358718|Experimental|general analgesia combined with epidural analgesia|Patients in this group will receive combined epidural and general anesthesia with intraoperative and postoperative epidural ropivacaine-based analgesia.
9519524|NCT03286322|Sham Comparator|control group|
9967186|NCT01267448|Active Comparator|Saxagliptin + Metformin XR|Saxagliptin 5 mg + Metformin XR 1000 mg will be automatically titrated weekly in 2 weeks to Saxagliptin 5 mg + Metformin XR 2000 daily for a total duration of 12 weeks.
9967187|NCT01267448|Active Comparator|the Control goup Glipizide XL|The control group will receive Sulphonylurea (Glipizide XL 10mg orally) for a total duration of 12 weeks.
9967188|NCT01267474|Experimental|Nutritional education|
9967189|NCT01267474|No Intervention|Control|
9967190|NCT01267487|Active Comparator|Fixed doses plus PO protamine|"Intraoperative fixed dose schemes (as in fixed doses plus placebo group) plus continuous infusion of 25mg/hour of protamine during first 6 PO hours"
9967191|NCT01267487|Active Comparator|Titrated doses plus PO protamine|"Same as titrated doses arm, plus continuous infusion of 25mg/ hour of protamine during first 6 PO hours"
9967192|NCT01267487|No Intervention|Fixed doses plus placebo|"Before CPB, fixed heparin dose of 400 Units per kg of body weight to achieve an Activated Coagulation Time (ACT) > 480 seconds.~Reversal of heparin after CPB using 1 : 1 ratio (1 mg of protamine for each 100 units (1mg) of heparin), plus 0.8 mg/kg of protamine at the end of the surgery.~Continuous infusion of placebo (saline 0.9%) during the first 6 PO hours."
9967193|NCT01267487|Active Comparator|Titrated doses plus placebo|"Titrated doses of heparin before and during CPB and reversal with protamine after CPB calculated by the construction of individualized Bull's dose-response curve.~Continuous infusion of placebo (saline 0.9%) during first 6 PO hours."
9967194|NCT01267500|Experimental|Non-surgical therapy|patching or fusion exercises
9967195|NCT01267513||normal volunteers|Normal individuals, aged 18 -75
9967196|NCT01267513||Hospitalized patients|Pulmonary and cardiac ICU, Trauma
9967197|NCT01267552|Experimental|Non drainage arm|No drains will be placed during operation
9967198|NCT01267552|Active Comparator|Drainage arm|Closed suction drains will be placed during operation
9967199|NCT01267565|Other|intubated and ventilated patients|patients undergoing mechanical ventilation for an anticipated length of more than 48h
9967200|NCT01267565|Other|non intubated patients|non intubated patients with an independant indication of bronchoscopy including an endotracheal aspiration during the procedure
9967201|NCT01267578|Experimental|peptide vaccination|
9967202|NCT01267591||control|
9967203|NCT01267591||type 1 diabetes|
9967204|NCT01267591||obesity|
9967205|NCT01267604|Active Comparator|Recombinant FSH|225IU rFSH
9967206|NCT01267604|Experimental|Recombinant FSH Inositol Melatonin|225IU rFSH, 4g Inositol and 3mg Melatonin
9967207|NCT01267617||chronic hemodialysis outpatients|
9967208|NCT01267630||Surgical ICU|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48 hours .
9967209|NCT01267643|Experimental|Alefacept|
9967210|NCT01267669|Experimental|EVL plus Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
9967211|NCT01267669|Placebo Comparator|EVL plus Placebo|Emergency EVL plus placebo infusion for 5 days
9967212|NCT01267682|No Intervention|Usual care|Participants receive standard clinical care
9967213|NCT01267682|Experimental|Treatment|Behavioral: cognitive stimulation
10124123|NCT04358731|Experimental|NmCV-5|"A total of 1640 subjects 18 to 85 years of age will be accrued contemporaneously across three age groups - 18 to 29 years, 30 to 60 years, and 61 to 85 years.~Within each age group subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.~The NmCV-5 subjects in 18-29 year age group will be further randomized 1:1:1 into three different lots (Lot A, B & C) of NmCV-5.~Total 1230 subjects will be enrolled in NmCV-5 arm."
9967214|NCT01267708||Study Group|All those tested
9967215|NCT01267721||Study Group|A single group of 100 consecutive patients will undergo additional blood sampling at different time points
9967216|NCT01267734|Experimental|EECSS + DDAT|Promus Element stent + double-dose clopidogrel anti-platelet therapy
9967217|NCT01267734|Active Comparator|ZECSS + DDAT|Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy
9967218|NCT01267734|Experimental|EECSS + TAT|Promus Element stent + triple anti-platelet therapy
9967219|NCT01267734|Active Comparator|ZECSS + TAT|Endeavor Resolute stent + triple anti-platele therapy
9967220|NCT01267747||Atrial fibrillation or flutter patients|Patients with 'lone' paroxysmal, persistent, or permanent atrial fibrillation
9967221|NCT01267760|Active Comparator|conventional HD|conventional 4-hour HD
9967222|NCT01267773|Active Comparator|Sequential Treatment|
9967223|NCT01267773|Experimental|Integrated Treatment|
9967224|NCT01267786|Active Comparator|Sevoflurane|1MAC intraoperatively
9967225|NCT01267786|Active Comparator|desflurane|1 MAC intraoperatively
9967226|NCT01267799||photocopier exposure|
9967227|NCT01267799||control|
9967228|NCT01267838|Active Comparator|T Stenting group|PCI of bifurcation lesion with modified T Stenting.
9967229|NCT01267838|Active Comparator|Culotte stenting group|PCI of bifurcation lesion with Culotte stenting
9967230|NCT01267877|Active Comparator|Guideline unfavorable article|
9967231|NCT01267877|Active Comparator|Guideline favorable article|
9967232|NCT01267903|Experimental|320U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 young adults aged 16-22 years old on day0,28
9967233|NCT01267903|Experimental|640U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 young adults aged 16-22 years old on day0,28
9967234|NCT01267903|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 20 children aged 5-15 years old on day0,28
9967235|NCT01267903|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 children aged 6-15 years old on day0,28
9967236|NCT01267903|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 children aged 6-15 years old on day0,28
9967237|NCT01267916|Experimental|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
9967238|NCT01267916|Experimental|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
9967239|NCT01267916|Experimental|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
9967240|NCT01267916|Experimental|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
10124124|NCT04358731|Active Comparator|Menactra|"Subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.~In Menactra arm, total 410 subjects will be enrolled."
10124125|NCT04358783|Experimental|Plasma|Convalescent plasma from cured COVID-19 patients y Supportive management depending on individual needs
10124126|NCT04358783|Experimental|Best Available Therapy|Will receive supportive management depending on individual needs including.
10124127|NCT04358887|Experimental|periapical surgery with piezo.|After flap reflection bone and root end cutting are done with US6 piezoelectric surgical insert
10124128|NCT04358887|Active Comparator|Periapical surgery with bur.|After flap reflection bone and root end cutting are done with surgical bur.
10124129|NCT04358666|Active Comparator|surgery and focal radiosurgery of the surgical site|
10124130|NCT04358666|Active Comparator|hypofractionned radiosurgery|
10124131|NCT04358692|Experimental|Surgical Aortic Valve Replacement|Patients with aortic stenosis
10124132|NCT04358692|Other|Reference|Coronary bypass patients without hypertrophic left ventricular remodeling or sequelae of myocardial infarction
10124133|NCT04358601|Experimental|All-polyethylene tibial components|Triathlon PS Knee System with all-polyethylene tibial components
10124134|NCT04358601|Active Comparator|Metal-backed modular components|Triathlon PS Knee System with metal-backed modular components
10124135|NCT04358926|Active Comparator|Hyperbaric oxygen therapy|8 sessions in 4 days hyperbaric oxygen therapy
10124136|NCT04358926|No Intervention|Control|Standard of care
10124137|NCT04358770|Experimental|Test|Clocortolone Pivalate Cream, 0.1%
10124138|NCT04358770|Active Comparator|Reference|Cloderm® (clocortolone pivalate) Cream, 0.1%
10124139|NCT04358861|Experimental|Experimental group|Nonsurgical Root canal therapy was performed using dental operating microscope in the experimental group.
10124140|NCT04358861|Active Comparator|Control group|Nonsurgical Root canal therapy was performed without any magnification aid in control group.
10183270|NCT03766243|Active Comparator|Brochure and DVD only|"After recruitment, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use. At the same time, she contacted the research nurse to obtain the random allocation to one of the study groups for that patient.~These exercises had to be done every day for the entire duration of the program (12 months) and registered in the diary with any comments."
10183271|NCT03766217|Experimental|Mesenchymal stem cells associated with biomaterials|Mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials. The stem cells will be obtained by enzimatic digestion in GMP laboratory and will be seed into the biomaterial (hydroxyapatite/collagen).
10183272|NCT03766217|Active Comparator|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest. The prepare of the receptor area will be the same in both arms and will follow current recommendations.
10183273|NCT03766204||ARDS patients|137 patients were enrolled consecutively over a two-year time period (2017-2018) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 18 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
10183274|NCT03766204||Healthy volunteers|Forty healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
10183275|NCT03766191|Active Comparator|Food Ads and fMRI|
10183276|NCT03766191|Sham Comparator|Non-Food Ads and fMRI|
10183277|NCT03766191|Active Comparator|Food Ads and TV show|
10183278|NCT03766191|Sham Comparator|Non-Food Ads and TV show|
10183279|NCT03766178|Experimental|Nimotuzumab + SHR-1210|Nimotuzumab + SHR-1210
10183280|NCT03766152|Other|Adhear|Patients will be fitted with an adhesive bone conduction device for three weeks
10183281|NCT03766139|Experimental|SUPERCELL GLUE(STEM CELLS AND PRFM)|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites .
10183282|NCT03766139|Active Comparator|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites
10183283|NCT03766113|Other|Healthy volunteer|"50 subjects~A single neurofeedback coupling electroencephalogram and functional MRI in time actual ."
10183284|NCT03766113|Other|Patients at the early stage after stroke|"30 subjects~Effectiveness of an electroencephalogram-neurofeedback"
10183285|NCT03766113|Other|Patients at the chronic stage after stroke|"36 subjects~Effectiveness of a neurofeedback coupling electroencephalogram and functional MRI in time actual"
10183286|NCT03766100|Experimental|Intervention group|Cognitive Behavioural Therapy for Insomnia (CBT-i).
10183287|NCT03766100|No Intervention|Control group|Insomnia is untreated.
10183288|NCT03766087|Experimental|surgery group|Decompressive craniectomy associated with optimal medical management of intracranial pressure.
10183289|NCT03766087|No Intervention|conservative group|Optimal medical management of intracranial pressure only.
10183290|NCT03766074|Experimental|Intervention|vitamin D supplement every other week
10183291|NCT03766074|Placebo Comparator|control|Placebo every other week
10183292|NCT03766061|Active Comparator|Onlay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with onlay mesh hernioplasty in which we placed mesh on the anterior rectus sheath
10183293|NCT03766061|Active Comparator|Sublay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with sublay mesh hernioplasty in which we placed mesh in the retromuscular space
10183294|NCT03766048|Experimental|Single-Anterior-Mesh, SAM|
10183295|NCT03766048|Sham Comparator|Double-Mesh, DM|
10183296|NCT03766022|Experimental|Heavy smoker patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
10183297|NCT03766022|Active Comparator|non Smokers patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
10124141|NCT04358757||Cesarean patients|participants undergoing elective cesarean will have measures of recovery assessed (patient-reported outcome measures and activity data from watch)
10124142|NCT04358835|Experimental|Intubated patients with COVID-19 on a ketogenic diet only|4:1 ketogenic diet formula
10124143|NCT04358809|Experimental|Suspension of Mw + Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days + Standard therapy of COVID-19
10124144|NCT04358809|Placebo Comparator|Placebo|0.3 ml (0.1ml x 3 Injection) of intradermal Placebo for 3 consecutive days + Standard therapy of COVID-19
10124145|NCT04358575|Experimental|All-polyethylene tibial components|Triathlon CS Knee System with all-polyethylene tibial components
10124146|NCT04358575|Active Comparator|Metal-backed modular components|Triathlon CS Knee System with metal-backed modular components
10124147|NCT04358822|Active Comparator|30 second cord clamping|Infants in this group will receive delayed cord clamping for 30 seconds.
10124148|NCT04358822|Active Comparator|120 second cord clamping|Infants in this group will receive delayed cord clamping for 120 seconds.
10124149|NCT04358562|Experimental|Gefitinib with Anlotinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily and Anlotinib 10mg oral d1-14, every 3 weeks
10124150|NCT04358562|Experimental|Gefitinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily
10124151|NCT04358536||COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from COVID-19 patients"
10124152|NCT04358536||Non COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from subsets of non COVID-19 patients"
10124153|NCT04358263|Experimental|rtCGM|Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring).
10124154|NCT04358263|Experimental|isCGM|Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).
10124155|NCT04358406|Placebo Comparator|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
10124156|NCT04358406|Active Comparator|Rhu-pGSN|Recombinant human plasma gelsolin reconstituted for slow bolus injection.
10124157|NCT04358146|Experimental|Test|new thickened infant formula containing fibres
10124158|NCT04358146|Active Comparator|Control|infant formula thickened with locust bean
10124159|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection|Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0
10124160|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection|Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0
10124161|NCT04358471|Sham Comparator|Sham Intravitreal Injection|Intravitreal Sham injection administered once on Day 0
10124162|NCT04358380||Patients without Liver Injury|Hospitalized patients with COVID-19 disease who did not develop liver injury
10124163|NCT04358380||Patients with Liver Injury|Hospitalized patients with COVID-19 disease who develop liver injury
10124164|NCT04358302|Experimental|Device use|"All participants will be provided with the electronic pill bottle cap called Pillsy to use with their regular HCQ prescription bottles at the start of the study."
10124165|NCT04358250|Experimental|direct superior approach|Direct superior approach 25 patients
10124166|NCT04358250|Active Comparator|posterolateral approach|posterolateral approach 25 patients
10124167|NCT04358367|Active Comparator|Dexmedetomidine|spinal anesthesia and intravenous dexmedetomidine(1µg/kg)
10124168|NCT04358367|Placebo Comparator|Saline|spinal anesthesia and placebo (saline).
10124169|NCT04358341|Active Comparator|Irinotecan alone|150 mg/m2 iv drip d1; Repeat every 14 days.
10124170|NCT04358341|Experimental|Pegliposomal Doxorubicin and 5-FU|Pegliposomal Doxorubicin: 25mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h d1; Repeat every 14 days.
10124171|NCT04358432|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
10124172|NCT04358432|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
10124173|NCT04358432|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
10124174|NCT04358432|Experimental|AK102 75 mg|Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
10124175|NCT04358432|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
10124176|NCT04358432|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
10124177|NCT04358094|Experimental|Conversational hypnosis script|Patient who received conversational hypnosis script during peripherical veinous access set up
10124178|NCT04358094|Other|Standard script|Patient who received standard script during peripherical veinous access set up
10124179|NCT04358354|Experimental|FOLFOXiri group|Irinotecan 150 mg/m2 iv drip d1; Oxaliplatin 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
10124180|NCT04358354|Active Comparator|FOLFOX group|Oxaliplatin: 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
10124181|NCT04358523|Experimental|ASC18 (D1,D4-13）;RDV + SOF(D27,D30-39)|ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 1 and day 4 to 13. RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 27 and day 30 to 39.
10124182|NCT04358523|Experimental|RDV + SOF (D1,D4-13）;ASC18(D27,D30-39)|RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 1 and day 4 to 13. ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 27 and day 30 to 39.
10124183|NCT04358484|Experimental|Intervention Group|Participants attend The Incredible Years - ASLD parenting intervention and continue to receive usual care at their healthcare center
10124184|NCT04358484|No Intervention|Treatment As Usual (TAU) Group|Participants continue to receive usual care at their Healthcare Center
10124185|NCT04358510||COViage|Machine learning intervention
9967241|NCT01267916|Experimental|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
10124186|NCT04358497|Experimental|Interventional treatment plus best chronic medical treatment|Sandwich embolization ( 2% polidocanol + Coils) Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
10124187|NCT04358497|Active Comparator|Best chronic medical treatment alone|Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
10124188|NCT04358172|Experimental|Mobile app|Participants in this group is educated using the mobile application
10124189|NCT04358172|No Intervention|Control|Participants in this group is educated using the conventional method practised in the Faculty of Dentistry, National University of Malaysia (verbal instructions accompanied by demonstrations on dental models)
10124190|NCT04357990|Experimental|Viruxal Oral and Nasal Spray|The Device will be administered to the oral and nasal passages, three times per day.
10124191|NCT04357990|Placebo Comparator|Placebo|The placebo will be administered to the oral and nasal passages, three times per day.
10124192|NCT04358120|Other|Hyaluronic Acid Combined With Chondroitin Sulfate|The treatment consists of 3 intra articular injections of Hyaluronic Acid With Chondroitin Sulfate administered one per week for 3 consecutive weeks: the 1st at Visit 1 (Week 0), the 2nd at Visit 2 (Week 1) and the 3rd at Visit 3 (Week 2)
10124193|NCT04358055|Experimental|WET® gel|"At the screening/baseline visit (Visit 1, Day 1), eligible patients will be assigned to treatment with WET® gel, at the dose of 3-4 nasal applications/day (according to necessity), 1or 2 puff/nostril, for maximum 14 days.~Treatment will be administered according to patient's need without any relation with the time of the day (i.e. day time or night time administration), however within a maximum of 4 applications/day, which must include one administration in the morning upon awakening and one administration in the evening before retiring to bed."
9826001|NCT02404025|Experimental|Eltrombopag+rabbit ATG/CsA arm|Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
9826002|NCT02404103|Active Comparator|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
10124194|NCT04357977||Covid +|Laboratory obtained Covid+ specimen results will be compared to saliva specimen
10124195|NCT04357860|Experimental|Sarilumab 200 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 200 mg single dose.
10124196|NCT04357860|Experimental|Sarilumab 400 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 400 mg single dose.
10124197|NCT04357860|Active Comparator|Control|Subjects treated with the best available treatment up to 14 days.
10124198|NCT04357912|Experimental|Experimental group|
10124199|NCT04357912|Active Comparator|Control Group|
10124200|NCT04358016|Experimental|terlipression|terlipression 1mg；once every 6 hours；5days
10124201|NCT04358016|Active Comparator|Control|Somatostatin，3mg， once every 12 hours; 5 days
10124202|NCT04357873|Experimental|pembrolizumab + vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
10124203|NCT04357834||Smartwatch group|
10124204|NCT04357600|Experimental|intravenous injection of UC-MSC|The dosage of the intravenous route is 100 million MSCs for each subject.
10124205|NCT04357522|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose
10124206|NCT04357522|Active Comparator|Positive control group|Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose
10124207|NCT04357613|Experimental|Expérimental ARM|800mg/d IMATINIB during 14days
10124208|NCT04357613|No Intervention|Comparator ARM|Standard of care
10124209|NCT04357548||Feedback system|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
10124210|NCT04357626||Completed discharged hospital rehabilitation electronic record|Completed discharged hospital rehabilitation electronic record of patients who underwent inpatient rehabilitation as part of routine clinical care.
10124211|NCT04357561|Experimental|Exercise group (Schroth best practice)|Exercise program will consists of scoliosis-specific exercises (schroth best practice), which is a pattern specific scoliosis rehabilitation concept and provide three dimensional improvements and include patient education for maintaining corrected posture in daily life. In addition, these exercises provide improvements in neuromuscular control and the endurance of the postural muscles.
9826003|NCT02404103|Active Comparator|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
9967242|NCT01267916|Experimental|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
10124212|NCT04357561|No Intervention|Control group|Due to there is not a standard preoperative exercise protocol, additional exercise program will not be applied in control group. The patients will wait for the surgery in their routine daily life. Measurements will be performed at the same time frame in experimental group.
10124213|NCT04357639||Protease inhibitor exposed|HIV patients treated with antiretroviral drugs including a protease inhibitor
10124214|NCT04357639||Protease inhibitor non exposed|HIV patients treated with antiretroviral drugs without a protease inhibitor
10124215|NCT04357743|Experimental|Chin supported Arm ergometry with pursed lip breathing|Chin supported along with Arm ergometry with pursed lip breathing
10124216|NCT04357743|Active Comparator|Arm ergometry with pursed lip breathing|Arm ergometry with pursed lip breathing
10124217|NCT04357665|Active Comparator|Lap TAPP Group|Patients treated by laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
10124218|NCT04357665|Active Comparator|Open PP Group|Patients treated by open preperitoneal single mesh repair fixated using sutures
10124219|NCT04357665|Active Comparator|Bilateral LICHT Group|Patients treated by standard bilateral Lichtenstein repair using 2 separate meshes fixed by sutures
10124220|NCT04357704|Experimental|bilateral cochlear implant recipients|
10124221|NCT04357704|Active Comparator|normal hearing listners|
10124222|NCT04357769||Patients|Individuals aged 18-70 years with a diagnosis of severe mental disorder (schizophrenia or psychosis spectrum disorder; bipolar disorder; major depressive disorder) who were in a condition of psychopathological compensation, had their last clinical evaluation at the University of Naples Federico II outpatient unit of Psychiatry during January-February 2020, were not positive or suspected positive for COVID-19, and were under strict quarantine
10124223|NCT04357769||Controls (General Population)|Individuals aged 18-70 years who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine (e.g. not getting out for work)
10124224|NCT04357769||First-degree Relatives|Individuals aged 18-70 years who were first-degree relatives and caregivers of an individual included in the Patients group, who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine
10124225|NCT04357678|Experimental|Qi Gong Programme|Qi Gong Programme
10124226|NCT04357678|Experimental|Short Form Sun Style Tai Chi|Short Form Sun Style Tai Chi
10124227|NCT04357808|Experimental|Sarilumab plus standard of care|Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed
10124228|NCT04357808|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
10124229|NCT04357691|Other|Healthy individuals (low-high-mod)|Participants will undergo the calibration phase beginning with low intensity training, followed by high, and moderate intensity training. Each training intensity will be performed 3 days a week for 2 weeks
10124230|NCT04357691|Other|Healthy individuals (mod-high-low)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by high, and low intensity training. Each training intensity will be performed 3 days a week for 2 weeks
9668995|NCT04403802|Experimental|Arm A: Voxx socks followed by placebo socks|Continuous wear of Voxx Human Performance Technology Socks for 2 weeks, followed by continuous wear of placebo socks for 2 weeks (separated by a 2-week washout period)
10124231|NCT04357691|Other|Healthy individuals (mod-low-high)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by low, and high intensity training. Each training intensity will be performed 3 days a week for 2 weeks.
10124232|NCT04357535||Primary Cohort|"Patients enrolled in this study will have data collected from the beginning of their hospital stay until discharge.~Data collected will include:~Patient demographics (age, sex, weight, and height)~Indication for ACE-I, ARB therapy, duration and doses~Use of any a non ACE-I/ ARB sntihypertensive agents~Comorbidities, and COVID19 related markers: Including WBC, plateltes, ferritin, CRP, CK, and LD~CT scan reports~First positive COVID19 PCR~Admission to the intensive care unit (ICU) and data relating to ICU stay."
10124233|NCT04357509|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
10124234|NCT04357470|Active Comparator|USF Group|DRF with ulnar styloid fracture
10124235|NCT04357470|Active Comparator|NON-USF Group|DRF without ulnar styloid fracture
10124236|NCT04357483|Experimental|Collastat|Patients who were applied flowable thrombin containing collagen hemostat matrix after pancreatectomy
10124237|NCT04357483|Active Comparator|Collaseal|Patients who were applied thrombin coated L-dopa contained collagen patch after pancreatectomy
10124238|NCT04357353|Sham Comparator|Placebo|All arms will have phlebotomy (blood drawn). This group will receive saline injection only.
10124239|NCT04357353|Experimental|PRP|All arms will have phlebotomy (blood drawn). This group will receive PRP injection only.
10124240|NCT04357366|Experimental|Anakinra|Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.
10124241|NCT04357340|Experimental|Pulmonary Physiotherapy Techniques group|Pulmonary physiotherapy techniques, 6 sessions during 3 days and incentive spirometer.
10124242|NCT04357340|No Intervention|Control group|Incentive spirometer only
10124243|NCT04357275||ICU admissions due to COVID-19|
10124244|NCT04357444|Experimental|1: ILT101|ILT-101 in Subcutaneous route
10124245|NCT04357444|Placebo Comparator|2: Placebo Comparator|Placebo in subcutaneous injections every day during 10 days
10124246|NCT04357392|Experimental|Glucocorticoid intervention group|prednisone
10124247|NCT04357392|Placebo Comparator|Placebo control group|placebo
10124248|NCT04357418||hospital staff|
10124249|NCT04357418||close relatives.|
10124250|NCT04357431||study group|Health care providers include physicians, nurses, and health officers both medical and nursing subjects.
10124251|NCT04357093|Experimental|Grape seed extract mouthwash|Grape seed extract mouth wash 15% concentration
10124252|NCT04357093|Active Comparator|Sodium fluoride mouthwash|Sodium fluoride mouthwash 1000 ppm
10124253|NCT04357002|Experimental|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
9826004|NCT02404168|Active Comparator|lamotrigine brand tablet1|lamotrigine tablet Lamictal
9826005|NCT02404168|Experimental|lamotrigine generic tablet1|lamotrigine tablet Teva
10124254|NCT04357002|Active Comparator|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
10124255|NCT04357002|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
10124256|NCT04357028|Experimental|MMR vaccine|0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm
10124257|NCT04357028|Placebo Comparator|Control|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
10124258|NCT04357171|Active Comparator|Ileostomy|Loop protective ileostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
10124259|NCT04357171|Active Comparator|Colostomy|Loop protective transverse colostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
10124260|NCT04357223|Experimental|Experimental|
10124261|NCT04357223|Placebo Comparator|Placebo|
10124262|NCT04357301|Experimental|Closed-loop|Closed-loop administration of norepinephrine
10124263|NCT04357210||primary sphincteroplasty|end-to-end primary sphincteroplasty with interrupted sutures
10124264|NCT04357210||muco-muscular advancement flap|A U-shaped muco-muscular flap was mobilized and fixed to the anoderm with one-row interrupted absorbable sutures
10124265|NCT04357210||full-thickness low rectum posterior semicircular mobilization|Proximal parts of the internal sphincter and the longitudinal muscle were carefully separated from the underlying external sphincter and puborectalis muscle, moving further in the cranial direction, the Waldeyer's fascia was exposed and incised. Full-thickness posterior semicircular flap was fixed to anoderm
10124266|NCT04357080||Case|Patients with urethral stricture recurrence
10124267|NCT04357080||Control|Patients with normal, patent urethra
10124268|NCT04357288|Experimental|Patient Decision Aid|Participants in this arm will use the Patient Decision Aid (PDA), an online education tool about atrial fibrillation designed for patient use, prior to the encounter with their provider.
10124269|NCT04357288|Experimental|Encounter Decision Aid|Participants in this arm will use the Encounter Decision Aid (EDA), an online educational tool about atrial fibrillation designed for patient-provider use, during the encounter with their provider.
10124270|NCT04357288|Experimental|Patient & Encounter Decision Aids|Participants in this arm will use both the PDA & EDA as described above.
10124271|NCT04357288|No Intervention|Standard Care|Participants in this arm will receive standard care, that is they will not use either the PDA or EDA.
10124272|NCT04357119|Active Comparator|CL measured from Treitz ligament|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 200 cm distal to the ligament of Treitz with the same stapler using a 60 mm blue cartridge
10124273|NCT04357119|Active Comparator|CL measured from ileocecal valve|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 300 cm proximal to the ileocecal valve with the same stapler using a 60 mm blue cartridge
10124274|NCT04357106|Experimental|Convalescent Plasma|200 ml of convalescent plasma, single dose.
10124275|NCT04357197|Experimental|Closed-loop|Closed-loop administration of norepinephrine in critically ill patients
10124276|NCT04357327|Experimental|Symptomatic patients|Patients with symptoms associated with COVID-19, i.e., dyspnea, cough, fever, etc.
10124277|NCT04357327|Active Comparator|Asymptomatic subjects|Asymptomatic patients with low risk phenotype, that means patients with a previous negative swab, no relatives affected by COVID-19 and with reduced social interaction within the last two weeks.
10124278|NCT04357054|Active Comparator|Normal uterus|Darwish test
10124279|NCT04357054|Active Comparator|Myomatous uterus|Darwish test
10124280|NCT04357145|Active Comparator|Standard Exercise Group|Exercise training is given to patients in the form of a home exercise program.
10124281|NCT04357145|Experimental|High Dosage Exercise Group|The high dosage exercise training group will implement the recommended exercise program 3 times more than the standard exercise group.
10124282|NCT04357158|Other|Patients referred for colonoscopy|
10124283|NCT04357405||Experimental arm|This group consists of 100 EHPAD which will benefit from ECG teletransmission. all data will be collected
10124284|NCT04357405||Control arm|This arm consists of 50 EHPAD that have not benefited from ECG teletransmission. Only the global death occurrence data will be analyzed, no individual data will be collected.
10124285|NCT04357015|Experimental|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
10124286|NCT04357015|Active Comparator|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
10124287|NCT04357015|Placebo Comparator|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
10124288|NCT04356898||Diabetes fasting|Diabetes patients who decided to fast during the month of Ramadan
10124289|NCT04356898||Diabetes non-fasting|Diabetes patients who decided to not fast during the month of Ramadan
10124290|NCT04356898||Healthy|Healthy volunteers that decided to fast during the month of Ramadan
10124291|NCT04356911|Placebo Comparator|PLACEBO (Negative Control)|The dental elements of this group had no desensitizing treatment. After whitening therapy, a water-soluble placebo gel (KY®, Johnson & Johnson, SP, Brazil) was applied to dental oral surfaces, then the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of Low Level Laser Therapy (LLLT).
10124292|NCT04356911|Experimental|FBM|The group received the application of a placebo gel associated with LLLT after office bleaching.
9519525|NCT03286309|Experimental|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
10124293|NCT04356911|Experimental|ESTRÔNCIO|After whitening in-office bleaching, the group was treated with desensitization to 10% strontium chloride. Subsequently, a laser tip was positioned at two points (apical and cervical), without emitting light (placebo).
10124294|NCT04356911|Experimental|FBM+ESTRÔNCIO|After whitening in the office, the group received a 10% strontium chloride desensitizer associated with low level light therapy.
10124295|NCT04357067|Experimental|Lingual brackets|Patients with moderate crowding without extraction treated with Incognito lingual bracket (3M Unitek, Bad Essen, Germany)
10124296|NCT04357067|Experimental|Labial brackets|Patients with moderate crowding without extraction treated with labial bracket (3M Unitek, Ca, USA
10124297|NCT04356924|Experimental|Psychological treatment|The psychological treatment consists of 11 sessions (55 minutes per occasion), where the patient meets a psychologist face-to-face (either licensed or under training to be licensed) once a week. In between sessions, patients are supposed to complete homework exercises that are related to the contiguous sessions (2 x 45 minutes per week).
10124298|NCT04356924|Active Comparator|Cognitive training|Like the experimental group, the active control group also consists of 11 sessions (55 minutes per occasion), once a week. At those occasions, the patient will meet a psychology student under training or a MSc in psychology that coaches the patients during the cognitive training. In between sessions, patients are supposed to take 2 walks (45 minutes per occasion to meaningfully match the home exercises in the experimental group).
10124299|NCT04356924|No Intervention|Treatment as usual|This group receives no intervention. They receive regular health information that is given after the extended cognitive examination at the Cognitive Centers.
10124300|NCT04357132|Other|VR-Biofeedback|
10124301|NCT04357132|Other|VR-Distraction|
10124302|NCT04356872|Experimental|treatment|The patients with metastatic and unresectable soft tissue sarcoma including undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma will be enrolled and given sintilimab (PD-1) , doxorubicin and doxorubicin every three weeks for 6 cycles followed by sintilimab mono therapy till disease progression. The first enrolled six patients is safety run-in step for observing drug-limiting toxicity (DLTs). If the combinatory treatment is intolerable, the doses of chemo regimens will be reduced according to drug instruction.
10124303|NCT04356716|Active Comparator|Standard of Care Sildenafil|Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease.
10124304|NCT04356716|Active Comparator|Sildenafil|Participants are prescribed sildenafil 40-80 mg daily.
10124305|NCT04356729|Experimental|Atezolizumab and Bevacizumab|"The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.~Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks~Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.~Treatment will be administered on an outpatient basis Study treatment will continue until study doctors decide to stop therapy due to criteria which may include disease progression, adverse events or changes in condition. Participants will be followed for survival health information following treatment until the study ends, which could be approximately 5 years from start of treatment"
10124306|NCT04356859|No Intervention|Crystalloid|Subjects in the crystalloid group will receive fluid resuscitation with Lactated Ringer's titrated each hour to achieve a urine output of 0.5-1mL/kg predicted body weight.
10124307|NCT04356859|Active Comparator|Colloid|Subjects in the colloid group will receive fluid resuscitation with Lactated Ringer's and 5% human albumin solution introduced no earlier than 8 hours post burn and no later than 12 hours post burn in a ratio by volume of 1/3 albumin to 2/3 Lactated Ringer's, and titrated each hour to achieve a urine output of 0.5-1mL/kg (milliliter/kilogram) predicted body weight.
10124308|NCT04356703||Children submitted to fetoscopic surgery|Children submitted to fetoscopic in utero myelomeningocele repair using the SAFER (Skin-over-biocellulose for Anternatal FEtoscopic Repair) technique will evaluate the neuropsicomotor development at 30 months of chronological age or older
10124309|NCT04356508|Experimental|Intervention (n=10)|Nivolumab + best supportive care
10124310|NCT04356508|No Intervention|Non-intervention (n=5)|Best supportive care
10124311|NCT04356677|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
10124312|NCT04356677|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
10124313|NCT04356820|Experimental|acupressure|
10124314|NCT04356820|Experimental|music|
10124315|NCT04356820|No Intervention|control|
10124316|NCT04356664|No Intervention|Frozen embryo transfer with Hormonal Replacement Therapy (HRT)|Patient will received usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
10124317|NCT04356664|Experimental|Frozen embryo transfer with HRT and GnRH agonist|Patient will received 1 or 2 injection of GnRH agonist priori to usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
10124318|NCT04356833|Experimental|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 1|For patients in the rt-PA group, 10 mg of rt-PA dissolved in 5 ml of diluent will be given every 6 hrs for 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). 6 patients will be receiving Invasive mechanical ventilation and another six will be receiving Non Invasive ventilation.
10124319|NCT04356833|No Intervention|Historical matched controls - cohort 1|"Matched historical controls who received standard of care were also recruited at a ratio of 2 controls to every 1 treatment arm patient. Matching will be done according to the following criteria in the order stated:~Ventilation and oxygen type (IMV and non-invasive oxygen support)~Severity as determined by PaO2/FiO2 ratio~Gender~Age (+/- 2 years, up to a maximum of 10 years)~Ethnicity"
10124320|NCT04356833|Experimental|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 2|In cohort 2, fewer timepoints will be collected, which will allow for more rapid recruitment while at the same time not compromising safety monitoring. A more flexible dosing regimen for rtPA will be utilised. 30 patients will be recruited in total, with an aim to recruit a minimum of 10 IMV patients and 10 patients on non-invasive oxygen support.
10124321|NCT04356846|Experimental|R/R CLL|Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
10124322|NCT04356846|Experimental|R/R NHL|Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Patients, including SLL, FL, MZL, MCL, DLBCL, WM.
10124323|NCT04356807|Experimental|Reflex Locomotion Therapy|during 15 minutes once a day five days a week
10124324|NCT04356807|Experimental|Passive Joint Mobilizations|during 15 minutes once a day five days a week
10124325|NCT04356807|Placebo Comparator|Massage|during 15 minutes once a day five days a week
10124326|NCT04356521|Active Comparator|Group LS|Ultrasound-guided infraclavicular block - lateral sagittal approach (20 ml 0.5% bupivacaine)
10124327|NCT04356521|Active Comparator|Group CC|Ultrasound-guided infraclavicular block - costoclavicular approach (20 ml 0.5% bupivacaine)
10183298|NCT03765957|Experimental|Mesenchymal Stem Cells|The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.
10183299|NCT03765944|Active Comparator|NPC-12 granule|NPC-12 granules (1.0g: 2mg sirolimus)
10183300|NCT03765944|Active Comparator|NPC-12T tablet|NPC-12T 2 tablets (2mg sirolimus)
10183301|NCT03765931|Active Comparator|subjects treated with doxycycline|The participants treated by doxycycline 100 mg will have one dose but followed 5 days
10183302|NCT03765931|Placebo Comparator|subjects treated with amoxycilline|The participants treated with amoxycilline 500 mg will have 2 doses per days during 5 days treatement and follwed during these 5 days
10183303|NCT03765905||PCOS diagnosis area|The study group consisted of 40 reproductive age women between 18th and 35th years old women who were PCOS diagnosis (according to the 2003 Rotherdam criteria)
10183304|NCT03765905||PCOS is not diagnosed|Forty patients who did not have any complaints between the ages of 18-35 who applied to the gynecology policlinic as a control group but who had no PCOS orany other systemic problems and were similar in terms of age group and body mass index were included in the study after being approved for participation in the study
10183305|NCT03765892||Adult Case Group|Adults with type 1 narcolepsy according to the ICSD3
10183306|NCT03765892||Adult Control Group|Parents, cousins and / or friends of included narcoleptic adult patients, at least 18 years old and not suffering from narcolepsy.
10183307|NCT03765892||Children Case Group|Children with type 1 narcolepsy according to the OCSD3
10183308|NCT03765892||Children Control Group|Close friends and cousins of included narcoleptic children, minor and not suffering from narcolepsy.
10183309|NCT03765879|Experimental|Verum VGAIT Group|Participants in this group will receive verum (real) acupuncture and verum video-guided acupuncture imagery treatment (VGAIT).
10183310|NCT03765879|Placebo Comparator|Sham VGAIT Group|Participants in this group will receive sham acupuncture and sham VGAIT.
10183311|NCT03765866|No Intervention|Massive Transfusion Protocol Guided|Clinicians will only transfuse patients according to standard massive transfusion protocol (MTP)
10183312|NCT03765866|Experimental|Thromboelastometry guided transfusion|Clinicians will transfuse patients according to ROTEM results.
10183313|NCT03765853|Other|Stretching Postural®|
10183314|NCT03765853|No Intervention|Control|
10183315|NCT03765840||POCD group|patients occur cognitive decline after surgery according to scores in this group.
10183316|NCT03765840||NO POCD group|patients do not occur cognitive decline after surgery according to scores in this group.
10183317|NCT03765827|Experimental|Vitamin E acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
10183318|NCT03765827|Sham Comparator|Control group|No ointment will be applied
10183319|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fed)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.
10183320|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fasting)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
10183321|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fed)|Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.
10183322|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fasting)|Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
10183323|NCT03765775|Experimental|Anlotinib Hydrochloride+Sintilimab|Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle , Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
10183324|NCT03765710|Experimental|Recommended protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 13% protein, 54% carbohydrate, and 33% fat.
10183325|NCT03765710|Experimental|Elevated protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 26% protein, 44% carbohydrate, and 30% fat.
10183326|NCT03765697|Experimental|Lidocaine 5% medicated plaster|Up to 3 plasters were applied per day.
10183327|NCT03765671|Experimental|Mild Child-Pugh A|Single oral dose of elafibranor 120mg
10183328|NCT03765671|Experimental|Moderate Child-Pugh B|Single oral dose of elafibranor 120mg
10183329|NCT03765671|Experimental|Severe Child-Pugh C|Single oral dose of elafibranor 120mg
10183330|NCT03765671|Experimental|Healthy|Single oral dose of elafibranor 120mg
10183331|NCT03765658|Experimental|GRT0151Y dose escalation|GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
10124328|NCT04356625|Other|MEPic|"Ready for extubation (pass SBT)~Measurement of maximum expiratory pressure during the induced cough (MEPic)"
10124329|NCT04356651|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
10124330|NCT04356651|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
10124331|NCT04356560||healthcare workers|Actively working at Department of Otorhinolaryngology Head and Neck Surgery & Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark. During 2020 COVID 19 pandemic
10124332|NCT04356560||Patients|Patients presenting with complications to upper respiratory tract infections and patients undergoing surgery involving airway mucosa During 2020 COVID 19 pandemic
10124333|NCT04356469|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
10124334|NCT04356547|Active Comparator|Fiberoptic intubation using laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
10124335|NCT04356547|Active Comparator|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
10124336|NCT04356482|Experimental|single arm|"Determine the convalescent plasma dose to be administered to two groups: one severely ill (not intubated) and one very severely ill (intubated).~Second phase: safety and efficacy of the plasma dose found in the same two types of patients."
10124337|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & HGB|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and the Hipogastric component (HGB)
10124338|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & VBx|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and Viabahn Balloon Expandable ( VBx)
10124339|NCT04356352|Active Comparator|Lidocaine|1 mg/kg lidocaine to a max of 100 mg
10124340|NCT04356352|Active Comparator|Esmolol|0.5 mg/kg esmolol to a max of 50 mg
10124341|NCT04356352|Placebo Comparator|Placebo|Saline water
10124342|NCT04356274|Experimental|Participatory System Dynamics (PSD)|12 clinics assigned to PSD
10124343|NCT04356274|Experimental|Audit and Feedback (AF)|12 clinics assigned to AF
10124344|NCT04356391|Active Comparator|Connective Tissue Graft harvest from Palate|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Technique. The tooth assigned to the CTG technique will receive the graft harvested from the palate.
10124345|NCT04356391|Experimental|collagen resorbable membrane material|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Surgical Technique (PST). The tooth assigned to the PST technique will receive the collagen resorbable membrane material.
10124346|NCT04356248|Experimental|High-intensity interval training + energy management education|"High-intensity interval training (HIIT): physiologically defined heart rate-controlled cycling with 80-100 rounds per minute (rpm) at 95-100% of maximum heart rate (HRmax). Participants will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 min with the aim to achieve 60% of HRmax.~Energy management education (IEME): face-to-face education sessions of 6.5 h in duration over a 3-week period, all conducted by a trained occupational therapist. Participants acquire knowledge and understanding about factors that influence energy and the consequences of fatigue on their habits and lifestyle. Six weeks after returning home, the participants will receive a reinforcement letter in the form of information material to remember the content of the IEME and to reinforce the implementation of the behaviour change in managing energy."
10124347|NCT04356248|Active Comparator|Low-intensity training + progressive muscle relaxation|"Low-intensity training (ST): participants will exercise for 24 min continuously at 65% of participants' HRmax (60-70 rpm).~Progressive muscle relaxation (PMR): The aim of PMR is to achieve enhanced mental relaxation by reducing muscle tension. Participants will attend six 1-h group sessions over the 3-week intervention period, instructed by a trained physical therapist. Six weeks after returning home, the participants will receive a reinforcement letter with information material for remembering the content of the PMR techniques and to reinforce the implementation of the exercises at home."
10124348|NCT04356378||"infection with coronavirus SARS-CoV2 group"|"SARS-CoV2 infected patients group: in-patient in the acute phase then requiring rehabilitation."
10124349|NCT04356079||Migraine patients|
10124350|NCT04356079||Control|
10124351|NCT04356235||A:Exp-impl-mastopexy|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
10124352|NCT04356235||B: exp-impl-mastopexy+mesh|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
10124353|NCT04356235||C: exp-impl-mastopexy+implant|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
10124354|NCT04356235||D: exp-impl-mastopexy+implant+mesh|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
10124355|NCT04356235||E: simple masectomy|unilateral simple mastectomy
10124356|NCT04356235||F: bilateral exp-impl|after bilateral SSM, ASM, NSM, expander-implant exchange
10124357|NCT04356222|Experimental|Leptomeningeal Metastasis|Durvalumab + Intrathecal chemotherapy
10124358|NCT04356144||Critical infection|Patients with signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2 admitted to the ICU
10124359|NCT04356300|Experimental|The exosome of MSC arm|Exosome of MSC at a dose of 150mg will be given intravenously to Patients in the exosome of MSC arm once a day for 14 times.
10124360|NCT04356300|No Intervention|The control arm|Patients in the control arm will not be given exosome of MSC.
10124361|NCT04356131|Experimental|experimental group|Students in the experimental group were taught about massage and progressive relaxation exercises (PRE). The phases of the massage and PRE trainings were first explained by being demonstrated by the author on herself. In the meantime, the trainings were video-taped and uploaded to the mobile phones of the students. After the author, each student was made to perform massage and PRE. Both the exercises and massage techniques were daily performed 3 times a day after pain had started and relaxation exercises lasted 30 minutes whereas massage was performed for 15 minutes consecutively
10124362|NCT04356131|No Intervention|control group|The students in the control group continued their routines during the study.
10124363|NCT04356157|Other|Special day|The special day takes place with an extraordinary opening of the clinical centre once a month on a pre-festive day (Saturday). During this day, access will be reserved exclusively for men, including those who are not on treatment for HIV. The centre will offer free health promotion services to all participants.
10124364|NCT04356157|Other|Male Champions|"The male champion is a figure present in a few settings which carries out home visits with men and couples and follows up with men who did not accompany their partners to Antenatal Care visits. Usually, this role is covered by the female Expert Clients, namely HIV+ patients working in the organization as volunteers after appropriate training. Some men among patients who are on treatment will be identified and trained to cover this role."
10124365|NCT04356157|Other|Nudge|The intervention based on the use of incentives (nudge) to men who follow the prevention and treatment program aims to evaluate whether this action is effective in guiding behaviour change towards the test, treatment, involvement and adherence to therapy approach.
10124366|NCT04356157|Other|No intervention|No intervention will be carried out in a center.
10124367|NCT04356118|Experimental|Endostatin Therapy for NSCLC of LM|"Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer~Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.~intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.~Targeted drugs for non-small cell lung cancer:~EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs ."
10124368|NCT04356456|Experimental|Lumenato Supplement|Lumenato oleoresin
10124369|NCT04356456|Placebo Comparator|Placebo|paraffin oil
10124370|NCT04356170|Active Comparator|TPF (docetaxel, cisplatine, 5-FU)|Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
10124371|NCT04356170|Experimental|TPFm (docetaxel, cisplatine, 5-FU) modifié|Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
10124372|NCT04356040|Experimental|Main Study|
10124373|NCT04356040|Experimental|HSP Sub-Study|
10124374|NCT04355897|Experimental|Convalescent COVID 19 Plasma|Subjects will receive and intravenous infusion of 500 mls of Convalescent COVID 19 Plasma.
10124375|NCT04355845|Experimental|Sumatriptan and PF-06651600 DDI|In Period 1, participants will receive a single oral 25 mg dose of sumatriptan on Day 1 in the morning. In Period 2 on Day 1, participants will receive a single oral 25 mg dose of sumatriptan and a single 400 mg oral dose of PF-06651600 in the morning. In Period 3 participants will receive a single 400 mg oral dose of PF-06651600 in the evening of Day 1, and then a single oral 25 mg dose of sumatriptan in the morning of Day 2.
10124376|NCT04356001|Experimental|Socket preservation group|"Extraction sockets filled with a one-piece dual tissue graft harvested from the tuberosity using an adjusted trephine."
10124377|NCT04355988|Active Comparator|Well controlled diabetics|Nonsurgical root canal treatment
10124378|NCT04355988|Active Comparator|Poorly controlled diabetics|Nonsurgical root canal treatment
10124379|NCT04355988|Active Comparator|Healthy control group|Nonsurgical root canal treatment
10124380|NCT04355962|Experimental|Sevoflurane Sedation|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
10124381|NCT04355962|Active Comparator|Intravenous|No use of sevoflurane, but current intravenous sedation at discretion of the ICU physician in charge, e.g. with propofol, fentanyl, midazolam and dexmedetomidine
10124382|NCT04355949|Experimental|Patients with premature ejaculation|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
10124383|NCT04355949|Experimental|Normal subjects|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
10124384|NCT04355819|Experimental|Disclosure before|Patients will be told that a hernia was found on CT before the follow-up survey is administered.
10124385|NCT04355819|Experimental|Disclosure after|Patients will be told that a hernia was found on CT after the follow-up survey was administered.
10124386|NCT04356066|Other|Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise|"History taking: age, sex, disease duration, history of present illness, drug intake, past and family history.~Physical examination including thorough clinical examination.~Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018)."
10124387|NCT04355975||Medical Therapy / Anticoagulation|
10124388|NCT04355975||Systemic Lysis|
10124389|NCT04355975||Interventional Therapy for PE|
10124390|NCT04355975||Surgical Embolectomy|
10124391|NCT04356092|Experimental|Perfusion|Consecutive patients scheduled to undergo infrapopliteal angioplasty or stenting, or both, as part of their standard treatment for Rutherford-Becker class 5 and 6 chronic limb-threatening ischemia, were included in the study. All procedures were performed using local anesthesia. An antegrade access was used in all patients followed by the deployment of a 5 or 6 Fr arterial sheaths. A semi-lateral foot projection was preferred and the pre-revascularization DSA of the foot was performed via a 5 Fr angiographic catheter placed at the distal third of the popliteal artery. Following revascularization of one or more tibial arteries, the catheter was placed at the same popliteal segment and post-procedural DSA of the foot was performed following the exact pre-revascularization injection protocol at the same semi-lateral projection. The 2D-perfusion imaging and analysis of the DICOM files was performed after revascularization.
9519526|NCT03286309|Placebo Comparator|sham group|subjects will receive passive pre-programmed soft robot hand system.
10124392|NCT04355936|Experimental|TELMISARTAN|Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
10124393|NCT04355936|No Intervention|CONTROL|Patients in this group will receive standard care.
10124394|NCT04355754|Experimental|mechanically ventilated patients|"Adult ICU patients who are mechanically ventilated and who do not require complex modes of ventilation.~A designated flow divider (Ventil) will be used to divide inspiratory gas flow from ventilator in two separate streams - one to the patient and the second to the artificial lung"
10124395|NCT04355910|Experimental|Intermittent fasting mimic-diet (IFD)|Restrict 75% energy on two non-consecutive days each week.
10124396|NCT04355910|Active Comparator|Continuous calorie restriction (CCR)|A daily 25% energy-restricted Mediterranean-type diet
10124397|NCT04355910|No Intervention|Control|No advice to restrict energy
10124398|NCT04355806||Vaccinated NSCLC group|This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
10124399|NCT04355806||Vaccinated Health group|This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
10124400|NCT04355806||Unvaccinated NSCLC group|This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
10124401|NCT04355741||Ambulatory|Patients that are self-isolated at home
10124402|NCT04355741||Ward|Patients that are in an isolated room at the hospital
10124403|NCT04355741||ICU|Patients that are in the ICU of the hospital
10124404|NCT04355676|Experimental|Selinexor 40mg|Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
10124405|NCT04355676|Experimental|Selinexor 20mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
10124406|NCT04355559||conventional oxygen therapy|Continuous use of current oxygen therapy
10124407|NCT04355559||high flow nasal cannula|change the oxygen therapy to high flow nasal cannula
10124408|NCT04355559||Noninvasive ventilation|change the oxygen therapy to noninvasive ventilation
10124409|NCT04355598|Experimental|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
10124410|NCT04355598|Active Comparator|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
10124411|NCT04355598|Placebo Comparator|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
10124412|NCT04355637|No Intervention|Control|patients receiving standard of care to treat their pneumonia
10124413|NCT04355637|Experimental|Intervention|patients receiving standard of care to treat their pneumonia + inhaled budesonide
10124414|NCT04355650|Experimental|Clinical decision tool|Launch of clinical decision support tool at baseline visit with study clinician.
10124415|NCT04355351|Other|hospital staff exposed to SARS-Cov-2|
10124416|NCT04355351|Other|SARS-Cov-2 infected patient|
10124417|NCT04355468||Control group|General anaesthesia was induced with midazolam 0.1 mgkg-1, propofol 2 mgkg-1 and cisatracurium 0.15 mgkg-1. Anaesthesia was maintained with one minimal alveolar concentration (MAC1) sevoflurane. Patients awoke from anaesthesia in the postanaesthesia care unit (PACU) where extubation was performed by an anaesthetist after administration of incremental doses of atropine and neostigmine, as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia or until side effects occurred. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
10124418|NCT04355468||Opioid Free Aneasthesia group|General anaesthesia was induced with midazolam 0.1 mgkg-1, propofol 2 mgkg-1 and cisatracurium 0.15 mgkg-1. Anaesthesia was maintained with one minimal alveolar concentration (MAC1) sevoflurane. Patients awoke from anaesthesia in the postanaesthesia care unit (PACU) where extubation was performed by an anaesthetist after administration of incremental doses of atropine and neostigmine, as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia or until side effects occurred. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
10124419|NCT04355338||0-9 years|Participants aging 0-9 years
10124420|NCT04355338||10-19 years|Participants aging 10-19 years
10124421|NCT04355338||20-29 years|Participants aging 20-29 years
10124422|NCT04355338||30-39 years|Participants aging 30-39 years
10124423|NCT04355338||40-49 years|Participants aging 40-49 years
10124424|NCT04355338||50-59 years|Participants aging 50-59 years
10124425|NCT04355338||60-69 years|Participants aging 60-69 years
10124426|NCT04355338||70-79 tears|Participants aging 70-79 years
10124427|NCT04355338||80+ years|Participants aging 80 years or more
10124428|NCT04355416|Experimental|curcumin oral gel|
10124429|NCT04355416|Other|subgingival scaling and root planing|
10124430|NCT04355507||Patients with suspicions of COVID-19 pneumonia|Patients with suspicions of COVID-19 pneumonia
9519527|NCT03286296|Experimental|LZM009|
10124431|NCT04355377||Patients|
10124432|NCT04355312|Experimental|Kysindo|Group of 45 patients with short-term desire for pregnancy who will undergo laparoscopic ovarian cystectomy with use of indocyanine green. Evaluation of the ovarian reserve preoperatively and longitudinal cohort follow-up after surgery at 6 months and 12 months. Analysis by a new imaging technique.
10124433|NCT04355299|Experimental|Intervention group|a mixed exercise program including aerobic, balance, and resistance exercises that were personally tailored.
10124434|NCT04355299|Other|control group|usual care
10124435|NCT04355234|Experimental|all patients|
10124436|NCT04355234|Experimental|patients who presented a SARS-CoV-2 infection confirmed by PCR|
10124437|NCT04355286|Experimental|Part 1, one-arm open label pilot study|Part 1 is an open label, 1-arm pilot study to evaluate the systemic absorption and effects of multiple applications of a market-image topical sunscreen formulation containing BEMT (6%) under maximum use conditions in healthy adult subjects.
10124438|NCT04355520|Experimental|TQ-B3525 tablets combined with fulvestrant injection|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
10124439|NCT04355273|Experimental|Heparin with a concentration of 2 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
10124440|NCT04355273|Experimental|Heparin with a concentration of 4 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
10124441|NCT04355273|Placebo Comparator|normal saline|normal saline is placed in a pressure bag with a pressure of 300 mmHg
10124442|NCT04355325|Active Comparator|Experimental|modified monolithic zirconia crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
10124443|NCT04355325|Placebo Comparator|control|metal ceramic crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
10124444|NCT04355611||Patients with MS or NMO|Cohort study evaluating the epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
10124445|NCT04355533|Experimental|Hospitalized children or consulting at hospital|
10124446|NCT04355533|Experimental|Parents of one included child|
10124447|NCT04355533|Experimental|Children with potential COVID disease during the first wave|
10124448|NCT04355533|Experimental|School children SARS-coV2 positive|
10124449|NCT04355533|Experimental|person living under the same roof as children included in the study|
10124450|NCT04355403|Experimental|Hyalo Gyn gel|Vaginal application of Hyalo Gyn gel in prefilled applicators
10124451|NCT04355403|No Intervention|No treatment|No treatment application
10124452|NCT04355442||contained patients|contained patients
10124453|NCT04355442||Comparative patients|Comparative patients
10124454|NCT04355689|Experimental|NPI-001|NPI-001 Tablet, 250 mg, BID
10124455|NCT04355689|Placebo Comparator|Placebo|Placebo Tablet, BID
10124456|NCT04355429|Experimental|CAPTOPROL|Inhalation administration by nebulization
10124457|NCT04355429|No Intervention|STANDARS CARE|According to surviving covid-Campaign guidelines
10124458|NCT04355247|Experimental|Single Arm|"Patients will be admitted to a regular room in the hospital (not ICU)~They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
10124459|NCT04355455|Active Comparator|Citalopram|Administration of citalopram to assess the esophageal sensitivity in HV
10124460|NCT04355455|Placebo Comparator|Placebo|Administration of placebo to assess the esophageal sensitivity in HV
10124461|NCT04355260|Experimental|Hypertrophic Obstructive Cardiomyopathy|
10124462|NCT04355624||ICU patients|COVID-19 patients admitted in Intensive Care Units
10124463|NCT04355624||Non ICU patients|COVID-19 patients admitted in conventional units
10124464|NCT04355208|Experimental|Intervention|Restoration of anterior teeth using monochromatic layering technique using body shade (filtek universal from 3m
10124465|NCT04355208|Active Comparator|comparator|Restoration of anterior teeth using polychromatic layering technique using Enamel and Dentin shades (filtek Z350 xt from 3m
10124466|NCT04355221|Active Comparator|Group A|using the standard settings of pulsed radiofrequency technique (PRFT). two cycles, each one for 2 minutes at 45 Volts (V) with a pulse width of 10 milliseconds (ms) and a pulse frequency of 4 Hertz (Hz). The cut-off needle tip temperature is set at 420 Celsius (C).
10124467|NCT04355221|Experimental|Group B|using prolonged duration of PRFT. four cycles, each one for 2 minutes at 45V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
10124468|NCT04355221|Experimental|Group C|using higher voltage PRFT.. two cycles, each one for 2 minutes at 60V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
10124469|NCT04354857||RT-PCR SARS-CoV-2 positive|
10124470|NCT04354857||RT-PCR SARS-CoV-2 negative|
10124471|NCT04355000|Active Comparator|Hall Technique|In Hall Technique, SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
10124472|NCT04355000|Active Comparator|RMGIC restoration|In RMGIC(Vitremer) filling, carious lesion will be completely removed from primary molars using air rotor and local anaesthesia according to need and filled with vitremer rmgic material.
10124473|NCT04354987|Experimental|Group A|R+R+T+T Period 1 : R Period 2 : R Period 3 : T Period 4 : T
10124474|NCT04354987|Experimental|Group B|R+T+R+T Period 1 : R Period 2 : T Period 3 : R Period 4 : T
10124475|NCT04354987|Experimental|Group C|T+R+T+R Period 1 : T Period 2 : R Period 3 : T Period 4 : R
10124476|NCT04354987|Experimental|Group D|T+T+R+R Period 1 : T Period 2 : T Period 3 : R Period 4 : R
9826006|NCT02404168|Active Comparator|lamotrigine brand tablet2|lamotrigine tablet Lamictal
9826007|NCT02404168|Experimental|lamotrigine generic tablet2|lamotrigine tablet Teva
10124477|NCT04355026|Experimental|hydroxychloroquine and bromhexine|Bromhexine 16 mg TID + hydroxychloroquine 200 mg BID
10124478|NCT04355026|Active Comparator|hydroxychloroquine alone|hydroxychloroquine 200 mg BID
10124479|NCT04354844||Cyanotic and acyanotic group|questinnaire
10124480|NCT04355078|Experimental|Neuromuscular Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks. The involved leg is used if nothing else is stated that includes Walking on a treadmill, Squatting exercises, Single leg stance exercise Balance reach leg and arm exercises, Lunge exercises: anterior, lateral and posterior, Step-up and step down exercises, Single leg standing on balance mat, appropriate knee and hip position, Backwards and sideways walking for 5 steps on each side 1, 1 leg and 2 leg Wobble board Exercise and progress after every two weeks
10124481|NCT04355078|Experimental|Strength Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks that includes straight leg raising exercises, Supine position-isometric quadriceps contraction, Supine position-knee flexion and extension ROM exercises, the heel in contact with the bench during the ROM, Prone position-straight leg raising exercises, Prone position-knee flexion & Extension ROM exercises, Stationary biking-before reaching 100 degrees of flexion(Progression: stair climbing and strength exercises), Standing-full weight-bearing, controlled balance double-limb support during parallel and diagonal stance, controlled knee extension, emphasis on full knee extension in weight-bearing position 3 10 reps Standing heel rising exercises both legs and one leg, 1 leg and 2 leg Wobble board Exercise, Step Up and down low height, Squatting exercises without bars/weight, Hamstrings, hip adductor and abductor strengthening exercises and progress after every two weeks
10124482|NCT04355052|Active Comparator|A - HCQ + AZT|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
10124483|NCT04355052|Experimental|B - HCQ + CAM|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Camostat mesylat 200 mg TID for 10 days
10124484|NCT04355052|No Intervention|C - NI|No Intervention
10124485|NCT04354974|Active Comparator|Eco Program (Ecological Cognitive Training for Mood Disorders)|"Duration: four months, 16 sessions~Frequency: One one-hour session and one hour of personal work per week~Modalities: Paper and pencil exercises and manipulable tools~Objective: Learning problem-solving strategies for use in daily life~Modules: Psychoeducation, Information Processing, Memory, Concept Formation, Functional Disorders"
10124486|NCT04354974|Active Comparator|ThOR Program (Remission Oriented Therapy)|"Duration: four months, 16 sessions~Frequency: One one-hour session and one hour of personal work per week~Modalities: Paper tools and verbal exchange with the patient~Objective: Improvement of the patient's quality of life~Themes: Mood, social skills, autonomy, motivation, sleep"
10124487|NCT04354896|Experimental|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.
10124488|NCT04354896|Placebo Comparator|Placebo|Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
10124489|NCT04354961|Experimental|Almonertinib 110mg PO once daily|
10124490|NCT04354961|Active Comparator|Paclitaxel (175mg/m2, iv) and carboplatin (AUC=5, iv)|
10124491|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 50 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
10124492|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 65 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
10124493|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 80 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
10124494|NCT04355065|Experimental|Cognitive Training with Virtual Reality Videogame|"The Secret trail of mon is a therapeutic video game that has been created for the cognitive training of patients with ADHD.~Five mechanisms have been designed to work on five cognitive functions that are deficient in ADHD: attention, memory, reasoning, planning and visuospatial ability.~Patients have to go to the hospital once a week for training sessions of approximately forty minutes duration during 12 weeks."
10124495|NCT04355065|Experimental|Cognitive Training with Therapeutic chess|"The training in Therapeutic chess consists of four sections:~Video tutorial: Weekly videos have been recorded in which a chess board and the image of the psychologist explaining the lesson appear. Each week a chess concept will be explained.~Traditional chess exercises Therapeutic chess exercises: The exercises use the elements of chess but it is not necessary to know how to play chess to perform them. The purpose of the exercise is to work on a specific cognitive area each week.~Playing online games: The patient must play a minimum of 2 online games on the chess platform chess24.es . The psychologist will follow the progress of each patient.~At the end of the week, the patient should send an email to the psychologist with the completed exercises and then they will receive a personalised email. This group carries out all the treatment online from their home."
10124496|NCT04355065|Active Comparator|Control Group|This group corresponds to the control group. The control group continues with their prescribed pharmacological treatment without any cognitive intervention. The participants of this group are contacted by telephone once a week to follow up on possible difficulties and/or side effects.
10124497|NCT04355104|Experimental|Education+standard physical therapy|Consist of 37 patients will take education sessions in addition to standard physical therapy.
10124498|NCT04355104|Active Comparator|Standard physical therapy|Consist of 37 patients take just standard physical therapy.
10124499|NCT04355091|Experimental|Intervention Group|"The pregnant women in this group will be informed about the application of EFT with a written material.~The pregnant women who have undergone EFT will be interviewed a week or two after the application, and how they feel and whether the problem still disturbs him. If a new issue is reported, similar actions will be repeated for this new issue. The number of EFT sessions was decided based on the condition of the pregnant woman. After all EFT sessions are completed, a re-evaluation (post-test) of Edinburgh Postpartum Depression Scale, Stress Coping Scale and State-Trait Anxiety Inventory will be done.~The same participants will be asked to apply the other inventories and the postpartum interview form if she had birth three months and six months after the last application (follow-up). In the follow-up study performed three months after the last application, EFT will be applied to the pregnant women in need."
10124500|NCT04355091|No Intervention|control group|"The participants in this group will be talked about the problems they should have in routine midwifery care, the problems they encounter during pregnancy or postpartum period and the subjects they want to receive information.~If necessary, suggestions will be made for problems related to pregnancy, postpartum period or newborn care. Again, with these participants, after the depression risk determination (pre-test), after the interviews ended (post-test), three months and six months after the last application, Edinburgh Postpar All Depression Scale, Stressful Life Events List, Stress Coping Scale. If the pregnant woman has given birth, State-Trait Anxiety Inventory and postnatal interview form will be performed."
10124501|NCT04354766||Convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID + on the temporary sampling platform that was set up at HCL at the start of the epidemic, which notably concerns symptomatic healthcare professionals for whom hospitalization does not was not necessary.
10124502|NCT04354766||Hospitalized convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID +, hospitalized in the infectious diseases department of the Croix-Rousse hospital living in the metropolitan area of Lyon, having presented hypoxaemic pneumonia requiring hospitalization.
10124503|NCT04354883|Active Comparator|Schmitz-Hinkelbein-Method|
10124504|NCT04354883|Active Comparator|Hinkelbein-Schmitz-Method|
10124505|NCT04354948|Experimental|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 3 min wall squat exercise
10124506|NCT04354948|Placebo Comparator|No pain (Hypotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 3 min wall squat exercise
10124507|NCT04354935|Active Comparator|Méthode 1 ( iTBS)|target region: Dorsolateral Prefrontal left Fréquence : 50 Hz Intensity of the stimulation : 120% SM duration : 3 minutes Number of pulses : 600
10124508|NCT04354935|Active Comparator|Méthode 2 (French touch)|target region : dorsolateral prefrontal cortex right Frequency:1HZ Intensity:120% SM duration : 8 Min 30 Sec Number of plulses : 360
10124509|NCT04354935|Active Comparator|Méthode 3 (FDA)|target region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM duration : 37 minutes Number of pulses : 3000
10124510|NCT04354805|Experimental|Group A|The group of 50 patients are going to receive Chlorpromazine (oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days) every 24 hours for 14 days in addition to the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
10124511|NCT04354805|No Intervention|Group B|A group of 50 patients control group who will recieve only the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
10124512|NCT04355156|Experimental|Axitinib|small molecule multi-kinase inhibitor
10124513|NCT04355156|Placebo Comparator|Placebo|
10124514|NCT04354779||AUVA HCW|health care workers in Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA)
10124515|NCT04354571|Experimental|GROUP (Erector spinae block):|were given general anesthesia plus Erector spinae plane block
10124516|NCT04354571|Active Comparator|GROUP (caudal block):|were given general anesthesia plus caudal block
10124517|NCT04354727|Experimental|APG-1252|
10124518|NCT04354727|Experimental|APG-1252 + Ruxolitinib|
10124519|NCT04354662|Experimental|Toripalimab combined with FLOT|In the perioperative period, patients with resectable gastric cancer is treated with flot regimen combined with Toripalimab to observe whether the 3-year disease-free survival (DFS) rate, pathological remission rate, R0 resection rate, D2 radical resection rate, 5-year DFS rate and 5-year OS rate could be improved.
10124520|NCT04354714|Experimental|Ruxolitinib|-Ruxolitinib is an oral medication that will be given twice daily (BID). Dosing on Days 1 through 3 will be 5 mg BID; dosing on Days 4 through 10 will be 10 mg BID.
10124521|NCT04354441|Experimental|hydroxychloroquine|10-day course of hydroxychloroquine 200 mg tablet twice a day. To be taken orally.
10124522|NCT04354441|Placebo Comparator|Placebo|An identical appearing placebo. To be taken orally twice a day for 10-days.
10124523|NCT04354467||Acute Kidney Injury due to Nephrotoxic medication|
10124524|NCT04354467||No Acute Kidney Injury due to Nephrotoxic Medications|
10183332|NCT03765645|Active Comparator|3 doses on intra venous antibiotics|Patients will receive 3 doses of intra venous antibiotics. (1 dose preoperative, 1 intra operative and 1 post-operative)
10183333|NCT03765645|Active Comparator|9 doses of intra venous antibiotics|Patients will receive 9 doses of intra venous antibiotics. (1 dose preoperative, rest 8 doses at equal intervals)
10183334|NCT03765606|Placebo Comparator|Cocoa Flavanol beverage mix|Cocoa Flavanol beverage mix (flavanols, 566mg; caffeine, 11mg & theobromine, 93mg)
9668996|NCT04403802|Experimental|Arm B: Placebo socks followed by Voxx socks|Continuous wear of placebo socks for 2 weeks, followed by continuous wear of Voxx Human Performance Technology Socks for 2 weeks (separated by a 2-week washout period)
10183335|NCT03765606|Experimental|De-xanthinated Cocoa Flavanol beverage mix|De-xanthinated Cocoa Flavanol beverage mix (flavanols, 583mg; caffeine, 0.6mg & theobromine, 0.2mg)
10183336|NCT03765593||Study group 1|Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.
10183337|NCT03765593||Study group 2|Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.
10183338|NCT03765593||Study group 3|Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.
10183339|NCT03765593||Control group|Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.
10183340|NCT03765580|Placebo Comparator|Control group|No fish
10183341|NCT03765580|Experimental|1 portion of fish per week|140g fish/week
9668997|NCT04393935|Experimental|Pharmacy delivered PrEP Intervention|Customers of the study pharmacies who participate in the intervention to receive PrEP through the pharmacy.
9668998|NCT04382898|Experimental|Part 1 (mCRPC) - dose titration|W_pro1 monotherapy
10124525|NCT04354545||Group 1|Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks
10124526|NCT04354389|Experimental|DAS181 b.i.d.+ standard local care for COVID-19|4.5 mg DAS181 b.i.d nebulized inhalation for 10 consecutive days + standard local care for COVID-19
10124527|NCT04354389|Placebo Comparator|Placebo+ standard local care for COVID-19|nebulized inhalation for 10 consecutive days + standard local care for COVID-19
10124528|NCT04354389|Experimental|DAS181 q.d.+ standard local care for COVID-19|4.5 mg placebo q.d. nebulized inhalation for 10 consecutive days + standard local care for COVID-19
10124529|NCT04354350||Ramipril|Reference group
10124530|NCT04354350||Telmisartan|Exposure group
10124531|NCT04354324|Experimental|The test group|Oral administration of 30mci once on an empty stomach.
10124532|NCT04354324|Active Comparator|The control group|Oral administration of 100mci once on an empty stomach.
10124533|NCT04354428|Placebo Comparator|Ascorbic acid and Folic acid|Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)
10124534|NCT04354428|Experimental|Hydroxychloroquine and Folic Acid|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5])
10124535|NCT04354428|Experimental|Hydroxychloroquine and Azithromycin|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).
10124536|NCT04354428|Experimental|Lopinavir-ritonavir|LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)
10124537|NCT04354428|Placebo Comparator|Ascorbic acid|Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days
10124538|NCT04354740||Group A : Diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
10124539|NCT04354740||Group B: Non diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
10124540|NCT04354311|Experimental|Experimental|"Anesthetic induction : total target-controlled intravenous anesthesia d was used with propofol and remifentanil. The effect site was then gradually increased to obtain a satisfaction depth of anesthesia. Assisted ventilation was then started by facemask ventilation (Sat O2>95% and expired CO2 fraction normal, tidal volume of 8 mL/kg, a respiratory rate of 12 cycles per minute, with an FiO2 100% with no positive end expiratory pressure.~After stabilisation period of 2 minutes and record of the patient's parameters, a standardized nociceptive stimulation was applied at the level of the ulnar nerve (PTC of 50 Hz at 70 mA). The variation of ANI score and hemodynamic parameters were collected during the 2 following minutes.~After stabilization of ANI, orotracheal intubation was attempted. Maximal variation of heart rate (HR), blood pressure and the occurrence of somatic manifestations (intense cough, movement, tears) were recorded."
10124541|NCT04354610|Other|Patients hospitalized for Covid-19 infection|"Patients hospitalized for Covid-19 infection will undergo the following evaluations:~Clinical examination~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
10124542|NCT04354623||High Risk Subjects (n=50)|All subjects will be recruited from falls and geriatrics clinics at Vancouver General Hospital. These clinics see about 2500 patients per year and are currently used for research recruitment. Each clinic patient has gait speed measured, which will allow to recruit both high and low risk fallers. This test will allow us to recruit 50 subjects at marked risk for falls, providing us with prospectively gathered dataset of greater than 100 events, five times higher than any other sensor study.
10124543|NCT04354623||Low Risk Subjects (n=50)|We will use newspaper advertisements to recruit and then screen low risk subjects. All subjects will have a gait speed > 0.8 m/s and have had no falls in the last year.
10124544|NCT04354363|Active Comparator|PRP|women who will receive PRP before ICSI
10124545|NCT04354363|No Intervention|No PRP|women who willnot receive PRP before ICSI
10124546|NCT04354675|Experimental|Artificial intelligence program|Will complete consult with the use of an artificial intelligence program Chatbot.
10124547|NCT04354675|Active Comparator|in-person genetic counseling|Will complete a traditional in-person genetic counseling. consult by meeting with a Genetics Counselor
10124548|NCT04354636|Experimental|Silver modified atraumatic restorative treatment|Using silver diamine fluoride incorporated with atraumatic restorative treatment
10124549|NCT04354636|Active Comparator|Atraumatic restorative treatment|Using atraumatic restorative treatment without the application of silver diamine fluoride
10124550|NCT04354376||Loop diuretics, thiazides, dihydropyridines|Reference group
10124551|NCT04354376||Telmisartan|Exposure group
9668999|NCT04382898|Experimental|Part 2 Arm 1A (mCRPC) - expansion cohort|W_pro1 in combination with cemiplimab
10124552|NCT04354246|Experimental|COM902 monotherapy dose escalation.|Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.
10124553|NCT04354246|Experimental|Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).|COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks.
10124554|NCT04354246|Experimental|COM902 monotherapy cohort expansion at RDFE.|COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
10124555|NCT04354246|Experimental|COM902 + COM701 combination cohort expansion both at RDFE.|COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
10124556|NCT04354207||Atopic dermatitis|
10124557|NCT04354207||Asthma|
10124558|NCT04354207||Healthy individuals|
10183342|NCT03765580|Experimental|2 portions of fish per week|280g fish/week
10124559|NCT04354220||no shunt, no lung injury|ventilated newborns / infants / children with healthy lungs and without or corrected congenital heart disease and no intra-/extra-cardiac shunt
10124560|NCT04354220||mild lung injury|ventilated newborns / infants / children with mild lung injury (OI between 4 and 8)
10124561|NCT04354220||moderate-severe lung injury|ventilated newborns / infants / children with moderate or severe lung injury (OI above 8)
10124562|NCT04354220||shunt lesion|ventilated newborns / infants / children with cyanotic heart diseases and therefore existing intra-cardiac or extra- cardiac right-left shunt lesions
10124563|NCT04354194|Experimental|Conventional Physiotherapy Group|This group will receive 15 sessions of conventional physiotherapy programme 5 times per week.
10124564|NCT04354194|Experimental|Osteopathic Manipulative Treatment Group|This group will receive 9 sessions of Osteopathic Manipulative Treatment programme 3 times per week.
10124565|NCT04353999|Experimental|980 nm diode laser photocoagulation|980 nm diode laser was used to coagulate the blood over the bone graft particles and achieve a socket seal after socket grafting
10124566|NCT04353999|Active Comparator|Dense polytetrafluroethylene membrane|dPTFE membrane was used to seal the socket after grafting
10124567|NCT04354090|Experimental|Cohort 0.3-mg|Eligible subjects received 0.3 mg placebo or JY09 on day 1 in this cohort
10124568|NCT04354090|Experimental|Cohort 0.7-mg|Eligible subjects received 0.3 mg placebo or JY09 on days 1, and 0.7 mg placebo or JY09 on days 22
10124569|NCT04354090|Experimental|Cohort 1.5-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.5 mg placebo or JY09 on days 22
10124570|NCT04354090|Experimental|Cohort 3.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 3.0 mg placebo or JY09 on days 22
10124571|NCT04354090|Experimental|Cohort 6.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.0 mg placebo or JY09 on days 15, and 6.0 mg placebo or JY09 on days 30
10124572|NCT04354051|Experimental|Sodium nitrite|
10124573|NCT04354116|Experimental|MARPE|Maxillary expander anchored in mini-implants (MARPE)
10124574|NCT04354116|Active Comparator|Hyrax|Tooth-born anchored maxillary expanders, without mini-implants
10124575|NCT04353947||Healthy older adults|Healthy older adults with 65 years or older
10124576|NCT04353947||Older adults with Alzheimer's disease|Older adults with Alzheimer's disease with 65 years or older
10124577|NCT04353947||Older adults with Parkinson's disease|Older adults with Alzheimer's disease with 65 years or older
10124578|NCT04354142|Experimental|iSpy|In addition to usual care, participants in the intervention group will receive the iSpy intervention.
10124579|NCT04354142|No Intervention|Control|The control group participants will continue to use their usual method of carbohydrate counting for a 3-month period.
10124580|NCT04354129||PID/SID Cutaquig Treated Patients|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
10124581|NCT04353986|Experimental|Beta thalassemia|HCV infected Beta thalassemia major adolescents
10124582|NCT04353986|Active Comparator|Control|HCV infected, otherwise healthy, sex and age matched to the thalassemia group serving as control group
10124583|NCT04354532||209 patients were submitted to primary LBSG|All patients submitted to primary Laparoscopic Banded Sleeve Gastrectomy were examined. Collected data included demographic factors, pre-operative weight, pre-operative BMI, operative time, surgical complications, and clinical outcomes in terms of short and mid-term weight loss.
10124584|NCT04354415|Active Comparator|Tourniquet Group|Tourniquet application during procedures
9669000|NCT04382898|Experimental|Part 2 Arm 1B [1] (mCRPC) - expansion cohort|W_pro1 monotherapy
10124585|NCT04354415|Experimental|Non-Tourniquet group|No application of tourniquet for procedures
10124586|NCT04354337|Experimental|Intervention Group|8-weeks online program with weekly modules for parents to learn about specific sleep topics and implement behavioral changes to improve their child's sleep.
10124587|NCT04353882||patients with tumor recurrence|
10124588|NCT04353882||patients with-out tumor recurrence|
10124589|NCT04354298|Experimental|Fall 2019 ID Class|The ID group participated in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2019-December 2019.
10124590|NCT04354298|Experimental|Fall 2020 ID Class|The ID group will participate in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2020-December 2020.
10124591|NCT04354298|No Intervention|Control Group|Participants are pre- and post-tested 12-14 weeks apart after not having changed anything drastic in their daily life.
10124592|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939|Participants will be treated with escalating doses of IBI939 to determine the MTD.
9669001|NCT04382898|Experimental|Part 2 Arm 2 (LPC) - expansion cohort|W_pro1 in combination with cemiplimab
9669002|NCT04382898|Experimental|Part 2 Arm 3 (LPC) - expansion cohort|W_pro1 monotherapy
10124593|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab|Participants will be treated with escalating doses of IBI939 in combination with a fixed dose of Sintilimab to determine the MTD.
10124594|NCT04353830|Experimental|Phase Ib Expansion Stage:IBI939+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI939 in combination with Sintilimab in different cancer types.
10124595|NCT04353817|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA in the morning and IVA in the evening.
10124596|NCT04353817|Placebo Comparator|Placebo|Subjects will receive placebo matched to ELX/TEZ/IVA in the morning and placebo matched to IVA in the evening.
10124597|NCT04354480|Experimental|RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1.
10124598|NCT04354480|Placebo Comparator|Placebo|Participants will receive single IM injection in the deltoid muscle of matching placebo on Day 1.
10124599|NCT04353921||Single-Dose of Psilocybin|
10124600|NCT04353921||Niacin-Control|
10124601|NCT04353505|Experimental|Intra-Arterial Delivery of Ketorolac and Dexamethasone|
10183343|NCT03765554|Experimental|PF-06700841: IR followed by MR|Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR)
10124602|NCT04353479|Experimental|Camrelizumab(SHR-1210) Combined With Decitabine|Patients will be administered Camrelizumab(SHR-1210) at D1 and D15 and decitabine at D1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity.
10124603|NCT04353596|Experimental|Stopping/replacing ACEI/ARB|Chronic treatment with ACEI or ARB will be stopped or replaced.
10124604|NCT04353596|No Intervention|Control|No intervention, which means further treatment with ACEI or ARB.
10124605|NCT04353375|Experimental|HMPL-453|HMPL-453 150mg QD
10124606|NCT04353362|Experimental|Ofloxacin group|
10124607|NCT04353362|Active Comparator|Amoxicillin plus Metronidazole group|
10124608|NCT04353635||Patients with class III dentofacial deformity|No intervention as it will be a retrospective study
10124609|NCT04353856||twin pregnancy|Women followed for a twin pregnancy
10124610|NCT04353713|Experimental|Dextrose Gel|"Dextrose 40% gel will be given immediately following stabilization at birth via massage into the buccal membrane. This will be prior to transport from the Delivery Room to the Neonatal Unit.~A dose of 1 ml of gel (Dextrose) will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.~A total dose of 0.5 ml of gel (Dextrose) will be administered to infants born less than or equal to 29+0 weeks gestation.~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of administering person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
10124611|NCT04353713|Placebo Comparator|Placebo|"2% carboxymethylcellulose gel will be given following stabilization at birth via buccal route. This will be prior to in-house transport from the Delivery Room to the Neonatal Unit.~A standard total dose of 1 ml of placebo gel will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.~A total dose of 0.5 ml of gel (Placebo) will be administered to infants born less than or equal to 29+0 weeks gestation.~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
10124612|NCT04353336|Experimental|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine with standard of care treatment.
10124613|NCT04353336|No Intervention|No intervention|standard of care treatment alone.
10124614|NCT04353726|Experimental|Intervention group|Eligible participants will be in an intervention group led by a registered dietitian
10124615|NCT04353700|Active Comparator|Yoga group|A certified yoga instructor led the supervised yoga session. An exercise physiologist taught how to record your Rating of Perceived Exertion to monitor their exercise intensity during the in-home yoga intervention. During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks.
10124616|NCT04353700|No Intervention|Control group|If participants were in a CON group, they did not receive the yoga intervention. Instead, they were encouraged to maintain a normal daily lifestyle monitored by the BPAQ at one-month intervals during the 12-week intervention.
10124617|NCT04353687||Cohort 1 Open Surgeons|Primarily open inguinal hernia surgeon with no or limited previous robotic-assisted experience.
10124618|NCT04353687||Cohort 2 Laparoscopic Surgeons|Primarily laparoscopic inguinal hernia surgeon with no or limited previous robotic-assisted experience.
10124619|NCT04353466|Experimental|Trial to asses impact of Elelyso on bone involvement in patien|The infusions will be administered at the selected medical center or in the home care setup. The dose of intravenous (IV) infusions of Elelyso will be the same dose of the other ERTs . Bone parameters QCSI and BMD will be assessed at baseline, 12 months and 24 months.
10124620|NCT04353427|Experimental|Faith based educational group|"A seven-session faith-based small group educational program using the The Seven Pathways to Healing, Health and Wellness curriculum will be delivered."
10124621|NCT04353544|Active Comparator|Immediate cord clamping|Immediate cord clamping was defined as clampingwithin 15 seconds of birth
10124622|NCT04353544|Experimental|delayed cord clamping|when the cord stopped pulsing, or five minutes
10124623|NCT04353518|Experimental|Suspension of Mw|"Intradermal suspension of Mw will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal Mw in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal Mw administered."
10124624|NCT04353518|Placebo Comparator|Placebo|"Placebo will be administered in two divided doses:~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal placebo in two divided dose.~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal placebo."
10124625|NCT04353258|Experimental|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
10124626|NCT04353258|Active Comparator|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
10124627|NCT04353908|Active Comparator|kabat|Rehabilitation will be started in both groups of patients and it will be carried out according to Kabat et al., i.e. a proprioceptive neuromuscular facilitation procedure, twice a week for 8 weeks, by an experienced physioptherapist
10124628|NCT04353908|Experimental|collagen injection|Injections of an equally-balanced solution of MD Neural, MD Matrix and MD Muscle (Guna S.p.a., Milan-Italy), containing collagen of porcine origin, will be administered subcutaneously after applying lidocaine/prilocaine cream on the affected side, by a skilled otonaryngologist in the field of injection treatments, twice a week for 8 weeks
10124629|NCT04353388||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
10124630|NCT04353622|Active Comparator|Robot-assisted Treatment|Rehabilitation protocol was applied with robotic device (HOUSTONBIONİCS ExoRehab UE1).
10124631|NCT04353622|Active Comparator|Conventional Physiotherapy|Conventional physiotherapy program included neurophysiological approaches.
10124632|NCT04353219|Experimental|research group|training program with compression stocking
10124633|NCT04353219|Active Comparator|control group|training program without compression stocking
10124634|NCT04353245||Arm treatment (HCQ + Azithro)|Participants that used HCQ + Azithro in their treatment for COVID19
10124635|NCT04353245||Arm control (without HCQ + Azithro)|Participants that did not used HCQ + Azithro in their treatment for COVID19
10124636|NCT04353232||DANCAVAS I and II trials|Enrolment started September 2014 and ended in February 2019. Approx. 24 000 were invited, and approx. 15 000 were examined.
10124637|NCT04353232||VIVA screening trial|Enrolment started October 2008 and ended January 2011. In all, 18 749 men were screened.
10124638|NCT04353102|Experimental|YH002|All subject will receive YH002 intravenously as single agent every three weeks (Q3W) for up to 2 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first. Subjects who remain on treatment in the absence of disease progression for more than 2 years may continue to receive study drug through a single patient IND.
10124639|NCT04353323||Covid area|
10124640|NCT04353323||Non-Covid area|
10124641|NCT04352959|Active Comparator|mouth rinse with antiviral|
10124642|NCT04352959|Placebo Comparator|mouth rinse without antiviral|
10124643|NCT04353180|Active Comparator|13 cis retinoic acid doses orally plus the standard therapy|Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
10124644|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid plus the standard therapy|Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
10124645|NCT04353180|Active Comparator|13 cis retinoic acid doses orally|Infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
9967243|NCT01267942|Experimental|Intravenous intraoperative Enhancin|Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
10124646|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
10124647|NCT04353180|Sham Comparator|The standard therapy|Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days
10124648|NCT04353141||Pregnant patients with confirmed COVID-19 infection|
10124649|NCT04353141||Pregnant patients symptomatic for COVID-19|Symptomatic patients suspicious for COVID-19 infection (swab is taken on admission)
10124650|NCT04353141||Pregnant patients asymptomatic for COVID19|Patients asymptomatic for COVID19 with other feto-maternal diseases or who come for delivery or caesarean section
10124651|NCT04352751|Experimental|Single Arm|"Intervention: Convalescent plasma (Frozen Solution for infusion) obtained from COVID-19 recovered patients.~The dosage depends upon the clinical situation and underlying disorder. Children: 15 ml/kg over 4-6 hours once in patients under 35 kg body weight. Adults: maximum 450 - 500 ml over 4-6 hours once in all adults patients."
10124652|NCT04353050|No Intervention|Cohort 1 (retrospective)|Only data from medical records and formalin-fixed paraffin-embedded tissue blocks will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
10124653|NCT04353050|No Intervention|Cohort 2 (retrospective)|Only data from medical records, formalin-fixed paraffin-embedded tissue blocks and cytologic slides will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
10124654|NCT04353050|Other|Cohort 3 (prospective)|Patients with pigmented lesions on the skin or mucosa who are referred for excisional biopsy will be offered to apply investigated non-invasive adhesive system on their lesion just before the excisional biopsy. After biopsy cytological slides and FFPE tissue blocks will be prepared. All three types of obtained samples will be investigated separately (adhesive patches, cytologic slides and FFPE tissue blocks) for genetic markers whereas cytologic slides and FFPE tissue blocks will be processed also routinely and regular cytologic and histopathologic report will be generated.
9967244|NCT01267942|Active Comparator|Postoperative oral Enhancin.|Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.
10124655|NCT04352738||Healthy adults (group I)|
10124656|NCT04352738||Adults with type 1 diabetes (group II)|"T1D for ≥2 years or evidence of undetectable C-peptide (<100pmol/l with concomitant plasma glucose≥4.0mmol/l).~HbA1c≤8.0mmol/l (64mmol/mol)."
10124657|NCT04352738||Adults after bariatric surgery (group III)|"Female.~Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) ≥1 year ago.~Lack of a history of diabetes or pre-diabetes (HbA1c≤5.6% in the absence of anaemia)."
10124658|NCT04352972|Active Comparator|Hospital-based rehabilitation program|
9967245|NCT01267968|Experimental|Cohort 1|GSK2251052 1500 mg Single dose (i.v., 60 min)
9967246|NCT01267968|Experimental|Cohort 2|GSK2251052 1500 mg IV q12h x 5 doses infused over 60 minutes
10124659|NCT04352972|Experimental|Tele-monitored home exercise program|
10124660|NCT04353024|Placebo Comparator|Placebo|Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min, resulting in a total dose of 0 mg DMT.
10124661|NCT04353024|Experimental|Low dose|Intravenous bolus of 0 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 54 mg DMT.
9967247|NCT01267981|Placebo Comparator|Preparation 1|Standard diet: the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
9967248|NCT01267981|Active Comparator|Preparation 2|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~500 ml of polyethylene glycol 30 minutes after the ingestion of video-capsule endoscopy."
10124662|NCT04353024|Experimental|Low dose with bolus|Intravenous bolus of 15 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 69 mg DMT.
10124663|NCT04353024|Experimental|High dose|Intravenous bolus of 0 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 90 mg DMT.
10124664|NCT04353024|Experimental|High dose with bolus|Intravenous bolus of 25 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 115 mg DMT.
10124665|NCT04353193|Experimental|Terlipressin IV bolus|Terlipressin 1mg IV bolus
10124666|NCT04353193|Experimental|Terlipressin IV continuous infusion|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
10124667|NCT04353193|Experimental|Octreotide IV bolus plus continuous infusion|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
10124668|NCT04352920|Experimental|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
10124669|NCT04352998|Active Comparator|One dose pre-workout supplement condition|One dose/serving of a multi-ingredient pre-workout supplement was administered to the subjects.
10124670|NCT04352998|Active Comparator|Two dose pre-workout supplement condition|Two doses/servings of a multi-ingredient pre-workout supplement was administered to the subjects.
10124671|NCT04352998|Placebo Comparator|Placebo condition|One dose/serving of a placebo was administered to the subjects.
10124672|NCT04352868|Active Comparator|Toric soft contact lens|Toric soft contact lens
10124673|NCT04352868|Experimental|Multifocal toric soft contact lens|A multifocal toric soft contact lens with a +2.00 D add.
10124674|NCT04353076|Experimental|Young adults|Young adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
10124675|NCT04353076|Experimental|Older adults (no cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
10124676|NCT04353076|Experimental|Older adults (cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity) with ambient cooling intervention (i.e., exposure to an air-conditioned room) for hours 5-6.
10124677|NCT04352946|Experimental|Hydrocholoroquine Pre-exposure prophylaxis|HCQ will be administered as 400mg orally once for 60 days.
10124678|NCT04352946|Placebo Comparator|Placebo|Placebo will be administered as 400mg orally once for 60 days.
10124679|NCT04352803|Experimental|Autologous Adipose Derived Mesenchymal Cells|Conventional treatment plus MSC's IV
10124680|NCT04352803|No Intervention|Untreated|Conventional treatment only
10124681|NCT04352933|Active Comparator|Hydroxychloroquine - Daily dosing|"Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
10124682|NCT04352933|Active Comparator|Hydroxychloroquine - Weekly dosing|"Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
10124683|NCT04352933|Placebo Comparator|Placebo|"Placebo arm - 2 tablets twice daily for first 2 days (loading phase), followed by 1 tablet every day for 90 days plus 2 tablets every 7th day, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
10124684|NCT04352842||Non-survivors|Patients deceased during the study period
10124685|NCT04352842||Survivors|Patients survived during the study period
10124686|NCT04352725|Experimental|experimental procedure|"end-expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat<28cmH2o~incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
10124687|NCT04352894|Experimental|fluorescence guided peritoneal exploration|Indocyanine green (ICG) intravenous injection and peritoneal exploration with technology able to detect fluorescence generated by ICG
10124688|NCT04352829|Experimental|EXPERİMENTAL GROUP|1st day, patients were asked to use an MDI sample that didn't contain an active agent. At the same time, they filled the MDI Skill Evaluation Form, obtaining 'the scores of the 1st measurement'. Next, MDI use was explained through the video twice. After each video and explanation, the patients were asked to use the same MDI sample for 10 min. Simultaneously, the skills were marked by the researcher through observation on the form, obtaining 'the scores of the 2nd measurement'. 2nd day, they were again asked to use the MDI. While using the MDI, the form was marked and 'the scores of the 3rd measurement' were found. Later, a video session was held as on the 1st day, the video was watched twice, and after each repetition, were requested to use the MDI again. While they were using the MDI, the skills were simultaneously marked on the form and 'the scores of the 4th measurement were determined. 3rd day, all steps were repeated.
10124689|NCT04352829|No Intervention|CONTROL GROUP|20 patients were recruited to the control group. The controls received a routine training on MDI from their clinic nurses including verbal explanation of MDI use. The controls received training about MDI use in line with ethical principles and watched the video once after the 5th measurement. After the study, participants who wished to watch the training video again were provided internet links.
10124690|NCT04353063|No Intervention|control group|"The patients in the control group will not receive any walking exercise education until the 4-week intervention ends. They will then receive the same education material (How walking is beneficial to your health) and will be told about the benefits of walking."
10124691|NCT04353063|Experimental|experimental group|"Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days. The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials How walking is beneficial to muscle mass and your health. And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4."
10124692|NCT04352855||C/T|C/T cases: individuals fulfilling eligibility criteria and treated with ceftolozane-tazobactam
10124693|NCT04352855||C|C cases: individuals fulfilling eligibility criteria and treated with colomycine
10124694|NCT04353011||patient with chronic painful|
10124695|NCT04352712||Healthy Children|healthy children, untreated, donors of monocytes
9669003|NCT04382898|Experimental|Part 2 Arm 1B [2] (mCRPC) - expansion cohort|Following progression after W_pro1 monotherapy, patients in Arm 1b have the option to be treated with cemiplimab monotherapy
10124696|NCT04352712||GHD children|GHD children, untreated, donors of monocytes
10124697|NCT04353089||Basic Life Support Participants|All persons attending certified Basic Life Support Courses in Denmark from 2016 to 2019
10124698|NCT04353089||OHCA|Out-of-hospital cardiac arrest victims in Denmark from mid 2016 til mid 2019
10124699|NCT04352582||1|Survey respondants
10124700|NCT04352777|Active Comparator|Cohort 1|Fulvestrant plus abemaciclib
10124701|NCT04352777|Active Comparator|Cohort 2|Aromatase inhibitor plus abemaciclib (with or without ovarian suppression)
10124702|NCT04352686|Active Comparator|Buspirone|Buspirone 20 mg per oral
10124703|NCT04352686|Placebo Comparator|Placebo|Placebo
10124704|NCT04352543|Experimental|Older adults group|Group of older adults >60 years old.
10124705|NCT04352634||Healthcare workers|Workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)
10124706|NCT04352647||female athletes over the age of 18|the presence or absence of urinary incontinence in female athletes is studied. In addition, the quality of life and other aspects are evaluated
10124707|NCT04352621|Experimental|Ketamine plus rTMS|Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.
10124708|NCT04352244||Surgical Participants|Individuals undergoing abdominal surgery or radiologically-guided biopsies for clinical indications will be recruited prior to the planned procedures.
10183344|NCT03765554|Experimental|PF-06700841: MR followed by IR|Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR)
10183345|NCT03765541|Experimental|Standard salvage therapy + dexamethasone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness in combination with dexamethasone
10183346|NCT03765541|Active Comparator|Standard salvage therapy alone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness
10183347|NCT03765515|Experimental|Q-Fix|"Q-Fix has the advantages of all-suture implant and has the same or better performance than the traditional anchor.~Consistent activation effect~Excellent performance~Streamlined technique Q-fix is an experimental Arm."
10183348|NCT03765515|Active Comparator|Twinfix Ti|The Smith & Nephew's marketed Twinfix Suture Anchor is selected as the control product. This product is composed of anchor, suture, suture needle and inserter. The anchor is made of Ti6Al4V titanium alloy conforming to ISO5832-3. The Durabraid suture is made of polyester (Polyethylene terephthalate) conforming to YY 0167. Ultrabraid suture is made of two materials of UHMWPE and polypropylene monofilaments conforming to GB/T 19701.1. The suture needle is made of Type 420B stainless steel conforming to YY/T 0726. The stem portion of inserter that comes into contact with the body is made of Type 630B stainless steel conforming to YY/T 0726.
9669004|NCT04368780|No Intervention|Control group|Individuals who provide home care to an elderly person who is dependent on the bed
10183349|NCT03765489|Experimental|electrical muscle stimulation|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al. plus electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction"
10183350|NCT03765489|Active Comparator|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
10183351|NCT03765476|Active Comparator|TAU|treatment as usual
10183352|NCT03765476|Experimental|TAU plus SALIENCE|"treatment as usual plus computer-based intervention SALIENCE"
10183353|NCT03765450||Single Group Study|Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
9669005|NCT04368780|Experimental|Experimental group|Individuals who provide home care to an elderly person who is dependent on the bed. It is planned that the exercises will be conducted two days a week with the researcher and on the other days by the caregiver herself for a total of eight weeks.
9669006|NCT04368260|Active Comparator|Control swab|FDA cleared swab
9669007|NCT04368260|Experimental|Prototype swab|Injection molded polypropylene flocked nylon NP swab
10183354|NCT03765424||GCA cases|"GCA cases were patients with a clinical diagnosis of GCA based on a rheumatologists evaluation of history taking, physical examination, laboratory screening and initial PET report (reporting potential large vessel inflammation but not considering cranial artery inflammation).~GCA was considered large vessel (LV) and/or cranial (c) GCA cases:~LV-GCA cases were patients with a clinical diagnosis of GCA and verified LV inflammation by 18F-FDG PET/CT with or without concomitant c-GCA.~C-GCA cases, for the exploratory analysis of the performance of US and PET in c-GCA, were patients with a clinical diagnosis of GCA fulfilling the 1990 American College of Rheumatology (ACR) criteria, with or without concomitant LV-GCA."
10124709|NCT04352374|Experimental|Aerobic exercise group|"The therapist advised all participants of this group to drink a plenty of water before and after the exercise session to avoid excessive loss of body water during the session. Pregnant women were instructed to have a light meal about one hour before the performance of exercise and to wear comfortable clothes.~Participants in this group were given a Low-Intensity Aerobic Exercise with Borg scale RPE at 11. Participants were asked to maintain this intensity of rate of perceived exertion throughout the 45 minutes' duration of the aerobic training.~During the training session, the therapist stood near the patient to observe and detect signs of stopping the exercise. The therapist continuously asked the patient if she felt pain, dizzy or shortens of breath.~No complications were observed during physical exercise sessions, for example, hypertensive crisis, hypotension, hyperthermia, musculoskeletal lesions, or other complications identified that demanded interruption of the exercise."
10124710|NCT04352374|Active Comparator|Device guided breathing group|"At the beginning the researcher explained the device and study procedures to every participant of this group .The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.~The participant is instructed to alter their breathing rate, aiming for up to 10 breaths per minute, in response to a melody played to them via the asked to use the device for at least 40 min per week, with each session lasting at least 10 min"
10124711|NCT04352413|Experimental|Cohort A: PLM60|20 mg/m2, 4 weeks/cycle, administered on day 1 of each cycle
10124712|NCT04352413|Experimental|Cohort B: PLM60|15mg/m2, 3 weeks/cycle, administered on day 1 of each cycle
9827385|NCT02453672|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
10124713|NCT04352491||Patients with liver disease|All people who have shown at Institute of Liver and Biliary Sciences (1st January 2018 - 31st March 2020), will be sent the SMS for participation.
10124714|NCT04352387|Experimental|Montessori Method for Dementia|The design of the Montessori Method for Dementia program covered five aspects, namely cognitive stimulation, life skills, motor movements and fitness, sensory stimulation, and socialization. Each 1-hour session included two to three activities tailored to the local cultural context.
10124715|NCT04352387|Active Comparator|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
10124716|NCT04352283|No Intervention|palpation|Usual method to determinate needle puncture site
10124717|NCT04352283|Experimental|Ultrasound|Ultrasound preprocedural exam used to determinate needle puncture site
10124718|NCT04352322|Experimental|A+HA(tm)|20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
10124719|NCT04352322|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
10124720|NCT04352361|Experimental|TVB-2640 tablets|
10124721|NCT04352361|Placebo Comparator|placebo|
10124722|NCT04352530|Active Comparator|Rewind the Future|Fear appeal, video message to reduce sugar consumption or risk death
10124723|NCT04352530|Experimental|Hear No|"Video of spoken word poem from The Bigger Picture project, Hear No by Joshua Merchant; images of African-American male poet interspersed with images of environment"
10124724|NCT04352530|Experimental|The Longest Mile|"Video of spoken word poem from The Bigger Picture Project, The Longest Mile by Tassiana Willis; images of African-American female poet interspersed with images of environment"
10124725|NCT04352530|Experimental|A Taste of Home|"Video of spoken word poem from The Bigger Picture Project, A Taste of Home by Monica Mendoza; images of Hispanic female poet interspersed with images of environment"
10124726|NCT04352530|Experimental|Lost in Translation|"Video of spoken word poem from The Bigger Picture Project, Lost in Translation by Yosimar Reyes; images of Hispanic male poet interspersed with images of environment"
10124727|NCT04352530|Experimental|Bottled Up|"Video of spoken word poem from The Bigger Picture Project, Bottled Up by Eileen Torrez; images of Hispanic female poet interspersed with images of environment"
9669008|NCT04353895|Experimental|Robotic group (RG)|Patients in the RG group will be operated using the assistance of the Mazor X Stealth robot
10124728|NCT04352530|Experimental|The Corner|"Video of spoken word poem from The Bigger Picture Project, The Corner by Jose Vadi; images of Hispanic male poet interspersed with images of environment"
10124729|NCT04352530|Experimental|Thin Line|"Video of spoken word poem from The Bigger Picture Project, Thin Line by Ivori Holson; images of African-American female poet interspersed with images of environment"
10124730|NCT04352257||ultrasonography|pelvic and transrectal ultrasound
10124731|NCT04352348|Other|COVID-19 negative|Patients with exclusion diagnosis for COVID-19 infection
10124732|NCT04352348|Other|COVID-19 positive, not severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and not requiring hospitalization
10124733|NCT04352348|Other|COVID-19 positive, severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and requiring hospitalization
10124734|NCT04352348|Other|Follow-up after COVID-19 hospitalization|"Patients previously hospitalized for COVID-19 infection but not recruited for the study can be recruited during a follow-up visit in hospital scheduled in standard care at 3 to 6 months after the hospitalization.~For this arm, T0 = 3 to 6 months post-COVID-19 follow-up visit"
10124735|NCT04352504|Experimental|Almonds|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
10124736|NCT04352504|Active Comparator|Pretzels|Consume 2 oz. serving pretzels (216 calories) daily for 12 weeks
10124737|NCT04352400|Active Comparator|Nafamostat|Nafamostat mesylate on top of best standard of care.
9827386|NCT02453685|Experimental|BIAsp|
9827387|NCT02453685|Active Comparator|IGlar + IAsp|
9827388|NCT02453711|Experimental|Sema 0.05 mg|Dose 0.05 mg
9827389|NCT02453711|Experimental|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
9827390|NCT02453711|Experimental|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
9827391|NCT02453711|Experimental|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
9827392|NCT02453711|Experimental|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
10124738|NCT04352400|Placebo Comparator|Placebo|Placebo on top of best standard of care.
10124739|NCT04352595|Experimental|1% Hemay808|
10124740|NCT04352595|Experimental|3% Hemay808|
10124741|NCT04352595|Experimental|7% Hemay808|
10124742|NCT04352595|Placebo Comparator|vehicle|
10124743|NCT04352218|Active Comparator|PTA Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty of internal jugular vein non-thrombotic stenosis in patients with chronic headache
10124744|NCT04352218|Experimental|"PTA + Stenting using Petalo stent"|Percutaneous Transluminal Angioplasty + Stenting of internal jugular vein non-thrombotic stenosis in patients with chronic headache
10124745|NCT04352153|Experimental|Single-use group|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
10124746|NCT04352153|Experimental|Research group|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
10124747|NCT04352205|Experimental|Treatment (daratumumab-based treatment)|Patients receive daratumumab IV weekly of cycles 1-3 and on day 1 only of cycle 4, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV or PO on days 1-4 of cycle 1 and on day 1 of cycles 2-4 and PO on days 8 and 15 of all cycles. Beginning cycle 2, patients may also receive lenalidomide PO daily on days 1-14 or thalidomide PO QD on days 1-21. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
10124748|NCT04352478||Elder|elderly (≥60 years old).
10124749|NCT04352478||Young|young (<60 years old)
10124750|NCT04352465|Experimental|A|Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
10124751|NCT04352465|Experimental|B|Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
10124752|NCT04352465|Experimental|C|Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
10124753|NCT04352192|Experimental|Kinesiotaping Group|The group in which kinesiotaping is going to be applied to biceps brachii muscle of participants and will assess EMG activities before KT, immediately after KT, after 30 minutes and 24 hours of KT. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
10124754|NCT04352192|No Intervention|Control Group|The group in which kinesiotaping is not going to be applied. EMG activities will be assessed first assessment and after 10th minutes, 30th minutes and 24th hours of the first assessment. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
10124755|NCT04352075|Experimental|Microfat + PRP 3M platelets|microfat (5 ml) associated with PRP with a dose of 3 billions of platelets (5 ml)
10124756|NCT04352075|Experimental|Microfat + PRP 1M platelets|microfat (5 ml) associated with PRP with a dose of 1 billion of platelets (5 ml)
10124757|NCT04352075|Experimental|Microfat|microfat (5 ml) and saline solution (5 ml)
10124758|NCT04352114|Experimental|LY3461767 - Subcutaneous (SC)|LY3461767 administered SC.
10124759|NCT04352114|Placebo Comparator|Placebo - SC|Placebo administered SC.
10124760|NCT04352114|Experimental|LY3461767 - Intravenous (IV)|LY3461767 administered IV.
10124761|NCT04352023|Experimental|A (IV-PCA group)|IV-PCA drug: Fentanyl 3000 mcg and Oxycodone 100 mg were mixed Normal saline 200 ml
10124762|NCT04352023|Experimental|B (PCEA group)|"PCEA drug: Morphine 5 mg and Ropivacaine 750 mg were mixed Normal saline 400 ml~loading of preadministered Morphine 1 mg and Ropivacaine 11.25 mg"
10124763|NCT04351932|Active Comparator|bone marrow mesenchymal stem cell|Bone marrow mesenchymal stem cells 10 cc by intra articular injection once
10124764|NCT04351932|Active Comparator|adipose mesenchymal stem cells|Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once
10124765|NCT04351932|Active Comparator|Bone marrow and Adipose mesenchymal stem cells|Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once.
10124766|NCT04351724|Experimental|(Hydroxy)Chloroquine (STOPPED)|"Due to limited availability of the experimental substances, this arm will include both chloroquine and hydroxychloroquine treatment. However, both substances are similar chemically and also with regards to the mechanism of action comparable.~Dosage: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available"
10124767|NCT04351724|Experimental|Lopinavir/Ritonavir|Dosage: 200mg/50mg 4-0-4 on day 1 and 3-0-3 thereafter
10124768|NCT04351724|Other|Standard of Care|"patients will be treated with standard of care, which precludes treatment with lopinavir/ritonavir or (hydroxy-)chloroquine"
10124769|NCT04351724|Experimental|Rivaroxaban|5mg 1-0-1
10124770|NCT04351724|Active Comparator|Thromboprophylaxis|according to local standard
10124771|NCT04351724|Experimental|RAS Blockade|Renin-Angiotensin-System-Blockade (RAS) by candesartan intake starting with 4mg once daily and titrated to normotension patients > 120/80 mmHG are eligible
10124772|NCT04351724|Active Comparator|non-RAS-Blockade|non-RAS blocking antihypertensive agents titrated to normotension Those with normal blood pressure may only be controlled without further treatment
10124773|NCT04351724|Experimental|Asunercept 25mg|25mg 1x per week, maximum of four doses only patients with oxygen requirement
10124774|NCT04351724|Experimental|Asunercept 100mg|100mg 1x per week, maximum of four doses only patients with oxygen requirement
10124775|NCT04351724|Experimental|Asunercept 400mg|400mg 1x per week, maximum of four doses only patients with oxygen requirement
10124776|NCT04351724|Other|Best Standard of Care - Control Group for Asunercept|only patients with oxygen requirement
10124777|NCT04351724|Experimental|Remdesivir|200mg loading dose on day 1, 100mg for a total treatment duration of 5-10 days
10124778|NCT04351724|Experimental|Pentaglobin|Patients treated at the intensive care unit only, continuous infusion of 7ml/kg/day over 12h for 5 days
10124779|NCT04351724|Other|best standard of care|Patients treated at the intensive care unit only
10183355|NCT03765424||controls|Controls were GCA suspected patients in whom GCA diagnosis was dismissed.
10124780|NCT04351763|Experimental|Amiodarone|"Amiodarone - administered intravenously~Bolus of 150 mg is given over a minimum of 10 min, with subsequent continuous infusion of 1 mg/min for 6 h, next continuous infusion of 0.5 mg/min for 18 h, then switch to oral administration.~Oral administration~200 to 400 mg/day (adjust dosage based on cardiac response and age) up to discharge."
10124781|NCT04351763|Experimental|Verapamil|"Verapamil - administered intravenously~Bolus of 0.075-0.15 mg/kg (5-10 mg) over at least 3 minutes, then switch to oral administration.~Oral administration~120 to 480 mg/day in divided doses every 6-8 hours (adjust dosage based on cardiac response and age) up to discharge."
10124782|NCT04351763|No Intervention|Usual Care|
10124783|NCT04352049|Active Comparator|3TV group|Patients were randomly assigned to receive either three minutes tidal volume (3TV) with a fresh gas flow (FGF 100% O2) via facemask of 5 L/min
10124784|NCT04352049|Active Comparator|8DB group|Or eight vital capacity breaths for 1 minute with FGF of 10 L/min
10124785|NCT04352062|Experimental|Treatment Group|Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
10124786|NCT04352062|Placebo Comparator|Placebo|1 tablet twice daily (period 6 months)
10124787|NCT04352062|Other|Helicobacter pylori infected group|Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
10124788|NCT04351789|Experimental|Intervention Group|Patients randomized to the intervention group will receive a minimal psychoeducational intervention just prior to discharge from the hospital. The goal of the intervention is that patients will be prepared and learn to interpret and react to physical and psychological symptoms that are related to recovering from a COVID-19 infection. The intervention is based on psychoeducational theory and consists of both written and verbal information. A manual describing the content and procedures of the intervention will be developed to ensure that the intervention is both replicable and transparent. The intervention has a planned duration of 30 minutes and will be conducted by a designated study affiliated researcher, who has a background in healthcare (i.e. nurse or medical doctor).
10124789|NCT04351789|No Intervention|Control Group|Standard of Care at discharge of patients with COVID-19 from hospital is to inform the patients whom to contact in case of worsening of the physical condition, such as increasing e.g. shortness of breath, and of precautions regarding further isolation to avoid infection of household and other contacts, if relevant. Information regarding the patient´s psychological condition is not part of a standard conversation at discharge.
10124790|NCT04351828||Celiac patients compliant to gluten-free diet (GFD)|People with celiac disease who compliant to gluten-free diet (GFD) when they accepted in the study
10124791|NCT04351828||Celiac patients non-compliant to gluten-free diet(NGFD)|People with celiac disease who noncompliant to the gluten-free diet (NGFD) group when they accepted in the study
10124792|NCT04351997|Experimental|Early cord clamping|Cord clamping at 60 seconds after birth.
10124793|NCT04351997|Experimental|Delayed cord clamping|Cord clamping at 180 seconds after birth,
10124794|NCT04351919|Experimental|HCQ Arm|
10124795|NCT04351906|Other|ECCO2R|ECCO2R in patients with mild to moderate ARDS with/without AKI requiring dialysis.
10124796|NCT04351633||osteoporosis patient|
10124797|NCT04351841|Placebo Comparator|control|15 g maltodextrin per day consumed in the morning
9827393|NCT02453711|Experimental|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
10124798|NCT04351841|Experimental|Active|15 g arabinogalactan per day consumed in the morning
10124799|NCT04351971|Experimental|Intervention Group|The dorsal sliding technique C0-C1 will be applied to this group.
10124800|NCT04351971|Sham Comparator|Placebo group|A placebo dorsal mobilization technique will be applied
10124801|NCT04351854||Patients with SARS-CoV-2-infection|Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED
10124802|NCT04351854||Control group|Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.
10124803|NCT04351867|Experimental|experimental group|docetaxel plus oxaliplatin and capecitabine
10124804|NCT04351867|Active Comparator|control group|oxaliplatin plus capecitabine
10124805|NCT04351737|Experimental|Pterygium patients|patients with bilateral pterytium
10124806|NCT04352088||Allergic rhinitis patients|
10124807|NCT04352088||Allergic rhinitis and asthma patients|
10124808|NCT04352088||Healthy individuals|
10124809|NCT04351815|Experimental|Short prehabilitation|This arm will benefit from a 2 weeks prehabilitation program including a personalized dietetic and physical training program as well as psychological support.
10124810|NCT04351815|Other|No prehabilitation|This arm will not benefit from a prehabilitation program before surgery. Patients will be told to maintain a regular physical activity without support.
10124811|NCT04351646||SARS-CoV-2 negative inpatients|Hospitalised adult patients with SARS-CoV-2 negative tests.
10124812|NCT04351646||SARS-CoV-2 positive inpatients|Hospitalised adult patients with SARS-CoV-2 positive tests.
10124813|NCT04351646||SARS-CoV-2 suspected or confirmed NHS staff|Suspected or proven SARS-CoV-2 positive cases amongst health care professionals and lab staff.
10124814|NCT04351776|Other|VR-Biofeedback|
10124815|NCT04351776|Other|VR-Distraction|
10124816|NCT04351776|Other|360 Video|
10124817|NCT04351672|Experimental|Early Time-Restricted Feeding|
10124818|NCT04351672|Experimental|Late Time-Restricted Feeding|
10124819|NCT04351620|Experimental|Hydroxychloroquine|"Hydroxychloroquine 1200 mg daily administered as 600 mg BID for five days or until fevers abate (maximum ten days of treatment allowed).~If patients report gastrointestinal discomfort, the dose will be administered as 400 mg TID."
10124820|NCT04351607|Experimental|Verum|oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand
10124821|NCT04351607|No Intervention|Control group|no intervention
9827394|NCT02453711|Experimental|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
10124822|NCT04351607|Other|Patient with menstral bleeding - subcollective A|verum or control
10124823|NCT04351607|Other|Patient without menstral bleeding - subcollective B|verum or control
10124824|NCT04351503||SARSCoV-infected patients (cases)|
10124825|NCT04351503||non-SARS-CoV-2 infected patients (control)|non-SARS-CoV-2 infected patients with or without other respiratory viruses (control).
10124826|NCT04351477|Experimental|Massage chair group|Use mechanical massage chair for 20 minutes/1 session, 3 sessions/week, for 3 weeks
10124827|NCT04351477|No Intervention|Control|No use of mechanical massage chair for 3 weeks
10124828|NCT04351282|Experimental|SBRT|4-6 cycles of chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors were given. SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
10124829|NCT04351568||medical personel|
10124830|NCT04351568||non medical personel|
10124831|NCT04351204|Other|MRL|radiotherapy on MR linac
10124832|NCT04351542|Experimental|Ayurveda Care Group|Individualised ayurveda treatment was given to participants based on individual constitution.
10124833|NCT04351542|Active Comparator|Usual Care Group|Participants followed the usual care.
10124834|NCT04351412|Active Comparator|Tactile stimulus|The tactile stimulus was examined using an explorer (# 17/23), passing at a right angle to the bucco-cervical tooth surface of concern. Contributors evaluated participants' pain score on a 10-point visual analogue scale (VAS). The stimulus was used to assess dentine hypersensitivity at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
10124835|NCT04351412|Active Comparator|Air blast stimulus|For air blast stimuli, air was delivered by a three-way syringe from a typical dental unit air syringe at 40 psi (± 10 psi) and 70 °F (± 5 °F). The air flow was aimed at the tooth surface of concern, for 1 second, from a distance of 1 cm. The air blast stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for air blast stimuli at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
10124836|NCT04351412|Active Comparator|Cold stimulus|For cold hypersensitivity assessment, the tooth was isolated using cotton rolls; then, a few drops of extremely cold water were delivered to the tooth from a syringe that had previously been cooled. The cold stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for cold stimulus at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
10124837|NCT04351594|Experimental|Topical analgesia (+Menthol)|Biofreeze Topical Gel with active ingredient (Menthol 4%)
10124838|NCT04351594|Placebo Comparator|Topical analgesia (-Menthol)|Biofreeze Topical Gel with no active ingredient (Menthol 0%)
10124839|NCT04351347|Experimental|Ivermectin|Ivermectin alone in larger doses
10124840|NCT04351347|No Intervention|Standard treatment|Standard of care treatment
10124841|NCT04351399||patient with chronic painful inflammatory rheumatism|
10124842|NCT04351464|Active Comparator|Physical therapy and Reflexology group|Received reflexology implementation for 20-30 minutes on the sole along with the physical treatment involving NDT approaches. Within the scope of the implementation, all the reflex points on the sole were stimulated. The pituitary gland, which is related to sleep and control of salivation, oromotor area and areas of muscular and skeletal system were stimulated with further repetitions.
10124843|NCT04351464|Experimental|Just Physical therapy group|The group received a 45-minute physical therapy program involving NDT approaches as the control group. Within the scope of this program, the children were treated with intramuscular stretching and soft tissue mobilization, exercises that improved balance and that supported the development of postural control, position shifts, and stretching and reinforcement exercises in the necessary muscle groups.
10124844|NCT04351308|Experimental|API+apatinib|"AP = Doxorubicin (Adriamycin) 20 mg/m2/day * 2 day (total/cycle 40 mg/m²)~+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);~I = Ifosfamide 2000 mg/m2/day *5 day (total/cycle 10000 mg/m²);~apatinib = 500 mg QD;"
10124845|NCT04351308|Experimental|MAPI+camrelizumab|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);~camralizumab = 200mg ivgtt. Q2W;"
10124846|NCT04351308|Active Comparator|MAPI|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);"
10124847|NCT04351516|Experimental|hydroxychloroquine|
10124848|NCT04351516|Placebo Comparator|Placebo|
10124849|NCT04351256|Experimental|Arm A (HYPO group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~Thoracic radiation therapy (TRT): hypofractionated thoracic radiotherapy consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks (+9 days)"
10124850|NCT04351256|Active Comparator|Arm B (CON group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~Thoracic radiation therapy (TRT): conventional fractions of 30 x 2 Gy (60 Gy) within 6 weeks (+9 days)"
9669009|NCT04353895|Active Comparator|O-arm navigation group (NV)|Patients in the NV group will be operated using the guidance of the Stealth navigation
10124851|NCT04351490|Experimental|Group supplementation|
10124852|NCT04351490|No Intervention|Group usual treatment|
10124853|NCT04351217|Experimental|Music|Music was Indian Classical Flute music, 23 minutes long. It was played on a speaker at equal volume to ensure uniformity.
10124854|NCT04351217|Experimental|Progressive Muscle Relaxation|Progressive Muscle Relaxation was recorded for uniformity of delivery, and was 22 minutes in length. It was played on a speaker at equal volume to ensure uniformity.
10124855|NCT04351321|Experimental|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed for the treatment of patients assigned to this group.
10124856|NCT04351321|Active Comparator|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-assisted total gastrectomy will be performed for the treatment of patients assigned to this group.
10124857|NCT04351165|Experimental|Arm 1|"Period 1:~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);~Period 2:~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
10124858|NCT04351165|Experimental|Arm 2|"Period 1:~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);~Period 2:~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
10124859|NCT04351425|Experimental|study group|study group will be shifted from incubator to an unheated open cot a weight of 1400 grams
10124860|NCT04351425|Active Comparator|control group|control group will be shifted from incubator to an unheated open cot at a weight of 1600 grams
10124861|NCT04351191|Active Comparator|HCQ Regular dose|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
10124862|NCT04351191|Experimental|HCQ Loading dose|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
10124863|NCT04351191|Active Comparator|CQ regular dose|Cholorquine 500 mg BID for 5 days plus standard of care
10124864|NCT04351191|Placebo Comparator|Placebo|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
10124865|NCT04351178|Experimental|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0)
10124866|NCT04351178|Active Comparator|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
10124867|NCT04351581|Experimental|A: COVID+ Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissable for the clinician to stop treatment if necessary e.g. due to hypotension.
10124868|NCT04351581|Experimental|B: Covid+ Discontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during hospital admission. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
10124869|NCT04351581|Experimental|C: COVID% Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose.
10124870|NCT04351581|Experimental|D: COVID% DIscontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during the study period clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during the study period. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
10124871|NCT04351152|Experimental|Lenzilumab Arm|Participants will receive IV infusion of lenzilumab upon randomization at a pre-specified dosing interval and continued administration of standard of care
10124872|NCT04351152|Placebo Comparator|Placebo Arm|Participants will receive IV infusion of preservative-free 0.9% sodium chloride solution upon randomization matched to lenzilumab at same pre-specified dosing interval and continued administration of standard of care
10124873|NCT04351048|Experimental|SW|stepwise excavation
10124874|NCT04351048|Experimental|OneS|one step excavation
10124875|NCT04350827|Active Comparator|Platelet Rich Plasma|Procedure will be carried out with excellent sterile technique. 54ml of whole blood will be drawn. 54ml will be processed by centrifugation using the GPS III system (Zimmer Biomet, Warsaw, IN) and 1 ml will undergo a complete blood count (for a baseline comparison to determine the fold increase in platelets). The resultant PRP (5ml) will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) into the patellar tendon using ultrasound guidance to accurately direct the injection to the site of the tendon abnormality. The patient will rest after the injection for 15 minutes and then be dismissed.
10124876|NCT04350827|Active Comparator|Platelet Rich Plasma plus IGF|The PRP preparation and blood draw will be identical to the above. 55ml of whole blood will be drawn (1ml will undergo a CBC and the remaining 54ml will be used to make PRP). In addition to preparing the PRP, the resultant PPP (instead of discarding it) will be placed into the Plasmax device (Zimmer Biomet, Warsaw, IN) and concentrated via a second centrifugation cycle. The plasmax concentrate (concentrated IGF) will be added to the PRP (3ml of PRP + 2ml of plasmax concentrate for a total of 5ml) and then will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) under ultrasound guidance followed by the same rest period.
10124877|NCT04350853|Experimental|Surgical extrusion group|Surgical extrusion is performed in each patient of this group
10124878|NCT04350957|Experimental|Low-dose Imaging|Enrolled patients will undergo two separate dynamic contrast-enhanced MRI's, one with 25% of the contrast dose and one with 100% of the contrast dose recommended by weight. During the first visit, the subject will receive 25% of the standard dose of contrast media 0.1 mM/kg will be administered at 2 mls/second followed by the acquisition of a series of DCE images. On the second visit, the subject will receive 100% of the contrast media followed by the same imaging protocol as the one subsequent to the first contrast administration.
10124879|NCT04350931|Active Comparator|BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds (In Egypt, the available BCG vaccine is the Copenhagen BCG vaccine - The Danish Strain 1331 of Mycobacterium Bovis). Each 0.10 mL vaccine contains 200000-800000 colony forming units.
10124880|NCT04350931|Placebo Comparator|intradermal normal saline|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds.
10124881|NCT04350970|Active Comparator|Control|The cardiopulmonary exercise test was performed with patient breathing room air.
10124882|NCT04350970|Active Comparator|NIV|The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
10124883|NCT04350970|Active Comparator|HFNT|The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
10124884|NCT04350801||high risk MCI|MCI patients with amyloid beta positive (based on peripheral blood level)
10124885|NCT04350801||low risk MCI|MCI patients with amyloid beta negative (based on peripheral blood level)
10124886|NCT04351022|Experimental|CD38 positive relapsed or refractory acute myeloid leukemia|
10124887|NCT04351074|Active Comparator|group A , LIFT|39 patients underwnt ligation of the intersphincteric track( LIFT) for treatment of transsphincteric fistula
10124888|NCT04351074|Active Comparator|group B fistulectomy|39 patients under went fistulectomy for treatment of transsphincteric fistula
10124889|NCT04350814|Experimental|Self-Compassion Intervention Arm|Participants randomized to this condition will receive access to the audio Mindful Self-Compassion self-help intervention. The intervention is 7 weeks in duration (with a pacing of one lesson per week) and participants are asked to complete study measures once each week of the intervention.
10124890|NCT04350814|Active Comparator|Self-Reflection|Participants randomized to this active control condition will be asked to complete study measures at the same assessment intervals as those in the experimental arm. In addition to completing the measures, participants in the Self-Reflection Active Control condition will be asked to reflect on their self-reported symptoms and changes they may have experienced between assessment intervals.
10124891|NCT04350918|Experimental|Muscle Energy Technique (MET)|MET Group received 12 treatment sessions of MET (Nagrale et al, 2010) two times a week in addition to conventional physiotherapy. The procedures employ voluntary muscle contractions by the patient in a precisely controlled direction and intensity against a counterforce applied by the Physiotherapist. The technique requires the therapist to provide stabilization to the segment on which the distal aspect of the muscle attaches. A command for anisometric contraction of the muscle is given that causes accessory movement of the joint. Several specific muscle energy techniques are described for the subcranial region of the cervical spine.
10124892|NCT04350918|Experimental|Static stretching (SS)|"Subjects in SS Group received 12 treatment sessions of static stretching (Dutton et al, 2008) two times a week in addition to conventional physiotherapy.~Stretching involves the application of manual or mechanical force to elongate structures that have adaptively shortened and are hypo-mobile (Sullivan, 2007) Static stretching involves stretching a muscle to a point of discomfort and holding the stretch for a length of time, followed by a return to normal resting muscle length (Andrews et al, 2004). Muscles of the neck were stretched in especially in side flexion, extension, flexion and side rotation for 10 seconds and was repeated 10 times for a session."
10124893|NCT04350879||Diabetic patients|Women between 18 and 40 years old with type 1 and type 2 diabetes
10124894|NCT04350762|Experimental|Supplement + Fish Oil|"Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.~The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA)."
10124895|NCT04350762|No Intervention|Control|No dietary supplements. Participants will continue current intake.
10124896|NCT04351035||Children with CNS tumours|Patients newly diagnosed with CNS tumours in children younger than 18 y/o, who were under in-patient treatment, were labeled as candidate cases in the CNOG-MC001 cohort for reviewing.
10124897|NCT04351139||gynecological cancer|Patients over 18 with gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned during the period of COVID-19 pandemic during 2020
10124898|NCT04351139||control group|Patients over 18 with gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned outside the period of COVID-19 pandemic, on the end of the year 2019
10124899|NCT04351126|Other|Control group|patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)
10124900|NCT04351126|Experimental|treatment group|patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.
10124901|NCT04351126|Experimental|prevention group|patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis
10124902|NCT04350996||Continuous alcohol monitoring|Wearable BACtrack Skyn device
10124903|NCT04351100||Diacerein group|Osteoarthritis and dry eye patients treated with Diacerein
10124904|NCT04351087|Active Comparator|Platelet Rich Plasma|157cc of whole blood will be harvested via standard venipuncture from the antecubital fossa and mixed with 24cc ACD-A (manufacturer recommends 8cc ACD-A per 52cc of whole blood). 156ml of whole blood will be processed in the FDA Cleared Angel cPRP system at 2% hematocrit. 1ml of whole blood and the resultant PRP will be analyzed in the Sysmex XN-350 for complete analysis (platelet, leukocyte, red blood cell counts). The remaining PRP will be injected under sterile technique using ultrasound-guidance through a superolateral approach. For patient comfort, 2cc of 1% lidocaine can be administered using a 26-gauge needle (into soft tissues only). PRP will then be injected using a 25-guage needle. A maximum of 6ml of PRP will be injected. Injection site will be cleaned and bandaged and patient will be dismissed with post-injection precautions and 1 month follow-up scheduled.
10124905|NCT04351087|Active Comparator|Microfragmented adipose tissue|Adipose is aspirated from the subcutaneous tissue of the buttock or abdomen. Aspiration site is injected with 10ml 1% lidocaine with epinephrine. A small poke incision is made with an 11-blade scalpel. Then 120ml of Klein solution is injected into the adipose tissue. Solution sits for 15 minutes to allow for adequate anesthesia. Aspiration cannula is inserted and moved in a back and forth motion for 2 minutes to allow for adipose aspiration. 30ml fat will be aspirated. Aspiration site is cleaned and bandaged. The aspirated fat is processed using the Lipogems system. 30ml of adipose is transferred to the device, saline is run through the device to remove oils and then approximately 5-7ml of adipose tissue is removed and ready for injection. The Microfragmented adipose tissue are then injected in identical fashion to the PRP above.
10124906|NCT04350749|Experimental|Test group (PRF group)|PRF membrane is added to the bone block to evaluate if any effect on bone healing, soft healing, post-operativ pain
10183356|NCT03765411||Open Proctectomy Patients|Patients who underwent Proctectomy through an open approach
9827395|NCT02453711|Active Comparator|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
10124907|NCT04350749|Active Comparator|Control group (Standard operation)|A standard bone augmentation procedure, which is weel-described is performed to compare the outcome of the test group
10124908|NCT04350736|Experimental|TD-0903 for SAD (Part A)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
10124909|NCT04350736|Experimental|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
10124910|NCT04350736|Experimental|TD-0903 for MAD (Part B)|8 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
10124911|NCT04350736|Experimental|Placebo for MAD (Part B)|2 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
10124912|NCT04350645|Active Comparator|Tranexamic acid group|Tranexamic acid group will receive 1g slow bolus of tranexamic acid over 2 minutes at least 5 minutes before skin incision (at the end of spinal/general anaesthesia)
10124913|NCT04350645|Placebo Comparator|Control group|The placebo group will receive normal saline 0.9% (same amount as the tranexamic acid)
10124914|NCT04350476|Other|Vital Connect Patch Arm|"This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system:~VitalConnect Vital Sign Patch (FDA approved for this indication)"
10124915|NCT04350333|Experimental|CBT-I group|Five sessions composed of: psychoeducation on sleep change during pregnancy and postpartum; sleep hygiene principles; stimulus control technique, sleep restriction technique (f this technique will be too difficult for the participants to be apply, a replacement and less disabling technique will be applied: sleep compression); psychoeducation on the child's sleep at birth and on the change in the sleep-wake cycle in the early stages of the child's life; cognitive control technique; cognitive reconstruction technique and de-catastrophization; relapses prevention.
10124916|NCT04350333|Active Comparator|Assertive communication training|Five sessions composed of: psychoeducation and explanation of the importance of emotional and cognitive factors for good sleep. Psychoeducation about the concept of assertiveness, explanation of the passive, aggressive and assertive style; explanation and exercises regarding self-esteem and positive self-image; explanation of the development of sleep of the child in the first years of life; explanation and exercises on the phase of the management of feedback and requests; conflict management; relapses prevention.
10124917|NCT04350346|Active Comparator|The patient group who taken Motilitone|
10124918|NCT04350346|Active Comparator|The patient group who taken Gasmotin|
10124919|NCT04350320|Experimental|COLCHICINE|"The colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 28 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half.~+ standard therapy for COVID-19 according to the stablished hospital protocols."
10124920|NCT04350320|Placebo Comparator|control group|Standard therapy for COVID-19 according to the stablished hospital protocols.
10124921|NCT04350385|Experimental|Group 1|Agility Training
10124922|NCT04350385|Active Comparator|Group 2|.Conventional intervention
10124923|NCT04350619||Genetic study in retrospective and prospective groups|Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention
10183357|NCT03765411||Laparoscopic Proctectomy Patients|Patients who underwent Proctectomy through a Laparoscopic approach
10183358|NCT03765411||Robotic Proctectomy Patients|Patients who underwent Proctectomy through a Robotic approach
10183359|NCT03765398|Experimental|VR Cognitive-motor-balance training|Virtual reality based cognitive-motor balance (VR-CogMoBal) training will be delivered using the commercially available Wii-Fit Nintendo in conjunction with cognitive training. All participants will undergo 12 sessions of training in a tapering manner for four weeks with 90 minutes of training per session, i.e., 5 sessions for the first week, 3 sessions for the second week, and 2 sessions for the third and fourth week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
10183360|NCT03765385|Experimental|High-intensity training|Each high-intensity training (HIT) session will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIT is 20 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
10183361|NCT03765385|Active Comparator|Moderate-intensity continuous training|Each moderate-intensity continuous training (MICT) session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is 40 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
10183362|NCT03765346|Experimental|Oxycodone IR ADF and placebo to match oxycodone API|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of manipulated oxycodone IR ADF (mass of 540 mg, containing oxycodone hydrochloride 30 mg).
10183363|NCT03765346|Active Comparator|Oxycodone API and placebo to match oxycodone IR ADF|Participants receive a single intranasal dose of oxycodone API powder (mass of 30 mg, containing oxycodone hydrochloride 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
10183364|NCT03765346|Placebo Comparator|Placebo to match oxycodone API and to match oxycodone IR ADF|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
10183365|NCT03765307|Experimental|SyMap Bronchial Ablation Group|The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
10183366|NCT03765307|Active Comparator|Boston Scientific Bronchial Thermoplasty Group|The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
10124924|NCT04350554||Retrospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 and who became pregnant during this period.
10124925|NCT04350554||Prospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 who will become pregnant during the year 2020 and who agree to participate in a telephone survey.
10124926|NCT04350398|Experimental|Hippotherapy treated group|"During the initial week of intervention, sessions will be mainly carried on horseback. We will use the movement of the horse: (i) to allow patient re-appropriating her body and find harmony; (ii) to initiate rehabilitation of movements (shoulder, neck, upper extremity, whole body), gesture and femininity. The goal is to reconstruct a harmonic body image both in the private and public sphere, through different techniques. A few walking sessions may be needed to reinforce some landmarks.~During the short stages the work will be mainly done by walking alongside the horse. These reinforcement periods act like a trampoline, necessary to have a new momentum providing the opportunity to take a step back from the everyday, to regenerate somehow. The reaction time is generally optimized considering the imprint done during the initial long stage. One of the main themes that come up during this period is fear (relapse, the future, not achieving the goals, pain, relationship issues, etc.)."
10124927|NCT04350398|Placebo Comparator|Conventional therapy treated group|Patients in the control group are followed by dedicated personnel of the Montpellier Institut du Sein. This personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
10124928|NCT04350528||Chlorpromazine|
10124929|NCT04350528||Pentobarbital|
10124930|NCT04350372|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NT System
10124931|NCT04350515|Experimental|Cyberball: Other Exclusion|Cyberball Paradigm - the avatar will be excluded by the player
10124932|NCT04350515|Experimental|Cyberball: Player Exclusion|Cyberball Paradigm - the player will be excluded by the other players
10124933|NCT04350580|Experimental|Intervention - IGIV|Participants in the intervention group will receive a 2g/Kg infusion of human immunoglobulin which should be started before the 96th hours after the start of mechanical ventilation in 4 injections of 0.5 g/Kg over 4 consecutive days.
10124934|NCT04350580|Placebo Comparator|Placebo|Participants of the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.
10124935|NCT04350437|Other|induction of labor monitoring|meticulous data collection from patients and plotting that data in a machine learning model
10124936|NCT04350411|Experimental|Conventional diathermy|DIEP/ MS-TRAM breast reconstruction free flap raise performed with conventional diathermy
10124937|NCT04350411|Experimental|PEAK PlasmaBlade™|DIEP/ MS-TRAM breast reconstruction free flap raise performed with PEAK PlasmaBlade™
10124938|NCT04350502|Experimental|complicated pleural infection patients|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
10124939|NCT04350684|Experimental|Umifenovir|Umifenovir + Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
10124940|NCT04350684|Active Comparator|Control|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
10124941|NCT04350489||Control|Periodontally healthy group
10124942|NCT04350489||Periodontitis|Patients with periodontitis
10124943|NCT04350450|Experimental|Treatment Group|Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study
10124944|NCT04350450|No Intervention|Control Group|Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms
10124945|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 5 x week|"TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.~All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci."
10124946|NCT04350359|Active Comparator|Fixed-dose TTNS protocol|"Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes.~Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week."
10124947|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
10124948|NCT04350671|Experimental|Interferon-β 1a|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
10124949|NCT04350671|Active Comparator|Control|Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
10124950|NCT04350697||Mini-Sternotomy|Patients underwent aortic surgery by Mini-Sternotomy
10124951|NCT04350697||Mini-Thoracotomy|Patients underwent aortic surgery by Mini-Thoracotomy
10124952|NCT04349995||Amplatzer PFO Occluder|Percutaneous PFO Closure using Amplatzer PFO occluder
10124953|NCT04350060|Experimental|Intervention Group|Subjects with dementia will be living in a retro-fitted room with technological enhancements for a 12 month period.
9827396|NCT02453711|Placebo Comparator|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
10124954|NCT04350060|No Intervention|Standard of Care Group|
10124955|NCT04350034|Experimental|Xbox training group|The study group received Xbox training plus routine physical therapy protocol treatment. The dose of Xbox training was 50 min, three times a week for 12 weeks, using the Xbox gaming system (Xbox 360 Kinect console; Microsoft Inc., Redmond, Washington, USA).
10124956|NCT04350034|Placebo Comparator|Control group|patients participated in a routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
10124957|NCT04350047||Transabdominal inferior vena cava thrombectomy|Patients undergoing radical nephrectomy and inferior vena cava thrombectomy transabdominal without thoracotomy
10124958|NCT04350086|Experimental|Experimental arm|
10124959|NCT04350190|Experimental|Apatinib combined with PD-1|Eligible patients begin to use apatinib mesylate tablets and PD-1, apatinib mesylate tablets at the recommended dose of 250mg,oral, QD, continuous administration, 4 weeks (28 days) as an observation cycle. Until the disease progressed or unbearable adverse reactions appeared. If missed medication occurs during the medication period, it is confirmed that the next medication time is less than 12 hours, then there will be no replenishment. The recommended dose of PD-1 is 200mg/time, Q2W, intravenous injection, 4 weeks (28 days) as an observation cycle, until disease progression or intolerable toxicity.
10124960|NCT04350203||Intracorporeal Anatomosis (IA)|Laparoscopic Right colectomy with intracorporeal (IA) side-to-side isoperistaltic anastomosis
10124961|NCT04350203||Extracorporeal Anastomosis (EA)|Patients submitted to a Laparoscopic Right Colectomy with extracorporeal anastomosis (EA)
10124962|NCT04350281|Active Comparator|Treatment group|Subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3 and hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care
10124963|NCT04350281|Active Comparator|Control group|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care alone.
10124964|NCT04350164||treatment|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
10124965|NCT04349969|Experimental|Treatment|AK117 monotherapy
10124966|NCT04349943|Experimental|inflammatory bowel disease|According to the patient's disease condition, tube feeding time, internal and surgical diagnosis and treatment plan, standard step-based nutrition treatment was carried out for the patients with adaptive signs of nutrition treatment, and dynamic nutrition evaluation and efficacy evaluation were carried out.
10124967|NCT04350216|Experimental|Sarilumab therapy|Patients will be treated every two weeks with 200 mg of the anti-IL human monoclonal antibody-6Rα Sarilumab (Kevzara) with or without conventional DMARDs. Sarilumab administration will be subcutaneous (abdomen, thigh, or upper arm). The dose will be reduced to 150 mg in the event of neutropenia, thrombocytopenia, and elevated liver enzymes.
10124968|NCT04350229|Experimental|EXPERIMENTAL GROUP|"In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.~Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg."
10124969|NCT04350229|Active Comparator|CONTROL GROUP|Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg and dexamethasone 10mg.
10124970|NCT04350255|Active Comparator|Trident II Hemispherical cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Hemispherical acetabular cup
10124971|NCT04350255|Active Comparator|Trident II Tritanium cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Tritanium acetabular cup
10124972|NCT04349956||Patients from a randomized placebo-controlled study of UBX0101|Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
10124973|NCT04349878|Placebo Comparator|Control|scaling and root planing alone
10124974|NCT04349878|Active Comparator|phytotherapeutic|scaling and root planing plus phytotherapeutic agent
10124975|NCT04349930|Experimental|Cannabidiol|CBD vaginal suppository
10124976|NCT04349930|Placebo Comparator|Placebo|Placebo vaginal suppository
10124977|NCT04349683|Experimental|Experimental group|basic treatment combined with Jinshuibao
10124978|NCT04349683|Placebo Comparator|Control group|basic treatment and placebo
10124979|NCT04349774|Active Comparator|Control Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml 0.375% Bupivacaine
10124980|NCT04349774|Active Comparator|Treatment Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml Normal Saline.
10124981|NCT04349462|Other|VFSS and Water Sip Test|Enrolled patients will undergo a water sip test and Videofluroscopy Swallow Test (VFSS)
10124982|NCT04349592|Experimental|Combination therapy group|hydroxychloroquine 200mg TID for 7 days plus Azithromycin 500mg OD 1st day and 250 from day 2 to 5
10124983|NCT04349592|Active Comparator|Monotherapy therapy group|hydroxychloroquine 200mg TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
10124984|NCT04349592|Placebo Comparator|Control group|Placebo Cap TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
10124985|NCT04349488|Active Comparator|Treatment|Anode placed over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
10124986|NCT04349488|Placebo Comparator|Placebo|Anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
10124987|NCT04349709|Experimental|Brief school-based DBT-A|The students of classes randomized to experimental group receive the brief school-based DBT-A..
10124988|NCT04349709|No Intervention|control group|The students of classes randomized to control group continue their school activity as routine.
10124989|NCT04349800|Experimental|Single Ascending Dose - 5 mg|
10124990|NCT04349800|Experimental|Single Ascending Dose - 10 mg|
10124991|NCT04349800|Experimental|Single Ascending Dose - 20 mg|
10124992|NCT04349800|Experimental|Single Ascending Dose - 40 mg|
10124993|NCT04349800|Experimental|Single Ascending Dose - 80 mg|
9967249|NCT01267981|Active Comparator|Preparation 3|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~2 liters of polyethylene glycol between 7 pm and 9 pm.~500 ml of polyethylene glycol, 30 minutes after the ingestion of video-capsule endoscopy."
9967250|NCT01268007||Normal ECG measurements|Observational, un-blinded, non-interventional study designed to collect ECG data on at least one (1) male patient in an outpatient setting.
9967251|NCT01268020|Experimental|[18F]-FMH3-01 PET Imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
9967252|NCT01268033|Experimental|Rituximab|two infusions of Rituximab - at the dose of 375 mg/m²
9967253|NCT01268033|Placebo Comparator|placebo|two infusions of placebo
9967254|NCT01268072||Cohort 2|Subjects who are recruited on admission to hospital for AECOPD.
9967255|NCT01268072||Cohort 1|Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
9967256|NCT01268085|Experimental|Radiation Safety Alert|A provider placing an electronic order for a CAT scan will receive a radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part.
9967257|NCT01268085|Active Comparator|Control|Parallel control with no intervention
9967258|NCT01268124|Experimental|Treatment|
9967259|NCT01268137|Active Comparator|stimulation on|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
9967260|NCT01268137|Placebo Comparator|Stimulation off|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
9967261|NCT01268163|Active Comparator|1|European Taxotere® (Taxotere EU) 60-100 mg/m^2
9967262|NCT01268163|Experimental|3|Hospira Docetaxel Injection 60-100 mg/m^2
9967263|NCT01268163|Active Comparator|2|American Taxotere® (Taxotere US) 60-100 mg/m^2
9967264|NCT01268176|Active Comparator|Low fat meal|Those subjects who receive a low fat meal prior to vitamin D3 administration
9967265|NCT01268176|Active Comparator|High fat meal|Those subjects who receive a high fat meal prior to vitamin D3 administration
9967266|NCT01268176|Active Comparator|No meal|Those subjects who do not receive a meal and continue to fast. They only receive the vitamin D3 dose.
9967267|NCT01268202|Experimental|Pravastatin|Pravastatin : 40mg/day during 12 months
9967268|NCT01268215|Experimental|A (two study drugs group)|The standard management + two study drugs (endotracheal instillation of a mixture containing budesonide and Infasurf)
9967269|NCT01268215|Active Comparator|B (one study drug group)|The standard management + one study drug (endotracheal instillation of Infasurf only).
9967270|NCT01268215|Sham Comparator|C (no study drug group)|The standard management only.
9967271|NCT01268228||Residual ic ECG ST elevation in SB|
9967272|NCT01268228||Residual ic ECG ST elevation in MB|
9967273|NCT01268241||Observation|Hemizygous male or heterozygous female patients of any age with genetically confirmed diagnosis of Anderson-Fabry disease.
9967274|NCT01268254||red wine|red wine usual consumer versus abstemious
9967275|NCT01268319|Experimental|(+)HR-LCP and EPD|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation with an embolic protection device (EPD)in place prior to any angioplasty.
9967276|NCT01268319|Placebo Comparator|(+)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
9967277|NCT01268319|Placebo Comparator|(-)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will NOT contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 54 Subjects who meet this criteria will be assigned (not randomized) to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
9967278|NCT01268332|Experimental|Intravaginal Ring|Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
9967279|NCT01268332|No Intervention|No Intravaginal Ring|Intravaginal ring will not be inserted into participants.
9967280|NCT01268345|Experimental|Andon|Andon blood glucose test strips with test meter
9967281|NCT01268345|Active Comparator|Lifescan|
9967282|NCT01268358|Experimental|Lamazym 6.25|
9967283|NCT01268358|Experimental|Lamazym 12.5|
10124994|NCT04349800|Experimental|Single Ascending Dose - 160 mg|
9967284|NCT01268358|Experimental|Lamazym 25|
9967285|NCT01268358|Experimental|Lamazym 50|
9967286|NCT01268358|Experimental|Lamazym 100|
9967287|NCT01268371|Active Comparator|Promus Element|Everolimus-eluting stent
9967288|NCT01268371|Active Comparator|Nobori|Biolimus-eluting stent with biodegradable polymer
9967289|NCT01268384|Experimental|FDR_GX|Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
9967290|NCT01268397|Active Comparator|ORIF|Open reduction and internal fixation with a volar plate
9967291|NCT01268397|Active Comparator|plaster treatment|Closed reduction and plaster treatment
9967292|NCT01268410||acute respiratory failure|
10124995|NCT04349800|Experimental|Single Ascending Dose - 300 mg|
10124996|NCT04349800|Experimental|Single Ascending Dose - 600 mg|
10124997|NCT04349800|Experimental|Formulation Screen|
10124998|NCT04349800|Experimental|Food Effect|
10124999|NCT04349618|Active Comparator|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight
10125000|NCT04349618|Experimental|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20
10125001|NCT04349761|Experimental|Cohort 1 - 5mg MyMD1|8 subjects randomized to receive either 5mg MyMD1 (6 subjects) or Placebo (2 subjects)
10125002|NCT04349761|Experimental|Cohort 2 - 10mg MyMD1|8 subjects randomized to receive either 10mg MyMD1 (6 subjects) or Placebo (2 subjects)
10125003|NCT04349761|Experimental|Cohort 3 - 15mg MyMD1|8 subjects randomized to receive either 15mg MyMD1 (6 subjects) or Placebo (2 subjects)
10125004|NCT04349761|Experimental|Cohort 4 - 20mg MyMD1|8 subjects randomized to receive either 20mg MyMD1 (6 subjects) or Placebo (2 subjects)
10125005|NCT04349761|Experimental|Cohort 5 - 25mg MyMD1 or Placebo|8 subjects randomized to receive either 25mg MyMD1 (6 subjects) or Placebo (2 subjects)
10125006|NCT04349748|Experimental|Group 1|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the second observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
10125007|NCT04349748|Experimental|Group 2|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the third observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
10125008|NCT04349748|Experimental|Group 3|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fourth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
10125009|NCT04349748|Experimental|Group 4|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fifth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
10125010|NCT04349735|Experimental|Adults with asthma or COPD|Assessment of inhalation technique by three methods in all patients
10125011|NCT04349514||Friedreich ataxia|Individuals with a diagnosis of Friedreich ataxia.
10125012|NCT04349514||Control|Individuals without a diagnosis of Friedreich ataxia.
10125013|NCT04349787||Colorectal polyp patients|Patients who have a colonoscopy in regular care as part of the Dutch colorectal screening program, in the context of complaints or in the context of the follow-up of previously diagnosed bowel diseases. And who have at least one colorectal polyp found and resected during the examination.
10125014|NCT04349501|Experimental|RSI-MRI|Participants will undergo RSI-MRI at three time points: before androgen deprivation therapy (ADT); after neoadjuvant ADT but before radiation therapy (RT); and after RT.
10125015|NCT04349839||ACRODAT study arm|No intervention
10125016|NCT04349839||Standard Practice Arm|No intervention
10125017|NCT04349345||sperm count over time|observation
10125018|NCT04349553|Experimental|ZH9PA 1x10^9 CFU|1mL ZH9PA 1x10^9 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
10125019|NCT04349553|Experimental|ZH9PA 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
10125020|NCT04349553|Experimental|ZH9PA 1x10^10 CFU plus ZH9 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline and 1mL ZH9 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
10125021|NCT04349553|Placebo Comparator|Placebo|1mL (Cohorts 1 and 2) or 2mL (Cohort 3) normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
10125022|NCT04349696|Active Comparator|T2DM with Child-Pugh A|"All subjects with T2DM with normal hepatic function received a Mitiglinide Tablets 10 mg.~Intervention: Drug: Mitiglinide Tablets 10 mg"
10125023|NCT04349696|Experimental|T2DM with Child-Pugh B|"All subjects with T2DM with moderate impaired hepatic function received a MitiglinideTablets 10 mg.~Intervention:Drug: Mitiglinide Tablets 10 mg"
10125024|NCT04349631|Experimental|HB-adMSCs|Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2,6,10, 14, 18, 22, 26.
10125025|NCT04349397||Pediatric tonsillectomy patients|All patients enrolled into study prior to undergoing tonsillectomy or adenotonsillectomy
10125026|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Placebo PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
10125027|NCT04349085|Experimental|Placebo PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
10125028|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
10125029|NCT04349085|Placebo Comparator|Placebo PBMT/sMF before WOD and Placebo PBMT/sMF after WOD.|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
10125030|NCT04349527||RB Group|In this Group Patients receive round-block oncoplastic breast coserving surgery
10125031|NCT04349527||RG Group|In this Group Patients receive retrogladular oncoplastic breast coserving surgery
10125032|NCT04349228|Experimental|Hydroxychloroquine (HCQ)|Exposed health care professionals working in the intensive care unit
9967293|NCT01268423|Experimental|Early percutaneous tracheostomy|
9967294|NCT01268423|Active Comparator|Prolonged translaryngeal intubation|
9967295|NCT01268436||Injectable pain medication|Patients who receive an injectable form of pain medication.
9967296|NCT01268436||Oral pain medication|Patients who receive oral pain medication only
9967297|NCT01268449|Active Comparator|Laser group|
9967298|NCT01268449|Placebo Comparator|Placebo group|Randomly,half of the patients receive placebo.
9967299|NCT01268462|Experimental|Heliox + PEP (Group 1)|
9967300|NCT01268462|Experimental|Oxygen+PEP(Group 2)|
9967301|NCT01268462|Experimental|Heliox ( Group 3)|
9967302|NCT01268462|Active Comparator|Oxygen (Group 4)|
9967303|NCT01268540|Experimental|NHT15|Aspheric Toric Intraocular Lens Models NHT15
9967304|NCT01268540|Active Comparator|FY-60AD|Aspheric Non-toric Intraocular Lens: Model FY-60AD
9967305|NCT01268540|Experimental|NHT30|Aspheric Toric Intraocular Lens Model NHT30
9967306|NCT01268540|Experimental|NHT53|Aspheric Toric Intraocular Lens Models NHT53
9967307|NCT01268579|Experimental|ribavirin|This will be a single institution non-randomized study for patients with tonsil and/or base of tongue squamous cell cancer. This is a pilot study to obtain pharmacodynamic data regarding the effects of ribavirin on tonsil squamous cell cancer.
9967308|NCT01268592|Experimental|positive cancer diagnosis|female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
9967309|NCT01268605|Active Comparator|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
9967310|NCT01268605|Active Comparator|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
9976616|NCT01353443|No Intervention|Group A|Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
9976617|NCT01353443|Other|Group B|Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
9976618|NCT01353443|No Intervention|Group C|Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.
9976619|NCT01353456|Active Comparator|Dexmedetomidine|
9976620|NCT01353456|Placebo Comparator|Normal saline|
9669010|NCT04351880|Active Comparator|Meals - 2 weeks|Receive meal delivery for 2 weeks (1 meal per day for a total of 14 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
9976621|NCT01353469|Experimental|Insuman Comb 25|Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.
9976622|NCT01353469|Active Comparator|Novolin® 30R|Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R
9976623|NCT01353482|Active Comparator|Phase II only - Arm I|If the patient is randomised into the Vorinostat arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle plus the dose of Vorinostat determined in the phase I study.
9976624|NCT01353482|Placebo Comparator|Phase II only - Arm 2|If the patient is randomised into the placebo arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle with the placebo for the same number of days as in the vorinostat arm.
9976625|NCT01353534|Experimental|Group 1|3.8 mcg with AS03 adjuvant at D0 and 21
9976626|NCT01353534|Experimental|Group 2|15 mcg at D0 and 21
9976627|NCT01353534|Experimental|Group 3|15 mcg + 50 mcg VEP at D0 and 21
9976628|NCT01353534|Experimental|Group 4|30 mcg + 50 mcg VEP at D0
9976629|NCT01353547||Received anti-TNFa therapy|Received anti-TNFa therapy
9976630|NCT01353547||First-degree relative of MS patients|"First-degree relative (child, parent or sibling) of a diagnosed MS patient~A subgroup will be asked to undergo magnetic resonance imaging (MRI). Participants may be asked to donate a stool sample for gut flora analysis and a blood sample for ribonucleic acid (RNA) sequencing."
9976631|NCT01353547||Referred by the Partners MS Center|Referred by the Partners MS Center
9976632|NCT01353560||New patients of Osher Clinical Center|
9976633|NCT01353573|Active Comparator|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a Fixed Gantry Linear Accelerator
9976634|NCT01353573|Experimental|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic linear accelerator
9976635|NCT01353599|Experimental|Asmanex|Study participants will receive inhaled Mometasone Furoate (Asmanex) 220mcg once daily for 8 weeks.
9976636|NCT01353625|Experimental|CC-115|
9976637|NCT01353638|Other|Arm A|Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
9976638|NCT01353638|Other|Arm B|Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.
9976639|NCT01353651|Experimental|Endovascular treatment|
9976640|NCT01353651|Active Comparator|Open repair treatment|
9976641|NCT01353677||HSCT recipients|"Adult (≥ 18 years), or pediatric (≥ 2 years and < 18 years) allogeneic HCT recipient (related, unrelated, or CBU) at participating pilot study transplant centers.~Signed informed consent form from adult patient or parent/guardian of pediatric patient.~Patient must have a valid mailing address within the United States to receive QOL surveys.~Ability to speak and read English.~Patients with access to a telephone."
9976642|NCT01353690|Experimental|AMDC|
10125033|NCT04349228|Placebo Comparator|Placebo|Exposed health care professionals working in the intensive care unit
10125034|NCT04349163||Caregivers|Physicians and nurses working at the Emergency Department, Intensive care Unit, infectious disease Department, Anaesthesiology.
10125035|NCT04348994|Experimental|Laser therapy|Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
10125036|NCT04349293|Experimental|Patients with cancer|
10125037|NCT04349202||Beaumont employees|Beaumont employees (employees and affiliated non-employed physicians and advanced practice providers) undergoing serology testing for SARS-CoV-2 antibodies, their immediate family members, and members of other high-risk groups.
10125038|NCT04349410|Experimental|Treatment 1|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Azithromycin 500 mg IV on day 1, followed by 250 mg IV on days 2-5 (to prevent bacterial superinfection ).
10125039|NCT04349410|Experimental|Treatment 2|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Doxycycline 100mg IV q 12 hrs with each dose given over 1 to 4-hours (to prevent bacterial superinfection ).
10125040|NCT04349410|Experimental|Treatment 3|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
10125041|NCT04349410|Experimental|Treatment 4|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
9827397|NCT02453711|Placebo Comparator|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
10125042|NCT04349410|Experimental|Treatment 5|Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days. This treatment arm is not available for intubated patients due to the absence of an IV form of Primaquine.
10125043|NCT04349410|Experimental|Treatment 6|Remdesivir 200 mg IV on day 1, followed by 100 mg IV qD for a total of 10-days.
10125044|NCT04349410|Experimental|Treatment 7|"Tocilizumab 8mg/kg IV (not to exceed 800 mg) over 60-minutes. If clinical improvement is not noted, three additional doses may be administered at q 8-hour intervals from the initial infusion for a total of 4-doses maximum.~ANY PATIENT DEMONSTRATING CYTOKINE RELEASE SYNDROME WILL HAVE THIS TREATMENT ARM AUTOMATICALLY ADDED."
10125045|NCT04349410|Experimental|Treatment 8|Methylprednisolone 125 mg IV every 6-hours for 3 days; then 125 mg IV every 12-hours for 2 days; then 125 mg IV daily for 2 days; then 60 mg IV daily for 2 days [with each infusion given over 30-minutes]; then Solumedrol dose pack to taper off steroids.
10125046|NCT04349410|Experimental|Treatment 9|Interferon alpha-2b 5 million units per nebulizer BID.
10125047|NCT04349410|Experimental|Treatment 10|Losartan 25 mg po qD. IRB held due to questions about benefit.
10125048|NCT04349410|Experimental|Treatment 11|Convalescent Plasma 2-units ABO-compatible with antibody titer of 1:320 dilution. Each unit intravenously infused over 4-hours.
10125049|NCT04349241|Experimental|favipiravir|favipiravir in a regimen of 3200 mg (1600 mg 12 hourly) loading dose on day-1 followed by 1200 mg maintenance dose (600 mg 12 hourly daily) on day-2 to day-10
10125050|NCT04349241|Active Comparator|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10.
10125051|NCT04349176|Experimental|Group A 100U|
10125052|NCT04349176|Experimental|Group A 155U|
10125053|NCT04349176|Experimental|Group B 100U|
10125054|NCT04349176|Experimental|Group B 155|
10125055|NCT04349332|Active Comparator|Helmet non invasive ventilation (NIV)|Patients randomized to the intervention group will be extubated to helmet NIV.
10125056|NCT04349332|No Intervention|Control invasive mechanical ventilation|Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.
10125057|NCT04349384||Colon adenocarcinoma|Patient who underwent surgical resection for colon adenocarcinoma
10125058|NCT04349384||Rectal adenocarcinoma|Patient who underwent surgical resection for rectal adenocarcinoma
10125059|NCT04349137|Experimental|In-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a synchronized (in-phase) manner at a frequency of 6Hz
10125060|NCT04349137|Active Comparator|Anti-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a desynchronized (anti-phase, i.e. with a difference of 180deg) manner at a frequency of 6Hz
10125061|NCT04349137|Sham Comparator|Sham tACS|A sham transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC at a frequency of 6Hz using physical vibrations instead of electrical current
10125062|NCT04349826|Active Comparator|Azithromycin+Cefixime|Azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) AND Cefixime 20-30mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days.
10125063|NCT04349826|Placebo Comparator|Azithromycin+placebo|Azithromycin 20mg/kg/day oral dose once daily (Max 1gm/day) for 7 days AND Cefixime-matched placebo for 7 days.
9827398|NCT02453711|Placebo Comparator|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
10125064|NCT04348786|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline and bismuth subsalicylate
10125065|NCT04348786|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole
9827399|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
9827400|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
9827401|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
10125066|NCT04349033|Experimental|Emotional Disclosure and Brain Education|Patients are interviewed about stress and other emotional issues and are educated about how emotions and the brain influence pain.
10125067|NCT04349033|Active Comparator|Emotional Disclosure only|Patients are interviewed about stress and other emotional issues only.
10125068|NCT04349033|Placebo Comparator|Pain Information Control|Patients are interviewed about their pain history and experience.
10125069|NCT04348799||BPD group|premature infants diagnosed with BPD after postnatal day 28
10125070|NCT04348799||control group|premature infants without BPD after postnatal day 28
10125071|NCT04348929|Experimental|Confinement group|Delivery during covid-19 confinement period
10125072|NCT04348929|Other|Control group|Delivery after the withdrawal of all sanitary measures (mask, social distancing, limited visits during post-partum immediate)
10125073|NCT04348929|Other|Epidemic group|Delivery after confinement period and before the withdrawal of sanitary measures implemented (mask, social distancing, limited visits during post-partum immediate)
10125074|NCT04348812|Experimental|tDCS Active|Transcranial direct current stimulation with ABMT
10125075|NCT04348812|Sham Comparator|tDCS sham|Transcranial direct current sham stimulation with ABMT
10125076|NCT04348890|Experimental|Treatment Arm|
10125077|NCT04349007|Active Comparator|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in
10125078|NCT04349007|Experimental|School food ready-to-use|peanut-based school food ready-to-use
10125079|NCT04349007|Experimental|School food ready-to-use plus Milk|peanut-based school food ready-to-use with milk
10125080|NCT04348695|Experimental|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days."
10125081|NCT04348695|Other|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
10125082|NCT04348877|Other|Antibody-Rich Plasma|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
10125083|NCT04348643|Experimental|CEA+ CAR-T|CAR-T cell reinfusion is carried out in 1~3 times
10125084|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with surface lesions|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
9827402|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
10125085|NCT04348916|Experimental|Dose expansion of ONCR-177 in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
10125086|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with surface lesions|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
10125087|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory solid tumor cancer with liver metastases
9827403|NCT02453711|Placebo Comparator|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
10125088|NCT04348916|Experimental|Dose expansion of ONCR-177 by intratumoral injection in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory solid tumor cancer with liver metastases
10125089|NCT04348916|Experimental|Dose expansion of ONCR-177 and pembrolizumab in subjects with liver metastases|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory solid tumor cancer with liver metastases
10125090|NCT04348630|Experimental|HOT condition|Participants are exposed to 36°C and 45% relative humidity for 8 hours. These conditions were chosen to represent an extreme heat condition (i.e., heatwave) and are similar to peak domicile conditions measured in low-income high-rise apartment complexes during heatwaves.
10125091|NCT04348630|Experimental|WARM Condition|Participants are exposed to 31°C and 45% relative humidity for 8 hours. These conditions are similar to mean domicile conditions measured in a variety of domicile types during heat waves complexes during heatwaves and are consistent with the World Heath Organization recommendation for maximal indoor temperatures.
10125092|NCT04348630|Experimental|TEMPERATE Condition|Participants are exposed to 26°C and 45% relative humidity for 8 hours. These conditions are consistent with Toronto Public Health recommendation for maximal indoor temperatures, which are based on the increase in mortality associated with increases in outdoor temperature above these limits.
10125093|NCT04348630|Experimental|COOL Condition|Participants are exposed to 22°C and 45% relative humidity for 8 hours. These conditions are consistent with actively cooled (air-conditioned) domicile.
10125094|NCT04348760|Experimental|Intervention|Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week
9967311|NCT01268618|Experimental|Probiotic|
9967312|NCT01268618|Placebo Comparator|Placebo|
10125095|NCT04348968||Patient who received a Maxera Cup of large diameter|Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm between Nov 2011 and Feb 2018.
10125096|NCT04348825||Patients, depression|Patients who receive ECT as part of clinical care
10125097|NCT04348825||Healthy|Healthy controls who do not receive ECT but otherwise the same assessments.
10125098|NCT04348825||Patients, atrial fibrilation|Patients who receive Electro Cardio Version (ECV) due to Atrial Fibrilation
10183367|NCT03765294|Experimental|Treatment A: ACT-541468|50 mg once daily from Day 1 to Day 5 of Period A
10183368|NCT03765294|Placebo Comparator|Treatment B: Placebo|Matching placebo once daily from Day 1 to Day 5 of Period B
10183369|NCT03765281|Experimental|Navigation|Navigation intervention plus Resource List
10183370|NCT03765281|Active Comparator|Self-Navigation|Resource List intervention
10125099|NCT04348578|No Intervention|control group|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL NaOCl and 5mL sterile saline in the control group.The root canals were dried with sterile paper points and were filled with gutta-percha and AH Plus sealer with the cold lateral condensation method and the entry cavity was restored with composite. All treatments were performed following a standardized procedure by one operator. After completion of the root canal treatment, periapical radiographs were taken using the paralleling technique. All the patients were called for follow-up examination at 12 months, and were examined radiographically.
10125100|NCT04348578|Experimental|QMix 2in1|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL Mix 2in1 and 5mL sterile saline in the experimental group.
10125101|NCT04348903|Experimental|Virtual Reality Distraction|Virtual reality refers to a human-computer interface that completely immerse the child in a simulated environment. It integrates multiple perceptual senses including; the visual, auditory and kinaesthetic stimulation modalities. Virtual reality diverts children's attention away from the negative feelings associated with unpleasant experience.
10125102|NCT04348903|Experimental|Positive Pre-Visit Imagery Intervention|Positive pre-visit imagery is one of the superior cognitive- behavioral interventions. It is kind of psychological preparation that is designed to provide children with a step-by-step explanation of the dental local anaesthesia injection in an attractive approach
10125103|NCT04348773|Experimental|Dehydration|
10125104|NCT04348773|Experimental|Rehydration|
10125105|NCT04349046||Patient who received the Exception stem|Patient who received the Exception stem between January 2008 and September 2012 and consented to the original data collection.
10125106|NCT04348669|Experimental|Tele-yoga|This is a single group study with all subjects included in this single arm. All subjects will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
10125107|NCT04348565|Experimental|Diabetes Care Programme|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
10125108|NCT04348565|No Intervention|Standard Usual Care|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
10125109|NCT04348708||Dose Level Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
10125110|NCT04348708||Dose Level Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
10125111|NCT04348708||Dose Level Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
10125112|NCT04348591|Experimental|Misophonia Group|Participants who endorse Misophonia will undergo a neuroimaging session to identify different neurostimulation targets. Then Misophonic participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
10125113|NCT04348591|Active Comparator|Emotional Dysregulation Clinical Group|Participants who self report high emotional dysregulation and who meet diagnostic criteria for a DSM disorder will undergo a neuroimaging session to identify different neurostimulation targets. Then these participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
10125114|NCT04348292|Experimental|Treatment (sirolimus, durvalumab)|Patients receive sirolimus PO QD on days 1-21 in the absence of disease progression or unacceptable toxicity. Starting on day 22, patients receive durvalumab IV over 1 hour. Treatment with durvalumab repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within a 2-3 week period after the second dose of durvalumab, but not earlier than two weeks after the administration of durvalumab, patients undergo standard of care surgery.
10125115|NCT04348279|Active Comparator|custom made acrylic stent|the donor sites of the participants were covered with custom made acrylic stent
10125116|NCT04348279|Experimental|propylene mesh|in the test group, the donor sites received propylene mesh.
10125117|NCT04348305|Experimental|Hydrocortisone|"Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care.~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours)."
10125118|NCT04348305|Placebo Comparator|Isotonic Saline|"Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment).~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours)."
10125119|NCT04348435|Experimental|Allogeneic HB-adMSCs 200MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
10125120|NCT04348435|Experimental|Allogeneic HB-adMSCs 100MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
10125121|NCT04348435|Experimental|Allogeneic HB-adMSCs 50MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
10125122|NCT04348435|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14.
10125123|NCT04348526|Experimental|Corticision|Patients will undergo a corticision procedure in order to accelerate tooth movement
10125124|NCT04348526|Active Comparator|Traditional treatment|Patients will undergo traditional orthodontic treatment without any surgical intervention.
10125125|NCT04348422||Symptomatic|COVID-19 RT-PCR positive patients with reported symptoms
10125126|NCT04348422||Asymptomatic|COVID-19 RT-PCR positive patients without presenting any symptoms
10125127|NCT04348370|Experimental|BCG Group|FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing ~1x10^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (~2x10^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area.
10125128|NCT04348370|Placebo Comparator|Placebo Group|A single dose will consist of 0.1 mL saline
10125129|NCT04348513|Experimental|T3 solution for injection|T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
10125130|NCT04348513|Placebo Comparator|Placebo|Composition identical apart from the active substance. Same dosage.
10125131|NCT04348539|Experimental|Balance training|The balance training consists of 3 moments: warm up, main and stretch. Warm-up with mobility exercises for major joints and large muscle groups. The main part will have eight exercise stations divided into: a) five balance exercises (dynamic and static with or without object balance) on a varied floor, b) three agility exercises, and a stretching of the worked muscle groups and a final relaxation.
10125132|NCT04348539|Experimental|Strength training|Muscle strength training will consist of 3 moments: warm up, main and stretch. Warm up with mobility exercises for the main joints and large muscle groups. The main part will include strength exercises with lower and upper limbs with two sets of 6-12 repetitions according to periodization, and a stretching of the muscle groups worked
10125133|NCT04348539|Experimental|Cardiorespiratory endurance training|The older people walking training consists of 3 moments: warm up, main and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed, then walk according to the training cycle, and then a stretching of the main muscle groups. Will be held, twice a week for 45 minutes each session. The training intensity will follow 60-110% of the volume of the 6-minute Test (6MWT) and the Borg Scale at moderate to difficult intervals. the training
10125134|NCT04348539|No Intervention|Control group|control group: who will receive educational lectures on health, walking and aging.
10125135|NCT04348396||Elderly patients affected by COVID-19|The group taken into consideration consists of elderly patients hospitalized with diagnosed COVID-19.
10125136|NCT04348201|Active Comparator|foot reflexology|foot reflexology session which takes about 20 minutes.
10125137|NCT04348201|Active Comparator|dietary modification|diet must be rich in vitamins.
10125138|NCT04348487|Other|Standard procedure|For the conventional TIVAPS with cephalic vein approach, incision was made either in the midline of infraclivular or supraclavicular. Cathether was introduced to the central and then connected to the laterally implanted port in the deltopectoral region. The experience in the local center experienced several pitfalls with this method such as pneumothorax, pinch-off syndrome, compression of the catheter by the clavicle, kinking of the catheter, and loss of patencty.
10125139|NCT04348383|Experimental|Defibrotide + standard therapy|Defibrotide + standard therapy
10125140|NCT04348383|Placebo Comparator|Placebo|Placebo + standard therapy
10125141|NCT04348474|Experimental|HCQ + AZT|All patients included in the study will receive hydroxychloroquine (HCQ) 400 mg (00 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (AZT) (500 mg/ 5 days) on top of standard care.
10125142|NCT04348227||Before pandemic is declared|Positive endotracheal aspirates addressed from January 1st 2019 to January 1st 2020
10125143|NCT04348227||After pandemic is declared|Positive endotracheal aspirates addressed from February1st 2020 to February 1st 2021
10125144|NCT04348461|No Intervention|Control|Patients receiving regular respiratory distress treatment
10125145|NCT04348461|Experimental|Treatment|Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
10125146|NCT04348409|Experimental|nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
10125147|NCT04348409|Placebo Comparator|Placebo|Patients will receive placebo BID for 7 days
10125148|NCT04348617|Experimental|Exercise-Rest|This group will perform the exercise condition at least 1 week after the preliminary visit and will perform the resting condition a minimum of 15 days and a maximum of 2 months after the exercise condition.
10125149|NCT04348617|Experimental|Rest-Exercise|This group will perform the resting condition at least 1 week after the preliminary visit and will perform the exercise condition a minimum of 15 days and a maximum of 2 months after the resting condition.
10125150|NCT04348253|Active Comparator|Berger|Bergers capsulodesis
10125151|NCT04348253|Active Comparator|3LT|Three ligament tenodesis
10125152|NCT04348175|Experimental|Mild impairment|
10125153|NCT04348175|Experimental|Moderate impairment|
10125154|NCT04348175|Experimental|Severe impairment|
10125155|NCT04348175|Experimental|Normal (control)|
10125156|NCT04348188|Experimental|Supervised exercise group|Supervised intervention group: 3 weekly sessions of 1 hour during 6 weeks of therapeutic exercise in which aerobic physical activity will be combined with exercise strength of different muscle groups plus stretches on a supervised basis and strengthening of self-care.
10125157|NCT04348188|Active Comparator|Not supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
10125158|NCT04348344|Experimental|intervention group|"health education of pulmonary rehabilitation pulmonary rehabilitation including aerobic exercise，strength training and breath training.~Patients in stable stages using the home-based rehabilitation exercise prescription, taking home exercise, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training."
10125159|NCT04348344|No Intervention|control group|health education of pulmonary rehabilitation
10125160|NCT04348162|Active Comparator|Cocoa Flavanols|Cocoa is taken every day for 10-12 weeks.
10125161|NCT04348162|Active Comparator|Berries anthocyanins|Red-berries are taken every day for 10-12 weeks.
10125162|NCT04348162|Active Comparator|Cocoa flavanols plus berries anthocyanins|Cooa and red-berries are taken every day for 10-12 weeks.
10125163|NCT04348162|No Intervention|Control|Normal diet for 10-12 weeks
10125164|NCT04347876||Group A|COVID-19 positive with positive tuberculin test
10125165|NCT04347876||Group B|COVID-19 positive with negative tuberculin test
10125166|NCT04348071|Experimental|Ruxolitinib|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
10125167|NCT04347967|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
10125168|NCT04347915|Experimental|Clevudine|Clevudine 120mg (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
10125169|NCT04347915|Placebo Comparator|Placebo|Matching Placebo (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
10125170|NCT04348097|Experimental|activator trigger point therapy|"The Activator adjusting instrument used had force settings ranging from 1 to 6~. For this study a force setting of 3 was used."
10125171|NCT04348097|Active Comparator|Trigger point dry needling|First, a tight band was held between the index finger and the thumb of the non-dominant hand and the needle (0.25-40 mm - Shen Long) was perpendicularly inserted into the muscle with the dominant hand.
10125172|NCT04348006|Experimental|Induction Therapy|Bortezomib will be administered as part of VCD or VRD protocols
10125173|NCT04347863|Experimental|Experimental group|Group swallowing disorder diet preparation program
10125174|NCT04347863|No Intervention|Control group|No Intervention
10125175|NCT04347733|Experimental|Group A|Intra-articular injection, 20 mg (0.5 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.5 mL of normal saline
10125176|NCT04347733|Experimental|Group B|40 mg (1 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.0 mL of normal saline
10125177|NCT04347733|Active Comparator|Group C|20 mg (0.5 mL) of triamcinolone acetonide and 1 mL of hyaluronidase mixed with 2 mL of 2% lidocaine and 6.5 mL of normal saline
10125178|NCT04348110|Placebo Comparator|Placebo tablets|
10125179|NCT04348110|Experimental|Blueberry Chewable Tablets|
10125180|NCT04347902|Experimental|PN with SMOFLipid|Parenteral nutrition with MCT/LCT/olive oil/fish oil (SMOFLipid, Fresenius Kabi, Germany, SMOF group)
10125181|NCT04347902|Active Comparator|PN with Olive oil|Parenteral nutrition with Olive oil/LCT 80:20 (ClinOleic, Baxter Healthcare, USA, OO group)
10125182|NCT04347902|Active Comparator|PN with MCT/LCT|Parenteral nutrition with - Medium/long-chain triglycerides 50:50 (Lipofundin, B Braun Germany, MCT/LCT group)
10125183|NCT04347772|Experimental|Supplements Group - SS|"The SS will be received tailored and more intensive and ongoing nutrition support and lifestyle advice as compared with the NN and will be supplemented with ONS, available in 400g/can, providing 226 kcal/serving and 9.6 g protein/serving. Participants will be encouraged to consume the ONS in small, frequent, in between meals.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
10125184|NCT04347772|No Intervention|Control Group - NN|"While participants in NN which referred as control group will received the standard care of the clinic without supplemented with ONS. Nutritional advice will be based on a guideline specifically focused on treatment of symptoms such as nausea, vomiting, loss of appetite and diarrhoea, and how to deal with the symptoms through nutritional approaches. Basically, the advice will be given by the oncologist or nurses in the clinic.~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
10125185|NCT04347707|Experimental|BRIDGE Clinical Group|This group of mother-child dyads will have mothers who have been screened for and met diagnostic criteria for depression. Mothers in this group will participate in the 20-week group therapy and parent skills training intervention.
10125186|NCT04347707|No Intervention|Baseline Comparison Group|This group of mother-child dyads will not meet diagnostic criteria for depression and will serve as a comparison group for baseline measures. Dyads will be matched to the BRIDGE clinical group based on household income and child age.
10125187|NCT04348045|Experimental|ARM A - olaparib|Olaparib tablets at 300 mg orally twice daily until PD (RECIST 1.1) or unacceptable toxicity.
10125188|NCT04348045|Experimental|ARM B - durvalumab plus selumetinib|"Durvalumab plus selumetinib until PD (RECIST 1.1 and/or iRECIST), unacceptable toxicity, withdrawal of consent, or death.~Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle,~Selumetinib administered as 75 mg twice daily dose for 21 days on and 7 days off (a 28-day cycle)."
10125189|NCT04348045|Active Comparator|ARM C - FOLFIRI|FOLFIRI FOLFIRI (irinotecan 180 mg/m2 IV on day 1, folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2 every 2 weeks) until PD (RECIST 1.1) unacceptable toxicity, withdrawal of consent, or death.
10125190|NCT04347889|Experimental|Hydroxychloroquine|Oral loading dose of 800 mg followed by once weekly oral hydroxychloroquine 400 mg for 3 months
10125191|NCT04347889|Active Comparator|Vitamin C|Oral Vitamin C 1,000 mg daily for three months
10125192|NCT04348058|No Intervention|Control group|Invitation letter and reminder letter to screening colonoscopy
10125193|NCT04348058|Experimental|Call Center|Telephone recruitment by motivational conversation and colonoscopy appointment
10125194|NCT04348058|Experimental|Combined|Non responders to invitation and reminder letter will be recruited by telephone conversation
9967313|NCT01268631|Active Comparator|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
9967314|NCT01268631|Active Comparator|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
9967315|NCT01268657|Experimental|Cognitive Behavioral Exposure Therapy|
9967316|NCT01268670|Active Comparator|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
9967317|NCT01268670|Active Comparator|Oxycodone|Subjects will receive topical LET and oral oxycodone.
9967318|NCT01268670|Placebo Comparator|Placebo|Subjects will receive topical LET and oral placebo.
9967319|NCT01268696||control group|healthy volunteers
9967320|NCT01268696||Metabolic group|Patients with metabolic syndrome
9967321|NCT01268709|Active Comparator|doxepin|
9967322|NCT01268709|Active Comparator|nortriptyline|
9967323|NCT01268709|Placebo Comparator|placebo|
9967324|NCT01268722|Active Comparator|Balloon|
9967325|NCT01268722|Experimental|Stent|
9967326|NCT01268735|Experimental|Lubricating eyedrops containing HP-guar|
9967327|NCT01268748|Other|4 ports laparoscopic cholecystectomy|
9967328|NCT01268748|Other|One port transumb. laparoscopic surgery|
9967329|NCT01268761|Experimental|GnRH antagonist|• GnRH antagonist (Cetrorelix 0.25)
9967330|NCT01268761|Placebo Comparator|Placebo (saline solution)|• Placebo (saline solution)
9967331|NCT01268787|Active Comparator|EV 71 vaccine 5ug|EV71 Vaccine 5ug
9967332|NCT01268787|Experimental|EV 71 vaccine 10ug|EV71 vaccine 10ug
9967333|NCT01268800||AML induction|Adults AML patients who were referred for intensive induction therapy
9669011|NCT04351880|Active Comparator|Meals - 4 weeks|Receive meal delivery for 4 weeks (1 meal per day for a total of 28 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
9967334|NCT01268813|Experimental|Exhaled breath uptake blood test|Diabetic patients receiving oral hypoglycemic drug will be tested for biomarkers in their breath and blood samples
9967335|NCT01268813|No Intervention|Exhaled breath and blood test|Breath and blood samples will be collected from healthy volunteers and analyzed using Gas Chromatography-Mass Spectroscopy. The results will be compared to the experimental arm.
9967336|NCT01268826||dosage of the urinary osmolality|dosage of the urinary osmolality
9967337|NCT01268839|Experimental|001|Efavirenz 600mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 28 days
9967338|NCT01268852|Active Comparator|Damon|Standard self ligating orthodontic Damon brackets
9967339|NCT01268852|Experimental|Insignia|Innovative self ligating orthodontic bracket
9967340|NCT01268865||HBV-infected|
9967341|NCT01268865||HCV-infected|
10183371|NCT03765268|Active Comparator|Neurectomy|In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve
9967342|NCT01268904||Pediatric status epilepticus|
9967343|NCT01268917|Experimental|preoperative aspirin use|
9967344|NCT01268917|No Intervention|preoperative aspirin nonuse|
9967345|NCT01268930|Active Comparator|Bipolar coagulation|In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.
9967346|NCT01268930|Active Comparator|Hemostatic matrix|In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.
9967347|NCT01268956||Lymphatic progenitor cell|Circulating lymphatic progenitor cell
9967348|NCT01268956||Control|healthy people
9967349|NCT01268969|Active Comparator|excision and krydakis reconstruction|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
9967350|NCT01268969|Active Comparator|surgical excision and limberg closure|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia . The fasciocutaneous flap was transposed medially so that the defect would be covered without any tension.
9967351|NCT01268982|Experimental|preserved socket|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket.
9967352|NCT01268995|Experimental|Cyclosporine A|Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
9967353|NCT01268995|Active Comparator|Tacrolimus|Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
9967354|NCT01269021|Experimental|mycophenolate mofetil|
9967355|NCT01269021|Active Comparator|Prednisone|
9967356|NCT01269060|Experimental|Single incision sigmoidectomy|Single incision laparoscopic sigmoidectomy for sigmoid colon cancer
9967357|NCT01269086|No Intervention|Usual Care|Traditional care with no systematic assessment of family member´s health problems or risk factors.
9967358|NCT01269086|Experimental|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
10125195|NCT04347980|Experimental|Dexamethasone and Hydroxychloroquine (HCQ/DXM)|"Patients included in the HCQ / DXM group will benefit from standardized ventilatory management and administration of HCQ in the same manner as the HCQ group. They will receive in addition to DXM at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of DXM before."
10125196|NCT04347980|Active Comparator|Hydroxychloroquine (HCQ)|"Patients included in the HCQ  group will benefit from standardized ventilatory management. Patients included in the HCQ group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before."
10125197|NCT04347837|Experimental|Investigational device|The investigational device will be used for all participants
10125198|NCT04347785||Neurologic deficit|All consecutive patients from a tertiary referral center who underwent CEA for carotid artery stenosis who presented alterations in the neurologic examination after ICA clamping during CEA area selected
10125199|NCT04347785||control|The control patients are submitted to the same procedure but with no neurologic alterations, are consecutively selected. a 1 to 1 ratio is used
10125200|NCT04347798||Inflammatory arthritis patients on biologic + anti-malarial|Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
10125201|NCT04347798||Inflammatory arthritis patients on biologic + NO anti-malarial|Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
10125202|NCT04347850||Patient with Covid-19 confirmed (middle form)|Covid-19 confirmed: middle form
10125203|NCT04347850||Patient with Covid-19 confirmed (severe form)|Covid-19 confirmed : severe form
10125204|NCT04347850||Patient with Covid-19 not confirmed|Covid-19 not confirmed
10125205|NCT04348149|Experimental|Intervention group|
10125206|NCT04348149|No Intervention|Wait-list|
10125207|NCT04347746|Active Comparator|Clinical group|Individuals with bilateral idiopathic CTS with clinical criteria and mild to moderate ENMG severity and symptom evolution time above six months.
10125208|NCT04347746|Active Comparator|Surgical group|Individuals with bilateral idiopathic CTS with clinical criteria and severe ENMG in at least one hand and symptom evolution time above six months. These will be submitted to surgery on the severe hand and if equal severity on both hands, the dominant hand will be operated, with the patient's consent.
10125209|NCT04347720||Indomethacin Arm|Intravenous indomethacin at 0.1-0.3 mg/kg IV every 12-24h for a total of 3 doses as choice of initial pharmacotherapy.
10125210|NCT04347720||Standard dose ibuprofen Arm|Standard dose ibuprofen [Oral/intravenous] at 10 mg/kg followed by 2 doses of 5mg/kg at 24 h intervals irrespective of postnatal age as choice of initial pharmacotherapy.
10125211|NCT04347720||Adjustable dose ibuprofen Arm|Adjustable dose ibuprofen [Oral/intravenous] as choice of initial pharmacotherapy. The dose of ibuprofen will be 10 mg/kg followed by 2 doses of 5 mg/kg at 24 h intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by 2 doses of 10 mg/kg at 24 h intervals if treated after the postnatal age cut-off for lower dose as per the local center policy
10125212|NCT04347720||Acetaminophen Arm|Acetaminophen [Oral/intravenous] at 15mg/kg every 6h for 3-7 days as choice of initial pharmacotherapy.
10125213|NCT04347720||Control group|Infants <29 weeks GA with echocardiography-confirmed PDA but never received any pharmacotherapy
10125214|NCT04347720||Reference group|Infants <29 weeks GA who were never diagnosed with PDA
10125215|NCT04347525|Experimental|Intervention|This group will receive CaCBT based guided self-help using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
10125216|NCT04347525|No Intervention|Control|This group will receive treatment as usual
10125217|NCT04347551|Experimental|Eye movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
10125218|NCT04347551|Active Comparator|Head movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
10125219|NCT04347590|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
10125220|NCT04347590|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to at least 2 capillary glycemic tests per day.
10125221|NCT04347460||COVID 19|Patients requiring ICU treatment due to severe COVID 19 interstitial pneumonia or otherwise COVID-19 related disease
10125222|NCT04347668|Active Comparator|Usual Care|All residents are seen by a RN, with care by Registered Practical Nurse (RPN) and Personal Support Worker (PSW) staff 24/7. Residents supported by behavior support Ontario staff; include Behavior responsive team. Residents prior to admission have been assessed by the Geriatric program. Residents may receive psychotropic or cognitive enhancement medications. The residents are seen routinely seen once a week by the physician. Their Dementia is monitored weekly but the physician as well as daily by the registered staff. Quarterly or more frequently cognitive assessments are completed and referrals made to appropriate specialists. A day would include meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
10183372|NCT03765268|Active Comparator|Nerve Sparing|In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve
10183373|NCT03765255|Experimental|In the Know (ITK): sexual health education|Cohorts/participants in the experimental (treatment) arm receive an intervention that combines 6 hours of in-person sexual health and adolescent development education with an app that includes a resource locator, text message reminders (for one month), goal setting, and other resources.
9967359|NCT01269099|Active Comparator|Control|Control-group
10125223|NCT04347668|Experimental|Virtual Reality|"Virtual Reality (VR) is a scenario that simulates experiences. The immersive environment is similar to the real world, creating an experience. A person using virtual reality equipment is able to look around the artificial world, move around in it, and interact with virtual features or items. VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds that simulate a user's physical presence in a virtual or imaginary environment. A library has been developed, set to music, as well, we will use library items already part of the BroomX. We will attempt to use BroomX in their own room or in a suitable room within the LTC home. The participants still get the immersive experience, and the projection device has automatic controls that conform the visuals to a 360 experience no matter what size the room is, or what chairs, window blinds, are in the room."
10125224|NCT04347330|Experimental|Intensive BP Control|Participants randomized into the Intensive BP Control arm will have a goal of home SBP <120mmHg. For most participants in the Intensive Group, a two- or three-drug regimen should be initiated at randomization. Following the randomization visit, addition of another drug or medication dose titration is indicated if home SBP is ≥120 mmHg. Monthly visits will continue in the Intensive Group until home SBP <120 mmHg or no more titration planned. If the home SBP is not <120 mmHg at the every 6-month visit, then an antihypertensive drug from a class different from what is being taken should be added, rather than up-titration the dosage of previous drugs, unless there are compelling reasons against this practice.
10125225|NCT04347330|Active Comparator|Standard BP Control|Participants randomized into the Standard BP Control arm will have a goal of home SBP <135mmHg. The Standard BP protocol is designed to achieve a home SBP of 130-134 mmHg in as many participants as possible. Following the randomization visit, medication dose titration or addition of another drug is indicated if home SBP ≥135 mmHg. Monthly visits will continue in the Standard Group when home SBP ≥155 mmHg. Down titration (a reduction of the dose or number of antihypertensive drugs) should be carried out if the home SBP is <125 mmHg.
10125226|NCT04347395|No Intervention|Group 1: Control Group|Current best practice for prevention of HAP
10125227|NCT04347395|Experimental|Group 2: Intervention|Respiratory Bundle Intervention
10125228|NCT04347447|Experimental|normal protein diet|The normal protein diet (Control) will contain the RDA for protein of (0.8 g/kg/d), with the protein provided from a variety of animal and plant-based sources, including lean beef (one 3-oz portion per week), chicken, eggs, dairy, beans, grains, nuts, seeds.
10125229|NCT04347447|Experimental|a beef protein-rich diet|High protein diet predominantly provided from lean beef (one 3-oz portion per day; total beef intake 24 oz/week). The energy content of the additional protein foods will be isocalorically offset by substitution for low-protein foods.
10125230|NCT04347447|Experimental|a protein-rich diet non-red meat|High-protein group from a variety of animal and plant-based sources (excluding additional red meats).
10125231|NCT04347629|No Intervention|Usual Care|Usual clinical care
10125232|NCT04347629|Experimental|Video Decision Aid|The video intervention consists of a video decision aid along with a video declaration (ViDec), which is recorded by the patient. The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
10125233|NCT04347382|Experimental|Nigella Sativa & Honey Group|"Drug: Nigella Sativa seed Powder 80 mg/Kg/day grinded in capsule upto a max of 14 days) Drug: Natural Honey 1gm/kg/day orally upto a max of 14 days)~along with standard medical care"
10125234|NCT04347382|Placebo Comparator|Standard Medical Care|Standard supportive medical care prescribed by treating physician, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)
10125235|NCT04347369||Observed group|The patients who were detected COVID-19 disease by RT-PCR and CT imaging.
10125236|NCT04347512|Experimental|Hydroxychloroquine|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc)"
10125237|NCT04347512|Active Comparator|Control|The patient is given antibiotics only. Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc).
10125238|NCT04347512|Experimental|Hydroxychloroquine and Azithromycin|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Azithromycin is given for 5 days, with a loading dose of 500 mg at D1, and 250 mg for the next 4 days.~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc) In case of moderate renal failure (glomerular filtration rate between 30 and 60 mL/min/m²), hydroxychloroquine dosage are lowered by half."
10125239|NCT04347499|Experimental|Intervention|This group will receive CaCBT based guided selfhelp using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
10125240|NCT04347499|No Intervention|Control|This group will receive treatment as usual
10125241|NCT04347473|Experimental|Ilumya|Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
10125242|NCT04347642|Active Comparator|Umbilical port|A Hasson port will be inserted at the level of the umbilicus,in the midline, traversing only aponeurotic layers.
10125243|NCT04347642|Experimental|Paraumbilical port|A bladeless 12mm port will be inserted lateral to the midline, traversing aponeurotic layers and rectus abdominis muscle.
10125244|NCT04347278||Patients receiving treatment for COVID19|
10125245|NCT04347434|Experimental|Atorvastatin 80 mg|"Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.~If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day."
10125246|NCT04347434|Active Comparator|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C of ≤1.4 mmol / L and a decrease in the indicator by ≥50% after 5-6 weeks from the onset of AMI, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
10125247|NCT04347252|Experimental|Glucagon at basal glycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
10125248|NCT04347252|Experimental|Glucagon at hyperglycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
10125249|NCT04347252|Experimental|Glucagon at hyperglycemia with GLP-1R blockade|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study; concurrently exendin-(9-39) will be infused at 750 pmol/kg/min, also for the remaining 180 minutes. At time 240 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 30 or 60 minutes.
10125250|NCT04347291|Experimental|FAMS 2.0|"Patient participants will receive FAMS 2.0 components (monthly phone coaching and text message support for goals and medication adherence) for nine months. Linked support persons will receive text message support tailored to the goal set by the patient participant.~All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes."
10125251|NCT04347291|Placebo Comparator|Print Materials|All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes.
10125252|NCT04347317|Active Comparator|Low Intensity IMT|
10125253|NCT04347317|Experimental|High Intensity IMT|
10125254|NCT04347304|Experimental|cocoa polyphenols|21 grams of dark chocolate (289 mg polyphenols)
10125255|NCT04347304|Placebo Comparator|polyphenols free|21 grams of white chocolate (0 mg polyphenols)
10125256|NCT04347265|Experimental|NMP in level 1|Participants in this group received NMP of the sciatic nerve in the gluteus region
10125257|NCT04347265|Experimental|NMP in level 2|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
10125258|NCT04347265|Experimental|NMP in level 3|Participants in this group received NMP of the sciatic nerve before popliteus region
10125259|NCT04346927|Experimental|Study Group|The group to which the exercise protocol consisting of breathing exercises, posture exercises, peripheral muscle training and light aerobic exercises will be applied.
10125260|NCT04346927|Active Comparator|Control Group|group to be given an exercise brochure
10125261|NCT04346940|Experimental|Study Group|The group to which the exercise protocol consisting of chair-based exercises will be applied.
10125262|NCT04346940|Active Comparator|Control Group|Group to be given an exercise brochure
10125263|NCT04346914|Experimental|Combined treatment group|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w
10125264|NCT04346875|Experimental|Regularly changing group|Participants will undergo dressing every 3 days by the senior wound care nurse
10125265|NCT04346875|Active Comparator|Non-changing group|Participants will not be subject to dressing change.
10125266|NCT04346901|Other|Single Intervention|Before-and-After type of research
10125267|NCT04347031|Experimental|group 1 cohort 1|"80 patients who receive Mefloquine prescribed according to the following scheme:~1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
10125268|NCT04347031|Experimental|group 1 cohort 2|"80 patients who receive Hydroxychloroquine prescribed according to the following scheme:~• 1st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day; 2nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
10125269|NCT04347031|Experimental|group 2 cohort 1|A concomitant therapy consisting of Mefloquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Mefloquine is same as for group 1 cohort 1.
10125270|NCT04347031|Experimental|group 2 cohort 2|A concomitant therapy consisting of Hydroxychloroquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Hydroxychloroquine is same as for group 1 cohort 2.
10125271|NCT04346979|Experimental|Study Group|Telerehabilitation based yoga and mindfulness training will be given to the study group.
10125272|NCT04346979|Experimental|Control Group|Yoga and mindfulness training will be provided by sending a video recording to the control group.
10125273|NCT04346966|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
10125274|NCT04346966|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
9967360|NCT01269099|Experimental|IV-PCA|IV-PCA group
10125275|NCT04347096|Experimental|mHealth Intervention|The mHealth intervention group will have access to the Internet for using a newly developed Simple health web app and receive an activity tracker. The web app users are required to: (1) wear an activity tracker every day; (2) set goals of daily stand-up, physical activity, and healthy eating bi-weekly; (3) record stand-up, physical activity, and healthy eating behaviors daily; (4) set reminders to stand-up and record health behaviors; and (5) read educational and motivational tools. After completing the behavioral record, the personal advice will automatically provide to encourage, motivate and support the user. Moreover, the user will be able to look at his/her personal and team health ranking.
10125276|NCT04347096|Other|Control Intervention|The control intervention group will only receive educational tools (usual care).
10125277|NCT04347044|Experimental|Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up plus Pulmonary rehabiltation
10125278|NCT04347044|Active Comparator|Non-Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up
10125279|NCT04347005|Experimental|AR882 (Dose A)|
10125280|NCT04347005|Experimental|AR882 (Dose B)|
10125281|NCT04347005|Experimental|AR882 (Dose C)|
10125282|NCT04347005|Experimental|AR882 (Dose D)|
10125283|NCT04347005|Experimental|AR882 (Dose E)|
10125284|NCT04347005|Experimental|AR882 (Dose B) Solid Oral Formulation|
10125285|NCT04347005|Placebo Comparator|Placebo|
10125286|NCT04347005|Active Comparator|Allopurinol|
10125287|NCT04347005|Active Comparator|Febuxostat|
10125288|NCT04346862|Experimental|Acetyl-L-carnitine hydrochloride|
10125289|NCT04346862|Placebo Comparator|Placebo|
10125290|NCT04347109||Biventricular Pacing|Patients implanted with a device enabling cardiac resynchronization therapy.
10125291|NCT04347109||Right Ventricular Pacing|Patients implanted with a right ventricular pacing device.
10125292|NCT04346810||Recovery room caregivers|Caregivers working at a recovery room shifted into an intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
10125293|NCT04346810||Intensive care unit caregivers|Caregivers working at a conventional intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
10125294|NCT04347122|Active Comparator|Bony tumor treated with Tranexamic acid (TXA)|This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.
10125295|NCT04347122|No Intervention|Bony tumor treated without TXA|This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.
10125296|NCT04347122|Active Comparator|Soft tissue sarcoma treated with Tranexamic Acid (TXA)|This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA
10125297|NCT04347122|No Intervention|Soft tissue sarcoma treated without TXA|This group of participants will undergo soft tissue sarcoma resection of the lower extremity.
10125298|NCT04347057|Experimental|Arm 1|"Arm 1 (39 patients) included first the control period, followed by one-day wash-out, and then the intervention period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
10125299|NCT04347057|Experimental|Arm 2|"Arm 2 (39 patients) included first the intervention period, followed by one-day wash-out, and then the control period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
10125300|NCT04347174|Experimental|Suspension of Mw + Standard therapy of COVID-19|"0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days~+ Standard therapy of COVID-19"
10125301|NCT04347174|Placebo Comparator|Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of Placebo intra-dermal for 3 consecutive days
10125302|NCT04347018|Experimental|BRIUS|BRIUS orthodontic appliance (wire) will be used to treat the patients. BRIUS appliance will be engaged to regular orthodontic brackets intra-orally to initiate orthodontic treatment at the University at Buffalo Orthodontic Clinic.
10125303|NCT04347018|Active Comparator|Preadjusted edgewise full fixed appliance|regular full fixed orthodontic appliance (FFA) appliances will be used to treat patients. These are regular orthodontic brackets with standard orthodontic wires used to treat patients at the University at Buffalo Department of Orthodontics
10125304|NCT04347148|Experimental|SNAGs treatment|cervicogenic patients will undergo SNAGs treatment. Based on personal history, the offending active cervical movement (i.e. the movement predominantly causing dizziness) will be identified and treatment direction will be determined. As suggested, the active movement to most likely cause dizziness is cervical extension, though also rotation or flexion will be shown to provoke it. With the participant in an upright sitting position, a skilled physiotherapist (blinded to the allocation) will apply a sustained passive accessory movement (glide) while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing their symptoms. This procedure will be repeated six times.
10125305|NCT04347148|Placebo Comparator|Detuned Laser|cervicogenic patients will receive a sham treatment, carried out by the another skilled therapist (blinded to the allocation) and consisting in exposition to a detuned laser. A laser - deactivated by the manufacturer in order to produce no effective emission - will appear to operate normally, emitting a light signal and a beeping sound. Such procedure - which was shown to not activate somatosensory receptors and to have a very strong placebo effect - will be used for six applications, lasting 20 seconds, on various sites on the upper cervical spine, at a distance of 0.5-1cm from the skin.
10125306|NCT04346953|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
10125307|NCT04346953|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
10125308|NCT04347083|Experimental|Experiment|Reflex latency will be measured in this arm
10183374|NCT03765255|No Intervention|Control: do not receive ITK intervention|Cohorts/participants in the no intervention arm do not receive either the in-person education or the app. However, after completing the 10 month survey, they will have access to the app and will be invited to participate in the in-person program after the study implementation phase is completed (years 4 and 5).
10125309|NCT04346823|Experimental|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3 minutes. Then, parturients breath 1% of sevoflurane in mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min. Values of inspired (FI) and end-tidal (FET) concentrations of sevoflurane, oxygen and respiratory rate (RR) measured by end-tidal carbon dioxide (EtC02) were monitored continuously and recorded at 30 seconds intervals by a gas analyzer.~30 seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure. HR, FI and FET concentration of sevoflurane, Sp02 and EtC02 will be recorded at 30-s interval during ECV. Non-invasive BP will be recorded every one minute. Duration of ECV in addition to level of difficulty estimated by obstetrician will be recorded.~ECV considered successful when a cephalic presentation, confirmed by ultrasound scan, achieved."
10125310|NCT04346823|No Intervention|No sevoflurane|If the parturient is assigned to the control (nonintervention) group, the participants will not receive any medications neither tocolytics nor analgesics as the routine care in our hospital. However, the participants will be monitored throughout the procedure for vital signs and for pain scores as in the intervention group.
10125311|NCT04346888|Experimental|HBM9161 (680mg and 340 mg)|Subcutaneous injection; Blinded: HBM9161 680mg; Open-label: HBM9161 340mg;
10125312|NCT04346888|Experimental|HBM9161 (340 mg)|Subcutaneous injection; Blinded: HBM9161 340mg; Open-label: HBM9161 340mg;
10125313|NCT04346888|Placebo Comparator|Placebo, HBM9161 (340 mg)|Subcutaneous injection; Blinded: Placebo; Open-label: HBM9161 340mg;
10125314|NCT04347070||Patients accepted in ICU diagnosed with COVID-19|Patients accepted in ICU diagnosed with COVID-19
10125315|NCT04346797|Experimental|Eculizumab|Eculizumab
9669012|NCT04338269|Experimental|Atezo+Cabo|Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.
9827404|NCT02453750|Experimental|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
9827405|NCT02453841|Active Comparator|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
9827406|NCT02453841|Active Comparator|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
9967361|NCT01269112|Placebo Comparator|heparin|CVVHDF performed using unfractionated heparin as anticoagulant and Prismasol as reinjection and dialysate fluids
9967362|NCT01269112|Active Comparator|citrate regional anticoagulation|CVVHDF performed using Prismocitrate 18/0 solution (Trisodium citrate 18 mmol/L
9967363|NCT01269138||Factor VII Deficient Patients|Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled.
9967364|NCT01269151|Experimental|Lucentis (Ranibizumab)|
9967365|NCT01269164|Experimental|Face Transplantation|Surgical Procedure Composite Facial Transplant
9967366|NCT01269177||Patients with acute cardiogenic pulmonary edema|
9967367|NCT01269203|Active Comparator|Curcumin|1000 mg/day Curcumin + 5 -15 mg/day Lenalidomide
9967368|NCT01269203|Placebo Comparator|Placebo|Placebo daily + 5 -15 mg/day Lenalidomide
9967369|NCT01269216|Active Comparator|5-FU with leucovorin|
9967370|NCT01269216|Active Comparator|TS-1 with Irinotecan|
9967371|NCT01269242|Experimental|bindarit 600 mg|
9967372|NCT01269242|Experimental|bindarit 1200 mg|
9967373|NCT01269242|Placebo Comparator|placebo|
10125316|NCT04346797|No Intervention|Standard of Care|Best standard of care
10125317|NCT04346849|Experimental|MTA pulpotomy|Teeth receiving pulpotomy using MTA
10125318|NCT04346849|Experimental|Biodentine pulpotomy|Teeth receiving pulpotomy using Biodentine
10125319|NCT04346849|Experimental|Bioceramic pulpotomy|Teeth receiving pulpotomy using Bioceramic
10125320|NCT04346784|Experimental|maintaining positive working memory training|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
9967374|NCT01269255|Experimental|Combination group|
9967375|NCT01269268||active tuberculosis|active TB patients : diagnosed with TB through microbiologic examination
9967376|NCT01269268||healthy control|healthy control : no evidence of respiratory disease, no respiratory symptoms, and no history of close contact of active pulmonary TB patients
9967377|NCT01269281|Experimental|Sumatriptan Succinate tablets 100 mg|Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited
9967378|NCT01269281|Active Comparator|Imitrex 100 mg Tablets|Imitrex 100 mg Tablets of Glaxosmithkline
9967379|NCT01269294|Experimental|001|TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A
9967380|NCT01269294|Other|002|Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A
9967381|NCT01269294|Other|003|Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D
9967382|NCT01269294|Experimental|004|TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
9967383|NCT01269294|Other|005|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C
9967384|NCT01269294|Other|006|Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C
9967385|NCT01269294|Placebo Comparator|007|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D
9967386|NCT01269307|Active Comparator|1:1 ketamine - propofol mixture|
9967387|NCT01269307|Active Comparator|propofol|propofol
9967388|NCT01269333|Active Comparator|fluvoxamine|
9967389|NCT01269333|Experimental|omeprazole|
9967390|NCT01269333|Placebo Comparator|placebo|
9967391|NCT01269359||radiation|
9967392|NCT01269398|No Intervention|GO-LIF procedure, posetrior facets fusion|
10183375|NCT03765242||Patient initiating warfarin|
10125321|NCT04346784|Experimental|repressing negative working memory training|Repressing negative working memory training is a dual n-back task containing visual and auditory stimulus.Both two types of stimulus are negative.In this training, subjects are required to identify whether the location of picture presented on the screen or the word appeared in the headphone is the same as the picture or the word presented n before, then react with typing correspondingly.Each training session contains 16 blocks which are consisted with 20+n trails.
9826008|NCT02404220|Experimental|ENTO 200 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): Entospletinib (ENTO) 200 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 200 mg twice daily continuously in combination with vincristine (VCR) 0.5 mg intravenously (IV) on Days 1, 8, 15, and 22 of each cycle; dexamethasone (DEX) 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and central nervous system (CNS) prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a complete remission (CR) received stem cell transplant (SCT) (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a partial response [PR]) after induction were offered maintenance therapy with ENTO 200 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
9967393|NCT01269398|Other|solid fusion, GO-LIF procedure|ability to achieve solid fusion, comibing the GO-LIF procedure for spinal fixation and stabilization with percutaneous posetrior facets fusion
9967394|NCT01269411|Experimental|Treatment (RO4929097 and surgery)|"PART A: Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive oral RO4929097 once daily on days 1-7 and undergo surgery on day 8. Beginning 28 days later, patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
9967395|NCT01269437|Experimental|Budesonide, Novolizer|Budesonide Dry Powder Inhaler
9967396|NCT01269437|Active Comparator|BudesonideTurbuhaler|Budesonide Dry Powder Inhaler
9967397|NCT01269450|Active Comparator|Utrogestan|
9967398|NCT01269450|Placebo Comparator|placebo|
9967399|NCT01269463|Active Comparator|Methylphenidate HCl ER Capsules|Methylphenidate hydrochloride extended release capsules
9967400|NCT01269463|Placebo Comparator|Capsule without active drug|Double blind crossover assignment of the placebo comparator.
9967401|NCT01269476|Experimental|SNX-001|
9967402|NCT01269476|Placebo Comparator|Placebo|
9967403|NCT01269489||general population|a representative sample from general Slovenian population
9967404|NCT01269502|Experimental|Skin temperature measurement|Regular measurement of skin temperature on feet for one year
9967405|NCT01269502|Active Comparator|Active control|Daily inspection of feet for one year
9967406|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART-|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
9967407|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART-|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
9967408|NCT01269515|No Intervention|Control ART-|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
9967409|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART+|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
9967410|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART+|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
9967411|NCT01269515|No Intervention|Control ART+|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
9967412|NCT01269528||Born in 2007-2008|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
9967413|NCT01269528||Born in 2009-2010|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
9967414|NCT01269541|Active Comparator|Mupirocin|Topical treatment
9967415|NCT01269541|Active Comparator|Rifampicin+Clindamycine or Trimethoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
9967416|NCT01269554||Children with diarrhea in Bissau|
9967417|NCT01269554||Children without diarrhea in Bissau|
9967418|NCT01269554||Children without diarrhea in Finland|
9967419|NCT01269554||Children with diarrhea in Finland|
9967420|NCT01269554||Adults without diarrhea in Finland|
9967421|NCT01269554||Adults with diarrhea in Finland|
10183376|NCT03765242||Patient initiating apixaban|
9967422|NCT01269554||Adults without diarrhea in Bissau|
9967423|NCT01269554||Adults with diarrhea in Bissau|
9967424|NCT01269567|Active Comparator|Drainage|Rectal excision with aspiration pelvic drainage
9967425|NCT01269567|Experimental|No drainage|Rectal excision without aspiration pelvic drainage
9967426|NCT01269580||Diabetic|Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria
9967427|NCT01269580||Not diabetic|Adult not diabetic with chronic critical ischemia
9967428|NCT01269606|Experimental|Treatment sequence 1 - IM treatment group|
9967429|NCT01269606|Experimental|Treatment sequence 2 - IM treatment group|
9967430|NCT01269606|Experimental|Treatment sequence 1 - IV treatment group|
9967431|NCT01269606|Experimental|Treatment sequence 2 - IV treatment group|
9967432|NCT01269619|Experimental|Dynamic|Use of Dynamic back support
9967433|NCT01269619|Active Comparator|Static|Use of static back support
9967434|NCT01269632|Other|HIV infected|young adult infected by HIV
9967435|NCT01269632|Other|HIV uninfected|a control group of HIV uninfected young adult will be included for comparison in physiopathological module (metabolic, cardiovascular, and immunological)
9967436|NCT01269645|Active Comparator|Usual care|"Usual care and provision of National Cancer Institute brochure Taking Part in Cancer Treatment Research Studies. Participants will be asked to read this brochure after completion of the baseline surveys and will be given a copy to take home with them."
10125322|NCT04346784|Experimental|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
10125323|NCT04346784|Placebo Comparator|Positive placebo ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
9669013|NCT04338269|Active Comparator|Cabozantinib|Participants will receive cabozantinib every day.
10125324|NCT04346836|Experimental|Metabolic Syndrome|"Elderly women with Metabolic Syndrome~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
10125325|NCT04346836|Experimental|Non-Metabolic Syndrome|"Elderly women without Metabolic Syndrome.~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
10125326|NCT04346771|Experimental|Maintaining Positive Working memory|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
10125327|NCT04346771|Placebo Comparator|Positive Attention Bias Modification|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
10125328|NCT04346446|Experimental|Convalescent Plasma+Supportive Care|Convalescent Plasma+Supportive Care Convalescent plasma from recovered COVID-19 patients will be transfused to severely sick COVID-19 infected patients
10125329|NCT04346446|Active Comparator|Random Donor Plasma+Supportive Care|Random Donor Plasma+Supportive Care
10125330|NCT04346420|Experimental|O2 DTM+|The standard nasal cannula interface is accompanied with the DTM
10125331|NCT04346420|Active Comparator|O2 DTM-|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient, without the DTM
10183377|NCT03765229|Experimental|Single Arm: Entinostat + Pembrolizumab|Subjects in this trial will be administered entinostat, 5mg PO, once weekly (D1, D8, D15 of a 21-day cycle) starting on day 1 of study treatment. Pembrolizumab, 200 mg will be administered intravenously (IV) every 3 weeks and initiated at cycle 2 after the mandatory research tumor biopsy in the end of cycle 1, beginning of cycle 2 (day 21±2 days),. Combination therapy with both agents will continue if subject is receiving clinical benefit from therapy for up to 27 weeks (8 cycles of combination therapy or approximately 6 months). Study therapy will be discontinued for intolerable toxicity, disease progression or for other reasons at the discretion of the investigator.
10183378|NCT03765216|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
10183379|NCT03765216|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
10183380|NCT03765203|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to Natera's dd-cfDNA test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
10183381|NCT03765203|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to Natera's dd-cfDNA test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
10183382|NCT03765190|Experimental|Radiation: Proton Therapy+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
10183383|NCT03765151|Experimental|LLLT group|Low-level laser therapy and orthodontic retention
9976643|NCT01353716|Experimental|Cohort 1|Healthy subjects matched to the renal impaired subjects by gender, age and body mass index to the renal impaired subjects. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
10183384|NCT03765151|Placebo Comparator|control group|orthodontic retention and no laser treatment.
10183385|NCT03765125|Experimental|collagen peptide test|1 x daily consumption of 1 blister package of the collagen-peptide test powder dissolved in water over a period of 90 days
10183386|NCT03765125|Placebo Comparator|collagen peptide placebo|1y daily consumption of 1 blister package of the placebo powder dissolved in water over a period of 90 days
10183387|NCT03765112|Experimental|OCTA|Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.
10183388|NCT03765086|Active Comparator|Karydakis procedure|Karydakis Procedure: In this procedure the pilonidal sinus will be excised by semilunar incision so that the incision line closure will be away from midline.
9669016|NCT04333602|Experimental|Screening and Treatment of Asymptomatic Bacteriruria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. If we detect asymptomatic bacteriuria specific treatment will be instituted.
9669017|NCT04333602|No Intervention|Screening and NO treatment of Asymptomatic Bacteriuria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. No treatment will be instituted.
10125332|NCT04346576|Experimental|Probiotics (LcS per 65 mL) prevent health problems in children|Probiotic test product was fermented milk containing 6.5 billion of LcS per 65 mL (108 CFU/mL), manufactured by Yakult Vietnam, Co., Ltd. The nutritional composition of the test product is 0.8 g of protein, <0.1 g of fat, 12.4 g of carbohydrates, and the total energy is 52.7 kcal per bottle. Subjects were asked to drink one bottle of the test product per day after lunch for 12 weeks on consecutive days. The test products were stored in a refrigerator (< 10°C), protected from direct sunlight, and used before their expiration date. Adherence to the intervention protocol was confirmed as follows; teachers at kindergartens or parents at home provided the probiotic drinks (1 bottle/day x 7 days/week) after lunch.
10125333|NCT04346550|Active Comparator|Drain Group|Suction drain was placed in sub hepatic region through 5 mm lateral trocar site.
10125334|NCT04346550|No Intervention|Without Drain Group|No drain was placed
10125335|NCT04346680|Experimental|Experimental group|
10125336|NCT04346485|Experimental|SP TFL RIRS with 145 mcm fiber|Superpulse thulium fiber laser RIRS with 145 mcm laser fiber
10125337|NCT04346485|Experimental|SP TFL RIRS with 200 mcm fiber|Superpulse thulium fiber laser RIRS with 200 mcm laser fiber
10125338|NCT04346485|Active Comparator|Ho:YAG RIRS with 200 mcm fiber|Ho:YAG laser RIRS with 200 mcm laser fiber
9967437|NCT01269645|Experimental|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
10125339|NCT04346758|Other|Modified Shamrock approach|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
10125340|NCT04346563|Experimental|Kinesio tape, functional correction applying|The experimental group, trained by Certified Kinesio tape researcher will attache the kinesio tape. Attaching the kinesio tape by using functional correction techniques, apply tape from the front of the acromion process to the spinous process T10 on both sides, providing 50% of the tape's tension (Kase, 2003, Han JT et al) to create a scapular retraction.
10125341|NCT04346563|Placebo Comparator|Placebo Kinesio taping apply|Apply kinesio tape without tension.
10125342|NCT04346667|Active Comparator|Arm 1|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
10125343|NCT04346667|Experimental|Arm 2|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
10125344|NCT04346667|Active Comparator|Arm 3|Chloroquine 500 mg BID for 5 days plus standard of care
10125345|NCT04346667|Placebo Comparator|Arm 4|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
10125346|NCT04346472||Gliomes de grade II initial|Gliomes de grade II initial
10125347|NCT04346407|Experimental|Dronabinol|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
10125348|NCT04346407|Placebo Comparator|Placebo|Capsule with placebo daily starting with pre-op cocktail and continued twice daily for three days after surgery
10125349|NCT04346368|Experimental|Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)|Conventional treatment plus BM-MSCs
10125350|NCT04346368|Placebo Comparator|Placebo|Conventional treatment plus placebo
10125351|NCT04346732|Experimental|Vapocoolant spray|Vapocoolant spray was applied to the donors in the vapocoolant spray group.
10125352|NCT04346732|No Intervention|Control|The donors in the control group were not given any intervention during the blood collection process.
10125353|NCT04346706|Experimental|Immediate implantation|Tooth extraction, immediate insertion of an implant with immediate temporization
10125354|NCT04346706|Experimental|Delayed implantation|Implant inserted in a healed socket with immediate temporization
10125355|NCT04346589|Experimental|Antibodies (immunoglobulins) infusion|Anti-coronavirus antibodies obtained with double-filtration plasmapheresis (DFPP )from convalescent patients.
10125356|NCT04346602||patients with COVID-2019|Patients with COVID-2019 would be observed.
10125357|NCT04346355|Experimental|Experimental Arm|Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
10125358|NCT04346355|Other|Control Arm|Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
9967438|NCT01269671|Experimental|Melatonin, Peppermint Oil, Simethicone|
10125359|NCT04346498|Experimental|CB-SSC|The participant received CB-SSC for 2 hours per day for three consecutive days
10125360|NCT04346498|Placebo Comparator|CC-SSC|Following a 30 minute washout time, the same participant would continue to receive chest-to-chest (CC) SSC for 2 hours. This was also conducted for three consecutive days
10125361|NCT04346433|Experimental|Adolescents with Normal Weight|This group will be comprised of 30 adolescents with normal weight (BMI equal to or greater than the 5th percentile but less than the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
10125362|NCT04346433|Experimental|Adolescents with Overweight or Obesity|This group will be comprised of 30 adolescents with overweight or obesity (BMI equal to or above the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
10125363|NCT04346719|Experimental|10 kHz stimulation|"Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
9669018|NCT04330534|Experimental|BCX9930|Parts 1, 2 and 3
9967439|NCT01269671|Placebo Comparator|Sugar pill|
9967440|NCT01269684|Experimental|1|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
9967441|NCT01269697|Active Comparator|Nutrof|patient receive the treatment of Nutrof Total
10125364|NCT04346719|Experimental|20 kHz stimulation|"Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
10125365|NCT04346719|Sham Comparator|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
10125366|NCT04346264||General Cohort|Population general cohort from the Austrian LEAD Study
10125367|NCT04346004|Placebo Comparator|Control group|Participants in this group are administered N/S.
10125368|NCT04346004|Experimental|Iron isomaltoside group|Participants in this group are administered Iron isomaltoside & Vitamin B12.
10125369|NCT04346329|Placebo Comparator|Control|Controlled group with placebo medication similar to hydroxychloroquine (loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days)
9519528|NCT03286257|Experimental|Exercise Intervention|Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms. Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
10125370|NCT04346329|Experimental|treated|hydroxychloroquine with a loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days
10125371|NCT04346303|Other|Short-term Interactive Video Games|Short-term video games will be applied to patients with mental illness who are staying in communities. Games will be applied in a group-activity format with 8 to 12 patients in each session. The interventions will be conducted at a two sessions per week for a 3-week long period. There are 3 time points for data collection, including 2-weeks before the intervention, the week before the intervention, and the week after the intervention. Each patient will be his/her own controlled comparison.
10125372|NCT04346160||Patients with bilateral conjunctivitis|Hospitalized patient affected by COVID-19 disease with bilateral conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
10125373|NCT04346160||Patients without conjunctivitis|Hospitalized patient affected by COVID-19 disease without any signs of conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
10125374|NCT04346160||Healthy control group|group of healthy patients considered as controls
10125375|NCT04346173|Experimental|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
10125376|NCT04346290|No Intervention|Control|Standard anesthesia care for kidney donor
10125377|NCT04346290|Experimental|Dexmedetomidine|Standard anesthesia care and perioperative infusion of dexmedetomidine for kidney donor
10125378|NCT04346186||Hospital Staff in the Capital Region of Denmark|
9519529|NCT03286244|Experimental|CM082 plus paclitaxel|"In dose-escalation part, patients will be treated in dose levels at the following daily doses of CM082 and paclitaxel to establish the MTD and RP2D:~CM082 100mg qd + paclitaxel 80mg/m2/day; CM082 150mg qd + paclitaxel 80mg/m2/day; CM082 200mg qd + paclitaxel 80mg/m2/day; In dose-expansion part, patients will be treated at the RP2D established in dose escalation part."
9519530|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
9519531|NCT03286205|Active Comparator|Weekly Dosage|weekly dose of 100mg
9519532|NCT03286205|Active Comparator|3 week dosage|every 3 week dosage.
9519533|NCT03286192|Experimental|Single-Arm Intervention|All participants in this arm receive compassion cultivation training
9527663|NCT03218033|Active Comparator|Social Media (SM)|"The intervention phase was 8 weeks in duration. Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules. 8 The SM group answered the questions at the end of each module on a blogging site with other SM participants. SM participants were encouraged to provide feedback or questions about the material or personal questions that arose in response to each module.~All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies."
9527664|NCT03218020||Random Subcohort|Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
9669019|NCT04330534|Placebo Comparator|Placebo|Parts 1 and 2 only
9669020|NCT04330040|Experimental|Single Arm|Intervention: Drug: Olaparib
10125379|NCT04346186||Healthy volunteer blood donors|
10125380|NCT04346238||Patients with Friedriech Ataxia genetically confirmed|Patients with Friedriech Ataxia genetically confirmed
10125381|NCT04345926|Experimental|Dose-response|"- Concentration of propofol at the loss of consciousness (LOS) will be recorded in the presence of remifentanil (7.5 ng/mL) (LOS time).~- Patients will be intubated and remifentanil will be decreased to 4 ng/mL.~- Concentration of propofol that caused the LOS will be maintained for 20 minutes (Baseline time).~- Propofol will be increased in steps of 0.3 mcg/mL for 7 minutes until an episode of burst suppression will be observed (Burst suppression time).~EEG activity will be acquired using a SedLine® monitor during the complete protocol."
10125382|NCT04346030|Experimental|steroid and hydrodissection|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
10125383|NCT04346030|Active Comparator|steroid only|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)
10125384|NCT04346069|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group
10125385|NCT04346069|Other|Parent-child interaction therapy|Parent child interaction therapy will be provided to the experimental group
10125386|NCT04346212||Patients infected by SARS-CoV-2|Patients infected by SARS-CoV-2 at the Hospital de Mataró, Hospital de St. Jaume i Sta. Magdalena and other medicalized facilities in Mataró.
10125387|NCT04345965||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
10125388|NCT04345822||normotension|patients without diagnosis or treatment for hypertension
10125389|NCT04345822||hypertension|patients with diagnosis or treatment for hypertension
10125390|NCT04346095|Experimental|Oral Sedative|"Participants will receive oral triazolam 30 minutes prior to surgery.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg~Followed by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.~Vitals will monitored by the operating room nurses."
10125391|NCT04346095|Active Comparator|Intravenous Sedative|"This group will receive an intravenous sedative. The sedative is limited to midazolam, fentanyl, propofol.~Follow by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.~IV and monitoring will be performed by anesthesiologist or CRNA."
10125392|NCT04345978|Placebo Comparator|Normal Fasting|The patient starts fasting 8 hours before the operation,and does not take any solid or liquid foods and nutrients during the fasting process.The fasting period does not strictly limit the consumption of pure water,After surgery 8 hours,the patients was allowed to feeding.
10125393|NCT04345978|Experimental|Prolong Fasting|The patient starts fasting 24 hours before the operation, and does not take any solid or liquid foods and nutrients during the fasting process. The fasting period does not strictly limit the consumption of pure water.After surgery 24 hours,the patients was allowed to feeding.
10125394|NCT04346082|Experimental|online mindfulness group|
10125395|NCT04345874|Experimental|Nutrition technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
10125396|NCT04345874|Experimental|Children's environmental health technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
10125397|NCT04345939||GenSeizer|Sputum and lavage fluids are tested for pathogens using GenSeizer
10125398|NCT04345939||PCR reverse hybridization|Sputum and lavage fluids are tested for pathogens using PCR reverse hybridization
10125399|NCT04345939||Target sequencing after incubation|Sputum and lavage fluids are tested for pathogens using Target sequencing after incubation
10125400|NCT04346017|Experimental|Ventilation support|The experimental group will include Covid-19 infected patients with non-invasive or invasive ventilation support (BCRSS score ≥3).
10125401|NCT04346017|Other|Control group|The control group will include Covid-19 infected patients who don't have respiratory problems justifying a transfer to intensive care.
10125402|NCT04346147|Experimental|Imatinib 400 mg|Imatinib 400 mg 1 tablet 24 hours
10125403|NCT04346147|Experimental|Baricitinib 4 mg|Baricitinib 4 mg 1 tablet 24 hours
10125404|NCT04346147|Experimental|Supportive treatment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
9519534|NCT03286166||Study arm|"20 subjects will undergo one session of PRP in which 60 cc of blood is drawn and centrifuged into 3 months of autologous serum tears.~• Subjects will utilize autologous tears twice daily in the study eye."
10125405|NCT04346316|Active Comparator|SHR0302 Dose#1|
10125406|NCT04346316|Active Comparator|SHR0302 Dose#2|
10125407|NCT04346316|Active Comparator|SHR0302 Dose#3|
10125408|NCT04346316|Placebo Comparator|Placebo|
10125409|NCT04345848|Experimental|Therapeutic anticoagulation|Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
10125410|NCT04345848|Active Comparator|Prophylactic anticoagulation|Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.
10125411|NCT04345900|Experimental|20 mg/m^2 Plinabulin|Docetaxel + 20 mg/m^2 Plinabulin
10125412|NCT04345900|Experimental|10 mg/m^2 Plinabulin|Docetaxel + 10 mg/m^2 Plinabulin
9519535|NCT03286166||Control Arm|Subjects in the control arm will receive study vehicle to be used twice daily in the left eye.
9669021|NCT04313166|Experimental|Cu(II)ATSM|copper-containing synthetic small molecule
9827407|NCT02453841|Active Comparator|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
10125413|NCT04345900|Experimental|5 mg/m^2 Plinabulin|Docetaxel + 5 mg/m^2 Plinabulin
10125414|NCT04345900|Active Comparator|6 mg Pegfilgrastim|Docetaxel + 6 mg Pegfilgrastim
10125415|NCT04345809||GROUP A. MESH WITH OMEGA-3|Group A - 6.4-cm diameter circular prosthesis C-QUR V-Patch with an omega-3 coating
10125416|NCT04345809||GROUP B. MESH WITHOUT OMEGA-3|Group B - 6.4-cm diameter circular prosthesis BARD Hernia Patch , without omega-3 in its composition
10125417|NCT04345835|Active Comparator|prone flexed|prone flexed PCNL position
10125418|NCT04345835|Active Comparator|prone|prone position PCNL
10125419|NCT04345783|Experimental|Camrelizumab+Apatinib Mesylate+Tegio|
10125420|NCT04345523|Experimental|Treatment Arm|Pathogen-reduced CP from patients recovered from COVID-19, whom, for the purpose of this trial, are herein designated as donors.
10125421|NCT04345523|Active Comparator|Control Arm|Standard of Care (SOC) for COVID-19
10125422|NCT04345770|Sham Comparator|Without HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
10125423|NCT04345770|Experimental|With HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
10125424|NCT04345549|Experimental|Ayurveda|All the participants were advised to self-isolate for 7-days and maintain hygiene and self-care as per recommended guidelines. Along with that, participants were advised to constitution based Ayurveda treatment using herbs, life style and yoga.
10125425|NCT04345575|Experimental|VR Group|VR group participants were mailed an Oculus Go Virtual Reality headset preloaded with VR software developed by AppliedVR. Treatment content consisted of a variety of 21 sessions to support participants in learning cognitive and behavioral self-management skills based on evidence-based CBT principles and skills, biofeedback and mindfulness strategies used in pain management. The program was designed to improve self-regulation of cognitive, emotion, and physiological response to stress and pain.
10125426|NCT04345575|Active Comparator|Audio Group|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the Audio program included didactic and experiential content that was not identifical but was closely matched to the VR content (sans references to visual imagery that would be confusing in the absence of visual content). Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
10125427|NCT04345432|Experimental|Gabapentin|"The experiment will be divided into the following phases:~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~7 day drug washout phase - no medication will be taken~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
10125428|NCT04345432|Placebo Comparator|Placebo|"The experiment will be divided into the following phases:~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.~7 day drug washout phase - no medication will be taken~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
10125429|NCT04345692|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5
10125430|NCT04345692|No Intervention|Usual Care|usual care for hospitalized patients diagnosed with COVID-19
10125431|NCT04345601|Experimental|Mesenchymal stromal cells|Patients will receive up to 2 infusions of mesenchymal stem cells.
10125432|NCT04345601|Other|Control Group|Patients will receive supportive care or treatment designated by their treating doctor.
10125433|NCT04345445|Experimental|Tocilizumab|Tocilizumab is given at 8 mg/kg (body weight) once and administered as an intravenous infusion within no less than 60 minutes.
10125434|NCT04345445|Active Comparator|Methylprednisolone|Reconstituted methylprednisolone is infused over 30 minutes and administered at a dose of 120mg/day for 3 days
10125435|NCT04345380|Active Comparator|Acrysof Rotation|Implantation of the Acrysof SN60WF Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
10125436|NCT04345380|Active Comparator|Tecnis Rotation|Implantation of the Tecnis ZCB00 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
10125437|NCT04345380|Active Comparator|Envista Rotation|Implantation of the Envista MX60 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
10125438|NCT04345588|Active Comparator|group received dexamethasone perineural|injection dexamethasone 0.05 mg/kg perineural.
10125439|NCT04345588|Active Comparator|group received dexamethasone intravenous|injection dexamethasone 0.05 mg/kg intravenously.
10125440|NCT04345744|Experimental|Test group 1|administration of a hyaluronic and 0.2% chlorhexidine mouth rinse
10125441|NCT04345744|Experimental|Test group 2|administration of chlorhexidine 0.2% mouth rinse
10125442|NCT04345744|Active Comparator|Control Group|No administration of mouth rinses after surgery
10125443|NCT04345458|Experimental|group I|twice weekly 25 mg prefilled liquid etanercept
10125444|NCT04345458|Experimental|group II|once weekly 50 mg prefilled liquid etanercept
10125445|NCT04345458|Active Comparator|group III|25 mg twice weekly lyophilized etanercept powder
10125446|NCT04345419|Experimental|Remdesivir|Remdesivir with standard of care treatment standard of care treatment
10125447|NCT04345419|Placebo Comparator|Standard of care|Standard of care treatment alone.
10125448|NCT04345393|Experimental|Digital Transformation Network (DTN) Program|IBD patients at the 3 sites will be sent a message to their Smartphone
9669022|NCT04309799|Other|Single 10 minute session|Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
10125449|NCT04345393|Active Comparator|Control Arm|Patients will enter the control group once they initially complete the ePRO and online assessment tools. They will remain in the control group, and then at set intervals each site will transition these patients into the DTN intervention arm.
10125450|NCT04345484|Experimental|GMT Intervention + Health Lifestyle Program|The intervention group will participate in GMT, a standardized cognitive rehabilitation program which will be given as per the manual and which consists of 9 sessions each 2-hours in duration. They will also participate in the Healthy Lifestyle Program (HLP), which includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
9519536|NCT03286153|Experimental|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
10125451|NCT04345484|Active Comparator|Health Lifestyle Program|The control group enters directly into the HLP without any other study visits. The HLP includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
10125452|NCT04345679|Experimental|Hospitalized patients with SARS CoV-2 infection|
10125453|NCT04345406|Experimental|ACEIs|ACEIs with conventional treatment for COVID19
10125454|NCT04345406|Experimental|Conventional treatment of COVID19|Conventional treatment of COVID19
10125455|NCT04345640||Covid-19 with liver disease|Covid-19 with liver disease
10125456|NCT04345640||Covid-19 without liver disease|Covid-19 without liver disease
10125457|NCT04345471|Experimental|MD-120 100 mg|
10125458|NCT04345471|Experimental|MD-120 50 mg|
10125459|NCT04345471|Placebo Comparator|Placebo|
10125460|NCT04345614|Experimental|Auxora|Patients will be randomized 1:1 to receive either Auxora or placebo
10125461|NCT04345614|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive either Auxora or placebo
10125462|NCT04345315||asymptomatic population at high risk of infection|healthy individuals at high risk of infection, including individuals who have had contact with a patient tested positive for COVID-19, voluntary health workers and oncological patients candidate to immunosuppressive therapy
10125463|NCT04345315||COVID-19 patients|patients with confirmed diagnosis of COVID-19
10125464|NCT04345250|Experimental|Participants|"For a period of 6 days between the exercise trials (i.e., following visit 3), each participant will be put on a restricted energy restricted diet consisting of a 25% reduction in their habitual total daily calorie intake. To keep the diet consistent and standardized, participants will record their typical food intake during a control week using the Eat This Much app, which will then provide an overall portion plan and the 25% caloric restriction measure for the intervention week. Thus, the intervention diet will mirror the control diet in terms of types of food consumed, with the difference being in the amount consumed. There will be no restriction regarding water, but drinks will be restricted according to the overall calorie intake plan."
10125465|NCT04345289|Active Comparator|Convalescent plasma|Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
10125466|NCT04345289|Placebo Comparator|Infusion placebo|Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.
10125467|NCT04345237|Experimental|Experimental group 1 (TS + placebo)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.~Daily consumption for 3 months of placebo milk."
10125468|NCT04345237|Experimental|Experimental group 2 (TS + leucine)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.~Daily consumption for 3 months of milk enriched with leucine."
10125469|NCT04345237|Experimental|Experimental group 3 (HRC + placebo)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.~Daily consumption for 3 months of placebo milk."
10125470|NCT04345237|Experimental|Experimental group 4 (HRC + leucine)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.~Daily consumption for 3 months of milk enriched with leucine."
10125471|NCT04345237|Experimental|Experimental group 5 (no physical exercise + leucine)|"The subjects will not carry out any type of physical activity.~Daily consumption for 3 months of milk enriched with leucine."
10125472|NCT04345237|No Intervention|Control (no physical exercise + placebo)|"The subjects will not carry out any type of physical activity.~Daily consumption for 3 months of placebo milk."
10125473|NCT04345263|Active Comparator|MTA pulpotomy|Tooth will receive MTA & resin composite restoration
10125474|NCT04345263|Active Comparator|Biodentine pulpotomy|Tooth will receive Biodentine & resin composite restoration
10125475|NCT04345263|Active Comparator|Bioceramic pulpotomy|Tooth will receive Bioceramic & resin composite restoration
10125476|NCT04344938||medical personel|
10125477|NCT04344938||non medical personel|
10125478|NCT04344951|Experimental|UNIKINON (Chloroquine phosphate)|Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.
10125479|NCT04344964||Phone consult group|Information collected prospectively on FTA patients and questionnaire (satisfaction)
10125480|NCT04344964||Face-to-face consult group|Information collected retrospectively on FTA patients
10125481|NCT04345094|Experimental|Comparator|Emulsion containing 1% Hexylresourcinol
10125482|NCT04345094|Active Comparator|Intervention|Emulsion containing 2% Hydroquinone
10125483|NCT04345120|Experimental|SY-008-6mg/d|2mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，12mg/d.
10125484|NCT04345120|Experimental|SY-008-12mg/d|4mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，18mg/d.
10125485|NCT04345120|Experimental|SY-008-18mg/d|6mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
10125486|NCT04345120|Placebo Comparator|SY-008 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
10125487|NCT04345185||Project Viva|Project Viva (1999-present) enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age.
10125488|NCT04345185||Infant Feeding Practices Study II|The Infant Feeding Practices Study II (IFPS II, 2005-2007) enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (N=2,552) to 12 months of infant age, and at 6 years.
10125489|NCT04344847|Other|coincidental GIST during LSG patients|With institutional review board approval from Zagazig University Hospitals 338. A double-centre prospective study was conducted on prospectively collected data of all morbidly. 17 patients in Zagazig University Hospitals, Faculty of Medicine, Egypt and 321 patients done in bariatric surgery excellence unit in a tertiary hospital in Riyadh-KSA.
10125490|NCT04345146|Experimental|FSRT & Bevacizumab|Patients will receive Bevacizumab before and after FSRT: daily FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases with Bevacizumab(7.5mg/kg, q3w, IV)
10125491|NCT04344912||COVID19- Population|Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan
10125492|NCT04344912||COVID19+ Population|Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan
10125493|NCT04345055|Experimental|Fascial treatment|Treatment the lumbar fasciae
10125494|NCT04345055|Placebo Comparator|Placebo group|Introduce in a machine off
9669023|NCT04309799|Other|Optional Extension|Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
10125495|NCT04345276|Experimental|Danoprevir+Ritonavir group|
10125496|NCT04345081||SRNSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Reducing Nipple Sparing Mastectomy"
10125497|NCT04345081||SSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.~This Group receive Skin Sparing Mastectomy"
10125498|NCT04344990|Active Comparator|Group E- Epidural analgesia|Continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure. The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The epidural catheter is placed preoperatively.
10125499|NCT04344990|Active Comparator|Group F- Femoral blockade|Continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The femoral catheter is placed preoperatively.
10125500|NCT04344990|Active Comparator|Group I- Intraarticular infusion|Continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The intraarticular catheter is placed before the closure of the incision.
10125501|NCT04344925||Aerosol-reducing Mask|The participant will be placed on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
10125502|NCT04344925||Standard Mask|The patient will be placed on BIPAP using the standard mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
10125503|NCT04345198|Experimental|Intervension|Adrenal artery ablation is performed in PA patients with resistant hypertension.
10125504|NCT04345133|Active Comparator|Undersized Drilling Group|Exposed patients to the reduction of the final drill dimensions at the insertion implants protocol sequence
10125505|NCT04345133|Other|Conventional Drilling Group|Group with the conventional protocol recommended by the manufacturer
10125506|NCT04345159||Patient with autoimmune disease|Selected using appropriate keywords in the Foundation Rothschild Hospital EMR, consenting to participate in the study.
10125507|NCT04345016|Experimental|All Participants|Eligible participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) during the intervention/treatment phase. Each was followed for one year or until study disenrollment, health plan disenrollment, death, or end of the study and follow-up period. Outcomes data from eligible participants from the two years prior to the intervention/treatment phase and the period of time after the intervention ended through the analysis date (2020-01-01) were evaluated. For this period, these participants received standard medical and diabetic foot care.
10125508|NCT04344886|Experimental|Conventional (dual-phase) SPECT/CT|Adult patients with primary hyperparathyroidism undergoing conventional (dual-phase) SPECT/CT (after 10 and 150 minutes) and conventional minimally-invasive radio-guided parathyroidectomy in a time span 2-3 hours from radionuclide administration.
10125509|NCT04344886|Experimental|Multi-phase SPECT/CT|Adult patients with primary hyperparathyroidism undergoing multi-phase SPECT/CT (after 10, 90, 150, 210 minutes) and individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
10125510|NCT04344860|Active Comparator|rVWF plus TA|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia) plus Tranexamic Acid 1 gm IV within 3 hours of delivery; and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
10183389|NCT03765086|Active Comparator|Limberg Flap|Limberg Flap: In this procedure the pilonidal sinus will be excised by diamond shaped incision and the defect will be closed by random pattern flap.
9827408|NCT02454075|Experimental|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
9519537|NCT03286153|Experimental|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
9826009|NCT02404220|Experimental|ENTO 400 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
9826010|NCT02404220|Experimental|ENTO 400 mg + VCR 1.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
9826011|NCT02404220|Experimental|ENTO 400 mg + VCR 2.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
9826012|NCT02404285|Placebo Comparator|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
9826013|NCT02404285|Active Comparator|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
9826014|NCT02404311|Active Comparator|Part A, Group 1: Vaccine|ALVAC-HIV at months 0 and 1, and ALVAC-HIV + bivalent subtype C gp120/MF59 at months 3, 6, and 12
9826015|NCT02404311|Placebo Comparator|Part A, Group 2: Placebo|Placebo for ALVAC-HIV at months 0 and 1, and placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at months 3, 6, and 12
9826016|NCT02404311|Active Comparator|Part B, Group 1a: Vaccine|Participants originally in Part A Group 1 (Vaccine) receive ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
9826017|NCT02404311|Active Comparator|Part B, Group 1b: Vaccine + Placebo|Participants originally in Part A Group 1 (Vaccine) receive placebo for ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
9826018|NCT02404311|Placebo Comparator|Part B, Group 2: Placebo|Participants originally in Part A Group 2 (Placebo) receive placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at month 30
9826019|NCT02404350|Experimental|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks until week 100"
9826020|NCT02404350|Experimental|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
9826021|NCT02404350|Experimental|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks until week 100
9826022|NCT02404350|Placebo Comparator|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
9827409|NCT02454101|Other|cord milking|milking of the umbilical cord 5 times toward the neonate
9827410|NCT02454101|Other|delayed cord clamping|delayed cord clamping for 120 seconds
9967442|NCT01269697|Placebo Comparator|Placebo of Nutrof|Patient receive the treatment of the placebo of Nutrof Total
9967443|NCT01269723|Active Comparator|Broccoli sprout homogenate|"The broccoli sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
9967444|NCT01269723|Placebo Comparator|alfalfa sprout homogenate|"Alfalfa sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
9967445|NCT01269762|Experimental|LipoCol Forte|Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.
10125511|NCT04344860|Active Comparator|rVWF alone|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia); and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
10125512|NCT04345042|No Intervention|First Group|In the first group; the investigators applied the TP such as hot pack, ultrasound, exercise and TENS.
10125513|NCT04345042|Experimental|Second Group|In the second group; the investigators applied the classic massage (Swedish Technique) together with TP.
10125514|NCT04345172|Active Comparator|a lacrimal dilator group (Group LD)|The patients allocated to receive STB performed with a lacrimal dilator
10125515|NCT04345172|Active Comparator|a Wescott scissors (Group WS)|The patients allocated to receive STB performed with a Wescott scissors
10125516|NCT04345029|Experimental|Experimental group (Lippia citriodora + sabdariffa)|"Consumption for 60 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days."
10125517|NCT04345029|Placebo Comparator|control group Placebo (sucrose)|Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days.
10125518|NCT04344821|Placebo Comparator|Control|No diet or exercise intervention
10125519|NCT04344821|Experimental|No Diet plus Exercise|No diet, exercise only intervention
10125520|NCT04344821|Experimental|High Protein Diet plus Exercise|High protein diet and exercise intervention
10125521|NCT04344821|Experimental|High Carbohydrate Diet plus Exercise|High carbohydrate diet and exercise intervention
10183390|NCT03765060|Experimental|Small Stitch|"Patients requiring an urgent emergency laparotomy. The Small Stitch closure technique will be perform using a Monomax® 2/0 HR26 (Half-circle Round body):~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle (Half-circle Round body).~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
10183391|NCT03765060|Active Comparator|Large Stitch|"The intervention will be the classic large Stitch closure technique using a Monomax® 1 HR48 (Half-circle Round body).~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle (Half-circle Round body).~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
10183392|NCT03765047|Experimental|Intervention Arm|"This study arm includes the schools where the School Team (school teachers, coordinator) receives the physical activity intervention. The intervention consists of four parts:~School Engagement and Assessment~Training~Physical Activity Equipment and Resources~Ongoing Assessment and Technical Assistance"
10183393|NCT03765047|No Intervention|Control Arm|The control arm includes the schools where the School Team does not receive any intervention but all the necessary data will be collected.
10183394|NCT03765034|Experimental|Constraint-induced Movement Therapy|A passive constraint cast is applied to the participant's unaffected arm to prevent use for 8 weeks.
10183395|NCT03765034|Active Comparator|Usual Occupational Therapy|Usual and standard care occupational therapy is administered for 8 weeks.
10183396|NCT03765021|Experimental|Tranexamic acid injection (Kapron)|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
10183397|NCT03765021|Active Comparator|Fractional CO2 laser resurfacing|The other side of the face will be randomly assigned to do low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
10183398|NCT03765008|Active Comparator|High Water intake|5-days of High water intake according to IOM guidelines
10183399|NCT03765008|Experimental|Low Water Intake|5-days of Low water intake of 500 mL/day
10183400|NCT03764969|Active Comparator|standard smoking cessation program (SCP)|standard smoking cessation program
10183401|NCT03764969|Experimental|SCP + CRT|SCP plus cognitive remediation treatment (CRT)
10183402|NCT03764969|Experimental|SCP + ICHT|SCP plus an implicit computer-based habit-modifying training (ICHT)
10183403|NCT03764956|Experimental|Low Glycemic Index therapy|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only
9519538|NCT03286140|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
10183404|NCT03764956|Active Comparator|Modified Atkins Diet|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio
10183405|NCT03764891||Uphold|Patients who underwent Uphold procedure
10183406|NCT03764891||Perigee|Patients who underwent Perigee procedure
10183407|NCT03764865|Experimental|day 3 embryo transfer|embryo transfer 3 days after fertilization
10183408|NCT03764865|Experimental|day 5 embryo transfer|embryo transfer 5 days after fertilization
10183409|NCT03764852|Experimental|outpatient laparoscopic|Patients will have laparoscopic outpatients. The procedure is identical to that performed in hospital. What changes is that the patient will return home at night if her condition allows it.
10187627|NCT03724331|Experimental|Light Physical Activity 2|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
9519539|NCT03286140|Experimental|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
10125522|NCT04344834||Health care workers|Egyptian health care workers
10125523|NCT04344834||General population|Any Egyptian personnel
10125524|NCT04344834||Recovered fromCOVID-19|Patients recovered from COVID-19
10125525|NCT04344626|Experimental|Brain tonometry|Participants undergoing intra-operative brain tissue stiffness measurements using a digital tonometer. Evaluated brain tissue is both presumed normal and abnormal based on results of pre-operative evaluations.
10125526|NCT04344652|Experimental|Photoscreening|Photoscreening of patients 0 to 10 years of age
10125527|NCT04344509||COVID19-positive patients|
10125528|NCT04344509||COVID19-negative patients|
10125529|NCT04344483|Active Comparator|Group A ( Lidocaine + Adrenaline)|Group A patients will receive 2% Lidocaine and 1:100,000 adrenaline soaked gauze over skin graft donor site of thigh per operatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site.
10125530|NCT04344483|Placebo Comparator|Group B ( Normal Saline)|Group B patients will receive normal saline soaked gauze over skin graft donor site of thigh intraoperatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site
10125531|NCT04344717|Experimental|Short bowel syndrome|Single dose administration of 2.5 mg and 5 mg (1 week wash out between 2 doses) apixaban to patients with short bowel syndrome requiring long term parenteral nutrition
10125532|NCT04344717|Other|Normal gastrointestinal tract|Single dose administration of 2.5 mg or 5 mg apixaban to patients with a normal gastrointestinal tract with an indication for anticoagulation with apixaban (atrial fibrillation).
10125533|NCT04344756|Experimental|Active Coagulation|
10125534|NCT04344756|No Intervention|Standard of Care|Control patients will receive the best standard of care and a subcutaneous preventive anticoagulation for at least 14 days with enoxaparin 4000 IU/24h, tinzaparin 3500 IU/24h or dalteparin 5000 IU/24h if creatinine clearance (Cockcroft) ≥ 30mL/min or unfractionated heparin 5000 IU/12h if creatinine clearance < 30mL/min.
10125535|NCT04344691|No Intervention|Control|5 minutes waiting time
10125536|NCT04344691|Experimental|Stretching|Rectus femoris static stretching during 90' (with three hold-relax progressions until final ROM)
10125537|NCT04344782|Experimental|Bevacizumab|
10125538|NCT04344782|No Intervention|Standard of Care|
10125539|NCT04344730|Placebo Comparator|Standard oxygen 1|Standard oxygen and placebo of Dexamethasone
10125540|NCT04344730|Experimental|Standard oxygen 2|Standard oxygen and Dexamethasone
10125541|NCT04344730|Experimental|CPAP 1|CPAP and placebo of Dexamethasone
10125542|NCT04344730|Experimental|CPAP 2|CPAP and Dexamethasone
10125543|NCT04344730|Experimental|HFNO 1|HFNO and placebo of Dexamethasone
10125544|NCT04344730|Experimental|HFNO 2|HFNO and Dexamethasone
10125545|NCT04344730|Placebo Comparator|mechanically ventilated 1|placebo
10125546|NCT04344730|Experimental|mechanically ventilated 2|Dexamethasone
10125547|NCT04344548|Experimental|Treatment group|Adult patients with COVID-19 infection with NEWS 2 score >4
10125548|NCT04344743|Experimental|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
10125549|NCT04344561|Experimental|Postural Positioning|Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
10125550|NCT04344561|No Intervention|Standard Care|Participants in this group will have beds managed per standard nursing protocol.
10125551|NCT04344704||DX devices with SMART headset detection enabled|The SMART detection algorithm is designed to, with the aid of atrial rhythm assessment, discriminate between ventricular tachycardias and a variety of supraventricular tachyarrhythmias for which device intervention is not required or desired
9827411|NCT02454127|Active Comparator|Atkins Diet|Atkins Diet (dietary counseling)
10125552|NCT04344704||DX device programmed in single chamber mode|"with the activation of one of the available discrimination criteria:~Onset: distinguishes slow onset or onset tachycardias from sudden onset~Stability: distinguishes between irregularly transmitted supraventricular tachycardias and ventricular tachycardias requiring therapy by continuous interval monitoring.~Morphmatch: helps to distinguish between supra and ventricular signals through analysis of episode QRS width"
10125553|NCT04344808|Experimental|Navigation group|Dental implants will be placed using a dynamic computer assisted surgery system
10125554|NCT04344808|Active Comparator|Freehand group|Dental implants will be place without any guidance. Only virtually planning the ideal position on a 3D image (Cone beam computed tomography)
10125555|NCT04344236|No Intervention|Control|
10125556|NCT04344236|Experimental|Saline oral/nasal rinse|
10125557|NCT04344236|Experimental|0.5% Povidone/Iodine oral/nasal rinse|
10125558|NCT04344236|Experimental|0.12% Chlorhexidine oral/nasal rinse|
10125559|NCT04344288|Experimental|Prednisone group|Prednisone during 10 days after randomization
10125560|NCT04344288|Other|Control group|
10125561|NCT04344223|Experimental|Experimental balance shoes|Tests and familiarization phases with experimental balance shoes (Axis Comfort Development®)
10125562|NCT04344223|Active Comparator|Personal shoes|"Same tasks than the condition Experimental balance shoes but realized with personal shoes (own personal shoes of subjects)"
10125563|NCT04344613|Experimental|Blood samples|
10125564|NCT04344418|Active Comparator|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at the Kenyatta National Hospital (KNH) and Aga Khan University Hospital Nairobi (AKUHN). A diagnosis will be selected based on the same pre-defined checklist and the time the diagnosis is made recorded.
9519540|NCT03286127||PCU (unit)|Those patients who received specialised palliative care on a palliative care unit.(palliative care unit)
10183410|NCT03764839|No Intervention|Active Control Group (Digital Health Education)|"Demographics survey~Baseline surveys~Participants receive a digital information sheet on nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery~Post-surgery:~Pain check-ins (2 times per week) (detailed above)~Patients receive 30 second booster videos at 7, 14, and 21 days after surgery~Follow-up surveys (4, 8, and 12 weeks after surgery)"
10125565|NCT04344418|Experimental|Nurse-performed focused cardiac ultrasound (FoCUS)|The experimental arm will consist of nurse-performed FoCUS for patients with cardiorespiratory failure. A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
10125566|NCT04344405|Experimental|Vit D|
10125567|NCT04344405|Active Comparator|control|
10125568|NCT04344522|Experimental|sequential 2 stage procedure|In this arm , the procedure will be performed in two stages ; the first stage will include performing IOL exchange together with iridoplasty ( if required) and inferior peripheral iridectomy (PI) and the second stage is performing DMEK one month later
10125569|NCT04344522|Experimental|combined single stage procedure|In this arm, both IOL exchange and DMEK will be performed in the same setting
10125570|NCT04344600|Experimental|Peginterferon lambda alfa-1a|peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
10125571|NCT04344600|Placebo Comparator|Placebo|Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2
10125572|NCT04344379|Active Comparator|Arm Title : hydroxychloroquine|
10125573|NCT04344379|Placebo Comparator|Placebo of hydroxychloroquine|
10125574|NCT04344379|Active Comparator|azythromycin|
10125575|NCT04344314|Other|Small gauge arm|2 PIVCs of same gauge and different lengths
10125576|NCT04344314|Other|Large gauge arm|2 PIVCs of same gauge and different lengths
10125577|NCT04344210|Experimental|Tele-Intervention|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
10125578|NCT04344210|No Intervention|Usual Care|Participants will receive the usual care
10125579|NCT04344275|Experimental|Kinesio-taping (KT)|The skin will first be properly cleaned with rubbing alcohol. An I-shaped strip of Kinesio tape with a 5-cm width was applied over the middle trapezius from origin to insertion in the KT group. Kinesio-tape size was measured from the T3 spinal process to the acromion, while the subject is in sitting position relaxed with the arm at the trunk side. The subject was then instructed to move the arm into horizontal adduction and neck flexion. At this position, the tape was applied involving the middle trapezius, ending on the acromion, with 50% tension as recommended for this technique.
10125580|NCT04344275|Placebo Comparator|Placebo Kinesio-taping (KT)|Kinesio-tape was applied with no tension and technique on the middle trapezius.
10125581|NCT04343950|Experimental|Intervention 1: SMS reminders in colorectal cancer screening|SMS reminders will be sent to individuals who received an invitation letter from Colorectal Cancer Screening Program and haven't participated within 6 weeks.
10125582|NCT04343950|Active Comparator|Usual Care 1: Reminder letter in colorectal cancer screening|Reminder letters will be sent to individuals who received an invitation letter from the Colorectal Cancer Screening Program and haven't participated within 6 weeks.
10125583|NCT04343950|Experimental|Intervention 2: SMS reminders to return the screening test|SMS reminders will be sent to individuals who picked the fecal immunochemical test at the pharmacy and haven't returned it within 14 days.
10125584|NCT04343950|Active Comparator|Usual Care 2: No intervention|No reminders will be sent.
10125585|NCT04343950|Experimental|Intervention 3: SMS invitation among prior participants|Invitation by SMS will be sent to women who previously participated in the Breast Cancer Screening Program.
10125586|NCT04343950|Active Comparator|Usual Care 3: Invitation letter|Letter invitations will be sent.
10125587|NCT04343911|No Intervention|conventional positioning|positioning with shoulder braces
10125588|NCT04343911|Active Comparator|positioning on Pink Pad ®|
10125589|NCT04344002||lung cancer+COVID-19|lung cancer patients diagnosed with COVID-19
10125590|NCT04344665|Experimental|Virtual Care and Remote Automated Monitoring|
10125591|NCT04344665|No Intervention|Standard Care|
10125592|NCT04343833|Active Comparator|Control with Standard dental implant|Patients were treated with implants Inhex Ticare Standard (Mozo Grau, Ticare, Valladolid, Spain). The implants presented a surface treated with Reabsorbable Blast Media (RBM), conical macro-design with non-aggressive threads, internal connection, and platform switching. On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
10125593|NCT04343833|Experimental|Test with the new implant design|Patients were treated with Implants Inhex Quattro Ticare (Mozo Grau, Ticare, Valladolid, Spain). The implants also presented a surface treated with RBM, conical macro-design with expanded micro threads, internal connection, and platform switching.On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
10125594|NCT04343924|Experimental|Diving Group|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
10125595|NCT04343924|Active Comparator|Virtual reality Group|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates.
10125596|NCT04343924|No Intervention|Control Group|The subjects of this group will be monitored and treated for PTSD and will not attend the dive discovery course or virtual reality sessions.
10125597|NCT04343820||Breast reconstruction|Women who have had a mastectomy and want a secondary breast reconstruction by implant.
10125598|NCT04344106|Experimental|Prone positioning|"Participants are all turned to prone position for an optimal minimum duration of 3 hours .~Tolerance, oxygen saturation, heart rate and position are monitoring during all procedure. Arterial blood gases are realized before, 1 to 2 hours after the beginning of the prone position, and 6 to 12 hours after resupination."
10125599|NCT04344080|Active Comparator|CytoSorb-Therapy|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care in Addition with hemoadsorption using CytoSorb-Adsorber
10125600|NCT04344080|No Intervention|Standard of care|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care
10125601|NCT04344041|Experimental|Intervention group|High dose of vitamin D3
10125602|NCT04344041|Active Comparator|Comparator group|Standard dose of vitamin D3
10125603|NCT04344015|Other|Convalescent Plasma Donation|The goal of this study is to identify individuals who have previously been infected with COVID-19 and collect plasma from those who meet inclusion criteria for convalescent plasma donation. This protocol will allow for the collection, manufacturing, and storage of convalescent plasma that may be administered to patients with COVID-19 in the near future. In addition, it allows for testing of SARS-COV-2 antibody titers in the plasma that has been collected to inform studies assessing outcomes for patients currently infected with COVID-19 who have received convalescent plasma infusions.
10125604|NCT04343859|Experimental|IMMH-010-60mg|Part A Dose escalation study: 60mg, QD, Cycle0Day1, Cycle1Day1-CycleN
10125605|NCT04343859|Experimental|IMMH-010-120mg|Part A Dose escalation study:120mg, QD, Cycle0Day1, Cycle1Day1- CycleN
10125606|NCT04343859|Experimental|IMMH-010-240mg|Part A Dose escalation study: 240mg, QD, Cycle0Day1, Cycle1Day1- CycleN
10125607|NCT04343859|Experimental|IMMH-010-360mg|Part A Dose escalation study:360mg, QD, Cycle0Day1, Cycle1Day1- CycleN
10125608|NCT04343716|Experimental|White women|White women aged 65-75 with knee OA
10125609|NCT04343716|Experimental|Black women|Black women aged 65-75 with knee OA
10125610|NCT04344093|Experimental|Connected patch validation|
10125611|NCT04343976|Experimental|Lambda Treatment|Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda
10125612|NCT04343976|Placebo Comparator|Saline Placebo|Subcutaneous injection of saline placebo
10125613|NCT04343885|Experimental|177Lu-PSMA+ Docetaxel|7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles. Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
10125614|NCT04343885|Other|Docetaxel (Control)|Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
10125615|NCT04344067|No Intervention|Control Group|
10125616|NCT04344067|Experimental|Far Infrared Therapy Group|In this study, the top radiator of the far infrared emitter was set at a height of 25 cm above the umbilicus with a treatment time of 40 minutes during the initial 1 hour of both the first daily and the last night-time indwelling dialysate of each daily regular peritoneal dialysis regimen.
10125617|NCT04343794|Experimental|Biovitals|Continuous physiological monitoring using Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
10125618|NCT04343794|No Intervention|Control|Usual standard care
10125619|NCT04343625|Experimental|Modified sitting, gentle yoga class|Participants attended a modified sitting gentle yoga class,10 weekly classes, each 60 minutes in duration.
10125620|NCT04344158|Experimental|AK105 combined with Anlotinib|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
10125621|NCT04344158|Active Comparator|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
10125622|NCT04343690|Experimental|Health Care Workers|Faculty, staff, and trainees dealing with COVID-19 pandemic
10125623|NCT04343703|Experimental|Telephone-based management|Telephone-based management will consist of a three-phase intervention: 1) An initial 15-20 min call at 1 week of enrollment in which the cases manager introduces him/herself, and does a short assessment of the current suicide risk, 2) A 5-10 min telephone follow-up at 1, 3, 6, 9 and 12 months, 3) If suicide risk is detected, a 15-45 min crisis intervention call will be done, tailored to the participant's characteristics and context. If deemed necessary, an emergency face-to-face appointment will be scheduled. At each phone call information regarding the current treatment, adherence to mental health services, and current life stressors will be collected.
10125624|NCT04343703|Experimental|iFightDepression for Suicide|The iFightDepression-Survive (iFD-S) program is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iFD tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. To that end, the expertise of a panel of mental health experts in suicide and cognitive-behavioral interventions will be asked. The iFD-S also provides telephone guidance (2h per participant) during the use of the program.
10125625|NCT04343703|Active Comparator|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual. TaU will consist of any routine procedures applied at each participating site.
10125626|NCT04343703|Experimental|Self Awareness of Mental Health|The Self Awareness of Mental Health (SAM) is an adaptation of the Youth Awareness of Mental Health program, originally developed for the Saving and Empowering Young Lives in Europe (SEYLE) study. The SAM aims to raise mental health awareness about risk and protective factors associated with suicide, provide knowledge about depression and anxiety, and enhance the skills needed to cope with adverse life events and suicidal behavior. The intervention is delivered by trained clinical psychologists in five, 45-60 minutes, face-to-face sessions.
10125627|NCT04343872|Active Comparator|Receive lifestyle modification alone (DPP)|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services
10125628|NCT04343872|Experimental|Receive lifestyle modification with metformin therapy|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services plus metformin recommendation
10125629|NCT04343742||chlorine dioxide 3000 ppm. Bottle x 150 cc.|"Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).~Both the original dioxide bottle and the preparation for the day should be kept refrigerated."
10125630|NCT04343755|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
10125631|NCT04343599|Experimental|Hypopressive exercises|Patients completed 10 weeks of abdominal hypopressive exercises with two sessions of 30 minutes per week.
10125632|NCT04343599|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
10125633|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a|
10125634|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b|
10125635|NCT04343768|Active Comparator|Control group: hydroxychloroquine + Lopinavir / Ritonavir|
10125636|NCT04343547|Experimental|1|
10125637|NCT04343547|Experimental|2|
10125638|NCT04343547|Experimental|Experimental 3|
10125639|NCT04343729|Active Comparator|Methylprednisolone|0.5mg/kg injectable methylprednisolone sodium succinate, twice daily, for 5 days.
10125640|NCT04343729|Placebo Comparator|Placebo|Saline solution, twice daily, for 5 days. Injectable.
10125641|NCT04343937||Retrolaminar block|Retrolaminar block for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
10125642|NCT04343937||İntravenous analgesia|İntravenous analgesia for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
10125643|NCT04343963|Active Comparator|Pyridostigmine|Pyridostigmine bromide tablet (60mg P.O. once per day for 14 days)
10125644|NCT04343963|Placebo Comparator|Placebo|Placebo tablet (60mg P.O. once per day for 14 days)
10125645|NCT04343443|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
10125646|NCT04343586|Experimental|Adult treatment arm|Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
10125647|NCT04343508|Experimental|Fortified rice|fortified rice for daily lunch and dinner each day of the week (i.e. 14 meals/week) for six months
10125648|NCT04343651|Placebo Comparator|Placebo|
10125649|NCT04343651|Experimental|700mg Leronlimab|
10125650|NCT04343391|Experimental|Brief Individual Psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
10125651|NCT04343391|Experimental|Brief Group Psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
10125652|NCT04343391|Active Comparator|Treatment as usual|Medication provided by a general practitioner.
10125653|NCT04343326|Active Comparator|accelerated corneal cross linking+ delivery of systemic oxygen|corneal cross linking is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
10125654|NCT04343326|Active Comparator|accelerated corneal collagen cross-linking|corneal cross linking with the same accelerated protocol without additional oxygen therapy.
10125655|NCT04343326|Active Comparator|conventional corneal collagen cross-linking|Conventional corneal cross linking using 30 mW/CM2 UV-A ablation for 30 minutes
10125656|NCT04343430|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
10125657|NCT04343196|Experimental|Group A: Low-dose DVA group|Image acquisition at a reduced X-ray dose, 0.36 µGy/frame (70% reduction) image processing by DVA
10125658|NCT04343196|Active Comparator|Group B: Normal-dose DSA group|Image acquisition at a normal dose (1.2 µGy/frame) image processing by DSA
10125659|NCT04343612|Experimental|Anodal|Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation
10125660|NCT04343612|Experimental|Bilateral|Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation
10125661|NCT04343612|Experimental|Cathodal|Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation
10125662|NCT04343612|Placebo Comparator|Placebo|anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation
10125663|NCT04343131|Active Comparator|Mediterranean diet|Mediterranean diet for 7 days
10125664|NCT04343131|Active Comparator|Low-carb/high protein diet|Low-carb/high protein diet for 7 days
10125665|NCT04343131|Active Comparator|Reference diet|Reference diet for 7 days
10125666|NCT04343300|Other|Control group|Control group without Pilates exercise during 12 weeks Participants were advised to keep their routine Falls diary calendar
9827412|NCT02454127|Active Comparator|Zone Diet|Zone Diet (dietary counseling)
10125667|NCT04343300|Experimental|Pilates group|Pilates classes were held twice weekly for one hour. The classes were divided into a warm-up, mat Pilates with accessories and a cool-down. Participants used small items of equipment such as bands, circles or rings, blocks, spyke balls and foam rollers. The intervention lasted 12 weeks; the classes were supervised twice a week. The supervised exercises were evaluated every four weeks (frequency and intensity) focused on the lower limb (muscles related to gait), core and trunk (muscles related to posture). The participants were asked to perform supplementary at-home workouts three times a week using a booklet and video that was provided to the participants. The video and booklet to introduce the six principles of Pilates, warm-up exercises, exercises on the chair, mat Pilates exercises and cool-down exercises. Participants were advised to perform these exercises three times a week for 30 minutes at home.
10125668|NCT04343027|No Intervention|Standard of care group|Participants who did not have their physicians review their patient-reported outcome measurements with them during the office visit.
10125669|NCT04343027|Experimental|Consultation group|Participants who had their physicians review their patient-reported outcome measurements reviewed with them during the office visit.
10125670|NCT04343170|Placebo Comparator|control group|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.
10125671|NCT04343170|Experimental|ultra-short-term treatment|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
10125672|NCT04343183|Active Comparator|HBOT treatment group|Patients will receive hyperbaric oxygen therapy
10125673|NCT04343183|No Intervention|Standard of Care group|Patients will not receive hyperbaric oxygen therapy and will receive the current standardized treatment protocol
10125674|NCT04343157|Experimental|Image-guided cognitive sparing brain SRS|This is a single arm phase II study where enrolled subjects will receive intracranial SRS will performed identically to standard of care, except for implementing additional imaging techniques and software for additional regional avoidance for cognitive sparing (specifically sparing white matter and the bilateral hippocampus)
10125675|NCT04343248|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks
10125676|NCT04343248|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks
10125677|NCT04342988|Other|Cequa Treatment In Cataract Patients with Dry Eye Disease|Duration of Study Treatment - 4 weeks All patients will receive cyclosporine ophthalmic solution (0.09%) BID in both eyes for 28 days, 1 drop per dose. Dosing will be BID, both eyes, assuming both eyes will eventually undergo cataract surgery. Otherwise, single eye treatment in the operative eye will be permitted.
10125678|NCT04342936|Experimental|Camrelizumab for Injection|Participants receive Camrelizumab 200mg intravenously (IV) on Day 1 of each 2-week cycle
10125679|NCT04342936|Active Comparator|Chemotherapy|Participants receive investigator's choice of chemotherapy (Gemox, IGEV or DHAP) for up to 6 cycles.
10125680|NCT04343066|Experimental|External hex implant|External hexagone implant connection
10125681|NCT04343066|Experimental|Internal hex implant|Internal implant connection
10125682|NCT04343001|No Intervention|Standard care|Usual standard of care at the study hospital
10125683|NCT04343001|Experimental|Aspirin|Aspirin 150mg once daily
10125684|NCT04343001|Experimental|Losartan|Losartan 100mg once daily. Dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
10125685|NCT04343001|Experimental|Simvastatin|Simvastatin 80mg once daily
10125686|NCT04343001|Experimental|Aspirin and Losartan|Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
10125687|NCT04343001|Experimental|Aspirin and Simvastatin|Aspirin 150mg once daily and Simvastatin 80mg once daily
10125688|NCT04343001|Experimental|Losartan and Simvastatin|Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
10125689|NCT04343001|Experimental|Aspirin, Losartan and Simvastatin|Aspirin 150mg once daily, Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
10125690|NCT04343053|Other|SARS-Cov-2 infection|Single study group of patients with respiratory failure due to SARS-Cov-2 infection. Three blood samples will be collected at different stages of disease: early, defined as first 96 hours, mid, defined as time from 96 hours and 14 days, late. defined as >14 days
10125691|NCT04343079|Experimental|braeast cancer|breast cancer patients
10125692|NCT04343118||Group Removal|All patient receiving surgical removal of plate osteosynthesis
10125693|NCT04343014|Experimental|Tongue Root Retractor|Patients in this arm will receive fibroscopic endotracheal intubation with tongue root retractors.
10125694|NCT04343014|Active Comparator|Conventional Fibroscope|Patients in this arm will receive fibroscopic endotracheal intubation without any other devices.
10125695|NCT04343235|Experimental|labetalol + furosemide|labetalol + furosemide
10125696|NCT04343235|Active Comparator|labetalol only|labetalol only
10125697|NCT04343144|Experimental|Nivolumab|
10125698|NCT04343144|No Intervention|Standard of Card|
10125699|NCT04342845|Experimental|Motivational interviewing|The intervention group received an education program in small groups that included no more than ten members. The content was designed based on MI theory and the theory of patient empowerment. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise. Each module started with a brief introduction to relevant background knowledge, which was followed by small-group discussions about personal barriers and techniques for overcoming challenges. During the small group discussions, educators acted as MI facilitators, using group MI techniques to strengthen participants' motivation.
10125700|NCT04342845|Placebo Comparator|Traditional lectures|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI.
10125701|NCT04342754|Experimental|Deep Brain Stimulation ON (DBS ON)|The device will be turned ON
10125702|NCT04342754|Sham Comparator|Deep Brain Stimulation OFF (DBS OFF)|The device will be turned OFF
10125703|NCT04342559|Experimental|Group I|"Belamy with sinodor Vaginal Moisturizer with Odor Neutralizer - code: 062603-07~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
10125704|NCT04342559|Experimental|Group II|"Belamy without sinodor Vaginal Moisturizer without Odor Neutralizer - code: 062603-08~Participants will be instructed on how to use it as follows:~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
10125705|NCT04343105|Sham Comparator|sham group|will receive sham bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position
10125706|NCT04343105|Experimental|real group|will receive real bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position with 10 ml bupivacaine 0.5% + 10 ml lidocaine 2% in total volume 20 ml for each side.
10125707|NCT04342910|Experimental|camrelizumab (SHR-1210) combined with apatinib|Participants will receive camrelizumab on Day 1 and Day 15 of each 28-day cycle and apatinib mg/day up to 2 years.
10125708|NCT04342910|Active Comparator|Paclitaxel or Irinotecan|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle, or irinotecan on Days 1 and 15 of each 28-day cycle.
10125709|NCT04342676|Experimental|patients|LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
10125710|NCT04342637||Practicing gastroenterologists|Practicing physicians performing gastrointestinal endoscpy
10125711|NCT04342689|Experimental|Intervention|Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
10125712|NCT04342689|Placebo Comparator|Control|Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.
10183411|NCT03764839|Experimental|"My Surgical Success Treatment Group"|"Demographics survey~Baseline surveys~Intervention:~45-minute digital behavioral pain medicine intervention My Surgical Success that emphasized cognitive and emotional regulation of pain and downregulation of physiologic arousal.~downloadable app with an audio file~personalized plan that allows learners to incorporate the treatment information~Post-video survey (detailed above)~Post-surgery:~Pain check-ins (2 times per week) (detailed above)~Follow-up surveys (4, 8, and 12 weeks after surgery) Intervention: Behavioral: Perioperative Digital Behavioral Pain Medicine My Surgical Success"
10183412|NCT03764826|Experimental|CAABT|CAABT(Cochleural Alternating Acoustic Beam Therapy) is an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
10183413|NCT03764826|Active Comparator|TMT|TMT(tinnitus masking therapy) is a traditional tinnitus intervention. The masking sound is mainly white noise, and the intensity just covers tinnitus.
10183414|NCT03764787|Experimental|Radiation+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
10183415|NCT03764774|Experimental|LY3463251 Single dose|Single dose of LY3463251 administered subcutaneously (SC)
10183416|NCT03764774|Placebo Comparator|Placebo Single dose|Single dose of placebo administered SC
10183417|NCT03764774|Experimental|LY3463251 Multiple Dose|Multiple doses of LY3463251 administered SC
10183418|NCT03764774|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered SC
10183419|NCT03764748|Experimental|mini-FMT|Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
10183420|NCT03764722|Experimental|Levosimendan|
10183421|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The experimental arm will wear wireless monitoring for 5 days after transfer in subacute care unit"
10183422|NCT03764709|Active Comparator|Control arm GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The active comparator arm will be monitored by nursing staff."
10183423|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The experimental arm will wear wireless monitoring for 5 days after discharge at home"
10187628|NCT03724331|Active Comparator|Support Education Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will participate in a supportive cancer-related education activity each week for 6-weeks after returning home from the hospital.
10125713|NCT04342793|Placebo Comparator|Placebo|Placebo
10125714|NCT04342793|Experimental|ALS-L1023 1,200mg|ALS-L1023 600mg twice a day
10125715|NCT04342793|Experimental|ALS-L1023 1,800mg|ALS-L1023 900mg twice a day
10125716|NCT04342598||Adult outpatient pulmonary MDR-TB patients|
10125717|NCT04342598||Household contact controls|
10125718|NCT04342598||Non-household contact controls|
10125719|NCT04342858|Other|Standard of care|Control will receive standard oral hygiene instructions (OHI every three months)
10125720|NCT04342858|Active Comparator|Standard of care + Fluoride varnish|Intervention 1 will receive standard OHI and application of topical fluoride varnish containing 5% NaF (Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK) every three months
10125721|NCT04342858|Experimental|Standard of care + Fluoride varnish with Tricalcium phosphate|Intervention 2 will receive standard OHI and application of topical fluoride varnish containing 5% NaF + TCP (Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA) every three months
10125722|NCT04342832|Active Comparator|Early invasive treatment (cryoballoon ablation)|
10125723|NCT04342832|No Intervention|Standard medical care|
10125724|NCT04342728|Active Comparator|Ascorbic Acid|8000 mg of ascorbic acid divided into 2-3 doses/day with food.
10125725|NCT04342728|Active Comparator|Zinc Gluconate|50 mg of zinc gluconate to be taken daily at bedtime
10125726|NCT04342728|Active Comparator|Ascorbic Acid and Zinc Gluconate|8000 mg of ascorbic acid divided into 2-3 doses/day with food and 50 mg of zinc gluconate to be taken daily at bedtime.
10125727|NCT04342728|Other|Standard of Care|Standard of care medications only as prescribed by patient's physician.
10125728|NCT04342507|Other|Group A: conservative|conservative treatment with lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
10125729|NCT04342507|Experimental|Group B: probiotics|in addition to the conservative treatment they receive probiotics mixture (Streptococcus thermophilus, Lactococcus lactis, Lactobacillus delbrueckii subsp. bulgaricus) once a day up to 3 months.
10125730|NCT04342923||Complete cohort|All patients undergoing PD during study period in all participating center/units in Spain.
10125731|NCT04342624|Experimental|Cinnamon|Consume 4g of cinnamon capsules daily. Will be randomized, double blind, cross-over to other arm after.
10125732|NCT04342624|Placebo Comparator|Placebo|Consume 4g of placebo daily. Will be randomized, double blind, cross-over to other arm.
10125733|NCT04342741|Active Comparator|Foley catheter inpatient|Participants had intracervical ripening with foley catheter after admission into the ward.
10125734|NCT04342741|Active Comparator|Foley catheter outpatient|Participants had intracervical ripening with foley catheter and allowed home.
10125735|NCT04342650|Active Comparator|Intervention|CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration.
10125736|NCT04342650|Placebo Comparator|Placebo|Placebo tables of equal characteristics and duration of treatment.
10125737|NCT04342819|Experimental|SGLT2i|Empagliflozin 25 mg per oral once daily
10125738|NCT04342611|Experimental|Patients under the care of TA Oncologist|These patients will be under the care of an oncologist who will be randomized to training in the TA intervention.
10125739|NCT04342611|No Intervention|Patients under the care of Usual Care Oncologist|These patients will be under the care an oncologist who will be randomized to usual care.
10125740|NCT04342533|Experimental|ThuFLEP|Patients who underwent thulium fiber enucleation of the prostate
10125741|NCT04342533|Active Comparator|HoLEP|Patients who underwent holmium laser enucleation of the prostate
10125742|NCT04342455|No Intervention|traditional scanning protocol group|In coronary CTA examination,each subject will be injected 50 ml contrast agent (Iodixanol 320) with the flow rate of 5 ml/s in tube voltage of 120 kVp.
10125743|NCT04342455|Experimental|double-low scanning protocol group|In coronary CTA examination,the tube voltage(70，80,100kVp),contrast agent(Iodixanol 320) volume and flow rate of each subject are adapted to his or her cardiac ejection fraction(EF) and body mass index(BMI).
9827413|NCT02454127|Active Comparator|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
10125744|NCT04342416|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Experimental: Intervention phase ('B'):~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).~Intervention: Behavioral: Brief cognitive intervention"
10125745|NCT04342065|Active Comparator|Group (G)|received gabapentin 300 mg capsule 2 hours preoperative and the same dose 6 hours postoperative.
10125746|NCT04342065|Active Comparator|Group (C)|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
10125747|NCT04342104||NIV|Patients on Bilevel NIV
10125748|NCT04342104||CPAP|Patients on CPAP
10125749|NCT04342156|Experimental|Intervention|"Treatment arm will be given Hydroxychloroquine sulfate. Dose: 800 milligrams (mg) (4 pills of 200mg) in two divided doses on day 1 followed by 400mg (2 pills of 200mg) in two divided doses on day 2, 3,4, 5.~Mode of administration: Oral pills of 200mg of HCQ; Supply: The total supply of all the pills (12 pills of 200mg per subject in the study group) will be given to the recruited subject from day 1."
10125750|NCT04342156|Other|Standard Preventive Measures|No intervention. Standard recommended preventive measures by the ministry of health.
10125751|NCT04342091|Experimental|Microneedling|Participants with fibrosing alopecia will receive microneedling with a tattoo machine.
10183424|NCT03764709|Active Comparator|Control Arm GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The active comparator arm will perform usual checks by caregivers at home."
9827414|NCT02454127|Active Comparator|Ornish Diet|Ornish Diet (dietary counseling)
10125752|NCT04342377|Experimental|Selective Targeted Sampling|"During patients' Endobronchial Ultrasound (EBUS) procedure, they will first undergo:~Selective Targeted Sampling - endosonographic assessment of at least 3 mediastinal lymph node stations (4R, 4L, and 7) using the four criteria of the Canada Lymph Node Score (predictor of nodal disease during Endobronchial Ultrasound). Each lymph node will be assigned a CLNS ranging from 0 to 4. Triple Normal lymph nodes will be defined as those that appear normal on CT (diameter < 1 cm), AND normal on PET (SUV < 2.5), AND normal on EBUS (CLNS < 2). Lymph nodes that are found to be Triple Normal will be marked as Not for Biopsy, whereas all other lymph nodes will be biopsied."
10125753|NCT04342377|Active Comparator|Systematic Sampling|"Upon completion of Systematic Targeted Sampling, all patients will crossover and receive the standard of care:~Systematic Sampling - all lymph nodes previously marked as Not for Biopsy will be biopsied.~At the conclusion of the EBUS procedure, all nodal stations would have been sampled as is mandated by current guidelines."
10125754|NCT04342221|Experimental|Hydroxychloroquine Sulfate|First dose: 800 mg. From 2nd day on, each patient will get 600 mg (3 capsules) once a day until day 7 (6 more does of 600 mg).
10125755|NCT04342221|Placebo Comparator|Placebo|Equivalent number of placebo capsules at the day of inclusion (4 capsules) and the following days (3 capsules)
10125756|NCT04342247||androgen deficient|
10125757|NCT04342247||healthy|
10125758|NCT04342117||Duvelisib|Patients who take duvelisib.
10125759|NCT04342117||Other PI3K-inhibitors|Patients who take a PI3K-inhibitor other than duvelisib
10125760|NCT04342403||Sarcoidosis|Patients with sarcoidosis willing to participate
10125761|NCT04342351|Experimental|Experimental: sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg b.i.d to 100mg b.i.d. for 3 months
10125762|NCT04342351|Active Comparator|Active Comparator: perindopril|perindopril will be applied from 2mg q.d, to 8mg q.d for 3 months
10125763|NCT04342169|Experimental|HCQ|Participants randomized to the HCQ arm will receive HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days. The drug dose (2.4 gm over 5 days) falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
10125764|NCT04342169|Placebo Comparator|Placebo|Those randomized to placebo will receive a placebo to be taken on the same schedule.
10125765|NCT04342273|Experimental|KW-6356 therapeutic dose|Oral administration
10125766|NCT04342273|Experimental|KW-6356 supratherapeutic dose|Oral administration
10125767|NCT04342273|Placebo Comparator|Placebo|Oral administration
10125768|NCT04342273|Active Comparator|Moxifloxacin|Oral administration
10125769|NCT04342013|Experimental|Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations with use of the clinical decision support application in the perioperative setting.
10125770|NCT04342013|No Intervention|No Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations without use of the clinical decision support application in the perioperative setting.
10125771|NCT04342000|Experimental|Intervention Group|Movement Education Workshop
10125772|NCT04342000|Sham Comparator|Control Group|Sham Education Workshop
10125773|NCT04342026||Parent of patient with cryptorchidism|parent exposition of endocrine disruptors
10125774|NCT04342026||Parent of patient without cryptorchidism|Parent exposition of endocrine disruptors
10125775|NCT04341870|Experimental|Sarilumab + Azithromycin + Hydroxychloroquine|Sarilumab combined with Azithromycin and Hydroxychloroquine
10125776|NCT04341870|Active Comparator|Sarilumab|Sarilumab only
10125777|NCT04341935|Experimental|DPP4 group|Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
10125778|NCT04341935|Active Comparator|Control group|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
10125779|NCT04341922|Experimental|Intervention: Online Cognitive-Behavioral intervention|The three-week intervention is a structured self-guided program without therapist support, administered via a secure web platform and organized in five brief modules. The treatment is provided through an encrypted online platform (login through BankID and double authentication) provided by the eHealth Core facility at Karolinska Institutet
10125780|NCT04341922|No Intervention|Wait-list|The wait-list controlled composes of no intervention for three weeks. Participants randomized to the wait-list group will be crossed over to receive the Online Cognitive-Behavioral intervention after three weeks (post-treatment).
10125781|NCT04341831|Experimental|Group 1|We will be added 200mg teicoplanin powder around instrument for each level.
10125782|NCT04341831|No Intervention|Group 2|We will not used any antibiotic powder in this group.
10125783|NCT04341844|Experimental|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
10125784|NCT04341844|Placebo Comparator|Control|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
10125785|NCT04341857|Experimental|Sintilimab combined with FLOT regimen|Oxaliplatin#80mg/m2d1#iv infusion for 2 hours# Calcium leucovate#200mg/m2d1#iv infusion# Fluorouracil#2600mg/m2,intravenous drip for 24h# Docetaxel#50mg/m2,intravenous drip for 1 h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
10125786|NCT04341714||patients enrolled|Patients with telephone consultation on neurourology department, age > 18
10125787|NCT04341883|Experimental|anti-PD-1|PD-1+albumin-bound paclitaxel
10125788|NCT04341701|Other|COPD|COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist
10125789|NCT04341701|Other|Asthma|asthma according to GINA 2019 but without any smoking restriction
10125790|NCT04341688|Experimental|Povidone-Iodine 0.2% (BETADINE®)|0.2% Povidone-Iodine (BETADINE®) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
10125791|NCT04341688|Experimental|Hydrogen peroxide 1% (ActiveOxy)|ActiveOxy (1% Hydrogen peroxide) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
10125792|NCT04341688|Active Comparator|Neem extract (Azadirachta indicia)|Neem extract (Azadirachta indicia) gargle will be prepared by chemistry laboratory. patients will do 10ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
10125793|NCT04341688|Active Comparator|Hypertonic saline (2%NaCl)|10 ml gargle and nasal lavage using Hypertonic saline for 20-30 seconds, thrice daily for 6 days.
10125794|NCT04341688|Placebo Comparator|Positive controls|10 ml gargle and nasal lavage using distilled water for 20-30 seconds, thrice daily for 6 days.
10125795|NCT04341779|Experimental|Intervention arm|Point-of-care adherence testing and Point-of-care viral load testing
10125796|NCT04341779|No Intervention|Standard-of-care arm|No adherence testing and lab-based viral load testing
10125797|NCT04341987|Experimental|brief Imagery Rehearsal Therapy|"The brief two-session, behaviorally-based imagery rehearsal intervention is based on components from previous group and individual formats that have been published, but will be presented in an abbreviated manner. In the first session, Veterans will be presented with psychoeducation about dreaming, basics of sleep hygiene and stimulus control techniques, how to change negative dreams from a learned habit perspective, re-scripting, and how to rehearse new dream imagery. They will then be asked to complete in-session practice of imagery rehearsal with the new imagery developed. Veteran will be instructed in practice post-session."
10125798|NCT04341987|Other|Treatment As Usual|Patients in this condition are free to receive treatment as usual for nightmares, which may be a medication, supportive counseling or no treatment.
10125799|NCT04341974||surgical patients|Adult patients undergoing major elective general abdominal surgery for ontological disease
10125800|NCT04341402|Experimental|Experimental|miconazole 3% & diclofenac sodium 1% & urea 40% in topical gel daily for 6 months.
10125801|NCT04341584|Experimental|ANAKINRA|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
10125802|NCT04341584|No Intervention|Standard of care|
10125803|NCT04341428|Experimental|DWP14012 20mg|Orally, once daily
10125804|NCT04341428|Active Comparator|Lansoprazole 15mg|Orally, once daily
10125805|NCT04341649|Active Comparator|Head massage by therapist|Head massage therapist will practice massage covering the scalp, front head, occipital area and neck.
10125806|NCT04341649|Active Comparator|Helmet massage BREO|Breo helmet will be installed for massaging the head at different defined places.
10125807|NCT04341649|Active Comparator|Low Laser Therapy|Laser light can penetrate the skin and stimulate the nervous connections. The investigators will use a laser pen (Min Sheng).
10125808|NCT04341649|Active Comparator|Sham Low Laser Therapy|The investigators will use the same laser pen, but without laser beam.
10125809|NCT04341649|Active Comparator|TENS ear stimulation|The investigators will use the (Hwato) device that provides electrical pulse at various frequency and intensity. This TENS device is a prototype modified for ear stimulation.
10125810|NCT04341649|Active Comparator|Deep and Slow breathing|This intervention is guided by an app that leads to a full respiratory.
10125811|NCT04341649|Sham Comparator|Relaxed Reading time|Participants will read the newspaper in a quiet environment.
10125812|NCT04341571|Experimental|Probiotics|15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.
10125813|NCT04341571|Experimental|Metformin|15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.
10125814|NCT04341636|Experimental|vertical bitewing|All of the bitewing radiographs will be evaluated by two experienced restorative dentists for caries. All observers will be instructed on the definition of the rating scale before the examination sessions. The observers will be using the following a 5-point confidence scale as follows: 1=caries definitely absent; 2=caries probably absent; 3=equal chance of caries being present or absent; 4=caries probably present; 5=caries definitely present. If caries was detected a second 5-point confidence scale as follows: 1=caries mostly absent (< 25%); 2=caries slightly presence( 25%-50%) ; 3=about half of the border are presence; 4=caries probably clear ( most boarders are presence); 5=caries definitely clear ( all borders are presence ).
10125815|NCT04341636|Active Comparator|horizontal bitewing|All of the bitewing radiographs will be evaluated by two experienced periodontist for bone loss measurements. The steel wire will be used to determine the magnification factor as explained by G Li et al. 8 The steel wire and cemento enamel junction (CEJ) - if not obscure by caries - will be used as reference points for bone loss measurements. Each tooth will be measured mesially and distally twice and all these measurements will be adjusted using the steel measurement.9 All the measurements will be conducted using IC measure INK software.
10125816|NCT04341610|Active Comparator|ASC|100 million allogeneic adipose-derived mesenchymal stromal cell
10125817|NCT04341610|Placebo Comparator|Placebo|Saline
10125818|NCT04341519||Family members|"Age>18y~Non-opposition to participate to the telephone interviews~One family member per patient: the family member the most implicated in the patient's care~3 groups of Family members will be enrolled in the study corresponding to patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia (See below). 1 family member per patient will be recruited."
10183425|NCT03764683|Experimental|Drug-Drug|This arm will receive the active drug in the first and second phase of the study.
10183426|NCT03764683|Other|Placebo-Drug|This arm will receive placebo in the first phase of the study and the active drug in the second phase.
10183427|NCT03764683|Placebo Comparator|Placebo-Placebo|This arm will receive placebo in the first phase and second phase of the study.
10183428|NCT03764657||"16 patients, named Hot group"|"We considered 16 sinus excision by diathermy as a case group (named Hot group)"
10183429|NCT03764657||"13 patients, named Cold group"|"13 procedures performed by knife as control group (named Cold group)."
10125819|NCT04341519||Patients|"Patients:~Age>18y~Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic~Having received invasive or noninvasive mechanical ventilation~Non-opposition to participate to the telephone interviews.~3 groups of patients will be enrolled in the study: patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia.~COVID group : Patients admitted to the ICU for acute respiratory failure and having a positive 2019-nCOV RT PCR in a respiratory / nasal swab sample (GROUP COVID-19)~Group FLU : patients admitted to the ICU for acute respiratory failure and having a confirmed influenza pneumonia~Group CAP (Community-acquired pneumonia) : patients admitted to the ICU for acute respiratory failure and having a clinically or microbiologically documental community acquired pneumonia with negative COVID-19 and Influenza PCRs."
10125820|NCT04341519||healthcare providers|Two months after the official end of the COVID-19 peak in France, the local investigator will receive a set of 100 questionnaires. He/she will be responsible for proposing survey participation to volunteer healthcare providers. Those who are interested will be given the information letter and the questionnaires in an envelope. Once completed anonymously, they will seal the envelope and give it to the local investigator who will then send us all completed questionnaires by registered post.
10125821|NCT04341493|Experimental|Nitazoxanide + hydroxychloroquine|Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
10125822|NCT04341493|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg PO every 12 hours for 7 days
10125823|NCT04341753|Experimental|Pulmonary rehabilitation|"In addition to the usual evaluation, other tests will be carried out in addition and specifically for this study:~the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
10125824|NCT04341415|Experimental|Auricular neuromodulation|
10125825|NCT04341415|Sham Comparator|Control|
10125826|NCT04341675|Active Comparator|Sirolimus|Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.
10125827|NCT04341675|Placebo Comparator|Placebo|Matching placebo
10125828|NCT04341818|Experimental|Strength Training and Vitamin D monthly|Four weeks of Vitamin D (50.000 IU once per month) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
10125829|NCT04341818|Experimental|Strength Training and Vitamin D daily|Four weeks of Vitamin D (800 IU once per day) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
10125830|NCT04341818|Experimental|Strength Training and no Vitamin D|Four weeks of no vitamin D administration followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
10125831|NCT04341662|Experimental|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination & Escalation; and 3) an implementation strategy, focusing on simulation-based training, peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with action line, and MOTIVE emergency kits."
10125832|NCT04341662|Active Comparator|Usual care|Usual care with dissemination of the current guidelines
10125833|NCT04341597|Experimental|transperineal sonographic cervix assessment|
10125834|NCT04341597|Active Comparator|endovaginal sonographic cervix assessment|
10125835|NCT04341506||Participant ECG|The study has one arm, I.e., we will collect daily ECGs in 100 participants and track their ECG over three months. We will then compare ECGs pre and post COVID-19 diagnosis in any participant diagnosed with COVID-19 to assess for any early ECG changes that may aid with diagnosing.
10125836|NCT04341727|Active Comparator|Hydroxychloroquine alone|Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
10125837|NCT04341727|Active Comparator|Hydroxychloroquine plus azithromycin|"Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets."
10125838|NCT04341727|Active Comparator|Chloroquine alone|Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
10125839|NCT04341727|Active Comparator|Chloroquine plus azithromycin|"Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.~AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets."
10125840|NCT04341740|Experimental|Renal Cell Carcinoma or Urothelial Carcinoma Patients|Patients in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate and 75 ml of peripheral blood sample.
10125841|NCT04341805|Active Comparator|Group A. Physiological saline.|The surgical procedure in group A consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial was administered (Ecolav Physiological Washing Serum 0.9%, (SSF).
10183430|NCT03764644|Experimental|Combined ABMT and CBT|9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
10125842|NCT04341805|Experimental|Group B. Solution hyperoxygenated fatty acids|The surgical procedure in group B consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial (AGHO solution) was administered according to randomization.
10125843|NCT04341766||Patient hospitalised with COVID-19 infection|Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
10125844|NCT04341961|Experimental|Pom Juice|The study participants will all be asked to drink pomegranate juice for 2 weeks, and 4 weeks of continued usual diet and avoid pomegranate juice (other than what is given to you), berries (strawberries, blackberries, raspberries (red, black, yellow), cranberries), walnuts, pecans, hazelnuts, pecans, chestnuts, red and white guava, pomegranates, flaxseeds, dark chocolate and cocoa, coffee, tea, rose hip, olives, artichoke, dried herbs and beefsteak tongue mushrooms).
10125845|NCT04341480||Chemotherapy group|Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital. Total observation duration is 6 weeks.
10125846|NCT04341480||Control group|No treatment, based on patient's choice. Total observation duration is 6 weeks.
10125847|NCT04341389|Active Comparator|Arm 1|1×10^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
10125848|NCT04341389|Active Comparator|Arm 2|5×10^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
10125849|NCT04341389|Placebo Comparator|Arm 3|Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
10125850|NCT04341545|Experimental|Letrozole|Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection. Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
10125851|NCT04341545|Placebo Comparator|Placebo|Participants will be given identical looking placebo for one week and receive the same standard management for medical management of tubal ectopic pregnancies.
10125852|NCT04341142|Experimental|Serological tests will be applied on patients blood sampling|Serological tests will be applied on patients blood sampling
10125853|NCT04341285|Active Comparator|Early ECMO|Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
10125854|NCT04341285|Active Comparator|Late ECMO|Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.
10125855|NCT04341272|Active Comparator|Upper Extremity Compression Device|Patients randomized to have pneumatic compression device placed on upper extremity following surgery
10125856|NCT04341272|Other|Control|Patients randomized to have pneumatic compression device placed on lower extremity following surgery
10125857|NCT04340999||Manifested Group|Manifested Group , enrolled patients who had any of the following manifestations(Fatigue,muscle cramps or numbness)
10125858|NCT04340999||Non-Manifested Group|Non-manifested group in which enrolled patients didn't report any of the following manifestations
10125859|NCT04341337||expert|interviews of expert of pipac about ethical issues
10125860|NCT04341298|Experimental|Avulux® device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
10125861|NCT04341298|Sham Comparator|Control/sham device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
10125862|NCT04341363|Experimental|Microneedling|Participants with androgenic alopecia will receive microneedling with a tattoo machine.
10125863|NCT04340986||patients with Hepatocellular carcinoma|
10125864|NCT04340986||patients with Cholangiocarcinoma|
10125865|NCT04341064|Experimental|SHINE|Participants will be randomized to receive an intervention that provides information on skin cancer and preventive strategies, features a personalized skin cancer prevention packet that focuses on students' UVR exposure and skin cancer risk, and includes the creation of a individualized sun protection action plan.
10125866|NCT04341064|No Intervention|Standard Education|Participants will be randomized to receive information that covers general skin cancer education for pediatric populations.
10125867|NCT04341207|Experimental|Cohort 1|Advanced Cancer Patients with SARS-CoV-2 positive test & Covid19 symptoms
10125868|NCT04341207|No Intervention|Cohort 2|Advanced Cancer Patients with SARS-CoV-2 negative test & Covid19 symptoms. Patients with a chest CT-scan compatible with Covid19 disease shall be treated in part B.
10125869|NCT04341207|No Intervention|Cohort 3|Advanced Cancer Patients with SARS-CoV-2 positive or negative test & no Covid19 symptoms
10125870|NCT04341207|Experimental|Cohort 4|Advanced Cancer Patients with SARS-CoV-2 positive test AND chest CT-scan compatible with Covid19 disease & no Covid19 symptoms & Pretreated or with frail conditions following the HCSP definition
10125871|NCT04341311|Experimental|Marizomib|"All patients will initially receive marizomib (MRZ) alone (Course A1) The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design~-Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses."
10125872|NCT04341311|Experimental|Marizomib + Panobinostat|"If tolerated,combination of Marizomib: and panobinostat on subsequent cycles. The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design.~Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses.~Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course"
10125873|NCT04341181|Experimental|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
10125874|NCT04341181|Experimental|Atezolizumab|Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab.
10125875|NCT04341181|Experimental|Avelumab|Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab.
9519541|NCT03286127||IPCC (hospital)|"Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team.~(inpatient palliative care consultation team)"
9519542|NCT03286127||OPCC (outpatient)|Those patients who received specialised palliative care at home from an outpatient palliative care consultation team. (outpatient palliative care consultation team)
10125876|NCT04341181|Experimental|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
10125877|NCT04341181|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib.
10125878|NCT04341181|Experimental|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib.
10125879|NCT04341181|Experimental|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab.
10125880|NCT04341181|Experimental|Trastuzumab emtansin|Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin.
10125881|NCT04341181|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib.
10125882|NCT04341181|Experimental|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib.
10125883|NCT04341051||Case|we will observe the regional saturation of O2 through NIRS at the following time: T0(before peripheral anesthesia); T1 (5 minutes from the block); T2 (15 minutes from the block); T3 (30 minutes from the block); T4 (after revascularization); At each interval PA, SpO2 and NIRS were also recorded in the contralateral limb as control data.
10125884|NCT04341038|Experimental|Intervention|"Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml.~In addition, these patients can receive all the treatments considered necessary for their clinical management."
10125885|NCT04341038|No Intervention|Usual care|These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.
10125886|NCT04341168||Children and Adolescents with COVID-19|age range: newborn - 18 years old, subgroups will be established
9967446|NCT01269775|Experimental|Face to face lecture|The lecturer allocated 1.5 hours for delivering the lecture by using provided slides about the topic and 0.5 hours for question and answer.
10125887|NCT04341168||Adults with COVID-19|age range: from 18 years old, subgroups will be established
10125888|NCT04341168||Control group|all ages, any respiratory tract infection, subgroups will be established
10125889|NCT04341324||Active arm: Subjects received hormonal therapy|"Study subject inclusion criteria~Male patients 18 years or older~Adenocarcinoma of the prostate either histologically or cytologically confirmed~Decided to be put on ADT -bilateral orchidectomy or luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist, with or without additional antiandrogen~After ADT performed, serum testosterone level should reach castrated level, i.e. < 50 ng/dL after 6 weeks of treatment~Able to consent for the participate in the study"
10125890|NCT04341324||Control arm: Subjects do not plan to receive hormonal therapy|"Control subject:~Male patients 18 years or older~Adenocarcinoma of the prostate either histologically or cytologically confirmed~Able to consent for the participate in the study"
10125891|NCT04341077|Experimental|SHR3162|A single dose of fluzoparib was administered orally
10125892|NCT04341220|Experimental|Anodal tDCS + Exercise|Anodal tDCS applied over primary motor cortex (M1) - Dose: 1mA, 20 minutes + ( concomitantly) protocol of specific exercises for balance
10125893|NCT04341220|Sham Comparator|Sham tDCS + Exercise|Sham tDCS applied over primary motor cortex (M1) - Dose: 1mA, 30 seconds ON, + (concomitantly) protocol of specific exercises for balance
10125894|NCT04341155|Active Comparator|Dexamethasone|"Sixty nine patients will be administered randomly dexamethasone 20 mg IV for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
10125895|NCT04341155|Placebo Comparator|Placebo|"Sixty nine patients will be administered randomly Normal Saline 0,9% IV (4 cc) for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
10125896|NCT04340973|Active Comparator|Anodal|Anodal tDCS: Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
10125897|NCT04340973|Active Comparator|Bilateral|Bilateral : Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation, 5 days a week for 4 weeks
10125898|NCT04340973|Active Comparator|Cathodal|Cathodal : Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
10125899|NCT04340973|Active Comparator|Extracephalic|Extracephalic : Anode placer over the affected primary motor cortex, cathode over right shoulder. 2 mA, 20min stimulation, 5 days a week for 4 weeks
10125900|NCT04340973|Placebo Comparator|Placebo|Placebo : anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
10125901|NCT04340960|No Intervention|Control Group|"The control group will not be monitored with continuity of care. After this period 30 day emergency department visits will be measured and compared between the two groups, along with 30 day readmission rates, in-hospital length of stay, mortality, quality of recovery 40 item scale (QoR-40), European Quality of LIfe 5 Dimensions (EQ5D), patient satisfaction score, and societal and hospital cost.~No intervention will be administered."
10183431|NCT03764644|Sham Comparator|Combined Sham ABMT and CBT|9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
9519543|NCT03286101|Experimental|0.5% Ivermectin Lotion|
10125902|NCT04340960|Experimental|Home Monitoring Group|At the time of hospital discharge, the control group will be discharged without receipt of home monitoring and the intervention group will receive a home monitoring kit with (NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and ECG (electrocardiogram)) with instructions on how to use these devices. Patients in the intervention groups will receive digital communication for 4 weeks and have their ECG, NIBP, HR (heart rate), SPO2 and pain scores evaluated 4 times a day for 2 weeks.
10125903|NCT04340830|Experimental|smoker|Those consuming at least 10 cigarette a day for ten years were included in smoker group.
10125904|NCT04340830|Active Comparator|non-smoker|Patients who never smoke were included in non-smoker group. Patients who quit smoking were not included in this group.
10125905|NCT04340544|Experimental|Hydroxychloroquine|Hydroxychloroquine 600mg daily for 7 days
10125906|NCT04340544|Placebo Comparator|Placebo|Equivalent number of placebo capsules
10125907|NCT04340622|Active Comparator|Reduction in opioid cravings and use|These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.
10125908|NCT04340622|Placebo Comparator|Small reduction in opioid cravings and use|Sham condition.
10125909|NCT04340765|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
10125910|NCT04340635||Multi-center data collection|Without intervention
10183432|NCT03764605|Experimental|Metformin|"Patients will take metformin starting from 500 mg a day. They will up-titrate every week, if tolerating IMP, adding one 500 mg dose 8 hours after the former, till reaching 500 mg thrice a day.~The minimum tolerated dose requested in order to be admitted to the study is 500 mg twice a day.~Those reaching eGFR<45 ml/min will reduce the dose by one third. Those reaching eGFR<30 will drop out the study."
10183433|NCT03764605|Active Comparator|Tolvaptan|Patient will start Tolvaptan in a split dose regimen 45 mg as first dose, followed by 15 mg 8 hours later. Those tolerating this dose will uptitrate to 60/30 mg and then to 90/30 mg a day. Those not tolerating 45/15 mg a day will drop out.
10183434|NCT03764579|Active Comparator|sleep and diet intervention|
10183435|NCT03764579|Active Comparator|diet intervention|
10183436|NCT03764566||Trauma control group|Individuals with adverse childhood experiences (e.g.childhood abuse or neglect) will be included as the experimental group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
10183437|NCT03764566||Healthy control group|Individuals with no trauma history will be added as the healthy control group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
10183438|NCT03764566||Clinical control group|Individuals with Borderline Personality Disorder (BPD) will be added as a clinical control group. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
10183439|NCT03764553|Experimental|Liposomal irinotecan, leucovorin and 5FU|IV Nal-IRI 80 mg/m² (expressed as irinotecan hydrochloride (HCl) salt), folinic acid 400 mg/m², fluorouracil 2400 mg/m² over 46 h, every 2 weeks.
10183440|NCT03764553|Experimental|Carboplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and carboplatin area under the curve (AUC5), every three weeks.
10183441|NCT03764553|Experimental|oxaliplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2, every three weeks.
10183442|NCT03764540|Experimental|Cabazitaxel plus prednisone|"Cabazitaxel: Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as anhydrous and solvent-free basis, per 1.5 mL of solution. Cabazitaxel will be administered by IV route Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
10183443|NCT03764540|Active Comparator|Docetaxel plus prednisone|"Docetaxel is formulated in polysorbate 80 and commercially available as 80 mg/2.0 mL single-dose vials with accompanying diluent (13% ethanol in water for injection) for IV use.~Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
10183444|NCT03764527|Active Comparator|Artemether-lumefantrine (AL)|One tablet of artemether-lumefantrine (Coartem®) was administered twice daily for 3 days to children with a body weight of 9 to <15 kg, and 2 tablets were administered twice daily for 3 days to children with a body weight of >15 to 25 kg. All doses were taken under direct observation.
10183445|NCT03764527|Active Comparator|Artesunate + Amodiaquine (AA)|Artesunate + amodiaquine (ASAQ) was administered as follows: 4 mg/kg body weight of artesunate plus 10 mg/kg body weight of amodiaquine once daily for 3 days under direct observation.
10183446|NCT03764488|Experimental|BIIB067 High Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).
10183447|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 mL aCSF.
10183448|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 5 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 5 mL aCSF.
10183449|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in up to 20 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in up to 20 mL aCSF.
10183450|NCT03764462|Experimental|Raloxifene 60mg to AD-101 45mg|Period 1: Raloxifene 60mg, 1 tab, QD, Per oral / Period 2: AD-101 45mg, 1 tab, QD, Per oral
10183451|NCT03764462|Experimental|AD-101 45mg to Raloxifene 60mg|Period 1: AD-101 45mg, 1 tab, QD, Per oral / Period 2: Raloxifene 60mg, 1 tab, QD, Per oral
10183452|NCT03764436|Experimental|LEAPS-NCHD Program - Group 1|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
10125911|NCT04340934|Experimental|Use of REZUM system|Surgery of benign prostatic hyperplasia by REZUM system
10125912|NCT04340921||1. COVID-19+ (n=120)|"COVID-19 positive without evidence of myocardial injury (n=120). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection.~Exclusion criteria: No biochemical evidence of acute myocardial injury (serum troponin>99th centile within previous 48-hour period)."
10125913|NCT04340921||2. COVID-19+ Myocardial injury+ (n=20)|"COVID-19 positive with myocarditis (n=20). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection and clinically suspected or confirmed myocarditis including evidence of acute myocardial injury (troponin >99th centile within the previous 48-hour period) at the time of recruitment.~Exclusion criteria: significant chronic kidney disease (eGFR ≤30 or dialysis-dependent) or septic shock at the time of initial assessment. We will also exclude patients with a diagnosis of chronic heart muscle disease and those with known significant chronic or acute obstructive coronary disease."
10125914|NCT04340921||3. COVID-19+ Complication+ (estimated 10-25%)|Inclusion criteria: Participants form Groups 1 and 2 in whom a prespecified complication ocurs will be included in a derived Group3.
10125915|NCT04340804|Experimental|Kcal labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal counter synchronised with the food amount changes (i.e., increasing/decreasing).
10125916|NCT04340804|Experimental|PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes (i.e., increasing/decreasing) with 4 min being equivalent to 20 kcal.
10125917|NCT04340804|Experimental|Kcal and PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal and PACE counters synchronised to the food amount changes (i.e., increasing/decreasing).
10125918|NCT04340804|No Intervention|No labelling|Participants allocated to this group will only see on the screen the amount of food increasing or decreasing based how many times they tap on the corresponding keys.
10125919|NCT04340869|Experimental|Theobromine|Natural extract from Cocoa
10125920|NCT04340869|Active Comparator|Remin Pro|Fluoride , Hydroxyapatite , and Xylitol
10125921|NCT04340869|Experimental|Combination|Remin Pro and Theobromine
10125922|NCT04340661|Experimental|Bionocol arm|
10125923|NCT04340661|Placebo Comparator|Placebo arm|
10125924|NCT04340609|Experimental|Intravenous Group|Dosage of intravenous route is 2 million MSCs/kg for each subject.
10125925|NCT04340609|Experimental|Intracoronary Group|Dosage of intracoronary route is ±50 million MSCs for each subject.
10125926|NCT04340609|No Intervention|Control Group|Standard treatment of acute myocardia infarction
10125927|NCT04340687||IP group|All patients recevied pancreatic duct stent during ERCP and one single dose of 100mg rectal indomethacin after ERCP.
10125928|NCT04340687||IN group|All patients received one single dose of 100mg rectal indomethacin after ERCP.
10125929|NCT04340674|Experimental|Telerehabilitation based on aerobic exercise|Aerobic low-impact exercise guided by audiovisual material. The intensity of exercise is adapted to each participant and is established according to the perceived effort after each session, according to the modified Borg perceived effort scale.
10125930|NCT04340674|No Intervention|Control group|Group that maintain the same medical treatment and not receive additional intervention.
10125931|NCT04340778|Experimental|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion.
10125932|NCT04340778|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
10125933|NCT04340778|Placebo Comparator|placebo|inert placebo Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
10125934|NCT04340713|Experimental|Information support group|The experimental group was given information support program intervention on the basis of routine information communication.
10125935|NCT04340713|No Intervention|Routine care group|The control group was given routine information communication.
10125936|NCT04340791|No Intervention|Default proportion & no labelling|"No intervention:~Default proportion condition (33% lower energy density items - 67% higher energy density items). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~No labelling."
10125937|NCT04340791|Experimental|Default proportion & labelling|"When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
10125938|NCT04340791|Experimental|Increased proportion & no labelling|The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
10125939|NCT04340791|Experimental|Increased proportion & labelling|"The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.~When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
9519544|NCT03286101|Placebo Comparator|Vehicle control|
9827415|NCT02454153|Active Comparator|REMStar Positive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
9967447|NCT01269775|Experimental|Internet based teaching|For providing materials for interactive internet-based group the professor's lecture was converted to an interactive electronic content. This content started with a case introduction followed with asking questions and then based on each student's answer a learning pathway would be assigned to his/her.
9967448|NCT01269775|Experimental|Computer based teaching|For providing material for computer-based group the lecture of the same professor was recorded in studio environment and was synchronized with the slides that were similar to those for lecture-based group. Then the lecture and the slides were converted to a CD as a multimedia CD.
9967449|NCT01269788|Active Comparator|pH positive-omeprazole|
9967450|NCT01269788|Placebo Comparator|pH positive-placebo|
9967451|NCT01269788|Active Comparator|pH positive-fluoxetine|
9967452|NCT01269788|Active Comparator|pH negative-omeprazole|
9967453|NCT01269788|Active Comparator|pH negative-fluoxetine|
9967454|NCT01269788|Placebo Comparator|pH negative-placebo|
9967455|NCT01269814||Go-home group|The patients with a Rockall score of 0 or 1 will be prescribed medical therapy, and will be scheduled for elective gastroscopy.
9967456|NCT01269827|Experimental|pentoxifylline|
9967457|NCT01269827|Placebo Comparator|placebo|
9967458|NCT01269853|Experimental|Arm 2|
9967459|NCT01269853|Experimental|Arm 1|
9967460|NCT01269866|Other|Cymbalta|Cymbalta 60 to 120 mg
9967461|NCT01269879|Active Comparator|Active control (Flexi-Bar only)|Flexi-Bar vibration training only over 12 weeks with three distinct exercises and 10min training twice daily
9967462|NCT01269879|Experimental|Intervention Flexi-Bar + XCO-Trainer|Combination intervention using vibration device Flexi-Bar and XCO-Trainer (oscillating mass witin a tube moved during running 40-60min/week suggested)
9967463|NCT01269892|Other|lactose-free milk|it is kind of nutritional regime
9967464|NCT01269892|Other|conventional milk|it is kind of nutritional regime
9967465|NCT01269905||Group A|Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor.
9967466|NCT01269905||Group B|Group B patients received MHVR and their anticoagulation was managed by their general practitioners.
9967467|NCT01269905||Group C|Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners.
9967468|NCT01269931||Group 1 (EBUS-TBNA simulator training)|Group 1 (EBUS-TBNA simulator training): pulmonary medicine trainees with >30 bronchoscopy procedures experience, >nine months of pulmonary fellowship training and no clinical EBUS-TBNA experience (n=4).
9827416|NCT02454153|Other|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
9827417|NCT02454179|Experimental|Arm 1|pembrolizumab
9827418|NCT02454179|Experimental|Arm 2|acalabrutinib in combination with pembrolizumab
9827419|NCT02454283|Experimental|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
9967469|NCT01269931||Group 2 (Clinical EBUS-TBNA training)|Group 2 (Clinical EBUS-TBNA training): pulmonary medicine trainees in the 2nd half of their final year of pulmonary training or recent graduates (within one year), with >50 bronchoscopy procedures experience who completed a one-month elective with the Interventional Pulmonary Medicine (IPM) service with ≥15 and ≤25 EBUS-TBNA procedures experience (n=4).
9967470|NCT01269944||Medial compartment knee osteoarthritis|Patients with medial compartment osteoarthritis of the knee, as proven by x-rays and clinical examination
9967471|NCT01269957||Mouth breathing|
9967472|NCT01269957||Nasal breathing|
9967473|NCT01269970||locally advanced esophageal carcinoma (cT2-3N0/+)|
9967474|NCT01269983|Experimental|fascial manipolation|8 treatment sessions: 4 of fascial manipulation treatment, and 4 of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
9967475|NCT01269983|Active Comparator|physiotherapy|8 treatment sessions of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
9967476|NCT01269996|Active Comparator|Metformin followed by gliclazide and protaphane|
9967477|NCT01269996|Active Comparator|Janumet followed by Lantus insulin injection|
9967478|NCT01270022|Experimental|Implementation|
9967479|NCT01270022|Active Comparator|dissemination|
9967480|NCT01270035|Experimental|ADA 80 mg eow + MTX|
9967481|NCT01270048|Experimental|Bunsimgieum extract|"name of product: 'mild-x-gwarip'~standard code for item: 200005689~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
9967482|NCT01270048|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
9967483|NCT01270061|Active Comparator|HIV testing|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
9967484|NCT01270061|Experimental|General Health Screening|In Group 2 (Intervention), a theory-based video is used to obtain informed consent for a free general health screening that includes a blood pressure check, blood glucose measurement, and an HIV test.
9967485|NCT01270074|Experimental|azithromycin liquid preparation|azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age
9967486|NCT01270074|Active Comparator|inert liquid preparation|inert liquid preparation will be given three times per week from three months of age to three years of age
9967487|NCT01270087|Other|Adalimumab|
9967488|NCT01270100|Experimental|Recovery management intervention|
10125940|NCT04340518|Experimental|Post-scleral lens wear|Normal subjects without ocular diseased who have worn scleral lenses for at least 8 hours.
10125941|NCT04340427|Experimental|TQB3455 Tablets|TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
10125942|NCT04340908|Experimental|Treatment|Dapagliflozin 10 mg tablet
10125943|NCT04340908|Placebo Comparator|Control|matching placebo tablet
10125944|NCT04340258|Experimental|Pembrolizumab & Cesium-131|200 mg Pembrolizumab (Day -14 pre-surgery; Every 3 weeks after surgery) + Cesium-131 Seeds to deliver 60-70Gy of radiation (Single dose at the time of salvage surgery)
10125945|NCT04340466||Suspected or proven COVID-19 critically ill patients|
10125946|NCT04340466||Control|
10125947|NCT04340401|Experimental|TNT+SHR1210|"Patients with high-risk locally advanced rectal cancer will receive chemotherapy and SHR-1210 before chemoradiaton, after chemoradiaton, patient will receive consolidation chemotherapy. This arm is called Total Neoadjuvant Treatment (TNT) plus SHR-1210. The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX ( Capecitabine + Oxaliplatin ) plus SHR-1210 over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs."
10125948|NCT04340167|Experimental|Autologous humanized anti-CD22 CAR-T treatment|
10125949|NCT04340206|Experimental|face-to-face support and Chatbot online support group|Experimental, Intervention Group A: face-to-face support and Chatbot online support group: 5-week intervention according to ACT principles with the web- and mobile-based Youth Compass plus program, face-to-face support (2 meetings) and weekly online support and feedback from the Chabot eCoach built within the program (one third of the participants is randomly assigned to this group)
10125950|NCT04340206|Experimental|only chat-robot online support group|Experimental, Intervention Group B: only chat-robot online support group: 5-week intervention according to ACT principles with the web-and mobile-based Youth Compass plus program, no face-to-face support, and weekly online support and feedback from the chatbot eCoach built within the program (one third of the participants is randomly assigned to this group)
10125951|NCT04340206|Experimental|Experimental Control|"Experimental Control:~Control group, no intervention (one third of the participants is randomly assigned to this group)"
10125952|NCT04340219||Cancer patients|Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (CPDI, DASS-21, and WHOQOL-BREF).
10125953|NCT04340271|Experimental|Extracorporeal shock wave therapy group|Patients in the ESWT group were explained to select the most hypertrophic and retracting area for the treatment on dominant hand. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
10125954|NCT04340271|Sham Comparator|sham stimulation group|The same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy
10125955|NCT04340284|Experimental|Patients with nonunion of long bones|A total of 11patients ( november 2012 to august 2018) with atrophic non-union of long bones already treated with percutaneous SVF implantation
10125956|NCT04340349|Experimental|Experimental: Hydroxychloroquine plus Bromhexine|200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
10125957|NCT04340349|Placebo Comparator|Hydroxychloroquine plus Bromhexine|200 mg of Hydroxycholoroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
10125958|NCT04340128|Active Comparator|1|Intra-lesional injection of Glucantime once a week
10125959|NCT04340128|Experimental|2|Intra-lesional injection twice a week, 0.1/cm2
10125960|NCT04340414|Experimental|NCP patient with severe ARDS and/or high ventilator supported|The NCP patient with severe ARDS and/or high ventilator supported condition was eligibilitable for enrollment
10125961|NCT04340388|Active Comparator|Switch from a non-integrase based regimen to dolutegravir|Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.
10125962|NCT04340388|Active Comparator|Continue on non-integrase inhibitor based regimen|Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.
10125963|NCT04340089||observation group|the patients can go to squatting on the toilet at any time as they want to after taking the capsule
10125964|NCT04340089||control group|The patients can move freely
10125965|NCT04340492|Experimental|Adapted Physical Activity group|
10125966|NCT04340492|Sham Comparator|control group|
10125967|NCT04340102|Experimental|BecomeAnEx|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital program.
10125968|NCT04340440|Active Comparator|D1 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and limited D1 lymphadenectomy
10125969|NCT04340440|Active Comparator|D2 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and extended D2 lymphadenectomy
10183453|NCT03764436|Experimental|LEAPS-NCHD Program - Group 2|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
10183454|NCT03764436|Experimental|LEAPS-NCHD Program - Group 3|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
9827420|NCT02454283|Placebo Comparator|Placebo|identically matching placebo capsules, orally, single-dose
10125970|NCT04340297|Experimental|Experimental group|Tongjiang granules are taken orally in liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally in spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally in cold-heat complicated syndrome, one bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
10125971|NCT04340297|Placebo Comparator|Control group|Tongjiang placebo granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua placebo granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei placebo granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
10125972|NCT04340050|Experimental|Treatment with anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours
10125973|NCT04340310||Home respiratory poligraphy|Group A: Children between 4 and 14 years-old with initial OSA suspicion there will be allocated to Home Respiratory Polygraphy (HRP)
10125974|NCT04340310||Polysomnography|Group B: Children between 4 and 14 years-old with initial OSA suspicion and concommitant diseases and false negative suspicion from HRP there will allocated to Hospital Nocturnal Polysomnography
10125975|NCT04340141|Experimental|Arm I (perioperative chemotherapy, surgery)|Patients receive oxaliplatin intravenously (IV) over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Within 2-8 weeks of completing neoadjuvant chemotherapy, patients undergo surgical resection. Patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
10125976|NCT04340141|Active Comparator|Arm II (surgery, adjuvant chemotherapy)|Patients undergo surgical resection. Beginning 3-12 weeks after surgery, patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
10125977|NCT04340453|Active Comparator|Group 1 (Hip and Knee Exercise Program)|Standard exercise physiotherapy treatment of a Hip and Knee Exercise Program plus stretching.
10125978|NCT04340453|Experimental|Group 2 (BFR-training hip and knee exercise group)|BFR-training hip and knee exercise group plus stretching.
10125979|NCT04340479||Absent lung ultrasound findings of active COVID infection|Absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
10125980|NCT04340479||Present lung ultrasound findings of active COVID infection|Presence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
10125981|NCT04340232|Experimental|Baricitinib Arm|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of baricitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 2 mg baricitinib once daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving baricitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
10125982|NCT04340375|Experimental|AP green tea extracts|8 weeks
10125983|NCT04339985|Experimental|ATx201 OINTMENT 4%|ATx201 OINTMENT 4%
10125984|NCT04339985|Experimental|ATx201 OINTMENT 7%|ATx201 OINTMENT 7%
10125985|NCT04339985|Experimental|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
10125986|NCT04339946||Patients with suspicious of rectosigmoid endometriosis|
10125987|NCT04339959||Phase I|First, we will test proof-of-concept that participants will be able to follow the testing protocol and use the tablet computer to communicate with the investigator (10-12 participants). The test protocol will be refined based on what is learned after a minimum of 10 participants. We anticipate no more than 12 participants needed for this phase.
10125988|NCT04339959||Phase II|Next, 10-20 new participants will be enrolled to evaluate the validity of videoconference vs. face-to-face assessment (i.e., direct observation) of physical performance. Communication will occur between the remote assessor and the participant. The direct observer will not communicate directly to the participant, unless there is a safety issue. After completing 10 participants without a major change in the test protocol, we will proceed to the next phase.
10125989|NCT04339959||Phase III|This phase involves participants repeating the test protocol, but without the face-to-face assessment (i.e., direct observation). This will test the ability of the participant to receive the box of test instructions and materials in the mail, unpack the box, communicate with the remote assessor via videoconferencing, pack up the box, and return it (postage paid) to the study team. This step will involve 5-10 participants from Phases 1 and 2, who have provided approval for future contact (see approved Future Contact form). Once 5 participants have successfully and safely completed the test protocol, we will proceed to Phase 4.
10125990|NCT04339959||Phase IV|This phase is the same as Phase 3, except it includes newly enrolled participants, i.e., representing the first-time participants have enrolled/participated in this study. This will eliminate the practice effect that will occur in phase 3. This step will enroll 5-10 participants.
10183455|NCT03764423|Experimental|Salmon fishmeal|7,5 g fishmeal and 7,5 g microcrytalline cellulose per day in capsules by mounth for 8 weeks
10183456|NCT03764423|Placebo Comparator|Microcrystalline cellulose|7,5 g microcrystalline cellulose per day in capsules by mounth for 8 weeks
10125991|NCT04339660|Experimental|UC-MSCs treatment group|Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.
10125992|NCT04339660|Placebo Comparator|Control group|Participants will receive conventional treatment and Placebo intravenously.
10125993|NCT04339699|Active Comparator|NobleStitch EL|Participants treated with the NobleStitch EL device
10125994|NCT04339699|Active Comparator|Amplatzer PFO Occluder|Participants treated with the Amplatzer PFO Occluder device
10125995|NCT04339816|Experimental|HC-A group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and 500 mg of Azithromycin once in 24 hours (with the first dose of hydrochloroquine)~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval 250 mg of Azithromycin once in 24 hours (with the first daily dose of hydrochloroquine)"
10125996|NCT04339816|Active Comparator|HC group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)"
10125997|NCT04339816|Placebo Comparator|C group|• Day 1-5: Patients receive two doses of placebo in 12 hours interval and 1 extra dose of placebo once in 24 hours
10125998|NCT04339829|Other|Dacomitinib 45mg PO ,QD|Single arm
10125999|NCT04339842||Adults in quarantine due to the virus outbreak|Individuals over the age of 18 who spend most of their time at home in social isolation because of the Coronavirus to prevent the risk of contracting the virus
10126000|NCT04339673|Active Comparator|MNB- masseteric nerve block|masseteric nerve block with local anesthesia lidocaine single app.
10126001|NCT04339673|Active Comparator|LA -trigger point injection with local anesthetic|local anesthetic injections on trigger points in masseter
10126002|NCT04339673|Placebo Comparator|DN-dry needling|dren needling to masseter
10126003|NCT04339868|Active Comparator|Terlipressin group|Terlipressin acetate 1 mg in 0.9% normal saline (NaCl) 50 mL (0.02 mg/mL) Initial dose 20 mcg/hr (1 mL/hr) titrate increase 1 mL/hr every 30 min to 100 mcg/hr (5 mg/hr) to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease terlipressin until stop
10126004|NCT04339868|Placebo Comparator|Placebo group|Placebo 0.9% NaCl 50 mL Initial dose 1 mL/hr titrate increase 1 mL/hr every 30 min to 5 mg/hr to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease placebo until stop
10126005|NCT04339569||History of patellar tendinopathy|
10126006|NCT04339569||Healthy controls|
10126007|NCT04339647|Experimental|The SIMS Programme|The SIMS programme is a community-based intervention which improvised the usual care (defined as the existing preschool oral health programme) offered by the Ministry of Health. The target group is 5-6-year-old preschool children and their parents. Apart from the usual care, the 5-6-year-old children receive interventions carried out by teacher in school and home tooth brushing supervision by parents. In addition, parents/guardians will receive OHE from the DT team, free toothbrush and toothpaste (1000ppm F) for child home tooth brushing and supervised child home tooth brushing for 6 months.
10126008|NCT04339647|No Intervention|Control|The control group receives the usual care from the preschool oral health programme. The usual care is described as a DT team visiting the school to do an oral examination, provides OHE to the children, and applies fluoride varnish (20,000 ppmF) twice/year.
10126009|NCT04339725||Fecal DNA|Extraction fecal DNA and compare disease group to normal group
10126010|NCT04339543|Other|Longitudinal assessment|
10126011|NCT04339712|Experimental|anakinra|In case of diagnosis of MAS, IV anakinra 200mg three times daily (every eight hours) for 7 days. Patients who will receive anakinra treatment and who suffer from kidney dysfunction will receive 50% of the dose i.e. 100mg anakinra three times daily for 15 days
10126012|NCT04339712|Experimental|tocilizumab|"In case of diagnosis of immune dysregulation IV tocilizumab 8mg/kg body weight once up to a maximum of 800mg. These patients will receive anakinra at the above dose in case they meet one of the following contra-indications for tocilizumab:~absolute neutrophil count less than 2,500/mm3;~absolute platelet count less than 100,000/mm3; and~AST or ALT more than 1.5 x the upper normal limit"
10126013|NCT04339686||Suspicion of COVID 19|
10126014|NCT04339907|Sham Comparator|Cataract surgery only|Participants needing cataract surgery, without glaucoma or any other corneal diseases.
10126015|NCT04339907|Sham Comparator|Glaucoma surgery only|Participants needing glaucoma filtration surgery, without any prior corneal transplantation.
10126016|NCT04339907|Experimental|Corneal transplantation|"Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.~This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure."
10126017|NCT04339907|Experimental|Intraocular surgery following corneal transplantation|"Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation."
10126018|NCT04339907|Experimental|Glaucoma surgery following corneal transplantation|"Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).~This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation."
10126019|NCT04340037||proximal ureteral stone patient|Patients underwent percutaneous nephrolithotomy treating unilateral, solitary and proximal ureteral stones.
10126020|NCT04339504|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
10126021|NCT04339504|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
10126022|NCT04339504|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
10126023|NCT04339400|Experimental|TQ05105 Tablet|TQ05105 tablet 5mg administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
10126024|NCT04339465|Experimental|CARE-FAM|The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).
10126025|NCT04339465|Experimental|WEP-CARE|The online intervention WEP-CARE addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 10 standardized writing tasks on a secured internet platform. The 10 writing tasks will be conducted with a weekly frequency and participants will receive personalized feedback. WEP-CARE aims at enhancing mental health problems and the coping strategies of the family.
10126026|NCT04339465|Experimental|CARE-FAM + WEP-CARE|The families will receive both the face-to-face intervention CARE-FAM and the online intervention WEP-CARE.
10126027|NCT04339465|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
10126028|NCT04339439|No Intervention|Closure without vessel loop|These patients will receive standard of care closure of the carpal tunnel release incision.
10126029|NCT04339439|Experimental|Closure with vessel loop|These patients will receive closure of the carpal tunnel release incision with a vessel loop placed under the sutures.
10126030|NCT04339478||Autofluorescence|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
10126031|NCT04339478||Control|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection without autofluorescence device. The following intraoperative variables will be recorded for all patients:~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands"
10126032|NCT04339309|Active Comparator|Kiel Center|Non-surgical periodontal treatment with interdental hygiene devices in periodontitis patients.
10126033|NCT04339309|Active Comparator|Cairo Center|Non-surgical periodontal treatment without interdental hygiene devices in periodontitis patients.
10126034|NCT04339283|Experimental|Standardized Hibiscus sabdariffa tea Arm|300 mL of freshly prepared standardized Hibiscus sabdariffa tea (containing 102.49 mg/L of total monomeric anthocyanin) is administered daily to the participants for 28 days
10126035|NCT04339283|No Intervention|Water Arm|300 mL of distilled water is administered to the participants daily for 28 days.
10126036|NCT04339088||HIFU|Patients that have undergone high focused ultrasound treatment for varicose veins
10126037|NCT04339361|Experimental|lidocaine spray|four puffs (50ml, 10 mg/puff) of lidocaine spray will be applied to the cervical canal and cervix before tenaculum placement plus vaginal placebo will be given 3 hours before IUD insertion
10126038|NCT04339361|Active Comparator|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
10126039|NCT04339361|Placebo Comparator|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
10126040|NCT04339192|Experimental|Surgery group|receiving minimally invasive tricuspid surgery including tricuspid valve replacement or repair plus medical treatment.
10126041|NCT04339192|No Intervention|Medical group|receiving medical treatment only
10126042|NCT04338997|Experimental|IZD174|Intra subject dose escalation of IZD174
10126043|NCT04339010|Experimental|Hypopressive|"st session: the meetings were provided by a physiotherapist, who also discussed the location and function of the pelvic organs, PFM, and the transversus abdominis (TrA) muscles. The participants learned how to activate TrA muscles. The training was performed during full expiration, the physiotherapist check and coordinate the group to maintain the Tra contraction. The women were also trained to inhale through the nose and exhale through the mouth maintaining an apical breathing pattern.~nd session: The contractions were executed during six different positions the ones which they will keep following through the whole treatment.~rd session: The patients were exposed to all the six positions (supplementary material) and their three variations (positions 1, 3, 5 and 6 ). Every meeting obeyed the same schedule through the five weeks of treatment and was accompanied by two physiotherapists."
10126044|NCT04339010|Active Comparator|Hypopressive + PFMC|This group receives the same protocol than the Hypopressive group, but with a verbal command to realize the PFM contraction during the activation of the deep abdominal muscle.
10126045|NCT04339062|Experimental|Cohort 1 Cemiplimab|"Participants who received allogeneic hematopoietic stem cell transplant~-- Cemiplimab: via IV, flat predetermined dosage every 21 days"
10126046|NCT04339062|Experimental|Cohort 2 Cemiplimab + Everolimus/Sirolimus + Prednisone|"Participants who received a kidney transplant will receive~Cemiplimab via IV, flat predetermined dosage every 21 days~Everolimus or Sirolimus-least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab~Prednisone 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapering doses while receiving Cemiplimab"
10126047|NCT04339348|Experimental|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus vaginal inert placebo cream at the time of IUD insertion
10126048|NCT04339348|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine anesthetic cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo will be given 3 hours before LNG-IUD insertion
10126049|NCT04339348|Placebo Comparator|placebo|inert vaginal placebo cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours before LNG-IUD insertion
10126050|NCT04339231|Active Comparator|Ropivacaine group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with the anesthetic solution ropivacaine, at a concentration of 1%, advancing it through the nasal cavities towards the posterior nasopharynx wall. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that there is absorption of the anesthetic solution through the mucosa up to the sphenopalatine ganglion, which, in general, is found anatomically around 3 millimeters in depth from the surface. After the established time, the cotton buds are removed.
10126051|NCT04339231|Placebo Comparator|Saline 0,9% group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with saline solution, in a concentration of 0.9%, advancing it through the nasal cavities towards the posterior wall of the nasopharynx. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that the solution is absorbed by the mucosa up to the sphenopalatine ganglion, which, in general, is anatomically three millimeters deep from the surface. After the established time, the cotton buds are removed.
10126052|NCT04339153|Experimental|Parent Training (PT)|The goal of intervention plan is to teach the basic applied behaviour analysis techniques to find out the antecedent of the problem behaviour, enhance adaptive skills and reduce noncompliance. Sessions will be interactive, and action-oriented through the provision of workbooks, modelling, videos, rehearsal (with child when present), homework tasks, and feedback (Bearss et al., 2015). The parents will be trained on the protocol and delivered 60 to 90 minutes preferably individual sessions over 24 weeks.
10126053|NCT04339153|No Intervention|Parent Education (PE)|"The Parent education group will serve as an attention-placebo condition to control for general effects of the intervention.~There will be 12 core sessions and 1 home visit regarding knowledge of autism, learning about the principles of managing behavior, teaching new skills; improving social interaction and communication. Each session will last for 60 to 90 minutes over 24 weeks."
10126054|NCT04339114|Sham Comparator|Control meal|Pancake
10126055|NCT04339114|Active Comparator|Control meal + Cinnamon|Pancake seasoned with cinnamon
10126056|NCT04339114|Active Comparator|Control meal + Italian herb mix|Pancake seasoned with Italian herb mix
10126057|NCT04339114|Active Comparator|Control meal + Active-Herbs/Spice mix|Pancake seasoned with pumpkin spice
10126058|NCT04339127||Cohort NMDARE-HSE|Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
10126059|NCT04339075||Venablock|Patients that have undergone Venablock treatment
10126060|NCT04338958|Experimental|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days
10126061|NCT04339244|Active Comparator|ONSD measurement under lower blood pressure|ONSD measurement under mean blood pressure of 60~70 mmHg
10126062|NCT04339244|Active Comparator|ONSD measurement under highly normal blood pressure|ONSD measurement under mean blood pressure of 90~100 mmHg
10126063|NCT04339322||Patients with Covid-19|Patients with clinical presentation and confirmed as Covid-19 according to the definition of Egyptian Ministry of Health
10126064|NCT04338724|Experimental|CS1002|
10126065|NCT04338737|Active Comparator|fluid and soft food|It consists of 100 patients that will be allocated for early post-operative oral feeding receiving water and clear fluid approximately 2 hours after surgery, followed by soft food and regular diet 4 hours later irrespective to intestinal sounds, flatus or stool.
10126066|NCT04338737|Active Comparator|fluid only|It consists of 100 patients that will be allocated for early Postoperative oral feeding receiving water and clear fluid approximately 2 hours after surgery till the return of intestinal sounds, then soft food and regular diet later on.
10126067|NCT04338737|Active Comparator|Npo|It consists of 100 patients that will receive no oral feeding till passage of flatus instead 2 to 3 Litres of intravenous fluid will be used for feeding. Water and fluid will be then offered, followed by soft foods and then a regular diet.
10126068|NCT04338607||All study patients|All study patients will be in one group.
10126069|NCT04338750|Experimental|TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACTICs)
10126070|NCT04338750|Active Comparator|mEUC|minimally-Enhanced Usual Care (mEUC)
10126071|NCT04338672||Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in 2020.
10126072|NCT04338672||Pre Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in the following years: 2017, 2018, 2019,
10126073|NCT04338633|Active Comparator|Conventional calcium hydroxide paste|Application of Conventional calcium hydroxide paste
10126074|NCT04338633|Experimental|Calcium hydroxide nanoparticle|Application of Calcium hydroxide nanoparticle
10126075|NCT04338633|Experimental|Combined Calcium hydroxide with silver nanoparticle|Application of Combined Calcium hydroxide with silver nanoparticle
10126076|NCT04338568|Active Comparator|LUS observer 1|The subject will undergo a Lung Ultrasound by observer nr 1
10126077|NCT04338568|Active Comparator|LUS observer 2|The subject will undergo a Lung Ultrasound by observer nr 2
10126078|NCT04338711|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR E1 administered in the fasted state.
10126079|NCT04338711|Experimental|Treatment B|Single oral 10 mg dose of tofacitinib MR E2 administered in the fasted state.
9827421|NCT02454296|Active Comparator|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
10126080|NCT04338711|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR E3 administered in the fasted state.
10126081|NCT04338711|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR E1 administered in the fed state.
10126082|NCT04338711|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR E3 administered in the fed state.
10126083|NCT04338711|Active Comparator|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state.
10126084|NCT04338763|Experimental|Arm A: RP72 monotherapy|
10126085|NCT04338763|Experimental|Arm B: RP72 in combination with Gemcitabine|
10126086|NCT04338906|Experimental|Camostat + Hydroxychloroquine|Subjects will receive Camostat (400 mg tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
10126087|NCT04338906|Active Comparator|Placebo + Hydroxychloroquine|Subjects will receive placebo (tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
10126088|NCT04338802|Placebo Comparator|Placebo group|Empty capsules with the same appearance and ingredients as Nintedanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
10126089|NCT04338802|Experimental|Nintedanib group|Nintedanib cloth sulfonate soft capsule treatment: According to the drug manual recommendation, give Nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time. Continuous medication for 8 weeks.
10126090|NCT04338919|Experimental|O-APT group|Ticagrelor 90 mg twice daily plus aspirin 100mg once daily in the first month, Ticagrelor 90mg bid between the second and the sixth months Ticagrelor 45mg bid between the seventh and the twelfth months
10126091|NCT04338919|Active Comparator|S-APT group|ticagrelor 90 mg twice daily plus aspirin 100mg once daily for 12 months
10183457|NCT03764410|Experimental|Diabetic group DG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
10183458|NCT03764410|Active Comparator|No diabetic group NG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
10183459|NCT03764397|Experimental|Prehabilitation group|A 4-week prehabilitation educational programme (i.e., a behavioral change intervention) and to pilot that prehabilitation in combination with a 6-week gentle self-paced walking programme (with weekly telephone support) in people with FM.
10183460|NCT03764358|Active Comparator|Arteriovenous fistula|
10183461|NCT03764358|Experimental|Tunneled Cuffed Catheter|
10183462|NCT03764345|Experimental|Sofosbovir/Ledipasvir Daily|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
10183463|NCT03764332|Other|Stabilometry|The Podoprint pressure platform was used as a measuring device. The Podoprint platform is a low profile floor platform consisting of 1.4 sensors / cm2 with a sampling frequency of 40Hz.
10183464|NCT03764319|Active Comparator|Intervention group|Ultra-protective ventilator settings in patients with ARDS and ECMO.
10183465|NCT03764319|Active Comparator|Control group|Standard ventilator settings in patients with ARDS and ECMO.
10183466|NCT03764306|Active Comparator|Carotid Artery Stenting|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
10183467|NCT03764306|Active Comparator|Endarterectomy carotid artery|Subjects will undergo carotid endarterectomy
10183468|NCT03764293|Experimental|SHR-1210|SHR-1210+Apatinib
10183469|NCT03764293|Active Comparator|Control|Sorafenib
10183470|NCT03764280|No Intervention|MDI with Physician Adjusted Basal-Bolus Parameters|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Participants will undergo their conventional multiple daily injection (MDI) therapy.
10183471|NCT03764280|Experimental|MDI with Basal-Bolus Optimization Algorithm|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Once daily, the data from the glucose sensor and injection information will be entered into a computer and the optimization algorithm will be run. Once daily, participants' parameters may be changed based on the algorithm's recommendations.
10183472|NCT03764267|Active Comparator|remifentanil|MAC group
10183473|NCT03764267|Active Comparator|general anesthetic|TIVA group
10183474|NCT03764241|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy
10183475|NCT03764241|Active Comparator|Vitamin K Antagonist|warfarin will be added in addition to dual antiplatelet therapy
10183476|NCT03764228|Experimental|hAECs|Infusion of hAECs at the day before HSCT and 7th days after HSCT. The dose is 1×10^6, 2×10^6, 5×10^6 cell/kg, successively.
10183477|NCT03764215|Experimental|Group 1|Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If Nilotinib 150 mg per mouth daily dose is tolerated by the 1st group of 10 participants for 3 months, another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
10183478|NCT03764202|Other|CSEA，1μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
10183479|NCT03764202|Other|CSEA，1.5μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
10183480|NCT03764202|Other|GA，1μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
10183481|NCT03764202|Other|GA，1.5μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
10183482|NCT03764202|Other|CSEA，Epidural analgesia|"The puerpera received combined spinal epidural anesthesia~Postoperative analgesia was performed with epidural analgesia~Speed of epidural analgesia pump ：6ml/h（0.1% ropivacaine , 0.5μg/ml sufentanil）"
10183483|NCT03764189|No Intervention|en masse retraction only|anterior segment retraction on miniscrews without microosteoperforation
10183484|NCT03764189|Active Comparator|en masse retraction with alveocentesis|anterior segment retraction on miniscrews with microosteoperforation
10183485|NCT03764176|Active Comparator|Conventional impression|"The intervention of this arm will be conventional impression: polyether impression will be taken with a customized tray."
10126092|NCT04338659|Other|IBI322|
10126093|NCT04338867|Active Comparator|Therapeutic arm|Patients who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN) with the release of 10 mg in 24 hours, for 24 hours with a 12-hour rest interval (to avoid saturation of receptors)
10126094|NCT04338867|Active Comparator|Control arm|Patients who received whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions, in 10 days of treatment)
10126095|NCT04338854|Experimental|Root canal treatment|It's one of the restorative groups with LA (Local Anesthesia). An aerator and micromotor were used as cavity preparation in this group. Only conventional root canal treatment and extirpation were planned for the children included in the root canal treatment group in the measurement session.
10126096|NCT04338854|Experimental|Pulpotomy treatment|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. it was noted that at least one of the approximal surfaces of the teeth had decay and iron sulfate (ViscoStat®, UltraDent, South Jordan, USA) was used as pulpotomy material
10126097|NCT04338854|Experimental|two-surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
10126098|NCT04338854|Experimental|one surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group.
10126099|NCT04338854|Experimental|two-surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
10126100|NCT04338854|Experimental|one surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group.
10126101|NCT04338854|Experimental|fluoride application by disposable arch tray|It's one of the protective groups.Only the micromotor was used for polishing purposes in the protective treatment groups. 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
10126102|NCT04338854|Experimental|fluoride application by cotton roll|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
10126103|NCT04338854|Experimental|Fissure Sealant group|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups.
10126104|NCT04338841|No Intervention|Phase1: Before HOME-CoV rule implementation|"Observational assessment of current practices: no recommendation is performed.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion.~Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
10126105|NCT04338841|Experimental|Phase 2: After HOME-CoV rule implementation|"Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision.~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
10126106|NCT04338620|Experimental|A: Experimental Group|Participants receive totally 3 cycles of camrelizumab combined with albumin-bound paclitaxel and cisplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
10126107|NCT04338620|Experimental|B: Control group|Participants receive totally 3 cycles of albumin-bound paclitaxel combined with cisplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
10126108|NCT04338789|Experimental|Group 1|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed immediately before molar protraction on the left or right side of the patient.
10126109|NCT04338789|Experimental|Group 2|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed 3 months after molar protraction with no piezocision on the left or right side of the patient.
10126110|NCT04338789|No Intervention|Group 3|It consisted of 20 subjects (40 molars) where molar protraction was performed with no piezocesion.
10126111|NCT04338542||neoadjuvant chemotherapy plus bevacizumab|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy plus bevacizumab and, finally, the surgical resection of liver metastasis.
10126112|NCT04338542||neoadjuvant chemotherapy|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy and, finally, the surgical resection of liver metastasis.
10126113|NCT04338542||control group|Patients presenting with synchronous primary tumour and metastasis resected without any preoperative systemic therapy.
10126114|NCT04338295|Experimental|Microneedling|Participants with Alopecia Areata will receive microneedling with a tattoo machine.
10126115|NCT04338308||SVG PCI|
10126116|NCT04338412|Active Comparator|Group U|Performers' umbilicus
10126117|NCT04338412|Active Comparator|Group R|Performers' lowest rib margin
10126118|NCT04338412|Active Comparator|Group X|Performers' xiphoid process
10126119|NCT04338373|Experimental|experimental|"0.01% Atropine Sulfate solution in Comfort Drops, nightly instillations to both eyes"
10126120|NCT04338243|Experimental|Glumetinib+Osimertinib|The investigational product Glumetinib will be orally administrated when fasting at dose level of 300mg QD and Osimertinib will be orally administrated when fasting at dose level of 80mg QD
10126121|NCT04338282|Experimental|treatment arm|anti-PD-1 antibody (toripalimab) 240mg/d, every 3 weeks, for up to one year or until disease progression.
10126122|NCT04338334|Active Comparator|CONTROL GROUP|Control group includes physical therapy protocol composed of manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active arm therapeutic exercises.
10126123|NCT04338334|Experimental|COHESIVE BANDAGE GROUP|Cohesive bandage is a self-adherent lightweight bandage, made of a porous nonwoven polyester material. A single self-adherent inelastic bandage will be directly applied at full stretch on cleaned and dried skin (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States) in a spiral method around the limb, starting at the hand and a layer overlap of 50%, so that the greatest compression was located at the distal points, gradually decreasing toward the proximal shoulder part. Cohesive latex-free bandages will be available for those allergic women. Women will do progressive active arm therapeutic exercises with bandaging.
10126124|NCT04338464|Experimental|Treatment Group|
10126125|NCT04338503||HF patients|Decompensated heart failure patients undergoing right heart catheterization.
10126126|NCT04338425|No Intervention|No Communication group|Participants will not communicate with their surgeons until the post operative office visit.
10126127|NCT04338425|Active Comparator|Voice call group|Participants will receive voice call from the surgeon after being discharged and before their post operative office visit.
10126128|NCT04338425|Active Comparator|Video call group|Participants will receive video call from surgeon after being discharged and before their post operative office visit
10126129|NCT04338490|Experimental|Intervention|
10126130|NCT04338490|No Intervention|Control|
10126131|NCT04338451|Active Comparator|Music during the first part of ESWL|Patients listen to music during the first part of ESWL treatment (first 1800 SW).
10126132|NCT04338451|Active Comparator|Music during the second part of ESWL|Patients listen to music during the second part of ESWL treatment.
10126133|NCT04337996|Experimental|experimental arm|These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.
10126134|NCT04338191|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 6 cycles as adjuvant chemotherapy
10126135|NCT04338191|Active Comparator|mFOLFOX6 adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 6 cycles as adjuvant chemotherapy
10126136|NCT04338217|Experimental|Bionator|The modified Bionator was used to correct the open bite malocclusion. Patients were asked to wear the appliance every day.
10126137|NCT04338217|Active Comparator|Removable Appliance with Posterior Bite Planes|A removable appliance with poster bite planes was used to correct the open bite malocclusion. Patients were asked to wear this appliance full time expect eating times.
10126138|NCT04338438|Experimental|Apatinib Mesylate tablets combined with S-1 capsules|single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events
10126139|NCT04338256||Students enrolled in the Wellness Course|Students in this group are enrolled in the Wellness Course for the Spring 2020 or Fall 2020 semesters
10126140|NCT04338256||Controls|Students in this group are enrolled at study sites during the Spring 2020 or Fall 2020 semesters, but are not enrolled in the Wellness Course
10126141|NCT04338477|Experimental|Nephrosolid|Acute dosis day 1: 3X2 Nephrosolid tablets 0.5 h before intake of a meal Long-term dosis days 2-28: 2x1 Nephrosolid tablets 0.5 h before intake of a meal
10126142|NCT04338139|Experimental|Bio-oss Collagen|90% xengeneic bovine bone partciles + 10% collagen type I
10126143|NCT04338165|Experimental|Evolocumab, 420 milligrams|Single injection of 420 milligrams of evolocumab (REPATHA®) one month before coronary angiography and coronary microcirculation (IMR) measurement.
10126144|NCT04338165|No Intervention|Control arm|Measurement of coronary microcirculation (IMR) during coronary angiography, without prior evolocumab injection.
10126145|NCT04337970|Experimental|Phase Ib, Dose Level 1|3-6 participants
10126146|NCT04337970|Experimental|Phase Ib, Dose Level 2|3-6 participants
10126147|NCT04337970|Experimental|Phase Ib, Dose Level 3|3-6 participants
10126148|NCT04337970|Experimental|Phase II, Dose Expansion|Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)
10126149|NCT04338035||Patients with rectosigmoid endometriosis|
10126150|NCT04338126|Experimental|Tranexamic Acid Treatment|Oral dosing of tranexamic acid at dose of 1300 mg p.o. three times per day x 5 days; alternative dosing intravenously with loading dose of 10 mg/kg followed by 1 mg/kg/hr infusion x 5 days
10126151|NCT04338126|Placebo Comparator|Placebo Treatment|2 tablets of placebo three times per day x 5 days; alternative dosing intravenous normal saline at volumes similar to those use for experimental arm
10126152|NCT04337853|Experimental|Intervention group|N=6
10126153|NCT04337853|Active Comparator|Control group|N=7
10126154|NCT04338152|Experimental|FFT-CHR|Family-Focused Therapy for Clinical High-Risk Individuals
10126155|NCT04338152|Active Comparator|Enhanced Care|Enhanced Care Psychoeducation for Clinical High-Risk Individuals
10126156|NCT04337905|Experimental|Children with ADHD|Children with ADHD that running the ADHD-VR diagnostic test and also did the psychiatric examination to determine the ADHD diagnosis and to rule out other mental disorders
10126157|NCT04337905|Active Comparator|Children without ADHD|Healthy children that also running the ADHD-VR diagnostic test and also psyhchiatric examination to rule out the ADHD diagnosis and other mental disorders
10126158|NCT04338087||Fertility treatments|Men participating in fertility treatments.
10126159|NCT04338087||Spontaneous pregnancy|Men whose wives conceived spontaneously.
10126160|NCT04337736|Active Comparator|Aerobic training|12-weeks, 3-days-a week, supervised aerobic (Nordic walking or Walking) physical exercise (PhE) protocol; duration of each PhE session: 70 minutes; rate of perceived exertion (RPE): 10-11 (1st-4th week); 12-13 (5th-8th week); 13-14 (9th-12th week).
10126161|NCT04337736|Active Comparator|Resistance training|12-weeks, 2.3-days-a week (total of 28 lessons), supervised resistance physical exercise (PhE) protocol; duration of each PhE session: 50 minutes.
10183486|NCT03764176|Experimental|Digital impression|"The intervention of this arm will be digital impression: digital impression will be taken using a CS 3600 intraoral scanner ."
10126162|NCT04337801|Experimental|Acupressure|The acupressure was carried out as two sessions, postpartum second (the first session of intervention) and fourth hours (the second session of intervention). The intervention was applied bilaterally and clockwise (left Pericardium 6, left Large Intestine 4, right Large Intestine 4 and right Pericardium 6) in this study. The acupressure was applied for three minutes in average, one minute for massage and two minutes for pressure per point; with an average of 12 minutes for the whole application. In addition, the pain score of the women was assessed by themselves through the VAS before the intervention (Time 1) and 15 minutes (Time 2) after the intervention at postpartum second hour. Also, it was assessed before the intervention (Time 3) and 15 minutes (Time 4) after the intervention at postpartum forth hour. Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
10126163|NCT04337801|Placebo Comparator|Placebo|The Pericardium 6 and Large Intestine 4 points were slightly touched without pressure to women in the placebo group. Touches were applied to each acupressure point for three minutes similar to the acupressure group, each session of placebo lasted approximately 15 minutes. Similar to the acupressure group, In parallel with the acupressure, the pain score of the women was recorded at the postpartum second hour (Time 1) before intervention and 15 minutes later after intervention (Time 2), and at the fourth hour (Time 3) before intervention and 15 minutes later after intervention (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the researcher.
10126164|NCT04337801|No Intervention|Control Group|No intervention was applied to the control group except for the routine nursing care. The data collection process in the control group was conducted in parallel with the acupressure and placebo groups. Pain score of women was recorded prior to intervention in the acupressure and placebo groups. The duration of intervention in the acupressure and placebo groups was 12 minutes and the measurements were repeated 15 minutes after the intervention. The average duration between the first and the second measurements is 30 minutes in the acupressure and placebo groups. In parallel with the acupressure and placebo groups, the current pain score of the women was recorded at the postpartum second hour (Time 1) and 30 minutes later (Time 2), and at the fourth hour (Time 3) and 30 minutes later (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
10126165|NCT04337788|Experimental|gerontological telemonitoring action|"Nurses answer a daily resident-reported questionnaire (e.g. temperature, dyspnea, pain), edited by French health authorities. From D0 to D20, data are transmitted to the NHSP. Warning algorithms specially developed for older persons identify signs that are monitored by the NHSP geriatrician coordinator. A feedback is provided to the general physician for specific actions required and appropriate support.~A last questionnaire is completed at D30 by the nurse in order to stop monitoring and know event occurred between D20 to D30."
10126166|NCT04337788|No Intervention|routine care without gerontological telemonitoring|routine care
10126167|NCT04338230|Experimental|Experimental: Experimental group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points). Progressive muscle relaxation exercises are applied to the intervention group as 30-minute sessions three times a week for eight weeks.
10126168|NCT04338230|No Intervention|No Intervention: Control group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points).
10126169|NCT04337879|Experimental|AL2846 + mFOLFOX6|AL2846 capsule administered orally,once daily in 28-day cycle; oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle；calcium folate 400mg/ ㎡ IV on day 1, day 15 in 28-day cycle；5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 in 28-day cycle.
10126170|NCT04337879|Experimental|AL2846 + FOLFIRI|AL2846 capsule administered orally,once daily in 28-day cycle; irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle; calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle; 5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
10126171|NCT04337944|Experimental|Patients with KPro, PPV, and endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
10126172|NCT04337749|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to participants for 2 weeks
10126173|NCT04337749|Active Comparator|ZnO-NPs socks|ZnO-NPs socks were given to participants for 2 weeks
10126174|NCT04337749|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks were given to participants for 2 weeks
10126175|NCT04337749|Placebo Comparator|Placebo|Placebo socks were given to participants for 2 weeks
10126176|NCT04337918|No Intervention|Prevention - Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols).
10126177|NCT04337918|Experimental|Prevention - NORS + Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols) plus daily NORS treatment for 14 days.
10126178|NCT04337918|Other|Treatment Sub-Study|"Volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. Ten participants can be directly enrolled in the Treatment sub-study.~Participants enrolled in the Prevention study who meet the criteria in this section will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
10126179|NCT04337814|Experimental|COTA Arm|Patients getting combined (C) oral (O) and topical (T) analgesics (A)
10126180|NCT04337814|Experimental|OA Arm|Patients getting oral (O) analgesics (A) and topical placebo
10126181|NCT04337814|Placebo Comparator|Placebo Arm|Patients getting oral placebo and topical placebo
10126182|NCT04337593|Experimental|treatment arm|2500 IU/m2 pegaspargase given on day 1, 20 mg basiliximab given on day 1 and 8, repeated every 3 weeks
10126183|NCT04337632|Experimental|PP|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, day 1, intravenous drip, repeated every three weeks.
10126184|NCT04337632|Active Comparator|TP|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
10183487|NCT03764163|Experimental|Study Participants|Pulmonary Function Test, Questionnaires, CT scans, perfusion scan, ventilation scan, Xenon gas ventilation CT scan with hyperpolarized 3-Helium MRI Scan.
10126185|NCT04337658|Experimental|Trastuzumab± Pertuzumab+ Fulvestrant|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Fulvestrant(Faslodex): 500mg intramuscular injections at day 1, 15, 28 and every 4 weeks thereafter"
10126186|NCT04337658|Active Comparator|Trastuzumab± Pertuzumab+ Capecitabine|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.~Capecitabine: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination."
10126187|NCT04337671|Experimental|Training group (A)|The training was a moderate intensity aerobic training on a bicycle ergo-meter(corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions). In addition to their prescribed medications.
10126188|NCT04337671|No Intervention|control group (B)|Control group not receiving any training . They are taking their prescribed medications only.
10126189|NCT04337450|Active Comparator|SOC|Standard-of-care (SOC)
10126190|NCT04337450|Experimental|DTG/3TC|Dolutegravir (DTG) and lamivudine (3TC) (known as DTG/3TC)
10126191|NCT04337645|Experimental|Test group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline) combined with implantoplasty
10126192|NCT04337645|Active Comparator|Control group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline)
10126193|NCT04337710|Experimental|Exclusive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 60-80 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
10126194|NCT04337710|Active Comparator|Progressive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 20-30 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
10126195|NCT04337684||Historical Control|
10126196|NCT04337684||Treated with Copper Histidinate|
10126197|NCT04337255|Active Comparator|MIND DIET intervention|Allocation and blinding 3 year intervention of MIND Diet + counseling
10126198|NCT04337255|Placebo Comparator|Usual care diet intervention|3 year Intervention of usual care diet + counseling
10126199|NCT04337463|Experimental|ATG-008 and Toripalimab|Toripalimab will be combined with ATG-008.
10126200|NCT04337242|Experimental|Blended Dynamic Interpersonal Therapy (B-DIT)|B-DIT is based on the same treatment principles as face-to-face Dynamic Interpersonal Therapy (DIT) and has the same structure of treatment consisting of three phases: (a) an exploration and engagement phase, (b) a middle or working through phase, and (c) an ending phase. B-DIT consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
10126201|NCT04337242|Experimental|Blended Cognitive Behavioral Therapy (B-CBT)|B-CBT is based on the same treatment principles as face-to-face Cognitive Behavioral Therapy (CBT). These include (a) psycho-education about depression, (b) cognitive restructuring (i.e., identifying and challenging maladaptive thoughts and beliefs, fostering problem solving capacities), (c) mindfulness and acceptance based approaches, and (d) relapse prevention. B-CBT in this trial consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
10126202|NCT04337242|Active Comparator|Dynamic Interpersonal Therapy (DIT)|DIT is a short-term, integrative psychodynamic, 16 weekly sessions individual therapy for depression. DIT formulates the presenting symptoms of depression as responses to interpersonal difficulties or perceived threats to attachments (loss/separation) and hence also as threats to the self.
10126203|NCT04337242|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a brief talking therapy that consists of a maximum of 16 sessions, offered over 4 to 6 months. CBT is based on the assumption that depression is directly related to patterns of thinking. Specifically, dysfunctional and often automatic patterns of thinking are assumed to be related to the onset and maintenance of depression.
10126204|NCT04337385|Experimental|3 hours of Prolonged Sitting|Participants will sit continuously for three hours before receiving a mixed meal challenge.
10126205|NCT04337385|Experimental|3 hours of interrupted sitting with hourly HIIE|Participants will have their three hour sitting period interrupted with high intensity interval cycling exercise (HIIE) at 30, 90 and 150 minutes into the intervention. In each exercise bout, they will cycle at 90% peak power for 3 x 60 second periods with 75 seconds of recovery in-between.
9827422|NCT02454296|Sham Comparator|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
10126206|NCT04337502||severe group|The severe group was designated when the patients had one of the following criteria during hospitalization issued by the Chinese National Health Committee (Version 3-5). 1) Respiratory distress with respiratory frequency ≥ 30/min; 2) Pulse Oximeter Oxygen Saturation ≤ 93% at rest; 3) Oxygenation index (artery partial pressure of oxygen/inspired oxygen fraction, PaO2/FiO2) ≤ 300 mmHg; 4) One of the conditions as following: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.
10126207|NCT04337502||non-severe group|The non-severe group was designated when the patients did not occur in the mentioned severe criteria until discharged from the hospital.
10126208|NCT04337424||Participants with active infection test to SARS-COV2|Sampling of saliva (1 to 2 ml)
10126209|NCT04337424||Convalescent participants for SARS-COV2|Sampling of saliva (1 to 2 ml)
10126210|NCT04337424||Participants cured to SARS-COV2|Sampling of saliva (1 to 2 ml)
10126211|NCT04337424||Participants with negative test to SARS-COV2|Sampling of saliva (1 to 2 ml)
9967489|NCT01270152|Experimental|group 50 mg ascorbic acid|this arm received a dose of 50 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
9967490|NCT01270152|Experimental|group 100mg ascorbic acid|this arm received a dose of 100 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
9967491|NCT01270152|Experimental|group 200mg ascorbic acid|this arm received a dose of 200 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
9967492|NCT01270178||Entecavir|
9976644|NCT01353716|Experimental|Cohort 2|Subjects with severe renal impairment. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
9976645|NCT01353729|Experimental|Treatment A|Treatment A will include combination of zanamivir 600 mg IV plus placebo for moxifloxacin
9976646|NCT01353729|Experimental|Treatment B|Treatment A will include combination of zanamivir 1200 mg IV plus placebo for moxifloxacin
9976647|NCT01353729|Experimental|Treatment C|Treatment C will include zanamivir placebo plus placebo for moxifloxacin
9976648|NCT01353729|Experimental|Treatment D|Treatment D will include moxifloxacin plus zanamivir placebo
9976649|NCT01353742|Active Comparator|Lamivudine and Adefovir dipivoxil|One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
9976650|NCT01353742|Experimental|Fixed dose combination|One capsule (100mg lamivudine and 10mg adefovir dipivoxil)
9976651|NCT01353755|Experimental|recombinant Phleum (rPhleum) allergen cocktail|The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate. The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities. The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
9976652|NCT01353755|Placebo Comparator|Placebo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
9976653|NCT01353768||No treatment|zanamivir aqueous solution administered previously as part of the Compassionate Use Program
9976654|NCT01353781|Experimental|AZD5363|Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)
9976655|NCT01353794||Group 1|
9976656|NCT01353807|Active Comparator|Fish oil supplementation|These women received 4 1-g capsules of fish oil per day providing 2,7 grams long chain n-3 fatty acids per day, from gestation week 30 until delivery
9976657|NCT01353807|Placebo Comparator|Olive oil|These women received 4 1-g capsules with olive oil per day from gestational week 30 until delivery
9976658|NCT01353807|No Intervention|No oil supplement|These women received no capsules with oil
9976659|NCT01353820|Active Comparator|1 = Tested product|
9976660|NCT01353820|Sham Comparator|2 = Control product|
9976661|NCT01353833|Placebo Comparator|IL2-4|
9976662|NCT01353833|Experimental|IL2-2|1 millions IU of IL-2 per day
9976663|NCT01353833|Experimental|IL2-3|3 millions IU of IL-2 per day
9976664|NCT01353833|Experimental|IL2-1|0.33 millions IU of IL-2 per day
9976665|NCT01353846|Active Comparator|Natural cycle|
9976666|NCT01353846|Active Comparator|Artificial cycle|"Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.~Natural micronized progesterone, 400 mg/12 hours vaginal administration"
9976667|NCT01353872|Experimental|Sports Drinks|3 drinks : Nutrattente (before each match) / Nutraperf (during each match) / Nutrarecup (after each match)
9976668|NCT01353872|Placebo Comparator|Placebo|3 drinks : Nutrattente placebo (before each match) / Nutraperf placebo(during each match) / Nutrarecup placebo (after each match)
9976669|NCT01353885||Anterior Approach THA|500 Patients will be included who have received a total hip arthroplasty using the Anterior Approach. The anterior approach to total hip arthroplasty refers to an internervous approach to the hip, where the incision is made from the middle of the iliac crest, then curved distally and laterally to the anterior superior iliac spine (Kelmanovich et al., 2003). To optimize feasibility and applicability of our results, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size. Surgeons will use the manufacturer specific guides for insertion of the total hip arthroplasty.
9976670|NCT01353885||Posterior Approach THA|100 patients will be enrolled who have received a total hip arthroplasty using the posterior approach. The posterior approach is performed by making a curved incision posteriorly on the greater trochanter (Jolles & Bogoch, 2004). The fascia lata is then incised and the fibers of the gluteus maximus split using dissection (Jolles & Bogoch, 2004). To ensure the feasibility and applicability of our findings, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size used in the posterior approach.
9976671|NCT01353885||Anterolateral Approach THA|100 patients will be enrolled who have had a total hip arthroplasty using the anterolateral approach. An anterolateral approach to THA utilizes an intermuscular approach by incising the patient posteriorly and distally to the anterior superior iliac spine, extending distally to the greater trochanter along the shaft of the femur (Kelmanovich et al., 2003). To optimize the feasibility and applicability of our results, the implant manufacturer, femoral head size or the use of cemented components will not be standardized in this study.
9976672|NCT01353924|Active Comparator|Bet v 1aF1 + Bet v 1aF2 -Alum|
10126212|NCT04337541|No Intervention|Normal recommendations, no mask|Normal behavior according to the authority's recommendations or
9976673|NCT01353924|Placebo Comparator|Alum-Placebo|
9976674|NCT01353937|No Intervention|Standard of Care|All patients will be receiving the Standard of Care treatments regardless of whether or not they are receiving study drug.
9976675|NCT01353937|Active Comparator|Novel Combination Therapy|AMD3100 (Plerixafor) injection with Regranex Gel topical application
9976676|NCT01353937|Active Comparator|Becaplermin (Regranex Gel)|Topical application
9976677|NCT01353950||Adult Cystic Fibrosis Patients|Adults with Cystic Fibrosis will be followed longitudinally for 2 years
9976678|NCT01353989||>60 years|
9976679|NCT01353989||< 40 years|
10126213|NCT04337541|Experimental|Normal recommendations AND mask|Normal behavior according to the authority's recommendations AND use of facial masks
9967493|NCT01270191|Experimental|Exenatide|In the exenatide therapy group, subjects will be instructed in the techniques for injection and be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months. If FPG still greater than 200 mg/dL after 4 weeks of exenatide treatment, they will use insulin for rescue therapy and will be withdrawn from this study.
9967494|NCT01270191|Active Comparator|Humulin-N|In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
9967495|NCT01270204||Normal Volunteers|Patients older than 55 years of age with no history of voice, swallowing, reflux, or progressive neurologic disease affecting the swallowing mechanism.
9967496|NCT01270204||Patients with Dysphagia|Patients older than 55 years of age with the following condition: Dysphagia (the sensation of swallowing difficulty), globus, gastroesophageal reflux, or any other condition requiring referral for a dynamic swallowing study.
9967497|NCT01270217|Experimental|Brief motivational interview|
9967498|NCT01270217|No Intervention|No discussion|
9967499|NCT01270230|Experimental|Comparison Group, Standard HIV-CT|The comparison group will receive standardized HIV counseling and testing (HIV-CT), with referrals to case management.
9967500|NCT01270230|Experimental|Intervention Group, Bruthas Counseling|Participants assigned to this arm receive four individual HIV prevention counseling sessions.
9967501|NCT01270243||Control|No tonsilar or adenoid problems
9967502|NCT01270243||Adenotonsillectomy (recurrent)|Recurrent adenotonsillitis
9967503|NCT01270243||Adenotonsillectomy (obstruction)|Upper airway obstruction
9967504|NCT01270269|No Intervention|Patients (Controls)|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
9967505|NCT01270269|Experimental|Behavioral: Phys & Func Rehab|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
9967506|NCT01270269|Experimental|Behavioral: Cog/Phys/Func Rehab|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
9967507|NCT01270308|Experimental|Lansoprazole DR Capsules 30 mg|Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited
9967508|NCT01270308|Active Comparator|Prevacid 30 mg Capsules|Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA
9967509|NCT01270334||ph above cutoff|
9967510|NCT01270334||PH under cutoff|
9967511|NCT01270360||asymptomatic subjects with positive FOBT|individuals having undergone a positive faecal occult blood test (FOBT) and a reference colonoscopy
9967512|NCT01270373|Active Comparator|FAC x 3 followed by Docetaxel x 3|
9967513|NCT01270373|Experimental|Docetaxel x 3 followed by FAC x 3|
9967514|NCT01270386|Experimental|Apatinib|Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9967515|NCT01270386|Placebo Comparator|Placebo|Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9967516|NCT01270399||malignant neoplasm's cells|
9967517|NCT01270399||natural cells|
9967518|NCT01270412|Experimental|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml of platelet-derived preparation rich in growth factors
9967519|NCT01270412|Active Comparator|Hyaluronic acid|Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease
10126214|NCT04337411||Cohort 1|Non-ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≤ 2)
10126215|NCT04337411||Cohort 2|Ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≥ 3)
9967520|NCT01270438|Experimental|Arm I (RO4929097, combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9967521|NCT01270438|Experimental|Arm II (combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9967522|NCT01270451|Other|Lifestyle group counseling|Included patients will be randomised into two groups: to the intervention group or to the control group.
9967523|NCT01270477|Experimental|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment in an hyperbaric oxygen treatment chamber on an recognized treatment table.
9967524|NCT01270490|Experimental|Interferon-gamma|
9967525|NCT01270490|No Intervention|No intervention|No adjunctive treatment
9967526|NCT01270568|Experimental|Positive Psychology|8 weekly positive psychology exercises
9967527|NCT01270568|Active Comparator|Relaxation Response|Meditation-based treatment
9967528|NCT01270568|Sham Comparator|Recollection|Recollection of daily events, recorded weekly
9967529|NCT01270594|Experimental|COPD Counseling Intervention|Pharmacist counseling intervention delivered via telephone.
9967530|NCT01270594|Other|Usual Care|
9967531|NCT01270607|Experimental|Acupuncture|
9967532|NCT01270633|Other|Treatment|PriMatrix applied to appropriately debrided wound bed and covered with a non-adherent dressing. Dressings applied to maintain moist wound therapy.
9967533|NCT01270633|Active Comparator|Standard of Care|Non adherent dressing applied to appropriately debrided wound bed and moist wound therapy maintained.
9967534|NCT01270646|Experimental|Intraventricular Electrical Activation|
9967535|NCT01270672|Experimental|carvedilol, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9967536|NCT01270685||1|Veterans with spinal cord injuries and disorders
10126216|NCT04337515|Experimental|Patients receiving allogeneic hematopoietic cell transplant|"The test product is a stem cell product which has been alpha-beta T- cell depleted using the CliniMACS system. Alpha-beta T-cell depleted cells are given intravenously over a period of time as dictated by the final volume of the infused product (5 ml/kg/hour).~The target dose of CD34+ cells is ≥20x10^6/kg, but a minimum of~≥2.5x10^6/kg is required. The target dose of T-cell receptor (TCR) alpha-beta CD3+ cells is ≤1x10^5/kg."
10126217|NCT04337437|Experimental|Genakumab injection：5 groups|150 mg/1ml/bottle, single subcutaneous injection. Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,
10126218|NCT04337437|Placebo Comparator|Placebo for this trial : 5 groups|"The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.~Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,"
10126219|NCT04337528|Experimental|Thrust Group|Participant will receive the thrust technique manipulation of the affected sacroiliac joint.
10126220|NCT04337528|Active Comparator|Muscle-energy group|Participant will receive the muscle-energy technique manipulation of the affected sacroiliac joint.
10126221|NCT04337528|Placebo Comparator|Placebo Group|Participant will receive a placebo manipulation of the affected sacroiliac joint.
10126222|NCT04337398|Experimental|Wearables|Adults with several mental illness
10126223|NCT04337398|Experimental|Wearables and exergames|Adults with several mental illness
10126224|NCT04337333|Other|Two-in-one stent|Endoscopic placement of a Two-in-one stent into the extrahepatic bile duct, considering the longitudinal location of the stricture segment and predicted safety margin
10126225|NCT04337307||standard decontamination|incubators decontaminated with antiseptic molecules, healthcare workers involved in this decontamination, patients housed in these incubators
10126226|NCT04337307||steam pulverization|incubators decontaminated with steam pulverization, healthcare workers involved in this decontamination, patients housed in these incubators
10126227|NCT04337606|Experimental|chidamide in combination with decitabine|chidamide 10mg/day, days 1-5, 20mg/day, day 8, 11,15, 18; decitabine 10 mg/day, days 1-5, every 3 weeks
9527665|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
10126228|NCT04337606|Experimental|decitabine in combination with Camrelizumab|decitabine 10 mg/day, days 1-5, every 3 weeks; camrelizumab 200mg d6
10126229|NCT04337268|Active Comparator|human glucagon-like peptide-1|"Intervention:~Drug: human glucagon-like peptide-1 Other names: GLP-1"
10126230|NCT04337268|Placebo Comparator|Placebo|"Intervention:~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1"
10126231|NCT04337229|Experimental|artificial intelligence techniques|Facial and body movements of newborns will be recorded by camera, and images will be processed in computer environment by using artificial intelligence techniques. As a result, it is planned to create a technology that determines the comfort level of the newborn quickly and simply and can be used by the mobile device.
10126232|NCT04337567|Active Comparator|Patients over 75 years_RF ablation|Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.
10126233|NCT04337567|Active Comparator|Patients over 75 years_ballon cryoablation|Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.
10126234|NCT04337125|Other|ADHD group|ADHD children with their parents
10126235|NCT04337125|Other|Control group|Children with typical development and their parents
10126236|NCT04336878|Experimental|Healthy Habits in Pregnancy and Beyond intervention|Intervention delivered in early pregnancy during an existing antenatal appointment. 1:1 intervention session (15-20 minutes) with the intervention facilitator (clinician/researcher). Participants provided with a self-guided leaflet for weight management focusing on making 10 simple diet and activity behaviours habitual, including advice on food choice & purchasing, portion size, eating behaviour & keeping active. The tips promote habit formation, nutrition awareness, avoidance of behavioural relapse, and reiterate guidance for pregnant women. Participants provided with a record-keeping logbook and access to an 'app' to self-monitor their weight and behaviours against the 10 target behaviours, during pregnancy and up to 6 weeks postpartum.
10126237|NCT04336878|No Intervention|Control group|The control group will receive 'usual' antenatal care which does not involve routinely delivered specific or standardised dietary advice.
10126238|NCT04336852|Experimental|Arm 1|
10126239|NCT04336761||Child suspected of infection with COVID-19.|Child included with positive included
10126240|NCT04336891||Hypoactive Sexual Desire Disorder|Women with Hypoactive Sexual Desire Disorder (HSDD, n=23)
10126241|NCT04336891||Moderate to severe VVA|Women with dyspareunia due to moderate to severe vulvovaginal atrophy (VVA) (n=12)
10126242|NCT04336891||Mild to moderate VVA|Women with dyspareunia due to mild to moderate VVA (n=37)
10126243|NCT04336891||HSDD + VVA|Women with HSDD reporting also significant dyspareunia due to moderate to severe VVA (n=9).
10126244|NCT04336709|Active Comparator|Calcipex II|Calcipex group Manufactures Nishika, Yamaguchi, Japan Color- White Formulation- Water based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Water-based calcium hydroxide paste without radio contrast agent (Barium Sulfate) Packaging- (1 syringe of Calcipex Plain II (1.8g), 2 needles of Nishika Spin with 2 needle caps) Storage requirement- Room temperature (1-30℃).
10126245|NCT04336709|Active Comparator|Metapex|Metapex group Manufactures- Meta Biomed, Korea Color- Yellow Formulation- Oil based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Premixed oil-based paste composed of Calcium Hydroxide with Iodoform and silicon oil Packaging-2.2g paste in 1 syringe. 20 disposable tips. 1 ring rotator for direction control of the tip Storage requirement- Room temperature (1-30℃).
10126246|NCT04337086|Experimental|T4k|
10126247|NCT04337086|Active Comparator|Twin block|
10126248|NCT04336774|Experimental|Echocardiogram patients|Patients scheduled to have an echocardiogram (echo) and who are also being evaluated for, or are positive for COVID-19.
10126249|NCT04336930||Cardiac Arrest group|Patients remaining comatose after a cardiac arrest
10183488|NCT03764150||PaCO2> 45 mmHg|Diurnal hypercapnia defined by PaCO2> 45 mmHg
10126250|NCT04336904|Experimental|Favipiravir|"Experimental: Favipiravir Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction."
10126251|NCT04336904|Placebo Comparator|Placebo|"Comparator: Placebo Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
10126252|NCT04336956||hospitalized children with Covid19|- Children < 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
10126253|NCT04337034|Experimental|mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0)
10126254|NCT04337034|Active Comparator|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured
10126255|NCT04336995|Other|Exercise|Everyone is in this arm
10126256|NCT04337008|Active Comparator|Positive COVID 19 patient with no respiratory distress|
10126257|NCT04337008|Experimental|Positive COVID 19 patient with respiratory distress|
10126258|NCT04336813|Experimental|Group A|Receive ARS in lecture 1 and act as controller in lecture 2
10126259|NCT04336813|Active Comparator|Group b|Receive ARS in lecture 2 and act as controller in lecture 1
10126260|NCT04337047||Vik sein|Vik sein users
10126261|NCT04337047||Vik asthme|Vik asthme users
10126262|NCT04337047||Vik migraine|Vik migraine users
10126263|NCT04337047||Vik depression|Vik depression users
10126264|NCT04336917|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve Rhomboid Intercostal and Subserratus Plane Block under ultrasound guidence at the end of the surgery.
10126265|NCT04336917|No Intervention|Control Group|Routine standard perioperative and postoperative analgesic protocol will be given.
10126266|NCT04336696|Active Comparator|Comparison between the studied groups regarding management.|The postoperative RAI scan after 1 month, showed a positive residual tumour in lateral LN in 70 patients in the controlled group and 13 patients in Group II, 8 patients in group III. In group I, Patients with residuals were submitted to RAI ablation.
10126267|NCT04336696|Other|Recurrence free survival|patients with total thyroidectomy only had shorter recurrence free survival
10126268|NCT04336683|Other|Patient|Patients undergoing gynecological brachytherapy, will be imaged with a 3D ultrasound medical device for the purpose of efficacy testing.
10126269|NCT04336670|Experimental|Virtual Reality group|Immersive Virtual Reality exercise program.
10126270|NCT04336670|Active Comparator|Usual activities group|Usual center therapies
10126271|NCT04336553|Experimental|Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS). SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
10183489|NCT03764150||PaCO2 <45 mmHg|PaCO2 diurnal within the limits of normal (PaCO2 <45 mmHg)
10183490|NCT03764124||Kidney recipients|Kidney recipients aged over 18 and of all sexes recruited between 2007 and 2020 from the Centre Hospitalier Universitaire de Liege, who have e-GFR follow-up and data from protocol and for cause biopsies available at 1-year post transplant. PET/CT imaging will be performed with patient's approval for protocol and per cause biopsies we performed. Data will be collected in the follow up such as clinical, biological and histological data.
10183491|NCT03764111||large mobile ultrasound system|the ultrasound transducer is based on piezoelectric technology.
10183492|NCT03764111||handheld ultrasound machine|The handheld device utilizes Capacitive micro-machined ultrasound transducers (CMUTs) instead of piezoelectric technology
10187629|NCT03724318|Active Comparator|Closure|Patients randomized to the active Group will undergo closure of the left atrium appendage during Heart surgery by means of commercial clips
10187630|NCT03724318|No Intervention|Control|The left atrium appendage will remain open in patients randomized to the control group
10187631|NCT03724292|Placebo Comparator|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
10187632|NCT03724292|Experimental|VTP-43742 Dose 1|VTP-43742 administered as oral capsule(s) once daily
10187633|NCT03724292|Experimental|VTP-43742 Dose 2|VTP-43742 administered as oral capsule(s) once daily
10187634|NCT03724292|Experimental|VTP-43742 Dose 3|VTP-43742 administered as oral capsule(s) once daily
10187635|NCT03724292|Experimental|VTP-43742 Dose 4|VTP-43742 administered as oral capsule(s) once daily
10187636|NCT03724292|Experimental|VTP-43742 Dose 5|VTP-43742 administered as oral capsule(s) once daily
10187637|NCT03724279|Experimental|ByCross Atherectomy and Thrombectomy|Percutaneous intervention including ByCross atherectomy and Thrombectomy potentially followed with PTA and/or stent placement
10187638|NCT03724266|Experimental|chitosan|chitosan as intracanal medication 0.2% in form of gel
10187639|NCT03724266|Active Comparator|calcium hydroxide|intracanal medication
10126272|NCT04336579||Control|Retrospective review of patients (participants) with standard analgesia post total knee arthroplasty
10126273|NCT04336579||Diaphragmatic Breathing|Intervention: Participants will perform diaphragmatic breathing exercises postoperatively as part of their multi-modal pain regimen.
10126274|NCT04336566|Active Comparator|Melatonin|5mg dose of melatonin manufactured by Good Neighbor Pharmacy
10126275|NCT04336566|Placebo Comparator|Placebo|Good Neighbor Pharmacy placebo tablet that looks the same without active ingredient
10126276|NCT04336449|Experimental|Cohort 1 100 mg eptinezumab|
10126277|NCT04336449|Experimental|Cohort 2 300 mg eptinezumab|
10126278|NCT04336449|Placebo Comparator|Placebo|
10126279|NCT04336527|Experimental|Home Treatment with Peer Support|Patients receive a peer supported home treatment, i.e. treatment by a home treatment/crisis resolution team with a peer support worker.
10126280|NCT04336527|Active Comparator|Home Treatment without Peer Support|Patients receive conventional home treatment by a homehome treatment/crisis resolution team without contacts to a peer support worker.
10126281|NCT04336540|Experimental|Energy labelling|Energy labelling provided on restaurant menus
10126282|NCT04336540|No Intervention|No energy labelling|No energy labelling provided on restaurant menus
10126283|NCT04336540|Experimental|Increased availability of lower energy meals|Higher proportion of meals are 600kcals or less
10126284|NCT04336540|No Intervention|Baseline availability of lower energy meals|Proportion of meals that are 600kcals or less at baseline level
10126285|NCT04336514|Experimental|Experimental Arm|
10126286|NCT04336462|Experimental|oxyhydrogen|conventional treatment + hydrogen/ oxygen inhaled
10126287|NCT04336462|Experimental|oxygen|conventional treatment + oxygen inhaled
10126288|NCT04336592||Patients|Patients scheduled to receive a surgical spine procedure at Mayo Clinic
10126289|NCT04336592||Clinicians|Surgeons, Physician pain specialists and allied health caring for participating patients
10126290|NCT04336306|Experimental|Evaluation of chronic hemodynamic and autonomic repercussions|Participants in a cardiovascular rehabilitation program will be randomly allocated to CR + VRBT interventions. This group will hold 3 weekly sessions (one for VRBT and two for CR) for 12 weeks. In the first, sixth and last week, chronic hemodynamic data and autonomic data will be evaluated.Furthermore,at the end of 12 weeks, a focus group with therapists and a focus group with patients will be held to identify qualitative aspects in relation to the insertion of VRBT. And in all eligible patients of CR wiil be applied the Questionnaire of barriers identification in frequenters of Cardiovascular Rehabilitation.
10126291|NCT04336501|Experimental|IM19 CAR-T group|Subject will be treated with IM19 car-t cells
10126292|NCT04336436|Experimental|Mindfulness Training and Nutrition Counseling|"Baseline and 3-6 month follow up visits will be arranged for all participants.~Visits will be conducted at baseline prior to initiation of mindfulness training and nutrition counseling, and at the 3-6 month follow up. Clinical and laboratory assessments will be obtained at each visit."
10126293|NCT04336631|Other|Routine Medical Follow Up, Counseling & Usual Care|Behavioral counseling was provided to the patients on each consecutive follow up after enrolling in this study. They were adequately followed on physical exercise, reduced salt intake, lifestyle modifications, and smoking cessation. All measurements of blood pressure and weight were maintained and recorded.
10126294|NCT04336631|No Intervention|Routine Medical Follow Up & Usual Care|Usual routine medical care was provided to the study participants only.
10126295|NCT04336254|Experimental|hDPSCs group|Routine treatment + Intravenous injection of human dental pulp stem cells
10126296|NCT04336254|Placebo Comparator|Control group|Routine treatment + Intravenous saline injection (Placebo)
10126297|NCT04336332|Experimental|Arm 1: Hydroxychloroquine Sulfate + Azithromycin|"Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days~Azithromycin 500 mg taken by mouth on Day 1, followed by~Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days."
10126298|NCT04336332|Experimental|Arm 2: Hydroxychloroquine Sulfate alone|• Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
10126299|NCT04336332|No Intervention|Arm 3: Placebo|"Placebo pills Days 1-6.~If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days"
10126300|NCT04336488|Experimental|Orochem (Test)|fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
10126301|NCT04336488|Active Comparator|Conventional (Control)|fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
10126302|NCT04336319|Experimental|Patients with a confirmed diagnosis of UC who underwent IPAA|Patients who meet inclusion criteria will be enrolled and will sign an informed consent form. The study includes six visits to the IBD clinic and phone calls between visits.
10126303|NCT04336293|Experimental|active|active sTMS
10126304|NCT04336293|Sham Comparator|sham|sham sTMS
10126305|NCT04336007|Experimental|Radio-frequency group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode on.
10126306|NCT04336007|Placebo Comparator|Placebo group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode off.
10126307|NCT04336007|Sham Comparator|Control Group|NO INTERVENTION athlete's usual pre-competition warming-up
10126308|NCT04336423||Healthy smoker|Healthy smokers with smoking history at least 10 pack-years and normal spirometry value
10126309|NCT04336423||COPD patient|Patients with smoking history at least 10 pack-years and persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
10126310|NCT04336267|Experimental|Transcranial direct current stimulation (tDCS) group|7-day detoxification protocol + 5 consecutive days of anodal tDCS treatment over the primary motor cortex.
10126311|NCT04336267|Sham Comparator|Sham group|7-day detoxification protocol + 5 consecutive days of sham treatment over the primary motor cortex.
10126312|NCT04336605||Young-HUNT|The young-HUNT study is a renowned, representative, population-based study where all adolescents living in the Nord-Trøndelag county have been invited to participate in four subsequent waves, from 1995 to 2019. Information about the study can be found here: https://www.ntnu.edu/hunt/young-hunt. In this study data from the Young-HUNT1-4 studies (1995-2019) will be linked to longitudinal, individual data from the Norwegian prescription Database (NorPD) (2004-2020), providing a unique, longitudinal dataset in which research questions will be explored. To obtain good, reliable follow-up data and outcome measures for the young-HUNT3 participants (2006-2008) the investigators will additionally include longitudinal data from the HUNT4 study of young adults (2017-2019); applicable for those participating in both the YoungHUNT3 and the YoungHUNT4.
10126313|NCT04336176|Active Comparator|PulseFlow DF boot|PulseFlow DF boot
10126314|NCT04336176|Active Comparator|Usual Care|Measurements will be taken from patients wearing usual standard of care
10126315|NCT04336176|Sham Comparator|Sham|Sham shoe (closest to barefoot or baseline pressures)
10126316|NCT04336358|No Intervention|Standard Early medical abortion care|Counseling, history, instruction, family planning with clinic nurse. Ultrasound to assess gestational age.
10126317|NCT04336358|Experimental|Telemedicine|Online consultation questionnaire and counseling, family planning information. Instruction for the abortion received to the participants Facebook Messenger. Gestational age <9 weeks assessed by bimanual palpation, ultrasound only in case of uncertainty.
10126318|NCT04336072|Experimental|Reminder Focused Positive Psychiatry (RFPP)|RFPP aims to enhance contextual discrimination and emotional regulation, and promote the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
10126319|NCT04336072|Active Comparator|Trauma Focused Cognitive Behavioral Therapy (TFCBT)|TFCBT is inclusive of the trauma narrative (TN) & processing components facilitated the child talking about memories individually and in groups, the last sessions focused on grief-specific elements.
10126320|NCT04336228|Placebo Comparator|Healthy Control Group|The healthy placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
10126321|NCT04336228|Placebo Comparator|Obsessive-Compulsive Disorder Control Group|The OCD placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
10126322|NCT04336228|Experimental|Healthy Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
10126323|NCT04336228|Experimental|Obsessive-Compulsive Disorder Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
10126324|NCT04336111|No Intervention|control group|will receive sham bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position.
10126325|NCT04336111|Experimental|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
9669024|NCT04298229|Active Comparator|Protocolized diuretic therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol."
9669025|NCT04298229|Experimental|Protocolized diuretic therapy plus SGLT2 inhibitor therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.~The patient will receive SGLT2 inhibitor therapy with dapagliflozin 10 mg orally once daily until 5 days or hospital discharge."
10126326|NCT04336046|Sham Comparator|control group|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
10126327|NCT04336046|Experimental|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
10126328|NCT04336150|Experimental|Hypopressive exercisesE|"Hypopressive exercises described according to Dr. Caufriez~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive exercises according to the original method described by Dr. Caufriez, which is based on performing the hypopressive maneuver in 33 postures that he described (1,2)."
10126329|NCT04336150|Experimental|Hypopressive exercises&PFM contraction|"Hypopressive exercises + active pelvic floor muscle contraction:~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive exercises according to the original method described by Dr.Caufriez, which is based on performing the hypopressive maneuver in 33 postures he described, plus the active contraction of the pelvic floor muscles (PFM) during the hypopressive maneuver."
10126330|NCT04336150|Experimental|Hypopressive maneuver|"Hypopressive maneuver:~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive maneuver with transabdominal ultrasound biofeedback."
9669026|NCT04287946|Experimental|Ablation|
9669027|NCT04281225|Placebo Comparator|Placebo only condition|Participants in this condition will be told at the time of the initial assessments (T1) that the device they will be testing will improve their hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked if they perceive their hearing to be changed by the device in addition to qualitative descriptions of the audio. This group will allow researchers to investigate the main effect of the placebo hearing aid - without calling participant's attention to variability in their symptoms.
9827423|NCT02454478|Experimental|Lenvatinib plus Everolimus|
10126331|NCT04336150|Experimental|Hypopressive maneuver&PFM contraction|"Hypopressive maneuver + pelvic floor muscles contraction:~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive maneuver plus active contraction of the pelvic floor muscles with transabdominal ultrasound biofeedback."
10126332|NCT04335942|Other|AFNOR 3.6 alerts|"Alert called AFNOR 3.6 in connection with the dispersion index described by Drummond et al 1985 and validated by Sprigle et al 2003. This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),"
10126333|NCT04335942|Other|AFNOR 3.6 alerts and Guidelines|"AFNOR 3.6 alerts and Guidelines alerts. By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes (Bergstrom et al., 1992; Nixon, 1985; Ho and Bogie, 2007) over a period of 1 minute 51 (Coggrave and Rose 2003) for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block (Dicianno et al. 2009)."
10126334|NCT04335864|Active Comparator|Group A|39 patients with hydrosalpinx will have laparoscopic salpingectomy
10126335|NCT04335864|Active Comparator|Group B|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
10126336|NCT04335825|Active Comparator|phacotrabeculectomy|patients undergoing phacotrabeculectomy
10126337|NCT04335825|Active Comparator|ExPress device implantation|patients undergoing ExPress antiglaucoma surgery combined with phacoemulsification
10126338|NCT04335968|Experimental|Experimental group|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery
10126339|NCT04335968|Placebo Comparator|Control group|placebo of this drug with the same schedule, during the same period of time.
10126340|NCT04335877|Experimental|Private sector component + modified BCC|Private sector component + modified BCC + current standard of care
10126341|NCT04335877|No Intervention|Control|Current standard of care + standard BCC
10126342|NCT04335851|Experimental|Physical Activity Group|"Individuals in this group will be given walk at home exercise video made by American Hearth Association. Videos for each week will be chosen by therapist. They will be asked to do exercise 3 days a week for 4 weeks by following the videos. The intensity and duration of the exercises will be gradually increased by therapists each week. Exercise follow-ups will be done over the phone and by asking individuals to keep an exercise diary."
10126343|NCT04335851|No Intervention|Control Group|Physically inactive individuals will be included to study as control. Individuals will be asked to continue their daily routines.
10126344|NCT04336059|Other|group 1|will receive sham PENG block with normal saline in total volume of 20 ml.
10126345|NCT04336059|Experimental|group 2|will receive real PENG block with bupivacaine (0.25%) in total volume of 20 ml.
10126346|NCT04336085|Experimental|caudal group|Caudal block using ultrasound guidance. the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine and the depth and gain will be adjusted for optimal visual quality.the needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
10126347|NCT04336085|Experimental|PENG group|The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. the needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.
10126348|NCT04335838||Polytrauma Patients|Patients with an ISS >16 points, an AIS >3 in one body region and at least 2 different body regions affected were included.
10126349|NCT04335695|Other|Vascular Rehabilitation and Follow Up|All subjects will be enrolled in a 6-12 Vascular Rehab Program (VRP) and then be followed for one year following discharge from the VRP.
10126350|NCT04335721|Experimental|Voxelot|Voxelotor 1500mg once a day
10126351|NCT04335721|Other|Standard of Care (SOC)|Observational while receiving SOC
10126352|NCT04335734|Active Comparator|Nissen fundoplication with fixation of the wrap|In this arm, which included 87 patients we performed the following manipulations: NF was supplemented with suturing wrap to the diaphragmatic crura (52 patients) on each side using two non-absorbable stitches. In case of weak conditions of crura or short esophagus (35 patients) fundoplication wrap was sutured to the body of stomach using two non-absorbable stitches on each side. .
9827424|NCT02454530||Cancer patients treated with Nivestim®|
9827425|NCT02454608|Experimental|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
9827426|NCT02454608|Placebo Comparator|Control|Placebo, capsules for oral administration, TID, for 8 weeks
10126353|NCT04335734|Active Comparator|Nissen fundoplication without fixation of the wrap|Arm included 51 patients, who underwent classic Nissen fundoplication without wrap fixation.
10126354|NCT04335994|Active Comparator|Standard of Care|Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography.
10126355|NCT04335994|Experimental|Home Sleep Apnea Test|Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test.
10183493|NCT03764085|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
10126356|NCT04335760||Patients with Coronary Artery Disease|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
10126357|NCT04335760||healthy subjects|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
9669028|NCT04281225|Experimental|Placebo and ATV condition|Participants in this condition at the time of the initial assessments (T1) will be told that the device they will be testing will improve their hearing. They will then be told that in-order to receive the maximum benefit from the hearing device, they should focus on instances in which they can hear better and worse. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will asked 1) if they perceive their hearing to be changed by the device; 2) to note any changes in what they heard in the audio focusing on the story in the ballad; and 3) whether their hearing is possibly impacted by activities and behavior and what they were doing.This condition will enable researchers to test the effects of the interaction between attention to variability and the placebo effect.
9827427|NCT02454608|Experimental|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
10126358|NCT04335786|Experimental|Active treatment arm|Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
10126359|NCT04335786|Placebo Comparator|Placebo arm|Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure
10126360|NCT04335604|Experimental|JPI-547|
10126361|NCT04335461|Placebo Comparator|Placebo|Placebo group, with no regional nerve blockade administered.
10126362|NCT04335461|Experimental|Fracture block|Patients will have an intrafragmentary fracture block using fluoroscopy guidance after surgical fixation with 30cc 0.25% marcaine
10126363|NCT04335461|Experimental|Fascia iliaca block|Fascia iliaca compartment blockade administered after surgical fixation using the loss of resistance technique with 30cc 0.25% marcaine
10126364|NCT04335630||Cases|Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR.
10126365|NCT04335630||Controls|Age- and gender-matched subjects admitted to the hospital with similar symptoms but negative PCR testing for SARS-CoV-2 (one negative PCR test for patients of low clinical suspicion and two negative tests, 24 hours apart from each other, for patients of high clinical suspicion).
10126366|NCT04335487|Experimental|ICBT for PTSD Tailored for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy for PTSD tailored specifically for Canadian public safety personnel.
10126367|NCT04335487|Experimental|Transdiagnostic ICBT Tailored for PSP|Therapist-guided, transdiagnostic Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
10126368|NCT04335643|Experimental|TEACH|Participants will undergo CBT and continue medical TAU.
10126369|NCT04335643|No Intervention|Control|Participants will only continue medical TAU.
10126370|NCT04335578|Experimental|Zampilimab Cohorts|Participants will be randomized to receive zampilimab (UCB7858).
10126371|NCT04335578|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo.
10126372|NCT04335708|Experimental|Intervention|Daily consumption of 5 mL of edible gel with intracellular content of Lactobacillus casei CRL-431 during 30-d
9967537|NCT01270685||2|Comparison group: general Veteran population (without spinal cord injuries or disorders)
10126373|NCT04335708|Placebo Comparator|Placebo|Daily consumption of 5 mL of edible gel without intracellular content of Lactobacillus casei CRL-431 during 30-d
10126374|NCT04335617|Experimental|Investigational|Patients receive MMPF 500mg for one year
10126375|NCT04335617|Placebo Comparator|Placebo|Patients receive Placebo for one year
10126376|NCT04335565|No Intervention|Water|250 ml of water mixed with 1g of citric acid.
10126377|NCT04335565|Active Comparator|Sugar|65g of sugar dissolved in 250ml of water
10126378|NCT04335565|Experimental|Stevia|5g of stevia dissolved in 250ml of water
10126379|NCT04335409|Experimental|Participants irradiated for lung cancer|Participants who receive radiotherapy for lung cancer and have risk factors for developing radiation pneumonitis. Risk factors include mean dose to the ipsilateral lung >13 Gy plus at least one other factor (significant cardiovascular disease, history of heavy smoking (≥40 pack years), previous/concurrent chemotherapy or previous/adjuvant immunotherapy) or mean dose to the ipsilateral lung >20 Gy without other factors.
10126380|NCT04335422|Experimental|Robotic group|Robotic group will receive both routine physical and rehabilitation medicine program and additional upper extremity robot-assisted training by Armeo Spring. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and robotic therapy one hour/day. Routine PRM program and robotic therapy will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program plus robotic therapy).
10126381|NCT04335422|Active Comparator|Control group|Control group will receive only routine physical and rehabilitation medicine program. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program only).
10126382|NCT04335526|No Intervention|Metformin alone|
10126383|NCT04335526|Other|Metformin with cholestyramine|
10126384|NCT04335370||Patients with CF lung disease receiving Polymyxin B (PMB)|Participants receiving polymyxcin B as part of standard of care treatment for CF exacerbation will have blood drawn measure blood concentrations of PMB
10126385|NCT04335591|Experimental|Linzagolix 75 mg|
10126386|NCT04335591|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
10126387|NCT04335357|Placebo Comparator|placebo|The appearance and fill of placebo syringes will be identical to the active comparator.
10126388|NCT04335357|Active Comparator|TBR-760|TBR-760 is supplied as a ready-to-use solution in pre-filled syringes at a concentration of 5 mg/ml.
10126389|NCT04335292|Experimental|Treatment Arm|"First-line treatment = osimertinib, 80 mg, oral, daily; Second-line treatment = platinum (carboplatin or cisplatin) + pemetrexed chemotherapy, prescribed as per institutional standards; Third-line treatment = osimertinib rechallenge, 80 mg, oral, daily.~Patients may enter the study at first-line treatment, second-line treatment, or third-line treatment. This is dependent on meeting the eligibility criteria."
10126390|NCT04335474||Surgical drainage|Cases that have surgical management
10126391|NCT04335474||Percutaneous drainage|Cases that have the nonoperative management by percutaneous drainage
10126392|NCT04335279|Experimental|SPIN-CHAT: Videoconference Intervention|Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.
10126393|NCT04335279|No Intervention|Wait-list Control|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.
10126394|NCT04335396||adult patients with diabetes mellitus|Subgroup 1 - consecutive patients with diabetes mellitus with scleredema skin disorder Subgroup 2 - consecutive patients with diabetes mellitus without scleredema Subgroup 3 - patients with diabetes and scleredema - already cared in the tertiary center of the Rheumatology Department of the University of Pécs, in Hungary.
10126395|NCT04335318|Experimental|Colonoscopy with AI-assistance group|Colonoscopies were performed with AI-assistance.
10126396|NCT04335318|No Intervention|Standard Colonoscopy group|Standard clinical procedure
10126397|NCT04335747||Group 1|Patients with inflammatory rheumatic diseases who are hospitalised due to a COVID-19 infection
10126398|NCT04335747||Group 2|Patients without inflammatory diseases who are hospitalised due to a COVID-19 infection
10126399|NCT04335747||Group 3|Patients with inflammatory rheumatic diseases who are having routine blood samples taken under the COVID-19 epidemic after inclusion and who have NOT been hospitalised due to a COVID-19 infection
10126400|NCT04335747||Group 4|Healthy subjects from the Danish Blood Donors have NOT been hospitalised due to a COVID-19 infection
10126401|NCT04335305|Experimental|Tocilizumab plus Pembrolizumab (MK-3475)|"Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose) as an intravenous infusion over 60 minutes; single dose Pembrolizumab (MK3475) 200 mg as an intravenous infusion over 30 minutes; single dose.~Patients who are showing no clinical improvement in respiratory function after 12 hours could receive an additional dose of tocilizumab at the same dose level of the first administration. Patients who are showing SpO2 ≤ 94% on room air could receive an additional administration of pembrolizumab (MK-3475) at the same recommended dose after 3 weeks from treatment initiation and/or an additional dose of tocilizumab after 4 weeks from treatment initiation at physician's discretion."
10126402|NCT04335305|No Intervention|Continued Standard of Care|Standard care per local written policies or guidelines comprises, as necessary and at physician's discretion, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, glucocorticoid, tocilizumab, virally targeted agents, chloroquine or hydroxychloroquine.
10126403|NCT04335123|Experimental|Open Label Losartan|50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria or complete 14 days of therapy.
10126404|NCT04335448||Arterial Switch Operation - Transposition of Great Arteries|Patients with previous arterial switch operation for the treatment of a transposition of great arteries will constitute the sole group of the cohort.
10126405|NCT04335162||Patients with cardiovascular complications|Patients presenting with cardiomyopathies or venous thromboembolism
10126406|NCT04335162||Patients without cardiovascular complications|Patients without cardiomyopathies or venous thromboembolism
10126407|NCT04335162||Intensive Care Unit patients|Patients admitted in intensive care unit
10126408|NCT04335162||Hospital Ward patients|Patients admitted in hospital ward
10126409|NCT04335513|Experimental|Intervention|Early diabetes management and education including focused education based on pathophysiology of type 1 diabetes, factors which impact blood glucose, and effects of insulin using data from continuous glucose monitoring device (CGM) worn unblinded at least 20 days per month with interpretation and education on results. Early initiation of insulin therapy, when warranted based on a pattern of prolonged or repeated high blood glucose values.
10126410|NCT04335513|Active Comparator|Control|Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK (ongoing studies at BDC). This includes: blood glucose checks 2-3 times per month, participant-led contact with study personnel when abnormalities are noted and transition to clinical care when criteria for clinical type 1 diabetes are met.
10126411|NCT04335266|Experimental|Treatment group A|Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2
10126412|NCT04335266|Experimental|Treatment group B|Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2
10126413|NCT04335006|Experimental|Experimental A|Subjects receive Carelizumab in combination with Nab-paclitaxel plus Apatinib,each 4-week cycle
10126414|NCT04335006|Experimental|Experimental B|Subjects receive Carelizumab in combination with Nab-paclitaxel,each 4-week cycle
10126415|NCT04335006|Active Comparator|Comparator C|Subjects receive nab-paclitaxel intravenously each 4-week cycle.
10126416|NCT04335045|Active Comparator|100mg Dose|1 x 100 mg PH100 capsule (n=6)
10126417|NCT04335045|Placebo Comparator|Control for 100mg Dose|1 placebo capsule (n=2)
10126418|NCT04335045|Active Comparator|200mg Dose|1 x 200 mg PH100 capsule (n=6)
10126419|NCT04335045|Placebo Comparator|Control for 200mg Dose|1 placebo capsule (n=2)
10126420|NCT04335045|Active Comparator|400mg Dose|2 x 200 mg PH100 capsules (n=6)
10126421|NCT04335045|Placebo Comparator|Control for 400mg Dose|2 placebo capsules (n=2)
10126422|NCT04335045|Active Comparator|800mg Dose|4 x 200 mg PH100 capsules (n=6)
10126423|NCT04335045|Placebo Comparator|Control for 800mg Dose|4 placebo capsules (n=2)
10126424|NCT04335045|Active Comparator|1200mg Dose|6 x 200 mg PH100 capsules (n=6)
10126425|NCT04335045|Placebo Comparator|Control for 1200mg Dose|6 placebo capsules (n=2)
10126426|NCT04335045|Active Comparator|1600mg Dose|8 x 200 mg PH100 capsules (n=6)
10126427|NCT04335045|Placebo Comparator|Control for 1600mg Dose|8 placebo capsules (n=2)
10126428|NCT04335344||Control|Healthy patients
10126429|NCT04335344||Periodontitis|Patients with periodontitis
10126430|NCT04335344||Cardiovascular disease|Patients with cardiovascular disease
10126431|NCT04335344||Periodontitis + cardiovascular disease|Patients with Periodontitis + cardiovascular disease
10126432|NCT04335435|Experimental|Oat Bran Consumption|Each subject consumed 120 g of oat bran (by dry weight) in a single dose, and samples (urine and fecal) were collected at different time points following the administration of oat bran.
10126433|NCT04334902||Abnormal|The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism
10126434|NCT04334902||Normal|The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism
10126435|NCT04334993|Experimental|Blinatumomab pre-transplant to high risk Ph-negative ALL pts.|Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
10126436|NCT04335331|Experimental|PreDM CDS|The PreDM CDS arm engages patients, clinicians, and health educators in the following 3 intervention components, followed by audit and feedback for clinicians: 1) Evidence-based information about T2D prevention 2) Tailored referral to local ILI programs through a novel platform integrated into the CDS; and 3) Prompt to consider metformin prescription using the routine EHR medication order function embedded in the CDS.
10126437|NCT04335331|Placebo Comparator|Standard Care|Standard care includes no additional intervention above the care routinely provided at the clinical partner site, Erie Family Health Center.
10126438|NCT04335227|Experimental|Yoga therapy group|Structured yoga therapy program for 60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
10126439|NCT04335227|Experimental|Aerobic exercise group|Aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
10126440|NCT04335227|Experimental|Combined yoga therapy and aerobic exercise group|Combined yoga therapy for three days and vigorous aerobic exercise program for three days with nutritional management uniquely prepared by dietitian
10126441|NCT04335227|Active Comparator|Control group|Nutritional management uniquely prepared by dietitian
10126442|NCT04334824||Hydrochlorothiazide|Patients who received a new prescription for hydrochlorothiazide (alone or in combination with non-ACE inhibitor antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
10126443|NCT04334824||Angiotensin-converting enzyme (ACE) inhibitors|Patients who received a new prescription for an ACE inhibitor (alone or in combination with non-hydrochlorothiazide antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
10126444|NCT04334967|Experimental|Treatment Arm|Patients in the treatment arm will receive 200 mg oral hydroxychloroquine. Day 1: 400 mg doses twice (800 mg total). Days 2-5: 200 mg dose twice (400 mg total daily).
10126445|NCT04334967|Active Comparator|Control Arm|Patients in the control arm will receive 500 mg oral Vitamin C. Day 1: 1000 mg dose twice (2000 mg total) Days 2-5: 500 mg dose twice (1000 mg total daily).
10126446|NCT04335097|Active Comparator|Control|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
10126447|NCT04335097|Active Comparator|Intervention|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service. I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
10126448|NCT04335071|Experimental|Actemra|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
10126449|NCT04335071|Placebo Comparator|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
10126450|NCT04334694|Other|Atrial flow regulator|In this arm, patients who have elevated left ventricle filling pressures get (Occlutech® AFR device) and optimal therapy for Heart failure (HF).
9527666|NCT03218046|Experimental|EMDR group|This is the treatment arm that will receive EMDR therapy
10126451|NCT04334668|Active Comparator|Oral Sodium Chloride|Subject will be given 2 grams of oral sodium chloride three times daily with meals for approximately 4 days
10126452|NCT04334668|Placebo Comparator|Placebo|Subject will be given a placebo orally three times daily with meals for approximately 4 days
10126453|NCT04334928|Experimental|Emtricitabine/Tenofovir|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~Strength: 200 mg/245 mg tablets~Dose: one tablet once a day (both at dinner)"
10126454|NCT04334928|Experimental|Hydroxychloroquine|"Hydroxychloroquine 200 mg + Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg~Strength: 200 mg tablets~Dose: one tablet once a day (both at dinner)"
10126455|NCT04334928|Experimental|Emtricitabine/Tenofovir+Hydroxychloroquine|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Hydroxychloroquine 200 mg~Strength FTC/TDF:200 mg/245 mg tablets~Strength HC: 200 mg tablets~Dose: one tablet FTC/TDF plus one tablet HC once a day (at dinner)"
10126456|NCT04334928|Placebo Comparator|Placebo|"Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg~Placebo tablets with similar appearance to study drugs.~Dose: one tablet once a day (both at dinner)"
10126457|NCT04334863|Experimental|WP1066|There will be 5 groups based on the enrollment timing. The first group of participants will receive the lowest dose level of WP1066. Each subject within a group will receive an assigned dose of the investigational drug. The dose levels are 4, 6, 8 and 16 mg/kg of the investigational drug given twice a day. The first group will receive the lowest dose level, 4mg/kg twice a day, and subsequent groups will escalate to the next higher dose level. All groups will be treated identically, except for the dose of drug administered, with the liquid formulation of the drug.
10126458|NCT04334629|No Intervention|Standard of care|
10126459|NCT04334629|Experimental|Standard of care plus lipid ibuprofen|
10126460|NCT04334850|Experimental|Targeted antibiotic treatment according to the results of mPCR|a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
10126461|NCT04334850|Other|Control arm|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
10126462|NCT04334707||Acute Kidney Injury Cohort|The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy.
10126463|NCT04334707||Chronic Kidney Diseases Cohort|High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.
10126464|NCT04334551|Experimental|switch from etravirine to doravirine|switches to doravirine,
10126465|NCT04334785|Experimental|cryo-ablation group|In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery. In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.
10126466|NCT04334655||Clinic 1|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
10126467|NCT04334655||Clinic 2|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
10126468|NCT04334655||Clinic 3|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
10126469|NCT04334655||Clinic 4|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
10126470|NCT04334616|Active Comparator|Conventional Laryngocope|Patients in this arm will be intubated with conventional Macintosh laryngoscope
10126471|NCT04334616|Active Comparator|Video Laryngocope|Patient in this arm will be intubated with Karl Storz Video Laryngoscope
10126472|NCT04334733|Experimental|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography.
10126473|NCT04334733|Experimental|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
10126474|NCT04334733|Experimental|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography and the children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
10126475|NCT04334733|Experimental|Control group|No intervention was made to children in the control group
10183494|NCT03764085|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
9527667|NCT03217994|Active Comparator|37.5% gel|37.5% gel to bleach teeth
9967538|NCT01270685||3|Health care providers with face-to-face contact with Veterans with SCI/D
9967539|NCT01270685||4|Infection control Chiefs/Officers
9967540|NCT01270698|Experimental|IMMU-130|
9967541|NCT01270724|Experimental|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
9967542|NCT01270737|Active Comparator|Whole soy|
9967543|NCT01270737|Active Comparator|daidzein|
9967544|NCT01270737|Placebo Comparator|milk powder|
9967545|NCT01270763||The Look AHEAD Study|The Look AHEAD Study includes intensive lifestyle intervention treatment, focusing on caloric intake and physical activity, and a treatment arm focused on diabetes support and education.
9967546|NCT01270776|Experimental|Aqueous Chlorhexidine|The group received skin antisepsis using 2% aqueous chlorhexidine solution.
9967547|NCT01270776|Active Comparator|2% Chlorhexidine 70% isopropyl alcohol|The group will receive skin antisepsis with 2% chlorhexidine solution in alcohol.
9967548|NCT01270789|Experimental|Liraglutide|
9967549|NCT01270789|Placebo Comparator|Placebo|
9967550|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 400 to 500 calories|
9967551|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 600 to 750 calories|
9967552|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 800 to 1000 calories|
9967553|NCT01270815|Other|Pregabalin immediate release, 300 mg|Reference
9967554|NCT01270854|Experimental|Plasmalyte|Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital
9967555|NCT01270854|Active Comparator|Normal Saline|Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital
9967556|NCT01270893|Experimental|Nilotinib and Surgical Resection|
9967557|NCT01270893|Experimental|Nilotinib and Potential Resection|
9967558|NCT01270906|Experimental|CHIR-258 (TKI258)|
10183495|NCT03764059|Experimental|Interventional|The experimental group (Filtek Bulk fill posterior restoration) .After restoration,subjects will return to site for follow up visit at 1 week and 1 year postoperative for further clinical assessments.
9527668|NCT03217994|Experimental|6% gel|6% gel to bleach teeth
9527669|NCT03217916||normotensive groups|pregnant women with normal blood pressure
9967559|NCT01270932|Experimental|Lenalidomide and Dexamethasone|"Lenalidomide:Daily for 21 days of a 28 day cycle~Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4."
9967560|NCT01270984|Experimental|Luckyvec 400mg film coated tablet|400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
9967561|NCT01270984|Active Comparator|Glivec 100mg film coated tablet|100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
9967562|NCT01270997|Experimental|HD203|Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
9967563|NCT01270997|Active Comparator|Enbrel|Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.
9967564|NCT01271023|Experimental|Closed-Loop Control|The Control to Range algorithm will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
9967565|NCT01271049|Placebo Comparator|Control Food Product|Consumption of placebo food product
9967566|NCT01271049|Experimental|Novel Food Product|Consumption of novel food product
9967567|NCT01271062|Active Comparator|T2DM patients before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
9967568|NCT01271062|Active Comparator|Non-diabetic patient before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
9967569|NCT01271062|Active Comparator|non diabetic patients, non-bariatric abdominal surgery|oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.
9967570|NCT01271062|Active Comparator|severely obese T2DM patients following a very low caloric diet|oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.
9967571|NCT01271075|Active Comparator|Bilastine A|A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg
9967572|NCT01271075|Active Comparator|Bilastine B|B: Crossover Bilastine 80 mg, Placebo, Bilastine 40 mg, Bilastine 20 mg
9967573|NCT01271088|Experimental|N-acetylcysteine|N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
9967574|NCT01271088|No Intervention|Control|Vancomycine and/or amikacin alone
9967575|NCT01271101||anticoagulant|
9967576|NCT01271114|Experimental|Hypertonic Saline and Terlipressin|
9967577|NCT01271114|Active Comparator|Normal Saline and norepinephrine|
9967578|NCT01271140|Experimental|Insulin/dextrose clamp|
9967579|NCT01271153|Active Comparator|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours
9967580|NCT01271153|Placebo Comparator|Placebo|An equivalent infusion of placebo will be infused for 2.5 h
9967581|NCT01271166|Experimental|Glivec®, modified FOLFOX, Avastin®|
9967582|NCT01271179|Active Comparator|sequential perfusion|sequential perfusion of liver grafts with low-viscosity improved Ross solution and high-viscosity UW solution.
9967583|NCT01271179|Placebo Comparator|sole perfusion|sole perfusion of liver grafts with high-viscosity UW solution only
9967584|NCT01271192|Active Comparator|Surgical resection and adjuvant therapy|Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation
9967585|NCT01271192|Experimental|Neoadjuvant followed by operation|Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.
9976680|NCT01354041|No Intervention|Treatment-as-usual|Participants in the Treatment as usual (TAU) arm will not receive any specific Fear of Cancer Recurrence (FCR) intervention during the study period. However, they will be offered an optional full-day workshop at the end of the study.
9967586|NCT01271218|Placebo Comparator|Placebo|Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
9967587|NCT01271218|Active Comparator|Active Supplement|Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
9967588|NCT01271231|Placebo Comparator|Group IP1|
9967589|NCT01271231|Experimental|Group IP2|
9967590|NCT01271231|Active Comparator|Group IP3|
9967591|NCT01271257|Experimental|hourly misoprostol|20 microgram misoprostol intake per hour
9967592|NCT01271257|Active Comparator|traditional misoprostol|80 microgram misoprostol intake per 4 hours
9967593|NCT01271283|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
9967594|NCT01271296|Active Comparator|Liquorice|Liquorice eq to 150 mg glycyrrhizinic acid. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
9967595|NCT01271296|Active Comparator|Grapefruit juice|200 ml pink grapefruit juice three times a day. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
9967596|NCT01271296|No Intervention|Baseline|Baseline assessment without intake of liquorice or grapefruit juice
9967597|NCT01271309||Acute Myocardial Infarction patients|Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
9967598|NCT01271335|Experimental|Collagenase (MZ-004)|Local intra-coronary administration of MZ-004 at or into the CTO
9967599|NCT01271348|Active Comparator|Etoricoxib|
9967600|NCT01271348|Placebo Comparator|Placebo tablet|
9967601|NCT01271361|Experimental|primary PCI with thrombectomy|thrombectomy before implantation of drug eluting stent
9967602|NCT01271361|Active Comparator|primary PCI without thrombectomy|implantation of a drug eluting stent without thrombectomy
9967603|NCT01271374|Active Comparator|Hyzaar-Treatment Arm B|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
9967604|NCT01271374|Active Comparator|Azor-Treatment A|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
9967605|NCT01271387|Experimental|Moderate Hepatic Impairment|
9967606|NCT01271387|Experimental|Mild Hepatic Impairment|
9967607|NCT01271387|Experimental|Healthy Volunteers|
9967608|NCT01271439|Experimental|cetuximab|
9967609|NCT01271478|Experimental|Telmisartan plus Captopril|captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)
9967610|NCT01271478|Experimental|Telmisartan plus Placebo|telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day
9967611|NCT01271478|Experimental|Captopril plus Placebo|patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
9967612|NCT01271478|Placebo Comparator|Placebo|2 tablets of placebo orally twice a day
9967613|NCT01271491||Cases|Children hospitalized in the ICU with bronchiolitis
9967614|NCT01271491||Controls|Children hospitalized in the general ward with bronchiolitis
9967615|NCT01271517|Active Comparator|Insulatard|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars
9967616|NCT01271517|Active Comparator|Lantus|Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
9967617|NCT01271517|Active Comparator|Levemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
9967618|NCT01271530|Experimental|Exercise|
9967619|NCT01271530|No Intervention|Control|
9967620|NCT01271556|Experimental|1, salmeterol, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to each test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (salmeterol 50 mcg MDI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
10126476|NCT04334798|Experimental|PFM&electro&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the pelvic floor muscles (PFM) will be performed using intravaginal palpation and electrostimulation, together with biofeedback (BFB).
10126477|NCT04334798|Experimental|PFM&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with biofeedback (BFB).
10126478|NCT04334798|Experimental|PFM&electro&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation and electrostimulation, together with transabdominal ultrasound biofeedback (BFB).
10126479|NCT04334798|Experimental|PFM&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with transabdominal ultrasound biofeedback (BFB).
10183496|NCT03764059|Active Comparator|observational|The control group (Filtek™ Z350XT Universal Restorative which was approved by CFDA in 2010 and has been in the market for 5 years with some validated clinical data).After restoration,subjects will return to the site for follow up visits at 1 week and 1 year postoperative for for further clinical assessments.
10183497|NCT03764020|Experimental|Melatonin|"Intervention group1:~Melatonin,capsule,3 mg, one dose one hour before bedtime, three weeks"
10183498|NCT03764020|Placebo Comparator|Placebo|"Intervention group2 :~Placebo, capsule, 3 mg, one dose one hour before bedtime, for three weeks"
10183499|NCT03763981|Active Comparator|prolene seton|Prolene thread will be used as seton treatment for perianal fistulas
10183500|NCT03763981|Active Comparator|silk seton|Silk thread will be used as seton treatment for perianal fistulas
10183501|NCT03763955||PD patients|PD patients at 1-5 H&Y stage undergoes 4week Multidisciplinary Intensive Rehabilitation Treatment
10183502|NCT03763942|Experimental|HealthMindr App|Participants in the intervention arm will receive access to all HealthMindr app capabilities. The app information will cover the importance of testing, links to HIV prevention resources, resources to locate HIV testing and PrEP services, the Substance Abuse and Mental Health Services Administration (SAMHSA) substance abuse treatment resource locator, and other prevention information specific to their area.
10183503|NCT03763942|Placebo Comparator|Control App|Participants in the control arm will be directed to download a study app that allows study staff to interact with them.
10183504|NCT03763916|Active Comparator|Intra operative ureteric dissection|midline abdominal incision extending supraumbilical, incision of the SC tissue, dissection and splitting of the recti, classic midline incision of the uterus [above the site of placental insertion], delivery of the fetus , avoid traction of the placenta, quick closure of the uterus [in presence of the placenta] in one layer, clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
10183505|NCT03763916|Active Comparator|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter.
10183506|NCT03763903|Other|3D training|Basic laparoscopic skills (FLS tasks) training using 3D visualization
10183507|NCT03763903|Other|2D training|Basic laparoscopic skills (FLS tasks) training using 2D visualization
10183508|NCT03763864|Other|Inherited disorders|
10183509|NCT03763851|Experimental|Cannabis group|"Delta-9 Tetrahydrocannabidiol (THC) /Cannabidiol (CBD) ratio 1:1 capsule~These capsules contain different cannabis formulations with low-dose and high-dose preparations according to the treatment group:~Cannabis group low-dose capsule contains THC 1mg CBD 1mg~Cannabis group high-dose capsule contains THC 2.5mg CBD 2.5mg"
10183510|NCT03763851|Placebo Comparator|Placebo group|"The placebo capsule will have no cannabis, it will look identical to the active treatment capsule, and it will also be prepared in low-dose and high-dose presentations."
10183511|NCT03763825|Experimental|Intervention group|Patient will receive the Mini-AFTERc intervention after completion of primary breast cancer treatment.
10183512|NCT03763825|No Intervention|Control group|Patients will receive usual care after completion of primary breast cancer treatment.
10183513|NCT03763812|Other|Endovascular Aneurysm Repair (EVAR)|Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
10183514|NCT03763812|Other|Endovascular Aneurysm Sealing (EVAS)|Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
10183515|NCT03763799|Experimental|multiplex PCR strategy|FilmArray® Pneumonia Panel plus
10183516|NCT03763799|Active Comparator|standard strategy|
10183517|NCT03763786|Experimental|No GnRH antaogonist|Cetrorelix Acetate (NOT given) Daily 0.25mg Subcutaneous injection for 7 days
10183518|NCT03763786|Active Comparator|Standard GnRH antoagonist|Cetrorelix Acetate (control) Daily 0.25mg Subcutaneous injection for 7 days
10183519|NCT03763760|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
10183520|NCT03763760|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
10183521|NCT03763734|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
10183522|NCT03763734|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
10126480|NCT04334720||Observation group of positive F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
10126481|NCT04334720||Observation group of no abnormal changes in F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
10126482|NCT04334720||The control group|Corresponding to the observation group, the time, sequence and protocol were consistent
10126483|NCT04334590||Cleft Lip/Nose Repair without PSIO|Participants who will undergo cleft lip/nose repair prior to addition of PSIO as part of standard of care in Hopkins.
10126484|NCT04334590||Presurgical Infant Orthopedic Therapy|Participants who will undergo cleft lip/nose repair after addition of PSIO as part of standard of care in Hopkins.
10126485|NCT04334642|Experimental|Athletes from the Paralympic Boccia Brazilian Team|The research will have as a convenience sample 11 Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis. This study includes the category called Other participants formed by staff, freshmen, technicians and other professionals who are present during the interventions.
10126486|NCT04334603|Experimental|Home-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at home
10126487|NCT04334603|Active Comparator|Clinical-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital
10126488|NCT04334525|No Intervention|Generic placemats and frequent diner cards|Participants will receive generic placemats listing all of the restaurant's kids' meals. Families will also receive a generic frequent diner card, which after purchasing (any) kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
10126489|NCT04334525|Experimental|Placemats and frequent diner cards promoting healthier meals|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
10126490|NCT04334512|Experimental|Quintuple Therapy|Patients will be treated with quintuple therapy for 10 days.
10126491|NCT04334512|Placebo Comparator|Placebo|Patients will be treated with placebo.
10126492|NCT04334564|Active Comparator|Test team|Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally
10126493|NCT04334564|Placebo Comparator|Control group|Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally
10126494|NCT04334499||Age Related Macular Degeneration|Subjects with Age Related Macular Degeneration upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
10126495|NCT04334499||Glaucoma|Subjects with Glaucoma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
10126496|NCT04334499||Diabetic Retinopathy|Subjects with Diabetic Retinopathy upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
10126497|NCT04334499||Ocular Trauma|Subjects with Ocular Trauma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
10126498|NCT04334499||Control|Subjects with no ocular disease or trauma comorbidities upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
10126499|NCT04334265|Experimental|Anluohuaxian combined with regular treatment group|Anluohuaxian: 6g each time, twice a day
10126500|NCT04334265|No Intervention|regular treatment group|
10126501|NCT04334135|Experimental|MitoQ|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after acute MitoQ supplementation (80 - 160mg).
10126502|NCT04334135|Placebo Comparator|Placebo|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a placebo matched in appearance to the MitoQ.
10126503|NCT04334473|Other|cataract patients|Patients having cataract candidates for phacoemulsification with or without glaucoma are prepared to do cataract surgery with preoperative and postoperative assessment of intraocular pressure and ocular bio-metrics using UBM.
10126504|NCT04334239||Intervention|Cancer patients who have undergone substantial parts of inpatient treatment in a certified cancer centre.
10126505|NCT04334239||Control|Cancer patients who have not undergone inpatient treatment in a certified cancer centre.
10126506|NCT04334278|Experimental|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
10126507|NCT04334278|Active Comparator|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth. To control for in between session practice, participants will receive an mp3 recording and informational handout to complete after each session.
10126508|NCT04334226||Patient and Caregiver Dyad|Individuals who participated in the Stoma Boot Camp study and their caregiver will form a dyad
10126509|NCT04334200|Experimental|Cultivate yourself: support for caregivers of dementia persons|There will be six sessions (1 or 2 session per week). The duration of each session will be 1.5-2 hours per session. The contents include: introduction on dementia, caregivers' role, how to communicate with dementia persons, tips on caregiving, stress and emotional management. The training content has been verified by one social worker, family caregivers of individuals living with dementia and a teacher who teach Chinese, Chinese history and culture in the secondary school in Hong Kong. No adverse comments are received from them.
9527670|NCT03217916||hypertensive groups|pregnant women with severe preclampsia
10126510|NCT04334434|Experimental|Study Group|The group to which the exercise protocol consisting of aerobic and strengthening exercises will be applied.
10126511|NCT04334434|No Intervention|Control Group|Control group where evaluations will be made.
9669029|NCT04281225|Experimental|ATV only condition|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for design purposes. However, these participants will also be told that their input while wearing the device will help the team in developing the final device and allow the team to focus on how to best improve hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked 1) to note any changes in what they heard in the audio focusing on the story in the ballad and 2) whether their hearing might possibly be impacted by activities and behavior. They will also be asked 3) about their general health and wellness, as compared to the last time they were contacted by email. This condition will enable researchers to test the main effect of attention to variability, without an explicit placebo effect.
10126512|NCT04334330|Experimental|Treatment group|
10126513|NCT04334486|Experimental|Video Game Trained|Subjects will participate in video gaming for 10 minutes prior to Eyesi simulator test of surgical skills.
10126514|NCT04334486|No Intervention|No Video Game Training|No video gaming will occur for warm up to Eyesi simulator test of surgical skills
10126515|NCT04334447|Experimental|Intervention Group Patients|All HF patients that experience a HF education session
10126516|NCT04334356|Experimental|App Intervention|All participants will receive the web app for prevention of posttraumatic stress.
10126517|NCT04334369|Sham Comparator|Single Vision Contact Lenses|
10126518|NCT04334369|Experimental|Multifocal Contact Lenses|
10126519|NCT04334382|Experimental|Hydroxychloroquine|
10126520|NCT04334382|Active Comparator|Azithromycin|
10126521|NCT04334213|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.~Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets)."
10126522|NCT04334213|Experimental|Sequence 2|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days
10126523|NCT04334213|Experimental|Sequence 3|Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).
10126524|NCT04334213|Experimental|Sequence 4|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets).
10126525|NCT04334161||PHH patients|Patients with Roux-en-Y gastric bypass ≥1 year ago and confirmed postprandial hyperglycaemic hypoglycaemia (PHH). PHH is defined as postprandial plasma or sensor glucose<3.0mmol/l according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
10126526|NCT04334161||non-PHH gastric bypass patients|Patients with Roux-en-Y gastric bypass ≥1 year ago without evidence of PHH.
10126527|NCT04334161||non-PHH sleeve gastrectomy patients|Patients with sleeve gastrectomy ≥1 year ago without evidence PHH.
10126528|NCT04334161||non-PHH non-surgical controls|Absence of any conditions or previous surgery known to affect gastro-intestinal integrity and food absorption.
10126529|NCT04334421||Mesh group|After resection, pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) and covered with subcutaneous flap.
10126530|NCT04334096|Experimental|QoL diagnosis and therapy|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
10126531|NCT04334122|Experimental|Control group|"All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~As a traditional treatment, patients received hot packs, conventional transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound and exercise.~Hot packs used as superficial heat were wrapped in a towel and applied to the waist area for 20 minutes.~Conventional TENS used as analgesic current were applied to the waist region for 20 minutes with 4 electrodes with 2 outputs, with a current time of 180 ms at a frequency of 80 Hz.~It was applied with a dose of 1Mhz for 5 minutes with ultrasan (Chattanooga Intelect Mobile Combo model device) used to heat deep tissues.~Waist exercises were asked to be done during the treatment, with 10 repetitions, each exercise twice a day (morning and evening)."
10126532|NCT04334122|Experimental|Experiment group|"In addition to the traditional physiotherapy program, tool-assisted soft tissue mobilization was performed 3 times a week (12 sessions with 1 day interval) in the experimental group.~Instrument Assisted Soft Tissue Mobilization (IASTM) treatment was applied to ilicostalis lumborum, priformism, gluteus medius, erector spinas, quadratus lumborum muscles, superficial and deep fascia. Before applying the application, petroleum jelly was applied to the area and the tool was slipped.~IASTM treatment was applied to the treated muscle fibers for 6 minutes, each technique (SWEEP-FAN-BRUSH-SWEEP techniques) with 8-10 repetitions.~Sweep: Applied in all directions at 30 or 60 degree angle. Fan: It was applied by moving one side fixed arm at 30 degree angle. Brush: It was applied in straight steps at 30 degrees angle. Each stage of IASTM treatment was done by the physiotherapist."
10126533|NCT04333927|Experimental|Treatment|Patients in treatment group will receive camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. After 1 or 2 courses of camrelizumab, patients went on to receive capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week) concurrent with radiotherapy (45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed).
10126534|NCT04333927|Placebo Comparator|Observation|Patients in observation group will not receive any anti-cancer therapy.
10126535|NCT04333979|Experimental|Drain replacement|Effects of drainage
10126536|NCT04333979|No Intervention|Drain not placed|Effects of not using drain
10126537|NCT04334031|Experimental|IMMINeNT cohort|
10126538|NCT04334005|Active Comparator|Usual care|Prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations.
10126539|NCT04334005|Experimental|Intervention group|25000 UI of vitamin D supplement in addition to the above-mentioned drug recommendations.
10126540|NCT04333758|Experimental|Jintronix Intervention|"2 consecutive phases of intervention for all participants using Jintronix virtual reality telerehabilitation software.~Phase 1 consisted of 9 (3/week for 3 weeks) 45-min/session clinic-based sessions conducted by study team therapist, with concurrent caregiver training.~Phase 2 consisted of 20 (5/week for 4 weeks) 45min/session home-based sessions supervised by trained caregiver, with telemonitoring by study team therapist."
10126541|NCT04333875||TAVR/SAVR|Patients with critical aortic stenosis as defined by an AVA <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to transcatheter aortic valve replacement or surgical aortic valve replacement.
10126542|NCT04333875||Deferred Intervention|Patients with severe but not critical aortic Stenosis will undergo deferred intervention.
10126543|NCT04333745|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days. After one day on the diet, subjects will provide three 24-hour urine collections. On the last dayof the diet, subjects will come in a fasted state to ingest a small amount of carbon-13 oxalate and sucralose, with hourly urine collections and blood samples being taken before and after the ingestion.
10126544|NCT04333771|Placebo Comparator|Placebo|
10126545|NCT04333771|Experimental|SHR0302 dose1|
10126546|NCT04333771|Experimental|SHR0302 dose2|
10126547|NCT04333823|Experimental|Intervention (Dapagliflozin)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
10126548|NCT04333823|Placebo Comparator|Control (Placebo)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
10126549|NCT04333693||Cases|Adults (age>18years) undergoing any type of vascular surgery (open surgery, endovascular surgery or hybrid procedure) in an operating theatre and either before or after surgery: lab test confirmed COVID-19 or clinical diagnosis of COVI-19 infection (no test performed)
10126550|NCT04333992|Active Comparator|propofol-remifentanil group|"Anesthetic induction was achieved with an initial target concentration of propofol 4 ㎍/mL and remifentanil 3-4 ng/mL.~Anesthesia was maintained with a fixed target concentration of propofol 2-4 ㎍/mL and remifentanil 2-3 ng/mL"
10126551|NCT04333992|Active Comparator|sevoflurane-remifentanil group|"Anesthetic induction was achieved with thiopental 5 mg/kg and initial target concentration of remifentanil 3-4 ng/mL.~Anesthesia was maintained with 1.5-2.5% end-tidal concentration sevoflurane in 50% oxygen with air and remifentanil 2-3 ng/mL"
10126552|NCT04334044|Experimental|Ruxolitinib|Ruxolitinib 5 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan
10126553|NCT04333836|Experimental|Aligners group|Receiving full set of aligners ( Clear Removable Orthodontic appliance) until complete canine retraction
10126554|NCT04333836|Active Comparator|Conventional Brackets group|leveling and alignment of lower followed by complete canine retraction
10126555|NCT04333797|Other|Transitional age youth|Assessed group.
10126556|NCT04334018|Placebo Comparator|conventional CRT|
10126557|NCT04334018|Experimental|MPP CRT|
10126558|NCT04333914|Experimental|Autophagy inhibitor (GNS651)|
10126559|NCT04333914|Other|Standard of care|
10126560|NCT04333914|Experimental|anti-NKG2A (Monalizumab)|
10126561|NCT04333914|Experimental|anti-C5aR (Avdoralimab)|
10126562|NCT04333940|Experimental|1. 3D CBCT GROUP|Preoperative 3-dimensional CBCT will be taken.
10126563|NCT04333940|Active Comparator|2D PR GROUP|Preoperative 2-dimensional periapical radiographs will be taken using paralleling technique with customized Jig
10126564|NCT04333719||terminally ill patients in specialized palliative|terminally ill patients in specialized palliative care facilities
10126565|NCT04333667|Experimental|Intervention group|The intervention group will get an 8-week mindfulness-based internet intervention.
10126566|NCT04333667|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
10126567|NCT04333628|Experimental|low dose chloroquine|oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
10126568|NCT04333628|Experimental|Regular dose chloroquine|oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
10126569|NCT04333628|Other|Standard of care|The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
10126570|NCT04333641||small AAA patients|all patients with small AAA
10126571|NCT04333615|Sham Comparator|Control Session|The control session will consist of resting on the treadmill for 30 min. It will be recommended that the patient do cycles in which he / she stands for 3 to 5 minutes and sits for 2 to 3 minutes in between, aiming to minimize the effect of body positioning on cardiovascular responses.
9827428|NCT02454959|Experimental|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
10126572|NCT04333615|Experimental|Self-selected Session|In the self-selected exercise session, individuals will perform 30 min of exercise with self-selected intensity. This means that the duration of the series and the intensity (speed) of the treadmill are at the discretion of the patient. The important thing is that in the end it totals 30 minutes of exercise. This choice of intensity and duration of the series can be made regardless of the occurrence of pain.
10126573|NCT04333615|Active Comparator|Walking with pain|In the exercise until maximum pain session (current recommendation of walking exercise prescription for patients with PAD), individuals will perform series of 3 to 5 minutes with adjusted intensity so that they feel moderate to maximum pain. This means that the patient will start walking and the Physical Education professional, experienced and able to prescribe exercises for patients with PAD, will adjust the treadmill speed so that the patient walks with moderate pain or even maximum pain. There will be rest intervals of 2 to 3 minutes. The patient will be encouraged to complete a total of 30 minutes of exercise.
10126574|NCT04333550|Experimental|Experimental: Desferal addition to standard treatment|
10126575|NCT04333550|Experimental|Experimental: standard treatment|
10126576|NCT04333511|Experimental|Sequence 1|TPS first with crossover to Sham-TPS
10126577|NCT04333511|Experimental|Sequence 2|Sham-TPS first with crossover to TPS
10126578|NCT04333589|Experimental|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
10126579|NCT04333589|No Intervention|Regular treatment group|Treatments other than lopinavir and ritonavir, chloroquine phosphate, hydroxychloroquine sulfate, arbidol, and colomycin can be given.
10126580|NCT04333355|Experimental|COVID-19 patients receiving Convalescent Plasma|Convalescent Plasma from patients who recently recover from COVID-19
10126581|NCT04333381|Active Comparator|Common Practice|Patients included in the phase I will receive common practice.
10126582|NCT04333381|Experimental|Educational and organizational measures|Patients included in the phase II will be attended by emergency nurses that received the educational and organizational intervention.
10126583|NCT04333342|Experimental|Wearable device group|Participants use wearable device and their heart rate and activity are monitored. If their resting heart rate (rHR) increase beyond the set range or they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If their rHR stay within set range and they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
10126584|NCT04333342|No Intervention|Control group 1|articipants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
10126585|NCT04333342|No Intervention|Control group 2|Participants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 3 and 6 months after discontinuing anti-thyroid drugs.
10126586|NCT04333303|Experimental|Advance Care Planning Program|Implementation of a complex regional Advance Care Planning program.
10126587|NCT04333303|No Intervention|Care as usual|
10126588|NCT04333394|Active Comparator|Probiotic|The probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei PXN 37, Lactobacillus rhamnosus PXN 54, Streptococcus thermophilus PXN 66, Bifidobacterium breve PXN 25, Lactobacillus acidophilus PXN 35, Bifidobacterium longum PXN 30, Lactobacillus bulgaricus PXN 39)
10126589|NCT04333394|Placebo Comparator|Placebo|Placebo capsules have an identical appearance to probiotic capsules and contain microcrystal cellulose.
10126590|NCT04333329|Experimental|AD Patients|"All patients were treated with the TPS device (new name: NEUROLITH (Storz Medical AG))~- 6 sessions within 2 weeks, each sessions consisting of 6000 TPS pulses of 0.2 mJ/mm²"
10126591|NCT04333316|Other|large head group|study the postoperative patient's satisfaction
9827429|NCT02454959|Experimental|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
9827430|NCT02454972|Experimental|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
10126592|NCT04333316|Other|dual mobility group|study the postoperative patient's satisfaction
10126593|NCT04333238|Active Comparator|Standard template|Usual outpatient progress note with standard Subjective Objective Assessment Plan (SOAP) format
10126594|NCT04333238|Experimental|New template|The assessment and plan section is placed in the beginning, subjective data grouped into the assessment section, and elements not related to the current presentation were deemphasized
10126595|NCT04333264|Active Comparator|suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
10126596|NCT04333264|Active Comparator|no suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
10126597|NCT04333498|Experimental|Receiving Feedback From DBS|This arm of participants will receive monthly feedback from medical providers on their adherence measured through DBS.
10126598|NCT04333251|Experimental|convalescent plasma|This arm will receive convalescent plasma
10126599|NCT04333251|Placebo Comparator|best supportive care|Oxygen therapy
10126600|NCT04333433||MicroShunt treatment group|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 were implanted with the device
10126601|NCT04333433||Trabeculectomy control arm|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 underwent trabeculectomy procedure
10126602|NCT04333277|Experimental|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
10126603|NCT04333277|Placebo Comparator|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
10126604|NCT04332978|Experimental|Group I|"Drug names: Fluticasone Propionate - PLURAIR® brand Pharmaceutical form: Nasal spray (50mcg / dose) Administration: Topical nasal route Posology 02 jets in each nostril 1 time a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~Manufacturer: Libbs Farmacêutica Ltda. Presentation: Deliver 1 bottle of 120 doses in original packaging"
10126605|NCT04332978|Active Comparator|Group II|"Fluticasone Propionate - FLIXONASE® brand Nasal spray (50mcg / dose) Topical nasal route 02 jets in each nostril once a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.~GlaxoSmithKline. Deliver 1 bottle of 120 doses in original packaging"
10126606|NCT04332900|No Intervention|Control condition|In this condition there will not be any application of therapeutic approach.
10126607|NCT04332900|Experimental|Intervention proximal condition|The proximal therapeutic approach will be the SERF strap (S.E.R.F. strap; DonJoy Orthopedics, Inc., vista, CA).
10126608|NCT04332900|Experimental|Intervention distal condition|The distal therapeutic approach will be a pair of foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each (Propulsão Produtos Biomecânicos, Minas Gerais, Brazil).
10126609|NCT04332939|Experimental|Exercise + real tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of anodal tDCS (2 mA, 20 min)."
10126610|NCT04332939|Sham Comparator|Exercise + Sham tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of sham tDCS."
10126611|NCT04332965|Experimental|Patients with chronic periodontitis|Patients with CP (n=30) had teeth with 30% periodontal bone loss and ≥ 2 non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and bleeding on probing.
10126612|NCT04332965|Experimental|Patients with gingivitis|Participants with G (n=30) had gingival index ≥ 2 and other inflammation signs.
10126613|NCT04332965|No Intervention|Participants with periodontal healthy|The H group (n=30) consisted of individuals with no attachment loss, no history of periodontal disease, PD ≤3 mm, and whole-mouth bleeding scores <10%.
10126614|NCT04333017|Experimental|treated patient|Percutaneous radiofrequency ablation of parietal endometriosis
10126615|NCT04333030||Psychiatry|patients who come for psychiatric consultation
10126616|NCT04333030||addictology (other than tabacco)|patients who come for addictology consultation
10126617|NCT04333030||endocrinology|patients who come for endocrinology consultation
10126618|NCT04332874|Experimental|Participants with Sarcoma|Advanced/metastatic extremity sarcoma eligible for pembrolizumab and isolated limb infusion (ILI)
10126619|NCT04333134|Experimental|Dose level 1|Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.
10126620|NCT04333095|Active Comparator|Liposomal Bupivacaine Block|Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
10126621|NCT04333095|Placebo Comparator|Saline Block|Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
10126622|NCT04333212|Other|study arm|We projected a total of 1,100 study cases, which encompassed 100 cases of women with no intraepithelial lesion or malignancy (NILM) cytology, 300 cases of ASCUS, 300 cases of low grade squamous intraepithelial lesion (LSIL) and 400 cases high grade squamous intraepithelial lesion (HSIL) in cervical cytology.
10126623|NCT04333069|Other|Uncorrected and best corrected visual acuity|Measuring of uncorrected and best corrected visual acuity after phaco emulsification and irrigation aspiration cataract surgery
10126624|NCT04333173||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
10126625|NCT04333004|Experimental|Pembrolizumab Combined With Chemotherapy|
10126626|NCT04333043||Hearing Aids|Hearing Aids use
10126627|NCT04332848|Experimental|(B) Empirical therapy|choose antibiotics according to drug history
10126628|NCT04332848|Active Comparator|(A) Susceptibility testing guided therapy|choose antibiotics according to susceptibility testing
10126629|NCT04332627|Active Comparator|sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
10126630|NCT04332627|Placebo Comparator|neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
10126631|NCT04332718|No Intervention|24 Hour Holter|Patients who are randomised to the 24 Hour Holter monitoring will be contacted within one month from randomisation. The repeat 24 Hour Holter result will be explained to the patient at the end of 30-day follow-up.
10126632|NCT04332718|Active Comparator|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
10126633|NCT04332666|Placebo Comparator|Placebo|Standard of care treatment
10126634|NCT04332666|Experimental|Study drug|Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h
10126635|NCT04332731|Experimental|Renal angiography and Renal denervation|"Symplicity Spyral™ multi electrode renal denervation system~After renal angiography, participants in the experimental group will be immediately treated with renal denervation procedure using standard techniques. The participants will remain blinded throughout the procedure."
10126636|NCT04332731|Sham Comparator|Renal angiography|In the control group, the sham procedure will consist of only a renal angiogram. Participants will undergo diagnostic renal angiogram but will not receive any therapeutic endovascular treatment. Participants will remain on the procedure table for at least 20 min after the angiogram to prevent possible unblinding of randomization allocation.
10126637|NCT04332705||Patients with colon cancer|Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments
10126638|NCT04332705||Patients without colon cancer|Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments
10126639|NCT04332536|Experimental|Chronic Heart Failure|
10126640|NCT04332536|Active Comparator|Age-matched healthy controls|
10126641|NCT04332679|Active Comparator|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
10126642|NCT04332679|Experimental|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
10126643|NCT04332770||Hypothyroid group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to withdraw their levothyroxine for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
10126644|NCT04332770||Control group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to get rhTSH (not to withdraw their levothyroxine) for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
10126645|NCT04332757|Experimental|Training Intervention|18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation.
10126646|NCT04332757|No Intervention|Usual care control|Usual care acting as a control group.
10126647|NCT04332640|Experimental|Next Generation Phaco System|VERITAS Vision System
10126648|NCT04332822|Active Comparator|Arm A - R-mini-CHOP|"Cycles 1-6, duration 21 days~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
10126649|NCT04332822|Experimental|Arm B - R-pola-mini-CHP|"Cycles 1-6, duration 21 days~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6~Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6"
10126650|NCT04332835|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive the standard therapy defined by institutional protocol.
10126651|NCT04332835|Active Comparator|Control Group|Participants included in the control group will receive standard therapy defined by institutional protocol.
10126652|NCT04332562|No Intervention|normotensive control group|Normotensive volunteer
10126653|NCT04332562|No Intervention|hypertensive control group|Hypertensive patients with no restriction on their salt intake
10126654|NCT04332562|Experimental|hypertensive interventional group|intervention is going to be salt restriction
10126655|NCT04332809|Active Comparator|Saline-gentamicin irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline-gentamicin solution
10126656|NCT04332809|Active Comparator|Saline irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline solution
10126657|NCT04332809|No Intervention|No irrigation|ayer-by-layer irrigation of the appendectomy wound will not be performed
10126658|NCT04332796|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
10126659|NCT04332796|Active Comparator|ZnO-NPs socks|ZnO-NPs socks to patients for 2 weeks
10126660|NCT04332796|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks to patients for 2 weeks
10126661|NCT04332549|Active Comparator|Reconstitution Method 1|
10126662|NCT04332549|Active Comparator|Reconstitution Method 2|
10183523|NCT03763721|Experimental|iOCT optimized protocol (iOCT-p)|In the iOCT optimized protocol (iOCT-p) group, graft apposition will be assessed with special detail for graft orientation, interface fluid, and any peripheral folds as described by Xu et al. Potential tissue manipulations will be therefore based on the iOCT image. Apposition of the graft will be obtained using a complete filling of the anterior chamber with 20% sulphur hexafluoride (SF6) endotamponade for 1-2 minutes, whilst the OCT image is assessed and any graft manipulation can be performed if deemed necessary. After this period, the gas is partly exchanged for BSS (Balanced Salt Solution, Alcon) to achieve a bubble with a diameter of approximately the same size of the graft (i.e. 8.5mm)
10183524|NCT03763721|Active Comparator|current practice protocol (CP-p)|In the current practice protocol (CP-p), graft apposition will be obtained using a complete and pressurized (approx. 65mmHg) filling of the anterior chamber with 20% SF6, for 8 minutes. Tissue manipulations, such as corneal swiping, will be performed as deemed necessary by the surgeon, based on the en face view from the conventional microscope image. The intraocular pressure is normalized by exchanging the SF6 gas for BSS, to achieve a gas bubble approximately the size of the graft (i.e 8.5mm). Now, the graft apposition is assessed using iOCT, to ensure all trial patients eventually undergo advanced iOCT imaging. Should this iOCT image reveal improper graft adherence or any other irregularity, the surgeon will perform additional manipulations or interventions as deemed necessary
10183525|NCT03763695||Retrospective control group|Patients admitted in our PICU before the implementation of the protocol for VAP prevention (from 01/01/2016 to 12/31/2017)
10183526|NCT03763695||Prospective group|Patients admitted to our PICU since the VAP bundle has been introduced in the clinical practice (from 01/01/2018)
10183527|NCT03763682|Experimental|Genio(TM) system therapy|Genio(TM) bilateral hypoglossal nerve stimulation system
10183528|NCT03763669|Experimental|Intervention|Pregnant women randomly assigned to receive (n. 40) diet and folic acid (400 mcg per day) and myo-inositol supplementation
10183529|NCT03763669|Placebo Comparator|Control|Pregnant women randomly assigned to receive (n. 40) only diet and folic acid (400 mcg per day)
10183530|NCT03763630|Active Comparator|Intervention arm|House dust-mite SLIT
10183531|NCT03763630|Placebo Comparator|Control arm|Normal saline
10126663|NCT04332510|Experimental|Infant milk 1|
10126664|NCT04332510|Experimental|Infant milk 2|
10126665|NCT04332510|Experimental|Infant milk 3|
10126666|NCT04332510|Experimental|Infant milk 4|
10126667|NCT04332380|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol.
10126668|NCT04332315|Active Comparator|VALS|Vaginally asissted laparoscopic sacrocolpopexy
10126669|NCT04332315|Active Comparator|AS|Abdominal Sacrocolpopexy
10126670|NCT04332328||Ulcerative patients|
10126671|NCT04332328||Non ulcerative patients|
10126672|NCT04332302|Experimental|Power training group|Participants will be enrolled in a resistance training program.
10126673|NCT04332302|No Intervention|Control group|Participants will be doing their normal life.
10126674|NCT04332276|Experimental|Cerebroventricular administration of A- dopamine|Cerebroventricular administration of dopamine prepared and stored in anaerobia
10126675|NCT04332276|Active Comparator|Optimized oral dopaminergic treatment|Optimized oral dopaminergic treatment with L-dopa (at least 5 doses a day) with dopaminergic agonist, monoamine B inhibitor and catechol-o-methyl inhibitor (if tolerated) (A-dopamine replaced by saline un the pump during optimized oral dopaminergic treatment)
10126676|NCT04332289||PHH patients|Patients following Roux-en-Y gastric bypass surgery (≥1 year ago) with confirmed post-prandial hyperinsulinemic hypoglycemia
10126677|NCT04332289||Healthy controls|Non-PHH, non-surgical healthy individuals
10126678|NCT04332354||T2D diabetes obese subjects|Patients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery
10126679|NCT04332042|Experimental|tofacitinib|Tofacitinib cp 5mg: 2pills twice a day for 14 days
10126680|NCT04332185|Experimental|Vestibulart socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
9669030|NCT04281225|No Intervention|Control condition- no ATV or Placebo effect.|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for ergonomic purposes. They will listen to the audio and record volume levels at the start and at the end of the audio and provide feedback on the design. They will be told that each day they will listen to a brief audio (ballad of under 3 minutes) and will be asked a few similar questions twice daily for 6 days. After the 2nd audio of the day, they will be asked for feedback on the hearing device design. They will also be asked about their general health and wellness, as compared to the last time they were contacted.This group will allow researchers to test for the effects of having any device at all.
9669031|NCT04278898|Experimental|N-acetylcysteine then Placebo|
9669032|NCT04278898|Experimental|Placebo then N-acetylcysteine|
9669033|NCT04268849|Active Comparator|Oral Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
9669034|NCT04268849|Active Comparator|IV Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
10126681|NCT04332029|Experimental|CBT + WGP + CM|The experimental intervention includes three components: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation; 2) Weight Gain Prevention module (WGP) and; 3) Contingency Management (CM) procedure reinforcing tobacco abstinence.
10126682|NCT04332029|Active Comparator|CBT + WGP|The active comparator will include only the first two components of the experimental intervention: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation and 2) Weight Gain Prevention module (WGP).
10126683|NCT04332055|Experimental|ERVIN PLUS|The doctor and the patient will have access to the ERVIN generated data
10126684|NCT04332055|No Intervention|ERVIN MINUS|The doctor and the patient will not have access to the ERVIN generated data
10126685|NCT04332393|Experimental|metformin group|
10126686|NCT04332393|No Intervention|No treatment group|
10126687|NCT04332159|Experimental|Intervention group|Inhalation of Methoxyflurane through a Penthrox inhaler
10126688|NCT04332159|Placebo Comparator|Control group|Inhalation of placebo (0.9% salin solution) through a Penthrox inhaler
10126689|NCT04331990|Active Comparator|Standard Physical Therapy|Control group for the study. Intervention in the form of warm-up and strengthening, stretching and neuromuscular control exercises.
10126690|NCT04331990|Experimental|Intermittent Mechanical Traction|Standard care in addition to intermittent mechanical distraction of the knee joint.
10126691|NCT04331990|Experimental|Continuous Mechanical Traction|Standard care in addition to continuous mechanical distraction of the knee joint
10126692|NCT04331977|Experimental|Quadhelix Group|
10126693|NCT04331977|Active Comparator|Hyrax Group|
10126694|NCT04332133|Active Comparator|group 1|group 1 of DME which treated by SML
10126695|NCT04332133|Active Comparator|group 2|Group 2 of DME which treated by intravitreal injection of Ranibizumab
10126696|NCT04332133|No Intervention|group 3|control group of diabetic patients received no treatment
10126697|NCT04332094|Experimental|Intervention|Early administration of tocilizumab associated with hydroxychloroquine and azithromycin.
10126698|NCT04332094|Active Comparator|Control|Treatment of SARS-COV-2 (COVID-19) infection with hydroxychloroquine and azithromycin.
10183532|NCT03763630|No Intervention|Observation cohort|ITEC observational cohort, no intervention administered
10126699|NCT04332263|Experimental|Neuromuscular Electrical Stimulation - NMES|NMES will be applied bilaterally on the quadriceps femoris muscle of ICU patients. An electrical stimulation system and an ICU-designed dynamometer will be used with the patients lying in bed, with the hips and the knees flexed at 60 and 90 degrees, respectively. Supramaximal single-pulse's peak force will be used to determine the NMES intervention level. NMES (alternating biphasic current, stimulation frequency = 80 Hz, 1 ms pulse duration) will be used to evoke tetanic forces (EF) at 50% of the supra-maximal single-pulse EF (i.e., 10-12% of a maximal voluntary isometric contraction). NMES protocol will be performed five times a week, lasting 20 min. Muscle fatigue will be evaluated every 5 min of the intervention, and will be determined as a 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol. If and when a 10% reduction of the single-pulse EF is achieved, the intervention protocol will be terminated before the 20 min.
10126700|NCT04332263|No Intervention|Control Group - CG|The control group (CG) will only perform conventional physiotherapy and will not receive any NMES training, but will be evaluated through the same evaluations and in the same moments of the two above mentioned intervention groups. Conventional physiotherapy will be given to all three groups.
10126701|NCT04332120|Active Comparator|Mini Laparotomic|In patients undergoing spinal anesthesia, a suprapubic 3-5 centimeter incision was entered into the abdomen. After both tubes were isolated, bilateral tube ligation was performed by Pomeroy method. After bleeding control was achieved, it was repaired in accordance with the anatomy of the abdomen.
10126702|NCT04332120|Active Comparator|Laparoscopic|In patients undergoing general anesthesia, Verres was inserted into the abdomen through the umbilicus. Pneumo peritoneum was created with carbon dioxide (CO2). Optical imaging was placed into the abdomen from the umbilicus with 10-trochar. Auxiliary trochars from 3 centimeter supero-medial of both spina iliaca anterior superior were placed in the abdomen. bilateral tubas were isolated. Bilateral tubal ligation was performed with the help of bipolar cautery. bleeding control was achieved. trochars were taken out of the abdomen. the skin was closed.
10126703|NCT04332120|Active Comparator|posterior colpotomy|The patient underwent spinal anesthesia and was placed in a high lithotomy position. cervical uteri was observed with the help of speculum. A 3 centimeter vertical incision was opened 2 centimeter below the cervix uteri. Peritoneal cavity was entered from this area. bilateral tubas were isolated. Bilateral tubal ligation was performed using the pomeroy method. bleeding control was achieved. peritoneal and posterior cervical incision line was repaired.
10126704|NCT04332224|Experimental|Non-shivering cooling group|Cooling devices
10126705|NCT04332003|Active Comparator|RIC Treatment|Participants will receive active RIC treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
10126706|NCT04332003|No Intervention|SHAM Comparator|Participants will receive sham treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
10126707|NCT04331925|Other|Anxiety and depression screening|Hospital Anxiety and Depression Scale (HADS) questionnaire administered at the start of the study. After two weeks or at the time of discharge, participants will complete the HADS questionnaire again
10126708|NCT04331925|Experimental|Anxiety and depression screening with journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period. They will also complete the HADS questionnaire before and after the intervention period of two weeks. At the end of the intervention period, these parents will also complete a survey regarding their experience with journaling
10126709|NCT04331808|Experimental|TOCILIZUMAB|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
10126710|NCT04331808|No Intervention|Standard of care|
10126711|NCT04331873|Experimental|Ultrasound|An ultrasound will be obtained to evaluate placement of the gastrostomy tube prior to obtaining the standard contrast injection
10126712|NCT04331834|Experimental|Pre-exposure prophylaxis of SARS-CoV-2|Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
10126713|NCT04331834|Placebo Comparator|Control group with placebo|Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
10126714|NCT04332016||COVID-19 infected patients|
10126715|NCT04331652|Experimental|Polypectomy without anesthesia or analgo-sedation|Patient will undergo polypectomy without anesthesia.
10126716|NCT04332146|Experimental|Mindfulness-based intervention|
10126717|NCT04332146|Active Comparator|Booklet-based psychoeducation group|
10126718|NCT04331743|Experimental|PLM60|"Three dose levels will be tested according to the 3 + 3 dose-escalation design.The dose-limiting toxicity (DLT) will be assessed from the first administration of PLM60 to the end of the first cycle (28 days)."
10126719|NCT04331730|Experimental|AKST4290 (800 mg) + Aflibercept|Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
10126720|NCT04331730|Experimental|AKST4290 (1600 mg) + Aflibercept|Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
10126721|NCT04331730|Placebo Comparator|Placebo + Aflibercept|Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment
10126722|NCT04331626|Experimental|Low-dose Gemcitabine Combined With nivolumab|Bristol-myers squibb (BMS) company's nivolumab injection liquid (trade name: odiwal). Recommended dosage: 3mg/kg, intravenously injected once every 2 weeks for 60 minutes. As long as clinical benefit is observed, continue treatment with this product for up to 6 courses. Gemcitabine hydrochloride injection from eli lilly. Use 50% of the recommended dose, i.e. 500mg/m2, intravenously for 30 minutes. Day 1 and day 8 administration. Depending on the patient's tolerance to gemcitabine, a reduced dose may be considered for each treatment cycle or one treatment cycle. Use for 1 year. If a Ⅲ magnitude of adverse reactions, it is necessary to permanently discontinued.
10126723|NCT04331795|Experimental|Group A|Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation
10126724|NCT04331795|Experimental|Group B|Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation
10126725|NCT04331665|Experimental|Ruxolitinib to prevent COVID-19 pneumonia|All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.
10126726|NCT04331691|Active Comparator|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
10126727|NCT04331691|Experimental|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
10126728|NCT04331951|Experimental|Targeted biopsy within Sydney Protocol|"The patients with history of gastric intestinal metaplasia will be included and using targeted biopsy within Sydney Protocol; both targeted biopsy at suspicious lesions and random biopsy at no suspicious area.~All tissues will be sent to immunohistochemistry as a gold standard.~Sensitivity, specificity,positive predictive value, negative predictive value, accuracy will be calculated."
10126729|NCT04331535|Experimental|Polygenic risk score (PRS) - high risk stratum|Patient-participants in the PRS-high arm and their providers will receive their high-PRS results at baseline, along with educational resources about the results.
10126730|NCT04331535|Active Comparator|Usual care (UC) - high risk stratum|Patient-participants in the UC-high arm and their providers will receive their high-PRS results after a 24-month observation period, along with educational resources about the results.
10126731|NCT04331535|Experimental|Polygenic risk score (PRS) - average risk stratum|Patient-participants in the PRS-average arm and their providers will receive their average-PRS results at baseline, along with educational resources about the results.
10126732|NCT04331535|Active Comparator|Usual care (UC) - average risk stratum|Patient-participants in the UC-average arm and their providers will receive their average-PRS results after a 24-month observation period, along with educational resources about the results..
10126733|NCT04331600|Experimental|CHLOROQUINE|Standard of care + chloroquine phosphate + telemedical approach.
10126734|NCT04331600|Other|CONTROL GROUP|Standard of care + telemedical approach.
10126735|NCT04331522||Antibiotics|Children aged 0-18 years investigated for allergy to antibiotics
10126736|NCT04331522||Milk|Children aged 0-18 years investigated for allergy to milk
10126737|NCT04331522||Egg|Children aged 0-18 years investigated for allergy to egg
10126738|NCT04331522||Peanut|Children aged 0-18 years investigated for allergy to peanut
10126739|NCT04331522||Hazelnut|Children aged 0-18 years investigated for allergy to hazelnut
10126740|NCT04331522||Sesame|Children aged 0-18 years investigated for allergy to sesame
10126741|NCT04331522||Wheat|Children aged 0-18 years investigated for allergy to wheat
10126742|NCT04331522||walnut|Children aged 0-18 years investigated for allergy to walnut
10126743|NCT04331522||cashew|Children aged 0-18 years investigated for allergy to cashew
10126744|NCT04331522||Pistachio|Children aged 0-18 years investigated for allergy to pistachio
10126745|NCT04331522||Almond|Children aged 0-18 years investigated for allergy to almond
10126746|NCT04331522||Soy|Children aged 0-18 years investigated for allergy to soy
10126747|NCT04331522||Fish|Children aged 0-18 years investigated for allergy to fish
10126748|NCT04331522||Shellfish|Children aged 0-18 years investigated for allergy to shellfish
10126749|NCT04331522||Poppy seed|Children aged 0-18 years investigated for allergy to poppy seed
10126750|NCT04331444|Experimental|Group A, CGM|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group A (intervention) will, in similarity to the HCPs, receive a CGM-education and training session led by the study investigator and will be interactive and hands-on, using case studies. The training session will include spoken and written instructions on how to insert and wear the CGM device and how to interpret the CGM information to better understand the relation between participants blood glucose and their diabetes self-management."
9669035|NCT04266639|Active Comparator|Remote Ischemic Conditioning|"Remote Ischemic Conditioning (RIC) is applied during the in-hospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be 200 mmHg; if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~Initial Remote Ischemic Conditioning: < 2 hours from inclusion~Remote Ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy"
10126751|NCT04331444|Experimental|Group B, CGM + peer-support|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin plus 3 sessions of peer-support in groups of 6 participants.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group B (intervention incl. peer-support) will, in similarity to group A, receive a CGM-education and training session. The training and CGM-course for participants in group B are similar to the course for group A with the addition of three peer-support sessions. The approach will be participatory and adaptable to allow flexibility in the content of the peer-support sessions and involving customized use of participatory methods i.e. dialogue tools and exercises."
10126752|NCT04331444|Active Comparator|Group C, SMBG|"Standard self-monitoring of blood glucose according to standard guidelines, in 12 months.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly."
10126753|NCT04331613|Experimental|CAStem|A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg. If there is no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose.
10126754|NCT04331678|No Intervention|Usual Care|Participants will be complete survey at enrollment and then again in 3 months.
10126755|NCT04331678|Active Comparator|Active|"Participants in the App group will receive usual care and complete survey at enrollment and then again in 3 months.~In addition, they will be asked to download the study app to their mobile device and use it at least once per week during the 3-month study period."
10126756|NCT04331418|No Intervention|control group|"On arrival to operating room, Noninvasive monitors, such as electrocardiography, noninvasive blood pressure (NIBP), oxygen saturation (SpO2), will be attached and baseline parameters such as heart rate, mean arterial pressure, and peripheral oxygen saturation will be recorded .~General anesthesia will be induced with O2/sevo (FiO2 = 1 /sevoflurane 8% MAC), cis-atracurium 0.1 mg/kg iv, +/- fentanyl 1 mcg/kg iv. Trachea will be intubated with an appropriate sized, endotracheal tube and maintenance of anesthesia by O2/Air (FiO2 = 0.4), sevoflurane 2% MAC.~Dexamethasone 0.15 mg/kg iv will be given as PONV prophylaxis. Increments of fentanyl 0.5 mcg/kg iv and cis-atracurium 0.03 mg/kg iv will be given according to hemodynamics and capnography."
10126757|NCT04331418|Experimental|caudal group|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
10126758|NCT04331418|Experimental|dexmetomidine group|Children in this group will be received (1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr) with a suggested maximum dose of 2 mcg/kg.of dexmedetomidine is available in a 100 mcg/mL concentration in a 2 mL preservative-free vial. It may be prepared as a 2 to 4 mcg/mL solution using normal saline
10126759|NCT04331574||covid-19 patients|Patients with certified diagnosis of COVID-19 recruited in Italian hospitals
10126760|NCT04331340|Experimental|Pharmacist Intervention|Pharmacist assessment of LUTS, with recommendations and education regarding lifestyle, behaviour, and/or medications related to bladder health. Follow-up at 3 and 6 weeks.
10126761|NCT04331340|Active Comparator|Control|Pharmacist questions regarding presence of LUTS, with provision of healthy aging literature. Follow-up at 6 weeks.
10126762|NCT04331470|Experimental|Levamisole Pill + Budesonide+Formoterol inhaler+Standard care|This group will take Levamisole + Budesonide/Formoterol along side with standard treatment regime.
10126763|NCT04331470|Active Comparator|Standard care|This group will take standard treatment regime introduced by Ministry of health.
10126764|NCT04331431|Other|spinal cord tumors|
10126765|NCT04331327|Active Comparator|Allogenic lyophilized growth factors|Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
10126766|NCT04331327|No Intervention|Standard of care|The patients were kept on their traditional medications without any intervention
10126767|NCT04331405|Experimental|Pilot group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received hUCBMC infusions weekly (4 infusions overall) in addition to standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
10126768|NCT04331405|No Intervention|Control group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
10126769|NCT04331197|Active Comparator|Clomiphene Citrate-High BMI women|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
10126770|NCT04331197|Active Comparator|Letrozole-High BMI women|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
10126771|NCT04331184|Experimental|RFA using combined bipolar and monopolar energy delivery|Control group: The historic cohort is used to compare the results of the conventional alternating unipolar radiofrequency energy transfer mode with RFA.
10126772|NCT04331210|Active Comparator|Group 1|Using diclofenac sodium suppository 50 mg immediately after suturing and then every 8 hours
10126773|NCT04331210|Active Comparator|Group 2|Using diclofenac sodium tablets 50 mg every 8 hours after birth
10126774|NCT04331314|Experimental|SYMBIOS®|Sinus augmentation with SYMBIOS® Biphasic Bone Graft Material
10126775|NCT04331314|Active Comparator|Algipore®|Sinus augmentation with Algipore® Bone Substitution Material
10126776|NCT04331392|Experimental|Spatial navigation intervention|
10126777|NCT04331392|Active Comparator|Educational Videos|
10126778|NCT04331054|Active Comparator|1: Usual practice|arm will be follow during 30 days
10126779|NCT04331054|Experimental|2: Usual practice + SYMBICORT RAPIHALER|Usual practice + SYMBICORT RAPIHALER 200/6 µg ( 2 puffs bid during 30 days)
10126780|NCT04331171||Web-application users|questionnaire of comorbidity and symptomes completed by the user on his smartphone
10126781|NCT04331132|Placebo Comparator|Conventional diuretic group|The conventional furosemide treatment will follow the modified 2019 Position Statement from the ESC Heart Failure Association
10126782|NCT04331132|Active Comparator|Vasopressin-2 antagonist group|Tolvaptan 15mg once daily for 2 days will be added-on the furosemide strategy based on the modified 2019 Position Statement from the ESC Heart Failure Association
10126783|NCT04330976|Experimental|Nutrition and physical activity intervention|
10126784|NCT04330976|Other|Control|
10126785|NCT04330963||Hypersomnolence group|All patients referred to the outpatient clinic/sleep center for investigation due to complaints for excessive daytime sleepiness (EDS) and/or Hypersomnia (H) and/or suspected central disorder of hypersomnolence (CDH)
10126786|NCT04330963||Healthy controls|
10126787|NCT04330963||SDB controls|Patients with EDS and diagnosis of severe sleep related breathing disorder (SBD) significantly improving with therapy.
10126788|NCT04330872|Active Comparator|Enteric coated Aspirin|"EC aspirin loading dose 300mg followed by 100 mg (2 days).~The study's total duration is 3 days."
10126789|NCT04330872|Placebo Comparator|Plain Aspirin|"Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days)~The study's total duration is 3 days."
10126790|NCT04331028|Experimental|Shockwave therapy|After dental extraction, a shockwave therapy will be applied to the area.
10126791|NCT04331028|No Intervention|Control|After dental extraction, no treatment will be applied
10126792|NCT04330911|Experimental|The HIIT Group (High Intensity Interval Training Group)|
10126793|NCT04330911|Experimental|The MICT Group (Moderate Intensity Continous Training Group)|
10126794|NCT04330820|Experimental|Venetoclax+Cytarabin+ Mitoxantron|The treatment plan combines a fixed dose of venetoclax and mitoxantrone with increasing doses of cytarabine (V-MAC).
10126795|NCT04331093|Experimental|resectable stage III-IV Acral melanoma|
10126796|NCT04330859|Experimental|Intervention|Parent-driven intervention bundle of 6 evidence-based elements: vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy
9669036|NCT04266639|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham Remote Ischemic Conditioning (Sham-RIC) is applied during the in-hospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be always be 20 mmHg.~Initial Sham Remote Ischemic Conditioning: < 2 hours from inclusion~Sham Remote ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy."
10126797|NCT04330859|Placebo Comparator|Routine care|Routine care per unit guidelines
10126798|NCT04330924|Experimental|Virtual Reality|3D avatar in a virtual simulation environment
10126799|NCT04330924|No Intervention|Live Simulation|Live-based simulation in a simulation ward
10126800|NCT04330937|Experimental|experimental group|volunteers consume 1 capsule per day for 3 months. (500 mg citrolive).
10126801|NCT04330937|Placebo Comparator|control group Placebo (sucrose)|volunteers consume 1 capsule per day for 3 months. (saccharose).
10126802|NCT04330794|Experimental|NMFACT|record the caries index using the NMFACT chart
10126803|NCT04330794|Active Comparator|DMF index|record the caries index using the DMF chart
10126804|NCT04330781|Experimental|Intervention group|N=123
10126805|NCT04330781|Active Comparator|Control group|N=31
10126806|NCT04331106||Population in Germany|Reasonably large and representative sample of the general population in Germany
10126807|NCT04330768|Experimental|PRF|
10126808|NCT04330768|Active Comparator|MTA|
10126809|NCT04330729|Experimental|Dialysis patients|Patients will tablet acetylsalicylic acid 75mg x 1 for 4 weeks.
10126810|NCT04330560|Experimental|Electronic Activity Tracking system (EATs)|Receive the mHealth intervention by wearing activity tracker link with to the healthcare system with standard care
10126811|NCT04330560|Active Comparator|Fitness Tracker (FT)|Receive the mHealth intervention by wearing activity tracker without the link to the healthcare system
10126812|NCT04330560|Placebo Comparator|Control (C)|Standard care only
10126813|NCT04330690|Experimental|Artesunate|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
10126814|NCT04330690|Experimental|Imatinib|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
10126815|NCT04330690|Experimental|Infliximab|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
10126816|NCT04330690|Experimental|Losartan|Subjects will be randomized between Losartan vs standard of care
10126817|NCT04330690|Experimental|Dexamethasone|Subjects will be randomized between Dexamethasone vs standard of care.
10126818|NCT04330690|Experimental|LSALT Peptide|Subjects will be randomized between LSALT vs standard of care.
10126819|NCT04330690|No Intervention|Control (Standard Care)|This arm will receive standard supportive care guidelines for COVID-19. It is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
10126820|NCT04330755|Placebo Comparator|Group C|Control group will received saline
10126821|NCT04330755|Active Comparator|Group L|Levosimendan group will received levosimendan infusion
10126822|NCT04330755|Active Comparator|Group M|Levosimendan and Magnesium sulphate group will received both drugs
10126823|NCT04330352|Experimental|"Mindfulness-based STOP touching your face intervention"|"Eligibility participants who are allocated to the intervention group will be required to find a time to monitor and record their behavior of hand-to-face contacts, including the frequency and length (in second) of face-touching in any of the mucosal area (eyes, nose, mouth) and nonmucosal area (ears, cheeks, chin, neck, forehead, hair) during a 60-minute period. Then, they will receive the online mindfulness-based STOP touching your face program. Each participant will be required to practice this technique until they feel confident and natural. The systematic review showed the efficacy of single session of brief MBIs, the average length was 15 minutes, ranged from less than 5 to 25 min. Thus, the requirement practice time will be at least 15 minutes (excluding the time of reading the text and the first time of listening to the audio). Later (at least 1-hour interval), they will be asked to self-monitor and report their one-hour face-touching behavior again."
10126824|NCT04330352|No Intervention|Contron information intervention|"Participants who allocate to the control group will only receive information to thank them and encourage them to complete the study. They will receive STOP touching your face program after the end of this study. The repeat measurement of the face-touching behavior will be in at least 1-hour interval."
10126825|NCT04330300|Experimental|Alternative anti-hypertensive medication|Switch to an alternative BP medication (specifically a Calcium channel blocker [CCB] or Thiazide/Thiazide-like diuretic at an equipotent blood pressure lowering dose). The choice of either CCB or Thiazide/Thiazide-like anti-hypertensive provided as alternative therapy will be at the discretion of the patient's treating physician.
10126826|NCT04330300|Active Comparator|Continue ACEi/ARB antihypertensive|Continue with either the ACEi (Angiotensin Converting Enzyme Inhibitor) or the Angiotensin Receptor Blocker (ARB) that had already been prescribed for the treatment of hypertension.
10126827|NCT04330508||Group A|Chronic hepatitis C without Cirrhosis
10126828|NCT04330508||Chronic hepatitis C with Cirrhosis|
10126829|NCT04330508||Healthy Volunteers|
10183533|NCT03763617|Active Comparator|Test group|A d-ptfe membrane will be placed between the buccal bone and periosteum of an extraction socket during a 4 months healing time before it is surgically removed.
10183534|NCT03763617|No Intervention|Control group|The extraction socket will be left to heal naturally without a socket preservation intervention.
10126830|NCT04330547|Active Comparator|Analgesic administration|"The analgesic treatment will be tailored to the patient's medication and will be based on 3 levels (based on Ventafridda et al., 1985):~Level 1 : Non-opioid analgesics~Level 2 : Weak opioids analgesics~Level 3 : Strong opioids analgesics~If the patient is already on pain medications, we will add the lowest effective dose of the level above the level of the regular pain medications of the patient. (e.g. if the patient has no analgesic treatment, he will be given a non-opioid analgesic (level 1). If he already has a level 1 treatment, we will go for level 2 medication. If he has level 2 treatment, we will go for level 3. And if the patient is already at level 3, we will increase the dosage by steps (reference: 5mg oxycodone as first choice for level 3 drugs)). Preferably, the medication will be administered by oral intake or gastrostomy feeding tube. If it is not possible, other routes of administration are allowed."
10126831|NCT04330547|Placebo Comparator|Placebo administration|Folavit capsules will be used as a placebo
10126832|NCT04330586|Experimental|Ciclesonide|Ciclesonide 320ug oral inhalation q12h for 14 days
10126833|NCT04330586|No Intervention|Control|Standard care without ciclesonide
10126834|NCT04330365|Active Comparator|Whole Health Team (WHT) Intervention Arm|The WHT intervention arm includes four core elements: 1) An interdisciplinary WHT collaborating with primary care; 2) Personalized Health Planning with prioritization of multi-modal non-pharmacological and CIH pain management approaches; 3) Whole Health Coaching sessions to assist patients in developing and implementing a Personalized Health Plan for chronic pain care; and 4) the web/mobile Whole Health Resource Directory provided to patient participants (in addition to their providers) to support non-pharmacologic/CIH chronic pain care.
10126835|NCT04330365|Active Comparator|Primary Care Group Education (PC-GE) Intervention Arm|Primary Care Group Education (PC-GE) iss the comparator arm, which is an abbreviated form of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) adapted for group use in primary care.
10126836|NCT04330365|Placebo Comparator|Usual Primary Care (UPC) Arm|In VA, patient-aligned care teams (PACTs) or primary care is step 1 of VA's Stepped Care Model in the treatment of chronic pain. PCPs are expected to possess the requisite skill set for management of common chronic pain-causing conditions, which includes biopsychosocial assessment, multi-modal treatment, and coordination of specialty pain care after shared-decision making that incorporates patient preferences and values. Participants randomized to this arm will continue to have their PCP and PACT serve in this role.
10126837|NCT04330443|Experimental|Ultrasound group|The neonatologist-researcher (NR) performed the lung ultrasound at admission during the first hour of life. The neonatologist-assistant (NA) of the baby was not blinded to the result of the lung ultrasound. If the patient had a lung ultrasound score higher than >8 or when FiO2 exceeded 30% patient received surfactant therapy during in the first 72 hours of life
10126838|NCT04330443|No Intervention|Chest X Ray|The NR performed the LUS at admission/suspicion during the first hour of life. The NA was not blinded to the result of the LUS. Patient received surfactant therapy only when FiO2 exceeded 30% during the first 72 hours of life
10126839|NCT04330573||Chronic Non-Specific Neck Pain|Patients with chronic non-specific neck pain. No interventions
10126840|NCT04330573||Control/Healthy Group|Volunteers without pain. No interventions.
10126841|NCT04330456|Experimental|SaE treatment|"This group will receive combined treatment of soft tissue sarcoma that include 3 steps:~step - preoperative stereotactic radiation therapy in hypofractionation mode (5 fractions 5 Gy each)~step - operation~step - postoperative conformal radiation therapy in normofractionation mode (25 fractions 2 Gy each)"
10126842|NCT04330495|Experimental|Testing and prophylaxis of SARS-CoV-2|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
10126843|NCT04330495|Active Comparator|placebo|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
10126844|NCT04330404|Experimental|Cognitive strategy training|The experimental group will receive the Cognitive strategy training (CST), which includes awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments.
10126845|NCT04330404|Active Comparator|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
10126846|NCT04330378||Hospital-at-home|All patients who are enrolled into the NUHS@Home Programme will be recruited into this arm. Patients will be sent home via ambulance, where they will be reviewed by a NUHS@Home nurse. Intravenous therapies, pillboxes for medication, remote monitoring software, and telecommunication tools will be set up as indicated. NUHS@Home doctors will visit at least once daily, and nurses at least twice daily as required. Therapists will conduct home visits as necessary. The NUHS@Home team is available 24/7. When conventional discharge criteria are met, the patient will be discharged. The NUHS@Home clinical team will be under clinical governance of Division of Advanced Internal Medicine at NUH and patients will be considered 'inpatients' throughout the treatment period.
9519545|NCT03286075|Experimental|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
10126847|NCT04330378||Usual in-hospital care|Patients who would otherwise be eligible for NUHS@Home but are not able to be enrolled due to capacity will be recruited into this arm. They will receive usual care in the wards that they are already in until they are discharged.
10126848|NCT04330378||Rejected cohort|Patients who were offered but declined enrolments inot the NUHS@Home programme will be approached for consent to be in the rejected cohort. There will be no change to the patient's clinical management.
10126849|NCT04330677|Experimental|1. Oxytocin spray, 2. Estrogen gel|
10126850|NCT04330677|Experimental|1. Oxytocin spray, 2. Placebo gel|
10126851|NCT04330677|Experimental|1. Placebo spray, 2. Estrogen gel|
10126852|NCT04330677|Placebo Comparator|1. Placebo spray, 2. Placebo gel|
9527671|NCT03218124|Experimental|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
10126853|NCT04330313|Experimental|Traction and stretching|This grup received stretching exercises after traction therapy for 18 sessions, 3 times per week.
10126854|NCT04330313|Experimental|Laser therapy and stretching|This grup received stretching exercises after laser therapy for 18 sessions, 3 times per week.
10126855|NCT04330313|Experimental|Hot pack and stretching|This grup received stretching exercises after hotpack therapy for 18 sessions, 3 times per week.
10126856|NCT04330313|Experimental|Stretching only|This grup received only stretching exercises for 18 sessions, 3 times per week.
10126857|NCT04330339|Experimental|Fasting|"Eligible participants will undergo baseline assessments prior to starting the intervention.~Baseline assessments include measurements of weight, height, quality of life, fatigue, mood, levels of physical activity, and blood markers.~Participants will fast for 13 hours nightly for 12 weeks.~Assessments will be repeated at the completion of the 12-week intervention."
10126858|NCT04330196|Experimental|Glucose condition|In the experimental condition patients ingest 200ml of water containing 75g of glucose
10126859|NCT04330196|Placebo Comparator|Control condition|In the control condition patients ingest 200ml of water sweetened with 700mg of aspartame
10126860|NCT04330261||SARS-CoV-2 Positive Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-positive for SARS-CoV-2 will be considered the exposed group in this study. These children will have exactly the same prospective follow-up as the other group.
10126861|NCT04330261||SARS-CoV-2 Negative Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-negative for SARS-CoV-2 will be considered the unexposed (control) group in this study. These children will have exactly the same prospective follow-up as the other group.
10126862|NCT04330209||LowGI/nutrigenetic|"114 overweight (n=1) and obese (n=113) subjects (M = 55, F = 59, age 24-56y, all of Romanian heritage and similar socio-economic status), who were patients at a weight management clinic (Bucharest, Romania), gave written informed consent for their weight loss data to be prospectively analysed for this study.~Upon enrolment at the weight management clinic, the subjects self-selected either a ketogenic diet or a low-GI nutrigenetic diet. 61 subjects (34 female; age 42.0 ± 6.7y) selected the low-GI nutrigenetic diet plan."
10126863|NCT04330209||Ketogenic|As above + Fifty-three subjects (25 female; age 43.0 ± 7.2y) selected the ketogenic diet plan
10183535|NCT03763565||Vaccinated group|Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old
10183536|NCT03763565||Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
10183537|NCT03763539|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
10183538|NCT03763539|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
10183539|NCT03763513|Active Comparator|ESWT|the first group:The group that will receive Extra corporeal shock wave therapy
10183540|NCT03763513|Experimental|ESWT+KT|the second group:The group that will receive Extra corporeal shock wave therapy + Kinesiotaping application
10183541|NCT03763500|No Intervention|Care as usual|"Regular care at participating hospitals:~Extended written information and education of patients with atrial fibrillation."
10183542|NCT03763500|Active Comparator|Internet-based education|Patients randomized in this arm receive an Internet-based educational program in addition to extended written information. This includes 6 steps with detailed information on background, symptoms, investigations, treatment options, life-style as well as one part with guides to self management.
10183543|NCT03763487|Experimental|Patients|Ultrasound examination: scaled to spleen size (spleen volumetry) Methodology of laboratory tests: venous blood sampling
10183544|NCT03763487|No Intervention|healthy blood donors|No intervention in this group.
10183545|NCT03763474|Experimental|Euglyca|Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
10183546|NCT03763474|No Intervention|Control|
10183547|NCT03763461|Experimental|HFNC|HFNC will be started at flow of 40 L/min and FiO2 of 40%.
10183548|NCT03763461|Other|Oxygen Mask|Standard non-humidified oxygen therapy via an oxygen mask at 6 l/min will be performed.
10183549|NCT03763448|Experimental|Infrapatellar Fat Pad Preservation|The IPFP retention of more than 80% in actual operation shall be regarded as IPFP retention.
10183550|NCT03763448|Active Comparator|Infrapatellar Fat Pad Resection|In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
10183551|NCT03763435||Antenatal Classes Received|Women who are involved into at least 3 comprehensive session of Antenatal pregnancy classes (educational) during the prenatal period.
10183552|NCT03763435||Without education|Groups are not randomized for not to give rise to ethical problems in order to maximize the community health care. Only women who are not involved into the educational classes due to their inaccessibility related to their own conditions or wishes.
10183553|NCT03763409|Experimental|losartan|50 mg single-dose oral losartan
10183554|NCT03763409|Placebo Comparator|placebo|microcellulose placebo in identical capsule
10183555|NCT03763396|Experimental|Ketoconazole (KCZ) Single Dose Group|Single dose 400mg oral tablets 4-24 hours prior to surgery
10183556|NCT03763396|Experimental|Ketoconazole (KCZ) Repeated Dose Group|400mg oral tablets twice a day (BID) for 2-5 days prior to surgery
10183557|NCT03763396|Experimental|Posaconazole (PCZ) Single Dose group|Single dose 300 mg delayed release oral tablets 4-24 hours prior to surgery
10126864|NCT04330612|No Intervention|Control|In the control pathway, the surgeons communicated with the family only once near the completion of the procedure.
10126865|NCT04330612|Experimental|Intervention|In the intervention group, the families received additional standardized electronic updates via pagers.
10126866|NCT04330027|Experimental|Growth factors|Patients in this group will receive one lyophilized Growth Factors injection supplied as a powder in a tightly sealed container.
10126867|NCT04330027|Placebo Comparator|Saline|Patients in this group will receive an injection with equal volume of saline; i.e 2ml of 0.9% sodium chloride.
10126868|NCT04330638|Placebo Comparator|Usual Care|
10126869|NCT04330638|Active Comparator|Anakinra|
10126870|NCT04330638|Active Comparator|Siltuximab|
10126871|NCT04330638|Active Comparator|Anakinra + Siltuximab|
10126872|NCT04330638|Active Comparator|Tocilizumab|
10126873|NCT04330638|Active Comparator|Anakinra + Tocilizumab|
10126874|NCT04330326|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
10126875|NCT04330326|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
10126876|NCT04330066||Exogenous hormone replacement thaw cycle|Participants in this group will follow Boston IVF's standard exogenous hormone replacement protocol. Participants will take Estrace 3mg twice daily by mouth for endometrial preparation. After 16-18 days of Estrace, endometrial thickness will be measured by transvaginal ultrasound but medication and ultrasounds will be continued until the endometrial lining is ≥ 7 mm. Once the final endometrial lining is ≥ 7 mm (T1), the doctor of record will start the participant the following day with intramuscular progesterone daily or intramuscular progesterone every 3 days with daily vaginal progesterone. Frozen embryo transfers would occur on the sixth day of progesterone.
10126877|NCT04330066||Natural thaw cycle|Participants in this group will follow Boston IVF's standard natural thaw cycle protocol. Participants will be coming for blood and transvaginal ultrasound monitoring around day 11 of the participants cycle. Once the participant has a final measurement of the endometrial lining ≥ 7 mm (T1), a 17mm ovarian follicle, and a progesterone < 1.2 ng/mL, the doctor of record will schedule the patient to receive a trigger injection to induce ovulation followed by an embryo transfer 6-7 days later. Participants may be started on vaginal progesterone 4 days after the trigger injection for added supplementation per the doctor of record.
10126878|NCT04330469|Experimental|Periodontal therapy|Patients offered periodontal therapy in 2-4 sittings (n=40), Dental hygiene advised
10126879|NCT04330469|Sham Comparator|Control|Patients given standard medical treatment (n=40), Dental hygiene advised
10126880|NCT04330053|Experimental|Experimental|Information - Education about falls and Exercise for Fall Prevention
10126881|NCT04330053|Active Comparator|Control|Information - Education about falls without Exercise for Fall Prevention
10126882|NCT04330079|Experimental|Dapagliflozin|
10126883|NCT04330079|Other|Lifestyle modification|
10126884|NCT04329910||Lean|BMI < 25
10126885|NCT04329910||overweight|BMI 25 - 29.9
10126886|NCT04329910||class i obesity|BMI 30 -34.9
10126887|NCT04329910||class ii obesity|BMI 35 - 39.9
10126888|NCT04329910||class iii obesity|BMI >= 40
10126889|NCT04330235||Intervention Group|Children 2-10 years of age dining at fast-food restaurants in New York City and Philadelphia, where a healthy default beverage policy will be enacted.
10126890|NCT04330235||Control Group|Children 2-10 years of age dining at fast-food restaurants in northern New Jersey, where a healthy default beverage policy will not be enacted.
10126891|NCT04329793|Experimental|Intervention arm|Assisted gait training with Walkbot System and their usual Physical Therapy.
10126892|NCT04329793|Active Comparator|Control arm|Their usual Physical Therapy.
10126893|NCT04329676|Experimental|Deep Brain Stimulation|Patients will undergo bilateral implant of directSTIM system in the STN.
10126894|NCT04329689|Experimental|septal myectomy alone versus septal myectomy|"The aims of the present study is to:~Compare the results of adequate septal myectomy alone versus septal myectomy + mitral repair in patients with HOCM.~Effect of mitral repair on outcome of patients with systolic anterior motion that accompanies HOCM."
10126895|NCT04329845|Active Comparator|open splenectomy for splenic injury in trauma|open splenectomy as a technique for removal of the spleen in case of injury to spleen
10126896|NCT04329845|Active Comparator|laparoscopic splenectomy for splenic injury in trauma|laparoscopic splenectomy as a technique for removal of the spleen in case of injury to spleen
10126897|NCT04329624|Active Comparator|Levosimendan|Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours. Infusion will be started with surgical skin incision.
10126898|NCT04329624|Placebo Comparator|Placebo|Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours. Infusion will be started with surgical skin incision.
10126899|NCT04329611|Active Comparator|hydroxychloroquine|hydroxychloroquine 400 mg po bid loading dose for 1 day followed by 200 mg po twice daily for 4 days
10126900|NCT04329611|Placebo Comparator|Placebo|Matching Placebo
10126901|NCT04329637|Active Comparator|IHC (intergrative health care) arm|Meditation and care coordination in addition to usual care
10126902|NCT04329637|No Intervention|usual care|usual care
10126903|NCT04329650|Experimental|Siltuximab 11mg/Kg|
10126904|NCT04329650|Active Comparator|Methylprednisolone 250mg/24h|
10126905|NCT04329884|Active Comparator|Intra-articular corticosteroid injections|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. Radiology guidance will be used to guide needle placement within the affected hip to administer lidocaine and a corticosteroid intra-articularly.
10183558|NCT03763396|Experimental|Posaconazole (PCZ) Repeated Dose group|300 mg delayed release oral tablets twice a day (BID) for day 1; every day thereafter is a single dose of 300 mg delayed release oral tablets. Total treatment time is 7-10 days prior to surgery.
10183559|NCT03763383||Free lateral arm flap|included patients who had free lateral Arm flap
10183560|NCT03763383||pedicled lateral arm flap|included patients who had pedicled lateral arm flap
10126906|NCT04329884|Active Comparator|Cooled radiofrequency ablation|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. The HALYARD* COOLIEF* SINERGY* Cooled Radiofrequency Probe (sterile, single use) is inserted through a COOLIEF* SINERGY* Introducer used with fluoroscopy guidance in the AP view to visualize the hip joint and sensory nerve areas over the acetabulum (femoral) and ischium (obturator) where the cooled radiofrequency ablation will be applied to create a focal thermal lesion to encompass and denervate the targeted nerves.
10126907|NCT04329897|Experimental|Software Messaging|Acceptance and Commitment Therapy Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy
10126908|NCT04329897|No Intervention|Control|Subjects randomizing into this arm did not receive the text message study intervention.
10126909|NCT04329949|Experimental|Relacorilant with nab-paclitaxel|Patients will be treated with relacorilant, administered orally, once daily in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
10126910|NCT04329741|Experimental|Intervention|6-week basic dog obedience training course
10126911|NCT04329741|No Intervention|Control|Waitlist control
10126912|NCT04329858|Active Comparator|conventional glass ionomer|
10126913|NCT04329858|Experimental|zinc modified glass ionomer|
10126914|NCT04329858|Experimental|silver modified glass ionomer|
10126915|NCT04329806|Experimental|Moxonidine|Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
10126916|NCT04329806|Active Comparator|Amlodipine|Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
10126917|NCT04330144|Experimental|administration of hydroxychloroquine as PEP|
10126918|NCT04330144|Active Comparator|control with no PEP|
10126919|NCT04329988||Primary care patients aged 18 or more|All patients consulting in a general practitioner office, aged 18 or more, who completed the questionnaire
10126920|NCT04329962|Experimental|Group I (blueberry extract, blueberry powder)|Participants undergo a washout on days -7 to -1 and then consume blueberry extract confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry powder confection on day 8.
10126921|NCT04329962|Experimental|Group II (blueberry powder, blueberry extract)|Participants undergo a washout on days -7 to -1 and then consume blueberry powder confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry extract confection on day 8.
10126922|NCT04329663|Experimental|training group|Ten children with ADHD who got the 20 sessions training of the Indonesian computer-based game prototype. They we were assessed by CATPRS, BRIEF and fMRI BOLD
10126923|NCT04329546||Cases|Cases are patients with COVID-19.
10126924|NCT04329546||Contacts|Contacts are household contacts of an index (case) patient.
10126925|NCT04329585|Experimental|GABA antagonist|In the end of the experiment, 0.2mg of flumazenil(GABA antagonist) is given to the participant.
10126926|NCT04329585|Placebo Comparator|Placebo|In the end of the experiment, the same volume of normal saline is given to the participant.
10126927|NCT04329455||Intervention group|
10126928|NCT04329468|Experimental|DS-MCE examination|Subjects with or without digestive symptoms will be enrolled to take DS-MCE and conventional esophagogastroduodenoscopy (EGD) within 48h successively.
10126929|NCT04329572|Experimental|HCQ + AZT|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) and AZT (500 mg/ 5 days) on top of standard care.
10126930|NCT04329754|Other|iPure|"IPure IOL (PhysIOL, Belgium): a new single-piece hydrophobic acrylic IOL. The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration.~Patient were allocated into two groups. The study group received the iPure lens (Physiol, Liege) while the control group received Tecnis ZCB00 (Johnson&Johnson). Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
10126931|NCT04329754|Other|ZCB00|"ZCB00 IOL (Johnson&Johnson, United States): a standard IOL.The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design.~Patient were allocated into two groups. The study group received the iPure lens (Physiol, Liege) while the control group received Tecnis ZCB00 (Johnson&Johnson). Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
10126932|NCT04329416|Other|Predicted depth of insertion|The predicted insertion depth of the DLT was calculated using the formula [0.249 x (BH) 0.916] before induction of anesthesia using an application on the smartphone
10126933|NCT04329338|No Intervention|Gut and vaginal sample collection|Gut and vaginal samples were collected for Nugent score, and 16S rRNA metagenomics communities.
10126934|NCT04329338|Experimental|Gut and Vaginal sample after Lactobacillus|Seven women diagnosed with BV by Nugent score (7-10) provided vaginal and gut sample after 14 days oral intake of 3 grams (2.5X108 cfu/g) of Lactobacillus pentosus KCA1
10126935|NCT04329247|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 6 weeks.
10126936|NCT04329247|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 6 weeks. After this period of time, participants will begin the best treatment available.
10126937|NCT04329364|Experimental|Laser Haemorrhoidoplasty (LAH)|treatment that we would like to study
10126938|NCT04329364|Active Comparator|Conventional Open Haemorrhoidectomy (COH)|gold standard treatment as comparator
9527672|NCT03217851||Patients Presenting P. falciparum Malaria|
10126939|NCT04329533|Experimental|Intervention Group - access to meditation app|"Will receive a 30-day free trial of the mobile meditation app Calm on study day 0"
10126940|NCT04329533|No Intervention|Control Group - no access to meditation app|"Will not have the intervention until after the 30 day study period and then will receive a 30-day free trial of the mobile meditation app Calm on study day 30"
10126941|NCT04329273|Experimental|Training group|"For the balance exercise the participants will perform one-legged stance of certain duration, on a stable surface.~For the sliding leg curl exercise the participants lay supine on a mat, wearing only socks in order to create a slippery surface between their heels and the gym floor. The player begins by extending the hip and having the working leg on knee flexion. The contralateral limb is on hip flexion and knee flexion. The base of support is the shoulder blades, the elbows and the heel of the working leg. After assuming this position, the player begins to extend the knee, as slowly as possible, resisting the low friction properties of the ground.~The core stability program consists of front plank, side planks, supine bridge, leg lowering and superman exercise. These exercises will be performed at the end of the training session, in contrast to the balance and hamstring exercises which will be executed before the training session."
10126942|NCT04329273|No Intervention|Control group|The participants in this group will follow only the usual training program
10126943|NCT04329377||platelet count in iiron overload|
10126944|NCT04329403|Experimental|Test Group|Adapalene Gel, 0.1%, applied as thin film once daily for 12 weeks
10126945|NCT04329403|Active Comparator|Reference Group|Differin® (Adapalene) Gel, 0.1%, applied as thin film once daily for 12 weeks
10126946|NCT04329403|Placebo Comparator|Placebo Group|Placebo Gel, 0.1%, applied as thin film once daily for 12 weeks
10126947|NCT04329390||anticoagulant|Subjects of both sexes, aged 18 years or older, requiring the prescription of, or already on oral anticoagulant treatment, will be eligible for the study, irrespective of the index event, of the intended treatment duration, and the type of drug used.
10126948|NCT04329442|Experimental|PrEP Received|Participants will be provided with a free 30-day supply of PrEP.
10126949|NCT04329351|Experimental|Guided bone regeneration Group|After extraction, Guided bone regeneration was conducted using the PTFE-d membrane (CytoplastTM Ti-250 Titanium-Reinforced, Anterior Narrow 12 mm x 24 mm, Osteogenics, Lubbock, TX, USA) was customized with scissors and adjusted over the socket, exceeding three millimeters from its margins. Then, the membrane was inserted subperiostally under the buccal and palatal flaps with the help of the Molt detacher. Minimal flap reflection was performed to stabilize the membrane, which was maintained intentionally exposed to the oral environment. Before suturing, the passive stability of the membrane over the alveolus was confirmed, as well as the absence of folds or wrinkles in the membrane. The flaps were then be approached in the pre-extraction position and sutured with crossed sutures, aiming to increase the stability of the membrane, with PTFE 4-0 thread (Cytoplast PTFE, CS0618PREM, Osteogenics, Lubbock, TX, USA).
10126950|NCT04329351|Placebo Comparator|Non-Guided bone regeneration group|After extraction, no further treatment (No addition of Guided bone regeneration) was performed. The flaps were then repositioned and sutured with 5.0 nylon thread (Ethicon, Jonhson's Jonhson, São José dos Campos).
10126951|NCT04329299||Blood Biomarkers Analyses|15 ml of blood sample will be obtained from each study participant, for blood-based biomarkers analyses.
10126952|NCT04329052|Experimental|Experimental group|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
10126953|NCT04329052|No Intervention|Control group|Participants would have their usual activity without any intervention.
10126954|NCT04329130|Experimental|Chidamide combined Lenalidomide|"Chidamide, 20 mg, twice per week; lenalidomide, 25 mg, d1-21, and rest for 7 days.~one treatment cycle per 28 days.For patients with limited lesions and good drug response, local radiotherapy may be assessed by the investigator."
10126955|NCT04329195|Experimental|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
10126956|NCT04329195|Active Comparator|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
10126957|NCT04329429|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.5 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
10126958|NCT04329143|Active Comparator|open completion cholecystectomy|open completion cholecystectomy for cystic duct stump stone
10126959|NCT04329143|Active Comparator|laparoscopic completion cholecystectomy|lap completion cholecystectomy for cystic duct stump stone
10126960|NCT04329208||Cerebral vasospasm|13 patients developed symptomatic cerebral vasospasm detected by CT angiography and TCD
10126961|NCT04329208||Non Vasospasm|27 patients without cerebral vasospasm
10126962|NCT04329156|Experimental|Digitally Flip Technique|
10126963|NCT04329156|Active Comparator|Stock Healing Abutment|
10126964|NCT04329091|Experimental|Dexmedetomidine Arm|Dexmedetomidine: Administration of a 0.5 mcg/kg bolus followed by an infusion of 0.5-0.7 mcg/kg/hr, titrated up by 0.1 mcg every 1 minute until the subject spontaneously closes his or her eyes. When the subject spontaneously closes his or her eyes the infusion continues for 90 minutes from that point.
10126965|NCT04329234||acute heart failure|Patients with acute heart failure
10126966|NCT04329169|Experimental|Virtual Implant Planning|
10126967|NCT04328974||the lumbar CSF drainage group|We named the patients treated with the protocol and the lumbar CSF drainage as the lumbar CSF drainage group.
10126968|NCT04328870|Active Comparator|oxytocin and spinal anesthesia|spinal anesthesia combined with intravenous oxytocin infusion
10126969|NCT04328870|Active Comparator|general anesthsia|general anesthesia alone
10126970|NCT04329026|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
10126971|NCT04329026|Placebo Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
10126972|NCT04328935|Experimental|written exposure therapy|The treatment consists of written exposure therapy (WET), which is manualized trauma-focused CBT in five sessions over 5 weeks.
9669037|NCT04266639|No Intervention|Controls|The control group will not receive treatment with Remote Ischemic Conditioning.
10126973|NCT04328805|Experimental|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
10126974|NCT04328805|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
10126975|NCT04329000|Experimental|On-demand PPI therapy|The patients in this group were advised to take PPI for 8 weeks continuously, followed by on-demand PPI therapy for the following 40 weeks.
10126976|NCT04329000|Active Comparator|Continuous PPI therapy|The patients in this group were advised to take PPI QD continuously for 48 weeks.
10126977|NCT04328987||Clopidogrel user|"* Uninterrupted (continuous) use of clopidogrel: cessation of clopidogrel less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of clopidogrel is sum of before and after the CSP~patient who stopped clopidogrel only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 1 day.~patient who stopped clopidogrel from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of clopidogrel -> excluded from study.~patient who stopped clopidogrel from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of clopidogrel was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of clopidogrel -> excluded from study."
10126978|NCT04328987||Aspirin user|"* Uninterrupted (continuous) use of aspirin: cessation of aspirin less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of aspirin is sum of before and after the CSP~patient who stopped aspirin only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 1 day.~patient who stopped aspirin from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of aspirin -> excluded from study.~patient who stopped aspirin from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of aspirin was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of aspirin -> excluded from study."
10126979|NCT04328844|Experimental|Single arm with IOA-244|
10126980|NCT04328922|Active Comparator|Fecal microbial transplantation|FMT capsules fecal capsules on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will be matched to donors according to their CMV status (past exposure - CMV positive donors will be used for CMV positive patients, and CMV negative donors will be used for CMV negative patients).
10126981|NCT04328922|Placebo Comparator|Placebo|Placebo capsules placebo capsules- on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will receive placebo capsules.
10126982|NCT04328883|Active Comparator|162 mg Non-Enteric-Coated Chewable aspirin|Non-enteric coated aspirin (162mg, single dose)
10126983|NCT04328883|Experimental|50 mg ASA inhalation powder|Dry powder inhaled aspirin (50mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
10126984|NCT04328883|Experimental|100 mg ASA inhalation powder|Dry powder inhaled aspirin (100mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
10126985|NCT04328831|Other|IBI322|Single arm
10126986|NCT04329013|Active Comparator|Left lateral position|The patient will be in left lateral position during EGD
10126987|NCT04329013|Experimental|Prone position|The patient will be in prone position during EGD
10126988|NCT04328766|Experimental|DWP14012 Cohort A|
10126989|NCT04328766|Experimental|DWP14012 Cohort B|
9827431|NCT02455050|Other|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
10126990|NCT04328766|Experimental|DWP14012 Cohort C|
10126991|NCT04328792||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
10126992|NCT04328571|Experimental|OLE enzymatically treated|Participants will receive 1 capsule of OLE enzymatically treated + 1 stick of maltodextrin each day in the morning for 21 days
10126993|NCT04328571|Experimental|OLE + probiotic|Participants will receive 1 capsule of OLE + 1 stick of probiotic each day in the morning for 21 days
10126994|NCT04328571|Active Comparator|OLE|Participants will receive 1 capsule of OLE + 1 stick of maltodextrin each day in the morning for 21 days
10126995|NCT04328896|Experimental|Intervention|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Dexcom G5/6) that communicates via smart phone to a Tidepool designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Tidepool dashboard automatically emails daily alerts to the Certified Diabetes Educator (CDE). If alerts occurred, the CDE performed telemedicine outreach based on type of alert.
10126996|NCT04328545|Experimental|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 mins duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
10126997|NCT04328545|Active Comparator|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
9967621|NCT01271556|Placebo Comparator|2, placebo, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (placeboI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
9669038|NCT04257565|Active Comparator|Control group|The Control Group will receive usual and customary care from their vascular specialist.
10126998|NCT04328545|Sham Comparator|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
10126999|NCT04328597||Chronic postoperative pain|Patients scoring 3 or more on the EuraHS Quality of Life assessment after elective inguinal hernia repair
10127000|NCT04328597||Non chronic postoperative pain|Patients scoring less than 3 on the EuraHS Quality of Life assessment after elective inguinal hernia repair
10127001|NCT04328610|Experimental|LYMPHA technique group|LVA at the time of Axillary Dissection
10127002|NCT04328610|No Intervention|Non-LYMPHA technique group|No preventive surgical approach
10127003|NCT04328701|Experimental|Mindfulness-based CBT|All participants will receive four individual mindfulness-based CBT sessions.
10127004|NCT04328701|No Intervention|Treatment as Usual|All participants will undergo surgery as usual, with no additional intervention.
10127005|NCT04328636|Experimental|NebMag|Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo
10127006|NCT04328636|Active Comparator|IVMag|Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo
10127007|NCT04328753|Experimental|super oxidized water group|
10127008|NCT04328753|Active Comparator|chlorhexidene group|
10127009|NCT04328753|Placebo Comparator|distilled water|
10127010|NCT04328233|Experimental|Time-Restricted Eating|
10127011|NCT04328493|No Intervention|Control arm|Patients randomized to the control arm will receive a standard of care therapy (a supportive care/treatment according to VN MoH's guideline).
10127012|NCT04328493|Experimental|Intervention arm|"In addition to standard of care therapy, patients randomized to the intervention arm receive chloroquine phosphate as below.~For adult ≥ 53kg: 1000mg (4 tablets) at initial dose (T=0), followed by 500mg (2 tablets) at 6 hours later (T=6), and 500mg (2 tablets) once daily for 9 days.~For adult from 45 - 52kg: 875mg (3.5 tablets) at T=0, followed by 500mg (2 tablets) at T=6 and 500mg (2 tablets) once daily thereafter.~For adult weighted 38 -<45 kg: 750mg (3 tablets) at T=0, followed by 375mg (1.5 tablets) at T = 6 and 375mg (1.5 tablets) once daily thereafter.~For adult weighted <38 kg: 625mg (2.5 tablets) at T=0, followed by 375mg (1.5 tablets) at T=6 and 375mg (1.5 tablets) once daily thereafter.~The total duration of treatment with chloroquine will be 10 days."
10127013|NCT04328181|Experimental|SPCCT and standard DECT|Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
10127014|NCT04328246|Experimental|IES Device + Standard of Care|Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.
10127015|NCT04328246|Active Comparator|Standard of Care|Standard of care treatment for pressure injuries is turning the patient every two hours.
10127016|NCT04328168|Active Comparator|Group1|Conventional Physiotherapy
10127017|NCT04328168|Active Comparator|Group2|robot-assisted gait training
10127018|NCT04328519||patient(hospitalized)|patients who are admitted to the emergency department and hospitalized.
10127019|NCT04328519||control(not hospitalized)|patients who are admitted to the emergency department and not hospitalized.
10127020|NCT04328415|Experimental|healthy volunteers|
10127021|NCT04328415|Experimental|patients with Chronic Kidney Disease|
10127022|NCT04328363|Experimental|Intervention|The intervention will be carried out by primary care nurses over eight visits: baseline visit and follow-up visits which take place 15 days, 1, 2, 4, 6, 9, and 12 months after baseline with a final visit evaluation at 18 months. The intervention will be based on the social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles in people with prediabetes. The content of the intervention proposed is based on the NHS and it will be carried out at three levels (individual, group and community) to facilitate the patient empowerment and promotion of healthy lifestyles with a positive orientation using the community resources.
10127023|NCT04328363|No Intervention|Control|The Control group will receive routine standard care.
10127024|NCT04328350||AYA who are on treatment 2-12 months post -diagnosis|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (30 on-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
10127025|NCT04328350||AYA who are off -therapy 1 to 4 years|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.~Participants (20 off-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
10127026|NCT04328428|Experimental|(A)modified BL40 acupuncture|modified BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain.
10127027|NCT04328428|Active Comparator|(B)EM32 acupuncture|EM32 acupuncture Participants receive EM32 acupuncture once on the opposite site.
10127028|NCT04328428|Active Comparator|(C)BL40 acupuncture|BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain
10127029|NCT04328441|Experimental|BCG vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis.
10127030|NCT04328441|Placebo Comparator|Placebo|Intracutaneously 0.1ml of 0.9% NaCl solution
10127031|NCT04328285|Experimental|Hydroxychloroquine (HCQ) vs Placebo|"Group 1.1: HCQ 200 mg : 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards~Group 1.2: Placebo of HCQ, 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards."
10127032|NCT04328285|Experimental|Lopinavir/ritonavir (LPV/r) vs Placebo|"Group 2.1: LPV/r 200/50 mg, 2 tablets twice daily~Group 2.2: Placebo of LPV/r, 2 tablets twice daily"
10127033|NCT04328402||Children and adolescents submitted to PSG in sleep laboratory|Children (1 to 11 years) and adolescents (12 to 18 years), who were referred to a sleep laboratory and submitted to full-night polysomnography due to suspicious of sleep disorders.
10127034|NCT04328155|Experimental|Hotpack Group|Group I (15 subjects) received 18 sessions hotpack to hamstring muscles and self stretching exercise3 times per week.
10127035|NCT04328155|Experimental|Infrared Group|Group II (15 subjects) received 18 sessions infrared to hamstring muscles and self stretching exercise3 times per week.
10127036|NCT04328155|Experimental|Ultrasound Group|Group III (15 subjects) received 18 sessions ultrasound to hamstring muscles and self stretching exercise 3 times per week.
10127037|NCT04328155|Active Comparator|Control|Group IV (15 subjects) received 18 sessions self stretching exercise 3 times per week.
10127038|NCT04328480|Active Comparator|Local standard of care plus colchicine|Local standard of care plus colchicine (specific dosage schedule)
10127039|NCT04328480|Other|Local standard of care|Local standard of care for COVID-19 SARS moderate / high-risk patients
10127040|NCT04328311|Experimental|Active|Watermelon juice
10127041|NCT04328311|Other|Control|Low nitrate water.
10127042|NCT04328337|Experimental|Non-diabetic, normal weight individuals receiving Intralipid|Non-diabetic, normal weight individuals receiving Intralipid. Participants will receive an infusion of Intralipid 20% for 12 hours through an IV (prior to and during scan #2)
10127043|NCT04328337|Placebo Comparator|Non-diabetic, normal weight individuals receiving saline|Non-diabetic, normal weight individuals receiving saline. Participants will receive an infusion of normal saline (1:1 randomization) at 30 ml/hr for 12 hours through an IV (prior to and during scan #2
10127044|NCT04328454||COVID-19 patients|Hospitalized patients with COVID-19
10183561|NCT03763357|Experimental|Heat Therapy|Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.
10183562|NCT03763344|Experimental|Cohort C|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (Baseline),~intervention is fourteen sessions of Perceptual Cognitive Training (PCT) for seven weeks,~a post-treatment cognitive assessment (Week 7), and~a follow up cognitive assessment (Week 11)"
10183563|NCT03763344|No Intervention|Cohort D|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (baseline),~seven weeks of no intervention,~a post-treatment cognitive assessment (week 7), and~a follow up cognitive assessment (week 11)"
10183564|NCT03763331|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 91.4 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks..
10183565|NCT03763331|Active Comparator|Heat Therapy|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 110 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks.
10183566|NCT03763318|Experimental|EQ001 Dose Escalation (Part A)|Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.
10183567|NCT03763318|Experimental|EQ001 (Part B)|EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.
10183568|NCT03763318|Placebo Comparator|EQ001 Placebo (Part B)|Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.
10183569|NCT03763305|Experimental|Total intravenous anesthesia (TIVA)|Study participants are anesthetized by total intravenous anesthesia (TIVA) using propofol continuous infusion and remifentanil continuous infusion. During induction of general anesthesia, participants receive 3~5mcg/mL Propofol Fresenius and 3~5ng/mL and Remifentanil [Ultiva] as initial effect site concentrations. The effect site concentration is controlled with target-controlled infusion to maintain bispectral index (BIS) values between 40 and 60.
10183570|NCT03763305|Experimental|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, sevoflurane inhalant solution [Sojourn] is used to maintain 1 age-related minimum alveolar concentration (MAC).
10183571|NCT03763305|Experimental|Desflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane [Suprane] is used to maintain 1 age-related minimum alveolar concentration (MAC).
10183572|NCT03763292|Experimental|Information brochure|Intervention: The parents are given a specific information brochure that describes the procedures that the child is going through during anesthesia when it has been decided that the child is going to have the surgery.
10183573|NCT03763292|No Intervention|Information as usual|Information as usual, i.e. oral information about the procedures to parents when they arrive at the hospital with the child that is going to have the surgery.
10183574|NCT03763279|Experimental|Triclosan-coated barbed suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone barbed suture
10183575|NCT03763279|Experimental|Triclosan-coated monofilament suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone monofilament suture
10183576|NCT03763279|Sham Comparator|Monofilament suture|Abdominal wall closure will be performed using a monofilament suture
10183577|NCT03763266|Experimental|1 day low residue diet|Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
10183578|NCT03763266|Active Comparator|3 days low residue diet|Patients are instructed to complete a low residue diet three days prior the colonoscopy.
10183579|NCT03763253|Active Comparator|Control Arm: Standard of Care (SOC)|"Standard of Care (SOC) treatment as determined by treating physician (positive control) (androgen deprivation with or without docetaxel chemotherapy or other systemic standard of care treatment including but not limited to Abiraterone or Enzalutamide).~Radiotherapy to the prostate in this arm is defined as cytoreductive (for symptom control) in high volume (>/=4) metastases or to mirror current accepted local radiotherapy dose regimens for men with low volume metastases (<4 metastases).~Metastases directed therapy will not be permitted in the control arm. Palliative radiotherapy for symptom control or for prevention of fracture will be permitted as standard clinical practice."
10127045|NCT04328389|Placebo Comparator|Placebo Comparator: electric toothbrush|Participats will be instructed to used electric toothbrush for home supragingival plaque removal
10127046|NCT04328389|Experimental|Professional oral hygiene|Full-Mouth professional oral hygiene consisting in scaling and root planing, four quadrants in one session.
10127047|NCT04328272|Experimental|Hydroxychloroquine|tablet hydroxychloroquine (HCQ). Day-1 (initial) 1st dose, 3 tablets (200 mg per tablet), 2nd dose after 6 hours, 3 tablets (200 mg per tablet) per oral. From day 2 to 7 (maintenance dose), 2 tablets twice a day.
10127048|NCT04328272|Active Comparator|Azithromycin|Tablet azithromycin (AZC) 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 7.
10127049|NCT04328272|Placebo Comparator|Suger Tablets|Placebo (sugar tablet) twice daily for 7 days
10127050|NCT04328194|Experimental|Study Group|80 patients with breast cancer
10127051|NCT04328194|Placebo Comparator|Control Group|20 healthy controls aged ( 19 to 69 years ) from healthy volunteers after informed consent.
10127052|NCT04328142|Experimental|Qigong|The Qigong experimental group performed the 20 figures to improve health and longevity described by the master of Qigong 'Wang Ziping'. These are based on therapeutic exercises of Traditional Chinese Medicine. They work on breathing, flexibility and balance. Each figure was repeated 6 times. The sessions were administered twice a week during 45 minutes and were guided by a Doctor in Western Medicine who is also qualified as a Doctor of Traditional Chinese Medicine and Qigong teacher.
10127053|NCT04328142|Experimental|Physiotherapy|The physiotherapy experimental group completed an active exercises program guided by a qualified physiotherapist. The exercise programme was based on active shoulder, hips and spine kinesiotherapy. It included a warm up of 3-5 minutes walking, followed by 6 repetitions of shoulder and hip exercises in standing, cervical spine exercises in sitting or standing, according to the comfort of the patient, thoracic and lumbar spine exercises performed in supine on a mat and balance exercises in standing. Stretching exercises were also performed at the end of the session. The exercises were accompanied by gentle breathing coordinated with the movements. The sessions were administered twice a week during 45 minutes.
10127054|NCT04328142|No Intervention|Control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
10127055|NCT04327778|Experimental|Music therapy|Patients will be exposed every two weeks
10127056|NCT04327791|Experimental|baloxavir|Baloxavir: 40 mg po once for wt < 80 kg OR 80 mg po once for wt >/= 80 kg
10127057|NCT04327791|Placebo Comparator|placebo|placebo po once
10127058|NCT04327934|Active Comparator|Healthy Control|Healthy control participants.
10127059|NCT04327934|Experimental|AE-PCOS|Participants with AE-PCOS.
10127060|NCT04327869||Abdominal symptoms group|The investigators selected 10 subjects (male: female = 1: 1) from patients with a recent history of upper-gastrointestinal symptoms who met the indication of taking sucralfate suspension gel
10127061|NCT04327869||Healthy control group|The investigators selected another 10 subjects (male: female = 1: 1) from healthy volunteers.
10127062|NCT04327947|Experimental|women, 18-39 y|Health volunteers, 18-39 y, with vaginal dryness
10127063|NCT04327947|Experimental|premenopause women|Health volunteers, 40 years to premenopause, with vaginal dryness
10127064|NCT04327947|Active Comparator|climacteric women|Health volunteers, climacteric, with vaginal dryness
10127065|NCT04327765|Experimental|Cohort 1|Single orally-inhaled dose
10127066|NCT04327765|Experimental|Cohort 2|Single orally-inhaled dose
9669039|NCT04257565|Experimental|Intervention Group|The Intervention Group will receive usual and customary care from their vascular specialist and they will be provided and trained to use the wheeled knee walker.
10127067|NCT04327765|Experimental|Cohort 3|Single orally-inhaled dose
10127068|NCT04328051|Active Comparator|Ocean E.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and external hexagon connection.
10127069|NCT04328051|Active Comparator|Ocean I.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and internal hexagon connection.
10127070|NCT04328051|Active Comparator|Ocean C.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and conical connection.
10127071|NCT04327830||Older adults and their caregivers|Older adults who have received or are receiving home care services and their caregivers
10127072|NCT04327830||Interdisciplinary health and social care providers|Interdisciplinary health and social care providers who provide home care services to older adults
10127073|NCT04327856||Cataract surgery group|Patients which were administrated to the Ophthalmology Clinic Medical University of Bialystok due to scheduled cataract removal surgery
10127074|NCT04328064|Active Comparator|Rosuvastatin Drug|Active drug-rosuvastatin 40 mg
10127075|NCT04328064|Placebo Comparator|Placebo drug|Placebo oral tablet
10127076|NCT04327713||fish oil supplementation|"fish oil supplementation, usually capsules with a defined content of EPA and DHA~dosage and duration of intervention differ between the included studies of our meta-analysis"
10127077|NCT04327713||placebo supplementation|"placebo supplementation, usually capsules with a defined content of non-fish oil or other components~content, dosage and duration of intervention differ between the included studies of our meta-analysis"
10127078|NCT04328077|Experimental|TERN-101 dose level 1|Orally administered.
10127079|NCT04328077|Experimental|TERN-101 dose level 2|Orally administered.
9827432|NCT02455050|Other|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
10127080|NCT04328077|Experimental|TERN-101 dose level 3|Orally administered.
10127081|NCT04328077|Placebo Comparator|Placebo|Orally administered.
10127082|NCT04327817|Other|Multifidus ReActiv8 stimulator|The Mainstay ReActiv8 is an implantable electrical stimulation system that consists of an implantable pulse generator, implantable leads, programmer, activator and magnet.
10127083|NCT04327726|Placebo Comparator|Control group|received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days
10127084|NCT04327726|Active Comparator|Dexmedetomidine group|received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score <2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.
10127085|NCT04328025|Active Comparator|Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP|"For TGW in the intervention arm, peers will deliver HIVST and PrEP medications monthly in between quarterly clinic visits. Quarterly clinic-based testing will confirm accuracy of self-tests and identify inaccurate test results. Additionally, peers will remind TGW to self-test before opening a new PrEP bottle. They will also distribute STI self-sampling kits to TGW for own use, and with regular partners as needed. They will present smart phone instructional videos showing trans women how to self-collect pharyngeal, rectal and urine specimens for Neisseria gonorrhoeae and Chlamydia trachomatis testing.~Peers will: a) motivate ongoing adherence; b) promote repeat HIV testing; and c) support PrEP use as problems arise. Self-sampling for STIs will be performed monthly by participants (with questions answered by the peer or other study staff as needed)."
10127086|NCT04328025|No Intervention|Facility-Delivered Care|Participants will receive facility-based HIV counseling, PrEP prescriptions condoms, risk reduction counseling, and management of sexually transmitted infections as standard of care.
10127087|NCT04328116||Study Group|Neodent GM Zygomatic Dental Implants will be placed. Multiple implants may be placed in a single subject.
10127088|NCT04327739|Experimental|Intervention 1 Exercise|Participants allocated to this group received a 10 weeks exercise programme for neck and upper limbs muscles
10127089|NCT04327739|Experimental|Intervention 2 Exercise and INIT|Participants allocated to this group received the same exercise programme as group 1 in combination with the integrated neuromuscular inhibition technique (INIT)
10127090|NCT04327739|Experimental|Intervention 3 Exercise and SMT|Participants allocated to this group received the same exercise programme as group 1 in combination with cervical manipulation
10127091|NCT04327739|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home based general exercise sheet
10127092|NCT04328103|Active Comparator|Cognitive Behavior Therapy (CBT)|Following established procedures at the Depression Evaluation Service (DES) at New York State Psychiatri Institute (NYSPI), 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
10127093|NCT04328103|Placebo Comparator|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
10127094|NCT04327661|Experimental|Tradipitant High Dose|
10127095|NCT04327661|Experimental|Tradipitant Low Dose|
10127096|NCT04327661|Placebo Comparator|Placebo|
10127097|NCT04327596|No Intervention|Conventional Treatment|Subjects will receive management of AF consisting of either rate or rhythm control.
10127098|NCT04327596|Active Comparator|AF Ablation|Subjects will undergo early RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter
10127099|NCT04327648|Active Comparator|Social interaction treatment|During the treatment days, children in social interaction treatment group will have 30min social interaction each day for 3 months. ASD children are followed up closely.
10127100|NCT04327648|Sham Comparator|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. ASD children are followed up closely.
10127101|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment. ASD children are followed up closely.
10127102|NCT04327245|Experimental|Intervention ingest a 5000 mg of D-tagatose|Intervention: Women with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.e.
10127103|NCT04327245|No Intervention|No Intervention: Intervention ingest a water (control group)|Woman with resistance insulin who ingest a water (control group)
10127104|NCT04327245|Experimental|Intervention ingest a 15,3 mg of stevia|"Intervention: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
10127105|NCT04327401|Experimental|Intervention group|Dexamethasone. After randomization, dexamethasone [20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days] + standard treatment (according to the treatment protocol for 2019-nCoV infection).
10127106|NCT04327401|No Intervention|Control|Standard treatment (according to the treatment protocol for 2019-nCoV infection).
10127107|NCT04327362|Experimental|Cluster 1: Sham to active tDCS crossover at PE Session 4.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-3, and 20 min. of active tDCS prior to PE sessions 4-10.
10127108|NCT04327362|Active Comparator|Cluster 2: Sham to active tDCS crossover at PE Session 5.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-4, and 20 min. of active tDCS prior to PE sessions 5-10.
10127109|NCT04327362|Active Comparator|Cluster 3: Sham to active tDCS crossover at PE Session 6|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-5, and 20 min. of active tDCS prior to PE sessions 6-10.
10127110|NCT04327362|Active Comparator|Cluster 4: Sham to active tDCS crossover at PE Session 7.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-6, and 20 min. of active tDCS prior to PE sessions 7-10.
10127111|NCT04327362|Active Comparator|Cluster 5: Sham to active tDCS crossover at PE Session 8.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-7, and 20 min. of active tDCS prior to PE sessions 8-10.
10127112|NCT04327570||ICU-hospitalised COVID-19 patients|COVID-19 positive patients hospitalised in intensive care ('severe disease').
10127113|NCT04327570||ward-hospitalised COVID-19 patients|COVID-19 positive patients requiring hospitalisation,not on intensive care department ('non-severe').
9519546|NCT03286075|Experimental|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
10127114|NCT04327336|Active Comparator|Manual|In this group non invasive mechanical ventilation will be manually titrated during a polysomnography. The Philips A40 ventilator will be used in Spontaneous-Timed (ST) mode.
10127115|NCT04327336|Active Comparator|Automatic|In this group the ventilator will run in an automatic mode (AVAPS) with the same Phillips A40 ventilator.
10127116|NCT04327492||Carotid endarterectomy|"This study is a non-interventional prospective cohort study. The population corresponds to patients submitted to CEA under regional anesthesia. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) will be prospectively recruited. The expected patient follow-up will be of 5 years.~The demographics will be recorded in a prospective, protected database. Blood samples will be collected in clot activator serum tubes at three timepoints: timepoint 1 - before surgery (until 15 days before surgery); timepoint 2 up to 48h postoperatively; timepoint"
10127117|NCT04327544|Experimental|Frailty Intervention group|A multi-domain intervention program that includes nutrition education and low to moderate multi-component exercise intervention.
10127118|NCT04327544|No Intervention|Control group|Respondents in the control group will not receive any nutritional education or exercise intervention activities.
10127119|NCT04327349|Other|COVID-19 Patients|
10127120|NCT04327518|Experimental|TECNIS® Toric II|Subjects will be implanted in one or both eyes with the study lens
10127121|NCT04327375||observational|observational
10127122|NCT04327453|Experimental|XP-endo Finisher file|removal of double antibiotic paste intracanal medication with XP-endo Finisher file
10127123|NCT04327453|Experimental|Irrisafe Ultrasonic tip|removal of double antibiotic paste intracanal medication with passive ultrasonic irrigation
10127124|NCT04327453|Active Comparator|side vented needle|removal of double antibiotic paste intracanal medication with conventional syringe irrigation
10127125|NCT04327414|Experimental|Intervention group|Implementation of standing desks in classroom. To ensure that adolescents will spend sufficient time at the standing desks, 1/3 to half of the classroom will be provided with standing desks. The school will be asked to actually replace some traditional desks with these standing desks, instead of just adding standing desks to the classroom set-up to ensure as much as possible that the desks are being continuously used throughout the intervention period.
10127126|NCT04327414|No Intervention|Control group|No implementation of standing desks in classroom.
9519547|NCT03286075|Placebo Comparator|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).~Subjects will receive a 30-minutes SHAM session of tDCS."
10127127|NCT04327232|Experimental|Active|"For patients randomized to active experimental arm: Spironolactone~Patient will receive study drug for 18 months. Study drug dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day, with 1 tablet being 25mg spironolactone. Study drugs are titrated every 3 months based on patients' potassium and eGFR blood tests results."
10127128|NCT04327232|Placebo Comparator|Control|"For patients randomized to control arm: Placebo~Patient will receive placebo for 18 months. Placebo dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day. Placebo are titrated every 3 months based on patients' potassium and eGFR blood tests results."
10127129|NCT04327115|Other|Arm 1|"(C-I-I-I) : the centers apply the Control strategy in Period 1 and then apply the Intervention strategy in Periods 2 to 4."
10127130|NCT04327115|Other|Arm 2|"(C-C-I-I) : the centers apply the Control strategy in periods 1 and 2 and then apply the Intervention strategy in periods 3 and 4."
10127131|NCT04327115|Other|Arm 3|"(C-C-C-I) : the centers apply the Control strategy in periods 1, 2 and 3 and then apply the Intervention strategy for period 4."
10127132|NCT04327128|Active Comparator|Intervention group|Standard heart failure care and a digital heart failure support system
10127133|NCT04327128|Other|Control group|Standard heart failure care
10127134|NCT04326920|Active Comparator|Active sargramostim treatment group|Inhaled sargramostim 125mcg twice daily for 5 days on top of standard of care. Upon progression to ARDS and initiation of mechanical ventilator support within the 5 day period, inhaled sargramostim will be replaced by intravenous sargramostim 125mcg/m2 body surface area once daily until the 5 day period is reached. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment
10127135|NCT04326920|Placebo Comparator|Control group|standard of care. Subjects progressing to ARDS and requiring invasive mechanical ventilatory support, from day 6 onwards, will have the option (clinician's decision) to initiate IV sargramostim 125mcg/m2 body surface area once daily for 5 days
10127136|NCT04326998|Active Comparator|non-solvent|mechanical or heat treatment
9519548|NCT03286062|Experimental|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
10127137|NCT04326998|Experimental|solvent|GuttaClear
10127138|NCT04327167|Other|Digital intervention|
10183580|NCT03763253|Active Comparator|Intervention Arm 1: Minimally Invasive Ablative Therapy (MIAT)|"MIAT to prostate in form of cryotherapy or high intensity focused ultrasound (HIFU), in addition to SOC systemic treatment. No local prostate radiotherapy will be given as part of this intervention. Radiotherapy can be given subsequently for palliative reasons.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
9519549|NCT03286049||Healthy children (HC)|10 healthy children
10127139|NCT04327102|Experimental|Experimental : intervention group|Combination of health education tools and health literacy intervention: on the basis of the control group, the hypertension health education tools are used as the education media to encourage patients to find out the elements of the tool chart, use the picture content to guide the topic development, encourage patients to discuss with each other, realize heuristic questions, rather than a single indoctrination, so as to deepen the understanding and memory of patients. At the end of the course, patients are encouraged to set short-term goals to encourage behaviors that continue to achieve larger goals. At the same time, health literacy lectures were organized during the hospitalization. Health literacy lecture is mainly to learn the information that hypertension needs to pay attention to in order to improve the health literacy of hypertension patients and other indicators.
10127140|NCT04327102|No Intervention|No intervention:The control group|No intervention except conventional care were performed for the control group
10127141|NCT04327440||Nyambi, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
10127142|NCT04327440||Nyambi, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
10127143|NCT04327440||Kalembo, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
10127144|NCT04327440||Kalembo, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
10127145|NCT04327154|Experimental|Digital nerve repair|There is no comparator for this study. All patients are in the treatment allocated group for digital nerve repair with the TISSIUM™ Nerve Coaptation Device.
10127146|NCT04327011|Experimental|Experimental|Single arm Toca 511 vector/5-FC prodrug
10127147|NCT04327076|Experimental|Robot system intervention|"Evaluate the patient and sign the informed consent~The patient was given general anesthesia~Use magnetically guided tracheal intubation and airway cleaning robot system"
10127148|NCT04327089|Experimental|Part 1- Cohort 1|Single oral dose of 400 mg Setanaxib administered as 1x400 mg tablet in fasting conditions.
10127149|NCT04327089|Experimental|Part 1- Cohort 2|Single oral dose of 800 mg Setanaxib administered as 2x400 mg tablet in fasting conditions.
10127150|NCT04327089|Experimental|Part 1- Cohort 3|Single oral dose of 1200 mg Setanaxib administered as 3x400 mg tablet in fasting conditions.
10127151|NCT04327089|Experimental|Part 1- Cohort 4|Single oral dose of 1600 mg Setanaxib administered as 4x400 mg tablet in fasting conditions.
10127152|NCT04327089|Experimental|Part 2- Cohort 5|Repeated 10-Day dosing of 1200mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 1x400mg tablet in the evening in fedding conditions.
10127153|NCT04327089|Experimental|Part 2- Cohort 6|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions.
10127154|NCT04327089|Experimental|Cohort 7|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions. Additionnaly, this cohort includes the evaluation of potential Drug-Drug interactions with CYPs and transporters.
10127155|NCT04327180||patients suspected of infection with COVID-19.|Patients included with positive PCR and patients with negative PCR included
10127156|NCT04327050|Experimental|Magnetic-ESD|Patients in MAG arm will be treated using magnetic anchored guided endoscopic submucosal dissection.
10127157|NCT04326959|Experimental|UC-MSCs + CM|A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
10127158|NCT04326959|Experimental|CM + CM|A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
10127159|NCT04326959|Experimental|Triamcinolon acetonide|A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.
10127160|NCT04326907|Experimental|CAT injection group|After fistulectomy for complex anal fistula, CAT (harvested from abdominal subcutaneous adipose tissue by Coleman's procedure) was injected into the tissue surrounding the internal opening, and inside the perianal wound obtained after fistulectomy.
10127161|NCT04326907|No Intervention|No CAT injection group|Patients of this group were treated with anal fistulectomy without CAT injection.
10127162|NCT04326985|Experimental|Autologous Mesenchymal Stem Cells Treatment (MSCs)|"The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.~The treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.~T0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
10127163|NCT04326985|Active Comparator|Hyaluronic acid (HA)|"The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.~T0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
10127164|NCT04326894|Experimental|Methotrexate|25mg oral MTX tablets
10127165|NCT04326894|Placebo Comparator|Placebo|25 mg/week placebo tablets
10127166|NCT04326881|Experimental|SHR-1314 A|single dosing SHR-1314 A
10127167|NCT04326881|Experimental|SHR-1314 B|single dosing SHR-1314 B
10127168|NCT04326881|Experimental|SHR-1314 C|single dosing SHR-1314 C
10127169|NCT04326868|Active Comparator|Albendazole|ABZ (400mg)
10127170|NCT04326868|Experimental|Albendazole and Mebendazole|ABZ 400mg + 1 tablet of MBZ (500mg)
10127171|NCT04326868|Experimental|Albendazole and Pyrantel|ABZ (400mg) + Pyr (125 mg)
10127172|NCT04326855|Experimental|20 patients with advanced COPD|This will be a cross sectional observational study. COPD patients will be recruited from those referred to the Pulmonary Rehabilitation programme at RVI Hospital in Newcastle upon Tyne. Potentially eligible patients will be identified by the physiotherapy team within the Trust, who will provide initial information about the study. Delegated investigators will confirm eligibility and discuss full details of the trial. Patients will be given time to consider participation in the trial before written informed consent is obtained.
10127173|NCT04326556|Experimental|Prospective cohort for etiological and prognostic purposes|
10127174|NCT04326764|Experimental|Panobinostat|Panobinostat 20 mg oral three times weekly every second week
10127175|NCT04326764|No Intervention|Standard of Care|Treatment according to local standards
10127176|NCT04326634|Experimental|Controlled exercises Group|
10127177|NCT04326634|Experimental|Non controlled exercises Group|
10127178|NCT04326777|Other|Ballon pulmonary angioplasty|Ballon pulmonary angioplasty(BPA) is a stepwise procedure requiring several separate sessions. The interval of a series of BPA is one month. In a series of BPA, there are 2 sessions, which are repeated at a 2-week interval. BPA is performed primarily on one side of the lung in the first session, then after 2 weeks, performed on the other side of the lung. In each session, the fluoroscopy time or the amount contrast are less than 60min and 200ml, respectively.
10127179|NCT04326647|Experimental|Kinesiotaping Group|We used kinesiotaping (gastrocnemius and lumbar back) plus exercise
10127180|NCT04326647|Active Comparator|Exercise Group|We used only exercise
10127181|NCT04326790|Experimental|Intervention|Colchicine, on top of standard treatment
10127182|NCT04326790|Active Comparator|Control|Standard treatment, including all medications recommedned by the National Public Health Organization
10127183|NCT04326829|Experimental|QL1604 Injection|
10127184|NCT04326517||Emphysematous pyelonephritis|This is a single-group cohort study. A sub-classification will be used in order to differentiate patients that did not require intensive care, the ones who admitted to intensive care and mortality.
10127185|NCT04326803|Experimental|Vaccine group|Administration of 3 doses hepatitis B vaccine (recombinant hepatitis B vaccine, injectable suspension for intramuscular use) at month 0, 1 and 2.
10127186|NCT04326673||diurnal variation assessment|Assessment of diurnal variation in salivary testosterone adjusted for prandial state
10127187|NCT04326673||Glucose load measurements|Measurement of salivary and serum testosterone and related biomarkers before and after a standard 75g oral glucose load
10127188|NCT04326816|Active Comparator|Direct Composite Restorations (DCR)|"All teeth were reconstructed with directly applied composite restorations. No preparation of teeth was performed except in cases of sharp occlusal edges.~Rubberdam or cotton rolls and suction devices were used for moisture control. For bonding, a 3-step etch-and-rinse adhesive was applied according to manufacturer's instructions, using 37% phosphoric acid (DMG, Hamburg, Germany), Clearfil SA Primer, and Clearfil Photobond (Kuraray, Osaka, Japan). A micro-hybrid composite (Clearfil AP-X, Kuraray) was used for posterior restorations and palatal veneer restorations. Restorations were placed according to the DSO-technique (Direct Shaping by Occlusion). In front teeth, both a palatal and buccal veneer restoration was placed.~Experimental restorations were all restorations on first molars and all palatal veneer restorations on maxillary anterior teeth."
10127189|NCT04326816|Experimental|Indirect Composite Restorations (ICR)|"Indirect 'tabletop' restorations were placed on all first molars (n=4) and palatal veneers ('backings') (n=6) on maxillary anterior teeth. Remaining teeth received directly applied restorations. Preparation of teeth for indirect restorations was limited to removal of sharp edges.~All indirect restorations were laboratory manufactured using a micro-hybrid composite (Clearfil Estenia C&B, Kuraray, Osaka, Japan). Adhesive surfaces of the restorations were air-abraded with aluminum-oxide powder (<50 µm). Rubberdam or cotton rolls were used for moisture control during cementation. Seating of indirect restorations was checked intraorally, followed by cleaning of its adhesive surface with phosphoric acid 37% and application of silane (Clearfil Ceramic Primer, Kuraray, Osaka Japan).The adhesive surface of the abutment tooth was etched with phosphoric acid and ED-primer II (Kuraray) was applied. Finally, restorations were cemented, using Panavia F (Kuraray)."
10127190|NCT04326712||Group 1|Unilateral transtibial amputees using conventinional manufactured socket
10127191|NCT04326712||Group 2|Unilateral transtibial amputees using 3D manufactured socket
10127192|NCT04326686|Other|N-of-1 study|For 24 weeks, each participant will measure their blood pressure and respond to questionnaires daily, and visit the institute to provide a blood sample every 4 weeks. The study is split into three 8-week phases, the first of which will start when each participant is enrolled. For the first 8-week observation phase (A1) the participant is instructed to continue with their usual diet and exercise habits. For the second 8-week intervention phase (B), the participant will be provided with wholegrains and nuts and recommended to substitute these in place of refined grains and other snacks, respectively. They will also receive dietary advice for following the Dietary Approaches to Stop Hypertension (DASH) diet. For the final 8 week follow-up period (A2), provision of wholegrains and nuts will cease but the participant will continue with measurements at the same frequency as previously.
10127193|NCT04326595|Active Comparator|surgical termination|
10127194|NCT04326595|Active Comparator|medical termination|
10127195|NCT04326699|Active Comparator|Sacroiliac joint injection group|The active group will receive bilateral sacroiliac joint injection of 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) under ultrasound guidance.
10127196|NCT04326699|No Intervention|control group|The other group will not receive the sacroiliac joint injection
10127197|NCT04326569|Experimental|adults with trans-sphenoidal endoscopic pituitary surgery|adult with trans-sphenoidal endoscopic pituitary surgery for tumour of the sellar region
10127198|NCT04326621|Experimental|PRT group|pressure Release Technique and exercises
10127199|NCT04326621|Active Comparator|Exercises group|Only exercises
10127200|NCT04326491||HCC|Participants are diagnosed with HCC on top of cirrhosis
10127201|NCT04326491||Cirrhosis with no HCC|Participants are diagnosed with cirrhosis but have no HCC
9519550|NCT03286049||Children with non allergic rhinitis (NAR)|10 children with non allergic rhinitis
9519551|NCT03286049||Rhinitis children, perennial allergy (PAR)|10 rhinitis children, sensitized to perennial allergens
10127202|NCT04326725||Hydroxychloroquine|Subjects with prophylaxis
10127203|NCT04326465|Experimental|Fractional CO2 Laser Therapy at 10-15% Laser Density Coverage|Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 10-15% laser density. The patient will receive three laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
10127204|NCT04326543||ADHD and typically developing controls|120 subject: 53 with an ADHD clinical diagnosis and 57 typically developing controls aged between 3 and 16 years old.
10127205|NCT04326348|Experimental|TQ05105 Tablet|TQ05105 tablet administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
10127206|NCT04326387||Research Participants (Patients)|"Inpatients symptomatic of suspected COVID-19 Baseline swab of nose/throat, nasopharyx, or endotracheal tube aspirate. SAMBA II point of care test on this swab.~Standard of care bloods taken for PHE and additional confirmatory diagnostic PCR assessment.~Serum antibody tests on any excess blood tests during inpatient stay for immune response monitoring.~Outcome assessment at 1 month"
10127207|NCT04326205|Experimental|Dual-aided|active tDCS to the ipsilesional primary motor cortex (M1lesioned) followed by FES to the paretic hand during MT
10127208|NCT04326205|Active Comparator|FES-alone|sham tDCS to the M1lesioned followed by FES to the paretic hand during MT
10127209|NCT04326205|Active Comparator|tDCS-alone|active tDCS to the M1lesioned followed by sham FES to the paretic hand during MT
10127210|NCT04326205|Placebo Comparator|Dual-sham|sham tDCS to the M1lesioned followed by sham FES to the paretic hand during M
10127211|NCT04326153|Experimental|experimental arm|Sintilimab+Albumin paclitaxel:+Carboplatin:
10127212|NCT04326426|Experimental|Tradipitant|Tradipitant 85 mg PO BID
10127213|NCT04326426|Placebo Comparator|Placebo|2 capsules of matching placebo
10127214|NCT04326296|Experimental|Experimental Group|PD-L1 Monoclonal Antibody Combined With Lenalidomide
10127215|NCT04326452|Experimental|Enrolled Subjects|The purpose of this study is to compare the use of our bidirectional oxygenation mouthpiece with conventional oxygen support versus conventional oxygen support of any Person Under Investigation for infection by the COVID-19 virus.
10127216|NCT04326218|Other|Cohort|All patients included will have to be taken blood samples
10127217|NCT04326439|Experimental|Aflac-AML Regimen for Low Risk AML Patients|"Participants in this arm will receive the standard Aflac-AML Regimen with the following chemotherapy:~Induction-1: patients on Induction-I will receive gemtuzumab + ADE therapy based on genotyping. Lasts a total of 28 days.~Induction II - MA~Intensification I - AE~Intensification II - HD ARAC/LASP~Patients with low risk status who had low risk markers and were MRD positive at the end of Induction I and continue to be MRD positive after Induction II will come off protocol."
10127218|NCT04326439|Experimental|Aflac-AML Regimen for High Risk AML Patients|"Participants in this arm will receive standard Aflac-AML Regimen with the following chemotherapy:~Induction-1: patients will receive gemtuzumab in addition to ADE therapy based on genotyping. Induction I lasts a total of 28 days.~Induction 1 for FLT3-ITD patients - ADE (10+3+5) with GO with Sorafenib~Induction II - MA~Induction II for FLT3-ITD patients - MA with Sorafenib~Intensification I - AE~Intensification I for FLT3-ITD patients - AE with sorafenib~Intensification II - HD ARAC/LASP~Intensification II for FLT3-ITD patients - HD ARAC/LASP with sorafenib~Hematopoietic stem cell transplantation (HSCT)~If a patient is classified as High risk after Induction I, they may proceed to best allogenic donor SCT following Induction II. These patients may receive a third course of chemotherapy prior to HSCT. In cases where HSCT is not an option, patients can receive 4 cycles of chemotherapy. Only patients with FLT3-ITD mutation will receive sorafenib."
10127219|NCT04326374|Experimental|TransCon hGH|"TransCon hGH will be self-administered or injected by parents once weekly. The dose will be adjusted based on subject's weight.~The treatment will continue 52 weeks."
10127220|NCT04326374|Active Comparator|Daily hGH|"Daily hGH will be self-administered or injected by parents once daily. The dose will be adjusted based on subject's weight.~The treatment will continue 52 weeks."
10127221|NCT04326400||Hospital de la Princesa employees|
10127222|NCT04326140|Experimental|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
10127223|NCT04326140|Sham Comparator|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
10127224|NCT04326478|Experimental|Azithromycin Group|Enrolled children in a household randomized to the experimental group will receive a single weight-based dose of azithromycin administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera. They will then complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
10127225|NCT04326478|Placebo Comparator|Non-antibiotic Placebo Group|Enrolled children in a household randomized to the placebo arm will receive a single dose of non-antibiotic placebo during their first study visit, which will occur within 12 hours of a member of their household testing positive for cholera. Like the participants in the intervention arm, they will complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
10127226|NCT04325945|Experimental|Laser acupuncture|808nm low level laser therapy
10127227|NCT04325945|Sham Comparator|Sham laser acupuncture|no low level laser output but same device
10127228|NCT04326244||Snoring obesity patient|Constitution in Chinese Medicine Questionnaire, physical examination, blood test and genetic test are provided to subjects. The blood test includes High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin; the DNA test includes FTO、MC4R、BDNF、PPARG、ADRB3、UCP1. Epworth Sleepiness Scale, laryngoscope and polysomnography are also performed in the patients enrolled
10127229|NCT04326166||Group A|Patients who receive Double therapy or Insulin
10127230|NCT04326166||Group B|Patients who receive DPP-4 inhibitor
10127231|NCT04326166||Group C|Drug-naïve patients
10127232|NCT04326270|Active Comparator|nCPAP prongs|
10127233|NCT04326270|Active Comparator|Infant cannula|
10127234|NCT04326049|Experimental|LLETZ with videocolposcopy|The LLETZ procedure will be performed using a videocolposcopy
10127235|NCT04326049|Active Comparator|LLETZ with binocular colposcopy|The LLETZ procedure will be performed using a binocular colposcope
10127236|NCT04325984||Dexamethasone group|Group of patients receiving dexamethasone 8 mg as part of the multimodal analgesia.
10127237|NCT04325984||Control group|Group of patients receiving multimodal analgesia, not comprising dexamethasone; moreover, ondansetron 4 mg is administered for the control of PONV.
10127238|NCT04325971|Experimental|Healthy Subjects|All healthy subject are gathered in one arm
10127239|NCT04326127||Control|Healthy volunteers
10127240|NCT04326127||Case|Volunteers with diagnosed sleep apnea
10127241|NCT04326114|Experimental|Inspiratory training|
10127242|NCT04326114|Experimental|Expiratory training|
10127243|NCT04326114|No Intervention|Control|
10127244|NCT04326062|Experimental|Main Study|A pharmacist will join the practice team for six months.
10127245|NCT04326062|Experimental|PROM Study|A nested Patient Reported Outcome Measure (PROM) study will be undertaken during month four and five of the six-month intervention period to explore the impact of the intervention in older adults (aged ≥65 years).
10127246|NCT04325867|Experimental|All patients with known cardiovascular disease|"All these patients will be provided an electronic account on a dedicated platform were they can be supervised and can call for advice / help.~This kind of tele-medical project aims to keep these patients in a so-called proximity, monitoring their vital parameters, checking their medication and providing dedicated advices according to their complaints.~Moreover, all these patients will receive digital watches with ecg-recording capabilities, thus a dedicated physician could correlate their symptoms with few clear paraclinical variables.~All of these patients' complaints will be stratified according to elaborated protocols based on the European Cardiovascular Guidelines.~Moreover, a psychologist and a chaplain will deal with their (new) problems due to social isolation."
10127247|NCT04325932|Experimental|Urinary Kallikrein group|Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
10127248|NCT04325932|No Intervention|control group|with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
10127249|NCT04325997|Experimental|an ordinary laryngos with mouth opener|
10127250|NCT04325997|No Intervention|Video laryngoscopy intubation|
10127251|NCT04325997|Experimental|Video laryngoscope with mouth opener|
10127252|NCT04325841|Experimental|Autologous Murine Anti-CD19 CAR-T treatment|
10127253|NCT04326322|Experimental|Methionine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
10127254|NCT04326088||head and neck cancer with free flap reconstruction|patients with head and neck cancer who underwent tumor wide excision and primary free flap reconstruction or secondary free flap reconstruction between March 2008 and February 2017
10127255|NCT04326231|Experimental|Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
10127256|NCT04325893|Active Comparator|Hydroxychloroquine|
10127257|NCT04325893|Placebo Comparator|Placebo|
10127258|NCT04325854||Ectopic pregnancy population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all ART procedures (both I and II level) performed between 2009 and 2018.
10127259|NCT04325815||CADDIE|The endoscopist will be assisted with CADDIE system to detect polyps. The endoscopist will perform optical diagnosis of polyps with the assistance of the CADDIE's polyp characterisation function.
10127260|NCT04325815||Standard Procedure|In addition to routine colonoscopy the endoscopist will perform optical diagnosis of detected polyps without the assistance of the CADDIE.
10127261|NCT04325620|Experimental|HIP1601 Amg|The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.
10127262|NCT04325620|Placebo Comparator|HGP1805|The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks.
10127263|NCT04325633|Experimental|1: Naproxen|Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
10127264|NCT04325633|Placebo Comparator|2: Standard of care|Standard of care
10127265|NCT04325568|Other|Clinician Manual|"Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability.~Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'."
10127266|NCT04325568|Other|AutoTutor (PsyGist)|"AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing.~PsyGist will guide participants through its three components."
10127267|NCT04325516|Experimental|People with a lower limb amputation|"Participants will perform four tasks in a randomized order:~sit to stand~dorsi flexion of the foot~knee extension~hip extension"
10127268|NCT04325516|Experimental|Able bodied individuals|"Participants will perform four tasks in a randomized order:~sit to stand~dorsi flexion of the foot~knee extension~hip extension"
10127269|NCT04325607|Experimental|Negative Pressure Wound Therapy with instillation|Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
10127270|NCT04325607|Active Comparator|Negative Pressure Wound Therapy|Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
10127271|NCT04325672|Experimental|Convalescent Plasma Group|Subjects will receive 1-2 units (300-600 mL) of plasma with an anti-SARS-CoV-2 titer of >1:64.
9967622|NCT01271556|Active Comparator|3, salmeterol, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
10127272|NCT04325594|Experimental|Main Group|Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1×10 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy
10127273|NCT04325594|Active Comparator|Control Group|Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy
10127274|NCT04325724|Other|Beginner psoriatic arthritis patients|Every patients consulting in dermatologic or rheumatologic department for a skin psoriasis with clinical symptoms which may lead to the suspicion of psoriatic arthritis
10127275|NCT04325724|Other|Confirmed psoriatic arthritis patients|Every patients with psoriatic arthritis followed in rheumatologic department
10127276|NCT04325724|Other|Rheumatoid arthritis or Digital osteoarthritis patients|Followed in rheumatologic department
10127277|NCT04325724|Other|Skin psoriasis patients without any articular symptoms|
10127278|NCT04325711|Experimental|CSPCH131 dose Escalation and expansion|"In the dose escalation part of Stage I, five dose levels will be tested according to the 3 + 3 dose-escalation design. Whether and how to carry out the follow-up study parts will be decided by the PI and sponsor on the basis of the achieved results of safety, tolerability and effectiveness of CSPCHA131."
10127279|NCT04325490|Experimental|Liquid powder|Liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin on the selected intertrigo area.
10127280|NCT04325490|Active Comparator|Hydrocortisone|1% hydrocortisone cream
10127281|NCT04325503|Experimental|Treatment|carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks
10127282|NCT04325698|Experimental|Arm A|PF-06439535 (CN) + paclitaxel + carboplatin
10127283|NCT04325698|Active Comparator|Arm B|Bevacizumab-EU + paclitaxel + carboplatin
10127284|NCT04325555||Respondents on PrEP|"On PrEP status will be operationalized in multiple ways, and sensitivity analyses will be conducted using multiple definitions as a result of the self-reported nature of the study.~Respondents on PrEP are respondents who reported that they are currently on PrEP~Respondents on PrEP are respondents who reported to have ever been on PrEP~When respondents are used as their own controls, years on PrEP will be those in which they reported to have been on PrEP for at lest 6 months, and PrEP initiation will be the first such year~A comparison group will be constructed by matching on a variety of characteristics, when this method is applied. Most importantly, age, and STD testing frequency among others, which influence the likelihood of being on PrEP and via that avenue sexual practices, as well as the likelihood of detecting STDs (i.e., ascertainment bias). In other models adjustments will be made for these factors."
10127285|NCT04325581|Experimental|Post LSG with Liraglutude|Liraglutide in incremental dose upto maximum of 1.8 mg per day subcutaneously once a day.
10127286|NCT04325581|Placebo Comparator|Post LSG without Liraglutide|Normal Saline in equivalent per day subcutaneously once a day
10127287|NCT04325776|Experimental|AL2846+An analog of zoledronic acid injection|AL2846 capsules 150 mg given orally, once daily in 28-day cycle, an analog of zoledronic acid injection (5ml:0mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
9669040|NCT04256070|Experimental|Education, tele-consultation and training booklet|"Informed Consent Form will be taken in written from those who agree to participate in the research.~In the first intervention, Information Form Based on Watson's Human Care Theory, Chronic Obstructive Pulmonary Disease Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected. Subsequently, education, counseling nursing care and education booklet based on Watson's Human Care Theory will be given.~Teleconsultation based on Watson's Human Care Theory will be given during the intervention at weeks 2, 4, 6, 8 and 10.~24-hour tele-consultancy will be given on subjects determined for the management of COPD in case of necessity at the request of the individual.~In the last intervention in the 12th week, face to face with the individual, Consultancy based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form, Telephone Interview Evaluation Form will be applied."
9827433|NCT02455050|Other|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
10127288|NCT04325776|Active Comparator|An analog of AL2846+ zoledronic acid injection|An analog of AL2846 capsules 0 mg given orally, once daily in 28-day cycle, zoledronic acid injection (5ml:4mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
10127289|NCT04325425|Experimental|mFOLFIRINOX|mFOLFIRINOX will be administered once every 14 days for up to 12 cycles. One cycle consists of 14 days (2 weeks) with injection on D1 of each cycle (D1=D15). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
10127290|NCT04325425|Active Comparator|platinum - etoposide|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
10127291|NCT04325438|Experimental|Pharmaceutical Care|Groups with usual care by health professionals and additional health interventions provided by pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
10127292|NCT04325438|No Intervention|Non-Pharmaceutical Care|Groups with usual care from health providers other than pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
10127293|NCT04325256||study group|All pregnant women who will attend the labor unit for induction of labour due to different indications during the study period will be invited to participate in the study.
10127294|NCT04325347|Experimental|Virtual reality|Virtual Reality will be provided to all participants, just before sleeping.
10127295|NCT04325347|No Intervention|Control|No specific intervention will be provided.
10127296|NCT04325113|Placebo Comparator|NaCl 0,9%|patients receive 5ml of NaCl 0,9% at the level of the tonsils lodge
10127297|NCT04325113|Active Comparator|Xylocaine 2%|patients receive 5ml of Xylocaïne 2% at the level of the tonsils lodge
10127298|NCT04325113|Active Comparator|Levobupivacaine 0,5%|patients receive 5ml of Levobupivacaine 0,5% at the level of the tonsils lodge
10127299|NCT04325295|Active Comparator|Surgical treatment strategy:|
10127300|NCT04325295|Active Comparator|Gonadotrophins treatment strategy|
10127301|NCT04325750|Placebo Comparator|Control|The simulated mode technique is applied (machine off)
10127302|NCT04325750|Experimental|TECAR THERAPY|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
10127303|NCT04325334|Experimental|Running volume increase|Participants will be be given a running program based on their running mileage on inclusion and supported by regular contacts with the study trainer.
10127304|NCT04325360|Experimental|Cathodal Transcranial Direct Current Stimulation (c-tDCS)|Participants in this arm of the study will receive cathode transcranial direct current stimulation.
10127305|NCT04325360|Sham Comparator|Sham-tDCS|Participants in this arm of the study will receive sham transcranial direct current stimulation.
10127306|NCT04325399|Experimental|Planning|"The volitional help sheet (VHS) comprises of a list of challenges to being physically active (e.g. If I'm tempted not to go to the gym because it's cold outside) and a list of possible ways to overcome thes (e.g. then I will make myself go to the gym anyway because I know I will feel better afterward). In the experimental VHS link group, participants are asked to form if-then plans by drawing a line between challenges and solutions to link them together."
10127307|NCT04325399|No Intervention|No planning|Participants in the VHS tick group are presented with the exact same volitional help sheet as the experimental group, the only difference being that participants in this group are not asked to make if-then plans. Rather, participants in the control group are asked to tick challenges and solutions that they feel are relevant to them.
10127308|NCT04325022||Primary Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in primary THA
10127309|NCT04325022||Revision Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in revision THA
10127310|NCT04325035|Experimental|Istaroxime|Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min
10127311|NCT04325035|Placebo Comparator|Placebo|Placebo (lactose lyophilized powder) IV infusion for 24 hours
10127312|NCT04324970|Experimental|Tookie vest|Participant issued with Tookie vest
10127313|NCT04325308|Experimental|Protein-enriched human milk diet|Infants in this group will receive protein-enriched expressed human milk or donor human milk during the first 2 weeks after birth.
10127314|NCT04325308|Active Comparator|Usual human milk diet|Infants in this group will receive either expressed human milk or donor human milk during the first 2 weeks after birth.
10127315|NCT04325477|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
10127316|NCT04325165|Experimental|1: Chronic SCI subjects|"These subjects will undergo:~Bilateral implantation of PPN DBS electrodes;~Electrical stimulation of the DBS electrodes and~Intensive locomotor training"
10127317|NCT04324892||Treat to target|The study has only 1 cohort with treat-to-target strategy
10127318|NCT04325191|Experimental|High Salt and Melatonin|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with 10 mg (single dose) of melatonin at night.
10127319|NCT04325191|Placebo Comparator|High Salt and Placebo|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with a lactose placebo (single dose) at night.
10127320|NCT04324879|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
10127321|NCT04325152|Experimental|FCSEMS+Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. One to two centimeters of distal end of FCSEMS was left outside of the papilla and the stent was released. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
10127322|NCT04325152|Sham Comparator|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
10127323|NCT04324905|Experimental|Sequence 1|
10127324|NCT04324905|Experimental|Sequence 2|
10127325|NCT04325178|Experimental|Animal|Participants receive the majority of their protein from animal-derived protein sources (1.8g.kg.day).
10127326|NCT04325178|Experimental|Non-animal|Participants receive all their protein from non-animal-derived protein sources (1.8g.kg.day).
10127327|NCT04324918|Experimental|HCP1102|
10127328|NCT04324918|Active Comparator|HGP1408|
10127329|NCT04325100|Experimental|Switch - i|Individual sessions
10127330|NCT04325100|Experimental|Switch - g|Group programme
10127331|NCT04324788||Group 1|"Transtibial amputation~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
10127332|NCT04324788||Group 2|"Transfemoral amputation~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
10127333|NCT04324931|Experimental|Biomechanical corrections|In this group, biomechanical correction will be perform with the help of mobilization with movement to correct biomechanical misalignment and along with this conventional treatment, in which Hydrocollatoral packs for 20 minutes, Interferential Therapy for 15 minutes with beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program for 3 sessions of 20 minutes on alternative days for 3 weeks. Which will be given for three days a week for three weeks.
10127334|NCT04324983|Other|Biomarker|This single-arm study is a Phase I study to exploratively identify potential biomarkers in patients with early prostate cancer relapse and limited metastases in PSMA-PET, who need further assistance in treatment decisions (for or against local treatment options).
10127335|NCT04325074|Experimental|Mental practice|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice group was n=12.
10127336|NCT04325074|Experimental|Mental practice + skill training|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice + skills training group was n=13.
10127337|NCT04325074|Active Comparator|Control group|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of control group was n=10.
10127338|NCT04324801|Experimental|Single arm|This is a within-subject repeated-measures design.
10127339|NCT04325243|Experimental|study group|50 mg oral sildenafil citrate tablet
10127340|NCT04325243|Placebo Comparator|placebo group|placebo tablets of the same shape, color and size of sildenafil citrate tablets
10127341|NCT04325061|No Intervention|Control group|Patients will be treated with standard intensive care
10127342|NCT04325061|Active Comparator|Dexamethasone|Standard intensive care plus dexamethasone
10127343|NCT04325009|Experimental|RTRT|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
10127344|NCT04325009|Experimental|TRTR|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
10127345|NCT04324996|Experimental|NK cells|The NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
10127346|NCT04324996|Experimental|IL15-NK cells|The NK cells secreting super IL15 superagonist are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
10127347|NCT04324996|Experimental|NKG2D CAR-NK cells|The NKG2D CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
10127348|NCT04324996|Experimental|ACE2 CAR-NK cells|The ACE2 CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
10127349|NCT04324996|Experimental|NKG2D-ACE2 CAR-NK cells|The NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
10127350|NCT04324866||Group 1|Patients with chronic plaque psoriasis on immunosuppressant therapy
10127351|NCT04324866||Group 2|Psoriatic patients' partners
10127352|NCT04324866||Group 3|Patients with atopic dermatitis treated with dupilumab
10127353|NCT04325087|Experimental|Active iTBS|Active stimulation of the dlPFC directly after trauma exposure and on the following two days
10127354|NCT04325087|Placebo Comparator|Placebo iTBS|Same procedure as in the active stimulation group but with a placebo stimulation imitating the sensation of a real iTBS protocol.
10127355|NCT04324723|Experimental|Intervention|Participants in this group received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
10127356|NCT04324723|No Intervention|Control|Participants in this group did not received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
10127357|NCT04325126||RBP4 in diabetes|RBP4 in diagnosed diabetes.
10127358|NCT04325126||RBP4 in pre-diabetes (pre-DM)|RBP4 in pre-diabetes (pre-DM).
10127359|NCT04325126||RBP4 in DM-CVD|RBP4 in diabetic cardiovascular disease.
10127360|NCT04325126||RBP4 in CVD|RBP4 in single coronary artery disease.
10127361|NCT04325126||RBP4 in NC|RBP4 in healthy controls.
10127362|NCT04324775||Group 1|Exercise+Manual Lymphatic Drainage
10127363|NCT04324775||Group 2|Exercise+Swedish Massage
10127364|NCT04324827|Experimental|Graston Technique® Group|The application was applied by a GT® certified therapist with 12 years of experience in orthopedic rehabilitation and soft tissue treatments. Hamstring, gastrosoleus and plantar fascia were scanned with GT® instruments and the treated soft tissue was treated. The instruments used differ according to the application protocol and regions are determined with reference to the GT® manual. The treatment lasted 8 minutes for each leg and was applied to both legs equally and by the same person for a total of 16 minutes.
10127365|NCT04324827|Experimental|Foam Roller Group|FR was applied to gastrosoleus and hamstring muscle groups and plantar fascia. TriggerPoint Grid X Foam Roller and Nano Foot X Roller were used in the application. Hamstring, gastrosoleus and plantar fascia for 3 minutes were performed for a single leg. The treatment lasted 8 minutes on one leg and was applied equally to both legs for a total of 16 minutes. Before the application, the participants were informed with verbal and visual warnings about how to do the applications. During the application, the participant was instructed about the time with a stopwatch. The patient himself regulated the pressure applied to the FR; however, the participant was instructed to apply FR as much body weight as possible. The frequency of application was about 0.5 Hz (ie, each rolling cycle lasted for about 2 seconds).
10127366|NCT04324827|Experimental|Dynamic Stretch|DS protocol was prepared with reference to the work of Faigenbaum et al 2005. The protocol consists of 10 dynamic exercises of 10 minutes of medium and high intensity. Each dynamic stretching exercise was performed at a distance of 13 meters. The participants were given a 10-second rest period between each exercise. The participants were given verbal feedback about their postures during the exercises and the video of the exercises was shown to the participant.
10127367|NCT04324411|Experimental|treatment group|combined sirolimus(serum concentration to be 4-10ng/ml) and ATRA (20mg bid) for at least 6 months
10127368|NCT04324489|Experimental|DAS181 Treatment|Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days
10127369|NCT04324424|Experimental|Undialyzed ESRD subjects (P1)|"Part 1: Undialyzed end stage renal disease (ESRD) patients to receive a single dose of HMS5552 ( 25mg ) tablets orally~."
10127370|NCT04324424|Experimental|Healthy volunteers (H)|"Part 1: Matched healthy volunteers to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~H group and P1 group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
10127371|NCT04324424|Experimental|Severe renal impaired subjects (P2)|"Part 2：Severe renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P2 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
10127372|NCT04324424|Experimental|Moderate renal impaired subjects (P3)|"Part 2：Moderate renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P3 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
10127373|NCT04324424|Experimental|Mild renal impaired subjects (P4)|"Part 2：Mild renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P4 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
10127374|NCT04324749|Experimental|Group A (roasted peanuts)|Group A: Habitual diet + 25 g/day of whole skin roasted peanuts (RP)
9967623|NCT01271556|Placebo Comparator|4, placebo, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment (placebo), pulmonary function tests were performed.
9967624|NCT01271569|Other|In the treatment arm|
10127375|NCT04324749|Experimental|Group B (peanut butter)|Group B: Habitual diet+ 2 tbsp/day (32 g/day) of peanut butter (PB)
10127376|NCT04324749|Experimental|Group C (control)|Group C: Habitual diet + 2 tbsp/day (32 g/day) of control supplement
9827434|NCT02455050|Other|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
9967625|NCT01271582|Experimental|FOLFIRI|Patients with colorectal cancer or gastric cancer will be treated with FOLFIRI(Irinotecan, 5FU, leucovorin) regimen upto 12 cycles. (Single arm study)
10127377|NCT04324372|Experimental|HEC68498|HEC68498 will be administered daily
10127378|NCT04324736||Patients with diabetes|
10127379|NCT04324736||Patients without diabetes|
10127380|NCT04324346|Experimental|PICC-Line|Women allocated to PICC-line when receiving chemotherapy
10127381|NCT04324346|Experimental|Subcutaneous Venous Access Port (SVAP)|Women allocated to SVAP when receiving chemotherapy
10127382|NCT04324853||S. haematobium positive|Preganant women infected with Schistosomia hematobium alone
10127383|NCT04324853||geohelminths positive|pregnant women infected with geohlminths alone
10127384|NCT04324853||Helminth negative|Pregnant women free of anyn helminths infection
10127385|NCT04324502||Neuroendocrine neoplasms (tumours)|Patients with a diagnosis of neuroendocrine neoplasm who are due to undergo one of the following treatments: chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor targeted therapy, embolization/ ablative therapies or surgery.
9967626|NCT01271595|Active Comparator|acupuncture|12 sessions of acupuncture according to TCM
10127386|NCT04324619|Experimental|Immediate|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning immediately.
10127387|NCT04324619|Experimental|3 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 3 months.
10127388|NCT04324619|Experimental|6 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 6 months.
10127389|NCT04324619|Experimental|12 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 12 months.
10127390|NCT04324398|No Intervention|group I (control )|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping, between each file and till the final rinse
10127391|NCT04324398|Experimental|Group II|irrigation with 5% cold sodium hypochlorite (2-5°C) from the beginning of cleaning and shaping and between each file. Final rinse was done by 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
10127392|NCT04324398|Experimental|Group III|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
10127393|NCT04324398|Experimental|Group IV|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of cold saline (2-5°C) for 5 minutes
10127394|NCT04324450|Experimental|Patients radiotherapy +|Patients cured of a brain tumour and who have received radiotherapy in childhood
10127395|NCT04324450|Experimental|Patients radiotherapy -|Patients cured of a brain tumour and who have received surgery and/or chemotherapy but were not irradiated
10127396|NCT04324450|Experimental|Healthy volunteers|"Healthy volunteers (control group) matched in age, manual laterality, gender and parental education to Patients radiotherapy +"
10127397|NCT04324528|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
10127398|NCT04324528|Other|control-arm: vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
10127399|NCT04324541||Mexican American Adults|No intervention
10127400|NCT04324515|Other|Study Arm without cholecystectomy|Study Arm: Patients with gastric bypass without concomitant cholecystectomy
10127401|NCT04324515|Other|Control Arm with cholecystectomy|Control Arm: Patients with gastric bypass with concomitant cholecystectomy
9967627|NCT01271595|Sham Comparator|sham acupuncture|superficial acupuncture at non acupuncture sites
9967628|NCT01271621|Active Comparator|Macintoch group|Intubation with Macintoch Laryngoscope
10127402|NCT04324138|Experimental|Experimental group|Jianpi Qinghua granules, 3 times a day and 1 hour after a meal
10127403|NCT04324138|Sham Comparator|Control group|Jianpi Qinghua placebo granules(inclued 5% of experimental drug),3 times a day and 1 hour after a meal
10127404|NCT04324229|Active Comparator|liraglutide|
9967629|NCT01271621|Experimental|Glidescope|Inubation by Glidescope
10127405|NCT04324229|Placebo Comparator|placebo|
10127406|NCT04324307|Experimental|PD-L1/CTLA4 BsAb|For 2nd line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W
10127407|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + GP|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Gemcitabine 1000 mg/m2 and Nab-paclitaxel 125 mg/m2 , 28days/cycle
10127408|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + FOLFIRINOX|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Oxaliplatin 68 or 85 mg/m2, Irinotecan 135 or 150 or 180 mg/m2, Calcium Folate 400 mg/m2, Fluorouracil 2400mg/m2, 14 days/cycle
10127409|NCT04324593|Experimental|IV line with an attached Deltran BP transducer|After device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test. At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
10127410|NCT04324476|Experimental|Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI|"Induction chemotherapy:~Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI:~Bevacizumab: 5mg/kg, iv, 30min, d1, 2w; Oxaliplatin: 85mg/㎡, iv, 120min, d1, 4w; Irinotecan: 150mg/㎡, iv, 90min, d15, 4w; Capecitabine: 1000mg/㎡, bid, d2-8, 2w.~Maintenance chemotherapy:~Bevacizumab: 7.5mg/kg, iv, 30min, d1, q3w; Capecitabine: 1000mg/㎡, bid, d2-15, 2w."
10127411|NCT04324034|Experimental|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
10127412|NCT04324034|Active Comparator|laparoscopy|conventional laparoscopy
10127413|NCT04324320||outpatients (oncological rehabilitation)|the population studied in this cross-sectional study includes patients with malignant tumour diseases and benign CNS tumours who present to the Outpatient Clinic for Oncological Rehabilitation at the Department of Physical Medicine and Rehabilitation of the Medical University of Vienna
10127414|NCT04324242||Group1|visual feedback
10127415|NCT04324242||Group2|traditional feedback
10127416|NCT04324086|Experimental|XP-endo Finisher file|removal of calcium hydroxide intracanal medication with XP-endo Finisher file
9967630|NCT01271647|Experimental|chinese herb|
10127417|NCT04324086|Experimental|Irrisafe Ultrasonic tip|removal of calcium hydroxide intracanal medication with passive ultrasonic irrigation
10127418|NCT04324086|Active Comparator|side vented needle|removal of calcium hydroxide intracanal medication with conventional syringe irrigation
10183581|NCT03763253|Active Comparator|Intervention Arm 2: Radical Therapy|"Radical therapy in form of prostatectomy (any approach) or external beam radiotherapy (radical dose) in addition to SOC systemic treatment. Modality based on physician and patient preference and patient co-morbidities.~For patients undergoing radical prostatectomy no local prostate radiotherapy will be given as part of the intervention. Radiotherapy can be given subsequently for palliative reasons.~Radical radiotherapy doses in this arm will be higher than SOC.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
10183582|NCT03763227|Active Comparator|Carbonic Anhydrase Inhibitor (CAI) Arm|Patients who have received carbonic anhydrase inhibitor (CAI) therapy namely oral acetazolamide or topical brinzolamide
10183583|NCT03763227|Experimental|Intravitreal ranibizumab (IVR) arm|"Intravitreal ranibizumab (IVR) injection administered to patients who have not shown adequate response or who have not tolerated CAI therapy~IVR therapy = Three 0.5mg IVR injection at monthly intervals"
10183584|NCT03763214|Experimental|Stenting with PTFE-coated stent (HILZO)|The bile duct is stented with a PTFE-coated stent by duodenoscopy to allow bile duct flow
10183585|NCT03763214|Active Comparator|Stenting standard silicone coated stent|The bile duct is stented with a standard silicone-coated stent by duodenoscopy to allow bile duct flow
9967631|NCT01271647|Experimental|placebo|
9967632|NCT01271660|Active Comparator|Pregabalin|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
10183586|NCT03763201||rheumatoid arthritis|recently diagnosed rheumatoid arthritis patients in whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum and synovial fluid (if clinically determined knee effusion)
10183587|NCT03763201||control group|age and sex matched healthy volunteers whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum.
10183588|NCT03763188||the group BEFORE|Retrospective group. The daily urinary urea excretion was unknown.
10183589|NCT03763188||the group AFTER|Prospective group. Use the daily urinary urea excretion to guide the renal replacement therapy weaning.
10183590|NCT03763123|Experimental|Sevacizumab +Chemotherapy Combined chemotherapy drug including|Investigators selected single-agent chemotherapy on an individual patient basis from the following options, with appropriate premedication according to local standards: paclitaxel 80mg/m2 intravenously (IV)on days 1, 8, 15, and 22 every 4 weeks; or topotecan 4 mg/m2 IV on days 1, 8, and 15 every 4 weeks.
10183591|NCT03763110|Experimental|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
10183592|NCT03763110|Active Comparator|Antibiotic paste|Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation
10127419|NCT04324255||Low ratio|Liver recipient with low preoperative von Willbrand factor-to-protein C ratio
10127420|NCT04324255||High ratio|Liver recipient with high preoperative von Willbrand factor-to-protein C ratio
10127421|NCT04324190|Experimental|Online support program|Guided online support program, consisting of modules (structured in chapters) aiming at reduce stress related to the COVID-19 pandemic.
10127422|NCT04324190|Active Comparator|Waiting period (WHO recommendation)|"Waiting period (2 weeks duration) during which subjects are provided with the WHO recommendations Coping with stress during the 2019 nCoV outbreak. Following the 2 weeks waiting period, subjects are provided with the guided online support program outlined in the arm 'online support program'."
10127423|NCT04324190|No Intervention|No intervention (natural course)|"This non-randomised arm (recruited separately; anticipated sample size of 500 subjects, not counted in the overall anticipated sample size) consists of subjects not intending to participate in the Selfapy online support program. Assessment points in this arm are comparable to those in the arm Online support program (in the 'No intervention (natural course)' arm, T1 refers to time of study inclusion)."
10127424|NCT04324216|Experimental|Experimental group|3D virtual reality and hands-on aromatherapy
10127425|NCT04324216|No Intervention|Control group|No intervention
10127426|NCT04324060|Active Comparator|TPO treatment group|Danazol 0.2g tid po+rhTPO (recombinant human thrombopoietin injection) 300U/kg/d×14d si every month (stop when PLT≥100×10e9/L or increased more than 50×10e9/L), total course 6 months
10127427|NCT04324060|Placebo Comparator|control|Danazol 0.2g tid po+ control (sodium chloride)×14d si every month, total course 6 months
10127428|NCT04324294|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
10127429|NCT04324268|Placebo Comparator|Placebo|Placebo
10127430|NCT04324268|Experimental|SC 0.3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.
10127431|NCT04324268|Experimental|SC 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered subcutaneously.
10127432|NCT04324268|Experimental|SC 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered subcutaneously.
10127433|NCT04324268|Experimental|SC 5 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 5 mg/kg of lirentelimab (AK002) administered subcutaneously.
10127434|NCT04324268|Experimental|IV 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered intravenously.
10127435|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously.
10127436|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002) (Priming)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously from an IV bag prepared with extra volume for priming IV set.
10127437|NCT04324268|Experimental|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 300 mg of lirentelimab (AK002) administered subcutaneously.
10127438|NCT04324268|Experimental|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive a total of 450 mg of lirentelimab (AK002), administered as two separate subcutaneous injections.
10127439|NCT04324333|Experimental|Using Digital wearable system for fall detection|Digital wearable system (Owlytics Healthcare's app) enables a 24/7 health-tracking service, collecting personal health data from wearable wristbands and insoles. The data is analyzed by machine-learning algorithms that can detect abnormal physiological patterns. This allows the prediction and prevention of potentially harmful health events (such as falls).
10127440|NCT04324073|Experimental|SARILUMAB|Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1).
10127441|NCT04324073|No Intervention|Standard of care|best standard of care
10127442|NCT04323982|Experimental|New Cataract Surgery|Traditional surgery combined triamcinolone staining of the anterior vitreous (TA)
10127443|NCT04323982|Active Comparator|Traditional Cataract Surgery|For patients younger than 2 years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + A-vit) For patients older than 2years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + primary intraocular lens implantation + anterior vitrectomy (ACCC+ I/A + PCCC + IOL + A-vit)
10127444|NCT04324203|Experimental|Experimental group|Three-dimensional Virtual Reality and Horticultural Therapy
10127445|NCT04324203|No Intervention|Control group|No intervention
10127446|NCT04323787||COVID19 test positive/pending or high clinical suspicion|COVID19 test positive/pending/high clinical suspicion- patient admitted to hospital
10127447|NCT04323670|Other|Selectra 3D|Guiding catheter to position the brady lead into a untypical heart position
10127448|NCT04323865||Study 2. Repeatability of FHRV|
10127449|NCT04323748|Experimental|rituximab|All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
10127450|NCT04323826|Experimental|salads with olive oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water mixture will be provided to consume.
10127451|NCT04323826|Experimental|salads with olive oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
10127452|NCT04323826|Experimental|salads with coconut oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
10127453|NCT04323826|Experimental|salads with coconut oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water mixture will be provided to consume.
10183593|NCT03763097||participants|Patients who are scheduled for single-incision needleless (Contasure-needleless®) mini-sling for their stress urinary incontinence. They will be assessed by Pelvic floor ultrasound
9519552|NCT03286049||Rhinitis children, seasonal allergy, outside season (OSR)|10 rhinitis children sensitized to seasonal allergens, observed outside the allergen season
10127454|NCT04323735|Active Comparator|Low Dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 ]LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
10127455|NCT04323735|Active Comparator|High dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
10127456|NCT04324008|Experimental|Constic|Constic (DMG, Hamburg, Germany)
10127457|NCT04324008|Experimental|G-ænial Universal Flo|G-ænial Universal Flo (GC Corporation, Tokyo, Japan) in combination with G-Premio Bond (self-etch mode)
10127458|NCT04324008|Experimental|Tetric N-Flow (self-etch)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (self-etch mode)
10127459|NCT04324008|Experimental|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (etch&rinse mode)
10127460|NCT04323813||Cases|CRC patients: primary, Stage I-IV (localized, node negative or node positive) colon carcinoma confirmed by tissue biopsy, and patients with advanced adenoma (including high-grade dysplasia, HGD).
10127461|NCT04323813||Controls|Controls subjects as well as healthy clean colonoscopy subjects or with hyperplastic polyps, and healthy subjects with diminutive adenoma-low grade dysplasia (LGD) and with inflammatory bowel disease (IBD).
10127462|NCT04323956|Experimental|Treatment (parsaclisib, R-CHOP)|Patients receive parsaclisib PO QD on days 1-10 or 1-14, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
10127463|NCT04323722|Experimental|Empty bladder|Planning CT scan and CBCTs with empty bladder after standard Planning CT scan and CBCTs with filling bladder
10127464|NCT04323566|Experimental|Treatment-first arm|Participants receive i.v. infusions with 500 mg Rituximab at 0 and 4 months, followed by placebo infusions (NaCl) at 8 and at 12 months, Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
10127465|NCT04323566|Experimental|Placebo-first arm|Participants receive placebo (NaCl) i.v. infusions at 0 and 4 months, followed by 500-mg-Rituximab infusions at 8 and 12 months. Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
10127466|NCT04323904||Hantavirus Group|Patients with cultural, serological, molecular evidence of hantavirus infection
10127467|NCT04323904||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
10127468|NCT04323618|Other|Free breathing or Breathe Well|Free breathing or Breathe Well
10127469|NCT04323709||levosimendan group|All patients undergoing VA-ECMO from January 2012 to December 2018 and treated with levosimendan were eligible.
10127470|NCT04323709||group control|All patients undergoing VA-ECMO from January 2012 to December 2018 but not treated with levosimendan were eligible.
10127471|NCT04323696|Other|Over-sewing|Patients under over-sewing arm are subjected to staple line reinforcement using over-sewing method
10127472|NCT04323696|Other|Plication|Patients under over-sewing arm are subjected to staple line reinforcement using plication method
10127473|NCT04323449|Experimental|Vision-guided control|New custom control method
10127474|NCT04323449|Experimental|Default control|Default control method (joystick or switch)
10127475|NCT04323605|Experimental|outpatient assistance program|
10127476|NCT04323930|Experimental|eyeWatch|
10127477|NCT04323930|Experimental|Trabeculectomy|
10127478|NCT04323683||Low progesterone|Women with progesterone level below 15 ng/ml
10127479|NCT04323683||Normal progesterone|Women with progesterone level above 15 ng/ml
10127480|NCT04323969|Experimental|Specific Modification Target|A 15 degree relative increase to foot progression angle
10127481|NCT04323969|Experimental|Self-directed Modification|"A self-directed increase to foot progression angle that is as much as is comfortable."
10127482|NCT04323917||Cases|Subjects affected by Pancreatic carcinoma (PC) confirmed by tissue biopsy
10127483|NCT04323917||Controls|Healthy Subject enrolled following colon cancer screening via colonoscopy
10183594|NCT03763084|Experimental|acetaminophen|For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
10183595|NCT03763084|Active Comparator|Sufentanil|Sufentanil injection 500μg /10ml in normal saline, total volume 50 ml.Constant infusion dosage is 0.05μg/kg/h. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
10183596|NCT03763071||Participants|Pregnant women in the 2nd or 3th trimester Patient-reported scales to measure sleep disorders
10127484|NCT04323384|Experimental|Biotene® followed by Sham|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into either Protocol A or Protocol B. In their first session, participants in Protocol A will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the experimental condition. For the experimental condition, participants will be instructed to apply Biotene® Oralbalance Moisturizing Gel according to package directions. Testing will then be repeated. In the second session, after baseline testing, participants will receive the sham condition (instead of the experimental condition). For the sham condition, participants will be instructed to rinse their mouth with room temperature distilled water. Testing will then be repeated.
10127485|NCT04323384|Experimental|Sham followed by Biotene®|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into two protocols: 1) Protocol A and 2) Protocol B. In their first session, participants in Protocol B will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the sham condition. Testing will then be repeated. In the second session, after baseline testing, participants will receive the experimental condition (instead of the sham condition). Testing will then be repeated.
10127486|NCT04323410|Experimental|Cast immobilization|"In the casting group, padded synthetic dorsal above elbow and volar below elbow splints are applied in ED without local or general anesthesia. Dorsal displacement and shortening of the radius are not corrected, but the forearm is attempted to be manipulated straight during application of the splints. The casted forearm is then supported by a collar and cuff sling. Splints are removed in an outpatient clinic at 4 weeks.~Cast immobilization is discontinued after 4 weeks and when the fracture site is nontender. If palpated tenderness is still present, the patient is given a dorsal forearm splint which can be removed (maximum of 2 weeks usage)."
10127487|NCT04323410|Active Comparator|Percutaneus pinning|In the surgery group, a padded dorsal above elbow splint is applied in ED. Reduction and percutaneous pinning are performed under anesthesia in operating room by an experienced attending pediatric orthopedic surgeon within 7 days from the injury. Pin fixation is performed with two 1.6 mm pins. Padded dorsal above elbow and volar below elbow splints are applied. Splints and pins are removed at the outpatient clinic at 4 weeks after surgery.
10127488|NCT04323657|Experimental|Phase 1|The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort.
10127489|NCT04323657|Experimental|Phase 2|The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen.
10127490|NCT04323332|Experimental|Traditional Chinese Medicine|TCM prescription and conventional treatments
10127491|NCT04323332|No Intervention|Control|conventional treatments
10127492|NCT04323579||prospective cohort of stage I-II lung cancer patients|A prospective cohort of stage I-II lung cancer patients (N=80) candidates to surgery at Humanitas, and 40 controls with benign nodules.
10127493|NCT04323579||retrospective screening cohort of 50 patients|A retrospective screening cohort of 50 patients with screened lung cancer at MUG.
10127494|NCT04323579||prospective screening cohort of 30 patients|A prospective screening cohort of 30 patients with screened lung cancer and 100 matched negative controls enrolled at Humanitas cohort of 1000 participants (expected annual rate 1.5%).
10127495|NCT04323579||retrospective screening cohort from the NELSON study|A retrospective screening cohort from the NELSON study.
10127496|NCT04323579||Prospective cohort of stage IV lung cancer patients|A Prospective cohort of stage IV lung cancer patients (N=30) candidate to systemic therapy.
10127497|NCT04323488|Experimental|Lindamood-Bell Seeing Stars|Subjects receive reading instruction focusing on the building blocks of reading
10127498|NCT04323488|No Intervention|Control|Subjects are followed longitudinally but do not receive intervention
10127499|NCT04323527|Active Comparator|Low Dose Chloroquine Diphosphate (5 days) (Study stage 1) - Clorocovid 1|Low dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
10127500|NCT04323527|Active Comparator|High Dose Chloroquine Diphosphate (10 days) (Study stage 1) - Clorocovid 1|High dose chloroquine group consists of 600 mg bid (4 tablets of 150 mg, every 12 hours) for 10 days. Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
10127501|NCT04323527|Placebo Comparator|Placebo (5 days) (Study stage 2) - Clorocovid 3|Placebo group consists of 3 placebo tablets bid (day 1), and 3 placebo tablets once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
10127502|NCT04323527|Active Comparator|Low Dose Chloroquine Diphosphate (5 days) (Study stage 2) - Clorocovid 3|Low dose chloroquine group consisted of 450 mg bid (3 tablets of 150 mg) on D1, and 3x150mg tablet once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
10127503|NCT04323540|Active Comparator|Xenograft+collagen membrane|Reconstructive approach (Xenograft+collegen membrane)
10127504|NCT04323540|Experimental|Xenograft+collagen membrane+autologous soft tissue graft|Reconstructive approach (Xenograft+collegen membrane) plus soft tissue graft (autologous, harvested as FGG)
10127505|NCT04323514|Experimental|Patients with COVID-19 pneumonia|Consecutive patients with COVID-19 pneumonia admitted to ARNAS Civico-Di Cristina-Benfratelli, Palermo
10127506|NCT04323644||Cohort 1|Patients with COVID-19 infection undergoing surgery
10127507|NCT04323423|No Intervention|Control (CON)|1) Condition A (CON): This will be the control condition. It will consist of uninterrupted sitting from 8 am until 7 pm, only rising from the chair to void.
10183597|NCT03763045|Experimental|Sildenafil 25|Twenty hemodialysis patients will receive a dose of 25mg sildenafil daily for 3 months.
10183598|NCT03763045|Experimental|Sildenafil 50|Twenty hemodialysis patients will receive a dose of 50mg sildenafil daily for 3 months.
10127508|NCT04323423|Experimental|one 10 minute bout - (LONG)|will consist of completing one 10-minute bout of light intensity walking (RPE 6-9) 30 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform this bout. The participant will repeat this after lunch and dinner, for an accumulated total of 30 minutes of light walking.
10127509|NCT04323423|Experimental|four 2.5 minute bouts SHORT|will consist of interrupting sitting with four 2.5-minute bouts of light walking at 30 minutes, 60 minutes, 90 minutes and 120 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform these bouts. The participant will repeat this after breakfast, lunch and dinner for an accumulated total of 30 minutes of light walking.
9826023|NCT02404350|Placebo Comparator|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders were switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
10127510|NCT04323345|Experimental|Natural Honey Group|"Natural Honey~1gm/kg/day divided into 2 to 3 doses for 14 days in addition to standard care"
10127511|NCT04323345|Active Comparator|Standard Care|Current standard care including supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
10127512|NCT04323501|Experimental|Experimental treatment group|"This group will undergo an intensive-rehabilitation treatment of post-stroke sensorimotor disability based on a guided self-rehabilitation contract. This approach is based on the fact that the patient must complete a diary of his self-rehabilitation activity in order to verify its correct and full execution. The treatment protocol will be defined on the basis of the clinical picture (patterns) manifested by the patient (the intensity and frequency of the exercises will be adapted according to the characteristics of each patient). The duration of treatment will be the same for all patients. The exercises will be performed every day throughout the study period (12 months).~Before undertaking the intensive self-management treatment, each patient will undergo 10 sessions of neurorehabilitation treatment at the UOC Neurorehabilitation of the Integrated University Hospital according to normal clinical practice, during which the patient will be provided with infographic support material."
10127513|NCT04323501|Active Comparator|Control group|The patients allocated to the control group, during the study period they will undergo conventional outpatient rehabilitation treatment (usual care) at the Neurorehabilitation Unit of the AOUI according to the clinical practice through the procedures provided for by the Health System National.
10127514|NCT04323631|Experimental|The intervention group|The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).
10127515|NCT04323631|Other|The control group|The control group will not receive hydroxychloroquine.
10127516|NCT04323358|Active Comparator|IOL Master® 700|Biometry will be performed three times consecutively.
10127517|NCT04323358|Active Comparator|Pentacam®|Keratometry will be performed three times consecutively.
10127518|NCT04323358|Active Comparator|Casia II®|Keratometry will be performed three times consecutively.
10127519|NCT04323358|Active Comparator|Spectralis Anterion®|Biometry will be performed three times consecutively.
10127520|NCT04323371||Acute decompensated heart failure|patients admitted with Acute decompensated heart failure Complicated by cardiogenic shock
10127521|NCT04323319|Experimental|ESWT Group|Patients in the ESWT group will be treated with ESWT once a week for 4 weeks. Each patient was treated with epine calcaneus and its surroundings. The treatment dose of 10 Hz, 2.5 bar, 2000 shock wave with BTL L-6000 SWT device will be applied by the same therapist. Patient completed plantar fascia and gastrocnemius streching exercises right after treatment. The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
10127522|NCT04323319|Experimental|Graston Technique® Group|The application was carried out by Graston Technique® (GT®) certified, a therapist with orthopedic rehabilitation and soft tissue treatments for over 12 years. GT® instruments were used to diagnose and treat the damaged soft tissue of gastrocnemius and plantar fascia. The application protocol and the instruments used according to the regions were determined with reference to the GT® manual. GT® treatment can be given to the same region twice a week. A minimum of 2 days break was given between the applications. Gastrocnemius and plantar fascia application completed in 5 minutes in one leg. GT2, GT4 and GT6 instruments used for application.The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
10127523|NCT04323319|Experimental|Control Group|Stretching group was accepted as the control group. the patient monitored once a week at the hospital and continue home stretching program at home. These patients will be given information about plantar fasciitis as well as other groups. Plantar fascia and gastrosoleus self-stretching exercises will be required to be performed twice a day for thirty seconds and three repetitions for 4 weeks. The patients will be followed with an exercise follow-up form.
10183599|NCT03763045|Placebo Comparator|Placebo|Twenty hemodialysis patients will receive a placebo tablet daily for 3 months.
10183600|NCT03763032|Experimental|Stepped Interventions|Patient navigation intervention, plus various psychosocial interventions
9519553|NCT03286049||Rhinitis children, seasonal allergy, within season (WSR)|10 rhinitis children sensitized to seasonal allergens, observed during the allergen season
9519554|NCT03286036||Lung cancer patients|Patients with lung cancer who undergo surgical resection of the tumor
9519555|NCT03286023||Stereotactic radiation|Stereotactic radiation for brain metastases
9826024|NCT02404389|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
10127524|NCT04322955|Experimental|Treatment with cabozantinib and nivolumab with nephrectomy|"All study participants will receive the same study medications, cabozantinib and nivolumab. The study drug, nivolumab, will be administered through an IV infusion every 4 weeks and cabozantinib will be administered orally daily. Initially participants will receive study treatment for 12 weeks. The cabozantinib will then be stopped prior to the nephrectomy. Initially patients enrolled on the study will be assigned to cohort 1.~Patients who are assigned to cohort 1 will be treated with cabozantinib until 21 days prior to surgery. A patient in cohort 1 will be evaluable for assessment of the cabozantinib washout interval (evaluable patients) if they~complete at least 10 of the 14 scheduled cabozantinib doses in the two week period prior to stopping cabozantinib AND~have surgical resection of the primary tumor.~In cohort 2, subjects will receive cabozantinib until 14 days prior to nephrectomy."
10127525|NCT04323280|Active Comparator|Conventional Therapy|Ibuprofen 600mg every 8 hours for one week followed by tapering of dose by 200mg every week (3 weeks of therapy), in addition to Colchicine 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg) for 3 months
10127526|NCT04323280|Experimental|Dexamethasone therapy|Dexamethasone therapy 20 mg once daily per os for 4 day in addition to colchicine therapy for 3 months 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg)
10127527|NCT04322994|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
10127528|NCT04322994|Experimental|Intervention|"Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-4L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.~Intervention: Device: High-flow nasal cannula"
10127529|NCT04323007|Other|Nephrotic syndrome patients|This study is to evaluate Thyroid Hormone profile in patients with Nephrotic syndrome to identify clinical predictor of Thyroid dysfunction in patients with Nephrotic syndrome
9826025|NCT02404389|Experimental|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
10127530|NCT04323085|Active Comparator|Speech-in-Noise Treatment Program|A behavioural speech therapy program involving 12, one-hour treatment sessions over a 4-week period
10127531|NCT04323085|Active Comparator|Speech-to-Noise Feedback Device Program|A speech treatment program involving the use of a speech-to-noise feedback device during 12, one-hour treatment sessions over a 4-week period
10127532|NCT04323085|No Intervention|Delayed Treatment|Assessments but no intervention for a period of 13 weeks.
10127533|NCT04323267|Experimental|Digital Home Exercise Program|Limber Digital Application Device (3 x a week for 8 weeks)
10127534|NCT04323267|Active Comparator|Physical therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
10127535|NCT04323241|No Intervention|control group|In group 1, plasenta is removed manually. Manual removal of the placenta will be performed by placing surgeon's dominant hand in the uterine cavity and removing the placenta by detaching it from the uterine wall as soon as possible after the delivery of the infant. The emptiness of the uterine cavity is verified manually.
10127536|NCT04323241|Experimental|Study Group|In group 2, plasenta is removed by controlled cord traction. Spontaneous removal will be performed by external uterine massage and traction on the umbilical cord are performed to assist spontaneous delivery of the placenta.
10127537|NCT04323072|Experimental|Group A|Resection of antrum proximally 2 cm to the pylorus
10127538|NCT04323072|Active Comparator|Group B|Resection of antrum proximally 6 cm to the pylorus
10127539|NCT04323059|Experimental|Standardized milk-based formulation|Formulation of maize with milk that is rich in methionine
10127540|NCT04323059|Experimental|Standardized non-milk based formulation|Formulation of maize with soybeans that is rich in methionine and lysine
10127541|NCT04323059|Active Comparator|Hospital-based formulation|Formulation of maize, milk and soybeans
10127542|NCT04323176|Experimental|Village Model|Participate as a member of the Village using a website for 12 months.
10127543|NCT04323215||Support system users|Usual care (behavioral treatment) plus the support system for self-monitoring of weight and communication with the clinic during one year of treatment.
10127544|NCT04323215||Control group|Children treated with usual care according to regular treatment routines registred in BORIS the Swedish childhood obesity treatment register
10127545|NCT04323228|Experimental|Intervention|the intervention groups will receive daily oral antioxidant supplement enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc.
10127546|NCT04323228|Placebo Comparator|Placebo|Placebo group will receive daily intervention in form of cellulose-containing gelatin capsules with the same color and shape.
10127547|NCT04322942||Non-infection|
10127548|NCT04322942||Infection without sepsis|
10127549|NCT04322942||Sepsis-2|
9826026|NCT02404389|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
9826027|NCT02404389|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
10127550|NCT04322942||Sepsis-3|
10127551|NCT04322916||RM Pressfit vitamys|Participants treated with a RM Pressfit vitamys hip cup in combination with a Mathys hip stem
9967633|NCT01271660|Placebo Comparator|Placebo|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
10127552|NCT04323020|Experimental|Comatose cardiac arrest patients|Comatose cardiac arrest patients will be undergoing CT perfusion test
9826028|NCT02404389|Active Comparator|Aldara|Aldara cream 3 applications per week
10127553|NCT04322903|Experimental|Trauma-informed mindfulness-based stress reduction program|The program includes three 2-hr sessions to promote physical and emotional wellbeing through mindfulness techniques and health promotion activities; two home visits to provide individualized sessions with a nurse and a community health navigator; and a follow-up session 4 weeks after intervention to discuss perception of the intervention.
10127554|NCT04322929|Experimental|Oral roflumilast|Oral roflumilast 250 microgram daily will be started at the baseline visit for 4 weeks. For those who can tolerate the initial 4-week treatment, roflumilast will be increased to 500 microgram daily, allowing subsequent dose reduction back to 250 microgram daily in case of CTCAE grade 3 or 4 toxicities.
10127555|NCT04322760|Active Comparator|Group A (control group)|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly without lidocaine patch
10127556|NCT04322760|Experimental|Group B|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly with a patch of lidocaine 5% was applied to the skin
10127557|NCT04322656|Active Comparator|Effect of Lipiflow treatment on biometrical outcomes|One eye of each patient will be treated with Lipiflow
10127558|NCT04322656|No Intervention|Control eye|The contralateral eye will serve as control eye
10127559|NCT04322565|Experimental|Colchicine|Administration of Colchicine 1mg (or 0.5 mg in CKD)/day + standard of care for COVID-19 pneumonia
10127560|NCT04322565|No Intervention|Standard of care|Standard of care for COVID-19 pneumonia
10127561|NCT04322630||Pediatric Cardiac Bypass Patients|Blood samples obtained from patients ages from birth-19 years-old as well as cyanotic and acyanotic cardiac lesions who underwent cardiac bypass.
10127562|NCT04322604|Placebo Comparator|Placebo|Placebo
10127563|NCT04322604|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): a first dose of 1 mg/kg followed by 5 monthly doses of 3 mg/kg.
10127564|NCT04322643|Experimental|CPI therapy|Patients will be treated with CPI therapy for at least 24 weeks (+/- 4 weeks) as per standard of care (SOC), at which time those with a tumor burden reduction of 10% or greater will suspend CPI therapy.
10127565|NCT04322747||Participants scheduled to undergo skull-based surgery|Participants scheduled to undergo skull-based or mastoid surgery as part of their standard care will receive Audiometry for extended high frequencies, DPOAE, ECochG before and after the procedure in the non operated ear.
10127566|NCT04322877|Experimental|Body surface mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and non-invasive body surface mapping.
10127567|NCT04322877|Experimental|Catheter-based mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and invasive catheter-based mapping.
10127568|NCT04322825|Experimental|intervention|24 weeks of TENS
10127569|NCT04322552|Experimental|Treament|In phase A, subjects receiving a single 0.25 mg of digoxin orally and wash-out for 5 days, then apatinib once daily will be conducted on D5 through D16 ； In addition, a single dose of 0.25 mg digoxin (in combination with apatinib) will be orally administered in fasting conditions on D12；
10127570|NCT04322773|Experimental|Roactemra iv|Single dose treatment with 400 mg tocilizumab intravensously
10127571|NCT04322773|Experimental|Roactemra sc|Single dose treatment with 2 x 162 mg tocilizumab subcutaneously
10127572|NCT04322773|Experimental|Kevzara sc|Single dose treatment with 1 x 200 mg sarilumab subcutaneously
10127573|NCT04322773|Active Comparator|Standard care|Management as usual
10127574|NCT04322734||ASD (General)|150 children with ASD and unknown MD status
10127575|NCT04322734||ASD (With MD)|50 children with ASD and confirmed MD
10127576|NCT04322734||ASD (No MD)|50 children with ASD and ruled out MD
10127577|NCT04322734||Epilepsy|50 children with epilepsy (primary) and no ASD
10127578|NCT04322734||Brain Tumor|50 children with brain tumor (primary) and no ASD
10127579|NCT04322734||Psychiatric Disorder|50 children with psychiatric disorder (primary) and no ASD, using lithium treatments
10127580|NCT04322734||MD (No ASD)|50 children with MD (primary) and no ASD
10127581|NCT04322734||TD (With ASD Sibling)|50 TD children with a sibling with ASD/neurodevelopmental delay
10127582|NCT04322734||TD (No ASD Sibling)|50 TD children with no siblings with ASD/neurodevelopmental delay
10127583|NCT04322695|Experimental|Rehabilitation Education Care Program (RECP)|Cancer rehabilitation program and patients education can improve disability and promote return to work.
10127584|NCT04322695|Other|Usual care|Usual care
10127585|NCT04322838||Patients|30 patients with self-reported seasonal allergic airway symptoms in the period from 1st of August to 15.th of october
10127586|NCT04322838||Controls|15 non-allergic individuals
10127587|NCT04322812|Active Comparator|Active PBMT|Active PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
10127588|NCT04322812|Placebo Comparator|Placebo PBMT|Placebo PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
10127589|NCT04322708|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo.
10127590|NCT04322708|Experimental|1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).
10127591|NCT04322708|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.
10127592|NCT04322786||ACEI user|Individuals with an ACEI prescription in the study population.
10127593|NCT04322786||Matched controls|Individuals without an ACEI prescription, and matched to the users by sex and 10-year age categories.
10127594|NCT04322799|Experimental|Acetabular cup HXLPE (Intervention)|Randomization to HXLPE acetabular component.
10127595|NCT04322799|Experimental|Acetabular cup Conventional PE (control)|Randomization to Coventional PE as control group
10127596|NCT04322851||B-line positive|
10127597|NCT04322851||B-line negative|
10127598|NCT04322461|Experimental|Parkinson disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
10127599|NCT04322461|Experimental|Alzheimer's disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
10127600|NCT04322435|Other|Adrenal insufficiency|Patients followed in the paediatric endocrinology department of the Necker Hospital, with primary and secondary adrenal insufficiency, aged from 6 months to 6 years.
10127601|NCT04322344|Experimental|oral escin group|Standard therapy+Escin tablet 40mg*3, os for 12 days
10127602|NCT04322344|Sham Comparator|control group|standard therapy
10127603|NCT04322344|Experimental|parenteral escin group|standard treatment + sodium Escinate 20mg iv/day for 12 days
10127604|NCT04322422|Experimental|ICS/LABA plus Montelukast|
10127605|NCT04322422|Active Comparator|ICS/LABA only|
10127606|NCT04322175|Experimental|Single dose pharmacokinetic test|The 72 healthy subjects enrolled were admitted to the trial ward the day before the trial. On the day of dosing, the subjects were given 0.1% meloxicam eye drops once, 1 drop / time.
10127607|NCT04322175|Experimental|Multiple dose tolerance test|Eight healthy subjects were enrolled in the trial ward the day before the trial. 0.1% meloxicam eye drops were administered 4 times, 1 drop / time, and were administered at 8:00, 12:00, 16:00 and 20:00 daily for 3 consecutive days.
10127608|NCT04322214|Experimental|COBI period (5 days) + Placebo period (5 days)|volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB
10127609|NCT04322214|Experimental|Placebo period (5 days) + COBI period (5 days)|volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB.
10127610|NCT04322240|Experimental|type 2 DM with peripheral neuropathy|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication, antidiabetic drugs, or medications used for managing arterial hypertension or dyslipidaemia during the study.
10127611|NCT04322188||group 1|Patients in Cohort A were treated with siltuximab after the use of continuous positive airways pressure (CPAP) or non-invasive ventilation (NIV). Patients in Cohort B were treated after intubation
10127612|NCT04322188||Group 2|The control cohort will include all the patients with pneumonia/ARDS in need of non-invasive ventilation (CPAP or NIV) or intubation and not receiving experimental treatments in the ReCOVID-19-2020
10127613|NCT04322045|Experimental|participants|All tested serum PSA. Some conducted mpMRI with/without prostate biopsy under instruction.
10127614|NCT04322227|Experimental|Healthy|
10127615|NCT04322227|Experimental|PD|
10127616|NCT04322201|Experimental|Intervention group - Continuous passive paracentesis|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care.
10127617|NCT04322201|Active Comparator|Control group - Large volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter performed and repeated during ICU stay according to standard-of-care clinical practice.
10127618|NCT04322331||T1N+|T1 tumor with positive lymph node,N1/N2/N3
10127619|NCT04322331||T2/T3N0|T2/T3 tumor with negative lymph node
10127620|NCT04322019||"Amikacin treatment group"|Intensive care patients on renal replacement therapy with Amikacin treatment
10127621|NCT04322253|Experimental|Neladenoson bialanate, mild hepatic impairment|Subjects with Child Pugh score 5 or 6 received a single immediate-release (IR) tablet dose of 10 mg neladenoson bialanate in the fasted state
10127622|NCT04322253|Experimental|Neladenoson bialanate, moderate hepatic impairment|Subjects with Child Pugh score 7-9 received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
10127623|NCT04322253|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
10183601|NCT03763019|Active Comparator|Respiratory rehabilitation|"Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.~Respiratory exercises 30 minutes, once daily, (incentive spirometric trainer, forced expiration, percussion, postural drainage etc.)"
10183602|NCT03763019|Placebo Comparator|Conventional rehabilitation|Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
10183603|NCT03763006|Experimental|Ocudox lid wiped|
10183604|NCT03763006|Active Comparator|Povidone Iodine|
10183605|NCT03762980|Experimental|Right hemiplegic patients|
10183606|NCT03762980|Experimental|Left hemiplegic patients|
10183607|NCT03762967|Experimental|Lipoaspiration and SVF introduction I.|Patients with azoospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
10183608|NCT03762967|Active Comparator|Standard therapy I.|Patients with azoospermia that introduce with Standard therapy only.
10183609|NCT03762967|Experimental|Lipoaspiration and SVF introduction II|Patients with oligospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
10183610|NCT03762967|Active Comparator|Standard therapy II.|Patients with oligospermia that introduce with Standard therapy only.
10183611|NCT03762954||Research Subjects|All adults aged 60 years or older scheduled to undergo outpatient ERCP and/or EUS at Vanderbilt University Medical Center (VUMC) will be invited to participate in the study. Invited patients who consent to participate as study subjects will undergo neurocognitive and functional assessment pre-procedure and at 90 days post-procedure.
10183612|NCT03762928|Experimental|midazolam/efavirenz|
10183613|NCT03762928|Experimental|PF-06651600/midazolam/efavirenz|
10183614|NCT03762915|Experimental|SRP with minocycline HCl microspheres|The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.
10183615|NCT03762915|No Intervention|SRP without minocycline HCl microspheres|The control group will not have minocycline HCl microspheres, 1 mg administered.
10183616|NCT03762889|Experimental|Eyeprotx™ Group|This group of participants will use the Eyeprotx™ General Anesthesia Protective Goggles when intubated perioperatively under general anesthesia.
10127624|NCT04322266|Experimental|Sequence 1 (Reference-Test)|Period1: HCP1306+HGP0904+HGP0608, Period 2: HCP1701
10127625|NCT04322266|Experimental|Sequence 2 (Test-Reference)|Period1: HCP1701, Period 2: HCP1306+HGP0904+HGP0608
10127626|NCT04322110|Experimental|VLCK diet group|Subjects undergoing treatment with weight loss program PronoKal Method
10127627|NCT04322110|Active Comparator|Control group|Subjects undergoing treatment with low calorie diet
10127628|NCT04322071||Lower risk of long term complications|Young people with diabetes who have HbA1c <58mmols/mol, and family members.
10127629|NCT04322071||Higher risk of long term complications|Young people with diabetes who have HbA1c ≥75mmols/mol and <100mmols/mol, and family members.
10127630|NCT04322136|Other|IPC (with talc pleurodesis if suitable)|"The patients will undertake daily drainage to day 14 post insertion. The drainage will either be performed by the participant's carer or nurses in the community. A bottle or bag will be attached to the drain to allow for removal of accumulated pleural fluid. Once completed the drain will be reattached to the pleural catheter.~Participants will be taught how to perform pleural drainage by the main study doctor at the hospital or a specialist nurse. They will drain their own IPCs at home with the either the help of a family member or friend or have access to community nursing support systems."
10127631|NCT04322136|Other|Pleurodesis via VATS|Participants will undergo VATS within two weeks of randomisation. VATS is usually performed in an operating theatre, using either general anaesthesia or local anaesthesia with sedation. The pleural fluid will be removed and adhesions can be divided (adhesiolysis). Assessment of lung re-expansion will be performed intra-operatively. If lung re-expansion is adequate (as judged by the operating surgeon), a variety of techniques may be employed to induce a pleurodesis, including, but not limited to, talc poudrage and mechanical abrasion. Decortication may be performed if deemed appropriate and feasible by the operating surgeon. A chest drain will be left in situ after the surgery. Post-operative care will be administered as per local practice.
10127632|NCT04322292|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene.
10127633|NCT04322409|Experimental|NMES|The experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus.
10127634|NCT04322409|Placebo Comparator|TENS|The placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus
10127635|NCT04322032|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
10127636|NCT04322032|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
10127637|NCT04321967|Experimental|Nitroglycerine paste|The randomized breast will receive Nitroglycerine paste and Dermabond.
10127638|NCT04321967|Placebo Comparator|Dermabond|The control breast will receive Dermabond only
10127639|NCT04321941|Experimental|CTE (Computerised Tomography Enterography)|CTE examination performed with experimental contrast agent, Lumentin.
10127640|NCT04321941|Active Comparator|MRE (Magnetic Resonance Enterography)|Comparative diagnostic method performed with the contrast agent Movprep®
10127641|NCT04321811||Participants|"Adult men and women currently in the United States and willing to provide written informed consent and:~who are feeling sick but have not tested positive for COVID-19~who are feeling sick and have tested positive for COVID-19~People who are not feeling sick but want to participate"
10127642|NCT04321798|Experimental|Physical Activity|Promoting Engagement in Physical Activity
10127643|NCT04321785|Placebo Comparator|Placebo|
10127644|NCT04321785|Experimental|Caffeine|
10127645|NCT04321655|Experimental|High Intensity LASER Therapy group (HILT)|Forty patients with chronic KOA in HILT group will received Class IV LASER therapy. A Class IV LASER emits power more than 500 milliwatt (mW) .
10127646|NCT04321655|Experimental|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in ibuprofen gel phonophoresis (IGP) group will administered with continuous ultrasound set at a frequency of 1 megahertz (MHz) and an intensity of 1 W/cm2 was applied on a circular basis.
10127647|NCT04321655|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with chronic KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
10127648|NCT04321655|Active Comparator|Conventional physiotherapy group (CPT)|Individual with chronic KOA will be educated on how to do the set of exercises correctly at their home during the first session. All the groups will receive the same, standardized exercise protocol for KOA which consisted of nine exercises including muscle strengthening and flexibility training.
10127649|NCT04321642|Experimental|Entonox|Inhalation Entonox in active phase of labor ( cervical dilatation more than 5 cm ) Inhaled Entonox before true uterine contraction in 30 sec , inhaled in 4-5 times for 1 contraction
10127650|NCT04321642|Active Comparator|Not receive Entonox|Not receive any gas when archive in active phase of labor( cervical dilatation more than 5 cm )
10127651|NCT04321850|Placebo Comparator|Group1|Control
10127652|NCT04321850|Experimental|Group 2|Intervention (Zinc)
10127653|NCT04321616|Active Comparator|Hydroxychloroquine|
10127654|NCT04321616|Active Comparator|Remdesivir|
10127655|NCT04321616|Active Comparator|Control group - SoC|
10127656|NCT04321590|Experimental|3 g 35% beta-glucan|Supplement containing 3 g of 35% oat beta-glucan
10127657|NCT04321590|Experimental|5 g 35% beta-glucan|Supplement containing 5 g of 35% oat beta-glucan
10127658|NCT04321590|Experimental|3 g 70% beta-glucan|Supplement containing 3 g of 70% oat beta-glucan
10127659|NCT04321590|Experimental|5 g 70% beta-glucan|Supplement containing 5 g of 70% oat beta-glucan
10127660|NCT04321499||lung cancer|stage IA-IIIA lung cancer
10127661|NCT04321499||benign nodules|ruled out lung cancer via Operation or CT-scan follow-up
10127662|NCT04321603|Other|People living with HIV|Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three.
10127663|NCT04321876||NMG IM 211 E Chicago Ave|
10127664|NCT04321876||NMG IM ARKES|
10127665|NCT04321876||NMG IM 1460 N Halsted St|
10127666|NCT04321876||NMG IM 201 E Huron St|
10127667|NCT04321876||NMG Integrative Medicine 150 E Huron St|
10127668|NCT04321876||NMG IM 1776 N Milwaukee Ave|
10127669|NCT04321876||NMG IM 20 S Clark St|
10127670|NCT04321876||NMG IM FM 1704 Maple Ave|
10127671|NCT04321876||NMG IM 259 E Erie St|
10127672|NCT04321876||NMG IM 1135 S Delano Ct|
10127673|NCT04321876||NMG IM 1333 W Belmont Ave|
10127674|NCT04321824||the innovative programm (PASS de ville)|specific care for precarious people
10127675|NCT04321824||the standard of care|
10127676|NCT04321720|Experimental|3-g footbath|Footbath with 3g mustard flour per liter of water
10127677|NCT04321720|Experimental|6-g footbath|Footbath with 6g mustard flour per liter of water
10127678|NCT04321720|Experimental|12-g footbath|Footbath with 12g mustard flour per liter of water
10127679|NCT04321720|Placebo Comparator|Warm water footbath|Footbath with warm water only
10127680|NCT04321629|Experimental|Autologous Fat Tissue Group|Group of patients treated with intra-articular injections of autologous adipose tissue.
10127681|NCT04321629|Active Comparator|PRP Group|Group of patients treated with intra-articular injections of platelet-rich-plasma.
10127682|NCT04321772|Experimental|High Intensity Interval Resistance Training (HIIRT)|"HIIRT technique consisted of three sets of: 6 repetitions at 80% 1RM (1 repetition maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30 rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets."
10127683|NCT04321772|Active Comparator|Traditional Resistance Training (TRT)|"TRT protocol performed 3 series of 15 repetitions at 60% 1RM with 75 of rest between sets."
10127684|NCT04321837|Active Comparator|Coral calcium complex and ibandronate|
10127685|NCT04321837|Active Comparator|Ibandronate and vitamin D|
10127686|NCT04321837|Active Comparator|Coral calcium complex|
9967634|NCT01271673||Women undertaking Breast Self Examination|Women attending Preventive Oncology Clinic during the month of November- December 2010,and undertaking BSE training whose Residential address mentioned as Mumbai and whose Contact number is available.
10127687|NCT04321538||Failed Vision Screen Cohort|This cohort represents the entire group of study participants- children who were referred to Yale New Haven Hospital and Yale Medicine for a failed vision screen by either their primary care provider or their school.
10127688|NCT04321863||Adults with Crohn's disease in remission|All patients recruited will submit two samples to facilitate faecal zinc and qFIT in addition to FC which is standard of care. All patients recruited will have an additional tube of blood taken to measure serum zinc at the same time as they have their routine (standard of care) monitoring bloods taken - no additional venepuncture will be required.
10127689|NCT04321902|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used as before and during surgery."
10127690|NCT04321902|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~Sencond-generation cephalosporin (Shincef inj., 750mg, Cefuroxime sodium, Shin-poong pharm.co.) was used as before and during surgery."
10127691|NCT04321577||Residual disease|Participants with incidental gallbladder cancer with presence of residual disease in the re-resection specimen or in intra-operative findings.
10127692|NCT04321577||No residual disease|Participants with incidental gallbladder cancer with absence of residual disease in the re-resection specimen or in intra-operative findings.
10127693|NCT04321889|Experimental|BEO|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
10127694|NCT04321889|Placebo Comparator|Placebo|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
10127695|NCT04321707|Experimental|15O-H2O PET/MR|All included patients will have two 15O-H2O PET/MR scan performed.
10127696|NCT04321551|Experimental|Provocative Hormonal Testing|"Recombinant follicle stimulating hormone (r-FSH) will be administered intravenously one time at a dose of 150 IU during the early follicular phase of the first menstrual cycle after enrollment (Menstrual Cycle I).~Subjects will receive no intervention during Menstrual Cycle II (washout cycle).~During the early follicular phase of Menstrual Cycle III, subjects will receive an intramuscular (i.m.) injection of estradiol valerate 5 mg on study day 1, followed by an i.m. injection of progesterone in oil 50 mg on study day 2."
10127697|NCT04321746|Active Comparator|Ketamine|
10127698|NCT04321746|Placebo Comparator|Control|
10127699|NCT04321525|Active Comparator|Cognitive-behavioral therapy (CBT)|Individual Cognitive Behavioral Therapy
10127700|NCT04321525|Experimental|Personal construct therapy (PCT)|Individual Personal Construct Therapy
10127701|NCT04321525|Experimental|Personal construct therapy with virtual reality (PCT-VR)|Individual Personal Construct Therapy with an immersive virtual reality app
10127702|NCT04321356||Stryker Triathlon PCR TKA|Subjects implanted with a Stryker Triathlon PCR TKA
10127703|NCT04321356||Stryker Triathlon PS TKA|Subjects implanted with a Stryker Triathlon PS TKA
10127704|NCT04321356||Zimmer Persona PCR TKA|Subjects implanted with a Zimmer Persona PCR TKA
10127705|NCT04321356||Zimmer Persona PS TKA|Subjects implanted with a Zimmer Persona PS TKA
10127706|NCT04321304|Sham Comparator|Sham|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial, but stays at 0 mA in the intervening time.
10127707|NCT04321304|Experimental|2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
10127708|NCT04321304|Experimental|4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
10127709|NCT04321421|Experimental|treated|treated with hyperimmune plasma
10127710|NCT04321148|Other|standard of care PCI|
10127711|NCT04321148|Experimental|Impella-protected PCI|
10127712|NCT04321434|Experimental|Hyperoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
10127713|NCT04321434|Placebo Comparator|Normoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
10127714|NCT04321109|Experimental|Collagen cone|Collagen matrix
10127715|NCT04321109|Active Comparator|Allograft|mineralized corticocancellous allograft
10127716|NCT04321447|Experimental|Clinical practice guideline (CPG) group|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme
10127717|NCT04321447|No Intervention|Usual care group|Usual care
10127718|NCT04321083|Experimental|O2 brain (central) measurement|INVOS will be applied simultaneously for monitoring along with the regular polysomnography (sleep lab) workup
10127719|NCT04321122|Experimental|Ultrasound cyclo plasty(UCP)|Ultrasound cyclo plasty treatment for primary open-angle glaucoma patients.
10127720|NCT04321278|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]
10127721|NCT04321278|Active Comparator|Hydroxychloroquine|Hydroxychloroquine [400mg 2x/day, 12/12h]
10127722|NCT04320992||tested group|
10127723|NCT04320992||controlled group|
10127724|NCT04320953|Experimental|Non-contact MCE examination|Study subject in this arm receives non-contact MCE examination.
10127725|NCT04321161|Experimental|AML relapse under DLI and Bicanorm treatment|Analysis of T cell metabolism, immune phenotype and serum pH before and after Bicanorm (Sodium bicarbonate) treatment.
10127726|NCT04321135|Experimental|Guided Lifestyle Program|The Intervention will be conducted in a cohort of 20 (anticipated) and is designed to increase self-efficacy, social support and perceived access to healthy eating and exercise resources and promote weight loss. Participants assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies. The second hour will be supervised exercise including aerobics and resistance training. The second weekly session will be a one-hour supervised exercise session. Participants will also receive 2-3 text messages weekly.They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.The Guided Lifestyle program is four months long (16 weeks). Please note, the Guided Lifestyle program participants will be offered a booster session off-study.
10127727|NCT04321135|Active Comparator|Self-Guided Lifestyle Program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
10127728|NCT04321070|Experimental|Clindamycin Phosphate|Topical, once daily, for 84 days.
10127729|NCT04321070|Active Comparator|Clindamycin Phosphate RLD|Topical, once daily, for 84 days
10127730|NCT04321070|Placebo Comparator|Vehicle of the test product|Topical, once daily, for 84 days
10127731|NCT04321226|Experimental|Femtosecond Laser guided Arcuate Keratotomy|Arcuate keratotomy will be performed together with Laser cataract surgery
10127732|NCT04321096|Placebo Comparator|Placebo|2 pills 3 times daily for 5 days
10127733|NCT04321096|Experimental|Camostat Mesilate|2x100 mg pills 3 times daily for 5 days
10127734|NCT04320836||Cervical epidural steroid injection|This group will receive an interlaminar cervical ESI at C6-7 or C7-T1 with 1 mL steroid (depo-methylprednisolone 40 mg at Johns Hopkins and the DC VA Hospital or dexamethasone 10 mg at Seoul National University) and 2 mL normal saline.
10127735|NCT04320914|Experimental|High Intensity LASER Therapy group (HILT)|Fourty patients with chronic KOA in HILT group will receive Class IV LASER therapy. A Class IV LASER emits power more than 500 mW .
10127736|NCT04320914|Active Comparator|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in IGP group will administered with continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis
10127737|NCT04321018|Experimental|Meal with medium chain triglycerdies first|Arm 1: participants randomized to receive the mixed meal with medium chain triglycerides first.
10127738|NCT04321018|Active Comparator|Meal with medium chain triglycerdies second|Arm 2: participants randomized to receive the mixed meal without medium chain triglycerides first.te
10127739|NCT04320875|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
10127740|NCT04320875|Active Comparator|Conventional Physiotherapy (CPT) group|Individual with KOA will be educated on how to do the set of exercises correctly at their home during the first session. Consisted of nine exercises including muscle strengthening and flexibility training.
10127741|NCT04320966||Acquired Anemia|Otherwise healthy individuals with hemoglobin below 10.5 g/dl or hematocrit below 32
10127742|NCT04320966||Control|Age and sex matched individuals with hemoglobin in the upper quartile of normal
10127743|NCT04320784|Experimental|Time restricted eating (TRE)|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
10127744|NCT04320784|Active Comparator|Control (CTRL)|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
10127745|NCT04320706|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
9519556|NCT03285997|Experimental|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
10127746|NCT04320706|Placebo Comparator|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
10127747|NCT04320771|Experimental|Neladenoson bialanate, mild renal impairment|Subjects with eGFR ≥60 - <90 mL/min/1.73 received a single immediate-release (IR) tablet dose of 10 mg of neladenoson bialanate in the fasted state
10127748|NCT04320771|Experimental|Neladenoson bialanate, moderate renal impairment|Subjects with eGFR ≥30 - <60 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
10127749|NCT04320771|Experimental|Neladenoson bialanate, severe renal impairment|Subjects with eGFR <30 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
10127750|NCT04320771|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
10127751|NCT04320758|Experimental|single crown in dental aesthetic zone|teeth in dental aesthetic zone
9669041|NCT04256070|No Intervention|Standart care, no intervention|"Informed Consent Form will be taken in writing from those who agree to participate in the research.~At the first meeting, Information Form Based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected.~Interventions will not be applied to individuals in this group and routine treatment and follow-up will continue.~- COPD Self-efficacy Scale, face-to-face meeting at the end of the 12th week. George Quality of Life Scale, Respiratory Function Test Form will be repeated.~A training booklet for COPD management will be provided."
9967635|NCT01271699||Observation|Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS
10127752|NCT04320758|Experimental|teeth need single crown in dental aesthetic zone|teeth in dental aesthetic zone
10127753|NCT04320745|Experimental|Androderm®|All participants to receive standard dose of Androderm of 4 mg/day applied nightly on Visit 1. At Visit 2 testosterone concentration will be measured.
10127754|NCT04320368||Alzheimer's disease cohort|"40-100 years old (≥ 40 years old, ≤ 100 years old)~cognitive impairment: Alzheimer's questionnaire >4 and MMSE<22~informed consent is signed by the patient or his family members"
10127755|NCT04320368||Vascular cognitive impairment cohort|"40-100 years old (≥ 40 years old, ≤ 100 years old)~acute cerebral infarction is first diagnosed according to WHO criteria 1~the time from onset to hospital ≤7 days~informed consent is signed by the patient or his family members"
10127756|NCT04320368||A cohort of people with normal cognitive function|"40-100 years old (≥ 40 years old, ≤ 100 years old), without cognitive impairment, Alzheimer's questionnaire ≤4 and MMSE≥22~informed consent is signed by the patient"
10127757|NCT04320433|Experimental|Experimental|Participants will undergo two trials visit (with a week of separation). During the visits they will ingest an oral glucose load solution (oral glucose tolerance test) and gas exchange will be measured over the following 3-hours. The glucose levels will be monitored through a Glucose meter in different time frames.
10127758|NCT04320446|Experimental|Caffeine|A dose of 3 mg/kg of caffeine (i.e. a vegetable extraction from green coffee beans, Harrison Sport Nutrition®, Spain) was ingested before the beginning of each test.
10127759|NCT04320446|Placebo Comparator|Placebo|A dose of 3 mg/kg of placebo (i.e. 100% purity microcrystalline cellulose, Acofarma, Spain) was ingested before the beginning of each test.
10127760|NCT04320654|Experimental|advice of staying active|The patients will be advised to stay as physically active as possible and continue their everyday activities as normally as possible.
10127761|NCT04320654|Experimental|walking program|Patients will be encouraged to go about their normal daily activities. At week one, patients will be asked to familiarize themselves with wearing the pedometer and recording their daily steps in a walking diary for the subsequent 7 days. The patients will return to see the physiotherapist at the end of week one to discuss any issues with the program, pedometer or recording of desired information. A step target for week two will be agreed between the physiotherapist and the patient by referring to the mean daily step count recorded at baseline, and the average step count calculated from the walking diary
10127762|NCT04320654|Experimental|Backward walking|All patients will be instructed to walk at their desired pace 3 days per week with a steady rhythm. The duration of each training session will initially be 15 minutes and will gradually increase, and finally reach 25 minutes, for every session (Hao Chen, 2011). There will be no constraint or indication about head and trunk position during backward training
10127763|NCT04320654|Experimental|Targeted home-based hip exercise|Patients who will be assigned in this group will perform a hip exercise program for six weeks, three times / week to ensure an adequate recovery between exercise sessions (appendix V). The strengthening exercises will focus on strengthening the gluteus maximus (GMax), gluteus medius (GMed), gluteus minimus (GMin) and short hip external rotator muscles (Distefano et al., 2009).
10127764|NCT04320654|No Intervention|control group|The patients will not be given any intervention and will be asked to come after 6 weeks for re-assessment
10127765|NCT04320602|Experimental|Ravulizumab|Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).
10127766|NCT04320394|Other|Septic shock patients|Patients with septic shock will be taken from an additional tube to analyze their immune response
10127767|NCT04320355|Experimental|Soft tissue manual therapy|The researcher student will place the gloves with the force sensor on the thumb of her right and left hand. She will evaluate the Caesarean section scar and identify the most rigid scar areas when compression is applied. On these identified areas, the researcher student will apply the manual therapy procedure described in the independent variable (compression + shear) section. This procedure will be applied to all identified rigid areas of the Caesarean section scar.This procedure will last 10 minutes (approximately 2 minutes per rigid area). After this time, the researcher-student will remove the force sensor and leave the room.
10127768|NCT04320550||abdominal pain|one group of children complaining of recurrent abdominal pain
10183617|NCT03762889|Active Comparator|Eyelid Tape Group|This group of participants will be receiving the eyelid tape as the preventative measure when intubated perioperatively under general anesthesia.
10183618|NCT03762889|Active Comparator|Eye Ointment Group|This group of participants will be receiving the ointment application when intubated perioperatively under general anesthesia.
9669042|NCT04251182|Placebo Comparator|Placebo|Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.
10127769|NCT04320420|Experimental|Experimental arm|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~3 supervised APA sessions/week on site:~two muscle strengthening sessions, stretching, flexibility in the gym~a cardio session (Nordic Walking: outdoors)~at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~the first 3 months:~2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~1-hour cardio session/week independently~the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
10127770|NCT04320472||Follow up|Follow up of all included patients up to 3 months after enrollement
10127771|NCT04320524|Experimental|All subjects|
10127772|NCT04320576|Experimental|Bulk-fill resin composite|Bulk-fill resin composite will be places with bulk technique.
10127773|NCT04320576|Active Comparator|Nano-fill resin composite|Nano-fill resin composite will be placed with 2 mm thickness layering technique.
10127774|NCT04320537||MJ user|non-treatment-seeking chronic heavy marijuana (MJ) users of both sexes and all ethnicities between the ages of 21-40 years who are willing to follow the study protocol and abstinence from marijuana for three weeks
10127775|NCT04320537||Control|age- and sex-matched healthy control participants who are willing to follow the study protocol and remain in the study for three weeks
10127776|NCT04320641|Experimental|acupressure|
10127777|NCT04320641|Experimental|music|
10127778|NCT04320641|No Intervention|control|
10127779|NCT04320589|Active Comparator|General Anesthesia|Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) & Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
10127780|NCT04320589|Active Comparator|Dexmedetomidine|Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
10127781|NCT04320459||ankylosing spondylitis|55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic
10127782|NCT04320459||healthy control|age and sex matched healthy controls
10127783|NCT04320316|Experimental|Crysvita (burosumab-twza) Treatment|"The starting dose will be 0.3 mg/kg to be given every 2 weeks. If required dose may be titrated with increments of 0.1 mg/kg/dose every 4 weeks up to a maximum of dose of 2.0mg/kg (not to exceed 90mg per dose) until phosphorus level is WNL.~Patient will receive study drug via SC injection to the abdomen, upper arms, thighs, or buttocks; the injection site will be rotated with each injection. If the dose level exceeds 1.5 mL in volume, the dose should be administered at two injection sites.~Duration of treatment is 52 weeks. Subjects that complete treatment through week 52 may have the option to continue KRN23 treatment. If this is warranted based on preliminary efficacy, the current protocol will be amended to allow for an extension."
10127784|NCT04320303|Experimental|adaptive NK cells infusion post transplantation|Adaptive donors expanded NK cells infusion at day 20±3d and 27±3d post transplantation
10127785|NCT04320238|Experimental|low-risk group|medical staff work in non-isolated general wards or laboratories, not directly contact with COVID-19 patients.
10127786|NCT04320238|Experimental|high-risk group|doctors and nurses work in isolated ward, directly contact with COVID-19 patients.
10127787|NCT04320563|Active Comparator|Full power treatment 4|These group of participants will receive the full power treatment 4
10127788|NCT04320563|Placebo Comparator|Comparative Power 1|These group of participants will receive the comparative power 1 treatment
10127789|NCT04320121|Experimental|Nelutri™ group|This group takes Nelutri™ for 12 weeks
10127790|NCT04320121|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
10127791|NCT04320290|Experimental|Treatment with Direct Acting Antiviral for HCV|8 weeks of treatment with HCV Direct Acting Antiviral tablet
10127792|NCT04320199|Experimental|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
10127793|NCT04320199|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
10127794|NCT04320095|Experimental|Bizact device for one tonsil|Bizact tonsillecotmy device which is an advanced bipolar device using radiofrequency and pressure to ligate the encountered vessels during tonsillectomy.
10127795|NCT04320095|Active Comparator|Electrocautery for second tonsil|Electrocautery is the standard technique used at our institution.
10127796|NCT04320095|Experimental|Bizact device for both tonsils|Consecutive cases of tonsillectomy will be done using Bizact device and compare the operative time collectively for those cases and compare it to same number of cases done using the standard procedure ( Electrocautery)
10127797|NCT04320095|Active Comparator|Electrocautery for both tonsils|As explained on the above arm description
9669043|NCT04251182|Experimental|15mg T3D-959|T3D-959 15 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest one size 0, 15mg capsule and two placebo capsules once per day in the morning.
10127798|NCT04320004|No Intervention|Baseline|"Participating clinics will enter a baseline period where no interventions are used, but survey collection of baseline information about patient storage and disposal is collected. The baseline period varies depending on the cohort timing for each clinic but will last a minimum of one month for each clinic. In order to generate a survey list, the investigators will institute a silent best practice alert (BPA) in these clinics. This Silent BPA is not seen by providers, but a silent report is generated for reporting purposes, and for the study team to generate the baseline survey list."
10127799|NCT04320004|Active Comparator|Education Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose. Between 30-45 days following the new opioid prescription, the survey call center will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, and mailed educational material.
10127800|NCT04320004|Active Comparator|Education Intervention with Reminder|This arm will follow the Education Intervention arm (BPA, provider education, mailed education and follow up survey) Approximately 50% of patients in the Education Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
10127801|NCT04320004|Active Comparator|Education + Disposal Bag Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose plus a postage paid medication disposal mail bag and instructions for use. Between 30-45 days following the new opioid prescription, the survey unit will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, mailed educational material and mail-back bags.
10127802|NCT04320004|Active Comparator|Education + Disposal Bag Intervention with Reminder|This arm will follow the Education+ Disposal Bag Intervention arm (BPA, provider education, mailed education+ disposal bag and follow up survey) Approximately 50% of patients in the Education + Disposal Bag Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
10127803|NCT04320277|Experimental|Patients|All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks.
10127804|NCT04320277|Active Comparator|Controls|All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.
10127805|NCT04320212|Active Comparator|lumber epidural analgesia|: the patient will be placed in the lateral position, Lidocaine will be given using 5 ml syringe and a 18 G Tuohy needle will be introduced in the epidural space, using the ultrasound, under strict aseptic precautions. The ultrasound probe will be placed 90 degrees into transverse orientation and slided cephalad or caudad to obtain the transverse interspinous view (TI view) 2 levels above the operation level. patient will receive 20 ml of 0.25% plain bupivacaine after negative aspiration for blood or cerebrospinal fluid. Then, the patient will be placed in prone position to start the surgical procedure
10127806|NCT04320212|Active Comparator|erector spinae analgesia|the patient will be placed in the prone position. Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer. The Erector Spinae muscle and transverse process will be then identified, and a 18 G Tuohy needle will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side)
10127807|NCT04320056|Active Comparator|Control group|"Usual care will be provide to patients concerning their medical management.~In the Control Group usual, oxygen will be delivered as per usual local practices"
10127808|NCT04320056|Experimental|Intervention group|"Usual care will be provide to patients concerning their medical management.~In the Intervention group, automated oxygen administration will be delivered with FreeO2"
10127809|NCT04320082||Elderly cohort|Patients >70 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
10127810|NCT04320082||Young cohort|Patients between 18 and 30 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
10127811|NCT04320069|Experimental|Single|All subjects using the Omnipod Horizon™ Automated Glucose Control System in Manual Mode without a connected CGM for 7 days and with a connected CGM for 7 days.
10127812|NCT04319861|Experimental|Anal fistula plug|The anal fistula plug procedure was performed as followings. A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
10127813|NCT04320264||Low oxidizers/high lactate|Individuals with low aerobic oxidation
9967636|NCT01271738|Active Comparator|Breast Conserving Surgery (BCS)|
9669044|NCT04251182|Experimental|30mg T3D-959|T3D-959 30 mg dose: Subjects will ingest two size 0, 15mg capsules and one placebo capsule once per day in the morning.
9826029|NCT02404441|Other|patients with solid tumors|Phase I Dose escalation cohorts
10127814|NCT04320264||High oxidizers/low lactate|Individuals with high aerobic oxidation
10127815|NCT04320264||Obese|Severely obese scheduled for surgery
10183619|NCT03762863|Experimental|Appropriate application of a CAT tourniquet|All study subjects attended an American College of Surgeons Stop the Bleed Basic course with live training by approved instructors. 6 months after participation in the Stop the Bleed class volunteers study subjects are randomly solicited to return for a refresher session. During this refresher session the volunteer study subjects are observed to determine if they have retained tourniquet application skills and to what degree they have retained them. A 10 point check list will be used to evaluated tourniquet application skill retention.
10183620|NCT03762850|Experimental|sparsentan|Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg and continue treatment to Week 110.
10183621|NCT03762850|Active Comparator|irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
10183622|NCT03762837||Exposure group：Benign gallbladder disease|Patients with benign gallbladder diseases, such as gallbladder polyps, gallstones, etc.
10183623|NCT03762837||Non-exposed group: healthy people|Patients without benign gallbladder diseases
10183624|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated patients|Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
10183625|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated controls|Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
10183626|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
10183627|NCT03762824|Active Comparator|PCV13 to previous PPV23-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.
10183628|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated controls|Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
10183629|NCT03762811|Other|NanoFUSE® PMCF|NanoFUSE® Bioactive Matrix will be implanted according to labeling and the intended surgical treatment plan of the surgeon.
10183630|NCT03762798|Experimental|Treatment|All participants will receive the Bridge device.
10183631|NCT03762785|Active Comparator|nebulized dexmedetomidine 2ug/kg|inhalation of dexmedetomidine in the dose of 2ug/kg by nebulization
10183632|NCT03762785|Active Comparator|nebulized dexmedetomidine 3ug/kg|inhalation of dexmedetomidine in the dose of 3ug/kg by nebulization
10183633|NCT03762772|Experimental|TAF/EVG vaginal insert|Post-dose sampling at 4 and 48 hours or at 24 and 72 hours, per randomization
10183634|NCT03762759|Experimental|Arm I (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
10183635|NCT03762759|Active Comparator|Arm II (68Ga-PSMA, PET/CT)|Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
10183636|NCT03762746|Active Comparator|Active|Intervention with transcranial magnetic stimulation (TMS) low frequency 1 Hz , 1000-pulse train, 20 minutes, 90% motor threshold in left temporo-parietal cortex for 10 consecutive days for 20 schizophrenia patients with auditory hallucination
10183637|NCT03762746|Sham Comparator|Control|Control group is received treatment as usual
10183638|NCT03762720|Experimental|Physium treatment|Patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for a month
10183639|NCT03762642||Mastectomy|
10183640|NCT03762642||Breast-Conserving Surgery|
10183641|NCT03762629|Experimental|Obese intervention group|Obese children were received exercise and diet intervention for 6 weeks.
10183642|NCT03762629|No Intervention|Normal weight control group|Normal weight children were recruited as a control group without any intervention.
10183643|NCT03762603|Experimental|robotic exoskeleton device|Patients who are scheduled to be discharged to a ECF will be asked if they would want to use the exoskeleton device ( for which safety and comfort has been established) instead of going for ECF.
10183644|NCT03762577|Experimental|Training Group|Training group will attend ground-based walking training under the supervision of a physiotherapist for 2 days and 30 minutes a week. Patients will walk for 1-2 days in a week without supervision.
10183645|NCT03762577|No Intervention|Control Group|Patient education will be given and no intervention will be made.
10183646|NCT03762564|Experimental|Arm A (Paclitaxel + Ramucirumab)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 plus Ramucirumab 8 mg/kg as 1 hour intravenous infusion on day 1 and 15 qd 28
10183647|NCT03762564|Active Comparator|Arm B (control arm)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 qd 28
10183648|NCT03762551|Experimental|vitiligo|assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB
10183649|NCT03762551|Active Comparator|psoriasis|assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB
10183650|NCT03762551|Other|controls|assess the level of JAK1 in controls
10183651|NCT03762538||G/G group|Patients who are determined to be G/G genotype.
10183652|NCT03762538||G/A A/A group|Patients who are determined to be G/A or A/A genotypes.
10183653|NCT03762525|Other|ECG gated CTA pre and post operative at Gore IBE|To prospectively enroll 15 patients that are scheduled for endovascular aneurysm repair using the Gore IBE device in conjunction with its dedicated self expanding Internal Iliac component. Each patient will have an ECG gated CTA scan before the operation and 6-8 weeks after operation, in stead of a regular CT scan.
10127816|NCT04319991|Placebo Comparator|Placebo|
10127817|NCT04319991|Experimental|Probiotics product|
10127818|NCT04320225||Lower vitamin D level group|The vitamin D level is lower than 20 nmol/L.
10127819|NCT04320225||Higher vitamin D level group|The vitamin D level is higher than 20 nmol/L.
10127820|NCT04319848|Experimental|TE-EK treatment group|The TE-EK surgery will be performed by the Principle Investigator with a standard DSAEK technique. The PI has performed over 300, EK surgeries and we have previously shown that the corneal endothelial loss rates from the PI are 16% at 1 year with a primary graft failure rates of <1.5%. A patient's participation in the study or not will not change the treatment strategy in any manner.
10127821|NCT04319978|Active Comparator|Group A|Group A will receive single dose of dexamethasone IM 8mg 1 hour pre-operatively.
10127822|NCT04319978|Active Comparator|Group B|Group B will receive a single dose of dexamethasone IM 8mg immediately after surgery.
10127823|NCT04319939||Participants receiving mechanical ventilation|
10127824|NCT04320108|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
10127825|NCT04320108|Sham Comparator|Control group|Sham therapy
10127826|NCT04320147|Experimental|MRI tartget biopsy|"MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.~Next conventional ultrasound-guided 12-core systematic biopsy would be performed by urologist. This portion will be performed without information of the MRI report."
10127827|NCT04320160|No Intervention|Positive control group|Include the thirty patients before any treatment
10127828|NCT04320160|Active Comparator|PRP group|Include fifteen patients that will recieve PRP sessions .Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
10127829|NCT04320160|Active Comparator|Fractional CO2 group|Include fifteen patients that will recieve FR: CO2 laser sessions.Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
10127830|NCT04320173|Experimental|Lidocaine Patch (Sequence ABC)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied in Period 1, and 3 lidocaine 5% patches were applied in Period 2, and 3 lidocaine 5% medicated plasters were applied in Period 3.
10127831|NCT04320173|Experimental|Lidocaine Patch (Sequence CAB)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 2, 3 lidocaine 5% medicated plasters were applied in Period 1, and 3 lidocaine 1.8% patches were applied in Period 2, and 3 lidocaine 5% patches were applied in Period 3.
10127832|NCT04320173|Experimental|Lidocaine Patch (Sequences BCA)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 3, 3 lidocaine 5% patches were applied in Period 1, and 3 lidocaine 5% medicated plasters were applied in Period 2, and 3 lidocaine 1.8% patches were applied in Period 3.
10127833|NCT04319926|Experimental|Lidocaine Patch (Sequence T1T2)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
10127834|NCT04319926|Experimental|Lidocaine Patch (Sequence T2T1)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.
10127835|NCT04320186|Active Comparator|Treatment|Participants viewed informational video content plus entertainment content
10127836|NCT04320186|Placebo Comparator|Control|Participants viewed entertainment content only
10127837|NCT04320017||COVID-19 patients|Patients diagnosed with COVID-19 by PCR done on nasal sample.
10127838|NCT04320043||Anterior cervical decompression surgery|Adult patients who underwent anterior cervical decompression surgery for radiculopathy and/or myelopathy due to cervical degenerative disc disease. Patients underwent one of the following interventions: ACD, ACDF, ACDF with plating or corpectomy.
10127839|NCT04319874|Sham Comparator|sham group|Treated with conventional chemotherapy drugs
10127840|NCT04319874|Placebo Comparator|NC group|Treated with conventional chemotherapy drugs and Placebo
10127841|NCT04319874|Experimental|experimental group|Treated with conventional chemotherapy drugs and Ganoderma lucidum
10127842|NCT04319900|Experimental|favipiravir tablets+chloroquine phosphatetablets tablets group|favipiravir tablets+chloroquine phosphatetablets tablets
10127843|NCT04319900|Experimental|favipiravir tablets group|favipiravir tablets
10127844|NCT04319900|Placebo Comparator|placebo treatment group|placebo
10127845|NCT04319835|Experimental|Microdialysis catheter|Surface Microdialysis catheter will be placed onto the surgical reconstruction after esophagectomy and will be evaluated for clinical safety and performance. The metabolic profile as measured by Microdialysis will be correlated to the clinical outcome. No interventions based on the results will be performed.
10127846|NCT04319809|Experimental|Device feasibility|To investigate the utility of a device adaptation allowing Argus II users to detect the presence and location of desired objects. Performance of the unaided Argus II system will be compared with performance using the system augmented with object recognition.
10127847|NCT04319757|Experimental|ACE1702 Dose Level 1|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.~Dose Level: 1 Planned number of subjects: 1 to 6"
10127848|NCT04319757|Experimental|ACE1702 Dose Level 2|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 2 Planned number of subjects: 1 to 6"
10127849|NCT04319757|Experimental|ACE1702 Dose Level 3|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 3 Planned number of subjects: 3 to 6"
10127850|NCT04319757|Experimental|ACE1702 Dose Level 4|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 4 Planned number of subjects: 3 to 6"
10127851|NCT04319757|Experimental|ACE1702 Dose Level 5|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 5 Planned number of subjects: 3 to 6"
10127852|NCT04319757|Experimental|ACE1702 Dose 6|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.~Dose Level: 6 Planned number of subjects: 3 to 6"
10127853|NCT04319796||Ataxia & HSP|Patients suffering of Ataxia or HSP or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these Rare Neurological Disease (RND).
10127854|NCT04319796||Leukodystrophies|Patients suffering of Leukodystrophies or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
10127855|NCT04319796||Frontotemporal Dementia|Patients suffering of Frontotemporal Dementia or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
10127856|NCT04319796||Dystonia, Paroxysmal Disorders and Neurodegeneration with|Patients suffering of Dystonia, Paroxysmal Disorders and Neurodegeneration with Brain Iron Accumulation (NBIA) or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
10127857|NCT04319796||Atypical Parkinsonism|Patients suffering of Atypical Parkinsonism or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
10127858|NCT04319796||Huntington's Disease & Choreas|Patients suffering of Huntington's Disease or Choreas or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
10127859|NCT04319497|Other|Refraction reproducibility and agreement|Subjective and objective refraction will be performed in all patients
10127860|NCT04319510|Experimental|Craniosacral therapy|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
10127861|NCT04319510|Experimental|Craniosacral self-help group training|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
10127862|NCT04319510|Other|Treatment as usual / wait list control|Waiting period of six months.
10127863|NCT04319471|Experimental|Sufficient Chemotherapy Combine With Maintenance Chemotherapy|Patients with oligometastatic Nasopharyngeal Carcinoma was given S-1 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving sufficient chemotherapy and consolidative local therapy
10127864|NCT04319588|Experimental|Parasternal Group|"The parasternal group of patients will receive the pre-operative parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia."
10127865|NCT04319588|Active Comparator|Case control group|"The case control group will only receive drainage infiltration with local anesthetic and standard intraoperative management with opioids."
10127866|NCT04319770|Active Comparator|periodontal regenerative surgery + EMD (control)|periodontal regenerative surgery with enamel matrix derivative
10127867|NCT04319770|Experimental|periodontal regenerative surgery + HA (test)|periodontal regenerative surgery with hyaluronic acid
10127868|NCT04319484|Experimental|lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
10127869|NCT04319484|Placebo Comparator|Placebo|The placebo pills are made identical to the investigating lenvatinib in appearance
10127870|NCT04319458|Experimental|Fotonovela|Fotonovela mental health literacy intervention: Secret Feelings/Sentimientos Secretos
10127871|NCT04319458|Active Comparator|Control|Control mental health literacy intervention: NIH publication - Depression: What You Need to Know
10127872|NCT04319744||Assistants who have a habit of playing video|"Group I:Anesthesia assistants who have a habit of playing video games before Video game will be played for 5 days a day with 0.5 hours mobile phone (Pubg mobile) for those who have previous game experience.~Intubation training will be provided with video style.Within the scope of this training, 1-All participants will watch videos about Video style application.~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first~4-Responsible investigators will practice and show on the real patient.~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
10127873|NCT04319744||Assistants who do not have the habit of playing video|"Group II:Anesthesia assistants who do not have the habit of playing video games No video game will be played before intubation with video style for this group.~Intubation training will be provided with video style. Within the scope of this training, 1-All participants will watch videos about Video style application.~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first~4-Responsible investigators will practice and show on the real patient.~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
10127874|NCT04319562|Experimental|needle-embedding therapy|The participants in this group will be treated with intradermal thumbtack needle.
9967637|NCT01271738|Active Comparator|Breast Conserving Surgery with Additional 5 Margins (BCS + M)|
10127875|NCT04319562|Sham Comparator|shame needle-embedding therapy|The participants in this group will be treated with shame intradermal thumbtack needle.
10127876|NCT04319601|Experimental|rituximab combined with chidamde and lenalidomide|rituximab and chidamide, lenalidomide
10127877|NCT04319575|Experimental|Chitosan calcium hyroxide paste|after the access preparation and cleaning and shaping, chitosan calcium hydroxide paste will be placed in the canal and kept for 4 weeks.
10127878|NCT04319575|Active Comparator|triple antibiotic paste|after the access preparation and cleaning and shaping, ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.
10127879|NCT04319666|Experimental|PCI to left main with IVL|
10127880|NCT04319783|Experimental|Darolutamide|Darolutimide 600mg BD
10127881|NCT04319783|Experimental|Local consolidation Radiotherapy + Darolutamide|Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease
10127882|NCT04319640|Experimental|CBTI|N= 80 participants are offered Cognitive behaviour therapy for insomnia (CBT-I)
10127883|NCT04319640|Active Comparator|psychoeducation|N= 80 participants are offered psychoeducation about information on ASD
10127884|NCT04319692|Experimental|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks.
10127885|NCT04319692|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
10127886|NCT04319731|Experimental|Treatment|"Treatment groups:~1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)"
10127887|NCT04319705|Experimental|Azithromycin|Azithromycin, 500mg capsule, 3 times per week, during a 12-week period, administered orally
10127888|NCT04319705|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP, capsule, 3 times per week, during a 12-week period, administered orally
10127889|NCT04319679|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
10127890|NCT04319679|Sham Comparator|Control group|Sham therapy
10127891|NCT04319406|Experimental|PROLOTHERAPY|Prolotherapy will be performed with 12.5 % Dextrose into superior joint space of involved TMJ
10127892|NCT04319406|Active Comparator|DRY NEEDLING|Dry needling will be performed into superior joint space of involved TMJ
10127893|NCT04319393|Experimental|CBT Nurses|Interventional group
10127894|NCT04319393|No Intervention|Consultation Nurses|Control Group
10127895|NCT04319614|Experimental|Tranexamic acid|
10127896|NCT04319614|Placebo Comparator|Saline|
10127897|NCT04319328||Cefazolin|n = 20
10127898|NCT04319328||Ceftazidime|n = 20
10127899|NCT04319328||Ciprofloxacin|n = 20
10127900|NCT04319250|Active Comparator|Group 1|Ischemic compression and rehabilitation program applied to the group 1
10127901|NCT04319250|Active Comparator|Group 2|IASTM and rehabilitation program applied to the group 2
10127902|NCT04319549|Experimental|group 1 ketorolac tromethamine irrigant|group 1 patients with acute irreversible pulpitis with apical periodontitis
10127903|NCT04319549|Active Comparator|group 2 sodium hypochlorite irrigant|group 2 patients with acute irreversible pulpitis with apical periodontitis
10127904|NCT04319536||Healthy individuals|
10127905|NCT04319367|Active Comparator|Arm A|ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion followed by intensively monitored Antiretroviral Treatment Interruption (ATI)
10127906|NCT04319367|Placebo Comparator|Arm B|ART plus placebo infusion followed by an ATI (control arm). On re-starting ART, participants will receive immediate dual LS bNAbs and then a second ATI 24 weeks after bNAb infusion.
10127907|NCT04319432|Experimental|3 days voice rest|
9669045|NCT04251182|Experimental|45mg T3D-959|T3D-959 45 mg dose: Subjects will ingest three size 0, 15mg capsules once per day in the morning.
10127908|NCT04319432|Experimental|7 days voice rest|
10127909|NCT04319289|Experimental|Group (A)|"Included 15 patients who are participating in an aerobic interval training exercise program with vitamin D supplementation (cholecalciferol 400 IU/day).~The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks."
10127910|NCT04319289|Experimental|Group (B)|Included 15 patients who are receiving vitamin D supplementation only . One capsule containing (cholecalciferol 400 IU) was taken every day for 12 weeks
10127911|NCT04319289|Experimental|Group (c)|Included 15 patients who are participating in an aerobic interval training exercise program only. The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks.
10127912|NCT04319133|Experimental|intervention|Participants will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
10127913|NCT04319133|No Intervention|control|Participants will not doing fasting or intake restriction within 8 weeks
10127914|NCT04319042|Active Comparator|Immediate Loading|Group A. The implant receives an artificial tooth the same day as it is placed.
10127915|NCT04319042|Active Comparator|Early Loading|Group B. The implant receives an artificial tooth 4 weeks after placement.
10127916|NCT04319003|No Intervention|Control School|This school did not receive intervention (until after the study was completed)
10127917|NCT04319003|Experimental|Intervention School|This school received a one-week sugar-reduction intervention
10127918|NCT04319302||Paediatric biliary obstruction|This was a retrospective review of all paediatric patients who had undergone an IVGT graft procedure for biliary tract anatomical obstruction in the past five years. We looked at the indications for surgery, the demographic profile of the patients, outcomes following surgery and outlined the surgical technique used.
10183654|NCT03762525|Other|ECG gated CTA post operative at Gore IBE and Cook IBD|To compare 15 patients that have been treated in the period October 2006- July 2016 with the Cook IBD with a non-dedicated IIA component (Advanta-V12 or Fluency) and 15 matched patients treated with Gore IBE device. Each patient will have an ECG gated CTA after the operation, at the first doctor's appointment, in stead of a regular CT scan.
10127919|NCT04318990|Experimental|Distal radial artery access|Wrist rests on a comfortable underground which brings the wrist in passive ulnar flexion. Patient is asked to bring the thumb under the other four fingers. After disinfection, patient is covered with a sterile drape. Brachial drape is applied to the hand exposing the anatomical snuff box and the proximal radial. Under ultrasound guidance, local anesthesia applied by SC injection of 5cc of lidocaine filling the radial fossa. Puncture performed at the point of maximal pulsation proximal in the anatomical snuffbox. If fails, a puncture more distal, can be attempted. After successful anterior wall puncture a radial sheath wire is advanced. Proper position verified by fluoroscopy or by ultrasound to ensure the wire didn't traverse the palmar arch, followed by introduction of a hydrophilic sheath. After administration of a spasmolytic cocktail containing 200-400 mcg of nitroglycerin and 5 mg of verapamil, the operator can take up a position at the level of the patient's knees.
10127920|NCT04318990|Active Comparator|Proximal radial artery access|Half of the patients enrolled in the study undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized proximal radial access for cardiac catheterization.
10127921|NCT04319107||Marfan Syndrome (MFS) patients|Patients who had a clinical diagnosis of MFS according to the revised Ghent criteria (ectopia lentis was not taken into account for the diagnosis), confirmed by FBN1 sequencing.
10127922|NCT04319107||Control patients|Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.
10127923|NCT04319068||Healthy|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years.
10127924|NCT04319068||Hypertensive|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years
10127925|NCT04319120||questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed.
10127926|NCT04319224|Experimental|Vopratelimab|Participants will continue to receive vopratelimab monotherapy per parent protocol.
10127927|NCT04319224|Experimental|Vopratelimab with ipilimumab|Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
10127928|NCT04319224|Experimental|Vopratelimab with nivolumab|Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.
10127929|NCT04319081||Uncontrolled patients with hypercholesterolemia|Patients that meet criteria inclusions and they have just started to take Alirocumab or Evolocumab
10127930|NCT04319354|Experimental|pCR|
10127931|NCT04319354|Experimental|Partial responders|
10127932|NCT04319354|Active Comparator|Non-responders|
10127933|NCT04319263|Experimental|intermediate and high risk non muscle invasive bladder cancer|
10127934|NCT04319146|Other|robot-assisted radical prostatectomy|patient with a prostate cancer will be operated with a robot-assisted method. They will be supported on an outpatient basis
9669046|NCT04244682|Other|Healthy participants receiving rTMS|Participation will require up to three visits. One visit will take up to an hour, and the other visits will each take up to three hours each. During the first visit, participants will be consented, and their brains will be scanned using magnetic resonance imaging. Participants will receive rTMS during two study visits.
10127935|NCT04319211||People who isolate at home with the danger of coronavirus|Demographic data of the individuals participating in the study will be recorded. International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
10127936|NCT04319419|Experimental|Supplement with micronutrients|Nutrition education with a supplement
10127937|NCT04319419|Experimental|Nutrition education|Group received only nutrition education
10127938|NCT04319029|No Intervention|Non-intervention|Patients received a conventional pharmaceutical care plan, the patients offered optimal pharmacological therapy wit statin.
10127939|NCT04319029|Active Comparator|Intervention|The Patients offered to predesign pharmaceutical care plans aimed to improved patient's knowledge, adherence, satisfaction, and quality of life. The patients offered optimal pharmacological therapy wit statin.
10127940|NCT04319185|Experimental|Intervention|All patients who qualify for the study will receive the intervention
10127941|NCT04318834|Experimental|Individuals with advanced biliary tract cancer|Following a tumour biopsy for molecular profiling, chemo-naive patients with advanced biliary tract cancer will receive first-line gemcitabine-based chemotherapy or an investigational drug on a participating clinical trial.
10127942|NCT04318873|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
10127943|NCT04318873|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
10127944|NCT04318847|Experimental|Ondransetron|Administration of ondansetron
10127945|NCT04318847|No Intervention|Habitual Clinical Practice|Habitual Clinical Practice
10127946|NCT04318899|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 20 weeks for adolescents (DBT-A) or 52 weeks for adults (standard DBT.
10127947|NCT04318977|Experimental|high-frequency repetitive transcranial magnetic stimulation|repetitive transcranial magnetic stimulation over left dorsolateral prefrontal cortex using 3000 pulses applied with 10Hz and 120% resting motor threshold
10127948|NCT04318977|Experimental|theta burst stimulation|intermittent theta burst stimulation over left dorsolateral prefrontal cortex using 600 pulses applied in trains of 10 triplets/bursts (50Hz) with 8s intertrain-interval and 120% resting motor threshold
10127949|NCT04318977|Placebo Comparator|sham rTMS|half of the patients with high-frequency repetitive transcranial magnetic stimulation and half of the patients with theta burst Stimulation with angled coil (45 degree) or sham coil
10127950|NCT04318509|Experimental|PKU GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
10127951|NCT04318444|Experimental|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
10127952|NCT04318444|Placebo Comparator|Placebo|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
10127953|NCT04318626|Other|PMPBB3|"Name: [18F] PMPBB3，[18F]1-Fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)ben~Dosage form: intravenous injection~Dose(s): 7mCi~Dosing schedule: Visit 2~Mechanism of action (if known): high affinity radiotracer for the tau protein~Pharmacological category：Radio pharmaceutical"
10127954|NCT04318626|Other|THK|"Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline~Dosage form: intravenous injection~Dose(s): 10mCi~Dosing schedule: Visit 2~Mechanism of action (if known): high affinity radiotracer for the tau protein~Pharmacological category：Radio pharmaceutical"
10127955|NCT04318769|Experimental|AFFIRM|AFFIRM is an 8-session psychoeducational weekly group intervention
10127956|NCT04318769|No Intervention|Waitlisted control|Waitlisted control
10127957|NCT04318730|Experimental|Arm 1|
10127958|NCT04318483||Angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
10127959|NCT04318483||Without angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
10127960|NCT04318522|Experimental|Stimulation Group|
10127961|NCT04318522|Sham Comparator|Control Group|
10127962|NCT04318678|Other|CD123-CAR T cell therapy|CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.
10127963|NCT04318756||Italian patients suffering from mucinous neoplasms|Italian patients suffering from mucinous neoplasms will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
10127964|NCT04318756||Italian patients with familiarity/genetic predisposition|Italian patients with familiarity/genetic predisposition will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
10127965|NCT04318743|Experimental|autoinjector - vial/syringe - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
10127966|NCT04318743|Experimental|vial/syringe - autoinjector - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
10127967|NCT04318743|Experimental|vial/syringe - vial/syringe - autoinjector|Single dose of Glepaglutide 10 mg for each treatment sequence
10127968|NCT04318782|Experimental|Thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
10127969|NCT04318795|Experimental|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
10127970|NCT04318795|Experimental|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
10127971|NCT04318574|Experimental|Interventional|Balance, Agility, Strengthening Exercise (BASE) class intervention - a 6-week exercise class to determine the change in balance performance, fear of falling and self-efficacy
10127972|NCT04318600|Experimental|human amniotic mesenchymal stem cell treatment group|
10127973|NCT04318600|No Intervention|blank control group|
10127974|NCT04318639|Experimental|Donepazil+CRT|Donepazil+CRT
10127975|NCT04318431|Other|Data collection and rhinopharyngeal swab|"After information, the collection of consent will be carried out. A clinical information sheet will be completed by the investigator in order to collect socio-demographic data, history, clinical symptoms and signs, and complementary examinations performed.~During the same consultation, a rhinopharyngeal swab will be taken for the detection of SARS -Cov2 and other respiratory pathogens by PCR."
10127976|NCT04318652|Other|Methylprednisolone eye drops|Preservative free steroids methylprednisolone 5% eye drops (prepared by dilution of methyleprednisolone 500mg in 10 ml distilled water (Solu-Medrol, Pfizer company) was prepared and given for all enrolled cases by the following regimen 5 times/day for 5 days with gradual decrease every third day over the following 2 weeks
10127977|NCT04318652|Placebo Comparator|distilled water eyedrops|Distilled water eyedrops instilled 3 times per day for two weeks
10127978|NCT04319380|Active Comparator|SMC with SP+AQ|Administration of tetanus/diphtheria toxoids vaccine followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
10127979|NCT04319380|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1 and 2.
10127980|NCT04319380|Active Comparator|RTS,S/AS01 plus SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
10127981|NCT04318470||PPROM|Preterm premature rupture of membranes between 16 0/7 and 33 6/7 weeks gestation
10127982|NCT04318470||Healthy controls|Gestational-age-matched controls without preterm premature rupture of membranes or other pregnancy complications
10127983|NCT04318587|Experimental|Allosure Arm|All subjects will be in arm one and will have AlloSure blood draws at multiple time points.
9967638|NCT01271751|Experimental|GFT505 80mg|
10127984|NCT04318158|Experimental|Group(B)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% on each side.
10127985|NCT04318158|Active Comparator|Group(BD)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
10127986|NCT04318158|Active Comparator|Group(BF)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
10127987|NCT04318054|Experimental|Immediate intervention group|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, in the 2 months following the randomization, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
10127988|NCT04318054|Other|Deferred intervention group|Deferred intervention group : fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, one year after the inclusion, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
10127989|NCT04318171||Carotid arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
10127990|NCT04318171||Peripheral arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
10127991|NCT04318171||AVF.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
10127992|NCT04318171||Vein mapping|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
10127993|NCT04318236|Experimental|Online-Program + factors 1,2,3,4|"In this arm all four factors are set to active (i.e. yes):~diagnostic interview~motivational module~guidance~e-mail reminders"
10127994|NCT04318236|Experimental|Online-Program + factors 1,2,3|"In this arm three factors are set to active (i.e. yes):~diagnostic interview~motivational module~guidance"
10127995|NCT04318236|Experimental|Online-Program + factors 1,2,4|"In this arm three factors are set to active (i.e. yes):~diagnostic interview~motivational module~e-mail reminders"
10127996|NCT04318236|Experimental|Online-Program + factors 1,2|"In this arm two factors are set to active (i.e. yes):~diagnostic interview~motivational module"
10127997|NCT04318236|Experimental|Online-Program + factors 1,3,4|"In this arm three factors are set to active (i.e. yes):~diagnostic interview~guidance~e-mail reminders"
10127998|NCT04318236|Experimental|Online-Program + factors 1,3|"In this arm two factors are set to active (i.e. yes):~diagnostic interview~guidance"
10127999|NCT04318236|Experimental|Online-Program + factors 1,4|"In this arm two factors are set to active (i.e. yes):~diagnostic interview~e-mail reminders"
10128000|NCT04318236|Experimental|Online-Program + factor 1|"In this arm one factor is set to active (i.e. yes):~- diagnostic interview"
10128001|NCT04318236|Experimental|Online-Program + factors 2,3,4|"In this arm three factors are set to active (i.e. yes):~motivational module~guidance~e-mail reminders"
10128002|NCT04318236|Experimental|Online-Program + factors 2,3|"In this arm two factors are set to active (i.e. yes):~motivational module~guidance"
10128003|NCT04318236|Experimental|Online-Program + factors 2,4|"In this arm two factors are set to active (i.e. yes):~motivational module~e-mail reminders"
10128004|NCT04318236|Experimental|Online-Program + factor 2|"In this arm one factor is set to active (i.e. yes):~- motivational module"
10128005|NCT04318236|Experimental|Online-Program + factors 3,4|"In this arm two factors are set to active (i.e. yes):~guidance~e-mail reminders"
10128006|NCT04318236|Experimental|Online-Program + factor 3|"In this arm one factor is set to active (i.e. yes):~- guidance"
10128007|NCT04318236|Experimental|Online-Program + factor 4|"In this arm one factor is set to active (i.e. yes):~- e-mail reminders"
10128008|NCT04318236|Experimental|Online-Program + no factor|"In this arm no factor is set to active (i.e. yes):"
10128009|NCT04318379|Experimental|Low dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
10128010|NCT04318379|Experimental|High dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of high dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
10128011|NCT04318210|Experimental|TDF-FTC as PrEP|Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
10128012|NCT04318223|Experimental|single-arm study following a Simon's two-stage optimal design|Single-arm study with the primary objective of assessing the efficacy and safety of palbociclib in combination with fulvestrant (Faslodex) in women with HR+, HER2-negative metastatic breast cancer, regardless of their menopausal status, whose disease has progressed after prior treatment with AI plus a CDK4/6 inhibitor.
10183655|NCT03762499|Active Comparator|Prospective participants|250 participants will be recruited prospectively during the hypertension clinic, where a full set of data will be collected from each participant as part of their standard hypertension clinical service. An additional echocardiography scan will be performed for this cohort by the study team, if the scan has not been performed as a part of the clinical care service
10183656|NCT03762499|No Intervention|Retrospective participants|500 participants will be recruited retrospectively, and no additional echocardiography scan will be required for them.
10183657|NCT03762486|Active Comparator|TENS to around the incision|The Patient Controlled Analgesia infusion was started right after the surgery. TENS was applied to around the incision.
10183658|NCT03762486|Active Comparator|TAES to the acupuncture points|The Patient Controlled Analgesia infusion was started right after the surgery. TAES was applied to acupuncture points.
10183659|NCT03762486|No Intervention|No stimulation|No stimulation was performed to the patients in the control group.
10183660|NCT03762460|Experimental|Online eHealth Tool|Participants randomized to this group will use a personally-owned smartphone, tablet, or computer to access the online eHealth tool.
10183661|NCT03762460|Placebo Comparator|Informational website (control)|Participants randomized to this group will receive information about online resources for mental health
10183662|NCT03762434|Active Comparator|mobile app|Mobile app: The participants will receive a Life style Modification Program with the support of mobile application (MetS app). The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area of the Mets app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the app installment and briefing.
10128013|NCT04318106|Experimental|'Experimental' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be the optimum chromaticity to alleviate visual stress symptoms. To be worn for a minimum of 10 weeks for concentrated tasks.
10128014|NCT04318106|Placebo Comparator|'Control' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be individually determined as being sub-optimal to alleviate visual stress symptoms. This colour will be as similar to the 'experimental' colour as possible and will not be aversive to the participant. To be worn for a minimum of 10 weeks for concentrated tasks.
10128015|NCT04318093|Experimental|BMS-986259|
10128016|NCT04318093|Placebo Comparator|Placebo|
10128017|NCT04318184|Experimental|Exercise|Submaximal aerobic exercise protocol
10128018|NCT04318262||Patient with Staphylococcus lugdunensis infection|All consecutive patients with S. lugdunensis infection (microbiological and clinical data)
10128019|NCT04318262||Patient with Staphylococcus aureus infection|Patients with S. aureus infection (microbiological and clinical data), matched to the hospital sector for S. lugdunensis infections
10128020|NCT04318262||Patient with other coagulase negative Staphylococcus infection|Patients with CoNS infection (microbiological and clinical data),matched to the hospital sector for S. lugdunensis infections
10128021|NCT04318067|Experimental|Sleep problems i Attention Deficit Hyperactivity Disorder|Children age 6 to 12 years having ADHD and Sleeping problem will be treated with Melatonin 3 mg one a day (before bedtime)
10128022|NCT04318340|Active Comparator|Standard Applicators|All patients will be fitted with the 2.6 cm applicator and sized up to the 3.0 cm applicator if tolerable.
10128023|NCT04318340|Experimental|Tapered Applicator|All patients will be fitted with the novel tapered 3.0 cm applicator. Patients have the option of having magnetic resonance imaging with the tapered applicator in place.
10128024|NCT04318028|Experimental|Diagnostic (7 Tesla MRI)|Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and 6-9 months.
10128025|NCT04318353||early enteral feeding|start enteral feeding within 2 days postoperative
10128026|NCT04318353||control|start enteral feeding after 2 days postoperative according to clinician discretion based on clinical progress(ranging from 1-5 days after passage of flatus or stool.
10128027|NCT04317950|Other|Vojta group|All participants were properly instructed and signed an informed consent previous to the interventions. They were comfortably laid down on their back with eyes open, wearing the EEG cap and electromyography electrodes during the intervention. They were asked to remain relaxed and still during the whole process. After a first minute of resting, the experimental group received a continuous reflex locomotion stimulus during the next 8 minutes.
10128028|NCT04317950|Sham Comparator|Control group|On the contrary, the control group received a continuous sham stimulus during the next 8 minutes.
10128029|NCT04317885|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
10128030|NCT04317989|Experimental|Practice Facilitation (top 50th percentile)|Practices with performance in the upper 50th percentile will receive practice facilitation for the duration of the intervention period.
10128031|NCT04317989|Experimental|Practice Facilitation + Embedded Teleheath|The lower 50th percentile of practices (based on performance after 6 months of practice facilitation) will be randomized to 2 arms. Of those practices randomized, this arm will receive continued practice facilitation plus embedded telehealth services related to interventions for unhealthy alcohol use.
10128032|NCT04317989|Experimental|Practice Facilitation (bottom 50th percentile)|The lower 50th percentile of practices (based on uptake of services after 6 months of practice facilitation) will be randomized to 2 arms. Of those practices randomized, this arm will receive ongoing practice facilitation for the duration of the intervention period (but will not receive embedded telehealth services).
10128033|NCT04318002|Experimental|Group 1A|Volunteers (aged 18-45 years) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2
10128034|NCT04318002|Experimental|Group 1B|Volunteers (aged 18-45 years) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
10128035|NCT04318002|Experimental|Group 2A|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2.
10128036|NCT04318002|Experimental|Group 2B|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 6.
10128037|NCT04318002|Experimental|Group 2C|Volunteers (aged 5-17 months) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
10128038|NCT04318002|Experimental|Group 2D|Volunteers (aged 5-17 months) of high malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
10128039|NCT04317976|Active Comparator|Centrally located oesophagus post GA|Oesophagus remained central after general anaesthesia, cricoid pressure applied by fingertips under ultrasound guidance
10128040|NCT04317976|Experimental|Eccentric located oesophagus post GA|Oesophagus eccentric located after general anaesthesia, paralaryngeal pressure and cricoid pressure applied by fingertips under ultrasound guidance
10128041|NCT04317963||Cases|Patients who have received bezlotoxumab 10 mg/kg intravenously in addition to standard CDI treatment.
10128042|NCT04317963||Controls|Patients who have received only standard CDI treatment.
10128043|NCT04317846|Active Comparator|Intra-radial group|intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
10128044|NCT04317846|Experimental|Intravenous-post group|intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
10128045|NCT04317846|Experimental|Intravenous-pre group|intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
10128046|NCT04317898|Active Comparator|serratus plane block|20 ml of Bupivacine 0.25% +80mg triamcinlone will be injected in serratus plane under ultrasound.
10128047|NCT04317898|Active Comparator|paravertebral block|10 ml of bubivacine 0.25% +80 mg triamcinlone will be injected at T2 level (paravertebral) under ultrasound.
10128048|NCT04317677|Other|Babies hospitalized in the pediatric sleep unit|
10128049|NCT04317638||breastfed group|Infants on exclusive breast feeding for the first 6 months of life and their mothers
9519557|NCT03285997|Active Comparator|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
10128050|NCT04317638||formula fed group|Infants on exclusive formula feeding for the first 6 months of life
10128051|NCT04317638||mixed fed group|Infants on mixed feeding (formula & breast feeding) and their mothers
10128052|NCT04317664|No Intervention|Control Group|The Control Group will have the in-vehicle device installed in the teen's car, but all feedback features will be disabled.
10128053|NCT04317664|Experimental|Feedback Only Group|The Feedback Only Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens can review their driving data. Teens will also receive biweekly cumulative driving reports.
10128054|NCT04317664|Experimental|Feedback and Parent Communication Group|The Feedback and Parent Communication Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens and parents can review their driving data. The parent will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a motivational interviewing professional. A second booster session will also occur two months after the initial training. Both teens and parents will receive a biweekly cumulative driving report.
10128055|NCT04317794||All Participants|Participants who were prescribed with nusinersen sodium injection in Korea according to local marketing authorization.
10128056|NCT04317625|Experimental|participants|All of the participants tested serum PSA, some of them conducted mpMRI with/without prostate biopsy under instruction.
10128057|NCT04317768|Experimental|Study group|They will be educated and motivated by an intensive program consisting of verbal instructions, Power Point lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
10128058|NCT04317768|Other|Control group|They will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
10128059|NCT04317872|Experimental|Current protocol|"Current protocol: patients will receive a single shot of 25mg of aacidexam iv (5cc) at induction. After 12 hours these patients will another shot of 10mg of aacidexam iv (2cc) on the ward."
10128060|NCT04317872|Active Comparator|Old protocol|"Old protocol: patients will receive a single shot of 5mg of aacidexam iv at induction (5cc). After arrival 12 hours these patients will receive a placebo, i.e. a shot of 2 cc of NaCl 0.9% iv (Mini-Plasco van B. Braun)."
10128061|NCT04317833|Experimental|Dose Escalation SSS17|Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)
10128062|NCT04317833|Placebo Comparator|Escalation matching Placebo|Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)
10128063|NCT04317859|Experimental|Behavioural Activation (Intervention)|Originally a component of Cognitive Therapy, Behavioural Activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to modify one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations and mood symptoms.
10128064|NCT04317859|No Intervention|Waitlist (Control)|The Control group (waitlist) will receive treatment as usual while waiting to receive BA intervention (at the end of intervention group therapy time, which will consist of 18 sessions over an 14 week period). This group will be assessed by clinical staff that offer treatment as usual for mood symptoms and quality of life measures during the waiting time.
10128065|NCT04317469||ARDS group ,|
10128066|NCT04317469||non ARDS group|
10128067|NCT04317924|Experimental|Reinforcement of air leak|Participants in this arm will receive reinforcement with the NEOVEIL (polyglycolic acid felt) which will be impregnated with human fibrinogen and thrombin.
10128068|NCT04317924|Active Comparator|No reinforcement of air leak|Participants in this arm will receive standard of care for air leak post lung resection.
10128069|NCT04317365|Active Comparator|patients receiving remembering|
10128070|NCT04317365|No Intervention|patients not receiving extra remembering|
10128071|NCT04317547|No Intervention|Control Group|The Azūga™ in-vehicle driving feedback technology will be installed.32 This driving feedback technology consists of a pager-sized device plugged into the vehicle's on-board diagnostic (OBD) port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone). All feedback features will be disabled. Control dyads will receive no driving feedback. The parent will not receive STS. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
10128072|NCT04317547|Experimental|Intervention Group|Parents will receive STS, which will include 1) Individualized virtual communication training and a booster session delivered by a traffic safety communication specialist; and 2) An online parent-teen safe driving communication guide. In addition, the Azūga™ in-vehicle device and app will be installed as described above and all feedback features will be enabled. Three types of feedback will be provided to teens: 1) Direct audio feedback; 2) Detailed cumulative driving data; and 3) A customized weekly driving summary report. Parents in this group will receive access to the teen's cumulative driving data and a weekly driving summary report. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
9519558|NCT03285945||PET3|Post-therapeutic FDG PET/CT performed after 3 days of steroid treatment
9519559|NCT03285945||PET10|Post-therapeutic FDG PET/CT performed after 10 days of steroid treatment
9527673|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 1)|Participants with AML will receive intevenous (IV) infusion of AZD2811 Dose 1 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
9967639|NCT01271751|Placebo Comparator|Matching placebo|
9967640|NCT01271764|No Intervention|endometrial cancer|
10128073|NCT04317729|Experimental|Diagnostic|Collection of whole blood via fingerstick and venipuncture
10128074|NCT04317391|Experimental|Pain management program|All enrolled patients participate in a 20 hour pain management program over a period of 8 weeks. The program is based on Mindfulness Based Stress Reduction with modifications to fulfill needs of the Taiwanese chronic pain population.
10128075|NCT04317495|Experimental|Computerized Cognitive Training (CCT)|The patients will receive CCT during their standard rTMS treatments (after having 5 days of treatment until the pre-taper treatment).
10128076|NCT04317339|Experimental|Zhigancao Tang granule group|Participants in experimental group will receive Zhigancao Tang granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters, diuretics as needed.
10128077|NCT04317339|Placebo Comparator|Zhigancao Tang placebo group|Participants in experimental group will receive Zhigancao Tang placebo granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
9826030|NCT02404441|Other|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
10128078|NCT04317703|Experimental|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
10128079|NCT04317703|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
10128080|NCT04317300|Experimental|E-cigarette users|Participants who are regular users of e-cigarettes will be treated with a 12 week course of varenicline for stopping vaping.
10128081|NCT04317352||Multivisceral resection (MRV)|MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
10128082|NCT04317755|Experimental|Intervention|Comics-based body image programme
10128083|NCT04317755|No Intervention|Control|Schools lessons as usual
10128084|NCT04317599||Non interventional|All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
10128085|NCT04317573|Active Comparator|Personalised card|The personalised card was printed by the attending ophthalmologist for the patient via a web accessible software we have developed. The software allowed the reviewing physician to select the medications the patient was prescribed and auto-generate a personalised card that will be sent to the network printer. The card illustrated the patient's eye drop regime in a simple pictorial format using coloured pictures of the eye drop bottles and universally recognised symbols. It can be folded to a compact size of 11cm x 7.5cm to allow patients to carry around in their wallets. This card will be given to patients at the end of their consult and explanation will be provided by the attending physician who will manually tick in the corresponding boxes depending on the frequency of administration
10128086|NCT04317573|Active Comparator|Personalised card and telereminder|Patients who were recruited into the group receiving tele-monitoring were contacted via text messages daily by a programmed software at the scheduled time of eye drop administration. They were required to acknowledge the reminder by replying a 'Yes' if they had administered the eyedrop and 'No' if they had not. A nil reply was taken as a 'No'.
10128087|NCT04317573|No Intervention|No intervention|No intervention
10128088|NCT04317508|Active Comparator|Intervention group|Topicale® topical anesthetic gel patch (Benzocaine 18%)
10128089|NCT04317508|Placebo Comparator|control group|Opahl® topical anesthetic gel (Benzocaine 20%)
10128090|NCT04317274|Experimental|High Cholesterol Good Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see good video first and poor video second.
10128091|NCT04317274|Experimental|Colorectal Cancer Good Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see good video first and poor video second.
10128092|NCT04317274|Experimental|High Cholesterol Poor Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see poor video first and good video second.
10128093|NCT04317274|Experimental|Colorectal Cancer Poor Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see poor video first and good video second.
10128094|NCT04317443||Super-Mini Percutaneous Nephrolithotomy|Patients undergo SMP
10128095|NCT04317443||Extracorporeal Shock Wave Lithotripsy|Patients undergo ESWL
10128096|NCT04317560|Active Comparator|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
9826031|NCT02404493|Active Comparator|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
9826032|NCT02404493|Experimental|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
9826033|NCT02404532|Experimental|1|
9826034|NCT02404610|Experimental|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
9967641|NCT01271777|Experimental|GFT505 80mg|
9967642|NCT01271777|Placebo Comparator|Matching placebo|
10128097|NCT04317560|Experimental|Arthrocentesis plus i-PRF injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. Only the second needle was removed without removing the first needle inserted. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
10128098|NCT04317430|Active Comparator|Treatment group|Niclosamide tablets 1 gram once daily
10128099|NCT04317430|Placebo Comparator|Control group|Lactose tablets
10128100|NCT04317235|Active Comparator|3 ml ropivacaine|interscalene block using 3 ml under ultrasound put medication on each nerve
10128101|NCT04317235|Active Comparator|5 ml ropivacaine|interscalene block using 5 ml under ultrasound put medication on each nerve
10128102|NCT04317261|Experimental|Hematuria patients|
10128103|NCT04317248|Experimental|MSDCV immune therapy combined with radical surgery therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time before the first time of MSDCV immune therapy
10128104|NCT04317248|No Intervention|Radical surgery therapy|Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time
10128105|NCT04317248|Experimental|MSDCV immune therapy combined with TACE therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: the first time of TACE therapy must perform before the first time of MSDCV immune therapy， then perform when necessary according to subjects condition
10128106|NCT04317248|No Intervention|TACE therapy|Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: perform when necessary according to Subjects condition
10128107|NCT04317248|Experimental|MSDCV immune therapy combined with targeted agents therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
10128108|NCT04317248|No Intervention|Targeted agents therapy|Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
10128109|NCT04317287|Experimental|Cardio formulation|Tomato-based formulation with dietary supplement
10128110|NCT04317287|Placebo Comparator|Placebo|Placebo softgels
10128111|NCT04317222|Experimental|eCRRT group|Initiated CRRT within the first 24 post-transplant hours.
10128112|NCT04317222|No Intervention|Control group|Standard treatment.
10128113|NCT04316949||Derivation cohort|"Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020.~."
10128114|NCT04316949||Validation cohort|Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
10128115|NCT04316936|Experimental|Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg|Omidria (= ketorolac + phenylephrine) and intracanalicular dexamethasone insert (punctal plug)
10128116|NCT04316936|Experimental|Omidria + Dexycu|Omidria (= ketorolac + phenylephrine) and intraocular dexamethasone suspension
10128117|NCT04316936|Active Comparator|Omidria + Prednisolone Acetate 1%|Omidria (= ketorolac + phenylephrine) and topical prednisolone acetate ophthalmic drops
10128118|NCT04316962|Experimental|Complex rehabilitation|See intervention described elsewhere.
10128119|NCT04316923||Children with cardiomyopathies|Children aged 0-18 years that have been diagnosed with DCM, HCM or LVNC on the basis of a two-dimensional echocardiography with color Doppler.
10128120|NCT04316923||Healthy children|The control group will be composed of healthy children, in whom heart disease will be excluded using echocardiography.
10128121|NCT04316975|Other|Biopsy: Barrett's Esophagus, Intramucosal adenocarcinoma|"Subjects will undergo standard of care (SOC) standard esophagogastroduodenoscopy (EGD) for the treatment of their condition (BE or IMC). Four (4) research biopsies will be taken from the midpoint of current disease. In cases where EMR (Endoscopic Mucosal Resection) is performed clinically, no research biopsies will be taken. Following CEIM, four (4) additional research biopsies will be collected, from the midpoint of previous BE site.~Laboratory Biomarker Analysis: Correlative studies~Esophagogastroduodenoscopy: Standard of care, research biopsies will be collected if clinical biopsies are taken"
10128122|NCT04317027|Experimental|All subjects|All subjects in this trial will receive the new fighting clothing while performing the study protocol
10128123|NCT04317144|Active Comparator|Web-based follow-up programme|Participant randomized to the Web-based follow-up programme receive access to web-portal called www.1177.se
10128124|NCT04317144|Active Comparator|No follow-up.|Participants does not receive the web-based follow-up programme. e-questionnaires are sent out.
10128125|NCT04316819|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
10128126|NCT04316819|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
10128127|NCT04317209|Experimental|SHR0410 low dosage|
10128128|NCT04317209|Experimental|SHR0410 medium dosage|
10128129|NCT04317209|Experimental|SHR0410 high dosage|
10128130|NCT04317209|Placebo Comparator|Placebo|
10128131|NCT04317092|Experimental|tocilizumab treatment|All the patients enrolled are treated with tocilizumab.
10128132|NCT04317157|Experimental|Caffeine Clinical Trial|Participants will ingest 6 mg.kg-1 of caffeine ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
10128133|NCT04317157|Placebo Comparator|Placebo Clinical Trial|Participants will ingest placebo ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
10128134|NCT04317157|Experimental|Placebo-deceived Caffeine|Participants will be lead to believe that they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
10128135|NCT04317157|Placebo Comparator|Placebo-deceived Placebo|Participants will be informed they are ingesting placebo ~45 minutes before the trial.
10128136|NCT04317157|Active Comparator|Control-Caffeine|Participants will be informed they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
10128137|NCT04317157|No Intervention|Control|Participants will perform a baseline trial with no intervention.
10128138|NCT04317079|Active Comparator|15mg of hydroxytyrosol|15 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given three times daily before main meals (totally 6 capsules daily) in combination with diet
10128139|NCT04317079|Active Comparator|5mg of hydroxytyrosol|5 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given in the morning and at night before meals and 2 capsules of placebo before lunch (totally 6 capsules daily) in combination with diet
10128140|NCT04317079|Placebo Comparator|placebo|2 capsules of placebo given 3 times daily before meals (totally 6 capsules daily) in combination with diet
10128141|NCT04317183|Experimental|Chamomile topical gel|"Topical oral chamomile gel three times daily for three weeks.~Topical oral chamomile gel is prepared with the aid of Pharmacognosy and pharmaceutics departments, faculty of pharmacy, Alexandria University and mucoadhesive hydrogels (Carbopol® 970)."
10128142|NCT04317183|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel BBC oral spray Oracure gel~Dose: Three times a day for three weeks"
10128143|NCT04317183|Experimental|combination therapy|"Topical oral chamomile gel three times daily for three weeks in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel BBC oral spray Oracure gel~Symptomatic treatment dose: Three times a day for three weeks"
10128144|NCT04317001|Active Comparator|Active treatment with modafinil|active intervention
10128145|NCT04317001|Placebo Comparator|Placebo|placebo intervention
10128146|NCT04316988||Ultrasonography|Ultrasonography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by ultrasound machine over the trachea.
10128147|NCT04316988||Capnography|Capnography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by capnograph, evaluationg the graph character and end tidal CO2 value.
10128148|NCT04316858|Active Comparator|Water|Water will be used as solvent for sodium phosphate
10128149|NCT04316858|Active Comparator|Zero calorie carbonated drink|Zero calorie carbonated drink will be used as solvent for sodium phosphate
10128150|NCT04317170|Experimental|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia.
10128151|NCT04317170|No Intervention|No Music|Patients will undergo their routine procedure without being played music.
10128152|NCT04316845|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
10128153|NCT04316793|Experimental|Dry needling (DN)|Intramuscular insertion
10128154|NCT04316793|Sham Comparator|Sham needling (SN)|Intradermal insertion
10128155|NCT04316780||Nintedanib until 0 day - 2 days before transplant|Nintedanib taken until 0 - 2 days before receiving transplant
10128156|NCT04316780||Nintedanib until 3 days - 28 days before transplant|Nintedanib taken until 3-28 days before receiving transplant
10128157|NCT04316780||Nintedanib until > 28 days before transplant|Nintedanib taken until more than 28 days before receiving transplant
10128158|NCT04316780||Pirfenidone until 0 day - 1 day before transplant|Pirfenidone taken until 0 - 1 day before receiving transplant
10128159|NCT04316780||Pirfenidone until 2 days - 28 days before transplant|Pirfenidone taken until 2-28 day before receiving transplant
10128160|NCT04316780||Pirfenidone until > 28 days before transplant|Pirfenidone taken more than 28 days before receiving transplant
10128161|NCT04316767|Experimental|App Intervention|Participants will download a mobile self-care app on their smartphones. The app guides users through exercises based on cognitive behavioral therapy principles. Participants will be able to use the app as frequently as desired throughout the course of the study.
10128162|NCT04316767|No Intervention|Control|Participants will receive usual supportive care provided to family members of ICU patients.
10128163|NCT04316598|Experimental|Cannabis (B)|"Subjects will be admitted in the center to receive 4 doses of inhaled cannabis in 3 days.~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every cannabis administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
10128164|NCT04316598|Placebo Comparator|Cannabis placebo (B)|"Subjects will be admitted in the center to receive 4 doses of an inhaled treatment based on placebo-THC in 3 days.~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
10128165|NCT04316429|Active Comparator|Egg phase:|Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets.
10128166|NCT04316429|Placebo Comparator|Control phase:|The participants will consume a vegan diet for 6 weeks.
10128167|NCT04316390|Experimental|Hesperidin (A)|study drink without hesperidin and without vitamin C compared to study drink with hesperidin
10128168|NCT04316390|Experimental|Hesperidin + Vitamin C (B)|study drink with vitamin C compared to study drink with hesperidin and vitamin C
10128169|NCT04316520|Experimental|Ketogenic diet|Ketogenic diet + standard of care
10128170|NCT04316507|Experimental|Oncologist led genetic counselling and testing|All subjects receive Oncologist Led Genetic Counselling and Testing
10128171|NCT04316624|Experimental|C-CAR066|Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
10128172|NCT04316338|Experimental|Active intermittent theta-burst stimulation (iTBS)|6 weeks of iTBS delivered at 80% resting motor threshold will be delivered to personalized regions in the prefrontal cortex based on each individual's functional connectivity.
10128173|NCT04316715|Experimental|Life-Steps for PreP|Participants in this group will receive standard of care treatment plus daily text message reminders. A subset of participants who demonstrate continued adherence challenges will also receive 4-6 weekly sessions of the Lifesteps for PrEP intervention.
10128174|NCT04316715|No Intervention|Standard of Care|Participants in this group will not receive an intervention outside the standard of care.
10128175|NCT04316676|Other|Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR|Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
10128176|NCT04316377|Active Comparator|Treatment|Chloroquine therapy in addition to standard of care
10128177|NCT04316377|No Intervention|No Treatment|Standard of care
10128178|NCT04316702|Active Comparator|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
10128179|NCT04316702|Active Comparator|Pharmacotherapy|Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 2 weeks, patients will be evaluated and dose will be adjusted as necessary and tolerated, up to the maximum dosage recommended for FM. Patients may also be switched from one medication to the other according to clinical judgment of the physician.
10128180|NCT04316416|Active Comparator|T7 Bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging T7 (7th thoracal vertebrae ) transverse process accompanied by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
9967643|NCT01271816||Presymptomatic ARVC gene carriers|ARVC gene positive patients without manifest ARVC after standard screening clinical testing.
9967644|NCT01271829|No Intervention|Control|While on the control arm subjects will be given a meal with no avocado.
9967645|NCT01271829|Active Comparator|Avocado supplement|While on the avocado supplement arm subjects will be given a meal in which a given amount of calories will be replaced by calories contributed by avocados.
9967646|NCT01271829|Active Comparator|Avocado included|While on the avocado included arm subjects will be given a meal in which the calories of avocado will be added to the calories of the control meal.
9967647|NCT01271842||Extra corporeal oxygenation|Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
10128181|NCT04316416|Active Comparator|T9 bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging transverse process T9 (9th thoracal vertebrae) by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
10128182|NCT04316416|Placebo Comparator|Control group|Postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard pain follow-up and monitorization will be performed. No block will be performed in this group.
10128183|NCT04316351|Experimental|Toripalimab + Pemetrexed + Anlotinib|
10128184|NCT04316481|Other|AngelMed Guardian System|All eligible subjects will have the AngelMed Guardian System implanted with alerting features turned ON; receive an external device which provides additional alerting; and receive training on system use.
10128185|NCT04316403|Experimental|Laser-assisted corticotomy|Er:YAG laser beam was used to perform several perforations to the alveolar bone around the canine in one side of the mouth hoping that would accelerate canine retraction
10128186|NCT04316403|No Intervention|Traditional treatment|Canines in this group were retracted by the conventional manner.
10128187|NCT04316455|Experimental|Integrative Yoga Therapy|Participants engaging in a 6-week chronic pain self-management program. Intervention: Integrative Yoga Therapy
10128188|NCT04316442|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
10128189|NCT04316000||A - Removal of the Subepithelial Tumour|The subephitelial tumour is successfully removed by endoscopic band ligation without resection.
10128190|NCT04316000||B - Non Removal of the Subepithelial Tumour|The subephitelial tumour is not successfully removed due to various reasons (size >15-mm, not technical success,...).
10128191|NCT04316000||C - Not Observed or Benign Subepithelial Tumour|The subephitelial tumour is not observed or is a benign entity, which does not require further interventions for these patients.
10128192|NCT04316026|Experimental|interventional group|group receiving shock wave therapy
10128193|NCT04316026|Sham Comparator|control group|sham shock wave therapy
9967648|NCT01271842||No extracorporeal oxygenation|Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
9967649|NCT01271881|Active Comparator|Percutaneous Transluminal Angioplasty (PTA) alone|Intervention: Procedure: PTA alone without use of the GORE VIABAHN
9967650|NCT01271881|Experimental|PTA with covered stent|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
9967651|NCT01271894|Experimental|Reduced dose Efavirenz arm|Participants randomized in main study to receive EFV (400 mg once daily; 2 x 200 mg + 1 x placebo once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
9967652|NCT01271894|Active Comparator|Normal Efavirenz dose arm|Patients randomized in the main study to receive EFV (600 mg once daily; 3 x 200 mg once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
9967653|NCT01271972|Experimental|Cohort 1|Dose 1
9967654|NCT01271972|Experimental|Cohort 2|Dose 2
9967655|NCT01271972|Experimental|Cohort 3|Dose 3
9967656|NCT01271972|Experimental|Cohort 4|Dose 4
9967657|NCT01271972|Experimental|Cohort 5|Dose 5
9967658|NCT01271972|Experimental|Expansion Cohort 1|Dose 4
9967659|NCT01271972|Experimental|Expansion Cohort 2|Dose 5
9967660|NCT01271985|Active Comparator|PolyPill|PolyPill once daily and Minimal Care
10128194|NCT04315974||Nonvalvular atrial fibrillation patients (NVAF)|Eligible patients comprise men and women aged 18 years or older with nonvalvular atrial fibrillation diagnosis undergoing ablation procedure.
10128195|NCT04316312|Experimental|Inspiratory muscle training group|
10128196|NCT04316104|Experimental|CuidTXT|This intervention, CuidaTXT [Spanish for self-care and texting], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
10128197|NCT04315987|Experimental|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
10128198|NCT04315987|Placebo Comparator|Placebo|Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
10128199|NCT04316325||Women and girls seeking abortion.|
10128200|NCT04316208|Experimental|Supratentorial tumor surgery|Patients undergoing elective supratentorial tumor surgery under general anesthesia will be ventilated with positive end-expiratory pressures of 0, 5 and 10 cmH2O after craniotomy.
10128201|NCT04316195||Patient admitted for an acute traumatic spinal cord injury|
10128202|NCT04316221|Active Comparator|Control|The standard of nutrition care in Guatemala includes the following clinical care, as determined to be necessary by the MHA medical and nutrition teams: frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
10128203|NCT04316221|Experimental|Intervention|The intervention group will receive an intervention to promote daily egg consumption for a six month period, in addition to the local standard of nutrition care. Specifically, intervention group participants will be provided with enough eggs for the infant to consume one egg, daily, for six months, and also with education on preparation and consumption of eggs.
10183663|NCT03762434|Active Comparator|booklet|The participants will receive the Life Style Modification programme with the support of a Hong Kong version Metabolic Syndrome (MetS) booklet to take home and use for 3 months. The booklet had been modified from a booklet of a Life Style Intervention Programme (LIP) in China and the principal investigator of this proposal was the core team members of the previous project . The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management . The major component of the booklet for the change is the language translated from simplified Chinese to traditional Chinese and slight adjustment about the advice on vegetable choice due to difference in type of available vegetables in Hong Kong.
10183664|NCT03762421|Experimental|Psychosocial skills development workshops based on PM plus|A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
10183665|NCT03762421|Active Comparator|Control Arm|The control group will receive 5 routine training induction sessions.
10183666|NCT03762408|Experimental|ENKO 1|ENKO 1 administered by single intra-articular injection.
10183667|NCT03762408|Active Comparator|Durolane|Durolane administered by single intra-articular injection.
10183668|NCT03762395|Experimental|CXA-10|Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.
10183669|NCT03762395|Placebo Comparator|Matching Placebo|Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.
10183670|NCT03762382|Experimental|TFV/LNG IVR (10mg/20μg) (Continuous)|Tenofovir/Levonorgestrel Intravaginal Ring
10183671|NCT03762382|Experimental|TFV IVR (10mg) (Continuous)|Tenofovir Intravaginal Ring
10183672|NCT03762382|Placebo Comparator|Placebo IVR (Non-eluting)|Placebo Intravaginal Ring
10183673|NCT03762369|Experimental|CKD-351|Latanoprost+D930
10183674|NCT03762369|Active Comparator|Latanoprost|
10183675|NCT03762369|Active Comparator|D930|
10183676|NCT03762343|Experimental|Greater occipital nerve block group (group GONB)|Patient in this group will receive 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
10183677|NCT03762343|Placebo Comparator|Control group (group C):|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
10183678|NCT03762330|Active Comparator|COPD structured self-management plan|Participants will receive usual care for COPD and in addition, a structured self-management education plan.
10183679|NCT03762330|No Intervention|Usual care|COPD participants receiving only usual care
10183680|NCT03762317|Active Comparator|clonidine|Clonidine is started at 6mcg/kg/day and increased to 12 mcg/kg/d for the duration of the study period
10183681|NCT03762317|Placebo Comparator|Placebo|Placebo solution will be given for the duration of the study period
10183682|NCT03762304||Intervention group|The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
10128204|NCT04316013|Active Comparator|A|Sevoflurane + intravenous lidocaine
10128205|NCT04316013|Active Comparator|B|Sevoflurane + placebo
10128206|NCT04316013|Active Comparator|C|Propofol TIVA + intravenous lidocaine
10128207|NCT04316013|Active Comparator|D|Propofol TIVA + placebo
10128208|NCT04316065|Other|Group 1|15 subjects, Cross-over, Single dose of comparator on day 1, Single dose of YHP1906 on day 8
10128209|NCT04316065|Other|Group 2|15 subjects, Cross-over, Single dose of YHP1906 on day 1, Single dose of comparator on day 8
10128210|NCT04316039|Experimental|RT+TMZ|
10128211|NCT04316039|Active Comparator|RT|
10128212|NCT04316728|Other|negative Patients|Adult HCWs with no signs or symptom of coronavirus infection and no known previous history of contact with patients positive for COVID-19, working in a primary care setting and Adult patients with at least 2 chronic medical conditions routinely attending a General Practioner (GP) practice or an outpatients departments or a primary care facility
10128213|NCT04316234|No Intervention|A. Clean Air|Clean air - no vaping was done.
10128214|NCT04316234|Experimental|B. Passive vaping|E-cigarette users were present in an adjacent chamber during both exposures, but only in situation B they were vaping and the vape-polluted air was passed on to the exposure chamber.
10128215|NCT04316052|Experimental|aerobic training group|At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine.
10128216|NCT04316052|Experimental|strength training group|Strength training prescriptions will be in accordance with recommendations of the American College of Sports Medicine.
10128217|NCT04315935|Experimental|butorphanol group|Butorphanol (10-20 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
10128218|NCT04315935|Active Comparator|fentanyl group|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
10128219|NCT04316091|Experimental|Experimental group|neoadjuvant chemotherapy+SPIONs/SMF
10128220|NCT04316091|Sham Comparator|Control group|neoadjuvant chemotherapy
10128221|NCT04315909|Experimental|Intervention group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus vitamin supplements (E (200 IU/ 2day) and C (250 mg/ 2day) ) for 8 weeks.
10128222|NCT04315909|Experimental|Control group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus placebo for 8 weeks.
10128223|NCT04315922||Severe Ischemic Stroke|Severe Stroke as defined by inclusion criteria
10128224|NCT04315922||Mild Ischemic Stroke|Mild Stroke as defined by inclusion criteria
10128225|NCT04315922||Transient Ischemic Attack|Transient Ischemic Attack as defined by inclusion criteria
10128226|NCT04315597|Experimental|Hypericum extract STW 3-VI (Laif® 900, BAY98-7108)|
10128227|NCT04315597|Placebo Comparator|Placebo|
10128228|NCT04315740|Sham Comparator|Clean Air|Just clean air - no exposure
10128229|NCT04315740|Experimental|Cooking|Four ovens were frying pork - one at a time. When the first oven finished, the next oven started and so forth for approx. 7 hours.
10128230|NCT04315740|Experimental|Candles|10 lit candles were placed at a table. Burning for approx. 7 hours with light ventilation.
10128231|NCT04315753||cancer patients (clinical stage I and II) +controls|70 lung cancer patients (clinical stage I and II) diagnosed outside screening and candidates to surgical resection at Humanitas Hospital, and 70 controls with benign nodules. Cancer patients will undergo blood collection before and at 4 months after surgical resection. Blood will be used for CTC analysis, exosome antigens and circulating free DNA (cfDNA) mutational analysis.
10128232|NCT04315753||prospective screening cohort of high risk individuals|a prospective screening cohort of high risk individuals enrolled at Humanitas Hospital (1000) will allow to recruit 50 patients with screening detected lung cancer and a large number of negative controls. Analysis of CTC, exosome antigens and cfDNA mutation profile will be performed.
10128233|NCT04315584|Experimental|Diagnostic|Study subjects will receive 18FDG via an IV before undergoing one PET/CT scan over 60 minutes. They will then receive an IV injection of Gadovist for contrast before undergoing a multiparametric MRI scan. Subjects will also receive (18)F-FDOPA via an IV before undergoing another PET/CT scan over 60 minutes.
10128234|NCT04315857||diabetics|diabetics receiving chemotherapy for cancer
10128235|NCT04315805|Experimental|Integrative Yoga Therapy|Integrative Yoga Therapy will be provided by yoga therapist once a week and participants will be encouraged to practice at home once or twice a day.
10128236|NCT04315805|No Intervention|Wait-list Control|Participants in waiting list will serve as control group for the intervention period. After the ftherapy group has received treatment, the same program will be offered to participants in the wait-list control group.
10128237|NCT04315558|Experimental|Revefenacin|Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.
10128238|NCT04315558|Active Comparator|Ipratropium|Nebulized ipratropium will be delivered via nebulizer Q6 hours.
10128239|NCT04315714|Experimental|IBS Yoga Intervention (delivered online/virtually via Zoom)|Ten participants with IBS will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
10128240|NCT04315714|Experimental|IBS Waitlist Control Condition|Ten participants with IBS will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
10128241|NCT04315714|Experimental|HC Yoga Intervention (delivered online/virtually via Zoom)|Ten participants serving as HC will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
10128242|NCT04315714|Experimental|HC Waitlist Control Condition|Ten participants serving as HC will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
10128243|NCT04315792|Experimental|Endoxifen Arm|Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks
9967661|NCT01271985|Active Comparator|Minimal care|Minimal care.
10128244|NCT04315792|Placebo Comparator|Placebo Arm|Placebo tablets of endoxifen. Patients will continue administration with their initial randomized medication for 3 weeks
10128245|NCT04315519|Experimental|Blood Flow Restricted Aerobic (BFRA)|Low intensity Aerobic exercise with Blood Flow Restriction
10128246|NCT04315519|Experimental|Moderate Aerobic Exercise (MAE)|moderate intensity aerobic exercise
10128247|NCT04315480|Experimental|tocilizumab|
10128248|NCT04315571|Active Comparator|Group A|Routine Large Volume Paracentesis (LVP) with albumin infusion
10128249|NCT04315571|Active Comparator|Group B|Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
10128250|NCT04315688||Tresiba®|Patients with type 2 diabetes
10128251|NCT04315727|Other|Study population|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. In addition, healthy parents of volunteers will be recruited if available to facilitate Trio studies.~Study related procedures: Blood sampling, hair collection, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures, organoid cultivation)."
10128252|NCT04315428||premature swaddled|the childs in this group will be wrap in a lange (swaddled)
10128253|NCT04315428||premature no swaddled|the childs in this group will be not swaddled
10128254|NCT04315779|Active Comparator|Conventional laparoscopy|In this arm, patients will be treated via conventional laparoscopy
10128255|NCT04315779|Active Comparator|Transvaginal natural orifice transluminal endoscopic surgery|In this arm, patients will be treated via transvaginal natural orifice transluminal endoscopic surgery
10128256|NCT04315662|Experimental|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
10128257|NCT04315662|Active Comparator|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
10128258|NCT04315675|Experimental|Guided Imagery Intervention|Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs The Guided Imagery Programs include: 1.) Relaxation and Wellness; 2.) Immune System Imagery; and 3.) Healing Trauma.
10128259|NCT04315675|Experimental|Cognitive Power Intervention|The participant who is randomly assigned to this group completes The Power as Knowing Participation in Change Version II (PKPCT) to determine 1.) Freedom to Act Intentionally, 2.) Involvement in Creating Change, 3.) Freedom to Act Intentionally and 4.) My Involvement in Creating Change.
10128260|NCT04315675|Experimental|Cognitive Power Intervention and Guided Imagery|The participant is randomly assigned to this group completes both the Guided Imagery Intervention and the Cognitive Power Intervention.
10128261|NCT04315675|No Intervention|Control Group|The participant is randomized to the control group and completes all study measures twenty-one days after the baseline data are competed. .
10128262|NCT04315649|Experimental|3D movie|3D movie viewing
10128263|NCT04315844|Experimental|balloon|To evaluate the efficacy and security of Ewata combined with a stent device in the treatment of acute ischemic stroke within 8 hours To prove whether the clinical efficacy and safety of Ewata r is not inferior to other guidings.
10128264|NCT04315545||Healthy women pregnant of singleton with a BMI ≥25 kg/m2|Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.
10128265|NCT04315532|Active Comparator|Pregnancy Group|"GCF and saliva samples were taken from pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from pregnant periodontal healty individuals baseline and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed for pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
10128266|NCT04315532|Active Comparator|Non-Pregnancy Group|"GCF and saliva samples were taken from non-pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from periodontal healty individuals baseline and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed for non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
10128267|NCT04315389||EXPERIMENTAL|OPEN LABEL USING HEALTHCARE ROBOTS IN PARALLEL (non comparison) EXPOSURE: 90 MINUTES 3 TIMES PER DAY FOR 3 DAYS, NON CONSECUTIVE
10128268|NCT04315454|Placebo Comparator|Group A|patients will receive 20 ml of normal saline into interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
10128269|NCT04315454|Experimental|Group B|Patients will receive 20 mg 0.25% Levobupivacaine into the interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
10128270|NCT04315467|Experimental|SGM-101|SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.
10128271|NCT04315493|Experimental|A|
10128272|NCT04315493|Experimental|B|
10183683|NCT03762304||Control group|The control group consists of individuals with a measured blood pressure just below the hypertensive cut-off of 140 mmHg systolic and 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact lower bound on blood pressure will be determined empirically. These individuals were not given the care encouragement intervention.
10128273|NCT04315623|Experimental|Reginal citrate anticoagulation|Patients accepted regional citrate anticoagulation for CRRT. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L. Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+. Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level.
10128274|NCT04315623|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
10128275|NCT04315883||Standard Treatment|"Evaluation of change of HRQOL survey responses will be performed:~at baseline (time of treatment) and~1 month post treatment~6 months post treatment~12 months post treatment~5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
10128276|NCT04315285|Active Comparator|Control group|12 sessions of treadmill training with instruction of 'swing your arms'
10128277|NCT04315285|Experimental|Heel-strike group|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
10128278|NCT04315285|Experimental|Big step group|12 sessions of treadmill training with instruction of 'lift your foot up high'
10128279|NCT04315285|Experimental|Internal focus heel-strike|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
10128280|NCT04315285|Experimental|External focus shoe-strike|12 sessions of treadmill training with instruction of 'strike the ground with your shoe-heel'
10128281|NCT04315402||Group 1 (provider-patient concordant)|
10128282|NCT04315402||Group 2 (provider-patient discordant)|
10128283|NCT04315337|Experimental|Virtual Training Arm|This is a within-participant study with one arm. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task and a control task.
10128284|NCT04315194||clarithromycin-naproxen-oseltamivir|Efficacy of clarithromycin-naproxen-oseltamivir combination therapy vs. oseltamivir alone for hospitalised paediatric influenza patients
10128285|NCT04315220|Experimental|Experimental group (Core stability training (CST))|"Core stability training (CST) consists of two levels: level 1- Mat exercises (includes abdominal muscle contraction, bridging,cat stretch,single leg circle and superman) and level 2- Swiss ball exercises (includes abdominal muscle contraction, bridging and squatting by using therapy ball).~There will be three sets of 15 repetitions of each exercises. The first set will consist of 10 seconds hold period, follow by 12 seconds hold in second set and 15 seconds hold in third set respectively. The entire session will last for approximately 30 minutes."
10128286|NCT04315220|Active Comparator|Control group|Will not receive any kind of training.
10128287|NCT04315207|Active Comparator|In-person visit|"In-person meeting with the patient in the out-patient department. The patient is free to bring up to four* relatives or other persons of their own choice to the in-person meeting.~(* Restriction due to space limitation)."
10128288|NCT04315207|Experimental|Telephone call|Telephone call with the patient. The patient is free to turn on loudspeaker to include relatives or other persons in the telephone conversation, alternatively to ask the physician to call and inform one relative or other person after the patient-doctor telephone call
10128289|NCT04315259|Experimental|Laser activated irrigation|conventional root canal treatment was done , 2.5% sodium hypochlorite was used and was activated by 980 nm with a repeated pulse mode using a pulse duration of 5 s and a pulse interval of 0.2 ms. The laser irradiation will be delivered for 1 minute into the canal up to 1 mm short of the working length, with circling movements from the apical part moving towards the coronal part (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100)
10128290|NCT04315259|Experimental|Soft tissue laser application|"Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices.~Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product"
10128291|NCT04315259|No Intervention|conventional root canal|conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with no laser intervention
10128292|NCT04315376|Experimental|Exercise-Diet Group|The participants receive a personal exercise program according to Astrand-rhyming test baseline results, and a hypo-caloric diet intervention
10128293|NCT04315376|Active Comparator|Diet Group|The participants no receive a personal exercise program, only the hypo-caloric diet
10128294|NCT04315155|Experimental|Double Regimen|belinostat in combination with nivolumab
10128295|NCT04315155|Experimental|Triplet Regimen|belinostat in combination with nivolumab and ipilimumab
10128296|NCT04315441||Soldiers|any soldier who attended the Military Medical Center of Sector N°5 for the annual re-engagement medical visit during the period from January 1, 2017 to November 13, 2018.
10128297|NCT04315441||Civilians|The civilian populations were recruited from two free cardiovascular risk factors screening campaigns carried out from January 04, 2017 to January 10, 2017 and from November 12, 2018 to November 18, 2018
10128298|NCT04315116|Experimental|Treament|Subjects receiving a single oral dose of pyrotinib maleate and wash-out for 6 days, then receiving Loperamide 4 mg bid from day 7 to day 13, with a single oral dose of pyrotinib maleate coadministered on day 10 .
10128299|NCT04315103|Experimental|the combined-injection group|patients received a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
10128300|NCT04315103|Active Comparator|the one-injection group|patients received a single injection of 3 ml PRP
10128301|NCT04315051|Placebo Comparator|Placebo Gel|Placebo gel daily application for 4 weeks
10128302|NCT04315051|Active Comparator|Cohort 1|DBI-001 Gel daily application for 4 weeks
10128303|NCT04315129|Other|Single arm|A single arm will have biosensor (experimental) diagnoses compared to clinical (control, current standard of care). All participants in this group willl have a biosensor, with the data masked to patients, providers and clinical researchers
10128304|NCT04314934|Experimental|Active|ANAVEX2-73
10183684|NCT03762278|Experimental|Immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the uni-laterally immobilised leg.
10128305|NCT04315077|Experimental|Experimental Group|Subjects will consume one serving per day (25mg) of the treatment condition (Oceanix ®) for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
10128306|NCT04315077|Placebo Comparator|Placebo Group|Subjects will consume one serving per day (25mg) of the microcrystalline cellulose-based placebo condition for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
10128307|NCT04314973|Active Comparator|Control phase|Patients will follow walking exercises sessions, without wearing the robotic device, for 30 sessions of 45 min.
10128308|NCT04314973|Experimental|Intervention phase|Patients will walk with the robotic device, for 30 sessions of 45 min.
10128309|NCT04315064|Experimental|Treatment with MTX110|
10128310|NCT04315025|Active Comparator|Conditioned Medium (CM)|a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar
10128311|NCT04315025|Active Comparator|UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar
10128312|NCT04315025|Active Comparator|UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar
10128313|NCT04314713|Placebo Comparator|Scopolamine HBT 0.005 mg/kg|Dose of Scopolamine 0.005mg/kg verses Placebo
9527674|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 2)|Participants with AML and myelodysplastic syndrome (MDS) will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
9669047|NCT04229004|Active Comparator|Gemcitabine combined with nab-paclitaxel|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted as long as drug dosing and modification guidelines are followed.
10128314|NCT04314713|Placebo Comparator|Scopolamine HBT 0.007 mg/kg|Dose of Scopolamine 0.007mg/kg verses Placebo
10128315|NCT04314713|Placebo Comparator|Scopolamine HBT 0.011 mg/kg|Dose of Scopolamine 0.011mg/kg verses Placebo
10128316|NCT04314713|Placebo Comparator|Scopolamine HBT 0.014 mg/kg|Dose of Scopolamine 0.014mg/kg verses Placebo
10128317|NCT04314713|Placebo Comparator|Scopolamine HBT 0.021 mg/kg|Dose of Scopolamine 0.021mg/kg verses Placebo
10128318|NCT04314713|No Intervention|Placebo|Placebo controlled
10128319|NCT04314804|Experimental|Smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
9967662|NCT01271985|No Intervention|Usual care|Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.
10128320|NCT04314804|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
10128321|NCT04314869|Experimental|Recipient|Patient with absolut uterine factor will undergo uterus transplantation.
10128322|NCT04314817||Patients treated for Covid-19|
10128323|NCT04314908|Experimental|Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0."
10128324|NCT04314908|Experimental|Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0 and sonic activation assisted irrigation will be applied."
10128325|NCT04314908|Experimental|Non Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point."
10128326|NCT04314908|Experimental|Non Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point and sonic activation assisted irrigation will be applied."
10128327|NCT04314960|Experimental|CAI subjects|Subjects in this group will receive eight 20-minutes gait training sessions with functional electrical stimulation.
10128328|NCT04314856|Experimental|Fragile X Syndrome|"Adult males aged 18-30 years diagnosed with FXS will undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.~These participants will only be administered once with 18F-FTC-146."
10128329|NCT04314856|Experimental|Healthy Volunteers (Control)|"Adults aged 18-65 years undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.~Test-retest studies will be performed where these individuals will each be injected twice with 18F-FTC-146."
10128330|NCT04315012|Experimental|Receiving mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
10128331|NCT04315012|No Intervention|Standart|not to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
10128332|NCT04314726|Active Comparator|amelogenins group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. Amelogenins effect was evaluated by applying them only in the test site and comparing healing results with those obtained on the contra-lateral site
9826035|NCT02404610|Experimental|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
10128333|NCT04314726|Placebo Comparator|placebo group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. In this group (control site) the conventional treatment was performed, and healing was ensured only by the simple blood clot
10128334|NCT04314999||Patients diagnosed with a chronic spontaneous urticaria|Patients with a chronic spontaneous urticaria who were being treated at the allergology of the university hospital Basel between the 1st of June and the 30th of September
10128335|NCT04314739|Active Comparator|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
10128336|NCT04314739|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
10128337|NCT04314661|Experimental|Arthoscopy + UC-MSCs + CM + CM|After arthroscopy patient will be given UC-MSCs 5 million cells, after 2 weeks patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
10128338|NCT04314661|Experimental|Non Arthoscopy + UC-MSCs + CM + CM|Patient will be given UC-MSCs 5 million cells, after 2 weeks patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
10128339|NCT04314661|Experimental|Non Arthoscopy + CM + CM|Patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
10128340|NCT04314596|Placebo Comparator|Placebo Group|Participants will engage in a one day, whole-body, cross-training course while consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
10128341|NCT04314596|Experimental|Experimental Group|Participants will engage in a one day, whole-body, cross-training course while consuming the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
10128342|NCT04314765|Experimental|bayonet flap|Bayonet flap is performed to extract the the lower third molar
10128343|NCT04314765|Experimental|envelope flap|Envelope flap is performed to extract the the lower third molar
10128344|NCT04314609|Experimental|Ultrasound , fluroscope|After injection of corticosteroids with 1 ml contrast in sacroiliac joint using ultrasound and withdrawal of the needle, an antero-posterior fluoroscopy image will be obtained and recorded for the injected joint to detect the spread pattern of the contrast and whether its pre-dominantly intra or periarticular.
10128345|NCT04314622|Experimental|Supaglutide (Part A)|Four investigational doses of Supaglutide administered weekly (or bi-weekly) and subcutaneously (SC) in T2DM patients.
10128346|NCT04314622|Placebo Comparator|Placebo(Part A)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
10128347|NCT04314622|Experimental|Supaglutide (Part B)|Two investigational doses of Supaglutide administered weekly (or bi-weekly) and SC in T2DM patients.
10128348|NCT04314622|Placebo Comparator|Placebo (Part B)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
10128349|NCT04314830|Active Comparator|Gait training without perturbation|Walking on a treadmill with the same duration as a participants of the experimental arm matched for initial gait speed. Treadmill speed did not change along the training program
10128350|NCT04314830|Experimental|Gait training with perturbations|Walking on a treadmill with perturbations produced by changes in the speed of one of the belt of the split-belt treadmill during one gait cycle. Changes in treadmill speed were applied on the paretic or non-paretic side, with and increase or a decrease of the speed of the belt in various magnitude. Perturbations were either repeated with the same characteristics or with different characteristics. Outside of perturbations, treadmill speed did not change along the training program.
10128351|NCT04314648|Active Comparator|START|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid and alcohol use disorders, and to increase linkage to aftercare.~The components of the START intervention are as follows:~Triage~Engage, Assess, and Plan~Treat~Communicate and Coordinate~Follow up~Monitor"
10128352|NCT04314648|No Intervention|Usual Care|Usual care for people with alcohol or opioid use disorder.
10128353|NCT04314687|Experimental|UCMSCs + CM|UCMSCs + CM is administered via intrathecal injection
10128354|NCT04314687|Experimental|UCMSCs|UCMSCs is administered via intrathecal injection
10128355|NCT04314687|Active Comparator|Standard Therapy|Physiotherapy
10128356|NCT04314570|Experimental|Ropivacaine Treatment|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Ropivacaine through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
10128357|NCT04314570|Placebo Comparator|Saline Control|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
10128358|NCT04314583|Active Comparator|Attention Control Group|Adult patients attending cardiovascular rehabilitation.
10128359|NCT04314583|Experimental|Gratitude Journaling Group|Adult patients attending cardiovascular rehabilitation.
10128360|NCT04314310|Active Comparator|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
10128361|NCT04314310|Placebo Comparator|placebo|equal volume of normal saline
10128362|NCT04314375|Experimental|Low Dose Budesonide|
10128363|NCT04314375|Experimental|High Dose Budesonide|
10128364|NCT04314375|Placebo Comparator|Placebo|
10128365|NCT04314258|Experimental|Drinking Moringa oleifera tea|The experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.
10128366|NCT04314258|No Intervention|Drinking plain water|The control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.
10128367|NCT04314362|Experimental|AZR-MD-001 Active|AZR-MD-001 ointment/semi-solid drug (1.0%)
10128368|NCT04314362|Experimental|AZR-MD-001 Active + Conventional Treatment|AZR-MD-001 ointment/semi-solid drug (1.0%) plus Hylo-Forte®
10128369|NCT04314362|Experimental|AZR-MD-001 vehicle|AZR-MD-001 vehicle control
10128370|NCT04314453||T group|The degenerative lumbar spinal stenosis patients accepted the PELD with TESSYS procedure.
10128371|NCT04314453||U group|The degenerative lumbar spinal stenosis patients accepted the PELD with U route procedure.
10128372|NCT04314492|Experimental|Intracapsular tonsillectomy with coblation|(Total) Intracapsular tonsillectomy (ICTE) with coblation
10128373|NCT04314479|Experimental|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes
10128374|NCT04314479|Other|Symptom Assessment Only|For participants randomized to the control condition weekly symptom assessment telephone calls will be completed by staff at the University of Arizona Cancer Center Behavioral Measurements Interventions Shared Resource (BMISR). At week 13 an exit interview will be completed by the study coordinator to record participants feedback regarding study intervention, length, coaches, etc… In addition, staff from BMISR will call to repeat all baseline measures with the exception of the demographic questionnaires. Symptom assessment calls will take approximately 15 minutes.
10128375|NCT04314427||Gastric by-pass|Roux-en-Y gastric bypass (RYGB); the stomach is divided with staplers to create a small gastric pouch, while the jejunum is divided 30 to 50 cm distal to the ligament of Treitz. The distal limb is then anastomosed to the small gastric pouch and a jejunojejunostomy is performed 50 to 150 cm distal from the gastrojejunostomy.
10128376|NCT04314427||Sleeve gastrectomy|Sleeve gastrectomy reduces the stomach size by vertical stapling
10128377|NCT04314921|Experimental|10-week Yoga|Eighteen healthy elderly people, who were classified into two age groups, participated in this study. All participants had not practiced yoga before and were asked not to perform any sports activities while the research was ongoing. In the experimental group, participants (n = 18) had to participate in 10 weeks of yoga classes. In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life. All experimental group subjects participated in Himalayan yoga classes, which lasted 10 weeks: 2 times per week, 90 min per session. Yoga classes were conducted by 16-year-old qualified yoga instructor from Yoga Academy, Kaunas.
10128378|NCT04314921|No Intervention|Control|In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life.
10128379|NCT04314986|Experimental|AR882 (Dose A)|
10128380|NCT04314986|Experimental|AR882 (Dose B)|
10128381|NCT04314986|Experimental|AR882 (Dose C)|
10128382|NCT04314986|Experimental|AR882 (Dose D)|
10128383|NCT04314986|Placebo Comparator|Placebo|
10128384|NCT04314440|Experimental|Music therapy|After the initial warm up session music therapy will be delivered three times a week for 15-20 minutes. All babies in the experimental group will be exposed to three weeks of music therapy sessions that is a total of 9 music therapy session prior to discharge from the hospital. The baby will be placed at the bassinet 15 minutes before music therapy begins. The baby will be in the bassinet during music therapy and 15 minutes post music therapy to allow measurement of physiological indicators. If parents are present during music therapy they will not engage in kangaroo care during the music therapy session or when physiological measurements are being taken pre and post music therapy, but can do so at other times.
10128385|NCT04314440|No Intervention|Control|Infants in this group will not receive any music therapy but will receive all other standard care provided to infants at the Regina General Hospital (RGH). All measurements will be carried out for all the infants in this group at the time when observations are carried out for infants in the music therapy group.
10128386|NCT04314245||Urothelial carcinoma group|Subjects who diagnosed with incident or recurrent urothelial carcinoma (including bladder/ureter/renal pelvis) by surgical pathology.
10128387|NCT04314245||interference group|Subjects who diagnosed with incident or recurrent bladder cancer other than urothelial carcinoma (including bladder squamous cell carcinoma/bladder adenocarcinoma/other bladder-related cancers/prostate cancer/rectal cancer) by surgical pathology.
10128388|NCT04314245||Control group|Subjects who clinically diagnosed with benign disease of the urinary system, such as Urinary calculi, urinary tract infection (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis.
10128389|NCT04314245||Healthy volunteers group|Volunteers who have a normal routine urine test / ultrasound examination of the urinary system and do not carry suspected tumors of other organs.
10128390|NCT04314297|Experimental|Anlotinib In Combination With Durvalumab|
10183685|NCT03762278|Active Comparator|Non-immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the non-immobilised leg.
10183686|NCT03762278|Placebo Comparator|Immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the uni-laterally immobilised leg.
10183687|NCT03762278|Placebo Comparator|Non-immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the non-immobilised leg.
10183688|NCT03762252|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the scalene muscles
10183689|NCT03762252|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the scalene muscles
10187640|NCT03724240|Placebo Comparator|Placebo solution|Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
9967663|NCT01271998|Experimental|healthy volunteer|healthy volunteers
10128391|NCT04314206|Experimental|VNRX-5024|Capsule formulation
10128392|NCT04314206|Placebo Comparator|Placebo|Placebo for VNRX-5024
10128393|NCT04314791||US scan with calculation of the PAI|
10128394|NCT04314674|Active Comparator|%3 HS bolus 3 mL.kg-1|After the head fixation 3 mL.kg-1 %3 hypertonic saline will be administered over the 20 min intravenously.
10128395|NCT04314674|Active Comparator|%3 HS infusion 20 ml/h|After the head fixation 3% hypertonic saline at 20 ml/h infusion rate will be administered during the operation
10128396|NCT04314674|Active Comparator|%20 mannitol 0,6 gr.kg-1|After the head fixation %20 mannitol 0,6 gr.kg-1 will be administered over the 20 min intravenously.
10128397|NCT04314505|Experimental|Opioid Sparing Protocol|Preemptive(before incision): Parecoxib sodium 40 mg Postoperative: Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses.
10128398|NCT04314505|Active Comparator|Opioid Based Patient Controlled Analgesia|Preemptive(before incision) and Postoperative: the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours; adjusted by the PCA staff
10128399|NCT04313985|Active Comparator|Electrical Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
10128400|NCT04313985|Sham Comparator|Sham Electrical Stimulation|"Treat the patient's wound area:~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
10128401|NCT04313946||Symptomatic Patients|Our goal is to identify an artificial intelligence algorithm that can be run on lung radiographs in patients with influenza / respiratory viral symptoms who come to the emergency department / triage. This algorithm aims to identify the radiographs of patients with COVID-19 and those with influenza pneumonitis, with accuracy verified by COVID-19 tests.
10128402|NCT04313959|Active Comparator|Local anesthetic|Patients assigned for local anesthetic group will receive a single-shot ultrasound-guided erector spine plane block with 25 mL of 0.2% of ropivacaine
10128403|NCT04313959|Active Comparator|Local anesthetic + steroid|Patients assigned for local anesthetic + steroid group will receive a single-shot ultrasound-guided erector spine block plane with 25 mL of 0.2% of ropivacaine with 4 mg dexamethasone
10128404|NCT04313894|Experimental|Stem Cell Therapia Group|A total of 11 patients with Kellgren-Lawrence grade II-III knee OA who were admitted to the outpatient clinic with knee pain and who had received conservative treatment for a period of 6 months and who had not benefited from it will be taken. Patients will be evaluated 7 (V1-7) during the study period. Patients who comply with the study criteria will be included in the study. The clinical, immunological and radiological efficacy of the treatment and clinical improvement will be evaluated in all follow-up patients at the beginning and at the beginning of the treatment.
10128405|NCT04314128|Other|Patients suspected of IIH at baseline|"Intervention: TOS and TCD measurements at baseline, and at routine follow-ups.~Healthy controls will be recruited to match the patients."
10128406|NCT04314180||Slit-lamp image quality assessment|Device: an artificial intelligence system for quality assessment of slit-lamp images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center
10128407|NCT04314102||1|"Individuals will be evaluated before knee arthroplasty surgery. They will come for control in the 1st and 3rd months after surgery.~No intervention will be made."
10128408|NCT04314154||Study group|Group of all patients hospitalized in the SMHC and due participate in rehabilitative procedures
10128409|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 1: A-B-C|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
10128410|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 2: A-C-B|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
10128411|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 3: B-A-C|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
10128412|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 4: B-C-A|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
9967664|NCT01272024|Active Comparator|Information/Education Group|Assistance in using Symptom Management Toolkit
10128413|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 5: C-A-B|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
10128414|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 6: C-B-A|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
10128415|NCT04314193|Experimental|methotrexate|
10128416|NCT04314193|Active Comparator|prednisolone|
10128417|NCT04314141||Transgender patients|Transgender patients who carry out sex reassignment surgery.
10128418|NCT04314141||Cismale patients|Cismale patients who carry out surgery to correct a congenital or acquired lack of penis.
10128419|NCT04314167|Experimental|LDL lowering therapy|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
10128420|NCT04313816||unique group|patients visiting their family physician
10128421|NCT04313920|Experimental|Nutritional Supplement|Ready to drink liquid
10128422|NCT04313829|Active Comparator|Intervention group|The intervention group received Pharmacist counseling for 15 minutes include giving standard medicine information service and explaining the validated pharmacist counseling module which contained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed dose.
10128423|NCT04313829|No Intervention|Control group|The control group received standard medicine information services by Pharmacists.
10128424|NCT04313751|Experimental|Education, Physical Activity, and Stress Management Program|Classes for the intervention group will be run by a bilingual interventionist and will last 120 minutes weekly for 12 weeks and then monthly for 3 months.
10128425|NCT04313751|Active Comparator|Wait-list Control|Data in the wait-list control group will be collected at the same time intervals as the intervention group. After Time 3 data collection, they will be offered the Phase I intervention (12 weekly sessions).
10128426|NCT04313907|Experimental|Acitve laser+topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus topical clonazepam 1 mg, 3 times at day, same 14 days both
10128427|NCT04313907|Sham Comparator|Sham laser+topical clonazepam|Using sham laser (six sesions) plus topical clonazepam 1 mg, 3 times at day, same 14 days both
10128428|NCT04313907|Placebo Comparator|Active laser+placebo of topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus placebo of topical clonazepam (lactose), 3 times at day, same 14 days both
10128429|NCT04313738|Experimental|Intervention group|Experimental: Intervention group Intervention group: Home visit, health education, telephone counseling At the intervention group; the researcher firstly made spirometry meausurement in hospital. After, the researcher made pretest (baseline measurement) before nursing interventions at the first home visit. At the first home visit, the researcher was offered education and guide smoking cessation. Second, Third and fourth home visit were made 15 days later, one and six months after visit first visit. During the second, third and fourth home visits, firstly the patient's stage of change was determined and then appropriate nursing intervention was performed in accordance with the guidelines.Between the third and fourth home visits, the participants were contacted through telephone calls once a month. At fourth home visit, the researcher made posttest. After the patient was invited to the hospital and spirometry measurements were repeated.
10128430|NCT04313738|No Intervention|Control Group|At the control group; No home visits were paid to the control group. The researcher made measurements twice at in the first and sixth months in the hospital. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
10128431|NCT04313725|Experimental|Boost|Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.
10128432|NCT04313725|Placebo Comparator|Placebo|Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.
10128433|NCT04313790|Experimental|Heparin Infusion|heparin infusion 500unit \hour
10128434|NCT04313790|Other|Subcutaneus Heparin|subcutaneous heparin 5000unit \ 8 hours
10128435|NCT04313803||American Fork|CGM usage months 1 and 3
10128436|NCT04313803||Central Orem|CGM usage for month 1
10128437|NCT04313803||North Canyon, Saratoga Springs, and Lehi|CGM usage for 1-3 months
10128438|NCT04313777|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
10128439|NCT04313777|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
10128440|NCT04313595|Experimental|Breathing frequency monitoring|
10128441|NCT04313517|Experimental|Yoga@Work|Yoga session were developed to practice at work anytime feasible.
10128442|NCT04313517|No Intervention|Wait list Control group|Control group with no intervention. After Intervention period, group was offered same sessions.
10128443|NCT04313673||randomized|Patients who were followed up in our clinic with a diagnosis of preterm labor that spontaneously took action and were born before 37 weeks of gestation will form a group.
10128444|NCT04313582|Experimental|SmartPrompt|
10128445|NCT04313660|Experimental|Anlotinib In Combination With PD-1/L1 Inhibitor|
10128446|NCT04313491|Experimental|Yoga@Work|
10128447|NCT04313465|No Intervention|Control (Routine Care)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a cardiac troponin blood test upon admission to the Emergency Department. Participants will then have a repeat cardiac troponin blood test in 3 hours.
10128448|NCT04313465|Experimental|Intervention (Immediate Discharge)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a troponin blood test upon admission to the Emergency Department. Participants will then be discharged.
10128449|NCT04313764|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
10128450|NCT04313764|Active Comparator|Group Infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
10128451|NCT04313569|No Intervention|Conservative treatment|Use of medications, like analgesic, muscle relaxants, non-steroidal anti-inflammatory drugs (NSAID) and local painkillers, depending on the patient condition, and physiotherapy, lifestyle and daily activity modification, patient education about positioning of the knee
10128452|NCT04313569|Other|Arthroscopic menisctomy|
10128453|NCT04313504|Experimental|Niraparib & Dostarlimab|"Niraparib starting on Day 0. Niraparib will be administered as continuous daily dose, orally 200 or 300 mg.~Dostarlimab IV administered via a 30-minute infusion on Day 1 of every 21 day cycle. 500mg for first 4 doses followed by 1000 mg every 6 weeks."
10128454|NCT04313543|Experimental|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. There is 3 days for wash out period. These tests will be repeated for 3 times for baseline glucose calculation. After that, volunteers take 50 g of longan syrup in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. Glycemic index of longan syrup is calculated from area under the curved of blood glucose after longan syrup taking divided to mean of area under the curved of blood glucose after glucose taking
10128455|NCT04313452|Placebo Comparator|regular diet|50% of energy from carbohydrates, 30% fat and 20% from protein
10128456|NCT04313452|Active Comparator|Mediterranean diet|60% of energy from carbohydrates, 25% fat and 15% from protein
10128457|NCT04313686|Experimental|Mindfulness-based therapy|The mindfulness training program included mindfulness meditation practices, self-enquiries, mindful movement as well as understanding of stress physiology and cognitive awareness in the Breathworks/ Paradigm system of mindfulness-based approaches. Participants were enrolled in 5-10-person groups that met weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
10128458|NCT04313686|Active Comparator|No-Intervention|The control group would attend their routine follow-up visits at the neurology outpatient clinic.
10128459|NCT04313439|Experimental|Treatment|Online Cognitive Therapy (I-CT)
10128460|NCT04313556|Other|Lateral patellar release|Arthroscopic lateral patellar retinacular release
10128461|NCT04313634|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
10128462|NCT04313634|Experimental|Fisetin Treatment Group|Subjects will receive Fisetin (F; ~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
10128463|NCT04313634|No Intervention|Untreated Control Group|Subjects will not receive any intervention
10128464|NCT04313270||Patients with FH starting a treatment with Evolocumab®|
10128465|NCT04313218||A|recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
10128466|NCT04313218||B|women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
10128467|NCT04313257|Active Comparator|Passive Occlusion|This arm will include those participants who will follow a daily occlusive treatment of 2 hours.
10128468|NCT04313257|Experimental|Active Occlusion|This arm will include patients who will be treated with monocular therapy with video-games of one hour on a daily regimen.
10128469|NCT04313400|Experimental|Part 1 Dose Escalation: 3% to 70% of the BSA|Open-label AMTX-100 CF 1.1% w/w, topically applied twice a day for 7 consecutive days to all treatable AD affected areas from 3% to 70% of the Body Surface Area (BSA) (3% BSA ≤ AD Affected Area ≤ 70% BSA)
10128470|NCT04313400|Experimental|Part 2 Group A: Low dose concentration (0.11% w/w)|AMTX-100 CF Low dose concentration (0.11% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
10128471|NCT04313400|Experimental|Part 2 Group B: Medium dose concentration (0.33% w/w)|AMTX-100 CF Medium dose concentration (0.33% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
10128472|NCT04313400|Experimental|Part 2 Group C: High dose concentration (1.1% w/w)|AMTX-100 CF High dose concentration (1.1% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
10128473|NCT04313400|Placebo Comparator|Part 2 Group D: Placebo|Placebo (Vehicle) (0% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
10128474|NCT04313387||Control group - Normal eyes (CG)|"• Control group - Normal eyes (CG): 351 eyes without KC of 351 patients who underwent LASIK or photorefractive keratectomy (PRK), stable after at least 18 months of follow-up, without any changes in the posterior elevation at the 18-month Pentacam in relation to the preoperative exam (surgeries performed in 2012-2018). Our objective topographic criteria were: both eyes with a KISA% index of less than 60%, Kmax of 47.2 D or less, and I-S difference of less than 1.45 D. Because no truly established tomographic parameter(s)/cut-off(s) for differentiating normal from keratoconus suspect eyes exist, we adapted our classification for normal eyes to the recent publication by Ambrósio et al. by adding the criterion of overall subjective normal topography and tomography examinations based on the evaluation of experienced refractive surgeon (GCAJ). Only one eye was randomly selected for further statistical analysis."
10128475|NCT04313387||Very assimetric ectasia with normal topography|• Very assimetric ectasia with normal topography group (VAE-NT G): 88 eyes of 88 patients with very asymmetric ectasia with normal topography (VAE-NT) in one eye and frank ectasia (VAE-E) in the fellow eye. The inclusion criteria followed previous studies (28, 32, 33) Eyes in this group with insufficient topographic findings to meet diagnostic criteria for keratoconus, and following features normal-appearing cornea on slit-lamp biomicroscopy, keratometry, retinoscopy. These cases were the less affected eye (fellow eye) of a keratoconic patient was included if the following criteria were met: KISA% index of less than 60%, I-S difference of less than 1.45 D, and Kmax of 47.2 D or less (ie, same topographic criteria as in normal eyes, except than in normal eyes, both eyes of the patient met the criteria). These patients can be considered with corneas highly susceptible to ectasia.
10128476|NCT04313387||Keratoconus group (KCG)|• Keratoconus group (KCG): 148 patients (one eye each) with bilateral clinical KC. The KCG included one eye randomly selected from 148 patients with keratoconus; one eye was randomly included per patient to avoid selection bias related to the use of both eyes from the same patient. The inclusion criteria were the same as for VAE-E, except that both eyes of the patient met the ectasia criteria.
10128477|NCT04313127|Experimental|Low-dose Group|Subjects received one dose of 5E10 vp Ad5-nCoV at 18 to 60 years old
10128478|NCT04313127|Experimental|Middle-dose Group|Subjects received one dose of 1E11 vp Ad5-nCoV at 18 to 60 years old
10128479|NCT04313127|Experimental|High-dose Group|Subjects received one dose of 1.5E11vp Ad5-nCoV at 18 to 60 years old
10128480|NCT04313426|Experimental|Integrative Yoga Therapy|Self managed Yoga based practices were included in one to one sessions for 6-sessions.
10128481|NCT04313101||Cases (ICUAW)|57 critically ill patients developing ICUAW during their stay in the intensive care unit will be included in the study as cases.
10128482|NCT04313101||Controls|A total of 57 Critically ill patients in the same period who did not develop ICU acquired weakness during their ICU stay will be included as controls.
10128483|NCT04313062|Experimental|Intervention|"The intervention group will receive the PM ACTIVAS' intervention model. This intervention will be done by a member of the technical staff (previously trained) at the patient's home (house call). In the house call, the trainee will perform a multidimensional assessment of the patient's falling risks factor (internal and external), deliver a  Falling Prevention Kit  and lastly establish together (with the patient and their family) a plan to change the hazards in their home. The patients will receive a telephone follow-up by the same technical staff member until the final house call, which will be 12 months after the recruiting. Finally, 12 months after recruitment, they will receive a last house call where the trainee will assess with the patient and the family the plan, ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period), and conduct the final survey."
10128484|NCT04313062|No Intervention|Standard care|"The control group will receive the standard care from the community health center. They will not receive a telephone follow-up. They will receive a house call 12 months after recruitment by a trainee, who will conduct the final survey and ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period). Lastly, they will receive an abbreviated intervention for falling prevention and be given the  Falling Prevention Kit ."
10128485|NCT04313179|Experimental|Music group|"Deep Sleep music track from Bedtime Mozart: Classical Lullabies for Babies, played through smart phone speakers, at maximum sound up to 45 dB, starting 20 minutes before the heel prick procedure, continuing through the procedure and for 5 minutes after the procedure. Also given 0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure for baseline pain relief."
10128486|NCT04313179|Placebo Comparator|Placebo group|0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure. No music played.
10128487|NCT04313296|Experimental|Patients identified at PBMC with a documented diagnosis of AF|Patients identified at PBMC with a documented diagnosis of AF (at any point in time) and who have undergone any cardioversion.
10128488|NCT04313374|Active Comparator|Morphine PCA 1 mg|The patient controlled analgesia device give 1mg morphine for each demand of the patient.
10128489|NCT04313374|Active Comparator|Morphine PCA 0,5 mg|The patient controlled analgesia device give 0,5 mg morphine for each demand of the patient.
10128490|NCT04313374|Placebo Comparator|Placebo|The patient controlled analgesia device give 2 mL serum physiologic for each demand of the patient.The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours. If the VAS skore more than 4 the Group 3 patients will take 1 g paracetamol every 6 hours.
10128491|NCT04313322|Experimental|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
10128492|NCT04313335|Experimental|Duloxetine|Apart from the standard treatment, participants in the Duloxetine Arm will be administered with oral duloxetine (up to 60 mg per day) in the acute herpes zoster period.
10128493|NCT04313335|No Intervention|Control|Participants will be given the standard treatment during the acute herpes zoster period.
10128494|NCT04313309|Experimental|Support Group|This is the only group in the study consisting of patients with chronic musculoskeletal pain who are receiving the Integrative Yoga Therapy Program
10128495|NCT04313413|Experimental|Yoga@Work|Yoga sessions specifically designed for office workers were provided in work settings. participants were given handouts and encouraged to practice in their own time and space during work days.
10128496|NCT04313205|Active Comparator|Capsule|JKB-122 capsule on period 1 followed by JKB-122 Tablet on period 2
10128497|NCT04313205|Active Comparator|Tablet|JKB-122 tablet on period 1 followed by JKB-122 capsule on period 2
9669048|NCT04229004|Experimental|SM-88|"460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.~All four agents (SM-88, methoxsalen, phenytoin, and sirolimus) should be dosed with approximately 240 mL (8 fl. oz.) of water in the morning. All four agents should be taken together consistently. SM-88 used with MPS should ideally be taken approximately 1 hour before or 2 hours after a meal."
9669049|NCT04229004|Active Comparator|mFOLFIRINOX|Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion
9669050|NCT04229004|Experimental|pamrevlumab (FibroGen)|"Experimental: Pamrevlumab in combination with gemcitabine/nab-paclitaxel.~Subjects enrolled to this treatment arm will receive treatment with pamrevlumab in combination with gemcitabine and nab-paclitaxel.~Gemcitabine and nab-paclitaxel are FDA approved therapies for metastatic pancreatic cancer and will be supplied or obtained according to local clinical study agreements and in accordance with local guidelines."
9827435|NCT02455076|Active Comparator|Exenatide inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
10128498|NCT04313192|Experimental|Pulse rate 2Hz (hertz)|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
10128499|NCT04313192|Experimental|Pulse rate 10Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
10128500|NCT04313192|Experimental|Pulse rate 150Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
10128501|NCT04312997|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3 and 6
10128502|NCT04312997|Placebo Comparator|Sterile saline for inhalation|Sterile saline for Inhalation given by nebulization on Study Days 1, 3 and 6
10128503|NCT04313049|Active Comparator|Motor control|
10128504|NCT04313049|Experimental|Vocal control|
10128505|NCT04313023|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3, 6, and 10
10128506|NCT04313023|Placebo Comparator|Sterile saline for inhalation|Sterile saline for inhalation given by nebulization on Study Days 1, 3, 6, and 10
10128507|NCT04312880|No Intervention|Control|Patient will receive no transexemic acid of any kind
10128508|NCT04312880|Experimental|IV-transexemic acid|weight adjusted standard dose of TXA will be administered to these subset of patients prior to incision in IV-form
10128509|NCT04312880|Experimental|Topical-transexemic acid|the wound site after the surgery is completed will be bathed in TXA for a standardized period of time prior to skin closure
10128510|NCT04312893|Experimental|Acupuncture group (ACU)|Patients in acupuncture group will receive traditional Chinese acupuncture combined with Tung's style acupuncture using Press Tack Needle (PYONEX Φ0.20×0.6 mm made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles. The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment will use bilateral acupuncture (if patient's condition does not allow it, unilateral acupuncture will be done). The patient will lie in a supine position during the treatment. Acupuncturist will disinfect the acupoint location with an alcohol pad (70% alcohol), then the acupuncturist will press the needles sticker to the mentioned above acupoints. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
10128511|NCT04312893|Placebo Comparator|Control group (CON)|Patients randomized to the control group will receive press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment methods and patients position will be identical to acupuncture group. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
9827436|NCT02455076|Active Comparator|Exenatide plus glargine insulin inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
10128512|NCT04313036|Experimental|Defibrotide|5 day course of defibrotide at standard dosing 25 mg/kg/day in 4 divided doses of 6.25 mg/kg. If not in CR by day 5, will be given for >/= 21 days or per discretion of enrolling physician.
10128513|NCT04312919|Experimental|Intervention Group|3 in-person visit group
10128514|NCT04312919|Active Comparator|Control/Crossover Group|5 in-person visit group
10128515|NCT04312841|Experimental|Treatment (letermovir)|Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.
10128516|NCT04312750|Experimental|Lidocaine Patch|All subjects received one lidocaine topical system, which was applied to a predetermined fixed area on subject's left side of the back or right side of the back (lower/mid back) according to randomization schedule and worn for 12 hours.
10128517|NCT04312958||Trauma patients|Trauma patients experiencing traumatic injuries requiring a full trauma team response.
10128518|NCT04312958||Liver transplant patients|Patients undergoing liver transplant surgery.
10128519|NCT04312685|Active Comparator|Prometra Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refills 1-3) and will be compared to 3 months retrospectively collected pain scores (VAS, ODI and Global Pain Scale Assessments) and drug doses prior to peristaltic pump explant.
10128520|NCT04312685|No Intervention|Retrospective records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
10128521|NCT04312698|Experimental|Experimental Group 1|
10128522|NCT04312698|Placebo Comparator|Comparator Group 1|
10128523|NCT04312698|Placebo Comparator|Comparator Group 2|
10128524|NCT04312802||Observational|Single arm observational study
10128525|NCT04312568|Experimental|Fadanafil|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
10128526|NCT04312568|Placebo Comparator|Placebo|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
10128527|NCT04312464||Discharged group|The individual which is defined as patient discharged from hospital
10128528|NCT04312464||Dead group|The individual which is defined as patient with all-cause death
10128529|NCT04312776||Patients infected with CA-MRSA|It is an observational study, no interventions to any of the two study arms.
10128530|NCT04312776||Healthy people without any infection|It is an observational study, no interventions to any of the two study arms.
10183690|NCT03762239|Active Comparator|Purified air|Purifying the air with a Pure Airbox device (Zonair 3D). Use of air purifier (Pure Airbox, Zonair 3D) in the classroom 30 minutes before the participants enter the room and during the 2 hours of the experiment.
10128531|NCT04313010|Experimental|Regenerative endodontics therapy with PRF|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. Only the apex 1/3 of the root canal need to be filled with blood. PRF was injected into the root canal to a level below the CEJ, then wait for 10-15min to coagulate.
10128532|NCT04313010|Active Comparator|Regenerative endodontics therapy with BC|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. The adequate blood need to be full with canal space and below the CEJ, then wait for 10-15min to coagulate.
10128533|NCT04312425||Group C|General anesthesia was induced with classic rapid sequence induction protocol.
10128534|NCT04312425||Group M|General anesthesia was induced with modified rapid sequence induction protocol.
10128535|NCT04312477|Experimental|Experimental group|Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
10128536|NCT04312477|Active Comparator|Control group|Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
10128537|NCT04312646||patients with thyroid nodules|
10128538|NCT04312815|Experimental|SM03 600 mg|"SM03: 600 mg intravenous (IV) Randomizd period:on week 0,2,4 and 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.~Open-lable treatment on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
10128539|NCT04312815|Placebo Comparator|Placebo|"placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.~SM03: 600 mg intravenous (IV) on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
10128540|NCT04312607||Philadelphia chromosome positive|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
10128541|NCT04312607||Philadelphia chromosome negative|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
10128542|NCT04312724|Active Comparator|Clinical need|Participants enrolled that require a new socket.
10128543|NCT04312724|Experimental|No clincal need|Participants enrolled that do not require a new socket
10128544|NCT04312347|Experimental|Personalized dosing of tamoxifen|Increase tamoxifen dose into 40 mg/day for patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype.
10128545|NCT04312334|Experimental|Treatment 1|Treatment 1: Hand cleaning with the Supertowel for 15 seconds. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recorded by means of weighing the towel before and after soaking. The volunteers will use the soaked Supertowel for 15 seconds to clean their pre-contaminated hands.
10128546|NCT04312334|Experimental|Treatment 2|Treatment 2: Hand cleaning with a Supertowel that is damp for 60 seconds The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The water on the Supertowel will then be squeezed out so that it is not dripping. The Supertowel will be weighed before soaking and after squeezing. Volunteers will clean their pre-contaminated hands with the damp Supertowel for 60 seconds.
10128547|NCT04312334|Experimental|Treatment 3|"Treatment 3: Hand cleaning for 60 seconds with a Supertowel that has been soaked in contaminated water.~A Supertowel will be soaked in water which has artificially contaminated with non-pathogenic E.coli. The water will be designed to mimic highly contaminated grey water so it will be contaminated at 2,000 cfu/100 ml which is double the acceptable level of contamination for handwashing. Volunteers will clean their pre-contaminated hands with the contaminated Supertowel for 60 seconds."
10128548|NCT04312334|Experimental|Treatment 4|"Treatment 4: Hand cleaning for 60 seconds with a Supertowel that is visibly dirty and oily.~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water .The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 60 seconds."
10128549|NCT04312334|Experimental|Treatment 5|"Treatment 5: Hand cleaning for 30 seconds with a Supertowel that is visibly dirty and oily and it is soaked in whater which has artificially contaminated with non-pathogenic E.coli.~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water (which will be contaminated with E.coli).The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 30 seconds."
10128550|NCT04312334|Experimental|Treatment 6|Treatment 6: Hand cleaning with the Supertowel which is fully dry for 60 seconds.
10128551|NCT04312334|Other|Control 1|Control 1: Hand washing with bar soap and water for 15 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 15 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
10128552|NCT04312334|Other|Control 2|"Control 2: Handwashing with bar soap and water for 60 seconds The control group will wash their pre-contaminated hands with normal bar soap and water for 60 seconds by following the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps was given to them, appendix). After handwashing, hands will be allowed to dry for 3 minutes"
10128553|NCT04312334|Other|Control 3|"Control 3: Handwashing with bar soap and contaminated water for 60 seconds. Water which is contaminated with non-pathogenic E.coli. at 2,000 cfu/100ml will be stored in a bucket which has a tap at the base. The control group volunteers will wash their hands with the contaminated water and bar soap for 60 seconds. They will follow the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps will be given to them). After handwashing, hands will be allowed to dry for 3 minutes."
10128554|NCT04312334|Other|Control 4|Control 4: Hand cleaning for 60 seconds with a clean Supertowel. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recordedby means of weighing the Supertowel before and after soaking. The control group will clean their pre-contaminated hands of with thesoaked Supertowel for 60 seconds.
10128555|NCT04312334|Other|Control 5|Hand washing with bar soap and water for 30 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 30 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
10128556|NCT04312529|Experimental|Overhead athletes|
10128557|NCT04312243|Experimental|Treatment Group|Inhaled NO (160 ppm) before and after the work shift. Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
10128558|NCT04312243|No Intervention|Control Group|Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
10128559|NCT04312217|Active Comparator|Medical clowning|Preoperative medical clown exposure
10128560|NCT04312217|No Intervention|Control|Normal preop care
10128561|NCT04312399|Other|oral hormonal therapy|Postmenopausal women who start with oral hormonal therapy (Progesteron + uterogestan) according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128562|NCT04312399|Other|transdermal hormonal therapy|Postmenopausal women who start with transdermal hormonal (Oestrogel + uterogestan) therapy according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128563|NCT04312399|Other|oral hormonal therapy + hysterectomy|Postmenopausal women who start with oral hormonal therapy (progesteron) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128564|NCT04312399|Other|transdermal hormonal therapy + hysterectomy|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128565|NCT04312399|Other|oral hormonal therapy + IUD|Postmenopausal women who start with oral hormonal therapy (Progynova) according to standard of care practice and have already an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128566|NCT04312399|Other|transdermal hormonal therapy + IUD|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and have an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128567|NCT04312399|Other|selective oestrogenreceptor modulators|Postmenopausal women who start with hormonal therapy according to standard of care practice and take selective oestrogenreceptor modulators (Nolvadex) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128568|NCT04312399|Other|aromatase inhibitors|Postmenopausal women who start with hormonal therapy according to standard of care practice and who taken aromatase inhibitors (Femara) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128569|NCT04312399|Other|Duavive|Postmenopausal women who start with hormonal therapy according to standard of care practice and who take duavive because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128570|NCT04312399|Other|Control|Postmenopausal women who don't start with hormonal therapy according to standard of care practice. At the first study visit blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
10128571|NCT04312321|No Intervention|CONTROL|CONTROL group: low urgency cases with routine operation of paramedic crew with optional consultation with a doctor over the phone.
9519560|NCT03285932|Experimental|Post-operative SRS of resection cavity|"High-resolution contrast-enhanced post-operative MRI imaging in preparation for Cyberknife SRS. Cyberknife SRS of the resection cavity and all potential additional metastases diagnosed in the treatment planning MRI (up to 10 lesions)~Resection cavity:~7 x 5 Gy @ 95%-isodose~Potential additional brain metastases:~20 Gy @ 70%-isodose (lesions < 2 cm max. diameter) 18 Gy @ 70%-isodose (lesions 2 - 3 cm max. diameter) 6 x 5 Gy @ 70%-isodose (lesions > 3 cm max. diameter)"
10128572|NCT04312321|Experimental|PHONE|In the PHONE group, there will be a mandatory consultation of a doctor over the phone in all low urgency cases.
10128573|NCT04312321|Experimental|VIDEO|In the VIDEO group, there will be a mandatory consultation of a doctor over the audiovisual consultation in low urgency cases
10128574|NCT04312438|Experimental|13 mo to 15 yo children diagnosed with Cow's Milk Allergy|oral food challenge with cow's milk proteins
10128575|NCT04312360|Experimental|intervention track 1|"14 patient with right-sided colon cancer receive intervention before the hemicolectomi.~both arms of this study use the same intervention."
10128576|NCT04312360|Experimental|intervention track 2a|"14 patient with right-sided colon adenoma receive intervention before the endoscopic mucosa resection.~both arms of this study use the same intervention."
10128577|NCT04312295|Experimental|ACP-SCT program|The ACP simulation-based communication training (ACP-SCT)program was designed 12 hours (4hours/week) workshop for nephrology nurses.
10128578|NCT04312295|No Intervention|Without ACP-SCT program|The control group only gives the ACP simulation-based communication training program handbook.
10183691|NCT03762239|Sham Comparator|Normal air|Using a sham air purifier (same device without filters). Use of the same air purifier but without filters, so that it only recirculates the air without purifying it. Used for the same time period than the other arm.
10183692|NCT03762226||Patient with Macular edema|Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.
10183693|NCT03762187|Experimental|Self-affirmation|Participants completed a written self-affirmation manipulation before completing the standard counseling provided by the clinic.
10183694|NCT03762187|Active Comparator|Positive living counseling|Participants completed the standard counseling provided by the clinic (treatment as usual control condition).
10183695|NCT03762148|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
10183696|NCT03762148|Experimental|ferrous sulphate|labelled iron as ferrous sulphate
10183697|NCT03762148|Experimental|ferric pyrophosphate|labelled iron as ferric pyrophosphate
10183698|NCT03762148|Experimental|ferrous fumarate + 3.5 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS
10183699|NCT03762148|Experimental|ferrous fumarate + 7 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS
10183700|NCT03762148|Experimental|ferrous sulphate + 15 g GOS|labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS
10183701|NCT03762148|Experimental|ferrous fumarate + Vitamin C|labelled iron as ferrous fumarate + Vitamin C
10183702|NCT03762148|Experimental|ferric pyrophosphate + 15 g GOS|labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS
10183703|NCT03762148|Experimental|ferrous fumarate + 7 g GOS + Vitamin C|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C
10183704|NCT03762096|Experimental|Resveratrol|
10183705|NCT03762096|Placebo Comparator|Placebo|
10183706|NCT03762083|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of BV.
10183707|NCT03762057||Surgical patients|All postoperative patients admitted to surgical ICU with foley catheter in place
10183708|NCT03762044|Experimental|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|10 sessions of 30 minutes, twice a week in a total 5 week period of Activity-oriented Proprioceptive Antiedema Therapy (TAPA in Spanish)
10183709|NCT03762044|Active Comparator|Complete Decongestive Therapy (CDT)|10 sessions of 30 minutes, twice a week in a total 5 week period of complete decongestive therapy (CDT).
10183710|NCT03762031|Experimental|GC4711 30mg|
10183711|NCT03762031|Experimental|GC4711 60mg|
10183712|NCT03762031|Experimental|GC4711 90mg|
10183713|NCT03762031|Experimental|GC4711 120mg|
10183714|NCT03762031|Placebo Comparator|Placebo|
10183715|NCT03762031|Experimental|GC4711 75mg|
10183716|NCT03762031|Experimental|GC4711 105mg|
10183717|NCT03762005|Experimental|CRT guided resuscitation|Fluid resuscitation will be aimed at normalizing capillary refill time (CRT) during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of CRT until achieving normal values, or the patient becomes fluid unresponsive, or a safety issue develops.
10183718|NCT03762005|Active Comparator|Lactate guided resuscitation|Fluid resuscitation will be aimed at normalizing or decreasing lactate levels by more than 20% every 2 hours during the intervention during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of lactate every 2 hours until reaching target, or the patient becomes fluid unresponsive, or a safety issue develops.
10183719|NCT03761992|Active Comparator|Gingko Biloba Extract|Gingko Biloba Extract 240 mg.
10183720|NCT03761992|Placebo Comparator|Placebo|Placebo Pill
10183721|NCT03761979|Active Comparator|Strontium dose of 170 mg|The Sponsor provided each 170 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
10183722|NCT03761979|Active Comparator|strontium dose of 340 mg|The Sponsor provided each 340 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
9967665|NCT01272024|Experimental|Nurse Intervention|Participants are given intensive nurse contacts to reduce uncertainty and maximize problem solving, and later, to transition to the treatment phase of their cancer.
10128579|NCT04312308||Non-Small Cell Lung Cancer Treated with Atezolizumab|Patients with Non-Small Cell Lung Cancer Treated with Atezolizumab
10128580|NCT04312165|Experimental|Duramesh Laparotomy Closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
10128581|NCT04312165|Active Comparator|Control group-Conventional suture closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
10128582|NCT04312581|Experimental|First group (shock wave)|Extracorporeal shock wave therapy
10128583|NCT04312581|Active Comparator|Second group (conventional rehabilitation)|conventional rehabilitation
10128584|NCT04312113|Experimental|Autologous mesenchymal stem cells|Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis.
10128585|NCT04312204|Experimental|Sintilimab+Gemcitabine+Carboplatin|
10128586|NCT04312282|Experimental|Cohort 1, Sequence 1A: Fed then fasted|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fed conditions~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions"
10128587|NCT04312282|Experimental|Cohort 1, Sequence 1B: Fasted then fed|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fed conditions"
10128588|NCT04312282|Experimental|Cohort 2: Tesetaxel plus itraconazole|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and itraconazole on Day -3 through Day 14 of a 21-day cycle"
10128589|NCT04312282|Experimental|Cohort 3: Tesetaxel plus rifampin|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and rifampin on Day -6 through Day 14 of a 21-day cycle"
10128590|NCT04312152|Active Comparator|PMS Placebo|"If body weight is up to 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
10128591|NCT04312152|Active Comparator|ASD Placebo|"If body weight is up to 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
10128592|NCT04312152|Experimental|PMS Active compound|"If body weight is up to 20 kg:~Q10 ubiquinol, 50 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Q10 ubiquinol, 100 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
10128593|NCT04312152|Experimental|ASD Active compound|"If body weight is up to 20 kg:~Q10 ubiquinol, 50 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Q10 ubiquinol, 100 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
10128594|NCT04311931|Experimental|Experimental Creative Dance group|The experimental group intervention will attend the creative dance program. The program integrates 3 sessions / week of 60 minutes on alternated days.
10128595|NCT04311931|No Intervention|Control group|"The control group will maintain the usually daily activities, not attending any exercise program.~After study end, the control group will have the opportunity to participate on an exercise program."
10128596|NCT04311866|Active Comparator|Spica cast|Standard practice for the management of the femoral shaft fractures.
10128597|NCT04311866|Experimental|Synthetic fabric|Offer resistance, durability and low weight to treatment of femoral shaft fractures
10128598|NCT04312035|Experimental|End-range mobilization|End-range mobilization performed in end-position of the knee joint
10128599|NCT04312035|Experimental|Non end-range mobilization|Non end-range mobilization performed in loose-packed position of the knee joint
10128600|NCT04312035|Placebo Comparator|Control|Sham technique performed in loose-packed position of the knee joint
10128601|NCT04311957|Active Comparator|Boosted PI Group|"Continuation of the same second-line regimen taken prior to entry:~This includes either Lopinavir/ritonavir (LPVr) 400 mg/100 mg BID or Atazanavir/ritonavir (ATV/r) 300 mg/100 mg QD~plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)."
10128602|NCT04311957|Experimental|B/F/TAF Group|Combination tablet of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
10128603|NCT04311736|Active Comparator|Exergame|Moderate intensity cycling only 3 times per week for 12 weeks + concurrent virtual reality cognitive training, supervised by an exercise specialist
10128604|NCT04311736|Active Comparator|Cycling|Moderate intensity cycling only 3 times per week for 12 weeks, supervised by an exercise specialist
10128605|NCT04311736|Sham Comparator|Stretching|Stretching 3 times per week for 12 weeks, supervised by a therapist
10128606|NCT04311827||Serratus anterior plane block and traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
10128607|NCT04311827||Traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
10128608|NCT04311970|Other|EoE patients|Patients will all be administered the EsoCheck device as a diagnostic test
10128609|NCT04311879|Experimental|Soft tissue laser Diode laser application|Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices. Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product
10128610|NCT04311879|Placebo Comparator|conventional root canal treatment|Placebo : conventional root canal conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with mock laser intervention
10128611|NCT04312009|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
10128612|NCT04312009|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
10128613|NCT04312100||Mild cases with conventional oxygen therapy|COVID-19 patients who were considered mild cases will receive conventional oxygen therapy in addition to standard treatment
10128614|NCT04312100||Moderate/Severe cases with nasal high flow oxygen inhalation|COVID-19 patients who were considered Moderate/Severe cases will receive nasal high flow oxygen inhalation in addition to standard treatment
10128615|NCT04312100||Moderate/Severe cases with non-invasive ventilation|COVID-19 patients who were considered Moderate/Severe cases will receive non-invasive positive pressure ventilation in addition to standard treatment
10128616|NCT04311801|Experimental|OCT Arm|Each patient underwent OCT examinations.
10128617|NCT04311775||video laryngoscopy|video laryngoscope is a camera laryngoscope system used to see the larynx with camera
10128618|NCT04311775||laryngoscopy|laryngoscopy is a method used to see the larynx.
10128619|NCT04312022|Experimental|Berry extract intake|Intake of a berry extract supplement (hawthorn berry extract, tart cherry extract, and bromelain)
10128620|NCT04312022|Placebo Comparator|Placebo intake|Intake of a placebo (flour capsule)
10128621|NCT04312087|Experimental|MLND|Modified lateral neck dissection (compartment II-V) is performed in all patients.
10128622|NCT04312087|Experimental|SLNB|Sentinel lymph node biopsy in the lateral neck is performed. The decision of neck dissection is based on the result of sentinel lymph node biopsy.
10128623|NCT04311840||SAH patients with nimodipine|Patients with SAH receiving nimodipine as prevention of vasospasms and as a nootropic drug.
10128624|NCT04311840||SAH patients without nimodipine|Patients with SAH not receiving nimodipine as prevention of vasospasms and as a nootropic drug or in whom the drug has been temporarily discontinued.
10128625|NCT04311905|Experimental|Laser activated irrigation LAI|Diode Laser activated irrigation
10128626|NCT04311905|Placebo Comparator|conventional root canal treatment|mock LAI , conventional root canal treatment 2.5% sodium hypochlorite
10128627|NCT04311788|Experimental|Intervention group|Prophylactic self gripping mesh (Program, Medtronic) will be placed in rectorectus space to prevent incisional hernia.
10128628|NCT04311788|Active Comparator|Control group|Abdomen of the patients in the control group will be closed by using small stitch closure with suture to wound length of 4:1 and slowly absorbable monofilament suture.
10128629|NCT04311983|Active Comparator|Tobacco Quitline only|Smokers in this study group will be offered their state Tobacco Quitline programs
10128630|NCT04311983|Experimental|Tobacco Quitline plus Smoke Free Homes|Smokers in this study group will be offered their state Tobacco Quitline programs, but if they decline, they will be offered a Smoke Free Homes intervention
10128631|NCT04311814|Other|v-MUCP value|All patients referred for urodynamics explorations will have a measure of the MUCP during a Valsalva manoeuver
10128632|NCT04312048|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
10128633|NCT04312048|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
10128634|NCT04312061|Experimental|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
10128635|NCT04312061|Placebo Comparator|placebo|oral placebo tablet given 1 hour before LNG-IUD insertion
10128636|NCT04311944|Experimental|Early Fast-Track Care|Participants will be eligible for fast-track care after 8 to 12 weeks, if viral load is suppressed (<200 copies/mL)
10128637|NCT04311944|Active Comparator|Standard (Deferred Fast-track) Care|Participants will be eligible for fast-track care after 24 weeks, if viral load is suppressed (<200 weeks)
10128638|NCT04311749||Fetal growth restriction|
10128639|NCT04311749||Severe preeclampsia|
10128640|NCT04311749||Low PAPP-A|
10128641|NCT04311749||Healthy control|
10128642|NCT04311489|Experimental|Ularitide|Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.
10128643|NCT04311489|Placebo Comparator|Placebo|Matching placebo. Continuous IV infusion for 48 hours.
10128644|NCT04311450|Experimental|Behavioral Weight Loss|Behavioral: Participants randomized assigned to this arm will received 12 weeks of Behavioral Weight Loss (BWL) counseling.
10128645|NCT04311450|No Intervention|Waitlist Control|Waitlist Control: Participants assigned to this arm will attend follow-up visits to control for the effect of time. Following completion of post-treatment assessment participants in the waitlist control group will be offered an abbreviated BWL treatment.
10128646|NCT04311515|Active Comparator|30 mg PU AD|75 subjects will be treated with active PU-AD on a 1:1 ratio qd
10128647|NCT04311515|Placebo Comparator|30 mg Placebo|75 subjects will be treated with placebo SyrSpend on a 1:1 ratio qd
10128648|NCT04311593||group 1|control group with normal platelet count
10128649|NCT04311593||group 2|patients with acute ITP
10128650|NCT04311593||group 3|patients with chronic ITP
10128651|NCT04311671|Experimental|Moxidectin|Moxidectin 8 mg per oral on Day 0
10128652|NCT04311671|Active Comparator|Ivermectin|Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0
10128653|NCT04311697|Experimental|Aviptadil IV in escalating doses + standard of care|Patients will be administered Aviptadil IV in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr
10128654|NCT04311697|Experimental|Placebo + standard of care|Patients will first be treated with placebo infusion + maximal intensive care
10128655|NCT04311580|Experimental|urothelial high risk non-muscle invasive bladder cancer|patients with urothelial high risk non-muscle invasive bladder cancer after failed intravesical bacillus Calmette-Guérin treatment.
10128656|NCT04311398||Respiratory infection group|Patients went to fever clinic with respiratory infectious symptoms in Huashan Hospital affiliated to Fudan University
10128657|NCT04311359||Group/Cohort|Brain Oedema induced by drugs reported to the FAERS database from inception till first quarter of 2019
10128658|NCT04311294|Active Comparator|ANS-6637 Low Dose|200mg ANS-6637 (2 tablets)
10128659|NCT04311294|Active Comparator|ANS-6637 High Dose|600mg ANS-6637 (2 tablets)
10128660|NCT04311294|Placebo Comparator|Placebo|0mg matched placebo (2 tablets)
10128661|NCT04311632|Experimental|Arm 1|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
10128662|NCT04311632|Experimental|Arm 2|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
10128663|NCT04311632|Active Comparator|Arm 3|ATG administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
10128664|NCT04311385||Diverticulitis|"Patients admitted as an emergency with acute diverticulitis diagnosed by CT scan.~Inclusion criteria~Patients over 18 years old~Informed consent form signed~Diagnosed of acute diverticulitis~CT scan reported as 1-2 pericolic bubbles with or without free fluid~Exclusion criteria~o CT scan showing free distant bubbles in the abdomen"
10128665|NCT04311424|Experimental|14C Tirzepatide|A single dose of [14C]-tirzepatide administered subcutaneously (SC).
10128666|NCT04311684||Patients with proteinuria|Patients with newly diagnosed glomerulonephritis with different range of proteinuria at the age between 18-65 years and estimated glomerular filtration rate (GFR) ≥60 ml/min will be included for urine protein measurements
10128667|NCT04311684||Healthy volunteers|Healthy men/women between age group 18-65 years will be included for urine protein measurements
10128668|NCT04311658|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG-IUD insertion
10128669|NCT04311658|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to LNG- IUD insertion
10128670|NCT04311619|Experimental|Major Depression Disorder Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer before and after Repetitive Transcranial Magnetic Stimulation (rTMS) treatment
10128671|NCT04311645|Other|1st group|Oral activated charcoal in a dose of 30 gm/day
10128672|NCT04311645|Other|2nd group|Dry seeds in a dose of 1 gm/ day
10128673|NCT04311645|No Intervention|3rd group|control group
10128674|NCT04311372|Experimental|Educational session+Material+Videos (Group 1)|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
10128675|NCT04311372|Active Comparator|Educational session+Material ONLY (Group 2)|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
10128676|NCT04311476|Placebo Comparator|Placebo|0.9% sodium chloride infusion within 24 hours after birth
10128677|NCT04311476|Experimental|ACBMNC|Autologous Umbilical Cord Blood Mononuclear Cells intravenously within 24 hours after birth,dose is 5×107cells/kg ,
10128678|NCT04311346||Cardiac transplant|Patients exposed to cardiac transplantation
10128679|NCT04311281||Suspected AD|"Participants with suspected AD enrolling in the trial must meet all of the following criteria:~Cognitive deficits do not occur exclusively in the context of a delirium.~Cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia).~There is insidious onset and gradual progression of impairment in one or more cognitive domains.~The participant has documented memory problems in one or more other cognitive domains, such as language, visual-spatial functioning, executive functioning, etc. (Busse et al., 2006)."
10128680|NCT04311281||Suspected CTE / TES|"Required Features:~Persistence of symptoms for longer than 2 years; no other neurologic disorder that is more likely to account for all the clinical features; history of head trauma exposure; progressive course; and at least 1 supportive feature~History of head trauma exposure, typically associated with history of concussion, although may be limited to subconcussive trauma~Head trauma exposure is repetitive in nature~Demonstrated progressive course~Delayed symptom onset~Self-report or observer report of cognitive dysfunction, confirmed with objective cognitive decline documented by results of formal neuropsychological testing. Cognitive decline typically affects more than 1 domain (executive, visuospatial, memory, and language).~Supportive Features (only 1 required):~Emotional dysregulation~Behavioral change~Motor disturbance"
10128681|NCT04311333|Experimental|All patients|"All patients undergo endostomal three-dimensional ultrasonography, computerized tomography, clinical examination and laparotomy/laparoscopy.~At all the respective examinations, the presence of a parastomal hernia as well as hernia location and size is evaluated."
10128682|NCT04311255|Active Comparator|intercostal group|group of patient receiving inrercostal nerve block as analgesia
10128683|NCT04311255|Active Comparator|pecs group|group of patient receiving pectoralis nerve block as analgesia
10128684|NCT04311021||Diabetes type 1|
10128685|NCT04310995|Experimental|Nicorandil|oral Nicorandil 5mg (Tablets) three times daily for 168 days
10128686|NCT04310995|Active Comparator|Diltiazem Hydrochloride|oral Diltiazem 180mg (Sustained-release Tablets) once daily for 168 days
10128687|NCT04310995|Active Comparator|Isosorbide Mononitrate|oral Isosorbide Mononitrate 50mg (Sustained-release Capsules) once daily for 168 days
9967666|NCT01272063||Dry AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
10128688|NCT04310891||Markerless|Markerless Tumour Tracking will be used to observe the radiation beam is accurately targeting the tumour.
10128689|NCT04310917|Other|Lipoprotein a level|blood lipoprotein (a) test
10128690|NCT04310930|Active Comparator|Intensive Therapy A|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin AND clofazimine.
10128691|NCT04310930|Experimental|Intensive Therapy B|Following Randomisation 1, Participants will receive inhaled amikacin (IA), IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin AND clofazimine.
10128692|NCT04310930|Experimental|Intensive Therapy C|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin.
10128693|NCT04310930|Active Comparator|Consolidation A|Oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
10128694|NCT04310930|Experimental|Consolidation B|Inhaled amikacin (IA), oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
10128695|NCT04311112|Placebo Comparator|ZA placebo|
10128696|NCT04311112|Active Comparator|ZA low dose|
10128697|NCT04311112|Active Comparator|ZA high dose|
10128698|NCT04310943|Experimental|Arm 1|Tislelizumab (200mg,Q3W )+Bevacizumab(15 mg/kg,Q3W)+Albumin paclitaxel(100mg/m2,d1,8,15) for 4 cycles, and if there is no disease progression, patients will receive Tislelizumab(200mg,Q3W) until progression or death.
10128699|NCT04311125|Active Comparator|total hip arthroplasty via the mini posterior approach|total hip arthroplasty via the mini posterior approach. This approach was first described by Kocher and Langenbeck and later modified by Gibson in 1950. There is a convex incision centered on the posterior rim of the major trochanter. The incision follows the curve of the buttock and at the height of the posterior lip of the major trochanter, it is peripherally oriented along the posterior outer surface of the femur. The major gluteus is divided along the muscle fibers. Guiding sutures are inserted into the tendon mass of the hip rotor muscles just prior to their origin on the major trochanter and dissected to expose and subsequently retract the posterior hip capsule.
10128700|NCT04311125|Active Comparator|THR via the anterior approach without traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
10128701|NCT04311125|Active Comparator|THR via the anterior approach with a traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
10128702|NCT04310982||Health Adults|Forty-nine healthy participants (30 females, 19 males) completed the test-retest protocol with 7 days between tests. Participants were; 23,58±2,65 years of age, 62,9±10,08 kg of weight and 168,76±8,31 cm of height. Participants included in the study did not have any musculoskeletal, neurological or other pathology potentially affecting their gait and jump performance.
10128703|NCT04310969|Experimental|treatment group|Patients are treated every two weeks for a total of three times. Forceful expression of the meibomian glands is followed after each therapy.
10128704|NCT04310969|Sham Comparator|control group|Forceful expression of the meibomian glands only for patients.
10128705|NCT04310969|Active Comparator|active control group|LipiFlow® treatment is used as an active comparator.
10128706|NCT04311138|Experimental|Experimental group|Experimental group receive a 10-wk diversified community-based reablement service.
10128707|NCT04311138|Active Comparator|Control group|Control group receive a 10-wk multicomponent training.
10128708|NCT04311047|Experimental|USPIO-enhanced MRI|Ferumoxtran-10 contrast will be intravenously administered 24-36 before performing an MRI scan. The MRI scan will be discussed with the surgeon prior to resection. Findings on MRI will be compared to pathology.
10128709|NCT04311099|Experimental|Ultrasound-guided TAP|Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
10128710|NCT04311099|Experimental|Laparoscopic assisted TAP|Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
10128711|NCT04311099|Placebo Comparator|Placebo|Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
10128712|NCT04311164||Steno Tech Survey Respondents|A cohort of individuals with type 1 diabetes treated with CSII at either SDCC or NOH participating in the Steno Tech Survey.
10128713|NCT04311164||General Type 1 Diabetes Population|A cohort consisting of the entire population of people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort (ca. 25.000 individuals).
10128714|NCT04311190|Experimental|ICU A|Family members' involvement in the care of their beloved one
10128715|NCT04311190|No Intervention|ICU B|Standard care
10128716|NCT04311229|Experimental|Negative-Pressure Wound Therapy group|NPWT was applied three times for Class III and pressure ulcers. An initial pre-treatment measurement was used as a baseline, followed by three post-treatment measurements after each round to evaluate wound healing. A total of four measurements were performed for each subject. Wound healing was measured using the PUSH Tool and the 3DWM device in both groups.
10128717|NCT04311229|Other|CONTROL GROUP|wet to dry dressing group
10128718|NCT04311177|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
10128719|NCT04311177|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
10128720|NCT04311151|Experimental|self seizures visualization group|Visualization of the own epileptic seizures occured during hospital admission.
10128721|NCT04311151|No Intervention|usual management|Usual way management
10128722|NCT04310904||ICU cardiac output (CO) assessment patients|all ICU patients intubated/ventilated with a central line and an arterial catheter who need trans esophageal echocardiography examination with a saline contrast test.
10128723|NCT04311203|Experimental|Mental Health First Aid Intervention|Two-day MHFA training provided by MHFA England. Organisations will raise awareness of the presence of MHFA in the workplace, with delivery of MHFA by trained members to participants in the workplace.
10128724|NCT04311203|No Intervention|Control|A brief consultation from MHFAE on the promotion of mental health and well-being in the workplace.
10128725|NCT04310865|Experimental|Yinhu Qingwen Granula Group|Based on the standard medical treatment, the patients will be given Yinhu Qingwen Granula for 10 days.
10128726|NCT04310865|Placebo Comparator|Yinhu Qingwen Granula Low-dose Group|Based on the standard medical treatment, the patients will be given 10% dose of Yinhu Qingwen Granula for 10 days.
10128727|NCT04310722||Gram-negative bacilli and MRSA infections in ICU|Carbapenem-resistant Gram-negative bacilli [Carbapenem-resistant Acinetobacter baumannii (CRAB), Carbapenem-resistant Klebsiella pneumoniae (CRKP), and Carbapenem-resistant Pseudomonas aeruginosa (CRPsA) ] and methicillin-resistant Staphylococcus aureus (MRSA) is prevalent around the world, and the isolation rate and resistance rate has increasing in China, especially in ICU. So, investigators aim to study transmission mechanism, resistance mechanism and horizontal transfer mechanism of these pathogens.
10128728|NCT04310670|Experimental|Patients with FND|Diagnosis of Functional Neurological Disorder of movement clinically established according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria
10128729|NCT04310644||Postural Orthostatic Tachycardia Syndrome|Patients with orthostatic intolerance because of Postural orthostatic tachycardia syndrome diagnosed in our outpatient clinic by tilt table examination.
10128730|NCT04310644||Ehlers Danlos Syndrome|Patients with hypermobile or classical EDS who are already diagnosed including genetical testing for classical or vascular EDS and Marfan Syndromes
10128731|NCT04310644||Autoimmune autonomic neuropathy/Pure autonomic failure|Patients who have an autoimmune autonomic neuropathy based on clinical diagnosis and antibody testing in our outpatient clinic. Cardial MIBG Scintigraphy should have been performed.
10128732|NCT04310644||Healthy controls|Healthy controls with no documented cardiovascular or neurological disorders and no symtoms of autonomic failure/dizziness/fainting
10128733|NCT04310553|Experimental|Arm 1|This project plans to enroll 40 patients receiving nanoknife treatment, our center enrolls 20 patients, and the other two centers will enroll 10 patients each. The number of patients expected to participate in the study is 240.
10128734|NCT04310605||Step 1 only|Participants in the study who only receive Step 1 of specialised CBT
10128735|NCT04310605||Step 1 and 2|Participants who receive both Step 1 and Step 2 of speciliased CBT for tinnitus.
10128736|NCT04310657|Experimental|Precision therapy|
10128737|NCT04310657|No Intervention|control|
10128738|NCT04310683|Other|natural cycle for endometrium preparation|patients will have ovulation before embryo transfer
10128739|NCT04310683|Experimental|hormone replaced cycle for endometrium preparation|patients will do not have ovulation before embryo transfer
10128740|NCT04310527|Experimental|Treatment A: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib reference formulation will be given under fasted condition.
10128741|NCT04310527|Experimental|Treatment B: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib test formulation will be given under fasted condition.
10128742|NCT04310527|Experimental|Treatment C: Administration of ensidenib fed|A single oral 100 mg dose of enasidenib test formulation will be given under fed condition.
10128743|NCT04310618||Adults with bronchiectasis|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase
10128744|NCT04310579|No Intervention|Lead-In|Read Rebreathing Reproducibility Assessment
10128745|NCT04310579|Active Comparator|Part 1 Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) tablets and intravenous (IV) placebo 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day.~Note: Initial doses of oxycodone will be 10 mg, but may be increased to 15 mg if necessary based on criteria specified in protocol. Initial doses of midazolam will be 0.0375 mg/kg but may be increased to 0.075 mg/kg based on criteria specified in protocol."
10128746|NCT04310579|Active Comparator|Part 2 Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
10128747|NCT04310709|Experimental|REGONIVO|"Nivolumab - 480 mg IV on Day 1, every 4 weeks~Regorafenib~- 80 mg per oral once daily for 21 consecutive days starting on Day 1, every 4 weeks."
10128748|NCT04310514|Active Comparator|Experimental: glucose - fructose - xylitol - saccharose|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
10128749|NCT04310514|Active Comparator|Experimental: fructose - glucose - saccharose - xylitol|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
10128750|NCT04310514|Active Comparator|Experimental: xylitol - saccharose - glucose - fructose|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
10128751|NCT04310514|Active Comparator|Experimental: saccharose - xylitol - fructose - glucose|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
10128752|NCT04310813||Endoscopic urologic patients|Patients with bladder cancer or benign prostate hyperplasia undergoing urologic endoscopic procedures.
10128753|NCT04310761||pregnancy population after one single blastocyst transfer|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from a period between 2014 and 2018.
9967667|NCT01272089|Experimental|Pataday|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once daily for one week
10128754|NCT04310462|Experimental|New eRX Interface|Providers assigned to the intervention arm will be presented with a new eRX interface upon writing new prescriptions for hydroxychloroquine in the EHR.
10128755|NCT04310462|No Intervention|Standard Interface|Providers assigned to the no intervention arm will be presented with the usual ordering interface when prescribing new prescriptions for hydroxychloroquine in the EHR.
10128756|NCT04310696|Experimental|Buteyko group|Buteyko breathing exercises
10128757|NCT04310696|Active Comparator|Pursed lip breathing|Pursed lip breathing exercises
10128758|NCT04310774|Experimental|Consolidation therapy|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
10128759|NCT04310826|Experimental|Prevention (dietary intervention)|Patients receive a dietary magnesium intervention consisting of a food reference list and phone calls or video interviews from a registered dietitian, integrative medicine physician, or a mid-level provider over 10-20 minutes once a week for up to the 6th cycle of chemotherapy (average 15 weeks).
10128760|NCT04310501||CKD Patients|"Patients (n=150) with CKD (Stages 1-5 pre-dialysis, undergoing dialysis, kidney transplantation) who fulfil the inclusion criteria from the Nephrology Dept and Renal Transplant Unit of the University Hospital of Ioannina.~Sixty patients will be selected for the pilot study which will include blood and urine tests and specific polymorphism analysis (pharmacogenetic tests)"
10183723|NCT03761979|Active Comparator|Strontium dose of 680 mg|The Sponsor provided each 680 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
10183724|NCT03761966||Pregnant women|"Pregnant women older than 18 years old atended at the Mónica Pretelini Sáenz Maternal-Perinatal Hospital (HMPMPS), Health Institute of the State of Mexico (ISEM)."
10183725|NCT03761940||Disease free|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires are disease free.
10183726|NCT03761940||Local recurrences|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with local recurrence and may be undergoing treatment for this.
10183727|NCT03761940||Distant disease|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with distant disease and may be undergoing treatment for this.
10183728|NCT03761940||Mastectomy|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have undergone a mastectomy.
10183729|NCT03761927|Active Comparator|Hearing Aid without NR enabled.|Hearing Aid without Noise Reduction (NR) enabled serves as reference condition.
9967668|NCT01272102||Glaucoma|subjects with glaucoma
9967669|NCT01272154|Experimental|Primary cervical dystonia Patients|
10183730|NCT03761927|Experimental|Hearing Aid with NR(1)|Hearing Aid with Noise Reduction I (NR) enabled.
10183731|NCT03761927|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
10183732|NCT03761901||Patients with EGFR mutation positive NSCLC|
10183733|NCT03761888||Labetalol|Patients who will receive labetalol in IV route in first intention
10183734|NCT03761888||Nicardipine|Patients who will receive nicardipine in IV route in first intention
10183735|NCT03761875|Other|CHB patients|a blood sample is done during a follow-up visit
10183736|NCT03761875|Other|Control group|a blood sample
10183737|NCT03761862||Control|The control group with bilateral tubal ligation
10183738|NCT03761862||Neural Therapy|The treatment group
10183739|NCT03761836|Experimental|ShangRing|Males aged 13 years and above will undergo circumcision through ShangRing procedure, with regular follow-up visits to evaluate pain, wound healing and incidence of adverse events. The ShangRing will be removed after 7 days, with a last follow-up visit at 60 days.
10183740|NCT03761797||Subjects with type 2 Diabetes Mellitus|
10183741|NCT03761771||colonoscopy withdrawal with the ADS monitoring|The ADS automatically initiated once the ileocecal valve was pictured by the colonoscopist or the colonoscopist recorded any image of colon during the insertion. When colonoscopists withdrew the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the ADS, which made it feasible to identify and classify lesions in real time.
10183742|NCT03761758|Experimental|Lens Design 1|Spectacle lenses design 1, fitted into spectacle frames
10183743|NCT03761758|Experimental|Lens Design 2|Spectacle lenses design 2, fitted into spectacle frames
10183744|NCT03761758|Experimental|Lens Design 3|Spectacle lenses design 3, fitted into spectacle frames
10183745|NCT03761732|Experimental|PTSD lay-led group treatment program|The group will go through the Islamic Trauma Healing Program
9967670|NCT01272154|Experimental|Primary upperlimb Dystonia Patients|
9967671|NCT01272154|Experimental|Secondary Cervical or Upperlimb Dystonia due to cerebral palsy|
9967672|NCT01272154|Other|Healthy volunteers|
9967673|NCT01272206|Experimental|A|
9967674|NCT01272206|Experimental|B|
9967675|NCT01272258|Experimental|Arm 1|PRO 140
9967676|NCT01272258|Placebo Comparator|Arm 2|Placebo
9967677|NCT01272271||Children|
10128761|NCT04310436|Experimental|Looking down to naval.|Modifying Saccade origin by looking down to naval.
10128762|NCT04310436|Placebo Comparator|Looking up in the air.|Modifying Saccade origin by looking up in the air.
10128763|NCT04310332||1L-PEG|Hospitalized patients who are prescribed colonoscopy with 1L-polyethylene glycole (PEG) plus ascorbic acid as bowel preparation.
10128764|NCT04310332||4L-PEG|Hospitalized patients who are prescribed colonoscopy with 4L-polyethylene glycole (PEG) as bowel preparation.
10128765|NCT04310345|Experimental|Animal-Assisted Interaction|Children and their caregivers will spend approximately 10-15 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
10128766|NCT04310306||Rescue stenting group|
10128767|NCT04310410|Experimental|Combined Focused Ultrasound and Radiotherapy|Combination of focused ultrasound and external beam radiotherapy
10128768|NCT04310241||Control subjects|Subjects who state they have no eye or neurologic problems or disease other than perhaps wearing glasses or contact lenses and upon review of medical history.
10128769|NCT04310241||Amblyopia|Clinical diagnosis of amblyopia
10128770|NCT04310254|Active Comparator|EDTA and CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA and CHX solution.
10128771|NCT04310254|Active Comparator|EDTA solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA solution.
10128772|NCT04310254|Active Comparator|CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for CHX solution.
10128773|NCT04310280|Experimental|Topical insulin glargine|The wound surface is treated locally with glargine insulin injected sub-dermal in a daily matter for 7 days. Allocation is randomized.
10128774|NCT04310280|Placebo Comparator|0.9% saline solution|The wound surface is treated with conventional wound care in a daily matter for 7 days. Allocation is randomized.
10128775|NCT04310267|Active Comparator|classic occlusal level, low point of force application|the point of force application for maxillary protraction is at the level of the occlusal plane.
10128776|NCT04310267|Active Comparator|Nasal level, Medium point of force application|the point of force application for maxillary protraction is at 20 mm from the occlusal plane (Nasal floor).
10128777|NCT04310267|Active Comparator|Infrorbital level, High level|the point of force application for maxillary protraction is at the level of the infraorbital foramen
10128778|NCT04310228|Experimental|Favipiravir Combined With Tocilizumab group|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
10128779|NCT04310228|Active Comparator|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
10128780|NCT04310228|Active Comparator|Tocilizumab group|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
10128781|NCT04310176|Active Comparator|Standard|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab for 12 cycles (24 weeks)~Maintenance treatment (Standard): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab until disease progression or unacceptable toxicity"
10128782|NCT04310176|Experimental|Experimental|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab + Valproic Acid administered oral daily from day -14 increasing doses and an intra-patient titration for a target serum level of 50-100µg/ml for 12 cycles (24 weeks)~Maintenance treatment (Experimental): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab + Valproic Acid until disease progression or unacceptable toxicity"
10128783|NCT04310800|Experimental|LIFT-plug|The LIFT-plug procedure was performed as followings. A portion of the fistula tract was excised from ei¬ther end within the intersphincteric space. One porcine small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures.
10128784|NCT04310800|Experimental|LIFT|The LIFT procedure was performe as followings. The curvilinear incision and dissection of the intersphincteric tract were made as in the LIFT-plug technique. After the tract was isolated, the tract was doubly-ligated and suture-ligated with absorbable sutures as close as possible to the lateral margin of the internal anal sphincter and the medial margin of the external anal sphincter. The tract was then divided between the two sutures. A portion of the fistula tract was excised after ligation of ei¬ther end within the intersphincteric space. The medial ligature was very close to the internal opening, and nearly obliterated the internal opening. The external opening was then enlarged to allow adequate drainage. The internal and external sphincters were then re-approximated, and the skin was closed loosely with interrupted 3/0 absorbable suture.
10128785|NCT04310215|Experimental|Microfracture + CARTISTEM®|CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.
10128786|NCT04310215|Active Comparator|Microfracture|Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.
10128787|NCT04310202||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and additional follow-up visits after surgery.
10128788|NCT04310384|Active Comparator|Endotracheal Intubation, gold standart|Standart of Care with Macintosh laryngoscope
9519561|NCT03285932|Other|Post-operative WBRT|Post-operative WBRT will be performed according to the following dose regimen: 10 x 3 Gy
9967678|NCT01272271||Adults|
10128789|NCT04310384|Active Comparator|Alternative|Endotracheal Intubation with novel device
10128790|NCT04309903|Experimental|Manual Therapy|The experienced physiotherapist has applied manual therapy (MT) to the arthropathic joints. MT was started with myofascial release techniques (MRT), then continued with mobilization techniques using Kalternborn. Superficial MRT consisted of 3 strokes, via manual movement on the tissue, encourage release of the superficial fascia. In the Kalternborn mobilization technique, Grade I-II mobilization was applied with traction without using a strap. The same exercises given to the home exercise group were given to the patients in this group as well.
10128791|NCT04309903|Active Comparator|Home Exercise|The home exercises (HE) consisted of active ROM exercises, passive stretching exercises, progressive resistive exercises, weigh-bearing and stance exercises were performed by the patient for 30 minutes at home.
10128792|NCT04309968|Experimental|solid tumors|Experimental: Solid tumors Part 1 - Dose-escalation of SYHA1801 in patients with advanced solid tumors.Daily dosing of SYHA1801 on Days 1 and 4-31 of 28-day cycle. Escalating dose cohorts.
10128793|NCT04309968|Experimental|advanced cancers|Part 2 - Dose-expansion of SYHA1801 in patients with advanced cancers potentially sensitive to BRD4 inhibitor.The dose level and schedule of SYHA1801 of 28-day cycle at the MTD determined in Part 1.
10128794|NCT04310397|Experimental|Treatment (dabrafenib, trametinib, surgery, spartalizumab)|"NEOADJUVANT TREATMENT: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgical resection of melanoma.~ADJUVANT TREATMENT OF pCR PATIENTS: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT TREATMENT OF NON pCR PATIENTS: Patients receive spartalizumab IV over 30 minutes on day 1, dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity."
10128795|NCT04310111|Experimental|EUS-RFA|Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was applied for 90-120 seconds at 5 Watts. Wait 1 minute before repositioning the Habib™ EUS RFA needle and repeat procedure as many times as needed to ensure complete ablation of the tumor. EUS-guided celiac plexus neurolysis (EUS-CPN) was performed on patients with intractable upper abdominal pain.
10128796|NCT04310319|Other|Normal salt, low protein treatment period|6 grams of sodium chloride daily / Placebo
10128797|NCT04310319|Other|Normal salt, normal protein treatment period|6 grams of sodium chloride daily / 40 grams of protein daily
10128798|NCT04310319|Other|Low salt, low protein treatment period|Double placebo
10128799|NCT04310319|Other|Low salt, normal protein treatment period|Placebo / 40 grams of protein daily
10128800|NCT04309994||Experimental|bypass surgery with blood cardioplegia by means of MPS
10128801|NCT04309994||Active Comparator|bypass surgery with blood cardioplegia by means of Cardioplexol ®
10128802|NCT04309890||Study group|
10128803|NCT04310371|Experimental|Obese adolescents|BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention
10128804|NCT04310371|No Intervention|Control group|to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
10128805|NCT04310046|Other|PCI before TAVI|PCI is performed within 1-45 days before TAVI.
10128806|NCT04310046|Experimental|PCI after TAVI|PCI is performed within 1-45 days after TAVI.
10128807|NCT04310072|Experimental|neuromuscular electrical stimulation group|"For patients who underwent NMES therapy, four electrodes (two 50/100 mm and two 50/50 mm, Compex Performance) were placed on the skin above the quadriceps muscle approximately 5 cm below the inguinal fold and 3 cm above the upper patella border.~The electrical stimulation protocol consisted of electrical current at frequency of 10 Hz, 20 seconds stimulation time (time on) and 20 seconds resting time (time off) with variable intensity (until visible muscular contraction) for one hour per day until discharge (Compex).The NMES therapy was on top of conventional rehabilitation described below."
10128808|NCT04310072|No Intervention|Control group|"The control group consisted of patients who performed daily active upper and lower limbs exercise in bed and in a stand position (3x10 repetitions, somewhat hard on the Borg scale)."
10128809|NCT04310059|Active Comparator|Folic acid 5mg|
10128810|NCT04310059|Active Comparator|Folic acid 0.5mg|
10128811|NCT04310059|Active Comparator|Materna|
10128812|NCT04310293|Other|POOR RESPONDERS|poor responders low AMH LOW AFC
10128813|NCT04309825|Experimental|G-tube endoscopies patients|patients who will undergo an endoscopy through g-tube port
10128814|NCT04310033||Cases|"> 18 years old~Non-opposition of the patient or relatives~Lung, head and neck or colorectal cancer~Non scheduled ICU admission~At least 24 hours of ICU stay~Alive at ICU discharge~Able to answer by phone to quality of life questionary"
10128815|NCT04310033||Controls|"Cancer patients not admitted in ICU, matched with the cases according to~the type of primary cancer~the presence or absence of oncogenic addiction~the setting of anticancer treatment (curative/palliative)~the line of anticancer treatment (none/L1/L2-L3/>L3)."
10128816|NCT04309929||Women with breast cancer|Female patients (age> 18yrs) in ASA class <4; candidate for a planned surgery for simple mastectomy, simple mastectomy with immediate reconstruction, mastectomy with sentinel node biopsy, modified radical mastectomy (unilateral or bilateral)
10128817|NCT04309955|Experimental|modified thoracic drainage group|After surgery, both a chest tube and a pigtail catheter are inserted into the middle and posterior axillary lines of the 7th intercostal space, respectively.
10128818|NCT04309955|No Intervention|traditional thoracic drainage group|After surgery, only a chest tube is inserted into the midaxillary line of the 7th intercostal space, traditionally.
10128819|NCT04310098||CADASIL patients|
10128820|NCT04310098||Asymptomatic carriers of CADASIL|
10128821|NCT04310098||Relatives of CADASIL patients and carriers|
10128822|NCT04310098||Unrelated healthy controls|
9967679|NCT01272297|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
9967680|NCT01272310|Experimental|Combination therapy|
9967681|NCT01272323||Placebo|Subjects previously randomised to receive placebo in study CP005
10128823|NCT04309812|Active Comparator|Short Stimulation|1 minute duration of stimulation per day for 30 days
10128824|NCT04309812|Experimental|Long Stimulation|30 minutes duration of stimulation per day for 30 days
10128825|NCT04309760|Active Comparator|gender dysphoria subjects|Patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy
10128826|NCT04309760|Other|control subjects|Control group inclusions, of open-label patients without gender dysphoria.
10128827|NCT04309747|Experimental|nanosecond knife group|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
10128828|NCT04309630|Active Comparator|intercostal block|patients received intercostal block will be evaluated by visual analog score for pain assesment
10128829|NCT04309630|Experimental|erector spina plane block|patients received erector spina plane block will be evaluated by visual analog score for pain assesment
10128830|NCT04309643|Experimental|CTP-543|In Period 1, participants will receive a single oral dose of the combination oral contraceptive (OC) on Day 1. There will be a washout period of 7 days between dosing in Period 1 and the first dose in Period 2. In Period 2, participants will receive twice daily oral doses of CTP-543 for 8 consecutive days with a single dose of the combination OC co-administered on Day 4.
10128831|NCT04309656|Experimental|Panel 1: Pretomanid after meal|Each participant will receive four single-dose treatments. Panel 1 will receive a meal before dosing.
10128832|NCT04309656|Experimental|Panel 2: Pretomanid after fast|Each participant will receive four single-dose treatments. Panel 2 will fast before dosing.
10128833|NCT04309669|Experimental|Tot'hema|three ampoules per day during 12 weeks daily dose: 150mg of iron per day.
10128834|NCT04309448|Experimental|Perturbation-based balance training with FES|
10128835|NCT04309734|Experimental|Part A - 60 mg AT-777 single dose|
10128836|NCT04309734|Experimental|Part A - 120 mg AT-777 single dose|
10128837|NCT04309734|Placebo Comparator|Part A - Placebo single dose|
10128838|NCT04309734|Experimental|Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks|
10128839|NCT04309435|Experimental|Self-esteem intervention|"The self-esteem intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~Engagement and listening~Positive regard and empathy~Collaboration~Development of a shared understanding of low self-esteem (a 'psychological formulation')~Provision of written or audio-visual information relating to low self-esteem~Between-session activity for participant~Provision of structured self-help material relating to low self-esteem~Testing of beliefs related to low self-esteem~Practicing new strategies related to low self-esteem~Development of a shared plan to maintain gains in self-esteem"
10128840|NCT04309435|Placebo Comparator|Self-esteem control group|'Assessment and support' for participants with low self-esteem will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
10128841|NCT04309435|Experimental|Self-stigma intervention|"The self-stigma intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~Engagement and listening~Positive regard and empathy~Collaboration~Development of a shared understanding of high self-stigma (a 'psychological formulation')~Provision of written or audio-visual information relating to self-stigma~Between-session activity for participant~Provision of structured self-help material relating to self-stigma~Testing of beliefs related to self-stigma~Practicing new strategies related to self-stigma~Development of a shared plan to maintain reductions in self-stigma"
10128842|NCT04309435|Placebo Comparator|Self-stigma control group|'Assessment and support' for participants with high self-stigma will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
10128843|NCT04309435|Experimental|Jumping to conclusions intervention group|"The 'jumping-to conclusions' (JTC) intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~Engagement and listening~Positive regard and empathy~Collaboration~Development of a shared understanding of role of JTC (a 'psychological formulation')~Provision of written or audio-visual information relating to JTC~Between-session activity for participant~Provision of structured self-help material relating to JTC~Testing of beliefs related to JTC~Practicing new strategies related to reducing JTC~Development of a shared plan to maintain reductions in JTC"
10128844|NCT04309435|Placebo Comparator|Jumping to conclusions control group|'Assessment and support' for participants who demonstrate the JTC bias will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
10128845|NCT04309721|Experimental|Perampanel|immediate enteral administration of Perampanel, 12 mg
10128846|NCT04309721|Placebo Comparator|Placebo|immediate enteral administration of placebo
10128847|NCT04309526|Experimental|NCO-48 Fumarate|NCO-48 Fumarate
10128848|NCT04309526|Placebo Comparator|Placebo|Placebo Comparator
10128849|NCT04309539|Active Comparator|Fascia iliaca block|Patients will receive Fascia iliaca block
10128850|NCT04309539|Active Comparator|combined LFCN block with PENG block|Patients will receive a combined lateral femoral cutaneous nerve block with pericapsular nerve group block
10128851|NCT04309383||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
10128852|NCT04309708|Experimental|Original Perfusor Line(Art.No.8723017)|
10128853|NCT04309708|Active Comparator|Original Perfusor Line(Art.No.8723010)|
10128854|NCT04309578|Experimental|treatment arm|Single arm
10128855|NCT04309487||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
10128856|NCT04309344|Experimental|RF|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage
10128857|NCT04309344|Active Comparator|Control|The mechanical shaver is used to remove superficial fibrillations.
10128858|NCT04309695|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
10128859|NCT04309331|Experimental|PKU Motion|amino acid based protein substitute
10128860|NCT04309240|Experimental|rivaroxaban|oral Rivaroxaban 10mg per day for 90days
10128861|NCT04309240|No Intervention|blank control|mechanical prophylaxis
9967682|NCT01272323||Cat-PAD Group 1|Subjects previously randomised to receive Cat-PAD dose 1 in study CP005
10128862|NCT04309253|Other|PMPBB3|"Primary endpoint(s):~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.~Secondary endpoints:~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
10128863|NCT04309253|Other|AV45|"Primary endpoint(s):~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.~Secondary endpoints:~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
10128864|NCT04309279|Experimental|Zentangle group|
10128865|NCT04309279|No Intervention|Wait-list Control Group|
10128866|NCT04309227|Experimental|Traditional High-Intensity Training|Participants will perform their training at ~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
10128867|NCT04309227|Experimental|Low Intensity plus Blood Flow Restriction Training|Participants will perform their training at ~30% of their 1-repetition maximum, and will have blood flow partially occluded (60-70%) to the training limb. Each of the diagnoses (RA, OA, myositis) will have a Low-Intensity plus Blood Flow Restriction arm.
10128868|NCT04309227|No Intervention|Control|Each of the diagnoses (RA, OA, myositis) will have a control arm. The control groups will be evaluated at time 0, 4 weeks, and 8 weeks but will not receive intervention.
10128869|NCT04309318||Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
10128870|NCT04309318||High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
10128871|NCT04309214|Experimental|MCT fats|MCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption.
10128872|NCT04309136|Experimental|Neoadjuvant Anlotinib|
10128873|NCT04309045|Experimental|DBT|Standard DBT treatment
10128874|NCT04309045|Active Comparator|DDP|dynamic deconstructive psychotherapy (DDP) treatment, is part of a trend of dynamic therapies to treat borderline personality disorder. DDP is a treatment specifically developed for a population with more severe symptoms those dealing with borderline personality disorder.
10128875|NCT04309045|Placebo Comparator|control group|patients on the waiting list for treatment, or patients in the hospital under routine care. Which will form the control group.
10128876|NCT04309071|Experimental|Salivary insulin responses to mixed meal tolerance test|Saliva samples and finger prick glucose will be collected after at least 4 hours of fasting and then at 60 and 90 minutes following ingestion of a standardized meal tolerance test.
10128877|NCT04309084|Experimental|Phase I|Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.
9967683|NCT01272323||Cat-PAD Group 2|Subjects previously randomised to receive Cat-PAD dose 2 in study CP005
9967684|NCT01272336|Active Comparator|AIH/Sham|Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
10128878|NCT04309006|Experimental|CTG and customized healing abutment|Customized healing abutment used with connective tissue graft
10128879|NCT04309006|Experimental|CTG and conventional healing abutment|Conventional healing abutment (same diameter of the implant) used with connective tissue graft
10128880|NCT04309006|Active Comparator|customized healing abutment|Customized healing abutment used without connective tissue graft
10128881|NCT04309006|Active Comparator|conventional healing abutment|Conventional healing abutment (same diameter of the implant) without connective tissue graft
10128882|NCT04308954|Experimental|Fragile X Syndrome|Adult males aged 18-30 years diagnosed with FXS will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
10128883|NCT04308954|Experimental|Idiopathic Intellectual Developmental Disorder|Adult males aged 18-30 years diagnosed with idiopathic intellectual developmental disorder will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
10128884|NCT04309058|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
10128885|NCT04309058|No Intervention|Control|The other group do not interfere.
10128886|NCT04309123|Experimental|Treatment|TransAeris stimulation therapy adjunctive to continued mechanical ventilation will begin 24 hours after leaving the operating room, if subject remains on mechanical ventilation. TransAeris stimulator settings (stimulus intensity, stimulus frequency, and burst on/off) will be programmed to optimize diaphragm recruitment without compromising patient comfort.
10128887|NCT04308928||Children with suspected meningitis|Patients must have a clinical diagnosis of meningitis including one or more of the following symptoms: headache, irritability, vomiting, fever and neck stiffness (Table 1). The diagnosis of probable or possible TBM is based on 1) clinical findings 2) CSF results 3) neuroimaging findings 4) evidence for TB outside the central nervous system and 5) additional laboratory criteria. A scoring system then determines whether a patient falls in the probable or possible TBM category. Points are allocated for a positive finding in each of the categories, with a maximum score for each category. A total score of at least 10 is compatible with probable TBM, while a total score of at least 6 equates with a possible TBM diagnosis.
10128888|NCT04308928||Children with definite tuberculous meningitis|Definite TBM requires demonstration of acid- fast bacilli in the CSF, Mycobacterium tuberculosis culture from CSF, a positive nucleic acid amplification test (PCR) of CSF or histopathological evidence of Mycobacterium tuberculosis from a central nervous system site.
10128889|NCT04308967|Experimental|Balance exercises and information|Balance exercises six weeks and three days in a week and information about central sensitisation.
10128890|NCT04308967|No Intervention|Information|Information about central sensitisation.
10128891|NCT04308941|Active Comparator|Scleral Tonopen|The first 10 subjects will be randomly chosen for the first cohort (scleral TonoPen)
10128892|NCT04308941|Active Comparator|Scleral Pneumatonometer|The second 10 subjects will be randomly chosen for the second cohort (scleral pneumatonometry)
10128893|NCT04308941|Active Comparator|Diaton|The third 10 subjects will be randomly chosen for the third cohort (Diaton).
10128894|NCT04308980|Experimental|Active treatment|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use specialized medical nutrition product together with diet based on the measured individual requirements in energy and protein intake.
10128895|NCT04308980|Placebo Comparator|Control group|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use masked placebo together with diet based on the measured individual requirements in energy and protein intake.
10128896|NCT04309110|No Intervention|Standard care with geko™ T3 device|Current geko™ device incorporating hydrogel adhesive designated KM10T
10128897|NCT04309110|Active Comparator|geko™ X-T3|Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
10128898|NCT04309162|Experimental|soft tissue therapy|Soft tissue therapy includes various techniques which is usually done by manipulating the soft tissues. The techques like stroking, petrissage, percussing maniulations are proved helpful in managing various painful conditions. The main effect of the soft tissue therapy is enhanced blood circulation to the area. When the techniques of soft tissue therapy are applied they will results in stretching and rubbing the muscular tissue which results in increased venous flow to heart and removal of the lactic acid accumulation occurs as the fresh supply of blood to the area will increased. Endorphins the natural pain relievers are released as there is improved oxygenation and perfusion of oxygen in tissues.
10128899|NCT04308824|Active Comparator|Clipping|Prophylactic endoscopic clip will be placed after polypectomy
10128900|NCT04308824|Experimental|Cyanoacrilate|A solution of Cyanoacrilate will be nebulized after the placement of prophylactic clip
10128901|NCT04309175|Experimental|Slow-Fast|
10128902|NCT04309175|Experimental|Fast-Slow|
10128903|NCT04308876|Experimental|Manual therapy and strengthening exercises|Manual therapy and strengthening exercises were applied totally 15 sessions for 5 weeks 3 times a week in hospital by physiotherapist.
10128904|NCT04308876|Active Comparator|Strengthening exercises|Patients in this group performed the strengthening exercises given to the experimental group on their own at home with experimental group at the same time, frequency and dose.
10128905|NCT04308733|Active Comparator|real tDCS|30 patients will be treated with real anodal tDCS over the contralateral pharyngeal motor cortex
10128906|NCT04308733|Sham Comparator|sham tDCS|30 patients will be treated with sham tDCS over the contralateral pharyngeal motor cortex
10128907|NCT04309149|Experimental|MCT fats|Kanso MCT oils and margarine will be consumed daily for 7 days each to assess tolerability and compliance
10128908|NCT04308772|No Intervention|Usual Care|Those randomised to the usual care arm will receive a leaflet which contains a standard programme of exercises Participants will be asked to complete their exercise programme as prescribed (at least once per day).
10128909|NCT04308772|Experimental|Web-based physiotherapy|Participants will receive a six week exercise programme, based on those in the usual care exercise sheet delivered via the web-based physio website (www.giraffehealth.com).
10128910|NCT04309032|Experimental|Bladder fill|Retrograde bladder filling of 250cc of 0.9% normal saline for irrigation prior to removal of foley catheter
10128911|NCT04309032|No Intervention|No bladder Fill|no filling prior to removal of foley catheter
10128912|NCT04308863|Experimental|Chitosan scaffold/ MTA pulp dressing material|
10128913|NCT04308863|Active Comparator|MTA pulp dressing material|
10128914|NCT04308577|Experimental|Ketogenic diet with MCT|Ketogenic Diet supplemented with MCT everyday for 6 weeks.
10128915|NCT04308811|Other|platelet rich plasma group|intrauterine platelet rich plasma injection and intrauterine balloon insertion after hysteroscopic lysis of intrauterine adhesions
10128916|NCT04308811|Other|amniotic membrane graft group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon covered by freeze-dried amniotic membranes.
10128917|NCT04308811|Other|intrauterine balloon group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon
10128918|NCT04308798|Experimental|Control group|No surgical glove changing during total knee arthroplasty procedure
10128919|NCT04308798|Experimental|Treatment 1 group|Changing surgical glove after draping and before cementation during total knee arthroplasty procedure
10128920|NCT04308798|Experimental|Treatment 2 group|Changing surgical glove before cementation during total knee arthroplasty procedure
10128921|NCT04308551|Experimental|Indobufen|200 mg Indobufen, bid po, 90 days
10128922|NCT04308551|Active Comparator|Aspirin|100 mg Aspirin, qd po, 90 days
10128923|NCT04309097|Experimental|Digital intervention|Participants will have access to a live-streaming App that offers Recess and Exercise Advocate Program (REAP).
10128924|NCT04309097|Active Comparator|Information-only intervention|Participants will have access to health information only.
10128925|NCT04308447|Experimental|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
10128926|NCT04308460|Active Comparator|arthrocentesis group|the group of internal derangement patients which was treated with arthrocentesis procedure
10128927|NCT04308460|Active Comparator|operative arthroscopy group|the group of internal derangement patients which was treated with operative arthroscopy procedure
10128928|NCT04308915|Experimental|Game-based training|Participants play games for cognitive training
10128929|NCT04308421|Experimental|Low level red light/laser|Patients will be treated twice a week for 12 weeks with low irradiation 650 nm +/- 5 nm red light on one randomly allocated side of the face or body
9967685|NCT01272336|Active Comparator|Sham/AIH|Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH
10128930|NCT04308421|No Intervention|Control side|An affected area on the contralateral side of the face or body or within a single patch will not be treated
10128931|NCT04308616||Psoriasis|Patients with psoriasis
10128932|NCT04308850|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
9967686|NCT01272349|Experimental|Low oxygen|
9967687|NCT01272349|Sham Comparator|Room Air|
9967688|NCT01272362|Experimental|Indacaterol|
9967689|NCT01272375|Experimental|Treatment A PF-04764793|PF-04764793 using inhaler A
9967690|NCT01272375|Experimental|Treatment B PF-04764793|PF-04764793 using inhaler A
10128933|NCT04308850|No Intervention|Control|The other group do not interfere.
10128934|NCT04308746|Experimental|Individualistic|Participants write 3 statements to 3 questions relating to his/her differences from his/her immediate community
10128935|NCT04308746|Experimental|Collectivistic|Participants write 3 statements to 3 questions relating to his/her similarities with his/her immediate community
10128936|NCT04308629|Experimental|tDCS over PMAs|One session of transcranial direct current stimulation (tDCS) over premotor areas (PMAs)
10128937|NCT04308629|Active Comparator|tDCS over M1|One session of transcranial direct current stimulation (tDCS) over primary motor area (M1)
10128938|NCT04308499|Experimental|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions
10128939|NCT04308499|Active Comparator|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions
10183746|NCT03761693|Experimental|Severe/classical MCADD|"Severe MCADD will be defined by ACADM mutations associated with clinical ascertainment or residual MCAD enzyme activity < 10 %, as defined previously (Touw et al., 2012).~Interventions include fasting challenges at two and six months of age."
10183747|NCT03761693|Experimental|Mild MCADD|"Mild MCADD will be defined by the remaining ACADM genotype variants and residual MCAD enzyme activity ≥ 10%.~Interventions include fasting challenges at two and six months of age."
10183748|NCT03761667|Experimental|NBI|The group of NBI inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
10183749|NCT03761667|No Intervention|White light endoscopy (WLE)|The group of WLE inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
10183750|NCT03761654||"Patients with a non-severe subarachnoid hemorrhage"|
10183751|NCT03761628|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of VVC.
9967691|NCT01272375|Experimental|Treatment C PF-04764793|PF-04764793 using inhaler A
9967692|NCT01272375|Experimental|Treatment D PF-04764793|PF-04764793 using inhaler A
9967693|NCT01272375|Experimental|Treatment E PF-04764793|PF-04764793 using inhaler B
9967694|NCT01272375|Experimental|Treatment F PF-04764793|PF-04764793 using inhaler B
9967695|NCT01272375|Experimental|Treatment G PF-04764793|PF-04764793 using inhaler B
9967696|NCT01272401||Breast cancer patients and survivors|
9967697|NCT01272414|Experimental|BoTox Treatment|Subjects receive BoTox injection to levator complex
10128940|NCT04308408|Active Comparator|Mexican Guideline Daily Allowance (GDA)|Guideline Daily Amounts (GDA) is a purely numerical and reductive labeling system, indicates the grams and percentages (according to the guideline-based daily intakes) per portion of kilocalories, saturated fats, other fats, sugars, and sodium, with no specific judgement, opinion or recommendation.
10128941|NCT04308408|Experimental|Ecuador's Multiple Traffic Light (MTL)|Multiple traffic light labels, an interpretive nutrient-specific FOP label, use the typical traffic light colors (green, yellow/amber, red) and text descriptors to indicate the high, medium, or low content of total fat, sugar and salt.
10128942|NCT04308408|Experimental|Chilean Warning Labels in Red|Warning Labels (WL), another nutrient-specific interpretive FOP labelling scheme, include 'high in' symbols for products that exceed limits of energy, sodium, sugar and saturated fat.
10128943|NCT04308525||ERAS Group|Prospectively included patients after introduction of an ERAS programme
10128944|NCT04308525||Control group|We retrospectively evaluated our procedures for the period 2014-2016
10128945|NCT04308538|Active Comparator|Standard Recession|Bilateral lateral rectus muscle recession using standard tables stated by Parks.
10128946|NCT04308538|Experimental|Reduced Recession|Bilateral lateral rectus muscle recession using reduced numbers by one millimeter than the standard tables.
10128947|NCT04308473|Experimental|Arm 1: Ultra-processed Meal + Antibiotics to supress gut flora|Subjects in Arm 1 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of ultra-processed foods.
10128948|NCT04308473|Experimental|Arm 2: Ultra-processed Meal + No Antibiotics|Subjects in Arm 2 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of ultra-processed foods.
10128949|NCT04308473|Experimental|Arm 3: Whole Food Meal + Antibiotics to supress gut flora|Subjects in Arm 3 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of whole, unprocessed foods.
10128950|NCT04308473|Experimental|Arm 4: Whole Food Meal + No Antibiotics|Subjects in Arm 4 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of whole, unprocessed foods.
10128951|NCT04308317|Experimental|Tetrandrine Cohort|"After the subjects were enrolled, they were given Tetrandrine 60mg QD for a course of 1 week(Take 6 days, stop using for 1 day)"
10128952|NCT04308317|No Intervention|Control Cohort|Treatment according to standard protocols without intervention
10128953|NCT04308369|Other|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
10128954|NCT04308200|Other|CO-OP+NDT group|The CO-OP+NDT group received twelve sessions of CO-OP approach, with the baseline and end of treatment assessments, each lasting approximately one hour. Parents and / or caregivers were advised to observe sessions as often as possible to encourage adaptation and transfer to life. Furthermore, CO-OP+NDT group received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist.
10128955|NCT04308200|Other|NDT group|NDT group received just NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity and postural reactions.
10128956|NCT04308213|Experimental|Bone Marrow aspirate|All the patients enrolled in the study will be treated with the bone marrow aspirate obtained with the Bone Marrow Cellution Kit.
10128957|NCT04308343|Active Comparator|Methotrexate group|
10128958|NCT04308343|Active Comparator|Letrozole group|
10128959|NCT04308343|Active Comparator|Gonadotropins releasing hormone antagonist group|
10128960|NCT04308395|Experimental|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
10128961|NCT04308174|Experimental|Durvalumab + Gem/Cis|"<Investigational arm: preoperative phase (up to 4 cycles)> Durvalumab 1,500 mg IV on Day 1, every 3 weeks (preop period) 1,500 mg IV Day 1, every 4 weeks (postop period) Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
10128962|NCT04308174|Active Comparator|Gem/Cis|"<Control arm: preoperative phase (up to 4 cycles)> Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
10128963|NCT04308226|No Intervention|Usual care without patient navigation|Participants assigned to this arm will be given basic educational materials on general lung health and referred back to their primary care provider (PCP) for management as per usual practice.
10128964|NCT04308226|Experimental|Usual care with patient navigation|Participants assigned to this arm will be informed about lung cancer screening (LCS), provided educational materials on LCS and patient navigation, and offered access to an LCS navigator who will partner with participants and primary care providers (PCPs) to facilitate low-dose computed tomography (LDCT) completion and follow-up.
10128965|NCT04307901||Incomplete colonoscopy|Individuals referred to colon capsule endoscopy due to incomplete colonoscopy investigation.
10128966|NCT04307901||Colonoscopy general anesthesia|Individuals referred to colon capsule endoscopy as alternative to colonoscopy under general anesthesia.
10128967|NCT04307901||Colonoscopy declined|Individuals referred to colon capsule endoscopy after completion of bowel preparation for colonoscopy, but who have declined colonoscopy to be carried out.
10128968|NCT04307875||Rohingya refugee camp population|A sample of 1500 randomly selected individuals aged 18 years and above living in the Rohingya refugee camp 1E.
10128969|NCT04307875||Shamlapur refugee hosting community population|A sample of 1500 randomly selected individuals aged 18 years and above living in the refugee hosting community Shamlapur neighbouring the Rohingya refugee camps.
10128970|NCT04307823|Active Comparator|Treadmill training group|Treadmill training according to American College of Sports Medicine's guidelines
10128971|NCT04307823|Experimental|Treadmill protocol and respiratory training group|Treadmill training, slow breathing training and incentive spirometry
10128972|NCT04308018|Active Comparator|S1|Caudal end of the instrumentation at S1
10128973|NCT04308018|Active Comparator|S2alar-iliac|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
10128974|NCT04308161|Experimental|vitamin D oral gel|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks.~Topical oral Vitamin D gel is prepared with the aid of pharmaceutics department, faculty of pharmacy, Alexandria University. It is prepared by using Cholecalciferol 2ml ampoule (200.000 I.U.) within topical oral gel formulation."
10128975|NCT04308161|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Dose: Three times a day for six weeks"
10128976|NCT04308161|Experimental|combination therapy|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Symptomatic treatment dose: Three times a day for six weeks"
10128977|NCT04308083|Active Comparator|convergent neck|Group A Sweden & Martina Prama (P). Transgingival tapering machined collar, 2.8 mm in height.
10128978|NCT04308083|Sham Comparator|divergent neck|Group B Straumann Tissue Level (TL). Transgingival widening polished collar, 1.8 mm in height.
10128979|NCT04308096|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks (adult) 2 weeks (pediatric)
10128980|NCT04307888||Study group|Patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in who percutaneous access closure device is used for implanting devices at aorta level.
10128981|NCT04307784|Experimental|Vitamin D3 alone Group|Treated with VD3 (50.000 IU/week)
10128982|NCT04307784|Experimental|Omaga-3 alone Group|Treated with (1000 mg) wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
10128983|NCT04307784|Experimental|Vitamin D3 and Omega-3 Combination, Group|Treated with 50.000 IU VD3 per week and 1000 mg wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
10128984|NCT04307784|Experimental|Control Group|No intervention was given.
10128985|NCT04308031|Experimental|Ivabradine|Subject will be randomly assigned to either Ivabradine or Digoxin group. Ivabradine starting dose is 2.5 mg twice daily(BID). ECG will be performed at each visit during the treatment phase and dose will be adjusted based on the heart rate result from the ECG. Total treatment phase is 16 weeks ( 4 months).
10128986|NCT04308031|Active Comparator|Digoxin|Subject will be randomly assigned to either Ivabradine or Digoxin group. Digoxin starting dose is 0.125mg once daily(QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg every other day (QOD) in estimated Glomerular filtration rate(eGFR)<60. Dose adjustment will be based on heart rate result from ECG performed at each treatment visit and Digoxin level from blood sample collected from each visit during treatment phase. Total treatment phase is 16 weeks ( 4 months).
10128987|NCT04307771|Experimental|m-health application|a mobile app designed to send reminders for brushing and give information on maintaining oral health
10128988|NCT04307771|Other|Leaflet|This is the control arm. An educational leaflet for maintaining oral hygiene will be given to participants in this arm
10128989|NCT04307979|Experimental|Bulletproof Coffee|A black coffee (bullet proof coffee keurig pod) with 29 grams of added fat (1 tablespoon bullet proof brain octane medium chain triglyceride oil, and 1 tablespoon bullet proof grass fed ghee) blended for 20 seconds with butter scent that is added to the lid.
10128990|NCT04307979|Placebo Comparator|Black Coffee|Black coffee that is blended for 20 seconds with butter scent added to the top of the lid.
10128991|NCT04308070|Experimental|Catheter without Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter without hemostatic agent
10128992|NCT04308070|Experimental|Catheter with Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter with hemostatic agent
10128993|NCT04307914|Active Comparator|External Beam Radiotherapy|In the control arm, patients will undergo standard radiotherapy for painful bone metastases.The radiation schedule is at the discretion of the treating radiation oncologist.
10128994|NCT04307914|Experimental|MR-HIFU|In the intervention arm, patients will be offered MR-HIFU treatment instead of standard radiotherapy. Treatment will be given following the international guidelines for MR-HIFU.
10128995|NCT04307914|Experimental|Combination EBRT + MR-HIFU|In the combination arm, patients will undergo standard radiotherapy followed by MR-HIFU in a short timeframe.
10128996|NCT04308044||Chronic MSK Pain|Participants who have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), and psychological state via the completion of questionnaires by the patient.
10128997|NCT04308044||Healthy Control|Participants who do not have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), insole assessment (40 healthy control participants), and psychological state via the completion of questionnaires by the patient.
10128998|NCT04307966||Intervention|537 pre-adolescent grade 6 learners and their parent (n=537) were invited to participate. Trained educators delivered lessons about HIV and obesity to all Grade 6 students at 5 government-run schools. The classroom curriculum for students required delivery of a five-hour face-to-face intervention delivered weekly through 10 30-minute lessons. Students were asked to communicate their learnings to their parents at home. Parents were requested to read through the lesson in a workbook and to sign acknowledgement that they had read the content. The workbook contained shared student-parent homework activities that took approximately 30 minutes per week. Data was only collected from Learners (n=425) and parents (n= 427)who had consented to the study. A pretest was conducted. The intervention was then implemented. A posttest was conducted afterwards. Both parents and learners answered self-reported questionnaires.
10128999|NCT04307745||Physiotherapist|
10129000|NCT04307745||Doctor|
10129001|NCT04307745||Physical trainer|
10129002|NCT04307745||Trainer|
9967698|NCT01272414|Placebo Comparator|Saline injection|Saline injection to levator complex
9967699|NCT01272427|Experimental|noncaloric beverage|noncaloric sweetened beverage administered 30 min prior to mealtime
10129003|NCT04307758||Healthy Adults|Healthy subjects aged 18-35 years were enrolled in this study. The muscle strength assessment of the foot intrinsic muscles was assessed with the make test and the break test. The tests were performed with the hip and knee semiflexed in prone position with a hand-held dynamometer. The experimental protocols and methods were explained in detail to all subjects. All participants provided written informed consent in keeping with the ethical principles of the Declaration of Helsinki.
9967700|NCT01272427|Experimental|noncaloric beverage (60 min)|noncaloric sweetened beverage administered 60 min prior to mealtime
9967701|NCT01272427|Experimental|glucose beverage|glucose beverage administered 30 min prior to mealtime
9967702|NCT01272427|Experimental|glucose beverage (60 min)|glucose beverage administered 60 min prior to mealtime
9967703|NCT01272427|Experimental|whey protein beverage|whey protein beverage administered 30 min prior to mealtime
9967704|NCT01272427|Experimental|whey protein beverage (60 min)|whey protein beverage administered 60 min prior to mealtime
9967705|NCT01272453||Control Group|Data from patients in the control group will be obtained retrospectively from patient medical records and stored image data
9967706|NCT01272453||Prospective Patient Group|Data from patients in the Flash group will be obtained prospectively from scanner consoles and medical records.
9967707|NCT01272466|Experimental|peptides from antiapoptotic proteins|
9967708|NCT01272479||HCV (+)|Hemodialysis patients with chronic hepatitis C
9967709|NCT01272479||HCV (-)|Hemodialysis patients without chronic hepatitis C
9967710|NCT01272479||Control|Healthy volunteers
9967711|NCT01272492|Experimental|Computer Use|Participants use the computer with the infant/toddler nutrition/feeding education modules
9967712|NCT01272492|No Intervention|Control|Only answers survey questions.
9967713|NCT01272505|Placebo Comparator|conventional SILC|Conventional method of single incision laparoscopic cholecystectomy
9967714|NCT01272505|Active Comparator|HS-SILC|
9967715|NCT01272531||lithium|All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
9967716|NCT01272531||valproate|Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
9967717|NCT01272544||participation in a dental health program|Group 1 - children who participated to a dental health program Group 2 - children who did not participate to dental health program
10129004|NCT04307706|Experimental|Intervention group|''Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group
10129005|NCT04307706|No Intervention|Control group|Only data collection was carried out. No attempt was made by the researcher during the study.
9967718|NCT01272544||participation in a preventive program|Group 1 - children who participated to the preventive program Group 2 - children who did not participate
9967719|NCT01272557|Active Comparator|Sorafenib 400 mg bid (oral) continuously|Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).
9967720|NCT01272557|Experimental|q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19|During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period
9967721|NCT01272570||Aromatase Inhibitor|"Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease.~Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole). Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study as long as the past therapy did not exceed 12 months and the current therapy has not exceeded 12 months."
9967722|NCT01272570||Control|• No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of thyroid or skin cancer).
9967723|NCT01272596||Multiple Sclerosis Patients|Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
9967724|NCT01272609|Experimental|LCP + Timolol|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
9967725|NCT01272609|Active Comparator|LCP|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.
9967726|NCT01272622|Other|Arm I|"Children and adolescents >= 18 years of age new diagnosed with craniopharyngioma~>= 5 years of age and with incomplete resected tumor => randomized in two arms: immediate irradiation after surgery"
9967727|NCT01272622|Other|Arm II|incomplete resection, wait and watch, MRI-controls every 3 months, and irradiation at the time of progression of residual tumor
9967728|NCT01272648|Active Comparator|Rehabilitation|note intervention
9967729|NCT01272648|Placebo Comparator|Control|same radiotherapy but no rehabilitation
9967730|NCT01272674|Active Comparator|exercise training|4 weeks of supervised physical exercise training
9967731|NCT01272674|No Intervention|control|sedentary lifestyle
9967732|NCT01272674|No Intervention|healthy control|
9967733|NCT01272687||Observation|Adults (>18 years) with a confirmed diagnosis of Parkinson's disease
9967734|NCT01272700|Experimental|PCV|Peak airway pressure were set to deliver a tidal volume of 10 ml/kg of ideal body weight
9967735|NCT01272700|Active Comparator|VCV|After anesthetic induction, anesthesia maching were set to deliver a tidal volume of 10 ml/kg of ideal body weight
10129006|NCT04307693|Experimental|Lopinavir/ritonavir|Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days
10129007|NCT04307693|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days
10129008|NCT04307693|No Intervention|Control|No lopinavir/ritonavir and hydroxychloroquine
10129009|NCT04307680|Active Comparator|Kegel exercise|Using high-intensity Kegel exercise regimen for 8 weeks (5 times a week; 3 times a day involved; 3 sets of 10-12 contractions)
10129010|NCT04307680|Active Comparator|Magnetic stimulation|Using 16 extracorporeal magnetic innervation treatments during 8 weeks (2 times a week).
10129011|NCT04307537|Experimental|pcRUG|Peri-catheter retrograde urethrography
10129012|NCT04307537|Active Comparator|VCUG|Voiding cysto-urethrography
10129013|NCT04307589||Caregiving grandparents|
10129014|NCT04307589||Non-caregiving grandparents|
10129015|NCT04307589||Middle-aged and older adults not being a grandparent|
10129016|NCT04307524|Experimental|laparoscopic repair|suture repair of cesarean scar niche using laparoscopy
10129017|NCT04307524|Active Comparator|medical treatment|conservative management
10129018|NCT04307550|Experimental|Isopropyl Alcohol|10 inhalations of an isopropyl alcohol pad held within 2cm from the nares
10129019|NCT04307550|Placebo Comparator|Sterile Saline|10 inhalations of a sterile saline pad held within 2cm from the nares
10129020|NCT04307602|Experimental|Children with cerebral palsy GMFCS IV-V|Exercise intervention in the waling aide Innowalk
10129021|NCT04307602|Active Comparator|Children with cerebral palsy GMFCS I-II|Exercise intervention on spinning bikes
10129022|NCT04307602|Active Comparator|Children without disabilities|Exercise intervention on spinning bikes
10129023|NCT04307641|Experimental|Intervention|Pharmacists who received in the intervention.
10129024|NCT04307641|No Intervention|Control|Pharmacists who did not received in the intervention.
10129025|NCT04307615|Experimental|Oxygen + CPAP-treatment|
10129026|NCT04307615|Active Comparator|Oxygen-treatment|
10129027|NCT04307264||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, liver stiffness measurement and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, Prothrombin time, albumin).
10129028|NCT04307303|Experimental|Abdominal functional electrical stimulation|
10129029|NCT04307303|Sham Comparator|Low dose abdominal functional electrical stimulation arm|
10129030|NCT04307342||Posterior MIPO|Patients treated with posterior MIPO for Humerus Diaphyseal Fractures With Extra-articular Distal Humeral Anatomical Plate
10129031|NCT04307316|Experimental|ACBT group|Active cycle breathing technique
10129032|NCT04307316|Active Comparator|Conventional treatment group|Conventional treatment group
10129033|NCT04307563|Other|Mindfulness group|Participants will attend 6 weekly educational and mindfulness sessions.
10129034|NCT04307459||Coronavirus Infection|All patients admitted to the Respiratory Unit with SARS-CoV-2 infection and respiratory failure
10129035|NCT04307420|Experimental|Sonic Fill Restoration|Using sonic activation system turns the highly filled sonic fill composite into a flowable which enables the material to rapidly fill the cavity effortlessly- greatly reducing procedure time.
10129036|NCT04307420|Active Comparator|Composite Resin Restoration|Direct composite restorations are the most requested and performed dental procedures. The incremental placement technique is the gold standard for posterior universal composite placement.
10129037|NCT04307472|No Intervention|Control|Control arm will receive no intervention.
10129038|NCT04307472|Experimental|Clinician nudge|"The clinician nudge using an active choice intervention in the electronic health record will be delivered to the clinician during the patient's visit. This will be through a Best Practice Advisory that describes the guideline criteria for which the patient is eligible for statin therapy, provides pre-selected options for a statin with alternative options.~The clinician nudge using monthly peer comparison messages will be sent as an inbox message through the electronic health record. Clinicians will be told what percent of their eligible patients have been prescribed a statin and how that compares to peer clinicians at Penn Medicine."
10129039|NCT04307472|Experimental|Patient nudge|The patient nudge will be a text message. Patients with a visit scheduled with their primary care clinician will be identified and sent this text 72 hours before their scheduled visit. The text will remind them of the visit, inform them of their eligibility for a statin, describe the benefits and risks of statin therapy, and ask the patient to discuss statin therapy with their primary care clinician during the visit.
10129040|NCT04307472|Experimental|Clinician Nudge and Patient Nudge|The clinician nudge and patient nudge will be implemented.
10129041|NCT04307368|Experimental|FODMAP diet|Patients with IBS. Interventions: 8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
10129042|NCT04307368|Experimental|Elimination-rotational diet|Patients with IBS. Interventions: During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
10129043|NCT04307368|Experimental|Classic diet|Patients with IBS. Interventions: 8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
10129044|NCT04307238|Other|Propofol group|General anesthesia will be maintained by continually intravenous administered propofol.
10129045|NCT04307238|Other|Sevoflurane Group|General anesthesia will be maintained by inhalative administered sevoflurane.
10129046|NCT04307199|Experimental|Group A|Membrane sweep @ 39 weeks' gestation only
10129047|NCT04307199|Experimental|Group B|Membrane sweep @ 40 weeks' gestation only
10129048|NCT04307199|Experimental|Group C|Membrane sweep @ 39, 40 and 41 weeks' gestation or until onset of labour
10129049|NCT04307199|Experimental|Group D|Membrane sweep @ 40 and 41 weeks' gestation or until onset of labour
10129050|NCT04307199|No Intervention|Control Group|Women in the control arm will not receive a membrane sweep and will receive usual care (as defined by local hospital protocols and vaginal examination to determine Bishop score only).
10129051|NCT04307173|Experimental|Cohort 1|9 subjects for MAD 1 cohort. 6 subjects on KBL693, 3 subjects on placebo.
10129052|NCT04307173|Experimental|Cohort 2|9 subjects for MAD 2 cohort. 6 subjects on KBL693, 3 subjects on placebo.
10129053|NCT04307160||Group I|Patients ≤ 5 years of age
10129054|NCT04307160||Group II|Patients ≥ 7 years of age
10129055|NCT04307290|Experimental|DEX group|received intravenous dexmedetomidine (0.5 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg/h infusion from 10 min before the start of surgery to the end of surgery
10129056|NCT04307290|Placebo Comparator|CON group|received an equivalent volume of normal saline bolus and infusion as placebo until the end of surgery.
10129057|NCT04307147|Experimental|NX (vinorelbine and capecitabine )|Standard therapy plus NX chemotherapy for 4 cycles, (vinorelbine 25 mg/m² d1,8 and capecitabine 1250 mg/m² d1-14, every 3 weeks)
9967736|NCT01272713|Other|Oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~In-hospital oxygen as per hospital protocol"
10129058|NCT04307147|No Intervention|Control group|Standard therapy
10129059|NCT04307004|Other|Unattended vs Attended Blood Pressure|Participants blood pressure will be measured three times attended and three times unattended. Whether investigators measure blood pressure attended first and then unattended or unattended first and then attended will be assigned using a random number generator. At visit 2, clinic blood pressure will be measured three times attended and three times unattended, as at visit 1, but in the reverse order.
10129060|NCT04307004|Other|ABPM vs HBPM|Participants will be fitted with either the Microlife WatchBP O3 ambulatory blood pressure monitoring device or instructed on how to use the Microlife WatchBP Home N home blood pressure device, depending on which they are assigned to complete first. The order in which participants undergo ambulatory or home blood pressure monitoring will be assigned through a random number generator.
10129061|NCT04307082|Experimental|Ibrexafungerp|Oral [14C]-Ibrexafungerp Single Dose
10129062|NCT04306796|Experimental|intervention group|Patients receiving 3D-printed made to measure splints for postoperative or post-traumatic treatment in hand surgical patients
10129063|NCT04306796|Active Comparator|control group|Patients receiving thermoplastic splints individually adjusted by occupational therapists
10129064|NCT04306835|Active Comparator|CPAP + CBT-i|Patients treated simultaneously with CPAP for their OSAS and cognitive behavioral therapy for their insomnia.
10129065|NCT04306835|No Intervention|CPAP only|Patients suffering from OSAS and insomnia, but only treated with CPAP.
10129066|NCT04306783|Experimental|Arm A: In-Home Sensor Monitoring|Older adults with cancer undergoing systemic cancer treatment will undergo passive monitoring with motion sensors and bed sensor. Passive infrared (PIR) motion sensors will be installed in their homes to detect presence in a particular room (e.g., bathroom or kitchen) as well as for specific activities. There will also be a bed sensor, which is a pneumatic strip installed under the bed linens, which measures displacement of the resident's upper torso as he or she lies on the bed. Participants will complete a baseline primarily self-administered survey, an abbreviated assessment with each follow up clinic visit (at least once per month) for 6 months of follow up and a final end of study assessment.
10129067|NCT04306783|No Intervention|Arm B: Survey Only|Patients that choose to not proceed with in-home sensor monitoring will be asked to complete a brief survey that explores attitudes regarding in-home sensor monitoring
10129068|NCT04307069|Experimental|Immediate oxytocin infusion|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, she will receive oxytocin for augmentation of labor.
10129069|NCT04307069|Experimental|Expectant management for 24 hours|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, we will wait for spontaneous delivery to occur. After 24 hours of rupture of membranes, the woman will receive oxytocin for augmentation of labor.
10129070|NCT04306770|Active Comparator|Intervention|OPTIMUM Programme
10129071|NCT04306770|No Intervention|Control|Treatment as usual
10129072|NCT04307056|Experimental|HIFU|Patients Treated with high intensity focused ultrasound (HIFU)
10129073|NCT04307056|Active Comparator|Prostatectomy|Patients Treated by Radical Prostatectomy
10129074|NCT04306887|Experimental|TQ-B3101|TQ-B3101 capsule administered orally.
10129075|NCT04306965|Experimental|Apremilast|Apremilast will be administered to patients as 30 mg oral tablets taken twice daily for 24 weeks. An initial 5-day titration will be implemented to improve tolerability.
10129076|NCT04306705||Tocilizumab|Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no less than 60 minutes. Tocilizumab was administered according to the local label.
10129077|NCT04306705||Continuous Renal Replacement Therapy|Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive 3 times or more.
10129078|NCT04306705||Standard care|Standard of care therapy per local written policies or guidelines.
10129079|NCT04307043||postnatal age|
10129080|NCT04307043||General information and echocardiographic data|General information:(1)Record the gestational age, birth weight, length, delivery way, Apgar score, maternal pregnancy status, prenatal bleeding or not after admission.(2)PS use, ventilator mode, other illness and complications should be recorded during hospitalization. (3) Record the baby's heart rate, respiratory rate, blood pressure, body surface area on every check.
10129081|NCT04306861||Treatment Naïve PDAC Patients|Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC) who qualifies for neoadjuvant chemo-radiation therapy.
10129082|NCT04306757|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during cardiac surgery until admission to postoperative ICU. Individualisation will be established by compliance guided end-expiratory and peak pressure setting, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
10129083|NCT04306757|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during cardiac surgery until admission to postoperative ICU. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
10129084|NCT04306900|Experimental|Combo 1|TTX-030 plus budigalimab plus mFOLFOX6
10129085|NCT04306900|Experimental|Combo 2|TTX-030 plus budigalimab plus docetaxel
10129086|NCT04306900|Experimental|Combo 3|TTX-030 plus mFOLFOX6
10129087|NCT04306900|Experimental|Combo 4|TTX-030 plus pembrolizumab
10129088|NCT04306900|Experimental|Combo 5|TTX-030 plus budigalimab (selected tumors evaluated in expansion)
10129089|NCT04306900|Experimental|Combo 6|TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine
10129090|NCT04306900|Experimental|Combo 7|TTX-030 plus nab-paclitaxel + gemcitabine
10129091|NCT04306900|Experimental|Combo 8|Budigalimab plus mFOLFOX6
10129092|NCT04306809|Experimental|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
10129093|NCT04306926|Experimental|TQB2450+SBRT|SBRT three days before TQB2450.
10129094|NCT04306991|Experimental|Fever|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
10129095|NCT04306991|Experimental|Apyrexia|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
10129096|NCT04306913|Active Comparator|Control|
10129097|NCT04306913|Experimental|Esmolol|
10129098|NCT04306978|Active Comparator|CareLink Express RM system|Patients in the remote monitoring (RM) group will undergo the implantation of Ensura DR MRI SureScan pacing system. Patients in the RM group should visit the main follow-up clinic 12 weeks after discharge, and then the device data will be remotely transmitted to the CareLink Express Network at least once in 3 months. Research personnel will contact patients by telephone once in 6 months. If participants indicate they have experienced a study outcome event (corresponding to the study endpoints), the event will be recorded. If remote transmission or telephone call data require to make clinical decision an in-hospital visit will be induced.
10129099|NCT04306978|Active Comparator|Standard follow-up|Patients in the control group will receive Adapta DR pacing system without remote monitoring using. All patients from the control group should have the first in-hospital visit 12 weeks after pacemaker implantation. Then, the follow-up will be provided according to the standard guidelines
10129100|NCT04306718|Experimental|studyarm|Hyalocytes from ERM and ILM are cultured in alphaMEM to examine their proliferation habits
10129101|NCT04306874|Experimental|High Protein Supplement|60 g total protein per day, administered via twice daily ensure max protein shakes
10129102|NCT04306874|No Intervention|Control|No intervention on diet; routine dietary practice
10129103|NCT04306666||Walant group|Walant group
10129104|NCT04306666||Axillary Brachial Plexus Block|Axillary Brachial Plexus Block
10129105|NCT04307030||0 ~ 18 years old children|Children During Outpatient or Hospitalization
10129106|NCT04306653|Experimental|ACTH|patients with acute gout treated with ACTH
10129107|NCT04306653|Active Comparator|Betamethasone|patients with acute gout treated with betamethasone
10129108|NCT04306731|Experimental|Interventional (Group M)|The group of patients given nanotechnology structured water magnalife
10129109|NCT04306731|Active Comparator|Control (Group T)|The group of patients given Trimethoprim
10129110|NCT04306731|Placebo Comparator|Placebo (Group O)|The group of patients given ordinary bottled drinking water
10129111|NCT04306692|Experimental|Inositol group|Myo-inositol 4000 mg Dosing: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged) during 3 consecutive treatment cycles.
10129112|NCT04306692|Active Comparator|Clomiphene citrate group|Each tablet contains 50 mg of clomiphene citrate Dosing: 1 tablet per day, per os, from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days during 3 consecutive treatment cycles.
10129113|NCT04306679|Experimental|Interventional arm|The intervention, which was aimed to educate children on how to use pain scales and provide reliable pain assessments was based on a two short animation clips, lasting approximately 5 min each, and a short (5 min) guided interaction between the study nurse and the participants, in between the two clips.
10129114|NCT04306679|Other|Control|Children underwent the routine pre-operative preparations, which included a section on pain assessment.
10129115|NCT04306640|Experimental|intervention group|the intervention group will receive the denneroll cervical traction orthotic in an attempt to improve the altered sagittal cervical spine alignment (AHT and ARA C2-C7).
10129116|NCT04306640|Active Comparator|Control group|Both the intervention group and the control group will complete a multimodal program of 10 weeks consisting of myofascial release, thoracic spine mobilization and manipulations, and physical pain relief methods.
10129117|NCT04306627|Active Comparator|Perindopril/Amlodipine arm|"Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study.~Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure < 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia."
10129118|NCT04306627|Active Comparator|Perindopril/Amlodipine/Atorvastatin arm|Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . We will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol.
10129119|NCT04306354|Experimental|Conventional oxytocin treatment (T + OC)|32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
10183752|NCT03761615||type 1 diabetes and pregnancy|Pregnant women with T1D on insulin pumps (CSII/SAP/PLGS) will be offered enrollment in a prospective study that will capture: 1) Dexcom G6 CGM data, 2) self-monitoring of blood glucose (SMBG), 3) insulin pump settings, 4) insulin delivery records, and 5) maternal and fetal outcomes.
10183753|NCT03761602||Proper selenium and iodine condition|"The subjects should have proper dietary intake of selenium and iodine, according to Chinese Dietary Reference Intakes (DRIs) (intake of selenium 65μg/d and iodine 230 μg/d).~The Serum iodine concentration are 45-92μg/L，and the urinary I/Cr 150-249μg/g Cr.~The Serum selenium concentrations are 18-40μg/L."
10129120|NCT04306354|Placebo Comparator|Conventional treatment with placebo administration (T + PBO)|32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
10129121|NCT04306354|No Intervention|Conventional treatment (T)|32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization.
10129122|NCT04306276||Patients undergoing direct IVF|Patients directly undergo IVF without receiving previous hormonal treatment
10129123|NCT04306276||Patients pretreated with DNG|Patients having received a three-month treatment with DNG before undergoing IVF
10129124|NCT04306471|Experimental|Treatment arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition the study intervention involving a monthly subcutaneous injection of evolocumab 420 mg for 12 months
10129125|NCT04306471|Placebo Comparator|Control arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition a Placebo subcutaneous injection for 12 months.
10129126|NCT04306237|Experimental|IMB-1018972|Participants will receive IMB-1018972 (200 mg) MR tablets twice daily for 16 weeks
10129127|NCT04306237|Placebo Comparator|Placebo|Participants will receive matching placebo tablets twice daily for 16 weeks
10129128|NCT04306367|Experimental|Experimental|"Pembrolizumab Q3W, IV infusion (day 1 of each 3 week cycle)~Olaparib bid, Oral tablet continuously"
10129129|NCT04306406|Other|Raspberry Smoothies|Single serving smoothies drink made with red raspberries to be consumed daily for two weeks
10129130|NCT04306328|Experimental|Neurostimulation|
10129131|NCT04306549|Experimental|Bulk-fill resin composite-sonic activated|5 mm bulk-filling without capping lightcured 40s
10129132|NCT04306549|Experimental|Bulk-fill resin composite|4 mm bulk-filling without capping lightcured 10s
10129133|NCT04306549|Experimental|Microhybrid resin composite|2 mm layers, lightcured 20s
10129134|NCT04306536|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
10129135|NCT04306536|No Intervention|Control group|Best local diet
10129136|NCT04306562|Experimental|Intervention group|Patients in an intervention group will be ask about a history of food consumption in the past seven days to analyze a nutritive value of food consumption with a program (INMUCAL-Nutrients V.4.0, Institute of Nutrition, Mahidol University) and estimate an enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day with nutritional counseling by researchers. Special enteral formula will be selected if patients have specific conditions including renal failure, hyperglycemia/diabetes and liver failure, acute and chronic pulmonary disease and immunocompromised states. Otherwise, standard formula will be provided. Duration of enteral protein supplementation is at least 14 days from a preanesthetic clinic visit to a day of surgery.
10129137|NCT04306562|No Intervention|Control group|Patients in a control group will be sent to assess and improve nutritional status by primary doctor as a conventional care pathway.
10183754|NCT03761602||Excessive selenium or iodine condition|"The subjects have excessive dietary intake of selenium and iodine, usually more than 2 times of DRIs. The Serum iodine concentration are more than 100μg/L，and the urinary I/Cr more than 300μg/g Cr.~The Serum selenium concentrations are more than 40μg/L."
10183755|NCT03761602||Insufficient selenium or iodine condition|"The subjects have insufficient dietary intake of either selenium or iodine, compared with DRIs. The Serum iodine concentration are less than 45μg/L，and the urinary I/Cr less than150μg/g Cr.~The Serum selenium concentrations are less than 18μg/L."
10183756|NCT03761589|Experimental|AFL Intervention Group|The AFL intervention consisted of twice a week physical activity and nutrition sessions for children and twice a week educational and physical activity sessions for parents. Each session lasted 90 minutes and all sessions were conducted in a municipal recreation center. The child program was delivered in English while the parent program was delivered in separate English-only or Spanish-only classes.
10183757|NCT03761589|Other|Wait-List Control Group|The wait-list control group received the 12-week AFL intervention after all follow-up data had been completed.
10183758|NCT03761524|Experimental|Customized V plate fixation|Computed tomography (CT) scan of the Facial bones (Axial cuts, DICOM file, Gantry tilt zero and minimal thickness of 1mm )is taken for the patients and a customized V pattern plate
10183759|NCT03761524|Active Comparator|Conventional miniplates fixation|Conventional superior-inferior miniplates fixation of mandibular angle fixation
10183760|NCT03761511|Active Comparator|Treatment arm|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
10183761|NCT03761511|Placebo Comparator|Placebo arm|Matching Placebo (capsules) once daily
10183762|NCT03761485|Experimental|Dentifrice 750 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
10183763|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF neutral|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
10183764|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
10183765|NCT03761472|Active Comparator|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2 ml solution, once initially.
10183766|NCT03761472|Active Comparator|Platelet-rich plasma injection|Platelet-rich plasma 5 ml, once initially
10183767|NCT03761472|No Intervention|Unaffected side Hyaluronic acid|Unaffected sides of the patients will be controls for hyaluronic acid group, no intervention.
10129138|NCT04306484||patients with tumoral brain lesion|The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients.
10129139|NCT04306484||patients with non-tumoral brain lesion|The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection).
10129140|NCT04306614|Experimental|Capillary technique|
10129141|NCT04306614|Placebo Comparator|Suction technique|
10129142|NCT04306458|Experimental|Robot assisted minimally invasive esophagectomy|Robot assisted minimally invasive esophagectomy
10129143|NCT04306458|Active Comparator|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
10129144|NCT04306302|Experimental|Medium-dose ExPEC10V or Placebo: Group 1|Participants will be randomized to receive a single intramuscular (IM) injection of medium dose of ExPEC10V or Placebo on Day 1.
10129145|NCT04306302|Experimental|High-dose ExPEC10V or Placebo: Group 2|Participants will be randomized to receive a single IM injection of high dose (based on safety assessment through Day 15 postvaccination of medium dose) of ExPEC10V or Placebo on Day 1.
10129146|NCT04306497||Cohort of western medicine|"Routine treatment：~① support treatment:maintain water and electrolyte balance .~②oxygen therapy: give nasal catheters to inhale oxygen.~③ basic treatment of traditional Chinese and western medicine: antiviral drugs and proprietary Chinese medicines with similar composition or function to the observed scheme of differentiation and treatment of traditional Chinese medicine are not included in the scope of such drugs.~Antiviral drugs ：Clinicians can judge according to the patient's condition according to the latest version of the diagnosis and treatment plan for COvID-19 issued by the General Office of the National Health Commission / the Office of the State Administration of traditional Chinese Medicine (currently the latest version is the sixth trial edition). Select any of the recommended antiviral drugs(for example:IFN-α、lopinavir-ritonavir、Ribavirin、Chloroquine Phosphate、Arbidol)or a combination of two antiviral drugs."
10129147|NCT04306497||Cohort of integrated TCM and western medicine|"routine treatment + Antiviral drugs + the following TCM regimens. 1.TCM regimens:① Early stage: Dampness trapped in exterior and interior. Recommended prescription: Huoxiang 15g, Suye15g, Cangzhu15g, Houpo10g, Qianhu15g, Chaihu15g, Huangqin10g, Qinghao20g, Xingren10g, JInyinhua15g, Lianqiao15g.~Take decocted or granule, one dose a day.~② Middle stage: Dampness-toxicity blocking lung Recommended prescription: Zhimahuang9g, Xingren10g, Sangbaipi30g, Tinglizi20g, Dongguazi20g, Fabanxia10g, Houpo10g, Suzi15g, Baijiezi10g, Gualoupi15g, Xuanfuhua9g, Xiangfu10g, Yujin10g, Taoren10g, Huangqi20g.~Take decocted or granule, one dose a day."
10129148|NCT04306224|Experimental|IMC-002|Dose escalation will follow the traditional 3+3 design.
10129149|NCT04306289|Active Comparator|Real tDCS|The participant will receive anodal tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
10129150|NCT04306289|Sham Comparator|Sham tDCS|Identical to the real tDCS, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
10129151|NCT04306133|Experimental|PENG BLOCK AND WOUND INFILTRATION|Participants receiving PENG block combined to wound infiltration
10129152|NCT04306133|Active Comparator|WOUND INFILTRATION|Participants receiving wound infiltration alone
10129153|NCT04306055|Experimental|Questionnaire with precaution information|Questionnaire in this group includes information about precaution of blood donation during epidemic of COVID-19.
10129154|NCT04306055|Experimental|Questionnaire without precaution information|Questionnaire in this group dose not include information about precaution of blood donation during epidemic of COVID-19.
10129155|NCT04306055|No Intervention|No questionnaire group|Ever donors in this group would not receive the questionnaire.
10129156|NCT04306198|Active Comparator|Lag Screw|Device: Trochanteric Fixation Nail (TFN) whit lag screw Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
10129157|NCT04306198|Active Comparator|Helical Blade|Device: Trochanteric Fixation Nail (TFN) whit helical blade Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
10129158|NCT04306159|Sham Comparator|General anesthesia|Basal blood pressure and heart rate were recorded after midazolam administration of 0.02 mg/kg. Anesthesia was induced with sufentanil 0.4 μg/kg and propofol 2-2.5 mg/kg, IV route. An IV bolus of cisatracurium 0.1 mg/kg IV was given to facilitate tracheal intubation. Anesthesia was maintained with propofol 4-6 mg/kg/h combined dexmedetomidine 0.2 μg/kg/h(after 0.2 μg/kg/h loading dose within 15min)by bispectral index (BIS) 40-60 and additional bolus doses of remifentanil 0.2-0.5 μg/kg/min to keep arterial pressure values around 20% below baseline values. Sufentanil 0.1-0.2 μg/kg and flurbiprofen 100mg was administrated once the abdomen was closed, then a patient controlled analgesia pump was used. No RSB was performed.
10129159|NCT04306159|Experimental|Subcostal TAP combined with General anesthesia|After induction, TAP was performed. The transversus abdominis plane is imaged with the ultrasound probe obliquely on the upper abdominal wall, along the subcostal margin near the midline.The needle tip was advanced to the desired position where 20 mL 0.375%ropivacaine(Dexamethasone 5mg was added)were injected.The technique is repeated on the opposite side. Anesthesia method and management was same as general anesthesia group.
10129160|NCT04306159|Experimental|Modified RSB combined with General anesthesia|After induction, Modified RSB was performed based on midline incision-guided. The rectus muscle is imaged with the ultrasound probe in a transverse orientation below the xiphisternum and above the umbilicus.The needle tip was advanced to the two desired position where 10 mL ropivacaine 0.375% were injected causing hydrodissection of the rectus muscle away from the posterior rectus sheath.The technique is repeated on the opposite side.Anesthesia method and management was same as general anesthesia group.
10129161|NCT04306185|Experimental|OVARIAN FRAGMENTATION|Ovarian fragmentation through laparoscopy in patients who meet criteria ( Poor ovarian responders and poor ovarian reserve).
10129162|NCT04306263|Experimental|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics (Human milk oligosaccharide, Glucooligosaccharides) and probiotics.
10129163|NCT04306263|Active Comparator|Standard formula|Infants receiving a standard infant formula.
10129164|NCT04306263|Active Comparator|Breastfeeding arm|Infants exclusively or predominantly breastfed (>75%).
10129165|NCT04306068|Experimental|Experimental group|Athletes included in the experimental group will perform a plyometric exercise protocol. Each session will consist of a 4-station circuit with 1 minute rest between each station and 30 seconds between sets
10129166|NCT04306068|No Intervention|Control group|Athletes included in the control group will follow their usual warm-up routine.
10129167|NCT04305990|Experimental|Demand-driven delivery followed by free-flow delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a demand-driven delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
10129168|NCT04305990|Experimental|Free-flow delivery followed by demand-driven delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
10129169|NCT04306107|Experimental|NIV with prone position|Use of prone position during NIV
10129170|NCT04306107|Placebo Comparator|NIV (conventional)|NIV on conventional position
10129171|NCT04306107|Experimental|HFNC on prone position|Prone position during HFNC
10129172|NCT04306107|Placebo Comparator|HFNC (conventional)|HFNC on conventional position
10129173|NCT04305743|Experimental|5 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 5 injections of 2 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
10129174|NCT04305743|Active Comparator|20 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 20 injections of 0.5 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
10129175|NCT04305847||Qual'AXI group|patients for whom distal arm surgery was performed under Axillary Brachial Plexus Block
10129176|NCT04305808||Recurrent Urinary tract infection|Menopausal women, with two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year
10129177|NCT04305808||Healthy controls|Menopausal women, without prior history of UTIs or other urologic abnormalities.
10129178|NCT04306172||Readmitted inpatients/Cases|"Outcome 1: Patients who were readmitted within 18 days of index hospitalization discharge date to the same hospital, with a diagnosis leading to the same Major Diagnostic Group as the index stay (definition according to Swiss Diagnosis Related Groups system, case merger)~Outcome 2: Patients with an unplanned readmission within 30 days of index hospitalization discharge date to the same hospital. An unplanned readmission was defined as a readmission through the emergency department."
10129179|NCT04306172||Non-Readmitted inpatients/Controls|Outcome 1 & 2: Patients who were not readmitted within 30 days of index hospitalization discharge date.
10129180|NCT04305665||HIV-1 positive persons|
10129181|NCT04305964|Experimental|Nastent® users|Patients with an established diagnosis of obstructive sleep apnea with apnea/hypopnea-index (AHI) < 20/ hour sleep who receive Nastent® as treatment modality
10129182|NCT04306042||Treatment|Patients diagnosed with primary stage IIIB-IV squamous cell lung cancer and treated in 92 medical centers between 01 September 2019 and 30 June 2020 will be targeted for study inclusion.
10129183|NCT04305717|Experimental|ReDS-guided strategy|For patients in this arm, daily measurements from the device will be revealed to the treating physician. Discharge can be planned when the clinical stability is achieved and the ReDS value is ≤35%. In case of a ReDS value >35%, treating physicians will follow a predefined algorithm before discharge to improve the results of ReDS test.
10129184|NCT04305717|No Intervention|Standard of care strategy|The drugs dosage, especially diuretics, will be selected according to the presence of symptoms and signs of systemic congestion and according to current recommendations. All the daily ReDS measurements will be blinded to the treating physician.
10129185|NCT04305691|Experimental|Treatment (ixazomib)|Patients receive ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
10129186|NCT04305977|Other|WAVE-TW Arm|All participants will receive the WAVE-TW intervention.
10129187|NCT04305860|Active Comparator|Modified starch without flavoring|Patients thicken water with modified starch during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
10129188|NCT04305860|Active Comparator|Modified starch with flavoring|"Patients thicken water with modified starch adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
10129189|NCT04305860|Active Comparator|Xanthan gum without flavoring|Patients thicken water with xanthan gum during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
10129190|NCT04305860|Active Comparator|Xanthan gum with flavoring|"Patients thicken water with xanthan gum adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization.They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
10129191|NCT04305886|Experimental|Intervention|Providers were placed in small groups and given the intervention of a discussion guide to facilitate discussion.
10129192|NCT04305886|No Intervention|Control|Providers were placed in small groups and not given a discussion guide to facilitate discussion.
10129193|NCT04305730|Experimental|Pedometer Group|This group will be given a pedometer following radical cystectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 1,000/day. POD 3-6: 2,000/day. POD 7-9: 3,000/day. POD 10-14: 4,000/day. POD 14-21: 5,000
10129194|NCT04305730|Active Comparator|Control group|This is the control group. Following radical cystectomy subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
10129195|NCT04306003|Experimental|Enhanced Recovery After Surgery (ERAS) pathway|"Preop~Diet: Solids until midnight before surgery with a carbohydrate rich drink before midnight and 3-hours prior to surgery.~Analgesia: Acetaminophen 975mg & Celecoxib 400mg administered PO 1-hour before surgery.~Intraop~Hypothermia prevention: Forced-air warming units and core temperature monitoring.~Fluid management: Euvolemic fluid management with balanced crystalloid solution.~Analgesia: 0.25% bupivacaine block of intercostal nerves and rectus sheath by the surgical team. Additional IV analgesia by anesthesiologist with the goal to minimize opioids.~PONV prophylaxis: Ondansetron 4-8mg IV during emergence.~Postop~Diet: Clear fluids immediately post-op. Saline lock and advance to DAT on POD#1.~Analgesia: Routine administration of Acetaminophen 975mg PO q6h & Celecoxib 200mg PO q12h. Opioids used as breakthrough analgesia only. No PCA.~Early mobilization: Mobilization within the first 24 hours after surgery with assistance."
10129196|NCT04306003|Active Comparator|Standard Perioperative Care|Patients in the control arm received routine perioperative care as determined by respective surgeons participating in the study.
10129197|NCT04305652|No Intervention|Control group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below )
10129198|NCT04305652|Experimental|Experimental group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below) The caregivers of Alzheimer's patients will be trained for 3 months according to the Progressively Lowered Stress Threshold Model with a home visit.
10129199|NCT04306081|Experimental|Treatment Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of evolocumab 420 mg via subcutaneous injections for 6 months.
10129200|NCT04306081|Placebo Comparator|Control Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of placebo via subcutaneous injections for 6 months.
10129201|NCT04305574||Community sample|We plan to recruit a representative sample of the Singapore population.
10129202|NCT04305587|Experimental|Active Obesity|Part B
10129203|NCT04305587|Placebo Comparator|Placebo Obesity|Part B
10129204|NCT04305587|Experimental|Active T2DM|Parts A and C
10129205|NCT04305587|Placebo Comparator|Placebo T2DM|Parts A and C
10129206|NCT04305392|Experimental|Normal liver function|Patients will receive single dose of SHR4640
10129207|NCT04305392|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR4640
10129208|NCT04305392|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR4640
10129209|NCT04305353|Experimental|ICU Diary Group|Patients randomized to this group receive the ICU diary, along with PTSD education
10129210|NCT04305353|Other|PTSD Education-only Group|Control Group: patients randomized to this group only receive PTSD education
10129211|NCT04305236|Experimental|Abemaciclib and Fulvestrant|Abemaciclib will be administered orally at the dose of 150 mg twice daily. Fulvestrant will be administered intramuscularly at an initial loading dose of 500mg on days 1 and 15 of the first cycle and then 500 mg intramuscularly every first day of each subsequent cycle. One cycle is 28 days.
10129212|NCT04305509||LDH patients|Patients with lumbar disc herniation which was treated with manual therapy
10129213|NCT04305522|Experimental|Probiotic 1 group|A commercially-available multi-strain probiotic with added magnesium and vitamin B6
10129214|NCT04305522|Experimental|Probiotic 2 group|A multi-strain probiotic
10129215|NCT04305522|Placebo Comparator|Placebo group|Identical placebo
10129216|NCT04305457|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
10129217|NCT04305457|No Intervention|Control|Patients assigned to the control group will not receive any gas therapy.
10129218|NCT04305457|Experimental|Nitric Oxide Inhalation (Non-Randomized)|All subjects part of this arm will receive nitric oxide gas either as an inpatient or outpatient. Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system. Patients in this arm will not be randomized, so that all patients receive the study medication.
10129219|NCT04305535|Active Comparator|Peptidic+Probiotic|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and mix of probiotics during 6 months
10129220|NCT04305535|Active Comparator|Peptidic+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
10129221|NCT04305535|Placebo Comparator|Polymeric+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
10129222|NCT04305197|Experimental|Lower Dose|
10129223|NCT04305197|Experimental|Medium Dose|
10129224|NCT04305197|Experimental|Higher Dose|
10129225|NCT04305197|Placebo Comparator|Placebo|
10129226|NCT04305340|Experimental|SKIIN Textile Device in children with healthy hearts|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down.
10129227|NCT04305340|Experimental|SKIIN Textile Device in children with heart failure|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down
10129228|NCT04305171||coronary heart disease patients with periodontitis|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.~Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth."
10129229|NCT04305171||coronary heart disease patients without periodontitisHD|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.~Non-periodontitis classified as having PD ≤ 3 mm."
10129230|NCT04305171||non-coronary heart disease patients with periodontitis|Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth.
10129231|NCT04305171||non-coronary heart disease patients without periodontitis|Non-periodontitis classified as having PD ≤ 3 mm.
10129232|NCT04305223|Experimental|Dry needling and upper extremity stretching program Arm|"Participants will receive a combination of dry needling and upper extremity stretching.~Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin America, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.~A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter."
10129233|NCT04305223|Active Comparator|Dry Needling Arm|Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin American, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.
10129234|NCT04305418|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
10129235|NCT04305418|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
10129236|NCT04305379|Experimental|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction (Sling + Intussusception)
10129237|NCT04305379|Active Comparator|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction (Intussusception Only)
10129238|NCT04305132||Depression|Subjects with depression treated with electroconvulsive therapy
10129239|NCT04305132||Healthy|Healthy subjects
10129240|NCT04305483|Active Comparator|Laser Bleaching|35% Hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative containing bleaching agent activated with diode laser
10129241|NCT04305483|Active Comparator|Chemical Bleaching|35% Hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water containing chemical bleaching agent used for control group without a laser activation
10129242|NCT04305210|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
10129243|NCT04305210|Experimental|18F-florbetapir|18F-florbetapir (AV45) imaging
10129244|NCT04305288||Gemox|The patients received conventional chemotherapy Gemox
10129245|NCT04305288||mFOLFIRINOX|The patients received chemotherapy modified FOLFIRINOX
10129246|NCT04305158|Experimental|Nitrous Oxide|Patient receiving Nitrous Oxide are evaluated for success of the procedure
10129247|NCT04305158|Active Comparator|IV Sedation group|In this group a combination of Midazolam and Fentanyl is used per endoscopic discretion
10129248|NCT04305028||Experimental: Rivaroxaban [2.5 mg] + Aspirin|Drug: Rivaroxaban 2.5 mg twice daily, tablet Drug: Aspirin 75-100 mg once daily, tablet
10129249|NCT04305028||Active Comparator: Aspirin|Drug: Aspirin 75-100 mg once daily, tablet
10129250|NCT04304859||Cases referred from GP|BASIC (Brief Assessment of Impaired Cognition) MMSE (Mini Mental State Examination) Extensive diagnostic work-up including clinical interview, neurological and physical examination, laboratory screening tests, structural neuroimaging
10129251|NCT04304859||Healthy controls|"Test performed:~BASIC MMSE GDS-15 (Geriatric Depression Scale)"
10129252|NCT04304807|Experimental|Group I|Forty five preterm infants with signs of feeding intolerance who received 20 mg of melatonin treatment in addition to traditional antibiotic treatment.
10129253|NCT04304807|Sham Comparator|Group II|Forty five preterm infants with signs of feeding intolerance who received traditional antibiotic treatment only.
10129254|NCT04304846||AMPLIFy group|Mother, premature child and teacher will complete questionnaires and interviews on attachment, maternal stress and child behavior
10129255|NCT04304833|Active Comparator|Provider-Based Care Model Arm|Non-connected home vital sign equipment will be given to patients in this group. The patients in the group will be instructed to record their daily readings on a paper log provided by the research team. These monitoring devices will not transmit readings to a centralized location and no one will be alerted to out-of-range readings or compliance with taking daily vital sign measures. At the front page of the log, normal ranges will be described with brief instructions about what participants/caregivers should do if their readings are out-of-range. Logs will be collected at baseline, 3-months and 6-months.
10129256|NCT04304833|Experimental|mHealth Model Arm|Connected home vital sign equipment (mHealth) will be given to patients in this group. The patients will be instructed to take their daily readings, which will automatically be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse (RN) Call Center will be automatically alerted and the event will be triaged. Daily measures and medical follow-up from the measures will be counted and collected at baseline, 3-months, and 6-months.
10129257|NCT04304794||Group with prophylaxis|Group of 13 patients with euthyroid goiter who received prophylactic treatment before and after iodinated contrast medium (ICM) injection. 6 patients received thiamazole with sodium perchlorate, one day prior to ICM and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily). 7 patients received only thiamazole as prophylactic treatment due to lack of sodium perchlorate at the time.
10129258|NCT04304794||Group without prophylaxis|Group of 23 patients with euthyroid goiter who received no prophylactic treatment before iodinated contrast medium injection.
10129259|NCT04304950|Experimental|Ulcerative Colitis: Azathioprine|Participants with Ulcerative Colitis taking Azathioprine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
10129260|NCT04304950|Experimental|Ulcerative Colitis: 6-Mercaptopurine|Participants with Ulcerative Colitis taking 6-Mercatopurine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
10129261|NCT04304950|Experimental|Crohn's Disease: Azathiopurine|Participants with Crohn's Disease taking Azathioprine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
10129262|NCT04304950|Experimental|Crohn's Disease: 6-Mercaptopurine|Participants with Crohn's Disease taking 6-Mercaptopurine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
10129263|NCT04304898||Single Group Assignment|Intervention group without a control group
10129264|NCT04304924|Experimental|Personalised telephone-based health education|"The personalized telephone based intervention:~Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
10129265|NCT04304924|No Intervention|Standard health educational program|
10129266|NCT04304885||Sonication method|The treatment strategies of all patients will be based on the cultural results to be made by the sonication method.
10129267|NCT04305106|Experimental|Bevacizumab Group|
10129268|NCT04305106|No Intervention|Control Group|
10129269|NCT04304963||T1DM and intact awareness of hypoglycaemia|200 participants with T1DM and intact awareness of hypoglycaemia
10129270|NCT04304963||T1Dm and impaired awareness of hypoglycaemia|50 participants with T1Dm and impaired awareness of hypoglycaemia
10129271|NCT04304963||insulin treated T2DM|350 participants with insulin treated T2DM ( > 1 injections / day)
10129272|NCT04304976|Experimental|Training with ROBERT® Passive|Training performed with ROBERT® in passive mode, resulting in active assistive training.
10129273|NCT04304976|Experimental|Training with ROBERT® Active|Traning performed with ROBERT® in Active mode, resulting in active resistive training.
10129274|NCT04305015|Active Comparator|Routine opioid management|Clinicians will be blinded to NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when
10129275|NCT04305015|Experimental|NOL-guided opioid administration|Clinicians will titrate fentanyl to keep NOL under 25 - always using good clinical judgement for individual patients
10129276|NCT04304989|Experimental|Intervention|This group of participants will receive a video-based mHealth program which includes two main elements: 1) nurse case management supported by a social service team, 2) individual-specific video messages covering self-care topics delivered via smartphone
10129277|NCT04304989|Other|Control|The participants in this group will receive usual care
10129278|NCT04304937||Cohort 1|test-retest at baseline and 7 days later
10129279|NCT04304937||Cohort 2|test at baseline and 8 weeks post treatment
10129280|NCT04305080|Experimental|Anodic Oxidation of implant abutment|
10129281|NCT04305080|Sham Comparator|Untreated implant abutment|
10129282|NCT04304716|Active Comparator|Fibular free flap-Block performed|For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
10129283|NCT04304716|Active Comparator|Anterolateral thigh free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
10129284|NCT04304716|Active Comparator|Radial forearm free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
10129285|NCT04304716|No Intervention|Fibular free flap -Control|No additional procedures beyond the normal standard of care will be performed
10129286|NCT04304716|No Intervention|Anterolateral thigh free flap-Control|No additional procedures beyond the normal standard of care will be performed
10129287|NCT04304716|No Intervention|Radial forearm free flap-Control|No additional procedures beyond the normal standard of care will be performed
10129288|NCT04305002|Experimental|Exenatide|
10129289|NCT04305002|Placebo Comparator|Placebo|
10129290|NCT04304638||Radiation(Chemo-radiation)|Patients in this group had been treated with definitive radiation/Chemo-radiation followed by no treatment until progression.
10129291|NCT04304638||radiation+EGFR-TKI|Patients in this group had been treated with one of the following three ways: 1) definitive radiation and concurrent EGFR-TKI followed by EGFR-TKI till progression; 2) EGFR-TKI followed by radiation and continue TKI util progression; 3) radiation and TKI thereafter until progression.
10129292|NCT04304638||EGFR-TKI|Patients in this group had been treated with EGFR-TKI without any other treatment until progression.
10129293|NCT04304547|Active Comparator|Sequence A|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
10129294|NCT04304547|Active Comparator|Sequence B|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
10129295|NCT04304547|Active Comparator|Sequence C|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
10183768|NCT03761472|No Intervention|Unaffected side Platelet-rich plasma|Unaffected sides of the patients will be controls for Platelet-rich plasma group, no intervention.
10129296|NCT04304573||Patients with hypocalcemia symptoms and low serum calcium|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
10129297|NCT04304573||Patients with hypocalcemia symptoms and normal serum calcium|Patients with hypocalcemia symptoms but without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
10129298|NCT04304521||Intensive care|Patients admitted in the intensive care unit of the University Hospital of Saint-Etienne, France between December 2018 and July 2019
10129299|NCT04304560|Placebo Comparator|Control Group|Control group will receive the standard therapy for DM & HFrEF and placebo.
9967737|NCT01272713|Other|No oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%."
10129300|NCT04304560|Experimental|Dapagliflozin|Intervention group will receive 10mg of Dapagliflozin (Forxiga) ® tablet and standard therapy for HFrEF.
10129301|NCT04304664|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
10129302|NCT04304664|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
10129303|NCT04304690|Other|caregiver|caregivers from emergency, ICU, virology and infectious disease services
10129304|NCT04304677||Pre PCI state|The current study will analyze the pre-PCI pullback recording and amount of FFR step-up. The association of the amount of FFR step-up with post-PCI percent FFR increase, post-PCI FFR, and clinical outcome at 2 years will be analyzed
10129305|NCT04304287|Experimental|Experimental|Preoperative blood donations 14 day before total hip replacement procedure Donation of one dose of autologous blood 14 day before total hip replacement procedure
10129306|NCT04304287|Active Comparator|Active comparator|Preoperative blood donation 72 hours before total hip replacement procedure Donation of one dose of autologous blood 72 hours before total hip replacement procedure
10129307|NCT04304287|Other|Other|Without preoperative blood donation
10129308|NCT04304430||Dapagliflozin|Patients who initiated a new therapy with dapagliflozin
10129309|NCT04304430||DPP-4i|Patients who initiated a new therapy with a DPP-4i
10129310|NCT04304209|Experimental|Cohort A|Four cycles of neoadjuvant PD1 antibody Sintilimab, followed by curative surgery or watch and wait, then four cycles of adjuvant PD1 antibody Sintilimab ± Capeox according to pathologic response
10129311|NCT04304209|Experimental|Cohort B-arm 1|Four cycles of neoadjuvant PD1 antibody Sintilimab, Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy
10129312|NCT04304209|Active Comparator|Cohort B-arm 2|Four cycles of neoadjuvant Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy
10129313|NCT04304326|Experimental|Intervational|"FT: Functional training with elastic band Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group.~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
10129314|NCT04304326|Experimental|Arms and Interventions|"Resistance exercise with weight training machines. Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
10129315|NCT04304391|Experimental|Group A|Conventional Gingivectomy:Technique is performed with conventional surgical instruments.
10129316|NCT04304391|Experimental|Group B|Diode Laser Assisted Gingivectomy: Technique is performed with using diode laser.
10129317|NCT04304391|Experimental|Group C|Er:YAG Laser Assisted Gingivectomy: Technique is performed with using Er:YAG laser.
10129318|NCT04304391|No Intervention|Group D|Negative Control Group
10129319|NCT04304495|Experimental|Intervention|"In addition to the usual care arm, the Intervention arm will receive a physical therapy and pharmacy consultation in the ED. PTs will perform a fall risk assessment and provide recommendations on the safety of discharge. Pharmacists will perform medication review, recommend cessation or tapering of medication that increase fall risk using motivational interviewing (MTM) techniques.~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
10129320|NCT04304495|No Intervention|Usual care arm|"The ED clinician will perform a standard medical evaluation, including a focused history and exam to identify injuries, laboratory tests and radiologic imaging. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics).~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
10129321|NCT04304157|Experimental|satisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
10129322|NCT04304157|Experimental|unsatisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
10129323|NCT04304404|Experimental|Intervention group (BrCaRRP)|Individual interventions based on the Health Belief Model and the The Health Promotion Model involving education, guidance, counseling, case management and surveillance for women with high breast cancer risk
10129324|NCT04304404|No Intervention|Control Group|An information note will be given to the control group. The post-tests will be collected at the end of 12 weeks
10129325|NCT04304365|Active Comparator|Clinic follow-up group|All participants in this group will receive the standard of care at BMC which includes receiving a follow-up visit date and time before leaving the initial visit, when they receive the medications for abortion. Patients then return to clinic 1-2 weeks later to be seen by a provider with an ultrasound for confirmation of abortion completion. Participants who do not come for a return visit receive one phone call to reschedule their appointment.
10129326|NCT04304365|Experimental|Home follow-up group|Participants enrolled in the home follow-up group will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. At enrollment, they will receive instruction for timing of contact, how to use the LSPT, as well as the test itself. The participant will take the pregnancy test at home in 14 days and answer completion questions by text message for follow-up. Patients that screen positive will be asked to return to clinic for a visit with a provider.
10129327|NCT04304352|Experimental|Metronomic VEX|Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
10129328|NCT04304378|Active Comparator|Stabilization Techniques (ST)|"Participants randomized into ST will receive 6 weekly 1-hour sessions of Stabilization Techniques from a Khmer-speaking mental health professional. Sessions provide an opportunity to improve emotion regulation and provide coping skills for managing symptoms of PTSD.~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
10129329|NCT04304378|Experimental|Stabilization Techniques with Behavioral Activation (ST+BA)|"Participants randomized into ST+BA will receive 3 weekly 1-hour sessions of ST and 3 weekly 1-hour sessions of BA from a Khmer-speaking mental health professional. Sessions include stabilization techniques and behavioral skills that aim to establish and maintain routines, reduce avoidance, and manage negative emotions.~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
10129330|NCT04304300||Study group|Glioma, IDH mutated, grade 2 and 3
10129331|NCT04304261|Experimental|Dapagliflozin|12 weeks of Dapagliflozin(10mg/day) treatment, randomly
10129332|NCT04304261|Experimental|Metformin|12 weeks of Metformin (1500-2000mg/day) treatment, randomly
10129333|NCT04304248|Experimental|Neoadjuvant chemo-immunotherapy|"Neoadjuvant treatment (Albumin-bound paclitaxel + carboplatin + toripalimab) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment."
10183769|NCT03761433||SPI group|All patients who received the liver resection surgery will receive surgical pleth index
10183770|NCT03761407|Experimental|Group 1 (100 mg GRT0151Y)|"The dose of 100 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 100 mg. On Day 5 the last dose of 100 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group."
10183771|NCT03761407|Experimental|Group 2 (125 mg GRT0151Y)|"The dose of 125 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 125 mg. On Day 5 the last dose of 125 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
10183772|NCT03761407|Experimental|Group 3 (150 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 150 mg. On Day 5 the last dose of 150 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
10183773|NCT03761407|Experimental|Group 4 (225 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the dose of 225 mg will be administered twice (b.i.d.). On Day 5 the last dose of 225 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
10183774|NCT03761381||Early Dementia|This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
10183775|NCT03761381||Dementia-Free Controls|This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
10183776|NCT03761342|No Intervention|Control|A control arm that mirrors a traditional web-grocery store with no but with no FOP labels.
10129334|NCT04304235|Active Comparator|Control|Hospital nurses will triage participants using the Emergency Triage and Treatment (ETAT) guidelines, the triage policy that is currently in place at the study hospital sites.
9967738|NCT01272726||ADHD|Women with symptoms of ADHD. Women who either think they may have ADHD or have been previously diagnosed with ADHD but have not been treated for it.
9967739|NCT01272739|Experimental|Study Group|Subjects will take 500 mg of the investigational product 15 minutes prior to the 3 main meals of the day.
9967740|NCT01272739|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
9967741|NCT01272752|Experimental|Study Group|Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
9967742|NCT01272752|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
10129335|NCT04304235|Experimental|Intervention|Hospital nurses will triage participants using the digital triage tool (mhealth intervention).
10129336|NCT04304313|Experimental|Sildenafil citrate tablets|
10129337|NCT04304196|Experimental|TEMPO|These patients and caregivers will be able to access the TEMPO modules and will receive technical support to use it effectively. Patients will receive usual care throughout the study.
10183777|NCT03761342|Experimental|Multiple Traffic Light Labels|Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.
9967743|NCT01272765|Placebo Comparator|Control Group|
9967744|NCT01272765|Experimental|Risperdal Group|Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
9967745|NCT01272765|Experimental|Seroquel Group|Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
9967746|NCT01272765|Experimental|Zyprexa Group|Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
9967747|NCT01272778|Experimental|Lorazepam 0.2 mg|All subjects receive lorazepam 0.2 mg in this crossover design.
9967748|NCT01272778|Experimental|Lorazepam, 0.5 mg|All subjects receive lorazepam 0.5 mg in this crossover design.
9967749|NCT01272778|Experimental|Lorazepam, 1.0 mg|All subjects receive lorazepam 1.0 mg in this crossover design.
9967750|NCT01272778|Experimental|Lorazepam, 2.0 mg|All subjects receive lorazepam 2.0 mg in this crossover design
9967751|NCT01272778|Placebo Comparator|Sugar pill|All subjects receive a sugar pill in this crossover design.
9967752|NCT01272817|Other|Cladribine + melphalan|Cladribine + melphalan conditioning
9967753|NCT01272817|Other|TLI|Total lymphoid irradiation conditioning
9967754|NCT01272843||Carotid endarterectomy patients|
9967755|NCT01272843||Lumbar stenosis laminectomy patients|
9967756|NCT01272856|Experimental|Open Label Abatacept|
9967757|NCT01272895|Experimental|GENOUS stent|
9967758|NCT01272973|Experimental|Oral 1|
9967759|NCT01272973|Experimental|Oral 2|
9967760|NCT01272973|Experimental|Oral 3|
9967761|NCT01272973|Active Comparator|S.c.|
9967762|NCT01272986|Placebo Comparator|Healthy patients|
9967763|NCT01272986|Active Comparator|Asymptomatic myocardial Ischemic patients|
9967764|NCT01272986|Active Comparator|Acute Coronary Syndrome Patients|
9967765|NCT01273012|Placebo Comparator|Placebo|The group of patients treated with placebo.
9967766|NCT01273012|Experimental|Infloran|The group of patients treated with Infloran.
9967767|NCT01273090|Experimental|Treatment|
9967768|NCT01273103|Experimental|Treatment|[14C]- GSK2248761 200 mg
9967769|NCT01273116|Experimental|CWS in Hospital|CWS in Hospital in addition to usual care
9967770|NCT01273233|Experimental|Group 1: 200U EV71 vaccine|12 adults received 3 doses of 200U EV71 vaccine 14 days apart
9967771|NCT01273233|Experimental|Group 2: 400U EV71 vaccine|12 adults received 3 doses of 400U EV71 vaccine 14 days apart
9967772|NCT01273233|Placebo Comparator|Group 1: Placebo|6 adults received 3 doses of placebo 14 days apart
9967773|NCT01273233|Placebo Comparator|Group 2: Placebo|6 adults received 3 doses of placebo 14 days apart
9967774|NCT01273246|Experimental|Children Group 1: 200U EV71 vaccine|12 children received 3 doses of 200U EV71 vaccine 28 days apart
9967775|NCT01273246|Placebo Comparator|Children Group 1: Placebo|6 children received 3 doses of placebo 28 days apart
9967776|NCT01273246|Experimental|Children Group 2: 400U EV71 vaccine|12 children received 3 doses of 400U EV71 vaccine 28 days apart
9967777|NCT01273246|Placebo Comparator|Children Group 2: Placebo|6 children received 3 doses of placebo 28 days apart
9967778|NCT01273246|Experimental|Infants Group 1: 100U EV71 vaccine|24 infants received 3 doses of 100U EV71 vaccine 28 days apart
9967779|NCT01273246|Placebo Comparator|Infants Group 1: Placebo|8 infants received 3 doses of placebo 28 days apart
9967780|NCT01273246|Experimental|Infants Group 2: 200U EV71 vaccine|24 infants received 3 doses of 200U EV71 vaccine 28 days apart
9967781|NCT01273246|Placebo Comparator|Infants Group 2: Placebo|8 infants received 3 doses of placebo 28 days apart
9967782|NCT01273246|Experimental|Infants Group 3: 400U EV71 vaccine|24 infants received 3 doses of 400U EV71 vaccine 28 days apart
9967783|NCT01273246|Placebo Comparator|Infants Group 3: Placebo|8 infants received 3 doses of placebo 28 days apart
9967784|NCT01273272|Experimental|Cognitive Behavioral Therapy (CBT)|Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
9967785|NCT01273272|Active Comparator|Treatment as usual (TAU)|Standard Treatment (medical and psychosocial)
9967786|NCT01273298|Experimental|Bisoprolol|
9967787|NCT01273298|Placebo Comparator|Sugar pill|
9967788|NCT01273324||ADM|ADM Cup
9967789|NCT01273337|Experimental|ALD-401|ALD-401 is derived from Autologous Bone Marrow of the Stroke Subject
9967790|NCT01273337|Sham Comparator|Sham Comparitor|Sham Bone Marrow harvest and sham dosing procedure.
9967791|NCT01273350|Other|Single arm|"Single arm observational study looking at a low risk cohort of individuals with carotid stenosis"
10129338|NCT04304196|Active Comparator|Control|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
10129339|NCT04304222|Other|Sequence A|To receive the conventionally made denture framework then the 3D printed denture framework.
10129340|NCT04304222|Other|Sequence B|To receive the 3D printed denture framework then the conventionally made denture framework.
10129341|NCT04304170|Experimental|Verum group|The dietary supplement under study was composed of fructo-oligosaccharides - FOS: 4.95 gr / sachet and Bifidobacterium animalis lactis: VES002 (LMG P-28149): 5 billion / sachet. They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
10129342|NCT04304170|Placebo Comparator|Placebo group|The comparative product was a placebo that looked strictly identical to the verum and contained only excipients (60% maltodextrin / 40% sucrose).They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
10129343|NCT04304456||HA-BSI|Patients with HA-BSI treated in an ICU
10129344|NCT04304092|Experimental|Low amount, low intensity|
10129345|NCT04304092|Experimental|Low amount, high intensity|
10129346|NCT04304092|Experimental|High Amount, low intensity|
10129347|NCT04304092|Experimental|High Amount, high intensity|
10129348|NCT04304092|No Intervention|Control|
10129349|NCT04304053|Active Comparator|No Intervention- SARS-CoV-2 surveillance|"Study 1- Contacts will complete a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and day 14.~Study 2- Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3 and 7.~Isolation of patient and contact tracing as per national guidelines."
10129350|NCT04304053|Experimental|Testing, treatment and prophylaxis of SARS-CoV-2|"Study 1- Contacts receive Hydroxychloroquine prophylaxis. Contacts will complete a survey collecting demographic, epidemiological and clinical and provides a swab for RT-PCR testing at baseline and day 14.~Study 2- Index case receives Hydroxychloroquine. Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3, and 7.~Isolation of patient and contact tracing as per national guidelines."
10129351|NCT04303975||Group 1: Patients with neoadjuvant chemotherapy|"The patients of group1 will receive one of the following treatments:~neoadjuvant chemotherapy & concurrent chemoradiotherapy~neoadjuvant chemotherapy & radiotherapy~neoadjuvant chemotherapy & radiotherapy & adjuvant chemotherapy"
10129352|NCT04303975||Group 2: Patients without neoadjuvant chemotherapy|"The patients of group2 will receive one of the following treatments:~concurrent chemoradiotherapy~concurrent chemoradiotherapy & adjuvant chemoradiotherapy~radiotherapy & adjuvant chemotherapy"
10129353|NCT04303832|Experimental|eye exercise group|This group made different types of eye exercises beside the traditional treatment of strabismus which is eye glasses
10129354|NCT04303832|Sham Comparator|control group|This group had traditional treatment of strabismus which is eye glasses
10129355|NCT04303871|Active Comparator|patients|pregnant female with hypertension admitted in ICUfor control of BP invasive assessment of BP by radial cannulation was compared against non-invasive assessment of BP by an automated oscillometric BP device (Mobil-O-Graph )
10129356|NCT04303871|Placebo Comparator|control|matched control females of the same age but not pregnant invasive compared to non-invasive measurement of BP by same technique
10129357|NCT04303741|Experimental|Camrelizumab +Apatinib+Eribulin|Camrelizumab 200mg(3mg/kg for patient whose weight is below 50kg) iv Q3W combination with Apatinib 250mg, po, daily (d1-d21)and Eribulin1.4mg/m2 iv d1, d8 Q3W
10129358|NCT04304066|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans
10129359|NCT04303806|Experimental|Group 1|40 preeclamptic parturient receive 20 mg rosuvastatin orally once daily.
10129360|NCT04303806|Experimental|Group 2|40 preeclamptic parturient receive 40 mg rosuvastatin orally once daily.
10129361|NCT04304040|Experimental|Single Arm|
10129362|NCT04303884|Experimental|Experimental: Pembrolizumab|Chemo-resistant gestational trophoblastic neoplasias treated with pembrolizumab
10129363|NCT04303923||Male group|Male patients who performed transthoracic echocardiography with arterial ultrasonography
10129364|NCT04303923||Female group|Female patients who performed transthoracic echocardiography with arterial ultrasonography
10129365|NCT04303845|Experimental|Treatment with Erenumab|Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
10129366|NCT04303988|Experimental|Cohort HR+/HER2+|Hormone receptor negative, HER2 positive participants will receive Pyrotinib in combination with Temozolomide until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10129367|NCT04303988|Experimental|Cohort HR-/HER2-|Hormone receptor negative, HER2 negative participants will receive SHR1316 in combination with bevacizumab plus cisplatin or carboplatin until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10129368|NCT04304027|Experimental|Tailored exercise intervention|8 weeks of aerobic interval training at moderate intensity which is modified according to the levels of self-reported fatigue
10129369|NCT04304027|Active Comparator|Standard exercise intervention|8 weeks of aerobic interval training at a moderate intensity
10129370|NCT04304027|No Intervention|Usual care control|Participants in the usual care control group will continue to receive their standard care independent of this study
10129371|NCT04303819||newly diagnosed T2DM participants|newly diagnosed T2DM participants without anti-diabetic drugs intake
10129372|NCT04303767|Experimental|Test (ART + CPP-ACP)|In this group, teeth selected will receive intervention with CPP-ACP and restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
10129373|NCT04303767|Active Comparator|Control (ART)|in this group, teeth selected will receive restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
10129374|NCT04304014|Experimental|L. reuteri|"Group that will receive L. reuteri one dose per day in an oral suspension~Intervention: Dietary Supplement: L. reuteri"
10129375|NCT04304014|Experimental|B. longum and P. Pentosaceus|"Group that will receive B. longum and P. Pentosaceus one dose per day in an oral suspension.~Intervention: Dietary Supplement: B. longum and P. Pentosaceus"
10129376|NCT04303715|Experimental|No SLNB group|The study arm - BCS without SLNB
10129377|NCT04303715|Other|SLNB group|The Control Arm - BCS with SLNB(+/-ALND)
10129378|NCT04303949|Experimental|Experimental|e-book for termination
10129379|NCT04303949|Other|Control|routine care Written form health education
10129380|NCT04303936|Other|Patients with severe HA under FVIII concentrates prophylaxis|
10129381|NCT04303481|Other|normal diet|
10129382|NCT04303481|Experimental|weight loss program kit|
10129383|NCT04303481|Experimental|weight loss program kit with A. muciniphila prebiotics|
10129384|NCT04303520|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/CD22 CAR-T cells in the CD19-positive ALL patients
10129385|NCT04303390|Active Comparator|24 hour Cefuroxime arm|25% of the entire study participants are assigned to 24 hours and second generation cephalosporin
10129386|NCT04303390|Active Comparator|24 hour Cefazolin arm|25% of the entire study participants are assigned to 24 hours and first generation cephalosporin
10129387|NCT04303390|Active Comparator|48 hour Cefuroxime arm|25% of the entire study participants are assigned to 48 hours and second generation cephalosporin
10129388|NCT04303390|Active Comparator|48 hour Cefazolin arm|25% of the entire study participants are assigned to 48 hours and first generation cephalosporin
10129389|NCT04303338|Experimental|Masotherapy with neural tension|The investigators are going to massage the patient´s upper limb applying a radial nerve neural tension. In order to the upper limb should be positioned lowering the scapula, elbow extended, internal rotation glenohumeral, forearm pronation, bend and cubital deviation of the wrist, fingers bended and thumb adduction, and finally glenohumeral abduction.
10129390|NCT04303338|Active Comparator|Masotherapy with non-neural tension|The investigators are going to practice a conventional upper limb massage
10129391|NCT04303585||SAP block|This group includes patients who receive preoperative Serratus Anterior Plane block
10129392|NCT04303585||ESP block|This group includes patients who receive preoperative Erector Spinae Plane block
10129393|NCT04303364||Subjects without T2DM and without HF|
10129394|NCT04303364||Patients without T2DM and with HFpEF|
10129395|NCT04303364||Patients with T2DM and without HFpEF|
10129396|NCT04303364||Patients with T2DM and HFpEF|
10129397|NCT04303364||Patients without T2DM and with hypertrophic cardiomyopathy|
10129398|NCT04303364||Patients with T2DM and with hypertrophic cardiomyopathy|
10129399|NCT04303533|Experimental|EFP-NF|
10129400|NCT04303377|Experimental|Evolocumab|Evolocumab administration in the acute phase of ST elevation myocardial infarction
10129401|NCT04303377|No Intervention|Standard of care|
10129402|NCT04303299|Experimental|Oseltamivir plus Chloroquine in Mild COVID19|Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 800 mg per day In mild COVID19
10129403|NCT04303299|Experimental|Darunavir and Ritonavir plus oseltamivir|Darunavir 400 mg every 8 hours Ritonavir 200 mg (or 2.5 mg/kg ) per day plus plus Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 400mg per day in Mild COVID19
10129404|NCT04303299|Experimental|Lopinavir and Ritonavir plus Oseltamivir in mild COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In mild COVID19
10129405|NCT04303299|Experimental|Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In moderate to critically ill COVID19
10129406|NCT04303299|Experimental|Favipiravir lopinavir /Ritonavir for mod. To severe|Lopinavir 800 mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day in Mild COVID19 In moderate to critically ill COVID19
10129407|NCT04303299|Experimental|Darunavir /ritonavir oseltamivir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg (or 4-6 mg /kg ) per day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
10129408|NCT04303299|Experimental|Darunavir /ritonavir favipiravir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
10129409|NCT04303299|No Intervention|Conventional Qurantine|Patient who unwilling to treatment and willing to quarantine in mild COVID19
10129410|NCT04303312|Active Comparator|Benzydamine Hydrochloride|"Control Group:Benzydamine Hydrochloride spray by mouth three times daily for 20 days.~Follow up: The patients will be recalled at one week interval for 20 days."
10129411|NCT04303312|Experimental|90%solcoseryl and 10% pumpkin seed oil|Intervention group: 90% solcoseryl and 10% pumpkin seed oil spray by mouth three times daily for 20 days
10129412|NCT04303494||Experimental1|preterm infants will be routinely immunised during primary hospitalisation
10129413|NCT04303494||Experimental2|preterm infants discharged and readmitted for immunisation during the 3-year period
10129414|NCT04303494||Control|healthy control infants
10129415|NCT04303546||< 30 years|
10129416|NCT04303546||30-60 years|
10129417|NCT04303546||> 60 years|
10129418|NCT04303403|Experimental|Dose Escalation and Expansion|"Dose Escalation:~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb (2mg starting dose) daily and oral ruxolitinib (5mg starting dose) twice daily at assigned doses.~Dose Expansion:~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb daily and oral ruxolitinib twice daily at the maximum tolerated dose (MTD) established at the Dose Escalation phase.~A cycle of therapy will comprise of 28 days of combination trametinib and ruxolitinib treatment."
10129419|NCT04303442||Patients undergoing TEP|Patients diagnosed with unilateral or bilateral primary and/or recurrence inguinal hernia undergoing Total Extraperitoneal laparoscopic hernia repair.
9826036|NCT02404649|Active Comparator|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
9967792|NCT01273363||1|Male and female over 18. Patients with asthma diagnosed in accordance with the Global Initiative for Asthma within 6 months before inclusion into the study and without changes in treatment for 2 months before inclusion
10129420|NCT04303416|Experimental|Patients|Patients before and after the treatment
10129421|NCT04303455||Study group|"The study will evaluate a cohort of participants meeting the following inclusion criteria:~Admission to ICU after elective and emergency cardiac surgery following cardiopulmonary bypass~Age 18 years and above~Arterial, central venous and pulmonary arterial catheters have been inserted as part of routine care~Data collection, serum renin among routine blood collection on admission, 6 and 24 hours after admission to ICU"
10129422|NCT04303637||High school student|13-18 year old students enrolled in schools within Singapore.
10129423|NCT04303429|No Intervention|observation group|Patients enrolled in the observation group will not receive any chemotherapy drugs
10129424|NCT04303429|Experimental|adjuvant chemotherapy group|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
10129425|NCT04303624||Community sample|Representative sample of the Singapore population
10129426|NCT04303598|Experimental|FNC Treatment Group|FNC 3mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;3TC placebo 1 tablet;daily oral before bedtime
10129427|NCT04303598|Active Comparator|3TC control group|3TC 300mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;FNC placebo 1 tablet;daily oral before bedtime
10129428|NCT04303247|Experimental|CD19+CD22 targeted CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.~dosage: the number of anti CD19+CD22 CAR T cells~-1(if needed) 1×10^5/KG~3×10^5 /KG~6×10^5 /KG~1×10^6/KG~Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion."
10129429|NCT04303234|Active Comparator|Artinibsa|"Powerful local anesthetic with short time for patients who can not tolerate normal doses of vasoconstrictor latency.~High lipid solubility gives a better diffusion through the soft tissue and bone being very effective in infiltrative techniques.~Duration:~Latency time: 2 minutes~Each mL contains:~4%Articaine 1:100000. Hydrochloride 40.00 mg, Epinephrine (D.C.I) 0.005 mg tartrate"
10129430|NCT04303234|Experimental|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
10129431|NCT04303143||Primary|Primary
10129432|NCT04303221|Experimental|GAJL - Young adult with lymphedema|Women age 35 to 59 years (young adult) with lymphedema - exercise group
10129433|NCT04303221|Experimental|GAJ - Young adult without lymphedema|Women age 35 to 59 years (young adult) without lymphedema - exercise group
10129434|NCT04303221|Experimental|GIL - Elderly with lymphedema|Women aged 60 to 80 years (elderly) with lymphedema - exercise group
10129435|NCT04303221|Experimental|GI - Elderly without lymphedema|Women aged 60 to 80 years (elderly) without lymphedema - exercise group
10129436|NCT04302935||chronic pain patients|
10129437|NCT04302974||Sub-study 1: Trajectory study|All HA primary care patients aged 18 years or above with doctor-documented HT and/or DM receiving care in HA General Out-patient Clinics or Family Medicine Clinics (FMC) identified from the HA CMS database between 2006 and 2019, to explore the trajectory patterns for clinical, treatment and complication profiles and investigate the impact of multi-morbidity, continuity-of-care, different service delivery models and management strategies (including investigation frequency and specific drug regimens) on outcomes and health service utilization.
10129438|NCT04302974||Sub-study 2: RAMP-DM|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who attended the first RAMP-DM assessment between August 2009 to September 2010
10129439|NCT04302974||Sub-study 2: usual care only|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who have never attended any RAMP-DM assessment between August, 2009 to December, 2019
10129440|NCT04302974||Sub-study 3: RAMP-HT|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who attended the first RAMP-HT assessment between October 2011 to March 2013
10129441|NCT04302974||Sub-study 3: usual care only|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who have never attended any RAMP-HT assessment between October 2011 to December 2021
10129442|NCT04302974||Sub-study 4: PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have received the first PSCC call between September, 2012 to August, 2016 after the first RAMP-DM assessment
9967793|NCT01273376|Experimental|RX-10100 high dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
10129443|NCT04302974||Sub-study 4: without PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have never received any PSCC services between September 2012 to December 2021
10129444|NCT04302844|Active Comparator|Imago Relationship Therapy (IRT)|Couples will receive 12 to 16 Imago relationship therapy sessions (90 minutes each; one session per week) with an experienced and certified Imago Relationship therapist.
10129445|NCT04302844|Active Comparator|Waitlist with Bibliotherapy followed by Workshop|Couples will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read during that time. After 12 weeks and the 12-week assessment has been completed, couples will receive a Getting the Love You Want workshop.
10129446|NCT04302831|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
10129447|NCT04302831|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
10129448|NCT04303208|Other|study group|2 ml of whole blood sample will be collected on EDTA tube for detection of Plasmacytoid dendritic cells and Toll like receptor 8 by flow cytometry
10129449|NCT04303208|Other|control group|2 ml of whole blood sample will be collected on EDTA tube for detection of Plasmacytoid dendritic cells and Toll like receptor 8 by flow cytometry
10129450|NCT04302792|No Intervention|Stage 1: Interviews and focus group sessions|"Group A: Cancer patients (requiring or have required texture-modified foods and/or experiencing or have experienced taste&smell alterations in the last 12 months) will be required to attend a one-hour online interview.~Group B: Relatives of cancer patients (requiring texture-modified foods and/or experiencing taste&smell alterations) will be required to attend a 2-hour online focus group session.~Group C: Healthcare professionals with a minimum of a year's experience with oncological patients that require texture-modified foods and/or have taste & smell alteration will be required to attend a 2-hour online focus group session.~A food diary will be given to Group A and B to complete for 7-days prior to their session. Topics to be discussed during the interview and the focus group sessions will include the food requirements of cancer patients, the barriers of the current food products, possible solutions to these requirements if any and their expectations towards new food solutions."
10129451|NCT04302792|Experimental|Stage 2: Texture-modified foods for cancer patients|The study will involve conducting a tasting trial over a 2-weeks period where participants will be required to consume a maximum of three 3D printed texture-modified food based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
10129452|NCT04302792|Experimental|Stage 3: Taste-optimised foods for cancer patients|The study will involve conducting a home test over a one-month period where participants will be required to consume taste-optimised products based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
10129453|NCT04302779|Experimental|Solid Model|Whey Permeate Lemon Cupcake and Protein Fortified Lemon Cupcake
10129454|NCT04302779|Experimental|Liquid Model|Whey Protein Beverage
10129455|NCT04302870|Experimental|Memantine|
10129456|NCT04302870|Experimental|Trazodone|
10129457|NCT04302870|Placebo Comparator|Placebo|
10129458|NCT04303026|Active Comparator|Treatment Group|Participants receiving active treatment with two infusions of Zoledronic Acid 5 mg with 3 months interval mixed in 100 ml 0.9% saline
10129459|NCT04303026|Placebo Comparator|Placebo Group|Participants receiving Placebo with two infusions of 100 ml 0.9% saline with 3 months interval.
10129460|NCT04302883|Experimental|Intervention group|TEE FEES
10129461|NCT04302883|Active Comparator|Control group|FEES
9827678|NCT02464657|Experimental|Ph 1 Nivolumab (1mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
10129462|NCT04303013|Active Comparator|Standard of Care|
10129463|NCT04303013|Experimental|Meditation|
10129464|NCT04303052|Active Comparator|over-the-wire technique with 145 cm guidewire|Catheter tip placement using Seldinger over-the-wire technique with 145 cm guidewire
10129465|NCT04303052|Active Comparator|modified technique with 70 cm guidewire|Catheter tip placement using Seldinger modified technique with 70 cm guidewire
10129466|NCT04303130|Experimental|Camrelizumab (SHR-1210) Combined With Endostar|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
10129467|NCT04303039|Experimental|Treatment A|Single 1.0 mg dose of ABP-671 in the fasted state.
10129468|NCT04303039|Experimental|Treatment B|Single 1.0 mg dose of ABP-671 in the fed state, after a standardized breakfast.
10129469|NCT04302909|Active Comparator|Active Comparator|fESWT
10129470|NCT04302909|Sham Comparator|Sham Comparator|Sham fESWT
10129471|NCT04303065|Experimental|Dexamethasone|"Dexamethasone will be a short and descending course: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).~Dexamethasone (Fortecortin®) will be acquired from ERN, SA. Laboratories (Barcelona, Spain). The Son Espases Pharmacy Department will be in charge of developing and conditioning the 4mg, 2mg and 1mg dexamethasone / placebo capsules needed for 12 days of treatment, keeping the researchers blind"
10129472|NCT04303065|Placebo Comparator|Control|"The preparation and conditioning of the capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).~The Son Espases Pharmacy Department will be responsible for identifying the containers and sending them by courier to the participating hospitals. A record of the dispensing of test samples will be kept and will be sent in acknowledgment of receipt for control"
10129473|NCT04302714|Active Comparator|cervical injection|Fluorescent SLN Imaging With Indocyanine Green (ICG), using near-infrared fluorescence imaging, will be used as a dye for SLN mapping. Injections will be performed intraoperative. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room, and 4 mL is injected directly into the cervix. This solution was injected intracervically at 3 and 9 o'clock positions, both submucosally and deep into the cervical stroma. A spinal needle 18-gauce is used to inject the ICG. The 4 mL can be divided into 4 separate injections (1 mL each). The ICG should be injected slowly, at a rate of 5 to 10 seconds per quadrant.
10129474|NCT04302714|Experimental|hysteroscopic injection|hysteroscopy is performed using an operative hysteroscope. Uterine distension is obtained by means of saline solution. Usually, the fluid bag is placed 50 cm above the patient's plane so that the intracavitary pressure does not exceed 40 mm Hg. After visualization of uterine cavity a 22-gauce, 40-mm needle was introduced into the operative port and IGC is injected peritumorally. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room. The injection is performed subendometrially around the lesion, or, if the uterine cavity was totally involved by disease, at 3, 6, 9, and 12 o'clock . The depth of needle placement is modulated by visualizing endometrial elevation during injection.
10129475|NCT04302727|Experimental|Med-South Weight Loss Intervention|The intervention will be delivered in 3 phases over 24 months: Phase I (4 months) provides a foundation for adopting and maintaining a healthful dietary pattern (Med-style, tailored for the southeastern United States); Phase II (8 months) focuses on weight loss; and Phase III (12 months) on maintenance of or continued weight loss, as appropriate.
10129476|NCT04302727|Active Comparator|Augmented Usual Care (WW)|The intervention that will be offered to control group participants is WW™ (formerly known as Weight Watchers). The study will provide access to the 'Workshop + Digital' option of WW™ during the 2 year intervention.
10129477|NCT04302805|Placebo Comparator|PE/rATG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg).
10129478|NCT04302805|Active Comparator|PE/rATG/IVIG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg) and IVIG 0.5g/kg intravenous infusions, on 1st, 3rd and 5th postoperative day. This is a center standard of care regimen.
10129479|NCT04303104|Active Comparator|Mobile ACF|Xpert Edge performed at point-of-care employing a low-cost panel van that is staffed by three health care workers. Patients identified with active TB will be initiated on TB treatment on the same day at the nearest clinic. On site HIV testing will also be offered. Thus, the interventional package is one of ACF + POC TB testing (TB testing by Xpert will occur on site at the van).
10129480|NCT04303104|Placebo Comparator|Centralised ACF|Similar to active arm but Xpert Ultra will be performed at a centralized laboratory (samples will be transported to the laboratory with results being available in a few days). Thus, the standard of care package is ACF + distant TB testing (TB testing by Xpert will occur at a distant laboratory site).
10129481|NCT04302948|No Intervention|Treatment as usual|TaU includes screening for anti-HCV using a rapid point-of-care (PoC) test to screen for exposure to HCV followed by counseling, brief education and referral to provider for further evaluation for HCV treatment.
10129482|NCT04302948|Experimental|Rapid PoC RNA testing|Intervention arm includes Tau ( screening for anti-HCV using a rapid point-of-care (PoC) test, and a rapid PoC screening test for HCV RNA, counseling plus, brief education and referral to a provider for further evaluation for HCV treatment. Rapid HCV RNA testing will be conducted using Cepheid Xpert (r) system.
10129483|NCT04302701|Experimental|Dichoptic arm|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
10129484|NCT04302701|Active Comparator|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near. Adherence to the treatment protocol will be assessed by having the parent call / send a message to an investigator at the start and end of the occlusion sessions completed each day, thus making the most as accurate as possible assessment of the patient's adherence to the prescribed treatment
10129485|NCT04303182|Active Comparator|Standard 3 port TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
10129486|NCT04303182|Active Comparator|LESS TEP|Group B will undergo laparoscopic TEP inguinal hernia repair with a single skin incision 2-3cm.
10129487|NCT04303091|Experimental|Exercise group|Single-arm study. Participants enrolled engaged in a 12-week exercise program.
10129488|NCT04302519|Experimental|Pulp mesenchymal stem cells|1. 3, 7 days to increase the injection of mesenchymal stem cells
10129489|NCT04302623|Experimental|Online yoga program|An 8-week online live facilitator-led yoga program.
10129490|NCT04302623|Experimental|Control|Advice only group.
10129491|NCT04302363||Control Group|Healthy controls must be 18-75 years old with no tumors and no history of cancer.
10129492|NCT04302363||Test Group|Inclusion criteria in the experimental group are age 18-75 years old, colonoscopy revealing colon or rectal tumor, biopsy-confirmed adenocarcinoma or adenoma, no chemotherapy or surgery, and no history of other cancer. Both groups must be able to understand and be willing to sign informed consent.
10129493|NCT04302532|Active Comparator|Clomiphene|clomiphene citrate 150 mg once a day for 5 days
10129494|NCT04302532|Experimental|clomiphene and coenzyme q10|clomiphene citrate 150 mg once a day for 5 days and coenzyme q 10 120 mg each day
10129495|NCT04302415||only liver metastasis|There is no other intervention, only clinical treatment.
10129496|NCT04302415||only lung metastasis|There is no other intervention, only clinical treatment.
10129497|NCT04302415||only brain|There is no other intervention, only clinical treatment.
10129498|NCT04302415||No distant metastasis|There is no other intervention, only clinical treatment.
10129499|NCT04302415||More than two organs metastasis|There is no other intervention, only clinical treatment.
10129500|NCT04302506||Patients with drug-induced liver injury|Patients who underwent liver biopsy and were diagnosed with drug-induced liver injury were diagnosed as DILI.
10129501|NCT04302649|Experimental|Intervention group|Patients received Peritoneal Equilibration Test (PET). In the intervention group, dialysate was warmed in a specific microwave oven calibrated to 37°C and infusion temperature was confirmed to be 37°C before infusion
10129502|NCT04302649|No Intervention|Control group|Patients received Peritoneal Equilibration Test (PET). In the control group, current practice was used (batch warming with a pad calibrated to 37°C) and dialysate temperature was measured just before infusion.
10129503|NCT04302389|Experimental|Lifestyle Modification Program|This 6-month intervention includes the use of three components: WW's mobile app, virtual workshops, and a private online community. The WW Program involves: self-monitoring of weight, dietary intake, and physical activity; making dietary changes; increasing physical activity; shifting to a more helpful mindset; and learning behavioral strategies to manage these goals. Each week, participants will set goals and weigh-in with a coach via virtual workshop. Participants will be encouraged to use the app and private online community daily and attend weekly virtual workshops. The weekly virtual workshop led by a trained WW Coach features a behavior change technique and enables the participant to practice it to support their goals. These are actionable techniques and strategies that are grounded in scientific research.
10129504|NCT04302402|Active Comparator|Rifaximin|Rifaximin 550mg thrice daily for 14 days Other Name: Normix
10129505|NCT04302402|Placebo Comparator|Placebo|Placebo thrice daily for 14 days
10129506|NCT04302441|Experimental|NXH group|Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).
10129507|NCT04302441|No Intervention|H group|Patients should receive trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year.
10129508|NCT04302688||modeling cohort|The 445 patients were grouped in chronological order.
10129509|NCT04302688||validating colort|The remaining 224 patients.
10129510|NCT04302376||Catheter-related thrombosis|The presence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
10129511|NCT04302376||No catheter-related thrombosis|The absence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
10129512|NCT04302675|Experimental|Prevention, Maternal Immunization|
10129513|NCT04302337|Active Comparator|Conventional Curettage Adenoidectomy|Adenoidectomy with Beckmann Adenoid Curette
10129514|NCT04302337|Experimental|Curettage Adenoidectomy With Transoral Endoscopic Ablation|Transoral endoscopic adenoidectomy with Coblator 2 system
10129515|NCT04302571|No Intervention|Healthy control|Voluntary subjects without peripheral arterial disease
10129516|NCT04302571|Sham Comparator|IC patients, no exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, given advices to perform regular aerobic activity
10129517|NCT04302571|Active Comparator|IC patients, exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, home-based combined physical exercise
10129518|NCT04302597|Active Comparator|Staples|Women who underwent repeated cesarean section with skin closure using staples.
9967794|NCT01273376|Experimental|RX-10100 low dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
10129519|NCT04302597|Experimental|Tissue adhesive|Women who underwent repeated cesarean section with skin closure using 2-octylcyanoacrylate tissue adhesive.
10129520|NCT04302584|Active Comparator|NE|patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)
10129521|NCT04302584|Active Comparator|NE/VP|patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)
10129522|NCT04302610|Experimental|HME MASK|During the Exercise, participants wore either an HME mask (MASK) (ColdAvenger® expedition balaclava, USA, www.coldavenger.com)
10129523|NCT04302610|Sham Comparator|SHAM mask|a sham mask (SHAM) which was the same HME mask with holes cut across the entire ventilator cup and the ventilator removed
10129524|NCT04302610|No Intervention|Control|No mask (CONT) wearing only the balaclava to which the HME and SHAM mask were attached. Mouth and face not covered.
10129525|NCT04302480|Experimental|Alternative smoking products (ASP)|
10129526|NCT04302480|Active Comparator|Sugar-sweetened beverages (SSB)|
10183778|NCT03761342|Experimental|Nutri-Score|Similar to Arm 2, with Nutri-Score labels instead of MTL labels displayed on all products FOP. A 60-second introductory video briefly explaining the NS scheme will be shown to shoppers in this condition.
9967795|NCT01273376|Placebo Comparator|Placebo|Matching placebo is to be given orally, in tablet form, twice daily, for 8 weeks
10129527|NCT04302350|Active Comparator|group A 100% O2|After the targeted segment bronchus, artery, and intrasegmental vein were identified and dissected by ligation or stapler cutting, the sputum suction operation was performed on the healthy and surgical lungs,by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate of the ventilator (group A is 100% O2 ), adjust the APL valve to 20cmHg, so that the storage gas bag is filled with test gas, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg, after the lungs where the target segment is completely expanded, perform pure oxygen mechanical single lung ventilation, waiting for clear presentation of the plane between segments.
10129528|NCT04302350|Experimental|group B 75% N2O|After the surgeon has finely dissected the target artery, vein, and bronchi, accurately judged and processed it,and the patient with the end-of-breath carbon dioxide sampling tube on the monitor was terminated to a portable TD600-SH-N2O detection end of the nitrous oxide concentration detector to measure the test gas concentration (express in vol%), by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate to 1 and N2O flow rate of the ventilator to 3( group B 75% N2O), adjust the APL valve to 20cmHg, making the N2O concentration detector reach the predetermined gas concentration, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg.
10129529|NCT04302350|Experimental|Group C 50% N2O|After the surgeon has finely dissected the target artery, vein, and bronchi, accurately judged and processed it, and the patient with the end-of-breath carbon dioxide sampling tube on the monitor was terminated to a portable TD600-SH-N2O detection end of the nitrous oxide concentration detector to measure the test gas concentration (express in vol%), by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate to 1 and N2O flow rate of the ventilator to 1( group C 50% N2O), adjust the APL valve to 20cmHg, making the N2O concentration detector reach the predetermined gas concentration, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg.
10129530|NCT04302467|Experimental|GDFT group|Fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, when SVV>13%, 4 mL/kg bolus of hydroxyethyl starch will be infused within 5 min. If SVV falls below 13%, the bolus will be suspended. If SVV is still more than 13%, 100 μg of phenylephrine will be administered when CI is more than 2.5 L/min/m2, 1 mg of dopamine will be administered when CI is less than 2.5 L/min/m2. When SVV<13%, but mean arterial pressure (MAP)<65 mmHg, 8 μg of norepinephrine will be administered. The hemodynamic status will be repeatedly measured every 10 min.
10129531|NCT04302467|Experimental|restrictive fluid therapy group|fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, hydroxyethyl starch will be infused to supply blood loss, the ratio of hydroxyethyl starch to blood loss is 1:1. 0.01-0.1 μg/kg/min of norepinephrine will be administered to maintain MAP>65 mmHg.
10129532|NCT04302298|Experimental|Virtual Reality Group|This group will go through the virtual reality simulation of a procedure prior to doing it on a plastic SawBone.
10129533|NCT04302298|No Intervention|Technique Guide Group|This group will go be able to read through a technique guide on the procedure prior to doing it on a plastic SawBone. This is the current method of learning in surgical residencies.
10129534|NCT04302116|Experimental|Combination therapy with vigabatrin and prednisolone|"Vigabatrin (tablet of 500 mg) dose based on weight divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment. Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks.~Prednisolone (tablet of 5 mg), 40 mg of prednisolone (10 mg oral 4 times a day) for 14 days. Prednisolone will be increased to 60 mg/day (20 mg oral 3 times a day) if seizures still occur at Day 7 or recur within Day 8 - 14. Then, prednisolone will be reduced every 5 day until completely off within 1 month. Total prednisolone duration is 1 month."
10129535|NCT04302116|Active Comparator|Vigabatrin alone|"Vigabatrin (500 mg/tab) dose will be calculated on weight basis divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment.~Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks."
10183779|NCT03761329|Active Comparator|Bier's block|Upperarm intravenous regional anesthesia (Bier's block) with lidocaine 0.5% 40ml
10183780|NCT03761329|Experimental|Mini-Bier's block|Forearm intravenous regional anesthesia (mini-Bier's block) with lidocaine 0.5% 25ml
10183781|NCT03761316||FBSS patients|patients with Failed Back Surgery Syndrome, eligible for SCS
10183782|NCT03761303|Active Comparator|active rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
10183783|NCT03761303|Sham Comparator|sham rTMS|Patients in the control group receive sham rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
10183784|NCT03761264|Experimental|Intra-canal Odontopaste®|Single visit placement of Odontopaste®
10183785|NCT03761264|Active Comparator|Intra-canal Pulpdent|Single visit placement of Pulpdent
10183786|NCT03761264|Active Comparator|Oral Amoxicillin|Amoxicillin 15mg/kg tds for 5 days
9967796|NCT01273402|Experimental|TF2 and IMP288|TF2 will be administered at least 4 days before the radiolabeled IMP-288.
9967797|NCT01273415||hormone receptor-positive breast cancer|postoperative hormone receptor-positive breast cancer
9967798|NCT01273428|Active Comparator|HP011-101|
9967799|NCT01273428|Active Comparator|HP828-101|
9967800|NCT01273428|Other|Standard Care|
9967801|NCT01273441|Active Comparator|Sequential treatment:|
9967802|NCT01273441|Experimental|Concomitant treatment|
9967803|NCT01273454||001|OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
10129536|NCT04302194||Patients with Phenylketonuria|
10129537|NCT04302194||normal healthy children|
10129538|NCT04302220||high myopia|Population who have high myopia.
10129539|NCT04302129|Experimental|ultrasound guided erector spinae block and general anaesthesia|Ultrasound guided erector spine plane block is done after general anaesthesia and prone positioning
10129540|NCT04302129|Active Comparator|Multimodal analgesia with general anaesthesia|Multimodal analgesia given with general anaesthesia in form of ketorolac and paracetamol
10129541|NCT04302142|Experimental|Intervention group|
10129542|NCT04302142|Placebo Comparator|Control Group|
10129543|NCT04302259|Experimental|SCI Patient|Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10
10129544|NCT04301999|Active Comparator|PDT group|Patients in PDT group underwnt PDT
10129545|NCT04301999|Experimental|RFA group|Patients in RFA group underwent RFA
10129546|NCT04302155|Experimental|Nintendo Wii|Balance-specific exer-games focusing on dynamic aspects of center of pressure (COP) on Wii fit system.
10129547|NCT04302155|Experimental|Traditional|Mini trampoline two balance exercises of 6 minutes on mini trampoline for a total duration of 3 min on each leg Inflatable discs 4 balance exercises of 12 minutes on BOSU ball 6 minutes on rounded side and 6 minutes on rigid side.
10129548|NCT04302285|Experimental|Exercise trial|In this trial, participants were asked to exercise for one hour under controlled laboratory conditions. Participants were exercising on the treadmill at speed and grade corresponding to 60% of their V̇O2max. Participants were wearing a HR monitor and a face mask while exercising, connected to indirect calorimetry equipment. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
10129549|NCT04302285|Experimental|Control trial|In this trial, participants were asked to rest for one hour. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
10129550|NCT04301960|Experimental|Single task group|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
9827437|NCT02455076|Active Comparator|Basal bolus regimen inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
10129551|NCT04301960|Experimental|Dual-task|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
10129552|NCT04301947|Active Comparator|Standard warm-up protocol|The standard warm-up protocol consists of 5 (five) minutes of stationary cycling, followed by calf, hamstring and quadriceps stretching. For all stretching positions 30 (thirty) seconds will be set. For calf stretching, the participant places his hands on the waist and projects his dominant limb behind of the center of mass line, the contralateral limb will be placed forward until the stretch sensation on the dominant limb start. For hamstring stretching, the participant will be instructed to bend over the hip, reaching the foot of the dominant limb in dorsiflexion. Emphasis will be placed on maintaining the heel of the dominant limb on the floor and maintaining posture. Finally, for quadriceps stretching, the participant will perform a knee flexion and will hold the dominant lower limb foot close to the gluteus with the ipsilateral upper limb hand. Emphasis will be placed on maintaining trunk posture.
10129553|NCT04301947|Experimental|Gluteal activation warm-up|"The gluteal activation warm-up protocol consists of performing a standard warm-up protocol with additional shell exercise. The shell exercise will be performed with the participant side-lying with hip and knee flexed, an elastic band (PREFORM BETTER Inc. Rhode Island, USA) will be placed around the distal thigh to promote resistance and the participants will be instructed to perform hip abduction movements. The exercise will be performed in multiple sets (3 sets) of 12 repetitions, with 30 seconds interval between exercises in order to minimize the fatigue effect. Medium and heavy elastic bands tensions will be used and adjusted according to the effort perception parameter from the OMNI scale for effort perception for resistance training."
10129554|NCT04301908||antiviral therapy group|Patients with chronic hepatitis B and cirrhosis were treated with antiviral drugs
10129555|NCT04302090|Experimental|pain level changes according to the use of the Winner flow|"each included patient will experience :~a period of consecutive spontaneous uterine contractions without using the regulated expiration mouthpiece~a period of consecutive uterine contractions managed by the regulated expiration method using the Winner flow"
10129556|NCT04301921|Other|Group 1|Traditional puncture site + no anticoagulation
10129557|NCT04301921|Other|Group 2|Traditional puncture site + ACT-guided anticoagulation
10129558|NCT04302038|Experimental|Potato protein|Participants will be provided with 25 g of potato protein twice per day in addition to a diet set at the recommended daily allowance. Total protein intake for this group will be 1.6 g/kg/day
10129559|NCT04302038|Placebo Comparator|Control group|This group will consume protein from food sources set at 0.8 /kg/day including 2 pudding placebo cups per day.
10129560|NCT04301973|Other|Healthy people|
10129561|NCT04302181|Experimental|Stellate Ganglion Block|One time administration of a stellate ganglion block
10129562|NCT04301986|Experimental|TNE Followed by EGD|Subjects will undergo administration of a transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
10129563|NCT04301986|Experimental|Cytosponge, then TNE, followed by EGD|Subjects will undergo administration of Cytosponge and transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
10129564|NCT04301895|Other|Interactive|Subject will be asked to continually interactive with the investigators, answering a series of standard questions during the remifentanil infusion and recovery periods.
10129565|NCT04301895|Other|Non-interactive|All verbal interaction will be avoided and extraneous sounds will be eliminated from the environment during the remifentanil infusion and recovery periods.
10129566|NCT04302233|Experimental|New pharmaceutical support (NPS)|"An NPS is an interview comprising the following elements:~The delivery of the identification sheet of their implants with:~a quiz to focus the patient's attention~a description of the characteristics of their prosthesis using a specific photo of their implant~a presentation of the medical device vigilance.~an explanation of the value of the identification sheet for their implant, An in-depth presentation of an information booklet on living at home with their prosthesis and on medical and paramedical monitoring.~For patients in orthopedic surgery: a booklet specific to their prosthesis and the surgical approach For plastic surgery patients, the information sheets published by the French Society of Plastic Reconstructive and Aesthetic Surgery (SOF.CPRE).~A time to answer any questions the patient may have"
10129567|NCT04302233|No Intervention|Usual pharmaceutical support (UPS)|"An UPS is an interview comprising the following elements:~The delivery of the same patient-implant sheet as in arm 1, but without additional oral information.~The delivery and oral presentation of the same booklet as practiced in the arm 1 (NPS).~And a time to answer any questions from the patient months"
10129568|NCT04301882||interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
10129569|NCT04301882||direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
10129570|NCT04301869|Active Comparator|Intravenous therapy|Intravenous antibiotics administered for pleural space infection
10129571|NCT04301869|Active Comparator|Oral therapy|Oral antibiotics administered for pleural space infection
10129572|NCT04301674||Occupational Asthma|Patients refered for assesment of occupational asthma
10129573|NCT04301674||Respiratory Healthy Control|Employees at Oslo University Hospital
10129574|NCT04301544|Experimental|INDAK & Standardized Vascular Care Group|The experimental arm will receive training on the ballroom dance modules called INDAK (Improving Neurocognition through Dance and Kinesthetics), nutrition counseling and vascular risk management
10129575|NCT04301544|Active Comparator|Standardized Vascular Care Group|The control group will receive nutrition counseling and vascular risk management
10129576|NCT04301479|Active Comparator|Steroid|Patients assigned for steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
10129577|NCT04301479|Placebo Comparator|Control|Patients assigned for control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
10129578|NCT04301492|Experimental|Vortioxetine|first visit medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit (Week 1 - Visit 2) to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day (Visit 3- Phone contact). At Week 4-8-12 (Visits 4-5-6) patients will return to the site to perform all clinical evaluations required and to receive study drug. Visit 7 subjects will return to the site to perform all the assessment required by protocol.
10129579|NCT04301505|No Intervention|control|Usual care.
10129580|NCT04301505|Other|Intervention 1|COPD management checklist will be delivered at the beginning of the study.
10129581|NCT04301505|Other|Intervention 2|COPD management checklist will be delivered at the beginning of the study and repeated after 6 months.
10129582|NCT04301804|Experimental|Dose level 1|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 1
10129583|NCT04301804|Experimental|Dose level 2|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 2
10129584|NCT04301804|Experimental|Dose level 3|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 3
10129585|NCT04301648|Active Comparator|Common Practice|Patients included in the phase before will receive common practice.
10129586|NCT04301648|Experimental|STAR Nurse|Patients included in the phase after will receive care by a STAR Nurse.
10129587|NCT04301700|Experimental|relaxation|The progressive muscle relaxation intervention, designed by Jacobson (1987), will be consist of sessions involving straining and relaxing all muscle groups from head to foot with deep breathing and last for 20 min. The patients will be asked to tense a very muscle group for 5 s and relax after counting up to 10 s while breathing out. In this way, facial, head, neck, shoulders, arms, chest, abdomen, legs, hips, feet and fingers muscles are stretched and relaxed on purpose for relaxing in patients with COPD.
10129588|NCT04301700|Experimental|mindfulness meditation|The research team closely will be following the mindfulness meditation intervention, developed by Kabat-Zinn, Lipworth, and Burney (1985), which is a part of the mindfulness-based stress reduction program. Mindfulness meditation is including interventions such as yoga, body scan, walking meditation, and sitting meditations. In the present study, the researchers will prefer sitting meditation. In this context, the second co-author will want patients to sit up in the chair in an upright and comfortable position. The patients will focus on deep breathing and felled the breath flowing throughout their body during the interventions that will last for 20 min in each session.
9827438|NCT02455076|Active Comparator|Exenatide outpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
9967804|NCT01273467|Experimental|001|CNTO 0007 or placebo (Stage A) a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
9827439|NCT02455076|Active Comparator|Insulin Only|Patients with Type 2 Diabetes will be treated with Insulin only
9967805|NCT01273467|Experimental|002|CNTO 0007 or placebo (Stage B) a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
9967806|NCT01273480|Experimental|002|Sequence 2 Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
9967807|NCT01273480|Experimental|001|Sequence 1 Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
9967808|NCT01273493|Experimental|Trabectedin 1.3 mg/m^2 plus Dexamethasone|Control group Trabectedin 1.3 mg/m^2 i.v.will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
9967809|NCT01273493|Experimental|Trabectedin 0.58 mg/m^2 plus Dexamethasone|Hepatic dysfunction group Trabectedin 0.58 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
9967810|NCT01273506|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose
9967811|NCT01273506|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose
9967812|NCT01273532|Experimental|001|tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose
9967813|NCT01273532|Experimental|002|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
9967814|NCT01273545||001|PRILIGY (dapoxetine hydrochloride) The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists and in Italy by urologists
9967815|NCT01273558|No Intervention|Part 1: no Intervention|In Part 1 of the study, patients will not receive any study drug.
9967816|NCT01273558|Experimental|Part 2: canagliflozin|In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.
9967817|NCT01273571|Experimental|001|Canagliflozin/Metformin Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8 followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
9967818|NCT01273584|Active Comparator|Metformin|"Tablet Metformin 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
9967819|NCT01273584|Placebo Comparator|Placebo|"Tablet Placebo 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
9967820|NCT01273610|Experimental|Lapatinib and trastuzumab|Patients receive lapatinib ditosylate PO QD and trastuzumab IV once weekly OR once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9967821|NCT01273649|Experimental|ice, rate of force development|to monitor the long term effect of cryotherapy in rate of force development.
9967822|NCT01273662|Experimental|Axitinib|
9967823|NCT01273688|Active Comparator|Eccentric training only|Eccentric training only active control group (Flex-Bar)
9967824|NCT01273688|Experimental|Eccentric training and elbow brace|Combined eccentric training (Flex-Bar) and elbow brace (Epi-Hit)
9967825|NCT01273701|Experimental|TSTSU-N|TSTSU-N stands for Treatment for Schedule Two Substance Use, No Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-N will not receive telephone reminding before each visit.
9967826|NCT01273701|Experimental|TSTSU-T|TSTSU-T stands for Treatment for Schedule Two Substance Use, Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-T will receive telephone reminding before each visit.
9967827|NCT01273701|Active Comparator|OPD|OPD stands for Outpatient Department. Subjects in this arm will be methamphetamine users who voluntarily visit psychiatric clinics for treatment of mental disorders in National Taiwan University Hospital, Yunlin Branch. They will be referred to this study by their treating psychiatrists.
9967828|NCT01273714|Active Comparator|BST|bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each)
9967829|NCT01273714|Experimental|TT|extracapsular total thyroidectomy
9967830|NCT01273727|No Intervention|No Ozurdex|Arm 1(control) - Patients who have had epi-retinal membrane peeling and have macular edema at least 3 months (90 days) after surgery. These patients will followed without Ozurdex. The patients will be treated with current standard of care, including topical and intravitreal or subtenon's medication.
9967831|NCT01273727|Experimental|Ozurdex 3 months after surgery|Patients who have had epi-retinal membrane peeling and have residual macular edema 3 months after surgery. These patients will receive an Ozurdex implant
10129589|NCT04301700|No Intervention|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
10129590|NCT04301856||CF children treated with CFTR modul|Cystic fibrosis patients under 18 years treated with CFTR modulators according to french health recommendations observational cohort study
10129591|NCT04301661||ABC/3TC Cohort|"Persons on abacavir/lamivudine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
10129592|NCT04301661||TAF/FTC Cohort|"Persons on tenofovir alafenamide/emtricitabine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
10129593|NCT04301661||Switch Cohort|"Persons switching from abacavir/lamivudine-containing therapy as part of their standard HIV care will change to their newly prescribed regimen.~Participants will be on study for 3 weeks, and will have blood drawn at Days 0, 1, 3, 7, 10, 14, 18, and 21 following their switch."
10129594|NCT04301739|Experimental|HLX10 + chemotherapy→ HLX10|HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9 cycles)
10129595|NCT04301739|Placebo Comparator|Placebo + chemotherapy→ Placebo|Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → Placebo (9 cycles)
10129596|NCT04301518|Experimental|PTB Prevention|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the PTB Prevention arm will receive the PreTRM® test results. If high risk, women will be consented to take part in the intervention. Those not higher risk will continue on with standard of care.
10129597|NCT04301518|No Intervention|Control|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the Control arm will not receive the PreTRM® test results. Control arm subjects will continue on with standard of care.
10129598|NCT04301752||Neurobrucellosis|Brucellosis associated with neuropsychiatric manifestations
10129599|NCT04301752||Non-neurobrucellosis|Brucellosis not associated with neuropsychiatric manifestations
10129600|NCT04301596||SSc patients|
10129601|NCT04301466|Experimental|Qi Zhi Tong Luo group|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. Each capsule was weighted 0.5g. Qi Zhi Tong Luo capsule (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
10129602|NCT04301466|Placebo Comparator|Placebo group|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
10129603|NCT04301531|Experimental|Arm 1 (intervention arm)|Arm 1 or the intervention arm will involve seven communities: 4-monthly mass screening, and treatment of those who test positive by CHWs will be conducted. Febrile cases will be tested and treated by CHWs any time
10129604|NCT04301531|Other|Arm 2 (control arm)|Arm 2 or the Control arm will involve 2 communities: mass screening and treatment only done at baseline and at evaluation. Febrile cases will be tested and treated by CHWs any time.
10129605|NCT04301583|Active Comparator|Procyanidin B2 enriched cocoa|Participants receiving cocoa capsules
10129606|NCT04301583|Placebo Comparator|Placebo group|Participants maltodextrin capsules
10129607|NCT04301557|Experimental|PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC|Induction regimen: Capeox+PD1 antibody for 1 cycle, Concurrent chemoradiotherapy regimen: Capeox+PD1 antibody for 2 cycles and concurrent , Interval regimen: Capeox+PD1 antibody for 1 cycle, TME surgery or watch and wait for cCR patients Adjuvant regimen: Capeox+PD1 antibody for 2 cycles, Capecitabine+PD1 antibody for 2 cycles
10129608|NCT04301570|Other|Ultrasound|The intervention measurement is the determination of bone age using the ultrasound device.
10129609|NCT04301570|Other|XR|The control measurement is the determination of the bone age by the imaging method using X-rays.
10129610|NCT04301609|Active Comparator|ImmunoVita®|250 mg Yeast beta-glucan + 3.75 microg Vitamin D3 + 1.05 mg Vitamin B6 + 7.5 mg zinc)
10129611|NCT04301609|Placebo Comparator|Placebo|473,2 mg microcristalline cellulose + 0,06 mg Brown Oxide dye + 0,27 mg yellow A oxide dye
10129612|NCT04301726|Experimental|Deutetrabenazine|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
10129613|NCT04301726|Placebo Comparator|Placebo|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
10129614|NCT04301427|Other|Obese patient|
10129615|NCT04301635||Preoperative (Pre-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, preoperative
10129616|NCT04301635||Postoperative (Post-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, postoperative
10129617|NCT04301440|Active Comparator|patients with anxious and / or depressive characteristics : treated group|patients with anxious and / or depressive characteristics, The device with the electromagnetic wave will be connected
10129618|NCT04301440|Placebo Comparator|patients with anxious and / or depressive characteristics : placebo group|The device with the electromagnetic wave will not be connected
10129619|NCT04301349|Experimental|vaginal dinoprostone|vaginal dinoprostone 6 mg (two tablets) 3 hours prior to IUD insertion
10129620|NCT04301349|Active Comparator|vaginal misoprostol|vaginal misoprostol 400 mcg (two tablets) 3 hours prior to IUD insertion
10129621|NCT04301349|Placebo Comparator|placebo|two tablets of placebo similar in shape ,color, odor to the study drugs
10129622|NCT04301245||ETEP group|Exercise Training and Educational Program (ETEP) group. Patients who accepted the educational program in addition to the exercise training.
10129623|NCT04301245||ET group|Exercise Training (ET) group. Patients who refused the educational program and did only the exercise training.
10129624|NCT04301141|Experimental|Virtual Reality Assisted Cognitive Behavioural Therapy|Between 8 to 20 individual in-person sessions of VR-assisted CBT will be delivered on a weekly basis by NHS therapists who are trained in delivering CBT to this patient group.
10183787|NCT03761251|Experimental|Pet Fish|Participants will be instructed to partner thrice daily and once weekly fish care activities with diabetes care activities for 3 months
10129625|NCT04301336|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
10129626|NCT04301336|Experimental|Vit-D experimental group|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
10129627|NCT04301336|Experimental|Zinc supplements experimental group|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
10129628|NCT04301336|Experimental|Statin experimental group|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
10129629|NCT04301336|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.~in addition, Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response in addition, Morphine medication as a pain killer is administered, if Patient weight <50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.~This group received regular blood transfusion session."
10129630|NCT04301037|Active Comparator|Tension band wiring|This group was treated by k-wires fixation and tension band wiring
10129631|NCT04301037|Active Comparator|Cannulated screws|This group was treated by 2 cannulated screws
10129632|NCT04301063||RV3278A arm|"study product RV3278A is applied twice a day on the face during the whole study.~In case of reaction resulting from the use of the product, the subject will inform the investigator who will explain to him/her what to do : application reduction or stop applications for a while"
10129633|NCT04301024||nitrous oxide misusers|nitrous oxide misusers among the teenagers consulting in an addictology center dedicated to young drug users in Montpellier
10129634|NCT04301232||Fast-Track Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Patients who fulfilled criteria of all scoring systems were defined as eligible for PACU by-pass (fast-tracking) and transferred into phase II recovery area in the ward without observation in PACU (Group FT = Fast Track;)
10129635|NCT04301232||PACU Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Ineligible patients were taken into PACU where their treatments were continued until discharge criteria were achieved (Group PACU)
10129636|NCT04301115|Active Comparator|conventional group|conventional partial denture
10129637|NCT04301115|Experimental|attachment group|unlateral attachment retained partial denture
10129638|NCT04301115|Experimental|tooth implant supporeted prosthesis|tooth implant supported bridge
10129639|NCT04301167|Experimental|Single group|An AB single-case experimental design will be used. An RCT would be inappropriate since the befriending intervention is known to improve wellbeing. As such participants will have data collected in a pre- and post-intervention phase, for a maximum of 13 time points. This approach has been identified by What Works Clearinghouse as an acceptable empirical design to include in evidence based practice reviews (Kratchowill et al., 2010).
10129640|NCT04301193|Other|Pregnant Women|All subjects will have the same intervention. Samples will be taken and manipulated in the laboratory for use of the Hemosonic Qauntra Analyzer
10129641|NCT04301206|Experimental|Intervention: Receiving video material|The parents who accepts to participate and receives videos and action cards by sms
10129642|NCT04301206|No Intervention|Control group|The parents who accepts to participate, but proceed to 1813 and do not receive videos and action cards
10129643|NCT04301284|Experimental|CAD-1883|"Capsules of 150 mg of CAD-1883 will be administered orally, twice daily (BID). The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.~The initial dose regimen evaluated will be 150 mg BID. Additional dose regimens up to 600 mg BID will be determined based on forthcoming clinical data."
10129644|NCT04301284|Placebo Comparator|Placebo|Matching placebo will be provided in capsules, to be administered orally, twice daily. The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
10129645|NCT04301401|Experimental|Patients being evaluated for changes in microbiota|Patients being evaluated for changes in vaginal microbiota following transvaginal surgery.
10129646|NCT04301388|Experimental|TVCL-based|Monitor progression of labor by shortening of cervix examined by transvaginal cervical length
10129647|NCT04301388|Active Comparator|Conventional-based|Monitor progression of labor by per vaginal exam to detect cervical change
10129648|NCT04301323|Experimental|BHVI1|BHVI1 eye drops
10129649|NCT04301323|Experimental|BHVI2|BHVI2 eye drops
9826037|NCT02404649|Active Comparator|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
9827440|NCT02455167|Experimental|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
10129650|NCT04301323|Experimental|BHVI3|Combination of BHVI1 and BHVI2 eye drops
10129651|NCT04301323|No Intervention|Non-randomized control group|a separate control group including 105 children enrolled and followed with only single-vision spectacles.
10129652|NCT04300959|Experimental|Experimental group|Anlotinib in combination with Sintilimab with Gemcitabine plus(+)Cisplatin
10129653|NCT04300959|Active Comparator|Control group|Standard platinum-based chemotherapy
10129654|NCT04300972|Other|fixed dose|
10129655|NCT04300972|Experimental|weight and body type adapted dose|
10129656|NCT04301128|Experimental|EXPERIMENTAL GROUP|Patients in the experimental group were able to install and set up mobile application on android phones via Bluetooth and were informed about the sick android application. Patients were reminded and guided by subcutaneous anti-TNF drug treatments from mobile application. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales.
10129657|NCT04301128|Active Comparator|CONTROL GROUP|An anti-TNF drug administration training booklet were given to patients in the control group and were required to take advantage of the booklet on subcutaneous anti-TNF drug production. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales. At the end of the study (twenty forth week) was applied to all patients.
10129658|NCT04301050|Experimental|Yoga Intervention|Participants will complete 8-week course (75-minute, weekly yoga classes) delivered online via videoconferencing software. Participants will complete patient-reported outcomes at baseline (prior to class 1) and post-intervention (after class 8), as well as post-intervention measures of feasibility/acceptability.
10129659|NCT04301375|Experimental|Study treatment|
10129660|NCT04300842||Cancer patient|This project expects to enroll 60 cancer patients and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
10129661|NCT04300842||Healthy population|This project expects to enroll 60 healthy population and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
10129662|NCT04300907|Experimental|Provant Infinity Therapy|Open-label treatment with Provant Infinity Therapy
10129663|NCT04300946||TMS on the cerebellum followed by placebo TMS|TMS preceding the time prediction and language tests
10129664|NCT04300946||Placebo TMS followed by TMS on the cerebellum|TMS preceding the time prediction and language tests
10129665|NCT04300946||TMS on the cerebellum set in time on waiting periods|
10129666|NCT04300946||TMS on the cerebellum not set in time on waiting periods|
9826038|NCT02404792|Active Comparator|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
10129667|NCT04300829|Experimental|Simple hygiene rules of the site + Cicaderma ointment|Hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and Cicaderma ointment application)
10129668|NCT04300829|Active Comparator|Preventive standard cares|Preventive standard cares of the site including hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and a maximum of one topical treatment
10129669|NCT04300933|Experimental|Neurofeedback therapy|Fifty participants conduct neurofeedback daily for 5 days.
10129670|NCT04300686|Active Comparator|Tocilizumab|This group of 20 TAK cases are prescribed with tocilizumab (Dose: 8mg/kg. qm. ivgtt.) for 24 weeks.
10129671|NCT04300686|Experimental|Adalimumab|This group of 20 TAK cases are prescribed with adalimumab (Dose: 40mg.bim.IH.) for 24 weeks.
10129672|NCT04300712|Other|Tracking of the children with difficulties|All parents and teachers will respond to the questionnaires and the beginning and end of school year which is not done in the routine for tracking the children in difficulty.
10129673|NCT04300582|Active Comparator|Standard pharmaco-invasive strategy|Cardiac catheterization 3 to 24 hours after thrombolytic completion in STEMI patients.
10129674|NCT04300582|Experimental|Fast pharmaco-invasive strategy|Cardiac catheterization less than 3 hours after thrombolytic completion in STEMI patients.
10129675|NCT04300517|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
10129676|NCT04300517|Placebo Comparator|maltodextrin|Control patients will be received protein diet (1.2 g/kg/day) and maltodextrin for 1 month after surgery.
10129677|NCT04300569||Patients and Caregivers: Overall Population|"Overall population of this study will include both patients with ISWRD associated with AD-D, AD-D with CVD, and/or VaD, and care givers of patients. Patients and caregivers will undergo all study procedures. Caregivers may care either for a patients who undergo all study procedure (including interview) as well for patients who do not undergo any study procedures but give consent or assent for the use of their medical records in the study (non-interviewed patient)."
9967832|NCT01273727|Experimental|Ozurdex 6 months or longer after surgery|Patients who have had epiretinal membrane peeling and have residual macular edema at least 6 months after surgery
10129678|NCT04300881|Experimental|Treatment|Eplerenone
10129679|NCT04300881|No Intervention|Control|
10129680|NCT04300777||Treated with Non-Cervical Pedicle Screw Systems|
10129681|NCT04300764|No Intervention|Control|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Control participants' steps will be passively monitored. Data will continue to be collected for 30 days after discharge.
10129682|NCT04300764|Experimental|Gamification Intervention|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Intervention patients will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Data will continue to be collected for 30 days after discharge.
10129683|NCT04300725|No Intervention|Verbal Counseling|Patients in one study arm receive only verbal counseling prior to their induction of labor.
10129684|NCT04300725|Experimental|Video Counseling|Patients in other study arm will receive verbal + video counseling prior to their induction of labor.
9826039|NCT02404792|Experimental|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
9967833|NCT01273740|Experimental|External support|Bypass graft with external support
9967834|NCT01273740|Experimental|No external support|Bypass with graft without external support
9967835|NCT01273753|Active Comparator|Exercise|After baseline measurements, all subjects will undergo a phase involving intradialytic exercise. Subjects will serve as their own controls.
9967836|NCT01273779|Placebo Comparator|Placebo|
9967837|NCT01273779|Experimental|Talactoferrin alfa|
9967838|NCT01273792||Patients with Susac syndrome|
9967839|NCT01273792||Matched healthy controls|
9967840|NCT01273831|Other|atracurium|Patients who underwent general anesthesia received atracurium
9967841|NCT01273831|Other|cisatracurium|Patients who underwent general anesthesia received cisatracurium
9967842|NCT01273844|Experimental|Bortezomib|Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
9976681|NCT01354041|Experimental|Acceptance and Commitment Therapy|"Participants in the intervention arm will receive seven sessions of a mindfulness and values-based living intervention, led by a trained licensed facilitator, conducted in groups of 10-12 participants and include components specifically designed to reduce FCR. The intervention arm will include six weekly 90 minute group sessions and one followup 90 minute group session booster session held three weeks later. The group sessions will be interactive and experiential and include homework practice for generalizing skills."
9976682|NCT01354054|Experimental|High frrequency TENS|100 Hz TENS, 100 usec
9976683|NCT01354054|Experimental|Low frequency TENS|4 Hz, 100 usec TENS
9976684|NCT01354054|Experimental|Placebo TENS|100 Hz, 100 usec, set at motor minus 10% then ramps to off in 45 sec, 40 minutes
9976685|NCT01354054|No Intervention|Control|Age matched controls, no intervention
9976686|NCT01354067|Active Comparator|Control group|The control group will receive standardized patient education four times, once every two weeks, during the eight week intervention period.
9976687|NCT01354067|Experimental|High-repetitive single limb training|The experimental group will receive a high-repetitive single limb exercise regime, three times a week for two months. In addition, the exercise group will receive patient education at four occasions during the intervention period.
9976688|NCT01354080|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
9976689|NCT01354080|Active Comparator|classical massage|In this group of patients classical massage sessions were applied
9976690|NCT01354093||MacTel Type 2 20 mg/day dose group|Participants will have macular telangiectasis type 2 as confirmed by the reading center. Participants will take 20 mg of zeaxanthin per day.
9976691|NCT01354093||MacTel Type 2 10 mg/day dose group|Participants will have macular telangiectasia type 2 as confirmed by the reading center. Participants will take 10 mg of zeaxanthin per day.
9976692|NCT01354119|Active Comparator|Early intervention|Early intervention: stent-graft just after acute phase
9976693|NCT01354119|No Intervention|Conservative|Conservative: medial follow-up without early intervention
9976694|NCT01354158|Experimental|Droxidopa|The dose-titration response to ascending doses of Droxidopa (placebo, 100mg, 200mg, 400mg) will be measured four separate days.
9976695|NCT01354171|No Intervention|TRUS guided biopsy|
9976696|NCT01354171|Experimental|MRI Assisted TRUS guided biopsy|
9826040|NCT02404805|Experimental|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
9826041|NCT02404805|Experimental|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
9826042|NCT02404805|Experimental|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
9976697|NCT01354184|Experimental|CRD007 10 mg tablet|
9976698|NCT01354184|Experimental|CRD007 25 mg tablet|
9976699|NCT01354184|Experimental|CRD007 40 mg tablet|
9976700|NCT01354184|Placebo Comparator|CRD007 matching placebo tablet|
9976701|NCT01354236||School dropouts|Students who quit school without graduation
9976702|NCT01354236||Controls|Normally enrolled students matched for age, gender, school and educational level
9976703|NCT01354249|Placebo Comparator|water|Patients will receive water 3h before operation in the same volume of the study group
9976704|NCT01354249|Experimental|whey protein plus carbohydrate|The CHO-P group will receive 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
9976705|NCT01354262|Experimental|Lower dose vitamin D|Fixed daily doses of 600 IU vitamin D oral supplementation.
9976706|NCT01354262|Experimental|Higher dose vitamin D|50,000 IU supplementation bi-monthly.
9976707|NCT01354262|No Intervention|Control Group|Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.
9976708|NCT01354275|Active Comparator|GnRH Agonist|oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
9976709|NCT01354275|Active Comparator|GnRH Agonist Arm|Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach >17 mm hCG will be administered.
9976710|NCT01354288|Experimental|Therapeutic education|
9976711|NCT01354288|No Intervention|Classical management|
9976712|NCT01354301|Experimental|Thymoglobulin and everolimus|single dose antithymocyte globulin, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
9976713|NCT01354301|Experimental|Basiliximabe and everolimus|basiliximab, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
10129685|NCT04300491||Beneficiaries of suspension walking|
9967843|NCT01273909||Perforator Flap Breast Reconstruction|Patients who undergo perforator flap breast reconstruction with or without concomitant vascularized lymph node transfer
9967844|NCT01273909||Vascularized Lymph Node Transfer|Patients who undergo perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
9967845|NCT01273922|Placebo Comparator|Low Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo.
9967846|NCT01273922|Placebo Comparator|High Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo
9967847|NCT01273935||Responder|Responder versus Non-Responder as a result of platelet function test
9967848|NCT01273935||Non-Responder|According to the result of platelet function test
9967849|NCT01273948|Experimental|Bavituximab 3 mg/kg|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
9967850|NCT01273948|Experimental|Bavituximab 0.3 mg/kg|Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
9967851|NCT01273948|Active Comparator|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
9967852|NCT01273974|Experimental|intradermal influenza vaccine|
9967853|NCT01273974|Active Comparator|intramuscular influenza vaccine|
9967854|NCT01273987|Experimental|neobladder with round lig|ileal neobladder suspened with round ligament
9967855|NCT01273987|No Intervention|standard neobladder|conventional standard neobladder
9967856|NCT01274000|Placebo Comparator|placebo group|
9967857|NCT01274000|Experimental|YM060 low-dose group|
9967858|NCT01274000|Experimental|YM060 middle-dose group|
9967859|NCT01274000|Experimental|YM060 high-dose group|
9967860|NCT01274013||Study Group|Individuals with chronic Hepatitis C
9967861|NCT01274013||Control Group|Healthy individuals
9967862|NCT01274026||evaluation of benefit of sapropterin|Intervention 'sapropterin dihydrochloride': 20 individuals, either known to be non-responsive, or naive to sapropterin, are given a 4 week administration of sapropterin. Pre-, and Post- evaluation of behavior, executive function, neurotransmitter function, and genomic expression are assessed and evaluated for change.
9967863|NCT01274039||Patient with a trabeculectomy planed|
9967864|NCT01274052||Gestational Diabetes Mellitus|Women with Gestational Diabetes Mellitus
9967865|NCT01274052||Normal Glucose Tolerance|Women with Normal Glucose Tolerance
9967866|NCT01274065||Psychiatric illnesses|Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.
9967867|NCT01274078|No Intervention|conventional food|Regular eating habits during exercise period
9967868|NCT01274078|Active Comparator|Blueberries|Intervention: Addition of blueberries (150g/day) to regular food during the exercise period on days with exercise
9967869|NCT01274091|Experimental|P/S-ratio 1.0|"Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:~polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0."
9967870|NCT01274091|Experimental|P/S-ration 0.3|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
9967871|NCT01274104|Active Comparator|Vitamin D|Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
9967872|NCT01274104|Placebo Comparator|Control|Subjects will take 3 capsules of placebo every day for 14 days
9967873|NCT01274117|Placebo Comparator|One-stage transposition of the basilic vein|One-stage transposition of the basilic vein
9967874|NCT01274117|Experimental|Two-stage transposition of the basilic vein|Two-stage transposition of the basilic vein
9967875|NCT01274130|Experimental|Ranitidine|
9967876|NCT01274130|Experimental|Verapamil|
9967877|NCT01274143|Active Comparator|Telephone-delivered risk intervention|Participants in this arm receive a personalized telephone-risk assessment intervention provided by a trained cancer risk counselor.
9967878|NCT01274143|Active Comparator|Mailed pamphlet intervention group|Participants in this group receive a mailed pamphlet containing information about familial colorectal cancer risk and screening.
9967879|NCT01274156|Active Comparator|shock wave treatment|
9967880|NCT01274156|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
9967881|NCT01274195|Experimental|Busulfan|
9967882|NCT01274208||Gaucher Disease with Hepatitis C|
9967883|NCT01274221|Placebo Comparator|Placebo|
9967884|NCT01274221|Active Comparator|SPD489|
9967885|NCT01274234|Experimental|COMBO Stent|COMBO Stent
9967886|NCT01274247|Active Comparator|Topical Benzocaine|For infants treated with topical benzocaine prior to the procedure
9967887|NCT01274247|No Intervention|no benzocaine|No benzocaine applied
9967888|NCT01274260|Active Comparator|Experimental Group|Intervention: Subjects in this study group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
9967889|NCT01274260|Placebo Comparator|Placebo Group|Intervention: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline. The placebo group with receive the masked study drug in infusion rates that mimic the infusions received by the experimental group.
9967890|NCT01274273|Experimental|Interleukin-2, interferon, bevacizumab|
9967891|NCT01274273|Active Comparator|Interleukin-2 and interferon-alfa|
9967892|NCT01274299||Infants|Healthy 0-4 years of age both boys and girls
9967893|NCT01274325|Experimental|Sereflo|Sereflo (25/125)
9967894|NCT01274325|Active Comparator|Seretide|Seretide (25/125)
10129686|NCT04300491||Non-Beneficiaries of suspension walking|
9967895|NCT01274364|Experimental|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
9527675|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 3)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 3 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
9694622|NCT04787146||Patients|"From Monday to Friday, the study will be offered to patients selected consecutively and who have fallen within the previous 24 hours (between 7.55 a.m. the day before and 7.55 a.m. the next day).~After delivery of the written information note to the patient, the investigating physician answers the patient's questions and accepts his non-objection. The patient should be given sufficient time to think things through to make the decision to participate in the study.~Its non-opposition will be traced in the computerized medical file created on the day of its inclusion in the protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
9967896|NCT01274364|Active Comparator|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
9967897|NCT01274377|Experimental|Recipients Using 3-5/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 Human Leukocyte Antigen (HLA) Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
9967898|NCT01274377|Experimental|Recipients Using 6/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 HLA Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
9967899|NCT01274390||Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
9967900|NCT01274390||Longer-storage red blood cell units|Red blood cell units stored >= 21 days
9967901|NCT01274403|Experimental|Melphalan, prednisone plus Thalidomide|
9967902|NCT01274403|Active Comparator|Melphalan and Prednisone|
9967903|NCT01274442|Active Comparator|CONTROL: no dental implants lost|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, who did not lose their implants.
9967904|NCT01274442|Experimental|CASE: patients lost one or more implants|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, but who lost one or more implants.
9967905|NCT01274455|Experimental|Therapy|
9967906|NCT01274481|Experimental|Iloprost|All patients will have their response to Iloprost compared to baseline pre-treatment.
9967907|NCT01274507|Other|All participants|
9967908|NCT01274546||"In Office"|These subjects will come into the office to perform the consenting process, and complete all evaluations required at the only visit in the study.
9967909|NCT01274546||"Telephone Arm"|These subjects will be consented over the phone and give a verbal consent to participate. They will complete all aspects of the study over the phone except for the knee society score evaluation and the x-ray.
9967910|NCT01274598|Experimental|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|Lactobacillus rhamnosus GG ATCC 53103 1 x 10^10 twice a day for 28 days
9967911|NCT01274650|Other|Decubitis Ulcer|Patients admitted to the hospital with decubitus ulcers in the ischial, sacral, or coccyx area.
9967912|NCT01274663|Experimental|10 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
9967913|NCT01274663|Experimental|30 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
9967914|NCT01274663|Experimental|100 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
9967915|NCT01274663|Experimental|300 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
9967916|NCT01274663|Experimental|600 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
9967917|NCT01274663|Experimental|800 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
9967918|NCT01274663|Experimental|xxx mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
9967919|NCT01274676|Active Comparator|carotid stenting with MOMA|
9967920|NCT01274676|Active Comparator|Carotid stenting with filter wire EZ|
9967921|NCT01274689||cohort|cohort of consecutively enrolled patients with lagophthalmos
9967922|NCT01274702|Experimental|Visual Reconstitution Therapy|
9967923|NCT01274702|Active Comparator|Saccadic Eye Movement Training|
9967924|NCT01274728||ST-elevated myocardial infarction|Those with a condition of chestpain (or equal complains) and ECG changes confirming STEMI.
9967925|NCT01274741|Active Comparator|Seeking Safety (SS)|17 sessions of present-focused therapy Seeking Safety
9967926|NCT01274741|Experimental|Creating Change (CC)|17 sessions of past-focused Creating Change
9967927|NCT01274754||erythromycin group|Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.
9967928|NCT01274754||control group|no administration of erythromycin
9967929|NCT01274767||High risk cohort|Patients having history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have a negative test for H. pylori based on histology
9967930|NCT01274767||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
9967931|NCT01274780|Experimental|Darunavir / Ritonavir|
9967932|NCT01274780|Experimental|Atazanavir / Ritonavir|
9967933|NCT01274793|Active Comparator|Mosapride|In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found.
9519562|NCT03285919|Experimental|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
9967934|NCT01274793|Experimental|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
9967935|NCT01274793|Experimental|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
9967936|NCT01274806|No Intervention|Usual care|
9967937|NCT01274806|Experimental|Physical therapy|
9967938|NCT01274819|Experimental|Dynamic light|ICU patients exposed to dynamic light during ICU stay
9967939|NCT01274819|No Intervention|Normal Light|control group is exposed to normal light during ICU stay
9967940|NCT01274832||Late-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease > 10 years
9967941|NCT01274832||Early-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease <7 years
9967942|NCT01274845|Other|Heliox|
9967943|NCT01274858||lung cancer surgery|
9967944|NCT01274871||lung cancer surgery|
9967945|NCT01274884|Active Comparator|Acromioclavicular joint dislocation|Surgery: Arthroscopic repair using the Tightrope fixation device
9967946|NCT01274910|Active Comparator|Fish oil group|Treatment Group.
9967947|NCT01274910|Placebo Comparator|Control group|Placebo group
9967948|NCT01274923|Sham Comparator|shock wave treatment|
9967949|NCT01274923|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
9967950|NCT01274936|Experimental|Qishe|
9967951|NCT01274936|Placebo Comparator|Control|Qishe Placebo
9967952|NCT01274949|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
9694623|NCT04787276|Experimental|E.coli Nissle 1917|probiotic, oral, for the first 4 days, 1 capsule, and then 2 capsules per day for 1 month treatment
9967953|NCT01274962|Experimental|A - neoadjuvant chemotherapy|Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
9967954|NCT01274962|Experimental|Arm B - adjuvant chemotherapy|Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
9967955|NCT01274988|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
9967956|NCT01274988|Active Comparator|Standard Control|methadone maintenance treatment
9967957|NCT01275001||Intervention children|Children who are receiving a Suzuki-like violin instruction through their participation in an Early Childhood/Headstart preschool program
9967958|NCT01275001||Control Group|Preschool-age children who are not receiving Suzuki-like violin instruction
9967959|NCT01275014|Placebo Comparator|Placebo|
9967960|NCT01275014|Experimental|Dexamethasone|
9967961|NCT01275027|Experimental|Nutralin|Individuals with Type 2 Diabetes
9967962|NCT01275027|Placebo Comparator|Placebo|Individuals with Type 2 Diabetes
9967963|NCT01275040|Experimental|Mobile screening team|The Primary Health Care clinics where the mobile screening team will visit and active screening for DM complications will take place.
9967964|NCT01275040|Active Comparator|No mobile screening team|No mobile team will visit clinics and active screening for DM complications will not be done. Patients and Health Workers will receive Education, same as intervention arm but no enhanced care.
9967965|NCT01275157|Experimental|LY2452473|15 mg, containing 100 micro curies of 14C labeled LY2452473 taken once only
9967966|NCT01275183|Experimental|Raltegravir and cisplatin|
9967967|NCT01275209|Experimental|HCD122|
9967968|NCT01275235||Exposure to Type II Diabetes for two siblings|Two sibling pairs with the same parents, between the ages of 20 to 34 in the Baton Rouge Area, having mother with diabetes while pregnant with one.
9967969|NCT01275248|Experimental|Ondansetron 0.5 mg|Ondansetron oral tablet 0.5 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
9967970|NCT01275248|Experimental|Ondansetron 0.75 mg|Ondansetron oral tablet 0.75 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
9967971|NCT01275248|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
9967972|NCT01275261|No Intervention|Foley catheter|Usual care - patients will have a Foley catheter placed on admission.
9967973|NCT01275261|Experimental|Nursing protocol to avoid Foley Catheter|No catheter will be placed on admission, and a nursing order protocol will be followed to avoid catheterization and avoid complications.
9967974|NCT01275274|Active Comparator|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
9967975|NCT01275274|Experimental|Retinoic acid|Tretinoin in addition to standard of care
9967976|NCT01275287|Active Comparator|Standard of care|Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here.
9967977|NCT01275287|Experimental|Eculizumab arm|"Standard of care for ANCA vasculitis + eculizumab treatment~Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here."
9967978|NCT01275352|Active Comparator|Arm 1|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
9967979|NCT01275352|Active Comparator|Arm 2|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
10129687|NCT04300452|Active Comparator|Carbetocin group|In the carbetocin group will be administered 100 mcg of carbetocin diluted in 100 cc of N/S 0.9% in a continuous rapid-flow intravenous infusion.
10129688|NCT04300452|Active Comparator|Ergometrin group|In the ergometrine maleate group will be administered intravenously 0.2 mg of the substance slowly in a bolus administration.
10129689|NCT04300699|Other|Ovarian cancer patients over 70 years receiving chemotherapy|Patients with ovarian cancer receiving chemotherapy as either first line treatment (i.e. newly diagnosed advanced stage III/IV cancer) or at first relapse. Patients to receive a Geriatric Assessment including interventions for functional or other identified deficits and appropriate specialist algorithm-determined interventions.
10129690|NCT04300621|Experimental|Treatment Sequence 1: OTF 1, 4, 2, 3|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 1 in period 1; followed by OTF 4 in period 2; followed by OTF 2 in period 3; followed by OTF 3 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
10129691|NCT04300621|Experimental|Treatment Sequence 2: OTF 2, 1, 3, 4|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 2 in period 1; followed by OTF 1 in period 2; followed by OTF 3 in period 3; followed by OTF 4 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
10129692|NCT04300621|Experimental|Treatment Sequence 3: OTF 3, 2, 4, 1|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 3 in period 1; followed by OTF 2 in period 2; followed by OTF 4 in period 3; followed by OTF 1 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
10129693|NCT04300621|Experimental|Treatment Sequence 4: OTF 4, 3, 1, 2|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 4 in period 1; followed by OTF 3 in period 2; followed by OTF 1 in period 3; followed by OTF 2 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
10129694|NCT04300413|Experimental|High-Intensity Rehabilitation plus Mobility (HeRo)|The HeRo group will receive a behavior-change intervention based in the principals of behavioral economics to improve mobility. Physical and occupational therapists have been trained to deliver a high-intensity, functional intervention as the standard of care in this skilled nursing facility.
10129695|NCT04300465|Experimental|Rheumatoid arthritis - With Partner Group|In this group patients with stable rheumatoid arthritis and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
10129696|NCT04300465|Active Comparator|Rheumatoid arthritis - Without Partner Group|"In this group patients with stable rheumatoid arthritis undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.~For the patients with rheumatoid arthritis, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
10129697|NCT04300465|Experimental|Chronic Kidney Disease - With Partner Group|In this group patients with stable stage 3 or 4 chronic kidney disease and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
10129698|NCT04300465|Active Comparator|Chronic Kidney Disease - Without Partner Group|"In this group patients with stable stage 3 or 4 chronic kidney disease undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.~For the patients with chronic kidney disease, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
10129699|NCT04300374||Sevoflurane only|inhalation of sevoflurane during general anesthesia
10129700|NCT04300374||Remifentanil and Sevoflurane|remifentanil infusion and inhalation of sevoflurane during general anesthesia
10129701|NCT04300751|Experimental|Alcohol|Participants will receive experimental doses of active or placebo alcohol, p.o. Alcohol/placebo will be administered once per session.
10129702|NCT04300751|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered orally
10129703|NCT04300751|Experimental|Opioid Agonist/Alcohol Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with experimental doses of active alcohol placebo. Opioid/placebo and alcohol/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Both opioid and alcohol doses will be administered orally.
10129704|NCT04300361||Non-Western patients|Patients of non-Western descent with an indication for treatment with fluoropyrimidine-based chemotherapy. A patient is classified as non-Western if a one (1) of the parents or more than two (>2) of the grand parents are of non-Western descent.
10129705|NCT04300322|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
10129706|NCT04300322|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
10129707|NCT04300205|Experimental|High intensity LED light treatment|Participants treated with high intensity LED phototherapy
9967980|NCT01275352|Placebo Comparator|Arm 3|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
9967981|NCT01275352|Placebo Comparator|Arm 4|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
9967982|NCT01275378|Active Comparator|Collaborative Care Plus|Collaborative care model with specific theory-based elements to address common reasons for ADHD treatment failure
9967983|NCT01275378|Active Comparator|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
9967984|NCT01275391|No Intervention|Treatment as Usual Group 1|Participants will receive treatment as usual and will complete a baseline and 1-month post-visit assessment
9967985|NCT01275391|No Intervention|Treatment as Usual Group 2|Participants will receive treatment as usual and complete only the 1-month post-visit assessment
9967986|NCT01275391|Experimental|Intervention Group 1|Computer Screening, Brief Intervention, Referral toTreatment. Participants will receive the intervention and complete a baseline and 1-month post-visit assessment
9967987|NCT01275391|Experimental|Intervention Group 2|Computer Screening, Brief Intervention, Referral toTreatment Participants will receive the intervention and complete only the 1-month post-visit assessment
9967988|NCT01275404|Experimental|(SMRP) + nurse practitioner information phone calls|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
9967989|NCT01275404|Experimental|SMRP+ACT-ED|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
9967990|NCT01275417||adult|100 volunteers age ranged 18-80 years old
9967991|NCT01275417||children|60 children under 10 years old.
9967992|NCT01275443|Experimental|300mg TMC278LA|Single gluteal intramuscular injection (300mg) at day 1
9967993|NCT01275443|Experimental|1200mg TMC278LA|Single gluteal intramuscular injection (1200mg) at day 1
9967994|NCT01275443|Experimental|600mg TMC278LA|Single gluteal intramuscular injection (600mg) at day 1
9967995|NCT01275443|Experimental|150mg TMC278LA|This arm was included in the adaptive design of the study, but was not recommended for use based on the review of results from 300mg and 600mg arms by the protocol steering committee
9967996|NCT01275469|Experimental|GFT505 80mg|
9967997|NCT01275469|Placebo Comparator|Matching placebo|
9967998|NCT01275482|Experimental|isolated contractions caused|The investigators do TFM causing isolated contractions in de muscle fibers containing de latent trigger point.
9967999|NCT01275482|Active Comparator|No isolated contraction caused|The investigators don´t cause contraction during the TFM
9968000|NCT01275495|Experimental|Telephone Assessment and Skill-Building Kit (TASK II)|The TASK II group will fill out a checklist about their needs and concerns, and will receive written tip sheets by mail that address the needs and concerns that they feel are most important. A nurse will call by telephone (lasting about 30 minutes or less) once a week for a total of 8 weeks, with another call at 12 weeks, to provide more information, answer questions, and to discuss more written tip sheets based on the caregiver's needs and concerns.
9968001|NCT01275495|Active Comparator|Information, Support, and Referral (ISR)|The ISR group will receive existing educational materials about stroke and caregiving developed by the American Stroke Association and weekly telephone calls by a nurse (lasting about 30 minutes or less) for a total of 8 weeks, with another call at 12 weeks.
9968002|NCT01275508|Experimental|FITC-Adalimumab|
9968003|NCT01275521|Experimental|BONT-A intra-prostatic injection|
9968004|NCT01275521|Active Comparator|optimized medical BPH treatment|
9976714|NCT01354301|Active Comparator|Basiliximabe and mycophenolate|basiliximab, reduced concentration tacrolimus, mycophenolate and prednisone.
9976715|NCT01354327|Experimental|Limicol|
9976716|NCT01354327|Placebo Comparator|Placebo|
9976717|NCT01354340|Experimental|Limicol simple dose|
9976718|NCT01354340|Experimental|Limicol double doses|
9976719|NCT01354340|Placebo Comparator|Placebo|
9976720|NCT01354366||Control|Marketed hypoallergenic infant formula containing a probiotic
9976721|NCT01354366||Experimental 1|An investigational hypoallergenic infant formula with a different protein content, containing the same probiotic as the control
9976722|NCT01354366||Experimental 2|An investigational hypoallergenic infant formula with a different protein content, without a probiotic
9976723|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Pipette|
9976724|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette|
9976725|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Nasal Spray|
9976726|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray|
9976727|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray|
9976728|NCT01354392|Experimental|AZD1152|
9976729|NCT01354405||Lanreotide|
9976730|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fasted|Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods
9976731|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fed|Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
9976732|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fasted|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods
10129708|NCT04300205|Experimental|Sham high intensity LED light treatment|Participants set up to be treated with light device but after being masked, the device is moved off the wound
10129709|NCT04300153|Experimental|ESP Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml 0.25% bupivacaine at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
10129710|NCT04300153|Sham Comparator|Control Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml normal saline at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
10129711|NCT04300439|Active Comparator|Arm A: metallic reusable ancillary.|This control group will be constituted of patients who will have the GMK® prosthesis with metallic reusable ancillary.
10129712|NCT04300439|Experimental|Arm B: Efficiency single use ancillary.|This group will be constituted of patients who will have the GMK® prosthesis with Efficiency single use ancillary.
10129713|NCT04300075||CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
10183788|NCT03761238|Experimental|Standard medical treatment + MARS|Patients assigned to the control arm will receive standard medical treatment (SMT) and liver dialysis using Molecular Adsorbent Recirculating System (MARS).
10183789|NCT03761238|Active Comparator|Standard medical treatment|Patients assigned to the control arm will receive standard medical treatment (SMT) as specified in the study protocol.
10183790|NCT03761212||Patient with ankylosing spondylitis or axial spondyloarthritis|No intervention - observational study
10183791|NCT03761212||Healthy controls|Age and sex matched healthy controls
10183792|NCT03761199|Experimental|a group of patients with AD|15 people with clinically diagnosed atopic dermatitis (AD), established on the basis of criteria Hanifin and Rajka
10183793|NCT03761199|Other|control group|15 healthy persons which will form the control group
10183794|NCT03761186|Active Comparator|traditional diabetes diet|Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
10183795|NCT03761186|Experimental|moderately low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
10183796|NCT03761186|Experimental|strictly low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
10183797|NCT03761121|Experimental|Primary Testing Group|"This scan is in the same imaging session as the participant's scheduled clinical MRI and is no longer 15 minutes~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
10183798|NCT03761121|Experimental|Software Testing Group|"Participants will receive hour research-only scan~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
10183799|NCT03761043|No Intervention|Pre-Intervention Arm|The nurses will have not been exposed to the behavior change intervention.
10183800|NCT03761043|Experimental|Post-Intervention Arm|The nurses will have been exposed to the behavior change intervention.
10183801|NCT03761004|Experimental|WD-1603 single dose|"WD-1603 single dose:~A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
10183802|NCT03761004|Experimental|WD-1603 BID dose|"WD-1603 BID dose:~A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch.~Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose."
10183803|NCT03761004|Active Comparator|Sinemet single dose|"Sinemet single dose:~A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
10183804|NCT03760978||dex group|Critically ill patients <18 year-old receiving prolonged sedation with endovenous dexmedetomidine (dosage 0.2 mcg/Kg/hour to 1.8 mcg/Kg/hour) more than 24 hours
10183805|NCT03760926|Experimental|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
10183806|NCT03760900|Experimental|infusion group|Autologous Umbilical Cord Blood Stem Cells Therapy
10183807|NCT03760887|Sham Comparator|No Home Sensory training|Patients who perform a home exercise program only
10183808|NCT03760887|Experimental|Home sensory training|Patients who perform home exercise and home sensory training
10183809|NCT03760874||Non Vitamin K Oral Anticoagulant|Dabigatran, Rivaroxaban, Apixaban, Edoxaban
10183810|NCT03760874||Vitamin K Oral Anticoagulant|Warfarin, Acenocoumarol.
10183811|NCT03760861|Experimental|Prototype Microcapsule Treatment Arm|Intervention by placement of prototype weight-loss microcapsule in the stomach. Subjects will have a weight-loss microcapsule deployed endoscpically in the stomach. The intragastric balloon in the capsule will be inflated using an external magnet..
10183812|NCT03760848|Other|Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin|Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)
10183813|NCT03760822|Experimental|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
10183814|NCT03760822|Active Comparator|Ramucirumab + Paclitaxel|IV ramucirumab at 8 mg/kg on D1 and D15 IV paclitaxel at 80 mg/m² on D1, D8 and D15
10183815|NCT03760809|Experimental|group A|Dexmedetomidine(0.5 μg／kg)/hydromophine-based general anesthesia
10183816|NCT03760809|Experimental|group B|Dexmedetomidine(1μg／kg)/hydromophine-based general anesthesia
10183817|NCT03760770|Experimental|Riboflavin at 4ºC|patients treated with Riboflavin at 4ºC in crosslinking (cases).
10183818|NCT03760770|Experimental|Riboflavin at room temperature|patients treated with Riboflavin at room temperature in crosslinking (controls)
10129714|NCT04300192|Experimental|Group 1: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of whole-cell pertussis (wP) vaccine during the first 2 years of life
10129715|NCT04300192|Experimental|Group 2: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 3 doses of wP followed by 1 dose of acellular pertussis (aP) vaccine during the first 2 years of life
10129716|NCT04300192|Experimental|Group 3: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 2 doses of wP vaccine followed by 2 doses of aP vaccine during the first 2 years of life
10129717|NCT04300192|Experimental|Group 4: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 1 dose of wP vaccine followed by 3 doses of aP vaccine during the first 2 years of life
10129718|NCT04300192|Experimental|Group 5: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of aP vaccine during the first 2 years of life
10129719|NCT04300192|Experimental|Group 6: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of wP vaccine during the first 2 years of life
10129720|NCT04300192|Experimental|Group 7: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of aP vaccine during the first 2 years of life
10129721|NCT04300114|Experimental|Maintenance Fluzoparib monotherapy|
10129722|NCT04300114|Placebo Comparator|Maintenance placebo monotherapy|
10129723|NCT04300062|Experimental|Rebiopsy|
10129724|NCT04300348|Active Comparator|Heel2Toe Group|The Heel2Toe group will have 5 therapy sessions to learn to trigger the sensor with a strong heel strike and how to use device for home practice for 3 months. During the home practice, participants will be instructed to walk with the device for a minimum of 10 minutes per day in feedback mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
9669051|NCT04227951|Sham Comparator|Drain|Participants enrolled in this arm have an abdominal drain positioned at the end of the operation (any type, inserted from right flank with the tip close to the esophago-jejunal or Gastro-jejunal anastomosis and the duodenal stump). Drain will stay in place until postoperative day (POD) 4th (drain output and quality will be registered). If normal drain debt and patient have no abdominal complications that need reoperation and/or percutaneous drain placement until POD 4, a methylene-blue test is be performed (200 ml water + 5 ml blue orally, check drain after 60 minutes: negative test if no blu was seen in the drain). If negative-blue test drain can be removed according to centre preference (no strict POD defined); if positive-blue test complication will be treated according to centre preference. Only in this arm drain related complications are registered. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
9669052|NCT04227951|Experimental|No Drain|Participants enrolled in this arm do not have any abdominal drain placed at the end of the operation. Postoperative management (e.g. resume of oral intake, anastomosis integrity tests) is left to centre preference. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
9669053|NCT04211194||Patients with upper gastrointestinal bleeding|Patients with upper gastrointestinal bleeding undergoing endoscopic procedures at AdventHealth Hospitals in Central Florida
9669054|NCT04210076|Experimental|Mindfulness-Based Attention Training for Teams (MBAT-T)|Teams randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
9669055|NCT04210076|Active Comparator|Mindfulness-Based Attention Training for Individuals (MBAT-I)|Individuals randomized to this group will receive 4, 2-2.5-hour sessions delivered over 4 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises, that will be delivered and tracked using a measuring mindfulness application.
9669056|NCT04210076|No Intervention|No-training|Teams will not engage in any mindfulness training
9669057|NCT04197726|Experimental|sbeIIa/b white bread|sbeIIa/b white bread with high resistant starch content
9669058|NCT04197726|Active Comparator|Control white bread|Reference white bread (wild-type)
9968005|NCT01275547|Experimental|S-ketamine & midazolam spray|all 20 minutes as a patient controlled analgesia alternating s-ketamine / midazolam
9968006|NCT01275547|Active Comparator|morphine, patient controlled analgesia|morphine as an active comparator as a patient controlled analgesia system
9968007|NCT01275560|Experimental|Metronidazole|3 intakes per day during 10 days
9968008|NCT01275560|Active Comparator|Carbosylane|3 intakes per daysduring 10 days
10129725|NCT04300348|Other|No-feedback Control Group (Control group)|The Control group will do the same 5 sessions of training and 3 months of practice but without the Heel2Toe device in feedback mode, just in data acquisition mode. They will be provided with a workbook outlining simple exercises targeting functions needed to walk well (Walk-BEST Workbook) in paper and as a mobile app.
10129726|NCT04300335|Experimental|High Risk - Individual Exercise|Patients who show an increased fracture risk and/or increased risk of fall in the screening assessments and are therefore allocated to an individualized personal training.
10129727|NCT04300335|Experimental|Low Risk - Group Exercise|Patients who show neither increased fracture risk nor increased risk of fall in the screening assessments and are therefore allocated to the exercise group.
9968009|NCT01275573|Other|healthy volunteers|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
9968010|NCT01275573|Other|painful Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
9968011|NCT01275573|Other|painless Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
9968012|NCT01275599|Experimental|Open-Label Arm|"The treatment period will include 3 phases:~14 day run-in period~7 day co-administration period~31 day follow-up period"
9968013|NCT01275612|Experimental|Cell therapy|
9968014|NCT01275638|Placebo Comparator|Prednisolone (20 mg/day) for 10 days.|
10129728|NCT04300387|No Intervention|customary care|customary care for CKD
10129729|NCT04300387|Active Comparator|multidisciplinary care|multidisciplinary team care for CKD
10129730|NCT04300231|Active Comparator|Thoracic epidural|1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.
10129731|NCT04300231|Active Comparator|Rectus Sheath Block|2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected into 4 locations below the rectus abdominis muscle.
10129732|NCT04300231|Active Comparator|Surgeon Infiltration with Liposomal Bupivacaine (LB)|3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.
10129733|NCT04300231|Active Comparator|Surgeon Infiltration|4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.
10129734|NCT04300049|Experimental|Change in Glycerol Ra|The difference in rate of lipolysis (glycerol Ra) during the basal state (-120 -0 minute) between subjects receiving glucagon and saline represents the change in whole body lipolysis caused by glucagon.
10129735|NCT04300010|Active Comparator|Blue Light Therapy|FDA cleared blue light product, Omniluxblue (Globalmed Technologies, Glen Elen, CA), which emits a 415 nm blue light irradiance of 40mW/cm2. Following the application of blue light protective eyewear, the blue light therapy device will be centered over the deltopectoral interval according to device standardized use instructions and a 23-minute treatment will be administered to dry skin. As was done in the topical BPO group, following treatment, a skin swab culture of the treatment shoulder will be taken, then both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder. Participants and research personnel conducting the blue light treatments will be wearing medical grade blue light protective glasses for safety.
10129736|NCT04300010|Active Comparator|5% Topical Benzoyl Peroxide Gel|A pea-sized amount, ~0.5 grams, will be applied to a 10cm strip over the deltopectoral interval beginning the morning 48 hours prior to schedule research visit to obtain cultures. The benzoyl peroxide will be applied on dry skin after a shower. The gel will be applied once in the morning and once in the evening for two consecutive days as well as the morning of the scheduled research visit. Following treatment, a skin swab culture of the treatment shoulder will be taken, both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder.
10129737|NCT04300010|Active Comparator|Light and Gel|Prior to treatment, a skin swab culture will be taken, 5% topical benzoyl peroxide treatment will be performed on dry skin immediately after a shower as described in the above paragraph. Again, five total treatments will be performed prior to research visit. On the day of the research visit, the blue light therapy protocol described above will be performed exactly the same followed by culture obtainment.
10129738|NCT04300400||Delphi panel|Urologists of the Belgian Working group of Functional Urology willing to participate on the Delphi project.
10129739|NCT04300166|Active Comparator|Telemedicine & Humidification Intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse/sleep technologist is checking the downloaded data three times per week. The contacts will be due to:~CPAP usage <4h/ night for 3 consecutive night~the median leakage was above 0.4 L/sec on 3 consecutive nights The nurse/sleep technologist informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits) will be discussed. The patient is encouraged to use CPAP every night. In the case of adherence >4h/night and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail."
10129740|NCT04300166|No Intervention|Control without Telemedicine & humidification|In the control arm, no wireless telemedicine and humidifier will be used with CPAP but data stored in the CPAP machine are collected at the follow-up visit after 1 month
10129741|NCT04299984||Open Conversions|Patients undergoing total or partial endograft explantation for any EVAR complication.
10129742|NCT04299984||SemiConversions|Patients undergoing open or laparoscopic surgery for any EVAR complication (mostly endoleak correction) with complete endograft preservation.
10129743|NCT04300426|Experimental|ACHIM by gastroduodenoscopy|"Intestinal microbiota (acronym ACHIM - anaerobically cultured human intestinal microbiota) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml, containing approximately 10^9 bacteria / ml.~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
10129744|NCT04300426|Placebo Comparator|Placebo by gastroduodenoscopy|"ACHIM culture media (no bacteria) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml.~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
10129745|NCT04299945|Experimental|Dietary nitrate supplementation|The dietary nitrate supplement will be a concentrated, nitrate-rich beetroot juice (70 ml providing ∼400mg nitrate per serving)
10129746|NCT04299945|Placebo Comparator|Placebo|The placebo will be a concentrated, nitrate-depleted beetroot juice (70 ml with trace amounts of nitrate)
10129747|NCT04300036|Experimental|longan syrup|Take 15 ml of longan syrup once a day for 3 months
10129748|NCT04300036|Placebo Comparator|Placebo syrup|Take 15 ml of placebo syrup once a day for 3 months
9669059|NCT04196842|Experimental|Telemonitoring|Blood pressure and heart rate monitoring, scale, activity tracker.
9669060|NCT04196842|No Intervention|No intervention|No intervention.
10129749|NCT04300283|Experimental|Pre-operative hypnosis|
10129750|NCT04299971|Active Comparator|methotrexate|This group of 38 TAK cases are prescribed with methotrexate tablets (Dose: 15.0 mg. qw. p.o.) for 24 weeks.
10129751|NCT04299971|Experimental|Tofacitinib|This group of 38 TAK cases are prescribed with tofacitinib tablets (Dose: 5.0 mg. bid. p.o.) for 24 weeks.
10129752|NCT04300023|No Intervention|Study 1: Normal Care Control Group|Study 1: Normal Care Control Group [will crossover and complete the cycling intervention following the initial 6-months]
10129753|NCT04300023|Experimental|Study 1: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
10129754|NCT04300023|Experimental|Study 2: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
10129755|NCT04300023|Experimental|Study 2: Solo Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to cycling without a partner for a target duration and intensity.
10129756|NCT04300101||DLBCL patients|All patients with diagnosis of DLBCL
10129757|NCT04299919||Recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
10129758|NCT04299919||Non-recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
10129759|NCT04299932|Experimental|Electroacupuncture(EA) group|Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 [Zhongliao], BL35 [Huiyang] and Spleen Meridian (SP) 6 [Sanyinjiao]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
10129760|NCT04299932|Sham Comparator|Sham Electroacupuncture (SA) group|Participants in SA group will receive treatment at bilateral sham BL33 [Zhongliao], sham BL35 [Huiyang] and sham SP6 [Sanyinjiao]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
10129761|NCT04299932|No Intervention|Waiting List (WL) group|Participants in WL group will be followed up for 20 weeks. Participants only receive healthcare education and advice on lifestyle modification, which will be received by all the participants in the three groups.
10129762|NCT04299906|Experimental|Solaris Vascular Stent Graft|Implant of Solaris Vascular Stent Graft in aorto-iliac lesions
10129763|NCT04299724|Experimental|Injection of Covid-19/aAPC vaccine|
10129764|NCT04299711||Baseline|This study intends to recruit 3,428 Chinese adolescent students exposed to the novel coronavirus disease 2019 in the baseline survey
10129765|NCT04299711||6-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 6 follow-up study.
10129766|NCT04299711||12-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 12 follow-up study.
10129767|NCT04299711||18-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 18 follow-up study.
10129768|NCT04299893|Experimental|Ozone Group|"Drug: Ozone Ozone Group: Usual treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.~Other Names: O3"
10129769|NCT04299893|Placebo Comparator|Control Group|"Drug: Oxygen Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.~Other Names: O2"
10129770|NCT04299737||First patient in the case pair|This patient will receive the treatment bundle. S. aureus transmission surveillance will be conducted.
10129771|NCT04299737||Second patient in the case pair|This patient will receive usual care. S. aureus transmission surveillance will be conducted.
10129772|NCT04299607||AFI patients|"Blood will be collected from patients presenting with an undifferentiated fever.~Samples will be tested with:~the Malaria Ag Pf/Pan test SD Bioline~the SD Bioline Dengue Duo IgM/IgG/NS1~the DPP Zika Chikungunya Dengue test from Chembio~the DPP Fever Panel II assay~the Leptospira IgM ELISA test from Serion~an in-house ELISA tests for scrub and murine typhus IgM~blood culture for detection of Burkholderia pseudomallei"
10129773|NCT04299750|Experimental|Alveolar Ridge Preservation|Patients in this arm will undergo atraumatic extraction of an hopeless tooth and a socket preservation procedure. Alveolar ridge preservation will be performed using a slow-resorption bone substitute and a collagen membrane that covers the graft.
10129774|NCT04299750|Active Comparator|Natural healing|Patients in this arm will undergo atraumatic extraction of an hopeless tooth. The socket will follow natural healing.
10129775|NCT04299516|Experimental|Two-team SBA|Two-team simultaneous bilateral total knee arthroplasty
10129776|NCT04299516|Active Comparator|Single-team SBA|Single-team simultaneous bilateral total knee arthroplasty
10129777|NCT04299633|Experimental|Part 1: vadadustat plus sevelamer carbonate|Participants will receive vadadustat 300 milligrams (mg) once on Days 1, 3, 5, and 7. Participants will receive sevelamer carbonate 1600 mg once on Days 3, 5, and 7.
10129778|NCT04299633|Experimental|Part 2: vadadustat plus calcium acetate|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive calcium acetate 1334 mg once on Days 3, 5, and 7.
10129779|NCT04299633|Experimental|Part 3: vadadustat plus Auryxia®|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive Auryxia® 2 grams once on Days 3, 5, and 7.
10129780|NCT04299698||Carbohydrate reduction group|Participants chose to control their body fat mass by reducing their carbohydrate intake through observation study periods.
9669061|NCT04193514|Experimental|Acceptance and Commitment Therapy|
9669062|NCT04193514|No Intervention|Treatment as Usual|
10129781|NCT04299698||Fat reduction group|Participants chose to control their body fat mass by reducing their fat intake through observation study periods.
10129782|NCT04299698||Intense exercise group|Participants chose to control their body fat mass by vigorously increasing the time and intensity of exercise through observation study periods.
10129783|NCT04299698||Moderate exercise group|Participants chose to control their body fat mass by moderately increasing the time and intensity of exercise through observation study periods.
10129784|NCT04299646|Experimental|Steretactic radiotherapy plus systemic treatment|
10129785|NCT04299646|Active Comparator|Systemic treatment|
10129786|NCT04299789||Probable Civilian|This cohort represents those in which the Military Service Identification Tool has determined are a civilian and have not served in the Armed Forces.
10129787|NCT04299789||Probable Veteran|This cohort represents those in which the Military Service Identification Tool has determined are a military veteran and have served in the Armed Forces.
10129788|NCT04299763|Experimental|Beta-Glucan (BETA)|experimental group, received a supplement of oats beta-glucan (5 g) for 12 weeks.
10129789|NCT04299763|Placebo Comparator|Control (CN)|placebo group, received a supplement of cellulose microcrystalline (5g) for 12 weeks.
10129790|NCT04299412||Melioidosis cases|serum samples collected from patients with B. pseudomallei positive cultures
10129791|NCT04299412||Non-melioidosis cases|serum samples collected from patients with B. pseudomallei negative cultures
10129792|NCT04299815|Active Comparator|Oral lactate|Sodium D/L lactate solution, 25g/L in 300mL water
10129793|NCT04299815|Placebo Comparator|Iso-lactic intravenous lactate infusion|iv sodium D/L lactate to elevate [lactate] to the same levels as measured on day 1 + oral sodium chloride, 300 mL
10129794|NCT04299802|Active Comparator|Leukocyte-Rich Platelet-Rich Plasma (LR-PRP)|LR-PRP will be administered via usual protocol with venous blood draw and concentration via centrifugation. The LR-PRP will be injected under ultrasound guidance into the gluteus minimus and gluteus medius tendons, enthesis and surrounding bursae.
10129795|NCT04299802|Active Comparator|Percutaneous Ultrasonic Tenotomy|Percutaneous Ultrasonic Tenotomy will be administered via usual protocol within an outpatient surgical setting or in-office procedure. Patient will be anesthetized with local anesthetic and a <5mm incision will be made along the lateral hip with an #11 scalpel. A 14-G angiocath will be introduced through the defective area of the tendon down to the enthesis. Multiple passes will be made and then the percutaneous ultrasonic tenotomy device will be introduced to the defective area. No more than 5 minutes of energy cutting time will be used to address the defective area down to the enthesis, which will debride abnormal tissue but leave normal healthy tissue intact.
10129796|NCT04299854||Vaginal Dinoprostone|Induction of labor by 10mg of vaginal dinoprostone
10129797|NCT04299854||Single Balloon Foley Catheter|Induction of labor by single balloon Foley catheter
10129798|NCT04299256|Experimental|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
10129799|NCT04299256|No Intervention|Control|Like the intervention group, the control group session (attention-matched education) which composed of 10-12 participants were performed with a booklet containing hemodialysis and its use in a silent room located in the hemodialysis units. The patient information provided in-person training on hemodialysis and its use for 20 min in a group session at the hemodialysis unit, on the first day of the study. During the study period, the participants in the control group were not subjected to any additional intervention.
10129800|NCT04299542|Active Comparator|conventional Multi-detector CT (MDCT)|Percutaneous lung biopsy using MDCT
10129801|NCT04299542|Active Comparator|cone-beam CT (CBCT)|Percutaneous lung biopsy using CBCT
10129802|NCT04299529|Experimental|HTM plus UPP|Urinary proteomic profiling administered on top of home blood pressure telemonitoring and guideline-endorsed non-pharmacological and pharmacological management of risk factors
10129803|NCT04299529|Other|HTM alone|Home blood pressure telemonitoring administered on top of non-pharmacological and pharmacological management of risk factors
10129804|NCT04299243|Experimental|Spherical Lens|Randomized to Spherical Lens worn in a daily disposable mode
10129805|NCT04299243|Active Comparator|SiHy Daily|Randomized to SiHy Daily worn in a daily disposable mode
10129806|NCT04299165|Experimental|Device: KAIA COPD-App (Medical Mobile Application).|The study intervention is an exercise training program that requires only a chair or water bottles, consisting of training elements with progressive levels of intensity, individually adaptable to the participant's exercise level. This training program is delivered to the participants with the help of KAIA COPD-App. Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.
10129807|NCT04299165|Active Comparator|Usual Care|"The Training of the control-group is performed by regular recommendations/ Standard of care. Standard of care in this context means to hand out the brochure  Besser Leben mit COPD  including an emergency plan, providing exercise training examples, to hand out addresses of out-patient physiotherapists and to hand out a detailed medical report including medical recommendations.Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database."
10129808|NCT04299568|Experimental|Anti gravity treadmill training|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization followed by Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes.
10129809|NCT04299568|Active Comparator|Control|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization only
10129810|NCT04299308|Experimental|Moderate Intensity Aerobic Exercise|45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.55 + Resting HR
10129811|NCT04299308|Experimental|High Intensity Aerobic Exercise|65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.75 + Resting HR
10129812|NCT04299399||nomal|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of biomechanics with other groups will be performed.
10129813|NCT04299399||seasonal allergic conjunctivitis(SAC)|Eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of corneal biomechanics with other groups and correlation analysis of corneal biomechanical parameters and other measurement indicators will be performed.
10129814|NCT04299399||vernal keratoconjunctivitis (VKC)|At first visit, eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured. All patients will adopt a unified medication regimen:0.1% tacrolimus eye drops four times daily; 0.1% flumirone eye drops twice daily; azelastine hydrochloride eye drops four times daily; hyaluronic acid sodium eye drops four times daily. After 1M, 0.1% flumilone eye drops will be replaced with 0.02% flumirone eye drops twice daily, and rest of the medication will remain unchanged. The same ophthalmological examinations will be performed again after 3 month medication.
10129815|NCT04299399||keratoconus|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of these parameters with other groups will be performed.
10129816|NCT04299360||standard BIV|the following group describes the effects of the left ventricular stimulation involving a dipole of two electrodes located inside a suitable vessel branch of the coronary sinus (CS). Standard BIV pacing modality can be achieved by either a quadripolar electrode implanted in the CS, of which only two poles will be used for cardiac resynchronization therapy, or by a bipolar electrode equipped with just two electrodes. The latter describes the old technology, requiring a change into typology of generator which has to display an IS-1 connection (due to different distal terminal of the electrode itself), instead of the new one IS-4 connection that has been developed for quadripolar electrodes.
10129817|NCT04299360||MPP BIV|Such modality of left ventricular stimulation requires a dynamic use of the four electrodes located in the proximal segment of the electrocatheter that allows the recruitment of a vast area of the left ventricle. It is limited by the presence of scars on left ventricle surface, or phrenic nerve inadvertent stimulation.
10129818|NCT04299672|Experimental|Postural reconstruction|"Maximum external rotation of the hip in lower limb elevation and the dorsal flexion of the ankle with flexion of the toes, performed in both lower limbs alternately and independent.~Participant must control breathing. The detail phases of a general intervention are:~PASSIVE displacement of the segment until reaching CRITICAL AMPLITUDE, which corresponds to the light myofascial stress or to the appearance of evoked responses.~ACTIVE MAINTENANCE of the critical amplitude.~WORK BREATHING.~INDUCTIVE ACTIVE APPLICATIONS with movements of great relative amplitude.~FINISHING CRITERIA: reduction or extinction of evoked responses, patient fatigue or execution of the technique for 15 minutes without any of the above premises having been reached."
10129819|NCT04299074|Other|Addiction|problematic addiction
10129820|NCT04299152|Experimental|Stem Cell Educator therapy treat patients with SARS-CoV-2|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
10129821|NCT04299152|No Intervention|Conventional treatment of patients with SARS-CoV-2|Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.
10129822|NCT04299282|Active Comparator|CanGaroo|The treatment group will receive a CanGaroo envelope with implantation of a CIED
10129823|NCT04299282|No Intervention|No CanGaroo|The control group will not receive a CanGaroo envelope with implantation of a CIED
10129824|NCT04298996||study group (passive smoking children)|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
10129825|NCT04298996||control group|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
10129826|NCT04298944||BeHealthY Cohort|Children from BeHealthY cohort who are obese/overweight but do not have mood disorders are eligible for this study. The children will be given additional questionnaires to assess emotional/behavioral well being.
10129827|NCT04298944||CHAMPION trial Cohort|"Children who are overweight/obese and have severe mental illness, and who have agreed to be contacted for future research.~Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments."
10129828|NCT04298944||Pediatric Medical Psychiatric (PMP) Clinic Cohort|Children from the PMP Clinic who have severe mental illness but healthy weight. Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments.
10129829|NCT04298879|Experimental|IBI376|IBI376 will be administered orally at a dose of 20 mg once daily for 8 weeks followed by 2.5 mg once daily.
10129830|NCT04299087|Experimental|Dystonia and/or tremor|Adults with a diagnosis of dystonia and/or tremor
10129831|NCT04299087|Experimental|Control|Healthy adults without a history of any neurological disorder, with a similar age distribution and sex ratio as the dystonia and/or tremor group
9694624|NCT04787276|Active Comparator|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
9694625|NCT04787276|Active Comparator|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
9826043|NCT02404805|Experimental|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
9968015|NCT01275651||Ancillary-Correlative (AR activity in CRPC)|Previously collected bone marrow tissue and blood samples are analyzed for AR activity, AR splice variations, expression of androgen transport/synthesis/metabolism genes, AKR1C3 protein levels, and testosterone and dihydrotestosterone levels via RT-PCR, SNP microarrays, IHC, gene expression analysis, and mass spectrometry methods.
9694626|NCT04787081|Experimental|Sleep Care Positioning Training Program GRP1|A sleep care positioning lesson created by a University's postural-care scholars using Camtasia® video creation software with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of interactive videos embedded with learning checkpoints. All videos included narration and closed captioning. The following link contains the videos which were modified post-study to reflect some of the participant's feedback: https://stkatentpc.weebly.com/
9968016|NCT01275690||subjects with PH undergoing right heart catheterization|
9968017|NCT01275703||patients with PH undergoing exercise testing|
9968018|NCT01275716|Experimental|Patients who are shown the images|
9968019|NCT01275716|No Intervention|Patients who are not shown the images|
9968020|NCT01275729|Experimental|Lasix|Pt to get dose of furosemide after meeting entry criteria - dose dependent on previous exposure to diuretics
9968021|NCT01275742|No Intervention|Usual Care|
9968022|NCT01275768|Experimental|Experimental arm|Insertion and activation of the endo-biliary RF catheter at the site of the stricture before insertion of a Self-expandable Metal Stent (SEMS)
9968023|NCT01275768|Placebo Comparator|Control arm|Insertion and sham activation of the endo-biliary RF catheter at the site of the stricture before insertion of a SEMS
9968024|NCT01275781|Experimental|A|[14C]-AZD9742 1000 mg intravenous over 2 hours
9968025|NCT01275794||1|Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
9968026|NCT01275807|Experimental|acupuncture|10 acupuncture sessions
9968027|NCT01275807|Active Comparator|self care|psychological support, phisical exercice, diet, self care groups
9968028|NCT01275820||Nutralin|All 10 subjects in the study will consume the investigational food product.
9968029|NCT01275859|Experimental|Letrozole, Lapatinib|Letrozole 2.5mg po qd + Lapatinib 1500mg po qd for 18-21 wks
9968030|NCT01275872|Experimental|Guided Imagery and Progressive Muscle Relaxation|
9968031|NCT01275885|Active Comparator|Vitamin D3 10µg|
9968032|NCT01275885|Active Comparator|Vitamin D3 30µg|
9968033|NCT01275885|Active Comparator|Vitamin D3 40µg|
9968034|NCT01275898||Beach chair|Patients scheduled for surgical procedure in beach chair position (Shoulder surgery)
9968035|NCT01275898||Sitting position|Patients scheduled for surgical procedure in sitting position (Neurosurgery)
9968036|NCT01275898||Head down position|Patients scheduled for surgical procedure in head down position (daVinci robotic surgery)
9968037|NCT01275898||Prone position|Patients scheduled for surgical procedure in prone position
9968038|NCT01275911|Experimental|Esmolol|
9968039|NCT01275911|Active Comparator|Remifentanil|
9968040|NCT01275924|Active Comparator|Tightrope|Treatment with Tightrope Syndesmosis Repair Kit
9968041|NCT01275924|Active Comparator|Syndesmotic screw|Treatment with a quadricortical syndesmotic screw
9968042|NCT01275937|Other|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days followed by40mg once daily orally for two months.
9968043|NCT01275937|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days followed by 40mg once daily orally for two months.
9968044|NCT01275963||Control|Healthy individuals without structural heart disease
9968045|NCT01275963||CAD|Patients with coronary artery disease
9968046|NCT01275963||DCM|Participants with dilated cardiomyopathy
9968047|NCT01275963||HNCM|Patients with hypertrophic non-obstructive cardiomyopathy
9968048|NCT01275963||HOCM|Patients with hypertrophic obstructive cardiomyopathy
9968049|NCT01275963||RCM|Patients with restrictive cardiomyopathy
9968050|NCT01275963||Amyloidosis|Patients with cardiac manifestation of amyloidosis
9968051|NCT01275963||HFPEF|Patients with heart failure with preserved ejection fraction (diastolic heart failure)
9968052|NCT01275976|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor, 100 U/kg bodyweight
9968053|NCT01275976|Placebo Comparator|Saline 0.9%|Saline 0.9%
9968054|NCT01275989|Sham Comparator|21|sham acupuncture
9968055|NCT01275989|No Intervention|15|Control
9968056|NCT01275989|Active Comparator|20|intervention
9968057|NCT01276002|No Intervention|No stenting|Control group, no stenting of the pancreatic duct in case of a disrupted duct
9968058|NCT01276002|Active Comparator|Pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
9968059|NCT01276015|Experimental|botulinum toxin A|botulinum toxin A diffusion in cerebral palsy
9968060|NCT01276028|Experimental|Acupuncture|This group will start acupuncture treatments within 3 weeks of consent and continue to receive up to 20 treatments over a six month period. The number of treatments will be jointly determined by the participant and the acupuncturist.
9968061|NCT01276028|Other|Waitlist|This group of participants will be asked to wait 6 months and will then be allowed to receive acupuncture.
9968062|NCT01276067|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
9968063|NCT01276067|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
9968064|NCT01276080|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
9968065|NCT01276080|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
9968066|NCT01276093|Experimental|PVI ablation|Pulmonary Vein Ablation
9968067|NCT01276093|Active Comparator|Amiodarone medical treatment|Amiodarone medical treatment
9968068|NCT01276119|Experimental|Cohort A, CDP6038 0.001 mg/kg, iv|
9968069|NCT01276119|Experimental|Cohort B, CDP6038 0.01 mg/kg, iv|
9968070|NCT01276119|Experimental|Cohort C, CDP6038 0.03 mg/kg, iv|
9968071|NCT01276119|Experimental|Cohort D, CDP6038 0.1 mg/kg, iv|
10129832|NCT04299217|Active Comparator|Mango Leaf Extract|300 mg Mangifera indica (mango) leaf extract standardized to ≥ 60% mangiferin (Zynamite®), plus carrier
9968072|NCT01276119|Experimental|Cohort E, CDP6038 0.3 mg/kg, iv|
9968073|NCT01276119|Experimental|Cohort G, CDP6038 1.0 mg/kg, iv|
9968074|NCT01276119|Experimental|Cohort I, CDP6038 3.0 mg/kg, iv|
9968075|NCT01276119|Experimental|Cohort K, CDP6038 10.0 mg/kg, iv|
9968076|NCT01276119|Placebo Comparator|Cohort A, Placebo, iv|
9968077|NCT01276119|Placebo Comparator|Cohort B, C, D, E, G, I, K, Placebo, iv|
9968078|NCT01276119|Experimental|Cohort F, CDP6038 0.3 mg/kg, sc|
9968079|NCT01276119|Experimental|Cohort H, CDP6038 1.0 mg/kg, sc|
9968080|NCT01276119|Experimental|Cohort J, CDP6038 3.0 mg/kg, sc|
9968081|NCT01276119|Placebo Comparator|Cohort F, H, J, Placebo, sc|
9968082|NCT01276132||Subjects who are designated to receive same-day PCI|
9968083|NCT01276132||Subjects who had been admitted to the hospital after their PCI|
9968084|NCT01276158|Active Comparator|Ultrasound|Arterial line placed with Ultrasound guidance.
9968085|NCT01276158|Active Comparator|Doppler|Arterial line placed with doppler guidance
9968086|NCT01276210|Experimental|Treatment|See Detailed Description
9968087|NCT01276249||Fortevo Endograft|All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who meet the inclusion/exclusion criteria for the registry, are eligible for enrollment if treated with the Fortevo Endograft.
10129833|NCT04299217|Placebo Comparator|Placebo|Carrier (placebo)
9968088|NCT01276262|Placebo Comparator|Treatment A|Monophasic oral contraceptive (Microgynon® 30) with placebo tablets
9968089|NCT01276262|Experimental|Treatment B|Monophasic oral contraceptive (Microgynon® 30) and fostamatinib
9968090|NCT01276275||Exposure Group 1|First time users of ticagrelor
9968091|NCT01276275||Exposure Group 2|First time users of clopidogrel
9968092|NCT01276275||Exposure Group 3|First time users of prasugrel
9968093|NCT01276340||1|women with urinary incontinence
9968094|NCT01276366|Active Comparator|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
9968095|NCT01276366|Active Comparator|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
9968096|NCT01276366|Active Comparator|Breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
9968097|NCT01276392||Heparin|10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
9968098|NCT01276392||CiCa|10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
9968099|NCT01276405||Cohort|
9968100|NCT01276418|Experimental|Treatment|
9968101|NCT01276431|Other|Buprenorphine transdermal patch|For two age groups: 50-60 years and >= 75 years of age
9968102|NCT01276444|Active Comparator|Pulmonary artery catheter (PAC)|PAC was used to guide hemodynamic therapy after combined valve repair
9968103|NCT01276444|Active Comparator|COMPLEX|An combination of transpulmonary thermodilution and continuous monitoring of central venous saturation was used to guide hemodynamic therapy after combined valve repair surgery.
9968104|NCT01276496|Experimental|Treatment (cilengitide, paclitaxel)|"Patients receive cilengitide IV over 1 hour on days* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16."
9968105|NCT01276522|Experimental|Canakinumab|A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.
9968106|NCT01276548|Experimental|Genexol®-PM plus Carboplatin|
9968107|NCT01276548|Active Comparator|Genexol® plus Carboplatin|
9968108|NCT01276561|Active Comparator|Single Incision Splenectomy|Patients will undergo splenectomy through a single incision in the umbilicus regardless of the technique or equipment used
9968109|NCT01276561|Active Comparator|Laparoscopic Splenectomy|Patient will undergo standard laparoscopic splenectomy, port placement is surgeon dependent
10129834|NCT04298957|Other|See and treat|Cone biopsi is offered to women age ≥ 45 years referred to Department of Obstetrics and Gynecology due to a positive cervical screening test and partly or invisible transformation zone.
10183819|NCT03760757|Experimental|PCSO-524® (no krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. Amounts per day equal to 800 mg olive oil, 400 mg lipid extract (~58 mg EPA and 44 mg DHA) and 1.8 mg vitamin E (d-alpha-tocopherol).
9968110|NCT01276600|Experimental|Arm 1|1 tablet orally weekly
9968111|NCT01276600|Experimental|Arm 2|One tablet orally twice weekly
9968112|NCT01276600|Experimental|Arm 3|Two tablets orally twice weekly
9968113|NCT01276600|Experimental|Arm 4|One tablet orally daily
9968114|NCT01276613|Experimental|Intraoperative Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal.
9968115|NCT01276613|Experimental|Intraoperative Gemcitabine + Losartan|"Losartan 50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.~Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal."
9968116|NCT01276626|Experimental|Bifidobacterium longum|
9968117|NCT01276626|Placebo Comparator|Maltodextrin|
9968118|NCT01276665|Experimental|Restrictive regimen group|treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.
10129835|NCT04299191|Experimental|Dose Escalation|"The dose level corresponds to 80% of the maximum tolerated dose of 2-OHOA in adult patients when adjusted for body surface area. The escalation will be to the 100%, and 120% of the maximum tolerated dose of 2-OHOA in adult patients when adjusted for body surface area. Dose escalation decisions will be made by all active Investigators in collaboration with the Medical Monitor when at least three patients have completed the DLT observation period (Cycle 1) at each dose level. When the third patient at any given dose level has received 14 days of therapy, an escalation teleconference will be scheduled after that patient has completed the DLT observation period (Cycle 1). The decision to progress to the next dose level will be made on the basis of review of all significant 2-OHOA-related toxicities."
10129836|NCT04299204|Experimental|Years 1997-2007|Group-1, PCNL was performed in the first 10 years period (Years 1997-2007);
10129837|NCT04299204|Experimental|2008- to the present|The PCNL was performed in the second ten years period from 2008 to the present.
10129838|NCT04298866|Other|Experimental arm|
10129839|NCT04299477|Experimental|Patients with periodontitis and osteoporosis|Group 1 : Patients who have periodontitis and osteoporosis prescribed with bisphosphonates
10129840|NCT04299477|Experimental|Systemically healthy patients with periodontitis|Group 2: Patients who have no systemic diseases but diagnosed as periodontitis
10129841|NCT04299477|No Intervention|Systemically and periodontally healthy individuals|Group 3: Healthy controls
10129842|NCT04298892||hematologic disorder or malignancy|
10129843|NCT04299022||Prospective Registry|Treatment for diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with Vivigen Cellular Bone Matrix
10129844|NCT04299022||Retrospective Data Collection|Treatment of diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with adjunct bone graft utilized in the acute, delayed, non-union and fusion settings.
10129845|NCT04298970|Active Comparator|Intervention|Consuming a product containing 35-40 gram of freeze dried kale a day.
10129846|NCT04298970|Placebo Comparator|Placebo|Consuming a placebo product.
10129847|NCT04299126|Experimental|high absorption pad for blood and pus|High absorption pad for blood and pus with natural antimicrobial agent composes of sericin and chitosan. It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
10129848|NCT04299126|Active Comparator|commercial wound dressing|Commercial wound dressing is gauze dressing impregnated with paraffin, containing 0.5% chlorhexidine acetate (Bactigras). It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
10129849|NCT04298775|Active Comparator|spinal anesthesia with morphine|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine + 200 mcg of Morphine
10129850|NCT04298775|Active Comparator|spinal anesthesia without morphine + peripheral nerve block|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine and peripheral nerve block with 0.2 to 0.375% Ropivacaine, in a volume of 20 to 30 mL.
10129851|NCT04298723|Experimental|Left Atrial Appendage Occlusion|Percutaneous closure of the LAA by use of CE-mark approved LAA occlusion device Watchman / Watchman FLX
10129852|NCT04298723|No Intervention|Best medical therapy for anticoagulation|Standard of care (according to current guidelines)
10129853|NCT04298645|Experimental|High GI carbs breakfast / dinner|Participants will receive a meal rich in high GI carbohydrates for breakfast (day 5) first. After the wash-out day (day 6), the identical meal will be provided for dinner (day 7).
10129854|NCT04298645|Experimental|High GI carbs dinner / breakfast|Participants will receive a meal rich in high GI carbohydrates for dinner (day 5) first. After the wash-out day (day 6), the same meal will be provided for breakfast (day 7).
10129855|NCT04298931||Patients undergoing open abdominal surgery|
10129856|NCT04298762|Placebo Comparator|Comparison Group|Physicians in the control group did not receive peer comparison emails.
10129857|NCT04298762|Experimental|Intervention Group|Physicians in the intervention group received peer comparison emails.
10129858|NCT04298840|Experimental|Creatine Monohydrate|
10129859|NCT04298840|Placebo Comparator|Placebo|
10129860|NCT04299035|Experimental|Thoracic surgery + ESPblock|Thoracic surgery + ESPblock + standard pain management
10129861|NCT04299035|Experimental|Abdominal surgery + ESPblock|Abdominal surgery + ESPblock + standard pain management
10129862|NCT04299035|Experimental|Spinal surgery + ESPblock|Spinal surgery + ESPblock + standard pain management
10129863|NCT04299035|No Intervention|Thoracic surgery|Thoracic surgery + standard pain management
10129864|NCT04299035|No Intervention|Abdominal surgery|Abdominal surgery + standard pain management
10129865|NCT04299035|No Intervention|Spinal surgery|Spinal surgery + standard pain management
10129866|NCT04298710|Experimental|Arm Cycling|Arm cycling on an arm crank ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
10129867|NCT04298710|Experimental|Leg Cycling|Leg cycling on a leg cycling ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
10129868|NCT04298710|Placebo Comparator|Sitting|Participants will remain seated after carbohydrates consumption.
10129869|NCT04298528|Experimental|dronabinol|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
10129870|NCT04298528|Placebo Comparator|placebo|Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.
10129871|NCT04298788|Placebo Comparator|White dishware|standard white dishware used in the home
10129872|NCT04298788|Experimental|blue dishware|specially designed blue dishware, plates and bowls
10129873|NCT04298489|Experimental|stage III/IV gastrointestinal cancer patients|The study group (Personalized drug sensitivity test) was treated according to the physician's opinion. Tumor tissues are obtained during the surgery or via biopsy with informed consent, for the purpose of ex vivo assay.
10129874|NCT04298749|Experimental|GX-P1 dose level 1|GX-P1 dose level 1
10129875|NCT04298749|Experimental|GX-P1 dose level 2|GX-P1 dose level 2
10129876|NCT04298749|Experimental|GX-P1 dose level 3|GX-P1 dose level 3
10129877|NCT04298671|Experimental|Yoga-Pilates Group|The 30-minute web-based video exercise program will combine the best yoga-Pilates exercises focused on the pelvic floor, based on prior research and expert opinion, in collaboration with yoga-Pilates instructors that participants will complete 4 times per week for 8 weeks.
10129878|NCT04298658||HIV and Insomnia|Participants will test positive for HIV and Insomnia.
10129879|NCT04298658||HIV Without Insomnia|Participants will test positive for HIV and test negative for Insomnia.
10129880|NCT04298658||Non HIV with Insomnia|Participants will test negative for HIV and test positive for Insomnia.
10129881|NCT04298658||Non HIV Without Insomnia|Participants will test negative for HIV and test negative for Insomnia.
10129882|NCT04298684|Experimental|Metformin|In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control.
10129883|NCT04298684|Placebo Comparator|Sitagliptin|In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months.
10129884|NCT04298385||Individuals with oblique proximal phalanx fractures of finger|Traction orthosis and exercise
10129885|NCT04298294|Experimental|injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with i-PRF& bone graft
10129886|NCT04298294|No Intervention|no injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with bone graft
10129887|NCT04298333|Experimental|BP-C1|BP-C1 will be used as supportive care
10129888|NCT04298554|Experimental|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration - 1 ml (20mg) qd PO, hold under tongue for 1 minute and swallow daily
10129889|NCT04298554|Placebo Comparator|Placebo (hemp oil)|CBD PURE Hemp Oil- 1 ml qd PO, hold under tongue for 1 minute and swallow daily
10129890|NCT04298281||Parents of patients who have a family care conference criteria|These will be parents of patient who have one of our defined family care conference criteria
10129891|NCT04298281||Parents of patients who do not have a family care conference criteria|These will be parents of patients who do not have one our defined family care conference criteria
10129892|NCT04298736|Experimental|Bariatric Surgery|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to either laparoscopic Roux-en-Y Gastric Bypass or laparoscopic Sleeve Gastrectomy
10129893|NCT04298736|Active Comparator|Lifestyle Modification|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to guided diet and physical activity.
10129894|NCT04298580|Active Comparator|PVB before surgery|
10129895|NCT04298580|Active Comparator|PVB after surgery|
10129896|NCT04298801|Experimental|Nurse-driven HIV screening for key populations+UD|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing (UD)
10129897|NCT04298801|Active Comparator|Physician-directed diagnostic testing alone|
10129898|NCT04298476|Placebo Comparator|A|Saline will be placed in syringe instead of ropivicaine 0.2% and the nerve block will be placed in the adductor canal at the desired location by the anesthesiologist
10129899|NCT04298476|Active Comparator|B|An adductor canal block will be placed with local anesthetic in the proximal 1/3 of the operative leg
10129900|NCT04298476|Active Comparator|C|An adductor canal block will be placed with local anesthetic in the middle 1/3 of the operative leg
10129901|NCT04298476|Active Comparator|D|An adductor canal block will be placed with local anesthetic in the distal 1/3 of the operative leg
10129902|NCT04298424|Experimental|Peer-led|The experimental group will conduct a 4-week peer self-management program and receive the original outpatient routine care.
10129903|NCT04298424|No Intervention|No Peer-led|The control group will only issue a self-management manual and receive the original outpatient routine care.
10129904|NCT04298216|Active Comparator|Assessment of Inferior Vena Cavae with Subcostal View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the subcostal region.
10129905|NCT04298216|Experimental|Assessment of Inferior Vena Cavae with Transhepatic View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the transhepatic region.
10129906|NCT04298346||Case|
10129907|NCT04298346||Control|
10129908|NCT04298112||relapse after radical treatment for prostate cancer|prostate cancer patients with biochemical relapse following radical treatment, or patients with persistently elevated PSA levels after radical prostatectomy, that have been (or will be) referred to PSMA PET/CT and PSMA PET/MRI at one of the participating hospitals.
10129909|NCT04298515|Other|Type 2 Diabetes group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
10129910|NCT04298515|Other|Insulin resistance group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
9826044|NCT02404805|Experimental|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
10129911|NCT04298515|Other|Obesity group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
10129912|NCT04298411|Experimental|Experimental Arm|Participants will take part in 12 one-hour rehabilitation sessions over 12 weeks in the clinic at Holland Bloorview Kids Rehabilitation Hospital and Institut de réadaptation en déficience physique de Québec, during which they will play games developed for the Novint Falcon.
10129913|NCT04298320|Experimental|SHR-1210 + AIN457|SHR-1210 was administered 200mg iv every 2 weeks in combination with AIN457 150mg or 300mg ih every 2 weeks
10183820|NCT03760757|Experimental|ESPO-572® (75% PCSO-524®, 25% krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. ESPO-572®, a 75/25% PCSO-24®/Krill oil blend. Each capsule of the ESPO-572® contains green lipped mussel oil, krill oil, olive oil and vitamin E.
9519563|NCT03285919|Active Comparator|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
10129914|NCT04298125|Experimental|Exercise in Pregnancy in Community|The Expecting intervention at the ACNC includes three 30-45 minute, in-person exercise sessions per week. The sessions are gradually increased in length over the first weeks of participation, and are comprised of 15-30 minutes of moderate aerobic activity (recumbent bike, walking on a treadmill or on an elliptical machine) as well as 5-10 minutes of resistance training using hydraulic exercise equipment. The sessions conclude with stretching exercises. Throughout the session, a personal trainer assesses the rating of perceived exertion using the 6 to 20 point Borg scale of exhaustion.41 Between sessions, participants are asked to monitor their daily step count with a target of 10,000 steps per day using a pedometer provided to the participant. This number is reported to or downloaded by the personal trainer at each in-person session. These elements will be adapted to provide a similar exercise experience that is accessible to women in their local community.
10129915|NCT04298125|No Intervention|Standard Care|Participants will receive guidance on exercise from their physician as usual.
10129916|NCT04298697|Experimental|TDF/FTC for one week|The first 10 participants (Arm A) will take TDF/FTC for three consecutive days of one week and will have biologic specimens collected at 8 study time points.
10129917|NCT04298697|Experimental|TDF/FTC for four weeks|The second 10 participants (Arm B) will take TDF/FTC for three consecutive days for four weeks and will have biologic specimens collected at 20 study time points.
10129918|NCT04298177|Experimental|QDOT-LAWT|"A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used.~The primary ablation mode for PVI will depend on the calculated LAWT at each atrial point, as follows:~**< 3.5-mm LAWT (red, and yellow colors): vHPSD ablation will be performed. If <1-mm LAWT (red color): Power 90 W; the duration of RF applications will be reduced to 2 seconds. If 1-3.5 mm LAWT (yellow color): Power 90 W; the duration of RF applications will be 4 seconds, according to the QDOT-FAST protocol.~**> 3.5-mm LAWT (green color): QMODE ablation will be performed. 50 W with AI target = 500"
10129919|NCT04298177|Active Comparator|CLOSE|"In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. A ThermoCool® SmartTouch® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA) will be used. The ablation will be performed using a proprietary RF generator (SMARTABLATE®; Biosense Webster, Diamond Bar, CA, USA).~Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of ≥ 400 at the posterior wall/roof and ≥ 550 at the anterior wall are reached."
10129920|NCT04298450|Experimental|Active SMS Intervention|Participants assigned to the experimental arm will receive the active SMS intervention. Participants in the active intervention group who consent to participate will be asked to complete a web-based survey. Based on survey findings, purposive sampling will be used to select a subsample of 12 to 20 participants for qualitative interviews.
10129921|NCT04298450|Sham Comparator|Sham SMS|Participants assigned to the sham comparator will receive the sham SMS intervention. They will not be re-contacted.
10129922|NCT04298164|Experimental|Intervention group|Group that receives the intervention
10129923|NCT04298164|Active Comparator|Control group|Group that receives treatment as usual
10129924|NCT04297943|Active Comparator|3D Orthosis|See summary
10129925|NCT04297943|Active Comparator|Custom Thermoplastic Orthosis|See summary
10129926|NCT04297865|Experimental|A dose as CJ-15314 or placebo|Oral administration of A as CJ-15314 or placebo once a day
10129927|NCT04297865|Experimental|B dose as CJ-15314 or placebo|Oral administration of B as CJ-15314 or placebo once a day
10129928|NCT04297865|Experimental|C dose as CJ-15314 or placebo|Oral administration of C as CJ-15314 or placebo once a day and once daily for 7 days
10129929|NCT04297865|Experimental|D dose as CJ-15314 or placebo|Oral administration of D as CJ-15314 or placebo once a day and once daily for 7 days
10129930|NCT04297865|Experimental|E dose as CJ-15314 or placebo|Oral administration of E as CJ-15314 or placebo once a day and once daily for 7 days
10129931|NCT04297865|Experimental|F dose as CJ-15314 or placebo|Oral administration of F as CJ-15314 or placebo once a day and once daily for 7 days
10129932|NCT04297878|Experimental|Group A|Taking two SsK12 lozenges at night on days 1, 7 and 14.
10129933|NCT04297878|Active Comparator|Group B|One SsK12 daily at night for 14 days.
10129934|NCT04298047|Experimental|Intervention group|The participants in the Intervention group will be participants of the MMFA participatory art-based activity.
10129935|NCT04298047|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the MMFA participatory art-based activity.
10129936|NCT04298021|Experimental|AZD6738 + Durvalumab|"Durvalumab 1500 mg iv on D1~AZD6738 240 mg bid on D15-D28 Every 4 weeks C1D1 dose of durvalumab will be delivered, and AZD6738 of 240 mg bid will be dosed at D15-D28. Every cycle consists of 4 weeks."
10129937|NCT04298021|Experimental|AZD6738 + Olaparib|"AZD6738 160 mg qd on D1-D7~Olaparib 300 mg bid on D1-D28 Every 4 weeks Every cycle consists of 4 weeks. AZD6738 of 160 mg qd will be administered on D1-D7. Olaparib will be delivered as 300 mg bid dose on D1-D28."
10129938|NCT04298138|Experimental|Low dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
10129939|NCT04298138|Experimental|Medium dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
10129940|NCT04298138|Experimental|High dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
10129941|NCT04297995|Experimental|HLX10 Plus HLX07 (stage 1L)|3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly
10129942|NCT04297995|Experimental|HLX10 Plus HLX07 (Stage 1H)|3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly
10129943|NCT04298008|Experimental|AZD6738 + Durvalumab Cohort|This is a study enrolling advanced BTC patients who have been previously treated with immunotherapy, to explore the combination of AZD6738+durvalumab
10129944|NCT04297982|Experimental|Intervention group (Mandala activity)|Scales were applied to the experimental group in the first encounter with the adolescent (pre-test). Then, a total of two sessions of individual mandala activities were performed at least 48 hours apart. Each adolescent freely drawn and painted the unstructured mandala on white paper, starting from the center and expanding. The same scales were reapplied last (post-test).
10129945|NCT04297982|Other|Control group|Scales were applied to the control group with an interval of 5 days and received routine nursing care (pre-test, post-test).
10129946|NCT04298593|Other|ECG monitoring|All patient will be under telemetry
10129947|NCT04298619||Standard cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:~symptom assessment~blood tests~physical examination"
10129948|NCT04298619||Imaging cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:~symptom assessment~blood tests~physical examination~Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes"
10129949|NCT04297969||GCK Glow fixation|Patients screened with GoCheck Kids flash concentrated iPhone 7+
10129950|NCT04297930||Paul Glaucoma Implant Surgery|Patients who had surgery with the Paul Glaucoma Implant
10129951|NCT04298398|Experimental|Mindfulness (MBCT)|Group therapy based on Mindfulness Based-Cognitive Therapy (MBCT).
10129952|NCT04298398|Experimental|Emotion Focused Therapy (EFT-CR)|Group therapy based on Emotion Focused Therapy for Cancer Recovery (EFT-CR).
10129953|NCT04298398|Other|Control Group|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
10129954|NCT04298060|Experimental|DAS181 SD group Cohort 1, Stage 1|DAS181 SD group 4.5mg/day for 7 or 10 days
10129955|NCT04298060|Experimental|DAS181 HD group Cohort 1, Stage 1|DAS181 HD group 9mg/day for 7 or 10 days.
10129956|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 1|Placebo 0mg/day for 7 or 10 days
10129957|NCT04298060|Experimental|DAS181 group, Cohort 1, Stage 2|DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.
10129958|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 2|Placebo 0mg/day for 7 or 10 days
10129959|NCT04298060|Experimental|DAS181 group, Cohort 2, Stage1 and 2|DAS181 4.5mg/day or 9mg/day for 7 or 10 days
10129960|NCT04297891||ARSACS|Participants with genetically confirmed ARSACS (ORPHA:98) will be recruited. Target sample size for the ARSACS cohort is 120.
10129961|NCT04297891||SPG7|Participants with genetically confirmed SPG7 (ORPHA:99013) will be recruited. Target sample size for the SPG7 cohort is 72.
10129962|NCT04297891||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as the ARSACS and SPG7 cohort. Target sample size for the control cohort is 50.
10129963|NCT04297787|Other|Treatment|The treatment protocol the study team will be following is as follows for all enrolled patients. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
10129964|NCT04297761|Placebo Comparator|Filtered air|Subjects will be exposed once to filtered air for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
10129965|NCT04297761|Experimental|Wood Smoke|Subjects will be exposed to air containing wood smoke for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
10129966|NCT04297774|Experimental|virtual reality group|18 sessions of standard treatment plus virtual reality treatment.
10129967|NCT04297774|Active Comparator|standard treatment group|18 sessions of standard treatment plus balance training.
10129968|NCT04297813|Active Comparator|Control|The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.
10129969|NCT04297813|Experimental|Test|Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate
10129970|NCT04297839|Active Comparator|Control Group|"Patients in this group will receive heparin during hemodialysis sessions, at a dose of 1.000 units at the beginning and 500 units per hour in a syringe infusion pump.~If the patient has a contraindication for the heparin use, it will receive saline continuous administration.~This is the actual standard of care performed in extended hemodialysis sessions."
10129971|NCT04297839|Experimental|Citrate Group|Patients in this group will receive regional citrate anticoagulation, with acid-citrate-dextrose 2.2% (ACD). Dose of 3 mmol per liter of filtered blood. The systemic calcium levels are measured every two hours and a solution of calcium chloride is infused in a peripheral venous access, accordingly to citrate infusion rate and the systemic calcium values.
10129972|NCT04297540|Experimental|Active-tDCS group|8 sessions (in two weeks) of active tDCS combined with a virtual reality training
10129973|NCT04297540|Sham Comparator|Sham-tDCS group|8 sessions (in two weeks) of sham tDCS combined with a virtual reality training
10129974|NCT04297735|Active Comparator|Standard of care group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
10129975|NCT04297735|Experimental|Telemedicine group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
10129976|NCT04297384|Active Comparator|Group I (standard educational materials, surveys)|Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
9519564|NCT03285906|Experimental|Treatment group|Apatinib：500 mg，po，qd
9519565|NCT03285893||Native Hawaiian cigarette smokers|oral cell DNA adducts
9968119|NCT01276665|Active Comparator|Control group|treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)
9968120|NCT01276678||Control|300 healthy controls free from any pharmacologic therapy
9968121|NCT01276678||Suspected CAD - Cardiac Cathetrization|subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
9968122|NCT01276691|Active Comparator|Acute, Aspirin|81 mg asprin provided 30 minutes prior to firefighting- Acute single dosage
9968123|NCT01276691|Placebo Comparator|Acute, Placebo|Acute single dosage of placebo provided 30 minutes prior to firefighting
9968124|NCT01276691|Active Comparator|Chronic, Aspirin|81 mg asprin provided prior to firefighting- 14 day dosage
9968125|NCT01276691|Placebo Comparator|Chronic, Placebo|14 day dosage of placebo provided prior to firefighting
9968126|NCT01276704|Experimental|flaxseed lignan, SDG|Secoisolariciresinol diglycoside
9968127|NCT01276704|Placebo Comparator|Placebo|Matched Placebo
9968128|NCT01276717|Experimental|Vorinostat + Carfilzomib|
9968129|NCT01276730|Experimental|Group A|Treatment consists of Interferon, given as a sub-cutaneous injection, 3 times per week for 4 weeks, 20 mg Retinoic Acid tablets, 2 times a day for 30 days. starting from the first day of radiation.
9968130|NCT01276730|Active Comparator|Group B|"Treatment consists of radiation and chemotherapy using Cisplatin. Cisplatin, given intravenously, will be administered on the first day of each week, mixed with saline solution, before and after the Cisplatin infusion.~Radiation will be given for a few minutes daily, five days a week, for approximately 5 weeks.~Two weeks after completion of external radiotherapy, subject will receive internal radiation (brachytherapy) once a week for two weeks. For this internal radiation a specially designed instrument will be inserted into the vagina that will be connected to a machine for a few minutes."
9968131|NCT01276743||T1DM|Children and adolescents with T1DM
9968132|NCT01276743||Unaffected Population|Population not known to be affected by T1DM
9968133|NCT01276769|Active Comparator|ET|The control arm receive the paclitaxel plus epirubicin
9968134|NCT01276769|Experimental|PC|the experimental arm which receive the paclitaxel combined with carboplatin
9968135|NCT01276782|Placebo Comparator|Pregnant SLE|Pregnant SLE patients with autoimmune thyroid antibodies will be randomized to levothyroxine or Placebo
9968136|NCT01276795|Experimental|Glucose and whey protein|Patients who are randomly allocated to this group will receive a drink made of anhydrous beet dextrose and pressurized whey protein in water (200 g/L + 100g/L). Patients will sip the drink for 4 hours of the 6 hour study.
9968137|NCT01276795|Active Comparator|Glucose only|The patients who are randomly allocated to this arm will receive a drink composed of anhydrous beet dextrose in water (200g/L). They will sip the drink for 4 hours of the 6 hour study.
9968138|NCT01276808|Experimental|Magnetic navigation PCI|These patients will be treated with magnetically navigated percutaneous coronary intervention
9968139|NCT01276808|Active Comparator|Conventional PCI|These patients will be treated with normal standard percutaneous coronary intervention
9968140|NCT01276834|Experimental|everolimus-based immunosuppression|immunosuppression with everolimus, prednisone and mycophenolate
9968141|NCT01276834|Active Comparator|standard immunosuppression|immunosuppression with tacrolimus, prednisone and mycophenolate
9968142|NCT01276873|Experimental|Closed System|Application of Tracheal aspiration closed system, controlled by the use of Open system to tracheal aspiraiton.
9968143|NCT01276886||Acute Diverticulitis|
9968144|NCT01276899||Neoadjuvant setting|
9968145|NCT01276899||Metastatic setting|
9968146|NCT01276925|Active Comparator|B3: Blockade of three nerves|Peripheral nerve blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with ropivacaine.
9968147|NCT01276925|Active Comparator|B2: Blockade of 2 nerves|"Peripheral nerve blockade of the anterior division of the obturator nerve and the lateral femoral cutaneous nerve with ropivacaine.~Sham blockade of the femoral nerve with saline."
9968148|NCT01276925|Sham Comparator|K: Control group|Sham blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with saline.
9968149|NCT01276938|Active Comparator|IORT 21 Gy|Single fraction 21 Gy Intraoperative Radiation Therapy for breast tumors with diameter between 10 and 25 mm
9968150|NCT01276938|Experimental|IORT 18 Gy|Single fraction 18 Gy Intra Operative Radiation Therapy in breast tumors smaller than 10 mm.
9968151|NCT01276951|Placebo Comparator|Placebo|
9968152|NCT01276951|Active Comparator|6,5g Dose Group|
9968153|NCT01276951|Active Comparator|12g Dose Group|
9968154|NCT01276951|Active Comparator|25g Dose Group|
9968155|NCT01276951|Active Comparator|50g Dose Group|
9968156|NCT01276964||1. Women in the fertile age|Healthy women in the fertile age (between 20-45 years) with apparently normal periods
9968157|NCT01276977|Experimental|Zolmitriptan 5 mg nasal spray|
9968158|NCT01276977|Active Comparator|Eletriptan 40 mg Tablet|
9968159|NCT01276990|Placebo Comparator|Placebo|Matching placebo in dosing regimen 1-8
9968160|NCT01276990|Experimental|BI 224436 dosing regimen 1|Dosing regimen 1
9968161|NCT01276990|Experimental|BI 224436 dosing regimen 2|Dosing regimen 2
9968162|NCT01276990|Experimental|BI 224436 dosing regimen 3|Dosing regimen 3
9968163|NCT01276990|Experimental|BI 224436 dosing regimen 4|Dosing regimen 4
9968164|NCT01276990|Experimental|BI 224436 dosing regimen 5|Dosing regimen 5
9968165|NCT01276990|Experimental|BI 224436 dosing regimen 6|Dosing regimen 6
9968166|NCT01276990|Experimental|BI 224436 dosing regimen 7|Dosing regimen 7
9968167|NCT01276990|Experimental|BI 224436 dosing regimen 8|Dosing regimen 8
9968168|NCT01277003|Experimental|Aculife Magnetic Wave Therapist|patients with carpal tunnel syndrome treated with Aculife
9968169|NCT01277003|Active Comparator|TENS|patients with carpal tunnel syndrome treated by TENS
9968170|NCT01277016|No Intervention|MDex:|"MDex:~Administration of oral melphalan (M) at 0.22 mg/kg and dexamethasone (Dex) at 40 mg daily for 4 consecutive days every 28 days (MDex) until end of therapy"
10129977|NCT04297384|Experimental|Group II (personalized information, surveys)|Participants receive personalized information about their cancer, treatment, and side effects. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
10129978|NCT04297670||Unvaccinated against HPV boys|Sexually active unvaccinated against HPV 16-20 years old boys.
10129979|NCT04297410|Experimental|Neoadjuvant LuPSMA|
10129980|NCT04297371||CTD with RVH|The diagnosis of CTD was made based on the clinical classification criteria. The RVH patient was diagnosed by an echocardiography demonstration (later confirmed by CMR) of a hypertrophic RV (maximal end-diastole RV wall thickness >4 mm) due to CTD.
10129981|NCT04297371||CTD without RVH|The diagnosis of CTD was made based on the clinical classification criteria.The subjects were enrolled as having non-RVH if their RV wall thickness was ≤ 4 mm (later confirmed by CMR).
10129982|NCT04297371||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
10129983|NCT04297748|Experimental|Cohort A|Patients (pts) will receive an initial trace (100 mg, IV) dose of zirconium-89 (1.8-2.5 mCi) labelled M7824 (89Zr-M7824) on day 1, sequential PET imaging over 1 week will be performed to determine the biodistribution 89Zr-M7824 into the tumour and normal tissues. All patients who remain on study after Day 14 will have a 1200 mg dose of M7824 q2w beginning on Cycle 1 Day 15. Pts will then receive a 2nd infusion of 100 mg of 89Zr-M7824 with cold M7824 making a total dose of 1200mg on Day 29. All patients will then receive a dose of cold 1200mg M7824 on Cycle 1 Day 43. Patients will continue to receive a therapeutic dose of 1200 mg q2w of M7824 until disease progression or unacceptable toxicity. Patients who do not achieve a CR after 3 doses of M7824 in Cycle 1, may then commence treatment with concurrent chemotherapy with carboplatin and pemetrexed at conventional doses.
10129984|NCT04297748|Experimental|Cohort B|Cohort A will determine whether or not high PD-L1 positive disease is required at study entry to Cohort B. All other assessments within cohort A will be undertaken.
10129985|NCT04297280|Experimental|TACE in combination with sintilimab|TACE treatment starts at day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator decision. Sintilimab will be initiated on day 14 after the first TACE session. Sintilimab will be administered every three weeks (200mg fixed dose IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10129986|NCT04297696|Experimental|exercise group|therapeutic exercises
10129987|NCT04297696|No Intervention|control group|
9968171|NCT01277016|Experimental|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
10129988|NCT04297215|Placebo Comparator|Control group|This group will receive therapeutic clothing without antimicrobial agents
10129989|NCT04297215|Active Comparator|Chitosan group|This group will receive antimicrobial therapeutic clothing based on chitosan
10129990|NCT04297215|Active Comparator|Silver group|This group will receive antimicrobial clothing based on silver.
10129991|NCT04297657|Experimental|intervention group|
10129992|NCT04297657|No Intervention|control group|
10129993|NCT04297202|Experimental|Apatinib Combined With SHR-1210 Injection|"SHR-1210 Injection: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle; Apatinib : D1-D21 : 250 mg, orally, qd; Before surgery, the patient's surgical pathology samples still need to be collected.~D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation;~After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. The cycle of a three-week plan will be performed with a total of 8 cycles with the treatment of Apatinib combination with SHR-1210 Injection."
10129994|NCT04297176|Experimental|Traditional monitoring method|Patients are dosed using two timed vancomycin serum concentrations
10129995|NCT04297176|Active Comparator|One concentration method|Patients are dosed based on one timed vancomycin serum level
10129996|NCT04297163|Active Comparator|Hospital management|Patient's receive no intervention, the follow up is the usual for a patient following CPAP therapy.
10129997|NCT04297163|Experimental|Telemedicine management|CPAP remote monitoring of patients, including a mobile application and a voicemail.
10129998|NCT04297553|Active Comparator|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
10129999|NCT04297553|Active Comparator|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
10130000|NCT04297189|Experimental|Coaching Intervention|Single arm pilot study of coaching intervention
9826045|NCT02404805|Experimental|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
9826046|NCT02405091|Experimental|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
9826047|NCT02405091|Experimental|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
9968172|NCT01277029||lower urinary tract symptoms|
9968173|NCT01277068|Active Comparator|the adjustable gastric banding|
9968174|NCT01277068|Active Comparator|the sleeve gastrectomy|
9968175|NCT01277068|Active Comparator|the gastric bypass|
9968176|NCT01277094|Experimental|1|
9968177|NCT01277094|Placebo Comparator|2|
9968178|NCT01277107|Experimental|Zaleplon AP formulation|Gastric Retentive Dual Release Zaleplon (Zaleplon AP)
9968179|NCT01277107|Placebo Comparator|Placebo|Identical placebo capsule
9968180|NCT01277120||Cohort|
9968181|NCT01277133||Cohort|
9968182|NCT01277146|Experimental|OMP-59R5|
9968183|NCT01277172|Experimental|Group 1 / PBO-326|This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.
9968184|NCT01277172|Active Comparator|Group 2 / Mabthera|This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.
9968185|NCT01277172|Experimental|Group 3 / PBO-326|This group will be treated six cycles with PBO-326
9968186|NCT01277172|Active Comparator|Group 4 / Mabthera|This group will be treated six cycles with Mabthera
9968187|NCT01277185|Active Comparator|Low Calcium Diet (600-1200 mg/d)|
9968188|NCT01277185|Active Comparator|High Calcium Diet (1100-2300mg/d)|
9968189|NCT01277198||surgery without using a flexible cystoscopy|surgery without using a flexible cystoscopy: patients who did not undergo a flexible cystoscopy during laparoscopic stone surgery
9968190|NCT01277198||surgery with using a flexible cystoscopy|surgery with using a flexible cystoscopy: patients who underwent a flexible cystoscopy during laparoscopic stone surgery
9968191|NCT01277224|Experimental|Movi2 Program|
9968192|NCT01277224|No Intervention|Control|
9968193|NCT01277237|Active Comparator|Omacor|
9968194|NCT01277237|Placebo Comparator|Lactose tablet|
9968195|NCT01277250|Other|Usual Care|Standard smoking cessation information provided to all hospitalized patients as part of discharge packet.
9968196|NCT01277250|Experimental|Smoking Cessation Program|"Web-based program tailored to patients who smoke and are hospitalized. Program is tailored to participant's specific hospital experience and other characteristics. E-messages, social support and a transition coach are provided to each participant in this condition."
9968197|NCT01277276||Diagnostic tool|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
9968198|NCT01277289|Experimental|Ery-dex|Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
9968199|NCT01277289|Placebo Comparator|Placebo|placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
9968200|NCT01277328||Cohort|Cohort
9976733|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fed|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
9976734|NCT01354457|Experimental|Epratuzumab and 90Y-Epratuzumab|Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
9976735|NCT01354470|Experimental|Modafinil|
9976736|NCT01354470|Placebo Comparator|placebo (cornstarch)|
9976737|NCT01354483|Experimental|Treatment Group A|Umbilical cord blood mononuclear cell, 1.6 million
9976738|NCT01354483|Experimental|Treatment Group B|Umbilical cord blood mononuclear cell, 3.2 million
9976739|NCT01354483|Experimental|Treatment Group C|Umbilical cord blood mononuclear cell, 6.4 million
9976740|NCT01354483|Experimental|Treatment Group D|Umbilical cord blood mononuclear cell, 6.4 million; mehtylprednisolone
9976741|NCT01354483|Experimental|Treatment Group E|Umbilical cord blood mononuclear cell, 6.4 million; methylprednisolone; 6 week course of lithium carbonate tablet
9976742|NCT01354509||Current protocol group|Patients treated with current standards based on physician discretion.
9976743|NCT01354509||Normothermia group|Normothermia protocol, using Hydrogel cooling Pads(Arctic Sun) applied for 96 hrs starting upon admission to the ICU
9976744|NCT01354522|Active Comparator|TAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
9976745|NCT01354522|Experimental|TCX|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
9976746|NCT01354535|Active Comparator|Cable plating with strut|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
9976747|NCT01354535|Active Comparator|isolated plating|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
9976748|NCT01354548|Experimental|TheraBite grupp|
9976749|NCT01354548|No Intervention|Conventional treatment|
9976750|NCT01354561|Sham Comparator|control group|Physiotherapy in the control group were also done at hospital, in dorsal decubitus position at 30-degree elevation, all receiving the same treatment given for the paediatric inpatients, except nasotracheal suction, which was not performed due to ethical reasons.
9976751|NCT01354561|Active Comparator|respiratory disease group|Respiratory disease group consisting of hospitalized children with acute viral bronchiolitis
9976752|NCT01354574|Experimental|High Glycemic Index meals|Three days of run-in diet with meals containing high glycemic index carbohydrates followed by test day with breakfast meal containing high glycemic index carbohydrates.
9976753|NCT01354574|Experimental|Low Glycemic Index meals|Three days of run-in diet with meals containing low glycemic index carbohydrates followed by test day with breakfast meal containing low glycemic index carbohydrates.
9968201|NCT01277367|Active Comparator|A|These members will be offered no additional incentives
9968202|NCT01277367|Experimental|B|These members will receive regular communications by Discovery Vitality.
9968203|NCT01277367|Experimental|C|These members will nominate a charity which will benefit financially based on participants' level of physical activity.
9968204|NCT01277367|Experimental|D|These members are entered into a prize draw for a monthly cash prize if they achieve physical activity targets.
9968205|NCT01277367|Experimental|E|These members will receive a direct payment.
9968206|NCT01277367|Experimental|F|These members will be offered the opportunity to choose one of three incentive options at the time of enrollment in the study.
9968207|NCT01277380||Experimental Group|
9968208|NCT01277380||Control Group|
9968209|NCT01277380||Negative control group|
9968210|NCT01277393||Experimental Group|
9968211|NCT01277393||Control Group|
9968212|NCT01277406|Experimental|4SC-201+FOLFIRI|
9968213|NCT01277406|Active Comparator|FOLFIRI|
9968214|NCT01277419||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist
9968215|NCT01277419||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist
9968216|NCT01277419||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
9968217|NCT01277419||Crohn's disease|Patients with Crohn's disease
9968218|NCT01277419||Acute anterior uveitis|Patients with acute anterior uveitis
9968219|NCT01277419||Axial psoriatic arthritis|Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)
9968220|NCT01277432||Psychiatrist interview|"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
9968221|NCT01277432||Depression screening|"All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.~All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.~Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;~Patient Health Questionnaire (PHQ-9)~Depression Anxiety and Stress Scale (DASS-21)~Diabetes Distress Scale (DDS-17)~Life events questions (Inter-Heart Study)~Diabetes Empowerment Scale (C-DES 20)~Summary of Diabetes Self Care Activities (SDSCA-15)~Euroqol-5D (EQ-5D)"
9968222|NCT01277445|Placebo Comparator|Placebo|15g/day maltodextrin for 28 days
9968223|NCT01277445|Active Comparator|Prebiotic|Consumption of 15g/day of inulin-fructan for 28 days
9968224|NCT01277458||Non white HIV positive men who have sex with men|
9968225|NCT01277471|Experimental|Arm A: 6 and 2 meals/day|6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
9968226|NCT01277471|Active Comparator|Arm B: 2 and 6 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
10130001|NCT04297254|Experimental|Lenvatinib 12 mg or 8 mg|Participants with body weight (BW) greater than or equal to (>=) 60 kilogram (kg), will receive lenvatinib 12 milligram (mg) (03 capsules), and participants with BW less than (<) 60 kg, will receive lenvatinib 8 mg, (02 capsules), orally, once daily with or without food in 28-day cycles for a maximum 6 cycles of 4 weeks each for a total of 24 weeks or until disease progression, death, intolerable or unacceptable toxicity, or withdrawal of consent, whichever occurs earlier.
9968227|NCT01277484|Experimental|Decitabine, MDS treatment, IV injection|For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day ~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
9968228|NCT01277497|Experimental|Sevelamer carbonate|1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
9968229|NCT01277497|Active Comparator|Calcium acetate|1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks
9968230|NCT01277536||hospitalization >24 hours|
9968231|NCT01277562||Breast Cancer|Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
9968232|NCT01277562||Prostate Cancer|Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
9968233|NCT01277575|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
9968234|NCT01277575|Sham Comparator|Placebo stimulation|Sham stimulation (placebo condition) no intervention
9968235|NCT01277588||Patient|
9968236|NCT01277588||Physcician|
9968237|NCT01277614|Experimental|Lifestyle counseling|This is a 6-month intervention in which participants with 2 or more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
9968238|NCT01277614|Placebo Comparator|Health Literature|
9968239|NCT01277627|Active Comparator|Nevirapine|
9968240|NCT01277627|Active Comparator|Non-nevirapine|
9968241|NCT01277640|Placebo Comparator|matched placebo|
9968242|NCT01277640|Placebo Comparator|universal placebo|
9968243|NCT01277640|Active Comparator|dapivirine|
9968244|NCT01277653||PIVKA-II and AFP 6 months|PIVKA-II and AFP measurement every 6 months
9968245|NCT01277653||tumor maker interval every 6 month|tumor maker interval every 6 month
9968246|NCT01277679|Other|Healthy Volunteer|Healthy Volunteer cohort
10130002|NCT04297527|Experimental|Conventional Physiotherapy Group|Group I (18 subjects) received 15 sessions of Conventional Physiotherapy program (CPP) 5 times per week.
10130003|NCT04297527|Experimental|Mulligan Mobilization Group|Mulligan Mobilization was administered 9 sessions (3 days a week, for 3 weeks). .
10130004|NCT04297527|Experimental|Conventional Physiotherapy plus Mulligan Mobilization Group|Conventional Physiotherapy (15 session) plus Mulligan Mobilization Programme (9 session) were applied in this group. CP were applied 5 days a week and CP+MM 3 days a week for 3 weeks.
10130005|NCT04297475||rheumatoid arthritis|The patients are diagnosed with RA according to the American College of Rheumatology (ACR) criteria, and the current clinical state was in-active or relapse. The patients receive final diagnosis and disease evaluation by two experienced rheumatologists
10130006|NCT04297501||All participants|All enrolled participants in this study
10130007|NCT04297462|Experimental|3-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during three consecutive days after the contact with influenza
10130008|NCT04297462|Active Comparator|7-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during seven consecutive days after the contact with influenza
10130009|NCT04297228|Experimental|Step by Step Program|"Thirteen 1.5 hour weekday educational sessions, five 1-hour weekday fitness classes and seventeen 1 hour weekend walks/farmer's market trips were scheduled over 22 weeks. The planned total contact time was 41.5 hours, above the minimum effective amount and recommended by the USPSTF. Children participated in all activities. Weekly text messages with motivational messages and reminders were planned.~Educational Topics included:~Intro and Goal Setting How to Read Nutrition Labels How to Build a Healthy Meal Choose My Plate/Walking for Fitness Healthy Fast Food Add More Fruits/Vegetables to Meals Add More Physical Activity Each Day Healthy Snacks and Drinks Healthy Desserts Circuit Training at Home Favorite Recipe Makeover Step by Step Jeopardy Celebration of Completion"
10130010|NCT04297267|Experimental|GP group|Patients should receive four cycles of GP regimen (cisplatin at 75 mg/m2 iv infusion on day 1 plus gemcitabine at 1250 mg/m2 iv infusion over 30 min on day 1 and 8 every 3 weeks).
10130011|NCT04297319|Experimental|1 - Laser intervention|Laser diiodo treatment, 3 procedures of 5-10 minutes at intervals of 4 weeks
10130012|NCT04297319|Placebo Comparator|2 - Laser placebo|Only the laser speculum is placed in the vagina but the laser is not activated. 3 procedures of 5-10 minutes at intervals of 4 weeks
10130013|NCT04297332|Experimental|Arm I (active EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
10130014|NCT04297332|Experimental|Arm II (active EFT, control FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.
10130015|NCT04297332|Experimental|Arm III (control EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
10130016|NCT04297332|Active Comparator|Arm IV (control EFT, control TFP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.
10130017|NCT04297306|Active Comparator|Exercise prescription|"This group will be provided with a prescript exercise program, taken from UK National Guidance.~The advice will be directed to be undertaken for 6 weeks immediately prior to surgery."
10130018|NCT04297306|Experimental|Exercise prescription and Virtual Reality Exercise Gaming|"This group will be provided with a prescript exercise program as in Arm 1. However, this group of patients will also be presented with a Virtual Reality Headset, pre-programmed with Exercise promoted games which will be provided to support and encourage their exercise regimen.~Again this advice and support will be directed to be undertaken for 6 weeks immediately prior to surgery."
10130019|NCT04297137|Experimental|Mycoprotein|Ingestion of 30 g mycoprotein drink
10130020|NCT04297137|Experimental|Spirulina|Ingestion of 30 g spirulina protein drink
10130021|NCT04297137|Experimental|Chlorella|Ingestion of 30 g chlorella protein drink
10130022|NCT04297137|Experimental|Pea|Ingestion of 30 g pea protein drink
10130023|NCT04297137|Experimental|Lupin|Ingestion of 30 g lupin protein drink
10130024|NCT04297137|Active Comparator|Milk|Ingestion of 30 g milk protein
10130025|NCT04296955|Experimental|Health communication intervention|Motivational interview as a new health communication intervention (one arm)
10130026|NCT04296955|No Intervention|Standard care|Standard care
10130027|NCT04297072||Rivaroxaban|Participants in this group administered oral anticoagulant Rivaroxaban
10130028|NCT04297072||Vitamin-K antagonists (VKAs)|Participants in this group administered oral anticoagulants VKAs
10130029|NCT04296929|Experimental|Affected arm in lymphedema patients|Complex decongestive physiotherapy treatment will be applied to the arm (affected arm) that develops lymphedema after unilateral breast cancer treatment.
9826048|NCT02405325|Experimental|Physical Activity|The program will be run by peer Leaders and senior center staff with the support of UCSD staff. Participants will work towards a 2000 increase in daily steps through self-paced incidental walking and peer led group walks.
10130030|NCT04296929|No Intervention|Unaffected arm in lymphedema patients|After unilateral breast cancer treatments, the non-lymphedema side in the upper extremities, is the unaffected arm. No treatments will be applied to the unaffected side.
10130031|NCT04296916|Experimental|Intervention arm|medical reduction of IOP by eyedrops
10130032|NCT04296916|No Intervention|control arm|follow up without medication
10130033|NCT04296786|Experimental|Chidamide plus Sintilimab|Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.
9519566|NCT03285893||White (European Americans) cigarette smokers|oral cell DNA adducts
10130034|NCT04297085|Experimental|Cases|
10130035|NCT04297033|Experimental|Lovastatin intervention|combination of 40mg/d 12m lovastatin and symptomatic treatment drugs as a treatment strategy for BAVM .
10130036|NCT04297033|Placebo Comparator|placebo|combination of placebo and symptomatic treatment drugs as a treatment strategy for BAVM
10130037|NCT04297111|Placebo Comparator|Placebo|Maltodextrin containing capsule
10130038|NCT04297111|Experimental|Probiotic|Probiotic containing capsule
10130039|NCT04297059|Experimental|Intervention group|Implementation of Ajyal Salima intervention to promote healthy eating and encourage physical activity in Lebanese school-children.
10130040|NCT04297059|No Intervention|Control group|Group of students not receiving any intervention
10130041|NCT04297020||Pre-menopausal BCS + ET|Pre-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
10130042|NCT04297020||Post-menopausal BCS + ET|Post-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
10130043|NCT04297020||Pre-menopausal Healthy Control|Pre-menopausal healthy control group
10130044|NCT04297020||Post-menopausal Healthy Control|Post-menopausal healthy control group
10130045|NCT04297046|Active Comparator|QLB for total abdominal hysterectomy|Quadratus lumborum block (QLB) was performed bilaterally with 0,3 ml/kg 0.25% bupivacaine (maximum dose 3 ml/kg) solution injection on each side.Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
10130046|NCT04297046|Active Comparator|TAPB for total abdominal hysterect0my|The transversus abdominis plane block (TAPB)was performed bilaterally with 0.3 ml/kg of 0.25% bupivacaine (maximum dose 3 ml/kg) solution . Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
10130047|NCT04296968|Experimental|Expectation and experimental pain in humans|
10130048|NCT04296721|Experimental|Intensive weight-loss program|The life style change program will consist of two stages. The first will consist of a 3-month period of intensive diet and progressive exercise with biweekly consultations with a nutritionist (in groups or individually). The second stage will last for 9 months, until completion, with a diet that is progressively higher in calories, with more intense exercise, under the supervision of a community nurse and an individual nutritional consultation at 9 months.
10130049|NCT04296721|Active Comparator|Standard dietary recommendations|Patients will be followed according to the usual recommendations: A written diet (designed by a hospital nutritionist) and an exercise plan, depending on the patient's age and activity level, without any other type of evaluation or visit Visits in the Sleep Disorders Unit will be scheduled at 3 and 12 months
10130050|NCT04296851|Experimental|niclosamide|650mg daily
10130051|NCT04296851|Placebo Comparator|placebo|identical- appearing placebo
10130052|NCT04296669|Experimental|Full desk allocation|All children within this classroom received a sit-stand stand
10130053|NCT04296669|Experimental|Partial desk allocation|six sit-stand desks were provided in this classroom. Children were rotated between these desks and traditional desks
10130054|NCT04296669|No Intervention|Control|Traditional classroom furniture was used
9519567|NCT03285893||Japanese American cigarette smokers|oral cell DNA adducts
9519568|NCT03285880|Experimental|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
10130055|NCT04296708|Experimental|ExerCube group|The ExerCube is an immersive fitness game setting that combines innovative soft- and hardware designs with state of-the-art training concepts. The ExerCube has three walls which serve as virtual reality projection screens and haptic interfaces. The ExerCube is a playful physical-cognitive exergame training. The user navigates a virtual environment/reality via whole body exercise. The video game navigates the user and triggers various cognitive functions. The used physical exercises are functionally and elicit the improvement of endurance and strength components. Via different monitoring systems (points and heart rate), the game adapts to the individual abilities and training level to tailor workout intensity. The ExerCube training consists of two sessions a week each session will last about 30 minutes of which 25 minutes will be pure playtime
10130056|NCT04296708|No Intervention|Control group|The control group does not have any additional ExerCube training.
10130057|NCT04297007|Active Comparator|Group P = PECS-II group|In group P, PECS will be performed with patients in the supine position at the end of the surgery before extubation by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions the high frequency linear probe (11-12 MHz) will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. US probe will be placed on the 4th rib. The muscles PMm, Pmm and Sam will be visualized. At the anterior axillary level or mid-axillary level, via the in-plane technique, Pecs II will be applied by injecting 20 mL of 0.25% bupivacaine in a cephalad to caudad direction to the fascia on Sam.
10187641|NCT03724240|Experimental|gpASIT+™ (Grass Pollen-ASIT+™)|Experimental: gpASIT+™ The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 with a grass pollen peptide concentration of 100 µg/mL. Excipients are sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml.The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
9519569|NCT03285880|Experimental|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
9519570|NCT03285880|Experimental|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
9519571|NCT03285867||HCC received TACE|observational study set only one group with HCC received TACE
9519572|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
9519573|NCT03285841||Vulvar sites|Imaging vulvar lesions
9826049|NCT02405325|No Intervention|Usual Care|Measurement at baseline, 6, 12, 18 and 24 months only with a health related event at each time point.
9968247|NCT01277679|Other|Heart Failure|Heart Failure cohort
10130058|NCT04297007|Active Comparator|Group R = RIB group|In group R, RIB block will be performed with patients in the lateral decubitus position at the end of the surgery before extubation. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injectted into the fascial plane.
10130059|NCT04297007|No Intervention|Group C = Control group|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
10130060|NCT04296994|Experimental|Open-label Dose Escalation and Expansion Study of QL1706|"Part 1 (Dose escalation): QL1706 will be administered in sequential cohorts each receiving 1 of 4 doses of QL1706 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The PK parameters of QL1706 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
10130061|NCT04296682|No Intervention|Atraumatic Extraction Without Gingival Graft|Alveolar closure with elevation of total flaps and simple suture (Silk thread 4.0, Ethicon, Johnson & Johnson, SJC).
10130062|NCT04296682|Experimental|Atraumatic Extraction With Gingival Graft|Closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual palate.
10130063|NCT04296760||Women with suspicious of deep posterior pelvic endometriosis|
10130064|NCT04296825|Placebo Comparator|P|Patients received cow milk for 4 consecutive weeks (two times per day, 10 gram each time).
10130065|NCT04296825|Active Comparator|CA|Patients received camel milk with Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
10130066|NCT04296825|Experimental|C|Patients received camel milk for 4 consecutive weeks (two times per day, 10 gram each time).
10130067|NCT04296825|Experimental|A|Patients received Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
10130068|NCT04296604|Experimental|Traumatic Brain Injury|This group consists of individuals diagnosed with traumatic brain injury. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130069|NCT04296604|Experimental|Major Depressive Disorder|This group consists of individuals diagnosed with major depressive disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130070|NCT04296604|Experimental|Bipolar Disorder|This group consists of individuals diagnosed with bipolar disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130071|NCT04296604|Experimental|Schizophrenia|This group consists of individuals diagnosed with schizophrenia. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130072|NCT04296604|Experimental|Attention Deficit Hyperactivity Disorder|This group consists of individuals diagnosed with attention deficit hyperactivity disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130073|NCT04296604|Experimental|Borderline Personality Disorder|This group consists of individuals diagnosed with borderline personality disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130074|NCT04296604|Experimental|Substance Use Disorder|This group consists of individuals diagnosed with substance use disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130075|NCT04296604|Active Comparator|Healthy Controls|This group consists of individuals diagnosed with healthy controls. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
10130076|NCT04296838|Experimental|refractory UME patients treated with Conbercept|patients in this arm should meet the inclusion criteria and the definition of refractory UME
10130077|NCT04296812|Experimental|Injeti Self-Love Model|"Psychoeducational intervention focusing improving self-esteem and increasing self-awareness.~The session will start with discussion on healthy relationships, self-esteem.~A white board will be used in group format and regular 8.5 by 11 paper during individual session to illustrate the Self-Love model and the characteristics and traits that are effected by self-love and lack of self-love.~At the end of illustration and discussion there will be handout of the self-love intervention.~The session will end by answering questions and emphasizing the importance of having self-awareness of traits that promote low-self-esteem, and finally, strategies to promote and maintain self-esteem."
10130078|NCT04296630|Active Comparator|Message #1|This arm will receive one of three social media messages that is preferred by our target population through focus groups that are being conducted as part of a previous study.
10130079|NCT04296630|Active Comparator|Message #2|This arm will receive the second social media message that is preferred by our target population as identified from our previous focus group study.
10130080|NCT04296630|Active Comparator|Message #3|This arm will receive the third social media message that is preferred by our target population as identified from our previous focus group study.
10130081|NCT04296630|Active Comparator|Tailored Arm|This arm will receive social media messages that will be tailored by one of the following variables: gender (men/women), age (younger/older), location (urban/rural), or social economic status (level of education). Testing to be conducted in a previous study will identify the variable that messages are tailored by.
10130082|NCT04296513||High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white-light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.
10130083|NCT04296513||High-definition magnification with digital chromoendoscopy.|The subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
10130084|NCT04296422|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
10130085|NCT04296422|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
10130086|NCT04296422|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
10130087|NCT04296474|Active Comparator|Active ILIT treated|Patients that have received ILIT with birch and grass allergen 5-6 years previously
10130088|NCT04296474|Placebo Comparator|Non- AIT treated|Patients that have received placebo ILIT 5-6 years previously and patients with birch and grass pollen induced allergic rhinitis that have not previously been treated with allergen immunotherapy (AIT).
10130089|NCT04296747|Experimental|Induction therapy|patients would accept toripalimab combined with chemotherapy as induction therapy, then radical treatment(surgery or chemoradiotherapy) according to whether the tumor could be resectable or the evaluation result according to RECIST1.1. Ones with PD after induction therapy will enter survival follow-up directly
10130090|NCT04296591||study group|The study group consisted of late preterm cases(34-37 weeks of gestation) and
10130091|NCT04296591||control group|the control group consisted of term cases (<37 weeks of gestation).
10130092|NCT04296656|Active Comparator|Intervention group|"Mothers in the intervention group were taught the infant calming technique 5 S's, a part of The Happiest Baby (THB) method. THB is based on the theory that infants have an innate calming reflex that can soothe infant fussing, excessive crying and prolong sleep. This reflex is triggered by five activities that mimic the sensory milieu of the womb. The 5 S's include swaddling, side position, sound (white noise), swing and suck.~The intervention consisted of a 20-minute face-to-face guidance session with the researcher, executed individually in the mother's hospital room. Each mother was given a leaflet to take home that explained the 5 steps in short. Safety issues, such as safest sleep position (supine), allowing hips to flex and how to avoid overheating when swaddled, were addressed. The same researcher executed each guidance session to maintain standardization."
10130093|NCT04296656|No Intervention|Control group|Standard care on postpartum ward (breastfeeding and infant care guidance and support in recovering from childbirth and transitioning into parenthood).
10130094|NCT04296500||Decision tree algorithm training/testing|The investigators divided data of 67 patients into 5 groups to do 5 fold cross validation. Four groups were used to train decision tree algorithm and one group was used to test it.
10130095|NCT04296643|Experimental|Medical Mask|Medical Mask worn when providing care to patient with febrile respiratory illness
10130096|NCT04296643|Active Comparator|N95 respirator|N95 respirator worn when providing care to patient with febrile respiratory illness
10130097|NCT04296331||POC only|Participants who enter the DC Department of Corrections within the first 2 months of the study will be offered opt-out Point-of-Care (POC) rapid testing
10130098|NCT04296331||POC + Ag/Ab|Participants who enter the DC Department of Corrections within the third and fourth months of the study will be offered opt-out POC and 4th generation laboratory-based antigen/antibody testing (Ag/Ab)
9826050|NCT02405390|Experimental|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
9968248|NCT01277692|Experimental|Part 1: Single Dose Escalation in Healthy Subjects|The doses currently planned are 10, 30mg, 100mg, 200mg
9968249|NCT01277692|Experimental|Part 2: Repeat Dose Escalation in Healthy Subjects|The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
9968250|NCT01277692|Experimental|Part 3: Single Dose Escalation in HCV Infected Subjects|The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
9968251|NCT01277705|Experimental|Group A|
9968252|NCT01277705|Experimental|Group B|
9968253|NCT01277705|Active Comparator|Group C|
9968254|NCT01277731|Experimental|Methylprednisolone replacement|"This study will enroll the patients who were previously experienced dexamethasone-induced hiccup. Patients who experienced dexamethasone-induced hiccup during chemotherapy will enroll to study arm.~Run-in period * Dexamethasone 10mg-20mg q day iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Treatment period * Methylprednisolone 60mg-125mg iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Response will be evaluated by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and NRS to hiccup at 24hrs after start methylprednisolone.~Nausea and vomiting will be assessed as CTCAE 4.0"
9968255|NCT01277770||Kidney Transplant Recipients|Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
10130099|NCT04296331||Ag/Ab only|Participants who enter the DC Department of Corrections within the fifth and sixth months of the study will be offered Ag/Ab testing.
10130100|NCT04296877|Active Comparator|Habitual Contact Lens|All subjects are re-fit into habitual Acuvue® Oasys® contact lenses. Subjects are requested to wear the lenses for one week, for a minimum of at least 6 hours per day for 5 days.
10130101|NCT04296877|Active Comparator|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for two weeks, for a minimum of at least 6 hours per day for 10 days.
10130102|NCT04296526|Experimental|Precontemplation|
10130103|NCT04296526|Experimental|Contemplation|
10130104|NCT04296526|Experimental|Preparation|
10130105|NCT04296578|Experimental|Cohort 1: 5.5 mg selenite|Given orally, 5.5 mg selenite with food (within 30 mins of eating), for 5 weeks and monthly there after
10130106|NCT04296578|Experimental|Cohort 2: 11 mg selenite|Given orally, 11 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
10130107|NCT04296578|Experimental|Cohort 3: 16.5 mg selenite|Given orally, 16.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
10130108|NCT04296578|Experimental|Cohort 4: 22 mg selenite|Given orally, 22 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
10130109|NCT04296578|Experimental|Cohort 5: 27.5 mg selenite|Given orally, 27.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
10130110|NCT04296578|Experimental|Cohort 6: 33 mg selenite|Given orally, 33 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
10130111|NCT04296552|Experimental|12 week lowFODMAP dietary intervention|Patients with IBS-D are enrolled in a 12 week strict lowFODMAP dietary intervention study.
10130112|NCT04296461|Experimental|Welgenaleucel (UWC19)|Part I The safety and efficacy of Welgenaleucel (UWC19) will be evaluated in a standard 3+3 dose escalation approach.The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10^6 CAR-T cells/kg administered intravenously once.
10130113|NCT04296695|Experimental|B/F/TAF|50mg/600mg/300mg
10130114|NCT04296695|Active Comparator|TDF/3TC/EFV|300mg/300mg/400mg
10130115|NCT04296266|Experimental|Alda-341 treatment|Alda-341 treatment at 2 g/day for 14 days up until the day before regular medical care surgery.
10130116|NCT04296409||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Deglutition Handicap Index, and Turkish version of the Eating Assessment Tool.
10183821|NCT03760731|Experimental|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
10183822|NCT03760731|Active Comparator|Present Centered Therapy|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
10183823|NCT03760705||Coronary Artery Disease|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
10183824|NCT03760705||Heart Failure|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
10183825|NCT03760705||Atrial Fibrillation|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
10183826|NCT03760666|Experimental|Brequinar|Brequinar dosed orally. Multiple doses.
10183827|NCT03760666|Other|Brequinar + Ribavirin|Subjects in Cohort 2 may roll over to add ribavirin dosing; subjects in Cohort 3 will start with brequinar alone then add ribavirin dosing.
10183828|NCT03760653|Experimental|Physical Exercise and probiotic group|The subjects will receive 3 weekly sessions of combined exercise supervised by professionals in a specialized gym (60 minutes each one). The exercise will consist of a combination of aerobic and strength exercises involving the main muscle groups. They will take the probiotic supplementation at the established dose, 3 capsules/day before bedtime. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
10183829|NCT03760653|Experimental|Probiotic group|Participants will follow their usual sedentary lifestyle (i.e to practice less than 3 days a week of physical exercise, as is specified in the inclusion criteria). They will take the probiotic supplementation at the established dose. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum
10183830|NCT03760653|Placebo Comparator|Placebo group|They will follow their sedentary lifestyle. Placebo probiotic will consist of a maltodextrin capsule.
10183831|NCT03760614|Experimental|Entinostat + FOLFOX|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. Entinostat dose will vary between 2mg and 5mg depending on time of enrollment and observed toxicities. Dosing will begin at 3mg.
10183832|NCT03760601|No Intervention|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
10183833|NCT03760601|Experimental|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task selfguided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
10183834|NCT03760588|Experimental|Sacubitril/valsartan|Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: Sacubitril/valsartan 24/26 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by sacubitril/valsartan 49/51 mg b.i.d. for 2-4 weeks. Provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to sacubitril/valsartan 97/103 mg b.i.d. will be performed.
10130117|NCT04296487|Experimental|Autologous Chondrocyte Injection|Autologous chondrocytes were isolated and expanded in laboratory, then injected at 2x10^6 of cells per cm^2 of the cartilage defect.
10130118|NCT04296214||A|Azacitidine 50 mg/m2 for 10 days each 28 days
10130119|NCT04296214||B|Azacitidine 75 mg/m2 for 7 days each 28 days
10130120|NCT04296240|Experimental|Neoadjuvant chemotherapy|Oxaliplatin 130mg/m2 d1 and Capecitabine 1250mg/m2 bid1-14 or other fluorouracils, every 21 or 14 days for 2 to 4 cycles, and efficacy evaluation every 2 cycles;
10130121|NCT04296370|Experimental|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
10130122|NCT04296370|Experimental|Single Arm|Fluzoparib
10130123|NCT04296370|Active Comparator|Physician's choice chemotherapy|Capecitabine or Vinorelbine
10130124|NCT04296344|Experimental|Treatment|Participants with chronic pain to receive acupuncture therapy treatments and yoga therapy sessions.
10130125|NCT04296383|Experimental|Azithromycin plus Xiyanping injection group|
10130126|NCT04296383|Active Comparator|Azithromycin group|
10130127|NCT04296188|Active Comparator|serratus anterior plane block|The serratus anterior plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via patient controlled analgesia (PCA) device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
10130128|NCT04296188|Active Comparator|erector spina plane block|The erector spina plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via PCA device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
10130129|NCT04296279|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP014 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
10130130|NCT04296279|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,2 month."
10130131|NCT04296279|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 4,5,6 month."
10130132|NCT04296279|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
10130133|NCT04296279|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
10130134|NCT04296279|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
10130135|NCT04296201|Experimental|Treatment in the face area|5 female subjects will receive treatment in the face area
10130136|NCT04296201|Experimental|Treatment in the buttocks area|5 female subjects will receive treatment in the buttocks area
10130137|NCT04296201|Experimental|Treatment in the abdominal region|5 male subjects will receive treatment in the abdominal region
10130138|NCT04296175|Active Comparator|conventional group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 or 3 weeks followed by paclitaxel 80mg/m2 d1,d8,d15, every 3 weeks.
10130139|NCT04296175|Experimental|carboplatin group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 weeks followed by paclitaxel 80mg/m2 and carboplatin AUC=2 d1,d8,d15, every 4 weeks.
10130140|NCT04295980||Geschwind's area BAVMs|
9826051|NCT02405390|Active Comparator|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
10130141|NCT04295980||Healthy controls|
10130142|NCT04296162|Experimental|Single arm|6 cycle of oral vinorelbine or capecitabine combined with trastuzumab (21 days per cycle), followed by sequential single trastuzumab to 1 year
10130143|NCT04296045|Placebo Comparator|Glucose|
10130144|NCT04296045|Experimental|MCE|
10130145|NCT04296045|Experimental|MCE + Glucose|
10130146|NCT04296097|Experimental|Deep Brain Stimulation (DBS) activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position ON
10130147|NCT04296097|Other|Deep Brain Stimulation (DBS) non-activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position OFF
10130148|NCT04296032|Experimental|virtual reality group|Standard treatment 30 minutes plus virtual reality game 30 minutes, twice a week for 9 weeks.
10130149|NCT04296032|Active Comparator|standard treatment group|Standard treatment 60 minutes, twice a week for 9 weeks.
10130150|NCT04295798|Experimental|Traditional tDCS|At the beginning of stimulation, the current will be increased manually from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. Participants will be instructed to notify study personnel if and when they feel any uncomfortable sensation. The ramp-up will be stopped at this point and for the remainder of the session tDCS will be delivered at an intensity of 0.1 mA below the highest level reached. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
10130151|NCT04295798|Sham Comparator|Traditional Sham|A traditional sham will be used to maximize blinding of traditional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration as described with the Traditional tDCS will be used; however, current will automatically be ramped down 60 seconds after ramp-up.
10130152|NCT04295798|Experimental|Personalized tDCS|Baseline MRI's will enable personalization of tDCS via current flow modeling and optimized to each participant with the goal of generating an average nE over the dlPFC of the same size as the one delivered by a traditional montage using sponges in an average subject at 1.5 mA of current. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
10183835|NCT03760588|Placebo Comparator|Placebo|Matched to the comparator.
10130153|NCT04295798|Sham Comparator|Personalized Sham|An active sham will be used in which very low-level currents (0.5mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
10130154|NCT04295993|Experimental|methylene blue group|The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.
10130155|NCT04295993|Active Comparator|Norepinephrine group|The patients in this group will receive norepinephrine infusion.
10130156|NCT04295850||Low Dose Aspirin|Pregnant singletons with at least one high risk factor for preeclampsia (prior preeclampsia, chronic hypertension, pregestational diabetes, lupus, antiphospholipid antibody syndrome, or chronic kidney disease) who are planning to, but have not yet started, aspirin therapy <16 weeks' gestation. Patients will take 81mg aspirin as prescribed.
10130157|NCT04295967||1|presence of recurrence of urothelial carcinoma
10130158|NCT04295967||2|absence of recurrence of urothelial carcinoma
10130159|NCT04296149|Experimental|Y-90-DOTATOC|Patients affected by Small Intestine neuroendocrine tumors
10130160|NCT04295811|Experimental|EsoCheck and EsoGuard vs. EGD with or without biopsies|All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
10130161|NCT04295954|Experimental|Yoga Intervention|"This group will receive the Yoga Intervention for dysmenorrhea that will consist of 3 yoga sessions a week of 30 minutes each, for 12 weeks. The first 4 weeks 1 of the sessions will be face to face and the other 2 home sessions guided by a vieo and a brochure, and tutored from the virtual platform by the yoga teacher and researchers. This space will also serve for participants to share experiences.~After the first 4 weeks, participants will continue with the virtually tutored home yoga program, consisting of 3 weekly sessions of 30 minutes until completing the 12 weeks. They will be protected in all cases by the teacher and researchers.~All intervention group participants will be invited to participate in online focus groups during week 12 to explore their experiences and satisfaction with the progress of the study and to implement adaptations, if necessary.~They will be evaluated before the start of the yoga program per month, 3 months, 6 months and a year after the intervention."
10130162|NCT04295954|No Intervention|Control group without intervention|Participants in the comparison group without intervention will not receive yoga intervention, will follow their conventional treatment and their usual daily activities. They will be told not to do yoga. They will be evaluated in advance, per a month, 3 months, 6 months and a year after the intervention.
10130163|NCT04296110|Active Comparator|Control|Participants will receive music relaxation therapy. They will be asked to listen to designated music daily for 12 weeks.
10130164|NCT04296110|Experimental|Biofeedback|Participants will receive a biofeedback intervention. They will be asked to practice breathing at their designated resonance frequency using provided biofeedback device daily for 12 weeks.
10130165|NCT04296058||SOX4 high|Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group
10130166|NCT04296058||SOX4 low|Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group
10130167|NCT04295824||Mild AD|"20 subjects with mild local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally mild)."
10130168|NCT04295824||Moderate AD|"20 subjects with moderate local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally moderate)."
10130169|NCT04295824||Severe AD|"20 subjects with severe local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally severe)."
10130170|NCT04295824||Healthy|20 healthy volunteers
10130171|NCT04295876|No Intervention|Standard of Care|Women assigned to the control arm will receive self-directed (non-PN supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment [e.g., depression, substance use]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment.
10130172|NCT04295876|Experimental|BRIDGES Arm|Women assigned to The BRIDGES Project intervention arm will be connected with and receive Ryan White HIV/AIDS Program services (see above as described under Control Arm), as well as receive Peer Navigation support via one-on-one sessions, phone/text-based check-ins, and 6 unique syndemic-responsive 120 -minute group sessions designed to build coping skills (3 sessions) and assertive communication and behavior (3 sessions).
10130173|NCT04295746|Experimental|Serious Game ShopAut|Each participant played 10 game sessions, one per week, for no more than 30 minutes.
10130174|NCT04295655|Experimental|Global Exercise Group|all patients received the Control Group treatment added to global exercise treatment. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises. The number of repetitions was adapted to the subject's response taken into account the perceived dyspnea and fatigue during the exercise performance.
10183836|NCT03760549||Extension of NasoVAX high dose|A serum sample will be collected from each eligible subject who received NasoVAX at the 1×10(11th) vp dose in Study ALT-103-201 for evaluation of influenza hemagglutination assay against influenza A/California/07/2009(H1N1), a strain homologous to the one used for NasoVAX (monovalent AdcoCA09.HA). Ad5 antibody neutralization assay may also be performed.
10187642|NCT03724214|No Intervention|Pre-intervention|Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
9519574|NCT03285828|Other|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
10130175|NCT04295655|Experimental|Functional Electrostimulation Group|"all patients received the Control Group treatment plus neuromuscular stimulation therapy (SEFAR Rehab X2, DJO France S.A.S., France) on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
10130176|NCT04295655|Active Comparator|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy.
10130177|NCT04295473|Experimental|Reduced port laparoscopic gastrectomy|The definition of reduced port laparoscopic gastrectomy was 1-3 ports used in laparoscopic gastrectomy for gastric cancer.
10130178|NCT04295473|No Intervention|Standard laparoscopic gastrectomy|5 ports were used in standard laparoscopic gastrectomy
10130179|NCT04295460|Experimental|Dual Therapy|Dolutegravir plus lamivudine
10130180|NCT04295460|Active Comparator|Triple Therapy|Dolutegravir plus TAF/FTC
10130181|NCT04295525|Placebo Comparator|Controls subjects placebo|Placebo mucoadhesive oral tablet
9827441|NCT02455336|Experimental|Fenofibrate|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months
10130182|NCT04295525|Experimental|Controls subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
10130183|NCT04295525|Placebo Comparator|Diseased subjects placebo|Placebo mucoadhesive oral tablet
10130184|NCT04295525|Experimental|Diseased subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
10130185|NCT04295590|Experimental|Frequency then Intensity|Training period 1: Frequency comparison Training period 2: Intensity comparison
10130186|NCT04295590|Experimental|Intensity then Frequency|Training period 1: Intensity comparison Training period 2: Frequency comparison
10130187|NCT04295564|Experimental|eCPAP|Participants will remain on CPAP for 2 additional weeks once CPAP stability criteria is met.
10130188|NCT04295564|No Intervention|dCPAP|Participants will discontinue CPAP as per usual care once CPAP stability criteria is met.
10130189|NCT04295408|Placebo Comparator|PLACEBO|Pericapsular Nerve Group block with 40 ml saline
10130190|NCT04295408|Experimental|Pericapsular nerve group block|Pericapsular Nerve Group block with 2 mg.kg-1Ropivacaine in 40 ml of saline
10130191|NCT04295733||Cohort 1|Hematopoietic Stem Celi Transplant (HSCT) patients
10130192|NCT04295733||Cohort 2|HIV infected subjects
10130193|NCT04295733||Cohort 3|Patients candidates for / in treatment with biological drugs such as monoclonal antibodies anti CD-20 (rituximab or ocrelizumab)
10130194|NCT04295317|Experimental|Combined the therapy using Capecitabine and PD-1|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 2500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
10130195|NCT04295395||group1|preterm infant with closed ductus arteriosus, <32 weeks birth weight < 1500g, and > 72 hours of age
10130196|NCT04295395||group2|preterm infant with PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
10130197|NCT04295395||group3|preterm infant with hemodynamically significant PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
10130198|NCT04295720|Experimental|Transcranial magnetic stimulation (TMS)|We propose to test the efficacy of rTMS for the treatment of PCCI. Efficacy measures will include baseline and post-rTMS neuropsychological testing, functional MRI and biometry data using body worn sensors.
10130199|NCT04295447|Other|Standard of care|"Observation only or~An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
10130200|NCT04295447|Experimental|Apalutamide|30 cycles apalutamide 240 mg (4 x 60 mg) once daily on days 1-28 of a 28-day cycle in addition to standard of care
10130201|NCT04295642|Placebo Comparator|Part 1|Will include 4 subjects (3 active + 1 placebo) that will receive a single 15mg dose with approximately 48 hours of confinement and a follow-up after 7 days.
10130202|NCT04295642|Experimental|Part 2|"2A: will include 14 subjects to complete 12 with 28 days of dosing with 7 days (+/-2) of follow-up, with at least 14 days of confinement.~-or- 2B: will include 20 subjects to complete 12 with 2 dosing days and 5 days of washout with 7 days (+/-2) of follow-up, with 4 days of confinement (may be increased up to 12 days at the investigators discretion)."
10130203|NCT04295616|Experimental|IPV & active breathing training|"Intrapulmonary Percussive Ventilation (IPV) and active breathing exercises, provided by trained speech and language therapists.~This training will be performed in combination with a multidisciplinary rehabilitation programme."
10130204|NCT04295616|Active Comparator|Active breathing training only|Active breathing training provided by trained speech therapists. This training will be performed in combination with a multidisciplinary rehabilitation programme.
10130205|NCT04295551|Experimental|Experimental group of ordinary COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
10130206|NCT04295551|Active Comparator|Control group of ordinary COVID-19|ritonavir/ritonavir treatment
10130207|NCT04295551|Experimental|Experimental group of severe COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
10130208|NCT04295512|No Intervention|Usual Care|Community therapists delivering routine care to participant children with no training in UOT
10130209|NCT04295512|Experimental|UOT Training|Therapists enrolled in UOT Training
10130210|NCT04295369|Experimental|Lifestyle Medicine Group|
10130211|NCT04295369|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment.
10130212|NCT04295343||Patients with suspicious of rectosigmoid endometriosis|
10130213|NCT04295304|Experimental|NR600 device implantation|Retinal surgery and implantation of epi-retinal prosthesis
10130214|NCT04295603|Experimental|Toucher Massage intervention|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes on the foot area .
10130215|NCT04295603|Experimental|Homedics Machine intervention|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes."
10130216|NCT04295707|Experimental|Monthly replacement orthokeratology without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
10130217|NCT04295707|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
10130218|NCT04295707|Active Comparator|Yearly replacement lenses with weekly protein removal|Subjects will be prescribed with orthokeratology lenses which will be replaced at least every 12 months during the study period. They will be required to perform both daily cleaning and weekly protein removal for their lenses.
10130219|NCT04295668||Usual care|A contemporaneous control group of patients was build using propensity score matching (PSM) methodologies taking into account the following matching variables: type of surgery, age, sex, American Society of Anesthesiologists Index (ASA) and adjusted morbidity groups (GMA) grading.
10130220|NCT04295668||Prehabilitation|"Prospective sample of risk patients who are candidates for major surgery attended in the outpatient offices of the Hospital Clínic de Barcelona.~Inclusion criteria: i) American Society of Anesthesiologists Index (ASA) 3-4; and / or, ii) age ≥ 75 years; and / or iii) major aggressive surgery; and, iv) solid organ transplant candidate.~Exclusion criteria: i) Non-elective surgery; ii) Known metastatic disease before surgery; iii) Unstable respiratory or heart disease; or, iv) Locomotive or cognitive limitations that prevent adherence to the program."
10130221|NCT04295330|Experimental|Lidocaine group|at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery.
10130222|NCT04295330|Placebo Comparator|placebo group|the same volume of normal saline will be administered during anesthesia.
10130223|NCT04295421|Active Comparator|Canal adductor block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
10130224|NCT04295421|Experimental|IPACK block|"IPACK was realized after spinal anesthesia. Patient was placed in a supine position and knee placed in position of 90° flexion. A low-frequency ultrasound probe was positioned in the popliteal crease, and the needle was inserted from medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle was placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.2% ropivacaine was injected for each side.~A ACB was done postoperatively with 20 ml ropivacaine 0.2% and a catheter was kept for 48H with 4 ml/h saline"
10130225|NCT04295629|Active Comparator|VAS (Visüel Analog Score)|VAS : 0-10 points 0 means: no pain 10 means: incredible pain
10130226|NCT04295629|Active Comparator|LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)|LANSS 0-24 points >12 points : has chronic neuropathic pain <12 points: no chronic neuropathic pain
10130227|NCT04295148|Active Comparator|Semitendinosus graft|Participants receive the Semitendinosus Graft technique during ACL reconstruction.
10130228|NCT04295148|Active Comparator|Quadriceps tendon-bone graft|Participants receive the Quadriceps Tendon-Bone Graft technique during ACL reconstruction.
10130229|NCT04295226||Participants in Structured post-stroke follow-up in Malmö|"Consecutive patients with acute ischemic stroke or intracerebral hemorrhage, treated in-hospital at Skåne University Hospital in Malmö and discharged straight to own home.~The intervention consists of a structured follow-up visit, managed by a stroke nurse, 3 months after stroke followed by a multidisciplinary team rounds resulting in an individual treatment plan for stroke-related health problems, and a final follow-up at 12 months"
10130230|NCT04295278||Systemic inflammatory response syndrome|Systemic inflammatory response syndrome in patients in the pediatric intensive care unit.
10130231|NCT04295109|Active Comparator|Fentanyl group(group F)|Fentanyl citrate injection, specification: 10mL: 0.5mg / piece (production unit: niching chang rendu Pharmaceutical Co., Ltd., valid period: 48 months) For group F patients,0.5mg fentanyl was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
10130232|NCT04295109|Experimental|Oxycodone group(group O)|Oxycodone hydrochloride injection, specification: 1mL: 10mg / branch (production unit: HAMOL LIMITED, valid period: 60 months) For group O patients,30mg oxycodone was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
10130233|NCT04295109|Experimental|Butorphanol group(group B)|Butorphanol tartrate injection, specification: 1 mL: 1 mg / branch (production unit: Jiangsu henryi Pharmaceutical Co., Ltd., valid period: 24 months); For group B patients,10mg butorphanol was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
10130234|NCT04295070|Placebo Comparator|Placebo|Saline (0.9%) delivered intranasally via dropper
10130235|NCT04295070|Experimental|Low dose cohort|CodaVax-RSV delivered intranasally via dropper
10130236|NCT04295070|Experimental|High dose cohort|CodaVax-RSV delivered intranasally via dropper
10130237|NCT04295161|Active Comparator|Reference|
10130238|NCT04295161|Experimental|Prototype 1|
10130239|NCT04295161|Experimental|Prototype 2|
10130240|NCT04295161|Experimental|Prototype 3|
10130241|NCT04295161|Experimental|Prototype 4 fasted|administered in fasted state
10130242|NCT04295161|Experimental|Prototype 4 fed|Administered in fed state
10187643|NCT03724214|Active Comparator|Post-intervention|Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
10130243|NCT04295122|Active Comparator|Phacoemulsification + ECP laser|"Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. The viscoelastic will be washed-out of the capsular bag after IOL insertion. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment.~Intracameral cefuroxime and dexamethasone will be injected into the anterior chamber and sutures used to close the incisions as required."
10130244|NCT04295122|Active Comparator|Phacoemulsification alone|Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. For this study, monofocal IOLs are required.
10130245|NCT04295135|Experimental|OneSheet access|Clinics or providers who receive access to, and training in the Chronic Pain OneSheet, and use it while caring for patients with chronic pain.
10130246|NCT04295135|No Intervention|Normal practice|Clinics or providers who do not receive access to, or training in the Chronic Pain OneSheet, and care for patients with chronic pain as they would normally.
10130247|NCT04295265|Experimental|Smartphone|Receive daily whatsapp/ SMS message remind the drug intake.
10130248|NCT04295265|No Intervention|Control|receive instruction to take the medication at recruitment
10130249|NCT04295252||cardiogenic shock patients|All-comers cardiogenic shock patients Admitted to the Intensive Coronary Care Units
10130250|NCT04295018|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
10130251|NCT04295096|Other|Experimental|Healthy donor
10130252|NCT04295213|Experimental|oligosaccharide group|intervention with oligosaccharides, total duration of study is 13 weeks
10130253|NCT04295213|Placebo Comparator|placebo group|Placebo comparator, total duration of study is 13 weeks
10130254|NCT04294784|Experimental|Nab-P/PD-1|Patients in this arm receive albumin-bound paclitaxel and SHR-1210 (PD-1 inhibitor) thepary.
10130255|NCT04294784|Active Comparator|Nab-P|Patients in this arm receive albumin-bound paclitaxel single-agent chemotherapy.
10130256|NCT04294875|Other|MPT0B640|There is Single Arm in this Clinical Trials.
10130257|NCT04294745|Experimental|Group A|Buccal infiltration of 4% Articaine
10130258|NCT04294745|Active Comparator|Group B|Inferior alveolar nerve block of 4% Articaine
10130259|NCT04294771||Myocarditis and other cardiovascular toxicities ICI-related|Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity
10130260|NCT04294771||Non case|Non-case will be patients exposed to ICI without cardiovascular toxicities
10130261|NCT04294823||FRANCE - CHU creteil|An internal physical examination including vital signs measurements and a 13C-UBT with the standard test meal (Helicobacter Test INFAI) will be performed. Patients with a positive UBT will undergo upper endoscopy. All biopsy samples will be analysed in the local laboratory of the centre. Patients with a negative UBT will undergo also upper endoscopy. Endoscopic procedures and subsequent investigations will be identical in patients with a positive and with a negative UBT. H. pylori positive and negative patients will perform the 13 C-UBT breath tests with new test meal on Day 30. The study will be conducted in outpatients. Starting on Day 1, H. pylori positive and negative patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast. Patients will return to the hospital/medical practice for UBT breath tests with new test meal on Day 30. Patients will be followed-up for 7 days after discontinuation of PPI treatment.
9519575|NCT03285828|Other|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
9519576|NCT03285815|Experimental|Proton Therapy 60 CGE|60 CGE (3CGE X 20) for 4wks
10130262|NCT04294719||Inpatient Clients|Have a chart diagnosis of a schizophrenia spectrum illness, capacity to consent or availability of a substitute decision-maker to consent with the assent of the participant and is residing on a CAMH inpatient forensic unit (general security)
10130263|NCT04294836|Experimental|Curcumin|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) 2000mg daily (each 6h)
9519577|NCT03285815|Experimental|Proton Therapy 47 CGE|47 CGE (4.7CGE X 10) for 2wks
10130264|NCT04294836|Placebo Comparator|Placebo|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Placebo Capsules 500mg 2000mg daily (each 6h)
9968256|NCT01277809|No Intervention|Usual Care|Participants will receive care as usual (Usual Care Group; UCG) that is provided by their long-term care unit.
10130265|NCT04294966|Placebo Comparator|Placebo|
10130266|NCT04294966|Active Comparator|7.5 mg THC|
10130267|NCT04294966|Active Comparator|15 mg THC|
10130268|NCT04295200|Experimental|Dry needling with electrical stimulation|Use of dry needles (this is the generic name for sterile, solid filament needles) are inserted into the lumbar multifidi. Intramuscular electrical stimulation will then be applied by attaching a six-lead electrical stimulation unit to the needles. Electrical stimulation will be applied through the needles at the participant's desired frequency (between 4-6 Hz) and for up to 10 minutes total.
10130269|NCT04294940|Other|Group A: standard of care|The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.
9519578|NCT03285802|Experimental|Letrozole and Everolimus|Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
9519579|NCT03285776||Study group|Children with coordination disorder between the ages of 5 to 7 years.
9519580|NCT03285776||control group|children with typical development between the ages of 5 to 7 years.
9519581|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
10130270|NCT04294940|Other|Group B: standard of care + mobile application CardiCare™|The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™
10130271|NCT04294732|Placebo Comparator|Only spinal anesthesia|Only spinal anesthesia without peripheral nerve block
10130272|NCT04294732|Active Comparator|high concentration|8 ml saline with 8 ml bupivacaine
10130273|NCT04294732|Experimental|low concentration|8 ml bupivacaine with 16 ml of saline
10130274|NCT04294979|Experimental|Rehabilitation|Conventional Physical Therapy
10130275|NCT04295044|Experimental|High protein diet|received high protein diet, prescribed by dietitian
10130276|NCT04295044|Active Comparator|Normal protein diet|received normal protein diet, prescribed by dietitian
10130277|NCT04295031||DM2 without renal disease|patients with type 2 diabetes with normal renal function
10130278|NCT04295031||DM2 with renal impairment|patients with type 2 diabetes with impaired renal function
10130279|NCT04294953|Active Comparator|Group (I) (D) : (Duloxetine group)|
10130280|NCT04294953|Placebo Comparator|Group (II) (P): (placebo group)|
10130281|NCT04294992|Experimental|Granisteron group|
10130282|NCT04294992|Active Comparator|Ondansetron group|
10130283|NCT04294888|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80% of a patient's active motor threshold. rTMS will be administered in an excitatory iTBS pattern. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
10130284|NCT04294888|Sham Comparator|Sham stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80% of a patient's active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory performance, or whether practice effects or other non-specific effects are responsible for any changes in memory which may be observed.
10130285|NCT04294927|Experimental|Risk-reducing salpingectomy with delayed oophorectomy|Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy.
10130286|NCT04294927|Active Comparator|Risk-reducing salpingo-oophorectomy|Risk-reducing salpingo-oophorectomy.
10130287|NCT04295187||Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
10130288|NCT04295187||Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
10130289|NCT04295083|Experimental|Experimental group|The experimental group will be six 1,5 h weekly of clay based group study and interviewed face-to-face twice by the researchers.
10130290|NCT04295083|No Intervention|Control group|The control group will interviewed face-to-face twice
10130291|NCT04294706|Experimental|Hemp arm|Randomly assignment to Hemp arm (60 mg/day of hemp oil extract x 6 weeks)
10130292|NCT04294706|Placebo Comparator|Placebo arm|Randomly assigned to Placebo arm (60 mg/day of cellulose x 6 weeks)
10130293|NCT04294485|Experimental|Experimental group|Physical therapy intervention Efficacy of electrostimulation intervention combined with lower limbs exercise.
10130294|NCT04294485|No Intervention|Control group|Participants will no receive physical therapy intervention
10130295|NCT04294433|Active Comparator|Infanrix-hexa+Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2, 4 and 18 months with a standard dose of Infanrix-hexa
10130296|NCT04294433|Experimental|Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa
10130297|NCT04294433|Experimental|Infanrix-hexa+Twinrix|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa and a standard dose of Infanrix-Junior, respectively
10130298|NCT04294472|Experimental|Cohort 1|Cohort 1: MAU868 1350 mg IV approximately every 28 days for a total of 4 doses
10130299|NCT04294472|Experimental|Cohort 2|Cohort 2: MAU868 6750 mg IV on Study Day 1 and then 1350 mg IV approximately every 28 days for a total of 4 doses
10130300|NCT04294472|Experimental|Cohort 3|Cohort 3: MAU868 6750 mg IV approximately every 28 days for a total of 4 doses
10130301|NCT04294472|Placebo Comparator|Placebo Cohort 1, 2, 3|5% dextrose in water [D5W] IV delivered every 28 days for a total of 4 doses
10130302|NCT04294511|Experimental|Experimental|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
10130303|NCT04294576|Experimental|Arm 1; BJ-001|Phase 1a Part 1 and Part 2: dose escalation for BJ-001 as single agent
10130304|NCT04294576|Experimental|Arm 2; BJ-001 and PD-1 or PD-L1 inhibitor|Phase 1a Part 3: dose escalation for BJ-001 in combination with an PD-1 or PD-L1 inhibitor. Approximately Phase 1b: expansion cohorts for the combination of BJ-001 and an PD-1 or PD-L1 inhibitor.
10130305|NCT04294368|Other|Control|Standard fortification of breast milk
10130306|NCT04294368|Experimental|Experimental|Targeted fortification of breast milk
10130307|NCT04294394||rhomboid block|With a 6-13 Mhz linear USG probe, at the thoracal level of 6-7 vertebra in the sagittal position, in the cranio-caudal direction with a 22 G and 100 mm block needle in the medial of the scapula, after entering the facial plane between the rhomboid muscle and the intercostal muscle, 0.25% bupivacaine 20 ml of the local anesthetic solution will be given.
10130308|NCT04294394||erector spinae group|After the patient is taken in the lateral position, the probe T5 is 3 cm lateral to the spinous process, 22 G and 100 mm block needle with 6-13 Mhz linear ultrasonography and the facial plane between the transverse proces and the erector spina muscle is entered, and 20 ml of a local anesthetic solution consisting of 0.25% bupivacaine will be given.
10130309|NCT04294394||control group|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
10130310|NCT04294381|Experimental|pilot of SMART-goal-setting health behavior decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
10130311|NCT04294537|Experimental|TAP block|Bilateral ultrasound-guided single-shot TAP block with 0,15% levobupivacaine 0,75 mg/kg per side.
10130312|NCT04294537|Active Comparator|LIA - local wound infiltration|Wound infiltration with 0,5% levobupivacaine 1.5 mg/kg
10130313|NCT04294615|Experimental|FMT through a naso-jejunal tube|The purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
10130314|NCT04294615|Active Comparator|FMT through TET|The purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
10130315|NCT04294602|Experimental|Exercise Program|This group received therapeutic exercises and patient education. For patients to encounter fewer problems and to reduce their problems, some recommendations were made that should be taken into consideration in daily life. These suggestions were given in writing. The exercise program included muscle stretching, massage of painful muscles, guided opening and closing movements, gentle isometric tension exercises against resistance, correction of body posture and relaxation techniques. All exercises were done in 6 repetitions a set, 3 sets a day, 3 days a week, treatment program lasted 4 weeks.
10130316|NCT04294602|Experimental|Low Level Laser Therapy Program|This group received LLLT, therapeutic exercises and patient education in the therapy programs. LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points. The application was applied to MTrP or sensitive points in the mastication and cervical muscles.LLLT program was done in 3 days a week, the treatment program lasted 4 weeks.
10130317|NCT04294602|Experimental|Manual Pressure Release Program|ThisThis group received manual pressure release (MPR), therapeutic exercises and patient education in the therapy programs. MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, MTrPs in the mastication and neck muscle. Applied pressure gradually with finger over the MTrPs until the subject reported a 'moderate but easily tolerable' pain value of 7 out of 10. When the pain value decreased to at least 3 or 4 therapist increased pressure again until discomfort and/or pain appeared again. This process was repeated until there was no MTrP tension/tenderness or 60 s had elapsed. MPR program was done in 3 days a week, the treatment program lasted 4 weeks.
10183837|NCT03760536||16-week Exercise Program|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
10183838|NCT03760497|Experimental|CIV Group|Temporary Restoration with Glass Ionomer (Equia Forte® - GC Corporation, Tokyo, Japan) for 30 days + Restoration in Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA).
10183839|NCT03760497|Experimental|Composite Resin Group|Restoration with Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, United States).
10183840|NCT03760497|Experimental|Composite Resin Group + Laser|Composite Resin Restoration (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA) + Application of Diode Laser.
10183841|NCT03760484|Experimental|fecal transplant with fidaxomicin|FMT per rectum x 3 days in conjunction with fidaxomicin (dificid) PO 200 mg bid x 7-10 days
10183842|NCT03760445|Experimental|Part 1 - first line (1L) AML|1L acute myeloid leukemia (AML) subjects receiving HDM201 in various doses/schedules in combination with cytarabine/anthracyclines
10183843|NCT03760445|Experimental|Part 1 - relapsed/refractory (R/R) AML|R/R AML subjects receiving HDM201 in various doses/schedules in combination with cytarabine
10183844|NCT03760445|Experimental|Part 2 - Expansion Cohort 1|1L de novo AML subjects without documented FLT3 mutation receiving HDM201 at the recommended dose of expansion (RDE) in combination with cytarabine/anthracyclines
10183845|NCT03760445|Experimental|Part 2 - Expansion Cohort 2|1L de novo AML subjects with documented FLT3 mutation status receiving HDM201 at RDE in combination with cytarabine/anthracyclines and midostaurin
10183846|NCT03760445|Experimental|Part 2 - Expansion Cohort 3|1L secondary AML subjects receiving HDM201 at RDE in combination with liposomal cytarabine/daunorubicin
10183847|NCT03760445|Experimental|Part 2 - Expansion Cohort 4|R/R AML subjects receiving HDM201 at RDE in combination with cytarabine
10183848|NCT03760445|Experimental|Part 3 - DDI Cohort 1|R/R AML subjects receiving HDM201 at adjusted recommended Phase 3 dose (RP3D) determined in Part 2 in combination with cytarabine and posaconazole added in Cycle 1
10183849|NCT03760445|Experimental|Part 3 - DDI Cohort 2|R/R AML subjects receiving HDM201 at RP3D in combination with cytarabine and midazolam
10183850|NCT03760432|Experimental|Surgery|OCT-guided custom laser CXL
10183851|NCT03760406|Experimental|Severe essential tremor treated by DBS|
10183852|NCT03760393|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
10183853|NCT03760393|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
10183854|NCT03760380|Experimental|Phase 1 Short Term|Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
10187644|NCT03724175|Experimental|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks to treat pouchitis in ulcerative colitis patients with antibiotic refractory or antibiotic dependent pouchitis
10130318|NCT04294251|Experimental|DWP450|
10130319|NCT04294251|Placebo Comparator|Placebo|
10130320|NCT04294329|Experimental|Group Quadratus lumborum block with bupivacaine|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine where a solution of 0.25% bupivacaine 0.2 ml /kg (lean body weight) is used on each side with care not to exceed the toxic dose.
10130321|NCT04294329|Placebo Comparator|Group Quadratus lumborum block with saline|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine.A volume of 0.2ml/kg normal saline will given for each side.
10130322|NCT04294303|Experimental|Telemonitoring|Subjects were assigned to web based telemonitoring system.
10130323|NCT04294303|Other|Control|Subjects were assigned to conventional monitoring.
10130324|NCT04294316|Other|Sonovue group|ICU patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest who are eligible for enhanced-contrast brain ultrasound, extracranial echo-color duplex, and ocular ultrasound.
10130325|NCT04294121|Experimental|Children|"Children aged 5-13 years, all genders, will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Children will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Children will also be asked to rank the cereals in order of their preference (i.e., Most (1) to Least (6)). Children will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
10130326|NCT04294121|Experimental|Parents|"Parents or guardians of the children in the study will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Parents will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Parents will also be asked to rank the cereals in order of which they would be most likely to purchase for a child (i.e., Most (1) to Least (6)). Parents will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
10130327|NCT04294407||Stroke group|20 to 65 years old patients, with the clinical diagnosis of stroke (Mini-mental state examination (MMSE) score of ≥25)
10130328|NCT04294407||Healthy group|20 to 65 years old healthy subjects, without the clinical diagnosis of stroke
10130329|NCT04294056|Experimental|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
10130330|NCT04294056|Active Comparator|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
10130331|NCT04294134|Experimental|MIO-CPP|The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO. The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added.
10130332|NCT04294134|Active Comparator|CPP-only|"CPP (control) is typically offered through weekly sessions with the mother-child dyad that last 1 to 1.5 hours. The CPP control intervention will last 9 months. CPP is offered by mental health Child-Parent Specialist, who receive ongoing consultation and supervision in addition to initial training. This is the model that will be followed for the control group.~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008)"
10130333|NCT04294173|Experimental|video group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the experimental group in the classroom setting. Video presentation including powerpoint presentation and tracheostomy care skill application will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained by the researchers to the video group students in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be watched by the video-assisted teaching method, and the video of tracheostomy care The videos will be sent to students via e-mail. A two-day warning message will be sent to the students from the WhatsApp group to watch the video by the researchers. A week later, students will be invited to the basic skills laboratory for tracheostomy care.
10130334|NCT04294173|No Intervention|demonstration group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the control group in the classroom setting. Powerpoint presentation will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained to the control group students by the researchers in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be taken to the basic skills laboratory and tracheostomy care will be performed on the dummy by the researchers using the demonstration method. Then, students will be given the output of the powerpoint presentation and asked to study the lecture notes for a week. A two-day warning message will be sent by the researchers to students from the WhatsApp group to study. A week later, students will be invited to the basic skills laboratory to practice tracheostomy care.
10130335|NCT04294342|Active Comparator|Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program which consists of three blocks. All sessions include: Balance, Strength, power and break fall exercises. The intervention group i tested before and after the 10 week exercise.
10130336|NCT04294342|No Intervention|Control Group|The subjects in the control group go about their normal life for 10 weeks without any intervention. The control group is tested before and after the 10 week period.
9519582|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
9519583|NCT03285737|Experimental|Whey protein supplement|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
10130337|NCT04294082||Mindfulness based intervention|A shortened version of a mindfulness-based intervention originally developed by Jon Kabat-Zinn for management of chronic pain.
10130338|NCT04294238|Experimental|Post-exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage of peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
10130339|NCT04293809|Experimental|Cohort 1 - EXPAREL|A total of 15 subjects will be enrolled in this cohort. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of saline
10130340|NCT04293809|Experimental|Cohort 2 - EXPAREL|A total of 15 subjects will be enrolled. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of 0.5% bupivacaine HCl (150mg)
10130341|NCT04293822|Experimental|Study group|Group of 30 patients randomly selected will use topical Cetirizine 1% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
10130342|NCT04293822|Active Comparator|Control group|Group of 30 patients randomly selected will use topical Minoxil 5% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
10130343|NCT04293874|Experimental|Low Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 6 oz. wild salmon (1 steak, 6oz /steak)or 14.3 oz. (5.5 packs, 2.6 oz/pack) of chunk light tuna (1020 mg Omega-3LC/week) for 6 weeks.
10130344|NCT04293874|Experimental|High Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 12 oz. wild salmon (2 steak,12 oz /steak)or 28.6 oz. (11 packs, 2.6 oz/pack) of chunk light tuna (2040 mg Omega-3LC/week) for 6 weeks.
10130345|NCT04293939||Preterm children|Children born before the 37th week of gestation: clinical sample
10130346|NCT04293939||Full-term children|Children born after the 37th week of gestation: control sample
10130347|NCT04293887|Experimental|Standard therapy + interferon therapy|Standard treatment + recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days.
10130348|NCT04293887|No Intervention|Standard therapy + blank therapy|Standard therapy
10130349|NCT04293835||Cancer group|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.
10130350|NCT04293835||Normal group|200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
10130351|NCT04293861|Experimental|HYMOVIS Arm|A treatment cycle consists of two injections administered at one week interval. For the purpose of this study, two treatment cycles of two injections of HYMOVIS® at baseline and 6 months will be performed per patient at V1 (Day 0), V2 (Day 7), V5 (Day 180) and V6 (Day 187).
10130352|NCT04293757|Experimental|Rotational angio|Patients that will undergo 3D rotational angiography before cryoballoon ablation
10130353|NCT04293757|No Intervention|No rotational angio|Patients that will receive no preprocedural imaging before cryoballoon ablation
9827442|NCT02455336|Other|No Intervention|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive no therapy for 4 months
10130354|NCT04293991|Active Comparator|High flow nasal cannula (HFNC) group|HFNC group will receive immediate connection to HFNC with a flow of 60L/min, and FIO2 adjusted to have SpO2 of 92% or more, through a heated humidifier and a oxygen blender of the same machine. In case of patient intolerance to high flow, flow will be diminished to the highest tolerated by the patient. Patients will be encouraged to have their mouth closed during HFNC to augment positive end expiratory pressure (PEEP) created by high flow.
10130355|NCT04293991|Active Comparator|Non invasive ventilation (NIV) group|NIV group, patients will be connected to ICU ventilatoron NIV mode for at least 4 hours, through a NIV continuous positive airway pressure (CPAP)mask with ventilator settings; pressure support (PS) level of 8 cmH2O and PEEP level of 5 cmH2O,which can be increased to 10 cmH2O to maintain tidal volume between 6-8 ml/Kg and FiO2 adjusted to keep SpO2 equal or more than 92%.At least patient will be on NIV for 12 hours during the day, alternating with Venturi mask 10-15 L/min to keep FiO2 equal or more than 92%.
10130356|NCT04293848|Experimental|music with low-sinusoidal sound (vibrations)|Participants will listen to music and low-sinusoidal sound (vibroacoustic therapy).
10130357|NCT04293848|Placebo Comparator|Control Group|Participants will listen to music alone.
10130358|NCT04293900||Study cohort|24-hour dietary recall, hand grip strength, accelerometer, International Physical Activity Questionnaire (IPAQ), Patient-reported outcomes survey (NCI-PRO-CTCAE), Pittsburgh Sleep Quality Index (PSQI), Functional Assessment of Cancer Treatment - Lymphoma (FACT-lym), urine sample (optional), fecal sample (optional)
10130359|NCT04294017||patients|participants undergoing a diagnostic laparoscopy and have a histologically confirmed Endometriosis
10130360|NCT04294017||controls|participants undergoing a diagnostic laparoscopy where no evidence of Endometriosis could be found
9519584|NCT03285737|Active Comparator|Collagen peptide supplement|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides.
9976754|NCT01354587|Active Comparator|Hizentra|Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra
10130361|NCT04293965|Experimental|Single Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in a single dose to assess the safety, tolerability, PK and PD profile of X842.
10130362|NCT04293965|Experimental|Multiple Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in multiple doses to assess the safety, tolerability, PK and PD profile of X842. The dose ascending at this stage will be based on the results of the single dose tolerability study.
10130363|NCT04293965|Experimental|Food Effect Study|A randomized, open label, single-dose, self-controlled, double-cycle, two-way crossover clinical trial.
10130364|NCT04293978|Experimental|Virtual Reality relaxation|Participants may request to use the application at any time during their stay at the ward, as many times as they wish. Participants sign in using an anonymous study ID and sessions (and outcomes) are automatically logged by the device to this ID.
10130365|NCT04293796|Experimental|TNBC group|A group with TNBC in neoadjuvant therapy will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then 12 cycles of neoadjuvant polychemotherapy according to the paclitaxel 60-100 mg / m² scheme in 1 day + carboplatin AUC 2 1 p in 7 days. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
10130366|NCT04293796|Experimental|HER2-positive breast cancer group|ER + - / HER2 + will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then docetaxel 75-100 mg / m² on the 1st day + trastuzumab 6 mg / kg (loading dose of 8 mg / kg) on the 1st day + pertuzumab 420 mg (loading dose of 840 mg) on the 1st day; 4 cycles, 1 time in 21 days and surgical treatment. In adjuvant therapy, a group of patients with HER2-positive breast cancer will receive trastuzumab for up to one year and hormone therapy with an antiestrogen (tamoxifen) or aromatase inhibitors in ER + / HER2 + tumors. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
10130367|NCT04293731|Active Comparator|Symbiter-Smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
10130368|NCT04293731|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
10130369|NCT04293926|No Intervention|Control|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises.
10130370|NCT04293926|Experimental|Exercise|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises. In addition, a 8-week resistance exercise training program will be performed.
10130371|NCT04293952|Experimental|BRACE group|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
10130372|NCT04293952|Active Comparator|BRE group|this group include Balance Resistance Exercises Stretching Range Of Motion exercises Ankle flexion Ankle extension Knee flexion Knee extension Hip flexion Hip extension Hip adduction Hip abduction
10130373|NCT04293783|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 two tablet by mouth 1 time per day
10130374|NCT04293783|Placebo Comparator|Placebo|Placebo two tablet by mouth 1 times per day
10130375|NCT04293770|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
10130376|NCT04293913|Experimental|intervention group|In the intervention group, communication was established with the illustrated communication material. The pain, anxiety scores, and hemodynamic data of the patients were recorded by the intensive care nurse in three consecutive measurements starting with the first communication (0th minute) and at 30th and 60th minutes. On the first postoperative day, the satisfaction of the communication established with them, as well as their evaluations regarding the adequacy of this communication and their comfort levels were determined during the time they received mechanical ventilation therapy.
10130377|NCT04293913|No Intervention|control group|no intervention
10130378|NCT04293718||Acute erosive gingivitis|Patients presenting acute erosive gingivitis, isolated or predominant compared to other oral lesions, which required at least one papillary gingival biopsy for diagnostic purposes. Patients were included in the study regardless of age and general health.
10130379|NCT04293705|Experimental|regular TOPS group|Patients are required to perform the regular TOPS program, composed of 10 core sessions and other eventual supplementary sessions. In addition, biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim to monitor patients' activities on problem-solving related to the TOPS program contents and the problem solving process in real life. The program has a specific focus on problem-solving, executive functions, behavioral strategies and social skills.
10130380|NCT04293705|Active Comparator|modified TOPS group|Patients are required to perform the modified TOPS program, composed of 10 sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim of monitoring training adherence and discuss the program's contents.
10130381|NCT04293354|Active Comparator|Serratus Plane Block|The Serratus plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
10130382|NCT04293354|Sham Comparator|Control|No block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
10130383|NCT04293458|Experimental|EsoCheck vs. EGD with or without biopsies|All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
10130384|NCT04293497|Experimental|Pancreatic Cancer|This arm includes patients with pancreatic cancer. Cytology specimens will be obtained with endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer. Cytology staining will be performed in the cytology specimens.
10130385|NCT04293315|No Intervention|Control|This is the usual care arm. Healthcare workers will provide people with the Fecal Occult Blood Test (FOBT) and information about risk to develop CRC and the importance of early detection.
10130386|NCT04293315|Experimental|Intervention|The same as the Control Arm plus the primary care team of the PCCs will be trained and participate in 8 improvement cycles.
10187645|NCT03724097||Group 1|Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
10130387|NCT04293549||rhNGF group|Therapeutic contact lens use was discontinued during the duration of the study. Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment. Changes in the corneal epithelium and stroma were evaluated by slit lamp biomicroscopy and photo documentation of the cornea after fluorescein staining.
10130388|NCT04293549||control comparator group|control comparator group was matched for age and gender and underwent assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline.
10130389|NCT04293367|Experimental|Exercise|14 African American Women with obesity will be randomly assigned to the 14-week high intensity interval training program
10130390|NCT04293367|No Intervention|Control|14 African American Women with obesity will be randomly assigned to serve as a reference group, i.e. follow the same protocol as the experimental group, however, they will not undergo exercise training
10130391|NCT04293510||group study 1|children and adolescents who diagnosed as lupus patients
10130392|NCT04293510||group study 2|age and sex matched healthy children free from any infection with no family history of immunological diseases
10130393|NCT04293692|Experimental|UC-MSCs treatment group|Participants will receive conventional treatment plus 4 times of 0.5*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).
10130394|NCT04293692|Placebo Comparator|Control group|Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7.
10130395|NCT04293406||Established Prostate Cancer Group|Established Prostate Cancer Group will consist of a qualitative study of 12 semi-structured interviews with self-identified AA patient undergoing prostate treatment (stages I-III) (N-12 patients) and 12 semi-structured interviews with H/L patient undergoing prostate treatment (stages I-III) (N=12 patients) at NYPH Queens and NYPH-BM. Interview content will focus on psycho-social and socio-cultural factors associated with prostate cancer decision making, social support, and physician-patient communication.
10130396|NCT04293406||At Risk of Prostate Cancer Group|"At Risk of Prostate Cancer Group will recruit 58 self-identified AA or H/L men at risk of prostate cancer (stages I-III) receiving care at NYPH-Queens and NYPHQ (29 at each hospital) to participate in the evaluation of the tailored DNI intervention. Men who consent to participate in the study will complete a baseline survey. After biopsy appointment, participants with a negative Prostate Cancer biopsy will receive a study closure phone call, ending study participation.~Participants with positive Prostate Cancer biopsy will proceed with study procedures and be randomly assigned to decision navigation intervention (DNI) or standard of care (SOC). Participants with a positive Prostate Cancer biopsy will be followed for 6 months and complete assessments at 2 weeks, 1 month, and 6 months (close of the study)."
10130397|NCT04293328|Experimental|Monthly replacement lenses without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
10130398|NCT04293328|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
10130399|NCT04293380|Other|normal karyotype|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
10130400|NCT04293380|Other|down syndrome|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
10130401|NCT04293653|Experimental|Care bundle|Patients above 75 years where emergency surgery is indicated and with a Clinical Frailty Scale Score of 1-6 will be included in a perioperative care-bundle. While waiting for surgery patients will be monitored and optimized if deteriorating. Antibiotics will be administered if indicated. Surgery is delivered within 2, 6 or 24 h depending on suspected abdominal pathology and clinical condition.
10130402|NCT04293484|Experimental|Real tDCS - Real tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
10130403|NCT04293484|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
10130404|NCT04293666|Experimental|Kefir drink|(2) The first phase of Kefir, the second phase of the placebo group (hereinafter referred to as group B
10130405|NCT04293666|Placebo Comparator|placebo|(1) first-stage placebo and second-stage Kefir group (hereinafter referred to as group A).
10130406|NCT04293575||In list group|patients on active heart transplantation (HTx) list with a low likelihood to receive a donation shortly (e.g. for body weight or blood group)
10130407|NCT04293575||"Bridge to decision BTD group"|patients suitable for HTx, but that were still waiting for clinical decision
10130408|NCT04293575||"(Bridge to candidacy BTC group)"|patients who could not be yet in list for HTx because of concomitant, potentially reversible, contraindications such as severe pulmonary hypertension, elevated pulmonary-vascular-resistance, unsatisfactory response to vasodilator challenge or other causes resulting in a prohibitive peri-procedural risk (as pre-transplant body mass index [BMI] >35 kg/m2, severe renal dysfunction with creatinine clearance <30 mL/min) and other reasons (current alcohol, tobacco or drug abuse, poor social support, non-residents)
10130409|NCT04293432||Group/Cohort|Torsade de Pointes induced by drugs reported to the FAERS database from inception till first quarter of 2019 (1990-2019)
10130410|NCT04293302||Brain abnormality|Newborn who had any gestational brain sonographic abnormality
10130411|NCT04293302||No brain abnormality|Newborn who did not have any gestational brain sonographic abnormality
10130412|NCT04293289|Other|Treatment|"BNCT(Boron Neutron Capture Therapy)~SPM-011 iv administrates at 200 mg/kg/hr for 2 hours before neutron irradiation. During neutoron irradiation with CICS-1, SPM-011 iv continues at 100mg/kg/hr."
10130413|NCT04293107||Phase 1: Content Validity Testing|Cohort of 6 parents/carers of children with cerebral palsy and GORD, who will be interviewed regarding the content validity of the PGSQ when used to assess symptoms of GORD in children with cerebral palsy.
10130414|NCT04293107||Phase 2: Reliability (test-retest) Testing|Cohort of 20 parents/carers of children with cerebral palsy and GORD, who will review and complete the adapted version of the PGSQ (post Phase 1) at two time points, two weeks apart.
10130415|NCT04293081|Active Comparator|chlorpheniramine maleate group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to chlorepheniramine maleate group (A)
10130416|NCT04293081|Placebo Comparator|placebo group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to placebo group (A)
10130417|NCT04293120|Experimental|Training|Training 4 sessions over a one week time period of 180 catches/stops with a medicine ball.
10130418|NCT04292951|Experimental|GDT group|Intraoperative fluid and inotropic/vasoactive drugs management based on information from FloTrac/EV1000
10130419|NCT04292951|Active Comparator|Control group|Intraoperative fluid and inotropic/vasoactive drugs management based on CVP, blood pressure, heart rate, and clinical signs at the discretion of attending anesthesiologists
10130420|NCT04293159|Experimental|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
10130421|NCT04293263|Experimental|MCI patients hospitalised in the research departments|each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.
10130422|NCT04293263|Active Comparator|MCI patients hospitalized in the research departments|each of the elderly in the control group will Listen to random music twice a week for about 40 minutes each time, on personal headphones.
10130423|NCT04293003|Experimental|Fasting|6-hour morning fasting
10130424|NCT04293003|Experimental|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
10130425|NCT04293003|Experimental|Mediterranean|Consumption of a Mediterranean breakfast
10130426|NCT04293172|Experimental|Ticagrelor|The double-blinded study drug dose will be weight dependent.
10130427|NCT04293172|Placebo Comparator|Placebo|The double-blinded study drug dose will be weight dependent
10130428|NCT04292990|Experimental|Fentanyl|Intervention: Drug: Fentanyl Transdermal Patch
10130429|NCT04292990|Active Comparator|Morphine|Intervention: Drug: Morphine Controlled-Release Tablets
10130430|NCT04293250|Experimental|Physical activity group|"Investigators employ the recommendations of the American College of Sport Medicine and the World Health Organization for adults to divide our enrolled patients having moderate-intensity as 30-60 min∙d-1 (≥150 min∙wk-1 ) or vigorous-intensity as 20-60 min∙d-1 (≥75 min∙wk-1) for 6-8 weeks preoperatively.~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.~The operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
10130431|NCT04293250|Experimental|non-physical activity group|"No any moderate-intensity or vigorous-intensity physical activity for our enrolled patients preoperatively.~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.~Various types of operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
10130432|NCT04292938|Active Comparator|Ketogenic diet|patients will follow a low carbohydrate high lipid personalized diet causing blood BOHB level to be between 1.5-4 mmol/l for six months
10130433|NCT04292938|No Intervention|control group|Patients will be asked to maintain their usual dietary regimen
10130434|NCT04292925|Experimental|Experimental Group|Intervention with the new treatment protocol will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
10130435|NCT04292925|Active Comparator|Control group|Intervention with conventional therapy will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
10130436|NCT04293068||Control group|Related tests were normal, because the male factor alone required the first IVF/ICSI cycle; Follow-up of included patients was conducted to determine whether embryo transplantation was performed, and the score of transferred embryos was recorded, and the final control group would be confirmed after achieving clinical pregnancy
10130437|NCT04293068||Recurrent implantation failure|Previous ≥3 consecutive embryo transfer failures
10130438|NCT04293068||Recurrent spontaneous abortion(miscarriage)|≥2 consecutive spontaneous abortions or embryo damage
10130439|NCT04293211||Control|Upon completion of B-Con presentation, this group will be tested regarding tourniquet placement using the rubric. A tourniquet is regarded as appropriately placed if it is 2 inches above the wound, not located on a joint, appropriate tightness (meaning a finger cannot be placed under it and it is indenting the mannequin). This is as per prior studies. Feedback will be given at the end of this session.
10130440|NCT04293211||Simulation|This group will have to interact with a panicked actor/actress as well as the SIM MAN 3G who will have two wounds under his clothes. One that will be actively pumping a large amount of arterial blood that will require tourniquet placement and the other wound with trace venous bleeding that will require simple pressure with a clean cloth. Participants will be given feedback on items that they missed. The observer will fill out the rubric and give feedback to the group.
10130441|NCT04292821||Patients consulting for breast lesion Bi Rads 4 or 5|Patients consulting for breast lesion Bi Rads 4 or 5
10130442|NCT04292886|Active Comparator|thin endometrium ,treatment,Tamoxifen|From the 2nd day of the menstrual cycle, the patient took tamoxifen and femoston
10130443|NCT04292886|Placebo Comparator|thin endometrium ,treatment,Vitamin C|From the 2nd day of the menstrual cycle, the patient took Vitamin C and femoston
10130444|NCT04292756|Active Comparator|Triamcinolone Acetonide 40 mg|Arm 1
10130445|NCT04292756|Active Comparator|Triamcinolone Acetonide 4 mg|Arm 2
10187646|NCT03724097||Group 2|Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
10187647|NCT03724097||Group 3|Patients receiving palliative care
10130446|NCT04292743|Experimental|Eryaspase plus FOLFIRINOX|"Eryaspase will be administered on day 1 and 15 of a 4 week cycle (intravenous infusion) in dose escalating/reduction depending on the cohort the patient is assigned to~mFOLFIRINOX dosing will include 5-fluorouracil 2400 mg/m² over 46 hours, oxaliplatin 85 mg/m², Irinotecan 150 mg/m² (intravenous infusion) on Day 1 and 15 of the 4 weeks cycle for a maximum of 12 cycles."
10130447|NCT04292717|Active Comparator|Deficit-oriented training group|
10130448|NCT04292717|Active Comparator|Non-specific, standardised walking training group|
10130449|NCT04292847|Experimental|Geriatric Assessment|Participants fill out the geriatric assessment during a clinic visit and receive recommendations based on results
10130450|NCT04292418||study group 1|(rejector group )include Paediatric living donor kidney transplant recipients (aged 4-18 years) at least 35 child recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the study group 1 measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test
10130451|NCT04292418||study group 2|the second group (non rejector group ) include Paediatric living donor kidney transplant recipients (aged 4-18 years) recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the studied group at least 35 child measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test in the study group 2
10130452|NCT04292457|Experimental|Propofol|Anesthesia is maintained with Propofol
10130453|NCT04292457|Experimental|Sevoflurane|Anesthesia is maintained with Sevoflurane
10130454|NCT04292444|Experimental|RAGE polymorphism (TT)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TT) will be selected and scanned twice.
10130455|NCT04292444|Experimental|RAGE polymorphism (TA/AA)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TA/AA) will be selected and scanned twice.
10130456|NCT04292548||study group (passive smoking children)|
10130457|NCT04292548||control group|
10130458|NCT04292652||EVAR group|Individuals undergoing endovascular aortic repair. n=40
10130459|NCT04292652||OR group|Individuals undergoing open repair. n=40
10130460|NCT04292574||Participants with Spinal Muscular Atrophy|
10130461|NCT04292587||Women with hirsutism|Women between the ages of 18-45 with hirsutism
10130462|NCT04292587||Women without hirsutism|Women between the ages of 18-45 without hirsutism
10130463|NCT04292678|Experimental|Relaxation|Caregivers of patients with advanced cancer will apply 20 minutes of progressive muscle relaxation exercise twice a week, for 8 weeks with a group session.
10130464|NCT04292678|Active Comparator|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
9694627|NCT04787081|Active Comparator|Sleep Care Positioning Training Program GRP2|A sleep care positioning lesson created by a research assistant along with the principal investigator with modules on evidence for night-time postural care, risk factor monitoring, sleep system types and set up, positioning methods, and outcome measures. This lesson consisted of primarily written summary statements and links to freely available web-based information. Most of this lesson's modules included written information that the participant would need to read with the exception of the positioning methods modules. For the positioning module, participants were provided with links to manufacturers' websites which contained video clips on how to place postural supports.
9976755|NCT01354600|Other|Energy Balance|
10130465|NCT04292496|Experimental|Intraperative leak testing group|i) the integrity of the anastomosis can be directly observed under gastroscopy. ii) the distal of Roux limb was temporarily blocked, then the bowel of anastomosis was inflated by air, following 60 milliliter methylene blue.
10130466|NCT04292496|No Intervention|Non-intraoperative leak testing group|Non intraoperative leak testing was performed intraoperatively.
10130467|NCT04292665|Experimental|Classical Massage|Patients will receive a total of fourteen individual applied classical massage sessions, twice daily for seven days, each session lasting 30 minutes.
10130468|NCT04292665|Experimental|Relaxation|Patients will receive a total of fourteen individual counseling sessions, in a quiet room, twice daily for seven days, each session lasting 20 minutes.
10130469|NCT04292665|Other|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
10130470|NCT04292626|Experimental|Lymphoma|At least five (5) evaluable subjects with Hodgkin Lymphoma or Non Hodgkin Lymphoma. The tested injected dose of 500 MBq.
9976756|NCT01354600|Other|Positive Energy Balance|
10130471|NCT04292808|Other|Penthrox|Low Dose Methoxyflurane
10130472|NCT04292691|Experimental|Ropivacaine|A cumulative amount of approx. 40ml ropivacaine 0.5% (≙400mg (2x200mg) ropivacaine) is applied immediately before surgery. They are applied in a ring wall 10 cm cranially of the tip of the medial and lateral malleolus (N. peroneus superficialis (N. cutaneus dorsalis medius et intermedius, N. saphenus, N. suralis), as well as sonographically controlled (N. peroneus profundus and N. suralis)
10130473|NCT04292691|Placebo Comparator|Ringer's Lactate|Analog to the Experimental Arm, but the same amount of Ringer (40ml) will be plicated instead Ropivacaine
10130474|NCT04292509|Experimental|SAP with predictive stop before low|Sensor-augmented pump therapy with the use of the predictive stop before low mode of action
10130475|NCT04292509|Active Comparator|SAP with stop on low|Sensor-augmented pump therapy with the use of the predictive stop on low mode of action
10130476|NCT04292769|Experimental|Decitabine combined with DC-CIK|Test group: decitabine combined with autologous DC-CIK cells infusion: decitabine 10mg / d, intravenous administration of d-5 to d-1, autologous DC-CIK cells infusion: first course: d1-d3 The second course: d14-d16; the total number of cells is about 5-10 × 109; IL-2: 200,000 IU / d subcutaneous injection, the first course: d0-d4, the second course: d13-d17, every 2 weeks 1 course of treatment, 2 courses in total.
10130477|NCT04292769|Active Comparator|DC-CIK|Control group: autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109; One course: d0-d4, the second course: d13-d17, 1 course every 2 weeks, a total of 2 courses.
10130478|NCT04292795|Experimental|Group A|Intervention: Shortwave Diathermy Frequency: 27.12 MHz Time Duration: 10min Duration of Treatment: 4 weeks. Sessions per Week: 2 sessions per week
10130479|NCT04292795|Experimental|Group B|Intervention: Therapeutic Ultrasound Frequency: 1-3MHz Intensity: 0.2-1W/cm2 Time Duration: 10mins Duration of Treatment: 4 weeks Sessions per Week: 2 sessions per week
10183855|NCT03760380|Experimental|Phase 2 Long Term|Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
10183856|NCT03760367|Experimental|Blue Covarine Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste containing blue covarine (Pepsodent White Now Gold, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
10183857|NCT03760367|Active Comparator|Control Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste (Colgate Advanced Whitening, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
10183858|NCT03760354|Experimental|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
10183859|NCT03760354|Placebo Comparator|Placebo (no corticosteroid treatment)|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
10183860|NCT03760341|Active Comparator|cold adenoidectomy group|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - cold method
10183861|NCT03760341|Active Comparator|hot method adenoidectomy|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - hot method
10183862|NCT03760328|Active Comparator|therapeutic stimulation|Therapeutic Stimulation: optimal therapy setting for home use
10183863|NCT03760328|Sham Comparator|sham stimulation|Sham Stimulation (Control Group): stimulation voltage programmed at 0.1 volts
10183864|NCT03760315||targeted treatment by mNGS|In the mNGS targeted treatment group，Clinicians figure out sepsis patients' microbe by mNGS and alter or confirm targeted treatment.
10183865|NCT03760315||targeted treatment by Culture|In the Culture targeted treatment group，Clinicians figure out sepsis patients' microbe by Culture and alter or confirm targeted treatment.
10183866|NCT03760315||Experience treatment|In the experience treatment group，Clinicians didn't figure out sepsis patients' microbe even with Culture and mNGS of the plasm and other secretion to alter or confirm targeted treatment.
10183867|NCT03760302||Patient given analgesics or hypnotics|All patients treated with any kind of analgesics or hypnotics are analyzed and compared.
10183868|NCT03760276|Experimental|Voriconazole TBD mg tablet orally, every 12 hours for 7 days|
10183869|NCT03760263|Active Comparator|Envarsus|Once-daily extended-release tacrolimus
10183870|NCT03760263|Active Comparator|Prograf|twice-daily tacrolimus
10183871|NCT03760237||Acute Leukemia|Observation only. Patients newly diagnosed with acute leukemia who are scheduled to start treatment with chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
10183872|NCT03760224|Experimental|Intervention|WhatsApp group will receive at least 3 messages each week and allow real-time group discussion for the intervention period (8 weeks).
10183873|NCT03760224|Active Comparator|Control|The control group will receive 3 mobile phone text messages each week in the 8 weeks after recruitment. This will be a one way message and no real-time discussion will be available.
10183874|NCT03760198|Experimental|botulinum toxin type A|
10183875|NCT03760198|Placebo Comparator|Placebo|
10183876|NCT03760172||Prevalence of NAFLD in patients with IMID|To analyze the global prevalence of NAFLD in patients with an immune-mediated inflammatory disease IMID
10183877|NCT03760172||Prevalence of High-risk NASH in patients with IMID|To evaluate the prevalence of high-risk NASH (NASH with advanced fibrosis) in patients with IMID through clinical, radiological and histological evaluation
10183878|NCT03760172||Immunophenptypic characterization|To investigate the existence of common and differential immunophenotypes between the subjects with NASH with and without IMID, and patients with IMID without liver involment
10183879|NCT03760172||Genetic and Molecular characterization|Liver molecular characterization of NASH associated to IMID
9519585|NCT03285698|Other|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue.
10183880|NCT03760159||Group RESPIRATORY SIMUL (Study A)|In 46 healthy subjects, a computer program will generate random instructions of periods of normal breathing, voluntary end-expiratory breathing cessation periods (as surrogate of central apnoea) and Muller's manœuvre (as surrogate of obstructive apnoea). Meanwhile, the KCG will record the parameters of biological interest. ECG, heart rate, beat to beat non-invasive blood pressure (Finometer), ventilation, end-tidal CO2 (AD instruments), O2 saturation (Nellcor), cardiac output (CO) (Philips) will also be recorded.
10183881|NCT03760159||Group SDB (Study B)|In patients suspected of sleep apnoea and admitted to the sleep unit of the Erasme hospital to perform sleep test as required by their medical condition, the investigators will simultaneously record KCG and PSG and qualitatively compare the data (Bland-Altman plots).
10183882|NCT03760159||Group nCPAP (Study C)|In patients with a diagnosis of sleep apnea, the investigators will determine if KCG is capable to reliably assess the efficacy of the nCPAP therapy in comparison to simultaneous PSG recording. Ongoing adjustment in the CPAP therapy pressure during the night, and its effect on cardiovascular haemodynamic assessed by the KCG, will be taken into account as well.
10183883|NCT03760159||Group UNSELECTED (Study D)|After validation of the three previous steps, the investigators plan to extend the recordings on 100 unselected consecutive patients, without recruitment restrictions, which will undergo PSG recordings because of complains of sleep apnoea.
10183884|NCT03760133|Active Comparator|with Probiotics|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
10130480|NCT04292392|Experimental|A - ACB + Periarticular Block|Group A: patient will receive a preop ACB, followed by Intra-articular block during TKA surgery
10130481|NCT04292392|Experimental|B - ACB + IPACK Block|Group B: patient will receive a preop ACB+IPACK block before TKA surgery only
10130482|NCT04292392|Experimental|C - ACB + IPACK + Periarticular Block|Group C: patient will receive a preop ACB+IPACK block, followed by Intra-articular block during TKA surgery
10130483|NCT04292782|Active Comparator|CAUDAL BLOCK|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and needle of diameter and length respectively between 22G and 25G, 35mm and 40mm according to the child's size (Braun).The patient is positioned laterally with their hips flexed to 90°. The sacral hiatus is forming with the two posterior superior iliac spines an equilateral triangle. The puncture is performed between the two sacral cornuae. The sacrococcygeal ligament gives a perceptible 'pop' when crossed. After crossing the sacro-coccygeal ligament, the needle is redirected 30° to the skin surface, and then advanced a few millimeters into sacral canal. After verifying absence of spontaneous reflux of blood or cerebrospinal fluid, slowly injection of Ropivacaine 0.25% 1ml/ kg
10130484|NCT04292782|Experimental|anterior Quadratus lumborum block|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and a 22G, 50-mm, insulated facet type needle (BBraun Stimuplex Ultra 360°). Patients were placed in the lateral position, a probe was placed transversely to the abdominal flank. The needle was inserted using an in-plane technique and was preceded further into the fascia between the QLM and PM. Following confirmation of the correct space with the administration of 0.5-1 ml local anesthetic, block was induced with 1 ml/kg, 0.25% Ropivacaine,
10130485|NCT04292704|Experimental|Laser group|Fractional CO2 laser therapy in consolidation treatment once a month for 3 months and treatment was prohibited during menstrual period.
10130486|NCT04292704|Other|Clotrimazole group|Clotrimazole tablets 500mg PV biw q3d in consolidation treatment once a month for 6 months and treatment was prohibited during the menstrual period.
10130487|NCT04292119|Experimental|Lorlatinib and Crizotinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~Phase 1 (the dose-finding portion of the study) will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days~Crizotinib will be administered orally twice daily at a predetermined dose for 28 days~Phase II patients will be treated with Lorlatinib and Crizotinib at a dose recommended based on the phase I study."
10130488|NCT04292119|Experimental|Lorlatinib and Binimetinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days~Binimetinib will be administered orally twice daily at a predetermined dose for 28 days.~Phase II patients will be treated with Lorlatinib + Binimetinib at a dose recommended based on the phase I study."
10130489|NCT04292119|Experimental|Lorlatinib and TNO155|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~Lorlatinib will be administered orally once daily at a predetermined dose for 21 days~TNO155 will be administered orally once daily at a predetermined dose for 14 out of 21 days.~Phase II patients will be treated with Lorlatinib + TNO155 at a dose recommended based on the phase I study."
10130490|NCT04292093|Experimental|Home rehabilitation training|Home rehabilitation training
10130491|NCT04292093|Active Comparator|Home control activity|Home control activity
10130492|NCT04292184|Active Comparator|UW (perfusion solution) + sodium thiosulfate (STS)|We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
10130493|NCT04292184|No Intervention|UW (perfusion solution)|Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.
10130494|NCT04292210|Experimental|CAPD handling|"A connecting device simplifying the steps during a cycle of Peritoneal dialysis. Instead of directly doing a manual connection and manually breaking a frangible, the device assist in connecting and breaking the frangible.~This study was done demonstrating a continuous ambulatory peritoneal dialysis (CAPD)"
10130495|NCT04292249||Elective on-pump cardiac surgery patients|Adult patients (≥18 years) undergoing elective on-pump cardiac surgery (isolated coronary artery bypass graft (CABG), single and multiple valvular procedures, combined CABG and valvular surgery, and others).
10130496|NCT04292067||patients with SPA|100 SPA patients
10130497|NCT04292067||Healthy subjets|200 healthy subjets in control group
10130498|NCT04292067||patients with RA|100 RA patients
10130499|NCT04292236|Placebo Comparator|Placebo|Administered at time 0 min and 300 min. Cellulose was used as the placebo.
10130500|NCT04292236|Active Comparator|Dietary Supplement|Administered at 0 min and 300 min. Combination of lauric acid, perilla oil and diindolylmethane was used as the dietary supplement.
10130501|NCT04292145|Experimental|Relaxation Application|Participants will follow the relaxation application.
10130502|NCT04292145|Active Comparator|Relaxation Only|Participants will use any relaxation technique they normally use to relax.
10130503|NCT04292132|Active Comparator|Conventional loading|Loading of 4 interforaminal implants three months after surgery.
10130504|NCT04292132|Experimental|Immediate Loading|Loading of 4 interforaminal implants immediately after surgery.
10130505|NCT04292158||Main Group|Hospitalized for at least 1 day clinic stay at the participating hospitals
10130506|NCT04292262||AKI|
10130507|NCT04292262||Non AKI|
10130508|NCT04292288||Foreign body granuloma|men injecting paraffin oil
10130509|NCT04292054|Active Comparator|active group|"The antibiotic prophylaxis will be cefazolin 2 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump, in case of absence of colonization to Pseudomonas aeruginosa prior to the surgical procedure.~The dose administer is 2g.~Antibiotic prophylaxis will be piperacilline-tazobactam 4 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe driver in patients with burn wound colonized to Pseudomonas aeruginosa.~The dose administer is 4g."
10130510|NCT04292054|Placebo Comparator|Placebo group|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
10130511|NCT04292028|Experimental|pilates group|The Pilates group participated in an 8-week clinical Pilates training program
10130512|NCT04292028|Active Comparator|Control group|Control group were given a home-based exercise program
10130513|NCT04292366|Experimental|Intervention arm I|pre-notification approximately ten days prior to intervention, invitation and one reminder (three-staged intervention)
10130514|NCT04292366|Experimental|Intervention arm II|invitation, one reminder after 45 days and a second reminder three months after invitation (three-staged invitation procedure)
10130515|NCT04292366|Experimental|Intervention arm III|pre-notification, invitation, reminder after 45 days and reminder after three months (four-staged invitation procedure)
10130516|NCT04292366|Active Comparator|Control group|invitation and one reminder after 45 days (usual care)
10130517|NCT04292314|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
10130518|NCT04292314|Experimental|Nigella sativa experimental group|"50 patients from each participating hospital that will receive Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months.~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
10130519|NCT04292314|Experimental|Hydroxyurea experimental group|"50 patients from each participating hospital that will receive hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
10130520|NCT04292314|Experimental|Natural honey experimental group|"50 patients from each participating hospital that will receive natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
10130521|NCT04292314|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of iron chelator agent of deferoxamine or deferasirox (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.~in addition to iron chelator agent, this group receive regular blood transfusion session."
10130522|NCT04292301|Experimental|STrategically Acquired Gradient Echo (STAGE)|STAGE Inputs are flow compensated 3D gradient echo MR images acquired at optimal parameters which are used to calculate multiple contrasts for brain imaging. All subjects within the study are imaged using both a conventional MR protocol and STAGE protocol.
10130523|NCT04292002|Experimental|Health Checks|Workplace health checks - in this intervention employees can select from a range of optional health checks/tests and receive tailored health advice and a health resource pack.
10130524|NCT04291833|Active Comparator|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
10130525|NCT04291833|Active Comparator|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
10130526|NCT04291833|Placebo Comparator|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
10130527|NCT04291781|Experimental|RC18 160mg|RC18 160mg SC once weekly ,and total of 24 doses
10130528|NCT04291781|Experimental|RC18 240mg|RC18 240mg SC once weekly ,and total of 24 doses
10130529|NCT04291781|Placebo Comparator|Placebo|Placebo SC once weekly ,and total of 24 doses
10130530|NCT04291742|Experimental|0: cognitive|target prostate biopsies by cognitive fusion
10130531|NCT04291742|Experimental|1: software|target prostate biopsies by software
10130532|NCT04291807|Experimental|Video education|A video of ERCP procedure has been viewed to the patients who will undergo ERCP and questions about the procedure had been answered by the primary investigator (experienced endoscopy nurse)
10130533|NCT04291807|No Intervention|Direct ERCP|Patients arranged ERCP for any reason underwent directly to the ERCP without any video education.
10130534|NCT04291716|Other|Single Arm|This is a single-arm study. All subjects enrolled in the study will wear the device during stay in the EMU.
10130535|NCT04291898|Active Comparator|Device: ASO|Participants implanted with the AMPLATZER™ Septal Occluder (ASO)
10130536|NCT04291898|Active Comparator|Device: FSO|Participants implanted with the Occlutech Figulla Flex II® (FSO).
10130537|NCT04291898|Active Comparator|Device: GSO/GAO|Participants implanted with the GORE® CARDIOFORM ASD Occluder (GSO/GAO)
10130538|NCT04291794|Active Comparator|Conventional bolus induction|Hypnotic component of general anesthesia induction will be a single bolus of propofol 2mg/kg followed by turning on sevoflurane 2% at a fresh gas flow of 2L/min.
10130539|NCT04291794|Experimental|Target-controlled induction|Hypnotic component of general anesthesia induction will be target-controlled propofol infusion tritiated to loss of consciousness. Propofol target-controlled infusion will be maintained.
10130540|NCT04292015|Experimental|Standard then Intervention|Infant will undergo standard method of examination with binocular indirect opthalmoscope (BIO) followed by retinal imaging with Optos ultra-wide field retinal imaging device.
10130541|NCT04292015|Experimental|Intervention then Standard|Infant will undergo retinal imaging with Optos ultra-wide field retinal imaging device followed by standard method of examination with binocular indirect opthalmoscope (BIO).
10130542|NCT04291729|Experimental|Ganovo+ritonavir with or without interferon nebulization|
10130543|NCT04291846|Experimental|A|
10130544|NCT04291846|Experimental|B|
10130545|NCT04291924||Ablebodied individuals|
10130546|NCT04291924||Spinal Cord Injured Individuals|
10130547|NCT04291963|Active Comparator|DGG + TUN|The multiple adjacent gingival recession sites were treated with DGG in conjunction with TUN technique.
10130548|NCT04291963|Active Comparator|SCTG + TUN|The multiple adjacent gingival recession sites were treated with SCTG in conjunction with TUN technique.
10130549|NCT04291989|Experimental|Earlobe and Finger Prick versus venous blood lactate sampling|Compare blood Lactate levels between ear lobe and finger against venous forearm blood sample using the electronic hand held lactate device in hip fracture patients with good cognitive function (AMT >/= 7)
10130550|NCT04291872|Experimental|Non-Heated Arm|Proximal cavities were restored with Equia Forte (GC Corporation, Europe) according to manufacturer's orders.
10130551|NCT04291872|Experimental|Heated Arm|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
10130552|NCT04291976|Experimental|back-to-back HDWLE|Similar to single-pass HDWLE, with a second segmental inspection after the first examination in the same session. Equipment is similar to 1.
10130553|NCT04291976|Active Comparator|single-pass HDWLE|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
10130554|NCT04291976|Active Comparator|Chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or 0.3% indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two arms.
10130555|NCT04291768|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
10130556|NCT04291768|Active Comparator|Control group|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician
10130557|NCT04291677|Experimental|Intervention group in which musical intervention|Group A: Experimental group in which musical intervention will be applied between the first and the third day of mechanical ventilation.
10130558|NCT04291677|Other|Control group|Group B: Control group with standard treatment without musical intervention.
10130559|NCT04291755||Checkpoint inhibitor therapy|Patients will be administered a checkpoint inhibitor therapy, including but not limited to pembrolizumab, nivolumab, ipilimumab, and atlizumab, at the standard dosing regimen prescribed by their physician. Stool, blood, and urine samples will be collected from patients prior to start of treatment, and at 4 more timepoints over the next 12 months.
10130560|NCT04291443|Experimental|Upper First Premolar One Side|Heavy force (225 g)
10130561|NCT04291443|Experimental|Upper First Premolar Other Side|Light Force (25 g)
10130562|NCT04291664|Experimental|Prostate Cancer|
10130563|NCT04291547|Experimental|Computerised Behavioural Activation Programme|All recruited young people will be given the BALM (Behavioural Activation for Low Mood) programme to work through
10130564|NCT04291638|Experimental|Remote Caregiver Training|The Remote Caregiver Training arm consists of participation in a 5-hour, videoconferencing-based caregiver training program.
10130565|NCT04291638|Experimental|Remote Caregiver Training + Intensive Treatment|The Remote Caregiver Training + Intensive Treatment arm consists of participation in a 5-hour, videoconferencing-based caregiving training program, followed by participation in the videoconferencing-based intensive group behavioral treatment program.
10130566|NCT04291586|Experimental|Virtual Reality|The Virtual Reality group will perform personalized activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
10130567|NCT04291586|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalized to their deficits and generated automatically through a Task Generator.
10130568|NCT04291417||CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis. Results will not be used to manage patients.
10130569|NCT04291482|Experimental|Intervention arm|The intervention group participants will be assessed with EMA and they will provide daily data regarding their predictors of weight loss outcomes and their adherence to the personal weight loss plan (phase I, month 0-3). Then participants will receive tailored information regarding the most predictive factors relevant to their weight loss trajectories (phase II, month 3-6). The information will be tailored and delivered through emails and text messages.
10130570|NCT04291482|Other|Control arm|Control group participants will receive basic educational weight loss information in a form of educational factual emails and text messages.
10130571|NCT04291287||Triple antithrombotic therapy|patients taking Triple antithrombotic therapy (aspirin and a P2Y12 inhibitor, in addition to either a DOACs or warfarin/acenocumarol)
10130572|NCT04291287||Dual antithrombotic therapy|patients taking Dual antithrombotic therapy (aspirin or P2Y12 inhibitor in addition to either a DOACs or warfarin/acenocumarol)
10130573|NCT04291300|Experimental|Lutetium treatment|Drug: Lutetium-177-PSMA-I&T, 4 cycles of 7.4 GBq intravenously, every 6 weeks.
10130574|NCT04291365|Other|Normal weight|
10130575|NCT04291365|Other|Obesity Class 1|
10130576|NCT04291365|Other|Obesity Class 2|
10130577|NCT04291365|Other|Obesity Class 3|
10130578|NCT04291313|Placebo Comparator|Current recommended dose of vitamin D|Women in this study arm receive 10 µg of vitamin D3 per day, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
10130579|NCT04291313|Experimental|Higher dose of vitamin D|Women in this arm receive 90µg of vitamin D3 per day: 10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3.
10130580|NCT04291261|Other|Extracorporeal photopheresis (ECP) with Uvadex|Patients in this single Arm study all receive the intervention consisting of ECP with Uvadex plus the standard of care treatment which consists of systemic corticosteroids 2mg/kg. Response to treatment will be evaluated on day 28. Patients will receive study treatment till day 56 and thereafter be followed until 1 year.
10130581|NCT04291560|Experimental|Prenatal Heart Smart Intervention|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, the group will complete a sequential static stretching exercise 5 days per week for 10 weeks. The stretching exercise consists of 20 seconds of stretching, for 3 repetitions per muscle group.
10130582|NCT04291560|No Intervention|Usual Care (Control)|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, this group will complete moderate-intensity walking 5 days per week for 10 weeks in accordance to usual care.
10130583|NCT04291651||Retrospective|The registry will be populated with a retrospective cohort of patients previously identified as having pancreatic cysts.
10130584|NCT04291651||Prospective|The prospectively enrolled patients in this study are the primary population of interest.
10130585|NCT04291378|Active Comparator|Photon radiation therapy|The patient is treated with standard radiation therapy based on photons
10130586|NCT04291378|Experimental|Proton radiation therapy|The patient is treated with experimental radiation therapy based on protons
10130587|NCT04291495|Experimental|ANDROSITOL®TEST|At least 45 patients (13 for each category: low, medium, and high responders, + 15% of hypothetical drop-outs)
10130588|NCT04291612||Part 1|Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.
10130589|NCT04291612||Part 2|Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)
10130590|NCT04291248|Experimental|Anlotinib+AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
10130591|NCT04291248|Experimental|AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
10130592|NCT04291625|Other|congenital ptosis|children who had congenital ptosis with levator function of 4mm or better, underwent levator muscle resection guided by intraoperative lagophthalmos formula.
10130593|NCT04291352|Experimental|Taurine|675mg taurine four times daily
10130594|NCT04291352|Placebo Comparator|Placebo|placebo four times daily
10130595|NCT04291339|Experimental|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
10130596|NCT04291339|Active Comparator|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
10130597|NCT04291456|Experimental|Minocycline|Minocycline 100 mg oral twice daily for up to 24 month
10130598|NCT04291235|Active Comparator|Airway Management Pathway|An airway management pathway consisting of daily assessments and removal of the breathing tube as soon as patients can breathe on their own and appear able to protect their airway
10130599|NCT04291235|Active Comparator|Usual Care|The usual clinical practice is often to keep the patient on artificial respiration for longer in the hope that the patient will wake up before removing the tube, or performing a tracheostomy if the patient doesn't wake up
10130600|NCT04291209|Active Comparator|Experimental arm with Intratympanic NAC injection|One ear will be randomly chosen for the experimental treatment and receive intratympanic NAC injections 60 minutes prior to their scheduled chemotherapy sessions
10130601|NCT04291209|No Intervention|Control arm with No injection|The control ear will not receive any injections
10130602|NCT04291183|Experimental|elderly people to undergo hortic culture therapy|Horticultural Therapy will be applied to the elderly in the experimental group in the form of two days a week visit for eight weeks. Flower and vegetable seedlings suitable for the season will be planted in the garden with the elderly. The elderly will be asked to take care of the plants they planted every day (irrigation and collecting extra herbs) and the elderly people will be observed by doing these processes twice a week
10130603|NCT04291183|No Intervention|elderly people who will not receive horticultural therapy|pre-test data forms will be applied to the control group. Post-test data forms will be reapplied after 8 weeks
10130604|NCT04291222|Experimental|IBS implantation|Implantation of IBS in PDA in duct-dependent cyanotic CHD
10130605|NCT04291170|Experimental|QDASH|Completing the tasks on the QuickDASH
10130606|NCT04291170|Active Comparator|KOOSJR|Completing the tasks on the KOOSJR
10130607|NCT04291157|Experimental|Proactive CVD prevention|Proactive invitation to total CVD risk estimation incorporating the PRS and provision of guideline based preventive interventions.
10130608|NCT04291157|Active Comparator|Usual care|Usual GP care (opportunistic CVD risk estimation and prevention upon usual GP contacts).
10130609|NCT04291027|Experimental|Aquatic Group Exercise|
10130610|NCT04291027|Active Comparator|Land Based Group Exercise|
10130611|NCT04290832|Experimental|CO intervention|"South Africa: All health facility staff working in facilities assigned to the intervention arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers) plus the CO intervention.~Mexico: Doctors/anyone eligible to be an abortion provider working in facilities assigned to the intervention arm receive the CO intervention."
10130612|NCT04290832|No Intervention|Control|"South Africa: All health facility staff working in facilities assigned to the control arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers).~Mexico: No intervention"
10130613|NCT04290819|Experimental|Resistance Training with Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
10130614|NCT04290819|Experimental|Resistance Training with Caffeine|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
10130615|NCT04290819|Experimental|Resistance Training with Caffeine and Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
10130616|NCT04290819|Placebo Comparator|Resistance Training with Placebo|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
10130617|NCT04290936|Experimental|Arm 1|NUC-naïve patients will be randomization into Tenofovir Alafenamide(TAF) treatment.
10130618|NCT04290936|Placebo Comparator|Arm 2|NUC-naïve patients will be randomization into placebo arm.
10130619|NCT04290936|Active Comparator|Arm 3|NUCs-treated patients will be switched to Tenofovir Alafenamide(TAF) treatment.
10130620|NCT04290871|Experimental|Treatment Group|Nitric Oxide gas will be administered in the ventilatory circuit.
9519586|NCT03285698|Experimental|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue.
10130621|NCT04290871|Sham Comparator|Control Group|The delivery system will be set up anyway without study gas administration
10130622|NCT04291040|Experimental|Decision Aid|
10130623|NCT04291040|Active Comparator|Routine Care|
10130624|NCT04291014|Experimental|BWLT once daily|Participants in this arm will receive bright white light therapy daily once a day (in the evening)
10130625|NCT04291014|Experimental|BWLT twice daily|Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).
10130626|NCT04291014|Experimental|BWLT weekly|Participants in this arm will receive bright white light therapy once weekly (in the evening).
10130627|NCT04291014|Experimental|DRLT twice daily|Participants in this arm will receive dim red light twice daily (morning and evening).
10130628|NCT04290806||ESCC|250 patients with esophageal squamous cell carcinoma
10130629|NCT04290806||GAC|250 patients with gastric adenocarcinoma
10130630|NCT04290806||GEJAC|250 patients with gastroesophageal junction adenocarcinoma
10130631|NCT04291066|Experimental|Treatment|oral N-acetyl cysteine and oral multivitamin tablets
10130632|NCT04291066|No Intervention|Non-Treatment|Routine Care
10130633|NCT04290884|Experimental|Local administration of tranexamic acid|"All patients hip fracture will be treated according to the hospital standard procedure~Check complete blood count on admission and Day 3 post-operation.~10ml tranexamic acid injected under the deep fascia around the fracture site under x-ray control~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.~Transfusion when clinically indicated or Hb < 8g/dL~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.~After discharge, patients will be seen in 6 weeks and 3 months"
10130634|NCT04290884|No Intervention|Control group|"All patients hip fracture will be treated according to the hospital standard procedure~Check complete blood count on admission and Day 3 post-operation.~10ml normal saline injected under the deep fascia around the fracture site under x-ray control~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.~Transfusion when clinically indicated or Hb < 8g/dL~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.~After discharge, patients will be seen in 6 weeks and 3 months"
10130635|NCT04290910|Experimental|Weight Loss Program|Single arm, all participants receive the weight loss program
10130636|NCT04290793|Experimental|Experimental group|Patients will receive the test drug (Pyrotinib) combined with Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
10130637|NCT04290793|Active Comparator|Control group|Patients will only receive Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
10130638|NCT04290858|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
10130639|NCT04290858|No Intervention|Control|The control group will receive the standard of treatment without any active, placebo or sham Comparator.
10130640|NCT04290962|Experimental|Supportive Care (web-based lifestyle intervention)|Participants complete the 12-month Precision Nutrition Coaching Program web-based lifestyle intervention consisting of physical activity at home or a local gym, nutritional/lifestyle habit with a new focus biweekly, and educational lessons about health, nutrition, fitness, or behavior change.
10130641|NCT04291144||Patients|Inclusion criteria are mild to moderate DLB, age above 50, ability to give informed consent.
10130642|NCT04291144||Healthy controls|Age above 50.
10130643|NCT04291131||Veterans with COPD|Veterans with COPD who will participate in a physical activity intervention or exercise program
10130644|NCT04290767|Other|Sonovue|ICU patients with acute shock status (septic or non-septic) who are eligible for enhanced-contrast brain ultrasound with sulphur hexafluoride microbubbles contrast (Sonovue, BRACCO, Milan, Italy) examination.
10130645|NCT04291118|Other|Medical Management and Sinus Surgery in private system|These patients will first receive medical management for their symptoms and then will undergo sinus surgery much earlier than the other group as they will include patients being operated in the private system.
10130646|NCT04291118|Other|Medical Management and Sinus Surgery in public system|These patients will first receive medical management for their symptoms, and then will undergo sinus surgery after a waiting period of at least 1 year since they are on the public wait-list.
10130647|NCT04291118|Other|Medical Management Only|These patients will only receive medical management for their symptoms as they will not require sinus surgery.
10130648|NCT04290754|Experimental|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
10183885|NCT03760133|No Intervention|without Probiotics|Participants included in this group will not be taken probiotics for 1 month after bowel preparation for colonoscopy.
10183886|NCT03760107|Experimental|Incentive Level High, Call|
10130649|NCT04290754|Active Comparator|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive-behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
10130650|NCT04290715||group A|
10130651|NCT04290715||group I|
10130652|NCT04290611||Enzalutamide drug-induced toxicity|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by enzalutamide, with a chronology compatible with the drug toxicity
10130653|NCT04290533|Experimental|Active HD-tDCS|
10130654|NCT04290533|Sham Comparator|Sham HD-tDCS|
10130655|NCT04290442|Active Comparator|Adductor canal block (ACB)|
10130656|NCT04290442|Experimental|Adductor canal block plus SPANK block|
10130657|NCT04290637|Experimental|No sea swimming|Stop sea swimming for 4-6 weeks
10130658|NCT04290637|Active Comparator|Sea swimming|Continue sea swimming for 4-6 weeks
10183887|NCT03760107|Experimental|Incentive Level High, No Call|
10183888|NCT03760107|Experimental|Incentive Level Medium, Call|
10183889|NCT03760107|Experimental|Incentive Level Medium, No Call|
10183890|NCT03760107|Experimental|No Incentive, Call|
10183891|NCT03760107|Experimental|No Incentive, No Call|
10183892|NCT03760094|Experimental|Study group|patients with lymphadenopathy
10183893|NCT03760055||Glaucoma and glaucoma suspects|Patients with at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits. Patients considered suspects for glaucoma must have an intraocular pressure (IOP) greater than 21 millimeters of mercury (mmHg) or suspicious appearance of the optic nerve head but with reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
10183894|NCT03760055||Age-related macular degeneration|"Patients will be considered as having AMD if one or more of the following are present on posterior biomicroscopy (fundoscopy), indirect ophthalmoscopy or Optical Coherence Tomography (OCT) exams:~Presence of at least intermediate-size drusen (63µm or larger in diameter)~Retinal pigment epithelium (RPE) abnormalities such as hypopigmentation or hyperpigmentation~Reticular pseudodrusen (also called sub retinal drusenoid deposit)~Presence of any of the following features: geographic atrophy of the RPE, choroidal neovascularization (exudative, wet), polypoidal choroidal vasculopathy, or retinal angiomatous proliferation."
10183895|NCT03760055||Other eye diseases|Patients with other retinal degenerations such as retinitis pigmentosa or with other diseases affecting the visual pathways such as tumors, ischemic neuropathy or optic neuritis may also be included. Their diagnosis will be extracted from their clinical visits.
10183896|NCT03760055||Healthy subjects|To be considered healthy, subjects have to have IOP < 22 mmHg with no history of elevated IOP and with at least two reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
10187648|NCT03724071|Experimental|Phase 1, Arm A - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with repeated administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
10187649|NCT03724071|Experimental|Phase 1, Arm B - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with closer administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
10187650|NCT03724071|Experimental|Phase IIa - Efficacy of TG6002 and flucytosine combination|Repeated administrations of TG6002 in combination with flucytosine in patients with colorectal cancer and liver metastases
10187651|NCT03724058|Experimental|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty using Trident II Clusterhole HA Acetabular Shells
10187652|NCT03724058|Active Comparator|Trident® Hemispherical Acetabular Shell|Hip arthroplasty using Trident Hemispherical Acetabular Shell
10187653|NCT03724045|Experimental|Back Side of the Moon|"Patients will be screened and enrolled at the ICU. Extraordinary measurements concerning nutritional status will be performed, to investigate whether patients at the ICU actually meet their nutritional needs. The same patients as above will be followed up, once discharge from ICU to a low-care ward has taken place. From there, they will be followed up until discharge from the hospital. The procedures are the same as in the ICU. The results obtained at the low-care ward will be compared to those from the ICU. 6 months after hospital discharge, morbidity and mortality will be assessed.~A substudy of included COVID-19 positive patients will be analysed and compared to non COVID-19 patients."
10187654|NCT03724006|Experimental|INTERVENTION group (I)|Group I will be composed by parents of children with the diagnosis of CHD who will receive a psychoeducational intervention plus usual routines of the Service.
10187655|NCT03724006|No Intervention|CONTROL group (C)|Group C will be composed by parents of children with the diagnosis of CHD who will receive the usual routines of the Service. After completing the data collection, the possibility of receiving the psychoeducational intervention under study will be offered to this group.
10187656|NCT03723993|Placebo Comparator|Control group|control group will have non inflated cuff around the arm.
10187657|NCT03723993|Active Comparator|RIPC group|Inflated cuff will be done systematically and regularly
10187658|NCT03723941|Experimental|A - adjuvant therapy|adjuvant therapy with four cycles of cisplatin plus etoposide +/- mitotane according to investigator's preference versus
10187659|NCT03723941|Other|B - observation or mitotane alone|observation or mitotane alone according to the investigator's preference
10188054|NCT03720054|Experimental|MapTrek|Veterans in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so veterans can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
10130659|NCT04290728|Experimental|High flow|Apply high-flow nasal oxygenation during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
10130660|NCT04290728|Active Comparator|Control|Apply nothing during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
10130661|NCT04290702|Active Comparator|epidural|
10130662|NCT04290702|Active Comparator|combined|
10130663|NCT04290702|Active Comparator|dural puncture epidural|
10130664|NCT04291053|Experimental|experimental group|Standard therapy+Huaier granule Huaier granule 20g, po, tid for 2 weeks( or until discharge)
10130665|NCT04291053|No Intervention|control group|standard therapy
10130666|NCT04290455|Experimental|treatment arm|using the microblepharoexfoliative procedure
10130667|NCT04290455|Active Comparator|control arm|using eyelid wipe (Optase)
10130668|NCT04290416|Experimental|Microwire electrodes|Activity of individual neurons will be recorded via microwire contacts. These microwire electrodes do not interfere with the macrowire clinical recordings.
10130669|NCT04290429|Experimental|SR-GI-GVHD|Analysis of patient's stool frequency, albumin serum levels and quantification of Paneth cell numbers in GI biopsies before and during teduglutide treatment.
10130670|NCT04290988|Experimental|Active EEG Neurofeedback|15 sessions of active EEG neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
10130671|NCT04290988|Sham Comparator|Sham Feedback|15 sessions of sham neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
10130672|NCT04290572|Experimental|Isotretinoin 10 mg/day|One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.
10130673|NCT04290572|Experimental|Isotretinoin 20 mg/day|One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.
10130674|NCT04290572|Active Comparator|Isotretinoin 30 mg/day|One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.
10130675|NCT04290585|Experimental|Health Services Research (text message reminder)|Patients receive 1-2 text messages a few weeks before and 1 text message 24 hours before their mammography screening appointment. Patients also receive a phone call reminder as per standard practice.
10130676|NCT04290663|Active Comparator|RAI group|
10130677|NCT04290663|Experimental|GUIDED FOLLOW-UP group|
10130678|NCT04290650|Other|Modified CBT for insomnia|All patients admitted to one of the psychosis ward will be offered the same customized treatment focusing on sleep in addition to treatment as usual.
10130679|NCT04290650|Other|Treatment as usual|All patients admitted to the other two psychosis wards will only receive treatment as usual.
10130680|NCT04290312|Other|Mastiha oil|As a control to the experimental design, timepoint 0 was considered.
10130681|NCT04291092|Experimental|single-arm|single-arm
10130682|NCT04290390|Active Comparator|Annovera (alone)|Annovera taken alone (without itraconazole or rifampin)
10130683|NCT04290390|Active Comparator|Annovera with itraconazole use|Subjects will dose with 200 mg/day of itraconazole for five days before Annovera insertion and through Days 1 to 8 of Annovera use
10130684|NCT04290390|Active Comparator|Annovera with rifampin use|Subjects will dose with 600 mg/day rifampin for 8 days, between Days 4 to 11 of Annovera use during their respective treatment cycles
10130685|NCT04290338|Experimental|PIOMI Group|Patients in this group will receive the intraoral and extraoral stimulations provided by the PIOMI protocol. These stimulations will last 5 minutes and will be performed once a day for 7 consecutive days for each patient.
10130686|NCT04290338|No Intervention|Control Group|Patients in this group will receive classic care.
10130687|NCT04290364||Prospective cohort|Patients newly diagnosed with pancreatic cancer included in the prospective part of the study
10130688|NCT04290364||Retrospective cohort|Patients diagnosed with pancreatic cancer before early palliative care was introduced (historical control patients)
10130689|NCT04290377|Active Comparator|Conventional OT + Motor Imagery OT|Conventional OT (30 minutes/day) plus Motor Imagery OT (30 minutes/day) for 10 days.
10130690|NCT04290377|Experimental|Conventional OT + BMI-assisted Motor Imagery OT|Conventional OT (30 minutes/day) plus BMI-assisted motor imagery OT (30 minutes/day) for 10 days.
10130691|NCT04290195|Experimental|ziv aflibercept patients|20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO
10130692|NCT04290182|Experimental|Single arm: MSC administration to vocal fold scar|1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)
10130693|NCT04290143|Active Comparator|Colored healing water|Colored medical water in a bath tub. A single 20 minutes-long treatment will be performed.
10130694|NCT04290143|Placebo Comparator|Placebo - Colored tap water|Colored tap water. The temperature and the pH of the tap water will be adjusted to the temperature pH of the healing water. A single 20 minutes-long treatment will be performed.
10130695|NCT04290013|Experimental|norethisterone -women with Dysfunctional uterine bleeding|
10130696|NCT04290013|Experimental|tranexemic acid-women with Dysfunctional uterine bleeding|
10130697|NCT04290273|Experimental|Morning exposure in week 1|Participants will have their first week of testing starting in the morning
10130698|NCT04290273|Experimental|Afternoon exposure in week 1|Participants will have their first week of testing starting in the afternoon
10130699|NCT04290156|Experimental|Joint visits|Subjects in the intervention arm attend a total of four joint transition visits performed with the participation of both the adult and the pediatric gastroenterologist.
10130700|NCT04290156|No Intervention|Usual care|Adolescents meet only the pediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologists with respect the patient's treatment plan.
10130701|NCT04290325|Experimental|HMPL-453|HMPL-453
10130702|NCT04290208|Active Comparator|Intravenous Administration of Acetaminophen|A single peri-operative dose of acetaminophen 1000 mg IV over 15 minutes after skin is closed.
10130703|NCT04290208|Active Comparator|Per Oral Administration of Acetaminophen|A pre-operative liquid dose of acetaminophen 1000mg orally in the on-call to Operative Room.
10130704|NCT04289896|Experimental|Experimental group|Each session will last 20 minutes, taking place 2 days a week, for a period of 4 weeks. Prior to the completion of the routine training of each team, the plyometric exercise program will be carried out in the experimental group. When the intervention ends, the members of the experimental group will perform the usual training
10130705|NCT04289896|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
10130706|NCT04290169|Other|Adults with hemiplegic spastic cerebral palsy|Adults (> 18 years old) with hemiplegic spastic cerebral palsy, with reduced hand function and spasticity as prevalent finding under clinical examination. Also these patients can walk but have problems with balance. Participants' cognitive function does not limit them to perform video game training.
10130707|NCT04290247|Experimental|Ultrasound + X-ray|Ultrasound first then x-ray examination
10130708|NCT04289948|Experimental|Phage|
10130709|NCT04289948|Placebo Comparator|Placebo|
10130710|NCT04290234||Non-medicated healthy adults with childhood maltreatment|The 25-item retrospective Childhood Trauma Questionnaire (CTQ) will be administered to assess history of abuse and neglect. The CTQ measures five types of maltreatment: emotional, physical, and sexual abuse and emotional and physical neglect.
10130711|NCT04289909|Other|MS patients|RRMS Patients with optic neuritis, RRMS patients without optic neuritis or Progressive MS patients
10130712|NCT04289909|Other|Control group|Healthy volunteers
10130713|NCT04290221|Experimental|Percutaneous electrolysis in the lumbar nerv|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
10130714|NCT04290221|Active Comparator|Percutaneous electrolysis in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 3 weeks).
10130715|NCT04290260|Experimental|Use of breast bra|Patients allocated on this group wear a breast bra from admission to hospital discharge.
10130716|NCT04290260|Active Comparator|Usual care|Usual care: participants will not wear a breast bra until discharge from the hospital
10130717|NCT04290104|Experimental|1gr oral ampicillin/sulbactam group|The group to be prescribed 1 g oral ampicillin/sulbactam twice a day while discharged after laparoscopic cholecystectomy due to ACC.
10130718|NCT04290104|No Intervention|Antibiotic not prescribed group|Antibiotics not prescribed when discharged after laparoscopic cholecystectomy due to ACC.
10130719|NCT04290026|Active Comparator|metoclopramide versus granisetron|Ultrasound assessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section: A randomized, double-blind, placebo-controlled study
10130720|NCT04290117|Experimental|ACT-Chrono|First Acceptance and Commitment (ACT) training, followed by chronobiological training
10130721|NCT04290117|Experimental|Chrono-ACT|First chronobiological training, followed by ACT training
10130722|NCT04290117|Other|Chrono|First no training, followed by chronobiological training
10130723|NCT04290117|Other|ACT|First no training, followed by ACT training
10130724|NCT04290078|Experimental|Kaia Back Pain Study Intervention|"The study intervention consists of training sessions conducted daily by the participant via Kaia back pain program. This content combines several approaches that may be effective when used together such as physical exercises, relaxation practices and learning modules. Additionally, there is availability of an electronic motion coach on a set of exercises.~Users also receive behavioural health coaching provided by Kaia's coaching staff based on a coaching curriculum."
10130725|NCT04290078|Active Comparator|Control Group|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth.
10130726|NCT04290091||Patients with CAD|Patients who have hemodynamically significant CAD.
10130727|NCT04290091||Patients without CAD|Patients who don't have hemodynamically significant CAD.
10130728|NCT04289805|Active Comparator|standard-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the French participating centres.
10130729|NCT04289805|Experimental|letrozole-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the Belgian participating centres.
10130730|NCT04289805|No Intervention|non-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and who have access to the Fertility Clinics in all the participating centres but are not willing to preserve their fertility by undergoing oocyte/embryo cryopreservation.
10130731|NCT04289584|Experimental|Experimental group|Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session. Prior to training, strength and proprioception exercises will be performed.
10130732|NCT04289584|No Intervention|Control group|The players included in the control group will follow their usual routine prior to their Taekwondo training.
10130733|NCT04289831|Active Comparator|Direct Surgery (DS) group|patients subjected to direct surgery (DS) within 1 week after randomization
10130734|NCT04289831|Active Comparator|Preoperative Biliary Drainage (PBD) group|patients managed by Preoperative Biliary Drainage followed by surgery after 4-6 weeks.
10130735|NCT04290065|Experimental|Experimental group|The intervention will take place over a period of 4 weeks, with 2 weekly sessions, with an estimated execution time of 1.50 to 3 minutes each. A manual therapy technique of inhibition of the suboccipital musculature and an axial traction of the upper hemiarchy will be performed
10130736|NCT04290065|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
10187660|NCT03723902|Experimental|Strength training + protein supplement|Heavy-load strength training, Protein supplementation
9669063|NCT04192760|Active Comparator|Culotte Technique|Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.
10130737|NCT04289844|Experimental|Experimental group|Each session of the intervention will have a duration of 15 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength and resistance strength
10130738|NCT04289844|Active Comparator|Control group|Each session of the intervention will have a duration of 10 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength
10130739|NCT04289818|No Intervention|Control|Conventional Education Class
9968257|NCT01277809|Active Comparator|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program. This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the walking group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
9968258|NCT01277809|Experimental|Walking Program|Participants will walk five times per week under the supervision of a licensed physiotherapist.
9968259|NCT01277835|Experimental|Lidocaine Infusion|
9968260|NCT01277835|Placebo Comparator|Placebo|Saline Infusion
10130740|NCT04289818|Experimental|Coaching|Health Coaching
10130741|NCT04289675||Interferon-Beta|Patients with first treatment : interferon beta (1a subcutaneous 22 or 44 µg thrice a week OR 1a intramuscular 30 µg once a week OR 1b subcutaneous 250 µg every other day OR 1a PEGylated subcutaneous 125 µg every two weeks)
9968261|NCT01277874|Active Comparator|Nasal CPAP|Standard Nasal CPAP
10130742|NCT04289675||Dimethyl fumarate|Patients with first treatment : dimethyl fumarate (oral, 240 mg twice a day)
10130743|NCT04289675||Teriflunomide|Patients with first treatment : teriflunomide (oral, 14 mg once a day)
10130744|NCT04289636|Experimental|Weight loss and self-compassion|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week mindfulness-based self-compassion program which combines the skills of mindfulness and self-compassion as a means for improving emotional resilience, well-being, and weight control.
10187661|NCT03723902|No Intervention|Control|No intervention
9968262|NCT01277874|Active Comparator|Oscillatory NCPAP|NCPAP will be given to infant via prongs in the infant's nose. A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
9968263|NCT01277900||Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
9968264|NCT01277913|Experimental|Vitamin D 1000 IU|vitamin D will be given 1000 IU for 12 months
9968265|NCT01277913|Active Comparator|Vitamin D 500IU|vitamin D 500 IU will be given for 12 months once daily
9968266|NCT01277939|Experimental|Therapeutic Education System (TES)|Experimental (E) condition, the Therapeutic Education System (TES) delivered via effective informational technologies and multimedia learning tools.
9968267|NCT01277939|Active Comparator|Standard Care|The Control (C) condition, Standard Care, consisting of psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
9968268|NCT01277952|Experimental|DBS Surgery|Deep brain stimulation (DBS) will be the treatment option in this study along with behavioral interventions for participants with severe disability due to Traumatic Brain Injury (TBI) 24 months post their injury, the participants will have severe disabilities in behavioral and emotional self-regulation, cognitive impairments and somatic symptoms.
9968269|NCT01277965|Other|50% VO2 max, BFR reduced by 50%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
9968270|NCT01277965|Other|50% VO2 max,BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
9968271|NCT01277965|Other|75% VO2 max, BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%.
9968272|NCT01277965|Other|75% VO2 max, pump switched off|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed.
9968273|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change.
9968274|NCT01277978||Carbetocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 100 ug Carbetocin (the clinical standard dose) following delivery of the baby.
9968275|NCT01277978||Oxytocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 5 IU oxytocin (the clinical standard dose) following delivery of the baby.
9968276|NCT01277991|Experimental|Sequence 1|
9968277|NCT01277991|Experimental|Sequence 2|
9519587|NCT03285685|Experimental|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
10130745|NCT04289636|Active Comparator|Weight loss and nutrition/cooking education|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week nutrition and cooking education program which will provide basic nutrition knowledge and cooking skills for healthy eating.
10130746|NCT04289857|Experimental|Experimental group|Each session will last a maximum of 5 minutes, taking place for 3 days a week, over a period of 4 weeks. The intervention will be performed at the start of training (before warm-up).
10130747|NCT04289857|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
10130748|NCT04289766|Active Comparator|Conventional Treatment|Conventional Treatment includes exercises limbs
10130749|NCT04289766|Experimental|Focal Muscle Vibration (120Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 120 Hz.~Conventional Treatment"
10130750|NCT04289766|Experimental|Focal Muscle Vibration (60Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 60 Hz.~Conventional Treatment"
10130751|NCT04289506||Community-acquired pneumonia (Sepsis)|Community-acquired pneumonia with organ dysfunction
10130752|NCT04289506||Abdominal sepsis|Abdominal infection due to peritoneal soiling, biliary infection, urinary tract infection leading to organ dysfunction
10130753|NCT04289506||Infection of unknown origin (Sepsis)|Infection of unknown origin of less than 72 hours duration, including bacteraemia with organ dysfunction
10130754|NCT04289506||Organ dysfunction related to non-infectious cause (SIRS)|Patients admitted to the ICU following out-of hospital cardiac arrest OR Patients admitted to the ICU following major trauma (ISS>12) OR Patients admitted to the ICU following pancreatitis with organ dysfunction
10130755|NCT04289506||Healthy volunteers|Healthy volunteers
10130756|NCT04289987|Experimental|CVI-HBV-002|"CVI-HBV-002 1.0mL(20ug/dose)~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
10130757|NCT04289987|Placebo Comparator|Normal Saline|"Normal Saline Choonwae Inj. 1.0 mL~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
10130758|NCT04289974||Palbociclib+fulvestrant|"100 cases of patients with ER+, HER2- breast cancer, experienced resistance after first line endocrinotherapy, will be assigned participants into treatment regimen, including palbociclib combined with fulvestrant.~FFPE blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals on the points before administration and since resistance appearance. The tissue will be sequenced by a pan-cancer DNA panel (500+ genes) and whole transcriptome sequencing (WTS).~5-10 ml peripheral blood will be collected from each patient on the points before administration, 1 month after treatment, every subsequent visit and resistance appearance. The liquid biopsy will be sequenced by a pan-cancer ctDNA panel (300+ genes).~The genomic characteristics of patients received resistance will be analyzed. The relevant pathway mechanisms will be identified."
10130759|NCT04289883|Experimental|High molecular weight whey protein-alginate/Calcium alginate|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
10130760|NCT04289883|Experimental|Nano-particulated whey protein/Non-particulated whey protein|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
10130761|NCT04289727||Group 1|Those with Type 1 Diabetes.
10130762|NCT04289727||Group 2|Those without Type 1 Diabetes.
10130763|NCT04289792|Experimental|SBRT with concurrent chemotherapy|SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy
10130764|NCT04289545|Placebo Comparator|Control Bread|no added guar gum
10130765|NCT04289545|Active Comparator|Functional Bread 1|10% guar gum, low molecular weight
10130766|NCT04289545|Active Comparator|functional Bread 2|10% guar gum, high molecular weight
10130767|NCT04289545|Active Comparator|Functional Bread 3|15% guar gum, low molecular weight
10130768|NCT04289545|Active Comparator|Functional Bread 4|15% guar gum, high molecular weight
10130769|NCT04289701||Hypertension Cohort|"Hypertension patients recruited in the Hypertension Prevention and Control Initiative in China project."
9968278|NCT01278004|Placebo Comparator|Placebo|Placebo capsule
10130770|NCT04289610|Sham Comparator|Control Group|In this group a pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). The device is not going to be activated in the control group. The device will be set at 0 V. TCPRF treatment is going to be applied for one session.
10130771|NCT04289610|Active Comparator|Study Group|A pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). It will be activated in the study group. In the study group device will be set at 80 V, every pulse will continue for 10 milliseconds and 5 pulses per second. TCPRF treatment is going to be applied for one session in both groups.
10130772|NCT04289532|Experimental|99mTc-RWY SPECT/CT|Volunteers and patients were injected intravenously with 11.1 MBq/kg of 99mTc-RWY in one dose and underwent SPECT/CT scan 30-60 min later.
10130773|NCT04289649|Experimental|K-924 LD|K-924 LD tablet once daily
10130774|NCT04289649|Experimental|K-924 HD|K-924 HD tablet once daily
10130775|NCT04289649|Active Comparator|Pitavastatin 2 mg|K-924 LD Placebo tablet once daily
10130776|NCT04289649|Active Comparator|Pitavastatin 4 mg|K-924 HD Placebo tablet once daily
10130777|NCT04289337|Experimental|Combined probiotics (1)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
10130778|NCT04289337|Experimental|Combined probiotics (2)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66.
10130779|NCT04289337|Experimental|Combined heat-killed probiotics (1)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
10130780|NCT04289337|Experimental|Combined heat-killed probiotics (2)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32 and Lactobacillus paracasei ET-66.
10130781|NCT04289337|Experimental|Probiotic metabolites|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66 metabolites.
10130782|NCT04289337|Placebo Comparator|Placebo|Does not contain probiotics, heat-killed probiotics and related metabolites.
10130783|NCT04289558|Experimental|Sodium Nitrite|Single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute)
10130784|NCT04289441|Active Comparator|probiotic treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Lactobacillus salivarius LS01 (DSM 22775): 10^9 CFU Bifidobacterium breve B632 (DSM 24706): 10^9 CFU Maltodextrin and silicon dioxide"
10130785|NCT04289441|Placebo Comparator|Placebo treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Maltodextrin and silicon dioxide"
10130786|NCT04289662|Experimental|K-924 LD|K-924 LD once daily
10130787|NCT04289662|Experimental|K-924 HD|K-924 HD once daily
10130788|NCT04289389||HUNT4 70+|All inhabitants in Nord-Trøndelag 70 years of age and older were invited.
10130789|NCT04289389||HUNT4 Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age and older were invited.
10130790|NCT04289272|Experimental|Dove Confident Me|Dove Confident Me body image intervention to be delivered to students 1 lesson per week for 5 weeks (5 x 45 minute lessons).
10130791|NCT04289272|No Intervention|Control|Students receive lessons-as-usual.
10130792|NCT04289415|Experimental|Individual Placement and Support|"The intervention used in this study will be a time-limited version of IPS. The employment specialist offers up until nine months job-search support and four months in-work support, giving a total of 13 months job-related support. If a participant succeeds in obtaining work before nine months has passed the remaining job-search support months may be transferred to in-work support time.~In the follow-up time while seeking employment, the employment specialists will work with the participants to identify skills and aspirations, establish contact with potential employers and ensure economic advice and help with benefits planning. The in-work support involves individual and regular contact with the participant and the employer.~All participants who receive this intervention will do so in addition to their clinical treatment. The treatment provider and the employment specialist should cooperate and clarify roles together with the patient."
10130793|NCT04289415|Active Comparator|Selv help kit and work shop|The participants in the control intervention will be offered a self-help tool kit and a following introduction course to help participants see what their opportunities are, and specific tips on how to get further help. The course will last three hours a session over four days, with the offer of an individual one hour follow up session with the course leader when the course is over. The goal of the control group intervention is to enable the participants to make use of the services offered at the ordinary labor and welfare service.
10130794|NCT04289324|Experimental|Intervention|lung recruitment maneuvers performed every twelve hours during HFOV
10130795|NCT04289324|No Intervention|Control|no regular lung recruitment maneuvers during HFOV
10130796|NCT04289181|Experimental|Medically Tailored Meals (MTM)|Participants randomized to the MTM arm will receive MTM for 4 weeks. Meals will be prepared and delivered by Meals on Wheels, a non-profit organization that has been delivering meals to seniors nationwide for decades. Meals on Wheels will deliver 21 complete meals to the patient's home each week. They can accommodate a wide range of patient needs and preferences (e.g., low sodium, gluten-free, no pork products, cultural preferences). Meals on Wheels will contact the patient directly to set up an initial assessment phone call to collect relevant data (e.g., specific patient goals for their HF) and to set up a delivery schedule. Nearing the 4-week mark when meal delivery ends, investigators will check-in with each participant to track progress, assess treatment fidelity and answer any questions. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
10130797|NCT04289181|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with HF. This includes regular visits with a HF provider (primary care or cardiology), standard nutrition teaching, medication optimization and post discharge support. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and HF self-management. These services follow guideline directed medical therapy. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
10130798|NCT04288986|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 8-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 8-weeks. The activity sessions will include semi-structured free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
10130799|NCT04289064||Fundus image quality assessment|Device: an artificial intelligence system for quality assessment of fundus images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center.
9968279|NCT01278004|Experimental|Drug|
9968280|NCT01278017|Experimental|ceftriaxone|
10130800|NCT04289012|Experimental|Helicobacter Screening|All patients with confirmed MI (both STEMI and NSTEMI) will be tested for Hp infection with bedside UBT.
10130801|NCT04288973||Typical development children|Control sample
10130802|NCT04288973||Children with developmental disability|Clinical sample
10130803|NCT04289168|Experimental|Music Class|Music Class attendance
10130804|NCT04289168|No Intervention|Play Class|Play date class attendance
10130805|NCT04289103|Experimental|Inolimomab/Leukotac|"Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~Treatment phase - Leukotac will be given up to D28~Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion"
10130806|NCT04289259||Biopsy sample|Tumor mutational burden (TMB) will be assessed on a sample of the biopsy done during standard care of patients.
10130807|NCT04289259||Surgical sample|TMB will be assessed on a sample of the tumor surgical specimen resected during standard care of patients.
10130808|NCT04289259||Biopsy sample + surgical sample|TMB will be assessed both on a sample of the biopsy and a sample of the tumor surgical specimen resected during standard care of patients.
10130809|NCT04289220|Experimental|Anti-CD19 CAR-T Cells Injection|Anti-CD19 CAR-T Cells Injection, Dosage form：injection Dosage:1-2.5x10^6/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
10130810|NCT04289129|Experimental|men|
10130811|NCT04289129|Experimental|women|
10130812|NCT04289077||Patients with histopathological proven DTF|
10130813|NCT04289467|Experimental|Fenfluramine treatment|Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.
10130814|NCT04289090|Experimental|Group A|Group A will begin anesthesia maintenance with sevoflurane-only, then will be switched after 30 minutes to anesthesia with propofol-only.
10130815|NCT04289090|Experimental|Group B|Group B will begin anesthesia with propofol-only then will be switched to sevoflurane-only.
10130816|NCT04289194|Experimental|HCR040 (Phase 1)|Participants with moderate to severe acute respiratory distress syndrome (6 patients)
10130817|NCT04289194|Placebo Comparator|Control group (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
10130818|NCT04289194|Experimental|HCR040 (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
10130819|NCT04289207|Experimental|Romiplostim and danazol|Treatment group (romiplostim and danazol)
10130820|NCT04288999|Experimental|Arm A|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)~Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV)~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
10130821|NCT04288999|Active Comparator|Arm B|"Surgery plus Adjuvant chemotherapy~Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
10130822|NCT04289246|Experimental|Treatment Group (TG)|On the first day of the intervention phase, research assistants visited TG's participants to introduce the MAD in the presence of caregivers. After the training session, which lasted 40 min approximately, the MAD was personalized according to the participant's prescriptions and through discussions with them on an appropriate schedule for presenting the reminders. Research assistants used the MAD administrator sub-system to enter the medication names, health problems to address, timetables, and the frequency at which medications should be taken. Then, they attached and configured NFC tags to each of the pill containers, which included selecting the images that best represented the pills and their containers to be used to form the visual reminders. Afterward, the MAD was placed in the homes' area where participants reported taking medications. MAD was used for 5 weeks during which data on medication adherence and system adoption was collected from the TG.
10130823|NCT04289246|No Intervention|Control Group (CG)|Participants in the CG followed their medication routine as usual. During 5 weeks data on medication adherence was collected.
10130824|NCT04288934|Active Comparator|patients with complete transection of the spinal cord|This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.
10130825|NCT04288934|Active Comparator|patients with SCI without total transaction.|This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla.
10130826|NCT04288921|Experimental|Nasal swab|Nasal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
10130827|NCT04288921|Experimental|Nasopharyngeal swab|Nasopharyngeal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
10130828|NCT04288609|Experimental|Intendu FBT inpatient|Motion Based Cognitive Video Games Software
10130829|NCT04288609|Active Comparator|paper and pencil tasks|paper and pencil tasks
10183897|NCT03760042|Other|Group A (Crisaborole RIGHT SIDE / Vehicle LEFT SIDE)|Crisaborole ointment 2% applied to sensitive skin locations on right side of body. Crisaborole placebo vehicle ointment applied to sensitive skin locations on left side of body
10130830|NCT04288739||Acute Myeloid Leukemia (AML) group|"patients who are diagnosed as Acute Myeloid Leukemia (AML) based on peripheral blood, bone marrow, immunophenotyping and who fulfill the WHO 2016 criteria.~Complete blood count (CBC), bone marrow aspirate, flow cytometric immunophenotyping, cytogenetic analysis and fluorescence in situ hybridization (FISH) for XIST gene will be performed for all AML patients in the study."
10130831|NCT04288635||Septic shock admitted in Angers' ICU|Patients aged more than 18, admitted in University Hospital of Angers, who meet the full criteria of septic shock
10130832|NCT04288804||Control (healthy, non-PD participants)|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
10130833|NCT04288804||PD|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
10130834|NCT04288791|Experimental|Equia Forte Fil|
10130835|NCT04288791|Experimental|Zirconomer Improved|
10130836|NCT04288765|Experimental|Group A - Non transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone
10130837|NCT04288765|Active Comparator|Group B - transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone Autologous stem cell transplantation (ASCT)
10130838|NCT04288817|Active Comparator|Cryotherapy and intralesional tuberculin PPD|Efficacy of cryotherapy combined with intralesional tuberculin purified protein in treatment of multiple common warts
10130839|NCT04288817|Active Comparator|Intralesional tuberculin PPD|Efficacy of Intralesional tuberculin purified protein deravative monotherapy in the treatment of multiple common warts
10130840|NCT04288622|Experimental|ESM-derived personalised feedback (ESM-F) group|Participants will be required to participate in an ESM data collection procedure. Participants will be required to complete a beep-questionnaire 3 days a week, over a 6-week period. The mobile app will be programmed to emit a beep 10 times per day at random intervals between 7.30 and 22.30. At each beep, participants will use the app to digitally complete a brief beep-questionnaire, which covers current affect, current context and activities. Moreover, participants will receive weekly standardized feedback on personalized patterns of positive affect.
10130841|NCT04288622|No Intervention|ESM group|Participant will be required to participate in the same ESM data collection procedure as the ESM-F group. The personalised feedback report will be given to the participant after the whole study period (32 weeks) instead of weekly during data collection process.
10130842|NCT04288622|No Intervention|Control (CON) group|Participants will not be required to participate in the 6-week ESM data collection procedure. They will also receive the personalised feedback report based on the ESM data collected at baseline and week 7.
10130843|NCT04288674||Leptospirosis group|Patients with cultural, serological, molecular or histological evidence and clinical evidence of invasive leptospirosis disease.
10130844|NCT04288674||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
10130845|NCT04288388|Experimental|massage group|Immediately before the episiotomy repair was started (after exit of placenta and applying local anesthetic agent), women assigned to the study (massage) group were asked to place plastic gloves filled with ice pieces in the LI4 point on hand. This application was made for 5 minutes to the right hand and for 5 minutes to the left hand. The episiotomy was opened by the same midwife as all the women to the right mediolateral and repaired by the same midwife with the same technique and material.The ice massage was repeated until the episiotomy repair was over; total massage time and episiotomy repair time were recorded. Women were asked to mark the perceived pain level before the application and at the end of the application using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair).
10130846|NCT04288388|No Intervention|Control group|I the control group women were not excluded from routine practice; women were asked to mark the perceived pain level before episiotomy repair begin and at the end the repair using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair) like the study (massage) group.
10183898|NCT03760042|Other|Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE)|"Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body.~Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body"
10183899|NCT03760016|Active Comparator|Moderate-Intensity Aerobic Training|
10183900|NCT03760016|Experimental|High-Intensity Interval Training|
10183901|NCT03760003|Experimental|ABX464|ABX464 will be administrated orally (Capsules) and daily for 16 weeks
10183902|NCT03760003|Placebo Comparator|Matching Placebo|Matching placebo will be adminstrated orally (Capsules) and daily for 16 weeks
10183903|NCT03759990|Active Comparator|insertion time|
10183904|NCT03759990|Active Comparator|intubation time|
10183905|NCT03759977|Experimental|Adapted Physical Activity group|This group will receive 3 sessions per week of specific physical activity.
10183906|NCT03759977|No Intervention|Usual accompaniment group|This group will continue to follow the usual accompaniment of the nursing home.
10183907|NCT03759964|Active Comparator|Ferric Carboxymaltose group|Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
10183908|NCT03759964|Placebo Comparator|Placebo group|Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery
10183909|NCT03759938|Experimental|Early initiation of DOAC|Early initiation of any direct oral anticoagulant (DOAC) at a dose licensed for stroke prevention in AF, within four days (96hrs) of onset of acute ischaemic stroke
10183910|NCT03759938|Active Comparator|Standard Initiation of DOAC|Standard initiation of any DOAC at a dose licensed for stroke prevention in AF, no sooner than day 7 and no later than day 14 after the onset of acute ischaemic stroke (i.e. between 144hrs and 336hrs from onset).
10183911|NCT03759886||Oral Antibiotics|The patients get mechanical bowel preparation and oral antibiotic prophylaxis with 4g Paromomycin (Paromomycin Sulfate Powder) and 1 g Metronidazole p.o. and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
10183912|NCT03759886||iv Antibiotics|The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
9968281|NCT01278056|Experimental|Exjade|
10130847|NCT04288700|Active Comparator|Group A|
10130848|NCT04288700|Active Comparator|Group B|
10130849|NCT04288700|Active Comparator|Group C|
10130850|NCT04288700|Active Comparator|Group D|
10130851|NCT04288440|Active Comparator|Silicone filled eyes|Eyes filled with silicone oil
10130852|NCT04288440|Active Comparator|Idiopathic ERM|Eyes not filled with silicone oil
10130853|NCT04288596||Eligible for Registry|All consecutive patients who undergo any of the five ACHDi interventions (complex catheterization, ASD closure, PFO closure, CoA stenting, and PPVI) at the time of Registry launch, who have also consented to participate.
10130854|NCT04288531||Pregnant and pregnant to be on iodine supplementation|Women in preconception, pregnant and lactating, receiving iodine supplementation
10130855|NCT04288531||Pregnant and pregnant to be not on iodine supplementation|Women in preconception, pregnant or lactating, not receiving iodine supplementation
10130856|NCT04288531||Women of childbearing age|Women of childbearing age not planning to become pregnant.
10130857|NCT04288505|Experimental|single arm|
10130858|NCT04288869||Interventional radiology or surgery under general anesthesia|Monitoring of patients (mean arterial blood pressure, Transcranial Doppler , bispectral index, near infrared spectroscopy) who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anaesthesia during the interventional neuroradiology or orthopedic surgery in adults .
10130859|NCT04288908|Experimental|Social exclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives fewer passes than the other two participants (i.e., 10 out of 60).
10130860|NCT04288908|Active Comparator|Social inclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives a comparable number of passes than the other two participants (i.e., 20 out of 60).
10130861|NCT04288518|Experimental|Primary Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.~At least five (5) evaluable subjects with primary brain tumor. The tested injected dose 500 MBq."
10130862|NCT04288518|Experimental|Recurrence of Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.~At least five (5) evaluable subjects with recurrence of brain tumor. The tested injected dose 500 MBq"
10130863|NCT04288414||fNIRS applied|All of the participants' brain activity was evaluated with fNIRS.
10130864|NCT04288349|Active Comparator|epinephrine + ropivacaine +saline|1% epinephrine solution + 30 ml of 1% ropivacaine solution diluted with 20 ml of 0.9% saline for achievement a 0.75% anesthetic solution in a ratio of 1: 200 000
10130865|NCT04288349|Placebo Comparator|epinephrine + saline|1% epinephrine solution + 50 ml of 0.9% saline in a ratio of 1: 200 000.
10130866|NCT04288336|Experimental|Prevention (intermittent fasting)|Beginning when patients' PSA is detectable up to 24 months after surgery, patients follow a daily intermittent fasting routine consisting of restricting the daily eating period to 8 hours (e.g. between 1PM-9PM) followed by 16 hours of prolonged nightly fasting for up to 1 year or until secondary therapy commences.
10130867|NCT04288375|Experimental|extremity soft tissue sarcoma (STS)|Postoperative radiation therapy to the primary site with a reduction in radiation dose and volume. Specifically, the tumor bed plus a margin of 2cm craniocaudally and 1.5cm radially will be utilized to create the clinical target volume. The total dose will consist of 50 Gy in 25 fractions.
10130868|NCT04288492|Experimental|biofeedback|Respiratory exercise using biofeedback device(ResCalm) 2-3 times / day for 3 minutes until discharge from hospital, once in recovery room before surgery
10130869|NCT04288492|No Intervention|general|General surgical schedule without control exercise
10130870|NCT04288245|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
10130871|NCT04288245|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
10130872|NCT04288180||Social Anxiety Disorder|A group of adults with social anxiety disorder will be recruited for a psychological/behavioral research study.
10130873|NCT04288258|Experimental|Treatment|Health and Wellness Program
10130874|NCT04288297||distal minimally invasive distal chevron|The investigators compare the results of a consecutive cohort of patients treated with the above mentioned technique in comparison to the results of patients treated with the minimally invasive Reverdin-Isham technique, presented in literature
10130875|NCT04288232|Experimental|Intravitreal aflibercept|Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.
10130876|NCT04288219|Active Comparator|Standard of Care Treatment|Continuous supplemental oxygen and nifedipine 30mg will be administered to patients.
10130877|NCT04288219|Experimental|Non-Invasive Positive Pressure Ventilation Management|CPAP at 10mmHg with supplemental oxygen, as well as nifedipine 30mg will be administered to patients.
10130878|NCT04287972|Experimental|LSG-DPC|Laparoscopic Sleeve Gastrectomy and Diaphragmatic Pillar Closure.
10130879|NCT04287972|Active Comparator|LSG|Laparoscopic Sleeve Gastrectomy
10130880|NCT04288141||Group 1: Early HER2 positive breast cancer|Study participants in Group 1 will include patients prescribed neoadjuvant systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive early breast cancer.
10130881|NCT04288141||Group 2: Metastatic HER2 positive breast cancer|Study participants in Group 2 will include patients prescribed systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive metastatic breast cancer.
10130882|NCT04288128||SCA early-manifest and premanifest patients|This cohort is defined by individuals with a SARA score between 0 and 15 (both values included).
10130883|NCT04288128||Control participants|This cohort is defined by individuals with a SARA score less than 5 and no significant neurological symptoms.
10130884|NCT04288466|Active Comparator|Adults|Adults < 60 years-old maltodextrin solution 450ml
10130885|NCT04288466|Active Comparator|Elders|Elders 65 or more years-old maltodextrin solution 450ml
10130886|NCT04288102|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|Participants will receive standard of care plus 3 does of UC-MSCs
10130887|NCT04288102|Placebo Comparator|Placebo|Participants will receive standard of care plus 3 does of placebo
10130888|NCT04287933|Active Comparator|Drain|
10130889|NCT04287933|No Intervention|No drain|
10130890|NCT04288024|Experimental|Postural|During training, participants in this group are instructed to focus on their posture during weight-shifting.
10130891|NCT04288024|Experimental|Suprapostural|During training, participants in this group are instructed to focus on their suprapostural task during weight-shifting.
10130892|NCT04287907|Experimental|Monitor|Qualitative End Tidal Co2 detector will be attached to the face mask used to provide mask ventilation to the preterm baby before connected to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
10130893|NCT04287907|No Intervention|Control|face mask used to provide mask ventilation to the preterm baby will be connected directly to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
10130894|NCT04288284||Emergency group|Patients presented to emergency by complicated colorectal cancer ( Obstruction, bleeding or perforation)
10130895|NCT04288284||Elective group|Patients presented with uncomplicated colorectal cancer for resection treatment
10130896|NCT04288167|Experimental|Patients with suspected brain injury|This arm will consist of up to 30 pediatric patients who entered the Emergency Room and who are suspected of having mild traumatic brain injury. Two sample sets will be collected within the first 10 hours from the injury.
10130897|NCT04288167|Active Comparator|Healthy controls|This arm will consist of up to 30 healthy control subjects, the samples of whom will be compared to the samples of brain injury patients (Arm 1). One sample set will be collected from healthy children without any known brain injury.
10130898|NCT04288076|Experimental|PEEP Titration Arm|
10130899|NCT04287881|Other|Adult patients who have epileptic seizures|Patients with adult-onset epileptic seizures and diagnosed ischemic stroke.
10130900|NCT04287894|Experimental|Cohort 1A (firste cohort)|1 course Durvalumab (1500mg) + Tremelimumab (75mg) + 1 course of Durvalumab (1500mg) followed by CRT
10130901|NCT04287894|Experimental|Cohort 2A|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
10130902|NCT04287894|Active Comparator|Cohort 2B|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
10130903|NCT04287803|Experimental|intervention Arm|Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)
10130904|NCT04287790||Health professionals after intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (July 2020)
10130905|NCT04287790||Hospitalized patient before intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 18 months before the start (January 1st 2020) of the implementation intervention
10130906|NCT04287790||Health professionals before intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (December 2019)
10130907|NCT04287790||Hospitalized patient after intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 12 months after the start (January 1st 2020) of the implementation intervention
10130908|NCT04287725|Experimental|exercise + active Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.~Photobiomodulation therapy: will be performed using the active super pulsed laser (904nm)."
10130909|NCT04287725|Placebo Comparator|exercise + placebo Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.~Photobiomodulation therapy: will be performed using the placebo super pulsed laser (904nm)."
10130910|NCT04287738|Experimental|Navigated Care|Telephone-based collaborative dementia care navigation
10130911|NCT04287738|No Intervention|Survey of Care|Control group that will receive usual care and undergo the same regular assessments as patients enrolled in Navigated Care
10130912|NCT04287569|Experimental|video recording of endoscopy|Record of sequences of video-endoscopy and the reflectance of light through fibroscopy
9519588|NCT03285685|Experimental|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
9519589|NCT03285685|Sham Comparator|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
10130913|NCT04287582||Level 1 DMD|According to Brooke Lower Extremity Functional Classification Level 1
10130914|NCT04287582||Level 2-3 DMD|According to Brooke Lower Extremity Functional Classification Level 2 or 3
10130915|NCT04287582||Healthy Group|healthy children with similar demographic characteristics with children with DMD
10187662|NCT03723863|Experimental|Supportive care (Occupational therapy)|Patients receive in-person occupational therapist-led work consultation
10130916|NCT04287699|Experimental|labor dance group|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment.The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
10130917|NCT04287699|No Intervention|Control group|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
10130918|NCT04287751|Other|Overnight Oximetry|Participants record simultaneously overnight oximetry on night 1 and continue with prolonged recordings alone for a total of 4 nights
10130919|NCT04287634|Experimental|Segmental Mobilization|Hot Fermentation Soft tissue mobilization + Targeted Segmental Mobilization Home plan exercise= cervical muscles stretching, postural care
10130920|NCT04287634|Experimental|Entire Spine Mobilization|Hot fermentation Soft tissue mobilization + Entire spine mobilization Home plan exercises=cervical muscles stretches, postural care
10130921|NCT04287595|Experimental|intervention group|inhalation aromatherapy with orange essential oil
10130922|NCT04287595|No Intervention|control group|routine care
10130923|NCT04287491|Experimental|Virtual Reality Group|This group will receive the virtual reality intervention during out-patient bedside procedures.
10130924|NCT04287777|Experimental|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
10130925|NCT04287777|Active Comparator|Mupirocin ointment|Topical administration of Mupirocin ointment 20mg/g TID for 7 days.
10130926|NCT04287777|Placebo Comparator|Placebo|Topical administration of Placebo (ointment) TID for 7 days
9519590|NCT03285672|Experimental|Arm 1|FP-101
9519591|NCT03285672|Placebo Comparator|Arm 2|Placebo Comparator
10130927|NCT04287829|Experimental|pembrolizumab and lenvatinib|"Patients will receive pembrolizumab 200mg/iv (fixed dose) every 3 weeks and lenvatinib 20mg QD in a three weekly cycle.~Treatment continues until disease progression by modified (i)RECIST for MPM, severe toxicity, serious intercurrent illness, patient request for discontinuation, need or use for any other anti-cancer agent other than protocol treatment, except for palliative radiotherapy, for a maximum period of 35 cycles"
10130928|NCT04287647|Active Comparator|Transpyloric stent|In this group, patient's will be randomized to receive a transpyloric stent for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
10130929|NCT04287647|Sham Comparator|Sham|In this group, patient's will be randomized to sham for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
10130930|NCT04287686|Experimental|rhACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
10130931|NCT04287686|No Intervention|Control group|Standard of care; no placebo
10130932|NCT04287673|Experimental|RIST-UR|"Group having performed the rehabilitation involving strongly the trunk for the first 3 months and then having performed its usual rehabilitation for the last 3 months.~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
10130933|NCT04287673|Experimental|UR-RIST|"Group having performed its usual rehabilitation for the first 3 months and then having performed the rehabilitation involving strongly the trunk for the last 3 months.~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
10130934|NCT04287673|No Intervention|Typically Developing children|Typically developing children who served as a control group in the first assessment (Trunk Control Measurement Scale, dynamic posturography on an unstable sitting device, clinical gait analysis)
10130935|NCT04287842|No Intervention|control|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. This provides complete suppression of animal responses to pain, fixation, tracheal intubation. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed.
10130936|NCT04287842|Experimental|training ischemia|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. Comparison of a total GSK-3 and phosphorytated (Ser9) GSK-3beta (pGSK3b) in brain tissuesupracardiac bundle of vessels by means of a special hook after cardiac arrest and absence of ventilation lasts 10 min.
10130937|NCT04287842|Active Comparator|desflurane|Intervention. Drug: Desflurane. Desflurane 8 vol% anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Surgery: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
10130938|NCT04287842|Active Comparator|sevoflurane|Sevoflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
9519592|NCT03285659|Experimental|Intervention: INDI Implementation|Primary care centres which will implement the collaborative (INDI) care model for depression
10130939|NCT04287712||Participants received surgery|Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.
10130940|NCT04287439|Experimental|Relaxation|"Patients will receive a training session for progressive muscle relaxation exercise.~They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence."
10130941|NCT04287439|Experimental|Meditation|Patients will receive a training session for minfullness meditation They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
10130942|NCT04287439|Active Comparator|Attention matched control group|Patients will receive a training session focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods.
10130943|NCT04287335||High risk CRC screening group|Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer
10130944|NCT04287335||CRC group|Retrospective enrollment of subjects with confirmed colorectal cancer
10130945|NCT04287426|Active Comparator|Group receiving rocuronium at induction|Rocuronium 0,6 mg/kg at induction
10130946|NCT04287426|Active Comparator|Group receiving remifentanil at induction|Remifentanil 2 μg/kg at induction
10130947|NCT04287504||Yeast, control|Women negative for vulvovaginal candidosis on Gram stain smear.
10130948|NCT04287504||Yeast, study group|Women positive for vulvovaginal candidosis on Gram stain smear.
10130949|NCT04287504||Bacterial vaginosis, control|Women negative for bacterial vaginosis on Gram stain smear.
10130950|NCT04287504||Bacterial vaginosis, study group|Women positive for bacterial vaginosis on Gram stain smear.
10130951|NCT04287530|Experimental|Tachidino + PUFA supplementation|Group 1 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform). The program will be delivered during four weeks, starting two months after the pre-testing session. Additionally, the children will receive daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
10130952|NCT04287530|Active Comparator|Tachidino + Placebo|Group 2 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session, exactly as Group 1. Additionally, the children will receive daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
10130953|NCT04287530|Experimental|PUFA supplementation|Groups 3 will receive only daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
10130954|NCT04287530|Placebo Comparator|Placebo|Groups 4 will receive only daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
10130955|NCT04287530|No Intervention|Control group|Typically Developing participants, as a comparison group for experimental tasks and for PUFA levels in the blood
10130956|NCT04287296|Experimental|App users|The app users who are at least 18 years old.
10130957|NCT04287231|Experimental|Dual-tDCS & PT|Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about 1 hours). Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program for lower limb performence.
10130958|NCT04287231|Active Comparator|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performence.
10130959|NCT04287244|Experimental|Active tSDCS|Anodal tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (designed by Sooma). The anode will be positioned over the spinal cord area at the level of the spinous processes of 10th-11th thoracic vertebra.
10130960|NCT04287244|Sham Comparator|Sham tSDCS|Sham stimulation will be delivered to the same spinal cord area using a sham tSDCS device that delivers a direct current for 10 seconds at the beginning and end of tSDCS to provide sensory experiences similar to active stimulation.
10130961|NCT04287543|Experimental|Melatonin group|Patients with PD who will receive 25 mg of melatonin gel at 12 hours a day and half an hour before sleeping for 12 months
10130962|NCT04287543|Placebo Comparator|Placebo group|Patients with PD who will receive 25 mg of placebo gel at 12 hours a day and half an hour before sleeping for 12 months
10130963|NCT04287361||Loading dose < 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam < 0.03 mg / kg
10130964|NCT04287361||Loading dose ≥ 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam ≥ 0.03 mg / kg
10130965|NCT04287140|Experimental|Saline|1000 ml of 0.9% normal saline bolus over one hour.
10130966|NCT04287140|No Intervention|No Saline|10 ml of 0.9% normal saline over one hour.
9827443|NCT02455388|Experimental|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
10130967|NCT04287387|Experimental|Glucophage group|
10130968|NCT04287387|Experimental|Acarbose group|
10130969|NCT04287387|Experimental|Sitagliptin group|
10130970|NCT04287387|Experimental|Dapagliflozin group|
10130971|NCT04287387|Experimental|Pioglitazone group|
10130972|NCT04287387|Experimental|Glimepiride group|
10130973|NCT04287153|Experimental|Croytherapy on abdomen and saddlebags|Six (6) to 10 applicators (application area of 17 cm X 6 cm) are applied on the dorsal side (back, waist, saddlebags) for 45 minutes and then on the ventral side (belly) for 45 minutes, with adjustments according to the size of the participant. The temperature applied with the device is variable (-10°c to -7°C).
10130974|NCT04287101|Experimental|home PAC|A home PAC team will care for patients in his/her home within 3 weeks after acute hospitalization. The patient will get a physical therapy (PT) or occupational therapy (OT) 1 to 6 session(s) per week.
10130975|NCT04287101|Active Comparator|hospital PAC|A rehabilitation PAC team will care for patients in the hospital within 3 weeks after acute hospitalization. The patient will have 1 to 2 session(s) of PT or OT on weekdays, and a daily physician visit and nurse care.
10130976|NCT04287101|No Intervention|conventional care group|usual care
10130977|NCT04287322|Experimental|Tactile-kinesthetic stimulation|Received tactile-kinesthetic stimulation three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
10130978|NCT04287322|Experimental|Recorded maternal voice|Listened to recorded maternal voice stimulation, three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
10130979|NCT04287322|No Intervention|Control|Received only standard nursery care
10130980|NCT04286997|Experimental|GRAIL population|patients are treated with 20 sessions of GRAIL rehabilitation, associated to 20 traditional physiotherapy sessions (1+1 a day, during a period of 30 days)
10130981|NCT04286997|Active Comparator|traditional population|subjects are treated with 40 sessions of traditional physiotherapy (2 a day, during a period of 30 days)
10130982|NCT04287205|Experimental|women with endometriosis|
10130983|NCT04287452|Placebo Comparator|Control|Emergency department patients enrolled in the control arm will receive usual care. Emergency department providers enrolled in the control arm will work their shift as usual.
10130984|NCT04287452|Active Comparator|Intervention|Emergency department patients and providers in the intervention arm will be exposed to and/or interact with a certified therapy dog and handler
10130985|NCT04287374|Experimental|Multi-component Well-being Intervention|Reading and writing activities based on cognitive restructuring (rephrasing automatic negative thoughts), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities)
10130986|NCT04287374|Sham Comparator|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
10130987|NCT04287062|Placebo Comparator|Placebo|Placebo sleep medication (2 placebo oral capsules)
10130988|NCT04287062|Active Comparator|Suvorexant|Sleep medication (20mg suvorexant; 2 10mg capsules; patients can self-titrate to 1 10mg capsule)
10130989|NCT04287257|Active Comparator|Standard treatment + Active FHP|The PEMF device - FHP (supplied by commercial support) will be placed under the cast in the ER after diagnosing the fracture and will be applied for 24 hours a day continuously for 30-40 days.
10130990|NCT04287257|Sham Comparator|Standard treatment + Sham FHP|Half of the PEMF devices will be not activated at random before the application to the patients. Two types of activators will be provided by the company: active and sham. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device. The company supplying the PEMF-devices will have no knowledge of patient outcome.
9827444|NCT02455388|Experimental|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
10130991|NCT04287270|Other|Assesment of MSA patients and healthy controls|Demographic information (sex, age, occupation, height, bodyweight ...), clinical and medical status, diagnosis date and Mini-Mental Status Scale data of all participants will be recorded at the first visit. Inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure and maximal inspiratory mouth pressure, expiratory muscle strength will be evaluated with expiratory mouth pressure. Also, the pulmonary function test will be applied.
10130992|NCT04287114|Experimental|Healthy young men and women|Single group consisting of 10 men and 10 women
10130993|NCT04286724|Experimental|Intervention|
10130994|NCT04286984||Pre-upPBM|Patients with a diagnosis of gastric cancer before the upPBM implementation in their attending center
10130995|NCT04286984||Post-upPBM|Patients with a diagnosis of gastric cancer after the upPBM implementation in their attending center
10130996|NCT04287023|Experimental|Group Physical therapy|1 physical therapists and groups of 10 patients during the sessions
10130997|NCT04287023|Active Comparator|Individual physical therapy|1 physical therapist and 1 patient during the sessions
10130998|NCT04287075||Surgery|Participants who elect to undergo surgery for the treatment of their chronic, neuropathic pain
10130999|NCT04287075||Non-surgery|Participants who elect to not have surgery for the treatment of their chronic, neuropathic pain
10131000|NCT04286919|Active Comparator|ExRx#1: Physical Activity Guidelines|ExRx#1 uses the Frequency, Intensity, Time, and Type or FITT principle of exercise prescription to prescribe the Physical Activity Guidelines for Americans which is a weekly goal of 150-minutes of moderate intensity aerobic physical activity plus 2 days of muscle strengthening physical activity. ExRx#1 communicates the ultimate goal of the physical activity guidelines for Americans using an image adopted from the physical activity guidelines website that depicts the weekly goal. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the physical activity guidelines ultimate weekly goal by providing a weekly prescription of Frequency, Intensity, Time, and Type of physical activity that accomplishes meeting the physical activity guidelines weekly goal.
10131001|NCT04286919|Experimental|ExRx#2: Heat Map|ExRx#2 uses the heat map image published in the 2018 Physical Activity Guidelines Advisory Committee Scientific Report that communicates the dose-response relationship between increased physical activity and improved health to prescribe the message that all physical activity across all Frequencies, Intensities, Time bouts and Types (FITT) counts towards health. ExRx#2 is founded in the Integrated Behavior Change Theory and emphasizes that all physical activity matters regardless of FITT as depicted by the heat map image. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the ExRx#2 heat map ultimate weekly goal of moving more throughout the day across all intensities in order to achieve optimal health as represented by the deep green color on the bottom right of the heat map image.
10131002|NCT04286698|Active Comparator|Complex decongestive physiotherapy program group|Manuel lymph drainage, compression mask, exercises and skin care
10131003|NCT04286698|Active Comparator|Home program group|Self-manuel lymph drainage and home exercises
10131004|NCT04286698|No Intervention|Control group|No intervention
10131005|NCT04286893||TAVI group|Consecutive patients undergoing TAVI
10131006|NCT04286828||Females with Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
10131007|NCT04286828||Healthy Females|20 healthy volunteers with matching ages and genders.
10131008|NCT04287283||HBOT|Patients with chronic brain injury or cognitive complaints that have been treated with Hyperbaric oxygen therapy and underwent computerized cognitive tests before and after the treatment
10131009|NCT04286841||Neoadjuvant immunotherapy|
10131010|NCT04286711|Experimental|Albumin-paclitaxel Combined With Apatinib and Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day; Repeat the therapeutic schedule every 3 weeks
10131011|NCT04286945|Other|SENSORY EXOTROPIA PATIENTS WITH LARGE ANGLES .|Patients with monocular low vision or loss of vision due to congenital or acquired cause with exodeviation of the poorly seeing eye ≥ 50PD, were included in the study.
10131012|NCT04286802|Experimental|Salt-meter|Patients received salt-meter in conjunction with dietary education by trained dietician to help monitoring the salt content in food, as well as usual care by their primary physicians.
10131013|NCT04286802|Active Comparator|Control|Patients received dietary education by trained dietician and usual care by their primary physicians.
10131014|NCT04286672||Group 1:|• 35 bladder cancer patients diagnosed by biopsy before treatment.
10131015|NCT04286672||Group 2:|35 apparently healthy individuals who were matched by age and sex .
10131016|NCT04286542|Experimental|Provocation with cold air|Participants will be exposed to cold dry air for 15 minutes
10131017|NCT04286906||One group (cohort)|Asthmatic patients
10131018|NCT04286737|Experimental|Intervention Group|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
9519593|NCT03285659|No Intervention|Control: no INDI implementation|Primary care centres in which the collaborative care strategy INDI will not be implemented, but will be compared in terms of their clinical practice towards depression
9519594|NCT03285633|Other|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
10131019|NCT04286737|No Intervention|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
10131020|NCT04286464||Term born group (H)|Healthy, white and term Born infants and Children Born 38-42 weeks postconceptional
10131021|NCT04286464||Preterm group (P)|Healthy, white preterm Born infants and Children Born <37 weeks postconceptional Which comply with the international criteria (Jobe and Bancalari) of a diagnosis of bronchopulmonary dysplasia (BPD), or of chronic lung disease of the new-born (CLD)
10131022|NCT04286464||Risk pregnancy group (RP)|White preterm Born infants and Children, including Twins Born <37 weeks postconceptional With fetal growth restriction (FGR), intrauterine growth restriction (IUGR) or preeclampsia (PE) With gestational Diabetes (GDM) With IVF or Amnion dysfunction
10131023|NCT04286750|Experimental|ACT-1004-1239 Dose level 1 (30 mg) to 5|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
10131024|NCT04286750|Placebo Comparator|Placebo|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
10183913|NCT03759860|Experimental|Selective Retina Therapy and ranibizumab combination therapy|"Perform R:GEN laser (SRT) on the 6,000 microns diameter region including macular edema, while excluding the 500 microns diameter region from the fovea, with the appropriate treatment energy determined.~Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) injection into the vitreous cavity at 3.5-4.0 mm posterior to the corneal limbus, towards the center of the eye, avoiding horizontal meridians. Then, 0.05 mL of the injection solution is slowly injected.~In study group and the control group, ranibizumab is administered 5 times in total from the baseline to month 4."
10183914|NCT03759860|Sham Comparator|Sham Selective Retina Therapy and ranibizumab monotherapy|"For the participants assigned to the control group, sham procedures are performed in Sham Mode. All procedures except for the absence of laser light emission at the laser irradiation stage are the same with the study group.~Sham SRT is performed three times in total, one time for each visit for month 1, 3, and 5. At the time of month 1 and 3, Sham SRT should be performed before administration of ranibizumab."
9827445|NCT02455388|No Intervention|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
10131025|NCT04286386||Arm Ia (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy.
10131026|NCT04286386||Arm Ib (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy and at a second time 3-4 weeks after.
10131027|NCT04286386||Arm II (MRSI, surgery)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy, followed by standard of care surgery within 6 months after.
10131028|NCT04286477||15 conventional hemodialysis patients|15 patients undergoing hemodialysis with high-flux dialyzer
10131029|NCT04286477||15 patients undergoing online-hemodiafiltration|15 patients undergoing conventional hemodialysis with high-flux dialyzer will be allocated to online-hemodiafiltration with the same dialyzer
10131030|NCT04286477||15 patients undergoing expanded hemodialysis with MCO dialyzer|15 hemodialysis patients undergoing hemodialysis with a high-flux dialyzer will be allocated to HDx with an MCO dialyzers (THERANOVA dialyzer, Baxter International Inc. (NYSE: BAX))
10131031|NCT04286477||15 patients undergoing peritoneal dialysis|15 patients undergoing peritoneal dialysis
10131032|NCT04286516|Experimental|Reaching with TMS|All participants enrolled in this group will receive TMS while performing reaching movements in a robotic system.
10131033|NCT04286763||Hilar stricture|Bile duct Stricture (corresponding to E3, E4 and E5 from of Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
10131034|NCT04286763||Low level Stricture|Bile duct Stricture (corresponding to E1 and E2 from Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
10131035|NCT04286815|Experimental|Experimental Group|a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency）.
10131036|NCT04286425|Placebo Comparator|Placebo|"500 µl of saline solution applied in the vaginal volt twice :~one month before the IVF procedure during the ovulation period~Same month of the IVF procedure after ovum pick up"
9968282|NCT01278082|Experimental|A|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
10131037|NCT04286425|Active Comparator|seminal plasma|"500 µl of seminal plasma applied in the vaginal volt twice :~one month before the IVF procedure during the ovulation period~Same month of the IVF procedure after ovum pick up"
10131038|NCT04286594|Experimental|CBD|0.5ml of sublingual CBD solution (30mg/ml) administered twice daily for six weeks.
10131039|NCT04286594|Placebo Comparator|Placebo|Matched placebo solution administered twice daily for six weeks.
10131040|NCT04286880|Experimental|TEST GROUP|Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle.
10131041|NCT04286880|Active Comparator|CONTROL GROUP|In control group, dry needling will be performed.
10131042|NCT04286308|Experimental|Brain signal data collection|Brain signal data collection at the time of deep brain stimulation (DBS) surgery.
10131043|NCT04286334|Active Comparator|Group A - control Group|Customized titanium mesh without collagen membrane 15 patients will undergo bone regeneration with custom-made mesh without a collagen membrane. (Meshes - 3D-mesh BTK, Biotec, Vicenza, Italy.) Digitally designed by an operator before the surgery (digital technique).
10131044|NCT04286334|Experimental|Group B - Test Group|Customized titanium mesh with collagen membrane 15 patients will undergo bone regeneration with a custom-made titanium mesh (BTK, Biotec- Vicenza, Italy). Digitally designed by an operator before the surgery (digital technique), covered by collagen membrane (Cytoplast RTM, Osteogenics, deore materials, Verona, Italy).
10131045|NCT04286555|Active Comparator|DASH4D diet with lower sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 1500 mg/day
10131046|NCT04286555|Active Comparator|DASH4D diet with higher sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 3700 mg/day
10131047|NCT04286555|Active Comparator|Comparison diet with lower sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 1500 mg/day
10131048|NCT04286555|Other|Comparison diet with higher sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 3700 mg/day
10131049|NCT04286399|Other|Intensive Treatment Group|High dose of RAASi and beta-blockers (unless contraindicated) as well as preferential use of SGLT2i as per local drug label guidelines on top of standard therapy.
10131050|NCT04286399|No Intervention|Control Group|Standard therapy where the use of SGLT2i at randomization is not encouraged but RAASi and beta-blockers (except for maximal dosage) are allowed. Prescription or up-titration of the study drugs listed under Intensive Treatment is not encouraged. If investigators/treating physicians feel that further prescription or up-titration is required, a thorough justification is mandatory. Unless there is clinically irrefutable reason, every attempt should be made to use other blood pressure lowering drugs than RAASi or beta-blockers, as well as glucose lowering drugs than SGLT2i, in the control group.
10131051|NCT04286490|Experimental|Prone position|
10131052|NCT04286282|Active Comparator|Standard of Care|The first 100 participants with HIV and depression will receive standard of care including SSRI therapy.
10131053|NCT04286282|Experimental|Standard of Care + Group Support Psychotherapy|The second 100 participants with HIV and depression will receive standard of care, including SSRI therapy, and group support psychotherapy.
10131054|NCT04286282|Active Comparator|Standard of Care (Non-Depressed)|100 participants with HIV and without depression will receive standard of care therapy for HIV and no depression treatment.
10131055|NCT04286178|Experimental|Treatment|patients in this arm will be treated with creatine and coenzyme Q10 supplements
10131056|NCT04286178|Placebo Comparator|Placebo|patients in this arm will be given placebo supplements that look and taste identical to the active supplements
10187663|NCT03723837|Active Comparator|Study Arm A|Children {Age > 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
9968283|NCT01278082|Placebo Comparator|B|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
9968284|NCT01278095|Experimental|GLPG0555 solid dispersion, fasting|50 mg as solid dispersion capsule, in fasting condition
10131057|NCT04286165|Active Comparator|BPS webSTAIR 6 Levels with Per Support|Participants in BPS webSTAIR will complete a baseline, posttreatment and 2-month follow-up assessment. In the BPS webSTAIR condition, participants will first complete a welcome module to orient them to the program. After randomization, participants will have 10 weeks to complete the 6 modules. Every time the Veteran logs on they will have the opportunity to engage with a Veteran peer for support through the web program. Contacts can last for up to an hour. Veterans will receive a series of automated reminders and engagement emails that the Vets Prevail program sends at various points in the program.
10131058|NCT04286165|No Intervention|Wait List|In Wait list, they will be asked to go about your life as usual. They will be asked not to participate in any other programs for PTSD or depression symptoms for 10 weeks. After the 10 weeks you can begin any other program for PTSD or depression. They will also be given the option of participating in BPS webSTAIR or be provided with information about other web-based programs that might be of interest or relevant to them.Participants in the WL condition will complete a baseline, a second assessment at the 10th week, conclude their involvement in the study and be offered the Vets Prevail coping program. During their time in the study wait list participants are asked to not seek any treatment from VetsPrevail or other entities for a period of 10 weeks. They are instructed to simply go about their lives as normal.
10131059|NCT04286503|Experimental|Carrimycin|basic treatment + Carrimycin
10131060|NCT04286503|Active Comparator|lopinavir/ritonavir or Arbidol or chloroquine phosphate|any of basic treatment + lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
10131061|NCT04286204|Experimental|Basic Life Support Training based on ICTs|It will be conformed with students from one highschool random selected. They will receive a basic life support training based on Information and communication technologies.
10131062|NCT04286204|Active Comparator|Classic Basic Life Support Training|It will be conformed with students from another highschool random selected. They will receive a full and conventional basic life support training based on American and Hear Association recommendations.
10131063|NCT04286256|Experimental|Treatment Group|The treatment group received motivational interviewing.
10131064|NCT04286256|No Intervention|Control Group|The control group received standard information only.
10131065|NCT04285840|Other|Single arm study|To establish a standardized procedure for venous ACT sampling during atrial fibrillation ablation. Analyses will examine the relationship and agreement between venous and arterial ACTs.
10131066|NCT04285905|Active Comparator|Enhanced standard of care|"Access to Fast Track TB Clinic~Information leaflet for primary male partner"
10131067|NCT04285905|Active Comparator|Group 2|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners"
10131068|NCT04285905|Active Comparator|Group 3|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
10131069|NCT04285905|Active Comparator|Group 4|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners~Female partner delivered oral HIV self-testing kits for primary male partner"
10131070|NCT04285905|Active Comparator|Group 5|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners~Female partner delivered oral HIV self-testing kits for primary male partner~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
10131071|NCT04285918||Cohort A|Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature)
10131072|NCT04285918||Cohort B|Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO
10131073|NCT04285957||pre-test Group|"Consecutive recruitment of 10 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.~Inclusion criteria: age 18-90, stroke occurred within 3 months from enrollment; clinical stability (SIC = 0). The exclusion criteria are: stroke recurrence; visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the the patients' understanding of and the reliable answering to the two assessment tools"
10131074|NCT04285957||Validation Group|Recruitment of 60 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.Inclusion criteria: age 18-90, stroke occurred within 8 months from enrollment; clinical stability (SIC = 0). If the following criteria are present: visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the patients' understanding of and the reliable answering to the two assessment tools, the interview shall be carried out with a proxy
10131075|NCT04286061|Experimental|Experimental group|Each session will last 1 or 2 minutes, with one intervention being carried out a week, over a period of 4 weeks. Prior to the start of training, the instrument-assisted soft tissue mobilization technique will be performed
10131076|NCT04286061|No Intervention|Control group|Players included in the control group will follow their usual training routine.
10131077|NCT04286022|Experimental|Speed Loss 20% Group|The SL20% group will carry out a program based on the limitation of the speed loss, allowing to perform the exercise only until a speed loss of 20% is achieved, following a similar methodology previously published (Pareja-Blanco et al., 2017). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 6-series routine with an open number of repetitions will be carried out twice, allowing as many repetitions as possible to perform until a 20% loss of execution speed is reached. The intensity of work will be 70% 1RM, resting 4 minutes between sets. As an only exercise, an elbow flexion (bicep curl) with dumbbell will be performed.
10131078|NCT04286022|Experimental|Reduced Rest Time Group|The RRT group will carry out a program based on the reduction of rest time between series, following a previously published methodology (Stragier et al., 2019). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 5 series routine with progressive repetition volume (3 to 7) at 70% 1RM will be performed twice, resting 15 seconds between sets and 150 seconds between each of the 2 blocks. The exercise to be performed will be an elbow flexion (bicep curl) with dumbbell.
10131079|NCT04285970||Medullary injured|Injured Medullary users of manually driven wheelchairs for daily locomotion
10131080|NCT04285970||Healthy volunteers|Healthy volunteer with at least 2 hours' experience using a manual wheelchair
10131081|NCT04286035|Active Comparator|Femoral group|
10131082|NCT04286035|Active Comparator|Adductor group|
10131083|NCT04286074|Experimental|Experimental group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the muscle training technique will be performed against a resistance of 50% of the maximum inspiratory pressure of each athlete"
10131084|NCT04286074|Active Comparator|Control group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the muscle training technique will be performed against a resistance of 10% of the maximum inspiratory pressure of each athlete"
10131085|NCT04286087|Experimental|Investigational Arm|
10131086|NCT04286087|Active Comparator|Control Group|
10131087|NCT04286048|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session.~Prior to training, each pitcher will perform his normal warm-up routine, notifying the investigator when he feels ready to perform the training. The intervention through weight implements will consist in the application of the protocol described by Fleising et al. The objective of the application of the technique is to produce an increase in the speed of the throws."
10131088|NCT04286048|No Intervention|Control group|Athletes included in the control group will conduct their training and activities on a daily basis
10131089|NCT04285996|Other|All patients|Pilot study: All registered patients will undergo a PET scan using [18F]-FBA-A20FMDV2.
10131090|NCT04285710|Other|Control|Subjects enrolled in the subject group will receive standard care treatment for infected diabetic wounds, including debridement surgery and wound dressings. However, in order to maintain consistency with the phototherapy arm, subjects within the control group will visit the clinic twice a week, with the first visit being for the debridement surgery, and the second visit being for clinical wound dressing redressing.
10131091|NCT04285710|Experimental|Phototherapy|For this intervention therapy, subjects enrolled in the experimental group will still receive standard care treatment for infected diabetic wounds. However, experiment group subjects will receive phototherapy treatments alongside standard care. A mobile pulsed laser device will be utilized to apply nanosecond pulsed 410 nm light onto both the cellulitis afflicted regions and open wound portions of a patient's infected diabetic ulcer wound twice a week over the course of the 3 month study. The device will be designed and produced by the Ji Xin Cheng Lab located at the Boston University Charles River Campus. Phototherapy sessions will occur twice a week, with the first session occurring after debridement surgery, and the second session occurring later in the week during clinical wound dressing redressing.
10131092|NCT04285762||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA by a single surgeon from March 2016 to October 2018.
10131093|NCT04285814||Normal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with normal results.
10131094|NCT04285814||Abnormal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with abnormal results.
10131095|NCT04285944|Active Comparator|Study|
10131096|NCT04285944|No Intervention|Control|
10131097|NCT04285775||Insertion of Dialysis Catheter|Hospital inpatients planned for dialysis catheter insertion, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
10131098|NCT04285775||Removal of Dialysis Catheter|Hospital inpatients planned for dialysis catheter removal, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
10131099|NCT04285853|Experimental|Oxycodone Arm|"Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 rescue medications, in the Oxycodone arm will be placebo rescue medications.~All participants will also receive the following as part of standard of care:~Oral non-opioid (1000 mg acetaminophen), every 8 hours.~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~Intraoperative education on post-surgical pain management."
10131100|NCT04285853|Placebo Comparator|Placebo Arm|"Patients in placebo group will receive 15 placebo tablets. All patients will also receive 8 rescue medications: Patients who randomize to the non-opioid arm will receive 5mg oxycodone rescue tablets.~All participants will also receive the following as part of standard of care:~Oral non-opioid (1000 mg acetaminophen), every 8 hours.~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.~Intraoperative education on post-surgical pain management."
10131101|NCT04286152|Experimental|Mirabegron and narcotic analgesia|Drug: Mirabegron 50mg tablet, oral, daily from stent insertion until removal - 7days Drug: Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
10131102|NCT04286152|Placebo Comparator|Placebo|Drug: Placebo for Mirabegron, 1 tablet, oral, daily from stent insertion until removal - 7days Drug:Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
10131103|NCT04285619|Experimental|Experimental group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
10131104|NCT04285619|Active Comparator|Control group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
9968285|NCT01278095|Experimental|GLPG0555 solid dispersion, fed|50 mg as solid dispersion capsule, after breakfast
10131105|NCT04285593|Experimental|Experimental group|"Each session will last 10 minutes, taking place two days a week, over a period of four weeks. The intervention will take place at the beginning of the training session.~The players included in the experimental group will perform an exercise protocol with Bulgarian squats."
10131106|NCT04285593|No Intervention|Control group|The players included in the control group will continue with their usual warm-up routine.
10131107|NCT04285502|No Intervention|CONTROL GROUP|patients without a drain
10131108|NCT04285502|Experimental|CASE GROUP|Patients a drain inserted
10131109|NCT04285632|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the Counter Movement Jump and Drop Jump exercises will be performed"
10131110|NCT04285632|No Intervention|Control group|Athletes included in the control group will continue with their usual warm-up routine.
10131111|NCT04285645|Experimental|Experimental group|Each session will last 15 minutes, taking place 2 days a week, over a period of 4 weeks. Prior to training, the exercise protocol will be carried out. Prior to the start of the intervention, the exercises to be performed will be explained to the participants and it will be verified that they are capable of performing them correctly.
10131112|NCT04285645|No Intervention|Control group|Athletes included in the control group will continue with their usual training routine.
10131113|NCT04285606|Experimental|Patient-led rehab group|Immobilization in arm sling for a short period time followed by patient-led shoulder exercises for rehab following reverse shoulder arthroplasty
10131114|NCT04285606|No Intervention|Supervised rehab group|Prolonged immobilization in arm sling followed by supervised physical therapy by therapists for rehab following reverse shoulder arthroplasty
10131115|NCT04285697|Experimental|group 1|During the outpatient clinic visit, an information leaflet will be given about the subjects that should be considered for prevention of SSI before surgery. 2% mupirocin ointment will be applied to the nostrils with the swab twice-daily before surgery and once on the morning of surgery. Body cleaning will be done with 4% chlorhexidine gluconate shower the night before the surgery. Prophylactic antibiotics by weight will be administered within 60 minutes of anesthesia induction. The planned aseptic technique will be applied and a strict draping will be used in the incision site. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form. Before the skin closes, the surgical site will be washed with warm Isotonic NaCl solution. Wound care education will be provided to the patient and family before discharge.
10131116|NCT04285697|No Intervention|group 2 control|The pre-operative service sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form.
10131117|NCT04285736|Experimental|Group A Ivabradine Group|
10131118|NCT04285736|Active Comparator|Group B Control Group|
10131119|NCT04285749|Experimental|Fluvastatin|"Participants will receive Fluvastatin for 2 weeks.~RNA-sequencing and gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision."
10131120|NCT04285528|Experimental|General Anesthesia|The first group which will undergo general anesthesia, will be anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway will be inserted afterwards.
10131121|NCT04285528|Experimental|PFK group|The second group will undergo intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine will be added, this aims to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water for injection will be added to the mixture.
10131122|NCT04285450|Experimental|Vitamin K 1mg|
10131123|NCT04285450|Placebo Comparator|Control|
10131124|NCT04285437|Experimental|massage|neonates are massaged by their mother during the first 2 months after birth.
10131125|NCT04285437|No Intervention|control|neonates are not massaged.
10131126|NCT04285216|Experimental|Dry needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
10131127|NCT04285216|Active Comparator|Strain counter strain|Hot pack 10 minutes, stretching,Neck isometrics, Strain counter strain (S C S)
10131128|NCT04285424|Experimental|HSCT patients with acute steroid-resistant GI-related GVHD|Patients will receive 500ml fecal microbiota which were sprayed evenly on the entire colon through colonscopy or duodenal nutrition tube injection which collected from one unrelated healthy donors. Patients receiving FMT treatment will be followed for at least 1,3,5,7 days.Stool, blood and colonic mucosa samples will be serially collected and tested (before pre-treatment, 1,3,5,7 days after FMT).
10131129|NCT04285060|Experimental|Training Group|All participants are assigned to the training group with the Samsung GEMS-H.
10131130|NCT04285177||Horizontal muscle surgery|Patients suffering from esotropia or exotropia, will have medial/lateral rectus recession/resection
10131131|NCT04285177||Patients with Inferior Oblique Overaction|Will undergo inferior Oblique Myectomy
10131132|NCT04285177||Patients with combined horizontal and oblique muscle surgery|Having combined surgery
10131133|NCT04285385|Experimental|Aromatherapy|0.10 ml of lavender essential oil 30 minutes prior surgery
10131134|NCT04285385|Sham Comparator|Sham Aromatherapy|0.10 ml mineral oil 30 minutes prior surgery
10131135|NCT04285281|Experimental|Gabapentin|Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
10131136|NCT04285281|No Intervention|Control group|Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
10131137|NCT04285203|Experimental|Educational Video|Participants were exposed to 2 educational videos in addition to standard of care education.
10131138|NCT04285203|No Intervention|Standard of Care|Participants received standard of care education.
10131139|NCT04285073|Experimental|Paclitaxel-eluting graft|Single-arm
10131140|NCT04285099|Experimental|PD patients with FOG after STN-DBS[A]|Initially started by A setting
10131141|NCT04285099|Experimental|PD patients with FOG after STN-DBS[B]|Initially started by B setting
10131142|NCT04285268|Experimental|Treatment (rituximab, venetoclax, bortezomib)|Patients receive rituximab IV on day -1 of cycle 1, then on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-14 and bortezomib IV or SC on day -1 of cycle 1, then on days 1, 8, and 15 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles for rituximab and up to 26 cycles for venetoclax and bortezomib in the absence of disease progression or unacceptable toxicity.
10131143|NCT04285190|Experimental|The T89 treatment group|Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID(every morning and evening), for 10 days (Depending on clinical need and practicability, the use can be extended for up to 14 days).
10131144|NCT04285190|No Intervention|The blank control group|All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
9519595|NCT03285620|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral dose of AL-034 (oral solution) (the starting dose in Cohort 1 of Part 1 will be 0.2 milligram [mg]) or matching placebo under fasted condition (Cohorts 1 to 5 or optional Cohort 7) on Day 1. Participants may receive AL-034 in a fed state (Cohort 6) to evaluate the effect of food on the pharmacokinetics (PK) of AL-034.
9519596|NCT03285620|Experimental|Part 2: Multiple-Dose Administration (MAD)|Participants will receive multiple oral doses of AL-034 or matching placebo for 4 consecutive weeks either once weekly (Qwk - for 4 doses) or every two weeks (Q2wk - for 3 doses) under fed or fasted conditions. The starting dose for Part 2 will be determined based on the initial PK and safety/tolerability data from Part 1.
9519597|NCT03285607|Experimental|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
10131145|NCT04285320|Active Comparator|Intravesical antibiotic instillation|
10131146|NCT04285320|Active Comparator|Oral antibiotic suppressive therapy|
10131147|NCT04285346|Other|Open-label|ganaxolone suspension (50 mg/ml) TID for 12 weeks with 24 week extension
10131148|NCT04285333|Active Comparator|fascial iliaca|: A linear high frequency ultrasound probe (10-15MHz) was placed in a transverse direction over the anterior thigh below the inguinal ligament. We identified the femoral artery and the iliacus muscle lateral to it, covered by the fascia iliaca. The needle was inserted in plane and a 22 gauge, 50 mm needle was advanced until the tips placed underneath the fascia iliaca. Following negative aspiration, the local anesthetic solution was injected in 5mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine
10131149|NCT04285333|Experimental|Percapsular nerve group block|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine.
10131150|NCT04285138|Experimental|Phantom limb exercises|Participants in this group will be treated with routine physical therapy, mirror therapy and Phantom limb exercises. Treatment time: 1 hour
10131151|NCT04285138|Active Comparator|conventional treatment|In this group, participants will be treated by routine physical therapy and mirror therapy protocol. Treatment time: 35 minutes
10131152|NCT04285372|Experimental|Test group|No intervention on the side branch in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
10131153|NCT04285372|Active Comparator|Control group|Side branch protection: Ballooning or Kissing Balloon Technique, in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
10131154|NCT04285008|No Intervention|standard Colonoscopy|"Control arm~Colonoscopy procedure using standard flushing and suctioning - standard of care"
10131155|NCT04285008|Other|Pure-Vu System|Intervention - Colonoscopy procedure using Pure-Vu System
10131156|NCT04284982|Experimental|Heavy resistance training program|
10131157|NCT04284683|Experimental|Normal and overweight participants|"Healthy males and female, age 6 to 30. BMI range for participants age 6 to 18 is between 5th percentile to 85th percentile, overweight BMI between the 85 and 95th percentile, and obese, above the 95th percentile.~BMI range for participants age 18 to 30 is between 18.5 to 24.9 for normal weight, 25-30 for overweight and above 30 for obese."
10131158|NCT04284865|Experimental|Intervention group|The web platform includes three respiratory exercises: diaphragmatic breathing, thoracic expansion exercise and thoracic expansion exercise assisted upper limbs. It is suggested to do each of the three exercises once a day (AM and PM), four repetitions each. An electronic logbook is also available on the platform to record the duration and the type of others cardiorespiratory exercise of their choice (cycling, walking, using stairs, etc.) as well as strengthening (upper and lower body).
10131159|NCT04284709|Experimental|exercise group|exergames with simultaneous cognitive-physical training
10131160|NCT04284709|Active Comparator|control group|multicomponent exercise intervention focused on physical and cognitive training
10131161|NCT04284748|Experimental|Plyometric training with blood flow restriction|Routine physiotherapy program + Plyometric training with blood flow restriction, 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
10131162|NCT04284748|Active Comparator|Plyometric training|Routine physiotherapy program + Plyometric training 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
10131163|NCT04284839|Active Comparator|Direct Oral Anticoagulation (DOAC)|Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
10131164|NCT04284839|Placebo Comparator|Vitamin K Antagonist|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
10131165|NCT04284878||A|patients with inflammatory bowel disease
10131166|NCT04284878||B|healthy subjects
10131167|NCT04284696|Active Comparator|Verum|"patients with emesis gravidarum who take a chewing gum with vitamin C (verum) ad libitum several times daily for 2 weeks"
10131168|NCT04284696|Placebo Comparator|Placebo|"patients with emesis gravidarum who take chewing gum without vitamin C (placebo) ad libitum several times daily for 2 weeks"
10131169|NCT04284696|No Intervention|Nihil|patients with emesis gravidarum who do not use chewing gum during the study phase
10131170|NCT04284826|Experimental|mitomycin C injection group|A submucosal needle injection of 4mL of a MMC preparation (0.5mg/mL) into the tearing esophageal wall after esophageal bougie dilation on refractory benign esophageal stricture
10131171|NCT04284917|Experimental|Receive Carglumic Acid|Experimental Case_ Carglumic Acid
10131172|NCT04284735|Other|Controls|Patients with RA and without ILD
9827446|NCT02455453|Experimental|Diagnostic FFNP-PET/CT Scan|"(2) 18F-FFNP-PET/CT scans~First one prior to estradiol challenge test~Second one immediately following one day of estradiol challenge test~(1) FDG-PET/CT scan at screening~The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
10131173|NCT04284735|Other|Cases|Patients with RA and ILD
10131174|NCT04284969|No Intervention|Control arm|Patients treated according current practice of the inclusion center. If interventions are implemented locally (geriatric assessment, nutrition, physical activity) they may be proposed to the patient.
10131175|NCT04284969|Experimental|Intervention arm : PROADAPT program|Patients benefiting from the PROADAPT (interventional arm) program.
10131176|NCT04284670|Experimental|Eccentric treadmill training|The intervention group will perform an 8 week program, 2 sessions a week for a total of 16 sessions. training will be done on a designated negative gradient treadmill. first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
10131177|NCT04284670|Experimental|Control group|The control group will receive the same amount of training under neutral gradient surface(0%).The program will be 8 weeks while in each week there will be two exercise sessions and a total of 16 sessions. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. Training intensity will be 70%-80% out of maximal heart-rate.
10131178|NCT04284904||matched sibling hematopoietic stem cell transplantation|aGVHD biomarker in matched sibling donor hematopoietic stem cell transplantation
10131179|NCT04284904||unrelated allogeneic hematopoietic stem cell transplantation|aGVHD biomarker in unrelated donor hematopoietic stem cell transplantation
10131180|NCT04284904||haploidentical hematopoietic stem cell transplantation|aGVHD biomarker in haploidentical donor hematopoietic stem cell transplantation
10131181|NCT04284592|No Intervention|Control group|Patients do not receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
10131182|NCT04284592|Experimental|RIP group|Patients receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
10131183|NCT04284644|Experimental|Group P|Patient received a dose of 1.5 mg/kg of Propofol slowly over 2 minutes for induction.
10131184|NCT04284644|Experimental|Group S|Patient received 8% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen.
10131185|NCT04284644|Experimental|Group C|Patient received 4% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
10131186|NCT04284956|Experimental|Proximal group|Proximal segment of saphenous veins are harvested from the thigh by No-Touch technique and randomized to bypass the left or right territory of coronary system
10131187|NCT04284956|Active Comparator|Distal group|Distal segment of saphenous veins are harvested from the shank of the ipsilateral leg by No-Touch technique and used to bypass the right or left territory of coronary system (depending on the randomizing result of the proximal segments)
10131188|NCT04284722|Active Comparator|Metformin +|The study intervention involves the self-administration of metformin in the same dosage as the patient's regular dosage according to regular dosing schedule and randomization.
10131189|NCT04284722|No Intervention|Metformin -|The control group involves no intervention, which means cessation of oral metformin therapy 24 hours prior to surgery according to the local guidelines of the anesthesia department and the national anesthesiology guidelines.
10131190|NCT04284761|Experimental|Biolen|Biolen bicalutamide implant. Single implantation. In situ until prostatectomy
10131191|NCT04284852|Experimental|Experimental arm|Niraparib 200 or 300mg daily orally for 18 cycles unless disease progression or intolerable side effects (whichever occurs first)
10131192|NCT04284514|Experimental|AKB-9778 Ophthalmic Solution|Up to 4 daily dose levels of AKB-9778 Ophthalmic Solution will be evaluated. Doses will be administered in both eyes daily for 7 days.
10131193|NCT04284514|Placebo Comparator|Vehicle Control Ophthalmic Solution|Matched vehicle-control ophthalmic solution will be administered in both eyes daily for 7 days.
10131194|NCT04284618||assessment of radiographic angles on standardized films|On Standing standardized radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
10131195|NCT04284618||assessment of radiographic angles on off axis view films|On off axis view radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
10131196|NCT04284501||Study|children with Migraine headache
10131197|NCT04284501||Control|Healthy children
10131198|NCT04284995|Experimental|Cohort 1|Cohort 1: 0.075 mg/kg RUC-4. 8 STEMI Patients will be enrolled.
10131199|NCT04284995|Experimental|Cohort 2|Cohort 2: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
10131200|NCT04284995|Experimental|Cohort 3|Cohort 3: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
10131201|NCT04284449||Enrolled Participants|This is a whole-practice precision medicine model in which a participant-specific Naturopathic treatment program is developed and implemented for older adults with cognitive complaints.
10131202|NCT04284358|No Intervention|Standard Instruction workshop|Standard instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and then attempt it themselves.
10131203|NCT04284358|Experimental|Technology Integrated Instruction workshop|Technology integrated instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application.
10131204|NCT04284345|Experimental|Saline Pd/Pa|Eligible subjects will undergo invasive coronary physiology measurements including whole cycle resting Pd/Pa, iFR, RFR, cFFR, Saline Pd/Pa and FFR
10131205|NCT04284215|Experimental|Albumin paclitaxel|"Albumin paclitaxel 40mg/m2/week was injected into normal saline at the same time as radiotherapy, once a week. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and 2 days. (Because toxicity and heart problems can replace DDP)] Repeat every cycle (21-28 days/cycle, minimum 2 cycles).~Three-dimensional radiotherapy:~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
10131206|NCT04284215|Active Comparator|Paclitaxel|"Paclitaxel 175 mg/m2 was injected into saline solution on the first day. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and on the second day. (Because toxicity and heart problems can replace DDP)]Repeated every cycle (21-28 days/cycle, minimum 2 cycles).~Three-dimensional radiotherapy:~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
10131207|NCT04284202|Experimental|PD-1 plus Dasatinib|
10131208|NCT04284241|Experimental|Intervention group|"Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. Parents also undergo and active health education by the investigator with the  Parents' Health-Education Handbook, and Handbook will be given to them. Handbook includes the knowledge of symptoms, hazards, epidemiology, risk factors, therapy, and prevention of pediatric urolithiasis, and also baby's right feeding methods. Follow up is made every year in the first three years, and the program is done as the baseline."
10131209|NCT04284241|No Intervention|Control group|Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Newborns' parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. But parents do not undergo active health education. And Handbook will not be given to them. However, a poster which has the same content as the Handbook is normally displayed in the maternity ward. Parents have the opportunity to see the poster, but without any special remind. Follow up is made every year in the first three years, and the program is done as the baseline.
10131210|NCT04284137|Experimental|Modified FE-SaLiR|FE-SaLiR is based on modified Ba Duan Jin and Wu Qin Xi exercises that include low to moderate intensity age-tailored activities targeting different parts of the body, integrating breathing and mindfulness. A trained Community Health Worker will serve as the class instructor.
10131211|NCT04284137|Experimental|Unmodified Chinese Medicine Exercise|The Ba Duan Jin and Wu Qin Xi low- to moderate- intensity exercises published by the General Administration of Sport of China. A trained Community Health Worker will serve as the class instructor.
10131212|NCT04284137|Active Comparator|Active Control|The active control program is a health education program for attention control. The participants will learn knowledge and skills about healthy aging and nutrition in a group with hands-on activities.
10183915|NCT03759821|Experimental|Nutrition, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
10131213|NCT04284462|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
10131214|NCT04284462|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
10131215|NCT04284462|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
10131216|NCT04284462|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
10131217|NCT04284462|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
10131218|NCT04284462|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
10131219|NCT04284176|Experimental|Mirrow therapy and action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. The first 15 minutes will include myrror therapy 6 activities and the remaing 45 minutes both unimanual and bimanual action-observation therapy activities.
10131220|NCT04284176|Experimental|Action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. There protocol includes both unimanual and bimanual action-observation therapy activities.
10131221|NCT04284267|No Intervention|Healthy Control|This group consists of individuals with no psychiatric diagnosis.
10131222|NCT04284267|Experimental|Bipolar Group|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive high-dose TMS (i.e., 1800 pulses) and sham TMS.
10131223|NCT04284163|Experimental|Gamification group|Problem solving based methodology
10131224|NCT04284163|Active Comparator|Traditional teaching group|Master lesson methodology
10131225|NCT04284579|Experimental|time for cannulation|intravenous cannulation after sevoflurane induction
10131226|NCT04284280|Experimental|Early Routine Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) when feeds of 150 ml/kg/day are reached (120Kcal/kg/day)
10131227|NCT04284280|Active Comparator|Selective Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) only for weight gain less than 15g/kg/day after full feeds of 180 ml/kg/day are achieved (120 Kcal/kg/day). If milk of any infant in the selective fortification group gets fortified the volume will be decreased to 150 ml/kg/day to keep the total caloric intake equal.
10131228|NCT04284553|Experimental|Base Order Entry Alert|
10131229|NCT04284553|Experimental|Base Open Encounter Alert|
10131230|NCT04284553|Experimental|Order Entry + Follow-up booster Alert|
10131231|NCT04284553|Experimental|Open Encounter + Follow-up booster Alert|
10131232|NCT04284553|Experimental|Order Entry + Cold State outreach|
10131233|NCT04284553|Experimental|Open Encounter + Cold State outreach|
10131234|NCT04284553|Experimental|Order Entry + Simplified|
10131235|NCT04284553|Experimental|Open Encounter + Simplified|
10131236|NCT04284553|Experimental|Order Entry + Sign-off alert|
10131237|NCT04284553|Experimental|Open Encounter + Sign-off alert|
10131238|NCT04284553|Experimental|Order Entry + Pre-commitment|
10131239|NCT04284553|Experimental|Open Encounter + Pre-commitment|
10131240|NCT04284553|Experimental|Order Entry + Different Risks|
10131241|NCT04284553|Experimental|Open Encounter + Different Risks|
10131242|NCT04284553|Experimental|Standard Epic Basic Alert|
10131243|NCT04284553|No Intervention|No Alert (Usual Care)|
10131244|NCT04284566|Experimental|TAU + multicomponent treatment FIBROWALK|FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
10131245|NCT04284566|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option. Patients were offered the opportunity to participate in the next wave of group intervention at the end of the study (3 months).
10131246|NCT04284228|Experimental|Safety Evaluation Phase|Treatment with NEXI-001 T cells, derived from PBMCs of original HLA- matched HCT donor.
10131247|NCT04284228|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI-001 T cell product at the dose established from the Safety Evaluation Phase.
10131248|NCT04284098|Placebo Comparator|GA group|Group I (GA group): Standard general anesthesia (GA) .
10131249|NCT04284098|Active Comparator|Bupivacaine group|Group II (B group): ultrasound-guided PECS block using bupivacaine 0.25% + standard GA.
10131250|NCT04284098|Active Comparator|Dexmedetomidine&bupivacaine group|Group III (D group): ultrasound-guided PECS block using bupivacaine 0.25% and Dexmedetomidine 1µg/kg+standard GA.
10131251|NCT04284410|Experimental|CLASP-PE arm|
10131252|NCT04284085|Experimental|Intervention group|There will be psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
10131253|NCT04284085|No Intervention|Control group|They will receive a fact sheet on suicide and also tips on how to increase suicidal ideation.
10131254|NCT04284150|Experimental|dexmedetomidine or Midazola treat supraventricular tachycardia|Comparison of efficacy of dexmedetomidine and Midazolam in the treatment of SVT
10131255|NCT04284046||High CT score|
10131256|NCT04284046||Low CTscore|
10131257|NCT04284111||Children with myopia|"A total of 1,000 children from 8 hospitals in China is required to undergo ophthalmic examinations and complete questionnaires at baseline and~1yr after wearing ortho-k lenses."
10131258|NCT04284072|Experimental|All subjects|Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.
10131259|NCT04284033|Experimental|Standard then Extended Infusion Set|Participants will start with wearing the standard infusion set for up to 7 days, then switch to the Extended Wear infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
10131260|NCT04284033|Experimental|Extended then Standard Infusion Set|Participants will start with wearing the Extended Wear infusion set for up to 7 days, then switch to the standard infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
10131261|NCT04284540|Experimental|Adjuvant Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have undergone surgery
10131262|NCT04284540|Experimental|Definitive Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have not had surgery
10131263|NCT04284059|Active Comparator|vitamin AD group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin A 6000 IU/day and vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks.
10131264|NCT04284059|Experimental|vitamin D group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks. After the study, vitamin D group will be administrated with vitamin A on the basis of serum retinol concentration after the study.
10131265|NCT04284059|Placebo Comparator|placebo group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive placebo once a day in addition to methylphenidate for 8 weeks. After the study, the placebo group will be prescribed with vitamin A and vitamin D supplementation on the grounds of retinol and 25 (OH)D concentration.
10131266|NCT04283760||Healthy Group|"Demographic Information~Mental Chronometry Test~Movement Imagination Questionnaire- Revised Second~Beck Depression Inventory"
10131267|NCT04283760||Acute Stroke Patients|"Demographic Information~Mental Chronometry Test~Movement Imagination Questionnaire- Revised Second~Beck Depression Inventory~Trail Making Test~Barthel Index~Motor Assessment Scale~Trunk Impairment Scale~Mini Mental Test~Glaskow Coma Scale"
10131268|NCT04283799|Experimental|The new HMF group|Very preterm infants tolerating 80mL/kg/day of enteral feeding for >24 hours are started to receive the new human milk fortifier. Study procedure is from the first day of full-strength fortification feeding to the 21th days of that.
10131269|NCT04283799|No Intervention|Other HMF group|This group is a historical control group using the other HMF. Infants with similar gestational age, birth weight, feeding start time and length of hospitalization are enrolled into the control group.
10131270|NCT04283734|Experimental|Intervention group|Long/diffuse coronary lesion should be evaluated and guided by iFR pullback with Syncvision software to achieve a final iFR of 0.90
10131271|NCT04283734|No Intervention|Control group|Long/diffuse coronary lesion should be treated guided by angiography
10131272|NCT04283721|No Intervention|No Video|These patients will not see the educational video on epidural/spinal analgesia and will receive the usual Irish standard of care.
10131273|NCT04283721|Experimental|Antenatal Video|These patients will see the educational video on epidural/spinal analgesia only at the antenatal classes.
10131274|NCT04283721|Experimental|Labour Video|These patients will see the educational video on epidural/spinal analgesia only at the beginning of labour.
10131275|NCT04283721|Experimental|Video Twice|These patients will see the educational video on epidural/spinal analgesia twice (during antenatal classes and at the beginning of labour).
10131276|NCT04283916||Botox injection|30 consecutive patients will have 300 IU of botulinum toxin injected to six spots in abdominal wall to gain abdominal wall musculature relaxation.
10131277|NCT04283825|Experimental|Humanistic care|In addition to routine therapy, the combinations of different psychological and physical rehabilitation activities will be applied to the patients.
10131278|NCT04283825|No Intervention|Non-humanistic care|Patients only receive routine therapy.
10131279|NCT04283838|Experimental|Humanistic care|Psychological and physical rehabilitation based humanistic care regimen was used to prevent depression and PTSD in healthcare workers who participated in the treatment of COVID-19.
10131280|NCT04283929|Experimental|Intervention 1 (Int1)|Facilities assigned to the enhanced package for Int1 will receive alerts and reminders to promote linkage of HIV positives from diagnosis to care.
10131281|NCT04283929|No Intervention|Control 1 (Ctrl1)|Facilities assigned to the Ctrl1 will not receive any additional equipment, software tools, training or other forms of support.
10131282|NCT04283929|Experimental|Intervention 2 (Int2)|Randomise the Intervention 1 group into two additional arms: Intervention 2 (Int2) and Control (Ctrl2). Facilities assigned to Int2 will also receive alerts and reminders to improve lab reporting as part of their enhanced package.
10131283|NCT04283929|No Intervention|Control 2 (Ctrl2)|Facilities assigned to the Ctrl2 will not receive any additional equipment, software tools, training or other forms of support to improve lab reporting as part of their enhanced EMR.
10131284|NCT04283929|Experimental|Intervention 3 (Int3)|Randomise the Intervention 2 group into two additional arms: Intervention 3 (Int3) or Control (Ctrl3). Facilities assigned to Int3 will receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
10131285|NCT04283929|No Intervention|Control (Ctrl3)|Facilities assigned to Ctrl3 will not receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
10131286|NCT04283981|Active Comparator|Control Group|
10131287|NCT04283981|Experimental|Treatment Group|
9827447|NCT02455518|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
10131288|NCT04284007|Active Comparator|Perineural levobupivacaine with intravenous saline|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous saline.
10131289|NCT04284007|Experimental|Perineural dexamethasone in addition to levobupivacaine|Patients will receive levobupivacaine-dexamethasone in interscalene brachial plexus block plus intravenous saline.
10131290|NCT04284007|Experimental|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous dexamethasone.
10131291|NCT04283968|Experimental|Treatment arm|All patients will receive 4 fecal microbial transplantations from healthy donors each 2 weeks apart
10131292|NCT04283968|Placebo Comparator|Placebo followed by treatment arm|All patients will receive 4 placebo fecal transplantations followed by 4 fecal microbial transplantations from healthy donors each 2 weeks apart
10131293|NCT04284020|Experimental|Educational program & pelvic floor muscle training|"The educational strategy will consist of explaining a healthy lifestyle guide with videos, mobile apps and activities about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, high impact sports, constipation, smoking, or drinking too much caffeine and alcohol. They will also instruct in toilet habits.~The pelvic floor muscle training (PFMT) protocol will be applied. Participants will perform exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
10131294|NCT04284020|Active Comparator|PFMT group|"They will receive a basic behavioral educational strategy in the first session including pelvic anatomy and physiology, recommendations to avoid risk factors and toilet habits.~The PFMT protocol will be applied. Participants will perform PFMT exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
10131295|NCT04283877|Experimental|Methylphenidate|30 mg methylphenidate, 60 minutes before testing
10131296|NCT04283877|Placebo Comparator|Control|30 mg of lactose pill, 60 minutes before testing
10131297|NCT04283643|Experimental|Healthy Human Subjects|Healthy human subjects will complete study procedures in the research lab at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation.
10131298|NCT04283643|Experimental|Acute Pain Patients|Acute Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
10131299|NCT04283643|Experimental|Chronic Pain Patients|Chronic Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
10131300|NCT04283630|Active Comparator|Randomization and Dietary supplement Interventions|The dietary nitrate supplement was provided in the form of commercial beetroot juice (Sport Beet IT shot, Heartbeet Ltd) for all participants, whereas vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the concentrated beetroot juice with breakfast meals, and then the vitamin C supplement (1000 mg)or placebo at the same time one-hour post beetroot juice supplementation
10131301|NCT04283630|Placebo Comparator|Placebo|Vitamin C placebo was matched with the active vitamin c capsules in shape, color, and size.
10131302|NCT04283708|Experimental|Skeletal chin deficiency|Advancement genioplasty with submental liposuction
10131303|NCT04283786||General Practitioner|General Practitioners working within primary care in the UK
10131304|NCT04283786||Primary Care Patients|Patients cared for in primary care who started on oral bisphosphonates within the last 24 months for prevention of fragility fractures
10131305|NCT04283786||Secondary Care Clinicians|Clinicians working in secondary care as specialists (e.g. nurses, consultants) involved in the treatment of osteoporosis
10131306|NCT04283786||Secondary Care Patients|Patients cared for in secondary care receiving hospital based (intravenous) bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months
10131307|NCT04283786||Clinical Academics|Clinical academics involved in osteoporosis research
10131308|NCT04283786||Secondary Care Clinicians - Novel Care|Clinicians working in secondary care as specialists (e.g. nurses, consultants) from the osteoporosis service in Nottingham and Sheffield with insight into alternate bisphosphonate treatments
10131309|NCT04283786||Secondary Care Patients - Novel Care|Patients cared for in secondary care receiving alternative bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months at the osteoporosis service in Nottingham or Sheffield
10131310|NCT04283786||Commissioners|Commissioners involved in osteoporosis services
10131311|NCT04283695|Experimental|Part 1|IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg
10131312|NCT04283695|Experimental|Part 2|IV: [14C]-GX-I7 40 µg
10131313|NCT04283695|Experimental|Part 3|IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg
10131314|NCT04283942|Experimental|Intermittent Calorie Restriction (ICR)|Eat only instant nutrition bar in two consecutive days each week, 4 sticks / day, 1 for breakfast, 2 for lunch, 1 for dinner. And the total caloric intake is 497.2kcal/day. In the rest 5 days each week, subjects are allowed ad libitum to their usual food.
10131315|NCT04283942|Other|Control|Followed by NAFLD guidelines' recommendation of 25 kcal / kg / day, we only ask them to adjust their daily diet. No experimental foods or drugs are supplied.
10131316|NCT04283604|Experimental|ADHD with MPH|ADHD participants, taking MPH before the second session
10131317|NCT04283604|No Intervention|ADHD no MPH|ADHD participants will perform motor tests in both session, without any intervention, for evaluation of learning effect among ADHD participants.
10131318|NCT04283604|No Intervention|Healthy participants|Non-ADHD participants will serve as a control group for learning effect on motor tests
10131319|NCT04283448|Experimental|Lentil|0.66 cups lentils
9968286|NCT01278095|Experimental|GLPG0555 nanosuspension, fed|50 mg as nanosuspension, given after breakfast
9968287|NCT01278108|Experimental|1|single ascending doses
9968288|NCT01278108|Placebo Comparator|2|single dose placebo
10131320|NCT04283448|Sham Comparator|Control|0.0 cups lentils
10131321|NCT04283422||patintes on mechanical ventilation|
10131322|NCT04283422||patintes not on mechanical ventilation|
10131323|NCT04283474|Experimental|XG005-03|XG005-03 in 3 dose levels
10131324|NCT04283474|Placebo Comparator|Placebo|Placebo in all cohort
10131325|NCT04283487|Experimental|Fructans solution|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody.The fructans solution used in this study is 500 ml water containing 40g fructans
10131326|NCT04283487|Active Comparator|Glucose solution|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a positive control in this study. The glucose solution used in this study is 500 ml water containing 40g glucose.
10131327|NCT04283487|Placebo Comparator|Saline solution|The saline solution does't contain any sugar and used in this study is 500ml 0.9% normal saline.
10131328|NCT04283331|Experimental|Bandage Contact Lens + Proparacaine|The eye that receives a bandage contact lens soaked in proparacaine.
10131329|NCT04283331|No Intervention|Bandage Contact Lens WITHOUT Proparacaine|The eye that receives a bandage contact lens (standard of care).
10131330|NCT04283435|Placebo Comparator|estradiol valerate + placebo|preparation of the endometrium with Estradiol valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova) .from the first day of the cycle till 12th day and we add placebo from the first day of the cycle till the day of start progesterone (we stop 3 days before embryo transfer).
10131331|NCT04283435|Experimental|estradiol valerate + Sildenafil citrate|We add Sildenfil citrate 50 mg daily from the first day of the period till the day of starting the progesterone. and stop 3 days before the embryo transfer.
10131332|NCT04283305|Experimental|Virtual reality approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training in the virtual reality. Alcoholic beverages are pushed away with a controller and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
10131333|NCT04283305|Active Comparator|Computer-based approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training on the computer. Alcoholic beverages are pushed away with a joystick and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
10131334|NCT04283305|No Intervention|Treatment as usual|Participants will receive treatment as usual on the wards. For ethical reasons, participants in this condition will get the offer to undertake the already scientifically validated computer-based approach avoidance training after their completion of the study.
10131335|NCT04283357|Active Comparator|Exercise Group|One group only treated with short foot exercises.
9827448|NCT02455518|Active Comparator|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen (5 mg/300 mg)
9968289|NCT01278108|Experimental|3|multiple dose, 7 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
9968290|NCT01278108|Placebo Comparator|4|multiple dose, capsules, 7 days; scheme to match that of Study Arm 3.
9968291|NCT01278121|Other|Diet A: High-fat diet|"Diet given for 3 days to reset all of the participants"
9968292|NCT01278121|Active Comparator|Diet B: A carbohydrate-restricted diet|The diet will be given for 10 days, 6 meals a day
9968293|NCT01278147|No Intervention|controle|patient without fatigue education program
9968294|NCT01278147|Experimental|Education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
9968295|NCT01278186|Experimental|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)
9968296|NCT01278186|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent
10131336|NCT04283357|Active Comparator|Virtual Reality Group|The second group treated with virtual reality
10131337|NCT04283292|Experimental|Capsaicin|capsaicin 0.075% cream applied once topically
10131338|NCT04283292|Active Comparator|Placebo|placebo cream applied once topically
10131339|NCT04283344|Experimental|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula: (1) a fixed deduction, depending on county of residence, for transportation costs for six round trips to the grocery store per month; and (2) an earnings deduction equal to 10 percent of earned income for households with at least one employed household member.
10131340|NCT04283344|No Intervention|Control Group|Households in the control group continued to receive their regular monthly SNAP benefit amounts.
10131341|NCT04283526|Experimental|NIS793 + MBG453|treatment with NIS793 + MBG453
10131342|NCT04283526|Experimental|NIS793 + MBG453 + Spartalizumab|Treatment with NIS793 + MBG453 + Spartalizumab
10131343|NCT04283526|Experimental|NIS793 + MBG453 + Decitabine|treatment with NIS793 + MBG453 + Decitabine
10131344|NCT04283526|Experimental|NIS793|treatment with NIS793
10131345|NCT04283526|Experimental|MBG453|treatment with MBG453
10131346|NCT04283370|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
10131347|NCT04283370|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
10131348|NCT04283513|Experimental|Efficacy of IV Ribavirin|The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
10131349|NCT04283565|No Intervention|Strategy 1: Usual practice|No systematic screening of asymptomatic AOMI and routine management of FRCV.
10131350|NCT04283565|Experimental|Strategy 2: Motivationnal interviewing|No systematic screening of asymptomatic AOMI and management of CVRF by a motivationnal interviewing.
10131351|NCT04283565|Experimental|Strategy 3: Systematic screening of AOMI by BPI measurement|Systematic screening of AOMI by BPI measurement and routine management of FRCV.
10131352|NCT04283565|Experimental|Strategy 4: Both strategies|Systematic screening of AOMI by BPI measurement and management of CVRF by a motivationnal interviewing.
10131353|NCT04283279|Experimental|Virtual reality exercise|20 participants will be randomised to this arm
10131354|NCT04283279|Experimental|Vestibular rehabilitation exercise|20 participants will be randomised to this arm
10131355|NCT04283279|Other|Control|20 participants will be randomised to this arm
10131356|NCT04283214|Active Comparator|Traditional manikin|CPR performed on a traditional manikin
10131357|NCT04283214|Experimental|Traditional manikin with athletic equipment|CPR performed on a traditional manikin wearing athletic equipment
10131358|NCT04283214|Experimental|Bariatric manikin|CPR performed on a bariatric manikin
10131359|NCT04283214|Experimental|Bariatric manikin with athletic equipment|CPR performed on a bariatric manikin wearing athletic equipment
10131360|NCT04283539||CPI with ircAE|Participants on check point inhibitors with immune related cutaneous adverse event
10131361|NCT04283539||no ircAE|Participants who do not have a cutaneous adverse event
10131362|NCT04283266|Active Comparator|Synbiotic group|The synbiotic was composed of fructo-oligosaccharides (FOS): 4.95 g/ sachet and Bifidobacterium animalis lactis: 5 billion / sachet (n=13)
10131363|NCT04283266|Placebo Comparator|Placebo group|A placebo was composed of maltodextrin (60%) and sucrose (40%) : 5 g /sachet (n =14)
10131364|NCT04283201|Experimental|Diet|
10131365|NCT04283201|Experimental|Physical activity|
10131366|NCT04283240|Active Comparator|Sildenafil|50 mg sildenafil oral. One dose
10131367|NCT04283240|Placebo Comparator|Placebo|Placebo pill. One dose
10131368|NCT04283591|Experimental|Experimental Intervention|Acupuncture Treatment Group: will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week. They also will continue to receive the conventional rehabilitation programme.
10131369|NCT04283591|Other|No Intervention|Control Group: will be included in the conventional rehabilitation programme and no interventional procedures will be made.
10131370|NCT04283188|Experimental|Adolescents with bipolar disorder|25 adolescents aged 14 to 21 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
10131371|NCT04283123|Experimental|Treatment|Participants assigned to this group will receive an automated bidet (TOTO Washlet S300e with remote control) and an occupational therapy intervention over 3-4 in-home visits.
10131372|NCT04283123|Active Comparator|Waitlist Control|Caregivers will wait for 30 days and then will be offered the intervention.
10131373|NCT04283175|Other|Neuromuscular disease (MNM) subjects|
10131374|NCT04283175|Other|Hemiparetic subjects|
10131375|NCT04283175|Other|Healthy subjects|
10131376|NCT04282902|Experimental|Pirfenidone group|This study was designed to randomize approximately 147 adult subjects.The patients were stratified according to whether the onset time was less than 14 days, and randomly divided into groups at a ratio of 1:1. The group received pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer.
10131377|NCT04282902|No Intervention|Standard treatment group|This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤ 14 days and randomly divided into groups of 1: 1. This group only receives standard treatment
10131378|NCT04283162|Experimental|conventional treatment plus calcium dobesilate|maintain lifestyle habits and the usual treatment, plus the use of calcium dobesilate (500 mg, orally, 3 times per day) for 12 months
10131379|NCT04283162|Active Comparator|conventional treatment group|maintain lifestyle habits and the usual treatment for 12 months
10131380|NCT04282876||Degarelix|Patients undergoing radiation therapy for bladder cancer while also being treated with Degarelix (androgen deprivation therapy)
10131381|NCT04282876||Control|Patients undergoing radiation therapy for bladder cancer with or without simultanous treatment with androgen deprivation therapy (not Degarelix)
10131382|NCT04282850|Experimental|Pulmonary Vein Isolation (PVI) Group|Subjects randomized to this treatment arm will undergo atrial fibrillation ablation, and undergo routine post-procedural follow-up.
10131383|NCT04282850|No Intervention|Medical Management|Subjects randomized to this treatment arm will undergo medical management of the arrhythmia, but will not undergo invasive electrophysiologic procedures to address subject's AF.
10131384|NCT04282798|Experimental|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
10131385|NCT04282772||Ectopic Eruption|The ectopic eruption of PFMs were classified in two ways: impacted and self-corrected.
10131386|NCT04282824|Experimental|Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
10131387|NCT04282824|Experimental|Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
10131388|NCT04282863|Active Comparator|robotic-assisted laparoscopic myomectomy (RM)|After randomization, participants who are assigned to the robotic-assisted laparoscopic myomectomy (RM) agree to receive RM.
10131389|NCT04282863|Placebo Comparator|Conventional laparoscopic myomectomy (LM)|After randomization, participants who are assigned to the Conventional laparoscopic myomectomy (LM) agree to receive LM.
10131390|NCT04282837||NW|normal weight control
10131391|NCT04282837||MHO|metabolic healthy obesity
9827449|NCT02455518|Active Comparator|Codeine/acetaminophen|Codeine/acetaminophen (30 mg/300 mg)
10131392|NCT04282837||LMO|hypometabolic obesity
10131393|NCT04282837||HMO-U|hypermetabolic obesity with hyperuricemia
10131394|NCT04282837||HMO-I|hypermetabolic obesity with hyperinsulinemia
10131395|NCT04283032||Multiparametric magnetic resonance + transrectal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transrectal biopsy (BPTE)
10131396|NCT04283032||Multiparametric magnetic resonance + transperineal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transperineal biopsy (BPTP)
10131397|NCT04283032||Transrectal biopsy|The patient underwent a transrectal biopsy (BPTE)
10131398|NCT04283032||Transperineal biopsy|The patient underwent a transperineal biopsy (BPTP)
10131399|NCT04283136|Active Comparator|Type 1 tablet - part 1|Subjects will receive a single dose of padsevonil Type 1 tablet in the period defined by the pre-specified sequence they were randomized on to.
10131400|NCT04283136|Experimental|Type 2 tablet - part 1|Subjects will receive a single dose of padsevonil Type 2 tablet in the period defined by the pre-specified sequence they were randomized on to.
10131401|NCT04283136|Experimental|Type 3 tablet - part 1|Subjects will receive a single dose of padsevonil Type 3 tablet in the period defined by the pre-specified sequence they were randomized on to.
10131402|NCT04283136|Experimental|Type 4 tablet - part 1|Subjects will receive a single dose of padsevonil Type 4 tablet in the period defined by the pre-specified sequence they were randomized on to.
10131403|NCT04283136|Experimental|Type 5 tablet - part 1|Subjects will receive a single dose of padsevonil Type 5 tablet in the period defined by the pre-specified sequence they were randomized on to.
10131404|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fasted)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
10131405|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fed)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
10131406|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fasted)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
10131407|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fed)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
10131408|NCT04282954|Experimental|Group 1|JP-1366 A mg
10131409|NCT04282954|Experimental|Group 2|JP-1366 B mg
10131410|NCT04282954|Experimental|Group 3|JP-1366 C mg
10131411|NCT04282954|Active Comparator|Goup 4|Esomeprazole 40 mg
10131412|NCT04283149|Experimental|EVO ICL Surgery for Myopia|Enrolled subjects with myopia will undergo ICL surgery in one or both eyes with EVO MICL model.
10131413|NCT04283149|Experimental|EVO+ ICL Surgery for Myopia|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ MICL model.
10131414|NCT04283149|Experimental|EVO TICL Surgery for Myopia with Astigmatism|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO TICL.
9827450|NCT02455518|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/1000 mg)
9827451|NCT02456103|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
9968297|NCT01278199|Other|2|Medicals measures in the treatment of non-severe acute hemoptysis
10131415|NCT04283149|Experimental|EVO+ TICL Surgery for Myopia with Astigmatism|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ TICL.
10131416|NCT04283006|Experimental|Administration of CD20/CD22 dual Targeted CAR T-cells|A dose levels of 3-5*10E6/kg are administrated for each subject.
10131417|NCT04283019|Experimental|CBD without THC|oral formulation containing 100mg CBD and 0mg THC
10131418|NCT04283019|Experimental|CBD with 3.7 mg THC|oral formulation containing 100mg CBD and 3.7mg THC
10131419|NCT04283019|Experimental|CBD with 2.8 mg THC|oral formulation containing 100mg CBD and 2.8 mg THC
10131420|NCT04283084|Experimental|Study group|Number of participants in this group is anticipated to be 25. Participants in this group will be receiving 10 minutes of exercise with the virtual reality based balance and coordination training system (MARBES). In the MARBES system two exercises (1. Balance exercise, 2. Coordination exercise) will be played for 5 minutes each.
10131421|NCT04282941|Experimental|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
10131422|NCT04282941|Experimental|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
10131423|NCT04282993|Experimental|Wearable Devices Monitoring|Patients will be provided with wearable devices for at-home monitoring heart rhythm and rate, blood pressure, pulse oximetry, quality and quantity of sleep, and pace counting.
10131424|NCT04282993|Active Comparator|Standard of Care Monitoring|Patients will be evaluated by periodical clinical visits.
10131425|NCT04282980|Experimental|DCC-2618|DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle.
10131426|NCT04283110|Active Comparator|Midazolam group|Midazolam group will receive 1 mg intrathecal midazolam once during induction for anethesia
10131427|NCT04283110|No Intervention|control group|control group will receive placebo ( 0.5cm of sterile saline
10131428|NCT04282785||Cohort of patients with severe infections|Patients with severe infections admitted to the Uppsala University Hospital and gets treated with either Piperacillin-Tazobactam, Meropenem or Cefotaxim
10131429|NCT04283097|Experimental|KPG-818|KPG-818 dose escalation
10131430|NCT04282928|Active Comparator|Routine treatment group|"Participants will receive the treatment according to the treatment principle of severe and critical cases in Influenza diagnosis and treatment plan (2019 version)"
10131431|NCT04282928|Experimental|HUC-MSCs adjuvant Group|Participants will receive intravenous infusion of definitive HUC-MSCs (1×10^6 cells/Kg × body weight(kg), which was selected by immunomodulatory assay through coculture with BV2 cell) on the basis of the routine treatment.
10131432|NCT04282746|Experimental|JNJ-54135419|Participants will receive a single oral dose of JNJ-54135419-AAA oral solution for sublingual administration in 1 of 3 serial dose escalating cohorts in fasted conditions.
10131433|NCT04282707|Experimental|Endoscopic closure|Prospectively collected patients for gastric ESD and would undergo closure of defect
10131434|NCT04282707|Other|Historical control|Historical control of patients who underwent gastric ESD
10131435|NCT04282577||patients with chron's disease|
10131436|NCT04282577||patients with ulcerative cholitis|
10131437|NCT04282460|Experimental|Baduanjin practice|Baduanjin practice group will be asked to use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
10131438|NCT04282460|Active Comparator|Regular physical exercise|The regular physical exercise group will be asked to take physical exercise for at least half an hour every day in addition to regular physical activities at school.
10131439|NCT04282343|Other|Arm I- Usual care|Patients receive usual care consisting of general cancer treatment information on a sheet of paper before attending video-recorded meetings with their oncologist to discuss treatment plans.
10131440|NCT04282343|Other|Arm II - DISCO app|Patients use the DISCO education and communication app before attending video-recorded meetings with their oncologist to discuss treatment plans.
10131441|NCT04282499|Experimental|combined exercise|combined exercise (aerobic+resistance training)
10131442|NCT04282499|Active Comparator|aerobic exercise|aerobic exercise only
10131443|NCT04282395|Experimental|Resilience-Based Diabetes Self-Management Education|The RB-DSME structure involves 8 weekly classes, 8 bimonthly support group sessions, and 2 booster sessions. The RB-DSME builds on foundational resilience resources (e.g., self-efficacy, social support), infusing novel resilience resources (e.g., adaptation to stress, finding positive meaning, spiritual coping) into the RB-DSME curriculum.
10131444|NCT04282395|Active Comparator|Standard Diabetes Self-Management Education|The scope and sequence of the standard diabetes self-management education (DSME) curriculum are aligned with national standards of the American Diabetes Association. DSME groups receive a 10-month intervention: 8 weekly educational sessions, followed by 8 bimonthly support group sessions, followed by 2 booster sessions.
9527676|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 4)|Participants with AML and MDS will receive IV infusion of AZD2811 Dose 4 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
10131445|NCT04282226|Active Comparator|active tVNS|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical
10131446|NCT04282226|Placebo Comparator|sham tVNS|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
10187664|NCT03723837|Active Comparator|Study arm B|Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month
10131447|NCT04282252|Experimental|IV fluid restriction group|"No IV fluids should be given unless one of the below occurs; in these cases, IV fluid may be given:~In case of severe hypoperfusion or severe circulatory impairment defined by:~Lactate 4 mmol/L or above or mean arterial blood pressure below 50 mm Hg or mottling beyond the kneecap or urinary output less than 0.1 mL/kg bodyweight/h, but only in the first 2 hours after randomisation. A bolus of 250-500 mL of IV crystalloid solution may be given.~In case of overt fluid losses (eg, vomiting, large aspirates, diarrhoea, drain losses, bleeding or ascites tap) IV fluid may be given to correct for the loss.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to correct dehydration or electrolyte imbalances and/or to ensure a total fluid input of 1 L per 24 hours."
10131448|NCT04282252|Active Comparator|Standard care group|There will be no upper limit for the use of IV or oral/enteral fluids. In particular: IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte imbalances.
10131449|NCT04282369|Active Comparator|HHFNC|In this group patients will receive respiratory support by high flow nasal cannula.
10131450|NCT04282369|Active Comparator|nCPAP|In this group patients will receive respiratory support by nasal CPAP.
10131451|NCT04282369|Active Comparator|nIPPV|In this group patients will receive respiratory support by nasal IPPV.
10131452|NCT04282369|Active Comparator|nHFO|In this group patients will receive respiratory support by nasal high frequency oscillatory. ventilation.
10131453|NCT04282655|Active Comparator|Control|Standard method of warming breast milk in a hot water bath prior to feeding.
10131454|NCT04282655|Experimental|Treatment Guardian Milk Warmer (Medela TM)|External continuous milk warmer that heats milk within the tubing just posterior to the feeding tube to provide milk at body temperature for feeding infusion.
9827452|NCT02456636|Active Comparator|Fee-for-Service Model (FFS, In clinic individual visits)|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
9968298|NCT01278199|Experimental|1|bronchial artery embolization (BAE)
10131455|NCT04282616|Experimental|Home-based unstructured physical activity program|According to each patient's baseline physical activity level, the facilitator will advise patients to start or to increase their spontaneous activity by giving counselling on total exercise time, mode, intensity and frequency as suggested by the American College of Sport Medicine guidelines. Every patient will be provided with a log-book and a wearable physical activity monitor, which has to be returned in the subsequent controls, to favor adherence and objectively measure the exercise activities
10131456|NCT04282616|Experimental|Home-based structured low-intensity physical activity program|According to each patient's baseline physical activity level, a semi-personalized walking program, will be provided. This program, derived from previous experience on renal patients, includes a 10-min session/day of intermittent walking (1- or 2-min work and 1-min seated rest) to be performed at home at prescribed speed. The speed, converted into walking cadence and followed by a metronome, is weekly increased. Patients will be provided with a daily log containing the detailed exercise prescription and spaces to give a feedback on training execution and related symptoms.
10131457|NCT04282616|Experimental|In-hospital structured supervised physical activity program|"Patients will join the room properly equipped for the exercise program in groups of maximum four subjects for a 2-time/week thirty minutes training sessions, to be performed for dialysis patients immediately before or after the dialysis treatment, or in non-dialysis according to their preferences.~Each sessions will include low-intensity walking exercises (similar to the structured home-based training), resistance and power exercises with elastic bands and light weights. Each sessions will begin and end with a warm-up and cool-down period of stretching. The total duration of the session will be about 30 minutes. Rate of perceived exertion will be collected and the training intensity will be set according to the patient's baseline capacity and weekly increased."
10131458|NCT04282616|No Intervention|No-training|Patients choosing this option will not start any physical activity program, but they will perform the outcome measures, acting as a control group.
10131459|NCT04282291||SIPB (block)|patients who underwent a modified BRILMA (intercostal rami block, middle axilary line) ultrasound-guided block with portable device with lineal probe and needle 80 mm. With the patient lying supine, the probe was placed in the sagittal plane of the middle axillary line to identify the aim thoracic structures. Under aseptic conditions, the needle was inserted in plane, caudo-craneal, to reach the fascial plane between the serratus anterior muscle and the external intercostal muscle at the eighth rib. A bolus dose of levobupivacaine 0.25% was administered, 3 ml of local anesthetic for each segment we want to block
10131460|NCT04282291||control (morphine)|PCA (patient controlled analgesia) morphine was initiated immediately postoperatively using CADD Smith Medical pumps. All patients received PCA-morphine with the initial dose being 0.5-1 mg. The bolus dose was 0.01mg/kg mg morphine, with lockout time interval of 15 - 30 min, limiting of 8mg/hour, as the default program. The continuous (basal) dose was increased after 12-24 hours if using frequent demand doses or if pain not controlled and decreasing if no bolus was taken.
10131461|NCT04282265|Placebo Comparator|Placebo|
10131462|NCT04282265|Experimental|Red Spinach Extract|
10131463|NCT04282512|Experimental|Group A : sodium bicarbonate-rich mineral water and tap water|"First 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.~15-days washout period Last 15-days period with daily intake of 1.5l of tap water."
10131464|NCT04282512|Experimental|Group B : tap water and sodium bicarbonate-rich mineral water|First 15-days period with daily intake of 1.5l of tap water. 15-days washout period Last 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
10131465|NCT04282200|No Intervention|Standard of Care|Patients receiving standard of care pain management including opioids.
10131466|NCT04282200|Active Comparator|Ketorolac|Patients will receive standard of care pain management plus intravenous ketorolac.
9968299|NCT01278212|Experimental|AHF-RT|"accelerated hypofractionated radiotherapy (AHF-RT)~30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy"
9968300|NCT01278238|Active Comparator|Phenylephrine|
10131467|NCT04282538|Active Comparator|Group A - Active|Active rTMS for Gait Dysfunction of Hemiplegia
10131468|NCT04282538|Sham Comparator|Group A - Sham|Sham rTMS for Gait Dysfunction of Hemiplegia
10131469|NCT04282538|Active Comparator|Group B - Active|Active tDCS for Frontal Gait Dysfunction
10131470|NCT04282538|Sham Comparator|Group B - Sham|Sham tDCS for Frontal Gait Dysfunction
10131471|NCT04281992|Experimental|AUP1602-C|AUP1602-C will be administered topically once or repeatedly three times per week during the treatment period.
10131472|NCT04281966|Experimental|Experiment|For young people from schools randomly assigned to the experimental ASEP condition will participate in the ASEP intervention. The ASEP intervention is a Third-Party Policing partnership that involves a partnership between police and school, an ASEP conference and follow up which is organized and led by a conference facilitator with the young person, their parent (or guardian), a school representative (e.g., teacher), and a uniformed school-based police officer. The police and school representatives will be trained by the facilitator to utilize procedurally just dialogue during the entirety of the conference. The ASEP conference script will utilize a procedurally just dialogue to increase both the young person and their parents' perceptions and knowledge of the legitimacy of the truancy laws, police, and schools in order to gain willing compliance to follow the rules.
10131473|NCT04281966|No Intervention|Control|"Participants allocated to the control condition will be given the business-as-usual' approach to handling school non-attendance. The control participants will be sanctioned in the usual manner for engaging in truancy through the requirements denoted in the Queensland Education (General Provisions) Act (2006)."
10131474|NCT04282135||Infected|patients with detected Influenza RNA in nasopharyngeal swabs
10131475|NCT04282135||not infected|patients without detected Influenza RNA in nasopharyngeal swabs
10131476|NCT04282135||SARS CoV2|patients with SARS-Cov-2 infection
10131477|NCT04282057|Experimental|shockwave therapy group|This group performed aerobic exercise just after shock wave therapy in the abdominal region.
10131478|NCT04282057|Experimental|radiofrequency group|This group performed aerobic exercise just after radiofrequency in the abdominal region.
10131479|NCT04282057|Active Comparator|control group|This group only performed aerobic exercise.
10131480|NCT04282096|Experimental|Caseine micellar|
10131481|NCT04282096|Other|Sodium Casein|
10131482|NCT04282096|Other|Calcium casein|
10131483|NCT04281927||Atrial fibrillation|Patients with presumed atrial fibrillation will undergo monitoring with the device and Holter ECG.
10131484|NCT04281927||Sinus rhythm|Patients with presumed sinus rhythm will undergo monitoring with the device and Holter ECG.
10131485|NCT04281927||Sinus rhythm and frequent extrasystoles|Patients with presumed sinus rhythm and frequent extrasystoles will undergo monitoring with the device and Holter ECG.
10131486|NCT04282174|Experimental|Regimen A|Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: Hyperfractionated total body irradiation to dose of 1375cGy fractions at 4-6 hour intervals three times a day for a total of 11 or 12 doses depending on age and disease risk, followed by Thiotepa 5mg/kg/day x 2 (or 10mg/kg/day x 1) and cyclophosphamide 60mg/kg/day x 2 (or Fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
10131487|NCT04282174|Experimental|Regimen B|Regimen B: Busulfan/Melphalan/Fludarabine: Busulfan 0.8mg/kg/dose every six hours x 10-12 doses (depending on disease), Melphalan 70mg/m2/day x 2 and Fludarabine 25mg/m2/day x 5.
10131488|NCT04282005|Experimental|surgery group|Fourteen patients who meet study criteria will be assigned to the study group and will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
10131489|NCT04282005|Active Comparator|lifestyle and diet|Fourteen patients matched to the surgery group for age, gender, BMI, diabetes status, and NALFD score will undergo additional lifestyle interventions, dietary counselling and or meal replacement by a dietician aimed at inducing at least a 5-7% weight reduction, prior to their surgery (while on the waiting list for surgery).
10131490|NCT04281862|Experimental|Group A|Dextenza
10131491|NCT04281862|Active Comparator|Group B|Topical Prednisolone
10131492|NCT04282161|Experimental|Axys EX device|
10131493|NCT04281836|Experimental|Breathing awareness through use of virtual reality breathing|Healthy participants were recruited in this group.
10131494|NCT04281836|Active Comparator|Traditional breathing awareness|Healthy participants were recruited in this group.
10131495|NCT04282031|Experimental|phase 1 (dose escalation)|Participants will first receive single dose BPI-1178 orally at dose levels of 25mg, 75mg, 150mg, 250mg and 400mg followed by a 7-day washout period , and then start receiving the 28 days/cycle continuous treatment until disease progression or unacceptable toxicity.
10131496|NCT04282031|Experimental|phase 2a cohort A|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with fulvestrant for 3 weeks followed by 1 week off as a treatment cycle, until disease progression or unacceptable toxicity.
9968301|NCT01278238|Active Comparator|Lower limb compression|
9968302|NCT01278238|Placebo Comparator|Placebo|
10131497|NCT04282031|Experimental|phase 2a cohort B|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with letrozole for 3 weeks followed by 1 week off as a treatment cycle, until disease progression or unacceptable toxicity.
10131498|NCT04281797||Kidney transplant recipients|Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
10131499|NCT04281797||HSCT-recipients|Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
10131500|NCT04281797||MSCT-recipients|Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
10131501|NCT04281797||Liver transplant recipients|Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
10131502|NCT04281979|Experimental|Study Agent|
10131503|NCT04281979|Placebo Comparator|Placebo|
10131504|NCT04281758|Active Comparator|Caffeine beverage (control)|Flavored still beverage with caffeine 100 mg
9968303|NCT01278251||Endobutton|
10131505|NCT04281758|Experimental|Caffeine beverage plus bioactive 1|Flavored still beverage with caffeine 100 mg + quercetin 250 mg
10131506|NCT04281758|Experimental|Caffeine beverage plus bioactive 2|Flavored still beverage with caffeine 100 mg + curcumin 80 mg
10131507|NCT04281758|Experimental|Caffeine beverage plus bioactive 3|Flavored still beverage with caffeine 100 mg + methylliberine 75 mg
10131508|NCT04282044|Experimental|Dose Escalation|Dose escalation cohort for treatment of solid tumors that are relapsed, refractory or intolerant to standard care, or refusing standard therapies.
10131509|NCT04281953||People with ototoxicity|People living with and beyond who experience ototoxicity as a result of chemotherapy
10131510|NCT04281823||Cardiovascular Magnetic Resonance|All patients who present to the Houston Methodist CMR Laboratory
10131511|NCT04281745|Experimental|Coretox®|Botulinum toxin type A to be intramuscularly injected at 4 sites of corrugator muscle and at 1 site of procerus muscle with 0.1 mL (4U) at each site, for a total of 0.5 mL (20U). The administration of the investigational product was performed once at the start of each cycle
10131512|NCT04281810|Experimental|TEDS|Subjects received transcutaneous electrical diaphragm stimulation (TEDS) for 30min/ day till the end of the weaning trial
10131513|NCT04281810|No Intervention|Control|Subjects received similar medical treatment except for the TEDS program.
10131514|NCT04281576|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with XELOX. For HER-2 positive patients, Trastuzumab is given together with XELOX.
10131515|NCT04281407|Experimental|Probiotics treatment on midazolam and acetaminophen metabolism|"Experimental:~Day 1: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV) Days 1-28: Visbiome (2 capsules) administered BID Day 11: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV)"
10131516|NCT04281498|Experimental|Patients with MPN|Ruxolitinib and Enasidenib combination therapy
10131517|NCT04281615|Experimental|Intervention (Generic Message)|Receives promotional materials that feature a generic messaging approach.
10131518|NCT04281615|No Intervention|Control (Threshold Message)|Receives promotional materials that use traditional, threshold messages.
10131519|NCT04281589|Experimental|Group 1|tidal volüm is 4 ml/kg
10131520|NCT04281589|Experimental|Group 2|tidal volüm is 6 ml/kg
10131521|NCT04281589|Experimental|Group 3|tidal volüm is 8 ml/kg
10131522|NCT04281589|Experimental|Group 4|tidal volüm is 10 ml/kg
10131523|NCT04281706||Etomidate-Time-Frame|Patients that underwent cardiac surgery between October 1st, 2012 and September 30th, 2013
10131524|NCT04281706||Propofol-Time-Frame|Patients that underwent cardiac surgery between February 1st, 2014 and January 31st, 2015
10131525|NCT04281433|Experimental|unilateral|
10131526|NCT04281433|Experimental|bilateral|
10131527|NCT04281693|Experimental|Screening participants|
10131528|NCT04281394|Experimental|Robot assisted gait training|Robot assisted gait training(RAGT) group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks. SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements.
10131529|NCT04281394|Active Comparator|conventional physical training group|The conventional group underwent conventional physical therapy( even level gait training and range of motion exercises) twice a day, 5 times a week in 12 weeks.
10131530|NCT04281628|Placebo Comparator|Control group|control group: where normal saline will be administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
10131531|NCT04281628|Active Comparator|ketamine group|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
10131532|NCT04281667|Experimental|Mechanical Bowel Preparation and Oral Antibiotics|Mechanical Bowel Preparation and Oral Antibiotics
10131533|NCT04281667|Active Comparator|Mechanical Bowel Preparation Only|Mechanical Bowel Preparation Only
10131534|NCT04281680||Pasireotide|Patients who received pasireotide perioperatively
10131535|NCT04281680||Octreotide|Patients who received perioperative octreotide
10131536|NCT04281680||Control|Patients who received no additional medication in the timely cohort
10131537|NCT04281381||Desmoid Fibromatosis|Participants will have a clinical diagnosis of desmoid fibromatosis, either new or newly recurrent
10131538|NCT04281563|Experimental|the MCT oil massage|The neonates received massage with MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
10131539|NCT04281563|Placebo Comparator|massage alone|The neonates received massage without MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
10131540|NCT04281563|No Intervention|no massage groups|no intervention
10131541|NCT04281602||Rheumatoid arthritis patients|Adult patients suffering from rheumatoid arthritis, diagnosed according to American College of Rheumatology/European League Against Rheumatism 2010 criteria and requiring a anti-IL-6 treatment
10131542|NCT04281602||Healthy controls|Healthy controls not suffering from acute or chronic inflammatory disease at inclusion.
10131543|NCT04281459|Experimental|SCT 4/7|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with short cycle scheme of 4 consecutive days on and 3 days off treatment
10131544|NCT04281459|Active Comparator|Control|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with standard scheme of 7 days per week of treatment
10131545|NCT04281550|Experimental|Think drink intervention|The Think Drink multicomponent hydration intervention was introduced into the intervention group care homes through a staff workshop.
10131546|NCT04281524|Experimental|CSL312 Cohort 1 (Dose 1)|CSL312 administered as IV infusion
10131547|NCT04281524|Experimental|CSL312 Cohort 2 (Dose 2)|CSL312 administered as IV infusion
10131548|NCT04281524|Experimental|CSL312 Cohort 3 (Dose 3)|CSL312 administered as IV infusion
10131549|NCT04281524|Experimental|CSL312 Cohort 4 (Dose 4)|CSL312 administered as IV infusion
10131550|NCT04281524|Placebo Comparator|Placebo|Placebo administered as IV infusion
10187665|NCT03723824|Experimental|Zepatier therapy|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
10131551|NCT04281446|Experimental|G-FBM-CEN|Photobiomodulation application in women of endogenous cycle. Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, acting 180 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius.
10131552|NCT04281446|Sham Comparator|G - Sham - CEN|"Sham Photobiomodulation (disabled) application in women of endogenous cycle.~The procedure and equipment will be the same as for the experimental groups, however no dosage will be applied:~Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, with 0 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius."
10131553|NCT04281290|Experimental|Experimental group|Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
10131554|NCT04281342|Experimental|Aprocitentan 25 mg|Therapeutic dose level
10131555|NCT04281342|Experimental|Aprocitentan 100 mg|Supratherapeutic dose level
10131556|NCT04281342|Placebo Comparator|Matching placebo|
10131557|NCT04281342|Other|Moxifloxacin|
10131558|NCT04281303||Endoscopic vertical gastroplasty|Proof-of-concept study that will prospectively include a number of patients undergoing endoscopic vertical gastroplasty + lifestyle modifications to evaluate the effect of this technique in an adult population with obesity and NASH cirrhosis
10131559|NCT04281316|Active Comparator|Non Invasive Ventilation device group|The patients in the NIV arm will receive treatment as in their usual care with an additional educational session of one hour for improving compliance.
10131560|NCT04281316|Experimental|Nasal High Flow (MyAirvo) device group|The patients in the NHF arm will receive NHF treatment and two hours training adaptation session will be conducted in the hospital.
10131561|NCT04281160||Clinical Metric|Patients and healthy controls were evaluated by expert raters with standard clinical metrics of neurologic function.
10131562|NCT04281160||Mobile Activity Metric|Patient performed mobile activity
10131563|NCT04281641|Experimental|TCHP|"Neoadjuvant Therapy (Cycles 1-7):~Cycle 1: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) Cycle 2-7: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) + followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~Adjuvant Therapy:patients would complete 1 year of PH-based regimen in the adjuvant setting.~Patients are assessed by [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 68Ga-Affibody HER-2 Imaging PET. Besides, the changes of biomarkers would be examined by gene sequencing and organoid drug sensitivity test."
10131564|NCT04281355|Experimental|Randomisation A - Intervention|In pathologically node-negative patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, no regional radiotherapy is given and no axillary lymph node dissection are performed.
10131565|NCT04281355|Experimental|Randomisation B - Intervention|In pathologically node-positive patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, full axillary and regional radiotherapy is given but no axillary lymph node dissection performed.
10131566|NCT04281264|No Intervention|NorCON|Normoxia Control Group
10131567|NCT04281264|Active Comparator|HypCON|Hypoxia Control Group
10131568|NCT04281264|Placebo Comparator|NorCIR|Normoxia Circuit Training with Elastic Bands Group
10131569|NCT04281264|Experimental|HypCIR|Hypoxia Circuit Training with Elastic Bands Group
10131570|NCT04281264|Placebo Comparator|NorVIB|Normoxia Whole-body Vibration Training Group
10131571|NCT04281264|Experimental|HypVIB|Hypoxia Whole-body Vibration Training Group
10131572|NCT04281082||ICP|To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives
10131573|NCT04280952|Experimental|CONVIVO|tumor tissue identification with the CONVIVO system
10131574|NCT04281277|Active Comparator|low target group|"target of mean arterial pressure(MAP) at 65-70 mmHg.~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
10131575|NCT04281277|Experimental|high target group|"target of mean arterial pressure (MAP) at 80-85 mmHg.~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
10131576|NCT04281199|Experimental|Treatment (TBI, IMRT)|Patients undergo TBI using IMRT with VMAT or tomotherapy BID on days -7 to -4 then undergo stem cell transplantation on day 0.
10131577|NCT04281121|Active Comparator|supplemented|Life style modification, diet regimen and Omega-3 fatty acids supplementation
10131578|NCT04281121|Active Comparator|non supplemented|Life style modification and diet regimen
10131579|NCT04280978||Aquired Brain Injury|Suitable potential participants would be children with ABI, at least 6 months post onset, from 6 to 11 years old, without diagnosis of aphasia, dysarthria, apraxia, and/or sensorial difficulties (visual and hearing), with Italian as a first language.
10131580|NCT04281238|Experimental|yoga group|Participants in this group will be given yoga training 3 days a week for 8 weeks. In addition, patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
10131581|NCT04281238|Other|Control group|Patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
10131582|NCT04280861|Experimental|Intervention Group|The intervention group will participate in multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
10131583|NCT04280861|No Intervention|Control Group|Usual clinical care,
10131584|NCT04281017|Experimental|TIVA anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
10131585|NCT04281017|Active Comparator|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, the depth of anesthesia will be maintained at a minimum alveolar concentration of 1 to 1.25 using isoflurane in oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During the surgery, subjects will be mechanically ventilated using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
10131586|NCT04281056|No Intervention|Control|
10131587|NCT04281056|Experimental|Tooth removal|Tooth removal and their replacement by means of a denture Teeth have been removed and replaced by means of dentures for at least one year
10131588|NCT04281095|Experimental|Botulinum toxin type A(ATGC-110)|
10131589|NCT04281095|Active Comparator|Botulinum toxin type A|
10131590|NCT04281212||CTO|Period of 1 month in the participating centers, during which all the patients with CTO and responding to all selection criteria may be included in the study, in order to describe which therapeutic choices have been chosen for this type of patient.
10131591|NCT04281212||CTO with attempted angioplasty|Period of 2 months in the participating centers, during which all the patients for whom an angioplasty has been attempted after a CTO, and responding to all selection criteria, may be included in the study, in order to evaluate the success of the procedure
10131592|NCT04280874|Active Comparator|GROUP A|106 randomly selected pregnant women
10131593|NCT04280874|Active Comparator|GROUP B|106 randomly selected pregnant women
10131594|NCT04281069||"patients visiting the centre de santé"|Women visiting to the selected health centres in the Oujda province will be invited to participate
10131595|NCT04280809|Experimental|Laser|Subsequently to the suture, laser was applied in the right or left side randomly on each patient, according to a sheet of randomization. GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2.
10131596|NCT04280809|No Intervention|Non-laser|Every patient, on the control side, the same handpiece was applied intraorally, but laser was not activated
10131597|NCT04280913||COVID-19 patients|Hospitalized patients with COVID-19
10131598|NCT04280900|Experimental|cybertherapy|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
10131599|NCT04280900|Other|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
10131600|NCT04280822|Experimental|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)"
10131601|NCT04280822|Active Comparator|Neoadjuvant chemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
10131602|NCT04280796|Experimental|Substudy 1|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 1 an operant learning paradigm will be implemented to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement and vice versa.~Primary objectives:~To develop psychophysical methods that allow the independent assessment of sensory-discriminative and emotional-motivational pain responses and~to show that emotional-motivational and sensory-discriminative pain components can be dissociated~Secondary objective:~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in how strongly sensory-discriminative and emotional-motivational pain responses can be dissociated"
10183916|NCT03759821|Experimental|Nutrition, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and the groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
10131603|NCT04280796|Experimental|Substudy 2|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients.~Primary objective:~To demonstrate that in chronic pain patients, emotional-motivational pain responses are increased relative to sensory-discriminative pain responses~Secondary objective:~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in the present dissociation of sensory-discriminative and emotional-motivational pain responses in chronic pain patients"
10131604|NCT04280796|Experimental|Substudy 3|"All participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component. No arms will perform.~Primary objective:~To assess whether metacognition on pain perception are involved and subjective ratings of perceived pain and how metacognition relates to pain intensity.~Secondary objective:~To assess whether confidentiality as a personality trait , pain catastrophizing, and skin conductance responses are related to metacognition in pain."
10131605|NCT04280588|Experimental|Treatment group|
10131606|NCT04280588|No Intervention|Control group|
10131607|NCT04280510||Active coeliac patients|Patients with active coeliac disease
10131608|NCT04280510||Treated coeliac patients|Patients with coeliac disease on gluten free diet
10131609|NCT04280510||Sprue type I|Patients with refractory coeliac disease of type I
10131610|NCT04280510||Sprue type II|Patients with refractory coeliac disease of type II
10131611|NCT04280510||Intestinal Lymphoproliferations|Patients with intestinal lymphoproliferations
10131612|NCT04280510||Non coeliac enteropathies|Patients with non coeliac immune-mediated enteropathy
10131613|NCT04280510||Patients without neoplastic or inflammatory intestinal disease|Patients without neoplastic or inflammatory intestinal disease
10131614|NCT04280757||Arm 1|Biopsied ICSI embryos
10131615|NCT04280757||Arm 2|Non biopsied ICSI embryos
10131616|NCT04280757||Arm 3|Natural pregnancy embryos
10131617|NCT04280770|Sham Comparator|Non retinal detachment group|35 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
10131618|NCT04280770|Active Comparator|retinal detachment group|15 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
10131619|NCT04280679|Other|Arm of patient treated by HIFU|Compression bandages
10131620|NCT04280731|Experimental|Fermented drink|
10131621|NCT04280432||Cesarean|Women hospitalized for cesarean section
10131622|NCT04280835|Experimental|Group Psychoeducation that Focused on Social Skill Development|The Psychoeducation program that focused on social skill development, consists of 8 sessions, one day a week, each lasting an average of 60 Minutes. Psychoeducation was conducted in three groups and each of them consisted of eight patients.
10131623|NCT04280835|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
10131624|NCT04280484|Experimental|Acute Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts
10131625|NCT04280484|Sham Comparator|Sham Acute Intermittent Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts.
9968304|NCT01278264|Active Comparator|iTAP-group|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
10131626|NCT04280497|Experimental|Biomarker CIRCI neg: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
10131627|NCT04280497|Placebo Comparator|Biomarker CIRCI neg: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
10131628|NCT04280497|Experimental|Biomarker endocan: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
10131629|NCT04280497|Placebo Comparator|Biomarker endocan: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
10131630|NCT04280497|Experimental|Biomarker GILZ: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
10131631|NCT04280497|Placebo Comparator|Biomarker GILZ: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
10131632|NCT04280497|Experimental|Biomarker CPD: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
10131633|NCT04280497|Placebo Comparator|Biomarker CPD: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
10131634|NCT04280497|Experimental|Biomarker Transcriptomic SRS: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
10131635|NCT04280497|Placebo Comparator|Biomarker Transcriptomic SRS: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
10131636|NCT04280497|Experimental|Biomarker Endotype B: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
10131637|NCT04280497|Placebo Comparator|Biomarker Endotype B: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
10187666|NCT03723785|Experimental|Participants with normal renal function|Participants with normal renal function (glomerular filtration rate [GFR] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
10187667|NCT03723785|Experimental|Participants with mildly decreased renal function|Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
10131638|NCT04280419||Healty Subjects|Healthy Subjects Twenty-five healthy individuals will be included in the study. Physical properties of cases will be recorded. Respiratory functions and respiratory muscle strength will be evaluated. Physical activity will be assessed using the International Physical Activity Survey (IPAQ). Respiratory muscle endurance will be evaluated using an incremental workload test and fixed threshold load test. Tests will be repeated three times as motivational music, slow-paced music, and music. Heart rate, respiratory frequency, perceived exertion will be evaluated before and after the test.
10131639|NCT04280341|Experimental|RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody|RC48-ADC(Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate) JS001(Recombinant Humanized Anti-PD1 Monoclonal Antibody)
10131640|NCT04280406|Active Comparator|Test|- 500mg of azithromycin one hour before implant placement
10131641|NCT04280406|Placebo Comparator|control|- identical placebo one hour before implant placement
10131642|NCT04280289|Experimental|Cannabidiol extract|"10 healthy subjects (5 female, 5 male), will be enrolled into the study. Each subject will receive a single CBDE dose delivering 2.5 mg/kg CBD, after consumption of a standardized meal.~Nine (9mL) of blood for PK analysis, at each of the following timepoints: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the study drug administration.~Urine will be collected at the following timepoints: Predose, 0-4 hrs, 4-8 hrs, 8-12 hrs, 12-24 hrs, 24-36 hrs, 36-48 hrs, and 48-72 hrs for PK analysis"
10131643|NCT04280380||Mechanical ventilated patients without cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
10131644|NCT04280380||Mechanical ventilated patients with cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
10131645|NCT04280393|Experimental|Endocuff|Colonoscopy procedure with the use of endocuff
10131646|NCT04280393|Active Comparator|Control|Standard Colonoscopy procedure
10131647|NCT04280042||Thoracoscopic surgical ablation|Participants in CASA AF Trial who underwent thoracoscopic surgical ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
10131648|NCT04280042||Cather ablation|Participants in CASA AF Trial who underwent conventional catheter ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
10131649|NCT04280120|Experimental|Neural Mobilisation Group|"Massage therapy.~Faradic electrical stimulation.~Exercises in front of the mirror.~Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest."
10131650|NCT04280120|Active Comparator|Conservative group|"Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.~Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.~Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes."
10131651|NCT04279938|Other|Safety Run in & Main Efficacy Part|"Part 1 (safety run-in) aims to evaluate the maximum tolerated dose (MTD) of tinostamustinein combination with pembrolizumab (200mg Q3W) and rituximab (375mg/m2 Q3W). The dose of tinostamustineestablished to be safe and tolerable in this combination will be used in part 2 of the trial (main efficacy part).~The aim of part 2 is to detect signals of anti-tumour activity and to further assess the safety of this combination treatment in r/r DLBCL. The study has a strong focus on correlative research in order to identify mechanisms of response and resistance to pembrolizumab and the pembrolizumab/R-tinostamustinecombination."
10131652|NCT04280003|Experimental|Treatment group|15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.
10131653|NCT04280003|Placebo Comparator|Placebo group|15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group.
9827453|NCT02456636|Active Comparator|Patient Centered Medical Home (PCMH, In clinic group visits)|Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
9968305|NCT01278264|Active Comparator|aTAP-group|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
10131654|NCT04279964|Experimental|Boot Camp Translation|Intervention practices will undergo the Boot Camp Translation process.
10131655|NCT04279964|Active Comparator|Control|Control practice will behave as usual.
10131656|NCT04280133|Experimental|Educational Video Tool|Patients randomized to the intervention arm will watch a 3-minute video educational tool about CAR-T cell therapy prior to admission for CAR-T cell therapy.
10131657|NCT04280133|No Intervention|Standard Care|Patients randomized to the control arm will receive usual care per the treating team. Any questions regarding CAR-T cell therapy will be directed to the patient's medical team
10131658|NCT04280146|Active Comparator|Degree of food processing|unprocessed vs ultra-processed foods according to NOVA table.
10131659|NCT04280146|Active Comparator|eating rate|slow vs fast eating rate (kcal/min), manipulated by food form
10131660|NCT04280237||Cefazolin in liver transplantation|Patient undergoing liver transplant surgery and receiving antibiotic prophylaxis with Cefazolin
10131661|NCT04280250|Active Comparator|Group 1|Active control arm: Volitional help-sheet with instruction: We want you to plan to increase your level of physical activity. Research shows that if people can identify situations in which they are likely to be tempted not to be physically active and ways to overcome temptation they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page are a series of common situations in which people feel tempted not to be physically active; please tick all those that apply to you personally. On the right hand side of the page are a series of possible solutions; please tick all those that apply to you personally. Tick as many or as few situations and solutions as you like.
10131662|NCT04280250|Experimental|Group 2|"Experimental arm: Volitional help-sheet with instruction:~We want you to plan to increase your level of physical activity. Research shows that if people link being tempted not to be physically active with a way to overcome that temptation, they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page below is the temptation not to be physically active; on the right hand side of the page are a series of possible solutions. Please draw lines linking being tempted not to be physically active (left hand side) to solutions (right hand side) that you think might work for you personally. Please make as many situation-solution links as you like."
10131663|NCT04280211||COPD Group|Patients who are over 40 years old, diagnosed with COPD
10131664|NCT04280211||Control Group|Healthy adults over 40 years old
10131665|NCT04280068|Active Comparator|Clinician Guide|Clinician Guide is an evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
10131666|NCT04280068|Active Comparator|Clinician Guide plus HealthCall|Clinician Guide plus the use of HealthCall, a smartphone application to monitor daily alcohol use, ART adherence and other health behaviors.
10131667|NCT04280172|Experimental|Cultural Competence Education|Participants in the intervention group will attend cultural competence education
10131668|NCT04280172|Active Comparator|Standard Mentoring Education|Participants in the control group will complete standard mentoring education that does not include a cultural competence component
10131669|NCT04280198|No Intervention|No Intervention: Group 1 - Control|Participants will attend three laboratory visits: baseline 1, baseline 2, and post-test. At baseline 2 and post-test, the primary outcome of child RRV of food vs. parent child interaction is measured. Other measures include child height and weight, child self-regulation, and parenting in the context of a parent-child interaction task. Participants in the control group will not be assigned to complete any intervention activities during the 4-week intervention phase (which takes place between baseline 2 and post-test visits); however, they will receive contacts from a member of the lab each week in the form of electronic reminders (i.e. texts) to remind them of their upcoming post-test laboratory appointment and will receive some intervention materials after the post-test assessment.
10131670|NCT04280198|Experimental|Experimental: Group 2 - Intervention|Participants will attend the same three laboratory visits as the control group. The intervention group will also participate in a 4-week intervention, which consists of the parent watching brief weekly parenting videos from the online Triple P Parenting Program and completing interactive parent-child activities from activity boxes created by our laboratory (~60 min of interactive activities/week). Participants will use their activity boxes to practice specific parenting skills from the week's parenting video. Throughout the intervention phase, participants will receive regular text messages to remind them of the week's activities and ask several questions about engagement in study activities over the past 24 hours. The intervention group will also complete an exit interview about the intervention following the post-test assessment to provide insights on fidelity and acceptability.
10131671|NCT04280263|Active Comparator|Caffiene|This group will receive 150mg caffeine tablets to be taken twice per day
10131672|NCT04280263|Placebo Comparator|placebo|
10131673|NCT04280185|Experimental|Hyperthermic Intraperitoneal chemotherapy|Hyperthermic Intraperitoneal chemotherapy was started immediately after CRS, or the first HIPEC was completed within 48 hours after surgery: temperature 43℃, duration 60 minutes, Paclitaxel (60mg/m2) was selected. The second HIEPC was completed 7 days after the first HIPEC: temperature 43℃, duration 60min, carboplatin AUC (5-6) was selected. 30 minutes before using Paclitaxel, 10ML saline + 10mg dexamethasone intravenous infusion, 20mg diphenhyramine intramuscular injection, and 100ML saline + 0.3g cimetidine intravenous infusion. On the eighth day, intravenous chemotherapy with Paclitaxel (135mg/m2) was finally completed. 5 courses of TC intravenous chemotherapy were performed after 3 weeks
10131674|NCT04280185|No Intervention|intravenous chemotherapy|intravenous chemotherapy were performed 6 Cycles after CRS. Paclitaxel: 175mg/m2, iv infusion, no less than 3h per infusion, followed by carboplatin: AUC 5-6, iv infusion, no less than 1h per infusion, 1 dose on the first day of a week, 1 cycle every 3 weeks, a total of 6 cycles. Paclitaxel should be pretreated to prevent severe allergic reactions.
9527677|NCT03217838|Experimental|Group 1 Arm A (AZD2811 Dose 5)|Participants with AML will receive IV infusion of AZD2811 Dose 5 on Days 1 and 4 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
9527678|NCT03217838|Experimental|Group 1 Arm B (AZD2811 Dose 2)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
10131675|NCT04280081|Experimental|Selpercatinib|Selpercatinib given orally.
10131676|NCT04280302|Experimental|Virtual reality based therapy|
10131677|NCT04280302|Active Comparator|Conventional Therapy|
10131678|NCT04279977||Inpatient Rehabilitation Facility|Individuals post-stroke who are discharged to an inpatient rehabilitation facility.
10131679|NCT04279977||Skilled Nursing Facility|Individuals post-stroke who are discharged to a skilled nursing facility.
10131680|NCT04280367||Comparator group|Specific learning disorders group
10131681|NCT04280367||neuro-developmental complexed group|Group of neuro-developmental complexe of learning
10131682|NCT04280367||Complexed with anxiety|Disorders in learning with anxiety
10131683|NCT04279951|Experimental|Omega 3|"Intake of 1 gram omega-3 (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
10131684|NCT04279951|Placebo Comparator|Placebo|"Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
10131685|NCT04279951|No Intervention|Control|No intervention
10131686|NCT04280055|Experimental|Psilocybin|
10131687|NCT04279912|Experimental|Patients with Multiple Sclerosis and Tremor|Participants will undergo MRgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
10131688|NCT04279990||Functional dyspepsia patients with JHS|Patients with functional dyspepsia as defined by the Rome III criteria and joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
10131689|NCT04279990||Functional dyspepsia patients without JHS|Patients with functional dyspepsia as defined by the Rome III criteria and WITHOUT joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
10131690|NCT04279990||Healthy subjects|Healthy subjects with no gastrointestinal diseases including no functional dyspepsia
10131691|NCT04279678||patients undergone mitral repair|includes all patients undergone repair of mitral valve with CABG
10131692|NCT04279678||patients with no mitral repair|includes all patients where no repair done for mitral valve , only CABG
10131693|NCT04279821||Colonic diverticulosis and macroscopic signs of inflammation|No interventional study
10131694|NCT04279873||Adults with nosocomial pneumonia|Diagnostic procedures on pulmonary secretion collected by tracheal suctioning and bronchoalveolar lavage.
10131695|NCT04279743|Experimental|ApoE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
10131696|NCT04279743|Experimental|ApoE4 non carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
10131697|NCT04279782||Exclusion group|Patients with two consecutive negative results of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swabs
10131698|NCT04279782||Confirmed group|Patients with positive result of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swab
10131699|NCT04279626||LETS-M|Women who were older than 20 years old and had not reached menopause, with symptomatic uterine myomas, such as hypermenorrhea, infertility, a mass effect-related urinary frequency, and constipation, received LETS-M.
10131700|NCT04279756|Active Comparator|Mildly Impaired Group|This group is with participants with mildly impaired hip internal range of motion, from 25-30 degrees.
10131701|NCT04279756|Active Comparator|Moderately Impaired Group|This group is with participants with moderately impaired hip internal range of motion, from 20-24 degrees.
10131702|NCT04279756|Active Comparator|Severely Impaired Group|This group is with participants with severely impaired hip internal range of motion, less than 20 degrees.
10131703|NCT04279639||qigong practice|Patients in this arm participated in qigong as part of their treatment at the Pain Management Unit
10131704|NCT04279639||control|Patients attend the pain management unit but do not undertake qigong practice.
10131705|NCT04279652|Experimental|Supervised exercise group|The treatment program was determined as 3 sessions per week for 8 weeks and 60 minutes per session. The treatment program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
10131706|NCT04279652|Active Comparator|Home exercise group|The exercise program, which is prepared for the individual, will be applied to the home exercise group with 60 minutes of 3 times a week.
10131707|NCT04279652|No Intervention|Control group|Children will not be included in any treatment program. The assessments will be done again 8 weeks later.
10131708|NCT04279886|Other|Three-dimensional scan arm|
10131709|NCT04279665|Experimental|Subjects undergoing electrophysiology procedure|Subjects will wear a virtual reality (VR) headset for a total of 40 minutes separated over 2 sessions during an electrophysiology procedure they are already scheduled to undergo.
10131710|NCT04279834|Active Comparator|PAP Treatment|Participants will receive a PAP device and will attend four weekly sessions to receive education about this treatment.
10131711|NCT04279834|Active Comparator|Sleep Education I|Participants will attend four weekly sessions to receive education about strategies to improve sleep.
10131712|NCT04279834|Active Comparator|Sleep Education II|Participants will attend four weekly sessions to receive education about sleep health.
10131713|NCT04279717||Subjects with von Willbrand Disease Acquired|
10131714|NCT04279717||Subjects with von Willbrand Disease Congenital|
10131715|NCT04279470||Adverse Events with cellular therapies|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Chimeric Antigen Receptor T-cell and Cellular Therapies, with a chronology compatible with the drug toxicity
10131716|NCT04279509|Experimental|Cancer patient|Histological or cytological diagnosis of head and neck squamous cell carcinoma (HNSCC), colorectal, breast or epithelial ovarian cancer.
10131717|NCT04279483|Experimental|7-11 Group|Participants visit 7-11 every weekday during the 4-week (20 store visits total) intervention period
10131718|NCT04279483|Experimental|CVS Group|Participants visit CVS every weekday during the 4-week (20 store visits total) intervention period
10131719|NCT04279483|No Intervention|Control|Participants are not asked to alter their behavior during the 4-week (0 store visits) intervention period
10131720|NCT04279600|Experimental|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
10131721|NCT04279600|Active Comparator|Taurine supplementation associated to exercise training|"Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
10131722|NCT04279600|Placebo Comparator|Placebo supplementation associated to exercise training|"Placebo supplementation composed of capsules of starch powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
10131723|NCT04279808|Experimental|measured distance|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will measure the distance between the skin puncture site and the outside of anterior wall of the jugular vein. Next, we will insert the dilator on the guidewire by the measured length."
10131724|NCT04279808|No Intervention|conventional method|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will insert the dilator on the guidewire as commonly used method of the practitioners."
10131725|NCT04279418|Experimental|Mixed functional foods group with SCD|Thirty participants in this group will take mixed functional foods for three months.
10131726|NCT04279418|Placebo Comparator|Placebo group with SCD|Thirty participants in this group will take placebo for three months.
10131727|NCT04279444|Experimental|Active BKR-017|Open label study. All patients will receive 28 days of active treatment.
10131728|NCT04279587|Experimental|Residential camp participant|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at a regional camp.
10131729|NCT04279457|Active Comparator|Standardized Hydration protocol|These cases will follow Charleston Area Medical Centers standard Hydration protocol
10131730|NCT04279457|Active Comparator|Hydration + Device|These cases will follow Charleston Area Medical Centers standard hydration protocol plus use the DyeVert Plus System
10131731|NCT04279405|Experimental|YY-20394|treatment with YY-20394 will be continued until tumor progression or development of unacceptable toxicity.
10131732|NCT04279353|Experimental|Mindfulness Based Intervention|Participants was asked to answer PSS-10 questionnaire to measure their stress level, then they received Mindfulness Based Intervention program for 4 weeks and did the PSS-10 test again after 4 weeks.
10131733|NCT04279054|Active Comparator|Group A: 150 mcg morphine|Patients in this group will receive 150mcg of morphine in their neuraxial block
10131734|NCT04279054|Experimental|Group B: 50 mcg morphine|Patients in this group will receive 50mcg of morphine in their neuraxial block
10131735|NCT04279041|Experimental|Fanta and Zunba rotatory files|Fanta and Zunba rotatory files
10131736|NCT04279041|Active Comparator|manual K-files|manual K-files
10131737|NCT04279379|Experimental|treatment arm|Sintilimab,200mg,ivdrip,day1 Decitabine 10mg d1-5, ivdrip, repeated every 3 weeks.
10131738|NCT04279366||Winter course|The recruited particpants attending the winter course
10131739|NCT04279366||Fall course|The recruited particpants attending the winter course
10131740|NCT04279093||Pregnant/postpartum women and their partners|"The investigators aim to recruit 20 women in late pregnancy from the Antenatal Assessment Unit and the Antenatal Clinic at St Mary's Hospital. Their partners will be invited to participate where applicable.~Inclusion and exclusion criteria for pregnant women are as follows:~Inclusion: after 36 weeks gestation, aged over 18 years and fluent in English, under the care of Manchester University NHS Foundation Trust~Exclusion: current stillbirth (women experiencing a stillbirth during the study will be withdrawn from the study), fetal abnormality, or multiple pregnancy~Inclusion criteria for partners: male or female partners of a mum participating in the study, aged over 18 and fluent in English."
10131741|NCT04279106|Experimental|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
10131742|NCT04279106|Active Comparator|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
10131743|NCT04279106|Active Comparator|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
10131744|NCT04279106|Placebo Comparator|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
10131745|NCT04279080||1|rectal cancer patients
10131746|NCT04279080||2|ovarian cancer patients
10131747|NCT04279249|Active Comparator|HEPA Filtration|
10131748|NCT04279249|Sham Comparator|Sham HEPA Filtration|
10131749|NCT04279015|Active Comparator|Conventional rehabilitation treatment|Conventional physiotherapy program, consisting of standardised active (exercise) and passive (hotpack, ultrasound, conventional TENS) physical therapy methods, was applied by the same physiotherapist.
10131750|NCT04279015|Active Comparator|Kinesio tape procedure|In addition to the conventional physiotherapy program Kinesio tape was performed every day of conventional treatment immediately after the session ended by the same physiotherapist.
10131751|NCT04279223|Active Comparator|5 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
10131752|NCT04279223|Sham Comparator|10 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
10131753|NCT04279288|Experimental|participants enrolled with epistaxis and/or nasal fractures|
10131754|NCT04279210|Experimental|PRP Treatment|Women with SUI received PRP injection into anterior vaginal wall (near external urethral sphincter) once per month for three times.
10131755|NCT04279145|Experimental|pulmonary hypertension group 1|each patient will be submitted to : swan-ganze catheterization detailed echocardiography blood sample for biomarkers (troponin, uric acid and micro RNA)
10131756|NCT04279002||Respiratory rehabilitation course|Patients who has completed at least one respiratory rehabilitation course at the Espace du Souffle (Tours France) within the 5 years prior to inclusion
10131757|NCT04279275||Survey|Knowledge survey
10131758|NCT04278950|Active Comparator|Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with 0.10% PVP-I (0.01% available iodine). Patients will be instructed to dilute 2.5mL of the betadine (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
10131759|NCT04278950|Placebo Comparator|Placebo Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with a placebo PVP-I solution. Patients will be instructed to dilute 2.5mL of the placebo PVP-I (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
10131760|NCT04278911||Participates|This is an observational study
10131761|NCT04279262||Anonymised records from 6 ambulance services|The total available sample for analysis for this cohort is estimated to be at least 50,000 incidents across 6 ambulance trusts. The investigators will describe the epidemiology of CFR provision to rural health areas using an anonymised dataset.
10131762|NCT04279262||Interviews with patients (and/or relatives)|The investigators will interview about 15-20 patients (and/or relatives) who have been attended by CFRs.
10131763|NCT04279262||Interviews with CFRs|The investigators will interview about 15-20 CFRs/ CFR scheme leaders.
10131764|NCT04279262||Interviews with Ambulance staff|The investigators will interview about 15-20 ambulance staff who have experience of working with CFRs.
10131765|NCT04279262||Interviews with GPs and commisioners|The investigators will interview about 10-15 GPs and ambulance service commissioners.
10131766|NCT04279028|Active Comparator|Standard CBT|
10131767|NCT04279028|Experimental|Adapted CBT|
10131768|NCT04278976|Experimental|CoBaTriCE|Implementation of CoBaTrICE. The implementation of CoBaTrICE is based on: 1. Training the trainers; 2. Multiple Workplace-based assessment exercices; 3. The use of an electronic portfolio.
10131769|NCT04278976|No Intervention|Control|The participants of the control group will follow the current official model of training in ICM in Spain, which is based on exposure to experiences through time-based clinical rotations; a generic report, non-based on formal assessment, about knowledge, technical and nontechnical skills is performed after every clinical rotation, and yearly by the tutor.
10131770|NCT04278729|Experimental|Nephrotic Syndrome Arm|Patients diagnosed with Nephrotic syndrome will be in this arm.
10131771|NCT04278729|Experimental|Healthy Arm|Healthy volunteers will be in this arm.
10131772|NCT04278963|Experimental|Yin Hu Qing Wen Decoction Group|Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen Decoction (Granula) for 10 days.
10131773|NCT04278963|Placebo Comparator|Yinhu Qingwen Decoction low-dose group|Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen Decoction (Granula) for 10 days.
10131774|NCT04278963|Active Comparator|Integrated Chinese and Western Medicine group|Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into 3 times(once with 200ml). The Chinese medicine decoction will be given 200ml per time, three times a day for 10 days.
10131775|NCT04278859|Experimental|0.3mg/kg repeat dose every 21 days up to 2 years|
10131776|NCT04278859|Experimental|1 mg/kg repeat dose every 21 days up to 2 years;|
10131777|NCT04278859|Experimental|3 mg/kg repeat dose every 21 days up to 2 years;|
10131778|NCT04278859|Experimental|10 mg/kg repeat dose every 21 days up to 2 years;|
10131779|NCT04278703|Active Comparator|15 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
10131780|NCT04278703|Active Comparator|25 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
10131781|NCT04278703|Active Comparator|35 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
10131782|NCT04278807|Experimental|PENG-group|Ultrasound-guided PENG-block - 30 patients
10131783|NCT04278807|Experimental|FIB-group|Ultrasound-guided Fascia Iliaca block - 30 patients
10131784|NCT04278677|Active Comparator|Melatonin supplementation|5mg melatonin tablets to be taken for 6 weeks
10131785|NCT04278677|No Intervention|No supplementation|
10131786|NCT04278820|Experimental|Climbing group|
10131787|NCT04278820|Experimental|Titration group|
10131788|NCT04278820|Experimental|Extension group|
10131789|NCT04278742|Experimental|Interventional - collaborative education|Collaborative style of communication whereby the clinician and patient co-creates the treatment plan
10131790|NCT04278742|No Intervention|Control group|Traditional directive and didactic style of patient information will be provided
9827454|NCT02456636|Active Comparator|Disease Management (DM, Phone group visits)|Participants will take part in group weight-management counseling by telephone.
10131791|NCT04278833|Other|Particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 10-80mg of triamcinolone or 3-9mg of betamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
10131792|NCT04278833|Other|Non-particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 4-10mg of dexamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
10131793|NCT04278638|Experimental|with IORT|
10131794|NCT04278638|Active Comparator|without IORT|
10187668|NCT03723785|Experimental|Participants with moderately decreased renal function|Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
10131795|NCT04278612|Experimental|Intervention|"Provision of comprehensive care including the following:~Baby:~Measure weight and length Plot on appropriate growth charts in Road to Health Card (RTHC) Discuss with mother about the growth of the baby Identification of malnutrition and appropriate management Age-appropriate nutrition counselling Immunisation Developmental screening Vitamin A supplementation Deworming HIV Care: If mother is HIV positive -~Polymerase chain reaction (PCR) test for the baby repeated at 10 weeks~Nevirapine for the baby for six weeks~Mother:~Cervical cancer screening Provide family planning Screening tuberculosis (TB) and sexually transmitted infections (STIs)~HIV Care:~HIV positive mothers - provide ART for the mother and adherence support~HIV negative mothers- HIV test every three months while breastfeeding"
10131796|NCT04278612|Active Comparator|Control|Routine maternal and child care service delivery
10131797|NCT04278846|Experimental|DepoFoam bupivacaine|local anesthetic
10131798|NCT04278846|Active Comparator|bupivacaine HCl|local anesthetic
10131799|NCT04279132||TOTAL INTRAVENOUS ANESTHESIA|
10131800|NCT04279132||INHALATION ANESTHESIA|
10131801|NCT04278599|Experimental|Test group|The patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
10131802|NCT04278599|Placebo Comparator|Control group|The patients will be administered Placebo tablets for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
10131803|NCT04278586|Experimental|Live-Online Mindful Recovery OUD Care Continuum|Live-Online Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed for patients with OUD prescribed buprenorphine to be delivered in a live-online environment. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. The live-online M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then a mindfulness maintenance check-in support group.
10131804|NCT04278586|Active Comparator|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
10131805|NCT04278716||Utilization of a safe return to play checklist|Athletes who were treated for a capsulolabral tear who have undergone arthroscopic capsulolabral repair surgery will be evaluated using an objective checklist prior to being allowed to return to their sport. The utilization and outcome of using this checklist will be evaluated
10131806|NCT04278456||general anesthesia|c-section with general anesthesia
10131807|NCT04278456||spinal anesthesia|c-section with spinal anesthesia
10131808|NCT04278456||epidural anesthesia|c-section with epidural anesthesia
10131809|NCT04278937|Active Comparator|Azithromycin group|women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
10131810|NCT04278937|No Intervention|Control group|women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
10131811|NCT04278378|Active Comparator|Riboflavin|1.6 mg riboflavin / day for 24 weeks
10131812|NCT04278378|Experimental|Folic Acid|0.4 mg folic acid/ day for 24 weeks
10131813|NCT04278378|Experimental|Riboflavin + Folic Acid|1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
10131814|NCT04278378|Placebo Comparator|Placebo|
10131815|NCT04278430|Experimental|Real tDCS group|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 1.5 mA intensity
10131816|NCT04278430|Sham Comparator|Sham tDCS|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 0 mA intensity.
10131817|NCT04278430|Active Comparator|Control|The normal heathy children age matched undergo the same activity and brain stimulation as the real tDCS group.
10131818|NCT04278755|Experimental|Continuous OC|Continuous daily oral drospirenone + ethinyl estradiol for 84 days (i.e., 12-weeks).
10131819|NCT04278287|Experimental|Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy|Chemoradiotherapy arm receives intensity-modulated radiation therapy, volume modulated arc therapy or tomotherapy concurrently with albumin-bound paclitaxel and cisplatin (weekly intravenous infusion in 5-6 weeks).
10131820|NCT04278443||Low dose rate brachytherapy|20 patients receiving low dose rate brachytherapy
10131821|NCT04278443||High dose rate brachytherapy|20 patients receiving high dose rate brachytherapy.
10131822|NCT04278508|Active Comparator|Group A|P < 10.0 ng/ml with increasing P dosage from 800 mg to 1200 mg daily from the FET day.
10131823|NCT04278508|Active Comparator|Group B|P < 10.0 ng/ml without change in drug regimen.
10131824|NCT04278508|Active Comparator|Group C|P ≥ 10.0 ng/ml without change in drug regimen.
10131825|NCT04278248|Experimental|experimental group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine(experimental vaccine), 0.5 ml/dose
10131826|NCT04278248|Active Comparator|Positive control group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine (positive control vaccine), 0.5 ml/dose
10131827|NCT04278274||patients will be evaluated by artificial intelligence system and expert radiologist|the patients with locally advanced rectal cancer (LARC) finished the neoadjuvant treatment, and not yet receive total mesorectum excision (TME) surgery will be enrolled. The post-neoadjuvant treatment MRI images features of each enrolled patients will be captured by the artificial intelligence system, and evaluated by experienced radiologists as well. Blind to the pathologic report of TME specimen, both approaches further respectively yield a predicted pathologic response to neoadjuvant treatment for each enrolled patient, shown as pCR or non-pCR.
10131828|NCT04278495|Active Comparator|Losartan|"to receive the medication Cozaar (Losartan Potassium 25mg Merck Sharp & Dohme-UK),"
9968306|NCT01278277|Placebo Comparator|placebo supplementation|patients will be assigned, in a cross-over design, to placebo or supplement administration
10131829|NCT04278495|Placebo Comparator|Placebo|to receive either placebo
10131830|NCT04278391|Experimental|A (RT)|Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)
10131831|NCT04278391|Experimental|B (TR)|Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)
10131832|NCT04278469|Active Comparator|Patients with chemotherapy|
10131833|NCT04278469|No Intervention|Patients without chemotherapy|
10131834|NCT04278547|Experimental|Experimental group|Preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis;
10131835|NCT04278547|No Intervention|Control group|Standard of care, universal prophylaxis with valgancyclovir for 3 months).
10131836|NCT04278222|Experimental|Anlotinib Plus Toripalimab|the combination of Anlotinib Plus Toripalimab as first-line treatment
10131837|NCT04278170||Case group|Rheumatoid arthritis patients who met the American College of Rheumatology (ACR) 2010 RA classification
10131838|NCT04278339|Experimental|CONTROLLED SUBJECTS|In this arm, only controlled subjects (pathological-free) will be investigated.
10131839|NCT04278339|Experimental|PATIENTS|In this arm, only patients with scyzophrenic syndrome will be investigated.
10131840|NCT04278300||case|patient with age-related exudative macular degeneration
10131841|NCT04278300||control|Patient with no macular disorder and in need of cataract surgery
10183917|NCT03759821|Experimental|Nutrition+parenting, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
10183918|NCT03759821|Experimental|Nutrition+parenting, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
10183919|NCT03759821|No Intervention|Standard of care control|Local standard of care
10183920|NCT03759782|Experimental|Group 1|Tenofovir (TDF) 300 mg po once a day (OD)
10183921|NCT03759782|Active Comparator|Group 2|Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if <70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg
10183922|NCT03759769|Experimental|simulator|Practice at home all activities of the wheelchair simulator, at least 20 minute per session, at least one session every second day
9827455|NCT02456662|Placebo Comparator|Placebo|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
10183923|NCT03759769|Active Comparator|control|Practice on a computer video game, at least 20 minute per session, at least one session every second day
10183924|NCT03759756||AI visible group|the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process
10183925|NCT03759756||AI invisible group|the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process
10183926|NCT03759743|Experimental|Probiotics|
10183927|NCT03759743|Placebo Comparator|Placebo|
10183928|NCT03759704||Hyperpolarized 13CPyruvate and gadolinium|Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
10183929|NCT03759691||Stroke patients|Structured interviews of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
10183930|NCT03759691||Bystander|Structured interviews of bystanders of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
10183931|NCT03759678|Experimental|Treatment with IB1001|"6-weeks treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)~After the 6-week treatment period, patients will enter a 6-week post-treatment washout period."
10183932|NCT03759678|No Intervention|Post-Treatment Washout|After the 6-week treatment period, patients will enter a 6-week post-treatment washout period.
10183933|NCT03759665|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
10183934|NCT03759665|No Intervention|Post-Treatment Washout|After the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
10183935|NCT03759652||infected, before-after studyt: 2003|neurosurgical patients; 2003: the beggining of active and target HAI surveillance
10183936|NCT03759652||infected, before-after studyt: 2017|neurosurgical patients; 2017: the effective of active and target HAI surveillance
9827456|NCT02456662|Active Comparator|Ondansetron|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline
10131842|NCT04278261|Experimental|Focal therapy|Using focal therapy(Irreversible electroporation) to treat patients with localized Prostate cancer
10131843|NCT04278261|Active Comparator|Radical prostatectomy|Using radical prostatectomy to treat patients with localized Prostate cancer
10131844|NCT04278365|Experimental|AMP-A|Participants will complete 11, 90-minute sessions of positive affect training. The positive affect training will be conducted in an individual setting. Positive affect training directly targets reward and positive valence processing and has been shown by previous research to enhance positive affect (and decrease negative affect).
10131845|NCT04278118|Experimental|Cohort I (hypofractionated radiation therapy)|Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
10131846|NCT04278118|Experimental|Cohort II (hypofractionated radiation therapy)|Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
10131847|NCT04278092|Experimental|Paclitaxel plus Cetuximab|Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
10131848|NCT04278053|Experimental|Nitrosigine supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Nitrosigine (1.5 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
10131849|NCT04278053|Experimental|Citrulline-Malate supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Citrulline-Malate (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
10131850|NCT04278053|Placebo Comparator|Placebo|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, dextrose (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
9694628|NCT04787029|Experimental|prophylactic medical compression therapy group|"This study provides medical compression stockings from the start date of Docetaxel administration for patients who have undergone mastectomy and axillary lymphectomy for breast cancer, and who are planning to receive Docetaxel adjuvant chemotherapy. The intervention group wears medical compression stockings for upper limbs with a pressure level of 1 (15-21mmHg) during the day from the start of docetaxel administration to 3 months after the end of administration.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
9968307|NCT01278277|Active Comparator|Saffron|Saffron Supplementation 20 mg/die
10131851|NCT04277832||single arm|Group of psoriasis patients will select randomly. All selected psoriasis patients will be consulted to a physician experienced in rheumatology and all of patients will fill TUPAST and TOPAS 2 forms.
9968308|NCT01278290|Active Comparator|Triptorelin test AND LHRH test|Patients undergo two tests with a test interval of at least 15 days
10131852|NCT04278105|Experimental|HD-tCES & upper extremity rehabilitation|The experiment group will receive HD-tCES combined with upper extremity rehabilitation of affected side.
10131853|NCT04278105|Sham Comparator|Sham HD-tCES & upper extremity rehabilitation|The sham control group will receive sham HD-tCES combined with upper extremity rehabilitation of affected side.
10131854|NCT04278027|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy. CRT will be based on CIRCuiTS, a computerized program.
10131855|NCT04278027|No Intervention|Treatment as usual|Treatment as usual
10131856|NCT04277780|Experimental|CGM Sensor|Subjects will receive the Libre Pro Freestyle continuous glucose monitor (CGM) sensor that will be applied to their upper arm at the time of hospital discharge. They will be asked to peel off the sensor after 14 days and mail it to the endocrinology clinic in a stamped envelope that will be provided. They will also be provided the conventional diabetes management which will include instructions on fingerstick blood glucose monitoring and logging which they will start after the CGM sensor is removed. The sensor data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time the sensor is placed for further management of their diabetes.
10187669|NCT03723785|Experimental|Participants with severely decreased renal function|Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
10131857|NCT04277780|Active Comparator|Conventional Diabetes Care|Subjects will receive only the conventional diabetes management at the time of hospital discharge which includes instruction on fingerstick blood glucose monitoring and logging onto a blood glucose log sheet for 14 days. They will then be asked to fax/mail/call-in the blood glucose log. The log data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time of hospital discharge for further management of their diabetes.
10131858|NCT04278040|Experimental|Non-cystic fibrosis bronchiectasis (NCFB) patients|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 5 consequent days
10131859|NCT04277949|Experimental|Erbium laser|All participants will receive Erbium laser treatment on their right post-auricular region
10131860|NCT04277949|Experimental|DNA repair enzyme|All participants will apply topical DNA repair enzymes on their left post-auricular region
10131861|NCT04277884|Experimental|Firibastat|Capsules
10131862|NCT04277884|Placebo Comparator|Placebo|Matching capsules
10131863|NCT04277845|Experimental|Group 1|"Bortezomib 1.3mg/m2 SC D1, 8, 15~- Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15~Lenalidomide 25mg/d D1-21~Dexamethasone 40mg D1, 8, 15~Dose adjustment for more than 75 years old: 20mg If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1.~If a patient is frail, the starting dosage will be as follows.~Bortezomib 1.0mg/m2 SC D1, 8, 15~- Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15~Lenalidomide 15mg/d D1-21~Dexamethasone 40mg D1, 8, 15~Dose adjustment for more than 75: 20mg"
10131864|NCT04277845|Active Comparator|Group 2|"Lenalidomide 25mg/d D1-21~Dexamethasone 40mg D1, 8, 15, 22~Dose adjustment for more than 75: 20mg~If a patient is frail in both study group, the starting dosage will be as follows.~Lenalidomide 15mg/d D1-21~Dexamethasone 40mg D1, 8, 15~Dose adjustment for more than 75: 20mg ."
10131865|NCT04278001|Other|Ambulatory blood pressure measurement|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
10131866|NCT04277767||mild cognitive impairment (MCI)|observational
10131867|NCT04277767||Patients with mild to moderate AD|observational
10131868|NCT04277767||Normal controls|observational
10131869|NCT04277702|Experimental|Montelukast + standard treatment|
10131870|NCT04277702|Placebo Comparator|Placebo+ standard treatment|
10131871|NCT04277793|Experimental|Monitored self-guided problem solving intervention|Monitored self-guided problem solving intervention
10131872|NCT04277663|Experimental|IBI310 + IBI308|Participants will be treated with IBI310 in combination with IBI308
10131873|NCT04277663|Experimental|IBI308|Participants will be treated with IBI308
10131874|NCT04277663|Active Comparator|high-dose recombinant interferon a-2B|Participants will be treated with recombinant interferon a-2B
10131875|NCT04277988||Crossed leg position|Patients in this group will be randomly allocated to sit in crossed leg position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
10131876|NCT04277988||Standard Sitting position|Patients in this group will be randomly allocated to sit in standard position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
10131877|NCT04277754||two-year-old children with typical development|
10131878|NCT04277871|Experimental|The intervention group|The intervention group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The intervention group attended on-site group practice sections and performed individual home-based practice.
10131879|NCT04277871|Active Comparator|The comparison group|The comparison group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The comparison group performed individual home-based practice only.
10131880|NCT04277650|Active Comparator|Once weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided once weekly clinical evaluations
10131881|NCT04277650|Experimental|Twice weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided twice weekly clinical evaluations
10131882|NCT04277923|Experimental|SMOF lipid emulsion|the SMOF lipid emulsion is SMOFlipid.
10131883|NCT04277923|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin.
10131884|NCT04277741|Experimental|Resistant starch bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.
10131885|NCT04277741|Active Comparator|Native wheat bar|The control group will consume one native wheat starch bar per day.
10131886|NCT04277689|Experimental|Brain signal data collection|Collection of brain data during deep brain stimulation
10131887|NCT04277715|Experimental|Parent training|Parents of participating children with chronic symptoms will receive the intervention in a virtual group format. Groups will last 90-minutes and run for 6-8 weeks. Groups will be co-led by a clinical psychologist and pediatric physician with expertise in child behavioral interventions and medically unexplained symptoms.
10131888|NCT04277806|No Intervention|Standard group|No interventions would be conducted in this group and the preterm infants would be fed in the normal way.
10131889|NCT04277806|Experimental|Intervention group|The preterm infants in this group would be fed according to the new process.
10131890|NCT04277897|Experimental|Drug SAD Cohorts|Hepenofovir Fumarate Tablets Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily in one single administration.
10131891|NCT04277897|Placebo Comparator|Placebo SAD Cohorts|Matching placebo, orally, once daily in one single administration.
10131892|NCT04277897|Experimental|Drug MAD Group|Hepenofovir Fumarate Tablets Dose 3 orally, once daily for 7 days.
10131893|NCT04277897|Placebo Comparator|Placebo MAD Group|Matching placebo, orally, once daily for 7 days.
10131894|NCT04277897|Experimental|Food-influnced Group|Hepenofovir Fumarate Tablets Dose 4 orally, once daily in one single administration in fast condition,cross-over 7 days later in fed condition.
10131895|NCT04277312|Experimental|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
10131896|NCT04277312|Experimental|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
10131897|NCT04277312|Experimental|Nourish and Engage|This arm of the intervention delivered both the Nourish and Engage interventions as detailed above.
10131898|NCT04277312|No Intervention|Delayed|The delayed arm of the intervention was the control arm. Schools randomised to this arm of the study were offered the Engage intervention resources after endpoint data collection.
10131899|NCT04277351|Experimental|tACS in individuals with and without dyslexia|Each participant in both the group of normo-readers and individuals with dyslexia receive all tACS stimulation conditions (fixed frequencies and sham) over different experimental days.
10131900|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.~Subjects withdrawn from the study for any reason will be replaced."
10131901|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 2000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.~Subjects withdrawn from the study for any reason will be replaced."
10131902|NCT04277338|Experimental|The tested injected doses of 99mTc-HE3-G3 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced."
10131903|NCT04277390||Controls|145 systemically and periodontally healthy pregnant women Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
10131904|NCT04277390||Group A|"Group A-100 Systemically healthy pregnant women with chronic periodontitis.~Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155."
10131905|NCT04277390||Group B|Group B- 100 Preeclamptic pregnant women with chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
10131906|NCT04277390||Group C|Group C-100 Preeclamptic pregnant women without chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
10131907|NCT04277429||Normal cardiac function|Normal cardiac function
10131908|NCT04277429||Heart failure with reduced ejection fraction|Heart failure with reduced ejection fraction
10131909|NCT04277429||Heart failure with preserved ejection fraction|Heart failure with preserved ejection fraction
10131910|NCT04277416||Entrada Hip System|All orthopaedic patients that are scheduled to undergo primary total hip arthroplasty using the Entrada™ Hip System within 12 weeks will be screened for the following eligibility criteria.
10131911|NCT04277364|Active Comparator|High dose phosphatidic acid|750mg of phosphatidic acid per day for 8 weeks
10131912|NCT04277364|Active Comparator|Low dose phosphatidic acid|375mg of phosphatidic acid per day for 8 weeks
10131913|NCT04277364|Placebo Comparator|Placebo|750mg of corn starch per day for 8 weeks
10131914|NCT04277494|Experimental|Clorethyl cold spray® (Vapocoolant spray)|"23 volunteer athletes who are studying at the Faculty of Health Sciences of Acıbadem University, between the ages of 18-23, with a subcutaneous fold thickness of the quadriceps muscle between 5 mm and 15 mm (Shadgan et al., 2015).~From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application."
10131915|NCT04277481||Group 1 (10 minute cold pack)|10 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
10131916|NCT04277481||Group 2 (12 minute cold pack)|12 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
10131917|NCT04277481||Group 3 (15 minute cold pack)|15 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
10131918|NCT04277481||Group 4 (20 minute cold pack)|20 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
10131919|NCT04277520|Active Comparator|Continous rotation|instrumentation was done in continuous rotation motion
10131920|NCT04277520|Active Comparator|Reciprocation|instrumentation was done in reciprocation motion
10131921|NCT04277520|Active Comparator|Adaptive motion|instrumentation was done in adaptive motion
10187670|NCT03723785|Experimental|Participants with end-stage renal disease|Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
10131922|NCT04277624|Experimental|Fezolinetant: Test Formulation then Reference Formulation|Participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 2.
10131923|NCT04277624|Experimental|Fezolinetant: Reference Formulation then Test Formulation|Participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 2.
10131924|NCT04277533||Patient group|NEC preterm neonates with gestational ages are between 28-36 weeks regardless of birth weight. NEC diagnosis and staging will be according to Bell's staging criteria .
10131925|NCT04277533||Control group|Stable preterm neonate with matched gestational and postnatal ages without infectious diseases.
10131926|NCT04277572||Aortic valve replacement|using different ways of aortic valve replacement either by prosthetic valves or by ozaki technique
10131927|NCT04277585|Experimental|OASIS Clients|Clients of the OASIS Program who live at least 45 minutes away from an Early Psychosis Coordinated Specialty Care Program and are willing to engage in some of their services through telehealth.
10131928|NCT04277403|Experimental|HA-WBRT+SIB|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis
10131929|NCT04277403|Active Comparator|SRS|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases
10131930|NCT04277221|Experimental|Standard therapy with ADCTA vaccine (study group)|"- ADCTA vaccine as study treatment~Dose(s): Ten doses, including 2~4×10^7 cells for the 1st dose (double doses), and 1~2×10^7cells for the 2nd to 10th doses.~Administrative route: The ADCTA vaccine will be injected in axillar or inguinal regions close to lymphnodes subcutaneously at clinic.~Frequency: The primary immunization inoculation is followed by 3 vaccines bi-weekly and then 6 vaccines monthly inoculation, for a total of 10 doses.~- Bevacizumab as standard therapy"
10131931|NCT04277221|Active Comparator|Standard therapy (control group)|"No study treatment~Bevacizumab as standard therapy"
10131932|NCT04277247|Experimental|Botulinum Toxin Type A Treatment|Injections
10131933|NCT04277247|Placebo Comparator|Placebo|Injections
10131934|NCT04277260||Full term delivery|In the cooperative obstetric hospital, 30 cases of full-term delivery healthy mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
10131935|NCT04277260||Preterm delivery(35-37 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(35-37 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
10131936|NCT04277260||Preterm delivery(32-35 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
10131937|NCT04277260||Preterm delivery(28-32 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(28-32 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
10131938|NCT04277195||NUH Adjuvant Breast Cancer Cohort: Historical|This is a series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (1986-1999; n=1650). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
10131939|NCT04277195||NUH Adjuvant Breast Cancer Cohort: New|A series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (2000-2006; n=2000). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
10131940|NCT04277195||NUH Neoadjuvant Breast Cancer Cohort|For many years clinical data on this cohort of breast cancer patients has been collected in a master clinical database by the clinical team supporting Dr Chan (1996-2021; n=900 patients). This has been used for internal audits and reviews of clinical practice. The study research team will work with a pseudo-anonymised copy of this dataset.
10131941|NCT04277195||NUH Oncotype DX tested Adjuvant Breast Cancer Cohort|A list of patients tested with Oncotype DX as part of their standard treatment pathway (2015-2021; n=200) will be collected and will form the basis of a master clinical database for this cohort. The database will be managed and populated by the clinical team supporting Dr Chan. The study research team will work with a pseudo-anonymised copy of this dataset.
10131942|NCT04277182|Placebo Comparator|Control group|It will be accepted as the control group and 4 experimental burn wounds will be created on the back of the rats in the group and no treatment will be given.
10131943|NCT04277182|Active Comparator|1% Silver Sulfadiazine|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 1% Silver Sulfadiazine will be done on the back of the rats every day for 21 days.
9694629|NCT04787029|No Intervention|control group|"The control group proceeds as an observation, but interventions such as providing stockings in the event of lymphedema are performed.~Basic education of upper limb exercises (joint motion range enhancement exercises and upper limb muscle pumping exercises) is provided to both the intervention group and the control group."
9694630|NCT04786886|Experimental|Virtual Reality Visual Field Group|Participants in this group will have virtual reality visual field testing during standard of care follow-up visit.
10131944|NCT04277182|Active Comparator|%0.2 Nitrafurozon|4 experimental burn wounds will be created on the back of the rats in the group and dressing with %0.2 Nitrafurozon will be done on the back of the rats every day for 21 days.
10131945|NCT04277182|Experimental|10% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 10% Propolis will be done on the back of the rats every day for 21 days.
10131946|NCT04277182|Experimental|15% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 15% Propolis will be done on the back of the rats every day for 21 days.
10131947|NCT04277182|Active Comparator|Propolis vehicle|4 experimental burn wounds will be created on the back of the rats in the group and dressing with Propolis vehicle will be done on the back of the rats every day for 21 days.
10131948|NCT04277117|Experimental|Medically Tailored Meal Delivery|1 ready-to-eat and 1 frozen medically tailored meal delivered by Meals on Wheels volunteers/drivers Monday through Friday.
10131949|NCT04277117|Other|Remain on interest list|participants randomized to remain on the Meals on Wheels interest list will receive regular Meals on Wheels services when they reach the top of the list (typically 4-6 months from placement on the list).
10131950|NCT04277143||critical ill patient with bloodstream infections|Severe patients with bloodstream infections often have sepsis / septic shock, acute kidney injury (AKI), hypoproteinemia, and renal replacement treatment.
10131951|NCT04276935||Health Services Research (cognitive interviews)|Participants take part in cognitive interviews in Spanish over 45-60 minutes.
10131952|NCT04277039|Experimental|OMT+CT|It consists of 8 sessions of osteopathic treatment and two 20-min sessions of cognitive training per week per 2 months
10131953|NCT04277039|Active Comparator|osteopathic treatment|It consists of 8 sessions of osteopathic treatment throughout the 2-month study period
10131954|NCT04277039|Other|usual care|patients will continue the routine care as established by international guidelines
10131955|NCT04276922|Experimental|Visual Arts Group|Visual Arts group - sketch journals
10131956|NCT04276922|Experimental|Music Group|Music group involves music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making.
10131957|NCT04276922|Experimental|Dance/Movement Group|Dance/Movement group - movement check-in, gentle physical warm-up, and then either a structured or improvisational movement process.
10131958|NCT04276922|Experimental|Writing/Poetry Group|Writing/Poetry group uses writing workshops using integral elements of good writing.
10131959|NCT04276922|Experimental|Control Group|Surveys at baseline and 12 weeks later.
10131960|NCT04276961|Experimental|Acupuncture plus usual care|Acupuncture will be given on the basis of usual care. A total of 12 sessions of acupuncture will be given over a period of 4 weeks.
10131961|NCT04276961|Sham Comparator|Sham acupuncture plus usual care|Sham acupuncture refers to acupuncture at sham points. Sham acupuncture will be given on the basis of usual care. A total of 12 sessions of sham acupuncture will be given over a period of 4 weeks.
10131962|NCT04277130|Experimental|Intervention group|Intervention with active video games
10131963|NCT04277130|No Intervention|Control group|No intervention
10131964|NCT04276805|Active Comparator|tVNS group|Participants will undergo cognitive training with tVNS
10131965|NCT04276805|Sham Comparator|Sham group|Participants will undergo cognitive training with earlobe sham
10131966|NCT04276883|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms Dexmedetomidine
10131967|NCT04276883|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms Dexmedetomidine
10131968|NCT04276883|Placebo Comparator|Placebo|Sublingual placebo film
10131969|NCT04276766|Experimental|Beetroot|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the beetroot group were asked to consume 140ml beetroot juice (James White Drinks Company, Suffolk, UK). The 140 ml of beetroot juice equate to approximately 8.4 mmol of NO3- ."
10131970|NCT04276766|Placebo Comparator|Placebo|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the placebo group were asked to consume 140 ml nitrate-depleted beetroot juice (James White Drinks Company, Suffolk, UK)."
10131971|NCT04276844||Non diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test ≥ 16 mm for women and ≥ 18 mm for men
9694631|NCT04787016|Experimental|Pilate training|The participants of this group perform pilate training along with conventional cricket training.
10131972|NCT04276844||Persistent diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test < 16 mm for women and < 18 mm for men
10131973|NCT04277052|Experimental|Group 1|Muscle disorders
10131974|NCT04277052|Experimental|Group 2|Disc displacements
10131975|NCT04277052|Experimental|Group 3|Other common joint disorders
10131976|NCT04277052|Experimental|Group 4|Mix type
10131977|NCT04277052|Experimental|Group 5|Healthy individuals
10131978|NCT04276714|Experimental|Adjustable socket|First week of the study is with adjustable socket
9694632|NCT04787016|No Intervention|Conventional training|The participants perform only conventional cricket training.
9694633|NCT04787068|Experimental|Treatment group|Intervention is occupational therapy support
9694634|NCT04787068|No Intervention|Control group|No intervention was provided, only educational material was given.
10131979|NCT04276714|Experimental|Classical socket|First week of the study is with classical socket
10131980|NCT04276857|Other|Single arm study|All eligible patients will receive combination chemotherapy and if there i s a positive response they will undergo IRE.
10131981|NCT04277156|Experimental|Flostrum Baby|"The test product will be Flostrum Baby, which is a food supplement consisting of two bacterial strains: Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri DSM 29063, 5x10^9 CFU and 1x10^8 CFU, respectively, per seven drops.~Flostrum Baby - in children below 12 years of age, 7 drops, twice daily; in children older than 12 years, 14 drops, twice daily."
10131982|NCT04277156|Active Comparator|Dicoflor|"The control product will be Dicoflor, which is a food supplement containing L rhamnosus ATCC 53103, 5x10^9 CFU, per five drops.~Dicoflor - the manufacturer recommends 5-10 drops daily, with no age specification. For the purposes of this study, 5 drops, twice daily, in children below 12 years of age; 10 drops, twice daily, in children older than 12 years."
10131983|NCT04276753|Experimental|Terminalia Chebula fruit extract|"The test product is an emulsion. It contains Terminalia Chebula fruit extract.~Test product will be applied topically on full face twice a day for 8 weeks."
10131984|NCT04276753|Placebo Comparator|Placebo|"The placebo product is an emulsion with same appearance as the experimental product but without Terminalia Chebula fruit extract.~Placebo emulsion will be applied topically on full face twice a day for 8 weeks."
10131985|NCT04276831|Active Comparator|Laryngoscope McCoy|Patients will be intubated using laryngoscope McCoy
10131986|NCT04276831|Active Comparator|Laryngoscope Macintosh|Patients will be intubated using laryngoscope Macintosh
10131987|NCT04277091|No Intervention|Control|No exercise
10131988|NCT04277091|Experimental|High-intensity interval exercise|10 x 60 s intervals at 80% peak power output (interspersed with 60 s recovery intervals at 10% peak power output)
10131989|NCT04277091|Experimental|Moderate-intensity continous exercise|50% peak power output (duration determined to elicit same energy expenditure as high-intensity interval exercise condition)
10131990|NCT04276818|Active Comparator|PRP group|Second-degree superficial burn group treated with PRP
10131991|NCT04276818|Active Comparator|conventional treatment group|second-degree superficial burn group treated with cream containing silver sulfadiazine
10131992|NCT04276948|Experimental|Active1|312 mg dose of active
10131993|NCT04276948|Experimental|Active2|812 mg dose of active
10131994|NCT04276948|Placebo Comparator|Placebo|placebo
9527679|NCT03217838|Experimental|Group 1 Arm B (AZD2811 Dose 6)|Participants with AML will receive IV infusion of AZD2811 Dose 6 on Days 1, 4, 15, and 18 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
10131995|NCT04276987|Experimental|MSCs-derived Exosomes Treatment Group|Conventional treatment and aerosol inhalation of MSCs-derived exosomes treatment participants will receive conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
10131996|NCT04277026|Experimental|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals. The intervention will take place two times per week for four weeks (Weeks 1-4). During weeks 5-8 the experimental group will continue treatment as usual and will not be receiving the mindful walking intervention.
10131997|NCT04277026|No Intervention|Control|Participants will engage in treatment as usual during the first four weeks and will not be receiving the experimental intervention (mindful walking) during weeks 1-4. After the experimental group completes the mindful walking intervention, the control group will complete the mindful walking intervention (weeks 5-8).
10131998|NCT04276896|Experimental|pathogen-specific DC and CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
10131999|NCT04276688|Active Comparator|Study group|triple combination
10132000|NCT04276688|Active Comparator|Control group|single
10132001|NCT04276727|Active Comparator|Menthol|Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
10132002|NCT04276727|Placebo Comparator|Placebo|Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
9694635|NCT04787003|Experimental|Oncolytic virus (OVV-01) injection for patients with advanced solid tumors|Oncolytic virus (OVV-01) injection combined with or without immune checkpoint inhibitors in the treatment of patients with advanced solid tumors.
9968309|NCT01278290|Active Comparator|LHRH test AND Triptorelin test|Patients undergo two test with a test interval of al least 15 days.
9528284|NCT03212209|Experimental|CPAP C- Flex-Plus by Philips Respironics|Four consecutive weeks with CPAP C- FLEX PLUS treatment. After these 4 weeks, patients will undergo full PSG with CPAP FLEX- PLUS. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
10132003|NCT04276662|Experimental|Cohort 1: Mild hepatic impairment|Participants who have mild hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
10132004|NCT04276662|Experimental|Cohort 2: Moderate hepatic impairment|Participants who have moderate hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
10132005|NCT04276662|Experimental|Cohort 3: Healthy participants|Healthy participants who have normal hepatic function with sex, age (±10 years [y]), and weight (±20%) matching with the mild and moderate hepatic impairment cohorts.
10132006|NCT04276740|Active Comparator|MitoQ|Participants will take oral MitoQ 40 mg daily
10132007|NCT04276740|Placebo Comparator|Placebo|Participants will take an oral matched placebo daily
10132008|NCT04276649||Caltrate+Mesalazine|Patients in this group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months.
10132009|NCT04276649||Mesalazine|Patients in this group were received with Mesalazine 4g/d orally at least 12 months.
10132010|NCT04277104|Experimental|Healthy intervention|Acoustic stimulation
10132011|NCT04277104|Sham Comparator|Healthy sham|No stimulation
10132012|NCT04277104|Experimental|At risk intervention|Acoustic stimulation
10132013|NCT04277104|Sham Comparator|At risk sham|No stimulation
10132014|NCT04277104|Experimental|MCI (mild cognitive impairment) intervention|Acoustic stimulation
10132015|NCT04277104|Sham Comparator|MCI (mild cognitive impairment) sham|No stimulation
10132016|NCT04277065|Experimental|Bulldog tourniquet in laparoscopic Hepatectomy|The bulldog tourniquet , a reusable vessel occlusion instrument forblocking the liver inflow-blood in laparoscopic liver resection, was uniformly employed in all patients randomized to Bulldog laparoscopic hepatectom group in the present study.
10132017|NCT04277065|Active Comparator|cotton tourniquet in laparoscopic Hepatectomy|The cotton tourniquet ,a reusable vessel occlusion instrument for blocking the liver inflow-blood in laparoscopic liver resection
10132018|NCT04276701|Experimental|Systemic lupus erythematosus (SLE)|
10132019|NCT04276636|Experimental|Caltrate|This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
10132020|NCT04276636|No Intervention|Control|The other group do not interfere.
10132021|NCT04276389|Active Comparator|OCT-guided arm|
10132022|NCT04276389|Placebo Comparator|Angiography-guided arm|
10132023|NCT04276350|Experimental|Acupuncture|"Acupuncture Regime:~2-3 sessions per week, each lasting an hour, over a period of 10 weeks (with deviation of 2 weeks for scheduling), total of 30 sessions"
10132024|NCT04276350|Active Comparator|Best medical therapy|"Best Medical Therapy Regime:~3 sessions to be completed over a period of 10 weeks (with deviation of 2 weeks for scheduling), with subjects learning and practicing biofeedback exercises daily"
10132025|NCT04276376|Experimental|Cohort 1A-D|"Molecularly selected cohorts that harbor DNA repair deficiency, defined as bi-allelic loss-of-function alteration (mutation and/or deletion) in at least one of the following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, PALB2, RAD51C, RAD51D, FANCA, NBN, RAD51, RAD54L.~1.A - Non-Small Cell Lung Cancer~1.B - Urothelial Bladder Cancer~1.C - metastatic Castration Resistant Prostate Cancer~1.D - others: any histology, excepted breast cancer or serous ovarian cancer"
10132026|NCT04276376|Experimental|Cohort 2A-C|Platinum-sensitive disease 2.A - Non-Small Cell Lung Cancer 2.B - Urothelial Bladder Cancer 2.C - Gastric or gastro-esophageal junction adenocarcinoma
10132027|NCT04276376|Experimental|Cohort 3|Metastatic Castration Resistant Prostate Cancer (mCRPC)
10132028|NCT04276376|Experimental|Cohort 4|Clear Cell Renal Cell Carcinoma
10132029|NCT04276506|Experimental|information booklet group|information session before the coronary angiography
10132030|NCT04276506|Experimental|music group|music session before the coronary angiography
10132031|NCT04276506|No Intervention|control group|No information or music session before the coronary angiography
10132032|NCT04276298|Active Comparator|Metronidazole|Group A receiving 10% metronidazole cream
10132033|NCT04276298|Active Comparator|Metronidazole + Diltiazem|Metronidazole 10% + Diltiazem 2%
10132034|NCT04276298|Active Comparator|Metronidazole + Lignocaine|Metronidazole 10% + Lignocaine 4%
10132035|NCT04276298|Active Comparator|Metronidazole + Diltiazem + Lignocaine|Metronidazole 10% + Diltiazem 2% + Lignocaine 4%
10132036|NCT04276480|Experimental|Intervention|The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
10132037|NCT04276428|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
10132038|NCT04276428|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
10132039|NCT04276402|Experimental|Right side of the maxilla|
10132040|NCT04276402|No Intervention|Left side of the maxilla|
10132041|NCT04276454|Experimental|Single arm|
10132042|NCT04276597|Experimental|Lu177 DOTATOC treatment|4 doses of 200mCi 177Lu- DOTATOC PRRT
10132043|NCT04276610|No Intervention|Healthy Control Participants|Older adults (65+) without impairments in vision or hearing. This groups will simply be followed for the study period (1 year), measured at 6 months intervals, to provide control comparison data for all outcome measures
10132044|NCT04276610|Experimental|Low Vision Participants|Older adults (65+) with impairments in vision but without hearing impairment. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
10132045|NCT04276610|Experimental|Dual Sensory Impairment Participants|Older adults (65+) with impairments in both vision hearing hearing. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
10132046|NCT04276285|Active Comparator|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
10132047|NCT04276285|Active Comparator|US TAP|Subcostal TAP block will be performed after surgery under ultrasound guidance
10132048|NCT04276285|No Intervention|No TAP|No TAP block will be performed
10132049|NCT04276519|Experimental|Experimental|Physiotherapeutic non-invasive position-induced opening of the intervertebral foramen and pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
10132050|NCT04276519|Active Comparator|Control group|Pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
10132051|NCT04276220|Other|Tenosynovial Biopsy|
10132052|NCT04276363|Experimental|Thrive Professional Learning plus ParentCorps|1) Professional Development, Program Training and Coaching; 2) Program for Parents of Pre-K Students; and 3) Program for Pre-K Students. The three intervention components are expected to strengthen relationships and communication between parents and teachers and promote safe, nurturing and predictable environments, which contribute to child mental health and achievement.
10132053|NCT04276363|Experimental|Thrive Professional Learning only|Best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders.
10132054|NCT04276363|Experimental|Inspire Professional Learning|Led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
10132055|NCT04276246|Experimental|Experimental|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to retentive components (Group A, Test) which are connected to the implants to retain the RPD
10132056|NCT04276246|Experimental|Control|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to supportive components (Group B, Control), which are connected to the implants to support the RPD
10188055|NCT03720054|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the veterans a Fitbit.
10132057|NCT04276324|Active Comparator|Control Group|Only testing sessions
10132058|NCT04276324|Experimental|Resistance training group|Ten weeks of resistance training
10132059|NCT04276545|Experimental|IV administration of dexmedetomidine|IV administration of a single loading dose DEX (0.5μg/kg)
10132060|NCT04276545|Active Comparator|IV administration of midazolam|IV administration of midazolam (0.05mg/kg)
10132061|NCT04276142|Experimental|Tension-Type Headache - ceprica|online program: ceprica, additional to care as usual
10132062|NCT04276142|Active Comparator|Tension-Type Headache - Placebo|Other: online evidence-based information regarding headache, additional to care as usual
10132063|NCT04276142|Experimental|Migraine - ceprica|online program: ceprica, additional to care as usual
10132064|NCT04276142|Active Comparator|Migraine - Placebo|Other: online evidence-based information regarding headache, additional to care as usual
10132065|NCT04276077|Experimental|High-frequency electrical muscle stimulation|
10132066|NCT04276077|Experimental|Low-frequency electrical muscle stimulation|
10132067|NCT04276077|No Intervention|Control|
10132068|NCT04276090|Experimental|Colorectal liver metastases|Patients with unresectable colorectal liver metastases will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (FOLFOX, FOLRIRI, or oxaliplatin/irinotecan, or panitumumab if KRAS/NRAS wild type)
10132069|NCT04276090|Experimental|Intrahepatic cholangiocarcinoma|Patients with unresectable intrahepatic cholangiocarcinoma will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (gemcitabine/oxaliplatin or gemcitabine alone)
10132070|NCT04276155|Experimental|Device|Acute Coranary Syndrome and de novo Atrial Fibrilation patients treated by DAPT only, in association with an implantable cardiac monitoring device and a follow-up by telecardiology. The anticoagulant treatment will only be administered to patients presenting a recurrence of Atrial Fibrilation
10132071|NCT04276155|No Intervention|Control|Acute Coranary Syndrome and de novo Atrial Fibrilation patients with standard management: DAPT in association with an anticoagulant treatment.
10132072|NCT04276129|Experimental|post-surgical CHX mouth-rinses (treatment group - CHX)|periodontal surgery + post-surgical CHX mouth-rinses + buccal attached gingival (G) biopsies 24 hr after surgical procedure
10132073|NCT04276129|Other|NO post-surgical mouth-rinses treatment (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
10132074|NCT04276025||German cohort Bayreuth|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
10132075|NCT04276025||German cohort Hof|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
10132076|NCT04276025||Chinese cohort Beijing|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
10132077|NCT04275986|Experimental|Experimental arm|Endoscopic resection+ concurrent chemoradiotherapy
10132078|NCT04276064|Experimental|Patients with insomnia|Patients with insomnia disorder according to DSM-5 criteria
10132079|NCT04276064|Experimental|Healthy controls|Healthy controls
10132080|NCT04275687|Experimental|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost. Concurrent chemotherapy consists of weekly docetaxel and nedaplatin."
10132081|NCT04275960|Experimental|Arm_25 + 75 mg (Fasted)|Healthy male participants receive a single dose of 25 mg selitrectinib (Period 1) and 75 mg selitrectinib (Period 2) in fasted state.
10132082|NCT04275960|Experimental|Arm_50 + 50 mg (Fasted/Fed)|Healthy male participants receive a single dose of 50 mg selitrectinib in fasted state (Period 1) and 50 mg selitrectinib in fed state (Period 2).
10132083|NCT04275960|Experimental|Arm_100 + 150 mg (Fasted)|Healthy male participants receive a single dose of 100 mg selitrectinib (Period 1) and 150 mg selitrectinib (Period 2) in fasted state.
10132084|NCT04275830|Experimental|Baseline and HRVB+DS group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to HRVB+DS arm. This group will receive a standardized HeartMath© Inner balance device and HRV biofeedback training session at the start of the two-week intervention period. They will be asked to attend either a group or one-on-one 30-minute HRVB training session and asked to practice their HRV biofeedback skills at home for 10 minutes each day for a two-week period. Participants will also be asked to watch four digital stories of other HCT patients (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
10132085|NCT04275830|Other|Baseline and HRVB waitlist +DS control group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to HRVB waitlist +DS control arm. After the baseline data collection, during two weeks, they will be provided four digital stories of other HCT patients sharing their experiences (challenges, feelings, strategies, coping, each 2-3 minutes long). At the end of the two-week period, participants will be scheduled for a final in-person session including T2 survey and HRV assessment. They will be also provided HRVB training session at T2.
10132086|NCT04275765|No Intervention|Arm 1: Routine Care|Participants will undergo routine care but take part in assessments.
10132087|NCT04275765|Active Comparator|Arm 2:Behavioral Intervention with nudges & Facebook|Participants will receive nudges and be enrolled in social media platform.
10132088|NCT04275765|Active Comparator|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
10132089|NCT04276038|Active Comparator|Active LLLT|"Patients will self-treat at home (active or sham), twice a day (excluding Weekends) for 1 month. The duration of each session will be 15-20 minutes and will include treatment over painful point on the knee and over regional lymph nodes (popliteal, inguinal). The treatment dose should be initiated gradually for the first week until reaching the maximum dose of 6-8 minutes per treatment point. This is the recommended dose for near infrared lasers for the indication of knee pain by the World Association for Laser Therapy (WALT). In the first days an increase in pain may be felt before the reduction in pain. If the increase in pain continues for more than a week under graded dosimetry, the treatment must be stopped.~Laser therapy will be administered to the patients in addition to standard of care therapy as customary in our institution."
10132090|NCT04276038|Sham Comparator|Sham LLLT|Half of the LLT devices will be not activated at random before the application to the patients. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device.
10132091|NCT04275804|Active Comparator|Control group: conventional dressing|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Dressing by a specialized wound-nurse is the current gold-stand of treatment for diabetic ulcers.
10132092|NCT04275804|Experimental|Vibration group: conventional dressing and LMHFV|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Alternate dat 20-week course of whole-body vibration therapy Alternate day 20min sessions on a self-designed vibration platform with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm). Since the participants will return for dressing change on alternate days, the vibration group will also undergo the LMHFV on the same attendance.
10132093|NCT04275934||Cohort|This project will evaluate the impact of self-insured employers implementing an innovative care model utilizing pharmacist-delivered MTM services for health plan beneficiaries with high blood pressure.
10132094|NCT04275895|Experimental|Prematurely born Children|"Evaluation of different attention or/and postural activities :~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~Child perception of the vertical compared to the real vertical~Evaluation of the posture of the child during different visual conditions~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
10132095|NCT04275895|Active Comparator|Term born Children|"Evaluation of different attention or/and postural activities~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~Child perception of the vertical compared to the real vertical~Evaluation of the posture of the child during different visual conditions~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
10132096|NCT04275609|Experimental|Artificial Intelligence generating endoscopic report|In this group, the endoscopic report was generated by artificial intelligence (AI) based on the structured diagnostic report generation system.
10132097|NCT04275609|Active Comparator|Physicians writing endoscopic report|In this group, the endoscopic report was writing by physicians.
10132098|NCT04275921|Experimental|Study participants cohort I|3 stage III NSCLC patients receiving radiotherapy will be imaged, each for a single MRI session using TWIST and HASTE sequences.
10132099|NCT04275921|Experimental|Study participants cohort II|12 patients will be imaged, each for two MRI sessions taking place during the radiotherapy schedule and separated by at least a week.
10132100|NCT04276012|Experimental|Intervention group|The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)
10132101|NCT04276012|No Intervention|Control group|Usual clinical care
10132102|NCT04275648|Experimental|Asthmatuner field tests vs laboratory tests|Each participant will perform two standardized field tests either before or after Eucapnic Voluntary Hyperpnea or Methacholine bronchial provocation test. In addition, unstandardized field tests will be performed in case of exercise induced respiratory symptoms.
10132103|NCT04275739|Experimental|Experimental: Episodic Future Thinking|
10132104|NCT04275739|Active Comparator|Control: Vivid Memory Task|
10132105|NCT04275947||Training|
10132106|NCT04275947||Validation|
10132107|NCT04275596|Active Comparator|2QR complex|Patients who undergo anal surgery will apply 2QR complex topical agent on the wound until healing
10132108|NCT04275596|Active Comparator|Placebo|Patients who undergo anal surgery will apply placebo cream on the wound until healing
10132109|NCT04275713|Experimental|Standard Chemoradiotherapy +/- metformin|Metformin will be given orally at doses of 850 mg twice a day. Metformin will be started one week prior to the start of standard cisplatin-based chemoradiotherapy, and will be continued throughout the entire radiation treatment
10132110|NCT04275713|Active Comparator|Standard chemoradiotherapy|"Standard chemoradiotherapy is given as a combination of EBRT and IGT:~45 Gy in 1.8 Gy/fraction to the pelvis/abdomen, 5 fractions/week~55-57.5 Gy in 2.2-2.3 Gy/fraction to pathological lymph nodes as a simultaneously integrated boost (SIB)~4 fractions of brachytherapy, 7.8 Gy/fraction, to the cervix~Concomitant Cisplatin weekly during the external beam radiotherapy (EBRT)"
10132111|NCT04275635||Children with myopia|A total of 3,000 children from Zhongshan Ophthalmic Center is required to undergo ophthalmic examinations and complete questionnaires at baseline and 1yr after wearing Ortho-K.
10132112|NCT04275414|Experimental|bevacizumab plus standard care|Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.
10132113|NCT04275570|Active Comparator|Motivational Interview.|Repeated motivational interview during prenatal care visits
10132114|NCT04275570|No Intervention|Usual intervention|Usual intervention
10132115|NCT04275453|Experimental|Ketogenic diet - 24 hours|Subjects will undergo FDG PET/CT after 1 day of dietary modification (ketogenic diet for at least 3 meals) and 12 hours of fasting prior to FDG injection.
10132116|NCT04275453|Experimental|Ketogenic diet - 72 hours|Subjects will then undergo FDG PET/CT after 3 day of dietary modification (ketogenic diet for at least 9 meals) and 12 hours of fasting prior to FDG injection.
10132117|NCT04275453|Experimental|Exogenous ketone ester|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants. The KE drink will be administered approximately 45 minutes prior to FDG injection as concentrations of ~3 mmol/L are reached within 60 minutes . By way of comparison, website marketing of the commercial drink recommends ingestion 30 minutes prior to athletic performance. We will also perform echocardiography immediately before and 30 minutes after the drink.
10132118|NCT04275583|Experimental|TQB3602 capsule|TQB3602 capsule administered orally on day 1, 8, 15 in 28-day cycle.
10132119|NCT04275622|Experimental|Intervention|Intervention group receives lifestyle intervention for hypertriglyceridemia.
10132120|NCT04275622|No Intervention|Control|Control group receives regular surveillance.
10132121|NCT04275518|Experimental|APG-115/APG-115+Cytarabine in Relapse/Refractory AML|
10132122|NCT04275518|Experimental|APG-115/APG-115+Aza in relapsed/progressed high risk MDS|
10132123|NCT04275375||hyperbaric bupivacaine|The dosage of hyperbaric bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
10132124|NCT04275375||plain bupivacaine|The dosage of plain bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
10132125|NCT04275375||bupivacaine with intrathecal fentanyl|The dosage of bupivacaine with intrathecal fentanyl decided by the clinical anesthesiologist. This study is an observational study.
10132126|NCT04275466|Experimental|necrotic cavity lavage|This arm was performed necrotic cavity lavage after debridement
10132127|NCT04275466|No Intervention|non-necrotic cavity lavage|This arm was not performed necrotic cavity lavage after debridement
10132128|NCT04275479||SDS - without Diabetes diagnosis|SDS - without Diabetes diagnosis
10132129|NCT04275479||SDS with Diabetes Diagnosis|SDS with Diabetes Diagnosis
10132130|NCT04275479||Cystic Fibrosis (CF) patients data & lab results|De-identified data from age matched population norms, CF patients associated pancreatic insufficiency known or treated diabetes
10132131|NCT04275388||Xiyanping injection +other drugs|Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
10132132|NCT04275388||other drugs|Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
10132133|NCT04275505|Active Comparator|treatment group|the participants were given 10 sessions of shortwave diathermy treatment and elbow splint and told to avoid symptom provoking activities
10132134|NCT04275505|Placebo Comparator|control group|the participants were given 10 sessions of placebo shortwave diathermy treatment (the device was not turned on), elbow splint and told to avoid symtpom provoking activities
10132135|NCT04275284||PCV10 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks and 9 months of age.
10132136|NCT04275284||PCV13 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks and 9 months of age.
10132137|NCT04275284||PCV10 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 14 weeks and 9 months of age.
10132138|NCT04275284||PCV13 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 14 weeks and 9 months of age.
10132139|NCT04275284||PCV10 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
10132140|NCT04275284||PCV13 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
10132141|NCT04275271|Experimental|Intervention group|Intervention group will be received sexuality teaching skills for promotion of professional competence based on information, motivation and behavioral skills model for adolescent sexuality after signing informed consent form and being informed about the goals and details of intervention for 6 sessions (one two hour session per week).
10132142|NCT04275271|No Intervention|Control group|The control group will not receive any intervention until the end of the research.
10132143|NCT04275401||patients|patients with clinical presentions of change in muscle tone
10132144|NCT04275401||volunteers|healthy volunteers with normal muscle tone
10132145|NCT04275258|Experimental|Intervention group|"Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge. In addition, subjects will receive:~A face-to-face meeting prior to discharge where the PA will discuss with the subject their individualized pain management plan and individualized opioid taper plan.~PA will contact subject on the phone within the first week after hospital discharge to ensure subject plans to follow up with PCP and to troubleshoot any subject concerns related to pain management."
10132146|NCT04275258|No Intervention|Control group|Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge.
10132147|NCT04275206|Experimental|Medicinal water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in tap water.)
10132148|NCT04275206|Placebo Comparator|Tap water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in medicinal water.)
10132149|NCT04275219|Experimental|Tong-Fu-Xing-Shen herbal formula|Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.
10132150|NCT04275219|Placebo Comparator|The Placebo of Tong-Fu-Xing-Shen herbal formula|The Placebo of Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12 days.
10132151|NCT04275492|Experimental|Fasting group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects were given 1 tablet of test preparation (T) orally and 240mL warm water on an empty stomach, and the other 15 subjects were given 1 tablet of reference preparation (R, Siforl®) orally and 240mL warm water on an empty stomach.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
10132152|NCT04275492|Experimental|Feeding group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects took 1 tablet of the test preparation (T) orally and 240mL warm water about 30min after the high-fat meal, and another 15 subjects took 1 tablet of the reference preparation (R, Siforl®) orally and 240mL warm water about 30min after the high-fat meal.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
10132153|NCT04275440|Experimental|Exercise group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
10132154|NCT04275440|Experimental|Caloric restriction group|The caloric restriction plan will be designed based on individual basal metabolic rate.
10132155|NCT04275440|Experimental|Combined intervention group|Participants will receive both exercise and caloric restriction intervention at the same time.
10132156|NCT04275362||DJO subjects for surgical technique|Subjects who meet the inclusion criteria and receive a DJO Empowr total knee replacement but will not participate in motion data collection
10132157|NCT04275362||DJO subjects for data collection|Subjects who meet the inclusion criteria and consent to be in the study will receive a DJO Empowr total knee replacement and participate in motion data collections at pre-op, and 6 and 12 months post-op. Subjects will also participate in pre-op, 6 month, 1 year, 2 year, 5 year, and 10 year post-op clinical data collections
10132158|NCT04275362||Prospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
10132159|NCT04275362||Stryker TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Stryker Triathlon total knee replacement and participated in motion analysis pre-surgery and 6 and 12 months post-surgery.
10132160|NCT04275362||Biomet TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Biomet Vanguard total knee replacement and participated in motion analysis pre-surgery and 12 months post-surgery.
10132161|NCT04275362||Retrospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
10132162|NCT04275427|Experimental|study laser group|laser therapy on knee for 2 weeks
10132163|NCT04275427|No Intervention|control group|no intervention
10132164|NCT04275349||Exposure group(continuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)
10132165|NCT04275349||Exposure group(uncontinuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )
10132166|NCT04275349||Completely unexposed group|xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)
10132167|NCT04275349||Incompletely unexposed group|xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital
10132168|NCT04275037|Experimental|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
10132169|NCT04275037|Active Comparator|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
10132170|NCT04275037|No Intervention|Control Group|The control group will receive usual medical care
10132171|NCT04275115|Experimental|Foliglurax|Foliglurax, iv midazolam and cocktail of CYP450 probe substrates
10132172|NCT04275076|Experimental|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate
10132173|NCT04275076|Experimental|bipolar transurethral enucleation of the prostate|bipolar transurethral enucleation of the prostate
10132174|NCT04275050|Experimental|TQB3303 Tablet|TQB3303 Tablet administered orally once. Then TQB3303 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
10132175|NCT04275193|Experimental|Zishenqing|The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks
10132176|NCT04275193|Placebo Comparator|Placebo|The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks
10132177|NCT04275180|No Intervention|control|Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
10132178|NCT04275180|Experimental|Argatroban group|Argatraban is used on the basis of standard medical treatment.
9694636|NCT04787055|Experimental|Receiver in the canal hearing instrument|Group of subjects who will get the receiver in the canal hearing instrument for a 6 month period.
9694637|NCT04786782||Three-dimensional reconstruction group|Portal hypertension is controlled with upper endoscopic screening and vPPG was detected by the noninvasive PPG-detecting software
10132179|NCT04275167|Experimental|Feasibility of TCE and TNE|Feasibility is measured by the number of participants that we have successfully deployed the Trans-nasal imaging device/Tethered capsule device in.
9694638|NCT04786782||Natural follow-up group|Portal hypertension is controlled with the most updated guideline for clinical practice, namely, cirrhotic patients with either liver stiffness measurement >15kPa or PLT<150*10^9 should be screened with upper GI endoscopy and treated according to endoscopic results
10132180|NCT04274959|Active Comparator|ceramic onlay with shoulder preparation design.|posterior ceramic onlay restoration with shoulder design with 1 mm shoulder thickness
10132181|NCT04274959|Experimental|ceramic onlay with butt joint preparation design|posterior ceramic onlay with butt joint preparation design with flat occlusal reduction with inclined surface
10132182|NCT04275102|Experimental|Three times weekly symptom screening|Three times weekly symptom reporting by guardians and children using the SPARK platform for 8 weeks
10132183|NCT04275011|Active Comparator|Static Posture and Balance Exercise|Participants in the control group will receive equal attention through a static posture and balance exercise class two times per week, in a small group setting.
10132184|NCT04275011|Experimental|Progressive Resistance and Impact Exercise|The exercise program will include two progressive resistance and impact exercise training sessions per week in a small group setting. Exercises will be individually tailored to the participants' abilities and designed to achieve a maximum 80-85% 1RM.
10132185|NCT04274933|Experimental|Dose Escalation: Venetoclax and Capecitabine|Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
10132186|NCT04274933|Experimental|Dose Expansion: Venetoclax and Capecitabine|Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
10132187|NCT04274946|Active Comparator|RAI+PB+US|Sentinel lymph node mapping with dual tracer (radioisotope and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
10132188|NCT04274946|Experimental|RAI+ICG+US|Sentinel lymph node mapping with dual tracer (radioisotope and ICG) and intraoperative ultrasound to identify SLN in the breast cancer patients
10132189|NCT04274946|Experimental|RAI+PB+ICG+US|Sentinel lymph node mapping with triple tracer (radioisotope,ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
10132190|NCT04274946|Experimental|PB+ICG+US|Sentinel lymph node mapping with triple tracer (ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
10132191|NCT04275128||Conventional Genicular Ablation|This group is scheduled to receive conventional genicular ablation to treat their chronic knee pain.
10132192|NCT04275128||Cooled radiofrequency Ablation|This group is scheduled to receive cooled radiofrequency ablation to treat their chronic knee pain.
10132193|NCT04274985||1|Patients with temporomandibular disorders
10132194|NCT04275245|Experimental|Meplazumab|10mg Meplazumab by intravenous infusion, every day for 2 days
10132195|NCT04274920|Experimental|Bioactive Glass|18 teeth were capped indirectly with dental adhesive containing bioactive glass applied according to the manufacturer's instructions and cured for 20 seconds and then resin composite restoration containing bioactive glass applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
10132196|NCT04274920|Active Comparator|Light cured calcium hydroxide|18 teeth were capped indirectly with light cured calcium hydroxide (control group) applied according to the manufacturer's instructions by calcium hydroxide applicator and light cured for 20 seconds then resin composite restoration was applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
10132197|NCT04274998|Experimental|patient with Alzheimer disease|Patient is diagnosed with Mild Cognitive Impairment or Alzheimer's disease.
10132198|NCT04274998|Experimental|Healthy volunteer|Subject must be a Healthy.
10132199|NCT04274868||Children and adolescents with liver tumor|Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.
10132200|NCT04274972||Pancreaticoduodenectomy patients|All patients, affected by a resectable PDAC of the head of the pancreas, visited at the Department of Pancreatic Surgery of Verona, will be enrolled. All the patients must be scheduled for an elective PD. The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated.
10132201|NCT04275024|Experimental|Experimental group|"AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.~The basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
10132202|NCT04275089|Experimental|Reia Vaginal Pessary|
10132203|NCT04274907|Experimental|Dose Escalation Phase: Venetoclax + Pembrolizumab|Participants will receive escalating doses of venetoclax in combination with pembrolizumab Dose A.
10132204|NCT04274907|Experimental|Randomization Phase: Venetoclax + Pembrolizumab|Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab Dose A.
10132205|NCT04274907|Active Comparator|Randomization Phase: Pembrolizumab Monotherapy|Participants will receive pembrolizumab Dose A
10132206|NCT04274842|Other|D-OCT image observational|Patients clinically eligible for IPL treatment of facial telangiectasia were D-OCT scanned before, after, 1-3 days after and 1 month after treatment
10132207|NCT04274608|Experimental|Intervention Arm|"Patients in the intervention arm will receive 300units of Botulinum Toxin A (Botox; Allergan Inc., Irvine, Ca, USA) diluted to 10mls of saline. Endoscopy will be performed using a single-lumen gastroscope. Injection of the solution will be done using a 23Gauge Interject needle catheter. 20 separate injections of 0.5ml each will be performed in a concentric ring 1cm apart. 10 injections will be performed into the body of the stomach, and 10 injections into the fundus, from the level of the CEJ and above~Patients will undergo a 12-week weight management program approximately 2 weeks after the injection of Botox."
10132208|NCT04274608|Active Comparator|Control Arm|Patients will undergo a 12-week weight management program.
10132209|NCT04274595|Experimental|Psoriasis patients|
10132210|NCT04274530|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy (CBT). Participants will complete a series of online modules via a mobile application in addition to standard of care for their fracture injury. Participants will be assigned a dedicated CBT therapist, and receive feedback and support from their therapist via in-app messaging. The CBT program will last approximately 6-8 weeks.
10132211|NCT04274530|No Intervention|Control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
10132212|NCT04274660|Experimental|DWELL Intervention|People with type 2 diabetes participating in the 12-week DWELL (Diabetes and WELLbeing) Programme
10188056|NCT03720041|Active Comparator|R1: IRD induction therapy (reactive)|In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol.
10132213|NCT04274660|No Intervention|DWELL non-intervention/Control|People with type 2 diabetes who are receiving routine care from their GP and healthcare team. People with type 2 diabetes will continue to receive routine standard care. Routine care in this respect constitutes usual health and social care or any other nationally or locally commissioned education programmes
10132214|NCT04274647|Experimental|Device and Control|"NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose. 0.2ml"
10132215|NCT04274504||patients|metatstatic breast
10132216|NCT04274816|Experimental|Tremelimumab|Intradermal injection of tremelimumab at the primary melanoma excision site, 7 days prior to sentinel node biopsy (SNB), with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
10132217|NCT04274803|Experimental|Intralipid group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily. In addition intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
10132218|NCT04274803|Active Comparator|Standard care group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
10132219|NCT04274478|Other|Single group|
10132220|NCT04274829||PTMC|Patients with papillary microcarcinoma of the thyroid
10132221|NCT04274569|Active Comparator|Sodium fluoride (NaF)|Group 1: Quarterly application of a 5% NaF varnish (Duraphat® Varnish, Colgate-Palmolive Ltd, (UK) Ltd., Guildford, Surrey, UK)
10132222|NCT04274569|Experimental|NaF plus tricalcium phosphate (TCP )|Group 2: Quarterly application of 5% NaF-TCP (ClinproTM White Varnish; 3M ESPE, St Paul, MN, USA)
10132223|NCT04274569|Experimental|NaF plus CPP-ACP|Group 3: Quarterly application of a 5% NaF plus casein phosphopeptide-stabilized amorphous calcium phosphate complexes (CPP-ACP) (MI Varnish TM; GC corporation, Itabashi-Ku, Tokyo, Japan)
10132224|NCT04274634||Conditions with predisposition to lens oscillations|Marfan Syndrome and Pseudoexfoliation
10132225|NCT04274634||Age-matched with normal axial lengths|
10132226|NCT04274634||Age-matched with extreme axial lengths|
10132227|NCT04274634||Intraocular lens|
10132228|NCT04274634||Pre- and post- cataract surgery|
10132229|NCT04274634||Normals|
10132230|NCT04274790||Metastatic colon cancer|Patient with metastatic colon cancer operated on and followed up at the Centre Leon Berard for liver metastasis.
10132231|NCT04274686|Experimental|Tegaderm application|Patients will receive bag-mask ventilation with Tegaderm placement.
10132232|NCT04274686|Active Comparator|No Tegaderm|Patients will receive bag-mask ventilation without Tegaderm placement.
10132233|NCT04274738|Experimental|Mavorixafor and Ibrutinib|Each participants will initially receive mavorixafor at Dose Level 1 (200 mg QD) in combination with ibrutinib 420 mg. Cohort A will comprise the first 6 participants enrolled in the study that complete at least their first cycle at Dose Level 2 (400 mg QD). Cohort A participants will start at Dose Level 1 and be allowed to dose escalate after the first cycle to Dose Level 2, if no DLTs are observed during the first cycle of each participant. Cohort B will comprise the next 6 participants enrolled into the study that complete at least their 1st cycle at Dose Level 3 (600 mg QD). Cohort B participants will start at Dose Level 1 and be allowed to dose escalate up to Dose Levels 2 and 3. Cohort C will comprise the remainder of participants enrolled up to the total of 18. Cohort C participants will start at Dose Level 1 and be allowed to escalate to 400 and 600 mg after each dose level has been deemed safe by participants from Cohort A and B.
10132234|NCT04274543|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of normal saline (0.9%) solution into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
10132235|NCT04274543|Active Comparator|Saline|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
10132236|NCT04274439|Experimental|Internet-Based Pain Education and Exercise|"Patients allocated to the intervention group will receive a login and password for individual access to the website designed for the study. The content of this intervention will include videos and animations based on pain education, physical activity promotion and general exercises. The pain education component will be based on the E-pain intervention developed by Reis et al (2017), which includes nine main features: (1) acceptance, (2 and 3) education about pain, (4) sleep hygiene, (5) recognizing stress and negative emotions, (6) increasing positive coping in lifestyle, (7) exercises, (8) communication and (9) relapse prevention. The exercise component will include general exercises aiming to improve strength, flexibility, control and coordination.~Patients in this group will also receive weekly text messages and a health coaching over the telephone. The text messages will include information on the benefits of exercises, motivation, and positive messages about dealing with pain."
10132237|NCT04274439|Active Comparator|Online Booklet|The patients allocated to the control group will have access to an online booklet containing general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. They will also receive one phone call at week 4 and text messages once a week during the study period.
10132238|NCT04274673|Other|low (less 10ng/dl)|Patients who have low cotinine levels (less 10ng/dl)
10132239|NCT04274673|Other|medium (10-500ng/dl)|Patients who have medium cotinine levels (less 10-500ng/dl)
10132240|NCT04274673|Other|high (more 500ng/dl)|Patients who have high cotinine levels (less 10-500ng/dl)
10132241|NCT04274582|Experimental|Chokeberry extract consumption|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
10132242|NCT04274348|Other|Skin biopsies and blood samples|
10132243|NCT04274400||Patients referred for polysomnography|Patients referred for polysomnography will be classified according to the presence of OSA, insomnia or both.
10132244|NCT04274452|Experimental|efgartigimod|Patients receiving an intravenous infusion of efgartigimod
10132245|NCT04274452|Placebo Comparator|placebo|Patients receiving an intravenous infusion of placebo
10132246|NCT04274270|Experimental|experimental group|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
10183937|NCT03759639|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
10183938|NCT03759639|No Intervention|Post-Treatment Washout|After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
10183939|NCT03759626|Active Comparator|pupils benefiting from the impulsive intervention|Secondary school pupils from general secondary schools
10183940|NCT03759626|Active Comparator|pupils benefiting from the reflective intervention|Second year students from general high schools.
10183941|NCT03759613|Experimental|Experimental Group|Thirty subjects with unilateral upper burn injury will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. Their evaluations will be made within 5 days following burn injury.
10183942|NCT03759613|Active Comparator|Control Group|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, they will be asked to walk their natural walking.
10183943|NCT03759613|Sham Comparator|Control Grup (Restricted arm swing)|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, their arms will be fixed with a bandage on their bodies. Their arm swing will be restricted.
10183944|NCT03759574||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
10183945|NCT03759574||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
10183946|NCT03759561|Active Comparator|Videolaryngoscope group|In the videolaryngoscope group, tracheal intubation was performed using videolaryngoscop under cervical collar application.
10183947|NCT03759561|Active Comparator|Fiberoptic bronchoscope group|In the fiberoptic bronchoscope group, tracheal intubation was performed using fiberoptic bronchoscope via oral cavity under cervical collar application.
10183948|NCT03759548||Breast Cancer|Breast Cancer's patients undergoing pharmacological treatments prior or after surgery.
10183949|NCT03759548||Colorectal Cancer|Colorectal Cancer's patients undergoing pharmacological treatments prior or after surgery.
10183950|NCT03759535||Control group and Case group|"Control group:~The allograft kidneys function normally. The rejection of allograft kidneys are excluded. The patients have no infectious complications.~Case group:~There is obvious evidence for acute rejection of the allograft kidneys. The patients have no infectious complications."
10183951|NCT03759509|Experimental|aerobic exercise training|three times a week, a total of twenty-four times in eight weeks
10183952|NCT03759509|No Intervention|control|routine activity
10183953|NCT03759483||AI group|The visual field reports in this group will be evaluated by the convolutional neural network.
10183954|NCT03759483||Human group|The visual field reports in this group will be evaluated by 3 ophthalmologists independently.
10183955|NCT03759470||Evaluation of different methods for diagnosis of meningitis|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperaturetemperature.Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.."
10183956|NCT03759457|Experimental|High Flow Nasal Cannula|High Flow Nasal Cannula is a relatively new technique able to deliver both oxygen and high flow in order to improve oxygenation and waking out CO2 from the upper airways
10183957|NCT03759444||women with eating disorders|"women with eating disorders (age: M = 26.88; SD = 5.82)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
10183958|NCT03759444||healthy female controls.|"healthy female controls (age: M = 24.27; SD = 6.49)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
10183959|NCT03759431|Experimental|Vocal-cord Radiotherapy|
10183960|NCT03759431|Active Comparator|Complete Larynx Radiotherapy|
10183961|NCT03759405|Experimental|Chronic heart failure treatment group|One case of CHF caused by coronary heart disease, one case of CHF caused by dilated heart disease and one case of CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation.
10132247|NCT04274140||Obese Pregnant Women|obese, BMI 30-50
10132248|NCT04274140||Normal weight pregnant women|normal weight, BMI 18.5-25
10132249|NCT04274114|Experimental|Experimental group|Patients in this group will receive flexible doses of L-glutamine ranging from 5 to 25 grams once daily for 8 weeks. L-glutamine is administered as a powder dissolved in water.
10132250|NCT04274114|Placebo Comparator|Placebo group|Patients in this group will receive flexible doses of placebo ranging from 5 to 25 grams once daily for 8 weeks. Placebo is administered as a powder dissolved in water.
10132251|NCT04274101||Nifurtimox|Patients treated with Nifurtimox from 1984 to 2017
10132252|NCT04274101||Benznidazole|Patients treated with Benznidazole from 1984 to 2017
10132253|NCT04274166|Experimental|Experimental|2 s.c. secukinumab 150 mg injections
10132254|NCT04274387|Experimental|MBSR group|participants who receiving 8-week MBSR between the pretest and posttest
10132255|NCT04274387|No Intervention|passive control group|participants who not undergoing any interventions for 8 weeks between the pretest and posttest
10132256|NCT04274205|Active Comparator|Influence on brief supportive psychotherapy|Intervention group
10132257|NCT04274205|Active Comparator|Influence of brief supportive psychotherapy|Control group
10132258|NCT04274309||Patient's tissues exposed|Tonsil of each patient will be imaged using the medical device
10132259|NCT04274309||Patient's tissues not exposed|Tonsil of each patient will not be imaged using the medical device
10132260|NCT04274413|Experimental|Interventional Arm|All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
10132261|NCT04274257|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
10132262|NCT04274257|Experimental|Double-Blind Rituximab|Participants will receive double-blind rituximab from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
10132263|NCT04274179|Experimental|Diet therapy|Modified Atkins Diet - high fat, low carbohydrate, outpatient initiated approach. Parents will check urine ketones twice weekly and follow by email, phone and clinic. Labs at baseline and 3 months. Dietitian support.
10132264|NCT04274179|Active Comparator|Drug therapy|Families will have the usual care for absence epilepsy at the discretion of the family's neurologist and the family choice. Typically ethosuximide bis in die (BID), however, if convulsions have occurred or other factors are involved, the child may be started on valproate or lamotrigine. The child will continue medications with dose adjustment and antiseizure drug levels checked as usual.
10132265|NCT04274088||Tecnis;|Patients who received the Tecnis multifocal IOL.
10132266|NCT04274088||Diffractiva|Patients who received the Diffractiva multifocal IOL.
10132267|NCT04274764|Experimental|Personalized eHealth Education & Motivational Interviewing|Personalized eHealth Glaucoma Education & Motivational Interviewing
10132268|NCT04274764|No Intervention|Standard Education|Participant will receive standard glaucoma education.
10132269|NCT04274036||Fibromyalgia Patients|Fibromyalgia patients diagnosed according to the 2016 American College of Rheumatology criteria.
10132270|NCT04274036||Healthy-Controls|Healthy controls without pain or chronic illness
10132271|NCT04273971|Experimental|Plyometric exercise|
10132272|NCT04273893|Experimental|SBRT Additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
10132273|NCT04273893|Active Comparator|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
10132274|NCT04273906|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
10132275|NCT04273906|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
10132276|NCT04273880|Experimental|10 mg Psychostimulant|Drug: Methylphenidate (MPH) Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 10mg of MPH an hour and a half before the testing session is set to begin, to account for the time taken for the effects of the drug to start.
10132277|NCT04273880|Placebo Comparator|90 mg Vitamin C|Placebo: Vitamin C Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 90mg of Vitamin an hour and a half before the testing session is set to begin, to follow the exact protocol that is used for MPH.
10183962|NCT03759353|Active Comparator|Lactoferrin Group|Includes 49 pregnant women receiving lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin (R) , Hygint pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
9669064|NCT04192760|Active Comparator|DK-Crush Technique|"Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed).~After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment)."
9669065|NCT04185610|Experimental|Qi Gong|Weekly QiGong for Chemotherapy-Induced Neuropathy classes for 10 weeks
9669066|NCT04183335|Experimental|Dupilumab|Dose regimen 1 on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
10132278|NCT04273997|Active Comparator|Metronidazole Ointment|"Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.~One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound"
10132279|NCT04273997|Placebo Comparator|Placebo Ointment|"Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.~One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound."
10132280|NCT04273919|Sham Comparator|Mindfulness Mediation|Subjects will undergo virtual reality in a non-embodied (no first person bodily experience) program called Lumen, which was developed by Stanford University's Virtual Human Interaction Lab.
10132281|NCT04273919|Experimental|Graded Motor Imagery|The subjects will engage in 2 therapeutic modules intended to help them practice increasing range of motion safely, and using small movements of the lower back.
10132282|NCT04274244|Experimental|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"The study participants will first undergo SCALE AND ROOT PLANING. This procedure is the same as that used in the active comparator group and the control group.~Eight weeks following the initial therapy, reevaluation of the intrabony defects in the interproximal sites with a clinical probing depth >5 mm will be performed by radiographs as well as by using William's graduated periodontal probe to confirm the indication for periodontal surgery. Pairs of premolar and molar teeth in the maxilla or the mandible will be randomized to receive the test treatment (REGENERATIVE PERIODONTAL SURGERY with adjunctive hyaluronic acid gel application) or to serve as active comparators (regenerative periodontal surgery with adjunctive enamel matrix derivative application)."
10132283|NCT04274244|Active Comparator|Enamel Matrix Proteins|"SCALE AND ROOT PLANING~REGENERATIVE PERIODONTAL SURGERY: Application of enamel matrix derivative."
10132284|NCT04274244|No Intervention|Scale and root planning|Control group: Just SCALE AND ROOT PLANING is performed
10132285|NCT04274127|Other|children aged 16 to 24|estimate the positive predictive value of an early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
10132286|NCT04274153|Experimental|Gardasil9|Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
10132287|NCT04274322||Cohort 1|High NUTRIC score
10132288|NCT04274322||Cohort 2|low NUTRIC score
10132289|NCT04273984|Active Comparator|1- Group 1 (misoprostol 200 mcg|"Group 1 :will take 1 tablet (200 mcg) of misoprostol and 1 placebo tablet,~.,"
10132290|NCT04273984|Active Comparator|2- Group 2 (misoprostol 100 mcg)|Group 2: will take1 tablet (100 mcg) of misoprostol and 1 placebo tablet,
10132291|NCT04273984|Placebo Comparator|3- Group 3 (placebo group)|Group 3 ): will take2 placebo tablets
10132292|NCT04274062||peri partum integrated nursing care of placenta previa|"Part (1) personal data:~Part (2) baseline and characteristics of the patients participants:~Tool II- An observation checklist: This tool is develop by researcher according to guideline of Royal College of Obstetricians and Gynaecologists, 2018), and divide into three main parts: preoperative, intraoperative and postoperative.~Part (1) pre-operative: includes assessment of :~patients general condition~investigation~reserved blood~Hemoglobin level~Impact of hysterectomy option. -9-~Part (2) Intra-operative:~Includes assessment of :-~Investigation~Vital signs~Hypothermia~Blood loss~I.V fluid~Blood gases~Fetal condition and APGAR score.~Part (3) Post-operative: Includes:~maternal complication~fetal complication~psychological satisfaction"
10132293|NCT04274062||peri partum regular care of placenta previa|Routine nursing care of all cases of placenta previa (preoperative, intraoperative and postoperative)..
10132294|NCT04273841|Active Comparator|Caffeine Group|This group will receive caffeine gum.
10132295|NCT04273841|Placebo Comparator|Placebo|This group will receive gum without caffeine.
10132296|NCT04273789|Experimental|far infrared reflecting sleepwear|Sleepwear (shorts + tshirt) with far infrared reflecting ceramic print produced by Dagsmejan AG (Zurich, Switzerland)
10132297|NCT04273789|Placebo Comparator|Placebo sleepwear|Sleepwear (shorts + tshirt)
10132298|NCT04273698|Experimental|Clinical intervention|The project involved recruiting families, with children under the age of five years old, who were experiencing one or more difficulties, and these families were offered five therapeutic sessions, based on a psychodynamic parent-infant psychotherapy approach.
10132299|NCT04273776|Active Comparator|Suvorexant Arm|10 mg of Suvorexant
10132300|NCT04273776|Active Comparator|Zolpidem Arm|5 mg of Zolpidem
10132301|NCT04273776|Placebo Comparator|Placebo|10mg of Avicel
10132302|NCT04273958|Experimental|Virtual reality|The intervention will consist of the use of a virtual reality helmet during the painful medical procedure. The content has been developed by a private company with the goal of providing a relaxing and soothing exploration of a virtual world.
10132303|NCT04273958|Active Comparator|Computer screen|The comparator will consist in the screening of the same virtual world on the computer screen.
10132304|NCT04273763|Experimental|Group A|Treatment group
10132305|NCT04273763|Active Comparator|Group B|Control group
10132306|NCT04273815|Experimental|TQ-A3334 tablets|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle.
10132307|NCT04273815|Experimental|TQ-A3334 tablets + anlotinib capsules|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
10132308|NCT04273568|Experimental|Group1 (PNF group)|Scapular PNF and exercise program was applied to the PNF group.
10132309|NCT04273568|Active Comparator|Group 2 (Exercise group)|Exercise program was applied to the exercise group
10132310|NCT04273659|Experimental|Pulses and Cereal 1|Pulses and cereal 1 containing study product is served. Dietary intervention.
10132311|NCT04273659|Experimental|Pulses and Cereal 2|Pulses and cereal 2 containing study product is served. Dietary intervention.
10132312|NCT04273633|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant shoulder
10132313|NCT04273633|Placebo Comparator|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant shoulder
10132314|NCT04273360|Active Comparator|Systematic use group|
10132315|NCT04273360|Experimental|Restrictive use group|
10132316|NCT04273373|Active Comparator|Standard dose albumin+SOC|20% albumin1.5 g/kg at diagnosis and 1 g. SOC (Standard of Care)
10132317|NCT04273373|Experimental|Low dose albumin+SOC|20% albumin.5 g/kg at diagnosis and 0.5 g/kg. SOC (Standard of Care)
10132318|NCT04273581|Placebo Comparator|Control group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. placebo：100mg/d，qn，for 14 days.
10132319|NCT04273581|Experimental|Thalidomide group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. thalidomide：100mg/d，qn，for 14 days.
10132320|NCT04273464|Experimental|Brava-group|External tissue expanders will be used 3 weeks prior to operation and 2 weeks postoperatively in order to enhance the volume and survival of fat cells. We expect that each patient in the fat transplantation group will need 4-6 transplantation sessions of about 1.5 to 2 hours each to achieve satisfactory volume and shape of the breast.30 participants.
10132321|NCT04273464|Active Comparator|DIEP-group|30 participants. We expect 1-2 operative sessions of respectively 5-7 and 2-3 hours duration in the DIEP group. The risk of reoperation (second operation during the first postoperative week) in the DIEP group is 5-10 %
10132322|NCT04273412|Experimental|lifestyle intervention (LI)|moderate-intensity lifestyle intervention (Individualised counseling on diet, physical activity, and target weight gain) by license dietitian
10132323|NCT04273412|No Intervention|usual standard care group (UC)|standard antenatal care as per usual clinic protocol
10132324|NCT04273399|Experimental|Crohn's Disease|Twelve week jumping based exercise intervention
10132325|NCT04273399|Active Comparator|Controls|Age and sex matched controls will undertake the same twelve week intervention for active comparison between groups
10132326|NCT04273607|Experimental|No anticoagulation|Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin
10132327|NCT04273607|No Intervention|Anticoagulation, ECMO standard of care|Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.
10132328|NCT04273646|Experimental|UC-MSCs Treatment Group|"Conventional treatment plus UC-MSCs:~Participants will receive conventional treatment plus 4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1，Day 3，Day 5，Day7)."
10132329|NCT04273646|Placebo Comparator|Conventional Control Group|"Conventional treatment plus Placebo:~Without UC-MSCs Therapy but conventional treatment should be received. Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day 1，Day 3，Day 5，Day7)."
10132330|NCT04273620|Experimental|Intervention-Control (IC)|In the Intervention-Control (IC) arm, patients will first receive the intervention (OKS-READ) containing 15 individual therapy sessions within a maximum time period of 28 days. Afterwards they will receive the control therapy (again 15 sessions within max. 28 days).
10132331|NCT04273620|Active Comparator|Control-Intervention (CI)|In the Control-Intervention (CI) arm, patients will first receive the control therapy (15 sessions within max. 28 days), followed by the intervention phase (15 therapy sessions OKS-READ within a maximum time period of 28 days).
10132332|NCT04273347||patient with brain trauma|all patient with brain trauma in intensive care unit
10132333|NCT04273347||patient with spinal cord injury|all patient with spinal cord injury in intensive care unit
10132334|NCT04273529|Placebo Comparator|Control group|placebo
9528189|NCT03213132|Experimental|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
10132335|NCT04273529|Experimental|Thalidomide group|thalidomide
10132336|NCT04273334|Experimental|68Ga-NEB injection and PET/CT scan|Patients for lymphatic disorders imaging: The patients were subcutaneously injected with 68Ga-NEB and underwent PET/CT scan 20~40min after the injection.
10132337|NCT04273308|Experimental|whole-body vibration training|a 12-week whole-body vibration training that conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time.
10132338|NCT04273503|Experimental|Intervention|All participants will receive education on maintaining a healthy diet and improving physical activity.
10132339|NCT04273321|Experimental|MP group|
10132340|NCT04273321|No Intervention|Con group|
10132341|NCT04273295|No Intervention|the control group|This group receives senna-based laxatives.
10132342|NCT04273295|Experimental|the study group|This group managed by abdominal massage with senna-based laxatives.
10132343|NCT04273282|Active Comparator|Dexycu Group|A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.
10132344|NCT04273282|Active Comparator|Control Group|A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
10132345|NCT04272996|Other|surgery alone|craniotomy for SDH evacuation
10132346|NCT04272996|Active Comparator|Surgery plus embolization|surgery for evacuation of SDH followed by embolization of middle meningeal vessel
10132347|NCT04272866|Active Comparator|Group 1|Teeth in this group will be sealed with clinpro sealant
10132348|NCT04272866|Experimental|Group2|Teeth in this group will be sealed with embrace wetbond sealant
10132349|NCT04272866|Experimental|Group3|Teeth in this group will be sealed with triage sealant
10132350|NCT04273113|Experimental|Heart Rate Variance (HRV) biofeedback training|Patients to participate in 15 biofeedback sessions, 3 times a week (5 weeks in total).
10132351|NCT04272944|Experimental|MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W). The planned doses starts at 3 mg/kg to 20 mg/kg, but dose levels or the dosing interval may be adjusted during the study based on emerging data.
10132352|NCT04272970|Active Comparator|New gene / protein variant functional study|Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional familial thrombocytopenia.
10132353|NCT04272970|Sham Comparator|Normal gene / protein variant functional study|"Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to provide control observations / analyses / measures for the Active Comparator arm"
10132354|NCT04273269|Experimental|8x10^12 vg/Kg LYS-GM101|Subjects will receive a single infusion: 8x10^12 vg/Kg LYS-GM101
10132355|NCT04272957|Experimental|HMPL-306|HMPL-306 administered continuously as a single agent orally every day in a 28-day cycle.
10132356|NCT04272892|Experimental|Digital CBT-I|6 weeks digital (online) cognitive behavioural therapy for insomnia
10132357|NCT04272892|Active Comparator|Sleep hygiene information|Leaflet of sleep hygiene information
10132358|NCT04273152||children with allergy|children with allergies
10132359|NCT04273152||healthy control|healthy control (non allergic children)
10132360|NCT04273256|Experimental|Myo-inositol arm|Patients will be supplemented with 2 grams of Myo-inositol + at least 400 μg of folic acid (received from routinely prescribed multivitamins) every day for 3 months before the IVF cycle.
10132361|NCT04273256|No Intervention|Control arm|Patients will receive at least 400 μg of folic acid from routinely prescribed multivitamins every day for 3 months before the IVF cycle.
10132362|NCT04273009|Active Comparator|Renew Anal Insert|The device is intended for self-insertion through the anal canal aided by a fingertip applicator.
10132363|NCT04273009|Active Comparator|Percutaneous tibial nerve stimulation|A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points.
10132364|NCT04273204|Experimental|UCP Group|
10132365|NCT04273204|Other|Control Group|
10132366|NCT04273126|Experimental|Intervention|This arm consists of approximately 8-10 modules lasting approximately one hour and consisting of psychoeducation and core components including communication, problem solving, goal setting, and dealing with stress, tailored to families with experiences of homelessness and parental substance use.
10132367|NCT04273126|No Intervention|Treatment as usual|Families in the standard care condition will receive treatment as usual at their facility, which may include case management at the facility, and mental health services and supportive services from organizations affiliated with the sites.
10132368|NCT04273191|Experimental|Brexanolone|Participants will receive a single dose of commercial brexanolone as part of standard of care.
10132369|NCT04272931|Experimental|Portal and Hepatic Vein Embolization|3 patients per center over one year approximately 90 patients in total. Patients will undergo portal vein and hepatic vein embolization instead of only portal vein embolization.
10132370|NCT04272918|Experimental|CSM condition|Social Worker 1 of CSM conditions will work with caregivers according to the guidelines and template of the Care Support Model, including the formulation of the intervention plan based on CNA scores of different need domains, the use of the caregiver intervention plan template, service matching drawing reference from caregiver resource database, service formulation based on CNA scores of different strength domains, the use of the case monitoring template and guideline.
10132371|NCT04272918|No Intervention|Non-CSM condition|Social Worker 2 of the Control Group will not be notified of the CNA scores of his/her caregivers. The intervention plan, services assignment and case management of participants of the control group will be based on Social Worker 2's own judgement using the information shared by the caregivers, and the social worker's own observation.
10132372|NCT04272918|Experimental|PP-E condition|Experimental Group will be led a consultant who is an expert, with the help of a degree-holder social worker to facilitate capacity building, empowerment and long-term well-being. Measurement of outcome variables will be conducted before the start of the program, at the end of the program, and 3 months after the program ended.
10132373|NCT04272918|No Intervention|Non PP-E condition|Measurement of outcome variables will be conducted at the same point of time as PP-E condition. There will be no treatment or intervention for the control group.
10132374|NCT04273048|Active Comparator|Diet and Exercise|Group 1 = Diet Intervention group: They will be asked to follow a personalized diet during study period and record what they eat. The meal plan for this study is Mediterranean style and nutritionally complete for 8 to 12 weeks or until oocyte retrieval procedure. Exercise Intervention: Exercise 3 times/week at a gym of their choice or at home for 8 to 12 weeks or until oocyte retrieval procedure. Exercises will be light intensity and short duration at first and will gradually increase to moderate intensity and longer duration during the first 3 weeks. They will also be encouraged to walk an average 10,000 steps per day and wear a pedometer to monitor progress.
10132375|NCT04273048|No Intervention|Standard Care|Group 2 = Standard: They will receive standard care from the Little Rock Fertility Center.
10132376|NCT04273217|Experimental|AV-1|Single dose
10132377|NCT04273217|Placebo Comparator|Placebo|Single dose
10132378|NCT04273100|Experimental|Treatment group|The participants will receive the combined treatment of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE, lobaplatin and epirubicin and anti-angiogenic therapy (lenvatinib)
10132379|NCT04272905||Maternity patients|"> 18 years~Post-natal following any form of delivery~Between 4 and 48 hours after delivery~Able to understand English adequately to give consent and complete the questionnaire"
10132380|NCT04272905||Maternity Unit Staff|"Doctors, midwives and other staff~Work on labour ward"
10132381|NCT04273035|Active Comparator|Midazolam Group|"Midazolam(Buccolam 5mg/ml)~0.5mg/kg oral, max 12mg~one time~given 30 min prior to going to holding"
10132382|NCT04273035|Active Comparator|IPAD group|"No premedication~IPAD when arriving at the holding~any games, movies, clips, puzzles"
10132383|NCT04273061|Experimental|Breast Cohort|Cohort of participants whose primary tumour type is breast.
10132384|NCT04273061|Experimental|Lung Cohort|Cohort of participants whose primary tumour type is lung.
10132385|NCT04273061|Experimental|GI Cohort|Cohort of participants whose primary tumour type is gastrointestinal (including pancreas and hepatobiliary).
10132386|NCT04273061|Experimental|GU Cohort|Cohort of participants whose primary tumour type is genitourinary.
10132387|NCT04273061|Experimental|Gyne Cohort|Cohort of participants whose primary tumour type is gynecological.
10132388|NCT04273061|Experimental|Sarcoma Cohort|Cohort of participants whose primary tumour type is sarcoma.
10132389|NCT04273061|Experimental|Primary Unknown Cohort|Cohort of participants whose primary tumour type is unknown.
10132390|NCT04273061|Experimental|Other Cohort|Cohort of participants whose primary tumour type is not classified as one of the other study arms. This cohort includes participants with cancers from the head and neck, skin, or rare cancers.
10132391|NCT04273074|Other|preoperative sonographic assessment group|preoperative sonographic assessment to airway
10132392|NCT04272827|Active Comparator|Intervention group|In the intervention group, patients will receive liposuction treatment (number of surgeries at the discretion of the attending study physician: a maximum of 4 surgical procedures, with a minimum of 5 and a maximum of 7 weeks between each surgery) with concomitant complex decongestive therapy (CDT), if necessary, to maintain surgical outcomes as required by the patient.
10132393|NCT04272827|Other|Control group|"After randomisation, the control group will be treated for 12 months with complex decongestive therapy (CDT) alone.~After these 12 months, patients can opt for liposuction treatment if they continue to meet the inclusion and exclusion criteria."
10132394|NCT04272814|Experimental|Compression therapy|compression therapy
10132395|NCT04272814|Active Comparator|Standard treatment|standard treatment
10132396|NCT04272853||Athletes|440 subjects will be recruited (see calculation of the sample size for details): all subjects will be athletes, professional or non-professional, belonging to any sporting discipline, members of one of the sports federations of the Lombardy region, officially recognized by CONI (National Committee of Italian Olympic Team).
10132397|NCT04272788||CD patients|CD patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.CD patients are followed for 14 weeks after the first administration of infliximab. At week 14 of Infliximab treatment, CD patients are classified as remission group (CDAI<150 and endoscopic mucosal healing, R group) and non-remission group (CDAI≥150 and/or mucosal non-healing group, N group).
10132398|NCT04272788||Healthy controls|Healthy controls without Crohn's Disease.
10132399|NCT04272580|Sham Comparator|Control group|No preload was given before spinal anesthesia
10132400|NCT04272580|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia
10132401|NCT04272580|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
10132402|NCT04272580|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
10132403|NCT04272593|Experimental|Simultaneous Control|Simultaneous pattern recognition style of control allows prosthetic users to actuate more than one hand/arm function on their device at the same time.
10132404|NCT04272593|Active Comparator|Conventional Control|Conventional, seamless sequential pattern recognition style of control allows prosthetic users to actuate a single hand or arm functions on their device at a time.
10132405|NCT04272697||Heterozygous Familial Hypercholesterolaemia|Adults and children with Heterozygous Familial Hypercholesterolaemia.
10132406|NCT04272697||Homozygous Familial Hypercholesterolaemia|Adults and children with Homozygous Familial Hypercholesterolaemia
10132407|NCT04272697||Unaffected (non-FH) relatives of FH individuals|Adults and children with unaffected (non-FH) relatives of FH individuals
10132408|NCT04272645|Experimental|Arm A - Abemaciclib 200 mg|Abemaciclib twice daily. 1 cycle of treatment is 21 days in length.
10132409|NCT04272645|Experimental|Arm B - Abemaciclib 150 mg + atezolizumab|Atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily.
10132410|NCT04272645|Experimental|Experimental: Arm C - Patients with CDK12 loss|"Group 1 - Atezolizumab: Patients with CDK12 loss will receive atezolizumab monotherapy on the first day of each 21-day cycle~Group 2 - Abemaciclib 150 mg + atezolizumab: Patients with CDK12 loss will receive atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily."
10132411|NCT04272658||value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of immune checkpoint inhibitors in metastatic melanoma"
10132412|NCT04272684|Experimental|Interventional|Driving Assessment
10132413|NCT04272398|Active Comparator|Treatment|Used dynamic elastomeric fabric orthoses with physiotherapy and rehabilitation program
10132414|NCT04272398|Experimental|Control|Only physiotherapy and rehabilitation program
10132415|NCT04272567|Sham Comparator|Control group|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
10132416|NCT04272567|Experimental|0.025 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).
10132417|NCT04272567|Experimental|0.05 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).
10132418|NCT04272567|Experimental|0.075 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).
10132419|NCT04272567|Experimental|0.1 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).
10132420|NCT04272528|Experimental|experimental group|Nurses provide uniform care to patients according to the quality standards.
10132421|NCT04272528|Placebo Comparator|control group|Nurses provide the routine care to patients.
10132422|NCT04272476|Experimental|Acupuncture and moxibustion|Acupuncture points: Baihui(GV 20), Mingmen(GV 4), Bilateral Neiguan(PC 6), Bilateral Shenmen(HT 7), Bilateral Hegu(LI 4), Bilateral Zusanli(ST 36), Bilateral Taichong(LR 3). Each treatment takes about thirty minutes,3 times a week(treatment on Monday, Wednesday and Friday) for 8 weeks.
10132423|NCT04272476|Active Comparator|Western medicine|Fluoxetine 20 mg capsule by mouth every day for 8 weeks.
10132424|NCT04272541|Active Comparator|Psychoeducation program|The intervention program consists of psychopharmacology (standard intervention in mental health services) + individual psychoeducation (individual treatment including learning of Healthy Lifestyle). This program is implemented for three months, allocated in several sessions.
10132425|NCT04272541|Active Comparator|Habitual intervention|Intervention program consists of psychopharmacology (standard intervention in mental health services). This program is implemented for three months.
10132426|NCT04272502|Experimental|Sequence A|CKD-828, D326, D337, CKD-F1, CKD-F2
10132427|NCT04272502|Experimental|Sequence B|CKD-828, D326, D337, CKD-F1, CKD-F2
10132428|NCT04272502|Experimental|Sequence C|CKD-828, D326, D337, CKD-F1, CKD-F2
10132429|NCT04272749|Experimental|Dairy and non-dairy milks|Questionnaires and consumption behaviors of dairy and non-dairy milks
10132430|NCT04272515|Experimental|BA patients and their parents|"Collection of blood samples from BA patients and their parents~Collection of explanted liver tissue and skin biopsy of BA patients"
10132431|NCT04272437|Experimental|TRA group|"Tokoro Combination and Rehmannia and Akebia Formula (TRA) in each one batch number were manufactured by Chuang Song Zong Pharmaceutical Co., Ltd., a famous manufacturer of concentrated herbal extract granules in agreement with the standards of good manufacturing practices (GMP) in Kaohsiung City, Taiwan.~TRA contains Tokoro Combination and Rehmannia and Akebia Formula Tokoro Combination and Rehmannia and Akebia Formula consists of Dioscorea Hypoglaucae Rhizoma, Acori Graminei Rhizoma, Linderae Radix, Alpiniae Oxyphyllae Fructus, Poria, Rehmanniae Radix, Akebiae Caulis, Lophatheri Hebra, and Glycyrrhizae Radix at a 2:2:2:2:1:1.3:1.3:1.3:2.5 ratio."
10132432|NCT04272437|Placebo Comparator|placebo group|The placebo was also prepared as granules by Chung Song Zong Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of TRA.
10132433|NCT04272489|Experimental|Adaptive Control|The adaptive control system updates the pattern recognition control algorithm by incorporating new EMG data each instance the prosthetic user recalibrates their device.
10132434|NCT04272489|Active Comparator|Non-Adaptive Control|The conventional, non-adaptive control systems resets the pattern recognition control algorithm by deleting old EMG data each instance the prosthetic user recalibrate their device.
10132435|NCT04272424|Active Comparator|group A|laparoscopic hernioplasty with no fixation
10132436|NCT04272424|Active Comparator|group B|laparoscopic hernioplasty with tacker fixation
10132437|NCT04272424|Active Comparator|group C|laparoscopic hernioplasty with histoacryl fixation
10132438|NCT04272359||Group 1|SGLT2 inibitori +/- Metformin
10132439|NCT04272359||Group 2|DPP4 inibitori +/- Metformin
9669067|NCT04183335|Placebo Comparator|Matched placebo|Placebo on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
10132440|NCT04272359||Group 3|GLP1-RA + Long-Acting Insulin +/- Metformin
10132441|NCT04272359||Group 4|SGLT2 inibitori + DPP4 inibitori +/- Metformin
10183963|NCT03759353|Active Comparator|Ferrous Sulfate Group|Includes 49 pregnant women receiving 200 mg of dried ferrous sulfate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset (Feosol (R) , Meda pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
10183964|NCT03759301|Active Comparator|Growth Hormones Somatropin Recombinant|Growth hormone (Somatropin) 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup for the treatment group which consists of 70 women.
10183965|NCT03759301|Placebo Comparator|Placebo saline solution|Control group consisting of 70 women who will receive subcutaneous placebo injection in the same dosing as the treatment group
10183966|NCT03759262|Experimental|Vitamin D (Cholecalciferol)|All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.
10183967|NCT03759249|Experimental|Treatment group|Standard Treatment of Sleep disorder according to applicable guideline
10183968|NCT03759249|No Intervention|Waiting list|Continuation of former treatment, after completing the study standard treatment of Sleep disorder according to applicable guidelines
10183969|NCT03759236|Experimental|Health Messaging via SMS|Clinics randomized to this arm will receive the health messaging via SMS intervention. Flyers and information cards will be made available in all exam rooms and the waiting room, which contain information about the health messaging program. Patients must voluntarily elect to enroll in the program using their mobile device. Patients who enroll will receive a variety of health messages on topics including HPV Vaccine, Cervical Cancer screening, Birth Control options, Menstrual Problems, diet and exercise. Text messages are sent out using a third party interface, Twilio, at a frequency of 2 times each week for a duration of 1 year. These are one-way messages which only allow for texts to be sent to the participant.
10183970|NCT03759236|Active Comparator|CDC Pamphlets|The clinic randomized to this control arm will receive standard Center for Disease Control health pamphlets about the HPV Vaccine. Flyers are posted in the clinic waiting room and exam room.
10183971|NCT03759223|Experimental|E-PST|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training.
10132442|NCT04272164|Active Comparator|technical taekwondo training|Light jogging,running, Stretching exercises,Pushups and sit ups, Punches,Kicks
10132443|NCT04272164|Experimental|weighted rope taekwondo training|weighted rope jump training along with tachnical taekwando training
10132444|NCT04272229|Active Comparator|Control Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
10132445|NCT04272229|Experimental|Migrain Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
10132446|NCT04272151|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
10132447|NCT04272307||Acute Severe Ulcerative Colitis group|
10132448|NCT04272307||Non-severe Ulcerative Colitis group|
10132449|NCT04272372||Group 1|Complete Decongestive Therapy
10132450|NCT04272372||Group 2|Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel
10132451|NCT04272372||Group 3|Complete Decongestive Therapy + Local Ketoprofen gel
10132452|NCT04272255|Active Comparator|DPI-386 nasal gel|"DPI-386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.1 g dose, with each dose therefore described as 0.2 mg / 0.1 g"
10132453|NCT04272255|Placebo Comparator|placebo nasal gel|Placebo nasal gel product is the same but does not contain scopolamine HBr
10132454|NCT04272255|Experimental|Transderm Scop®|TDS patch delivers 1.5 mg of scopolamine over a 72-hour period. TDS arm will apply two TDS patches over the six treatment days.
10132455|NCT04272112|Active Comparator|Glass-ceramic|30 dental crowns of lithium-disilicate glass-ceramic
10132456|NCT04272112|Active Comparator|Zirconia|30 dental crowns of high translucent zirconia
10132457|NCT04272112|Active Comparator|Zirconia with mini-veneer|30 dental crowns of high translucent zirconia with a mini-veneer of porcelain
10132458|NCT04272086|Placebo Comparator|Bupivacaine TAP|TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side
10132459|NCT04272086|Experimental|Liposomal bupivacaine TAP|TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side
10132460|NCT04272320|No Intervention|Group C|
10132461|NCT04272320|Active Comparator|Group TFP|Transversalis fascia plane block, before the surgical procedure.
10132462|NCT04272125|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
10132463|NCT04272346|Experimental|Peer helping condition|Participants in the peer helping condition will be asked to write about their cancer experience with an emphasis on using the experience to benefit a newly-diagnosed AYA cancer patient.
10132464|NCT04272346|Experimental|Processing + peer helping condition|Participants in the processing + peer helping condition will be asked to first write about their deepest thoughts and feelings about their cancer experience (3 writings), then share advice to a newly-diagnosed AYA cancer patient (final writing).
10132465|NCT04272346|Placebo Comparator|Facts-only writing condition|Participants in the facts-only writing condition will be asked to write about their cancer experience. Unlike the previous conditions, they will not be instructed to write for the benefit of a newly-diagnosed AYA cancer patient.
10132466|NCT04271943|Active Comparator|COMPUTER BASED EXERCISES|
10132467|NCT04271943|Active Comparator|AEROBIC EXERCISES|
10132468|NCT04271917|Active Comparator|Treatment As Usual (TAU)|"Participants will receive a 5-day supply of acetaminophen 500mg and ibuprofen 200mg.~Instructions for use: Take one tablet of each medication at the same time every 4-6 hours as needed for pain."
10132469|NCT04271917|Placebo Comparator|Placebo|"Participants will receive a 5-day supply (15mL) of inactive placebo in a dropper vial.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
10132470|NCT04271917|Experimental|CBD 17mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 17mg/mL.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
10132471|NCT04271917|Experimental|CBD 37 mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 37mg/mL.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
10132472|NCT04271891|Experimental|With WBPC|Intensive rehabilitation programs :The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks additional WBPC: The duration will be 30 minutes a time
10132473|NCT04271891|Placebo Comparator|Control|Intensive rehabilitation programs: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks without WBPC.
10132474|NCT04271787||strongly dissatisfied|
10132475|NCT04271787||dissatisfied|
10132476|NCT04271787||neutral|
10132477|NCT04271787||satisfied|
10132478|NCT04271787||strongly satisfied|
10132479|NCT04271787||don't know|
10132480|NCT04271865|Other|therapy induced anemia for HCV treated patients|"Four types of interventions:~Educational to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits~Provision of Dates : Dates fruit intake for all the anaemic patients~Recipe book~Model kitchen for all patients having Hemoglobin lower than normal hemoglobin levels; less than 13.2 grams (g) of hemoglobin per deciliter (dL) of blood for men and less than 11.6 for women."
10132481|NCT04271839|Experimental|Fluticasone/formoterol k-haler (medium strength)|In this arm, uncontrolled patients who arrive at the consultation with their fixed combination of ICs (Inhaled CorticosteroidS) / LABA (Long-Acting Beta2-Agonist) (medium strength) will change their treatment to Fluticasone / formoterol k-haler (medium strength)
10132482|NCT04271839|Active Comparator|Standard of Care (SoC)|In this arm, uncontrolled patients arriving at the consultation with their fixed combination of ICs / LABA (medium strength) will change their treatment to the same fixed combination of ICs / LABA (high strength)
10132483|NCT04272177|Experimental|SDM group|Shared decision making using PDAs. PDAs is used as a tool explain the advantages and disadvantages of the traditional reversal drugs and sugammadex. And by following SDM principles, the patients are guided to consider their individual values and preferences and helped to make a choice that best meet their needs.
10132484|NCT04272177|No Intervention|Control group|Current approach to explain details of anesthesia using a single introductory sheet made by the two hospitals or provided by the pharmaceutical companies is used.
10132485|NCT04271800|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
10132486|NCT04272099||PG1 (patients with diabetes 0-25 years of age)|Patients 0 to 25 years of age, with a diagnosis of diabetes that are either followed at Kay Mackenson Pediatric Clinic, Haiti, or who are of Haitian ancestry, defined as both maternal and paternal grandparents being born in Haiti, and attend one of the three diabetes clinics in Montreal.
10132487|NCT04272099||PG2 (patient's principal caregiver)|The patient's principal caregiver (a parent of legal guardian).
10132488|NCT04271852|Experimental|UUI patients|50 UUI patients will have biofeedback treatment once a week.
10132489|NCT04271852|No Intervention|Control|
10132490|NCT04272203|Experimental|Dose Escalation: Participants With AML|Participants with relapsed or refractory (R/R) AML will receive escalating doses of ABBV-184
10132491|NCT04272203|Experimental|Dose Escalation: Participants With NSCLC|Participants with relapsed or refractory (R/R) NSCLC will receive escalating doses of ABBV-184
10132492|NCT04272203|Experimental|Dose Expansion: Participants With AML|Participants with R/R AML will receive ABBV-184 at recommended Phase 2 dose (RP2D) determined in dose escalation phase for AML
10132493|NCT04272203|Experimental|Dose Expansion: Participants With NSCLC|Participants with R/R NSCLC will receive ABBV-184 at RP2D determined in dose escalation phase for NSCLC
10132494|NCT04272021|Experimental|ADHD sample|Children with a diagnosis of ADHD
10132495|NCT04271826|Experimental|cases with normal CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
10132496|NCT04271826|Experimental|cases with proven appendicitis on CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
10132497|NCT04272268||Nasal High flow Oxygen|Following consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
10132498|NCT04271930|Experimental|Mindfulness Awareness Practices for Insomnia|Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with 5 minutes and increasing to 20 minutes over the course of the 6-week intervention - as is standard with the Mindfulness Awareness Practices (MAPs) course - with practice prior to bedtime. An intervention training manual is the cornerstone of standardized delivery of MAP-I. Participants are also provided with a book on mindfulness (Fully Present: The Science, Art, and Practice of Mindfulness, authored by the Mindfulness Awareness Research Center (MARC) leader and MAP-I instructor Diana Winston) as well as access to the University of California Los Angeles (UCLA) Mindful App courtesy of the MARC at UCLA (via personal iPhone or study-administered tablets per patient preference), which contains pre-recorded guided meditations for use in daily practice.
10132499|NCT04271930|Active Comparator|Sleep Health Education|Six individual 1-hour videos will be shown to participants at the same time points as, and with equal duration to, the MAP-I intervention. These videos will be recorded presentations that have been modified for HCT recipients based upon similar SHE interventions delivered in prior studies. Similar to the intervention group, patients in the SHE group will also participate in group Zoom chat sessions with equal frequency and duration lead by a study research coordinator. These sessions will allow for general patient interaction to discuss sleep and any questions or comments they may have, as lead by the group facilitator.
10132500|NCT04271709|Active Comparator|Enhanced Intervention|Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
10132501|NCT04271709|Placebo Comparator|Usual Care|Consented subjects living in buildings randomized to Usual Care arm who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
10132502|NCT04271813|Experimental|Anlotinib and Sintilimab|the combination of Anlotinib with Sintilimab as first-line treatment
10132503|NCT04271774||Infants with ASD-affected sibling|Infants, enrolled at 0-6 months of age, who have a sibling diagnosed with ASD.
10132504|NCT04271553|No Intervention|Control|Patient will undergo standard workflow for elective surgical admissions.
10132505|NCT04271553|Experimental|Video|In addition to standard workflow, will also receive the intervention bundle which consists of a cartoon video and sets of activity sheets
10132506|NCT04271618|Active Comparator|Traditional Treatment Arm|Participants in this group will receive conventional rehabilitation program for postural correction 2 hours/3 sessions' weekly/3 successive months.
10132507|NCT04271618|Experimental|TheraTogs Undergarment Arm|Participants in this group will receive the same conventional rehabilitation program as in traditional group in addition to wearing of TheraTogs soft orthotic undergarment with strapping system.
10132508|NCT04271462||Study group|Patients undergoing surgery (>120 min) with the use of sevoflurane based general anaesthesia (in 1.0 MAC concentration).
9669068|NCT04181723|Experimental|Drug - Trofinetide|Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
10132509|NCT04271423|Active Comparator|Control|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
10132510|NCT04271423|Experimental|Test|The test will be a flapless technique, no flap will be reflected.
10132511|NCT04271592|Experimental|Part 1: SAD Cohorts 1-7 ABI-H3733 Liquid Form|A single dose of ABI-H3733 liquid oral dosage form administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
10132512|NCT04271592|Placebo Comparator|Part 1: SAD Cohorts 1-7 Placebo Liquid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
10132513|NCT04271592|Experimental|Part 1: MAD Cohorts 8-10 ABI-H3733 Liquid Form|Once-daily doses of ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
10132514|NCT04271592|Placebo Comparator|Part 1: MAD Cohorts 8-10 Placebo Liquid Form|Once-daily doses of placebo matching ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
10132515|NCT04271592|Experimental|Part 2: Single Dose Fasted Cohort 11 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
10132516|NCT04271592|Placebo Comparator|Part 2: Single Dose Fasted Cohort 11 Placebo Solid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
10132517|NCT04271592|Experimental|Part 2: Single Dose Fed Cohort 12 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
10132518|NCT04271592|Placebo Comparator|Part 2: Single Dose Fed Cohort 12 Placebo Solid Form|A single dose of placebo matching ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
10132519|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active|Increasing doses of RPT193 will be administered to healthy volunteers
10132520|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo|Matching placebo will be administered to healthy volunteers
10132521|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active|Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
10132522|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo|Matching placebo will be administered once/day for 7 days to healthy volunteers
10132523|NCT04271514|Experimental|COMPLETED ENROLLMENT -- Expansion Part C - active|RPT193 will be administered daily for 28 days to patients with atopic dermatitis
10132524|NCT04271514|Placebo Comparator|COMPLETED ENROLLMENT -- Expansion Part C - placebo|Matching placebo will be administered daily for 28 days to patients with atopic dermatitis
10132525|NCT04271722|Experimental|Mifepristone|Mifepristone 200mg 24hours before the induction day
10132526|NCT04271722|Active Comparator|Balloon catheter|Balloon catheter with 40ml placed 24hours before the induction day
10132527|NCT04271579|Active Comparator|Unilateral lymphnode dissection|Salvage lymphnode dissection is performed on the PSMA PET positive side, according to template (obturator, iliac external, iliac internal, iliac commun) and possibly including other anatomical pelvic regions
10132528|NCT04271579|Active Comparator|bilateral Lymphnode dissection|In addition, a salvage lymphnode dissection is performed on the opposite side with resection of the corresponding fields, which were taken on the PSMA-PET positive side
10132529|NCT04271397|Other|Active tuberculosis|
10132530|NCT04271397|Other|Latent tuberculosis infection|
10132531|NCT04271631|No Intervention|Control|Received conventional education group
10132532|NCT04271631|Experimental|Intervention 1|Received conventional education group and Mobile Application-Based Diabetes Education
10132533|NCT04271631|Experimental|Intervention 2|Received Mobile Application-Based Diabetes Education and Health Coaching
10132534|NCT04271670|Experimental|Warm water footbath with ginger powder|Footbath with ginger powder with a maximum duration of 20 minutes.
10132535|NCT04271670|Experimental|Warm water footbath with mustard powder|Footbath with mustard powder with a maximum duration of 20 minutes.
10132536|NCT04271670|Active Comparator|Warm water only footbath|Warm water only footbath with a maximum duration of 20 minutes.
10132537|NCT04271644|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
10132538|NCT04271410|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
10132539|NCT04271566|Experimental|Experimental|Patients receiving an education program along with usual medical care
10132540|NCT04271566|No Intervention|Non Experimental|Patients receiving usual medical care
10132541|NCT04271306|Experimental|Groups 1A & 1B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
10132542|NCT04271306|Experimental|Groups 2A & 2B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
9669069|NCT04181723|Placebo Comparator|Placebo|Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
10132543|NCT04271306|Experimental|Groups 3A & 3B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
10132544|NCT04271306|Experimental|Group 3C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
10132545|NCT04271306|Experimental|Groups 4A & 4B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
10132546|NCT04271306|Experimental|Group 4C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0 and 1 and a dose of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at month 6.5
10132547|NCT04271527|Experimental|cognitive targeted biopsy|a novel three-dimensional matrix positioning based cognitive fusion targeted biopsy combined with a standard 20-region template guided biopsy
10132548|NCT04271527|Active Comparator|software targeted biopsy|software-based fusion targeted biopsy combined with a standard 20-region template guided biopsy
10132549|NCT04271332|Experimental|Arbaclofen|Arbaclofen will be dosed flexibly, with maximum permissible dose depending on age.
10132550|NCT04271332|Placebo Comparator|Placebo|The placebo tablet is manufactured to match arbaclofen in shape, size, color, and taste, and will be administered in the same manner as arbaclofen.
10132551|NCT04271319|Experimental|BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.
10132552|NCT04271319|Sham Comparator|Electrical Stimulation - Sham Comparator|Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.
10132553|NCT04271085||Patients in the last phase of life|Patients in the last phase of life and their families
10132554|NCT04271046|Experimental|Experimental Group- STAR-C-VTF|"This study will use a parallel, two-arm randomized trial design. Participants will be 100 Person-with-Dementia-Caregiver dyads in which the person with dementia lives at home and recently filled a new prescription for antipsychotic medication. The experimental intervention will combine three elements:~self-directed learning in which the caregiver will receive training materials delivered electronically through a web-based learning portal;~one orientation phone visit with a coach;~ongoing support from the coach via telephone and secure messaging in the web-portal.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
10132555|NCT04271046|Active Comparator|Control|"One orientation phone visit with a coach. Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages.~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
10132556|NCT04271267||Acute Rejection Cohort|The subset of samples corresponding to biopsy-proven acute rejection
10132557|NCT04271267||Rejection-free Cohort|The subset of samples corresponding to a transbronchial biopsy free of acute cellular rejection.
10132558|NCT04271228|Experimental|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
10132559|NCT04271007|Active Comparator|Group I|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Sanofi, Medley on the opposite side
10132560|NCT04271007|Active Comparator|Group II|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Aché on the opposite side
10132561|NCT04271111|Experimental|Active treatment|Computerized intervention aimed at reducing perceived hostility.
10132562|NCT04271111|Active Comparator|Control condition|Computerized intervention aimed at increasing overall physical health.
10132563|NCT04271150|Experimental|Self-etch|Self-etch mode of the universal adhesive will be used
10132564|NCT04271150|Active Comparator|Total-etch|Total etch mode of the universal adhesive will be used
10132565|NCT04270994|Experimental|Misoprostol|
10132566|NCT04271189|Experimental|POLYCHEM|Metformin (extended release), Pioglitazone, Sitagliptin and Empaglifozin.
10132567|NCT04271189|Active Comparator|STANDARD CARE|Standard of care according to the local health service.
10132568|NCT04271384|Experimental|SABR + Nivolumab|"Pre-operative treatment with standard SABR (3 x 18 Gy or 5 x 10 Gy or 8 x 7.5 Gy) concomitant with nivolumab at 360 mg every 21 days x3 doses.~Standard-of-care surgery to be performed after 12 weeks from D1 of treatment."
10132569|NCT04271124|Active Comparator|PR|
10132570|NCT04271124|Experimental|PR+ET|
10132571|NCT04270981|Experimental|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250|single administration of 960 mg (4 × 240 mg capsules) acoziborole in oral and fasted condition
10132572|NCT04270890|Experimental|Study participants|Patients will be dual scanned; one with 4D-CT in free-breathing and one wearing the compression belt.Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction. The belt will be inflated to a tolerable level by the patient and recorded for consistency each fraction. The position of the belt will be referenced to the anterior and lateral tattoos to ensure accurate and consistent placement each fraction.
10132573|NCT04271215||Overweight/Obesity|BMI at diagnosis will be used. Using WHO software (version 3.2.2, World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient. According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999), overweight (2 to 2.9999) and obesity (≥3). In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999), underweight (< p5), overweight (p85-94.9999), and obese (≥ p95). The nutritional classification and measurements regarding weight and height recorded in clinical files will be used to classify patients' nutritional status in present research has been previously described.
10132574|NCT04270955|Active Comparator|Symptomatic, standard of care|Patients in this group will be offered all procedures and care deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
10132575|NCT04270955|Experimental|Symptomatic, MMA embolization + standard of care|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Symptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
10132576|NCT04270955|Active Comparator|Asymptomatic, standard of care|Patients in this group will be offered all procedures deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
10132577|NCT04270955|Experimental|Asymptomatic, standard of care + MMA embolization|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Asymptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
10132578|NCT04271241|No Intervention|Control (Ctrl)|Ctrl group di not undergo any training
10132579|NCT04271241|Experimental|PS bilateral limbs (PSBil)|PSBil underwent 12 weeks of passive stretching on both the lower limbs
10132580|NCT04271241|Experimental|PS monolateral limb, stretched limb (PSMonoSL)|PSMonoSL underwent 12 weeks of passive stretching on just one lower limb (SL). Outcomes form this group were obtained from the stretched
10132581|NCT04271241|Experimental|PS monolateral limb, contralateral limb PSMonoCL|PSMonoCL involved the same participants as in PSMonoSL. Outcomes form this group were obtained from the contralateral not stretched limb (CL). Data from this limb helped in identify possible PS-induced crossover effects in the vasomotor response.
10132582|NCT04270942|Experimental|Teplizumab treated|Administration of teplizumab by intravenous infusion
10132583|NCT04271098||Open-heart surgery|Patients undergoing open-heart surgery with cardiopulmonary bypass
10132584|NCT04270864|Experimental|Regimen A1|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod Q3W
10132585|NCT04270864|Experimental|Regimen A2|Combination between nivolumab IV Q3W and dual intratumoral injections of Ipilimumab and Tilsotolimod QW
10132586|NCT04270877|Experimental|Naltrexone|"Low Dose Naltrexone (LDN) is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets once daily in the evening."
10132587|NCT04270877|Placebo Comparator|Placebo|"LDN-placebo is administered for 12 weeks, including a titration phase of 4 weeks.~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.~The medicine is taken orally as tablets (similar in size, shape and taste to the active medication), once daily in the evening."
10132588|NCT04270968|Experimental|ESWT Group|received ESWT once a week for 4 weeks (0.25 ml/mm2, 1000 shocks) plus topical none steroidal anti-inflammatory drug (NSAID; 3 times /day for 4 weeks).
10132589|NCT04270968|Experimental|control group|received only topical NSAID.
10132590|NCT04270929|Experimental|Oxaliplatin PEDD-PRVI|Two infusions of oxaliplatin (dose escalation: 20-40 mg) over the course of 4 weeks by Pancreatic Retrograde Venous Infusion (PRVI) utilizing Pressure Enabled Drug Delivery (PEDD) technology.
10132591|NCT04270812|Experimental|Sleep Treatment|This arm consists of the sleep treatment that will be administered to all participants in the single-arm open trial.
10132592|NCT04270799||Lung Nodules|"A cohort of 1000 patients with incidental lung nodules will be identified using clinical records at participating NHS sites.~Link-anonymised CT scan images and data will be stored using a central database for radiomics and artificial intelligence research, to predict the risk of malignancy."
10132593|NCT04270825|Experimental|CBT with IPT|Group CBT with IPT will consist of 20 weekly two-hour sessions and has been developed for the proposed study based on the protocols for group CBT for HD and group IPT. Treatment includes strategies from CBT, including cognitive restructuring, behavioral exposures, and organizational strategies, as well as strategies from IPT, including role-play, interpersonal skills building, communication analysis, and decision analysis.
10132594|NCT04271137|Other|Orbital fractues|Orbital fractures
10132595|NCT04270851||Borderline Resectability|Patients with colorectal liver metastases where the decision-making on technical resectability is difficult, i.e. 'borderline resectable,' where a group of liver surgeons might reasonably be expected to find the decision whether to operate to be challenging. A group of up to 20 such patients will undergo pre-operative LiMAx test and HepaT1ca pre-operative scanning. Recruited participants' data will be used to create anonymised online case scenarios to be used in a survey, assessing whether liver surgeons find these pre-operative assessments helpful in their decision-making on technical resectability.
10132596|NCT04270734|Active Comparator|normal 25-36 gestational week preterm infant|
10132597|NCT04270734|Experimental|25-36 gestational week preterm infant with IVH|25-36 gestational week preterm infant with Intraventricular haemorrhages (IVH)
10132598|NCT04270578||Women with GDM|
10132599|NCT04270578||Women without GDM|
10132600|NCT04270773|Other|Only arm|Single arm, Receiving treatment
10132601|NCT04270656|Experimental|Insulin pump therapy|
9669070|NCT04171323|Experimental|CTa|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
10132602|NCT04270656|Active Comparator|Multi-injection treatment ( MDI ).|
9669071|NCT04171323|Experimental|CTab|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
9669072|NCT04171323|Experimental|CTac|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
10132603|NCT04270721|Experimental|After intervention (sequence 1)|'After intervention' group receives the training immediately and data are only collected after the intervention.
10132604|NCT04270721|Experimental|Before and after intervention (sequence 2)|For the 'Before and after intervention' group, data are collected both before and after the training.
10132605|NCT04270721|No Intervention|Before intervention (sequence 3)|"The 'before intervention' group collects data only before the training.~*This arm will receive the educational intervention after data collection is completed."
10132606|NCT04270903||Phototype I - II|EPR measurement at the surface of the skin (arm)
10132607|NCT04270903||Phototype III - IV|EPR measurement at the surface of the skin (arm)
10132608|NCT04270903||Phototype V - VI|EPR measurement at the surface of the skin (arm)
10132609|NCT04270695||blood flow restriction|An inflatable cuff (14 cm in width * 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver both condition of BFR and BFR-free twice a week, for six weeks.
10132610|NCT04270708|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 3mcg/kg
10132611|NCT04270708|Active Comparator|Triclofos|Oral Triclofos Sodium 50mg/kg
10132612|NCT04270539|Experimental|Experimental Group (nap)|The experimental group will be allowed to take a brief nap daily on school days during the study period.
10132613|NCT04270539|No Intervention|Control Group (no nap)|The control group will not be allowed to take daily nap on school days during the study period.
10132614|NCT04270565|Experimental|Intervention Group|The intervention group will receive real-time gait-training interventions along with a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and wear a Garmin watch to get information from the sensors to the watch for feedback. They will also do home exercises during the study, and to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises and get instructions on feedback for the next week.
10132615|NCT04270565|Active Comparator|Control Group|The control group will receive only a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and do home exercises during the study. Participants will be asked to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises.
10132616|NCT04270552|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
10132617|NCT04270552|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
10132618|NCT04270487|Experimental|IBS diet|The simple IBS diet is a diet based on the Low FODMAPs diet and the NICE (National Institute of Health and Care Excellence) IBS diet. Patients will be aid to follow the diet with a mobile app.
10132619|NCT04270487|Active Comparator|Otilonium bromide|Otilonium bromide is a a frequently used musculotropic spasmolytic. The dosis used will be 40 mg t.i.d.
10132620|NCT04270513||EVT by Flying Intervention Team in primary stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, for whom a Flying Intervention Team is flown to the primary stroke center in order to perform endovascular treatment.
10132621|NCT04270513||EVT after secondary transfer to comprehensive stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, who are transferred to a comprehensive stroke center for endovascular treatment.
10132622|NCT04270383||2019-nCoV infection group|Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019-nCoV infection group.
10132623|NCT04270383||Control group|Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019-nCoV infection group are classified as the control group.
10132624|NCT04270461|Experimental|Arms|NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
10132625|NCT04270448|Active Comparator|Control|Practice of a joystick based motor sequence task. Participants receive feedback that they have completed the practice trials in that block of practice.
10132626|NCT04270448|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
9669073|NCT04171323|Experimental|CTabc|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
9669074|NCT04171323|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
10132627|NCT04270448|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
10132628|NCT04270370|Experimental|LY3478045 (Part A)|LY3478045 administered orally.
10132629|NCT04270370|Placebo Comparator|Placebo (Part A)|Placebo administered orally
10132630|NCT04270370|Experimental|LY3478045 (Part B)|LY3478045 administered orally.
10132631|NCT04270370|Placebo Comparator|Placebo (Part B)|Placebo administered orally
10132632|NCT04270370|Experimental|LY3478045 + Atorvastatin (Part B)|LY3478045 co-administered with atorvastatin orally.
10132633|NCT04270370|Placebo Comparator|Placebo + Atorvastatin|Placebo co-administered with atorvastatin orally.
10132634|NCT04270279|Experimental|Xueshuanxinmaining Tablet|"Patients were given Xueshuanxinmaining tablet orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
9669075|NCT04170621|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
10132635|NCT04270279|Placebo Comparator|Placebo|"Patients were given Xueshuanxinmaining tablet simulation orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
10132636|NCT04270305|Experimental|orientation|Orientation training with GRAIL
10132637|NCT04270305|Active Comparator|walking|Walking training with GRAIL
10132638|NCT04270136|Experimental|breast cancer mastectomy|
10132639|NCT04270097||Emirati Genetic T2D cohort|
10132640|NCT04270331|No Intervention|A Before group|No protocol assigned
10132641|NCT04270331|Experimental|An After group|PADS (pain, agitation, delirium, sleep deprivation assessment and management) protocol assigned
10132642|NCT04270149|Experimental|ESR1 peptide vaccine|200 mcg ESR1 peptides plus 1ml Montanide and 100 mcg GM-CSF administered subcutaneously weeks 0, 1, 2, 4, 5, 6 for a total of 6 injections.
10183972|NCT03759223|Active Comparator|Control|Healthy Living Messages (Control) arm. Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care.
10183973|NCT03759171|Experimental|Immediate Entry Group|Following the baseline interview, veterans randomized to the immediate entry group directly engaged in the Guitars for Vets Intervention and were interviewed at the end of the intervention period, roughly 6 weeks later. The intervention content and duration (6 weeks) was the same across both groups.
10183974|NCT03759171|Experimental|Delayed Entry Group|Those randomized to the delayed entry group had their baseline interview repeated at the end of the delayed entry period (4 weeks) prior to receiving the 6-week Guitars for Vets Intervention as well as after intervention completion. The intervention content and duration (6 weeks) was the same across both groups.
10183975|NCT03759158|Experimental|NAC Arm|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
10183976|NCT03759158|Placebo Comparator|Placebo|
10183977|NCT03759145|Experimental|Intervention arm, usual rehabilitation + Jintronix exergame|On top of the usual out-patient rehabilitation sessions planned for the participant, participants attend sessions to use the Jintronix system for up 30 minutes up to 3 times per week
10183978|NCT03759145|Other|Control group|Participants continue their prescribed rehabilitation sessions
10183979|NCT03759132|Experimental|Anodal tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes"
10183980|NCT03759132|Sham Comparator|Sham tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes (30s ON)"
10183981|NCT03759119|Experimental|Tummy Time and Parent Education|This group will receive tummy time and parent education and be encouraged to perform tummy time on their own. They will utilize the PT Pal application to record their tummy time adherence. The primary investigator performs the intervention to the participants two times a day for 10 minutes for 4 weeks.
10183982|NCT03759119|No Intervention|Parent education|This group will receive parent education only and utilize the PT Pal application to record their adherence. The primary caregiver will be encouraged to perform the same dosage of tummy time (2x/day, 10 minutes each, 4 weeks) and record their adherence on the PT Pal application.
9669077|NCT04147338|Experimental|Reference Device: Guselkumab|Participants will receive subcutaneous (SC) injections of guselkumab in reference device.
10183983|NCT03759106|Other|No Intervention: Usual care|All study participants in the control group will receive an 8-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
10183984|NCT03759106|Experimental|Experimental: Telerehabilitation system|Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
10183985|NCT03759093|Active Comparator|Standard of Care|Dosing of VCD(bortezomib, cyclophosphamide, dexamethasone) or VTD (bortezomib, thalidomide, dexamethasone) combinations according to standard of care
10183986|NCT03759093|Experimental|CURATE.AI-guided dosing|CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone) or bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) combinations
10183987|NCT03759080|Active Comparator|intervention of PNF|PNF group: 30 individuals, these subjects received proprioceptive neuromuscular facilitation training.
10183988|NCT03759080|Experimental|MP|PNFMP group:30 individuals, these subjects received mental practice.
10183989|NCT03759067|Active Comparator|LD group|clopidogrel 600 mg once loading, usually 2-24 h before the procedure
10183990|NCT03759067|Experimental|MD group|After randomization, the routine therapy using daily clopidogrel 75mg
10183991|NCT03759067|Active Comparator|RL group|After randomization, additional clopidogrel 300 mg reloading for patients who were taking a maintenance dose.
10183992|NCT03759028|Experimental|Ibuprofen|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed ibuprofen for breakthrough pain (liquid oral medication, 10mg/kg/dose every 8 hours as needed, max dose 40mg/kg/day).
9669078|NCT04147338|Experimental|Test Device 1: Guselkumab|Participants will receive SC injections of guselkumab in test device 1.
10183993|NCT03759028|Active Comparator|Oxycodone|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed oxycodone for breakthrough pain (liquid oral medication, 0.1mg/kg/dose every 6 hours as needed).
10183994|NCT03759002||Patients|Children with end stage renal disease
10183995|NCT03759002||Controls|Healthy sex- and age adjusted children
10183996|NCT03758989|Experimental|Baseline PET|R-CHOP
10187671|NCT03723759|Experimental|Group A|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation D, faster aspart 100 U/mL, formulation B, formulation A, formulation C, formulation E.~The dosing visits will be separated by wash-out periods (2-21 days)."
10132643|NCT04270162|Experimental|New intervention protocol with inspirometer|Respiratory exercises without use of inspirometerwill be taken out 50% and 80% to have it as muscle strength training values for the respiratory muscles based on the contra-relax technique)
10132644|NCT04270162|Active Comparator|Protocol of use of inspirometer in a conventional way|This gonna be a experimental group 2 with conventional use of the conventional way.
10132645|NCT04270162|Active Comparator|Respiratory exercises without use of inspirometer|This group gonna be a control group with breathing exercises without the use of inspirometer.
10132646|NCT04270175|Experimental|daratumumab/pomalidomide/dexamethasone|"Pomalidomide:~(4mg orally) on days 1-21 of a 28-day cycle~Dexamethasone:~20mg IV as premedication on days 1, 8, 15, and 22~20mg orally the day after daratumumab dosing for cycles 1-2 of induction~40mg IV as premedication on days 1 and 15 on daratumumab treatment days~40mg orally on non-daratumumab days (8 and 15) for cycles 3-6~20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond)~If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction.~Daratumumab:~1800mg sub-cutaneously weekly x8 weeks~1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6)~1800mg sub-cutaneously every 4 weeks cycles 7 and beyond"
10132647|NCT04269954|Experimental|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin.
10132648|NCT04269954|Other|Low-molecular-weight heparin therapy|Low-molecular-weight heparin combined with routine drug therapy.
10132649|NCT04270201||Case group|OSCC patients (n = 60)
10132650|NCT04270201||Control group|Healthy volunteers (n = 240)
10132651|NCT04270266|Experimental|Group I (meditation)|Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.
10132652|NCT04270266|Active Comparator|Group II (educational)|Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.
10132653|NCT04270318|Active Comparator|CH pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the CH pulpotomy.Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
10132654|NCT04270318|Experimental|CH pulpotomy-NaOCl|After hemorrhage control,pulp chamber was cleansed with 5% NaOCl for 30 s prior the CH pulpotomy. Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
10132655|NCT04270318|Active Comparator|MTA pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs.
10132656|NCT04270318|Experimental|MTA pulpotomy-NaOCl|"After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. MTA NaOCl (n = 31 teeth): Pulp chamber was cleansed with 5% NaOCl for 30 s prior the MTA pulpotomy.~Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs."
10132657|NCT04270253|Experimental|End-range mobilization|End-range mobilization applied 6 times for 2*2 min in end-range of flexion and extension end-range of the tibiofemoral and patellofemoral joint beside the same conservative therapy, as used for the Control
10132658|NCT04270253|Active Comparator|Control|Conservative therapy including aquatic exercises (5-times), land-based exercises (3-times), balneotherapy (5-times) and TENS therapy (3-times)
10132659|NCT04270071|Experimental|Yangxin Shengmai Granules|"Patients were given Yangxin Shengmai granules orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
10132660|NCT04270071|Placebo Comparator|Placebo|"Patients were given Yangxin Shengmai granules simulation orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
10132661|NCT04270110||Case|Patients with subclinical hypothyroidism
10132662|NCT04270110||Control|Patients with Normal thyroid function
9669079|NCT04147338|Experimental|Test Device 2: Guselkumab|Participants will receive SC injections of guselkumab in test device 2.
9669080|NCT04143516|Experimental|Patients with Colon Cancer Liver Metastases|The standard of care thermal ablation procedure, post-ablation biopsies and pre- and post-ablation PET scans. If the PET scan is positive (shows areas of cancer in the treated metastases), study participants will undergo additional needle biopsies of the positive areas on the scan. If the biopsies show areas of cancer cells that are still alive, the participants will be immediately retreated with a second ablation procedure.
9669081|NCT04140903|Experimental|Oral antibiotics|Patients will be randomised to oral antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
9669082|NCT04140903|Active Comparator|Standard treatment|Patients will be randomised to continuation of standard intravenous antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
9968310|NCT01278316|Experimental|Cognitive training|Cognitive Intervention Tasks Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
10132663|NCT04269980|Active Comparator|Group (PHN)|Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure
9968311|NCT01278316|Active Comparator|Control|The control group will perform computerized tasks that utilize cognitive performance, but were not systematically developed to improve cognitive performance.
9968312|NCT01278329|Experimental|Music|"Mothers in the music group were provided a pre-recorded Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India) with a running duration of approximately 50 minutes and a cassette player with headphones. They were asked to listen to the recorded music daily in the evening just before going to the bed with a minimum of ambient noise."
9968313|NCT01278329|No Intervention|Control|Standard routine ante-natal care.
9968314|NCT01278355||Pain Patients|
9968315|NCT01278368|Active Comparator|Preoperative chemotherapy (PCHT)|Patients who underwent pancreatic resection after PCHT.
9968316|NCT01278368|Active Comparator|Control|Patient who underwent pancreatic resection without preoperative therapy
9968317|NCT01278381||Pancreaticoduodenectomy (PD)|Patients undergoing PD from 2002 to 2010
9968318|NCT01278420|Other|Tecnis MF|
9968319|NCT01278420|Other|ReSTOR|
9968320|NCT01278433|Experimental|Study Group|Participants receiving their first dose of polio vaccine
9968321|NCT01278446|Experimental|Test Formula|New hydrolyzed whey formula
9968322|NCT01278446|Active Comparator|Control Formula|Commercially available hydrolyzed infant formula
9968323|NCT01278459|Experimental|Atorvastatin first|Participants receive 4 week treatment with atorvastatin 20mg/day, followed by 4 week washout, followed by 4 week treatment with placebo.
9968324|NCT01278459|Experimental|Placebo first|Participants receive 4 week treatment with placebo, followed by 4 weeks washout, followed by 4 weeks treatment with atorvastatin 20mg/day.
9968325|NCT01278472|Experimental|Single Port Cholecystectomy|Laparoscopic Cholecystectomy with single port transumbilical access
9968326|NCT01278472|Active Comparator|4 Port Cholecystectomy|Laparoscopic Cholecystectomy using 4 separate conventional trocars
9968327|NCT01278498|Experimental|escitalopram|prevention of poststroke depression in patients with acute stroke.
9968328|NCT01278498|Placebo Comparator|placebo|prevention of poststroke depression in patients with acute stroke.
9968329|NCT01278511|Experimental|Canadian C-Spine Rule|
9968330|NCT01278524||Critically ill patients|Patients staying in the ICU on the 25th of January
9968331|NCT01278537|Experimental|Empowerment, shared-decision making,|Patients receive a booklet with informations. Assessment of health-related risk factors. Assessment of psychological and physical social support Delirium protection. Early mobilization.
9968332|NCT01278537|No Intervention|control group|
9968333|NCT01278550||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
9968334|NCT01278550||High risk cohort|Patients have history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have successful eradication of H. pylori based on histology
9968335|NCT01278576|Experimental|Intramuscular ending Targeting|Botox 200 units placed at the upper 2/10-3/10 length of the GCM
9968336|NCT01278576|Active Comparator|Midbelly Targeting|A total of 200 units will be placed at the four quadrants of the midbelly portion of the GCM.
9968337|NCT01278589|Experimental|• Plantago asiatica L. extract 5g|
9968338|NCT01278589|Experimental|Plantago asiatica L. extract 10g|
9968339|NCT01278589|Experimental|Plantago asiatica L. extract 20g|
9968340|NCT01278589|Placebo Comparator|Placebo|
9968341|NCT01278602|Experimental|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
9968342|NCT01278628|Experimental|Lifestyle modification|
9968343|NCT01278641|Experimental|1|Intervention i arm 1 comprises graded strength resistance training, 75 minutes twice a week for 12 weeks.
9968344|NCT01278641|Experimental|2|Intervention in arm 2 comprises low intensive temperate pool exercise 50 minutes, twice a week for 12 weeks.
9968345|NCT01278641|No Intervention|3|Reference group, continues with normal activities during the study period of 12 weeks.
9968346|NCT01278654|Active Comparator|Personal incentive|If participants attain their walkstation usage goal, they are entered into bi-weekly lotteries to win money.
9968347|NCT01278654|Active Comparator|Token incentive|Participants who attain their walkstation usage goal will be entered into a bi-weekly prize to win a token reward.
9968348|NCT01278680|No Intervention|Hold-out control|Hold-out control: participants will be asked to refrain from using the walkstations for the duration of the study (90 days).
9968349|NCT01278680|Active Comparator|Personal incentive|Personal incentive: Participants will receive $3 for each time they use the walkstation.
9968350|NCT01278680|Experimental|Charitable incentive|Charitable incentive: $3 will be donated to charity every time the participant uses the walkstation.
9968351|NCT01278693|Other|placebo|it is as like as L-carnitine in shape
9968352|NCT01278693|Other|L-carnitine|it is kind of supplement
9968353|NCT01278706|No Intervention|no treatment|
9968354|NCT01278706|Experimental|one biopsy, proliferative phase|
9968355|NCT01278706|Experimental|one biopsy, secretory phase|
9968356|NCT01278706|Experimental|two biopsies|
9968357|NCT01278719||Antrochaonal polyp; non recurrent type|
10132664|NCT04269980|Active Comparator|Group MG|Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
10132665|NCT04270019|Experimental|Experimental|This group will receive polyethylene glycol (50% weight/volume) applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
10132666|NCT04270019|Placebo Comparator|Control|This group will receive normal saline applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
10132667|NCT04270045||Single|Non-invasive forced airway oscillometry
10132668|NCT04269941||prognostic factors of gastrointestinal stromal tumors|for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy.
10132669|NCT04269876|Experimental|Marine Lipid Oil concentrate|Dietary Supplement: Marine Lipid oil concentrate softgel and dietary supplement capsules
10132670|NCT04269876|Placebo Comparator|Placebo|Placebo softgels with Placebo capsules
10132671|NCT04270006|Experimental|Exosomes|
10132672|NCT04270214|Other|Dysport|Single arm study, all participants will receive Dysport injections
10132673|NCT04270123||Group 1|Group 1 consists of breast cancer patients with local or locally advanced disease. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. A subgroup of participants within this group (those who have changed disease or treatment status) will be asked to complete the above questionnaires again, three months later (+-1 week). They will also complete an anchor question. Completing twice is for the responsiveness to change analysis.
10132674|NCT04270123||Group 2|Group 2 consists of metastatic breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires at one time point only.
10132675|NCT04270123||Group 3 - follow up|Group 3 consists of follow up breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. One-to two weeks later, a subgroup of participants in this group (with no evidence of disease and /or change in health status) will complete the above questionnaires, as well as an anchor question. Completing twice is for the test-retest analysis.
10132676|NCT04269915|Experimental|Intervention|Volunteers will be exposed to escalating doses of female Schistosoma mansoni cercariae
10132677|NCT04269837|Experimental|Supportive Care (sexual health counseling)|Patients receive sexual health counseling prior to starting and at the completion of radiation.
10132678|NCT04269590|Experimental|Dual Task (DT) training - PD|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of patients with Parkinson's disease (PD)
10132679|NCT04269590|Active Comparator|Single Task (ST) training - PD|Practice of the Swipe Slide Pattern task alone for a group of patients with Parkinson's disease (PD)
10132680|NCT04269590|Experimental|Dual Task (DT) training - HC|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of healthy age-matched controls.
10132681|NCT04269590|Active Comparator|Single Task (ST) training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls
10132682|NCT04269655|Experimental|Intervention CB CGM|On CB CGM patients, CGM data will also be transmitted from the bedside smartphone to the Digital Dashboard. The Digital Dashboard will integrate CGM data for CB CGM's participants for presentation via two views: (1) Real-Time Management and (2) Clinical Optimization. Telemetry technicians to conduct site-based monitoring, and the Diabetes APN will conduct remote management of patients at the site from a central, Scripps Diabetes Hub, per below. (Note, as CGMs are not FDA-approved for in-hospital glucose management, CB CGM participants will also have their glucose monitored via the hospital's standard POC testing protocol described for UC).
10132683|NCT04269655|No Intervention|Usual Care|For UC, CGM data will be blinded to the care team and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours for patients who are not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring: UC (and intervention) participants' glucose levels will be managed using the glucose management protocol and the Diabetes APN will assess UC participants' POC data documented in the EMR from the previous 24-48 hours and make recommendations for changes to the basal/bolus regimen to improve glucose management.
10132684|NCT04269863|Experimental|Control Group|This group of 75 patients is the control group that will be receiving the standard lowest dosage of 81mg aspirin.
10132685|NCT04269863|Experimental|Treatment Group|This group of 75 participants is the treatment group that will be receiving personalized aspirin dosage between 81mg-325mg (within standard clinical recommendations), which will be determined based on platelet analysis via PFA-200.
10132686|NCT04269772|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
10132687|NCT04269772|Other|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided by prison and community providers, as part of routine care in the criminal justice re-entry context. Study staff will provide no additional treatment in this arm.
10132688|NCT04269720|No Intervention|Control|Participants will not receive biofeedback intervention.
10132689|NCT04269720|Experimental|Biofeedback|Participants will receive a biofeedback intervention daily for 8 weeks. Each biofeedback session lasts approximately 10 minutes.
10132690|NCT04269759||Pregnancy women|
9827457|NCT02456727|Active Comparator|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
10132691|NCT04269928|Experimental|Adrenal Artery Ablation|Patients in the intervention group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
10132692|NCT04269928|No Intervention|Adrenalectomy|Patients in this group will be treated with unilateral laparoscopic adrenalectomy
10132693|NCT04269798|Active Comparator|Traditional Treatment Arm|Will receive conventional rehabilitation program for the lower limbs, balance and gait training. Two hours of conventional physical therapy program /session - 3 sessions/week/ three successive months.
10132694|NCT04269798|Experimental|Functional Electrical Stimulation Group|Will receive 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
10132695|NCT04269681|Experimental|High Flow Nasal Cannula Arm|Participants will receive HFNC if they have no delirium and signs of ARF. The device is supposed to be used continuously in the nose with some changes in flow and/or temperature according to tolerance. There is no crossover to the standar of care arm.
10132696|NCT04269681|Active Comparator|Standard respiratory support|Participants will receive standard of care with low flow oxygen catheter or mask initially. If there is any sign of clinical deterioration NIV can be offered if tolerated by the patient. There will be no cross over with HFNC arm.
10132697|NCT04269733||Subjects with a DDD-pacemaker due to high-degree AV block|
10132698|NCT04269850|Experimental|FMT+ruxolitinib+steroids|ruxolitinib 10 mg bid, fecal microbiota transplantation 2 caps/kg single dose, methylprednisone 0.5 mg/kg bid
10132699|NCT04269746||Control group|The control population comprised normal healthy individuals.
10132700|NCT04269746||Precancerous group|patients with precancerous colorectal diseases
10132701|NCT04269746||CRC group|patients with colorectal cancer
10132702|NCT04269811|Experimental|Flu-Bu-Mel|Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2
10132703|NCT04269694|No Intervention|Control|No dressing applied in the donor site after harvesting the graft
10132704|NCT04269694|Experimental|Test|An antibacterial honey dressing material (Medihoney, http://www.medihoney.com) will be applied to donor site.
10132705|NCT04269616|Experimental|Numerical survival, followed by disability information|Participants in this arm were presented with a pictograph displaying numerical survival information, followed by a pictograph displaying disability information.
10132706|NCT04269616|Experimental|Survival with description, followed by disability information|Participants in this arm were presented with a pictograph displaying survival information including the average course of stay in the NICU, followed by a pictograph displaying disability information.
10132707|NCT04269616|Experimental|Disability information, followed by numerical survival|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying numerical survival.
10132708|NCT04269616|Experimental|Disability information, followed by survival with description|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying survival information including the average course of stay in the NICU.
10132709|NCT04269564|No Intervention|group A|Group A patients received the standard ventilation protocol as follows: volume-controlled ventilation mode, with VT 6 ml/kg of ideal body weight, inspiratory : expiratory ratio 1 : 2, a PEEP of 4 cmH2O, and respiratory rate 10-12 breaths/min that will be adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mmHg and inspired oxygen fraction of 0.5.
10132710|NCT04269564|Active Comparator|group B|Patients in group B received the standard ventilation protocol with stepwise peep until end of surgery and extubation.
10132711|NCT04269642|Placebo Comparator|PT320 2.0mg Placebo|will be injected subcutaneously once a week for 48 weeks
10132712|NCT04269642|Experimental|PT320 2.0mg treatment 1|will be injected subcutaneously once a week for 48 weeks
10132713|NCT04269642|Experimental|PT320 2.5mg treatment2|will be injected subcutaneously every two weeks for 48 weeks. (Actually, patients will be injected PT320 2.5 mg and placebo alternately once a week.)
10132714|NCT04269538|Experimental|SAD Cohorts 1-2 Experimental Arm|Experimental Arm Active drug 150 mg and 450 mg SC dosing
10132715|NCT04269538|Placebo Comparator|SAD Cohorts 1-2 Placebo Arm|Placebo Arm
10132716|NCT04269525|Experimental|pneumonia|According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4), patients enrolled will be divided to serious pneumonia group or critical pneumonia group. All subjects will receive UC-MSCs 3.3 * 107 cell number / 50ml / bag, 3 bags each time. And UC-MSCs will be infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. The efficacy and safety of the treatment, patients' adverse reactions will be monitored.
10132717|NCT04269577|Experimental|SSP training - early PD|Practice of the Swipe Slide Pattern task alone for a group of patients with early Parkinson's disease (PD)
10132718|NCT04269577|Experimental|SSP training - mid PD|Practice of the Swipe Slide Pattern task alone for a group of patients with mid-stage Parkinson's disease (PD)
10132719|NCT04269577|Experimental|SSP training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls (HC)
10132720|NCT04269499|Other|Study patients|All patients receive holmium radioembolization as per usual
10132721|NCT04269304||Observational|Intermediate Age-Related Macular Degeneration Patients
10132722|NCT04269382|Other|Combined non-invasive and invasive BP measurements|Patients will all undergo measurement of BP through 3 different techniques over a 30-min period: continuous noninvasive BP measurement (with the finger cuff and Clearsight™ device), repeated intermittent oscillometric NIBP measurements with a cuff placed around a calf or an arm, and continuous invasive BP measurement (through an indwelling arterial catheter).
10132723|NCT04269252|Placebo Comparator|CHI-804 at 6 mL|Standard 6 mL dose of placebo oil.
10132724|NCT04269252|Active Comparator|CHI-907 at 1.5 mL|Subjects are assigned to receive one dose of CHI-907.
10132725|NCT04269252|Active Comparator|CHI-907 at 3 mL|Subjects are assigned to receive one dose of CHI-907.
10132726|NCT04269252|Active Comparator|CHI-907 at 6 mL|Subjects are assigned to receive one dose of CHI-907.
9968358|NCT01278719||Antrochoanal polyp; recurrent type|
9968359|NCT01278719||Ethmoidal polyp - non recurrent type|
10132727|NCT04269317|Experimental|Tixel C|Tixel Treatment, between 3-5 treatment session according to investigator's review of subject response follow by 3 Follow up sessions, 1,3 and 6 month after last treatment visit. Subject would be questioned about pain levvel, subjective dountime assessment and subjective response assessment. Images would be taken before treatment visit and in Follow-Up.
9968360|NCT01278719||Ethmoidal polyp - recurrent type|
10132728|NCT04269239|Other|Healthy Habits|This group will meet with a study therapist to discuss strategies to implement healthy habits that may enhance recovery from knee or hip surgery.
10132729|NCT04269239|Other|Sleep Habits|This group will meet with a study therapist to discuss strategies to implement healthy sleep habits that may enhance recovery from knee or hip surgery.
9968361|NCT01278732||untreated persons with suspected hypertension|
9968362|NCT01278758|Experimental|ASA404 + standard therpy|
9968363|NCT01278784|Experimental|Healthy volunteer|
9968364|NCT01278810|Experimental|Icaritin|
9968365|NCT01278823|Experimental|surgery|Surgery: laparoscopic roux en y gastric bypass operation
9968366|NCT01278823|Active Comparator|Medical treatment|Medical Treatment: Comprehensive medical management of diabetes including medications, diet intervention, lifestyle modification, exercise regimen
9968367|NCT01278836|Other|fascio-cutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
9968368|NCT01278849|Experimental|ASA404 + standard therpy|
9968369|NCT01278875||Acute Coronary Syndrome|Subjects with ACS within 72 hours of clinical presentation
9968370|NCT01278875||Stable CAD subjects|Patients with stable, chronic CAD
9968371|NCT01278875||Control subjects|Healthy individuals
9968372|NCT01278888|Active Comparator|PLEACE 1|Anterolateral vs. posterolateral thoracotomy
9968373|NCT01278888|Active Comparator|PLEACE 2|Video assisted thoracic surgery (VATS) vs. anterolateral thoracotomy
9968374|NCT01278901||Cohort of consecutive patients undergoing EGD treated with PPI|Patients positive for helicobacter pylori undergoing EGD, started on PPI therapy for a month, repeated diagnostic tests for Helicobacter pylori after a month of therapy (urease test, histology and breath test)
9968375|NCT01278940|Experimental|Dendritic Cells (DC) malignant melanoma|22 patients were included in this arm.
9968376|NCT01278940|Experimental|DC vaccine plus IL-2|To improve the efficacy of the DC vaccine, IL-2 was administrated at the vaccination site through direct lymph node injection. 9 patients were included in this arm.
9968377|NCT01278966|Experimental|The Modified Atkins Diet|Treatment with the Modified Atkins Diet for 6 months
9968378|NCT01278979|Active Comparator|Assessment of perineal tears|Consenting women sustaining perineal tear after child birth
9968379|NCT01278979|Other|Visual and digital assessment|Consenting women that sustained perineal tear after child birth.
9968380|NCT01279005||20-50 YEARS OLD MSM|
9968381|NCT01279018||Patients treated with docetaxel|Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
9976757|NCT01354613|Experimental|HFpEF|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will receive amlodipine, oral administration for a period of 12 weeks.
9976758|NCT01354613|Experimental|Pulmonary Disease|20 patients with pulmonary disease and no clinical evidence of cardiovascular disease
9976759|NCT01354613|Experimental|LVH/HTN|20 subjects with known left ventricular hypertrophy and clinically diagnosed hypertension without the diagnosis of heart failure.
9976760|NCT01354613|Placebo Comparator|HFpEF placebo|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will be administered a placebo for a period of 12 weeks.
9976761|NCT01354626|Experimental|High fat diets|High-fat-Low-protein or High-fat-high-protein
9976762|NCT01354626|Other|Control group|Low-protein-low-fat (according to healthy eating guidelines)
9976763|NCT01354639||Group 1|Group 1 : conventional open thyroidectomy group (papillary thyroid carcinoma patient who underwent conventional open bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
9976764|NCT01354639||Group 2|Group 2 : robotic thyroidectomy group (papillary thyroid carcinoma patient who underwent robotic bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
9976765|NCT01354665||Group 1|
9976766|NCT01354678|Active Comparator|group of bone marrow cell therapy|
9976767|NCT01354678|Sham Comparator|group of sham therapy|
9976768|NCT01354704|Active Comparator|lovenox|patient under lovenox 4000 IU
9976769|NCT01354704|Active Comparator|enoxa|patients under Enoxa 4000 IU
9976770|NCT01354704|No Intervention|total knee replacement|patients undergoing total knee replacement
9976771|NCT01354704|No Intervention|total hip replacement|patient undergoing total knee replacement
9976772|NCT01354730||Exposed cohort|The woman received AdimFlu-S (A/H1N1) vaccination between 2009/10 and 2010/02. The woman was pregnant at the time of vaccination.
9976773|NCT01354730||Unexposed cohort|The woman was gestation after April 2009.
9976774|NCT01354743|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass
9976775|NCT01354756||bariatric population|obese patients in whom a bariatric surgery is planified
9976776|NCT01354769||Non-intubated patients|
9976777|NCT01354769||Intubated patients|
9976778|NCT01354782|Experimental|Roflumilast|(This is a pharmacokinetic study)
9976779|NCT01354795|Experimental|1.EUS-FNA with or without suction|During EUS FNA is performed, with or without self-retracting 10-mL syringe
9976780|NCT01354795|Experimental|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet into the needle or injecting air
10132730|NCT04269330|Sham Comparator|1-Normal size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
10132731|NCT04269330|Active Comparator|2- small size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
10132732|NCT04269369|Experimental|Group A|Dosage according to French guidelines
10132733|NCT04269369|Experimental|Group B|Dosage according to literature
10132734|NCT04269460|Active Comparator|subcostal transversus abdominis plane block (sTAP)|patients will be in the supine position; after preparing the skin with with povidone iodine, a high frequency (5-10 MHz) ultrasound probe will be used tp identify the rectus abdominis muscle, then 1 mL/Kg of bupivacaine 0.25% will be injected in the plane between rectus abdominis and transversus abdominis muscles.The patient will then be positioned for the procedure if other than supine position is chosen.
10132735|NCT04269460|Active Comparator|quadratus lumborum block (QLB)|patients will be positioned in the lateral decubitus position so that the blocked side will be the uppermost one. After skin sterilization with povidone iodine the ultrasound probe will be positioned to identify the quadratus lumborum muscle. then 1 mL/Kg of bupivacaine 0.25% will be injected behind the QL muscle on the lateral border of the erector spinae muscle.The patient will then be positioned for the procedure if other than lateral decubitus position is chosen.
10132736|NCT04269395|Active Comparator|MAL Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit of the active cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
10132737|NCT04269395|Placebo Comparator|Vehicle Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit in the vehicle cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
10132738|NCT04269473|Experimental|Experimental Group|Participants in the experimental group will receive a telehealth gait retraining intervention in addition to standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
10132739|NCT04269473|Active Comparator|Control Group|Participants in the control group will receive standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
10132740|NCT04269434|No Intervention|Screening|In the screening arm, Ng/Ct results will be sent by the STI Laboratory to the study physicians and these participants will be treated and partner contact tracing will be done.
10132741|NCT04269434|Other|No screening|In the no screening arm, the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
10132742|NCT04269018|Experimental|Cancer specific Mobile text message|This arm will receive daily mobile text message related with cancer risks and prevention
10132743|NCT04269018|Active Comparator|general health messages|This arm will receive general health message once a week
10132744|NCT04269265|Experimental|All Participants|In this single-arm study, all participants will receive the intervention
10132745|NCT04269187|Experimental|With theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU and before administration of theophylline; 200 mg/d orally for 12 days then reassessment of diaphragm by ultrasound.
10132746|NCT04269187|No Intervention|No theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU then reassessment of diaphragm by ultrasound before discharge
10132747|NCT04269122||Part 1|30 eligible subjects will be asked to participate in 3 inpatient visits, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
10132748|NCT04269122||Part 2|90 eligible subjects will be asked to participate in 1 inpatient visit, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
10132749|NCT04268966|Experimental|CMX001|Initial dose of 200mg followed by 4 doses of 100mg
10132750|NCT04268992|Experimental|Long-term exercise|Supervised exercise training three times a week for three months.
10132751|NCT04268992|No Intervention|Usual care|Patients are not offered supervised exercise.
10132752|NCT04269148||Head and Neck Cancer patients|Turkish patients diagnosed with head and neck cancer
10132753|NCT04269226|Experimental|Recruitment maneuver|Recruitment maneuver
10132754|NCT04269226|Active Comparator|No recruitment maneuver|No recruitment maneuver
10132755|NCT04269278||0 ng/ml|Blood specimen which was added 0 ul of dexmedetomidine
10132756|NCT04269278||0.5 ng/ml|Blood specimen which was added 0.25 ul of dexmedetomidine
10132757|NCT04269278||1.0 ng/ml|Blood specimen which was added 0.5 ul of dexmedetomidine
10132758|NCT04269278||1.5 ng/ml|Blood specimen which was added 0.75 ul of dexmedetomidine
10132759|NCT04269109||Control Cohort|A control cohort from September 1, 2018 - October 31, 2018
10132760|NCT04269109||Intervention Cohort|An intervention cohort from March 1, 2019 - April 30, 2019
10132761|NCT04268953|Experimental|AC-SD-03|Study drug administered concurrently with a standard meal
10132762|NCT04268875|Experimental|OCT|"Patient witch coronary artery disease who has been stented and is hospitalised for stable angina or acute coronary syndrome requiring a further coronary angiogram (regardless of time since implantation or type of the initial stent.~- Identification of intrastent restenosis during coronary angiography and realisation of an immediate or deferred OCT."
10132763|NCT04268888|Active Comparator|TACE/TAE Alone|Transarterial Chemoembolisation (TACE) and/or Transarterial Embolisation (TAE) Alone.
10132764|NCT04268888|Experimental|TACE/TAE and Nivolumab|As above for TACE/TAE. Nivolumab adminstered as a flat dose of 480mg IV.
10132765|NCT04269031|Experimental|Cohort 1|On Day 1, randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
10132766|NCT04269031|Experimental|Cohort 2|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
9976781|NCT01354808|Active Comparator|DAPT|
10132767|NCT04269031|Experimental|Cohort 3|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
10132768|NCT04269031|Experimental|Cohort 4|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
10132769|NCT04269031|Experimental|Cohort 5|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
10132770|NCT04269031|Experimental|Cohort 6|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 6 (6 subjects) or matching placebo (2 subjects).
10132771|NCT04268745|Experimental|Virtual Reality|Progressive immersive training with the virtual reality app Scenes: start from most salient to the patient, eventually do all Duration: start at 60 seconds, increase over time up to 3 minutes per scene Complexity: start minimal, gradually increase up to most complex Tasks: standing with diverse base of support (BOS), head turns (progress with speed, planes); stepping, turning 8 weeks, 1 visit per week, 30 minutes long In home: Gait and balance exercises, No exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long
10132772|NCT04268745|Active Comparator|Traditional Vestibular Rehabilitation|"Progressive gait, gaze stability and balance exercises Gait: walking with head turns, progress with range, speed and planes of head movement; change of walking BOS: wide, normal, tandem Gaze: focus on a target while moving head side to side / up down. Progress with speed, duration, busier background, standing to walking.~Balance: standing balance tasks, progress with BOS (wide to narrow to tandem), support surface, eyes closed, duration, head turns.~8 weeks, 1 visit per week, 30 minutes long In home: Gait, gaze stability and balance exercises, including exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long"
10132773|NCT04268927|Experimental|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
10132774|NCT04268927|Active Comparator|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
10132775|NCT04268797|Experimental|HR rTMS H7-coil intervention group|
10132776|NCT04268797|Sham Comparator|sham control group|
10132777|NCT04268667|Experimental|Upper cervical spine manipulation group|Spinal thrust joint manipulation on the atlantoaxial joint
10132778|NCT04268667|Active Comparator|Cervicothoracic spine manipulations group|Different spinal thrust joint manipulations on the thoracic spine (T6), mid-cervical spine (C3-C4) and cervicothoracic junction (C7-T1).
10132779|NCT04268719||Gastro-Esophageal Reflux Disease|Patients defined as having GERD as per Lyon Consensus
10132780|NCT04268719||Non-acid Reflux|Patient excluded for GERD as per Lyon Consensus
10132781|NCT04268810|Experimental|Chondroitin sulphate 2%|chondoritin sulphate 2% ( Uracyst) for bladder instillation. One bladeer instillation per week during 6 weeks.
10132782|NCT04268810|Active Comparator|DMSO 50%|DMSO 50% in saline for bladder instillation. One bladder instillation per week during 6 weeks
10132783|NCT04269083|Experimental|experimental arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
10132784|NCT04269083|Active Comparator|control arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
10132785|NCT04269057||HFpEF|heart failure patients with preserved ejection fraction who using ARNI
10132786|NCT04269057||HFrEF|heart failure patients with reduced ejection fraction who using ARNI
10132787|NCT04268641|Experimental|Use of positioning equipment order 1|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
10132788|NCT04268641|Experimental|Use of positioning equipment order 2|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
10132789|NCT04268641|Experimental|Use of positioning equipment order 3|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
10188057|NCT03720041|Experimental|R1: IRD induction therapy (adaptive)|In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail.
10132790|NCT04268641|Experimental|Use of positioning equipment order 4|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
10132791|NCT04268641|Experimental|Use of positioning equipment order 5|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
10132792|NCT04268641|Experimental|Use of positioning equipment order 6|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
10132793|NCT04268602|Experimental|Intervention Group|intradermal 1% lidocain injection 4 cc+ exercise and transcutaneous electrical nerve stimulation
10132794|NCT04268602|No Intervention|Control Group|exercise and transcutaneous electrical nerve stimulation
10132795|NCT04268589|No Intervention|control group|routine study
10132796|NCT04268589|Experimental|virtual reality group|Three days a week, 2 times a day, 15 minutes in the morning and in the evening for 9 days in total
10132797|NCT04268355|Experimental|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers
10132798|NCT04268459|Active Comparator|Regular exchange|Patients will be appointed each 3 months for regular exchange of voice prosthesis.
10132799|NCT04268459|Active Comparator|Leakage exchange|Patients will have voice prosthesis exchange when leakage occurs.
10132800|NCT04268407|Experimental|2-day prophylactic antibiotics|use prophylactic antibiotic for 2 days after transoral thyroidectomy
10132801|NCT04268407|Other|7-day prophylactic antibiotic|use prophylactic antibiotic for 7 days after transoral thyroidectomy
10132802|NCT04268303|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms dexmedetomidine
10132803|NCT04268303|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms dexmedetomidine
10132804|NCT04268303|Placebo Comparator|Placebo|Sublingual placebo film
10132805|NCT04268420|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP013 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
10132806|NCT04268420|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,2 month."
10132807|NCT04268420|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 4,5,6 month."
10132808|NCT04268420|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
10132809|NCT04268420|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
10132810|NCT04268420|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
10132811|NCT04268381||Healthy (n=23)|
10132812|NCT04268381||Gingivitis (n=20)|
10132813|NCT04268381||Periodontitis (n=40)|
10132814|NCT04268524|Experimental|monotherapy miltefosine|Miltefosine capsules (Impavido®) 2.5 mg/kg daily PO for 28 days <30 kg BW allometric miltefosine dose based on fat-free mass. (approx. 2.5 mg/kg); >30 - ≤44kg BW: 100 mg/day BID; ≥45kg BW 150mg TDS
10132815|NCT04268524|Experimental|Thermotherapy|Thermotherapy (ThermoMed 1.8 ®) 50°C for 30 seconds, 1 session
10132816|NCT04268524|Experimental|Combination miltefosine and thermotherapy|Miltefosine capsules 2.5 mg/kg daily PO for 21days, and thermotherapy 50°C for 30 seconds, one session on day 1 of the miltefosine.
10132817|NCT04268524|Active Comparator|° Meglumine antimoniate (Glucantime®) intralesional|Meglumine antimoniate (Glucantime®) intralesional injections 0.5-3ml, 8 sessions, bi-weekly
10132818|NCT04268563|Placebo Comparator|Placebo|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
9976782|NCT01354808|Experimental|TAPT|
10132819|NCT04268563|Experimental|Metformin|Intervention group 1: received Metformin (Glucophage, Merck, West Drayton, UK; 500 mg ,two times daily
10132820|NCT04268563|Experimental|Sitagliptin|Intervention group2: received Sitagliptin (Januvia, Merck,West Drayton, UK. 50 mg, two times daily
10132821|NCT04268563|Experimental|sitagliptin/metformin|Intervention group3: received Sitagliptin/metformin (Janumet, Merck,West Drayton, UK. 50/500 mg), two times daily
10132822|NCT04268472|Experimental|TR Sequence|In first Intervention period subjects was administered test medecine (GP30101) and in seconde Intervention period subjects was administered reference medecine (Prezista)
10132823|NCT04268472|Experimental|RT Sequence|In first Intervention period subjects was administered reference medecine (Prezista) and in seconde Intervention period subjects was administered test medecine (GP30101)
10132824|NCT04268537|Experimental|PD-1 group|Anti-PD-1 antibody, 200mg, IV, one time
10132825|NCT04268537|Experimental|thymosin group|Thymosin, 1.6 mg sc qd, last for 5 days
10132826|NCT04268537|Placebo Comparator|control group|stand treatment
10187672|NCT03723759|Experimental|Group B|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation C, formulation B, formulation D, formulation E, formulation A, faster aspart 100 U/mL.~The dosing visits will be separated by wash-out periods (2-21 days)."
10132827|NCT04268225|Experimental|Ultrasound Guided Dynamic Needle Tip Positioning Technique|In this arm the US transducer, protected with a sterile cover and sterile gel will be placed in the short axis above the distal end of the selected vein, moving the probe to place the vein in the center of the ultrasound screen under the middle mark of the image. The catheter needle will be inserted close to the transducer. The needle tip will be visualized as a white dot on the ultrasound screen. Then, the transducer will be shifted slightly proximally until the white dot disappears from the screen. The needle and the transducer will be moved alternately toward the patient several times to visualize the needle tip in real time. After penetrating the anterior wall of the vein, these steps will be repeated a few more times with a smaller insertion angle to visualize the white dot in the vein. Finally, the outer catheter will be fully advanced and the needle core will be extracted.
10132828|NCT04268225|Active Comparator|Traditional insertion group|For traditional insertion technique insertion attempt will be blind or tactile. Otherwise, the same protocol and measurements as elaborated for the US guided group will be applied.
10132829|NCT04268511||Caudal epidural block group|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
10132830|NCT04268511||Pudendal nerve block group|The long axis of the ultrasound probe was positioned on a horizontal line connecting the ischial tuberosity that had been previously located by palpation to the anus. The ischial tuberosity could be easily identified as a hypoechoic area that is bounded superiorly by a hyperechoic line. The probe was then moved medially on the same axis until the rectum appeared as another hypoechoic area.
10132831|NCT04268342|No Intervention|Standard care|When clinical services are in the standard case phase of the study, all cases of gonorrhoea infection diagnosed at those services will be managed according to current standard of care management guidelines i.e. all cases of gonorrhoea infection will be treated with ceftriaxone by injection plus oral azithromycin tablets as first line therapy, regardless of whether the treatment is given at the initial clinic or the return clinic visit.
10132832|NCT04268342|Active Comparator|Implementation|When clinical services are assigned to the implementation phase, first line treatment for gonorrhoea infection for patients treated at their first clinic visit will remain the same as it is currently: ceftriaxone by injection plus oral azithromycin tablets. However, patients who are not treated presumptively will be treated at their return visit on the basis of the drug resistance test results. Patients with gonorrhoea infection that is shown to be susceptible to ciprofloxacin will be treated with oral ciprofloxacin therapy when they return for review at clinical services in the implementation phase. Patients with gonorrhoea infection that is not susceptible to ciprofloxacin or with an indeterminate ciprofloxacin result will be treated with ceftriaxone by injection.
9669083|NCT04133532|Experimental|metoprolol-no metoprolol|After a washout period of one month following discontinuation of preceding beta-blocker medication patients will be given metoprolol 50 mg daily. The effect will be evaluated after three months of treatment. After that, another one-month washout period will commence followed by three months without metoprolol medication. Then, a final reevaluation will be performed.
9826052|NCT02405442|Experimental|Andecaliximab 150 mg Every 2 Weeks|Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
10132833|NCT04268186|Experimental|Direct tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target mid-cingulate cortex directly.
10132834|NCT04268186|Experimental|Indirect tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target the middle frontal gyrus, a brain area connected to mid-cingulate cortex.
10132835|NCT04268186|Experimental|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be individually optimized to simultaneously stimulate key nodes connected to mid-cingulate cortex, including anterior insula, MFG and supramarginal gyrus.
10132836|NCT04268186|Sham Comparator|Sham tDCS|Placebo transcranial direct current stimulation (tDCS) will be applied.
10132837|NCT04268147||Spinocerebellar Ataxia-1|individuals with a genetically confirmed diagnosis of SCA-1
10132838|NCT04268147||Spinocerebellar Ataxia-2|individuals with a genetically confirmed diagnosis of SCA-2
10132839|NCT04268147||Spinocerebellar Ataxia-3|individuals with a genetically confirmed diagnosis of SCA-3
10132840|NCT04268147||Spinocerebellar Ataxia-6|individuals with a genetically confirmed diagnosis of SCA-6
10132841|NCT04268147||Freidreich's Ataxia|individuals with a genetically confirmed diagnosis of FA
10132842|NCT04268147||FA Controls|Healthy, age-matched controls
10132843|NCT04268147||SCA Controls|Healthy, age-matched controls
10132844|NCT04268238|Experimental|Control group|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate). Afterwards, this group will receive no treatment. Instead of the sealant, water will be used and the laser will remain with power 0W, that is, there will be no light emission, giving the group the characteristic of the control group, no treatment.
10188058|NCT03720041|Active Comparator|R2: Lenalidomide plus placebo maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus placebo maintenance.
9669084|NCT04133532|Experimental|no metoprolol-metoprol|After a one-month washout period following discontinuation of preceding beta-blocker medication patients will continue another three months without a metoprolol medication. After that, an evaluation will be performed. Then they will be given metoprolol 50 mg daily for three months followed by a reevaluation.
9968382|NCT01279031|Experimental|Abbott WHITESTAR Signature System|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
10132845|NCT04268238|Experimental|Sealant group|In this group, besides the instructions described in the control group, the teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal (sealant) for 5 seconds to the tooth surface and light curing for 20 seconds.
10132846|NCT04268238|Experimental|Low Level Laser Group|In this group, besides the instructions described in the control group, volunteers will receive irradiation with AsGaAl laser, wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, energy density of 35 J/cm2 (considering a spot size of 0.028 cm2 of this equipment), the dose will be 1 J per point. The irradiation will be performed at a cervical, an apical point and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
10132847|NCT04268238|Experimental|Low Level Laser + Sealant Group|In this group, patients will receive the treatments described in Control group, Sealant group and Low Level Laser Group.
10132848|NCT04268329|Other|Educational website: Patient|Patients with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. Patients will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. Patients will be asked to review the material on the website between their initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. Patients will be asked to record the number of times they visit the website and the time spent during each visit. Patients will be given a log sheet to document their use/time on the website. During the 2nd clinic visit patients will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, the patient's participation in the study will be completed.
10132849|NCT04268329|Other|Educational website: Family member|A family member of a patient with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. They will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. They will be asked to review the material on the website between their relatives initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. The family member will be asked to record the number of times they visit the website and the time spent during each visit. They will be given a log sheet to document their use/time on the website. During the 2nd clinic visit the family member will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, their participation in the study will be completed.
10183997|NCT03758963|Experimental|Active Laser|"Once the energy to be applied for the treatment is determined through the laser irradiation testing, conduct laser therapy after selecting T corresponding to treatment laser on GUI.~At irradiation, excluding the circle area with a 100 μm radius (200 μm diameter) from the center of the fovea, irradiate laser in the form of surrounding the leakage site with an interval of 0.5-1 spot diameter (fovea = 1 spot size). As for the test spots, the serial number needs to be given for each treatment spot with the order of irradiation, as described above.~If pigment epithelial detachment (PED) occurs at the leakage site, irradiate laser around the PED (excluding the circle area with a 100 μm radius (200 μm diameter) from the center), not to the leakage site.~Within 2 hours after therapy, perform tests for efficacy evaluation (color fundus photography and fluorescein angiography)."
10183998|NCT03758963|Sham Comparator|Sham Laser procedure|"Select C corresponding to Sham Therapy on GUI of the laser device, and then perform Sham therapy.~During Sham therapy, for patient's blinding, both light from the slit lamp and sound from laser oscillation are same as laser irradiation, and no laser oscillation will occur for treatment.~Perform subsequent procedures in the same manner as the procedure of study group."
10183999|NCT03758950|Placebo Comparator|Placebo|Once daily inhaled placebo
10184000|NCT03758950|Active Comparator|Mometasone|Inhaled Mometasone Furoate 220 mcg DPI
10184001|NCT03758937|Active Comparator|volume-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
10184002|NCT03758937|Active Comparator|pressure-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
10184003|NCT03758924|Experimental|Active arm|Week 0-7: Take 1 ml orally of the product daily (solution of ANAVEX2-73)
10184004|NCT03758924|Placebo Comparator|Placebo arm|Week 0-7: Take 1 ml orally of the product daily (placebo)
10184005|NCT03758911||bone marrow/blood stem cell donors|Participants underwent a one time semi-structured telephone interview to understand the perspectives of bone marrow/stem cell donors experience, including how family dynamics impacted participants' decision to donate and identifying unique supportive care needs of bone marrow/stem cell donors.
10184006|NCT03758898|Experimental|Treatment|Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
10184007|NCT03758898|Placebo Comparator|Group 2|only mobilisation was applied to the patients in the second group
10184008|NCT03758885|Experimental|Nolasiban 900 mg|Nolasiban dispersible tablets for single oral administration
10184009|NCT03758885|Placebo Comparator|Placebo|Placebo dispersible tablets for single oral administration
10184010|NCT03758872||historical comparaison whithout cuff|517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection
10184011|NCT03758859|Experimental|sodium hyaluronate eye drops|the randomly allocated eye will receive sodium hyaluronate drops, followed by a repeat OCT scan; images are then evaluated for clarity by the masked assessor.
9968383|NCT01279031|Experimental|Alcon Infiniti|Alcon Infiniti with the OZIL Torsional Handpiece
9968384|NCT01279083|Experimental|Concentration 1|
10132850|NCT04268394|Experimental|Part 1: CC-99677 with Methotrexate and Sulfasalazine|Fixed-sequence involving CC-99677 + Methotrexate 7.5 mg and sulfasalazine 1000 mg
10132851|NCT04268394|Experimental|Part 2: CC-99677 with Itraconazole and Rifampin|Fixed-sequence involving CC-99677 + Rifampin 600 mg and Itraconazole 200 mg
10132852|NCT04268394|Experimental|Part 3: CC-99677, Midazolam, Digoxin, Metformin, Rosuvastatin|Fixed-sequence involving CC-99677 + Midazolam 2 mg, Digoxin 0.25 mg, Metformin 500 mg, and Rosuvastatin 10 mg.
10132853|NCT04268251|Experimental|Deep learning based denoising MR|1 mm slice thickness coronal contrast-enhanced T1 weighted imaging with deep learning based denoising vs. 3 mm slice thickness coronal contrast-enhanced T1 weighted imaging
10132854|NCT04268212|Experimental|Bitter Melon|The participants were asked to consume 100 ml of bitter melon juice 15 minutes prior to the 75-g oral glucose intake. Participants drank the juice within 5 minutes. Participants remained seated throughout the following 2 hours.
10132855|NCT04268212|Experimental|Exercise|Participants performed 30 minutes of treadmill walking at 65% of the age-predicted maximum heart rate. The exercise started 15 minutes after the 75-g oral glucose intake.
10132856|NCT04268108||group 1|"arm 1: secondary resistance to anti-PD-1 therapy: this patients group received liquid tumor infiltrating lymphocytes combined anti-PD-1 therapy.~arm 2: primary resistance to anti-PD-1 therapy: this patients group received FC preconditioning before received liquid tumor infiltrating lymphocytes"
10132857|NCT04268199|Other|Self Injection of Bortezomib|Subcutaneous self administration of bortezomib
10132858|NCT04268121|Experimental|Phase II|Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas
10132859|NCT04268121|Active Comparator|Prospective cohort|Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy
10132860|NCT04268290|Experimental|SILS plus one assistant ERAS|"Preoperative:~preadmission information, education, counseling, optimization ( breathing training), shortening fasting time and carbohydrate load~Intraoperative:~The intravenous fluid therapy is restricted. All patients undergo single incision plus one port laparoscopic surgery(SILS plus one).~A suitable warming device (such as forced-air heating blankets) and warmed intravenous fluids are been adopted routinely to keep body temperature~Postoperative:~multimodal analgesia (surgical site infiltration, a nonsteroidal anti-inflammatory drug, epidural analgesia) early oral intake and move. nasogastric tubes should not be used routinely. Nasogastric tubes inserted during surgery are been removed before reversal of an aesthesia."
10132861|NCT04268134|Experimental|Omega 3 fatty acid supplement|Omega-3 ethyl esters orally daily (containing 465 mg eicosapentaenoic acid [EPA] and 375 mg docosahexaenoic acid [DHA] per capsule,supplied as 4 x 1gm capsule)
10132862|NCT04268160||Patients with severe aortic stenosis undergoing TAVR|GPx activity levels will be measured on the day of TAVR procedure, the day of discharge, 1 month, and 6 months after the procedure
10132863|NCT04268160||Patients without aortic stenosis|GPx activity levels will be measured on day of recruitment
10132864|NCT04268056||RT patients|100 patients with breast cancer undergoing radiation therapy
10132865|NCT04268082|Experimental|Experimental Group|The Experimental Group followed the training wearing sensorized insoles that provided plantar pressures and shift of foot center of pressure images reported on monitors.
10132866|NCT04268082|Active Comparator|Control Group|The Control Group followed verbal instructions of physiotherapist during training.
10132867|NCT04268017|Experimental|Healthy volunteer|
10132868|NCT04268043|Experimental|flexible laryngeal airway|
10132869|NCT04268043|Experimental|proseal laryngeal mask airway|
9669085|NCT04128696|Experimental|Participants receiving feladilimab and pembrolizumab|Participants were administered feladilimab (humanized anti-ICOS immunoglobulin G4 [IgG4] monoclonal antibody [mAb]) and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an intravenous (IV) infusion once every three weeks.
10132870|NCT04268030||GBA mutation carriers with PD undergoing STN-DBS|
10132871|NCT04267952|Experimental|first group|Hand hygiene intervention program prepared by using planned behavior theory will be applied to the students in this group.
10132872|NCT04267952|Active Comparator|second group|Students in this group will be given classic hand hygiene training
10132873|NCT04267874|Experimental|Arm I (BRB nectar, placebo, biospecimen collection)|Patients receive BRB nectar PO BID for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
10132874|NCT04267874|Experimental|Arm II (placebo, BRB nectar, biospecimen collection)|Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
10132875|NCT04267991||Tacrolimus|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
10132876|NCT04267991||Phototherapeutic Keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
10132877|NCT04267991||Control|patients received only artificial tears eyedrop
10132878|NCT04267965||Group A|Patients who have been successfully operated on with total parathyroidectomy for symptomatic secondary hyperparathyroidism and their PTH levels are below 72 pg/dL within one week after surgery.
10132879|NCT04267965||Group B|Patients who have had regular dialysis and their iPTH levels are around 500 pg/dL
10132880|NCT04268069|Placebo Comparator|Placebo Ophthalmic Solution (vehicle)|vehicle
10132881|NCT04268069|Active Comparator|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution
10132882|NCT04268095|Experimental|No dressing change|Patients do not change dressing from procedure to first clinic followup after 14 days.
9669086|NCT04128696|Active Comparator|Participants receiving placebo and pembrolizumab|Participants were administered placebo and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an IV infusion once every three weeks.
9669087|NCT04126135|Active Comparator|Usual Care Group|Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days.
9968385|NCT01279083|Experimental|Concentration 2|
10132883|NCT04268095|Experimental|Ambulatory dressing change|Patients change dressing by an ambulatory nurse (not associated with the study) 2 times a week from surgery to first clinic followup after 14 days
10132884|NCT04268095|Experimental|No dressing|Patients take off dressing at post operative day 1 and clean it 3 times per day as instructed.
10132885|NCT04267718|Experimental|Patients with the Padua and IMPROVE Bleeding scores|A number of centres will be randomized to systematically evaluate all eligible patients with the Padua and IMPROVE Bleeding scores within 48 h after hospitalization.
9968386|NCT01279083|Experimental|Concentration 3|
10132886|NCT04267718|No Intervention|Patients will be evaluated according to clinical judgment only|A number of centres will be randomized to the Control arm of the study, in which patients will be evaluated for their thrombotic and hemorrhagic risk according to clinical judgment only.
10132887|NCT04267653|Active Comparator|lactoferrin|Oral bovine lactoferrin (bfl) 100 mg once daily on empty stomach
10132888|NCT04267653|Active Comparator|ferrous sulfate|Oral ferrous sulfate 3-6 mg/kg of elemental iron/day in divided doses
10132889|NCT04267653|Active Comparator|combined|combined therapy (both lactoferrin and ferrous sulfate)
10132890|NCT04267900|Experimental|99mTc-HPArk2 SPECT/CT|The patients were injected with 11.1 (MBq) per kilogram body weight of 99mTc-HPArk2 in one dose intravenously and underwent SPECT/CT scan 30-60 min later.
10132891|NCT04267822|Experimental|RV521 Capsules|RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
10132892|NCT04267822|Placebo Comparator|RV521 Placebo Capsules|RV521 placebo capsules will contain mannitol and microcrystalline cellulose only. They are a white, opaque capsule and administered orally.
10132893|NCT04267679|Experimental|Cannabidiol|Participants will take 25 mg full-spectrum CBD soft gel capsules (2 to 4 per day) for 12 weeks.
10132894|NCT04267666|Experimental|Inspiratory Muscle Strength Training|in the form of: Inspiratory threshold muscle trainer in addition to traditional chest physical therapy intervention (Deep breath, cough training)
10132895|NCT04267666|Experimental|Incentive Spirometer|incentive spirometer, three sessions per week for six weeks
10132896|NCT04267913|Experimental|Arm A (docetaxel, dexamethasone, sapanisertib)|Patients receive docetaxel IV and dexamethasone IV over 30 minutes on days 1 and 8 and sapanisertib PO QD on days 2-4, 9-11, and 16-18. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. If docetaxel is discontinued, patients receive sapanisertib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10132897|NCT04267913|Active Comparator|Arm B (standard of care treatment)|Patients receive standard of care treatment comprising either docetaxel IV and dexamethasone IV over 30 minutes on day 1 or docetaxel IV, dexamethasone IV over 30 minutes, and ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10132898|NCT04267614||Patients with Rheumatoid Arthritis (RA)|Patients receiving etanercept from Baghdad teaching hospital registry(Rheumatology center) from 2012 till 2017. Patients were identified as receiving early versus delayed etanercept treatment.
10132899|NCT04267835||MICS (Minimal invasive coronary surgery)|Patients undergoing MIDCAB surgery.
10132900|NCT04267835||OPCABG (thoracotomy off-pump CABG)|Patients undergoing thoracotomy OPCABG surgery
10132901|NCT04267757|Experimental|group 1|RVF with Martius flap
10132902|NCT04267757|Experimental|group 2|RVF without Martius flap
10132903|NCT04267523|Experimental|Web-based parenting intervention|Families randomized to this intervention group will receive a self-administered web-based parenting intervention. Parents have access to a weekly 6-modules parenting intervention.
10132904|NCT04267523|Active Comparator|Face-to-face parenting intervention|Families randomized to this intervention group will receive a face-to-face group parenting intervention. Groups will meet weekly for 120 minutes for 4 weeks.
10132905|NCT04267705|Active Comparator|Black bean|A cup of black bean 7 days/week over a 12-week period
10132906|NCT04267705|Active Comparator|Chickpea|A cup of chickpea 7 days/week over a 12-week period
10132907|NCT04267705|Placebo Comparator|Control|A cup of white rice 7 days/week over a 12-week period
10132908|NCT04267809|Experimental|Metformin 850mg once daily|Metformin 850mg tablet will be administered orally once daily for 10 consecutive days.
10132909|NCT04267809|Experimental|Metformin 850mg twice daily|Metformin 850mg tablet will be administered orally twice daily for 10 consecutive days.
10132910|NCT04267809|Experimental|Metformin 1000mg once daily|Metformin 1000mg tablets will be administered orally once daily for 10 consecutive days.
10132911|NCT04267809|Experimental|Metformin 1000mg twice daily|Metformin 1000mg tablets will be administered orally twice daily for 10 consecutive days.
10132912|NCT04267484||Older adults with mild cognitive impairment|"WP1, older adults with cognitive impairment will use a GPS tracker for 2 weeks, during which they are asked 1) to keep a daily diary about their activity (travel diary), 2) take the researcher on a walk that they often do (walking interview), and 3) participate in an in-depth interview after 2 weeks, in which their experience with the GPS ans the travel diary data are discussed.~WP2, older adults with mild cognitive impairment, caregivers, health professionals and technology developers will collaborate during group discussion meeting to co-design the e-decision support platform to be adapted.~WP3, older adults with mild cognitive impairment, caregivers and health professionals will then be asked to use the adapted e-decision support platform and fill a survey."
10132913|NCT04267497|Experimental|Nebulized Amphotericin B|Amphotericin B.
10132914|NCT04267497|Placebo Comparator|Nebulized Placebo|Sterile water for injection.
10132915|NCT04267627|No Intervention|Usual Care|No intervention.
10132916|NCT04267627|Experimental|CARING with telemedicine|Patients will receive the nurse-led supportive care intervention over telemedicine videoconferencing from home or from a satellite telemedicine site in Virginia.
10132917|NCT04267627|Experimental|CARING face-to-face|Patients will receive the nurse-led supportive care intervention in person.
10132918|NCT04267419||healthy Control|MDA and NO in saliva
10132919|NCT04267419||keratosis|MDA and NO in saliva
10132920|NCT04267419||leukoplakia|MDA and NO in saliva
10132921|NCT04267419||Oral lichen Planus|MDA and NO in saliva
9968387|NCT01279083|Experimental|Concentration 4|
10132922|NCT04267419||oral Squamous cell carcinoma|MDA and NO in saliva
10132923|NCT04267471|Experimental|Tai Chi|3 sessions of Tai Chi per week for 12 weeks
10132924|NCT04267471|Active Comparator|Walking|3 sessions of walking per week for 12 weeks
10132925|NCT04267471|No Intervention|Waiting-list|
10132926|NCT04267458|Other|HCV infected patients with non-elevated sCr than basal levels|a group of egyption patients with HCV infection with non-elevated sCr than basal levels and treated with sofuspovir as an direct acting antiviral drug
10132927|NCT04267445||Embolization patients|"Single center, open label, pilot study. Eligible patients will undergo transarterial embolization of the prostatic vasculature. Each patient will undergo a single embolization procedure.~After completion of treatment in the first 2 patients and a review of follow-up assessments after 7 days, subsequent patients will be enrolled if no safety concerns have arisen in the first 2 patients.~Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.~Magnetic resonance imaging (MRI) and CEUS is used to assess changes in prostate volume and in central gland enhancement characteristics using 3D volume assessment software."
10132928|NCT04267549|Experimental|treatment|eligible patients will be given sintilimab (200mg, iv, q3w,)， apatinib (250mg/d， QD)，S1 （50mg PO，b.i.d d1-14 ）and nab-paclitaxel (260mg, iv, 3h, d1,q3w) for 3-6 cycles. If patients converted to surgery, then administer treatment post surgery upto 3cycles. Then give sintilimab and apatinib each 3 weeks for maintenance .
10132929|NCT04267432|Placebo Comparator|Placebo|Placebo
10132930|NCT04267432|Experimental|TCI633|Testing product
10132931|NCT04267432|Active Comparator|Type 2 collagen|Known drug for OA
10132932|NCT04267367|Experimental|Intervention|The intervention will include a dietitian-led nutrition education, counseling session and individual basis diet plan emphasis on glycemic control diet targeted to T2DM patients attending during the OPD visits in hospital.
10132933|NCT04267367|No Intervention|Usual care|The usual care arm will be only provided general education.
10132934|NCT04267354|Experimental|Arm cycling|Participants will perform arm cycling using a table-top arm cycler. Cadence and resistance of the exercise will be determined as per each individual's tolerance. All exercise will be supervised by the neuromuscular specialist physio, to ensure it is completed safely. Participants will be able to have plenty of breaks during the assessments.
10132935|NCT04267341||Mild Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 1-2
10132936|NCT04267341||Moderate Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 2.5-3
10132937|NCT04267341||Healthy Control|Healthy People
10132938|NCT04267692|Experimental|Harm Reduction Treatment Circles (HaRTC)|Participants will attend 8, weekly Harm Reduction Treatment Circles. We will not limit participants' access to other treatment or services.
10132939|NCT04267692|No Intervention|No-Treatment control|We will not limit participants' access to other treatment or services.
10132940|NCT04267107|Experimental|Managing Fatigue:The Individual Program|"Participants in the experimental group will receive the 6-week MFIP. Individuals in experimental group :~will participate in six one-to-one sessions (each takes 60 to 90 minutes)~will complete the Feasibility Questionnaire #1, after each session (10 questions) (Appendix 6)~will complete Feasibility Questionnaire #2 after completing all six-sessions (12 questions) (Appendix 7)~will complete the post-test measurement after completion of the program (approximately 60 minutes to complete)~will complete the follow-up measurement, three months after the completion of the program (approximately 60 minutes to complete)~will be advised to continue with their current healthcare services.~may participate in one focus group (one-hour session)"
10132941|NCT04267107|No Intervention|Control Group|"Participants in the control group will not receive the IMFP and they will be advised to continue with their current healthcare services.~Participants in the control group:~will complete post-test measurements after 6 weeks (approximately 60 minutes),~will complete the follow-up measurements three months later after completing the program (approximately 60 minutes).~will be advised to continue with their current healthcare services.~Following the study, participants in the control group will be offered the manual of the program and a three-hour training workshop after (three months after the baseline testing). In this workshop, they will learn about the about the program, including the pre-session activities, in-session activities, and homework. This workshop will be conducted by occupational therapists."
9968388|NCT01279083|Placebo Comparator|Vehicle Solution|
10132942|NCT04267159|Active Comparator|Conventional treatment by acute cardioversion|Participants in the conventional treatment arm will be returned to sinus rhythm in the emergency department within 48 hours of symptom onset unless they convert to sinus rhythm spontaneously.
10132943|NCT04267159|Experimental|Elective treatment by delayed cardioversion|Participants in the elective treatment arm will be returned to sinus rhythm in an out-patient clinic approximately one week after randomizatio unless they convert to sinus rhythm spontaneously.
10132944|NCT04267315|Active Comparator|Active|3 weekly sessions of TPI. Participants will undergo 1mL injections of 1% lidocaine in the muscles identified with either active or latent trigger points at the initial assessment. The same muscles will be injected at all procedures.
10132945|NCT04267315|Sham Comparator|Placebo|3 weekly sessions of subcutaneous saline injections. Participants will undergo 0.2mL subcutaneous saline injections superficial to the trigger points identified at initial assessment. The same superficial sites will be injected in all procedures.
10132946|NCT04267289|Experimental|iCBT treatment group|Subjects were given license to use Beating the Blues, a commercially available iCBT program. Subjects were given 3 months to use the program.
10132947|NCT04267211|Experimental|Illustrated Consult|
10132948|NCT04267211|Experimental|Standard Consult|
9968389|NCT01279083|Active Comparator|Timolol Maleate Ophthalmic Solution|
9968390|NCT01279122|No Intervention|Nanoflex IOL|
9968391|NCT01279135|Active Comparator|Conventional RT|Patients in this arm will receive conventional radiation with or without chemotherapy
9968392|NCT01279135|Experimental|Tomotherapy based IGRT|Patients in this arm will receive Tomotherapy based IGRT with or without chemotherapy
9976783|NCT01354821|Active Comparator|Endovascular therapy branched|Endovascular therapy branched or fenestrated stent-graft
10132949|NCT04267237|Experimental|Atezolizumab|Participants will receive atezolizumab on Day 1 of each 28-day cycle (Q4W) for 12 cycles.
10132950|NCT04267237|Experimental|Atezolizumab + RO7198457|Participants will receive atezolizumab Q4W along with RO7198457 for 12 cycles.
10132951|NCT04267224||Early group|Patients receiving the loading dose of Ticagrelol 90 mg more than 60 minutes before PCI.
10132952|NCT04267224||Late group|Patients receiving the loading dose of Ticagrelol 90 mg less than 60 minutes before PCI.
10132953|NCT04267263|No Intervention|Delayed Treatment Control group|Participants will receive the treatment after completion of the 3-month follow-up assessment
10132954|NCT04267263|Experimental|Lifestyle group|Participants will receive the treatment immediately
10132955|NCT04267250|Experimental|Sequence 1|In sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into period 2 where they will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10.
10132956|NCT04267250|Experimental|Sequence 2|In sequence 2, period 1, participants will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10. After a wash-out period of at least 10 days, participants will continue into period 2 where they will receive an additional single dose of OC.
10132957|NCT04266990|Experimental|Epilepsy patients|Epilepsy patients admitted for clinical purposes in the EEG monitoring units at the UZ
10132958|NCT04266990|Active Comparator|Healthy volunteers|Healthy volunteers recruited from among colleagues from the department and hospital staff
10132959|NCT04267042|Active Comparator|Budesonide via Mucosal Atomization Device (MAD)|"Patients in this arm will administer budesonide using a mucosal atomization device (MAD, Wolfe-Tory Medical, Salt Lake City, UT) once a day at least 5 times a week for 6 months postoperatively. The MAD atomizes the medication into particles from 30-100 um in size thus increasing the surface area for drug absorption.~Budesonide is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the MAD syringe."
10132960|NCT04267042|Active Comparator|Budesonide via nasal saline irrigation (INSI)|"Patients in this arm will administer impregnated budesonide in nasal saline irrigation (INSI) using a NeilMed squeeze bottle (NeilMed Pharmaceuticals, Santa Rosa, California) once a day at least 5 times a week for 6 months postoperatively.~Budesonide is provided in nebules (1mg/2cc).Patients will place two nebules of budesonide into the 240mls of saline."
10132961|NCT04267133|Experimental|All Participants|
10132962|NCT04267029||Cases: CRTR (cardiorespiratory transfusion reaction)|Respiratory/cardiovascular disturbances after transfusion (>/=2 of respiratory distress, pulmonary edema, cardiovascular system changes, fluid shifts, cardiac strain indicators), with or without accompanying (or pre-existing) fever
10132963|NCT04267029||Controls: HRFTR (high risk febrile transfusion reactions)|Post-transfusion fevers requiring laboratory investigation (Tmax>/=39C, or lesser deflections if accompanied by chills/rigors), without respiratory features (hypoxia or dyspnea)
10132964|NCT04267302|Other|Baby Bouncer Group|Participants in the group will be receiving a baby bouncer for use from infant's birth up to 8 months after birth.
10132965|NCT04267302|Other|Baby Bouncer Group with Infant T-Shirt with LENA|A subsample of the participants in the baby bouncer group will also receive infant t-shirts with wearable audio recorders.
10132966|NCT04267302|Other|Baby Carrier Group|Participants in the group will be receiving a baby carrier for use from infant's birth up to 8 months after birth.
10132967|NCT04267302|Other|Baby Carrier Group with Infant T-Shirt with LENA|A subsample of the participants in the baby carrier group will also receive infant t-shirts with wearable audio recorders.
10132968|NCT04267068|Experimental|Intervention|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
10132969|NCT04267068|Active Comparator|Control|Online daily activity scheduling interactive article (control)
10132970|NCT04267081|Experimental|Arm 1 (de novo AML)|"This arm will recruit the patients with de novo AML unfit for conventional chemotherapy. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
10132971|NCT04267081|Experimental|Arm 2 (relapsed, refractory or secondary AML)|"This arm will recruit the patients with relapsed, refractory or secondary AML. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
10132972|NCT04267185|Experimental|Immediate Intervention|PwMS-CG dyads will receive six group telerehabilitation sessions (~60 min each) every other week for a period of 12 weeks. This will be interspersed with brief one-on-one support telephone calls in the weeks that group sessions do not occur. All participants will be taught techniques for monitoring PA behaviour, setting personalized goals to increase PA and reduce sedentary time, and strategies for overcoming challenges to PA participation. Make-up sessions will be offered to those who miss group sessions. The one-on-one support telephone calls will serve to reinforce the information provided during the group sessions, monitor safety and troubleshoot any issues with intervention content.
10132973|NCT04267185|No Intervention|Delayed Control|The delayed control group will not receive the intervention during the study period. Participants assigned to the control group will be offered the intervention once the study is completed.
10132974|NCT04267146|Experimental|newly diagnosed high-grade glioma|"Phase I : Open label, non-randomized, safety run study in nine patients. In case of safety issue a -1 dose level will be tested.~Phase II : Open label, non randomized, efficacy study of nivolumab in addition to radiotherapy and temozolomide. This phase will start when the RP2D has been defined after the last patients evaluable for DLT achieved the first 6 weeks of treatment (the radio-chemotherapy period) with a DLT rate below 30% during the the phase I study."
10132975|NCT04267016||All Subjects Enrolled|Renal transplant recipients who are undergoing routine management
10132976|NCT04266977|Experimental|Treatment Dexamethasone|"The restrictive DEX regimen is applied from referral to the neurosurgical center until discharge. All administered steroids will be stopped immediately after study inclusion.~If one or more of the previously defined failure criteria occurs, patients will be treated with DEX."
10132977|NCT04266886|Active Comparator|Arm I (usual care)|Patients receive usual care including receipt of multi-modal analgesia and the injection of a local analgesic at the time of surgery on the ERAS pathway.
10132978|NCT04266886|Experimental|Arm II (usual care, self-hypnosis guided relaxation)|Patients receive usual care as in Arm I. Patients also receive self-hypnosis guided relaxation by listening to MP3 on the ERAS pathway.
10132979|NCT04266847|Experimental|unilateral mild cataract patients|The patients who underwent monocular IOL implantation before and then present mild cataract in the fellow eye.
10132980|NCT04266873|Experimental|AffloVest HFCWO intervention|Use of the AffloVest for 30 mins, twice a day for 6 weeks
10132981|NCT04266769|Experimental|Patients with Malocclusion|
10132982|NCT04266938|Active Comparator|Prospective RAPID|The prospective RAPID arm will include all patients who meet inclusion criteria and who start BIC/F/TAF within 7 days of HIV diagnos
10132983|NCT04266938|Active Comparator|Prospective Non- RAPID|The prospective non-RAPID arm will include all patients identified as having new HIV diagnosis per health department records, but who failed to establish care at the 550 Clinic and begin BIC/F/TAF within one week of diagnosis
10132984|NCT04266938|Active Comparator|Retrospective Non- RAPID|The retrospective Non-RAPID arm will include historic controls who enrolled in the treatment program from 2012, when universal ART guidelines were implemented, until prior to the implementation of RAPID start of ART.
10132985|NCT04266821|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
10132986|NCT04266821|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
10132987|NCT04266808|Experimental|An interactive telehealth monitoring and biofeedback system|Participants in this group will receive feedback of pressure relief maneuvers and wheelchair propulsion activity. Feedback for pressure relief will include information during the activity to identify adequate duration and magnitude of pressure relief activity, reminders of when the next pressure relief is due, and daily aggregate information regarding the number of successful pressure relief maneuvers performed.
10132988|NCT04266808|Sham Comparator|Education Control|Participants will receive education on the importance and recommended frequency of pressure relief maneuver for prevention of pressure ulcer/injury and on the importance and recommended amounts of physical activity for health.
10132989|NCT04266860|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
10132990|NCT04266860|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
10132991|NCT04266743|Experimental|Hemiparetic patient|patients who had a stroke at least 6 months before inclusion
10132992|NCT04266834|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
10132993|NCT04266834|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
10132994|NCT04266899|Experimental|FDS+Treadmill gait training|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Treadmill gait training during two weeks.
10132995|NCT04266626|Experimental|Group A kinesiotaping therapy|"Protocols mentioned in kinesiological taping i.e. 45 minutes will be pursued as with longer sessions children may tire out easily. Taping Technique for lip muscles would be used by cutting 2 I tapes according to the structure of lip muscles.The tape will be fixed in the center of the mouth on the upper lip, will be placed on an open mouth and a 10% tension will be given to the paper. The tape will then end at the corner of the upper lip. Kinesiotape wouldn't be placed on the lips. The second tape piece will be fixed to the center of the lower lip.The edges of the tape should overlap slightly.~The other piece of tape will be placed under chin (base of tongue) on sub mandibular triangle, inside the jaw line on the base of the tongue. A strip 1-1 ½ inch long will be cut, and then will further be cut in half such that the stretch is horizontal. It will be anchored in the middle on sub mandibular triangle. Paper off the tension to both sides."
10132996|NCT04266626|Active Comparator|Group B Oral Motor Manipulation therapy|"For the oral motor manipulation technique CP chair will be required to maintain the good sitting posture of children. Trunk will be in upright position with cut out lap board of the CP chair. Hips, knees and ankles would be flexed to 90 degrees. Shoulders and arms will be rested in symmetrical manner by keeping them rested in lap board and foot rest will be used to rest the feet tightly to control movement and maintain good posture. Each child would be taken for 12 weeks of therapy with three sessions per day of 15 minutes each. Oral motor manipulation like tapping protocols would be used for 45 minutes; slow, even rhythmic pressure will be applied around lip muscle and base of tongue muscle, keeping in view the comfort level of patient.~Training to do manipulation exercises will be given to the parents of children with CP at ."
10132997|NCT04266587|Experimental|Healthy volunteers|blood sampling is done on healthy volunteers
10132998|NCT04266782|Experimental|Physical exercise program and Long-walking|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
10132999|NCT04266782|No Intervention|Usual care|The subjects will be followed according to current standard.
10187673|NCT03723759|Experimental|Group C|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation E, formulation C, formulation A, formulation B, faster aspart 100 U/mL, formulation D.~The dosing visits will be separated by wash-out periods (2-21 days)."
10133000|NCT04266782|Active Comparator|Control group-intervention|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
10133001|NCT04266691||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
10133002|NCT04266691||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
10133003|NCT04266574|Experimental|Near Infrared Spectroscopy (NIRS)|
10133004|NCT04266574|Active Comparator|Standard Care|
10133005|NCT04266678|Experimental|Elastic band resistance training|Resistance training with elastic resistance bands two days per week for 6-weeks.
10133006|NCT04266678|Active Comparator|Dumbbell resistance training|Resistance training with dumbbell weights two days per week for 6-weeks.
10133007|NCT04266678|No Intervention|Non-exercise Control|Education and guidance for exercise recommendations in older adults but no active training sessions.
10133008|NCT04266756|Experimental|Cohort 1: Selexipag Matrix Tablets|Participants will receive oral doses of selexipag matrix tablets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
10133009|NCT04266756|Experimental|Cohort 2: Selexipag Encapsulated Pellets|Participants will receive oral doses of selexipag encapsulated) pellets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
10133010|NCT04266717|Experimental|Baby Play Parent Education Group|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
10133011|NCT04266717|Active Comparator|Milestone Education Group|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
10133012|NCT04266444|Active Comparator|Level 4|10Cubes game in virtual reality using very small bouncing blocks
10133013|NCT04266444|Active Comparator|Level 3|10Cubes game in virtual reality using very small non-bouncing blocks
10133014|NCT04266444|Active Comparator|Level 2|10Cubes game in virtual reality using large bouncing blocks
10133015|NCT04266444|Active Comparator|Level 1|10Cubes game in virtual reality using large non-bouncing blocks
10133016|NCT04266496|Other|<2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention~Complete a 3 day Frequency Volume chart~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
10133017|NCT04266496|Other|=> 2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention~Complete a 3 day Frequency Volume chart and collection of the urine of the last day and night to complete osmolality and sodium testing.~Measuring the circumference off the lower limbs just after awakining and before falling asleep~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
10133018|NCT04266652|Experimental|Autogenous bone block|the monocortical block grafts were harvested from the retromolar region (i.e. linea oblique) by using of rotating (i.e. carbide burs)
10133019|NCT04266652|Experimental|Tooth block|In the first group, a second mucoperiosteal flap was elevated to surgically remove the respective wisdom tooth. After its removal and during the same surgery, the crown was decapitated at the cemento -enamel junction using a rotating carbide bur under gentle sterile saline cooling and the exposed pulp was preserved. The separated tooth root was adapted to match the size and shape of the defect area. To improve ankylosis between the graft and the defect site, the layer of cementum at the respective downward aspects of the root was carefully removed using a diamond bur until the underlying dentin was entirely exposed
10133020|NCT04266600|Experimental|Prospective arm (extended mesenteric resection)|"Surgery can be performed either laparoscopically or open depending on surgeon preference and the circumstances of the surgery. Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis. The entire mesentery related to the specimen will be removed.~Outcomes in the prospective arm will be compared to historical controls."
10133021|NCT04266600|No Intervention|Retrospective arm|Retrospective patient data will be obtained by querying the Opera operating room database of both study institutions. Electronic records will be analyzed for all patients undergoing a first-time ileocolic resection for Crohn's Disease between January 1, 2009 - December 31, 2018.
10133022|NCT04266548|Experimental|super-selective hepatic artery ICG injection group|single arm for feasibility study of intra-hepatic artery base fluorescent segmental demarcation
9976784|NCT01354821|Other|Open surgical repair|Open surgical repair or aortic replacement with revascularization of visceral arteries
10133023|NCT04266613||All Subjects Enrolled|High immune risk transplant recipients who are undergoing routine management under current standard of care
10133024|NCT04266561|Other|lap. recurent inguinal hernia repair|After induction of general anesthesia, the patient was placed supine in Trendelenburg's position. Insertion of the main umbilical port. Laparoscopic hernia repair was done by intracorporeal insertion of purse string technique with some modifications
10133025|NCT04266353|Experimental|Single arm|Participants with receive resveratrol at 150 mg daily for 6 weeks
10133026|NCT04266262|Experimental|High-Intensity interval training (HIIT)|
10133027|NCT04266262|Experimental|High-intensity resistance training (HIRT)|
10133028|NCT04266262|No Intervention|Usual care (UC)|Provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
10133029|NCT04266405|Placebo Comparator|Placebo drink|
10133030|NCT04266405|Experimental|Collagen and Zhuyin Drinks|
10133031|NCT04266535||TCI|Patients receiving Target Controlled Infusion (TCI) Anesthesia
10133032|NCT04266535||MCI|Patients receiving Manually Controlled Infusion (MCI) Anesthesia
10133033|NCT04266509|Experimental|Rifampin and PF-06651600 DDI|In Period 1, participants will receive a single oral 50 mg dose of PF-06651600. In Period 2, participants will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, in the morning of Day 8 participants will be administered with rifampin 600 mg 2 hour prior to administration of a single 50 mg oral dose of PF-06651600.
10184012|NCT03758846|Experimental|Cognitive-motor Exergaming|A total of 6 Wii-fit games: Bubble balance, Table Tilt, Tightrope walking, Soccer head, Basic Run and Basic Step. A total of 6 cognitive tasks namely Digit recall, repeated letter, word list generation (category and alphabets), mental arithmetic, analogies. Each session was divided into 3 sub-sessions. Every Wii-fit game was played with any 3 cognitive tasks. The combination of games with cognitive tasks was randomized in such a manner that all the cognitive tasks were played with the Wii-fit games in that session. Breaks were provided after each sub-session or when the participant demanded one or when the research personnel noticed any discomfort of the participant.
10184013|NCT03758846|Active Comparator|Conventional balance Training for people with Chronic stroke|The sessions were divided into 10 minutes of warm-up that involved active movements of the body (arm movements, trunk twists, lunges). Next 15 minutes consisted of functional strengthening exercises like high stepping, lunges, squats, resistance training using therabands and weights. Following 35 minutes included balance training exercises like one leg standing, tandem standing, sit to stand exercises, reach outs and step-ups. Last 10-15 minutes were spent treadmill walking. Breaks were provided in between the exercise training as and when needed by the participant.
10184014|NCT03758846|Experimental|Dance Therapy for Stroke|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
10184015|NCT03758846|Experimental|Dance Therapy for Older Adults|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
10184016|NCT03758846|Active Comparator|Conventional therapy - Home education for Older adults|Participants received a one-hour education on conventional physical exercises and fall prevention.
10184017|NCT03758833|Active Comparator|SET|patients receiving the elective single embryo transfer
10184018|NCT03758833|Experimental|SET+NGS|patients receiving the elective single embryo transfer evaluated genetically by NGS
10184019|NCT03758833|Active Comparator|DET|patients receiving the elective double embryo transfer
10184020|NCT03758833|Experimental|DET+NGS|patients receiving the elective double embryo transfer evaluated genetically by NGS
10184021|NCT03758820|Experimental|BCT group|"Intervention : Behavorial Cognitive Therapy (BCT) will be delivered by two psychologists at six once-weekly sessions of 90 minutes (with homework activities between the sessions) + 4 booster sessions at week 6, 12, 18 and 36 after the end of the programme.~It was designed for groups of 8 to 10 people. The programme is standardised: PowerPoints presentations support each session and a detailed facilitator manual and companion patient workbook. accompany the programme."
10184022|NCT03758820|No Intervention|Control group|Usual local practice
9976785|NCT01354834||hMG|
10184023|NCT03758807|Sham Comparator|Passive treatment|Passive treatment will consist of Manual Therapy with biomechanical explanation of the technique.
10184024|NCT03758807|Experimental|Active Treatment|Active treatment will consist of Manual Therapy with a neuroplasticity explanation of the technique.
10184025|NCT03758794|Active Comparator|interactive lecture module|interactive lecture
10184026|NCT03758794|Active Comparator|online educational module|online educational using a special link
10184027|NCT03758768|Experimental|Blue monochromatic light|Three consecutive mornings of one hour exposure to monochromatic light (20 lx, irradiance = 49.65 µW/cm2) with peak wavelength of 455 nm (blue light), with equal photon flux as the control condition.
10188059|NCT03720041|Experimental|R2: Lenalidomide + ixazomib maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus ixazomib maintenance.
10188060|NCT03720028||Child w Angelman/Rett syndrome|Children with Angelman or Rett syndrome, up to 14 years of age
9976786|NCT01354847||cardiac surgery patients|cardiac surgery patients scheduled for elective complex cardiac surgery
9976787|NCT01354860|Experimental|Moxibustion treatment plus usual care|
9976788|NCT01354860|No Intervention|usual care alone|
9976789|NCT01354886|Experimental|FSH-GEX 25 IU|25 IU single dose
10133034|NCT04266327|Experimental|I-125 Seed Implantation|All the enrolled patients were treated with ct-guided radioactive i-125 seed implantation assisted by 3D printing template.Prescription dose 110-130gy.
10133035|NCT04266522|Active Comparator|Arm I (printed materials)|Patients receive printed materials describing the technical aspects of their treatment.
10133036|NCT04266522|Experimental|Arm II (printed materials, physicist interaction)|Patients receive printed materials as in Arm I. Patients also receive a minimum of 2 direct physicist interactions to describe the technical aspects of their treatment either immediately prior to or immediately after treatment simulation.
10133037|NCT04266236|Active Comparator|L3 LPB technique (P group)|ultrasound-guided shamrock approach L3 lumbar plexus block with single-needle technique
10133038|NCT04266236|Active Comparator|T12 combined with L3 and L4 LPB technique (TP group)|ultrasound-guided posterior approach thoracic 12 combined with L3 and L4 lumbar plexus block with mulitple-needle technique
10133039|NCT04266236|Experimental|L3 LPB combined with QLB (LPQLB-SNT, PQ group)|ultrasound-guided shamrock approach L3 lumbar plexus block combined with quadratus lumborum block with single-needle technique
10133040|NCT04266392|Experimental|1|
10133041|NCT04266288|Experimental|Ketamine|Ketamine 0.5 mg/kg in 0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose.
10133042|NCT04266288|Placebo Comparator|Placebo|0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose
10133043|NCT04266340|Placebo Comparator|placebo|no premedication
10133044|NCT04266340|Experimental|oralmidazolam|0.5 mg/kg oral midazolam group
10133045|NCT04266340|Experimental|intravenous midazolam|0.05 mg/kg intravenous injection midazolam group
10133046|NCT04266340|Experimental|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
10133047|NCT04266366|Active Comparator|Face-to Face rehabilitation program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience. This program will be developed in the rehabilitation service of the study health centers. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
9669088|NCT04126135|Experimental|Treatment Group|Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time.
10133048|NCT04266366|Experimental|Telemedicine Program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 8 weeks, with a total of 24 sessions
10133049|NCT04266184|Experimental|Kinesio tape (KT)|Abdominal and symphisis pubis supported lumbopelvic KT will be applied. This group will also receive the same educational program with the control group.
10133050|NCT04266184|Active Comparator|Pelvic belt (PB)|A narrow and flexible adjustable pelvic belt will be used in high position (just under the spina iliaca anterior superior). This group will also receive the same educational program with the control group.
9976790|NCT01354886|Experimental|FSH-GEX 75 IU|75 IU single dose
10133051|NCT04266184|Other|Control group|This group will receive a 1-hour educational program composed of neuroscience education and ergonomic training.
10133052|NCT04266132|Active Comparator|Retrolamianar block (RLB)|General anaesthesia will be induced.Ultrasound-guided RLB will be performed under strict aseptic precautions with patient in the lateral position.The anesthetic solution will be injected.
10133053|NCT04266132|Active Comparator|Ilioinguinal nerve block (INB)|General anaesthesia will be induced. Ultrasound-guided INB will be performed under strict aseptic precautions with patient in the supine position.The anesthetic solution will be injected.
10133054|NCT04266106|Placebo Comparator|Placebo Comparator|
10133055|NCT04266106|Experimental|probiotic|
10133056|NCT04266171|Experimental|CGMS Diet Education|
10133057|NCT04266171|Active Comparator|Conventional Diet Education|
10133058|NCT04266210|Experimental|Fuji Bulk|Glass ionomer (Fuji Bulk, GC, Tokyo Japan)
10133059|NCT04266210|Experimental|G-ænial Posterior|Posterior composite resin(G-ænial Posterior, GC, Tokyo Japan)
10133060|NCT04266119|Experimental|Intervention|"The HOPE intervention can be accessed through web. It consists of two sessions per week, with a total of four sessions. In this study, participants will be sent weekly weblinks for access to each session. Each session take about ten minutes to complete. Each session consist of pre-post multiple-choice and/or open-end question, video(s) and mental health information. The first session is about depression. The second session is about positive psychology and consists of relevant exercises such as gratitude, affect-based and strength-based exercises. The third session describes anxiety disorder. The last session describes relaxation techniques and self-management of unhelpful thoughts.~Each session consists of quizzes, video(s), and graphical / written information"
10133061|NCT04266119|Active Comparator|Control|The group will receive a control website intervention that consists of several graphical inspirational quotes. Examples of the quotes are, 'Today is full of possible' and 'You can do anything'.
10133062|NCT04266223|Experimental|Mask-free surface monitoring|Lay in treatment position for 20 minutes with surface monitoring technology activated
10133063|NCT04265781|Experimental|Dose escalation BAY1817080|Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.
10133064|NCT04265781|Experimental|Dose expansion BAY1817080|Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.
10133065|NCT04265781|Placebo Comparator|Dose escalation Placebo|Participants receive placebo tablets orally as a single dose on Day 1.
10188061|NCT03720028||Parent|Parents of Children with Angelman or Rett syndrome
9669089|NCT04125095||Head Scans|Includes patients receiving proton therapy for tumors in the brain, skull, and head and neck region. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
9976791|NCT01354886|Experimental|FSH-GEX 150 IU|150 IU single dose
9519598|NCT03285607|Experimental|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
9528190|NCT03213132|Active Comparator|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
9968393|NCT01279148||Biopsy/Ablation - CONTROL GROUP|The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again.
9968394|NCT01279148||Biopsy/Ablation - STUDY GROUP:|"The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will then be un-blinded and shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure, and if clinically indicated, a verification CT computed tomography scan will be taken with the needle in place and, sent to the PercuNav. Radiation dosage, due to CT imaging, will also be recorded."
9968395|NCT01279161||diabetes|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
9968396|NCT01279161||control|Reference group will be made of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes was excluded. In these children diagnostics procedures will be conducted for reasons other than body weigh related diseases (excluding simple obesity). The children will not receive any treatment that might influence their body weight.
9968397|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
9968398|NCT01279174|Experimental|Whole-body-vibration exercises|Patients in this study group will attend whole body vibration exercise sessions of one hour three times a week for six weeks, using the Galileo® Fitness device. Initial training sessions will focus on patient acclimatization, and afterwards improved on muscular capacity and body coordination. During exercise sessions, patients will do 6 training cycles of 3 minutes each. The goals of this treatment are improved proprioception of the ankle and knee joints, as well as optimization of neuronal reactivation of the muscles and thereby improved joint stability. This should also increase endogenous analgesia
9968399|NCT01279213|Active Comparator|paliperidone clozapine BPRS|patients assigned to clozapine plus paliperidone controls at 6 and 12 weeks
9968400|NCT01279213|Placebo Comparator|clozapine plus placebo BPRS|patients assigned to placebo plus clozapine should show less improvement
9968401|NCT01279239||Poly trauma|20 Patients suffering from poly trauma who meet inclusion criteria would be recruited
9968402|NCT01279239||Healthy control|20 healthy volunteers would be recruited to obtain basal metabonomics fingerprinting
9968403|NCT01279252|Experimental|Antibiotic regimen|
9968404|NCT01279278|No Intervention|Control|
9968405|NCT01279278|Experimental|Co-signed Letter|
9968406|NCT01279291|Experimental|KHK2866 as monotherapy|Groups of subjects will receive a weekly infusions of KHK2866 as treatment for advanced cancer. If there no severe side effects, the dose will be increased for future subjects. A total of four groups are anticipated. Once an acceptable dose is determined an additional seven subjects will be treated at that dose.
9968407|NCT01279291|Experimental|KHK2866, gemcitabine+carboplatin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with gemcitabine and carboplatin. The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
9968408|NCT01279291|Experimental|KHK2866, weekly paclitaxel|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with weekly paclitaxel (80 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
9976792|NCT01354886|Experimental|FSH-GEX 300 IU|300 IU single dose
9976793|NCT01354886|Active Comparator|Gonal-f|150 IU single dose
9976794|NCT01354886|Active Comparator|Bravelle|150 IU single dose
9976795|NCT01354886|Placebo Comparator|Placebo|single dose
9976796|NCT01354925|Active Comparator|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. .
9968409|NCT01279291|Experimental|KHK2866, pegylated liposomal doxorubicin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with monthly PLD (40 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
9968410|NCT01279304||Group 1. Low risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. all nodes negative: ycN0~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~a. only micrometastases in the SN, and no risk factors (grade 3, LVI, tumour size > 3 cm)~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~no metastases in the post chemo SN"
9968411|NCT01279304||Group 2: Intermediate risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 1-3 nodes positive: ypN1~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~micrometastases in the SN and at least 1 risk factor; or~≤ 2 macrometastases and no risk factor~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~micrometastases in the post chemo SN and no risk factors (grade 3, LVI, tumour size > 3 cm)"
9968412|NCT01279304||Group 3. High risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 4 or more nodes positive: ypN2~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~≤ 2 macrometastases in the sentinel node prior to primary systemic treatment in the presence of risk factors like Grade 3, lymphangioinvasion, tumour size > 3 cm; or~3 macrometastases, 2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases.~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~Micrometastases in the post chemo SN, and at least one risk factor~≤ 3 macrometastases in the post chemo SN; or~2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases"
9968413|NCT01279330|No Intervention|Control|Patients receive by mail the materials needed for stool samples.
9968414|NCT01279330|Experimental|Co-signed Letter|
9968415|NCT01279356||Patients with liver diseases of various etiologies|"viral hepatitis~cholestatic liver diseases~auto-immune hepatitis~NAFLD~ALD~sarcoidosis of the liver"
9968416|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control treatment in IBS treatment
9968417|NCT01279382|Other|Hypnotherapy (HYP)|HYP was given to a subgroup of patients as intervention in IBS treatment
9968418|NCT01279382|Other|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
9968419|NCT01279395||naproxen|Patients age 40-70 who fulfill the American College of Rheumatology (ACR) criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed naproxen (1000 mg/day) for a minimum of two weeks.
9968420|NCT01279395||diclofenac|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis. The group consists of patients who have been prescribed diclofenac (150 mg/day)for a minimum of two weeks.
9968421|NCT01279395||celecoxib|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed celecoxib (200 mg/day) for a minimum of two weeks.
9968422|NCT01279421|Experimental|Social Network HIV Testing|Participants in this arm will be recruited through social networks and will receive an HIV test.
9968423|NCT01279421|Experimental|Peer Network Intervention|Eight (8) current or former crack users will be recruited to facilitate small networks of crack users in a three-day intervention. They will also facilitate monthly meetings open to all community members regarding HIV prevention and interpersonal violence.
9968424|NCT01279434|Experimental|Vitamin E plus Pentoxiphyllin|
9968425|NCT01279434|Active Comparator|Vitamin E|
9968426|NCT01279460||CKD Cohort of patients with renal insufficiency|patients with renal insufficiency grade II-IV
9968427|NCT01279473|Experimental|Nilotinib|
9968428|NCT01279499|Active Comparator|SEVO group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes.If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
9968429|NCT01279499|Active Comparator|SEVO-BIS group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target BIS of 40 - 50 .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes. If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
9968430|NCT01279499|Active Comparator|Propo- Remi group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR > 15% of baseline will be followed by a R bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of R to 1.0 μg/kg/min . If HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of stress responses that required intervention is recorded."
9976797|NCT01354925|Active Comparator|Standard treatment during Ramadan|Standard of care according to physicians choice
10133066|NCT04265781|Placebo Comparator|Dose expansion Placebo|Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.
10133067|NCT04265833|Active Comparator|calcium hydroxide|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with calcium hydroxide. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed to prevent pulp exposure. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity.The residual demineralized dentin was covered with a thin layer of Ca(OH)2 (approximately 1 mm2) in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
10133068|NCT04265833|Experimental|Biodentine|Thirty seven primary molar teeth were selected to apply indirect pulp therapy with Biodentine. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide-bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. A thin layer of tricalcium silicate-containing pulp-capping material (Biodentine) (approximately 1 mm2) consisting of powder and liquid was applied to the demineralized dentin tissue and a 12-min setting time was allowed for hardening, in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
9826053|NCT02405442|Experimental|Andecaliximab 150 mg Weekly|Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
10133069|NCT04265833|Experimental|TheraCal LC|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with TheraCal LC. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. Flowable form of resin-reinforced tricalcium silicate-containing material (TheraCal LC) was applied directly onto the demineralized dentin at a maximum thickness of 1 mm and was polymerized for 20 sec (Valo LED), in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
10133070|NCT04266002|Other|HIV-1 infected adult associated neurocognitiv|HIV-1 infected adult subjects with HIV-associated neurocognitive disorders despite effective antiretroviral therapy in plasma for more than one year, analyzing the evolution of cognitive disorders with Global Deficit Score and HAND classification, and markers of macrophagic inflammation in blood and cerebrospinal fluid, after a change in HIV treatment with an increased of the new scale CHARTER score ≥ 3 (total treatment score to be ≥ 9)
10133071|NCT04266067|Active Comparator|PNF exercise|In the PNF exercise group; exercises were performed in company with a physiotherapist 5 days a week (30 minutes ) for 4 weeks. Five specific techniques were applied to the patients: dynamic stabilization, rhythmic stabilization, combined isotonic contractions, and hold-relax active motion
10133072|NCT04266067|Active Comparator|Frenkel exercise|In the Frenkel exercise group, Frenkel coordination exercises were given in home exercise program 5 days a week for 4 weeks.The physiotherapist demonstrated Frenkel exercises to them once.
10133073|NCT04265820|Experimental|Group 1|The unilateral cataract patients in the Group 1 will undergo phacoemulsification and unilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
10133074|NCT04265820|Active Comparator|Group 2|The bilateral cataract patients in the Group 2 will undergo phacoemulsification and bilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
10133075|NCT04265807|Active Comparator|Intervention Group|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on an upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
10133076|NCT04265807|Sham Comparator|Control Group|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
10133077|NCT04265716|Active Comparator|L. reuteri|Topical administration of ointment with L. reuteri DSM17938, rubbed into skin twice per day
10133078|NCT04265716|Placebo Comparator|Placebo|Rubbed into skin twice per day
10133079|NCT04265859|Experimental|Depressed|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
10133080|NCT04265859|Other|Healthy Control|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
10133081|NCT04265872|Experimental|Bortezomib followed by pembro/cis|There is only one arm.
10133082|NCT04266041|Experimental|High-density EEG localization in epilepsy|High-density EEG will be used for brain localization in epilepsy patients
9976798|NCT01355003||All Participants|Participants who were vaccinated with GARDASIL™ by their physician
9976799|NCT01355016|Experimental|MDT-637|Active formulation
10133083|NCT04266041|Active Comparator|High-density EEG localization in healthy controls|High-density EEG will be used for brain localization in healthy controls
10133084|NCT04266041|Experimental|High-density EEG localization in tumor patients|High-density EEG will be used for brain localization in tumor patients
10133085|NCT04266041|Experimental|High-density EEG localization in peripheral nerve patients|High-density EEG will be used for brain localization in patients with peripheral nerve dysfunction
10133086|NCT04266041|Experimental|High-density EEG localization in stroke patients|High-density EEG will be used for brain localization in patients who have recently experienced a stroke
10133087|NCT04265729|Other|single test product arm|use of Neocate Infant and Junior marketed products (product type depending on subject's age and condition)
10133088|NCT04265846|Experimental|bifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and bifocal IOLs implantation.
10133089|NCT04265846|Experimental|mix bifocal IOL group|The cataract patients who ask for phacoemulsification and mix different bifocal IOLs implantation bilaterally
10133090|NCT04265846|Experimental|trifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and trifocal IOLs implantation.
10133091|NCT04265846|Experimental|EDOF IOL group|The cataract patients who ask for bilateral phacoemulsification and EDOF IOLs implantation.
10133092|NCT04265846|Experimental|blend vision group|The cataract patients who ask for phacoemulsification and different IOLs implantation bilaterally.
10133093|NCT04265846|Experimental|monovision designed group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
10133094|NCT04265846|Active Comparator|monofocal IOL group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
10133095|NCT04265768|Placebo Comparator|No Soft tissue augmentation surgery|No soft tissue augmentation concomitant to implant placement. Negative control group.
10133096|NCT04265768|Experimental|Soft tissue augmentation surgery with Fibro-Gide|"Soft tissue augmentation concomitant to implant placement with a porcine, volume-stable cross-linked collagen matrix (Fibro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland).~Test group."
10133097|NCT04265768|Active Comparator|Soft tissue augmentation surgery with patient's CTG|"Soft tissue augmentation concomitant to implant placement with a connective tissue graft (CTG) taken from the patient's palate or retromolar area.~Positive control group."
10133098|NCT04265742|Experimental|Group A. Normal BMD, no fracture|Post-menopausal women with normal bone density (BMD t-score >-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
10133099|NCT04265742|Experimental|Group B. Normal BMD, with fracture|Post-menopausal women with normal bone density (BMD T-score >-1.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
10133100|NCT04265742|Experimental|Group C. osteoporotic, no fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
10133101|NCT04265742|Experimental|Group D. osteoporotic, with fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
10133102|NCT04265924|Active Comparator|>0.85 FIO2 group|This group receives FIO2 >0.85 during the surgery.
10133103|NCT04265924|Active Comparator|<0.7 FIO2 group|This group receives FIO2 <0.7 during the surgery.
10133104|NCT04265898||Test Group|Reported mild cognitive deficits
10133105|NCT04265898||Control Group|No cognitive deficits
10133106|NCT04266028|Experimental|Cohort 1|Cohort 1 randomized in 2:1 will receive a single s.c. dose of DM-101 or matching placebo
10133107|NCT04266028|Experimental|Cohort 2|Cohort 2 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
10133108|NCT04266028|Experimental|Cohort 3|Cohort 3 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
10133109|NCT04266028|Experimental|Cohort 4|Group 4 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
10133110|NCT04265989|Experimental|coronary artery aneurysm with branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, accompany with branches origin from the aneurysm
10133111|NCT04265989|Experimental|coronary artery aneurysm without branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, without any branch origin from the aneurysm
10133112|NCT04265989|Experimental|Coronary artery aneurysm with localized stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. localized stenosis defined as lesion to more than 70% stenosis and length less than 20 mm
10133113|NCT04265989|Experimental|Coronary artery aneurysm with diffuse stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. Diffuse stenosis defined as lesion to more than 70% and length more than 20 mm
10133114|NCT04265963|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
10133115|NCT04265703|Active Comparator|Internal jugular vein site|Ultrasound-guided central venous catheterization at internal jugular vein site
10133116|NCT04265703|Active Comparator|Subclavian vein site|Ultrasound-guided central venous catheterization at subclavian vein site
10133117|NCT04265703|Active Comparator|Innominate vein site|Ultrasound-guided central venous catheterization at innominate vein site
10184028|NCT03758768|Active Comparator|Full spectrum light control condition|"Three consecutive mornings of one hour exposure to full spectrum light (2500 Kelvin, irradiance = 37.72 µW/cm2) with equal photon flux as the blue light.~We will adjust the light intensity to make sure that the photon energy is the same across the two conditions."
9528191|NCT03213132|Placebo Comparator|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
10133118|NCT04265560|Experimental|Progressive Resistance Training|"The intervention group will receive 8 weeks of Progressive Resistance Training (PRT), twice a week, in addition to usual care. An upper limb functional goal will be identified through discussion with the researcher and the participant. PRT will be individually tailored to target two muscle groups and will be chosen in order to develop strength to progress towards the participants functional goal.~The chronic spinal cord injury exercise guideline parameters will be applied (3 sets of 8-10 repetitions, 1-2 mins rest between sets). Participants will be inducted to their PRT programme and will then independently complete the 8 week programme. During each of the following sessions, assistance for set up of equipment and/or limb position will be given by the researcher and/or the participants family, friend or carer, once they have been trained. PRT sessions will be recorded in a diary to monitor sets and repetitions completed, and intensity (visual analogue scale (VAS))."
10133119|NCT04265560|No Intervention|Usual care only|Participants will continue with their usual care, consistent with standard National Health Service (NHS) care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting up to 90 minutes. Physiotherapists provide a combination of group exercise and one to one function-orientated physiotherapy sessions to improve balance, general muscle strength, wheelchair and/or transfer skills.
10133120|NCT04265469|Experimental|Patients with diabetics get mobile education|Patients with diabetics get mobile education
10133121|NCT04265469|No Intervention|Patients with diabetics|Patients with diabetics
10133122|NCT04265417||RARC group|Participants in this group underwent robotic assisted rectal cancer resection
10133123|NCT04265417||NOSE group|Participants in this group underwent robotic rectal cancer resection assisted rectal with natural orifice extraction
10133124|NCT04265547|Experimental|Intervention Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Participants in the intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion.
10133125|NCT04265547|No Intervention|Control Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion. Control arm participants will be offered the chemical-free products, cleaning supplies, and air filter at this time.
10133126|NCT04265443||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured invasive physiologic indices after PCI
10133127|NCT04265690|Experimental|Teen and Tot Centering subjects|The cooking classes and text messages will supplement the subject's standard of care by incorporating text messages and a cooking class.
9968431|NCT01279499|Active Comparator|Propo-Remi-BIS group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (IBW).~The depth of anesthesia will be adjusted to accomplish a BIS score 40 -50. If BP or HR is > 15% of baseline will a bolus of R IV (1 μg/kg IBW) will be given and an the infusion rate of R will be increased to 1.0 μg/kg/min . If this response persists and HR < 70/ min, Nifedipine 10 mg will be given s.l. and if HR > 70/ min Diltiazem 10-20 mg IV will be given, followed by esmolol infusion if no response is observed."
9968432|NCT01279512|Experimental|Metformin reciepiants|Infertile overweight women with PCO who received Metformin
9968433|NCT01279512|Experimental|Acarbose reciepiants|Infertile overweight women with PCO who received Acarbose
9968434|NCT01279525|Experimental|Multifactorial intervention|Multifactorial intervention to prevent falls
9968435|NCT01279538|Experimental|ASKP1240 lowest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
9968436|NCT01279538|Experimental|ASKP1240 low dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
9968437|NCT01279538|Experimental|ASKP1240 high dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
9968438|NCT01279538|Experimental|ASKP1240 highest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
9968439|NCT01279538|Placebo Comparator|Placebo|Participants received a single 30-minute matching placebo infusion on Study Day 1, followed by a 90-day follow-up period.
9968440|NCT01279551|Experimental|GTN|In this arm the investigators administer local application of 0.4% nitroglycerin ointment and ketorolac tromethamine 10 mg
9968441|NCT01279551|Active Comparator|Control|In this arm the investigators administer local application of lidocaine cloridrato 2.5% and ketorolac tromethamine 10 mg.
9968442|NCT01279577|Experimental|Low dose TSO|Low dose suspension of TSO
9968443|NCT01279577|Experimental|Medium dose TSO|Medium dose suspension of TSO
9968444|NCT01279577|Experimental|High dose TSO|High dose suspension of TSO
9968445|NCT01279577|Placebo Comparator|Placebo|Placebo solution
9968446|NCT01279603|Experimental|GO-203-2c|
9968447|NCT01279629||Tazarotene 0.1%|
9968448|NCT01279629||Calcipotriol 0.005%|
9968449|NCT01279642|Experimental|ultrasound|Use of ultrasound to PICC placement
9968450|NCT01279642|Active Comparator|Control group|PICC placement by inspection and visualization of site
9976800|NCT01355016|Placebo Comparator|Placebo|Matched Placebo Comparator
10133128|NCT04265352||Prenetal cardiac echogenic focus|Newborn infants who had prenatal cardiac echogenic focus
10133129|NCT04265391|Experimental|Snakehead fish cookies|Subjects who were given intervention of snakehead fish cookies during the study period
10133130|NCT04265391|Placebo Comparator|Standard cookies|Subjects who were in control group and received standard cookies
10133131|NCT04265677|Experimental|Telemedicine FCR|These patients will be eligible to use telemedicine for Family Centered Rounds
10133132|NCT04265677|Placebo Comparator|Control|These patients will not be eligible to use telemedicine for Family Centered Rounds (standard of care)
10133133|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg IV Pregabalin|The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg based on Safety Monitoring Committee decision).
10133134|NCT04265456|No Intervention|Placebo|Saline solution
10133135|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg +/- 25 IV Pregabalin|Decisions to escalate or decrease the dose for Cohorts 2 through 6 will be dependent upon blinded review of emerging safety and tolerability data by the Safety Monitoring Committee (SMC). However, PK data is not part of the SMC review, but may be reviewed by a SMC designee at a later time.
10133136|NCT04265612|Experimental|Negative Pressure dressing|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
10133137|NCT04265612|Active Comparator|Aquacel hydrogel dressing|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
10133138|NCT04265495||DUAL TRIGGERING|PATIENTS WILL RECEIVE DUAL TRIGGERING
10133139|NCT04265495||URINARY HCG|PATIENTS WILL RECEIVE URINARY HCG
10133140|NCT04265495||RECOMBINANT HCG|PATIENTS WILL RECEIVE RECOMBINANT HCG
10133141|NCT04265586|No Intervention|No insomnia|This group contains participants who report only mild symptoms of insomnia (Insomnia Severity Index, ISI<15).
10133142|NCT04265586|Experimental|Digital Cognitive Behavioural Therapy (iCBT)|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Intervention is iCBT for participants with insomnia (7-16 weeks).
10133143|NCT04265586|Experimental|Sleep hygiene education|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Sleep hygiene education (approximately 1 hour)
10133144|NCT04265326||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
10133145|NCT04265508||Low MELD score|MELD score of 6 - 11
10133146|NCT04265508||High MELD score|MELD score of ≥ 17
10133147|NCT04265521|Experimental|Biocool Footcare|"Treatment regime:~During week 1: Once daily for 7 days (7 doses) During week 2 and 3: Once every second day for 14 days (7 doses)"
10133148|NCT04265625|No Intervention|blind tracheotomy|no endoscopic guidance tracheotomy
10133149|NCT04265625|Experimental|endoscopic guidance tracheotomy|With endoscopic guidance tracheotomy
10133150|NCT04265313||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
10133151|NCT04265339|No Intervention|None smokers|50 participants who are non-smokers
10133152|NCT04265339|Experimental|Smoking Cessation|50 smokers who quit smoking
10133153|NCT04265339|No Intervention|Active smokers|50 smokers who continue smoking
10133154|NCT04265300|No Intervention|Control|No intervention provided
10133155|NCT04265300|Experimental|Creative Roots|The intervention group will receive Creative Roots beverages and be instructed to have at least one drink (251mL) available at each meal (i.e. breakfast, lunch, and dinner) and drink as much as they would like throughout the day (i.e. ad libitum) of either Creative Roots or any other beverage they would normally consume. Subjects will be asked the keep their empty Creative Roots bottles to return them to the lab. Subjects will be instructed to refrigerate the beverages for better taste, and to refrigerate the beverages after opening.
10133156|NCT04265274|Experimental|Disulfiram, vinorelbin, cisplatin, copper|Vinorelbine 25mg/m2 day 1 and 8, Cisplatin 75mg/m2 day 1, every 3 weeks, Disulifiram um 400mg daily and 2 mg of elementary Copper daily, continuously.
10133157|NCT04265157||Early occlusion of hepatoduodenal ligament|Early occlusion of hepatoduodenal ligament during mobilization of the liver of the recipient by using portal vein clamp or occlusive temporary bands.
10133158|NCT04265157||classical occlusion of hepatoduodenal ligament|classical occlusion of hepatoduodenal ligament after mobilization of the liver of the recipient immediately before explantation by suing of portal vein clamp
10133159|NCT04265222|Other|Conventional Fluoroscopy|Participants undergoing femoroplasty with conventional treatment
10133160|NCT04265222|Experimental|HipCheck|Participants undergoing femoroplasty with Stryker HipCheck System
10133161|NCT04265235|Experimental|Home-based Exercise Program|12-weeks, remotely monitored home-based exercise program consisting or aerobic and resistance exercise
10133162|NCT04265196|Experimental|cognitive behavioral group therapy|A Cognitive Behavioral Therapy intervention is based on a unique protocol built in the light of previous research in the field and includes a 10-week treatment focused on coping with pain and stress.
10133163|NCT04265196|Experimental|Mindfulness-based group therapy|A mindfulness-based group therapy intervention was built inspired by a mindfulness protocol that is effective in treating pain, and includes adjustments to the physical distress of fibromyalgia patients as well as an emphasis on coping with stress and pain.
10133164|NCT04265196|No Intervention|control group|A control group will wait for 3 months, during which the subjects will complete the questionnaires and only after the end of the period will they participate in the treatment so that it will serve as a control group without intervention.
10133165|NCT04264936|Experimental|RC48-ADC and JS001|
9976801|NCT01355042||Severe Sepsis and Septic Shock|
9976802|NCT01355042||Other Critical Ill with or without Shock|Severe Trauma, Neurological Injury, Other Shock (not Septic)
10133166|NCT04265118|Experimental|Sideward Tilt of Bed|During sleep, while lying in supine position, the participant will be tilted sidewards by the bed. In practice, the experimenter activates the bed at timepoints during the night where the participant is lying in supine position. Activating the bed results in one half of the bed lifting 10 to 40 Degrees sidewards.
10133167|NCT04264949|Experimental|group application (GA)|"benefit from conventional care in a rehabilitation center, therapeutic education program and education in the use of the smartphone application mon coach dos"
10133168|NCT04264949|Active Comparator|Groupe conventional care (GCC)|benefit from conventional care in a rehabilitation center and therapeutic education program
10133169|NCT04265079|Experimental|Added weight to hand|
10133170|NCT04265144|Experimental|subjects SSc diagnosed|Patient with systemic scleroderma according to the American College of Rheumatology (ACR) / EULAR 2013 criteria
10133171|NCT04265105|Active Comparator|standard of care|Short acting beta agonist or inhaled corticosteroids
10133172|NCT04265105|Experimental|fluticasone-vilanterol|LABA-ICS A combination of Long acting beta agonist and inhaled corticosteroid
10133173|NCT04265248|Experimental|Virtual Reality|"The subjects will use Fulldive VR as the first degree of difficulty where only tilt movements are necessary, for the second degree of difficulty the game VR Ocean Aquarium 3D will be used, where bending, extension and rotation movements will be integrated, also introducing a sensory element to integrate the sound of the sea.~For these patients to perform the same work as group 2, the physiotherapist will have to count and control in each exercise the number of movements that the patient performs so as not to exceed the proposed dose in the active comparator group (3 sets of 10 repetitions of each exercise)."
10133174|NCT04265248|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
10133175|NCT04265001|Active Comparator|Control group|Topical cholrhexidine hydrochloride 125 mg/100 ml available commercially (Hexitol; Arab Drug Company for Pharmaceutical and Chemical Industries, Cairo, Egypt) mouthwash. Topical cholrhexidine hydrochloride mouthwash treatment has been repeated three times per day for one week.
10133176|NCT04265001|Experimental|Hyaluronic acid group (HA group)|Topical hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash (Aftamed; Bioplaxpharma, UK).Topical hyaluronic acid mouthwash treatment has been repeated three times per day for one week.
10133177|NCT04264858|Experimental|Treatment group|Immunoglobulin of cured patients
10133178|NCT04264858|Placebo Comparator|Control group|γ-Globulin
10133179|NCT04264975|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation in patients who have advanced solid cancer with primary (group 1) or secondary resistance (group 2) to immuno-oncology
10133180|NCT04265131|Experimental|Experimental group|art therapy is delivered on top of treatment as usual (TAU). TAU means that individual verbal therapy takes place on a regular basis, whereby the frequency varies depending on the severity of the eating disorder and the patient's request for help. Cognitive-behavioral therapy is provided with elements of dialectical behavioral therapy, and there is also the possibility of family or couple counseling by a family-based therapist.
10133181|NCT04265066||Measurement of sublingual microcirculation|
10133182|NCT04264988||Patients who had pelvic hemorrhage|Patients who had pelvic hemorrhage during complex abdomino-pelvic surgery
10133183|NCT04264845||Provider Focus Group|All heart failure providers at the participating centers will be screened as potential participants.
10133184|NCT04264845||Patient Interview Group|Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
10133185|NCT04264845||PROs/Clinical Data Integration Group|"Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.~This group includes a sub-study of patients providing blood samples."
10133186|NCT04265014|Active Comparator|Goal-directed fluid treatment|"Fluid management will be performed according to SVV and CI monitoring. When patients have SVV>10%, 250 cc crystalloid will be administered and when SVV fell below 10% during 30-minute monitoring standard (5 mL/kg/hr) crystalloid infusion continues. If SVV continues above 10%, a second fluid bolus of 250 cc colloid (minifluid challenge) will be administered.~If the desired SVV level can not be reached, the Hct values will be examined. Blood replacement will be performed when Hct<30% in patients with coronary artery disease (CAD) and when Hct<25% for other patient groups. If the desired SVV level can not be reached in spite of blood replacement products, if CI will be below 2.5 L/min/m2 vasopressor will begun. If SVV will be at normal values with CI below 2.5 L/min/m2, inotrop will begun."
10133187|NCT04265014|Active Comparator|liberal fluid treatment|"Fluid management will be performed according to MAP, HR and urine output.~If peroperative urine amounts will be <0.5 mL/kg/hr during two-hour monitoring, with MAP<65 mmHg, HR>100/min for at least 30 minutes and CVP falls 20% compared to basal values, the same anesthesiologist will begin additional fluid replacement of 5 mL/kg/hr based on clinical experience.~Blood product replacement will be provided at Hct<30% for those with coronary artery disease and at Hct<25% for other patients."
10133188|NCT04265183|Experimental|patients treated with preformed metal crowns|All patients included received a preformed metal crown on their HSPM affected teeth.
10184029|NCT03758755|Experimental|BFR Therapy|This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
10133189|NCT04265027|Experimental|Group 1 (50 mg Dose)|"Test IMP: 50 mg BIA 9 1067 and Reference IMP: 50 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
10133190|NCT04265027|Experimental|Group 2 (25 mg Dose)|"Test IMP: 25 mg BIA9 1067 and Reference IMP: 25 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
10133191|NCT04264923|Experimental|All patients enrolled|All patients enrolled with receive the HyGIeaCare Prep with a new lab sampling technique to be used on all patients enrolled in the study.
10133192|NCT04264832||observation group|Participants were eligible if they met the Rotterdam diagnostic criteria of polycystic ovary syndrome (PCOS) and meet the inclusion and exclusion criteria , and all study participants received questionnaires and underwent the physical, transvaginal ultrasound and body composition examination. Blood samples were collected for analysis of metabolic markers, metabonomics and hormones.
10133193|NCT04264832||control group|The control group participants are normal women and had no history of any type of diabetes, cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization), stage 2 hypertension , malignant disease or severe renal or hepatic disease. They accepted the same examinations as the observation group.
10133194|NCT04264910|Experimental|Calm Meditation|Participants (n=49) will be provided free access to and asked to register for the consumer-based mobile meditation app on their phone. Participants (n=49) will then receive an email containing 28 weeks of free access to Calm. Participants (n=49) will be asked to use Calm at least 10 minutes per day and encouraged to use it as much as they would like during the intervention. This prescription mimics how a new, paying member would use the app (full exposure with autonomy).
10133195|NCT04264910|No Intervention|Control|The control group will be asked to maintain normal activity and refrain from using Calm meditation app.
10133196|NCT04264806|Experimental|Azacitidine: Participants with MDS or CMML|Participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) will receive azacitidine 75 milligram per meter square (mg/m^2) body surface area (BSA) subcutaneously or Intravenously per local label on Days 1 through Day 7 of each 28-day cycle. Participants will be treated until disease progression; relapse from complete remission (CR), partial remission (PR), or marrow complete remission (mCR); transformation to acute myeloid leukemia (AML); death; or unacceptable toxicity.
10133197|NCT04264806|Experimental|Azacitidine and Cusatuzumab: Participants with MDS or CMML|Participants with higher-risk MDS or CMML will receive azacitidine 75 mg/m^2 BSA subcutaneously or Intravenously per local label on Days 1 through 7 and cusatuzumab 20 mg/kg IV on Days 3 and 17 of each 28-day cycle. Participants will be treated until disease progression; relapse from CR, PR, mCR; transformation to AML; death; or unacceptable toxicity.
10133198|NCT04264793|Experimental|Intervention|Behavioral Lifestyle Intervention (3 health centers): In addition to usual care in the health center, the intervention included individual counseling and group education on nutrition and physical activity.
10133199|NCT04264793|Active Comparator|Control|Control (4 health centers): Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
10133200|NCT04264780||Younger than 50 years of age|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently less than 50 years of age
10133201|NCT04264780||50 years of age or older|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently 50 years of age or more
10133202|NCT04264754||Cases Group|Subjects who have already been diagnosed with liver cancer, however did not yet undergo any surgery, ablation, embolization or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
10133203|NCT04264754||Control Group|"Cancer free subjects with high risk to development HCC. High risk subjects include the following:~Subjects with HCV (hepatitis C virus) and cirrhosis~Subjects with HBV (hepatitis B virus) and cirrhosis~Non-cirrhotic chronic HBV subjects at intermediate or high risk of HCC, according to EASL (European Association for the Study of the Liver) Clinical Practice Guidelines for the management of hepatocellular carcinoma~Subjects with NAFLD (Non-Alcoholic Fatty Liver Disease) with cirrhosis~Cirrhotic patients due to any other reasons, including alcohol disease"
10133204|NCT04264767||Cases Group|Peripheral blood collection via routine venipuncture
10133205|NCT04264767||Control Group|Peripheral blood collection via routine venipuncture
10133206|NCT04264741|Experimental|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 4 weeks.
10133207|NCT04264741|Sham Comparator|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday. Treatment will lasted for 4 weeks.
10133208|NCT04264676|Active Comparator|Metronidazole|supplement of metronidazole 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6(6 treatments totally),and every 6 weeks for CapeOX (4 treatments totally).
10133209|NCT04264676|Placebo Comparator|Placebo|supplement of identical-appearing placebo 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6 (6 treatments totally),and every 6 weeks for CapeOX 4 treatments totally).
10133210|NCT04264429|Experimental|Infrapatellar strap|This group will perform the functional tests with the infrapatellar strap positioned on the painful knee.
10133211|NCT04264429|Experimental|Elastic Band|This group will perform the functional tests with the elastic band positioned on the painful knee.
9976803|NCT01355107||chronic hcv, no liver cirrhosis, no HCC|patients with chronic hepatitis c- infection: no cirrhosis of the liver (= Desmet IV), no HCC - suspected lesion in the liver
10133212|NCT04264429|No Intervention|Control|This group will perform the functional tests without elastic band or infrapatellar strap positioned on the painful knee.
10133213|NCT04264533|Experimental|VC|12g Vitamin C+sterile water for injection; total volume: 50ml. 12ml/h; infusion pump；q12h.
10133214|NCT04264533|Placebo Comparator|Sterile water for injection|50ml water for injection. 12ml/h; infusion pump; q12h.
10133215|NCT04264520|Experimental|PTSD Psychoeducation + Skills Intervention|
10133216|NCT04264481|Experimental|Adductor Canal Block|Adductor Canal Block (Saphaenous Nerve Block) done under Ultrasonographic guidance with 5cc of Bupivacaine, 5cc of lidocaine diluted with 10 cc of Normal Saline
10133217|NCT04264481|Active Comparator|Intra-articular Steroid and Lignocaine|Intra-articular knee joint injection of 40mg triamcinolone and 1-2cc of lidocaine
10133218|NCT04264572|Experimental|Medically Tailored Meals (MTM)|Participants in this arm will receive MTM for 12 weeks. Meals will be prepared and delivered by MANNA, a non-profit organization that has provided MTM for patients with chronic illnesses in Philadelphia and Southern New Jersey since 1990. MANNA will deliver 21 complete meals to the patient's home each week, providing 45-60 grams of carbohydrates per meal for optimal glucose control based on ADA guidelines and 100% of overall nutritional requirements based on USDA guidelines. In addition, children and any senior dependents for whom the participant is the primary caregiver will receive meals for the entire 12 weeks for no additional cost, as this is standard of care of MANNA services. MANNA registered dieticians will cater the program to meet the specific needs (e.g., dietary restrictions, cultural preferences). Investigators will provide information on community resources in the area, including food resources, for all patients.
10133219|NCT04264572|Experimental|MTM + tele-Medical Nutrition Therapy (MNT)|Patients in this arm will receive MTM services as well as tele-MNT over 12 months. The tele-MNT intervention will be delivered by a registered dietician within the Jefferson endocrine clinic, with assistance by other endocrine dieticians and fellows. In the first months, video visits focus on supporting individuals who are not selecting, preparing or purchasing their own meals. As the end of MTM services approaches, the intervention shifts to focus on the transition from MTM to self-directed eating. Based on Academy of Nutrition and Dietetics recommendations, each participant's MNT will include the following core features: nutrition assessment, intervention, care coordination, monitoring and evaluation. The following will also be addressed: nutrition prescriptions, nutrient intake, energy intake, glycemic index and load, alcohol consumption and physical activity. The schedule includes individual visits in the first 6 months and monthly group session in months 7-12.
10133220|NCT04264572|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with DM, which includes regular visits with a diabetes provider (primary care or endocrine), standard ADA information pamphlets and referral to 1) diabetes education classes and 2) nutrition counseling by dieticians and nurse practitioners. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and diabetes self-management (e.g., diabetes.org). The standard of care at Jefferson for patients with DM is to begin with a single group MNT visit lasting from 60-90 minutes. Each participant's need for additional sessions and general time-frame for follow-up is individually determined following the group session, based on patient preference. Historically, only about 2% of the Jefferson population engages in these services, thus minimizing dilution of the effect of the tele-MNT.
10133221|NCT04264624|Experimental|Guided Biofilm Therapy with Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the adjunctive treatment, he/she will also receive subgingival biofilm removal with Perioflow combined with Erythritol powder at sites with PD≥ 5 mm, including the experimental sites, prior to subgingival biofilm removal with USD.
10133222|NCT04264624|Active Comparator|Guided Biofilm Therapy without Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the control treatment, all teeth present will receive the application of disclosing agent, full-mouth supragingival and intra-sulcular biofilm removal with Airflow at sites with PD up to 4 mm, full mouth supra gingival calculus removal with USD, and subgingival biofilm removal with USD at sites with PD> 4 mm, including the experimental sites, as required.
10133223|NCT04264559|Other|Healthy control group|This group will include 40 healthy adults.
10133224|NCT04264559|Other|CSAP group|This study will include 40 patients with chronic stable angina pectoris (CSAP).
10133225|NCT04264559|Experimental|Healthy intervention group|This group will include 40 healthy adults. They will receive moxibustion intervention.
10133226|NCT04264546|Experimental|Experimental Adult Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
10133227|NCT04264546|Experimental|Experimental Children Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
10133228|NCT04264546|Experimental|Experimental Infant Group - High dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
10184030|NCT03758755|Active Comparator|No BFR|This group of patients will undergo physical therapy exercises per the current standard of care after their ACL reconstruction without BFR
10184031|NCT03758729|Experimental|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
10184032|NCT03758703|Experimental|Pre-recorded music intervention group|The experimental group will be receiving the pre-recorded music care intervention. The intervention is to be delivered once a day for 30 minutes, over one week, on a portable Bluetooth speaker system. Participants will select their own music from the list of pre-recorded songs playlist and are free to switch to another playlist within their treatment arm should they desire. This music was specifically designed for use in palliative care. Specifically, all songs are played at 60 beats per minute to mimic resting heart rate. Instrumentation was specifically chosen to be soothing and calming
10133229|NCT04264689|Active Comparator|thoracic epidural|thoracic epidural will be done before induction of general anesthesia
10133230|NCT04264689|Experimental|serratus anterior block|ultrasound guided serratus anterior block will be done after induction of general anesthesia
10133231|NCT04264689|Experimental|erector spinae block|ultrasound guided erector spinae block will be done after induction of general anesthesia
10133232|NCT04264611|Experimental|Short Foot Exercise Group|The group that received the short foot exercise
10133233|NCT04264611|Experimental|Towel Curl Exercise Group|The group that received the towel curl exercise
10133234|NCT04264611|No Intervention|Control Group|The group that received no exercise
10133235|NCT04264702||Prospective arm|Patients who have undergone surgery for stage I to IV colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
10133236|NCT04264702||Control Arm|The control arm will consist of matched Stage I to Stage IV CRC cases using the following criteria: sex, age of diagnosis and ECOG performance prior to ACT, and a minimum of 3 evaluations per year. The patient cases would have a minimum of 2 years follow-up data and received treatment no more than 3 years prior to study start date.
10133237|NCT04264598|Experimental|Experimental Adult Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
10133238|NCT04264598|Experimental|Experimental Children Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
10133239|NCT04264598|Experimental|Experimental Infant Group - Medium dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV Intervention: Biological: Three-dose regimen of medium dosage investigational sIPV
10133240|NCT04264598|Active Comparator|Control Infant Group - commercialized sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV Intervention: Biological: Three-dose regimen of commercialized sIPV
10133241|NCT04264598|Active Comparator|Control Infant Group - commercialized IPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV Intervention: Biological: Three-dose regimen of commercialized IPV
10133242|NCT04264455||Biomonitor only|Patients receive a Biomonitor only
10133243|NCT04264455||Wearable Cardioverter-Defibrillator (Life Vest) + Biomonitor|Patients receive a Wearable Cardioverter-Defibrillator (Life Vest) combined with a Biomonitor
10133244|NCT04264455||ICD Implantation|Patients receive an ICD only
10133245|NCT04264715|Experimental|405nm light room|In this room, surgeries will be performed under ambient light including the wavelength 405nm
10133246|NCT04264715|No Intervention|Control room|In this room, surgeries will be performed under ambient light from regular phosphorescent light does not include 405nm frequencies
10133247|NCT04264416|Experimental|Whole-Body Electromyostimulation|16 weeks of dynamic WB-EMS: one supervised session per week, 20 min session; impulse-frequency: 85 Hz; impulse breadth 350 µs; intermittent 4-6 s; of impulse - 4 s of impulse break; impulse intensity RPE 7 (hard+ to very hard) on Borg CR 10 Scale.
10133248|NCT04264416|No Intervention|Non exercising control|...maintained physical activity and exercise habits during the study period.
10133249|NCT04264468||response group and the non-response group|Received neoadjuvant chemotherapy according to the routine clinical diagnosis and treatment, and evaluated the clinical efficacy once every two cycles of chemotherapy. According to the clinical efficacy, the patients were divided into the neoadjuvant chemotherapy response group and the non-response group (evaluation standard RECIST1.1).
9826054|NCT02405442|Experimental|Andecaliximab 300 mg Weekly|Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
9976804|NCT01355107||chronic hcv, liver cirrhosis, no HCC|patients with hcv- associated cirrhosis of the liver, but with no HCC - suspected lesions in the liver
10133250|NCT04264494|Experimental|PRP group|Fifty RA patients were injected intra-articularly with 3 doses of PRP in their joints
10133251|NCT04264494|Placebo Comparator|placebo group|Fifty RA patients were injected intra-articularly with 3 doses of saline in their joints.
10133252|NCT04264377||Healthy|26 healthy subjects
10133253|NCT04264377||Asthma|26 subjects with asthma
10133254|NCT04264442|Experimental|Losmapimod|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until study drug approval or until the study is discontinued by the Sponsor.
10133255|NCT04264650|No Intervention|Control group|Standard care
10133256|NCT04264650|Experimental|One active intervention group|provided with COOL Passport, a mobile healthcare application
9976805|NCT01355107||hcv-infection, HCC|patients with hcv- associated HCC
10133257|NCT04264650|Experimental|The other active intervention group|provided with access to the Health Promotion Cloud system and use of game-based interactive platforms along with COOL Passport
10133258|NCT04264364||laparoscopic sleeve gastrectomy|Patients who underwent laparoscopic sleeve gastrectomy
10133259|NCT04264364||endoscopic sleeve gastroplasty|Patients who underwent endoscopic sleeve gastroplasty
9669090|NCT04125095||Body Scans|Includes proton irradiation to shoulders, thorax, abdomen, pelvis, spine (thoracic or lumbar), extremities, and other body sites. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
10133260|NCT04264078|Experimental|anti-CD7 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
10133261|NCT04264026|Experimental|Open Label|Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 40 mg MDMA.
10133262|NCT04264039|Experimental|anti-CD19 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD19 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
10133263|NCT04264052||CBE & MRIE|Forty healthy volunteers split in different age ranges (20-30 years n=10, 30-40 years n=10, 40-50 years n=10 and 50-60 years n=10) will undergo two airway assessments at rest and during exercise. The exercise assessments will be a continuous bronchoscopy during exercise (CBE-1st visit) and magnetic resonance imaging during exercise (MRIE-2nd visit) separated by at least three days to ensure for a sufficient cardiorespiratory and musculoskeletal recovery.
10133264|NCT04264104|Experimental|Low dose neural mobilization|Four series of 10 repetitions of neural mobilization targeting the tibial nerve.
10133265|NCT04264104|Active Comparator|High dose neural mobilization|Eight series of 10 repetitions of neural mobilization targeting the tibial nerve.
10133266|NCT04264325||Malignant pleural effusions : diaphragmatic ultrasound measure|
10133267|NCT04264260|Experimental|colchicine group|The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.
10133268|NCT04264130|Active Comparator|artemisinin-based combination therapies|subjects given Artemisinin-based combined therapies according to the study instruction
10133269|NCT04264130|Sham Comparator|non-artemisinin drugs|subjects given non artemisinin based combined therapies like describe in the study protocol
10133270|NCT04264117|Active Comparator|FlexAbility (Mesh-like irrigated tip catheter) group|
10133271|NCT04264117|Experimental|TactiCath (Contract force monitoring catheter) group|
10133272|NCT04264156|Experimental|160 mg/kg|Lucinactant for inhalation, 160 mg total phospholipids (TPL)/kg Delivered as an aerosol once, with up to 3 repeats of 80 mg/kg allowed within 36 hours of birth
10133273|NCT04264156|Sham Comparator|nCPAP Only|nCPAP Only as sham comparator. Bubble nCPAP is standard of care. Treatment time behind barrier to match active treatment delivery time
10133274|NCT04264286|Active Comparator|Esmolol group|Patients will receive intravenous esmolol after the end of the surgical procedure.
10133275|NCT04264286|Placebo Comparator|Placebo group|Patients will receive intravenous saline after the end of the surgical procedure.
10133276|NCT04264299|Active Comparator|T tube drainage|Closure of common bile duct after choledocholithotomy over T tube
10133277|NCT04264299|Experimental|Primary closure|Primary closure of the common bile duct after choledocholithotomy
10133278|NCT04264299|Experimental|Antegrade stenting|Closure of common bile duct over antegrade biliary plastic stent
10133279|NCT04264273||Participants with Parkinson´s disease.|Participants who fulfilled the diagnostic criteria of Parkinson´s disease.
10133280|NCT04264273||Participants without a neurological disease|25 neurologically healthy patients of the local otolaryngological clinic, in whom submandibular gland needle biopsy was performed due to a clinical indication.
10133281|NCT04263961||COPD GOLD I - II|"Inclusion for mild-moderate COPD patients (n = 100):~Age between 45-65 years.~GOLD classification I or II according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].~Cessation of smoking for ≥6 months.~≥5 packyears of smoking.~Absence of asthma.~Written informed consent."
10133282|NCT04263961||Controls|"Inclusion for healthy controls (n = 100):~Age between 45-65 years.~Absence of COPD according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].~Cessation of smoking for ≥6 months.~≥5 packyears of smoking.~Absence of asthma.~Written informed consent."
10133283|NCT04264195|Experimental|Constraint-induced movement therapy|Constraint-induced movement therapy (PEPS-MIT)
10133284|NCT04264195|Active Comparator|Bimanual manipulation|Bimanual manipulation (PEPS-Bimanual)
10133285|NCT04263870|Experimental|Sintilimab plus capecitabine and oxaliplatin|Subjects enrolled are treated with oral capecitabine 1000mg per m2 bid for two weeks（every 3 weeks）and intravenous oxaliplatin 130mg per m2（every 3 weeks）in combination with sintilimab 200mg (every 3 weeks)
10133286|NCT04263883|Active Comparator|Conventional treatment|Usual Care Group: Conventional treatment: moist hot pack. manual therapy, Therapeutic Exercise.Home program routine.
10133287|NCT04263883|Experimental|Study or Experimental Group|"moist hot pack.~manual therapy.~Therapeutic Exercise.~Home program routine. 5.3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill. For 10 weeks(3Times/week for 20 minutes)."
10133288|NCT04263753|Experimental|conservative surgery for bladder in placenta accretta|
10133289|NCT04263740|Experimental|Kinesio Taping plus Traditional Physical Therapy|Kinesio Taping plus Traditional physical therapy
10133290|NCT04263740|Other|Traditional Physical Therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises.
10133291|NCT04263779|No Intervention|Default List (case manager level)|In this condition, all SNF options will be presented to case managers in Repisodic in rank order according to Repisodic's algorithm that weights dimensions such as Centers for Medicare & Medicaid Services (CMS) quality metric ratings, distance, and the match between SNF features and specific patient need. The list only includes SNFs that accept the patient's insurance.
10187674|NCT03723759|Experimental|Group D|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation A, formulation D, formulation C, faster aspart 100 U/mL, formulation E, formulation B.~The dosing visits will be separated by wash-out periods (2-21 days)."
9669091|NCT04115319|Experimental|SEP363856|SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
10133292|NCT04263779|Experimental|P-SNF Top-Sorted List (case manager level)|"This condition is the same as the Default List, except that relevant providers (i.e., those meeting patient needs and located within a threshold distance to be determined per hospital) who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.~Situations in which there are no relevant P-SNFs will be flagged yet still assigned to this condition, in an intent-to-treat analysis; the default algorithm-based rank-ordered approach will be applied to all non-preferred providers."
10133293|NCT04263779|No Intervention|Full List/Full Map/Default Video (patient level)|All SNF options, both P-SNFs and NP-SNFs (up to a maximum of 10 by default) that case managers preselected for patients will be presented to patients in rank order (according to Repisodic's algorithm, as described above). Patients will also have the option of viewing the default Repisodic map, which will show the SNFs on the list, and patients will be provided the link to an introductory video presenting the SNF selection and discharge process. When only a paper printout is available, the same SNF sorting order will be presented on paper.
10133294|NCT04263779|Experimental|P-SNF List/P-SNF Map/P-SNF Video (patient level)|This is the same as the Full List condition, except that both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. Moreover, the link to viewing the optional introductory video will be highlighted, and the video will include sections describing the advantage of P-SNFs for care coordination. When only a paper printout is available, the same SNF sorting order will be presented on paper, with only the P-SNFs presented on the first page.
10133295|NCT04263662||Pre-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours prior to implementation of an analgesia-sedation algorithm.
10133296|NCT04263662||Post-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours after implementation of an analgesia-sedation algorithm.
10133297|NCT04263714|Experimental|Exercise|All subjects will perform both aerobic and resistance exercise
10133298|NCT04264221|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
10133299|NCT04264221|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
10133300|NCT04263844|Active Comparator|Dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine 1 mcg/kgBB thirty minutes before induction
10133301|NCT04263844|Active Comparator|Midazolam|subject will receive premedication with intranasal midazolam 0,1 mg/kgBB thirty minutes before induction
10133302|NCT04264208|Experimental|68Ga-RM2 PET MRI/68Ga PMSA11 PET/MRI|Subjects will undergo either 68Ga RM2 PET/MRI followed within 2 weeks by 68Ga PMSA11 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
10133303|NCT04264208|Experimental|68Ga-PSMA-11 PET MRI/68Ga-RM2 PET MRI|Subjects will undergo 68Ga PMSA11 PET/MRI followed within 2 weeks by 68Ga RM2 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
10133304|NCT04263636||Study group|Patients that underwent uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs (PanOptix or PanOptix toric, Alcon Laboratories, Inc., Fort Worth, TX, USA)
10133305|NCT04263636||Control group|Patients of similar age without cataract that their crystalline lens has not been replaced.
10133306|NCT04263623|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
10133307|NCT04263623|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
10133308|NCT04263623|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
10133309|NCT04263805|Experimental|Vignette with research climate|Participants in this arm will receive vignettes describing a dilemma situation in research (e.g adding honorary author) with additional sentence describing research climate (i.e. an environment where their peer had detrimental practice in a similar situation)
10133310|NCT04263805|Active Comparator|Vignette without research climate|Participants in this arm will receive vignettes describing a dilemma situation in research without the additional sentence describing research climate
10133311|NCT04263610|Experimental|Non-Germany: Dimethyl fumarate standard scheme|"Part 1: Participants will receive Dimethyl fumarate (DMF) standard scheme from baseline to Week 16.~Part 2: Participants achieving a Psoriasis Area and Severity Index (PASI) 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
10133312|NCT04263610|Experimental|Germany: Dimethyl fumarate standard scheme|Part 1: Participants will receive DMF standard scheme from Baseline to Week 16. Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40.
9669092|NCT04115319|Active Comparator|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
10133313|NCT04263610|Experimental|Germany: Dimethyl fumarate simplified scheme|"Part 1: Participants will receive DMF simplified scheme from Baseline to Week 16.~Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
10133314|NCT04263701|Active Comparator|Conventional Physiotherapy Group|45 minutes, 2 days in a week for 8 weeks
10133315|NCT04263701|Experimental|Dual Task Training Group|45 minutes, 2 days in a week for 8 weeks
10133316|NCT04263558|Active Comparator|LHF|Long intervention (16 sessions) High parental involvement (5 sessions) Feedback
10133317|NCT04263558|Active Comparator|LHN|Long intervention (16 sessions) High parental involvement (5 sessions)
10133318|NCT04263558|Active Comparator|LLF|Long intervention (16 sessions) Low parental involvement (Brochure) Feedback
10133319|NCT04263558|Active Comparator|LLN|Long intervention (16 sessions) Low parental involvement (Brochure)
10133320|NCT04263558|Active Comparator|SHF|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions) Feedback
10133321|NCT04263558|Active Comparator|SHN|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions)
10133322|NCT04263558|Active Comparator|SLF|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure) Feedback
10133323|NCT04263558|Active Comparator|SLN|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure)
10133324|NCT04263688||Immunotherapy effective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
10133325|NCT04263688||Immunotherapy Ineffective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
10133326|NCT04263415|Placebo Comparator|group P|once-weekly injection with placebo pen.
10133327|NCT04263415|Experimental|group S|Once-weekly application of semaglutide
10133328|NCT04263519|Active Comparator|Low Serum Level|Stable Blood Tacrolimus of 2-5 ng/ml.
10133329|NCT04263519|Active Comparator|High Serum Level|Stable Blood Tacrolimus of 5.1-10 ng/ml.
10133330|NCT04263506|Experimental|Vignette with supervisor's opinion|Participants in this arm will receive vignettes with an additional sentence describing supervisor's opinion (i.e. supervisor does not oppose to detrimental research practice)
10133331|NCT04263506|Active Comparator|Vignette without supervisor's opinion|Participants in this arm will receive vignettes without an additional sentence describing supervisor's opinion.
10133332|NCT04263818|Experimental|Motions during colonoscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for
10133333|NCT04263545|Active Comparator|Intervention|
10133334|NCT04263545|Placebo Comparator|Standard Care|
10133335|NCT04263428|Experimental|Irregular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights, including an adaptation night and a baseline night of 7.5 h time in bed (0:00-7:30). Afterwards, they are instructed to sleep in bed on a schedule alternated between 6 h, i.e. 1:30-7:30, and 9 h, i.e. 22:30-7:30).
10133336|NCT04263428|No Intervention|Regular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights of 7.5 h time in bed (0:00-7:30).
10133337|NCT04263402|Experimental|Methylprednisolone(<40mg/d)|
10133338|NCT04263402|Experimental|Methylprednisolone(40~80mg/d)|
10133339|NCT04263233||Other|This program, which is provided for all patients new to dialysis at the participating units, will be evaluated by assessing patient clinical outcomes and the results of surveys measuring patient-reported symptoms, quality of life, knowledge and activation. In addition, satisfaction with the program will be assessed.
10133340|NCT04263051|Experimental|UCPVax + Nivolumab|"UCPVax vaccine (0,5 mg)~Nivolumab (480 mg)"
10133341|NCT04263051|Other|Standard second line chemotherapy|"Standard second line chemotherapy at the choice of the investigator.~This arm will permit to assess the good calibration of the hypothesis on the experimental arm."
10133342|NCT04263194|Experimental|Default Mode Network (DMN)|The treatment will consist in the individually tailored stimulation of a DMN node (i.e. left inferior parietal lobe).
10133343|NCT04263194|Experimental|Central Executive Network (CEN)|The treatment will consist in the individually tailored stimulation of a CEN node (i.e. left dorsolateral prefrontal cortex).
10133344|NCT04263194|Placebo Comparator|Placebo|The treatment will consist in targeting the upper part of the scalp (i.e. CZ) while using a sham rTMS coil.
10133345|NCT04263259|Experimental|Attentional Bias Modification|Participants complete attentional bias modification using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
10133346|NCT04263259|No Intervention|Attentional Bias Control|Participants complete attentional bias assessment-only using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
10133347|NCT04263298|Experimental|Fulvestrant Group|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
10133348|NCT04263298|Active Comparator|Capecitabine Group|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
10133349|NCT04263272|Experimental|Upper Body Exercise|Seated upper body circuit training program for 16-weeks. Frequency - 1 to 3 one-hour sessions per week.
10133350|NCT04262960|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
10133351|NCT04262960|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
10133352|NCT04263103|Experimental|Experimental group with SJ-RS-WL2015|Item code: SJ-RS-WL2015, a visual training software program, 15 minutes of one section, twice a day, and for 1 year
10133353|NCT04263103|No Intervention|control group|No special treatment, but observation
10133354|NCT04263220|Experimental|Prototype exoskeleon 1|The experimental trial will be performed with the prototype exoskeleton
10133355|NCT04263220|Experimental|Prototype exoskeleon 2|The experimental trial will be performed with the prototype exoskeleton
10133356|NCT04263220|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
10133357|NCT04263337||Low Cognitive Functioning/Low Concussion History|Former NFL players with low cognitive function and low concussion history will be included in this group.
10133358|NCT04263337||High Cognitive Functioning/ High Concussion History|Former NFL players with high cognitive function and high concussion history will be included in this group.
10133359|NCT04263337||Low Cognitive Functioning/High Concussion History|Former NFL players with low cognitive function and high concussion history will be included in this group.
10133360|NCT04263337||High Cognitive Functioning/Low Concussion History|Former NFL players with high cognitive function and low concussion history will be included in this group.
10133361|NCT04263337||Healthy Male Controls|Healthy male demographically matched controls will be included in this group.
10133362|NCT04263337||Low Cognitive Functioning/Medium Concussion History|Former NFL players with low cognitive function and medium concussion history will be included in this group.
10133363|NCT04263337||Medium Cognitive Functioning/Low Concussion History|Former NFL Players with medium cognitive functioning and low concussion history with be included in this group.
10133364|NCT04263337||Medium Cognitive Functioning/Medium Concussion History|Former NFL Players with medium cognitive functioning and medium concussion history with be included in this group.
10133365|NCT04263337||Medium Cognitive Functioning/High Concussion History|Former NFL Players with medium cognitive functioning and high concussion history with be included in this group.
10133366|NCT04263337||High Cognitive Functioning/Medium Concussion History|Former NFL Players with high cognitive functioning and high concussion history with be included in this group.
10133367|NCT04263012||Patients with an implanted LVAD|Patients which received an implantation of a left ventricular assist device (LVAD) at the University Hospital Basel since 2014
10133368|NCT04263168|Experimental|Bariatric Surgery Candidates|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
10133369|NCT04263168|Sham Comparator|Laparoscopy Cholecystectomy|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
10133370|NCT04263116|Experimental|BAM group|Balloon assisted maturation
10133371|NCT04263116|Experimental|NO BAM|NO Balloon assisted maturation
10133372|NCT04263324|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
10133373|NCT04263324|No Intervention|Control group|No intervention
10133374|NCT04263155|Experimental|Experimental: The Body Project for high school young women|The 4-hour Body Project workshop delivered by trained peer leaders
10133375|NCT04263155|No Intervention|Control|The business-as-usual comparison group does not participate in the Body Project but may engage in any other programs or services they normally would
10133376|NCT04263077|Placebo Comparator|PLACEBO|IN THE PLACEBO GROUP, THE ENDS OF THE TAPES WILL BE APPLIED NO TENSION WITHOUT OVERLAPPING EACH OTHER.
10133377|NCT04263077|Other|50% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 50% TENSION.
10133378|NCT04263077|Other|75% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 75% TENSION.
10133379|NCT04263077|Other|100% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 100% TENSION.
10133380|NCT04262973|Experimental|experimental group|The experimental group will not only receive six-hour dementia care course, but also a half-day interprofessional education workshop, maintain a six-month interprofessional practice model, and join interprofessional practice experience-sharing conferences.
10133381|NCT04262973|Active Comparator|control group|The control group will only receive six-hour dementia care course.
10133382|NCT04262739|Experimental|NYH817G|
10133383|NCT04262739|Experimental|NYH100P|
10133384|NCT04262739|Experimental|NYH817G and NYH100P|
10133385|NCT04262999||drug sodium valproate|individuals on antiepileptic drug sodium valproate for at least 1 year at the time of participation of the study.
10133386|NCT04262999||drug levetiracetam|individuals on antiepileptic drug levetiracetam monotherapy for at least 1 year at the time of participation of the study.
10133387|NCT04262999||drug sodium valproate + levetiracetam|individuals on antiepileptic drug sodium valproate + levetiracetam combination therapy for at least 1 year at the time of participation of the study.
10133388|NCT04262999||control group|systemically healthy individuals
10133389|NCT04262934|Experimental|Cholecalciferol treatment|Arm A : Cholecalciferol 100.000 UI - oral - every month
10133390|NCT04262934|Active Comparator|No treatment|Arm B : No vitamin D administration
10133391|NCT04262635|Experimental|ArmA Cetuximab plus Capecitabine|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W); plus capecitabine in 2-week cycles until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
9968451|NCT01279655|Experimental|tDCS and training|Transcranial Direct current stimulation (tDCS) is applied together with a bimanual learning task. tDCS is delivered through two gel-sponge electrodes (eldith DC Stimulator, neuroConn GmbH, Ilmenau, Germany) embedded in a saline-soaked solution. tDCS will be applied for 20 min, with a current intensity of 1mA.
9968452|NCT01279655|No Intervention|Control|No intervention is applied
10133392|NCT04262635|Active Comparator|ArmB Cetuximab|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W) until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
10133393|NCT04262661|Experimental|NNC0472-0147 Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147.
10133394|NCT04262661|Placebo Comparator|Placebo Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo.
10133395|NCT04262661|Experimental|NNC0472-0147 Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days
10133396|NCT04262661|Active Comparator|Insulin glargine Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days.
10133397|NCT04262830||All Study Participants|This is an observational study where all study participants are within a single group.
10133398|NCT04262700|Experimental|Intervention 01|Subjects use new LifeScan provided BGMS for 12 weeks.
10133399|NCT04262817|Experimental|E-cigarette flavor|In this arm, participants will receive two experimental e-cigarette flavors
10133400|NCT04262817|Experimental|E-cigarette nicotine form|In this arm, participants will receive two forms of nicotine in an e-cigarette
10133401|NCT04262648|Experimental|Treatment|
10133402|NCT04262648|Placebo Comparator|Control|
10133403|NCT04262843|Experimental|Treatment (fludarabine, TMLI, HCT, cyclophosphamide)|"CONDITIONING: Patients receive fludarabine IV QD on days -7 to -5, and undergo TMLI BID on days -4 to 0 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard."
10133404|NCT04262752|Experimental|chronically constipated people|Adults with chronic constipation due to either neurogenic bowel dysfunction (NBD) as consequence of a neurogenic condition such as Multiple sclerosis or Parkinson Disease, or to unkwon origin (Idiopathic No-NBD)
10133405|NCT04262765|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:~Age: 18-49 years~Weight: 55-105 kg~Height: 163-188 cm~BMI 18.5-29.9 kg/m²"
10133406|NCT04262804|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
10133407|NCT04262804|Active Comparator|Trastuzumab & Chosen Chemotherapy|The dosage and administering of Trastuzumab is 8 mg/kg loading dose then 6 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
10133408|NCT04262674|Experimental|Cognitive-motor training|Simultaneous cognitive-motor training (i.e. exergame) and strength training
10133409|NCT04262674|No Intervention|Control|Passive control group
10133410|NCT04262882|Experimental|Multilevel Family Planning Intervention|A multi-level, community-based intervention delivered in groups of couples to increase contraceptive uptake, reduce discontinuation, and reduce the incidence of unintended pregnancy, and improve intermediate outcomes (knowledge, attitudes, norms, communication, equity).
10133411|NCT04262882|Active Comparator|Time and attention-matched control|A community sanitation intervention delivered in groups of couples to increase at-home and community hygiene practices.
10133412|NCT04262401|Active Comparator|Standard health coaching|Standard health coaching to increase health behaviors
10133413|NCT04262401|Experimental|Habit-focused health coaching|Health coaching enhanced with a focus on habit formation using a mobile application called Habit Design
10133414|NCT04262518|Other|Outcomes4Me App Users|This cohort will download and use the Outcomes4Me mobile app for breast cancer.
10133415|NCT04262570|Experimental|SMA patients (therapy arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~Magnetic Resonance Imaging (MRI) of lower leg~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
10133416|NCT04262570|Active Comparator|SMA patients (control arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~Magnetic Resonance Imaging (MRI) of lower leg~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
10133417|NCT04262544|Experimental|mHealth|Intervention group
10133418|NCT04262544|Active Comparator|Usual Care|Control group
10133419|NCT04262557|Experimental|Sunrise+PSG|PSG and Sunrise® will be set at the patient's home by IC@dom. The first night, the patient will be equipped by both PSG and Sunrise® and only by the Sunrise® for the two following nights.
10133420|NCT04262505|Experimental|Mediterranean Diet Group (Group A)|The intervention is based on components of the traditional Mediterranean diet which is primarily a plant based diet and emphasises intakes of vegetables, whole grains and fruit with the main added fat being extra virgin olive oil.The diet will be modified and tailored to cultured preferences by the registered dietitian. Participants will be informed of their diet allocation group during the baseline teleconsultation and will commence the diet the following day or as soon as is feasible for 12 weeks. Participants will be provided with resources specifically designed to explain the components of the Mediterranean diet and how it will be followed.
10133421|NCT04262505|Experimental|Healthy Eating Group (Group B)|Participants assigned to the Healthy Eating group will be advised to adhere to the current healthy eating guidelines and will be provided with resources to inform them of these guidelines and sample meal plans that are readily available on the Healthy Ireland website.
10133422|NCT04262245|Other|irrigation activation method|Irrigation activation is a crucial stage of root canal treatment. Therefore, the effect of activation methods on post treatment is an important fact for the comfort of patients.
10133423|NCT04262622|Active Comparator|Group TEA|
10133424|NCT04262622|Active Comparator|Group RSB|
9669093|NCT04113499|Active Comparator|Direct Endoscopic Necrosectomy|The subject will have endoscopic drainage and necrosectomy at the time of the index intervention.
10133425|NCT04262388|Experimental|Window|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with locally advanced disease (window) and treated with durvalumab 1500 mg given by IV x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to definitive therapy (e.g. surgery)."
10133426|NCT04262388|Experimental|Metastatic|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with recurrent/metastatic (metastatic) disease and treated with durvalumab 1500 mg given by IV every 4 weeks and oleclumab 3000 mg given by IV every 2 weeks x 4 doses then IV every 4 weeks till disease progression, toxicity, withdrawal of subject consent, or another discontinuation reason."
10133427|NCT04262180|Experimental|Base intervention- Fitbit with EHR integration|All participants will receive a first-line intervention (i.e., Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal) and will be evaluated for response/non-response every 4 weeks until week 20.
10133428|NCT04262180|Experimental|Nonresponders -Stepped up to Online gym|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Online gym."
10133429|NCT04262180|Experimental|Nonresponders -Stepped up to Coaching calls|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Coaching calls."
10184033|NCT03758703|Active Comparator|Pre-recorded soothing poetry group|The control group will be provided pre-recorded soothing poetry which they will self-select. Participants are allowed to switch playlists within their treatment arm each day should they desire. This control group is designed to control time, attention, and placebo effect. Thus, the soothing poetry will be offered the identical time duration of listening to recorded soothing poetry readings and played at the same time the intervention group receives the pre-recorded music.
10184034|NCT03758690|Experimental|Treatment Group|Treatment with the investigational device - High-Intensity Focused Electromagnetic (HIFEM) Field Device
10184035|NCT03758677|Experimental|Patients who progressed after EGFR-TKI without T790M mutation|Single arm; Plan to enroll 30 cases; Patients who progressed after EGFR-TKI treatment without T790M mutation
10184036|NCT03758664|Experimental|ICP-192|The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
10184037|NCT03758625|Experimental|ARM A|a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
10184038|NCT03758625|Experimental|ARM B|a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
10184039|NCT03758625|Active Comparator|ARM C|a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
10184040|NCT03758625|Experimental|ARM D|pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
10184041|NCT03758625|Experimental|ARM E|pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
10184042|NCT03758625|Active Comparator|ARM F|pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
10184043|NCT03758612|Active Comparator|Cohort 1 (sentinel group) - Active|Single dose of TBI-223 50 mg (n=2) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
10184044|NCT03758612|Placebo Comparator|Cohort 1 (sentinel group) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
10184045|NCT03758612|Active Comparator|Cohort 1 (remainder of cohort) - Active|Single dose of TBI-223 50 mg (n=4).
10184046|NCT03758612|Placebo Comparator|Cohort 1 (remainder of cohort) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1).
10184047|NCT03758612|Active Comparator|Cohort 2 - Cohort 7 - Active|Single dose of TBI-223 100, 300, 600, 1200, 2000, 2600 mg; n=3 per dosing group.
10184048|NCT03758612|Placebo Comparator|Cohort 2 - Cohort 7 - Placebo|Single dose of matching Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg, n=1 per dosing group.
10184049|NCT03758612|Active Comparator|Cohort 3b - Active - Oral Capsule|Single dose of 300 mg in oral enteric capsule, n=4 per dosing group.
10184050|NCT03758612|Placebo Comparator|Cohort 3b - Placebo - Oral Capsule|Single dose of placebo for 300 mg in oral enteric capsule, n=1 per dosing group.
10184051|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 1|Single dose of TBI-223 sustained-release (SR) tablet prototype 1, 3 x 600 mg, n=6 per cohort.
10184052|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 2|Single dose of TBI-223 SR tablet prototype 2, 3 x 600 mg, n=6 per cohort.
10184053|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 3|Single dose of TBI-223 SR tablet prototype 3, 2 x 900 mg, n=6 per cohort.
10184054|NCT03758612|Active Comparator|Cohort 8 - IR Tablet fasted|Single dose of TBI-223 immediate-release (IR) tablet prototype 4, 2 x 1000 mg, n=6 per cohort; fasted prior to dose.
10184055|NCT03758612|Active Comparator|Cohort 9 - IR Tablet with meal|Single dose of TBI-223 immediate-release (IR) tablet, 2 x 1000 mg, n=6 per cohort; fed prior to dose.
10184056|NCT03758599|Experimental|Climbing Exercise Group|At the beginning of each session, a standardized body-centered, mind-setting warmup of ten minutes will take place. The general warm-up will be followed by climbing specific warm-up, which will consist of bouldering (20-30 minutes). Afterwards the rope climbing session will start. Climbing sessions also contain several sport-specific skill-development training sessions to familiarize the participants with gear and rope management, to acquire footwork and route finding, and to locate good belay spots and resting positions while climbing. At the end of the climbing session a short cool-down of five minutes will be executed.
10184057|NCT03758599|Experimental|Aerobic Exercise Group|As the climbing exercise group, the aerobic exercise group will start with a ten minutes body-centered, mind-setting warm-up, followed by 60 minutes of Nordic walking and five minutes cool down. A physiotherapist or sport scientist will instruct and guide the group. Nordic walking will be performed at a moderate pace at varying paths.
10187675|NCT03723759|Experimental|Group E|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~faster aspart 100 U/mL, formulation A, formulation E, formulation D, formulation B, formulation C.~The dosing visits will be separated by wash-out periods (2-21 days)."
10133430|NCT04262076|Experimental|Combination of pulpine with Polyamidoamine Dendrimer|Removal of Caries infected dentin from the walls and floor of the cavity and then apply polyamidoamine Denrimer for 30 secs ,then washed out of the cavity followed by placement of Pulpine over affected Dentin.
10133431|NCT04262076|Active Comparator|Pulpine|Removal of Caries infected dentin from the walls and the floor of the cavity followed by application of Pulpine over affected Dentin.
10133432|NCT04262310||Study Aims|To obtain normative data (median, 10th and 90th percentile) as well as inter-individual coefficient of variation (COV, assessed by [SD/mean]) with approximately 15 participants in each age group: 18-30, 31-45, 46-60, and 60-70 years old. To assess intra-individual COV [assessed by [SD/mean]. To assess effect of standard diets containing 16.25 or 32.5 g fiber/day during the two 24 hour periods before and during the measurement of permeability
10133433|NCT04262219|Experimental|iShare|Participants will be asked to listen to a podcast intervention.
10133434|NCT04262375|Experimental|Durvalumab and Oleclumab|A single dose level for oleclumab and durvalumab will be used, comprising of Oleclumab 3000 mg IV Q2W for 4 doses, then Q4W AND Durvalumab 1500 mg IV Q4W
10133435|NCT04262349|Experimental|intervention|"Every week because of differences in the number of pregnant women who attended the school participating women were divided into two groups using a random number table created in the program via the computer itself. The purpose of the study was explained to pregnant women, informed consent form and data collection tools of the study were collected by face to face interview technique. In the first interview to all pregnant women; Personal Information Form, Course Information Form, Pittshburg Sleep Quality Index (PUKI) and General Self-Efficacy Scale were applied. Pregnant women in the intervention group were given a two-session training program to improve sleep quality and Sleep Guide and Safe Baby Sleep Conditions Brochure."
10133436|NCT04262349|No Intervention|control|"Pregnant women in the control group were subjected to routine practice without any training given by the researcher. Four weeks after the completion of the sleep training, all pregnant women were contacted by telephone and the data collection tools were applied for the second time and the final test applications were completed. After completion of the data collection process made a new plan for training to improve the quality of sleep to pregnant women in the control group and the Sleep Guide and Safe Baby Sleep Conditions Brochure is given."
10133437|NCT04262063|Experimental|tell play do technique|Tell play do technique with a dental imitation toy and using euphemisms instead of demonstrating on a model or observing one. Tell play do technique provides a better explanatory concept of the dental procedure and can lead to more cooperation of the children patients which can influence the dental treatment in a good and positive way.
10133438|NCT04262063|Active Comparator|tell show do technique|Tell show do is the gold standard of the non-pharmacological behavior management techniques. It is based on the principle of learning theory and it is performed by the dentists themselves . It is the most important behavior modification technique practiced by dentists and it is commonly used for management of children anxiety in the first dental visit .
10133439|NCT04262193|Placebo Comparator|Suvorexant placebo|Placebo (inert) tablet
10133440|NCT04262193|Experimental|Suvorexant 10mg|Suvorexant 10mg tablet
10133441|NCT04262193|Experimental|Suvorexant 20mg|Suvorexant 20mg tablet
10133442|NCT04262102|Active Comparator|Group 1 (SD_SF)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
10133443|NCT04262102|Experimental|Group 2 (SD_BLW)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
10133444|NCT04262102|Experimental|Group 3 (HFV_SF)|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
10133445|NCT04262102|Experimental|Group 4 (HFV_BLW)|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
10133446|NCT04262050|Experimental|TMS + tDCS group|
10133447|NCT04262050|Experimental|sham TMS + tDCS group|
10133448|NCT04262050|Experimental|tDCS group|
10133449|NCT04262050|Experimental|TMS group|
10133450|NCT04262089|Experimental|primary dMMR uterine cancer patients|primary dMMR uterine cancer patients
10133451|NCT04262089|Experimental|primary POLE-EDM uterine cancer patients|primary POLE-EDM uterine cancer patients
10133452|NCT04262037|Experimental|HPPV|will receive high frequency positive pressure ventilation during cardiopulmonary bypass at tidal volume 2 ml/kg and respiratory rate 80. Lung ultrasound will be done at the beginning and end of surgery
10133453|NCT04262037|Experimental|CPPV|will receive continuous positive airway pressure of 10 cmH2o during the bypass. Lung ultrasound will be done at the beginning and end of surgery
10133454|NCT04262037|No Intervention|Control|will be disconnected from the ventilation (passive deflation). Lung ultrasound will be done at the beginning and end of surgery.Lung ultrasound will be done at the beginning and end of surgery
10133455|NCT04262011|Other|immediate treatment|After randomization, patients who are allocated to the immediate treatment group will receive treatment.
9826055|NCT02405442|Placebo Comparator|Placebo|Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
10133456|NCT04262011|Other|postponed treatment|After randomized patients will be allocated to this group, they will wait for the follow-up of the study to receive delayed treatment.
9826056|NCT02405780|Experimental|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
9826057|NCT02405780|Active Comparator|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
9968453|NCT01279655|Placebo Comparator|Sham tDCS + Training|The training consists of a bimanual training task. tDCS is only applied for a few seconds and will than be ramped-down.
9968454|NCT01279668|Experimental|Montelukast|
9968455|NCT01279668|Placebo Comparator|Placebo|
9968456|NCT01279707|Experimental|A: Veltuzumab and chemotherapy|Veltuzumab and modified UKALL XII chemotherapy
9968457|NCT01279707|Experimental|B: epratuzumab and chemotherapy|epratuzumab and modified UKALL XII chemotherapy
9968458|NCT01279707|Experimental|C: veltuzumab and epratuzumab and chemotherapy|Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
9968459|NCT01279720|Experimental|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
9968460|NCT01279733||Microarray Analysis|
9968461|NCT01279746||ultrasond compression of deep veins|
9968462|NCT01279785||Prostate Cancer Patients|Male participants who are scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center and have evidence of a recent (within 12 months of study entry) trans-rectal biopsy documenting adenocarcinoma of the prostate.
9968463|NCT01279811|Other|Single Arm|Vasopressor Crossover - Dopamine & NORepinephrine
9968464|NCT01279824|Active Comparator|Usual Care|Patients will receive behavioral swallowing therapy comprising combination's of treatment strategies / exercises chosen from an approved hierarchy. This formulation of treatment will be designed and applied by the treating clinician.The treatment will be provided daily for a one-hour over a consecutive 3-week period.
9968465|NCT01279824|Placebo Comparator|sham NMES|Patients will receive behavioral swallowing therapy comprising combinations of treatment strategies / exercises chosen from an approved hierarchy with the addition of non stimulating electrodes. A faux NMES device will be utilized with an active current display and non stimulating electrodes. The treatment will be provided daily for a one-hour over a consecutive 3-week period.
9968466|NCT01279824|Experimental|NMES therapy|Patients will receive a protocol of standardized behavioral swallowing intervention combined with NMES. This formulation of treatment will be prescribed from a standard protocol and will be applied daily for one-hour over a consecutive 3-week period.
9968467|NCT01279837|No Intervention|Usual care|Control (Usual care) group in which patients will receive swallowing and prescribed dietary intervention during the radiotherapy period prescribed by the attending physician.
9968468|NCT01279837|Experimental|High Intensity Pharyngocise|Patients receive twice daily swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises.
9968469|NCT01279837|Active Comparator|Low Intensity Pharyngocise|Patients will receive a one time only swallowing intervention session by a speech language pathologist, instructing them in the battery of isometric / isotonic exercises plus a home practice instruction digital video tape to support self directed practice of this program at home.
9968470|NCT01279876|Active Comparator|Melatonin|
9968471|NCT01279876|Placebo Comparator|Placebo|
9968472|NCT01279889||Cesarean Delivery|Healthy pregnant women having an elective cesarean delivery
9968473|NCT01279902|Experimental|Rituximab plus CHOP Immunochemotherapy|"Interventions: conventional R-CHOP every 3 weeks for 3 cycles~Rituximab 375 mg/M2 IV day 1~Cyclophosphamide 750 mg/M2 IV day1~Vincristine 1.5 mg/M2 (max. 2 mg) IV day1~Prednisolone 50 mg bid day 1-5, every 3 weeks"
9968474|NCT01279915|Experimental|ASP group|ASP0456 receiving group
9968475|NCT01279915|Placebo Comparator|Placebo group|Placebo treatment
9968476|NCT01279928||Type 1 Diabetes Paediatric|Paediatric patients aged 8-18 with diagnosed Diabetes Mellitis Type 1 attending paediatric clinic at John Hunter Hospital.
9669094|NCT04113499|Active Comparator|Step-up Endoscopic Interventions|The subject will only have endoscopic drainage of the pancreatic necrotic collection at the time of index intervention.
9669095|NCT04109950|Experimental|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg flexibly dosed once daily
9968477|NCT01279941|No Intervention|Testing Only|
9968478|NCT01279941|Experimental|Testing & Intervention|
9968479|NCT01279967|No Intervention|A|Arm A is control arm with best supportive care.
9968480|NCT01279967|Experimental|B|Arm B is the treatment arm with best supportive care plus ADI-PEG20.
9968481|NCT01279980|Active Comparator|Epidural|Subjects will have an epidural catheter placed to provide postoperative pain relief. This is standard care for those undergoing an enhanced recovery program.
9669096|NCT04103593|Experimental|exercise group|High-intensity circuit exercise training will be performed 3 times weekly for 12 weeks in a group setting. Circuit training is an exercise modality consisting of a series of exercises at different stations. Exercise training will be delivered by VTEL broadcast from the Salem VAMC to participants at the Atlanta VAMC and Baltimore VAMC. Rooms will be equipped with steps, hand and ankle weights, dumbbells, chairs and bands. No stationary exercise equipment will be used in either AEX or RT.
9968482|NCT01279980|Active Comparator|Painbuster|Subjects will have a local anaesthetic wound catheter inserted into the wound at time of surgery rather than an epidural for the provision of postoperative pain relief.
9968483|NCT01279993|Experimental|Kerato refractive Surgery|
9968484|NCT01280019|Experimental|FRC guided|Patients receive an alveolar recruitment manoeuvre if FRC falls below 94% of baseline FRC
9968485|NCT01280019|Active Comparator|Saturation guided|Patients receive an alveolar recruitment manoeuvre if peripheral oxygen saturation falls below 90%
9968486|NCT01280032|Experimental|Kypho-IORT|
9968487|NCT01280045|Experimental|AROMATASE INHIBITOR|this would be compared before and after VAGINAL HYSTERECTOMY
9968488|NCT01280045|Active Comparator|GNRH ANALOG|this would be compared before and after VAGINAL HYSTERECTOMY
9968489|NCT01280071|Experimental|dipyridamole, aminophylline|
9968490|NCT01280084||No labour analgesia/nitrous oxide|Women who use no analgesia during labour or who only used nitrous oxide.
9968491|NCT01280084||Systemic opioids|Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
9968492|NCT01280084||Intermediate dose epidural fentanyl|Women who receive a total epidural fentanyl dose less than 150 micrograms
9968493|NCT01280084||High dose epidural fentanyl|Women who receive a total epidural fentanyl dose more than 150 micrograms
9968494|NCT01280097||Prospective cohort study|Observational only
9669097|NCT04103593|No Intervention|control group|Sedentary activity (confirmed at eligibility no more than 1 structured physical activity/week) will be continued in participants randomized to the control group. Participants have the option after 12-week intervention phase to enter ?delayed? exercise training to assure that all participants can receive exercise training.
9669098|NCT04093700||SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
9669099|NCT04092816|Experimental|FAMILY|Patient-co-parent dyads will participate in the FAMILY intervention in-person.
9669100|NCT04072016|Experimental|Beacon Aqueous Microshunt|
9968495|NCT01280136|Experimental|It's Your Game Tech|An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
9968496|NCT01280149|Experimental|substance P-low dose allergen|Substance P injections with 8 sequential, increasing doses of allergen
9968497|NCT01280149|Experimental|substance P-moderate dose allergen|Substance P with sequential, increasing doses of allergen
9968498|NCT01280149|Experimental|substance P-low/moderate dose allergen|substance P with 16 sequential increasing doses of allergen
9968499|NCT01280149|Active Comparator|substance P-placebo|Placebo injections of substance P and placebo
9968500|NCT01280149|Experimental|placebo-low dose allergen|Placebo injections with 8 sequential increasing low dose allergen injections
9968501|NCT01280149|Placebo Comparator|placebo-placebo|substance P placebo and allergen placebo (weekly)
9968502|NCT01280162|Experimental|3 day therapy|Total dose split over 3 days (3 tablets per day)
9968503|NCT01280162|Experimental|2 day therapy|Total dose split over 2 days (4.5 tablets per day)
9968504|NCT01280175|Experimental|pMDI + charcoal block|BDP/formoterol 100/6 µg pMDI with charcoal ingestion
9968505|NCT01280175|Experimental|pMDI + Aerochamber Plus|BDP/formoterol 100/6 µg with Aerochamber Plus
9968506|NCT01280175|Active Comparator|pMDI|BDP/formoterol 100/g µg pMDI
9968507|NCT01280188|Experimental|Desmopressin|Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.
9968508|NCT01280214|Experimental|Triamcinolone|
9968509|NCT01280227|Experimental|1|Patients uses the symptom assessment tool SiSom. A summary of their reported symptoms are printed out and given to the pediatrician and nurse before the consultation. The consultation is videotaped.
9968510|NCT01280227|No Intervention|2|"The control group do not use the symptom assessment tool SiSom before the consultation. The control group receives usual care and the consultation is videoptaped."
9968511|NCT01280240|Active Comparator|Monofer 500 mg|
9968512|NCT01280240|Active Comparator|Monofer 250 mg|
9669101|NCT04057872|Active Comparator|TPE in Septic Shock|The patients in this arm will receive TPE
9968513|NCT01280279||group with nocturnal polyuria and nocturia|Patients were enrolled when they had the urine volume at nighttime more than one third of total daily urine volume (NPU) and voided more than two times at nighttime (nocturia)
9968514|NCT01280305|Experimental|raloxifene|
9669102|NCT04057872|No Intervention|Reference Population|The patients will receive the standard of care for septic shock treatment
9669103|NCT04038736|Experimental|Healthy subjects at averge risk for CRC|All subjects are healthy who didn't have any known polyps in past colonoscopy and who arw candidates for CRC screening
9669104|NCT04038736|Experimental|Healthy subjects at high risk for CRC|Subjects who had polyps in former colonoscopy, subjects who have family history of CRC or subjects who have positive stool blood test.
9968515|NCT01280305|Placebo Comparator|Placebo|
9968516|NCT01280318|Other|1|patients with operable head and neck squamous cell carcinoma
9968517|NCT01280318|Other|2|patients treated by neck ansd head surgery for a non-oncological disease
9968518|NCT01280318|Experimental|3|patients treated before surgery with 3 doses of neoadjuvant cetuximab
9968519|NCT01280370||1|1.patients treated in a laparoscopic manner
9968520|NCT01280370||2.|2. patients treated in open operative manner
9968521|NCT01280383|Experimental|non-invasive NAVA|application of non-invasive NAVA in critically ill patients
9968522|NCT01280396||SGAs|patients receiving SGAs
9968523|NCT01280448||Case Group|
9968524|NCT01280448||Control Group|
9968525|NCT01280461||Experimental Group|
9968526|NCT01280461||Control Group|
9968527|NCT01280487|Experimental|Oral ZSTK474|Daily oral dosing for 21 days per cycle
9968528|NCT01280513|Experimental|High Protein intake|
9968529|NCT01280513|Experimental|Low Protein intake|
9968530|NCT01280526|Experimental|Romidepsin dose 10mg/m²|Romidepsin dose 10mg/m²
9968531|NCT01280526|Experimental|Romidepsin dose 12mg/m²|Romidepsin dose 12mg/m²
9968532|NCT01280526|Experimental|Romidepsin dose 14mg/m²|Romidepsin dose 14mg/m²
9968533|NCT01280526|Experimental|Romidepsin dose 8mg/m²|Romidepsin dose 8mg/m²
9968534|NCT01280539|Experimental|TENS|Transcutaneous electrical nerve stimulation will be applied on the impaired hand
9968535|NCT01280539|Sham Comparator|Sham TENS|Sham TENS will be applied to the impaired hand
9968536|NCT01280669|Experimental|Group 1|Intravitreal injections of 440mcg sirolimus (low-dose monthly group)
9968537|NCT01280669|Experimental|Group 2|Intravitreal injections of 880mcg sirolimus (high-dose every other month group)
9968538|NCT01280682|Experimental|rituximab|
9968539|NCT01280708||Capture data|
9968540|NCT01280734|Active Comparator|Melatonin|Circadin(R) 2 mg tablet 2 hours at 23:00
9968541|NCT01280734|Active Comparator|Zolpidem|Stilnox (R) 10 mg tablet at 23:00
9968542|NCT01280734|Placebo Comparator|Placebo|
10133457|NCT04261998|Experimental|Service-learning group|Intervention group will perform a service-learning program with real patients with heart transplantation and coronary syndrome, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
10133458|NCT04261998|No Intervention|Control group|Control group will perform a physical therapy program for heart transplantation and coronary syndrome, but without meeting real patients. One meeting will be performed in order to establish groups and search information based on evidence in scientific databases.
10133459|NCT04261725||Squamous Cell Lung Cancer|Genetic analysis for searching EGFR mutation
10133460|NCT04261985|Active Comparator|Mobile Phone Obesity Intervention|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the intervention arm. Every week for 4 weeks, caregivers will receive 4 interactive multi-media phone prompts to support the intervention's targeted topics. Each mobile phone prompt starts with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share their goal/s, perceived barriers, questions, tips and strategies that may be helpful to other participants. Each week, caregivers will also receive strategies, and individual and group feedback on changing unhealthy behaviors. The content shared by caregivers are summarized by a team research assistant and sent back to participants at the end of every week.
10133461|NCT04261985|No Intervention|Control|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the control (no intervention) arm. Every week for 4 weeks, these caregivers will receive 4 interactive multi-media phone prompts around managing common illness in young children (i.e. fever, vomiting, constipation, etc.) Each mobile phone prompt will start with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share questions and strategies that may be helpful to other participants. Each week, caregivers will also receive tips and group feedback based on group questions. The content shared by caregivers will be summarized by a team research assistant and sent back to participants at the end of every week.
10133462|NCT04261790|Other|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
10133463|NCT04261816||Operating room extubation group|extubation in the operating room immediately following liver transplantation
10133464|NCT04261816||ICU extubation group|extubation in the ICU following liver transplantation
10133465|NCT04261868|Experimental|Virtual Reality|Dichoptic playing games with fine stimulation will present to the amblyopic eye.
10133466|NCT04261868|Active Comparator|Patching|Non- amblyopic eye will be recommended to patch.
10133467|NCT04261933||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
10133468|NCT04261881|Active Comparator|Nutraceutical intervention, 5 capsules twice daily.|Participants will consume the nutraceutical blend ATP-Fuel at 5 capsules twice daily.
10133469|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules once daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules once daily.
10133470|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules twice daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules twice daily.
10133471|NCT04261907|Experimental|ASC09/ritonavir group|ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
10133472|NCT04261907|Active Comparator|lopinavir/ritonavir group|Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment
10133473|NCT04261855|Experimental|Arm A|Avelumab plus External Beam Radiation Therapy (EBRT)
10133474|NCT04261855|Experimental|Arm B|Avelumab plus External Beam Radiation Therapy (EBRT)
10133475|NCT04261855|Experimental|Arm C|Avelumab plus Lutetium-177 (177Lu)-DOTATATE
10133476|NCT04261712|Experimental|Paltusotine|
10133477|NCT04261647|Experimental|Experimental group 1|kinesio- taping technique plus traditional physical therapy program.
10133478|NCT04261647|Experimental|Experimental group 2|Pelvic floor exercise plus traditional physical therapy program.
10133479|NCT04261647|Active Comparator|Control group|traditional physical therapy program in the form of stretching of piriformis, stretching of iliopsoas and clam shell exercise, seat cushioning and seat kitz.
10133480|NCT04261829||Autologous Fat Transfer|
10133481|NCT04261634|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
10133482|NCT04261634|Active Comparator|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
10133483|NCT04261959||myoActivation only|Participants who receive one or more sessions of myoActivation. They may receive 1:1 counselling also, but will not receive physiotherapy or group counselling
10133484|NCT04261959||Physiotherapy only|Participants who receive one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive myoActivation or group counselling
10133485|NCT04261959||myoActivation and Physiotherapy|Participants who receive one or more sessions of myoActivation AND one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive group counselling
10133486|NCT04261803||Familial Hypercholesterolemia children|
10133487|NCT04261803||Control children|
10133488|NCT04261673|Experimental|Decompressive Craniectomy|After the evacuation of epidural hematoma, the bone flap should not be replaced at the end of the operation.
10133489|NCT04261673|Experimental|Craniotomy|After the evacuation of epidural hematoma, the bone flap must be replaced and fixed with an appropriate fixation system.
10133490|NCT04261920|Experimental|Single decoction group: Huangqi Guizhi Wuwu decoction|The dosage of granules: Sheng huangqi granule 5.5g/bag, Guizhi granule 0.9g/bag, Baishao granule 1.6g/bag, Ganjiang granule 1.7g/bag, Dazao granule 7g/bag. Take twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
10133491|NCT04261920|Placebo Comparator|Simulator group: Huangqi Guizhi Wuwu decoction Placebo|The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
10133492|NCT04261660||fresh|NO INTERVENTION
10133493|NCT04261660||Frozen embro transfer natural|NO INTERVENTION
10133494|NCT04261660||Frozen embro transfer hormonal|NO INTERVENTION
10133495|NCT04261595|Active Comparator|Dates group 1|For the group of the date 1, Diagnosed autistic patients will be given three pieces of Dates will be given on daily basis for 12 weeks as follow: Three pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
10133496|NCT04261595|Active Comparator|Dates group 2|For the group of the date 2, Diagnosed autistic patients matched for age and sex will be given five pieces of Dates will be given on daily basis for 12 weeks as follow: five pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
10133497|NCT04261595|Active Comparator|Group 3|Group 3 (no- Dates fruit group): Diagnosed autistic patients matched for age and sex will not receive any dates
10133498|NCT04261400|Experimental|MAMAACT|Post graduate training of midwives in intercultural communication and health education materials for the pregnant women.
10133499|NCT04261400|No Intervention|Control|Care as usual
10133500|NCT04261309||Elderly with back pain in primary healthcare|Consecutive women and men 55 years of age or older who seek primary care (GP, physiotherapist or chiropractor) with a new episode of back pain (preceded by 6 months without visiting a primary care provider for similar complaints)
10133501|NCT04261543|Experimental|High Protein and Early Exercise|High protein is defined as a protein prescription of ≥2.2 gram/kg body weight; Early exercise is defined as exercise by using cycle ergometry for 45 minutes per day within 24 hours of randomization
10133502|NCT04261543|Active Comparator|Usual Care|Usual care has a protein prescription of ≤1.2 gram/kg body weight and exercise prescription as per the discretion of attending clinicians
10133503|NCT04261374||Measurement of sublingual microcirculation|
10133504|NCT04261556|Experimental|Real HD-tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal high definition transcranial direct current stimulation (HD-tDCS).~In the first 20 min of the 40 min-intervention, HD-tDCS and CCT will be provided simultaneously."
10133505|NCT04261556|Sham Comparator|Sham HD-tDCS + CCT|40 min/day of CCT + 20 min/day of apparent (sham) HD-tDCS. In the first 20 min of the 40 min-intervention, HD-tDCS and CCT will be provided simultaneously.
10133506|NCT04261504|Experimental|Integrative Body Mind Training (IBMT)|mindfulness
10133507|NCT04261504|Active Comparator|Relaxation Training (RT)|relaxation
10133508|NCT04261426|Experimental|IVIG therapy+ standard care|
10133509|NCT04261426|Placebo Comparator|Standard care|
10133510|NCT04261296|Experimental|Dry needling|Arm 1: Dry needling group. Dry needling will be done with painful trigger point and it will be waited for about 20 minutes. This treatment will be repeated once a week for 3 weeks.No medication is used in this treatment.
10133511|NCT04261296|Experimental|balneotherapy|Arm 2: Balneotherapy A total of 15 sessions, 20 minutes a day, 5 days a week for 3 weeks, will be held in the spa, which operates within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.
10133512|NCT04261296|Experimental|Dry needling + balneotherapy|Arm3: dry needling + balneotherapy Both of these methods will be applied to patients in the third group.
10133513|NCT04261335|Experimental|CL2020 cells|Intravenous injection of CL2020 cells
10133514|NCT04261530|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
10133515|NCT04261530|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
10133516|NCT04261530|Experimental|Self-care|It is a 7-months 2 hours-session (1 session per month) of self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
10133517|NCT04261530|Experimental|Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
10133518|NCT04261322|Experimental|rabies patient 1|not received immunoglobulins and symptomatic
10133519|NCT04261322|Experimental|rabies patient 2|received immunoglobulins and symptomatic
10133520|NCT04261322|Experimental|rabies patient 3|not received immunoglobulins and not yet symptomatic
10133521|NCT04261322|Experimental|rabies patient 4|received immunoglobulins and not symptomatic
10133522|NCT04261478|Active Comparator|Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be revascularized with a stent during the acute thrombectomy procedure.
10133523|NCT04261478|No Intervention|No Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be not revascularized with a stent during the acute thrombectomy procedure.
10133524|NCT04261465|Experimental|Paclitaxel Carboplatin Olaparib|"Subjects will receive weekly therapy with paclitaxel 60 mg/m2 IV and carboplatin AUC 2 IV for 3 weeks out of 4, and olaparib tablets at the dose of 150 mg bid administered orally for 3 consecutive days (D1-D3), every week for each cycle.~After 3 cycles patients will be evaluated for interval debulking surgery. After surgery they will receive consolidation treatment with paclitaxel and carboplatin according to Investigator's choice"
10133525|NCT04261491|Experimental|postmenopausal women with low BMD and chronic periodontitis|postmenopausal women with low BMD and chronic periodontitis will be evaluated after SRP for serum bone resorption markers- CTX and inflammatory markers TNF-α, IL-6
10133526|NCT04261517|Experimental|Hydroxychloroquine and conventional treatments|After randomization, subjects take hydroxychloroquine 400mg per day for 5 days, also take conventional treatments.
10133527|NCT04261517|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without hydroxychloroquine.
10133528|NCT04261569|Experimental|Illuminated arm|patients with intraventricular near-infrared light illumination
10133529|NCT04261569|No Intervention|control arm|patients without any medical device
10133530|NCT04261140|Experimental|High-viscosity glass ionomer|
10133531|NCT04261140|Experimental|flowable composite|
10133532|NCT04261140|Experimental|bulkfill composite|
10133533|NCT04261140|Experimental|nanohybrid composite|
10133534|NCT04261179|Other|Lymphoseek + Nanocoll|Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams
10133535|NCT04261452|Other|COPD|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
10133536|NCT04261452|Other|Overlap|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
10133537|NCT04261166|Experimental|BOL-PK-ST-02F|Sublingual tablets
10133538|NCT04261166|Experimental|BOL-PK-ST-02E|Sublingual tablets
10133539|NCT04261166|Experimental|B3 is BOL-PK-ST-02D|Sublingual tablets
10133540|NCT04261166|Experimental|BOL-PK-ST-02A|Drops
10133541|NCT04261166|Experimental|BOL-PK-ST-02C|Drops
10133542|NCT04261166|Experimental|BOL-PK-ST-02B|Drops
10133543|NCT04261283|Experimental|Circuit Training|Specific exercise are designed in circuit training
10133544|NCT04261283|Active Comparator|Control Group|Conventional treatment
10133545|NCT04261270|Experimental|ASC09F+Oseltamivir|
10133546|NCT04261270|Experimental|Ritonavir+Oseltamivir|
10133547|NCT04261270|Experimental|Oseltamivir|
10133548|NCT04261244|Experimental|Experimental Arm|preoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
10133549|NCT04261244|Active Comparator|Standard treatment|standard treatment (postoperative radiotherapy) in breast cancer after neoadjuvant chemotherapy
10133550|NCT04260919|No Intervention|Control|The participants just received standard medical treatment
10133551|NCT04260919|Experimental|Intervention|The participants received medical treatment and chest physiotherapy sessions
10133552|NCT04260906|Active Comparator|Vagus nerve stimulation|Patients were admitted to the treatment as day visitors. Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears . The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
10133553|NCT04260906|Active Comparator|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
10133554|NCT04260893|Experimental|Tixel Treatment|3 Tixel treatment sessions, 2 weeks apart follow by 3 Follow up sessions
10133555|NCT04260971|Experimental|Cyclical Stimulation|This group will undergo cyclical stimulation mode of stimulation
10133556|NCT04260971|Active Comparator|Continuous Stimulation|This group will undergo the standard continuous mode of stimulation
10133557|NCT04260750|Experimental|Expert-chosen content, regular guidance|Content chosen by the therapist, weekly guidance by a therapist.
10133558|NCT04260750|Experimental|Expert-chosen content, on-demand guidance|Content chosen by the therapist, guidance upon request from the health care team.
10133559|NCT04260750|Experimental|Participant-chosen content, regular guidance|Content chosen by participants themselves, weekly guidance by a therapist.
9669105|NCT04015856|Experimental|Full TP intervention including emphasized social norms change|Participants in this study arm will receive the full TP intervention, including emphasized social norms change, for 18 months.
10133560|NCT04260750|Experimental|Participant-chosen content, on-demand guidance|Content chosen by participants themselves, guidance upon request from the health care team.
10133561|NCT04261062||Subject|Patients in surgical intensive unit
10133562|NCT04261101|Experimental|Block A|Test intervention with questions regarding diabetes and adrenal
10133563|NCT04261101|Active Comparator|Block B|Test intervention with questions regarding thyroid and hypophysis
10133564|NCT04261023|Experimental|Abatacept|Treatment arm - 125mg sub-cutaneous injection at week 0 and once weekly thereafter for a maximum of 48 weeks
10133565|NCT04261023|No Intervention|Control arm - CCP Next Generation|Observational study cohort - usual care
10133566|NCT04260997|Experimental|Oral Probiotic Product|
10133567|NCT04260997|Placebo Comparator|Placebo product|
10133568|NCT04260763|Experimental|Social Cognition Group|Social Cognition Group
10133569|NCT04260737|No Intervention|Standard Care|The control group will receive standard care for localized prostate cancer, i.e., information from their doctor and an information brochure.
10133570|NCT04260737|Experimental|Decision Aid + Standard Care|"The intervention group will receive standard care and intervention that includes a website with the Decision Aid which covers the following:~An overview about prostate cancer;~An overview of different treatment options (e.g. surgery and active surveillance)~The pros and cons of different treatment options (e.g., physical, emotional, social).~A value clarification exercise that is designed to assist participants to weigh the pros and cons of each prostate cancer management option."
10133571|NCT04261036|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1g of vitamin C for 14 days.
10133572|NCT04261036|Placebo Comparator|Women on a placebo regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take placebo for 14 days
10133573|NCT04261010|Experimental|Ustekinumab|Group 1 (n=12): ustekinumab 45 mg (or 90 mg for patients > 100 kg) subcutaneously at baseline (W0), 4 weeks later (W4), and every 12 weeks until week 24 (i.e. W0, W4, and W16).
10133574|NCT04261010|Experimental|Guselkumab|Group 2 (n=12): guselkumab 100 mg subcutaneously (regardless of the weight of the patient) at weeks 0 and 4, followed by a maintenance dose every 8 weeks through week 24 (i.e. W0, W4, W12 and W20).
10133575|NCT04261010|Active Comparator|ADALIMUMAB|Group 3 (n=12): adalimumab 40 mg (regardless of the weight of the patient), subcutaneously every other week, starting from the baseline until week 24 (i.e.W0, W2, W4, W6, W8, W10, W12, W14, W16, W18, W20 and W22).
10133576|NCT04260815|Experimental|anodal tDCS on the left inferior frontal gyrus (IFG)|
9968543|NCT01280747||1|Eligible fibromyalgia patients receive usual care with pregabalin prior authorization requirements in place
10133577|NCT04260815|Experimental|anodal tDCS on the right IFG|
10133578|NCT04260815|Sham Comparator|sham tDCS|
10133579|NCT04261049|Experimental|ZILRETTA Injection|All patients upon enrolling in the study will receive a single 5 mL injection of 32 mg ZILRETTA into the affected knee joint.
10133580|NCT04260724|Active Comparator|TMS group|Transcranial magnetic stimulation for four weeks
10133581|NCT04260724|Sham Comparator|Sham group|sham coil stimulation for four weeks (Although the sound of sham coil is the same to that of real TMS during intervension, no stimulation is applied. )
10133582|NCT04260828|Active Comparator|Aspirin|
10133583|NCT04260828|Placebo Comparator|Placebo (sugar pill)|
10133584|NCT04260490||Cases|"Cases will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected.~Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
10133585|NCT04260490||Controls|"Controls selected after stratification on department of residence, sex and age of the cases and who give a written informed consent to participate.~Controls will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses in both cases and controls. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected. Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
10133586|NCT04260711|Experimental|Discontinuation of DMT|Discontinuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
9528192|NCT03213041|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
9528193|NCT03213015|Experimental|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
9528194|NCT03212872|Other|Endoscopy|
9528195|NCT03212729|Active Comparator|Control Group|CONVENTIONAL ENDODONTIC TREATMENT
9528196|NCT03212729|Experimental|Test Group|CONVENTIONAL ENDODONTIC TREATMENT ASSOCIATED WITH ANTIMICROBIAL PHOTODYNAMIC THERAPY
9968544|NCT01280747||2|Eligible fibromyalgia patients receive usual care without pregabalin prior authorization requirements in place
10133587|NCT04260711|No Intervention|Continuation of DMT|Continuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
10133588|NCT04260607|Experimental|Experimental-Ketamine|single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes
10133589|NCT04260607|Placebo Comparator|Placebo-Saline|100ml Normal Saline infused over 40 minutes
10133590|NCT04260516|Active Comparator|N-acetylcysteine group|Patients received oral n-acetylcysteine syrup on dose of 10 mg/kg/day as single dose for 3 months
10133591|NCT04260516|No Intervention|Non n-acetylcysteine group|Thalassemia major patients on regular chelation therapy who didn't receive n-acetylcysteine and served as controls
10133592|NCT04260594|Experimental|Arbidol tablets + basic treatment|
10133593|NCT04260594|Sham Comparator|basic treatment|
10133594|NCT04260568||Persistent Postural Perceptual Dizziness|Semi-structured interviews
10133595|NCT04260438|Experimental|Group 1|"Period 1: Treatment A~Period 2: Treatment B~Period 3: Treatment C"
10133596|NCT04260438|Experimental|Group 2|"Period 1: Treatment A~Period 2: Treatment C~Period 3: Treatment B"
10133597|NCT04260438|Experimental|Group 3|"Period 1: Treatment B~Period 2: Treatment A~Period 3: Treatment C"
10133598|NCT04260438|Experimental|Group 4|"Period 1: Treatment B~Period 2: Treatment C~Period 3: Treatment A"
10133599|NCT04260438|Experimental|Group 5|"Period 1: Treatment C~Period 2: Treatment A~Period 3: Treatment B"
9968545|NCT01280747||3|Eligible painful diabetic peripheral neuropathy patients receive usual care with pregabalin prior authorization requirements in place
9968546|NCT01280747||4|Eligible painful diabetic peripheral neuropathy patients receive usual care without pregabalin prior authorization requirements in place
9968547|NCT01280760||Non invasive ventilation|Non-invasive ventilation after invasive mechanical ventilation weaning
9968548|NCT01280773|No Intervention|PSV weaning|Patinens in the PSV group will be weaned using PSV mode.
9968549|NCT01280773|Experimental|NAVA weaning|Patients in NAVA group will eb weaned using NAVA mode.
9968550|NCT01280786|Experimental|Elesclomol Sodium|
9976806|NCT01355120|Experimental|a human immunoglobulin|Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
9976807|NCT01355146||Fabry's Disease under Replagal|
9976808|NCT01355198|Experimental|Cysteine/glycine|Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
9977737|NCT01364805|Experimental|PK Intravenous Vitamin C and Gemcitabine|Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
9977738|NCT01364818||Placebo Comparator: Placebo|No treatment/ performance of somatosensory task (cortical metrics) without any intervention. The somatosory task will be performed before any intervention/at the midpoint/ and finally at the end.
9977739|NCT01364818||Active Comparator: Active Medication|Treatment (memantine, lurasidone)/ performance of somatosensory task (cortical metrics) with intervention. The somatosory task will be performed before any intervention has started/at the midpoint/ and finally at the end.
9977740|NCT01364844|Experimental|DS7423|
9977741|NCT01364857|Other|PWS cohort|search for polymorphisms of RASA1 gene
9977742|NCT01364883|Experimental|Group 1|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
10133600|NCT04260438|Experimental|Group 6|"Period 1: Treatment C~Period 2: Treatment B~Period 3: Treatment A"
10133601|NCT04260451|Experimental|Driving pressure group|Positive end expiratory pressure is adjusted to tidal volume of 5 mL/kg of ideal body weight, inspiratory:expiratory=1:2, and minimize driving pressure (plateau pressure minus end expiratory pressure) during one-lung ventilation. Other procedures are same with the control arm.
10133602|NCT04260451|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 5mL/kg of ideal body weight and positive end expiratory pressure of 5cmH2O during one-lung ventilation
9977743|NCT01364883|Experimental|Group 2|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
9977744|NCT01364883|Experimental|Group 3|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
9977745|NCT01364883|Experimental|Group 4|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
9977746|NCT01364883|Experimental|Group 5|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
9977747|NCT01364883|Experimental|Group 6|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
9977748|NCT01364883|Experimental|Group 7|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
9977749|NCT01364909|Placebo Comparator|Control (usual practice)|
9977750|NCT01364909|Experimental|Exercise|
9977751|NCT01364948|Experimental|Coconut oil application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day starting at 12 hrs of life. Four ml of coconut oil was applied using both hands of the caregiver in four strokes. First stroke was from the clavicles over the chest and abdomen till the groin, second from the front of thighs over the knee and leg upto the sole, the third one from the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back, starting from the upper back, continuing over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life).
9977752|NCT01364948|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
9977753|NCT01364961|Placebo Comparator|Cellulose capsules|
9977754|NCT01364961|Experimental|Resveratrol capsules|
9977755|NCT01364974|Experimental|Group A|low dose, all male
9977756|NCT01364974|Experimental|Group B|medium dose, all male
9977757|NCT01364974|Experimental|Group C|high dose, all male
9977758|NCT01364974|Experimental|Group D|medium dose, all female
9977759|NCT01364974|Placebo Comparator|Placebo|
9977760|NCT01364987|Experimental|ASP015K and Mycophenolate Mofetil|
9977761|NCT01365000|Experimental|NKTR118 Formulation 1|Fasted
9977762|NCT01365000|Experimental|NKTR118 Formulation 2|Fasted
9977763|NCT01365000|Experimental|NKTR118 Formulation 3|Fasted
9977764|NCT01365000|Experimental|NKTR118 Formulation 1a|Fed
9977765|NCT01365000|Experimental|NKTR118 Formulation 3a|FED
9977766|NCT01365013|Experimental|Lifestyle counseling|
9977767|NCT01365013|Active Comparator|control group|
9977768|NCT01365026|Experimental|PVS intervention|
10133603|NCT04260503||Biliary Atresia|Disease group
10133604|NCT04260503||Choledochal cyst|Disease control
10133605|NCT04260503||Neonatal hepatitis|Disease control
10133606|NCT04260503||Healthy baby|Healthy control
10133607|NCT04260581|Experimental|PD patients who have taken amantadine|
10133608|NCT04260633|No Intervention|Group 1|22-hour tray wear time, DM assisted aligner change frequency
10133609|NCT04260633|Active Comparator|Group 2|22-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
10133610|NCT04260633|Sham Comparator|Group 3|22-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
10133611|NCT04260633|Active Comparator|Group 4|12-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
10133612|NCT04260633|Sham Comparator|Group 5|12-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
10133613|NCT04260646|Active Comparator|Standard Urotherapy without enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch.
10133614|NCT04260646|Experimental|Standard Urotherapy with enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch. In addition an enuresis alarm will be provided and worn by the participants during the night.
10133615|NCT04260412|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO membrane, then dialysis for 4 weeks with MCO membrane and increased fiber intake
10133616|NCT04260412|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
10133617|NCT04260373|Experimental|[14C]SHR4640|Patients will receive single dose of [14C]SHR4640 (Suspension, 10mg/80μCi).
9968551|NCT01280799|Experimental|Active Treatment|
10133618|NCT04260685|Active Comparator|lidocaine|the Patient will receive IV bolus of 1.5mg/kg lidocaine 1% over ten minutes followed by continuous infusion of 1.5mg/kg/h
10133619|NCT04260685|Active Comparator|esmolol|the Patient will receive IV bolus of esmolol 0.5 mg/kg over ten minutes followed by continuous infusion of 100-300 ug/kg/min
10133620|NCT04260555|Experimental|TEST|tid PO, DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml
10133621|NCT04260555|Active Comparator|Reference 1|tid PO, Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml
10133622|NCT04260555|Active Comparator|Reference 2|tid PO, Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml
10133623|NCT04260321||AI|Artificial intelligence colonoscopy
10133624|NCT04260321||Control|White light colonoscopy
10133625|NCT04260308||residents|"Voluntary residents~Can use mobile phone or computer"
10133626|NCT04260308||medical staff|"Voluntary residents~Can use mobile phone or computer"
10133627|NCT04260386||Staff receiving the MOMS training|Delegates taking part in the routine Multidisciplinary Obstetric and Midwifery Simulation (MOMS) training course at the Chelsea and Westminster Hospital.
10133628|NCT04260178|Experimental|Experimental groups|For the experimental group, EBIP was implemented in three stages:(1) hospital training;(2) home visits + training, which includes motivational interventions that facilitate chronic disease self-care and symptom management with nurse-patient cooperation; and (3) telephone follow-ups and assistance. A handbook was developed in line with the relevant literature and input from two specialist physicians (1,17-20). The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior. The trainings sessions were conducted in a hospital seminar room using PowerPoint presentations. Afterward, patients were asked to demonstrate what they learned, and the parts that were not clear were explained again. The training was concluded after deciding for the first home visit appointment. For patients that could not effectively use the handbook, a close relative was included to all steps of the study.
10133629|NCT04260178|Other|Control groups|Control groups were evaluated with an introductory survey form, PFT, BDI, BMI and SCMP-G scales before and after the study. There were no additional interventions to the control group.
10184058|NCT03758599|Active Comparator|Social Contact Control Group|Patients allocated to the social contact control group will receive the same amount of social interaction as the exercise groups. A physiotherapist or sport scientist will be present while participants watch movies with relevant content to disease followed by interactive group discussions. This group is required to control for the impact of social contact/support on AD/PTSD and secondary outcomes.
10184059|NCT03758586|Active Comparator|Study group|Surgical residents undergoing spatial skill training.
10184060|NCT03758586|Sham Comparator|Control group|Surgical residents not undergoing spatial skill training.
10184061|NCT03758573|Experimental|Inspiratory Muscle Training (IMT)|IMT by means of the Powerbreath equipment (Classic, London, UK), according to the following parameters: initial loading of 40% of MIP, 3 sets of 10 repetitions with interval of 1 minute between each sets, 7 days a week, 2 times a day , with the patients in the bed with the angulation of 45 °. The IMT load settings will be adjusted according to the values evaluated weekly. If there is need for addition of supplemental oxygen will be performed to perform the IMT.
10184062|NCT03758573|Active Comparator|Intensive Physiotherapy (IPT)|IPT will be to individualized and supervised intervention program consisting of any of the following procedures: passive, assisted, active or resisted mobilization, sedation and orthostasis depending on the functional level of the patient, as well as bronchial hygiene therapy and pulmonary expansion therapy.
10184063|NCT03758547|Experimental|in-exufflator and percussion technique|"assess the physiological effects, of a common daily practice of secretion removal in intubated patients, that are: in-exufflator technique and percussion technique"
10187676|NCT03723759|Experimental|Group F|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation B, formulation E, faster aspart 100 U/mL, formulation C, formulation D, formulation A.~The dosing visits will be separated by wash-out periods (2-21 days)."
10187677|NCT03723746|Experimental|Cohort 1: Dose 1 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (single day [SD] Dose 1) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
9976809|NCT01355237||OCC Patients|Patients being treated for chronic low back pain at the Osher Clinical Center of Brigham and Women's Hospital
9968552|NCT01280838|Experimental|Theory-based behavioral intervention|Participants in this arm will receive a single-session, theory-based intervention (Hombre Seguro) at baseline that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and Motivational Interviewing (MI) to increase clients' use of condoms with FSWs. The intervention lasts approximately 45 minutes.
9968553|NCT01280838|Active Comparator|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
9968554|NCT01280864||Interstitial Cystitis Alone|
9968555|NCT01280864||Irritable Bowel Syndrome Alone|
9968556|NCT01280864||Healthy Controls|
9968557|NCT01280877|Experimental|Verum stimulation|Complete treatment with transorbital alternating current stimulation (tACS)
9968558|NCT01280877|Sham Comparator|Sham stimulation|Same electrode montage set-up is used during tACS- and placebo-stimulation. Sham stimulation condition consists of minimal treatment with low intensity/few impulses tACS.
9968559|NCT01280890|Experimental|Staff training using VIPS framework|The staff will be trained to give person-centred care using the VIPS framework
9968560|NCT01280890|Experimental|Staff training using DCM|Staff will be supervised in how to give person-centred care using Dementia Care Mapping
9968561|NCT01280890|Placebo Comparator|Control group|Traditional lectures using films will be given to care staff
9968562|NCT01280916|Experimental|Mind-body intervention|Mindful Awareness in Body-oriented Therapy
9968563|NCT01280916|No Intervention|Treatment as Usual|
9968564|NCT01280929|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
9968565|NCT01280929|Experimental|Ranibizumab|Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
9968566|NCT01280929|Experimental|Ranibizumab + Panretinal Photocoagulation (PRP)|Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.
9968567|NCT01281020||Treatment with fixed combination|Patients who receive treatment with latanoprost/timolol fixed combination
9968568|NCT01281020||Treatment with unfixed therapy|Patients who receive latanoprost and timolol therapy
9968569|NCT01281033|Active Comparator|thrombus-aspiration group|In patients in the thrombus-aspiration group, the thrombus-aspiration is manually performed.
9968570|NCT01281033|Experimental|AngioJet Rheolytic Thrombectomy|AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter.
9968571|NCT01281085||No treatment|Shoulder conditions including rotator cuff condition treated conservatively, shoulder instability treated conservatively, diaphyseal humerus fracture or subcapital humerus fracture treated surgically and frozen shoulder
9968572|NCT01281098|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at week-0 that can be repeated every 6 weeks.
9968573|NCT01281098|Experimental|Pegaptanib + Panretinal Photocoagulation (PRP)|Group 2: Combination treatment of pegaptanib intravitreous injections at weeks 0, 6 and 12 that can be repeated every 6 weeks. Plus PRP after first injection (2 weeks +/- 1 week)and that can be repeated every 12 weeks.
9968574|NCT01281111|Experimental|BG00012 plus ASA|
9968575|NCT01281111|Experimental|BG00012 plus ASA matching placebo|
9968576|NCT01281111|Placebo Comparator|BG00012 Placebo plus ASA|
9968577|NCT01281111|Experimental|BG00012 Placebo plus ASA matching placebo|
9968578|NCT01281111|Experimental|BG00012|modified dose regimen
9968579|NCT01281150|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"DOSE-ESCALATION: Patients receive veliparib PO twice daily BID on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes in course 1 and 3 hours in subsequent courses on days 3, 10, and 17. After 4 courses, patients receive paclitaxel and carboplatin on days 3 and 10 only. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (Completed as of 12/2012)~EXPANSION COHORT: Patients receive veliparib PO BID on days 1-21 and paclitaxel IV over 1 hour and carboplatin IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
9968580|NCT01281163|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD on days 1 and 15-28 of course 1 and on days 1-28 of subsequent courses. Patients also receive AKT inhibitor MK2206 PO QD on days 8, 15, and 22 of course 1 and on days 1, 8, 15, and 22 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9968581|NCT01281215|Experimental|Pharmaceutical Education|The patients will receive pharmaceutical education.
9968582|NCT01281215|No Intervention|Control|
9968583|NCT01281228|Experimental|exenatide|Infusion of exenatide; loading dose 50 ng/min during 30 min, followed by a maintenance dose 20ng/min for the rest of the tests.
9968584|NCT01281228|Experimental|exenatide + exendin (9-39)|exenatide infusion: loading dose 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the test. And infusion of exendin(9-39) 600pM/kg/min.
9968585|NCT01281228|Placebo Comparator|saline|saline infusion, with the same infusion speed
9968586|NCT01281267|Experimental|Face transplantation|
9968587|NCT01281280||VNS Therapy|
9968588|NCT01281280||Best Medical Practice|
9968589|NCT01281319||Asymptomatic normal pregnant women|
9968590|NCT01281319||Women with high risk pregnancy|Women at risk for preterm birth or recurrent abortions that are being followed at the high risk pregnancy unit (outpatients clinic, high risk day care center)
9968591|NCT01281319||Women admitted with preterm labor|Women that are admitted to the gynecology department due to pregnancy complications: preterm labor with intact membranes (PTL) or with preterm PROM.
9968592|NCT01281332|Active Comparator|Menopod device|Menopod®
9968593|NCT01281332|Sham Comparator|Sham device|Inactive device.
9977769|NCT01365026|No Intervention|Control group|
10133630|NCT04260152|Active Comparator|Control: CAF + CTG|Following root preparation and conditioning, the CTG is obtained from the palate according to the randomization scheme and shaped to the recipient site and may be sutured to the papilla region and the coronally advanced flap (CAF) is sutured into place.
10133631|NCT04260152|Experimental|Test: CAF + Geistlich Fibro-Gide® (test)|Following root preparation and conditioning, Geistlich Fibro-Gide® is cut to size and shaped to the recipient and may be sutured and the coronally advanced flap (CAF) is sutured into place.
10133632|NCT04260399|Experimental|Lavender Aromatherapy|Passive exposure via an ambient essential oil diffuser to lavender aromatherapy
10133633|NCT04260399|Placebo Comparator|Placebo Aromatherapy|Passive exposure via an ambient essential oil diffuser to saline water aromatherapy
10133634|NCT04260360|Experimental|NanoDoce|Intratumoral injection of NanoDoce (2.0 to 6.0 mg/mL) at a volume not to exceed 5.0 mL. NanoDoce will be administered on up to two occasions with at least 4 weeks between doses.
10133635|NCT04260009|Experimental|Phase 1: Brigatinib|Brigatinib tablet or age-appropriate formulation (AAF), orally once daily in 28-day Cycles with reference to adult dose of 90 mg in Week 1 and 180 mg starting in Week 2 based on participant's weight as dose level 1. Participants could receive dose level 2 based on safety and tolerability of dose level 1 in dose escalation phase (Ph).
10133636|NCT04260009|Experimental|Ph 2:Brigatinib (Unresectable/Recurrent ALK+ IMT) Participants|Brigatinib recommended phase 2 dose (RP2D) determined during phase 1, tablet or AAF orally QD in participants with Unresectable/ Recurrent ALK+ IMT for up to 2 years in dose expansion phase.
10133637|NCT04260009|Experimental|Ph 2 :Brigatinib (Relapsed/Refractory ALK+ ALCL) Participants|Brigatinib RP2D determined during phase 1, tablet or AAF orally QD in participants with Relapsed/ Refractory ALK+ ALCL for up to 2 years in dose expansion phase.
10133638|NCT04259970|Experimental|Phase 1|Phase 1 will include implementation of a centralized analysis program of repeated 129Xe MRI scanning in CF patients with mild lung disease to define the intra-subject variability of the primary outcome ventilation defect percentage (VDP). Patients will undergo baseline 129Xe MRI scanning and repeated measurements the same day, as well as at 28 days (± 7 days). Phase 1 will establish the intra-subject reproducibility to facilitate future use of 129Xe MRI in multi-site studies. Furthermore, the reproducibility limits defined will inform the overall design of future studies and will compare to established pulmonary function and multiple-breath washout testing (via measurement of the lung clearance index, LCI).
10133639|NCT04259970|Experimental|Initiation of CFTR Modulator|Phase 2 will be an observational study of patients assessed before and after the clinical initiation of triple-combination modulator therapy (after presumed FDA and Health Canada approval). The primary endpoint for Phase 2 is the change of VDP after 28 days of triple-combination modulator therapy. Within Phase 2, this study will also address how highly-effective modulator therapies affect lung function trajectories by measuring 129Xe MRI at 28 days (± 7 days), 6 months (± 28 days), and 12 months (± 28 days) after start of therapy (paralleling time points of the PROMISE study). Finally, to understand how 129Xe MRI can be used in combination with existing measures of lung function (e.g. spirometry, multiple breath washout), the investigators will directly compare the repeated data collected in both Phase 1 and Phase 2 to these established measures of lung function that are currently used in observational and interventional studies.
10133640|NCT04260035|Active Comparator|Vasoactive Intestinal Polypeptide (VIP)|"Intravenous infusion of 8 pmol/Kg/min of Vasoactive Intestinal Polypeptide (VIP).~The infusion is administered at constant speed by an automatic pump, lasting 120 minutes."
10133641|NCT04260035|Placebo Comparator|Sterile, isotonic, non-active saline (Placebo)|Intravenous infusion of sterile, isotonic, non-active saline 9 mg/ml (placebo). The infusion is administered at constant speed by an automatic pump, lasting 120 minutes.
10133642|NCT04260204|Active Comparator|Retrograde priming|retrograde autologous Blood Priming of Cardiopulmonary Bypass (RAP) in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
10133643|NCT04260204|Active Comparator|conventional priming|conventional cardiopulmonary priming in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
10133644|NCT04259931||No relapses|Patients with clostridium difficile infections without relapses
10133645|NCT04259931||Relapsing patiens|Patients with clostridium difficile infections with relapses
10133646|NCT04259983||Patients with CF with normal obstruction severity|In CF children with normal obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
10133647|NCT04259983||Patients with CF with mild obstruction severity|In CF children with mild obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
10133648|NCT04259983||Patients with CF with moderate obstruction severity|In CF children with moderate obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
9669106|NCT04015856|Active Comparator|Light TP intervention without emphasized social norms change|Participants in this study arm will receive the light TP intervention, without emphasized social norms change, for 18 months
9669107|NCT04015856|No Intervention|Control|The control group will not have any study interventions.
9669108|NCT04004533||Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
9669109|NCT03997448|Experimental|Abemaciclib and Pembrolizumab|Abemaciclib 150mg days 1-21, and Pembrolizumab 200mg IV, Day 1
9669110|NCT03997318|Experimental|AMDC-USR|AMDC-USR is the study product (Autologous Muscle Derived Cells for Urinary Sphincter Repair).
10133649|NCT04260230|Experimental|Lifetemp/Lifetouch sensors|Participants will be asked to wear the sensors for six weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care in any way.
10133650|NCT04260282||Neutrophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils <300/mm3 in blood and <3% in induced sputum
10133651|NCT04260282||Eosinophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils >300/mm3 in blood and/or >3% in induced sputum
10133652|NCT04260243|Sham Comparator|Sham Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + sham Myofascial Release
10133653|NCT04260243|Experimental|Experimental-Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + Myofascial Release
10133654|NCT04259918|Experimental|Control|no applying alveolar recuritment maneuver
10133655|NCT04259918|Active Comparator|Low ARM|Applying 30 cmH2O of alveolar recruitment maneuver 5 times every 5sec
10133656|NCT04259918|Active Comparator|High ARM|Applying 60 cmH2O of alveolar recruitment maneuver 5 times every 5sec
10133657|NCT04260100|Experimental|Intervention Group|
10133658|NCT04260100|No Intervention|Control Group|Routine care group
10133659|NCT04259879|Experimental|Fasting|The participants will follow a short-term fasting period for 36 hours
10133660|NCT04260165|Experimental|Proximal Row Carpectomy|
10133661|NCT04260165|Active Comparator|Four-corner fusion|
10133662|NCT04259957||Clinician using Virtual Reality in Pain Management Program|Clinicians who have used immersive virtual reality as part of Pain Management program group.
10133663|NCT04260113|Experimental|Apatinib Arm|
10133664|NCT04260061|Experimental|exoskeleton group|The Hand of Hope therapy device will be used in this group. The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
10133665|NCT04260061|Experimental|end effector group|The Amadeo Hand-Therapy-System will be used in this group. The Amadeo is a mechatronic rehabilitation device that allows each individual finger to move independently and separately. The main target group are patients suffering from functional motor disabilities of the distal upper extremity. The Amadeo consists of the electrically driven moment mechanism, a supportive framework which is adjustable in height and includes a hand-arm support, and a control and operating unit (all-in-one PC). The finger slides can produce flexion/extension movement of the fingers and the thumb. The fingers and the thumb of the affected hand are attached to the slides and then passive, assistive, active or interactive therapy regime can be started. The integrated sensors for force and position measurement enable quantitative recording and evaluation of the finger range of movement and force.
10133666|NCT04259840||Peri-implantitis|Patients who underwent resective surgical treatment for peri-implantitis at the University of Michigan Graduate Periodontics clinic from January 1, 1990 through July 1, 2018
10133667|NCT04259853|Experimental|QFR-guided PCI group|QFR-guided revascularization on non-culprit vessels in patients with STEMI
10133668|NCT04259853|Active Comparator|CAG-guided PCI group|CAG-guided revascularization on non-culprit vessels in patients with STEMI
10133669|NCT04259593|Experimental|Exercise Training Group|Exercise training group performed three weekly sessions for 16 weeks. This program consisted of moderate intensity aerobic, resistance, balance, and stretching exercises. The duration of every exercise session was 35 minutes during the first week and 65 minutes from the second week onward.
10133670|NCT04259593|No Intervention|Control Group|The control group received usual lymphoma care
10133671|NCT04259567|Active Comparator|Filter|Patients with CytoSorb absorber
10133672|NCT04259567|No Intervention|Control|Patients without CytoSorb absorber
10133673|NCT04259619|Experimental|Low-Level Laser Therapy|During 2-3 days this group receives three low-level laser therapy (LLLT) treatments with the Soft Power Laser carried out by a specially trained breastfeeding consultant.
10133674|NCT04259619|Placebo Comparator|Placebo Therapy|During 2-3 days this group receives three placebo treatments with an identically looking laser, which in contrast submits only red colored light. The therapy is also carried out by a specially trained breastfeeding consultant.
10133675|NCT04259827|Experimental|Online cognitive training|6-week online personalized cognitive training using Neuronation platform 4 training session three times a week. Each session is composed of 5 exercises from one out of 4 cognitive domains: Memory, Attention, Speed and Reasoning
10133676|NCT04259827|Active Comparator|Aspecific online games|online application not created with a cognitive training purpose, for the same amount of time and frequence as the experimental group
10133677|NCT04259827|No Intervention|No online cognitive training|normal clinical follow-up without cognitive training or gaming
10133678|NCT04259684|Experimental|gNO Group|Participants in the treatment group will receive gNO added to the oxygenator gas flow at 20 ppm throughout the duration of cardiopulmonary bypass.
10133679|NCT04259684|No Intervention|Control Group|Participants in the control group will receive standard conduction of cardiopulmonary bypass.
10133680|NCT04259814|Experimental|Speech-Language Treatment plus mCIMT|"4 participants~Baseline phase: Speech-language treatment (SLT), 1 hour a day, 3 days a week. The length of the baseline phase will be staggered across subjects.~Treatment phase: SLT combined with modified constraint-induced movement therapy(mCIMT) 1 hour a day, 3 days a week.~Total of baseline and treatment sessions will be 20 to 30 sessions."
10133681|NCT04259606|Active Comparator|Cassia Cinnamon|Cassia cinnamon, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
10133682|NCT04259606|Placebo Comparator|Calcined Magnesia|Placebo consists in calcined magnesia, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
10133683|NCT04259723|Experimental|Intervention|
10133684|NCT04259723|No Intervention|Control|
9528197|NCT03212716|Experimental|diltiazem|oseltamivir + diltiazem
9669111|NCT03997318|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
10133685|NCT04259697|Experimental|Clinical pilates|Exercises will be performed two times per week for twelve weeks.
10133686|NCT04259697|Experimental|Whole body vibration|Exercises will be performed two times per week for twelve weeks.
10133687|NCT04259268||Web based questionnaire|Information registered by patient in the web based questionnaire
10133688|NCT04259268||Outpatient assessment|"Information registered by the anesthesiologist and based on the web based questionnaire, the electronic records of patient and the face to face interview"
10133689|NCT04259268||Virtual assessment|Information registered by the anesthesiologist and based on the web based questionnaire and the electronic records of patient
10133690|NCT04259385|Active Comparator|Calorie/Control Label Condition|Beverages at the concession stand and in the parent survey in this arm will display solely a calorie label.
10133691|NCT04259385|Experimental|Text Warning Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display both a text warning and a calorie label.
10133692|NCT04259385|Experimental|Sugar Graphic Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display a sugar graphic warning label depicting the amount of sugar in the product, the same text warning, and a calorie label.
10133693|NCT04259398|Experimental|TIVA|propofol infusion targeting bispectral index 40-60
10133694|NCT04259398|Active Comparator|inhalation (Sevoflurane)|sevoflurane targeting bispectral index 40-60
10133695|NCT04259463||Concious sedation|Patients undergoing third molars extraction under concious sedation. The patient is fully familiarized with the sedation procedure. The anesthesiologist suppresses the patient's consciousness with the help of intravenous medication;
10133696|NCT04259463||Full anesthesia|Patients undergoing third molars extraction under full anesthesia. . The patient is fully acquainted with the procedure of general anesthesia. It is a controlled state of unconsciousness when protective reflexes disappear, the patient cannot breathe and does not respond to verbal commands. A special intubation tube is introduced into the airways.
9826058|NCT02405962|Placebo Comparator|Control group|Parents of children with asthma will receive one session of asthma educational talk as the usual care, plus three weekly sessions of telephone calls to assess the child's asthma symptoms
9968594|NCT01281358|Experimental|HOP-ON intervention|Participants will receive a CD-ROM (or DVD and booklet if no access to computer) highlighting motor skills which could be encouraged with premature infants
10133697|NCT04259710|Placebo Comparator|Pedometer only|participants will be given a pedometer and instructed how to use it, but will not participate in the goal setting intervention.
10133698|NCT04259710|Active Comparator|Pedometer and intervention|participants will be given a pedometer and participate in a weekly goal setting meeting with the investigator and will receive weekly tips.
10133699|NCT04259710|Experimental|Pedometer, intervention and implementation intentions|participants will be given a pedometer and participate in the weekly goal setting as above. In addition, 3 times during the intervention they will fill out a form that encourages performance of implementation intentions.
10133700|NCT04259554|Experimental|OFC rTMS|repetitive transcranial magnetic stimulation
10133701|NCT04259502|Experimental|RIB Group|A single injection Rhomboid intercostal block will be performed under ultrasound guidance
10133702|NCT04259502|Active Comparator|ESP Group|A single injection Erector spinae plane block will be performed under ultrasound guidance
10133703|NCT04259437|Experimental|High Protein, Energy Dense Nutritional Supplement|2 servings per day
10133704|NCT04259489|No Intervention|Traditional therapy group|All patients in the control group will receive routine diabetes management, including lifestyle education, health guidance, blood glucose monitoring and medicine adjustment and other treatments which conducted by the endocrinology medical team. After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
10133705|NCT04259489|Active Comparator|Shared Care group|The Patients download the Shared Care mobile application and connect with the smart-glucometer BG1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
10133706|NCT04259515|Active Comparator|Bukcberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
10133707|NCT04259515|Experimental|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
10133708|NCT04259476|Active Comparator|group A|WIll be given low dose perioperative ketamine infusion, as well as a ketamine bolus at start of surgery.
10133709|NCT04259476|Placebo Comparator|group B|will be given normal saline infusion and bolus at start of surgery.
10133710|NCT04259242|Experimental|premenopausal women with low BMD and periodontitis|Experimental: postmenopausal women with low BMD and chronic periodontitis postmenopausal women with low BMD and chronic periodontitis will be evaluated after SRP for serum bone resorption markers - CTX and inflammatory markers TNF-α, IL-6
9826059|NCT02405962|Experimental|ACT group|Parents of children with asthma will receive four sessions of group-based ACT intervention integrated with asthma education (its content will be the same as that of the Control Group).
9968595|NCT01281358|Active Comparator|SMILES|Participants will received a CD-ROM (or DVD and booklet if no access to a computer) which contains information on interacting with their premature infant
9968596|NCT01281384|Active Comparator|Standard imaging (echocardiography)|Subjects will undergo their clinically indicated echocardiogram as ordered by their attending physician.
9968597|NCT01281384|Active Comparator|Advanced Imaging (Cardiac MRI)|Subjects will undergo their clinically indicated echo as ordered by their attending physician, plus a cardiac MRI, which will be scheduled within 14 days of the echo.
10133711|NCT04259671|Experimental|Intervention- My Autism Passport App|"Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. The contact information for a member of the research team who will be able to provide technical support will be available on the consent form. Families will use the mobile application for a total of 18 months.~Given that this is a pragmatic trial of a tool that tracks services, it also may be used to communicate service access to other providers."
10133712|NCT04259671|No Intervention|Control-Standard of care|Families in the control group will continue with standard of clinical care, and receive any of the usual supports their clinic and region provides, including access to physicians, service navigators, social workers, nurses, etc.
10133713|NCT04259333|Experimental|Test Arm|celecoxib 200 mg tablet by mouth every 12 hours for 7 days postoperatively prn pain
10133714|NCT04259333|Active Comparator|Control Arm|codeine 30mg-acetaminophen 300mg-caffeine 15 mg tabelt by mouth every 4 hours for 7 days postoperatively prn pain
10133715|NCT04259528|Experimental|Patients with esophageal stricture following surgical repair|Patients with esophageal atresia following surgical repair who developed an esophageal stricture
9669112|NCT03975907|Experimental|CAR-BCMA T Cells|Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm
9669113|NCT03970967|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
9968598|NCT01281397||Patients undergoing elective cardiac surgery|Patients undergoing elective cardiac surgery will be enrolled in study. Data about antiplatelet therapy ingestion prior to surgery will be included.
9968599|NCT01281410|No Intervention|Standard physiotherapy|Standard Physiotherapy without Inspiratory Muscle Training
9968600|NCT01281410|Experimental|Inspiratory muscle training|Inspiratory muscle training with a device named Respifit in addition to the usual physiotherapy program
9968601|NCT01281436|Other|Web-based Provider training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
9968602|NCT01281436|Active Comparator|HeartSmartKids with web-based training|The providers assigned to Group 2 will receive the web-based training described in the other arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
9968603|NCT01281488|Experimental|Treatment 1 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
9968604|NCT01281488|Experimental|Treatment 2 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
9968605|NCT01281488|Experimental|Treatment 3 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
9968606|NCT01281488|Experimental|Treatment 4 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
9968607|NCT01281488|Experimental|Treatment 5 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
9968608|NCT01281514|Experimental|Treatment|See Detailed Description
9968609|NCT01281527|Experimental|Paliperidone Palmitate|Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)
9968610|NCT01281540|Experimental|001|Cisapride one 10 mg tablet 4 times a day for 8 weeks
9968611|NCT01281540|Placebo Comparator|002|Placebo one placebo tablet 4 times a day for 8 weeks
9968612|NCT01281553|Experimental|001|Cisapride 0.2 mg/kg suspension q.i.d.for 8 weeks.
9968613|NCT01281553|Placebo Comparator|002|Placebo Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
9968614|NCT01281566|Experimental|001|Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
10133716|NCT04259294|Experimental|Telerehabilitation group via mobile apps|The experimental group will receive home-based treatment program through mobile apps
10133717|NCT04259294|Active Comparator|Control group via paper and pencil instructions|The control group will receive treatment via written home program sheets
9669114|NCT03962855|Active Comparator|Ifetroban|Ifetroban 250 mg oral capsule administered once daily for a minimum of 4 weeks.
9669115|NCT03962855|Placebo Comparator|Placebo|Matching placebo administered once daily for a minimum of 4 weeks.
9669116|NCT03943264|Experimental|0.3 mg/kg XPro1595|0.3 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
9669117|NCT03943264|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
10133718|NCT04259229|Experimental|Mushroom intervention|Subjects will be randomized and assigned to consume the Mediterranean Diet with mushrooms for eight weeks.
10133719|NCT04259229|Active Comparator|Control|Subjects will be randomized and assigned to consume the Mediterranean Diet without mushrooms for eight weeks.
10133720|NCT04259307|Experimental|Intensive nutrition group|Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks
10133721|NCT04259307|No Intervention|Control group|Standard nutritional support only per day for 3 weeks
10133722|NCT04259216|Experimental|IMPACT Intervention|"Remote brief video session, introducing basic principles of cognitive behavioral theory and the structure of the mobile application message portion of the intervention.~Eight-weeks longitudinal tailored Cognitive Behavioral Therapy (CBT)-based messaging program"
10133723|NCT04259216|Active Comparator|Control Enhanced Online Resources (EOR)|1. We will provide a link to an online resource packet with information on bullying and mental health resources.
10133724|NCT04259099||QUALITY OF LIFE QUESTIONNAIRES|The group is anticipated to consist of 150 female and male with osteoporosis, osteopenia or normal bone mineral density.
10133725|NCT04259112|Experimental|high pressure + deep block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards post-tetanic count (PTC) 1-2.
10133726|NCT04259112|Experimental|high pressure + moderate block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards train-of-four (TOF) twitch 1-2.
10133727|NCT04259112|Experimental|low pressure + deep block|Intra-abdominal pressure will be set to 7-10 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards PTC 1-2.
10133728|NCT04259112|Experimental|low pressure + moderate block|Intra-abdominal pressure will be set to 7-10 mmHg. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards TOF twitch 1-2.
10133729|NCT04259073|Placebo Comparator|Group C|two capsules filled with sugar
10133730|NCT04259073|Active Comparator|Group P150|two capsules; one of them containing sugar (like the placebo one), the other is the active drug (pregabalin 150 mg)
10133731|NCT04259073|Active Comparator|Group P300|two capsules of pregabalin (150 mg)
10133732|NCT04259034||systemically healthy individuals with oral lichen planus|systemically healthy individuals diagnosed with oral lichen planus on clinical and histopathological basis.
10133733|NCT04259034||systemically healthy individuals without oral lichen planus|systemically healthy individuals without any clinical feature of oral lichen planus.
10133734|NCT04259164|Active Comparator|QMF149|Mometasone furoaat / Indacaterol
10133735|NCT04259164|Experimental|QVM149|Mometasone furoaat / Indacaterol / Glycopyrronium
10133736|NCT04259203|Experimental|Erickson hypnosis|5 sessions of Erickson hypnosis (1 session per week), associated with autohypnosis at home in-between sessions.
10133737|NCT04259203|No Intervention|Usual care|Usual management of pain symptoms
10133738|NCT04258982||AECOPD group|The study incruit AECOPD patients with type II respiratory failure who need the NIV treatment.
10133739|NCT04259190|Experimental|Values rationale|Interoceptive exposure exercises will be introduced as a way to help participants engage in more that they value.
10133740|NCT04259190|Active Comparator|Standard rationale|Interoceptive exposure exercises will be introduced as a way to help participants experience less discomfort.
10133741|NCT04258865|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
10133742|NCT04258865|Experimental|Sequence 2|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
10133743|NCT04258865|Experimental|Sequence 3|"Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
10133744|NCT04258865|Experimental|Sequence 4|Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
10133745|NCT04258865|Experimental|Sequence 5|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
10133746|NCT04258865|Experimental|Sequence 6|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions"
10133747|NCT04259008|Active Comparator|Standard neonatal trace elements|"Parenteral nutrition containing 5 mCg/kg/day manganese from Multitrace-4 Neonatal."
10133748|NCT04259008|Experimental|Manganese-free neonatal trace elements|"Parenteral nutrition containing the same trace element doses as Multitrace-4 Neonatal minus manganese."
10133749|NCT04258930|Active Comparator|Group A: Aluminum sulphate and calcium acetate drying soaks|Group A will receive 10 minute soaks every 8 hours with a solution prepared with aluminum sulphate and calcium acetate powder (Domeboro® (Advaita Pharmaceuticals, México)) diluted in 500 ml of clean cold water.
10133750|NCT04258930|Experimental|Group B: Topical sterile silicone gel for wounds|Group B will receive topical silicone sterile gel for wounds (Stratamed gel®, (Stratapharma, Switzerland)) applied every 8 hours.
10133751|NCT04258930|Experimental|Group C: Hydrocolloid dressing|Group C will apply an extra thin hydrocolloid dressing to all the open areas (Duoderm Extra Thin® (Convatec, USA)) with dressing changes every 48 to 72 hours depending on the amount of wound exudate.
10133752|NCT04258748|Experimental|Motivational Interviewing (MI)|
10133753|NCT04258748|Experimental|Gaming and MI|
10133754|NCT04258748|Active Comparator|Conventional dental health education|
10133755|NCT04258709|Experimental|Antenatal Milk Expression (AME) Intervention Group|Weekly video interactions (weeks 37-40 of pregnancy) with International Board Certified Lactation Consultants (IBCLCs) to teach and reinforce antenatal milk expression. At-home practice of hand expression and collection of any expressed milk.
10133756|NCT04258709|Active Comparator|Video-based Infant Care Education Control Group|Weekly video education (weeks 37-40 of pregnancy) on various topics related to infant care (e.g., safe sleep, car seat safety, etc.).
10133757|NCT04258657|Experimental|Paclitaxel-albumin and S-1|
10133758|NCT04258670||Cross-reactive loiasis|This cohort will prospectively enroll 50 adults (age 18+) with cross-reactive antigenemia based on a positive filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
10133759|NCT04258670||non-cross-reactive loiasis|This cohort will prospectively enroll 10 adults (age 18+) with a negative filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
10133760|NCT04258605||ASHCOM Shoulder System subjects|Subjects implanted with the ASHCOM Shoulder System
10133761|NCT04258618|Active Comparator|CBT-I (Cognitive Behavioral Therapy for Insomnia) with TMS|
10133762|NCT04258618|Other|rTMS (repetitive Transcranial Magnetic Stimulation)|Subjects will be getting Transcranial Magnetic Stimulation as part of their standard of care.
10133763|NCT04258969|Experimental|Pedaling Group|During the first 2 hours of their chemotherapy infusions, participants will pedaling for 30 minutes using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. Additionally, subjects will complete both a physical activity questionnaire (International Physical Activity Questionnaire) and a quality of life questionnaire (European Organization for Research and Treatment of Cancer QLQ - CR 29) at baseline and following their last chemotherapy treatment. A questionnaire on chemotherapy side effects (Memorial Symptom Assessment Scale) will be gathered at baseline, during chemotherapy cycles 3, 6, and/or 12, and following completion of chemotherapy treatment. Lastly, muscular strength and physical performance will be measured via grip strength tests and TGUG tests within 2-4 weeks of the post-surgery and chemotherapy completion CT scans.
10133764|NCT04258553||Cervix cancer|Cervix cancer n=62
10133765|NCT04258553||Healthy controls|Healthy volunteers n=61
10133766|NCT04258839|Experimental|Arm 1|Brexpiprazole
10133767|NCT04258514|Experimental|Virtual Reality Vasectomy|This group of men will undergo vasectomy while wearing VR goggles.
10133768|NCT04258514|Experimental|Standard Vasectomy|This group of men will undergo a standard vasectomy without using VR goggles.
10133769|NCT04258787||Group A: No Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy but do not require surgery per standard-of-care guidelines.
10133770|NCT04258787||Group B: Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy, who require Descemet's Stripping Endothelial Keratoplasty (DSAEK), Descemet's Membrane Endothelial Keratoplasty (DMEK), or Descemet's Stripping Only (DSO) surgery. All treatment decisions will be made by the attending physician based on standard-of-care guidelines. (The study does not designate a treatment modality or pay for the treatment.)
10133771|NCT04258501|Experimental|Mulberry fruit extract|1.5 g of mulberry fruit powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
10133772|NCT04258501|Experimental|Mulberry leaf extract|1.0 g of mulberry leaf powdered extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
10133773|NCT04258501|Experimental|White bean extract|3 g of white bean powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
10133774|NCT04258501|Experimental|Apple extract|2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
10133775|NCT04258501|Experimental|Elderberry extract|2 g of elderberry powder extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
10133776|NCT04258501|Experimental|Turmeric extract|0.18 g of curcumin powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
10133777|NCT04258501|Experimental|Turmeric extract + Apple extract|0.18 g of curcumin powdered extract + 2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
10133778|NCT04258501|Experimental|Turmeric extract + Elderberry extract|0.18 g of curcumin powdered extract + 2 g of elderberry powder extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
10133779|NCT04258501|Placebo Comparator|Rice porridge control|Bowl containing 60 g of extruded rice + 300 ml of boiling water
10133780|NCT04258475|Experimental|Raltegravir-Calcium PK measure|"Patients will have a total of 8 visits during the study after initial screening visit to gauge patient eligibility:~Day 1 visit: Oral administration of Raltegravir. Day 7 visit: Oral administration of Raltegravir and Calcium 500 mg in the morning. Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 8).~Day 8 visit: day 7's 24 hour phlebotomy visit. Day 14 visit: Oral administration of Raltegravir and Calcium 1000 mg in the morning. Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 15).~Day 15 visit: Day 14's 24 hour phlebotomy visit. Day 21 visit: Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 22).~Day 22 visit: Day 21's 24 hour phlebotomy visit. Day 51: Final safety visit. Follow-up for patient safety and data collection from diary."
10133781|NCT04258579|Experimental|Video PROTECT|Participants will receive PROTECT therapy once a week for 9 weeks.
10133782|NCT04258540|Experimental|Intervention group|The intervention group received a yoga course for 12 weeks, two times a week. Each yoga class was 1.25 hr in duration.
10133783|NCT04258540|Active Comparator|Control group waitlist|The control group were on a waitlist during the period of measurements, and received the same yoga course after all measurements had been completed.
10133784|NCT04258644|Experimental|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1~21, 250 mg, po qd Paclitaxel-albumin：D1&D8, 100～120 mg/m2 S-1：D1~14, 60mg bid
10133785|NCT04258800|Experimental|With music|Colonoscopy performed with music
10133786|NCT04258800|No Intervention|Without music|Colonoscopy performed without music
10133787|NCT04258696|Active Comparator|Gingival retraction by ultrapak retraction cord|
10133788|NCT04258696|Experimental|Gingival retraction by diode laser|
10133789|NCT04258436|Active Comparator|Group 1-Block Arm|Group1 will receive an ultra-sound guided serratus anterior block after induction of general anesthesia
10133790|NCT04258436|No Intervention|Group 2-No Block Arm|Group 2 will not receive a serratus block after induction of general anesthesia
10133791|NCT04258735|Other|Metastatic breast cancer cohort|Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
10133792|NCT04258683|Experimental|Pembrolizumab with CyBorD|This will be a single arm study of pembrolizumab with cyclophosphamide, bortezomib and dexamethasone (CyBorD).
10133793|NCT04258592|Experimental|Patients|A single dose of 18F-MFBG will be intravenously injected in 10 patients with neural crest tumors or neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and efficacy assessment.
10133794|NCT04258631|Active Comparator|Arm I (laparotomy, liposomal bupivacaine)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine.
10133795|NCT04258631|Experimental|Arm II (laparotomy, liposomal bupivacaine, hydromorphone)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine and hydromorphone IT.
10133796|NCT04258163||MCT Group|People who received chemotherapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
10133797|NCT04258163||MET Group|People who received endocrine therapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
10133798|NCT04258163||Observation Group|People who didn't receive any maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks.
10133799|NCT04258254|Experimental|Multimodal|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in tasks requiring interpersonal synchrony, multilimb coordination (asymmetrical and ipsi/contralateral motions), and balance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
10133800|NCT04258254|Active Comparator|General Movement|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in structured physical activity focused on flexibility, strength, and endurance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
10133801|NCT04258254|Active Comparator|Standard of Care|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in seated play focused on reading, building, and art-craft activities. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
10133802|NCT04258384||Patient|The study included individuals whose native language is Turkish, who are literate, over the age of 18, diagnosed with rheumatoid arthritis, without cognitive impairment and communication problems, and who want to participate in the study.
10133803|NCT04258527|Experimental|Patients with advanced malignancies with FGF/FGFR alterations|
10133804|NCT04258345|Other|Active Feeding Arm|This is a feeding study.
10133805|NCT04258774|Active Comparator|Healthy Adults|
10133806|NCT04258774|Active Comparator|Adults diagnosed with vascular pathology of the brain|
10133807|NCT04258176||Intervention group|Patients seen in the multidisciplinary pathway
10133808|NCT04258176||Comparison group|Multimorbid patients seen several outpatient clinics who did not undergo the trajectory
10133809|NCT04258319|Experimental|Affected (Lymphedema)|Subjects affected lymphedema extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
10133810|NCT04258319|Active Comparator|Unaffected (Control)|Subjects unaffected extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
10133811|NCT04258241|Active Comparator|Local infiltration analgesia with local anesthetic (LIA+)|Local infiltration analgesia will be performed at the end of the surgery by injection of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
10133812|NCT04258241|Placebo Comparator|Local infiltration analgesia without local anesthetic (LIA-)|Local infiltration analgesia will be performed at the end of the surgery by injection of 0.3 mg of epinephrine and 120 ml of normal saline.
10133813|NCT04258189|Experimental|Panel 1: Treatment Sequence ABDC|Participants will receive Treatment A (a single dose of JNJ-64417184 [oral solution with preservatives] in fasted condition) in treatment Period 1; followed by Treatment B (a single dose of JNJ-64417184 [oral solution with preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment D (a single dose of JNJ-64417184 [oral solution without preservatives] in fed [high-fat meal] condition) in treatment Period 3, followed by Treatment C (a single dose of JNJ-64417184 [oral solution without preservatives] in fasted condition) in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133814|NCT04258189|Experimental|Panel 1: Treatment Sequence BCAD|Participants will receive Treatment B in treatment Period 1; followed by Treatment C in treatment Period 2; followed by Treatment A in treatment Period 3, followed by Treatment D in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133815|NCT04258189|Experimental|Panel 1: Treatment Sequence CDBA|Participants will receive Treatment C in treatment Period 1; followed by Treatment D in treatment Period 2; followed by Treatment B in treatment Period 3, followed by Treatment A in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133816|NCT04258189|Experimental|Panel 1: Treatment Sequence DACB|Participants will receive Treatment D in treatment Period 1; followed by Treatment A in treatment Period 2; followed by Treatment C in treatment Period 3, followed by Treatment B in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133817|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EFG|Participants will receive Treatment E (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fasted condition) in treatment Period 1; followed by Treatment F (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment G (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133818|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133819|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133820|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133821|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10133822|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
10184064|NCT03758521||BCH Cohort|Patients enrolled at BCH will travel to BCH every 2 years at a minimum for comprehensive evaluation taking place over a 48 hour period. Visits to BCH may occur within ± 2 months of the scheduled visit date. Electronic surveys will be sent out every 6 months.Visits will consist of clinical assessments (demographics, medical history, physical examination, neurological exam, medication history, neuropsychological assessments, and clinical severity score), neurophysiological assessments (Brain Magnetic resonance imaging [MRI/MRS/DTI], Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]), and yearly bio-specimen collection.
10184065|NCT03758521||iNTD Cohort|Patients enrolled at iNTD sites will travel to their iNTD site according to standard of care requirements. Data collection includes clinical history and relevant laboratory-chemical, therapeutic, instrumental and neuropsychological parameters by the study centers. Data collection takes place within the framework of elective outpatient visits. The collected parameters are congruent with the current standard investigations. Electronic surveys will be sent out every 6 months. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the site's ongoing research. Yearly bio-specimen collection will be attempted after consent is obtained from the family.
10184066|NCT03758521||Standard of Care Cohort|Patients enrolled at other sites will attend their visit at their regular clinical site as mandated by standard of care. Data collection includes medical history, family history, medications, and all clinical and neuropsychological assessments listed. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the clinical site's ongoing research. Yearly bio-specimen collection will be attempted.
10184067|NCT03758495||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
10184068|NCT03758495||Patients with Major Depressive Disorder|Individuals who have been previously diagnosed with major depressive disorder and meet our research criteria for symptoms indicative of major depressive disorder within their lifetime.
10184069|NCT03758495||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
10184070|NCT03758482|Other|Men|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
10184071|NCT03758482|Other|Women|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
10184072|NCT03758469|Experimental|HSK3486|0.4 mg/kg
10184073|NCT03758469|Experimental|rifampin , HSK3486|600 mg;0.4 mg/kg
10184074|NCT03758456|Placebo Comparator|HAL-MRE1 0 AUeq|15 subjects will receive placebo. Subjects will receive 7-9 incremental weekly injections. All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
10184075|NCT03758456|Experimental|HAL-MRE1 5,000 AUeq|10 subjects will receive HAL-MRE1 5,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 5,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
10184076|NCT03758456|Experimental|HAL-MRE1 10,000 AUeq|10 patients will receive HAL-MRE1 10,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 10,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
10187678|NCT03723746|Experimental|Cohort 2: Dose 2 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (Dose 2) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
9528198|NCT03212716|Placebo Comparator|oseltamivir + placebo|oseltamivir + placebo of diltiazem
10133823|NCT04258423|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
10133824|NCT04258423|Experimental|Study Arm|Everolimus as maintenance immunosuppression
10133825|NCT04258202|Experimental|positive end expiratory pressure group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. PEEP increased in a stepwise manner from 5 to 20 cmH2O, until plateau pressure 30 cmH2, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with positive end expiratory pressure (PEEP) 5cmH2O.
10133826|NCT04258202|Experimental|tidal volume group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. Tidal volume increased in steps of 4mL/kg of ideal body weight until plateau pressure 30 cmH2O, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with PEEP 5 cmH2O.
10133827|NCT04258267|Experimental|Early mobilization|Patients will be allowed to use their shoulder earlier. The immobilization period is shorter.
10133828|NCT04258267|Experimental|Delayed mobilization|The immobilization period is longer.
10133829|NCT04258306|Active Comparator|Resveratrol|180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.
10133830|NCT04258306|Experimental|REVIFAST|180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold & Zucc. Root supported on Magnesium hydroxide).
10133831|NCT04258280|Active Comparator|Usual Care|
10133832|NCT04258280|Experimental|Enhanced Care|
10133833|NCT04258215|Experimental|Positive pressure achieved with PSA|Maximum airway inflation pressure achievable before a significant leak occurs.
10133834|NCT04258371|Experimental|Dapagliflozin Treatment Arm|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
10133835|NCT04258371|Placebo Comparator|Placebo Arm|Placebo Matching Dapagliflozin Tablet for 12 weeks
10133836|NCT04258072|Experimental|open label,single arm|Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours
10133837|NCT04258098||OA+MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
10133838|NCT04258098||MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. No oral antibiotics was administered to the patients.
10133839|NCT04258111|Experimental|IBI310 + Sintilimab|
10133840|NCT04258007|Placebo Comparator|Reversal Neostigmine|Patients undergoing cardiac catheterization will receive a combination of 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
10133841|NCT04258007|Active Comparator|Reversal Sugammadex|Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
10133842|NCT04257994||patients with arrhythmic disorders|Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust as well as family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis.
10133843|NCT04257955||Pancreatic cancer|"Outpatients seen at the Gastroenterology, Pancreatic Surgery and Oncology Clinics of the Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele, Milan (Italy) will be considered includable if:~Adult patients (≥18 years);~Of Italian mother tongue;~Have a histologic diagnosis of PDAC obtained during the 4 weeks before the visit~The visit is the first visit after completion of diagnostic procedures and is set to communicate the diagnosis and treatment strategies~Give full, written informed consent~The following exclusion criteria will be applied:~PDAC recurrence after previous diagnosis and treatment~poor performance status (ECOG ≥ 3);"
10133844|NCT04257981|Experimental|Experimental group|"Transcranial direct stimulation + virtual related group:~Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp Virtual reality (KVR) is the use of a computer interface involving upper limb activity in pediatric rehabilitation. VR creates an artificial environment, presented to the user through appropriate sensory stimulations."
10133845|NCT04257981|Sham Comparator|Control group|Sham Transcranial direct stimulation Group + virtual related group; The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies.
10133846|NCT04257838||Piperacillin-Tazobactam or Meropenem Cohort|Patients hospitalized for sepsis or septic shock that are treated with Piperacillin-Tazobactam or Meropenem and meet all the inclusion criteria and none of the exclusion criteria.
10133847|NCT04258124|Experimental|Experimental group|"Each session will last 10 minutes, taking place 3 days a week, over a period of 6 weeks. The intervention will take place at the beginning of the training session. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.~Exercise 1. In quadruped position, keeping the back flat, making an isometric contraction of the transverse muscle, and raising one arm and one leg contralaterally.~Exercise 2. Training of the deep cervical flexor muscles, supine. Players will move their heads slowly towards craniocervical flexion.~Exercise 3. In standing position, an ocular-cervical coordination exercise by means of a cranio-cervical flexion, adding a rotation, guided by an eye feedback provided by the physiotherapist by means of a laser projected on a wall."
10133848|NCT04258124|No Intervention|Control group|Athletes in the control group will be asked to follow their usual warm-up routine.
10184077|NCT03758456|Experimental|HAL-MRE1 20,000 AUeq|10 patients will receive HAL-MRE1 20,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 20,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 year). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
10133849|NCT04257916|Experimental|Experimental group|"The intervention by kinesiotape will be done with the player in supine position with the foot in dorsal flexion, anchoring the strip below the sole of the foot without tension, adding 50-70% tension until internal and external malleolus, and ending without tension. Another strip will be placed under the external malleolus, anchoring the bandage and following the talus (50-70% tension), leaving the scaphoid bulge free, surrounding the plant without tension and leaving the 5th metatarsal free. The bandage continues on the peroneal-astragalin ligament and the external malleolus (50-70% tension), until the tendon without tension. In the end we will surround the internal malleolus to the Achilles tendon without tension, ending with the same tension in the external malleolus and the neck of the talus.~The myofascial technique and strength training will be the same in both groups."
10133850|NCT04257916|Active Comparator|Control group|"The myofascial technique will be carried out by positioning the caudal hand of the physiotherapist in the astragalin and heel region, and the cranial hand in the middle foot. With a tibiotarsal traction, the foot will be everted, performing a shear in the astragalin zone, using a combined and slow technique.~All players will warm up for 10 minutes on tape, at a speed of 7 km / h without inclination. The strength work was carried out with an isoinertial machine (Space Whell) with intervalic methodology: 20 -10, with 4 series and doing three exercises: Squat, Lunges and Deadlift. One minute breaks will be made between sets."
10133851|NCT04258033|Experimental|PLB1001|Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
10133852|NCT04257825|Other|Initial Off|Individuals were asked to not use their device on weeks 1 and 3 of the study. They were asked to use their device on weeks 2 and 4.
10133853|NCT04257825|Other|Initial On|Individuals were asked to not use their device on weeks 2 and 4 of the study. They were asked to use their device on weeks 1 and 3.
10133854|NCT04257851|Active Comparator|Group T (n=30)|Theophylline group
10133855|NCT04257851|Active Comparator|Group S (n=30)|Sumatriptan group
10133856|NCT04257968|Experimental|Diagnostic intervention|Complete diagnostic intervention
10133857|NCT04257877||Diabetes type 1|Patients= diabetes type1
10133858|NCT04257877||Healthy participants|Healthy participants = Control group
10133859|NCT04257799||Women with breast cancer diagnosis|Women with diagnosis of invasive breast cancer based on pre-surgical biopsy, and scheduled for breast-conserving surgery in the Dartmouth-Hitchcock (DH) Outpatient Surgical Center.
10133860|NCT04257890|Experimental|CBT intervention group|In addition to the information about IGD of the control group, the intervention group will receive eight weekly group-based 90-minute CBT sessions.
10133861|NCT04257890|Active Comparator|Wait-list control group|Members will receive printed education material about IGD but not CBT during the treatment period.
10133862|NCT04257812||Ceftolozane-Tazobactam cohort|Patients older than 18 years old that are hospitalised in the Virgen Macarena University Hospital that are being treated with Ceftolozane-Tazobactam in empiric or targeted treatment.
10133863|NCT04257734||optic neuritis|Aquaporin 4 antibody seropositive optic neuritis patients, Myelin oligodendrocyte glycoprotein antibody seropositive optic neuritis patients, and double antibodies seronegative optic neuritis patients
10133864|NCT04257786|Active Comparator|Group 1|1ry surgery
10133865|NCT04257786|Active Comparator|Group 2|Neoadjuvant Chemotherapy followed by surgery
10133866|NCT04257760|No Intervention|Standard care|These ALS patients and their caregivers will receive standard care.
10133867|NCT04257760|Experimental|Early palliative care|These patients will receive a palliative care consultation that would not be requested by their care team as standard of care.
10133868|NCT04257773|Experimental|Immediate Treatment|Participants in this group will receive treatment/intervention immediately.
10133869|NCT04257773|Experimental|Delayed Treatment|Participant in this group will receive treatment/intervention 2-week later.
10133870|NCT04257409|Experimental|DF patient active|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
10133871|NCT04257409|Active Comparator|DF patient control|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
10133872|NCT04257409|Experimental|Diabetic patient with mild neuropathy|Patients with Type 2 diabetes mellitus with mild form of peripheral sensory neuropathy
10133873|NCT04257409|Experimental|Diabetic patient with severe neuropathy|Patients with Type 2 diabetes mellitus with severe form of peripheral sensory neuropathy
10133874|NCT04257513||Healthy controls subjects|Subjects without known family history of HD, or tested negative for the HD expansion mutation.
10133875|NCT04257513||Symptomatic HD subjects|Subjects HD gene expansion carriers who have clinical diagnostic motor symptoms of defined HD, and disease stage I to III.
10133876|NCT04257513||Presymptomatic HD subjects:|Subjects HD gene expansion carriers who not have clinical diagnostic motor features of HD.
10133877|NCT04257396|Experimental|Arm 1 CARA Positioning|Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.
10133878|NCT04257396|No Intervention|Arm 2 Standard of Care|Arm 2 patients will not receive CARA breast support. Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre. These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD. Published rates of MD for the control arm thus pertain to a cross section of these methods. The control arm of this study will look at all of these methods combined. There may be centre specific preference for the control method and stratification by centre will be done.
10133879|NCT04257461|No Intervention|Group1 Arm A|Observation only
10133880|NCT04257461|Other|Group 1 Arm B|Mono- or bichemotherapy: fluoropyrimidine with or without Oxaliplatin (choice by physician/patient or by randomisation)
10133881|NCT04257461|Other|Group 2 Arm C|Monochemotherapy: fluoropyrimidine
10133882|NCT04257461|Other|Group 2 ARM D|Bichemotherapy: fluoropyrimidine with oxaliplatin
9528199|NCT03212807|Experimental|Investigational|Durvalumab + Lenalidomide
10133883|NCT04257591|Experimental|hamstring strengthening|8-week protocol (3 days per week) based on isometric, concentric and excentric exercisesof hamstrings
10133884|NCT04257591|No Intervention|Control|No intervention added to regular training.
10133885|NCT04257331|Experimental|SREIA group|Participants in this arm will be families who attend the first wave of the two rounds of delivery. They will be the intervention group.
10133886|NCT04257331|No Intervention|Waitlist Control|Participants in this arm will be families who attend the second wave of the two rounds of delivery. They will be the control group.
10133887|NCT04257604||Perampanel|Participants with partial-onset seizures, with or without secondary generalization will receive perampanel tablets as add-on therapy according to the approved summary of product characteristics (SmPC) after the baseline visit as part of the clinical practice and will be observed after 3 months (visit 1), 6 months (visit 2), and 12 months (final visit).
10133888|NCT04257708||normal uterine cavity|
10133889|NCT04257708||abnormal uterine cavity|
10133890|NCT04257682|Active Comparator|Bupivacaine|The participant will receive Bupivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
10133891|NCT04257682|Active Comparator|Ropivacaine|The participant will receive Ropivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
10133892|NCT04257682|Active Comparator|Mepivacaine|The participant will receive Mepivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
10133893|NCT04257539|Experimental|Intervention Group|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior. This will include an initial, in-person behavioral intervention with a health coach trained and a 4 week phone call. Participants will receive a wrist-worn activity prompter to aid in sedentary behavior reduction.
10133894|NCT04257539|No Intervention|Wait-list Control Group|Chronic low back pain participants in this group will not receive the intervention until completion of the study. Over the 8 week intervention period, participants will be asked to maintain currently levels of physical activity, sedentary behaviors, and treatment for low back pain.
10133895|NCT04257539|No Intervention|Pain-free Control Group|These subjects will be healthy, pain-free adults and receive no intervention. Over the 8 week intervention period, participants in this group will be asked to maintain currently levels of physical activity, sedentary behaviors, and medication regimen.
10133896|NCT04257435|Active Comparator|Traditional Behavioral Health Treatment|
10133897|NCT04257435|Experimental|Positive Psychological Group Treatment|
10133898|NCT04257357|Experimental|Exercise group|Eight-week supervised exercise program: Patients in the intervention group receive the same usual care as the patients in the control group. In addition, the patients participate in an eight-week supervised interval training program. Briefly put, the patients are required to participate in at least 16 out of 20 possible training passes over the period of eight weeks. The training consists of a brief warm up followed by 35-50 minutes of interval training on a bicycle. The intensity and duration will increase over time
10133899|NCT04257357|Active Comparator|Control group|"Patients in the control group receive usual care as a minimum. This includes three-five days of hospitalization where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.~It is considered an active comparator as all patients in the control group perform a watt-max cycle ergometer test with VO2 measurement 3 times, and this in it-self can influence patients' activity level."
10133900|NCT04257448|Experimental|Romidepsin/nab-Paclitaxel/Gemcitabine (Arm A)|Part 1a: Romidepsin (2 mg/m² or 3.3 mg/m² or 7 mg/m²) will be administered in combination with nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
10133901|NCT04257448|Experimental|Azacitidine/nab-Paclitaxel/Gemcitabine (Arm B)|Part 1a: Azacitidine (20 mg/m² or 30 mg/m² or 40 mg/m²) will be administered on Days -7 to Day -3 of each treatment cycle. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
10133902|NCT04257448|Experimental|Romidepin/Azacitidine/nab-Paclitaxel/Gemcitabine (Arm C)|Part 1a: The intervention to be administered depends on the determined dose in Arm A and Arm B. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
10133903|NCT04257448|Active Comparator|nab-Paclitaxel/Gemcitabine (Standard Arm)|nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be administered on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle.
10133904|NCT04257448|Experimental|Arm C or B or A|In Part 1b (expansion part) of the study, one of the treatment arms (Arm C over Arm B over Arm A) will be continued. Treatment will only be performed with the study drug that were tolerable in Part 1a (dose escalation).
10133905|NCT04257448|Experimental|Durvalumab/Lenalidomide|Part 2: All patients from Part 1 who have not progressed after three cycles receive standard fixed dose Durvalumab (1500 mg) on Day 1 of each 28-day treatment cycle by IV infusion in combination with orally administered low-dose Lenalidomide (10 mg) on Days 1 to 21 until documented disease progression. Study treatment is given for a maximum of 13 cycles.
10133906|NCT04257747|Sham Comparator|Healthy volunteers|
10133907|NCT04257747|Active Comparator|patients requiring radial forearm flap reconstruction|
10133908|NCT04257747|Experimental|patients having received hand allotransplantation|
10133909|NCT04257500|Experimental|Contraceptive Ring|Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing), which releases 120 mcg of etonogestrel and 15 mcg of ethinyl estradiol daily.
10133910|NCT04257422|Experimental|Intentional Rounding|In the centers randomized to Intentional Rounding the ward nurses will have to adopt a new proactive care method towards hospitalized patients
10133911|NCT04257422|No Intervention|Control|In randomized controlled centers, nurses guarantee the standard care provided by the ward
10133912|NCT04257643|Experimental|Experimental group|water-based exercise was conducted at a hydrotherapy pool for the Eden Heelth Care,Cairo The pool measures 8 × 15 m and ranges from 1 to 1.8 m in depth with access via steps. Interventions were conducted predominately in the deeper section of the pool so participants immerse their neck in water. Thermo neutral water temperature, 30-32 °C at room temperature. Females were instructed to adjust water depth completely covering clavicles from standing position. Diaphragmatic breathing during exercise routine to assist with lymph fluid clearance. Exercise continuously for 40 to 45 min Full-body warm-up exercise for 10 min and cooling down for 10 minutes. Plus land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.
10133913|NCT04257643|Active Comparator|Control group|Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles
10133914|NCT04257617|Experimental|Single arm, ZL-1201|Single arm, ZL-1201
10133915|NCT04257370|Experimental|Kerecis™ Omega3 Wound|
10133916|NCT04257370|Active Comparator|Standard of care|
10133917|NCT04257656|Experimental|Remdesivir group|active remdesivir
10133918|NCT04257656|Placebo Comparator|Control group|Placebos matched remdesivir
10133919|NCT04257487|Active Comparator|Treatment A|Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
10133920|NCT04257487|Active Comparator|Treatment B|Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
10133921|NCT04257487|Placebo Comparator|Treatment C|2 indistinguishable placebo capsules BID, for 12 months
10133922|NCT04257695|Experimental|TapPro|Biweekly telephone and in-person visits with a clinician over six months. At each visit, a protocol adapted from the Prescription Opioid Taper Study will be provided to participants, who will learn about pain coping, distraction techniques, diaphragmatic breathing, sleep techniques, and progressive muscle relaxation techniques. All are specifically designed for patients with chronic pain on chronic opioid therapy. During visits, taper parameters will be discussed and the provider will work through a dose reduction schedule, if participants are in agreement. Additionally, urine drug screens will be obtained.
10133923|NCT04257695|No Intervention|Usual Care|Participants randomized to the usual care arm will continue seeing their primary care providers as indicated.
10133924|NCT04257318|Experimental|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregn
10133925|NCT04257253|Experimental|Targeted exercise program|Targeted motor control and isolated lumbar extensor strengthening exercises. Supervised 12-week program, 2 times a week.
10133926|NCT04257253|Active Comparator|General exercise program|General exercise program including upper body and lower body strengthening and flexibility exercises. Supervised 12-week program, 2 times a week.
9968615|NCT01281566|Placebo Comparator|002|Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
10133927|NCT04257266|Experimental|Cryo Cooling Pack|Cryo cooling pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
10133928|NCT04257266|Active Comparator|Commerical Ice Pack|The commercial ice pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
9968616|NCT01281579|Experimental|001|Canagliflozin 50 mg Tablets oral 50-mg once daily on Day 1 and on Days 4 through 9.
9968617|NCT01281579|Experimental|002|Canagliflozin 100 mg Tablets oral 100-mg once daily on Day 1 and on Days 4 through 9.
9968618|NCT01281579|Experimental|003|Canagliflozin 300 mg Tablets oral 300-mg once daily on Day 1 and on Days 4 through 9.
9968619|NCT01281592|Experimental|LOR-253 HCl|LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
10133929|NCT04257240||study group|patients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver
10133930|NCT04257240||control group|patients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
10133931|NCT04257175|Experimental|Cyclophosphamide, Flodarabine,CAR-T cells|"The appropriate participants will undergo lymhopheresis to collect lymphocytes from PBMC peripheral blood. CAR T CD19 cells will be produced. The participants will receive cyclophosphamide 300 mg / m² and flodarabine 30 mg / m² lymphodeplition intravenously daily for 3 days.~The CAR-T CD19 cells will be given on the 5 to 7 day post lymphodeplition ."
10133932|NCT04256915|Experimental|CBT-I + Bright Light|n = 50
10133933|NCT04256915|Active Comparator|CBT-I + Placebo Light|n = 50
10133934|NCT04256915|No Intervention|Wait-list Control|n = 50
10133935|NCT04256876|Active Comparator|Active TTNS|Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
10133936|NCT04256876|Sham Comparator|TTNS sham intervention|"Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.~Home therapy: Daily stimulation during 60 minutes."
9968620|NCT01281605|Active Comparator|Active titration algorithm|titrate insulin dose by contacting with investigator by telephone weekly.
9968621|NCT01281605|Experimental|Usual titration algorithm|contact with investigator only at routine study visit.
9968622|NCT01281618||Those with barrett's esophagus|Those with barrett's esophagus: no dysplasia or low grade dysplasia
9968623|NCT01281657||Prescribed fingolimod 0.5 mg/day|
9968624|NCT01281670|No Intervention|No vibration|
9968625|NCT01281670|Active Comparator|vibration|
9968626|NCT01281683||TACE|
9968627|NCT01281683||RFA|
9968628|NCT01281696|Experimental|Bevacizumab, etoposide, cisplatin (BEEP)|
9968629|NCT01281722||healthy adults|healthy adults with the age among 20 to 95 years old
10133937|NCT04257110|Experimental|Part 1: Dose-escalation|Eight doses levels have been selected for evaluation in the Part 1 of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle.
10133938|NCT04257110|Experimental|Part 2: Cohort 1|Subjects will be administered BB-1701 at one or two dose levels (e.g. MTD and the dose below MTD)
10133939|NCT04257110|Experimental|Part 2: Cohort 2|Subjects will be administered BB-1701 at one or two dose levels (e.g. MTD and the dose below MTD)
10133940|NCT04256954|Experimental|Peer navigation|Those who are assigned to the intervention arm will receive peer navigation service by a trained peer navigator who will link them with mental health, medical and substance use services in the community.
10133941|NCT04256954|No Intervention|Standard of Care|SOC consists of TAU + monitoring and emergency referral, as is required to fulfil ethical obligations to trial participants. To determine the naturalistic effects and costs of adding peer navigation intervention, participants in both conditions can receive any other treatment available to them and we will not exclude participants receiving other treatment. We will carefully characterize TAU for each condition as part of our service utilization assessment.
10133942|NCT04257214|No Intervention|Treatment as usual|Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.
10133943|NCT04257214|Active Comparator|Office based CBT|Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.
10133944|NCT04257214|Active Comparator|CRS/CPS|Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.
10133945|NCT04257214|Active Comparator|CBT+CRS/CPS|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
10133946|NCT04257136|Experimental|Treatment|Treatment with VBI-S
10133947|NCT04256889|Experimental|nfant(R) feeding system|Addition of nfant(R) technology, along with visual assessments and cue-based feeding practices, to facilitate an infant's progression to full oral feeding and potentially improve developmentally supportive feeding practices.
10133948|NCT04256993||Ra-223 initiators|"Patients diagnosed with mCRPC (Metastatic Castration-Resistant Prostate Cancer) who start treatment with Ra-223. Patients will be identified from the Patient-overview Prostate Cancer (PPC), a sub-registry of the Prostate Cancer data Base Sweden (PCBaSe) data set."
10133949|NCT04256993||Initiators of other standard of care|The comparator cohort will be patients using standard of care other than Ra-223.
10133950|NCT04257227|Experimental|rTMS Intervention Group|
10133951|NCT04257006|Experimental|patients undergoing CRRT with oXiris membrane|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.~Indications for CRRT (SCUF) with oXiris after ICU admission:~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.~Or high risk of pulmonary edema after cardiac surgery:~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)~CVP (central venous pressure) ˃ 12 mm H2O.~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.~In this arm the treatment of fluid overload will be provided via SCUF with oxiris membrane"
10133952|NCT04257006|No Intervention|standard protocol|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.~Indications for CRRT (SCUF) with oXiris after ICU admission:~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.~Or high risk of pulmonary edema after cardiac surgery:~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)~CVP (central venous pressure) ˃ 12 mm H2O.~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.~In this arm the management of fluid overload will be provided via diuretics or IHD (in condition diuretics treatment resistance)"
10133953|NCT04257149|Experimental|Hemorrhagic stroke group (group A)|Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
10133954|NCT04257149|Experimental|Ischemic stroke group (group B)|Patient group B is defined as patients that are diagnosed with ischemic stroke.
10133955|NCT04257149|Experimental|Stroke mimic group (group C)|Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
10133956|NCT04256928|Experimental|Intervention group|"This group of participants will have any body hair in the operative field clipped with an electrical clipper by hospital personnel, during preparation for planned surgery.~4 microbiological samples will be taken from all participants in this group."
10133957|NCT04256928|No Intervention|Control group|"This group of participants serve as the control group. Any body hair in the operative field is left intact.~4 microbiological samples will be taken from all participants in this group."
10133958|NCT04257045||Observational (interview, survey)|"STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.~STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes."
10133959|NCT04256798|Experimental|Mouthwash and liberal oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.
10133960|NCT04256798|Active Comparator|No mouthwash and liberal oxygen during surgery|No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.
10133961|NCT04256798|Experimental|Mouthwash and restrictive oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.
10133962|NCT04256798|Active Comparator|No mouthwash and restrictive oxygen during surgery|No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.
10133963|NCT04256837|Experimental|VNS - Live donor kidney recipients.|Live donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
10133964|NCT04256837|Sham Comparator|sham VNS - Live donor kidney recipients.|Live donor kidney recipients. As above, but without applying any VNS
10133965|NCT04256837|Experimental|VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
10133966|NCT04256837|Sham Comparator|sham VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. As above, but without applying any VNS
10133967|NCT04256850|Experimental|Acceptance and Commitment Therapy (ACT)|Focuses on addressing cognitive and emotional barriers to successful weight loss maintenance.
10133968|NCT04256850|Experimental|Self-Regulation (SR)|Focuses on using self-monitoring and self-reinforcement techniques to improve weight loss maintenance.
10133969|NCT04257084|Active Comparator|CE-NBI|High definition chromoendoscopy with target biopsy, at 1st surveillance colonoscopy during the trial High definition NBI with target biopsy, at 2nd surveillance colonoscopy during the trial
10133970|NCT04257084|Active Comparator|NBI-CE|High definition NBI with target biopsy, at 1st surveillance colonoscopy during the trial High definition chromoendoscopy with target biopsy, at 2nd surveillance colonoscopy during the trial
10133971|NCT04256980|Experimental|Pemigatinib in patients with advanced/metastatic or surgically|Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma
10133972|NCT04256863|Experimental|Breakfast / Lunch (BFL)|This group will complete a 16-week standard behavioral weight control intervention in which they will be asked to consume >50% of their daily energy goal before 3PM. To do so, they will complete weekly experiential learning sessions in conjunction with the SBT lessons.
10133973|NCT04256863|Active Comparator|Dinner (DIN)|This group will complete a 16-week standard behavioral weight control intervention. They will not be given any recommendations regarding the timing of their energy consumption, but instead encouraged to follow the same energy goals at the BFL group.
10133974|NCT04257032|Experimental|Reference 1 (R1)|
10133975|NCT04257032|Experimental|Test 1 (T1)|
10133976|NCT04257032|Experimental|Reference 2 (R2)|
10133977|NCT04257032|Experimental|Test 2 (T2)|
10133978|NCT04257019|Experimental|Lavender|Lavender mask before and during procedure
10133979|NCT04257019|Active Comparator|Almond|Almond oil mask before and during procedure
10133980|NCT04257019|Sham Comparator|Water|Water mask before and during procedure
10133981|NCT04256642|Active Comparator|Intrathecal morphine|
10133982|NCT04256642|Experimental|Erector Spinae Plane Block|
10133983|NCT04256746|Placebo Comparator|Boiled Rice|63 g of raw rice was cooked.
10133984|NCT04256746|Experimental|Boiled Rice+0.37 gr extract|63 g of raw rice was cooked and 0.37 gr mulberry fruit powdered extract added and mixed
10133985|NCT04256746|Experimental|Boiled Rice+0.75 gr extract|63 g of raw rice was cooked and 0.75 gr mulberry fruit powdered extract added and mixed
10133986|NCT04256746|Experimental|Boiled Rice+1.12 gr extract|63 g of raw rice was cooked and 1.12 gr mulberry fruit powdered extract added and mixed
10133987|NCT04256746|Experimental|Boiled Rice+1.50 gr extract|63 g of raw rice was cooked and 1.50 gr mulberry fruit powdered extract added and mixed
10133988|NCT04256746|Placebo Comparator|Rice porridge|60 g of rice porridge was rehydrated with 300 ml boiling hot water
10133989|NCT04256746|Active Comparator|Rice porridge+1.50 gr extract|60 g of rice porridge was rehydrated with 300 ml boiling hot water and 1.50 gr mulberry fruit powdered extract added and mixed
10133990|NCT04256733|Experimental|Supra-threshold capsaicin|Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
10133991|NCT04256733|Placebo Comparator|Sub-threshold capsaicin|Participants will be exposed repeatedly to a single sub-threshold dose of aerosolized capsaicin through a nebulizer during treatment. This sub-threshold dose will elicit minimal or no urge-to-cough.
10133992|NCT04256694||Healthy Adult Subjects|
10133993|NCT04256382|Experimental|experimental group|The experimental group took two-hour online course about dementia pain care in two weeks.
10133994|NCT04256382|Active Comparator|comparison group|The comparison group took two-hour online course about dementia care in two weeks.
10133995|NCT04256499||Water load test|Patients experiencing a syndrome of inappropriate antidiuresis who had an acute water load test
10133996|NCT04256499||Control group|Patients who had an acute water load test and who did not experience any water homeostasis anomalies
10133997|NCT04256668|Active Comparator|good embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with normal embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal fertilization rate >50% and normal blastocyst development rate >50%).
10133998|NCT04256668|Active Comparator|poor embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with poor embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal or slightly reduced fertilization rate <50% and low or absent blastocyst development (0 or only 1 blastocyst).
10133999|NCT04256668|Placebo Comparator|natural conception|20 previously infertile men, normal history, normal genital status, normal sperm count, DNA fragmentation rate <20% (as given by TUNEL) and achieving pregnancy naturally (without medical intervention).
10134000|NCT04256551|Experimental|Machine Learning App + Registered Dietitian facilitator|The ML-RD group will be provided access to the Heali mobile application as well as a personal RD to provide nutrition support and answer any questions through a real-time messaging system within the mobile app. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
10134001|NCT04256551|Active Comparator|Machine Learning App|The ML-APP group receives access to the Heali mobile dietary application. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
10134002|NCT04256551|Placebo Comparator|Standard Dietary Education|Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
10134003|NCT04256616||Bladder cancer patients|80 patients with carcinoma of the bladder; divided in 20 patients Ta (low grade), 20 patients Ta/T1 (high grade) and 20 patients T2. Only for liquid samples collection we will include 20 CIS (carcinoma in situ) patients
10134004|NCT04256616||Controls- Healthy subjects|30 age and sex-matched subjects not suffering from carcinoma of the bladder, already hospitalized in ICH; we expect to enroll 24 males and 6 females of which 10 of 40- 60 years old, 10 of 60-70 years old, 10 of >70 years old.
9968630|NCT01281722||melanoma cases|the people who are diagnosed melanoma in NTU hospital
9968631|NCT01281748|Experimental|methylprednisolone|
9968632|NCT01281748|Placebo Comparator|normal saline solution|
9968633|NCT01281761|Experimental|cetuximab/irinotecan/simvastatin|"D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily)~every 2weeks"
9968634|NCT01281774|Experimental|CSL112|Multiple ascending intravenous doses of CSL112
9968635|NCT01281774|Placebo Comparator|Placebo|Multiple intravenous infusions of placebo
9968636|NCT01281787|Active Comparator|Losartan|angiotensin II-receptor blocker
9968637|NCT01281787|No Intervention|no treatment|no preventive treatment
9968638|NCT01281787|Active Comparator|Metoprolol|beta-adrenergic antagonist
9968639|NCT01281800|Active Comparator|Cisplatin with pemetrexed|
9968640|NCT01281800|Experimental|Cisplatin with gemcitabine in long infusion|
9968641|NCT01281813|Experimental|001|Darunavir (DRV) 400 milligram (mg) tablet intake of 2 tablets once daily in combination with Ritonavir (rtv)
9968642|NCT01281813|Experimental|002|Darunavir 600 mg tablet intake of 1 tablet twice a day in combination with Ritonavir
9968643|NCT01281813|Experimental|003|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
9968644|NCT01281813|Experimental|004|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
9968645|NCT01281813|Experimental|005|Darunavir 375 mg composed via various tablets (2x150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir (1x 100mg rtv tablet) twice daily
9968646|NCT01281813|Experimental|006|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir oral solution 80 milligram per milliLitre (mg/mL) (dose dependent on weight) twice daily
9968647|NCT01281813|Experimental|007|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir powder for oral suspension prepared as 100mg/10mL (dose dependent on weight) twice daily
9968648|NCT01281813|Experimental|008|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir 100mg tablet twice daily
9968649|NCT01281813|Experimental|009|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir oral solution as 80 mg/mL (dose dependent on weight) twice daily
9968650|NCT01281813|Experimental|010|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir powder for oral suspension prepared as 100 mg/10 mL (dose dependent on weight) twice daily
9968651|NCT01281852|Experimental|Treatment (paclitaxel, cisplatin, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IV over 1 hour on day 2, and veliparib PO on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9968652|NCT01281878|Experimental|Pyridoxal-phosphate|Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight. treatment duration 24 weeks
9968653|NCT01281891|Experimental|Local Infiltration Analgesia|Combination of ropivacaine, ketorolac and adrenaline
9968654|NCT01281891|Active Comparator|Intrathecal morphine|Morphine special (preservative-free) injected intrathecally
9968655|NCT01281904|No Intervention|Standard of Care|Participants randomized into the standard of care group will be asked to continue following the instructions of the healthcare provider throughout the 10 week study period. They will not be asked to perform any study intervention.
9968656|NCT01281904|Active Comparator|Relaxation Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their relaxing effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
9968657|NCT01281904|Active Comparator|Stimulating Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their excitatory effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
9968658|NCT01281930|Experimental|Wick placement into abscess cavity|
10134005|NCT04256330||Lean and metabolically healthy|
9968659|NCT01281930|Active Comparator|Full packing of abscess cavity|
9968660|NCT01281943|Experimental|Temsirolimus and Pegylated Liposomal Doxorubicin|Temsirolimus 25mg andPegylated liposomal doxorubicin 25mg/m2
9968661|NCT01282008||Focus Groups|Focus Groups about smoking messages
9968662|NCT01282034|Active Comparator|Marrow stimulation|
9968663|NCT01282034|Experimental|Medical device: MaioRegen|
9968664|NCT01282047|Experimental|Lenalidomide|
9968665|NCT01282073|Experimental|Mycophenolate mofetil, low dose steroid|
10134006|NCT04256330||Lean and metabolically unhealthy|
10134007|NCT04256330||Overweight and metabolically healthy|
10134008|NCT04256330||Overweight and metabolically unhealthy|
10134009|NCT04256330||Obese and metabolically healthy|
10134010|NCT04256330||Obese and metabolically unhealthy|
10134011|NCT04256447||Sixty-eight children and adolescents with type 1 diabetes|Sixty-eight children and adolescents aged between 4 and 18 years with type 1 diabetes. Patients with celiac disease, thyroid disease, other autoimmune diseases, concurrent illness, patients with diabetic nephropathy, other renal disease and in therapy with natriuretic drugs were excluded.
10134012|NCT04256590||Study|Patients aged 16 years or younger who were to undergo adenoidectomy surgery were eligible for inclusion in this group. Tongue surface areas were measured twice by submental USG.The first measurements (TSA2) were done immediately after endotracheal intubation but before insertion and placement of the tongue depressor. The second measurements (TSA1) were done after adenoidectomy surgery and after removal of the tongue depressor but just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue swelling.
10134013|NCT04256590||Control|This group included patients aged 16 years or younger who did not need adenoidectomy surgery and any head and neck procedures. Tongue surface areas of the patients were measured twice by submental USG as in the study group. TSA1s were done immediately after endotracheal intubation, and TSA2s were done at the end of the surgical procedure just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue edema.
10134014|NCT04256577||patients proven having (SLE)|20 patients proven to have systemic lupus Erthematosus without renal impairment (eGFR) ≥ 80 ml/min/1.73 m2 and albumin / creatinine ≤ 30 mg/g)
10134015|NCT04256577||patients proven to have (LN) by renal biopsy|Group (2) 25 patients proven to have LN by renal biopsy before starting treatment and after 3 cycle of treatment (eGFR < 80 ml/min/1.73 m2 and albumin/creatinine ratio > 30 mg/g)
10134016|NCT04256577||healthy control|(20) patients healthy control matched in age and sex
10134017|NCT04256473|Experimental|Intervention|"Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.~Depending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes)."
10134018|NCT04256473|Active Comparator|Control|Usual care with alteplase 0.9 mg/kg in 60 minutes
10134019|NCT04256135|Experimental|Experimental mobilization: Mulligan|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
10134020|NCT04256135|Active Comparator|Control mobilization: AP Maitland|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
10134021|NCT04256655|Experimental|Cohort 1 0.225 g|Randomized to treatment with either CDX-6114 0.225g or matching Placebo
10134022|NCT04256655|Experimental|Cohort 2 0.75g|Randomized to treatment with either CDX-6114 0.75g or matching Placebo
10134023|NCT04256655|Experimental|Cohort 3 2.25g|Randomized to treatment with either CDX-6114 2.25 g or matching Placebo
10134024|NCT04256343|Experimental|D2O Dose 1|Lower dose of D2O for MPS
10134025|NCT04256343|Experimental|D2O Dose 2|Moderate dose of D2O MPS
10134026|NCT04256343|Experimental|D2O Dose 3|Higher dose of D2O for MPS
10134027|NCT04256460|Experimental|Intervention arm|Behavior intervention including health education on diet, exercises and self management support through peer support, and also receive regular care and follow up in community health centers
10134028|NCT04256460|No Intervention|Control arm|Receiving regular care and follow up in Community health centers
10134029|NCT04256252|Experimental|Rituximab|Intravenous rituximab was administered at a fixed dose of 100 mg once weekly for 3 weeks, followed by maintenance treatment with 100 mg rituximab every 6 months.
10184078|NCT03758430||Combined Diabetes Management Data|Participants with type 1 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their continuous glucose monitor and insulin pump. Combined data will be used for diabetes management.
10184079|NCT03758391|No Intervention|Traditional Didactic Education|Education will be provided to fellows using the traditional didactic approach (lecture-based).
10184080|NCT03758391|Experimental|Flipped Classroom Education|Education will be provided to fellows using the flipped classroom approach.
9669118|NCT03943264|Experimental|3.0 mg/kg XPro1595|3.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
10184081|NCT03758378|Experimental|Dietary intervention|
10184082|NCT03758352|Experimental|intervention group (rIC)|The rIC procedure will be applied on seated patients, who have been resting for at least five minutes. The active rIC procedure consists of four five-minute inflations of a pneumatic tourniquet to 100 mmHg above the patient's systolic blood pressure separated by five-minute periods of complete deflation. Placement of the pneumatic tourniquet will be unilaterally on a lower limb (right thigh)
10184083|NCT03758352|Other|control group (non-rIC)|The control group will be a retrospective group, who have undergone a liver transplantation and meet the inclusion criteria.
10184084|NCT03758339|Experimental|Tucatinib|
10187679|NCT03723746|Experimental|Cohort 3: Dose 1 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Multiple Day [MD] Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days without antibiotic pretreatment after an overnight fast in Part 2.
10187680|NCT03723746|Experimental|Cohort 4:Antibiotic + Dose 1 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
9669119|NCT03940326|Experimental|Levetiracetam|
9669120|NCT03940326|Active Comparator|Valproate|
9968666|NCT01282073|Active Comparator|Cyclosporin, low dose steroid|
9968667|NCT01282099||Cardiac patients|Postoperative congenital heart disease patients requiring stay in the PICU
10134030|NCT04256525|Experimental|Aspirin 100mg|
10134031|NCT04256525|Experimental|rivaroxaban 10mg|
10134032|NCT04256525|Experimental|low molecule heparin|
10134033|NCT04256525|No Intervention|Reference|mechanical prophylaxis
10134034|NCT04256564|Experimental|Oblique visualization linear probe|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein
10134035|NCT04256564|Experimental|Y-shape visualization micro-convex probe|A micro-convex endocavity ultrasound probe will be utilized to place the central catheter into the brachiocephalic vein
10134036|NCT04256200|Active Comparator|Dienogest|Deinogest (Visanne) 2mg/day orally for 24 weeks
10134037|NCT04256200|Active Comparator|Oral Contraceptive Pills|Oral contraceptive pill (Yasmin, 0.03mg Ethinyl Estradiol and 3mg Drospirenone) orally daily for 24 weeks
10134038|NCT04256239|Experimental|Dignity Therapy Group|"Dignity Therapy is a short-term psychotherapy aimed at improving patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress. Therapy sessions, lasting between 20 and 60 minutes, were offered at the patients' bedside and audiotaped, and were conducted by a trained psyco-oncologist. After each therapy session, the audiotaped interview data were transcribed verbatim by a different psycho-oncologist and edited and reshaped into a written narrative by an expert in DT over the course of the next two to three days. Once the editing process was completed, another session was held to allow the therapist to read the generativity document to the patient and to make any editorial changes the patient deemed necessary. The final version of the generativity document was given to the patient to bequeath it to individuals of their choosing"
10134039|NCT04256239|No Intervention|Control Group (Standard Palliative Care)|Standard Palliative Care was performed by a multidisciplinary care team composed of a palliative doctor, a psycho-oncologist, a nurse, a physiotherapist, a healthcare assistant, a social assistant, a volunteer and a spiritual assistant, tailoring care to the needs of patients and their families.
10134040|NCT04256278|Experimental|Intervention Group|
10134041|NCT04256278|Placebo Comparator|Control Group|
10134042|NCT04256538||Crohn's Disease Group|Patients are diagnosed as Crohn's disease and have no history of colectomy.
10134043|NCT04256538||Ulcerative Colitis Group|Patients are diagnosed as ulcerative colitis and have no history of colectomy.
10134044|NCT04256538||Healthy Control Group|Individuals that have no past medical history.
10134045|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at double dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 4,6 g per 100g of powder (group fed with double dosage of fermented matrix compare trial FERCT15)
10134046|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at triple dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 6,9 g per 100g of powder (group fed with triple double dosage of fermented matrix compare trial FERCT15)
9968668|NCT01282099||non-cardiac patients|non-cardiac patients requiring stay in the PICU
10134047|NCT04256356|Placebo Comparator|Infants born by CS-fed standard formula|Infants born by CS-fed formula milk without fermented matrix
10134048|NCT04256356|Other|Infants born by CS-breastfed|Infants born by cesarean section fed with mother milk during were the reference group
10134049|NCT04256187||Healthy group|Caregivers of children who treated with botulinum toxin.
10134050|NCT04256057|Other|magnesium sulphate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
10134051|NCT04256213|Experimental|Nivolumab + Ipilimumab|
10134052|NCT04255953|Active Comparator|Treatment as Usual|Following baseline assessment, patients randomized to the TAU arm will receive monthly dietary pamphlets and web-based obesity prevention educational materials from the U.S. Office of Disease Prevention and Health Promotion (https://healthfinder.gov/HealthTopics/). After the 6-month assessment, TAU patients will begin the weight loss intervention arm.
10134053|NCT04255953|Experimental|Group Telehealth Obesity|Participants will receive 24 weekly group phone counseling sessions and monthly individual sessions that encourage healthy eating and exercise. The planned intervention is guided by a social-cognitive framework and includes self-monitoring, goal setting, stimulus control, social support, cognitive reframing of unrealistic and negative thoughts, and developing positive expectancies for long-term weight control. The primary objective is to decrease caloric intake and increase physical activity to produce weight loss of approximately .4 to.9 kg per week, with the study goal of 10% reduction from baseline.
10134054|NCT04256096|Experimental|thrombectomy|mechanical thrombectomy with stent-retriever and/or thromboaspiration
10134055|NCT04256096|Active Comparator|Clinical treatment|Best Medical treatment
10134056|NCT04256122||Responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.~Patient treated with adjuvant MMC or BCG that did not experience recurrence for at least 42 months after TURBT~Patients are tumor-free at the moment of the analysis"
10134057|NCT04256122||Non responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.~o Patient treated with adjuvant MMC or BCG that experienced recurrence in the first 24 months after TURBT."
10134058|NCT04255979|Experimental|Cohort 1|Single dose of HY209 0.1 mg/kg or placebo.
10134059|NCT04255979|Experimental|Cohort 2|Single dose of HY209 0.2 mg/kg or placebo.
10134060|NCT04255979|Experimental|Cohort 3|Single dose of HY209 0.4 mg/kg or placebo.
10134061|NCT04255979|Experimental|Cohort 4|Single dose of HY209 0.8 mg/kg or placebo.
10134062|NCT04255979|Experimental|Cohort 5|Single dose of HY209 1.6 mg/kg or placebo.
10134063|NCT04255979|Experimental|Cohort 6|Single dose of HY209 3.2 mg/kg or placebo.
10134064|NCT04256148|Experimental|ALXN1830 Dosing Regimen 1|
10134065|NCT04256148|Experimental|ALXN1830 Dosing Regimen 2|
10134066|NCT04256148|Experimental|ALXN1830 Dosing Regimen 3|
9968669|NCT01282125||sleep apnea|100 patients suffering from obstructive sleep apnea syndrome
9968670|NCT01282125||controls|100 subjects matching cases to age, sex, and body weight
9968671|NCT01282151|Experimental|Taxotere|Docetaxel plus Cisplatin
9968672|NCT01282151|Active Comparator|Pemetrexed|Pemetrexed plus Cisplatin
10134067|NCT04256148|Active Comparator|Placebo|
10134068|NCT04255966||Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
10134069|NCT04256174|Experimental|Part 1:15mg cohort|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.
10134070|NCT04256174|Experimental|Part 1: 50mg cohort|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.
10134071|NCT04256174|Experimental|Part 1: 150mg cohort|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.
10134072|NCT04256174|Experimental|Part 1: 300 mg cohort|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.
10134073|NCT04256174|Experimental|Part 1: 600 mg cohort|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.
10134074|NCT04256174|Experimental|Part 2: low dose cohort|Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
10134075|NCT04256174|Experimental|Part 2: medium dose cohort|Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
10134076|NCT04256174|Experimental|Part 2: high dose cohort|Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
10134077|NCT04256031||Excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are higher than 30
10134078|NCT04256031||Non-excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are 30 or less
10134079|NCT04256083||AFE (amniotic fluid embolism)|Women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS criteria.
10134080|NCT04256083||Control 1|Women admitted for prophylactic elective cesarean section.
10134081|NCT04256083||Control 2|Women with acute collapse in the peripartum period (with systolic blood pressure <80 mmHg twice and for> 5 minutes or acute peri-partum shock, for which the diagnosis of amniotic embolism has been ruled out).
10134082|NCT04255992|Active Comparator|Calcium arm|1000 mg Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
10134083|NCT04255992|Active Comparator|Vitamin D/Calcium|1000 mg/800UI of VitaminD/Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
10134084|NCT04255940||After outbreak|
10134085|NCT04255940||Past 3 months|
10134086|NCT04255940||Last year|
10134087|NCT04255862|Experimental|Test 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1).
10134088|NCT04255862|Other|Reference 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1).
9826060|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram [mg] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
9968673|NCT01282190|Experimental|Motivational interview|
10134089|NCT04255862|Experimental|Test 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2).
10134090|NCT04255862|Other|Reference 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).
10134091|NCT04255719|Experimental|Unilateral DBS of the subthalamic nucleus (STN)|To deliver unilateral STN DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral STN DBS. The STN stimulation will be programmed as previous parameter configuration with optimal therapeutic benefits. Participants will be asked to complete a comprehensive set of assessments under unilateral STN stimulation in the off-medication state. 45 minutes after taking regular medication, participants need to complete the second set of assessments in the on-medication state.
10134092|NCT04255719|Experimental|Unilateral DBS of the globus pallidus interna (GPi)|To deliver unilateral GPi DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral GPi DBS. The study protocol is identical to the intervention of unilateral STN DBS but it was done on a different day.
10134093|NCT04255836|Experimental|Durvalumab therapy|Chemo+Durvalumab (PD-L1 monoclonal antibody)1500 mg every 3 weeks [q3w] intravenously [iv] for 4 cycles, then SBRT 50-60 Gy/≤10f + Durvalumab 1500 mg q4w, then Durvalumab 1500 mg q4w for up to 24 months or until progression or other discontinuation criteria are met.
10134094|NCT04255914|Experimental|Root coverage procedure along with orthodontic treatment|subepithelial connective tissue graft and orthodontic levelling and alignment
10134095|NCT04255914|Active Comparator|Root coverage procedure only|sub epithelial connective tissue graft procedure for recession coverage
10134096|NCT04255732|Other|Extent of retinal periphery area viewing|For the 30 patients fundus photography will be performed using two ultra-wide-field imaging systems.
10134097|NCT04255771|Experimental|Effect of adjuvant chemotherapy on pTanyN0M0 UTUC with LVI|This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+) patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma, respectively.
10134098|NCT04255771|Placebo Comparator|Effect of placebo on pTanyN0M0 UTUC with lymphatic invasion|As a control, this clinical trial also set up a placebo control group. The effect of adjuvant chemotherapy was obtained by random grouping and comparing the effects of patients in the experimental group and the control group.
10134099|NCT04255758|Experimental|Vigorous-intensity Aerobic Exercise|Vigorous-intensity aerobic exercise, single intervention
10134100|NCT04255472|Experimental|WHO caregiver skills training program|Strategies to support children's communication skills by learning to engage in play activities and daily home routines activities with their caregivers.
9968674|NCT01282268|Active Comparator|Arbaclofen|
9968675|NCT01282268|Placebo Comparator|Placebo|
10134101|NCT04255472|Experimental|Treatment as usual (TAU)|TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets.
10134102|NCT04255485||Short time anesthesia group|Unilateral cochlear implantation,which time of anesthesia is less than 3 hours
10134103|NCT04255485||Long time anesthesia group|Bilateral cochlear implantation, which time of anesthesia is more than 3 hours
10134104|NCT04255667||Study group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing with hemostat at start of surgery
10134105|NCT04255667||Control group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing without hemostat
10134106|NCT04255524|Experimental|Group 1/Control|Spherical equivalent: -2.00～+2.00 D
10134107|NCT04255524|Experimental|Group 1/Myopia|Spherical equivalent: -3.00～-6.00 D
9528200|NCT03213002|Experimental|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
10134108|NCT04255524|Experimental|Group 3/High|Spherical equivalent: -6.00～-10.00 D
10134109|NCT04255524|Experimental|Group 4/Super High|Spherical equivalent: <-10.00
10134110|NCT04255420|Experimental|SPG Block|Sphenopalatine ganglion block using cotton-tipped applicators soaked in 1% lidocaine will be performed.
10134111|NCT04255420|Active Comparator|Standard Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg.
10134112|NCT04255888|Active Comparator|Thick periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
10134113|NCT04255888|Active Comparator|Thin periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
10134114|NCT04255797|Experimental|experimental group|The experimental group will perform massage in an incubator. The researchers provide a natural plant-based massage oil for the parents.
10134115|NCT04255589|Experimental|Experimental Group|Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)
10134116|NCT04255589|Active Comparator|Active comparator Group|Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)
10134117|NCT04255459|Other|Moist Snuff users|Subjects for whom moist snuff is their usual brand of tobacco product.
10134118|NCT04255459|Other|Camel Snus users|Subjects for whom Camel Snus is their usual brand of tobacco product.
10134119|NCT04255459|Other|Dual users of Camel Snus and cigarette|Subjects who use both Camel Snus and cigarettes as their usual brands of tobacco products.
10134120|NCT04255459|Other|Dual users of moist snuff and cigarettes|Subjects who use both moist snuff and cigarettes as their usual brands of tobacco products.
10134121|NCT04255459|Other|Cigarette smokers|Subjects for whom cigarettes is their usual brand of tobacco product.
10134122|NCT04255459|Other|Non-tobacco users|Subjects who do not use tobacco products.
10134123|NCT04255628||with cancer pain|head and neck and esophageal cancer patients. with cancer pain
10134124|NCT04255628||without cancer pain|head and neck and esophageal cancer patients. without cancer pain=30
10134125|NCT04255693|Experimental|Change in disease manifestations|The data of all the patients will be assessed from the viewpoint of changes in the disease flow (severity and frequency of symptoms, grade of oesophagitis). They will be compared to the changes of the major factors that could influence the disease flow: adherence to anti-secretory agents, presence of concomitant medications and their doses, adherence to diet, change in physical activity. These will be compared to the initial data. Thus, it would be possible to make a multivariate comparison and try to establish the influence (and, possibly, weight) of each of the con-founder on the disease flow.
10134126|NCT04255693|Active Comparator|No change in disease flow|"To this arm patients with no change in the disease manifestations will be assigned, based on the end-point evaluation. The same as in the experimental groups factors will be analysed to establish the difference."
10134127|NCT04255706|Other|Biometric measurement repeatability|Biometric measurements will be performed in all patients
10134128|NCT04255641||frozen embryos|
10134129|NCT04255654|Experimental|Brief Intervention|There is only 1 intervention for this study. They will have the brief intervention completed on them. There is no control group.
10134130|NCT04255576|Experimental|Experimental: JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg SC Q4W with a loading dose of 2 mg/kg SC on study days 8 and 15.
10134131|NCT04255498|Experimental|Etanercept|50 MG/ML Prefilled Syringe (once a week for 4 weeks)
10134132|NCT04255498|Experimental|Mifepristone|(300 mg once a day for 7 days) will follow the etanercept.
10134133|NCT04255537||Patients with STEACS intended for urgent angio/reperfusion.|This population mostly includes STEACS patients for whom primary PCI is intended. A minority of this population includes patients with STEACS intended for urgent angiography for persistent ST elevation and/or symptoms but with symptoms onset > 12 hours (secondary PCI), urgent angiography after failed fibrinolysis (rescue PCI), or patients receiving fibrinolysis.
10134134|NCT04255537||Patients with STEACS NOT intended for urgent angio/reperfusion|This population mostly includes STEACS patients not receiving reperfusion for late presentation (i.e. > 12 hours) or patient preference. Note that patient in this category may receive diagnostic angiography for better diagnostic assessment and/or risk stratification but NOT on an urgent basis.
10134135|NCT04255537||Patients with NSTEACS intended for invasive management|This population includes patients with NSTEACS managed invasively with coronary angiography within 72 hours. Most patients are a high-risk feature (i.e. positive troponin, GRACE risk score > 140, hemodynamic/electrical instability) for whom angiography is intended.
10187681|NCT03723746|Experimental|Cohort 5: Dose 2 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily without antibiotic pretreatment for 14 days after an overnight fast in Part 2.
9968676|NCT01282281||Individuals aged 14-18 and 19-65 with a diagnosis of BD|
9977770|NCT01365065|Experimental|Vorinostat|Vorinostat 400mg ( 4 X 100mg ) orally daily for 14 days
10134136|NCT04255537||Patients with NSTEACS NOT intended for invasive management|This population includes patients who are candidate for an initially conservative strategy. Note that this category may include patients who are subsequently managed with coronary angiography, including recurring symptoms of myocardial ischemia, or hemodynamic/ electrical instability.
10134137|NCT04255342|Active Comparator|Group 1|Group 1: 3 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
10134138|NCT04255342|Active Comparator|Group 2|Group 2: at 6 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed.
10134139|NCT04255342|Active Comparator|Group 3|Group 3: 9 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
10134140|NCT04255563||DCB treatment|DCB (Sequent® Please) treatment will be performed for suitable patients with CAD.
10134141|NCT04255368|Experimental|Water-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.
10134142|NCT04255368|Experimental|Fat-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.
10134143|NCT04255368|Active Comparator|No choline|A breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.
10134144|NCT04255290|Experimental|Experimental group|Leg Squat Lounge: The player will be placed in squat position and her partner will be placed behind, suspending the most posterior leg in the air. With the leg that is supported, you will perform a monopodal jump with controlled fall, supporting the foot from tip to heel. It will be done with both lower limbs performing 1 series of 5 repetitions with 30 seconds of rest between sets. 180 jump: The footballer will start in bipodal support, with the trunk erect and hands on the hips. Perform a bipodal jump with a 180º turn during this, keeping the fall for 2 seconds. Each repetition, the turn will be done in a different sense. It will carry out 2 series of 20 sec of execution with 20 sec of rest between series. Brad jump stick landing: The player will stand in hands-free standing. Perform a bipodal jump as far as possible. The knees will not exceed the tip of the foot and the fall will be with a trunk position as straight as possible. He will make 5 jumps the first two weeks.
9968677|NCT01282307|Experimental|Method Guided Self-Determination|The Method Guided Self-Determination consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
9968678|NCT01282307|No Intervention|Treatment as usual|
9968679|NCT01282320|Experimental|Increased Physical Activity|Individually tailored training one hour, 2-3 sessions per week.
10134145|NCT04255290|Active Comparator|Control group|"Nordic Funds: One player will stand on her knees, while the other, behind, fixes her legs. The kneeling footballer must drop forward in a controlled manner until she touches the ground and returns to the starting position. The Diver: Player in monopodal support on the lower limb to work, performing hip flexion with the arms forward and the opposite lower limb back, looking for a horizontality in the pelvis (with 10º-20º knee flexion) It will be done with both lower limbs.~The Glider: With the footballer standing in front of her partner, holding both of them by the shoulders, she lets one leg slide back while the other stays fixed. To return to the starting position, it will be helped by the other player, while the knee will not exceed 10 degrees of flexion. The distribution of all the exercises will be: 2 sets of 5 repetitions with 20 sec rest between sets"
10134146|NCT04255446||Dysfunctional Breathing|Patients with Dysfunctional breathing age between 16 to 75 will be included.
10134147|NCT04255446||Healthy Volunteers|Healthy Volunteers without any respiratory problems age between 16 to 75 will be included.
10134148|NCT04255680||FRDA Subjects|Male and female subjects with FRDA confirmed by genetic testing (aim for a 50:50 distribution of males to females)
10134149|NCT04255680||Controlled Subjects|Male and female control subjects (matched by age [+/- 2 years] and sex)
10134150|NCT04255316|Experimental|Modified eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a modified eversion carotid endarterectomy
10134151|NCT04255316|Active Comparator|Standard eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a standard eversion carotid endarterectomy
10134152|NCT04255355|Active Comparator|Pelvic alignment and forceful expiration exercise|
10134153|NCT04255355|Experimental|Pelvic repositioning exercise|
10134154|NCT04255355|Experimental|Diaphragmatic breathing exercise|
10134155|NCT04255238|Experimental|Gemigliptin 50 mg and Dapagliflozin 10 mg|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin 10 mg per day~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
10134156|NCT04255238|Active Comparator|Gemigliptin 50 mg and Dapagliflozin placebo|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin placebo per day~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
10187682|NCT03723746|Experimental|Cohort 6:Antibiotic + Dose 2 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
9968680|NCT01282320|No Intervention|"Activity as usual (Buisness as usual)"|
9976810|NCT01355237||Comparison|Patients being treated for chronic low back pain at Brigham and Women's Hospital, other than at Osher Clinical Center
9977771|NCT01365078|Experimental|Echium oil (SDA-rich oil)|
9977772|NCT01365078|Placebo Comparator|High-oleic acid sunflower oil (HOSO)|low in SDA
10134157|NCT04255238|Active Comparator|Gemigliptin placebo and Dapagliflozin 10mg|"Subject shoud took 1 tablet of Gemigliptin placebo and 1 tablet of Dapagliflozin 10 mg per day~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
10134158|NCT04255225|Experimental|10-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
10134159|NCT04255225|Experimental|20-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
10134160|NCT04255225|Experimental|30-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
10134161|NCT04255264||Study patients|Obese subjects scheduled to undergo abdominoplasty surgery are included. These are later classified according to metabolic status.
10134162|NCT04255251|Experimental|Intervention group|Subjects in this group will receive Silver Diamine Fluoride around their crown margins every six month for the next 3 years.
10134163|NCT04255251|Active Comparator|Fluoride varnish group|Subjects in this group will receive fluoride varnish around their crown margins every six month for the next 3 years.
10134164|NCT04255160|Experimental|Estradiol|Transdermal estradiol (0.1mg/day patch)
10134165|NCT04255160|Placebo Comparator|Placebo|Placebo
10134166|NCT04255134|Experimental|Abatacept|Drug administered to participants with active rheumatoid arthritis
10134167|NCT04255134|Active Comparator|Adalimumab|Comparator drug administered to participants with active rheumatoid arthritis
10134168|NCT04254887|Experimental|EPBD|Small incision of the duodenal nipple + EPBD
10134169|NCT04254887|Active Comparator|EST|Large incision of the duodenal nipple
10134170|NCT04255186|Experimental|Thermal CRMRF|"9 sessions in 3 week of Thermal CRMRF: The power of the RFCR equipment in this intervention will be 35 VA in capacitive method (10% of the maximum power of the equipment) and 30 W in the resistive method (15% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessiones a week).~In Thermal CRMRF it will be necessary to adapt to the patient's thermal sensitivity"
10134171|NCT04255186|Experimental|Subthermal CRMRF|9 sessions in 3 week of Subthermal CRMRF: The power of the RFCR equipment in this intervention will be 7 VA in capacitive method (2% of the maximum power of the equipment) and 4 W in the resistive method (2% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessions a week).
10134172|NCT04255186|Sham Comparator|Sham CRMRF|9 sessions in 3 week of sham stimulation: The application will be carried out in the same way as in the experimental groups, but in this case the manufacturer will introduce a simulated stimulation protocol so that the device does not emit current + 15 sessions in 3 week of exercise protocol (5 sessiones a week).
10134173|NCT04254965|Experimental|Group 1|Participants of integrated music therapy (integration of active and passive music therapy) includes instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process. The four stages of activities are warm-up, main activities, secondary activities, and the ending section.
10134174|NCT04254965|Active Comparator|Group 2|Participants of the music listening group will receive background music listening, music selection based on the musical preference and background of subjects, for relax or boost the spirit of the subjects.
10134175|NCT04254965|Sham Comparator|Group 3|Participants in the control group receive their regular occupational therapy during the experimental period.
10134176|NCT04255017|No Intervention|Symptomatic supportive treatment|Symptomatic supportive treatment
10134177|NCT04255017|Experimental|Abidol hydrochloride was added on the basis of group I.|Abidol hydrochloride 0.2g once,3 times a day,2 weeks
10134178|NCT04255017|Experimental|Oseltamivir was added on the basis of group I.|Oseltamivir 75mg once,twice a day,2 weeks
10134179|NCT04255017|Experimental|Lopinavir/ritonavir was added on the basis of group I.|Lopinavir/ritonavir 500mg once,twice a day,2 weeks
10134180|NCT04254835|Experimental|intervention group|Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will applied to this group once at the beginning of the study.Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.
10134181|NCT04254835|Active Comparator|control group|"Varnish containing Fluoride (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein). will applied to this group once at the beginning of the study.~Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks."
10134182|NCT04255004|Active Comparator|A-PBMNC therapy|Patients in A-PBMNC therapy are treated with wound bed multiple perilesional and intramuscular injections of PBMNC cells suspension (0.2-0.3cc in boluses). This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
10134183|NCT04255004|No Intervention|No A-PBMNC therapy|Patients in No A-PBMNC therapy receive only supportive treatment including wound care and pain killer drug.
10134184|NCT04255173|Experimental|Geriatric osteoporotic patients|We measured different anthropometric and body composition measurements as body weight, BMI, percentage body fat, skeletal muscle index (SMI), ABSI, waist (WC) and hip circumference (HC) in geriatric population to investigate the relation to osteoporosis.
10134185|NCT04255121|Experimental|alkalinization of adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
10134186|NCT04255121|Active Comparator|adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using a adrenaline lidocaine solution
10134187|NCT04254861|Experimental|Simplified Papilla Preservation Flap (SPPF) and PRGF|
10134188|NCT04254861|Active Comparator|Simplified Papilla Preservation Flap (SPPF) and GTR|
10134189|NCT04255095|Active Comparator|Nasobiliary drainage|
10134190|NCT04255095|Experimental|Naso-pancreatic drainage(negative pressure)|
10134191|NCT04254991||Infectious disease group|
10134192|NCT04254991||Non-infectious disease group|
10134193|NCT04254822|Experimental|HVPG-guided therapy|HVPG will be determined before randomization. In this arm, patients with an adequate reduction in HVPG (responders) receive carvedilol whereas nonresponders receive TIPS.
10134194|NCT04254822|Active Comparator|Standard therapy|In this group, both responders and nonresponders will receive combination therapy of carvedilol and endoscopic variceal ligation as first-line therapy. If first-line therapy fails, TIPS will considered.
10134195|NCT04254848|Experimental|completely edentulous patients with maxillary tori|20 completely edentulous patients with maxillary tori will be recruited for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
10134196|NCT04254848|Active Comparator|completely edentulous patients without maxillary tori|20 completely edentulous patients without maxillary tori will serve as control group for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
10134197|NCT04254900||Male wheelchair athletes|Other
10134198|NCT04254900||Female wheelchair athletes|Other
10134199|NCT04255056|Experimental|Pyrotinib|"Eligible patients will receive four cycles of epirubicin and cyclophosphamide combined with pyrotinib.~Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
9976811|NCT01355263|Experimental|iron tablet, vitamin a capsule|children in Group I received a 200,000 IU vitamin A capsule just one time initially; Group II received ferrous sulfate (element Fe 1-2 mg/kg•day) once a day for 6 months;.
10134200|NCT04255030|Experimental|First stage: Self-directed Coping Together|
10134201|NCT04255030|Experimental|First stage: Minimally guided telephone support (lay coaching)|
10134202|NCT04255030|Experimental|Second stage: High intensity Motivational Interviewing (MI)|
10134203|NCT04254913|Experimental|MT-1186|Patients receive the edaravone oral suspension.
10134204|NCT04254757|Other|Percutaneous endoscopic surgery group|
10134205|NCT04254757|Other|Open decompression and fusion surgery group|
10134206|NCT04255069|Placebo Comparator|Placebo|Placebo, oral, daily
10134207|NCT04255069|Experimental|Dose 1|JKB-122, Dose 1, oral, daily
10134208|NCT04255069|Experimental|Dose 2|JKB-122, Dose 2, oral, daily
10134209|NCT04254874|Experimental|Abidol hydrochloride|Standard symptomatic support therapy (SMT) plus abidol hydrochloride(0.2g, 3 times a day).
10134210|NCT04254874|Experimental|Abidol Hydrochloride combined with Interferon atomization|Interferon(PegIFN-α-2b) atomization was added(45ug, add to sterile water 2ml, twice a day) on the basis of group I.
10134211|NCT04254744||Acyanotic children|Acyanotic children undergoing cardiac surgery due to congenital heart disease
10134212|NCT04254744||Cyanotic children|Cyanotic children undergoing cardiac surgery due to congenital heart disease
10134213|NCT04254926|Experimental|Revie ⊕ intervention early|participants randomized into (i) the intervention group (IG) receive the Revie ⊕ intervention early on.
10134214|NCT04254926|Experimental|Revie ⊕ intervention later|The control group (CG) receives the same intervention Revie ⊕ but later on (i.e., after eight weeks).
10134215|NCT04255043|Experimental|IVUS-guided DCB|In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.
10134216|NCT04255043|Active Comparator|Angiography-guided DCB|In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.
10134217|NCT04254718|Experimental|Digital Storytelling|Legacy intervention via digital story for NICU parents
10134218|NCT04254705|Other|Subjects with CF and R334W mutation|Subjects with CF and R334W mutation
10134219|NCT04254523|Experimental|Programmed intermittent epidural bolus (PIEB)|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour.
10134220|NCT04254523|Experimental|Continuous epidural infusion (CEI)|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate in milliliters per hour.
10134221|NCT04254445|Experimental|Training video arm|Patients will watch a personalized custom training video, in addition to the standard explanation provided by the medical staff
10134222|NCT04254445|No Intervention|Verbal explanation arm|Patients will standard explanation about the procedure, provided by the medical staff
10134223|NCT04254601|Experimental|Experimental group 1|Patients in group (A) consisted of 15 participants, received a program of NBUB, DIXWELL EMLY 98 -ABRP 64 ,made in France (wavelength 311 to 313nm) , in addition to topical aknemycin medications (topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period after 8 weeks).
10134224|NCT04254601|Experimental|Experimental group 2|Participants in-group (B) consisted of 15 participants, received a program of R-LLLT that was conducted through laser equipment InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia) with fluence 12 J/cm2, two sessions per week for 8 weeks Plus topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
10134225|NCT04254601|Active Comparator|Control group|Patients in the group C, consisted of 15 participants, were asked to apply topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
10134226|NCT04254432|Experimental|remote ischemic conditioning arm|Device: remote ischemic conditioningRIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 30+/-2days. Other Names:• RICDevice: ambulatory blood pressure monitoring diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment
10134227|NCT04254692|Active Comparator|Liposomal Bupivacaine|Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall.
10134228|NCT04254692|Other|Bupivacaine|Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.
10134229|NCT04254679|Experimental|Opioid analgesia|
10134230|NCT04254679|Active Comparator|Opioid-free analgesia|
10134231|NCT04254380|Experimental|Experimental: Gan & Lee Insulin Lispro Injection|Gan & Lee Insulin Lispro Injection for subcutaneous injection, 100 U/mL, in a disposable multidose pen injector with a pre-filled 3-mL type I glass cartridge. Subjects randomized to the Gan & Lee Insulin Lispro Injection group will participate in the study for 26 weeks.
10134232|NCT04254380|Active Comparator|Active Comparator: Humalog|EU-authorized Humalog KwikPen® - insulin lispro injection, solution for subcutaneous injection, 100 U/mL (pre-filled). Subjects randomized to the Humalog group will participate in the study for 26 weeks.
10134233|NCT04254367|Experimental|Intervention group - experimental TAU + intervention|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
10134234|NCT04254367|No Intervention|TAU - no intervention|Treatment as usual following local routines on each primary care center
10134235|NCT04254458||PACG group|Cases who had first acute attack of primary angle closure glaucoma
10134236|NCT04254354||transgender men|no intervention
10134237|NCT04254211||EVAR|Patinets with AAA, treated electively by EVAR. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively. Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause
10134238|NCT04254393|Experimental|Early Adolescent Skills for Emotions (EASE) Program|Early Adolescent Skills for Emotions (EASE) is a new, brief, targeted, group psychological intervention program (Dawson et al., 2019) based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (WHO, 2016).
10134239|NCT04254393|Placebo Comparator|Treatment as Usual (TAU)|Participants in control arm will be able to avail the routine services available in school settings.
10134240|NCT04254588||Adult patients with abdominal pain|Adult patients with abdominal pain presenting to the MGH ED.
10184085|NCT03758300|Experimental|Radiofrequency group|In this group patients will receive in a sterile fashion continuous radiofrequency for 4 minutes to the 3 genicular nerves in the operative knee as well as Pulsed Radiofrequency at 42 degrees celsius, for 4 minutes (60-70 volts) to the saphenous nerve and the nerve to the Vastus Medialis, at the level of the adductor canal. The procedure is done under local anesthesia on an ambulatory basis. After the radiofrequency, Ropivacaine 0.5% 5 ml is injected to each one of the nerves, along with 5 milligrams of Methylprednisolone to each nerve. Once the procedure is completed (takes about 20 minutes), patients will be observed in the preoperative program facility for 30 minutes and then discharged home.
10184086|NCT03758300|Sham Comparator|Control (Sham Radiofrequency) group|In this group patients will receive injections of the local anesthetic and steroids in the same anatomical locations, without activating the radiofrequency generator.
10184087|NCT03758287|Experimental|CT053PTSA +Gefitinib|"Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.~CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .~Gefitinib will be administered daily, at a dose of 250 mg orally ."
10184088|NCT03758235|Experimental|Incobot/A 100 U|Incobot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
10184089|NCT03758235|Experimental|Incobot/A 200 U|Incobot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered in patients performin intermittent catheterization.
10184090|NCT03758235|Active Comparator|Onabot/A 100 U|Onabot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
10184091|NCT03758235|Active Comparator|Onabot/A 200 U|Onabot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered to patients performing intermittent catheterization
10184092|NCT03758222|Experimental|Arm-1: Device implantation for 1 month|Treatment group receives intervention with the XFLO Expander System implantation for 1 month, and then retrieved.
10184093|NCT03758222|Experimental|Arm-2: Device implantation for 6 months|Treatment group receives intervention with the XFLO Expander System implantation for 6 months, and then retrieved.
10184094|NCT03758222|Experimental|Arm-3: Device implantation for 12 months|Treatment group receives intervention with the XFLO Expander System implantation for 12 months, and then retrieved.
10184095|NCT03758209|Experimental|Prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~Physical status (walking, respiratory training)~Nutrition (nutritional supplements)~Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
10184096|NCT03758209|Active Comparator|ERAS|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
10184097|NCT03758196|Experimental|Renal sympathetic denervation from the adventitia|Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
10184098|NCT03758196|No Intervention|optimized medication regimen|optimized medication regimen
10187683|NCT03723746|Experimental|Cohort 7 (Optional): Laxative + Dose 2 or Placebo (Part 3)|Participants may receive pretreatment with an oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 7 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
10134241|NCT04254471|Experimental|Dose escalation (AL3810 + carboplatin + etoposide)|Phase II:Participants will receive AL3810 orally in combination with carboplatin and etoposide during the Cycles 1-4 . AL3810 dose escalated form 5mg to 10mg step-up to determine the recommended dose of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
10134242|NCT04254471|Experimental|AL3810+ carboplatin + etoposide|Phase III:Participants will receive AL3810(recommended dose will be determined by safety monitoring committee (SMC) in Phase II) orally in combination with carboplatin and etoposide during the Cycles 1-4. Thereafter, participants will receive maintenance AL3810 until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
10134243|NCT04254471|Placebo Comparator|Placebo+ carboplatin + etoposide|Phase III:Participants will receive placebo orally in combination with carboplatin and etoposide during the induction Cycles 1-4. Thereafter, participants will receive maintenance placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
10134244|NCT04254614|Experimental|Personalised mobile application for IBD patients|This is a cohort study with a 1 arm intervention group, without a control group. Patients included in this study will be invited to use a mobile application. The content and functionalities of this application are described in the intervention section.
10134245|NCT04254237|Active Comparator|Intervention group|Infraumbilical Hasson trocar incision.
10134246|NCT04254237|Sham Comparator|Control group|Supraumbilical Hasson trocar incision.
10134247|NCT04254328|Experimental|Nintendo Wii Fit|Nintendo Wii Fit group work program; 13 exercises in 5 groups including 3 yoga exercises, 3 balance exercises, 2 aerobic, 2 training plus exercises and 3 muscle-workout will be done respectively. Patients in this group will exercise for 8 weeks, 3 days in a week and 40-50 minutes of exercise within resting interval.
9519599|NCT03285607|Experimental|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
9976812|NCT01355276|Experimental|1|
10134248|NCT04254328|Experimental|Respiratory|Respiratory training group participants' will do deep breathing exercise against resistance of 30% of intraoral pressure. This exercise will be applied for 8 weeks, each day of the week, twice in a day for 15 minutes and 4-5 normal breaths after 4-5 deep breaths. Each week, intraoral pressure will be measured and new training intensity values will be determined.
10134249|NCT04254328|No Intervention|Control|Patients in the control group will not be included in any exercise program, but all groups will be advised of walking in order to increase physical activity level.
10134250|NCT04254510|Experimental|Study Group|Myofascial relaxation technique
10134251|NCT04254510|No Intervention|Control group|
10134252|NCT04254640|Experimental|C-CAG|cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.
10134253|NCT04254198|Placebo Comparator|Control|Modified Attention Placebo Control
10134254|NCT04254198|Experimental|TERTULIAS structured dialogue peer support groups|Structured Dialogue peer support group
9976813|NCT01355276|Active Comparator|2|
10134255|NCT04254224||Diverticulitis Hinchey I-IV|Patients with complicated diverticulitis (Hinchey I-IV) treated conservatively (iv antibiotics with or without percutaneous, transrectal or transvaginal drainage) or surgically.
10134256|NCT04254120|Active Comparator|Cognitive-behavioral therapy (CBT)|
10134257|NCT04254120|Experimental|Integrated motivational interviewing and CBT|
10134258|NCT04254029|Experimental|Non-randomized single-arm of MOROLSTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days."
10134259|NCT04254185|Active Comparator|Simple decompression|In-situ decompression releases only the compressive ligamentous structures overlying the ulnar nerve.
10134260|NCT04254185|Active Comparator|Subcutaneous anterior transposition|Anterior transposition repositions the ulnar nerve, providing decompression and lengthening by moving the nerve anterior to the axis of elbow rotation
10134261|NCT04254016|Experimental|Non-randomized single-arm of HIBISTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted on the administration of Hibiscus-Stevia drink at a dose of 4 mg / kg / day / for Stevia and 4 g / day for Hibiscus for a period of 8 weeks and after meals."
10134262|NCT04254042|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
10134263|NCT04254042|Active Comparator|Zofenopril Arm|30 mg Zofenopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
9519600|NCT03285581|Other|Arm-1|Device:Treatment Subject(s) will receive 2 RF treatments
9976814|NCT01355328|Experimental|laser|
9976815|NCT01355328|No Intervention|control|
10134264|NCT04254055|Experimental|Experimental group|"Exercise 1 with medicine ball. Standing player with 90º shoulder abduction and elbow flexion. He will receive the ball with an external rotation returning it with internal rotation. Exercise 2 with elastic band. From standing, he will fix the elastic band with his foot and perform a shoulder flexion with his contralateral limb. Exercise 3 of iron with support of the hands on the floor and shoulder, elbow and wrist aligned. You should perform a scapula approach and separation without altering its initial position. Exercise 4 BodyBlade ©. From standing with 90º of 90 ° shoulder abduction and elbow flexion. It will perform an anteroposterior thrust, causing a wave effect to stabilize the shoulder joint for 30 seconds.~Athletes will do 15 repetitions of each exercise."
10134265|NCT04254055|No Intervention|Control group|Players included in the control group will not receive any intervention.
10134266|NCT04254003|Other|Test, then Control|DT1 Toric contact lenses worn first, followed by AO1DfA contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
10134267|NCT04254003|Other|Control, then Test|AO1DfA contact lenses worn first, followed by DT1 Toric contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
10134268|NCT04254081|Experimental|Buprenorphine 0.15mg + 1% lidocaine paracervical block|Paracervical block with 18mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate plus 0.15mg of buprenorphine
10134269|NCT04254081|Placebo Comparator|1% lidocaine paracervical block|Paracervical block with 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate
10134270|NCT04254146|Experimental|Study group|Aerobic exercise will be performed for a single session
10134271|NCT04254146|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
10134272|NCT04253990|Experimental|Precut-EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
10134273|NCT04253990|Active Comparator|Conventional EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~Conventional EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current"
10134274|NCT04254068|Experimental|Parent based prevention|Parent-Based Prevention (PBP; Sadeh-Sharvit & Lock, 2018) is a manualized preventive intervention, focused on increasing parental awareness and competence to facilitate healthy eating habits, body image, and self-regulation in children whose parent has an eating disorder history. PBP is comprised of three phases that focus on unique goals. The strategies in each session include psycho-education, behavioral experiment planning, and skill practicing to augment parents' insight into how the context of the parental cognitions and behaviors may impact child outcomes, with the goal of creating a longstanding effect.
10134275|NCT04254068|No Intervention|Usual care|Families randomized to usual care will be permitted to utilize any medical, psychological, or nutritional services they desire for the waitlist period of 16 weeks.
10134276|NCT04253925|Experimental|global postural correction exercises|global postural correction exercises in addition to Kegel exercises
10134277|NCT04253925|Active Comparator|Kegel exercises|only Kegel exercises
10134278|NCT04253912|Experimental|VBP-245|Topical 2% Povidone-Iodine Gel
10134279|NCT04253912|Placebo Comparator|Control|Placebo Gel (no Povidone-Iodine)
10134280|NCT04253704|Experimental|2% IDL lotion|The left arm of each subject was used for the test material hydrating lotion (IDL).
10134281|NCT04253704|Placebo Comparator|Control lotion|The right arm of each subject was used for control lotion lacking the IDL component.
10134282|NCT04253574||Patients with malignant melanoma|258 patients (w: 112, m: 146 age: 61±16 years) met the primary inclusion criteria. They were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)).
10134283|NCT04253730|No Intervention|Control Condition|Subjects will sit at rest wearing a liquid perfused suit containing thermoneutral water for 60 min. The suit will not be turned on during this period.
10134284|NCT04253730|Experimental|Cold Condition|Subjects will be cooled for 60-90 min at ~ 4-10°C using a liquid perfused suit. Subjects will then be rewarmed for 30 min at ~ 41°C using the liquid perfused suit.
10134285|NCT04253600|Other|MRI Acquisition|This does not refer to any group intervention. At-risk and control children will take part in a natural-sleep MRI protocol.
10134286|NCT04253678||Study group|"Study participants will be started on a flexible-dose of vortioxetine (5-20 mg) followed by a baseline assessment of primary outcomes using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Perceived Deficit Questionnaire - 5 items (PDQ-5), and secondary outcomes using the EORTC Quality of life Questionnaire (QLQ-C30) and Clinical Global Impression (CGI). The assessment timelines will be at week 2, week 4, week 8, and week 12.~Side effects, if any, will be recorded using the Antidepressant Side-effect Checklist (ASEC)."
10134287|NCT04253795|Active Comparator|Laryngeal mask group (Group 1)|Laryngeal mask will be placed in the airway by the anesthesiologist. Lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing
10134288|NCT04253795|Active Comparator|Double lumen tube Group (Group 2)|After the correct position of double lumen tube will be determined, one lung ventilation will be started. Lung isolation will be achieved by deflation of the nondependent lung.
10134289|NCT04253652||Oral iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed oral iron supplements as part of their treatment from their doctor. This will be in accordance with the NICE guidelines; 200mg capsules containing 65mg elemental iron, 2-3 times a day for a period of atleast 1 month.
10184099|NCT03758183||two-stage algorithm|Prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)
10184100|NCT03758183||one-stage algorithm|total knee arthroplasty (TKA)
9827458|NCT02456727|Active Comparator|Group/Community Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
10134290|NCT04253652||Intravenous iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed intravenous iron as part of their treatment from their doctor. Participants will receive an infusion of either 1000mg or 1500mg
10134291|NCT04253860|Experimental|TENS|Transcutaneous electrical neurostimulation will be applied for 30 minutes three times a week during 90 days
10134292|NCT04253860|Sham Comparator|Sham|A sham comparator will be applied for 30 minutes three times a week during 90 days. The device does not emit electrical impulses
10134293|NCT04253886|Active Comparator|Group A|The Ovassapian Fibreoptic Intubating Airway has a flat lingual surface that widens distally. This provides better retraction of the tongue to prevent it and the soft tissues of the anterior pharyngeal wall from herniating around the side of the airway. The airway has a pair of vertical sidewalls and two pairs of curved guide walls at its proximal section. These walls are separated by a gap which allows removal of the airway after intubation has been completed
10134294|NCT04253886|Active Comparator|Group B|"Fekry airway:~● It has two parts are: Airway body& Special connector~Airway body consists of:~Flange → it is the buccal end it is 7 cm wide to prevent it from~moving deeper into mouth & may also serve to fix airway in place.~Bite Portion → it is straight & fits between teeth &oral cavity.~Oral straight part → open anterior lingual part; it varies in length according to size~Pharyngeal curved part → extends backwards to correspond the shape oropharynx and ends below laryngeal inlet.~The connector: it is a special type (two sizes: adult and pediatric) can attach to all ventilating machines& it has a teeth rest act as a bite block."
10134295|NCT04253821|Active Comparator|Forward head posture|
10134296|NCT04253821|Active Comparator|Non-Forward head posture|
10134297|NCT04253756|No Intervention|18-gauge autogard catheter|Standard of care
10134298|NCT04253756|Experimental|20-gauge BD Nexiva Diffusics|Intervention
10134299|NCT04253561|Experimental|Ipatasertib + Trastuzumab + Pertuzumab|"Ipatasertib will be given from Day 1 to Day 21 in every 28-day cycles. The starting dose is 400 mg orally (PO) QD and may be decreased to 300 mg QD and further to 200 mg QD (dose levels 1, - 1 and -2, respectively).~Pertuzumab will be given IV every 21 days at the dose of 420 mg.~Trastuzumab will be given SC every 21 days at the dose of 600mg. Intravenous (IV) Trastuzumab"
10134300|NCT04253639||Chronic pain patients|
10134301|NCT04253743|Experimental|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households were randomly assigned to receive either: (1) $40 extra in SNAP benefits per eligible child (<5 years) per month (n=1,919); (2) $40 extra in SNAP benefits per eligible child per month plus case management and nutrition education (n=1,919); or (3) only regular monthly SNAP benefit (n=7,467). The first two groups were the treatment arms and the third was the control group.
10134302|NCT04253743|No Intervention|Control Group|The control group received regularly allotted SNAP benefits.
10134303|NCT04253951|Experimental|LUS-monitored management (LUS-m)|In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0). At any time point, they will undergo at least one LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities.
10134304|NCT04253951|Sham Comparator|Standard care management (SC-m)|Sham protocol with LUS performed at the same timepoints. LUS results in the SC-m group will be available only at the time of data analyses for comparison by investigators. They will not be used for clinical decisions.
10134305|NCT04253873|Experimental|Apatinib mesylate + temozolomide|Apatinib mesylate tablets (0-14 days, 500 mg, qd), one week apart, then temozolomide (150mg/m2, 5 days);Every 28 days is a cycle, the drug until the disease progress, the toxicity of intolerable.
10134306|NCT04253847|Experimental|RAMPS group|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
10134307|NCT04253847|Active Comparator|SRPS group|"Standard retrograde pancreatosplenectomy(SRPS) includes several key points. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
10134308|NCT04253938|Other|Education|"Visit 1 - Parent/Caregiver will complete a questionnaire about breastfeeding/formula feeding practices and food insecurity. The questionnaire includes a nutrition history, asking how much formula is consumed, number of times they are breastfed per day, what types and amounts of solid foods are consumed, and if vitamins and/or iron drops are given (including frequency and amount). After the questionnaire, the participant will be asked to demonstrate how they typically prepare infant formula. Finally, the PI or designee will provide a brief education about appropriate feeding practices as recommended by the AAP. This will include appropriate formula preparation methods, use of juice, introduction of cow's milk and solids, as well as basic nutrition information.~Visit 2 - If the family returns for a clinic visit again before the child turns 1 year of age, the same procedures as Visit 1 will be performed, including reinforcement of education."
10134309|NCT04253522|Experimental|Arm 1 (early phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 3 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 5 weeks
10184101|NCT03758144|Active Comparator|study|
10134310|NCT04253522|Experimental|Arm 2 (mid phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 4 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 4 weeks
10134311|NCT04253522|Experimental|Arm 3 (late phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 5 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 3 weeks
10134312|NCT04253197|Other|Morbidly adherent placenta|This arm was given stage according to ultrasound features.
9669121|NCT03919864|Other|CONNECT Intervention Group|CONNECT includes a multi-component e-tool with the following: (1) a brief educational video that seeks to empower and educate caregivers about the importance of self-care and benefits of supportive care resource use; (2) an assessment of multidimensional supportive care needs (e.g., psychological, behavioral, social, financial, educational, spiritual); (3) a tailored resource list that includes local and national resources corresponding to caregivers needs (Table1); and (4) an optional automated referral to a caregiver navigator to facilitate connection to resources.
9669122|NCT03919864|Other|CONTROL Group|Control arm participants will receive a generic (i.e., not tailored) printed list of hospital, community, and national supportive care resources. Control participants will not receive the educational video, complete the E-tool Preference survey, or have an option for an automated referral to a caregiver navigator
9669123|NCT03918278|Experimental|Part 1: MK-0482 Monotherapy|Participants receive escalating doses of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
9669124|NCT03918278|Experimental|Part 1: MK-0482 + Pembrolizumab Combination Therapy|Participants receive escalating doses of MK-0482 via IV infusion + pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
10134313|NCT04253132|Active Comparator|50 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
10134314|NCT04253132|Active Comparator|300 mg daily oral dose|300 mg daily, oral dose of tolfenamic acid
10134315|NCT04253132|Active Comparator|600 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
10134316|NCT04253132|Placebo Comparator|Placebo control - 50 mg daily oral dose|50 mg daily oral placebo control
10134317|NCT04253132|Placebo Comparator|Placebo control - 300 mg daily oral dose|300 mg daily oral placebo control
10134318|NCT04253132|Placebo Comparator|Placebo control - 600 mg daily oral dose|600 mg daily oral placebo control
10134319|NCT04253470||cleavage stage embryo|embryo which is on day 2 or 3
10134320|NCT04253470||blastocyst embryo|embryo which is on day 5
10134321|NCT04253171|Active Comparator|Lithoplasty lesion preparation|Balloon lithoplasty will be used as lesion preparation.
10134322|NCT04253171|Active Comparator|Conventional lesion preparation|Conventional and modified balloons will be used as lesion preparation.
10134323|NCT04253288|Other|Patients with severe radiation toxicity|Patients who received radiotherapy and developed abnormal radiation-induced toxicity
10134324|NCT04253145|Experimental|PM01183 w/ Atezolizumab|Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.) as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every three weeks (q3wk). Following analysis of cohorts, dose levels can be escalated from 2.5mg to 3.2, to a maximum dose of 3.5 mg of PM01183
9669125|NCT03918278|Experimental|Part 2: Cohort A|Participants with metastatic triple negative breast cancer (TNBC) first line treatment (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years) and paclitaxel 90 mg/m^2 via IV infusion until PD or discontinuation.
10134325|NCT04253457|Experimental|Corticosteroid injection|Single injection of 1ml of triamcinolone (40mg/1ml)
10134326|NCT04253457|Active Comparator|Corticosteroid and local anaesthetic injection|Single injection of 1ml of triamcinolone (40mg/1ml) + 1ml 1% Lidocaine
9519601|NCT03285568||Palbociclib|women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
9519602|NCT03285516|Experimental|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
9669126|NCT03918278|Experimental|Part 2: Cohort B|Participants with recurrent non-operable glioblastoma (GBM) current treatment of second line (2L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years).
10134327|NCT04253418|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of target lesion.
10134328|NCT04253431|Experimental|L01|Finger pricking using lancing device with personal lancets
10134329|NCT04253431|Experimental|L02|Finger pricking using lancing device with personal lancets
10134330|NCT04253431|Experimental|L03|Finger pricking using lancing device with personal lancets
10134331|NCT04253431|Experimental|L04|Finger pricking using lancing device with personal lancets
10134332|NCT04253431|Experimental|L05|Finger pricking using lancing device with personal lancets
10134333|NCT04253431|Experimental|L06|Finger pricking using lancing device with personal lancets
10134334|NCT04253431|Experimental|L07|Finger pricking using lancing device with personal lancets
10134335|NCT04253431|Experimental|L08|Finger pricking using lancing device with personal lancets
10134336|NCT04253431|Experimental|L09|Finger pricking using lancing device with personal lancets
10134337|NCT04253431|Experimental|L10|Finger pricking using lancing device with personal lancets
10134338|NCT04253106|Experimental|Unaffected carriers of constitutional mutations|Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
10134339|NCT04253106|Active Comparator|All patients with FOGD|without observation of macroscopic lesions paired with cases (age and sex)
10134340|NCT04253340|Experimental|Bone mineral analyser|"Diagnostic Test: Bone mineral analyser~high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12"
10134341|NCT04253353|Experimental|rosuvastatin and tafamidis fixed sequence|"Period 1: rosuvastatin 10 mg (single oral administration)~Washout~Period 2: tafamidis 61 mg capsule(multiple doses, twice a day) + rosuvastatin 10 mg (single oral administration)"
10134342|NCT04253301|Experimental|Treatment|Subjects will have the InnoVein Valve implanted
10134343|NCT04253405|Active Comparator|High Flow Nasal Cannula (HFNC)|The HFNC (Airvo2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
10134344|NCT04253405|Active Comparator|Non-invasive positive pressure ventilation (NIPPV)|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or an invasive mechanical ventilator with NIPPV mode are accepted. The interface should be an oronasal or full face mask.
10134345|NCT04253210|Experimental|Sexualized images / High photo modification|
10134346|NCT04253210|Experimental|Sexualized images / Low photo modification|
10134347|NCT04253210|Experimental|Nonsexualized images / High photo modification|
10134348|NCT04253210|Experimental|Nonsexualized images / Low photo modification|
10134349|NCT04253210|Experimental|Control images|
10134350|NCT04253223|Experimental|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses
10134351|NCT04253275|Other|Ischemic stroke patients|Patients with ischemic stroke diagnosed on clinical presentation and cerebral imaging
10134352|NCT04253275|Other|hemorragic stroke patients|Patients with hemorragic stroke diagnosed on clinical presentation and cerebral imaging
10134353|NCT04253275|Other|healthy controls|Stroke-free
10134354|NCT04253366|Other|Single arm|All patients perform standard breast screening and also MammoWave exam.
10134355|NCT04253158|Experimental|Educational standard|The aim of this arm is to increase knowledge about alcohol and other drug use.
10134356|NCT04253158|Experimental|Educational standard and Harm prevention|The aim of this arm is to increase knowledge about alcohol and other drug use and increase intentions for the use of harm prevention strategies.
10134357|NCT04253158|Experimental|Educational standard and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use and shift alcohol-related expectancies.
10134358|NCT04253158|Experimental|Expectancies and Harm prevention|The aim of this arm is shift alcohol-related expectancies and increase intentions to use harm prevention strategies.
10134359|NCT04253158|Experimental|Educational standard and Normative perceptions|The aim of this arm is to increase knowledge about alcohol and other drug use and correct erroneous alcohol-related normative perceptions.
10134360|NCT04253158|Experimental|Normative perceptions and Harm prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions and increase intentions to use harm prevention strategies.
10134361|NCT04253158|Experimental|Educational standard, Normative Perceptions, and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use, correct erroneous alcohol-related normative perceptions, and shift alcohol-related expectancies.
10134362|NCT04253158|Experimental|Normative perceptions, Expectancies, and Harm Prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions, shift alcohol-related expectancies, and increase intentions to use harm prevention strategies.
10134363|NCT04253067|Active Comparator|Active fCO2 laser treatment|Laser probe will be inserted into the vagina. The laser treatment is delivered at 6 points to the vaginal wall. Delivery begins at the most proximal and the wand is retracted by 1 cm and another row of laser treatment is delivered. The number of levels is determined by vaginal length.
10134364|NCT04253067|Sham Comparator|Sham fCO2 laser treatment|Laser probe will be inserted into the vagina. To prevent the delivery of laser energy, the laser will remain in standby mode during the visit. Keeping the laser in standby mode prevents laser exposure. The treatment will appear to be the same as the active treatment. The machine maintains a low humming noise while in standby mode.
10134365|NCT04252989||Children with active myopia treated with ATROPINE eye drops|
9976816|NCT01355341|Experimental|HERBMED PLUS|Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
10134366|NCT04252976|Experimental|Mantra Meditation|8 weeks of mantra meditation with weekly group sessions.
10134367|NCT04252976|Experimental|Mantra Meditation plus Ethical Practice|8 weeks of mantra meditation plus ethical practice with weekly group sessions.
10134368|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises|8 weeks of mantra meditation plus Yoga Exercises with weekly group sessions.
10134369|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises plus Ethical Practice|8 weeks of mantra meditation plus Yoga Exercises plus ethical practice with weekly group sessions.
10134370|NCT04252651||Blood Draw|This study will involve blood draws to test for specific cytokines
10134371|NCT04252859|Experimental|All Participants|One session of [18F]FES PET/CT Imaging
10134372|NCT04252963|Experimental|Mucolase|
10134373|NCT04252963|Placebo Comparator|Placebo|
10134374|NCT04252781|Other|Exhaustive exploration|Exhaustive exploration of newly diagnosed COPD patients (pulmonary pathology and associated comorbidities)
10134375|NCT04252729|Experimental|Psychotherapy|Psychotherapy sessions based on the theoretical line of Psychoanalytic Psychosomatics for 1 year, every 10 days.
10134376|NCT04252729|No Intervention|No psychotherapy|Follow-up according to institutional routine, without psychotherapy sessions.
10134377|NCT04252898|Experimental|Intervention arm|In this arm (site n°1), participants will purchase their products in the restaurant first in a control phase and then in an interventional phase with the Nutri-Score affixed on food products.
10134378|NCT04252898|No Intervention|Control arm|In this arm (site n°2), participants will purchase their products in the restaurant during the whole study without any label affixed on food products.
10134379|NCT04252716||VISTHESIA 1.5|Ophtalmologic surgery supported by Visthesia OVD
10134380|NCT04252716||ProVisc|Ophtalmologic surgery supported by Provisc OVD
10184102|NCT03758144|No Intervention|CONTROL GROUP|
9976817|NCT01355354|Experimental|1|Digoxin
10134381|NCT04253041|Experimental|Control|The control group will be exposed to 15 different appearance-neutral images of interior design, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was most prevalent in the previous image?) regarding characteristics of the last image they were exposed to.
10134382|NCT04253041|Experimental|Fitspiration|Participants assigned to the Fitspiration condition (n=30) will be exposed to 15 different fitspiration images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
10134383|NCT04253041|Experimental|Body Positive|Participants assigned to the Body Positive condition (n=30) will be exposed to 15 different body positive images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
10134384|NCT04252638|Experimental|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment therapy is a well-established treatment for other disorders including depression, anxiety and chronic pain, but has not been thoroughly investigated for insomnia. The therapy consists of mindfulness, acceptance, identification of personal life values and committed action. In addition, patients in this group will receive sleep restriction, a behavioral therapy component of cognitive behavioral therapy for insomnia. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
10134385|NCT04252638|Active Comparator|Cognitive Behavioral Therapy including Sleep Restriction|The control intervention is Cognitive Behavioral Therapy for insomnia (CBT-I). This is the first line treatment for adults with chronic insomnia. The therapy consists of education, relaxation, and behavioral therapy, including sleep restriction. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
10134386|NCT04252677|Active Comparator|Obesity Prevention Only|"Three topics to improve adolescents' obesogenic behaviors will be addressed in the intervention:~Health information:~• Factual information about healthy eating and activity (PA) including diet and PA recommendations, physical and health effects of prevention behaviors, risk perception for obesity-related chronic illnesses, compensatory beliefs about obesogenic behaviors~Motivation:~Personal: Create positive attitudes toward engagement in healthy eating and PA~Social: Enlisting social support to increase healthy eating and PA~Social: Identification of community resources that promote and support healthy eating and PA~Behavioral Skills~Tips for engaging in prevention behaviors and avoiding risk behaviors in the context of existing barriers~Skills for social situations around behaviors~Skills for making behavior part of routine~Build autonomy, self-efficacy and model good health decision-making for health behaviors"
10134387|NCT04252677|Experimental|Health Literacy and Obesity Prevention|"Obesity prevention and health literacy (HL).~Health Literacy~Functional HL: skills for reading/understanding nutrition labels and medication instructions.~Interactive HL: verbal skills for interacting with others on health issues.~Critical HL: connections between advocacy and health~Media HL: skills for accessing and identifying reliable source of media.~Health information:~• Factual information about healthy eating and activity (PA)~Motivation:~Create positive attitudes toward engagement in healthy eating and PA~Enlisting social support to increase healthy eating and PA~Identification of community resources that promote and support healthy eating and PA~Behavioral Skills~Tips for engaging in prevention behaviors and avoiding risk behaviors~Skills for social situations around behaviors~Skills for making behavior part of routine~Build autonomy, self-efficacy and good health decision-making for health behaviors"
10134388|NCT04252664|Experimental|Remdesivir group|active remdesivir
10134389|NCT04252664|Placebo Comparator|Control group|Placebos matched remdesivir
10134390|NCT04252794|Experimental|Patients who undergo GIM|If inclusion criteria are met, after randomisation, these group of patients will undergo splenic artery ligation (graft inflow modulation)
10134391|NCT04252794|Active Comparator|No splenic artery ligation|If inclusion criteria are met, after randomisation, these group of patients will not undergo splenic artery ligation (graft inflow modulation)
10134392|NCT04252820|No Intervention|Control|No prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer and zero-heat-flux temperature sensor will be used to measure the temperature throughout the perioperative period.
10134393|NCT04252820|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
10134394|NCT04252820|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
10134395|NCT04252820|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
10134396|NCT04252599||Control group|
10134397|NCT04252599||Multiple sclerosis group|
10134398|NCT04252599||Multiple sclerosis trunk impairment|
9976818|NCT01355354|Experimental|2|Fostamatinib
10134399|NCT04252768|Experimental|Eftilagimod alpha + Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15 and 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
10187684|NCT03723746|Experimental|Cohort 8 (Optional):Antibiotic+Laxative+Dose 2/Placebo(Part 3)|Participants may receive pretreatment with an oral antibiotic and oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 8 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
9976819|NCT01355367|Experimental|Arm 1|
9976820|NCT01355380||Group 1|Drug (incl. Placebo)
9976821|NCT01355432||Propofol|
10134400|NCT04252807|Experimental|Intervention arm|"Distressed mothers randomized to intervention arm will receive a common elements based integrated intervention that combines evidence based elements from packages of care addressing early stimulation, responsive feeding and perinatal depression. The integrated intervention is expected to a) improve mother psychological distress, b) improve family support, c) improve child development and d) promote mother-infant interaction.~The participants will receive 15 monthly sessions at home by lay health workers. First three sessions will be delivered to the participants in the third trimester of pregnancy, followed by 12 monthly sessions afterwards."
10134401|NCT04252807|Active Comparator|Treatment as Usual (TAU)|The participants in the control arm will receive the routine monthly visits by the trained Lady Health Workers (LHWs) of their respective areas.
10134402|NCT04252755|Other|EEG Neurofeedback|Within-subjects sessions of EEG neurofeedback
10134403|NCT04252833|Experimental|CT-044 600 mg|The dose to be utilized for the evaluation of food effect will be CT-044 600 mg single dose.
10134404|NCT04253028|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after bariatric surgery (this includes: Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Gastric Plication and Duodenal Switch).
10134405|NCT04252560||Colorectal|30 patients operated for colorectal cancer
10134406|NCT04252560||HIPEC|15 patients operated with CRS+HIPEC for peritoneal carcinomatosis
10134407|NCT04252911||Anaesthetised patients|50 patients undergoing robotic surgeries under general anesthesia
10134408|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 0.5 mg/kg|HAM8101 (Adrecizumab) : 0.5 mg/kg
10134409|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 2 mg/kg|HAM8101 (Adrecizumab) : 2 mg/kg
10134410|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 8 mg/kg|HAM8101 (Adrecizumab) : 8 mg/kg
10134411|NCT04252924||students|medical student, dental medicine student, pharmacy student, nursing student, physiotherapy student, dietetics student, kinesiology student, biomedical laboratory techniques student, biomolecular science student, psychology student, economy student, student of maritime sciences
10134412|NCT04252885|Experimental|Group A-Standard treatment+lopinavir/ritonavir|In group A, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days).
10134413|NCT04252885|Active Comparator|Group B-Standard treatment+arbidol|In group B, 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days).
10134414|NCT04252885|No Intervention|Group C-Standard treatment|In group C, 25 cases are only given ordinary treatment.
10134415|NCT04252703|Active Comparator|Minimalist|The 'Minimalist' strategy is PCI treatment of the culprit lesion only. Other coronary stenoses are to be managed medically. It is recognized that there may be multiple culprit lesions in such patients, though there are no data on how frequently this might be expected. Operators may elect to treat multiple putative culprit lesions in this case.
10134416|NCT04252703|Experimental|More complete|The 'More complete' strategy is PCI of the culprit lesion and fractional flow reserve (FFR)- or instantaneous wave-free ratio (iFR)-guided treatment of other angiographically significant (> 50% diameter) stenoses amenable to coronary stenting in vessels with reference diameters ≥2.5mm. Physiological assessment is strongly encouraged but not mandatory for lesions of ≥90% angiographic stenosis. PCI of chronic total occlusions will not be attempted as part of the study.
10134417|NCT04252586|Experimental|GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).
10134418|NCT04252872|Experimental|Sequence A|"Period 1 : HCP0605+HGP1405~Period 2 : HCP1401"
10134419|NCT04252872|Experimental|Sequence B|"Period 1 : HCP1401~Period 2 : HCP0605+HGP1405"
10134420|NCT04252417|Active Comparator|Patients with hepatic impaired function|8 patients with hepatic impairment of moderate Child Pugh category
10134421|NCT04252417|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired hepatic function patients
10134422|NCT04252365|Experimental|arm 1|"Patients with PD-L1 high expression (TPS≥50%) receive Sintilimab injection 200mg i.v. on day 1 every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.~Patients with PD-L1 low or negative expression (TPS<50%) receive Sintilimab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Sintilimab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
10134423|NCT04252365|Active Comparator|arm 2|"Patients with PD-L1 high expression (TPS≥50%) receive Pembrolizumab injection 200mg i.v. on day 1once every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.~Patients with PD-L1 low or negative expression (TPS<50%) receive Pembrolizumab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Pembrolizumab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
9976822|NCT01355445|Active Comparator|Vincristine / Irinotecan|Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV
10134424|NCT04252456|Other|standard chemotherapy for advanced colorectal cancer|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.
10134425|NCT04252352|Active Comparator|Ablative fractional CO2 laser resurfacing|One fractional CO2 laser treatment are performed of acne scars on one side of the face
10134426|NCT04252352|Active Comparator|Radio-frequency microneedling|One radio-frequency microneedling treatment are performed of acne scars on one side of the face
10134427|NCT04252508|Experimental|With animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
10134428|NCT04252508|No Intervention|Standard route|"The information about the surgery will be given by the surgeon during the consultation.~Those about anaesthesia will be delivered by anaesthesiologist during the anaesthetic consultation."
10134429|NCT04252469|Experimental|intervention|receiving oral care with 20mL of 0.12% CHX by medicine cup, gargling 30 seconds.
10134430|NCT04252469|No Intervention|Control|Standardized care
10134431|NCT04252430|Active Comparator|Patients with renal impaired function|6 patients with mild renal impaired function, 6 patients with moderate renal impaired function and 6 patients with severe ranal impaired function
10134432|NCT04252430|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired renal function patients
10134433|NCT04252482|Experimental|cpap|usage cpap 3month
10134434|NCT04252482|No Intervention|Usual care|Usual care 3month
10134435|NCT04252495|Experimental|Subjects with moderate hepatic impairment (Group 1)|
10134436|NCT04252495|Experimental|Healthy subjects (Group 2)|
10134437|NCT04252443|Other|Nurse|The research population consisted of 190 nurses working in a university hospital. Because all of the nurses in the research population could not be reached, a sample was selected using a simple random sampling method. One hundred twenty-seven nurses were interviewed in the research population, with a 95% confidence interval and a 5% sampling error.
10184103|NCT03758131|Experimental|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. Mi is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
10184104|NCT03758131|Active Comparator|Motivational Interviewing|In the Motivational Interviewing (MI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
10184105|NCT03758131|Placebo Comparator|Waitlist Control|Those dyads randomized to the Waitlist Control (WC) condition willl be offered teh PMI intervention at month 2 post-intervention for the PMI arm.
10184106|NCT03758118|Active Comparator|NAION patients OS-Citicoline treated|In a group of patients with NAION, OS-Citicoline will be administered (500 mg/day) for 6 months followed by three months of suspension
10184107|NCT03758118|No Intervention|NAION patients untreated|In one group of patients with NAION no type of treatment will be performed during 9 months of observation
10184108|NCT03758105|Experimental|Usual care and tDCS (Arm A)|Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
10184109|NCT03758105|Active Comparator|Usual care without tDCS (Arm B)|Arm B patient receives usual care: medication management and psychotherapy.
10184110|NCT03758079|Active Comparator|Doxepin|10 mg Doxepin daily for 4 weeks
10184111|NCT03758079|Active Comparator|Gabapentin|Gabapentin 100mg after each dialysis session
10184112|NCT03758066|Other|PlusCare|Patients and case managers who work with them will be given access to a web-/mobile-based application, PlusCare, to support various case management activities for one year.
10184113|NCT03758053||Individuals with alcohol use disorder + ACE|Individuals with AUD and varying levels of adverse childhood experiences (ACE)
10184114|NCT03758053||Healthy controls|Healthy individuals without AUD
10184115|NCT03758053||Individuals with alcohol use disorder, no ACE|Individuals with AUD and no adverse childhood experiences (ACE)
10184116|NCT03758040|Experimental|Slips on Turns|Slips administered during walking on a curved paths of radii 1.0, or 2.0 meters in early, middle or late stance to the inside or outside foot.
10184117|NCT03758040|Experimental|Slips on Slopes|Slips administered during walking on sloped ground of 5.0 or 10.0 degrees mediolaterally or anteroposteriorly, or flat ground, in early middle or late stance. For mediolateral slopes, slips will be administered to the uphill or downhill foot.
10184118|NCT03758027|Experimental|CARESS|"The proposed intervention for this study has three stages: communicate alternatively (CA), release endorphins (RE), and self-soothe (SS) (CARESS)~CARESS is a combined skill of three activities. Each section is timed and has specific activities:~CA - will last eight (8) minutes, and will be expression of emotion with drawing with crayons.~RE - will last six (6) minutes, and will be a butterfly hug with a blanket. SS - will last six (6) minutes, and will be a pre-recorded music selection."
10184119|NCT03758027|Active Comparator|ISOMETRIC|This is a one time five-minute isometric circuit involving contracting muscles in different parts of the body. In order to be equivalent in time spent with the experimental intervention, this circuit will be performed three times with a five-minute break between each instance
10184120|NCT03758014|Experimental|Chlorogenic Acid for Injection|3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
10184121|NCT03758014|Active Comparator|Lomustine|110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles
10184122|NCT03758001|Experimental|IBI101|IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.
10184123|NCT03758001|Experimental|IBI101 in combination with Sintilimab|"IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.~Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each."
10184124|NCT03757975||TAH|patients before and after total abdominal hysterectomy (TAH)
10184125|NCT03757975||TLH|patients before and after total laparoscopic hysterectomy (TLH)
10184126|NCT03757975||TVH|patients before and after total vaginal hysterectomy (TVH)
10184127|NCT03757975||SAH|patients before and after abdominal supracervical hysterectomy (SAH)
10184128|NCT03757975||SLH|patients before and after supracervical laparoscopic hysterectomy (SLH)
10184129|NCT03757962|Experimental|Dietary intervention|
10184130|NCT03757936|Experimental|HLX04+HLX10|HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
10184131|NCT03757923|Experimental|metformin|TAB METFORMIN 500mg TDS
10184132|NCT03757923|Experimental|pioglitazone|TAB PIOGLITAZONE 30 mg OD
10134438|NCT04252222|Experimental|VL3|Tracheal intubation with VL3 videolaryngoscope
10134439|NCT04252196|Experimental|Device Usability Study|Usability evaluators of medical device (Healthy volunteers).
10134440|NCT04252547|Experimental|Grup 1|"-During the Procedure Group 1 The preprocedural measurements(weight, heart rate and oxygen saturation ) will be applied to the infants in Group 1 before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother.~During the second feeding hour, his/her heart rate and oxygen saturation will begin to be recorded ten minutes before the feeding hour. The data will be recorded for ten minutes and then the infant will be taken out of the incubator and weight is measured only in his/her clean diaper. He/she will be handed over to the mother to breastfeed."
10134441|NCT04252547|Experimental|Grup 2|"- During the Procedure Group 2 The preprocedural measurements will be applied to the infants in Group 2 before the first feeding hour when they are included in the study and then they will be breastfed by their mothers.~The preprocedural measurements (weight, heart rate and oxygen saturation) will be applied to the infant during the second feeding hour and then he/she will be held on his/her mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother."
10134442|NCT04252248|Experimental|Stratum 1|Patients having received standard, definitive chemoradiotherapy according to current, national guidelines with curative intent and being at high risk for disease recurrence (patients are considered at high risk if they display a positive nodal status of their cancer (anogenital HPV-induced tumor) or if the tumor is locally advanced and/or if they display a positive nodal status with extracapsular extension (head and neck HPV-induced tumor). Study therapy (as additional therapy to standard chemoradiation) will start after a time interval of 6-8 weeks after finishing chemoradiotherapy
10134443|NCT04252248|Experimental|Stratum 2|"Patients with non-curative and progressive disease having received all standard, national approved systemic therapies (according to current, national guidelines with regard to the specific tumor entity), and/or presently not eligible for a respective therapy, and/or refused respective therapy. Study treatment thereby represents a potential palliative, last-line systemic therapy option (late salvage)."
10134444|NCT04252326|Active Comparator|Doctor|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
10134445|NCT04252326|Active Comparator|Nurse|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
10134446|NCT04252326|Active Comparator|Dentist|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
10134447|NCT04252131|Experimental|Cassia seed|oral administration of Cassia seed (3.0g), once/day for 12 weeks
10134448|NCT04252131|Placebo Comparator|Cassia seed placebo|oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks
10134449|NCT04252157|Experimental|kinesiotaping|Kinesotape will be apply with suitable tension and necessery region.
10134450|NCT04252157|Placebo Comparator|plesebo taping|Tape will be appy with randomly region without tension.
10134451|NCT04252157|Other|control|Nothing will be applied
10134452|NCT04252209|Experimental|patients with sjogren's received natural mixture|"The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
10134453|NCT04252209|Active Comparator|patients with sjogren's recievrd CMC|"the control is a moisturizing gel containing 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
10134454|NCT04252079|Other|We compare different endovascular techniques as an alternative|We compare different endovascular techniques as an alternative to surgical reconstruction to repair JAAS regarding ; success rates, 30-day mortality, endoleak events secondary intervention rates
10134455|NCT04252378|Experimental|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and external intercostal muscle near 5th rib.
10134456|NCT04252378|Active Comparator|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
10134457|NCT04252534|Active Comparator|Repetitive electromagnetic stimulation|Group 1 consists of 20 RP patients (40 eyes) who received combined rEMS with PRP. In this group, patients received rEMS for 30 minutes before subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
10134458|NCT04252534|Active Comparator|Platelet rich plasma|Group 2 consists of 20 RP patients (40 eyes). In this group, patients received only subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
10134459|NCT04252534|No Intervention|Natural course|Group 3 consists of 20 RP patients (40 eyes). Patients in this group did not accept any interventional application and were only followed up. The
10134460|NCT04252053|Experimental|Supervised Pilates-Based Core Stability Training Group|In order to detect the effects of pilates-based core stabilization training (PBCST) on isokinetic knee strength and postural sways, individuals with MS will receive pilates-based core stabilization training for 8 weeks and 2 days a week. One educational session will perform to teach basic principles of pilates based training. Individuals in this group will receive treatment at the clinic by physiotherapist supervision. All sessions will be individualized (not group training).
10184133|NCT03757910|Experimental|DPPOS Exposed to Metformin|DPPOS participants with exposure to metformin will be scanned with 18F-MK-6240 and 11C-PIB.
10184134|NCT03757910|Active Comparator|DPPOS Exposed to Placebo|DPPOS participants with no exposure to metformin but only placebo will be scanned with 18F-MK-6240 and 11C-PIB.
10134461|NCT04252053|Active Comparator|Home exercise group|The home exercise group will perform the same PBCST exercises at home during the same period (8 weeks, 2 days a week) as the brochures prepared for them. Individuals in this group will receive one educational session which includes basic principles of pilates and one session which includes two-week exercise program. Participants will be invited to the clinic every two weeks to ensure the progression of the exercises and the exercise program will be updated.
10134462|NCT04252391|Active Comparator|Standard care|Standard care will consist of standard physical therapy care which may include the following: cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, dry needling with or without electrical trigger point dry needling, soft tissue release and prescribed therapeutic exercises .
10134463|NCT04252391|Active Comparator|standard care with perineural electrical dry needling.|This arm will consist of standard care with perineural electrical dry needling, using a high frequency stimulation placed near the nerve, differing from addressing muscular trigger points. For example, a dry needle placed in the semispinalis capitus muscle along the greater occipital nerve pathway, stimulated at 80 Hz.
10134464|NCT04252118|Experimental|MSCs Treatment Group|Conventional treatment plus MSCs Participants will receive conventional treatment plus 3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
10134465|NCT04252118|No Intervention|Conventional Control Group|Without MSCs Therapy but conventional treatment should be received.
10134466|NCT04252274|Experimental|Darunavir, Cobicistat and conventional treatments|After randomization, subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments.
10134467|NCT04252274|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without darunavir and cobicistat.
10134468|NCT04252066||Cohort 1|Cohort 1 will be pregnant and/or breastfeeding patients who have Fabry Disease, and have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
10134469|NCT04252066||Cohort 2|Cohort 2 will be pregnant and/or breastfeeding patients who have Fabry Disease, who were not exposed to migalastat during pregnancy and/or breastfeeding.
10134470|NCT04252300|Experimental|Healthy subjects_Period 1|Healthy adults from USA receive a single dose of rosuvastatin (interaction drug) in Period 1.
10134471|NCT04252300|Experimental|Healthy subjects_Period 2|The healthy adults from Period 1 receive both rosuvastatin + BAY1817080 in Period 2.
10134472|NCT04252313|No Intervention|Group A|This arm represents the control group. They will be undergoing the circumcision without any music, with the established standard for analgesia [EMLA+Sucrose+Ring Block]
10134473|NCT04252313|Experimental|Group B: Music|"In addition to the standard analgesia as explained for group A, Music will be played from the Baby Go to Sleep playlist which includes nursery rhymes and lullabies metonymized to an actual human heartbeat (Houser, 1994). Music will start after the baby settles on the board and before the surgeon starts the procedure."
10134474|NCT04252261|Experimental|sulforaphane|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
10134475|NCT04252261|Placebo Comparator|placebo|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
10134476|NCT04252521|Active Comparator|metoclopramide+ dexketoprofen trometamol|10 mg metoclopramide+ 50 mg dexketoprofen trometamol
10134477|NCT04252521|Experimental|metoclopramide|10 mg metoclopramide
10134478|NCT04252521|Experimental|dexketoprofen trometamol|50 mg dexketoprofen trometamol
10134479|NCT04251910|Active Comparator|Cohort 1- 30 Micrograms|Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo
10134480|NCT04251910|Active Comparator|Cohort 2- 60 Micrograms|"Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo.~Additional 20 subjects receive 60 Micrograms or placebo."
10134481|NCT04251910|Active Comparator|Cohort 3- 90 Micrograms|Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo
10134482|NCT04251910|Active Comparator|Part B Cohort|Part B cohort consists 46 subjects receiving 40 Micrograms or placebo
10134483|NCT04251858|Experimental|Athletes with oral problems|Athletes with periodontal diseases or gingivitis
10134484|NCT04251858|No Intervention|Athletes without oral problems|Athletes diagnosed without oral problems
10134485|NCT04252001|Experimental|Group YT|Group receives YESS! game and transition-toolkit
10134486|NCT04252001|Experimental|Group GT|Group receives control game and transition-toolkit
10134487|NCT04252001|Experimental|Group T|Group receives transition-toolkit
10134488|NCT04252001|No Intervention|Group O|Group receives usual transition care
10134489|NCT04251923|Experimental|vagianl prolapse surgery accompanied with TVT sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need. Patient who falls in Group will undergo mid urethral sling with tension free vaginal tape (TVT) using TVT mid urethral sling.
10134490|NCT04251923|No Intervention|vaginal prolapse surgery not accompanied with sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need.
10134491|NCT04251962|Experimental|Bupivacaine|Epidural solution containing 0.1% bupivaacaine in normal saline
10134492|NCT04251962|Experimental|Bupivacaine + Fentanyl|Epidural solution containing 0.1% bupivacaine and 3 mcg/ml of fentanyl in normal saline
10134493|NCT04251975|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
10134494|NCT04251975|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
10134495|NCT04252170|Experimental|Feasibility study, Stroke Survivors|BAC feasibility study at PowerBack, Piscataway NJ, with stroke patients.
10184135|NCT03757897|Experimental|Dexmedetomidine induced sleep patients|All subjects will be measured for CSF volume, diffusion parameters and mechanical 'stiffness' of the brain during wakefulness and during sleep-induced with dexmedetomidine (DEXM).
10184136|NCT03757884|Experimental|Virtual Pod|Mindfulness breathing, privacy screen, noise cancelling headphones, diagnostic checklist, diagnostic support on-line application
10134496|NCT04251624|Experimental|Goal Management Therapy|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length. Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.
10134497|NCT04251624|Active Comparator|Psychosocial Education|Psychosocial education will provide educational materials (e.g., brain function, neuroplasticity) and lifestyle interventions (e.g., sleep hygiene, stress, exercise). They will be matched for length and for amount of facilitator contact with the Goal Management Therapy sessions. Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length. Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.
10134498|NCT04251871|Experimental|Conventional medicines and TCMs granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: one bag, p.o, bid, for 14 days."
10134499|NCT04251871|Active Comparator|Conventional medicines|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
10134500|NCT04251598|Experimental|Education group|"Only I am Protecting my Child From the Sun program was given."
10134501|NCT04251598|Experimental|Education + SMS group|"The I am Protecting my Child From the Sun program was given. After the program, an SMS message was sent on Wednesday and Saturday for 12 weeks. A total of 25 SMS messages were sent to remind the subject and applications."
10134502|NCT04251598|No Intervention|Control group|"No attempt was made by the researcher during the study. Only data collection was carried out. At the end of the research, the I am Protecting my Child From the Sun program was given.."
10134503|NCT04251767|Experimental|Observational group|5u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
10134504|NCT04251767|Placebo Comparator|Control group|5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
10134505|NCT04251793||Er:YAG laser-assisted debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with the aid of the laser treatment two years ago at the Graduate Periodontics Clinic at University of Michigan.
10134506|NCT04251793||Standard mechanical debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with dental scalers two years ago at the Graduate Periodontics Clinic at University of Michigan.
10134507|NCT04251650||low severity|patient with periodontitis stage I and II
10134508|NCT04251650||high severity|patient with periodontitis stage III and IV
10134509|NCT04251780|Experimental|Hyperaldosteronism treatment|Patients with Hyperaldosteronism will either be treated by adrenalectomy (adrenal adenoma) or receive medical treatment (Spironolactone/Eplerenone; bilateral hyperplasia) as indicated by the Endocrinological Guideline (J Clin Endocrinol Metab, May 2016). Before and after intervention tissue sodium and tissue potassium amount will be assessed by MRI.
10134510|NCT04251819|Placebo Comparator|Placebo|Participants randomized to this arm will receive Placebo.
10134511|NCT04251819|Experimental|Baclofen 5mg|Participants randomized to this arm will receive 5 mg of Baclofen.
10134512|NCT04251819|Experimental|Baclofen 10mg|Participants randomized to this arm will receive 10 mg of Baclofen.
10134513|NCT04251741|Active Comparator|Usual care group|Based on a secondary randomization schedule patients are treated with etanercept or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
10134514|NCT04251741|Experimental|'Drug concentration guided' group|Patients with a concentration <1.0 mg/L switch to etanercept and patients with a concentration ≥ 1.0 start a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
10134515|NCT04251845|Active Comparator|Trial group|Intervention : Topical Melatonin(3%) at dosage of 15 mg once daily
10134516|NCT04251845|Placebo Comparator|Control Group|Intervention : Placebo once daily
10134517|NCT04251832|Experimental|Ultrasound guided percutaneous lavage with STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using sodium thiosulfate 25 %: a volume of 1 mL of sodium thiosulfate will be prepared in a syringe and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. At the end of the procedure 1 mL (250 mg) of thiosulfate will be injected inside the calcific deposit. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.~Only a single procedure will be performed and the outcomes measured after 1 week, 1 month and 3 months."
9519603|NCT03285503|Experimental|400 mg group|Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).
10184137|NCT03757871|Experimental|Laser Stimulation|laser pen acupuncture projecting an infrared beam with a wavelength of 905nm bilaterally for 30 seconds on each point.
10184138|NCT03757871|Placebo Comparator|Placebo|The placebo group will have an application of the pen according to the same extinguished laser criteria.
10184139|NCT03757858|Experimental|HT+ACT|
10184140|NCT03757858|Experimental|HT+ACT+PD-1|
10184141|NCT03757858|Experimental|HT+ACT+CT|
10184142|NCT03757858|Active Comparator|HT+CT|
10184143|NCT03757819|Experimental|Before Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
9519604|NCT03285464|Active Comparator|Hip|This group will perform a known hip strengthening program
10134518|NCT04251832|Active Comparator|Ultrasound guided percutaneous lavage without STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using of saline solution and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.~Only a single procedure will be performed and the outcomes measured after 1week, 1month and 3months"
10134519|NCT04251637||adult patients scheduled for thoracic pulmonary|"Adult patients scheduled in Louis Pradel hospital operating theater (Lyon University Hospital) for elective Lung surgery (lobectomy, bilobectomy or pneumonectomy); by thoracotomy and / or thoracoscopy.~- Having stated their non opposition to be part of this protocol"
10134520|NCT04251611|No Intervention|Control group|The usual care in patients with myocardial ischemia without other cardiovascular risk factors (CVFR) will be to attend one visit per year with doctor and nurse of the local health center. In this visit, it will be done a blood test and an electrocardiogram. Blood pressure, weight, body mass index, abdominal circumference will be measured and, in case of detecting enolic habit, smoking or sedentary lifestyle, generic advice will be done. If the patient, apart from myocardial ischemia, presents diabetes mellitus type 2, 3-4 follow-up visits per year will be recommended and will be increased according to specific needs. In case of presenting hypertension, will be recommended 2 visits with the nurse and one visit with the doctor per year and will be increased according to specific needs. In addition, in this case the blood pressure is checked every 6 months. During all visits, professionals will reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
10134521|NCT04251611|Experimental|Intervention group|"Patient will go to health center to visit the cardiac rehabilitation (CR) reference team, which is composed for a doctor and a nurse. This team will establish the guideline of action in the maintenance and/or increase in the physical exercise practice, in function of the resources of each zone and the preferences and motivations of the patient. They also reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.~At the end of the visit, control visit will be given with the CR reference team at 3, 6 and 12 months after completing the supervised physical exercise program of phase II of the CRP. In case of detecting specific needs for the patient and/or relapses, the team will consult with the appropriate professional (cardiologist, cardiology nurse, physiotherapist, rehabilitator, nutritionist and/or psychologist). At the same time, the patient will be informed of the possibility of re-evaluating the CR reference team."
10134522|NCT04251520|No Intervention|Control Group|Standard care by Palliative Medicine physician
10134523|NCT04251520|Experimental|Intervention Group A|Standard care by Palliative medicine physician plus pharmacist review of medications
10134524|NCT04251520|Experimental|Intervention Group B|Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
10134525|NCT04251728|Experimental|Exercise plus AMPS group (AMPS-G)|Physical exercise and automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold, performed two times a week for 12 weeks.
10134526|NCT04251728|Sham Comparator|Exercise plus SHAM group (Exercise-G)|Physical exercise and simulated automated mechanical peripheral stimulation (AMPS) with intensity at the sensory threshold performed two times a week for 12 weeks.
10134527|NCT04251936|Experimental|Exercise training plus smoking cessation group program|
10134528|NCT04251936|Active Comparator|Smoking cessation group program|
10134529|NCT04251559|Active Comparator|patients with gestational diabetes mellitus|study group
10134530|NCT04251559|Placebo Comparator|healthy participants|control group
10134531|NCT04251988|No Intervention|Standard of Care (No VR) Randomization|Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.
10134532|NCT04251988|Experimental|VR Randomization|Patients will receive virtual reality in addition to standard of care.
10134533|NCT04251572|Experimental|HCV reinfection after DAA therapy in PWID|Hepatitis C virus reinfection after directly acting antiviral treatment in persons who inject drugs. DAA therapy is an inclusion criteria, not an intervention.
10134534|NCT04251494||Phenylketonuria (PKU) participants|"During their outpatient clinic appointment, participants will:~Undergo routine height and weight measurements and blood tests. A full patient history will be taken, including a record of cardiovascular disease within the family. Blood samples will be collected, including phenylalanine, lipids, vitamin B12 and related biomarkers.~Complete a 14-item diet history questionnaire, and fill in a 3 day diet diary before they arrive at their outpatient clinic appointment, which will be collected after the participant signs the informed written consent form.~Undergo assessment of carotid Intima-media thickness (CIMT), pulse wave velocity (PWV), ankle brachial pressure index (ABPI) and systolic and diastolic blood pressure."
10134535|NCT04251494||Age and gender matched reference controls|Only Phenylketonuria (PKU) patients will be studied. Controls are generated from the literature. Reference CIMT values exist for a healthy population based on age and gender (Engelen et al., 2013), eliminating the need to assess age- and gender-matched controls. The study would otherwise require performing blood tests and vascular assessments on healthy individuals, generating a risk of harm and a possible incidental finding. It would be inconvenient for controls because they would need to travel to hospital and undergo invasive venepuncture.
10134536|NCT04251312|Experimental|Preoperative dental hygiene education|Patients who are scheduled for elective esophageal or lung resections who consent to participate will undergo oral hygiene education and be given an oral hygiene packet. An oral hygiene assessment using the Plaque Assessment tool will be conducted in the clinic. A Dysphagia Screening Tool questionnaire will also be administered. Patients who screen positive for dysphagia will be referred to Speech Pathology for evaluation but for the study purposes, the only data collected from the evaluation will be whether or not the participant received this intervention. A repeat dental exam will occur on the day of surgery. Patients will be followed for 30 days post operatively.
10134537|NCT04251247||Acute aortic dissection|Patients with a diagnosis of acute aortic dissection.
9519605|NCT03285464|Experimental|Trunk|This group will use the trunk as a lever to strengthen the hip
10134538|NCT04251247||Acute pulmonary embolism|Patients with a diagnosis of acute pulmonary embolism
10134539|NCT04251247||Non-cardiac chest pain|Patients with non-cardiac chest pain
10134540|NCT04251169|Experimental|Pembrolizumab + Paclitaxel|Pembrolizumab 200 mg every 3 weeks (on D1 of each 21-day cycle, beginning in Cycle 1) in combination with paclitaxel 80 mg/m2 administered at days 1, 8, 15 of each 21-day cycle beginning at cycle 2.
10134541|NCT04251299|Experimental|Single Arm|All participants will receive the 10-month mentored, vegetable gardening intervention
10134542|NCT04251273|Experimental|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
10134543|NCT04251273|Other|Assessment only Control|After an initial enrollment message, participants will be contacted periodically to assess e-cigarette use. At the end of the intervention period, they will receive information on how to sign up for This is Quitting if they are interested in the program
10134544|NCT04251260|Experimental|Positioning in flexion|Intervention: Positioning of body in flexion and aligment towards midline with Snuggle up (Philips, USA)
10134545|NCT04251260|No Intervention|Control group|No intervention
10134546|NCT04251429|Experimental|Immediate Intervention Group|SHIFT study team provides coaching to Health and Safety Committee to implement a participatory program for increasing committee effectiveness.
10134547|NCT04251429|Other|Delayed Intervention Group|Active Comparator for 2 years: status quo program remains in place with new ongoing data collection. Then experimental intervention as above.
10134548|NCT04251364|Experimental|Acetazolamide|Oral acetazolamide (250 mg/day) intake for 9 months
10134549|NCT04251364|Experimental|Atorvastatin|Oral atorvastatin (40 mg/day) intake for 9 months
10134550|NCT04251364|Placebo Comparator|Placebo|Oral placebo pill (daily) intake for 9 months
10134551|NCT04251481|Experimental|Optimization of Techniques|To optimize the diffusion MRI methods for assessment of cell viability, metabolism and perfusion in head and neck cancer. There will be 24 subjects enrolled for 2 year duration. Treatment-naïve patients with cervical metastatic lymph nodes (diameter > 10 mm) of HNSCC will be recruited to have one research PET/MR scan (including dMRI) and one dMRI-only scan within three days prior to treatment. These data will be used to optimize the dMRI method and assess the repeatability.
10134552|NCT04251481|Experimental|: Longitudinal Monitoring|To assess the feasibility of using diffusion MRI metrics at early stages of treatment for prediction of treatment response in head and neck cancer patients undergoing standard-of-care chemoradiation therapy. There will be 36 subjects enrolled for 3 year duration. The study will do bi-weekly measurement to monitor tumor response longitudinally. This study will be restricted to treatment-naïve patients who present pathologically confirmed HNSCC with metastatic lymph nodes and who are scheduled to receive standard care of radiation therapy with concurrent chemotherapy. The patients enrolled in this arm of the study will have 4 dMRI scans. The imaging data for each patient will be the proposed dMRI measures at the baseline and their changes at each follow-up time period. DCE-MRI will be included in the baseline scan for tumor delination as in standard-of-care cancer imaging and to compare with the proposed dMRI method.
10134553|NCT04251390||trexo Home intervention|Participants family is renting a trexo Home from trexo. The decision to use the device was separate from this research, and the decision to do research on its use was secondary. The proposed procedures may be modified to adapt to the child and family's interest and needs. Participant will use the trexo Home in their home, school, and community.
10134554|NCT04251403|Experimental|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
10134555|NCT04251325||Basic Life Support Course Participants|The study population includes all Danish citizens who attended a BLS training course certificate from 2016-2018 above the age of 15.
10134556|NCT04251325||Background population|The entire danish population above 15 years whom have not attended a BLS training course certificate from 2016-2018.
10134557|NCT04251455||TMJ disease/disorder characterisation|Patients with the diagnosis disc displacement without reduction (DDwoR), or disc displacement with reduction (DDwR), or osteoarthritis (OA), or chronic inflammatory arthritis (CIA) were designated to TMJ surgery. According to the Swedish national guidelines on TMJ surgery DDwoR, OA, and CIA patients had arthroscopy and DDwR had discectomy.
10134558|NCT04251468|Other|GEPII|All patients who completed the study.
10134559|NCT04251234|Experimental|Healthy controls|"No co-morbid medical or psychiatry diagnoses~No family history of mental illness~No current medication use~Non-smoking"
10134560|NCT04251234|Experimental|Bipolar I disorder|"Clinical diagnosis of Bipolar I disorder~Can be (not required, not exclusionary) taking lithium and/or sodium valproate and/or antidepressants~Can be (not required, not exclusionary) light smokers"
10134561|NCT04251143||Ectasia|Keratoconus, Keratoconus suspects
10134562|NCT04251208||Integrated Care|This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
10134563|NCT04251208||Referral-Based Care|This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
10184144|NCT03757819|Experimental|During Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
10184145|NCT03757806|Experimental|Experimental group|The experimental group will receive the LiFE4D in addition to usual care (e.g., pharmacologic treatment).
10184146|NCT03757806|No Intervention|Control group|The control group will receive usual care only.
10134564|NCT04251104|Experimental|Level of personal relevance of images|This is an exploratory randomized controlled study to compare the effectiveness of three types of autobiographical stimuli, classified according to their level of personal relevance (high, medium and low), in the induction of positive emotions resulting from the retrieval of specific positive autobiographical memories. To this end, the investigators will use three types of images, classified according to their personal relevance: a) personal autobiographical photographs (high personal relevance); b) images of locations related to the participants' lives (medium personal relevance); and c) images from the Internation Affective Picture System (IAPS; low personal relevance).
10134565|NCT04251104|Other|Age (young and older adults comparison)|To analyse any age-related differences in the effectiveness of the use of the three types of images to regulate emotion, the investigators will compare the efficacy of the three categories of pictures (high, medium and low relevance) in inducing positive mood states in a group of young adults (age range: 18-35 years) and a group of older adults (65 years or over).
10134566|NCT04251091|Experimental|ReWalk Soft Exosuit|During this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out an 18 session training protocol.
10134567|NCT04250922|Placebo Comparator|Arm A: SoC + placebo for 2-OHOA|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm A will receive placebo every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance (Adjuvant) Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm A will receive placebo every day during the first 3 weeks of each 28-day cycle and until progression. Patients will continue with Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
10134568|NCT04250922|Experimental|Arm B: SoC + 12 g/day of 2-OHOA|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm B will receive 2-OHOA every day from Day 1 of week 3 to the end of this Phase.~The start of the first cycle during the Maintenance Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.~Subjects in Arm B will receive 2-OHOA during the Maintenance Phase. Patients will continue to be administered with 2-OHOA after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
10134569|NCT04250779|Placebo Comparator|Control Group|In this arm, patients are provided with standard-of-care instructions on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned off.
10134570|NCT04250779|Active Comparator|Treatment Group|In this arm, patients are provided with active guidance from CapMedic device on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned on.
10134571|NCT04250909||Passeo 18 PTA|Previous treatment with uncoated Passeo 18 PTA balloon catheter
10134572|NCT04250909||Passeo-18 Lux DCB|Previous teatment with Passeo-18 Lux DCB
10134573|NCT04250766|Other|Single arm echo-guided uterine biopsy|
10134574|NCT04250896|Other|Control|Control group will receive standard child care in health units plus exposure to EsIAN (Strategy of Integral Attention to Nutrition)
10134575|NCT04250896|Experimental|Intervention|Intervention group will receive SMS messages sent through a cell pone in addition to the control group receive (standard child care in health units plus exposure to EsIAN)
10134576|NCT04250948|Active Comparator|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
10134577|NCT04250948|Experimental|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
10134578|NCT05253521||South Asian Origin|Individuals who identify as having Anglo-Indian, Bangladeshi, Bengali, Bhutanese, Goan, Gujarati, Indian, Jatt, Kashmiri, Maharashtrian, Malayali, Nepali, Pakistani, Punjabi, Sindhi, Sinhalese, Sri Lankan, Tamil, Telugu, or other South Asian origin
10134579|NCT05253521||White Individuals of European Origin|Individuals who identify as having western European, other northern European, southern European, eastern European or other European origin
10134580|NCT05253508|Experimental|Healthy human participants|ring-block anaesthesia with lidocaine in one of the two visits
10134581|NCT05253469||Cryopreserved Aortic Homograft|"Include patients who received CAH for native (NVE) or prosthetic valve endocarditis (PVE).~The CAH are implanted using miniroot procedure. For extended aortic valve infection, aortic root replacement and reconstruction of regional contiguity is the recommended approach. Complicated aortic IE may present with destruction of a large portion of the aortic annulus, annular abscess and colonization of infected foci in contiguous cardiac structures (eg. Aortic root and intervalvular fibrosa).~Use of homograft in first time aortic valve replacement for IE decreased over time (9,4% to 5,6%) and in reoperation (37,5% to 28,5%) in a report from STS database between 2005-2011 (6). Nevertheless, the homograft was used more often in reoperations than in primary interventions (32.2% vs 7.0%, p < 0.0001) in both valve replacements (14,6%) and for root replacements (53,2%) (6)."
10184147|NCT03757793||Reliability of NIRS in DIEP flap surgery|In patients who underwent DIEP flap surgery, monitoring of postoperative tissue oxygen saturation of the flap by use of the FORE-SIGHT Elite monitor will be compared to standard of care physical examination.
10184148|NCT03757780||Pregnant ladies who are caffeine using|ladies who uses caffeine during pregnancy
10184149|NCT03757767|Experimental|Intervention arm|Fasting for 26-hours.
10134582|NCT05253469||Stented/Non stented xenograft|Stented/Non stented xenograft may be inserted using separate or continuos stich with or without teflon pledget. The use of biological valves increased from 57% to 67% for primary the operation during which the use of mechanical valves decreased from 30% to 24%. For reoperations, the use of biologic valves increased from 38% to 52% compared to the warning use of mechanical valves from 20% to 17%. A homograft was used in only 2.5% of valve replacements, while a biological valve was used in 68.7% of the cases. This trend is reversed both in NVE and PVE the aortic root was involved (6). In the presence of peri-annular abscess formation and mitro-aortic discontinuity, conventional stented /non stented xenograft are used in combination with synthetic patch for both NVE and PVE.
10134583|NCT05253469||Mechanical valve prostheses|Mechanical prostheses may be inserted using separate or continuos stich with or without teflon pledget. Prior to 2000, mechanical valves were used in 50% of patients compared to 14% since 2009. Analysis of the STS Database (6) showed that from 2005 to 2011 a progressive shift in favour of biological valves both as the primary operation (NVE) (73%) and in the reoperation (PVE) (27%) compared to mechanical prosthesis. For extended aortic valve infection, aortic root replacement and reconstruction of regional contiguity is the recommended approach. Complicated aortic IE may present with destruction of a large portion of the aortic annulus, annular abscess and colonization of infected foci in contiguous cardiac structures (eg. aortic root and intervalvular fibrosa). In the presence of peri-annular abscess formation and mitro-aortic discontinuity, conventional mechanical prostheses are used in combination with synthetic patch for both NVE and PVE
10134584|NCT05253456|Experimental|intervention group|patients underwent our newly modified technique for hypospadias repair
10134585|NCT05253430||D1 lymph node dissection (LND)|Patients with gastric cancer that underwent curative surgery with gastrectomy and D1 lymph node dissection
10134586|NCT05253430||D2 lymph node dissection (LND)|Patients with gastric cancer that underwent curative surgery with gastrectomy and D2 lymph node dissection
10134587|NCT05253417|Experimental|50 mg CBD|50 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Two capsules to be taken (plus two placebo capsules)
10134588|NCT05253417|Experimental|100 mg CBD|100 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Four capsules to be taken.
10134589|NCT05253417|Placebo Comparator|Placebo|Placebo capsules contain no CBD. Four capsules to be taken as a single oral dose.
10134590|NCT05253391||Patients treated for asthma exacerbation|
10134591|NCT05253365|Experimental|Memory Support System participants|
10134592|NCT05253300|Experimental|Semi Recumbent|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
10134593|NCT05253300|No Intervention|Control|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient has pain, the time when the patients' pain started was recorded, and only analgesic medication was administered to the control group."
10134594|NCT05253261|Experimental|Odontogenic cyst treated by decompression with an appliance.|Cystostomy procedure is carried out with the same day delivery of a decompression appliance fabricated with a fully digital workflow. Enucleation of the cyst is carried out following decompression.
10134595|NCT05253248|Experimental|Healthy adults|"We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days. Supplementation will provide the daily dietary recommendations of micronutrients, as these are established by the Department of Health, on top of the participant's free diet. Supplementation aims to correct any subclinical deficiencies the participants might have particularly those which are common in the general community. In the UK, a typical example is Vitamin D, due to lack of sunshine and selenium (a geochemical) whose content in the UK soil is depleted and therefore intake is often below the recommendations.~Fasted blood and urine samples will be collected before, and again two-to-three days, post-supplementation."
10134596|NCT05253235|Experimental|SAAF Intervention|Parents and youth will receive an online, family-centered intervention consisting of 7 weekly sessions.
10134597|NCT05253235|Other|Control Group|Control group members will receive a book entitled, Parenting for Liberation: A Guide for Raising Black Children
9519606|NCT03285386|Experimental|Priming Exercise|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
9519607|NCT03285386|Active Comparator|Control|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling only.
9519608|NCT03285360|Experimental|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.~Steps:~Isolation: D.M. will make proper isolation for the teeth using cotton rolls.~Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.~Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.~Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
9826061|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
10134598|NCT05253222|Experimental|retrograde imaging by colonic TET|Contrast fluid will be injected through colonic TET in participants with bowel obstruction. Image parameters detected by CT and X-ray fluoroscopy will be evaluated.
10134599|NCT05253209|Experimental|Active|"Patients will receive:~an L-citrulline bolus of 150 mg/kg at the initiation of cardiopulmonary bypass~the addition L-citrulline to maintain a steady state target concentration of approximately 100 μmol/L of L-citrulline during cardiopulmonary bypass~an L-citrulline bolus of 10 mg/kg 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hour continuous L-citrulline infusion or placebo for up to 48 hours post-first dose. The infusion rate will be adjusted (up or down titration of drug infusion) to achieve a target steady state concentration of 100 μmol/L.~Infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever occurs first."
10134600|NCT05253209|Placebo Comparator|Placebo|Plasma Lyte administered to the same schedule as the active treatment arm.
10134601|NCT05253196|Experimental|Use of Foley Catheter Assistive Device|All participants will use Foley Catheter Assistive Device
10134602|NCT05253170|Experimental|Hypofractionation|"For the cumulative total dose of 39-45.9 Gy to the chest wall, a daily dose of 2.5-3.0 Gy is administered 13-17 fractions.~Should be started within 3 months of completion of mastectomy or chemotherapy.~Clinical target volume (CTV) may include regional lymph nodes.~If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines."
10134603|NCT05253170|Active Comparator|Conventional Fractionation|"For the cumulative total dose of 45-50.4 Gy to the chest wall, a daily dose of 1.8-2.0 Gy is administered 23-28 fractions.~Should be started within 3 months of completion of mastectomy or chemotherapy.~Clinical target volume (CTV) may include regional lymph nodes.~If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines."
10134604|NCT05253144|Experimental|Arm A: Prioritise Radiotherapy|Radical radiotherapy to macroscopic tumour and/or to the tumour bed if already excised, plus a wide margin.
10134605|NCT05253144|Experimental|Arm B: Prioritise Surgery|Wide Local Excision (WLE), aiming for complete excision of all MCC, plus a wide margin
10134606|NCT05253118|Experimental|Treatment|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed. And pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
10134607|NCT05253105|Experimental|TAB006 60mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
10134608|NCT05253105|Experimental|TAB006 240mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
10134609|NCT05253105|Experimental|TAB006 600mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
10134610|NCT05253105|Experimental|TAB006 1800mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
10134611|NCT05253105|Experimental|Dose Expansion / TAB006 RP2D and Torpalimab 240mg repeat dose every 21 days up to 2 years|
10134612|NCT05253105|Experimental|Indication Specific / TAB006 RP2D and Torpalimab 240mg repeat dose every 21 days up to 2 years|
10134613|NCT05253092|Other|Virtual mindfulness meditation|
10134614|NCT05253079|Active Comparator|subcostal transversus abdominis plane block group|subcostal transversus abdominis plane block
10134615|NCT05253079|Active Comparator|erector spinae plane block group|erector spinae plane block
10134616|NCT05253066|Experimental|Chidamide group|Chidamide combined with exemestane (+/- goserelin)
10134617|NCT05253066|Active Comparator|chemotherapy group|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
10134618|NCT05253053|Experimental|Arm A: TT-00420 Tablet Monotherapy|TT-00420 tablets will be administered once daily in 21-day cycles. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
9519609|NCT03285360|Active Comparator|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.~Steps:~Preparation: The tooth will be properly cleaned, and the surface will be air-dried.~Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.~Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
9519610|NCT03285347|Experimental|Brain+ Evolution|"Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
9826062|NCT02406027|Placebo Comparator|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
10134619|NCT05253053|Experimental|Arm B: TT-00420 tablet in combination with Atezolizumab Injection (Tecentriq ®)|TT-00420 tablets will be administered once daily in 21-day cycles. Atezolizumab(1200 mg/20 mL) will be administered intravenously on Day 1 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
10134620|NCT05253053|Experimental|Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®)|TT-00420 tablets will be administered once daily in 21-day cycles. Nab-paclitaxel 125 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
10134621|NCT05253040|Experimental|Intervention group|"The experimental group will receive:~Online education modules Online group discussions facilitated by Specialist Physiotherapist"
10134622|NCT05253040|Active Comparator|Control Group|The comparator for this study is usual care pathway. Under the usual care pathway, participants will receive education booklets on exercise by Parkinson's UK.
10184150|NCT03757754|Experimental|HPPH 2.5 mg/m2|HPPH 2.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
10134623|NCT05253014|Active Comparator|lidocaine group|
10134624|NCT05253014|Active Comparator|bupivacaine group|
10134625|NCT05253014|Active Comparator|conservative group|
10134626|NCT05252975|Active Comparator|Supine|Patients undergo supine setup and imaging for radiation planning
10134627|NCT05252975|Experimental|Prone|Patients undergo prone setup and imaging for radiation planning
10134628|NCT05252949|Active Comparator|Study Supplement: OEA|26 subjects will take the supplement (oleoylethanolamide) during the first phase of the study. 200mg will be taken twice a day for the 10-week period in phase one.
10134629|NCT05252949|Placebo Comparator|Control|26 subjects will take the placebo during the first phase of the study (10 weeks).
10134630|NCT05252871|Experimental|Experimental: The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
10134631|NCT05252871|Active Comparator|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
10134632|NCT05252845|Experimental|R21/Matrix-M + DHA-PIP+PQ|The R21/Matrix-M vaccine (IM injection) + co-formulated Dihydroartemisinin/Piperaquine tablets + one single low dose of Primaquine
10134633|NCT05252845|Experimental|R21/Matrix-M only|The R21/Matrix-M vaccine (IM injection) only
10134634|NCT05252845|Active Comparator|DHA-PIP+PQ only|Co-formulated Dihydroartemisinin/Piperaquine tablets + one single low dose of Primaquine
10134635|NCT05252793|Experimental|Diabetes Education Program Based on Health Belief Model|"Experimental: Intervention Patients will be given links to training videos once or twice a week depending on the length of the training module for 6 weeks.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
10134636|NCT05252793|No Intervention|Control|"No intervention will be taken against the patients.~At the 6th week, the Diabetes Patients Health Belief Model scale, the Diabetes Self-Efficacy Scale and the Healthy Lifestyle Scale-II will be administered as an interim measure.~Health Belief Model scale in Diabetes Patients, Self-Efficacy Scale in Diabetes and Healthy Lifestyle Scale-II will be applied to the patients at the 12th week as the last measurement."
10134637|NCT05252780|Experimental|Intervention group|My Body, My Rhythm, My Voice
10134638|NCT05252780|No Intervention|Control group|No intervention
10134639|NCT05252767|Experimental|Cohort A - Patient Engagement Tools|Participants will be enrolled from the a pain management clinic. Participants randomized into the experimental cohort will receive access to a clinic brochure, clinic website, as well as 'My Pain Passport' and 'My Treatment Plan' tools.
10134640|NCT05252767|Sham Comparator|Cohort B - Educational Guide|Participants randomized into the control cohort will receive a brief educational guide on general pain management.
10134641|NCT05252754|Experimental|Oral Tacrolimus + Indomethacin|"Tacrolimus Capsule 1-2 hours prior to the endoscopy~Rectal Indomethacin immediately after ERCP, in high-risk patients"
10134642|NCT05252754|Placebo Comparator|Oral Placebo + Indomethacin|"Placebo Capsule 1-2 hours prior to the endoscopy~Rectal Indomethacin immediately after ERCP, in high-risk patients"
10134643|NCT05252728||Healthy control|
10134644|NCT05252728||Childhood-onset type 1 diabetes|
10134645|NCT05252728||Adult-onset type 1 diabetes|
10134646|NCT05252728||Type 2 diabetes|
10134647|NCT05252715|Experimental|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 20 µg/dose. Primary vaccination at 0, 1 and 2 months of age, respectively. Booster vaccination at 18 months of age.
10134648|NCT05252715|Active Comparator|Meningococcal A and C Polysaccharide Conjugate Vaccine|Meningococcal A and C Polysaccharide Conjugate Vaccine, 20 µg/dose. Primary vaccination at 0, 1 and 2 months of age, respectively.
10134649|NCT05252676||Patients|Patients with ground glass opacity featured lung adenocarcinoma who are candidates for surgery.
10134650|NCT05252663|Experimental|Study group|Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds.
10134651|NCT05252663|Active Comparator|Control group|Percussion, vibration and shaking were used accompanied with postural drainage.
10134652|NCT05252650||regional block|epidural / peripheral nerve block
10134653|NCT05252650||intravenous|intravenous analgesia
10134654|NCT05252637|Experimental|Duplication plus LSC|Laparoscopic duplication of posterior vagina plus mesh placement
10134655|NCT05252637|No Intervention|LSC|Laparoscopic Sacral Colpopexy with mesh placement on posterior vagina
10134656|NCT05252624|Active Comparator|Active Comparator: Henagliflozin|Single 5 mg tablet, administered orally once daily for 6 months
9826063|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
10134657|NCT05252624|Placebo Comparator|Placebo Comparator: Placebo|Single 5 mg tablet, administered orally once daily for 6 months
10134658|NCT05252598|Placebo Comparator|Placebo Arm|9 placebo pills and 1 non-hallucinogenic Chaga (Inonotus obliquus) mushroom powder capsule to mimic the after-taste of active Psilocybin pills (Psilocybe cubensis)
10134659|NCT05252598|Experimental|1mg Psilocybin Arm|9 placebo pills and 1 capsule containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 1mg of psilocybin
10134660|NCT05252598|Experimental|2mg Psilocybin Arm|8 placebo pills and 2 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 2mg of psilocybin
10134661|NCT05252598|Experimental|5mg Psilocybin Arm|5 placebo pills and 5 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 5mg of psilocybin
10134662|NCT05252598|Experimental|8mg Psilocybin Arm|2 placebo pills and 8 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 8mg of psilocybin
10134663|NCT05252598|Experimental|10mg Psilocybin Arm|0 placebo pills and 10 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 10mg of psilocybin
10134664|NCT05252585|Experimental|Everolimus|Participants with confirmed diagnosis of TSC-AML and who fulfil the local (Taiwan) reimbursement criteria of everolimus for TSC-AML treatment
10134665|NCT05252572|Experimental|Treatment of CLL1-positive Hematological Malignancies|Administration of CLL1 CAR T-cells A dose levels of 2-8*10E6/kg are administrated for each subject.
10134666|NCT05252546|Experimental|pyrotinib alone, then pyrotinib + Montmorillonite Power or Loperamide|Sequential treatments of pyrotinib alone followed by pyrotinib + Montmorillonite Power or Loperamide, with a washout period in between.
10134667|NCT05252494|Experimental|animal assisted therapy group|Animal assisted therapy group will watch aquarium fish while bloodletting prosedure.
10134668|NCT05252494|No Intervention|Control Group|Control group will not watch aquarium fish while bloodletting prosedure.
10134669|NCT05252481|Active Comparator|Active tDCS|Transcranial current direct stimulation. 8 days.
10134670|NCT05252481|Sham Comparator|Sham tDCS|Sham transcranial current direct stimulation. 8 days.
10134671|NCT05252455|Other|exercise group|pelvic and abdominal mechanics exercise
10134672|NCT05252455|No Intervention|control group|Normal prenatal examination
10134673|NCT05252429|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression or up to 35 cycles.
10134674|NCT05252416|Experimental|BLU-222 Monotherapy|Dose Escalation: Multiple doses for BLU-222 for oral administration Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation as well as a group consisting of BLU-222 + Fulvestrant (group 4)
10134675|NCT05252416|Experimental|BLU-222 + Carboplatin|
10134676|NCT05252416|Experimental|BLU-222 + Ribociclib + Fulvestrant|
10134677|NCT05252403|Experimental|CARCIK-CD19|
10134678|NCT05252377|Experimental|Breathing Exercise Group|Breathing exercise program; It was prepared by the researchers in accordance with the literature and based on the studies in which breathing exercise was applied to reduce invasive pain experienced during cannulation, blood collection and postoperative pain. Patients will be given an exercise based on rhythmic breathing. The exercise will be started before the cannulation application, the patient will be told to perform the breathing exercise twice, and he will be asked to continue doing the breathing exercise until the cannulation process is completed. The patient will wait by taking five normal breaths between each breathing exercise. The patient will be told that he can count by using his fingers in the steps he is asked to count up to three.
10134679|NCT05252377|No Intervention|Control Group|No intervention will be made by the researcher on the patients in this group, and a pain assessment will be made by the nurse in charge of dialysis immediately after the cannulation procedure by the dialysis nurse working in the unit.
10134680|NCT05252351||Adults with congenital aortic stenosis|
10134681|NCT05252325|Other|HAL on the right side of the face; HA on the left side of the face|the subjects will receive HAL ( hyaluronic acid +lidocaine)in the right side of the face, HA (hyaluronic acid without lidocaine) in the left side
10134682|NCT05252325|Other|HAL on the left side of the face; HA on the right side|the subjects will receive HA in the right side of the face, HAL in the left side
10134683|NCT05252312||Healthy adult population aged 18 to 80 years|"After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?)."
10134684|NCT05252299|Experimental|Refresher Training Group|"This study will use telemedicine to facilitate an innovative use of rolling refresher training (RRT), a technique used in medical education to provide hands-on interactive training at regular intervals with the goal of improving psychomotor skills required for high stakes procedures such as cardiopulmonary resuscitation. This study seeks to interrogate our hypothesis that providing instruction on CSS use to caretakers via telemedicine every 3 months during the first year of an infant's life is feasible and acceptable to caregivers."
10134685|NCT05252299|No Intervention|Traditional Group|They leave the hospital without the additional training and under hospital's normal discharge plan
10134686|NCT05252273||Open-label observational study|This study will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
10134687|NCT05252260|Experimental|Diode Laser|Vestibuloplasty operation was performed via diode laser
10134688|NCT05252260|Other|Diode laser + Low-level laser therapy|Vestibuloplasty operation was performed via diode laser and following low-level laser therapy was applied
10134689|NCT05252260|Active Comparator|Conventional surgery|Vestibuloplasty operation was performed via scalpel
10134690|NCT05252260|Other|Conventional surgery + Low-level laser therapy|Vestibuloplasty operation was performed via scalpel and following low-level laser therapy was applied
10134691|NCT05252247|Experimental|Conditions|Participants will attend three sessions where two consist of immobilisation or exercise interventions.
10134692|NCT05252130|Experimental|Auscultation with a newly developed electronic stethoscope: uSteth|Identification of abnormal heart and lung sounds in study participants
10134693|NCT05252117|Experimental|Articaine 4%|With the patient in the lithotomy position, asepsis of the thighs, vulva and vagina will be performed with aqueous chlorhexidine; insertion of vaginal speculum; puncture in the uterine cervix, at the 12h point, injecting 1.8 ml of articaine. After a latency of five minutes, the procedure to insert the IUD will start with clamping the cervix at 12 hours with the Pozzi clamp, followed by rectification of the uterus and hysterometry with the hysterometer. After confirming the hysterometry, the IUD will be inserted with its own applicator and the excess wire will be cut.
10134694|NCT05252117|Experimental|Mepivacaíne 3%|With the patient in the lithotomy position, asepsis of the thighs, vulva and vagina will be performed with aqueous chlorhexidine; insertion of vaginal speculum; puncture in the uterine cervix, at the 12h point, injecting 1.8 ml of Mepivacaine. After a latency of five minutes, the procedure to insert the IUD will start with clamping the cervix at 12 hours with the Pozzi clamp, followed by rectification of the uterus and hysterometry with the hysterometer. After confirming the hysterometry, the IUD will be inserted with its own applicator and the excess wire will be cut.
10134695|NCT05252091|Experimental|herombopag olamine tablets|
10134696|NCT05252078|Experimental|Anlotinib|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally (D1-D14); TQB 2450 1200 mg, iv (D1).~If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg, until un-tolerable toxicity again."
10134697|NCT05252065||Patients with NSCLC|all stage N2-3 non-small cell lung cancer patients receive intensity-modulated radiotherapy (IMRT). The prescription dose of PTV is 60-70Gy.
10134698|NCT05252052||Adolescents 14-24 years old|Adolescents 14-24 years old
10134699|NCT05252052||Health care providers in rural Haiti|Health care providers in rural Haiti
10134700|NCT05252039|Experimental|Goals in Focus Therapy|Participants in this arm will receive 24 weekly sessions with Goals in Focus therapy (GiF) over 6 months.
10134701|NCT05252039|No Intervention|Waitlist Control|Participants in this arm will not receive any psychological treatment for 6 months. After 6-months, they will receive 24 sessions of Goals in Focus Therapy.
10134702|NCT05252026|Experimental|PROCARE-I (UP-A for indicated purposes)|To ensure cost-effectiveness, PROCARE-I intervention will be designed as a brief 8-session child-focused programme by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical indicated preventive intervention format focused on cost-effectiveness.
10134703|NCT05252026|Experimental|Active control condition|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for one alternative compare condition to PROCARE-I. The U Talk programme support-based group condition will be used as active control condition."
10134704|NCT05252013|Placebo Comparator|Plain Bread|Participants will be attending the Human Nutrition Unit in the morning (day 1), following an overnight fast. Fasted blood samples will be taken and one portion of plain bread (122g) served with 25g of jam will be consumed by the volunteers. The meal will be consumed within 15 minutes and postprandial blood samples will be collected. Participants will be provided with the meals for the rest of the day to take away and for days 2 and 3. In total, they will consume 6 plain bread rolls on days 1, 2 and 3 (2 bread rolls/day).
10134705|NCT05252013|Experimental|Broad bean hull bread|Participants will be attending the Human Nutrition Unit in the morning, following an overnight fast. Fasted blood samples will be taken and one portion of the bean hull bread (155g) served with 25g of jam will be consumed by the volunteers. The meal will be consumed within 15 minutes and postprandial blood samples will be collected. Participants will be provided with the meals for the rest of the day to take away and for days 2 and 3. In total, they will consume 6 bean hull bread rolls on days 1, 2 and 3 (2 bread rolls/day).
10134706|NCT05252000|Experimental|mechanical debridement and adjunctive aPDT|
10134707|NCT05252000|Active Comparator|mechanical debridement and sham aPDT|
10134708|NCT05251987||High PD1+ T Cell Expression|high PD1+ T cell expression in peripheral blood
10134709|NCT05251987||Low PD1+ T Cell Expression|low PD1+ T cell expression in peripheral blood
10134710|NCT05251935|Experimental|Foot Muscle Exercise|
10134711|NCT05251935|Active Comparator|Arch Support Insole and One Leg Balance Activities|
10134712|NCT05251896|Experimental|Plasma-free procedure|
10134713|NCT05251870|Experimental|Intranodal TolDCB29 (low dose)|Two administrations of 5 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
10134714|NCT05251870|Experimental|Intranodal TolDCB29 (intermediate dose)|Two administrations of 10 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
10134715|NCT05251870|Experimental|Intranodal TolDCB29 (high dose)|Two administrations of 15 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
10134716|NCT05251870|Experimental|Intranodal TolDCB29 (recommended dose)|Two administrations of the recommended dose of autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). The recommended dose will be advised by the data safety monitoring board after data review of the first three arms. This cohort will consist of nine patients.
10134717|NCT05251857|Experimental|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|The intervention group is the group in which the investigors applied animation education program Intervention: Behavioral: Animation Education Program
10134718|NCT05251857|No Intervention|Standard Clinical Care Applied to Laparoscopic Sleeve Gastrectomy Patients|The control group is the group that receives standard clinical care
10134719|NCT05251844|Experimental|Email warning|"some individuals that accessed patients' data without authorization were randomly selected to receive an email warning. A sample email:~Dear Colleague,~The {Organization} proactive electronic record monitoring system has flagged you as having accessed the electronic patient record of {Patient_Name} on {Case_Event_Date}. A clear work-related purpose has not been identified for this access, and there are no approvals in place by the {Organization} Privacy Office to allow access to this record for personal purposes in accordance with A065. {Organization} takes the privacy of patient information very seriously. The {Organization} Privacy Office is now investigating this access as a potential privacy breach.~This potential noncompliance needs to be resolved immediately. To help determine whether a privacy breach has occurred, please respond to this email with answers to the following questions no later than 5 days from the date of this email...omitted due to length"
10134720|NCT05251844|No Intervention|No eamil warning|individuals that were flagged as accessing patients' data without authorization on the same day as the experimental group were used as the control group
10134721|NCT05251831|Experimental|Activated plasma rich in platelets|Group A: patients were treated by intradermal injections of PRP activated with Calcium chloride 10% solution.
10134722|NCT05251831|Placebo Comparator|Non- activated plasma rich in platelets|Group B: patients were treated by intradermal injections of PRP without activation.
9519611|NCT03285347|Experimental|Scientific Brain Training PRO|"Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
9976823|NCT01355445|Experimental|Vincristine / Irinotecan / Temozolomide|Vincristine, Irinotecan, Temozolomide
10134723|NCT05251805|Experimental|Costal bone marrow aspiration|10 NSCLC patients undergoing surgery from which blood samples, bone marrow aspirate and lung tumor tissue will be collected
10134724|NCT05251792||Primary Angle Clousure Diseases Eyes|Over 40 years old, regardless of gender. Patients diagnosed with PACD (PACG or PAC or PACS) with phakic eyes. Peripheral iridectomy or trabeculectomy, more than 3 months after operation.
10134725|NCT05251792||Matched Eyes|Healthy population matched by sex and age.
10134726|NCT05251779|Experimental|Cang-Ai Group|The test group inhaled the volatile oil of Cang-Ai at a concentration of 1% by inhalation once a day for 30 minutes
10134727|NCT05251779|Active Comparator|Bergamot group|The control group inhaled the bergamot essential oils at a concentration of 1% by inhalation once a day for 30 minutes
10134728|NCT05251766|Active Comparator|Arm1: epirubicin + cyclophosphamide followed by docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 4 cycles, Follow Docetaxel :75 mg/m2, D1, q3W, 4 cycles
10134729|NCT05251766|Experimental|Arm2: epirubicin + cyclophosphamide followed by nab-paclitaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 4 cycles, Follow Nab-paclitaxel :260 mg/m2, d1, q3W; 4 cycles
10134730|NCT05251766|Experimental|Arm3: nab-paclitaxel combined with epirubicin + cyclophosphamide|Nab-paclitaxel :260 mg/m2, D1, q3W; Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 6 cycles
10134731|NCT05251740|Experimental|Standing program|The child completes a 60-minute home standing program five days per week over eight weeks.
10134732|NCT05251688|Other|participants|The participants were encountered two times (before and after the application of cryoanalgesia).
10134733|NCT05251662|Experimental|experimental group1|Sintilimab Combined With GEMOX + IBI305
10134734|NCT05251662|Experimental|experimental group2|Sintilimab Combined With GEMOX
10134735|NCT05251662|Active Comparator|Comparator|GEMOX
10134736|NCT05251649|Experimental|tACS combined with 40 Hz sound stimulation group|15 daily (Monday-Friday) 20min sessions of tACS combined with 40 Hz sound stimulation
10134737|NCT05251649|Experimental|tACS group|15 daily (Monday-Friday) 20min sessions of tACS stimulation
10134738|NCT05251649|Experimental|40 Hz sound stimulation group|15 daily (Monday-Friday) 20min sessions of 40 Hz sound stimulation
10134739|NCT05251636|Experimental|ESB adjunct to IAI|Single ESB treatment adjunct to intravitreal aflibercept injections (IAI)
10134740|NCT05251636|Active Comparator|IAI monotherapy|Intravitreal aflibercept injections (IAI)
10134741|NCT05251623|Experimental|pedometer|walking with pedometer
10134742|NCT05251623|No Intervention|control|no intervention
10134743|NCT05251610|Active Comparator|PROPRANOLOL GROUP|Participants will receive 20mg of oral propranolol 10 minutes prior to initiation of augmentation or induction of labor with oxytocin
10134744|NCT05251610|Placebo Comparator|OXYTOCIN ONLY GROUP|Participants had outright augmentation or induction of labor with oxytocin only
10134745|NCT05237102|Experimental|The patients did not respond to CSF tap test|Participants assigned to the experimental group did not respond to the CSF tap test and did not show improvement in general symptoms of hydrocephalus and disturbance of consciousness, but there may be changes in eeg and imaging parameters (it is unknown whether such changes are related to surgical outcome).
10134746|NCT05237102|Other|The patients did respond to CSF tap test|The improvement of symptoms in these participants after the CSF tap test predicts a favorable prognosis for CSF shunt.
10134747|NCT05228873||Investigational arm|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days plus the Standard of Care (SOC) for the treatment of COVID-19 acute stage based on the Vietnam Ministry of Health guideline at this time
10134748|NCT05228873||• Controlled arm|Patient who receive the Standard of Care (SOC) for the treatment of COVID-19 acute stage based on the Vietnam Ministry of Health guideline at this time
10134749|NCT05228678||Dyspnea group|"Patients with prior diagnosis of COVID-19 and present with persistent dyspnea after 12 weeks of occurrence of symptoms every patient in this group will undergo Cardiopulmonary exercise test (CPET) protocol: -~As regard CPET protocol we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.~The following parameters observed:~Metabolic response~Oxygen consumption VO2 (ml/ min):~P ETO2: Is the end-tidal O2 tension as measured from the exhaled air.~P ETCO2: Is the end-tidal CO2 tension as measured from the exhaled air. Normally decreased during exercise.~Anaerobic Threshold (AT): Is defined as the VO2 (in L/min) at which there is substantial transition to anaerobic metabolism to produce extra energy~Ventilatory response~Minute ventilation :~Breathing reserve(BR): Breathing reserve = measured/predicted minute ventilation maximum~Tidal volume (VT):~Respiratory frequency (RF)"
10134750|NCT05228678||Control group|"Patients with prior diagnosis of COVID-19, fully recovered, without persistent dyspnea every patient in this group will undergo Cardiopulmonary exercise test (CPET) protocol: -~As regard CPET protocol we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.~The following parameters observed:~Metabolic response~Oxygen consumption VO2 (ml/ min):~P ETO2: Is the end-tidal O2 tension as measured from the exhaled air.~P ETCO2: Is the end-tidal CO2 tension as measured from the exhaled air. Normally decreased during exercise.~Anaerobic Threshold (AT): Is defined as the VO2 (in L/min) at which there is substantial transition to anaerobic metabolism to produce extra energy~Ventilatory response~Minute ventilation :~Breathing reserve(BR): Breathing reserve = measured/predicted minute ventilation maximum~Tidal volume (VT):~Respiratory frequency (RF)"
10134751|NCT05227443|No Intervention|Control|The control group did not receive exercise training and the participants were informed to complete their medications provided by the treating physician.
10134752|NCT05227443|Active Comparator|Lower limb (LL) exercise training|All the participants in this modality of training were subjected to only lower limbs aerobic exercise training.
10134753|NCT05227443|Active Comparator|Upper, lower and breathing (ULB) exercise training|All the participants in this modality of training were subjected to upper and lower limb aerobic exercise training as well as breathing training.
10134754|NCT05227248|Experimental|Main study arm|Patients received intervention 1 and then intervention 2 after 7 weeks
10134755|NCT05227235|Experimental|3D Telemedicine|3D Telemedicine system allowing patient to be seen in 3 dimensions
10134756|NCT05227235|Active Comparator|2D Telemedicine|2D Telemedicine system allowing patient to be seen in standard video call
10134757|NCT05226117|Experimental|Treatment arm|Patients with muscle-invasive urothelial carcinoma of the bladder, who are suited for and accept radical cystectomy (RC)
10134758|NCT05226039|Other|Young adult group|One group will consist of 20 to 30 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
10134759|NCT05226039|Other|Older adult group|The other group will consist of 60 to 70 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
10134760|NCT05225987|Experimental|Experimantal Group|Postpartum Nurse Navigation Program based care
10134761|NCT05225987|No Intervention|Control group|This group will take routin care
10134762|NCT05224362|Experimental|Hip Region|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the hip region.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
10134763|NCT05224362|Experimental|Chest Region|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
10134764|NCT05224362|Placebo Comparator|No elastic band|"Pre intervention: Force plate Posturography Pre selected exercises (8) will be performed by the participant.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold. Cool down. Post intervention- Force plate Posturography and a Semi-structured Interview schedule"
10134765|NCT05223855|Active Comparator|Intervention group|The intervention group receives intervention for 8 weeks
10134766|NCT05223855|No Intervention|control group|The control group receives usual care for 8 weeks and is then offered participation in a de-stress class for 8 weeks.
10134767|NCT05223062||Psoriatic arthritis|Patients with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR).
10134768|NCT05222737|Active Comparator|test group|intra pocket diode laser application
10134769|NCT05222737|Active Comparator|control group|antibiotic adminstration
10134770|NCT05220865|Active Comparator|Hall Technique|A preformed metal crown will be cemented on the carious primary molar tooth without any tooth preparation and local anesthesia.
10134771|NCT05220865|Experimental|Modified Hall Technique|In the Modified Hall technique only infected soft dentin tissue will be removed with hand instruments and a preformed metal crown will be placed with Hall technique.
10134772|NCT05219591|Other|Polysomnographic night|intermittent application of the EPR technology on CPAP device during step 2, on polysomnographic night of the study.
10134773|NCT05219591|Other|Outpatient CPAP use|Application of EPR technology during outpatient CPAP usage, on steps 3 and 4 of the study
10134774|NCT05218070|Experimental|Low Dose Vaccine|35 mcg dose for both vaccinations at day 0 and day 14 (low dose, 15 subjects)
10134775|NCT05218070|Experimental|High Dose Vaccine|70 mcg dose for both vaccinations at day 0 and day 14 (high dose, 15 subjects)
10134776|NCT05218070|Placebo Comparator|Placebo|Placebo for both injections at day 0 and day 14 (Placebo, 15 subjects)
10134777|NCT05217823|Experimental|Er:YAG laser|Teeth treated with Er:YAG laser
10134778|NCT05217823|Active Comparator|Hand instruments|Teeth treated with Gracey curettes
10134779|NCT05213507|Experimental|Inhaled Amikacin plus Conventional Therapy|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
10134780|NCT05213507|Other|Conventional Therapy|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long-term oxygen therapy.
10134781|NCT05212493|Active Comparator|Seach CBD:THC 20:1 cannabis oil|cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Seach LTD and oil manufactured by Nextar Pharma LTD.
10134782|NCT05212493|Active Comparator|Candoc CBD:THC 20:1 cannabis oil|cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Candoc LTD and oil manufactured by Panaxia LTD.
10134783|NCT05210907|Experimental|CD19 CAR-T therapy|SNUH-CD19-CAR-T is administered as an intravenous infusion.
10134784|NCT05204732|Experimental|Experimental group|"Speech training: 4 times 1 hour of intonation training for 4 weeks~Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 2 postmeasurements)"
10134785|NCT05204732|Sham Comparator|Control group|"Speech training: : 4 times 1 hour sham therapy (info sessions + active intervention non-verbal communication) during 4 weeks + 4 times 1 hour intonation training during 4 weeks~Standard voice assessment (voice recording, VAS, questionnaire(s)) (1 premeasurement and 3 postmeasurements)"
10134786|NCT05194293|Experimental|Treatment (regorafenib, durvalumab)|Patients receive regorafenib PO QD on days 1-21 and durvalumab IV on day 1. Treatment repeats every 28 days until surgery or up to 2 years post registration unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
10134787|NCT05192174|Experimental|NIB101 Dose Level 1|1 x 10^7 cells/body as chimeric antigen receptor (CAR) positive viable cells will be administered intravenously on Day 0.
10134788|NCT05192174|Experimental|NIB101 Dose Level 2|1 x 10^8 cells/body as CAR positive viable cells will be administered intravenously on Day 0.
10134789|NCT05192174|Experimental|NIB101 Expansion Cohort|Recommended dose determined on dose escalation phase will be administered intravenously on Day 0.
9968681|NCT01282333|Experimental|Treatment (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib orally every 12 hours on days 1-12, gemcitabine hydrochloride IV over 30 minutes on days 3 and 10, and cisplatin IV over 60-120 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with suspected or known germline BRCA mutations may continue to receive single-agent veliparib continuously in the absence of disease progression or unacceptable toxicity. Patients may undergo blood, tumor tissue, and hair follicle sample collection periodically for pharmacokinetic and correlative studies.
9968682|NCT01282359|Other|Clinical Practice Group|Patients collected in centres randomized as usual clinical practice, who will not receive the limited educational asthma program.
9968683|NCT01282359|Other|"Gold Standard educational group"|Patients will receive a formal program of structured and individualized education, enrolled in centres recognized by using high standard procedures in asthma education.
9968684|NCT01282359|Other|Intervention group|This group will receive a limited educational asthma program (minimal educational intervention)
9968685|NCT01282385|Experimental|simvasatin|"a) patients responding to treatment with beta-blockers, in which she was treated with nadolol Subsequently randomized into two treatment arms, double-blind:~a.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~a.2: placebo capsules with external characteristics similar to simvastatin.~b) non-responders to treatment with beta blockers, receive treatment with carvedilol.Subsequently randomized into two treatment arms, double-blind~b.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~b.2: placebo capsules with external characteristics similar to simvastatin."
9968686|NCT01282385|Placebo Comparator|placebo|
9968687|NCT01282398|Experimental|simvastatin|The experimental group will take simvastatin 40mg for at least two years.
9968688|NCT01282398|Placebo Comparator|placebo|the control group wiil take placebo pills for at least two years.
9968689|NCT01282437|Experimental|Prophylactic Cranial Irradiation|
9968690|NCT01282437|No Intervention|Observation|Patients will not receive PCI, but will be observed and the same items will be measured as in the PCI-arm.
9968691|NCT01282450|Experimental|Single arm|Eligible patients
9968692|NCT01282502|Experimental|Midostaurin with chemoradiation|
9968693|NCT01282515|Experimental|ELP active|one PDT treatment with 2 ml hexaminolevulinate 6 mg/ml gel
9968694|NCT01282515|Active Comparator|topical steroids|treatment with clobetasol propionate 0.05% ointment used daily for 6 weeks
9968695|NCT01282541|Active Comparator|Transconjunctival|
9968696|NCT01282541|Active Comparator|Transcutaneous|
9968697|NCT01282554|Experimental|stimulated group|stimulated group
9968698|NCT01282554|No Intervention|control group|Control group : non stimulated group.
9968699|NCT01282567|Other|diabetic patients|
9968700|NCT01282580|Experimental|Dietary fish (canned salmon, albacore)|Fish products: Canned albacore and salmon will be provided at no cost to the patient. Supplies of tuna and salmon will be provided in quantities sufficient for one month of daily intake by the subject. If desired, a subject can request a sufficient amount to allow for preparation of a meal for the family or household at no more than two times per week. Labels or portions of labels from the cans will be collected at the monthly study visits, and canned supplies will be replenished monthly or at more frequent intervals if needed. Subjects will be allowed to keep unused cans.
9968701|NCT01282580|Experimental|Lovaza-Omega 3 fatty acid capsules|Lovaza capsules will be provided at no cost to the patient. Pill bottles will be provided to the patient, with the start date and number of pills recorded. The supplement will be provided in sufficient supply for one month at a time. Pill bottles will be collected at monthly follow-up visits, and any unused capsules will be documented and discarded as biohazardous waste.
9968702|NCT01282593|Other|CD9 expression level|Impact of CD9 expression level on motility assays
9968703|NCT01282619|Experimental|Huperzine A Sustained-Release Tablet|
9968704|NCT01282619|Active Comparator|Huperzine A Tablet|
9968705|NCT01282619|Placebo Comparator|Placebo|
9968706|NCT01282632|Experimental|Risperidone|Commence at 0.5 mg once daily Increase, blindly, to 1 mg and then by 1 mg at discretion of clinicians through weeks 1-4 to a maximum of 3 mg.
9968707|NCT01282632|Experimental|Olanzapine|Commence at 2.5 mg once daily Increase to 5.0 mg, blindly, and then by 5 mg at the discretion of the clinician through weeks 1 - 4 to a maximum of 15 mg
9968708|NCT01282645||PSI in PEEK|All study subjects have received a Patient Specific Implant (PSI) made of PEEK to repair a cranial defect
9968709|NCT01282658||Colorectal cancer|
9968710|NCT01282671|Experimental|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months.
10134790|NCT05185401||non-Brugada population|Adult patients who underwent general anaesthesia (with propofol as induction agent) at the catheterisation laboratory of the UZ Brussel
9968711|NCT01282671|No Intervention|Control group|No breathing exercises.
9976824|NCT01355536||Preterm birth group|Women with prior preterm birth
9976825|NCT01355536||Term birth group|Women with prior term birth
9976826|NCT01355549|Experimental|Platelet-rich plasma therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
9976827|NCT01355601|Experimental|Group 1 - Control A|Nutritional beverage containing varying types and levels of carbohydrates
9976828|NCT01355601|Experimental|Group 2 - Experimental A|Nutritional Beverage with varying types and levels of carbohydrates
9976829|NCT01355614|Experimental|QAX576|
9976830|NCT01355614|Other|Infliximab|
10134791|NCT05183165|Other|Patients with Wilson's disease declaring pregnancy,|Patients with Wilson's disease declaring pregnancy.Followed in the reference, constituent, and competence centers for Wilson's disease and other rare copper-related diseases, spread over French national territory.
10184151|NCT03757754|Experimental|HPPH 3 mg/m2|HPPH 3 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
10184152|NCT03757754|Experimental|HPPH 3.5 mg/m2|HPPH 3.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
10184153|NCT03757754|Experimental|HPPH 4 mg/m2|HPPH 4 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
10184154|NCT03757754|Experimental|HPPH 5 mg/m2|HPPH 5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
10184155|NCT03757754|Experimental|HPPH 6 mg/m2|HPPH 6 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
10184156|NCT03757741||AF-SG 01|Study subjects with atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
10184157|NCT03757741||AF-SG 02|Study subjects without atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
10184158|NCT03757728|Other|open haemorrhoidectomy|Open haemorrhoidectomy is performed using an anal retractor, exposed haemorrhoids at 3 - 7- 11 hours are excised using cautery. The arteries are ligated or cauterized. Open or closed technique is used (the choice of the surgeon). The Spongostan plug is then introduced
10184159|NCT03757728|Other|Haemorrhodal pedicle ligation|Haemorrhodal pedicle ligation is performed using operating proctoscope. The pedicle of symptomatic haemorrhoid is suture ligated with absorbable Vycril 2/0. Mucopexy is performed simultaneously if the prolapse is noticed. No tissue removal is performed
10184160|NCT03757728|Other|Intrahaemoroidal laser coagulation|Intrahaemoroidal laser coagulation is performed using disposable THD kit [Biolitec Co]. The haemorrhoidal pedicle is sutured. 1mm opening is created at the external haemorrhoid (skin level). Laser is then introduced up to pedicle and coagulation performed. This is repeated to all the piles. The procedure is finished with placing Spongostan plug into anal canal
10184161|NCT03757702||Fibromiyalgia group|women with FMS between 18-65 years of age and being volunteered.
10184162|NCT03757702||Healthy group|healthy women and being volunteereed
10184163|NCT03757676|Experimental|No Play|This 'no play' group functioned as the control group.
10184164|NCT03757676|Experimental|At Will Play|This group functioned as 1 of the 2 play groups.
10184165|NCT03757676|Experimental|Goal Oriented Play|This group functioned as 1 of the 2 play groups.
10184166|NCT03757663|Experimental|UV Dosimeter|UV Dosimeter will measure participants' UV exposure for two separate 3-week periods.
10184167|NCT03757650|Active Comparator|HP eradication therapy positive-HP positive|who has HP positive endoscopic biopsy will take HP eradication therapy one month before the surgery
10184168|NCT03757650|Active Comparator|HP eradication therapy negative-HP positive|who has HP positive endoscopic biopsy and will not take any medication about HP
10184169|NCT03757650|No Intervention|HP negative-Control group|who has HP negative endoscopic biopsy and will not take any medication. (control group)
10184170|NCT03757624|Active Comparator|Gastric specimen measurements after 24 hours from % 10 formol|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after formol solution
10184171|NCT03757624|Active Comparator|Gastric specimen measurements after surgery in operating room|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after surgery in operating room peroperatively
10184172|NCT03757611|Experimental|tabetri|Tabetri capsule will be administered orally twice daily for 12 weeks
10184173|NCT03757611|Placebo Comparator|Placebo|Placebo capsule will be administered orally twice daily for 12 weeks
10184174|NCT03757598|No Intervention|Paper Partograph|The comparison group used the standard WHO Standard Paper Partograph approved in Kenya to monitor labor. Copies of the partograph were made available to the facilities.
10184175|NCT03757598|Experimental|ePartogram|ePartogram use by skilled birth attendant providers in health facilities. The intervention arm used the novel ePartogram or electronic partogram. The interface was of the same WHO approved partograph on an Android tablet. There were reminders to spur provider actions and alerts that were programmed in an algorithm.
10184176|NCT03757585|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
10184177|NCT03757585|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400 mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700 mg QD) based on age.
10184178|NCT03757572|Experimental|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Alginate dressings with silver and high-G cellulose, which combine increased absorption properties, antimicrobial action and high coherence will be used. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials for latent breathing of the skin with dressing dimensions based on the wound size, will be also placed.~Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
10134792|NCT05141747|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
10134793|NCT05141552|Experimental|dapa group|subjects will be treated with dapagliflozin (10mg per day) and standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)
10134794|NCT05141552|No Intervention|control group|subjects will be treated with standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)
10134795|NCT05131815|Experimental|Virtual Group-Based Physical Activity (BurnAlong) and Discussion Board|Participants will be asked to complete a 12 week virtual physical activity program delivered by the BurnAlong app, participate in a discussion board, and engage in live physical activity sessions with an exercise physiologist.
10134796|NCT05128409|Active Comparator|XKH001 Injection|XKH001 Injection,hypodermic injection，single dose，5 dose cohorts: 0.5 mg/kg, 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
10134797|NCT05128409|Placebo Comparator|XKH001 Placebo Injection|XKH001 Placebo Injection,hypodermic injection，single dose，4 dose cohorts: 1.67 mg/kg, 3.34 mg/kg, 5.0 mg/kg and 10.0 mg/kg.
10134798|NCT05127837|No Intervention|Treatment as Usual (TAU)|CBT for psychosis distance learning course.
10134799|NCT05127837|Experimental|CBTpro|In addition to TAU, clinicians and clients receive the CBTpro training.
10134800|NCT05119660|Experimental|Prefrontal cortex|In this arm, participants will receive stimulation to the left dorsolateral prefrontal cortex. They will complete one active session and one sham session.
10134801|NCT05119660|Experimental|Parietal cortex|In this arm, participants will receive stimulation to the left inferior parietal lobule. They will complete one active session and one sham session.
10134802|NCT05117944|Experimental|Drama|Students in the intervention group will act as the patient and act out the case given to them. Nursing care to be provided by a professional nurse to the student who will play the role of the patient in line with the case content includes helping the patient (student) eat, perform personal hygiene (oral care, etc.), dress and move. The case content will not be shared with the students in advance, and the student will not need to make any preliminary preparations. However, ten minutes before the start of the practice, the situations that are expected to be portrayed as the patient specified in the case will be explained to the students. The skills laboratory will be used as three separate patient rooms (with two or three patients), in which students in the role of inpatient will receive care from a professional nurse. Each student will experience the patient role only once.
10134803|NCT05117944|No Intervention|Control|Students in the control group will fill in the datasheet, Altruism Scale and Empathy Scale simultaneously with the intervention group, without any intervention, and then the Altruism Scale and Empathy Scale at the 1st and 3rd months.
10134804|NCT05117658|Experimental|HA121-28|Patients will receive HA121-28 tablets at 450 mg once daily (QD) for 21 days on a 28-day treatment cycle.
10134805|NCT05112679|Active Comparator|Proprio Foot|microprocessor-controlled prosthesis that regulates the angle of ankle dorsiflexion during the swing phase
10134806|NCT05112679|Active Comparator|Empower Ankle|a powered prosthesis that provides active propulsion in late stance to mimic the positive work performed by the ankle plantar-flexors in push-off. The Empower has been shown to improve affected leg kinematics (increased ankle range of motion and reduced knee flexion) on smooth flat ground, ramp ascent, and gravel
10134807|NCT05082844|Experimental|Evaluation of clinical and radiographic findings after surgical treatment for cuff rotator lesion|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
10134808|NCT05074433|Experimental|casirivimab+imdevimab Initial + Q4W|Initial subcutaneous (SC) dose, then SC dose every 4 weeks (Q4W)
10134809|NCT05074433|Experimental|casirivimab+imdevimab Q4W|SC dose Q4W
10134810|NCT05074433|Experimental|casirivimab+imdevimab Q12W|SC dose every 12 weeks (Q12W)
10134811|NCT05074433|Placebo Comparator|Placebo|SC dose Q4W
10134812|NCT05072379|Experimental|Mobile health app group|routine care and mobile health app
10134813|NCT05072379|No Intervention|control group|routine care
10134814|NCT05039099|Experimental|AP-101|AP-101 is administered by IV.
10134815|NCT05039099|Placebo Comparator|Placebo|Placebo is administered by IV.
10134816|NCT05031988||University Students|To assess the determinants of physical activity and mental health among university students during and after Covid-19 lockdown.
10134817|NCT05011578|Experimental|clinical and radiographic findings after surgical treatment for radiocapitellar fracture|30 patients will be included in a interventional study for an evaluation of the clinical and radiographic finding after at least 10 years after radiocapitellar surgery
10134818|NCT04993352|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody.
10134819|NCT04987112|Experimental|CAN1012 single agent|CAN1012 intratumoral injection given alone
10134820|NCT04982354|Experimental|Investigational Treatment|Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.
10134821|NCT04980027|Experimental|Insuline Glargine (U300) (Gla-300)|Insulin glargine (U300) once daily for 24 weeks on top of non-insulin antidiabetic drug. Insulin dose will be adjusted according to the recommended titration algorithm
10134822|NCT04974125|Experimental|Arm A :Aspiration of peritoneal gas through a drain|"Patients in experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out by a drain.~Then, patients will be followed-up during 7 days after surgery."
10134823|NCT04974125|Active Comparator|Arm B : Manual evacuation of the peritoneal gas, via the trocar|"Laparoscopic or robotised laparoscopic surgery + Trocar~Patient in this experimental arm will receive surgery (either laparoscopic or robotised laparoscopic surgery). The exsufflation will be carrying out carried out manually using the trocar (standard of care).Then, patient will be followed-up during 7 days after surgery."
10134824|NCT04963946|Experimental|watch and monitor|After 18 months of acalabrutinib treatment, patients will stop acalabrutinib treatment for watch and monitor until month 60. If progression disease, patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria.
10134825|NCT04963946|Active Comparator|Acalabrutinib|After 18 months of acalabrutinib treatment, patients will continue acalabrutinib treatment until month 60. If progression disease or unacceptable toxicity, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria
10134826|NCT04962503|Experimental|Afamelanotide|
10134827|NCT04953078|Experimental|10 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (10 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
10134828|NCT04953078|Experimental|50 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (50 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
10134829|NCT04953078|Experimental|100 μg Baiya SARS-CoV-2 VAX1, Adult Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
10134830|NCT04953078|Experimental|10 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (10 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
10134831|NCT04953078|Experimental|50 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (50 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
10134832|NCT04953078|Experimental|100 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
10134833|NCT04950777|No Intervention|standard of care|
10134834|NCT04950777|Experimental|patient education|The intervention group will receive the patient education document with their questionnaire, randomization will occur by the study team prior to subject visits. The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
10134835|NCT04938895|Experimental|Black Expert|Survey respondents are exposed to a Black person wearing expert attire.
10134836|NCT04938895|Experimental|Black Layperson|Survey respondents are exposed to a Black person wearing layperson attire.
10134837|NCT04938895|Experimental|White Expert|Survey respondents are exposed to a white person wearing expert attire.
10134838|NCT04938895|Experimental|White Layperson|Survey respondents are exposed to a white person wearing layperson's attire.
10134839|NCT04938895|Experimental|Black Woman Investigator|Survey respondents are exposed to a Black woman investigator.
10134840|NCT04938895|Experimental|Black Man Investigator|Survey respondents are exposed to a Black man investigator.
10134841|NCT04938895|Experimental|White Woman Investigator|Survey respondents are exposed to a white woman investigator.
10134842|NCT04938895|Experimental|White Man Investigator|Survey respondents are exposed to a white man investigator.
10134843|NCT04938882|Placebo Comparator|Normal saline in transversus abdominis plane block|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
10134844|NCT04938882|Active Comparator|Ropivacaine in transversus abdominis plane block|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
10134845|NCT04938882|Active Comparator|Compound lidocaine at low-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
10134846|NCT04938882|Active Comparator|Compound lidocaine at high-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
10134847|NCT04937998|Experimental|Autologous PRP injection|This group of patients will be treated with single intra-articular injection of Autologous PRP.
10134848|NCT04937998|Active Comparator|HA injection|This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)
10134849|NCT04934332|Experimental|Newly hospitalized patients|Patients admitted for the first time to a post intensive care rehabilitation unit after severe neurological trauma.
10134850|NCT04933903|Experimental|Protocol Therapy|Ipilimumab: 1mg/kg IV day 1. Nivolumab: 3mg/kg IV days 1, 15, 29. SBRT delivered as 1-2 fractions to the gross primary tumor and nodal disease following day 1 infusion and completed by day 3 (7Gy x 1; 4Gy x 2).
10134851|NCT04917224|Experimental|Cohort A: Central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from a lobar bronchus
10134852|NCT04917224|Experimental|Cohort B: Ultra-central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from the mainstem bronchus, trachea, or esophagus
10134853|NCT04911517|Experimental|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
10134854|NCT04911088||Analgesic calibration|Participants will receive calibration of electromyography at state entropy of 90.
9976831|NCT01355640|Experimental|breast-feeding group|Mothers console their babies by breast-feeding during heel lance.
10134855|NCT04911088||Sedated calibration|Calibration will be started at state entropy of 70.
10134856|NCT04911088||No calibration|Participants will not receive calibration of electromyography. Measurements will start simultaneously to the standard electromyography with a default current of 60mA at state entropy of 50.
10134857|NCT04901273|Experimental|Homologous PRP|This group of patients will be treated with single intra-articular injection of Homologous PRP. At the 6-month follow-up visit, the patient will be informed about the treatment received.
10134858|NCT04901273|Placebo Comparator|Saline solution|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months.
10134859|NCT04891757|Experimental|FHD-286 dose escalation|Approximately 25-50 patients will be enrolled in the dose escalation arm.
10134860|NCT04880174|Other|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
10134861|NCT04879017|Experimental|FHD-286 dose escalation and expansion|Up to approximately 100 patients will be enrolled in dose escalation and expansion
10134862|NCT04871282|Experimental|Part A Main Study 1.2 mg daily|AL102 1.2 mg
10134863|NCT04871282|Experimental|Part A Main Study 2 mg Intermittent|AL102 2 mg
10134864|NCT04871282|Experimental|Part A Main Study 4 mg Intermittent|AL102 4 mg
10134865|NCT04871282|Experimental|Part B AL102|AL102, recommended dose regimen from Part A
10134866|NCT04871282|Placebo Comparator|Part B Placebo|Placebo to match recommended dose regimen from Part A
10134867|NCT04866329||In Vitro Fertilisation protocol|Women followed in the department for an in vitro fertilisation protocol
10134868|NCT04865978|Experimental|Apixaban|LVAD patients randomized to the experimental arm will be prescribed apixaban 5 mg twice daily.
10134869|NCT04865978|Active Comparator|Warfarin|LVAD patients randomized to the control arm will be prescribed warfarin which will be dosed to achieve an INR goal of 2-2.5
10134870|NCT04853563|Experimental|High PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 8 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. Thereafter, the PEEP level is adjusted to 1 centimetre of water higher to a minimum PEEP level of 10 with every 30 minutes.
10134871|NCT04853563|Active Comparator|Low PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 5 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. In this arm, the PEEP level is adjusted to 1 centimetre of water lower to a minimum PEEP level of 3 with every 30 minutes while maintaining a partial pressure of arterial blood oxygen above 65 millimeter of mercury or oxygen saturation >92% with pulse oxymetry.
10134872|NCT04853095|Experimental|Intervention group (PerFix)|Peritoneal fixation technique
10134873|NCT04853095|Active Comparator|Control group (no PerFix)|Standard of care (i.e. no fixation)
10134874|NCT04829214|Experimental|OTO-313|
10134875|NCT04829214|Placebo Comparator|Placebo|
10134876|NCT04818645|Experimental|Confirm Rx insertable cardiac monitor|The Confirm RX implantable cardiac monitor (ICM) is an FDA-approved device that can be injected into the subcutaneous tissue and can provide automatic as well as patient triggered electrocardiographic recordings of symptomatic episodes during long term follow-up. This Implantable cardiac monitor is paired with a remote monitoring smartphone application called My Merlin that capable of rapid remote review of electrograms to be utilized in this study for arrhythmia detection. The Confirm Rx ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.
9519612|NCT03285347|No Intervention|Control group|This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.
9694639|NCT04786769|Experimental|Iron supplementation|"Intravenous ferric carboxymaltose will be administered according to weight and hemoglobin values at randomization as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention (if determined by dose calculation, otherwise placebo) 12 weeks after valve intervention (if iron deficiency persists, otherwise placebo)"
10134877|NCT04818645|Active Comparator|Conventional Management|The conventional management arm will use arrhythmia signs and symptoms to determine occurrence of arrhythmias.
10134878|NCT04816513|Active Comparator|Ustekinumab (Using Reference Device)|Participants will receive a single subcutaneous (SC) injection of ustekinumab in Device 1 as a reference device on Day 1.
10134879|NCT04816513|Experimental|Ustekinumab (Using Test Device)|Participants will receive a single SC injection of ustekinumab in Device 2 as a test device on Day 1.
10134880|NCT04810026|Active Comparator|Group 1: Education only|Push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
10134881|NCT04810026|Experimental|Group 2: Education and Meals|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
10134882|NCT04810026|Experimental|Group 3: Education, Meals, Coaching|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, coaching program (e.g., diabetes-specific coaching and education, push notifications for lifestyle education modules, community support) for 12 weeks, and passive access to lifestyle education for final 4 weeks
10134883|NCT04804735|Experimental|REV : local anesthesia and virtual reality|Use of virtual reality device in Implanted Venous Access Device (IVAD) procedure under local anesthesia
10134884|NCT04804735|Experimental|MUS : local anesthesia and music therapy|Use of musicotherapy tool in Implanted Venous Access Device (IVAD) procedure under local anesthesia
10134885|NCT04804735|No Intervention|CONTROL : standard local anesthesia|Implanted Venous Access Device (IVAD) procedure under local anesthesia as standard of care
10134886|NCT04790305|Experimental|Huaier Granule + Conventional Treatment/visit|"Huaier Granule: oral administration, 20g each time, 3 times a day. The starting time of Huaier granule: from the beginning of adjuvant therapy to the end of adjuvant therapy, and within 60 days after the end of adjuvant therapy is also acceptable.~Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine."
10134887|NCT04790305|No Intervention|Conventional Treatment/visit|Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine.
10134888|NCT04787328|Experimental|HA121-28 tablets|Patients will receive HA121-28 tablets at 450 mg once daily (QD) for 21 days on a 28-day treatment cycle.
10134889|NCT04785378|Experimental|Study Group|
10134890|NCT04754594|Experimental|BNT162b2|2 doses
10134891|NCT04754594|Placebo Comparator|Placebo|2 doses
10134892|NCT04740671|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
10134893|NCT04740671|Active Comparator|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
10134894|NCT04731844|Experimental|Prostate Cancer|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
10134895|NCT04731844|Experimental|Smoldering Multiple Myeloma (SMM)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
10134896|NCT04731844|Experimental|Monoclonal Gammopathy of Unknown Significance (MGUS)|Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
10134897|NCT04730804|Experimental|Cohort 1: ALXN1830 Single Dose 1/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
10134898|NCT04730804|Experimental|Cohort 2: ALXN1830 Single Dose 2/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
10134899|NCT04730804|Experimental|Cohort 3: ALXN1830 Multiple Dose 1/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
10134900|NCT04730804|Experimental|Cohort 4: ALXN1830 Multiple Dose 2/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
10134901|NCT04730804|Experimental|Cohort 5: ALXN1830 Multiple Dose 3/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
10134902|NCT04730804|Experimental|Cohort 6: ALXN1830 /Placebo in Japanese Population|Japanese participants will receive multiple SC doses of ALXN1830 (HTD) or placebo.
10134903|NCT04713553|Experimental|Arm 1|30-microgram dose of US manufactured drug substance (Lot 1)
10134904|NCT04713553|Experimental|Arm 2|30-microgram dose of US manufactured drug substance (Lot 2)
10134905|NCT04713553|Experimental|Arm 3|30-microgram dose of US manufactured drug substance (Lot 3)
10134906|NCT04713553|Experimental|Arm 4|30-microgram dose of EU manufactured drug substance (Lot 4)
10134907|NCT04713553|Experimental|Arm 5|20-microgram dose of US manufactured drug substance (corresponding to Arm 1, 2 or 3 lot)
10134908|NCT04713553|Experimental|Booster 1: BNT162b2|30-microgram dose
10134909|NCT04713553|Experimental|Booster 2: BNT162b2.B.1.351|30-microgram dose
10134910|NCT04702919||Healthy volunteers|
10134911|NCT04687137|Experimental|TAK-743|
10134912|NCT04687033|Experimental|Dual-tDCS & PT|"Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about~1 hour). The current intensity is fixed at 2 mA and the current will flow continuously. Physical therapist will give an intervention program for lower limb performance."
10134913|NCT04687033|Active Comparator|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, the current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performance.
10134914|NCT04684979|Experimental|HLA-compatible Related Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
10134915|NCT04684979|Experimental|Unrelated Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
10134916|NCT04681872|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
10134917|NCT04681872|Active Comparator|Pulmonary vein isolation arm|
10134918|NCT04674670|Active Comparator|Substudy 1: Fibromyalgia patients, active comparator|Substudy 1 incorporates a 12-weeks a pharmacological intervention (drug or placebo) in patients with fibromyalgia and two MRI testing sessions pre- and post-treatment. Low-dose naltrexone (LDN) will be administered as the active comparator in substudy 1 to down-regulate microglial activation.
10134919|NCT04674670|Placebo Comparator|Substudy 1: Placebo comparator for Fibromyalgia patients|Substudy 1 incorporates a 12-weeks a pharmacological intervention (drug or placebo) in patients with fibromyalgia and two MRI testing sessions pre- and post-treatment. In this arm, a placebo will be administered for comparison with the low dose naltrexone as the active comparator.
10134920|NCT04674670|Experimental|Substudy 2: Healthy controls|In this arm of substudy 2, healthy controls will be administered placebo or a dopamine receptor agonist or a dopamine receptor antagonist on separate days to investigate the role of dopamine and fronto-striatal functional connectivity in relation to emotional-motivational pain processing.
10134921|NCT04674670|Experimental|Substudy 2: Fibromyalgia patients|In this arm of substudy 2, fibromyalgia patients will receive placebo or a dopamine receptor agonist to investigate the effects of normalizing dopamine transiently on fronto-striatal connectivity and emotional-motivational pain processing.
10134922|NCT04672122|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity will be at 2 mA (sham mode). The scope of intervention is to investigate effect of sham tDCS on muscle strength.
10134923|NCT04672122|Experimental|Cathodal-tDCS 1 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
10134924|NCT04672122|Experimental|Cathodal-tDCS 1.5 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1.5 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
10134925|NCT04672122|Experimental|Cathodal-tDCS 2 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
10134926|NCT04672109|Experimental|Anodal-tDCS|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the supraorbital area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
10134927|NCT04672109|Experimental|Cathodal-tDCS|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) of non-dominant hemisphere and Anode on the supraorbital area of dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
10134928|NCT04672109|Experimental|Dual-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the primary motor area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
10134929|NCT04672109|Sham Comparator|Sham-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins. Anode on dominant hemisphere, Cathode on non-dominant hemisphere. The scope of intervention is to investigate effect of tDCS on muscle strength.
10134930|NCT04669132|Experimental|Olanzapine + Netupitanto + Palonosetron|Olanzapine 5 mg/day d 0-4 + Netupitanto 300 mg/day d 1 + Palonosetron 0.56 mg/day d 1;
10134931|NCT04664179|Experimental|Arm A: Treatment without lymphodepletion chemotherapy|"C7R-EBVSTs~Group B will be activated if only limited expansion and clinical efficacy is observed in Group A"
10134932|NCT04664179|Experimental|Arm B: Treatment with lymphodepletion chemotherapy|C7R-EBVSTs with lymphodepletion chemotherapy
10134933|NCT04648319|Experimental|locally advanced, metastatic or recurrent cholangiocarcinoma|D1: Compound: BMS-936558 treatment d8: radiotherapy D 20: CT guided Biopsy D 28: BMS-936558 treatment monthly: BMS-936558 treatment CT CAP: after 4doses
10134934|NCT04642976||Atrial fibrillation ablation|All patients undergoing ablation with undergo pre-procedural CT as well as HFS mapping and ablation of GPs.
10134935|NCT04641819|Experimental|Yangzheng Compound Mixture plus conventional treatment|"Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least.~Conventional treatment:~Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
10134936|NCT04641819|Other|conventional treatment only|"Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
10134937|NCT04640922|Active Comparator|Gedea Pessary|pHyph, vaginal tablet, daily in Part 1 and once weekly in Part 2
10134938|NCT04640922|Placebo Comparator|Placebo|placebo, vaginal tablet, daily in Part 1 and once weekly in Part 2
10134939|NCT04631900|Experimental|Spiritual Intervention Programme|"The intervention is a 8 weeks' programme. The Christianity approach as the framework for spiritual intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group.~Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose."
10134940|NCT04631900|No Intervention|Wait-list Control group|Participants recruited in the waitlist control will be initially tested to generate pre-test scores and will then tested six weeks later which is equivalent to the timespan between the pre-test and post-test for the experimental spiritual programme. In between these two testing sessions, the waitlist control group will not receive any type of spiritual intervention. For ethical reasons, following the second testing session, the participants in the waitlist group will be given the opportunity to participant in the spiritual intervention programme.
10134941|NCT04625530|Experimental|ferric carboxymaltose|ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7.
10134942|NCT04625530|Experimental|tranexamic acid|tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively
10134943|NCT04625530|Experimental|ferric carboxymaltose and tranexamic acid|"ferric carboxymaltose (Ferinject® 1000 mg/20 ml) between day -27 and day~-7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by Infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively will be administered."
10134944|NCT04625530|No Intervention|"no treatment accordingly current standard of care"|"no treatment accordingly current standard of care will be given"
10134945|NCT04617366|Experimental|Individualized rTMS strategy|The individualized strategy will adjust the rTMS parameters promptly based on the results of fNIRS. This arm selects either the high-frequency rTMS to the contralesional dorsal premotor cortex (PMd) or the low-frequency rTMS to the contralesional primary motor cortex (M1) based on the lateralization index of the PMd measured by fNIRS.
10134946|NCT04617366|Active Comparator|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1.
10134947|NCT04596930|Experimental|LITT arm|Patients will be randomized to receive biopsy and LITT (n=10)
10134948|NCT04593628|Experimental|All Participants|
9694640|NCT04786769|Placebo Comparator|Placebo|"Intravenous 0.9% NaCl (placebo) will be administered as follows:~2-4 weeks before valve intervention On the day of admission to valve intervention 12 weeks after valve intervention"
10134949|NCT04589260|Experimental|TD-1058|"Part A (SAD): 6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of TD-1058~Part B (MAD): 6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of TD-1058~Part C (IPF subjects): 8 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of TD-1058~Part D (Healthy Subjects): 6 subjects (1 cohort) will receive a single dose of TD-1058. After receipt of initial dose, subjects will recieve infusion of radiolabeled TD-1058 microtracer."
10134950|NCT04589260|Placebo Comparator|Placebo|"Part A (SAD): 2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of placebo~Part B (MAD): 2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of placebo~Part C (IPF subjects): 4 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of placebo"
10134951|NCT04576429|Experimental|experimental group|
10134952|NCT04576429|Active Comparator|comparator group|
10134953|NCT04568460|Experimental|Intervention Group Sessions|Intervention group sessions will be delivered by lay health counselors. The sessions will reflect principles of co-learning, participatory design, and empowerment to promote engagement of young people in critical thinking and problem solving - including modeling, roleplaying, and interactive activities.
10134954|NCT04568460|No Intervention|Standard of Care|This is the standard of care arm. Participants newly diagnosed with HIV will get a referral to the local primary health care setting of their choice for further management, including ART.
10134955|NCT04546217|Experimental|Treadmill training +Transfer package (TT+TP)|"The TT+TP group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist. In combination with the gait training, participants in this group will also receive a group of behavioral strategies called the Transfer Package (TP). Each intervention session will last 1.5h, 1h for the gait training and 30 minutes dedicated for the transfer package.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
10134956|NCT04546217|Active Comparator|Treadmill training (TT)|"The TT group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
10134957|NCT04539873|Active Comparator|COLHICINE PLUS STANDARD TREATMENT|Patients treated in the exposed group will consist of a decreasing dose of colchicine: a dose of 1.5 mg orally on the first day (initial 1 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
10134958|NCT04539873|Placebo Comparator|STANDARD TREATMENT|In this case, the centers where the patients will be included adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases), and to standard treatment
10134959|NCT04538092|No Intervention|Control|Standard post op complex spine orders placed for patients undergoing deformity correction
10134960|NCT04538092|Experimental|ERAS|Enhanced recovery after surgery protocol is applied to the patients undergoing deformity correction
10134961|NCT04533594|Experimental|NOVELA|Hospice family caregivers will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the video (3-6 mins) over the course of 4 hospice telehealth visits.
10134962|NCT04532307|Experimental|Standard of Care SOC|Youth friendly services at Isisekelo Sempilo clinics
10134963|NCT04532307|Experimental|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples for gonorrhea, chlamydia and trichomonas
10134964|NCT04532307|Experimental|Peer-support (Thetha-Nami)|Peer support and needs assessment from an area-based peer navigator
10134965|NCT04532307|Experimental|SOC + SRH + peer-support|Combination of all arms
10134966|NCT04532125|Experimental|ARGX-117 IV|Subjects receiving ARGX-117 IV
10134967|NCT04532125|Placebo Comparator|Placebo IV|Subjects receiving placebo IV
10134968|NCT04532125|Experimental|ARGX-117 PH20 SC|Subjects receiving ARGX-117 PH20 SC
10134969|NCT04532125|Placebo Comparator|Placebo PH20 SC|Subjects receiving placebo PH20 SC
10134970|NCT04532125|Experimental|ARGX-117 + rHuPH20|Subjects receiving ARGX-117 + rHuPH20
10134971|NCT04532125|Placebo Comparator|Placebo + rHuPH20|Subjects receiving placebo + rHuPH20
10134972|NCT04496219|Experimental|Arm I (acupuncture, BCG)|Patients undergo acupuncture therapy and receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management.
10134973|NCT04496219|Active Comparator|Arm II (BCG, standard of care)|Patients receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management. Patients may undergo acupuncture therapy after completion of intravesical BCG therapy.
10134974|NCT04405349|Experimental|Combination Therapy|VB10.16 vaccinations. 11 intramuscular (i.m.) vaccinations for up to 48 weeks from first vaccination. 5 vaccinations of 3 mg VB10.16 during the first 12 weeks, followed by vaccination every 6 weeks for up to 48 weeks + Atezolizumab (1200 mg) intravenous (i.v.) infusion every 3 weeks.
10134975|NCT04401020|Experimental|Dose escalation|SAR442257 will be given intravenously with lead-in doses (LID) in the first-week, followed by twice weekly until week 4 (Cycle 1) and twice weekly for each subsequent cycle(s).
10134976|NCT04373564|Experimental|Linear GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a linear gadoliniumbased contrast agent (GBCA, i.e. Eovist/ Primovist, MultiHance or Omniscan) prior to MRI. Each participant will receive the same GBCA throughout the study.
10134977|NCT04373564|Experimental|Macrocyclic GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a macrocyclic gadolinium-based contrast agent (GBCA, i.e. Gadavist/ Gadovist, Dotarem, Magnescope or ProHance) prior to MRI. Each participant will receive the same GBCA throughout the study.
10134978|NCT04373564|Other|No GBCA (Control arm)|Adult participants who were never exposed to any gadolinium-based contrast agent and matching the population characteristics of the two GBCA arms. They will not receive any gadolinium-based contrast agent over the study course, but may undergo clinically indicated imaging (e.g. unenhanced magnetic resonance imaging (MRI), unenhanced or enhanced computed tomography, ultrasound and/or X-ray).
10134979|NCT04247048|Experimental|Control group|Patients with no major LDL cholesterol abnormalities (patients eligible for LDL-apheresis, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / LDL-C) dl in primary prevention)) and a level of Lp (a) <50 mg / dl
10134980|NCT04247048|Experimental|High-dose group|Patients with no major LDL-cholesterol abnormalities (LDL-apheresis eligible patients, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / dl in primary prevention)) and a level of Lp (a)> 80 mg / dl
10184179|NCT03757572|Active Comparator|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Wound care will be performed with the application of simple gauze dressings. Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
10184180|NCT03757559|Experimental|Cebranopadol 200 micrograms (Treatment A)|"Cebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
10184181|NCT03757559|Experimental|Cebranopadol 400 micrograms (Treatment B)|"Cebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
10184182|NCT03757559|Experimental|Cebranopadol 800 micrograms (Treatment C)|"Cebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
10184183|NCT03757559|Active Comparator|Hydromorphone IR 8 milligrams (Treatment D)|"Hydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
10184184|NCT03757559|Active Comparator|Hydromorphone IR 16 milligrams (Treatment E)|"Hydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
10184185|NCT03757559|Placebo Comparator|Placebo (Treatment F)|"Placebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
9669127|NCT03918278|Experimental|Part 2: Cohort C|Participants with metastatic pancreatic ductal adenocarcinoma (PDAC) (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years), Nab-Paclitaxel 125 mg/m^2 via IV infusion and gemcitabine 1000 mg/m^2 via IV infusion until PD or unacceptable toxicity that requires discontinuation.
10184186|NCT03757559|Placebo Comparator|Placebo (Treatment G)|"Placebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
10184187|NCT03757520|Active Comparator|Regular user group|Their number: 300; female and male students, will earn 39 points or less of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
10184188|NCT03757520|Active Comparator|Heavy user group|Their number: 300; female and male students, will earn 40 points or more of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
10184189|NCT03757507|Experimental|Optoacoustic imaging|Optoacoustic Imaging before and after tracer administration
10184190|NCT03757494|Experimental|Use of Alpha Stim|Use of Alpha Stim Device
10184191|NCT03757481|Other|no intervention|patients with history of PE (pulmonary embolism) with acute DVT (deep veinous thrombosis) treated with heparin plus edoxaban or heparin plus warfarin
10184192|NCT03757468|Active Comparator|RME (rapid maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with the standard hyrax expansion screw anchored on second deciduous molars
10184193|NCT03757468|Experimental|Leaf (leaf maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with Leaf Expander appliance anchored on second deciduous molars.
10184194|NCT03757429||RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
10184195|NCT03757429||Non-RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
10184196|NCT03757416||Flexor tenosynovectomy surgery|Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.
10184197|NCT03757403|Experimental|RDD1609 followed by Placebo|Application on the perianal area BID
10184198|NCT03757403|Experimental|Placebo followed by RDD1609|Application on the perianal area BID
10184199|NCT03757390|Experimental|Sequence 1|"period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg~period 2: receive CJ-30060 5/160/10mg"
10184200|NCT03757390|Experimental|Sequence 2|"period 1: receive CJ-30060 5/160/10mg~period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg"
10184201|NCT03757377|Active Comparator|BackBeat Moderato System (PHC ON)|Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
10184202|NCT03757377|Placebo Comparator|BackBeat Moderato System (PHC OFF)|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
10134981|NCT04241003|Experimental|SmartDrive - baseline and intervention|One arm for all users. Baseline - two weeks data collection documenting usage of wheelchair prior to intervention. Introduction of SmartDrive, a time period to get used to the SmartDrive and then two weeks data collection documenting usage of wheelchair with the intervention.
10134982|NCT04238429|Experimental|Toothpaste containing effective ingredients|Use the toothpaste containing 10% high cleaning silica base,0.5% sodium phytate and 0.5% sodium pyrophosphate to brush teeth twice daily for 8 weeks
10134983|NCT04238429|Placebo Comparator|Negative control toothpaste|Use the negative control dentifrice to brush teeth twice daily for 8 weeks
10134984|NCT04199949|No Intervention|Control|5 consecutive days of normal daily levels of physical activity and matched food intake
10134985|NCT04199949|Experimental|Inactivity|5 consecutive days of reduced step count by 80% compared to the Control trial, whilst placing the non-dominant arm in a sling, and reduced food intake (~ 20%) to match the reduction in energy expenditure induced by inactivity
10134986|NCT04193345|Active Comparator|Early cord clamping|The umbilical cord will be clamped within 15 seconds from delivery of the baby
10134987|NCT04193345|Active Comparator|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds from delivery of the baby
10134988|NCT04188574|Experimental|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
10134989|NCT04188574|Experimental|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
10134990|NCT04188574|Experimental|BB2603-1|Treatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine
10134991|NCT04188574|Other|Vehicle Control|0.3% polyhexanide/ 20% ethanol/ water formulation.
10134992|NCT04173312|Active Comparator|Infused analgesic|Patients will be assigned to receive local anesthetic through continuous infusion by pump.
10134993|NCT04173312|Placebo Comparator|Infused saline|Patients will be assigned to receive saline through continuous infusion by pump.
10134994|NCT04171453||Open-label|This study was open-label with only one treatment group. Lyrica CR was prescribed in accordance with usual clinical practice.
10134995|NCT04168073|Experimental|High sodium diet|
10134996|NCT04168073|Experimental|Low sodium diet|
10134997|NCT04163718|Experimental|Treatment with Umbralisib|
10134998|NCT04160325|Experimental|3 months exclusive enteral nutrition plus azathioprine|patients underwent surgery in this arm will given 3 months exclusive enteral nutrition,and free diet after 3 months. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
10134999|NCT04160325|Active Comparator|normal diet plus azathioprine|patients underwent surgery in this arm will given free diet all through. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
10135000|NCT04158154|Experimental|Primary Health Care Centers|Selected primary health care centers in Abuja will implement a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for hypertension diagnosis and treatment.
10135001|NCT04139486|Experimental|combined EMBOTRAP II or III and Contact Aspiration|
10135002|NCT04139486|Active Comparator|Contact Aspiration alone|
10135003|NCT04126083|Experimental|Lofexidine|Patients will receive lofexidine 0.54 mg 4 times daily and the baseline opioid dose will be reduced by 10% daily.
10135004|NCT04113200|Experimental|F+ALG|An alginate containing feed: MerMed One (Kaneka Corporation). 300mls administered nasogastrically over one hour.
10135005|NCT04113200|Other|F-ALG|A standard enteral feed commonly used in practice. Nutricomp Soy Fibre (B.Braun). 300mls administered nasogastrically over one hour.
10135006|NCT04099797|Experimental|C7R-GD2.CAR T cells|This is a single arm study. Patients will be treated at 4 dose levels. At dose level 0, patients will only receive GD2.CART cells without C7R and they will receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
10135007|NCT04079244|Active Comparator|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children"
10135008|NCT04079244|Active Comparator|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
10135009|NCT04077671|Experimental|SAD - Cohort A - CHF6467 0.3 µg/mm2|Cohort A: will be administered with CHF6467 0.3 µg/mm2 ulcer area as single dose.
10135010|NCT04077671|Experimental|SAD - Cohort B - CHF6467 1 µg/mm2|Cohort B: will be administered with 1 µg/mm2 ulcer area as single dose.
10135011|NCT04077671|Experimental|SAD - Cohort C - CHF6467 3 µg/mm2|Cohort C: will be administered with 3 µg/mm2 ulcer area as single dose.
10135012|NCT04077671|Experimental|SAD - Cohort D - CHF6467 6 µg/mm2|Cohort D: will be administered with 6 µg/mm2 ulcer area as single dose.
10135013|NCT04077671|Experimental|MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2|Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
10135014|NCT04077671|Experimental|MAD - Cohort F - CHF6467 1 or 3 µg/mm2|Cohort F: will be administered with 1 or 3 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
10135015|NCT04075292|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity
10135016|NCT04075292|Active Comparator|Rituximab and Chlorambucil|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles
10135017|NCT04014296|Experimental|High Protein Diet|Enrollment in State of Slim (SOS) weight loss program with a high protein diet.
10135018|NCT04014296|Experimental|Resistance Training|Enrollment in State of Slim (SOS) weight loss program with resistance training counseling sessions.
10135019|NCT04004845||Pregnant women|We are including only women who are age 18 or over, who have a single baby (not twins), with the baby's head down, and are between 36 weeks 6 days and 42 weeks 0 days of pregnancy.
10135020|NCT03986541||Retrospective cohort|Patients with advanced colorectal cancer previously treated with an anti-EGFR agent (panitumumab or cetuximab).
10135021|NCT03986541||Prospective cohort|Patients with advanced colorectal cancer newly starting treatment with an anti-EGFR agent (panitumumab or cetuximab).
10135022|NCT03969992|Other|nCPAP alone|Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary
10135023|NCT03969992|Experimental|Drug: Low Dose AeroFact|AeroFact-low dose SF-RI 1
10135024|NCT03969992|Experimental|Drug: High Dose AeroFact|AeroFact-high dose SF-RI 1
10135025|NCT03955367|Active Comparator|Pelvic Irradiation|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, and pelvic lymph nodes regions. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with IMRT.
10135026|NCT03955367|Experimental|Prophylactic EFI|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.
9826064|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
9826065|NCT02406248|Experimental|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
10135027|NCT03952468|Active Comparator|TMS + Brief Cognitive Behavioral Therapy|Combined transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
10135028|NCT03952468|Sham Comparator|Sham TMS + Brief cognitive behavioral therapy|Sham Transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
10135029|NCT03947541|Active Comparator|No Brace|Patients randomized to the no-brace group will not be required to wear a brace, postoperatively.
10135030|NCT03947541|Experimental|Brace|Patients randomized to the brace group will wear the brace when out of bed and will be allowed to remove the brace when in bed. This intervention will continue through their 6-week postoperative visit, after which point, patients will be allowed to wear the brace for comfort.
10135031|NCT03901300|Experimental|Fundamental Motor Skills (FMS)|The FMS group will utilize the PLAY FMS app that provides instructional lessons, peer modeling videos, and activity breaks to deliver 720 minutes of targeted, structured FMS instruction time to the child over a 12 week period.
10135032|NCT03901300|Active Comparator|Unstructured Physical Activity|The active comparator group will use a version of the PLAY app that provides instructional lessons to promote the equivalent dosage of unstructured physical activity for the child.
10135033|NCT03899857|Experimental|Pembrolizumab|Temozolomide-based radiochemotherapy (TMZ/RT=>TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=>TMZ.
10135034|NCT03898362|Active Comparator|pneumatically powered wheelchair or scooter|participants will use pneumatic powered wheelchair or scooter
10135035|NCT03898362|Active Comparator|battery powered wheelchair or scooter|participants will use battery powered wheelchair or scooter
10135036|NCT03880279|Experimental|TAC01-CD19|TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.
10135037|NCT03871543|Other|Part 1|All eligible subjects enrolled into Part 1 will be fit and dispensed with Test Lens 1
10135038|NCT03871543|Other|Part 2|All eligible subjects (based on CLDEQ responses) enrolled into Part 2 will be fit and dispensed with Test Lens 2 and will follow the same procedures as Part 1.
10135039|NCT03859388||Chronic ABMR|Single arm; patients with chronic ABMR diagnosed by Banff 2017 criteria and recommended for monthly treatment with tocilizumab will undergo monthly testing for donor-derived cell-free DNA (Allosure) and then have a follow-up biopsy after six monthly infusions of tocilizumab
10135040|NCT03854019|Experimental|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|Dextromethorphan/quinidine (DM/Q) 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
10135041|NCT03854019|Placebo Comparator|Placebo|Placebo one capsule once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
10135042|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv3 (M3) given IM at Day 0
10135043|NCT03844386|Experimental|MVA.tHIVconsv4 (M4)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv4 (M4) given IM at Day 0
10135044|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)+MVA.tHIVconsv4 (M4)|Participants in this arm receive a single combined dose containing each vaccine type MVA.tHIVconsv4 (M3) + MVA.tHIVconsv4 (M4) given IM at Day 0
10135045|NCT03844386|Placebo Comparator|Placebo|Participants in this arm receive one saline (placebo) dose given IM at Day 0
10135046|NCT03809429|Experimental|FE 999049 + GnRH agonist (GONAPEPTYL)|
10135047|NCT03809429|Experimental|FE 999049 + GnRH antagonist (CETROTIDE)|
10135048|NCT03786484|Experimental|PBF-999 20 mg|
10135049|NCT03786484|Experimental|PBF-999 40 mg|
10135050|NCT03786484|Experimental|PBF-999 80 mg|
10135051|NCT03786484|Experimental|PBF-999 120 mg|
10135052|NCT03786484|Experimental|recommended phase 2 dose (RP2D)|
10135053|NCT03751774|Experimental|MAMAACT|Training of midwives in intercultural communication. A 6 hours course and 2 one hour booster sessions. Distribution of health education materials on warnings signs of pregnancy and health system navigation to pregnant women during antenatal care visits.
10135054|NCT03751774|No Intervention|Control|Care as usual
9826066|NCT02406261|Experimental|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;~20 mg simvastatin, single oral dose on Days 2 and 36;~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;~50 mg lanabecestat, single oral dose on Day 4;~50 mg lanabecestat, single oral dose, Days 10 to 37"
10135055|NCT03744637|Experimental|Panel A: MK-5475 120 ug/165 ug/240 ug/240 ug/240 ug (Parts 1 and 2)|Participants in Panel A will receive a single inhaled dose of MK-5475 120 ug in Period 1 of Part 1, followed by MK-5475 165 ug in Period 2, followed by MK-5475 240 ug in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2 Period 2, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a right heart catheterization (RHC). In Part 2 Period 3, participants will receive a single inhaled dose of MK-5475 240 ug and undergo a functional respiratory imaging (FRI).
10135056|NCT03744637|Experimental|Panel B: 300 ug/360 ug/360 ug (Part 2)|Participants in Panel B will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
10135057|NCT03744637|Experimental|Panel C: 300 ug/360 ug/360 ug (Part 2, Expansion)|Participants in Panel C will receive a single inhaled dose of MK-5475 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
10135058|NCT03744637|Experimental|Panel D: 480 ug/120 ug/120 ug (Part 2)|Participants in Panel D will receive a single inhaled dose of MK-5475 480 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of MK-5475 120 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of MK-5475 120 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
10135059|NCT03744637|Placebo Comparator|Placebo (Part 1)|Participants will receive a single inhaled dose of matching placebo in Part 1.
10135060|NCT03741023|Other|Trauma Patients|"During Hospitalization:~Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population.~Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury."
10135061|NCT03741023|Other|Invasive Elective Surgery Patients|"During Hospitalization:~Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients <7 years of age (~3% total blood volume).~Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery."
10135062|NCT03741023|Other|Healthy Volunteers|Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit.
10135063|NCT03737370|Experimental|Dose escalation|"There are four dose cohorts (1, 1a, 2, 2a) in this arm and two dose levels of docetaxel (40mg/m^2 [level 1] and 50mg/m^2 [level 2]). Dosing of Radium 223 remains the same in all cohorts (55 KBq/kg given every 28 days for 6 cycles).~Maximum tolerated dose (MTD) of docetaxel will be assessed. MTD is defined as the highest dose-level, among those tested, associated with a rate of less than a 33% dose limiting toxicity (DLT)."
10135064|NCT03737370|Experimental|Dose expansion|If the maximum tolerated dose (MTD) of docetaxel is found in arm 1, this dose level will be expanded to include an additional 25 subjects to confirm the safety and explore the preliminary anti-cancer effect. If the MTD is not identified, the study will be stopped and the expansion cohort will not be accrued.
10135065|NCT03727893|Active Comparator|Roller-based intervention Group (IG)|A group participating in a high-intensity exercise on a roller-based system.
10135066|NCT03727893|Placebo Comparator|Control Group (CG)|A group participating in an independent workout program at an accessible community-based fitness facility.
10135067|NCT03727802|Experimental|TRK-250|
10135068|NCT03727802|Placebo Comparator|Placebo|
10135069|NCT03678545|Active Comparator|Dupilumab|
10135070|NCT03678545|Placebo Comparator|Placebo|
10135071|NCT03662022|No Intervention|No PEP|No PEP will be distributed
10135072|NCT03662022|Other|Household PEP|PEP will be given to all household contacts of an incident leprosy patient
10135073|NCT03662022|Experimental|PEP 100m|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
10135074|NCT03662022|Other|PEP 100m + positive for anti-PGL-I IgM Ab|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)
10135075|NCT03640312|Experimental|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
10135076|NCT03640312|Active Comparator|Candesartan|Patients randomized to the comparison arm will take a once daily 8mg candesartan.
10187685|NCT03723746|Experimental|Cohort 9 (Optional): Dose 2 or Placebo (Part 3) + Biopsy|Participants may receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. After final dosing collection of sigmoid biopsies will be performed. Cohort 9 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
10135077|NCT03606941|Experimental|electroacupuncture treatment|"Participants in the treatment group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of operation."
10135078|NCT03606941|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
10135079|NCT03576144|Experimental|BI 1265162|
10135080|NCT03576144|Placebo Comparator|Placebo|
10135081|NCT03571828|Experimental|Part 1: Dose Exploration|Dose exploration cohorts to estimate the MTD, safety, tolerability, and PK of different doses of AMG 562 in subjects with relapsed/refractory DLBCL, MCL or FL using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
10135082|NCT03571828|Experimental|Part 2: Dose Expansion|dose expansion part to gain further clinical experience, safety and efficacy data for AMG 562 in subjects with relapsed / refractory DLBCL. The dose to be evaluated will be at or below the MTD estimated in the dose exploration cohorts.
10135083|NCT03568994|Experimental|ADE 10+3+5 plus Atovaquone (AQ)|Induction I ADE: cytarabine, daunorubicin, etoposide 10+3+5, atovaquone daily
10135084|NCT03568994|Experimental|DA 3+10 with GO plus AQ|Induction I DA: daunorubicin, cytarabine 3+10 with GO: gemtuzumab ozogamicin, atovaquone daily
10135085|NCT03538899|Experimental|Gene therapy (AProArt)|Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells. The CliniMACS® CD34 Reagent System sorter device will be used to select CD34 cells. Patients will be conditioned with low dose busulfan prior to transplant.
10135086|NCT03520712|Experimental|valoctocogene roxaparvovec Open Label|Single administration of BMN270 at a dose of 6E13 vg/kg
10135087|NCT03499691|Experimental|Expanded Hemodialysis (HDx) Therapy|Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
10135088|NCT03499691|Active Comparator|Hemodiafiltration (HDF) Therapy|Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
10135089|NCT03447769|Experimental|canakinumab|Participants will be administered receive canakinumab for 18 cycles (approximately 54 weeks).
10135090|NCT03447769|Placebo Comparator|Placebo|Participants will be administered receive canakinumab placebo for 18 cycles (approximately 54 weeks).
10135091|NCT03444038|Experimental|Valbenazine|Valbenazine administered once daily for up to 24 weeks
10135092|NCT03432897|Experimental|Treatment|"Olaparib 300 mg BID q 4 weeks for up to 3 cycles. The 3rd cycle will not be given if patient is found to progress post cycle 2.~Between 22-42 days post Olaparib, patients will undergo a prostatectomy."
10135093|NCT03429816|Experimental|Interventional Arm|"Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.~Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients.~Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment."
10135094|NCT03398304|Experimental|Graded Exercise|Volunteers will participate in 3 study visits. The study visits will consist either of 20 minutes of walking, 20 minutes of running or 20 minutes of sitting. At the beginning of each study visit, prior to any exercise, a 4.5mL blood sample will be collected. The participant will then complete either 20 minutes of walking, running or sitting and will then have a 4.5mL blood draw taken from a new site.
10135095|NCT03398304|Experimental|Marathon Participation|On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
10135096|NCT03360942||DBS Long Term Follow Up|5 participants who were in a prior study to receive DBS are enrolled to have their progress and DBS devices monitored for a period of 12 years.
10135097|NCT03355157|Experimental|Palbociclib + endocrine therapy|Experimental arm for testing palbociclib + endocrine therapy.
10135098|NCT03355157|Active Comparator|Chemotherapy +/- endocrine maintenance therapy|Chemotherapy +/- endocrine maintenance as comparator arm.
10135099|NCT03336255|No Intervention|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
10135100|NCT03336255|Experimental|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
10135101|NCT03324035|Experimental|Treatment|Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
10135102|NCT03324035|Placebo Comparator|Placebo|Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
10135103|NCT03322774|Sham Comparator|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
10135104|NCT03322774|Experimental|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
10135105|NCT03322774|Sham Comparator|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
10135106|NCT03322774|Experimental|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
10135107|NCT03320018|Experimental|Hydrogen/Minocycline|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, TID for 3 days.~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
10135108|NCT03320018|Placebo Comparator|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
10135109|NCT03316742|Experimental|Intervention 1|Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
10135110|NCT03316742|Experimental|Intervention 2|Participants randomized to intervention 2 will complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant will attend 12 one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
10135111|NCT03274479|Experimental|PBF-1129_40mg|
10135112|NCT03274479|Experimental|PBF-1129_80mg|
10135113|NCT03274479|Experimental|PBF-1129_160mg|
10135114|NCT03274479|Experimental|PBF-1129_320mg|
10135115|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c<9 with who have wound 4weeks or longer with infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
10135116|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c<9 who have wound 4 weeks or longer without infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
10135117|NCT03265665|Experimental|ACTION Intervention|Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants during the adoptive phase (24-weeks) and 1 group session during the maintenance phase (12-weeks). Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
10135118|NCT03265665|Other|Enhanced usual care|Women in the Enhanced usual care arm will attend 1 asthma education/physical activity session and be given a Fitbit Charge HR to monitor their daily steps. They will be given a static step goal to achieve. Only reminder text messages for data collection visits will be sent.
10135119|NCT03256201|Experimental|Standard Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
10135120|NCT03256201|Experimental|Enhanced Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
10135121|NCT03225430|Active Comparator|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
10135122|NCT03225430|Experimental|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
10135123|NCT03201848|Experimental|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
10135124|NCT03201848|Placebo Comparator|Placebo|Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
10135125|NCT03196180|Experimental|Treatment (topical fluorouracil, imiquimod)|"The study has two phases:~Initiation Phase, which includes applications of 5-FU and imiquimod on alternating weeks for 8 applications. Participants will self-administer intravaginal 5-FU (2 g of 5% 5-fluorouracil, Effudex) once every other week for a total of 4 applications (wks 1, 3, 5, 7). Participants will receive provider-applied commercially available imiquimod cream 5% (12.5 mg imiquimod in 250 mg cream) directly to the cervix once every other week for a total of 4 applications (wks 2, 4, 6, 8).~Extension phase, which will include participants from the initiation phase who opt to continue their participation for applications of 5-FU and imiquimod on alternating weeks for 8 additional applications as described in the initiation phase.~Patients who are menstruating will delay application until the end of the menstrual cycle."
10135126|NCT03187210|Experimental|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
10135127|NCT03187210|Active Comparator|Arm A (Phase II)|"BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; Etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
10135128|NCT03187210|Experimental|Arm B (Phase II)|"Brentuximab Vedotin 1.8 mg/kg at day -8 together with standard BeEAM chemotherapy at days -7 to -1~BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
10135129|NCT03110666|Experimental|Autologous concentrated bone marrow aspirate|autologous concentrated bone marrow aspirate obtained from the BioCUE Concentration System
10135130|NCT03075423|Experimental|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a fixed dose of 240 mg nivolumab every two weeks or 480 mg every four weeks until progression.
10135131|NCT03075423|Active Comparator|Standard of Care therapy|Standard of Care therapy is administered according to the physician´s decision.
10135132|NCT03007511|Experimental|Fidmi|Placement of Fidmi enhanced enteral feeding device; internal tubes replacement during follow up and device removal after 3 month from placement Fidmi enhanced enteral feeding device
10135133|NCT02980731|Experimental|Venetoclax|Venetoclax will be administered orally 20 mg once daily (QD) beginning with a dose-titration phase, and then escalated up to 400 mg QD.
10135134|NCT02923947|Experimental|Normal renal function|For inclusion in the study as a patient with normal renal function, patients must have creatinine clearance ≥90 mL/min.
10135135|NCT02923947|Experimental|Severe renal impairment|For inclusion in the study as a patient with severe renal impairment, patients must have stable severe renal impairment (creatinine clearance <30 mL/min), as defined by the Cockcroft Gault equation, for at least 2 months prior to Day 1.
10135136|NCT02819141|No Intervention|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
10135137|NCT02819141|Experimental|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
10135138|NCT02816632|Experimental|healthy volunteers|
10135139|NCT02761187||Relapsed/refractory (R/R) MM|Patients who have received 1 to 3 prior lines of therapy
10135140|NCT02761187||Newly diagnosed (ND) MM|Patients within 3 months from initiation of treatment
10135141|NCT02739555|Active Comparator|1: Percutaneous treatment|Percutaneous treatment of OO is a thermal tumor destruction by radiofrequency or laser photocoagulation performed under CT control with strict aseptic approach and most often under general anesthesia. The introductive needle is inserted toward the nidus. Then the optic fiber or the radiofrequency probe is inserted in the nidus center and thermal destruction of the tumor is obtained.When the distance between the nidus and a nerve or the skin is less than 10 mm, infusion of normal saline or CO2 is introduced as spacing agent. When the nidus is in the subchondral bone, cold normal saline is introduced in the joint to protect the cartilage. In addition, a thermocouple is placed in the epidural or foraminal space to continuously monitor the temperature. A procedure typically required between 1 and 2 h from the time the patient entered the CT unit.
10135142|NCT02739555|Experimental|2: Bisphosphonate treatment|"The treatment consists of 3 infusions of zoledronic acid administered at a monthly interval. Bisphosphonate treatment is considered finished 1 month after the third bisphosphonate infusion (V4 visit). In few cases, the analgesic efficacy provided by 3 bisphosphonate infusions cannot be sufficient: 1 to 3 additional infusions could be proposed to the patient.~Zoledronic acid is supplied as a 4 mg/100 ml solution for infusion. It will be administered as infusion over 30 minutes under the supervision of a nurse. Adults will receive intravenous infusion of 4 mg of zoledronic acid. Children will receive infusion of 0.025 mg/kg of zoledronic acid.~The investigators propose abacus corresponding to zoledronic acid volume to infuse during 30 minutes for children."
10135143|NCT02725593|Experimental|Dapagliflozin|
10135144|NCT02725593|Placebo Comparator|Dapagliflozin placebo|
10135145|NCT02716675|Experimental|Group 1: Low-Dose VRC01|Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
10135146|NCT02716675|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
10135147|NCT02716675|Placebo Comparator|Group 3: VRC01 Placebo|Participants will receive an IV infusion of placebo for VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
10187686|NCT03723720||Patients after colonoscopy over 50 years|All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
10135148|NCT02636946|Active Comparator|SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)|"Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later."
10135149|NCT02636946|Experimental|Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)|"Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later."
10135150|NCT02631941|Experimental|A-B1-B2-C-D|"Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 days followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135151|NCT02631941|Experimental|B1-C-A-D-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135152|NCT02631941|Experimental|C-D-B1-B2-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135153|NCT02631941|Experimental|D-B2-C-A-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135154|NCT02631941|Experimental|B2-A-D-B1-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135155|NCT02631941|Experimental|D-C-B2-B1-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135156|NCT02631941|Experimental|B2-D-A-C-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135157|NCT02631941|Experimental|A-B2-B1-D-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
9669128|NCT03918278|Experimental|Part 2: Cohort D|Participants with metastatic soft tissue sarcoma (STS) (2L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years).
10135158|NCT02631941|Experimental|B1-A-C-B2-D|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135159|NCT02631941|Experimental|C-B1-D-A-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135160|NCT02623972|Experimental|Arm A: Eribulin > AC|"Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~Two research breast biopsies~Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~Radiation Therapy~Endocrine Therapy (if applicable)~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
10135161|NCT02623972|Experimental|Arm B: AC > Eribulin|"Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~Two research breast biopsies~Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~Radiation Therapy~Endocrine Therapy (if applicable)~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
10135162|NCT02617563||Minimally invasive lumbar fusion|A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.
10135163|NCT02598531||Test Arm|Test Arm participants will be enrolled in the standard of care bariatric surgery program and will undergo surgical weight loss through Laparoscopic Sleeve Gastrectomy or Laparoscopic Gastric Bypass. Approximately 9-13 months post surgery, each participant will be evaluated to determine if he/she is still eligible for a total knee replacement or if their need has been removed. If still eligible, participants will be enrolled in the standard of care TKA program and will undergo a TKA procedure. Participants will complete nine (9) research visits over 3.5-4 years.
10135164|NCT02598531||Control Arm|Control Arm participants will be enrolled in the standard of care TKA program and complete six (6) research visits over 2.5-3 years. This group of participants will undergo a TKA procedure without any surgical weight loss intervention.
10135165|NCT02576795|Experimental|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at escalating doses.
10135166|NCT02568215|Experimental|Group 1: Low-Dose VRC01|Participants will receive an IV infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
10135167|NCT02568215|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
10135168|NCT02568215|Placebo Comparator|Group 3: Placebo for VRC01|Participants will receive an IV infusion of placebo for VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
10135169|NCT02562378|Experimental|Experimental arm|Trastuzumab emtansine (T-DM1) will be administered at a fixed dose of 3.6 mg/kg IV on Day 1 every 3 weeks and three cohorts of patients with three different dose levels of conventional non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
10135170|NCT02528643|Experimental|Enzalutamide 160 mg|Participants received enzalutamide 160 milligrams (mg) capsules, orally QD during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Eligible participants received enzalutamide 160 mg capsules, orally QD during open label period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.
10135171|NCT02528643|Placebo Comparator|Placebo|Participants received enzalutamide matching placebo orally, once daily (QD) during double blind treatment period until disease progression, unacceptable toxicity, or any other discontinuation criterion was met. Median treatment duration was 64 days.
10135172|NCT02527434|Experimental|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
10184203|NCT03757364||19 patients with Ps|19 patients with Ps with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
9669129|NCT03918278|Experimental|Part 2: Cohort E|Participants with metastatic non-squamous non-small cell lung carcinoma (NSCLC) (1L) receive MK-0482 via IV infusion plus pembrolizumab 200 mg via IV infusion plus Pemetrexed 500 mg/m^2 via IV infusion on Day 1 of each 21-day cycle (Q3W) up to 35 administrations (up to approximately 2 years) plus carboplatin with desired dose of area under the curve (AUC) 5 and pemetrexed 500 mg/m^2, both administered via IV infusion, followed by maintenance therapy with pemetrexed 500 mg/m^2 via IV infusion for up to a total of 35 administrations (up to approximately 2 years).
9669130|NCT03899883|Experimental|Pegloticase|Single administration of pegloticase (8 mg IV in 250 mL 0.9% normal saline)
9669131|NCT03898908|Experimental|COMBO450|"Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets~In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death."
10135173|NCT02416011|No Intervention|Assessment Only (ASSESS)|Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time.
10135174|NCT02416011|Active Comparator|Generic Self-Help (GENERIC)|This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
9669132|NCT03892018|Active Comparator|Fed/ Fasted Treatment Sequence|"Subjects will be assigned a fed/fasted sequence.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose."
9694641|NCT04786639||Surgical Fixation Group|Open reduction with deltopectoral incision and humeral osteosynthesis with anatomic plates and screws will be performed for surgical fixation.
10135175|NCT02416011|Experimental|Targeted Self-Help (eTARGET)|Participants in this condition will receive the intervention created as the product of Study I.
10135176|NCT02387099|Active Comparator|Conventional Everolimus dosing according to label|"everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)~+ further treatment according to standard of care"
10135177|NCT02387099|Experimental|3 week Dose Induction of Everolimus|"an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)~+ further treatment according to standard of care"
10135178|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis
10135179|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis
10135180|NCT02377622|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis
10135181|NCT02377622|Active Comparator|FX CorDiax 800 dialyzer|FX CorDiax 800 dialyzer in high volume hemodiafiltration
10135182|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis treatment
10135183|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis treatment
10135184|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype CC|THERANOVA 400 dialyzer prototype CC in hemodialysis treatment
10135185|NCT02377570|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis treatment
10135186|NCT02332200||Early referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is less than or equal to 10 weeks.
9694642|NCT04786639||Non-Operative Group|Non-surgical treatment will be performed with sling immobilization.
10135187|NCT02332200||Later referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is >10 weeks.
10135188|NCT02299414|Experimental|Anti-hypertensive therapy to goal <140/90 mmHg|Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used
10135189|NCT02299414|Active Comparator|No anti-hypertensive unless BP is severe (≥160/105 mmHg|Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used
10135190|NCT02237508|Experimental|A-B1-B2-C-D|"Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 days followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135191|NCT02237508|Experimental|B1-C-A-D-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135192|NCT02237508|Experimental|C-D-B1-B2-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10184204|NCT03757364||13 patients with PsA|13 patients with PsA with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
10135193|NCT02237508|Experimental|D-B2-C-A-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135194|NCT02237508|Experimental|B2-A-D-B1-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135195|NCT02237508|Experimental|D-C-B2-B1-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135196|NCT02237508|Experimental|B2-D-A-C-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135197|NCT02237508|Experimental|A-B2-B1-D-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135198|NCT02237508|Experimental|B1-A-C-B2-D|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135199|NCT02237508|Experimental|C-B1-D-A-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
10135200|NCT02197234|Experimental|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
10135201|NCT02165345|Experimental|Tocilizumab|Participants will receive tocilizumab until the commercial availability of the drug or up to 5 years, whichever is earlier.
10135202|NCT02163733|Other|Fasted|AZD9291 tablets following a period of fasting
10135203|NCT02163733|Other|High-fat meal|AZD9291 tablets following a high-fat meal.
10135204|NCT02157883|Experimental|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
10135205|NCT01983241|Experimental|Alpha-1 MP 60 mg/kg|Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
10135206|NCT01983241|Experimental|Alpha-1 MP 120 mg/kg|Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
10135207|NCT01983241|Placebo Comparator|Placebo|0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
10135208|NCT01822288|Experimental|Tibolone group|Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.
10135209|NCT01822288|Active Comparator|Conventional hormone therapy group|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.
10135210|NCT01802632|Experimental|Daily dose of AZD9291|Daily oral dose of AZD9291
10135211|NCT01769924||Live kidney donors|Nephrectomy
10135212|NCT01769924||Healthy controls|Who also meet criteria to donate a kidney
10184205|NCT03757351|Experimental|DNL747 First, Placebo Second|
10184206|NCT03757351|Experimental|Placebo First, DNL747 Second|
10184207|NCT03757351|Experimental|Open-Label Extension|Conducted in the Netherlands only.
9694643|NCT04786925|Placebo Comparator|Control diet|A conventional diet based on the current Spanish Mediterranean dietary guidelines: Spanish Society of Community Nutrition (SENC).
9976832|NCT01355640|Experimental|non-nutritive sucking|"Every mother was given a vacuum pacifier( the brand is Goodbaby) to console her baby during heel lance."
10135213|NCT01706705|Experimental|Brachytherapy Treatment Planning|"MRI-compatible intracavitary applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.~Computed tomography (CT) scan and a magnetic resonance imaging (MRI) scan performed after the implant is placed in the operating room. The CT scan should take about 20 minutes and the MRI about 45 minutes."
10135214|NCT01696747||Diabetic|participants with a primary etiology of diabetic gastroparesis
10135215|NCT01696747||Idiopathic|participants with a primary etiology of idiopathic gastroparesis
10135216|NCT01696747||Post-Nissen|participants with a primary etiology of post-Nissen fundoplication gastroparesis
10135217|NCT01625286|Experimental|Part A: Intermittent schedule (2/5)|See intervention description below.
10135218|NCT01625286|Experimental|Part A: Intermittent schedule (4/3)|See intervention description below.
10135219|NCT01625286|Active Comparator|Part B: AZD5363 combined with paclitaxel|See intervention description below.
10135220|NCT01625286|Placebo Comparator|Part B: paclitaxel combined with placebo|See intervention description below.
10135221|NCT01609842|Experimental|Phone reminders and pharmacist|An alerted inpatient pharmacist or a designated study team member will bring the clopidogrel medication to the patient who has received a coronary stent. The patient will return home and receive IVR refill reminder calls.
10135222|NCT01609842|Other|Usual Care|The sites will have no interaction with the study personnel. The investigators will use database information to compare with the intervention sites
10135223|NCT01583283|Experimental|ACY-1215, Lenalidomide and Dexamethasone|Open label dosing cohorts will evaluate oral ACY-1215 (doses ranging from 40 - 480 mg days 1-5, 8-12, 15-19) in combination with oral Lenalidomide (doses ranging from 15 - 25 mg days 1-21) and oral Dexamethasone (40 mg once weekly).
10135224|NCT01397916||CLL-patients|
9669133|NCT03892018|Active Comparator|Fasted/ Fed Treatment Sequence|"Subjects will be assigned a fasted/fed sequence.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration."
10135225|NCT01397916||Controls|
10135226|NCT01363596||Natural Procreative Technology (NPT)|Patients who are treated or who consider being treated with Natural Procreative Technology (NPT) for infertility or history of spontaneous abortion.
10135227|NCT01341600|Experimental|Clopidogrel in poor metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 poor metabolizers (PM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
10135228|NCT01341600|Experimental|Clopidogrel in intermediate metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 intermediate metabolizers (IM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
10135229|NCT01341600|Experimental|Clopidogrel in extensive metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 extensive metabolizers (EM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
10135230|NCT01341600|Experimental|Omeprazole/Clopidogrel in PM|PM participants who have completed Arm 1 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
10135231|NCT01341600|Experimental|Omeprazole/Clopidogrel in IM|IM participants who have completed Arm 2 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
10135232|NCT01341600|Experimental|Omeprazole/Clopidogrel in EM|EM participants who have completed Arm 3 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
10135233|NCT01328626|Experimental|Arm A (CLL/SLL subjects)|Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) subjects
10135234|NCT01328626|Experimental|Arm B (NHL subjects)|Non-Hodgkin lymphoma (NHL) subjects
10135235|NCT01061684||NAFLD|pediatric patients with non-alcoholic fatty liver disease (NAFLD).
10135236|NCT01044901||Subjects with Sickle Cell Disease (SCD)|38 clinically stable black patients with Sickle Cell Disease (SCD) (including individuals with hemoglobin SS, SC, and β-thalassemia demonstrated by high-performance liquid chromatographic separation or gel electrophoresis).
10135237|NCT01044901||Healthy Volunteers|13 healthy control subjects were frequency matched to patients with SCD on age, sex, and race.
10135238|NCT01030484||NAFLD|adult patients with non-alcoholic fatty liver disease (NAFLD).
10135239|NCT01012596||Creighton Model|New and return users of the Creighton Model FertilityCare System, a method of Natural Family Planning.
9519613|NCT03285334|Experimental|XP-endo Shaper|The XP-endo Shaper is an innovative single instrument manufactured from Max wire. Its special ability to shift crystalline structure at body temperature in order to adapt to the root canal wall, has provided a unique instrument with the promise of anatomical shaping.
9669134|NCT03889899|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
9519614|NCT03285334|Active Comparator|iRace|rotary files
9519615|NCT03285282|Active Comparator|Intervention|Thoracolumber interfascial plane block
10135240|NCT00777712||Diabetics (HbA1c level >8%) with infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer with infection. N=50
10135241|NCT00777712||Normoglycemic- with infection|Non-Diabetic patients with wound(s) 4 weeks or longer with infection. N=50
10135242|NCT00777712||Diabetics (HbA1c level >8%) without infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer without infection. N=50
10135243|NCT00777712||Normoglycemic- without infection|Non-Diabetic patients with wound(s)4 weeks or longer without infection. N=50
10135244|NCT00777712||Diabetics (HbA1c level<8%) with infection|Patients with controlled diabetes with HbA1c level<8% who have wound (s) 4 weeks or longer and also with infection. N=50
10135245|NCT00777712||Diabetics (HbA1c level <8%) without infection|Patients with controlled diabetes with HbA1c level <8% who have wound (s) 4 weeks or longer and also without infection. N=50
10135246|NCT00682695||1|"Participants who have had a hemorrhagic stroke at University of Maryland, University of Cincinnati, Massachusetts General Hospital, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of the patient or legal representative to provide informed consent. Racial/ethnic category meets one of the following: African American, Caucasian or Hispanic.~Healthy volunteers who are matched to the study cases with hemorrhagic stroke within +/- 5 years of age, same gender and same race."
10135247|NCT00529113|Experimental|Phase 1 Cohort 1|Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135248|NCT00529113|Experimental|Phase 1 Cohort 2|Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135249|NCT00529113|Experimental|Phase 1 Cohort 3|Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135250|NCT00529113|Experimental|Phase 1 Cohort 4|Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135251|NCT00529113|Experimental|Phase 1 Cohort 5|Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135252|NCT00529113|Experimental|Phase 1 Cohort 6|Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135253|NCT00529113|Experimental|Phase 1 Cohort 7|Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135254|NCT00529113|Experimental|Phase 2 Cohort 1|Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135255|NCT00529113|Placebo Comparator|Phase 2 Cohort 2|Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
10135256|NCT00463814|Experimental|AZD6244|
10135257|NCT00288080|Active Comparator|Androgen suppression + Radiation Therapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
10135258|NCT00288080|Experimental|Androgen suppression + Radiation Therapy + Chemotherapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of RT. Following completion of RT, 6 cycles of docetaxel (premedicated with dexamethasone) and prednisone are delivered concurrently with androgen suppression.
10135259|NCT00099437|Experimental|1|Fulvestrant 500 mg
10135260|NCT00099437|Experimental|2|Fulvestrant 250 mg
10135261|NCT00087919||Maywood|The were 743 subjects were sampled from Maywood, Il. There was no intervention.
10135262|NCT00087919||Nigeria|There were 1188 Nigerian sampled from Igbo-Ora and Ibadan, Nigeria. There was no intervention.
10135263|NCT00003479|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
10135264|NCT04250792|Experimental|single arm|Low dose naltrexone was prescribed to the patients affected with psoriasis.
10135265|NCT04250974|Experimental|electroacupuncture|electroacupuncture at points after surgery
10135266|NCT04250974|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
10135267|NCT04250974|No Intervention|Control group|only oral or injection painkiller were used after surgery
10135268|NCT04251013|Active Comparator|Group A: RX Cytology brush, Boston Scientific FIRST|A first biliary brushing will be carried out during ERCP using a standard brush RX Cytology Brush, Boston Scientific, then a second brushing will be carried out using a brush INFINITY®, US Endoscopy
10135269|NCT04251013|Active Comparator|Group B: Infinity®, US Endoscopy FIRST|A first biliary brushing will be carried out during ERCP using an INFINITY® brush, US Endoscopy then a second brushing will be carried out using standard RX Cytology Brush, Boston Scientific
10135270|NCT04251000|Experimental|Joovv Pilot Experimenta Arm|Individuals will receive 90 day access to the Joovv infrared mini light device.
10135271|NCT04250961|Experimental|Shower Group|Patients who had a shower in 48-72 hours after Median Sternotomy
10135272|NCT04250961|Active Comparator|Control Group|Patients whose sternal incision site was not connected water until remove sutures
10135273|NCT04251039||PCI with pre-treatment with P2Y12 inhibitors|"SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo:~Assessment of platelet reactivity (Time 0, T0) (VFN)~PCI (start = T1; end= T2)"
10135274|NCT04251039||PCI with treatment with P2Y12 inhibitors only after procedure.|"SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo:~Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0)~Assessment of platelet reactivity (Time 0, T0) (VFN)~PCI (start of PCI= T1; end of infusion of Cangrelor= T2)"
10135275|NCT04250740|Experimental|Coffee A|
10135276|NCT04250740|Experimental|Coffee B|
10135277|NCT04250740|Experimental|Coffee C|
10184208|NCT03757338|Active Comparator|Fingolimod Reference Formulation|0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.
10135278|NCT04250844||Botulinum|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy with intrapyloric botulinum injections and if clinically applicable endoscopic functional luminal imaging probe (EndoFLIP). The dosage will be determined by the patient's physician.
10135279|NCT04250844||Control|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy without intrapyloric botulinum injections.
10135280|NCT04250831|Experimental|Glucomannan, oligofructose and chromium mixture|Agglomerated glucomannan, oligofructose and chromium mixture as the functional ingredient in a calorie
10135281|NCT04250584|Experimental|Test Device|Novel Mandibular Advancement Device
10135282|NCT04250584|Active Comparator|Predicate Device|Predicate Mandibular Advancement Device
10135283|NCT04250870|Active Comparator|Nursing Home Residents|Nursing home residents (n=59) were evaluated in five different nursing homes.
10135284|NCT04250870|Active Comparator|Community-Dwelling Elderly|The community-dwelling elderly people (n=59) were selected from two different municipalities of the city.
10135285|NCT04250623|Experimental|subjects, 18-70 y, healthy|subjects, 18-70 y, healthy
10135286|NCT04250701||Dyslexia (D)|
10135287|NCT04250701||Intellectual Disability (ID)|
10135288|NCT04250701||Control (C)|
10135289|NCT04250857||Suspected Sudden Cardiac Arrest|All subject with suspected of a circulatory arrest for any cause.
10135290|NCT04250649|Active Comparator|Intervention|Betadine solution disinfection of the subcutaneous tissue during primary shoulder surgery
10135291|NCT04250649|No Intervention|Controle|Control group with surgery without disinfection of the subcutaneous tissue but dissection with an electric cautery during primary shoulder surgery
10135292|NCT04250506|Experimental|Treatment A: Daridorexant 50 mg|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
10135293|NCT04250506|Experimental|Treatment B: Daridorexant 200 mg|Daridorexant (ACT-541468) administered as film-coated tablets (4 x 50 mg) for oral use.
10135294|NCT04250506|Placebo Comparator|Treatment C: Placebo|Placebo administered as tablets (4 x 50 mg) for oral use.
10135295|NCT04250506|Active Comparator|Treatment D: Moxifloxacin 400 mg|Moxifloxacin administered as film-coated tablets for oral use.
10135296|NCT04250675|Sham Comparator|Sham|Participants will apply Intermittent Pneumatic Compression (IPC) using a customized version of the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The sham device applies a compression sequence of 30 mmHg to the foot, ankle and calf with inflatable cuffs.
10135297|NCT04250675|Active Comparator|Active Comparator - Intermittent Pneumatic Compression|Participants will apply Intermittent Pneumatic Compression (IPC) using the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The Arterial Assist Device® applies a compression sequence of 120 mmHg to the foot, ankle and calf with inflatable cuffs.
10135298|NCT04250688|Experimental|Esko Bionics Suit + Functional Electrical Stimulation|
10135299|NCT04250688|No Intervention|Control|
10135300|NCT04250428|No Intervention|Control|Women in the control arm will have (standard) access to antenatal care.
10135301|NCT04250428|Experimental|Demand intervention|Women in this arm will receive a home visit by a study nurse at the beginning of their pregnancy that will inform them regarding the importance of iron and folic acid supplementation as well as malaria prophylaxis.
9968712|NCT01282684|Active Comparator|single oral dose of 200 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
10135302|NCT04250428|Experimental|Supply intervention|Women in this arm will get a monthly visit by study nurses. Women who did not obtain supplements or malaria prophyllaxis through routine antenatal care services will be directly provided with the supplements and malaria drugs by the study nurse.
10135303|NCT04250376|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
10135304|NCT04250480|Experimental|Beta-alanine|4 g by mouth, 3 times per day with regular meals for 14 days.
10135305|NCT04250480|Placebo Comparator|Placebo|4 g by mouth, 3 times per day with regular meals for 14 days.
10135306|NCT04250519|Experimental|1% sodium hypochlorite & dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
10135307|NCT04250519|Active Comparator|1% sodium hypochlorite as irrigant &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
10135308|NCT04250519|Experimental|5.25% sodium hypochlorite and dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
10135309|NCT04250519|Active Comparator|5.25% sodium hypochlorite &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
10135310|NCT04250532||Lifeguard|Lifeguards who work on the Atlantic coast of Gironde France.
10135311|NCT04250181||Standard RF|ablation with RF power of 30 Watts (30W) and with 25 Watts (25W) on posterior wall
10135312|NCT04250181||High RF 40W (40 Watts)|ablation with RF power of 40 watts (40W)
10135313|NCT04250181||High RF 50W (50 Watts)|ablation with RF power of 50 watts (50W)
10135314|NCT04250220|Experimental|intervention group|e-health-based strategy
10135315|NCT04250220|No Intervention|control group|symptom based AF-screening
10135316|NCT04250246|Experimental|Ipilimuamb plus nivoluamb plus guadecitabine|ipilimumab plus nivolumab combined with guadecitabine
10135317|NCT04250246|Active Comparator|Ipilimumab plus nivolumab|Ipilimumab plus nivolumab
10135318|NCT04250454|No Intervention|Control|Elsass Standard Care
10135319|NCT04250454|Active Comparator|Intervention|Enriched eviroment, Feed back training, Electrical stimulation, nutrition
10135320|NCT04250142|Active Comparator|Conventional Glass Ionomer|Selective removal of carious tissue to soft dentin. Deep carious dentin will be lined by a conventional glass ionomer, followed by a composite resin restoration.
9519616|NCT03285282|No Intervention|Control|
10135321|NCT04250142|Experimental|Self-etching Adhesive|Selective removal of carious tissue to soft dentin. Deep carious dentin will not be lined and a self-etching adhesive will cover the tissue, followed by a composite resin restoration.
10135322|NCT04250116|Experimental|Anticoagulation mono therapy|
10135323|NCT04250116|Active Comparator|Dual antithrombotic therapy|
10135324|NCT04250272|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
10135325|NCT04250272|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
10135326|NCT04250129||SLNB (-)&level 1-3 RT|SLNB (-)&level 1-3 RT
10135327|NCT04250129||SLNB (+)&level 1-3 RT|SLNB (+)&level 1-3 RT
10135328|NCT04250129||SLNB(+)&ALND&level 3 RT (+/-level 1-2)|SLNB(+)&ALND&level 3 RT (+/-level 1-2)
10135329|NCT04250350|Experimental|Lebrikizumab|every 2 weeks (Q2W)
10135330|NCT04250389||Patients with VS receiving methylene blue infusion|The studied population will be all patients receiving methylene blue for refractory vasoplegic shock (VS) after Cardiopulmonary Bypass (CPB). Refractory VS is defined as follow: a dose of norepinephrine > 0.5µg/kg/min to obtain a mean arterial pressure of 65-75 mmHg with a normal or increase cardiac (> 2 L.min-1.m-2). Patients will be included in the investigator's 20-bed adult cardiothoracic intensive care unit (ICU) in a tertiary teaching hospital (Hopital Cardiologique Louis Pradel, Hospices Civils de Lyon).
10135331|NCT04250064|Experimental|Concurrent low-dose Bevacizumab|Low-dose concurrent Bevacizumab with standard radiotherapy
10135332|NCT04250064|Experimental|Ultra-low-dose RT|Ultra-low-dose RT
10135333|NCT04250324|Experimental|BZ019|The subjects are enrolled into 2 dose-escalation cohorts, include 3x10^6/kg、6x10^6/kg, and dose-expansion cohorts, maybe 8x10^6/kg、10x10^6/kg.
10135334|NCT04250051|Experimental|Treatment (combination chemotherapy, ivosidenib)|"INDUCTION: Patients receive filgrastim SC QD on days 0-6, fludarabine phosphate IV QD over 30 minutes on days 1-5, cytarabine IV QD over 4 hours on days 1-5, and ivosidenib PO QD on days 7-28. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
10135335|NCT04250090||Long-term type ureteral stent set|Patients with Long-term type ureteral stent set due to ureteral stricture.
10135336|NCT04250298|Other|Iron deficient blood donors|Daily intake of 30 mg of sucrosomal iron during 90-120 days (male and female whole blood donors)
10135337|NCT04250012|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 10-week internet-based acceptance and commitment therapy intervention with three remote meetings with a psychologist"
10135338|NCT04250012|Active Comparator|Psychoeducation|"Group Psychoeducation will receive a self-help booklet and a link to mobile wellness training program"
10135339|NCT04250441|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
10135340|NCT04250025|Experimental|EXPERIMENTAL GROUPE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
10135341|NCT04250025|No Intervention|CONTRO GROUPE|60 patients benefit from standard treatment for 6 months i.e elastic compression and anticoagulation if needed. Notably, if patients were no longer on anticoagulant treatment at the time of screening and inclusion, this treatment will not be reintroduced.
10135342|NCT04249999|Experimental|Intervention|Access to online physical activity platform (www.activonline.com.au) in addition to usual care.
10135343|NCT04249999|No Intervention|Control|No access to online physical activity platform. Continue with usual care.
10135344|NCT04249713|Experimental|Brodalumab|Brodalumab 210mg subcutaneously every week for 24 weeks
10135345|NCT04249869|Experimental|Group A|Group A will receive VGH-AD1 two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 8 weeks. Post-follow up will be 4 weeks later.
10135346|NCT04249869|Placebo Comparator|Group B|Group B will receive placebo two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the VGH-AD1 for another 8 weeks. Post-follow up will be 4 weeks later.
9519617|NCT03285256|Experimental|Experimental Memory Training|Experimental memory training program
10135347|NCT04249908|Active Comparator|Healthy Subjects|
10135348|NCT04249908|Experimental|Mild Renal Impairment (RI)|
10135349|NCT04249908|Experimental|Moderate RI|
10135350|NCT04249908|Experimental|Severe RI|
9519618|NCT03285256|Active Comparator|Comparator Memory Training 1|Comparator memory training program
9519619|NCT03285256|Active Comparator|Comparator Memory Training 2|Alternative comparator memory training program
10135351|NCT04249921||Experimental|"Use acupuncture to treat the patients who received the surgery of CPA tumor. Acupoints of reference: Yifeng(TE17),Tinggong(SI19),Xiaguan(ST07),Wind Pool(GB20),Outer Pass(SJ5),Union Valley(LI4),Yang Mound Spring(GB34),Leg Three Li(ST36).~Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS)."
10135352|NCT04249921||Control|1.Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS).
10135353|NCT04249934|Experimental|Caffeinated Coffee|
10135354|NCT04249934|Active Comparator|Decaffeinated Coffee|
10135355|NCT04249752||Group 1 with GBS patients|GBS patients
10135356|NCT04249752||Group 2 with CIDP patients|with CIDP patients
10135357|NCT04249843|Experimental|Phase 1a: Dose Escalation|BGB-3245 administered orally (PO)
9519620|NCT03285243|Sham Comparator|Blue light - non monochromatic|
10135358|NCT04249843|Experimental|Phase 1b, Group 1: Dose Expansion|BGB-3245 administered orally (PO)
10135359|NCT04249726|Experimental|Direct composite resin restoration|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations
10135360|NCT04249726|Active Comparator|Full coverage metal-ceramic crown|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations followed by full coverage metal-ceramic crown
10135361|NCT04249960|No Intervention|Transition as usual|Young people in this group will receive usual care and transition as usual, they will be our control group.
10135362|NCT04249960|Experimental|Managed transition|Young people in this group will do the managed transition, they will be our experimental group.
10135363|NCT04249882|Placebo Comparator|Placebo|Matched to active medications
10135364|NCT04249882|Active Comparator|Varenicline|1 mg twice a day
10135365|NCT04249882|Active Comparator|Naltrexone|50 mg once a day
10135366|NCT04249570|Experimental|Iodine|gastrostomy feeding tube is coated with a layer of Betadine by aseptic gauze before PEG technique
10135367|NCT04249570|No Intervention|No iodine|gastrostomy feeding tube is not coated with a layer of Betadine by aseptic gauze before PEG technique
10135368|NCT04249856||Women examined by colposcopy|Women referred to colposcopy at our facilities who met inclusion criteria
10135369|NCT04249765|Experimental|Hand strength|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned.~The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer."
10135370|NCT04249817|Experimental|Video conferencing with extended role practitioner|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
10135371|NCT04249817|No Intervention|Usual care|Participant goes to their rheumatologist's clinic for follow-up, including physical assessment by their rheumatologist, as they would normally.
10135372|NCT04249700|Experimental|Whole-body Hyperthermia (WBH)|All participants receive WBH for 80-110 minutes in the Curve Sauna Dome infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
10184209|NCT03757338|Experimental|Fingolimod Test Formulation|0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.
10184210|NCT03757325|Experimental|DNL747 First, Placebo Second|Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
10184211|NCT03757325|Experimental|Placebo First, DNL747 Second|Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
10184212|NCT03757286|Experimental|FSF with CAD\CAM customized cutting guide|Maxillary reconstruction using free scapular flap with CAD/CAM customized osteotomy guide.
10184213|NCT03757286|Active Comparator|FSF without customized cutting guide|maxillary reconstruction using free scapular flap without customized osteotomy guide. CAD/CAM 3D model for maxilla will be used.
10184214|NCT03757273|Experimental|FFF with CAD/CAM customized cutting guide|Mandibular reconstruction using free fibular flap with CAD/CAM customized osteotomy guide.
10184215|NCT03757273|Active Comparator|FFF without customized cutting guide|Mandibular reconstruction using free fibular flap without customized osteotomy guide. CAD/CAM 3D model for mandible will be used.
10184216|NCT03757260|Experimental|Treatment Group|Antimicrobial photodynamic therapy with methylene blue applied to test site after mechanical debridement.
10184217|NCT03757260|Placebo Comparator|Placebo Group|Photodynamic therapy laser is not activated with saline water in the test site after mechanical debridement.
10184218|NCT03757221|Experimental|Combination ixazomib + daratumumab without dexamethasone|Elderly Relapse Refractory Multiple Myeloma Patients treated by Combination ixazomib + daratumumab without dexamethasone
10184219|NCT03757208|No Intervention|Fasting group|
9968713|NCT01282684|Active Comparator|single oral dose of 400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
10184220|NCT03757208|Active Comparator|Carbohydrate rich drink (CHD) group|
10184221|NCT03757195|Experimental|augmentation by xenograft|xenograft mixed with plasma extracted from blood
10184222|NCT03757169|Active Comparator|Control group|Verbal informations about the disease, and exercise behavior, and nutrition.
10184223|NCT03757169|Active Comparator|Hand grip group|Three supervised sessions por week: 4 series (2 at each arm) of two minutes of isometric hand grip contraction at 30% of maximal voluntary contraction. Between series there will be two minutes to rest.
10184224|NCT03757156|No Intervention|Aspirin maintenance group|People who are taking aspirin continue to take aspirin.
10184225|NCT03757156|Experimental|Aspirin withdrawal group|People who are taking aspirin stop to taking aspirin.
10184226|NCT03757143|Active Comparator|PVI et Insyte|Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
10184227|NCT03757143|Experimental|CHG et Insyte|Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
10184228|NCT03757143|Experimental|PVI et Nexiva|Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
10184229|NCT03757143|Experimental|CHG et Nexiva|Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
10184230|NCT03757117|Experimental|Intervention|Feminizing hormone therapy and peer navigation
10135373|NCT04249804|Experimental|Intrathecal Mg group|45 patients will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine
10135374|NCT04249804|Experimental|IV Mg infusion group|45 patients will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia
10135375|NCT04249804|No Intervention|control|0.5% heavy bupivacaine in the spinal with no additives
10135376|NCT04249544|Experimental|Impulsive group, placebo then pramipexole|half of the impulsive group will first get the placebo on the first day and pramipexole on the second day
10135377|NCT04249544|Experimental|Impulsive group, pramipexole then placebo|half of the impulsive group will first get the pramipexole on the first day and the placebo on the second day
10135378|NCT04249544|Experimental|Non-impulsive group, placebo then pramipexole|half of the non-impulsive group will first get the placebo on the first day and the pramipexole on the second day
10135379|NCT04249544|Experimental|Non-impulsive, pramipexole then placebo|half of the non-impulsive group will first get the pramipexole on the first day and the placebo on the second day
10135380|NCT04249791|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from live donor.
10135381|NCT04249635||Reference Group|Healthy term (> 37 weeks of gestation) newborns of women with pregestational body mass index (BMI) ≥18,5 and <24,9 in the first prenatal visit.
10135382|NCT04249635||Maternal obesity (MO) Group|Newborns of women with pregestational BMI ≥30 that received 200 mg/dayDHA supplementation.
10135383|NCT04249635||MO+DHA Group|Newborns from women with pregestational BMI ≥30 that received 800 mg/day DHA supplementation.
10135384|NCT04249531|Experimental|Amikacin|Patients will receive once amikacin i.v. 7,5 mg/kg in the first week
10135385|NCT04249427|Active Comparator|Erenumab|140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
10135386|NCT04249427|Placebo Comparator|Placebo|Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
10135387|NCT04249622|Experimental|Arm I (rifaximin, pertuzumab-based chemotherapy)|Patients that experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy receive rifaximin PO BID on days 1-5 and standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
10135388|NCT04249622|Active Comparator|Arm II (pertuzumab-based chemotherapy)|Patients that do not experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy continue receiving standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
10135389|NCT04249440||PST|patient accepts preoperative systemic treatment as upfront strategy
10135390|NCT04249440||upfront surgery|patient accepts upfront surgery and run postoperative systemic treatment
10135391|NCT04249648||Patients with new diagnosis of heart failure with reduced ejection fraction|Patients with new diagnosis of heart failure with reduced ejection fraction who will be started on renin-angiotensin-aldosterone system inhibitors or in whom there is a plan to increase renin-angiotensin-aldosterone system inhibitors (if already taking prior to diagnosis of heart failure).
10135392|NCT04249648||Patients with hyperkalaemia|Hospitalised patients and patients attending emergency department who have at least 1 blood test with a potassium level of ≥5.5 mmol/l.
10135393|NCT04249648||Healthcare professionals managing patients with hyperkalaemia|Healthcare professionals (doctors, pharmacists, non-medical prescribers) who manage patients with hyperkalaemia and/or heart failure and hyperkalaemia.
10135394|NCT04249518|No Intervention|nurse instruction of CPAP|Normal extradition. 45 minutes face to face with a nurse.
10135395|NCT04249518|Experimental|Video extradition|Access to 7 min video - explaining how to start CPAP and how to adjust the mask.
10135396|NCT04249206|Experimental|Hydraulic Sealer Group|"The single-cone obturation technique is based on a master cone of gutta-percha in conjunction with a hydraulic sealer.~Hydraulic endodontic cements exhibit excellent hydraulic properties, biocompatibility and bioactivity."
10135397|NCT04249206|Active Comparator|Zinc oxide-eugenol Sealer Group|The continuous wave of condensation of gutta-percha and a zinc oxide-eugenol (ZOE) sealer is a gold standard in endodontic obturation.
10135398|NCT04249479|Experimental|CM temperature 20° C|CM is administered to the patient at a temperature of 20° C.
10135399|NCT04249479|Active Comparator|CM temperature 37° C|CM is administered to the patient at a temperature of 37° C.
10135400|NCT04249154|Other|Post-op IMRT & hormonal therapy|The protocol is designed to recruit patients who have undergone prostatectomy and high risk features of the disease were found post-operatively or for patients that, after prostatectomy, a PSA rise has been documented will be enrolled in the Phase II trial. Patients will receive Eligard injection 8-12 weeks before starting radiation. The second injection is given 12 weeks after the first one concomitant with radiation therapy.
10135401|NCT04249128|Experimental|Veg Collagen & Keratin Free (Hair Skin Nails)|Participants will receive a free 3 month supply of Collagen & Keratin for Hair, Skin & Nail Health
10135402|NCT04249128|Experimental|Veg Collagen Extended with Powder Free (Hair Skin Nails)|Participants will receive a free 3- month supply of Collagen & Keratin for Hair, Skin & Nail Health extended with a pro-berry powder
10135403|NCT04249128|Experimental|Veg Collagen & Keratin $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin for Hair, Skin & Nail Health
10135404|NCT04249128|Experimental|Veg Collagen Extended with Powder $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin extended with pro-berry powder for Hair, Skin & Nail Health
10135405|NCT04249128|Experimental|Ceramides and Astaxanthin Free (Skin)|Participants will receive a free 3-month supply of ceramides and Astaxanthin for Hair, Skin & Nail Health
10135406|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder Free (Skin)|Participants will receive a free 3-month supply of Ceramides and Astaxanthin for Hair, Skin & Nail Health
9519621|NCT03285243|Experimental|Monochromatic blue light|
9519622|NCT03285217|Experimental|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
10135407|NCT04249128|Experimental|Ceramides and Astaxanthin $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
10135408|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
10135409|NCT04249089|Active Comparator|Relaxation Group|
10135410|NCT04249089|No Intervention|Control group|
10135411|NCT04249024|Experimental|Laser treatment|
10135412|NCT04249024|Active Comparator|Mucosal flap surgery|
10135413|NCT04249466||Patient with cystic fibrosis|
10135414|NCT04249141||ICU providers|Surveys and a concept mapping exercise will be administered to ICU providers who participated in the ICU Liberation Collaborative
10135415|NCT04249141||Secondary Data Analysis|Secondary data analysis will used information on patients and providers who participated in the ICU Liberation Collaborative
10135416|NCT04249349|Experimental|Robot-assisted Gait|Participants will receive assisted gait with a motorized ankle foot orthosis. Patient´s gait will be analyzed by a photogrammetry system during device assistance. Session will involve 1 hour of supervised training.
10135417|NCT04249284|Experimental|Treatment A : BMS-986165|
10135418|NCT04249284|Experimental|Treatment B: BMS-986165 prototype 1|
10135419|NCT04249284|Experimental|Treatment C: BMS-986165 prototype 2|
10135420|NCT04249284|Experimental|Treatment D: BMS-986165 prototype 2|
10135421|NCT04249193||Transfusion|
10135422|NCT04249115|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of targeted lesion.
10135423|NCT04249271||euthyroid, no antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
9968714|NCT01282684|Active Comparator|single oral dose of 800 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
9968715|NCT01282684|Active Comparator|single oral dose of 1600 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
10135424|NCT04249271||borderline euthyroid, no antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO <100 IU/l repeated serum sampling
10135425|NCT04249271||hypothyroidism, no antibodies|TSH >4.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
10135426|NCT04249271||euthyroid, with antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
10135427|NCT04249271||borderline euthyroid, with antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO >100 IU/l repeated serum sampling
10135428|NCT04249271||hypothyroidism, with antibodiesal|TSH >4.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
10135429|NCT04248998|Experimental|Chemotherapy plus Fasting-Mimicking Diet (FMD)|"Experimental Arm A will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD.~Chemotherapy will consist of:~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~twelve consecutive cycles of weekly paclitaxel 80 mg/mq~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles."
10135430|NCT04248998|Experimental|Fasting-mimicking diet plus metformin plus chemotherapy|"Experimental Arm B will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD and daily metformin~Chemotherapy will consist of:~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~twelve consecutive cycles of weekly paclitaxel 80 mg/mq~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles.~Metformin will be administered at an initial dosage of 850 mg/dya, and then escalated to the maximum dosage of 1700/day (two 850 mg tablets) if well tolerated. Metformin will be interrupted 7 days before surgery."
9968716|NCT01282684|Active Comparator|single oral dose of 1000 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
9968717|NCT01282684|Active Comparator|single oral dose of 1400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
10135431|NCT04249102|Experimental|CGM Group|The study group will be provided with a Continuous Glucose Monitoring system (Guardian Connect from Medtronic).
10135432|NCT04249102|Active Comparator|FGM Group|The control group will be provided with a Flash Glucose Monitoring system (Abbott Diabetes Care).
9968718|NCT01282684|Placebo Comparator|Placebo|2 patients per cohort will be randomly assigned to take placebo. 12 patients total will be randomized to take placebo in this study.
9968719|NCT01282697|Experimental|rapamycin+irinotecan at a given dose|
9976833|NCT01355640|No Intervention|control group|A research nurse also explained the study to the control group parents. Standard clinic procedure for infant injection was also implemented. Mothers in control group also lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed.
10135433|NCT04249050|Experimental|Intervention group|The intervention group is receiving a nutritional drink containing potential immune stimulating ingredients (fish oil, arginine, nucleotides)
10135434|NCT04249050|No Intervention|Control group|The Control group is receiving the hospital´s Standard Of Care.
10135435|NCT04249063|Experimental|Treatment Group|NovaSure EA with an injection of local anaesthetic into the fundus. Paracervical block and procedural sedation as per usual.
10135436|NCT04249063|Placebo Comparator|Control Group|NovaSure EA with an injection of normal saline into the fundus. Paracervical block and procedural sedation as per usual.
10135437|NCT04248946|Experimental|MRI stream|"In this stream all patients receive 2 experimental interventions (anodal tDCS and cathodal tDCS) and a sham intervention (sham tDCS). These are delivered in randomised order, ensuring a balanced distribution of participants across possible orders. They will receive 5 sessions per condition (on consecutive days), for a total of 15 sessions.~I. Anodal, cathodal, sham II. Anodal, sham, cathodal III. Cathodal, anodal, sham IV. Cathodal, sham, anodal V. Sham, anodal, cathodal VI. Sham, cathodal, anodal"
10184231|NCT03757104|Experimental|micro-incentives|micro-incentives only (8 communities)
9669135|NCT03885921|Experimental|Ezetimibe+Atorvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with atorvastatin 40 mg (starting dose) via oral tablet once daily in the morning (may be titrated up to a maximum daily dose of 80 mg for atorvastatin, if needed) for up to 24 months.
10135438|NCT04248946|Experimental|Bedside stream|"In this stream all patients receive 1 experimental interventions (either anodal tDCS or cathodal tDCS) and 1 sham intervention (sham tDCS). These include only 1 session per condition and are delivered in randomised order, resulting in the following possible combinations:~I. Anodal, sham II. Cathodal, sham III. Sham, anodal IV. Sham, cathodal~Participants will be randomly assigned to the above groups ensuring a balanced distribution of participants across them."
10135439|NCT04248907|Experimental|Socket A|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
10135440|NCT04248907|Active Comparator|Socket B|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
10135441|NCT04248907|Active Comparator|Socket C|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
10135442|NCT04248868|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
10135443|NCT04248894|Experimental|High-intensity interval training (HIIT)|High-intensity interval training (HIIT) = the exercise of high intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the HIIT session was established based on the HR and workload levels corresponding to 5% above the respiratory compensation point.
10135444|NCT04248894|Experimental|Moderate-intensity continuous training (MICT)|Moderate-intensity continuous training (MICT) = the exercise of moderate intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the MICT session was established based on the HR and workload levels corresponding to anaerobic threshold and respiratory compensation point
10135445|NCT04248894|Sham Comparator|No training|The patients are instructed to avoid any regular exercise program or any non-supervised exercise protocol during the study.
10135446|NCT04248647|Experimental|Intervention Group|4-week multimodal preoperative intervention (i.e., Prehabilitation) consisting of an aerobic and strength training program, nutritional counselling and psychological support to help improve physical and psychological health prior to surgical resection of colorectal cancer.
10135447|NCT04249037|Active Comparator|Arm A: Rapid Start Group|Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.
10135448|NCT04249037|Placebo Comparator|Arm B: Standard Group|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
10135449|NCT04248764|Experimental|Foam roller group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, foam roler will be applied to the participants' quadriceps femoris muscles in a prone position for five minutes.
10135450|NCT04248764|Experimental|Massage group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, sports massage will be applied on the quadriceps femoris muscles for five minutes.
10135451|NCT04248764|No Intervention|Control group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, the participants will rest in the long sitting position for 5 minutes.
10184232|NCT03757104|Experimental|EPIC-HIV|Empowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities)
9968720|NCT01282736|Experimental|Integrative Response Therapy|IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
9976834|NCT01355653|Experimental|Treatment A|thermal therapy
9669136|NCT03885921|Experimental|Ezetimibe+Simvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with simvastatin 40 mg (starting dose) via oral tablet once daily in the evening (may be titrated up to a maximum daily dose of 80 mg for simvastatin, if needed) for up to 24 months.
9976835|NCT01355653|Active Comparator|Treatment B|ThermaCare Lower Back/Hip heatwrap
10135452|NCT04248660||Uterine artery doppler measurements|"Uterine artery doppler measurements will be made in the same patients at 11-14 weeks and 20-22 weeks of pregnancy.~Doppler results will be classified according to pregnancy results and primary results will be doppler findings."
10135453|NCT04248920|Experimental|Intervention Group|Intervention Group. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO). As part of the C2C program, participants will be contacted 6 months later for a supplementary consultation over the telephone and to answer any questions. Epilepsy is unique among chronic, episodic disorders in that PWE lose their ability to make choices during a seizure and depend to a greater degree on the decisions of others including family, friends and colleagues. For this reason, we encourage the PWE to invite their support network to attend the patient education sessions.
10135454|NCT04248920|Other|Waitlist Control Group|Waitlist Control Group. The control group continues TAU and will be followed up 12 months after randomization. The control group will receive C2C after the 12-month follow-up.
10135455|NCT04248699|Experimental|Lumenato Supplement|tomato oleoresin
10135456|NCT04248790|Experimental|Experimental: the mobile App|Participants in the intervention arm will receive access to all the app capabilities. The app features include information on HIV testing locations, sex and PrEP diary and reminder of taking PrEP.
9519623|NCT03285217|Active Comparator|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
10135457|NCT04248959|Experimental|PREHAB|Facility and home-based multimodal prehabilitation (aerobic exercise training, resistance exercise training, mindfulness)
10135458|NCT04248959|No Intervention|USUAL CARE|Self-directed physical activity and provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
10135459|NCT04248881|Active Comparator|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
10135460|NCT04248881|No Intervention|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2020 (first timers) and have not yet received health education information."
10135461|NCT04248621|Experimental|Intermittent Androgen Deprivation|ADT including luteinizing hormone-releasing hormone (LHRH) agonist and antagonist, antiandrogen, or maximum androgen blockade (MAB) should be withdrawn after 6 months of ADT, if the prostate-specific antigen (PSA) reaches its nadir (< 4 ng/dL) and serum testosterone reaches castration level (< 50 ng/dL).
10135462|NCT04248621|Active Comparator|Continuous Androgen Deprivation|ADT including LHRH agonist and antagonist, antiandrogen, or MAB without any discontinuation during study period.
10135463|NCT04248803|No Intervention|Total etch control group|No gluma desensitizer application
10135464|NCT04248803|Experimental|TE - GLUMA application prior to acid etching|TE- Total Etch GLUMA - Desensitizing agent
10135465|NCT04248803|Experimental|TE - GLUMA application after acid etching|TE- Total Etch GLUMA - Desensitizing agent
10135466|NCT04248803|No Intervention|Self etch control group|No gluma desensitizer application
9519624|NCT03285204||ALS patients|
9519625|NCT03285204||Friedreich Ataxia patients|
9519626|NCT03285204||Healthy control|
10135467|NCT04248803|Experimental|SE - GLUMA application prior to acid etching|SE - Self Etch GLUMA - Desensitizing agent
10135468|NCT04248803|Experimental|SE - GLUMA application after acid etching|SE - Self Etch GLUMA - Desensitizing agent
10135469|NCT04248777|Other|left main PCI guided by OCT|The LM PCI strategy is guided by 3 OCT runs, according to a pre-defined standardized protocol.
10135470|NCT04248608|Experimental|erector spinae block|Ultrasound guided erector spinae block with will be done after induction of intravenous anesthesia. After identification of trapezius, rhomboid major, and erector spinae muscles. The needle will be inserted in a cephalad-to-caudal direction until the tip contact transverse process and the needle tip is visualized in the plane deep to the erector spinae muscle. The needle tip position is confirmed by visualizing linear spread of test dose between the muscles after injection. A total dose of 25 mL of 0.25% bupivacaine will be injected.
10135471|NCT04248608|Experimental|serratus anterior block|Ultrasound guided serratus anterior block will be done after induction of intravenous anesthesia. The serratus anterior, latissimus dorsi, and the intercostal muscles will be identified in the fourth and fifth intercostal level, an 18 G Tuohy needle will be advanced in the plane between the serratus anterior muscle and the intercostal muscles. A total dose of bupivacaine 25ml in a concentration of 0.25% will be administered under the serratus muscle after a test dose using an in-plane technique.
10135472|NCT04248608|Active Comparator|intravenous morphine|intravenous morphine will be administrated in a dose of 0.1 mg per kg after induction of general anesthesia
10135473|NCT04248426|Experimental|ATI-2173|
10135474|NCT04248426|Placebo Comparator|ATI-2173 Placebo|
10135475|NCT04248400|No Intervention|Control|No intervention
10135476|NCT04248400|Active Comparator|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
10135477|NCT04248400|Experimental|Tai Chi|A 24 weeks Tai Chi training with three 1-hour section per week
10135478|NCT04248686|No Intervention|Control|Referral to standard care - student health center on campus.
10135479|NCT04248686|Active Comparator|Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity.
10135480|NCT04248556|Experimental|subjects, 18-59 y, healthy|patch test with investigation product
10184233|NCT03757104|Experimental|micro-incentive and EPIC-HIV|micro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities)
9519627|NCT03285191||Subjects participating in the CE interview|Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
9519628|NCT03285191||Subjects participating in interview and real-time data capture|Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
10135481|NCT04248361|Experimental|TEM-PCR Diagnosis|The TEM-PCR diagnostic technology will be used to assess for a source pathogen involved in the subject's acute respiratory illness. Results of the TEM-PCR URI Panel will be used by the physician to guide treatment decisions. If indicated, the investigator may also utilize rapid strep testing and rapid influenza testing for diagnosis. In the event a lower respiratory infection is suspected a chest x-ray or complete blood count (CBC) with differential may also be performed.
10135482|NCT04248361|Active Comparator|SOC/Empiric Diagnosis|The Standard of Care for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
10135483|NCT04248270|Other|The relationship between image and AD disease|To evaluate the relationship between F-18-PMPBB3 PET image uptake pattern and AD disease classifications.
10135484|NCT04248322||Subjects who used a Connected Catheter|Subjects will have Neurogenic Lower Urinary Tract Dysfunction and will have participated in a study with a Connected Catheter. These characteristics will create a 2 (bladder management) x ~5 (etiology) = 10 cell matrix for recruiting for participant interviews.
10135485|NCT04248322||Caregiver of Subject who used a Connected Catheter|Caregiver (n=20) interviews will be done for those who care for individuals with similar bladder managements and etiologies.
10135486|NCT04248582|Experimental|Cryotherapy|Patients will receive neoadjuvant cryotherapy at specified dose frequency interval
10135487|NCT04248387|Experimental|Toripalimab group|The subjects in this group receive intravenous drip infusion of Toripalimab at a dose of 3 mg / kg once every 2 weeks for a total of two cycles
10135488|NCT04248439|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
10135489|NCT04248452|Experimental|Arm A (FOLXFOX)|Patients receive oxaliplatin IV over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10135490|NCT04248452|Experimental|Arm B (CAPOX)|Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
10135491|NCT04248452|Experimental|Arm C (radiation therapy, FOLFOX)|One week post induction of patients in ARM A, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
10135492|NCT04248452|Active Comparator|Arm D (FOLFOX)|Post induction of patients in ARM A, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
10135493|NCT04248452|Experimental|Arm E (radiation therapy, CAPOX)|One week post induction of patients in ARM B, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
10135494|NCT04248452|Active Comparator|Arm F (CAPOX)|Post induction of patients in ARM B, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
10135495|NCT04248478||Fibromiyalgia Patients|Patients diagnosed with fibromyalgia according to 2013 American College of Rheumatology criteria are planned to be included in this arm.
10135496|NCT04248478||Healthy Volunteers|Healthy volunteers are planned to be included in this arm.
10135497|NCT04248374|No Intervention|Fatty Acid Taste|Fatty acid taste without sour adaptation
10135498|NCT04248374|Experimental|Fatty Acid Taste after sour adaptation|Fatty Acid Taste after sour adaptation
10135499|NCT04248244|Experimental|Early Palliative Care Integration|12 months of PC with concurrent standard treatment for MM, QOL assessments
10135500|NCT04248309|Experimental|A1|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
10135501|NCT04248309|No Intervention|A2|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A2：without additional treatment
10135502|NCT04248309|No Intervention|B|Group B：serum progesterone ≥7.24ug/L， without additional treatment
10135503|NCT04247997|Experimental|Group D|disconnect pulmonary vague nerve branches
10135504|NCT04247997|No Intervention|Group P|preserve the pulmonary vague nerve branches
10135505|NCT04247932||Municipal|Individual participants receiving active labor market intervention from municipal providers
10135506|NCT04247932||Non-profit|Individual participants receiving active labor market intervention from non-profit providers
10135507|NCT04247932||Register|Matched sample from register data, no intervention provided
10135508|NCT04247867|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO (Theranova) membrane then dialysis for 4 weeks with MCO membrane and increased fiber intake
9669137|NCT03884452|Experimental|Atorvastatin 80 mg|80 mg atorvastatin taken orally, once daily for 12 weeks
10135509|NCT04247867|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
10135510|NCT04248205|Active Comparator|Intraoperative ketamine infusion|Subjects in this group will receive standard anesthesia during surgery and a dose of ketamine at 0.3 mg/kg IV bolus prior to surgical incision. If the procedure lasts more than 1 hour, an additional bolus dose will be given.
10135511|NCT04248205|No Intervention|Control group|This group will only receive the standard anesthesia during surgery with no ketamine.
10135512|NCT04247984|Experimental|mXELIRI+ Bevacizumab|
10135513|NCT04247984|Active Comparator|FOLFIRI + Bevacizumab|
10135514|NCT04247854|Active Comparator|Probiotic|
10135515|NCT04247854|Placebo Comparator|No intervention|
10135516|NCT04248049|Experimental|Experimental side|Roots covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
10135517|NCT04248049|Active Comparator|Control side|Roots covered with coronally advanced flap (CAR)
10135518|NCT04248088|No Intervention|Educational Control Group|Education provided for optional use
10135519|NCT04248088|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly for 6 months
10135520|NCT04248101|Active Comparator|Group 1|88 cases of umbilical granulomas who were treated with double ligation
10135521|NCT04248101|Active Comparator|Group 2|88 cases of umbilical granulomas who were treated with topical silver nitrate
10135522|NCT04248179|Active Comparator|Active|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Ropivacaine 5mg/ml corresponding to 3 * 10ml * 5mg/ml Ropivacaine = 150mg Ropivacaine.
10135523|NCT04248179|Placebo Comparator|Placebo|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Sodium chloride 9mg/ml corresponding to 3 * 10ml * 9mg/ml Sodium chloride = 189mg Sodium chloride.
10135524|NCT04248023|Experimental|Intervention Practices|Intervention practices will work with a practice facilitator to make practice specific changes to address unhealthy alcohol use.
10135525|NCT04248023|No Intervention|Control Practices|Control practices will continue to screening and address unhealthy alcohol use based on their existing practice patterns.
10135526|NCT04248075||Control|Patients who do not want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
10135527|NCT04248075||Dexmedetomidine|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, dexmedetomidine is administered for sedation during surgery."
10135528|NCT04248075||Propofol|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, propofol is administered for sedation during surgery."
10135529|NCT04248075||Midazolam|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, midazolam is administered for sedation during surgery."
10135530|NCT04248140|Experimental|WiFi - Sham|first Intervention WiFi, second intervention sham
10135531|NCT04248140|Experimental|Sham - WiFi|first intervention sham, second intervention WiFi
10135532|NCT04247893|Active Comparator|Exercises with blood flow restriction|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Device: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.
10135533|NCT04247893|Experimental|Exercises with blood flow restriction + photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.Photobiomodulation a mesh composed of multiple diodes containing 50 Infrared LEDs.
10135534|NCT04247893|Placebo Comparator|Blood flow restriction exercises + placebo photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted. Photobiomodulation turned off with a mesh composed of multiple diodes containing 50 Infrared LEDs.
10135535|NCT04247880|Experimental|Mentees|This arm consists of apprentice-level, female-identifying construction workers who will receive active mentorship (the intervention) for two years from trained journey-level mentors.
10135536|NCT04247880|No Intervention|Control Apprentices|This arm consists of apprentice-level, female-identifying construction workers who will not receive mentorship.
10135537|NCT04248062||IEM experts|Heterogeneous group of health professionals (physicians, psychologists, nutritionists) working in the field of Inborn Errors of Metabolism (IEM)
10135538|NCT04248062||Paediatric IEM patients|IEM patients between 10 and 18 years
10135539|NCT04248062||Parents of paediatric IEM patients and patient representatives|"Parents of IEM patients (between 0 and 18 years)~Patient representatives"
10135540|NCT04247945|No Intervention|HSC|
10135541|NCT04247945|Experimental|MSC+HSC|
10135542|NCT04247789||Total sample|This group consists of older adults living in a rest home, who are proper for inclusion criteria
10135543|NCT04247841|No Intervention|Phase I: Current Practice|This represents the first phase of the study in which a prospective cohort of patients will complete the survey to define baseline rates of recall of perioperative risk and level of patient satisfaction with risk discussion
10184234|NCT03757104|No Intervention|control|standard of care
10135544|NCT04247841|Experimental|Phase II Visual Aid & Scripted Risk Discussion|This will involve a group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
10135545|NCT04247841|Active Comparator|Phase II Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
10135546|NCT04247594|Experimental|Cohort A open label|Participants will receive progressively higher doses of voxelotor administration starting from 1500 mg
10135547|NCT04247594|Experimental|Cohort B open label|Participants will receive doses higher than 1500 mg administered without up-titration
10135548|NCT04247763|Experimental|Arm 1 (Saturated Fat Meal, Oleic Sunflower Oil Meal)|
10135549|NCT04247763|Active Comparator|Arm 2 (Oleic Sunflower Oil Meal, Saturated Fat Meal)|
10135550|NCT04247490||Pediatric AIH|Patients diagnosed with hepatitis type 1 and type 2 formulated between the ages of 0 and 18.
10135551|NCT04247451|Experimental|Interventional group|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using BIA (Nutrilab Akern) and REE using indirect calorimetry (Cosmed Q NRG) will be analyzed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
10135552|NCT04247776|Experimental|Prehab|General nutrition, relaxation, and exercise instructions. Home-based functional exercises, Fitbit goals, and nutrition supplements.
10135553|NCT04247776|Active Comparator|ERAS|Enhanced Recovery After Surgery standard of care plus Fitbit.
10135554|NCT04247568|Experimental|Hypnosis|
10135555|NCT04247568|Placebo Comparator|Control|
10135556|NCT04247529|Placebo Comparator|No exposure to conflict|
10135557|NCT04247529|Experimental|Exposure to conflict|
10135558|NCT04247620|Experimental|DiaBetter Together Intervention|Young Adult participants with type 1 diabetes (ages 17-25) who are approaching transfer from pediatric to adult care will be randomized to either the DiaBetter Together Intervention group or the Usual Care group. After randomization to the intervention group, young adults will be assigned a Peer Mentor. Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
10135559|NCT04247620|Other|Peer Mentors|Peer Mentors will deliver the DiaBetter Together intervention and will also be enrolled as study participants to permit assessment of their own outcomes from delivering this peer support intervention to younger people with diabetes. Peer Mentors will be experienced young adults with T1D who have transferred to adult diabetes care.
10135560|NCT04247620|No Intervention|Usual Care|Participants randomized to the comparison condition will receive usual diabetes care only, without additional intervention through the study. They will participate in all study activities related to data collection, but will not receive the Peer Mentor intervention. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
10135561|NCT04247659|Experimental|Experimental group|In the experimental group, sodium aescinate is added on the basis of conventional treatment(such as anti-platelet and improve circulation).The treatment course of sodium aescinate is 10 days,20mg/day.
10135562|NCT04247659|No Intervention|Control group|The control group will receive conventional treatment(anti-platelet and improve circulation) without sodium aescinate.
10135563|NCT04247633|Experimental|palbociclib plus endocrine therapy treatement|"Patients with Clinical high risk/Genomic High risk (in BCT score)-high and ER positive/HER2 negative EBC after Curative Surgery~Palbociclib at a dose of 125mg, orally once daily on Day 1 to Day 21 followed by 7 days off in a 28-day cycle for a total duration of 2 years~Standard adjuvant endocrine therapy for a duration of at least 5 years from the start of the treatment."
10135564|NCT04247477|Experimental|A-B-A-C|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B) - Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C)
10135565|NCT04247477|Experimental|A-C-A-B|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C) - Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B)
10135566|NCT04247646|Active Comparator|Melatonin|Melatonin 5 mg sublingual nightly x 29 nights, starting on post-operative day 0.
10135567|NCT04247646|Placebo Comparator|Placebo|Placebo troche, sublingual nightly x 29 nights, starting on post-operative day 0.
10135568|NCT04247724|Experimental|Active group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of men playing recreational handball"
10135569|NCT04247724|Experimental|Active group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of women playing recreational handball"
10135570|NCT04247724|Experimental|Inactive group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of men continuing their normal lifestyle patterns"
10135571|NCT04247724|Experimental|Inactive group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of women continuing their normal lifestyle patterns"
10135572|NCT04247685|Experimental|12-Lead ECG|The study group patients will have MRI with 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical
10135573|NCT04247685|Active Comparator|3-lead ECG gating system|the control group will have MRI with 3-lead ECG gating which is standard of care.
10135574|NCT04247815|Experimental|ATI-450 plus Methotrexate|ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate
10135575|NCT04247815|Placebo Comparator|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of Methotrexate
10135576|NCT04247464|No Intervention|Standard diet|The participants will follow an standard diet during the chemotherapy treatment
10135577|NCT04247464|Experimental|Fasting|The participants will follow a short-term fasting period for 44-48 hours, starting 24 hours before chemotherapy treatment
10135578|NCT04247711|Experimental|OTCH|OTCH is based on OTNY, a Coordinated Specialty Care program for people with first-episode psychosis. The program is implemented by a multidisciplinary team, who provide coordinated, evidence-based services based on the interests, needs, and preferences of each participant.
10135579|NCT04247711|Placebo Comparator|Usual FEP services|This is generally provided in mental health outpatient clinics which serve a population enrolled in the public health care system.
10135580|NCT04247360|Other|cuff pressure with 20cmH2O|continuous monitoring and maintaining cuff pressure with 20 cmH2O during surgery
10135581|NCT04247360|Other|cuff pressure with 30cmH2O|continuous monitoring and maintaining cuff pressure with 30 cmH2O during surgery
10135582|NCT04247386|Experimental|PEG-Mizone prep|"The evening before the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 60g Polyethylene Glycol (PEG-4000) with 0.6L Mizone+0.4L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 120g Polyethylene Glycol (PEG-4000) with 1.2L Mizone+0.8L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
10135583|NCT04247386|Active Comparator|PEG-ELS prep|"The evening before the colonoscopy: In the PEG-ELS prep group, all the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
10135584|NCT04247399|Experimental|Simulation-based learning + clinical training|
10135585|NCT04247399|No Intervention|Clinical training|
10135586|NCT04247373|Experimental|laparoscopic gastrectomy with pneumoperitoneum|
10135587|NCT04247334|No Intervention|Cautious Participants|Participants who have low scores on a self-report of inhibitory control abilities (BRIEF-Inhibit).
10135588|NCT04247334|Experimental|Impulsive Participants- Active Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to active stimulation.
10135589|NCT04247334|Sham Comparator|Impulsive Participants- Sham Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to sham stimulation.
10135590|NCT04247022|Experimental|female subjects, 18-59 y, healthy|74 female subjects, 18 to 59 years of age, healthy with complaints of vaginal dryness that will receive the heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days.
10135591|NCT04247321|Experimental|Subjects with acute brain injury|Subjects requiring placement of a Licox Brain Tissue Oxygen device for their clinical care will also have Near-infrared spectroscopy (NIRS) monitoring system placed
10135592|NCT04247230|Experimental|PET500 (0.1%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.1%) corresponding to a tetracaine total dose of 0.26mg"
10135593|NCT04247230|Experimental|PET500 (0.25%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.25%) corresponding to a tetracaine total dose of 0.65mg"
10135594|NCT04247230|Experimental|PET500 (0.5%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.5%) corresponding to a tetracaine total dose of 1.3mg"
10135595|NCT04247230|Experimental|PET500 placebo comparator|Each actuation of the pump spray dispenses 130µl PET500 [vehicle only]. Two pumps will dispense 260µl
10135596|NCT04247230|Active Comparator|STUD100 (9.6%)|Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of 23mg lidocaine. UK License Number PL/2294/5000R
10135597|NCT04247113|Experimental|PBP-B|Parent-based Prevention following a Bariatric Surgery (PBP-B) is a 6-session parent-based program designed to guide parents who have undergone a weight loss surgery and their partners in developing healthy eating habits in their children
10135598|NCT04246931||Pulmonologists|Interviews with pulmonologists
10135599|NCT04246931||General practitioners|Interviews with general practitioners
10135600|NCT04246931||Patients|Survey with COPD patients
10135601|NCT04247204|Experimental|Platelet-rich plasma (PRP) intrauterine infusion|
10135602|NCT04247087|Experimental|Intervention group|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
10135603|NCT04247087|Placebo Comparator|Control group|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
10135604|NCT04246970|No Intervention|Control group|Conventional medical care
10135605|NCT04246970|Experimental|Prehabilitation group|Conventional medical care and 8 weeks of a Prehabilitation supervised program
10135606|NCT04246970|Experimental|Prehabilitation and posttransplant training group|Conventional medical care, 8 weeks of a Prehabilitation supervised program and a posttransplant training program.
10135607|NCT04247152|Other|Intraoperative Aberrometry vs Preoperative Biometry|Retrospective view of existing chart data.
10184235|NCT03757091|Active Comparator|Arm A (flexible intubation scope)|Patients undergo flexible scope intubation up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
10184236|NCT03757091|Experimental|Arm B (flexible intubation scope,video laryngoscope)|Patients undergo flexible scope intubation and video laryngoscopy up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
10135608|NCT04247165|Experimental|Experimental|"Nivolumab 3 mg/kg will be given on day 1 (± 2 days) of each 28-day treatment cycle until the progression of disease, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given once only on day 1 cycle 1. Nivolumab will be administered as an IV infusion over 30 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Pre-medication for chemotherapy (based on standard-of-care and local institutional standards) and chemotherapy will then be administered after a further 30 minutes rest period.~The recommended dose of nab-paclitaxel is 100 mg/m2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8, and 15 of each 28-day cycle. Gemcitabine 800 mg/m2 will be administered over 30 to 40 minutes immediately after nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle."
10135609|NCT04246983|Experimental|Patients with HIV undergoing point of care ultrasound|
10135610|NCT04247191|Experimental|P-Chat|The P-Chat is a brief individually delivered intervention
10135611|NCT04247191|Experimental|PBI|The PBI is a handbook developed by the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
10135612|NCT04247191|Experimental|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above.
10135613|NCT04247191|No Intervention|Control|This group will only complete assessments and will not receive any intervention.
10135614|NCT04247269||Enteral formula standard|Children fed an intact protein formula
10135615|NCT04247269||Enteral formula semi-elemental|Children fed a semi-elemental protein formula
10135616|NCT04247295|Experimental|Wood cast|Participants will be trialling the woodcast plaster method
10135617|NCT04247295|Placebo Comparator|Traditional Cast|Traditional cast used to be compared to.
10135618|NCT04246905|Active Comparator|sulforaphane|sulforaphane treatment arm
10135619|NCT04246905|Placebo Comparator|placebo|placebo arm
10135620|NCT04246892||group before alarm withdrawal|
10135621|NCT04246892||groupe after alarm withdrawal|
10135622|NCT04246749|Experimental|Part A: [14C]-CRN00808 Oral Solution|Single oral dose of CRN00808 containing [14C]-CRN00808
10135623|NCT04246749|Experimental|Part B: CRN00808 Oral Capsule w/ [14C]-CRN00808 IV microtracer|Single oral dose of CRN00808 followed by [14C]-CRN00808 IV microtracer injection
10135624|NCT04246723|Experimental|Cohort A (Narlaprevir + Ritonavir + Sofosbuvir for 12 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg Once a day (QD)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 12 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
10135625|NCT04246723|Experimental|Cohort B (Narlaprevir + Ritonavir + Sofosbuvir for 8 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg QD (once daily)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 8 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.~Sofosbuvir can be taken with or without meals."
10135626|NCT04246736|Experimental|Intervention group|"The intervention group received a Recovery programme including three group sessions."
10135627|NCT04246736|No Intervention|Control group|The control group was on a waiting list to receive the intervention after the last follow-up measure (six months after the intervention group's last group session).
10135628|NCT04246775|Other|Treatment|Peristeen given
10135629|NCT04246515|Experimental|Blood Flow Restriction Training|As from week 2 in the rehabilitation proces, this experimental group will receive exercises in combination with blood flow restriction. While occluding the vascular flow of the limb (startpoint = above the injury site), participants will perform 3 exercises: wall squat, leg press and bridge (3 sets of 30 repetitions). These blood flow restricted exercises are always on top of the classic rehabilitation.
10135630|NCT04246515|Sham Comparator|Sham Blood Flow Restriction Training|The same description as the experimental arm is applicable here. However, The Blood Flow restriction material will be attached to the injured limb without occluding the vascular blood flow.
10135631|NCT04246515|Active Comparator|Classic rehabilitation|This group will undergo the classic rehabilitation program.
10135632|NCT04246684|Active Comparator|Control arm|In the control arm patients receive 5x5 Gy followed by 9 cycles of consolidation chemotherapy mFOLFOX6 or alternatively 6 cycles of CAPOX, followed by re-staging at week 22-24 as established as new preferred neoadjuvant regimen by the RAPIDO trial.
10135633|NCT04246684|Experimental|Experimental arm|The experimental arm starts with Fluoropyrimidin/Oxaliplatin-based CRT (1.8 Gy to 45 Gy to the primary tumor and pelvic lymph nodes; followed by sequential boost of 9 Gy to the gross tumor volume) followed by consolidation chemotherapy with 6 cycles mFOLFOX6 or alternatively 4 cycles CAPOX, followed by re-staging at week 22-24. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a W&W option with close follow-up is scheduled. In case of non-complete response, immediate TME surgery is performed.
9968721|NCT01282736|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy guided self-help (CBT-GSH), based on the restraint model of binge eating, has been adapted from individual format to a 10 session, group-based therapy for the purpose of this study. The book 'Overcoming Binge Eating' is employed in the present study and consists of Part 1, an educational background on BED, and Part 2, a 6 step treatment program to overcome binge eating.
10135634|NCT04246645|No Intervention|CONTROL GROUP|received the selective physiotherapy exercises
10135635|NCT04246645|Experimental|STUDY GROUP|received the same selective physiotherapy exercises program in addition to core stability exercises three times/week for 60 min for 12 weeks
10184237|NCT03757078||Patients with acute hemorrhoids|Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)
10184238|NCT03757052|Experimental|Skin testing and Graded Oral Challenge|Penicillin skin testing as described in the intervention section, followed by amoxicillin graded oral challenge as described in the intervention section
9968722|NCT01282749|Experimental|SisterTalk Hartford First|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
9968723|NCT01282749|Other|SisterTalk Hartford Second|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
9968724|NCT01282775|No Intervention|Environment / Usual Care|
9968725|NCT01282775|Other|WEB+ Environment|Web-based weight loss program (WEB) + Environment - Participants have access to a proven Web-based weight loss program with weekly lessons focused on lifestyle behavior changes
9968726|NCT01282775|Other|WEB + Cash Incentive for Weight Loss|Web-based Weight Loss Program + Cash Incentive for Weight Loss - participants have access to a proven web-based weight loss program plus they are paid cash based on the percent weight lost at 12 months compared to baseline.
9968727|NCT01282788|No Intervention|Traditional Diet|Infants in communities randomized to the traditional diet arm will not receive food supplements.
9968728|NCT01282788|Experimental|Cereal|All infants in communities randomized to the Cereal Arm will receive caterpillar cereal from 6-18 months of age.
9968729|NCT01282827|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
9968730|NCT01282827|Placebo Comparator|Placebo stimulation|no intervention (Sham stimulation)
9968731|NCT01282840|Other|Bladder wall blood perfusion pattern|
9968732|NCT01282853|Active Comparator|A1|one biopsy specimen taken from gastric antrum was put into RUT kit
9968733|NCT01282853|Experimental|A4|4 biopsy specimens taken from gastric antrum were put into RUT kit
9968734|NCT01282853|Experimental|B1|one biopsy specimen taken from gastric body was put into RUT kit
9968735|NCT01282879|Experimental|itraconazole, prophylaxis, Oral solution|For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.
9968736|NCT01282892||patients with NAFLD|
9968737|NCT01282892||excess of visceral fat|
9968738|NCT01282905||Healthy controls|
9968739|NCT01282905||Ulcerative colitis|
9968740|NCT01282918|Other|Study group|Patients without DF (Defibrillation) testing during ICD implantation
9968741|NCT01282918|Other|Control group|Patients with DF testing during ICD implantation (according to standardized procedure)
9968742|NCT01282944|Experimental|Combined Financial Incentive & Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Subjects connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. Participants also receive weekly feedback regarding which participants in the peer group achieved their walking goals during the previous week.~Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200.~Financial incentive and peer network terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
9968743|NCT01282944|No Intervention|Active Control|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or peer networks in this group."
9968744|NCT01282944|Experimental|Financial Incentive Arm|Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 2 months.
9968745|NCT01282944|Experimental|Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period.~Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant will be given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. All participants in a peer network will receive a list of ways in which his or her new network could support each individual's walking goals. Participants will also receive weekly feedback regarding which participants in the peer group were successful in achieving their walking goals during the previous week.~Peer network is terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
9968746|NCT01282957|No Intervention|Active Control|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 6 months
9968747|NCT01282957|Experimental|Financial Incentive Group I|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $100 and 2 in 10 odds of winning $10. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
9968748|NCT01282957|Experimental|Financial Incentives Group II|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $50 and 2 in 10 odds of winning $5. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
9968749|NCT01282970|Experimental|BI 135585|once daily doses as oral solution or tablet formulation over 14 days
9968750|NCT01282970|Placebo Comparator|Placebo to BI 135585|once daily doses as oral solution or tablet formulation over 14 days
9968751|NCT01282983|Active Comparator|fiber|
9968752|NCT01282983|Placebo Comparator|Placebo|
9669138|NCT03884452|Experimental|Ezetimibe + Atorvastatin 40 mg|10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
9968753|NCT01283048|Experimental|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
9968754|NCT01283061|Experimental|zafirlukast|Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited
9968755|NCT01283061|Active Comparator|Accolate|ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals
9968756|NCT01283074||Cohort|
9968757|NCT01283100|Experimental|Treatment A|GSK1349572 50mg q24h x 7 days
9968758|NCT01283100|Experimental|Treatment B|GSK2248761 200mg q24h x 7 days
9968759|NCT01283100|Experimental|Treatment C|GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
9968760|NCT01283126|Experimental|Euglycemic and hypoglycemic clamp|Subjects will complete clamp study visit.
9968761|NCT01283165||health education|This was an intervention follow up Knowledge Attitude and Practice study that investigated the distribution of polyparasitism with schistosomiasis, STHs and P. falciparum among primary schoolchildren.
9968762|NCT01283178|Experimental|Arm I|Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.
9968763|NCT01283191|Experimental|Behavioral Incentives|Vouchers for complying with target behavior
9968764|NCT01283191|Placebo Comparator|Education Control|Education class
9968765|NCT01283204|Active Comparator|SP(S-1 with cisplatin)|"SP <Every 3 weeks>~Day 1~14 : TS-1 80mg/m2/day (PO)~Day 1 : CDDP 60mg/m2/day IVF 2hours~Day 15~21 : Rest"
9968766|NCT01283204|Active Comparator|FL/Tax(Paclitaxel with Leucovorin with 5-FU)|"FL/Tax <Every q 3 weeks>~Day1 : Paclitaxel 175mg/m2 IVF for 2hours~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
9968767|NCT01283204|Active Comparator|FL/Doc(Decetaxel with Leucovorin with 5-FU)|"FL/Doc <Every q 3 weeks>~Day1 : Docetaxel 75mg/m2 IVF for 1hour~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
9968768|NCT01283204|Active Comparator|FOLFOX(Oxaliplatin with Leucovorin with 5-FU)|FOLFOX <Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
9968769|NCT01283217|Experimental|DS(Docetaxel with S-1)|Docetaxel with S-1
9968770|NCT01283217|Active Comparator|SP(S-1 with cisplatin)|S-1 with cisplatin
9968771|NCT01283230||chronic liver disease|Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.
9968772|NCT01283230||Healthy liver and kidney donor|Healthy liver and kidney donor who have normal liver condition
9968773|NCT01283243||HIV patients with normal liver status|HIV patients without abnormal liver function and chronic liver disease
9968774|NCT01283256||Experimental|
9968775|NCT01283269|Experimental|Memory Support System or Computer|
9968776|NCT01283295||Immune complications|Transplant recipients who develop a clinically recognized complication with potential immune etiology or ramifications. Examples include opportunistic infection, rejection, malignancy, alloantibody formation or immunosuppressive drug toxicity.
9968777|NCT01283295||Stable Transplant Recipient|Patients who demonstrate immune stability characterized by stable graft function without evident complication. These patients serve as comparators for Group 1
9968778|NCT01283295||Pre-Transplant Longitudinal|Patients who are candidates for kidney, pancreas, liver or lung transplant will be enrolled and followed longitudinally.
9968779|NCT01283295||Organ Donors|Donors for individuals meeting the criteria for Cohorts 1-3
9968780|NCT01283295||Disease state|Individuals with liver, renal or pulmonary diseases that may lead to the development or organ failure.
9968781|NCT01283295||Normal Volunteers|
9968782|NCT01283308|Active Comparator|Standard of Care|Participants randomized to the standard of care group will receive standard lifestyle advice for diabetes prevention consistent with expert recommendations for a healthy lifestyle, including losing 5-10% of their excess body weight, following standard dietary recommendations to reduce calorie and fat intake, and exercising at least 150 minutes per week.
9968783|NCT01283308|Experimental|Lifestyle Intervention|Intervention arm participants will participate in a step-wise model of diabetes prevention with the goal of reducing diabetes risk, primarily through (1) a weight loss of at least 7% and (2) 150 minutes or more per week of moderate level physical activity.
10187687|NCT03723707|Experimental|Intervention (INT)|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
9968784|NCT01283347|Experimental|18F-DTBZ for Parkinson's Disease|"25 age-matched healthy volunteers will be enrolled. For assessing the correlation between the 18F-DTBZ binding and the severity of disease, the patients with PD will be divided into three groups according to their motor scores: mild, moderate, and advanced. We will enroll 25 patients in each group. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study, as one screening visit, one imaging visit, and one safety evaluation visit.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
9968785|NCT01283360|Placebo Comparator|HEC Placebo Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
9976836|NCT01355666|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
9976837|NCT01355692|Experimental|Laser therapy|
9976838|NCT01355718||Repaglinide|
9976839|NCT01355731||Registered Nurse|This is quality improvement study that is descriptive and is utilizing a convenience sample of direct care registered nurses employed full-time for at least one year at St. Jude Children's Research Hospital.Participants will take a onetime researcher generated therapeutic boundaries questionnaire which will describe behaviors and attitudes regarding therapeutic boundaries.
10135636|NCT04246567|Active Comparator|Total intravenous anesthesia technique for group 1 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 6-10 mg / kg / h propofol and 0.0,4mcg / kg remifentanyl infusion / min. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
10135637|NCT04246567|Active Comparator|Inhalation anesthesia technique for group 2 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 40% Oxygen 60% N2O2 and Sevoflurane at a concentration of 1.5-3.5% with 2 L / minTGA to provide a value of BIS between 40-60. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
10135638|NCT04246580||Indocyanine green|Women with endometrial and cervical cancer undergoing indocyanine green-guided systematic pelvic lymphadenectomy by laparoscopy or robotic surgery
10135639|NCT04246580||Control|Women with endometrial and cervical cancer undergoing systematic pelvic lymphadenectomy by laparoscopy or robotic surgery without the use of indocyanine green tracer injection.
10135640|NCT04246879|Experimental|MRI|
10135641|NCT04246697|Active Comparator|Standard of Care A|"Randomized controlled prospective trial to compare two standards of care for head and neck surgery pain management. Arm A, will include:~Scheduled Tylenol 1000 mg IV one time dose intra-operatively, then 650 mg via PEG tube or PO Q4H to a max dose of 4gm/24 hrs~Opioids prn based on Numeric Pain Scale (0-10, with 0 indicating no pain and 10 indicating worst pain ever):~0-3: no prn meds, reassurance, listen to music, watch TV.~4-7: Oxycodone 5 mg q4h prn via PEG tube or PO with a maximum of 30 mg/24 hours.~8-10 Morphine 2 mg IV q2h prn breakthrough pain."
10135642|NCT04246697|Experimental|Standard of Care B|"Arm B, will include:~Arm A description with addition..~Scheduled Ketorolac starting post-op day #1, 15 mg q6h (max 120 mg/day), for a total of 5 days~Scheduled Gabapentin starting 7 days preoperatively to continue postoperatively~Regional block per anesthesia protocol - Initial block: 0.5% bupivacaine, 20 ml Continuous infusion: 0.125% bupivacaine at 6 ml/hr with a 5 ml bolus available every 30 mins"
10135643|NCT04246866|Experimental|Dose 1|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the lowest dose of GEM103
10135644|NCT04246866|Experimental|Dose 2|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the medium dose of GEM103
10135645|NCT04246866|Experimental|Dose 3|A single dose of GEM103 will be administered via intravitreal injection. This arm will be a higher dose of GEM103
10135646|NCT04246866|Experimental|Dose 4|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the highest (extension) dose of GEM103
10135647|NCT04246632|Experimental|Open label|Single arm study, all subjects receive device
10135648|NCT04246853|Active Comparator|Active tDCS of the resting state motor network|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
10135649|NCT04246853|Sham Comparator|Sham tDCS of the resting state motor network|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
10135650|NCT04246502|Experimental|A|
10135651|NCT04246502|Active Comparator|B|
10135652|NCT04246658|Experimental|Treatment group|gait training on platform swing walkway for 30 minute.
10135653|NCT04246658|Experimental|control group|conventional physical therapy program
10135654|NCT04246827|Experimental|Enhanced Lifestyle Weight Management Condition|The Enhanced Lifestyle Weight Management condition participants participated in a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors was integrated into a lifestyle behavioral weight loss intervention.
10135655|NCT04246827|No Intervention|Standard Care Control|Participants received standard care of rheumatoid arthritis.
10135656|NCT04246814|Placebo Comparator|CC + dressing|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
10135657|NCT04246814|Active Comparator|LG1 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
10135658|NCT04246814|Active Comparator|LG2 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
10135659|NCT04246814|Active Comparator|LG3 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
10135660|NCT04246463||Thoracic - TEVAR|
10135661|NCT04246463||Abdominal - EVAR|
10135662|NCT04246463||Custom Device|
10135663|NCT04246463||Other indications|Isolated Iliac Artery Aneurysm (IIAA)
10135664|NCT04246385|Experimental|Allocated to intervention|Participants will participate in a one on one session to complete their COPM and set their goal for the group. Participants will participate in 6 group sessions focusing on the CO-OP approach.
10135665|NCT04246385|No Intervention|Allocated to control|"The control group will receive usual care occupational therapy including a mix of individual sessions and occupational therapy groups that do not include the CO-OP group."
10135666|NCT04246411|Active Comparator|Ultrasound|Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field
10135667|NCT04246411|Placebo Comparator|Auscultation|Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field
10135668|NCT04246450|No Intervention|LVEF between 35%-50%, no noninvasive risk factors (NIRFs)|Follow up, no further intervention
10135669|NCT04246450|No Intervention|LVEF between 35%-50%, NIRFs present, noninducible|Follow up, no further intervention
10135670|NCT04246450|Active Comparator|LVEF between 35%-50%, NIRFs present, inducible|All patients in this group will receive an ICD
9669139|NCT03884452|Experimental|Ezetimibe + Atorvastatin 80 mg|10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
9669140|NCT03884452|Experimental|Simvastatin 80 mg|80 mg simvastatin taken orally, once daily for 12 weeks
10135671|NCT04246450|Sham Comparator|LVEF <35%, no NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
10135672|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
10135673|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, inducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
10135674|NCT04246190|Experimental|Group 1|"Period 1: CKD-501 and D759~Period 2: CKD-396"
10135675|NCT04246190|Experimental|Group 2|"Period 1: CKD-396~Period 2: CKD-501 and D759"
10135676|NCT04246333|No Intervention|Gastric Feeds|Patients in this arm will receive feeds via the standard route which is gastric feeds.
10135677|NCT04246333|Experimental|Duodenal Feeds|Patients in this arm will receive feeds via the experimental route which is duodenal feeds.
10135678|NCT04246320|Experimental|Intervention|Patients monitored and receiving a standard anesthesia plan in addition of a goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
10135679|NCT04246424|Active Comparator|Fitbit + Coaching|Fitbit + coaching will receive both the fitbit and coaching interventions.
10135680|NCT04246424|Active Comparator|Coaching|Coaching group will receive weekly remote coaching lessons by phone email or text for 1-6 weeks. They will also receive a weekly email lesson for 1-6 weeks on things such as basics of sleep, enhancing sleep environment and managing stress.
10135681|NCT04246424|Active Comparator|Fitbit|Fitbit group will receive a Fitbit and are asked to monitor their sleep over the smartphone application for 1-6 weeks.
10135682|NCT04246424|No Intervention|Self-management|Self-management participants will be given some information of improving sleep but asked to keep their same schedule. Once their participation concludes, they will be given the opportunity to receive a fitbit and coaching if they so choose.
10135683|NCT04246255|Placebo Comparator|Group C|Serum Physiologic %0,9 ampules ; 0,3ml {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
10135684|NCT04246255|Experimental|Group L|xylocaine %10 pump spray ; 30mg lidocaine {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
10135685|NCT04246216|Experimental|Percutaneous Electrical Nerve Stimulation|The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
10135686|NCT04246216|Active Comparator|Surgery|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
10135687|NCT04246229|Experimental|transcutaneous bilirubinometry|in this arm the bilirubin level to monitor the effect of phototherapy will be measured through transcutaneous mbiirubinometry
10135688|NCT04246229|Active Comparator|serum bilirubin|In this arm the bilirubin level to monitor the effect of phototherapy wil be measured through measurements of serum bilirubin obtained through blood draws
10135689|NCT04246099||Group opioid free anesthesia|Patient benefit of the opioid free anesthesia protocol
10135690|NCT04246099||Group opioid based anesthesia|Patient don't benefit of the opioid free anesthesia protocol
10187688|NCT03723707|Placebo Comparator|Control (CON)|During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.
9669141|NCT03884452|Experimental|Ezetimibe + Simvastatin 40 mg|10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
9669142|NCT03884452|Experimental|Ezetimibe + Simvastatin 80 mg|10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks
9669143|NCT03882996|Experimental|Ezetimibe 10 mg + Atorvastatin|Ezetimibe 10 mg plus atorvastatin 10 to 80 mg daily for up to 12 months
9669144|NCT03882905|Experimental|Ezetimibe: Base Study|10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
9669145|NCT03882905|Placebo Comparator|Placebo: Base Study|Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
9826067|NCT02406261|Experimental|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;~5 mg donepezil, single oral dose on Day 28, Period 2"
9968786|NCT01283360|Active Comparator|Tenofovir 1% Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
9968787|NCT01283373|Experimental|A|Dose escalation cohorts
9968788|NCT01283373|Experimental|B|Dose expansion cohorts
9968789|NCT01283399||Rituximab + Methotrexate|All participants with active refractory RA who were eligible to receive treatment with methotrexate and rituximab in the Investigators' opinion as per the routine clinical practice following inadequate response to a single cycle of anti-TNF therapy.
9968790|NCT01283412|Active Comparator|Arm P|Placebo infusion
9968791|NCT01283412|Experimental|Arm D|Dexmedetomidine infusion
9968792|NCT01283425|Experimental|Test|InsuPatch use for 3 months.
9968793|NCT01283425|No Intervention|Control|
9968794|NCT01283451||Exercise|NIRS values of all participants will be measured at baseline and following each 30-60 second exercise.
9968795|NCT01283477|Experimental|ACUPUNCTURE|
9968796|NCT01283477|Sham Comparator|SHAM ACUPUNCTURE|
9968797|NCT01283490|Active Comparator|DASD Group|Benzocaine 20% will be placed using the DASD for one minute. Immediately after DASD application a needle puncture with a 27 gauge needle to the depth of 3 millimeters will be performed.
9968798|NCT01283490|Sham Comparator|Sonic Vibration (SV)|A modified tooth brush which only allows sonic vibration (SV), that has the appearance and sound of the DASD will be used to apply the benzocaine 20% for one minute. Following application with the SV a needle puncture with a 27 gauge needle to the depth of 3millimeters.
9968799|NCT01283503|Experimental|BKM120|
9968800|NCT01283529||Children 0 - 15 years|Children undergoing neurosurgery in general anesthesia
9968801|NCT01283568||1 - Gamaline+Hipericin - fertile women|
9968802|NCT01283568||2- Gamaline+Hipericin - climateric women|
9968803|NCT01283568||3- Gamaline- control - fertile women|
9968804|NCT01283568||4 - Gamaline control - climateric women|
9968805|NCT01283607|Active Comparator|Digicoach|Women randomized in the Digicoach group will be treated by the Digicoach therapy. Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for in vitro fertilization (IVF) women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
9968806|NCT01283607|No Intervention|Control|Women in the control group will get the usual treatment, there will be no additional intervention.
9968807|NCT01283620|Other|Usual Care|
9968808|NCT01283620|Experimental|modified CIMT (mCIMT)|
9968809|NCT01283633|Experimental|programming with non-experienced nurse|Programming done by an experienced neuromodulation clinician will be compared to the patient satisfaction of a programming session with an inexperienced nurse via remote presence robotics, which will be directed by the experienced clinician
9968810|NCT01283646|Experimental|Apevitin BC|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
9968811|NCT01283646|Active Comparator|Vitamin B Complex + Vitamin C|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
9968812|NCT01283659|Active Comparator|Standard imaging (coronary angiography)|Subjects will undergo a coronary angiogram as planned by their attending doctor
9968813|NCT01283659|Active Comparator|Advanced imaging (CTA)|Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.
9968814|NCT01283698|Experimental|LAS 41004 dosage 1|dosage 1, once daily
9968815|NCT01283698|Experimental|LAS 41004 dosage 2|dosage 2, once daily
9968816|NCT01283698|Experimental|LAS 41004 dosage 3|dosage 3, once daily
9968817|NCT01283698|Placebo Comparator|placebo|once daily
9968818|NCT01283698|Active Comparator|Reference|once daily
9968819|NCT01283711|Experimental|apollo|
9968820|NCT01283724|Experimental|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
9968821|NCT01283737|Experimental|DBX|DBX Putty in glass syringe
9968822|NCT01283737|Active Comparator|Mosaicplasty|
9968823|NCT01283750|No Intervention|Augmented Usual Care|
9968824|NCT01283763|Experimental|Topical Imiquimod|16 weeks topical Imiquimod
9968825|NCT01283763|Active Comparator|Conization|Large loop excision of the transformation zone
9968826|NCT01283776|Experimental|treatment arm|Cyclophosphamide
9968827|NCT01283789|Experimental|Lapatinib and RAD-001|"RAD-001 will be administered orally as a once-daily dose of 5 mg (one 5 mg tablet) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD-001 in the morning, at the same time each day.~Lapatinib will be administered orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take lapatinib at bedtime, at the same time each day. Lapatinib should be taken by the patient in a fasting state."
9968828|NCT01283802||IOCUS|
9968829|NCT01283815|Active Comparator|Conservative management|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
9976840|NCT01355744||Spider bite patients|All patients treated for an actual spider bite by a Swiss physician during study period.
10135691|NCT04246294||Sleep apnea patients|"This group of patients will have been monitored over night with cardiorespiratory monitoring (CRM). CRM enables the physician to establish an Apnea-Hypopnea Index (AHI) which will be used for diagnosis. An AHI > 15 is considered moderate-to-severe sleep apnea, and this is the focus group of patients in the current project.~These patients will be followed for 12 months during continuous positive airway pressure (CPAP) treatment. Adherence to the CPAP treatment will be closely monitored."
9669146|NCT03882905|Experimental|Ezetimibe: Extension|10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
10135692|NCT04246398|Experimental|Fecal microbiota transplant (FMT)|"10 capsules per dose for 6 consecutive weeks, twice a week, for a total of 120 capsules.~Each inoculum will be prepared from the feces of 1 donor and a dose of 10 capsules contains sieved, concentrated material derived from a mean of 10 grams of fecal matter. Donors are healthy, nonpregnant adults aged 18 to 50 years, taking no medications, and with a normal body mass index (18.5-25 [calculated as weight in kilograms divided by height in meters squared])."
10135693|NCT04246398|Placebo Comparator|placebo|Placebo capsules will consist of a combination of saline/glycerol (same vehicle as FMT capsules). The inner capsules is dark (green colored), so the general appearance of the capsules is the same to the people who do not prepare them.
10135694|NCT04246268|Experimental|Treatment Group|"Device: INVOcell Intravaginal Culture System~Intervention: During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5-days vaginal incubation."
10135695|NCT04245826||Low-calorie Sweetened Beverages (LCSBs)|Beverages exclusively using zero-energy (e.g., acesulfame-potassium, aspartame, cyclamate, saccharin, sucralose, advantame, neotame), and /or reduced-energy food additives (e.g., stevia, monk fruit).
10135696|NCT04245930|Active Comparator|Bovine Pericardial Patch|Immediate implant breast reconstruction using bovine pericardial patch. n=88
10135697|NCT04245930|Experimental|TiLOOP® Bra Mesh|Immediate implant breast reconstruction using TiLOOP® Bra Mesh. n=88
10135698|NCT04245852|Experimental|Experimental group|Experimental group will receive standard physical therapy care in addition to being provided a strength education video.
10135699|NCT04245852|Active Comparator|Control Group|The control group will receive standard physical therapy care at the University of Illinois at Chicago Faculty Practice.
10135700|NCT04246125||Therapeutic interventional radiology|Patients undergoing an interventional radiology procedure, at risk for developing radiation-induced skin lesions, including acts of therapeutic interventional neuroradiology (angioplasties, embolization of aneurysms, embolization of arteriovenous malformations , etc…), embolizations and ablations of thoracic tumors, therapeutic cardiac acts (transluminal angioplasties and chronic coronary occlusions) and abdominal embolizations.
10135701|NCT04245969|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the shoulder
10135702|NCT04245969|Experimental|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the affected shoulder
10135703|NCT04245969|Experimental|No intervention group|To evaluate at the same time than the others groups but without being treated with 448 kilohertz Capacitive Resistive Monopolar Radiofrequency.
10135704|NCT04245956|Experimental|Transcatheter Mitral Valve Repair arm|Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system
10135705|NCT04245761|Experimental|Sonidor®|Application: following the summary of product characteristics (l tablet per day) At the 7-day phone call the Investigator can increase the dosage to 2 tablets per day only in non-responding subjects.
10135706|NCT04245943|Experimental|Exercise|18 weeks supervised strength and aerobic exercise training
10135707|NCT04246034|Experimental|Cases|As described by Saaristo et al. in 2012, the surgical technique starts with wide axillary scar removal, followed by elevation of contralateral dual flap which includes DIEP/MS-TRAM with attached groin lymph nodes and fat, then the anastomosis is preferably done to internal mammary vessels.
10135708|NCT04245878||intensive care unit inpatient|Inpatient intubated resuscitation patient with a scheduled extubation
10135709|NCT04245813|Experimental|Intervention|"Consists of 3 interdisciplinary educational sessions and Face-to-face with a fortnightly telephone follow-up and text messages. Each session will be directed by medical staff (cardiologist and / or physiatrist) and supported by other health professionals (physical therapist, occupational therapist, nutritionist and psychologist). The educational sessions, include the topics knowledge of the disease, recognition of alarm signs, pharmacological treatment, healthy lifestyle habits, mental health and regular aerobic exercise; The entire educational component will be based on the Colombian clinical practice guide for the prevention, diagnosis, treatment and rehabilitation of heart failure."
10135710|NCT04245813|No Intervention|Control|Once the patient ends phase II of the cardiac rehabilitation program, he/she will receive the usual care, which consists of a 5-minute educational intervention by a physiatrist at the end of the functional test, where recommendations are given on healthy lifestyle habits, adherence to pharmacological treatment and regular aerobic exercise. This educational intervention will be performed after each of the functional tests (at the end of phase II of the program and during the follow-up of patients at months 1, 3, 6 and 12 during Phase III of the program) performing 5 educational interventions in total .
10135711|NCT04245982||group (C)|healthy controls group
10135712|NCT04245982||group (P)|periodontitis group
10135713|NCT04245982||group (DP)|diabetes and periodontitis group
10135714|NCT04245787|Experimental|Self assembling peptide with fluoride|
10135715|NCT04245787|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|
10135716|NCT04245917||MNGIE Patients|Patients with mitochondrial neurogastrointestinal encephalomyopathy
10187689|NCT03723694|Active Comparator|650 mg of Cocoapro flavanols|Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
9519629|NCT03285165|Active Comparator|DEX I|Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
9519630|NCT03285165|Active Comparator|DEX II|Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
9669147|NCT03882905|Placebo Comparator|Placebo: Extension|Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
10135717|NCT04245774|Experimental|Group L (Hyperbaric Levobupivacaine)|"7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.~In order to obtain hyperbaric levobupivacaine, 1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) was added to 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water."
10135718|NCT04245774|Active Comparator|Group B (Hyperbaric Bupivacaine)|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (Marcaine® Spinal Heavy, 0.5%, 4 mL ampoule, AstraZeneca/England, Eczacıbaşı/Turkey, dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.
10135719|NCT04245696|Experimental|Single Group|Single Arm: All subjects will undergo treatment for skin laxity in the submentum with a Dermal and SubQ handpiece
10135720|NCT04245540|Experimental|Active|1,050 mg per day of encapsulated Pau d' Arco taken orally for 2 months.
10135721|NCT04245488|Other|taste testing|Participants will first taste 5 sour solution containing acetic acid for sour compounds, sucrose esters, and xanthan gum to help them stay dissolved). Then rate them for their taste intensities. Next, participants will taste 5 butyric acid solutions, 5 hexenoic acid solutions, 5 caprylic acid solutions, 5 lauric acid solutions, 5 palmitic acid solutions, 5 oleic acid solutions, and 5 linoleic acid solutions (all will also contain the sucrose esters and xanthan gums.) and rate them for their taste intensities. This should take no longer than 1 hour. Participants will spit all samples into a cup after tasting them. They will not swallow any samples.
10135722|NCT04245384|Experimental|Internet-based treatment|Internet-based dietetic treatment with video calls, no physical meetings
10135723|NCT04245384|Active Comparator|Standard treatment|Dietetic treatment with physical meetings
10135724|NCT04245566|Experimental|Prostatic Artery Embolization (PAE)|PAE will be performed as an inpatient or outpatient procedure by interventional radiologists who are familiar with the procedure and according to established techniques. A unilateral femoral sheath is placed in the right common femoral artery under local anaesthesia. The prostatic arterial supply is identified by selective internal iliac arteriography. Prostatic arteries are selectively catheterised and embolised by use of 250-600 μm microspheres . PAE is performed bilaterally if possible and considered successful in the absence of the normal blush of the prostate and stasis of flow in the prostate arteries on angiography after embolisation.
10135725|NCT04245566|Placebo Comparator|Pharmocotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations. Thus, patients with a prostate size smaller than 40mL will be treated with 0.4 mg tamsulosin once daily, while patients with larger prostates will be treated with 0.4 mg tamsulosin plus 0.5 mg dutasteride once daily during the complete study follow-up.
10135726|NCT04245358|Other|Ainara|Ainara is a class II medical device, already marketed in several EU countries. Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
10135727|NCT04245371|Active Comparator|Active|Lidocaine Patch 1.8% applied to affected hand at night for 2 weeks following FDA approved dosing recommendations, i.e. 12 hours during each 24-hour daily cycle.
10135728|NCT04245371|Placebo Comparator|Placebo|Placebo Patch applied to affected hand at night for 2 weeks for 12 hours during each 24-hour daily cycle.
10135729|NCT04245462||Participants|Older aged (>60 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco, Mexico).
10135730|NCT04245722|Experimental|FT596 Monotherapy, Lymphoma|FT596 monotherapy in adult subjects with r/r B-cell Lymphoma
10135731|NCT04245722|Experimental|FT596 in Combination with Rituximab, Lymphoma|FT596 in combination with Rituximab in adult subjects with r/r B-cell Lymphoma
10135732|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, Lymphoma|FT596 in combination with Obinutuzumab in adult subjects with r/r B-cell Lymphoma
10135733|NCT04245722|Experimental|FT596 Monotherapy, CLL|FT596 monotherapy in adult subjects with r/r CLL
10135734|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, CLL|FT596 in combination with Obinutuzumab in adult subjects with r/r CLL
10135735|NCT04245527|Experimental|Study Arm|20 minutes Joovv Solo every day for 8 weeks.
10135736|NCT04245410||Patients surgically treated of pancreatic metastases from RCC|Patients surgically treated of pancreatic metastases from renal cell carcinoma. Pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy are included.
10135737|NCT04245553|Experimental|All Participants|
10135738|NCT04245605||Early angiography|Patients admitted to hospital with acute heart failure undergoing coronary angiography within 14 days of hospital admission
10135739|NCT04245605||Control|Patients admitted to hospital with acute heart failure not undergoing coronary angiography within 14 days
9669148|NCT03882892|Placebo Comparator|Placebo + Atorvastatin|Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
9826068|NCT02406443|Experimental|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
9826069|NCT02406443|Placebo Comparator|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
9826070|NCT02406495|Experimental|filcon IV 1 and ocufilcon D|Habitual wearers of filcon IV 1 sphere lenses refitted with asphere ocufilcon D lenses.
10135740|NCT04245631||RAA assay for 2019-nCoV|a simple, fast and portable recombinase aided amplification (RAA) assay for 2019-nCoV
10135741|NCT04245592|Experimental|Extra Virgin Olive Oil|Women with fibromyalgia will consume Extra Virgin Olive Oil.
10135742|NCT04245592|Experimental|Refined Olive Oil|Women with fibromyalgia will consume Refined Olive Oil.
10187690|NCT03723694|Placebo Comparator|0mg Cocoapro flavanols|Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
10187691|NCT03723655|Experimental|Group 1|Active Treatment for participants with base target trough concentration
9669149|NCT03882892|Experimental|Ezetimibe + Atorvastatin|Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.
9826071|NCT02406573|Experimental|Crest® Sensi-Stop™ Strips|Professionally Applied
10135743|NCT04245579|Experimental|Experimental Group|"The experimental group carried out a 30-session multi-factorial group memory training program (UMAM method), with a frequency of three weekly sessions of 90 minutes each. The training program consists of four modules: 1- Stimulation of cognitive processes; learning and practicing internal memory strategies and solving everyday forgetfulness; 2- Instruction in basic concepts about memory; 3- Intervention on daily living and forgetting experiences, using internal and external strategies to solve everyday memory failures; 4- Metacognition or metamemory: the subjects were to reflect about their cognitive failures by analyzing the causes and variables of those failures.~In addition, the experimental group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.)."
10135744|NCT04245579|No Intervention|Control Group|The Control Group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.).
10135745|NCT04245709|Experimental|Open label Arm|This is an open label pilot trial in which 25 people with ALS will take clenbuterol orally at 40-80 micrograms twice daily for 24 weeks.
10135746|NCT04245670|Experimental|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
10135747|NCT04245501|Experimental|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized 16-session intervention aimed at reducing interpretation bias. In this study, CBM-I is personalized to youth anxiety symptoms. During CBM-I sessions, youth indicate whether word-sentence pairs are related, and are provided with feedback aimed to reduce bias.
10135748|NCT04245501|Placebo Comparator|Interpretation Control Condition (ICC)|"Computerized 16-session intervention that is not believed to significantly modify bias. In this study, youth see stimuli personalized to their anxiety symptoms. During ICC sessions, youth see word-sentence pairs and are required to indicate whether word and sentence are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
10135749|NCT04245332|Experimental|Fish Oil|This group will receive fish oil (4g/d).
10135750|NCT04245332|Placebo Comparator|Placebo|This group will receive coconut oil (4g/d) as an iso-energetic, iso-lipidic placebo comparator to the fish oil arm.
10135751|NCT04246151|Experimental|Vancomycin & probiotic placebo|Vancomycin 125 mg orally every 12 hours plus probiotic placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
10135752|NCT04246151|Experimental|Probiotic & vancomycin placebo|Culturelle probiotic 20 billion active units orally every 12 hours plus vancomycin placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
10135753|NCT04246151|Placebo Comparator|Probiotic placebo & vancomycin placebo|Vancomycin placebo orally every 12 hours and Culturelle placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
10135754|NCT04245007|Experimental|Intervention|Subject will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
10135755|NCT04245007|No Intervention|Control|Subject will prohibited from doing fasting or intake restriction within 8 weeks
10184239|NCT03757026|Active Comparator|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
10184240|NCT03757026|Experimental|Slip training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine intervention sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
10184241|NCT03757026|Experimental|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
10184242|NCT03757000|Experimental|YY-20394|"YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).~YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day."
10184243|NCT03756987|Experimental|ESPB group|Patient will receive a single shot of Ropivacaine injection 0.5% 25 mL injected at the erector spinae plane.
10184244|NCT03756987|Placebo Comparator|Control Group|Patient will receive a single shot of normal saline 25 mL injected at the erector spinae plane.
10184245|NCT03756974|Experimental|BX-1 (dronabinol)|BX-1
10184246|NCT03756974|Placebo Comparator|Placebo|Placebo of BX-1
10184247|NCT03756948|Active Comparator|Usual Care (Before)|No Thromboelastometry No Synthetic Factor Concentrates Usual Care
10184248|NCT03756948|Experimental|Thromboelastometry-Guided Therapy (After)|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
10184249|NCT03756922|Experimental|Part 1|To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
10135756|NCT04245098|Experimental|Amyloid|Biopsy
10135757|NCT04245059|Experimental|Transcranial Direct Current Stimulation|Each subject will receive transcranial electrical stimulation at primary motor cortex in both hemispheres. The pilot program will include 12 sessions with a frequency of 3 times per week during 4 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 milliamp using 6x4 cm electrodes. The participants will also complete a set of manual dexterity, grip and pinch tests bilaterally at baseline and post-intervention to determine if the subject responds to tDCS. Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin disorders and other possible side effects of tDCS.
10135758|NCT04245111||Open Fracture Cohort|Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion. Open fracture wound management that includes formal surgical debridement within 72 hours of their injury. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent.
10135759|NCT04245111||Complication Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
10135760|NCT04245111||Closed Fracture Cohort|"Patients 18 years of age or older Closed extremity fracture Planned definitive fracture management with external fixation, internal fixation, or joint fusion.~Provision of informed consent"
10135761|NCT04245046|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:~Age: 18-49 years~Weight: 55-105 kg~Height: 163-188 cm~BMI 18.5-29.9 kg/m²"
10135762|NCT04245020|Active Comparator|Text Message|Patients will be followed up with a series of text messages at 6-8 weeks
10135763|NCT04245020|Active Comparator|Telephone|Patients will be followed with a telephone conversation at 6-8 weeks
10135764|NCT04245020|Active Comparator|In person|Patients will be followed in person in the Outpatient department at 6-8 weeks
10135765|NCT04245163|Experimental|Intervention Group|Participants in the intervention group will be invited for the training program.
10135766|NCT04245163|No Intervention|Control Group|Participants who will be randomized in control group will receive normal care (the care that each clinic provides to the patients) and will be given an educational material (without telling them that they are in the control group). They will receive, however, the education class later (at the end of the study).
10135767|NCT04245176|Experimental|Quantitative Genetic Counseling|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:~-- Quantitative genetic counseling: Discussion is guided by tables and graphs."
10135768|NCT04245176|Active Comparator|STANDARD GENETIC COUNSELING|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:~-- Standard genetic counseling: Standard of care discussion"
10135769|NCT04245319|Other|NbUVB|Group A: patients will receive three NB-UVB sessions per week for 48 sessions.
10135770|NCT04245319|Experimental|Combined nbUVB and Acitretin|Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3mg/kg/day daily.
10135771|NCT04245072|Active Comparator|Ranibizumab|Arm 1
10135772|NCT04245072|Active Comparator|Aflibercept|Arm 2
10135773|NCT04245254|Experimental|Intervention Arm|Single arm study. Receives collagen protein powder.
10135774|NCT04244981|Experimental|PCC group|When APTT is prolonged (>1.5 times normal), patients will be given a 4-factor PCC based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg; INR>6, PCC 50 IU/kg).
10135775|NCT04244981|Active Comparator|FFP group|When APTT is prolonged (>1.5 times normal), patients will be given a dose of 10-15 ml/kg FFP.
10135776|NCT04245267|No Intervention|Control|Patients in the wait-list being attended with the standard model of care for diabetes in primary care units.
10135777|NCT04245267|Experimental|DIABEMPIC program|Intervention comprised by an interdisciplinary team care, patient-centered care approach, structured diabetes education program, promotion of self-management, audit, and guaranteed supply of anti-diabetic medication.
10135778|NCT04245293|Experimental|Ainara|Experimental: Ainara Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
10135779|NCT04245293|Active Comparator|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
10135780|NCT04245280|Active Comparator|PENG and LFCN blocks with ropivacaine|For the PENG block, and after negative aspiration, 20 ml of a solution of ropivacaine 0.5% with epinephrine 2.5 mcg/ml will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same solution will be injected with the same needle.
10135781|NCT04245280|Placebo Comparator|PENG and LFCN blocks with saline solution|For the PENG block, and after negative aspiration, 20 ml of a saline solution will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same saline solution will be injected with the same needle.
10187692|NCT03723655|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
9968830|NCT01283815|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group
9519631|NCT03285165|Active Comparator|Propofol I|Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.
10135782|NCT04245033|Experimental|IPTsc arm|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment in school children (IPTsc) will be given in all wards in the IPTsc arm at an interval of four months, three times a year.
10135783|NCT04245033|No Intervention|Control|No intervention will be given to wards randomised in this arm
10135784|NCT04245124|Experimental|SMART INTERVENTION|N= 81 20 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
10135785|NCT04245124|Experimental|TCR|N= 81 60 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
10135786|NCT04244929|Experimental|PCL removal|Patients will undergo surgery by sacrificing the PCL
10135787|NCT04244929|Active Comparator|PCL preservation|Patients will undergo surgery with retaining the PCL
10135788|NCT04244994|Other|Intervention and Control|Self-taken penile meatal swabs versus first-catch urine for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
10135789|NCT04244812|Other|CSAP group|"Participants in the CSAP group will receive examination of laser doppler flowmetry(LDF).~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian"
10135790|NCT04244812|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
10135791|NCT04244812|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
10135792|NCT04244799|Experimental|Behavioral nudges|Schools randomized to this arm will receive the behavioral nudges intervention and the Philippines Department of Education national WASH in Schools (WinS) policy.
10135793|NCT04244799|Active Comparator|Control group|Schools in the control group will not receive handwashing nudges but will receive DepEd's national WASH in Schools (WinS) policy.
10135794|NCT04244643||Patients with soft contact lenses|
10135795|NCT04244539|Experimental|Experimental group|a received routine physical therapy program, in addition to HILT. Patients in the study group received pulsed Nd: YAG laser treatment, produced by a HIRO 3 device (ASA Laser, Arcugnano, Italy). The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2),
10135796|NCT04244539|Active Comparator|Control group|The control group received traditional physical therapy program in the form of strengthening exercise, stretching , and range of motion exercise.for the affected digits and wrists. for one hour, three sessions per week for 8 weeks.
10135797|NCT04244526||Group1|Group 1:pregnant women with cystitis
10135798|NCT04244526||Group2|Group 2: pregnant women with Pyelonephritis
10135799|NCT04244526||Group3|Group 3: pregnant women with asymptomatic bacteriuria
10135800|NCT04244695|Experimental|Dexamethasone 16 mg|Dexamethasone (4mg) 4 tab oral once daily in the morning
10135801|NCT04244695|Active Comparator|Dexamethasone 8 mg|Dexamethasone (4mg) 2 tab and placebo 2 tab oral once daily in the morning
10135802|NCT04244695|Placebo Comparator|Placebo|Placebo 4 tab oral once daily in the morning
10135803|NCT04244669|Experimental|SCS with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% of pain in that area.
10135804|NCT04244669|Experimental|SCS with SCS DTM Stimulation|IIn this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms.
10135805|NCT04244513|Experimental|HD-DBS|This group will be routinely activated after surgery and then stimulated for 6 months.
9968831|NCT01283841|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
10135806|NCT04244513|Sham Comparator|HD-sham-DBS|This group of patients will be re-launched 3 months after surgery, continued stimulation for 3 months
10135807|NCT04244747|Active Comparator|induction of labour by breast stimulation|women at term with previous cesarean section and an indication to induce labor. In order to induce labour by breast stimulation, an electrical pump was used. The cup was alternated between the nipples every 15 minutes, with a pause of 15 minutes after each 30 minutes, with a total induction time of 6 hours.
10135808|NCT04244747|Active Comparator|induction of labour by catheter balloon|women at term with previous cesarean section and an indication to induce labor. In the catheter balloon group, a 16-F Foley catheter was inserted into the cervical canal and inflated with 60 cc sterile saline solution and was kept in place for 12 hours.
10135809|NCT04244747|No Intervention|spontaneous labour|women in latent phase of spontaneous labour .
10135810|NCT04244565||Self-directed clinical learning|examining the effect of Self-directed clinical learning model as compared to the traditional models to improve nurses' Airway management competencies and minimize airway related incidents.
10135811|NCT04244500||Influenza|Influenza testing
10135812|NCT04244617|Experimental|iCBT with addition of peer-support (iCBT-PS)|Participants in the iCBT-PS, are guided by both a psychologist and a peer-support in the iCBT-program used in the study.
10135813|NCT04244591|Placebo Comparator|standard care|standard care
10135814|NCT04244591|Experimental|standard care + methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
10135815|NCT04244760|Active Comparator|Verbal Patients|
10135816|NCT04244760|Active Comparator|Non-verbal Patients|
10135817|NCT04244604|Experimental|High Sodium Meal (2500 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a high sodium meal (2500 mg sodium).
10184250|NCT03756922|Experimental|Part 2|To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
10184251|NCT03756922|Experimental|Part 3|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
10135818|NCT04244604|Placebo Comparator|Low Sodium Meal (140 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a low sodium meal (140 mg sodium) which will serve as the control condition to demonstrate whether or not observed changes are due to high sodium or occur irrespective of sodium in the postprandial state.
10135819|NCT04244851||Malnourished patients|Malnourished patients
10135820|NCT04244838|Experimental|MP-TKA group|20 patients candidates for cemented TKA with MP design for tri-compartment gonarthrosis will be recruited on indications of the surgeon and according to normal clinical practice at the Orthopedic and Traumatological Clinic 2nd of the Rizzoli Orthopedic Institute.
10135821|NCT04244734|Active Comparator|Group 1|The control group receives regular treatment in the ICU, which includes muscle strengthening exercises, passive/assisted or active mobilizations, and respiratory physiotherapy with breathing muscle strengthening in a medium load (initially at 40% load from results in MIP).
10135822|NCT04244734|Experimental|Group 2|The experimental group receives a new early rehabilitation program based on a patient's in-bed cycling that allows controlled and adapted training to the patient's situation, along with coordinated exercise with neuromuscular electrostimulation and respiratory physiotherapy with breathing muscle strengthening in a high load (initially at 60% load from results in MIP).
10135823|NCT04244474|Experimental|vitamin D3 supplementation|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) . Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
10135824|NCT04244474|Placebo Comparator|Placebo|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
10135825|NCT04244825|Experimental|Cohort 1a BLD-2660|900 mg (6 x 150 mg capsules) BID
10135826|NCT04244825|Experimental|Cohort 1b BLD-2660|900 mg (6 x 150 mg capsules) BID (Optional)
10135827|NCT04244825|Experimental|Cohort 2 BLD-2660|600 mg (4 x 150 mg capsules) BID
10135828|NCT04244825|Experimental|Cohort 3 BLD-2660|300 mg (2 x 150 mg capsules) BID
10135829|NCT04244825|Placebo Comparator|Cohort 1a Placebo|900 mg (6 x 150 mg capsules) BID
10135830|NCT04244825|Placebo Comparator|Cohort 1b Placebo|900 mg (6 x 150 mg capsules) BID (Optional)
10135831|NCT04244825|Placebo Comparator|Cohort 2 Placebo|600 mg (4 x 150 mg capsules) BID
10135832|NCT04244825|Placebo Comparator|Cohort 3 Placebo|300 mg (2 x 150 mg capsules) BID
10135833|NCT04244708|Experimental|Radiotherapy plus temozolomide|Undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day), followed by six cycles of adjuvant temozolomide.
10135834|NCT04244708|Placebo Comparator|Radiotherapy plus placebo|Radiotherapy treatment alone undergoing fractionated radiotherapy, total 54 Gy, 2GyX27, received placebo.
10135835|NCT04244656|Experimental|CTX120|Administered by IV infusion following lymphodepleting chemotherapy.
10135836|NCT04244578|Experimental|Active-Sham tDCS|Each tDCS sessions will be delivered for 5 days for a total of non consecutive two weeks. The first session will be active tDCS and two months after, a sham tDCS will follow.
10135837|NCT04244578|Active Comparator|Sham-Active tDCS|"Each tDCS sessions (sham tDCS and active tDCS) will be delivered for 5 days for a total of non consecutive two weeks.~The first session will be sham tDCS and two months after, an active tDCS will follow."
10135838|NCT04244448|Other|BIKTARVY® ADMINISTRATION DISSOLVED IN WATER|BIKTARVY® route in healthy volunteers: dissolved in water in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of dissolved in water versus crushed and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
10135839|NCT04244448|Other|BIKTARVY® ADMINISTRATION CRUSHED|BIKTARVY® route in healthy volunteers: crushed in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of crushed versus dissolved in water and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
10135840|NCT04244448|Other|BIKTARVY® ADMINISTRATION SOLID|BIKTARVY® route in healthy volunteers: solid tablet in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of solid form of BIKTARVY® versus dissolved in water and crushed in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
10135841|NCT04244721|Sham Comparator|a group of children receiving the usual therapy (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
10135842|NCT04244721|Experimental|a group of children receiving TAU plus the PACT intervention.|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
9519632|NCT03285165|Active Comparator|Propofol II|Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.
9968832|NCT01283841|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
10135843|NCT04244422|Active Comparator|cyst enucleation using piezosurgery|SATLEC ACTEON peizotome 2 was used for bone cutting and separating the cystic lining from the surrounding bone.After complete removal of the cyst, the bony window was replaced back in place and the flap was sutured.
10135844|NCT04244422|Active Comparator|cyst enucleation using conventional surgery|A carbide bur was used to remove the bone to uncover the cyst. A periosteal elevator and a curette were used to aid in the removal of the cystic lesion.
10135845|NCT04244383|Experimental|chronic hepatitis C virus patients|50 chronic hepatitis C virus patients taking will be trated with direct acting antiviral treatment with three months regimen (Sofosbuvir + Daclatasvir).
10135846|NCT04244383|Experimental|treated chronic hepatitis C virus patients|the selected 50 chronic hepatitis C virus patients received direct acting antivirals: Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virological response at 12 weeks following the end of treatment (SVR12).
10135847|NCT04244305|Experimental|Treadmill Training|"Participants in the treadmill training group will perform endurance training during the post-operative period using a treadmill (Salter Housewares, UK) for a minimum of 20 sessions. Intensity of training will be set according to 80% of the mean speed achieved during the 6MWT for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week.~After the endurance training, participants will perform resistance training for 20 - 30 minutes for conditioning of the main muscles in the upper and lower limbs using elastic bands, dumbbells and body-weight exercises. Intensity will progressively increase up to 70% of the maximum isometric strength measured with a hand-held dynamometer. Volume of training will also increase from 1 to 3 sets of 12 repetitions each. When needed patients will also be taught breathing exercises and airway clearance techniques."
10135848|NCT04244305|Active Comparator|Cyclo-ergometry Training|Participants in this group will perfom endurance training during the post-operative period using a cycle ergometer (Monark 828e, Monark AB, Sweeden) for a minimum of 20 sessions. Intensity of training will be set according to the results of a symptom-limited incremental cycle-ergometry test performed on the first day to achieve 80% of the maximal workload obtained for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week. Participants in this group will also perfom resistance training and breathing exercises as in the treadmill training group.
10135849|NCT04244318|Experimental|Video Feedback ODISEA 2.0.|Once a week, the 5 session intervention of Video-feedback ODISEA 2.0 will be done with the family. In the first session, a play interaction between the child and the caregiver will be recorded for 10 minutes. The second session will be done between the therapist and caregivers, where they will watch different selected parts of the video, and will provide feedback through a mentalization constructed framework. Then, in the third session another play interaction video will be recorded, that will be discussed on the fourth session with the caregiver. Finally, in the fifth session a final interaction video will be recorded.
10135850|NCT04244318|No Intervention|Control Group.|Patients in control group will be placed as a non intervention group. After collecting the post-test data, they will be offered the same intervention than the experimental group.
10135851|NCT04244292|Other|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
10135852|NCT04244435|Experimental|Thoracic epidural analgesia|CABG and thoracic epidural analgesia will be used for perioperative analgesia postoperative period
10135853|NCT04244435|Active Comparator|Opioids|CABG and opioids will be used for perioperative analgesia
10135854|NCT04244435|Active Comparator|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
10135855|NCT04243967|Experimental|MUSIC THERAPY|
10135856|NCT04243967|Experimental|CONTROL|
10135857|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose = 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.~The PCA setting:~1) Continuous dose = 0; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
10135858|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose ≠ 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.~The PCA setting:~1) Continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
10135859|NCT04243954|Active Comparator|Oral Morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
10135860|NCT04243980||Group 1|Patients after total hip arthroplasty with short femoral stem
9976841|NCT01355757|Experimental|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
10135861|NCT04244071|Active Comparator|Group C|"Usual care (Group C): The patients in this group received routine hospital care.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
10135862|NCT04244071|Experimental|Group A|"The patients in Group A were warmed up using a gown blowing warm air starting at least 30 min prior to the surgery until they were anesthetized.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
10135863|NCT04244071|Experimental|Group B|"Routine care was provided for the patients in Group B in the preoperative and intraoperative periods. In the postoperative period, patients were warmed up using a gown blowing warm air after they were transferred to the post-anesthesia care unit, and continued to be warmed up on the basis of the temperature set by themselves until they wore their own clothes in the ward.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
10135864|NCT04244032|Experimental|Working Memory Training (WM)|Participants complete training in a working memory task designed to utilize individually-adapted difficulty levels.
10135865|NCT04244032|Experimental|Inhibitory Control Training (IC)|Participants complete training in an inhibitory control task designed to utilize individually-adapted difficulty levels.
10135866|NCT04244032|Active Comparator|Bias Modification Training (BM)|Participants complete training in an active comparator task designed to weaken approach responses to alcohol-associated cues.
9976842|NCT01355757|Active Comparator|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
9976843|NCT01355783|Active Comparator|E7777 + CHOP Chemotherapy|
9968833|NCT01283854|Experimental|Exercise group|Each participant randomised to the exercise group will receive routine, regular antenatal care. In addition, these women will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist.
9976844|NCT01355783|Active Comparator|CHOP alone|
10135867|NCT04244032|No Intervention|Non-Trained control (NTC)|No active intervention is delivered beyond typical care.
10135868|NCT04244149|Experimental|Intervention group|Participants will exert an exercise prolonged session
10135869|NCT04244058|Active Comparator|NMDA blocker|Comprehensive functional analyses of dynamic [18F]FPEB-PET signal at rest will be carried out in normal volunteers and patients with DOC due to severe brain injury over a 24-month time period. In each study, we will first evaluate mGluR5 occupancy within the frontal cortex, anterior cingulate cortex, insula, striatum and thalamus. Then, a single dose of amantadine (AMT), a compound that blocks NMDA-R and increases glutamate levels at the synaptic cleft, will be given to each subject or patient and at the time corresponding to the peak of the dose, a second [18F]FPEB-PET will be acquired.
10135870|NCT04244058|Experimental|NMDA blocker + L-DOPA|All the patients with DOC that participate in ARM 1 will follow the same methodology of ARM 1: measurement of mGluR5 occupancy at rest and following NMDA-R blockade with AMT by means of [18F]FPEB-PET after premedication with L-DOPA introduced 1 hour prior each [18F]FPEB-PET acquisitions.
10135871|NCT04244162||Study Group|brain scans, cognitive tests, blood biomarkers
10135872|NCT04244045|Experimental|Experimental group 1|suboccipital muscle inhibition plus passive stretch of hamstring muscle.
10135873|NCT04244045|Experimental|Experimental group 2|Neural slump strtch position plus passive stretch of hamstring muscle.
10135874|NCT04244045|Active Comparator|Control group|passive stretch of hamstring muscle
10135875|NCT04244123||growth hormone deficiency|growth hormone deficiency, requiring growth hormone treatment
10135876|NCT04244123||small for gestational age|small for gestational age and failure of post natal catch up height gain, requiring growth hormone treatment
10135877|NCT04244123||Turner syndrome|short stature due to Turner syndrome, on growth hormone treatment
10135878|NCT04244123||chronic renal failure|short stature due to chronic renal failure, treated with growth hormone treatment
10135879|NCT04244123||Prader Willi syndrome|short stature due to Prader Willi syndrome, treated with growth hormone treatment
10135880|NCT04244214||More Stamina users|This group of patients will use the app for 60 days and all information about utilization will be recorded
10135881|NCT04244344|Experimental|interventional|"all High fall risk subjects who meet the criteria by STRATIFY Tool"
10135882|NCT04244253|Experimental|OPC-64005 20 mg|
10135883|NCT04244253|Experimental|OPC-64005 10 mg|
10135884|NCT04244253|Placebo Comparator|Placebo|
10135885|NCT04244006|Experimental|Dupilumab|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of Dupilumab 300 mg (syringe of 2 mL for subcutaneous administration).
10135886|NCT04244006|Placebo Comparator|Placebo|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of placebo (syringe of 2 mL for subcutaneous administration)..
10135887|NCT04244097|Experimental|B group|-Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.
10135888|NCT04244097|Active Comparator|BN group|Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.
9669150|NCT03880240|Experimental|2 weeks of daily tACS sessions|10 daily (Monday-Friday) 1-hour sessions of tACS stimulation
10135889|NCT04244188||Patients treated for aortic arch aneurysms|Patients treated for aortic arch aneurysms by double branched endovascular repair (Bolton Medical) will be included.
10135890|NCT04244396||Drug refractory, symptomatic persistent atrial fibrillation|Asian population
10135891|NCT04244279|Experimental|Intervention group|The intervention group will participate in a workshop regarding ergonomic principles in baby care. Finally, a brochure will be distributed summarizing the main contents of the workshop. One month and two months after the intervention, the intervention group will receive a videotaped reminder of the principles presented at the workshop via an email or WhatsApp message.
10135892|NCT04244279|No Intervention|Control group|The control group will not receive any intervention during the data collection period. The intervention will be given three months after the beginning of the research, in the format of the brochure and videos sent via email or WhatsApp.
10135893|NCT04243928|Active Comparator|control group|15 diplegic children received regular exercise program including balance exercise
10135894|NCT04243928|Experimental|study group|15 diplegic children recieved regular exercise program plus putting kinesiotape
10135895|NCT04244201|Experimental|VHT treatment|Patients will be treated with VHT for 1 hour four times per week
10135896|NCT04243993|Other|Bio-MA|Calcium silicate cement containing calcium chloride accelerator
10135897|NCT04243993|Other|ProRoot MTA|Calcium silicate cement without calcium chloride accelerator
10135898|NCT04243915|Experimental|PNMES plus exercise|6-week intervention program with 3 treatment sessions of PNMES and motor control exercise program.
10135899|NCT04243915|Sham Comparator|Sham PNMES (introducing the needle) plus exercise|Sham PNMES (introducing the needle) plus motor control exercise program
10135900|NCT04243915|Active Comparator|TENS plus exercise|6-week intervention program with 3 treatment sessions of TENS plus motor control exercise program.
9669151|NCT03880240|Experimental|4 weeks of daily tACS sessions|20 daily (Monday-Friday) 1-hour sessions of tACS stimulation
10135901|NCT04243915|Placebo Comparator|Placebo PNMES (without inserting the needle) plus exercise|6-week intervention program with 3 treatment sessions of placebo PNMES (without inserting the needle) and exercise
9669152|NCT03880240|Experimental|4 weeks of twice daily tACS sessions|20 days (Monday-Friday) of 1-hour sessions of tACS twice per day
9669153|NCT03880240|Sham Comparator|2/4 weeks of Sham tACS sessions|10/20 days (Monday-Friday) of 1-hour sessions of tACS once/twice per day
9976845|NCT01355809|Active Comparator|Inhalation Nitrogen/Oxygen|Nitrogen/Oxygen (65%/35%)
9976846|NCT01355809|Experimental|Inhalation Helium/Oxygen|Helium/Oxygen (65%/35%)
10135902|NCT04243889|Experimental|NEOX Cord 1K applied fetoscopically|
10135903|NCT04243876||paraoxanase|Enzyme level
10135904|NCT04243876||Myocardial infarction|RESULTS OF ANGIOGRAPHY
10135905|NCT04243863|Experimental|VNRX-7145|Oral dosing
10135906|NCT04243863|Placebo Comparator|Placebo|Oral dosing
10135907|NCT04243655|Experimental|Hemoperfusion treatment with HA 330-II|Hemoperfusion treatment with HA 330-II, one unit for 2-4 hours treatment, for 3 consecutive days along with SMT as per patients requirement.
10135908|NCT04243655|Active Comparator|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
10135909|NCT04243603|Experimental|Internet-based ERITA-DK|ERITA is a youth-adapted version of Emotion Regulation Group Therapy (ERGT), based on cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and Acceptance and Commitment Therapy (ACT), which encounters emotional recognition and regulation, crisis strategies and skills training. The ERITA intervention is provided as add-on to TAU and consists of 12 weeks, manualized, therapist guided internet-based therapy. The intervention also provides six modules for the parents focusing on NSSI and other risk-taking behaviors, emotional awareness, and validation skills. The participants must complete one module every week while the parents must complete a module every second week. A mobile app is available to complement the online treatment. The app includes reminders of homework and skills and allows to report on both self-destructive behaviors and impulses daily.
10135910|NCT04243603|Active Comparator|Treatment as Usual (TAU)|Child and Adolescent Mental Health Services (CAMHS) offer specialized treatment for children and adolescents. TAU encounters a variety of clinical treatment and assessment offers, representing a highly inhomogeneous group of treatments, for instance: Pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy, supportive counselling and psychoeducation. Throughout the trial course the treatment responsibility is handled by clinicians providing TAU.
10135911|NCT04243564|Active Comparator|PLMA|The PLMA, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
10135912|NCT04243564|Active Comparator|I-gel|The I-gel, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
10135913|NCT04243551|Active Comparator|Latiglutenase|IMGX003
10135914|NCT04243551|Placebo Comparator|Placebo|Placebo
10135915|NCT04243694|Experimental|Intervention group|mindfulness intervention administered
10135916|NCT04243694|No Intervention|Control group|no intervention administered
10135917|NCT04243850|Experimental|Empagliflozin|Empagliflozine 7 days
10135918|NCT04243850|Placebo Comparator|Placebo|Placebo 7 days
10135919|NCT04243746|Experimental|Time Restricted Feeding +Standard Malaysian Healthy Plate(QQH)|Subjects practise time restricted feeding (TRF) in addition to the Standard Malaysian Healthy Plate (QQH).
10135920|NCT04243746|Active Comparator|Standard Malaysian Healthy Plate (QQH)|Subjects practise the QQH dietary plan.
10135921|NCT04243590||Neonatal brachial plexus palsy|"25 patients will be included. The level of the brachial plexus lesion will be recorded. Parents of all patients were asked to fill in the Turkish version of the Hand-at-Home Questionnaire and in addition, the upper extremity section of the Pediatric Outcomes Data Collection Instrument (PODCI) in patients with OBP."
10135922|NCT04243590||Unilateral cerebral palsy|"25 patients will be included. The level of Manual Ability Classification System (MACS) will be recorded. Parents of all patients were asked to fill out the Turkish version of the Hand-at-Home Questionnaire at Home, as well as the Children's Hand-Use Experience Questionnaire (CHEQ) in patients with CP."
10135923|NCT04243668|Experimental|ANTI REFLUX MUCOSAL ABLATION THERAPHY|In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.
10135924|NCT04243733|Other|calcium enriched mixture material (CEM)|Using CEM as a pulpotomy agent against MTA pulpotomy agent.
10135925|NCT04243733|Experimental|Mineral trioxide aggregate material (MTA)|Using MTA as a pulpotomy agent against CEM pulpotomy agent.
10135926|NCT04243473||Prostate Biopsy, Urine sample and Blood sample|For purposes of exploratory analyses, blood (whole blood, serum, plasma) and urine samples will be collected pre-IR treatment, 1-month post-implant, 6 month follow-up and 2 years follow-up. Patients will be asked to opt-in on the consent form specifically for the 2-year biopsy, otherwise they have the choice to opt out.
10135927|NCT04243811|Experimental|laser group|local anesthesia applyed with 940 nm diode laser
10135928|NCT04243811|Active Comparator|conventional group|local anesthesia applyed with topical anesthesia
10135929|NCT04243824|Experimental|All participants|All enrolled study participants will receive Ga-68MAA and PET/MRI scan.
10135930|NCT04243681|Experimental|Combination MSC and HSC|Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance
10135931|NCT04243681|Active Comparator|Standard of care for Cirrhosis management|Diuretics, Hepatoprotective agents and Lactulose
10135932|NCT04243772||Lithiasic patients|Lithiasic patients of the CHU Brugmann Hospital
10135933|NCT04243460|Experimental|CTG connective tissue graft augmentation|CTG connective tissue graft (CTG) was used for soft tissue augmentation. I
10135934|NCT04243460|Active Comparator|XCM Xenogeneic collagen matrix (XCM)graft augmentation|Xenogeneic collagen matrix (XCM) was used for soft tissue augmentation.
10135935|NCT04243434|Experimental|Cohort A|Marqibo formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1, and VSLI-RTU formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
10184252|NCT03756922|Experimental|Part 4|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
9519633|NCT03285087|Experimental|DEX 0.2 μg/kg/h|Patients will receive dexmedetomidine for sedation with initial maintenance dose rate of 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
10135936|NCT04243434|Experimental|Cohort B|VSLI-RTU formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1 and Marqibo formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
10135937|NCT04243174|Other|SMS Messages|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
10135938|NCT04243187|Experimental|Clinical Study|"9 visits, once a week, for bean intake (80 grams of dried beans, soaked for 12 hours, cooked in new water for 1.5 - 2 hours. This is approximately 160 grams of cooked beans).~Four varieties of beans (3 native and 1 commercial) will be analyzed, which will be consumed in duplicate by participants (8 visits).~A ninth visit will be made to perform a exhaled hydrogen test with raffinose (5 grams), as a positive control."
10135939|NCT04243135|Active Comparator|ESWT group|All patients in both groups were applied with a hot pack for 40-minutes, transcutaneous electrical nerve stimulation for 30-minutes (100 Hz frequency and 60 milliseconds pulse duration), and a home-based exercise program around the knee for 30-minutes per day for three weeks. Also, each patient in group 1 received shockwaves of continuous frequency and intensity (2000 shocks, 10 Hz, 2.0 to 3.0 bar), while the second group of patients received sham-ESWT. In group 1, for a total of 3 weeks, r-ESWT was undertaken with 2000 pulse each time at a week interval totaling 6000 pulse by using a radial shock wave therapy system (vibrolith ortho tip ESWT (ELMED Turkey)).
10135940|NCT04243135|Sham Comparator|Sham-ESWT group|The other group received sham-ESWT at 0.1 bar in the same area. The patients were placed supine with the affected knee at 90 degrees flexion at each treatment session. The shock wave probe was held stationary on painful points around the knee or at the patellofemoral and tibiofemoral borders of the target knee.
10184253|NCT03756896|Experimental|Carfilzomib, pomalidomide, dexamethasone|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10184254|NCT03756870|Experimental|CTO PCI|Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.
10184255|NCT03756870|No Intervention|OMT|Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.
10184256|NCT03756857|Experimental|Afterload transfer|First, an empty catheter passes to the level of the lower uterine segment under ultrasound guidance to a point where the inner catheter enters the endometrial cavity. The inner sheath is removed slowly, leaving the outer sheath just beyond the internal os. After verifying the catheter's position on the TA ultrasound scan, the physician gives the signal to the embryologist to start the embryo loading. The embryologist brings the loaded inner catheter and inserts it into the outer sheath, which is maintained in its position by the physician.
10184257|NCT03756857|Experimental|Trial Followed by Transfer|First a trial transfer is performed using both the inner catheter and outer sheath connected together in standard configuration, just before the actual embryo transfer. It is passed up to and just through the the internal os. When it appears that the actual transfer will be possible without great difficulty ,the trial catheter is withdrawn. An embryo transfer catheter is loaded and the actual transfer is performed
10184258|NCT03756844|Experimental|Just Right Challenge Food Club Protocol|There was only one arm in this study. All participants received the Just Right Challenge Food Club Protocol and single subject (time series) data was collected.
10184259|NCT03756831|Active Comparator|Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
10184260|NCT03756831|Active Comparator|Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
10184261|NCT03756831|Active Comparator|Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
10184262|NCT03756818|Experimental|Treatment (TAK-659 and paclitaxel)|Patients receive spleen tyrosine kinase inhibitor TAK-659 PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10184263|NCT03756805|Active Comparator|Group 1 (CPAP)|Patient, who are receiving a CPAP
9694644|NCT04786925|Experimental|Nutriprecision diet|A Mediterranean, balanced diet based on the inclusion of precision foods designed and developed within the framework of Nutriprecision project. A mobile application to empower and support the management of the dietary prescription. A digital tool for cognitive stimulation.
9694645|NCT04786795|Experimental|Compound Azintamide Enteric-coated Tablets|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the experimental group takes Compound Azintamide Enteric-coated Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
10184264|NCT03756805|Experimental|Group 2 (UAS)|Patient, who are receiving a device for upper airway stimulation
10184265|NCT03756779|Experimental|Low Saturated Fat Diet|Goal will be to attain <7% of daily calories from saturated fat. Replace it with energy from monounsaturated fat.
10184266|NCT03756779|Active Comparator|High Saturated Fat Diet|Goal will be to attain 15% of daily calories from saturated fat. Decrease intake of monounsaturated fat.
10184267|NCT03756727|Experimental|Ascorbic acid group|the patients received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery.
10184268|NCT03756727|Placebo Comparator|Control comparator group|the patients received 10ml saline at the night before surgery, during the surgery and five days after surgery.
10184269|NCT03756701|Experimental|Group 1|Initial participants in the 10 mind body sessions
10184270|NCT03756701|Active Comparator|Group 2|10 week no intervention groups - receives the mind body interventions after group 1 has completed.
10184271|NCT03756675||haplotype PBSCT group|"Subjects in this group will receive haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system in the treatment of acute leukemia."
10184272|NCT03756649||Control Group|Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
10184273|NCT03756649||Inflammatory bowel disease (IBD)|Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
10135941|NCT04243200||Analyses of repeat ambulance calls and costs|For our analyses of repeat ambulance calls and costs we will use routine anonymised data from routine call-and-dispatch and clinical records data from EMAS for 12 months before the intervention was first introduced (September 2017) to at least 6 months after the final step of the introduction in April 2019, i.e. October 2019. This is likely to involve the analysis of an estimated 11916 cases so that we can implement a stepped wedge (non-randomised control)design .
10135942|NCT04243200||Survey of patients receiving intervention|We will survey about 447 patients who received the intervention in order to obtain data from a sample of n=96
10135943|NCT04243200||Survey of ambulance staff|We will send out surveys/questionnaires to all front-line ambulance staff (n=approximately 600)
10135944|NCT04243200||Qualitative interviews of staff|We will sample 10-15 staff for qualitative interviews.
10135945|NCT04243200||Qualitative interviews of patients|We will sample 10-15 patients for qualitative interviews
10135946|NCT04243213|Experimental|Vibration Group|Intervention group I receives a unit of 10 minutes daily on the vibrating plate with an upright posture of 15 ° postoperatively from the 2nd to the 7th day
10135947|NCT04243213|Experimental|15° Tilt Group|Intervention group II is positioned postoperatively from day 2 to day 7 for 15 minutes at 15 degrees, but without vibration
10135948|NCT04243213|Placebo Comparator|Control Group|The control group only receives standard physiotherapy and no further treatments
10135949|NCT04243083|Experimental|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
10135950|NCT04243083|Experimental|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
10135951|NCT04243083|Experimental|Food Effect Panel|Twelve subjects will receive a single dose of TLL018 in 2 treatment periods, one after a high fat, high calorie breakfast (fed) and the second treatment period under fasted conditions to determine the effect of food on the PK of TLL018.
10135952|NCT04243265|Experimental|Patients treated with MPFL reconstruction|"Patients underwent MPFL reconstruction using a minimally invasive technique using a fascia lata allograft performed at the Rizzoli Orthopedic Institute between 2011 and 2015 by the team of Prof. Marcacci.~Clinical and radiographic evaluation will be performed during outpatients visits."
10135953|NCT04243395|Experimental|Pork|1 ounce lean pork
10135954|NCT04243395|Experimental|Egg|1 large whole egg
10135955|NCT04243395|Experimental|Black beans|0.5 cups of cooked black beans
10135956|NCT04243395|Experimental|Almonds|0.5 ounce of whole almonds
10135957|NCT04243096|Experimental|Exercise-based Physical Therapy|12 week in-person exercise-based physical therapy
10135958|NCT04243252|Experimental|Intervention Food Pantries|Food pantries will complete online training to help them rank foods by nutritional value and promote those foods to pantry clients; the effect on pantries and their clients will be measured.
10135959|NCT04243252|Active Comparator|Control Food Pantries|Food pantries will continue to operate as usual during the study period; the effect on pantries and their clients will be measured.
10135960|NCT04243161|Experimental|Group 1|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.
10135961|NCT04243161|Active Comparator|Group 2|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.
10135962|NCT04242979|Other|Human albumin use in liver cirrhosis|"Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5-Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6-Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7-Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians."
10135963|NCT04243018|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Intervention to improve well-being and reduce the negative effects of shame and self-stigma in a population of adults experiencing homelessness.This will involve participating in two sessions, lasting two and a half hours each, over a period of two weeks. Well-being will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition participants will be provided with an acceptance and commitment training workbook. The workbook will foster core processes of the ACT model through psycho-education, daily exercises, tips and tools.
10135964|NCT04243018|Active Comparator|Peer Support Group|This peer support group will involve discussing themes around experiencing homelessness, shame and stigma and will be facilitated by an experienced peer support group leader.This will involve participating in two sessions, lasting two hours each, over a period of two weeks.
10135965|NCT04242901||Colorectal cancer|Patients recently diagnosed colorectal cancer
10135966|NCT04243109|Experimental|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started.~Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
10135967|NCT04242875||PanOptix|Participants will receive the PanOptix intraocular lens.
10135968|NCT04243382|Experimental|group 1|Autologous umbilical cord blood transfusion Single dose of an Autologous umbilical cord blood transfusion
10184274|NCT03756636|Other|"Underwater mucosectomy"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
10184275|NCT03756623|Experimental|Drug: Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
9976847|NCT01355809|Experimental|Inhalation gas|Medicinal oxygen 100% via NIV with FiO2 of 0.35
9976848|NCT01355822|Placebo Comparator|Placebo|
10135969|NCT04243382|Experimental|group 2|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml,
10135970|NCT04242888|Experimental|Rotator Cuff Facilitation|The function of Rotator cuff muscles is passively augmented in one of the 5 trials
10135971|NCT04242888|Experimental|Serratus Anterior Stretch|Seratus anterior muscles is stretched through a novel technique
10135972|NCT04242888|Experimental|Posterior Capsular Stertch|Posterior capsule is stretched through a novel maneuver
10135973|NCT04242888|Experimental|Acromioclavicular Joint Mobilization|Acromio clavicular joint is mobilized posterio-anterior
10135974|NCT04242888|Experimental|Pragmatic Interventions|"The pragmatic interventions is a set of interventions which include~Rotator cuff facilitation~Posterior capsular stretch~Serratus anterior muscle stretch~Acromioclaicualr joint mobilization~Thoracic spine manipulation and~Stretch to the subclavious muscles"
10135975|NCT04243317|Active Comparator|Control|The control group will adhere to a 1200 kcal restriction daily for 12 weeks.
10135976|NCT04243317|Experimental|Experimental|The experimental group will adhere to a 1200 kcal restriction daily for 12 weeks and will maintain sleep improvement
10135977|NCT04242940|Experimental|Ponto 4 sound processor|All patients will be fitted with a bone-anchored sound processor (Ponto 4), unilaterally or bilaterally.
10135978|NCT04243408|Experimental|group 1|
10135979|NCT04243408|Placebo Comparator|group 2|
9976849|NCT01355822|Experimental|PETN|Pentalong, Actavis Germay: 80 mg twice a day
10135980|NCT04242966|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
10135981|NCT04242966|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
10135982|NCT04243304|Experimental|PD patients|At baseline and 2-year follow-up
10135983|NCT04243304|Active Comparator|Healthy controls|At baseline and 2-year follow-up
10135984|NCT04243031||All subjects|Those with TB and those without TB.
10135985|NCT04242914|Experimental|Research: Ketamine + Midazolam|Research group will receive ketamine and midazolam.
10135986|NCT04242914|Experimental|Control: Midazolam|Control group will receive midazolam.
10135987|NCT04242927|Experimental|Nicotinic acid + Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
10135988|NCT04242927|Active Comparator|Routine care|Routinely apply urea ointment and provide best supportive care.
10135989|NCT04242745|Experimental|Intervention group|Procedure/Surgery:The intervention group was given education and a wristwatch which gave an audible alarm to remind them to drink liquid.
10135990|NCT04242745|No Intervention|Control group|The control group was given only education.
10135991|NCT04242719|Active Comparator|Only electromagnetic stimulation|Only rEMS was preferred as the initial step
10135992|NCT04242719|Active Comparator|Combined with electromagnetic stimulation and PRP|Order to augment the effect of the rEMS, sub-tenon aPRP injection was added.
10135993|NCT04242719|No Intervention|Natural course|Served as control group, and existing systemic disorder(s) were consulted and treated accordingly.
10135994|NCT04242823|Other|Baseline screening cohort|This group undergoes hrHPV self-swab and triage if positive. Triage evaluation occurs in all women and includes visual inspection with acetic acid, colposcopy and image capture for automated visual evaluation
10135995|NCT04242732|Experimental|MPFL reconstructed|20 patients with previous recurrent patella dislocation who underwent MPFL reconstruction surgery with fascia lata allograft between 2012 and 2013
10135996|NCT04242797|Active Comparator|Calmare|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
10135997|NCT04242797|Active Comparator|Traditional TENS|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
10135998|NCT04242420|Other|Connexin genotype|Genotyping
10135999|NCT04242459|No Intervention|Feasibility Study|This is a radiotherapy planning study to evaluate the feasibility to acquire longitudinal MRI scans during radiotherapy (prior to the main study) thus, participants will receive standard-of-care chemoradiation therapy (CRT) as per departmental protocol without any treatment adaptation.
10136000|NCT04242459|Experimental|HPV associated OPC Participants|"Participants will be treated initially with the standard radiotherapy dose of:~65 grays (Gy) in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~In the 2nd week and 4th week of treatment, the participants will undergo Adaptive Radiotherapy to account for anatomical changes."
10136001|NCT04242459|Experimental|HPV negative OPC Participants - Radiotherapy dose escalation|"Participants will be treated initially with the standard radiotherapy dose of:~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~After 10 fractions the participants will be stratified into either responders or non-responders categories based on Apparent Diffusion Coefficients (ADC) response at week 2 of CRT.~Participants classified as responders will complete treatment without any radiotherapy dose changes. Their radiotherapy treatment target volumes will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour.~The non-responders will undergo an increase in dose per fraction to Clinical Target Volume-1 (CTV-1) primary for fractions 11 to 30."
10136002|NCT04242459|Experimental|Base of Skull HNC Participants|"Participants will be treated initially with the standard radiotherapy dose of:~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~Participants will undergo standard treatment with 3 cycles of induction chemotherapy followed by chemo-radiotherapy dose. Their radiotherapy treatment will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour."
10136003|NCT04242485|Other|AFTER MATCH + OMT|Players undertook a recording session the day after a rugby match and received osteopathic manipulative treatment
9976850|NCT01355835|Active Comparator|[STNmono]|Conventional stimulation on subthalamic contacts
9976851|NCT01355835|Experimental|[STN+SNr]|Combined subthalamic and nigral stimulation
10136004|NCT04242485|Other|AFTER MATCH + sham treatment|Players undertook a recording session the day after a rugby match and received sham treatment
10136005|NCT04242485|Other|NO MATCH + OMT|Players undertook a recording session the day after a resting day and received osteopathic manipulative treatment
10136006|NCT04242485|Other|NO MATCH + sham treatment|Players undertook a recording session the day after a resting day and received sham treatment
10136007|NCT04242836||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language~30 patients with low vision (LVG) with adequate literacy of written Greek language~These patients are tested on the printed Greek MNREAD"
10136008|NCT04242836||Study group|The same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
10136009|NCT04242563|No Intervention|CONTROL GROUP|No virtual reality
10136010|NCT04242563|Experimental|INTERVENTION GROUP|Patient equipped with Virtual reality in transfer room.
10136011|NCT04242641|Experimental|WW (formally Weight Watchers)|The intervention will consist of engaging with the WW programme for 12 weeks, including weekly attendance at a local WW workshop and access to digital tools. Only the parent will take part in the WW intervention. No modifications will be made to the current WW programme to support child weight loss.
10136012|NCT04242641|No Intervention|Control|Participants randomised to the control group will receive no intervention during the 3 month period. Following final data collection control participants will receive 3 month complimentary access to WW.
10136013|NCT04242433||Viremic Person living with HCV|All persons enrolled in the MMPHCRF treatment programme are provided free of charge direct acting antiviral agents and followed up for outcomes.
10136014|NCT04242706|Active Comparator|Control group|Endotracheal tube with evacuation lumen without Bactiguard coating.
10136015|NCT04242706|Experimental|Experimental group|Endotracheal tube with evacuation lumen with Bactiguard coating.
10136016|NCT04242511||Cases|"Tuberculosis patients with diabetes mellitus:~Subject aged 18 years of age or over~Written, informed consent obtained.~New diagnosis of tuberculosis and started on anti-tuberculosis treatment~Known diagnosis of diabetes or two consecutive raised IFCC HbA1c levels (>= 48 mmol/mol) at the time of TB diagnosis"
10136017|NCT04242511||Controls|"Tuberculosis patients without diabetes mellitus:~1), 2), 3) as above 4) IFCC HbA1c level < 48mmol/mol 5) Weight matched to cases (+/- 2kg)"
10136018|NCT04242589|Active Comparator|Radiotherapy|Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)
10136019|NCT04242589|Experimental|Vertebroplasty + Radiotherapy|"Vertebroplasty followed by radiotherapy within 2-3 weeks~Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)"
10136020|NCT04242472|Experimental|SMS group|Nutrition-related SMS messages in addition to standard of care TB treatment with directly observed therapy
10136021|NCT04242472|No Intervention|Control group|Standard care of TB treatment with directly observed therapy alone
10136022|NCT04242667|Experimental|Actionable gene result for cancer risk|
10136023|NCT04242667|Experimental|Actionable gene result for cardiovascular disease risk|
10136024|NCT04242771|Experimental|Experimental group|Participants will utilize a daily sleep program available within a widely used smartphone app, which includes seven soundtracks (10-15min each) for guided mindfulness practice at bedtime. Techniques include breathing exercises, mental imagery, awareness of body and mind, and muscle and body relaxation.
10136025|NCT04242771|No Intervention|Control group|Participants randomized to the waitlist control group will be asked to maintain their usual care during the one month after baseline assessment. They will be asked not to start any new treatments for their insomnia. At the end of the one-month study, they will be given access to the mobile app.
10136026|NCT04242680|Experimental|Brainstim DLPFC|tRNS over bilateral DLPFC + cognitive training
10136027|NCT04242680|Experimental|Brainstim PPC|tRNS over bilateral PPC + cognitive training
10136028|NCT04242680|Sham Comparator|Brainstim Sham|Sham tRNS (bilateral DLPFC/bilateral PPC) + cognitive training
10136029|NCT04242693|Experimental|Experimental Group|The experimental group were asked to count the number of times they ate any red/orange vegetables and set a goal to eat one more time the next day over three days.
9694646|NCT04786795|Placebo Comparator|Oryz-aspergillus Enzyme|If dyspeptic symptoms occur after laparoscopic cholecystectomy and are randomized, the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit.
9694647|NCT04786665|Experimental|Strawberry powder|Participants consume 1 package of standard strawberry powder (26 g) daily for 8 weeks
10136030|NCT04242693|No Intervention|Control Group|The control group uploaded photos and/or descriptions of their meals only. They did not self-monitor their vegetable intake nor set a goal to eat more.
10136031|NCT04242758|Experimental|Dapaglifozin|People undergoing SGLT2i (Dapaglifozin) therapy
10136032|NCT04242758|Experimental|Hydrochlorothiazide|People undergoing thiazide (Hydrochlorothiazide) therapy
10136033|NCT04242381|Experimental|Group 1: Cold application, Kinesiotaping treatment|"Cold application: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.~Kinesiotaping application: KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)."
10136034|NCT04242381|Experimental|Group 2: Cold application, EX treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
10136035|NCT04242381|Sham Comparator|Group 3: Cold application, sham-KT treatment|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
10136036|NCT04242407|Active Comparator|DMTS|DMTS applied to the upper arm
10136037|NCT04242407|Placebo Comparator|Placebo|Placebo system (with no drug) to match DMTS applied to the upper arm
10136038|NCT04242355|Active Comparator|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
10136039|NCT04242355|Placebo Comparator|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
9968834|NCT01283854|No Intervention|Control group|Women allocated to the control group will not participate in the home-based exercise program, and will continue their normal physical activity throughout pregnancy. This group will receive routine, regular antenatal care, together with the additional outcome assessments at baseline (14 weeks gestation) and cessation of the study (28 weeks gestation).
9968835|NCT01283867|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
9968836|NCT01283867|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
10136040|NCT04242069|Experimental|Intervention|Healthy for my Baby Intervention
10136041|NCT04242069|Other|Control|Usual care
10136042|NCT04242576|Experimental|Action Observation|Subjects will watch 30-second videos, with a one-minute break between videos. The videos show the actions that subjects should imagine while watching the video.
10136043|NCT04242576|Experimental|Right/Left Judgment Task|"The laterality will be trained with the Recognize® application. Once the subjects have been trained, they are instructed to solve the different sections of the application, starting with the simplest tasks until reaching the most difficult ones.~These tasks would consist of indicating left or right, among the different images that appear on the iPad screen, indicating if the image's neck is rotated to the left or right. Being every level more complicated, so that people of different skin tones, with clothes or in a work environment are added."
10136044|NCT04242576|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
10136045|NCT04242615||Prognostic score cohort|323 patients included between January 1, 2001 to December 31, 2004
10136046|NCT04242615||Prognostic score validation cohort|534 patients included between January 1, 2010 to December 31, 2013
10136047|NCT04242030|Other|COPD group|"Participants in the COPD group will receive examination of laser doppler flowmetry(LDF).~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian."
10136048|NCT04242030|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
10136049|NCT04242030|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
10136050|NCT04242277||WF-OCT imaging of excised breast lumpectomy tissue|Excised lumpectomy tissue from all consented patients will be imaged on an investigational OCT-based device. No clinical decisions will be made based on the images acquired.
9968837|NCT01283893||Laparoscopy group|Laparoscopy group: patients who underwent laparoscopic distal gastrectomy with D2 lymphadenectomy
9968838|NCT01283893||Open group|Open group: patients who underwent open distal gastrectomy with D2 lymphadenectomy
10136051|NCT04242329|Experimental|PD1-inhibitor + surgery|Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
10136052|NCT04242329|Active Comparator|PD1-inhibitor|Patients randomized to control study arm, receiving continued immunotherapy only. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
10136053|NCT04242212||Clinic-based|Women who get misoprostol from a clinic-based provider
10136054|NCT04242212||PMV-based|Women who get misoprostol from a patent medicine vendor
10136055|NCT04242290||Cervicogenic headache|The group with cervicogenic headaches
10136056|NCT04242290||Neck pain|The group with isolated neck pain
10136057|NCT04242342|Experimental|Experimental arm|Patient with a localized primary tumor (hepatocellular carcinoma or cholangiocarcinoma) or a secondary hepatic localization of a solid carcinoma, with one to three hepatic lesions accessible to a treatment by stereotactic radiotherapy.
10136058|NCT04242160|Experimental|Modified Clamshell Thoracotomy First|Participants randomized to perform the MCT first, then cross over to the perform the alternate LAT.
10136059|NCT04242160|Active Comparator|Left Anterolateral Thoracotomy First|Participants randomized to perform the LAT first, then cross over to the perform the alternate MCT.
10136060|NCT04242316|Experimental|Mirror Therapy|Patients performed customized bimanual upper limb exercises with a mirror. They can observe the mirror visual feedback of their non-paretic hand during the movements.
10136061|NCT04242316|Active Comparator|Bilateral arm training|Patients performed customized bimanual upper limb exercises without a mirror.
10136062|NCT04242368|Active Comparator|Isotonic rinse, then hypertonic rinse|Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses isotonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete hypertonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.
10136063|NCT04242368|Experimental|Hypertonic rinse, then isotonic rinse|"Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses of hypertonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete isotonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.~Fluticasone propionate nasal spray - two sprays to each nare twice a day used for the entire study duration"
10136064|NCT04242043||AI|
9968839|NCT01283906|Experimental|MuGard|Mucoadhesive Oral Wound Rinse
9968840|NCT01283906|Sham Comparator|Control Rinse|Aqueous Control Rinse.
10136065|NCT04242537|Experimental|High flow oxygen delivery|Oxygen delivery with high flow nasal cannula with head side elevation to 30 degrees
10136066|NCT04242537|Experimental|Low Flow oxygen delivery|Low flow oxygen delivery through nasal cannula with head side elevation to 30 degrees
10136067|NCT04242537|No Intervention|Standard practice of care|No oxygen delivery either high flow or low flow through nasal cannula
10136068|NCT04242186|Experimental|Nursing home residents and staff|Nursing home residents at high risk for injurious falls, as well as nursing home staff at participating facilities
10136069|NCT04242550|Experimental|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT with executive function training, enhancing CBT with a focus on teaching compensatory strategies, habit learning, and plan for generalization to real-world behaviors.
10136070|NCT04242550|Active Comparator|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
10136071|NCT04241939|Experimental|Numberless BDS and Modified-MI|Use of numberless BDS (color coded), app, and motivational interviewing. Participants will weigh daily and receive weekly motivational interviewing at clinic visits and via a weekly phone call.
10136072|NCT04241939|Active Comparator|Digital Scale|Use standard digital scale (number readout). Participants will weigh daily.
10136073|NCT04241965|Experimental|Intervention 1|Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
10136074|NCT04241965|Placebo Comparator|Placebo|Single dose; potential for a matching OPC-214870 dose to be administered.
10136075|NCT04241952|Experimental|Exercise group|Usual care and bedcycling.
10136076|NCT04241952|No Intervention|Control group|Usual care
10136077|NCT04242017|Active Comparator|salvage RT + 6 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 6 months ADT
10136078|NCT04242017|Experimental|salvage RT + 24 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 24 months ADT
10136079|NCT04241757||Patient with indication of ElectroCardioGram (ECG)|Patient with indication of ElectroCardioGram (ECG) will be included. They will have a collection of results ElectroCardioGram (ECG).
9968841|NCT01283919|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
10136080|NCT04241913|Experimental|Treatment|The treatment group receives the 10-week, group-based Mom Power intervention; intervention is provided to both mothers and children by trained providers. Treatment delivery will be consistent with the Mom Power manual.
10136081|NCT04241913|No Intervention|Waitlist control|Participants randomized to waitlist control will not receive treatment during the experimental period; they will be offered treatment following completion of post- assessments.
10136082|NCT04242303|Experimental|EM Technique|use of extramedullary technique by means of inertial sensors for the execution of femoral cuts
10136083|NCT04242303|Active Comparator|IM Technique|Use of conventional intramedullary technique for the execution of femoral cuts
10136084|NCT04242004|Experimental|DHA group|
10136085|NCT04242004|Placebo Comparator|placebo group|
10136086|NCT04241991|Experimental|Active laser|Each participant will receive the application of the active laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
10136087|NCT04241991|Placebo Comparator|Placebo laser|Each participant will receive the application of the placebo laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
10136088|NCT04242108||Angle closure group|
10136089|NCT04242108||Open angle group|
10136090|NCT04242108||Peripheral synechia (PAS) group|
10136091|NCT04242108||Non-peripheral synechia (PAS) group|
10136092|NCT04242056|Other|Using image to diagnosis Multiple sclerosis (MS)|In current study, we will enroll 38 patients with MS and evaluate their clinical severity; measure the WM lesion and disease activity by magnetic resonance imaging (MRI); myelination state and amyloid deposition by amyloid PET scan; tau deposition by state of-art tau PET scan
10136093|NCT04242082||patients with psoriasis vulgaris only|
10136094|NCT04242082||patients with psoriasis vulgaris and type 2 diabetes mellitus|
10136095|NCT04242082||healthy control|
10136096|NCT04241705|Active Comparator|Control arm|The control arm will provide optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services.
10136097|NCT04241705|Active Comparator|Reactive Case Detection (RCD) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive, passively-detected index cases at the health post or health center; individuals who reside within a 100-meter radius of the index case will receive diagnosis for malaria using a conventional RDT. Positive individuals will receive treatment and follow-up as per the national treatment guidelines. 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing. Additional procedures will include the collection of a dried blood spot.
10136098|NCT04241705|Experimental|Targeted Mass Drug Administration (tMDA) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive index cases at the health post or health center, all eligible individuals who reside within a 100-meter radius of the index case will receive presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) (0.25mg/kg daily). 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing.
10136099|NCT04241536|Other|No arm|This is an epidemiologic study. No arms are considered.
10136100|NCT04241588||3D prostheses users|Children with unilateral congenital upper-limb reductions
10136101|NCT04241588||Typically Developing Children|Age- and sex-matched control group of typically developing children.
10136102|NCT04241718|Other|Single-arm|No comparator, placebo, or randomization
10184276|NCT03756623|Experimental|Drug: Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
10184277|NCT03756623|Placebo Comparator|Drug: Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
9968842|NCT01283919|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
10136103|NCT04241575|Experimental|Intervention group|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
10136104|NCT04241575|No Intervention|Control group|Patients in the control group will undergo the same assessments as patients in the intervention group. Although physicians will have access to the raw liver biochemistry results and platelet count, the fibrosis score results will not be specifically shown, and there will be no electronic reminder messages regardless of the fibrosis scores. This is to mimic usual care when there is no dedicated care model for case identification.
10136105|NCT04241653|Active Comparator|Spontaneous Ventilation|Patients will spontaneously ventilated. Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
10136106|NCT04241653|Active Comparator|Unparalyzed Controlled Ventilation|Patients will be mechanically ventilated without muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
10136107|NCT04241653|Active Comparator|Paralyzed Controlled Ventilation|Patients will be mechanically ventilated with muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
10136108|NCT04241627|Experimental|Cell Phone Support|An adherence facilitator will deliver Cell Phone Support by daily phone calls Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
10136109|NCT04241627|Experimental|Live Text Support|An adherence facilitator will deliver Live Text Support, Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
10136110|NCT04241627|Active Comparator|Automated Text Reminders|"The comparison condition will include automated text message reminders, using this template: Take [name of medication] at [set time]. To confirm intake, press REPLY, type CARE 1, and press SEND."
10136111|NCT04241822|Experimental|Vestibular exercises combined with cognitive therapy|The intervention is in groups of 8-10 patients. The interventions consists of cognitive therapy, vestibular exercises and body awareness therapy, 8 group sessions
10136112|NCT04241822|Experimental|Exergaming|The intervention is individual and consist of non-immersive virtual reality exercises to improve balance
10136113|NCT04241848|Experimental|Powered Orthotic Exoskeleton Training Group|Participant in 36 session ambulation training using a powered orthotic exoskeleton.
10136114|NCT04241848|Active Comparator|Control Group|Participant in 36 session ambulation training without using a powered orthotic exoskeleton.
10136115|NCT04241484|Experimental|Piezowave|"Initiation of Piezowave MyACT treatment to include parameters from the user manual~Set for frequency of five pulses per second~Delivery of 500 to 1000 pulses over multiple injured area sites, not to exceed 4000 pulses per session~Intensity ranging from 0.1 to 18 millijoule per square millimeter. This intensity if energy flux as the rate of transfer of the energy through the surface of the tissue is applied.~Focal transducer~Head size will be variable based on depth of tissue treated. The user manual will be consulted for depth of penetration recommendations"
10136116|NCT04241731|Experimental|Raltitrexed Plus Cetuximab|Raltitrexed Plus Cetuximab
10136117|NCT04241861|Experimental|High-flow oxygen therapy|Nasal high flow oxygen therapy will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort33. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
10136118|NCT04241861|Experimental|Helmet PSV|"Dedicated helmets for noninvasive ventilation will be used and size will be chosen according to neck circumference or according to manufacturer recommendations.~Each patient will be connected to a compressed-gas based ventilator through a bitube circuit with no humidification.~The ventilator will be set in PSV, with the following suggested settings 34-38:~initial pressure support≥8-10 cmH2O and adequate to permit of a peak in the inspiratory flow of 100 l/min;~positive end-expiratory pressure=10-12 cmH2O and increased to achieve the oxygenation target according to the choice of the attending physician.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~Inspiratory flow trigger = 1 l/min or according to the practice of each institution;~fastest pressurization time;~expiratory trigger: 10-50% of the maximum inspiratory flow;~maximum inspiratory time 1.2 second."
10136119|NCT04241861|Experimental|Helmet CPAP|"Dedicated helmets for noninvasive ventilation will be uses and size will be chosen according to neck circumference or according to manufacturer recommendations.~Treatment will be delivered through a high-flow generator. The following settings will be applied:~Continuous air flow=50-60 L/min.~Expiratory positive end-expiratory pressure valve set to achieve a PEEP==10-12 cmH2O and eventually increased to achieve the oxygenation target according to the choice of the attending physician.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%. Pressure inside the helmet will be monitored with a manometer in order to maintain the set PEEP."
10136120|NCT04241692|Experimental|Application of Carnation Ambulatory Patch Monitoring System|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
10136121|NCT04241692|Experimental|Application Conventional 24-Hour Holter Monitor Recorder|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
9968843|NCT01283932|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
10136122|NCT04241614||The First Hospital of Ji Lin University|CT data and corresponding CT raw data of patients with lung nodule will be collected.
10184278|NCT03756610|Active Comparator|Active tACS & active boosting group|The active tACS & active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.
10136123|NCT04241900|Experimental|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
10136124|NCT04241744|Active Comparator|vancomycin oral solution|vancomycin oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
10136125|NCT04241744|Placebo Comparator|placebo oral solution|placebo oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
10136126|NCT04241887|Experimental|group PVB|standard analgosedation + paravertebral thoracic blockade with 20 ml 0.25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa warszawa S.A.)
10136127|NCT04241887|Active Comparator|group BB|standard analgosedation + local anesthesia of the skin and subcutaneous tissue with 5ml 0,5% lignocaine (Lignocainum hydrochlorici, WZF 1%).
10136128|NCT04241601|Active Comparator|low dose interleukin-2|Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC. Active and Placebo doses appearing identical at point of issue and administration.
10136129|NCT04241601|Placebo Comparator|Placebo|Commercially available dextrose 5% injection with a UK marketing authorisation at equivalent dose volume will be used for the placebo formulation. Placebo and Active doses appearing identical at point of issue and administration.
10136130|NCT04241666||normal renal function|individuals with renal clearance >89 ml/min/1.73m²
10136131|NCT04241666||mild renal insufficiency|individuals with renal clearance 60-89 ml/min/1.73m²
10136132|NCT04241666||moderate renal insufficiency|individuals with renal clearance 30-59 ml/min/1.73m²
10136133|NCT04241679|Experimental|Intervention Group|Patients undergoing a translabyrinthine approach for vestibular schwannoma resection will have the health of their auditory nerve monitored during tumor dissection. If the auditory nerve is visually confirmed to be intact, then concurrent cochlear implantation will be performed.
10184279|NCT03756610|Other|Active tACS & sham boosting group|The active tACS & sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
10184280|NCT03756610|Sham Comparator|Sham tACS & sham boosting group|The sham tACS & sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
10184281|NCT03756597||Cases Pathway A|"Case pathway A - Intention to diagnose population~Only patients with a very high clinical suspicion based on imaging are scheduled for surgical procedures.Subjects with a confirmed diagnosis of cancer after clinical work-up will be labelled cases. of the study.~Patients with Gastric or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy."
10184282|NCT03756597||Clinical Controls|"Clinical controls represent subjects that:~Are suspected of the same cancer or part of an at risk-group~Have undergone full per-guideline diagnostic work-up, resulting in confirmation the subject does not have cancer (see section 6)~Is matched to the case for age, gender and known risk-factors specific to that tumour type (section 5.4)"
10184283|NCT03756597||Healthy volunteers|Healthy volunteers will be recruited from the clinical research facility at Addenbrooke's Hospital (Cambridge) or from the Cambridge BioResource. These subjects will be selected to have a similar age and sex distribution as the overall PAN-study cases.
10184284|NCT03756597||Substudy Cases|Patients with a confirmed diagnosis of cirrhosis and providing up to 6 samples will be labelled as the washout substudy cases
10184285|NCT03756597||Cases Pathway B|"Case pathway B - Confirmed malignancy population~Patients with a Gastric, Liver or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy. Patients will be recruited by research staff at the clinic they are referred to for diagnosis and/or treatment"
10184286|NCT03756584|Experimental|Intermittent theta-burst stimulation|iTBS will be performed on the left lateral parietal cortex
10184287|NCT03756584|Active Comparator|Control stimulation|iTBS will be performed on the vertex
10184288|NCT03756558|Experimental|Cross-Seal System|The Cross-Seal System will be used in all subjects enrolled in the study
10184289|NCT03756519|Experimental|Exercise|Participants in the exercise intervention arm will receive the usual care protocol plus a standardized, evidence informed exercise intervention provided by trained physiotherapy students. The exercise intervention will begin with a brief assessment to rule out contraindications to exercise and to identify any directional preferences (e.g. pain with lumbar flexion and relief with extension). The PT will then be taught four standardized exercises: the pelvic tilt exercise, a rotational exercise, a tailored graded walking program taking into account the current abilities of the patient, and an exercise based on the directional preference of the individual. These will be re-enforced with a handout including the rationale, instructions and dosage recommendations for the exercises.
10184290|NCT03756519|Active Comparator|Usual care|Our usual care protocol was developed based on 30 responses to an 18 item survey of Queen's Department of Emergency Medicine physicians. Three themes emerged as interventions most commonly used. Each of these strategies has evidence for small, but positive treatment effects and low risk of harms: 1) advice to stay active and engaged in usual activities, 2) use of ice or heat to manage pain, and 3) recommendation for analgesia using NSAIDs if needed and appropriate.
10184291|NCT03756493|Experimental|OFD+ABG+L-PRF treated patients|Periodontal surgery with Leukocyte and Platelet Rich Fibrin (L-PRF) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous bone graft mixed with cutted L-PRF will be applied to the furcation defects; then, a L-PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures.
10184292|NCT03756493|Active Comparator|OFD+ABG treated patients|Periodontal surgery with Autogenous Bone Graft (ABG) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. ABG will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
10187693|NCT03723655|Experimental|Group 3|Active Treatment for participants dose titrated to clinical response
9694648|NCT04786665|Placebo Comparator|Placebo group|Participants consume 1 package of placebo powder (26 g) daily for 8 weeks
10136134|NCT04241497|Experimental|Patients with Pulmonary Arterial Hypertension|12 weeks home-based rehabilitation
10136135|NCT04241523|Experimental|Treatment|The patients will receive lenvatinib treatment and will be evaluated for the feasibility of liver resection every 8 weeks. For those who underwent liver resection, they will receive lenvatinib treatment for another 48 weeks. In case of tumor recurrence, intolerance, death, or need for other antitumor treatment, the treatment shall be stopped.
10136136|NCT04241796|Experimental|Elevated Risk and Non-Elevated Risk Groups|"Two cohorts:~Elevated risk group (approximately 70% of the total enrollment) on the basis of history of smoking, documented genetic cancer predisposition, or personal history of invasive or hematologic malignancy.~Non-elevated risk group (approximately 30% of the total enrollment) with none of the conditions listed in the Elevated Risk Group."
10136137|NCT04241471|Active Comparator|traditional incision and drainage (I&D)|
10136138|NCT04241471|Experimental|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
10136139|NCT04241406|Experimental|transcutaneous spinal cord stimulation|"Transcutaneous application of electrical (biphasic current, 1ms, 30Hz) stimulation over the back for a 10 minutes session.The intensity of the current will increase until motor reflex threshold. If it will not possible, intensity will be increase until participants report a strong but comfortable sensation.~Transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
10136140|NCT04241406|Experimental|sham stimulation|"Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequently.~Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
10136141|NCT04241237||Metastatic Breast Cancer patients|Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
10136142|NCT04241380|Active Comparator|Conventional treatment group|Patients in this group will received conventional treatments. Drug: None. Drug: For the high-risk patients, doctors will assess their risk factors and choose continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) if needed. Aspirin 5 mg/kg may be given every eight hours subsequently for 3 months.
10136143|NCT04241380|Experimental|Anti-coagulant treatment|Continuous infusion heparin. Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5mg/kg will be given every eight hours subsequently for three months. Study will follow the intention-to-treat principle.
10136144|NCT04241172|Experimental|Immersive Virtual Reality (HIVR)|"The HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving visual and auditory biofeedback."
10136145|NCT04241172|Active Comparator|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~exercises with patients sitting on the swimming pool edge with lower limb immersed in the water;~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~water walking exercises."
10136146|NCT04241172|Active Comparator|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~exercises with a patient sitting on a chair (3 minutes per exercise):~flexion-extension of the knee;~leg and hip circling;~flexion-extension of the ankle;~triple flexion;~walking (with and without aids)."
10136147|NCT04241133|Experimental|Experimental Group|A 12 week pilot trial will be conducted at two rural food pantries in Montana with 40 low-income adults to measure within-participant changes over time. The study will provide the initial investigation of the extent to which UP3 will improve overall dietary quality as measured by the Healthy Eating Index-2015 (HEI) compared to baseline. Psychosocial factors will be measured to understand changes in knowledge, attitudes, and perceptions about processed foods. Data on biomarkers of health (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to assess the feasibility of measuring potential short-term health effects of UP3.
10136148|NCT04241133|No Intervention|Control Group|20 separate participants from a different food pantry will be enrolled into a control group. The control group will be assessed at baseline and 12 weeks for dietary intake, height, weight, waist circumference, food security, demographics, and psychosocial factors.
10136149|NCT04241055|Active Comparator|Control|"The control condition of a standard values affirmation intervention"
10136150|NCT04241055|Experimental|Values affirmation|"The treatment condition of a standard values affirmation intervention"
10136151|NCT04241211|Active Comparator|Control group|
9968844|NCT01283932|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
10136152|NCT04241211|Experimental|TP group|
9694649|NCT04786691|Placebo Comparator|Black coffee first|12 oz of black coffee with no additives is the first intervention tested
9694650|NCT04786691|Active Comparator|Coffee with half and half first|12 oz of black coffee with 1 oz of half and half is the first intervention tested
9968845|NCT01283945|Experimental|Lucitanib|
9968846|NCT01283984|Experimental|1|AZD2115
10136153|NCT04241159|Experimental|Geriatric participants with frailty|"Geriatric participants aged 65-80 who have a diagnosis of frailty (Fried Frailty score of 3 or greater).~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
10136154|NCT04241159|Experimental|Geriatric participants with HFpEF|"Geriatric participants aged 65-80 who have a diagnosis of HFpEF.~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
10136155|NCT04241120|Experimental|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
10136156|NCT04241120|Placebo Comparator|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull.
10136157|NCT04241042||Down syndrome volunteers|Males and females from 16 to 35 years
10136158|NCT04241042||Healthy volunteers|Males and females from 18 to 35 years
10136159|NCT04241081|No Intervention|Control group-no exercise|A no-exercise control. Must maintain <4,500 steps per day for 3 consecutive days followed by a high fat tolerance test on day 4.
10136160|NCT04241081|Experimental|Exercise intervention 1|Two consecutive days of <4,500 steps per day followed by an intervention day on day 3. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 2 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
9826072|NCT02406586|Experimental|Salsalate|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
10136161|NCT04241081|Experimental|Exercise intervention 2|Two consecutive days of <4,500 steps per day followed by an intervention day. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 6 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
10136162|NCT04241458|Experimental|BI 706321|
10136163|NCT04241458|Placebo Comparator|Placebo|
10136164|NCT04241302|Active Comparator|Free Field Voice test|The examiner will inform the patient to repeat a sequence of Spondee words or a combination of numbers and letters whispered by the examiner initially. The examiner will be standing at the same distances as in the FFCT examination (starting with 2 feet). If the patient fails to hear the whispered voice at 2 feet, the examiner increases the loudness of voice to conversational tone at the same distance. The test is repeated thrice each time with a different set of Spondee words to avoid the patients recognizing the same sequence. If the patient is unable to respond, the examiner moves closer to 6 inches and whispers to the patient, and if no further response, then, conversational voice is used. The patient's free-field threshold is the voice and distance level at which more than 50% correct is obtained.
10136165|NCT04241302|Experimental|Free Field Click Test|The app is designed by our team by a broadband (500-3000 Hz) click sound of 30-40 dB for soft sound/whisper and 60-70dB for loud sound/conversation voice. This app is designed by the Flutter-Dart programming tool and the speaker is produced via hand-held devices of Apple and Android brands. The tone is produced 3 times, with 2 out of 3 answers are considered as the patient's hearing threshold. The examiner stands at the distance of 2 feet away behind the seated patient and a soft sound from the FFCT is tested. The patient is then asked to respond yes or to nod if able to hear the sound. When the patient is unable to answer or no response is received upon thrice testing, the examiner then moves closer to 6 inches to the patient and again the soft sound is tested thrice. Loud sound is then tested if the patient is unable to respond, starting from 2 feet distance for three times. And then, the loud sound is tested at 6 inches of distance if no further response is obtained.
10136166|NCT04241354|Active Comparator|Intra-articular LP-PRP Injection|A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.
10136167|NCT04241354|Experimental|Intra- and extra- articular LP-PRP Injection|A single injection of LP-PRP will be administered to the intra- articular space and the extra- articular structures under ultrasound guidance at the first visit.
10136168|NCT04241107|Active Comparator|Laparoscopic approach group(A)|Uterine niche will be repaired through Laparoscopic approach.
10136169|NCT04241107|Active Comparator|Transvaginal approach group(B)|Uterine niche will be repaired through Transvaginal approach.
10136170|NCT04240977|Experimental|Treatment Group|
10136171|NCT04241432|Active Comparator|Platform type 1|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
10136172|NCT04241432|Active Comparator|Platform type 2|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
10136173|NCT04240964||Dd group|Patients with diabetic foot osteomyelitis
10136174|NCT04240964||ND group|Foot osteomyelitis without diabetes
10136175|NCT04241263|Other|Comparative assessment of data quality|Quantitative comparison between the current wired system and the new wireless system
9968847|NCT01283984|Placebo Comparator|2|Placebo to AZD2115
10136176|NCT04241263|Other|Usability|Qualitative assessment of the new wireless system
10136177|NCT04241276|Active Comparator|Gemcitabine + nab-paclitaxel|Patients will receive Gemcitabine and nab-Paclitaxel in 28 day cycles until disease progression.
9976852|NCT01355848|Experimental|Brief Intervention|The brief intervention consists of stepped care protocol, including building rapport, functional analysis of suicidal behavior, and crisis planning
10136178|NCT04241276|Experimental|Gemcitabine + nab-paclitaxel + ATRA|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
10136179|NCT04241393|Experimental|Tavapadon|
10136180|NCT04240899|Experimental|Tele-yoga|This is a single group study, therefore all subjects will be included in this single arm and will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
10136181|NCT04240938|Other|Lacrimal sac mucocele|Adult patients with lacrimal sac mucocele
10136182|NCT04240847|Active Comparator|Midline incision|Skin incision at the midline, 1 cm medial to tibial tubercle
10136183|NCT04240847|Experimental|Lateral incision|Skin incision at 1 cm lateral to tibial tubercle
10136184|NCT04240782|Experimental|Education with Produce Allocations|Participants will attend nutrition education and hands-on cooking classes with weekly produce allocations from a local farm.
10136185|NCT04240782|Experimental|Education only|Participants will attend nutrition education and hands-on cooking classes (with produce coupons provided after intervention).
10136186|NCT04240782|No Intervention|Control group|Participants will receive a delayed intervention once the study period is over.
10136187|NCT04241419|Experimental|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
10136188|NCT04241016|Active Comparator|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery. Postoperative treatment consists of daily nasal douching, daily nasal steroid sprays, pain medication when necessary and at least one postoperative control visit including endoscopy two weeks after the operation. Additionally medical treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
10136189|NCT04241016|No Intervention|Control|Conservative treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
9968848|NCT01284010||Group 1|Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.
10136190|NCT04240886|Experimental|Cohort A: fosmanogepix (APX001)|
10136191|NCT04240886|Experimental|Cohort B: fosmanogepix (APX001)|
10136192|NCT04240691||60-Minutes-For-Health|60-Minutes-for Health: this is a psychological intervention which seeks to correct factors underlying decisions to delay or avoid HIV care and strengthen abilities to overcome HIV care utilization barriers. This is achieved through assistance identifying and reducing misinformation guiding HIV care attendance decisions; enhancing motivation to maintain HIV care via personal health goals; building skills for coping with negative feelings related to living with HIV; and increasing self-efficacy for navigating structural barriers and maintaining HIV care amidst competing priorities.
10136193|NCT04240691||Time-and-Attention Control Session|60 Minute diet & nutrition control session
10136194|NCT04240951|Other|Study Session 1|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the laboratory
10136195|NCT04240951|Other|Study Session 2 (repeat of Study Session 1)|Arm Type: Validation: Regional sweat collection with prototype vs. reference patch in the laboratory
10136196|NCT04240951|Other|Study Session 3|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
10136197|NCT04240951|Other|Study Session 4 (repeat of Study Session 3)|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
10136198|NCT04240951|Other|Study Session 5|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
10136199|NCT04240951|Other|Study Session 6 (repeat of Study Session 5)|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
10136200|NCT04240769||Knee Arthroplasty Patient|Patients undergoing primary total or unicompartmental knee arthroplasty for treatment of end-stage osteoarthritis.
10136201|NCT04240743|Active Comparator|cephalomedullary nail|Cephalomedullary nails was inserted and fixed to the femoral head. In this study, all patients were treated with short nails (Profin®, TST).
10136202|NCT04240743|Active Comparator|sliding hip screw|Sliding hip screws was inserted and fixed to the femoral head. In this study, all patients were treated with a side plate with three holes (DHS plate, TST).
10136203|NCT04240821|Experimental|Open-label theophylline|Oral theophylline - either once daily capsule or q6h elixir.
10136204|NCT04240639|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to MRI/US guided laser irradiation using an FDA cleared laser and an interstitial optical fiber diffuser.
9968849|NCT01284023||Controls|Uninjured volunteers
9976853|NCT01355848|No Intervention|care as usual|Patients randomized to the care as usual arm will not receive the brief intervention.
10136205|NCT04240990|Experimental|Prospective cohort|Children included in the cohort will all be in the same arm. The patients will benefit from standard-of-care TB diagnosis with additional diagnostic methods.
10136206|NCT04240717|Experimental|Patient Decision Aid|Patients review an interactive, web-based Patient Decision Aid regarding their treatment options. Afterwards they receive medical consultation.
10136207|NCT04240717|No Intervention|Treatment As Usual|Patients receive medical consultation.
10136208|NCT04240808|Experimental|UCD19 CAR T Cells|Participants will receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes
10136209|NCT04240613|Other|women treated by TVT-O|All women treated by TVT-O during the years this study was made were included.
10136210|NCT04240574|Other|Micro Water Jet Technology (Debritom)|"Debritom is a hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.~All subject will get the Debritom."
10136211|NCT04240873|Experimental|MASTER cell|Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis
10136212|NCT04240873|Placebo Comparator|Saline|Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis
10136213|NCT04240756|Experimental|Parent Stimulant Medication + Child Treatment Strategy|Parent stimulant medication first followed by a child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
9694651|NCT04786691|Active Comparator|Coffee with non-dairy creamer first|12 oz of black coffee with 1 oz of liquid non-dairy creamer is the first intervention tested
10136214|NCT04240756|Active Comparator|Child Treatment Strategy|Child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired. In this arm, parents do not receive stimulant medication before behavioral parent training.
10136215|NCT04240652||Subjects with fundus photography|Subjects diagnosed with diabetes or not who have fundus images from MMCs and other medical institutes.
10136216|NCT04240795|Experimental|Low lubricity (LL) hydrogels containing fibre-based beads|"Participants are given a preload of 30 g of low lubricity hydrogels (alginate beads in kappa-carrageenan hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
10136217|NCT04240795|Active Comparator|High lubricity (HL) hydrogels containing no fibre-based beads|"Participants are given a preload of 30 g of high lubricity hydrogels (no beads in kappa-carrageenan and alginate mixed hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
10136218|NCT04240795|Placebo Comparator|Water|"The water containing the same watermelon flavor, color and sweetness was given as control to match the gels. Participants receive the same amount of water like hydrogels - 30 g after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
10136219|NCT04240834|Experimental|LD group|Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months
10136220|NCT04240834|Active Comparator|Control group|Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months
10136221|NCT04240860|Experimental|platelet rich plasma preparation|"About 15 ml of autologous blood from the patient was collected slowly in 20 ml syringe containing 1.5 ml anticoagulant citrate dextrose solution A (ACDA) under complete aseptic precautions.~2- Blood was mixed by swinging the syringe slowly. 3- By using 18G needle, the gathered blood was transfused into tube maintaining a slope of 45°.~4- The centrifugation step was then done by using non digital angle type centrifuge :the tube was put with water tube on the opposite side to achieve centrifuge balance.~5- The centrifugation occurred in one step by power 3600 RPM for 6 minutes. 6- The buffy coat was elevated up to the buffy coat line (Figure 1). 7- the buffy coat (2-3 ml PRP) was extracted from slim neck by tornado technique so that sunk platelets can be floated and drawn easily.~8- the remaining platelet poor plasma(PPP) was drawn using 5 cc syringe. then inserted by ovum pick up needle into subendometrium"
10136222|NCT04240860|Active Comparator|endometrial scratch|using scissor of hysteroscopr 3 snips was done in the fundus
10136223|NCT04240431||Epiphora|Adult patients suffering from watering of the eye included in the study to detect level of obstruction
10136224|NCT04240730||extremely obese patients with early-stage endometrial cancer|
10136225|NCT04240600|Experimental|Hyperproteic, hypercaloric formula|Each patient will receive 2 bottles per day of Supportan DKN during the hospital stay (nutritional contribution: 600 kcal and 40 g of protein).
10136226|NCT04240600|Active Comparator|Standard formula|Each patient will receive 2 cans or bottles per day of Fresubin® Original DRINK (nutritional contribution: 474.2 kcal and 17.6 g of protein).
10136227|NCT04240444|Experimental|SeQuent® SCB|patients will receive sirolimus (rapamycin)-coated balloon (SeQuent® SCB)
10136228|NCT04240444|Active Comparator|SeQuent® Please Neo|patients will receive SeQuent® Please Neo balloon
10136229|NCT04240249|Experimental|Constructive self-assertiveness with guidance|10 weeks of internet-based treatment with weekly assignments. The homework is commented on by the guide using electronic communication.
10136230|NCT04240249|Experimental|Constructive self-assertiveness without guidance|10 weeks of internet-based treatment with weekly assignments. The homework is NOT commented on by any guide. Hence, same treatment as group 1 but without guidance.
10136231|NCT04240249|No Intervention|Waitlist control|No treatment, no guidance, just waiting for 10 weeks. After the ten weeks the participants will receive the treatment.
10136232|NCT04240236|Experimental|Group S|Group S received scalp block with 20 ml of 0.5% bupivacaine
10136233|NCT04240236|Placebo Comparator|Group C|Group C will not have any intervention
10136234|NCT04240275||Children with Cerebral Palsy|Children diagnosed with Spastic Cerebral Palsy (Unilateral or Bilateral) among the age range of 5-15 who can walk independently
10136235|NCT04240548|Experimental|Arm: A|regional nodal irradiation including axillary and supraclavicular lymph node groups along with chest wall or whole breast irradiation
10136236|NCT04240548|No Intervention|Arm: B|chest wall or whole breast only irradiation
10136237|NCT04240561|Experimental|Hearing Aid Fitting Order A|Participants wear hearing aids with a high level of signal manipulation, followed by a low level of signal manipulation
10136238|NCT04240561|Experimental|Hearing Aid Fitting Order B|Participants wear hearing aids with a low level of signal manipulation, followed by a high level of signal manipulation
10136239|NCT04240418||Lyon University Hospital employees|
10136240|NCT04240353||COPD group|Patients with high-risk COPD with recent exacerbation requiring hospitalisation (within last 12 months) or hypercapnia respiratory failure and/or sleep disordered breathing meeting criteria for provision of home NIV.
10136241|NCT04240496|Other|Schizophrenic patients|"Determination of trough plasma concentration of clozapine (C0)~Genotyping of CYP1A2 & CYP2C19 Drug: Leponex (Clozapine) : was started at a dose of 25 mg/j, the dose was gradually increased and was administered in one, two or three divided doses."
10136242|NCT04240366|Other|Group 1|Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone
10136243|NCT04240366|Experimental|Group 2|Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation
10184293|NCT03756493|Active Comparator|OFD treated patients|Periodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
9968850|NCT01284036|Other|PF-05230905|9 subjects will participate in each dose cohort. 6 subjects will receive investigational product (PF-05230905) and 3 subjects will receive placebo
9976854|NCT01355861|Experimental|1|Exercise group 1: Negative work exercise
9519634|NCT03285048|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
9519635|NCT03285035||Non-operable esophageal cancer|Cryotherapy treatment
9519636|NCT03285022|Experimental|Zinc modified glass ionomer|Zinc modified glass ionomer (chemfill rock) galss ionomer used as restoration for posterior teeth in case of partial caries removel
9968851|NCT01284049|Active Comparator|Intralipid 20%®|reference treatment by standard lipid emulsion not enriched in n-3 EFA (Intralipid 20%®)+ vitamin E.
9968852|NCT01284049|Experimental|OMEGAVEN 10%®|Interventional treatment by a lipid emulsion enriched in n-3 EFA (OMEGAVEN 10%®).
9968853|NCT01284075|Experimental|Guided Imagery and Music therapy group (GIMT)|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
9968854|NCT01284075|Active Comparator|White Noise Group (WN)|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
9968855|NCT01284075|Active Comparator|No Interventions Group (CP)|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
9968856|NCT01284088|Experimental|PrePex™|Adult male circumcision by the PrePex™ Device
9968857|NCT01284088|Active Comparator|Surgical|Adult male surgical circumcision
9968858|NCT01284101|Active Comparator|Forceps delivery of donor graft|Using the forceps to insert the donor graft.
9968859|NCT01284101|Experimental|Tan Endoglide for insertion of the donor graft|Use of the Tan Endoglide for insertion of the donor graft.
9968860|NCT01284166|Experimental|Triple Combination Therapy|Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
9968861|NCT01284179|Experimental|Hypnotherapy|Participants will be randomized to either the home hypnotherapy or educational group. The HHT protocol will consist of sequences of two different types of sessions, longer biweekly sessions (LS), each approximately 30-40 minutes in length, and shorter daily sessions (SS), approximately 12 minutes in length. On the first day of each sequence, the patient will listen to the appropriate LS. The patients will listen to the SS on a daily basis in between each LS. Every 2 weeks a new sequence will begin, for a total of 12 weeks of treatment.
9968862|NCT01284179|Other|Educational|Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
9968863|NCT01284192|Experimental|ASP3026|Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)
9968864|NCT01284205|Experimental|MCC|Intravesical Administration of Mycobacterial Cell-Wall DNA Complex
9968865|NCT01284205|Active Comparator|BCG|Intravesical Administration of Bacillus Calmette-Guerin
9968866|NCT01284218||Aripiprazole cohort|
9968867|NCT01284218||Other atypical cohort|
9968868|NCT01284218||Other antidepressant cohort|
9968869|NCT01284218||Mood stabilizer cohort|
9968870|NCT01284218||Stimulant cohort|
9968871|NCT01284231|Experimental|MEDI-565 - Dose Escalation|Up to 15 dose-escalation cohorts will be enrolled
9968872|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 1|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
9968873|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 2|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
9968874|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 3|Subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biological dose
9968875|NCT01284257||Enteric coated mycophenolate sodium (EC-MPS) arm|Patients to whom EC-MPS is prescribed by their practitioner.
9968876|NCT01284257||MMF arm|Patients to whom MMF is prescribed by their practitioner.
9968877|NCT01284270|Other|All Patients|All patients undergo the same study procedures
9968878|NCT01284283|Other|Single|Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
9968879|NCT01284309|Experimental|Mirabegron|
9968880|NCT01284309|Placebo Comparator|Placebo|
9968881|NCT01284322|Experimental|Fresolimumab|
9968882|NCT01284374||Male Adolescents|Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
9968883|NCT01284374||Parents of Male Adolescents|Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
9968884|NCT01284374||Health Care Providers for Males 13-17 yo|Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
9968885|NCT01284400|Experimental|Disease management|
9968886|NCT01284400|No Intervention|Usual treatment and care|
9976855|NCT01355861|Other|2|Exercise group 2: Negative work exercise (delayed start for single-arm crossover trial)
9976856|NCT01355874|Experimental|Iferanserin|
9976857|NCT01355874|Experimental|Placebo|
9976858|NCT01355874|Experimental|Iferanserin + Placebo|
9977773|NCT01365104|Experimental|Healthy young|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
10136244|NCT04240535|Experimental|Active- onabotulinumtoxinA|BOTOX Cosmetic (onabotulinumtoxinA) for injection, is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A intended for intramuscular use. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. The complex is dissolved in sterile sodium chloride solution containing Albumin Human and is sterile filtered (0.2 microns) prior to filling and vacuum-drying.
10136245|NCT04240535|Placebo Comparator|Placebo-Bacteriostatic 0.9% Sodium Chloride|Placebo subjects will have injections in the same manner, but will be injected with Bacteriostatic 0.9% Sodium Chloride.
10136246|NCT04240223|Experimental|50 mg Brilacidin tablet|
10136247|NCT04240223|Experimental|100 mg Brilacidin tablet|
10136248|NCT04240223|Experimental|200 mg Brilacidin (2 x 100 mg Brilacidin tablets)|
9968887|NCT01284413|Experimental|S-1, Gemcitabine, Cisplatin|
9968888|NCT01284439|Experimental|TearA|
10136249|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 50 mg tablet)|
10136250|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 100 mg tablet)|
10136251|NCT04240223|Placebo Comparator|Placebo (2 x replica of shape/size of 100 mg tablets)|
10136252|NCT04240132|Experimental|Adherence to hand hygene|The face-to-face interview will be held in an appropriate empty room in the intensive care unit (ICU) in a time schedule suitable for the healthcare workers. The researchers will provide training to healthcare workers working in the ICU in accordance with the World Helath Organization (WHO) Hand Hygiene Guidelines. One day training on nursing interventions related to enteral feeding treatment will be provided to nurses and their questions will be answered. At the end of the each training, trainees will be given a data collection form to assess the effectiveness of the training.
10136253|NCT04239794|Active Comparator|Inhalation anesthesia|Patients are anesthetized with sevoflurane and remifentanil infusion for maintenance of anesthesia during the surgery
10136254|NCT04239794|Experimental|Total intravenous anesthesia|Patients are anesthetized with target-controlled intravenous infusion of propofol and remifentanil infusion for maintenance of anesthesia during the surgery
10136255|NCT04239807|Experimental|Group 1 WBV - training with wbv|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training~Month 1:~Day 1: From this day subjects are supposed to start their training accoridng to protocol~Day 2: Telephone Visit~Day 5: Telephone Visit~Day 7: Telephone Visit~Day 10: Telephone Visit~Day 13: Telephone Visit~Day 20: Telephone Visit~Day 27: Telephone Visit~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training~Month 2:~Week 5, Day 34:~Week 6, Day 41:~Week 7, Day 48:~Week 8, Day 55:~Month 3:~Week 9, Day 62:~Week 10, Day 69:~Week 11, Day 76:~Week 12, Day 83: Final Visit"
10136256|NCT04239807|Other|Group 2 Control - training without WBV|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training~Month 1:~Day 1: From this day subjects are supposed to start their training accoridng to protocol~Day 2: Telephone Visit~Day 5: Telephone Visit~Day 7: Telephone Visit~Day 10: Telephone Visit~Day 13: Telephone Visit~Day 20: Telephone Visit~Day 27: Telephone Visit~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training~Month 2:~Week 5, Day 34:~Week 6, Day 41:~Week 7, Day 48:~Week 8, Day 55:~Month 3:~Week 9, Day 62:~Week 10, Day 69:~Week 11, Day 76:~Week 12, Day 83: Final Visit"
10136257|NCT04239820||RRMS patients initiating cladribine|Patients will be imaged using PET and MRI at baseline prior the cladribine treatment initiation and 18 months after baseline
10136258|NCT04239833|Experimental|SH-1028 tablets+Placebo Gefitinib|"SH-1028 tablets (200 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.~Interventions:~Drug: SH-1028 tablets 200 mg Drug: Placebo Gefitinib 250 mg"
10136259|NCT04239833|Active Comparator|Gefitinib+Placebo SH-1028 tablets|"Gefitinib (250 mg orally, once daily) plus placebo SH-1028 tablets (200mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).~Interventions:~Drug: Gefitinib 250 mg Drug: Placebo SH-1028 tablets 200mg"
10136260|NCT04239872|Experimental|Participants with normal to dry mouth|"Participants with normal to dry mouth will be treated, in a crossover design, with two interventions: a fluoride mouthwash alone, or a fluoride mouthwash preceded by a calcium mouthwash.~Participants will be randomized to determine which intervention they will use in the first experimental phase; the other intervention will the tested in the second phase."
10136261|NCT04240106|Experimental|Niraparib 100mg in combination with Aromatase Inhibitors|Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib either 300 mg or 200 mg orally, once daily, flat- fixed, continuously in 28-day cycles plus aromatase Inhibitors.
10136262|NCT04240015||Periodontitis|Periodontitis group consisted of patients diagnosed with periodontitis
10136263|NCT04240015||Patients without periodontitis|Patients without periodontitis group constituted patients without periodontitis
10136264|NCT04240067||Acute Heart Failure|
10136265|NCT04240067||No Acute Heart Failure|
10136266|NCT04239963||Healthy Controls|Subjects who have no history of clinical depression or other psychological disorder
9968889|NCT01284439|Experimental|TearB|
9968890|NCT01284452|Placebo Comparator|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
9968891|NCT01284452|Active Comparator|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
9968892|NCT01284465|Experimental|Intervention group|Education and patient liaison combination
9968893|NCT01284465|Experimental|Control group|Education only
9968894|NCT01284478|Other|Dexamethasone Implant|Patients will be treated with the Ozurdex (Dexamethasone Implant)
9968895|NCT01284543|Active Comparator|Busin glide delivery of donor graft|Use of the Busin glide to insert the donor graft
9968896|NCT01284543|Experimental|Tan EndoGlide for insertion of the donor graft|Use of the Tan EndoGlide for insertion of the donor graft
9968897|NCT01284556|Placebo Comparator|Placebo|placebo tablets
9968898|NCT01284556|Experimental|60 mg group|Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.
9968899|NCT01284556|Experimental|100 mg group|Patients titrated to 100mg phenobarbital maintenance period, then titrated down
9968900|NCT01284569|Experimental|ALX-0061|
9968901|NCT01284569|Placebo Comparator|Placebo|
9968902|NCT01284582|Experimental|ATH03 Group A|ATH03, 10 µg, 0.2% Alum
9968903|NCT01284582|Experimental|ATH03 Group B|ATH03, 30 µg, 0.2% Alum
9968904|NCT01284582|Experimental|ATH03 Group C|ATH03, 100 µg, 0.2% Alum
9968905|NCT01284595|Experimental|AZD8931|[14C] AZD8931
9968906|NCT01284647|Experimental|Teprenone capsule|
9968907|NCT01284647|Active Comparator|sucralfate|
9968908|NCT01284660|Active Comparator|I. DHA|Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
9968909|NCT01284660|Placebo Comparator|II. Placebo|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
9968910|NCT01284686|Active Comparator|dopamine|ON DOPA:The patient will take his usual treatment with dopamine
9968911|NCT01284686|Experimental|without dopa|OFF Dopa: The patient will be deprived of his treatment usual dopaminergique for at least 12 hours
9968912|NCT01284725|Experimental|immunosuppressive treatment discontinuation,|
9968913|NCT01284725|Active Comparator|Continuation of immunosuppressive therapy|with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids
9968914|NCT01284738|Active Comparator|TM patients|thalassemia major (TM) Need transfusion for survive
9968915|NCT01284738|Active Comparator|TI patients|thalassemia intermedia (TI) Patients with TI have a milder clinical phenotype than those with TM
9968916|NCT01284751||Breast cancer patients|Patients aged 30-70 years having a lumpectomy or mastectomy at the Department of Breast Surgery at Herlev Hospital, Copenhagen, Denmark.
9968917|NCT01284764|No Intervention|midnight fasting|The patients in this group will have midnight fasting the day before endoscopic examination
9968918|NCT01284764|Active Comparator|Mosapride, low volume of water|The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.
9968919|NCT01284777||patients|
9968920|NCT01284790|Experimental|Cochlear implants|
9968921|NCT01284803|Experimental|experimental arm|
9968922|NCT01284816|Other|severely obese patients|35 patients addressed for severe obesity in the Endocrinology department of Marseille North Hospital before (V1) and 6 months (V2) after bariatric surgery
9968923|NCT01284829|Experimental|adrenal tumors|adrenal tumors
9968924|NCT01284855|Active Comparator|Low initial dose|This arms corresponds to Nepal national protocol and involves the initial administration of 2 vials of antivenom over one hour followed by the slow infusion of 4 vials over 4 hours
9968925|NCT01284855|Experimental|High initial dose|This arms corresponds to Indian national protocol and involves the initial administration of 10 vials of antivenom over one hour followed by the slow infusion of saline over 4 hours
9968926|NCT01284868|Experimental|Mirabegron|
9968927|NCT01284881||OSAHS|
9968928|NCT01284894|Other|Conventional manometry|
9968929|NCT01284894|Experimental|High resolution manometry|
9968930|NCT01284907|Active Comparator|Vit D|
9968931|NCT01284907|Placebo Comparator|Placebo drops|
9968932|NCT01284920|Experimental|dose-escalation cohort-1|MDV3100 low dose arm
9968933|NCT01284920|Experimental|dose-escalation cohort-2|MDV3100 middle dose arm
9968934|NCT01284920|Experimental|dose-escalation cohort-3|MDV3100 high dose arm
9968935|NCT01284920|Experimental|dose-expansion cohort|dose expansion with MDV3100 middle dose
9968936|NCT01284933||Acute Ischemic Stroke, TIA|Patients admitted to a specialized stroke service because of an acute ischemic stroke or a transient ischemic attack (TIA).
9968937|NCT01284946|Experimental|Exjade|Safety and efficacy
9968938|NCT01284972||HINTEGRA|Patient Implanted with the HINTEGRA Total Ankle Prosthesis more than 2 years ago
9968939|NCT01284985||METIS|Patient who has an indication of : Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis and for which surgeon has recommended that a METIS® prosthesis be implanted.
9968940|NCT01284998||B-BOP lock|Subjects who needs a fixation of osteotomy of the basis of the first metatarsal and for whose surgeon has recommended that a B-BOP® Lock plate from INTEGRA be implanted can be enrolled in this study
9968941|NCT01285011||Ipp-On|Patient implanted with the Ipp-On
9968942|NCT01285037|Experimental|LY2801653|"This study consists of a dose escalation of LY2801653 (Part A) followed by dose confirmation cohorts in four tumor types (adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver metastasis, and cholangiocarcinoma) (Part B).~Part C consists of dose determination for LY2801653 in combination with cetuximab in participants with head and neck squamous cell carcinoma followed by an expansion cohort.~Part D consists of dose determination for LY2801653 in combination with cisplatin in participants with cholangiocarcinoma followed by an expansion cohort.~Part E consists of dose determination for LY2801653 in combination with gemcitabine and cisplatin.~Part F consists of dose determination for LY2801653 in combination with ramicirumab."
10136267|NCT04239963||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
10184294|NCT03756480||Case Group|"Clinical or surgical diagnosis of Endometriosis, patients undergoing surgical management~100 participants"
10184295|NCT03756480||Control Group|"No diagnosis of Endometriosis, Patients undergoing Laparoscopic Tubal Ligation~35 participants"
10184296|NCT03756467|No Intervention|Arm 1|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff
10136268|NCT04240028||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking as identified by an unintentional weight loss of ≥ 5% between two assessments, 2) Weakness as identified by a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy as identified by an answer of no to the question Do you feel full of energy? from the 30-item Geriatric Depression Scale; 4) Slowness as identified by an average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level as identified by a PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
10136269|NCT04240028||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.SCI will be defined using a proxy for subjective cognitive complaint (i.e. memory complaint) and following the procedure used in previous multicenter prevalence studies on MCR syndrome. Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item or 30-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?). Memory complaint in our study will be elicited from this item of 30-item GDS."
10136270|NCT04240028||Individuals with MCR|The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
10136271|NCT04240158|Experimental|IW-6463|IW-6463 tablets administered orally
10136272|NCT04240158|Placebo Comparator|Placebo|Matching placebo tablets administered orally
10136273|NCT04239898|Experimental|Red cabbage microgreens|2 cups of fresh red cabbage microgreens per day
10136274|NCT04239898|Experimental|Red beet microgreens|2 cups of fresh red beet microgreens per day
10136275|NCT04239950|Placebo Comparator|Placebo|Placebo, orally, twice daily after breakfast and dinner for 12 weeks.
10136276|NCT04239950|Experimental|Ethyl Icosapentate 1.8g|Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks.
10136277|NCT04239950|Experimental|Ethyl Icosapentate 3.6g|Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks.
10136278|NCT04240041||Pregnant women at 32-36 weeks gestational age|Pregnant women at 32-36 weeks gestational age with sure dates and crown-rump length dating ultrasound
10136279|NCT04239859|Experimental|Secukinumab|"Participants will be offered secukinumab as first-line systemic treatment for moderate to severe PsO. The indication for secukinumab will be equivalent to current registered indications. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months.~secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care."
10136280|NCT04239859|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
10136281|NCT04239768|Experimental|MonoDermà HA gel combined to a low level laser|"Monodermà HA Bio-revitalizing gel is a sterile, biodegradable, isotonic intradermal filler produced by Innate S.r.l. (Italy) and distributed by Giuliani S.p.A. (Italy) in non-pyrogenic pre-filled syringe of 2 ml containing 2% (20mg/ml) of medium chain (1.0-1.5 x 106 Dalton) hyaluronic acid (HA), obtained from bacterial fermentation, in a physiologic buffer (see Appendix 1) and used as a filler for the correction of deep skin sagging and roughness."
10136282|NCT04239560|Experimental|Boron-based Gel|During each radiation therapy session, 15 minutes before radiotherapy, 3% sodium pentahydrate panteurate will be used.
10136283|NCT04239560|Placebo Comparator|Radiation Traumatic Dermatitis Treated with Placebo|During each radiotherapy session, 15 minutes before radiotherapy, the gel will be free of any chemical treatments
10136284|NCT04239599|Experimental|Hypofractionation|Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost) + 18-36 months of Eligard Hormone injection.
10136285|NCT04239599|Active Comparator|Standard Fractination|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy + 18-36 months of Eligard Hormone injection.
10136286|NCT04239625|Experimental|ALK-001|
10136287|NCT04239482|Experimental|L-arginine + Nitrate/Nitrite|Subjects will receive 1 L-arginine tablet per day and drink 35 mL of beetroot juice for 8 weeks.
10136288|NCT04239482|Placebo Comparator|Placebo|Subjects will receive 1 cellulose tablet per day and drink 35 mL of nitrate/nitrite depleted beetroot juice for 8 weeks.
10136289|NCT04239469|Active Comparator|KL16-012|Patients will use a liquid standardized extract of cannabis sativa. Each drop will contain 1 mg of THC and 0.45 mg of CBD. Administration will be sublingual, while dosing will begin at 3 drops per day and be escalated to 15 drops per day by week 5 according to an escalation chart.
10136290|NCT04239469|Placebo Comparator|Placebo|Patients will use a liquid placebo identical to the active principle in both appearance and taste.
10136291|NCT04239664|Experimental|Acceptance Based Telephone Support (ABS+UC)|One face-to-face session to be informed of the group they have been randomised into and Acceptance Based Support, followed by five 30-minute telephone sessions of Acceptance Based Support. Usual care continues as normal.
10136292|NCT04239664|No Intervention|Usual Care (Control Group) (UC)|One face to face session to be informed of the group they have been randomised into and encouraged to ask any questions, and will be informed they will be contacted again in 8 weeks. Usual care continues as normal.
10136293|NCT04239677|Active Comparator|control|Conventional crystalloid solution-based priming
10136294|NCT04239677|Experimental|RAP|Retrograde autologous priming
9968943|NCT01285063|Experimental|physical activiy & nutrition|"25 kindergarten children in the ages of 4-6 who defined as suffering from overweigh (BMI percentage 85-95) or obesity (above BMI percentage 95).~Non-generalization criteria: children who suffer from obesity due to organic disease or children who take medicine which may influence body weight (e.g., steroids) will be excluded from the research."
9968944|NCT01285089||A|
9968945|NCT01285115|Placebo Comparator|Placebo; corn flour,|"raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: for each sack 7.67g~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
9968946|NCT01285115|Active Comparator|Gamisoyosan extract|"name of product: KyungBangn-Gamisoyosan-x-gwarip~standard code for item : 200005799~shape, type: extract(grayish brown)~usage, content : adults;three times a day , each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc."
9968947|NCT01285115|Active Comparator|Gamisoyosan extract powder|"name of product: KyungBangn Gamisoyosan~standard code for item: 200005591~shape, type: powder(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
9968948|NCT01285141|Experimental|Vaginal immunisation|CN54gp140 glycoprotein-hsp70 conjugate vaccine
9968949|NCT01285154||Traditional Steel Triple Osteotomy|Traditional technique
9968950|NCT01285154||Modified Triple Osteotomy|Modified technique
9968951|NCT01285167||DACOTA|
9968952|NCT01285180||DINO|
9968953|NCT01285193|Experimental|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
9968954|NCT01285206|Experimental|Routine practice|
9968955|NCT01285219|Active Comparator|AOB,pegylated filgrastim to filgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
9968956|NCT01285219|Active Comparator|BOA,ﬁlgrastim to pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
9968957|NCT01285232|Experimental|Anakinra|Anakinra 150 mg/day during four weeks
9968958|NCT01285232|Placebo Comparator|Placebo|Placebo during four weeks
9968959|NCT01285245|Experimental|kineret|
9968960|NCT01285258|Other|peripartum|patients whom underwent peripartum hysterectomy
9968961|NCT01285271|Experimental|Xenon|Xenon will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
9968962|NCT01285271|Active Comparator|Sevoflurane|Sevoflurane will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
9968963|NCT01285284|Experimental|Music|A previously defined list of songs will be administered by headphones to these patients during the colonoscopy.
9968964|NCT01285284|Sham Comparator|Control|These patients will receive an MP3 device (and headphones) which will be functioning but without volume.
9968965|NCT01285297|Experimental|TMR plus BMAC injection|Injection of bone marrow aspirate concentrate into reversibly ischemic myocardium with transmyocardial revascularization during the same open procedure.
9968966|NCT01285336|Experimental|The genetic and the functional study|
9968967|NCT01285362|Active Comparator|Fish Oil Supplementation (Group A)|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
9968968|NCT01285362|Placebo Comparator|Placebo Supplementation (Group B)|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
9968969|NCT01285375|Active Comparator|CDC graft perfusion|Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
9968970|NCT01285375|Sham Comparator|Sham perfusion|
9968971|NCT01285388|Experimental|MB12066 10mg|
9968972|NCT01285388|Active Comparator|MB12066 30mg|
10136295|NCT04239521||Cases|Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis.
9968973|NCT01285388|Active Comparator|MB12066 100mg|
9968974|NCT01285388|Active Comparator|MB12066 150mg|
9968975|NCT01285388|Active Comparator|MB12066 200mg|
9968976|NCT01285388|Placebo Comparator|placebo|
9968977|NCT01285414|Experimental|Verubulin & standard of care (RT & TMZ)|Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide
9968978|NCT01285414|Active Comparator|Standard of care (RT & TMZ)|Standard of care Radiation Therapy and Temozolomide
9968979|NCT01285440||Diagnostic Imaging|
9968980|NCT01285453|Experimental|ASA404|
9968981|NCT01285466|Experimental|BEZ235 + paclitaxel|
9968982|NCT01285466|Experimental|BKM120 + paclitaxel|
9968983|NCT01285466|Experimental|BEZ235 + paclitaxel + trastuzumab|
9968984|NCT01285466|Experimental|BKM120 + paclitaxel + trastuzumab|
9968985|NCT01285479||prescribed fingolimod 0.5 mg/day|
9968986|NCT01285505|Active Comparator|Alprazolam commercial sublingual tablet|
9968987|NCT01285505|Experimental|Alprazolam test sublingual tablet|
9968988|NCT01285531|No Intervention|Lumbar puncture|The participants randomly assigned to this arm will receive a lumbar puncture using standard procedures and equipment
9968989|NCT01285531|Experimental|Lumbar puncture with the Compass device|The participants randomly assigned to this group will receive a lumbar puncture with the use of the Compass device.
9968990|NCT01285544|Experimental|Lipinon-test formulation of atrovastain - 20mg|
9968991|NCT01285544|Active Comparator|Lipitor- branded formuation of atorvastatin-20mg|
10136296|NCT04239521||Controls|The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level.
10136297|NCT04239508||Minimal Neonatal Dataset MNDS|All Swiss live-born infants below 32 weeks gestational age or 1501g birth weight
9968992|NCT01285557|Experimental|S-1/cisplatin|
10136298|NCT04239508||Below 34, B34|All Swiss live-born infants between 32 0/1 and 33 6/7 weeks gestational age that are above 1500g birth weight
10136299|NCT04239508||Swiss Asphyxia and Cooling Registry, ASP|Infants between 35 0/7 and 42 6/7 weeks' gestational age with moderate or severe encephalopathy due to perinatal asphyxia
10136300|NCT04239547|Experimental|Recruitment|Patients classified to receive recruitment maneuver + 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
10136301|NCT04239547|Experimental|Non-recruitment|Patients classified to receive only 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
10136302|NCT04239612|Other|Physical exercise|Specified circular training, 60 minutes, 1-3 times/week
10136303|NCT04239690|Experimental|Micromethods for blood sample analysis|Blood gases are analysed using 0.045 ml whole blood Levels of CRP are analysed using 0.010 ml whole blood
10136304|NCT04239690|No Intervention|Standard clinical methods for blood sample analysis|Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood
10184297|NCT03756467|Experimental|Arm 2|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up
10184298|NCT03756467|Active Comparator|Arm 3|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up.
10184299|NCT03756441|Experimental|Experimental: Mindfulness group|This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion protocol. They will group with have eight meetings, one per week, during a half hour and will learn the techiques to practice everyday during the week.
10184300|NCT03756441|Active Comparator|Psychotherapy group|This group will learn group problem solving techniques during eight weeks
10184301|NCT03756428|Experimental|Deep dry needling in tibialis posterior|Deep dry needling will be applied in the tibialis posterior myofascial trigger point
10184302|NCT03756428|Placebo Comparator|Sham technique in tibialis posterior|Placebo tibialis dry needling
10184303|NCT03756415|Experimental|mask plus CO2 removal device|"a traditional mask with inserted a new CO2 removal device that is called DiMax Zero Total face mask R,"
10184304|NCT03756415|Active Comparator|traditional face mask|Traditional mask without a CO2 clearance device inserted
10184305|NCT03756389|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.
10184306|NCT03756389|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.
10184307|NCT03756363|Experimental|Non-solvent|Non-solvent use of a rotary retreatment system
10184308|NCT03756363|Experimental|Solvent|Solvent use in combination with a rotary retreatment system
10187694|NCT03723642|Active Comparator|OAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
10187695|NCT03723642|Active Comparator|LAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
10187696|NCT03723629||pulmonary GGO|Patients with pulmonary GGO.
10187697|NCT03723616|Active Comparator|Hookah Tobacco Smokers|Young adults, ages 18-34, who smoke hookah tobacco
10187698|NCT03723616|Active Comparator|Open to Smoking Hookah Tobacco|Young adults, ages 18-34, who do not smoke hookah tobacco but are open to trying
10187699|NCT03723577|Experimental|Fibrillar Collagen Powder Dressing|
10187700|NCT03723564|Experimental|Amnioinfusion|Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
10187701|NCT03723525|Experimental|Package of HIV care|Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI), Rapid antiretroviral therapy (ART) initiation and Enhanced adherence support.
10187702|NCT03723525|Experimental|Standard HIV care|Screening and management of common OIs, basic health assessment (CD4, viral load and other tests), ARV drugs and follow up.
10187703|NCT03723499||endoscopic treatment|Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.
10187704|NCT03723460||Households|Household here means a family unit comprising of at least both parents (mother and father) and a child under 5 years of age or an adolescent child.
10187705|NCT03723434|Active Comparator|Healthy Participants|Healthy participants without disorders or medications influencing brain function will be scanned with MRI and undergo single-pulse TMS and PAS during several visits, each with a different asynchrony, while EEG and MEPs are recorded.
10187706|NCT03723434|Experimental|Patients|Participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) will be scanned with MRI and undergo single-pulse TMS and paired associative stimulation during several visits while EEG is recorded.
9968993|NCT01285557|Active Comparator|5-FU/cisplatin|
9968994|NCT01285570|Experimental|Experimental 2|
9968995|NCT01285570|Experimental|experimental 1|
9968996|NCT01285570|Placebo Comparator|Placebo|Placebo comparator daily (QD)
10136305|NCT04239729|Experimental|ACT Website and Coaching Condition|Participants will be asked to complete 16 brief self-help website sessions, each taking around 15-20 minutes to finish, twice a week for eight weeks. Website exercises and examples primarily focus on hoarding, although some examples also discuss related mental health concerns such as anxiety, low mood, health behaviors, etc. The sessions use multimedia and are interactive. Participants assigned to the website condition will also receive coaching. The purpose of coaching will be to help participants engage with the website and adhere to the intervention. Coaching will consist of an initial phone call of 10-15 minutes followed by weekly email contact during the 8-week treatment period. Coaches will be graduate students trained in clinical psychology.
10136306|NCT04239729|No Intervention|Waitlist Condition|Participants assigned to the waitlist will be asked to wait 12 weeks without intervention (access to the website or coaching). They will receive access to the website after 12 weeks, but supportive coaching will not be provided to waitlist participants.
10136307|NCT04239742|Experimental|18F-PSMA PET/CT and 18F-Fluciclovin PET/CT|patients undergo an 18F-PSMA PET/CT scan and an 18F-Fluciclovin PET/CT scan, within a time frame of two weeks.
10136308|NCT04239586|Experimental|Sulfonylurea treatment group|Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.
10136309|NCT04239755|Active Comparator|Doxycycline|Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days.
10136310|NCT04239755|Placebo Comparator|Placebo|group (2) will be 25 patients will receive placebo in addition to the standard treatment.
10136311|NCT04239391|Experimental|Triferic via IV and Hemodialysate|Upon completion of the Baseline observational periods, all enrolled patients will transition to the interventional period where they will then receive Triferic. The Triferic will be administered via the liquid bicarbonate concentrate at a dialysate concentration of 2 uM or via IV at a dose of 0.1 mg Fe/kg, if the patient does not receive dialysis using liquid bicarbonate, for up to an additional 36 weeks (depending on duration of observational Baseline period). Hgb and CHr will continue to be measured bi-weekly and iron profiles will be obtained at 4 week intervals. In the Triferic phase of the study,changes in ESA dose will be allowed according to the study site existing protocol. IV iron will only be administered if ferritin meets the criteria for iron deficiency. Patients will remain in the interventional period for either 36 or 28 weeks (depending on randomization assignment), at which time a final study visit will take place
10136312|NCT04239391|No Intervention|Historic Control Observational Arm|Up to 75 patients will be enrolled in the Observational Arm. Patients who participate in the historical control observational arm will not receive any study medication, but will have Hgb, CHr and serum iron profiles collected at 4 week intervals for up to a total of 44 weeks.
10136313|NCT04239352||healthy pregnant women|"Blood samples taken from 40 healthy pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.~this group will be the control group."
10136314|NCT04239352||preeclamptic pregnant women|"Blood samples taken from 40 preeclamptic pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.~this group will be the study group."
10136315|NCT04239443|Experimental|SHR1210 and Apatinib|"NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).~The duration of treatment will till the disease progression, death, or unacceptable toxicity show up."
10136316|NCT04239365|Experimental|Group A: WLE followed by NBI|EMR scar is interrogated using WLE followed by NBI
10136317|NCT04239365|Active Comparator|Group B: NBI followed by WLE|EMR scar is interrogated using NBI followed by WLE
10136318|NCT04239378|Experimental|Test group -Autogenous dentin matrix and collagen membrane|Test group - After atraumatic tooth extraction , socket will be augmented with autogenous dentin matrix and covered with collagen membrane and sutures are placed.
9826073|NCT02406586|Experimental|Carvedilol|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
10136319|NCT04239378|Active Comparator|Control group-bovine derived xenograft and collagen membrane|control group- After atraumatic tooth extraction, socket will be augmented with bovine derived xenograft and covered with collagen membrane and sutures are placed.
10136320|NCT04239534|Other|Single Arm|In this Single Arm Study, Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access. Followed by the sue of an endocardial ablation catheter that will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.
10136321|NCT04239417|Experimental|The Study group A|graduated abdominal strengthening exercises group
10136322|NCT04239417|Experimental|The Study group B|Russian stimulation group
10136323|NCT04239417|Experimental|The Study group C|combination group
10136324|NCT04239417|No Intervention|The Control group D|presume in normal activities of daily living.
10136325|NCT04239144|No Intervention|Medical therapy group|Arm 1 Medical Treatment Control - 10 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming.
10184309|NCT03756350|Experimental|Treatment subjects|Single group of subjects which will have the treatment of a 1060nm diode laser administered to them.
9968997|NCT01285583|Other|Olesoxime|All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.
10136326|NCT04239144|Active Comparator|Catheter ablation|Intervention Arm 2 -10 patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
10136327|NCT04239144|Experimental|Left trunk sympathectomy|Interventional arm 3 - In 10 patients, left truck sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches.
10136328|NCT04238962|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
10136329|NCT04238962|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
10136330|NCT04238936||study group ; Patients with gestational diabetes|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
10136331|NCT04238936||control group ; healthy pregnant women|Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
10136332|NCT04238988|Experimental|Carboplatin-Paclitaxel-Pembrolizumab|"Patients will be treated with 3 cycles of neoadjuvant Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q 21)+ Pembrolizumab (200 mg flat dose every 3 weeks).~After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will undergo radical surgery.~After surgery, patients presenting with high risk factors will receive 3 cycles of adjuvant Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient consent withdrawal for up to 35 cycles."
10136333|NCT04239066|Experimental|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
10136334|NCT04239066|Experimental|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
10136335|NCT04239209|Placebo Comparator|Direct Communication (control)|A direct response where the intensivist acknowledges that he is not certain but believes the patient will not survive hospitalization.
10136336|NCT04239209|Active Comparator|Indirect - other patients|An indirect response describing the prognosis of other people similar to the patient in question.
10136337|NCT04239209|Active Comparator|Indirect - physiology|An indirect response describing the severe physiologic abnormalities present in the patient and potential future problems.
10136338|NCT04239209|Active Comparator|Redirection|Redirection to a conversation about the values of the patient and possible future decisions.
10136339|NCT04239300|Experimental|Main group|The participant in main group have water labour
10136340|NCT04239300|No Intervention|Control group|The participant in control group will not have water labour
10136341|NCT04239248|Experimental|ACTIVE-RCT-I Tasty&Healthy intervention group|Patients with mild-moderately symptomatic disease, will follow the Tasty&Healthy dietary approach.
9968998|NCT01285622||Gynecology patients|female subjects scheduled for elective robotic gynecological surgery under general anesthesia.
9968999|NCT01285648|Other|Cpap|This group joined chest physiotherapy with CPAP via nasal masks for two hours.CPAP was continued from the immediate postoperative day until the second postoperative day, twice a day.
10136342|NCT04239248|Active Comparator|ACTIVE-RCT-I Control group|Patients with mild-moderately symptomatic disease, will receive EEN with Modulen formula only.
10136343|NCT04239248|Experimental|MH-RCT-II Tasty&Healthy intervention group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will follow the Tasty&Healthy dietary approach.
10136344|NCT04239248|No Intervention|MH-RCT-II Control group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will continue their habitual diet.
10136345|NCT04239235|Experimental|Intervention|Community Reinforcement Approach and Family Training is a 10-session rolling group for the support person.
10136346|NCT04239235|No Intervention|Control|This condition is for support persons who do not receive CRAFT. They will receive no intervention or usual care services available at the clinic.
10136347|NCT04239287||Preterm|Children age 8-16 years born at <32 weeks gestation.
10136348|NCT04239287||Control|Children age 8-16 years born at >37 weeks gestation
10136349|NCT04238949|No Intervention|Standard Diabetes Care Group|Patients receive standard diabetes care.
9969000|NCT01285648|Other|Chest Physiotherapy|Chest Physiotherapy consisted of bronchial hygiene techniques and pulmonary expansion, in addition to exercises, and received oxygen supplementation to maintain the pulse oxymetry saturations > 90%.
10136350|NCT04238949|Experimental|Community Health Worker Group|Patients are assigned a community health worker for the first year in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
9969001|NCT01285661|Experimental|Proximal DVT|Patients whose veins have recanalized (either at the recruitment or later on during the follow-up) will receive the D-dimer determination before discontinuing sodium warfarin. Veins are defined as recanalized when the vein diameter under maximum compressibility is lower than 4 mm both at the common femoral and at the popliteal vein. In those with negative D-dimer sodium warfarin will be discontinued. These patients will have two further determinations of D-dimer (after 1 and 3 months, respectively). While patients with persistently negative D-dimer will no longer receive sodium warfarin, those in whom D-dimer is positive or reverts to positive values in the following determinations will have their sodium warfarin resumed and no longer discontinued.
9969002|NCT01285674|Experimental|Intra-tympanic steroid injection|
9969003|NCT01285687|No Intervention|Standard Analgesic Treatment|
10136351|NCT04239118|Experimental|Applications of autoplasma, enriched with platelets and|Endoscopic applications of autoplasma, enriched with platelets and granular sorbent aseptisorb-A in bleeding gastroduodenal ulcers
10136352|NCT04239118|Other|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents.
10136353|NCT04239105||Breast cancer Group|The biopsy result is breast cancer.
10136354|NCT04239157|Experimental|Treatment (canakinumab)|Patients receive canakinumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10136355|NCT04239170|Experimental|Camrelizumab(SHR-1210) Combined With GEMOX|
10136356|NCT04239014|Experimental|Arm 1 (ceralasertib+olaparib)|Participants received ceralasertib 160 mg QD PO on Days 1 to 7 plus olaparib 300 mg BD PO continuous (28 day cycle).
10136357|NCT04239014|Experimental|Arm 2 (olaparib monotherapy)|Olaparib 300 mg BD PO daily continuous.
10136358|NCT04239014|Experimental|Arm 3 (placebo)|Placebo to match olaparib BD PO daily continuous.
10136359|NCT04238923|Experimental|Topical Gentamicin and Vancomycin|Immediately prior to closure of the incision, 1g of vancomycin will be mixed in 4mL of normal saline and applied as a paste directly to the muscle, fascia and subcutaneous tissue. Gentamicin-eluting collagen sponges will be cut to the appropriate size to cover the defect and applied after application of vancomycin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
10136360|NCT04238923|No Intervention|Control|The surgical wound is closed in the standard fashion with 3 layer closure with staples for skin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
10136361|NCT04239001|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF): jinyouli injection was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle
10136362|NCT04238910|Experimental|Maximizing Energy|"The Maximizing Energy (MAX) intervention consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventions are delivered by occupational therapists.~The MAX intervention was developed by combining two active ingredients - Problem Solving Therapy and energy conservation strategy education. Participants engage in two introductory sessions during the first week of the intervention. During the first session in a week, participants practice the steps of MAX Intervention with a fatigue-related problem. At the end of the session, the participants identify a clearly defined action plan for solution implementation. Participants are asked to implement the solution over the next few days. The second session takes place later in the week. The interventionist reviews the problem, the identified solution, and its implementation. Participants use a workbook to support their application of the MAX Intervention."
10136363|NCT04238910|Active Comparator|Health Education|consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventionist delivered health education using a variety of health related topics relevant to individuals with TBI (e.g., characteristics and prevalence of fatigue after TBI, diet and nutrition, importance of exercise, energy conservation strategies).Participants use a workbook to follow along with the interventionist during the weekly sessions.
10136364|NCT04238975|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
10136365|NCT04238975|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
10136366|NCT04238897|Experimental|Ticon Aspherical Daily Disposable Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
10136367|NCT04238897|Placebo Comparator|Ticon Daily Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
10136368|NCT04238767||HIV-1-positive individuals|HIV-1-positive individuals eligible to receive a DTG-based ART regimen at enrolment.
10136369|NCT04238754|Experimental|All Participants|Each participant will receive Epidiolex oral solution and Cherry syrup oral solution (placebo) in a randomized fashion.
10136370|NCT04238806|Active Comparator|Desflurane Continuous|In Group 1 of 60 patients, desflurane inhalational agent was administered continuously during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg. For maintenance, in Group 1 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% during the whole surgical procedure and intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 1 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
10136371|NCT04238806|Active Comparator|Desflurane Intermittent|In Group 2 of 60 patients, desflurane inhalational agent was administered intermittently during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg/kg. For maintenance, in Group 2 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% before and after the cardiopulmonary bypass procedure as intermittently with the addition of intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 2 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
9969004|NCT01285687|Experimental|Standard Analgesic Treatment with Acupuncture|Patients will receive standard analgesic treatment and in addition acupuncture.
9969005|NCT01285700|Active Comparator|Lamazym 25|25 U/kg
10136372|NCT04238832|Active Comparator|Free Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and free base nicotine e-liquid to sample for one week.
9969006|NCT01285700|Active Comparator|Lamazym 50|50 U/kg
9969007|NCT01285739||NIMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged with tracheostomy but in domiciliary non invasive ventilation
9969008|NCT01285739||IMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged in domiciliary invasive mechanical ventilation (IMV)
9969009|NCT01285752|Experimental|1|
9969010|NCT01285752|Experimental|2|
9969011|NCT01285752|Active Comparator|3|
9969012|NCT01285765|Experimental|Early-PET-result-adapted treatment|4 to 6 RCHOP21
9969013|NCT01285765|Active Comparator|standard treatment|6 RCHOP21
9969014|NCT01285778|Experimental|Panitumumab, mytomicin C, 5-FU, radiation|
9969015|NCT01285804|Active Comparator|Cuffed ETT|
9969016|NCT01285804|Active Comparator|Uncuffed ETT|
9969017|NCT01285817|Experimental|traetment|
9969018|NCT01285830|Placebo Comparator|Placebo|
9969019|NCT01285830|Active Comparator|Lactobacillus reuteri|
9969020|NCT01285856|Active Comparator|buprenorphine|populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
9969021|NCT01285856|Active Comparator|methadone|populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
9969022|NCT01285869|Experimental|Multidisciplinar intervention|Patients that will receive the multidimensional intervention during the ambulatory follow-up.
9969023|NCT01285869|No Intervention|Conventional follow up|This is an observation only group and outpatient follow up will be indicated in accordance with usual and customary practices.
9969024|NCT01285882||Representations|
9969025|NCT01285921|Experimental|hippocampal surgery|"Vestibular test before and after hippocampal surgery~Principal criterion:~Research for an asymmetry of the vestibular responses (Caloric test, Vestibular Evoked Myogenic potentials: VEMp, Head Impulse Test: HIT, Eye Rotational Test: ERI). Investigator performs a blind vestibular test (single blind)"
9969026|NCT01285934|Experimental|Hematopoietic Stem Cell Transplantation|Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
9969027|NCT01285934|Other|control arm of intensive insulin therapy|The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
9969028|NCT01285986|Experimental|Vein collar at distal anastomosis|Vein collar at the distal anastomosis
9969029|NCT01285986|Experimental|No vein collar at the distal anastomosis|No vein collar at the distal anastomosis
9969030|NCT01285999|Experimental|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System (PROMUS Element)
9969031|NCT01285999|Active Comparator|TAXUS Liberté|TAXUS Liberté Paclitaxel-Eluting Coronary Stent System (TAXUS Liberté)
9969032|NCT01286025|Active Comparator|Video modality|
9969033|NCT01286025|Active Comparator|Text modality|
9969034|NCT01286051|Active Comparator|Follistim|standard treatment
9969035|NCT01286051|Experimental|Follistim plus single ganirelix injection|
9969036|NCT01286064|Experimental|patient with colo-rectal cancer|fluorescence spectra will be mainly characterized by the presence of an emission peaking at 620-630 nm
9969037|NCT01286064|Active Comparator|patient without colo-rectal cancer|fluorescence spectra will be characterized by the absence of an emission peaking at 620-630 nm
9969038|NCT01286090|Experimental|001|Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
9969039|NCT01286090|Experimental|002|Placebo One tablet taken orally 4 times a day for up to 8 weeks.
9969040|NCT01286103|Experimental|001|Canagliflozin 300 mg once daily and 150 mg twice daily Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
9969041|NCT01286103|Experimental|002|Canagliflozin 100 mg once daily and 50 mg twice daily Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
9976859|NCT01355900|Other|I tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after bone cement set.
9976860|NCT01355900|Other|II tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
10136373|NCT04238832|Active Comparator|Salt Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and salt base nicotine e-liquid to sample for one week.
10136374|NCT04238598|Active Comparator|Active|intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone + sham Pulsed Radiofrequency
10136375|NCT04238598|Placebo Comparator|Control|intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency
10136376|NCT04238598|Experimental|Experimental|intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency
10136377|NCT04238871||children or adults with Idiopathic Lung Disease|
10136378|NCT04238884|Experimental|Experimental group|Based on the genetic study carried out and the patient's characteristics (age, weight, indication), the Pharmacogenetics Unit of the University Hospital La Paz will indicate the dose to be administered based on the therapeutic individualization protocol guided by pharmacogenetics.
10136379|NCT04238884|Active Comparator|Control group|No information will be provided and procedure will be carried out according to normal clinical practice, with clinical monitoring by the doctor in charge.
10136380|NCT04238689|Experimental|Group 1 - 0,1mg/kg TB31F|0.1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. Subjects will be observed for the occurrence of any adverse events. There will be a minimum of 48 hours between TB31F administration to each subsequent volunteer. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
10136381|NCT04238689|Experimental|Group 2 - 1mg/kg TB31F|1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
10136382|NCT04238689|Experimental|Group 3 - 3mg/kg TB31F|3 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
10136383|NCT04238689|Experimental|Group 4 - 10mg/kg TB31F|10 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
10136384|NCT04238689|Experimental|Group 5 - 100mg TB31F|100mg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
10136385|NCT04238858|Active Comparator|Before application|Forty-nine eyes belonging to 37 patients before injection aPRP.
10136386|NCT04238858|No Intervention|After application|Forty-nine eyes belonging to 37 patients after injection aPRP.
10136387|NCT04238858|Sham Comparator|Sham application|11 patients before - after aPPP injection
10136388|NCT04238572|Experimental|Audiovisual distraction device|Audiovisual distraction device, analgesia nociception index monitoring, remifentanil added to local anesthesia technique
10136389|NCT04238572|Active Comparator|Active comparator group|Analgesia nociception index monitoring, remifentanil added to local anesthesia technique
10136390|NCT04238611|Experimental|Lactate microneedle|Measurement of lactate through microneedle
10136391|NCT04238793|Experimental|Cohort 1|KLS-2031 low dose(1x10^11 VG/DRG) or Placebo
10136392|NCT04238793|Experimental|Cohort 2|KLS-2031 medium dose(1x10^12 VG/DRG) or Placebo
10136393|NCT04238793|Experimental|Cohort 3|KLS-2031 high dose(1x10^13 VG/DRG) or Placebo
10136394|NCT04238702|Experimental|Empagliflozin + Losartan|Empagliflozin + Losartan
10136395|NCT04238702|Experimental|Losartan + Placebo|Losartan + Placebo
10136396|NCT04238702|Experimental|Empagliflozin + Placebo|Losartan + Placebo
10136397|NCT04238702|Placebo Comparator|Placebo + Placebo|Placebo + Placebo
10136398|NCT04238507|Active Comparator|Guedel airway (OPA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
10136399|NCT04238507|Active Comparator|McKay Airway (MA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
10136400|NCT04238533|Active Comparator|eADAPT|This arm includes transradial amputees who will be assessed while using the eADAPT trainer.
10136401|NCT04238533|Active Comparator|Conventional program|This arm includes transradial amputees who will be assessed while using the conventional training program.
10136402|NCT04238208|Active Comparator|Group LL|Group LL patients received the 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm containing 700 mg of Lidocaine for 60 minutes
10136403|NCT04238208|Placebo Comparator|Group LP|Group LP received an identical placebo patch
10136404|NCT04238208|Experimental|Group LC|Group LC received the 8% Capsaicin patch [8% w/w] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK).
10136405|NCT04238221|Experimental|Doxofylline+inhalation therapy|4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy, followed by 4-week treatment of maximal inhalation therapy only
10136406|NCT04238221|Experimental|Inhalation therapy|4-week treatment with maximal inhalation therapy only, followed by 4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy
10136407|NCT04238468|Experimental|Intradermal injection of stromal vascular fraction|Most lateral 5 cm of abdominal donor site will be injected with stromal vascular fraction just after the wound is closed.
10136408|NCT04238468|No Intervention|control|Most contralateral 5 cm of abdominal donor site will serve as control.
10136409|NCT04238260|Active Comparator|Usual Physical Therapy Care|Physical Therapists continue usual care
10136410|NCT04238260|Experimental|Enhanced Physical Therapy Usual Care|Best practice implemented
10136411|NCT04238286|Experimental|Dry needling group|Patients treated with dry needling
10136412|NCT04238286|Sham Comparator|Sham group|Patients treated with a simulated dry needling
10136413|NCT04238286|No Intervention|Control|Patients never treated
10136414|NCT04238273||HHHFNC|it included 63 preterm neonates on Heated, Humidified High Flow Nasal Cannula, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
10136415|NCT04238273||NCPAP|it included 60 preterm neonates on Nasal Continuous Positive Airway Pressure, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
10136416|NCT04238130||Perioperative ctDNA Dynamic Monitoring Group|Samples were obtained at multiple pre-specified time points including before surgery (plasma samples)，during surgery after tumor resection (tumor samples) and after surgery(plasma samples were obtained every 6 months from ctDNA positive patients at baseline in the following 2 years)
10136417|NCT04238169|Experimental|SBRT+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.~SBRT：30-50Gy/5F（2-4 locations)."
10136418|NCT04238169|Experimental|SBRT+Bevacizumab+Toripalimab|"Immunotherapy：Toripalimab: 240 mg once every three weeks，Until progress of disease or investigators determine that clinical benefit is no longer available or there are intolerable toxicity.~SBRT：30-50 Grays(Gy) in 5 fractions（2-4 locations）. Bevacizumab：7.5mg/kg once every three weeks."
10136419|NCT04238442|Experimental|BP oscillometric measurement|Oscillometric BP measurement
10136420|NCT04238195|Experimental|Treatment A|600 mg TBPM-PI-HBr (2 x 300 mg tablets) and TBPM-PI-HBr-matching placebo (2 x matching placebo tablets) administered at Hour 0 on Day 1.
10136421|NCT04238195|Experimental|Treatment B|1200 mg TBPM-PI-HBr (4 x 300 mg tablets) administered at Hour 0 on Day 1.
10136422|NCT04238195|Placebo Comparator|Treatment C|TBPM-PI-HBr-matching placebo (4 x matching placebo tablets) administered at Hour 0 on Day 1.
10136423|NCT04238195|Other|Treatment D|Positive Control - unblinded: 400 mg moxifloxacin (1 x 400 mg tablet) administered at Hour 0 on Day 1.
10136424|NCT04238182|Active Comparator|wet cupping|smokers in this group will receive single wet cupping session
10136425|NCT04238182|Active Comparator|dry cupping|smokers in this group will receive single dry cupping session
10136426|NCT04238364|Experimental|EI1071 Tablets|EI1071 tablet(s) administered orally as single ascending dose, multiple ascending daily doses
10136427|NCT04238364|Placebo Comparator|Placebo|Matching placebo tablet(s) administered orally
10136428|NCT04238351|Experimental|Control|usual mask ventilation during anethesia induction
10136429|NCT04238351|Active Comparator|THRIVE|Applying Transnasal humidified rapid insufflation ventilator exchange during anesthesia induction
10136430|NCT04238377|Active Comparator|Stellate Group|will receive pre-operative ultrasound guided stellate ganglion block one hour before surgery and multimodal analgesia and will be followed for 6 months for neuropathic pain as the Stellate Group
10136431|NCT04238377|Placebo Comparator|Control Group|will receive multimodal analgesia only and will be followed for 6 months for neuropathic pain as the control Group
10136432|NCT04238403|Experimental|Behavioral Parent Training|Parent training intervention based on social learning and operant conditioning theory, generally referred to as Behavioral Parent Training.
10136433|NCT04238234||study group|Participants will be adult patients (above 18 years), ASA I-II-III, scheduled for elective surgeries under general anesthesia.
10136434|NCT04238312|Experimental|RESPeRATE™|RESPeRATE™: 2breathe Tech. Ltd., Eshtaol, Israel. The device includes a belt-type respiration sensor worn outside of the clothing that is placed around the torso. It is connected to a computerized box that generates musical patterns listened through an earbud. The device guides the user interactively to slow breathing with a relatively prolonged expiration.
10136435|NCT04238312|Active Comparator|Tell, Show and Do technique|
10184310|NCT03756324|Experimental|CHPM (Chinese Herbal Patent Medicine )|"CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
10184311|NCT03756324|Experimental|CHPM & Antibiotics Cefdinir Capsules|"CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.~Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.~Education, basic medical order."
10184312|NCT03756324|Active Comparator|Antibiotics Cefdinir Capsules|"Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
10136436|NCT04238156|Experimental|Hypopressive abdominal exercises|"Hypopressive abdominal exercises will be performed in basic postures (standing, sitting and supine position). In each posture, three slow cost-diaphragmatic respiration will be performed followed by an expiratory apnea and a rib cage opening, during 2 to 10 seconds, and an exhalation of 10 to 30 seconds. Each exercise will be repeated three times.~There will be 3 stages of application throughout the 12 intervention sessions, supervised by a physical therapist:~First stage: To explain the concept of hypopressive respiration and how to perform it.~Second stage: To explain and apply the hypopressive abdominal exercises: 1. Axial auto-elongation (reducing curvatures in the sagittal plane); 2. Cervical auto-elongation (chin toward the neck); 3. Moving forward of gravity axis; 4. Activation of the shoulder girdle (shoulder joint decoaptation); 5. Slight knee flexion; 6. Dorsal ankle flexion.~Third stage: To review and update all the exercises, increasing their intensity."
10136437|NCT04238117|Experimental|LA group|The participants in LAT group underwent 10 sessions of LAT over 2 weeks, using a gallium aluminum arsenide Laser Pen. The participants in the LAT group received 0.375 J of energy at each of the following acupoints bilaterally: BL23 (Shenshu, B2), BL25 (Dachangshu, B2), BL26 (Guanyuanshu, B2), BL40 (Weizhong, B2) and SP6 (Sanyinjiao, B2).
10136438|NCT04238117|No Intervention|Control group|The participants of the control group received standard obstetric care.
10136439|NCT04238078||Polycystic ovary syndrome|Women with PCOS diagnosed according to Rotterdam criteria
10136440|NCT04238078||Healthy control|Healthy women without any feature of ovulatory dysfunction or androgen excess
10136441|NCT04238000|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
10136442|NCT04238000|Placebo Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
10136443|NCT04238065|Experimental|VR treatment|"The arm will use the virtual reality headset reproduces dynamic video content with perceptual learning and binocular perception (including stereopsis) that is visually perceived a little bit faster, brighter, and higher contrast to the amblyopia eyes .~The each VR therapy length is 30 minutes with 5 minute break after 15 minutes' therapy sequence, 3 times per week, total 13 weeks.~All amblyopia eyes are best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity."
10136444|NCT04238065|Placebo Comparator|control|"This arm of amblyopia eyes are all best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity.~No VR therapy."
10136445|NCT04237909|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
10136446|NCT04237831|Experimental|Arm A: Normal Renal Function|
10136447|NCT04237831|Experimental|Arm B: Mild Renal Impairment|
10136448|NCT04237831|Experimental|Arm C: Moderate Renal Impairment|
10136449|NCT04237831|Experimental|Arm D: Severe Renal Impairment|
10136450|NCT04237766|Experimental|Experimental group|All patients included in the experimental group should be on prophylactic treatment with factor 8 (FVIII) or factor 9 (FIX) concentrates. Likewise, the factor should be administered on the same day that they receive each movement display therapy treatment sessions. Each session will last approximately 40 minutes, with 7 physiotherapy sessions a week taking place over a period of 4 weeks.
10136451|NCT04237766|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through mirror therapy and motion display. They will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with factor 8 (FVIII) or factor 9 (FIX) concentrates. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
10136452|NCT04237883|Placebo Comparator|Arm 1: Standard Communication Arm|Monthly email communication: Monthly standard communication via email informing physicians of their health maintenance completion rate over the prior three-month period. The email will also include a link to the performance dashboard, a link to a FAQ page that outlines their incentive plan, a link to helpful resources such as care guidelines, key tips from top performers, the quality measure on which they are performing the best, and the two quality measures that they could improve on the most.
10136453|NCT04237883|Experimental|Arm 2: Arm 1 Message + Social Comparison Intervention|"Monthly email communication as in Arm 1~Social comparison: In addition to the information given in Arm 1 email messaging, physicians in this arm will receive a list of the names of the top 25 performers from the prior month, and a high performer benchmark. Each physician in this group will receive a personalized message and subject line based on where in the performance distribution they fall (categories: top 25 performers, high performers, nearly high performers, and low performers). Message content will incorporate language utilizing principles of social comparison theory."
10136454|NCT04237883|Experimental|Arm 3: Arm 2 Interventions + Leadership training|"Monthly email communication as in Arm 1 and Arm 2.~Social comparison as in Arm 2.~Quality improvement leadership training: Physician leads and clinic managers within clinics randomized to Group 3 will receive an in-person quality improvement and primary care clinic performance training, using the principles of quality improvement, self-determination theory and social comparison. Clinic leaders will be trained on how to guide these conversations, formulate their own performance/quality improvement goals, design effective strategies to reach these goals, and track their clinic's progress. Check-in emails and calls will be provided on a monthly basis to follow up on clinic-based quality improvement efforts and share key take-aways from the new Primary Care Clinical Excellence Recognition Program. This program aims to support a positive and collaborative culture of clinical excellence by recognizing and sharing best practices from high performing physicians and clinical teams."
10136455|NCT04237987|Experimental|Interleukin-2 and ciclosporin and corticosteroid|One million units of Recombinant Human Interleukin-2 (IL-2) will be administered subcutaneously every other day for 3 months. Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 3 months after withdraw of IL-2.
10136456|NCT04237987|Active Comparator|ciclosporin and corticosteroid|Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 6 months.
10136457|NCT04237779|Experimental|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in microTESE material.
10136458|NCT04237870|Active Comparator|Active treatment|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS repeat twice with 15 min interval. Treatment will be applied in central suleus.
10136459|NCT04237870|Sham Comparator|Sham treatment|Sham rTMS will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
10136460|NCT04238104||sea level|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center of sea level were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
10136461|NCT04238104||altitude <1000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude less than 1000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
10136462|NCT04238104||altitude 1000-2000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 1000-2000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
10136463|NCT04238104||altitude 2000-3000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 2000-3000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
10136464|NCT04238104||altitude 3000-4000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 3000-4000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
10136465|NCT04238104||altitude 4000-5000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 4000-5000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
10136466|NCT04237805|Experimental|SAF-189s|The phase I dose study will enrol patients with advanced malignant solid tumors that are ALK-positive, and the phase II study will be divided into two parts, Part I Some patients with ALK/ROS1 positive advanced non-small cell lung cancer were enrolled in the 210m,80mg,120mg and 160mg dose groups for safety evaluation.In the second part, two cohorts will be included and 110 ROS1 patients will be enrolled. Except for the PK induction period, all patients will receive oral administration of SAF189s once a day for a continuous period of 21 days.
10136467|NCT04237714|Experimental|IBI-based automated support|Internet-based intervention with automated support by the system. It consistes in phone text messages twice a week for users. The content of the messages focuses on motivating and reminding users to complete the activities proposed in the program and reviewing the treatment contents. Additionally an automatic email is send if participants have not access the program for a week. The program also provides continuous feedback to users through transversal tools.
10136468|NCT04237714|Experimental|IBI-plus human support|In this condition, the participants receive automated support explained above and additionally human support for a maximum of 5 minutes that consist in a weekly phone call provided by a psychologist. The content of phone calls is related with resolve questions or doubts about the use and clinical content of the IBI and also motivating and reminding the importance to complete activities in the program.
10136469|NCT04237714|No Intervention|Control group|Waiting list control group.
10136470|NCT04237818|Placebo Comparator|Placebo drink|
10136471|NCT04237818|Experimental|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|
10136472|NCT04237961|Experimental|Upper third interference|Botox & brow lift
10136473|NCT04237961|Experimental|Middle third|Botox and fat injection
10136474|NCT04237961|Experimental|Lower third|Suspension suture
10136475|NCT04238026|Experimental|Distal radial artery approach|Puncture in the snuff box area of the arm with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
10136476|NCT04238026|Active Comparator|Proximal radial artery approach|Puncture in the ventral side of the arm (2 cm proximal to the styloid apophysis) with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
9519637|NCT03285022|Active Comparator|Conventionel glass ionomer|Conventional glass ionomer used as restoration for posterior teeth in case of partial caries removel
10136477|NCT04237740|Experimental|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
10136478|NCT04237922||Clopidogrel 75 mg|Reference group
10136479|NCT04237922||Prasugrel 10 mg|Exposure group
10184313|NCT03756298|Experimental|Combination|Atezolizumab + capecitabine combination arm
10184314|NCT03756298|Active Comparator|Control|Capecitabine alone arm
10136480|NCT04237662|Experimental|Test Group|"Root Instrumentation + Enamel Matrix Derivative Application~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
10136481|NCT04237662|Active Comparator|Control Group|"Root Instrumentation~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour."
10136482|NCT04237935||Clopidogrel 75 mg|Reference group
10136483|NCT04237935||Ticagrelor 90 mg|Exposure group
10136484|NCT04237948|Active Comparator|physical therapy plus REAL tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.~Real Cerebellar tDCS will be applied for 10 days of time."
10136485|NCT04237948|Placebo Comparator|physical therapy plus SHAM tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.~Sham Cerebellar tDCS will be applied for 10 days of time."
10136486|NCT04237610||Bipolar disorder type I|
10136487|NCT04237610||Bipolar disorder type II|
10136488|NCT04237610||healthy controls|
10136489|NCT04237597|Experimental|K-877 & CSG452|K-877 Single dose on Day 1 and Day 15 CSG452 Repeat dose on Day 2 Through Day 15
10136490|NCT04237454|Experimental|Infrared Imaging undertaken|
10136491|NCT04237519|Experimental|SFL training|"Practice recommendation 3 times per week:~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).~Cognitive exercises: minimum of 15 min."
10136492|NCT04237519|Active Comparator|Active control training|"Practice recommendation 3 times per week:~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).~Cognitive exercises: minimum of 15 min."
10136493|NCT04237532|Experimental|Intranasal Dexmedetomidine|
10136494|NCT04237532|Experimental|Sublingual Dexmedetomidine|
10136495|NCT04237675||regional anesthesia|
10136496|NCT04237675||general anesthesia|
10136497|NCT04237298|Active Comparator|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
10136498|NCT04237298|Experimental|Modified vacuum-formed retainer covering the palate|The modified vacuum-formed retainer is designed to cover the palate. It is cheaper, easier to fabricate and more esthetic. Patients will be instructed to wear the retainer 24 hours during the study period.
10136499|NCT04237246|Experimental|Once daily Tacrolimus (Advegraf)|
10136500|NCT04237285|Experimental|Lavender 15|Participant who inhalates lavender oil for 15 minutes.
10136501|NCT04237285|Experimental|Lavender 60|Participant who inhalates lavender oil for 60 minutes.
10136502|NCT04237285|Placebo Comparator|Jojoba|Participant who inhalates jojoba oil for 15 minutes.
10184315|NCT03756272|Experimental|Stellate ganglion bupivacaine block|Nervus Sympathicus block. Stellate ganglion anaesthetic block in which 7 ml of 0.5% bupivacaine will be injected next to the stellate ganglion
10184316|NCT03756272|Placebo Comparator|Placebo ganglion block|Sham Nervus Sympathicus block. Stellate ganglion sham anaesthetic block using 7 ml of 0.9 % natrium chloride (NaCl)
10184317|NCT03756246|Experimental|Depression Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
9694652|NCT04786613|Active Comparator|20 mg, 1.0% hyaluronic acid injection groups|In the first group, 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.
10184318|NCT03756246|Active Comparator|Healthy Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
10184319|NCT03756233|Active Comparator|Remifentanil gradually withdrawal group|20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes.
10184320|NCT03756233|Active Comparator|Remifentanil immediately stop group|The control group stopped remifentanil 10 minutes before the end of the operation.
10184321|NCT03756220|Experimental|Treatment|Combination therapy of vitamin C and thiamine for 2 days.
10184322|NCT03756220|Placebo Comparator|Control|Normal Saline Solution
10184323|NCT03756207|Experimental|Multidisciplinary Therapy|Multidisciplinary bladder-preservation therapy: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
10184324|NCT03756194|Experimental|Experimental|"Participants will utilize the socially-assistive robot with a CARESSES cultural competence solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
10184325|NCT03756194|Other|Control arm 1|"Participants will utilize the socially-assistive control robot with an alternative CARESSES solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
10184326|NCT03756194|No Intervention|Control arm 2|"Participants will be receiving conventional human care with no robot intervention.~Baseline assessments will be conducted as soon as participants are recruited and allocated to the study arm. Follow-up assessments will be conducted in two weeks after the baseline data collection."
10187707|NCT03723421|Experimental|Rapid Injection Group Without Aspiration|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position by rapid injection technique without aspiration.
10187708|NCT03723421|Experimental|Control|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position with the standard injection technique.
9969042|NCT01286116|Experimental|Treatment|Parachute implant
10136503|NCT04237168||DLBCL patients|newly diagnosed DLBCL (de novo, all ages) patients treated with RCHOP (first-line treatment regimen)
10136504|NCT04237428|Experimental|hCD19 CAR-T cells Infusion|
10136505|NCT04237337||serious cancer ICSRs (cases)|
10136506|NCT04237337||other serious reactions ICSRs (non-cases)|
10136507|NCT04237363|Experimental|Exercise|Walk training
10136508|NCT04237389|Active Comparator|Ablation Index guided catheter radiofrequency ablation|30 patients, who undergo Ablation Index (AI) guided catheter RF ablation
10136509|NCT04237389|Active Comparator|Thoracoscopic surgical epicardial ablation|"30 patients, who undergo thoracoscopic ablation using Box-lesion set"
10136510|NCT04237376||Treatment Arm A: CHB Mothers treated with TAF during Pregnancy|120 pregnant women with double positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL were recruited from all four treatment centers. Mothers were enrolled and observed from gestational week 24-28 until postpartum week 28, and treated with TAF (25mg oral daily) from gestational week 28 until delivery (if the liver function is significantly abnormal after delivery, that is, ALT ≥ 5 × Upper Limit of Normal (ULN), the oral antiviral drug can be continued according to the wishes of the pregnant woman and the test results). All babies were given 3 HBV vaccines (0, 1, 6) and 1 routine Hepatitis B immunoglobin (HBIG) after birth. All babies were followed up to 2 years. According to the mother's wishes, if the mother agrees to collect breast milk and determine TAF concentration, breast milk was collected every day, and continuously collected 5-7 days for TAF concentration measurement. The time of last TAF dose taken as well as the time between milk collection and delivery was recorded.
10136511|NCT04237376||Comparative Arm C: CHB Pregnant Mothers|This arm C consists of 360 cases of pregnant women with HBsAg and HBeAg double-positive, and HBV DNA level ≥ 2 × 10^6 IU/mL. The mothers in this historical cohort did not receive any antiviral treatment during their pregnancy. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
10136512|NCT04237376||Comparative Arm B: CHB Pregnant Mothers treated with TDF|This retrospective cohort arm B consists of 120 cases of pregnant women with double-positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. Pregnant mothers were treated with TDF (300mg oral daily) starting from gestational week 28 and discontinued the drug at delivery. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
10136513|NCT04237415|Experimental|EMG biofeedback group|
10136514|NCT04237415|No Intervention|control group|
10136515|NCT04237493|Experimental|Low-dosage therapy|
10136516|NCT04237493|Active Comparator|Regular-dosage therapy|
10136517|NCT04237558|Active Comparator|Vaginal hysterectomy|Removal of uterus through vagina in absence of prolapse
10136518|NCT04237558|Active Comparator|Laparoscopic hysterectomy|Key hole surgery through small incisions of the abdomen
10136519|NCT04237324|Experimental|NAFL group|One side of the patient face has been therapied by 1565nm fiber nonablative fractional laser(Lumenis Co., Yokneam, Israel).
10136520|NCT04237324|Active Comparator|FMR group|Another side of the patient face has been therapied by FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
10136521|NCT04237402|Other|Intra individual|Before and after pregnancy, hair follicles will be analysed
10136522|NCT04237272|Active Comparator|Pod System|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
10136523|NCT04237272|Active Comparator|Customizable Tank|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week sampling period.
10136524|NCT04237272|Active Comparator|Control|Participants assigned to this arm will not receive any e-cigarette
10136525|NCT04237571|Experimental|CANE Adult Participants|This sample population consists of an active intervention group of prior Tanglewood to Table walking program adult participants.
10136526|NCT04237506|Experimental|Intervention group|All participants in this group will take the one-hour ballet dance class twice per week for six weeks
10136527|NCT04237259|Experimental|Parent-administered TCM massage group|Parents of subjects in the parent-administered TCM massage group (n=30) will attend 2 training sessions (5 hours in total) to learn and practice the parent-administered TCM massage for ADHD before treatment starts. The parents will be told to practice the TCM massage on their child every 2 days for 2 months.
10136528|NCT04237259|Active Comparator|Parent-child interaction group|Parents in the parent-child interaction group (comparison group, n=30) will attend a 3-hour training course on line and spend extra time on interacting with their child at home.
10136529|NCT04237129|Experimental|Gan & Lee Insulin Aspart|100 units/mL, 3 ml prefilled pen
10136530|NCT04237129|Active Comparator|NovoRapid® Insulin Aspart|"Product approved and marketed in the EU~FlexPen100 units/mL prefilled pen"
10136531|NCT04237129|Active Comparator|NovoLog® Insulin Aspart|"Product approved and marketed in the US~FlexPen100 units/mL prefilled pen"
10136532|NCT04237142|Experimental|Eligible patients who had consented to participate|Eligible patients who had consented to participate to the study, namely parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week with cervical dilation < 4cm and without known uterine malformation, fetal malformation, placenta previa or abundant metrorrhagia. Patients underwent vaginal swabbing and blood sample collection at the admission.
10136533|NCT04237103|Experimental|methotrexate|Methotrexate once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months after Methotrexate therapy for 6 months.
10136534|NCT04237103|Placebo Comparator|placebo|Placebo once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months afterplacebo therapy, for 6 months.
10187709|NCT03723408|Other|Single Arm post-approval study|Single Arm post-approval study.
9519638|NCT03285009|Other|Training intervention|See information elsewhere
10136535|NCT04237038|Experimental|laparoscopic Nissen fundoplication short gastric vessel divi|Randomized clinical trial conducted in forty patients submitted to short gastric vessel division (SGVD) forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life.
10136536|NCT04237090|Active Comparator|Diphenhydramine + placebo|"Diphenhydramine 50 mg intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion.~Lactose tablet 100 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water."
10136537|NCT04237090|Experimental|Cetirizine + placebo|"Cetirizine tablet 10 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water.~1 milliliter of sodium chloride 0,9 percent intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion."
10136538|NCT04236817|Experimental|Pre-packed blisters for distribution of medications|Patients in the intervention group received prescriptions pre-packaged in individual packets that were delivered by the pharmacy.
10136539|NCT04236817|Placebo Comparator|Routine distribution of medications|Patients in the control group continued to receive medications from pharmacies as they did prior to enrollment.
10136540|NCT04236895|Active Comparator|Lantus ® US|Insulin glargine (Lantus®, product approved and marketed in the USA (US RLD)), 100 U/mL in 3 mL pre-filled pens
10136541|NCT04236895|Active Comparator|Lantus ® EU|Insulin glargine (Lantus®, product marketed in Germany (EU RP)), 100 U/mL in 3 ml pre-filled pens
10136542|NCT04236895|Experimental|Gan & Lee Insulin Glargine|Insulin glargine 100 U/mL in 3 mL pre-filled pens
10136543|NCT04236934||All included patients|Patients with recurrent unilateral pleural effusion
10136544|NCT04236765|Experimental|TB infection-screening benefiting group|children VFRs under 15 years of age (which are children of immigrants and born or not in Spain) who travel to countries with an elevated incidence of TB will be screened for LTBI after their return.
10136545|NCT04236778|Experimental|Cohort 1|Cohort 1 received oral vancomycin followed by a single dose of VE303.
10136546|NCT04236778|Experimental|Cohort 2|Cohort 2 received oral vancomycin followed by a single day of 5 doses of VE303.
10136547|NCT04236778|Experimental|Cohort 3|Cohort 3 received oral vancomycin followed by a single day of 10 doses of VE303.
10136548|NCT04236778|Experimental|Cohort 4|Cohort 4 received oral vancomycin followed by 5 days of 10 doses daily of VE303.
10136549|NCT04236778|Experimental|Cohort 5|Cohort 5 received oral vancomycin followed by 14 days of 10 capsules daily of VE303
10136550|NCT04236778|Experimental|Cohort 6|Cohort 6 received 21 days of 10 doses daily of VE303
10136551|NCT04236778|Experimental|Cohort 7|Cohort 7 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
10136552|NCT04236778|Experimental|Cohort 8|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
10136553|NCT04236778|Experimental|Cohort 9|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
10136554|NCT04236778|Placebo Comparator|Vancomycin only|This cohort only received oral vancomycin.
10136555|NCT04236960|Experimental|18~55 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
10136556|NCT04236960|Experimental|2~17 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
10136557|NCT04236960|Experimental|7~23 mos|2 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between the first and second dose.
10136558|NCT04236960|Experimental|3 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between every two doses.
10136559|NCT04236960|Experimental|2 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. Two-month interval between every two doses.
10136560|NCT04236973|Experimental|clinical performance of the Truenat™ HCV assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the Common Technical Specifications 2009/886/EC (CTS) of the CE-IVDD and WHO TSS-10 (draft) for IVDs medical devices used for the qualitative and quantitative detection of Hepatitis C RNA.
10136561|NCT04236973|Active Comparator|comparison CE-IVD marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
10136562|NCT04236726||Non-invasive ventilation|Users of non-invasive ventilation
10136563|NCT04236726||Long term tracheostomy ventilation|Long term tracheostomy ventilated patients
10136564|NCT04237077|Experimental|"Group with telephone coaching program ."|subjects aged 75 years or more living at home, with telephone coaching program
10136565|NCT04237077|Active Comparator|"Group without telephone coaching program."|subjects aged 75 years or more living at home, without telephone coaching program
10136566|NCT04236921|Experimental|Treatment A|1 x DopaSnap® tablet, administered under fasting conditions.
10136567|NCT04236921|Active Comparator|Treatment B|1 x RLD of CD-LD tablet administered under fasting conditions.
10136568|NCT04236921|Experimental|Treatment C|Test - fed 1 x DopaSnap® tablet , administered under fed conditions.
10136569|NCT04236921|Experimental|Treatment D|DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.
10136570|NCT04236921|Experimental|Treatment E|½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose
10136571|NCT04236700||beach workers|"Workers must undergo clinical examinations of the upper and lower lips, performed by previously calibrated researchers, through semi-technical inspection and palpation maneuvers, in order to identify injuries. Photo cameras can be used to improve the visibility of the lips using the image enhancement feature, to confirm the diagnosis. The clinical examination will include: dryness, atrophy, scaly lesions, lip swelling, erythema, ulcerations, cloudy demarcations between the vermilion of the lip and skin, demarcated folds along the lip, white spots or plaques, crusts, stained or pale areas.~They should be evaluated with the application of a previously validated questionnaire containing information related to personal data, information on occupation and health was completed according to the responses of the volunteers. The OHIP-14 quality of life questionnaire will be applied together"
10136572|NCT04236583|Experimental|Telehealth|Eligible patients will be given the option to consent to having one virtual visit with their primary care physician within four weeks after discharge from the hospital. Usual follow-up care will occur during this visit.
10136573|NCT04236557|Experimental|Intervention|
10136574|NCT04236557|Placebo Comparator|Wait-list Control|
10136575|NCT04236440|Experimental|Part A: A1A2+Part B+Part C|"Part A: Participants will receive a single dose administration of BAY2586116 (A1) in treatment period 1, and a single dose administration of placebo (A2) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
10136576|NCT04236440|Experimental|Part A: A2A1+Part B+Part C|"Part A: Participants will receive a single dose administration of placebo (A2) in treatment period 1, and a single dose administration of BAY2586116 (A1) in treatment period 2.~Part B: After successfully completing Part A, participants will proceed to Part B of the study.~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3).~Part C: Participants completing Part B will be invited to participate in an additional treatment period with a single dose BAY2586116 (C)."
10136577|NCT04236362|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10136578|NCT04236453|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
10136579|NCT04236453|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COB] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
10136580|NCT04236479|Experimental|Bone marrow-derived mesenchymal stromal cell (BM-MSC)|The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD.
10136581|NCT04236674|No Intervention|No intervention|
10136582|NCT04236674|Experimental|Buzzy|Thermomechanical device for periprocedural analgesia
10136583|NCT04236674|Experimental|Music Selection|Patient specified music selection for procedural room
10136584|NCT04236674|Experimental|Buzzy and Music Selection|A combination of use of the Buzzy device and patient specified music selection
10136585|NCT04236661|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
10136586|NCT04237064||Patients with carotid artery stenosis|In this study, patients in the age of > 18 year will be included that are scheduled for an endarterectomy procedure at CZE.
10136587|NCT04236401|Other|electrosurgery will be used inanterior abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall electrosurgically.
10136588|NCT04236401|Other|scalpel will be used in abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall sharply.
10136589|NCT04236570|Other|Pain tests with the standardized protocol|This arm will consisted of pain tests using the standardized protocol (thermode(hot plate) and cold water bath)). The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the standardized protocol, the TS will consisted of a noxius heat stimulus generated by a thermode (hot plate), applied for two minutes on the non-dominant anterior forearm. The CS will consisted of a cold pressor test (CT), wherein participants immersed their dominant forearm in a cold water bath for two minutes.
10136590|NCT04236570|Other|Pain tests with the TENS protocol|This arm will consisted of pain tests using the TENS protocol. The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the TENS protocol, the TS will consisted of a noxius electrical stimulus generated by TENS, applied for 5 seconds on the non-dominant knee at a frequency of 1 Hz and 5 Hz. The CS will consisted of a noxius electrical stimulus generated by TENS' applied for 120 seconds on the non dominant knee and ankle at a frequency of 2 Hz
10136591|NCT04236622||Health|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
10136592|NCT04236622||Peri-implantitis|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
10136593|NCT04236323|Experimental|not used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair not used intraoperative remifentanil infusion
10136594|NCT04236323|No Intervention|used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair used intraoperative remifentanil infusion maintaining target concentration of 2-6ng/ml
10136595|NCT04236492||Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
10136596|NCT04236648|Other|Minimally-invasive non-surgical therapy (MINST)|Study treatment
10136597|NCT04236505|Experimental|ACT group intervention|4 weekly 2hour group therapy interventions drawing from an Acceptance and Commitment Therapy (ACT) based protocol.
10136598|NCT04236505|Experimental|Mindfulness skills group intervention|4 weekly 2 hour group therapy interventions drawing from an Mindfulness based stress reduction (MBSR) based protocol
10136599|NCT04236505|Placebo Comparator|Wait list control group|Wait list control group who at the time of the experimental group interventions are not attending a group and receiving treatment as usual. This group are offered a Mindfulness skills group intervention after the follow up data has been collected.
10136600|NCT04236427|Experimental|Treatment Group|Chinese Medicine of Angong Niuhuang Wan
10136601|NCT04236427|Placebo Comparator|Placebo Group|Placebo of Angong Niuhuang Wan
10136602|NCT04236349||CO1TB: observational|patients with pulmonary and extrapulmonary tuberculosis
10136603|NCT04236349||CO2TB: immunogenetics|"patient with pulmonary and extrapulmonary tuberculosis and meet the following criteria:~informed consent form signed by the patient or by the representative of parental authority~affiliation to social security (beneficiary or assignee)~HIV negative"
10136604|NCT04236310|Experimental|SHR6390+Anastrozole+Pyrotinib+Trastuzumab±Ovarian Suppression|
10136605|NCT04236466|Experimental|hyrax group|cleft lip and palate patients with hyrax appliance
10136606|NCT04236466|Experimental|haas group|cleft lip and palate patients with haas appliance
10136607|NCT04236544|Experimental|PExMS and DECIMS-Wiki|After allocation, the intervention group will receive access to PExMS and DECIMS-Wiki for a four-week period. The former is a multimedia website providing experiential information. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
10136608|NCT04236544|Active Comparator|DECIMS-Wiki|After allocation, the control group will receive access to the DECIMS-Wiki for a four-week period. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
10136609|NCT04236219|Experimental|ALLN-346|ALLN-346
10136610|NCT04236219|Placebo Comparator|Placebo|Placebo
10136611|NCT04236752|Experimental|Single arm radiotherapy|HDR Brachytherapy Boost of 15Gy to the prostate followed by Stereotactic Ablative Body Radiation (SBRT) 25 Gy in 5 fractions, once weekly to prostate, SVs and pelvic lymph nodes + 6-18 months of ADT
10136612|NCT04236232||Patients who will be diagnosed as Subclinical Hypothyroidism|50 pt who will be diagnosed as Subclinical Hypothyroidism by elevated level of TSH (TSH: >4.5 mu/l) and normal T4
10136613|NCT04236232||Patients with normal thyroid function|50 pt with normal thyroid function (TSH &T4)
10136614|NCT04236193||SIRVA|Subjects with shoulder pain >7 days after vaccination
10136615|NCT04236193||Controls|Subjects from a prospective influenza vaccine study
10136616|NCT04236687|Experimental|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
10136617|NCT04236687|Active Comparator|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected microspheres will slow the blood flow to the prostate.
10136618|NCT04236713|Experimental|Dietary intervention 1|
10136619|NCT04236713|Experimental|Dietary intervention 2|
10136620|NCT04236037|Active Comparator|Ultrasound-guided thoracentesis|Ultrasound guided thoracentesis
9519639|NCT03284983|Experimental|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
10136621|NCT04236037|Experimental|Ultrasound-guided pleural biopsy and thoracentesis|Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis
10136622|NCT04236115|Active Comparator|Articaine 4% with 1:00.000 Adrenaline|if the patient was in articaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
10136623|NCT04236115|Active Comparator|Prilocaine with 3% Felypressin (0.03 I.U. per ml)|if the patient was in prelocaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
10136624|NCT04236128|Experimental|Intervention Group|The intervention group will receive the same usual care as the control group plus be enrolled in the integrated discharge monitoring system.
10136625|NCT04236128|Active Comparator|Control Group|The control group will receive usual follow up care that is currently provided at the 3 participating centres.
10136626|NCT04236089|No Intervention|mirror therapy of healthy adults|Traditional mirror therapy in electroencephalography of healthy adults.
10136627|NCT04236089|Experimental|robotic mirror therapy of healthy adults|Robotic mirror therapy in electroencephalography of healthy adults.
10136628|NCT04236089|No Intervention|mirror therapy of stroke patients|Traditional mirror therapy in electroencephalography of stroke patients.
10136629|NCT04236089|Experimental|robotic mirror therapy of stroke patients|Robotic mirror therapy in electroencephalography of stroke patients.
10136630|NCT04236167|No Intervention|Control half of scar|one half of the scar will receive standard scar treatment with topical products and pressure garments, but no ablative fractional CO2 laser
10136631|NCT04236167|Experimental|Laser treatment half of scar|The other half of the scar will receive standard scar treatment with topical products and pressure garments and, in addition, will receive ablative fractional CO2 laser treatment
10136632|NCT04236024|Experimental|Experimental group|The students in this group will learn medication knowledge by using board game.
10136633|NCT04236024|Active Comparator|Comparison group|The students in this group will learn medication knowledge through tradition lecture.
10136634|NCT04236180|Active Comparator|Intervention Group|Patients enrolled in the Specialised Paediatric Palliative Care (SPPC) programme at the University Children's Hospital Zurich.
10136635|NCT04236180|No Intervention|Comparison Group|Patients treated at the Children's Hospital Aarau, University Children's Hospital Basel, and the University Hospital Inselspital Bern.
10136636|NCT04235881|Experimental|MBSR group|Enforcement of the standardized program Mindfulness-Based Stress Reduction
10136637|NCT04235881|Experimental|App group.|Enforcement of the emotional regulation program based on mindfulness (ERM) through the mobile phone application REM volver a casa
10136638|NCT04235881|No Intervention|Control group|Usual care
10136639|NCT04235985|Other|All time points|
10136640|NCT04235751|Experimental|Immediate Coaching Intervention|Subjects will receive 6 professional coaching sessions
10136641|NCT04235751|Experimental|Delayed Coaching Intervention|Subjects will receive no coaching for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
10136642|NCT04235842|No Intervention|Control Group (CG)|The CG will receive the standard indications routinely provided by the hospital which consists in information about practice of regular physical activity according to World Health Organization. A leaflet with illustrations and indications will be provided and will be explained by the principal investigator.
10136643|NCT04235842|Experimental|Moderate-intensity continuous exercise training group (GMICT)|The GMICT will be submitted to a physical exercise program in which the aerobic component will be a moderate-intensity continuous exercise training, performed at 60% of the heart rate reserve, two days a week, for 30 minutes.
10136644|NCT04235842|Experimental|High-intensity interval training exercise group (GHIIT)|The GHIIT will be will be submitted to a physical exercise program in which the aerobic component will be a high-intensity interval exercise training, performed in a protocol consisted of four one-min sprint at 90% of the heart rate reserve, alternated with one-min rest (at week 1) and progressing until reach 10 bouts of one-min sprint alternated with one-min rest.
10136645|NCT04235946|Experimental|accompanied and adapted water polo program|"16 and 20 aqua polo sessions (adapted water polo) over a period of 20 weeks, at the rate of one session per week at the Cercle des Nageurs de Marseille (CNM). They will be divided into 3 cycles imitating the preparation of the season of a high-level athlete: a first cycle intended for physical preparation, a second cycle intended for practical learning (technique and tactics) and the third cycle for preparation of a mini tournament.~Each session will be organized as follows: 1 hour of training in the water followed by 30 min of debriefing as a team or individually with the coach. The announced duration of the session will be 2 hours, transport and changing rooms included."
10136646|NCT04235816|Active Comparator|Group 1|AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age.
10136647|NCT04235816|Placebo Comparator|Group 2|Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age.
10136648|NCT04236258|Active Comparator|Nifedipine|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start nifedipine extended release 30 mg daily as their starting antihypertensive.
10136649|NCT04236258|Active Comparator|Enalapril|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start enalapril 10 mg daily as their starting antihypertensive.
10136650|NCT04236011|Experimental|GC012F treatment|BCMA+ R/R multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
10136651|NCT04235998||Systematic lung ultrasound|Patients with unilateral pleural effusion of unknown course
10136652|NCT04235868|Active Comparator|control group|
10136653|NCT04235868|Experimental|experimental group|
10136654|NCT04236076|Experimental|PulseHaler™|Patients will receive PulseHaler for home treatment
10136655|NCT04236076|Sham Comparator|Sham PulseHaler - CONTROL group|Patients will receive Sham device for home treatment
10136656|NCT04235920||Impaired Cognition|First group was cognitively impaired test with MoCA score of 25 or less.
10136657|NCT04235920||Preserved cognition|The second group was cognitively preserved with MoCA score of higher than 25.
10136658|NCT04235933|Experimental|Tai Ai(RC18) 80mg|·Experimental: Tai Ai 80mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
10136659|NCT04235933|Experimental|Tai Ai(RC18) 160mg|·Experimental: RC18 160mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
10136660|NCT04235933|Experimental|RC18 240mg|·Experimental: RC18 240mg Injection: subcutaneous injection on abdomen; Intervention: Biological: RC18
10136661|NCT04236063||Haematological malignancy|Patients with haematological malignancy
10136662|NCT04235803|Experimental|Telemedicine|Patients in the telemedicine arm will have their post-operative week one visit via a telemedicine portal.
10136663|NCT04235803|No Intervention|Routine|Patient in the routine arm will have their post-operative week one visit in clinic.
10136664|NCT04235790|No Intervention|Medical Student or Resident|Subjects will perform simulated central venous catheters (CVC) insertions.
10136665|NCT04235790|Other|Novice and Expert IBP Teachers|Expert teachers will be identified based on years as faculty, number of supervised procedures, prior teacher awards, and participation in IBP teaching at international conferences. Novice teachers will include those that have performed less than 50 CVCs. Teachers will supervise 3 simulated central venous catheters (CVC) insertions with increased complexity while wearing an eye tracking device.
10136666|NCT04235972|Other|Arthrodesis surgery patients|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
10136667|NCT04235959|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
10136668|NCT04235959|Placebo Comparator|Placebo|Placebo administered SC.
10136669|NCT04235647|Experimental|Study group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
10136670|NCT04235647|Active Comparator|Control group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
10136671|NCT04235478|Experimental|Cervical interlaminar epidural steroid injecion|Floroscopy-guided cervical interlaminar epidural steroid injecion will be applied to the patients with cervical radiculopathy related neck and arm pain
10136672|NCT04235426|Experimental|surgical group.|30 patients went to the surgical release of carpal tunnel.
10136673|NCT04235426|Experimental|medical group.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
10136674|NCT04235426|Experimental|injection group.|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
10136675|NCT04235452||Epileptic myoclonus|Juvenile Myoclonic Epilepsy and Progressive Myoclonic Epilepsy
10136676|NCT04235452||Non-epileptic myoclonus (secondary)|Post hypoxic myoclonus, Post ischemic stroke myoclonus, Hepatic, Chronic kidney disease, and Drug induced myoclonus
10136677|NCT04235387||Robotic prostatectomy|All patients undergoing robotic assisted prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
10136678|NCT04235387||Laparoscopic prostatectomy|All patients undergoing standard laparoscopic prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
10136679|NCT04235621||FSGS/TR-MCD|Patients with FSGS/TR-MCD
10136680|NCT04235621||Diabetic Nephropathy (DN)|Patients with DN
10136681|NCT04235595|Experimental|Connective Tissue Manipulation|The participants were administered CTM by a physiotherapist with 11 years of experience in the application from the point at which their menstrual cycles had ended to the beginning of the next cycle. Another assessment was made immediately after the treatment and this was repeated at the second, third and fourth menstrual cycles. The CTM took an average of 20-30 minutes to complete.
10136682|NCT04235595|Experimental|Transcutaneous Electrical Nerve Stimulation|Following the assessment made in the participants' first menstrual cycle, on the most painful day of their second cycle (1st or 2nd day of the cycle), high-frequency TENS was applied at a frequency of 120 Hertz, at intervals of 100 µsn for 20 minutes. The intensity of the current was increased until the participant felt it.
10136683|NCT04235465||Dyslexia Group|30 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7-day interval by two evaluators
10136684|NCT04235465||Healthy Control Group|30 healthy children will be included. Dynamic Gait Index will be performed.
10136685|NCT04235699|Experimental|Ketogenic Diet|This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood [3-OHB] ≥0.5 mM.
10136686|NCT04235699|Experimental|Low-fat mixed Diet|This arm will be provided food consisting of ~25% fat, and the remaining calories from carbohydrate (~55% after accounting for protein at ~20%).
10136687|NCT04235400||patient with dry eye disease|
10136688|NCT04235569|Experimental|Group I|"a group of 25 patients received 5mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period."
10136689|NCT04235569|Experimental|Group II|"a group of 25 patients received 3mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period."
10136690|NCT04235556||Historic cohort|Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.
10136691|NCT04235556||Prospective cohort|All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.
10136692|NCT04235673|Experimental|melatonin|melatonin oral drops; 3 mg/kg/day for 15 days
10136693|NCT04235673|Placebo Comparator|placebo|oral drops manufactured to mimic melatonin
10136694|NCT04235361||EVD patients|"The samples of all subjects (male, female, adults and children) meeting the WHO case definition of suspected and probable EVD case eligible for real time RT-PCR assay, according to the currently used case definition in DRC, will be tested by differential RPA."
10184327|NCT03756181|Experimental|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of compassion: self-kindness, mindfulness, and common humanity, and will work on soothing the processes of self-criticism, self-neglect and perfectionism that are believed to withhold upon experiencing psychological distress. There will also be sessions dedicated to incorporating self-compassion in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
10184328|NCT03756181|Active Comparator|Five-week Mindfulness-based Stress Reduction program (MBSR5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator will perform a brief check-in and may discuss the student's experience within the course of the session. These discussions will reinforce the guiding principles of meditation: awareness, non-judgment and acceptance and will work on automatic mental processes that are believed to be at the root of experiencing psychological distress. There will also be sessions dedicated to incorporating mindfulness into daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
10184329|NCT03756168|Experimental|Treatment subjects|Single group of subjects with will have the treatment of a 1060 nm diode laser administered to them
10184330|NCT03756142||Multiple sclerosis patients|Analysis of orthostatic posture, initiation of walking and walking in MS patients with an EDSS between 0 and 4 (included) by a motion analysis system
10184331|NCT03756142||Healthy volunteers|Analysis of orthostatic posture, initiation of walking and walking in a group of healthy volunteers
10184332|NCT03756116|Experimental|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
10187710|NCT03723395|Experimental|Part A|Tucatinib plus Itraconazole
9519640|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
10136695|NCT04235270|Experimental|Group 1 (Bioequivalence Part)|Participants will receive Treatment A (single oral dose of an fixed dose combination [FDC] of macitentan/tadalafil [10 milligram [mg]/40 mg] in fasted conditions [test]) or Treatment B (single oral dose of a free combination of 10 mg macitentan and 40 mg tadalafil in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment B or Treatment A on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
10136696|NCT04235270|Experimental|Group 2 (Food-effect Part)|Participants will receive Treatment C (single oral dose of an FDC of macitentan/tadalafil [10 mg/40 mg] in fed conditions [test]) or Treatment D (single oral dose of an FDC of macitentan/tadalafil (10 mg/40 mg) in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment D or Treatment C on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
10136697|NCT04236206|Experimental|SMS Recipients|• Mobile phone SMSs will be sent to the intervention group with the aim of improving medication adherence and knowledge about diabetes, its complications, diet and physical activity.
10136698|NCT04236206|No Intervention|Non-SMS Recipients|Control group with no intervention.
10136699|NCT04235283|Experimental|Group I|Primary total knee replacement by pinless navigation and minimally invasive technique
10136700|NCT04235283|Active Comparator|Group II|Primary total knee replacement by traditional jig and minimally invasive technique
10136701|NCT04235296|Active Comparator|control group|epidermal growth factor
10136702|NCT04235296|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
10136703|NCT04235894||Patients undergoing GI endoscopy at Osijek University Hospital|Observational study. A total of 130 consecutive patients undergoing gastrointestinal endoscopy were included. The anesthesia was provided with propofol, starting with 0,5 mg/kg, and titrated until a patient was unresponsive to painful stimuli and maintaining spontaneous breathing. The blood pressure, pulse and Bispectral index values were measured in 6 defined points. On the emergence from anesthesia, the patient's facial expression was rated numerically by the investigator.
10136704|NCT04236050|Experimental|rocuronium is administered via continuous infusion|"40 patients. General anesthesia is maintained with propofol and remifentanil, with standard anesthetic monitoring, bispectral index (BIS) and train-of-four(TOF). In experimental group, rocuronium was administered via continuous infusion so that theTOF ratio was 5%. Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
10136705|NCT04236050|Active Comparator|rocuronium is administered in bolus doses|"40 patients. General anesthesia was maintained with propofol and remifentanil, with standard anesthetic monitoring, BIS and TOF. In this group, rocuronium was administered in separate bolus doses with the TOF ratio of 5%.~Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
10136706|NCT04235231|Experimental|Lateral tilt bed|Bed tilting (15° lateral tilt, original product brand name LINET Eleganza 5)
10136707|NCT04235231|Experimental|Body positioning|Manual positioning of body by nurse.
10136708|NCT04236102|Experimental|EGFR, KRAS, BRAF Lung adenocarcinoma LBC|Will use residual material from existing LBC cytology samples sent to the laboratory. Routine testing will take priority. Cases identified as non small cell lung carcinoma will have the residual LBC sample tested on the Idylla platform for EGFR, KRAS and BRAF. The EGFR, KRAS and BRAF mutation results obtained using the routine diagnostic procedure (FFPE samples) will be compared to those produced using the LBC samples.
10136709|NCT04236102|Experimental|KRAS Pancreatic adenocarcinoma|Will involve testing archived FFPE clot samples from confirmed pancreatic adenocarcinoma patients since 2014 (Approximately 20 cases per year). KRAS testing will be performed using the Idylla platform to establish if there is a KRAS codon 12 mutation present in 94% percent of the cases reported at RCHT. Patients will have consented to the use of their tissue at the time of procedure. Prospectively new patients diagnosed with pancreatic adenocarcinoma will have KRAS testing on the FFPE clot made as part of the routine diagnostic work up and KRAS testing on the LBC sample.
10136710|NCT04236102|Experimental|EGFR, KRAS, BRAF Blood plasma|Will involve a blood sample being taken at the time of the procedure from patients that have a clinical suspicion of having lung or pancreatic cancer. The single blood sample will be taken from the cannula inserted for the procedure. The blood sample will be processed using the Biocartis Idylla ™ circulating tumour cell cartridges (EFGR, KRAS and BRAF for lung and KRAS for pancreas).
10136711|NCT04235244|Experimental|upper right abdomen|5 minutes before and after application to the right upper abdominal region. local cold application
10136712|NCT04235244|Experimental|upper left abdomen|Thermomechanical-analgesia device will be operated 30 seconds before the injection in the right lower abdominal region and the device will be injected by sliding the device to the side of the selected region during the injection,
10136713|NCT04235244|Experimental|lower left abdomen|Coolant spray will be applied to the upper left abdominal region for 15 sec.
9969043|NCT01286142||Influenza treatment with oseltamivir|Patients 24 months of age and younger initially presenting with confirmed or presumed influenza A or B infection treated with oseltamivir.
10136714|NCT04235244|No Intervention|lower right abdomen|SC injection will be applied to the left lower abdominal region without any cold application.
10136715|NCT04235166||Patient cohort|Different risk score was used to assess the prognosis of acute upper gastrointestinal bleeding in cirrhosis.
10136716|NCT04235075|Experimental|Pregnancy volunteer subjects|Subjects who will agree to participate in the study will be pregnant women referred to the Grenoble Alpes University Hospital for expert fetal cardiac ultrasound examination who have not revealed any abnormalities.
10136717|NCT04235088|Experimental|Somatosensory intensive intervention|
10187711|NCT03723395|Experimental|Part B|Tucatinib plus Rifampin
9969044|NCT01286142||Influenza prophylaxis with oseltamivir|Patients 24 months of age and younger prescribed oseltamivir for influenza prophylaxis
10136718|NCT04236284|Experimental|Home-based tDCS + Prolonged Exposure Therapy|Participants will come in person to the clinic office to complete the baseline visit and the in-person training for the use of both home-based self-administered tDCS and the home-based telehealth device (iPad) for the PE sessions. They understand that they will start the sessions of tDCS once they start the in vivo and imaginal exposures assignments at home. They will self-administer (under televideo supervision) the tDCS session before doing in vivo and/or imaginal exposures assignments. The participants will be remotely supervised by trained research staff at each stimulation to ensure the technique is correct and to monitor any adverse events. We will provide secure videoconferencing software (e.g., WebEx) and ensure the participants are comfortable using the telehealth software.
10136719|NCT04235439|Experimental|Gan & Lee Insulin Lispro Injection|Insulin lispro, 3 mL cartridge in prefilled pen, 100 units/mL (U-100)
10136720|NCT04235439|Active Comparator|EU - approved Humalog ®|Insulin lispro (product approved and marketed in the EU), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
10136721|NCT04235439|Active Comparator|US - licensed Humalog ®|Insulin lispro (product approved and marketed in the US), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
10136722|NCT04235660|Active Comparator|Yttrium-90 Radiation Segmentectomy|
10136723|NCT04235660|Active Comparator|Stereotactic Body Radiation Therapy|
10136724|NCT04235153||Patients with solid or hematological cancer|All the patients complete the CANUT-QVA questionnaire
10136725|NCT04235179|Experimental|SABR|Pelvic SABR for post-op endometrial cancer
10136726|NCT04235114|Experimental|Establish Imaging Time|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
10136727|NCT04235114|Experimental|Diagnostic Quality|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging once at the best time calculated from arm 1 participants. Vitals, blood sample and urine sample will be collected before imaging. Participants will be followed up for any adverse event until day 30 post administration
10136728|NCT04235114|Experimental|Establish Cold Dose|Participants will receive an i.v. injection of 1 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
10136729|NCT04235127||Catalan population|The target population consists of the dynamic cohort of all Catalan residents during the 6-year period 2014-2019. Annual total population of Catalonia is between 7.5-7.6 million, with annual rates for immigration, emigration, birth and death being ~2.5%, ~1.9%, ~0.9%, and ~0.8%, respectively. Based on these figures, we expect a maximum of ~9.1 million individuals with Catalan residency status on at least one point in time over the 2014-2019 period. However, we expect SA in Catalonia to be extremely rare before the age of 10, in line with findings that self-injurious behaviour generally occurs as from the adolescent period. We will therefore exclude cases and controls that have not reached age 10 by the end of the 2014-2019 period (i.e., ~10.9%), lowering the total expected target population to ~8.1 million.
10136730|NCT04235023|Other|OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index ≥ 15 per hour
10136731|NCT04235023|Other|non OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index < 15 per hour
10136732|NCT04234750|No Intervention|control group|no intervention
10136733|NCT04234750|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
10136734|NCT04234685|Experimental|HIPL Therapy™ group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).~The HIPL Therapy™ group will receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks. Participants will lay in a relaxed position on a therapy plinth with the light applied using the Invitalizer 2.0. The phototherapy will illuminate the affected knee for 20 minutes. In the case of bilateral knee OA, the treatment time will be doubled and applied to both knees. The knee will be positioned at a determined distance from the lamp with an intensity setting of 150 mW/cm2."
10136735|NCT04234685|Placebo Comparator|Placebo Control group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).~The placebo control group will also receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks, in the same setting as the HIPL Therapy™ group and for the same duration. However, the intensity setting will be set at 5 mW/cm2, a dosage, at which there is no therapeutic benefit expected, but the light will still be visible to the participant."
10136736|NCT04234724|Experimental|Variant|Volunteers with known ANGPTL3 variants
10136737|NCT04234724|Other|Non-variant|Healthy volunteers with no ANGPTL3 variants
10136738|NCT04234763|Experimental|T2D patients|T2D patients (n=24) will be randomized to high GI and low GI MCT randomly.
10136739|NCT04234763|Active Comparator|Healthy individuals|Healthy individuals (n=24) will be randomized to high GI MCT only.
10136740|NCT04234815|Experimental|CETA Short Session (CSS)|A single-session, 1.5-2 hour group workshop that includes psychoeducation, self-assessment, safety screening, and training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance. On this phone call they will also be asked about their use of the cognitive coping skill over the last week, and provided feedback if using it incorrectly.
10136741|NCT04234815|Active Comparator|Enhanced Treatment as Usual (eTAU)|A single-session, approximately 1-hour group workshop that includes the same psychoeducation, self-assessment, and safety screening as the experimental condition, but no training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance.
10136742|NCT04234971|Experimental|Intervention group (DBM/BMP)|Patient undergoes Alveolar bone graft with DBM/BMP
10136743|NCT04234971|Active Comparator|Control group(autologous ICBG)|Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.
9694653|NCT04786613|Active Comparator|32 mg, 1.6% hyaluronic acid injection groups|In the second group, 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.
10136744|NCT04234828||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings Sleep Device and overnight PSG
10136745|NCT04234841||Surgical Aortic Valve Replacement (SAVR)|This cohort includes patients who will be undergoing surgical aortic valve replacement
10136746|NCT04234841||Transcatheter Aortic Valve Implantation (TAVI)|This cohort includes patients who will be undergoing Transcatheter Aortic Valve Implantation
10136747|NCT04234802|Active Comparator|HEAT intervention group|Workers in the intervention group will receive the HEAT training, and supervisors in the intervention group will receive the HEAT awareness application and training on how to use it.
10136748|NCT04234802|No Intervention|Comparison group|The comparison group will not be offered HEAT trainings or the HEAT awareness application. They will be offered an alternative training on another topic.
10136749|NCT04234776|Experimental|Rapid-acting antidepressant|Subjects eligible to participate in the study will receive IM ketamine and will use 2 placebo tablets as randomized.
10136750|NCT04234776|Active Comparator|Comparator|Subjects eligible to participate in the study will receive IM saline and will use escitalopram 15 mg and aripiprazole 5 mg as randomized
10136751|NCT04234737|Experimental|Hypnotherapy|
10136752|NCT04234737|No Intervention|Control|
10136753|NCT04235049|No Intervention|In prison treatment arm|Of patients who achieved SVR, 100 inmates will be enrolled for long-term monitoring for re-infection after they have completed treatment. Patients will be seen every 6 months to test for reinfection, however they will not be subject to any medical or behavioral interventions through the study team. Limited opioid agonist therapy may be available as per the standard practice of the DOC, however syringe exchange and other harm reduction services will not be accessible to inmates, per DOC policy.
10136754|NCT04235049|Active Comparator|Community Linkage - Rapid Initiation Arm|The rapid initiation group will receive HCV medication immediately upon release from prison/jail.
10136755|NCT04235049|Active Comparator|Community Linkage - Clinic-Based Initiation Arm|The group will receive medication after attending first ANCHOR clinic visit.
10136756|NCT04235049|No Intervention|In prison - Retrospective Review|a retrospective review of de-identified available data provided by the DOC for all patients previously treated with DAAs through standard of care in the DOC will be reviewed for rates of SVR.
10136757|NCT04234789|Other|Cardiopulmonary exercising test|All patients underwent to diagnostic tests protocol
10136758|NCT04234958|Experimental|Experimental|Participants received osteopathic treatment
10136759|NCT04234958|Sham Comparator|Sham|Participants received sham therapy
10136760|NCT04234958|No Intervention|Control|Participants received no intervention
10136761|NCT04234893||Drug-coated balloon|The Patients who treated with Bingo drug-coated balloon
10136762|NCT04234997|Experimental|Suvorexant 20 mg|
10136763|NCT04234997|Placebo Comparator|Suvorexant 0mg|
10136764|NCT04234932|Experimental|Netarsudil alone|Topical application of netarsudil 0.02%
10136765|NCT04234932|Active Comparator|Netarsudil plus latanoprost|Topical application of netarsudil 0.02% with latanoprost 0.005%
10136766|NCT04235010|Experimental|Manual toothbrush|Patients used manual orthodontic toothbrush (Oral B Ortho, Procter & Gamble, USA) for four months
10136767|NCT04235010|Experimental|Genius toothbrush|Patients used genius orthodontic toothbrush (Oral B Genius 8900, Procter & Gamble, USA) for four months
10136768|NCT04234581|Experimental|Lysulin|Participants will be randomly allocated in blocks for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) per os with breakfast, lunch and dinner.
10136769|NCT04234581|Placebo Comparator|Placebo|Subjects will be instructed to take two tablets of placebo per os with breakfast, lunch and dinner.
10136770|NCT04234412|Experimental|Osteoarthritic knee patients|Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.
10136771|NCT04234503|Experimental|Ethics Quarter|Nurse managers perform 12 educational packages in web-page www.etiikanvartti.fi.
10136772|NCT04234503|No Intervention|Standard organisational ethics structures|Nurse managers continue in their standard organisational ethics structures
10136773|NCT04234711||Conventional surgical group|Patients with total pulmonary venous connection undergo conventional surgical repair
10136774|NCT04234711||Sutureless surgical group|Patients with total pulmonary venous connection undergo sutureless surgical repair
10136775|NCT04234542|Experimental|Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using a protocol developed in collaboration with BioFlexTM Laser. Each treatment will last approximately 45 minutes and will include the laser array first being applied to the skin overlying the sacral spine in a horizontal placement then in oblique placement bilaterally (red and infrared light) while a laser probe is applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light) and the focal probe will be applied to painful sites on the perineum. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. All the stages will involve use of the same array and probe placement, but at each stage the dosage will be increased according to the BioFlex protocol. During teach treatment session, women will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones.
10184333|NCT03756116|Active Comparator|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope; followed by octreotide.
10184334|NCT03756090|Experimental|Experimental group|Arm I: Palbociclib combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
10184335|NCT03756090|Placebo Comparator|Control group|Arm II: Placebo combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
10184336|NCT03756064|Experimental|Experimental group|Pyrotinib+Trastuzumab+Docetaxel +Carboplatin
10184337|NCT03756064|Placebo Comparator|Control group|Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin
10187712|NCT03723395|Experimental|Part C|Tucatinib plus Gemfibrozil
10136776|NCT04234542|Sham Comparator|Sham Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using the same protocol developed in collaboration with BioFlexTM Laser, but at an intensity of 1% output for all sites and at all stages. Each treatment will last approximately 45 minutes. At each visit, the laser array will first be applied to the skin overlying the sacral spine in a horizontal then oblique placement bilaterally (red and infrared light) concurrently with a laser probe applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light), followed by treatment at specific painful sites using the red light probe. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. Participants randomized to this group will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones while receiving the sham laser treatment.
10136777|NCT04234373|Experimental|Low Carb dietary Intervention|
10136778|NCT04234555||Provoked vestibulodynia (PVD)|Provoked vestibulodynia (PVD) is characterized by severe sharp and/or burning pain felt at the entrance to the vagina (i.e. the vulvar vestibule) when pressure is applied to this area or during attempts at vaginal insertional activities (i.e. provoked).
10136779|NCT04234555||Provoked vestibulodynia (PVD) + Vaginismus (VAG)|PVD is sometimes accompanied by intense, involuntary contraction of the PFMs3, termed vaginismus (VAG).
10136780|NCT04234555||Control|Participants matched by age (within 2 years), parity (parous vs nulliparous) and use of oral contraceptive medications (yes vs no) to women in the PVD group, with no signs and symptoms of PVD.
10136781|NCT04234321|Experimental|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
10136782|NCT04234321|Experimental|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
10136783|NCT04234321|Placebo Comparator|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
10136784|NCT04234594|Experimental|QL1203|Participants only receive QL1203, 6mg/kg on Day 1.
10136785|NCT04234594|Active Comparator|Vectibix®|Participants only received Vectibix®，6 mg/kg on Day 1.
10136786|NCT04234620||Toripalimab injection|Use of Toripalimab injection in the real world
10136787|NCT04234607|Experimental|TQB2450+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10136788|NCT04234607|Experimental|TQB2450（blank）+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+ Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10136789|NCT04234607|Active Comparator|TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib (blank) capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules (blank) 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10136790|NCT04234308|Experimental|Polyglycolic Acid Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
10136791|NCT04234308|Experimental|Chromic Gut Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
10136792|NCT04234308|Experimental|ePTFE Non absorbable suture|Periodontal and periimplant flaps closed with at least one suture with ePTFE Non absorbable suture, synthetic, 4-0. (TAGUM®)
10136793|NCT04234308|Experimental|Nylon Non absorbable sutures|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
10136794|NCT04234451|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
10136795|NCT04234451|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
10136796|NCT04234230||VAD Patients|Patients with implanted ventricular assist device in the outpatient setting
10136797|NCT04234243||HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis treated with cytoreduction and HIPEC
10136798|NCT04234243||No HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis, treated with systemic chemotherapy only
10136799|NCT04234282|No Intervention|Control Group|The control group will receive a 30-minute class on knee osteoarthritis diagnosis, prognosis, various treatment options, and will conclude with a question and answer session. This will account for the 30 minute face to face time provided in the treatment group
10136800|NCT04234282|Experimental|Manual Physical Therapy|The treatment group will receive one 30-minute session of orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment. The manual therapy and exercises are tailored to the individual based on their limitations and restrictions.
10136801|NCT04234516|Active Comparator|Buprenorphine|Sublingual buprenorphine-naloxone films
10136802|NCT04234516|Active Comparator|Morphine|Oral morphine sulphate tablets
10136803|NCT04234256|Experimental|Static exercise|The experimental group doing static exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
10136804|NCT04234256|Experimental|Dynamic exercise|This group doing dynamic exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
10136805|NCT04234256|No Intervention|Control group|Control group doing not the stretching exercise
10136806|NCT04234165|Active Comparator|Monopolar arm|monopolar cautery was used for TURBT
10136807|NCT04234165|Experimental|Bipolar Arm|bipolar cautery was used for TURBT
10136808|NCT04234152|Experimental|MV Photo-protection|Includes infants in whom the new procedure of MV separation and photo-protection will be applied. This arm will be stratified to male and female 1:1
10136809|NCT04234152|Placebo Comparator|Standard of care|Includes infants in whom the standard method of preparation and infusion of PN will be applied. This arm will be stratified to male and female 1:1
10136810|NCT04234438|Active Comparator|Before application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa Before subliminal micropulse laser application
10136811|NCT04234438|Active Comparator|After application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa After 12 months subliminal micropulse laser application
10136812|NCT04234269||Assessment Group|Individuals with spinal cord injury. There is one group.
10136813|NCT04234191|Experimental|Rapid Micro-Induction|On Day 1, participants will receive 0.5mg bup/nx sublingually (SL) every 3 hours (Q3H) - total daily dose of 4mg. On Day 2, they will receive 1mg bup/nx SL Q3H - total daily dose of 8mg. On Day 3, they will receive 12mg bup/nx SL once and 1-4mg bup/nx SL Q3H as needed (PRN) - maximum daily dose of 24mg. On Day 4, their day 3 total dose will be consolidated to once daily dosing - maximum daily dose of 24mg. On Days 1 and 2, participants will concurrently receive 1-16mg hydromorphone orally, intravenously, subcutaneously, or intramuscularly (PO/IV/SC/IM) every 1-3 hours (Q1-3H) PRN to meet their opioid requirements, titrated to effect - maximum daily dose of 96mg. For the 1st dose of hydromorphone on Day 1, a maximum 8mg PO or 4mg SC/IV/IM dose will be given. Hydromorphone will be discontinued on Days 3 and 4.
10136814|NCT04234191|Active Comparator|Standard Induction|Day 1 is initiated when participants score 11 or above on the Clinical Opiate Withdrawal Scale (COWS), and when they have been abstinent from short-acting opioids for at least 6-12 hours or from long-acting opioids for 24-72 hours. On Day 1, participants will start with 2-4mg bup/nx SL. If they do not experience withdrawal symptoms 60-90 minutes after this dose, additional dosing can be done in increments of 2-4mg bup/nx SL. The suggested total dose target for Day 1 is 8-12mg. On Day 2, participants will start with a dose equal to the total amount of bup/nx SL administered on Day 1. The dose will be then titrated in increments or decrements of 2-8mg bup/nx SL to a level that holds the patient in treatment and suppresses opioid withdrawal. On Day 3, their day 2 total dose will be consolidated to once daily dosing. For both Days 2 and 3, the suggested total daily dose is at least 8mg, recommended 12-16mg, maximum daily dose of 24mg.
10136815|NCT04233957|Experimental|High Sodium|Consumption of an extra 3900 mg of dietary sodium per day.
10136816|NCT04233957|Placebo Comparator|Placebo|Control Condition
10136817|NCT04233931|Experimental|participant|all participants in the study receive the mobile app.
10136818|NCT04233996|Experimental|Extended infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in half time of the dosing interval
10136819|NCT04233996|Active Comparator|Intermittent infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in 30 minutes
10136820|NCT04233983|Active Comparator|Study Group|The study group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will undergo laparoscopic endometriosis surgery after ICSI procedure with freezing all embryos. The patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed.
10136821|NCT04233983|No Intervention|Control Group|The control group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will be performed IVF&ICSI procedure with fresh embryo transfer without surgery. If there is no pregnancy, patients will be operated then.
10136822|NCT04233762||Female Natural Cycle Group|Females with regular natural menstrual cycle.
10136823|NCT04233762||Female Oral Contraceptive Pill Group|Females taking the combined oral contraceptive pill.
10136824|NCT04233762||Male Group|Males with no history of anabolic steroid use.
10136825|NCT04233866|Experimental|Arm A (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10136826|NCT04233866|Experimental|Arm B (fluorouracil, leucovorin, liposomal irinotecan)|Patients receive fluorouracil IV over 46 hours starting on day 1. Patients also receive leucovorin IV over 90-120 minutes and liposomal irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10136827|NCT04233684|Experimental|Study|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H&E stain and Giemsa stain~All tissues will be sent to immunohistochemistry as a gold standard"
10136828|NCT04234048|Experimental|Phase 1|"Accelerated Phase 1a + Standard Phase 1a + Phase 1b~Accelerated Phase 1a~Up to 8 patients for accelerated phase 1a (single patient cohort); dose levels of ST-001 nanoFenretinide (mg/m^2/day X 5 days every 21 days):~Dose Level 1 1.25 (1 patient) Dose Level 2 2.5 (1 patient) Dose Level 3 5.0 (1 patient) Dose Level 4 10 (1 patient) Dose Level 5 20 (1 patient) Dose Level 6 40 (1 patient) Dose Level 7 80 (1 patient) Dose Level 8 160 (1 patient)~Standard Phase 1a~Up to 18 patients for standard phase 1a (3+3 design); dose level (mg/m2/day X 5 days every 21 days):~Dose Level 9 320 (3-6 patients) Dose Level 10 448 (3-6 patients) Dose Level 11 627 (3-6 patients)~Phase 1b~20 patients for phase 1b at the maximum tolerated dose (MTD)"
10136829|NCT04233658|Placebo Comparator|Placebo|
10136830|NCT04233658|Experimental|Cynara Scolymus|
10136831|NCT04233697|Experimental|Copanlisib and Romidepsin|"Copanlisib and romidepsin will be both administered via IV (through a vein in arm) on days 1, 8, and 15 every 28 days, also called a cycle."
10136832|NCT04233853|Experimental|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
9826074|NCT02406586|Placebo Comparator|Placebo|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
9826075|NCT02406612|Experimental|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
9969045|NCT01286142||Influenza patients with no antiviral treatment|A comparator group of patients 24 months of age and younger presenting with confirmed or presumed influenza A or B and not treated with any influenza antiviral.
9969046|NCT01286155||with gastroesophageal reflux disease(GERD)|Subjects with gastroesophageal reflux disease (GERD)
9969047|NCT01286155||Non-GERD|Subjects with no history of gastroesophageal reflux disease (GERD)
9969048|NCT01286155||Barrett's esophagus|Subjects with confirmed barrett's esophagus in Olmsted county
9969049|NCT01286181|Experimental|Device-guided slow breathing|
9969050|NCT01286194||Experimental 1|
9969051|NCT01286220|Active Comparator|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
9969052|NCT01286220|Placebo Comparator|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
9969053|NCT01286233||Group 1: Metformin|850 mg orally twice a day for 5 years
9969054|NCT01286233||Group 2: Placebo|One caplet orally twice a day for 5 years
9969055|NCT01286246|Experimental|Vaginal progesterone|
10136833|NCT04233853|Active Comparator|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
9969056|NCT01286246|Placebo Comparator|Placebo|
9969057|NCT01286298|Experimental|Laser gingivectomy|
9969058|NCT01286337|Experimental|vessel sealing|axilla dissection using this device
9969059|NCT01286337|Active Comparator|control|standard surgical technique
9969060|NCT01286350|No Intervention|Control|Participants randomized control will continue with usual clinical care.
9969061|NCT01286350|Experimental|Intervention|"Participants randomized to intervention will receive the FL3X Flexible Lifestyle Empowering Change intervention. Adolescents will be paired with a health coach to help learn strategies for improving diabetes control"
9969062|NCT01286363||Brachyfacial|Subjects with a horizontal facial growth pattern
9969063|NCT01286363||Mesofacial|Subjects with a balanced facial growth pattern
9969064|NCT01286363||Dolichofacial|Subjects with a vertical facial growth pattern
9969065|NCT01286376|Active Comparator|symbiotic|
9969066|NCT01286376|Placebo Comparator|placebo|
9969067|NCT01286389|Active Comparator|Conventional medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
9969068|NCT01286389|Experimental|caloric restriction +medical care|Nutritional counseling individually and in groups, aiming to promote weight loss (10% of body weight) through caloric restriction, +Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise)
9969069|NCT01286415|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
9969070|NCT01286415|Active Comparator|Group Present Centered Therapy|
9969071|NCT01286467|Experimental|1|
9969072|NCT01286506||Mechanically ventilated patients|
9969073|NCT01286506||Non-mechanically ventilated patients|
9969074|NCT01286532||1|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination therapy with ICS(inhalation glucocorticosteroids) and LABA ( long-acting b2-agonist) who have completed at least one valid CACT assessment after the study entry
9969075|NCT01286545||Ankylosing spondylitis, long term treatment with infliximab|Patients with ankylosing spondylitis under long term treatment with infliximab within the open label clinical trials EASIC and DIKAS are now followed up in a registration study. No intervention is planned. Patients will be followed up for clinical outcome parameters and for radiographic progression.
9969076|NCT01286571|Experimental|BI 135585 (T)|single dose per subject as tablet formulation after high fat, high caloric meal
9969077|NCT01286571|Experimental|BI 135585 (R)|single dose per subject as tablet formulation after an overnight fast
9969078|NCT01286584|Active Comparator|varenicline group|
9969079|NCT01286584|Placebo Comparator|placebo group|
9969080|NCT01286597|Experimental|dietary|
9969081|NCT01286610|Other|vibration therapy and electrical muscle stimulation|
9969082|NCT01286636|Experimental|artificial neural network|
9969083|NCT01286636|Active Comparator|Polysomnogram|
9969084|NCT01286649|Other|Injection of verum and control|Patients will receive randomized, blinded, injections of BOTH autologous hair follicle cells in medium (verum) and of medium alone (control) into two separate pre-defined treatment areas on their scalp.
9969085|NCT01286675|Experimental|Eltrombopag|0 mg Eltrombopag
9969086|NCT01286688|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
9969087|NCT01286688|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
9969088|NCT01286701|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
9969089|NCT01286701|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
9969090|NCT01286714|Experimental|clips OST|
9969091|NCT01286727|Placebo Comparator|Normal Saline|Placebo
9969092|NCT01286727|Active Comparator|BB3|
9969093|NCT01286766|Active Comparator|DCS|DCS: docetaxel with cisplatin with TS-1
9969094|NCT01286766|Active Comparator|DCF|DCF : docetaxel with cisplatin with 5-FU
9969095|NCT01286831|Experimental|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
9977774|NCT01365104|Experimental|healthy old|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
10136834|NCT04234009|Experimental|Healthy lifestyle|Healthy lifestyle intervention, which includes physical activity and dietary advice according to the dutch guidelines.
10136835|NCT04234009|No Intervention|Control|Maintenance of habitual physical activity and diet
10136836|NCT04233892|Experimental|CBD-bFGF|
10136837|NCT04233892|Experimental|Collagen/BMMNCs|
10136838|NCT04233892|Experimental|Estrogen|
10136839|NCT04234087|No Intervention|Control group|The supervised exercise program included: continues endurance training on cycle ergometers (6 sessions a week). Every session included warm up (<50% target intensity 2 min, gradually increasing load 1-10 w/min up to target intensity within 5 - 10 min); exercise phase (100% of the target intensity (30-50% watts or 30-50% HRmax), starting with >5 minutes and gradually prolonged up to 30 min); cool down with gradual reduction of the load within 3 minutes); additional aerobic exercises performed sitting and/or standing (30 minutes, 5 days/week); respiratory muscle training (7 days/week, for 15 minutes) using ball trainer.
10136840|NCT04234087|Other|Intervention group|Exercise program as for a control group together with additional resistance and balance training 3 sessions/week. The resistance training was started with low intensity (<30% 1-RM, RPE ≤ 11, 5-10 repetitions), increased gradually to moderate intensity (30-50% and up to 60% 1-RM, RPE 12-13, after 8-15 repetitions) with 3 sets and 3 minute rest between sets, if tolerated. The balance training included exercises to improve static as well as dynamic balance ability. It was performed on 2-3 days/week for 10-15 minutes. The complexity of the balance exercises was selected and incremented individually by changing the stand-position, the base on which the stands were performed and/or using unstable surfaces. If tolerated, the visual information was varied and/or additional tasks performed while balancing. After completion participants were encouraged to continue exercise training at home according to recommendations.
10136841|NCT04233671|Experimental|Mindfulness based relapse prevention and peer mentoring|MiMP is a twelve week program, meeting once per week for 12 weeks for approximately two hours. Eight weeks are facilitated by a licensed counselor, and four weeks are facilitated by a peer mentor.
10136842|NCT04233671|No Intervention|12 Step Treatment Program Control|The control group will meet for 12 weeks for standard 12 Step Facilitation meetings.
10136843|NCT04233788||Patient Group 1 (15 Patients)|First two pulse sequence will be applied to this group at a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 2.
10136844|NCT04233788||Patient Group 2 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 1) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 3.
10136845|NCT04233788||Patient Group 3 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 2) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 4.
10136846|NCT04233788||Patient Group 4 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 3) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 5.
10136847|NCT04233788||Patient Group 5 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 4) will be applied to this group using a 3T Prisma and a 7T Terra scanner. At the end the best performing sequence will result.
10136848|NCT04233788||Healthy Control Group 1 (10 Persons)|First two pulse sequences will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used as normative data.
10136849|NCT04233788||Healthy Control Group 2 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 1) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
10136850|NCT04233788||Healthy Control Group 3 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 2) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used as normative data.
10136851|NCT04233788||Healthy Control Group 4 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 3) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
10136852|NCT04233788||Healthy Control Group 5 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 4) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
10136853|NCT04233736|Active Comparator|Treatment group|
10136854|NCT04233736|Sham Comparator|Control group|
10136855|NCT04233905||mute children|mute children and their mothers
10136856|NCT04233905||healthy children|healthy children control group
10136857|NCT04233905||mute adults|formerly mute adults
10136858|NCT04233905||healthy adults|healthy adults control group
10136859|NCT04233710|Experimental|Robot + tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period, with 20 minutes of 1mA cathodal tDCS applied to the contralesional M1 area during first 20 minutes of robotic therapy. Robotic therapy will be conducted using the Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
10136860|NCT04233710|Sham Comparator|Robot + sham tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period with 20 minutes of SHAM tDCS applied during the first 20 minutes of the robotic therapy. As with experimental arm, electrode will be placed on contralesional M1. Current will ramp up and then immediately ramp down to simulate the cutaneous sensations felt with actual tDCS. Robotic therapy will be delivered with Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
10136861|NCT04233645|Experimental|Study Group|The group will be given a standard scripted verbal and identical written instructions plus the study group will be shown a 5-minute educational video (available at https://youtu.be/rvYfDc-Yfus ) which depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
10136862|NCT04233645|Active Comparator|Usual Care Group|The group will be given a standard scripted verbal and identical written instructions as per usual care.
10136863|NCT04234074|Other|Breathing test or sleep study|infants undertaking cardiorespiratory polysomnography
10136864|NCT04233593|Experimental|LPS Challenge|Subjects will undergo one 120-minute [11C]PBR28 PET scan before and one scan 3-hours after LPS administration (1.0ng/kg; IV).
10136865|NCT04233593|No Intervention|LPS Follow-up|Subjects will undergo one 120-minute [11C]PBR28 PET scan 24+ hours after LPS.
10136866|NCT04233437|Experimental|CYP Cohort|MLC1501 & CYP cocktail drugs
10136867|NCT04233437|Experimental|Transporter Cohort|MLC1501 & Transporter cocktail drugs
10136868|NCT04233450||Patient group|
10136869|NCT04233294|Experimental|chidamide in combination with camrelizumab plus decitabine|chidamide 10mg/day, days 1-4, 20mg/day, day 8, 11, 15, 18; camrelizumab 200mg d6; decitabine 10 mg/day, days 1-5, every 3 weeks
10136870|NCT04233463|Active Comparator|Modulen Diet|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
10136871|NCT04233463|Active Comparator|Budesonide Treatment|Crohn patients will be given Budesonide treatment
10136872|NCT04233346|Experimental|Ponatinib|CP-CML:Chronic Phase Chronic Myeloid Leukemia; AP-CML:Accelerated Phase Chronic Myeloid Leukemia; BP-CML:Blast Phase Chronic Myeloid Leukemia; Ph+ ALL:Ph+ Acute Lymphoblastic Leukemia;
10136873|NCT04233203||Faster Aspart|All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII and insulin Faster Aspart.
10136874|NCT04233580|Active Comparator|Weekly AmnioEXCEL+ group|AmnioEXCEL+ will be applied weekly at study visits
10136875|NCT04233580|Active Comparator|PRN AmnioEXCEL+ group|AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)
10136876|NCT04233528|Experimental|healthy volunteers|metabolically healthy eutrophic individuals (BMI ≥18.5 and <25 kg / m2) without any IDF criteria for metabolic syndrome
10136877|NCT04233528|Experimental|metabolically healthy obesity|obese individuals (BMI ≥ 30.0 kg / m2) meeting the criteria for metabolically healthy obesity
10136878|NCT04233528|Experimental|metabolically unhealthy obesity|volunteers diagnosed with metabolically unhealthy obesity
10136879|NCT04233359|Active Comparator|US-guided pleural biopsy and thoracentesis|"Pleural biopsy:~Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis."
10136880|NCT04233359|Experimental|LAT and thoracentesis|Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed. The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start. The patient is sedated with midazolam and morphine. Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space. A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology. Pleural parietal biopsies are taken under direct visual guidance. The recommended number of biopsies is 10-15. If no abnormalities were seen, random biopsies are taken. After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.
10136881|NCT04233281|Experimental|Kori-tofu added to a carbohydrate rich meal|Kori tofu as part of a carbohydrate rich meal
10136882|NCT04233281|Active Comparator|Whey protein added to a carbohydrate rich meal|Whey protein as part of a carbohydrate rich meal
10136883|NCT04233229|Experimental|closed-loop and home care services|
10136884|NCT04233229|Active Comparator|usual care|
10136885|NCT04233307|Other|Wound photographs|Telethermographic photographs of fracture wound and contralateral limb before and after propofol infusion.
10184338|NCT03756051||Cohort|This study will collect prospective longitudinal data to characterize rates and identify correlates of a) physical harms due to follow-up tests, b) financial harms, and c) inappropriate screening using electronic medical record data and manual chart review. The study will also use surveys and semi-structured interviews to characterize rates and identify correlates of screening-related psychological harms, e.g. cancer specific worry, situational anxiety, mood disturbances, and decisional regret. Lastly, investigators will create and disseminate a balance sheet of benefits and harms to inform patients, providers, healthcare organizations, payers, and policymakers about the role of hepatocellular carcinoma screening in patients with cirrhosis.
10184339|NCT03756025|Experimental|Vitro Molar® (DFL, Rio de Janeiro, Brazil)|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Vitro Molar® (DFL, Rio de Janeiro, Brazil).
10184340|NCT03756025|Active Comparator|Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).
10184341|NCT03755999|Experimental|PIOMI treat group|Preterm infant receive oral massage using the premature infant oral motor intervention (PIOMI)
10184342|NCT03755999|No Intervention|Routine care group|Preterm infant receive routine care of neonatal intensive care unit(NICU)
10184343|NCT03755986|Other|ATOMO Diagnostic Test|All patients will receive an ATOMO diagnostic test to use. There is no comparative arm.
10184344|NCT03755960|Experimental|acupuncture plus routine care|12 session of semistandardized acupuncture together with pharmacological routine care
10184345|NCT03755960|Active Comparator|routine care alone|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
10184346|NCT03755947|Experimental|IGV|"Cytoreduction 3 cycles (I) Ibrutinib, [Imbruvica, Janssen]~Induction 6 cycles (G) Obinutuzumab, [Gazyva, Roche]~Consolidation 12 cycles (V) Venetoclax, [Venclexta, Abbvie]."
10184347|NCT03755921|Experimental|Brief and intensive therapy|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, daily
10184348|NCT03755921|Active Comparator|Therapy Weekly|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, weekly
10187713|NCT03723395|Experimental|Part D|Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
10187714|NCT03723395|Experimental|Part E|Tucatinib plus Digoxin
10136886|NCT04233411|Active Comparator|Milk|Acute ingestion of 20 g milk protein
10136887|NCT04233411|Experimental|20g|Acute ingestion of 20 g mycoprotein
10136888|NCT04233411|Experimental|40g|Acute ingestion of 40 g mycoprotein
10136889|NCT04233411|Experimental|60g|Acute ingestion of 60 g mycoprotein
10136890|NCT04233411|Experimental|80g|Acute ingestion of 60 g mycoprotein
10136891|NCT04233320|Experimental|silicone cream containing Allium Cepa extract|Silicone cream containing Allium Cepa extract will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
10136892|NCT04233320|Active Comparator|commercial scar gel|Commercial scar gel will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
10136893|NCT04233333|Active Comparator|mustache fixation|
10136894|NCT04233333|Experimental|W.K fixation|
10136895|NCT04233255||Patients with muscle disease(myositis, hereditary myopathy)|Includes 32 symptomatic patients with muscle disease subdivided into two subgroups (a) 16 patients with acute inflammatory myositis; And (b)16 patients with hereditary myopathy. The patients will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline,after 6 months and after 12 months. The number and location of studied muscles will be determined according to pattern of clinical presentation.
10136896|NCT04233255||Healthy volunteers as control group|Includes 32 healthy volunteers as control group. They will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline. Their age, sex, number and location of studied muscles will be matched with patients' group.
10136897|NCT04233424|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
10136898|NCT04233424|Other|Standard of care|The SoC for prophylactic antibiotic treatment is based on international guidelines
10136899|NCT04233502|Experimental|Melatonin|Slenyto® 1 mg / 5 mg prolonged release Melatonin tablets (pink and yellow) film coated 3 mm in diameter,
10136900|NCT04233502|Placebo Comparator|Placebo melatonin|Placebo melatonin will be identical in appearance (pink and yellow) and formulation to active Slenyto® tablets, but will contain no active melatonin.
10136901|NCT04233489|Experimental|Family Nurture Intervention (FNI)|This arm contains the combined GDM+FNI and control+FNI cohort.
10136902|NCT04233489|No Intervention|Non-FNI|This arm contains the combined GDM+no FNI and control+no FNI cohort.
10136903|NCT04233151|Experimental|mFOLFOX6 + QL1203|Participants receive QL1203, 6mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity
10136904|NCT04233151|Active Comparator|mFOLFOX6 + Placebo|Participants received Placebo，6 mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
10136905|NCT04233541||Fallers|Participants who reported one or more falls within the 12 months preceding the study consist the group of ''fallers''.
10136906|NCT04233541||Non-fallers|Participants with no fall history consist the group of ''non-fallers''
10136907|NCT04232774|Experimental|Treated by the study device|
10136908|NCT04232826|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
10136909|NCT04232800|Experimental|Riboflavin|Participants in this group will receive 100mg riboflavin TID during study participation.
10136910|NCT04232800|Placebo Comparator|Placebo|Participants in this group will receive inert placebo capsules TID during study participation.
10136911|NCT04233099||Healthy Subjects|20 Healthy subjects in a good state of health comparable by age and sex with the other selected groups
10136912|NCT04233099||Amyotrophic Lateral Sclerosis with Bulbar onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Bulbar onset, comparable by age and sex with the other selected groups
10136913|NCT04233099||Amyotrophic Lateral Sclerosis with Spinal onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Spinal onset, comparable by age and sex with the other selected groups
10136914|NCT04233099||Parkinson's Disease|20 subjects affected by Parkinson's Disease comparable by age and sex with the other selected groups
10136915|NCT04233099||Alzheimer's Disease|20 subjects affected by Alzheimer's Disease comparable by age and sex with the other selected groups
10136916|NCT04233125|Active Comparator|Core Decompression (CD) Only|Participants in this group receive standard care
10136917|NCT04233125|Experimental|Added Polymethylmethacrylate (PMMA)|Participants in this group receive standard care with an additional treatment
10136918|NCT04232930|Active Comparator|Music group|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
10136919|NCT04232930|No Intervention|Non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
10136920|NCT04232865|Experimental|Bןםפ Sטדאקצ|Biop Colposcopy procedure
10136921|NCT04232943|Active Comparator|IMOVAX Only|IMOVAX® Polio (Inactivated Poliomyelitis Vaccine) is to be administered by the IM route. Group 1, will receive one dose, 0.5mL of IPV.
10136922|NCT04232943|Experimental|IMOVAX + dmLT|Group 2 will receive IPV along with dmLT as an adjuvant, as a single dose. The vaccine product will be prepared in the clinical research pharmacy from the components described above on each day of vaccination as described in step by step formulation procedures summarized below and detailed in the Pharmacy Preparation Manual. The vaccine product preparation will be carried out by an unblinded qualified research pharmacist and witnessed by another study staff member. The research pharmacist will dispense the vaccine product in a blinded manner to the clinical staff.
10136923|NCT04232943|Active Comparator|bOPV|Group 3 and all the study participants later in the challenge phase of the study will receive one dose of bOPV vaccine in two drops, which are delivered from the polyethylene dropper supplied with the multi-dose container.
10136924|NCT04232904|Active Comparator|TAP Block Group|this is study group.
10136925|NCT04232904|No Intervention|Control Group|This patients are control group. TAP block will be not perform
10136926|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 1: 0.5mg CVL-936|Oral suspension/solution
10136927|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo|Matching Placebo; Oral suspension/solution
10136928|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 2:TBD mg CVL-936|Oral suspension/solution
10136929|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
10136930|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 3:TBD mg CVL-936|Oral suspension/solution
10136931|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
10136932|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 1:TBD mg CVL-936|Oral suspension/solution
10136933|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
10136934|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 2:TBD mg CVL-936|Oral suspension/solution
10136935|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
10136936|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 3:TBD mg CVL-936|Oral suspension/solution
10136937|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
10136938|NCT04232878|Active Comparator|Active Comparator: Group 3: TBD mg CVL-936|Oral suspension/solution
10136939|NCT04232878|Placebo Comparator|Placebo Comparator: Group 3: TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
10136940|NCT04232813|Active Comparator|Estradiol 10 micrograms vaginal tablets|One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
10136941|NCT04232813|Active Comparator|Promestriene 10mg./g vaginal cream|One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
10136942|NCT04233086||Patients referred through the BNP pathway|Patients throughout 2016 referred through the BNP pathway at Queen Alexandra Hospital will retrospectively be assessed for Reddy et al (2018) H2FPEF score.
10136943|NCT04233008|Experimental|6 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 6 hours, determined by randomization. At that point health care providers will manage active labor.
10136944|NCT04233008|No Intervention|12 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 12 hours, determined by randomization. At that point health care providers will manage active labor.
9519641|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
9519642|NCT03284944||Control (Before) Period|Use of standard-volume blood collection tubes (6 weeks)
9519643|NCT03284944||Intervention (After) Period|"Use of small-volume (soft-draw) blood collection tubes (6 weeks following 2-week washout period)"
10136945|NCT04232995|Experimental|Experimental Group|"Balance training by 9 positions with 1 min hold, repeated twice~Stand with feet together, eyes remain open~Stand with together, eyes closed~& 4) Tandem Standing with Right and Left in front alternately~5) Forward Reaching 6) & 7) Single Leg Standing, with Right and Left foot alternately 8) & 9) Step up, with Right and Left foot alternately~General Exercises for 25 min~Active Range of Motion Exercises and Foot Care Education-5 min~Treadmill- 15 min~Cycling -5 min~No. Of Sessions 24, thrice a week for 8 weeks"
10136946|NCT04232995|Active Comparator|Control Group|"General Exercises for 25 min~Active Range of Motion Exercises and Foot Care Education-5 min~Treadmill- 15 min~Cycling -5 min~No. Of Sessions 24, thrice a week for 8 weeks"
10136947|NCT04232787||Case|Thai patients with diagnosed Brugada syndrome by confirmed Brugada type 1 ECG.
10136948|NCT04232787||Control|Healthy volunteers without Brugada marker from ECG.
10136949|NCT04233021|Experimental|Osimertinib|Osimertinib 80 mg/d
10136950|NCT04232969|Active Comparator|Exenatide|Exenatide extended release 2mg (Bydureon) once weekly for 96 weeks n=100
10136951|NCT04232969|Placebo Comparator|Placebo|Exenatide extended release placebo once weekly for 96 weeks n=100
10136952|NCT04232696|Experimental|Neuspera Implantable Sacral Nerve Stimulation System|Implantation of the simulator.
10136953|NCT04232748||stage IV colorectal cancer|stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes
10136954|NCT04232475|No Intervention|Control|Seated control
10136955|NCT04232475|Experimental|1 minute SCD|1 minute of stair climbing and descending
10136956|NCT04232475|Experimental|3 minute SCD|3 minute of stair climbing and descending
10136957|NCT04232475|Experimental|10 minute SCD|10 minute of stair climbing and descending
10136958|NCT04232605|Active Comparator|GLP-1|Receive intravenous infusion of GLP-1.
10136959|NCT04232605|Placebo Comparator|Placebo|Receive intravenous infusion of saline.
10136960|NCT04232644|Active Comparator|Treatment A|crushed d-amphetamine IR tablets
10136961|NCT04232644|Experimental|Treatment B|manipulated ADAIR IR capsules
9519644|NCT03284931|Experimental|SAGE-217 high dose|SAGE-217
9519645|NCT03284931|Experimental|SAGE-217 low dose|SAGE-217
9519646|NCT03284931|Placebo Comparator|Placebo|Placebo
9977775|NCT01365117|Experimental|Cohort 1|
9977776|NCT01365117|Experimental|Cohort 2|
10136962|NCT04232592|Experimental|Stem cell preparation solution injection group|The solution of stem cells preparation will be injected.
10136963|NCT04232592|Experimental|Injected stem cell group|The stem cells will injected.
10136964|NCT04232488|Experimental|Angiography performed using distal radial artery|Patients undergoing coronary angiography with or without intervention using distal radial artery ('snuff box') as a vascular access
10136965|NCT04232488|Active Comparator|Angiography performed using proximal radial artery|Patients undergoing coronary angiography with or without intervention using proximal radial artery as a vascular access
10136966|NCT04232579||Chronic obstructive respiratory disease|The out-patient population with chronic obstructive respiratory disease consulted at Nguyen Tri Phuong Hospital, Ho Chi Minh city, Vietnam.
10136967|NCT04232735|Experimental|Intervention|"The Source tool is used by care givers for informing patients about the outcomes of treatment. Prediction models are developed and built in the website in order to generate a personalized prediction of the outcomes: survival, toxicity and/or complications and HRQL. These predictions are visualized in clear and comprehensible graphs with a broad variation of options available for tailoring of the visualizations.~In order for care givers to be able to use this tool effectively, we designed the Source training. This communication skills training is comprised of an e-learning, two face-to-face group sessions and an individual booster session. Aside from an instruction video on the navigation within the Source tool, the e-learning consists of theory and tips and tricks on how to inform patients and communicate risks. The face-to-face components of the training are focused on getting the skilled use of the source tool into practice, by receiving personal feedback on the performance."
10136968|NCT04232722|Experimental|Sorafenib + arsenical|After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w
10136969|NCT04232527||Professional Footballers|About 110 players (out of about 400 competing in the Premier League of Bosnia and Herzegovina) would be included in the research.
10136970|NCT04232501|Experimental|Cirvo Compression device post surgery|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
10136971|NCT04232501|No Intervention|Standard of Care Post Surgery|Patients receive standard-issue SCDs (pneumatic compression) and wear in surgery and after surgery until they are discharged home.
10136972|NCT04232345|Experimental|Cohort 1 (Part 1): AZD4831 Dose 1|Randomized subjects will receive oral suspension of AZD4831 Dose 1 once daily in the morning for a period of 10 days
10136973|NCT04232345|Experimental|Cohort 2 (Part 1): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
10136974|NCT04232345|Experimental|Cohort 3 (Part 1): AZD4831 Dose 3|Randomized subjects will receive oral suspension of AZD4831 Dose 3 once daily in the morning for a period of 10 days.
10136975|NCT04232345|Experimental|Cohort 4 (Part 2): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
10136976|NCT04232345|Experimental|Placebo (Part 1)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
10136977|NCT04232345|Experimental|Placebo (Part 2)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
10136978|NCT04232397|Experimental|therapy|therapy with 1 arm. Anlotinib 8mg qd po。
10136979|NCT04232514|Experimental|Part A|Subjects will receive HEC74647 on Day 1~7 and Day13~19, co-administration with HEC110114 on Day13~19.
10136980|NCT04232514|Experimental|Part B|Subjects will receive HEC110114 on Day 1~7 and Day13~19, co-administration with HEC74647 on Day13~19.
10136981|NCT04232436||Planned vaginal delivery|Planned vaginal delivery
10136982|NCT04232436||Planned cesarean delivery|Planned cesarean delivery
10136983|NCT04232410||OSA Pcrit-DISE|Patients diagnosed with OSA and eligible for non-CPAP treatments
10136984|NCT04232709|No Intervention|After-hours care|Patients in the after-hours care (AH) group will receive the usual (telemedicine) care. That is, they will have the option to call the after-hours centre and receive help from the oncology nurses using the COSTaRS practice guides to manage their after-hours symptoms.
9669154|NCT03878524|Experimental|Treatment (biospecimen collection, 2 drug combination)|"TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.~SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health & Science University (OHSU).~Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity."
10136985|NCT04232709|Experimental|After-hours care w/personal health info|Patients in the after-hours care with personal health information (AH-PHI) group will also receive the usual (telemedicine) care. However, if they call the telemedicine service, the oncology nurses will have access to some of their personal health information from the cancer centre (i.e., a shared electronic patient record) via the MedChart platform.
10136986|NCT04232332|Experimental|3.75μg (pre test)|Single dose
10136987|NCT04232332|Experimental|7.5μg|Single dose
10136988|NCT04232332|Placebo Comparator|15μg single dose|Intramuscular injection once
10136989|NCT04232332|Placebo Comparator|30μg single dose|Intramuscular injection once
10136990|NCT04232332|Placebo Comparator|45μg single dose|Intramuscular injection once
9669155|NCT03875313|Experimental|600 mg CB-839 + 1 mg Talazoparib|600 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with advanced or metastatic solid tumors.
9694654|NCT04786613|Active Comparator|48 mg, 2.0% hyaluronic acid injection groups|In the third group 2.4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in a single sessions will be applied.
10136991|NCT04232332|Placebo Comparator|60μg single dose|Intramuscular injection
10136992|NCT04232332|Placebo Comparator|75μg single dose|Intramuscular injection
10136993|NCT04232332|Placebo Comparator|90μg single dose|Intramuscular injection once
9519647|NCT03284918|Experimental|Plant stanol ester|Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar). Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
10136994|NCT04232332|Placebo Comparator|30μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
10136995|NCT04232332|Placebo Comparator|45μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
10136996|NCT04232241|Active Comparator|Treatment A|Allogeneic stem cell transplantation from 10/10 HLA matched unrelated donor
10136997|NCT04232241|Experimental|Treatment B|Allogeneic stem cell transplantation from haploidentical donor
10136998|NCT04232254|Active Comparator|Animal Protein - Skewed Distribution|Animal-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
10136999|NCT04232254|Experimental|Plant Protein - Skewed Distribution|Plant-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
10137000|NCT04232254|Experimental|Animal Protein - Balanced Distribution|Animal-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
10137001|NCT04232254|Experimental|Plant Protein - Balanced Distribution|Plant-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
10137002|NCT04232319|Experimental|Sleep Hygiene Training|The intervention will be delivered online by an occupational therapist. The intervention consists of 3 weekly sessions; each session will be 30-45 minutes long. The focus of the intervention is to teach breast cancer survivors sleep hygiene strategies to improve their sleep.
10137003|NCT04232046|Experimental|Intervention|Trigger point massage
10137004|NCT04232046|Active Comparator|Control|Treatment with standard drug Nortriptyline
10137005|NCT04232293|Experimental|Blood tests|Two diagnostic tests (eLift and FibroMeter) will be performed to evaluate liver fibrosis
10137006|NCT04232007|Experimental|Closed-loop|Closed-loop system to titrate vasopressor during surgery
10137007|NCT04232111|Sham Comparator|Thermoneutral|Neither heat nor vacuum applied to hand
10137008|NCT04232111|Experimental|Heat and Vacuum|Heat and vacuum applied to hand
10137009|NCT04232111|Experimental|Heat only|Only heat applied to hand
10137010|NCT04232098|No Intervention|Thermoneutral|thermoneutral condition
10137011|NCT04232098|Experimental|Feet heated|Hot water up to ankles
10137012|NCT04232098|Experimental|Calf heated|Hot water up to top of calves
10137013|NCT04231916|Experimental|Patients aged 5-18 years|"Patients with Osteogenesis Imperfecta (with known vertebral fractures)for phase one of the study.~Patients with Osteogenesis Imperfecta for phase 2 of the study In both groups patients will be aged 5 years and over"
9826076|NCT02406651|Experimental|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
10137014|NCT04232150|Experimental|Group C (control group)|control group will receive no sedation under spinal anesthesia.
10137015|NCT04232150|Experimental|Group O (single dose group)|patients will receive 0.025mg/kg midazolam sedation under spinal anesthesia.
10137016|NCT04232150|Experimental|Group M (double dose group)|patients will receive 0.025mg/kg midazolam sedation twice under spinal anesthesia.
10137017|NCT04231864|Experimental|Treatment (durvalumab, epacadostat)|Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice a day (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study.
10137018|NCT04232163|Experimental|Immediate Treatment Group|Participants will receive the intervention right away
10137019|NCT04232163|No Intervention|Delayed Treatment Group|Participants will receive usual care (no intervention), however, they will receive the intervention after a 3 week delay
9977777|NCT01365143|Active Comparator|Open Radical Prostatectomy|
10137020|NCT04231903||EAC|Patients undergoing surgery endo-aortic clamp.
10137021|NCT04231903||TTC|Patients undergoing surgery through trans-thoracic aortic clamp.
10137022|NCT04232033|Active Comparator|Fibroblast growth factor 21 infusion|Fibroblast growth factor 21 infusion
10137023|NCT04232033|Placebo Comparator|Placebo infusion (saline)|Saline infusion
10137024|NCT04231890|Experimental|IPI group|IPI monitoring
10137025|NCT04231890|No Intervention|Control group|Standard monitoring
10137026|NCT04231955|Experimental|pain rating scales|"patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10, on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end and on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
10137027|NCT04231994|Experimental|TPE|additive singular therapeutic plasma Exchange (TPE) using fresh frozen Plasma (FFP) as replacement fluid
10137028|NCT04231994|No Intervention|SMT|Standard medical Treatment (SMT) for septic shock following the present surviving sepsis guidelines
9977778|NCT01365143|Active Comparator|Robotic radical prostatectomy|
10137029|NCT04232085|Experimental|PID/IDS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.~Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
10137030|NCT04232085|Experimental|IBMFS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
10137031|NCT04232267||Patients prescribed Polysomnology (PSG - sleep study)|Patients that are at least 18 years old but not older than 75 years old, who have been referred to a sleep clinic for sleep disturbance.
10137032|NCT04231799|Experimental|Bathing within 24-48|Participants who will have their first bath in 24-48th hours after birth.
10137033|NCT04231799|Experimental|Bathing within 48-72|Participants who will have their first bath in 48-72th hours after birth.
10137034|NCT04231812|Other|open lable|Prospective, open-label
10137035|NCT04231669|No Intervention|Control: bolstered care|Female adolescents in the bolstered care will receive services/education as usual in their respective schools. The usual care will be bolstered by providing school notebooks and lunch in the control arm (bolstered care will also be provided to treatment arm). Primary school education is universal and free in Ghana. Yet notebooks and lunch are costly expenses for families that create a barrier to school attendance. Hence, these will be provided to participants in all study schools.
10137036|NCT04231669|Experimental|Anzansi Family Program|In addition to bolstered care, participants in this arm will receive the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG).
10137037|NCT04231851|Experimental|CPX-351 and Glasdegib|"In Induction, subjects receive 44mg/m2/100mg/m2 IV on days 1, 3 and 5 and Glasdegib 100mg PO daily on days 6 to 28.~If re-induction is needed: Subjects receive 44mg/m2/100mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~In consolidation: Subjects receive 29mg/m2/65mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~If maintenance is required, Subjects receive Glasdegib 100mg PO daily for up to one year"
10137038|NCT04231643|Experimental|Bipolar Disorder|adults with bipolar disorder
10137039|NCT04231643|Active Comparator|Healthy Volunteers|adults with no psychiatric disease
10137040|NCT04231474||Demographic and clinical features of the patients|Number of patients Time from injury to hospitalization Time from injury to urodynamic evaluation Duration of hospitalization
10137041|NCT04231474||Comparison of urodynamic outcomes|Treatment options in patients with level SCI : cervical, thoracical and lumbar spinal cord injury
10137042|NCT04231604|Experimental|A Lust for Life programme group|A Lust for Life programme will be delivered to adolescents by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
10137043|NCT04231604|Other|Waiting list control group|Participants will be placed on a twelve-week waiting list for the programme.
10137044|NCT04231526|Experimental|ARM A - Pembrolizumab + Surgery|
10137045|NCT04231526|Active Comparator|ARM B - Surgery|
10137046|NCT04231435|Experimental|Treatment Administration|"All subjects will receive the following oral doses of IP following an overnight fast in the fixed-sequence below:~Day 1 (Period 1): 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet.~Day 7 (Period 2): 6 × 100-mg fedratinib capsules PLUS (after approximately 1 hour from the time of fedratinib administration) 1 × 0.25 mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet."
10137047|NCT04231617|Active Comparator|CGRP and glibenclamide|Participants will recieve CGRP infusion after glibenclamide/placebo administration
10137048|NCT04231617|Active Comparator|CGRP and placebo|Participants will recieve CGRP infusion after glibenclamide/placebo administration
10137049|NCT04231682|Experimental|Denosumab receiving group.|Patients in this arm will receive denosumab injection 60 mg subcutaneously every 6 months. (A total of 4 injections)
10137050|NCT04231682|Placebo Comparator|Placebo receiving group.|Patients in this arm will receive Placebo injection subcutaneously every 6 months. (A total of 4 injections)
10137051|NCT04231656|Experimental|Sequence A before sequence B|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence A of positioning (before the procedure), and sequence B after the procedure.
10137052|NCT04231656|Experimental|Sequence B before sequence A|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence B of positioning before the procedure, and sequence A after the procedure.
10137053|NCT04231630|Other|Observational Case|1 infant will be enrolled as an observational case. Will receive an exclusive human milk diet at home.
10137054|NCT04231422||Treatment Group|Monthly intracavernosal platelet-rich plasma injection + daily physical manipulation.
10137055|NCT04231552|Experimental|Chemotherapy and PD1 inhibitor|CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
10137056|NCT04231578|Experimental|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
10137057|NCT04231578|No Intervention|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
10137058|NCT04231448|Experimental|CR-CHOP|
10137059|NCT04231448|Placebo Comparator|R-CHOP|
10137060|NCT04231721||Healthy controls|
10137061|NCT04231370|Experimental|treatment arm|Sintilimab, 200mg, iv day1 Lenalidomide, 25mg/d, oral, day 1-14 repeated every 3 weeks
10137062|NCT04231357|Experimental|Platelet rich plasma (PRP)|6-7 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
10137063|NCT04231357|Active Comparator|control|needle tenotomy with lidocaine
10137064|NCT04231292|Experimental|Experimental Group A +Group a|Group A: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week;Group a: refers to the weekly dose at the end of the first stage , once every two weeks, 19th~46th week
10137065|NCT04231292|Experimental|Experimental Group B +Group b|Group B: 1.2μg/kg RD01, once every two weeks, Day 1~ 18th week; Group b: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
10137066|NCT04231292|Experimental|Experimental Group C +Group c|Group C: 1.6μg/kg RD01, once every two weeks, Day 1~ 18th week; Group c: refers to the weekly dose at the end of the first stage , once every six weeks, 19th~46th week
10137067|NCT04231292|Experimental|Experimental Group D +Group d|Group D: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week; Group d: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
10137068|NCT04231292|Active Comparator|Experimental Group E +Group e|Group E: 150IU/kg rHuEPO, once a weeks, subcutaneous administration, Day 1~ 18th week; Group e: refers to the weekly dose at the end of the first stage , once a weeks, intravenous administration, 19th~46th week
10137069|NCT04231292|Placebo Comparator|Experimental Group F +Group f|Group F: 8μl placebo, once every two weeks, for 6 weeks; 150 IU/kg rHuEPO, once week, subcutaneous injection, 7th ~ 18th week; Group f: refers to the weekly dose at the end of the first stage , once a weeks, subcutaneous administration, 19th~46th week
10137070|NCT04231292|Experimental|Experimental Group G|Group G: 1.6μg/kg RD01, once every four weeks, Day 1~ 28th week;
10137071|NCT04231136|Experimental|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg tablet once a day
10137072|NCT04231136|Active Comparator|EAPA115|Oral administration of EAPA115 once a day
10137073|NCT04231136|Active Comparator|RAPA115|Oral administration of RAPA115 once a day
10137074|NCT04231045||Patients on PiCCO monitoring system|ALL intensive care patients on PiCCO monitoring system and over 18 years old and on PiCCO for more than 24 hours. Those medical or surgical patients admitted in a UK NHS unit, elective, semi-elective or emergency admission.
10137075|NCT04231097|Experimental|Virtual MBCT|Two cohorts of MBCT participants with approximately 10 participants per cohort.
10137076|NCT04231071|Active Comparator|Sutured group|Controlled group: Primary suture repair of the small umbilical hernia defect
10137077|NCT04231071|Experimental|Onlay Mesh group|Intervention group: Primary suture repair of the small umbilical hernia defects + a small Onlay mesh on the closed defect.
10137078|NCT04231110|Experimental|FMT and vedolizumab|People who are initiating vedolizumab per standard of care for ulcerative colitis will also be offered FMT weekly for 6 weeks.
10137079|NCT04231019||Dental practitioners (general, specialists or students)|Two self-administered questionnaires will be used in the study one to general practitioners and specialists and another one with a plain language describing the study will be distributed to the fifth year dental students in Egypt with total 1000 dentist to assess their knowledge, awareness and perception regarding MIH.
10137080|NCT04231149|Experimental|Test product 2|Test catheter 2
10137081|NCT04231149|Experimental|Test product 3|Test catheter 3
10137082|NCT04231149|Active Comparator|Comparator|SpeediCath Flex
10137083|NCT04231175|Experimental|experimental arm A|patients will undergo dedicated MRI imaging of the pelvis, abdomen, and thorax. Based on the findings of the MRI scan patients will be allocated to one of the diagnostic/treatment options
10137084|NCT04231175|No Intervention|arm B|patients will undergo the current standard diagnostic work-up of DLS at indication (MDT decision) and otherwise continue to CRS-HIPEC.
10137085|NCT04231006|Experimental|Single arm|Single arm
10137086|NCT04231214|Experimental|Treatment sequence 1|Spiolto® Respimat® on Day 1 0.9% nebulized saline on Day 9 Spiolto® Respimat® from Day 10 to Day 24
10137087|NCT04231214|Experimental|Treatment sequence 2|0.9% nebulized saline on Day 1 Spiolto® Respimat® on Day 9 Spiolto® Respimat® from Day 10 to Day 24
10184349|NCT03755908||asthmatic children|Children with the diagnosis of asthma and normal spirometry results. Each subject will undergo evaluation including: asthma control questionnaire, spirometry, FOT and Fractional exhaled nitric oxide (FeNO).
10184350|NCT03755869|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
10184351|NCT03755830|Active Comparator|vitiligo patients|Two skin biopsies (lesional and non-lesional) will be taken from every patient.
10184352|NCT03755830|Experimental|healthy controls|A skin biopsy will be taken from each control subject.
10184353|NCT03755817|Experimental|Scenar application|Application of SCENAR device on
10184354|NCT03755817|Placebo Comparator|Scenar application with the device off|Application of SCENAR device off
10184355|NCT03755778|Experimental|EDP-938 and itraconazole interaction (Part 1)|
10184356|NCT03755778|Experimental|EDP-938 and rifampin interaction (Part 2)|
10184357|NCT03755778|Experimental|EDP-938 and quinidine interaction (Part 3)|
10184358|NCT03755765|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
10184359|NCT03755765|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
10184360|NCT03755752|Experimental|Phacoemulsification with Trypan Blue|Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy
10184361|NCT03755752|Experimental|Phacoemulsification without Trypan Blue|Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with
10184362|NCT03755739|Experimental|Pembrolizumab via localized infusion|"This group dividied into two subgroups:~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a total dose of 150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
10137088|NCT04231240||Adult cardiac surgery with normothermia|
10137089|NCT04231240||Adult cardiac surgery with hypothermia|
10137090|NCT04231240||Pediatric cardiac surgery with normothermia|
10137091|NCT04231240||Pediatric cardiac surgery with hypothermia|
10137092|NCT04231240||Adult cardiac surgery without cardiopulmonary bypass|
10137093|NCT04231123|Experimental|PENG group|PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine
10137094|NCT04231123|Placebo Comparator|Placebo group|PENG block with 20 ml of 0,9% saline
10137095|NCT04231279|Active Comparator|ChiRhoStim Group 1|Patients undergoing EGD with ePFT for symptoms of suspected or known pancreatic insufficiency.
10137096|NCT04231279|Experimental|ChiRhoStim Group 2|Patients undergoing diagnostic EGD that consent to undergo ePFT.
10137097|NCT04230980|Experimental|Gabapentin|Participants receive Gabapentin 600mg tablet taken pre-operatively and 300mg taken three times a day for 3 days.
10137098|NCT04230980|Placebo Comparator|Placebo|Participants receive Placebo tablet taken pre-operatively and three times a day for 3 days
10137099|NCT04230993|Experimental|Ocean Bio Actif-Fluid+|Moderate hypertonic seawater solution (15 g / L NaCl) with polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
10137100|NCT04230993|Experimental|Ocean Bio Active-Stuffy nose|Moderate hypertonic seawater solution (15 g / L NaCl) without polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
10137101|NCT04230993|Active Comparator|Ocean Bio Active-Hygiene of the nose|Isotonic seawater solution (9 g / L NaCl). The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
10137102|NCT04230967|Experimental|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit InspireTM devices will be set to this goal and notifications will be given on the device for the participants meeting their goals. Upon enrollment, they will be given a pamphlet with instructions to ambulate out of the room at least once per day with a goal of 2,000 steps daily and their Fitbits will be pre-programmed with this goal. Study staff will also remind participants to ambulate via email, text or in-person if they are not meeting their goal of 2,000 steps per day.
9669156|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: ccRCC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received ≥ 2 prior systemic regimens including ≥ 1 vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy.
10137103|NCT04230967|Active Comparator|Routine Care|Participants in the routine care arm will be allowed ad lib activity but no encouragement to walk will be given. They will not have any goals set on their Fitbits. Upon enrollment, they will be given pamphlets with no instruction on whether or not to ambulate and their Fitbits will be pre-programmed to have no goal.
10137104|NCT04230915|Active Comparator|Low Dose Rocuronium|This group patients will determine as those who were administered 0.3 mg/kg rocuronium
10137105|NCT04230915|No Intervention|Strandart Dose Rocuronium|This group patients will determine as those who were administered 0.6 mg/kg rocuronium
10137106|NCT04230902|Experimental|Lipogems|The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo harvesting of their own adipose tissue for aMAT then this aMAT will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.
10137107|NCT04230902|Active Comparator|Steroid|The cases assigned to this group will be injected intra-articularly in the knee with corticosteroids. No extra preparation of any type is necessary in this case. It will be administered once at the baseline visit of the study.
10137108|NCT04230603|Experimental|Hyperspectral imaging|diagnostic hyperspectral imaging of the human tissue an correlation with local blood parameters and local pathological examination
10137109|NCT04230629|Active Comparator|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
10137110|NCT04230629|Active Comparator|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
10137111|NCT04230694|Active Comparator|Control Group|Control Group subjects will wear the CGM device during their hospitalization, up to 14 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.
10137112|NCT04230694|Experimental|Treatment Group|Treatment Group subjects will wear the CGM device during their hospitalization, up to 14 days, and glucose readings WILL be continuously monitored. Treatment Group subjects will have their glucose management guided by readings from the CGM device and standard of care finger sticks.
10137113|NCT04230655|Active Comparator|Control group|"All participants in the control group are treated with LED and CBT-based group treatment as described below.~All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants. Two groups of about the same size start simultaneously.~The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended."
10137114|NCT04230655|Experimental|IGB group|"All participants in the IGB group are treated with LED and CBT-based group treatment as described for the control group.~Participants in the intervention group are treated with an IGB for 6 months from 6 months from start."
10137115|NCT04230837|Experimental|A: Abutments of 1 mm|Definitive abutments of 1 mm height were located.
10137116|NCT04230837|Experimental|B: Abutments of 3 mm|Definitive abutments of 3 mm height were located.
10137117|NCT04230564||AML|Patients diagnosed with AML
9519648|NCT03284918|Placebo Comparator|Placebo|Cereal based snack bar without plant stanol ester. Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
9519649|NCT03284905|Active Comparator|Probiotics|
9519650|NCT03284905|Placebo Comparator|Placebo|
9519651|NCT03284840||Adults (18-65 years)|
10137118|NCT04230720|Experimental|Artificial Tears|One eye of each participant is randomized to receive Systane Complete artificial tears 4 times a day for 14 days
10137119|NCT04230720|No Intervention|No Artificial Tears|One eye of each participant is randomized to receive no artificial tears for 14 days
10137120|NCT04230590||Participants with schizophrenia spectrum disorders|Within 8 weeks post discharge from hospitalization at the Institute of Mental Health
10137121|NCT04230538|Experimental|DJO Walker|Application of DJO Walker
10137122|NCT04230538|Active Comparator|Traditional plaster cast|Application of traditional plaster cast
10137123|NCT04230798|No Intervention|Control|This group did not perform any specific exercise program nor injury prevention program. They continued their normal training routine
10137124|NCT04230798|Experimental|Prevention program|This group performed two sessions per week of the injury prevention program. The program included strength training, plyometrics and core stability training.
10137125|NCT04230642|Experimental|Robotic device|Needle placement to the tumor, one time, the day of the ablation procedure
10137126|NCT04230889|Other|Usual Diet Group|Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.
10137127|NCT04230889|Experimental|Group 1 Nutritional Shake|Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.
10137128|NCT04230889|Experimental|Group 2 Nutritional Shake|Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.
10137129|NCT04230616|Active Comparator|Conventional total knee arthroplasty|conventional total knee arthroplasty with standard intramedullary alignment guide
10137130|NCT04230616|Active Comparator|NAVIO total knee arthroplasty|NAVIO assisted total knee arthroplasty
10137131|NCT04230850|Active Comparator|Mildly Impaired Group|This group will consist of participants with 35-50 degrees of lumbar flexion.
10137132|NCT04230850|Active Comparator|Moderately Impaired Group|This group will consist of participants with 20-34 degrees of lumbar flexion.
10137133|NCT04230850|Active Comparator|Highly Impaired Group|This group will consist of participants with less than 20 degrees of lumbar flexion.
10137134|NCT04230759|Active Comparator|5FU+Mitomycin C|Radiochemotherapy for anal cancer
10137135|NCT04230759|Experimental|5FU+Mitomycin C+Durvalumab|Radiochemotherapy with Durvalumab for anal cancer
10137136|NCT04230772|Experimental|Natural Orifice Specimen Extraction Surgery|Natural orifice specimen extraction surgery will performed in patients assigned to this group.
10137137|NCT04230772|Active Comparator|Traditional Robotic-assisted Surgery|Traditional robotic-assisted surgery will performed in patients assigned to this group.
10137138|NCT04230863|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation.
10137139|NCT04230525||Bioimpedence|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia.
10137140|NCT04230551|Active Comparator|Reference Group|Five symptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
10137141|NCT04230551|Experimental|Study Group|Five asymptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
9519652|NCT03284840||Elderly (65-74 years)|
10137142|NCT04230551|No Intervention|Observation Group|Five asymptomatic HOCM patients with severe LVOT obstruction will not undergo PTSMA
10137143|NCT04230460|Placebo Comparator|0% THC/ 0% CBD|
9519653|NCT03284814|Active Comparator|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
10137144|NCT04230460|Experimental|THC (5-10% [37.5 mg]) / Low CBD (<1% [2.5 mg])|
10137145|NCT04230460|Experimental|THC (>10% [62.5 mg]) / Low CBD (<1% [2.5 mg])|
10137146|NCT04230460|Experimental|0.065% BAC|
10137147|NCT04230473|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
10137148|NCT04230330|Experimental|Nivolumab|After 4 doses of nivolumab, if the patient has complete responses (CR) or good partial response (PR), the patient will continue on nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment. During PET4-directed treatment with single agent nivolumab, if patient has PD, they will proceed to the Nivo+GDP/L-aspa arm.
10137149|NCT04230330|Experimental|Nivolumab + GDP/ L-asparaginase|After 4 doses of nivolumab, if the patient has PR, stable disease (SD), or progressive disease (PD), the patient will switch to nivolumab-GDP/L-aspa treatment. After 6 cycles of treatment, if CR is achieved, the patient will continue on single agent nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment.
10137150|NCT04230317|Experimental|Low dose chest CT simulation|VBN result driven using raw data acquired with low dose CTs taken with three different protocols
10137151|NCT04230317|Active Comparator|Standard protocol chest CT simulation|VBN result driven using raw data acquired with standard protocol CT
10137152|NCT04230369|Experimental|Internet-CBT|The internet-CBT will comprise 8 weekly modules with therapist-support, encouraging exposure for fear of asthma symptoms while ensuring a stable asthma medication through a written medical plan on medical adherence Participants work independently from home with the treatment and receive weekly support from their psychologist through written messages online.
10137153|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment, but psychological, from pre-assessments to 2 months after treatment completion. Participants in this arm will be crossed over to Internet-CBT after the primary endpoint at to 2 months follow up.
10137154|NCT04230343|Experimental|Self-benefit arm|
10137155|NCT04230343|Active Comparator|Social-benefit arm|
10137156|NCT04230044||Fycompa® (perampanel)|Fycompa® (perampanel) (oral tablets) treatment will be initiated at 2 milligram (mg) once daily according to the approved package insert, as an add-on drug in addition to other anti-epileptic drugs (AEDs) as prescribed by physician. The dose will be increased based on clinical response and tolerability (by increments of 2 mg/day to a maintenance dose of 4 to 12 mg/day) and participants will be enrolled and observed prospectively for up to 54 Weeks.
10137157|NCT04230083|Experimental|Dienogest Test Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
10137158|NCT04230083|Active Comparator|Dienogest Reference Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
10137159|NCT04230070|Experimental|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
10137160|NCT04230070|Active Comparator|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
10137161|NCT04230187|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
10137162|NCT04230187|Active Comparator|mFOLFOX6 Plus Bevacizumab|Patients will receive mFOLFOX6 plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
10137163|NCT04230096|Experimental|applied group|low level laser therapy applied in one group
10137164|NCT04230096|No Intervention|controlled group|other group will be controlled in which low level laser will not be applied
10137165|NCT04230447||a cohort of patients with sepsis encephalopathy|This study is an observational study without drug and other interventions
10137166|NCT04230447||a cohort of patients with sepsis|This study is an observational study without drug and other interventions
10137167|NCT04230447||a cohort of patients with SIRS|This study is an observational study without drug and other interventions
10137168|NCT04230057||Healthy volunteer|"In good general health and feeling well (no diagnosed disorders/illnesses)~At least 18 years old~BMI in the range of 18-29.9 kg/m²~No known history of substance abuse~No known allergies to food/drug"
10137169|NCT04230239|Experimental|CPX-351|
10137170|NCT04230226|Active Comparator|Pre-workout and Post-workout Product|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
10137171|NCT04230226|Placebo Comparator|Study Placebo|non-caloric powder mixed with water consumed within 30 minutes prior to exercise and within 15 minutes post exercise
10137172|NCT04230135|Active Comparator|Generic (surface adaptation)|The generic version of Hap-pas-Hapi includes only surface adaptations (i.e., adaptation of text and illustrations that are inacceptable or non-meaningful for the target group)
10137173|NCT04230135|Experimental|Adapted (deep structure adaptation)|For the experimental intervention, Hap-pas-Hapi was adapted to Albanian immigrants' cultural concepts of distress (CCD). An ethnopsychological study was conducted for this purpose, since evidence on CCD in South Eastern Europe is scarce. Based on this study, three deep-structure adaptations were done: i) the symptom narrative provided by the narrator in the app was re-written to reflect Albanian immigrants' CCD; ii) a new explanatory model builder was implemented to address the target group's fatalistic beliefs; and iii) a goal-setting task was programmed to address the target group's socio-centric notion of the self.
10137174|NCT04230382||Adults|Adults (above 18 years) with completed National Health and Health System Survey 2019 (without diagnosis of diabetes)
10137175|NCT04229979|Experimental|Galinpepimut-S|"A maximum of 15 total injections will be administered as follows:~First 6 galinpepimut-S injections: every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment. The first series of 6 injections of galinpepimut-S define the initial immunization induction phase.~Injections 7-12: every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment. The second series of injections of galinpepimut-S define the early immune booster phase.~Injections 13 to 15: every 6 weeks (between Weeks 40 and 52). The third series of injections of galinpepimut-S define the late immune booster phase."
10137176|NCT04229979|Active Comparator|Best Available Therapy|"Four options (per treating investigator's choice):~Observation (whereby palliative management with hydroxyurea is allowed), or~HMA (decitabine or azacitidine) monotherapy, or~Venetoclax monotherapy, or~Low-Dose Ara-C"
10137177|NCT04230174|Experimental|Multiple sclerosis patients|Multiple sclerosis patients will be evaluated with 11C-PBR28 MR-PET at baseline before and at 12 month follow up after Ocrelizumab therapy.
10137178|NCT04230018||primary and metastasis lesion|tissue of colorectal cancer primary lesion and tissue of colorectal cancer metastasis were obtained
10137179|NCT04230291|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP~Survey A~Routine clinic visit~Verbal consultation only~Survey B~Verbal consultation AND Written Action Plan~Survey C"
10137180|NCT04230291|Experimental|Written Action Plan|"INTERVENTION GROUP~Survey A~Routine clinic visit~Verbal consultation AND Written Action Plan~Survey C"
10137181|NCT04229953||US scan with 3D/4D VRU software|
10137182|NCT04230213|Experimental|Treatment Arm 1|Subcutaneous (SC) injection given every other week
10137183|NCT04230213|Active Comparator|Treatment Arm 2|SC injection given every other week
10184363|NCT03755739|Active Comparator|Checkpoint inhibitor (CPI) Pembrolizumab via vein infusion|Checkpoint inhibitor (CPI) such as Pembrolizumab is administrated with a total dose of 2mg/kg via vein infusion (30 min), every 3 weeks.
10184364|NCT03755700|Placebo Comparator|Placebo|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with the placebos of both vitamin E and NAC (i.e. the placebo of vitamin E as a soft gel capsule and the placebo of NAC as an effervescent tablets along with a glass of water with the same consumption order used in the groups 2 and 3, respectively).
9519654|NCT03284814|Active Comparator|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
10137184|NCT04229875|Experimental|CAG Bipolar|"Patients will be treated in a localized CAG Bipolar clinic within each psychiatric centre increasing the number of bipolar patients for each clinician~All clinicians will get certified in diagnosing and treating bipolar disorder by joining an educational course and ongoing courses continuously~Treatment will include a group-based psychoeducation program~Coordinated targets to improve quality of life of patients by increasing concordance between clinicians, patients and relatives on well-defined treatment goals~Continued ongoing supervision of patient cases in CAG Bipolar staff by the Copenhagen Affective Disorder Clinic~Three-month bidirectional exchange of two clinical staff members between the Copenhagen Affective Disorder Clinic and each CAG Bipolar clinic~Recovery mentors"
10137185|NCT04229875|No Intervention|Control group|Standard treatment
9519655|NCT03284814|Experimental|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
10137186|NCT04229784|Experimental|RF ARM|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
10137187|NCT04229927|Experimental|Arm 1|
10137188|NCT04229927|Placebo Comparator|Arm 2|
10137189|NCT04229589||Study population|Consecutive patients undergoing pacemaker implantation for bradyarrhythmic syncope
10137190|NCT04229758|Experimental|1 week|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
10137191|NCT04229758|Experimental|2 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
10137192|NCT04229758|Experimental|4 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
10137193|NCT04229862|Experimental|Evaluation with 14 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 14 cm high pillow.
10137194|NCT04229862|Active Comparator|Evaluation with 7 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 7 cm high pillow.
10137195|NCT04229706|Experimental|High dose group|xiangjurupining capsule ,8 capsules，tid
10137196|NCT04229706|Experimental|Lower dose group|xiangjurupining capsule, 4 capsules,tid, xiangjurupining capsule placebo ,4 capsules，tid，po
10137197|NCT04229706|Placebo Comparator|Placebo group|xiangjurupining capsule placebo ,8 capsules，tid，po
10137198|NCT04229719|Experimental|Melatonin group|Melatonin powder (N-Acetyl-5-methoxytryptamine) 1.2mg topical application in osteotomy site.
10137199|NCT04229719|No Intervention|Control group|No drug intervention
10137200|NCT04229810|Active Comparator|STD-02|Conventional standardized lung protective ventilation.
10137201|NCT04229810|Experimental|iOLA-iHFNC|Individualized ventilatory strategy that mantains an open lung condition.
10137202|NCT04229537|Experimental|SCT-I10A combined SCT200 in ESCC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
10137203|NCT04229537|Experimental|SCT-I10A combined SCT200 in CRC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
10137204|NCT04229537|Experimental|SCT-I10A combined SCT200 plus Chemotherapy in CRC|"SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W.~Chemotherapy: Capecitabine and Oxaliplatin."
10137205|NCT04229732|Experimental|ClearMate Intervention|Participants undergo passive isocapnic hyperventilation via the ClearMateTM device and have regular venous blood samples obtained to measure ethanol clearance kinetics.
10137206|NCT04229732|No Intervention|Supportive Management|Participants receive standard of care, supportive management, for alcohol intoxication, having regular venous blood samples obtained to measure ethanol clearance kinetics.
10137207|NCT04229524|Experimental|angiographic intervention group|Enrolled patients will undergo thoracoscopy combined with a three-incision esophageal carcinoma radical mastectomy and two-field (chest-abdomen) lymph node dissection.Quantitative assessment of blood supply in the gastic conduit was performed using fluoroscopy before esophagogastric anastomosis.
10137208|NCT04229524|No Intervention|control group|The same surgical method as the experimental group.The only difference is that the position of the gastic conduit anastomosis is determined based on the experience of the doctor.
10137209|NCT04229563||Study patients|Eligible PAD patients who are routinely treated with atherectomy by AURYON™ Atherectomy System.
10137210|NCT04229550|No Intervention|Control subjects|1 week of normal daily life and only by the National Health Board recommendated alcohol consumption.
10137211|NCT04229550|Experimental|Festival subjects|1 week's participation in Roskilde Festival 2016
10137212|NCT04229849|Experimental|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
10137213|NCT04229849|Active Comparator|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
10137214|NCT04229823||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
10137215|NCT04229823||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
10137216|NCT04229823||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
10184365|NCT03755700|Active Comparator|Vitamin E|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention plus the placebo of NAC with a consumption order similar to group 3.
10137217|NCT04229511||Infection caused by CRKp|Group 1 cases are constituted by one BSI episode or non-bactereamic invasive infection episode (eg. pneumonia, intra-abdominal infection or urinary tract infection) with CRKp and a positive rectal swab screening or invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other invasive infection with CRKp
10137218|NCT04229511||Infection caused by any other bacteria|Group 2 cases who are colonized with CRKp or had invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other types of invasive infection with any bacteria other than CRKp and develop subsequent BSI or non-bactereamic invasive infection with these bacteria
10137219|NCT04229511||No infection|Group 3 cases involve the colonized patients with CRKp who do not develop subsequent BSI or other invasive infections with CRKp or any other bacteria
10137220|NCT04229446|Experimental|Receive the music based intervention|After the healthcare workers have accomplished the MBC program the eight week intervention program will be applied by the trained staff at the intervention wards. The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement. The movement will be adapted to their physical capacity.
10137221|NCT04229446|No Intervention|Standard care group|Standard care
10137222|NCT04229459|Experimental|Neoadjuvant Treatment|All subjects will receive induction chemotherapy and chemoradiation combined with cetuximab followed by nivolumab and cetuximab as neoadjuvant treatment
10137223|NCT04229212|No Intervention|No drainage|No drainage
10137224|NCT04229212|Experimental|Drainage|a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed
10137225|NCT04229225|Experimental|UBX0101 single dose (SD)|"Cohort 1 (n=18): UBX0101 8.0 mg or placebo IA at Week 0~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
10137226|NCT04229225|Experimental|UBX0101 repeat dose (RD)|"Cohort 2 (n=18): UBX0101 4.0 mg or placebo IA at Weeks 0 and 4~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
10137227|NCT04229160|Experimental|patient with persistent atrial fibrillation|persistent atrial fibrillation is defined as lasting longer than 6 months documented by a 24h holter monitoring
10137228|NCT04229420|Active Comparator|Rectus sheath block group (RSB)|After preparing the skin, a high frequency (5-10 MHz) ultrasound probe will be placed in a longitudinal orientation above the level of the umbilicus with the Patient in the supine position. After identifying the rectus abdominis muscle, A 22 G echogenic needle using the in plane technique will be inserted just below the costal margin then, a total of 20 ml of 0.25% bupivacaine will be injected into the plane between the rectus muscle and posterior rectus sheath. Negative aspiration will be confirmed every 5 ml. The block will then be repeated on the other side.
10137229|NCT04229420|Active Comparator|Erector spinae plane block group (ESPB)|After induction of anesthesia; the patient will be positioned on the lateral position. The skin will be prepared with povidone iodine, and a high frequency (5-10 MHz) ultrasound probewill be placed in a transverse orientation on the T9 spinous process which will be located by palpating and counting down from the C7 spinous process. The tip of the T9 transverse process will be identified and centred on the ultrasound screen, the probe will then be rotated into a longitudinal orientation to produce a parasagittal view. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is conﬁrmed by injecting 0.5-1 ml saline and seeing the ﬂuid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20 ml of 0.25% bupivacaine will then be injected into the ESP of both sides.
10137230|NCT04229238||Home-dwelling older adults|Older adults (70 +) receiving regular health care from the home nursing service. Setting is two rural municipalities in southern Norway.
10137231|NCT04229433|Experimental|SHR2285|Participants received one of 3 dose levels of SHR2285 administered as multiple oral doses.
10137232|NCT04229433|Experimental|Placebo|Participants received one of 3 dose levels of placebo administered as multiple oral doses.
10137233|NCT04229329|Experimental|Intervention|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded visually and auditory when a higher degree of finger individuation will be measured. Specifically, when the applied force of the instructed fingers hit the predefined force target and at the same, the force in the non-instructed fingers stay as low as possible
10137234|NCT04229329|Sham Comparator|Control|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded in a way that is unrelated to the degree of individuation. In other words, a successful trial considered when the applied force of the instructed fingers hits the predefined force target regardless of the force exerted in the non-instructed fingers.
10137235|NCT04229264|Active Comparator|Control group|Aspirin 100 mg (oral, once-daily) for 1 year plus Clopidogrel 75 mg (oral, once-daily) for 3 months.
10137236|NCT04229264|Experimental|Apixaban group|Apixaban 2.5 mg (oral, twice daily) for 1 year plus Aspirin 100 mg (oral, once-daily) for 1 year.
10137237|NCT04229394|Experimental|2ccPA|"Only day 1 Intra-articular injection can be given under direct ultrasound guidance; the only one strength for 2ccPA injection vial is 2,400 μg (1.2 mL per vial).~IP name: 2-carba-cyclic phosphatidic acid (2ccPA)"
9969096|NCT01286844|Experimental|Cohort 1|Subjects ≥4 and< 12 years. First 6 subjects included, ≥8 and< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects < 21kg receive 2 SD periods (10mg and 50mg), Subjects > 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
9694655|NCT04786821|Placebo Comparator|Standard Exercise Training Programme|Participants will receive interventions by an exercise specialist based on the participant's tolerance. These sessions will be delivered by a exercise specialist.
10137238|NCT04229394|Placebo Comparator|Placebo|Only day 1 Intra-articular injection can be given under direct ultrasound guidance; placebo
10137239|NCT04229355|Experimental|DEB-TACE plus Sorafenib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive sorafenib (400 mg/d, po, bid) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
10137240|NCT04229355|Experimental|DEB-TACE plus Lenvatinib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive lenvatinib (8 mg/d, po, qd) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
10137241|NCT04229355|Active Comparator|DEB-TACE plus PD-1 inhibitor|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive PD-1 inhibitor (200 mg, iv, 3 weeks) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. PD-1 inhibitor will be taken for six months, untill tumor progression, or intolerable adverse reactions.
10137242|NCT04229316|Experimental|zLock Facet Locking Implant System|
10137243|NCT04229251|Experimental|Online Mindfulness-based Intervention|iMBI will be delivered to participants in 8 online sessions, approximately 2 hours per session.
10137244|NCT04229251|Sham Comparator|Online Introductory Psychology Program|An online introductory psychology courses will be delivered to participants in 8 online sessions, approximately 2 hours per session.
10137245|NCT04229576|Active Comparator|Using TENS to relief pain during hystroscopy|device intensity (amplitude) will be individually adjusted to each participant's maximum sensory level (strongest reported tingling feeling without pain and with no muscle contractions, the TENS output intensity will be increased during the treatment every time the patient accommodated to the TENS stimulus.
10137246|NCT04229576|Placebo Comparator|Using placebo TENS (not active) during hystroscopy|participants will be connected to the TENS unit in exactly the same way as participants in the active TENS group with the unit emitting the active indicator light and sound but delivering no electrical stimulation.
10137247|NCT04229199|Experimental|intervention group (IG)|Dyads of children and parents allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
10137248|NCT04229199|No Intervention|control group (CG)|Dyads assigned to the CG were provided only the standard practice on their day admission to the hospital.
10137249|NCT04229069|Active Comparator|Basica|4-week dietary supplementation with an alkaline salt (Basica)
10137250|NCT04229069|Placebo Comparator|Placebo|4-week dietary supplementation with a placebo
10137251|NCT04229121||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation positive.
10137252|NCT04229121||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation negative.
10137253|NCT04229277|Other|in tumours|consecutive enrollment of newly referred skin tumour patients
10137254|NCT04229602|Experimental|Venlafaxine Hydrochloride Sustained-Release Capsules|During the study session, healthy subjects will be administered a single dose of Hydrochloride Sustained-Release Capsules 75 mg under Fed conditions.
10137255|NCT04229602|Active Comparator|Active Comparator: EFEXOR® XR|During the study session, healthy subjects will be administered a single dose of EFEXOR® XR 75mg under Fed conditions.
10137256|NCT04229186|Experimental|Patients with assumption of EVOO-C|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg EVOO-C
10137257|NCT04229186|Experimental|Patients with assumption of ROO|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg ROO
10137258|NCT04229082||lean|BMI between 18-25
10137259|NCT04229082||obese|BMI between 27.5-35
10137260|NCT04229134|Other|Pilot Arm: Project CONNECT|8-week home based reciprocal peer support pain self-management program for chronic musculoskeletal pain
10137261|NCT04229108|Other|Healthy volunteer|Will record traditional timed up and go followed by two digitised versions
10137262|NCT04229498||Carbapenem resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
10137263|NCT04229498||Carbapenem hetero-resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-heteroresistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
10137264|NCT04229342|Active Comparator|Conventional|"In the conventional group, standard posterior myotomy will be performed and the sling or the oblique fibers will not be spared beyond the gastroesophageal junction."
9694656|NCT04786821|Active Comparator|Exoskeleton Exercise Programme|The Phoenix Exoskeleton suit will be used in this study. It is a powered Exoskeleton, with a modular design. Participants will receive interventions by an research physiotherapist based on the participant's tolerance.
9969097|NCT01286844|Experimental|Cohort 2|Subjects ≥1 and< 4 years, receive 2 SD (5mg and 25mg)
10137265|NCT04229342|Experimental|Oblique or sling fiber sparing group|In the oblique or sling fiber group, only the circular muscle fibers will be severed selectively and the sling fibers will be spared
10137266|NCT04229407|Experimental|Dietary supplement|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).~After 32 subjects in MRI strata is reached. subjects will be randomized to intake Dietary supplement twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks"
10137267|NCT04229407|Placebo Comparator|vitamin B|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).~After 32 subjects in MRI strata is reached. subjects will be randomized to intake placebo vitamin B twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks."
10137268|NCT04229043|Active Comparator|Early labor, no analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
10137269|NCT04229043|Placebo Comparator|Early Labor, no analgesia: Water|Subject will ingest 100 ml of water
10137270|NCT04229043|Active Comparator|Early labor, analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
10137271|NCT04229043|Placebo Comparator|Early labor, analgesia: Water|Subject will ingest 100 ml of water
10137272|NCT04228913|Other|Ah plus|The root canals obturated with Ah plus root canal sealer (Dentsply, Sirona) and gutta-percha cones with cold lateral condensation technique.
10137273|NCT04228913|Other|ROEKO GuttaFlow® 2|The root canals obturated with GuttaFlow 2 root canal sealer (Coltene,Whaledent) and single tapered gutta-percha cone with cold free flow compaction technique.
10137274|NCT04228913|Other|GuttaCore Obturators|The root canals obturated with GuttaCore obturators (Dentsply,Sirona) and Ah plus root canal sealer with thermoplasticized solid-core carrier technique
10184366|NCT03755700|Active Comparator|NAC|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention plus the placebo of vitamin E with the consumption order similar to group 2.
10184367|NCT03755674|Experimental|CHRONOTYPE-ADJUSTED DIET|Patients that undergo a chronotype adjusted diet
10184368|NCT03755674|No Intervention|CONTROL|Patients following a traditional or conventional hypocaloric diet
10184369|NCT03755648|Experimental|Treadmill training|Group A: received treadmill training along with traditional physiotherapy.. The motorized treadmill was used keeping treatment parameters as 50 Hertz, 10 Ampere and 220 Volts The treadmill training was provided by giving instructions first and then warm up was given for 5 minutes prior to the training. The children were upright with the feet flat on treadmill platform. The height of handrails was adjustable according to every child thus keeping their gaze forward. The training was ended at cool down period of 5 minutes
10184370|NCT03755648|Other|traditional physical therapy|Traditional therapy includes use of hot packs for 15 minutes and stretching for 20 minutes which will be applied to both groups prior to actual intervention
10184371|NCT03755648|Experimental|Delorme Resistance exercise|Group B received delorme resistance exercise with traditional physiotherapy. Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
10184372|NCT03755635|No Intervention|Standard of care|Continuously monitoring of neonatal sepsis under standard of care at one site
10184373|NCT03755635|Experimental|Hand hygiene|The WHO multimodal hand hygiene strategy is implemented at one site
10184374|NCT03755622|Active Comparator|Group C (Conventional)|Group C consists of patients who receive Transplatal Arch (TPA) fabricated from conventionally made stone working model.
10184375|NCT03755622|Experimental|Group 3D ( Three Dimensional)|Group 3D consists of patients who receive Transpalatal Arch (TPA) made from 3D recontructed model.
10184376|NCT03755609|Active Comparator|patients with oxycodone|
10184377|NCT03755609|Sham Comparator|patients with fentanyl|
10184378|NCT03755596|Experimental|Treatment|Oral treatment with single-dose 160mg Z. officinale extract in tablet form.
10184379|NCT03755583|Other|EEN group|Received exclusive enteral nutrition after enrollment.
10184380|NCT03755570||CRT: Main Arm|"Cardiac Resynchronisation Therapy (CRT): Main Arm ~98 participants~Prior to CRT Implantation & Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning, Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
10184381|NCT03755570||ICD and PPM: Control Arm|"Implantable Cardioverter-Defibrillator (ICD) and Permanent Pacemaker (PPM): Control Arm ~98 participants~Prior to ICD or PPM Implantation & Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
10184382|NCT03755557|Placebo Comparator|Placebo|Application of a placebo nasal spray once daily for 8 days Nasal Sprays
10184383|NCT03755557|Active Comparator|Rhinocort|"Nasal Sprays Application of Rhinocort Aqua 64 micrograms, nasal spray once daily for 8 days. Daily dosage 256 µg/d"
10184384|NCT03755557|Experimental|Budesolv|Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays
10184385|NCT03755531|Experimental|Carbetocin|One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection after labor of the baby at once.
9519656|NCT03284788|Experimental|ABT Weight Loss Intervention|Adolescent girls will attend healthy lifestyle sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
10184386|NCT03755531|Active Comparator|Oxytocin|One ml of Oxytocin (10 IU), was given as a bolus intravenous injection after labor of the baby at once.
10184387|NCT03755505||Healthy Smoker|Healthy smoker with normal spirometry value
10137275|NCT04228952||Smokers with very low or no CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with little or no CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of <0.6).
10137276|NCT04228952||Smokers with high CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with high CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of > 3.0)
10137277|NCT04228744|Experimental|Bilateral surgical implantation of DBS system|All the participants will receive bilateral surgical implantation of DBS system to VIC and NAc. The experimenter will active the DBS system and adjust the parameters for all the participants after surgery.
10137278|NCT04228887|Active Comparator|Control Group|The control group will be receive 45 minutes training sessions 3 times a week for 8 weeks; 2 days a week for home based balance training and 1 day for supervisory training with Bio-Dex Balance-System ®.
10137279|NCT04228887|Active Comparator|Training Group|The training group will receive inspiratory muscle training; 15 minutes sessions 5 times a week for 8 weeks in addion to balance training same as control.
10137280|NCT04229030|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL RZL-012 (5mg).~Lipomas in the size of:~2-3.9 cm will be dozed with 0.4mL RZL-012 (20mg). 4-5.9 cm will be dozed with 0.8mL RZL-012 (80mg). 6-7.9 cm will be dozed with 1 mL RZL-012 (100mg). 8-10 cm will be dozed with 1.2 mL RZL-012 (120mg)."
10137281|NCT04229030|Placebo Comparator|Vehicle of RZL-012|"A single-treatment injection, multiple subcutaneous injections of vehicle administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL vehicle.~Lipomas in the size of:~2-3.9 cm will be dozed with 0.4mL vehicle. 4-5.9 cm will be dozed with 0.8mL vehicle. 6-7.9 cm will be dozed with 1 mL vehicle. 8-10 cm will be dozed with 1.2 mL vehicle."
10137282|NCT04228770|Experimental|Warfarin patients|Patients on high risk medication - warfarin
10137283|NCT04228770|Experimental|Parkinson's patients|Patients with high risk disease - parkinson's
10137284|NCT04228692|Active Comparator|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary
9694657|NCT04786938|Experimental|Saccharomyces boulardii|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34) plus S. boulardii CNCM I-745 (approximately 22.5 x109 CFU
10137285|NCT04228692|Experimental|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
9694658|NCT04786938|No Intervention|No intervention|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34)
10137286|NCT04228809|Experimental|anodal tDCS|anodal tDCS stimulation
10137287|NCT04228809|Active Comparator|cathodal tDCS|cathodal tDCS stimulation
10137288|NCT04228809|Placebo Comparator|sham tDCS|sham tDCS stimulation (stopped after 30 seconds)
10137289|NCT04228835|Experimental|ICGFC-LC|ICG fluorescence cholangiography assisted laparoscopic cholecystectomy (ICGFC-LC) arm patients received intravenous bolus of 2.5mg of ICG before the induction of anaesthesia. Near infrared laparoscopic light camera was utilized intermittently during dissection of Calot's triangle until critical view of safety was achieved.
10137290|NCT04228835|No Intervention|Conventional LC|Conventional laparoscopic cholecystectomy (LC) arm patients underwent standard white light laparoscopic cholecystectomy without fluorescence cholangiography.
10137291|NCT04228926|Experimental|0.002% ZKY001 eye drops|Experimental group A: 35 subjects .0.002% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
10137292|NCT04228926|Experimental|0.004% ZKY001 eye drops|Experimental group B: 35 subjects .0.004% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
10137293|NCT04228926|Placebo Comparator|The placebo|Placebo group C: ZKY001 simulated eye drops .4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 simulated eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
10137294|NCT04228640|Experimental|Investigational Product|Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
10137295|NCT04228640|Placebo Comparator|Placebo|Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
10137296|NCT04228653|Experimental|No Arm|As this is the follow up study, there are no arms
10137297|NCT04228900|Experimental|Intervention group|Drug review and tailored nutritional supply.
10137298|NCT04228900|No Intervention|Control group|"Follow-up by home nurse service and family physician as usual."
10137299|NCT04228705||The elders|Patients aged over 59 years old
10137300|NCT04228705||The young adults|Patients aged from 18 to 59 years old
10137301|NCT04228939|Experimental|Intervention group (IG)|
10137302|NCT04228939|Active Comparator|Control group (CG)|
10137303|NCT04228627|Active Comparator|Treatment|Intravenous Iron to correct Iron deficiency without anaemia
10137304|NCT04228627|No Intervention|Prophylaxis|Usual antenatal care
10137305|NCT04228614||Retrospective cohort|Whole exome sequencing of 2500 retrospective tissue sample.
10137306|NCT04228614||Prospective cohort|Whole exome sequencing of 500 prospectively collected tissue samples. Panel sequencing of 451 genes of prospectively collected blood samples.
10137307|NCT04228484|Placebo Comparator|Placebo|Placebo infusion
10137308|NCT04228484|Active Comparator|GIP receptor antagonization|GIP(3-30)NH2 infusion
10184388|NCT03755505||COPD|Patients with smoking history at least 10 pack-year Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
10137309|NCT04228471|Experimental|Spontaneous Breathing Group|"Spontaneous breathing activity will be allowed during APRV within one hour after randomization throughout the first 48 hours.~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
10137310|NCT04228471|Experimental|Controlled Mechanical Ventilation Group|"Pressure controlled mechanical ventilation will be applied throughout the first 48 hours.~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
10137311|NCT04228757|Experimental|Investigational Herbal Blend|A phytoestrogen herbal blend
10137312|NCT04228757|Placebo Comparator|Placebo|Tablet without active ingredients
10137313|NCT04228666|Experimental|HB-adMSCs|HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells.
10137314|NCT04228601|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib+mFOLFIRINOX followed by Fluzoparib maintenance monotherapy
10137315|NCT04228601|Placebo Comparator|Placebo+mFOLFIRINOX|Placebo+mFOLFIRINOX followed by placebo maintenance monotherapy
10137316|NCT04228406|Experimental|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
10137317|NCT04228341|Other|Glucose Reference 1|Glucose solution 1
10137318|NCT04228341|Other|Glucose Reference 2|Glucose solution 2
10137319|NCT04228341|Other|Glucose Reference 3|Glucose solution 3
10137320|NCT04228341|Experimental|Brown Rice|Cooked brown rice
10137321|NCT04228341|Experimental|3 % polished rice|Cooked 3 % polished rice
10137322|NCT04228341|Experimental|6 % polished rice|Cooked 6 % polished rice
10137323|NCT04228341|Experimental|9 % polished rice|9 % polished rice
10137324|NCT04228341|Experimental|20 % Polished rice|Cooked 20 % Polished rice (White Rice)
10137325|NCT04228445|Experimental|HIGH DOSE|48 subjects randomly treated with 5 mL of drug
10137326|NCT04228445|Experimental|LOW DOSE|48 subjects randomly treated with 2.5 mL of drug
10137327|NCT04228445|Placebo Comparator|Saline|96 subjects treated with 5 ml of saline than crossover to treatment arm
10137328|NCT04228315|Experimental|Early primaquine group|Thirty (30) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and 15 mg/day of oral primaquine for 14 days
10137329|NCT04228315|Active Comparator|Delayed Primaquine group|Sixty (60) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and the primaquine regimen (15 mg/day for 14 days) not given until 42 days after enrollment
10137330|NCT04228315|No Intervention|Healthy control group|Ten (10) age- and gender-matched controls will be enrolled for one day to obtain biological samples to be compared to the 2 intervention arms
10137331|NCT04228497|Active Comparator|clear fluids fasting for one hour|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml one hour before surgery
10137332|NCT04228497|Placebo Comparator|clear fluids fasting for two hours|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml two hours before surgery
10137333|NCT04228510||Study group|ST elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention who will be followed up in Assiut University hospital.
10137334|NCT04228549|No Intervention|Control|Usual care
10137335|NCT04228549|Experimental|MyPADMGT|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed.
10137336|NCT04228549|Experimental|MyPADMGT + Nudging|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed. In addition, nudging support available to help patients make better choices and decisions.
10137337|NCT04228263|Other|hydroxychloroquine group|hydroxychloroquine 400 mg preconceptional
10137338|NCT04228263|Other|Placebo group|will receive placebo
10137339|NCT04228432|Experimental|Patients with breast cancer treated by adjuvant hormonotherapy|
10137340|NCT04228562|No Intervention|Non-modifiable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
10137341|NCT04228562|Experimental|Non-modifiable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
9969098|NCT01286883||Blood draws|Laboratory studies will be performed at baseline; Cycle 1, Day 1; Cycle 1, Day 7; Cycle 2, Day 1; Cycle 3, Day 1; Cycle 4, Day 1; Cycle 6, Day 1; Cycle 12, Day 1.
10137342|NCT04228562|Experimental|Non-modifiable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
10137343|NCT04228562|Experimental|Non-modifiable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
10137344|NCT04228419|Active Comparator|<-10 Degrees of Retroversion|
10137345|NCT04228419|Active Comparator|>-10 Degrees of Retroversion|
10137346|NCT04228523|Experimental|Therapeutic education workshop|Two group receive therapeutic education workshop already existing in Toulouse University Hospital
10137347|NCT04228523|Other|Speaking Therapy|One group receive speaking therapy already existing in Toulouse University Hospital
10137348|NCT04228588|Experimental|Mepolizumab|Mepolizumab 100mg, SC, every 4 weeks
10137349|NCT04228380||Inclusion|Inclusion criteria: The cohort is made up of adult patients over 18 years of age, admitted to intensive care units in Sweden, for other reason than postoperative care or simple monitoring.
10137350|NCT04228380||Exclusion|Exclusion criteria: Children under the age of 18 will be excluded as well as patients admitted for simple monitoring or postoperative care.
10137351|NCT04228393|Active Comparator|Standard treatment regimen|6-mercaptopurine was administered according to the Chinese Children Cancer Group (CCCG) protocol-ALL 2015.
10137352|NCT04228393|Experimental|Individualized treatment regimen|6-mercaptopurine was administered on the basis of Chinese Children Cancer Group (CCCG) protocol-ALL 2015 combined with Clinical Pharmacogenetics Implementation Consortium (CPIC), genotypes and the concentrations of 6-TGN in red blood cells.
10137353|NCT04228289|Experimental|Oxytocin|40 IU intranasal oxytocin
10137354|NCT04228289|Placebo Comparator|Placebo|intranasal saline spray
10137355|NCT04228185|Experimental|Laparoscopic banded sleeve gastrectomy|Group undergoing banded sleeve
10137356|NCT04228185|Active Comparator|Laparoscopic sleeve gastrectomy|Group undergoing standard sleeve
10137357|NCT04228068|Experimental|Intervention|The exercise program will be for the first 12 weeks after returning home. The intervention will be provided after patients return home. Each patient will receive 7 home visits in total over the intervention period by a physiotherapist (PT) and/or a physiotherapy assistant (PTA). Participants in the intervention group will receive a copy of the Toolkit before discharge from the hospital, and the study coordinator will walk them through it and explain what should be expected during the intervention period.
10137358|NCT04228068|Active Comparator|Conventional care|Usual care
10137359|NCT04228224|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 2 sessions per week for 12 weeks, each lasting about 1 hour.
10137360|NCT04228224|Active Comparator|Conventional Gait Rehabilitation|Participants in this group will perform conventional gait rehabilitation on a rehabilitation institution with assistance of a physical therapist. Training involve 24 sessions, 2 sessions per week, each session lasting about 1 hour.
10137361|NCT04228094||TDApp1|This cohort will use TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
10137362|NCT04228016|Experimental|Experimental: Device : nasal airway stent|All patients consulting for predominantly nocturnal nasal obstruction who have benefited from Nasal Respiratory Functional Exploration with detection of pathological resistance in the decubitus.
10137363|NCT04228198||Radical cystectomy|Patients with histologically confirmed diagnosis of bladder cancer undergoing radical cystectomy surgery at 28 Urology departments in Italy
10137364|NCT04227990|Active Comparator|TAC + Pegfilgrastim (6 mg)|
10137365|NCT04227990|Experimental|TAC + Plinabulin 10 mg/m^2|
10137366|NCT04227990|Experimental|TAC + Plinabulin 20 mg/m^2|
10137367|NCT04227990|Experimental|TAC + Plinabulin 30 mg/m^2|
10137368|NCT04227990|Experimental|TAC + Pegfilgrastim (1.5 mg) + Plinabulin (20 mg/m^2)|
10137369|NCT04227990|Experimental|TAC + Pegfilgrastim (3 mg) + Plinabulin (20 mg/m^2)|
10137370|NCT04227990|Experimental|TAC + Pegfilgrastim (6 mg) + Plinabulin (20 mg/m^2)|
10137371|NCT04228133|Experimental|Home-delivered attention control training (ACT)|A home-delivered ACT comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV).
10137372|NCT04228133|Placebo Comparator|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat.
10137373|NCT04228055|Experimental|CLIPP2|24 Week Lifestyle Modification Intervention
10137374|NCT04228120|Experimental|intervention group|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
10137375|NCT04228120|No Intervention|control group|routine care
10184389|NCT03755492||Group 1 (Provided absorbent pads)|Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
9519657|NCT03284762||Treatment-naïve NVAF patients in Korea and Taiwan|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation
10137376|NCT04228081||UTI Positive|"In phase I of the study testing residual urine samples the aim is to include at least 50 positive samples from each bacterial species known to be commonly associated with urinary tract infections. We selected 2000 positive urines to enable capturing enough of these organisms in the development process.~For phase II of the study, the same number of positive samples in order to include all common species causing urinary tract infection. The number of negative samples included is reduced to 1000.~Phase 3 - approximately one third of all urine sample submitted will be positive for a uropathogen. Sample size of 3000 we expect 1000 these to be culture positive. We expect most uropathogens occurring at a frequency of 5% or more will be included with sufficient numbers in the validation process."
10137377|NCT04228081||UTI Negative Control|2000 negative urine samples are being run as controlled to ensure the false positivity rate is low.
10137378|NCT04228458|Experimental|Thermal Imaging|Thermal Imaging acquisition
10137379|NCT04227886||Good response|TRG of 0-1 is defined as good response.
10137380|NCT04227886||Poor response|TRG of 2-3 is defined as poor response.
10137381|NCT04227886||Light toxicity|No grade 3-4 toxicities occur during neoadjuvant therapy.
10137382|NCT04227886||Heavy toxicity|Grade 3-4 toxicities occur during neoadjuvant therapy.
10137383|NCT04227938|Experimental|ALPN-101|All subjects will receive a single dose of ALPN-101. In Part A, ascending dose levels of ALPN-101 will be evaluated. In Part B, a single dose level of ALPN-101-as identified in Part A-will be evaluated.
10137384|NCT04227795|Experimental|Artificial intelligence-Assisted real time colonoscopy|AI assisted real-time detection of colonic lesions
10137385|NCT04227808|Experimental|Lenvatinib Arm|Experimental: Participants will be given lenvatinib (12 mg/d for body weight≥60kg, 8 mg/d for body weight < 60kg) for 12 months until disease recurrence or intolerance AEs or death.
10137386|NCT04227964|Experimental|Periodontal regeneration|Periodontal regeneration consisting of papilla preservation flaps, application of FDA approved CE marked periodontal regenerative devices, tooth splinting and root canal treatment as required.
10137387|NCT04227964|Active Comparator|Extraction and tooth replacement|Tooth extraction and replacement with a dental implant or a fixed partial denture following healing and reconstruction of the extraction area. Choice based on standard of practice.
10137388|NCT04228146|Experimental|CBT-I condition|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment six weeks after the post-intervention assessment.
10137389|NCT04228146|Other|Waitlist control condition|Participants in the waitlist control group complete the post-intervention assessment six weeks after the baseline assessment, start CBT-I (equivalent to that of the CBT-I group) immediately after completing the post-intervention assessment, and complete the follow-up assessment right after they finish the 6-week CBT-I.
10137390|NCT04228003|Experimental|Pendulum|Pendulum Glucose Control formulation for T2D will be taken twice daily - 1 capsule with the morning meal and 1 capsule with the evening meal for 8 weeks with an option of continuing up to 6 months.
10137391|NCT04228029|Active Comparator|Carboxytherapy|
10137392|NCT04228029|Active Comparator|Intralesional steroids|
10137393|NCT04228029|Active Comparator|Combination of carboxytherapy and intralesional steroids|
10137394|NCT04227678|Other|Control group- A0|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);~A0: without heparin administered"
10137395|NCT04227678|Other|LPLD group-A0|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A0: without heparin administered"
10137396|NCT04227678|Other|Control group-A1|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g OGTT glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
10137397|NCT04227678|Other|LPLD group-A1|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
10137398|NCT04227665|Experimental|Sea level|Sea level training camp
10137399|NCT04227665|Experimental|Altitude|Altitude training camp
10137400|NCT04227743|Experimental|patients with endobronchial lesions|flexible bronchoscoy will be performed to patients with endobronchial lesions and biopsy from the lesions by forceps and cryoprope will be obtained
10137401|NCT04227704|Placebo Comparator|Control|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection and 40-minute intravenous infusion of 0.9% sodium chloride.
10137402|NCT04227704|Experimental|Ketamine SC|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.5 mg/kg of ketamine and a 40-minute intravenous infusion of 0.9% sodium chloride.
9519658|NCT03284749|Experimental|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
10137403|NCT04227704|Experimental|Ketamine IVI|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.9% sodium chloride and a 40-minute intravenous infusion of 0.5 mg/kg ketamine.
10137404|NCT04228159|Experimental|Perturbation training|"Session1 - baseline assessment (detailed above) Session2 - 13 - each session will begin with reassessment and documentation of balance tutor parameters for each participant as were calibrated at the end of previous session.~After reassessment the training program will include:~Warm up - walking without perturbation.~Perturbation during standing position.~Perturbation during walking.~Perturbation during tandem position.~Perturbation with vestibular stimulation.~Rest according to patient needs The relative duration of each component, as well as intensity and frequency of perturbations, will be adjusted to each individual according to his ability, reassessment parameters and progression.~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
10184390|NCT03755492||Group 2 (not provided absorbent pads)|Patients enrolled in the control arm will not receive absorbent pads.
10137405|NCT04228159|Active Comparator|Balance and strengthening exercise|"Session1 - baseline assessment (detailed above).~Session2 - 13 - each session will include:~Warm up (free walking or cycling).~Static balance exercise - standing position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.~Dynamic balance exercise - walking position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.~Strengthening exercise - general strengthening, particularly for lower limb.~Cool down. Level of difficulty and duration of each component will be adjusted to each individual according to his ability and progression.~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
10137406|NCT04227782||NAFLD|
10137407|NCT04227782||NASH|
10137408|NCT04227782||Cirrhosis|
10137409|NCT04227782||Healthy Volunteers|
10137410|NCT04227834|Active Comparator|Single education|Single health hygiene education
10137411|NCT04227834|Experimental|Repeated education|Four-monthly health hygiene education
10137412|NCT04227860|Active Comparator|Group 1: G I primary KOA|Exercise and balance training
10137413|NCT04227860|Active Comparator|Group 2: G II primary KOA|Exercise and balance training
10137414|NCT04227860|Active Comparator|Group 3: G III primary KOA|Exercise and balance training
10137415|NCT04227860|Active Comparator|Group 4: G IV primary KOA|Exercise and balance training
10137416|NCT04227548|Experimental|Healthy individuals|
10137417|NCT04227769|Experimental|healthy individuals|Two crossover visits with a washout period of at least 4 days in-between visits and at most two weeks: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal. Treatments will be placebo controlled, crossover, double blinded. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
10137418|NCT04227769|Experimental|obese patients with type 2 diabetes|Three crossover visits with a washout period of at least 4 days in-between: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal, C) Additionally, after the second study day, participant in group 2 will be trained to self-inject the medication for 6 days. On the 7th day, an oral standardized meal test will be performed. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
10137419|NCT04227561|Active Comparator|Pudendal nerve block|Neurostimulation-guided pudendal nerve block
10137420|NCT04227561|Active Comparator|Penile nerve block|Ultrasound-guided penile nerve block
10137421|NCT04227912|Active Comparator|Group TAP|Ultrasound-guided TAP Block
10137422|NCT04227912|Active Comparator|Group Local|Ultrasound-guided Local Infiltration
10137423|NCT04227912|Active Comparator|Group Dexketoprofen|Intravenous Dexketoprofen
10137424|NCT04227639|Active Comparator|T-piece trial|In patients assigned to control group all spontaneous breathing trials will be performed using T-piece trial.
10137425|NCT04227639|Experimental|Pressure-Support trial|In patients assigned to experimental group all spontaneous breathing trials will be performed with a pressure-support level of 8 cm H2O without positive end-expiratory pressure.
10137426|NCT04227626|Experimental|GlucoSTAT|Type 1 diabetes and Type 2 diabetes with a total daily dose (TDD) of insulin that is > 0.75 u/kg or ≥ 2 u/kg.
10137427|NCT04227652|Experimental|Aggressive treatment strategy|The antipyretic strategy was initiated immediately upon increase of the temperature above 38.3°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
10137428|NCT04227652|Experimental|Conservative treatment strategy|The antipyretic strategy was initiated only after the body temperature exceeded 39.5°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
10137429|NCT04227691|Active Comparator|Long-pulsed Nd YAG laser treatment|Ten patients will be randomized to receive Long-pulsed Nd:YAG in either left or right axilla. (The other axilla will serve as within-person control)
10137430|NCT04227691|Active Comparator|IPL treatment|Ten patients will be randomized to receive IPL treatment in either left or right axilla. (The other axilla will serve as within-person control)
10137431|NCT04227418||Mental Health|
10137432|NCT04227418||Psychiatric|
10137433|NCT04227405|No Intervention|Control group|Control group of couples will receive no intervention
10137434|NCT04227405|Experimental|Intervention|Intervention group of couples received the intervention: case management (connection to community services), 20 hour pscycho-educational workshop on communication, conflict resolution, problem-solving, stress management, and financial management, booster session, and employment support services if needed
10137435|NCT04227340|Experimental|Photobiomodulation Therapy (PBM)|The PBM will be administered extra-oral and intra-oral.
10137436|NCT04227574|Experimental|Zero Time Exercise training + WhatsApp anti-inertia reminders|Subjects in this group will receive daily WhatsApp anti-inertia reminders from the research assistant to remind and encourage them to practice Zero Time Exercise.
10137437|NCT04227574|Active Comparator|Zero Time Exercise training alone|Subjects in this group will not receive any WhatsApp reminders from week 8 to 24.
10137438|NCT04227236|Experimental|E-based virtual training|Participants in the e-based virtual training (up to 8 participants per session) will be placed at one of eight computers (with headphones), which we estimate will take less time (about 40 minutes), due to the individualized learning and 1:1 nature of the training instead of 1:15. Participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
10184391|NCT03755479||Single Arm Group|Patient on multiple daily injections will start Hybrid Closed Loop System Insulin Pump Minimed 670G
10137439|NCT04227236|Active Comparator|In-person training|Participants in-person training will participate in a class with 15-20 participants like the usual MPC training environment. The training will last 1 hour. Like the e-based virtual training, participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
10137440|NCT04227496|Active Comparator|Noise1|A sound will be played while moving a body part through range of motion
10137441|NCT04227496|Active Comparator|Noise2|A sound (different from Noise 1) will be played while moving a body part through range of motion
10137442|NCT04227496|No Intervention|No noise|No sound will be played while moving a body part through range of motion
10137443|NCT04227210|Experimental|RSV Vaccine: Dosage Group #1|Participants in this group will receive a single dose of the RSV vaccine at dosage #1
10137444|NCT04227210|Experimental|RSV Vaccine: Dosage Group #2|Participants in this group will receive a single dose of the RSV vaccine at dosage #2
10137445|NCT04227392|Experimental|Experimental|women who undergo radiofrequency therapy
10137446|NCT04227197|Experimental|Intervention Group|The participants randomized to the intervention group completed the DSC2U questionnaire, and received online access to a personalized Caregiver Checklist and PCP plan. Caregivers were encouraged to share and discuss the PCP plan at their next wellness visit with the PCPs.
10137447|NCT04227197|No Intervention|Control Group|The participants randomized to the control group, received usual care for 7 months, after their scheduled PCP appointment. They did not receive DSC2U during these 7 months, but did receive the online, personalized health assessment tool (DSC2U) at the end of the 7 months, after the primary and secondary outcomes were measured.
10137448|NCT04227275|Experimental|Dose Escalation|Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer
10137449|NCT04227483|Active Comparator|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 5 mg (maximum duration of therapy, 4 months)
10137450|NCT04227483|Experimental|Deflazacort|Deflazacort 0.75 mg/kg/day for 4 weeks; 0.375 mg/kg/day for 4 weeks; 0.1875 mg/kg/day for 4 weeks. Then taper by 6 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 6 mg (maximum duration of therapy, 4 months)
10137451|NCT04227522|Experimental|Arm A (Rucaparib)|Rucaparib treatment (starting dose 600 mg, twice daily) after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
10137452|NCT04227522|Placebo Comparator|Arm B (Placebo)|Placebo treatment after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
10137453|NCT04227587|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx.
10137454|NCT04227587|Active Comparator|Sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse. Each subject will receive a handout and a sleep hygiene log.Subjects will be told to record their daily compliance with sleep hygiene instructions using yes/no questions in the sleep hygiene log.
10137455|NCT04227509|Experimental|Experimental|
10137456|NCT04227509|Placebo Comparator|Placebo|
10137457|NCT04227223|Experimental|Study Group|Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy
10137458|NCT04227223|Active Comparator|Control Group|Control Group - 14 patients, healthy volunteers.
10137459|NCT04226924|Experimental|Trehalose|Trehalose 9% solution: The dose is 0.75 g/kg administered IV over 60 ± 5 minutes once weekly.
9519659|NCT03284749|Placebo Comparator|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
10137460|NCT04226924|Placebo Comparator|0.9% Normal Saline|Normal saline: weight-based volume administered IV over 60 ± 5 minutes once weekly.
10137461|NCT04227262|No Intervention|the control group|Group (a) control group received traditional physical therapy program.
10137462|NCT04227262|Experimental|the study group|group (b) study group received the same traditional physical therapy program in addition to mirror therapy three times / weak for three successful months.
10137463|NCT04227184|Experimental|Placebo/Trospium|Placebo first for 12 weeks followed by Trospium for 12 weeks.
10137464|NCT04227184|Experimental|Trospium/Placebo|Trospium first for 12 weeks followed by Placebo for 12 weeks
10137465|NCT04227431||Tresiba®|A broad real world type 2 diabetes (T2D) patient population in China, treated with oral anti-diabetic drugs (OAD(s)) or basal insulin prior to treatment initiation with Tresiba®
10137466|NCT04227249||Experimental|women who do not undergo lymph node dissection
10137467|NCT04227132|Experimental|Labyrinth training, then Standard training|Patients will receive at first the Labyrinth training for 10 sessions of 45 minutes, delivered 4 days per week. The, they will undergo the Standard training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
10137468|NCT04227132|Experimental|Standard training, then Labyrinth training|Patients will receive at first the Standard training for 10 sessions of 45 minutes, delivered 4 days per week. Then they will undergo the Labyrinth training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
10137469|NCT04227093|Active Comparator|Acetazolamide|Acetazolamide will be prescribed in unembellished white capsules of 250 mg. The drug will be administered twice daily in the morning and evening (approximately one hour before bedtime). The total treatment length will amount to 16 weeks. In case of side effects hampering treatment adherence, the daily dosage will be reduced to a single evening dose of 250 mg.
10137470|NCT04227093|Placebo Comparator|Placebo|The placebo regimen will be identical.
10184392|NCT03755466|Active Comparator|BARI|
10184393|NCT03755466|Active Comparator|Bio|
9519660|NCT03284749|Experimental|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
10137471|NCT04227015|Experimental|Administration of CTA101|Dose escalation follows the standard 3+3 dose escalation design. A total of 2 dose levels are set for subjects.
10137472|NCT04227041|Experimental|HER2 positive metastatic colorectal cancer|
10137473|NCT04227054|Experimental|Intervention|
10137474|NCT04227067|Active Comparator|TENS|A TENS device consists of an electric pulse generator and pads that are attached to the skin on around the area of maximal pain. We will use the conventional mode, which provides nerve stimulation with a pulse width of 60 microseconds and a pulse rate of 60 pulses per second. The channel intensity will be gradually increased until the intensity is noticeable but not painful.
10137475|NCT04227067|Sham Comparator|SHAM TENS|In the SHAM TENS group the TENS pads will be attached to the pulse generator and the patients skin around the painful area. The investigator will turn the knobs on but the batteries will be removed from the device.
10137476|NCT04226781|Active Comparator|ICG|Fluorescence imaging for blood Perfusion of the gastrointestinal tissue
10137477|NCT04226781|Experimental|HSI|Hyperspectralimaging for blood Perfusion of the gastrointestinal tissue
10137478|NCT04226794|Experimental|a-tDCS and nutritional counseling|a-tDCS and nutritional counseling
10137479|NCT04226794|Active Comparator|s-tDCS and nutritional counseling|s-tDCS and nutritional counseling
10137480|NCT04226794|Active Comparator|a-tDCS|a-tDCS
10137481|NCT04226794|Active Comparator|Nutritional counseling|Nutritional counseling
10137482|NCT04226989|Experimental|Administration of CT-RD06|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
10137483|NCT04226703||Study group|Patients over the age of 18 who underwent surgery in the ear, nose and throat department.
10137484|NCT04226885|Active Comparator|fentanyl|patients will be given nebulized fentanyl 2μg/kg body weight 30 min before surgery
10137485|NCT04226885|Active Comparator|midazolam|The patients will be given nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
10137486|NCT04226885|Active Comparator|dexmedetomidine|The patients will be given nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
10137487|NCT04226651|Active Comparator|First dental visit|Virtual Reality Exposure Therapy
10137488|NCT04226651|Placebo Comparator|Second Dental Visit|Protective Glasses
10137489|NCT04226755|Experimental|Heart failure|After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks. A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
10137490|NCT04226755|Active Comparator|Healthy volunteer|After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
10137491|NCT04226625|Active Comparator|Propofol|Patients will receive Propofol as an intravenous (IV) agent, which is administered into a vein through an IV line as a continuous infusion.
10137492|NCT04226625|Active Comparator|Desflurane|Patients will receive Desflurane as a gas that is administered through an anesthesia machine.
10137493|NCT04226521|Experimental|Photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
10137494|NCT04226521|No Intervention|No prophylactic photopheresis|Standard post-transplant protocol without prophylactic extracorporeal photopheresis
10137495|NCT04226573||Low anxiety, Middle and High anxiety|State Trait Anxiety İndex Scale: Values of less than 60, Low anxiety State Trait Anxiety İndex Scale: Values above 60, Middle and High anxiety
10137496|NCT04226560|Experimental|41% Silicone hydrogel Soft contact lenses (SHSCL)|Healthy adult males or females age ≥20-45 years of age
10137497|NCT04226560|Active Comparator|ACUVUE® VITA™|Healthy adult males or females age ≥20-45 years of age
10137498|NCT04226456|No Intervention|Control|"Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
10137499|NCT04226456|Experimental|N-acetylcysteine|"Experimental arm (Arm B):~0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.~Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
10137500|NCT04226768|Experimental|"Enhanced Haematology Palliative Care (Fast-track) Group"|"Patients who are assigned to enhanced haematology palliative care (fast-track group) will be seen, within 2 days of enrollment, at the out-patient clinic or in-patient setting by the haematology palliative care team that comprises a palliative medicine specialist or a haematologist with palliative care experience, a full-time palliative care nurse, and a medical social worker concentrating on haematology palliative patients."
10137501|NCT04226768|Active Comparator|Conventional Supportive Care Group|"Patients who are assigned to the conventional supportive care group will be under care of haematologists and nurse specialists in haematology After 12 weeks of conventional supportive care, patients randomized to this group will receive services from the palliative care team and assessed every two weeks same the fast-track group"
10137502|NCT04226716|Other|Multiparous, pregnant women|
10137503|NCT04226443|Active Comparator|Group 1|In Group 1(n=50); continuous infusion of intravenous midazolam (Dormicum, Deva Pharmaceutical, Turkey) at a dose of 0.02 to 0.04 mg/kg/h was started at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
10184394|NCT03755466|Active Comparator|Tofa|
10184395|NCT03755453|Active Comparator|Audéo B-Direct fitted with fitting method A|Traditional standard fitting method which do not include adjustments from the participants.
10137504|NCT04226443|Active Comparator|Group 2|in Group 2 (n=49), intravenous bolus doses of midazolam at a dose of 0.015 mg/kg every 10 minutes were administered at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
9694659|NCT04786873|Active Comparator|standard GHST order randomized: arginine - clonidine|"At visit 2 (V2), all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at visit 3 (V3) and visit 4 (V4).~In this arm, those subjects will be presented which will have been randomized to the arginine GHST at V3 and the clonidine GHST at V4.~At visit 5 (V5) all subjects will perform the macimorelin GHST."
10137505|NCT04226430||Before cytosorb|Arterial blood samples were taken from patients before the Cytosorb therapy course.
10137506|NCT04226430||after cytosorb|Arterial blood samples were taken from patients immediately after the Cytosorb therapy course.
10137507|NCT04226534|Other|Maximal effort test|Physiological database
10137508|NCT04226482|Active Comparator|New Device|Laparoscopic appendectomy will be done using new ultrasonic shears.
10137509|NCT04226482|Experimental|Used Device|Laparoscopic appendectomy will be done using reprocessed ultrasonic shears.
10137510|NCT04226417|Active Comparator|Dual-tDCS & home program exercise|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered for 20 minutes before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
10137511|NCT04226417|Sham Comparator|Sham-tDCS & home program exercise|Sham transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered only 30 seconds before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
10137512|NCT04226339|Experimental|total knee arthroplasty with a kinetic alignment|
10137513|NCT04226339|Active Comparator|total knee arthroplasty with a mechanical alignment|
10137514|NCT04226235|Experimental|1-hour vinyasa yoga session|One hour of vinyasa yoga was completed by all participants while following a DVD.
10137515|NCT04226469||Subjects require canine retraction|Subjects require canine retraction during orthodontic tooth movement and their gingival crevicular fluid is collected during the tooth movement. The control is the initial timepoint.
10137516|NCT04226404|Experimental|CSD1905-11|Subjects will be assigned to flavor variant CSD1905-11 of 4.8% ENDS products based on their preferred flavor.
10137517|NCT04226404|Experimental|CSD1905-12|Subjects will be assigned to flavor variant CSD1905-12 of 4.8% ENDS products based on their preferred flavor.
10137518|NCT04226404|Experimental|CSD1905-13|Subjects will be assigned to flavor variant CSD1905-13 of 4.8% ENDS products based on their preferred flavor.
10137519|NCT04226404|Experimental|CSD1905-14|Subjects will be assigned to flavor variant CSD1905-14 of 4.8% ENDS products based on their preferred flavor.
10137520|NCT04226404|Experimental|CSD1905-15|Subjects will be assigned to flavor variant CSD1905-15 of 4.8% ENDS products based on their preferred flavor.
10137521|NCT04226404|Experimental|CSD1905-16|Subjects will be assigned to flavor variant CSD1905-16 of 4.8% ENDS products based on their preferred flavor.
10137522|NCT04226404|Experimental|CSD1905-17|Subjects will be assigned to flavor variant CSD1905-17 of 4.8% ENDS products based on their preferred flavor.
10137523|NCT04226300|Experimental|Laparoscopic-Assisted|Surgeons will place TAP block laparoscopically using a camera prior to beginning a surgical procedure.
10137524|NCT04226300|Active Comparator|Ultrasound-Guided|Anesthesiologists will use ultrasound to place TAP block prior to beginning a surgical procedure.
10137525|NCT04226105|Experimental|GP40081|Subcutaneous (SC), up to Week 26
10137526|NCT04226105|Active Comparator|NovoMix® 30 FlexPen®|Subcutaneous (SC), up to Week 26
10137527|NCT04226365|Experimental|Experimental|10mg capsule once daily for 4 weeks of nortriptyline
10137528|NCT04226365|Placebo Comparator|Control|10mg capsule once daily for 4 weeks of Thick-It filler
10137529|NCT04226040||DOW and illness perception|Exploration of the association between DOW and illness perception
10137530|NCT04226144|Active Comparator|Breath Stacking Group|The lungs are inflated as fully as possible by stacking successive breaths without expiration until the patients' maximal inspiratory capacity (MIC). The participant will be instructed to sustain the air in the lung, closing the glottis. Once the lungs are maximally inflated, the compressed air volume is released under expiratory muscle force, thus generating a cough with lung and chest wall recoil. They will perform 5-8 cycles of breath stacking per session, stacking 3-5 breaths per cycle.
10137531|NCT04226144|Experimental|Breath stacking and EMT|This group will perform the breath stacking technique in addiction with EMT. It will change the one-way valve in this group to VUP (Lumiar, Sao Paulo, Brazil) one-way valve, which allows the patients blow out the air with a counter resistance during all expiratory phase. The initial expiratory pressure will be 8 cmH2O, and could be changed at each visit according to participants' tolerance (either report easy or difficult to exhale assessed by research coordinators. The participants are encouraged to blow out the most slowly that they can do it.
10137532|NCT04226001||Patients|Patients screened for carriers infected or colonized by emerging highly resistant bacteria.
10184396|NCT03755453|Experimental|Audéo B-Direct fitted with fitting method B|Alternative fitting method which includes additional adjustments from the participants.
10137533|NCT04226157|Experimental|Home Blood Pressure Self Management|The HBPS group will check their blood pressure at home daily using a smart BP cuff with telemonitoring capability (Home Qardio) and guided to use a self-titration plan between office visits for persistently elevate blood pressures.
10137534|NCT04226157|Active Comparator|Usual Care|The Usual Care group will have their blood pressure monitored and medications adjusted by their primary care provider.
10137535|NCT04226378||Omnipod cohort|Adults with T1D who switch from MDI therapy to insulin pump therapy with Omnipod.
10137536|NCT04226378||MDI cohort|Adults with T1D who continue MDI therapy.
10137537|NCT04226118|No Intervention|Control Group|Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
10137538|NCT04226118|Experimental|Experimental Group|Patients who have a peripheral venous access by a procedure using a Vein Illumination System.
10137539|NCT04226066|Experimental|T601/T601+5-FC|Part 1: Dose-escalation study of T601 single-dose; Part 2: Dose-escalation study of T601 single-dose combined with 5-FC; Part 3: Dose-escalation study of T601 multiple-dose combined with 5-FC; Part 4: Extended study of T601 multiple-dose combined with 5-FC.
10137540|NCT04226287|Experimental|Monterey Pneumatic Compression Device|All participants will receive treatment with the Monterey investigational pneumatic compression device
10137541|NCT04226222||Triple negative Breast Cancer|Triple Negative Breast Cancer operatable from the outset
10137542|NCT04226196|Experimental|Axis 0|IOL Implantation at the 0 +/- 10 degrees axis
10137543|NCT04226196|Experimental|Axis 45|IOL Implantation at the 45 +/- 10 degrees axis
10137544|NCT04226196|Experimental|Axis 90|IOL Implantation at the 90 +/- 10 degrees axis
10137545|NCT04226196|Experimental|Axis 135|IOL Implantation at the 135 +/- 10 degrees axis
10137546|NCT04226508|No Intervention|Control|
10137547|NCT04226508|Experimental|Physical exercise|
10137548|NCT04226183|No Intervention|control group|pregnant women without pregnancy workout and consume guava juice
10137549|NCT04226183|Experimental|positive control group|prenatal pregnant women with pregnancy workout but not consume guava juice
10137550|NCT04226183|Experimental|treatment group|prenatal pregnant women with pregnancy workout and consume guava juice
10137551|NCT04226079||Normal control|Normal population with low prevalence of gastrointestinal bleeding who underwent EGD and CFS which revealed no abnormal finding.
10137552|NCT04226079||Patients with GI bleeding|Patients who visited emergency room and were highly suspected to have recent or active upper GI bleeding and scheduled for upper GI endoscopy.
10137553|NCT04225962||Women with cystic fibrosis|Women with cystic fibrosis
10137554|NCT04225910|Experimental|mCRPC for PSMA RLT|225Ac-PSMA 100KBq/kg, iv. Totally 2 doses, every 8 weeks.
10137555|NCT04226326|Other|Subjects with Chronic Total Occlusion (CTO)|All subjects in this study have been scheduled for a clinically-indicated cardiac catheterization.
10137556|NCT04226053|Experimental|Intervention Group|The treatment group will consist of 160 mothers who were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby through a combination of one-on-one sessions with an expert clinical social worker in-person every three months and provision of essential baby items and equipment.
10137557|NCT04226053|No Intervention|Control Group|The control group will consist of 160 mothers who will not receive Room to Grow services.
10137558|NCT04226092|Experimental|Subjects with atopic dermatitis|
10137559|NCT04226092|Experimental|Control subjects|
10137560|NCT04225949|Experimental|line graph|
10137561|NCT04225949|Active Comparator|bar graph|
10137562|NCT04225637|Experimental|Slow maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw once every other day.
10137563|NCT04225637|Experimental|Rapid maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw twice daily.
10137564|NCT04225806|Experimental|Investigational|Subjects will be treated with the investigational device and followed per protocol.
10137565|NCT04225780|Experimental|Treatment of low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group and low-dose IL-2 is defined as 1 million IU per day subcutaneously.
10137566|NCT04225780|Placebo Comparator|Treatment of ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in ganciclovir treatment group.
10137567|NCT04225611|Experimental|Dexamethasone|Therapeutic Contact Lens Drug Delivery System (TCL-DDS) of Dexamethasone, up to 300 μg per day with a total release of 1,100 μg over 7 days
10137568|NCT04225689|Experimental|CD-TREAT diet|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for a maximum of 21 days. Individualised diet based on energy requirements and physical activity levels."
10137569|NCT04225689|No Intervention|Unrestricted diet|Free, unrestricted diet. Daily for a maximum of 21 days.
10137570|NCT04225884|Active Comparator|DTx for pain|Treatment A software
10137571|NCT04225884|Sham Comparator|Control|Treatment B software
10137572|NCT04225884|Other|Standard care|Pain medication
10137573|NCT04226014||Patients with echo-endoscopic ultrasound of the pancreas|Patients requiring endoscopic ultrasound of the pancreas were included in the cohort.
10137574|NCT04225598|Experimental|XR-BUP|Injectable buprenorphine
10137575|NCT04225598|Active Comparator|Standard SL-BUP|Sublingual buprenorphine
10137576|NCT04225702||Group Aspirin|The elderly patients who using Aspirin at least three months before operation were in the Group Aspirin
10137577|NCT04225702||Group Control|The elderly patients who not using Aspirin before operation were in the Group Control
10137578|NCT04225845|Experimental|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
10137579|NCT04225845|Experimental|Phone therapy plus cash transfer|Weekly phone calls by lay trained personnel to deliver problem solving therapy. Combined with a one-time cash transfer of Rs.1000.
10137580|NCT04225845|Experimental|Cash transfer|One-time cash transfer of Rs.1000.
10137581|NCT04225845|No Intervention|Control|Control group.
10184397|NCT03755440|Experimental|PD-1 antibody|SHR-1210, 200mg, ivdrip, d1, every two weeks.
10137582|NCT04225585|Experimental|Targeted Pain Coping Skills Training (Targeted-PCST)|novel pain coping skills training intervention designed specifically for women with persistent pain (PP) following breast cancer surgery (active intervention group)
10137583|NCT04225585|Placebo Comparator|General health education|general health education Intervention (control group)
10137584|NCT04225585|No Intervention|Self-guided health education|usual health care and usual medical treatment for pain
10137585|NCT04225858|Experimental|Omission of sentinel lymph node biopsy|No surgical axillary staging (i.e. sentinel lymph node biopsy) will be performed.
10137586|NCT04225728|Active Comparator|Iron sucrose IV arm|Perfusion of diluted iron sucrose i.v. in two weeks. Half of the total dose at Day 0 and the other half at Day 14
10137587|NCT04225728|Active Comparator|Ferric polymaltose hydroxide complex IM arm|Injection in two series, begin at Day 0 and the second at Day 14. In each series, we administered 300 mg of iron IM until reach half of the dose
10137588|NCT04225728|Placebo Comparator|Placebo arm|100 ml i.v. of normal saline administered at Day 0 and at day 14.
10137589|NCT04225663|Active Comparator|Intervention group|The Intervention group will receive 30-minute sessions of guided meditation. During meditation, they will lie down with their backs and torsos elevated by a mat/soft blocks. They will undergo guided breath work.
10137590|NCT04225663|No Intervention|Control group|The Control group will not have intervention. They will have quiet, independent study for 30-minute sessions.
10137591|NCT04225520|Active Comparator|Treatment recommendation based on guidelines|Treatment of the patient assigned to this arm will be based on the current guidelines for CRT implantation, as issued by the European Society of Cardiology. All patients will receive CRT implantation, with bi-ventricular pacing ON.
10137592|NCT04225520|Experimental|Treatment recommendation based on mechanical dyssynchrony|Treatment of the patients assigned to this arm will be based on the presence of mechanical dyssynchrony. All patients will receive CRT implantation. Bi-ventricular pacing will be either turned ON or OFF, based on respectively the presence or absence of mechanical dyssynchrony.
10137593|NCT04225793|Active Comparator|Eziklen®|potassium, magnesium and sodium sulphates-based laxative
10137594|NCT04225793|Active Comparator|Macrogol|Macrogol-3350 + Sodium Sulfate + Potassium Chloride+ Sodium Chloride + Ascorbic Acid-based and Sodium Ascorbate-based Moviprep
10137595|NCT04225741|Experimental|training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs.22,23 Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.22-24
10137596|NCT04225741|No Intervention|Control Group|None of the interventions described above were applied to the control group.
10137597|NCT04225390|Experimental|Dacarbazine|Dacarbazine (day1 and day21) 850 mg/m² i.v. followed by re-exposure to the previous immunotherapy
10137598|NCT04225468|No Intervention|Treatment As Usual (TAU)|No intervention will be administered.
10137599|NCT04225468|Experimental|Opioid Exposure Reduction Program 1 (OERP1)|Participants will engage in a brief, educational intervention at their pre-surgery appointment approximately 2-3 weeks before ACL reconstruction surgery.
10137600|NCT04225468|Experimental|Opioid Exposure Reduction Program 2 (OERP2)|"Participants will engage in the same intervention as OERP1, but those in OERP2 will also receive a 5-minute booster intervention session 3 days after surgery."
10137601|NCT04225234|Active Comparator|Weight loss incentive|Participants will receive incentive rewards based on WEIGHT LOSS outcomes.
10137602|NCT04225234|Experimental|Weigh-in incentive|Participants will receive incentive rewards based on WEIGH-INs frequency
10137603|NCT04225234|Experimental|Combination incentive|Participants will receive half of the incentive from WEIGHT LOSS and WEIGH-INs
10137604|NCT04225234|Experimental|Choice option incentive|Participants will choose one out of the three incentive programs (Weight-loss, Weigh-ins, and Combination).
10137605|NCT04225247|Active Comparator|Group-I Single Bond Universal|"it is a seventh generation bonding agent used as desensitizer, manufactured by 3M ESPE.~applied on the affected surface of the group-I participants."
10137606|NCT04225247|Active Comparator|Group-II Xeno V+|"it is a seventh generation bonding agent used as desensitizer, manufactured by Dentsply.~applied on the affected surface of the group-II participants."
10137607|NCT04225247|Placebo Comparator|Group-III Bifluorid 12|it is a fluoride varnish used as desensitizer, manufactured by VOCO. applied on the affected surface of the group-III participants.
10137608|NCT04225364|Experimental|camrelizumab plus concurrent chemotherapy|Neoadjuvant immunotherapy, PD-1, plus concurrent chemotherapy（albumin-bound paclitaxel + Cisplatin） will be applied to patients with operable esophageal squamous cell carcinoma before surgery.
10137609|NCT04225182|Experimental|with instrumented Orthosis|patient will follow 8 weeks of muscular strengthening with the orthosis connected to the phone app associated
10137610|NCT04225182|Active Comparator|without instrumented Orthosis|patient will follow 8 weeks of traditional muscular strengthening without orthosis
10137611|NCT04225481||SVF from healthy subjects from aesthetic plastic surgery|Subjects undergoing plastic surgery as scheduled by clinic routine to obtain waste adipose tissue
10137612|NCT04225481||OA patients|Subjects undergoing prosthetic surgery as scheduled by clinic routine to obtain waste synovium and cartilage
10137613|NCT04225286|Experimental|Intranasal human breast milk|"Human breast milk delivered intranasally to preterm infants (<33 weeks gestation at birth, stratified < and ≥28 weeks) with any grade IVH/intraparenchymal hemorrhage/infarction identified on head ultrasound in the first 10 days of life.~Dosing: Escalating dose starting at 0.2mL into one nostril with repeat dose 10-15 minutes later 1-2x daily, depending on availability of fresh HM"
10137614|NCT04225325|Active Comparator|A: SYMTUZA|TAF/FTC 245 mg/200 mg single tablet QD +DRV /cobicistat 800 mg /150 mg single tablet QD
10137615|NCT04225325|Active Comparator|B: DESCOVY+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DTG 50 mg QD
10137616|NCT04225325|Experimental|C: SYMTUZA+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DRV/cobicistat single tablet QD + +DTG 50 mg QD
10184398|NCT03755427|Experimental|15μg H7N9 Vaccine|Participants will be inoculated with 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
10137617|NCT04225312|Experimental|Personalized extended interval dosing|Personalized dosing based on natalizumab trough concentration with an aim of natalizumab trough concentration of 10mcg/ml.
10137618|NCT04225312|Experimental|Low personalized extended interval dosing|Personalized dosing based on natalizumab trough concentration with a lower aim of natalizumab trough concentration of 5mcg/ml.
10137619|NCT04225312|Other|Standard interval dosing|Patients who prefer to stay on standard interval dosing.
10137620|NCT04225312|Other|Historic cohort|Historic cohort of natalizumab treated patients on standard interval dosing.
10137621|NCT04225208|Experimental|[14C]-AZD4205|A single dose of [14C]-AZD4205
10137622|NCT04225403|Experimental|Telephone-based motivational interviewing|Experimental intervention consisted of a motivational intervention for smoking cessation through telephone every 3 months for one year, performed by IBD nurse
10137623|NCT04225403|No Intervention|usual care|No intervention consisted of a single telephone contact one year after the star of the study
10137624|NCT04224909||Patients with Sudden Sensorineural Hearing Loss|
10137625|NCT04224844|Active Comparator|Erector spinae plane block group (Group 1)|Patients will receive erector spinae plane block in addition to intravenous patient-controlled analgesia device containing tramadol.
10137626|NCT04224844|Active Comparator|Control group (Group 2)|Control group will receive only intravenous patient-controlled analgesia device containing tramadol.
10137627|NCT04224935|Active Comparator|Leukocyte Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin will be used
10137628|NCT04224935|Active Comparator|connective tissue|connective tissue will be used
10137629|NCT04224857|Experimental|AMT-101|AMT-101
10137630|NCT04224857|Placebo Comparator|Placebo|Placebo
10137631|NCT04225143|Experimental|bilateral|25 patients with an overactive bladder
10137632|NCT04225143|Active Comparator|unilateral|25 patients with an overactive bladder
10137633|NCT04224922|Experimental|single-arm|weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer
10137634|NCT04225000|Active Comparator|Exercise Group|Hip & Knee Exercises
10137635|NCT04225000|Experimental|Mobilization Group|Tibiofemoral joint anterior-posterior mobilization combined Hip & Knee Exercises
10137636|NCT04225169|Experimental|Exercises|diaphragmatic breathing exercises
10137637|NCT04225169|No Intervention|Control|Patients in the control group received routine patient care consisting of cold therapy
10137638|NCT04225195|Experimental|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"Patients with invasive candidiasis (IC) will only receive intravenous treatment with ABCD. ABCD will be administered once a day at a dose of 3-4 mg/kg.~Patients with invasive aspergillosis (IA) will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. ABCD dosing regimen will be the same as that for IC patients."
10137639|NCT04225104|Experimental|Yogic breathing intervention|Participants assigned to this group will complete a 20-minute yogic breathing video at least 5 days per week for 4 weeks. All sessions except the initial yogic breathing session will be completed at home. Participants will complete the first session at Texas State under the supervision of the investigative team for familiarization.
10137640|NCT04225104|No Intervention|Control|Participants in the control group will be asked to maintain their current daily activities and will be given access to the yogic breathing video once all follow-up testing has been completed at the end of week 4.
10137641|NCT04224948|Experimental|PET-MR arm|Every eligible patient will be scanned by PET-MR at baseline and following 1 cycle of chemotherapy. PET-CT at baseline will also be obtained as it is the current standard of care and will be used to determine trial eligibility (no evidence metastasis at baseline).
10137642|NCT04224961|Experimental|Minimal to No Respiratory Weakness|MIP ≥ 70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
10137643|NCT04224961|Experimental|Mild to Moderate Inspiratory Weakness|MIP 40-70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
10184399|NCT03755427|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will be first inoculated with one dose of seasonal influenza vaccine and followed with one dose of aluminum hydroxide adjuvant at 21-day intervals.
10184400|NCT03755388|Experimental|Episealer group|Subjects with a focal cartilage lesion of the distal femur in which biological surgical methods have failed or are not eligible
10184401|NCT03755375|Active Comparator|E-stim Group|The E-stim Group will start treatment after the assessment. Interventions:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
10184402|NCT03755375|Active Comparator|Postural Group|The Postural Group will star treatment after the assessment. The interventions will be: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
9519661|NCT03284749|Placebo Comparator|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
10137644|NCT04225091|Placebo Comparator|Placebo drink|
10137645|NCT04225091|Experimental|Triple up® Collagen Drink|
10137646|NCT04225052|Other|Group1|16 subjects, Cross-over, Single dose of comparator on day1, Single dose of YHP1903 on day8
10137647|NCT04225052|Other|Group2|16 subjects, Cross-over, Single dose of YHP1903 on day1, Single dose of comparator on day8
10137648|NCT04225299|Experimental|TOOKAD®|TOOKAD® , lyophilized formulation, given at a dose of 4mg/Kg.
10137649|NCT04225299|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have intermediate risk localised prostate cancer
10137650|NCT04224805|Active Comparator|Control|Interocclusal conventional splint is used to reposition the maxilla.
10137651|NCT04224805|Experimental|Study|Bone-borne splint is used to reposition the maxilla.
10137652|NCT04225065|Active Comparator|Chlorhexidine prep|Chlorhexidine prep prior to their operation
10137653|NCT04225065|Active Comparator|Betadine prep|Betadine prep prior to their operation
10137654|NCT04224831|Active Comparator|Before application|"The chronic CSCR cases included here meet one or more of the following criteria:~Complaints of recurrent symptoms lasting longer than 3 months;~Recalcitrant or unresponsive to all known current treatment modalities including PDT and MPL;~Typical B-scan SD-OCT findings of chronicity such as elongation of photoreceptor outer segments indicating chronic nature of sub-macular fluid and/or the presence of serous flat-irregular RPED and focal areas of thickened RPE that lie below the collection of SRF;~Widespread RPE/photoreceptor damage, RPE mottling and atrophy along with chronic submacular fluid;~Widespread multifocal areas of chronic serous retinal detachment and/or flat-irregular RPEDs in those eyes that effective and reliable laser application is impossible."
10137655|NCT04224831|Active Comparator|After application|The changes in SMT, CMT, DRCD, and BCVA before and after the interventions were compared.
10137656|NCT04224896||NBI PATIENT|
10137657|NCT04224896||LUGOL PATIENT|
10137658|NCT04224818|Experimental|Dual trigger|Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
10137659|NCT04224818|Active Comparator|hCG (standard)|HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
10137660|NCT04224779|Experimental|Tumors and blood collection|"For all the patients included in the study :~Blood samples will be collected at different times T1 (Baseline), T2 (1 or 2 weeks after the beginning of the treatment), T3 (3 or 4 weeks before the surgery) and T4 (1 month after the surgery).~Tumors biopsy will be collected for some patients who will benefit from an initial biopsy in the course of his management care in our Institute (before the surgery).~In parallel to this biological collection, imaging and clinical data will be entered into a database treatment."
10137661|NCT04224714|Experimental|Coronary heart disease patient|Quantitative coronary angiography (QCA) showed that there was a critical lesion in the proximal or middle segment of the coronary artery (diameter stenosis rate was 50% - 70%), and the diameter of the artery was more than 2.5mm
10137662|NCT04224662||Patients with Gout|Patients who have been diagnosed with Gout
10137663|NCT04224701|Experimental|Investigational Product, 30 µg/ Placebo|30 µg IM, months 0, 2 and 6
10137664|NCT04224701|Experimental|Investigational Product, 300 µg/ Placebo|300 µg IM, months 0, 2 and 6
10137665|NCT04224649|Experimental|Test Device Group(HARA filler)|
10137666|NCT04224649|Active Comparator|Comparator Group(Restylane® Lidocaine)|
10137667|NCT04224636|Experimental|Up-front Atezo/Bev, then TACE|Patients will receive atezolizumab and bevacizumab iv every three weeks for up to 24 months. Upon detection of at least one unequivocal progressive hepatic lesion, selective TACE directed against progressive lesion(s) (sdTACE) will be performed. RFA or MWA are permitted as alternative to TACE to treat one or more lesion that cannot be reasonably selectively targeted by TACE
9519662|NCT03284736|Experimental|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
10137668|NCT04224636|Experimental|Atezo/Bev combined with TACE|First TACE will be performed as selectively as possible against all viable tumor lesions. Atezo/Bev will be initiated within three days from TACE. Upon detection of at least one unequivocal progressive hepatic lesion, treatment with Atezo/Bev will be continued if RFA or MWA can be used to treat this/these progressive lesion.
10137669|NCT04224532|Experimental|Group P|Pneumoperitoneum is induced before reverse Trendelenburg position.
10137670|NCT04224532|Experimental|Group RT|Pneumoperitoneum is induced after reverse Trendelenburg position.
10137671|NCT04224571|Experimental|rituximab and bortezomib|to test whether adding rituximab in CD20 positive patients will have improvement in remission rate. (this arm terminated in October 2020) to add bortezomib in high risk patients at Induction to improve remission rate.
10137672|NCT04224480|Experimental|Treatment|Neoadjuvant treatment will consist of one dose of IV pembrolizumab. Tumor resection will be performed approximately 4 weeks after neoadjuvant pembrolizumab. Adjuvant treatment with pembrolizumab will be administered 4 weeks after the surgery.
10137673|NCT04224402|Other|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion
10137674|NCT04224519|Experimental|Batch 1 of sIPV|The first commercial batch of sIPV
10137675|NCT04224519|Experimental|Batch 2 of sIPV|The second commercial batch of sIPV
10137676|NCT04224519|Experimental|Batch 3 of sIPV|The third commercial batch of sIPV
10137677|NCT04224597||Patients with acne vulgaris|patients with acne vulgaris aged between 18-25 year
10137678|NCT04224597||Healthy controls|healthy controls aged between 18-25 year
10137679|NCT04224727|No Intervention|Control|
10137680|NCT04224727|Experimental|Group Commitment Contract + Information|
10137681|NCT04224727|Experimental|Individual Monetary Rewards + Information|
10137682|NCT04224727|Experimental|Individual Commitment Contract + Information|
10137683|NCT04224727|Experimental|Group Commitment Contract|
10137684|NCT04224727|Experimental|Individual Monetary Rewards|
10137685|NCT04224727|Experimental|Individual Commitment Contract|
10137686|NCT04225013||Control (no CIN)|Patients who receive contrast media but do not develop contrast-induced nephropathy
10137687|NCT04225013||Case (yes CIN)|Patients who receive contrast media and develop contrast-induced nephropathy
10137688|NCT04224324||T & A patients|pediatric patients undergoing tonsillectomy and adenoidectomy
10137689|NCT04224285|Experimental|Early Dayzz|Participants receive a Sleep Health and Wellness education session and download the Dayzz app. Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries.
10137690|NCT04224285|No Intervention|Late Dayzz|Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries. At the end of nine months, participants have the opportunity to receive a Sleep Health and Wellness education session.
10137691|NCT04224259|Experimental|ultrasound pre-scan group|Perform ultrasound pre-scan before central venous cannulation
10137692|NCT04224259|Sham Comparator|landmark guidance group|Use the traditional landmark method to perform central venous cannulation
10137693|NCT04224675|Other|Ate|
10137694|NCT04224675|Other|Cap|
10137695|NCT04224467|Experimental|Indocyanine Green Fluorescent Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then, a NIR imaging systems included the NIR (800-900 nm) and white-light (400-650nm) dual-channel will be used to detect In situ lesions, metastatic lesions, lymph nodes, obturator nerve, pelvic autonomic nerve, etc during surgery according to disease and clinical needs.
10137696|NCT04224168|Experimental|Green Beans|Green beans will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from green beans will be given. This equates to 3x 4 ounce jars of green beans per day.
10137697|NCT04224168|Experimental|Liquid Pectin|Liquid pectin will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from liquid pectin will be given. This equates to 6 teaspoons or 30mL of liquid pectin per day.
10137698|NCT04224337|Experimental|Experimental|Durvalumab + doxorubicin + ifosfamide
10137699|NCT04224454||Primary Sjögren's syndrome|111 consecutive patients with primary Sjögren's syndrome (European-American 2002 criteria)
10137700|NCT04224441|Experimental|Standard protocol plus chlorpromazine (CPZ)|Combination of chlorpromazine to the standard treatment with temozolomide in the sole adjuvant phase of the standard protocol.Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide (TMZ)
10137701|NCT04224194|Other|Interventional, Single arm to evaluate autoinjector handling|To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who selfinject AVT02 (adalimumab) subcutaneously (SC).
10137702|NCT04224181||Women with HIV|Individuals with female nascent sex who have been diagnosed with HIV.
10137703|NCT04224181||Women without HIV|Individuals with female nascent sex who do not have HIV.
10137704|NCT04224506||Myasthenia Gravis|Patients who have been diagnosed with Myasthenia Gravis.
10137705|NCT04224389||Radiotherapy|IMRT on the primitive site and the lymph nodes. +/- Concomitant chemotherapy at the discretion of the meeting multidisciplinary
10137706|NCT04224389||Surgery|transoral resection of the primary tumor, with cervical lymph node dissection. Radiotherapy complementary according to the histological criteria of severity
10137707|NCT04224376|No Intervention|Conventional rehabilitation|Normal postoperative treatment protocol with physiotherapy after ACL surgery
10137708|NCT04224376|Experimental|Serious Gaming|In the training group each patient was additionally provided with a GenuSport knee trainer device (prototype plus tablet with software application) with the active knee extension training program for 6 weeks. Other postoperative treatment was identical.
10137709|NCT04224415|Other|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
10137710|NCT04224363|Experimental|Downward Staining|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
10137711|NCT04224363|Experimental|Upward Staining|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
10137712|NCT04224233|Experimental|Home-based physical activity group|The experimental group will receive the iLiFE.
10137713|NCT04224233|Active Comparator|Control group|The control group will receive a leaflet with exercises and PA recommendations.
10137714|NCT04224207|Active Comparator|Before application|RP patients with progressive visual acuity and visual field loss: before stem cell application.
10137715|NCT04224207|Active Comparator|After application|RP patients, after stem cell applications.
10137716|NCT04224012|No Intervention|Conventional therapy group (control group)|patients of the control Group receive usual care
10137717|NCT04224012|Experimental|Interventional group (training group)|Specialized exercise and respiratory therapy for patients with pulmonary hypertension
10137718|NCT04224428|Placebo Comparator|Control group|
10137719|NCT04224428|Active Comparator|Fexofenadine group|
10137720|NCT04223895|Experimental|Group 1|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F1(1 tab, once)/ Period 3: CKD-386 F2(1 tab, once)
10137721|NCT04223895|Experimental|Group 2|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F2(1 tab, once)/ Period 3: CKD-386 F1(1 tab, once)
10137722|NCT04223895|Experimental|Group 3|Period 1: CKD-386 F1(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once) Period 3: CKD-386 F2(1 tab, once)
10137723|NCT04223895|Experimental|Group 4|Period 1: CKD-386 F1(1 tab, once) / Period 2: CKD-386 F2(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
10137724|NCT04223895|Experimental|Group 5|Period 1: CKD-386 F2(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once)/ Period 3: CKD-386 F1(1 tab, once)
10137725|NCT04223895|Experimental|Group 6|Period 1: CKD-386 F2(1 tab, once) / Period 2: CKD-386 F1(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
10137726|NCT04224051|Experimental|Metformin target dose of 2g daily|Metformin tablets taken orally with target dose of 2g daily plus standard care
10137727|NCT04224051|Active Comparator|Standard care|Standard care includes help with smoking cessation if applicable; encouragement of physical activity and a healthy diet; blood pressure control; statin and anti-platelet therapy treatment if the patient have clinical manifestations of atherosclerotic disease.
10137728|NCT04224103||Inhaled nitric oxide|
10137729|NCT04224220|Active Comparator|Adult Medical Care Coordination|This group will receive adult medical care coordination following discharge from a recent hospitalization.
10137730|NCT04224220|Active Comparator|Remote Patient Monitoring|This group will receive remote patient monitoring following discharge from a recent hospitalization.
10137731|NCT04224220|No Intervention|Usual Care|The usual care group will not receive additional supportive care following discharge from a recent hospitalization beyond what is typically offered through their primary care team.
10137732|NCT04224077|Experimental|Intervention|Healthy volunteers
10137733|NCT04223999|Experimental|Intervention|In this arm, trial participants receive the intervention that is being tested, skullremodeling surgery. This is in combination with tumor treating fields and best practice medical treatment.
10137734|NCT04223999|Active Comparator|Control|"In this arm, the trial participant receives tumor treating fields and best practice medical treatment.~This serves as an active comparative control arm to the intervention."
10137735|NCT04224272|Experimental|ZW25 (zanidatamab) + palbociclib + fulvestrant|ZW25 (zanidatamab) plus palbociclib, fulvestrant
10137736|NCT04224116|Experimental|Group TA|receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
10137737|NCT04224116|Placebo Comparator|Group SSI|Serum saline isotonic (SSI) group: placebo with isotonic saline serum.
10137738|NCT04224350|Experimental|Once-Daily Tacrolimus|Experimental arm: TacroBell SR Cap.
10137739|NCT04224350|Active Comparator|Twice a Day Tacrolimus|Active Comparator arm: TacroBell Cap.
10137740|NCT04223986|Other|Ultrasound and Troponin T|5 images transferred to cardiologist
10137741|NCT04224142||PKU sphere|PKU sphere (an FSMP) as per individual requirements determined by a dietitian.
10137742|NCT04224246|Experimental|One arm with Gamma-OH® treatment|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours between 10 p.m. to 4 a.m.
9826077|NCT02406677|Experimental|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
9969099|NCT01286896|Experimental|Sunitinib|Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
10137743|NCT04223973|Experimental|Active Group|Using the Medtrum Pump A7+ during 3 months
10137744|NCT04223973|Active Comparator|Control Group|using the usual Insulet Patch pump
10137745|NCT04223921||Patients who will be discharged from hospital (acute geriatric|Patients who will be discharged from hospital (acute geriatric care unit) between January and March 2020
9969100|NCT01286909|Experimental|LaFlavon|
10137746|NCT04223908||FCS|patient with genetically documented familial chylomicronemia syndrome
10137747|NCT04223908||MCS|patient with genetically or phenotypically documented multifactorial chylomicronemia syndrome
10137748|NCT04224025|Experimental|exercise and respiratory therapy|Rehabilitation program for three weeks in-Hospital and continuation at home
10137749|NCT04223869|No Intervention|periodontally healthy group|Control
10137750|NCT04223869|Active Comparator|Chronic Periodontitis|non-surgical periodontal treatment was performed
10137751|NCT04223869|Active Comparator|Aggressive Periodontitis|non-surgical periodontal treatment was performed
10137752|NCT04223882|Experimental|Group Intervention- Management of stress|Patients in the intervention group will receive usual medical care and more stress management intervention. Stress management with cognitive behavioral techniques will be implemented one month after hospital discharge in the intervention group. Group sessions will be held between 6-9 people. There will be 4 1-hour meetings for 8 weeks. The intervention will be performed by psychologist.
10137753|NCT04223882|No Intervention|Group Control|Patients in the control group will receive usual medical care.
10137754|NCT04223505|Active Comparator|TEE arm|TEE will be performed as per clinical routine using multiple standard tomographic planes to rule-out LA/LAA thrombus. Echocardiographic analysis will include: LAA-emptying velocity, and grading the severity of LAA spontaneous ECHO. The severity of the SEC will be graded on a 4 point scale with 1 = minor homogeneous contrast enhancement, 2 = significant homogeneous contrast enhancement, 3 = significant, dense, and inhomogeneous, slow-moving contrast, and 4 = dense slow-moving contrast.
10137755|NCT04223505|Experimental|CCT arm|As per local protocol, a non-contrast enhanced prospective ECG-triggered image acquisition will be acquired. This will be followed by a contrast-enhanced prospective ECG-triggered will be acquired using a tri-phasic contrast protocols. Delayed CT images will be acquired 60 seconds after the initial contrast-enhanced CT scan.Cardiac CT image interpretation will be performed as per clinical routine. The LA and LAA will be assess for filling defects and characterized based upon attenuation values. If LA/LAA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. It will be recommended that patients with thrombus will undergo TEE.
10137756|NCT04223700|Experimental|Group 1|Ultrasound scanning of the rhomboid muscle
10137757|NCT04223778|Experimental|Immediate Switch to DOR/ISL|Participants receiving continuous antiretroviral therapy (ART) will switch to MK-8591A, a fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 96 weeks
9519663|NCT03284736|Active Comparator|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
9969101|NCT01286909|No Intervention|Placebo|
9969102|NCT01286922|Experimental|Interval Training|"The target intensity for the INT group is 2 min at about 95% of baseline VO2max followed by 2 min of recovery at 40-50% of VO2max. Regardless of the training method each participant will be locked into a weekly energy expenditure of 12 kilocalories per kilogram of body weight per week (KKW)."
10137758|NCT04223778|Active Comparator|Baseline Regimen with Delayed Switch to DOR/ISL|Participants receiving continuous ART for 48 weeks will switch to MK-8591A, a FDC of 100 mg DOR/0.75 mg ISL for 48 weeks
10137759|NCT04223466|Experimental|Subxiphoid group|Subxiphoid procedure for thymectomy.
10137760|NCT04223466|Active Comparator|VATS group|Video-assisted thoracoscopic thymectomy through chest wall.
10137761|NCT04223492|Other|Neoadjuvant systemic treatment|All patients undergo standard neoadjuvant treatment and additional multi-parametric MRI and liquid biopsies during neoadjuvant treatment.
10137762|NCT04223791|Experimental|DOR/ISL|A fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and placebo to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) for 96 weeks.
10137763|NCT04223791|Active Comparator|BIC/FTC/TAF|50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to FDC DOR/ISL for 96 weeks. Participants will be offered the option to receive open-label FDC DOR/ISL from Week 144 to Week 156.
10137764|NCT04223596|Experimental|Experimental: Brigatinib Arm|Brigatinib 90 mg for the first 7 days and then 180 mg daily thereafter for QW4 cycles of duration (28 days +- 3 days)
10137765|NCT04223518|Active Comparator|Serum Bovine Immunoglobulin|Study product: Serum bovine immunoglobulin, also known by the trade name of Enteragam Dosage form: powdered packet Dosage: Each packet (10 g net weight) consists of 5 g of serum-derived bovine immunoglobulin/protein isolate (SBI) which is the active ingredient Frequency: one packet a day Duration: 60 days
10137766|NCT04223518|Placebo Comparator|Hydrolyzed Collagen|Placebo: hydrolyzed collagen Dosage form: powdered packet Dosage: 10 g of hydrolyzed collagen per packet Frequency: one packet a day Duration: 60 days
10137767|NCT04223817|Experimental|7.0 Tesla MRI of both hands|Single 7.0 Tesla MRI of both hands for all the SSc and control subjects
10137768|NCT04223427|Active Comparator|Single ring STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
10137769|NCT04223427|Experimental|Directional STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
10137770|NCT04223440|Experimental|Postero-superior Rotator Cuff Tear|MRI, ultrasonographic explorations
10137771|NCT04223440|Other|Healthy Postero-superior Rotator Cuff|MRI, ultrasonographic explorations
10137772|NCT04223739|Active Comparator|Landiolol|Landiolol infusion starting at 2.5 µg/kg/min and titrating up to 80µg/kg/min with a heart rate goal of under 90 bpm.
10137773|NCT04223739|Active Comparator|Amiodarone|Amiodarone bolus of 5-7 mg/kg in 1 hour, followed by an infusion of 1g/day until conversion to sinus rhythm.
10137774|NCT04223544||GPs Healthcare Workers|
10137775|NCT04223544||Hospital Healthcare Workers|
10137776|NCT04223713|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
10137777|NCT04223713|Experimental|Aortic valve replacement|Biological prosthesis, Device: Edwards Perimount
10137778|NCT04223375|Experimental|Nutrition Group|"After the health status of the mothers in the experimental group was stabilized, approximately 20-30 minutes of nutritional education was given at the first interview before the hospital discharge. After nutrition education, motivational messages were sent to women's phones once a week. In addition, mothers were given nutritional counseling during their home visits during the 1st and 3rd months, and their questions and problems regarding nutrition were evaluated. The mother was supported where she needed it.~In nutritional education, information was given such as adequate and balanced nutrition in the postpartum period, adequate fluid intake, consumption and importance of prebiotic and probiotic foods, the importance of healthy microbiota for infant health and the amount of nutrients equivalent to one serving. In addition, the handbook which contains the educational content is given to the mothers to facilitate the recall."
10137779|NCT04223375|No Intervention|Control Group|No intervention was made to the control group.
10137780|NCT04223388|Experimental|Probiotic|
10137781|NCT04223388|Placebo Comparator|Placebo|
10137782|NCT04223271||Acutely Decompensated Heart Failure Patients|Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing. Testing with the Indicor device will occur every day during hospitalization, and twice a day for up to 30 days after discharge.
10137783|NCT04223310|Experimental|Virtual AAD TEST group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Preselect drug with optimal antiarrhythmic effects in the patient.~Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
10137784|NCT04223310|Active Comparator|Empirical AAD group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
10137785|NCT04223219|Active Comparator|High Opioid Group|-The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate >20% of baseline or hypertension: increase of mean blood pressure >20% of baseline).
10137786|NCT04223219|Placebo Comparator|Low Opioid Group|The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).
10137787|NCT04223219|Experimental|Non-Opioid Group|The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.
10137788|NCT04223102|Other|Tissue collection|Tissue collection
10137789|NCT04223193|Experimental|Tavapadon|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.
10137790|NCT04223193|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
10137791|NCT04223362|Experimental|Pulmonary rehabilitation + Community-based physical activity programme|After pulmonary rehabilitation, the experimental group will integrate a community-based physical activity programme.
10137792|NCT04223362|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates physical activity recommendations.
10137793|NCT04223349|Experimental|Part 1: Treatment A|Participants will receive JNJ-70033093 dose twice daily (BID) for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
10137794|NCT04223349|Experimental|Part 1: Treatment B|Participants will receive JNJ-70033093 dose BID for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
10137795|NCT04223349|Experimental|Part 1: Treatment C|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
10137796|NCT04223349|Experimental|Part 1: Treatment D|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
10137797|NCT04223349|Experimental|Part 2: Treatment Sequence EFG|Participants will receive Treatment E (JNJ-7003309 single dose in the morning in fasted condition) in treatment Period 1; followed by Treatment F (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 2; followed by Treatment G (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
10137798|NCT04223349|Experimental|Part 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
10137799|NCT04223349|Experimental|Part 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
10137800|NCT04223349|Experimental|Part 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
10137801|NCT04223349|Experimental|Part 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
10137802|NCT04223349|Experimental|Part 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
10137803|NCT04223167|Experimental|Energy Drink 1|The participants in this group are caffeine naive and consumed 473 ml Red Bull Energy Drink
10137804|NCT04223167|Experimental|Energy Drink 2|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately 130 mg caffeine and consumed 473 ml Red Bull Energy Drink
10137805|NCT04223167|Experimental|Energy Drink 3|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately more than 200 mg caffeine and consumed 473 ml Red Bull Energy Drink
10137806|NCT04223167|Placebo Comparator|Control|The participants in this group are caffeine naive and consumed 473 ml water
10137807|NCT04223336|No Intervention|Control Group|When a participant in the control group is identified via a mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will not receive any computer alerts for physical activity and fruits/vegetable consumption. However, practitioners will still have access to the physical activity and diet data as part of the baseline assessment (Screening). Practitioners will also continue to have access to all the same resources as they currently do (treatment as usual).
10137808|NCT04223336|Experimental|Intervention Group|When a participant in the intervention group is identified via mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will receive computer alerts (screening), prompting to provide participant with a brief intervention (risk communication) and a self-monitoring resource for physical activity and/or fruits/vegetable consumption.
10137809|NCT04223089||Revascularization|This group will include patients whose cutaneous oxygen partial pressure (PO2) around the wound of interest measures less than 40 mmHg and therefore require revascularization.
10137810|NCT04223089||Medical Management|This group will include patients whose cutaneous PO2 around the wound of interest measures greater than 40 mmHg and will be managed conservatively in wound clinic
10137811|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash control|Chlorhexidine 0.2%, Corsodyl Intervention rinsing 60 sec twice daily
10137812|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System|Chlorhexidine 0.2%, Curasept Intervention rinsing 60 sec twice daily
10137813|NCT04222946|Experimental|Experimental:|bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
10137814|NCT04223115|Experimental|Digitalized CBT intervention with phone coaching|Participants receive weekly sessions of internet-based CBT, including telephone coaching
10137815|NCT04223115|Active Comparator|Psychoeducation about depression|Participants receive psychoeducative material about depression in digitalized form.
10137816|NCT04223011|Experimental|In-Hospital Recovery Coach Intervention|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically in-hospital manualized sessions with the recovery coach.
10137817|NCT04223063|Experimental|Exercise Intervention|Participants allocated to the exercise intervention will engage in a multimodal, home-based program including strength and endurance exercises. Participants will initially be seen in person and instructed to begin a moderate-intensity (i.e., 3-4 on 10-point Borg Scale) walking (or preferred aerobic exercise) program for a minimum of 30 minutes/day, 3-5 days/week and perform strength exercises at least 2 days/week.
10137818|NCT04223063|No Intervention|Control|Participants allocated to the control group will not receive any formal exercise prescription or guidance, however they will be offered the opportunity to participate in a home-based intervention pending the completion of data collection.
10137819|NCT04223206|Experimental|Hemodialysis with sarcopenia|10 HD patients, affected by sarcopenia will a undergo 3-months supplementation with NATURLENS
9669157|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: TNBC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic triple-negative breast cancer (TNBC) estrogen receptor (ER)-, progesterone receptor (PR)-, and human epidermal growth factor receptor 2 (HER2)-negative who received ≥ 1 prior line of cytotoxic chemotherapy with no prior poly adenosine diphosphate ribose polymerase (PARP) inhibitor therapy for TNBC or platinum-based chemotherapy for metastatic TNBC.
9669158|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: CRC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with with incurable/locally advanced or metastatic colorectal cancer (CRC) who received appropriate oxaliplatin or irinotecan- and fluorouracil (5-FU)-based chemotherapy with or without bevacizumab.
10137820|NCT04223206|No Intervention|Controls|10 HD patients, affected by sarcopenia will be followed for 3 months without any supplementation
10137821|NCT04223180||Stroke patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with an upper limb impairment due to neurologic or orthopedic disorders.
10137822|NCT04223245|Experimental|exercise+MMSF|Group of PWPD who performed a base exercise program of speed and large amplitude stepping and standing balance exercises with Multimodal real-time sensory feedback
10137823|NCT04223245|Active Comparator|exercise only|Group PWPD who did the same exercise program without MMSF
10137824|NCT04223128|Active Comparator|Magnesium sulfate group(M)|Participants in group (M) will receive 50 mg/kg MgSO4 in 100 ml isotonic saline intravenous (I.V) over 20 minutes prior to induction of general anesthesia by 30 minutes then ultrasound guided TAPblock after closure of the abdomen
10137825|NCT04223128|Active Comparator|Dexamethasone group(D)|participants in group (D) will receive 2 mg Dexamethasone in 100 ml isotonic saline IV then ultrasound guided TAPblock after closure of the abdomen
10137826|NCT04223128|Placebo Comparator|Placebo group(C)|participants in group (C) will receive 100 ml isotonic saline IV (placebo) by the same route and over the same duration as control then ultrasound guided TAPblock after closure of the abdomen
10137827|NCT04222959|Experimental|Girls Invest Intervention|Girls Invest intervention participants will have been randomized to receive the intervention immediately upon completion of the baseline survey. Intervention participants will also complete the 6 month follow-up survey. (n=50 dyads; 100 total participants)
10137828|NCT04222959|No Intervention|Wait-List Control Condition Participants|Control condition participants will be randomized upon completion of the baseline survey and put on a wait-list to receive Girls Invest behavioral intervention after the 6 month follow-up survey. (n=50 dyads; 100 total participants)
10184403|NCT03755375|Placebo Comparator|E-stim Control Group|The E-stim Control Group will start treatment 3 months after the assessment: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
10184404|NCT03755375|Placebo Comparator|Postural Control Group|The Postural Control Group will start treatment 3 months after the assessment:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
10184405|NCT03755362|Active Comparator|Standard treatment (control)|Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
10184406|NCT03755362|Experimental|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
10184407|NCT03755349|Experimental|Intervention group|Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
10184408|NCT03755349|Active Comparator|Control group|None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
10184409|NCT03755310|Experimental|Suvorexant|10mg tabs during the first week, 10-20 mg tabs on the second week.
10184410|NCT03755310|Placebo Comparator|Placebo|Equivalent dosage, route of administration and dose regimen.
10137829|NCT04223050|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94%
10137830|NCT04223050|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92%
10137831|NCT04222842|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25mg BID/50mg QD/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
10137832|NCT04222933|Experimental|Motorized cryotherapy|Application of motorized cryotherapy after ACL reconstruction for 6 postoperative days
10137833|NCT04222933|Active Comparator|Classical cryotherapy|Application of ice bags for 6 postoperative days
10137834|NCT04222881||End To Side|End to Side Anastomosis
10137835|NCT04222881||Side To Side|Side To Side Anastomosis
10137836|NCT04222855|Experimental|Diltiazem|Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
10137837|NCT04222855|Active Comparator|Nifedipine|Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).
10137838|NCT04222920|Experimental|Low serum drug concentration|Adalimumab dose reduction aiming a drug level of 2 mg/L
10137839|NCT04222920|Active Comparator|High serum drug concentration|Adalimumab dose reduction aiming a drug level of 5 mg/L
10137840|NCT04222764||Real-time three-dimensional echocardiography|
10137841|NCT04222738|Experimental|Non-randomized single-arm of GINOFF1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted on the administration of Zingiber officinale Roscoe extracts, at a daily dose of 2g/day (equivalent overall daily dose of extract in simple powdered form) for a period of 6weeks. The extracts were given as capsules, either one capsule three times per day (1 capsule x 3 / day) and after meals. Each capsule contains 399mg of pure Zingiber officinale Roscoe extracts."
10137842|NCT04222777|Other|Heatlhy volunteers.|Healthy volunteers will undergo two cinematographic recordings of the cervical spine
9826078|NCT02406677|No Intervention|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
10137843|NCT04222517|Experimental|Standart sublay retromuscular technique|Apply standard intervention (sublay retromuscular)
10137844|NCT04222517|Experimental|Standart sublay retromuscular technique with Hemoblock|Local hemostatic Hemoblock is used in retro-muscular and subcutaneous spaces
10137845|NCT04222452||Hypophosphatasia patients (HPP)|Patients with known hypophosphatasia (HPP) as diagnosed using genetic testing.
10137846|NCT04222452||Controls|Healthy individuals (controls) matched to the cases by gender and age.
10137847|NCT04222400|Active Comparator|Transplantation|Frailty assessment before, after and 6 month after surgery
10137848|NCT04222400|Active Comparator|VAD Implantation|Frailty assessment before, after and 6 month after surgery
10137849|NCT04222582|Active Comparator|Active tDCS|"Administration of a 2 milliamp (mA) current delivered via two scalp electrodes for 20 minutes (ramp-in + ramp-out periods, 30s total) 2 times per day for 5 consecutive days, >3 hour interval between sessions, for a total of 10 tDCS sessions.~tDCS will be administered with a constant current regulator (NeuroConn DC-Stimulator Plus®, Germany) using 2 saline-soaked sponge electrodes applied over the scalp. Using the 10-20 international EEG system for tDCS electrode placement, the anode will be positioned midway between F3 and Fp1 (left DLPFC) and the cathode midway between T3 and P3 (left TPJ)."
10137850|NCT04222582|Sham Comparator|Sham tDCS|Administration of 2mA tDCS for 30 seconds followed by 19.5 minutes of no current via two scalp electrodes for 20 min (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
10137851|NCT04222582|Other|Open-label Active tDCS|Subjects who have received sham tDCS will be given the option to subsequently receive 10 sessions of open-label active tDCS (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
10137852|NCT04222582|No Intervention|Healthy Control|Healthy volunteers will complete the same questionnaires, EEG recording procedures, and neuroimaging scans as the schizophrenia patient group, but will not undergo tDCS.
10137853|NCT04222595|No Intervention|1- naive|Group 1: up to 10 children aged 4-6 years that never received LAIV before.
10137854|NCT04222595|Active Comparator|2- Fluenz Tetra nasal spray suspension|Group 2: up to 10 children aged 4-6 years that received LAIV once before. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
10137855|NCT04222595|Active Comparator|3- Fluenz Tetra nasal spray suspension|Group 3: up to 10 children aged 4-6 years that were vaccinated twice before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
10137856|NCT04222595|Active Comparator|4- Fluenz Tetra nasal spray suspension|Group 4: up to 10 children aged 4-6 years that were vaccinated 3 or 4 times before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
10137857|NCT04222491|Experimental|active peanut OIT|active peanut oral immunotherapy
10137858|NCT04222439|Experimental|AI monitoring gastrointestinal endoscopy|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
10137859|NCT04222621||Pregnant women|
10137860|NCT04222543|Active Comparator|HPV Negative tumours|Patients will receive four scans.
10137861|NCT04222543|Active Comparator|HPV positive tumours|Patients will receive four scans.
10187715|NCT03723382||Patients with stroke with structured management|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
9519664|NCT03284697|Active Comparator|DPC with Ca(OH)2|Direct pulp capping with Ca(OH)2.
9519665|NCT03284697|Active Comparator|DPC with MTA|Direct pulp capping with MTA
10137862|NCT04222673|Experimental|Peer Specialist|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
10137863|NCT04222686|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
10137864|NCT04222686|Active Comparator|Losartan Arm|100 mg Losartan tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
10137865|NCT04222530|Experimental|Linear EUS|patients underwent linear endoscopic ultrasonography followed by magnifying narrowband endoscopy
10137866|NCT04222530|Experimental|ME-NBI|patients underwent magnifying narrowband endoscopy followed by linear endoscopic ultrasonography
10137867|NCT04222296|Other|Cochlear Implant and Hearing Aid|Comparing performance of conventional hearing aid fitting to Phonak's Bimodal Fitting formula using the Phonak Naida Link hearing aid. All patients are tested in a bimodal (hearing aid plus cochlear implant) setup. Initial tests are completed with the Advanced Bionics Naida Q70 or Q90 sound processor and the patient's own hearing aid. In this arm, a patient's own hearing aid is replaced with the Phonak Naida Link hearing aid to test if there is a benefit.
10137868|NCT04222296|Other|Cochlear Implant alone|To determine if the addition of a contralateral routing of signal (CROS) microphone on the un-implanted ear improves performance. Baseline tests are completed with Advanced Bionics Naida Q70 or Q90 sound processors. Patients are then given the Phonak Naida Link CROS aid to test if there is a benefit.
10137869|NCT04222296|Other|Hearing Aid and Hearing Aid|Comparing performance of conventional hearing aid fitting to a modified signal processing strategy more aligned with how a cochlear implant manages sound. All patients are tested initially with their own hearing aids to obtain a baseline measurement. Patients are then fitted with a modified Phonak hearing aid to determine if performance improves.
10137870|NCT04222127|Experimental|EUS-guided injection of CYA of GVs|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate & lipidol using 19G EUS-FNA needle
10137871|NCT04222127|Experimental|Direct endoscopic injection of CYA of GVs|Direct endoscopic injection of CYA of the gastric varix using standard endoscopy
10137872|NCT04222062|No Intervention|Standard of Care Arm|The tumor will be removed surgically. Within 6 weeks after surgery, the resection will be treated with stereotactic radiosurgery (SRS).
10137873|NCT04222062|Experimental|GLIADEL Arm|Once the tumor has been removed, GLIADEL wafers will be applied to the resection cavity. The number of wafers used will be determined by the size of the cavity. Enough wafers should be used so that as much of the cavity is covered as possible.
10137874|NCT04222348|Experimental|Metformin|850-2550 mg every 24h.
10137875|NCT04222348|Active Comparator|Insulin Detemir|Individual doses according to glycemic controls.
10137876|NCT04222049|Experimental|spastic Tongue Dysarthria|The purpose of gadget is to transmit the mechanical vibration waves to the brain of the subjects.
10137877|NCT04222114|Experimental|Catumaxomab group|
10137878|NCT04222114|Active Comparator|IC group|IC group is defined as the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
10137879|NCT04222270|Experimental|Intervention|Caregiver peer support from Champion caregivers (Peer mentors) to caregivers of unsuppressed children living with HIV (CLHIV) on child care and medication adherence strategies to enhance achievement of viral suppression: Champion Caregivers (Peer Mentors) will be assigned to the intervention arm and will be trained to support 10-15 caregivers for 18 months post enrollment. Champion Caregivers (CCs) be trained using an adapted Mentor-Mother Peer Support curriculum and topics will include pediatric treatment gaps, ARV formulations/dosing, adherence counseling, and virological failure/suppression. Champion caregivers will conduct monthly-to-quarterly 30 min to 1 hr clinic-aligned caregiver group training sessions and home visits at least once quarterly, targeting Child living with HIV (CLHIV) adherence, age-appropriate disclosure, and keeping clinic appointments. The intervention arm will in addition to peer support intervention, receive routine standard of care at the health facility.
10137880|NCT04222270|No Intervention|Control|Unsuppressed Children living with HIV and their caregivers recruited in the control arm will receive no champion caregiver peer support intervention but will continue to receive the standard of care at their health facilities which include routine care, including age-appropriate antiretroviral therapy and clinic appointments (typically every 2-3 months). Routine, albeit brief (5-10 min) adherence counselling is provided to CLHIV/caregivers by trained healthcare workers (HCWs) at every visit. In Nigeria, routine VL is done at 6 months post-ART initiation and repeated 12 months post- initiation 20. VL is done yearly thereafter for suppressed clients. Those unsuppressed receive 3-months' enhanced adherence counselling (EAC) (15-30 min) by Healthcare workers, with intensified appointment schedules and repeat VL upon EAC completion. This rigorous intervention continues until viral suppression is achieved or ART is switched; drug resistance testing (DRT) is not routine.
10137881|NCT04222140|Experimental|ERIPTO Protocol|Protocol arm actively being studied
10137882|NCT04222140|Active Comparator|BMAC only|bone marrow aspirate concentrate only arm
10137883|NCT04222179|Other|Naso-enteric tube placement|The participants needed nutrition from naso-enteric tube feeding are enrolled into this study. Double-blind was not needed here.
10137884|NCT04222361|Experimental|KDIGO guide recommendations|Preventive recommendations the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for AKI
9519666|NCT03284684||circulating DNA plasma level test|
9826079|NCT02406742|Experimental|CC-122 Single Agent|An intrasubject dose escalation design was selected to determine the safety of single agent CC-122 (Arm A) in order to reach an optimal, clinically active dose and to mitigate the risk of early tumor flare reactions, based on earlier experience with lenalidomide monotherapy in CLL.
10137885|NCT04222361|No Intervention|Standard care|The patients assigned to the control group will receive the current standard care of the septic patients of the Unit according to our protocols
10137886|NCT04222088|Other|Patient|Participants recruited that pass the inclusion and exclusion criteria
10137887|NCT04222192|Sham Comparator|Conventional Epidural application|Epidural catheter insertions with conventional (anatomical landmarks use) method
10137888|NCT04222192|Active Comparator|Paramedian sagittal application|Epidural catheter insertions with real time ultrasound guided Paramedian sagittal approach
10137889|NCT04222192|Active Comparator|Transverse Interlaminar application|Epidural catheter insertions with real time ultrasound guided Transverse Interlaminar approach
10137890|NCT04222335|Other|Blood sampling|Blood sampling
10137891|NCT04222023|Experimental|IVIG group|Administration of a single dose of IVIG at day 10+/- 4 days, day 41 +/- 7 days and day 62 +/- 7 days. The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
10137892|NCT04222023|No Intervention|Control group|
10137893|NCT04221906|Experimental|BOS-475 0.5%|Daily application of BOS-475 0.5%
10137894|NCT04221906|Experimental|BOS-475 1%|Daily application of BOS-475 1%
10137895|NCT04221906|Experimental|BOS-475 2%|Daily application of BOS-475 2%
10137896|NCT04221906|Placebo Comparator|Active ingredient-free vehicle cream|Daily application of vehicle cream
10137897|NCT04221906|Active Comparator|Daivonex cream|Daily application of Daivonex cream (calcipotriol 0.005%)
10137898|NCT04221906|Active Comparator|Betnesol-V cream (betamethasone 0.1%)|Daily application of Betnesol-V cream (betamethasone 0.1%)
10137899|NCT04222075||Acute Pancreatitis|Patients after acute pancreatitis
10137900|NCT04222244||Headache Attributed to Rhinosinusitis Group (HAR)|No interventions will be provided.
10137901|NCT04222244||Headache-Free Control Group (Control)|No interventions will be provided.
10137902|NCT04222231|Experimental|Blood-flow restriction resistance training|Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.
10137903|NCT04222231|Experimental|Classical resistance training|Resistance training with high loads (60-80% RM).
10137904|NCT04222283|Experimental|open label, multicentric, non randomized|one arm study to evaluate the safety and efficacy of switching from ritonavir- or cobicistat- booster containing regimens to a fixed-dose combination (FDC) of tenofovir alafenamide (TAF), emtricitabine (FTC) and bictegravir (BIC) in over 65 years old HIV-1-infected patients with virological suppression. Polymedications and drug-drug interactions will be analysed.
10137905|NCT04222218|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
10137906|NCT04222218|Sham Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
10137907|NCT04221919|Experimental|Carvedilol|
10137908|NCT04221919|Experimental|Bisoprolol|
10137909|NCT04221919|Experimental|Metoprolol tartrate|
10137910|NCT04221919|Experimental|Metoprolol succinate|
10137911|NCT04221971|Experimental|AML patients with NK cells infusion|The relapsed/refractory AML patient received Flu+CTX (Flu 25mg/m2 (-6d to -2d)，CTX 1.0g/m2 (-6d to -5d) and haploidentical NK cells infusion postchemotherapy for at least 48 hours. NK cell dose was over 1+E07/ kg with 3 consecutive infusions. NK cells infusion interval was 1 day.
10137912|NCT04221854|Experimental|Stool-based SDC2 DNA methylation test group|Subjects will received the stool-based SDC2 DNA methylation test for the screening of colorectal advanced adenomatous polyps and cancer.
10137913|NCT04221854|Active Comparator|Fecal immunochemical test group|Subjects will received the fecal immunochemical test for the screening of colorectal advanced adenomatous polyps and cancer.
10137914|NCT04222309|Experimental|Laparoscopically harvested omental free flap|"Standard neurosurgical removal of recurrent GBM,~Removal of fat from the abdomen called omentum using a camera (laparoscopically),~Lining the brain tumor cavity with the piece of omentum,~Joining the blood vessels of the omentum to blood vessels in the scalp or neck to ensure that it maintains good blood flow."
10137915|NCT04222010|Experimental|serratus loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)
10137916|NCT04222010|Experimental|paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)
10137917|NCT04222010|Experimental|serratus and paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)
10137918|NCT04221880|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine and Saline iv. bolus and infusion (same volume as Group Lidocaine)
10137919|NCT04221880|Active Comparator|Group Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion and, Ultrasound-guided erector spinae plane block with 20 ml saline
10137920|NCT04221880|Sham Comparator|Group Control|Ultrasound-guided erector spinae plane block with 20 ml saline and, Saline iv. bolus and infusion (same volume as Group Lidocaine)
10137921|NCT04221867|Experimental|Esophageal stricture patients|Patients suffering from benign esophageal stricture are treated with through-the scope CRE dilation balloon. Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
10137922|NCT04221594||CAD detection/risk assessment|Patients with angina referred for the assessment of CAD will undergo imaging studies to develop tools to fuse coronary anatomic data obtained from CCTA with dPET data to non-invasively measure absolute MBF, MFR and RFR along vessels centerlines and across coronary lesions.
9519667|NCT03284671|Experimental|bifocal stimulation|Transcranial direct current Bifocal stimulation
10137923|NCT04221724|Experimental|Intervention Group|Multicomponent physical exercise intervention
10137924|NCT04221399|Experimental|DWP16001 Single dose|Single dose
10137925|NCT04221399|Experimental|DWP16001 Multiple dose|Up to 7 days
10137926|NCT04221516|Experimental|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks), from 4 to 12 weeks after the completion of radiotherapy.
10137927|NCT04221711|Experimental|Repetitive pulsed magnetic stimulation|Patients randomized in this group will receive rPMS (80 milliTesla ; 2 Hertz; OMNITRON® promed; Healthfactories Holding GmbH) three times a week for a total of 12 weeks. Thereby they will be lying in a prone position or sitting for 20 minutes with the magnet coil positioned over the mid-portion of the affected Achilles tendon (manufactures instruction).
10137928|NCT04221711|Active Comparator|Eccentric Calf Muscle Training for Achilles Tendinopathy|Two types of eccentric exercises will be used. The calf muscle will be eccentrically loaded both with the knee straight and with the knee bent. Each of the two exercises will include an increasing number of repetitions (1. Week, 2-3 weeks, 4-12 weeks) done in 3 sets (e.g. 3x15, 3x20, 3x30 repetitions). The patients will be informed that muscle soreness during the first 1 to 2 weeks of training was to be expected. Patients will receive a visual exercise protocol.
10137929|NCT04221555|Experimental|the main treatment group|pMMR tumor
10137930|NCT04221555|Active Comparator|the exploratory group|dMMR tumor
10137931|NCT04221672|Experimental|Terlipressin plus standard care|Immediately after hepatectomy, 1 mg terlipressin was given intravenously after hemostasis was achieved. After surgery, participants were routinely managed, and terlipressin were administrated at a dosage of 2 mg per day for 4 days.
10137932|NCT04221672|Other|Standard care|Participants were not administrated with terlipressin during surgery and were routinely managed after surgery.
10137933|NCT04221737|Active Comparator|Conventional ventilation|Protective lung conventional strategy with volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, with low tidal volume and adequate positive end expiratory pressure (PEEP) level.
10137934|NCT04221737|Experimental|Time-controlled adaptive APRV|Airway Pressure Release Ventilation with Time-controlled adaptive ventilation method. Allowing for spontaneous breathing.
10137935|NCT04221607|Experimental|Feasibility|Sensate Focus Exercises aim to help couples be more present with one another through talking and through touch.
10137936|NCT04221633|Experimental|Webinar only|Participants in this arm will attend a webinar training program (3 webinars over the course of 4 to 8 weeks) to receive training in evidence-based engagement strategies, trauma, evidence-based practices, and mental health screening.
10137937|NCT04221633|Experimental|Webinar plus consultation|Participants in this arm will receive the same webinar training as subjects in arm 1, but they will also receive 10 consultation calls over the course of four months to further develop their skills in engaging families and screening for mental health services.
10137938|NCT04221633|No Intervention|Delayed training group|This group will not receive any training for the duration of the study year, in order to serve as a waitlist control group. They will be eligible to receive the training after the randomized control trial has been completed.
10137939|NCT04221789|Experimental|intervention: TB treatment assistant|Patients receiving instructions to use phone application
10137940|NCT04221789|No Intervention|Control|Patients receiving instructions for usual care self administered treatment
10137941|NCT04221503|Experimental|Cohort A|Cohort A is for subjects with recurrent glioblastoma who do not have clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort A will initiate and continue TTFields therapy for 5-7 days prior to starting niraparib.
10137942|NCT04221503|Active Comparator|Cohort B|Cohort B is for subjects with recurrent glioblastoma who have a clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort B will receive TTFields for 5-7 days prior to planned surgical resection, undergo surgical resection, resume TTFields postoperatively, and initiate niraparib 5- 7 days after starting TTFields postoperatively.
10137943|NCT04221659|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
10137944|NCT04221659|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
10137945|NCT04221659|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
10137946|NCT04221581||Patients receiving FHK ASYMETRIQUE prosthesis|
10137947|NCT04221776|Experimental|Intensive toilet training group|Intervention group was subjected to an intensive TT group session lasting 2-hours during 2 consecutive days in daycare centers.
10137948|NCT04221776|Active Comparator|Standard care toilet training group|Children participating in control group did not receive the intensive training, but parents got a leaflet and were encouraged to start TT their child at home, in their own manner.
10137949|NCT04221685|Active Comparator|Artinibsa|Powerful local anaesthetic with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.4%Articaine 1:100000.
10137950|NCT04221685|Experimental|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride,Epinephrine (D.C.I) (tartrate) 0.01 mg
10137951|NCT04221438|Experimental|Treatment (18F-FLT, PET/CT, encorafenib, binimetinib, surgery)|"NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.~SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.~ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity."
10137952|NCT04221646|Experimental|Thighs circumference reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied simultaneously.
10137953|NCT04221646|Experimental|Saddlebags fat thickness reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied consecutively too.
10137954|NCT04221360|Experimental|Group 1|"Period 1: D390~Period 2: CKD-375"
10137955|NCT04221360|Experimental|Group 2|"Period 1: CKD-375~Period 2: D390"
10137956|NCT04221347||Group A - Hepatocellular carcinoma|"Patients with with proved hepatocellular carcinoma in cirrhosis.~N=100"
10137957|NCT04221347||Group B - Cirrhosis|"Cirrhotics of multiple aethiology will be sampled for spectroscopy in order to detect possible differences among cirrhotics with and without subsequent hepatocellular carcinoma.~N=100"
10137958|NCT04221347||Group C - Healthy controls|Healthy controls - healthy military personnel. N=50
10137959|NCT04221282||Epileptic elderly patients|Elderly patients with partial-onset seizures
10137960|NCT04221334|Active Comparator|Experimental Toothbrush 1|1. A connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
10137961|NCT04221334|Active Comparator|Experimental Toothbrush 2|2. A non-connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
10137962|NCT04221620|Experimental|EEG neurofeedback|All participants will receive 20 sessions of traditional occupational therapy services while receiving EEG neurofeedback.
10137963|NCT04221256|Experimental|Administration of SSRI|Participants will be administered either 5, 10 or 20mg of SSRI escitalopram prior to paired associative stimulation.
10137964|NCT04221256|Placebo Comparator|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
10137965|NCT04221698|Experimental|Gait Retraining Group|Athletes from the Triathlon Plan in High Performance of the Valencian Community in Spain performing individual gait retraining sessions
10137966|NCT04221204|Experimental|Open-Label, Dose-Escalation|"The starting dose in this dose-escalation study is 50 mg, and the preset 6 dose-escalation cohorts are 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively. This study adopts an i3+3 method for dose escalation.~All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily [QD], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first"
10137967|NCT04221217|Experimental|MND-2119 2g|MND-2119 2 g, orally, once daily after breakfast for 52 weeks.
10137968|NCT04221217|Experimental|MND-2119 4g|MND-2119 4 g, orally, once daily after breakfast for 52 weeks.
10137969|NCT04221165|Active Comparator|Opioid Analgesia|Opioids will be prescribed as per institutional standards. Examples of opioids are morphine and hydromorphone.
10137970|NCT04221165|Experimental|Multimodal Analgesia|Pregabalin (50 mg to 300 mg, oral, twice daily), acetaminophen (1000 mg, oral, 3 times per day), naproxen 250 mg to 500 mg, oral, twice daily), and pantoprazole magnesium (40 mg, oral, daily)
10137971|NCT04221321|Placebo Comparator|Atorvastatin 40 mg|Oral administration of Atorvastatin 40 mg tablet once daily for 7 days
10137972|NCT04221321|Experimental|Atorvastatin 40 mg + Tegoprazan 50 mg|Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days
10137973|NCT04221321|Active Comparator|Atorvastatin 40 mg + RAPA114|Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days
10137974|NCT04221126|Experimental|TMFI +cream|TMFI + ALA cream
10137975|NCT04221126|Experimental|TMFI + gel|TMFI + ALA gel
10137976|NCT04221126|Active Comparator|ALA creAM|ALA cream
10137977|NCT04221126|Active Comparator|ALA GEL|ALA gel
10137978|NCT04221126|No Intervention|Control|Untreated control with no intervention
10137979|NCT04221308||single port laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
10137980|NCT04221308||Vaginal hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
10137981|NCT04221386|Experimental|MIT group|Subjects will receive the developed Melodic Intonation Therapy.
10137982|NCT04221386|No Intervention|Control group|Subjects will not receive any intervention.
10137983|NCT04221529|Experimental|Atezolizumab|Four 21-day cycles of induction therapy with atezolizumab+carboplatin+etoposide followed by 21-day cycles of maintenance therapy with atezolizumab.
10137984|NCT04221243|Experimental|Group 1: Children with 3D printed space maintainer|
10137985|NCT04221243|Active Comparator|Group 2: Children with conventional band and loop|
10137986|NCT04221152|Experimental|Treatment of empagliflozin|"The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study.~The administration is oral administration with water once daily before or after breakfast."
10137987|NCT04220853|Experimental|Septoplasty|The patients indicated for septoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
10137988|NCT04220853|Experimental|Turbinoplasty|The patients indicated for turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
10137989|NCT04220853|Experimental|Septoplasty and turbinoplasty|The patients indicated for septoplasty and turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
10187716|NCT03723382||Patients with stroke without structured management|Control subject who have stroke and did not managed according to the SECRET 6 level metrics
10187717|NCT03723356||MS Patients|Definite diagnosis of RRMS
10137990|NCT04220931|Experimental|botulinum toxin injection|"Injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.~The endoscopic procedure will be performed under unconscious sedation with intravenous injection of propofol by an anesthesiologist."
10137991|NCT04220931|No Intervention|standard care|standard care (no endoscopy)
9969103|NCT01286922|Placebo Comparator|Aerobic Conditioning|During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
9969104|NCT01286935|Experimental|Low Dose (50mg/day)|
9969105|NCT01286935|Experimental|High Dose (100mg/day)|
9969106|NCT01286935|Placebo Comparator|Placebo|
9969107|NCT01286948|Active Comparator|Levonorgestrel (LNG) gel (Levogel)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
9969108|NCT01286948|Active Comparator|oral LNG (1.5mg)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
9969109|NCT01286961||outpatient colonoscopy, bowel preparation, split dose PEG|adult outpatients who undergo colonoscopy
9969110|NCT01286974|Experimental|ADME|[14C]linifanib
9969111|NCT01286974|Experimental|Extension|linifanib
9969112|NCT01287026|Experimental|1|Open Label
9969113|NCT01287052|Experimental|Nitrous Oxide|
9969114|NCT01287091|Experimental|Part 1|
9969115|NCT01287091|Experimental|Part 2|
9969116|NCT01287091|Experimental|Part 3: Group A|
9969117|NCT01287091|Experimental|Part 3: Group B|
9969118|NCT01287130|Experimental|DL 1|AZD6244 once daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
9969119|NCT01287130|Experimental|DL 2|AZD6244 twice daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
9969120|NCT01287182|Placebo Comparator|Placebo|
9969121|NCT01287182|Active Comparator|Ateronon|
9969122|NCT01287234|Other|All Patients|All patients will have an echocardiogram and SonR sensor readings completed.
9969123|NCT01287247||Cervical Dystonia|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.
9969124|NCT01287247||Blepharospasm|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.
9969125|NCT01287260|Experimental|Arm1|
10137992|NCT04220970||BIA-ALCL|
10137993|NCT04221100|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
10137994|NCT04221100|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
10187718|NCT03723356||Healthy Controls|gender aged match healthy
10187719|NCT03723343||Experimental: GP+IMRT|Test group: GP-induced chemotherapy (Gemcitabine 1000 mg/m2 d1, 8+Cisplatin 80 mg/m2 d1, once every 3 weeks, 4/6 course) + IMRT radiotherapy alone
9969126|NCT01287260|Active Comparator|Arm 2|
9969127|NCT01287273||Group A|Transfer at the day of embryo thawing
9969128|NCT01287273||Group B|Transfer of thawed embryos 24-72 hours post thawing
9969129|NCT01287286|Experimental|AC-Can|Antrodia cinnamomea and concomitant chemotherapy
9969130|NCT01287286|Placebo Comparator|control|Placebo and concomitant chemotherapy
9969131|NCT01287299|Experimental|Low Glycemic Load Diet|Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.
9969132|NCT01287299|Experimental|Low Fat Diet|Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.
9969133|NCT01287325|Experimental|DNK333|
9969134|NCT01287325|Placebo Comparator|Placebo|
9969135|NCT01287338|Experimental|Lower Puncta Delivery|
9969136|NCT01287338|Experimental|Double Puncta Delivery|
9969137|NCT01287351||IPDI: Qvar|ICS initiation as Qvar
9969138|NCT01287351||IPDI FP|ICS initiation as fluticasone
9969139|NCT01287351||IPDA Qvar|ICS step-up as Qvar
9969140|NCT01287351||IPDA FP|ICS step-up as fluticasone
9969141|NCT01287390|Active Comparator|standard radiotherapy treatment|These patients receive the normal standard treatment.
9969142|NCT01287390|Experimental|adaptive radiotherapy|These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.
9969143|NCT01287429||acute dyspnea|
9969144|NCT01287455|Active Comparator|vitamin D|vitamin D deficient asthmatic patients receiving vitamin D supplement
9969145|NCT01287455|Placebo Comparator|placebo|vitamin D deficient asthmatic patients receiving placebo
9969146|NCT01287468||Experimental Group|
9969147|NCT01287468||Control Group|
9969148|NCT01287481|Experimental|Stress and Emotions|Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
9976861|NCT01355900|Other|III tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after wound closure
10137995|NCT04221074|Active Comparator|Modified Pectoral Plane (PECSII ) block (P)|done after induction of general anaesthesia in supine position of the patient with his arm of the side of the operation abducted 90 degree with the probe with frequency L4-12t (Logiq e machine) at the midclavicular level and angled infero-laterally,the axillary artery and vein and the second rib identified the probe moved laterally until the pectoralis minor and serratus anterior are identified,the local anesthetic was injected at two points using (echoplext guge20 length 50 mm ) needle:the first injection of 10 ml of 0.25% Bupivacaine and 4 mg dexamethasone injected between the pectoralis major and minor muscles,and the second injection of 20 ml of 0.25% Bupivacaine and 4 mg dexamethasone between the pectoralis minor and serratus anterior muscles .
10137996|NCT04221074|Active Comparator|Erector Spinae Plane ( ESP )block (E)|after induction of general anaesthesia in lateral position of the patient where the surgical side up and at T4 level the probe with frequency L4-12t (Logiq e machine) placed lateral to the spine by 3 cm in parasagittal plane the needle (echoplext guge20 length 50 mm ) advanced between the transverse process and the erector spinae muscle at that level 20 ml of 0.25% Bupivacaine and 8 mg dexamethasone injected.
10137997|NCT04220944|Experimental|Locoregional therapies combined with Anti-PD-1 antibody|Percutaneous microwave ablation combined with simultaneous TACE was performed. Sintilimab will be initiated on day 3-7 after the first locoregional therapies. Sintilimab will be administered every three weeks (200mg fixed dose IV) until disease progression for up to one year.The second locoregional procedure will be repeated according to the enhanced CT images.
10137998|NCT04221035|Experimental|phase induction-R-I|R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.
10137999|NCT04221035|Experimental|Phase high dose chemotherapy consolidation|R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).
10138000|NCT04221035|Experimental|Phase of radiotherapy|R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease
10138001|NCT04221113|Active Comparator|Group A ( Immobilization protocol)|Group A patients will receive static splints.By the end of 4 weeks the splint will be modified and patients will start doing physiotherapy. Movement at MCPJ will be from 0 to 45 degrees.
10138002|NCT04221113|Active Comparator|Group B( early active mobilization protocol).|Group B patients will receive splints in such a way that from 3rd post operative day patients will be instructed to do physiotherapy. Initially MCPJ movement will be from 0 to 30 degrees.
10138003|NCT04221295|Experimental|Exercise Group|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
10138004|NCT04221295|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
10138005|NCT04221022|Active Comparator|Light physical activity (Group 1)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into Light Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
10138006|NCT04221022|Active Comparator|Moderate physical activity (Group 2)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into moderate Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
10138007|NCT04221022|Active Comparator|Vigorous physical activity (Group 3)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into vigorous Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
10138008|NCT04220957|Experimental|Digital Impression Technique|Impression with an intraoral scanner (TRIOS 3, 3Shape, Denmark)
10138009|NCT04220957|Active Comparator|Conventional Impression Technique|Conventional impression with alginate (Orthoprint, Zhermack)
10138010|NCT04221048||PREG-GUCH|Pregnant women with congenital heart diseases
10138011|NCT04220996|Experimental|Vortioxetine|10-20 mg vortioxetine tablets
10184411|NCT03755284|Experimental|sacral Massage Group|"The massage was applied only to the pregnant women in the intervention group at every phase of labour. There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~For the pregnant women included in the experimental group:~In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour."
9519668|NCT03284658||Observation|Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1
9519669|NCT03284645||ART Before or Early in Pregnancy|HIV positive pregnant women who started antiretroviral therapy (ART) before or early in pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
10138012|NCT04220827|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.
10138013|NCT04220879||Malignant Glaucoma|To determine the biometric measurements.
10138014|NCT04220879||Fellow Eyes|To determine the biometric measurements.
10138015|NCT04220879||Matched Eyes|To determine the biometric measurements.
10138016|NCT04220892|Experimental|Pembrolizumab plus Pemetrexed|Pembrolizumab plus Pemetrexed
10138017|NCT04220892|Experimental|Pembrolizumab plus Abemaciclib|Pembrolizumab plus Abemaciclib
10138018|NCT04220866|Experimental|Ulevostinag+Pembrolizumab|Participants receive ulevostinag 540 ug via intratumoral (IT) injection on Day 1 of every week for two 3-week cycles (Cycles 1-2), then on Day 1 of each 3-week cycle for up 33 cycles (Cycles 3-35), for a total of 35 cycles PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
10138019|NCT04220866|Active Comparator|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
10138020|NCT04220762|Experimental|Test Group 1|The randomized patients are administered 3 tablets of the investigational product (400mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
10138021|NCT04220762|Experimental|Test Group 2|The randomized patients are administered 3 tablets of the investigational product (800mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
10138022|NCT04220762|Experimental|Test Group 3|The randomized patients are administered 3 tablets of the investigational product (1200mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
10138023|NCT04220762|Placebo Comparator|Placebo group|The randomized patients are administered 3 tablets of the placebo drug twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
10138024|NCT04220801|Experimental|Cohort 1 of Part 1 (SAD)|300 mg ZM-H1505R or placebo
10138025|NCT04220801|Experimental|Cohort 2 of Part 1(SAD)|450 mg ZM-H1505R or placebo
10138026|NCT04220801|Experimental|Cohort 3 of Part 1(SAD)|150 mg ZM-H1505R or placebo (2 periods)
10138027|NCT04220801|Experimental|Cohort 4 of Part 1(SAD)|75 mg ZM-H1505R or placebo
10138028|NCT04220801|Experimental|Cohort 5 of Part 1(SAD)|25 mg ZM-H1505R or placebo
10138029|NCT04220801|Experimental|Cohort 1 of Part 2 (MAD)|75 mg ZM-H1505R or placebo
10138030|NCT04220801|Experimental|Cohort 2 of Part 2 (MAD)|150 mg ZM-H1505R or placebo
10138031|NCT04220801|Experimental|Cohort 3 of Part 2 (MAD)|300 mg ZM-H1505R or placebo
10138032|NCT04220710||Marker selection group|Methalation detection of circulating free DNA and FFPF samples from pathologically confirmed patients with ovarian endometriosis(30 cases), ovarian cancer (30 cases)and other benign ovarian tumors (30 cases)will be performed to select markers for ovarian endometriosis diagnosis.
10138033|NCT04220710||Marker validation group|The selected markers will be validated in patients with ovarian cysts (300 cases )found by ultrasound. The diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.
10138034|NCT04220697|Experimental|patients undergo lateral thoracotomy for primary lung cancer|"Electroencephalography (EEG) will be acquired before surgery~Questionnaires assessing psychological status of the patients before and after surgery~High frequency electrical stimulation of the skin (HFS) will be delivered before surgery~Quantification of mechanical sensitivity after HFS and after surgery"
10138035|NCT04220749|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
10138036|NCT04220749|Experimental|Arm 2, TOS + Neck Dissection|Trans-oral Surgery (TOS) + Neck Dissection (plus radiation is required)
10138037|NCT04220788|Experimental|Enhanced pharmacist service|The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist
10138038|NCT04220788|Active Comparator|Usual care|Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
10138039|NCT04220541|Experimental|Motor learning based exercise group|
10138040|NCT04220541|Experimental|Symptomatic exercise group|
10138041|NCT04220736||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
10138042|NCT04220736||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
10138043|NCT04220528|Experimental|Radical chemoradiotherapy plus oral capecitabine/teggiol|Patients with newly diagnosed, non-metastatic stage N3 NPC was given Teggio 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving radical chemoradiotherapy.
10138044|NCT04220463|Experimental|Hypnosis group|For the hypnosis group, hypnotic support is set up by an IDE previously trained and dedicated during the implementation of the NIV. The dedicated IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated IDE.
10138045|NCT04220463|Placebo Comparator|Control group|In the control group, in order to preserve the knowledge of the evaluator, the IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
10138046|NCT04220411|Experimental|AR100DP1 (1.25%)|topical application twice per day with at least 4 hour interval
10138047|NCT04220411|Experimental|AR100DP1 (2.5%)|topical application twice per day with at least 4 hour interval
10138048|NCT04220411|Experimental|AR100DP1 (5%)|topical application twice per day with at least 4 hour interval
10138049|NCT04220580|Other|Cold Pressor Test|The participants are instructed to keep the non-dominant hand submerged in ice-water for as long as possible with a maximum of 10 minutes.
10138050|NCT04220398|Experimental|NCHT Group|Neoadjuvant chemotherapy combined with hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection
10138051|NCT04220398|Active Comparator|NHT Group|Neoadjuvant hormonal therapy, radical Prostatectomy (RP)+ extended lymph node dissection.
10138052|NCT04220398|Other|RP Group|Radical Prostatectomy (RP)+ extended lymph node dissection alone.
10138053|NCT04220567|Experimental|Exercise and Patient-centred education|
10138054|NCT04220567|Active Comparator|Exercise|
10138055|NCT04220515|Experimental|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Primary 3-dose of sIPV and booster 1 dose of sIPV
10138056|NCT04220645|Active Comparator|Standard of care|Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
10138057|NCT04220645|Experimental|Opportunistic treatment|Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
10138058|NCT04220606|Other|Migraine without aura subjects|Drug: Glyceryl trinitrate (GTN)
10138059|NCT04220606|Other|Healthy subjects|Drug: Glyceryl trinitrate (GTN)
10138060|NCT04220437||CAG and OCT group|Images of CAG and OCT patients obtained from ISR patients were retrospectively collected and analyzed.
10138061|NCT04220632|Experimental|Itacitinib+corticosteroids|Itacitinib administered in combination with corticosteroids
10138062|NCT04220593|Experimental|aETCC before TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
10138063|NCT04220593|Experimental|aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
10138064|NCT04220593|Experimental|aETCC after TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
10138065|NCT04220593|Sham Comparator|Simulated aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
10138066|NCT04220554|Experimental|Intervention group|"Intervention group:~All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream.~During the study period, a nurse or pharmaconomist will deliver;~Improved support and instructions to the patients~Patients will receive a diary and access to more consultations."
10138067|NCT04220554|No Intervention|Non-intervention group|"All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream."
10138068|NCT04220476|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
10138069|NCT04220476|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
10138070|NCT04220372|Experimental|Tongxinluo Capsule|
10138071|NCT04220372|Placebo Comparator|Placebo Capsule|
10138072|NCT04220346|Experimental|Tablet group|The Tablet group played the game with Tablet during the whole circumcision.
10138073|NCT04220346|No Intervention|Control group|The control group did not play game with Tablet during the procedure.
10138074|NCT04220281|Active Comparator|propofol group|propofol group will receive propofol infusion
10138075|NCT04220281|Active Comparator|nitroglycerin group|will receive nitroglycerin infusion
10138076|NCT04220385|Active Comparator|Wii fit Plus|"This study group will perform the following Wii fit plus exercises~Single-Leg Extension~Arm and Leg Lift~Balance Bridge~Single-Leg Twist~Single-Leg Reach~Sideways Leg Lift~Single Arm Stand~Torso Twists~Plank"
10138077|NCT04220385|Active Comparator|Core Stability|"This study group will perform the following exercises.~Curl-up~Side Bridge~Bird Dog"
10138078|NCT04220502|Experimental|Magic Shave Powder Gold|This group will receive magic shaving powder gold and instructions on how to apply it. They will keep a log for their facial hair removal
10138079|NCT04220502|Other|Traditional Methods|This group will continue using traditional razors with the standard of care directions to shave. They will keep a log of their facial hair removal
10138080|NCT04220333|Placebo Comparator|Control|Participants received the instruction: 'please, lie down, relax and pay attention to your breath'. This procedure was carried during 15 minutes. Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings.
10187720|NCT03723343||Active Comparator: TPF+IMRT|Control group: TPF-induced chemotherapy (Docetaxel: 75 mg/m2d1, Cisplatin 75 mg/m2, d1~d5, 5-fluorouracil 750 mg/m2/dd1~d5, 4/6 course) + IMRT radiotherapy alone
10138081|NCT04220333|Experimental|Intervention|"The intervention protocol was divided in two steps: first, patients spent 5 minutes in the phase of harmonization with five colored stones of a size of a walnut (green, red, yellow, white and black) placed around their bodies.~Second, in accordance to the emotion chosen by the participant, a matching mandala was placed next to the feet, on the abdomen, or next to the head depending on the self-perceived personality type, intuitive, emotive and rational for the remaining 10 minutes (Figure 3B). The researcher also checked the control subjects once during the 15 fifteen minutes of experiment.~Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings."
10138082|NCT04220151||Hepatocellular carcinoma|Sixty patients with HCC
10138083|NCT04220151||Hepatic cirrhosis|Thirty patients with hepatic cirrhosis
10138084|NCT04220151||Healthy controls|Ten healthy controls.
9669159|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: Other Histology|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with other tumor types (prostate, urinary bladder, pancreas, and stomach).
10138085|NCT04220047|Experimental|Left Atrial Appendage Resection|
10138086|NCT04220047|No Intervention|off-pump coronary artery bypass|
10138087|NCT04220138|Other|cataract patients with poor red reflex|included cataract patients with poor red reflex
10138088|NCT04220008|Experimental|Treatment (busulfan, vorinostat, gemcitabine, clofarabine)|"Patients receive a low-level test dose of busulfan IV over up to 1 hour on days -15 to -9, vorinostat PO QD on days -8 to -4, gemcitabine IV over about 90 minutes on days -7 and -5, clofarabine IV over about 1 hour and high-dose busulfan IV over 3 hours on days -7 to -4. Patients with CD20 positive (+) lymphoma also receive rituximab IV over 3 to 6 hours on days -15, -8, 1, and 8. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 2 hours on days 3 and 4. Beginning day 5, patients receive standard of care tacrolimus IV over 24 hours and mycophenolate mofetil IV over 2 hours TID until they can be tolerated PO. Once tolerated PO, patients receive tacrolimus PO BID for 6 months and mycophenolate mofetil PO TID for up to 30 days in the absence of disease progression or unacceptable toxicity. After 30 days, patients who develop GVHD continue treatment with mycophenolate mofetil at physician's discretion"
10138089|NCT04219943|Experimental|Conservative Treatment for Impacted Femoral Neck Fracture|Conservative Treatment for Impacted Femoral Neck Fracture
10138090|NCT04219956|Experimental|Polyamine deficient diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
10138091|NCT04219956|No Intervention|Control|Usual Diet plus two snacks
10138092|NCT04220164||Dyslipidemic patients|Patients who meet the criteria of high-risk category according to 2017 Taiwan Lipid Guideline for High-Risk Patients have a abnormal serum LDL-C level
10138093|NCT04220177|Experimental|treatment arm|SETA LATECBA Stent Grafts, are tube shaped implantable devices, delivered by balloon catheter system which are intended to the treatment of infrarenal AAA by sealing the affected areas, avoiding the bleeding or perfusion inside the aneurysm and restoring the normal hemodynamics in the affected vessels. The product family is composed by a set of endovascular stent grafts, that can be used alone or in combination, according to the treatment strategy, extension and complexity of the AAA. One aortic bifurcated stent graft, ABK SETA LATECBA model, is the aortic trunk and two straight iliac stent grafts, RIK SETA LATECBA model, are the connections to both iliac arteries.
10138094|NCT04220021|Experimental|C9orf72 positive ALS|"Subjects with C9orf72 positive ALS will be instructed in the use of Metformin and receive the first dose of Metformin under supervision of the investigator during Visit 1, Day 2.~Subjects will then continue on Metformin per the dose escalation schedule twice daily for 24 weeks."
10138095|NCT04220099||schizophrenia patients needed ECT treatment|Whether patients need ECT treatment are assessed by clinicians according to American Psychiatric Association(APA) guidelines.
10138096|NCT04219969|Experimental|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minutes and then undergo PET-MRI over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
10138097|NCT04220112|Experimental|Real Time Functional MRI (rt-fMRI)|Real-time fMRI (rt-fMRI) neurofeedback (focused on amygdala down-regulation) intervention
10138098|NCT04220112|Sham Comparator|Sham|Sham-controlled group
10138099|NCT04220086|Experimental|Pediatric massage|Children with ASD will receive pediatric massage for 12 weeks.
10138100|NCT04220086|Sham Comparator|Waitlist control|Waitlist control
10138101|NCT04220086|Other|Healthy Control|15 healthy controls (age- and sex- matched with ASD patients) will be recruited. All of them will receive clinical evaluations, EEG and fNIRS detection.
10138102|NCT04220073|Experimental|JS005|
9669160|NCT03867318|Experimental|Atorvastatin Monotherapy|Participants receive double-blind atorvastatin 10 mg once daily (QD) via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 80 mg (10 mg open label plus 70 mg double blind).
10138103|NCT04220073|Placebo Comparator|placebo|
10138104|NCT04219995|Experimental|Interventional start|Patients who randomize to the interventional start arm will receive the study drug, methylprednisolone sodium succinate, in the first month of the study, followed by placebo in the cross-over phase of the study.
10138105|NCT04219995|Placebo Comparator|Placebo start|Patients who randomize to the placebo start arm will receive placebo in the first month of the study, followed by the study drug, methylprednisolone sodium succinate, in the cross-over phase of the study.
10138106|NCT04220307|Experimental|AK104|AK104 IV every 2 weeks (q2w)
10138107|NCT04219930||epileptic children|fifty patient with epilepsy
10138108|NCT04219930||Healthy controls|thirty healthy control
10138109|NCT04220268||Participants|All the patients with proved malignant ground glass nodule will be enrolled.
10138110|NCT04219865|Active Comparator|Compound Edaravone|10 mL per vial (containing edaravone 10 mg and 2-aminoethanesulfonic acid 200 mg)
10138111|NCT04219865|Placebo Comparator|Placebo|10 mL per vial
10138112|NCT04219982|Experimental|DPI-386 Nasal Gel|Active DPI-386 Nasal Gel
10138113|NCT04219982|Placebo Comparator|DPI-386 Placebo Nasal Gel|Placebo Nasal Gel
9969149|NCT01287481|Active Comparator|Thoughts and Behaviors|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
9969150|NCT01287481|Active Comparator|Brain and Body|Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
9969151|NCT01287494|Experimental|Depression Care Management|"DCM Intervention for Depressed Elders in Primary Care~Treatment guidelines (TG): Eight weeks treatment with Sertraline, another 8 weeks treatment augmentation with Bupropion if patients fail to respond in the initial trial, For more complicated cases, the transfer to psychiatrists is indicated.~Care managers: Screening, Adherence support, psychoeducation and communication.~Psychiatric Consultation"
9969152|NCT01287494|No Intervention|Care as Usual|
9969153|NCT01287507|Placebo Comparator|Placebo|In born VLBW infants with parental consent form signed will be given oral saline daily as placebo until discharge
9969154|NCT01287507|Experimental|Lactoferrin|In born VLBW infants with parental consent form signed will be given oral bovine lactoferrin daily until discharge
9969155|NCT01287533|Experimental|Ibandronate treatment|Ibandronate 150mg PO once every 4 weeks
9969156|NCT01287533|Placebo Comparator|Placebo arm|Placebo PO once every 4 weeks
9969157|NCT01287546|Experimental|LY2875358|
9969158|NCT01287546|Experimental|LY2875358 + erlotinib|
9969159|NCT01287546|Experimental|LY2875358 at Part A highest dose|
9969160|NCT01287546|Experimental|LY2875358 at Part A highest dose + trametinib|
9969161|NCT01287559||Subjects with NEC|Infants in which a possible diagnosis of NEC is suspected
9969162|NCT01287559||Control Infants|Age-matched and illness-severity matched to NEC subjects, controls are infants NOT suspected of having NEC.
9969163|NCT01287572||Conscious sedation group|Pediatric patients 0 to 18 years requiring conscious sedation for procedures done in the pediatric ICU excluding burned patients or patients with severe eczema or other skin disease.
9969164|NCT01287598|Experimental|Arm 1|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam
9969165|NCT01287598|Experimental|Arm 2|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
9969166|NCT01287624|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin)
9969167|NCT01287624|Active Comparator|Gemcitabine, Paclitaxel|GT (gemcitabine and paclitaxel combination)
9969168|NCT01287637|Experimental|Early reversal group|Early reversal of temporary ileostomy
9969169|NCT01287637|Active Comparator|Control group|Standard reversal of temporary ileostomy
9969170|NCT01287663|Placebo Comparator|no permethrin|
9969171|NCT01287663|Experimental|permethrin|
9969172|NCT01287689||Patient treated with any IgG|Any marketed SC or IV IgG can be documented
9969173|NCT01287702|Experimental|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
9969174|NCT01287702|Active Comparator|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL.
9969175|NCT01287715|Experimental|STOP-arm|Discontinuation of etanercept
9969176|NCT01287715|No Intervention|CONTROL-arm|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
9969177|NCT01287728|Experimental|treatment BY METROMIDAZOLE|
9969178|NCT01287741|Active Comparator|Rituximab+Chemotherapy|Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
9969179|NCT01287741|Experimental|Obinutuzumab+Chemotherapy|Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
9969180|NCT01287767|No Intervention|Control group, ordinary support|Home care as usual.
9969181|NCT01287767|Experimental|A multidimensjonalt support program|•Behavioral (e.g., Psychotherapy, Lifestyle Counseling) The family will receive individual consulting, teaching and problem solving in support groups.
9969182|NCT01287780|Active Comparator|Collagen-gentamicin sponges|Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
10138114|NCT04219982|Active Comparator|Transderm Scop® (TDS)|FDA approved Transderm Scop® (TDS).
9969183|NCT01287780|No Intervention|No intervention|
9969184|NCT01287793|Experimental|high dose tigecycline|
9969185|NCT01287793|Experimental|regular dose tigecycline|
9969186|NCT01287793|Active Comparator|moxifloxacin|
9969187|NCT01287793|Placebo Comparator|placebo|
9969188|NCT01287806|Sham Comparator|blank control group|
9969189|NCT01287806|Experimental|ulinastatin group|ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine
9969190|NCT01287819||APOE4 (+) and APE4 (-)|APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants
9969191|NCT01287845|Experimental|Arm 1|
9969192|NCT01287845|Experimental|Arm 2|
9969193|NCT01287858|Placebo Comparator|Placebo|Placebo
9969194|NCT01287858|Active Comparator|AC430|AC430
9969195|NCT01287871||Social media intervention|Women between the ages of 18-70 who have not been diagnosed with any type of cancer and are of African descent or Latina
9969196|NCT01287884|No Intervention|Venous Blood Gas|All subjects have an ABG and VBG drawn. No intervention.
9969197|NCT01287910|Other|All Patients|All patients undergo the same study procedures
9969198|NCT01287923||DLBCL|DLBCL patients included 075-GOELAMS trial or 075-like patient.
9969199|NCT01287923||Healthy controls|Blood donors from the EFS (French Blood Bank) of Rennes.
9969200|NCT01287923||Septic patients|septic patients included at the Rennes University Hospital.
9969201|NCT01287923||DLBCL in completed remission|DLBCL patients from the 075 GOELAMS study in completed remission.
9969202|NCT01287936|Experimental|SB623|Administration of modified stem cells, SB623
9969203|NCT01287949|Experimental|REPEVAX followed by REVAXIS administration|
9969204|NCT01287962|Experimental|Apatinib|750 mg，po，QD； 28 days every cycle
9969205|NCT01287962|Placebo Comparator|Placebo|
9969206|NCT01287975|Active Comparator|Standard Occupational Therapy|Standard Occupational Therapy for Wrist and Hand Training
9969207|NCT01287975|Experimental|BCI Haptic Knob|BCI controlled robotic-assisted training for wrist and hand
9969208|NCT01287975|Experimental|Haptic Knob|Robotic-assisted training for wrist and hand
9976862|NCT01355900|Other|IV control group|Do not use volume loading test. Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
9976863|NCT01355926|Experimental|Flexible Fiber-based CO2 Laser|In the CO2 excised group, the resection will be performed at 15W, at a distance of 1cm from the tissue. Here too, if required, the bipolar will be used to achieve hemostasis The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
9976864|NCT01355926|Experimental|electrocautery resection|In the electrocautery excised group, the cut and coagulation modes used will be each at 25 Malis power setting. First, cut mode will be used to mark out the lesion. Subsequently, coagulation mode will be used for excision. Bipolar cautery will then be used at 25 Malis for hemostasis. The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
9976865|NCT01355939||Abdominal surgery after prior VHR with barrier-coated mesh|
9976866|NCT01355939||Abdominal surgery after prior VHR with nonbarrier-coated mesh|
9976867|NCT01355939||Lap adhesiolysis during abdominal surgery after prior VHR|
9976868|NCT01355939||Open adhesioloysis during abdominal surgery after prior VHR|
9976869|NCT01355952|Experimental|Alpha Lipoic Acid|taking 1800mg daily (600mg 3 times per day) Alpha Lipoic Acid (ALA) open-label for 10 weeks.
9976870|NCT01355965|Experimental|Cohort 1 - One dose of cells|Subjects receive one dose of 1x108 cells on day 0 followed by one dose of 1x109 autologous transfected anti-mesothelin CAR T cells on day 7.
9976871|NCT01355965|Experimental|Cohort 2 - three doses of cells|receive three doses of 1x108 cells on day 0, 2, 4 (Monday-Wednesday-Friday (MWF) of Cycle 1) followed by three doses of 1x109 T cells on day 7, 9, 11 (MWF of Cycle 2). Total target dose for Cohort 2 is 3.3x109 cells.
9976872|NCT01355991|Active Comparator|Anticholinergic Agent|
9976873|NCT01355991|Active Comparator|Long Acting Beta 2 Agonist|
9976874|NCT01356004|Experimental|chicken pox vaccine, efficacy|
9976875|NCT01356004|Placebo Comparator|saline, efficacy|
9976876|NCT01356017|Experimental|Free combination of Telmisartan and S-amlodipine|Subjects received Telmisartan 80mg and S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
9976877|NCT01356017|Active Comparator|Telmisartan monotherapy|Subjects received Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
9976878|NCT01356030|Active Comparator|EUS-FNA|
9976879|NCT01356030|Active Comparator|ERCP Brushing and Biopsy|
9976880|NCT01356043|Experimental|Free combination of S-amlodipine and Telmisartan|Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
9976881|NCT01356043|Active Comparator|S-amlodipine monotherapy|Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
9976882|NCT01356056||Kinesia HomeView Monitoring|Uses Kinesia HomeView at home once per week
9976883|NCT01356056||Control|Assessed in the clinic every 4 weeks using traditional methods
9976884|NCT01356069|Experimental|SB-APP Psychotherapy|Patients, who signed the informed consent, were randomly assigned to SB-APP in addition to TAU (n=18) or to TAU alone (n=17) groups. The SB-APP group received the usual treatment plus SB-APP (40 weekly sessions) for 10 or 11 months. At the term of the first year (T12) the TAU group continued with the TAU management with supportive weekly session whilst the SB-APP group was carried on with the psychiatric, nurse, educational management without any individual psychological support. The number of sessions performed by the two groups in the first year (T0-T12) was programmed to be almost the same to reduce the number of sessions bias comparing the specific quality of treatments.
9976885|NCT01356069|Active Comparator|TAU treatment|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators. The medication was administered according to the APA guidelines [18] for good clinical practice with regard to BPD.
9976886|NCT01356082||Arterial blood pressure line|Patients receiving an arterial blood pressure line
9976887|NCT01356095|Active Comparator|PALM-Plus control|Health centers randomized to Palm-Plus intervention in larger trial this trial is embedded in, but not receiving the adherence intervention.
9976888|NCT01356095|Experimental|Adherence intervention|Intervention arm.
9976889|NCT01356095|No Intervention|Control|
9976890|NCT01356121|Active Comparator|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
9976891|NCT01356121|Active Comparator|Propofol|Propofol will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
9976892|NCT01356121|No Intervention|No Sedation|No sedation given in this group
9976893|NCT01356134||Multiple sclerosis and or Ehlers-Danlos|Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis
9976894|NCT01356134||Age matched normals|Age matched normals
9976895|NCT01356173|Experimental|A|
10138115|NCT04219917|Experimental|Hip|Gluteus medius facilitation tape
10138116|NCT04219917|Experimental|Knee|Patellar sling tape
10138117|NCT04219917|Experimental|Hip and Knee|Gluteus medius facilitation and patellar sling tape
10138118|NCT04220034||Patients receiving inhibitor checkpoint treatment|adult patients that will receive for the first time checkpoint inhibitor for a neoplasic disease in a center participating to the study
10138119|NCT04219462|Active Comparator|study group|twenty men receive extracorporeal shock wave (ESWT) twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura +sildenafil 5mg once daily for 3 months.
10138120|NCT04219462|Sham Comparator|control group|twenty men will receive sham treatment underwent identical therapy with Extracorporal shock wave therapy (ESWT) application with a similar appearance and sound as the active low intensity extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
10138121|NCT04219852||"bariatric surgery group"|Women between 18 and 50 years, who undergone bariatric surgery at the University Hospital of Reims.
10138122|NCT04219904|Experimental|Diagnostic (PET/MRI)|Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.
10138123|NCT04219527|Experimental|Dual-Target injection|Corticosteroid injection into the subacromial bursa and biceps tendon
10138124|NCT04219579|Experimental|Continuous infusion|Immediately after operation, 2000 international unit (IU) of Antithrombin-III (AT-III) concentrate is loaded for 1 hour. AT-III concentrate 3000 IU is continuously infused through following 71 hours.
10138125|NCT04219579|Active Comparator|Intermittent infusion|Every 6 hours, 500 IU of AT-III concentrate is infused through 1 hour during the first 72 hours after liver transplantation.
10138126|NCT04219488|Experimental|Neuromobilization group|The neuromobilization group received a supervised home program plus radial nerve mobilization. Radial nerve mobilization exercises were performed by the physiotherapist for 3 days a week for 3 weeks. The patients in the neuromobilization group also performed self-neuromobilization exercises at home for 6 weeks. Supervised home program including patient education and eccentric exercises was administered three times daily for 6 weeks.
10138127|NCT04219488|Active Comparator|Control group|The control group received a supervised home program. Supervised home program including patient education and eccentric exercises was administered 3 times a day for 6 weeks.
10138128|NCT04219592||SSc|74 SSc patients aged 18 - 85
10138129|NCT04219592||Healthy controls|80 Healthy blood-donors aged 18 - 85
10138130|NCT04219787|Experimental|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
10138131|NCT04219787|Active Comparator|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
10138132|NCT04219553|Other|Retrospective group|Comparator group (pre-intervention)
10138133|NCT04219553|Experimental|Prospective group|Study group (post-intervention)
10138134|NCT04219644|Other|Breathing test or sleep study|To evaluate the usability of the device in non-clinical and clinical settings
10138135|NCT04219618|Experimental|Off-Pump|
10138136|NCT04219618|Active Comparator|On-Pump|
10138137|NCT04219735|Experimental|Minocycline|Minocycline 100 mg BID
10138138|NCT04219735|Placebo Comparator|Placebo|Placebo capsules identical to experimental arm
10138139|NCT04219722|Active Comparator|Desirial only group|Administration of DESIRIAL® at Day 0 (Visit 1)
9519670|NCT03284645||ART Started Third Trimester|HIV positive pregnant women starting antiretroviral therapy (ART) during the third trimester of pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
10138140|NCT04219722|Placebo Comparator|Placebo and Desirial group|Administration of placebo at Day 0 (Visit 1). If still eligible 12 weeks (Visit 3) after placebo injection, patient will be treated with DESIRIAL®
10138141|NCT04219748|Experimental|Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual."
10138142|NCT04219748|No Intervention|Control|Only treatment as usual in the Emergency Department (and in the Health and Social Services Network).
10138143|NCT04219657|Experimental|skin grafting only|All the cases in this group are managed with skin grafting only. Every odd case are kept in skin grafting only group.
10138144|NCT04219657|Experimental|skin grafting and stem cell group|All the cases in this group are managed with skin grafting and application of stem cells. every even cases are kept in skin grafting and stem cells group.
10138145|NCT04219670||Inpatient Group|Inpatient stroke survivors who are currently undergoing rehabilitation at the Shirley Ryan AbilityLab setting
10138146|NCT04219670||Healthy Control Group|Individuals without any known significant health problems
10138147|NCT04219683|Experimental|Patient with resected Mandible|Patient with resected mandible who is candidate for free fibula flap
10138148|NCT04219631|Experimental|WINNER- FLOW-URO-MG GROUP|After admission to the delivery room, all women assigned to WF + group will have an interview with one of the midwifes responsible for the study. The latter will explain the use of the WINNER FLOW®-URO MG® device which is the expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate. Then, WF+ patients will use the expiratory mouthpiece device during all their childbirth process.
10138149|NCT04219631|No Intervention|NO WINNER-FLOW-URO-MG GROUP|Women enrolled in WF- group will be managed classically during their child birth process regardless to the study participation.
10138150|NCT04219501|No Intervention|Control Group|Subjects presenting for PVC/VT ablation will undergo ablation procedures using standard of care invasive electroanatomical mapping systems.
10138151|NCT04219501|Experimental|VIVO Arm|Subjects presenting for PVC/VT ablation, that have a previously acquired cardiac CT/MRI scan or are having a cardiac CT/MRI scan as per routine care, will undergo ablation procedures using VIVO, a novel, non-invasive mapping system.
10138152|NCT04219436|Active Comparator|periosteal suturing technique|periosteal suture is done to close the flap
10138153|NCT04219436|Active Comparator|figure of eight suturing technique|figure of eight suture is done to close the flap
10138154|NCT04219449||study group|Diagnosed beta-thalassemia patients at Assiut University Hospital.
10138155|NCT04219241|Experimental|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
10138156|NCT04219098|Experimental|Treatment|Butterfly IQ utilized to inject 10cc prior to surgery the remainder after incision
10138157|NCT04219098|Active Comparator|Control|Entire injection will be given after initial incision is made.
10138158|NCT04219124|Active Comparator|Dapagliflozin|Investigational product: Dapagliflozin 10 mg Dosage form and strength: Green, plain, diamond shaped, film coated 10 mg tablet with frequency of 1 tablet per day for 4 weeks
10138159|NCT04219124|Placebo Comparator|Placebo|Investigational product: Matching placebo for Dapagliflozin 10 mg. Dosage form and strength: Green, plain, diamond shaped, and film coated tablet with frequency of 1 tablet per day for 4 weeks
10138160|NCT04219306|Experimental|Machine alert|These cardiac suspected cardiac arrest will have had an alert generated by the machine learning model in addition to standard Emergency Medical Services response.
10138161|NCT04219306|No Intervention|Usual care|These suspected cardiac arrests will receive standard Emergency Medical Services response.
9969209|NCT01287988||Ocriplasmin|Subjects who were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study (TG-MV-006 or TG-MV-007)
10138162|NCT04219345|Active Comparator|Active group|In the group A will be administered anodic tDCS and instructed in mindfulness practices.
10138163|NCT04219345|Sham Comparator|Sham group|In the group B will be administered sham tDCS and instructed in mindfulness practices.
10138164|NCT04219150|Experimental|Electrical cardiometry (EC)|
10138165|NCT04219150|Experimental|"Fluid and Catheter Treatment Trial FACTT Lite"|
10138166|NCT04219020||Children with a CP diagnosis|"Children younger than 18 years with a CP diagnosis. Intervention will be determined later based on baseline results. Self- and/or proxy-reported survey and/or participation in interviews.~Parents of all participants will provide proxy report. Children with CP > 8 years of age and cognitively able (approx. 50%) will provide self-report."
10138167|NCT04219020||Controls|Siblings (12-17 years) of children with cerebral palsy. No intervention, self-reported survey.
10138168|NCT04219020||Health Care Professionals|Health Care Professionals identified as providers of pain care. No intervention, interview participants
10138169|NCT04219332|Experimental|Subserosal injection of indocyanine green tracer group|Subserosal injection of indocyanine green, with a concentration of 0.5 mg /ml, 6 points along the lesser and greater curvature of the stomach, 1.5 ml for each point.
10138170|NCT04219332|Active Comparator|Submucosal injection of indocyanine green tracer group|Submucosal injection of indocyanine green, with a concentration of 1.25mg /ml, four points around the primary tumor, each point 0.5 ml.
10138171|NCT04219358|Active Comparator|Placebo & Standard Treatment|
10138172|NCT04219358|Experimental|Imiquimod 5% & Standard Treatment|
10138173|NCT04219358|Experimental|Imiquimod 0.05% & Standard Treatment|
9669161|NCT03867318|Experimental|Ezetimibe + Atorvastatin|Participants receive double-blind ezetimibe 10 mg QD via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 40 mg (10 mg open label plus 30 mg double blind).
10138174|NCT04219358|Experimental|Imiquimod nanoencapsulated 0.05% & Standard Treatment|
10138175|NCT04219384||Critical-illness related cardiac arrest (CIRCA)|Those experiencing a critical illness-related cardiac arrest in a participating adult, general ICU
10138176|NCT04219007|Experimental|Genetic Short Stature|"Vosoritide, also known as BMN 111 or modified recombinant human C-type natriuretic peptide (CNP), is a 39-amino-acid peptide analog that includes the 37 C-terminal amino acids of the human CNP53 sequence plus the addition of 2 amino acids (Pro-Gly) on the N-terminus. This structural modification conveys resistance to neutral endopeptidase (NEP) degradation, resulting in prolonged half-life (t1/2) in comparison to endogenous CNP. This increase in t1/2 allows once daily subcutaneous (SC) administration.~Vosoritide will be administered as a single 15 μg/kg subcutaneous injection given daily for 12 months."
10138177|NCT04219410||Cases|Patients who underwent minimally invasive esophagectomy with this novel procedure at Kaiser Permanente, Northern California, Oakland Medical Center
9969210|NCT01287988||Placebo|Subjects who were exposed to a single intravitreal injection of placebo in a previous phase III study (TG-MV-006 or TG-MV-007)
9969211|NCT01288001|Experimental|Ostenil plus|Patient will get Ostenil plus injection and standard treatment of Osteoarthritis
10138178|NCT04219397|No Intervention|Control|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol. There will be no interventions provided. They will receive a follow up phone call survey and be asked to return a completed medication education calendar that is provided as a part of usual APS care.
10138179|NCT04219397|Experimental|Medication take back education intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive a standardized education intervention. This intervention will educate patients and their families about medication take back programs, and will provide tailored directions to the closest medication take back center from their home, and also an option for medication take back that is located in close proximity to Riley Hospital clinics.
10138180|NCT04219397|Experimental|Home disposal kit intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive standardized education about how to use the medication home disposal kit : Dispose Rx(r), and they will be instructed to use this kit to dispose of any left over opioid medications that they may have after they have competed therapy for pain management at home.
9969212|NCT01288014||Edlerly Recipients of Zoster Vaccine|Blood samples are collected before and after vaccination in people age 60 or more, who are getting the zoster vaccine as part of their routine health care.
9969213|NCT01288040|Experimental|Treadmill exercise|Split-belt treadmill training
9969214|NCT01288066|Other|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system.
9969215|NCT01288066|Other|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system.
9969216|NCT01288092|Experimental|BEZ235|
9969217|NCT01288105|Experimental|Optical Coherence Tomography|Patients enrolled in the study will undergo optical coherence tomography to evaluate the extent of stent strut coverage.
9969218|NCT01288131|Active Comparator|CSA+MMF|Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
9969219|NCT01288131|Active Comparator|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day
9969220|NCT01288144|Experimental|Intervention|Quality improvement initiative using computerized decision support
9969221|NCT01288144|No Intervention|Usual care|In control clinics, women will continue to receive usual care.
9969222|NCT01288157|Experimental|001|Golimumab Single dose of 50 mg subcutaneously
9969223|NCT01288157|Experimental|002|Golimumab Single dose of 100 mg subcutaneously
9969224|NCT01288170|Other|Nebcinal Tobi|crossover design
9969225|NCT01288170|Other|Tobi Nebcinal|crossover design
9969226|NCT01288183|Sham Comparator|sham tDCS|sham transcranial direct current stimulation The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region
9969227|NCT01288183|Active Comparator|active tDCS|active anodal tDCS over the right dorsolateral prefrontal cortex The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region Intensity of the stimulation: 2 mA Duration of the stimulation: 20 min 10 sessions, 2 per day
9969228|NCT01288196|Experimental|001|CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
9969229|NCT01288196|Experimental|002|CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
9969230|NCT01288196|Experimental|003|CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
9969231|NCT01288196|Placebo Comparator|004|Placebo IV A single 30-minute IV infusion of placebo
9969232|NCT01288196|Experimental|005|CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
9969233|NCT01288196|Placebo Comparator|006|Placebo SC A single SC dose of placebo administered in up to 3 SC injections
9969234|NCT01288222|Experimental|Unrelated Donor Transplant Patients|Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.
9969235|NCT01288235|Experimental|Proton Radiotherapy|Proton Radiotherapy
9969236|NCT01288248|Experimental|Airway laryngeal mask classic|Ventilation with Airway laryngeal mask classic during surgery
9969237|NCT01288248|Active Comparator|endotracheal tube|Ventilation with endotracheal tube during surgery
9969238|NCT01288261|Experimental|Treatment|Paclitaxel, bavituximab, laboratory biomarker analysis and pharmacological study
9969239|NCT01288274|Active Comparator|Injection by Health Extension Worker|Women who receive injectable contraceptive from clinic based health extension workers (HEWs) during the study period
9969240|NCT01288274|Active Comparator|Injection by Community Health Worker|Women who receive injectable contraceptive through community based distributors from community based reproductive health agents (CBRHAs) during the study period
9969241|NCT01288300|Active Comparator|Comprehensive diabetes self-management intervention|Diabetes education, self-empowerment training, exercise, patient navigator
9969242|NCT01288300|Other|Control|Diabetes self-management lecture
9969243|NCT01288313|Experimental|rapeseed oil|
9969244|NCT01288313|Experimental|n-3 margarine and rapeseed oil|
9969245|NCT01288313|Experimental|n-3 margarine|
9969246|NCT01288313|Active Comparator|Olive oil|
9969247|NCT01288326||A|
9969248|NCT01288339|Experimental|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP (MMP7+/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
9969249|NCT01288339|Experimental|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
9969250|NCT01288352|No Intervention|Usual care|Usual care closely follows the suggestions laid out in the current European Society of Cardiology (ESC) guidelines for AF treatment. In addition to antithrombotic therapy and therapy of underlying heart disease, usual care usually consists of an initial attempt to control symptoms by rate control therapy. Rhythm control interventions are recommended when symptoms can not be controlled by optimal rate control therapy in the usual care group.
9969251|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~Optimal antiarrhythmic drug therapy (Dronedarone, Amiodarone, Flecainide, Propafenone),~Catheter ablation with the aim of pulmonary vein isolation (PVI),~Antiarrhythmic drug therapy and catheter ablation may be supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
9969252|NCT01288365|Experimental|Exercise training|Protocol of 3 month exercise training program.
9969253|NCT01288365|No Intervention|Control|Control group
9969254|NCT01288378|Active Comparator|Empirical|Empirical approach (fever driven) for starting antifungal therapy
9969255|NCT01288378|Experimental|Pre-emptive|Pre-emptive approach (diagnostic driven) for starting antifungal therapy
9969256|NCT01288391|Experimental|100 mcg/kg|
9969257|NCT01288391|Experimental|200 mcg/kg|
9969258|NCT01288404|Placebo Comparator|Control|topical 0.1% fluorometholone eye drops
9969259|NCT01288404|Active Comparator|Bevacizumab group 1|Bevacizumab 1.25 mg/0.05mL
9969260|NCT01288404|Active Comparator|Bevacizumab group 2|Bevacizumab 2.5 mg/0.1mL
9969261|NCT01288404|Active Comparator|bevacizumab group 3|bevacizumab 3.75 mg/0.15mL
9969262|NCT01288417|Experimental|boceprevir + raltegravir|9 days of boceprevir 800mg TID; day 10 two doses of boceprevir 800mg and one dose of raltegravir 400mg
9969263|NCT01288417|Active Comparator|raltegravir alone|single dose of raltegravir 400mg
9969264|NCT01288482|Experimental|Asthma Subjects|
9969265|NCT01288495|Experimental|L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
9969266|NCT01288495|Placebo Comparator|Placebo|Subjects will consume the placebo prior to eating fructose-containing foods.
9969267|NCT01288508|Active Comparator|Supra Fiber|
9969268|NCT01288508|Active Comparator|Psyllium|
9969269|NCT01288547|Active Comparator|theobromine|theobromine (700 mg) in capsule
9969270|NCT01288547|Active Comparator|caffeine|caffeine (120 mg) in capsule
9969271|NCT01288547|Placebo Comparator|Placebo capsule|no theobromine or caffeine
9969272|NCT01288547|Active Comparator|theobromine + caffeine|Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine
9969273|NCT01288560|Active Comparator|Advanced cardiac imaging (PET/CT or CMR)|Patients will undergo cardiac imaging as evaluation of heart failure using 1 of the following alternate/advanced imaging modalities: Positron Emission Tomography (PET/CT), Cardiac Magnetic Resonance (CMR)
9969274|NCT01288560|Active Comparator|Standard cardiac imaging (SPECT)|Patients will undergo standard cardiac imaging procedures for evaluation of heart failure such as single photon emission computed tomography (SPECT).
9969275|NCT01288573|Experimental|Plerixafor 160 μg/kg|Patients will receive subcutaneous (SC) injection of 160 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
9969276|NCT01288573|Experimental|Plerixafor 240 μg/kg|Patients will receive subcutaneous (SC) injection of 240 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
9969277|NCT01288573|Experimental|Plerixafor 320 μg/kg|Patients will receive subcutaneous (SC) injection of 320 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
9969278|NCT01288586||Device|Scandinavian Total Ankle Replacement System (STAR Ankle)
9969279|NCT01288599|Experimental|Single port access laparoscopy|Single port access laparoscopy for benign adnexal disease.
9969280|NCT01288599|Active Comparator|Conventional laparoscopy|Conventional laparoscopy for benign adnexal disease.
9969281|NCT01288638|Experimental|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
9969282|NCT01288638|Placebo Comparator|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
9969283|NCT01288664|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months
9969284|NCT01288677|Experimental|001|TMC649128 Escalated doses
9969285|NCT01288690|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment.
9969286|NCT01288690|Experimental|Narrative Exposure Therapy|Patients in this condition receive 3 sessions of Narrative Exposure Therapy
9969287|NCT01288716|Placebo Comparator|Placebo|
9969288|NCT01288716|Active Comparator|Arbaclofen|
9969289|NCT01288742|Experimental|001|TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
9969290|NCT01288742|Experimental|002|Digoxin One 0.25-mg tablet for 1 day (Trt A)
9969291|NCT01288742|Experimental|003|Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
9969292|NCT01288742|Experimental|004|Rosuvastatin One 10-mg tablet for 1 day (Trt C).
9969293|NCT01288742|Experimental|005|Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
9969294|NCT01288755|Experimental|001|TMC278 One 25 mg tablet once daily for 11 days (TrtA and C)
9969295|NCT01288755|Experimental|002|Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC)
9969296|NCT01288768|Active Comparator|Arthroscopy|Knee arthroscopy + Exercise therapy
9969297|NCT01288768|No Intervention|Exercise therapy|Exercise therapy alone
9969298|NCT01288794|Active Comparator|Standard medical treatment plus albumin|The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
9969299|NCT01288794|Other|Standard medical treatment|The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites
9969300|NCT01288820|Experimental|DHP+PQ|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
9969301|NCT01288820|Active Comparator|AS-AQ +PQ|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
9969302|NCT01288846||Acutly ill, Medical ward, consent|group of acutely ill patient who uses three or more drugs, must be able to give consent.
9976896|NCT01356186|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
9969303|NCT01288872|Experimental|Praziquantel|45 women in 3 cohorts (15 early pregnancy: 12-16 weeks gestation; 15 late pregnancy: 30-36 weeks gestation; and 15 lactating nonpregnant women who are 5-7 months (inclusive) postpartum) given praziquantel (PZQ), 60 mg/kg orally in split dose (30 mg/kg each) separated by 3 hours.
9969304|NCT01288924|Active Comparator|Parecoxib|Parecoxib 2 ml intravenous
9969305|NCT01288924|Placebo Comparator|Control|0.9% sodium chloride 2 ml intravenous
9969306|NCT01288950|Experimental|Vitamin D3|
9969307|NCT01288950|No Intervention|Placebo|
9969308|NCT01288963||IL-2 subjects|Subjects receiving IL-2 for advanced melanoma
9969309|NCT01289054||Cohort 1 - Pregnancy/Fetal Exposure|
9969310|NCT01289054||Cohort 2 - Interrupted TKI|
9969311|NCT01289093||laparoscopic ingunal herniotomy|
9969312|NCT01289093||laparoscopic incisional herniotomy|
9969313|NCT01289093||Lichtenstein inguinal herniotomy|
9969314|NCT01289093||laparoscopic umbilical hernia repair|
9969315|NCT01289106|Active Comparator|Arm A|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
9969316|NCT01289106|Experimental|Arm B|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
9969317|NCT01289106|Experimental|Arm C|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
9969318|NCT01289132|Placebo Comparator|Placebo|
9969319|NCT01289132|Experimental|Azilsartan 5 mg QD|
9969320|NCT01289132|Experimental|Azilsartan 10 mg QD|
9969321|NCT01289132|Experimental|Azilsartan 20 mg QD|
9969322|NCT01289132|Experimental|Azilsartan 40 mg QD|
9969323|NCT01289132|Experimental|Azilsartan 80 mg QD|
9969324|NCT01289132|Active Comparator|Candesartan Cilexetil 8 mg titrated to12 mg QD|
9969325|NCT01289145|Experimental|Intervention|"Participants will be allocated to a motivational intervention, a volitional intervention or the active control group.~The motivational intervention promotes positive outcome expectancies on physical activity. The volitional intervention promotes the formulation of action plans for physical activity. Participants in the active control group, receive a quiz on physical activity and sports."
9969326|NCT01289158||non-classical CMAMMA, classical CMAMMA|
9969327|NCT01289171|Experimental|Glycolic acid|All who met the study criteria commenced once daily use of 15% glycolic acid lotion.
9969328|NCT01289184||control|
9969329|NCT01289184||exposure 2-3 years|
9969330|NCT01289184||exposure 3-5 years|
9969331|NCT01289184||exposure 5-10 years|
9969332|NCT01289184||exposure >15 years|
9969333|NCT01289197|No Intervention|No Feedback or services offered.|The Family Check-Up is not offered.
9969334|NCT01289197|Other|Intervention|Family Check Up is offered.
9969335|NCT01289223|Active Comparator|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
9969336|NCT01289223|Experimental|Bendamustine IV|Up to 8 cycles of Bendamustine (120mg/m2 Days 1 and 2, every 21 days (+ 3 days).
9969337|NCT01289236|Placebo Comparator|Placebo|Placebo BID (twice daily, approximately 12 hours apart)
9969338|NCT01289236|Active Comparator|milnacipran 200 mg|200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)
9969339|NCT01289236|Active Comparator|milnacipran 100 mg|100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)
9969340|NCT01289249||Children receiving meropenem|Children aged from 3 months to 18 years that receive treatment with meropenem.
9969341|NCT01289262|Active Comparator|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture.
9969342|NCT01289262|Active Comparator|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked closure technique.
9969343|NCT01289288|Experimental|Mailed printed materials and in-office training|
9969344|NCT01289288|No Intervention|Control|Usual care
9969345|NCT01289301|Experimental|mTOR-receiving arm|switching from calcineurin-inhibitor-based immunosuppression to mTOR-based immunosuppression
9969346|NCT01289301|Active Comparator|calcineurin-inhibitor keeping arm|continuing calcineurin-inhibitor based immunosuppression
9969347|NCT01289314|Active Comparator|Total laparoscopic hysterectomy|
9969348|NCT01289314|Active Comparator|Laparoscopic supracervical hysterectomy|
9969349|NCT01289327|Active Comparator|propofol|
9969350|NCT01289327|Active Comparator|midazolam+alfentanil|
9969351|NCT01289340||Polymem (R)|superficial burns treated with Polymem wound dressing until complete wound healing
9969352|NCT01289340||Biaten IBU|burns treated with Biaten IBU until complete wound healing.
9969353|NCT01289340||Hartmen dressing|burns treated with hartman or saline wet dressing until wound healing
9969354|NCT01289366||Patients with IBD|
9969355|NCT01289379|Experimental|HFJV|
9969356|NCT01289405|Placebo Comparator|placebo exercices|relaxation exercises and stretching neck, without therapeutic purpose.
9969357|NCT01289405|Active Comparator|phonoaudiologic therapy|isometric and isotonic exercises to improve posture, mobility and muscle tone of the soft palate, pharyngeal constrictor muscles, tip and base of tongue, cheeks and lips.
9969358|NCT01289444|Active Comparator|Healthy Living Control|"Session 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered, with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~Session 3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides. The Administered by the trained RA-Control to prevent contamination with the FACE condition."
9976897|NCT01356186|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
9976898|NCT01356199|Experimental|ARTRONAT|
9976899|NCT01356199|Placebo Comparator|PLACEBO|
10187721|NCT03723330|Experimental|Plant sterol with a healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided with specific instructions to consume plant sterols-enriched food (contains 2 g plant sterols).
9969359|NCT01289444|Experimental|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
9969360|NCT01289483|Active Comparator|fospropofol 6.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 6.5 mg/kg.
9969361|NCT01289483|Active Comparator|fospropofol 5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 5 mg/kg.
9969362|NCT01289483|Active Comparator|fospropofol 3.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 3 mg/kg.
9969363|NCT01289483|Active Comparator|fospropofol 2 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 2 mg/kg.
9969364|NCT01289496|Experimental|Peg-interferon alpha-2a, Ribavirin|"Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).~This is a pilot study with no control group."
9969365|NCT01289509|Experimental|Experimental 1|Drug: E5501
9969366|NCT01289509|Experimental|Experimental 2|Drug: E5501
9969367|NCT01289535|Experimental|antibody rates|
9969368|NCT01289561|Experimental|Alcohol self-administration|All participants will participate in seven sessions. In three sessions, each participant will consume a beverage containing alcohol and caffeine. In three separate sessions, participants will consume a beverage containing alcohol and caffeine-placebo. In the final session, all participants may choose which beverage they consume. Participants and research assistants will be blinded to inclusion of caffeine/caffeine-placebo in beverage, but each beverage will be labeled for identification (e.g., A or B).
9969369|NCT01289587|Experimental|Alternative frequency variant|An alternative variant of the DIAfit program (progressive increase of the number of administered PA sessions per week, namely one PA session per week during 4 weeks and then twice a week over a period of 16 weeks)
9969370|NCT01289587|Active Comparator|Standard frequency program|Standard usual program (3 times per week over a period of 12 weeks)
9969371|NCT01289600|Active Comparator|Pressure support ventilation, ARDSnet|"Mechanical ventilator is set to pressure support ventilation (6 ml/kg) for 30 min with positive end expiratory pressure (PEEP) set according to the higher arm of the ARDS network consensus."
9969372|NCT01289600|Active Comparator|Pressure control ventilation, ARDSnet|"Mechanical ventilator is set to pressure control ventilation (6 ml/kg) for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
9969373|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, ARDSnet|"Mechanical ventilator is set to NAVA for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
9969374|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, titrated|Mechanical ventilator is set to NAVA for 30 min with PEEP titrated using the diaphragm EMG signal.
9969375|NCT01289613||Children|Children
9969376|NCT01289613||Adults|Adults
9969377|NCT01289652||HCV + HIV|
9969378|NCT01289652||HCV|
9969379|NCT01289691|Experimental|Air/Oxygen Mixture|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
9969380|NCT01289691|Active Comparator|Oxygen|Patients in this group will be ventilated with only oxygen during one lung ventilation.
9969381|NCT01289704|Experimental|TreSPE|Treatment with treadmill, proprioceptive and stretching exercises
9969382|NCT01289704|Active Comparator|SPE|Proprioceptive and stretching exercises
9969383|NCT01289730|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice a week
9969384|NCT01289743|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice weekly
9969385|NCT01289756|Experimental|CYP2D6 EM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
9969386|NCT01289756|Experimental|CYP2D6 IM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
9969387|NCT01289756|Experimental|CYP2D6 PM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
9969388|NCT01289756|Experimental|CYP2D6 UM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
9969389|NCT01289769|Active Comparator|dexmedetomidine|
9969390|NCT01289769|Placebo Comparator|control|
9969391|NCT01289795||first-ever ischemic stroke|first-ever ischemic stroke according to the WHO definition
9969392|NCT01289808|Experimental|glucose 25%|"180 healthy babies born term in the Baruch Padeh Medical Center, Poriya.~There will be three study groups:~Study Group: 60 newborn infants who will receive 1cc 25% Glucose, 2-3 minutes prior red-reflex examination.~Base line (control) Group 1: 60 newborn infants who will receive 1cc Water for Injection (WFI), 2-3 minutes prior red-reflex examination.~Base line (control ) Group 2: 60 newborn infants who will not receive neither glucose nor Water for Injection (WFI), 2-3 minutes prior red-reflex examination"
9969393|NCT01289834|Active Comparator|Hi-Fatigue Bone Cement|CPT femoral stems fixed with Hi-Fatigue Bone Cement
9969394|NCT01289834|Active Comparator|Palacos Bone Cement|CPT femoral stems fixed with Palacos Bone Cement
9976900|NCT01356212|Experimental|Regimen A: Ketorolac tromethamine (Gentle Sniff - Upright)|Gentle sniff-inhalation with the volunteer upright for dosing and imaging
9976901|NCT01356212|Experimental|Regimen B: Ketorolac tromethamine (Vigorous Sniff - Upright)|Vigorous sniff-inhalation with the volunteer upright for dosing and imaging
9976902|NCT01356212|Experimental|Regimen C: Ketorolac tromethamine (Gentle Sniff - Semi-supine)|Gentle sniff-inhalation with the volunteer semi-supine for dosing and imaging
9976903|NCT01356225|Experimental|Intranasal Ketorolac tromethamine|
9976904|NCT01356225|Placebo Comparator|Intranasal placebo|
10138181|NCT04219423|Experimental|multimodal physical therapy|The multimodal intervention is 75 minutes in duration and meets two days per week for two weeks, then once per week for six weeks, followed by weekly phone calls to determine adherence to home-exercise program (HEP) for four weeks. The total duration of the intervention is twelve weeks. The intervention will be led in a group format with a ratio of one physical therapist to two participants and groups never exceeding 4 participants. All verbal and written communications in the intervention will be conducted in Spanish. The multimodal intervention consists of progressive lower extremity strengthening training targeting the quadriceps and gluteal groups in both legs, progressive stationary bicycle exercise, self-management training and education, manual therapy and home exercise program (HEP) instruction. Participants are asked to do their strengthening exercises at least three days per week for the 12-week study duration including sessions in the clinic
10138182|NCT04219267|Experimental|The intervention group|Character strengths-based intervention, 3 sessions every week for three weeks. 30 minutes each session.
10138183|NCT04219267|Placebo Comparator|The control group|Early memories for placebo control, 3 sessions every week for three weeks. 30 minutes each session.
10138184|NCT04218994|Experimental|Group A|Subjects instructed on flossing technique.
10138185|NCT04218994|No Intervention|Group B|No instructions for flossing provided. Subjects asked to continue their normal oral hygiene care.
10138186|NCT04219215|Experimental|HBO|Patients with T2D receive an 2 hour treatment with 100 % oxygen in a hyperbaric chamber
10138187|NCT04219215|Experimental|Ambient Air|Patients with T2D receive an 2 hour treatment with 21% oxygen in a hyperbaric chamber
10138188|NCT04219202|Active Comparator|Proton Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Proton Treatment
10138189|NCT04219202|Experimental|Carbon Ion Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Carbon Ion Treatment
10138190|NCT04219228||Students in urban counties|All first-grade students in urban counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
10138191|NCT04219228||Students in rural counties|All first-grade students in rural counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
10138192|NCT04219280|Active Comparator|Quillivant XR|Once-daily, long-lasting MPH solution with the following dosing schedules: 10mg/20mg/30mg/40mg for children 20-25kg, 20mg/30mg/40mg/50mg for children 26-30kg, and 20mg/33mg/46mg/60mg for children > 30 mg.
10138193|NCT04219280|Placebo Comparator|Placebo|Liquid-based suspension to match the color and banana-flavor of Quillivant XR.
10184412|NCT03755284|No Intervention|Control Group|"There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~One-on-one interviews were conducted with the pregnant women, and the voluntary disclosure forms, which explained the purpose of the study, were completed.~The prepared questionnaire form was applied. Routine nursing/midwifery care was applied. The state-trait anxiety inventory (STAI FORM TX-I) was applied and evaluated in the active (5-7 cm) phase.~The Visual Analogue Scale (VAS) was evaluated once in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases.~Birth action follow-up form and postpartum interview forms were applied"
10184413|NCT03755258|Experimental|GCK 100 mg group|GCK 100 mg+ Placebo 200 mg GCK tablet 100 mg + Placebo tablet 100 mgX2 tablets, once daily for 12 weeks (oral)
10184414|NCT03755258|Experimental|GCK 200 mg group|GCK 200 mg + Placebo 100 mg GCK tablet 100 mg X 2 tablets+ Placebo tablet 100 mg once daily for 12 weeks (oral)
10184415|NCT03755258|Experimental|GCK 300 mg group|GCK tablet 300 mg GCK tablet 100 mgX3 tablets once daily for 12 weeks (oral)
10184416|NCT03755258|Placebo Comparator|Placebo of GCK group|Placebo 300 mg Placebo tablet 100 mgX3 tablets, once daily for 12 weeks (oral)
10184417|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Intravenous 140 MBq bolus injection of [68Ga]Ga-DOTA-Siglec-9 radiopharmaceutical
10184418|NCT03755232|Experimental|scFOS treatment #1|Phase 1: 10g of scFOS Phase 2: 50g dextrose +15g scFOS Phase 3: 50g avCHO from white bread +15g scFOS
10184419|NCT03755232|Experimental|scFOS treatment #2|Phase 1: n/a Phase 2: 35g Dextrose +15g scFOS Phase 3: 35g avCHO from white bread +15g scFOS
10184420|NCT03755232|Active Comparator|Control #1|Phase 1: Water control (negative control) Phase 2: 35g Dextrose control 1 Phase 3: 35g avCHO from white bread (control 1)
10184421|NCT03755232|Active Comparator|Control #2|Phase 1: 10g Dextrose (positive control) Phase 2: 50g Dextrose control 2 Phase 3: 50g avCHO from white bread (control 2)
10184422|NCT03755219||StdPPM|Standard pure polypropylene mesh
10184423|NCT03755219||LWM|Lightweight mesh: Either a pure polypropylene mesh, or a polypropylene-based composite mesh
10184424|NCT03755219||Tacks, metal|Metal staples or tacks
10184425|NCT03755219||Tacks, absorbable|Absorbable synthetic staples or tacks
10184426|NCT03755219||Tacks, uncategorized|Staples or tacks were in SHR 2005-2011 not further categorized
10184427|NCT03755219||Fibrin glue|Biologic glue/sealant produced from human donor blood
10184428|NCT03755219||Non-fixation|Mesh is deployed without fixation
10184429|NCT03755206|Other|Intervention|Interrupted time series design
10184430|NCT03755193|Active Comparator|SERM plus ELD|To examine the effects of SERM plus ELD in osteoporosis patients
10184431|NCT03755193|Active Comparator|BP plus ELD|To examine the effects of BP plus ELD in osteoporosis patients
10184432|NCT03755193|Active Comparator|ELD alone|To examine the effects of ELD alone in osteoporosis patients
10184433|NCT03755180|Experimental|Group 1|Exercise Group
10184434|NCT03755180|Active Comparator|Group 2|Compression Group
10184435|NCT03755167|Experimental|IPL344|IV IPL344 administered once a day
10184436|NCT03755141|Experimental|Herzuma|Herzuma + TPC
10184437|NCT03755115|Experimental|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, D1,30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
10138194|NCT04218916|Experimental|Rhodiola Rosea Capsule|
10138195|NCT04218916|Placebo Comparator|Placebo Capsule|
10138196|NCT04219046|Experimental|Experimental Treatment|ERAS program with administration of experimental treatment: Naloxegol 25mg administrated once daily from surgery for up to 7 days
10138197|NCT04219046|Placebo Comparator|Placebo|ERAS program with administration of placebo: Placebo administrated once daily from surgery for up to 7 days
10138198|NCT04218929|Experimental|Study Formula (SF)|New infant formula for term infants
10138199|NCT04218929|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
10138200|NCT04218929|No Intervention|Human Milk Reference Group|Human milk
10138201|NCT04218942|Experimental|Prospective non randomised feasibility study|
10138202|NCT04219137||Localized Esophagogastric Adenocarcinoma|Patients diagnosed with gastroesophageal adenocarcinoma who will undergo surgical resection for curative intent, with or without neo-adjuvant chemotherapy or chemoradiotherapy.
10138203|NCT04219137||Metastatic Esophagogastric Adenocarcinoma|Patients diagnosed with de novo metastatic gastroesophageal adenocarcinoma who will undergo platinum based first line chemotherapy.
10138204|NCT04219371||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
10138205|NCT04218890||SLE patients without lupus nephritis|"40 SLE patients~40SLE patients( All SLE pt. satisfied the ACR criteria for SLE diagnosis) these patients will be without any evidences of nephritis"
10138206|NCT04218890||SLE patients with lupus nephritis|40SLE patients with evidences of nephritis
10138207|NCT04218890||healthy control group|20 healthy subjects matched age and sex with be enrolled as healthy control group
10138208|NCT04219293|Other|Microneedling with NO PRP|Patient will receive Standard of Care micro needling on randomized side of the face.
10138209|NCT04219293|Active Comparator|Microneedling WITH PRP|Patient will receive Standard of care microneedling with PRP on randomized side of the face.
10138210|NCT04218955||1|Asking parents if they can accept staining from treat their children by silver Diamine Flouride or Not
10138211|NCT04218981|Experimental|Schizophrenia group|"Schizophrenia was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~Choose one of the antipsychotics drugs treatment( olanzapine, risperidone, aminosulpiride) according to the patient's condition"
10138212|NCT04218981|Experimental|Bipolar disorder group|"Bipolar disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~Choose one of the mood stabilizer drugs treatment( lithium, valproate) according to the patient's condition"
10138213|NCT04218981|Experimental|Major depressive disorder group|"Major depressive disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~Choose paroxetine treatment"
10138214|NCT04218981|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
10138215|NCT04218968|Experimental|carvedilol therapy|
10138216|NCT04218513|Experimental|Compound Edaravone|30 mL (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg)
10138217|NCT04218513|Experimental|Edaravone|30 mL (containing edaravone 30 mg)
10138218|NCT04218513|Experimental|2-Aminoethanesulfonic Acid|30 mL (containing 2-aminoethanesulfonic acid 600 mg)
10138219|NCT04218500|Active Comparator|Niacinamide 4%|Niacinamide 4%, applied twice daily for 28 days
10138220|NCT04218500|Active Comparator|Virgin coconut oil 30%|Virgin coconut oil 30%, applied twice daily for 28 days
10138221|NCT04218526|Experimental|Vercise DBS Group|All participants will have the Vercise DBS system implanted.
10138222|NCT04218630|Experimental|Reformer pilates group|All participants were informed about the reformer machine and the treatment program by the physiotherapist in reformer pilates group. Reformer pilates exercises were applied in the form of general muscle strengthening and flexibility exercises under the supervision of physiotherapist. Exercises were performed in 2 times a week for 6 weeks. The duration of one session was 60 minutes.
10138223|NCT04218630|Active Comparator|Home mat pilates group|In home mat pilates group, clinical pilates exercises were applied as a home program. Brochures and exercise follow-up forms, which illustrated and written all the exercises in this program, which consisted of clinical pilates-based general muscle strength and flexibility exercises, were given to all participants in this group. Exercises were performed in 2 times a week for 6 weeks at home. Participants marked the follow-up form when they performed exercises. Attendance of participants to exercise was checked by phone calls.
10138224|NCT04218435||Observational|"Sacubitril/valsartan is a combination of a neprilysin inhibitor, sacubitril and an angiotensin II receptor blocker, valsartan.~The recommended starting dose is one 49/51 mg (sacubitril/valsartan) tablet twice-daily. Double the dose of Sacubitril/valsartan after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.~Reduce the starting dose to 24/26 mg (sacubitril/valsartan) twice-daily for:~Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.~Patients with severe renal impairment (CrCl less than 30 ml/min)~Patients with moderate hepatic impairment. (Child Pugh B) Double the dose of Sacubitril/valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient"
10138225|NCT04218487|Experimental|XFZY group|2.4g (6 capsules) three times daily for 12 weeks
10138226|NCT04218487|Placebo Comparator|Control group|2.4g (6 capsules) three times daily for 12 weeks
10138227|NCT04218617|Experimental|Arm 1 - Single fraction|sSRS 18 Gy in 1 fraction
10138228|NCT04218617|Active Comparator|Arm 2 - Two fraction|sSRS 24 Gy in 2 fractions
10138229|NCT04218474|Other|patient lost sensation ant half of lower lip|patient with injured inferior alveolar nerve at one side
10138230|NCT04218760|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day and have 3 sets of blood samples drown.
10138231|NCT04218669|Active Comparator|T-tube drainage|The T-tube was placed for biliary drainage
9976905|NCT01356238|Experimental|MRC media|Use MRC media in the human IVF-ET program
10138232|NCT04218669|Experimental|Roux-en-Y Hepaticojejunostomy|biliary-enteric anastomosis was performed
10138233|NCT04218721|Experimental|eHealth application|Participants get access to the eHealth application InvolveMe
10138234|NCT04218552|Experimental|Experimental 1|AD-209 High
10138235|NCT04218552|Experimental|Experimental 2|AD-209 Middle
10138236|NCT04218552|Experimental|Experimental 3|AD-209 Low
10138237|NCT04218552|Active Comparator|Active Comparator 1|Amlodipine Low
10138238|NCT04218552|Active Comparator|Active Comparator 2|Amlodipine High
10138239|NCT04218552|Active Comparator|Active Comparator 3|Telmisartan
10138240|NCT04218552|Placebo Comparator|Placebo comparator|Placebo
10138241|NCT04218604|Experimental|Personalized AF ablation using MDCT-derived LAWT|Pre-procedural MDCT images will be analysed in Teknon Medical Center (core-lab), using ADAS-3D™ (Galgo Medical, Barcelona, Spain) to obtain 3D atrial wall thickness maps that will be introduced into CARTO® navigation system (Biosense Webster, Diamond Bar, California, US). PVI will be performed point-by-point, aiming to complete a RF circle around the PV ostia (nephroid shape) on the 3D geometry using a ThermoCool® SmartTouch® 3.5-mm irrigated tip contact force-sensing RF ablation catheter (Biosense Webster, Inc.). AI targets will be defined by LAWT on the thickness color map, as follows: Thickness < 1 mm (red): 300; 1-2 mm (yellow): 350; 2-3 mm (green): 400; 3-4 mm (blue): 450; > 4 mm (purple): 500. The recommended power settings to reach these AI values will be, in general, 35 W for the posterior wall and 40 W for the anterior wall. Wherever local AWT is > 3 mm (green and blue colors), an increased RF power (50 W) will be permitted.
10138242|NCT04218682|Experimental|Immediate Game Use|AYACS randomly assigned to this arm will immediately play the Shadow's Edge Game following enrollment for a duration of 7 weeks. Following the designated 7-week game-play period, they will continue to have access to the game. They will continue to receive all usual care health care throughout and following the study.
10138243|NCT04218682|No Intervention|Wait-List Comparison Group|AYACS randomly assigned to this arm will begin to play the Shadow's Edge game 7 weeks following enrollment. They will continue to receive all usual health care throughout and following the study.
10138244|NCT04218578||Device group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with MitraClip
10138245|NCT04218578||Control group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with optimal medical treatment
10138246|NCT04218734|Experimental|metformin hydrochloride+DBPR108|metformin hydrochloride 500 mg+DBPR108 100 mg
10138247|NCT04218734|Placebo Comparator|metformin hydrochloride+placepo|metformin hydrochloride 500 mg+placebo 100 mg
10138248|NCT04218747|Experimental|VA 365 Demonstration Benefits|Children in treatment schools received: (1) three meals during the school day and food packages for weekends and school breaks; (2) $60 monthly Electronic Benefit Transfer (EBT) benefits during summer months if they were eligible for FRP meals; and (3) nutrition education for their parents.
10138249|NCT04218747|No Intervention|Control Group|"Schools in the control group operated under business as usual."
10138250|NCT04218695|Experimental|Treatment|1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization
10138251|NCT04218695|Placebo Comparator|Placebo|Normal saline (50cc) once daily for up to one week or until end of hospitalization
10138252|NCT04218214||LIFE-DM Group|The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and microfinance loans of 2 million VND. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union.
10138253|NCT04218149|Active Comparator|Group S|Serratus plane block with 25 ml %0.25 bupivacaine
10138254|NCT04218149|Active Comparator|Grup E|Erector spinae plane block with 25 ml %0.25 bupivacaine
10138255|NCT04218422|Experimental|Treatment|2 treatments of battlefield acupuncture to the bilateral ears spaced one week apart
10138256|NCT04218422|Sham Comparator|Control|2 treatments with sham acupuncture to the bilateral ears at acupuncture points not associated with pain relief (2 liver and 1 stomach)
10138257|NCT04218344||Acute Coronary Syndrome - Iscaemia|Patients who present with chest pain, undergo emergency angiogram and receive a cardiac stent.
10138258|NCT04218344||Acute Coronary Syndrome - Non-Ischaemic|Patients who present with chest pain but angiography reveals normal coronary arteries.
10138259|NCT04218162|Experimental|Lasmiditan 50mg|
10138260|NCT04218162|Experimental|Lasmiditan 100mg|
10138261|NCT04218162|Placebo Comparator|Placebo|
10138262|NCT04218383|Active Comparator|Experimental: Active Left OFC Group|2mA will be applied for 20 minutes with the tDCS anode applied to the left OFC and Cathode applied to the right primary motor cortex.
10138263|NCT04218383|Sham Comparator|Sham Comparator: Sham left OFC Group|Current will be ramped up for 30s followed by a 30s ramp down to mimic the physical sensation of stimulation and habituation. The anode placed over the left OFC and cathode placed over the right primary motor cortex.
10138264|NCT04218045|Active Comparator|Laparoscopic sleeve gastrectomy group|The group of morbidly obese patients undergoing laparoscopic sleeve gastrectomy
10138265|NCT04218045|Experimental|SASI bypass group|The group of morbidly obese patients undergoing laparoscopic single- anastomosis sleeve ileal bypass (the new procedure being evaluated)
10138266|NCT04218318|Active Comparator|Low-threshold group|Neonates in the low-threshold group phototherapy will be stopped if TSB reached ˃100 µmol/L below the AAP phototherapy threshold.
10138267|NCT04218318|Active Comparator|High-threshold group|Neonates in high-threshold group phototherapy will be ceased if TSB level is 50-100 µmol/L below the appropriate AAP phototherapy threshold.
10138268|NCT04218097||Addict patients|"Obese type 2 and 3 with food addict according to the Yale Food Addiction Scale (YFAS) questionnaire.~Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
10138269|NCT04218097||Control patients|"Obese type 2 and 3, non food addict Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
10138270|NCT04218019|Experimental|Early Tumor Treating Fields (TTFields, Optune®) treatment|TTF will be started together with hypofractionated radiotherapy (+/- 5 days) with or without Temozolomide (according to the standard and local physician's decision). Chemoradiotherapy with temozolomide and hypofractionated radiotherapy is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator.
10138271|NCT04218019|Active Comparator|Late TTF treatment|Patients will be treated with hypofractionated radiotherapy with or without temozolomide (according to the local standard and physician's decision). Radiotherapy and treatment with temozolomide is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator. Late TTFields treatment will start 4 weeks after the end of radiotherapy.
10138272|NCT04218227||Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
10184438|NCT03755102|Experimental|Cohort 1: Participants treated with dacomitinib alone|Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.
10184439|NCT03755102|Experimental|Cohort 2: Participants treated with dacomitinib in combination with osimertinib|Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation
9827459|NCT02456740|Placebo Comparator|Placebo|Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
9969395|NCT01289860|Active Comparator|Blueberry drink|30g of blueberry powder (equivalent to 200g fresh blueberries) and 300ml of semi-skimmed milk
9969396|NCT01289860|Placebo Comparator|Control drink|29g of powder consisting of sugars and vitamin C, values of which were matched to that of the blueberry drink, with 1 g of citric acid to match for taste.
9969397|NCT01289886|Other|Arm A|BR-A-657 20mg or placebo
9969398|NCT01289886|Other|Arm B|BR-A-657 60mg or placebo
9969399|NCT01289886|Other|Arm C|BR-A-657 120mg or placebo
9969400|NCT01289886|Other|Arm D|BR-A-657 240mg or placebo
9969401|NCT01289886|Other|Arm E|BR-A-657 480mg or placebo
9969402|NCT01289899|Experimental|Arm A|BR-A-657 120mg or placebo
9969403|NCT01289899|Experimental|Arm B|BR-A-657 360mg or placebo
9969404|NCT01289925|Experimental|Selenium|
9969405|NCT01289925|Placebo Comparator|Sugar Pill|
9969406|NCT01289938|Active Comparator|Metoclopramide|Metoclopramide treatment
9969407|NCT01289938|Active Comparator|Diphenhydramine|Diphenhydramine treatment
9969408|NCT01289951|Experimental|Patients with Child-Pugh C hepatic-cirrhosis.|VIH/VHC coinfected patients with advanced (Child-Pugh C) hepatic cirrhosis.
9969409|NCT01289951|Active Comparator|VIH/VHC coinfected patients without liver damage.|
9969410|NCT01289964|No Intervention|Waiting list control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
9969411|NCT01289964|Active Comparator|Treatment group|Received the 5 cupping treatments, application twice a week, non standardised application - individual determinations of trigger points
9969412|NCT01289977||Phlebotomus group|Those in the Phlebotomus group will have exposure to P. duboscqui sand fly
9969413|NCT01289977||Lutzomyia group|Those placed in this group will receive exposure to L. longipalpis sand fly bites.
9969414|NCT01290003|Experimental|Antibiotic Group|Neonates randomized to intervention Group(Antibiotic group)will receive the first line antibiotics (Piperacillin-Tazobactam and Amikacin) as per the unit policy for 72 hours. These neonates will also be monitored by performing sepsis screens and blood culture for development of sepsis.
9969415|NCT01290003|No Intervention|No Antibiotic Group|Neonates randomized to 'No antibiotic group' will receive supportive treatment as per standard unit protocol. These neonates will be monitored by performing sepsis screens and blood culture for development of sepsis.
9969416|NCT01290016|Active Comparator|Control 6-8 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention till the end of the study protocol.
9969417|NCT01290016|Experimental|2 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
9969418|NCT01290016|Experimental|4 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counselling to maintain the intake of 4 servings of dairy per day and also receive instruction on how to improve their physical activity.
9969419|NCT01290016|Experimental|4 servings dairy + exercise 9-12 yrs|Subjects in this group will receive family based counselling to maintain the standard recommended intake of 4 servings of dairy per day for 9-14 year olds according to the Canada's Food Guide and also receive instruction on how to improve their physical activity.
9969420|NCT01290016|Active Comparator|Control 9-12 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
9969421|NCT01290042|Active Comparator|Placebo arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
10138273|NCT04218227||Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
10138274|NCT04218227||Self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
10138275|NCT04218227||Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
10138276|NCT04218227||Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
10138277|NCT04218253|Experimental|nutritional intervention|300 or 500 calories nutritional support before operation according to the level of malnutrition
10138278|NCT04218253|Other|control group|Dietary education was conducted according to preoperative nutritional requirements
10138279|NCT04218331|Experimental|JASPER only|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
10138280|NCT04218331|Active Comparator|JASPER + PROMPT|This group will consist of the child and therapist having one-on-one, JASPER sessions plus Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT), twice a week.
10138281|NCT04218032|Experimental|blood pressure|blood pressure is measured from the participants, by using two methods. A new developed device and a reference device. The new device measures, using oscillometry, the blood pressure from the finger tip. The reference device is a standard sphygmomanometer.
10138282|NCT04218058|Active Comparator|study (ultrasound guided closed reduction of zygomatic arch))|reduction of zygomatic arch guided by ultrasound
10138283|NCT04218058|Active Comparator|control (open reduction of zygomatic arch)|open reduction of zygomatic arch through coronal incision
10138284|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 100mg twice a day.|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets）dose group for twice a day.
10138285|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 150mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 150mg （3 tablets）dose group for once a day.
10138286|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 100mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 100mg （2 tablets） dose group for once a day
10138287|NCT04217993|Experimental|Jaktinib Hydrochloride Tablets 200mg once a day|This is the dose group was given Jaktinib Hydrochloride Tablets 200mg （4 tablets）dose group for once a day.
10138288|NCT04218175|Experimental|neuromobilization stretching group|In the neuromobilization stretching group; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed.
9669162|NCT03867188|Experimental|Liiposomal Bupivacaine Group|Qualified participants with a soft tissue sarcoma of the thigh will be given the alternative protocol utilizing liposomal bupivacaine (Exparel®). The alternative protocol will utilize general or spinal anesthesia, but will also include the use of intraoperative liposomal bupivacaine instead of a regional nerve block.
10138289|NCT04218175|Experimental|neuromobilization shifting group|In the neuromobilization shifting group, the subjects were brought to shoulder depression and 90 degrees of abduction while the dominant forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side. Thus, the participants performed median nerve shift.
10138290|NCT04218175|No Intervention|Control Group|The dominant sides of the individuals are experimental sides and the other nondominant sides of the participants are control sides. And no intervention was made. All measurements were done bilaterally before and after.
10138291|NCT04217980|Experimental|Lung ultrasonography (LUS) group|Group 1: Lung ultrasonography is performed as the main (first) pulmonary image test
10138292|NCT04217980|Active Comparator|Chest X ray (CXR) group|Group 2: Chest X ray is performed as main (first) pulmonary image test
10138293|NCT04218396|Experimental|Standard Treatment, Then Virtual Reality + Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment only. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment AND virtual reality
10138294|NCT04218396|Experimental|Virtual Reality + Standard Treatment, Then Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment AND virtual reality. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment only.
10138295|NCT04217889||Adherent patient|This group is composed of adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
10138296|NCT04217889||Not-adherent patient|This group is composed of not-adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
9669163|NCT03867188|No Intervention|Control Group|A retrospective control group will be assembled from electronic medical records of 3 patients who underwent resection of a soft tissue sarcoma of the thigh and will be accessed and analyzed for the variable of interest.
10138297|NCT04217876||Clinically suspected infarct-like acute myocarditis|Diagnosis of infarct-like AM was based on five criteria: (a) history of flu-like symptoms within 8 weeks prior admission; (b) new onset of symptoms such as fatigue/breathlessness, chest pain, mild dyspnea, and/or palpitation; (c) ischemic ECG pattern (ST-segment elevation and/or T-wave anomalies); (d) increase of inflammatory markers (non-high- sensitivity CRP > 8 mg/L and/or white blood cell count > 11.000/mm3) and cardiac enzymes; and (e) preserved global systolic function (EF > 50%). We excluded patients with New York Heart Association (NYHA) functional heart classifications II-IV, LVEF < 50% and those patients with electrocardiographic evidence of bradyarrhythmias (≥second-degree atrioventricular block) or tachyarrhythmias (ventricular or supraventricular arrhythmias).
10138298|NCT04217733|Active Comparator|Mebeverine|Mebeverine 3 times daily for 3 months
10138299|NCT04217733|Experimental|Ethosuximide|Ethosuxemide 3 times daily for 3 months
10138300|NCT04217733|Experimental|Pentoxyifylline|pentoxyifylline 2 times daily for 3 months
10138301|NCT04218370|Active Comparator|Conventional|Thrice-weekly intermittent dialysis until pre-specified criteria for recovery are met
10138302|NCT04218370|Experimental|Conservative|Conservative dialysis strategy--dialysis prescribed only when specific metabolic or clinical indications are met. These indications are: blood urea nitrogen >112 mg/dL (40 mmol/L; blood potassium concentration >6 mmol/L; blood potassium concentration >5.5 mmol/L despite medical treatment; arterial blood gas pH <7.15, or in the absence of an available blood gas, serum bicarbonate <12 mmol/L, acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min or equivalent via face mask/tracheostomy mask to maintain SpO2 >95% or requiring FiO2 >50% in patients with tracheostomy already on invasive or non-invasive mechanical ventilation and despite diuretic therapy; clinician judgement
10138303|NCT04217941|Active Comparator|Health Education with practical demonstration|Participants assigned to the intervention arm received health education with practical demonstration of nasal spray and intranasal ointment .
10138304|NCT04217941|Placebo Comparator|Health education without practical demonstration|Participants assigned to the control arm received only health education regarding nasal spray and intranasal ointment .
10138305|NCT04218136||patient with head and neck cancer|Patients treated by standard treatment and have a minimum of 4 blood samples.
10138306|NCT04217629|Experimental|SY-005 single-dose 0.75mg|4 subjects will be envolved in this group and be injected with 0.75mg of SY-005.
10138307|NCT04217629|Placebo Comparator|SY-005 single-dose 2.5mg|This group will be intiated in healthy subjects at a 2.5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
10138308|NCT04217629|Placebo Comparator|SY-005 single-dose 5mg|This group will be intiated in healthy subjects at a 5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
10138309|NCT04217629|Placebo Comparator|SY-005 single-dose 10mg|This group will be intiated in healthy subjects at a 10mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
10138310|NCT04217629|Placebo Comparator|SY-005 single-dose 15mg|This group will be intiated in healthy subjects at a 15mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
10138311|NCT04217629|Placebo Comparator|SY-005 single-dose 20mg|This group will be intiated in healthy subjects at a 20mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
10138312|NCT04217629|Placebo Comparator|SY-005 multiple-doses 5mg|This group will be intiated in healthy subjects at a 5mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
10138313|NCT04217629|Placebo Comparator|SY-005 multiple-doses 10mg|This group will be intiated in healthy subjects at a 10mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
10138314|NCT04217629|Placebo Comparator|SY-005 multiple-doses 20mg|This group will be intiated in healthy subjects at a 20mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
10138315|NCT04217798|Experimental|Niparib combined with oral etoposide|Subjects will received niraparib 200mg or 100mg alternate once daily and oral etoposide 50mg on day 1-20 of a 30-day cycle. Oral etoposide was administered for a maximum of 6-8 cycles. Treatment was continued until disease progression, patient withdrawal or unacceptable toxic effects.
10138316|NCT04217928|Active Comparator|Arthroscopic Debridement|Patients who are randomized into this arm will receive arthroscopic debridement
10138317|NCT04217928|Active Comparator|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Patients who are randomized into this arm will receive arthroscopic hemi-trapeziectomy with mini tightrope
10138318|NCT04217772|Experimental|Eyes post-lensectomy|Eyes of children after cataract surgery
10138319|NCT04217772|No Intervention|Healthy Eyes|Eyes of healthy volunteers
10138320|NCT04217824|Active Comparator|karydakis flap|An asymmetric elliptical excision is performed, defective tissues between the lower and upper ends are removed until they reach healthy borders. The wound edge is then mobilized and the flap is slid over the corresponding wound edge by suturing to the fascia and the skin to the appropriate wound layers. Thus, the gluteal groove is lateralized. Subcutaneous tissue and skin are closed.
10138321|NCT04217824|Active Comparator|limberg flap|Rhomboid excision and pilonidal sinuses together with damaged tissue. On the right side of the patient, the intact skin is shifted to the medial area where the tissues are removed without tension. Thus, the defective part and gluteal groove are corrected.
9969422|NCT01290042|Active Comparator|Active arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
9969423|NCT01290055|Experimental|Group 1|In group 1, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 2 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.
9669164|NCT03867110|Placebo Comparator|Placebo|Placebo is to be taken orally once a day (QD) in the morning for 12 consecutive weeks.
10138322|NCT04217681|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
10138323|NCT04217681|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
10138324|NCT04217681|Experimental|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
10138325|NCT04217681|Experimental|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
10138326|NCT04217668|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day.
10138327|NCT04217759|Experimental|Intervention group|Intervention group went through a healthy lifestyle intervention using evidence-based SCT strategies emphasising on PA and diet for 12 weeks via face-to-face sessions and social media tools (Facebook and WhatsApp)
10138328|NCT04217759|No Intervention|Control group|Control group only received leaflets on healthy lifestyle with no further guidance.
10138329|NCT04217720|Experimental|SNS-301|SNS-301
10138330|NCT04217837||Major Depressive Disorder|Participants who meet the DSM-5 clinical diagnostic criteria, in the opinion of the treating clinician, for primary diagnosis of unipolar, non-psychotic MDD.
10138331|NCT04217850|Experimental|500 kcal Energy Deficit|The goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
10138332|NCT04217694|Experimental|Prevention (memantine, CogState)|Patients receive memantine PO BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT.
10138333|NCT04218305||The first group|Include One hundred patients with type 2 diabetes mellitus with average body mass index.
10138334|NCT04218305||The second group|Include One hundred patients whose body mass index is 30 or over without diabetes.
10138335|NCT04218305||The third group|Include One hundred type 2 diabetic obese patients whose body mass index is 30 or over.
10138336|NCT04218305||The fourth group|Include One hundred apparently healthy adult person as a control.
10138337|NCT04217863|Experimental|The experimental intervention (GDP): It includes three writing|"Participants will be required to describe memories associated with traumatic event in a sequential order, with an objective and detached attitude~They will be asked to describe~Their opinion regarding the traumatic event and emotions perceived during the experience~Its impact on their daily lives, and how it has altered their attitudes toward life.~The actual situation will be focused, while reviving the whole traumatic event experience which aids in exploring the following aspects:~Present thoughts and feelings regarding the traumatic experience, and also clarify the differences between the ones felt at the time of traumatic event in comparison to the current feelings.~How much they understand and appreciate themselves for successfully dealing with the traumatic event~To what extent the traumatic event has modified their vision, attitude, knowledge, and skills, and how it can help in their future;~What will be their future reactions to other similar events."
10138338|NCT04217863|No Intervention|The control intervention:|A day prior to each writing session, the researcher will communicate with each study subject via telephone in order to give them a reminder to perform the writing task and to check their understanding regarding the instructions given in the booklet. Details regarding the inability to contact the subject will also be recorded in the patient form.
10138339|NCT04217785|Active Comparator|A-AT eye drops|Optive Fusion UD eye drops + Genteal lubricant gel
10138340|NCT04217785|Active Comparator|B-UCS eye drops|UCS eye drops + GentTeal lubricant gel
10138341|NCT04217811||Late neutropenia|Neutrophil count < 1500
10138342|NCT04217811||No late neutropenia|Neutrophil count > 1500
10138343|NCT04217707|Other|Pre- and Post-Surgical Transgender Therapeutic Support Groups|
10138344|NCT04217642||Delay surgery|Patients who have passed more than 48 hours from admission to surgery
10138345|NCT04217304|Experimental|Sonothrombolysis|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity® plus Sonothrombolysis
10138346|NCT04217304|No Intervention|Standard of Care|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity®
10138347|NCT04217460|Active Comparator|Intervention for fluency difficulty (controls)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for controls.
10138348|NCT04217460|Experimental|Intervention for fluency difficulty (experimental)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for experimental group
10138349|NCT04217239|Experimental|Ivor-Lewis group|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
10138350|NCT04217239|Active Comparator|McKeown group|minimally invasive esophagectomy (MIE) with cervical anastomosis
9669165|NCT03867110|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) is to be taken orally QD in the morning for 12 consecutive weeks.
9669166|NCT03867110|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669167|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669168|NCT03867110|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669169|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669170|NCT03867110|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669171|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 40 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669172|NCT03867110|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669173|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 80 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
9669174|NCT03867032|Experimental|Cochlear implant users|The group will receive auditory training (psychophysical), and will be evaluated for speech recognition to determine the effect of training.
9669175|NCT03865082|Experimental|IO Naive Subjects MSS CRC|8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous
9969424|NCT01290055|Experimental|Group 2|In group 2, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 3 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.
9969425|NCT01290081|Active Comparator|Active referral|Case management intervention group - study personnel scheduled the TB doctor appointment for the participant, reminded to keep it, and transportation to the clinic was organized when needed.
9969426|NCT01290081|No Intervention|Passive referral|Participants were instructed to schedule an appointment with TB services themselves.
9969427|NCT01290133|Experimental|Active Drug|
9969428|NCT01290133|Placebo Comparator|Placebo|
9969429|NCT01290146|Active Comparator|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
9969430|NCT01290146|Experimental|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~SBP ≥100 mmHg: 0.1 mcg/kg/min"
9969431|NCT01290159||post heat stroke heat tolerant|
9969432|NCT01290159||post heat stroke heat intolerant|
9969433|NCT01290159||healthy controls|
9969434|NCT01290172|Experimental|Somatostatin|Patients in this group receive treatment with Somatostatin for 5 days.
9969435|NCT01290172|Placebo Comparator|Placebo|Patients in this group receive a placebo for 5 days.
9969436|NCT01290185|Experimental|Coiled Catheter|Placement of the coiled catheter for continuous infusion of local anesthetics close to the femoral nerve: To place coiled catheters ab 18-gauge Tuohy needle (Sonoline Curl Catheter Set, Pajunk® Medizintechnologie GmbH, Geisingen, Germany) of 8 cm length is placed adjacent to the nerve by ultrasound guidance and nerve stimulator control. At this position and after injection of 5 ml dextrose 5% in water to dilate the space the coiled catheter is blindly advanced 2 cm through the needle and the final position verified with ultrasound.
9969437|NCT01290185|Active Comparator|Conventional stimulating Catheter|For the control group a conventional stimulating catheter is placed adjacent to the femoral nerve as follows: To place the simulating catheter an 18-gauge Tuhoy needle s placed adjacenit to the nerve by ultrasound guidance. At this position a stimulation catheter is introduced through the needle and stimulated with a decreasing current from 1 mA to 0.4 mA, with a pulse width 0.1ms to verify the appropriate motor response of the quadriceps muscle. The catheter is slowly advanced 3 cm beyond the needle tip under continuous electric stimulation using a current that is subsequently adapted according to the motor response achieved. If muscles twitches disappear during catheter placement at a current above 1 mA, either the catheter or the needle are manipulated until muscle twitches reappear.
9969438|NCT01290198|Placebo Comparator|Vehicle without ANESDERM (lidocaine, prilocaine)|
9969439|NCT01290198|Active Comparator|Vehicle with ANESDERM (lidocaine, prilocaine)|
9969440|NCT01290198|Active Comparator|Fluconazole without ANESDERM (lidocaine, prilocaine)|
9969441|NCT01290198|Active Comparator|Fluconazole with ANESDERM (lidocaine, prilocaine)|
9669176|NCT03860844|Experimental|Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia|This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
9669177|NCT03840915|Experimental|Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824|
9669178|NCT03840915|Experimental|Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824|
9669179|NCT03840915|Experimental|Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824|
9969442|NCT01290211|Experimental|Cohort 1|Twice daily regimen
9969443|NCT01290211|Experimental|Cohort 2|Once daily regimen
9969444|NCT01290250|Experimental|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
9969445|NCT01290250|Placebo Comparator|Orange juice with low levels of polyphenols|2 daily doses (250 ml each) during 3 months
9976906|NCT01356238|Active Comparator|Sydney IVF media|Use Sydney IVF media in the human IVF-ET program
10138351|NCT04217291|Experimental|SY-004-1|a dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week
10138352|NCT04217291|Experimental|SY-004-2|a dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.
10138353|NCT04217291|Experimental|SY-004-3|a dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.
10138354|NCT04217291|Placebo Comparator|placebo|a dose of SY-004 matching placebo taken orally
10138355|NCT04217213|Experimental|ropivacaine combined with mecobalamine|Intercostal nerve block with 0.5% ropivacaine combined with mecobalamine (0.5mg).
10138356|NCT04217213|Active Comparator|ropivacaine|Intercostal nerve block with 0.5% ropivacaine alone.
10138357|NCT04217330|Experimental|Intervention|Pulmonary rehabilitation programs assigned to the intervention group will offer eligible participants the choice of participating in an 8-week program of either home-based pulmonary rehabilitation or traditional centre-based pulmonary rehabilitation.
10138358|NCT04217330|Active Comparator|Control|Pulmonary rehabilitation programs assigned to the control group will offer eligible participants the opportunity to participate in an 8-week centre-based pulmonary rehabilitation program, as per current practice.
10138359|NCT04217395||Reinforced support: X-ailes program users|
10138360|NCT04217265|Experimental|study group|2 tablets of Letrozole 2.5 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
10138361|NCT04217265|Placebo Comparator|control group|2 tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum three doses
10138362|NCT04217486|Experimental|A - will be shown their photograph at 2 weeks post-operative.|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
10138363|NCT04217486|Active Comparator|B - will not be shown their photograph|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will not be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
10138364|NCT04217408|Experimental|ON stimulation followed by OFF stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of ON (active) stimulation, followed by 2 weeks of OFF (sham) stimulation
10138365|NCT04217408|Experimental|OFF stimulation followed by ON stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of OFF (sham) stimulation, followed by 2 weeks of ON (active) stimulation
10138366|NCT04217538||EBH|
10138367|NCT04217564|Experimental|Intervention group|The intervention group will receive a counselling session then instructed on the subsequent follow up dates and final assessment by the end of the study.
10138368|NCT04217564|No Intervention|Control group|The control group will not receive nutritional counselling during the study period but will be instructed to attend for final assessment by the end of the study.
10138369|NCT04217447|Active Comparator|Experimental group|Patients intaking full-dose OAC + ASA 100mg od
9519671|NCT03284645||ART Started Postpartum|HIV positive women starting antiretroviral therapy (ART) after delivery for prevention of mother-to-child transmission of HIV and for their own health.
9519672|NCT03284632||Smokers|
10138370|NCT04217447|Placebo Comparator|Control group|Patients intaking full-dose OAC + Placebo of ASA 100mg od
10138371|NCT04217434|Experimental|Group 300µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 300 µm fibre length will be used in continuous contact mode at a power setting of 1.5 to 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
10138372|NCT04217434|Experimental|Group 300µm in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes, 300 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 - 3 W. Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
10138373|NCT04217434|Experimental|Group 400µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
10184440|NCT03755089|Active Comparator|Oral Phenazopyridine|Patients randomized to the oral phenzopyridine arm will receive 200mg phenazopyridine to take by mouth 1-2 hours before their scheduled procedure.
10184441|NCT03755089|Active Comparator|Intravesical Lidocaine|Patients randomized to the intravesical lidocaine arm will have the bladder back-filled with 30mL 2% lidocaine for the 20 minutes immediately preceding their procedure.
10187722|NCT03723330|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
9519673|NCT03284632||E-cigarette users|
10138374|NCT04217434|Experimental|Group 400µm in pulsed contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 t 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
10138375|NCT04217421|Active Comparator|Allopurinol|
10138376|NCT04217421|Placebo Comparator|Placebo|
10138377|NCT04217512|Active Comparator|Standard hydration alone|Cisplatin with standard hydration
10138378|NCT04217512|Active Comparator|Pantoprazole high dose|Cisplatin with standard hydration with pantoprazole 1.6 mg/kg
10138379|NCT04217512|Active Comparator|Pantoprazole Low dose|Cisplatin with standard hydration with pantoprazole 0.6 mg/kg
10138380|NCT04217343||non-complement mediated pAMR(H+)|
10138381|NCT04217343||complement mediated pAMR(I+)|
10138382|NCT04217317|Experimental|CPI-613 in Combination with Bendamustine|CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.
10138383|NCT04217187|Experimental|Electrical Stimulation Group|This arm will receive neuromuscular electrical stimulation to the antagonist muscles of the upper extremity.
10138384|NCT04217187|Sham Comparator|Sham Stimulation Group|This arm will receive sensory stimulation without muscle contraction to the antagonist muscles of the upper extremity.
10138385|NCT04217356||Hematopoietic stem cell transplant (HCT)|Standard of care hematopoietic stem cell transplant with a matched donor.
10138386|NCT04217356||Best available non-transplant therapies (BAT)|Standard of care treatment with a janus kinase (JAK) inhibitor drug called ruxolitinib or treatment with an antimetabolite drug called hydroxyurea.
10138387|NCT04217226||study group|adult patients (18-59 years), ASA I-II-III, scheduled for elective surgeries under general anaesthesia.
10138388|NCT04217369|No Intervention|Control|A control arm. The participant will be given a version of the Diabits app without predictions of blood glucose enabled. They will then use the Diabits app as if they were using their usual companion app to manage their diabetes for the duration of the study.
10138389|NCT04217369|Experimental|Intervention|The intervention arm. The participants in this arm will be provided with a version of the Diabits app which provides predictions of where their blood glucose will be one hour into the future, based on historic data and user inputs. The participant will then manage their blood glucose using these predictions for the duration of the study.
10138390|NCT04217174|Experimental|Avatar intervention app|The intervention is a mobile phone app that features a realistic talking human avatar who promotes adherence to ART and retention in care, motivates, and provides information and opportunities for HIV care-related behavioral skills.
10138391|NCT04217174|Other|Control app|The control app is a mobile phone app that features a realistic talking human avatar who primarily promotes food safety and also offers knowledge of sugar content in food. This app is expected to have no effect on ART adherence and retention in care, however, it has never been tested to determine if it may have any effect so it has been categorized as Other (arm type) rather than as placebo.
10138392|NCT04217252|Experimental|the experimental group|high throughput sequencing of infectious pathogens
10138393|NCT04217252|No Intervention|the control group|no intervention
10138394|NCT04217109|Experimental|Odour sampling|Odour collection will be obtained by positioning a compress on the breast concerned during the night preceding the day of samplings. The compress, once removed, will be placed in specific envelope for the study. Envelope will be given to the investigating centre during the appointment of percutaneous samples and then sent to the sponsor center (Institute Curie Paris).
10138395|NCT04217148|Experimental|ATRA and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and ATRA 10mg bid po, 12 consecutive weeks
10138396|NCT04217148|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
10184442|NCT03755076|Experimental|Perceptual cuing|Two perceptual cues will be provided: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context. The effect of the two cues on bimanual coordination will be determined.
10184443|NCT03755050||Sleigh Accident|Accident while using a sleigh
10184444|NCT03755050||Climbing Accident|Accident occurred while climbing (rock, ice)
10184445|NCT03755050||Cycle Accident|Accident occurred while using any form of cycle in the mountains (e.g. bike, mountainbike, e-bike)
10184446|NCT03755050||Canyoning Accident|Accident occurred while doing canyoning
10184447|NCT03755050||Hiking Accident|Accident occurred while hiking in mountainous area.
10184448|NCT03755050||Snowshoeing Accident|Accident occurred while doing Snowshoeing
10184449|NCT03755050||Mountainous Water-sport Accident|Accident occurred while doing any type of Water-sport (e.g. canoeing, kayaking, tubing, swimming) in mountainous environment.
10184450|NCT03755050||Skiing/Snowboarding|Accident occurred while using ski or a snowboard either in backcountry or on ski slope
10184451|NCT03755037|Active Comparator|Estradiol and cc|"Group 1 received estradiol, cc and placebo simillar to sildenafil for induction of ovulation.~CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient then ethinyl estradiol 0.05mg orally twice daily on the 8th day of same cycle till 11th day."
10184452|NCT03755037|Active Comparator|Sildenafil and cc|Group 2 received CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient, sildenafil citrate (Respatio) 20 mg tab orally 3 times daily from8th day of same cycle till 11th day and placebo simillar to estradiol.
9519674|NCT03284632||Non-smokers|
9669180|NCT03840915|Experimental|Cohort D: Docetaxel + M7824|
10138397|NCT04217005|Experimental|experimental group|amputees or diabetics receiving intervention
10138398|NCT04216836|Experimental|High magnesium diet (SUP condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
10138399|NCT04216836|Experimental|Low magnesium diet (CON condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
10138400|NCT04216979|Experimental|randomization|Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. Group (B):- The umbilicus is the primary entry site.
10138401|NCT04216979|Experimental|group A|these are the patient with palmars point as primary entry site
10138402|NCT04216979|Experimental|group B|these are the patient with umbilicus as primary entry site
10138403|NCT04217031||Decision variability assessment group|Patients with angiographically confirmed 3-vessel or left main disease will be enrolled. Patients data and heart team decision will be collected to analyze the variability between different heart team decisions.
10138404|NCT04217122|Experimental|Strawberry intervention group|Participants consume two packages of 13 g of standard strawberry powder in the morning and afternoon/evening per day for 4 weeks
10138405|NCT04217122|Placebo Comparator|Placebo group|Participants consume two packages of 13 grams placebo powder in the morning and afternoon/evening for 4 weeks.
10138406|NCT04216940|Experimental|M-pro|
10138407|NCT04216940|Experimental|Hyflex|
10138408|NCT04217161|Experimental|Dexcom G6 Continuous Glucose Monitor|
10138409|NCT04217096|Experimental|paclitaxel liposome + S-1|paclitaxel liposome at 175 mg/m^2 on day 1; S-1 at a dose according to the body surface area（<1.25m^2，40mg Bid；1.25~1.5m^2,50mg Bid；>1.50m^2,60mg Bid，d1-14，q3w）
10138410|NCT04217083||Colorectal cancer patients|Patients with histologically proven Colorectal cancer detected during the colonoscopy
10138411|NCT04217083||healthy controls|Patients with no sign of any colorectal disease who are submitted to colonoscopy
10138412|NCT04216849|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.
10138413|NCT04216849|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
10138414|NCT04216758|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
10138415|NCT04216758|Experimental|tegafur + gemcitabine|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; tegafur: Body surface area < 1.25 m^2, 60 mg/d; Body surface area ≥ 1.25 m^2 to < 1.5 m^2, 80 mg/d; Body surface area ≥ 1.5 m^2, 100 mg/d; Oral (po), Bid, D1-21
10138416|NCT04216784|Active Comparator|Furosemide (Lasix) alone|Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours
10138417|NCT04216784|Active Comparator|Combination of furosemide (Lasix) and albumin|Cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams IV BID for at least 48 hours
10138418|NCT04216732||Observational (questionnaire, blood pressure)|"AIM I & II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease.~AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks."
10138419|NCT04216914|Experimental|Use of hand outline for bone age xray|Where children and young people are having left hand X-rays for clinical purposes the radiographer will place a template under their hand. The plate is designed not to show up on the X-ray and to not interfere with the X-ray itself. They will be asked to match their hand to the hand outline on the template.
10138420|NCT04216706||Tailored treatment advise in suboptimal adaptation|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment are invited to participate in a follow-up program at four time-points during a subsequent pregnancy (i.e. at 12, 16, 20 and 30 weeks of gestational age). This program is additive to regular pregnancy check-ups, and all women are otherwise managed by their referring physicians. The aim of this program is to evaluate adaptation of maternal hemodynamic parameters in response to pregnancy, and to adjust deviant adaptation with tailored antihypertensive medication. Participation in this program is on voluntary basis, and not restricted to severity of complications in the first pregnancy.
10138421|NCT04216706||Care as usual during pregnancy|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment who do not participate in the additional follow-up program.
10138422|NCT04216966|Placebo Comparator|Control group|This group did not undergo any instrumentation.
10138423|NCT04216966|Experimental|Gracey Curette group|Teeth under this group were subjected to debridement with Gracey curette .
10138424|NCT04216966|Experimental|After Five group|Teeth under this group were subjected to debridement with After 5 curette .
10138425|NCT04216966|Experimental|Mini Five group|Teeth under this group were subjected to debridement with Mini Five curette .
10138426|NCT04216862|Experimental|Strengthening exercise treatment|This exercise targets the deep flexor muscles of the upper cervical region the longus capitis and longus colli muscles.
10138427|NCT04216862|Active Comparator|Stretching exercise treatment|The subject's forearm is stabilized by a vertical plane before the trunk is rotated in the opposite direction. Therefore the arm on the involved side is externally rotated and abducted to 90.
10184453|NCT03755037|Placebo Comparator|Placebo and cc|Group 3 received cc and placebo similar to sildenafil and placebo similar to estradiol with the same doses.
10184454|NCT03755024||normal group|fetuses with normal growth
10184455|NCT03755024||Growth retardation group|fetuses with retarded growth
10184456|NCT03755011|Experimental|patients exposed to white noise|Six patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined; pausing will be at nurse, provider, and patient discretion during routine care and conversations with the patients.
9669181|NCT03824132|Experimental|Intervention Group|
10138428|NCT04216992||Three dimensional-rotational epidurography (3D-RE)|3D-RE is obtained on a commercial digital bi-plane angiography system. Reconstruction time was 30 seconds. Detailed information regarding technical performance and reconstruction procedure has been reported. Postprocessing techniques provided by the software included real-time 3D volume rendering and multiplanar reformatting. Real-time 3D volume rendering creates a 3D model of the examined object. The software allows emphasizing bony structures or soft tissue by changing intensity, brightness, and opacity of different X-ray structures. Additionally, rotation of the 3D object in all directions is possible, as is a virtual stereoscopic view provided by the software in combination with special glasses. The multiplanar reformatting modus generates virtual sections according to the three main axes and free defined axes. The section planes can be freely chosen, and curved sectioning is also possible.
10138429|NCT04216641|Experimental|Intervention arm|"At each meal: different elements will be presented to the patient (starter / main course / side dish / dessert).~For each of these elements, the patient will be offered 4 versions (a standard version and 3 adapted versions of the same food):~The standard food.~The food refers to a more elaborate texture.~The food refers to a food with a stronger smell.~The food refers to a more important flavor.~The patient will indicate the version of the food that will be preferred."
10138430|NCT04216797|Active Comparator|Oral Administration|10 mg diazepam tablets to be taken orally once daily for 4 weeks.
10138431|NCT04216797|Active Comparator|Rectal Administration|10 mg diazepam tablets to be taken rectally once daily for 4 weeks.
10138432|NCT04216888|Experimental|Open label|Open label intranasal ketamine
10138433|NCT04216628|Other|Early amniotomy group|Amniotomy will be performed as the exclusive primary intervention. Oxytocin infusion will begin as per local standard dose protocol no earlier than 2 hours following amniotomy.
10138434|NCT04216628|Other|Late amniotomy group|Oxytocin infusion will begin as per local standard dose protocol. Amniotomy will be performed no earlier than 2 hours following the commence of oxytocin infusion
10138435|NCT04216654||Group(A)|52 cases of type 2 diabetic patients.They have +ve Serum antibody and Stool antigen specific for Helicobacter pylori.
10138436|NCT04216654||Group(B)|36 cases of type 2 diabetic patients. They have +ve Serum antibody and -ve Stool antigen-specific for Helicobacter pylori.
10138437|NCT04216654||Group(C)|112 cases of type 2 diabetic patients. They have -ve Serum antibody and Stool antigen-specific for Helicobacter pylori.
10138438|NCT04216693|Experimental|Digoxin tablet|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
10138439|NCT04216693|Placebo Comparator|Placebo|Digoxin-like oral placebo
10138440|NCT04216511||Case-Lung Cancer|Patients with definite lung cancer diagnosis
10138441|NCT04216511||Control|Either patients with benign pulmonary nodule, or healthy individuals without pulmonary nodule but with risk factors to develop lung cancer matched to lung cancer group
10138442|NCT04216576|Active Comparator|Standard of Care|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care
10138443|NCT04216576|Experimental|Standard of Care + Intervention|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
10138444|NCT04216667|Active Comparator|PVI|Pulmonary vein isolation alone will be performed using radiofrequency energy
10138445|NCT04216667|Experimental|PVI + PWI|Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
10138446|NCT04216667|Experimental|PVI + PWI + LAAEI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
10138447|NCT04216667|Experimental|PVI + PWI + LAAEI + CSI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy
10138448|NCT04216875||single primary care practices intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility following the best practice procedure of the diabetes score.
10138449|NCT04216875||primary care group practice intervention|Independent primary care practices with more than one medical doctor working in their responsibility following the best practice procedure of the diabetes score.
10138450|NCT04216875||single primary care practices no intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility without the intervention (not using Diabetes score)
10138451|NCT04216875||primary care group practice no intervention|Independent primary care practices with more than one medical doctor working in their responsibility without the intervention (not using Diabetes score).
10138452|NCT04216446|Experimental|Mobile Health Coaching Program during pregnancy|Eligible pregnant women would be randomized to intervention or the non-intervention arm after consenting to participate. Participants in the intervention arm will receive free subscription of m-Health program for six months of coaching. The program will provide individualized coaching on diet, supplement use and physical activity. Participants would undergo dietary screening at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow-up to monitor the improvement (if any) in diet, supplement use and physical activity. Women will receive advice in the form of recommendations after completing the questionnaire. Also, push messages containing tips and recommendations for diet, supplement use and physical activity would be delivered a maximum of three times a week. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line.
10184457|NCT03755011|Placebo Comparator|usual care|Six patients exposed to normal ICU activity noise.
10187723|NCT03723317||Training liver transplantation|Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
10187724|NCT03723317||Validation liver transplantation|Patients consecutively transplanted in the Karolinska Institute (N=520)
9519675|NCT03284619|Experimental|treatment arm|Single arm study, 5 patient with bone metastasis will be enrolled for palliative treatment with the Magnetic resonance imager linear accelerator (MR-Linac).
9669182|NCT03824132|Active Comparator|Waitlist Control Group|
9669183|NCT03811405|Experimental|Patients with Essential Tremor|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time. The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation. The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off. A 30-minute washout period will be applied between each of the random conditions. Therefore, each patient will serve as their own control.
9969446|NCT01290276|Experimental|Ond-PR1 followed by (Ond-PR1 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
9969447|NCT01290276|Experimental|Ond-PR2 followed by (Ond-PR2 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
9969448|NCT01290289|Active Comparator|Epidura, combined spinal epidura & IV|"Gp 1: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.5% lidocaine injected epidurally.~Gp 2: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.0625% bupivacaine injected epidurally.~Gp 3: received 50µg of E fentanyl analgesia, injected intrathecally & a bolus of 10 ml of 0.5% lidocaine, followed by lidocaine E top-ups.~Gp 4: received 50µg of E fentanyl injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine, followed by E bupivacaine top-ups.~Gp 5: 50mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg."
9969449|NCT01290302|Experimental|Luitpold Azacitidine|
9969450|NCT01290302|Active Comparator|Vidaza®|
9969451|NCT01290328|No Intervention|Standard of care|
9969452|NCT01290328|Experimental|Epoetin alfa|150 units/kg/week
9969453|NCT01290354|Experimental|lapatinib|unlabelled, administered orally
9969454|NCT01290367|Experimental|High Dose MPCs|Injection of High Dose MPCs with Hyaluronic Acid
9969455|NCT01290367|Experimental|Low Dose MPCs|Injection of Low Dose MPCs with Hyaluronic Acid
9969456|NCT01290367|Sham Comparator|Saline injection|Injection of saline solution.
9969457|NCT01290367|Placebo Comparator|Hyaluronic acid injection|Injection of hyaluronic acid solution
9969458|NCT01290380|Experimental|ASA 404 + standard chemotherapy|ASA 404 in combination with in combination with standard chemotherapy (paclitaxel + carboplatin or docetaxel) and a cocktail of caffeine, diclofenac, simvastatin and omeprazole
9969459|NCT01290393||Exposed vaccinated cohort|Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
9969460|NCT01290393||Non-exposed vaccinated cohort|Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.
9969461|NCT01290406|Experimental|BEZ235|
9969462|NCT01290419|Experimental|A: Dose 1 + adjuvant|
9969463|NCT01290419|Experimental|B: Dose 2 + adjuvant|
9969464|NCT01290419|Experimental|C: Dose 3 + adjuvant|
9969465|NCT01290419|Experimental|D: Dose 3 alone|
9969466|NCT01290419|Placebo Comparator|E: Placebo control|
9969467|NCT01290419|Experimental|F: Dose 4 alone|
9969468|NCT01290419|Experimental|G: Dose 4 +adjuvant|
9969469|NCT01290432|Experimental|Inofolic Plus|Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
9969470|NCT01290458|Experimental|Vitamin|
9969471|NCT01290458|Placebo Comparator|Control|
9969472|NCT01290471|Experimental|Part 1 Dose Escalation|Dose escalation of U3 1565 will follow a modified 3+3 study design with a starting intravenous (IV) dose of 2 mg/kg. A maximum of 2 new subjects will receive their first dose of U3-1565 per 24-hour period during the dose-escalation phase. Subsequent escalating doses of 8, 16, and 24 mg/kg are planned. Three to 6 subjects will be enrolled in 4 sequential dose level cohorts.
9969473|NCT01290471|Experimental|Part 2a Dose Expansion|For Part 2a, 6 or 12 subjects with advanced solid malignant tumors will be enrolled and treated at the MTD or MAD to further define the safety and tolerability of U3-1565. These additional subjects are expected to permit the detection of relatively rare toxicities that would not likely be observed during the dose escalation part of the study, whose 3+3 design implies a maximum of 6 subjects only will be treated at the MTD or MAD. Six subjects will be treated; however, if toxicities meeting the definition of DLT are observed during the first cycle of treatment, 6 more subjects will be treated for a total of 12 subjects.
9969474|NCT01290471|Experimental|Part 2b Dose Expansion and Anti-tumor Impact|For Part 2b, up to 30 subjects with advanced solid malignant tumors, with a preference for those with advanced ovarian cancer, will be enrolled and treated at the MTD or MAD. This number of subjects should allow demonstrating U3-1565 has anti-tumor impact by showing treatment-induced changes in pharmacodynamic biomarkers and clinical activity. Ovarian cancer may be more likely to be impacted by U3 1565 than other tumors, considering that in this cancer, high levels of HB-EGF have been associated with an unfavorable clinical outcome. Six subjects will be initially treated; at which point, a safety analysis will be conducted after these initial subjects have completed the first cycle of treatment, to allow the reevaluation of the appropriateness of the dosing level.
9969475|NCT01290497|Active Comparator|Hyaluronic acid 5 x 2.5 ml|
9969476|NCT01290497|Experimental|Hyaluronic acid 1 X 5 ml|
10187725|NCT03723304||Direct liver transplant|All the cases listed for liver transplantation and then transplanted/dropped-out without undergoing any neo-adjuvant loco-regional treatment
10187726|NCT03723304||Bridging followed by transplant|All the cases listed for liver transplantation and then transplanted/dropped-out after undergoing at least one neo-adjuvant loco-regional treatment
9519676|NCT03284606|Experimental|TAPING|taping in conjunction with common rehabilitation for hemiplegic patients
9969477|NCT01290497|Experimental|Hyaluronic acid 2 x 5 ml|
9969478|NCT01290510|Experimental|hyaluronic acid sodium salt|
10187727|NCT03723291|Active Comparator|Arm A|The current best standard of care [rehabilitation exercises]
10138453|NCT04216446|No Intervention|Standard Counseling|"For the non-intervention arm, dietary counseling will be provided face to face by the trained research assistant at the baseline and scheduled follow-ups using the AKUH educational leaflet Diet during Pregnancy and American College of obstetricians and gynaecologists guidelines for physical activity. Alike intervention group, the non-intervention group will complete an interviewer based paperless screening questionnaire at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow up. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line."
10138454|NCT04216459|No Intervention|Low risk group|no specific treatment will be given
10138455|NCT04216459|No Intervention|High risk control|no specific treatment will be given
10138456|NCT04216459|Active Comparator|High risk DP|patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day
10138457|NCT04216459|Active Comparator|High risk CB|Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
10138458|NCT04216264|Other|Response|
10138459|NCT04216264|Other|Non-response|
10138460|NCT04216355|Experimental|AZA with CAG derived regimen|Azacitidine 50mg/m²/day, D1-D5 (IV) Aclarubicin 5mg/m²/day, D1-D4 (IV) Cytarabine 10mg/m²/12h, D1-D6 (IV) G-CSF 5-10ug/kg/day, D1-D7 (SC)
10138461|NCT04216251|Experimental|AMR101|"Study procedures include screening for eligibility and study treatment including ARM101 Lifestyle questionnaire, Nutritional survey. Flexible sigmoidoscopy (24 biopsies of normal colorectal mucosa, one stool sample),blood, evaluations, and follow up visits.~- AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks"
10138462|NCT04216368|Experimental|experimental group|
10138463|NCT04216368|Other|controlled group|
9669184|NCT03793426||Fibryga|Fibryga (human plasma-derived fibrinogen concentrate)
10138464|NCT04216771|Experimental|IDA with ID Cytarabine|
10138465|NCT04216771|Active Comparator|ID Cytarabine|
10138466|NCT04216550||Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
10138467|NCT04216472|Experimental|Treatment (alpelisib, nab-paclitaxel)|Patients receive alpelisib PO QD on days 1-21, and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then undergo surgery to remove the tumor.
10138468|NCT04216485|Experimental|Lifestyle intervention|Intervention group: Intensive lifestyle intervention will be initiated from the first trimester (8-12wks) to delivery, with follow up every 2-4 weeks. Participants in the intervention group will be provided with an individualized dietary protocol with not less than 1500 calories per day in the first trimester and not less than 1800 calories per day after 13 weeks of gestation. Guidance on regular exercise is reinforced at the first and each follow up visit.
10138469|NCT04216485|Active Comparator|Standard Care|Standard care group: Participants will receive a 1.5-hour group session in which standard prenatal intervention on diet, nutrition and physical activity and recommendation for gestational weight gain are reviewed by a registered dietitian. Thereafter, participants will receive their regularly scheduled follow up visits without additional lifestyle guidance.
10138470|NCT04216147|Experimental|PNE group|Patients received 4 sessions, separated one week between them. The treatment consisted the application of a galvanic current through an acupuncture needle (0,30x30mm). The approach were performed with a transverse axis with a needle in plane, being superficial and deep interface of medium nerve the target tissue. The parameters will be 2 mA (milliamps), 10 seconds, 3 impacts (3: 3: 3).
10138471|NCT04216147|Experimental|Surgery group|Patients received surgery for median nerve release.
10138472|NCT04216407|Experimental|Remote Ischemic Preconditioning|Short-term tourniquet on to the lower extremity before surgery
10138473|NCT04216407|No Intervention|Control|No intervention
10138474|NCT04216615||patients with preoperative anxiety|
10138475|NCT04216615||patients without preoperative anxiety|
10138476|NCT04216173|Experimental|Acupuncture|
10138477|NCT04215978|Experimental|Phase 1a: BGB-A445 Monotherapy|Dose Escalation Part A: Participants will receive intravenous (IV) infusion of BGB-A445 in sequential cohorts of approximately 5 increasing dose levels on day 1 of each 21-day cycle
10138478|NCT04215978|Experimental|Phase 1a: BGB-A445 + Tislelizumab Combination Therapy|Dose Escalation Part B: Participants will receive IV infusion of BGB-A445 in sequential cohorts of approximately 3 increasing dose levels plus 200mg tislelizumab on day 1 of each 21-day cycle
10138479|NCT04215978|Experimental|Phase 1b:BGB-A445 Monotherapy or Combination with Tislelizumab|Dose Expansion: Participants will receive recommended Phase 2 doses (RP2D(s)) of IV BGB-A445 alone or in combination with tislelizumab as determined from Phase 1a Dose Escalation
10138480|NCT04216277|Experimental|Procalcitonin in addition to usual care|Procalcitonin values will be disclosed to the attending physician and assist in antibiotic guidance in addition to usual care
10138481|NCT04216277|No Intervention|Usual care|Usual best standard care. No procalcitonin values disclosed to attending physician .
10138482|NCT04216095|Active Comparator|Electroconvulsive Therapy (ECT)|Right unilateral (RUL, N=15), or Bitemporal (BT, N=15) ECT
10138483|NCT04216095|Active Comparator|Magnetic Seizure Therapy (MST)|High-dose magnetic seizure therapy (HD-MST)
10138484|NCT04216108|Experimental|23G gauge needle vitrectomy surgery|
10138485|NCT04216108|Experimental|27G gauge needle vitrectomy surgery|
10138486|NCT04216199|Experimental|Point of care Ultrasound|Point of care Ultrasound for placement of endotracheal tube
10138487|NCT04216199|No Intervention|Traditional|Traditional method of insertion of endotracheal tube
10138488|NCT04216186|Active Comparator|Atomoxetine and Coenzyme Q|Atomoxetine and Coenzyme Q
10138489|NCT04216186|Placebo Comparator|Placebo and Atomoxetine|Placebo and Coenzyme Q
9969479|NCT01290549|Experimental|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by an IV infusion of escalating doses (starting dose of 0.1 mg/kg, potentially to be followed by 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg doses) every 3 weeks (q3w) (Day 1 of each 21 day cycle).
10138490|NCT04216160|Experimental|Verum|Patients with mild to moderate acne using ACN Cream
10138491|NCT04216160|Experimental|Placebo|Patients with mild to moderate acne using the placebo cream
10138492|NCT04216420|Experimental|Electronic pillbox-enabled self-administered therapy (SAT)|Participants in the intervention arm (n = 72) will receive 15 days of HRZE-isoniazid, rifampicin, pyrazinamide, and ethambutol-fixed-dose combination therapy in the evriMED500 medication event reminder monitor device (Wisepill Technologies, South Africa) for self-administration. When returned, providers will count any remaining tablets in the device, download the pill-taking data, and refill based on preset criteria. Participants can consult the provider in cases of illness or adverse events outside of scheduled visits.
10138493|NCT04216420|No Intervention|Standard directly observed therapy (DOT)|Providers handle participants in the control arm (n = 72) according to the standard DOT.
10138494|NCT04216004|Experimental|Full-fat dairy|3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
10138495|NCT04216004|Active Comparator|Non-fat diary|3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.
10138496|NCT04216004|Placebo Comparator|Non-dairy control|3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.
10138497|NCT04215900|Experimental|High-Speed Multi-Directional Yoga|The duration of the intervention is 18 weeks, with 16 weeks of training.
10138498|NCT04215900|No Intervention|Waitlist control|During the course of the 18 week study this arm will receive no intervention. Participants will be encouraged to maintain their daily schedules.Following the completion of the study the participants will be offered eight yoga sessions over a one month period.
10138499|NCT04216017|Placebo Comparator|Controls|Patients receiving lidocaine
10138500|NCT04216017|Active Comparator|Cases|Patients receiving Kenalog
10138501|NCT04216069|Experimental|Total 12 regimen group|This group will use the following procedure: Colgate Ultrasoft toothbrush, Colgate Total 12 toothpaste and Plax Mouthwash.
10138502|NCT04216069|Experimental|Tooth brushing alone group|This group will use Colgate Ultrasoft toothbrush and Colgate Cavity Protection toothpaste.
10138503|NCT04215913||Normal lung tissue|Normal lung tissue from PSC patients
10138504|NCT04215913||PSC tissues|PSC tissues from PSC patients
10138505|NCT04215913||Metastasis tissues|Metastasis tissues from PSC patients
10138506|NCT04216082|Experimental|Anlotinib|Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
10138507|NCT04216056|Experimental|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI >=25 kg/m2, and/or waist circumference >=90 cm (male) or >=80 cm (female) during the 12-week study period.
10138508|NCT04216056|No Intervention|Control group|Subjects in the control group will be asked to maintain their usual diet and physical activity patterns over the 12 weeks.
10138509|NCT04215965|Experimental|Experimental Standard citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Biphozyl in the dialysate and postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
10138510|NCT04215965|Active Comparator|Conventionnal citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Prismocal B22 (calcium and phosphate free) in the dialysate mode, and Phoxilium in the postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
9519677|NCT03284606|Placebo Comparator|NO TAPING|Common rehabilitation for hemiplegic patients without taping
10138511|NCT04216030|Experimental|High iron Irish potato|Meal sequence B, IP High Fe
10138512|NCT04216030|Active Comparator|Regular Irish potato|Meal sequence A, OFSP control
10138513|NCT04215887||Sleep unit|Children admitted to sleep unit for sleep study
10138514|NCT04215887||School|Healthy children in school
10138515|NCT04215887||Emergency department|Children seen in triage in emergency department at SCH
10138516|NCT04215887||General practice|Adults or children attending general practice
10138517|NCT04215887||Ambulance|Adults or children in rapid response vehicle
10138518|NCT04215926||HIV-monoinfected outpatients|No intervention; cross-sectional study
10138519|NCT04215692|Experimental|Ultrasound Guided Fluid Therapy|
10138520|NCT04215692|No Intervention|Conventional Fluid Therapy|
10138521|NCT04215653|Experimental|Anaprazole Sodium + Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
10138522|NCT04215653|Active Comparator|Rabeprazole +Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
10138523|NCT04215939|Experimental|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138524|NCT04215939|Experimental|Thermoneutral environment participants with spinal cord injury|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10187728|NCT03723291|Experimental|Arm B|The current best standard of care [rehabilitation exercises] + the experimental intervention
10138525|NCT04215939|Experimental|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138526|NCT04215939|Active Comparator|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138527|NCT04215939|Active Comparator|Thermoneutral environment healthy male participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138528|NCT04215939|Active Comparator|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138529|NCT04215939|Active Comparator|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138530|NCT04215939|Active Comparator|Thermoneutral environment healthy female participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138531|NCT04215939|Active Comparator|Warm enviroment healthy fmale participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
10138532|NCT04215731|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive neoadjuvant mFOLFOXIRI plus bevacizumab once every two weeks for 4 cycles and the same mFOLFOXIRI for 2 cycles. After completing all 6 cycles chemotherapy, the patient will have an MRI scan to examine the tumor. If MRI restaging is ycT4a/b, or MRF involved, the patient will receive concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks). If MRI restaging is ycT0-3 and MRF negative, then the patient will proceed directly to surgery.
10138533|NCT04215731|Active Comparator|Induction FOLFOX Followed by Concomitant Chemoradiotherapy|Patients will receive induction FOLFOX chemotherapy for 4 cycles and followed by concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks), then the patient will proceed to surgery.
10138534|NCT04215562|Other|patients with peripheral facial palsy|collection of data from records on the outcome of rehabilitation therapy on patients with peripheral facial palsy and types of complications associated with this therapy type
10138535|NCT04215705|Active Comparator|Group Q|Patients in this group receive Quadratus Lumborum Block with 20 ml bupivacaine 0.5%
10138536|NCT04215705|Active Comparator|Group L|Patients in this group receive peritubal local infiltration at 6 and 12 o'clock position with 20ml bupivacaine 0.5%
10138537|NCT04215796|Experimental|ReX-C intervention|Subjects use ReX-C to receive CFTR modulators medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
10138538|NCT04215757|Experimental|Intervention group|"Patient received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.~For L4 radiculopathy Saphenous nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For S1 radiculopathy Sural nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%)"
10138539|NCT04215757|Placebo Comparator|Control group|"Patients received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.~For L4 radiculopathy Saphenous nerve block with 10ml distilled water For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 10ml distilled water For S1 radiculopathy Sural nerve block with10ml distilled water"
10138540|NCT04215744|Experimental|Ice water immersion group|Ice water immersion of the left hands(30 minutes before the infusion, during the infusion, and 30 minutes after the end of infusion).
10138541|NCT04215744|No Intervention|Control group|No intervention of the right hands as control.
10138542|NCT04215614|Active Comparator|Group Lateral Sagittal|Ultrasound-Guided lateral sagittal brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
10138543|NCT04215614|Active Comparator|Group Costoclavicular|Ultrasound-Guided costoclavicular brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
10138544|NCT04215666||Mild ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
10138545|NCT04215666||Moderate ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
10138546|NCT04215666||Severe ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
10138547|NCT04215588|Active Comparator|Individualized heparin and protamine titration|The device Hemostasis Management System Plus (Medtronic, Minneapolis, MN) will be used to determine the patients' sensitivity to heparin and its concentration in whole blood. Then, it will automatically calculate the necessary dose for anticoagulation during bypass. The protamine dose to eliminate heparin effect will be calculated from the remaining heparin concentration (0.75mg/100 International Units circulating heparin).
10138548|NCT04215588|Active Comparator|Activated Clotting Time guided heparin and protamine dose|Heparin initial dose will be determined according to the patients' weight to achieve a required Activated Clotting Time (ACT) to initiate cardiopulmonary bypass. Subsequent doses of heparin will be administered according to ACT and protamine dose will be calculated from total heparin dose (0.75mg protamine/100 International Units heparin)
10138549|NCT04215575|Active Comparator|BGI model 101-350 placement (BGI group)|A 350 mm2 Baerveldt glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits.The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures.
10138550|NCT04215575|Experimental|AGV model FP7 or S2 placement (AGV group)|A 184 mm2 Ahmed glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits. The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures
10138551|NCT04215718|Active Comparator|fistulotomy group|46 patients with simple anal fistula underwent fistulotomy and marsupialization of wound edges
10138552|NCT04215718|Active Comparator|fistulectomy group|46 patients with simple anal fistula underwent fistulectomy and closure of the wound
10138553|NCT04215497|Experimental|Physiotherapeutic Scoliosis-Specific Exercises|PSSE group will receive corrective exercise for scoliosis
10138554|NCT04215497|No Intervention|Control|Control group will be taken to the queue list.
10138555|NCT04215835|Experimental|study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
10138556|NCT04215835|Placebo Comparator|control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
10138557|NCT04215770|Active Comparator|Inj Co-amoxiclav|Group A children were advised Inj Co-amoxiclav 50 units/kg/day in 3 divided doses daily
10138558|NCT04215770|Active Comparator|Inj Benzyl Penicillin|Group B patients were advised inj Benzyl Penicillin 25000 units/kg/day in 3 divided doses
10138559|NCT04215822||acute myeloid leukemia patients - control group|acute myeloid leukemia
10138560|NCT04215549||Participants|OCD patients come from 13 hospitals located in the north, south, east and west of China
10138561|NCT04215536||DPP4i|Reference group
10138562|NCT04215536||Empagliflozin|Exposure group
10138563|NCT04215484||P|P (previa) : pregnant women with placenta previa on ultrasound and no suggestive signs of placenta accreta
10138564|NCT04215484||I|I (abnormal placental Invasion) : pregnant women with placenta previa on ultrasound,and suggestive signs of placenta accreta on ultrasound with or without MRI
10138565|NCT04215484||N|N (placenta normally located) : pregnant women without suggestive signs of placenta previa or accreta on ultrasound
10138566|NCT04215471|Experimental|NeoAdjuvant Therapy With PD-L1 Antibody SHR-1316 group|Patients will receive the neoadjuvant therapy with SHR-1316 followed by the operation.
10138567|NCT04215458|Other|sample collection|Collection of samples investigating for yeast colonization in either patients with inflammatory skin disease or healthy controls.
10138568|NCT04215354|Experimental|MAGNET GROUP|Patients were exposed to very low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional using magnet mattress.
10138569|NCT04215354|Experimental|VIRTUAL REALITY|"Balance training was done using the Wii Fit plus machine which required balance board .Using video game console designed by Nintendo.~The program consisted of three games: soccer heading, ski slalom and table tilt."
10138570|NCT04215354|Active Comparator|PLACEBO|Patients in the placebo group had identical program to magnet group. They were asked to lie down in the magnet mattress; however, the magnet was not switched on and the patient doesn't know (blind).
10187729|NCT03723252|Experimental|Dapagliflozin group|Participants will receive dapagliflozin 10mg po qd.
9969480|NCT01290549|Experimental|Polatuzumab Vedotin + Rituximab|Polatuzumab vedotin will be administered by an IV infusion q3w (Day 1 of each 21 day cycle). Rituximab was administered by an IV infusion at 375 milligrams per square meter (mg/m^2) body surface area dose q3w.
9969481|NCT01290562|Experimental|Stereotactic Body Radiotherapy (SBRT)|Cohort 1: Patients with spinal metastases and no prior radiation Cohort 2: Patients with spinal metastases in a previously radiated field Cohort 3: Post-operative patients with spinal metastases
9969482|NCT01290575|Active Comparator|Arm 1 BMS-820132 or placebo|
9969483|NCT01290575|Active Comparator|Arm 2 BMS-820132 or placebo|
9969484|NCT01290575|Active Comparator|Arm 3 BMS-820132 or placebo|
10138571|NCT04215354|No Intervention|HEALTHY SUBJECT|healthy subjects with age, gender and BMI matched with the patients with MS were recruited to participate in the study. This group was recruited to establish the normal balance and fatigue parameters. Subjects in this group sign the consent form of healthy subjects and all measurement was taken as balance, fatigue, depression, quality of life and urinary incontinence screening questionnaire.
10138572|NCT04215133|Experimental|İnspiratory muscle training group|
10138573|NCT04215133|Experimental|Calf muscle training group|
10138574|NCT04215133|No Intervention|Control|
10138575|NCT04215393|Experimental|Conbercept eye drop (0.1mg/ mL)|Subjects in this arm will receive 0.1mg/mL Conbercept eye drop 4 times a day, one drop at a time.
10138576|NCT04215393|Experimental|Conbercept eye drop (0.5mg/ mL)|Subjects in this arm will receive 0.5mg/mL Conbercept eye drop 4 times a day, one drop at a time.
10138577|NCT04215393|Experimental|Conbercept eye drop (1.0mg/ mL)|Subjects in this arm will receive 1.0mg/mL Conbercept eye drop 4 times a day, one drop at a time.
10138578|NCT04215198|Experimental|Move3™ (NEM + fish oil)|NEM, 500 mg, #0 capsule, + fish oil, 1,500 mg, softgels, once daily orally for 2 weeks
10138579|NCT04215198|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, + placebo oil, 1,500 mg, softgels, once daily orally for 2 weeks
10138580|NCT04215328|Experimental|Mixed-Meal|Ensure Nutrition Shake
10138581|NCT04215328|Placebo Comparator|Electrolyte Solution|Pedialyte Solution
10138582|NCT04215367|Experimental|High phenolic EVOO intake|Patients with CLL consumed before their meals, 40 ml/day of EVOO rich in oleocanthal and oleacin for 6 months,
10138583|NCT04215367|Experimental|No High phenolic EVOO intake|Patient's history were recorded for third and sixth month before dietary the intervention, taking into consideration that the patients did'nt consume high phenolic EVOO.
10184458|NCT03754998|Experimental|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
10184459|NCT03754985||Hyperbaric Oxygen Therapy|The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.
10184460|NCT03754972|Experimental|Lumbar spinal stenosis surgery candidate|Patients with lumbar spinal stenosis and spondylolisthesis that have previously consented to surgical treatment. After recording the initial surgical plan, the Sagittal plane shear index (SPSI) will be provided to the surgeon. The surgeon may change the initial surgical plan based on the stability metric.
10184461|NCT03754959|Experimental|Dose Group 1|
10184462|NCT03754959|Experimental|Dose Group 2|
10184463|NCT03754959|Experimental|Dose Group 3|
9969485|NCT01290575|Active Comparator|Arm 4 BMS-820132 or placebo|
10184464|NCT03754959|Experimental|Dose Group 4|
10184465|NCT03754959|Experimental|Dose Group 5|
10184466|NCT03754933|Experimental|Ad/PNP + fludarabine phosphate, 5 cycles|
10184467|NCT03754920|Experimental|prolonged fasting|Participants fast for five days, without any food, except unlimited mineral water, and do some fitness regimen(such as meditation and mild physical exercise ).
10184468|NCT03754907|Experimental|stapled anastomosis group|Following the first side-to-side anastomosis at the antimesenteric border in both intestinal limbs, the staple lines are oversewn to reinforce the crotch. Thereafter, the stapler is again fired across the joined intestinal limbs to close the enterotomies. The suture line of the side-to-side anastomosis should not overlap, and the staple lines are oversewn to reinforce the double-stapled areas.
10184469|NCT03754907|Active Comparator|hand-sewn anastomosis group|Patients chose HA group will performed in an end-to-end manner using absorbable suture material.
10184470|NCT03754894|Experimental|goup 1(with readymade plastic stent )|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
10184471|NCT03754894|Experimental|group 2 (control)|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement then suturing the flap in place.
10184472|NCT03754855||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria
10184473|NCT03754842|Placebo Comparator|Placebo|
10184474|NCT03754842|Experimental|Nicotinamide Riboside + Pterostilbene|
10184475|NCT03754829|Experimental|HSKA - Web Group|The first experimental group will receive direct access to the web version of HSKA.
10184476|NCT03754829|Experimental|HSKA - Mobile Group|The second experimental group will receive direct access to the mobile app of HSKA as well as automated supportive text messages based on PST.
10184477|NCT03754829|No Intervention|Control Group|The control group consists of a wait-list and for ethical reasons, participants in this group will gain access to the intervention (either web or mobile application) four months after the baseline.
9519678|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
9519679|NCT03284593||Azacitidine group|patients treated with azacitidine
9519680|NCT03284580|Experimental|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
9969486|NCT01290575|Active Comparator|Arm 5 BMS-820132 or placebo|
9969487|NCT01290575|Active Comparator|Arm 6 BMS-820132 or placebo|
9969488|NCT01290575|Active Comparator|Arm 7 BMS-820132 or placebo|
9969489|NCT01290575|Active Comparator|Arm 8 BMS-820132 or placebo|
9969490|NCT01290575|Active Comparator|Arm 9 BMS-820132 or placebo|
9969491|NCT01290588||Children of Caucasian descent|Healthy children of Caucasian descent.
10138584|NCT04215159|Experimental|Samfenet and Treatment of physician's choice|"Samfenet : 1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.~Treatment of physician's choice (Gemcitabine or Irinotecan)~Gemcitabine : 1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.~Irinotecan : 100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks."
10138585|NCT04215341|Experimental|1|The study contains a single arm. All children participating in the study will receive the primary intervention which is physiotherapy.
10138586|NCT04215172||macrolides group|"Every patient of this group will be educated and instructed about usage, dosing and side effects of the drug.~Dose: azithromycin 500 mg three times weekly for 6 months. added to the conventional treatment."
10138587|NCT04215172||conventional group|Every patient of this group will receive the conventional treatment.
10138588|NCT04215523||Dapagliflozin|Exposure group
10138589|NCT04215523||DPP-4 inhibitor|Reference group
10138590|NCT04215510|Experimental|endonasal endoscopic surgery group|143 participants in group 1 will undergo endoscopic surgery
10138591|NCT04215510|Active Comparator|radiation therapy group|143 participants in group 2 will undergo radiation therapy(IMRT)
10138592|NCT04215445|Active Comparator|Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
10138593|NCT04215445|Active Comparator|Non-Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
10138594|NCT04215250|Active Comparator|Andropulous method|"Andropulous method uses equations to determine the depth of CVC insertion.~For subject with <100 cm in height:~Depth of CVC insertion (cm) = (height (cm)/ 10)-1~For subject with >100 cm in height:~Depth of CVC insertion (cm) = (height (cm)/ 10)-2"
10138595|NCT04215250|Active Comparator|ECG method|change in p wave from ECG
10138596|NCT04215380|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form as 30-grams-dose for 12 weeks
10138597|NCT04215380|Placebo Comparator|Control group|This group will be provided with pectin powder provided as two-gram-dose fo
10138598|NCT04215432|Experimental|Test group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water, Propolis Extract (2%), Ascorbic Acid (0.2%) and Tocopherol Acetate (0.2%).
10138599|NCT04215432|Placebo Comparator|Placebo group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water and E155/151 coloring.
10138600|NCT04215302||laryngeal mask size|laryngeal mask size determines according to weight measurement
10138601|NCT04215276|Active Comparator|Valsalva Maneuver|Patient will do valsalva maneuver for 20 seconds
10138602|NCT04215276|Placebo Comparator|control|Patient will do nothing
10138603|NCT04215094||infected group|Intracranial infection were diagnosed according to the Centers for Disease Control (CDC) definitions
10138604|NCT04215094||non-infected group|the postoperative recovery was uneventful with no infection
10138605|NCT04215081|Experimental|ExoAtlet II Safety and Efficacy|20 participants with paraplegia from SCI will participate in gait training using ExoAtlet II powered exoskeleton.
10138606|NCT04215263||Geriatric patient underwent general anesthesia procedure|geriatric patients (≥60 years) ware assessed for cognitive impairment after general anesthesia for non-neurologic noncardiac surgery.
10138607|NCT04215237|Other|Atorvastatin regulates intestinal flora|
10138608|NCT04214938|Active Comparator|Hypertonic sea water|The patient was applied intranasal hypertonic sea water (3.5% sodium chloride) before the nasoendoscopy procedure.
10138609|NCT04214938|Active Comparator|Lidocaine|The patient was applied intranasal Vemcaine as TLA (10% lidocaine; AstraZeneca, Södertälje, Sweden) before the nasoendoscopy procedure.
10138610|NCT04214938|Active Comparator|Xylometazoline|The patient was applied intranasal Otrivine (0.1% xylometazoline hydrochloride, GlaxoSmithKline, Brentford, UK ) before the nasoendoscopy procedure.
10138611|NCT04214938|Placebo Comparator|0.9% Sodium chloride|The patient was applied intranasal placebo (0.9% sodium chloride) before the nasoendoscopy procedure.
10138612|NCT04214990|Active Comparator|Aspirin|Enteric coated aspirin
10138613|NCT04214990|Placebo Comparator|Placebo|Enteric coated aspirin placebo
10138614|NCT04214886|Experimental|CAR 5 x 105 transduced T cells/kg (Dose Level -1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 5 x 105 transduced T cells/kg.
10138615|NCT04214886|Experimental|CAR 1 x 106 transduced T cells/kg (Dose Level 1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1 x 106 transduced T cells/kg.
10138616|NCT04214886|Experimental|CAR 1.5 x 106 transduced T cells/kg (Dose Level 2)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1.5 x 106 transduced T cells/kg.
10138617|NCT04214886|Experimental|CAR 2 x 106 transduced T cells/kg (Dose Level 3)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 2 x 106 transduced T cells/kg.
10187730|NCT03723252|Placebo Comparator|Placebo group|Participants will receive placebo po qd.
10138618|NCT04215055|Active Comparator|study group|Group I (study group); children receiving intraoral injection of local anasethia using the vibration assisted syringe.
10138619|NCT04215055|Active Comparator|control group|Group II (control group): children receiving intraoral injection of local anasethia using the standard syringe.
10138620|NCT04215042|Active Comparator|Standard hydration|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and 6 hours after procedure
10138621|NCT04215042|Experimental|Short hydration|All patients received shot intravenous saline hydration (3 ml/kg for 1 hour before the procedure and after 1ml/kg/h for 6 hours)
10138622|NCT04214977|Experimental|group S|Patients in group S had spinal anesthesia in the sitting position under complete aseptic technique through a standard mid-line approach. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
10138623|NCT04214977|Experimental|group L|Patients in group L received standard general anesthesia. Proper (weight-based) classic laryngeal mask airway was then blindly inserted.
10138624|NCT04215029|Experimental|Group I (exercise plan, coaching calls, nutrition counseling)|Patients and their partners receive an exercise plan and printed materials that includes instructions for walking or other moderate-intensity activities. Patients and their partners also receive coaching calls discussing physical activity and diet related questions, each lasting 45-60 minutes and occurring every 2 weeks for 6 months. In addition, patients and their partners complete 2 nutrition counseling sessions over 1 hour each at baseline and before month 3 with an MD Anderson registered dietitian.
10138625|NCT04215029|Active Comparator|Group II (physical activity/healthy eating information)|Patients and their partners receive information/materials regarding physical activity and healthy eating.
10138626|NCT04215029|Experimental|Provider Interviews (interviews)|Healthcare providers participate in an interview regarding their opinions on family-focused care and its ability to improve health behaviors.
10138627|NCT04214847|Experimental|polypropylene plate of Ahmed Glaucoma Valve|polypropylene plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The polypropylene plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
10138628|NCT04214847|Active Comparator|silicone plate of Ahmed Glaucoma Valve|silicone plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The silicone plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
10138629|NCT04214912|No Intervention|General module|"General module will serve as a roadmap plan which will cover the most common problems and major issues related to current and future treatments, side effects, psychological distress, daily function and physical condition. The contents will be developed based on empirical review, our current research findings in Taiwan, OC health care experts' suggestions."
10138630|NCT04214912|Experimental|Personalized module|Personalized Survivor Care Plan (PSCP) will deliver based on what we assess or interview about patients' distress, concerns and care needs in each interview or/and assessment. We will assess OC patients of the above items by valid assessment tools. For the factors or concerns about RTW assessment, we will develop and test a modified instrument for the study purpose. For each assessment, the computer -assisted assessment will help the OC educator to immediately catch the patients care distress and care needs. It will provide the direction for caring of their personalized distress, concerns and needs.
10138631|NCT04214821|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138632|NCT04214821|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138633|NCT04214821|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138634|NCT04214821|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection
10138635|NCT04214821|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138636|NCT04214821|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138637|NCT04214821|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138638|NCT04214821|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138639|NCT04214769||Head and Neck Cancer patients|
10138640|NCT04214808|Experimental|Avodart Soft Capsule 0.5mg to AD-208|Period 1: Avodart Soft Capsule 0.5mg, 1 Capsule Period 2: AD-208, 1 tab
10138641|NCT04214808|Experimental|AD-208 to Avodart Soft Capsule 0.5mg|Period 1: AD-208, 1 tab Period 2: Avodart Soft Capsule 0.5mg, 1 Capsule
10138642|NCT04214925|Experimental|Group of Tai Chi intervention|Tai Chi exercise program will create by selecting the first-basic 10 forms from 24 short forms of Yang style. The forms' name: Beginning, Parting the Horse's Mane, Stork Spreading Its Wings, Brushing Your Knees and Stepping, Playing The Pipes, Fending Off the Monkey, Grasping the Sparrow's Tail Left, Grasping the Sparrow's Tail Right, Simple Whip, Moving Hands Like Clouds-Conclusion. All forms will be completed at 10 weeks. Each session will take 1 hour (15 min for warming up exercises, 30 min of Tai Chi forms, and 15 min for cooling down exercises). The 14 patients of SS in this group will be divided into two groups of 7.
9826080|NCT02406742|Experimental|CC-122 in combination with ibrutinib|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and ibrutinib to determine the NTD, MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee. The RP2D of the combination may be evaluated in ibrutinib-naïve and high-risk CLL patients in the dose expansion phase to continue to evalute safety and efficacy.
10138643|NCT04214925|Other|Group of home exercises|The home exercise group will receive a one-hour home program, 2 days a week. The first and last 15 minutes of the exercise program will consist of warm-up and cooling- down exercises. After warm-up exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles will be performed 10 times each for 30 minutes.
10138644|NCT04214782|No Intervention|Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images without the help of Artificial Intelligence (AI) algorithm
10138645|NCT04214782|Experimental|AI enabled Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images with the help of Artificial Intelligence algorithm
10138646|NCT04214665|Experimental|Test/Reference|Single dose of test tablet in period I. Followed by single dose of reference tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
10138647|NCT04214665|Experimental|Reference/Test|Single dose of reference tablet in period I. Followed by single dose of test tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
10138648|NCT04215016|Experimental|Humanized anti-CD19 and anti-CD20 dual specific CAR-T cells|
10138649|NCT04214834|Active Comparator|Rapid-wean|15% decrements from the stabilization dose of morphine/methadone
10138650|NCT04214834|Active Comparator|Slow-wean|10% decrements from the stabilization dose of morphine/methadone
10138651|NCT04214704|Experimental|Genteel arm|In the Genteel arm, the subjects exclusively use the Genteel device for the first 12 weeks, and then switch to the conventional method of SMBG for an additional 12 weeks. This arm will use Butterfly Touch Lancets (BTL) throughout the study.
9969492|NCT01290588||Adults of Caucasian descent|Healthy adult eyes of Caucasian descent.
10138652|NCT04214704|Active Comparator|Conventional arm|In the Conventional arm, the subjects use the conventional method of SMBG for the first 12 weeks and then switch to the Genteel device for an additional 12 weeks. This arm will use the lancet and lancing device which they were using prior to randomization to the study.
10138653|NCT04214795||Infants born after a complete course of antenatal steroids.|Preterm Infants born with less than 32 w GA whose mothers had received a complete course (two doses of celestone in the period between 24 hours and 7 days before delivery.
10138654|NCT04214795||Infants born without a complete course of antenatal steroids|Preterm Infants born with less than 32 w GA whose mothers did not received any dose of celestone or an uncompleted course (less than 24 hours or more than 7 days from delivery).
10138655|NCT04214626|Experimental|R-CHOP regimen Combined With Lenalidomide|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.~PS: Methotrexate, 3mg/m2, Intravenous administration on day 3 of each 3-week cycle, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.~Maintenance Treatment: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 4 weeks, up to 2 cycles; Lenalidomide, 10mg oral administration on day 1 to 21 repeated every 4 weeks, up to 12 cycles."
10138656|NCT04214678|Experimental|Underwater clip closure|The post-resection defect is closed using endoscopic clips with underwater technique
10138657|NCT04214678|Active Comparator|Conventional clip closure|The post-resection defect is closed using endoscopic clips with conventional gas insufflation (CO2)
10138658|NCT04214574|Experimental|Real time ultrasound-guided Parasagittal oblique technique|
10138659|NCT04214574|Experimental|Real time ultrasound-guided paramedian tranverse technique|
10138660|NCT04214496||Postoperative Delirium Risk Patients|Preoperative cognitive function testing- EEG monitorization during surgery - Postoperative function testing
10138661|NCT04214561||SB group|Patients diagnosed with SB.
10138662|NCT04214561||Healthy controls|Patients without diagnosed SB.
10138663|NCT04214327|Active Comparator|Strengthening Families Program Online eLearning Game|This arm of the study receives a 10-session online family-based intervention with separate, but intersecting, tracks for parents and youth. Each lesson contains 3 mini-lessons per week and includes behavioral skills training and interactive multimedia lessons with video vignettes that target parenting skills, family cohesion, organization, communication, social skills, and drug prevention for youth. The youth track is highly gamified to stimulate engagement and reinforce the core active ingredients. There are self-correcting quizzes to assess learning, and process evaluation to determine program fidelity and engagement. There are learning theory instructional design elements with scaffolding, stealth learning, and theoretical principles of social learning, social interactional, and family systems theory. There is a highly animated game families can play upon successful completion of each lesson, using game points they earned through quizzes and practices. There is a 3-month follow-up.
10138664|NCT04214327|Active Comparator|SFP Home-use DVD/video series|"This arm of the study receives an 11-session home-use DVD or coupon code for viewing the SFP videos online at home that contains the same SFP skills and lesson content as the online condition. However, the lesson material is not animated and involves simply viewing the videos at home. This arm represents an attention-control condition as the requirements of participation and exposure to the intervention will match the online condition, as participants use the Internet or a DVD player to view lesson material in a self-paced format. There are no differences in recruitment for this condition; all assignment to experimental conditions is based on their recruiter's location using a randomized control trial design. Participants in this condition will be provided a hyperlink URL to answer pre- and posttest assessments and at the 3-month follow-up. Process evaluation materials will be delivered via a hyperlink to a commercial survey vendor during the trial and at the conclusion."
10138665|NCT04214327|Active Comparator|Wait-Listed Control|"This arm of the study receives no active intervention for the initial intervention period of 22 weeks; however, following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention. During the initial trial of 22 weeks, participants in this condition receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. The intent of these weekly emails is to stimulate continued participation and reduce attrition.~Individual families will be randomly assigned to one of the three interventions with a computerized random number generator."
10138666|NCT04214327|No Intervention|SFP Group Norms|This arm of the study provides a means to conduct a non-inferiority trial contrasting the active intervention conditions (SFP Online and Home-use DVD/videos) to the traditional 14-session in-person group-delivery format, which serves as a benchmark of effectiveness for SFP. There is no data collection as the Group Norms are part of an existing database of families that already took SFP classes. All effect size comparisons are conducted using secondary data analysis. The expected margin of equivalence is set at 10% so that any condition that exceeds another in the magnitude of effect size is considered as 'good as' the comparison condition. All effect sizes will be adjusted for demographic and site-specific factors to control for clustering and within-site contextual factors that can influence program outcomes.
10138667|NCT04214171||group 2 years|The group underwent total hip arthroplasty at 2 years
10138668|NCT04214171||group 5 years|The group underwent total hip arthroplasty at 5 years
10138669|NCT04214171||group 10 years|The group underwent total hip arthroplasty at 10 years
10138670|NCT04214171||group control|healthy patients
10138671|NCT04214223||PANE -> PAC|First, the patient carry out her Pre-Anesthesic Numerical Evaluation and then she benefits from her Pre-Anesthesic Consultation.
10138672|NCT04214223||PAC -> PANE|First, the patient benefits from her Pre-Anesthesic Consultation and then, she carry out her Pre-Anesthesic Numerical Evaluation
10138673|NCT04214184|Experimental|Increased Sleep Duration Intervention|Following baseline assessments, participants will complete a 4-week increased sleep duration intervention followed by one night of sleep in the lab on this increased sleep duration schedule. In the morning, participants will have blood collected for metabolomics analyses and complete oral glucose tolerance testing
10138674|NCT04214210|Experimental|Tailored Family Gene Toolkit|"The tailored FGT will include 5 modules designed to increase knowledge of cancer genetics (1); provide decisional support for genetic testing (2); increase active coping to challenges faced by HBOC families (3); provide a 5-steps, skills-building communication training (4); and provide information about management of hereditary cancer risk (5).~Messages will involve shallow tailoring (e.g. sex of mutation carrier), and deep tailoring with complex elements of relevance (e.g. coping style). Tailoring will be based on personalization, tailored feedback, and content matching, based on Swiss and Korean languages and legislation, health insurance policy, and cultural values.~Participants will be asked to complete the 5 modules within 4 weeks after they first engage with the intervention. The 4-week interval will enable learning new information while having time to reflect and act. They will receive email alerts to complete the 5 modules with the URL link directing them to the FGT."
10138675|NCT04214210|Active Comparator|Targeted intervention|The comparator will provide targeted information about HBOC and enable sharing genetic test results. The Korean team will define the contents of the comparator that will mimic the structure and function of an existing website, already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and the three Swiss national languages. Both trial arms the tailored and the targeted platform will be technically implemented in the same system, in order to track access and usage of the platform and provide a user-friendly experience to participants. The Swiss team will also provide the implementation of the comparison website.
10138676|NCT04214353|Experimental|Experimental arm|Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
10138677|NCT04214197|Other|Crisaborole|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
9519681|NCT03284580|Experimental|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
9519682|NCT03284580|Other|Control or conservative group|A conservative intervention by general information for caregivers
10138678|NCT04214275|Experimental|intervention group|standard care and participated in a pulmonary rehabilitation program
10138679|NCT04214275|No Intervention|control group|received standard care after coronary artery bypass graft
10138680|NCT04214366|Experimental|Carbon Ion irradiation|22 x 3 Gy(RBE) Carbon Ions
10138681|NCT04214366|Active Comparator|Bimodal Arm|25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost
10138682|NCT04214145|Experimental|Phenylephrine|
10138683|NCT04214145|Experimental|Norepinephrine|
10138684|NCT04214145|Experimental|Vasopressin|
10138685|NCT04214470||Irritable Bowel Syndrome Patients|Patients with IBS.
10138686|NCT04214314||Control|The control group will continue to receive the integral rehabilitation provided by the center.
10138687|NCT04214314||Experimental|The participants of the experimental group, in addition to the integral rehabilitation of the center will receive the training of the attention through NeuronUp APT. There will be 3 rehabilitation sessions of one hour a week for about a month and a half or two.
10138688|NCT04214431|Experimental|Mindfulness-Based Childbirth Education|Women in the experimental group received eight week mindfulness-based childbirth education program delivered one class each week.
10138689|NCT04214431|No Intervention|Control group|Women in the control group received standardized care.
10138690|NCT04214548||Eczema|Patients diagnosed with eczema
10138691|NCT04214483||Diagnosis of Acne|Patients who have been diagnosed with acne, subdivided into the various types.
10138692|NCT04214522||Acute stroke patients|Acute stroke patients
10138693|NCT04214535|Experimental|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Cervical Cage at one or two-levels
10138694|NCT04214236|Experimental|ciNPT group|Subjects will receive post-operative incisional wound care by ciNPT (125 mmHg, continuous suction) for the first 7 days after surgery.
10138695|NCT04214236|Sham Comparator|Control group|Subjects will receive post-operative incisional wound care by standard non-adherent surgical dressing (vaseline petrolatum gauze),
10138696|NCT04214301|Experimental|BLI800|BLI800
10138697|NCT04214457||Myometrial tumor with suspected leiomyosarcoma|Women between 18 and 75 years of age diagnosed with a myometrial tumor (probably leiomyoma) with suspected leiomyosarcoma
10138698|NCT04214509||PD + LRRK2|Patients with LRRK2-associated Parkinson's syndrome
10138699|NCT04214509||no PD + LRRK2|Participants with LRRK2-mutations but without Parkinson's symptoms
9826081|NCT02406742|Experimental|CC-122 in combination with obinutuzumab|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and obinutuzumab to determine the , MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee.. The RP2D of the combination may be evaluated in CLL patients who failed a B-cell receptor pathway inhibitor or venetoclax in the dose expansion phase to continue to evalute safety and efficacy.
9969493|NCT01290588||Children of African-American descent|Healthy children of African-American descent.
10138700|NCT04214509||no PD + no LRRK2|Participants without mutations and without Parkinson's symptoms
10138701|NCT04214509||PD+ other than LRRK2|Parkinson patients with mutations in other genes than LRRK2
10138702|NCT04214509||PD+ no LRRK2|Patients with idiopathic Parkinson's disease
10138703|NCT04214158||Professional Folk Dancers|Individuals who have been actively dancing for at least two years will be included in the study.
10138704|NCT04214158||sedentary|According to the international physical activity questionnaire, individuals with low levels of physical activity will be included in the study.
10138705|NCT04214444|Active Comparator|Single-dose before treatment|12 patients will receive a single-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection
10138706|NCT04214444|Active Comparator|Single-dose after treatment|12 patients will receive a singe-dose of prevenar three weeks after the beginning of the immunochemotherapy (R-CHOP) following two months later by pneumovax injection
10138707|NCT04214444|Experimental|Double-dose before treatment|12 patients will receive a double-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection.
10138708|NCT04214379|Other|severe congenital ptosis|Patients with severe congenital ptosis with poor levator muscle function
10138709|NCT04214015||Patients with metastatic mesothelioma|Patients who have been diagnosed with metastatic mesothelioma
10138710|NCT04213950|Experimental|Post-implementation group|The post-implementation group will receive care that is enhanced by the rabies PEP quality improvement bundle.
10138711|NCT04213950|No Intervention|Historical control group|The historical control group received care prior to implementation of the quality improvement bundle.
10138712|NCT04214106||Thiamine group|group 1: ICU patients who did not receive IV thiamine
10138713|NCT04214106||Non-thiamine group|group 2: ICU patients who received IV thiamine,100-500 mg/day for at least one day
10138714|NCT04213924|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
9969494|NCT01290588||Adults of African-American descent|Healthy adults of African-American descent.
10138715|NCT04213924|Active Comparator|Group NSAII|lidocaine 5% gel and 800 mg ibuprofen intravenously
10138716|NCT04213872|Experimental|Meditative Movement (MM)|The Meditative Movement (Qigong/Tai Chi Easy) program will be 8 weeks in duration with sessions once a week. Each session is approximately one hour. The PI will lead the MM sessions. The PI and the CRC will maintain contact with the MM group during the 8 weeks by telephone or in person.
10138717|NCT04213937|Experimental|nab-paclitaxel|nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles
10138718|NCT04213937|Active Comparator|Topotecan|Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
10138719|NCT04213846|Experimental|Mobile Alcohol Expectancy Challenge (mAEC)|Participants randomized to the mAEC condition will receive twice daily intervention messages for three weeks and have access to other psycho-educational alcohol information.
10138720|NCT04213846|No Intervention|Assessment-only Control|Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.
10138721|NCT04214054|Experimental|Moldable self-hardening biphasic calcium phosphate graft|Easy graft, a moldable osteocondutive allograft formed of 60% hydroxylapatite and 40% β-tricalcium phosphate (Easy-graft, Sunstar, Gruidor, Degradable solutions AG, Swizerlard).
10138722|NCT04214054|Placebo Comparator|No graft material|
10138723|NCT04213898|Experimental|SHR-1210+Albumin-bound paclitaxel+Epirubicin|Neoadjuvant therapy：SHR-1210+Albumin-bound paclitaxel+Epirubicin
10138724|NCT04213976||Ileostomy in continuity|Paediatric patients having had an ileostomy in continuity as part of the treatment for a complex intestinal obstruction, as described by Santulli or by Bishop-Koop.
10138725|NCT04213976||Conventional ileostomy|Paediatric patients having had a loop ileostomy as part of the treatment for a complex intestinal obstruction.
10138726|NCT04213911||Morbid obese|BMI>40 kg/m2
10138727|NCT04213911||Non-obese|BMI<30 kg/m2
10138728|NCT04213833|Placebo Comparator|group I (control group)|patients will receive propofol 50 mg
10138729|NCT04213833|Active Comparator|group II|patients will receive propofol 50 mg + dexmedetomidine 0.5 mcg/ kg
10138730|NCT04213833|Active Comparator|group III|patients will receive propofol 50 mg +15 g palatable lidocaine gel
10138731|NCT04213781|Other|Usual care|Sedation according to Dixon's up-and-down method.
10138732|NCT04213781|Experimental|Audiovisual distraction|Audiovisual distraction using HappyMed Video Glasses during procedure. Sedation according to Dixon's up-and-down method.
10138733|NCT04214041|Experimental|Autologous fat grafting|
10138734|NCT04214041|Active Comparator|Sub-epithelial connective tissue graft|
10138735|NCT04214132|Experimental|virtual patients group|Only nursing undergraduates from AY2017/2018 cohort, who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module will receive additional training using Virtual Patients in each semester (2 semesters per year) of year 2 and year 3 before they go for the clinical posting. Students will have unlimited access to the Virtual Patients (available scenarios depend on which semester the student is in) by logging in through the school portal.
10138736|NCT04214132|No Intervention|Blended learning group|Nursing undergraduates from AY2016/2017 cohort who who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module that comprised of weekly online e-lectures and face-to-face tutorials.
10138737|NCT04213885|Experimental|Pulsed Accelerated|30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
10138738|NCT04213885|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
10138739|NCT04213755||patients with risks of intraoperative massive bleeding|patients with risks of intraoperative massive bleeding
10138740|NCT04213859|Experimental|Virtual Reality Exposure Therapy (VRET)|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~nd stage: During the week prior to treatment, participants will complete a brief measure of emotion-related variables every evening at a fixed time (08:00 pm).~rd stage: Participants will receive therapy for fear of flying using a Virtual Reality (VR) simulator. Therapy sessions will be held once a week during 4 weeks. Participants will complete a brief measure of emotion-related variables at a random time during the 12 hours before the therapy session at a random time during the 12 hours after the therapy session. This will occur for every therapy session.~th stage: After treatment, participants will complete measures of fear of flying and emotional variables."
10138741|NCT04213859|No Intervention|control|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~nd stage: During five weeks no therapy will be administered. Participants will fill questionnaires as follows: During the first week, participants will complete emotional measures every evening at a fixed time (08:00 pm)~rd stage: During each of the following 4 weeks, participants will complete two emotional measures during a 24 hour period.~th stage: Participants will complete measures of fear of flying and emotional variables."
10138742|NCT04213742|Active Comparator|Gratitude diary|
10138743|NCT04213742|No Intervention|No intervention|
10138744|NCT04213742|Active Comparator|Gratitude visit|
10138745|NCT04213768|Experimental|Plication|
10138746|NCT04213768|Active Comparator|Resection|
10138747|NCT04213508|Active Comparator|Isotonic saline with frequency of 2 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
9969495|NCT01290653|Experimental|Dry Needling of trigger point|Deep dry needling will be applied on the upper trapezius myofascial trigger point
10138748|NCT04213508|Active Comparator|Hypertonic saline with frequency of 2 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
10138749|NCT04213508|Active Comparator|Isotonic saline with frequency of 5 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
10138750|NCT04213508|Active Comparator|Hypertonic saline with frequency of 5 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
10138751|NCT04213638|Experimental|Group：1|Intervention: Other：Single Microneedle Radiofrequency therapy
10138752|NCT04213638|Active Comparator|Group：2|Intervention: Other：Photodynamic therapy
10138753|NCT04213443||Women of short stature|Women that are under 1.6 meters.
9969496|NCT01290653|Experimental|Strain-counterstraing technique|This manual technique will be applied at the upper trapezius.
10138754|NCT04213378|Experimental|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent restenosis with paclitaxel eluting PTCA balloon
10138755|NCT04213378|Active Comparator|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent restenosis with SeQuent® Please paclitaxel eluting balloon
10138756|NCT04213716|Experimental|intracanal medication|After instrumentation of the canals and drying , using Lentulo Spiral Filler medicaments will be placed under aseptic conditions into the canals experimental Intracanal medication of 1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
10138757|NCT04213716|Active Comparator|intracanal medicament|After instrumentation of the canals and drying , using Lentulo Spiral Filler comparator intracanal medicaments will be placed under aseptic conditions into the canals which is 100 mg Ca (OH) 2 mixed with 1ml sterile water
10138758|NCT04213469|Experimental|Quikin CD19-CART|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine 4-6 days before CART infusion. A dose of Quikin CD19-CART will be infused on day 0.
10138759|NCT04213586|Experimental|Whey Protein|Each participant will be supplemented with whey protein (7 d/wk) during 10 weeks.
10138760|NCT04213586|Experimental|Leucine-matched collagen|Each participant will be supplemented with collagen (7 d/wk) during 10 weeks.
10138761|NCT04213703||Patients with Epidermolysis Bullosa|Patients who have been diagnosed with Epidermolysis Bullosa
10138762|NCT04213664||non-metastatic renal cell carcinoma|Pretreatment lymphocyte to monocyte ratio in non-metastatic patients with renal cell
10138763|NCT04213612|Experimental|PLD+CTX+VCR|CTX 1g/m2/d，D1-2 VCR 1.5mg/m2，D1
10138764|NCT04213625|No Intervention|Control Group|Information sheet with only their surgeon's educational background.
10138765|NCT04213625|Experimental|Intervention|Experimental group will receive an information sheet with their surgeon's educational and personal background.
10138766|NCT04213651||Diabetes Mellitus|Patients with diabetes mellitus
10138767|NCT04213599||Anterior infarction|Patients with anterior ST-elevation myocardial infarction
10138768|NCT04213599||Inferior infarction|Patients with inferior ST-elevation myocardial infarction
10138769|NCT04213599||Lateral infarction|Patients with lateral ST-elevation myocardial infarction
10138770|NCT04213521|Experimental|Multisensory balance training group|The participants in the multisensory balance training group were provided with multiple-sensory balance exercises using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system-postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
10138771|NCT04213521|Active Comparator|Conventional balance training group|The participants in the Conventional balance training group performed conventional balance exercises, such as static and dynamic standing balance without altered sensory inputs.
10184478|NCT03754816|Experimental|Experimental group|The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
10184479|NCT03754803||Treatment naïve subjects with HIV infection|Treatment naïve HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included
10184480|NCT03754803||Pre-treated subjects with HIV infection|Pre-treated HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included.
10184481|NCT03754777|Experimental|Modified ERAS protocol group|"Laparoscopic appendectomy with modified ERAS protocol group Preadmission. Not available due to the emergency setting. Preoperative care.~1) Patient brochure with a detailed description of the type of pathology, surgery procedure, rehabilitation process, possible complications, and other.~Surgery.~Low pressure (8-9 mmHg) pneumoperitoneum.~Routinely remove of appendix mesentery in presence of any signs of its inflammation.~Additional local anesthesia with 0.25% ropivacaine.~Abdominal cavity draining only in patients with perforated appendicitis and diffuse peritonitis (Gomes 5).~Postoperative care.~Early mobilization (2 h after surgery)~Early fluid intake (2 h after surgery)~Early liquid food (6 h after surgery)"
10184482|NCT03754777|Placebo Comparator|Standard care group|"Standard care laparoscopic appendectomy. Preadmission. Not available due to emergency setting. Preoperative care. 1) Patient oral informing about the type of pathology, surgery procedure and possible complications. No brochure.~Surgery.~Standard pressure (12-14 mmHg) pneumoperitoneum~Abdominal draining for patients with perforated and not perforated appendicitis complicated by abscess, local or diffuse peritonitis (Gomez ≥ 3A).~Appendix mesentery removing in the appearance of its necrotic changes.~No intraabdominal anesthesia. Postoperative care.~1) Mobilization in 4-6 h after surgery 2) Fluid intake in 6 hours 3) Liquid food intake in 12 hours"
10184483|NCT03754751|Experimental|Modified ERAS program group|Laparoscopic cholecystectomy with the implementation of modified ERAS program
9969497|NCT01290653|Placebo Comparator|Placebo manual technique|A technique simulating strain-counterstrain, but without any therapeutic manoeuvre will be applied at the upper trapezius site.
10184484|NCT03754751|Active Comparator|Conventional care group|Laparoscopic cholecystectomy with standard perioperative treatment
10184485|NCT03754738|Experimental|Balloon guide catheter group|mechanical thrombectomy with a balloon guide catheter group
10184486|NCT03754738|Active Comparator|Non-balloon guide catheter group|mechanical thrombectomy with a non-balloon guide catheter group
10184487|NCT03754712|Active Comparator|Intervention Vitamin D3 along with SSRIs|One tablet of vitamin D3 (2000IU) per day for 8 weeks
10184488|NCT03754712|No Intervention|SSRIs|Patients treated with SSRIs
10184489|NCT03754686|Active Comparator|Oseltamivir|best medical care and oral oseltamivir 75 mg twice daily for five days.
10184490|NCT03754686|Active Comparator|Paracetamol|best medical care and oral paracetamol twice daily for five days.
10184491|NCT03754647|No Intervention|Patients receiving SSRIs|This group will be receive SSRIs only
10184492|NCT03754647|Active Comparator|Patients receiving Vitamin C with SSRIs|This group will be receive vitamin C (500mg) twice daily with SSRIs for 8 weeks
10184493|NCT03754634|Experimental|drugs|Eltrombopag and Diacerein
10138772|NCT04213495||Patients undergoing anesthesia in Czech Republic|Patients undergoing anesthesia in Czech Republic in the selected period from the confirmed Anesthesia Center
10138773|NCT04213170|Experimental|Sintilimab and Bevacizumab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 every 21 days
10138774|NCT04213482||oncology patients|For this study, panoramic images were taken from pediatric patients who received radiotherapy and/or chemotherapy because of any oncologic disease.
10138775|NCT04213482||healthy|panoramic images of patients(pediatric) who have no systemic disease were collected from the archive of dental radiology clinic of the university hospital.
10138776|NCT04213430||Training dataset|Retinal images collected from hospitals and multiple screening sites all over China
10138777|NCT04213430||Validation dataset|Retinal images separated from training dataset
10138778|NCT04213430||Testing dataset|Retinal images prospectively collected from the hospitals and ocular disease screening sites totally different from training dataset
10138779|NCT04213690||Patients with Lupus|Patients who have been diagnosed with Lupus
10138780|NCT04213560|Experimental|Weighted waist-hooping|Participants weighted waist-hooping on their own for ten minutes a day, four days a week, for six weeks resulting in a total of 40 minutes of weighted waist-hooping each week. Participants weighted waist-hooped with a three-pound weighted hula hoop at the waist for ten minutes. Half time hooping to the left and the other half hooping to the right. If discomfort while hooping occurred participants were instructed to take breaks, change directions more frequently, or where thicker clothing to lessen the impact of the hoop around their waists. The investigators would check in on the participants weekly to provide feedback on technique and answer all questions throughout the six-week intervention.
10138781|NCT04213560|No Intervention|Control|No Intervention
10138782|NCT04213339|Experimental|Kegal Exercises|
10138783|NCT04213339|No Intervention|Control|
10138784|NCT04213573|Experimental|Group 1: topical application of silver diamine fluoride|38% silver diamine fluoride liquid
10138785|NCT04213573|Active Comparator|Group 2: topical application of MI varnish.|MI Varnish:5% sodium fluoride varnish which also contains RECALDENT™* (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate
10138786|NCT04213352|No Intervention|Control Group|The subjects will be asked to type on a computer for 5 minutes without splint or taping. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
10138787|NCT04213352|Experimental|Splint Group|The subjects will be asked to type on a computer for 5 minutes with a splint. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
10138788|NCT04213352|Experimental|Rigid Taping Group|The subjects will be asked to type on a computer for 5 minutes with rigid taping which limits the wrist flexion at the dominant side. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
10138789|NCT04213144|Experimental|Magdent Cap MED|Soft and hard tissue healing with electomagnetic healing abutment.
10138790|NCT04213144|Sham Comparator|Sham MED|Soft and hard tissue healing with a regular healing abutment.
10138791|NCT04213287|Experimental|Peri-Articular Injections and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine~At the end of surgery;~PAI: 30 ml 0,025% bupivacaine and~IPACK: 20 ml 0,025% bupivacaine"
10138792|NCT04213287|Active Comparator|Adductor Canal Block, and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine~At the end of surgery;~ADD: 20 ml 0,025% bupivacaine and~IPACK: 20 ml 0,025% bupivacaine"
10138793|NCT04213417|Experimental|Bobath therapy plus Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the Bobath therapy was applied to the affected side of the body and lower extremity for 60 minutes in each session.
10138794|NCT04213417|Active Comparator|Bobath therapy|Both groups were treated with the Bobath therapy as a neurodevelopmental therapy.
10138795|NCT04213235|Experimental|Physical exercise|
10138796|NCT04213196|Active Comparator|HSK21542 0.2 μg/kg（15 min)|Healthy volunteers 0.2 μg/kg HSK21542
10138797|NCT04213196|Placebo Comparator|HSK21542 0.5 μg/kg|Healthy volunteers 0.5 μg/kg HSK21542 or Placebo
10138798|NCT04213196|Placebo Comparator|HSK21542 1 μg/kg （15min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
10138799|NCT04213196|Placebo Comparator|HSK21542 1 μg/kg （2min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
10138800|NCT04213196|Placebo Comparator|HSK21542 0.75 μg/kg|Healthy volunteers 0.75 μg/kg HSK21542 or Placebo
10138801|NCT04213196|Placebo Comparator|HSK21542 1.5 μg/kg|Healthy volunteers 1.5 μg/kg HSK21542 or Placebo
10138802|NCT04213196|Placebo Comparator|HSK21542 2.25 μg/kg|Healthy volunteers 2.25 μg/kg HSK21542 or Placebo
10138803|NCT04213196|Placebo Comparator|HSK21542 3.375 μg/kg|Healthy volunteers 3.375 μg/kg HSK21542 or Placebo
10138804|NCT04213196|Placebo Comparator|HSK21542 0.2 μg/kg（2min)|Healthy volunteers 0.2 μg/kg HSK21542 or Placebo
10138805|NCT04213209||Brentuximab Vedotin 1.8 mg/kg (body weight)|The usual dosage for intravenous administration is 1.8 milligrams per kilograms (mg/kg) (body weight) as Brentuximab Vedotin (genetic recombination) once every three weeks (up to 12 months). The dose may be reduced appropriately according to the participant's condition. Participants receive interventions as part of routine medical care.
10138806|NCT04213183||development dataset 01|Slit-lamp and retinal fundus images collected from Department of Hepatobiliary Surgery of the Third Affiliated Hospital of Sun Yat-sen University.
10138807|NCT04213183||development dataset 02|Slit-lamp and retinal fundus images collected from Affiliated Huadu Hospital of Southern Medical University.
10138808|NCT04213183||development dataset 03|Slit-lamp and retinal fundus images collected from Nantian Medical Centre of Aikang Health Care.
10138809|NCT04213183||test dataset 01|Slit-lamp and retinal fundus images collected from Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University.
10138810|NCT04213183||test dataset 02|Slit-lamp and retinal fundus images collected from Huanshidong Medical Centre of Aikang Health Care.
10138811|NCT04213391|Experimental|sulforaphane group|The patients will take sulforaphane for 24 weeks, 2550mg once a day.
10138812|NCT04213391|Placebo Comparator|Placebo group|The patients will take placebo for 24 weeks, 2550mg once a day.
10138813|NCT04213118|Experimental|Group A|Administration anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
10138814|NCT04213131|Other|Rehabilitation control group|Routine rehabilitation treatment for chronic spinal cord injury and Intravenous injection of 100 mL 0.9% saline solution.
10138815|NCT04213131|Experimental|hUC-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUC-MSCs
10138816|NCT04213131|Experimental|hUC-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUC-MSCs and 5 mL of cerebrospinal fluid
10138817|NCT04213131|Experimental|hUC-MSCs local administration group|hUC-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUC-MSCs/point.
10138818|NCT04213131|Experimental|hUCB-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUCB-MSCs
10138819|NCT04213131|Experimental|hUCB-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUCB-MSCs and 5 mL of cerebrospinal fluid
10138820|NCT04213131|Experimental|hUCB-MSCs local administration group|hUCB-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUCB-MSCs/point.
10138821|NCT04213105|Experimental|QL1206|QL1206 injection (60mg) by subcutaneous injection once on the first day
10138822|NCT04213105|Active Comparator|Prolia®|Prolia® injection (120mg) by subcutaneous injection once on the first day
10138823|NCT04213092||ERCP+LC|Patients in this group underwent 2-stage ERCP+LC in a single setting. And, it was compared with our control group
10138824|NCT04213092||OC+CBD|This group with 2-stage OC+CBD exploration in a single setting approach was taken as a control group.
10138825|NCT04213274|Placebo Comparator|Placebo - placebo|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to treatment (SDAS = 0) one more dose of placebo
10138826|NCT04213274|Other|Placebo - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) subcutaneous single injection of 80 mg RPH-104
10138827|NCT04213274|Experimental|80 mg RPH-104 - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to the treatment (SDAS = 0) one subcutaneous injection of placebo
10138828|NCT04213274|Experimental|80 mg RPH-104 - 160 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) one more subcutaneous injection of 80 mg RPH-104
10138829|NCT04213313||Control Group|health volunteers
10138830|NCT04213313||Infectious Keratitis Group|Infectious corneal patients
10138831|NCT04212819|Experimental|Before erythrocyte suspension (ES) transfusion group|50 (Female/Male: 25/25) patients were included in this study. Total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients after diagnoses of anemia.
10138832|NCT04212819|Experimental|After erythrocyte suspension transfusion group|24 hours after ES transfusion, total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients.
10138833|NCT04212741|Experimental|A+ HA(tm)|20 ml oral solution of hyaluronic acid mixture in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
10138834|NCT04212741|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
10138835|NCT04212793|Experimental|NIR endoscopic TSS with 4.5 mg bevacizumab-800CW|IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
10138836|NCT04212793|Experimental|NIR endoscopic TSS with 10 mg bevacizumab-800CW|IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
10138837|NCT04212793|Experimental|NIR endoscopic TSS with 25 mg bevacizumab-800CW|IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
10138838|NCT04212871|Experimental|watch mukbang|"In the online study, participants were assigned to watch a ramen mukbang, by Yuka Kinoshita (https://youtu.be/ArPaid2Iuck, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a hotpot mukbang by Alun (https://youtu.be/QCTOo9UGZD8, accessed: 2018-11-29)."
10138839|NCT04212871|Experimental|watch another food content video|"In the online study, participants were assigned to watch a donut mukbang, by Yuka Kinoshita (https://youtu.be/ntMT2y0MgHk, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a hotpot cooking show by the Cat's kitchen (https://youtu.be/EH5Ei-sMP60, accessed: 2018-11-29)."
10138840|NCT04212871|Placebo Comparator|watch a non-food content video|"In the online study, participants were assigned to watch a silent documentary introducing the Palace Museum by China Central Television (CCTV) (https://youtu.be/hWnm1BQOTZY, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a video introducing Cornell University is used for the non-food content video (https://youtu.be/GuM8vTq0jd4, accessed: 2018-11-29)."
10138841|NCT04212832|Active Comparator|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block with 0.5 ml/kg % 0.25 bupivacaine
10138842|NCT04212832|Other|No intervention|Standard Pain Followup and Monitorization
9969498|NCT01290692|Experimental|TVI-Brain-1|All patients will receive the full TVI-Brain-1 treatment.
10138843|NCT04212754||Procedure: Emergency surgery for traumatic brain injury|
10138844|NCT04212845|Active Comparator|Group ESP|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine and 8 mg dexamethasone
10138845|NCT04212845|Active Comparator|Group TF|Fluoroscopy-guided transforaminal injection with 4 ml of 0.25% bupivacaine and 8 mg dexamethasone
10138846|NCT04212962|Experimental|Treatment group|The treatment group receives the TCM intervention while in the hospital and during the first 90 days after returning to the community.
10138847|NCT04212962|Experimental|Control group|The control group receives usual discharge planning and post-discharge care.
10138848|NCT04212949|Experimental|Repetitive transcranial magnetic stimulation following TESI|Active repetitive transcranial magnetic stimulation will be performed to the patients with lumbar radiculopathy who receive transforaminal epidural steroid injection.
10138849|NCT04212949|Active Comparator|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection will be applied to the patients with lumbar radiculopathy.
10138850|NCT04212858|Experimental|case|myeloma patients
10138851|NCT04212858|Experimental|control|healthy control
10138852|NCT04212897|Experimental|Music Therapy|This group will be asked to practice a rhythmic auditory SFT intervention task at home.
10138853|NCT04212897|No Intervention|No Music Therapy|This group will not engage in an intervention task at home and will be asked to continue their normal daily routine.
10138854|NCT04213066|Active Comparator|Control group|This group received eye-hand practice for drawing pictures.
10138855|NCT04213066|Experimental|Grating group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies.
10138856|NCT04213066|Experimental|Random dot group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies constructed by random dots of stochastic resonance.
10138857|NCT04212780|Active Comparator|Treatment Naive|Participants receiving Long-term stimulation of the thalamus via dual leads for Essential Tremor
10138858|NCT04212780|Active Comparator|Refractory Participants|Patients with recurrent, debilitating intention tremor despite ongoing, optimized VIM DBS therapy
10138859|NCT04212936|No Intervention|Control group|8 mmHg pressure group
10138860|NCT04212936|Experimental|Study group|10 mmHg group
10138861|NCT04212975|Experimental|group 1|lavage by dextrose
10138862|NCT04212767|Experimental|Test group|Post-extraction sockets covered with Platelet-Rich Fibrin membrane (n=16)
10138863|NCT04212767|No Intervention|Control Goroup|Post-extraction sockets left to spontaneous healing/clot and primary closure (n=16).
10138864|NCT04213001|Other|measure|circumference measure, ultrasonographic measure
10138865|NCT04213027|Active Comparator|SSLF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Sacrospinous ligament fixation (SSLF) .
10138866|NCT04213027|Active Comparator|ISFF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Ischial spinous fascia fixation (ISFF)
10138867|NCT04213040||Open-Heart Surgery for a six months duration|In a single group of patients including 146 patients undergoing openheart surgery during a period of six months, the collected parameters include; serum levels of procalcitonin, C-reactive protein, and lactate as well as postoperative complications and after this, depending on the development of postoperative complications or not in the intensive care unit patients were divided into two groups. The Group Without Complications, n=112, includes patients without a postoperative complication after open-heart surgery with cardiopulmonary bypass. The Group With Complications, n=34, includes patients with a postoperative complication after open-heart surgery with cardiopulmonary bypass.
10138868|NCT04213014|Experimental|Guys/Girls Opt for Activities for Life Intervention (GOAL)|Receives the 4 month (16-wk) GOAL intervention, which has 3 components: (1) After-school GOAL Club: 26 events (2 d/wk; 120 min/event/day; 13 wks due to no club during 3 school break wks) for boys and girls to engage in physical activity and healthy eating and cooking activities;5 (2) Three parent-adolescent meetings (group meetings at each school): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior wk.
10138869|NCT04213014|No Intervention|Control|Received usual school activities.
10138870|NCT04212715|Experimental|Experimental arm|SABR 35Gy/5 to prostate, up to 50Gy/5 to MR nodule, and 25Gy/5 to pelvic nodes and SVs
10138871|NCT04212689|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. Physiotherapy approaches include stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
10138872|NCT04212689|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
10138873|NCT04212676|Experimental|PR+BAT Group|In addition to the PR program, the BAT will be administered to the experimental group by a physiotherapist with 5 years of experience in BAT for 8 weeks.
10138874|NCT04212676|Active Comparator|PR Group|Patients in the control groups will receive a 30-minute Pulmonary Rehabilitation (PR) program every day of the week for 8 weeks.
10138875|NCT04212429|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138876|NCT04212429|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
9969499|NCT01290705|Experimental|high exercise|High dose, high repetition exercise therapy, 3 times weekly in 12 weeks
10138877|NCT04212429|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138878|NCT04212429|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138879|NCT04212429|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138880|NCT04212429|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138881|NCT04212429|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138882|NCT04212429|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 8-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
10138883|NCT04212507||1|50 psoriatic patients
10138884|NCT04212507||2|30 age and sex-matched healthy volunteers as a control group
10138885|NCT04212442|Experimental|Immediate Intervention|Upon enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
10138886|NCT04212442|Experimental|Wait-list Control|Two months after study enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
10138887|NCT04212416|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD for days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue leflunomide for an additional 6 cycles as long as response or stable disease is maintained.
10138888|NCT04212494|Experimental|Thrombus aspiration|Upfront manual thrombus aspiration followed by PCI
10138889|NCT04212494|Active Comparator|PCI Alone|PCI without upfront manual thrombus aspiration
10138890|NCT04212559||NPV group|Patients who had treated in pulmonary rehabilitation unit with NPV
10138891|NCT04212377|Experimental|exploratory|single arm exploratory, single-centre study
10138892|NCT04212663|Placebo Comparator|control|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release
10138893|NCT04212663|Experimental|experiment|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release+ The tendon release of musculi tibialis posterior
10138894|NCT04212325|Active Comparator|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
10138895|NCT04212325|Active Comparator|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the single injection at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
10138896|NCT04212338|Experimental|study group 1|Before intravitreal injection music intervention: These patients received the standard treatment and listened to music for a period of 15 minutes 30 minutes before the injection.
10138897|NCT04212338|Experimental|study group 2|During-intravitreal injection music intervention:These patients received the standard treatment and listened to music during the injection (approximately 5 minutes).
10138898|NCT04212338|No Intervention|control group|The music intervention was not conducted with the patients in the control group. These patients received the standard treatment.
10138899|NCT04212585||children with upper gastrointestinal symptoms|
10138900|NCT04212585||children without upper gastrointestinal symptoms|
10138901|NCT04212637|Experimental|Healthy Volunteers|MRI exam
10138902|NCT04212637|Experimental|Parkinson patient|MRI exam
10138903|NCT04212611|Experimental|Group L|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L)
10138904|NCT04212611|Experimental|Group R|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% ropivacaine (group R).
10138905|NCT04212351||Patients with NF1 and active LGGs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of low grade glioma but no clinical or radiographic evidence of plexiform neurofibroma.
10138906|NCT04212351||Patients with NF1 and active PNs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of plexiform neurofibroma but no clinical or radiographic evidence of low grade glioma.
10138907|NCT04212351||Patients with NF1 with no active LGGs or PNs|Patients with Neurofibromatosis Type 1 with no clinical or radiographic evidence of both active plexiform neurofibroma and active low grade glioma.
10138908|NCT04212650|Experimental|Losartan|12.5mg Losartan capsules, oral administration, twice daily (25mg total per day), taken for 30 consecutive days starting on the evening of the second post-surgery day.
10138909|NCT04212650|Placebo Comparator|Placebo|Appearance-matched placebo capsules, oral administration, twice daily, taken for 30 consecutive days starting on the evening of the second post-surgery day.
10138910|NCT04212403|Active Comparator|Control|The control groups receives antimicrobial prophylaxis (AMP) as recommended by the guidelines.
10138911|NCT04212403|No Intervention|Treatment group|The treatment group receives no AMP.
10138912|NCT04212481|Experimental|single port group|Uniport video-assisted thoracoscopic surgery for NSCLC
9969500|NCT01290705|Experimental|low exercise|low dose, low repetition exercise therapy, 3 times weekly in 12 weeks
9826082|NCT02406859|Experimental|Anorectal Manometry|Part 1 [Anorectal Manometry]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
9969501|NCT01290744|Placebo Comparator|Placebo group|These patients will receive placebo for 12 months after completion of MDT.
9969502|NCT01290744|Experimental|Clofazimine for 12 months after MDT|Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.
9969503|NCT01290770||obese men|obese men with chest pain like angina
9969504|NCT01290783|Active Comparator|FOLFIRI|
9969505|NCT01290783|Experimental|FOLF(HA)iri|
9969506|NCT01290809||Prophylactic Cranial Irradiation|NSCLC patients treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
9969507|NCT01290809||no Prophylactic Cranial Irradiation|NSCLC patients not treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
9969508|NCT01290835|Experimental|Stereotactic radiotherapy|Accelerated stereotactic radiotherapy as an adjuvant treatment for early stage breast cancer.
9969509|NCT01290848|Experimental|Township of Uxbridge|The Take TIME for Your Child's Health campaign will target parents and caregivers of children up to 8 years of age.
9969510|NCT01290848|No Intervention|Township of Guelph/Ermosa|For a control group the investigators have selected a community that is similar in size, household composition, population density, distance from Toronto and economic status to the Township of Uxbridge.
9969511|NCT01290861||pre-manifest HD|
9969512|NCT01290861||early manifest HD|
9969513|NCT01290861||healthy controls|
9969514|NCT01290900|Experimental|CXL104|2000 mg NXL104 + 1500 mg Ceftaroline (IV)
9969515|NCT01290900|Experimental|CAZ104|Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
10138913|NCT04212481|Active Comparator|two ports group|video-assisted thoracoscopic surgery for NSCLC using two ports
10138914|NCT04212481|Active Comparator|three ports group|video-assisted thoracoscopic surgery for NSCLC using three ports
9969516|NCT01290900|Active Comparator|Moxifloxacin|Moxifloxacin 400mg (1 tablet)
9969517|NCT01290900|Placebo Comparator|Placebo|Placebo Infusion (saline)
9969518|NCT01290926|Experimental|Capecitabine & Sorafenib|Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
9969519|NCT01290939|Experimental|Arm 1|Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be according to investigators discretion). In the absence of hematological toxicity > grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle.
9969520|NCT01290939|Active Comparator|Arm 2|Lomustine single agent 110 mg/m² every 6 weeks (cap. 200 mg) (at further progression treatment will be according to investigators discretion).
9969521|NCT01290965|Placebo Comparator|Placebo comparator|
9969522|NCT01290965|Active Comparator|SCY-635 30 mg once daily|
9969523|NCT01290965|Active Comparator|SCY-635 100 mg once daily|
9969524|NCT01290965|Active Comparator|SCY-635 300 mg once daily|
10138915|NCT04212533|Active Comparator|supplementation arm|43 patients undergoing total thyroidectomy received 40000 IU vit D and once before operation and 500mg calcium tab 4 times in the day before surgery
9969525|NCT01290965|Active Comparator|SCY-635 100 mg three times daily|
9969526|NCT01290965|Active Comparator|SCY-635 200 mg three times daily|
9969527|NCT01290965|Active Comparator|SCY-635 300 mg three times daily|
9969528|NCT01290991|Other|Bone Graft|Single Arm.. Augment Bone Graft for Osteochondral Defects
9969529|NCT01291030|Experimental|hypomagnesemic + magnesium supplement|The patient group of hypomagnesesemic renal transplant recipients randomized to magnesium supplementation (number = 30). The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
9969530|NCT01291030|No Intervention|hypomagnesemic without magnesium supplement|The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains > 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
10138916|NCT04212533|Active Comparator|non-supplementation arm|43 patients undergoing total thyroidectomy received rice starch tablets /6 hrs in the day before surgery
10138917|NCT04212299|Experimental|Baseline ischial containment to subischial socket|
10138918|NCT04212273|Experimental|Diagnostic Sonazoid-CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions on US will receive Sonazoid-CEUS and EOB-MRI examinations.
9969531|NCT01291030|No Intervention|normomagnesemic without magnesium supplement|In the control group of normomagnesemic renal transplantation recipients (number = 10), only a baseline assessment will be performed. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion.
9969532|NCT01291043|Experimental|Shiatsu Group|
9969533|NCT01291043|No Intervention|Control Group|
9969534|NCT01291069|Experimental|Tadalafil Citrate|The study subjects will be given Tadalfil citrate, encapsulated, 0.8-1 mg/kg/day in 1 dose orally. Max dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
9969535|NCT01291069|Placebo Comparator|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.
9969536|NCT01291082||Breast cancer patients|Breast cancer patients
9969537|NCT01291095|Active Comparator|CONCURRENT CHEMO-RADIOTHERAPY ARM|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy).
9969538|NCT01291095|Experimental|ACCELERATED FRACTIONATION RADIOTHERAPY ARM|Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
9969539|NCT01291121|Active Comparator|group 1|Intravitreal ranibizumab 0.5mg only group
9969540|NCT01291147|Active Comparator|Levobupivicaine|
9969541|NCT01291147|Placebo Comparator|0.9% Saline|
9969542|NCT01291186|Experimental|BPV6NO|
9969543|NCT01291186|Experimental|BPV7NO|
9969544|NCT01291186|Experimental|BPV8NO|
9969545|NCT01291186|Experimental|BPV9NO|
9969546|NCT01291186|Experimental|BPV10NO|
9969547|NCT01291186|Experimental|BPV11NO|
9969548|NCT01291186|Active Comparator|BPV6O|
9969549|NCT01291186|Active Comparator|BPV7O|
9969550|NCT01291186|Active Comparator|BPV8O|
9969551|NCT01291186|Active Comparator|BPV9O|
9969552|NCT01291186|Active Comparator|BPV10O|
9969553|NCT01291186|Active Comparator|BPV11O|
9969554|NCT01291199|Experimental|Vardenafil 10 mg bid|
9969555|NCT01291199|Placebo Comparator|Placebo|
9969556|NCT01291212|Active Comparator|Testosterone and FSHr|
9969557|NCT01291212|Active Comparator|testosterone and FSHr-LHr|
9969558|NCT01291238|Experimental|Healthy lifestyle habits|Increased physical activity and healthy food with decreased sugar and fat content
9969559|NCT01291290|No Intervention|Control treatment|Usual transfusion regime to patients with rAAA
9969560|NCT01291290|Experimental|Thrombocyte|Early thrombocyte administration to patients with rAAA
9969561|NCT01291303|Experimental|1- optimized ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
9969562|NCT01291303|Experimental|2-standard setting of ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
9969563|NCT01291316|Experimental|clobazam|
9969564|NCT01291316|Active Comparator|clonazepam|
9969565|NCT01291316|Placebo Comparator|tolterodine|
9969566|NCT01291329|Experimental|WJ-MSC|Wharton's jelly- Derived Mesenchymal Stem Cells Transfer
9969567|NCT01291342||Preeclampsia|30 preeclamptic pregnant women with gestational age >24 weeks and no chronic medical disorders who are not in labor and their fetus is alive.
9969568|NCT01291342||Normal pregnancy|30 normotensive pregnant women with gestational age >24 weeks and no chronic medical disorders who has no obstetrical problems, not in labor and their fetus is alive.
9969569|NCT01291342||Healthy non-pregnant|30 healthy non-pregnant control women not on medications and has not delivered a baby or conceived during the year before the breath collection
9969570|NCT01291355|Experimental|Specific maternal position|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts. According to Dr de Gasquet, author of the description of this posture, the effect on the variety of presentation would be almost immediate."
9969571|NCT01291355|No Intervention|Control|Not specific intervention for this group- Only usual care
9969572|NCT01291381|Active Comparator|Dermatophagoides pteronyssinus extract|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
9969573|NCT01291381|Active Comparator|Pharmacotherapy|Persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
9969574|NCT01291407|Experimental|S-1,peroral BID,capsule|
9969575|NCT01291433|Experimental|PENTOCLO|Association pentoxifylline, tocopherol and clodronate
9969576|NCT01291433|Placebo Comparator|Placebo|Triple placebo
9969577|NCT01291446|Sham Comparator|High flatulogenic diet|3-day diet containing fermentable residues
9969578|NCT01291459|Experimental|single arm|Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks
9969579|NCT01291472|Other|ketorolac|Ketorolac will be given to all patients as a part of routine medical care
9969580|NCT01291485|Experimental|Lifestyle counseling|Intervention includes education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve HIV medication adherence and clinical outcomes.
9969581|NCT01291485|No Intervention|Treatment as Usual|
9969582|NCT01291511|Experimental|Iloperidone|After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.
9969583|NCT01291511|Placebo Comparator|Iloperidone (including Placebo)|Post-randomization matching placebo is administered orally bid during the double-blind period.
9969584|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 400-500 calorie|
9969585|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
9969586|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, bedtime|
9969587|NCT01291524|Other|Pregabalin immediate release, 300 mg|Reference Treatment
9969588|NCT01291537|Experimental|Duodopa|
9969589|NCT01291537|Active Comparator|Best medical treatment|
9969590|NCT01291550||Nerodegenerative diseases|Patients with parkinsonism and patients with dementia
9969591|NCT01291550||Controls|
9969592|NCT01291550||ADHD|Subjects diagnosed with ADHD
10138919|NCT04212624|Experimental|test arm|The 25G or 23G conjunctival seamless vitrectomy was performed on the anterior eye to remove the anterior-posterior direction and tangential direction of the rupture hole. The area outside the macular foveal lesion was selected, but 100 μl of HuRPE cell injection was injected within about 2 PD. In combination with the Medone syringe and the combined 35G or 37G needle, the silicone oil injection module is used for injection, and the injection is performed in an amount of 100 μl (depending on the cell concentration). The doses of the three dose groups from low to high were 300,000 cells, 500,000 cells, and 1 million cells, respectively, in a single injection.
10138920|NCT04212390||FISiM MDS patients|Patients receiving a diagnosis of MDS and prospectively enrolled in the FISiM registry.
10138921|NCT04212546|Placebo Comparator|Control drink|200 mL milk + 16 g maltodextrin
9969593|NCT01291563|Experimental|001|TMC207 8 tablets of TMC207 (100 mg/tablet) on Day 1
10138922|NCT04212546|Active Comparator|Test drink|200 mL milk + 16 g inulin + Lactobacillus casei [>106 cfu/mL]
10138923|NCT04212208|Experimental|Intervention group|EMLA cream + High-frequency USG probe kept for 15minutes.After 15 minutes IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
10138924|NCT04212208|Active Comparator|Control group|EMLA cream+Low frequency USG probe kept over the cream for 15 minutes. IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
10138925|NCT04212260|Experimental|Oro-pharyngeal exercises|Use of oro-pharyngeal exercises
10138926|NCT04212260|Sham Comparator|Sham control|Use of sham exercises.
10138927|NCT04212130|Experimental|Evaluation of environmental cleanliness|"In this study,~fluorescent marking,~microbiological sampling and~BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
10138928|NCT04211896|Experimental|anlotinib plus nivolumab|
10138929|NCT04212104|Experimental|watch mukbang|participants are assigned to watch a dim sum mukbang by a famous host, Peggie Neo (https://youtu.be/2dRf535eAPK, accessed: 2018-9-12)
10138930|NCT04212104|Placebo Comparator|watch non-food content video|participants are assigned to watch the Big Bang Theory, The Euclid Alternative ( https://youtu.be/V8kUL9owk6Q, accessed: 2018-9-12).
10138931|NCT04211883|Experimental|Active intervention|Participants will come to the Project Active clinic and be asked questions about their health history, assist in their health goals, medications will be adjusted, lab work and screening tests will be ordered. At end of each visit, current health recommendations and goals as well as previous health changes will be given after each visit.
10138932|NCT04211883|No Intervention|Standard Clinical Treatment|Participants will continue with their usual clinic care.
10138933|NCT04212195||Part 1|Genetic determinants (n=500)
10138934|NCT04212195||Part 2|Biomarker discovery (n=40)
10138935|NCT04212026|Experimental|Nivolumab|"Nivolumab treatment will be given every 2 weeks at a standard flat dose of 240 mg for a total of 5 doses, and the IRE procedure will be performed using the standard setting to ablate tumors at the level of the liver that is well tolerated by the patients. Two weeks after the last dose of nivolumab (Week 8), radiological restaging will be performed (=Week 10)."
10138936|NCT04212039|Active Comparator|ultrasound guided pericapsular nerve group block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection between to iliopubic eminentia and psoas tendon
10138937|NCT04212039|Sham Comparator|ultrasound guided sham block|Ultrasound guided 0.5 ml/kg saline injection injection between to iliopubic eminentia and psoas tendon
10138938|NCT04212078|Active Comparator|A-Levofloxacin|0.1 ml/0.5mg of levofloxacin 0.5% ophthalmic solution
10138939|NCT04212078|Active Comparator|B-Intracameral Cefuroxime|0.1 ml/1mg of Cefuroxime
10138940|NCT04212182|Experimental|HFNC group|AECOPD patients receive ventilation support via HFNC.
10138941|NCT04212182|Active Comparator|NPPV group|AECOPD patients receive ventilation support via NPPV.
10138942|NCT04212221|Experimental|MGD013|MGD013 monotherapy dose escalation and expansion
10138943|NCT04212221|Experimental|MGD013+Brivanib Alaninate|MGD013+Brivanib Alaninate dose escalation and expansion
10138944|NCT04211961|Placebo Comparator|Control|Participants randomised to the placebo group will receive one 15-minute IV infusion of Saline at 4 visits.
10138945|NCT04211961|Active Comparator|Treatment|Participants randomised to the treatment group will receive one 15-minute IV infusion of Scopolamine at 4 visits.
10138946|NCT04212052|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 30Gy/6f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 40Gy/8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly nab-paclitaxel(50mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, or nab-paclitaxel(30mg/㎡) and nedaplatin(10mg/㎡) twice every week.
10138947|NCT04212247|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
10138948|NCT04212247|Placebo Comparator|Control condition|The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.
10138949|NCT04211948|Experimental|robotic pancreatectomy|robotic pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
9969594|NCT01291563|Placebo Comparator|002|TMC207 placebo 8 tablets of TMC207 placebo on Day 1
10138950|NCT04211948|Active Comparator|open surgery|open pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
10138951|NCT04212143||children with kidney disease|Kidney transplant recipients age 3 to 21 years
10138952|NCT04212143||healthy control|Healthy children age 3 to 21 years
10138953|NCT04211987|Active Comparator|Fast track care protocol|patients treated using fast track care protocol
10138954|NCT04211987|Active Comparator|Standard care protocol|patients treated using standard care protocol
10138955|NCT04212065|Active Comparator|Sublingual Suboxone|Women randomized to sublingual dosing will be provided prescription to fill.
10138956|NCT04212065|Active Comparator|Subcutaneous Sublocade|Women randomized to subcutaneous administration will have drug administered by nurse during routine prenatal care visits.
10138957|NCT04211922|Experimental|Alkotinib 400mg QD|400mg orally once daily. Take Alkotinib at least 1 hour before or at least 2 hours after a meal.
10138958|NCT04212000|Experimental|Levoketoconazole|Levoketoconazole 150 mg
10138959|NCT04212000|Active Comparator|Ketoconazole|Ketoconazole 200 mg
10138960|NCT04212234|Experimental|free ultrasound propagation velocity|ultrasound exams will be performed using several ultrasound propagation velocities
10138961|NCT04212234|No Intervention|conventional ultrasound propagation velocity|ultrasound exams will be performed using the 1540m/s conventional celerity
10138962|NCT04211870|Active Comparator|Group 1|Treatment with low-level laser therapy.
10138963|NCT04211870|Sham Comparator|Group 2|Sham treatment (simulated laser therapy).
10184494|NCT03754621||Pregnants|400 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment and are TPOAb negative. Serum thyroid functions tests will be obtained on the first visit.
10187731|NCT03723226|Active Comparator|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
10187732|NCT03723226|Experimental|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
10187733|NCT03723187|Experimental|experimental group|use Normal saline
10187734|NCT03723187|Active Comparator|comparator group|use Heparin
10187735|NCT03723174||Single Arm|baseline data will be calculated before the oral health educational program using gingival index and after 3 months from the intervention
10187736|NCT03723161||Treatment|Bone Anchored Hearing surgery using a BHX implant manufactured by Oticon Medical
10187737|NCT03723122|Experimental|DCRI program|Patient-caregiver dyads will immediately attend the Dyadic communication reinforcement intervention. For both groups, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 2 weeks post-intervention. Pre-post assessments consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
10187738|NCT03723122|No Intervention|Waiting List|Patient-caregiver dyads are in a waiting condition for 6 weeks. They will attend the Intervention after the second assessment time if they want to. For both group, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 6 weeks after first assessment time. First and second assessment consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
10187739|NCT03723044|Experimental|healthy volunteers|
10187740|NCT03723031|Active Comparator|rectal misopristol|will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion.
10187741|NCT03723031|Active Comparator|intrauterine misopristol|will receive 400 microgram misoprostol inserted intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta.
10187742|NCT03723018|Experimental|Meditation - Headspace|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by the commercially available app/website Headspace (provided to participants for free). Participants in this arm will have access to the other meditation arm once they finish the study.
10187743|NCT03723018|Experimental|Meditation - Respite|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by Respite, a website created by the investigators for this study. Participants in this arm will have access to the other meditation arm once they finish the study.
10187744|NCT03723018|No Intervention|Observational|Participants in this arm will not receive any intervention. Their only study activity will be taking online surveys. They will have access to the two meditation arms once they finish the study.
10187745|NCT03723005||Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
10187746|NCT03723005||Standard-of-Care Phototherapy|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
9969595|NCT01291563|Active Comparator|003|Moxifloxacin 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
10187747|NCT03722992|Other|Mindfulness Cohort|Mindfulness-based stress reduction (MBSR) treatment group
10187748|NCT03722979|Other|All patients|
10187749|NCT03722940|Active Comparator|Magnesium sulphate|Group M
10187750|NCT03722940|Placebo Comparator|Na CL 0.9%|group C
10187751|NCT03722927|Experimental|Bupivacaine Group|Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
9969596|NCT01291563|Placebo Comparator|004|Moxifloxacin placebo 1 capsule of moxifloxacin placebo on Day 2
9969597|NCT01291576|Active Comparator|Rectal/colorectal segmental resection|
10138964|NCT04211935|Experimental|Patient Controlled Analgesia|This technique involves connecting a patient controlled analgesia pump to the intravenous line. The patient has the ability to push a button to obtain a predetermined dose of an intravenous opioid with a set lockout time period to minimize the potential for over sedation. PCA pumps will be connected to the intravenous line of the patient at the end of the MIRPE operation. anesthesiologists with experience in regional anesthesia.
10138965|NCT04211935|Experimental|Erector Spinae Block|This method consists of the anesthesiologist placing two catheters on each side of the vertebrae which then delivers pain medicine continuously via pumps for 2-3 days post-surgery.
10138966|NCT04211935|Experimental|Intercostal Nerve Cryoablation|The INC technique relies on multilevel freezing of the intercostal neurovascular bundle intraoperatively to block sensation and pain for approximately 2 months postoperatively. Trained pediatric surgeons will perform the INC at the time of a MIRPE procedure.
10138967|NCT04211792||Glaucoma suspect or patients|Patients who has or suspected Glaucoma will be approached for the recruitment into this study. IOP will be measured in the sitting position with Icare tonometers in a random order in both the eyes. IOP measurements by GAT will be taken after Icare measurements followed by CCT recording with ultrasound pachymeter.
10138968|NCT04211805||Arm (A) TAF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Alafenamide (TAF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
10138969|NCT04211805||Arm (B) TDF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Disoproxil Fumarate (TDF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
10138970|NCT04211493|Experimental|Experimental-Condition|"20 minutes whole-body-workout with simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
10138971|NCT04211493|Placebo Comparator|Placebo-Condition|"20 minutes whole-body-workout without simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout they are stimulated with the lowest possible stimulation intensity (1). This is perceptible as a slight tingling sensation but the impulse intensity lies below the muscular threshold and therefore generates no muscular activity."
10138972|NCT04211467||Depression|Patients who have been diagnosed with depression
10138973|NCT04211558|Experimental|Ozanimod 0.46mg|Ozanimod single doses of 0.46 mg (1 x 0.46 mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
10138974|NCT04211558|Experimental|Ozanimod 0.92mg|Ozanimod single doses of 0.92 mg (1 x 0.92-mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
10138975|NCT04211597|Sham Comparator|Group 1: Control|Participants receive no scar prevention and treatment for Cesarean wounds.
10138976|NCT04211597|Active Comparator|Group 2: Silicone gel|Each participant in Group 2 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months.
10138977|NCT04211597|Experimental|Group 3: Silicone gel plus Me-EGF|"The day of Cesarean delivery was recorded as Day 0. For participants in Group 3, on day 0 prior to final dermal closure, 4ml of Me-EGF (containing 40mcg microencapsulated polysaccharide and rhEGF) was sprayed evenly along the incision site, subsequently covered with antibiotic ointment and sterile gauze. Another 0.5 ml (5 mcg of Me-EGF) was sprayed during dressing change on day 1 and day 5 respectively. At each dressing change, the sutured wound was cleaned by sterile normal saline, followed by Me-EGF sprays, and waited for two minutes to allow for absorption, then covered with dry sterile gauze.~Each participant in Group 3 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months."
10138978|NCT04211519|Experimental|Permanent teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
10138979|NCT04211519|Experimental|Primary teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
9969598|NCT01291576|Active Comparator|Rectal nodule excision|
9969599|NCT01291589|Experimental|Cognitive-behavioral counseling|
9969600|NCT01291602|Experimental|NXL104|Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
9669188|NCT03773757|Experimental|IN-PEACE Dementia Care Coordination|In-PEACE intervention arm will have monthly contact with a dementia care coordinator (DCC) to to identify symptoms the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors.
9669189|NCT03773757|No Intervention|Usual Care|The usual care arm will have access to education and informational materials from the local chapter of the Alzheimer's Association and other community resources and will be reminded of these resources throughout the study.
9827460|NCT02456740|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
9969601|NCT01291602|Placebo Comparator|Placebo|Three Japanese subjects to receive placebo IV doses
9969602|NCT01291602|Experimental|Ceftazidime NXL104 (CAZ104)|Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
9969603|NCT01291615|Experimental|Gemcitabine group|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
9969604|NCT01291615|Experimental|S-1 group|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks
9969605|NCT01291628|Experimental|socks containing copper-oxide fibers|
9969606|NCT01291641|Placebo Comparator|Group A|HMGCoA reductase inhibitor continued
9969607|NCT01291641|Active Comparator|Group B|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID
9969608|NCT01291641|Active Comparator|Group C|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID + Cilostazol 100 mg PO, BID
9969609|NCT01291654|Experimental|Paracetamol|Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
9969610|NCT01291654|Experimental|NSAID|Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
9969611|NCT01291680||Pre - delivery pregnant women|Participants in the study will be pregnant women attending the obstetric ER for routine term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The current study will focus on women attending a regular followup, not considered to be at high risk.
9976907|NCT01356251|Experimental|Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group.
9976908|NCT01356251|Experimental|Non Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group
9976909|NCT01356264|Experimental|multimodal prehabilitation begun preop|The prehabilitation program will begin several weeks preop and continue in the postoperative period
9976910|NCT01356264|Active Comparator|Multimodal prehabilitation begun postop|The prehabilitation program will begin after the surgery.
9976911|NCT01356303|Experimental|Cisplatin, Docetaxel|Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
9976912|NCT01356316|Experimental|AdimFlu-S Influenza Vaccine|
9976913|NCT01356329|Experimental|Lovenox|Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)
9976914|NCT01356329|Experimental|Heparin|Group B:HeparinTM (Unfractionated Heparin)
9976915|NCT01356342|Experimental|AdimFlu-S 2010-2011, 6 months~<3 years|
9976916|NCT01356342|Experimental|AdimFlu-S 2010-2011,3~<9 years|
9976917|NCT01356342|Experimental|AdimFlu-S 2010-2011,9~<18 years|
9976918|NCT01356355|Experimental|Herbmed plus|One capsule twice a day daily till ureteral stent in situ
9976919|NCT01356355|Placebo Comparator|Placebo|One capsule twice a day daily till ureteral stent in situ
9976920|NCT01356355|Active Comparator|Tolterodine|One capsule twice a day daily till ureteral stent in situ
9976921|NCT01356368|Experimental|Cisplatin,Docetaxel,Gemzar, Premetrexed|Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.
9976922|NCT01356381|Experimental|vildagliptin|
9976923|NCT01356381|Experimental|Placebo|
9976924|NCT01356420|Experimental|Cholesterol supplementation|All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
9976925|NCT01356433|Other|arm1, vitamin C treated first|Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
9976926|NCT01356433|Other|Arm 2 control first|
9976927|NCT01356446|No Intervention|before surgical checklist|
9976928|NCT01356446|Active Comparator|after implementation surgical checklist|
9976929|NCT01356459|Experimental|Intervention|Patients in this arm will have Mepilex dressings applied to their sacrum and heels
9976930|NCT01356459|No Intervention|Control|Patients in this arm will have standard care
9976931|NCT01356472|No Intervention|Linezolid alone|the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
9976932|NCT01356485|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
9976933|NCT01356485|Placebo Comparator|Saline|Normal saline (0.9% sodium chloride solution)
9969612|NCT01291693|Experimental|Personal counseling|
9969613|NCT01291693|Experimental|Computer generated feedback letters|
9969614|NCT01291693|No Intervention|Control group|Treatment as usual
9969615|NCT01291706||Mild TBI with mild lesions on CT scan|Negative predictive value of transcranial doppler for patients with mild to moderate traumatic brain injury and mild brain lesions on initial CT scan (TCDB II)
9969616|NCT01291719|Experimental|insulin and glucose infusion|trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system
9969617|NCT01291732|Experimental|BI 135585 XX|single dose of BI 135585
9969618|NCT01291732|Placebo Comparator|matching placebo|single dose of matching placebo
9969619|NCT01291745||Patients with MYELODYSPLASTIC SYNDROMES|Patients diagnosed with MDS according to FAB, WHO and IPSS classifications. Patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine).
9969620|NCT01291758||GWI|Veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
9969621|NCT01291758||HC|Healthy veterans of the 1990-1991 Persian Gulf War
9969622|NCT01291771|Other|comparator|One group of patients with no myocardial ischemia on non invasive testing will be followed up for 2 years
9969623|NCT01291771|Experimental|coronary angiography group|One group of patients with myocardial ischemia on non invasive testing will undergo coronary angiography and measure of FFR + CFR to detect myocardial microvascular disease
9969624|NCT01291797||Neonates with congenital heart disease|The case group will consist of newborns born between 32 and 41 weeks gestation diagnosed with a congenital cardiac anomaly requiring surgical repair during their hospitalization and managed in the Mount Sinai Neonatal Intensive Care Unit. The control arm will include newborns born between 32 and 41 weeks without congenital cardiac anomalies. Both groups will undergo a neurological screening assessment and receive an AEEG to look at sleep wake cycles.
9969625|NCT01291810|Experimental|TNF Kinoid|
9969626|NCT01291810|Placebo Comparator|Placebo|
9969627|NCT01291823|Experimental|Concomitant Gefitinib and radiotherapy|Patients received Gefitinib and radiation therapy
9969628|NCT01291849|Experimental|remifentanil for intranasal surgery|
9969629|NCT01291875|Experimental|Intensive periodontal treatment|
9969630|NCT01291875|Active Comparator|Supragingival biofilm control|
9969631|NCT01291927|Experimental|Pancreas-sparing duodenectomy|
9969632|NCT01291927|Active Comparator|Pancreaticoduodenectomy|
9969633|NCT01291940|Experimental|Pediatric Moisturizer Intervention|Apply one of four moisturizers to one arm daily for four weeks.
9969634|NCT01291940|Experimental|Adult Moisturizer Intervention|Apply moisturizer to one arm once a day for four weeks.
9969635|NCT01291940|No Intervention|Adult Control|No intervention.
9969636|NCT01291953|Experimental|Screening|Opportunist Screening asymptomatic patients. Taking the arterial pulse. Will invite patient to realize an ECG, if pulse is irregular
9969637|NCT01291953|Active Comparator|Control|Case finding of patient whith symptoms of atrial fibrilation. Taking the arterial pulse. ECG if pulse is irregular
9969638|NCT01291966|Experimental|Motivational interview|
9969639|NCT01291979|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
9969640|NCT01291979|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
9969641|NCT01291992||Continuous EEG Monitoring|Immediately after surgery, while still sedated and in the cardiac surgery recovery unit, 9 sticker electrodes applied to the skin just below the hairline, which record brain activity onto a computer. The EEG will be recorded for 24 hours. This brain activity (EEG) will later be interpreted by a neurologist who will be looking for evidence of seizure activity in the brain waves. Other relevant information: age, sex, the nature of other health problems, drugs used, complications and whether or not seizures are found will be stored on our computer for further evaluation.
10138980|NCT04211623|Active Comparator|Constraint induced movement therapy group|Constrained on more affected side for three hours.
9969642|NCT01292031|Experimental|Colistin|Colistin 4.5 MU/iv.plus Colistin 3 MU/iv./8 h. 30 minutes infusion
9969643|NCT01292031|Active Comparator|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
9969644|NCT01292044|Experimental|The study population|The study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
9969645|NCT01292083|Experimental|Treatment|See Detailed Description
9969646|NCT01292109||PICOPREP®|
9969647|NCT01292122|Experimental|VCT-01-treated STSG donor site wound|Application of VCT-01 to STSG donor site wound at Day 0
9969648|NCT01292161|Other|Silymarin|Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
9969649|NCT01292174|Experimental|Group 1 - lowest dosage|120 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
9969650|NCT01292174|Experimental|Group 2 - middle dosage level|240 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
9969651|NCT01292174|Experimental|Group 3 - highest dosage level|480 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
9969652|NCT01292200|Experimental|watch DVD and small group discussion|Participants will watch the video in a group and discuss the video.
9969653|NCT01292200|Placebo Comparator|watch video only|watch a 22 minutes long video at home by herself.
9969654|NCT01292213||Cases|Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
9969655|NCT01292213||Controls|Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.
10138981|NCT04211623|Active Comparator|Bimanual activities group; BIM training|Set of bimanual activities performed.
10138982|NCT04211779|Experimental|Real tDCS and Exercise|tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and active tDCS intervention at the same time.
10138983|NCT04211779|Sham Comparator|Sham tDCS and Exercise|Sham tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and sham tDCS intervention at the same time.
9969656|NCT01292278||aSAH|consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
10138984|NCT04211779|Other|Exercise|Exercise group in which will receive the active intervention of aerobic exercise training no tDCS intervention.
10138985|NCT04211428||Bipolar Disorder|Patients with bipolar disorder
10138986|NCT04211844||sofosbuvir plus daclatasvir|50 patients receiving 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
10138987|NCT04211844||sofosbuvir plus ledipasvir|50 patients receiving 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
10138988|NCT04211545|Experimental|Administration of CC-92480 and Rabeprazole|Test Formulation CC-92480 and Reference Formulation will be administered orally at 1.6 mg. Rabeprazole will be administered orally at 40 mg.
10138989|NCT04211454||Migraine|Patients with migraine headaches
10138990|NCT04211571|Experimental|MCO group|Hemodialysis using Theranova 400 dialyzer
10138991|NCT04211571|Active Comparator|High-flux group|Hemodialysis using high-flux dialyzer (Fx CorDiax 60 and 80; Fresenius Medical Care)
10138992|NCT04211636||Complete SCI, AIS A|Patients with complete spinal cord injury (AIS A)
10138993|NCT04211636||Incomplete SCI, AIS B, C, D|Patients with incomplete spinal cord injury (AIS B, C, D)
10138994|NCT04211636||Vertebral injuries without SCI|Patients with vertebral injuries without spinal cord injury (control)
10138995|NCT04211649|Experimental|3 days of antibiotherapy|The patient viewed for the first time at the hospital and suspected of leptospirosis received a probabilistic antibiotherapy
10138996|NCT04211649|No Intervention|7 days of antibiotherapy (Amoxycilline or Doxycycline)|When the leptospirosis is confirmed ( PCR Leptospirosis positive) the pobabilistic antibiotherapy is switched to a prophylactic antibiotherapy with Amoxicillin or Doxycycline.
10138997|NCT04211610||Group 1 - Healthy subjects without any evidence of cardiac o|"Inclusion criteria:~Normal serum troponin (below the 99th percentile)~GFR 60ml/min~Proteinuria <1gr/gr creatinine~Blood and urine samples will be collected for troponin and other measures."
10138998|NCT04211610||Group 2 - Subjects with acute myocardial infarction and norm|"Inclusion criteria:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
10138999|NCT04211610||Group 3 - Subjects with acute myocardial infarction and decr|"Inclusion criteria - Group 3a:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~30 GFR <60ml/min/1.73m2~Inclusion criteria - Group 3b:~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.~GFR <30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
10139000|NCT04211610||Group 4 - Subjects with decreased GFR but without any eviden|"Inclusion criteria - Group 4a:~Normal serum troponin (below the 99th percentile)~No known past medical history of any cardiac disease and/or procedure.~30 GFR <60ml/min/1.73m2~Inclusion criteria - Group 4b:~Normal serum troponin (below the 99th percentile)~No known past medical history of any cardiac disease and/or procedure.~GFR <30ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
10139001|NCT04211610||Group 5 - Subjects with chronic myocardial injury and normal|"Inclusion criteria:~At least one measurements of serum troponin above the 99th percentile, with neither a rise nor fall in cardiac troponin levels.~GFR 60ml/min/1.73m2~Blood and urine samples will be collected for troponin and other measures."
10139002|NCT04211610||Group 6 - patients on RRT|"Inclusion criteria:~a. Patients who are dependent on renal replacement therapy, including hemodialysis, peritoneal or hemodiafiltration.~Blood and urine samples will be collected for troponin and other measures."
10139003|NCT04211662|Experimental|Intervention Group|Tailored Multidimensional Intervention
10139004|NCT04211662|No Intervention|Control Group|Regarding the control group, the participants will receive a simple educational booklet through one home visit.
10139005|NCT04211688|Experimental|Combined individual + group Schema therapy|Those who will receive both individual plus group schema therapy
10139006|NCT04211688|Active Comparator|Only group Schema therapy|Those who will receive group schema therapy
10139007|NCT04211272|Experimental|Part A: Macitentan + Substrate Drug (Sildenafil/Riociguat)|Participants will receive a single dose of film-coated tablet of sildenafil under fasted condition (Treatment A1), then riociguat under fasted condition (Treatment A2) followed by macitentan under fed condition (Treatment B1), then riociguat along with macitentan under fasted conditions followed by macitentan under fed conditions (Treatment B2) and then sildenafil along with macitentan under fasted condition (Treatment B3). Macitentan will be administered in an up-titration regimen.
10184495|NCT03754608||Diabetics/No cognitive impairment|These are individuals with diabetes who do not have vascular cognitive impairment as determined by VASCOG criteria.
10184496|NCT03754608||Diabetics with vascular cognitive impairment|These are individuals with diabetes who have vascular cognitive impairment as determined by VASCOG criteria.
9969657|NCT01292278||control group|no neurological disease but spinal anesthesia
9969658|NCT01292317|Active Comparator|intravenous hydration|intravenous application of 0.9% saline
9969659|NCT01292317|Active Comparator|oral hydration only|
9969660|NCT01292356|Experimental|cetuximab|
9969661|NCT01292369||Breast cancer|Women diagnosed with breast cancer by a positive biopsy test after mammography.
10139008|NCT04211272|Experimental|Part B: Macitentan + Substrate Drug (Rosuvastatin)|Participants will receive a single dose of film-coated tablet of rosuvastatin under fasted condition (Treatment A1), then macitentan under fed condition (Treatment B1) followed by rosuvastatin along with macitentan under fasted condition followed by macitentan under fed condition (Treatment B2). Macitentan will be administered in an up-titration regimen. Part B of the study will be conducted depending on the results of Part A and feedback from Health Authorities.
10139009|NCT04211311|Experimental|FES-legcycling with voluntary arm-work|FES-legcycling combined with arm ski-ergometer or arm-cycling
10139010|NCT04211259|Experimental|Cohort I (loratadine)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
10139011|NCT04211259|Placebo Comparator|Cohort II (placebo)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
10139012|NCT04211701|Experimental|Connective Tissue Massage|Connective tissue massage will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions, respectively. The treatment will be administered for four weeks, five days a week.
10139013|NCT04211701|Experimental|Classical Massage|Classic massage will be applied to the lower back and upper back, respectively, while the patient is lying in the prone position. The treatment will be administered for four weeks, five days a week.
10139014|NCT04211376||Anxiety|Patients with anxiety
10139015|NCT04211818|Experimental|Patients|
10139016|NCT04211415|Experimental|Part 1: DS-2741a Cohort 1, 5 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 5 mg.
10139017|NCT04211415|Experimental|Part 1: DS-2741a Cohort 2, 15 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 15 mg.
10139018|NCT04211415|Experimental|Part 1: DS-2741a Cohort 3, 50 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 50 mg.
10139019|NCT04211415|Experimental|Part 1: DS-2741a Cohort 4, 150 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 150 mg.
10139020|NCT04211415|Experimental|Part 1: DS-2741a Cohort 5, 500 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 500 mg.
10139021|NCT04211415|Experimental|Part 1: DS-2741a Cohort 6, 1000 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 1000 mg.
9969662|NCT01292369||Breast control|Women with negative biopsy result done due to a suspicious mammography exam.
10139022|NCT04211415|Placebo Comparator|Part 1: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
10139023|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, X mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a X mg, where X mg will be based on the maximum tolerated dose identified in Part 1.
10139024|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, Y mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a Y mg, where Y mg will be based on the maximum tolerated dose identified in Part 1.
10139025|NCT04211415|Experimental|Part 3: DS-2741a Cohort 1, Z mg (based on results of Part 1)|Participants will be randomized to receive a receive a single, subcutaneous injection of DS-2741a Z mg, where Z mg will be based on the maximum tolerated dose identified in Part 1.
10139026|NCT04211415|Placebo Comparator|Part 3: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
10139027|NCT04211129|Experimental|acupuncture group|Receiving acupuncture and moxibustion
10139028|NCT04211129|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion
10139029|NCT04211402||Obsessive-Compulsive Disorder|Patients with obsessive-compulsive disorder
10139030|NCT04211220|Experimental|Type 1 diabetes|
10139031|NCT04211324||TENS group|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
10139032|NCT04211324||electro-acupuncture group|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
10139033|NCT04211298|Active Comparator|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
10139034|NCT04211298|Placebo Comparator|Propofol|Propofol will be used for sedation during bronchoscopy
10139035|NCT04211350|Experimental|NightBalance Sleep Position Therapy|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
10139036|NCT04211350|Experimental|Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
10139037|NCT04211285||community dwelling elderly|community dwelling elderly patients (60 years or older), can read and write, able to use the android software applications
10139038|NCT04210908|Experimental|Biofeedback|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the study group, patients will observe the descent of the head during contraction on the ultrasound display screen.
10139039|NCT04210908|No Intervention|Control|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the control group, patients will not observe the ultrasound display screen.
9969663|NCT01292369||Colon cancer|Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.
9969664|NCT01292369||Colon control|Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.
10139040|NCT04210973|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
10139041|NCT04210973|Placebo Comparator|Placebo|Placebo,oral, twice per day
10139042|NCT04210856|Experimental|Sequence of Landscape exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
9969665|NCT01292382|Sham Comparator|rTMS versus Sham|rTMS: active coil Sham: inactive coil
9969666|NCT01292382|Active Comparator|rTMS versus sham|rTMS group: active coil Sham group: inactive coil
9969667|NCT01292395|Experimental|Protein level 1|
9969668|NCT01292395|Experimental|Protein level 2|
9969669|NCT01292395|Experimental|Protein level 3|
9969670|NCT01292408|Experimental|Daily HCQ|Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
9969671|NCT01292421|Placebo Comparator|Arm I|Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
9969672|NCT01292421|Experimental|Arm II|Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
9969673|NCT01292421|Experimental|Arm III|Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
9969674|NCT01292421|Experimental|Arm IV|Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
9969675|NCT01292434|Experimental|Lunch in the Bag Intervention|Lunch is in the Bag behavioral intervention: Parents receive a behavioral intervention that includes handouts/newsletters sent to parents from the early care and education (ECE) center, classroom activities and projects, an implementation support calendar, and teacher training.
9969676|NCT01292434|No Intervention|Control|Parents received no specific nutrition education intervention at the ECE center, other than usual practice.
9969677|NCT01292460|Active Comparator|Preservative-free timolol|
9969678|NCT01292460|Experimental|Preservative-free FDC and placebo|
9969679|NCT01292460|Active Comparator|Preservative-free tafluprost|
9969680|NCT01292460|Experimental|Preservative-free FDC|
9969681|NCT01292499|No Intervention|Pharmacological treatment|Pharmacological treatment consists of the administration of a single antidepressant drug. The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
9969682|NCT01292499|Experimental|Psychotherapy|Will receive psychotherapy as well (10 sessions). Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each. Psychotherapy will begin after 4-6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective. The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient. Psychotherapists will be free to follow the approach they were trained.
9969683|NCT01292499|Experimental|Psychoeducation|Will receive psychoeducation as well, with phone monitoring and regular follow-ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
9969684|NCT01292499|Experimental|Psychoeducation and psychotherapy|Will receive both psychoeducation and psychotherapy sessions.
9969685|NCT01292512|Experimental|Intervention group|"A) Professional level. B) Patient level.~Intervention~Professional level:~General Practitioners (GP) receive updated information on bereavement related symptoms, how to identify complicated grief, and the Dual Process Model (DPM) of coping.~GPs receive suggestions on how to provide psycho-educational support for the patient.~GPs are informed about the results of the initial assessment of their patient prognostic screening for complicated grief.~Patient level:~Patients receive updated information on bereavement related symptoms, the DPM of coping and suggestions on when to seek professional help.~Patients are informed of the results of their initial assessment of their prognostic grief screening.~Patients are encouraged to contact their GP if they worry about handling their bereavement reaction."
9969686|NCT01292512|Other|Control group|Treatment as usual (in the Danish health care system).
9969687|NCT01292525|Active Comparator|Tacrolimus|
9969688|NCT01292525|Experimental|Withdrawal of Tacrolimus|
9969689|NCT01292551|Active Comparator|Bosentan|
9969690|NCT01292551|Placebo Comparator|Placebo|
9969691|NCT01292564|Active Comparator|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
9969692|NCT01292564|Placebo Comparator|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
9969693|NCT01292577|Experimental|CET/PT|Behavioral Intervention: Participants will receive adapted Cognitive Enhancement Therapy/Personal Therapy.
9969694|NCT01292577|Active Comparator|Treatment as Usual|Behavioral Intervention: Participants will receive treatment as usual.
9969695|NCT01292590|Experimental|High fat meal|
9969696|NCT01292655|Experimental|Arm A1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
9969697|NCT01292655|Experimental|Arm A2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
9969698|NCT01292655|Experimental|Arm B1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
9969699|NCT01292655|Experimental|Arm B2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
9969700|NCT01292668|Experimental|Group I|Patients apply methyl-5-aminolevulinate hydrochloride (MAL) cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo laser light treatment for 3-5 minutes.
9969701|NCT01292668|Experimental|Group II|Patients apply MAL cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo light emitting diode treatment for 5-10 minutes.
9969702|NCT01292681|Other|Multi-modality imaging|
9969703|NCT01292694|Experimental|Losartan|Angiotensin II AT1 receptor antagonist which blocks the actions of angiotensin II
9969704|NCT01292694|Experimental|Captopril|ACE inhibitor which blocks the formation of angiotensin II
9969705|NCT01292694|Placebo Comparator|Placebo Tablet|A placebo tablet will be provided by the Vanderbilt Investigational Drug Service for these studies.
9976934|NCT01356511|Experimental|Prednisone group|Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
10139043|NCT04211012|Experimental|Treatment Arm|
10139044|NCT04211051|Experimental|Arm A|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
10139045|NCT04211142|Active Comparator|Laparoscopic repair|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)
10139046|NCT04211142|Active Comparator|Open repair|Open Inguinal Hernia Repair (Lichtenstein repair)
10139047|NCT04211025|Experimental|Modest|This approach is feasible to integrate into workflows of a wide-range of clinics, and should have a minimal impact on human resources. Materials and strategies to support staff in this work will be provided. .
10139048|NCT04211025|Experimental|Intensive|This approach is more robust, and requires a greater commitment of human resources.
10139049|NCT04210960||Patients group|50 multiple sclerosis patients
10139050|NCT04210960||Control group|30 normal healthy control
10139051|NCT04211038|Experimental|healthy subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
10139052|NCT04211038|Experimental|COPD subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
10139053|NCT04210921|Experimental|Treatment group|"In the treatment group, the Park needle with a real acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi (feeling of needle sensation refers to tenseness around the needle felt by the practitioner and numbness, distension, soreness, and heaviness around the point felt by the patient), and needles will be stimulated manually at least 10 s, then the needles will be retained for 30 minutes."
10139054|NCT04210921|Placebo Comparator|Control group|In the control group, the Park sham needle will instead of the real needle. It is retractile and adopts the sleeve type blunt needle design. When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin. The sham needle may be manipulated by lifting, thrusting or twirling as the real one, but it will not insert into the skin authentically.
10139055|NCT04211103|Experimental|Pembrolizumab single agent|"Pembrolizumab single agent as neoadjuvant treatment before surgical conization and/or partial or radical vulvectomy.~Pembrolizumab 200 mg flat dose will be administered every 3 weeks for 5 cycles. Within 3 weeks from the last Pembrolizumab administration patients will be submitted to surgical conization or partial or radical vulvectomy."
10139056|NCT04211233|Active Comparator|Invasive subdural arm|Implantation of invasive subdural electrode in patients after surgical treatment of acute subdural hematoma
10139057|NCT04211233|Sham Comparator|Standard treatment arm|Patients with acute subdural hematoma who underwent surgical Treatment and receive Standard medical treatment
10139058|NCT04210986|Experimental|Fisetin|Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
10139059|NCT04210986|Placebo Comparator|Placebo|Placebo capsules will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
10139060|NCT04211116||Pediatric patients indicated to CVC insertion|Paediatric patients indicated to central venous line insertion
10139061|NCT04211064|Other|Deep neuromuscular block|Patients undergoing deep neuromuscular blockade with rocuronium (TOF -- PTC 1-5)
10139062|NCT04211064|Active Comparator|Moderate neuromuscular block|Patients undergoing moderate neuromuscular blockade with rocuronium (TOF 1-3)
10139063|NCT04211077||Group 1|Occurrence of a SA according to PMSI
10139064|NCT04211077||Group 2|Occurrence of accidental opioid analgesics overdose according to PMSI code
10139065|NCT04211077||Group 3|Controls : Absence of SA and accidental opioid analgesics overdose
10139066|NCT04210817||Patients|Patients who have been diagnosed with Rheumatoid Arthritis
10139067|NCT04210895|Experimental|Warm footbath with ginger powder|Participants receive a daily warm water footbath with added ginger powder over a two-week period
10139068|NCT04210895|Active Comparator|Warm water only footbath|Participants receive a daily warm water footbath over a two-week period
10139069|NCT04211168|Experimental|Toripalimab Plus Lenvatinib|"Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
10139070|NCT04211584|Active Comparator|forearm radial artery access|traditional access (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
10139071|NCT04211584|Active Comparator|anatomic snuffbox access|access in the snuffbox area of the wrist (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
10139072|NCT04211090|Experimental|Camrelizumab with pemetrexed / carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer
10139073|NCT04210713|Active Comparator|AUD-Minocycline|Participants diagnosed with alcohol use disorder will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
10139074|NCT04210713|Placebo Comparator|AUD-Placebo|Participants diagnosed with alcohol use disorder will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
10139075|NCT04210713|Active Comparator|Healthy Control-Minocycline|Healthy control participants will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
10184497|NCT03754595|Active Comparator|2D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 2D Laparoscopic pancreatoduodenectomy
9976935|NCT01356511|Experimental|Dexamethasone group|DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped
9969706|NCT01292707|Active Comparator|Control|Prescribing staff in control facilities will receive the standard package of RDT training that is being provided by NMCP in Tanzania
9969707|NCT01292707|Active Comparator|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial.
9969708|NCT01292707|Active Comparator|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
9969709|NCT01292720|Placebo Comparator|Placebo|Placebo (herbal oil)
9969710|NCT01292720|Experimental|Vitamin D|
9969711|NCT01292733|Experimental|Ovarian Cancer Screening|CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires
9969712|NCT01292785||Transsexual|Female-to-Male and Male-to-Female Transsexuals receiving hormonal therapy
9969713|NCT01292785||Healthy control subjects|receiving no hormonal therapy
9969714|NCT01292811|Experimental|Functional electrical Stimulation|The functional electrical stimulation for the treatment group will begin by designing a stimulation protocol that can generate the palmar and/or the lateral grasp on demand. In other words, the stimulation sequence (protocol) will be developed for each patient individually using either Compex Motion or HEWHS stimulator; this will allow the patient, who otherwise cannot grasp, to do so with the system. Both stimulators will be used to deliver the same FES therapy. Stimulation parameters are: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from 250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
9969715|NCT01292811|Other|Control Group|"The Control group will receive conventional occupational therapy pertaining to hand function [15].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
9969716|NCT01292824|No Intervention|Standard liver transplant care|Liver Transplantation as per Standard of Care
9969717|NCT01292824|Experimental|ITX 5061|Liver Transplantation as per Standard of Care + ITX5061
9969718|NCT01292850||Healthy Volunteers|15 healthy volunteers were recruited
9969719|NCT01292863|Active Comparator|Conventional peritoneal dialysis solution|Subjects will be randomized to perform dialysis with the conventional peritoneal dialysis solution for 3 months. At the end of three months mesothelial cell shedding and apoptosis will be measured.
9969720|NCT01292863|Experimental|Novel biocompatible dialysis solution Delflex neutral pH|
9969721|NCT01292889||Seasonal Affective Disorder|Consists of Individuals with Seasonal Affective Disorder
9969722|NCT01292889||Subsyndromal Seasonal Affective Disorder|Consists of individuals who do not meet SAD criteria,but present more symptoms for the disorder than do controls.
9969723|NCT01292889||Major Depressive Disorder|Consists of individuals who have MDD.
9969724|NCT01292889||Controls|Consists of individuals who do not present symptoms of SAD or MDD.
9969725|NCT01292902|Active Comparator|healthy volunteers|
9969726|NCT01292902|Other|chronic heart failure|
9969727|NCT01292915||1|
9969728|NCT01292941|Active Comparator|Active comparator/Yellow catheter|SpeediCath coated catheter
9969729|NCT01292941|Experimental|NonCE marked intermittent catheter/red|
9969730|NCT01292941|Experimental|NonCE marked intermittent catheter/green|
9969731|NCT01292941|Experimental|NonCE marked intermittent catheter/Blue|
9969732|NCT01292954|Active Comparator|Low dose blueberry|
9969733|NCT01292954|Active Comparator|medium dose blueberry|
9969734|NCT01292954|Active Comparator|high dose blueberry|
9969735|NCT01292954|Placebo Comparator|control|
9969736|NCT01292967|Placebo Comparator|Low flavanol|Low-flavanol chocolate contained 48 mg of cocoa flavanols. macro- and micro-nutrient matched with active comparator
9969737|NCT01292967|Active Comparator|High-flavanol with sugar|High-flavanol chocolate made with added sugar containing 251 mg of cocoa flavanols
9969738|NCT01292967|Active Comparator|High flavanol Maltitol|High-flavanol chocolate made with the sugar substitute maltitol containing 266 mg cocoa flavanols
10184498|NCT03754595|Experimental|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
9969739|NCT01292993|Experimental|Treatment A|400 mg LX4211
9969740|NCT01292993|Experimental|Treatment B|1000 mg metformin
9969741|NCT01292993|Experimental|Treatment C|400 mg LX4211 + 1000 mg metformin
9969742|NCT01293019|Experimental|Experimental|Osteopathic treatment
9969743|NCT01293019|Placebo Comparator|Placebo|Sham osteopathic treatment
9969744|NCT01293019|Active Comparator|Usual care|Classic treatment of cystic fibrosis patients
9969745|NCT01293045|Experimental|HC Group|Group of volunteers fed with Hydrolyzed Collagen
9969746|NCT01293045|Active Comparator|CT Group|Group of volunteers fed with wheat proteins
9969747|NCT01293058|Other|Intravenous|The investigators administered intravenous naloxone for our opioid overdose patients
9969748|NCT01293058|Other|Intranasal|The investigators administered intranasal naloxone for treatment of our patients
9969749|NCT01293071|Active Comparator|Mixing arm|Antibiotic rotation, each consecutive initiated antibiotic treatment a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems)
9969750|NCT01293071|Active Comparator|Cycling|Antibiotic rotation, every 1.5 month a different preferred antibiotic treatment from a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems) is used for empiric treatment.
9519683|NCT03284567|Active Comparator|Football fitness|"Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury."
10139076|NCT04210713|Placebo Comparator|Healthy Control-Placebo|Healthy control participants will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
10139077|NCT04210752|Experimental|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
10139078|NCT04210752|Experimental|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
10139079|NCT04210752|Experimental|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
10139080|NCT04210752|Experimental|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
10139081|NCT04210752|Experimental|Treatment 5 (Shingrix)|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: Intramuscular injection"
10139082|NCT04210739|Experimental|trus guided betamethason injection arm|
10139083|NCT04210804|Experimental|Omega-3|1gEPA and 1gDHA in 200mls smoothie
10139084|NCT04210804|Placebo Comparator|Placebo|200mls smoothie without EPA or DHA. Looks and tastes identical to omega-3 arm
10139085|NCT04210570|Experimental|Memsorb GA|Memsorb Filter will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
10139086|NCT04210570|Active Comparator|CGA GA|Chemical CO2 absorber (CGA) will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
10139087|NCT04210570|Experimental|Memsorb low-flow|Memsorb Filter will be used during low flow general anesthesia (GA)
10139088|NCT04210570|Experimental|CGA low flow|Chemical CO2 absorber (CGA) will be used during low flow general anesthesia (GA)
10139089|NCT04210570|Experimental|Memsorb laparoscopic surgery|Memsorb Filter will be used during general anesthesia for laparoscopic surgery
10139090|NCT04210570|Experimental|CGA laparoscopic surgery|Chemical CO2 absorber (CGA) will be used during laparoscopic surgery
10139091|NCT04210518|Experimental|Neuromuscular training|"Neuromuscular training consisting of:~Single limb balance task.~Balance training on an unstable surface.~Hop drills."
10139092|NCT04210518|Experimental|Stroboscopic glasses group|"This group performed the same neuromuscular training with the addition of stroboscopic glasses during the training performance.~Single limb balance task.~Balance training on unstable surfaces.~Hop drills."
10139093|NCT04210518|No Intervention|Control group|This group received no intervention
10139094|NCT04210492|Experimental|45 Gy|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
10139095|NCT04210505|Experimental|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.
10139096|NCT04210505|No Intervention|Concurrent Control|Standard of Care. This will be usual care at each hemodialysis center.
10139097|NCT04210778|Experimental|CRAFT (Cognitive Training and Functional Treatment)|Over 12 weeks this group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training, in addition to a weekly 1 hour remote CO- OP (Meta cognitive strategy training) session. Each participant will set three occupational goals that will be the focus of the CO -OP treatment
10139098|NCT04210778|Active Comparator|Computerized Cognitive Training|This group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training
10139099|NCT04210778|No Intervention|Treatment As Usual|This group will receive no intervention
10139100|NCT04210531|Experimental|BJ supplementation|Acute beetroot juice (BJ) supplementation
10139101|NCT04210531|Placebo Comparator|PLA supplementation|Acute placebo (PLA) supplementation
10139102|NCT04210726|Active Comparator|Active Group - 25% Saline Bath|The Active group's patients will separately have an immersion bath in 25% Sea Salt in Water solution (made by adding pure Sodium Chloride in the form of Sea Salt to Tap Water Bath) at a temperature comfortable to every participant (please note that Solubility of Sodium Chloride in Water does not change significantly with change in temperature, therefore the concentration will remain the same regardless of water temperature), whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers.
10139103|NCT04210726|Placebo Comparator|Control Group - 0.9% Saline Bath|The Control group's patients will separately have a bath in 0.9% Sea Salt in Water (Isotonic solution, made by adding Sodium Chloride in form of Sea Salt to Tap Water) at a comfortable temperature whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers
10139104|NCT04210414|Experimental|Day 3 transfer|Transfer on day 3 when only one embryo is available
10139105|NCT04210414|Experimental|Day 5 transfer|Transfer on day 5 when only one embryo is available
10184499|NCT03754569|Experimental|Peritoneal biopsies|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
10139106|NCT04210674|Experimental|The traditional medicinal product of Argan spinosa oil|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the traditional medicinal product of Argan spinosa oil on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
10139107|NCT04210674|Active Comparator|The conventional topical steroid ointment|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the conventional topical steroid ointment on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
10139108|NCT04210466|Experimental|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|an ACT intervention + 2 sessions of explicit self-compassion meditation exercises.
10139109|NCT04210466|Active Comparator|Acceptance & Commitment Therapy (ACT)|an ACT intervention + 2 Q&A sessions.
10139110|NCT04210388|Experimental|AZD5718 tablet, Treatment A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions.
10139111|NCT04210388|Experimental|AZD5718 tablet, Treatment B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions.
10139112|NCT04210388|Experimental|AZD5718 tablet, Treatment C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
10139113|NCT04210388|Experimental|AZD5718 tablet, Treatment D|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
10139114|NCT04210388|Active Comparator|AZD5718 film-coated tablet|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions.
10139115|NCT04210648|Experimental|Intervention group|Those who will use the mobile app
10139116|NCT04210648|No Intervention|Non-intervention group|Those who will not use the mobile app
10139117|NCT04210323|Experimental|Shotblocker group|ShotBlocker® was used by an experienced registered nurse under the researcher supervision. The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
10139118|NCT04210323|Placebo Comparator|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
10139119|NCT04210323|No Intervention|Control group|Subcutaneous injection was performed with normal subcutaneous drug administration steps by an experienced registered nurse and no additional method was applied. The application process of each patient was managed by the researcher.
10139120|NCT04210336|Experimental|PAPILOCARE|"Randomized patients will receive two different guidelines depending on the time of randomization:~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
10139121|NCT04210336|Placebo Comparator|PLACEBO|"Randomized patients will receive two different guidelines depending on the time of randomization:~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
10139122|NCT04210167|Experimental|web-based training and telephone monitoring|The heart failure patients in the intervention group were given web-based training for three months after discharge and followed up by telephone at the first, fourth, eighth and 12th weeks. At the same time, a text message was sent once a week. Scale data were collected before the patient was discharged from the hospital and at the third month of discharge.
10139123|NCT04210479|Experimental|Filled-bladder|Bladder filling with 300ml diluted methylene blue.
10139124|NCT04210479|Active Comparator|non filled-bladder|
10139125|NCT04210427|Experimental|Intervention with polyethylene glycol & SmartPill|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
10139126|NCT04210453|Placebo Comparator|Control group|Participants in this group are administered IV normal saline.
10139127|NCT04210453|Experimental|Vitamin C group|Participants in this group are administered IV vitamin C diluted in normal saline.
10139128|NCT04210440|Experimental|Hip avascular necrosis|patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria
10139129|NCT04210765|Active Comparator|Clomiphene citrate group 1|Clomiphene citrate dose 50mg/day for 5 days starting on cycle day (2-4).
10139130|NCT04210765|Active Comparator|Clomiphene citrate group 2|Non-responsive to ovulation induction with Clomiphene Citrate with dose:50mg/day; and treated with dose:100mg/day in the succeeding cycle for 5 days, starting on cycle day (2-4).
10139131|NCT04210362|Experimental|Educational intervention for 30 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 30 months.
10139132|NCT04210362|Experimental|Educational intervention for 24 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 24 months.
10139133|NCT04210362|Experimental|Educational intervention for 12 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 12 months.
10139134|NCT04210362|No Intervention|Comparison group|Group comprised of children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca, Mexico. Children and their caregivers will not be exposed to the intervention at the moment of their measurements.
10139135|NCT04210128||Breast cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of breast neoadjuvant chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
10139136|NCT04210128||Pancreatic cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of pancreatic chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
10139137|NCT04210271|Experimental|HIV Self-testing|brief intervention to teach and support consistent self-testing with a friend
10139138|NCT04210271|Active Comparator|Generic Self-screening|time and attention control providing basic self-screening education on a range of health outcomes
10139139|NCT04210609|Experimental|VHT treatment|Patients will be treated with VHT for 55 minutes at a minimum frequency of 2 times per week
10139140|NCT04210544|Experimental|Dietary protein|Postprandial effects after consuming 20 g of a experimental dietary protein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
10139141|NCT04210544|Active Comparator|Casein|Postprandial effects after consuming 20 g of casein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
10139142|NCT04210544|Placebo Comparator|Water|Postprandial effects after consuming 20 g of water mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
10139143|NCT04210102|Other|CR + LUS|Patient will be performed first the Chest radiography then the Lung ultrasound.
10139144|NCT04210102|Other|LUS + CR|Patient will be performed first the Lung ultrasound then the Chest radiography
10139145|NCT04210050|Other|Usual care|Usual care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
10139146|NCT04210050|Active Comparator|Usual care plus NIPPV group only|Usual care for COPD based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines plus use of nocturnal ventilator device using the Breas VIVO 50 home ventilator, Breas Medical (or any newer models as available).
10139147|NCT04210193|Active Comparator|Active booster|After three basic open label grass allergen ILIT injections the patient is randomized to an active ILIT booster 1 year after the first treatment.
10139148|NCT04210193|Placebo Comparator|Placebo booster|After three basic open label grass allergen ILIT injections the patient is randomized to a placebo ILIT booster 1 year after the first treatment.
10139149|NCT04210063|Experimental|IMT Intervention|During the first month, participants will be in a month-long control wash in period where no intervention will be provided. During the second month, participants will be in a 4-week daily IMT intervention period. During the third month, participants will be in a month-long efficacy period with no intervention provided.
10139150|NCT04209751||Children with summer diarrhea|Children aged 0 to 16 years with diarrhea
10139151|NCT04209933|Active Comparator|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
10139152|NCT04209933|Active Comparator|Colloidal pectin bismuth capsules containing quadruple therapy|Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
10139153|NCT04209933|Active Comparator|Colloidal pectin bismuth particles A quadruple therapy|Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
10139154|NCT04209933|Active Comparator|Colloidal pectin bismuth particles B quadruple therapy|Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
10139155|NCT04209920|Active Comparator|PMMA crown Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
10139156|NCT04209920|Active Comparator|Cast metal coping Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
10139157|NCT04209842|Experimental|gastric ballon placement|will receive gastric balloon placed via endoscopy
10139158|NCT04209699|Experimental|Treatment A: BMS-986165 alone, fasted|
10139159|NCT04209699|Experimental|Treatment B: BMS-986165 alone, fed|
10139160|NCT04209699|Experimental|Treatment C: BMS-986165 with famotidine pretreatment, fasted|
10139161|NCT04209881||Patients with Ankylosing spondylitis|"Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
10139162|NCT04209881||Healthy women as controls|"Regular menstruation with intervals of 21-35 days; cycle length variations <4 days; and both ovaries still present healthy women will create the control group.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.~Amh will be looked for. (pmol / l). Antral folukul census in the overin folukular stage will be valued as number. Fsh (iu / l) and Estradiol (pmol / l) values will also be recorded."
10184500|NCT03754543|Active Comparator|Testmeal A|A new, whole-grain infant cereal fortified with ferrous fumarate
9969751|NCT01293097|Active Comparator|Intensive statin therapy|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
9969752|NCT01293097|Other|Usual care|Usual care, but statin dose should not be higher than that described in exclusion criteria.
9969753|NCT01293136||intravenous opioids|
9969754|NCT01293136||femoral nerve block|
9969755|NCT01293149|Experimental|Ropivacaine plus clonidine|Ropivacaine plus clonidine for femoral block
9969756|NCT01293149|Active Comparator|Ropivacaine|Ropivacaine alone for femoral block
9969757|NCT01293162||placebo|
9969758|NCT01293175|Experimental|Whole grains|Subjects will consume whole grains every day for two months
9969759|NCT01293175|No Intervention|Control|Subjects will consume their habitual diet
9969760|NCT01293188||Biopresthetic aortic valve replacement.|
9969761|NCT01293201|Experimental|STAHIST Investigational Medical Product|STAHIST Tablet, dosed one tablet BID
9969762|NCT01293201|Placebo Comparator|Placebo|Placebo tablet, identical appearance to IMP, dosed one tablet BID
9969763|NCT01293214|Experimental|Transplantation|Subjects will undergo single or multiple limb transplantation
9969764|NCT01293253|Experimental|Stair walking|Participants of this group is encouraged to use the stairs for 10 minutes a day at the workplace
9969765|NCT01293253|Active Comparator|Control|Receives a health examination before and after the intervention period, and are advised to stay active
9969766|NCT01293266|Active Comparator|Propofol|Anesthesia is changed from Sevoflurane to Propofol after obtaining baseline blood gas analysis from the heart catheterisation sheath.
9969767|NCT01293266|No Intervention|Sevoflurane|Sevoflurane anesthesia is maintained after obtaining a baseline blood gas analysis.
9969768|NCT01293279||HCV Patients who are treatment naive|Han ethnic Chinese male or female ≥ 18 years old with recent a confirmation of anti-HCV-antibody positive and HCV RNA positive but antiviral or interferon treatment naive at the time this study starts from 28 university affiliated hospital throughout China.
9969769|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine sulfate|Pharmaceutical form capsule.
9969770|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine Sulfate|Oral powder.
9969771|NCT01293305|Active Comparator|Condroflex®|Pharmaceutical form capsule.
9969772|NCT01293305|Active Comparator|CONDROFLEX®|Oral powder
9969773|NCT01293318||Acute pancreatitis|
9969774|NCT01293331||Study Cohort (Case )|Participants will be examined for fever in dengue endemic regions
9969775|NCT01293344|Experimental|Men and Mediterranean diet|Men who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
9969776|NCT01293344|Experimental|Women and Mediterranean diet|Women who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
9519684|NCT03284567|No Intervention|Control group|Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
9969777|NCT01293357|Experimental|Patches|
9969778|NCT01293370||vocational rehabilitation|Admitted and discharged psychiatric patients receiving vocational rehabilitation
9969779|NCT01293383|Other|LEO 90105|
9969780|NCT01293383|Other|Vehicle|
9976936|NCT01356524|Active Comparator|Supplementary progesterone|Women with mid-luteal progesterone levels that are less than 15 ng/dl will receive higher doses of supplementary progesterone
9976937|NCT01356524|No Intervention|No additional progesterone|No additional progesterone given to women with mid-luteal progesterone levels below 15 ng/dl
9976938|NCT01356537||Gaucher's Disease under VPRIV|
9976939|NCT01356550|Experimental|Healthy subjects|
9976940|NCT01356550|Experimental|Hepatic impairment|
9976941|NCT01356563|Experimental|clinical pharmacist intervention|
9976942|NCT01356563|No Intervention|usual care|Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
9976943|NCT01356615|Experimental|enoxaparin|enoxaparin sodium (Clexane) (40 mg) followed prospectively for 3 months (36 dialyses)
9976944|NCT01356615|Active Comparator|standard unfractionated heparin|standard unfractionated heparin followed prospectively for 3 months (36 dialyses)
9976945|NCT01356641|Experimental|Antibiotic treatment alone|"Intravenous administration:~Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily~Oral administration of:~Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)"
9976946|NCT01356641|Active Comparator|Appendectomy|Routine appendectomy either laparoscopic or open depending on the surgeon's preference
9976947|NCT01356654|Sham Comparator|SHAM TDCS|
9976948|NCT01356654|Active Comparator|True TDCS|
9976949|NCT01356680|Active Comparator|Arm A|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
9976950|NCT01356680|Experimental|Arm B|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
9976951|NCT01356693|Experimental|Active drug|Bromelin. Extract from Ananas comosus, 3,3g on vehicle (methylparaben, propylparaben, honey from apis mellifera, sodium benzoate, ethylic alcohol, water) 5ml.
9976952|NCT01356693|Placebo Comparator|Placebo|Placebo comparator with the same characteristics of experimental drug, 5ml, single dose.
9976953|NCT01356706||CRLM|patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)
9976954|NCT01356732|Experimental|Sufentanil|
9976955|NCT01356745|Experimental|premixed 50% nitrous oxide and oxygen|
9976956|NCT01356745|Placebo Comparator|medical air|
9976957|NCT01356758||Psoriasis topical treatment|Psoriasis topical treatment. No systemic drugs.
9976958|NCT01356758||Psoriasis biological treatment|Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
9976959|NCT01356758||Severe atopic dermatitis|Severe atopic dermatitis
9976960|NCT01356758||Control|No intervention. No inflammatory skin disease.
10139163|NCT04209972|Active Comparator|Patients on CT1|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a standard CT scanner. (Aquilion One Genesis, Canon Medical Systems)
10139164|NCT04209972|Active Comparator|Patients on CT2|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a UHRCT scanner. (Aquilion One Precision, Canon Medical Systems)
10139165|NCT04209985|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach will call patients up to five times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
10139166|NCT04209985|No Intervention|Usual care|Patients assigned to usual care have access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
9669190|NCT03746080|Experimental|Whole Brain Radiotherapy + Plerixafor +Chemoradiotherapy|After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.
9669191|NCT03722550|Active Comparator|Control Group|Standard Starter Infant Formula, Standard Follow-up Formula, and Standard Growing-up Milk
9669192|NCT03722550|Experimental|Test Group 1|Starter Infant Formula (same as Control Group) supplemented with 1.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
9669193|NCT03722550|Experimental|Test Group 2|Starter Infant Formula (same as Control Group) supplemented with 2.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
9669194|NCT03722550|Active Comparator|Breastfed Group|Non-randomized Breastfed reference group
10184501|NCT03754543|Active Comparator|Testmeal B|An alternative new whole-grain infant cereal recipe fortified with ferrous fumarate
10184502|NCT03754543|Placebo Comparator|Testmeal C|An existing, refined grain infant cereal fortified with ferrous fumarate
10184503|NCT03754543|Active Comparator|Testmeal D|An existing, whole-grain infant cereal fortified with ferrous fumarate
10184504|NCT03754543|Active Comparator|Testmeal E|An existing, whole-grain infant cereal fortified with ferrous bisglycinate
10184505|NCT03754530|Experimental|Icotinib|icotinib is administered orally three times per day. Until emerge the progression of the intracranial disease, then is given radiotherapy(>3 with WBRT or <=3 with SRS) after PD
10184506|NCT03754530|Experimental|Icotinib plus radiation therapy|Standard whole brain radiotherapy (WBRT) is given with 30GY/10 times(>3), or SRS(<=3) plus concurrent icotinib, which was administered orally three times per day. Until the disease progresses.
10184507|NCT03754517||Serofast status|The syphilitic patients who remain in a serologically positive state after therapy
10184508|NCT03754517||Untreated|untreated syphilis cases
10184509|NCT03754517||Serological cure|"In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.~In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer."
10184510|NCT03754504|Experimental|Cranberry|Whole Cranberry Powder Supplements
10184511|NCT03754504|Placebo Comparator|Placebo|Placebo
9669195|NCT03715933|Experimental|Dose Escalation|INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas.
9669196|NCT03715933|Experimental|Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
9669197|NCT03715933|Experimental|Expansion Gastric Adenocarcinoma|Subjects with gastric adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
9669198|NCT03715933|Experimental|Expansion Colorectal Adenocarcinoma|Subjects with colorectal (CRC) adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
9669199|NCT03715933|Experimental|Expansion Sarcomas|Subjects with certain sarcoma subtypes will be treated with single-agent INBRX-109 at either the MTD or RP2D.
9669200|NCT03715933|Experimental|Combination Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with INBRX-109 in combination with chemotherapies (carboplatin, cisplatin, carboplatin and pemetrexed, or cisplatin and pemetrexed)
10184512|NCT03754491|Experimental|One stage stone removal in mild cholangitis|one-stage stone removal at the first session of ERCP in mild cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
10184513|NCT03754491|Experimental|One stage stone removal in moderate cholangitis|one-stage stone removal at the first session of ERCP in moderate cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
10184514|NCT03754478||overweight subjects|Overweight male and females referred to a physical activity program by their primary care physician Intervention is being included in a 3-month physical activity training program
10184515|NCT03754465|Experimental|ALLO-ASC-DFU|Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
10184516|NCT03754465|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
10184517|NCT03754439||Inborn|"Infants born within Nottingham University hospitals~< 32 weeks gestational age~< 72 hours old"
9976961|NCT01356771|Other|Control Group|
10139167|NCT04209894||Psoriasis|They will undergo dermatological assessment and a blinded ultrasound (US) evaluation.
10139168|NCT04209894||Control|They will also undergo dermatological assessment and a blinded ultrasound (US) evaluation.
10139169|NCT04209777|Active Comparator|Antibiotics|The antibiotic group is provided with amoxicillin capsules 500mg and metronidazole tablets 400mg three times a day for 7 days along with the placebo of probiotics twice daily for 30 days.
10139170|NCT04209777|Experimental|Probiotics|The probiotic group is provided with Lactobacillus-reuteri probiotics (2x10(8)CFU) twice daily after brushing for 30 days.
10139171|NCT04209959|Experimental|low dose group|
10139172|NCT04209959|Experimental|middle dose group|
10139173|NCT04209959|Experimental|high dose group|
9669201|NCT03715933|Experimental|Combination Expansion Pancreatic Adenocarcinoma|Subjects with pancreatic adenocarcinoma will be treated with INBRX-109 in combination with 5FU/irinotecan based chemotherapy
10139174|NCT04209647|Active Comparator|Continuous Exercise|At %60 of maximal heart rate, 30-60 minutes exercise
10139175|NCT04209647|Experimental|REHIT Exercise|At %100 of heart rate 15 seconds, after this period 15 sec recovery period for all step
10139176|NCT04209725|Experimental|CPX-351 and Quizartinib treatment|Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
10139177|NCT04209803|Active Comparator|Minoxidil group|The first group will receive Minoxidil 5% topically twice daily for 4 months.
10139178|NCT04209803|Active Comparator|NAC group|The second group will receive NAC orally 600 mg 3 times a day for 4 months.
10139179|NCT04209803|Active Comparator|Minoxidil + NAC group|The third group will receive combined treatment of Minoxidil 5% twice daily and oral NAC 600 mg 3 times a day for 4 months.
10139180|NCT04209803|No Intervention|Control group|The fourth group will be the patients who are refusing the treatment and will be followed-up over 4 months.
10139181|NCT04209712|Experimental|haploid allogeneic NK cell therapy|haploid allogeneic NK cell therapy with chemotherapy
10139182|NCT04209439|Active Comparator|ultrasound guided erector spinae plane block|30 ml %0.25 ultrasound-guided erector spinae plane block at the level of T8
10139183|NCT04209439|Active Comparator|Dexketoprofen-trometamol|intravenous 50 mg dexketoprofen-trometamol
10139184|NCT04209452|No Intervention|Control|No intervention will be provided for participants enrolled in the control group.
10139185|NCT04209452|Experimental|Rehearsal|Participants will receive instruction on rehearsal strategy.
10139186|NCT04209452|Experimental|Reinforcement|Participants will receive reinforcement for correct recall.
10139187|NCT04209452|Experimental|Rehearsal + Reinforcement|The participants in this group will receive instruction on rehearsal strategy and reinforcement for correct recall.
10139188|NCT04209556|Placebo Comparator|Placebo|Placebo
10139189|NCT04209556|Experimental|PF-06826647 100 mg once a day (QD)|PF-06826647 100 mg once a day (QD)
10139190|NCT04209556|Experimental|PF-06826647 300 mg QD|PF-06826647 300 mg QD
10139191|NCT04209556|Experimental|PF-06826647 600 mg QD|PF-06826647 600 mg QD
10139192|NCT04209556|Experimental|Open Label Extension, PF-06826647 400 mg QD|PF-06826647 400 mg QD
10139193|NCT04209257|Experimental|Functional Electrical Stimulation protocol|Participants will be evaluated with and without the use of functional electrical stimulation while walking to determine the neuroprosthetic and neurotherapeutic effects.
10139194|NCT04209478|Experimental|TAP Block|Cases were assessed transversus abdominis plane block for postoperative analgesia
10139195|NCT04209478|Experimental|QL Block|Cases were assessed quadratus lumborum block for postoperative analgesia
10139196|NCT04209231||chronic periodontitis|
10139197|NCT04209231||chronic gingivitis|
10139198|NCT04209231||periodontally healthy|
10139199|NCT04209140||bipolar I disorders who initiate lithium treatment|
10139200|NCT04209088|Experimental|Pulmonary ultrasounds|All patients will be included in the experimental arm
10139201|NCT04209062|Experimental|Study device|
10139202|NCT04209062|Active Comparator|Control device|
10139203|NCT04209309|Experimental|leDLPFC|single session rTMS of the left dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F3)
10139204|NCT04209309|Experimental|riDLPFC|single session rTMS of the right dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F4)
10139205|NCT04209309|Sham Comparator|shamDLPFC|single session sham rTMS over the medial prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the midline with tilted coil)
10139206|NCT04209426||HMB-DMR-HA|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a hydroxyapatite-coated outer surface as well as two pegs and one screw.
10139207|NCT04209426||HMB-DM-CEM|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a bare metal outer surface to be covered with bone-compatible cement.
10139208|NCT04209374||HMB-DMR-HA|Primary total hip arthroplasty with hemispherical dual-mobility acetabular cup
10139209|NCT04209218|Placebo Comparator|Routine blood pressure management + placebo|Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.
10139210|NCT04209218|Experimental|Routine blood pressure management + dexamethasone|Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.
10139211|NCT04209218|Experimental|Targeted blood pressure management + placebo|Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.
10139212|NCT04209218|Experimental|Targeted blood pressure management + dexamethasone|Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
10139213|NCT04209244|Experimental|Fish oil|Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)
10139214|NCT04209244|Placebo Comparator|Placebo|Rapeseed Oil, 10 ml per day
10139215|NCT04209166|Experimental|FAD|the first-episode major depressive disorder with atypical feature
10139216|NCT04209166|Experimental|RAD|the recurrent major depressive disorder with atypical feature who have been medication-free for no less than 2 weeks
10139217|NCT04209166|No Intervention|BD|the depressive episode of bipolar disorder
10139218|NCT04209166|No Intervention|HC|healthy control
10139219|NCT04209400|Experimental|Sci-B-Vac®|The third-generation HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
10139220|NCT04209400|Active Comparator|Engerix-B®|The second-generation HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.
10139221|NCT04209179|Experimental|PCO371 Low Dose and Low administration frequency|PCO371 low dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
10139222|NCT04209179|Experimental|PCO371 High Dose and Low administration frequency|PCO371 high dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
10139223|NCT04209179|Experimental|PCO371 High Dose and High administration frequency|PCO371 high dose and high administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
10139224|NCT04209179|Placebo Comparator|Placebo|Placebo by oral administration.
10139225|NCT04209075|Experimental|Placebo then Prebiotic|Participant will take Placebo during Period 1 and Prebiotic during Period 2
10139226|NCT04209075|Experimental|Prebiotic then Placebo|Participant will take Prebiotic during Period 1 and Placebo during Period 2
10139227|NCT04209192|Active Comparator|Control group (Amikacin)|"Patients in the control group will receive amikacin as prophylactic antibiotic. It will be administered intravenously 30 minutes before procedure. Patients with an estimated glomerular filtration rate (EGFR) greater or equal than 70 ml/min will receive 1 gram of Amikacin. Patients with an EGFR less than 70 ml/min will received a calculated dose following the next parameters.~Patients with EGFR between 69-40 ml/min should receive: the calculated GFR x 0.18 = mg/kg.~Patients with EGFR less than 40 ml/min should receive: the calculated GFR x 0.36 = mg/kg."
10139228|NCT04209192|Experimental|Intervention group (Fosfomycin)|Patients in the intervention group will receive Fosfomycin trometamol as prophylactic antibiotic. It will be administered orally in the night before procedure. Patients must be on fasting and will receive 3 grams.
10139229|NCT04209036||3D laparoscopy arm|patients submitted to total hysterectomy using a 3D laparoscopic camera
10139230|NCT04209036||2D laparoscopy arm|patients submitted to total hysterectomy using a 2D laparoscopic camera (standard laparoscopic camera)
10139231|NCT04209049|Experimental|Normal renal function|All subjects will receive one dose of NNC0174-0833.
10139232|NCT04209049|Experimental|Mild renal impairment|All subjects will receive one dose of NNC0174-0833.
10139233|NCT04209049|Experimental|Moderate renal impairment|All subjects will receive one dose of NNC0174-0833.
10139234|NCT04209049|Experimental|Severe renal impairment|All subjects will receive one dose of NNC0174-0833.
10139235|NCT04208789||Positive Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Positive Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
10139236|NCT04208789||Negative Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Negative Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
10139237|NCT04209023|Experimental|navigated TMS|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest; these areas will provide the cerebral coordinates to be validated by TMS.
10139238|NCT04208672|Experimental|Patient attending for PSG in Sleep Assessment Unit|Subjects referred to the SAU will be invited to participate into this study
10139239|NCT04208893|Experimental|Aerobic training only|The aerobic training intervention will include 60 minutes/session, 3 times/week for 12 weeks at an intensity of 65% - 85% of participants' heart rate reserve (HRR), as determined by the CPET. Patients will be asked to wear a fitness-tracking device to monitor their heart rate response and in order to comply with the prescribed training intensity. All training sessions will start with a 10-minute warm up, 40-minute aerobic interventions, and ends with 10-minute of cool down. One study doctor will be on call during in-hospital training. Onsite supervised aerobic interventions will include play-based activities, whereas home-based aerobic activities will include stationary bikes and exercise activities that would target desired heart rate ranges. Home exercise equipment will be provided.
10139240|NCT04208893|Experimental|Combined aerobic and strength training|Participants in this group will perform a combination of aerobic and strength training activities for 60 minutes/session, 3 times/week for 12 weeks. Aerobic activities for this group will be similar to Arm 1. Strength training will be based on participant's individual assessment findings and developmental status. Resistance level will be set at approximately 50% of the patient maximal load and increased by 3 pounds (or the next level of resistance band) once the patient is able to perform 30 repetitions. Closed kinetic chain exercises such as pushups, squats, and lunges will be made more challenging by the addition of weight or change in body position. Training sessions will include a 10-minute warm up, 40-minute aerobic and strength exercises, and a 10-minute cooldown.
10139241|NCT04208841|No Intervention|Control - Patient|Participants who receive maternal health services at a facility not participating in the Quality Improvement Intervention or implementing the change package
10139242|NCT04208841|Experimental|Sustaining - Patients|Participants who received maternal health services at a facility where a quality improvement collaborative had been implemented
10139243|NCT04208841|Experimental|Spread - Patients|Participants who received maternal health services at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
10139244|NCT04208841|No Intervention|Control - Providers|Providers who work at a facility not participating in the Quality Improvement Intervention or implementing the change package
10139245|NCT04208841|Experimental|Sustaining - Providers|Providers who work at a facility where a quality improvement collaborative had been implemented
10139246|NCT04208841|Experimental|Spread - Providers|Participants who work at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
10139247|NCT04208932||MDD|major depressive disorder
10139248|NCT04208932||HC|healthy control
10139249|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
10139250|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells high-dose group
10139251|NCT04208646|Placebo Comparator|No mesenchymal progenitor cells|No mesenchymal progenitor cells
10139252|NCT04208984||Control|Patients randomized to this group will receive standard of care induction of anesthesia
10139253|NCT04208984||Study|Patients randomized to this group will receive induction of anesthesia using the Lullabreath game
10139254|NCT04208984||Music Video|Patients randomized to this group will receive induction of anesthesia using the music video game
10139255|NCT04208854||VINORELBINA|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
10139256|NCT04208776|Experimental|Midodrine+Propranolol|
10139257|NCT04208776|Active Comparator|Propranolol|
10139258|NCT04208880|Experimental|TBH Brain Workout 1.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be easy to master.
10139259|NCT04208880|Experimental|TBH Brain Workout 2.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be moderately difficult to master.
10139260|NCT04208880|Experimental|TBH Memory 1.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be easy to master.
10139261|NCT04208880|Experimental|TBH Memory 2.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be moderately difficult to master.
10139262|NCT04208880|Active Comparator|Book Club|The Book Club will be given a book to read on how to improve brain health and will discuss separate chapters across 8 sessions. These sessions will be led by the participants and no formal structure will be provided. No personal challenges will be asked of participants and no log will be required. All groups will have a sign-in sheet to record individual participation.
10139263|NCT04208880|No Intervention|No Contact Wait List|The Wait List group will simply take the the surveys at each time point as the other groups.
10139264|NCT04208867|Experimental|Intervention - Women|Women who receive MH services from a facility participating in the QI collaborative to improve PCC
10139265|NCT04208867|No Intervention|Control - Women|Women who receive MH services from a facility not participating in the QI collaborative to improve PCC
10139266|NCT04208867|Experimental|Intervention - Provider|Provider working at a facility participating in the QI collaborative to improve PCC
10139267|NCT04208867|No Intervention|Control - Provider|Provider working at a facility not participating in the QI collaborative to improve PCC
10139268|NCT04208919|Experimental|DCreg Prior to Weaning|Regulatory dendritic cells that were derived from the recipient's liver donor will be infused into the recipient one week prior to the initiation of immunosuppression weaning.
10139269|NCT04208945|Experimental|Inhaled colistin|Inhaled colistin three times daily for 10 days
10139270|NCT04208945|No Intervention|Standard management|
10139271|NCT04209127|Experimental|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment for adenomyosis
10139272|NCT04209127|Active Comparator|Control|Uterine artery embolization; percutaneous application of a catheter into the femoral artery or branches thereof
10139273|NCT04208737|No Intervention|control group|"3 FRC measurements will be perforemed, whereby : First measurement; after aneshesia induction and intubation. Second measurement; after pneumoperitoneum Third measurement; end of the operation~After the operation,Postoperative Room Air Test (RAT) will be applied."
10139274|NCT04208737|Experimental|study group|"5 FRC measurements will be performed We will apply recruitment maneuver two times to patients with 30cmH2O pressure for 15 seconds .~First Recruitment maneuver will be applied after the fşrst measurement of FRC following intubation Second Recuitment maneuver will be applied at the end of operation~First FRC measurement after anesthesia induction and intubation. Second FRC measurement after first recruitment maneuver Third FRC measurement; after pneumoperitoneum Fourth FRC measurement before second recruitment maneuver Fifth FRC measurement after second recruitment maneuver and at the end of operation"
10139275|NCT04209010||One-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in one stage using silicone implant and acellular dermal matrix.
10139276|NCT04209010||Two-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in two stages using expander to silicone implant technique.
10139277|NCT04208711|Other|positive HIV patient not treated by ARV yet|"Before starting HIV treatment, 15 patients will be included in the study and 50mL of whole blood will be taken. After treatment initiation 8 of the 15 patients will entered in the follow-up phase for 1 year (5 followup visit, M1, M3, M6, M9, M12) and 30mL of whole blood will be taken at each visit.~The duration of the study for the 7 other patients will be 1 day."
10139278|NCT04208958|Experimental|VE800 combination treatment with Nivolumab|Subjects will receive 5 days of oral vancomycin, followed by daily VE800 in combination with Nivolumab every 4 weeks.
10139279|NCT04208594|Active Comparator|GROUP (P):|will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia.
10139280|NCT04208594|Experimental|GROUP (I):|will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.
10139281|NCT04208555|Experimental|Boric acid vaginal suppository|
10139282|NCT04208555|Active Comparator|Terconazole vaginal suppository|
10139283|NCT04208763|Experimental|Imipenem+Tigecycline+GM-CSF|
10139284|NCT04208763|Active Comparator|Imipenem+Tigecycline|
10139285|NCT04208620|Placebo Comparator|Placebo|Placebo administered subcutaneously
10139286|NCT04208620|Experimental|Cotadutide|Cotadutide administered subcutaneously
10139287|NCT04208438||BVI Cohort|Cohort to have ultrasound and Mespere BVI device applied.
10139288|NCT04208373|Experimental|Panel 1: JNJ 64417184 plus Itraconazole|Participants will receive single oral dose of JNJ 64417184 on Day 1 followed by itraconazole once daily on Days 6 to 13 along with a single dose of JNJ 64417184 on Day 9 orally.
10139289|NCT04208373|Experimental|Panel 2: JNJ 64417184 plus Etravirine|Participants will receive single oral dose of JNJ-64417184 on Day 1 followed by etravirine twice daily on Days 6 to 19 along with single dose of JNJ 64417184 on Day 15.
10139290|NCT04208633|Other|Horizontal placement of the intraocular lens|The eyes randomised to have horizontal placement of intraocular lenses
10139291|NCT04208633|Other|Vertical placement of the intraocular lens|Fellow eye receiving vertical placement of intraocular lens.
10139292|NCT04208581|Experimental|Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive Yiqi Huoxue Huatan granule in addition to Western medicine.
10139293|NCT04208581|Placebo Comparator|Placebo Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive placebo Yiqi Huoxue Huatan granule in addition to Western medicine.
10139294|NCT04208412|Experimental|KVD900|
10139295|NCT04208412|Placebo Comparator|Placebo|
10139296|NCT04208451|Experimental|Experimental group|Patients on hemodialysis who consumed one month Standardized Aronia Melanocrpa extract
10139297|NCT04208425|Experimental|Project Personality|The web-based growth mindset intervention, called Project Personality, is delivered entirely via Qualtrics and takes approximately 30 minutes to complete. All intervention activities are self-administered by youth and delivered in a web-based format, including illustrations and audio-recordings of text. Intervention content is designed to maximize relevance for youths experiencing symptoms of depression, including excessive sadness and hopelessness.
10139298|NCT04208425|Active Comparator|Sharing Feelings Intervention|The Sharing Feelings Intervention is delivered entirely via Qualtrics, is self-administered by youth, and takes approximately 30 minutes to complete. It is structurally similar to the growth mindset intervention, but it is designed to mimic supportive therapy (ST). The goals of the ST intervention is to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions.
10139299|NCT04208568|Active Comparator|Gallbladder retrieval from umbilical port|Gallbladder retrieved from 10 mm umbilical port.
10139300|NCT04208568|Active Comparator|Gallbladder retrieval from epigastric port|Gallbladder retrieved from 10 mm epigastric port.
10139301|NCT04208269|Active Comparator|Postcard campaign|
10139302|NCT04208269|Active Comparator|Provider-only intervention|
10139303|NCT04208269|Active Comparator|Patient and provider intervention|
10139304|NCT04208269|No Intervention|Standard care|
10139305|NCT04208607|Experimental|Study group|Patients with bronchiectasis
10139306|NCT04208542|Active Comparator|Interventional|Under general anaesthesia, ultrasound guided ESP block will perform at the T5 level with 0.375% ropivacaine 20ml. Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
10139307|NCT04208542|No Intervention|Control|Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
10139308|NCT04208399|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
10139309|NCT04208399|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive a single oral dose of JNJ-56136379 in fed condition.
10139310|NCT04208399|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
10139311|NCT04208399|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
10139312|NCT04208308|No Intervention|Control negative group|Without supplementation
10139313|NCT04208308|Experimental|Experimental negative group I|"Chia seeds supplementation (25 g)~On dose (25g) of chia seeds contains:~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
9969781|NCT01293409|Placebo Comparator|Placebo|The amount of photic energy of light is considered to be non-therapeutical
10139314|NCT04208308|Experimental|Experimental negative group II|"Chia seeds supplementation (15 g)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
10139315|NCT04208308|Experimental|Experimental negative group III|"Combine supplementation: chia seeds and fish oil~Daily dose:~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
10139316|NCT04208308|Experimental|Experimental negative group IV|"Fish oil supplementation~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
10139317|NCT04208308|No Intervention|Control positive group|Without supplementation
10139318|NCT04208308|Experimental|Experimental positive group I|"Chia seeds supplementation (25 g)~On dose (25g) of chia seeds contains:~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
10139319|NCT04208308|Experimental|Experimental positive group II|"Chia seeds supplementation (15 g)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
10139320|NCT04208308|Experimental|Experimental positive group III|"Combine supplementation: chia seeds and fish oil~Daily dose:~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
10139321|NCT04208308|Experimental|Experimental positive group IV|"Fish oil supplementation~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
10139322|NCT04208334|Experimental|Curcumin|Curcumin 4000mg/day x 60 days
10139323|NCT04208334|Placebo Comparator|Placebo|Placebo x 60 days
10139324|NCT04208282|Experimental|Trial Arm A|Quickset infusion system for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the 7 day set infusion set, entering Phase 2.
10139325|NCT04208282|Active Comparator|Trial Arm B|7 day set infusion set for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the Quickset infusion systems , entering Phase 2.
10139326|NCT04208516|Active Comparator|Continuous nerve blocks|A total of 30 subjects equally distributed to either continuous Erector Spinae Plane block for unilateral thoracic surgery , or continuous Quadratus Lumborum block for major abdominal surgery. Patients in this group will receive 20ml 0.5% ropivacaine per block performed after positioning of the needle followed by continuous perineural infusion of 0.25% lidocaine (10ml/hr) beginning in the post-anesthesia care unit (PACU) and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
10139327|NCT04208516|Experimental|Single nerve blocks plus IV lidocaine infusion|A total of 30 subjects equally distributed to either Erector Spinae Plane block for unilateral thoracic surgery, or Quadratus Lumborum block for major abdominal surgery, will be included . Patients in this group will receive 20ml 0.5% ropivacaine, 4mg dexamethasone, and 20mcg dexmedetomidine (30mcg if only one block is performed) per block after proper positioning of the Tuohy needle. Upon patient arrival in the recovery room a continuous infusion of IV lidocaine 50 mg /hr will be started and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
10139328|NCT04208477|Experimental|BSG patients|
10139329|NCT04208152|Active Comparator|anle138b|Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
10139330|NCT04208152|Placebo Comparator|placebo|Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
10139331|NCT04208191|No Intervention|Control - Women|Participants who delivered or received family planning services at a facility that was not implementing a QI project on PCC
10139332|NCT04208191|Experimental|Intervention - Women|Participants who delivered or received family planning services at a facility that was implementing a QI project on PCC
10139333|NCT04208191|No Intervention|Control - Provider|Provider working in a facility that is not implementing a QI project on PCC
10139334|NCT04208191|Experimental|Intervention - Provider|Provider working in a facility that is implementing a QI project on PCC
10139335|NCT04208347|Experimental|Apatinib and Camrelizumab and S-1 and Oxaliplatin|
10139336|NCT04208347|Experimental|Apatinib and S-1 and Oxaliplatin|
10139337|NCT04208347|Active Comparator|S-1 and Oxaliplatin|
10139338|NCT04208386|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive single subcutaneous (SC) injection of JNJ-73763989 on Day 1 under fasted condition.
10139339|NCT04208386|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
10139340|NCT04208386|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
9669202|NCT03715933|Experimental|Combination Expansion Ewing Sarcoma|Subjects with Ewing sarcoma will be treated with INBRX-109 in combination with irinotecan/temozolomide based chemotherapy
10139341|NCT04208386|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive SC injection of JNJ-73763989 on Day 1 under fasted condition.
10139342|NCT04208165|Active Comparator|Group P (ultrasound-guided PVB)|In group P, the patient is in sitting position, a linear transducer (6-15 MHz) placed just lateral to the spinous process. Once the transverse processes and ribs are identified, the transducer is moved slightly cauded into the intercostal space between adjacent ribs to identify the thoracic paravertebral space (PVS) and the adjoining intercostal space. The hyper echoic line of the pleura and underlying hyper echoic air artifacts move with respiration. The needle stimuplex needle will be inserted and 0.5- 1 ml local anesthetic injection administered to show the displacement of pleura downward followed by 15 cc bupivacaine 0.25% into each side the PVS. A pop often is felt as the needle penetrates the internal intercostal membrane. Intravascular injection will be eliminated by negative aspiration before injection. Local anesthetic (15- 20 ml) is slowly injected in small increments, avoiding forceful high-pressure injection to reduce the risk of bilateral epidural spread.
10139343|NCT04208165|Active Comparator|Group T (ultrasound-guided TAB)|In group T, Subcostal blockage will be done in plane technique with 22 G needle (BRAUN Stimuplex D Plus 0,71 50- 80 mm 22 G). The puncture area and the ultrasound probe will be prepared in an aseptic manner. The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. On each side, The rectus abdominis and underlying transverses abdominis muscles near the costal margin and xiphoid process will be identified. In-plane image will be obtained and the needle will be inserted through the rectus muscle 2-3 cm medial to the probe. Once the tip of the needle is visualized to be in the plane, 0.25% bupivacaine will be administered incrementally. The drug will be injected along the oblique subcostal line, extending inferolaterally from the xiphoid towards the anterior part of the iliac crest by multiple punctures; a total of 15 ml will be given on each side.
10139344|NCT04208113|Experimental|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the eight week MBSR programme (2,5 hour group meeting once a week) and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b (48 hours) The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
10139345|NCT04208113|No Intervention|Usual practice|Usual practice
10139346|NCT04208178|Experimental|Part 1: Alpelisib + Trastuzumab + Pertuzumab|"In the Part 1, up to 3 alpelisib dose levels may be sequentially tested in 3 cohorts of subjects (Cohort A, Cohort B, and Cohort C)~Cohort A: Alpelisib 300mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)~Cohort B: Alpelisib 250 mg+ trastuzumab (6mg/kg) + pertuzumab (420 mg)~Cohort C: Alpelisib 200mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)"
10139347|NCT04208178|Experimental|Part 2: Alpelisib + Trastuzumab + Pertuzumab|trastuzumab (6mg/kg i.v.) + pertuzumab (420 mg i.v.) in combination with alpelisib at dose identified in Part 1
10139348|NCT04208178|Placebo Comparator|Part 2: Alpelisib matching Placebo + Trastuzumab + Pertuzumab|trastuzumab (6mg/kg i.v.) + pertuzumab (420 mg i.v.) in combination with alpelisib matching placebo
10139349|NCT04208204|Experimental|Somatocognitive physiotherapy|Every participant will maximally receive 15 individual sessions of somatocognitive physiotherapy
10139350|NCT04208061|Experimental|Panel 1: Dabigatran etexilate +DRV/COBI|Participants will receive Treatment A (single dose of Dabigatran etexilate orally) on Day 1 followed by Treatment B (single dose of Darunavir/ cobicistat [DRV/COBI] as fixed dose combination tablet orally and single dose of dabigatran etexilate) on Day 4 followed by Treatment C ([DRV/COBI] as fixed dose combination tablet orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
10139351|NCT04208061|Experimental|Panel 2: Dabigatran etexilate +DRV+rtv|Participants will receive Treatment D (single dose of dabigatran etexilate orally) on Day 1 followed by Treatment E (single doses of Darunavir, and ritonavir [rtv], and single dose of dabigatran etexilate on Day 4), followed by Treatment F (DRV and rtv orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
10139352|NCT04207905||Exempt for Evaluation Purposes|Individuals who would have been subject to the Healthy Michigan Plan (HMP) work requirements but have been randomly assigned to a control group that is exempt from reporting for evaluation purposes
10139353|NCT04207905||Work Requirement|Individuals who are subject to the Healthy Michigan Plan (HMP) work requirements
10139354|NCT04208048||FLXfit 15|The FLXfit 15 device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
10139355|NCT04207970||Clients under PDS Community Team|27 adult clients under PDS Community Team
10139356|NCT04207853|Experimental|whole body vibration in diabetics (G1)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
10139357|NCT04207853|Sham Comparator|the sham vibration group in diabetics (G2)|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
10139358|NCT04207853|No Intervention|diabetic control group (G3)|no treatment
10139359|NCT04207853|Active Comparator|whole body vibration group in non-diabetics (G4)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
10139360|NCT04207853|Sham Comparator|"the vibration group  sham in non-diabetics (G5)"|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
10139361|NCT04207853|No Intervention|non-diabetic control group (G6)|no treatment
10139362|NCT04208009|Experimental|Advance care planning animated videos|This arm consists of viewing four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
9669203|NCT03715933|Experimental|Combination Expansion Colorectal Adenocarcinoma|Subjects with colorectal adenocarcinoma will be treated with INBRX-109 in combination with FOLFIRI based chemotherapy
9969782|NCT01293409|Experimental|Intermediate dose|"The amount of photic energy of bright light is considered to be intermediate"
10139363|NCT04207801|Experimental|Arm-1|400 mg AUR101 twice daily
10139364|NCT04207801|Experimental|Arm-2|600 mg AUR101 twice daily
10139365|NCT04207801|Placebo Comparator|Arm-3|Matching Placebo twice daily
10139366|NCT04208074|Experimental|Exercise|Four months of muscle resistance training (exercise) designed to increase muscle mass and strength. The exercise protocol includes four different lifts with weights including, squats, bench press, dead lift and overhead press. The weights for each lift will be optimized for each participant and increased as the participant adapts to the exercise routine.
10139367|NCT04207957|Other|IV|2 h IV infusion (Groups A/B)
10139368|NCT04207957|Other|oral (fasted)|30 mg tablets given after an overnight fast (Groups A/B)
10139369|NCT04207957|Other|oral (fed)|30 mg tablets given after a high fat breakfast (Groups A/B)
10139370|NCT04207957|Other|oral (intact tablet)|30 mg tablets (Group C)
10139371|NCT04207957|Other|oral (NG tube)|30 mg tablets in water via NG tube (Group C)
10139372|NCT04207827|Experimental|xSmoker app|"The xSmoker app was developed with European Commission funding. xSmoker is a digital health coaching mobile app that helps individuals stop smoking and remain smoke free. The initial version of the xSmoker application was received from the developers and translated into Romanian by the research team. The content has been divided into three main sections: Daily Tips (approximately 630 items), which includes information on the beneficial effects of quitting smoking, Panic Tips (approximately 100 items), which can be accessed at that time when risk of smoking relapse is high, as well as a section called Library (about 120 items), where detailed information on the topics included in the first two sections is provided."
10139373|NCT04207827|Experimental|xSmoker app + SMSs|The xSmoker app + phone text messages with content based on the Motivation and Problem Solving approach and informed by our prior work. The investigators developed six categories of messages sent to participants: (1)Importance and trust, (2)Fear of relapse, (3)Partner support, (4)Breastfeeding, (5)The need to smoke, and (6)Relapse. Four major objectives were established based on the content of the SMS text messages, with the help of the literature: (1)supporting motivation, (2)supporting self-efficacy, (3)supporting dyadic effectiveness, and (4)developing problem-solving skills. The messages were delivered using Textit, a platform for visually building interactive SMS applications (htpps://textit.in). All the messages were uploaded in the platform and different flows and sub-flows were created for every day of the intervention to automatize the process of SMS delivery. A combination of trigger words and skip patterns was used in order to tailor the messages.
10139374|NCT04207827|Other|Control|Usual postnatal care
10139375|NCT04207814|Experimental|Cases|
10139376|NCT04207762||PET/CT Diagnostic Imaging|Each subject will have a PET/CT scan, using 18F-AmBF3-TATE. 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada.
10139377|NCT04207632||Intervention|The Group of patients will receive routine treatment of muscle hypertonia with botulinum toxin type A in their elbow flexors.
10139378|NCT04207684|Experimental|Testosterone|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration (6 fractions: 0-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h post-administration).
10139379|NCT04207671|Other|Omission of chest tube|After wedge resection and the air-leak test, patients will receive complete omission of chest tube and directly close the incision.
10139380|NCT04207671|Experimental|Improved drainage strategy|After wedge resection and the air-leak test, patients willreceive a two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-removal.
10184518|NCT03754439||Transported|- Infants born outside of Nottingham University Hospitals or transferred between units Phase 1 < 32 weeks gestational age and <72 hours old Phase 2 any gestation and age
10184519|NCT03754413|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
10184520|NCT03754413|Other|Comparator device|No-treatment
10184521|NCT03754400|Experimental|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
10184522|NCT03754400|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment.
10184523|NCT03754387|Active Comparator|Antibiotic therapy group|Ceftazidime will chosen as the antibiotic for this study because of its efficacy as a monotherapy for serious intraabdominal infections, requiring only a single, daily dose. Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) is administered for 3 days to patients in the AT group, with the first dose given in the emergency department. The clinical status of patients in the AT group is reevaluated within 12 to 24 hours after admission by the surgeon on call. If the surgeon suspected progressive infection, perforated appendicitis, or peritonitis, the patient will underwent appendectomy. Intravenous antibiotic treatment will followed by 7 days of oral cefuroxime (250mg twice daily).
10184524|NCT03754387|Experimental|Laparoscopic Appendectomy group|Laparoscopic appendectomy will performed using. Prophylactic antibiotics (ceftazidime sodium 50mg/kg/dose ) will administered approximately 30 minutes before the incision was made. No further antibiotics will given to patients in the surgical group unless a wound infection was suspected postoperatively.
10184525|NCT03754361|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment
10184526|NCT03754361|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent hemodialysis treatment 3-4 times per week,2-4 hours each time.
10184527|NCT03754348|Experimental|NT1 group|hypothalamus neuroinflammation evaluation in Narcoleptic patients
10184528|NCT03754348|Other|Control group|hypothalamus neuroinflammation evaluation in control patients (patients without hypersomnia or inflammatory pathology)
10184529|NCT03754348|Experimental|KLS group|hypothalamus neuroinflammation evaluation in Kleine-Levin syndrome patients
10184530|NCT03754335|Experimental|Lumbar puncture|Lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
10184531|NCT03754335|Active Comparator|Sham lumbar puncture|Sham lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
9969783|NCT01293409|Experimental|High dose bright light|The amount of photic energy of bright light is considered to be fully therapeutic
10139381|NCT04208022||Healthy Musician|At least 15 hypermobile musicians and at least 15 non-hypermobile musicians will be included in the study.
10139382|NCT04208022||Healthy Individuals|The study will include at least 15 healthy non-hypermobile individuals who do not deal with music and at least 15 healthy hypermobile individuals who do not deal with music.
10139383|NCT04207268|Experimental|Gardening and Nutrition Advice|Participate in gardening activities, food demonstrations and nutrition advice
10139384|NCT04207268|Placebo Comparator|Nutrition Advice alone|Participate in only nutrition advice
10139385|NCT04207359|Experimental|Creatine Supplement Group|Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.
10139386|NCT04207359|No Intervention|Exercise Only Control Group|Participants will not participate in the creatine intervention (creatine supplementation). Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Exercise sessions will be held by trained study staff held at the Medical Arts and Research Center Physical Therapy clinic (address listed above).
10139387|NCT04207372|Experimental|Whey protein isolate|
10139388|NCT04207372|Experimental|Zein|
10139389|NCT04207372|Placebo Comparator|Protein-free|
10139390|NCT04207294|Experimental|Vitamin D-enriched pork|One portion of Vitamin D-enriched pork
10139391|NCT04207294|Placebo Comparator|Control pork|One portion of control pork
10139392|NCT04207294|Active Comparator|Vitamin D supplement|Equivocal dose of Vitamin D supplement
10139393|NCT04207294|Experimental|Vitamin D-enriched chicken|One portion of Vitamin D-enriched chicken
10139394|NCT04207294|Placebo Comparator|Control chicken|One portion of control chicken
10139395|NCT04207411|Experimental|Bupivacaine|The dose received at each injection will be 5 mg. One injection per week will be carried out over 4 consecutive weeks
10139396|NCT04207411|Sham Comparator|Lidocaine|The dose received at each injection will be 1.25mg. An injection unique per week will be carried out over 4 consecutive weeks.
10139397|NCT04207320|Experimental|Stage I|Stage I will include eligible subjects between the ages of 10-25 years.
10139398|NCT04207320|Experimental|Stage II|Stage II will include eligible subjects between the ages of 2-25 years.
10139399|NCT04207385|Active Comparator|A group: Routine treatment group|Routine dosage of venlafaxine during the first 4 weeks.
10139400|NCT04207385|Experimental|B group: PGx-guided group|The PGx test results guide the dosage of venlafaxine during the first 4 weeks.
10139401|NCT04207385|Active Comparator|C group: Routine PGx-guided group|The PGx test results guide the dosage of venlafaxine between 4th and 8th weeks.
10139402|NCT04207385|Active Comparator|D group: The combination of PGx and TDM group|The PGx and TDM test results guide the dosage of venlafaxine between 4th and 8th weeks.
10139403|NCT04207515|Experimental|Removal of wisdom tooth under conscious sedation|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure, oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia , intraoperative time-after extraction , postoperative time . In this group removal of wisdom teeth was done under conscious sedation. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
10139404|NCT04207515|Active Comparator|Removal of wisdom tooth under local anesthesia|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure , oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia, intraoperative time-after extraction, postoperative time. In this group, removal of wisdom teeth was done under local anesthesia. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
10139405|NCT04207463|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10139406|NCT04207606||Epidural Steroid Injection Patients|Patients who are to receive an epidural steroid injection as an outpatient.
10139407|NCT04207554||Pregnancy Positive|Pregnant subjects within 11 weeks since the first day of last period.
10139408|NCT04207554||Pregnancy Negative|Non-pregnant subjects.
10139409|NCT04207307|Experimental|Multimodal exercise intervention|Behavioral: Multimodal exercise intervention with machine-based resistance, coordination and endurance training, 1-2 times per week for 30-45 min (increasing amount of training).
10139410|NCT04207307|Sham Comparator|Usual Care|General recommendations for healthy ageing, usual physical activity. No machine-based strength training intervention.
10139411|NCT04207580||Inclusion and follow up of pediatric patients|"Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome, from the beginning of the disease to 18 years old or transfer of the follow-up to a nephrology unit for adults.~130 new patients are expected to be included on an annual basis."
10139412|NCT04207450|Placebo Comparator|Placebo Group|Placebo Gel + Placebo Solution (Distilled Water)
10139413|NCT04207450|Experimental|Placebo Gel + Glutaraldehyde (GPG)|Placebo Gel + 5% Glutaraldehyde Aqueous Solution
10139414|NCT04207450|Experimental|Phosphoric Acid + Glutaraldehyde (GAG)|37% Phosphoric Acid + Glutaraldehyde Aqueous Solution (GAG)
9969784|NCT01293422|Experimental|Rifampicin|
9969785|NCT01293435||1|
10139415|NCT04207541|Experimental|Control group and Intervention group|For control group, participants will be treated with usual care. For intervention group, participants will be provided a session of education regarding insulin initiation with brief motivation interviewing.
10139416|NCT04207658|Experimental|Valsalva's Pushing|The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. At the expulsion phase (baby's head is visible in vulva), they are encouraged to perform the Valsalva's manoeuvre that they have practised in routines of delivery; When contractions start, breathe twice normally. Take a deep breath and hold. Compress the air with the help of diaphragm and abdominal muscles. Push strongly and long (for 10-15 sec). Breathe out and take another deep breath, hold it and push as strongly as possible for another 10-15 seconds. Stop pushing when contractions are mild. Breathe 2-3 times in normal style. Relax and have a rest until the next contraction.
10139417|NCT04207658|No Intervention|control|Practices on Spontaneous Pushing Group The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. Just after feeling the push, the gravitas are requested perform pushing as follows; Breathe normally until participants feel the push when contractions start, pull back muscles surrounding the uterus while breathing. Start pushing gradually and breathe out smoothly by minimizing lips. Push between breaths for 5-6 seconds while pushing downwards by breathing out. Breathe normally when contractions weaken.
10139418|NCT04207645||African|patients originating from Nigeria and Sudan (11 centres)
10139419|NCT04207645||Latin American|patients originating from Mexico (5 centres)
10139420|NCT04207645||South Asian|patients originating from India and Pakistan (10 centres)
10139421|NCT04207645||European|patients originating from Spain (11 centres).
10139422|NCT04207398|Experimental|TIPS|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver.
10139423|NCT04207398|Active Comparator|NSBB+EBL|Participants randomized to this group will receive the combination therapy of non-selective beta-blocker (NSBB) and endoscopic band ligation (EBL) . NSBB, including propranolol and carvidilol, will be started at day 5 after the index bleeding and elective EBL sessions started 2 weeks after the index bleeding.
10139424|NCT04207723|Experimental|TENS Therapy|Tens therapy + placebo drug therapy
10139425|NCT04207723|Sham Comparator|Control|Standard treatment (paroxetine 20 mg) + sham therapy
10139426|NCT04207723|Experimental|Combination therapy|Tens therapy + standard treatment (paroxetine 20 mg)
10139427|NCT04207528|Experimental|Peer Helping Condition|Participants in the peer helping condition will be asked to write about their experiences in their first-year at UCLA (freshman or first-year after post-transfer), with an emphasis on using the experience to benefit someone who is about to be a first-year student.
10139428|NCT04207528|Active Comparator|Facts-only Control|Participants in the facts-only writing condition will be asked to write facts about their experiences in their first-year at UCLA (freshman or first-year post-transfer). Unlike the previous conditions, they will not be instructed to write for the benefit of another individual.
10139429|NCT04207489||endoscopic submucosal injection of indocyanine green|
10139430|NCT04207567|Experimental|Intervention Arm|Participants in this arm will be instructed to perform one set each of push-ups, angled-rows and bodyweight squats every weekday without supervision for a total of 24 weeks. They will receive the equipment necessary to perform the exercises as well as guidance on proper performance. They will also receive training in the Tiny Habits® Method at baseline and digital coaching for the duration of the study.
10139431|NCT04207567|No Intervention|Waitlist Control Arm|"Participants in the control arm will be instructed to refrain from resistance training for the initial 12 weeks of the study.~Note that, after the 12-week follow-up assessment (at which the primary outcome of composite reps will be assessed), this group will begin the RT program. They will receive the same equipment, training, and coaching as the intervention group, and they will continue the RT program for 12 weeks, followed by a 24-week assessment."
10139432|NCT04207593|Active Comparator|Oxygen Therapy provided|Patients will be divided in a supplemental-oxygen group (primary intervention group) throughout the study
10139433|NCT04207593|Sham Comparator|no-supplemental-oxygen group (control group)|Patients of the control group will beginn the study without Oxygen Therapie and will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group).
10139434|NCT04207125|No Intervention|Without multilevel intervention|patients after liver or kidney transplantation / standard care
10139435|NCT04207125|Active Comparator|With multilevel intervention|patients after liver or kidney transplantation / multilevel intervention program
10139436|NCT04207112|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
10139437|NCT04207112|Experimental|Regimen 2: Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
10139438|NCT04207112|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
10139439|NCT04207112|Active Comparator|Control regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB
10139440|NCT04206943|Experimental|A Low Dose|4 x 10^6 Car-T cell/ kg
9969786|NCT01293474||glaucoma patients|patients with diagnosis of primary open angle glaucoma
10139441|NCT04206943|Experimental|B High Dose|6 x 10^6 Car-T cell/ kg
10139442|NCT04207034|Experimental|flap surgery and diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
10139443|NCT04207034|Active Comparator|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
10139444|NCT04207021|Experimental|intervention|"the study involves the intake of two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks of a nutritional supplement~INTERVENTION CAPSULE COMPOSITION active substances for 2 capsules Bio Curcumin 400 mg Polydatin 00 mg Beta-Caryophyllene 48 mg"
10139445|NCT04207021|Placebo Comparator|placebo|particpants included in the placebo group will take two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
10139446|NCT04207008|Experimental|iBDecide App Decision-support Arm|Participants will download the iBDecide app on their smartphone approximately two weeks prior to the scheduled clinic visit. Approximately one week after the clinic visit, survey data, along with demographic data will be collected from all participants via a brief telephone call. We will collect data on app use between installation and the clinic visit as well as in the 3 months following the clinic visit.
10139447|NCT04207008|No Intervention|Control Arm|Control participants will not use the iBDecide app prior to their clinic visit. They will complete a brief telephone survey approximately one week from clinic visit.
10139448|NCT04206865|Experimental|ARNI therapy|Patient's randomized to this arm will receive sacubitril-valsartan per study protocol and titrated per titration guidelines.
10139449|NCT04206865|Active Comparator|Standard Oral Vasodilator|Patient's randomized to this arm will receive the oral vasodilator that the clinician chooses including angiotensin receptor blocker (ARB), isosorbide dinitrate, hydralazine, and angiotensin-converting enzyme inhibitor (ACEi).
10139450|NCT04207060|Experimental|Oral indomethacin 50 mg po BID|The study intervention is oral indomethacin. Indomethacin is an FDA approved, commonly prescribed NSAID. Commercially available indomethacin will be utilized in this study. One capsule orally BID for 28 days. Those in the indomethacin arm will receive indomethacin 50 mg BID. Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication.
10139451|NCT04207060|Placebo Comparator|Placebo po BID|"Participants in both study arms will receive study medication, one capsule orally BID for 28 days. Those in the placebo arm will receive placebo capsules BID.~Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication."
10139452|NCT04206930|No Intervention|Control|Standard support: information on alcoholic pathology, medico-psycho-social assessment, relapse prevention program
10139453|NCT04206930|Experimental|Art-Therapy|in addition to standard treatment, art therapy treatment program: 1 session of 2 hours per week in a closed group for 10 weeks
10139454|NCT04207203|Other|Single arm study|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
10139455|NCT04206826|Experimental|PREDELFI Film|
10139456|NCT04206826|Placebo Comparator|CONTROL Film|
10139457|NCT04207099||ARM 1|Patients receive standard of care treatment for their diabetic foot ulcer
10139458|NCT04207099||ARM 2|Patients receive MolecuLight i:X guided treatment for their diabetic foot ulcer
10139459|NCT04206969|Experimental|Transcultural psychotherapy|In addition to usual care, the participants in the treatment group receive transcultural psychotherapy in the inclusion centers, which consists of 5 sessions every 7 weeks (W6, W13, W20, W27, and W34). During all the research process, participants from both groups continue their usual care provided by the referent medical team outside the inclusion center.
10139460|NCT04206969|No Intervention|standard care|usual care provided by the referent medical team
10139461|NCT04206657|Experimental|Single dose administration of 1mg KHK7580|
10139462|NCT04206657|Experimental|Single dose administration of 3mg KHK7580|
10139463|NCT04206657|Experimental|Single dose administration of 6mg KHK7580|
10139464|NCT04206657|Experimental|Single dose administration of 12mg KHK7580|
10139465|NCT04206657|Experimental|Multiple dose administration of 6mg KHK7580 for 8days|
10139466|NCT04206514|Experimental|Peer Counselor|Participants receive personalized text messages and phone calls from a peer counselor- a women who had an abortion and was trained in post abortion care and PCC
10139467|NCT04206514|Experimental|Nurse|Participants receive personalized text messages and phone calls from a nurse trained in post abortion care and PCC
10139468|NCT04206514|No Intervention|control|Participants receive the standard of care for post-abortion patients in Kenya.
10139469|NCT04206878||HIV-exposed infants (HEI) eligible for birth testing|All HEI live births born at, or presenting to, one of the 3 study sites, within 3 days of birth.
10139470|NCT04207047|Experimental|Group A|Group A (up to n=5): Genius exposure 1-3 hours before tissue resection
10139471|NCT04207047|Experimental|Group B|Group B (up to n=5): Genius exposure 30+7 days, 14+3 days, and 7+3 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
10139472|NCT04207047|Experimental|Group C|Group C (up to n=5): Genius exposure 90+14 days, 60+10 days, and 30+7 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
10139473|NCT04207047|Experimental|Group D|Group D (up to n=10): Genius, LaseMD, LaseMD FLEX, eCO2 and/or PicoPlus exposure 14+3 days, 7+3 days, and 1-3 hours before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
10139474|NCT04206709|Experimental|aerobic effort|Active upper limbs pedaling
10139475|NCT04206709|Sham Comparator|passive pedaling|passive pedaling
10139476|NCT04206605|Experimental|Lanadelumab|Participants will receive 300 milligrams (mg) of lanadelumab solution in a prefilled syringe (PFS) as subcutaneous (SC) injection once every 2 weeks (q2w) for 26 weeks.
9969787|NCT01293474||control group|age matched healthy controls
10139477|NCT04206605|Placebo Comparator|Placebo|Participants will receive placebo matched to lanadelumab SC injection once q2w for 26 weeks.
10139478|NCT04206540|Experimental|ABVN and Vagal Maeuvers|There is only one arm and subjects can choose the intervention.
10139479|NCT04206618||premenopausal normal|premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
10139480|NCT04206618||postmenopausal normal|postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
10139481|NCT04206618||postmenopausal osteopenia|postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage
10139482|NCT04206618||postmenopausal osteoporosis|postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage
10139483|NCT04206618||hip fracture|postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis
10139484|NCT04206618||controls (knee osteoarthitis)|postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls
10139485|NCT04206618||teriparatide group|postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months
10139486|NCT04206618||denosumab group|postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months
10139487|NCT04206631|Placebo Comparator|Doxycycline Group|Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
10139488|NCT04206631|Active Comparator|Comedone Extraction Group|Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.
10139489|NCT04206722|Experimental|Treatment group|Shock Wave therapy on the affected hip, for 10 days, 1 application every 2 days
10139490|NCT04206722|Active Comparator|Control group|Ultrasound therapy on the affected hip, for 10 days, 1 application daily
10139491|NCT04206527|Experimental|Intervention - Women|Women who receive enhanced FP counseling from an ASHA
10139492|NCT04206527|No Intervention|Control - Women|Women who receive standard FP counseling from an ASHA
10139493|NCT04206527|Experimental|Intervention - ASHA|ASHA who receive enhanced FP counseling training
10139494|NCT04206527|No Intervention|Control ASHA|ASHA who receive standard FP training
10139495|NCT04206748|Experimental|iGlucose Smart Meter|
10139496|NCT04206748|Placebo Comparator|Rx glucose meter|
10139497|NCT04206644||Systemic sclerosis patients|SSc patients according to the ACR/EULAR 2013 classification criteria
10139498|NCT04206644||Healthy donors|HD healthy donors from EFS (Etablissement Français du sang)
10139499|NCT04206644||LUPUS Patiets|Lupus patients according to the ACR 2019 classification criteria
10139500|NCT04206475|Experimental|IM-FTP|rehabilitated over 1-month through IM-FTP, including physio-kinesis/occupational, speech, and neuropsychology treatments
10139501|NCT04206475|Active Comparator|standard rehabilitation|physio-kinesis, occupational, speech, and neuropsychology treatments
10139502|NCT04206592|Active Comparator|i Gel LMA|The sealing pressure of the igel laryngeal mask will be measured during pneumoperitoneum in elective laparoscopic cholecystectomy
10139503|NCT04206592|Active Comparator|Ambu Aura Gain|It will be compared the Ambu Aura Gain LMA vs iGel in elective laparoscopic cholecystectomy
10139504|NCT04206579|Experimental|10% Dextrose|Oral 10% Dextrose
10139505|NCT04206579|Experimental|Natrium Dextrose|Oral Natrium Dextrose
10139506|NCT04206670|Experimental|In-Home Technology System|Participants (N=300) will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over a six month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter).
10187752|NCT03722927|Experimental|Liposomal Bupivacaine Group|Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
9969788|NCT01293487|Experimental|Arm 1|
9969789|NCT01293526|Experimental|Experimental 1|Patients who respond will have their leads placed based on study measurements.
10139507|NCT04206670|Other|Waiting Control|Participants (N=100) will be assigned a date for receiving and installing the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) six months after they enter the study. During that six-month period, questionnaires (e.g., health and well-being) will be administered 3 times (at the start of the study and every 3 months thereafter). At the end of the six-month period, participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over an additional six-month period with questionnaires (e.g., health and well-being) administered 2 times (every 3 months following installation).
10139508|NCT04206462||Osteoarthritis|Questionnaire of eating habits, markers of oxidative stress
10139509|NCT04206228|Active Comparator|Active treatment|Active drug: Intravenous iron isomaltoside dissolved in 100 ml NaCl 0.9 %
10139510|NCT04206228|Placebo Comparator|Placebo|Placebo: Intravenous NaCl 0.9 % dissolved in 100 ml
10139511|NCT04206202|Experimental|PSI group|3D-printed patient-specific instrumentation (PSI) will be used in the total knee arthroplasty (TKA) of this group.
10139512|NCT04206371|Other|Defibrillation testing during ICD replacment|
10139513|NCT04206241||High-risk infants|"Mother answered yes to any of the following questions on a risk-screening tool:~Mother diagnosed with HIV in labor and delivery?~Mother start ART after 32 weeks' gestation?~Maternal viral load above 1000 copies/ml in the 3rd trimester?~Mother seroconvert during pregnancy?~Was the mother not adhering to ART during pregnancy?"
10139514|NCT04206241||Low-risk infants|Mothers did not answer affirmatively to any of the four screening questions
10139515|NCT04206085|Experimental|Active treatment|Radiofrequency and Cryogen
10139516|NCT04206085|Active Comparator|Cryogen-Only|Crygen-Only
10139517|NCT04206085|Sham Comparator|Sham|Sham comparator
10139518|NCT04206267|Experimental|Acceledent group|Patients up to 18 years old who were planned first premolar extractions assigned to study group. AcceleDent Aura appliance was applied for 20 minutes per day. during canine retraction.
10139519|NCT04206267|No Intervention|Control group|Patients up to 18 years old who were planned first premolar extractions assigned to control group. The canine retractions were performed without any additional vibrational device.
10139520|NCT04206345|Experimental|Blood Flow Restriction Group|Elbow bending exercises with resistance exercise band (%20 of 1 maximum repetition) for one session. Blood flow restriction band will be placed during exercise session. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
10139521|NCT04206345|Experimental|Exercise Group|Elbow bending exercises with resistance exercise band (%70 of 1 maximum repetition) will be performed for one session.
10139522|NCT04206345|No Intervention|Control Group|10 minutes resting period will be given between evaluation.
10139523|NCT04206124|Experimental|Single Arm Study Group|Includes all consented patients, male and female, undergoing anterior cervical spine surgery, parathyroidectomy or thyroidectomy (18-60 years old), without history of diabetes mellitus and not pregnant or incarcerated.
10139524|NCT04206254|Experimental|gp96 group|"Patients only receive autologous gp96 vaccination after surgery (do not accept other anti-tumor treatments)~6 times of gp96 vaccination are administered via subcutaneous injection in 25μg doses within 8 weeks after surgery. gp96 is administered once a week."
10139525|NCT04206254|No Intervention|Control group|Patients do not accept any anti-tumor treatmentsafter surgery
10139526|NCT04206280|Experimental|Pedometer group|This group will be given a pedometer following radical prostatectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 2,000/day. POD 3-6: 3,000/day. POD 7-9: 4,000/day. POD 10-14: 5,000/day.
10139527|NCT04206280|Active Comparator|Control group|This is the control group. Following radical prostatectomy, subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
10139528|NCT04206410|Experimental|Probiotic|Multistrain probiotic mixture consisting of two Lactobacillus strains (L. rhamnosus and L. acidophilus) and three Bifidobacterium strains (B. longum, B. bifidum and B. lactis) administered for 8 weeks in a dose 1,0E+10/day, 2x sachets/day (5,0E+9/cfu per sachet)
10139529|NCT04206410|Placebo Comparator|Maltodextrin|Placebo - Maltodextrin manufactured with an appearance, taste and packaging (sachets) identical to the probiotic mixture administarted for 8 weeks 2x sachets/day
10139530|NCT04206358|Experimental|treatment group|The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001), Once every 2 weeks
10139531|NCT04206449|Experimental|Infrared thermography system|Therapeutic decision taken with infrared thermography system, integrated in an expert diagnostic algorithm (TIS), to determine the sleep stages and Apnea-Hypopnea Index (AHI).
10139532|NCT04206449|Active Comparator|Standard Polysomnography (PSG)|Therapeutic decision taken with Standard Polysomnography (PSG), to determine the sleep stages and Apnea-Hypopnea Index (AHI)
10139533|NCT04206423||Healthy Controls|Age and sex matched healthy controls
10139534|NCT04206423||Lateral epicondylitis|"Newly diagnosed lateral epicondylitis patients.~Pain in lateral epicondylitis region~Pain increase with palpation~Positivity in two diagnostic test out of three (Maudley's test, Mill's test or Cozen's test)"
9969790|NCT01293526|Experimental|Control|Leads will be placed using standard procedures.
10139535|NCT04206098||Sex|Male/Female
10139536|NCT04206111||Preoxygenation|
10139537|NCT04206436||on CFTR|For patients on or near time of initiation CFTR modulator therapy
10139538|NCT04206436||Controls|controls will be patients not eligible for available treatment
10139539|NCT04206137|Experimental|Group A (PNF rhythmic initiation group )|PNF rhythmic initiation with bilateral asymmetrical upper and lower limb pattern will administered on both sides, there will be 10 repetition and 3 sets for each side, 20 second rest between two sets.
10139540|NCT04206137|Active Comparator|Group B (Swiss ball exercise group)|Swiss ball exercises will be administered. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
10187753|NCT03722914|Active Comparator|benzonatate soft capsules group|
10139541|NCT04206046|Active Comparator|General Anaesthesia|Patients will receive a general anaesthetic, together with a femoral nerve block.
10139542|NCT04206046|Active Comparator|Spinal Anaesthesia|Patients will receive a spinal anaesthetic
10139543|NCT04206176|Experimental|Single group crossover|The patients who are on a maintenance dose of clopidogrel 75mg once daily will be transitioned to ticagrelor 45mg twice daily after which they will be tested.
10139544|NCT04206189|Active Comparator|Carbohydrate group|
10139545|NCT04206189|No Intervention|Control group|
10139546|NCT04206072|Experimental|D-0316|D-0316 (75 mg or 100 mg orally, once daily), in accordance with the randomization schedule.
10139547|NCT04206072|Active Comparator|Icotinib|Icotinib (125 mg orally, three times daily), in accordance with the randomization schedule.
10139548|NCT04205916|Experimental|Experimental Group|A total of 50 study subjects (50 eyes) will receive Dextenza dexamethasone intracanalicular insert placed in the lower punctum of their scheduled surgical eye at the time of surgery and will receive intracameral ketorolac during the procedure and 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure.
10139549|NCT04205916|Active Comparator|Control Group|A total of 50 study subjects (50 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, ketorolac 0.5% qid 1 day prior to surgery and for 1 month postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
10139550|NCT04205903|Experimental|Group I (paclitaxel, nilotinib hydrochloride monohydrate)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nilotinib hydrochloride monohydrate PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10139551|NCT04205903|Placebo Comparator|Group II (paclitaxel, placebo)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive placebo PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10139552|NCT04205942|Experimental|Plasma|regular treatment with Argon Plasma Jet according to manufacturer's instructions, 8 times within 14 days
10139553|NCT04205942|Sham Comparator|Placebo|Sham-treatment with Argon Plasma Jet, Plasma producing electric field switched off - no Plasma is produced, just argon gas as effluent, 8 times within 14 days
10139554|NCT04205929|Placebo Comparator|Placebo group|Placebo (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
10139555|NCT04205929|Experimental|Curcumin group|Curcumin 600 mg (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
10139556|NCT04206007|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
10139557|NCT04205643|Experimental|CT-P13 SC|
10139558|NCT04205643|Placebo Comparator|Placebo SC|
10139559|NCT04205981|Experimental|Aerobic exercise|Exercise intervention. The experimental group increased their energy expenditure according to American College of Sports Medicine and WHO-based physical activity recommendations for all adults to promote clinically significant weight loss and for additional health benefits: 300 min of moderate-intensity aerobic training throughout the week (WHO, 2010; Swift et al. 2014). Participants underwent five 60 min moderate-intensity cycling sessions per week for a period of 8 weeks, 40 sessions in total. Each session involved 5 min of warm up at 40 Watts, cycling for 50 min at a speed that increased their HR to a target HR obtained at 50-60% of peak VO2, and a 5 min of cool down at 40 Watts.
10139560|NCT04205981|No Intervention|Control|. In the control group, participants did not undergo any intervention and were instructed to maintain their regular physical activity and diet regime for 8 weeks.
10139561|NCT04205695|Active Comparator|CEMP (closed-ended multiport catheter) group|Infraclavicular closed-ended multiport nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
10139562|NCT04205695|Active Comparator|OESP (open-ended single port catheter) group|Infraclavicular open-ended single port nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
10139563|NCT04205721|Experimental|Scripted lesson plan life orientation curriculum|Participants in this arm were in schools where the life orientation teachers in grades 7-9 (in 2016 and 2017) and grade 10 in 2018 were trained to use the new life orientation curriculum that included scripted lesson plans for the sexual and reproductive health content of the program. There are eight lessons for grade 7, eight for grade 8, 11 for grade 9, and 10 for grade 10.
10139564|NCT04205721|No Intervention|Standard life orientation curriculum|Participants in this arm were in schools where the standard life orientation curriculum was used with no additional training and no use of the new materials.
10139565|NCT04205760|No Intervention|Control group|Standard Care as per local guidelines
10139566|NCT04205760|Experimental|Intervention|Oral nutrition support (ONS) and bed-cycling before surgery
10139567|NCT04205890|Experimental|Ketamine|The present study is designed as a prospective data analysis of patient response to the use of ketamine to treat treatment-resistant depression. For Phase I trail, 10 patients of any gender with an age range of 18 to 70 who have undergone the outlined procedure will be recruited for inclusion. A week before the scheduled ketamine treatment, the patients will have fMRI scans, including structural T1, Arterial Spin Labeling, and Resting BOLD. The scans take around 30 minutes at no charge to the patients. The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage will vary (see below) depending on every individual's unique treatment plan. The same scans will be taken two days after treatment.
10139568|NCT04205864|Active Comparator|Conventional pelvic lymphadenectomy|Conventional pelvic lymphadenectomy
10139569|NCT04205864|Experimental|Thrombin gel matrix pelvic lymphadenectomy|Thrombin gel matrix applicated after conventional pelvic lymphadenectomy
10139570|NCT04205851|Experimental|KIN-1901|Single or repeat (once weekly for 4 weeks) KIN-1901 subcutaneous injection
10139571|NCT04205851|Placebo Comparator|Placebo|Single or repeat (once weekly for 4 weeks) placebo subcutaneous injection
10139572|NCT04205877||Registry Group|All participants will have the same data collected at the same time points.
10139573|NCT04205682|Experimental|Cannabidiol (CBD)|Drug: Cannabidiol (day 1: 1200 mg (800 mg BD); day 2-4: 800 mg (400 mg BD); day 5: placebo BD).
9969791|NCT01293526|Experimental|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
10139574|NCT04205682|Placebo Comparator|Placebo|Drug: Placebo (days 1-5: placebo matched BD)
10139575|NCT04205604|Experimental|Single Arm,|Patients with clinically diagnosed congenital hyperinsulinism
10139576|NCT04205825|Experimental|New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
10139577|NCT04205825|No Intervention|Habitual Practice|Patients randomized in this arm they will receive the habitual practice.
10139578|NCT04205617|Experimental|Healthy Food Prescription|Participants receive services through the Living Hungry program for food insecure diabetic patients.
10184532|NCT03754322|Active Comparator|Standard of care|One third of individuals get allocated to the standard of care arm. At each antenatal visit as per Ethiopian guidelines, pregnant women enrolled in the study will be submitted to the standard of care for malaria in pregnancy. If the pregnant mothers are symptomatic for malaria, they receive microscopy (blood smear for Plasmodium detection) and then are treated with anti-malarial therapy if microscopy is positive for Plasmodium. If it is negative they receive no treatment. If they are asymptomatic, they do not receive any further investigations or treatment in relation to malaria.
10184533|NCT03754322|Experimental|Intervention arm|The remaining two-thirds of participants will be actively screened (symptomatic and asymptomatic) for Plasmodium infection at each antenatal visit, using both LAMP and conventional techniques (microscopy and RDT). If either is positive, participants will be treated with antimalarial therapy according to Ethiopian Ministry of Health guidelines. If both are negative then they receive no treatment.
10184534|NCT03754296||CATCHVIEW stent retriever|
10184535|NCT03754283|Experimental|Silicone|Indirect bonding performed with the silicone trays
10184536|NCT03754283|Active Comparator|Vacuum formed|Indirect bonding performed with the vacuum formed trays
10184537|NCT03754270|Active Comparator|Lifestyle advice|Patients receive instructions and advice on lifestyle according to current clinical practice.
10184538|NCT03754270|Experimental|Lifestyle advice and cervical collar|"Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it."
10184539|NCT03754218|Experimental|Amnion membrane product treatment area|The prepared amnion membrane powder will be directly applied to the prepared donor wound site (Site A). The wound will then be covered with the SOC dressing.
10184540|NCT03754218|Active Comparator|SOC Wound Covering treatment area|The donor wound site (Site B) will be covered per SOC (Standard of care).
10184541|NCT03754205|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following: (1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode."
9669204|NCT03713944|Experimental|Carboplatin, Pemetrexed, Atezolizumab plus Bevacizumab|"Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles.~Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities."
10184542|NCT03754205|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode."
10184543|NCT03754192|Other|perfusion computed tomography|Will be realsed before liver surgery
10184544|NCT03754179|Experimental|Arm A phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
10187754|NCT03722914|Placebo Comparator|control group|
10187755|NCT03722901||Late preterm infants|34 weeks and 0-6 days gestational age
10187756|NCT03722901||Moderate preterm infants|32 weeks and 0-6 days gestational age
10187757|NCT03722901||Reference|Term infants 9m/39-40
9969792|NCT01293565||HED Affected Males|
9669205|NCT03708224|Experimental|Atezolizumab Monotherapy|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery.
9969793|NCT01293565||Male Controls|
9969794|NCT01293578|No Intervention|Usual Care|Clinicians will present diabetes medication options to patients, in their usual way.
9969795|NCT01293578|Experimental|Diabetes Medication Decision Aid|In the decision aid arm, clinicians will use the diabetes medication decision aid cards (if they choose) when discussing diabetes medication options with their patients.
9969796|NCT01293591|Other|Control|270 kcal White bread with 15 g margarine
9969797|NCT01293591|Other|Garlic Treatment|270 kcal white bread with 15 g margarine and 5 g crushed garlic
9969798|NCT01293604|Experimental|Whole Grain Barley Diet|A controlled diet containing at least 4 daily servings of whole grain barley.
9969799|NCT01293604|Active Comparator|Whole Grain Oats Diet|A diet containing at least 4 servings of whole grain oats.
9969800|NCT01293604|Other|Low Whole Grain Diet|A control diet containing 0.7 daily servings of whole grain.
9969801|NCT01293617|Placebo Comparator|Gelatin|
9969802|NCT01293617|Experimental|Blackberries|
9969803|NCT01293630|Experimental|Cohort - 1 through 5|AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks
10139579|NCT04205591|Active Comparator|Autologous cortical plate|Thin autologous cortical plates that allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
10139580|NCT04205591|Experimental|Porcine cortical plate|Thin porcine cortical platesthat allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
10139581|NCT04205578|Active Comparator|Butylphthalide (NBP)|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
10139582|NCT04205578|Placebo Comparator|Normal saline|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
10139583|NCT04205461||Programmed ventricular stimulation before PVR|
10139584|NCT04205500|Experimental|Children with juvenile idiopathic arthritis|The specific carbohydrate diet has been shown to have beneficial effects on IBD and has been implemented in Seattle Children's IBD centre, with some patients using SCD either as primary or complementary therapy. The SCD is a nutritionally balanced diet focused on removing many complex carbohydrates such as grains, dairy products except for yoghurt fermented over 24 hours, vegetables rich in starch and sugars except for monosaccharides like in honey. Participants can eat meat but since it has to be unprocessed food the investigator's experience is that the amounts of meat are not very big. Fish, eggs, sea-food is allowed. Bread is baked from nut and almond flour.
10139585|NCT04205448|Experimental|Exercize group|10 weeks of physical exercise. Testing of strength and balance.
10139586|NCT04205448|No Intervention|Control group|Testing of strength and balance.
9669206|NCT03708224|Experimental|Atezolizumab (Adjuvant)|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery. The first 9 participants in Arm A (atezolizumab monotherapy) will also receive adjuvant atezolizumab 16 weeks after standard of care surgery and radiation, or chemoradiation therapy, at a fixed dose of 1200 mg IV every 3 weeks for an additional 12 cycles.
10139587|NCT04205513|No Intervention|Control Group|Standard titration management strategy, consisting of regular in-office visits.
10139588|NCT04205513|Experimental|Study Group|Remote titration management strategy, consisting of telephone contacts, which will utilize data from the Medly system.
10139589|NCT04205474|Active Comparator|VSRR with tricuspid aortic valve|Patients with a tricuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
10139590|NCT04205474|Active Comparator|VSRR with bicuspid aortic valve|Patients with a bicuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
10139591|NCT04205565|Active Comparator|L-oxiracetam|
10139592|NCT04205565|Active Comparator|Oxiracetam|
10139593|NCT04205565|Placebo Comparator|Plaecbo|
10139594|NCT04205487|Experimental|Contingency Management (CM) - Only|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
10139595|NCT04205487|Experimental|Motivational Interviewing (MI) - Only|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered.
10139596|NCT04205487|Experimental|CM+MI|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription. Participants who do not fill a PrEP prescription at 3 months will then receive 2 sessions of MI.
10139597|NCT04205487|Experimental|MI+CM|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered. Participants who do not fill a PrEP prescription at 3 months will receive CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
10139598|NCT04205279|Experimental|Treadmill training|Subjects randomly assigned to the treadmill training, would undergo either a stance or walking perturbation training protocol. The stroke subjects and older adults would be assigned to either the stance or walking perturbation training protocol. All the participants would be asked to perform voluntary stepping, backward and forward with both limbs pre and post perturbation training. Also, all the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd.
10139599|NCT04205279|Experimental|Overground training|Subjects randomly assigned to overground slip will be made to walk at their comfortable natural walking speeds either for 5-8 trials on the instrumented walkway (7 m 1.5 m) at their self-selected preferred speed. All the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd. After establishing baseline walking ability, a slip will be introduced without warning which will comprise the baseline slip test followed by a trip in the form of the trip plate. This is followed by a block of 8 trials for slip training, block of 8 trials for trip training and then the mixed block consisting of slip and trip trials interspersed with walking trials. Slips and trips could be induced under either of the limbs.
10139600|NCT04205279|Experimental|Surefooted training|"Subjects randomly assigned to Surefooted (Surefooted LLC) would be donned a safety harness and instructed that when you experience slip-like or trip-like movements, try to keep walking on the platform. Subjects would undergo 4-minute training block on each of the 6 different conditions. The first 3 training blocks would be unidirectional perturbation (either slip or trip) followed by 3 training blocks of mixed directional perturbations while the subjects are walking on the platform. 3 surface conditions- slippery (vinyl surface plate), normal friction with obstacles (surface plate with 6 tall structures embedded), and a foam surface with obstacles embedded would be used."
10187758|NCT03722888|Experimental|adolescents who have previously smoked|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, behaviors around smoking, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
9519685|NCT03284554|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
9969804|NCT01293643|Experimental|clindamycin/ketoconazole combination|
10139601|NCT04205253||Study|The first group is the study group. Patients aged 20 years or older and were to undergo suspension laryngoscopy procedure were eligible for inclusion in this group. Tongue areas were measured twice by submental USG. The first measurements (TA1) were done immediately after endotracheal intubation before introducing the rigid direct laryngoscope, whereas the second measurements (TA2) were done after the SL procedure and after removing the rigid direct laryngoscope just before extubation.The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
10139602|NCT04205253||Control|The second group was the control group, which included patients who did not need SL and any head and neck procedures.The tongue areas of these patients were measured twice by submental USG as in the study group. The TA1 measurements were done immediately after endotracheal intubation, whereas the TA2 measurements were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
10139603|NCT04205539|Experimental|Dexmedetomidine|All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.
10139604|NCT04205552|Experimental|Nivolumab|"Nivolumab 2 cycles, every two weeks (q2w)~o Nivolumab 240 mg i.v. over 30 min"
10139605|NCT04205552|Experimental|Nivolumab/Relatlimab|"Nivolumab/Relatlimab 2 cycles, every two weeks (q2w)~Nivolumab 240 mg i.v. over 30 min~Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)"
10139606|NCT04205240|Experimental|Treatment (conditioning regimen, stem cell transplant)|Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
10139607|NCT04205201|Experimental|Group A|Latanoprost
10139608|NCT04205201|Other|Group B|Brimonidine
10139609|NCT04205422|Active Comparator|BIPAP group|Biphasic Intermittent Positive Airway Pressure group
10139610|NCT04205422|Active Comparator|APRV group|Airway Pressure Release Ventilation group:
10139611|NCT04205188|Experimental|exercises and verbal information|therapeutic exercises 3 days in a week and total 8 weeks and 60 minutes verbal information
10139612|NCT04205188|No Intervention|verbal information|60 minutes information about effects of exercises on joint functions
10139613|NCT04205292|Active Comparator|Dilatation and Evacuation (D&E)|Women in this group will receive an in-patient treatment with Dilatation and Evacuation (D&E) after two doses of Methotrexate .
10139614|NCT04205292|Experimental|hysteroscopic surgery|Women in this group will receive hysteroscopic surgery after two doses of Methotrexate .
10139615|NCT04205214|Experimental|Integrative Cognitive Behavioural Therapy Intervention Group|The group receive 12 weekly individual Integrative Cognitive Behavioural Therapy sessions from the principal investigator and Trainee counselling Psychologist. The sessions last up to 60 minutes on a weekly basis. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week intervention.
10139616|NCT04205214|No Intervention|Wait List Control Group|The group do not receive the intervention and are told that they can start the intervention after 12 weeks. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week waiting period. After this 12-week waiting period, they are offered the individual therapy and their data is added to the experimental group data.
10139617|NCT04205331||obese patients|compare between ultrasonography and conventional clinical methods of airway assessment prior to induction of anesthesia correlating it to the Cormack-Lehane scoring system after induction of anesthesia in obese patients
10139618|NCT04205227|Experimental|ENB003 150 ug + Pembrolizumab|150 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
10139619|NCT04205227|Experimental|ENB003 300 ug + Pembrolizumab|300 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
10139620|NCT04205227|Experimental|ENB003 500 ug + Pembrolizumab|500 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
10139621|NCT04205227|Experimental|ENB003 750 ug + Pembrolizumab|750 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
10139622|NCT04205227|Experimental|ENB003 1000 ug + Pembrolizumab|1000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
10139623|NCT04205227|Experimental|ENB003 RP2D from dose eascalation + Pembrolizumab|The recommended phase 2 dose (RP2D) of ENB003 will be selected from the dose escalation portion of the study and administered in combination with a fixed dose of pembrolizumab (200mg)
10139624|NCT04205305|Active Comparator|Conventional blood pressure control group|systolic blood pressure <180 mmHg
10139625|NCT04205305|Experimental|Intensive blood pressure control group|systolic blood pressure <140 mmHg
10139626|NCT04205344|Experimental|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
10139627|NCT04205344|Experimental|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
10187759|NCT03722875|Experimental|SHR-1210+ apatinib|"SHR-1210 (200mg fixed dose every 3 weeks, one cycle is three weeks, total~1 year ) will be administered as an intravenous infusion over 30 minutes.~apatinib 250 mg qd ， one cycle is three weeks, total 1 year"
9969805|NCT01293643|Active Comparator|tetracycline hydrochloride/amphotericin B combination|
9969806|NCT01293656||CD and UC participants|All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
9969807|NCT01293708||Hospital Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed until hospital d/c
9969808|NCT01293708||Longitudinal Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed for 12 months
9969809|NCT01293721|No Intervention|control|
9969810|NCT01293721|Experimental|Treatment|Receive vibration therapy
9969811|NCT01293734|Experimental|cold type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type
9969812|NCT01293734|Experimental|heat type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.
9969813|NCT01293734|Experimental|Asthenia type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.
9969814|NCT01293734|Active Comparator|Western medicine control group|
9969815|NCT01293747|Experimental|Estradiol 0.5 mg/Progesterone 15 mg microspheres|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension
9969816|NCT01293747|Experimental|Estradiol 1 mg/Progesterone 20 mg microspheres|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension
9969817|NCT01293760|Other|6 weeks interval insertion|IUD is inserted 6 weeks following c-section delivery of baby and placenta
9969818|NCT01293760|Experimental|Immediate insertion|IUD is inserted immediately following c-section delivery of baby and placenta
9969819|NCT01293773|Active Comparator|Taxus Element|Patients treated with paclitaxel-eluting stent (Taxus Element, Boston Scientific, MN)
9969820|NCT01293773|Active Comparator|Xience Prime|Patients treated with Everolimus-eluting stent (Xience Prime, Abbott, IL)
9969821|NCT01293773|Active Comparator|Integrity Resolute|Patients treated with ABT 578-eluting stent (Integrity Resolute, Medtronic, MA)
9969822|NCT01293786||Kidney transplant recipients|
9969823|NCT01293786||Chronic kidney disease|
9969824|NCT01293799|Experimental|The follow-up group|The intervention in the follow-up group consists of regular tests of the patients´ theoretical and practical skills regarding peritoneal dialysis. The test goals should be passed. If not, retraining will be given if needed til the goals are reached. The peritonitis rate in this group will be compared with that of the control group.
9969825|NCT01293799|No Intervention|Control group|Patients randomised to the control group will be treated according to the routines of the clinic.
9969826|NCT01293812|Experimental|sucrose po|"88% sucrose solution (Syrup B.P.). The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution."
9969827|NCT01293812|Placebo Comparator|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
9969828|NCT01293877|Other|LGP|Patient underwent surgery for morbid obesity treatment between 18 to 60 years, and BMI of 40 ore more will divided in two groups, one hundred will be schedule for laparoscopic gastric plication. Our theory for this arm is that the procedure can offer the same results than the second arm with less cost and safety, reversibility included.
9969829|NCT01293877|Other|LSG|The patients in a total of one hundred will be schedule for laparoscopic sleeve gastrectomy. The is our control for development of the study.
9969830|NCT01293890||COPD patients with hospital admission for exacerbation|
9969831|NCT01293903|Experimental|Qiliqiangxin capsule|
9969832|NCT01293903|Placebo Comparator|Placebo|
9969833|NCT01293916|Active Comparator|Double leg spica cast|The current accepted treatment is the double leg spica cast in the treatment of pediatric diaphyseal femur fractures.
9969834|NCT01293916|Experimental|Single leg spica casts|The study group is the single leg spica cast group
9969835|NCT01293929||Non- obese group|
9969836|NCT01293929||Obese group|
9969837|NCT01293942|Experimental|IXO+A|IXO regimen with Avastin
9969838|NCT01293955|Experimental|JOINS 200mg|One tablet of JOINS 200mg is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.
9969839|NCT01293955|Placebo Comparator|Placebo|One tablet of Placebo is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.
9969840|NCT01293981||Lumbar Degenerative Disc Disease|
9969841|NCT01294033|Placebo Comparator|Fractional inspired oxygen 0.21|Cardiopulmonary exercise test performed by subject on Fractional inspired oxygen 0.21
9969842|NCT01294033|Active Comparator|Fractional inspired oxygen 0.28|Cardiopulmonary exercise test performed on supplemental oxygen (Fractional inspired oxygen 0.28)
9969843|NCT01294059|Placebo Comparator|Sugar pill|One sugar pill twice daily over 6 weeks
9969844|NCT01294059|Active Comparator|Milnacipran|Milnacipran 50 mg bid over 6 weeks
9969845|NCT01294072|Experimental|Arm 1: Curcumin alone|Subjects take curcumin orally.
9969846|NCT01294072|Experimental|Arm 2: Curcumin with plant exosomes|Subjects take curcumin conjugated with plant exosomes.
9969847|NCT01294072|Experimental|Arm 3: no treatment|
9969848|NCT01294111|Experimental|Tai Chi training|Participation in a group of 15 patients, completing a 60 minutes tai chi training programme twice-weekly for 16 weeks.
9969849|NCT01294111|No Intervention|Control|Living as usual, following ordinary care plans and personal activities. Participants will be called to hospital for data collection. Participants are asked not to start any of the activities Tai Chi, Qui Gong or Yoga during the study period.
9969850|NCT01294124||No Tinnitus|The absence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
9969851|NCT01294124||Tinnitus|The presence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
9969852|NCT01294137|Active Comparator|ventilatory polygraphy|
9969853|NCT01294176|Active Comparator|Oral Lipoic Acid|Lipoic acid is a natural antioxidant available as an oral dietary supplement. A higher than average dose of 1200mg will be administered in this trial.
10139628|NCT04205357|Other|Sulfasalazine in addition to stereotactic radiosurgery|"3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin.~The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery."
10139629|NCT04205162|Experimental|Verofilcon A / Etafilcon A|The participant will wear Verofilcon A in their right eye and Etafilcon A in their left eye.
10139630|NCT04205162|Experimental|Etafilcon A / Verofilcon A|The participant will wear Etafilcon A in their right eye and Verafilcon A in their left eye.
10139631|NCT04205526|Experimental|Active rTMS|Sub-acute stroke patients will be randomized to receive actual rTMS treatment. 1Hz rTMS will be applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
10139632|NCT04205526|Sham Comparator|Sham control|Sub-acute stroke patients randomized to receive sham rTMS. For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
10139633|NCT04205097|Placebo Comparator|Moderate NMB group|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
10139634|NCT04205097|Experimental|Deep NMB group|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2~4 mg/kg
10139635|NCT04205084|Experimental|Standard Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. The subjects will be allowed to eat meals and use their own insulin as usual, under observation, in the clinical center. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose will be collected at the same time as the CGM timestamp every 15 min and analyzed.
10139636|NCT04205084|Experimental|Hypoglycemic Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. Hypoglycemia will be induced using a hyperinsulinemic infusion and samples will be obtained at 5 - 10 min intervals. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose collected at the same time as the CGM timestamp and analyzed.
10139637|NCT04205084|Experimental|Hyperglycemic Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. Hyperglycemia will be induced using a dextrose infusion and samples will be obtained at 5 -10 min intervals. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose collected at the same time as the CGM timestamp and analyzed.
10139638|NCT04205123||sickle cell syndrome|Inclusions of sickle cell patients aged over 17 years followed regularly in the participating centers.
10139639|NCT04205071|Experimental|Treatment (lorcaserin)|Patients receive lorcaserin PO on day 1. The starting dose of lorcaserin will be 10 mg.
10139640|NCT04204824|Experimental|Ultrasound and exercise|This group will receive ultrasound treatment, strengthening exercises and stretching exercises.
10139641|NCT04204824|Active Comparator|Sham Ultrasound and exercise|This group will receive sham ultrasound treatment, strengthening exercises and stretching exercises.
10139642|NCT04204759|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the ventromedial prefrontal cortex and one cathodal electrode (35cm2) will be placed over the occipital cortex. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 30 seconds at the beginning and end of the stimulation period.
10139643|NCT04204759|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
10139644|NCT04204837|Experimental|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
10139645|NCT04204850|Experimental|Cabozantinib|Cabozantinib, at a dose of 60 mg orally (by mouth), once a day (at bedtime), continuously.
10139646|NCT04204720|Active Comparator|Group Whitacre|Group whitacre receives the whitacre needle during caudal block
10139647|NCT04204720|Experimental|Group Chiba|Group chiba receives the chiba needle during caudal block
9669207|NCT03708224|Experimental|Atezolizumab + Tiragolumab|Participants will receive 840 mg of atezolizumab IV and 600 mg of Tiragolumab during the 15-day neoadjuvant period prior to definitive surgery.
10139648|NCT04205032|Experimental|CARDIOSPACE II|Test of the different devices integrated in cardiospace II.
10139649|NCT04204980|Experimental|Dose escalation and full dose|"Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab~Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab"
10139650|NCT04204915|Active Comparator|Group A: Aortic valve replacement|Participants randomised to AVR will be investigated and managed according to local protocols and standard practice. Participants will be placed on the waiting list with the aim that surgery will be performed within 3 months, dependent on local hospitals' waiting lists.
10139651|NCT04204915|No Intervention|Group B: Expectant management|Participants randomised to expectant management will continue to have regular monitoring of their condition in line with the procedures and standard practices of their hospital.
10139652|NCT04204876||patients with GCA|All patients presenting with a new diagnosis of LV-GCA and all patients already treated for LV-GCA and planned for treatment termination
10139653|NCT04205045||Non-Habitual Milk Consumers (NHMC)|"Healthy subjects who are non-habitual milk consumers because of gastrointestinal discomforts upon milk consumption.~Lactose breath test; Gut permeability test; Milk test."
10139654|NCT04205045||Habitual Milk Consumers (HMC)|"Healthy subjects with regular milk consumption.~Intervention to be performed:~Lactose breath test; Gut permeability test; Milk test."
10139655|NCT04204694||Patient in septic shock|
10139656|NCT04204694||blood donor tests|
10139657|NCT04204954|Other|Group 1: Topical 0.3% Ciprofloxacin [Cipro]|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.
10139658|NCT04204954|Active Comparator|Group 2: Cipro + 50% diluted baby shampoo|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.
10139659|NCT04204954|Active Comparator|Group 3: Cipro + Blephaclean|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.
10139660|NCT04204954|Experimental|Group 4: Cipro + Tea tree oil.|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.
10139661|NCT04204707||Conservative surgery|
10139662|NCT04204707||Radical surgery (segmental resection)|
10139663|NCT04205058|Experimental|standard coffee|Hot standard coffee with caffeine (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
10139664|NCT04205058|Placebo Comparator|caffeine-free coffee|Hot caffeine-free coffee (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
10139665|NCT04205058|Sham Comparator|water|Hot water (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
10139666|NCT04204681||Study|Patients aged 16 years or younger who were to undergo tonsillectomy surgery were eligible for inclusion in this group. Tongue areas were measured twice by submental USG.The first measurements (TA2) were done immediately after endotracheal intubation but before insertion and placement of the tonsillar retractor. The second measurements (TA1) were done after tonsillectomy surgery and after removal of the tonsillar retractor but just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
10139667|NCT04204681||Control|This group included patients aged 16 years or younger who did not need tonsillectomy surgery and any head and neck procedures. Tongue areas of the patients were measured twice by submental USG as in the study group. TA1s were done immediately after endotracheal intubation, and TA2s were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
10139668|NCT04204603|Placebo Comparator|Placebo|
10139669|NCT04204603|Experimental|CKD-506 Dose A|
10139670|NCT04204603|Experimental|CKD-506 Dose B|
10139671|NCT04204603|Experimental|CKD-506 Dose C|
10139672|NCT04204993|Experimental|Experimental: Influenza A|Participants will be inoculated with Influenza A/Belgium/4217/2015 at a dose of 5x105 TCID50 in a volume of 0,5mL via intranasal drops or spray. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood, respiratory tract sampling, and sensor monitoring. Following discharge, they will be followed up for up to 6 months post-inoculation.
10139673|NCT04204798|Experimental|Dexmedetomidine group|Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.
10139674|NCT04204798|Placebo Comparator|Placebo group|Normal saline is infused for the same duration as in the dexmedetomidine group.
10139675|NCT04204590|Other|Participants|The aim of this study is to test the feasibility of this algorithm as an intervention to carry out deprescribing a targeted medication group, proton pump inhibitors (PPI's) and statins, among nursing home residents.
10139676|NCT04204525||Patients with chronic whiplash associated disorders|Male or female, aged between 18 and 65 years. Inclusion: 1) whiplash trauma (at least three months old) and pain since at least 3 months, self-reported mild to severe pain-related disability (score of 5/50 or more on the neck disability index), classified as wad II or wad III on the modified Quebec task force scale; 2) not undertaking exercise 1 day before the experiment; 3) not starting new treatments or medication and continuing their usual care 6 weeks prior to and during study participation (to obtain a steady state); 4) native dutch speaker and 5) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments
10139677|NCT04204525||Healthy controls|Male or female, aged between 18 and 65 years. Inclusion: 1) no history of whiplash trauma, no pain with a mean pain intensity of more than 2/10 on the visual analogue scale for > 8 consecutive days in the preceding year in the neck-shoulder-arm region 2) painfree at the day of testing 3) native dutch speaker and 4) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments.
10139678|NCT04204746||3 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
10139679|NCT04204746||6 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
10139680|NCT04204889|Experimental|Oxaloacetate|3+3 dose escalating trial starting with 500mg twice daily orally and ending with 2500mg twice daily.
10139681|NCT04204629|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
10139682|NCT04204629|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
10139683|NCT04204642||Cerebral amyloid angiopathy (CAA)|Cerebral amyloid angiopathy (CAA) patients
9669208|NCT03708224|Experimental|Atezolizumab + Tocilizumab|Participants will receive 840 mg of atezolizumab IV and 6 mg/kg of Tocilizumab during the 15-day neoadjuvant period prior to definitive surgery.
9669209|NCT03701360||Aspirin alone group|- Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed
10139684|NCT04204772|Experimental|Daily AC|A total of 4 combinations (2 activated Charcoal doses and 2 solutions) is given to the participants. The dose levels are 12 and 25 of medical grade oral AC. The AC will be mixed with 4 oz of either tap water or apple juice for a total of 4 combinations.
10139685|NCT04204421|Experimental|Experience Sampling Method (ESM)|Both patients with functional dyspepsia and healthy controls will be asked to fill out ESM questionnaires during 1 week. Moreover, at the end of this week, usual questionnaires for complaints assessment will be filled out.
10139686|NCT04204564||paclitaxel coated balloon angioplasty|Procedures with paclitaxel coated balloon angioplasty of the superficial femoral-popliteal artery
10139687|NCT04204564||plain balloon angioplasty|Procedures with plain balloon angioplasty of the superficial femoral-popliteal artery
10139688|NCT04204564||paclitaxel eluting stent|Procedures with paclitaxel eluting stenting of the superficial femoral-popliteal artery
10139689|NCT04204564||bare metal stenting|Procedures with bare metal self expanding stenting of the superficial femoral-popliteal artery
10139690|NCT04204551|Experimental|PD-TR|"Intervention~exercise, dose: two cycles of 12-week HIIT program (three times a week) separated with 3 months break~& conventional physical therapy"
10139691|NCT04204551|Active Comparator|PD-NTR|conventional physical therapy
10139692|NCT04204551|No Intervention|Healthy Controls|healthy controls without any kind of therapy
10139693|NCT04204785|No Intervention|Pre-Education|Patient and Anesthesiologist participants completing surveys prior to OR staff education sessions.
10139694|NCT04204785|Experimental|Post-Education|Patient and Anesthesiologist participants completing surveys after OR staff education sessions.
10139695|NCT04204577|No Intervention|Thermal ablation|Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
10139696|NCT04204577|Experimental|Thermal ablation combined with apatinib|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take about half an hour after a meal (the daily dose should be as much as possible), and take it with warm water. Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib."
10139697|NCT04204577|Experimental|Ablation combined with apatinib and PD-1 antibody SHR-1210|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take it with warm water about half an hour after a meal (the daily dose should be as much as possible). Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib.~SHR-1210, 200mg, intravenous infusion for 30 minutes (including the time of the tube,the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks; the first dose with the apatite Simultaneous administration of PD, PD-1 injection is not affected by thermal ablation."
10139698|NCT04204902|Experimental|Test Treatment then Reference Treatment|Participants will receive a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 1 followed by a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 2. The treatment periods will be separated by 21 day washout period.
10139699|NCT04204902|Experimental|Reference Treatment then Test Treatment|Participants will receive a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 1 followed by a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 2. The treatment periods will be separated by 21 day washout period.
10139700|NCT04204356|Experimental|tDCS group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment with active tDCS.
10139701|NCT04204356|Sham Comparator|Sham group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment without active tDCS (sham)
10139702|NCT04204486|Experimental|Face to face exercise intervention|Participants will participate in face to face exercise programme delivered by a strength and conditioning coach. Sessions will last 1 hour, 3 times a week, and will be offered at the work place. The coach will register attendance in order to monitor compliance.
10139703|NCT04204486|Active Comparator|Online exercise intervention|"Participants will be given the same training programme as the face to face group, but via an online app. Sessions should last 1 hour and should be completed 3 times a week. Participants will be asked to post a work-out picture on the social platform of the app as proof that they completed their session."
10139704|NCT04204486|No Intervention|Control|This group will undergo all pre and post tests, but will not receive an intervention.
10139705|NCT04204278|Other|Monovisc|
10139706|NCT04204395|Experimental|Experimental group|"When complete the admission process, the caregiver will give a peanut ball to perform, besides the routine health brochure.~The participants will be at independent compartment."
10139707|NCT04204395|No Intervention|Control group|Take the routine health brochure. The participants will be at independent compartment.
10139708|NCT04204369|Experimental|Teaching arm|This group received the teaching intervention and was evaluated before and after the intervention. Improvement was compared to their performance prior to the intervention.
10139709|NCT04204226|Experimental|Social Worker vs Autism Behavioral Health Navigation (ABHN)|"Phase 1: Families providing informed consent will then be randomized to social work consultation or to the Autism Behavioral Health Navigation (ABHN) intervention.~Non-responders to ABHN will move to ABHN + Complex Autism Program (CAP)."
10139710|NCT04204226|Experimental|Social work + ABHN vs Social work + ABHN + CAP|"At 3 months, children who are considered to be responders to their current treatment will continue; children who are nonresponders in the social work arm of the study will be randomized to either ABHN or ABHN+CAP. Children in the ABHN arm who are non-responders will receive ABHN + CAP"
10139711|NCT04204382|Experimental|test group|"CKI was injected intravenously for 7 days, once a day, 20ml each time；~Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time,"
9969854|NCT01294176|Placebo Comparator|Avicel™|The placebo is Avicel™ (microcellulose crystal) and 4.3 mg quercetin (a bioflavanoid).
10139712|NCT04204382|Other|control group|Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time.
10139713|NCT04204252|Active Comparator|Inhaled AAT|"Daily inhalation of 80 mg/day Kamada-AAT for Inhalation for 104 weeks"
10139714|NCT04204252|Placebo Comparator|Placebo|Daily inhalation of a solution of NaCl in phosphate buffer solution with 0.01% TWEEN-80
10139715|NCT04204083|Other|Monovisc|
10139716|NCT04204109|Experimental|Interprofessional case-based learning|The experimental intervention will be the interprofessional group receiving case-based learning about gastro-intestinal toxicities and side effects of children and adolescents with cancer.
10139717|NCT04204109|Active Comparator|Monoprofessional case-based learning|The control group is the monoprofessional group that will receive the same case-based learning as the intervention group.
10139718|NCT04204096|Experimental|Vi-DT Multi-dose|"750 participants (6 mo - 45 yrs)~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (multi-dose formulation Vi-DT contains preservative 2 PE)~Mode of Administration: Intramuscular injection~Frequency of administration: Once"
10139719|NCT04204096|Experimental|Vi-DT Single-dose|"750 participants (6 mo - 45 yrs)~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (single dose formulation Vi-DT without any preservative)~Mode of Administration: Intramuscular injection~Frequency of administration: Once"
10139720|NCT04204096|Active Comparator|Control|"300 participants (6 mo - 45 yrs)~Dose: 0.5mL, Locally available Meningococcal conjugate vaccine~Dosage form: Lyophilized white powder~Mode of Administration: Intramuscular injection~Frequency of administration: Once (For participants 6 months to 1 year, one more dose will be provided after the study unblinding)"
10139721|NCT04204148||Clinical characteristics of the patients|including sex,age,smoking history,tumor location and tumor diameter
10139722|NCT04204148||Logistic regression analysis of influencing factors of c|The Leicester Cough Questionnaire in Mandarin Chinese (LCQ-MC) was used to evaluate the degree of cough in patients. The LCQ-MC is divided into three dimensions: physical, psychological and social. There are a total of 19 questions, and each question has seven options (positive scoring, grades 1-7; the higher the score is, the lighter the cough).
10139723|NCT04204304|Experimental|Isotretinoin-induced adverse effect group|Patients receiving isotretinoin with dose of 0.5-1 mg/kg/day and had musculoskeletal adverse effects
10139724|NCT04204304|Active Comparator|Control group|Pateients receiving isotretinoin with dose of 0.5-1 mg/kg/day had no musculoskeletal adverse effects
10139725|NCT04204161|Experimental|CAR-T19/CAR-T22|CAR-T19/CAR-T22 (autologous T cells transduced with CD19 / 22 CAR-ζ/4-1BB vector) will be administered to children with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity.
10139726|NCT04204213||8 Section Brocade Tai Chi Therapy|Subject participants with end stage osteoarthritis knee were enrolled into a customised multidisciplinary education program that consisted of one hour healthcare education seminars followed by another hour of 8 Section Brocade (Baduanjin) sitting Tai Chi classes for 4 consecutive weeks.
10139727|NCT04204174|Experimental|Tyrosine loading|
10139728|NCT04204018|Experimental|Experimental|Experimental-arm providers will complete four simulated patient cases (CPVs) with two additions described in the next column:
10139729|NCT04204018|No Intervention|Control|These providers will complete four simulated patient cases (CPVs) only.
10139730|NCT04204005|Active Comparator|Probiotics|Composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams)
10139731|NCT04204005|Placebo Comparator|Placebo|Composition: maltodextrin (2 grams)
10139732|NCT04204070|Experimental|Group I Accuro|epidural catheter insertion using the Accuro ultrasound imaging assisted technique
10139733|NCT04204070|Experimental|Group II APAD|epidural catheter insertion using the real time ultrasound guided technique combined with the use of the acoustic puncture assist device (APAD) technique.
10139734|NCT04204291|Experimental|All|
10139735|NCT04204031|Other|Presentation of the adherence record|"Following a first observation period of 15 days, participants whose actual time of use will be less than prescribed will be offered an intervention which will consist of a presentation of the adherence record. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.~Only participants with an actual time of use less than prescribed will be offered this intervention and will continue the monitoring over a period of 15 additional days."
10139736|NCT04203966||Common mental disorders/ versus no common mental disorders|No intervention This is a prevalence study- presence of common mental disorders (CMDs) will be assessed using the 12-item general Health Questionnaire, with responses above validated cut-points taken to indicate presence of CMDs
9969855|NCT01294189||ICU-patients that died on the ICU|ICU-patients (post-operative and non operative patients) will be enrolled in the study. All patients are followed until their death on the ICU.
10139737|NCT04203966||Alcohol use disorders/ versus no alcohol use disorders|No intervention This is a prevalence study- presence of alcohol use disorders will be assessed using the World Health Organization (WHO) AUDIT, with responses above validated cutpoints taken to indicate presence of alcohol use disorders
10139738|NCT04204044|Experimental|GROUP A ( metformin 500 mg TDS)|Life style modifications, Weight reduction and folic acid will be prescribed with metformin 500 mg three times a day
10139739|NCT04204044|Experimental|GROUP B( myoinositol 2000mg x BD )|Life style modifications, Weight reduction and folic acid will be prescribed with myoinositol 2000 mg two times a day
10139740|NCT04204044|Experimental|GROUP C.(both metformin,& myoinositol)|Life style modifications, Weight reduction and folic acid will be prescribed with both metformin,& myoinositol three and two times a day respectively
10139741|NCT04204265|Other|Monovisc|
10139742|NCT04203745|Experimental|Single Group|Single Group - single arm study
10187760|NCT03722862|Placebo Comparator|Control Arm|Healthy volunteers will continue normal healthy diet with a placebo.
9826083|NCT02406859|Experimental|Bowel Biofeedback Training|Part 2 [Bowel Biofeedback]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
9826084|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in VSG|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing vertical sleeve gastrectomy
10139743|NCT04203719|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10139744|NCT04203810|Experimental|Ectoin® Mouth and Throat Spray Althaea Honey|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
10139745|NCT04203810|Active Comparator|EMSER® Hals- und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
10139746|NCT04203940|Active Comparator|Cyanoacrylate|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue (Histoacryl®).
10139747|NCT04203940|Active Comparator|Suture|mesh fixation was done with polypropylene 2/0 sutures
10139748|NCT04203888|Other|Massage|A licensed massage therapist will deliver 60-minute Swedish Massage in the participant's home, 2 times per week with at least 48-hours between massage sessions. Each massage arm will be 2 weeks in length, and consist of 4 total Swedish massages.
10139749|NCT04203888|Other|Yoga|"A certified yoga instructor will deliver 60-minute yoga instruction in the participant's home, 2 times per week with at least 48-hours between yoga session. Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005). Each yoga arm will be 2 weeks in length, and consist of 4 total yoga sessions."
10139750|NCT04203888|No Intervention|Usual Care|Participants will be instructed to abstain from any massage or yoga activity, and instructed to treat their chronic lower back pain as they normally would. Each usual care arm will be 2 weeks in length.
10139751|NCT04203732||Total Joint Arthroplasty|The cohort includes patients undergoing outpatient primary total joint replacement surgeries from 2017 to 2019. Primary total joint surgery is defined as patients who undergo unilateral total knee replacement or total hip replacement for the first time during the study years
10139752|NCT04203784||Meropenem treated patients|
10139753|NCT04203784||Piperacillin treated patients|
10139754|NCT04203706|Experimental|Normal-weight subjects|
10139755|NCT04203628|Experimental|Prospective cohort|"Any child with presumptive TB will be proposed to participate in the study.~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies.~For children identified from the routine practice, the nurse will collect 2 respiratory samples (sputum or GA) in consecutive children with presumptive TB to be tested using Ultra as done in routine care, record symptoms and refer the child for clinical exam and for chest X-ray. For the purpose of the study, 2 stool samples will be collected to be tested with Ultra. In addition, for study purpose the two respiratory samples will be tested with Mycobacterial culture as this test is not routinely prescribed for TB diagnosis in the study sites"
10139756|NCT04203628|Experimental|Enrichment cohort|"Any child with presumptive TB and a positive Xpert result from one respiratory sample (NPA, IS or GA) will be proposed to participate in the study.~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies~For children identified from the routine care, once enrolled, samples collected as routine practice will be tested with mycobacterial culture in addition to Xpert. If needed an additional respiratory sample will be collected (sputum or GA) and tested with Mycobacterial culture. The nurse will also record symptoms, refer the child for clinical exam and for chest Xray, and collect stool samples. HIV-testing will be offered for children with unknown HIV-status"
10139757|NCT04203615|Active Comparator|PD patients with real rTMS|Patients will receive real rTMS in a two weeks long sessions (10 sessions).
10139758|NCT04203615|Sham Comparator|PD patients with sham rTMS|Patients will receive sham rTMS in a two weeks long sessions (10 sessions).
10139759|NCT04203693||Cohort 1: Tildrakizumab Treated Participants|Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies
10139760|NCT04203693||Cohort 2: Newly Tildrakizumab Prescribed Participants|Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)
10184545|NCT03754179|Active Comparator|Arm B phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily until disease progression. At disease progression, add-on of hydroxychloroquine 200 mg twice daily. Treatment until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment"
10187761|NCT03722862|Experimental|Low fiber|Healthy volunteers will be randomized to receive 3 grams of Sunfiber.
10187762|NCT03722862|Experimental|High fiber|Healthy volunteers will be randomized to receive 6 grams of Sunfiber.
9969856|NCT01294215|Experimental|Arm 1|
10139761|NCT04203602|Experimental|Telepresence round|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
10139762|NCT04203602|Active Comparator|conventional round|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
10139763|NCT04203992|Experimental|Videogame|Educational videogame, five 60-minute sessions over one month
10139764|NCT04203992|Active Comparator|Booklet|Educational booklet, one session
10139765|NCT04203758|Experimental|Wholegrain rye products with a high content of dietary fiber|Cereal products based on wholegrain rye
10139766|NCT04203758|Active Comparator|Refined wheat products with a low content of dietary fiber|Cereal products based on refined wheat
10139767|NCT04203862|Experimental|1|Single administration of low dose NPC-22
10139768|NCT04203862|Experimental|2|Single administration of low/middle dose NPC-22
10139769|NCT04203862|Experimental|3|Single administration of middle dose NPC-22
10139770|NCT04203862|Experimental|4|Single administration of middle/high dose NPC-22
10139771|NCT04203862|Experimental|5|Single administration of high dose NPC-22
10139772|NCT04203862|Experimental|6|Single administration of placebo dose NPC-22
10139773|NCT04203771|Experimental|Probiotic|Orodispersible tablets containing AB-DENTALAC probiotic formula.
10139774|NCT04203771|Placebo Comparator|Control|Orodispersible tablets without probiotic strains (excipients only).
10139775|NCT04203914|Experimental|Intervention|Empagliflozin 25mg daily add-on therapy
10139776|NCT04203576|Experimental|FIRE1 System|FIRE1 System
10139777|NCT04203654|Other|Cognitive-behavior group therapy group|
10139778|NCT04203680|Sham Comparator|HTK group|Patients received 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
10139779|NCT04203680|Active Comparator|blood cardioplegia group|patients received one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
10139780|NCT04203589|Experimental|The Explorer Early Intervention Program|The Explorer Early Intervention Program is used in this group.
10139781|NCT04203589|Active Comparator|Neurodevelopmental Therapy|Neurodevelopmental therapy is used in these group by two experienced and certificated physiotherapist
10139782|NCT04203563|Experimental|Group 1|Group 1 participants attend twice weekly progressive strength training classes with CPR certified and Strong People trained educators in fall 2019 for 12 weeks. Intervention Group.
10139783|NCT04203563|Other|Group 2|Group 2 participants receive twice weekly progressive strength training classes in January 2020 for 12 weeks. Delayed Intervention Group.
10139784|NCT04203394|Experimental|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
10139785|NCT04203394|Experimental|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
10139786|NCT04203238|Experimental|Potatoes Lean Meat (PLM)|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
10139787|NCT04203238|Experimental|Lean Meat Pulses (LMP)|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
10139788|NCT04203407|Experimental|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
10139789|NCT04203407|Active Comparator|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
10139790|NCT04203446||Adults with asthma or COPD|Adults (18-85 years old) with asthma or COPD diagnosed at least 3 months earlier, who are regularly treated with at least one inhlaer daily
10139791|NCT04203186|Active Comparator|Group 1 - PfSPZ, (NF54) strain|Group 1 (N=9) will receive PfSPZ Challenge (NF54) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum (Pf) NF54 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
10139792|NCT04203186|Active Comparator|Group 2 - PfSPZ, (7G8) strain|Group 2 (N=9) will receive PfSPZ Challenge (7G8) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum 7G8 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
10139793|NCT04203381|Other|Transgender Participant|Transgender children at Tanner stage II or early Tanner stage III between the ages of 9 and 14. Must be a current patient at a gender patient and within 6 weeks of initiating pubertal blockade treatment
10139794|NCT04203381|No Intervention|Cisgender Control Participant|Cisgender children Tanner II or early Tanner III between 9 and 14 matched by race, age, and BMI.
10139795|NCT04203342|Experimental|Ketoconazole 2% cream (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Test product is Ketoconazole 2% cream manufactured by Douglas Pharmaceuticals America Ltd.
10139796|NCT04203342|Active Comparator|Ketoconazole 2% cream (Teva Pharmaceuticals USA)|Subject will be randomized to either test product/active comparator/placebo comparator. Active comparator is Ketaconazole 2% cream manufactured by Teva Pharmaceuticals USA.
10139797|NCT04203342|Placebo Comparator|Placebo (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Placebo comparator is manufactured by Douglas Pharmaceuticals America Ltd.
10139798|NCT04203368|Active Comparator|adenosine group|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil
10139799|NCT04203368|Sham Comparator|verapamil group|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
10139800|NCT04203459||Pancreatic cancer patient|(1) patients with pancreatic cancer confirmed by imaging, pathology and body fluid biopsy, or patients who recovered well one month after operation but still had residual lesions, recurrence or metastasis. ② age ≥ 30 and ≤ 75. ③ no chemotherapy, radiotherapy or targeted drugs were used before admission. ④ patients who had used immunosuppressive drugs, hormones, antibiotics and probiotics one month before admission were excluded. ⑤ patients with HIV positive and active hepatitis B or C infection were excluded. ⑥ exclude the previous history of other malignant tumors or the current combination of other malignant tumors. The patients with serious cardiopulmonary disease and liver and kidney dysfunction were excluded. ⑧ patients with obstructive jaundice were excluded.
10139801|NCT04203459||Healthy person|(1) no history of digestive tract diseases, infectious diseases or immune diseases.(2) no history of smoking or drinking.(3) did not take antibiotics and other drugs and probiotics for 1 month before enrollment.
10139802|NCT04203550|Active Comparator|Irrigation group (IR)|A burr-hole craniostomy is performed and the dura is opened sharply and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. Subdural space is irrigated by repeated rinsing with body temperature saline solution with a syringe and blunt needle until surgeon considers exudate to be clear. Minimum volume of irrigation will be 200 ml per operated side. The subdural drain is inserted 3-5 cm underneath the skull and parallel to it. The total volume of irrigation as well as the duration of operation is recorded.
10139803|NCT04203550|Experimental|No-Irrigation group (N-IR)|A burr-hole craniostomy is performed and a small incision to the dura is made and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. The subdural drain is inserted approximately 3-5 cm underneath the skull and parallel to it. The duration of operation is recorded.
10139804|NCT04203472|Experimental|Budesonide or budeosonide/formoterol administered by DPI|In every patient cough severity and tolerance of therapy will be analyzed during therapy with budesonide and/ or formoterol administered by DPI for 14 days
10139805|NCT04203472|Active Comparator|Budesonide or budeosonide/formoterol administered by MDI|In every patient inhaler will be changed and cough severity and tolerance of therapy will be analyzed during therapy with the same drugs administered by MDI . Order of using different types of inhalers will be accidental
10139806|NCT04203316|Experimental|Treatment (enasidenib)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
10139807|NCT04203108|Experimental|ATG group|ATG group refers to treatment with a protocol including low-dose ATG, CsA, short-term MTX and MMF as GVHD prophylaxis.
10139808|NCT04203108|Active Comparator|non-ATG group|Non-ATG group refers to treatment with a protocol including CsA, short-term MTX and MMF as GVHD prophylaxis.
10139809|NCT04203277|Experimental|Step Wedge Randomized Group 1|Includes two pediatric practices randomized to the first step of the step-wedge randomized trial
10139810|NCT04203277|Experimental|Step Wedge Randomized Group 2|Includes two pediatric practices randomized to the second step of the step-wedge randomized trial
10139811|NCT04203277|Experimental|Step Wedge Randomized Group 3|Includes two pediatric practices randomized to the third step of the step-wedge randomized trial
10139812|NCT04203277|Experimental|Step Wedge Randomized Group 4|Includes two pediatric practices randomized to the fourth step of the step-wedge randomized trial
10139813|NCT04203212||Endometriosis Group|20 premenopausal women with surgically verified endometriosis who will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration.
10139814|NCT04203212||Control Group|20 age- and BMI-matched premenopausal, health women who will receive no treatment and be monitored for 6 months.
10139815|NCT04203056|Experimental|AL-LAI: Long-Acting Injectable Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: For patients assigned to the AL-LAI (aripiprazole lauroxil- long-acting injections), initiation of AL-LAI will begin with a one-day initiation regimen (using AL-NCD IM (aripiprazole lauroxil NanoCrystal Dispersion)). Subsequent dosing of AL-LAI will be flexible based on clinician judgment. Treatment with AL-LAI can be initiated at a dose of 441mg or 661mg (administered monthly), 882mg (administered monthly or every 6 weeks), or 1064mg (administered every 2 months).
10139816|NCT04203056|Active Comparator|ARI-ORAL: Aripiprazole Oral Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: Patients assigned to the oral medication condition will continue with ARI-ORAL. ARI-ORAL dosage will be flexible and dosage will be at the discretion of the treating psychiatrist. Patients discontinuing ARI-ORAL study drug after Randomization to oral antipsychotic medication, can remain in active treatment and follow-up within the study, and may be prescribed any of a number of first-line oral antipsychotics.
10139817|NCT04203017|Experimental|AutoHSCT + FMT|AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)
10139818|NCT04203004|Experimental|HOPE-CytoSorb|Patients transplanted with livers preserved by HOPE with cytokine filtration by CytoSorb, a CE approved medical device for extracorporeal cytokine removal
10139819|NCT04203004|No Intervention|HOPE-standard|Patients transplanted with livers preserved by HOPE without cytokine filtration
10139820|NCT04203121|Experimental|arm1|"An initial 5 patients will be enrolled in the first treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.~subjects 1-5 : 9 Gy in 5 fractions of 1.8 Gy on 5 consecutive days"
10139821|NCT04203121|Experimental|arm2|"Subjects in this arm will be enrolled in the second treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.~subjects 6-10 : 5.4 Gy in 3 fractions of 1.8 Gy on 3 consecutive days"
10139822|NCT04203043|Active Comparator|Pycnogenol oral product to prevent Hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
9669210|NCT03701360||Aspirin + Clopidogrel resinate group|"Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed~Clopidogrel resinate: 75mg once per day, initial loading dose of 300mg/d is allowed"
10139823|NCT04203043|Placebo Comparator|Placebo to prevent hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
10139824|NCT04203030|Experimental|Physical Activity|16 week physical activity intervention
10139825|NCT04203069|Placebo Comparator|Control group : Day-time compression sleeve|Control group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) during 90 days.
10139826|NCT04203069|Experimental|Day-time compression sleeve and Night-time MOBIDERM Autofit|Intervention group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) + night-time Auto-Adjustable MOBIDERM® Autofit Armsleeve device with the possibility to wear an additional MOBIDERM® glove if a patient has a finger edema during 90 days.
10139827|NCT04203095||patient with PD1 antibody treatment|"Investigators will detect cfDNA CIN of lung cancer patients 1day (Day 0) before treatment with PD1 antibody, then Day 22 and Day 64 after treatment with PD1 antibody, as well as at the time of disease progression confirmed.~The correlation of CIN and drug resistance to PD1 antibody was analyzed."
10139828|NCT04202900|Other|Phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
10139829|NCT04203420||patients with PA|patients who finally been diagnosed with primary aldosteronism
10139830|NCT04203420||patients without PA|patients who finally been diagnosed without primary aldosteronism
10139831|NCT04202926|Experimental|10hz group|a high frequency stimulation
10139832|NCT04202926|Sham Comparator|sham group|a sham coil which frequency is 10hz but do not induce stimulation
10139833|NCT04202809|Experimental|Chemo- and Radiochemotherapy + Durvalumab|
10139834|NCT04202809|No Intervention|Chemo- and Radiochemotherapy|
10139835|NCT04202913|Experimental|Health Coaching|1:1 Health coaching with student
10139836|NCT04202978|Experimental|Camrelizumab+ Apatinib +XELOX +RFA|Camrelizumab combined with Apatinib 、XELOX 、RFA in the treatment of liver metastases of colorectal cancer
10139837|NCT04203147|Experimental|Home DM-BAT Intervention|A trained nurse educator will deliver the manualized Home DM-BAT intervention. Subjects will receive 8-weekly sessions of behavioral activation and monthly booster sessions from months 3-12 via telephone.
10139838|NCT04203147|Active Comparator|Control Group (GHE+ST)|Patients randomized to the control group will receive in-home 8-weekly sessions of combined general health education (GHE) and supportive therapy (ST) and monthly booster sessions from months 3-12 via telephone.
10139839|NCT04203511|Experimental|Chemoradiation therapy + INCMGA00012|
10139840|NCT04203511|Active Comparator|Chemoradiation therapy + Placebo|
10139841|NCT04202718|Other|Single group|Where a wearable biosensor is being considered for use in the health management of individuals at high-risk for poor health outcomes, and in the detection or prevention of adverse events within settings where traditional monitoring devices are not currently in use, the ECG interpretation will provide Arrhythmia detection which will help ensure that irregular rhythms will be reported quickly.
10139842|NCT04202952|Experimental|600 mg multiple doses|Subjects receiving 600 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
10139843|NCT04202952|Experimental|800 mg multiple doses|Subjects receiving 800 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
10139844|NCT04202952|Experimental|1200 mg multiple doses|Subjects receiving 1200 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
10139845|NCT04202783|Experimental|Treatment of Craniofacial Neuralgia|All patients will receive the same amount (5mL concentrated) of exosomes delivered via ultrasound-guided, regional epineural injection and the same amount (5mL unconcentrated) delivered via IV. Patients will be given 3 mL of the exosome product intravenously, which contains about 45mg of the exosome product containing 15-21 million neonatal stem cell products, and 3 mL of the exosome hyperconcentrate product delivered epineurally using ultrasound guidance, which contains about 15mg of the exosome product carrying 5-7 million neonatal stem cell products.
10139846|NCT04202822|Other|Biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) at T0 and T24
10139847|NCT04202835|Experimental|ATG/PTCy|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.
10139848|NCT04202835|Active Comparator|ATG|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).
10139849|NCT04202770|Experimental|Treatment|Patients deemed potentially appropriate candidates for exosome and focused ultrasound therapy for either treatment refractory depression (trMDD), anxiety, or neurodegenerative dementia will be treated with exosomes derived from healthy, full-term Cesarean section amniotic fluid. Up to one hour of transcranial focused ultrasound will be administered immediately prior to exosome treatment in an attempt to facilitate enhanced deployment to the subgenual cingulate for trMDD, the amygdala for anxiety, or the hippocampus for dementia. Target location will be determined by the physician upon enrollment depending on the patient's specific syndrome. Patients will be given 15cc of unconcentrated solution allogenic exosomes (equivalent to 21 million stem cells, Kimera Corporation) intravenously in 200 ccs of normal saline dripped over thirty minutes to one hour.
10139850|NCT04202939||nursing homes residents|all residents present in a nursing home unit on nutritionDay
10139851|NCT04203485|Experimental|Camrelizumab 200mg + Apatinib Mesylate 250mg|Camrelizumab 200mg q2w ivgtt+ Apatinib Mesylate 250mg once daily po qd
10139852|NCT04203485|Experimental|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
10139853|NCT04203485|Active Comparator|Pemetrexed/Paclitaxel injection+ Carboplatin|For non-squamous NSCLC: Pemetrexed disodium for injection + Carboplatin; For squamous NSCLC: Paclitaxel injection + Carboplatin
10139854|NCT04202653|Active Comparator|Naive:ETV|Entecavir 0.5 mg po daily for 24 weeks in naive patients
10139855|NCT04202653|Experimental|Naive:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in naive patients
10139856|NCT04202653|Experimental|Naive:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus inhibitor of TQ-B2450 for 24 weeks in naive patients
10139857|NCT04202653|Active Comparator|Experienced:ETV|Entecavir 0.5 mg po daily for 24 weeks in treatment experienced patients
10139858|NCT04202653|Experimental|Experienced:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in treatment experienced patients
10139859|NCT04202653|Experimental|Experienced:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus TQ-B2450 for 24 weeks in treatment experienced patients
10139860|NCT04202731|Experimental|Sleep Extension|Participants will be asked to extend their time in bed with the goal of improving the total time they sleep each night.
10139861|NCT04202744||Water Polo Group|"Participants were active water polo players who train regularly with ages in between 10-30 years.~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
10139862|NCT04202744||Non-Water Polo Group|"Participants who do not engage in overhead sports with ages in between 10-30 years.~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
10139863|NCT04202510|Active Comparator|iStent|iStent Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
10139864|NCT04202510|Active Comparator|iStent Inject|iStent Inject Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
10139865|NCT04202510|Active Comparator|Hydrus|Hydrus Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
10139866|NCT04202666|No Intervention|not convex skin barrier|no intervention
10139867|NCT04202666|Experimental|convex skin barrier|intervention
10139868|NCT04202692|Experimental|GERDOff Plus|Hyaluronic acid + chondroitin sulphate + magnesium trisilicate melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
10139869|NCT04202692|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period, patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
10139870|NCT04202523|Experimental|RT&RFA|
10139871|NCT04202523|Active Comparator|RFA|
10139872|NCT04202640|Experimental|Arm A - Mechanical Stimulation|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, mechanical stimulation
10139873|NCT04202640|Sham Comparator|Arm B - Massages|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, massages.
10139874|NCT04202432||Coronary Artery Bypass Surgery patients|Patients undergoing coronary artery bypass surgery (on-pump / off-pump) measured perioperatively and postoperatively.
10139875|NCT04202887|Active Comparator|Low Fentanyl (LF)|fentanyl cumulative dose below 100mcg
10139876|NCT04202887|Active Comparator|High Fentanyl (HF)|fentanyl cumulative dose above 100mcg
10139877|NCT04202861|Experimental|in vitro antibiotic combination testing (iACT)|For the intervention arm, CRGNB isolates from the index culture should be transported to the Pharmacy Research Lab in Singapore General Hospital as soon as possible to begin iACT. For external sites, a licensed medical courier will be engaged. Once testing is complete, the iACT results will be sent to the physicians and the ID specialist managing the patient. Several antibiotic combinations can usually be used to treat the infection; a subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and/or the consulting infectious disease doctor may exercise their discretion in continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement, according to the clinical conditions and reactions of the patient to the treatment
10139878|NCT04202861|No Intervention|Control|The standard arm will receive standard therapy of either antibiotic monotherapy or unguided combination therapy, a choice based on treating physicians' best clinical judgment. iACT will only be performed on CRGNB isolates from the standard arm at least 30 days after enrolment for collection of microbiological, proteomic and molecular data. Antibiotic combinations found from delayed iACT will be made known to the Infectious Diseases physician caring for the participant.
10139879|NCT04202315|No Intervention|Control|Standard of care, no Virtual Reality
10139880|NCT04202315|Experimental|Virtual Reality|Standard of care plus Virtual Reality
10139881|NCT04202536|Experimental|TDF switch to Besifovir Dipivoxil Maleate|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Besifovir Dipivoxil Maleate 183mg daily
10139882|NCT04202536|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
10139883|NCT04202484|Experimental|Toripalimab combine CT|
10139884|NCT04202380|Other|Azithromycin 1 day group|Patients will receive Azithromycin 1000mg once orally
10139885|NCT04202380|Other|Azithromycin 5 days group|Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days
10139886|NCT04202601|Experimental|Neoadjuvant therapy group|
10139887|NCT04202601|Experimental|first-line therapy group|
10139888|NCT04202601|Experimental|≥second-line therapy group|
10139889|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.25%|Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block
10139890|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.125%|Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block
10139891|NCT04202250|Active Comparator|CEMP (closed-ended multiport catheter) group|closed-ended multiport femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
10139892|NCT04202250|Active Comparator|OESP (open-ended single port catheter) group|open-ended single port femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
10139893|NCT04202562|Experimental|Combined surgery|Participants intervened of combined ab interno trabeculectomy and cataract surgery at the same time
10139894|NCT04202562|Active Comparator|Cataract surgery|Participants intervened of cataract surgery alone
10139895|NCT04202471|Experimental|Chlorhexidine Cloth|The intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive preoperative abdominal application of 2% chlorhexidine cloths.
10139896|NCT04202471|No Intervention|Standard Preoperative Care|The no intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive standard preoperative care.
10139897|NCT04202419|Experimental|Single Group|Single Arm: All subjects will undergo treatment of pigmented lesions with a 1940 nm diode laser
10139898|NCT04202289|Active Comparator|Silver Sulfadiazine Cream 1%|In the control group, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of Silver Sulfadiazine Cream 1% was applied and covered with gauze and bandage. The dressing changes occurred every 48 hours. The patients were evaluated every 48 hours for the study parameters.
10139899|NCT04202289|Experimental|Nile Tilapia Fish Skin|In the test group, the treatment was Nile Tilapia Fish Skin, which have a patent registered at the National Institute of Industrial Property (INPI) under number BR 10 2015 021435 9. Nile Tilapia Fish Skin was subjected to a rigorous process of chemical sterilization, glycerolization and irradiation, followed by microbiological tests for bacteria and fungi, before storage in sterile refrigerated packaging. Prior to its use in the patient, the skin was washed thrice in sterile 0.9% saline for 5 minutes, in order to remove glycerol. Regarding application in the study patients, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, Nile Tilapia Fish Skin was applied and covered with gauze and bandage. Throughout the treatment, dressings with Nile Tilapia Fish Skin were only changed if the biomaterial was not properly adhered to the wound bed. The patients were evaluated every 48 hours for the study parameters.
10139900|NCT04202575|No Intervention|conventional setup|Blood and gas from the coronary and cardiotomy suction devices is continuously evacuated via the additional reservoir to the standard reservoir.
10139901|NCT04202575|Experimental|Intervention setup|The connecting tube between the additional and standard venous reservoir is clamped. Thus, blood and gas from the coronary and cardiotomy suction devices are collected in the additional venous reservoir. During the intervention setup, the blood in the additional venous reservoir is only evacuated to the standard reservoir if the volume exceeded 800ml, and always with a remaining volume of 100 mL blood to keep the CO2-gas trapped in the additional venous reservoir.
10139902|NCT04202406|Experimental|Acetaminophen, codeine,and caffeine|Oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine.
10139903|NCT04202406|Experimental|Acetaminophen|Oral single dose of 1000mg acetaminophen.
10139904|NCT04202406|Placebo Comparator|Placebo|Maize starch.
10139905|NCT04202224|Experimental|Study|Receives pre-emptive analgesia 30min. prior to third molar extraction. NSAID: Ibuprofen 400mg and Acetaminophen 500mg/
10139906|NCT04202224|Placebo Comparator|Placebo|Receives glucose tablets as pre-emptive analgesia 30min. prior to third molar extraction.
10139907|NCT04202224|Active Comparator|Control|Receives no medication prior to third molar extraction.
10139908|NCT04202211|Placebo Comparator|Placebo oral & enema|twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema
10139909|NCT04202211|Active Comparator|LYO-FMT oral + placebo enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema
10139910|NCT04202211|Active Comparator|LYO-FMT oral + LYO-FMT enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema
10139911|NCT04202198|Experimental|pinhole surgical technique with Platelet Rich Fibrin|minimally invasive tunneling procedure followed by coronal advancement with placement of Platelet Rich Fibrin membrane
10139912|NCT04202198|Active Comparator|pinhole surgical technique only|coronal advancement following minimally invasive tunneling procedure
10139913|NCT04201964|Experimental|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
10139914|NCT04202133|Experimental|WW (formerly Weight Watchers)|16-weeks of the group-based WW program
10139915|NCT04202133|Other|Waitlist Control|16-weeks on waitlist then participants will be provided with 16-weeks of the group-based WW program
9519686|NCT03284554|Sham Comparator|Non-encapsulated nutrients|"Nutrients known to be able to stimulate GLP-1 and PYY release if they are encapsulated to provide release at pH ≈7.0 (in the distal part of the ileum). The same capsules in a non-coated form will be provided in order to study the effect of the coating.~The non-encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
9694660|NCT04786873|Active Comparator|standard GHST order randomized: clonidine - arginine|"At V2, all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at V3 and V4.~In this arm, those subjects will be presented which will have been randomized to the clonidine GHST at V3 and to the arginine GHST at V4.~At V5 all subjects will perform the macimorelin GHST."
10139916|NCT04201951|Active Comparator|Tranexamic group|Group A will receive 1gm Tranexamic acide diluted in 20 ML 5% glucose water
10139917|NCT04201951|Placebo Comparator|Placebo group|Group B will receive 30ML 5% glucose water
10139918|NCT04202029|Other|pulseoxymetry arm|pulseoxymetry arm: standard monitoring: pulseoxymetry and non-invasive blood preassure monitoring
10139919|NCT04202029|Experimental|thoracic impedance monitoring arm|thoracic impedance monitoring arm: standard monitoring and additionally thoracic impedance measurement)
10139920|NCT04202042|Experimental|Psychological first aid|PFA responders are trained to deliver 8 core actions in the aftermath of traumatic event (: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services (within the first 24 hours)
10139921|NCT04202042|Active Comparator|Usual organisational intervention|One phone call by workplace psychologist (within the first 48 hours) and reference to employee aid program
10139922|NCT04202185||G1a|infants under 3 years deaf severe to deep
10139923|NCT04202185||G1b|children under 16 years of age with audiologically proven auditory neuropathy
10139924|NCT04202185||G2|patients <25 years old with one or two Otoferlin mutations
10139925|NCT04201912|Placebo Comparator|control patients|Evaluation of Toll like receptor activity from whole saliva obtained from control patients
10139926|NCT04201912|Active Comparator|Periodontal patients without diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients without diabetes
10139927|NCT04201912|Active Comparator|Periodontal patients with diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients with diabetes
10139928|NCT04202068|Experimental|Ceftriaxone sodium and Sulbactam Sodium for injection|combinations of β-Lactamase inhibitors
10139929|NCT04201925||blepharoplasty|Patients will undergo blepharoplasty surgery
10139930|NCT04202055||Neuromyelitis optica with anti-MOG|
10139931|NCT04202055||Patients with Neuromyelitis optica with anti-AQP4|
10139932|NCT04202055||Seronegative patients with Neuromyelitis optica|
10139933|NCT04202055||Patients with recurrent-remitting multiple sclerosis|Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement
10139934|NCT04202055||Progressive multiple sclerosis patients|
10139935|NCT04202055||Symptomatic controls|
10139936|NCT04202094|Experimental|Biopsy group|Young adults (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment (with an ≥80% risk of later fertility problems) during childhood and who have chosen to undergo a testicular tissue biopsy procedure at a young age as a fertility preservation strategy.
10139937|NCT04202094|Experimental|No biopsy group|Young adults (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment (with an ≥80% risk of later fertility problems) during childhood and who have refused to undergo a testicular tissue biopsy procedure at a young age as a fertility preservation strategy.
10139938|NCT04202094|No Intervention|Control group|Spontaneously conceived young adults whose data on reproductive health have already been published (Belva F et al., 2016/2017/2019).
10139939|NCT04202120|Experimental|Age-related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with age-related primes.
10139940|NCT04202120|Active Comparator|Non-age related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with NON age-related primes.
10139941|NCT04201938|Active Comparator|Symbiter-Omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
10139942|NCT04201938|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
10139943|NCT04202016|Experimental|Piezocision on high facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
10139944|NCT04202016|No Intervention|High facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
10139945|NCT04202016|Experimental|Piezocision on average facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
10139946|NCT04202016|No Intervention|Average facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
10139947|NCT04202172|Active Comparator|BIOFREEDOM|Implantation of Drug-eluting coronary stent without polymer in patients with myocardial infarction.
10139948|NCT04202172|Experimental|COMBO|Implantation of Bioactive coronary stent in patients with myocardial infarction.
10184546|NCT03754179|Experimental|Phase 1|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
10184547|NCT03754166|Experimental|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
10184548|NCT03754166|No Intervention|Usual care|Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.
10184549|NCT03754140|Experimental|Polidocanol Injection|Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion
10184550|NCT03754075||CME group|The CME group consisted of patients, who underwent elective CME for right-sided colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2013.
10184551|NCT03754075||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for right-sided adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
10184552|NCT03754062|Placebo Comparator|Placebo|Placebo control
10184553|NCT03754062|Experimental|Haloperidol 3mg|Haloperidol
10184554|NCT03754062|Experimental|L-Dopa 150 mg & Domperidone 10mg|L-Dopa
9694661|NCT04786574|Experimental|Tolvaptan (OPC-41061)|
10139949|NCT04201808|Experimental|Single Arm Intervention Group|All approximately 100 patients experienced previous suboptimal response to other direct acting antivirals. Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence. All patients in this study are in the same arm.
10139950|NCT04201886|Other|RA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
10139951|NCT04201886|Other|OA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
10139952|NCT04202003|Experimental|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
10139953|NCT04201847|Active Comparator|Infertile women with normal ovarian reserve|Infertile women with normal ovarian reserve will be included.
10139954|NCT04201847|Active Comparator|Infertile women with high ovarian reserve|Infertile women with high ovarian reserve will be included.
10139955|NCT04201847|Active Comparator|Infertile women with poor ovarian reserve|Infertile women with poor ovarian reserve will be included.
10139956|NCT04201977|Active Comparator|Exercise session followed passive recovery|Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). The interval between each exercise session will be one week. Volunteers will not perform any form of recovery for 20 min after resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
10139957|NCT04201977|Active Comparator|Exercise session followed active recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Active recovery for 20 minutes (MIKA et al., 2016; CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010);
10139958|NCT04201977|Active Comparator|Exercise session followed immersion in cold water recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will be immersed in cold water immediately after exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009).
10139959|NCT04201977|Active Comparator|Exercise session followed foam roller recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will undergo an FR session immediately after resistance exercise session (PEARCEY et al., 2015).
10139960|NCT04201860||Blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue handled explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
10139961|NCT04201860||Not blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue did not handle explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
10139962|NCT04201990|Experimental|treatment group|Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years
10139963|NCT04201795|Experimental|pressure and traction|pressure and traction durin 5 minutes will be applied in plantar fascia
10139964|NCT04201795|Sham Comparator|Laser|Applied during 5 minutes each plantar fascia of sham laser
10139965|NCT04201665|Experimental|carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
10139966|NCT04201665|Active Comparator|oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
10184555|NCT03754036|Experimental|Sleep Extension|Increase in time in bed of 1.5 hours per night for one week
10184556|NCT03754036|Experimental|Sleep Restriction|Decrease in time in bed of 1.5 hours per night for one week
10139967|NCT04201678|Active Comparator|CLIA (conventional local anesthesia infiltration) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
10139968|NCT04201678|Active Comparator|EPIAA (Extrapedicular infiltration anesthesia) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
10139969|NCT04201678|Active Comparator|ESP (Erector Spina Plane Block) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 Megahertz (MHz) linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
10139970|NCT04201782|Experimental|Cohort 1|Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.
10139971|NCT04201470|Experimental|MS patients|Patients with atypical MS identified in our cohort
10139972|NCT04201470|Active Comparator|Controls|
10139973|NCT04201574|Placebo Comparator|Vehicle Ophthalmic Solution|
10139974|NCT04201574|Experimental|ALY688 Ophthalmic Solution Concentration 1|
10139975|NCT04201574|Experimental|ALY688 Ophthalmic Solution Concentration 2|
10139976|NCT04201587|Experimental|Henna application group|
10139977|NCT04201587|No Intervention|Control group|
10139978|NCT04201769|Experimental|Arm A|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~No further anti-emetic prophylaxis on days 2 thorough 4."
10139979|NCT04201769|Experimental|Arm B|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~Oral dexamethasone 4 mg once per day in the morning of days 2 and 3."
10139980|NCT04201769|Active Comparator|Arm C|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~Oral dexamethasone 4 mg twice per day on days 2 thorough 4."
10139981|NCT04201613|Active Comparator|Early Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive one hour of treatment per day for 20 days.
10139982|NCT04201613|Active Comparator|Early Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
10139983|NCT04201613|Active Comparator|Late Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive one hour of treatment per day for 20 days.
10139984|NCT04201613|Active Comparator|Late Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
10139985|NCT04201613|Active Comparator|Control Group|This group will receive usual care with robotic assessment.
10139986|NCT04201743|Active Comparator|1 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 1 mL NyDYN injection.
10139987|NCT04201743|Active Comparator|2 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 2 mL NyDYN injection.
10139988|NCT04201717|Active Comparator|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed.After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
9976962|NCT01356771|Other|Tailored Intervention|We will mail three separate pamphlets created specifically for the participant. The information in the pamphlets will be based on answers from the first survey.
9976963|NCT01356784|Experimental|Tailored Physical Activity|
9669211|NCT03696082|Experimental|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
9976964|NCT01356784|Active Comparator|"Chronic Pain Self-management Programme"|
9976965|NCT01356784|Other|Health Counselling|
9976966|NCT01356797|Active Comparator|hyperbaric bupivacaine|
9976967|NCT01356797|Experimental|hypobaric levobupivacaine with fentanyl|
10139989|NCT04201717|Experimental|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion.In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
10139990|NCT04201704|Active Comparator|Liberal IV Fluid|"Maintenance fluid rate calculated by 4-2-1 formula for patients <110kg: 4 mL/kg for first 0-10kg + 2 mL/kg for 11-20kg + 1 mL/kg for each kg >20kg~Patients >110kg maintenance 150 mL/hr~Bolus Criteria: change in 1 of: >20% decrease in systolic blood pressure 50th percentile for age and sex, >20% increase in heart rate over 50th percentile for age, base excess > -5mmol/L, blood lactate >2mmol/L, AND urine output (UO) <1 mL/kg/hr if <50kg or <50 mL/hr if >50kg~If criteria met: bolus 20 mL/kg if <50kg or 1 L if ≥50 kg~For transfusion: give 10 mL/kg packed red blood cells, platelets, or fresh frozen plasma up to 250 mL. If >25kg give 250 mL.~Diuresis- after minimum 24hrs: if UO <2 mL/kg/hr (or <100 mL/hr if >50 kg) continue maintenance rate and bolus per initial phase. If UO >2 mL/kg/hr (or >100 mL/hr if >50kg), and lactate, systolic blood pressure, heart rate, creatinine are normal then lower IV fluid rate to ½ maintenance rate and then to keep vein open once on regular feeds"
10139991|NCT04201704|Experimental|Restricted IV Fluid|"Maintenance fluid rate calculated by 70% of 4-2-1 formula if <110 kg: 4 mL/kg for first 0-10 kg, + 2 mL/kg for 11-20 kg, + 1 mL/kg for every kg >20 kg~Patients >110 kg: maintenance is 105 mL/hr~If same bolus criteria met: 10 mL/kg for patients <50kg, or 500 mL if ≥50 kg~If meet transfusion criteria: transfuse 10 mL/kg with packed red blood cells, platelets, or fresh frozen plasma by weight up to 250 mL. Patients >25 kg get 250 mL per transfusion~Diuresis (after minimum 24 hrs): if UO <1 mL/kg/hr (or <50 mL/hr if >50 kg) then continue IV fluids at maintenance rate and bolus as needed. If UO 1-2 mL/kg/hr (or 50-100 mL/hr if >50 kg) then decrease IV rate to ½ maintenance rate. If UO >2 mL/kg/hr (or >100 mL/hr if >50 kg), and Lactate, systolic blood pressure, heart rate, creatinine normal then reduce to keep vein open and consider Furosemide for goal UO >2-4 mL/kg/hr (100-200 mL/hr if >50 kg) until euvolemic"
10139992|NCT04201405|Experimental|Haematopoietic stem cell gene therapy for MPS IIIA|Open label
10139993|NCT04201691|Experimental|conventional group|Conventional group is received conventional rehabilitation program.
10139994|NCT04201691|Experimental|mobilization group|Mobilization group is received cervical mobilization in addition to conventional rehabilitation program.
10139995|NCT04201366||Sample 1|All participants fulfilling the inclusion criteria.
10139996|NCT04201366||Sample 2|Participants fulfilling the inclusion criteria and reports no neck/shoulder pain at baseline.
10139997|NCT04201522|Active Comparator|Training intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance
10139998|NCT04201522|Sham Comparator|Sham intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance in the training group compared to the sham group.
10139999|NCT04201626|Experimental|ERAS|
10140000|NCT04201626|No Intervention|Control|
10140001|NCT04201535||Group 1A:|at least 10 patients, maximum 70,with RA in remission, but presenting p• Group 1B: at least10 patients maximum 70, with RA in remission, without bone erosion A group of 80 controls,
10140002|NCT04201535||Group 2:|10 patients with osteoarthritis (OA) who must undergo a surgical procedure.
10140003|NCT04201535||Group 3|"70 without RA and OA but hospitalized for any other orthopedics pathology who must undergo a surgical procedure.~rogressive bone erosion who must undergo a surgical procedure."
10140004|NCT04201561|Experimental|Experimental group|The patient will receive an intravenous selenium 2000 μg/40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
10140005|NCT04201561|Placebo Comparator|Placebo group|The patient will receive an intravenous normal saline 40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
10140006|NCT04201639|Experimental|Refit|Refit and dispense patient with Verofilcon A contact lenses and evaluate lens performance.
10140007|NCT04201483|Active Comparator|DCE group|DCE exercise without RUSI feedback
10140008|NCT04201483|Experimental|DCE + RUSI group|DCE exercise with RUSI feedback
10140009|NCT04201379||neck pain patients|servical disk hernisi servical spondilosis servical problems
10140010|NCT04201379||control|healthy people
10140011|NCT04201652|Active Comparator|Superficial|Intervention: Superficial local anesthetic infiltration.
10140012|NCT04201652|Active Comparator|Deep|Intervention: Superficial and deep local anesthetic infiltration.
10140013|NCT04201353|Experimental|Conditional Cash Transfer|Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.
10140014|NCT04201353|No Intervention|Control|Participants attending control clinics will receive the standard of care.
10140015|NCT04201730|Experimental|ERAS|Perioperative intervention with individual Enhanced Recovery After Surgery （ERAS）
10140016|NCT04201314|Placebo Comparator|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
10140017|NCT04201314|Experimental|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
10140018|NCT04201327|Active Comparator|PrEP information only arm|Information to for accessing HIV prevention tools will be provided to participants.
10140019|NCT04201327|Experimental|PrEP counseling arm|Stigma focused counseling (one-session) aimed at addressing barriers to health care access will be provided.
10140020|NCT04201327|Experimental|PrEP counseling plus text messaging arm|Stigma focused counseling (one-session) and interactive text messaging aimed at addressing barriers to health care access will be provided.
10140021|NCT04201327|Experimental|PrEP counseling plus text messaging and on demand counseling|Ongoing stigma focused counseling and interactive text messaging aimed at addressing barriers to health care access will be provided.
10140022|NCT04200950|Experimental|Intervention|Previse alert arm
10140023|NCT04200950|No Intervention|Control|No alert
10140024|NCT04201041|Active Comparator|trans-gluteal approach|received pudendal nerve pulsed radiofrequency through trans-gluteal approach
10140025|NCT04201041|Active Comparator|trans-vaginal approach|received pudendal nerve pulsed radiofrequency through trans-vaginal approach
10140026|NCT04201015|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
10140027|NCT04201015|Active Comparator|Rate-response settings off|Patients allocated to deactivated rate-response settings.
10140028|NCT04201015|Experimental|Optimized rate-response settings|Patients allocated to optimised rate-response settings.
10140029|NCT04201236|Experimental|Oropharyngeal exercises|Oropharyngeal exercises include soft palate, tongue and facial muscle exercises as well as stomatognathic function exercises. Training sessions were held once a day, 5 days a week for 12 weeks under the supervision of a mirror.
10140030|NCT04201236|Experimental|Inspiratory muscle training|The inspiratory muscle training group was administered for 12 weeks starting from 30% of maximal oral pressure, 7 days a week, 15 minutes twice a day. Patients came to the control once a week, mouth pressures were measured and training pressure was adjusted in 30% of the new value.
10140031|NCT04201236|No Intervention|Control|This group was only monitorized without any rehabilitation intervention.
10140032|NCT04201106|No Intervention|Control|In the control group, the participants will not be taking any placebos or undergoing any other study-related treatments.
10140033|NCT04201106|Experimental|Open Label Placebo Group with Rationale|
10140034|NCT04201106|Active Comparator|Open Label Placebo Group without Rationale|
10140035|NCT04201158||Obese Group (Girl)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria.Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
10140036|NCT04201158||Obese Group (Boy)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
10140037|NCT04201158||Control Group (Girl)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
10140038|NCT04201158||Control Group (Boy)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
10140039|NCT04201054|Experimental|Fluconazole|Subjects receive a single-dose treatment.Urine samples will be collected after administration (4 fractions: 0-12, 12-24, 24-48, 48-72 hours post-administration).
10140040|NCT04201145|Experimental|Run in cohort: pembrolizumab only|"Treatment with pembrolizumab as a single agent for 56 days~- 2 doses during treatment cycle, intravenous, at predetermined protocol dose"
10140041|NCT04201145|Experimental|Cohort 1: pembrolizumab + defactinib 12 days|"Treatment with Defactinib in combination with Pembrolizumab for 12 days~Defactinib oral, twice daily, per predetermined dose for 12 days of treatment in combination~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
10140042|NCT04201145|Experimental|Cohort 2: pembrolizumab + defactinib 35 days|"Treatment with defactinib in combination with pembrolizumab to 35 days~Defactinib oral, twice daily, per predetermined dose for 35 days of treatment in combination~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
10140043|NCT04201145|Experimental|Expansion cohort|Tolerated phase IA regimen will be administered in a phase IB expansion cohort
10140044|NCT04201132|Experimental|Carotid artery stenting|Carotid artery stenting procedure with Neuroguard IEP System
10140045|NCT04201275|Experimental|Cohort 1|up to HEC74647PA capsule 50 mg once daily for 3 days
10140046|NCT04201275|Experimental|Cohort 2|up to HEC74647PA capsule 100 mg once daily for 3 days
10140047|NCT04201275|Experimental|Cohort 3|up to HEC74647PA capsule 200 mg once daily for 3 days
10140048|NCT04201275|Placebo Comparator|Cohort 4|up to placebo once daily for 3 days
10140049|NCT04201093|Experimental|Tavapadon 5 mg|Participants will receive tavapadon tablet titrated up to 5 milligram (mg) once daily (QD) orally for 27 weeks.
10140050|NCT04201093|Experimental|Tavapadon 15 mg|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) QD orally for 27 weeks.
10140051|NCT04201093|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
10140052|NCT04201119|Experimental|With Oxiris|
10140053|NCT04201119|No Intervention|Without Oxiris|
10140054|NCT04200989|Experimental|Treatment|Peanut ILIT
10140055|NCT04200924||Children with idiopathic toe walking|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
10140056|NCT04200924||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
10140057|NCT04201249|Active Comparator|Mesotherapy with piroxicam and lidocaine|
10140058|NCT04201249|Sham Comparator|Mesotherapy without piroxicam and lidocaine|
10140059|NCT04201080|Experimental|Part A: TRV250 for SC injection|2 SC injections of (10 mg/ml per injection)
10140060|NCT04201080|Placebo Comparator|Part A: Placebo for SC injection|2 SC injections (identical to the TRV250)
10140061|NCT04201080|Experimental|Part B: TRV250 dose 1 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
10140062|NCT04201080|Experimental|Part B: TRV250 dose 2 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
10140063|NCT04201080|Experimental|Part B: TRV250 dose 3 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
10140064|NCT04201080|Placebo Comparator|Part B: Placebo for SC injection|Placebo (using syringes identical to the TRV250 arms)
10140065|NCT04201223|Experimental|FLARE Intervention|Participants will be randomized to receive an intervention that works with melanoma survivors and their children as a family unit to improve melanoma preventive behaviors.
10140066|NCT04201223|No Intervention|Standard Education|Participants will be randomized to receive information on child sun protection that is publicly available.
10140067|NCT04200885|Active Comparator|Postoperative NSAID Prescription|Patients in this arm received common postoperative prescriptions following removal of their impacted third molars for seven days; twice a day 500 mg amoxicillin+125 mg clavulanic acid, twice a day 25 mg dexketoprofen trometamol and three times a day 1.5 mg/ml clorhexidine gluconate+1.2 mg/ml benzydamine hydrochloride containing 200 ml mouthwash.
10140068|NCT04200885|Active Comparator|Preoperative Submucosal Corticosteroid Injection|Patients in this arm were administered 8mg/2ml dexamethasone 21-phosphate preoperatively after local anesthesia were obtained. Injection site was the depth of buccal sulcus near operation site. For the patients in this arm 25 mg dexketoprofen trometamol was excluded from postoperative prescription in order not to affect the anti-inflammatory effects of corticosteroid. Instead of NSAID, three times a day 500 mg paracetamol was prescribed. The patients were advised not to exceed maximal dosage of 3000 mg (6 tablets) in a day.
10140069|NCT04200885|Active Comparator|Postoperative Therapeutic Elastic Bandage Application|In this arm the therapeutic elastic bandage applications were immediately performed after removal of mandibular third molars. The distance between tragus-lateral commissura line and supraclavicular lymph nodes was measured and the tapes were then cut into 5 tails. The base of the tape was placed on supraclavicular lymph nodes and tails were placed on the site to cover parotid, submandibular, submental and superficial cervical lymph nodes. The tapes were removed on postoperative second day.
10140070|NCT04201028|Experimental|Video Conferencing Health Coaching with devices|The DEV group participants will meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) to discuss exercise and diet goals. Participants in this group were provided with a blood pressure and body weight scale which connected to the CoachCare App®.
10140071|NCT04201028|Experimental|Video Conferencing Health Coaching with no devices|The NODEV group participants meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) for health coaching to discuss exercise and diet goals. Participants in this group did not receive devices.
10140072|NCT04201210|Experimental|Experimental Arm|Patients with no matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the experimental arm
10140073|NCT04201210|Active Comparator|Control Arm|Patients with a matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the control arm
10140074|NCT04200794|Experimental|musical instrumental training|Bi-weekly musical string instrument training in a group setting, over 24 months, provided by professional string instrument teachers
10140075|NCT04200794|Active Comparator|sensitization to music|Bi-weekly sensitization to music in a group setting, over 24 months, involving listening, playing small percussive instruments and choir singing, provided by professional school music teachers
10140076|NCT04200833||group 1|All JIA patients that were switched from adalimumab to golimumab because of Treatment failure of their JIA associated uveitis at the Medical University of Graz Austria from 2010 to 2019
10140077|NCT04200872||biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
10140078|NCT04200872||without biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
10140079|NCT04200807||Healthy preterm neonate|Neonate 26 weeks to 36 weeks + 6 days of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
10140080|NCT04200807||Healthy term neonate|Neonate from 37 weeks of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
10140081|NCT04200807||Sick neonate|Neonate of any gestation, without congenital heart defects, with clinically and laboratory-identified infection.
10140082|NCT04200703|Experimental|Intervention|Implementation of the Adult and Survivor Centered Approach.
10140083|NCT04200703|No Intervention|Comparison|No implementation of intervention.
10140084|NCT04200677|Experimental|MCN1|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
10140085|NCT04200677|Experimental|BCN05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve
10140086|NCT04200677|Experimental|BCN1|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
10140087|NCT04200677|Experimental|BCN2|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve
10140088|NCT04200677|Experimental|MCM1|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
10140089|NCT04200677|Experimental|BCM05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly
10140090|NCT04200677|Experimental|BCM1|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
10140091|NCT04200677|Experimental|BCM2|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly
9669212|NCT03696082|Experimental|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
10140092|NCT04200677|Experimental|BC25|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly
10140093|NCT04200716|Active Comparator|Moderate intensity continuous training - session|The volunteers perform a 30-minute moderate-intensity exercise session on the exercise bike.
10140094|NCT04200716|Active Comparator|High intensity interval training - session|The volunteers perform a session of high intensity interval exercise on the exercise bike.
10140095|NCT04200599|Experimental|Early oxytocin Infusion|labour augmentation with oxytocin was started early following amniotomy.
9976968|NCT01356810|Placebo Comparator|Standard Care|Delirium management defined by the attending physician.
10140096|NCT04200599|Active Comparator|Late oxytocin infusion|oxytocin augmentation was delayed at two hours after amniotomny and this practice is currently being used as standard protocol in this hospital to manage women in labour.
10140097|NCT04200612|Experimental|Intervention Group|Participants in the intervention group will go through the 5-week EAP program consisting of the clinical processing following some activities found in EAP manuals.
9669213|NCT03696082|Experimental|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
9669214|NCT03696082|Experimental|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
10140098|NCT04200612|Active Comparator|Active-control group|Participants in the active-control group will undergo a 5-week program that only involves interactions with horses without any clinical input (i.e. commonly coined as animal-assisted activities).
10140099|NCT04200612|Placebo Comparator|Placebo-control group|Participants in the placebo-control group will undergo a 5-week movie screening of 1 hour each session that is related to horses.
10140100|NCT04200638|Experimental|ProTaper Next group|Clean and shape the necrotic canals with ProTaper instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
10140101|NCT04200638|Experimental|WaveOne Gold group|Clean and shape the necrotic canals with Wave One Gold instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
10140102|NCT04200859|Experimental|Cold application with ice pack|Before the chest tube was removed, two ice packs with a size of 15.5x9cm were inserted around the chest tube so as to make as much contact as possible
9669215|NCT03694353|Experimental|Pegvaliase|Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in 165-302 or PAL-003 (pegvaliase dosing should continue without interruption from the previous study). Subsequent revisions to dosing regimens are allowed following consultation with the medical monitor.
9669216|NCT03689855|Experimental|Ramucirumab + Atezolizumab|"Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg.~Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg."
9669217|NCT03681561|Experimental|Ruxolitinib and Nivolumab|
9669218|NCT03678883|Experimental|9-ING-41|Drug: 9-ING-41
9976969|NCT01356810|Experimental|Environmental Intervention|
10140103|NCT04200859|Experimental|Cold application with gel pad group|Before the chest tube was removed, a gel pad with a radius of 15 cm was completely inserted around the chest tube
10140104|NCT04200859|No Intervention|Control group|Routine analgesic drugs are not administered to patients before removal of the chest tube in thoracic surgery clinic. However, analgesic is performed according to the severity of pain after the procedure.
10140105|NCT04200768|Other|Standard|Standard of care
10140106|NCT04200404|Experimental|Phase Ib arm|arms 1. Phase Ib: advanced or refractory solid tumors;
10140107|NCT04200404|Experimental|Phase II arm|arms 2.Phase II: subjects with tumor of specific types
10140108|NCT04200573|Experimental|Normal Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with normal hepatic function
10140109|NCT04200573|Experimental|Mild Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment
10140110|NCT04200573|Experimental|Moderate Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment
10140111|NCT04200573|Experimental|Severe Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment
10140112|NCT04200521||Healthy weight individuals|Cross-sectional observation on healthy participants who will be recruited from the general population from both genders (Lebanese and Emirati Subjects).
10140113|NCT04200521||Obese individuals|Prospective study of 3 months duration (pre and post design) on obese Emirati and Lebanese participants undergoing bariatric procedure irrelevant of the study, from Qassimi Hospital In sharja and Middle East Institute of Health University Hospital, Lebanon
10140114|NCT04200586|Experimental|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground
10140115|NCT04200781|Experimental|Shengdi Dahuang Decoction|To clarify the clinical effects of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke and to explore the possible mechanism. Participants will take the granules of Shengdi Dahuang Decoction that contains 15 grams of rehmannia and 5 grams of rhubarb, one pack per time, twice a day for 7 days.
10140116|NCT04200781|Placebo Comparator|Placebo|To explore the effective clinical therapy in acute hemorrhagic stroke. Participants will take placebo contains 2% rehmannia and rhubarb, one pack per time, twice a day for 7 days.
10140117|NCT04200469|Experimental|QFR Intervention|Patients submitted to a coronary angiogram with at least one non-left main stable coronary stenosis between 50 and 90% and PCI indication with paired assessment of QFR, dFR, RFR and FFR, before and after PCI once informed consent is provided.
10140118|NCT04200729|Experimental|Irrigation with PVI|
10140119|NCT04200729|Active Comparator|Usual care|
10140120|NCT04200846|Experimental|Exercise intervention|Private supervised strength training exercise (e.g., body weight or dumbbell exercises) will occur in the Cancer Center Exercise Medicine Unit or the Hershey Center for Applied Research (HCAR) two days a week. In addition, subjects will be instructed to exercise on their own, at home, three days a week doing 30 minutes of moderate intensity aerobic exercise (e.g., walking at 45-55% maximum heart rate determined by the formula max heart rate = 220bpm - 0.64*age in years).
10140121|NCT04200846|No Intervention|Control|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional and to maintain their current exercise level. Weekly phone calls will be performed to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for interim history and physical to confirm self-reports. Subjects will also be given a FitBit ChargeHR3 and downloaded data review will be performed monthly at the in-person visits.
10140122|NCT04200287|Experimental|Young adult female (YA-F) cancer survivors|YA-F cancer survivors will complete a baseline survey (T1) of sociodemographic and patient reported outcomes (PRO) and then will be sent a link to access the decision aid tool (website) with instructions to review the website before their upcoming visit. A follow-up survey (T2) will be emailed 4-weeks post-baseline, prior to their clinic visit, to evaluate website access and PROs. A post-visit survey (T3) will be emailed 6- weeks post-baseline (after their survivorship care visit) to assess PROs.
9969857|NCT01294254|Experimental|experimantal: wound site will be treated with Oleogel-S10|"The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg~Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)~Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site"
9969858|NCT01294254|Active Comparator|Moist wound healing dressing alone|Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
10140123|NCT04200820|Experimental|Trampoline|The participants will jump on a mini-trampoline for 30 seconds and then will have a 30 seconds break. This will be repeated 16 times. This resulted in a cumulative total intervention time of 8 minutes.
10140124|NCT04200560|Experimental|Healthy Adult Subjects|Healthy adult subjects (18 - 30 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise
10140125|NCT04200560|Experimental|Healthy Older Adult Subjects|Healthy older adult subjects (> 60 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise and after Chronic Exercise Training.
10140126|NCT04200547|Experimental|Immunomonitoring-based follow-up|Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum.
10140127|NCT04200547|Active Comparator|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. This strategy is the standard strategy for post-operative follow-up of Crohn's disease patients.
10140128|NCT04200690|Experimental|Interdisciplinary management|Interdisciplinary combined clinical care
10140129|NCT04200690|Active Comparator|Usual-care management|Usual-care
10140130|NCT04200235|Experimental|High weight group|High weight group
10140131|NCT04200235|Experimental|Low weight group|Low weight group
10140132|NCT04200131|Experimental|Moray micro-forceps|
10140133|NCT04199962||pneumonia without sepsis|adult patients with community acquired pneumonia change in SOFA score <2 (other than respiratory component)
10140134|NCT04199962||pneumonia with sepsis|adult patients with community acquired pneumonia change in SOFA score greater or equal to 2 (other than respiratory component)
10140135|NCT04200014||Syncope and Implantable loop recorder|Patients implanted with a subcutaneous Loop Recorder after syncope in Nancy University Hospital
10140136|NCT04199884|Experimental|Active IU-focused Psychoeducation Intervention|
10140137|NCT04199884|Active Comparator|Health-focused Psychoeducation Intervention|
9669219|NCT03678883|Experimental|9-ING-41 plus Gemcitabine|Drugs: Gemcitabine - 21 day cycle. 9-ING-41
9669220|NCT03678883|Experimental|9-ING-41 plus Doxorubicin|Drugs: Doxorubicin. 9-ING-41
9669221|NCT03678883|Experimental|9-ING-41 plus Lomustine|Drugs: Lomustine. 9-ING-41.
9969859|NCT01294280||Ancillary-Correlative (IHC)|Previously collected tissue samples are analyzed by IHC.
9669222|NCT03678883|Experimental|9-ING-41 plus Carboplatin|Drugs: Carboplatin. 9-ING-41.
9669223|NCT03678883|Experimental|9-ING-41 plus nab paclitaxel Gemcitabine|Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.
9669224|NCT03678883|Experimental|9-ING-41 plus Paclitaxel/Carboplatin|Drugs: Paclitaxel. Carboplatin. 9-ING-41.
9669225|NCT03678883|Experimental|9-ING-41 plus Irinotecan|Drugs: Irinotecan. 9-ING-41.
10140138|NCT04200144|Active Comparator|active endoscopic treatment|Patients that will undergo Endoscopic Sleeve Gastroplasty
10140139|NCT04200144|Active Comparator|standard medical therapy control diet group|Patients that will undergo diet
10140140|NCT04200027||Robotic total mesorectal Excision|robotic assissted total mesorectal excision
10140141|NCT04200027||Transanal total mesorectal excision|Transanally assissted total mesorectal excision
10140142|NCT04200183|Experimental|iACTwithPain|
10140143|NCT04200183|Experimental|ACT-only intervention|
10140144|NCT04200183|No Intervention|Wait list (inactive control)|
10140145|NCT04200105|Active Comparator|EBUS TBNA|Patients will undergo a standard EBUS examination, with sampling using a standard 22G EBUS needle.
10140146|NCT04200105|Experimental|Acquire TBNB|Patients will undergo a standard EBUS examination, with sampling using an Acquire TBNB needle.
10140147|NCT04200079||COPD|Long term (at least 10 years) multidimensional (clinical, laboratory, physiological and radiological) follow up of chronic Obstructive Pulmonary Disease patients.
9969860|NCT01294293|Experimental|Treatment (TLR8 agonist VTX-2337, PLD, and Paclitaxel)|Patients receive TLR8 agonist VTX-2337 SC on days 3, 10, and 17 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 or TLR8 agonist VTX-2337 SC on days 1, 8, and 15 and paclitaxel IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9969861|NCT01294345||personalized genomics|genetic/genomic syndromes
10140148|NCT04200261|Experimental|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
10140149|NCT04200261|Placebo Comparator|placebo|sodium chloride injection Once daily for 7 days
10140150|NCT04199936|Experimental|EMG leg|Quadriceps muscle group of postoperative patients randomly selected leg which will undergo electrical muscle stimulation for upto 2 hours on each postoperative day
10140151|NCT04199936|No Intervention|Control leg|Quadriceps muscle group of postoperative patients leg not selected to undergo electrical muscle stimulation
10140152|NCT04200157||1|"Group assigned to the following answer combination:~2 sessions~4 sessions"
10140153|NCT04200157||2|"Group assigned to the following answer combination:~2 sessions~4 sessions~7 sessions"
10140154|NCT04200157||3|"Group assigned to the following answer combination:~2 sessions~7 sessions"
10140155|NCT04200157||4|"Group assigned to the following answer combination:~2 sessions~7 sessions~10 sessions"
10140156|NCT04200157||5|"Group assigned to the following answer combination:~2 sessions (30 minutes)~4 sessions (60 minutes)"
10140157|NCT04200157||6|"Group assigned to the following answer combination:~2 sessions (30 minutes)~4 sessions (60 minutes)~7 sessions (105 minutes)"
10140158|NCT04200157||7|"Group assigned to the following answer combination:~2 sessions (30 minutes)~7 sessions (105 minutes)"
10140159|NCT04200157||8|"Group assigned to the following answer combination:~2 sessions (30 minutes)~7 sessions (105 minutes)~10 sessions (150 minutes)"
10140160|NCT04200157||9|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~4 sessions (60 minutes) - 30% chance of quitting"
10140161|NCT04200157||10|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~4 sessions (60 minutes) - 30% chance of quitting~7 sessions (105 minutes) - 30% chance of quitting"
10140162|NCT04200157||11|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~7 sessions (105 minutes) - 30% chance of quitting"
10140163|NCT04200157||12|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~7 sessions (105 minutes) - 30% chance of quitting~10 sessions (150 minutes) - 30% chance of quitting"
10140164|NCT04199871|Experimental|Group1|dichoptic 3D movies
10140165|NCT04199871|Sham Comparator|Group 2|dichoptic standard movies
10140166|NCT04200092|Experimental|Cohort 1|Single orally-inhaled dose
10140167|NCT04200092|Experimental|Cohort 2|Single orally-inhaled dose
10140168|NCT04200092|Experimental|Cohort 3|Single orally-inhaled dose
10140169|NCT04200092|Experimental|Sequence 1|Single orally-inhaled dose
10140170|NCT04200092|Active Comparator|Sequence 2|Single IV administered dose
10140171|NCT04199975|Other|Orthoses|Only one single arm in this study
10140172|NCT04200222||Preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
10140173|NCT04200222||Control|Pregnant women with uncomplicated pregnancies were randomly selected to serve as controls. Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications were accepted into the control group.
10140174|NCT04200170|Experimental|Intervention Arm|Eligible participants had been scheduled for either weekly or biweekly sessions with their therapists. Participants in the intervention arm were asked to download the Rose application on to their personal mobile phones and were given their therapist's unique ID for verification in the app. During the first week of the study, participants were prompted to complete key surveys and assessments at predetermined time intervals. Participants seen weekly will use the app for a total of 5 weeks and receive weekly in-person therapy for a total of 4 weeks (one-week application only lead-in, four weeks application plus in-person psychotherapy). Participants seen biweekly will use the app for a total of 10 weeks and receive biweekly in-person therapy for a total of 8w weeks (two-week application only lead-in, eight weeks application plus in-person psychotherapy).
9969862|NCT01294410|Experimental|Cohort 1: Induction|Placebo or Anti-IP-10 Antibody
10140175|NCT04200170|No Intervention|Waitlist Control Arm|The participants in the waitlist control arm served as controls for the study. They completed the pre-pilot and post-pilot assessments only. The waitlist participants continued their standard care and were offered entrance to the intervention arm at the end of the study period or earlier if patients in the intervention arm dropped out mid-study. During their time on the waitlist, participants could reach out to study personnel if they needed assistance with their psychiatric care.
10184557|NCT03754010|Placebo Comparator|Scaling and root planning (SRP)|Under local anesthesia, full-mouth SRP was performed within 24 h in a single or two sessions using ultrasonic and hand instruments (Gracey, Hu-Friedy, Chicago, IL, USA) by a single investigator (DA). Immediately after the SRP, HA gel (Gengigel, Hyaluronic acid, gingival gel, Ricefarma S.R.L, Italy) or mouthrinse was performed according to the groups' procedure. In Group 1, the periodontal sulcus was irrigated with saline solution after SRP.
10184558|NCT03754010|Experimental|Hyaluronic acid gel (HA) and SRP|Group 2, after SRP was performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA was applied intrasulcular.
10184559|NCT03754010|Experimental|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse (Gengigel, Hyaluronic acid, Hydrogel moutrinse for gums, Ricefarma S.R.L, Italy) were used as an irrigator after SRP.
10184560|NCT03754010|Experimental|HA mouthrinse+gel and SRP|In Group 4, after SRP was performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel was applied.
10184561|NCT03753997|No Intervention|Conventional therapy|Patiens´s will come to the clinic for regular contact with a diabetes nurse.
10184562|NCT03753997|Experimental|Treatment by a Psychologist|Patients will meet with a diabetes educated psychologist over 9 months and will come to the clinic for regular contact with a diabetes nurse
10184563|NCT03753984|Experimental|Healthy group|The protocol consists of Low-level laser therapy (LLLT) application in the dominant side brachialis muscle in healthy subjects prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, electromyography associated with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration by means of the lactimeter, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
10184564|NCT03753984|Experimental|Post stroke group|The protocol consists of Low-level laser therapy (LLLT) application in the hemiparetic side brachialis muscle post stroke individuals prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, surface electromyography with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
10184565|NCT03753971|Experimental|Apneas with and without intervention|Each patient will be his own control.
10184566|NCT03753958|Experimental|Control group|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
10184567|NCT03753958|Experimental|aPDT group|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
10184568|NCT03753932|Experimental|Intervention|Dentures (fixed oral prosthesis) compared with standard treatment (removable oral prosthesis).
10184569|NCT03753906|Experimental|Osmed® hydrogel expander implantation|Implantation of Osmed® hydrogel expander was done in subperiosteal positions using the pouch technique in the mandibular anterior region.
10184570|NCT03753880|Experimental|Hemopatch|Hemopatch used to cover the resection surface after LR
10184571|NCT03753867|Experimental|Acitretin treatment|
9969863|NCT01294410|Experimental|Cohort 2: Induction|Placebo or Anti-IP-10 Antibody
9969864|NCT01294410|Experimental|Cohort 3: Induction|Placebo or Anti-IP-10 Antibody
10184572|NCT03753854|Active Comparator|SS patients|"Homozygous sickle cell patients~Each patient will undergo the following:~polysomnography and oxygen saturation exam~calculation of VOC rate within the two previous years~Blood samples~Physiological measurements"
9969865|NCT01294410|Experimental|Maintenance|Placebo or Anti-IP-10 Antibody
9969866|NCT01294410|Other|Open Label|
9969867|NCT01294475|Experimental|Cell Phone Enhanced Parent Training|Cell phones will be provided to mothers participating in Planned Activities Training.
9969868|NCT01294488|Experimental|Phone Consultation|Therapists receive phone consultation for 6 months during the course of the project.
9969869|NCT01294488|Experimental|Remote Real-Time Consultation|Therapists receive consultation for 6 months via polycommunication technology.
10140176|NCT04199910||Liver cirrhosis with spironolactone|
10140177|NCT04199910||Liver cirrhosis with rifaximin|
10140178|NCT04199910||Liver cirrhosis without spironolactone or rifaximin|
10140179|NCT04199910||Pneumonia|
10140180|NCT04199910||Crohn's disease|
10140181|NCT04199910||Ulcerative colitis|
10140182|NCT04200040|Experimental|treatment group|"OrienX010 will be administered once every two weeks by intratumoral injection. The treatment dose , depends on the patient's tumour size, The maximum dose of OrienX010 in at each treatment , the expected accumulated dose in 10 mL. The investigator should be confirmed the injectable tumor size and adequate dose within 24 hours prior to treatment.~OrienX010 treatment will be continuous and extend from first dose of study medication until to complete response, clinical related progression disease (PDr), untolerated toxicities, lost to follow up, death or meet end of treatment criteria."
10140183|NCT04200040|Active Comparator|Control group|Dacarbazine will be administered once every three weeks by intravenous 1000mg/square meter. Dacarbazine treatment will be continuous and extend from first dose of study medication until to progression disease (PD), untolerated toxicities, lost to follow up, death or meet end of treatment criteria.
10140184|NCT04200001||adjuvant hormonal therapy for breast cancer|women less than 51 years old, during adjuvant hormonal therapy for breast cancer
10140185|NCT04199832||Nasogastric tube|The patient had difficulty swallowing before chemoradiotherapy and placed a nasogastric tube.
10140186|NCT04199832||gastrostomy feeding|Patients with dysphagia before chemoradiotherapy began to voluntarily choose gastrostomy feeding.
10140187|NCT04199832||Oral intake|Patients with normal swallowing or not receiving tube feeding.
10140188|NCT04199858|Experimental|Nocebo induction|Conditioning and evocation of a nocebo response to a sham (inert) medication contained in a blue or a brown jar, controlled within subjects.
10140189|NCT04199845|Experimental|PS128|PS128 will be given twice daily for 8 weeks Active capsule containing 300 mg of probiotics, equivalent to 3 x10^10 CFU of Lactobacillus plantarum PS128.
10140190|NCT04199845|Placebo Comparator|placebo|Placebo containing starch will be given twice daily for 8 weeks.
10140191|NCT04199819|Other|HBsAg-negative recipients|Recipients who are HBsAg-negative will undergo a panel of test to detect HBV viral markers. In addition, real-time PCR will be used to determine the presence of intrahepatic HBV DNA and cccDNA on the explant histology. Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis. For those without evidence of OBI, that is, negative for all biomarkers, no antiviral prophylaxis will be given.
10140192|NCT04199546|Other|A child with Coffin-Lowry Syndrome|A boy with a known CLS diagnosis with a history of coughing during eating, long-lasting wheezing, sputum and inability to intake solid food will be included.
10140193|NCT04199780|Experimental|Group 1- real tDCS and real CBI|4 active treatments of tDCS and active cognitive behavioral intervention (CBI)
10140194|NCT04199780|Experimental|Group 2- real tDCS and sham CBI|4 active treatments of tDCS and education-only-control cognitive intervention
10140195|NCT04199780|Experimental|Group 3- sham tDCS and real CBI|4 sham treatments of tDCS and active cognitive behavioral intervention (CBI)
10140196|NCT04199780|Sham Comparator|Group 4- sham tDCS and sham CBI|4 sham treatments of tDCS and education-only-control cognitive intervention
10140197|NCT04199806|Other|Questionnaire Review|
10140198|NCT04199585|Experimental|Cohort A: single-ascending oral dose|Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
10140199|NCT04199585|Experimental|Cohort B: (fasting/fed conditions)|"Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.~B1: fed-fasting-fasting condition (spiked dosage)~B2: fasting-fed-fasting condition (spiked dosage)~B3: fasting-fasting-fed condition"
10140200|NCT04199611|Experimental|Integrated Therapy Group|Both liposuction and psychological therapy are delivered to the participants in this group.
10140201|NCT04199611|Active Comparator|Liposuction Group|This group experiences only liposuction and do self-help care after the liposuction.
10140202|NCT04199611|Active Comparator|Psychological Therapy Group|This group experiences only cognitive behavioral therapy (CBT; psychological therapy) during the intervention period.
10140203|NCT04199611|No Intervention|Self-help Group|This group do not receive any interventions and do self-help care.
10140204|NCT04199598|Experimental|Treatment A (test product): Abediterol (2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
10140205|NCT04199598|Experimental|Treatment B (Test Product): Abediterol (4.8 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
10140206|NCT04199598|Experimental|Treatment C(Test Product):Abediterol(2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via OMRON NE-C900-E nebulizer following an overnight fast of at least 8 hours
10140207|NCT04199598|Experimental|Treatment D (Reference Product): Abediterol (2.5 μg)|Randomized subjects will receive single dose treatment of Abediterol (as napadisylate) inhalation powder via dry powder inhaler (DPI) following an overnight fast of at least 8 hours
10140208|NCT04199507||Autism|Assessment of physical activity level and physical fitness
10140209|NCT04199507||Healthy|Assessment of physical activity level and physical fitness
10140210|NCT04199923|Experimental|15 Day immobilisation|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 15 continuous days
10140211|NCT04199923|Experimental|5 Day immobilisation young|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
10140212|NCT04199923|Experimental|5 Day immobilisation old|The dominant leg of aged patients (65-80 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
10140213|NCT04199377|Experimental|hip or knee replacement|total hip or knee replacement
9826085|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in RYGB|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.
10140214|NCT04199650||Mild ARDS|153mmHg<PaO2/FiO2≤230mmHg
10140215|NCT04199650||Moderate ARDS|76mmHg<PaO2/FiO2≤153mmHg
10140216|NCT04199650||Severe ARDS|PaO2/FiO2≤76mmHg
10140217|NCT04199390|Active Comparator|Clinic-based Physical Therapy|
10140218|NCT04199390|Active Comparator|Home-based Physical Therapy|
10140219|NCT04199520|Experimental|surgery combined with systemic therapy|surgery combined with systemic therapy
10140220|NCT04199520|Active Comparator|systemic therapy|systemic therapy
10140221|NCT04199559|Experimental|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal.
10140222|NCT04199637|Experimental|Experimental group|Experimental group is provided therapeutic video games
10140223|NCT04199637|No Intervention|Control group|Control group is provided regular care
10140224|NCT04199676||Intervention|75g glucose tolerance test to be administered during postpartum hospitalization
10140225|NCT04199715|Experimental|Heplisav-B Vaccine Recipient|There will be a single group of 18 immune compromised patients who will receive the Heplisav-B vaccine.
10140226|NCT04199338|Experimental|Randomized|Randomized
10140227|NCT04199364|Experimental|Low FiO2 threshold|A fraction of inspired oxygen (FiO2) of 25% to have an oxygen saturation (SpO2) of 90-92%.
10140228|NCT04199364|Experimental|Medium FiO2 threshold|A fraction of inspired oxygen (FiO2) of 35% to have an oxygen saturation (SpO2) of 90-92%.
10140229|NCT04199689|Experimental|9vHPV vaccine|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
10140230|NCT04199689|Placebo Comparator|Placebo|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
10140231|NCT04199455|Experimental|Integrative Treatment Group|Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
10140232|NCT04199455|Placebo Comparator|Control Group|Patients randomly assigned to the control group will receive recipe simulators as placebo, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
10140233|NCT04199416|Experimental|mRehab app|Participants randomized to the intervention group will be given the mRehab app free of charge to perform self-management of their knees in their homes.
9826086|NCT02406937|Experimental|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
10140234|NCT04199416|Sham Comparator|Sham app|Participants randomized to the control group will receive a sham app free of charge to perform self-management of their knees in their homes.
10140235|NCT04199325|Experimental|Intervention group|
10140236|NCT04199325|Placebo Comparator|Control group|
10140237|NCT04199091|Experimental|Craniosacral self-help techniques (CST)|The experimental group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. The course starts with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients will also receive a script with theoretical CST basics and descriptions of the techniques, which should facilitate the correct practice at home.
10140238|NCT04199091|Active Comparator|Progressive muscle relaxation (PMR)|The active control group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. Every week patients will meet for 2 TUs. The patients will also receive a script with theoretical basics and descriptions of the PMR techniques, hich should facilitate the correct practice at home.
10140239|NCT04199299||Persons who cannot communicate unequivocally|Persons with intellectual disability, childhood autism, and/or cerebral palsy who cannot communicate unequivocally and therefore cannot communicate their needs and wishes, e.g. whether they are uncomfortable, in pain, scared, angry, happy, pleased.
10140240|NCT04199078|Experimental|A - papilocare alternative days treatment|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
10140241|NCT04199078|Experimental|B - papilocare semiintensive treatment|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
10140242|NCT04199078|Experimental|C - papilocare intensive treatment|Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months
10140243|NCT04199078|No Intervention|D - standard of care|Arm D: usual clinical practice - no treatment
10140244|NCT04199039|Experimental|ET fixation with ET holder|ET fixation of the patients in the study group was performed with an ET holder when they arrived at the CVS ICU
10140245|NCT04199039|No Intervention|ET fixation with plaster|ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted.
10140246|NCT04199221|No Intervention|Lecture|an initial brief lecture with no further training
9826087|NCT02406937|Active Comparator|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
9826088|NCT02406937|Placebo Comparator|Breast Feeding|Oral intake of breast milk
9826089|NCT02407041|Experimental|GR-MD-02|active arm
10140247|NCT04199221|Experimental|Stress management|an initial brief lecture with stress management lecture
10140248|NCT04199221|Active Comparator|Hands-on training|an initial brief lecture with addition hands-on training for the task
10140249|NCT04199221|Experimental|Stress management and hands-on training|an initial brief lecture with both stress management lecture and additional hands-on training
10140250|NCT04199312|Experimental|Muscle Toning, Firming and Strengthening|The EMS device will be evaluated for muscle toning, firming and strengthening in the abdomen.
10140251|NCT04199143|Experimental|healthy voluntary controls|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
9826090|NCT02407054|Experimental|Part A: 200 mg LY3023414 BID + 160 mg of Enzalutamide QD|Participants received 200 milligrams (mg) LY3023414 orally twice daily (BID) during the initial week to assess pharmacokinetics (PK). Thereafter, participants received 200 mg of LY3023414 BID in combination with 160 mg of enzalutamide QD beginning Cycle 1 Day 1. A treatment cycle was defined as 28 days.
9826091|NCT02407054|Experimental|Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD|Participants received 200 mg LY3023414 orally BID in combination with 160 mg enzalutamide orally once daily (QD).
9969870|NCT01294501|Experimental|Fever assessment and management|Medication administration educational module for low literacy subjects on how to administer common medications appropriately and safely.
9969871|NCT01294527|Experimental|Implant|Implant of the WiCS-LV system
9969872|NCT01294540|Experimental|Experimental: 1|
9969873|NCT01294540|Placebo Comparator|Placebo Comparator: 2|
9969874|NCT01294566|Experimental|Cohort 1|GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)
9969875|NCT01294566|Experimental|Cohort 2|GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)
9969876|NCT01294605|Experimental|Group A|
9969877|NCT01294605|Experimental|Group B|
9969878|NCT01294605|Active Comparator|Group C|
9969879|NCT01294618|Experimental|nilotinib + pegylated interferon alpha 2a (PEG-IFN).|
9969880|NCT01294631|Experimental|001|"Canagliflozin 300 mg once daily and HCTZ 25 mg once daily Period 1: canagliflozin tablets oral 300 mg once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets oral 25 mg once daily for Days 1 to 28 followed by canagliflozin tablets oral 300 mg once daily taken with HCTZ tablets oral 25 mg once daily on Days 29 to 35.."
9969881|NCT01294657||HE Group|Health Education [HE] - Counseling, referrals to resources + self-help materials; 2 HE interventions at Baseline + 6 month visits.
9969882|NCT01294657||MAPS Group|Motivation And Problem Solving (MAPS) - HE + 12 telephone counseling sessions over 1-year period (average 1 call/month).
9969883|NCT01294735|Experimental|Part A, MK-4827 + temozolomide dose escalation cohort|
9969884|NCT01294735|Experimental|Part B, MK-4827 + temozolomide melanoma cohort|
9969885|NCT01294735|Experimental|Part B, MK-4827 + temozolomide glioblastoma multiforme cohort|
9969886|NCT01294761|Experimental|Raltegravir, Darunavir/r|"An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD~to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID"
9969887|NCT01294761|No Intervention|Tenofovir, Emtricitabine, Lopinavir/r|An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
9969888|NCT01294774|Experimental|KRP203 - 1.2 mg|
9969889|NCT01294774|Placebo Comparator|Placebo to KRP203 - 1.2 mg|
9969890|NCT01294813|Experimental|Bronchoscopy-EIT|Patients who routinely undergo bronchoscopy will be measured by EIT directly before, directly after and 10, 30, 60 minutes after bronchoscopy with a rubber belt which is placed around their chest. The EIT measurements will take 1-2 minutes; the total examination will last 1.5 hours.
9969891|NCT01294826|Experimental|AUY922 plus Cetuximab|
9969892|NCT01294839|Experimental|RVOTs|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVOTs arm, the RV lead of this group patients will be implanted in right ventricular outflow tract septum,the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
9969893|NCT01294839|Experimental|AAI|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in AAI arm, the RV lead of this group patients will be implanted in right ventricular apex.
9969894|NCT01294839|Active Comparator|RVA|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVA arm, the RV lead of this group patients will be implanted in right ventricular apex, the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
9969895|NCT01294852|Experimental|immediate bolus surfactant|
9969896|NCT01294852|Experimental|post-resuscitation surfactant|
9969897|NCT01294865||septic|Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
9969898|NCT01294865||non-septic|Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
9969899|NCT01294878|Experimental|treatment with omalizumab|Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used
9969900|NCT01294891||Control|Age matched healthy subjects
9969901|NCT01294891||Sickle Cell Patients|Patients with established SCD
9969902|NCT01294891||Paroxysmal Nocturnal Hemoglobinuria patients|Patients with PNH
9969903|NCT01294904||renal transplant patients|Patients undergoing transplantation
9969904|NCT01294904||dialysis patients|hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session
9969905|NCT01294904||patients with renal insufficiency|outpatient patients with chronic kidney disease stage 2, 3 and 4
9969906|NCT01294904||Chronic kidney disease|outpatient cohort. Those with mild renal insufficiency
9969907|NCT01294930||hip fracture|Patients operated for hip fracture, giving informed consent
9969908|NCT01294943||Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
9969909|NCT01294956|Experimental|FID 115958D|Lubricant Eye Drop
9969910|NCT01294956|Active Comparator|Refresh Liquigel|Lubricant Eye Drop
9969911|NCT01294969|Experimental|AL-4943A|One drop per day in both eyes
9969912|NCT01294982|Experimental|1.6 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
9969913|NCT01294982|Experimental|3.2 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
9969914|NCT01294982|Placebo Comparator|Placebo|Matching Placebo Capsules
9969915|NCT01294995|Experimental|Tea-flavor Liquor, taken with meal|including 12 males and 11 females
9669226|NCT03673852|Other|Peer Wellness Enhancement (WE Harambee)|This project employs a pragmatic, stepped wedge experimental design in which 60 BHH participants are randomly assigned to one of 3 waves of WE Harambee implementation (20 in each wave) during the 2 year study. Participants in this arm receive the WE Harambee Wellness Enhancement and are enrolled in a Behavioral Health Home. WE Harambee is a 6-month peer-delivered whole health intervention intended to address the 8 dimensions of wellness and the social determinants of health.
10140252|NCT04199143|Experimental|Depressive Patients|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
10140253|NCT04199182|Experimental|Exercise|Progressive, multi-component supervised exercise training group.
10140254|NCT04199182|Active Comparator|Healthy Aging Attention Control|A health education program that addresses topics relevant to older adults.
10140255|NCT04199533||Classroom Observation|The investigators will use day-long observational and interview procedures with eight staff from four schools. The classroom observation will focus on documenting episodes of classroom disruptive behavior, including antecedents and consequences to the behaviors. The interview will involve discussing with staff decision-making processes and current needs around classroom behavioral management.
10140256|NCT04199533||RUBI Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing adaptation or pruning needs related to RUBI content and structure to ensure the redesigned curriculum (RUBIES) is contextually appropriate for schools.
10140257|NCT04199533||RUBIES Collaborative Design|Eight staff from 4 schools will attend one of four 2-hour in-person feedback sessions to support collaborative feedback around RUBI redesign, including feasibility and appropriateness and methods supporting implementation.
10140258|NCT04199533||RUBIES Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing final RUBIES adaptation or pruning needs.
10140259|NCT04199247|Experimental|Exercise|Within 1 week of injury, participants will be randomized to either a sub symptom threshold exercise program (intervention group) or usual care (recommendation from their doctor). Those in the intervention group will participate in an exercise program 5x/week, 20-30 minutes/session, for 2 months.
10140260|NCT04199247|No Intervention|Usual Care|Participants will continue with their return to play progression based upon the advice given to them at their initial post-injury evaluation.
10140261|NCT04199260||Papilocare|all patients gonna received papilocare treatment as per usual practice.
10140262|NCT04199234|Experimental|experimental group|60 mg Encapsulated Iron
10140263|NCT04199234|Active Comparator|control group|60 mg Iron sulphate
10140264|NCT04198974|Experimental|PreVenture Training (PTtT)|Schools randomized to this arm will identify 4 staff members to participate in a 2-day training workshop + 3 hours of supervised practice and will be provided with access to screening and PreVenture intervention materials through the local trainer. Local trainers will deliver 2-day workshops and then supervise school staff in the delivery of two 90-minute group sessions (for at least one personality profile).
9826092|NCT02407054|Active Comparator|Part B: Placebo + 160 mg Enzalutamide QD|Participants received placebo in combination with 160 mg enzalutamide QD.
9826093|NCT02407132|Active Comparator|Standard DSME|Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
10140265|NCT04198974|Experimental|PreVenture Training + Implementation Facilitation (PTtT+IF)|Schools randomized this arm will receive the standard PreVenture TtT protocol plus an additional Implementation Facilitation package that will contain 3 new components designed to increase the likelihood that schools will continue to implement the program with high quality and satisfaction: 1) Youth Engagement, 2) ongoing coaching and supervision for Facilitators, and 3) access to easy-to-use performance metrics.
10140266|NCT04198974|No Intervention|Control (TAU)|For schools randomized to this arm, students will have usual access to drug and alcohol prevention through the standard curriculum and mental health care provided through student counseling at the participating schools. The schools will be incentivized to participate in the study with the promise of free PreVenture training and materials in subsequent years of the trial. Information on other drug prevention efforts implemented at the school will be collected, but the randomized design should control for any potential differences between intervention conditions on this random factor.
10140267|NCT04199013|Active Comparator|Ropivacaine With Fentanyl|2.5ml of 0.75% Isobaric ropivacaine with 0.5ml (25mcg) Fentanyl
10140268|NCT04199013|Active Comparator|Ropivacaine Without Fentanyl|2.5ml of 0.75% Isobaric Ropivacaine with 0.5ml of Normal Saline
10140269|NCT04199286|Active Comparator|Asymmetrical surgery|This asymmetrical horizontal muscle surgery done as recess-resect in one eye or 3 muscle surgery
10140270|NCT04199286|Active Comparator|Symmetrical|This symmetrical horizontal muscle surgery includes bilateral medial rectus recession in esotropia cases or bilateral lateral rectus recession in exotropia
10140271|NCT04199169|Experimental|Cohort 1, Group 1|"Ten subjects in the first cohort will receive a 10 mcg dose of HeV-sG-V on Visits 1 and 6.5 (Days 1 and 169*).~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
10140272|NCT04199169|Placebo Comparator|Cohort 1, Group 2|"Two subjects in the first cohort will receive a dose of the placebo on Visits 1 and 6.5 (Days 1 and 169*).~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
10140273|NCT04199169|Experimental|Cohort 2, Group 3|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) with placebo on Visit 3 (Day 29).
10140274|NCT04199169|Experimental|Cohort 2, Group 4|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) with placebo on Visit 2 (Day 8)
10140275|NCT04199169|Placebo Comparator|Cohort 2, Group 5|Twelve subjects in the second cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
10140276|NCT04199169|Experimental|Cohort 3, Group 6|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visit 1 (Day 1) and placebo on Visits 2 and 3 (Days 8 and 29).
10140277|NCT04199169|Experimental|Cohort 3, Group 7|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) and placebo on Visit 3 (Day 29).
10140278|NCT04199169|Experimental|Cohort 3, Group 8|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) and placebo on Visit 2 (Day 8).
9669227|NCT03673852|Other|Behavioral Health Home enrollment|"In the stepped wedge experimental design, 40 participants at any time during the 2 year study are receiving only the Behavioral Health Home (BHH) intervention. The 2010 Patient Protection and Affordable Care Act (ACA) established a health home option under Medicaid that serves enrollees with chronic conditions including serious mental illness and chronic physical illness."
9826094|NCT02407132|Experimental|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
9827461|NCT02456740|Experimental|Erenumab 140 mg QM|Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
9827462|NCT02456896|No Intervention|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
10140279|NCT04199169|Placebo Comparator|Cohort 3, Group 9|Eighteen subjects in the third cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
10140280|NCT04199208|Active Comparator|Standard Care Arm|Standard perioperative care is given.
10140281|NCT04199208|Experimental|Interventional Arm|Intervention of prehabilitation and immunonutrition is given prior to surgery
10140282|NCT04199429|Experimental|Experimental|"Each nurse applied the RBC model through the treatment Take 5 minutes (T5M), to parents allocated to the experimental group. This consisted in devoting some time (from 5 to 10 minutes) to improving the relationship with the parent. This treatment can be considered as the practical development of the core principles of the RBC model by the study team.~During the T5M the nurse applied the strategies of empathic communication and active listening, learned during the education and training phase. The treatment lasted from 5 to 10 minutes and was delivered once per day during the admission of the patient.~The T5M time was considered as additional or supplementary, but not substitutive, of the standard nursing time dedicated daily to patients and parents."
10140283|NCT04199429|Active Comparator|Control|Standard nursing time dedicated daily to patients and parents.
10140284|NCT04198935|Experimental|Intervention|Participants will be enrolled on to a 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
10140285|NCT04198909|Experimental|Cohort 1|
10140286|NCT04198844||Warfarin user|
10140287|NCT04198844||Apixaban user|
10140288|NCT04198753||Parent of Peanut Allergic Child|"The researchers will identify patients or study subjects aged 1-18 who have been diagnosed with peanut allergy based on skin prick testing, serologic testing, and/or history of reaction. They will then contact mothers or fathers of these patients/subjects who are 18 and older and enroll those who do not themselves have a history of food allergy, with a goal of 40 subjects per group.~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
10140289|NCT04198753||Parent of Non-atopic Child|"To establish normal controls, the researchers will enroll parents age 18 or older with no history of food allergy or eczema in themselves or their offspring.~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
10140290|NCT04198662|Active Comparator|Cryoneurolysis|Active cryoneurolysis: 3 mL of normal SALINE will be injected into the muscle superficial to the nerve followed by an ACTIVE cryoneurolysis procedure using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
10140291|NCT04198662|Sham Comparator|Sham|Sham cryoneurolysis: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block followed by a SHAM cryoneurolysis procedure with a probe that vents the nitrous oxide prior to reaching the probe tip using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
10140292|NCT04198727|Experimental|DPD activity|
10140293|NCT04198688||With cancer|Patients diagnosed with cancer (with at least one of the following ICD-10 diagnoses: C00-43; C46.1-99; D09)
10140294|NCT04198688||Without cancer|Patients without cancer (without any of the following ICD-10 diagnoses: C00-99; D09; D30.1-9; D32-33; D35.2-4; D41.1-9; D44.3-5)
10140295|NCT04198740||Control group|Healthy, normal ocular surface
10140296|NCT04198740||Dry eye syndrome|"Patients suffering from either:~Lacrimal insufficiency~Anterior blepharitis~Posterior blepharitis~Sjögren syndrome"
10140297|NCT04198740||Allergic conjunctivitis|Patients suffering from allergic conjunctivitis
10140298|NCT04198740||Mucous membrane pemphigoid|Patients suffering from mucous membrane pemphigoid
10140299|NCT04198740||Infectious keratoconjunctivitis|"Patients suffering from keratitis and/or conjunctivitis of various etiology:~Viral~Bacterial~Fungal~Acanthamoeba"
10140300|NCT04198792||ECPR patients|Patients that is put om ECMO during cardiac arrest
10140301|NCT04198792||ECMO patients, non-ECPR|Patients that is put on ECMO due to circulatory failure but not cardiac arrest
10140302|NCT04198883|Experimental|Protheracytes|Single arm study : Stem cells injection called Protheracytes
10140303|NCT04198831|Experimental|acupuncture group|Receiving acupuncture and moxibustion treatment
9669228|NCT03656718|Experimental|Part A, Group 1: nivolumab (dose 1) + rHuPH20|
9669229|NCT03656718|Experimental|Part B, Group 3: nivolumab (dose 2) + rHuPH20|
9669230|NCT03656718|Experimental|Part B, Group 2: nivolumab (dose 1)|
9669231|NCT03656718|Experimental|Part B, Group 4: nivolumab (dose 2)|
10140304|NCT04198831|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion treatment
10140305|NCT04198896||CAD-only|patients with diagnosed coronary artery diseases (CAD) without any other atherosclerotic cardiovascuar diseases at the entry of SHIP
10140306|NCT04198896||CAD with poly-arterial diseases|patients with diagnosed coronary artery diseases (CAD) with other atherosclerotic cardiovascuar diseases such as any of aortic and/or peripheral artery diseases at the entry of SHIP
10140307|NCT04198441|Active Comparator|Omeza Value-based Bundle Test|The Omeza value-based bundle consists of lidocaine lavage, flowable collagen matrix and skin protectant products.
9669232|NCT03656718|Experimental|Part C: nivolumab (dose 3) + rHuPH20|
10140308|NCT04198441|Active Comparator|Standard Wound Care Control|Standard wound care control is saline wound wash and wet to dry dressing.
10140309|NCT04198610|No Intervention|healthy|Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.
10140310|NCT04198610|No Intervention|chronic gingivitis|Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm, relative attachment loss (RAL) ) less than or equal to 3mm and more than to 25% sites with gingival bleeding present (BOP)
10140311|NCT04198610|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy"
10140312|NCT04198506|Experimental|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.
10140313|NCT04198506|Active Comparator|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
10140314|NCT04198571||Zinforo Treated|Only those Adults treated with this treatment for CAP or cSSTi
10140315|NCT04198779|Experimental|APPLI|Care support with implementation of the application
10140316|NCT04198779|No Intervention|CONTROL|Conventional care support
10140317|NCT04198389|Experimental|partial knee replacement|medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI
10140318|NCT04198636|Experimental|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
9519687|NCT03284554|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The placebo capsules will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
10140319|NCT04198636|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
10140320|NCT04198532|Experimental|Complex Regional Pain Syndrome(CRPS) group|Stroke patients with complex regional pain syndrome
10140321|NCT04198532|Other|Control Group|Stroke patients without complex regional pain syndrome
10140322|NCT04198467|Experimental|PRP (100billion platelets)|platelet rich plasma having 100 billion platelets in 10 ml plasma prepared from 60 ml blood
10140323|NCT04198467|Placebo Comparator|hyaluronic acid|Four ml of high-molecular-weight hyaluronic acid (HMWHA) with a concentration of 22mg/ml
10140324|NCT04198480|Experimental|JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.
10140325|NCT04198493|Experimental|Continuous Positive Airway Pressure(CPAP)|"Patients with CPAP treatment. Titration will be performed by polysomnography CPAP to determine the optimal treatment pressure.~This group will also be instructed in sleep hygiene and dietary counseling~Intervention:~Device: CPAP Other: Conservative treatment for OSA"
10140326|NCT04198493|Active Comparator|CONSERVATIVE TREATMENT for OSA|Sleep hygiene and dietary counseling. Sleep hygiene (regular sleep schedule, physical exercise) and dietary counseling Intervention: Other: Conservative treatment for OSA
10140327|NCT04198519|Active Comparator|Poor Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Poor cardiovascular health is considered for two or less metrics.
10140328|NCT04198519|Active Comparator|Ideal-intermediate Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Ideal cardiovascular health is considered for those with five or more metrics within this qualification, and intermediate for the presence of three or four metrics.
10140329|NCT04198324|Active Comparator|Entire fold uterine closure|The uterus will be sewn with full fold locked sutures that pass through myometrium and endometrium.
10140330|NCT04198324|Experimental|Non-endometrial uterine closure|The uterus will be sewn with locked sutures that pass through myometrium without endometrium.
10140331|NCT04198285|Experimental|Retrograde filled|This arm will contain patients who had retrograde bladder filling upon completion of surgery with 200 milliliters (mL) of sterile saline.
10140332|NCT04198285|No Intervention|Control|This arm will contain patients who simply had the urinary catheter removed upon completion of surgery, and were left with an empty bladder.
10140333|NCT04198077|Experimental|CONSERVATIVE|Participants in the conservative group will receive the lowest FiO2 to maintain SpO2 between 94 and 98 percentage, or when available a PaO2 between 70 mmHg and 100 mmHg. A SpO2 alarm limit of 99 percent will apply whenever supplemental oxygen is being administered. The FiO2 will be reduced or oxygen supplementation discontinued whenever the SpO2 or PaO2 exceeded 98 percent or 100 mm Hg. An oxygen supplementation will be given only if SpO2 falls below 94 percent. Pre-oxygenation with FiO2 1.0 will not be performed during in-hospital transports or in anticipation of diagnostic and therapeutic manoeuvres.
9669233|NCT03656718|Experimental|Part D, Group 5: nivolumab (dose 3) + rHuPH20|
9669234|NCT03656718|Experimental|Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20|
10140334|NCT04198077|Active Comparator|CONVENTIONAL|In the conventional group, participants will receive a FiO2 aiming to maintain a SpO2 equal or major than 98 percentage, accepting an upper limit of PaO2 of 150 mmHg and a lower limit of 70 mmHg. The use of a FiO2 of less than 0.3 whilst ventilated is discouraged. According to standard Intensive Care Unit practice, control patients will receive a FiO2 of 1.0 during endotracheal intubation manoeuvre, airway suction or in-hospital transfers.
10140335|NCT04198298|Active Comparator|Group 1 EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
10140336|NCT04198298|Active Comparator|Group 2 ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
10140337|NCT04198298|Active Comparator|Group 3 Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
10140338|NCT04198376|Experimental|The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes. Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures
10140339|NCT04198376|Experimental|Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator .A second surgical site will be prepared to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site. After sutures are slid through each tunnelled interdental area the needle will be pushed through the CTG before it is guided back through the undermined tissues.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.
10140340|NCT04198129|Experimental|Treatment|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
10140341|NCT04198129|Active Comparator|Control|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.
10140342|NCT04198155|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to bilateral renal arteries determined by CT-guidance.
10140343|NCT04198233|Experimental|Diazepam group|Rectal Diazepam suppository
10140344|NCT04198233|Placebo Comparator|Placebo group|Placebo suppository
10140345|NCT04198402||Patient with digestive neuroendocrine tumor|naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment
10140346|NCT04198402||Patient without tumor|Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.
10140347|NCT04198051|Experimental|treatment group|
10140348|NCT04198350|Experimental|Islet implantation|
10140349|NCT04198103|Experimental|SoracteLite|Transperineal Focal Laser Ablation (TPLA)
10140350|NCT04198168||ICU patients|ICU patients who are assessed by their attending physician as having need for fluid therapy and are planned to receive IV crystalloid fluid due to oliguria and/or to improve GFR.
10140351|NCT04198194||Participants with events|Individuals who have experienced any of the listed outcomes
10140352|NCT04198194||Participants without events|Individuals who have not experienced any of the listed outcomes
10140353|NCT04198272|Experimental|Facilitated|"Schools that are randomized to this arm will be exposed to all of the components in the self-service version in addition to the following:~-Peer facilitation of the CyberRwanda platform at the school-based cyber clubs that will house an online tablet with the educational components of CyberRwanda with a facilitator."
10140354|NCT04198272|Active Comparator|Self-service|"Schools that are randomized to this arm will be exposed to the following components of the intervention:~Availability of the fully functional online CyberRwanda web portal through school-based cyber clubs;~SMS-based ordering of contraceptives and SMS-based FAQs Online (through web portal on computer or smartphone) ordering of contraceptives;~Facility finder: A list of the closest health centers and pharmacies where youth can get contraceptives and other FPRH services;~Promotion of the CyberRwanda program through school launch events; and~Access to Youth Centers (1 per district) that will house tablets with the fully functional online CyberRwanda web portal"
9669235|NCT03639246|Experimental|Phase 1b: AVB-S6-500+PLD|
10140355|NCT04198272|No Intervention|Control|Schools in this arm will not receive any intervention
10140356|NCT04198064|Experimental|Group A- Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/~2 cups of %0.9 saline solution) during the insertion of the cystocopy tube during their cystoscopy."
10140357|NCT04198064|Other|Group B- No Bag Squeeze|Participants will receive a standard cystoscopy procedure.
10140358|NCT04198142|Experimental|Imagery Rehearsal Therapy Intervention|This group receives one to two sessions of Imagery Rehearsal Therapy.
9669236|NCT03639246|Experimental|Phase 1b: AVB-S6-500+Pac|
9669237|NCT03639246|Experimental|Phase 2: AVB-S6-500+PLD|
9669238|NCT03639246|Experimental|Phase 2: AVB-S6-500+Pac|
9669239|NCT03639246|Active Comparator|Phase 2: Placebo+PLD|
10140359|NCT04198142|Active Comparator|Treatment as Usual with dream diaries|This group receives the usual inpatient care without additional Imagery Rehearsal Therapy sessions, but also keeps dream diaries.
10140360|NCT04198259|Active Comparator|interventional devascularization|Interventional devascularization includes BRTO and similar procedure. Several variations of the technique exist, such as balloon-occluded antegrade transvenous obliteration or occlusion of the collateral by the placement of a vascular plug or coils.
10140361|NCT04198259|Experimental|Transjugular intrahepatic portosystemic shunt|TIPS is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein.
10140362|NCT04197960|Experimental|microwave ablation|ablate all tumors including at least 5mm safe margin except for tumors adjacent to thyroid capsule.
10140363|NCT04197960|Active Comparator|surgical resection|lobectomy + central lymph node dissection
10140364|NCT04197947|Experimental|PD patient who have FoG|
10140365|NCT04198038|Experimental|cognitively impaired children|This is a single-group study; all participants will be offered the songwriting intervention.
10140366|NCT04197856|Active Comparator|Control / Family-mediated disclosure (standard care)|Genetic counseling according to current clinical practice
10140367|NCT04197856|Experimental|Intervention / Health-care assisted disclosure|Genetic counseling according to current clinical practice with the addition of an offer from health care provider to mail letters directly to eligible at-risk relatives.
10140368|NCT04197674||Peritoneal dialysis group|Patients who randomized to peritoneal dialysis
10140369|NCT04197674||Hemodialysis group|Patients who randomized to conventional in-center hemodialysis
10140370|NCT04197791|Experimental|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular Electrical Stimulation will be applied to 18 patients with idiopathic pulmonary fibrosis. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
10140371|NCT04197791|Experimental|Core Stabilization Exercises|Core stabilization exercises will be applied to 18 patients with idiopathic pulmonary fibrosis. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
10140372|NCT04197804||Tourette group|20 subjects with Tourette Syndrome undergoing an evaluation to identify the IQ. Subsequently, 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
10140373|NCT04197804||Control group|20 subjects without Tourette Syndrome subjected to an evaluation to identify the IQ. Subsequently 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
10140374|NCT04197778|Experimental|group A|
10140375|NCT04197778|Experimental|group B|
10184573|NCT03753854|Experimental|SS patients apneic|"Homozygous sickle cell patients after one year of continuous positive airway pressure treatment~Each patient will undergo the following:~polysomnography and oxygen saturation exam~calculation of VOC rate within the two previous years~Blood samples~Physiological measurements"
10184574|NCT03753841|Active Comparator|Adjustment of oral diet|Patients who need a change in their diet regime, in whom FEES shows that they have not the adequat diet.
10184575|NCT03753841|No Intervention|No adjustment of oral diet|Patients who have the adequat diet based on FEES findings.
10184576|NCT03753815|Active Comparator|19G FNA needle|Patients referred for EUS-guided tissue acquisition of AIP
10184577|NCT03753815|Active Comparator|20G FNB needle|Patients referred for EUS-guided tissue acquisition of AIP
10184578|NCT03753802|Experimental|Treated|The treated group will receive chest physiotherapy treatment using slow extended and passive expiratory maneuvers.
10184579|NCT03753802|Placebo Comparator|Control|The control group will not receive physiotherapy treatment.
10184580|NCT03753776|Placebo Comparator|Radium bromatum placebo group|Placebo group will receive placebo pills of Radium bromatum during radiotherapy
10184581|NCT03753776|Experimental|Radium bromatum group|Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy
10184582|NCT03753776|Placebo Comparator|Radium bromatum/Apis mellifica/Belladonna placebo group|Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis
10184583|NCT03753776|Experimental|Radium bromatum/Apis mellifica/Belladonna group|Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis
10184584|NCT03753750|Experimental|Actual stimulation|Subjects enrolled in the
10184585|NCT03753750|Sham Comparator|Sham stimulation|
10184586|NCT03753737||Chemsex|Men who have Sex with Men (MSM) attending an addiction care center for past or present mild, moderate or severe substance-related disorder(s) according to DSM-V criteria, occurring in a sexual context and concerning cathinones, GHB/GBL, methamphetamine, cocaine and/or ketamine.
10184587|NCT03753737||Control|Men who have Sex with Men (MSM) consulting for a PrEP (HIV Pre-Exposure Prophylaxis) prescription who have never used cathinones, GHB/GBL, methamphetamine, cocaine or ketamine before or during sex.
10184588|NCT03753724||Group 1|On review of the scans by an expert, no further follow up or investigation is required, as the nodule(s) has been categorised as benign. As the patient was unaware the scan was being reviewed and no further investigations are required. Patient is invited to take part in the study (by telephone).
10184589|NCT03753724||Group 2|On review, the nodule is indeterminate and further scanning at a later date is required. The patient is informed of this, usually via a telephone call from either the doctor or nurse specialist working in the Lung Nodule Clinic (LNC) or site equivalent. This LNC is usually a virtual clinic - no physical interaction with the patient - and the follow up scan is reviewed and the patient contacted again via the virtual clinic. Patient is invited to take part in the study (by telephone, by post or in clinic if appropriate).
10184590|NCT03753724||Group 3|On review, the nodule is regarded as potentially malignant and further scans and a clinic appointment is made for the patient. Patient is invited to take part in the study (in clinic if appropriate).
10184591|NCT03753711|Experimental|LDH (lumbar disc hernia)|
10140376|NCT04197817|Active Comparator|JS002|JS002, Subcutaneous or intravenous injection
10140377|NCT04197817|Placebo Comparator|Placebo,|Placebo,Subcutaneous or intravenous injection
10140378|NCT04197752||Obese patients|Body mass index > 30 kg/m2
10140379|NCT04197752||Non-obese patients|Body mass index < 30 kg/m2
9669240|NCT03639246|Active Comparator|Phase 2: Placebo+Pac|
9669241|NCT03635645|Experimental|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
10140380|NCT04197570|Active Comparator|Opioid-based anesthetic|"Premedication~-midazolam 2mg IV x 1 as need for anxiety, at the discretion of the anesthesiologist~Induction~Fentanyl 2-4 mcg/kg IV bolus~Propofol 1-3 mg/kg IV~Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~Fentanyl 1-2 mcg/kg IV bolus immediately prior to sternotomy & aortic cannulation~Fentanyl 1-2mcg/kg IV bolus immediately following removal of bypass cannula~Dexmedetomidine 0.4 mcg/kg/hr IV infusion~Isoflurane titrated at the discretion of the anesthesiologist~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~start Propofol 25-75mcg/kg/min IV infusion~continue dexmedetomidine 0.4mcg/kg/hr IV infusion~titrate off isoflurane~Acetaminophen 1000mg IV"
10140381|NCT04197570|Experimental|Opioid-free anesthetic|"Premedication~-midazolam 2mg IVx1 as needed for anxiety, at the discretion of the anesthesiologist~Induction~Dexmedetomidine 1mcg/kg IV~Propofol 1-3mg/kg IV~Paralytic and vasoactive medications at the discretion of the anesthesiologist~Maintenance~Dexmedetomidine 0.8-1.0 mcg/kg/hr IV infusion~Isoflurane titrated at the discretion of the anesthesiologist~May add propofol infusion if clinically indicated~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management~During chest closure:~start Propofol 25-75mcg/kg/min IV infusion~continue dexmedetomidine 0.4 - 1.0 mcg/kg/hr IV infusion~titrate off isoflurane~Acetaminophen 1000mg IV"
10140382|NCT04197882|Experimental|treatment|"This study consisted of 3 stage of neoadjuvant treatment, surgical, and adjuvant treatment. Neoadjuvant treatment period: OrienX010 intratumoral injection in combination with Toripalimab infusion. Toripalimab : 3 mg/kg, IV infusion: Once every 2 weeks for 6 doses ; OrienX010: Maximum injection volume 8 × 108 pfu, intratumoral injection: Once every 2 weeks for 6 doses ; Surgical treatment period: 2 weeks after the last dose of neoadjuvant treatment (± 7 days), the investigator designed the surgical protocol of the melanoma radical surgery according to the patient's individual disease, and performed postoperative care according to the patient's condition.~Adjuvant treatment period: 3 weeks after operation (± 7 days), the patient was given Toripalimab infusion. Toripalimab 3 mg/kg intravenously given every 3 weeks (every 3 weeks per cycle) for up to 1 year (the one-year duration will be counted from 1st dose in neoadjuvant treatment)."
10140383|NCT04197661|Active Comparator|Elderly groupⅠ|Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486
10140384|NCT04197661|Active Comparator|Elderly group Ⅱ|Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486
10140385|NCT04197661|Active Comparator|Elderly group Ⅲ|Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486
10140386|NCT04197661|Active Comparator|Non-elderly group IV|Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486
10140387|NCT04197843|Experimental|NaviCam (ANKON)|NaviCam (ANKON)
10140388|NCT04197895|Experimental|test group|Socket preservation with APRF
10140389|NCT04197895|Active Comparator|control group|natural healing
10140390|NCT04197908|Experimental|EUS-guided gallbladder drainage (EGBD)|The procedure would be performed with a linear echoendoscope using a 10mm x 10mm or a 15 x 10mm stent. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder would be completely emptied by suction and irrigation until the effluent through the stent is clean.
10140391|NCT04197427|Experimental|Experimental Oral Rinse|"In this arm the test article,oral rinse, a proprietary formulation of agents including xylitol, Caffeine, Essential oils, Monk fruit extract, which can reduce the plaque formation Subjects rinse twice a day with 10 mL of the oral rinse for 2 minutes for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
9669242|NCT03632707|Other|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial PD,T2 and PD-SPIR weighted images, and correlate the results with Knee Arthroscopy.while the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing.
10140392|NCT04197427|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
10140393|NCT04197375|Experimental|Pre-cooling scenario|One hour before a tennis match, the pre-cooling group was wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes.
10140394|NCT04197375|Sham Comparator|Sham evaluation|Participants were monitored during a usual game without any kind of pre-cooling strategy
10140395|NCT04197622|Experimental|Hydrochlorothiazide|Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).
9669243|NCT03628612|Experimental|AUTO CAR T cell therapy|Patients who received previous treatment with AUTO CAR T Cell Therapy
9827463|NCT02456896|Experimental|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
9827464|NCT02456909|Experimental|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
10140396|NCT04197596|Experimental|BK CTL|Eligible patients with refractory BK infection will receive up to 5 infusions of BK CTLs that are donor derived.
10140397|NCT04197739|Experimental|Fixed dose|patients will receive a fixed, single daily dose of amikacin, 500 mg, a day.
10140398|NCT04197739|Active Comparator|Adjusted body weight dose|patients will receive a weight adjusted dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram.
9827465|NCT02456909|Placebo Comparator|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
10140399|NCT04197505|Experimental|Acute fracture specific|The FLIR E95 camera will be used for the study. The injured extremity will be scanned with the thermal camera and a second scan will be performed on the non-injured extremity to provide an internal control for any differences in room temperature and humidity. Prior to scanning, both the injured and non-injured extremity will remain uncovered for 10 minutes, about the length of an average office visit, and the areas to be scanned will remain free from contact by the patient or interviewer during this time period. The camera will be held 2 feet away from the extremity at a 90º angle to limit reading contamination from objects other than the patient.
10140400|NCT04197323|Experimental|Alprostadil liposomes for injection|
10140401|NCT04197323|Active Comparator|KAISHI for injection|
10140402|NCT04197492|Experimental|HSRT With Anlotinib|"Hypofractionated stereotactic radiotherapy using CyberKnife 25Gy/5fx, 5 days a week for 1 week.~Anlotinib once daily (12mg/d) orally administered on days 1-14 of a 21-day cycle until disease progression or treatment intolerance."
10140403|NCT04197349|Experimental|Part A Cohort 1-8|ALD1910/Placebo; Single Dose IV infusion on Day 1
10140404|NCT04197349|Experimental|Part B Cohort 9|ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1
10140405|NCT04197349|Experimental|Part B Cohort 10|ALD1910/Placebo; Single dose subcutaneous injection on Day 1
10140406|NCT04197479|Experimental|Open label: resmetirom|100 mg daily
10140407|NCT04197479|Placebo Comparator|Double blinded: matching placebo|Placebo daily
10140408|NCT04197479|Experimental|Double blinded: resmetirom 80 mg|80 mg daily
10140409|NCT04197479|Experimental|Double blinded: resmetirom 100 mg|100 mg daily
10140410|NCT04197518|Experimental|Children With Enlargement Adenoid and Tonsils|Children With Enlargement Adenoid and Tonsils
10140411|NCT04197466|Experimental|Pelvic Floor Exercise Group|Pelvic floor muscle exercises will be recommended as a home program for 6 weeks every day of the week.
10140412|NCT04197466|Experimental|Kinesiotape Group|In addition to pelvic floor exercise,kinesio tape application will be performed by ligament technique to the sacral region.
10140413|NCT04197466|Experimental|Electrical Stimulation Group|In addition to pelvic floor exercise,electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
10140414|NCT04197648|Experimental|Exercise group|24 week, supervised exercise program at the PPMC (pavillon de prevention des maladies cardiaques). 3x/week. Blood pressure response evaluated during every session.
10140415|NCT04197648|No Intervention|Control goup|No exercise program. Continuation of the daily life activities. Consultation with a kinesiologist at baseline, 3 months and 6 months for advice on physical activities and lifestyle habits.
10140416|NCT04197271||Patients with acutely symptomatic abdominal wall hernia|Patients presenting to emergency surgical services with acutely symptomatic abdominal wall hernia (excluding parastomal).
10140417|NCT04197206|Experimental|Costotransverse block|The Costotransverse block will be administrated to this group before induction of anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively.
10140418|NCT04197206|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine. No block will be performed.
10140419|NCT04197284|Active Comparator|Control group|In control group subjects will undergo individual kinesitherapy- isometric exercise for strengthening of the quadriceps muscle.
10140420|NCT04197284|Active Comparator|Biofeedback group|Biofeedback group will perform physical therapy using biofeedback device for better activation control of the quadriceps muscle with audio and visual signal. They will also perform isometric exercise.
10140421|NCT04197284|Active Comparator|Electrical stimulation|Electrical stimulation group will receive electrical stimulation of the quadriceps muscle and they will also perform isometric exercise.
10140422|NCT04197531|Experimental|EndoActivator|
10140423|NCT04197531|Experimental|Conventional Endodontic Syringe|
10140424|NCT04197440|Experimental|Bam8-22|
10140425|NCT04197440|Experimental|SPT pricks|
10140426|NCT04197414||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
10140427|NCT04197414||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
10140428|NCT04197414||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
10140429|NCT04197414||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
10140430|NCT04197089|Experimental|Vitamin D treatment|Treatment with 10.000 IU or 50.000 IU Vitamin D weekly during 4 weeks
10140431|NCT04197024|Experimental|Traditional exercise capacity test|Patients of the Ministry of the Interior and Administration hospital in Głuchołazy with a diagnosed disease unit of Chronic Obstructive Pulmonary Disease (COPD).
10140432|NCT04197024|Experimental|Immersive virtual reality exercise capacity test|Healthy volunteers, Students of Department of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
10140433|NCT04197037||People with schizophrenia treated with clozapine|People more than 18 with diagnosis of schizophrenia and treated with clozapine in a stable dose and stable status of the disease (at least 2-3 weeks).
10140434|NCT04197245|Experimental|group on treatment|saline injection has been given intradermal in atrophic scars of acne on face.
10140435|NCT04196985|Experimental|Patients with HNSCC|Patients who have histologically confirmed HNSCC and have received CRT for it
10140436|NCT04197167|Experimental|Women undergoing hysteroscopy|Patients scheduled to undergo hysteroscopy for the evaluation of abnormal bleeding or abnormal cervical or uterine findings.
10140437|NCT04197154|Experimental|1. Control nocebo group|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
10140438|NCT04197154|Experimental|2. High-pain nocebo group|Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
10140439|NCT04197154|Experimental|3. High-threat nocebo|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
10184592|NCT03753698|Experimental|eCoin|Neuromodulation of posterior tibial nerve
10184593|NCT03753685|Experimental|X-396(Ensartinib) Capsule|
10140440|NCT04197258|Experimental|intervention group|"For 6 months after discharge, patients in the intervention group will benefit from peer support by a trained patient (number and frequency of contacts defined according to the patient's needs).~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon discharge at home, including identifying and seeking for the necessary health or social resources"
10140441|NCT04197258|No Intervention|control group|Patients included in the control group before intervention will receive the usual practices. As part of the study, they will be contacted for data collection 6 months after the transition to home by a clinical research associate.
10140442|NCT04197219|Experimental|Pembrolizumab & axitinib|All participants enrolled will receive pembrolizumab as standard of care (SOC) combined with axitinib. Axitinib will be self-administered orally twice daily at 5 mg. On days when both drugs are administered, axitinib will be administered first, followed by pembrolizumab. Treatment will continue until disease progression or unacceptable grade 3/4 toxicities. For patients with a complete response to therapy, maintenance therapy with both drugs will be continued for 12 months.
10140443|NCT04196855|Experimental|Intervention - Teriparatide Treatment|Teriparatide 20ug/day from confirmation of stress fracture for 16 weeks, with the potential to extend to 24 weeks if required.
10140444|NCT04196855|No Intervention|Control - Standard Care|Standard rehabilitation care with additional monitoring to assess healing.
10140445|NCT04197076||Neoadjuvant immunotherapy|pd-1 or pd-l1 inhabitors
10140446|NCT04197076||Neoadjuvant targeted therapy|TKIs
9827466|NCT02457065|Experimental|Receive Plaque|"Treatment~Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators gave the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors."
9969916|NCT01294995|Placebo Comparator|Guizhou Meijiao Liquor, taken with meal|including 11 males and 11 females
10140447|NCT04197076||Neoadjuvant chemotherapy|chemotherapy
10140448|NCT04196829|Experimental|silver diamine fluoride ⁄ potassium Iodide|38% silver diamine fluoride and a saturated solution of potassium iodide
10140449|NCT04196829|Active Comparator|silver diamine fluoride|38% silver diamine fluoride
10140450|NCT04197102|Active Comparator|CBD Isolate|300 mg/day of CBD isolate
10140451|NCT04197102|Active Comparator|CBD Broad Spectrum|300 mg/day of CBD Broad Spectrum Oil
10140452|NCT04197102|Placebo Comparator|Placebo oil|Matched Placebo Oil
10140453|NCT04197063|Experimental|Current SSB restaurant portions purchase refill|Offered a menu with current SSB restaurant portion sizes with the option to purchase refills
10140454|NCT04197063|Experimental|Current SSB restaurant portions free refill|Offered a menu with current SSB restaurant portion sizes plus free beverage refills
10140455|NCT04197063|Experimental|</= 16 oz. SSB portions with the option to purchase refills|Offered a menu with </= 16 oz. SSB portion sizes with the option to purchase refills
10140456|NCT04197063|Experimental|</= 16 oz. SSB portions plus free refills|Offered a menu with </= 16 oz. SSB portion sizes plus free refills
10140457|NCT04197180|Experimental|Hybrid Argon Plasma Coagulation|The Hybrid-Argon Plasma Coagulation probe combines waterjet technology with Argon Plasma Coagulation. The probe comprises a central water channel for the submucosa injection function and a peripheral gas channel for the Argon Plasma Coagulation function
10140458|NCT04196946|Experimental|Group I|25 mcg fentanyl intrathecally
10140459|NCT04196946|Experimental|Group II|250 mcg alfentanil intrathecally
10140460|NCT04197128|Active Comparator|Resorbable collagen membrane and bone graft|Subjects will receive bovine derived bone graft and resorbable collagen membrane for augmentation.
10140461|NCT04197128|Experimental|Ribose cross-linked collagen matrix|Subjects will receive ribose cross linked collagen matrix for augmentation
10140462|NCT04197050|Experimental|sacubitril/valsartan group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. sacubitril/valsartan will be given.
10140463|NCT04197050|No Intervention|control group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. Valsartan will be given.
10140464|NCT04197115|No Intervention|Phase 1|Septic patients admited to ICU whick will be treated as specified in current guidelines.
10140465|NCT04197115|Active Comparator|Phase 2|"Septic patients admitted to ICU which will be treated as specified in current guidelines adding:~Vitamin C Hydrocortisone B complex (Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg)"
10140466|NCT04196933|Experimental|Normal Controls|"normal control subjects - no history of neurologic or inner ear disease~The investigators will characterize vestibular spatial and temporal precision by calculating perceptual thresholds and reaction times for vestibular (yaw rotation, ytranslation) stimuli in normal subjects over a wide age range. Vestibular-visual temporal binding is then performed on each subject and the relationship between the principal parameters (vestibular perceptual thresholds [inversely related to spatial precision], vestibular reaction time variability [inverse of temporal precision], and the PSS and TBW from the temporal binding paradigm) will be examined. The investigators will collect qualitative assessments of dizziness/disbalance (DHI: dizziness handicap index) and quantitative measurements of balance and vestibular function (FGA: functional gait analysis, postural sway, and standard rotational testing - VOR gain, time constant, asymmetry)."
10140467|NCT04196933|Experimental|Central Vestibular Dysfunction|"Migraine and Vestibular Migraine patients~The investigators intend to evaluate vestibular (yaw rotation or y-translation) - visual temporal binding in people with a wide range of motion sickness sensitivities (as quantified with standard questionnaires), including normal subjects, people with migraine and with vestibular migraine. The investigators will use our standard adaption method to narrow the TBW in these subjects, and will also employ PSS adaptation if a consistent pattern emerges that relates MS sensitivity to the PSS. The investigators will induce motion sickness using a pseudo-Coriolis task (so susceptibility can be quantified pre and post training)."
9969917|NCT01295008||Patients with the classic form|
10140468|NCT04196933|Experimental|Peripheral Vestibular Dysfunction|"Vestibular Schwannoma patients~The basic approach is to characterize the precision of their vestibular information (perceptual thresholds for spatial precision, reaction times for temporal precision), and their temporal binding characteristics for vestibular (yaw rotation or y-translation)-visual inputs, in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months). At each state the investigators will also assess the quality of their vestibular-mediated behaviors through questionnaires (e.g. DHI), postural sway, functional gait analysis, and standard rotational testing (VOR gain, time constant, and asymmetry)."
10140469|NCT04196933|Experimental|Implant Subjects|"Cochlear Implant (CI)/Vestibular Implant (VI) patients~A causative role for vestibular precision in temporal binding will be investigated in the VI patients, since the noise characteristics of the vestibular channel will be varied and to determine how this affects thresholds and temporal binding. As part of a second aim, the investigators will use VI and CI prosthetic signals in patients who have never received them together to see how the brain process sensory cues to which it is essentially naïve. Finally, after the acute experiments the investigators will provide 8 hours of 'physiologic' VI and CI stimulation by turning both implants on, sound modulates activity in the CI as usual, and angular head motion modulates activity in the VI while the subject actively explores the hospital environment."
10140470|NCT04196998|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
10140471|NCT04196998|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
10140472|NCT04196998|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
10140473|NCT04196972|Experimental|Arm A (ECHO telementoring)|Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
10140474|NCT04196972|Experimental|Arm B (wait-list, ECHO telementoring)|Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
10140475|NCT04197232||exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
10140476|NCT04197232||not exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
10140477|NCT04197011||Prosthesis users|Individuals with unilateral transfemoral amputation.
10140478|NCT04197011||Control|Individuals without unilateral transfemoral amputation.
9669244|NCT03607942|Experimental|Experimental Formula|The experimental group will receive a liquid supplement containing 2 specific HMOs
10140479|NCT04196881|Experimental|Training|group will receive training about ADHD
10140480|NCT04196881|No Intervention|Control|group will not receive training about ADHD
10140481|NCT04196660|Experimental|The Dance Practitioner Spouse/Partner Group|The Dance Practitioner Spouse/Partner Group (DPSG)
10140482|NCT04196660|Experimental|The Dance Practitioner Midwife Group|The Dance Practitioner Midwife Group (DPMG) included 40 pregnant women and midwives who had received labor dance training
10140483|NCT04196660|No Intervention|The Control Group|The Control Group included 80 pregnant women who were subjected to routine treatment without dance
10140484|NCT04196673|Experimental|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
10140485|NCT04196673|Experimental|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
10140486|NCT04196634||People on sick leave|People on sick leave due to musculoskeletal conditions for at least 4 weeks.
10140487|NCT04196543|Experimental|écho-doppler with ultrasonar Sonovue® injection|
10140488|NCT04196621|Active Comparator|High viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, high viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
10140489|NCT04196621|Active Comparator|Low viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, low viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
10140490|NCT04196452||Arm A: participants 12 to under 18|
9669245|NCT03607942|Placebo Comparator|Control Formula|The control group will receive a liquid placebo
10140491|NCT04196452||Arm B: participants under 12|
10140492|NCT04196738|Experimental|Dual Mode first|Four consecutive steps (45 min per step) in the following order: APRV (A), Dual Mode (B) , APRV (A) and VAC (C). (ABAC)
10140493|NCT04196738|Experimental|VAC fist|Four consecutive steps (45 min per step) in the following order: APRV (A), VAC (C) , APRV (A) and Dual Mode (B). (ACAB)
10140494|NCT04196400|Active Comparator|Steroid injection|Steroid (betamethasone) 2 ml is injected subcutaneously after finishing the operation at the repair site.
10140495|NCT04196400|No Intervention|Control Group|
10140496|NCT04196426|Experimental|nutrition education group|The nutrition education group receive the intervention first, which include 2 nutrition lessons about osteoporosis and calcium and calcium rich foods. The 2 lessons are delivered in one week for 2 hours each lesson. After this week, participants in the intervention group receive handouts about osteoporosis and calcium once a week for a period of 4 weeks.
10140497|NCT04196426|Active Comparator|delayed nutrition education group|After the intervention group finish their intervention (5 weeks period), post data collection will be administered in both nutrition education and delayed nutrition education group. After this post data collection, the delayed nutrition education group receive the same intervention.
10184594|NCT03753672||preload responsive|defined as an increase in Velocity time integral of the sub-aortic flow greater or equal to 10%
10184595|NCT03753672||preload unresponsive|defined as an increase in Velocity time integral of the sub-aortic flow lower than 10%
9669246|NCT03596242|Experimental|High Blood Pressure Monitoring by SMS|Will receive the text message intervention and will be provided with a blood pressure cuff in addition to standard blood pressure control education received at clinic visits
9969918|NCT01295008||Fabry disease and healthy controls|
10140498|NCT04196777|Experimental|Intervention|We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.
10140499|NCT04196777|No Intervention|Control|"After the 3 intervention sites are identified, 3 control sites will be chosen. To qualify as a control site, a hospital's baseline rate of excessive post-procedural antimicrobial use must be comparable to that of its matching intervention site. Matching on the outcome of interest will minimize selection bias and will make the study less subject to regression to the mean, which is the key threat when selecting poor performers.To further ensure that intervention and control sites are as similar as possible, attempts will also be made to match each intervention site to a comparable control site based on academic affiliation (yes/no), VHA-defined hospital complexity, urologic procedural volume, antimicrobial stewardship resources, and location (rural versus urban).~Feedback will not be provided to the control sites."
10140500|NCT04196582|Active Comparator|Gastro-laryngeal tube Group (Group G)|Patients wear Gastro-laryngeal tube after receiving general anesthesia for biliopancreatic procedures
10140501|NCT04196582|Active Comparator|LMA Gastro Airway Group (Group L)|Patients wear LMA Gastro Airway® after receiving general anesthesia for biliopancreatic procedures
10140502|NCT04196556|Experimental|Active Families|Usual care plus intervention active families. This intervention, based on the methodology of meaningful learning, will have two components: group education directed to parents (caregivers) and education directed to children in the reviews in consultation. The group intervention will consist of 6 sessions, with a biweekly / monthly frequency, will be taught as determined in the program monitoring annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
10140503|NCT04196556|Active Comparator|Control group|"Usual care:~The activities included in the Service for Attention to Patients with Childhood Obesity will be carried out in the Cartera de Servicios Estandarizados de Atención Primaria de Madrid, which establishes a monthly follow-up in the first 6 months and bimonthly of month 6 to 12. To this At least the child and the primary caregiver, the child's educational agent, will be consulted and will receive support documentation to exercise and reinforce their role."
10140504|NCT04196309|Experimental|Tinzaparin group|LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)
10140505|NCT04196309|No Intervention|Control group|No intervention
10140506|NCT04196712||Coronary angiography arm|Patient undergoing invasive coronary angiography
10140507|NCT04196517|Experimental|Arm 1 - PALS|The Patient Activated Learning System (Palsforhealth.com)
10140508|NCT04196517|Experimental|Arm 2 - WebMD|WebMD.com
10140509|NCT04196725|Experimental|Physical therapy treatment|
10140510|NCT04196725|Experimental|Lifestyle treatment|
10140511|NCT04196725|No Intervention|Control|Parallel control group, not undertaking any treatment and not part of the cross-over design
9969919|NCT01295047|Active Comparator|ATENOLOL|ATENOLOL 75MG FOR 4 WEEKS
10140512|NCT04196608||P. aeruginosa isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
10140513|NCT04196608||Enterobacterales isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
10140514|NCT04196465|Experimental|Neoadjuvant IMC-001|Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma
10140515|NCT04196296|Active Comparator|Psychoeducation|
10140516|NCT04196296|Experimental|Psychoeducation plus Motivation Enhancement|
10140517|NCT04196270|Experimental|Ropivacaine|This double-blind dose-finding trial is based on a biased coin up-and-down sequential design, where the volume of local anesthetic administered to each patient depends on the response from the previous one. The TQL block is performed preoperatively, and the first patient recruited receives 20 mL of ropivacaine 0.75%. In case of block failure, the next patient will receive a higher volume (defined as the previous volume with an increment of 2 mL). Given a successful block for the first patient, the next patient will be randomized to either a lower volume (defined as the previous volume with a reduction of 2 mL) or the same volume as the previous patient. The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume. Block success is defined as patient reported numeric rated scale (NRS) pain (NRS value ≤ 3 (0-10/10)), 30 minutes after arrival in the post anesthesia care unit (PACU).
10140518|NCT04196322||Controlled|
10140519|NCT04196322||Uncontrolled|
10140520|NCT04196439|Active Comparator|continuous epidural analgesia|continuous lumbar epidural catheter inserted preoperatively before induction of general anaesthesia
10140521|NCT04196439|Active Comparator|continuous supra-inguinal fascia iliaca compartment block|ultrasound guided supra-inguinal FICB with insertion of catheter for continuous infusion before induction of general anaesthesia.
10140522|NCT04196361||Ventilated72h|Patient that were ventilated for at least 72 hours
9969920|NCT01295047|Active Comparator|VERAPAMIL|240MG VERAPAML FOR 4 WEEKS
9969921|NCT01295047|Active Comparator|PERINDOPRIL|4MG PERINDOPRIL FOR 4 WEEKS
9969922|NCT01295073|Active Comparator|A|Oral Trientine 1500mg x 1 week before cataract surgery and 3 days post surgery
9969923|NCT01295073|Placebo Comparator|B|Oral Placebo x 1 week before cataract surgery and 3 days post surgery
10140523|NCT04196153|Active Comparator|Neuronavigation / O-arm group|Under neural navigation with the use of intraoperative three dimensional imaging quality O-arm , pedicle screws inserted at the thoraolumbar/lumbar spine after insertion of the reference frame at the spinous process above or below the level of instrumentation followed by O-Arm imaging and uploading the images to the stelth navigation system and pedicle tract identification using instrumented tools guided by the Navigation polyaxial screws is inserted.
10140524|NCT04196153|Active Comparator|Cervical distractor screws group|pedicle screws inserted using marker screws after posterior exposure of thoracolumbar /lumbar spine by either open midline posterior exposure or minimal invasive posterior wiltse style exposure with expandable tubular retractor, anatomical landmark for insertion of pedical screws identified and followed by inserting of a cervical distraction screw size 3 / 12 mm as a stable marker using high speed drill. C-arm floro is used to take antroposterior and lateral view to confirm the position of the marker screws at this stage.free hand technique supported by the images provided to cannulate the pedicle with the use of information on the images taken for all the marker screws simultaneously.
10140525|NCT04195971|Experimental|Liver CT with dual arterial phase|
10140526|NCT04196140|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
10140527|NCT04196088|Active Comparator|Ultivision AI Software enhanced screening colonoscopy|Ultivision Artificial Intelligence enhanced screening colonoscopies will be performed.
10140528|NCT04196088|Placebo Comparator|No AI enhancement screening colonoscopy|Screening colonoscopies without Artificial Intelligence enhancement will be performed.
10140529|NCT04196205|Experimental|Anti-CD19 CAR-T|Anti-CD19 CAR-T
10140530|NCT04196166||Cases|nested from on going retrospective cohort study. Participants who had change in their surgical plan after hospitalization.
10140531|NCT04196166||Controls|nested from on going retrospective cohort study. Participants who didn't have change in their surgical plan after hospitalization.
10140532|NCT04196244|Experimental|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
10140533|NCT04196244|Active Comparator|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
10140534|NCT04196127||TTH|Patients with tension-type headache. They may not experience migraine, but can experience neck pain and/or temporomandibular dysfunction.
10140535|NCT04196127||Healthy controls|Participants without frequent headaches. They may experience neck pain and/or temporomandibular dysfunction.
10140536|NCT04196179|Experimental|SAD|"A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral~A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral~A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral~Day 15 ANG-3070 200mg (n=6) / Placebo (n=2) Oral~A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral~A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) Oral~D1 Single Dose Food Effect: Day 1 ANG 3070 600 mg *with and without food* (n=6)/ Placebo (n=2) Oral"
10140537|NCT04196179|Experimental|MAD|"B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2)~B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2)~B3 ANG-3070 250 mg BID (n=6) / Placebo (n=2)~B4 ANG-3070 500 mg, BID (n=6)/ Placebo (n=2)~C1 ANG-3070 400 mg, QD(n=6)/ Placebo (n=2)~C2 ANG-3070 600 mg, QD (n=6)/ Placebo (n=2)"
10140538|NCT04196231|Active Comparator|FR insulin/GLP-1RA|Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
10140539|NCT04196231|Active Comparator|Insulin/SGLT-2i|Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
10140540|NCT04196231|Active Comparator|Basal Bolus|Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals
10140541|NCT04196114|Experimental|All patients|All patients implanted.
10140542|NCT04195997|Experimental|bivalurudin|Bivalirudin will be given as a bolus of 0.75 mg/kg once transseptal puncture is successully performed with no pericardial effusion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
10140543|NCT04195997|Active Comparator|heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
10140544|NCT04196036|Active Comparator|Day 3 vitrification|Day of vitrification of supernumerary embryos is day 3
10140545|NCT04196036|Active Comparator|Day 5 vitrification|Day of vitrification of supernumerary embryos is day5
10140546|NCT04195932|Experimental|Exercise|6 moths of supervised moderate intensity aerobic and resistive exercise training
10140547|NCT04196348|Active Comparator|Short BPL RYGB in glucose-tolerant participants|Procedure: short biliopancreatic limb (BPL) Roux en Y Gastric Bypass (RYGB) Obese patients without type 2 diabetes mellitus (T2DM) to be submitted to short BPL (n=10)
10140548|NCT04196348|Active Comparator|Long BPL RYGB in glucose-tolerant participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome without T2DM to be submitted to long BPL (n=10)
10140549|NCT04196348|Active Comparator|Long BPL RYGB in diabetic participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome and T2DM to be submitted to long BPL (n=10)
10140550|NCT04195828|Experimental|Camrelizumab + Apatinib + nab-paclitaxel +S-1|Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
10140551|NCT04195828|Active Comparator|nab-paclitaxel +S-1|nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
10140552|NCT04195789||Sample population|Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.
10140553|NCT04195763||Participants with Pediatric-onset HPP|Adult participants diagnosed with pediatric-onset HPP, newly prescribed treatment with asfotase alfa, and registered in the patient support program managed by OneSource.
9969924|NCT01295086|Experimental|Her-TEX|
10140554|NCT04195724|Experimental|Patients with decompensated ascites and receiving TIPS|Patients with decompensated ascites and receiving TIPS will be enrolled. In this study, diagnostic paracentesis will be performed to get the ascites sample before the patients receiving TIPS. Next, the blood sample from superior mesenteric vein and hepatic vein will be collected under the procedure of TIPS.
10140555|NCT04195698|Experimental|Upadacitinib|Participants will be administered with upadacitinib once daily (QD)
10140556|NCT04195737|Experimental|Root coverage with ossix volumax collagen matrix|Evaluation of root coverage achieved by collagen matrix in conjunction with coronally advanced flap in patients with multiple gingival recession.
9669247|NCT03596242|Active Comparator|Usual Care Plus Standard Blood Pressure Monitoring|Will receive standard blood pressure care and education, as well as a blood pressure cuff at their clinic visits
9669248|NCT03583554|Placebo Comparator|Placebo, then AV-101 720mg, then AV-101 1440mg|Participants first received oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules).
9669249|NCT03583554|Experimental|AV-101 720mg, then AV-101 1440mg, then placebo|Participants first received oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo.
10140557|NCT04195737|Active Comparator|Root coverage with connective tissue graft|Evaluation of root coverage achieved by connective tissue graft in conjunction with coronally advanced flap in patients with multiple gingival recession
10184596|NCT03753659|Experimental|Pembrolizumab with local ablation|"Pembrolizumab 200mg IV Q3W on day 1 of cycle 1 and 2~Radio Frequency Ablation (RFA) / Microwave Ablation (MWA) / brachytherapy or combination of TACE with RFA, MWA or brachytherapy will be performed on day 1 of cycle 3~Pembrolizumab 200mg IV administration 2 days after local ablation~Pembrolizumab 200mg IV Q3W for up to 12 months total treatment duration"
10184597|NCT03753633|Experimental|Speech therapy Group|25 patients will be treated with speech therapy, once a week, during 40 minutes for 12 weeks. Oropharyngeal exercises will be performed under the supervision of a speech therapist. Patients will perform the oropharyngeal exercises at home every day.
10184598|NCT03753633|Sham Comparator|Control Group|25 patients will perform inspiratory and expiratory exercises recruiting diaphragmatic muscle.
10184599|NCT03753620|Experimental|Music listening|The participants listens to their favorite emotional musical extracts. While listening, their Hemodynamic activity (with fMRI), their cerebral electric activity (with EEG) and their peripheral physiological parameters are recorded simultaneously
10184600|NCT03753594||H group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.5% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests at 5 min were assessed before the block and at 5-min intervals till 30 min after the block.
10184601|NCT03753594||L group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.25% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests were assessed at 5 min before the block and at 5-min intervals till 30 min after the block.
10184602|NCT03753581|Experimental|Care protocol plus microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.~Intervention with microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer."
10184603|NCT03753581|Placebo Comparator|Care protocol plus placebo microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.~Placebo microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer previously handled that do not emit current."
10184604|NCT03753568|Experimental|Study group|The participants use either direct oral anticoagulants or oral diabetic medication.
10184605|NCT03753542|Experimental|Intervention|The Intervention group will received multimedia education, booklet and weekly tele-nursing follow-up about chemotherapy and side effects management
10184606|NCT03753542|No Intervention|Control|The Control group will receive routine care
10184607|NCT03753529|Experimental|deep friction massage group|
10184608|NCT03753529|Experimental|pressure release group|
10184609|NCT03753529|Experimental|control group|
10184610|NCT03753516|Active Comparator|Laparoscopic - Vaginal Cuff Closure|
10184611|NCT03753516|Active Comparator|Vaginal - Vaginal Cuff Closure|
10184612|NCT03753503|Experimental|PD-TR|"Intervention:~exercise, dose: 8-week HIIT program (three times a week) & conventional physical therapy"
10184613|NCT03753503|Active Comparator|PD-NTR|conventional physical therapy
10184614|NCT03753503|No Intervention|Healthy controls|healthy controls without any kind of therapy
10184615|NCT03753477|Experimental|Test Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
10184616|NCT03753477|Active Comparator|Reference Drug|Sevikar and Crestor
10184617|NCT03753464||Peri-implantitis|Patients undergoing surgical treatment for peri-implantitis. Gingival and blood samples will be collected during the treatment for peri-implantitis.
10184618|NCT03753464||Healthy|Healthy patients undergoing treatment for either wisdom tooth extraction or gingivectomy. Gingival and blood samples will be collected during either wisdom tooth extraction or gingivectomy.
10184619|NCT03753451|No Intervention|Group 1|20 patients without periodontal disease and coronary artery disease
10184620|NCT03753451|No Intervention|Group 2|20 patients without periodontal disease and with coronary artery disease
10184621|NCT03753451|Active Comparator|Group 3|20 patients with periodontal disease and with coronary artery disease received treatment of periodontal disease
10184622|NCT03753451|Active Comparator|Group 4|20 patients with periodontal disease and without coronary artery disease received treatment of periodontal disease
10184623|NCT03753438||Intragastric Balloon|Intragastric Balloon will be placed for 6 months
10184624|NCT03753425||PEG4L, four liters polyethylene glycol|PEG4L, four liters polyethylene glycol
10184625|NCT03753425||PEG2L, two liters polyethylene glycol with ascorbic acid|PEG2L, two liters polyethylene glycol with ascorbic acid
10184626|NCT03753425||Pico, sodium picosulfate|Pico, sodium picosulfate
10184627|NCT03753425||NaP, sodium phosphate|NaP, sodium phosphate
10140558|NCT04195711||blinq screened|Patients screened by new birefringent screener
10140559|NCT04195516|Experimental|Health Promotion Group|Experimental group will be applied Health Promotion Model Basic Health Promotion Program. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.
10140560|NCT04195516|No Intervention|Control Group|The control group will be given educational brochures to develop healthy eating and physical activity behaviors.
10140561|NCT04195659||Top Surgery|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, and who are undergoing mastectomy and chest masculinization in one of three plastic surgery practices in Chicago.
10140562|NCT04195659||Control|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, were seen in a gender development clinic in Chicago, and who are not planning to undergo top surgery. Controls will be matched with top surgery patients on age and number of months of testosterone.
10140563|NCT04195542||women in obstetric ward in Rennes CHU|women in obstetric ward in Rennes CHU
10140564|NCT04195542||CHU professionals|All CHU professionals contacted via their email address
10140565|NCT04195841|Experimental|Test group|Two horizontal incisions placed 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles.
10140566|NCT04195841|Experimental|Control group|Sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth
10140567|NCT04195672||Children under 3 years-old intubated/sedated in intensive care|NIPE and CBS ware measured for each included patient
10140568|NCT04195490|Other|children with disorders of sex development|children with disorders of sex development needing feminizing genitoplasty
10140569|NCT04195412|Experimental|tDCS|Bihemispheric tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After stimulation, individual and intensive upper limb rehabilitation will be performed.
10140570|NCT04195412|Sham Comparator|Control|Bihemispheric sham tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After sham stimulation, individual and intensive upper limb rehabilitation will be performed.
10140571|NCT04195464|Experimental|DN|
10140572|NCT04195464|Sham Comparator|Sham-DN|
10140573|NCT04195464|No Intervention|Control|
10140574|NCT04195451|Experimental|Live Video-Supervised Exercise Intervention Arm|Patients randomized to exercise intervention at baseline will participate in live-video-supervised exercise sessions x3/week for 3 months, and then will follow a maintenance regimen for 6 months. During maintenance, patients will continue live-video-supervised exercise sessions, only x1/week, and will be instructed to exercise on their own x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
10140575|NCT04195451|Experimental|Live-Video-Supervised Exercise Control Arm|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the 3-month exercise intervention of live-video-supervised exercise sessions x3/week for 3 months.
10140576|NCT04195386|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
10140577|NCT04195386|Active Comparator|Resin-Modified Glass ionomer Cement|Single placement of Resin-Modified Glass ionomer Cement on atypical cavities.
10140578|NCT04195438|Other|Intervention Arm|CO and ABG Testing Arm
10140579|NCT04195477|Experimental|vDPP|Participants will take part in a 4 week study to develop the program.
10140580|NCT04195646|Experimental|EndoVigilant CAD Software assisted Colonoscopy Procedure|The gastroenterologist performing the colonoscopy procedure will be able to observe a standard colonoscopy video on the primary monitor and video augmented by EndoVigilant CAD software on the second monitor. The gastroenterologist will primarily rely on the second monitor but the standard procedure monitor will be always operational and available for maneuvers such as fast insertion, polypectomy etc.
10140581|NCT04195867|Experimental|Salmeterol|Subjects receive a 3-day treatment and collect urine from 2 days before first administration to 24 hours post-administration.
10140582|NCT04195360||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
10140583|NCT04195360||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
10140584|NCT04195373|Experimental|TMV-018 + 5-FC|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
10140585|NCT04195373|Experimental|TMV-018 + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
10140586|NCT04195373|Experimental|TMV-018 + 5-FC + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
10140587|NCT04195295|Experimental|periosteal membrane and egg shell graft|Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material and periosteal pedicle as barrier membrane.
10140588|NCT04195295|Experimental|only egg shell graft|Only Egg shell derived nano hydroxyapatite (EnHA) as graft material.
10140589|NCT04195295|Active Comparator|open flap debridement|open flap debridement procedure only.
10140590|NCT04195282|Active Comparator|Plasma exchange group|10 patients will receive conventional treatment plus plasma exchange
10140591|NCT04195282|Experimental|RL-1 Novel Human-derived Bio-artificial Liver treatment group|10 patients will receive conventional treatment plus RL-1 Novel Human-derived Bio-artificial Liver treatment
10184628|NCT03753425||MPS, sodium, magnesium and potassium sulphates|MPS, sodium, magnesium and potassium sulphates
10140592|NCT04195139|Experimental|Nivolumab and Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive Nivolumab with concurrent adjuvant temozolomide treatment
10140593|NCT04195139|Active Comparator|Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive the standard treatment of adjuvant temozolomide treatment
10140594|NCT04195113||Direct Oral Anticoagulants (DOACs)|In this study, DOACs include apixaban, dabigatran, edoxaban and/or rivaroxaban.
10140595|NCT04195113||Vitamin K Antagonist (VKA)|In this study, the VKA is warfarin.
10140596|NCT04195165|Experimental|SIT|Subject will be asked to take <3,000 steps for two intervention days prior to an oral glucose tolerance test on the third day.
10140597|NCT04195165|Experimental|SIT+EX|Subject will be asked to take <3,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
10140598|NCT04195165|Experimental|ACTIVE+EX|Subject will be asked to take >10,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
10140599|NCT04195152||Difficult intubation group|An intubation is called difficult if a normally trained anesthesiologist needs more than 3 attempts or more than 10 min for a successful endotracheal intubation.
10140600|NCT04195152||Non difficult intubation group|An intubation is called non difficult if a normally trained anesthesiologist needs only one attempt for a successful endotracheal intubation.
10140601|NCT04195334|Experimental|IMN and union|putting an intramedullary nail in femoral shaft fractures and finding a relation between the nail diameter to femoral canal diameter and how this will affect healing or predict union
10140602|NCT04195191|Placebo Comparator|Placebo|The usual practice by community pharmacies
10140603|NCT04195191|Experimental|ANM|This is an intervention based on pharmaceutical-patient communication through an open and fluid conversation, aimed at evaluating the patient's relationship with their new prescription, detecting possible problems, concerns and false beliefs or visual expectations.
10140604|NCT04195243|Experimental|Dapagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal"
10140605|NCT04195243|Experimental|Empagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal"
10140606|NCT04195243|Placebo Comparator|Placebo|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal"
10140607|NCT04195100|Active Comparator|Low dose pilocarpine|low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day
10140608|NCT04195100|Active Comparator|High dose pilocarpine|high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
10140609|NCT04195269|Experimental|Pure Green Sublingual Tablet - Daily|Subjects will take 2 tablets daily, one in the morning and one in the evening, and are able to take up to 2 additional tablets per day as needed for pain.
10140610|NCT04195321|Active Comparator|norepinephrine group|patients will receive NE infusion at a starting of rate of 1 ml/min of 8 mcg/ml solution (prepared by diluting 4 mg NE in 500 ml normal)
10140611|NCT04195321|Active Comparator|phenylephrine|patients will receive PE infusion at a starting rate of 1 ml/min of 100 mcg/ml solution (prepared by diluting 10 mg of PE in 100 ml normal saline)
10140612|NCT04195048||Cancer patients with acute ischemic stroke|Eighty patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke
10140613|NCT04195048||Control patients with acute ischemic stroke without cancer|Eighty patients with acute ischemic stroke without cancer
10140614|NCT04195308|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
10140615|NCT04195308|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
10140616|NCT04195087||Non-hypotension|Patients with a mean arterial pressure reduction of less than 20% and/or systolic arterial pressure above 80 mmHg after spinal anesthesia.
10140617|NCT04195087||Hypotension|Patients with a 20% reduction in mean arterial pressure and/or systolic arterial pressure below 80 mmHg after spinal anesthesia.
10140618|NCT04195126|No Intervention|Control group|Patients are treated according to most recent guidelines in burn trauma and corresponding emergency and intensive therapy. All patients included are treated with early continous veno-venal renal replacement therapy.
10140619|NCT04195126|Active Comparator|Treatment group|Besides treatment strategies of the control group, the investigators start early haemadsorption treatment right after patient admission (and inclusion).
10140620|NCT04195022|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
10140621|NCT04195022|Active Comparator|Bulk fill resin composite|Single placement of Bulk fill resin composite on atypical cavities.
10140622|NCT04194983|Experimental|Fish oils and dairy fats|
10140623|NCT04194983|Placebo Comparator|Fish oils and plant fats|
10140624|NCT04194931|Experimental|Mixed BCMA/CD19 CAR-T Transfer|Subjects with BCMA/CD19+ multiple myeloma will be infused with CD19-targeting CAR T Cells and BCMA-targeting CAR T Cells in one time or in parts
10140625|NCT04195074|Experimental|ETV group|100 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
10140626|NCT04195074|Experimental|TDF group|100 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
10140627|NCT04195074|Experimental|TAF group|100 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
10140628|NCT04194827|Experimental|Concentration guided dose reducion|Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.
10184629|NCT03753399|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
10140629|NCT04194827|Active Comparator|Disease activity quided dose reduction|Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab
10140630|NCT04194918|Experimental|Prevention (Flexiquit+, text message, handout)|Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
10140631|NCT04194762|Experimental|treadmill training|Three training sessions per week for two months of treadmill. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
10140632|NCT04194762|Active Comparator|Cycling|Three training sessions per week for two months of cycling. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
10140633|NCT04194879||Cancer|Case subjects (at least 50) will be men and women age 40-74 who are recently diagnosed, through colonoscopy, with different stages of colorectal cancer and have not yet had surgical intervention.
10140634|NCT04194879||Negative|Approximately 250 prospectively enrolled subjects will be men and women age 40-74 who are at average risk of developing colorectal cancer and eligible for colonoscopy. About 150 Control subjects will be enrolled prospectively, who have no colorectal neoplasia detected on colonoscopy, including cancer, advanced adenoma, sessile serrated lesions and small, non-advanced adenoma.
10140635|NCT04194749|Experimental|Digital Media Therapy|The digital media based group will receive a modified post immobilization protocol. This will include giving the patients a Universal Serial Bus (USB) drive loaded with a 12 week physical therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health & Science University website.
10140636|NCT04194749|Active Comparator|Traditional Therapy|The traditional group will have clinic-based physical therapy protocol.
10140637|NCT04194957|Experimental|Wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
10140638|NCT04194957|Experimental|heterozygous carrier of c.1236G>A or c.2846A>T DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for c.1236G>A or c.2846A>T of these SNPs
10140639|NCT04194957|Experimental|Homozygous or compound heterozygous carrier of DPYD variants|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be homozygous or compound heterozygous for these SNPs
10140640|NCT04194892|Experimental|Pegilodecakin Vial|Pegilodecakin administered subcutaneously (SQ) in one of two study periods.
10140641|NCT04194892|Experimental|Pegilodecakin Pre-filled syringe (PFS)|Pegilodecakin administered SQ in one of two study periods.
10140642|NCT04194853|Experimental|EMG Biofeedback assisted Quadriceps exercises.|Hot Pack will be applied before session for general relaxation for 10 minutes. Knee isometric exercises will be performed via an EMG Biofeedback device; patients in the EMG BF group will receive visual and auditory feedback.Knee isometrics will be performed with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets) Session will be performed thrice a week for six weeks.
10140643|NCT04194853|Active Comparator|Quadriceps exercises without EMG Biofeedback|Hot Pack will be applied before session for general relaxation 10 minutes. In the control group, the active electrode will not be connected, so subjects will not receive any feedback from the device. Knee isometrics perform with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets)Session will be performed thrice a week for six weeks.
10140644|NCT04194866|Other|Day group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group ( 8:00-12:00)
10140645|NCT04194866|Other|Night group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
10140646|NCT04194736|Experimental|Children|Minor patients hospitalized in pediatric intensive care unit having a percutaneous central venous catheter.
10140647|NCT04194697|Experimental|Exercise group|Participants will conduct exercise programs provided by the app 3 times a week for 12 weeks. Except for the exercise program provided by the app, the amount of activity and exercise in daily life will not change from before the study.
10140648|NCT04194697|Other|Non-exercise group|Participants will not change the amount of activity or exercise in daily life from before the study.
9528285|NCT03212209|Experimental|CPAP with Sensawake by Fisher and Paykel|Four consecutive weeks with CPAP Sensawake treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
10140649|NCT04194996||Operative|"Inclusion criteria:~≥18 years old at time of treatment~Diagnosis of cervical deformity- must meet one or more of the following criteria:~C2-C7 sagittal kyphosis (Cobb > 15o)~T1S-CL > 35o~Segmental cervical kyphosis > 10o between any 2 vertebra between C2-T1 or > 15o across any 3 vertebra between C2-T1~Cervical scoliosis > 10o (Cobb angle must include end vertebra within the cervical spine)~C2-C7 SVA > 4cm~McGregor's slope > 20 degrees or CBVA > 25 degrees~Plan for surgical correction of cervical deformity in the next 6 months"
10140650|NCT04194632|Experimental|Single Arm|All patients will undergo hemodynamic measurements at baseline, with the intervention, and post-intervention thus serving as their own control.
10140651|NCT04194710|Active Comparator|Arthroscopic Resection|43 patients will be assigned to this arm. This is the standard technique to treat lateral epicondylitis. After randomization, patients will be informed and the surgery will be scheduled.
10140652|NCT04194710|Experimental|Cytokine rich serum injection|43 patients will be assigned to this arm. After randomization, patients will be informed and the first injection of serum rich cytokines will be scheduled. After 15 days, they will be injected again with serum rich cytokines.
10140653|NCT04194905|Experimental|Levonorgestrel Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
10140654|NCT04194905|Active Comparator|Levonorgestrel Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
10140655|NCT04194658|Active Comparator|Case group|Case group will receive pretreatment letrozole 12.5 mg for 2 days before administration of misoprostol in a dosage according to ACOG guidelines based on gestational age.
10140656|NCT04194658|No Intervention|Control group|Control group will receive only misoprostol in a dosage according to ACOG guidelines based on gestational age.
10140657|NCT04195035|Experimental|Air-Q intubating laryngeal airway mask|"Where Air-Q intubating laryngeal airway will be used for ventilation & intubation through fiberoptic bronchoscope.~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Air-Q will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2were recorded 5 minutes after device insertion.~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
10140658|NCT04195035|Experimental|Ambu-Aura intubating laryngeal mask|"Ambu-Aura intubating laryngeal mask will be used for ventilation & intubation through fiberoptic bronchscope.~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Ambu-Aura laryngeal mask will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2 will be recorded 5 minutes after device insertion.~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
10140659|NCT04194684|Experimental|Assigned Interventions|Nab-paclitaxel
10140660|NCT04194645|Experimental|BI 474121|
10140661|NCT04194645|Placebo Comparator|Placebo|
10140662|NCT04194970|Experimental|Group I (monitoring with live-feedback system)|MarWAS is a product that can monitor the pressure under the foot and provide live feedback (if this option activated) to the user in case of exceeding the specified limits. Its components are insole with pressure sensors and mobile applications (IOS, Android). Post-operative patients (osteochondral lesion of the talus) will be monitored with the MarWAS product in case live feedback is turned on. We aimed to ensure the compliance of patients to specified weight bearing limits. We will follow up this grup for 6 weeks periods with MarWAS. Pre-op. and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. Also we will monitor the compliance success of patients with MarWAS during 6 week. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate.
10140663|NCT04194970|Active Comparator|Group II (monitoring without live feedback)|"The post-operative patients (osteochondral lesion of talus), follow-up with product in live-feedback closed condition.~After surgery, we will educate the patients about weight bearing protocol on post-op first day and post op 3 week. The protocol is  first 3 weeks, %0 body weight bearing (BWB), second 3 weeks between %10-%20 BWB. Patients' compliance to BWB protocol will be monitored daily with the MarWAS product in case live-feedback is turned off. Pre-op and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate."
10140664|NCT04194502|Other|Pre-operative and intra-operative TEE|All patients enrolled in the study will undergo a pre-op research TEE and a intra-op clinical transesophageal echo.
10140665|NCT04194567|Experimental|Black Ragi|During one week of the study, participants are to consume pancakes made from the dark variety of ragi.
10140666|NCT04194567|Experimental|White Ragi|During the second week of the study, participants are to consume pancakes made from the white variety of ragi
10140667|NCT04194489|Experimental|FMF Connect Intervention|
10140668|NCT04194463|Experimental|ChemoFit exercise prehabilitation intervention|Exercise intervention consisting of walking and increasing daily step count. This is monitored by wearing a pedometer device. Other part of intervention are 5 simple strengthening exercises.
10140669|NCT04194606|Active Comparator|Forearm radial access|Patients who undergo coronary angiography or intervention by forearm radial artery access
10140670|NCT04194606|Experimental|Distal radial access|Patients who undergo coronary angiography or intervention by accessing the distal radial artery in the area of the anatomical snuff-box
10140671|NCT04194723|Experimental|Antireflux Mucosectomy|Antireflux mucosectomy targeted at resection of gastric cardia muocsa to induce fibrosis and improve on the flap value over the gastroesophageal junction
10140672|NCT04194580|Experimental|Physical activity|In the program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors
10140673|NCT04194580|No Intervention|Physical activity control|This group will not participate in the intervention
10140674|NCT04194801|Experimental|Fisogatinib in combination with CS1001|
10140675|NCT04194515||YH1 group|
10140676|NCT04194515||Metformin group|
10140677|NCT04194593||Glioma|FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)
10140678|NCT04194333||Standard Fluoroscopy Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and standard fluoroscopy using the C-arm under general anesthesia.
10140679|NCT04194333||Cone Beam CT Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
10140680|NCT04194320|Placebo Comparator|"Group I Placebo"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 ml 0.9% normal saline.
10140681|NCT04194320|Active Comparator|"Group II Nalbuphine "|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 10 mg nalbuphine hydrochloride (completed to 2 ml with 0.9% normal saline).
10140682|NCT04194320|Active Comparator|"Group III Dexamethasone"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 mL dexamethasone 0.4% (8 mg).
9669250|NCT03583554|Experimental|AV-101 1440mg, then placebo, then AV-101 720mg|Participants first received oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules).
9669251|NCT03572543|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
9669252|NCT03572543|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
10140683|NCT04194281|Experimental|Action Observation Therapy [AOT]|
10140684|NCT04194541|Experimental|Treatment Group|Participants will be provided a kit containing 3 dressings: Cutimed Sorbact Hydroactive B, Cutimed Siltec, and Sorbion Sana multi-star. Participant can use their dressing of choice and can change their dressings as needed for 6 consecutive weeks.
10140685|NCT04194242|Experimental|HEC96719 tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240 mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
10140686|NCT04194242|Placebo Comparator|placebo tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
10140687|NCT04194385|Active Comparator|Upper trunk block|In the supraclavicular region, UTB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
10140688|NCT04194385|Active Comparator|Costoclavicular brachial plexus block|In the infraclavicular region, CCBPB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
10140689|NCT04194359|Experimental|Sintilimab + XELOX + Bevacizumab|Sintilimab + XELOX + Bevacizumab
10140690|NCT04194359|Active Comparator|XELOX + Bevacizumab|XELOX + Bevacizumab
10140691|NCT04194424|Experimental|Multidisciplinary program|Multidisciplinary weight loss program
10140692|NCT04194424|Other|Control|Standard care
10140693|NCT04194372||Metabolic Patient|"Patients with a metabolic desease, defined as~Metabolic Syndrom~Diabetic~Obese"
10140694|NCT04194268|Experimental|Interventional arm|Carbon Ion Radiation 12 x 4 Gy (RBE) within 2 weeks
10140695|NCT04194294|Active Comparator|Liocaine|Group Lid
10140696|NCT04194294|Active Comparator|Na CL 0.9%|group C
10140697|NCT04194125|Experimental|177Lu-DOTATOC combined with CAPTEM|"The therapy will include 4 courses (14 days per one) with 8-week intervals;~177Lu-DOTATOC in doses from 5,55GBq up to 7,4 GBq will be administered i.v. up to four times at 10th day;~Concomitant amino acids will be given with each administration;~Capecitabine will be administrated for 14 days (twice a day) followed by Temozolomide at 10-14th days in each therapy sessions."
10140698|NCT04194086|Experimental|posaconazole as antifungal prophylaxis|
10140699|NCT04194099|Experimental|20 Hz rTMS (Brain) + Anode tsDCS (Spinal)|"Brain:~Train pulse: 2 sec~Inter-train: 28 sec~Total time: 1200 sec~Spinal:~Continuous direct current (DC): 1200 sec"
10140700|NCT04194099|Experimental|20 Hz rTMS (Brain) + 20 Hz current square-wave pulses (Spinal)|"Brain and spinal:~Train pulse: 2 sec~Inter-train: 28 sec~Total time: 1200 sec"
10140701|NCT04194099|Experimental|iTBS rTMS (Brain) + Anode tsDCS (Spinal)|"Brain:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 190 sec~Spinal:~Continuous direct current (DC): 190 sec"
10140702|NCT04194099|Experimental|iTBS rTMS (Brain) + iTBS (Spinal)|"Brain and spinal:~Train pulse: 2 sec~Inter-train: 8 sec~Total time: 190 sec"
10140703|NCT04194099|Sham Comparator|sham (no stimulation on brain nor spinal)|Sham stimulation.
10140704|NCT04194216|Active Comparator|Treatment arm A|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."
10140705|NCT04194216|Active Comparator|Treatment arm B|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg every 4 hours or clindamycin 150mg every 6 hours, for a duration of three days."
10140706|NCT04194034|Experimental|TG6002 and flucytosine (5-FC) combination|
10184630|NCT03753399|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
10184631|NCT03753399|No Intervention|Usual care|Chemotherapy without acupuncture
10184632|NCT03753386|Experimental|Healthy subjects|Subjects not presenting any pulmonary pathology that will follow the intervention Oxygen therapy simulation.
10184633|NCT03753360|Other|Intervention Group|internet-based mindfulness meditation program
10184634|NCT03753360|Other|Active Control Group|relaxing music
10140707|NCT04194138||Operative|"A. Multicenter, prospective, nonrandomized analysis of operatively treated complex ASD patients meeting the following Inclusion Criteria~18 years of age or greater at the time of treatment~Diagnosis of adult congenital, degenerative, idiopathic or iatrogenic spinal deformity~Full body EOS radiographic assessment (sagittal and coronal visualization from skull to foot)~Complex patients are defined as and meeting any one of the subsequent criteria:~a. Radiographic criteria: i. PI-LL ≥ 25 degrees ii. TPA ≥ 30 degrees iii. SVA>15cm iv. Thoracic scoliosis ≥ 70 degrees v. Thoracolumbar/lumbar scoliosis ≥ 50 degrees vi. Global coronal malalignment >7cm b. Procedural criteria: i. Posterior spinal fusion > 12 levels ii. 3 column osteotomy or ACR c. Geriatric criteria: i. Age >65 years and minimum 7 levels of spinal instrumentation during surgery"
10140708|NCT04194255|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
10140709|NCT04194255|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
10140710|NCT04194255|Experimental|ferrous fumarate + 15 g FOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g FOS
10140711|NCT04194255|Experimental|ferrous fumarate + 15 g acacia gum|labelled iron as ferrous fumarate + prebiotics in the form of 15 g acacia gum
10140712|NCT04194177|Experimental|protective|
10140713|NCT04194177|Active Comparator|conventional|
10140714|NCT04193930|Other|Soft ovarian stimulation protocol|
10140715|NCT04193930|Other|conventional ovarian stimulation protocol|
10140716|NCT04193839||Paper Order Entry cohort|Patients admitted to the NICU during the pre-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the pre-intervention period will be handled with the paper order entry
10140717|NCT04193839||CPOE + BCMA cohort|Patients admitted to the NICU during the post-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the post-intervention period will be handled with the Computerized Provider Order Entry + Bar Code Medication Administration (BCMA)
10140718|NCT04193826|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the Conformal LAAC device will be performed according to the device Instructions for Use, based on ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
10140719|NCT04193878|Placebo Comparator|Placebo|4 ml aerosolized 0.9% saline every 12 hours x 10 doses
10140720|NCT04193878|Active Comparator|Intervention|aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
10140721|NCT04193891||Diet Group|Participants choosing to newly initiate the modified Atkins diet, a high fat low carb diet, for improved epilepsy control.
10140722|NCT04193891||Control Group|Participants not choosing to initiate dietary therapy for epilepsy. The participants in the control group will continue with the treatment regimen they have chosen together with their physician.
10140723|NCT04193813||POAF|
10140724|NCT04193813||Non POAF|
10140725|NCT04193774|Placebo Comparator|Drop of artificial tears|
10140726|NCT04193774|Active Comparator|Drop op anesthetic|
10140727|NCT04193982|Experimental|Saraglitazar|Patients will receive Saraglitazar 4 mg once daily for 6 months
10140728|NCT04193982|Experimental|Vitamin E|Patients will receive Vitamin E 400mg twice daily for 6 months
10140729|NCT04193982|Experimental|Combination|Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months
10140730|NCT04193982|Active Comparator|Lifestyle|Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months
9694662|NCT04786678|Experimental|All participants|All participants will have a baseline before all participants undergo intervention. The purpose is to pilot the intervention to establish possible effects, as well as to determine if there are any usability or other issues.
10140731|NCT04193852|Experimental|Dienogest and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
10140732|NCT04193852|Active Comparator|Dienogest and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
10140733|NCT04194112|Other|NMIBC patients|Patients with primary or recurrent NMIBC for whom complete TURBT was done.
10184635|NCT03753347|Experimental|influenza vaccine recipients|Participants of an earlier clinical trial (TITRE I) to receive one dose of the 2018-19 quadrivalent inactivated influenza vaccine
10184636|NCT03753321|Experimental|Whey protein|Whey protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
10184637|NCT03753321|Experimental|Soy protein|Soy protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
10184638|NCT03753321|Placebo Comparator|Placebo (maltodextrin)|Isoenergetic, maltodextrin (7 day pre-loading phase and 3 day training phase)
10184639|NCT03753308||1a, HBV patients / no scheduled biopsy|"Intervention : Blood Sampling~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral"
10184640|NCT03753308||1b, HBV patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral~Patient with a liver biopsy indication as part of the treatment within 3 months."
10140734|NCT04193995|Experimental|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday and fasting is terminated at 0800 on Monday and Thursday.
10140735|NCT04193904|Experimental|MRx0518 with hypofractionated preoperative radiation|Subjects will take one capsule of MRx0518 twice daily from one week prior to radiation therapy until surgical resection (6 to 9 weeks approx.) Radiation therapy will be delivered as 30Gy/10 fractions over 2 weeks.
10140736|NCT04193761|Active Comparator|Control|
10140737|NCT04193761|Active Comparator|Chronic hepatitis|
10140738|NCT04193761|Active Comparator|Cirrhosis|
10140739|NCT04193761|Active Comparator|Hepatocellular carcinoma|
10140740|NCT04193722|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy consists of 30-40 treatment sessions (1 session per day during 5 days per week). During the hyperbaric oxygen (HBO) sessions the pressure will be raised to 2.4 atmospheres absolute in a hyperbaric chamber and patients breath in 100% oxygen during 4 times 20 minutes.
10140741|NCT04193722|No Intervention|Usual care|Usual care may consist of physiotherapy, analgetics, edema therapy
10140742|NCT04193631|Experimental|Pure Green Tablet|A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).
10140743|NCT04193579|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
10140744|NCT04193579|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
10140745|NCT04193618|Experimental|Conservative surgery for placenta accretta|
10140746|NCT04193800||Rotational paramedic pilot group|
10140747|NCT04193800||Paramedic control group|
10140748|NCT04193592|Experimental|Oral Pirfenidone 2403 mg per day|Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day. Pirfenidone will be supplied in 267 mg capsules.
10140749|NCT04193969|Experimental|Radiculopathy due to nerve root compression|"Participants with radicular leg pain due to lumbar disc herniation or to foraminal- or recess stenosis.~Baseline assessments of pain intensities are performed through questionnaires prior to protocol. Data regarding initial pain, function, age, gender, pain-duration, weight and height is retrieved from the clinical registry SpineData.~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit in the treatment program. The protocol is repeated at the last visit in the treatment program."
10140750|NCT04193969|Experimental|Healthy controls|"Healthy controls Healthy age and gender-matched controls. Gender, weight and height are registered on questionnaires prior to protocol.~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit. The tests are repeated at the next visit. The interval between the two sessions will be determined by the averaged interval between tests in the patient group."
10140751|NCT04193670|Experimental|Atopic dermatitis classical form|15 patients
10140752|NCT04193670|Experimental|Atopic dermatitis with atopic prurigo type|10 patients
10140753|NCT04193696|Experimental|radiotherapy plus PD-1|
10140754|NCT04193735||CIPO (case)|MRI scan of gastrointestinal content and activity
10140755|NCT04193735||Chronic constipation (control)|MRI scan of gastrointestinal content and activity
9528286|NCT03212209|Active Comparator|CPAP fixed pressure|Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
10140756|NCT04193657||Chemotherapy|30 participants starting chemotherapy
10140757|NCT04193657||Abiraterone|20 participants starting Abiraterone
10140758|NCT04193657||Enzalutamide|20 participants starting Enzalutamide
10140759|NCT04193657||Radium-223|20 participants starting Radium-223
10140760|NCT04193709|No Intervention|Measure symptomatic indices of autonomic dysreflexia|The purpose of this arm is to systematically measure symptomatic indices of autonomic nervous system activation and corresponding cardiovascular changes in persons with spinal cord injuries during bladder filling and bowel stimulation.
10140761|NCT04193709|Experimental|Cardiovascular spinal cord epidural stimulation|The purpose of this arm is to use spinal cord epidural stimulation for maintenance of blood pressure and heart rate in the lab during cystometry (bladder filling) and anorectal filling (bowel distension) and in the at-home setting for maintenance of normative blood pressure and heart rate that can be triggered from bladder filling and during bowel evacuation.
10140762|NCT04194073|Experimental|Pulse oximeter calibration population|All subjects within this single arm of the study will undergo the calibration experiment as described in the Detailed Description
10140763|NCT04193358|Experimental|FERTILIS HOMME® group (group A)|Group A will receive 2 FERTILIS HOMME capsules twice daily to be taken with meals for 3 months.
10140764|NCT04193358|Placebo Comparator|Placebo group (group B)|Group B will receive 2 placebo capsules twice daily to be taken with meals for 3 months
10140765|NCT04193501|Experimental|Experimental arms|Melatonin dose: 3mg/OD
10140766|NCT04193501|Placebo Comparator|Control arms|Placebo
10140767|NCT04193488|Active Comparator|MTP block (Group MTP)|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasaggital scan, the block needle (50 mm 22 Gauge will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
10140768|NCT04193488|Active Comparator|ESP block (Group ESP)|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
10140769|NCT04193488|Active Comparator|no block (Group C)|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
10140770|NCT04193462|Experimental|Post-partum depression- Dyadic psychotherapy|Mothers and infants will be treated with 8 weeks dyadic psychotherapy at their home using video-feedback of mother-infant interaction to discuss main issues in the mother-infant relationship.
10140771|NCT04193462|Active Comparator|Post-partum depression- Psycho-educational therapy|8 weeks of supportive therapy for the mother at her house, involving the baby. Each session will include different aspects of psycho-education regarding development of the baby.
10140772|NCT04193462|No Intervention|Control- Healthy mothers and their babies|No intervention for 8 weeks.
10140773|NCT04193553|Experimental|Lenvatinib + Best Supportive Care|
10140774|NCT04193553|Placebo Comparator|Placebo + Best Supportive Care|
10140775|NCT04193319|Other|Single arm|
10140776|NCT04193566|Active Comparator|Dapagliflozin|"Patients in the active arm will be treated with dapagliflozin 50 mg once on site for visit 2 and once at home on the evening before visit 3.~Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf."
10140777|NCT04193566|Placebo Comparator|Placebo|"Patients in the placebo arm will be treated with placebo once on site for visit 2 and once at home on the evening before visit 3.~Placebo drug:~The composition equals the composition of Forxiga® - just with the active ingredient omitted. Active drug and placebo are similar in appearance and smell."
10140778|NCT04193293|Experimental|Duvelisib BID + Pembrolizumab q3w|"Stage 1: Duvelisib BID for 1 week followed by combination therapy with duvelisib BID + pembrolizumab q3w. (Cycle 1 will be 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib. Subsequent cycles will be 3 weeks .)~Stage 2: Duvelisib BID + pembrolizumab q3w in 3 week cycles."
10140779|NCT04193241|Active Comparator|Conventional purse-string suture closure|A common-place conventional method of closure of chest tube or thoracostomy wound using a Prolene 1 purse-string suture (also known as U-suturing), at the time of chest tube removal.
10140780|NCT04193241|Experimental|Suture-less occlusive-absorbent dressing closure|Unconventional method of closing chest tube or thoracostomy wounds using Occlusive adhesive-absorbent dressing material (Primapore*) application i.e. Un-reapproximated wound edges, at time of chest tube removal
10140781|NCT04193267|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
10140782|NCT04193436|Experimental|PF-06835919 with severe hepatic impairement|This arm includes participants with severe hepatic impairment who will receive a 25mg oral dose of PF-06835919
10140783|NCT04193436|Experimental|PF-06835919 with moderate hepatic impairement|This arm includes participants with moderate hepatic impairment who will receive a 25mg oral dose of PF-06835919
10140784|NCT04193436|Experimental|PF-06835919 with mild hepatic impairement|This arm includes participants with mild hepatic impairment who will receive a 25mg oral dose of PF-06835919
10140785|NCT04193436|Experimental|PF-06835919 without hepatic impairment|This arm includes participants without hepatic impairment who will receive a 25mg oral dose of PF-06835919
10140786|NCT04193449||Adult patients undergoing colonoscopy|All patients' ≥18 years of age who underwent endoscopy at Portsmouth Hospitals NHS Trust, including repeat colonoscopies performed for surveillance purposes aged ≥18 in either males or females.
10140787|NCT04193748|Active Comparator|Control group|Topical triamcinolone acetonide 0.1% available commercially (Kenacort- in orabase) has been used. Topical corticosteroid treatment has be repeated four times per day for four weeks.
10140788|NCT04193748|Experimental|Group S|Topical pomegranate seeds extract treatment has been repeated four times per day for four weeks.
10140789|NCT04193748|Experimental|Group P|Topical pomegranate peel extract treatment has been repeated four times per day for four weeks.
10140790|NCT04193540||ACE questionnaire|Every patient under mechanical ventilation (intubated or tracheotomized), with or without sedatives, able to communicate and alert (RASS -1 to +1), and not delirious (CAM-ICU negative) will be assessed by Johns Hopkins ACE questionnaire by a person not in charge of the patient.
10140791|NCT04193124||Prolonged vasospasm|Adult patients with a diagnosis of subarcnoid hemorrhage CT scan or presence of blood in the cerebrospinal fluid were incorporated. Patients with vasospasm were followed daily with transcranial doppler. Prolonged vasospasm was defined for patients who persisted with vasospasm after day 21 of cerebral bleeding.
10140792|NCT04193215|Experimental|V114|Participants will receive an intramuscular (IM) injection.
10140793|NCT04193215|Other|Control|
10140794|NCT04193228||People with distal hereditary motor neuropathy|This is a single arm, feasibility study
10140795|NCT04192981|Experimental|Concurrent GDC-0084 with Radiation|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily, with a potential de-escalation cohort to 30mg, to determine MTD in combination with whole brain radiation therapy radiation therapy to 30Gy in 10 fractions. Once MTD is determined, 12 additional patients will be treated with GDC-0084 at MTD in combination with whole brain radiation therapy.
10184641|NCT03753308||2, NASH patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~The existence of at least one element of metabolic syndrome~Steatosis detected by non-invasive tests (echo, CAP, MRI)"
10140796|NCT04193150||Reassessment Cohort|"150 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.~Intervention includes:~Extensive pulmonary and allergy assessments. Questionnaires, FeNO-measurement, Skin prick-test, Spirometry, Blood sampling, Body Plethysmography and Diffusion capacity measurement, Bronchial challenge test, Induced sputum.~Treatment optimization As per GINA and Nordic Severe Asthma Network guidelines. Treatment can either be stepped up (e.g. added biological treatment), stepped down or held constant.~Treatment is then monitored with regard to symptoms and socioeconomical parameteres such as sick leave over a 12 month period using questionnaires and official databases."
10140797|NCT04193150||Control Cohort|"400 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.~The control cohort is followed for 12 months using questionnaires and official databases with regard to disease control and socioeconomic parameteres such as sick leave."
10140798|NCT04193020||steroid only group (SG)|
10140799|NCT04193020||combined (steroid and adjuvant drug) group (CG)|
9528287|NCT03212196|Active Comparator|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
9969925|NCT01295099|Active Comparator|5-Fluorouracil|Patients with small keloidal scars to have intralesional 5FU injected
9969926|NCT01295099|Active Comparator|Radiotherapy|Large keloid scars undergo extralesional excision and radiotherapy
9969927|NCT01295099|Active Comparator|TAC|
9969928|NCT01295125|Experimental|XenMATRIX|Use of XenMATRIX mesh to repair hernia
9969929|NCT01295125|Active Comparator|Native tissue|Repair with participants native tissue
9969930|NCT01295138|Experimental|Lactulose group|Group receives 48 hours of lactulose post Caesarean section.
9969931|NCT01295138|No Intervention|Non-lactulose group|Group receives no lactulose post Caesarean section.
9969932|NCT01295151|Experimental|TNF-blocking drug|
9969933|NCT01295151|Experimental|Abatacept|
9969934|NCT01295151|Active Comparator|Rituximab|
9969935|NCT01295164|Active Comparator|Group 1|Measurement of aberrations in patients with keratoconus of grade 1
9969936|NCT01295164|Active Comparator|Group 2|patients with keratoconus of grade 2
9969937|NCT01295164|Experimental|Group 3|patients with keratoconus of grade 3
9969938|NCT01295164|Experimental|Group 4|patients with keratoconus of grade 4
9969939|NCT01295177|Placebo Comparator|vehicle cream|Intervention: Placebo cream vehicle. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream (cream with the same constitution but without insulin). The placebo cream vehicle was used for 8 weeks.
9969940|NCT01295177|Placebo Comparator|cream insulin|Intervention: insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with insulin cream (cream with the same constitution but with insulin). The insulin cream was used for 8 weeks.
9969941|NCT01295190||Propofol|Patients receiving Propofol during cardiopulmonary bypass.
9969942|NCT01295190||Sevoflurane|Patients receiving sevoflurane during cardiopulmonary bypass
9969943|NCT01295203|No Intervention|Control group|The control group were not given access to the intervention website and received no additional information.
9969944|NCT01295229|Active Comparator|Lifestyle Intervention|
9969945|NCT01295229|Active Comparator|Surgery|
9969946|NCT01295268|Active Comparator|Emu Oil|
9969947|NCT01295268|Placebo Comparator|inert oil|
9969948|NCT01295294|Experimental|tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with tranexamic acid
9969949|NCT01295294|Experimental|mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with mefenamic acid
9969950|NCT01295294|Placebo Comparator|placebo + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive placebo
9969951|NCT01295307|Experimental|Single Arm|Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available
9969952|NCT01295333|Other|conventional approach|conventional traitment
9969953|NCT01295333|Experimental|experimental approach|early and systematic traitment
9976970|NCT01356823|Experimental|30μg HPV|Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
9976971|NCT01356823|Experimental|60μg HPV|Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
9976972|NCT01356823|Experimental|90μg HPV|Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
9976973|NCT01356823|Placebo Comparator|hepatitis B vaccine|Participants in this arm would receive hepatitis B vaccine.
9976974|NCT01356836||Good-poor collateral|Patients who had good and poor collaterals formed 2 groups
9976975|NCT01356836||Good collateral, Poor collateral|
9976976|NCT01356862|Experimental|PASIREOTIDE|INTRAMUSCULAR INJECTION OF PASIREOTIDE 60 MG
9976977|NCT01356862|Placebo Comparator|PLACEBO|INTRAMUSCULAR INJECTION OF PLACEBO
9976978|NCT01356875|Experimental|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycles of hydralazine and valproic acid.
9976979|NCT01356875|Active Comparator|best supportive care (BSC)|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
9976980|NCT01356888|Active Comparator|Abbott Laboratories - Xience Prime DES|
9976981|NCT01356888|Experimental|Biotronik - Orsiro DES|
9976982|NCT01356901||Treatment naïve and pre-treated CHB patients|subanalysis with migrant and non-migrant patients
9977779|NCT01365169|Experimental|Arm I (colorectal cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
10140800|NCT04193020||bilogic therapy group (BTG)|
10140801|NCT04192838|Experimental|LVHR|Laparoscopic incisional ventral hernia repair
10140802|NCT04192838|Active Comparator|OVHR|Open incisional ventral hernia repair
10140803|NCT04192864|Experimental|Lingually based triangular flap|
10140804|NCT04192864|Active Comparator|Buccally based triangular flap|
10140805|NCT04192877||Experimental|30 healthy subjects from both genders, aged between 18 and 60 years will be screened for neurological deficits. If neurological examination will be negative markers for motion capture, analysis will be placed on the chest and shoulders and a rubber band, with 3 markers, will be placed on the forehead. The subjects will be invited to lay on a medical table and heart rate (HR) will be assessed at rest. The vagus nerve neurodynamic test (VN-NDT) will be performed by an expert and a novice, in a random order, and under ultrasound imaging (USI). Assessors will be blinded to their results. Heart rate (HR) of the subjects will be monitored and a pain drawaing tools will be used to describe and locate the symptoms induced during the test administration.
10140806|NCT04192851|Experimental|Tent Pole Grafting Technique|"Bone graft [NanoBone® granulate 0,6 mm (24% Silica / 76% Hydroxylapatite)] is mixed with the patient blood and placed to cover the screws completely, the defect is overcorrected with particulate material in anticipation of future graft resorption.~PRF membrane is prepared by:~Ten milliliters of whole venous blood will be collected in sterile glass test tubes without anticoagulant. Then the test tubes will be placed in a table centrifuge machine at 3000 revolutions per minute (rpm) for 10 minutes.After separation of PRF, the membrane is prepared compression device."
10140807|NCT04193072||Obstetric brachial plexus palsy|
10140808|NCT04193072||Healthy|
10140809|NCT04193137||Primary Aldosteronism(PA)|plasma aldosterone /renin ratio (ARR)>10 pg/μIU and plasma aldosterone concentration(PAC) post-FST≥60pg/ml；or PAC>200 pg/ml，plasma renin concentration(PRC)<2.5μIU/ml，with hypokalemia
10140810|NCT04193137||non Primary Aldosteronism|ARR<10 pg/μIU or ARR>10 pg/μIU and PAC post FST<60pg/ml
10140811|NCT04193059|Active Comparator|PANSY-1: EC-T|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+ cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of T (docetaxel 100 mg/m^2 ivgtt d1, 21 days per cycle)
10140812|NCT04193059|Experimental|PANSY-1: PCb|6 cycles of weekly PCb (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15+ carboplatin Area Under Curve (AUC)=2 ivgtt d1, d8, d15, 28 days per cycle)
10140813|NCT04193059|Active Comparator|PANSY-2: EC-TH(P)|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of TH(P) (docetaxel 100 mg/m^2 ivgtt d1 + trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). After 8 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
10140814|NCT04193059|Experimental|PANSY-2: PCbH(P)|6 cycles of weekly PCbH(P) (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15 + carboplatin AUC=2 ivgtt d1, d8, d15 + trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). Participants may also choose to receive trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy. After 6 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
10140815|NCT04192890|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
10140816|NCT04192916||MPN patients treated with DOACs|
10140817|NCT04193098|Experimental|Arm: CTL plus PD-1 inhibitor|CTL , Toripalimab Toripalimab intravenous infusion 240mg d1; CTL, 1x10^9, intravenous infusion,d14; Q3W.
10140818|NCT04193007|Experimental|molecular targeted therapy group|Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
10140819|NCT04193007|Experimental|Brain Radiotherapy and molecular targeted therapy group|Brain Radiotherapy (stereotactic radiotherapy was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain )was used for more than 3 intracranial lesions);Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
10140820|NCT04193111||Positive TMD pain screener|Patients who have ≥3 points on the TMD pain screener (0-7 range) are anticipated to have a painful TMD based on the DC/TMD and are therefore considered having a positive outcome on the TMD pain screener.
10140821|NCT04193111||Negative TMD pain screener|Patients who have <3 points on the TMD pain screener (0-7 range) are anticipated NOT to have a painful TMD based on the DC/TMD and are therefore considered having a negative outcome on the TMD pain screener.
10140822|NCT04192968||Patients|Children implanted cochlear since 3 years in uni or bilateral and followed in the pediatric otolaryngology department of Necker-Enfants Malades Hospital.
10140823|NCT04192968||Patients with disappointing language development or poor cortical responses|Children having participated in the main ImplantHear3 study and who present with disappointing language development or poor cortical responses.
10140824|NCT04193163||Patients receiving ESOP 2 stem|
10140825|NCT04192942|Experimental|intensive care management|Administration of childern with major burn in intensive care to improve out comes
10140826|NCT04192786|Experimental|Treatment Group 50 Hz|
10140827|NCT04192786|Experimental|Treatment Group 100 Hz|
10140828|NCT04192786|Active Comparator|Control Group|
10140829|NCT04192812|Experimental|GnRHa|3,75 MG LEUPROLIDE ACETATE FOR EVERY 4 WEEKS THROUGHOUT 3 MONTHS BEFORE SURGERY
10140830|NCT04192812|Placebo Comparator|no GnRHa|NO TREATMENT
10140831|NCT04192708|Experimental|DV-ICNB group|intercostal nerve block under direct vision
10140832|NCT04192708|Experimental|UG-ICNB group|intercostal nerve block under ultrasound guidance
10140833|NCT04192708|Experimental|PV group|thoracic paravertebral block under ultrasound guidance
9528288|NCT03212196|Active Comparator|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
10140834|NCT04192695|Experimental|Cytosponge|"This part of the study will have an active prospective recruitment of patients. Recruitment will involve two patient populations:~Patients with ESCC~Patients at high risk for ESCC~Following inclusion in the study, subjects will be asked to complete a behavior questionnaire, have blood collected, and undergo a Cytosponge™ procedure followed by diagnostic gastroscopy using advanced imaging with biopsies. During gastroscopy, additional tissue samples will be collected for research purposes. These samples, along with cytological specimens from the Cytosponge™, will be analyzed to assess the diagnostic accuracy of biomarkers in the diagnosis of LG-IEN, HG-IEN, and ESCC."
10140835|NCT04192617|Experimental|SM03 600 mg*2|SM03: 600 mg intravenous (IV) on week 0,2, and week 12,14; placebo: 600 mg intravenous (IV) on week 4 and16; Methotrexate: 7.5-20 mg/wk oral.
10140836|NCT04192617|Experimental|SM03 600 mg*3|SM03: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
10140837|NCT04192617|Placebo Comparator|placebo*3|placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
10140838|NCT04192773|Experimental|IV lidocaine|"1000mg/hour IV lidocaine administered for up to 30 minutes (500mg max). Patients will be continuously monitored by a nurse every 5 (±2) minutes to check specifically for vital signs (BP, HR, and RR), patient tinnitus levels, and reports of side effects.~The infusion is continued until any of the following criteria are met: 1) the patient has completed the 30-minute infusion; 2) the patient reports intolerable or concerning side effect, such as dizziness, nausea, or vomiting; 3) the patient experiences bradycardia <50 and a drop of systolic blood pressure (BP) more than 20 mmHg and diastolic pressure more than 10 mmHg during the infusion; 4) the patient reports that tinnitus is resolved, or 5) the patient wishes to stop the study.~Serum lidocaine levels will be drawn by a research nurse upon completion of MRI. The Tinnitus Handicap Inventory, the Tinnitus Functional Index, and the Visual Analog Scale will be administered after IV infusion."
10140839|NCT04192643|Experimental|TRANEXAMİC ACİD|. 1 gr tranexamic acid in 100 ml salin given in 15 minutes
10140840|NCT04192643|Placebo Comparator|NO TRANEXAMİC ACİD|100 ml salin solution
10140841|NCT04192578|Experimental|Unilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140842|NCT04192578|Experimental|Bilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140843|NCT04192578|Experimental|Unilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140844|NCT04192578|Experimental|Bilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140845|NCT04192578|Experimental|Unilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140846|NCT04192578|Experimental|Bilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140847|NCT04192578|Experimental|Unilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140848|NCT04192578|Experimental|Bilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
10140849|NCT04192539|Active Comparator|Control|
10140850|NCT04192539|Active Comparator|Inflammation|
10140851|NCT04192539|Active Comparator|Benign group|
10140852|NCT04192539|Active Comparator|Malignant group|
10140853|NCT04192500|Experimental|OVX836 - 90µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 90µg dose on Day 1.
10140854|NCT04192500|Experimental|OVX836 - 180µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180µg dose on Day 1.
10140855|NCT04192500|Active Comparator|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|Licensed quadrivalent seasonal influenza subunit vaccine for season 2019-2020. One full dose to be administered at Day 1
10140856|NCT04192565|Experimental|Robotic Endoluminal Resection|Robotic resection of mucosal lesions of the colon and rectum
10140857|NCT04192461|Experimental|tooth guided immediate implant placement group|
10140858|NCT04192682|Experimental|Anlotinib Combined With Sintilimab|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
10140859|NCT04192383||Cyberknife|
10140860|NCT04192227|Experimental|Wellness Group 1|Administered by wellness facilitator and co-facilitator.
10140861|NCT04192227|Active Comparator|Wellness Group 2|Administered by wellness facilitator and co-facilitator.
10140862|NCT04192552|Active Comparator|Apixaban|Patients currently taking apixaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
10140863|NCT04192552|Active Comparator|Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
10140864|NCT04192552|Active Comparator|Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
9528289|NCT03211871|Active Comparator|Group D|Group D received dexmedetomidine infusion 0,5 mcg/kg/h from induction in anesthesia to extubation
9969954|NCT01295346||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
9969955|NCT01295359|Experimental|Trained Group|This group will receive the usual care of the hospital and a ground walking training program associated with respiratory exercises.
10140865|NCT04192669||Anxio-depressive patients|Patients with a depressive or anxious disorder going to the Psychiatry Department of the CHU Brugmann Hospital.
10140866|NCT04192305||lung protective ventilation (LPV)|lung protective ventilation low tidal volume, minimum PEEP and higher PEEP and lung recruitment based on total lung compliance, low inspiratory oxygen concentration and CPAP during extubation without prior suctioning inside the endotracheal tube.
10140867|NCT04192305||routine lung ventilation (LV)|ventilation and adapting PEEP, LRM and oxygen only when saturation drops.
10140868|NCT04192266|Experimental|Prolonged Exposure (PE) therapy with estradiol|A 2.0 mg pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD. A single dose of estradiol 2mg or placebo will be taken at home by the study participant 5-6 hours before each of 5 PE treatment sessions (sessions 2 to 6)
10140869|NCT04192266|Placebo Comparator|Prolonged Exposure (PE) therapy with placebo|A 2.0 mg placebo pill will be given with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD.
10140870|NCT04192435|Active Comparator|Tranexamic acid|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
10140871|NCT04192435|Placebo Comparator|Placebo|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
10140872|NCT04192292|No Intervention|No Treatment|No change to participants standard care
10140873|NCT04192292|Experimental|Low dose sulphonylurea alone|Participants will be given a single dose of low dose sulphonylurea once daily for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily.
10140874|NCT04192292|Experimental|DPP4 inhibitor alone|Participants will be given a single dose of DPP4 inhibitor once daily for 14 days as a physiological stimulus. The DPP inhibitor given in this study will be sitagliption 100mg orally once daily.
10140875|NCT04192292|Experimental|Low dose sulphonylurea + DPP4 inhibitor|Participants will be given a single dose of low dose sulphonylurea once daily and a single dose of DPP4 inhibitor for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily and the DPP4 inhibitor will be sitagliptin orally100mg once daily.
10140876|NCT04192721|Experimental|Cognitive Behavioral Therapy-Based Group Counseling|The CBT-based group counseling provided to the intervention group was carried out as a group intervention with structured sessions in which various techniques and methods of CBT, having mainly educational content, were applied, including an experiential interaction process. The counseling was performed in a total of six 60- to 90-minute sessions, comprising one session per week for four groups consisting of six to 10 members each.
10140877|NCT04192721|No Intervention|Control group|No counseling was given to the control group during the study.
10140878|NCT04192253|Experimental|neo-adjuvant Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
10140879|NCT04192123|Experimental|Experimental|"All patients will receive an occlusive patch per test treatment as follows:~Treatment 1: HM242-Solution~Treatment 2: HM242-Gel~Treatment 3: HM242-Solution and HM242-Gel~Treatment 4: Irritant control (sodium lauryl sulfate (SLS))~Treatment 5: Negative control"
10140880|NCT04192513|Active Comparator|Cohort 1 DBI-001 Gel and placebo|Cohort 1 DBI-001 Gel with low dose CFU's of J. lividum and placebo
10140881|NCT04192513|Active Comparator|Cohort 2 mid dose DBI-001 Gel and placebo|Cohort 2 DBI-001 Gel with mid dose CFU's of J. lividum and placebo
10140882|NCT04192513|Active Comparator|Cohort 3 high dose DBI-001 Gel and placebo|Cohort 3 DBI-001 Gel with high dose CFU's of J. lividum. Drug: J. lividum and placebo
10140883|NCT04192162|Experimental|Group of sulfur balneotherapy and mud pack therapy|Experimental group patients underwent sulfur balneotherapy and mud pack therapy. The duration of spa therapy program was 12 days.From the blood of patients, serotonin values, parameters of complete blood count, lipid status and inflammatory markers were analyzed before and after the therapy.
10140884|NCT04192162|Active Comparator|Group of sulfur balneotherapy, mud pack therapy and exercise|Control group of patients had mud pack therapy, sulfur balneotherapy and exercise in hygienic water. This group is a hydro group. From the blood of patients we analyzed parameters od complete blood count, serotonin values, lipid status and inflammatory markers before and after the therapy.
10140885|NCT04192656|Experimental|PAP plus medication|patients treated by both PAP and medication
10140886|NCT04192656|Active Comparator|medication|patients treated by medication only
10140887|NCT04192084|Experimental|Traumatic amputations of the digits|we will perform microvascular partial toe transfer for patients with traumatic amputations of one or more digits
9969956|NCT01295359|No Intervention|Usual Care Group|This group will only receive the usual care of the hospital, including physical therapy
9969957|NCT01295372|Experimental|Zicronapine|
9969958|NCT01295372|Active Comparator|Risperidone|
9969959|NCT01295385|Experimental|healthy volunteers|
9969960|NCT01295385|Active Comparator|patients with a diabetic cardiomyopathy|
9969961|NCT01295398|Other|conventional jet-nebulizer|(particles diameter of 4-5 µm)
9969962|NCT01295398|Experimental|a jet-nebulizer adapted for infants|(particles diameter of 2-2.5 µm),
9969963|NCT01295398|Experimental|a mesh-nebulizer adapted for infants|(particles diameter of 2-2.5 µm).
9969964|NCT01295411|Other|schizophrenia PATIENTS|
9969965|NCT01295424||Single group study|
10140888|NCT04192214|Active Comparator|BC 007|The treatment arm will comprise 20 randomly allocated β1-AAb positive dilative cardiomyopathy (DCM) patients. Participants will receive a continuous 75 minute infusion of 1350 mg BC 007 at day 1. The β1-AAb status will be monitored 10 days after treatment and every month. Treatment is repeated once up to month 11 if the participant's β1-AAbs were not neutralized after 1st dosing on day 1 or reoccur.
10140889|NCT04192214|No Intervention|Control|The control arm will comprise 10 randomly allocated β1-AAb positive DCM patients. Participants will receive standard therapy but no intervention. The β1- AAb status will be monitored every month.
10140890|NCT04192149|Experimental|Patients receiving Craniotomy|Patients receiving an awake or asleep craniotomy for brain tumors and/or epilepsy will undergo a brain mapping procedure using electrical stimulation as a part of their normal care. The research procedures will duplicate this mapping with an invasive Focused Ultrasound mapping.
10140891|NCT04192149|Experimental|Epilepsy Patients|Patients undergoing long term monitoring for epilepsy will receive a non-invasive form of Focused Ultrasound stimulation which will be measured by their EEG cap and intracranial electrodes which are a part of their normal care.
10140892|NCT04192149|Experimental|Tremor Patients receiving FUS|Patients undergoing high intensity FUS treatment for tremor will be asked to wear a research provided EEG cap while undergoing a non-invasive low intensity Focused Ultrasound research procedure and changes in their tremor will be monitored.
10140893|NCT04192149|Experimental|Tremor Patients receiving DBS|Patients undergoing Deep Brain Stimulation (DBS) treatment for tremor will receive a non-invasive Focused Ultrasound stimulation observed through their newly implanted electrode.
10140894|NCT04192149|Experimental|Patients receiving Spinal Surgery|Patients receiving a spinal surgery will undergo a spinal stimulation using electrical stimulation as a part of their normal care. The research procedures will duplicate this with an invasive Focused Ultrasound stimulation.
10140895|NCT04192058|Sham Comparator|sham tDCS|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
10140896|NCT04192058|Experimental|active tDCS|The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively.
10140897|NCT04191902||1|control
10140898|NCT04191902||2|treated
10140899|NCT04192071|Active Comparator|high interactive virtual human administered nutrition module|The virtual health assistant will interactively collect nutrition information (alcohol, red meat, and processed meat intake) and report risk information back to users in visual and audio format
10140900|NCT04192071|Active Comparator|low interactive virtual human module|Complete the current intervention module that includes items assessing alcohol and meat intake.
10140901|NCT04192071|Sham Comparator|attention control module|The attention control group, will complete a related module not related to colorectal cancer or nutrition
10140902|NCT04191876|Experimental|Active|This study has only one arm. All patients enrolled will take part in the experimental arm.
10140903|NCT04191889|Experimental|TRIPLET|
10140904|NCT04191980||Patients with a MRI on a 3 Tesla (T) unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 3T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
10140905|NCT04191980||Patients with a MRI on a 1.5 Tesla unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 1.5T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
10140906|NCT04191954|Active Comparator|Fasudil eye drops (concentration 0.5 percent)|twice daily
10140907|NCT04191954|Placebo Comparator|receive artificial tears drop with the same frequency|
10140908|NCT04192279||lactate group|Lactate early guide resuscitation
10140909|NCT04192279||control group|early guide resuscitation without lactate
10140910|NCT04192032|Experimental|Preferred flavor (5% nicotine)|Preferred flavor Juul pod (5% nicotine)
10140911|NCT04192032|Active Comparator|Classic Tobacco Flavor|Control flavor (5% Classic Tobacco flavor Juul pod)
10140912|NCT04192032|Experimental|Preferred flavor with HWL|Preferred flavored Juul pod (5% nicotine) with HWL
10140913|NCT04192032|Experimental|Preferred flavor (3% nicotine)|Preferred flavored Juul pod (3% nicotine)
10140914|NCT04192032|Experimental|Preferred flavor (0% nicotine)|Preferred flavored Juul pod (0% nicotine)
10140915|NCT04192019|Experimental|Micro-dose glucagon|80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
10140916|NCT04192019|Experimental|Mini-dose glucagon|150 µg mini-dose of subcutaneous Dasiglucagon 5 min before exercise the start of exercise
10140917|NCT04192019|No Intervention|No treatment|No treatment before the start of exercise
10140918|NCT04192448|Experimental|AlcoholxAnger|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
10140919|NCT04192448|Experimental|AlcoholxControl|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
10140920|NCT04192448|Experimental|SoberxAnger|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
10140921|NCT04192448|Sham Comparator|SoberxControl|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
10140922|NCT04192331||2/3dose strategy|HER2 negative advanced breast cancer patient
10140923|NCT04192331||3/4dose strategy|HER2 negative advanced breast cancer patient
10140924|NCT04191941|Experimental|Novel CAR-T|Novel CAR-T cells will be administered intravenously
10140925|NCT04191694|Other|Control|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively)
10140926|NCT04191694|Active Comparator|Chewing Gum|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively) they will also receive chewing in the recovery room and on the post-natal ward.
10184642|NCT03753308||3, Blood samples from healthy donors|"No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research.~The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor)."
10184643|NCT03753295||Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
10184644|NCT03753295||Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
10184645|NCT03753295||Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
10184646|NCT03753282||Population 1|Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
10184647|NCT03753282||Population 2|Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
10184648|NCT03753269|Experimental|Fasudil Hydrochloride|Fasudil Hydrochoride will be delivered into culprit vessel right after the first wire passage
10184649|NCT03753269|Placebo Comparator|Placebo saline|Same volume of 0.9% saline will be delivered into culprit vessel right after the first wire passage
10184650|NCT03753256|Active Comparator|Transbond XT|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive a bonding primer (Transbond XT) The investigators will evaluate in this arm~the development of demineralization~its adverse effects after application"
10184651|NCT03753256|Experimental|Protecto®CaF2Nano|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Protecto®CaF2Nano).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
10184652|NCT03753256|Experimental|Pro Seal®|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Pro Seal®).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
10184653|NCT03753256|Experimental|Opal® Seal|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Opal®Seal).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
10184654|NCT03753230|Experimental|EEG Device 1|Participants are listening to music while their neural activity is recorded with Emotiv Epoc+
10184655|NCT03753230|Experimental|EEG Device 2|Participants are listening to music while their neural activity is recorded with g.tec
10184656|NCT03753230|Active Comparator|High density EEG|Participants are listening to music while their neural activity is recorded with high density 256 electrodes EEG Geodesic
10184657|NCT03753217|Experimental|qCON Monitor|Simultaneous measurement of BIS and qCON
10184658|NCT03753191|Experimental|People with Dementia|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. A 2mA direct current for active tDCS (current density : .057 mA/cm2) with a 20 mins stimulation period
10184659|NCT03753191|Sham Comparator|Health Control|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. After a fade in period of 10s to mimic initial tDCS peripheral skin sensations, the stimulator will be turned off in order to prevent the induction of any neuromodulatory effect.
10184660|NCT03753165|Experimental|High Intensity Interval Exercise group|Patients suffering from chronic low back pain perform 12 sessions of high intensity interval exercise (HIIE) over a period of 6 weeks at an intensity of 80% of their maximal Heart rate. In addition they also receive conventional physiotherapy in the form of hot pack or TENS
10184661|NCT03753165|No Intervention|Conventional physiotherapy|Patients suffering from chronic low back pain will receive conventional physiotherapy such as TENS and hot packs applied over appropriate areas over a period of 6 weeks
10184662|NCT03753152|Experimental|Investigational medical device|Neuramis® Deep Lidocaine
10184663|NCT03753152|Active Comparator|Comparator device|YVOIRE® Volume Plus
10184664|NCT03753139||Atrial fibrillation|Patients with atrial fibrillation as recorded by Holter
10184665|NCT03753139||Sinus rhythm|Patients with sinus rhythm as recorded by Holter
10184666|NCT03753126|Other|Cardiac CT imaging|
10184667|NCT03753100|Active Comparator|Periprosthetic BMD; anterolateral approach|Periprosthetic bone mineral density will be measured using a DXA scanner from GE Lunar Prodigy. The initial scan was performed post-operatively during hospitalization
10184668|NCT03753100|Active Comparator|Periprosthetic BMD; lateral approach|Periprosthetic bone mineral density will be measured using DXA scanner from GE Lunar Prodigy.The initial scan was performed post-operatively during hospitalization.
10184669|NCT03753061|Experimental|Aspiration Catheter|Mechanical thrombectomy with Aspiration Catheter.
10184670|NCT03753061|Active Comparator|Stent Retriever (Solitaire FR)|Mechanical thrombectomy with Solitaire FR.
10184671|NCT03753048|Active Comparator|Y-Graft|The group includes patients who underwent CABG in Y-Graft Configuration.
10184672|NCT03753048|Active Comparator|In-Situ|The group includes patients who underwent CABG in In-Situ Configuration.
10184673|NCT03753035||epileptic children|Completion of questionnaire, during medical consultation, on compliance and quality of life
9528290|NCT03211871|Placebo Comparator|Croup C|group C (control) received normal saline infusion
10140927|NCT04191850|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
10140928|NCT04191850|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
10140929|NCT04191772|Experimental|MS - training goal 1|Persons with Multiple Sclerosis (PwMS) with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
10140930|NCT04191772|Experimental|HC - training goal 1|Healthy control (HC) persons with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
10140931|NCT04191772|Experimental|MS - training goal 2|PwMS with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
10140932|NCT04191772|Experimental|HC - training goal 2|HC with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
10140933|NCT04191772|No Intervention|MS - sedentary control group|Twenty PwMS will receive no intervention, only usual care.
10140934|NCT04191772|No Intervention|HC - sedentary control group|Twenty HC will receive no intervention, only usual care.
10140935|NCT04192097|No Intervention|Traditional teaching|No specific curriculum about professionalism
10140936|NCT04192097|Experimental|Professionalism curriculum|Traditionnal teaching + professionalism curriculum
10140937|NCT04191512||Upper airway stimulation|
10140938|NCT04191512||Continuous positive airway pressure|
10140939|NCT04191525|Experimental|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
10140940|NCT04191525|Placebo Comparator|Placebo|1 capsule/day
10140941|NCT04191837|Experimental|Self-administered acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
10140942|NCT04191837|Active Comparator|Knee health education|A course regarding knee health will be offered to the subjects in this group.
10140943|NCT04191798|Experimental|KinexConnect|Rehab at Home Patients
10140944|NCT04191798|Active Comparator|Outpatient PT|In-person PT patients
10140945|NCT04191759|Experimental|Test-Retest reproducibility group|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
10140946|NCT04191538|Experimental|Conditioning electrical stimulation|Patients will receive percutaneous electrical stimulation one week prior to carpal tunnel release. They will receive sham stimulation immediately after surgery to ensure blinding.
10140947|NCT04191538|Active Comparator|Postoperative electrical stimulation|Patients will receive electrical stimulation immediately following carpal tunnel release, per out previous studies. They will receive sham stimulation 1 week prior to surgery to ensure blinding.
10140948|NCT04191538|Sham Comparator|No electrical stimulation|Patients will not receive electrical stimulation. They will receive electrical stimulation before and after surgery to ensure blinding.
10140949|NCT04191369|Placebo Comparator|EGD evaluation|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
10140950|NCT04191369|Experimental|EUS evaluation|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
10184674|NCT03753022|Sham Comparator|Group G5|Patients submitted to CABG and peep 5
10184675|NCT03753022|Experimental|Group G10|Patients submitted to CABG and peep 10
10184676|NCT03753022|Experimental|Group G15|Patients submitted to CABG and peep 15
10184677|NCT03753009||iontophoretic transepithelial corneal cross-linking (I-ON CXL)|Twenty eyes of 15 patients with keratoconus (mean age 13±3.5 [SD] years, range 9 to 18) underwent Iontophoresis epi-on CXL
10184678|NCT03753009||epithelium-off collagen cross-linking (epi-off CXL)|Twenty eyes of 13 patients with keratoconus (14±4 [SD] years, range 10 to 18) underwent standard epi-off CXL
10184679|NCT03752983||cases|patients with SLE
9969966|NCT01295437|Active Comparator|Vypro II mesh|A partly absorbable polypropylene-polyglactin mesh (50g/m2).
9969967|NCT01295437|Active Comparator|Premilene LP|A lightweight polypropylene mesh (55 g/m2)
10140951|NCT04191681|Experimental|Sacubitril-valsartan study arm|"Start medication-naïve patients on low-dose sacubitril-valsartan (24/26 mg PO BID) without a washout period per guideline and label recommendations.~Switch patients to equivalent dose sacubitril-valsartan if on prior ACE inhibitor (after a 36 hour washout period) or ARB therapy (after discontinuing one day prior).~If therapeutic range MAP (65 to 85 mm Hg), discontinue other oral vasodilator (e.g., hydralazine, isordil) or non-rate limiting dihydropyridine calcium channel blocker (non-DHP CCB, e.g., amlodipine) therapy on the day prior to sacubitril-valsartan initiation. If MAP > 85 mm Hg, low-dose sacubitril-valsartan will be added with or without discontinuation of other oral vasodilator or non-DHP CCB per physician's discretion based on drug tolerability and maintenance of therapeutic range MAP.~Sacubitril-valsartan can be up-titrated every 2-4 weeks per standard practice guidelines per physician's discretion as above."
10140952|NCT04191681|Active Comparator|Usual care (standard-of-care) arm|"1. Continue current regimen of patients on oral vasodilator therapy (e.g., ACE inhibitor, ARB, hydralazine, isordil), allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above.~2. Start medication-naïve patients de novo on one of the oral vasodilators as below per guideline and label recommendations, allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above: i. ACE inhibitor: Enalapril 2.5 mg PO BID or Lisinopril 5 mg PO daily; ii. ARB: Valsartan 20 mg PO BID or Losartan 25 mg PO daily; iii. Other: Hydralazine 10 mg PO TID or Isordil 5 mg PO TID."
10140953|NCT04191395||Inflammatory bowel disease|
10140954|NCT04191395||Chronic inflammatory rheumatic disease|
10140955|NCT04191343|Experimental|The control group|
10140956|NCT04191408|Experimental|Mechanically ventilated patients after surgery|After ICU admission the patient's hemodynamics (MAP, HR, CO, PPV) will be measured in supine position. It will be remeasured after PEEP has been increased from +5 to +15 cmH20. Then the baseline measurement will be repeated. Then passive leg raise will be performed and all the parameters will be remeasured.
10140957|NCT04191863||Children with enuresis|28 epileptic children with induced secondary nocturnal enuresis in valproate monotherapy.
10140958|NCT04191863||Children without enuresis|232 epileptic children without induced secondary nocturnal enuresis in valproate monotherapy.
10140959|NCT04191473|Experimental|group P|
10140960|NCT04191473|Other|group C|
10140961|NCT04191447|Experimental|FLAMBOYANT 200/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 200/12 capsule~1 Budesonide/formoterol Placebo capsule."
10140962|NCT04191447|Active Comparator|Budesonide/formoterol 400/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 400/12 capsule~1 Flamboyant 200/12 Placebo capsule."
10140963|NCT04191629|Experimental|50K to 200K cells|
10140964|NCT04191629|Experimental|50K to 200K cells with endothelial brushing|
10140965|NCT04191629|Experimental|500K cells|
10140966|NCT04191629|Experimental|500K cells with endothelial brushing|
10140967|NCT04191486|Experimental|T-817MA (448 mg)|
10140968|NCT04191486|Placebo Comparator|Placebo|
10140969|NCT04191551||Gastric intestinal metaplasia|Subjects with histologically-confirmed intestinal metaplasia found during endoscopy with protocoled biopsies.
10140970|NCT04191551||Controls|Subjects without intestinal metaplasia found during endoscopy with protocoled biopsies (age and sex matched to cases)
10140971|NCT04191577|Placebo Comparator|Placebo|Placebo to be administered once daily.
10140972|NCT04191577|Active Comparator|CVN424 (Low Dose)|Low dose of CVN424 to be administered once daily.
10140973|NCT04191577|Active Comparator|CVN424 (High Dose)|Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.
10140974|NCT04191603|Active Comparator|MONOPOLAR HOOC|COLPOTOMY WITH USAGE MONOPOLAR HOOC
10140975|NCT04191603|Active Comparator|PLASMAKINETIK BIPOLAR SPATULA|COLPOTOMY WITH USAGE MONOPOLAR HOOC
9528291|NCT03211845|Experimental|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
10140976|NCT04191564|Experimental|low perfusion|fluid restriction based on the goal directed fluid therapy is maintained during the whole case and a state of low perfusion is created by reducing the systolic blood pressure below 100 mmHg by vasoactive medications like cleviprex or nicardipine, by increasing positive end expiratory pressure (PEEP) and by a very short period of a high IAP of 20 mmHg only during firing.
10140977|NCT04191564|Experimental|normal perfusion|Perfusion pressure is maintained above 100 mmHg with free fluid loading iv and the lowest IAP possible during the whole procedure.
10140978|NCT04191330|No Intervention|Control|Subjects in the Control Arm will receive standard of care as normally provided in the clinical center where the study is being conducted.
10140979|NCT04191330|Experimental|Intervention|Subjects randomized to the Intervention Arm will be remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT with and outside of normal or traditional clinical encounters.
10140980|NCT04191720|No Intervention|Control group|The control group, or usual care group, will receive occupational therapy standard of care. Occupational therapy standard of care provide training, education, and therapeutic activities including relaxation strategies. These coping mechanisms are aimed at reducing the impact of anxiety on a patient's performance and participation in necessary and meaningful activities of daily living, refeeding and medical stabilization. Specifically, these interventions will include diaphragmatic and yogic breathing exercises, mindfulness-based cognitive therapy (MBCT) education and exercises, therapeutic restorative yoga activities, occupational therapy group participation, aromatherapy, identifying and promoting engagement in meaningful leisure activities, client-centered sensory diets to provide patients with consistent preferred sensory experiences, and individualized checklists and schedules to grade the self-initiation of effective coping strategies.
10184680|NCT03752983||controls|Healthy people
9528292|NCT03212131|Experimental|Normal hepatic function|Subjects with normal hepatic function
10140981|NCT04191720|Experimental|Weighted blanket group|In the weighted blanket intervention group, patients will receive usual occupational therapy care in addition to a weighted blanket. The patient will be given an appropriately weighted blanket, within 1 lb +/- of 10% of body weight as measured on day of admission. Further, the occupational therapy will provide education to the patient on the use of the weighted blanket. Patients will be free to use the weighted blanket at their discretion, however, during meals, over the shoulders or head, and during ambulation, weighted blanket use will not be permitted.
10140982|NCT04191434|Experimental|FLAMBOYANT 125/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Flamboyant 125/12 capsule~1 Budesonide/formoterol 200/6 Placebo capsule."
10140983|NCT04191434|Active Comparator|Budesonide/formoterol 200/6|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:~1 Budesonide/formoterol 200/6 capsule~1 Flamboyant 125/12 Placebo capsule."
10140984|NCT04191811||Depression Internet-delivered CBT|12 weeks of guided internet-delivered CBT for depression.
10140985|NCT04191811||Insomnia Internet-delivered CBT|12 weeks of guided internet-delivered CBT for insomnia.
10140986|NCT04191811||Health Anxiety Internet-delivered CBT|12 weeks of guided internet-delivered CBT for health anxiety.
10140987|NCT04191317|Experimental|Pain Neuroscience Education and gradual exposure|"Education explaining the neurophysiological processes that lead to chronic pain, in order to change maladaptive belief towards disease, reconceptualising them and desensitizing the Central Nervous system.~On first session of gradual exposure the patients are challenged to create a hierarchically list with the functional activities they experience fear, and exposure begins with the one they have less. Both the therapist and participant will determine a specific group of exercises after the patient understands the benign nature of pain, and will be evaluated the maximal performance of the individual to perform each exercise separately."
10140988|NCT04191317|Active Comparator|Pilates and postural education|In the first session, basic Pilates principles will be taught and reinforced at the beginning of the follow up sessions, including: postural alignment (neutral spine position, shoulder blade and neck position) and core recruitment along with a controlled breathing. Each session will have a warm up, mobility, stability and strengthening exercises and a cool down period.
10140989|NCT04190953|Experimental|Twin Block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion using Twin block prior to Hyrax
10140990|NCT04190953|Experimental|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement using Hyrax prior to Twin block
10140991|NCT04190953|No Intervention|Control|Patients will wait 1,5 years before the start of treatment
10140992|NCT04190927|Experimental|Treatment|All patients will be symptomatic peri or post menopausal and will all be started on the same protocol. The Dosing schedule of topical estradiol and topical progesterone will be modified for each subject in the first three months to address individual symptoms. The dosing will be relatively unique to each patient. Patients will remain on their dosing schedule for the remainder of the three year study and will be assessed during at the end of the study for changes in mood, symptoms of menopause, breast health, BMD and thickness of uterine lining .
10140993|NCT04191135|Experimental|pembrolizumab + carboplatin and gemcitabine|Participants receive both carboplatin Area Under The Curve (AUC) 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will continue to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
10140994|NCT04191135|Experimental|pembrolizumab + olaparib|Participants receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
10140995|NCT04190979|Experimental|Single arm|TrackCath
10140996|NCT04191291|Experimental|Shortened lunch period|The lunch period will last only 20 minutes.
10140997|NCT04191291|Experimental|Longer lunch period|The lunch period will last 30 minutes.
10140998|NCT04191278|Active Comparator|Varenicline|An α4β2 nicotinic acetylcholine receptor partial agonist
10140999|NCT04191278|Experimental|Varenicline + mobile app|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications
10141000|NCT04191278|Experimental|Varenicline + mobile app + contingency management|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications + monetary reinforcers for being adherent to medication
10141001|NCT04191044||NAFLD with mild steatosis and grade <3 fibrosis in patients|NAFLD with mild steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
10141002|NCT04191044||NAFLD with severe steatosis and grade <3 fibrosis in patients|NAFLD with severe steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
10141003|NCT04191044||NAFLD with advanced fibrosis|NAFLD with advanced fibrosis (i.e. grade 3 or 4 fibrosis) without previous portal hypertension-related complications
10141004|NCT04191044||Decompensated NAFLD cirrhosis|Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage, and/or hepatic encephalopathy) up to Child B (9 points)
10141005|NCT04190966|Active Comparator|Integrated smoking cessation|Integrated smoking cessation delivered by trained health-care practitioners in the thoracic surgical pathway: a three part package of behaviour interventions and pharmacotherapy as per NICE/NCSCT guidance which is supported by an adjunct web-based application.
10141006|NCT04190966|No Intervention|Usual care smoking cessation|Usual care of standard community/hospital based NHS smoking cessation.
10141007|NCT04191083|Experimental|Motor Imagery|
10141008|NCT04191083|Experimental|Double Time Motor Imagery|
10141009|NCT04191083|Experimental|Action observation|
9528293|NCT03212131|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
10141010|NCT04191083|Placebo Comparator|Placebo group|
10141011|NCT04190940|Experimental|High Intensity Focused Ultrasound|Patients receiving high intensity focused ultrasound as a treatment will be asked to complete the behavioral task pre and post their treatment.
10141012|NCT04190940|Experimental|Deep Brain Stimulation|"Patients receiving deep brain stimulation as a treatment will be asked to complete the behavioral task while their DBS electrode is on and off."
10141013|NCT04190992|Experimental|Application (APP) group|After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a pamphlet and an E-based & personalized breast reconstruction surgery decision aid at clinic.
10141014|NCT04190992|Other|Usual care group|After completing the questionnaires at baseline, participants in the control group will only receive a pamphlet as usual care
10141015|NCT04191070|Experimental|Class II correction using infrazygomatic crest miniscrews|class II correction by distalization using infrazygomatic crest miniscrews (G1)
10141016|NCT04191070|Experimental|Class II correction using zygomatic miniplates|class II correction by distalization using zygomatic miniplates (G2)
10141017|NCT04191109||1|Subacute stroke patients admitted to an inpatient rehabilitation facility.
9969968|NCT01295437|Placebo Comparator|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
10141018|NCT04191213|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks
10141019|NCT04191213|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age & two-gram-dose for children above 5 years of age
10141020|NCT04191096|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
10141021|NCT04191096|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
10141022|NCT04191174||Adults undergoing lung resection for lung cancer|
10141023|NCT04191239||PRVC|Preterm infants with need of mechanical ventilation will receive PRVC mode until extubation
10141024|NCT04191239||Bilevel VG|Preterm infants with need of mechanical ventilation will receive Bilevel VG mode until extubation
10141025|NCT04191161|Experimental|Brace group|patients will receive their brace 2 weeks after the first consultation (usual delay to conceive and deliver the brace), they will be asked to wear the brace all day and will be allowed to redraw it at night. Brace must be worn for 3 months. A specific eduction on how to wear the brace will also be delivered. A thermal sensor chip will be placed in the brace to assess the observance. No physiotherapy will be prescribed during this period. Patient will attend to 3 consultations, day 0, 3 months and finally at 6 months later. These three consultations are part of usual care.
9528294|NCT03212131|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
10141026|NCT04191161|Placebo Comparator|Control group|patients will continue physiotherapy sessions if already prescribed but no extra sessions will be prescribed. Pain killers will be adjusted. Patients will also attend to three consultations such as described above. Main outcome will be assessed at M3. After M3, patients who did not receive the brace will have the choice to receive it for the next 3 months and secondary outcome will be assessed at 6 months.
10141027|NCT04190836|Experimental|Self-Managed Exercise Strategy|
10141028|NCT04190862|Experimental|Cell Therapy Treatment|Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
10141029|NCT04190771|Experimental|TAU + multicomponent treatment NAT-FM|NAT-FM is a multicomponent non-pharmacological program based on mindfulness ingredients, pain neuroscience education, and nature exposure. NAT-FM is conceived as an add-on therapy.
10141030|NCT04190771|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for fibromyalgia, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
10141031|NCT04190901|Experimental|Simulated Black Male Physician|Participants are randomized to view the clinical vignette with a simulated Black Male physician.
10141032|NCT04190901|Experimental|Simulated Black Female Physician|Participants are randomized to view the clinical vignette with a simulated Black Female physician.
10141033|NCT04190901|Experimental|Simulated White Male Physician|Participants are randomized to view the clinical vignette with a simulated White Male physician.
10141034|NCT04190901|Experimental|Simulated White Female Physician|Participants are randomized to view the clinical vignette with a simulated White Female physician.
9969969|NCT01295450|Active Comparator|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
10141035|NCT04190576|Experimental|Minimally invasive ridge augmentation with LLLT|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) and low-level laser therapy
10141036|NCT04190576|Active Comparator|Minimally invasive ridge augmentation|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) alone
9528295|NCT03211806|Experimental|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
9528296|NCT03211806|Active Comparator|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
9976983|NCT01356927||DMPA|DMPA given at the time of mifepristone for medical abortion
9976984|NCT01356927||Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone for medical abortion
9969970|NCT01295450|Experimental|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
9969971|NCT01295489||Group A (IP catheter removed)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and blood (for cell, plasma, and serum isolations) is collected before courses two and three for translational research.
9969972|NCT01295489||Group B (IP catheter in place)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolations) before courses two and three for translational research.
9969973|NCT01295502|Experimental|Treatment (radiation, cisplatin, paclitaxel, carboplatin)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9969974|NCT01295528||Blood Pressure, Heart Rate, Monitor|
9969975|NCT01295541||4 months of observation|CVICU
9969976|NCT01295554||Peripheral arterial disease|Peripheral arterial disease
9969977|NCT01295567|Placebo Comparator|placebo|
9969978|NCT01295567|Experimental|dipyridamole|
9969979|NCT01295593|Experimental|valproic acid combined with CdA|valproic acid, oral daily intake, combined with 2-chlorodeoxyadenosine administered intravenously for 4 cycles
9969980|NCT01295606|No Intervention|Cefazolin, antibiotic prophylaxis|All included patients will received iv cefazolin
9969981|NCT01295619|Experimental|I-020805|This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.
9969982|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 90 mg|
9969983|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 135 mg|
9969984|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 90 mg|
9969985|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 135 mg|
9969986|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 200 mg|
9969987|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 135 mg|
9969988|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 200 mg|
9969989|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
9969990|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
9969991|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
9969992|NCT01295658||Cancer Survivors|"This is a broad observational study conducted online at www.cancerexperienceregistry.org, or via pen and paper survey obtained by calling the cancer support helpline at 888-793-9355~Any individual who has ever received a cancer diagnosis, regardless of disease type, stage, treatment, and time since diagnosis, can take part in this study."
9969993|NCT01295684|Placebo Comparator|placebo|Base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage.
9969994|NCT01295684|Experimental|Cranberry Juice|Base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day.
9969995|NCT01295723|Experimental|Intraoperative Electron Radiation Therapy|A single dose of electron irradiation given at the surgical site during the operation to remove the cancerous tumor will replace the usual 5-8 days of localized radiation. Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days post operatively.
9969996|NCT01295736|Active Comparator|Actif arm|Sildenafil 20mg TID during 90 days
9969997|NCT01295736|Placebo Comparator|Sugar pill|Placebo pills TID during 90 days
9969998|NCT01295749|Active Comparator|ventilation by laryngeal tube|ventilation by laryngeal tube and continuous chest compression
9969999|NCT01295749|Sham Comparator|ventilation by bag valve mask|ventilation by bag valve mask and interrupted chest compression
9970000|NCT01295762|Other|Type of neuroblastoma|Neonatal stages I Localized immediately resectable stages Localized immediately unresectable stages High-risk neuroblastoma Relapsed neuroblastoma
9970001|NCT01295775|Active Comparator|Sulodexide group|50 mg of sulodexide a day will be administered by oral route (1+1 capsule/day) for 360 days
9970002|NCT01295775|Placebo Comparator|Placebo group|Sulodexide placebo will be administered at the same schedule (1+1 capsule/day) and for the same lengths of time (for 360 days) as Sulodexide group
9970003|NCT01295788|Experimental|Simultaneous RT-CGM and Pump Initiation|The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
9970004|NCT01295788|Active Comparator|Delayed RT-CGM Initiation|The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
9970005|NCT01295801||Linezolid+vitamin B6|
9970006|NCT01295801||Linezolid|
9970007|NCT01295853|Active Comparator|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
9976985|NCT01356953|Experimental|Aerobic Exercise|
9976986|NCT01356979||Patients underwent medical thoracoscopy|Patients who require medical thoracoscopy for undiagnosed exudative pleural effusion by other clinical or radiological investigations.
9976987|NCT01356992|Active Comparator|Clexane® (enoxaparin - Sanofi)|
10141037|NCT04190615||0 to 3 months|0 (term newborns) to 3 month of age
10141038|NCT04190615||4 to12 months|infants from 4month to 12month of age
10141039|NCT04190615||13 to 24 months|children from 13month to 2years of age
10141040|NCT04190615||2 to 5 years|children from 2 to 5 years of age
10141041|NCT04190615||6 to 10 years|children from 2 to 10 years of age
10141042|NCT04190615||11 to16 years|children from 11 to 16 years of age
10141043|NCT04190784|Experimental|60 seconds stretching group|"Stretching exercises for upper Trapezius and Levator scapula .~From supine position , the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times."
10141044|NCT04190784|Experimental|30 seconds stretching group|The same procedures while the therapist will maintain the stretch for 30 seconds.
10141045|NCT04190784|Experimental|15 seconds stretching group|The same procedures while the therapist will maintain the stretch for 15 seconds.
10141046|NCT04190784|Placebo Comparator|60 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 60 seconds
10141047|NCT04190784|Placebo Comparator|30 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 30 seconds
10141048|NCT04190784|Placebo Comparator|15 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 15 seconds
10141049|NCT04190732|Experimental|Physician phone call|Participants will receive a five-minute phone call from one physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will not have access to patient specific IVF cycle details. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation.
10141050|NCT04190732|No Intervention|Routine care|Participants will receive routine care and no physician phone call will be performed during the waiting period between embryo transfer and the pregnancy test.
10141051|NCT04190810|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures that are not related to smoking by swiping/pulling them towards themselves, whereas pictures with tobacco-related content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
10141052|NCT04190810|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon non-smoking related images by swiping/pulling towards themselves the picture. Pictures containing tobacco-related content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
10141053|NCT04190810|Sham Comparator|Control group|This type of active control group receives the instructions to swipe tobacco-related pictures to the left and non-tobacco related pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
10141054|NCT04190485|Experimental|Placebo and GMNL-143 Probiotic Toothpastes|Subjects will receive placebo and GMNL-143 probiotic toothpastes.
10141055|NCT04190485|Experimental|Placebo and GMNL-464 Probiotic Toothpastes|Subjects will receive placebo and GMNL-464 probiotic toothpastes.
10141056|NCT04190563|Experimental|Pain De-Catastrophizing|Brief behavioral education on how to modify the interpretation of pain.
10141057|NCT04190563|Placebo Comparator|Pain Education|Brief behavioral education on pain.
10141058|NCT04190459||LSG|laparoscopic sleeve gastrectomy
10141059|NCT04190459||LRYGB|laparoscopic Roux-en-Y gastric bypass
10141060|NCT04190654|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment (Child-Pugh class A score of 5 or 6)
10141061|NCT04190654|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment (Child-Pugh class B score of 7 to 9)
10141062|NCT04190654|Experimental|Healthy Subjects|Healthy adults matched with the subjects in Group A and Group B at 1:1 for age (± 10 years), sex, and BMI (± 20%)
10141063|NCT04190797|Experimental|Experimental|Photobiomodulation + patiente controled anaethesia (PCA) group (G1): patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
10141064|NCT04190797|Active Comparator|Control|Placebo + PCA group (G2): patients undergoing knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve blockade (femoral nerve and obturator nerve). With conventional analgesia and with the PCA apparatus.
10141065|NCT04190472||IOP VPH test|Immediately after the LEEP, a cervical sample is token for the IOP-HPV test
10141066|NCT04190511|Experimental|Prebiotic-containing dairy intervention group|
10141067|NCT04190511|Active Comparator|Dietary intervention group|
10141068|NCT04190511|No Intervention|Conventional care group|
10141069|NCT04190381|Experimental|FR-Mask application|
10141070|NCT04190745|Experimental|The control group|
10141071|NCT04190745|Experimental|The experimental group|
10141072|NCT04190498||NASH-related HCC|The study is focused on patients suffering from NASH-induced HCC. Each patient with NASH-related HCC will be paired with 2 patients with non NASH-related HCC (HCV-induced CHC).
10141073|NCT04190498||HCV-related HCC|HCV-related HCC has been chosen as control population for several reasons: HCV represent a common etiology of HCC; with a distinct pathophysiology distinct from that of post-NASH HCC; populations with post-NASH and post-HCV CHC share similar epidemiological characteristics.
10141074|NCT04190589|Experimental|Robotic CME|Robot-assisted extended right colectomy
10141075|NCT04190446|Experimental|Arm I (proton beam radiation therapy)|Patients undergo proton beam radiation therapy 5 days a week over 3 weeks.
10141076|NCT04190446|Experimental|Arm II (IMRT)|Patients undergo IMRT 5 days a week over 5 weeks.
10141077|NCT04190407|Other|Pediatric patients scheduled for day case surgery|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
10141078|NCT04190706|Experimental|bioactive components fortified food products|
10141079|NCT04190706|Placebo Comparator|control food products|
9528297|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
10141080|NCT04190264|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
10141081|NCT04190264|Active Comparator|Cold Water Immersion|Participants, following exercise-induced hyperthermia, will be cooled using cold water immersion. Participants will be immersed up to their chest in cold water (~50-55 Degrees Fahrenheit).
10141082|NCT04190264|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
10141083|NCT04190251|Other|Intervention group A|Intervention group A will benefit of the medication adherence support program during 12 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
10141084|NCT04190251|Other|Intervention group B|Intervention group A will benefit of the medication adherence support program during 6 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
10141085|NCT04190238|Experimental|Spasticity after stroke 1|Physical therapy with super inductive system on the agonist and antagonist muscles
10141086|NCT04190238|Active Comparator|Spasticity after stroke 2|Physical therapy with super inductive system on the agonist muscles
10141087|NCT04190355|Active Comparator|5.25% NaOCl solution|5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation
10141088|NCT04190355|Active Comparator|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water will be used as irrigation solution at every file change during root canal preperation
10141089|NCT04190199||Type 2 diabetes mellitus (T2DM)|Subjects in this group are diagnosed with type 2 diabetes mellitus. They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
10141090|NCT04190199||Pre-diabetes (IFG or IGT)|Subjects in this group are diagnosed with pre-diabetes (impaired fasting glucose [IFG] or impaired glucose tolerance [IGT]). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
10141091|NCT04190199||Non-type 2 diabetes mellitus (healthy)|Subjects in this group are not diagnosed with type 2 diabetes mellitus or pre-diabetes (healthy). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
9528298|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
10141092|NCT04190316|Other|Evaluation of patient and patient-care environment ESBL|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
10141093|NCT04190719|Experimental|Paprika group|Patients coming for elective major surgery will participate to Paprika program
10141094|NCT04190719|No Intervention|Historical group|Patients previously operated with same characteristics
10141095|NCT04190173|Experimental|Prucalopride|Prucalopride (Trade name: Resolor) 2 mg oral or tube feeding once daily 5 consecutive days Decrease dose to 1 mg once daily in patient with end stage kidney disease or Cirrhosis Child Pugh C
10141096|NCT04190173|Placebo Comparator|Placebo|Placebo tablet to mimic Prucalopride made by starch
10141097|NCT04190095|Experimental|User Interaction with Device|A user will wear motion sensors and VR device to interact with object or another user in VR environment
10141098|NCT04190069|No Intervention|OPTIFAST only|Control group will consist of participants that have not undergone behavioral modifications with the Prescription for Wellness Program. These are participants that only go through the OPTIFAST Program.
10141099|NCT04190069|Experimental|UPMC PFW followed by OPTIFAST|The intervention group will consist of participants that have undergone behavioral modifications with the Prescription for Wellness Program. These are participants who undergo the Prescription for Wellness Program prior to the OPTIFAST Program.
10141100|NCT04189900|Experimental|Triptorelin|The subjects in this group receive a single dose treatment. Biologic sample collection (urine) from 48 hours pre-administration to 48 hours post administration.
10141101|NCT04190160|Experimental|6 months treatment|replacement of whatever pre-existing hypoglicaemic therapeutic scheme, with or without insulin, with a single daily and flexible administration of IDegLira in a pilot little group of very old diabetic patients
10141102|NCT04190004|Experimental|vasopressin|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
10184681|NCT03752944|Experimental|prebent plate|fixation of le fort I osteotomy using prebent plate
9976988|NCT01356992|Experimental|Versa® (enoxaparin - Eurofarma)|
9976989|NCT01357005||Schizophrenia Family|
9976990|NCT01357018||patients with rheumatoid arthritis|
10141103|NCT04190004|Placebo Comparator|Placebo|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
10141104|NCT04190147||Moderate-to-late preterm group|
10141105|NCT04190147||Full-term group|
10141106|NCT04189965|Other|Pilot group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses to validate it.~The subject will also have headphones and different shouts or noises will be broadcast and he will have to rate the level of dislike of each sound stimulation."
10141107|NCT04189965|Other|Experimental group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses. He will also have headphones and different shouts or noises will be broadcast and an electric stimulation glove to study in humans the mechanisms of long-term memory of pain by exploring the parallel between memory of pain and memory of a traumatic event.~3 sessions of stimulation will be done (D0, D2 and D30)"
10141108|NCT04190290|Experimental|Intervention|Mobilizations and exercises training Respiratory exercises Body image exercises
10141109|NCT04190290|Active Comparator|Control|Muscle strength evaluation and Eating behavior evaluation and Quality of life
10141110|NCT04189978||2001-2002 study participants|Children who participated in the study conducted in 2001-2002, their parents and the siblings who were exposed to the same environment at this period.
10141111|NCT04190108||Case patients|All consecutive, new patients older than 18 years with PsA (CASPAR criteria) at onset observed over 3-year period, who had any abdominal symptoms.
10141112|NCT04190108||Controls|All consecutive new patients meeting the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) at onset.
9669253|NCT03572374|Experimental|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
9669254|NCT03572374|Active Comparator|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
9976991|NCT01357018||patients with ankylosing spondylitis|
9976992|NCT01357031|Experimental|Melatonin|Melatonin 3 mg at bedtime
10141113|NCT04190134|Experimental|Immediate Robot|One month after study entry, participants will receive the robot at home for two months, followed by a three month observation period without the robot.
10141114|NCT04190134|Active Comparator|Delayed/Waitlist Robot|Three months after study entry, participants will receive the robot at home for three months.
10141115|NCT04190121|Experimental|GROUP A|
10141116|NCT04190121|No Intervention|GROUP B|
10141117|NCT04190303||Baseline (pre-intervention)|Current routine care
10141118|NCT04190303||Post-intervention|Care following development and delivery of the system-level intervention
10141119|NCT04189835||Kidney transplant recipients|Adults and children undergoing kidney transplantation in Norway and the western part of Denmark.
10184682|NCT03752944|Active Comparator|Conventional four miniplates|fixation of le fort I osteotomy using conventional four miniplates
10184683|NCT03752931|Active Comparator|Celiprolol|receiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
10184684|NCT03752931|Active Comparator|Diltiazem|receiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.
10184685|NCT03752905|Experimental|PTR-01 0.1 mg/kg|Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.
10184686|NCT03752905|Experimental|PTR-01 0.3 mg/kg|Three intravenous infusions of PTR-01 at 0.3 mg/kg with doses 2 weeks apart.
10184687|NCT03752905|Experimental|PTR-01 1.0 mg/kg|Three intravenous infusions of PTR-01 at 1.0 mg/kg with doses 2 weeks apart.
10184688|NCT03752905|Placebo Comparator|Normal Saline|Saline control to mimic PTR-01.
10184689|NCT03752905|Experimental|PTR-01 3.0 mg/kg|Three intravenous infusions of PTR-01 at 3.0 mg/kg with doses 2 weeks apart.
10184690|NCT03752879||Case (Kristaller Group)|Group of kristeller maneuver applied in the second stage of labor due to clinical necessity.
10184691|NCT03752879||Control (no Kristaller Group)|The control group not required to kristeller maneuver
10184692|NCT03752853|Experimental|iCBT for depression - behavioral activation first (BAF)|internet-based intervention for mild to moderate depression: patients receive behavioral activation first, followed by cognitive restructuring
9976993|NCT01357031|Placebo Comparator|Placebo|Placebo
9669255|NCT03568344||Community based tx seeking: baseline|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
9669256|NCT03568344||tx seeking @ referral facility: baseline|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
10141120|NCT04189770||Observational (questionnaire, accelerometer, EMA, survey)|Patients and partners complete questionnaires over 60 minutes about demographic information, stress, coping, and lifestyle behaviors at baseline and end of study. Patients and partners also receive an accelerometer and complete EMA questionnaire on stress, coping, physical activity, and eating behaviors over 5-10 minutes QID (7:30 am, 11:30 am, 3:30 pm, and 7:30 pm) via an smartphone app for 14 days. Patients and partners also complete a survey on nutrition BIW for a total of 4 surveys.
10141121|NCT04189874|Active Comparator|Conventional stool testing|"All patients randomly allocated to this arm will have their stools tested for the following:~a) Bacterial culture for Salmonella, Shigella, E.coli O157 and Campylobacter - specimen in Enteric Pathogen Transport medium (EPT) planted to: i) MacConkey agar, Sorbitol-MacConkey agar, Hektoen agar and Selenite broth all incubated overnight at 350C ii) Campylobacter agar incubated for 48 hours at 420C in a microaerophilic atmosphere b) Bacterial culture for Yersinia (≤ 18 years old): EPT specimen sent to Dynacare Laboratories for processing, results back in 10-14 days c) Ova & Parasites investigation: Sodium acetate-Acetic Acid-Formalin specimen sent to the Public Health Laboratories (PHL) for testing, results back in 7-10 days d) Viral culture: rarely requested, requires a specimen in a sterile container, sent to the PHL for testing, results back in 5-7 days e) Clostridioides difficile: specimen in sterile container, results in 1h (GeneXpert)"
10141122|NCT04189874|Experimental|BioFire FilmArray Gastrointestinal Panel|All patients randomly allocated to this arm will have their stools tested using a PCR-based molecular assay that can simultaneously test for 22 different infectious pathogens with a turnaround time of approximately 1 hour. As results become available, they will be available for review by the patient's healthcare providers in the electronic medical record.
10141123|NCT04189991|Active Comparator|Manual then automated oxygen titration|First will be performed the manual oxygen titration and then the automatic oxygen titration.
10141124|NCT04189991|Active Comparator|Automatic then manual oxygen titration|First will be performed the automatic oxygen titration and then the manual oxygen titration.
10141125|NCT04189705|Experimental|MCT-SR|Drug: MCT-SR 2 times/day for 2 weeks
10141126|NCT04189705|Active Comparator|Mucosta Tab.|Drug: Mucosta Tab. 3 times/day for 2 weeks
10141127|NCT04189718|Experimental|osseodensification protocol|Experimental: In the test group, osteotomy site preparation was performed using Osseodensification technique at 1100 rpm and implant was placed
10141128|NCT04189718|Active Comparator|conventional implant site preparation protocol|Control: in the control group, osteotomy site was prepared using conventional drilling protocol at 1100 rpm and implant was placed.
10141129|NCT04189679||First line|20 patients in first line of treatment
10141130|NCT04189679||Second or third line|40 patients in second and third line of treatment
10141131|NCT04189796|Active Comparator|Jarlsberg|Daily intake of Jarlsberg Cheese in at least 6 weeks
10141132|NCT04189796|Sham Comparator|Camembert|Daily intake of Camembert Cheese in 6 weeks
10141133|NCT04190277|Experimental|36-week Closed-Loop|2-week baseline period in open-loop condition, then 12-week period in closed-loop condition followed by a 24-week extension period in closed-loop condition
10141134|NCT04190277|Active Comparator|12-week open-loop and 24-week closed-loop|2-week baseline period in open-loop condition, then 12-week period in open-loop condition followed by a 24-week extension period in closed-loop condition
10141135|NCT04189744|Placebo Comparator|IPTp-SP plus MTZ placebo (control)|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and metronidazole placebo administered as directly observed therapy.
10141136|NCT04189744|Active Comparator|IPTp-SP plus MTZ|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and 4 tablets each containing 500mg metronidazole administered as directly observed therapy .
10141137|NCT04189744|Active Comparator|IPTp-DP plus MTZ|3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine, first dose and will be administered as directly observed therapy with the remaining two doses on the next two consecutive days at home. 4 tablets each containing 500mg metronidazole administered as directly observed therapy.
10141138|NCT04189588|Active Comparator|Cohort A|Cetirizine HCl 10 mg/mL: a single 1 mL injection.
10141139|NCT04189588|Active Comparator|Cohort B|Diphenhydramine 50 mg/mL: a single 1 mL injection.
10141140|NCT04189887||PD+AEX|The group of people with PD which will perform aerobic exercise after motor skill acquisition
10141141|NCT04189887||PD-AEX|The group of people with PD which will not perform aerobic exercise after motor skill acquisition
10141142|NCT04189887||CON+AEX|The group of control participants which will perform aerobic exercise after motor skill acquisition
10141143|NCT04189887||CON-AEX|The group of control participants which will not perform aerobic exercise after motor skill acquisition
10141144|NCT04189783|Active Comparator|Arm I (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity.
10141145|NCT04189783|Experimental|Arm II (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.
10141146|NCT04189354|Experimental|Active t-DCS|Use of the t-DCS machine with the following stimulation parameters: current intensity of 2mA, electrode size of 25 cm2, duration of stimulation 20 minutes (excluding the fade-in and fade-out periods of 15 seconds).
10184693|NCT03752853|Experimental|iCBT for depression - cognitive restructuring first (CRF)|internet-based intervention for mild to moderate depression: patients receive cognitive restructuring first, followed by behavioral activation
10184694|NCT03752840|Experimental|Screening|
10184695|NCT03752840|Active Comparator|Case detection|
9976994|NCT01357031|Active Comparator|Amitriptyline|Amitriptyline 25 mg
10141147|NCT04189354|Sham Comparator|Sham t-DCS|"The condition of use in sham mode follows the same procedure as the active t-DCS except that the active stimulation lasts only 30 seconds at 3mA (60 seconds of active stimulation taking into account the periods of fade in and fade out).~The stimulator remains switched on during the procedure but does not deliver current. The devices are fully automatic and deliver an active or sham current according to a randomized stimulation code whose meaning is unknown by the operator, in order to respect the triple blind."
10141148|NCT04189406||Girls with Turner syndrome|"Girls with a pre- or perinatal diagnosis TS who are born in a medical centre in the Netherlands during the duration of the study.~The subjects will have an extra venapuncture of 3.5 mL blood at 3 and 9 months."
10141149|NCT04189601||Study subjects|Patients with Fabry disease, Gaucher disease, or Niemann-Pick disease, type D
10141150|NCT04189601||Controls|Age- and sex-matched to Study subjects
10141151|NCT04189653||General Ward Inpatients 2017-2018|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2017-august 31st 2018.
10141152|NCT04189653||General Ward Inpatients 2018-2019|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2018-august 31st 2019.
10141153|NCT04189562|Experimental|SMS Intervention|All parents of participants will receive customized text messages once a day, Sunday through Friday, for a duration of 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
9669257|NCT03568344||Community based tx seeking: Post RAS|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
10141154|NCT04189523|Active Comparator|Standard of Care Pain Management|
10141155|NCT04189523|Experimental|Early Administration of US Guided Nerve Blocks|
10141156|NCT04189120|Active Comparator|Thoracic epidural analgesia (TEA)|Under full aseptic conditions and wearing sterile gloves while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine, then an 18-G Epidural needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal or IV injection. After negative response, 15 ml of 0.25% epidural bupivacaine will be injected and the patient will be turned to the supine position.
10141157|NCT04189120|Active Comparator|Ultrasound-guided superficial serratus plane block (SSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. The muscles will be identified easily overlying the fifth rib, the latissimus dorsi , teres major and serratus muscles . A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle beneath the latissimus dorsi. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected
10141158|NCT04189120|Active Comparator|Ultrasound-guided deep serratus plane block (DSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane between the posterior border of the serratus anterior muscle and the corresponding surface of the rib. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected deep to the serratus muscle separating the serratus anterior muscle from the external intercostal muscle.
10141159|NCT04189172||Neuro-Patch|Patients receiving Neuro-Patch® for duraplasty
10141160|NCT04189237|Experimental|electroacupuncture|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of two times per week for six weeks, for a total of twelve times.~Acupoint selection: needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints."
10141161|NCT04189237|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of two times per week for six weeks, for a total of twelve times.
10141162|NCT04189250|Placebo Comparator|Optimized carbonmonoxid rebreathing protocol (oCO)|2 min rebreathing period seated position capillary blood sampling
10141163|NCT04189250|Active Comparator|Automatized carbonmonoxide rebreathing protocol (aCO)|10 minutes rebreathing period supine position venous blood sampling
10141164|NCT04189185|Active Comparator|K-wire tension band wiring|The patient is treated with 1.6 mm k-wires and 1 mm cerclage
10141165|NCT04189185|Active Comparator|Suture fixation|The fracture is reduced and fixed with 2.0 Orthocord suture.
10141166|NCT04189146|Other|Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
10141167|NCT04189484|Experimental|Arm A: Evolocumab low dose|Single dose of evolocumab 21 mg subcutaneous (SC)
10141168|NCT04189484|Experimental|Arm B: Evolocumab intermediate low dose|Single dose of evolocumab 35 mg SC
9976995|NCT01357044|Active Comparator|Plant extracts|
9976996|NCT01357044|Placebo Comparator|Placebo|
10141169|NCT04189484|Experimental|Arm C: Evolocumab intermediate high dose|Single dose of evolocumab 70 mg SC
10141170|NCT04189484|Experimental|Arm D: Evolocumab high dose|Single dose of evolocumab 140 mg SC
10141171|NCT04189484|Experimental|Arm E: Alirocumab low dose|Single dose of alirocumab 15 mg SC
10141172|NCT04189484|Experimental|Arm F: Alirocumab intermediate low dose|Single dose of alirocumab 25 mg SC
10141173|NCT04189484|Experimental|Arm G: Alirocumab intermediate high dose|Single dose of alirocumab 50 mg SC
10141174|NCT04189484|Experimental|Arm H: Alirocumab high dose|Single dose of alirocumab 100 mg SC
10141175|NCT04189484|Placebo Comparator|Arm I: Placebo|Single dose of placebo SC
10141176|NCT04189575|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
10141177|NCT04189302|Experimental|palatal connective tissue graft harvest with KPM blade|palatal connective tissue graft is harvested using single incision technique using KPM blade
10141178|NCT04189302|Active Comparator|palatal connective tissue graft harvest with 15C blade|palatal connective tissue graft is harvested using single incision technique using 15 C blade
10141179|NCT04189211|Experimental|1.2mg/kg of BAT8001|BAT8001 100mg/box, 1.2mg/kg IV infusions
10141180|NCT04189211|Experimental|2.4mg/kg of BAT8001|BAT8001 100mg/box, 2.4mg/kg IV infusions
10141181|NCT04189211|Experimental|3.6mg/kg of BAT8001|BAT8001 100mg/box, 3.6mg/kg IV infusions
10141182|NCT04189211|Experimental|4.8mg/kg of BAT8001|BAT8001 100mg/box, 4.8mg/kg IV infusions
10141183|NCT04189211|Experimental|6.0mg/kg of BAT8001|BAT8001 100mg/box, 6.0mg/kg IV infusions
10141184|NCT04189380|Experimental|Cohort 1|liver transplanted patient
10141185|NCT04189315|Experimental|Group 1 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 36 weeks.
10141186|NCT04189315|Experimental|Group 2 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 12 weeks and then asfotase alfa at a lower dose for 24 weeks.
10141187|NCT04189328|Active Comparator|control group|conventional macrosurgical implant placement
10141188|NCT04189328|Experimental|test group|microsurgical implant placement
10141189|NCT04189458|Experimental|Multimodal exercise program|The experimental group intervention will attend the multimodal exercise program. The program integrates 3 sessions / week of 60 minutes on alternated days. The multimodal exercise program includes exercises promoting simultaneous motor and cognitive stimulation.
10141190|NCT04189458|No Intervention|Control Group|Usual care. After the study, it will be offered the opportunity to integrate a similar exercise program for the control group (CG) participants.
10141191|NCT04189276|Active Comparator|Group1|T101+ETV(Entecavir) /TDF(Tenofovir)
10141192|NCT04189276|Active Comparator|Group2|T101+ETV/TDF
10141193|NCT04189276|Active Comparator|Group3|ETV or TDF
10141194|NCT04189276|Active Comparator|Group4|Peg-IFNα-2b+ETV/TDF
10141195|NCT04189289|Active Comparator|ESP block group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. patient controlled analgesia (PCA) protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
10141196|NCT04189289|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. PCA analgesia protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
10141197|NCT04189367|Experimental|Western medicine + TCM|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.~Blood test and physiological assessment, and do the TCM model.~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks.~TCM therapy: one bag of Qingre Liangkou Ningxin Fang, three times a day for 12 weeks."
10141198|NCT04189367|Active Comparator|Western medicine|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.~Blood test and physiological assessment, and do the TCM model.~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks."
10141199|NCT04189094|Experimental|Sintilimab + CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions). After PCI, Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
10141200|NCT04189094|Active Comparator|CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
10141201|NCT04189055|Experimental|Cohort #1|Cetuximab monotherapy (500mg/m² IV, day 1)
10141202|NCT04189055|Experimental|Cohort #2|Cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).
10141203|NCT04189016|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
10141204|NCT04189016|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
10141205|NCT04188808|Experimental|Popliteal artery aneurysm|Asymptomatic popliteal artery aneurysm patients will undergo surgery with a femoropopliteal/femorodistal bypass
10141206|NCT04188808|Active Comparator|Peripheral artery disease|Patients with peripheral artery disease defined as (ankle - brachial index, ABI <0.5 or typical symptoms); intermittent claudication (IC), or resting pain and/or minor tissue loss. Will undergo surgery with a femoropopliteal/femorodistal bypass
9970008|NCT01295853|Active Comparator|t4 sypathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
9970009|NCT01295866||nasal nitric oxide, atypy status|
9970010|NCT01295892|Placebo Comparator|placebo|placebo (transdermal gel)
9970011|NCT01295892|Experimental|Estrogen|1mg of 17B-estradiol/day (transdermal gel)
9970012|NCT01295918|No Intervention|Placebo, antibiotic, diarrhea|
9970013|NCT01295918|Placebo Comparator|L. reuteri, Antibiotic, diarrhoea|L. reuteri will be ingested by patients on antibiotic therapy, effect of probiotic on AAD will be assessed.
9970014|NCT01295931|Experimental|IC-Green + Imaging|Indocyanine Green (IC-Green) Injections + Imaging
9970015|NCT01295957|Active Comparator|reminiscence therapy, story telling|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. Refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography. Three main variables contributed to successful reminiscing: individuality, evaluation and structure.
9970016|NCT01295957|Placebo Comparator|comparison|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, but they didn't participate in reminiscence sessions to rule out the possibility that improvement in quality of life was due only to attention received and social stimulation.
9970017|NCT01295957|No Intervention|control|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour,
9970018|NCT01295970|Active Comparator|Radiosurgery (SRS)|
9970019|NCT01295970|Active Comparator|Surgery|
9970020|NCT01296009|Experimental|traditional Chinese medicine|The pregnancy rate in traditional Chinese medicine group is higher than the control group
9970021|NCT01296022|Active Comparator|Subcutaneous ICD|Subcutaneous Implantable Cardioverter Defibrillator
9970022|NCT01296022|Active Comparator|Transvenous ICD|Transvenous Implantable Cardioverter Defibrillator
9970023|NCT01296048||Body Analysis|
9970024|NCT01296061||Failed Kidney Transplant|Adults ≥ 18 years, initiating chronic dialysis
9970025|NCT01296074|Experimental|Corticosteroid|Methylprednisolone will be given during cardiopulmonary bypass.
9970026|NCT01296100|Experimental|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
9970027|NCT01296100|Experimental|Lifestyle counseling (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
9970028|NCT01296113|Experimental|A|
9970029|NCT01296139|Experimental|A|All subjects will receive 7.5 mg/kg Fe
10141207|NCT04188938||Occult pneumothorax in trauma patients|Age>16, multi-trauma, consulted thoracic surgeon, underwent CXR- CT.
10141208|NCT04188951|Other|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|
10141209|NCT04188925|Experimental|Group A|True LA with EA
9970030|NCT01296165||Travellers visiting India|People that are older than 18 years and planning to visit India for a period of at least 5 days will be approached by the personal at the travel clinics to participate in the study. Informed consent will be obtained prior to enrolling subjects.
9970031|NCT01296204|Experimental|BB4 antibody-Iodine 131|
9970032|NCT01296217|Experimental|lymph nod detection|
9970033|NCT01296230|Experimental|Hormone/semen measurements before and after varicocelectomy|We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.
9970034|NCT01296243|Experimental|Tesetaxel once every 3 weeks|
9970035|NCT01296256|Experimental|Bendamustine-EAM|
9970036|NCT01296269|Experimental|Vasopressin|vasopressin condition
9970037|NCT01296269|Experimental|oxytocin|oxytocin condition (syntocinon)
9970038|NCT01296269|Placebo Comparator|placebo|
9970039|NCT01296282||Heart failure patients|
9970040|NCT01296295|Experimental|Spirometry and lifestyle counseling|Intervention group: The intervention is to give brief structured smoking cessation advice combined with a detailed and structured discussion of the spirometric results.
9970041|NCT01296295|No Intervention|Lifestyle counseling|No intervention group: the patients of the control group will receive a brief structured smoking cessation advice.
9970042|NCT01296308||type 2 diabetics with neuropathy|
9970043|NCT01296321|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
9970044|NCT01296321|Active Comparator|Waitlist|Waitlist.
9970045|NCT01296334|Experimental|morphine low dose|morphine infusion 10 mg over a 210 min period
9970046|NCT01296334|Experimental|morphine high dose|morphine infusion 20 mg over a 210 min period
9970047|NCT01296334|Experimental|buprenorphine low dose|buprenorphine infusion 0.3 mg over a 210 min period
9970048|NCT01296334|Experimental|buprenorphine high dose|buprenorphine infusion 0.6 mg over a 210 min period
9970049|NCT01296334|Placebo Comparator|placebo|placebo (normal saline) infusion 0.6 mg over a 210 min period
9976997|NCT01357057||Derivation cohort|Arm 1: Derivation cohort (from 2003 to 2007)
10141210|NCT04188925|Sham Comparator|Group B|Sham LA with EA
10141211|NCT04189159|Experimental|PROMPT Treated|PROMPT treatment, twice a day, for 5 days a week, for 3 consecutive weeks
9516802|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
9970050|NCT01296373||HIV-1-infected, off ART|HIV-1-infected, antiretroviral naive or off antiretroviral therapy for at least 12 months with CD4+ T-cell counts less than or equal to 350 cells/µL who are about to commence combination antiretroviral therapy
9970051|NCT01296386|Experimental|IC84, 75 µg w/ Alum|75 µg w/ Alum (microgram with Alum)
9970052|NCT01296386|Experimental|IC84, 75 µg w/o Alum|75 µg w/o Alum (microgram without Alum)
9970053|NCT01296386|Experimental|IC84, 200 µg w/ Alum|200 µg w/ Alum (microgram with Alum)
9970054|NCT01296386|Experimental|IC84, 200 µg w/o Alum|200 µg w/o Alum (microgram without Alum)
9970055|NCT01296399||Bare metal stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary bare metal stent, for de-novo stenosis
9970056|NCT01296399||Drug eluting stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary drug eluting stent, for de-novo stenosis
9970057|NCT01296438|Experimental|Treatment sequence 1|
9970058|NCT01296438|Active Comparator|Treatment sequence 2|
9970059|NCT01296451|Experimental|Arm A, group1|Intervention: MVA-NSmut. Administration schedule: 1 dose MVA-NSmut 2 x 10^8 pfu. Subjects: 4 healthy volunteers
9970060|NCT01296451|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 10 healthy volunteers"
9970061|NCT01296451|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose MVA-NSmut 2 x 10^8pfu at week 22, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
9970062|NCT01296451|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; MVA-NSmut.. Administration schedule: 1 dose AdCh3NSmut 2.5 x 1010vp at week 2 and 1 dose MVA-NSmut 2 x 108pfu at week 10, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
9970063|NCT01296451|Experimental|Arm C, group 1|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8pfu at week 8.~Subjects: 4 patients"
9970064|NCT01296451|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8pfu at week 8, 1 dose AdCh3NSmut 2.5 x 10^10vp at week 16 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 24.~Subjects: 5 healthy volunteers"
9970065|NCT01296451|Experimental|Arm A, group 4|"Intervention: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp (at least 6 months after they were initially enrolled) and 1 dose MVA-NSmut 2 x 10^8 pfu 8 weeks later.~Subjects: up to 5 healthy volunteers who were previously in group A2"
9970066|NCT01296451|Experimental|Experimental: Arm A, group5|"Intervention: AdCh3NSmut1. MVA-NSmut. Administration schedule:1 dose AdCh3NSmut1 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8 pfu at week 8 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 40.~Subjects: 5 healthy volunteers"
9970067|NCT01296451|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut1. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^7 pfu at week 8.~Subjects: 5 healthy volunteers"
9970068|NCT01296451|Experimental|Arm A, group 7|"Interventions: AdCh3NSmut1; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^6 pfu at week 8.~Subjects: 5 healthy volunteers"
9970069|NCT01296464|Experimental|Stalevo|levodopa/carbidopa/entacapone
9970070|NCT01296464|Placebo Comparator|Placebo|
9516803|NCT03312166|Experimental|Compression device|
9516804|NCT03312153|Experimental|Neem (Azadirachta indica)|Neem (Azadirachta indica) (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
9970071|NCT01296477||Asthma IQ Primary Care Tool|
9970072|NCT01296477||Usual Asthma Care in Primary Care|
9970073|NCT01296490|Experimental|Stress test|The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
9970074|NCT01296503|Active Comparator|Dexamethasone (Arm A)|Sixty days (D+60) after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days)
9970075|NCT01296503|Experimental|Thalidomide and Dexamethasone (Arm B)|"D+60 after ASCT: dexamethasone plus thalidomide 200 mg by mouth daily for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
9970076|NCT01296516|Placebo Comparator|Control Group|A group matched for age and BMI will be selected to serve as control subjects in this study.
9970077|NCT01296516|Active Comparator|Face-to-face group|Participants randomized to the face-to-face intervention will attend motivational meetings held once per week in Phase I and biweekly in Phase II. Behavioral sessions will be led by a trained interventionist and will take place at Pennington Biomedical Research Center.
9970078|NCT01296516|Active Comparator|Telehealth Group|Participants randomized to the Telehealth intervention will receive behavioral counseling through Trestletree, phone system.
9970079|NCT01296529||HIV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HIV antibodies and/or HIV viral RNA, and a negative antibody test for HCV
9970080|NCT01296529||HCV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HCV antibodies and HCV viral RNA, and a negative antibody test for HIV
9970081|NCT01296529||HIV and HCV coinfection|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, and positive tests for HCV antibodies and HCV RNA.
9970082|NCT01296529||HIV/HCV coinfection with HCV clearance|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, a positive tests for HCV antibodies, and undetectable HCV RNA without hepatitis C treatment (spontaneous clearance) or >6 months after hepatitis therapy (sustained virologic response)
10141212|NCT04189159|No Intervention|Control|Usual treatment
10141213|NCT04188795|Experimental|Intervention|"Participants who met the criteria for inclusion in the study and volunteered to participate in the study were divided into experimental and control groups by block randomization method.~After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
10141214|NCT04188795|No Intervention|Control Group|After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Routine nursing care was applied to hip fracture patients in the control group. Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day.
10141215|NCT04189432|Experimental|SCM-CGH|"Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells~Dose: 1x10^6 cells/Kg"
10141216|NCT04189432|Placebo Comparator|Placebo|3 times with 2-week intervals by IV infusion.
10141217|NCT04188782||Pediatric patients undergoing radiotherapy|"Pediatric patients undergoing general anesthesia for radiotherapy treatment. General anesthesia will be accomplished exclusively by the administration of sevoflurane.~The inhalatory induction will be performed with sevofluorane at 8% with O2 4Lt/min. The maintenance will be with sevofluorane at an end tidal of 2.5% with 1Lt/min of O2.~The EEG will be obtain with SedLine monitor"
10141218|NCT04189666|Active Comparator|Group R: patients receive Rivastigmine patch|receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative
10141219|NCT04189666|Active Comparator|Group M: patients receive Melatonin patch|receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative
10141220|NCT04188977|Other|Usual Practice|OTPs are able to request from state and federal health department officials to utilize interim methadone treatment to address admission delays in their OTP.
10141221|NCT04188977|Experimental|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
10141222|NCT04189198|Experimental|Articaine group|Patients in this group are assigned to recieve 30 ml of Articaine 2%
9827467|NCT02457065|No Intervention|Do Not Receive Plaque|"Control~No Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators did not give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors or any other intervention."
9827468|NCT02457182|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based Stress Reduction (MBSR)
10141223|NCT04189198|Experimental|Bupivacaine|Patients in this group are assigned to recieve 30 ml of bupivacaine 0.5%
10141224|NCT04189029||HFpEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≥ 50%, 1000 patients anticipated among which 300 with extensive phenotyping
10141225|NCT04189029||HFrEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≤ 40%, 1000 patients anticipated among which 100 with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
10141226|NCT04189029||Subjects apparently without heart failure|Subjects without history or signs of heart failure, 100 subjects anticipated with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
10141227|NCT04188821|Active Comparator|output based group|Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days with no further signs of infection, fluid collection or impaired wound healing
10141228|NCT04188821|Experimental|early-removal group|Investigators remove the drains at hospital discharge, 3-4 days after surgery, regardless of the output at that time
10141229|NCT04188704|Placebo Comparator|Anterior cruciate ligament normal|normal Anterior cruciate ligament reconstruction
10141230|NCT04188704|Experimental|Anterior cruciate ligament reconstruction|Anterior cruciate ligament reconstruction and Position screw fixation
10141231|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fasted|Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.
10141232|NCT04188730|Active Comparator|LUCEMYRA (lofexidine) tablets, fasted|Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours
10141233|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fed|Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.
10141234|NCT04188691|Experimental|vaccine group 1|vaccine produced by NVSI , Specification: GI.1 / GII.4 (low), 0.5ml / dose
10141235|NCT04188691|Experimental|vaccine group 2|vaccine produced by NVSI , Specification: GI.1 / GII.4 (middle), 0.5ml / dose
10141236|NCT04188691|Experimental|vaccine group 3|vaccine produced by NVSI , Specification: GI.1 / GII.4 (high), 0.5ml / dose
10141237|NCT04188691|Placebo Comparator|Normal saline|（0.5ml / dose）produced by NVSI
10141238|NCT04188691|Placebo Comparator|Aluminum adjuvant|（0.5ml / dose）produced by NVSI
10141239|NCT04188743|Experimental|Allogenic FMT|Participants in the allogenic FMT- group will receive FMT-treatment using healthy donor microbiota supplied by the Ghent Stool Bank. The donor stool (50g) is processed shortly after production and tested intensively. It's frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
10141240|NCT04188743|Placebo Comparator|Autologous FMT|Participants in the autologous FMT- group will receive FMT-treatment using their own microbiota to account for effects due to the treatment itself. Their stool is processed as close to the treatment as feasible. It's processed and frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
10141241|NCT04188743|No Intervention|No intervention|"Participants in the No intervention-group will not receive any treatment but will be monitored similarly as the Allogenic FMT and Autologous FMT groups."
10141242|NCT04188535|Experimental|Esophageal Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
9669258|NCT03568344||tx seeking @ referral facility: Post RAS|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
9669259|NCT03556202|Experimental|Mirikizumab Dose 1|Mirikizumab administered subcutaneously (SC).
9669260|NCT03556202|Experimental|Mirikizumab Dose 2|Mirikizumab administered SC.
10141243|NCT04188535|Experimental|Glioblastoma Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
10141244|NCT04188535|Experimental|Glioblastoma Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
10141245|NCT04188535|Experimental|Prostate Cancer Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~Genomic testing of biopsy sample"
10141246|NCT04188535|Experimental|Prostate Cancer Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards.~Genomic testing of biopsy sample"
10141247|NCT04188535|Experimental|Vulvar Cancer Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
10141248|NCT04188535|Experimental|Pediatric Glioma Cohort|"The research study procedures include:~Screening for eligibility~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
10141249|NCT04188444||Agonist|Ovarian stimulation with agonist of GnRH
10141250|NCT04188444||Antagonist|Ovarian stimulation with antagonist of GnRH
10141251|NCT04188522||Minor Stroke|"We will enroll a cohort of 15 adult patients previously admitted to Johns Hopkins Bayview Medical Center with small/minor acute ischemic stroke visible on neuroimaging. Patients will follow-up in clinic 4-6 weeks following hospital discharge. To be eligible for the study, patients must have a minor stroke, defined as NIH Stroke Scale score at follow-up of less than or equal to 8, modified Rankin score of 0-2, be competent speakers of English, and have no prior history of stroke, dementia, or untreated psychiatric disease. Those with proximal large vessel (M1) or branch (M2) occlusions will be excluded.~*Based on preliminary results we have expanded our trial and will continue to recruit up to 40 patients with minor stroke."
10141252|NCT04188522||Controls|For comparison, we will recruit a group of age-similar controls (n=15) without neurologic disease or prior clinical history of stroke.
10141253|NCT04188483|Experimental|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days. Thirty days after the start of the supplementation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
9669261|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
9669262|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
9669263|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
9669264|NCT03528603|Experimental|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
9669265|NCT03528603|Placebo Comparator|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
9827469|NCT02457182|Placebo Comparator|Usual Care|Usual medical therapy
9669266|NCT03528486|Experimental|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
9827470|NCT02457195|Experimental|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
10141254|NCT04188483|Other|Non-Selenium Supplementation|The control group will not receive selenium supplementation. Thirty days after allocation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
10141255|NCT04188431|Experimental|Dexamethasone|Single intraoperative administration of 0.15 mg/kg of Dexamethasone intravenously with a maximum dose of 5 mg
10141256|NCT04188431|Placebo Comparator|Sodium chloride|Single intraoperative administration of Sodium Chloride (NaCl) 0.9% intravenously
10141257|NCT04188496|Experimental|PULMONARY FUNCTION TEST (PFT) GROUP|"Thoracic joint Mobilization was applied on Experimental group.~Thoracic Flexion:~Patient sits on the treatment table with arms across the chest and hands on opposite shoulders. Stand facing the patient's left side.~Thoracic Extension:~Performed by asking sits on a treatment chair with arms folded across the chest and hands on opposite shoulders.~Thoracic Segment Rotation:~Performed by asking the patient to lie on left side. Place a pillow under patient's waist to assist left side bending. Position the patient's arms are folded across the chest with hands on opposite shoulders to stabilize the shoulder girdle and minimize movement there."
10141258|NCT04188496|Other|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
10141259|NCT04188626|Experimental|Driving session|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving.
10141260|NCT04188561|Active Comparator|Intraarticular injection Group|Patients included in the study had been received 2 ml hyaluronic acid with concentration of 22mg/ml . Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval
10141261|NCT04188561|Active Comparator|Radiofrequency Group|Radiofrequency Generator is a four electrode pain management for interventional pain management procedures. Patients had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
10141262|NCT04188366|Experimental|FAMES Modification|3-month trial of FAMES. Results from modifications will be used to by stakeholders (i.e., family members, client, providers, organizational leadership,) to inform finalization and implementation of FAMES
10141263|NCT04188366|Experimental|FAMES Pilot Trial|Pilot testing of FAMES and implementation toolkit
10141264|NCT04188587|Experimental|177Lu-PSMA-I&T|177Lu-PSMA-I＆Tradioligand therapy with 2.0-8.0GBq in every circle were performed. And then 177Lu-PSMA post-therapy scans were performed at 24 h and 48 h respectively, and the fusion phenomenon was performed at the second day to pre evaluate the efficacy of the patients.
10141265|NCT04188340|Placebo Comparator|control group|using bergamot massage oil apply to GV20, GV24 SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
10141266|NCT04188340|Experimental|test group|using Su-Man formula massage oil ap-ply to GV20, GV24, SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
10141267|NCT04188470|Experimental|person-centered care model|healthcare multidisciplinary team will review the appropriateness of medication by a person-centered care model and then the healtcare team will propose changes in the therapeutic plan to the patient or caregiver
10141268|NCT04188470|No Intervention|usual care|the healthcare team will practice usual care
10141269|NCT04188613|Experimental|HFJV|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. The patient was extubated, and the jet ventilator catheter was inserted to trachea and ventilation will be start.
10141270|NCT04188613|Active Comparator|ETT|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed through the vocal cords.
10141271|NCT04188613|Active Comparator|LMA|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed and laryngeal mask airway device inserted.
9669267|NCT03528486|Active Comparator|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
9669268|NCT03505996|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
10141272|NCT04188106|Experimental|Hydroxyzine and Varenicline|Participants enrolled in the study will take the FDA approved starter kit of varenicline for the first week of medication administration (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7). During the first week, participants will also receive hydroxyzine dosed in a similar manner, 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night. After the first week, participants will receive the FDA-approved dose of varenicline (1 mg twice daily) combined with hydroxyzine, 25 mg in the morning and 50 mg at nighttime. All medications will be dosed orally.
10141273|NCT04188275||Metastatic Castration Resistant Prostate Cancer|Metastatic Castration Resistant Prostate Cancer patients who are eligible for endocrine therapy with ARTA plus LHRH agonist.
10141274|NCT04188249||RA patients|"Patients (or a representative) must provide informed consent before any procedures occur.~Main Inclusion Criteria:~18 years and older~Fulfil the ACR/EULAR classification criteria for RA in 2010~Patients able to understand and complete self-evaluation questionnaires.~General Exclusion Criteria:~Contraindications for golimumab~Prior exposure to TNFi/JAKi"
10141275|NCT04188119|Experimental|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
10141276|NCT04188119|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
9669269|NCT03498378|Experimental|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
9669270|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
9669271|NCT03466801|Experimental|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
9669272|NCT03466801|Active Comparator|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight >60kg,500mg/d;<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
9669273|NCT03466450|Experimental|Glasdegib and Temozolomide Oral Capsule|"During Phase Ib, Four to six weeks after surgical diagnosis, concurrent with radiotherapy (STUPP) + temozolomide (75mg/m2/day for 42 days) + PF-04449913 (Glasdegib) (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered.~During Phase II, Radiation therapy, temozolomide and glasdegib will be administered. This last, as the dose that have been selected previously, based on the Phase Ib results. Glasdegib ( PF-04449913) recommended dose until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
9970083|NCT01296555|Experimental|Phase I, Stage 1: GDC-0032 as Single Agent|Participants with locally advanced or metastatic solid tumors will receive increasing doses of GDC-0032 administered orally daily in 28-day cycles. Dose escalation decisions will be based upon the observed incidence of DLTs.
9970084|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Fulvestrant|Participants (Cohorts F, J, K, L, and M) will receive GDC-0032 in combination with fulvestrant until disease progression.
9970085|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Letrozole|Participants (Cohorts E, N, P, Q, R, and S) will receive GDC-0032 in combination with letrozole until disease progression.
9970086|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 as Single Agent|Participants (Cohorts A, B, C, D, G, H, T, T2, and X) will receive GDC-0032 until disease progression.
9970087|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Midazolam|Participants (Cohort C) will receive GDC-0032 in combination with midazolam.
9970088|NCT01296555|Experimental|Phase II: GDC-0032 + Fulvestrant|Post-menopausal females with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer will receive GDC-0032 in combination with fulvestrant until disease progression.
9970089|NCT01296594|Active Comparator|Usual Care|
9970090|NCT01296594|Experimental|usual care with cell phone monitoring and CM|In the CM condition, patients will carry a cell phone and record and send in time- and date-stamped self videos of medication ingestion.
9970091|NCT01296607|Other|Urocortin 2|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 2 in the presence and absence of a saline washout between incremental doses.
9970092|NCT01296607|Other|Urocortin 3|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 3 in the presence and absence of a saline washout between incremental doses.
9970093|NCT01296620|Experimental|Experimental 1|
9970094|NCT01296620|Experimental|Experimental 2|
9970095|NCT01296620|Placebo Comparator|Placebo|
9970096|NCT01296633|Experimental|Medtable|The Medtable is a patient education tool used for collaborative planning. The Medtable focuses patients on how to take their medication and prompts them to anchor this task to familiar routines. The tool serves as an external workspace that helps provider and patient jointly visualize how to integrate constraints from medications (e.g., which can be taken together; dose spacing) and patients' routine (e.g., typical meal times) in order to create an optimal daily schedule. The completed Medtable shows providers how patients are thinking about taking their medications, allowing them to clear up any confusion. It encourages teach-back and teach-to-goal strategies recommended for patients with low health literacy. Completing the Medtable helps patients implement as well as create plans by encouraging them to think about when and where they will actually take their medication. It also provides a template developed with their providers that could help patients load pill organizers at home.
9970097|NCT01296633|Active Comparator|Usual care|Patients in the usual care condition at both research sites will receive the medication counseling and communication that is standard of care at these sites. This includes a medication reconciliation process, where patients are given a card with list of medications that is periodically checked. This provides an opportunity for providers to correct patient knowledge of their medications, and is similar to the process of creating a list for the Medtable. However, the Medtable also encourages patients and providers to collaborate in order to organize this list in terms of the patient's routine to create a patient-specific, concrete plan for taking the medications.
9970098|NCT01296659|Experimental|AIM Arm|Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)
9970099|NCT01296659|Experimental|TG Arm|Ridaforolimus combined with docetaxel and gemcitabine (TG)
10141277|NCT04188600|Experimental|treatment group|"The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations:~Responding patients: this population, defined by FSFI score > 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks).~Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks)."
9970100|NCT01296685||oxygenator with arterial filter|
9970101|NCT01296685||arterial filter|
9970102|NCT01296724|Other|newborn with digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and digestive pathology
9970103|NCT01296724|Other|Newborn without digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and without digestive pathology
9970104|NCT01296750|Active Comparator|Early Physiotherapy|Physiotherapy to begin within 1 day post op.
9970105|NCT01296750|No Intervention|Late Physiotherapy|Physiotherapy to start 6 weeks post op
9970106|NCT01296776|Active Comparator|whole-body electromyostimulation|20 min of whole-body electromyostimulation with sequences of 6 sec of current and 4 sec at 85 Hz performed during low-intensity/low amplitude movements. 3 sessions / 14 days for 12 months
10141278|NCT04188600|Active Comparator|active control group|The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)
10141279|NCT04188262|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
10141280|NCT04188054|Experimental|Intervention|Will be asked to change the position they lie on their bed when sleeping; that is, to re-position themselves when lying on their back so that their feet (and ankles) hang over the end of the mattress.
10141281|NCT04188054|Placebo Comparator|Control|Will be asked to make no change in the way they normally lie on their mattress when sleeping
9827471|NCT02457247|Experimental|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.
10141282|NCT04188197|Experimental|e-Cigarette Matched to Usual Brand Cigarette|"JUUL and cigarette flavor matched (Mint for menthol smokers and Virginia Tobacco for non-menthol smokers);"
10141283|NCT04188197|Experimental|e-Cigarette Unmatched to Usual Brand Cigarette|"JUUL and cigarette flavor unmatched (Virginia Tobacco for menthol smokers and Mint for non-menthol smokers)."
10141284|NCT04188288|Experimental|Neurofeedback|Three imaging (fMRI) sessions of experimental feedback.
10141285|NCT04188288|Other|Control feedback|Three imaging (fMRI) sessions of control feedback.
10141286|NCT04188327|Sham Comparator|Control group(Group I)|Patients will receive sham stellate ganglion block weekly for three times
10141287|NCT04188327|Experimental|Stellate Ganglion block group (Group II)|Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg
10141288|NCT04187937|Experimental|Experimental|Stereotactic image-guided non-anatomical resection
10141289|NCT04188457||Stroke - usual follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with regular follow-up
10141290|NCT04188457||Stroke - intensive follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with intensive follow-up
10141291|NCT04188457||myocardial infarction - usual follow-up|Patient who has had a first or recurrent myocardial infarction with usual follow-up
10141292|NCT04188457||myocardial infarction -intensive follow-up|Patient who has had a first or recurrent myocardial infarction with intensive follow-up
10141293|NCT04187885|Active Comparator|Group/Cohort 1 : CTL|"Label : control~Type : comparator~Description: Outside academic stress period (represented by exams), without the physical activity program (no Intervention)."
10141294|NCT04187885|Experimental|Group/Cohort 2: PAP|"Label : physical activity program without stress Type : experimental~Description: outside academic stress period (exams), with the physical activity program:60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday."
10141295|NCT04187885|Experimental|Group/Cohort 3: AS|"Label : academic stress Type : experimental~Description: during academic stress period (exams), without the physical activity program (no Intervention)"
10141296|NCT04187885|Experimental|Group/Cohort 4: ASPAP|Label : academic stress and physical activity program Type : experimental Description: during academic stress period (exams), with the physical activity program: 60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday.
10141297|NCT04188158|Experimental|Intervention Group|3 cycles XELOX + Surgery+ 5 cycles XELOX
10141298|NCT04188158|Other|Control group|Surgery + 8 cycles XELOX
10141299|NCT04188184|Active Comparator|tranexmic acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
10141300|NCT04188184|Active Comparator|Epinephrine roup|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
10141301|NCT04187963|Experimental|Group physical therapy|Groups of 6 patients and 1 physical therapist for the 1.5 hour physical therapy session
10141302|NCT04187963|Active Comparator|Individual physical therapy|1.5 hour physical therapy session 1 on 1 (1 patient and 1 physical therapist)
10141303|NCT04187950|Placebo Comparator|Yogurt with inactivated B. lactis and added cane sugar|Participants will consume yogurt with heat inactivated B. lactis and added cane sugar twice daily for 14 days.
10141304|NCT04187950|Experimental|Yogurt with B. lactis and added honey|Participants will consume yogurt with B. lactis and added honey twice daily for 14 days.
10141305|NCT04187976||Patients with moderate to severe uncontrolled asthma|Patients with moderate to severe uncontrolled asthma defined on clinical assessment and spirometric criteria. Non controlled asthma is considered when ACQ score ≥ 1.5 or in case of acute exacerbation
10141306|NCT04187976||Patients with recalcitrant CRSwNP requiring sinus surgery|The medical failure in CRSwNP is defined as persistent disease in spite of 3 courses of oral corticosteroid and double dose of local corticoid over 12 months
10141307|NCT04187976||Patients with concomitant CRSwNP and uncontrolled asthma|Patients with concomitant CRSwNP and moderate to severe uncontrolled asthma
10141308|NCT04187976||Healthy subjects|Patients without any airway inflammatory disease or atopy
10141309|NCT04187859|Other|Education Session|The participant will receive an education session in their home, lasting between 15-30 minutes from a District Nurse. The District Nurses will advise the participant on how to drink more fluids, the importance of hydration and the effects of dehydration.
10141310|NCT04187859|Other|Prompting Cup|Participants will receive a Droplet Cup with an electronic prompting device and a brief tutorial session from the District Nurse. The Droplet Cup will encourage the participant to stay hydrated during the day, by emitting a voice or light to encourage them to drink more.
10141311|NCT04187859|No Intervention|Control Group|There will be no change to the care the participant receives from the District Nurse.
10141312|NCT04187859|Other|Prompting Cup and Education|Participants will receive a Droplet Cup with an electronic prompting device and an education session on the importance of hydration and the effects of dehydration.
9669274|NCT03449888||St. Louis VA Healthcare System stress testing referrals|St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
9669275|NCT03442426|Experimental|Intervention Cohort|Integrated model of primary care
9669276|NCT03415854|Experimental|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
9669277|NCT03409614|Other|Chemo|Part 1: Chemotherapy
9669278|NCT03409614|Experimental|REGN2810+Chemo Part 1|Part 1: REGN2810+chemo
9669279|NCT03409614|Experimental|REGN2810+AbbrevChemo+ipi|Part 1: REGN2810+abbrev chemo+ipi
9669280|NCT03409614|Experimental|Placebo+Chemo|Part 2: Placebo plus chemo
9669281|NCT03409614|Experimental|REGN2810+Chemo Part 2|Part 2: REGN2810+chemo
9669282|NCT03408873|Experimental|Patient Noncompliance|Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention
9669283|NCT03396471|Experimental|Single Arm Assignment|Pembrolizumab + External Beam Radiation Therapy
9669284|NCT03363763|Active Comparator|Arm 1|Sirolimus 0.2% ointment applied topically hs x 12 weeks
9669285|NCT03363763|Active Comparator|Arm 2|Sirolimus 0.4% ointment applied topically hs x 12 weeks
9669286|NCT03363763|Placebo Comparator|Arm 3|Placebo ointment applied topically hs x 12 weeks
9669287|NCT03332667|Experimental|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
9970107|NCT01296776|Placebo Comparator|wellness control group|Low intensity, low frequency exercise that focus on well being. 1 session/week for 10 weeks. 10 blocks of exercise with intermittent periods of 100 weeks of rest
9970108|NCT01296789|Active Comparator|Tissue perfusion guided protocol|Active comparator group, where parameters of tissue perfusion are used to guide hemodynamic therapy
9970109|NCT01296789|Other|Usual Care|Usual Care
9970110|NCT01296802|Placebo Comparator|Placebo|
9970111|NCT01296802|Experimental|Dexfenfluramine|Dexfenfluramine HCL
9970112|NCT01296828||MOUTH BREATHING CHILDREN|
9970113|NCT01296854|No Intervention|Standard|The patients randomized into this arm of the study will not have spa therapy.
9970114|NCT01296854|Experimental|Spa Therapy|The patients randomized into this arm of the study will have 3 weeks of spa therapy
9970115|NCT01296880||LCM group|Patients who are having lacosamide (LCM) added to their anti-epileptic drug regimen
9970116|NCT01296880||control group|Patients who are NOT having lacosamide (LCM) added to their anti-epileptic drug regimen
9970117|NCT01296893|No Intervention|Delayed exercise control|Participants asked to maintain usual lifestyle and provided with abbreviated version of intervention upon completion of end of study testing.
9970118|NCT01296893|Experimental|Exercise|Aerobic exercise Intervention as per below
9970119|NCT01296906|Experimental|Population-based Reminder/Recall|Recall is performed centrally by public health departments for all children in need of immunizations in a geographic area.
9970120|NCT01296906|Experimental|Practice-based Reminder/Recall|Reminder/Recall is performed by individual private practices for their patients who appear in need of immunizations.
9970121|NCT01296919||Sinus drainage|Adult patients with chronic rhinosinusitis who failed treatment with antibiotics and topical corticosteroids and underwent endoscopic sinus surgery. Preoperative evaluation included paranasal sinus CT scans. The diagnosis was confirmed by endoscopic examination showing purulent and/or mucopurulent discharge in the middle and/or superior meatus.
9970122|NCT01296945|Active Comparator|Kiosk|
9970123|NCT01296945|Active Comparator|Paper|
9970124|NCT01296945|Active Comparator|Kiosk PLUS paper|
9970125|NCT01296945|Active Comparator|kiosk PLUS web|
9970126|NCT01296958|Experimental|Targeted screening|Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
9970127|NCT01296958|Active Comparator|Education|Community education about Taenia solium prevention.
9970128|NCT01296971|Experimental|A|genotype 1, treatment-naive
9970129|NCT01296971|Experimental|B|genotype 2 and 3, treatment-naive
9970130|NCT01296971|Experimental|C|all genotypes, non-responders or relapses
9970131|NCT01296984||Extralevator APR|The perineal part of the APR is done with the intent to create a cylindrically shaped specimen thus removing part of or the entire levator muscle with the specimen.
9970132|NCT01296984||Traditional APR|The perineal part of the APR is performed with the intent to remove the tumour with CRM free of tumour and the levator left in place.
9669288|NCT03332667|Experimental|131I-MIBG with Dinutuximab and Vorinostat|Patients will receive vorinostat on days 0-13. 131I-MIBG will be received on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
9669289|NCT03321045|Experimental|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab [89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 millicurie (mCi) at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.
9669290|NCT03312842|Experimental|CS1001|
10141313|NCT04188080|Experimental|Jarlsberg cheese starting dose|The participants obtaining an Osteocalcin increase > 10% during the previous 6 weeks intake of Jarlsberg cheese, will get a percent reduction in the daily cheese-dose equal to the increase in the Osteocalcin level
10141314|NCT04188171|Experimental|Polidocanol foam sclerotherapy|"During the intervention period the participants are observed at 3-week intervals (maximum of 3 sessions).~The required number of polidocanol foam sclerotherapy sessions (maximum of 3) is determined by clinical and anoscopic evaluation (if the participant is non-symptomatic and/or there is no significant hemorrhoidal disease on anoscopy, the patient will not be a candidate for additional instrumental therapy moving directly to the follow-up period). After each session all patients were instructed to adopt dietary measures and adequate hydration maintaining therapy with systemic venotropic, topical and laxative if necessary.~After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
10141315|NCT04187924|Active Comparator|Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage. Sputum will be collected during the session.
10141316|NCT04187924|Active Comparator|SIMEOX + Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage with the SIMEOX device. Sputum will be collected during the session.
10141317|NCT04188223|Experimental|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
10141318|NCT04188223|Active Comparator|Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
10141319|NCT04187911|Experimental|Intervention - Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. DDP aims to treat trauma-related problems and Attachment Disorders over about 20 1-hour sessions using the core communication techniques of Playfulness, Acceptance, Curiosity and Empathy (PACE)
10141320|NCT04187911|Active Comparator|Control - Services as Usual (SAU)|SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise.
10141321|NCT04188314|Experimental|Desflurane Interventional Group|"The intervention group will receive desflurane for maintenance of anaesthesia. Standard protocols for induction and maintenance of anaesthesia will be followed, as discussed with Prof. F. Puehringer, an international expert in the field of desflurane use. A detailed leaflet describing the protocol has been developed, which will be handed to the treating anaesthetist on the day of surgery.~After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the desflurane vaporiser is opened to 12%. This is maintained until 1MAC is reached. The fresh gas flow will then be turned down to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand."
10141322|NCT04188314|Active Comparator|Isoflurane Control Group|The control group will receive Isoflurane for maintenance of anesthesia. After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the Isoflurane vaporiser is opened and adjusted to attain 1MAC. Once 1MAC is attained, the fresh gas flow will be reduced to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser will be adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand.
9669291|NCT03308396|Experimental|Single Arm|"This is a non-randomized, single arm, open label Phase Ib/II study.~Phase Ib:~Days 1-5~Guadecitabine:~Dose 0: 60 mg/m^2~Dose -1: 45 mg/m^2~Phase II:~Days 1-5 Guadecitabine (at Ph II dose)~Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)"
10184696|NCT03752814|Experimental|SYNOSTE Nitinail System|The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
9669292|NCT03294408|Other|Imaging|multimodal imaging and clinical assessment
9669293|NCT03290612|Experimental|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
9669294|NCT03290612|Experimental|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
9669295|NCT03285321|Experimental|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
9516805|NCT03312153|Active Comparator|2.5%sodium hypochlorite|2.5% sodium hypochlorite, anti-bacterial root canal irrigant solution
9516806|NCT03312140|Other|Choline Chloride|Patients receive choline chloride (1g Choline) three times a day for 12.6 weeks as a food supply
9669296|NCT03285321|Experimental|Arm 2|Nivolumab 3mg/kg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
9970133|NCT01296997|Experimental|calcium phosphate|
9970134|NCT01296997|Placebo Comparator|placebo|
9669297|NCT03284866|Experimental|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
9669298|NCT03284866|Placebo Comparator|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
9970135|NCT01297010|Placebo Comparator|Dexamethasone|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg) at the beginning of the procedure.
9970136|NCT01297010|Placebo Comparator|Dexamethasone and ondasetron|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling) and ondansetron (0.1 mg / kg dose of 4mg ceiling)at the beginning of the procedure.
9970137|NCT01297023|Experimental|calcium phosphate|
9970138|NCT01297023|Experimental|vitamin d|
9970139|NCT01297023|Experimental|calcium phosphate and vitamin d|
9970140|NCT01297023|Placebo Comparator|placebo|
9970141|NCT01297036|Active Comparator|Reference arm|Treated with Reference (Aricept, 10 mg donepezil tablet)
9970142|NCT01297036|Experimental|Test arm|Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)
9970143|NCT01297049|Experimental|Lifestyle counseling|
9976998|NCT01357057||Validation cohort|Arm 2: Validation cohort (from 2008 to 2009)
9976999|NCT01357070|Active Comparator|Brocco-sprout homogenate|
9977000|NCT01357070|Sham Comparator|Alfalfa sprout homogenate|
9977001|NCT01357083||Major Depression Disorder|This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
9977002|NCT01357096|No Intervention|Comparison group|
9977003|NCT01357096|Experimental|Integrated health care team|
9977004|NCT01357109|Experimental|Bosentan|
9977005|NCT01357109|Placebo Comparator|Placebo|
9977006|NCT01357122|Experimental|NCI Insertion|
9977007|NCT01357122|Active Comparator|Standard Forceps Insertion|
9977008|NCT01357174||All Participants|Infants who were vaccinated with ROTATEQ™
9977009|NCT01357187|Other|Control|
9977010|NCT01357187|Experimental|Treatment|
9977011|NCT01357200||critically ill obese adults|Age ≥ 18 years, body mass index (BMI) ≥ 30, in intensive care unit (ICU) requiring tube feeding ≥ 3 days
9977012|NCT01357213|Placebo Comparator|Arm 2|Placebo in all three cohorts
9977013|NCT01357213|Experimental|Arm 1|XOMA 3AB in 3 dose levels/cohorts A, B or C.
9977014|NCT01357226||All patients over the age of 18|
9977015|NCT01357252|Experimental|vildagliptin|
9977016|NCT01357252|Placebo Comparator|placebo|
9977017|NCT01357265|Other|1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
9977018|NCT01357278|Experimental|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
10141323|NCT04188132|Experimental|EEG BCI closed loop feedback for rehabilitation of upper limb|"This study is a pilot study to examine the feasibility of a SMR based EEG BCI using motor task and motor imagery and involve a gaming feedback for same.~The first two days will be used for calibrating the BMI using commands in computer screen followed by further two days for testing the BMI and feedback control during gaming in computer to move the ball in the computer screen."
9977019|NCT01357278|No Intervention|Patient education|Patient education will be offered every eight week.
9977020|NCT01357291|Experimental|Recidivism Reduction Program|Inmates who were assigned to the RRP intervention.
9977021|NCT01357291|Active Comparator|Business-as-usual|Business-as-usual are those inmates not assigned to RRP and who receive standard inmate programming.
9977022|NCT01357304|Experimental|Group treatment and PAR|
9977023|NCT01357304|No Intervention|Usual care|
9977024|NCT01357317|Active Comparator|Lanthanum Carbonate|Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP>=80%.
9977025|NCT01357317|Active Comparator|Calcium Acetate|Calcium Acetate: initial dose 667 mg TID with meals, titrated at monthly intervals in 667 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis. The maximum daily intake of elemental calcium should not exceed 1500 mg in order to comply w/recommendations from K-DOQI [5](this is approximately equal to three 667mg tablets of calcium acetate TID).
9977026|NCT01357317|Active Comparator|Dietary instructions|Dietary instructions consisting of pamphlets describing foods high in phosphorus and consultation with a renal dietitian if necessary, with the goal of return to normal the level of the abnormal marker of phosphorus homeostasis. Rescue therapy with a phosphorus binder of the treating physician's choice will be allowed in patients who fail to normalize elevated baseline serum phosphorus levels after 3 months following dietary instructions.
9977027|NCT01357330|Experimental|Dose Escalation|Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
9977028|NCT01357343|Active Comparator|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping
9977029|NCT01357343|Active Comparator|Chiropractic care|Chiropractic adjustments and active and passive physical modalities.
10141324|NCT04187820|Experimental|Acupuncture group|Participants receiving acupuncture and mild moxibustion.
10141325|NCT04187755|Active Comparator|Group I|Participants were given ceftazidime as the antibiotic therapy with standard regimens and dose of antibiotic
9826095|NCT02407223|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
9826096|NCT02407223|Experimental|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
9826097|NCT02407223|Experimental|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
9826098|NCT02407457|Active Comparator|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
9826099|NCT02407457|Active Comparator|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
9826100|NCT02407704|Experimental|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
9826101|NCT02407704|Active Comparator|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
9977030|NCT01357343|Active Comparator|Integrated Chiropractic and Acupuncture|
10141326|NCT04187755|Experimental|Group II|Participants were given cefepime as the antibiotic therapy with standard regimens and dose of antibiotic
10141327|NCT04187690|Experimental|Jin-shui Huan-xian granule|Participants in this arm will be given Jin-shui Huan-xian granule.
10141328|NCT04187690|Placebo Comparator|Jin-shui Huan-xian granule placebo|Participants in this arm will be given Jin-shui Huan-xian granule placebo.
10141329|NCT04188015|Experimental|2.5mg ANX007|1 in every 3 subjects will be randomized to 2.5mg dose of ANX007.
10141330|NCT04188015|Experimental|5.0mg ANX007|1 in every 3 subjects will be randomized to 5.0mg dose of ANX007.
10141331|NCT04188015|Sham Comparator|Sham Procedure|1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.
10141332|NCT04187664|Experimental|EXCARE Pathway Group|The proposed pathway comprises a range of actions that include individual patient-centered risk assessment by the SAMPE Risk Model (30-day probability of death), specialized care in Post-Anesthetic and Intensive Care Units, and also in the surgical wards performed by the nursing, anesthesia, clinic and surgery teams.
10141333|NCT04187651|Experimental|PRP gel application|PRP application for perianal fistula
10141334|NCT04187781|Other|external microphone old|
10141335|NCT04187781|Other|external microphone new|
10141336|NCT04188002|Other|Control - Fruit and Vegetable|Participants in this arm will receive usual care.
10141337|NCT04188002|Other|Physical Activity Intervention|Participants in this arm will be encouraged via tailored newsletters and email/or text reminders to improve diet and physical activities.
10141338|NCT04187807|Experimental|Melatonin 5mg|Melatonin 5mg, every 24 hours for 14 days
10141339|NCT04187807|Placebo Comparator|Placebo|Starch based placebo, every 24 hours for 14 days
10141340|NCT04187430||Retrospective group|
10141341|NCT04187430||Prospective group|
10141342|NCT04187898|Experimental|Eflapegrastim @ 30mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 30 minutes from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
10141343|NCT04187898|Experimental|Eflapegrastim @ 3 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 3 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
9970144|NCT01297075|Experimental|Outreach visits|Practices allocated to outreach visits may receive up to three outreach visits in order to motivate and support general practice clinics in implementing two chronic care programmes for chronic obstructive Pulmonary disease and Type 2 diabetes.
9826102|NCT02407756|Experimental|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
9826103|NCT02407756|Experimental|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
9826104|NCT02407990|Experimental|BGB-A317 Phase 1A|
9826105|NCT02407990|Experimental|BGB-A317 Phase 1B|
9970145|NCT01297075|No Intervention|Control (late intervention)|These practices are allocated to outreach visits after the initial evaluation stops at 12 months.
9970146|NCT01297088|Experimental|Arm 1|
9970147|NCT01297114||Participants aged 60-70|Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
9970148|NCT01297114||Participants aged 20-30|Younger participants will not undergo PET scanning that will be studied with other methods.
9970149|NCT01297127||Cohort|
9970150|NCT01297140|Experimental|questionary|
9970151|NCT01297153|Active Comparator|Aphakia|"The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. If it is aphakia,IOL will not be implanted.Aphakia will be corrected with aphakic glasses / contact lenses. Bilateral aphakes are given both contact lenses and glasses. So when they do not wear contact lenses they can put on aphakic glasses. Unilateral aphakes are given only contact lenses. Contact lenses should be fitted in the eye in OT immediately after the operation.~Aphakic glasses :~Prescribed within 2 weeks of surgery for both eyes."
9970152|NCT01297153|Active Comparator|Pseudophakia|The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. Hydrophobic Acrysof IOL is implanted.All pseudophakic children will be refracted and given the residual correction within a month of surgery.
9970153|NCT01297166|Experimental|LEO 27989 ointment|
9970154|NCT01297192|Other|Treatment Arm 1|The effect of mirabegron on the pharmacokinetics of solifenacin
9970155|NCT01297192|Other|Treatment Arm 2|The effect of solifenacin on the pharmacokinetics of mirabegron
9970156|NCT01297205|Experimental|PNEUMOSTEM®|
9970157|NCT01297218|Experimental|NEUROSTEM®-AD|
9970158|NCT01297231||Breast cancer|This prospective study will recruit patients with stage 0-3 breast cancer who have had or are scheduled for a breast MRI prior to treatment.
9970159|NCT01297361|Other|Plasma Vitamin B12 and Folic acid levels|Blood sample was drawn
9970160|NCT01297374|Experimental|dietetic counseling|
9970161|NCT01297374|Experimental|physical activities|
9970162|NCT01297374|Experimental|Lifestyle counseling|
9970163|NCT01297387||Revascularization of limb ischemia|Procedure/Surgery
9970164|NCT01297413|Experimental|Stem cells|All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
9970165|NCT01297426||Group 1|Lean and obese, diabetic and non diabetics
9970166|NCT01297439|Other|group M|"Normal delivery without pushing maneuver suctioning of fetal nose and mouth during delivery"
9970167|NCT01297439|Experimental|group C|"Pushing maneuver on the fetal head"
9970168|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)
9970169|NCT01297452|Experimental|BKM120 (days 1 - 28, ) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
9970170|NCT01297452|Experimental|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.
9970171|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B|Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle
9970172|NCT01297530|Experimental|Arm 1|
9970173|NCT01297556|No Intervention|Control group|Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
9970174|NCT01297556|Experimental|Treatment|Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
9970175|NCT01297569|Experimental|Ranibizumab|
9970176|NCT01297582|Experimental|E|
9669299|NCT03283761|Experimental|Treatment Arm|All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A on days 1 and 15 of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m^2 and leucovorin IV 400 mg/m^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every other cycle (starting with Cycle 3) to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
9669300|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
10141344|NCT04187898|Experimental|Eflapegrastim @ 5 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).~Supplied in prefilled single-use syringes for subcutaneous injection.~Cycle 1: Administered on the same day as TC chemotherapy, 5 hours from the end of TC administration.~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
10141345|NCT04187586||Extracorporeal shock wave therapy group|The ESWT group received shock waves with low-energy flux density (0.05-0.30 mJ/mm2). The interval between treatments is a 1-week. To evaluate the effect of ESWT, we reviewed the skin test results (thickness, melanin, erythema, TEWL, sebum, and skin elasticity levels) immediately before ESWT and immediately after the sixth session. And also the ESWT group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
10141346|NCT04187586||conventional therapy without extracorporeal shock wave therapy|Conventional therapy group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
10141347|NCT04187469|Experimental|Regimen 1: 2HRM/4HR|Two month of chemotherapy with Moxifloxacin, Isoniazid and Rifampicin, followed by four month of Isoniazid and Rifampicin only.
10141348|NCT04187469|Active Comparator|Regimen 2: 2HRZE/4HR (control regimen)|Two month of chemotherapy with Isoniazid, Rifampicin, Pyrazinamide and Ethambutol, followed by four month of Isoniazid and Rifampicin only.
10141349|NCT04187443|Experimental|MS-553 low dose|low dose of MS-553 taken orally
10141350|NCT04187443|Experimental|MS-553 mid dose|mid dose of MS-553 taken orally
10141351|NCT04187443|Experimental|MS-553 high dose|high dose of MS-553 taken orally
10141352|NCT04187703|Experimental|5AZA-alt-DEC|"Participants will be treated for a minimum of 24 weeks in the absence of clear evidence of progressive disease. Patients who have any response will be permitted to continue treatment until relapse or progression of disease that is not sensitive to protocol defined dose escalation.~Treatments will include:~5-azacytidine (50mg/m^2) Day 1 every week~Decitabine (5mg/m^2) Day 4 every week~Weeks 1-8 will be an induction phase, and weeks 9+ will be a long-term treatment phase"
10141353|NCT04187677|Active Comparator|Hand Therapy Group|
10141354|NCT04187677|Experimental|Sensory Training Group|
10141355|NCT04187599|Experimental|Paragon CRT®100 Contact Lens|participants will wear the Paragon CRT®100 lens with a follow up for no less than 12 months.
9669301|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
9669302|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
9669303|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
9669304|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
9970177|NCT01297582|Placebo Comparator|P|
10141356|NCT04187625|Experimental|Intervention|Patients will be given autologous endothelial progenitor cells
10141357|NCT04187716|Experimental|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
10141358|NCT04187716|Other|remedies|Treatment for anemia will include remedies such as iron (oral or intravenous), hematopoietic accelerators, and blood transfusions, and will be determined by researchers at each institution to provide optimal treatment for patients.
10141359|NCT04187521|Other|Sensitivity defect|Participants defined as having abnormal insulin sensitivity without an absolute defect in insulin secretion.
10141360|NCT04187521|Other|Secretory defect|Participants defined as having abnormal insulin secretion without a defect in insulin sensitivity.
10141361|NCT04187521|Other|Unclassified|Participants who cannot be classified as having abnormal insulin secretion or abnormal insulin sensitivity or who have both abnormal insulin sensitivity and abnormal insulin secretion.
10141362|NCT04187508|Experimental|AZD8154|Subjects will receive AZD8154 QD dosing for 10 days
10141363|NCT04187508|Placebo Comparator|Placebo|Subjects will receive AZD8154 matching placebo QD dosing for 10 days
10141364|NCT04187547|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
10141365|NCT04187547|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
10141366|NCT04187638|Experimental|Olive oil|Participants will receive 30ml/day of olive oil for two weeks
10141367|NCT04187638|Placebo Comparator|Butter|Participants will receive 30g/day of butter also for two weeks.
10141368|NCT04187222|Experimental|Test Group|Mechanical treatment + Bifidobacterium animalis subsp. lactis
10141369|NCT04187222|Placebo Comparator|Control Group|Mechanical treatment + Placebo
10141370|NCT04187313|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention package (i.e. private practitioners in the selected areas who agree to participate).
10141371|NCT04187313|No Intervention|Control|Private practitioners in the control areas will receive no intervention.
10141372|NCT04187417|Experimental|Topical tetracaine|Topical tetracaine hydrochoride 1%
10141373|NCT04187417|Placebo Comparator|Balanced artificial tear solution|Balanced artificial tear solution (Systane)
10141374|NCT04187131|Experimental|augmented reality|
9970178|NCT01297608|Experimental|treatment|
9970179|NCT01297608|Placebo Comparator|placebo|
9970180|NCT01297621|Experimental|Breast reduction|Breast hypertrophy women allocated to this arm will undergo reduction mammaplasty
9970181|NCT01297621|Other|Control|Patients in this arm will be assessed twice, without surgical intervention
9970182|NCT01297634|Other|Botulinum Toxin Type-A 1U|
9970183|NCT01297634|Other|Botulinum Toxin Type-A 2U|
9970184|NCT01297634|Other|Botulinum Toxin Type-A 3U|
9970185|NCT01297647|Experimental|Spinal cord injured|Patients with neurogenic lower urinary tract infection (Spinal Cord Injury,MS,M. Parkinson)
9970186|NCT01297660||patients with SCI for at least 5 years|Ages Eligibility: minimum 18 years Genders Eligibility: female and male
9970187|NCT01297673||Spinal cord injury|Patients with neurogenic lower urinary tract dysfunction due to spinal cord injury with regular urodynamic examination
9970188|NCT01297686|Experimental|Exercise|Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
9970189|NCT01297686|Active Comparator|Standard of Care|This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
9970190|NCT01297699|Experimental|Tocilizumab|
9970191|NCT01297699|Placebo Comparator|Sterile 0.9% Sodium Chloride|
9970192|NCT01297712|Active Comparator|Hi Line|This arm is examined with latest generation HDTV colonoscopes
9970193|NCT01297712|No Intervention|Classic Line|control group undergoing colonoscopy with older generation scope currently in use in most centers
9970194|NCT01297725|Experimental|Right sharp, left blunt|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
9970195|NCT01297725|Experimental|Right blunt, left sharp|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
9970196|NCT01297738|Experimental|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which is high in fat and sugar (Nutridrink®)
9970197|NCT01297738|Experimental|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume this caloric surplus with their meals, which results in an increase in meal size.
9970198|NCT01297738|Experimental|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which has a high fat and sugar content(Nutridrink®). Subjects consume the Nutridrink 3 times a day in between meals. which results in an increase in meal frequency.
9970199|NCT01297738|Experimental|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
9970200|NCT01297738|No Intervention|Control group|Subjects will not follow any diet but their own ad-libitum, healty diet.
9970201|NCT01297764|Experimental|carfilzomib for MML|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone - This study will be conducted as an open-label Phase I/II, single-center study in which subjects will receive carfilzomib, lenalidomide, vorinostat and dexamethasone, for relapsed and/or refractory multiple myeloma. Study treatment will be administered in sequential cohorts, with 3-6 subjects in each cohort. Treatment will be administered in 28-day cycles, with the fourth week as a rest week, for 12 cycles or until disease progression or unacceptable toxicity develops.
9970202|NCT01297777|Experimental|Imatinib mesylate|Imatinib mesylate 300 or 400 mg daily for 12 months.
9970203|NCT01297790||Asthma|Subjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
9970204|NCT01297790||Chronic obstructive pulmonary disease|Subjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
9970205|NCT01297790||Healthy Volunteers|Healthy non smoking adults.
9970206|NCT01297790||Healthy smokers|Current smokers with normal breath tests (spirometry)
9970207|NCT01297790||Chronic cough|Subjects with idiopathic chronic cough.
9516807|NCT03312127|Experimental|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
9970208|NCT01297803|Active Comparator|Mitomycin_c application before sclera flap dissection|
9970209|NCT01297803|Active Comparator|Mitomycin_c application after sclera flapdissection|
9970210|NCT01297816|Placebo Comparator|placebo|100mg-
9970211|NCT01297816|Placebo Comparator|minocyclin|
9970212|NCT01297829|Active Comparator|IV Caldolor|
9970213|NCT01297829|Placebo Comparator|Placebo|
9970214|NCT01297842|Experimental|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
9970215|NCT01297842|Active Comparator|Meropenem or Imipenem|Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days
9970216|NCT01297855|Active Comparator|Colistin|Colistate
9970217|NCT01297855|Experimental|Colistin plus Rifampicin|Colistate Rifampin
9970218|NCT01297868||exercise group|
9970219|NCT01297881||Caucasian outpatients with respiratory symptoms|all consecutive new Caucasian outpatients with respiratory symptoms like dyspnoea, cough, sputum but without diagnosis who are being examined for the first time.
9970220|NCT01297894|Active Comparator|colistin|Colistimethate sodium 2.5-5mg/kg iv
9970221|NCT01297894|Active Comparator|colistin plus fosfomycin|colistimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
9970222|NCT01297907||Crohn's Patients|Random Crohn's Disease Patients that can perform Methacholine Challenge Test (MCT)
9970223|NCT01297907||Negative MCT|Patients evaluated for functional cough who had negative Methacholine Challenge Test (MCT)
9970224|NCT01297946|Placebo Comparator|Open-loop|Conventional continuous subcutaneous insulin infusion (CSII) therapy
9970225|NCT01297946|Experimental|Dual-hormone closed-loop|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. The infusion rates are based on continuous glucose sensor reading and a control algorithm.
9970226|NCT01297998|Experimental|gemcitabine , cisplatin|
10141375|NCT04187534|Experimental|Albumin Fluid Resuscitation Optimization Intervention|Our quality improvement intervention seeking to improve appropriate use and reduce inappropriate use of albumin for fluid resuscitation will consist of establishing a clinical champion, educating clinicians, changing the process for albumin ordering through development of an albumin order sheet, and providing quarterly unit-level audit/feedback data to clinicians on albumin utilization.
9970227|NCT01298011|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|
10141376|NCT04187534|Active Comparator|Usual Practice|Stepped-wedge roll out of 'Albumin Fluid Resuscitation Optimization Intervention' will permit those ICUs wherein intervention has not yet been implemented to serve as controls. These ICUs will prescribe albumin according to usual practice and not be exposed to any components of the intervention.
10141377|NCT04187209|Other|Non-traumatic hemiplegia in post stroke acute subacute phase|
10141378|NCT04187157||Blue-light filtering intraocular lens (IOL)|Bilateral implantation of blue-filtering intraocular lens. Blue-IOL, in addition to ultraviolet, also impede the transmission of the lower visible blue spectrum between 400 and 500nm.
10141379|NCT04187157||Conventional intraocular lens (IOL)|Bilateral implantation of conventional ultraviolet light-blocking intraocular lens
10141380|NCT04187287|Active Comparator|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will be given for 3 weeks, 1 days in a week. Moreover 10-12 minutes cold pack will apply for every session.
10141381|NCT04187287|Active Comparator|Deep Friction Massage|Deep Friction Massage treatment will be given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
10141382|NCT04187326|Experimental|6 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test.
10141383|NCT04187326|Experimental|12 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test. Participants in this group will complete this task twelve month after their first visit.
10141384|NCT04187339|Experimental|NGM395 Dose 1|NGM395 Subcutaneous Injection
10141385|NCT04187339|Experimental|NGM395 Dose 2|NGM395 Subcutaneous Injection
10141386|NCT04187339|Experimental|NGM395 Dose 3|NGM395 Subcutaneous Injection
10141387|NCT04187339|Experimental|NGM395 Dose 4|NGM395 Subcutaneous Injection
10141388|NCT04187339|Experimental|NGM395 Dose 5|NGM395 Subcutaneous Injection
10141389|NCT04187339|Experimental|NGM395 Dose 6|NGM395 Subcutaneous Injection
10141390|NCT04187339|Placebo Comparator|Placebo|Placebo
10141391|NCT04187456|Experimental|Midazolam + Savolitinib|"Treatment Period 1: Single administration of midazolam (1 mg) will occur on Study Day 1, after a high fat, high calorie breakfast, followed by PK sampling for 24 hours.~Treatment Period 2: Single administration of midazolam 1 mg in combination with a single administration of savolitinib (600 mg), after a high fat, high calorie breakfast will occur on Study Day 5 and PK sampling will occur for 24 hours."
10141392|NCT04187235||Keyhole rapair|74 patients who undervent parastomal hernia repair with keyhole technique 1997-2009
9669305|NCT03280303||non-interventional study|This prospective, observational study will be conducted according to each site's routine clinical practice.
10141393|NCT04187235||Sugarbaker repair|61 patients who undervent parastomal henia repair a.m. Sugarbaker 2009-2015
10141394|NCT04187170|Experimental|Healthy sedentary subjects exposed to the training program|
10141395|NCT04187391|Experimental|Active tDCS plus individual language training|Active tDCS plus individual language training
10141396|NCT04187391|Active Comparator|placebo tDCS plus individual language training|placebo tDCS plus individual language training
10141397|NCT04187391|Active Comparator|Active tDCS plus unstructured cognitive stimulation|Active tDCS plus unstructured cognitive stimulation
10141398|NCT04187560|Active Comparator|Part A Cohort 1|LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day
10141399|NCT04187560|Active Comparator|Part A Cohort 2|LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day
10141400|NCT04187560|Active Comparator|Part A Cohort 3|LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day
10141401|NCT04187560|Active Comparator|Part A Cohort 4|LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day
10141402|NCT04187560|Active Comparator|Part A Cohort 5|LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day
10141403|NCT04187560|Active Comparator|Part B Cohort 6|LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
10141404|NCT04187560|Active Comparator|Part B Cohort 7|LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
10141405|NCT04187560|Active Comparator|Part B Cohort 8|LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
10141406|NCT04187118||Lymphoma patients|Patients being in complete response after a first therapy for malignant lymphoma.
10141407|NCT04187092|Experimental|KneeBright group|Participants in this group will perform exercises aimed to improve the muscle strength, balance and precision. Participants will perform exercises three times a week for 12 weeks. Each session will last for an hour. Some of the exercises will be performed with the KneeBright Device while playing a video game.
10141408|NCT04187092|Active Comparator|Standard Rehabilitation group|Participants in this group will perform exercises with the same focus and frequency. No exercises will be performed with the KneeBright device.
10141409|NCT04186923|Experimental|Intervention group (IG)|Families receive permanent contact persons to support in the organisation of everyday life, financial applications, during emotional coping with illness and open communication within the family.
10141410|NCT04186923|No Intervention|Control Group|In the control group the families are treated according to the standard of care.
10141411|NCT04187066||Obese|severe obesity
9970228|NCT01298024|Experimental|Early neuromusclar exercise|
9970229|NCT01298024|Active Comparator|Treatment as usual (late training)|
9970230|NCT01298050||Extracorporeal Membrane Oxygenation|All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
9516808|NCT03312101|Experimental|Experimental|exercise program
9669306|NCT03276962|Experimental|R012-20 Group|Subjects will receive full doses of RTS,S/AS01E at Month 0, Month 1, Month 2 and a full dose at Month 20.
9669307|NCT03276962|Experimental|R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and yearly full doses at Month 14, Month 26, Month 38.
9669308|NCT03276962|Experimental|Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38.
9669309|NCT03276962|Experimental|Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32.
9669310|NCT03276962|Experimental|Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2.
9669311|NCT03269396|Experimental|Larynx Allograft Transplantation|Cadaveric laryngotracheal transplantation
9669312|NCT03251911|Experimental|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
9669313|NCT03221400|Experimental|Phase 1a PEN-866 Sodium (Single Agent)|Dose escalation of PEN-866 Sodium administered intravenously
9970231|NCT01298076|Active Comparator|AVASTIN|intravitreal bevacizumab
9970232|NCT01298076|Active Comparator|OZURDEX|intravitreal dexamethasone
9970233|NCT01298102|Experimental|influenza vaccine|Pandemrix vaccine (Influenza A/H1N1 2009)to be injected to renal transplant patients, haemodialyzed patients, and controls
10141412|NCT04187066||Control|Control group with normal weight
10141413|NCT04186715||TOETVA|The demographic data of the patients undergoing TOETVA surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
9970234|NCT01298115||Stage 5 chronic kidney disease|Incident patients commencing renal replacement therapy or conservative care
9970235|NCT01298154|Experimental|Intact Pea Protein (20 g)|
9970236|NCT01298154|Experimental|Hydrolyzed Pea Protein (20 g)|
9970237|NCT01298154|Experimental|Intact Whey Protein|
9970238|NCT01298154|Experimental|Hydrolyzed Whey Protein|
9970239|NCT01298154|Experimental|Water|
9970240|NCT01298180|Experimental|SPW|Children presenting a Prader-Willi Syndrome
9970241|NCT01298180|Experimental|GHD|Patient deficient in Growth Hormone
9970242|NCT01298180|Experimental|SPW-B|Patient with Prader-Willi Syndrome who has Biopsy
9970243|NCT01298180|Experimental|T|Patient Control
9970244|NCT01298180|Experimental|SPW-GH-B|Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
9970245|NCT01298206||H1N1 not exposed controls|For every enrolled H1N1 case, the study will enroll 2 sex matched controls. On the date of enrollment of a case, 2 sex-matched controls will be located from the same clinic from which the case was enrolled. Enrolled controls will then be verified to be free from influenza infection at the time of enrollment by RT-PCR.
9970246|NCT01298206||H1N1 exposed Cases|A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
9970247|NCT01298232|No Intervention|EMAT-guided therapy|electromechanical activation time (EMAT, obtain by phonocardiogram, Audicor, USA)
9970248|NCT01298232|No Intervention|Symptomatic-guided therapy|HF therapy guided by clinical symptoms
9970249|NCT01298245||Case: diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those with known positive results of diabetic retinopathy
9970250|NCT01298245||Control: no diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those without known positive results of diabetic retinopathy
9970251|NCT01298258|Placebo Comparator|placebo|control group
9970252|NCT01298258|Experimental|Aliskiren|Aliskiren 150 mh
9970253|NCT01298271|No Intervention|Cyanoacrylate|Endoscopic Cyanoacrylate Injection treatment of primary prevention GVB
9970254|NCT01298271|Active Comparator|Propranolol|Propranolol is used for primary prevention of GVB
9970255|NCT01298284|No Intervention|EVL\GVS Alone|Endoscopic ligation treatment in the 2nd prevention of gastroesophageal variceal bleeding in patients with HCC
10141414|NCT04186715||Open thyroidectomy|The demographic data of the patients undergoing open thyroidectomy surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
10141415|NCT04186702|Active Comparator|visual acuity letter score|visual acuity letter score is used to compare between the two groups after interventional procedures
9970256|NCT01298284|Active Comparator|EVL\GVS Combined Propranolol|"Propranolol and endoscopic ligation treatment is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~<EVL\GVS Combined Propranolol>"
9970257|NCT01298297|Active Comparator|Buprenorphine + Placebo|
9970258|NCT01298297|Placebo Comparator|Morphine + Placebo|
9970259|NCT01298310|Active Comparator|Xylocaine_1mg|1 injection of Xylocaine (1 mg/mL)
9970260|NCT01298310|Active Comparator|Xylocaine_10mg|1 injection of Xylocaine (10 mg/mL)
9970261|NCT01298310|Placebo Comparator|Placebo|1 injection of placebo
9970262|NCT01298336|Experimental|Clarithromycin|
9970263|NCT01298336|Experimental|Moxifloxacin|
9970264|NCT01298349||schizophrenic patients|
9970265|NCT01298349||normal population|
9970266|NCT01298401|Experimental|Arm A|Dose level -1A (Ganitumab 6 mg/kg, Capecitabine 825mg/m2)
9970267|NCT01298401|Experimental|Arm B|Dose level 1A (Ganitumab 12 mg/kg, Capecitabine 825mg/m2)
9970268|NCT01298401|Experimental|Arm C|Dose level 2A (Ganitumab 20 mg/kg, Capecitabine 825mg/m2)
9970269|NCT01298401|Experimental|Arm D|Dose level -1B (Ganitumab 6 mg/kg, Capecitabine 625mg/m2)
10141416|NCT04186702|Active Comparator|macular thickness(CST)|macular thickness(CST)is used to compare between the two groups after interventional procedures
10141417|NCT04186689||children in fully food secure households (G1)|preschool children live in a fully food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
10141418|NCT04186689||children in marginally food secure households (G2)|preschool children live in a marginally food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
10141419|NCT04186689||children in food insecure households (G3)|preschool children live in a food-insecure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
10141420|NCT04186936|Experimental|Treatment Sequence AB|Participants will receive Test Product A (single dose of 2 caplets [Combination caplet with loperamide hydrocloride [HCl] 2 milligram [mg] + simethicone 125 mg]) orally on Day 1 followed by Reference Product B (single dose of 2 Imodium Express tablets-lyophilizate [2*2 mg loperamide HCl] + 6 Espumisan capsules [6*40 mg simethicone]) orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
10141421|NCT04186936|Experimental|Treatment Sequence BA|Participants will receive Reference product B orally on Days 1 followed by Test product A orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
10141422|NCT04186962|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
10141423|NCT04186962|No Intervention|Usual care|Usual care
10141424|NCT04187001||Judges|Professionals that assess the content validity of the exercise protocol
10141425|NCT04187001||Target population|People that assess the exercise protocol for cultural adaptation
10141426|NCT04186741||HBO Group|Patients already recieving hyperbaric oxygen therapy for treatment of other medical conditions requiring it as in diabetic foot , cerebral infarctions
10141427|NCT04187053|Experimental|Conventional mechanical therapy with aPDT adjunct|Traditional non-surgical mechanical debridement along with antimicrobial photodynamic therapy will be done at implant sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. The dye will be applied topically confined to the epithelialized space surrounding the implant fixture and will not be internalized. After 5 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the implant using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
10141428|NCT04187053|Sham Comparator|Conventional mechanical therapy with sham aPDT treatment|"Control group will have conventional mechanical instrumentation of implant site with Sham aPDT treatment with saline and non-light emitting laser"
10141429|NCT04187014|Active Comparator|Tranexamic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid are 650 mg each. The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
10141430|NCT04187014|Experimental|Aminocaproic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic tablets are 1000 mg each.The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 6 grams (6 tablets) divided between the 3 administrations (2 gram each, ie 2 tablets of 1000 mg) will be administered."
10141431|NCT04186598|Experimental|Experimental: CPAP|Participants will be treated with CPAP. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
10141432|NCT04186598|Placebo Comparator|Control: High flow oxygen|Participants will be treated with an altered CPAP mask that will deliver high flow oxygen. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
10141433|NCT04186559|Experimental|Topical pentoxifylline (PTX) gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical PTX gel in their initial course of treatment will receive topical placebo gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
10141434|NCT04186559|Placebo Comparator|Topical placebo gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical placebo gel in their initial course of treatment will receive topical PTX gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
10141435|NCT04186546||Cases|Zephyr Valve Procedure
10141436|NCT04186897|Experimental|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
10141437|NCT04186897|Sham Comparator|No occlusal reduction|Occlusal surfaces kept intact. No actual occlusal reduction..
9669314|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid|Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
10141438|NCT04186754|Experimental|Comprehensive functional care plan|"The intervention will be carried out thanks to the reeducation to the effort carried out in the individuals, which will have the following interventions:~The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy."
10141439|NCT04186754|Active Comparator|Traditional intervention without rehabilitation|"Nursing care.~Medical care.~Spiritual attention."
10141440|NCT04186910|Placebo Comparator|Control group|The control group will not receive any feedback on levels of physical activities but will receive any planned usual care rehabilitation activities
9669315|NCT03221400|Experimental|Phase 2a PEN-866 Sodium (Single Agent)|Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
10141441|NCT04186910|Experimental|Feedback group|The feedback group will have an active feedback intervention of physical activities, consisted of daily feedback, received through a Fitbit application, and weekly meeting group focused on enhancing behavioral strategies to increase self-efficacy and motivation. The experimental group will receive any planned usual care rehabilitation activities.
10141442|NCT04186767|Experimental|Weight loss|
10141443|NCT04186520|Experimental|8/12 Day Production of CAR-T|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at eight or 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
9669316|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Niraparib|Dose escalation of intravenous administration of PEN-866 Sodium in combination with niraparib
9669317|NCT03197662|Experimental|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
10141444|NCT04186520|Experimental|12-Day Production of Car-T Cells|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.~Phase 1b: Six to nine patient expansion cohorts at 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
10141445|NCT04186520|Experimental|Phase 2 - Efficacy of CAR-20/19-T cells in MCL|"Single-stage Phase II design with 3-month CR as the target endpoint.~Optimal production times will be determined following phase 1 of the study."
10141446|NCT04186676||MINOCA patients|Prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in consecutive patients with Myocardial Infarction with Non-Obstructive Coronary Arteries admitted to study clinical sites
10141447|NCT04186533|Experimental|Default Intervention|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
10141448|NCT04186533|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read brief nutrition education handouts before online grocery shopping.
10141449|NCT04186728|Placebo Comparator|Placebo to magnesium|Participants will be asked to consume a daily placebo (cellulose) capsule for 12 weeks. They will then cross-over and consume 200mg of elemental magnesium in the form of magnesium glycinate daily for 12 weeks.
10141450|NCT04186728|Experimental|Magnesium to placebo|Participants will be asked to consume 200mg of elemental magnesium in the form of magnesium glycinate daily. They will then cross-over and consume a daily placebo (cellulose) capsule for 12 weeks.
10141451|NCT04186468|Experimental|ICU follow-up clinic|Participants will be invited to visit the ICU follow-up clinic.
10141452|NCT04186468|No Intervention|Usual care|Participants will solely receive usual care.
10141453|NCT04186611|Experimental|Early daily occupational therapy intervention|A daily occupational therapy intervention is performed with the patients included. The intervention will consist of assessment as well as early positioning and/or rehabilitation in activities of daily living.
10141454|NCT04186585|Experimental|First design level|All the 8 patients receives a daily oral dose of BP-C2 in ml equals the body weight divided by 5 for 4 weeks. This represents 15 ml for a patient of 75 kg
10141455|NCT04186585|Experimental|Second design level|Based on the results from the first design level, the daily BP-C2 dose will individually be increased by a factor of 1.4 or 1.2 in case of none or mild toxicity increase. If moderate or severe increase in toxicity is observed, the individual dose will be reduced by 0.8 or 0.6, respectively. Duration of the treatment is 4 weeks
10141456|NCT04186585|Experimental|Third design level|Based on the results from the second design level, the daily BP-C2 dose will individually be increased in case of none or mild toxicity increase and reduced if moderate or severe increase in toxicity is observed. Duration of the treatment is 4 weeks
10141457|NCT04186975||Low-risk pregnant women|Normal cohort: this cohort consists of pregnancies which are not at risk. Data are recorded during the normal checkup happening as part of the usual care pathway
10141458|NCT04186975||High-risk pregnant women|Risk cohort: this cohort consists of pregnancies at risk and which are regularly recorded for the purpose of fetal surveillance. Specifically, the investigators recruit pregnancies with intra uterine growth restricted fetuses for this study.
10141459|NCT04186624|Experimental|Supervised Exercise Program|The exercise program that applied at the hospital includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
10141460|NCT04186624|Active Comparator|Home-based Exercise Program|The home-based exercise program given with a brochure that includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
9669318|NCT03197662|Placebo Comparator|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
10141461|NCT04186273|Sham Comparator|Donor Site Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
9516809|NCT03312101|No Intervention|Control|observation
9669319|NCT03138720|Experimental|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
9669320|NCT03137888|Experimental|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
9669321|NCT03136809|Experimental|Cu(II)ATSM|Cu(II)ATSM administered once daily
9970270|NCT01298401|Experimental|Arm E|Dose level 1B (Ganitumab 12 mg/kg, Capecitabine 625mg/m2)
9970271|NCT01298401|Experimental|Arm F|Dose level 2B (Ganitumab 20 mg/kg, Capecitabine 625mg/m2)
9970272|NCT01298466|Experimental|Pregabalin|Open label study. All patients fulfilling the protocol inclusion/exclusion criteria will receive pregabalin in a flexible-dosing regimen.
10141462|NCT04186273|Experimental|Donor Site Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
10141463|NCT04186273|Experimental|Donor Site Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested)
10141464|NCT04186273|Sham Comparator|Skin Graft Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the skin grafted wound site.
10141465|NCT04186273|Experimental|Skin Graft Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the skin grafted wound site.
10141466|NCT04186273|Experimental|Skin Graft Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the skin grafted wound site.
10141467|NCT04186338||Patients with myelomeningocele|Patients diagnosed myelomeningocele with the neurological level between L5 and S3
10141468|NCT04186338||Healthy controls|age-, sex-, and body mass index-matched healthy controls
10141469|NCT04186507||Prelaminary group|To confirm that Li+ is detectable in sweat .
10141470|NCT04186507||Spectrophon LTD biosensors for Li+ detection in sweat|In this group will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat
10141471|NCT04186234|Experimental|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 35 to 50 Grays in 5 fractions over 5 to 14 days.
10141472|NCT04186260|Experimental|NAFLD-specific weight loss intervention|Participants will attend 12 weekly 30-45-minute individual counseling sessions and receive tailored lesson materials focused on behavioral strategies for adopting and maintaining healthy eating and physical activity (PA) behaviors. Participants will self-monitor their body weight, eating, and PA behaviors in a weekly journal. Dietary recommendations will follow nutritional guidelines for the treatment of NAFLD. To facilitate the adoption of the dietary recommendation, participants will be provided culturally-tailored meal plans and grocery lists that allow them to make small, practical dietary changes of ~100 calories. Participants will be prescribed weekly exercise goals with the duration increasing from 15-45 minutes, 5 days/week, over the 12-month program. After the completion of 12 weekly individual counseling sessions, participants will complete a 12-week follow-up including bi-weekly phone calls, followed by a 6-month follow-up period in which no intervention contact is made.
10141473|NCT04186260|Other|Wait-list control|The wait-list control group will receive the same intervention strategies described for the NAFLD-specific weight loss intervention after study comparisons have been made.
10141474|NCT04186390||Medical doctors|Medical doctors with no prior experience in the evaluation of small bowel capsule endoscopy.
10141475|NCT04186364|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the ED visit will serve as our intervention group. The participants will be assigned an Ambassador throughout the child's ED visit and will complete a patient satisfaction survey afterwards. The investigators hold to enroll 120 controls.
10141476|NCT04186364|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the ED visit will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the ED visit, however no ambassador will be assigned during the ED visit. The investigators hope to enroll 120 controls.
10141477|NCT04186351|Experimental|Encounter notification service|For participants randomized to the intervention group, their encounter information stored in the eHRSS will be provided to the SCHSA via the automated notification service. Healthcare professionals of the SCHSA would access the electronic health record and provide caring support and services via telephone calls during the 12-month study period.
10141478|NCT04186351|No Intervention|Usual care service|For participants randomized in the control group, no notification will be sent to the SCHSA. Usual care service will be provided during the 12-month study period. In addition, each control participant will receive placebo phone calls at least once every three months (e.g., the calls could be about greeting and general checking).
10141479|NCT04186299|Experimental|Clonidine + articaine/epinephrine|1.7mL of 4% articaine/epinephrine(1:100,000) + clonidine (15ug/ml)
10141480|NCT04186299|Active Comparator|articaine/epinephrine|1.7mL of 4% articaine with 1:100,000 epinephrine
10141481|NCT04186312|Experimental|Immediate Treatment|Cognitive-Behavioral Treatment program known as ACCESS
10141482|NCT04186312|Other|Delayed Treatment|Allowed to receive treatment as usual during study, then received ACCESS after delay of two-semesters
10141483|NCT04186377|Active Comparator|Standard-of-care managed group|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
10141484|NCT04186377|Experimental|S26E|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers plus daily S26E application
10141485|NCT04186416||Patients less than 6 months old|Patients less than 6 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
10141486|NCT04186416||Patients between 6 and 12 months old|Patients between 6 and 12 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
9516810|NCT03312075||cystic fibrosis patients|Sputum and blood samples
9516811|NCT03312062|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
9516812|NCT03312062|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
9516813|NCT03312036|Experimental|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
9970273|NCT01298479||Group 1|All subjects
9970274|NCT01298505|Experimental|PF-03654764 2.5mg plus fexofenadine 60mg|
9970275|NCT01298505|Experimental|PF-03654764 5mg plus fexofenadine 60mg|
10141487|NCT04186416||Patients between 1 and 6 years old|Patients between 1 and 6 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
10141488|NCT04186416||Patients between 6 and 10 years old|Patients between 6 and 10 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
10141489|NCT04186039|Experimental|Congenital diaphragmatic and parietal malformations|Patients with fetal magnetic resonance imaging as part of their usual medical care, for fetal / placental indications of diaphragmatic hernia, omphalocele or gastroschisis.
10141490|NCT04186078||obstructive sleep apnea (OSA)|5 or more predominantly obstructive respiratory events [obstructive and mixed apneas, hypopneas or respiratory effort-related arousals (RERAs)] per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
10141491|NCT04186078||central sleep apnea (CSA)|"PSG shows all of the following:~5 or more central apneas and/or central hypopneas per hour of sleep.~The number of central and/or central hypopneas is > 50% of the total number of apneas and hypopneas."
10141492|NCT04186078||control|apnea-hypopnea index < 5 per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
10141493|NCT04185974|Experimental|C12 irradiation|Evaluation of Safety and Toxicity of C12 ion reirradiation
10141494|NCT04185974|Active Comparator|Photon irradiation|Evaluation of Safety and Toxicity of photon re-irradiation
10141495|NCT04186000|Experimental|group 1|Booster vaccine with AD26.ZEBOV after 1 year
10141496|NCT04186000|Experimental|group 2|Booster vaccine with AD26.ZEBOV after 2 years
10141497|NCT04186182|Other|CICI - Feasibility trial study group|The feasibility of the entire CICI-protocol will be evaluated. See details above.
10141498|NCT04185870|Experimental|3D scan and standard photography arm|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum. In addition, all participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
10141499|NCT04186104|Experimental|Patients with routine outpatient service process|After registration, the patient waits in line at the door of the doctor's office. His doctor uses traditional methods to enter medical records by hand and make diagnosis independently. Then the patient waits in line to pay the bill and queues up for examination. Finally, the patient would take the examination report back to the doctor.
10141500|NCT04186104|Experimental|Patients with AI assisted outpatient service process|After registration, the patient binds his information to the mobile phone application through outpatient' number. First, AI system would ask the patient a series of questions. Then it would make a judgment based on the patient's response. The system transmits the examination items to the doctor's computer and, with the doctor's approval, sends items back to the patient. So, patient could go straight to do the examination. While waiting for his turn, the patient enters the phone program again, and the AI system collects his medical history. The information is sent back to the doctor. When the patient goes to the doctor's office with the examination report, the doctor's computer already has his medical records. The doctor only needs to adjust the history according to the actual situation. After writing the medical history, the AI system could automatically make the diagnosis. Doctor uses the AI' results and his own judgment to make a comprehensive diagnosis.
10141501|NCT04186013|Experimental|Experimental arm|Atezolizumab 1200 mg intravenous infusion every 3 weeks for a total of 6 doses combined with External Beam Radiation Therapy (EBRT) (dosage: 60 Gy in 30 fractions overs 6 weeks at 2Gy/day)
10141502|NCT04185961|Experimental|EVERA-RAPHA with 60mmHG|EVERA-RAPHA apply 15 minutes with 60mmHG every day for 4 weeks
10141503|NCT04185961|Experimental|EVERA-RAPHA with 100mmHG|EVERA-RAPHA apply 15 minutes with 100mmHG every day for 4 weeks
10141504|NCT04186156|Experimental|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
10141505|NCT04186143|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, closed cinetic chain exercises were applied for 12 weeks.
10141506|NCT04186143|Active Comparator|Active Comparator|In addition to the conservative treatment of the control group, opened cinetic chain exercises were applied for 12 weeks.
10141507|NCT04186143|Other|Control Group|Conservative treatment was applied for 12 weeks.
10141508|NCT04185987|Experimental|Microbial colonisation|microbial sample collection was done at the end of the time periods T1 (6 weeks after bonding ), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
10141509|NCT04185987|Experimental|Plaque index|Plaque index was measured prior to bonding (T0), 6 weeks after bonding (T1),10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
10141510|NCT04185987|Experimental|Gingival index|Gingival index was measured prior to bonding (T0), 6 weeks after bonding (T1), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
10141511|NCT04185987|Experimental|surface roughness|surface roughness was measured before usage and after 4-weeks usage
10141512|NCT04185922|Experimental|Hemopatch|The RARP and BPLND are performed in the usual manner. Towards the end of the operation, Hemopatch is laid over the ends of raw truncated lymphatic tissue.
10141513|NCT04185922|No Intervention|Control|The RARP and BPLND are performed in the usual manner. Hemopatch will not be applied to control group.
10141514|NCT04186026|Other|Saline+Saline|
10141515|NCT04186026|Other|Neurotensin+Saline|
10141516|NCT04186026|Other|GLP-1+Saline|
10141517|NCT04186026|Other|Neurotensin + GLP-1|
10141518|NCT04186052|Experimental|BCMA CAR-T cells Infusion|
10141519|NCT04185935||Ancillary-correlative (biospecimen collection)|Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
10141520|NCT04185792||Patients with spinal cord injury|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
10141521|NCT04185792||Patients with multiple sclerosis|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
9970276|NCT01298505|Placebo Comparator|placebo|
10141522|NCT04185779||Group A (Cross-sectional arm)|This group will comprise of 10,000 patients who have been referred for a colonoscopy. We will be collecting information on their past medical history, smoking history, alcohol history, medication history and family history in addition to their colonoscopy findings. In 6000 of these patients, they will have blood tests, Faecal Immunochemical Test (FIT) level, blood or saliva for DNA extraction and stool microbiome taken. In 4000 of these patients, we will record recent blood tests of interest and they will have no new samples taken. All 10000 patients will also either complete a food frequency questionnaire or endoscopy patient experience questionnaire.
10141523|NCT04185779||COLO-SPEED (Group B, consent for contact arm)|This will be 10,000 patients who will consent for future contact for future research studies.
10184697|NCT03752788|Experimental|Dual-task Training Fixed Priority|"Dual-task Training with fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
10184698|NCT03752788|Active Comparator|Dual-task Training Variable Priority|"Dual-task Training with variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
10184699|NCT03752775|Experimental|subacute device assisted group|
10184700|NCT03752775|Active Comparator|subacute conventional group|
10184701|NCT03752775|Other|chronic device assisted group|
10184702|NCT03752749|Experimental|Prednisolone + Acute Intermittent Hypoxia|
10184703|NCT03752749|Placebo Comparator|Placebo + Acute Intermittent Hypoxia|
10184704|NCT03752736|Active Comparator|Extended intervention|"Upon completion of the two-week baseline period and two-week standard intervention period, the two classrooms assigned to the Extended intervention condition will receive the I wear sunscreen everyday song-based video intervention daily for two additional weeks."
10184705|NCT03752736|No Intervention|Maintenance|"The two classrooms assigned to the Maintenance condition will continue to receive a two- minute window for sunscreen application, but no I wear sunscreen everyday song-based video instruction.~Change trajectories from Time 3-Time 4 (two-week follow up) will be compared by follow-up assignment condition and will provide preliminary information about dosing and maintenance effects."
10184706|NCT03752697||Neurological injury|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
10184707|NCT03752697||Healthy control|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
10184708|NCT03752671|Experimental|the IntraSPINE® device associated with discectomy|
10184709|NCT03752671|Active Comparator|discectomy alone|
10184710|NCT03752658||Tenofovir alafenamide (TAF)|Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
10184711|NCT03752645|Experimental|intervention|Transverse Many Channels Laser Instrument
10184712|NCT03752645|No Intervention|control|
10184713|NCT03752632|Experimental|Veinplicity with tourniquet (treatment)|Veinplicity with tourniquet
10184714|NCT03752632|Active Comparator|Tourniquet (control)|Control: Tourniquet
10184715|NCT03752606|Active Comparator|TACHOSIL GROUP|Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
10184716|NCT03752606|No Intervention|GROUP WITHOUT TACHOSIL|The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.
10184717|NCT03752593||Obese|Patients with a BMI of greater than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
10184718|NCT03752593||Non-Obese|Patients with a BMI of less than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
10184719|NCT03752580|Experimental|Arm|Experimental: User Instructions of a Novel Nasal Mask Participants to interpret user instructions in a one hour daytime visit.
10184720|NCT03752541|Experimental|BCMA-UCART|Each subject will accept one of the following dosages of BCMA-UCART cells intravenously (IV) on day 0: 0.5-1*10~6/KgBW, 1-2*10~6/KgBW,2-3*10~6/KgBW.
10184721|NCT03752515||case|
10184722|NCT03752515||control|
10184723|NCT03752502|Experimental|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
10184724|NCT03752502|Experimental|Combined stimulation|"Active transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
10184725|NCT03752502|Sham Comparator|Sham cerebral stimulation|"Sham transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes (30s ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
10141524|NCT04185909|Experimental|All Subjects|Subjects will be treated with the Renuvion Dermal System.
10141525|NCT04185857||Patients with primary aldosteronism (PA)|"After two biochemical and clinical evaluations under baseline conditions PA patients will be treated with canrenone 50-100 mg orally once a day.~After one month of such therapy they will undergo the a clinical and biochemical evaluation (FW1). After, they will continue with a combination therapy with canrenone, plus olmesartan starting with 10 mg a day for oral administration, a dose that can be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2)."
10141526|NCT04185675|Active Comparator|Macintosh laryngoscope|
10141527|NCT04185675|Experimental|nonadjustable videolaryngoscope|
10141528|NCT04185675|Experimental|adjustable videolaryngoscope|
10141529|NCT04185701|Experimental|Eye examination by expert and SiVIEW software|Eye examination by an expert and by a technician with the SiVIEW system.
9669322|NCT03132467|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.
10141530|NCT04185766|Placebo Comparator|Placebo (0,5 ml/Kg)|
10141531|NCT04185766|Placebo Comparator|Placebo (1 ml/Kg)|
10141532|NCT04185766|Experimental|Destrogel (0,5 ml/Kg)|
10141533|NCT04185766|Experimental|Destrogel (1 ml/Kg)|
10141534|NCT04185597|Experimental|HFP Intervention: Delivery by Community Farmers|"HFP- Delivered by community farmers, supported by the study and linked to eligible households to educate on growing nutritious food and poultry rearing or fish culture~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female community nutrition promoters (CNPs) will refer PLW to service delivery points; gradually this will be completed by peer leaders~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will later be replaced by peer leaders"
10141535|NCT04185597|Experimental|HFP Intervention: Delivery by agricultural Retailers|"HFP- Delivered by agricultural Retailers, supported by the study and linked to eligible households to educate on growing nutritious food and either poultry raring or fish culture~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female CNPs will refer PLW to service delivery points; gradually this will be completed by peer leaders~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will be replaced by peer leaders"
9528299|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
9528300|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
9528301|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
9669323|NCT03115918|Active Comparator|Pancreatic Duct Stent Placement|Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.
10141536|NCT04185597|Active Comparator|Standard of Practice|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
10141537|NCT04185636||Skin Graft Patients|There will only be 1 group, patients receiving a skin graft and MolecuLight i:X imaging
10141538|NCT04186169|Placebo Comparator|Arm 1: Paroxysmal AF - PVI arm|The subjects with paroxysmal AF undergo pulmonary vein isolation (PVI).
10141539|NCT04186169|Placebo Comparator|Arm 2: Persistent AF - PVI arm|The subjects with persistent AF undergo pulmonary vein isolation (PVI).
10141540|NCT04186169|Experimental|Arm 3: Persistent AF - PVI + Fat-targeted ablation|The subjects with persistent AF undergo pulmonary vein isolation (PVI) and additional ablation to target the inflammatory fat tissue
10141541|NCT04185831|Experimental|NF1/MAP2K1|Cobimetinib, 60mg po daily. 28 day cycle; day 1-21 60mg daily, day 22-28 rest period.
10141542|NCT04185831|Experimental|MTOR/TSC1/TSC2|Everolimus, 10mg po daily.
10141543|NCT04185831|Experimental|Mutation burden|Atezolizumab. 1200mg iv every 3 weeks.
10141544|NCT04185558|Experimental|ActiGraft|Whole blood clot (WBC) gel
10141545|NCT04185558|Active Comparator|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
10141546|NCT04185948|Experimental|Mediterranean diet plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
9669324|NCT03115918|Active Comparator|No Pancreatic Duct Stent Placement|Subject will not have a pancreatic Duct stent placed.
9669325|NCT03107988|Experimental|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
9669326|NCT03107988|Experimental|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
10141547|NCT04185948|Active Comparator|Eatwell guide plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
10141548|NCT04185753||Obese adolescents with CI|Obese adolescents with chronotropic incompetence
10141549|NCT04185753||Control group|Obese adolescents without chronotropic incompetence
10141550|NCT04185519|Experimental|AI (model)|This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
10141551|NCT04185519|No Intervention|DR1|Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl.
10141552|NCT04185818|Experimental|Reading group|"Participants will:~Read a book for 15 to 30 mins~Read immediately before trying to go to sleep."
10141553|NCT04185818|No Intervention|Control Group|"Participants will:~1. Not read a book"
10141554|NCT04185805|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
9970277|NCT01298557||Traumatic brain injured patients|This group consists of participants who suffered a traumatic brain injury an average of 4 months to 4 years prior to testing. Patients must not have history of prior head injury, substance abuse, psychiatric illness, or contraindications to MRI.
9970278|NCT01298557||Controls (no traumatic brain injury)|This group consists of participants who do not have a history of brain trauma. Furthermore, controls must not suffer from substance abuse, psychiatric illness, or have contraindications to the MRI.
10141555|NCT04185805|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
10141556|NCT04185467|No Intervention|Usual care(both arms)|Usual care (both arms): Patients in both arms will receive usual medical, physiotherapy and nursing care according to usual protocols. This does not involve exercise rehabilitation or advice.
10141557|NCT04185467|Experimental|Intervention (exercise rehabilitation)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
10141558|NCT04185740|Experimental|Home-based validation|The home-based validation of the TTT will give insight in the task performance of patients OFF-medication compared to ON-medication and on different time points in the medication cycle during 7 days
10141559|NCT04185532|Experimental|Rebound ACL brace and physiotherapy|The intervention will be the use of rebound ACL brace for 9 weeks, which initially is locked followed by a gradually increased range of motion. A standardized rehab protocol is applied.
10141560|NCT04185532|Active Comparator|Physiotherapy|A standardized rehab protocol comparable to the experimental group but with no brace
9669327|NCT03107988|Experimental|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
10141561|NCT04185714|Experimental|Experimental group|Experimental group will be applied Kinesotaping , exercise programme will be given.
10141562|NCT04185714|No Intervention|Control group|Exercise programme will be given.
10141563|NCT04185714|Placebo Comparator|Placebo group|Sham taping will be applied, exercise programme will be given.
10141564|NCT04185688||Multiple Sclerosis|"Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~Biodex Balance System: Biodex Balance System is used to evaluate limits of stability. The limits of stability test consists of standing on the platform and leaning in eight directions to make a cursor displayed on the system's screen hit a target.~Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
10141565|NCT04185688||Healthy People|Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.
10141566|NCT04185727|No Intervention|Standard of Care (SOC)|Therapy control group
10141567|NCT04185727|Experimental|Standard of Care (SOC) + strength training|Strength training intervention as add on to therapy
10141568|NCT04185649|Experimental|BAT8001 for injection|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
10141569|NCT04185649|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
10141570|NCT04185480|No Intervention|Conventional|Historical cohort of patients that underwent axillary clearance without hemopatch.
10141571|NCT04185480|Experimental|Intervention|Prospective cohort of patient undergoing axillary clearance with hemopatch
10141572|NCT04185506|Experimental|DBT and behavioral weight loss|The intervention is a 16-week group-based behavioral program consisting of a combination of Dialectical Behavioral Therapy (DBT) skills and behavioral weight loss techniques.
10141573|NCT04185324|Experimental|Standard zippering vest|Children receive three supervised sessions for them to practice engaging and pull up a zipper, using a standard teaching zippering vest.
10141574|NCT04185324|Experimental|Modified zippering vest|Children receive three sessions of specially designed zippering instruction using a modified zippering vest, where they can practice engaging and pulling up a zipper after being read a related story.
10141575|NCT04185350|Experimental|68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 60 min later.
10141576|NCT04185402|Active Comparator|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
10141577|NCT04185402|No Intervention|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
10141578|NCT04185181|Active Comparator|virtual reality|
10141579|NCT04185181|Active Comparator|propreoceptive neuromuscular facilitation|
10141580|NCT04185376||group A 200 patients|patients with one or more PFDs significant psychological strain in at least one pelvic floor domain
10141581|NCT04185376||group B 200 patients|patients without any pelvic floor complaints
10141582|NCT04185623||Group A (immediate denudation)|Oocytes were denudated immediately after oocyte retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
10141583|NCT04185623||Group B ( 2hs denudation after ovum pickup)|Oocytes were denudated 2 hours after retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
10141584|NCT04185493||CCTA Cohort|Consecutive patients with suspected coronary artery disease and low/intermediate pre-test probability
10141585|NCT04185454|Experimental|First design level|Three Healthy Voluntary (HV) women were give the same starting daily dose of 100 g Jarlsberg
10141586|NCT04185454|Experimental|Second design level|Based on the results from the starting dose 5 + 5 HV get a new daily doses of Jarlsberg cheese
10141587|NCT04185454|Experimental|Third design level|Based on the results from the second design level, the daily dose of Jarlsberg cheese for the next 7 HVs was given
10141588|NCT04185662|Placebo Comparator|placebo|intake 200 ml water daily for 3 months
10141589|NCT04185662|Experimental|low dose sucrolose group|intake 12.3mg sucralose in 200 ml water daily for 3 months
10141590|NCT04185662|Experimental|moderate dose sucrolose group|intake 73.8mg sucralose in 200ml water daily for 3 months
10141591|NCT04185233|Experimental|iPad distraction|"Children of this group will receive the iPad when the nurse will prepare the material for the venous track. They will choose a game adapted to their age and will be able to play it during all the procedure time.~Intervention : game on iPad"
10141592|NCT04185233|Active Comparator|Nitrous Oxide|"Children of this group will receive the Nitrous Oxide 3 minutes before the intervention (venous track). They will keep the mask during all the procedure time.~Intervention : Nitrous Oxide"
10141593|NCT04185142||combined procedure group|patients underwent cryoballoon ablation and left atrial appendage closure
10141594|NCT04185571|Experimental|PEPA membrane|PEPA membrane is an adsorbant synthetic copolymer (Poly Ester Poly Arylate)
10141595|NCT04185571|No Intervention|non adsorbent membrane|Comparison with non adsorbent membrane used in routine
10141596|NCT04185155|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
10141597|NCT04185155|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
10141598|NCT04185051|Experimental|Cohort 1: JNJ-67953964 or Placebo|Participants will receive JNJ-67953964 or matching placebo oral capsules once daily (QD) over 4 weeks (28 days).
10141599|NCT04185051|Experimental|Cohort 2: JNJ-67953964 or Placebo|Participants in this cohort will receive JNJ-67953964 only or will be randomly assigned to receive JNJ-67953964 or matching placebo.
10141600|NCT04185025|Experimental|CeraVe Moisturising Lotion|
10141601|NCT04185025|Active Comparator|Half Mu ceramide body milk|
10141602|NCT04185064|Experimental|Cryopnematic Device (Randomized Component)|Game Ready shoulder wrap is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises.
10141603|NCT04185064|Active Comparator|Standard Care|Ice is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the ice will be applied by the patient or a health care provider; as cold as comfortable; 30 min on:60 min off; use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off; use minimum of twice/day. The patients in the control group will receive pain management strategies as would be normally dictated by the physician/therapist. This may include the use of ice, ice packs and compression bandages, as well as pain medications, range of motion, and positioning exercises
10141604|NCT04185064|Other|Cryopneumatic Device (Observational Cohort)|Game Ready® shoulder wrap is applied in the operating room and used in the recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises
10141605|NCT04185389||Control|Women in the original HPV FOCAL control arm who completed the 48 month exit screen (HPV/LBC co-test) and who had no CIN2+ detected during the trial or at trial exit will be invited to submit another LBC sample for HPV and cytology co-testing.
10141606|NCT04185129|Experimental|Foster|uncontrolled asthma patients were randomized into Foster treatment group
10141607|NCT04185129|Active Comparator|Relvar|uncontrolled asthma patients were randomized into Relvar treatment group
10141608|NCT04184843|Experimental|iWalk Toolkit|"Intervention period: 5 months~Intervention:~A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~Access to a clinical expert by email or phone"
10141609|NCT04184947||SGLT2i|Patients who received new prescription of a SGLT-2 inhibitor
10141610|NCT04184947||GLP-1RA|Patients who received new prescription of a GLP-1 receptor agonist
10141611|NCT04185077|Experimental|Experimental|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
10141612|NCT04185077|Active Comparator|Control|a bolus dose of 100 U/kg Heparin was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
10141613|NCT04185116|Experimental|3D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
10141614|NCT04185116|No Intervention|2D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
10141615|NCT04185116|Experimental|3D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
10141616|NCT04185116|No Intervention|2D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
10141617|NCT04184856||Binge eating disorder (BED) patients|Individuals with BED diagnosis.
10141618|NCT04184856||non-BED controls|Individuals that do not experience binges
10141619|NCT04184856||subsyndromal BED controls|individuals that experience binges but do not fulfill the requirements for BED diagnosis.
10141620|NCT04185194|Active Comparator|group A|received especially designed physical therapy program
10141621|NCT04185194|Experimental|group b|received pulsed ultrasound in addition to physical therapy program
10141622|NCT04185194|Experimental|group c|received lidocaine phonophoresis in addition to physical therapy program
10141623|NCT04185090|Active Comparator|ID1801|qd daily for 6days Intervention: Drug: administration of ID1801 for 6days.
10141624|NCT04185090|Active Comparator|ID1803|qd daily for 10days Intervention: Drug: administration of ID1803 for 10days.
10141625|NCT04185090|Experimental|ID1801 and ID1803|qd daily for 7days Intervention: Drug: administration of ID1801 and ID1803.
10141626|NCT04184986||inflammatory bowel disease|100-150 pts with dg. inflammatory bowel disease
10141627|NCT04184986||unspecific GI symptoms|100-150 pts unspecific GI symptoms
10141628|NCT04184869|Other|Wild Type UGT1A1|"Cohort A: Wild Type, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
10141629|NCT04184869|Other|Heterozygous UGT1A1*28|"Cohort B: Heterozygous, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
10141630|NCT04184869|Other|Homozygous UGT1A1*28|"Cohort C: Homozygous, UGT1A1, Belinostat IV Dose: 750 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
10141631|NCT04184869|Other|Belinostat & Atazanavir|"Arm: Homozygous UGT1A1*28 genotype subjects with Belinostat IV & Atazanavir~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir)~Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
10141632|NCT04185168|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 tablets)
10141633|NCT04185168|Placebo Comparator|control|2 tablets of placebo
10141634|NCT04184960||Gastric cancer cohort|Cohort of patients with gastric cancer
10141635|NCT04184960||Non-gastric cancer cohort|Cohort of patients without gastric cancer
10141636|NCT04185103||Sacubitril-Valsartan cohort|Patients with left systolic disfunction (left ventricle ejection fraction<40%) heart failure and diagnosed with grade II heart failure that have been treated with an ACE or ARA II+betablocker at stable doses during the last 4 weeks and after being evaluated by the cardiologist start Sacubitril-Valsartan treatment.
10184726|NCT03752502|Experimental|Peripheral stimulation|"Active peripheral electrical stimulation (PES).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
9669328|NCT03107988|Experimental|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
10141637|NCT04184921||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
10141638|NCT04184921||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
10141639|NCT04184908|Experimental|GROUP EXPERIMENTAL|Gel xerostomia Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
10141640|NCT04184908|Placebo Comparator|CONTROL GROUP|Gel placebo Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
10141641|NCT04184674|Other|Acute Respiratory Distress Syndrome|Children of more than one month of age and adults hospitalized in Intensive Care Unit for Acute Respiratory Distress Syndrome.
10141642|NCT04184700|Experimental|EHCF + LGG|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
10141643|NCT04184700|Active Comparator|RHF|Extensively hydrolyzed rice formula
10141644|NCT04184700|Active Comparator|EHWF|Extensively hydrolyzed protein formula
10141645|NCT04184700|Active Comparator|AAF|Amino acid based formula
10141646|NCT04184713|Experimental|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
10141647|NCT04184713|Active Comparator|Control group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
10141648|NCT04184830|Experimental|tDCS arm|"Active stimulation:~Direct current will be transferred using a pair of saline-soaked surface sponge electrodes (5x7). For anodal stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 minutes, which will result in current density of 0.08 mA/cm².In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
10141649|NCT04184830|Sham Comparator|tDCS sham|"Sham stimulation:~During the sham stimulation a pair of saline-soaked surface sponge electrodes (5x7) will be places on the scalp For sham stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 seconds.In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
10141650|NCT04184544|Experimental|Maternal and Newborn health districts|Group one included maternal and newborn health districts. These districts are further divided into three sub groups. Sub group 1 will receive only interventions focusing on maternal health (1 district (Sangher)); sub group 2 will receive interventions focusing only on newborn health (1 district (Nasirabad)); sub group 3 will receive combined maternal and newborn interventions (two districts (, Lasbila and Badin).
10141651|NCT04184544|Experimental|Child Health|Group two will receive child health interventions focusing on the implementation of the global action plan for pneumonia and diarrhea (GAPPD [4districts, Qamabar Shahdadkot Muzaffargarh, Rahim Yar Khan Jafferabad).
10141652|NCT04184739|Active Comparator|Group A|Standard treatment information (verbal and written) and access to a basic version of the App with a toothbrushing timer. The timer is necessary as the health behaviour outcome is toothbrushing duration.
10141653|NCT04184739|Experimental|Group B|As for group A, however, additionally the App will provide generic treatment information (a combination of videos and text)
10141654|NCT04184739|Experimental|Group C|As for group B, however, the patients will have access to the full functionality of the App and the App will allow patients to input their own personalised treatment information (including progress photographs), set goals, develop plans for achieving these and provide the patient and clinicians with appropriate dashboards to monitor progress.
10141655|NCT04184596||Stated-Preferences Observational Group|A discrete choice experiment will be conducted with participants with peripheral neuropathic pain in the stated-preferences observational group. The instrument will measure patient preferences for topical versus systemic pain treatment.
10141656|NCT04184817||Medical data collection|The medical data of patients diagnosed by Achondroplasia will be collected. The radiological data will analyse to evaluate the severity of stenosis as well as its clinical tolerance and evolution.
10141657|NCT04184687|Experimental|Nanofractures treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction with concomitant treatment of the cartilaginous lesions with nanofractures technique.
10141658|NCT04184687|Active Comparator|no treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction. Cartilaginous lesions won't be treated
10141659|NCT04184414|Experimental|CART cells|dosage：Once dose，1.0*10^6cells/kg CART cells Administration mode:Intravenous infusion
10141660|NCT04184752||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
10141661|NCT04184752||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
10141662|NCT04184752||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
10141663|NCT04184778|Experimental|Woman tube size 6.0|Smaller tube than normal
10141664|NCT04184778|No Intervention|Woman tube size 7.0|Usual tube size
10141665|NCT04184778|Experimental|Man tube size 7.0|Smaller tube than normal
10141666|NCT04184778|No Intervention|Man tube size 8.0|Usual tube size
10141667|NCT04184440|Placebo Comparator|placebo|corn starch；capsule，2 g/day，2 times/day；3 months
10141668|NCT04184440|Experimental|Cyclocarya paliurus extract|aqueous extract of Cyclocarya paliurus；capsule，2 g/day，2 times/day；3 months
10141669|NCT04184440|Experimental|Cyclocarya paliurus compounds|mixed aqueous extract of Cyclocarya paliurus and other traditional Chinese herbal medicines including Astragalus propinquus Schischkin，Dioscorea oppositifolia L.，Dendrobium nobile Lindl.，Salvia miltiorrhiza Bge. and Inulin；capsule，2 g/day，2 times/day；3 months
10141670|NCT04184310|Experimental|old patient with rectal prolapse|old co-morbid patient with complete rectal prolapse unfit for abdominal operation
10141671|NCT04184232|Experimental|Dendritic cells|Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
10141672|NCT04184232|Active Comparator|Control|Patients with the recurrent bladder cancer receiving standard treatment
10141673|NCT04184518|Experimental|Cediranib plus durvalumab|
10141674|NCT04184661||hypophosphatemic rickets patients|30 hypophosphatemic rickets patients older than 2 years will be included in this study
10141675|NCT04184661||controls patients|10 controls patients from pediatric nephrology unit without hypophosphatemic rickets, older than 2 years will be included in this study
10141676|NCT04184193||Pulmonary Rehabilitation|
10141677|NCT04184466|Experimental|Insulin Aspart|Single subcutaneous administration of Insulin Aspart in dose 0.3 IU / kg
10141678|NCT04184466|Active Comparator|NovoRapid® Penfill®|Single subcutaneous administration of NovoRapid® Penfill® in dose 0.3 IU / kg
10141679|NCT04184167|Active Comparator|intermittent fasting|intermittent fasting before ICSI
10141680|NCT04184167|Placebo Comparator|No intermittent fasting|Usual diet
10141681|NCT04184206|Active Comparator|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness influence
10141682|NCT04184206|Active Comparator|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness influence
10141683|NCT04184206|Active Comparator|attention training intervention 3|14-day smartphone-based audio-guided intervention without mindfulness emphasis
10141684|NCT04184388|Experimental|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng extract for 1g/day
10141685|NCT04184388|Placebo Comparator|Placebo|Hydrolysed Red Ginseng extract for 0g/day
10141686|NCT04184492|Experimental|GP-40081|Single subcutaneous administration of GP-40081 in dose 0.4 IU / kg
10141687|NCT04184492|Active Comparator|NovoMix® 30 Penfill®|Single subcutaneous administration of NovoMix® 30 Penfill® in dose 0.4 IU / kg
10141688|NCT04184804|Experimental|Behavioral Intervention|School-based intervention
10141689|NCT04184804|No Intervention|Control|Control. No intervention (usual education). The school does not receive any material and gets the information that they are part of a study on eating habits of primary school children.
10141690|NCT04184557|Experimental|"App Staying Calm in the OR"|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) or Mindfulness Self Compassion (MSC)."
10141691|NCT04184557|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) arm will not download the app until the study is completed.
10141692|NCT04184427|Active Comparator|Group I|6 mm height of power arm
10141693|NCT04184427|Experimental|Group II|3 mm height of power arm
10141694|NCT04184427|Experimental|Group III|9 mm height of power arm
10141695|NCT04184401|Experimental|Replacement with albumin|"Check drain amount every 4 hour after SICU admission~Replacement of 70% of drainage from previous 4 hours over next 4 hours~30% of the drainage with 5% albumin~40% of drainage with Hartmann's solution~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
10141696|NCT04184401|Active Comparator|Replacement with Hartmann's solution|"Check drain amount every 4 hour after SICU admission~Replacement of 70% of drainage from previous 4 hours with Hartmann's solution over next 4 hours~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
10141697|NCT04184531||Children with Sensenbrenner Syndrome|Children with Sensenbrenner followed from 2005. Variable phenotype related to the mutation gene will be analysed to determine some possible prognostic factors of the risk of developing end-stage kidney disease.
10141698|NCT04184258|Experimental|SLE patients MSC treatment|Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols
10141699|NCT04184258|Active Comparator|SLE patients standard treatment|Patients with SLE, who receive standard treatment according to the Clinical protocols
10141700|NCT04184505|Active Comparator|Standard clinical treatment|"If BM-blasts >= 10%: Conventional chemotherapy: induction one cycle (3+7 protocol) and one optional consolidation cycle, followed by HSCT if a suitable sibling or unrelated donor is available versus~If BM blasts are <10%: HSCT upfront"
10141701|NCT04184505|Experimental|Experimental treatment|"If BM-blasts >= 10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available~If BM blasts are <10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available"
10141702|NCT04184063|Experimental|active treatment with NBMI|
10141703|NCT04184063|Placebo Comparator|Placebo|
10141704|NCT04183985|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
10141705|NCT04183985|Active Comparator|Conventaional total knee arthroplasty|Use conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
10141706|NCT04183881|Experimental|Brodalumab 210mg SC|Brodalumab 210mg subcutaneous injection
10141707|NCT04184102|Experimental|Intervention exercise|The experimental group received education and exercise training before a mastectomy.
9826106|NCT02408016|Experimental|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
9826107|NCT02408016|Experimental|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
10141708|NCT04184102|No Intervention|Control|Received routine hospital care which did not include any exercise education
10141709|NCT04183907|No Intervention|Control group|The control group completes three questionnaires in months 1, 3 and 6, including questions on health behaviours, workaholism and work outcomes.
10141710|NCT04183907|Experimental|Transform|Intervention (see next page)
10141711|NCT04183933|Active Comparator|Pilates Exercise Group|Pilates exercises will given for 6 weeks, 3 days in a week.
10141712|NCT04183933|Active Comparator|Combined Exercise group|Combined exercises will given for 6 weeks, 3 days in a week.
10141713|NCT04184141|Experimental|alprazolam|
10141714|NCT04184141|Experimental|hydroxyzine|
10141715|NCT04184141|Placebo Comparator|control|
10141716|NCT04184115|Experimental|DPI-386 Nasal Gel + placebo patch|DPI-386 Nasal Gel: Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
10141717|NCT04184115|Placebo Comparator|Placebo nasal gel + Placebo patch|Placebo
10141718|NCT04184115|Active Comparator|placebo nasal gel + TDS patch|Transderm Scop® is a commercial transdermal scopolamine (TDS) patch worn behind the ear containing a 1.5 mg reservoir of scopolamine to be delivered over a 72-hour period.
10141719|NCT04184011||SRT for keloid scars|Individuals who are voluntarily scheduled to be treated at one of the participating study sites with SRT (SRT-100™, SRT-Vision™ or SRT-100+™) for the treatment of one or more recurrent keloids.
10141720|NCT04183855|Experimental|control|no supplement will be provided on the day of the experiment
10141721|NCT04183855|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
10141722|NCT04183855|Experimental|Mirexus PhytoSpherix|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
10141723|NCT04183972|Experimental|Image collecting Group|An computer algorithm will be developed and evaluated by these image data.
10184727|NCT03752489|Experimental|Fluid treatment-specific algorithm|The experimental arm will involve patients monitored by the fluid treatment-customized version of InSight.
10184728|NCT03752489|Active Comparator|Standard InSight|The control arm will involve patients monitored with the standard, non-treatment specific version of InSight.
10184729|NCT03752476||case|Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
10184730|NCT03752476||control|Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
10184731|NCT03752463|Experimental|DAOI-A group|
10184732|NCT03752463|Experimental|DAOI-B group|
10184733|NCT03752463|Experimental|DAOI-C group|
10184734|NCT03752463|Placebo Comparator|Placebo group|
10184735|NCT03752437|Experimental|Real Weight|Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
10184736|NCT03752437|Experimental|Ideal Weight|Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
10184737|NCT03752424|Active Comparator|Silver nanoparticles group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms.
10184738|NCT03752424|Placebo Comparator|Topical approved anti-microbial gel|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream.
10184739|NCT03752411|Experimental|Research Bottle|This group will have medication dispensed in a research bottle.
10184740|NCT03752411|Placebo Comparator|Regular prescription Bottle|This group will have medication dispensed in a regular prescription bottle
10184741|NCT03752398|Experimental|XmAb®23104 Monotherapy|XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles
10184742|NCT03752398|Experimental|XmAb®23104 Combination Therapy with Ipilimumab|XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab)
10184743|NCT03752385|No Intervention|Control Group|No intervention
10184744|NCT03752385|Experimental|Intervention Group|"Will cut their smartphone screen time in half, sleep without phone in bedroom, and have a bedtime for their phone use."
10184745|NCT03752372||HSCT cohort|IL10RA-deficient patients who received hematopoietic stem cell transplantation
10184746|NCT03752359|Experimental|whey protein group|Participants received a dose of 35 grams of whey protein after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
9826108|NCT02408016|Experimental|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
9970279|NCT01298583|Experimental|ankle tracking|subjects track a target with ankle movement
10141724|NCT04184089|No Intervention|Control group|High flow rate of 5 L/min and FiO2 of 40%
10141725|NCT04184089|Experimental|Group 1|Nasal cannula at flow rate of 15 L/min and FiO2 of 40%
10141726|NCT04184089|Experimental|Group 2|Nasal cannula at flow rate of 30 L/min and FiO2 of 40%
10141727|NCT04184089|Experimental|Group 3|Nasal cannula at flow rate of 60 L/min and FiO2 of 40%
9970280|NCT01298583|No Intervention|ankle movement|
10141728|NCT04183920|Active Comparator|Group A|Participants in this arm will be provided cranberry juice to consume for 42 days in total. After a 10-21-day washout period participants will receive placebo juice for 42 days.
9669329|NCT03096288|Experimental|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
9669330|NCT03096288|Placebo Comparator|Placebo|0.9% sodium chloride s.c. single injection
9669331|NCT03090165|Experimental|Arm A - Phase I|"Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.~Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.~Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.~Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 25 patients."
9669332|NCT03081156|Active Comparator|Glycopyrrolate/Formoterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
10141729|NCT04183920|Active Comparator|Group B|Participants in this arm will be provided placebo juice to consume for 42 days in total. After a 10-21-day washout period participants will receive cranberry juice to consume for 42 days
9827472|NCT02457247|Experimental|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
10141730|NCT04184076|No Intervention|Dietary counseling alone|"Controls will be instructed to maintain their weight throughout the trial, and not to change their eating or physical activity habits. Controls will visit the research center on a weekly basis for weigh-ins. Body composition and metabolic disease risk variables will be assessed in control subjects every 12 weeks.~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.~The blood draws will be taken at approximately 11:00 am. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
10141731|NCT04184076|Experimental|Time-restricted feeding (TRF) with dietary counseling|"Subjects will be instructed to eat ad libitum from 10:00 to 18:00 h daily, and fast from 18:00 to 10:00 h daily. During the 8-h feeding window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, subjects will be encouraged to drink plenty of water and will be permitted to consume energy-free beverages.~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.~The blood draws will be taken at approximately 11:00 am, especially prior to the first consumption of food by subjects in the TRF group. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
10141732|NCT04184128||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
10141733|NCT04184128||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
10141734|NCT04184128||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
10141735|NCT04183959|Active Comparator|Group- video stylet intubation (VS)|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
10141736|NCT04183959|Active Comparator|Group- fiberoptic intubation (FO)|: intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
10141737|NCT04184024|Active Comparator|Massage group|Patients in this group were applied to massage plus neck stabilization exercise.
10141738|NCT04184024|Active Comparator|Kinesio taping group|Patients in this group were applied to Kinesio taping plus neck stabilization exercise.
10141739|NCT04183816|Experimental|Total cold-water immersion group|"Participants allocated to the TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C. Each Participant was totally immersed in a pool while his/her head and neck remained above water level. The water's temperature was continuously measured by a mercury-in-glass thermometer and maintained at the aforementioned temperature by continuously adding ice blocks.~With respect to depth of immersion, TCWI is more efficient than partial CWI since exposing a larger area of the body is needed for cardiovascular changes to occur (Murray and Cardinale, 2015; Stephens et al., 2016)."
10141740|NCT04183816|Active Comparator|Ice massage group|Participants in the IM group were seated. The investigator in charge of this intervention group applied Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
9970281|NCT01298609|Active Comparator|Suprathreshold Stimulation|Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
9970282|NCT01298609|Sham Comparator|minimal stimulation|Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
10141741|NCT04183543|Experimental|Pulsed Electromagnetic Field Therapy|Study participants will receive 20 minutes of PEMFs (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
10141742|NCT04183543|Sham Comparator|Sham Therapy|Study participants will receive 20 minutes of placebo treatment (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
10141743|NCT04183686|Experimental|Part A (SAD): Dose A1|Single dose A1 of ACT-1014-6470; soft capsule for oral use.
10141744|NCT04183686|Experimental|Part A (SAD): Dose A2|Single dose A2 of ACT-1014-6470; soft capsule for oral use.
10141745|NCT04183686|Experimental|Part A (SAD): Dose A3|Single dose A3 of ACT-1014-6470 under fasted and fed conditions, separated by at least 18 days; soft capsule for oral use.
10141746|NCT04183686|Experimental|Part A (SAD): Dose A4|Single dose A4 of ACT-1014-6470; soft capsule for oral use.
10141747|NCT04183686|Experimental|Part A (SAD): Dose A5|Single dose A5 of ACT-1014-6470; soft capsule for oral use.
10141748|NCT04183686|Experimental|Part A (SAD): Dose A6|Single dose A6 of ACT-1014-6470; soft capsule for oral use.
10141749|NCT04183686|Experimental|Part B (MAD): Dose B1|Multiple doses B1 of ACT-1014-6470; soft capsules for oral use.
10141750|NCT04183686|Experimental|Part B (MAD): Dose B2|Multiple doses B2 of ACT-1014-6470; soft capsules for oral use.
10141751|NCT04183686|Experimental|Part B (MAD): Dose B3|Multiple doses B3 of ACT-1014-6470; soft capsules for oral use.
10141752|NCT04183686|Experimental|Part B (MAD): Dose B4|Multiple doses B4 of ACT-1014-6470; soft capsules for oral use.
10141753|NCT04183634|Experimental|Period 1: Rotigotine TTS (Test) - Period 2: Neupro (Reference)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
10141754|NCT04183634|Active Comparator|Period 1: Neupro (Reference) - Period 2: Rotigotine TTS (Test)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
10141755|NCT04183517|Experimental|Fasted|PXS-5382A administered as a single dose in the fasted state
10141756|NCT04183517|Experimental|Fed|PXS-5382A administered as a single dose in the fed state
10141757|NCT04183517|Experimental|Twice daily|PXS-5382A administered twice daily for 5 days in the fed state
10141758|NCT04183595|Experimental|Arm A: NBMI (Study Medication)|400mg / day N1, N3-BIS- (2-MERCAPTOETHYL) ISOPHTHALAMIDE (NBMI) treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours.
10141759|NCT04183595|Placebo Comparator|Arm B: Placebo|((Excipients microcrystalline cellulose, silica and magnesium stearate)) capsules will be administered every 24 hours for 14 days.
10141760|NCT04183647|Active Comparator|Local Vibration / Whole body vibration|"Local vibration will be sequentially applied to the bilateral gastrosoleus complex with the Vibrasens © device. Application, the largest part of the muscle, each limb 5'er for a total of 10 minutes, static semi-squat position will be done.~The vibration frequency is 80 Hz and the amplitude is 1 mm."
10141761|NCT04183647|Active Comparator|Whole body vibration/local vibration|Whole body vibration application will be done with Compex® Winplate device. During this application, patients will be asked to continue static semi-squat position with 5 minutes of vibration and then 5 minutes of vibration.Vibration frequency, 30 Hz amplitude will be selected 2 mm.
10141762|NCT04183556|Active Comparator|1/NSAI(nonsteroidal anti-inflammatory agent) group|Patients with naproxen drug therapy for early onset dysmenorrhea.
10141763|NCT04183556|Placebo Comparator|2/NSAI+ Turmeric (1 gram oral powder formula per day )|NSAI(nonsteroidal anti-inflammatory agent) + Turmeric for early onset dysmenorrhea (1 gram oral powder formula in mens time)
10141764|NCT04183569||Primary diffuse cutaneous B-cell lymphoma, leg type|Cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international standards through RCP monthly cutaneous lymphomas managed by Professor Beylot-Barry and inclusion of cases in the national database of rare cancer network French Study Group of Cutaneous Lymphomas in Bordeaux managed by Prof. Beatrice Vergier.
10141765|NCT04183725|Experimental|Experimental group|Reduning injection +Oseltamivir phosphate granule simulants
10141766|NCT04183725|Active Comparator|Control group|Oseltamivir phosphate granules+ Reduning injection simulants
10141767|NCT04183504|Experimental|Early Steps Coaching|Coaching session on positive parenting practices and promoting child development.
10141768|NCT04183582|Experimental|Intervention Group|Single arm group receiving Behavioural Activation, a facilitated self-help programme delivered by trained Health Visitors as six one hour sessions over four weeks.
10141769|NCT04183842|Experimental|LACIME Anti-hangover|Combination of plant extracts under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
10141770|NCT04183842|Placebo Comparator|Placebo|Carrot juice under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
10141771|NCT04183946|Other|Online Cognitive Behavioural Therapy|Screened participants diagnosed with minor to moderate anxiety and/or depression will receive online CBT therapy (8 interactive sessions) aiming to treat their symptomatology. Each session can be completed at one's own pace.
10141772|NCT04183608|Active Comparator|Group Standard of care|In standard of care, patient only visits every 3 months the doctor so the optimization of treatment can be done only at this frequency.
10141773|NCT04183608|Active Comparator|Groupe T2T with telemonitoring and patient education|Treatment with e-Monitoring, home fecal calprotectin testing and therapy education.
10141774|NCT04183465|Active Comparator|Health Education|All patients randomized to health education during the inclusion visit are managed according to current guidelines and as follows. Quality of life, functional capacity and home physical activity are assessed by proper tools.
10141775|NCT04183465|Experimental|Exercise Intervention|All patients randomized to physical activity (PA) intervention will start the program with a supervised PA session immediately after the inclusion visit. Quality of life, functional capacity and daily activities will be assessed by proper tools. The program provides 6 supervised PA sessions (30, 60, 90, 180, 270 and 360 days after hospital discharge [T0]). At the end of each supervised session, calisthenics exercises derived from Otago Exercise Program are prescribed.
10141776|NCT04183738|Active Comparator|SOC|darunavir/ritonavir 800/100mg + 2 NRTIs po od
10141777|NCT04183738|Experimental|DOL|darunavir/ritonavir 800/100mg + dolutegravir 50mg po od
10141778|NCT04183738|Experimental|D2N|dolutegravir 50mg + tenofovir + emtricitabine or lamivudine po od
10141779|NCT04183491|Experimental|Arm A: Interferon beta-1a low dose|Single dose of interferon beta-1a 7.5 µg intramuscular (IM)
10141780|NCT04183491|Experimental|Arm B: Interferon beta-1a intermediate dose|Single dose of interferon beta-1a 15 µg IM
9827473|NCT02457247|Experimental|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.
10141781|NCT04183491|Experimental|Arm C: Interferon beta-1a high dose|Single dose of interferon beta-1a 30 µg IM
10141782|NCT04183491|Experimental|Arm D: Peginterferon beta-1a low dose|Single dose of peginterferon beta-1a 31.25 µg subcutaneous (SC)
10141783|NCT04183491|Experimental|Arm E: Peginterferon beta-1a intermediate dose|Single dose of peginterferon beta-1a 62.5 µg SC
10141784|NCT04183491|Experimental|Arm F: Peginterferon beta-1a high dose|Single dose of peginterferon beta-1a 125 µg SC
10141785|NCT04183491|Placebo Comparator|Arm G: Placebo|Single dose of placebo
10141786|NCT04183413|No Intervention|Standard of Care|Health services for diabetes and hypertension are provided as was the standard of care prior to the healthcare reform. Healthcare for diabetes and hypertension is provided only through physician-led teams at hospitals and health centers.
10141787|NCT04183413|Experimental|PEN|Screening for diabetes and hypertension, as well as all care for uncomplicated cases of diabetes and hypertension, will be provided through nurse-lead teams at primary healthcare facilities.
10141788|NCT04183413|Experimental|enhanced PEN (ePEN)|"This arm consists of all activities of arm 2 (the PEN arm) plus additional responsibilities for community health workers."
10141789|NCT04183478|Experimental|Best Support Care Plus K-001|Best support care including analgesic treatment, anti-infection therapy, biliary obstruction treatment, nutritional support, psychological support, reasonable advice from physicians, good communication with patients and etc. K-001 9,720mg per day which means that take K-001 capsule 18 tablets (270mg per tablet) orally twice a day (morning and evening), 56 days as a cycle.
10141790|NCT04183478|Placebo Comparator|Best Support Care Plus placebo|Best support care is the same as experimental arm. Placebo is take 18 placebo tablets which is the same as K-001 in appearance orally twice a day (morning and evening), 56 days as a cycle.
10141791|NCT04183803|Experimental|rosa robot assistance|Patients with ACL rupture requiring surgical treatment will be included. The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
10141792|NCT04183348|Experimental|Group A|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
10141793|NCT04183348|Experimental|Group B|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
10141794|NCT04183361||Patients with noise exposure and salivary cortisone|"male and female~ages 19-35~exposure to noise level ≥ 85 dB (A) per week at the workplace~work in noise from 1 to 16 years~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)~unilaterally or bilaterally normal otoscopic findings~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
10141795|NCT04183361||Patients without noise exposure and salivary cortisone|"male and female~ages 19-35~no exposure to noise level ≥ 85 dB (A) per week at the workplace~work in noise from 1 to 16 years~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)~unilaterally or bilaterally normal otoscopic findings~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
10141796|NCT04183192|Experimental|Arm A: Mepolizumab low dose|Single dose of mepolizumab 3 mg SC
10141797|NCT04183192|Experimental|Arm B: Mepolizumab low intermediate dose|Single dose of mepolizumab 6 mg SC
10141798|NCT04183192|Experimental|Arm C: Mepolizumab high intermediate dose|Single dose of mepolizumab 12 mg SC
10141799|NCT04183192|Experimental|Arm D: Mepolizumab high dose|Single dose of mepolizumab 24 mg SC
10141800|NCT04183192|Experimental|Arm E: Reslizumab low dose|Single dose of reslizumab 0.1 mg/kg IV
10141801|NCT04183192|Experimental|Arm F: Reslizumab intermediate low dose|Single dose of reslizumab 0.2 mg/kg IV
10141802|NCT04183192|Experimental|Arm G: Reslizumab high intermediate dose|Single dose of reslizumab 0.4 mg/kg IV
10141803|NCT04183192|Experimental|Arm H: Reslizumab high dose|Single dose of reslizumab 0.8 mg/kg IV
10141804|NCT04183192|Placebo Comparator|Arm I: Placebo|Single dose of placebo
10141805|NCT04183140|Active Comparator|Transradial|
9970283|NCT01298609|Active Comparator|Subthreshold Stimulation|Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
9970284|NCT01298622||controls|
9970285|NCT01298622||OCD patients|
10141806|NCT04183140|Active Comparator|Transulnar|
10187763|NCT03722849|Experimental|Chronic cough participant|"Twenty-five (25) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), will be recruited.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
10141807|NCT04183179|Experimental|Program|"The 14-week healthy eating program activities including four components:~A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
10141808|NCT04183400|Experimental|Safety Awareness For Empowerment (SAFE)|Brief mindfulness-based cognitive-behavioral skill-building intervention
10141809|NCT04183400|No Intervention|Usual case management only|Control condition receives only services as usual
10141810|NCT04183322||Women of childbearing age|Healthy non-pregnant women between 18 and 45 years old living in Goroka, Papua New Guinea, will receive one dose of 13-valent pneumococcal conjugate vaccine (PCV).
10141811|NCT04183127||ACP|ACPs, either qualified or in training, working in the South Yorkshire and Bassetlaw area.
10141812|NCT04183010|No Intervention|Control|At the end of this initial week of monitoring, participants will be randomized to a control group or an intervention group. Both groups will be followed for three months, with outcome measurements collected monthly. Both arms will continue to receive their seven day physical activity assessment using the phone's core motion sensors and HealthKit/ Google Health step count. Both groups will also be prompted to complete monthly fitness tests: the 6-minute walk test, a 12 minute run test, and the Tecumseh step test.
10141813|NCT04183010|Experimental|Physical activity coaching|"In addition to the tasks performed and feedback received by the Control arm (see above), the intervention arm will also undergo daily coaching with the goal of increasing their daily step count. Members of this arm will receive daily app notifications indicating that they have activities to complete. They will be provided with 5 exercise options:~Low intensity activity options (i.e. walking in the part, bicycling to the store, etc.).~Moderate to vigorous endurance activity, performed on their own (running, bicycling, rowing, swimming, etc)~An on demand group session video~No exercise today~Alternate physical activity -- the participants will have the option to record alternate physical activity that they performed~Participants will be asked to indicate if they completed the exercise with three options:~Yes~No~Request for a different exercise to be shown"
10141814|NCT04183036|No Intervention|Small EST combined with EPLBD|
10141815|NCT04183036|Experimental|Large EST combined with ECPP|
10141816|NCT04183387|Experimental|Simvastatin and standard treatment|40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis
10141817|NCT04183387|No Intervention|standard treatment|conventional treatment of uveitis
10141818|NCT04183114|Experimental|IP batch MRUK-0317|135 Subjects received Bio Farma's vaccine batch MRUK 0317
10141819|NCT04183114|Experimental|IP Batch MRUK-0417|135 Subjects received Bio Farma's vaccine batch MRUK 0417
10141820|NCT04183114|Experimental|IP Batch 550118|135 Subjects received Bio Farma's vaccine batch MRUK 0417
10141821|NCT04183114|Active Comparator|Control|135 Subjects received SII's MR vaccine batch 012W72230Z
10141822|NCT04183153|Experimental|Healthy Arm|
10141823|NCT04183023||Single arm|"There is a unique arm in which all the participants will be included. The intervention consists in the collection of a salivary sample Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and a subset of 4,000 DNA will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
10141824|NCT04183075|Experimental|FontActiv Superprotein/Hypercaloric Fiber|Full Nutritional Supplement
10141825|NCT04183075|Active Comparator|Carbohydrates and C Vitamin|Nutritional Supplement
9669333|NCT03081156|Placebo Comparator|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
9669334|NCT03041688|Experimental|Treatment (decitabine, navtemadlin)|"Patients receive decitabine IV over 1 hour on days 1-10 and navtemadlin PO QD on days 4-10. Treatment repeats every 28 days for up to 4 cycles in patients with evidence of persistent AML.~Starting cycle 2, patients with no morphologic evidence of AML receive decitabine IV over 1 hour on days 1-5 and navtemadlin PO QD on days 4-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9970286|NCT01298622||OCD parents|
9970287|NCT01298635|Active Comparator|trab|
9970288|NCT01298635|Active Comparator|phacotrab|
10141826|NCT04183257|Experimental|vitamin D|vitamin D arm will receive oral vitamin D in escalating dosage.
10141827|NCT04183257|No Intervention|Conventional|This arm will receive conventional treatment only.
10141828|NCT04182971|Active Comparator|Whole fruit|Phase 1 of study is an orange, Phase 2 of study is an apple
10141829|NCT04182971|Active Comparator|Juice|Phase 1 of study is orange juice, Phase 2 of study is apple juice
10141830|NCT04182971|Experimental|Juice plus pomace fiber|Phase 1 is orange juice with added fiber, Phase 2 is apple juice with added fiber
10141831|NCT04183244|Active Comparator|Erector spinae block|"Ultrasound guidance will be used to visualize the transverse processes of T2 and the overlying muscles.~Under sterile conditions, a 5-cm, 21-gauge needle will be inserted using the out-of-plane technique parallel to the sagittal plane directly over the transverse process,then 30mL of the local anesthetic solution will be injected and observed for the linear spread of LA the under direct ultrasound visualization"
10141832|NCT04183244|Active Comparator|infraclavicular subomohyoid block|Performing posterior approach infraclavicular BP block followed by subomohioid block via the same puncture site under ultrasound guidance.
10141833|NCT04183296|Experimental|TIVA(Total Intravenous Anesthesia and Volatile Anesthesia )|In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
10141834|NCT04183296|Active Comparator|Inhalation|Arm Description: In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
10141835|NCT04183088|Experimental|Part 1: Tislelizumab intravenously + regorafenib orally|Part 1 is a single-arm study. All eligible patients will receive tislelizumab 200 mg intravenously on day 1 every 3 weeks plus regorafenib orally 80 mg per day.
9528302|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
9669335|NCT03041363|Experimental|Triheptanoin|Dose 1 C7 administered as 40% daily caloric intake. Dose 2. C7 administered as 45% daily caloric intake.
10141836|NCT04183088|Experimental|Groups (1) of part 2: Tislelizumab intravenously + regorafenib|Tislelizumab 200 mg intravenously on Day 1+Regorafenib its dosage in the randomized cohort will be determined according to results in the safety cohort.
10141837|NCT04183088|Active Comparator|Groups (2) of part 2: regorafenib|"Daily dose of regorafenib 80mg/day is for week 1; Daily dose of regorafenib 120mg/day is for week 2; Daily dose of regorafenib 160mg/day is for week 3; Dosing-free interval is for week 4.~The dose of regorafenib will not be escalated if treatment-related AE > grade 1 occurs at the previous dose level.~For subjects in the group 2, when imaging evaluation of tumor response indicates stable disease or progressive disease, according to RECIST v1.1, study treatment will be shifted to regorafenib + tislelizumab combination regimen."
9970289|NCT01298713|Active Comparator|A|Tamoxifen 20mg/d
9970290|NCT01298713|Experimental|B|Tamoxifen 20mg/d + RAD001 10mg/d
10141838|NCT04183283|Experimental|LY3526318|LY3526318 administered orally in three of four study periods.
9970291|NCT01298726|Other|PHARMACEUTICAL CARE|
10141839|NCT04183283|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
10141840|NCT04182984||Patients with autoimmune ocular MG|Newly-onset OMG patients who agreed to join the follow-up cohort
10141841|NCT04183062|Experimental|Chemotherapy plus BIO-11006|Patients will receive BIO-11006 in addition to GemTax chemotherapy. The BIO-11006 inhalation solution will be given by mouth inhalation twice daily. BIO-11006 will be given during the first three cycles of GemTax and then will be stopped. Subjects will continue with GemTax treatment for three additional cycles. If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment.
10141842|NCT04182945|Other|Unobtrusive data collection|Unobtrusive data collection using noninvasive sensor systems.
10141843|NCT04182932|Experimental|CJ-40010 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
10141844|NCT04182932|Experimental|CJ-40010 EV71 B dose|Inactivated EV71 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
10141845|NCT04182932|Experimental|CJ-40010 CVA16 C dose|Inactivated CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
10141846|NCT04182932|Experimental|CJ-40010 CVA16 D dose|Inactivated CVA16 vaccine(D dose) or placebo in 10 healthy adults (three doses, 28 days interval)
10141847|NCT04182932|Experimental|CJ-40010 Bivalent E dose|Inactivated EV71/CVA16 vaccine(E dose) or placebo in 10 healthy adults (three doses, 28 days interval)
10141848|NCT04182932|Experimental|CJ-40010 Bivalent F dose|Inactivated EV71/CVA16 vaccine(F dose) or placebo in 10 healthy adults (three doses, 28 days interval)
10141849|NCT04182893||Pulmonary nodules population|We will enroll 300 pulmonary nodules penplein this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
9970292|NCT01298726|Other|HEALTH USUAL CARE|
9970293|NCT01298791|Experimental|Provider sitting|Providers seated during communication through hospitalization
10141850|NCT04182893||Healthy population|We will enroll 100 healthy penple in this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
10141851|NCT04182737|Experimental|IgM titer-based treatment|The treatment with IgM preparation will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The calculation of the dose is based on IgM single compartment distribution. The first dose of IgM preparation will be calculated on IgM serum concentration obtained within 24 hours after shock appearance to achieve serum titers above 100mg/dl. In the next days, the daily IgM preparation dose will be assessed individually on the basis of IgM serum titers assessment performed in the morning with the purpose of maintaining IgM serum titers above 100 mg/dl, up to discontinuation of vasoactive drugs or day 7 after enrolment. Daily, the calculated dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg per hour (20mg/kg per hour). IgM preparation will be administered up to the withdrawal of vasoactive drugs with a maximum allowed of 7 days of therapy and a maximum dose of 350mg/Kg/day.
10141852|NCT04182737|Active Comparator|IgM Flat treatment|The IgM treatment will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The dose of IgM preparation will be 250mg/kg for 3 days, the dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg (20mg/kg per hour) until reaching 250mg/kg.
10141853|NCT04182568|Experimental|nab-paclitaxel|
10141854|NCT04182568|Active Comparator|Docetaxel|
10141855|NCT04182594|Experimental|Degarelix|GnRH Antagonist
9970294|NCT01298791|Experimental|Provider standing (control)|Providers standing during communication through hospitalization
9970295|NCT01298804|Experimental|Problem Solving Education|
9970296|NCT01298804|No Intervention|Control|
9970297|NCT01298817|Experimental|Soy, Prepared Meals|Soy-based meal replacement weight loss group with additional meals provided
10141856|NCT04182594|Active Comparator|GnRH-agonist|GnRH Agonist
10141857|NCT04182750|Experimental|Intervention group|Pharmacist consultation in early pregnancy (gestation week <12)
9970298|NCT01298817|Active Comparator|Non soy prepared meals|Non-soy based meal replacement weight loss group with additional meals provided
10141858|NCT04182750|No Intervention|Control group|Standard care.
10141859|NCT04182542|Experimental|RF|The right side will be treated with radiofrequency
10141860|NCT04182542|No Intervention|NI|The left side will not receive treatment.
10141861|NCT04182646|Experimental|Single arm|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required.
10141862|NCT04182581|Experimental|CAR-T treatment group|The patients will receive one dose of BCMA/CD19 dual-target CAR-T. BCMA/CD19 dual-target CAR-T dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.
10141863|NCT04182711|Experimental|Device Arm|The aim in the 1st phase is to benchmark the device against manual counting of respiration (number of breaths per minute). The aim in the 2nd phase is to benchmark the device against existing technologies, namely lead-based-ECG sensing, acoustic sensing and capnography. This phase can have a mix of patients having either COPD, asthma, pneumonia or any other respiratory diseases
10141864|NCT04182698|Experimental|Experimental|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
10141865|NCT04182880|Placebo Comparator|Placebo|Placebo
10141866|NCT04182880|Experimental|CPL-01|CPL-01
10141867|NCT04182529|Experimental|Photoneuromodulation Therapy|In this study low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800 will be used. The United States Food and Drug Administration (FDA) has approved this type of device as imposing insignificant risk (FDA-cleared for home treatment, 2005). At each visit, LED clusters will be applied simultaneously for 20 minutes on the Fp1, Fp2 and Pz regions according to the International 10-20 system (Homan, Herman and Purdy, 1987) (energy density, 13 Joules/cm2 [J/cm2] per each LED cluster head placement). The total LED treatment time per visit was 20 minutes.
10141868|NCT04182529|Sham Comparator|Control Group|Subject will not be given any active stimulation
10141869|NCT04182854|Experimental|diuretics|
10141870|NCT04182724|Experimental|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib 250 mg p.o. qd Nab-paclitaxel 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
10141871|NCT04182789|Experimental|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
10141872|NCT04182906|Active Comparator|No ACEs screen|Participants complete all measures except an ACEs screening tool
10141873|NCT04182906|Experimental|Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences.In this version, specific ACEs items are reported, Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
10141874|NCT04182906|Experimental|De-Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences. In this version,total number of ACEs items are reported, only. Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
10141875|NCT04182555|Experimental|Newborns in St.Olavs Hospital and Haugesund Hospital|All newborns will be examined through 4 different methods of determining jaundice.
10141876|NCT04182503||Beijing|
10141877|NCT04182503||Guangzhou|
10141878|NCT04182503||Jinan|
10141879|NCT04182503||Nanjing|
10141880|NCT04182503||Hangzhou|
10141881|NCT04182503||Wuhan|
10141882|NCT04182503||Zunyi|
10141883|NCT04182503||Xiangyang|
10141884|NCT04182503||Nantong|
10141885|NCT04182503||Suizhou|
10141886|NCT04182503||Huangshi|
10141887|NCT04182503||Changzhou|
10141888|NCT04182503||Suqian|
10141889|NCT04182503||Shiyan|
9970299|NCT01298830|Experimental|GLP-1 CellBeads|
10141890|NCT04182503||Xiaogan|
10141891|NCT04182503||Huanggang|
10141892|NCT04182828|Placebo Comparator|Placebo Group(PG)|It will be normal saline 0.9%
10141893|NCT04182828|Active Comparator|Lidocaine Group(LG)|It will be lidocaine 2%
10141894|NCT04182477||Patients with at least one general anesthesia in anamnesis|Patients who underwent during their life at least one anesthesia in anamnesis
10141895|NCT04182477||Patient without general anesthesia in anamnesis|Patients who never underwent general anesthesia during their life
10141896|NCT04182191|Experimental|Interventional group|89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
10141897|NCT04182165|Experimental|Subjects measured by the study staff|Subjects measured by the study staff via the investigational device at the hospital (up to 50 subjects).
10141898|NCT04182165|Experimental|Subjects measuring themselves autonomously|Subjects measuring themselves autonomously with the investigational device at their homes (up to 10 subjects from the first arm).
10141899|NCT04182113|Experimental|1 Hz rTMS Stimulation|
10141900|NCT04182113|Experimental|20 Hz rTMS Stimulation|
10141901|NCT04182113|Sham Comparator|Sham rTMS Stimulation|
10141902|NCT04182243|Other|Emergency Health Care Provider|Working in emergency health services in Northern Cyprus
10141903|NCT04182152|Experimental|Bronchoscopic ICG localization|The nodule will be located preoperatively by ENB-Guided bronchoscopic ICG injection; During the VATS operation, a near-infrared fluorescence thoracoscopy will be used to identify ICG distribution in the visceral pleura to guide an accurate surgical resection.
10141904|NCT04182152|Active Comparator|percutaneous hook-wire localization|The nodule will be located preoperatively by percutaneous placement of hook wire; During the VATS operation, the resection scope is determined by the location relationship between hook wire and the nodule under CT scan.
10141905|NCT04182347|Other|People with IDD and caregivers|
10141906|NCT04182178||Gastroesophageal reflux|Laparoscopic total (Nissen) or posterior 270 degree (Toupét) partial fundoplication for the treatment of gastroesophageal reflux disease.
10141907|NCT04182282|Experimental|Immediate|Immediate participants receive the intervention (online training and certification exam) during the study.
10141908|NCT04182282|Experimental|Control|Control participants do not receive the intervention (online training and certification exam) during the study. However, they do receive access to the intervention program (at no cost) at the conclusion of the study.
10141909|NCT04182022|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
10141910|NCT04182022|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
10141911|NCT04182256|Experimental|MS group|In the MS group, the MS grips the HVC through the magnet adsorbed onto the wall of the basin containing the liver. By changing the position of the MS on the wall of the basin, the surgeon is able to expose the surgical field.
10141912|NCT04182256|No Intervention|MA group|In MA group, assistants use vessel forceps to pull the HVC according to the attending's requirements.
10141913|NCT04182399|Active Comparator|Patients 25 ZNS|30 patients receive oral 25 mg ZNS daily
10141914|NCT04182399|Active Comparator|Patients 50 ZNS|30 patients receive oral 50 mg ZNS daily
10141915|NCT04182399|Placebo Comparator|Patients Placebo|30 patients receive placebo
10141916|NCT04182087||Focal Brain Injury|Patients with focal brain injury (post-stroke or post-cortical resection)
10141917|NCT04182412|Active Comparator|Suture|laparoscopic narrowing of linea alba with continuous suture
10141918|NCT04182412|Active Comparator|suture and mesh|narrowing of linea alba with continuous suture and mesh
10141919|NCT04182269||Study Group|Multiple Sclerosis Patients
10141920|NCT04182269||Control Group|Healthy Subjects
10141921|NCT04181944|Experimental|Exercise Treatment Group|
10141922|NCT04181918|Experimental|AOT|This group will observe videos depicting daily actions and afterwards they will execute the seen actions
10141923|NCT04181918|Experimental|MI|This group will imagine motorically the same action as the first group and afterwards they will execute the imagined actions
10141924|NCT04181918|No Intervention|Control|This group will neither observe nor imagine actions, but simply observe videos with no motor content. Afterwards they will execute the same actions as in AOT and MI.
10141925|NCT04182295|Experimental|real acupuncture-full disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
10141926|NCT04182295|Experimental|real acupuncture-partial disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
10141927|NCT04182295|Sham Comparator|sham acupuncture-full disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
10141928|NCT04182295|Sham Comparator|sham acupuncture-partial disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
10141929|NCT04182139|Experimental|30 seconds and %50 intensity stretching|The participants in this group performed an 30 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
10141930|NCT04182139|Experimental|30 seconds and %75 intensity stretching|The participants in this group performed an 30 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
10141931|NCT04182139|Experimental|30 seconds and %100 intensity stretching|The participants in this group performed an 30 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
10141932|NCT04182139|Experimental|60 seconds and %50 intensity stretching|The participants in this group performed an 60 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
10141933|NCT04182139|Experimental|60 seconds and %75 intensity stretching|The participants in this group performed an 60 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
10141934|NCT04182139|Experimental|60 seconds and %100 intensity stretching|The participants in this group performed an 60 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
10141935|NCT04182061|Experimental|The AMTE Protocol|"Will receive the AMTE (Aprende a Manejar tus Emociones) Protocol; this is a modified UP-A adapted as an internet-based program of T-CBT, consisting in 10 modules delivered over 12 weeks."
10141936|NCT04182061|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
10141937|NCT04181983|Experimental|Personalized exercise program|A home-based personalized exercise program using a smartphone app
10141938|NCT04181983|Active Comparator|Active Control WHO guidelines|A standard exercise program based upon WHO guidelines
10141939|NCT04181983|No Intervention|Control|No exercise program
10141940|NCT04181892|Experimental|CAF+ CTG positioned apical to the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG apical of the CEJ level
10141941|NCT04181892|Other|CAF+CTG positioned on the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG on the CEJ level
10141942|NCT04182009|Other|Omron|Omron group will undergo sputum induction with the Omron nebuliser at Visit 1, followed by the Akita Jet nebuliser at Visit 2.
10141943|NCT04182009|Active Comparator|Akita|Akita group will undergo sputum induction with the Akita Jet nebuliser at Visit 1, followed by the Omron nebuliser at Visit 2.
10184747|NCT03752359|Placebo Comparator|placebo group|Participants received a dose of 35 grams of maltodextrin after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
10184748|NCT03752346|No Intervention|control group|Control group maintained their regular lifestyle and received the routine care
10184749|NCT03752346|Experimental|exercise group|Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home. Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
10184750|NCT03752333|Experimental|Pembrolizumab|All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
10184751|NCT03752320||POP+ and POP-|POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia
10184752|NCT03752294|Active Comparator|Dabigatran|Participants will receive 150mg dabigatran daily for a total of 9-months.
10184753|NCT03752294|Placebo Comparator|Placebo|Participants will receive placebo daily for a total of 9-months.
10184754|NCT03752294|Active Comparator|Open Label|All study participants are assigned to receive 150mg dabigatran daily for a total of 12 months (study month 9 through month 21)
10184755|NCT03752281||Health and activity|The cohort consists of long-term social assistance recipients where there is need to investigate the health status and working ability.
10184756|NCT03752268|No Intervention|Enhancing Cancer Pain Management Part 1|"Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline~Will then use MEMS to monitor LA opioid intake over approximately 8 weeks~A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews"
10184757|NCT03752268|Experimental|Enhancing Cancer Pain Management Part 2|"Enhancing Cancer Pain Management will consist of 3 individual manualized sessions~The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors.~Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens.~Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks."
9826109|NCT02408068|Active Comparator|Chronocort : fed|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).
9516814|NCT03311997|No Intervention|Non-operative treatment|Active rehabilitation program
10184758|NCT03752255|Experimental|Anxiety measurement method|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). Then patients will watch a video about impacted tooth. This video will include the complications that patients may face and what should be done after the procedure. After the watching the video, patients will fill the both DAS and STAI.
10184759|NCT03752255|Placebo Comparator|Control|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). The verbal information in detail will be given to the patients by the surgeon.This verbal information will include the complications that patients may face and what should be done after the procedure.
10184760|NCT03752242|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
10184761|NCT03752242|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Acne of the face.
10184762|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 610|
10184763|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
10184764|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 430|
10184765|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 420|
10184766|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 520|
10184767|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 450|
10184768|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 545-549|
10184769|NCT03752229|Experimental|Owem Mumford lancet|
10184770|NCT03752229|Experimental|Medicore lancet|
10184771|NCT03752229|Experimental|Arkray lancet|
10184772|NCT03752229|Experimental|Medipurpose lancet|
10184773|NCT03752229|Experimental|Sterilance lancet|
10184774|NCT03752229|Experimental|Dynarex lancet|
10184775|NCT03752229|Experimental|Ypsomed lancet|
10184776|NCT03752229|Experimental|Promismed lancet|
10141944|NCT04182438|Experimental|Low potassium then normal potassium|After giving the vegetables with low potassium content vegetables for 2 weeks, the serum potassium level was recorded; after 2 weeks of washing time, the normal potassium content vegetables was given for 2 weeks, and the serum potassium concentration was recorded and the test was terminated.
10141945|NCT04182438|Experimental|Normal potassium then low potassium|After giving the normal potassium content vegetables for 2 weeks, the serum potassium concentration was recorded; after 2 weeks of washing time, the low potassium content vegetables use for 2 weeks, then the serum potassium level was recorded at the time. The test was terminated.
10141946|NCT04182464|Experimental|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
10141947|NCT04182464|Placebo Comparator|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
10141948|NCT04181957|Placebo Comparator|Placebo|Participants receive placebo tablet composed of lactose.
10141949|NCT04181957|Active Comparator|Active|Participants receive a 50mg tablet of lisdexamfetamine dimesylate (LDX) once.
10141950|NCT04182126|Placebo Comparator|Regular long-lasting insecticidal nets|All participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
10141951|NCT04182126|Experimental|Piperonyl butoxide-treated LLIN|"All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1 and Stage 2 interventions provided that PBO-LLINs are effective at Stage 1 interventions. Each household will be provided on PBO-LLIN per two people with appropriate eduction.~PBO-LLIN: Olyset Plus, containing 2% permethrin and 1% PBO."
10141952|NCT04182126|Experimental|PBO-LLIN plus larval source management|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including both physical and chemical methods by physical filling or removal of temporary larval habitats and larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. We will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
10141953|NCT04182126|Experimental|PBO-LLIN plus enhanced methods|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2. The enhanced intervention is determined by machine learning method.
10141954|NCT04182126|Experimental|LLIN plus indoor residual spraying|All participants will received regular LLINs plus indoor residual spraying (IRS) (LLIN+IRS) at Stage 1 and Stage 2 interventions provided that LLIN+IRS is effective at Stage 1 interventions. For LLIN+IRS clusters, each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl (Actellic 300CS) at the recommended dosage of 1g/m² and at the recommended frequency of once a year.
10141955|NCT04182126|Experimental|LLIN+IRS+LSM|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. LSM will be added on these clusters at Stage 2 interventions. LSM at Stage 2 will be the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
10141956|NCT04182126|Experimental|LLIN+IRS plus enhanced method|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. Enhanced method will be added on these clusters at Stage 2 interventions.The enhanced intervention is determined by machine learning method.
10141957|NCT04181840|Experimental|Impedance spectroscopy|"Maximum 56 women up to 16 weeks from a natural delivery, with at least one perinatal anal sphincter injury risk factor, such as: the extended second delivery phase, instrumental delivery (vacuum or forceps), shoulder dystocia, birth weight of the child > 4kg, episiotomy, uncontrolled perineal laceration (in patients with crotch protection).~The planned interventions are:~Blood and faeces tests~Impedance spectroscopy test~Full gynecological and proctological examination~Transanal ultrasonography~Anorectal manometry"
10141958|NCT04181931|Experimental|neo-TACE-HAIC with surgery|neoadjuvant TACE-HAIC with surgery for HCC patients with PVTT
10141959|NCT04181931|Active Comparator|surgery alone|surgery alone for HCC patients with PVTT
10141960|NCT04181710|Experimental|HEMO2life|HEMO2life® will be used for ex vivo graft preservation at the dose of 1g per liter of preservation solution.
10141961|NCT04181710|Other|Control|Organ preserved in preservation solution routinely used according to the local practice
10141962|NCT04181684|Experimental|Experimental: LITT with Hypofractionated radiation therapy|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 35Gy/10 fractions.
10141963|NCT04181580|Other|Fit test of made-to-measure garments|Healthy subjects will test maximum 2 compression garments out of 6 garments under investigation
10141964|NCT04181853|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
10141965|NCT04181853|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
9516815|NCT03311997|Active Comparator|Operative treatment|Surgical reattachment of hamstring tendons using suture anchors followed by active rehabilitation program
10141966|NCT04181853|No Intervention|No Intervention: Control group|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
10141967|NCT04181814||Diabetic patients|Diagnosed as diabetes
10141968|NCT04181645|Experimental|SHR-120, Paclitaxel-albumin and Gemcitabine|"Subjects receive SHR-1210 200mg (Day 1) and Paclitaxel-albumin 125mg/m2 (Day1 and Day8) and gemcitabine 1000mg/m2 (Day 1 and Day 8) of each 21-day cycle for at most 6 cycles until documented PD or intolerable adverse event or new anti-cancer treatment or loss to follow-up or death.~Subjects receive SHR-1210 200mg (Day1) to maintain after 6 cycles treatment without PD or listed situation to terminate."
10141969|NCT04181528|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned TKA implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
10141970|NCT04181528|Active Comparator|Conventaional total knee arthroplasty|Use conventional TKA implant (Legion total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
10141971|NCT04181658|Experimental|Real tDCS and Physical Therapy|This arm combines tDCS and Physical Therapy intervention. The real tDCS will be delivered before each physical therapy visit for up to 10 combined sessions. The tDCS montage was designed to target the left dorsal lateral prefrontal cortex (DLPFC) for around 20 minutes. The direct current delivered by any electrode will not exceed 2.0 milliamp(mA) and the total amount of current from all electrodes will not exceed 4 mA.
10141972|NCT04181658|Sham Comparator|Sham stimulation and Physical Therapy|This arm combines sham stimulation and Physical Therapy intervention. The sham stimulation will be delivered before each physical therapy visit for up to 10 combined sessions. We will use an active sham stimulation in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This montage was designed to deliver currents not significantly influence their cortical tissue, but still, mimic the cutaneous sensations induced by tDCS over the same brain site (i.e. left DLPFC).
10141973|NCT04181541|Active Comparator|Women receiving abortion care by physicians|Patients who receive second trimester medical abortion care from a physician.
9970300|NCT01298843|Other|Study of Blood Levels of Ceftaroline Fosamil|Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
10141974|NCT04181541|Experimental|Women receiving abortion care from midlevel providers|Patients who receive second trimester medical abortion care from a midlevel provider.
10141975|NCT04181554||DRAM group|The post-partum women with DRAM
10141976|NCT04181567|Experimental|electroconvulsive therapy + agomelatine|electroconvulsive therapy 2 times weekly + agomelatine 50 mg daily
10141977|NCT04181567|Active Comparator|electroconvulsive therapy + placebo|electroconvulsive therapy 2 times weekly + placebo
10141978|NCT04181736|Experimental|Guanfacine Treatment Group|Participants will be prescribed tabs containing guanfacine immediate release (GIR) to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg.
10141979|NCT04181736|Placebo Comparator|Placebo Group|Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment.
10141980|NCT04181749|No Intervention|No treatment|Patients will not be prescribed aspirin and statin
10141981|NCT04181749|Active Comparator|Aspirin and Atorvastatin|Patients prescribed aspirin and atorvastatin
10141982|NCT04181697||PwH A|People with Haemophilia (PwH) A, moderate or severe.
10141983|NCT04181697||Controls|Demographically and seasonally matched non-haemophilia controls.
10141984|NCT04181671|Experimental|Low Resistance Training Group|The experimental group will receive low resistance blood flow restriction training with 30% of 1 RM.
10141985|NCT04181671|Active Comparator|High Resistance Training Group|Participants of this group will receive High resistance training (80% of 1 RM) without blood flow restriction.
10141986|NCT04181632|Active Comparator|Shot Blocker|The three interventional groups are currently marketed distraction devices. Arm 1 will be Shot Blocker® Number 1-25 (RED).
10141987|NCT04181632|No Intervention|Control Group|The control group is the current clinical standard of care option for pre-allergy injection application. Ethyl Chloride/Pain Ease Spray Number 76-100 (YELLOW).
10141988|NCT04181632|Active Comparator|Buzzy I|The three interventional groups are currently marketed distraction devices. Arm 2 will be Buzzy® I (vibrating only) Number 26-50 (GREEN).
10141989|NCT04181632|Active Comparator|Buzzy II|The three interventional groups are currently marketed distraction devices. Arm 3 will be Buzzy® II (vibrating and ice wings) Number 51-75 (BLUE).
10141990|NCT04181281||young adult|18 - 40 years old (n=10) Healthy male or female and able to give informed, written consent.
10141991|NCT04181281||older adult|70 years or older (n=10) Healthy male or female and able to give informed, written consent.
10141992|NCT04181281||AKI patients|Admitted patients with AKI stage 3
10141993|NCT04181593|Experimental|OmegaD|OmegaD Softgels
10141994|NCT04181593|Placebo Comparator|Placebo|Placebo Softgels
10141995|NCT04181463|Experimental|Arm I (isopropyl alcohol)|Patients receive isopropyl alcohol via nasal inhalation.
10141996|NCT04181463|Placebo Comparator|Arm II (placebo)|Patients receive placebo via nasal inhalation.
10141997|NCT04181424|Active Comparator|Group 1- Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
10141998|NCT04181424|Experimental|Group 2 - Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
10141999|NCT04181424|Experimental|Group 3 - Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
10142000|NCT04181424|Experimental|Group 4 -- Diabetes Education Plus Combination of Monthly Food|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
10142001|NCT04181216|Experimental|anatomically aligned total knee arthroplasty prosthesis|Total knee arthroplasty with anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew)
10142002|NCT04181216|Active Comparator|Conventaional total knee arthroplasty group|Total knee arthroplasty with conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew)
10142003|NCT04181268|Active Comparator|Rotational Atherectomy|"The procedure is performed by using a Rotablator system, which consists of a spring coil shaft with a burr at the tip. The front edge of the burr is the ablating portion, oval shaped, and covered with fine diamond crystals.~The rotational atherectomy catheter is introduced into the coronary artery over a dedicated long rotational atherectomy wire, which consists of a monofilament stainless steel 0.09-inch wire.~The device is connected to a console that houses the turbine that rotates the burr with pressurized nitrogen gas. Typically the rpm is set at 150,000 to 180,000 rpm.~After the lesion is crossed with the wire, the lesion is crossed with multiple pecking movements of the burr, with each run lasting not more than 20 seconds. After successful rotational atherectomy with one or more burrs, the procedure is completed with balloon angioplasty and stent placement. This can be achieved by exchanging the rota wire with a workhorse wire and using standard equipment."
10142004|NCT04181268|Active Comparator|Intravascular Lithotripsy|"The procedure is perforemed with a Coronary intravascular lithotripsy (IVL) System that consists of a generator, a connector cable with a push button to allow manually controlled delivery of electric pulses, and semi-compliant balloon catheter.~The balloon integrates two radiopaque lithotripsy emitters 6 mm that receive electrical pulses from the generator vaporising the fluid within the balloon and creating a rapidly expanding and collapsing bubble. This bubble can transmit unfocused circumferential pulsatile mechanical energy into the vessel wall, in the form of sonic pressure waves equivalent to approximately 50 atmospheres (atm). The IVL therapy consists on a maximun of 8 runs of 10 pulses (80 pulses). The number of therapies needed per lesion will depend on lesion resistance; however, a mínimum of 20 pulses is recommended.~Alter IVL, an optional additional post-dilatation with non-compliant balloons, a stent is implanted"
10142005|NCT04181268|Active Comparator|Excimer Laser|"Excimer laser is pulsed gas laser that use Xenon chloride (XeCl) as the active medium to generate pulses of short wavelength, high-energy ultraviolet (UV) light.~Excimer laser tissue ablation is mediated through three distinct mechanisms: photochemical, photo-thermal and photomechanical. UV laser light is absorbed by intra-vascular material and breaks carbon-carbon bonds (photochemical). It elevates the temperature of intra-cellular water, causing cellular rupture and generates a vapor bubble at the catheter tip (photo-thermal). Expansion and implosion of these bubbles disrupts the obstructive intra-vascular material (photomechanical). The laser catheter is advanced slowly over a conventional wire while the therapy is aplied and saline is inffused. After laser, balloon dilatation is usually performed finishing the procedure with stent implantation"
10142006|NCT04181385|Experimental|Olanzapine|Olanzapine, 10mg, oral, single dose
10142007|NCT04181385|Experimental|Olanzapine plus bromocriptine|Olanzapine, 10mg, oral, single dose Bromocriptine, 5mg, oral, single dose
10142008|NCT04181385|Placebo Comparator|Placebo|Placebo, oral, single dose
10142009|NCT04181177||Informed group|This group will receive the Cosmetic product RV4429A balm and targeted educational action between V1 and V2 or between V2 and V3 according to the randomization
10142010|NCT04181177||Control group|"The control group, in the first period between V1 and V2, is a group not informed about his skin condition, not receiving any emollient product and not receiving targeted educational action. It's representative of the real life called best supportive care/Supportive care: the doctor prescribes what it seems to be the best for his patient according to his opinion in view of his condition, at a given moment.~A high variability exists within this group. In order to answer the investigator's hypothesis and demonstrate the effectiveness of the RV4429A balm, the parallel group design is chosen for the first follow-up period and then a second follow-up period is chosen for the initial control group to replace the inter-individual variability by intra-individual variability."
10142011|NCT04181489|Experimental|Sintilimab + R-CHOP|
10142012|NCT04181372|Experimental|Anlotinib plus Platinum-based chemotherapy|"Take anlotinib hydrochloride 12mg once daily for two weeks, stop for one week, the program repeats every 21 days for 2 cycles.~Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles."
10142013|NCT04181372|Active Comparator|platinum-based chemotherapy|Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
10142014|NCT04181398|Experimental|Baseline high hs-CRP|"Anthropometry:~Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio.~Blood pressure (mean of 3 measurements)~Peripheral arterial tonometry~Questionnaire~Blood sample (hsCRP)"
10142015|NCT04181398|Experimental|Baseline low hs-CRP|"Anthropometry:~Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio.~Blood pressure (mean of 3 measurements)~Peripheral arterial tonometry~Questionnaire~Blood sample (hsCRP)"
9516816|NCT03311984||LMWH qd|receiving Low-molecular-weight Heparin（LMWH）qd
9516817|NCT03311984||LMWH q12h|receiving Low-molecular-weight Heparin（LMWH）q12h
10142016|NCT04181294|Experimental|Pre-intervention|Baseline data on patient characteristics and outcomes will be collected for 4 months prior to intervention.
10142017|NCT04181294|Experimental|Post-intervention|The quality improvement intervention will be conducted sequentially at all 3 medical centers (LAC-USC, Olive View, and Harbor-UCLA Medical Centers). Data on patient characteristics and outcomes will be collected for 4 months after the intervention
9970301|NCT01298856|Active Comparator|hydrotherapy|hydrotherapy and ankle taping and land based exercise
10142018|NCT04181437|Experimental|NVP-1203-R1|"Drug: NVP-1203-R1~1 tablet, oral dosing"
10142019|NCT04181437|Experimental|NVP-1203-R2|"Drug: NVP-1203-R2~1 tablet, oral dosing"
10142020|NCT04181437|Experimental|NVP-1203-R1 and NVP-1203-R2|Drug: NVP-1203-R1 1 tablet and NVP-1203-R2 1 tablet co-administration(oral dosing)
10142021|NCT04181346|Experimental|Pregabalin|Pregabalin 75mg, twice a day, from the night before chemotherapy to day 5
10142022|NCT04181346|Experimental|Placebo|Placebo, twice a day, from the night before chemotherapy to day 5
10142023|NCT04181125||Children with increased femoral anteversion|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
10142024|NCT04181125||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
10142025|NCT04181229|Experimental|DBS Treatment|Patients in the treatment arm will receive DBS of bilateral centromedian nucleus (2 electrodes per patient). DBS is a standard of care treatment option for drug-resistant epilepsy patients who have previously failed VNS at 12 months or more after instigation and optimization of therapy.
10142026|NCT04181229|No Intervention|Continued VNS (control)|For the control arm, the patients will be monitored for one year with the same standard assessments used for the measurement of seizure frequency and severity. No changes will be made to these patients' treatment plan. These patients will be placed on a wait list for CM-DBS treatment of seizures if that is the desire of the patient and/or their family. After the 12 months of observation, these patients can choose to undergo DBS surgery.
10142027|NCT04181203|Active Comparator|SRT + 6 months of LHRHa|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
10142028|NCT04181203|Experimental|SRT + 6 months of LHRHa + 6 months of Apalutamide|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.~Treatment with apalutamide (240 mg PO daily) should start the same day as the first LHRHa administration, for 6 months.~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
10142029|NCT04181164||HPP-Group|Adults with hypophosphatasia.
10142030|NCT04181164||Control-Group|Healthy control subjects.
10142031|NCT04181502|Experimental|Inflation of a pneumatic tourniquet|
10142032|NCT04181502|Sham Comparator|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
10142033|NCT04181021|Experimental|Intervention|Providers and community-based promoters will participate in the VCAT workshop. Providers and community-based promoters will take part in two different workshops at different times.
10142034|NCT04181021|No Intervention|Control|Providers and promoters in the control arm will not be invited to participate in the VCAT workshop.
10142035|NCT04180982|Experimental|Treatment group A|SHR4640 dose1 Oral Tablet plus Febuxostat dose1 Oral Tablet Day1~Day28 qd.
10142036|NCT04180982|Experimental|Treatment group B|SHR4640 dose1 Oral Tablet plus Febuxostat dose2 Oral Tablet Day1~Day28 qd.
10142037|NCT04180982|Experimental|Treatment group C|SHR4640 dose2 Oral Tablet plus Febuxostat dose3 Oral Tablet Day1~Day28 qd.
10142038|NCT04180865||Parkinson's disease patients|150 de novo treatment naive Parkinson's disease patients.
10142039|NCT04180865||Healthy control subjects|150 Healthy sex- and age-matched controls, also matched according to presence and severity of constipation, serving as a control group for microbiome composition analyses.
10142040|NCT04180956|Experimental|Intervention|The bias-reduction intervention opened with a didactic on health disparities, stereotypes, microaggressions, interracial provider-patient interactions and racism. Then, a guided, interracial eye-contact mindfulness exercise was performed to increase providers' awareness and acceptance of subtle bias that occurs in interracial interactions. Then, in small, mixed-race groups, participants practiced the above mindfulness skills while reciprocally sharing and responding with empathy to each other's personal life histories and personal narratives of loss and/or betrayal. The intervention ended with explicit practice component, involving practice and feedback.
10142041|NCT04180956|No Intervention|Control|The control condition was a waitlist condition. Doctors were given workshop materials after the study ended.
10142042|NCT04180930||Cohort 1|Individuals randomized to Cohort 1 will be assigned to the CAPS-5 and will complete between two and seven research visits. Participants will be administered the CAPS-5 during visit 2, and then will be randomized a second time into groups 1-A and 1-B. Group 1-A will end participation after visit 2. Group 1-B will complete visits 3-7 and will be administered the CAPS-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
10184777|NCT03752229|Experimental|Cambridge Sensors lancet|
9970302|NCT01298856|Active Comparator|land-based|land-based and ankle taping program
10142043|NCT04180930||Cohort 2|Individuals randomized to Cohort 2 will be assigned to the PSSI-5 and will complete between two and seven research visits. Participants will be administered the PSSI-5 during visit 2, and then will be randomized a second time into groups 2-A and 2-B. Group 2-A will end participation after visit 2. Group 2-B will complete visits 3-7 and will be administered the PSSI-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
10142044|NCT04180930||Cohort 3|Individuals randomized to Cohort 3 will have three office visits and will complete the CAPS-5 and the PSSI-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
10142045|NCT04180930||Cohort 4|Individuals randomized to Cohort 4 will have three office visits and will complete the CAPS-IV and the CAPS-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
10142046|NCT04180774|Experimental|Melanoma Adjuvant|Patients with completely resected stage III or IV melanoma receiving GMV in the adjuvant setting
10142047|NCT04180774|Experimental|Melanoma Therapeutic|Patients with incompletely resected stage III or IV melanoma receiving GMV in the therapeutic setting
10142048|NCT04180774|Experimental|Renal Cell Adjuvant|Patients with completely resected stage III or IV kidney cancer receiving GMV in the adjuvant setting
10142049|NCT04180774|Experimental|Renal Cell Therapeutic|Patients with incompletely resected stage III or IV kidney cancer receiving GMV in the therapeutic setting
10142050|NCT04181190||Mepolizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL-5 monoclonal antibody (Mepolizumab)
10142051|NCT04181190||Benralizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL5 receptor monoclonal antibody (Benralizumab)
10142052|NCT04180839|Experimental|gaming-related retrieval-extinction|about 30 individuals with IGD will be randomly assigned to the R-E training group
10142053|NCT04180839|Other|nongaming-related retrieval-extinction|about another 30 individuals with IGD will be randomly assigned to the NR-E training group
10142054|NCT04181073|Active Comparator|Jet Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Jet Nebuliser
10142055|NCT04181073|Experimental|Vibrating Mesh Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Vibrating Mesh Nebuliser
10142056|NCT04181099|Other|Zirconia structure|The participants will carry an orthodontic device containing 4 discs of differently structured zirconia and titanium to test the biofilm formation in order to determine the ideal structure for the neck area of zirconia dental implants.
10142057|NCT04180852||Neurosurgical patients|"Non-elective admission to the neurosurgical ICU with one of the following acute intracranial pathologies which also serve as predefined subgroups:~Intracranial hemorrhage (subarachnoid, subdural hemorrhage or intracerebral hemorrhage)~Acute and severe head trauma with an initial Glasgow Coma Scale ≤10"
10142058|NCT04180852||Elderly patients|Age ≥ 70 years, predefined subgroups: ≥ 70 years and ≥80 years
10142059|NCT04180852||Obese patients|BMI ≥ 35 kg/m2, furthermore predefined subgroups of patients with BMI ≥ 40 kg/m2 and BMI ≥ 45 kg/m2
10142060|NCT04180852||Cardiac surgery patients|"Admission to the cardiosurgical ICU after one of the following procedures using cardiopulmonary bypass, which also serve as predefined subgroups:~Coronary revascularization (coronary artery bypass graft)~Heart valve surgery~Combined or complex heart surgery"
10142061|NCT04180852||Abdominal surgical patients|Admission to the abdominal surgery ICU after abdominal surgery
10142062|NCT04181008|Experimental|0.2 mg|
10142063|NCT04181008|Experimental|0.4 mg|
10142064|NCT04181008|Experimental|0.6 mg|
10142065|NCT04181112|Experimental|Fecal microbiota transplantation|
10142066|NCT04181112|Experimental|Fecal microbiota transplantation with antibiotic pre-treatment|
10142067|NCT04181112|No Intervention|No intervention follow-up|
10142068|NCT04180826||Stenosis|Patients with stenosis
10142069|NCT04180826||No stenosis|Patients without stenosis
10142070|NCT04181034|Experimental|PYD|Case managers meet with participating pregnant and parenting females at least two times a month over 12 months. In the short term, the program seeks to improve social competence, problem-solving skills, autonomy, increased sense of purpose, improved knowledge and use of contraceptives, increased linkages and support networks, improved quality of relationships, increased access to and strengthen relationship with a trusted adult, increased knowledge of and access to healthcare and improved health and well-being of expectant or parenting mother. In the long term, the program aims to delay subsequent pregnancy and reduction in health risk behaviors, improved health and well-being of parent and child, improved educational and employment outcomes and increased self-sufficiency.
10142071|NCT04181034|Active Comparator|AFLP|Case managers meet with participating pregnant and parenting females once a month over 24 months to deliver older, business-as-usual version of the program that does not have positive youth development component.
10142072|NCT04180657||Patients with protein C deficiency|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
10142073|NCT04180657||Healthy controls|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
10142074|NCT04180631|Experimental|Quantitative ultrasound imaging parameter|Quantitative ultrasound imaging parameter (QUS)
10142075|NCT04180787|Experimental|Keto Coffee|VPX Bang® Keto Coffee beverage
10142076|NCT04180787|Placebo Comparator|Placebo|Flavor-matched placebo beverage
10142077|NCT04180592|Experimental|CT Fusion Biopsy + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
10142078|NCT04180592|Other|Transrectal U/S Guided Prostate Biopsy + CT Fusion Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
10142079|NCT04180800||Folic acid deficiency|Those with a folic acid defiency
10142080|NCT04180800||No deficiency|Those with no folic acid deficiency
10142081|NCT04180878|No Intervention|Control Arm|Participants in this group were informed to continue to receive usual care.
10142082|NCT04180878|Experimental|Intervention Arm|Received an interactive physical activity monitoring system (the Gruve®).
10142083|NCT04180878|Experimental|Intervention Arm 2|Received an interactive physical activity monitoring system (the Gruve®) and group based phone counseling (GBPC).
10142084|NCT04180735||Perforation|Perforation
10142085|NCT04180735||No perforation|No perforation
10142086|NCT04180748||Normal skin|
10142087|NCT04180748||Oily skin|
10142088|NCT04180748||Dry skin|
9669336|NCT02979769|Experimental|Palovarotene|"All participants will receive non-flare-up based treatment of 5 mg palovarotene once daily for 24 months.~Participants who continued non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to an additional 48 months (therefore 72 months over the entire study).~Participants who start non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to 48 months.~Participants that are skeletally immature will receive weight-adjusted doses.~In the event of an eligible flare-up all participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days. Participants under the age of 18 years will receive weight-adjusted doses."
9669337|NCT02962115|Experimental|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
9669338|NCT02942290|Experimental|Venetoclax + Azacitidine|
10142089|NCT04180748||Combination skin|
10142090|NCT04180748||Sensitive skin|
10142091|NCT04180761|Experimental|HIPEC-Treatment|"Doxorubicin (15 mg/m²/body surface) Cisplatin (75 mg/m²/body surface) applied as hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy.~All drugs used are approved."
10142092|NCT04180527||Pre-Quality Improvement Initiative|This group of patients have not received previous patients' stories about their hip or knee surgery before undergoing their own hip or knee surgery.
10142093|NCT04180527||Post-Quality Improvement Initiative|This group of patients have received previous patients' stories regarding about their hip or knee surgery before undergoing their own hip or knee surgery.
10142094|NCT04180553|Experimental|Point-Of-Care Ultrasound Guided Resuscitation|Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission.Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and IVC study performed post-operatively in PACU, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two. Based on ultrasound findings, their fluid resuscitation will be guided to a fluid liberal or fluid restrictive strategy at the time of each assessment.
10142095|NCT04180553|Active Comparator|Usual Care|The comparator arm in this trial is randomization to usual care. Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria
10142096|NCT04180683||Semi-structured interview group|Participants assigned to this group will be administered the GDS-30, GDS-15, GDS-10 nad GDS-5, and also the BDI-II and a semi-structured interview based on the DSM-5 criteria. The psychologists performing the assessment will answer a questionnaire about which GDS version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
10142097|NCT04180683||No semi-structured interview group|Participants assigned to this group will be administered the GDS-30 and the GDS-15, and also the BDI-II.
10142098|NCT04180722|Experimental|Intervention|Participants will receive multi-component Virtual Transition Intervention facilitated through the aTouchAway™ platform including the usual care provided by specialist HMV programs.
10142099|NCT04180722|No Intervention|Control|Usual care will be delivered in accordance with the Canadian Thoracic Society (CTS) clinical practice guidelines and includes scheduled face-to-face clinic visits with the ventilator team with the ventilator team within the first month of starting HMV and then every 3, 6, or 12 months depending on medical stability with additional telephone calls/email contact for equipment trouble shooting and management of intercurrent illnesses as needed.
10142100|NCT04180566|Other|Weekly antenatal testing|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive weekly antenatal testing (biophysical profile) starting at 34 weeks as well as growth ultrasound every 4 weeks.
10142101|NCT04180566|Other|Growth ultrasound examination every 4 weeks|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive ultrasound examination (growth ultrasound) every 4 weeks starting at 34 weeks.
10142102|NCT04180644||Atopic Dermatitis|Participants with atopic dermatitis active lesions
10142103|NCT04180644||Healthy Control|Participants without a history of atopic dermatitis
10142104|NCT04180332|Experimental|Healthy|The patients were healthy subjects without Periodontal disease or any systemic manifestation
10142105|NCT04180332|Experimental|Periodontal disease without diabetes|Patients with periodontal diseases without diabetes
10142106|NCT04180332|Experimental|Periodontal disease with diabetes|Patients with periodontal disease and diabetes
10142107|NCT04180280|Active Comparator|Phone Delivered|Participants receive 5 sessions of phone-delivered behavioral counseling to improve HIV care.
10142108|NCT04180280|Active Comparator|Office Delivered|Participants receive 5 sessions of office-delivered behavioral counseling to improve HIV care.
10142109|NCT04180293|Other|Military Veterans and their families|This group will participate in both the pilot psychoeducation program and its evaluation.
10142110|NCT04180449||Dysphagia screening positive|
10142111|NCT04180449||Dysphagia screening negative|
10142112|NCT04180618|Experimental|Patients(Care givers)|"1,000 patients(caregivers) are enrolled and use the personal health wallet service.~They fill out questionnaire to evaluate the service~Some of them are invited for an in-depth interview."
9669339|NCT02919436|Experimental|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
9970303|NCT01298869||Chronic kidney disease|Chronic kidney disease stage IV and V
9970304|NCT01298882|Experimental|Diacerein|
10142113|NCT04180618|Experimental|Medical staffs|"12 medical staffs are enrolled and use the personal health wallet service.~After that, they are invited for an in-depth interview."
9516818|NCT03311971|Sham Comparator|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
9669340|NCT02919436|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
9669341|NCT02879136|Active Comparator|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
9970305|NCT01298882|Placebo Comparator|Placebo|
10142114|NCT04180358|Experimental|Impact group|The impact group will receive the interventions in the classrooms
9970306|NCT01298895||PEX group|The first group consisted of 47 eyes with cataract complicated with pseudoexfoliation syndrome (PEX).
10142115|NCT04180358|Placebo Comparator|Comparison group|Comparison group will not receive the intervention
10142116|NCT04180397|Active Comparator|Furosemide|Bolus of 5-40 mg (0.5 - 4 ml) of furosemide iv at physicians discretion followed by infusion of furosemide. Infusion rate: 0-40 mg/hour. Starting rate: 20 mg/hour. The infusion is adjusted according effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
9970307|NCT01298895||control group|The control group included 177 eyes with uncomplicated cataract in eyes without other ocular pathology
9970308|NCT01298908|Other|Operative treatment|vein stripping
10142117|NCT04180397|Placebo Comparator|Placebo|Isotonic saline dosed the same way and by the same algorithm as for furosemide. Start bolus of 0.5-4 ml at physicians discretion. Infusion rate: 0 - 4 ml/hour. Infusion is started at 2 ml/hour and adjusted according to effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is assessed neutral.
10142118|NCT04180410|Other|EIT|Electrical Impedance Tomography is performed before extubation, during follow up visits of extubation and 48H after extubation
10142119|NCT04180605|Active Comparator|Standard of care treatment arm|"When patients are randomized to the standard treatment arm, patients will be treated according to the participating site's routine practice. As pre-procedural imaging, a cardiac CT-scan has to be performed; this can also be complemented with TEE at the discretion of the operator. The LAA closure procedure should be performed according to routine practice of the participating site - either in general or local anesthesia.~For those cases randomized to the standard treatment arm, the pre-procedural CT-scans will still be collected at completion of the study and FEops HEARTguideTM simulations will be generated, blinded for the procedural images and outcome. These simulations will be compared with the final device size and implant position and will be used for an additional comparative PREDICT-LAA sub-study."
10142120|NCT04180605|Experimental|Computational simulation arm|When patients are randomized to the computational simulation arm, the procedure will still be performed according to the participating site's routine practice - however, the procedure will only be performed after careful review of the FEops HEARTguideTM simulation results. The only prerequisite is that all patients randomized to this arm will have to undergo a pre-procedural cardiac CT-scan that will be uploaded into the FEops HEARTguideTM platform. Following this upload, a pre-procedural simulation plan will be provided to the operator, containing a set of optimal and suboptimal closure device sizes and implant positions. Software and technology upgrades of the FEops HEARTguideTM platform will be allowed during the course of the study.
10142121|NCT04180514||Intradialytic hypotension|subjects with intradialytic hypotension episode
10142122|NCT04180514||Non-intradialytic hypotension|subjects without intradialytic hypotension episode
10142123|NCT04180423||Off-the-Shelf Total Knee Arthroplasty Patients|
10142124|NCT04180423||Conformis iTotal Total Knee Arthroplasty Patients|
10142125|NCT04180501|Experimental|SRS sequential sintilimab|
10142126|NCT04180345||Validation of the questionnaire|Items reduction, ajustment and psychometric validation of the questionnaire
10142127|NCT04180384|Experimental|Oraxol (paclitaxel capsules+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
10142128|NCT04180384|Active Comparator|Oraxol (paclitaxel tablets+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg tablets~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
10142129|NCT04180241|Active Comparator|total division of the muscle layer|POEM- total division of the circular muscle layer into the gastroesophageal junction
10142130|NCT04180241|Active Comparator|partial division of the muscle layer|POEM - partial division of the circular muscle layer into the gastroesophageal junction
10142131|NCT04180254|Experimental|Experimental: normal-hearing and hearing-impaired participants|normal and hearing-impaired participants
10142132|NCT04180189|Active Comparator|Weighted fiber blanket|Using a weighted blanket
10142133|NCT04180189|Placebo Comparator|Regular fiber blanket|Using a specially designed fiber blanket without extra weight.
10142134|NCT04180124|Experimental|GaitRite|"Patients will walk on the GaitRite.~forward walking at comfortable gait speed (6 x 10 meter)~backward walking at comfortable gait speed (4 x 10 meter)"
10142135|NCT04180124|Experimental|Treadmill walking self-paced|"Patients will walk on the treadmill in self-paced mode. They can control walking speed by themselves.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
10142136|NCT04180124|Experimental|Treadmill walking fixed speed - comfortable speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at comfortable gait speed, which is determined in the familiarization period.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
10142137|NCT04180124|Experimental|Treadmill walking fixed speed - fast speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at a gait speed, which is 1 minimal clinical difference faster than their comfortable gait speed.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
9970309|NCT01298908|Other|Laser ablation|Ultrasound guided laser ablation
9669342|NCT02879136|Active Comparator|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
10142138|NCT04180124|Experimental|Treadmill walking fixed speed - backward walking|"Patients will walk on the treadmill in fixed speed mode. Patient will walk backwards on the treadmill if they are able to.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
10142139|NCT04180072|Experimental|Atezolizumab plus bevacizumab|Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Study treatment will continue until documented tumor progression or occurrence of unacceptable toxicity.
10142140|NCT04180163|Experimental|Lanadelumab|Participants will receive 300 milligram (mg) lanadelumab solution once every 2 weeks (q2w) for 26 weeks (treatment period A), followed by treatment period B during which participants may remain on treatment period A regimen or will receive 300 mg lanadelumab solution once every 4 weeks (q4w) for 26 weeks if well tolerated with overall treatment period of 52 weeks.
10142141|NCT04179773||Cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
10142142|NCT04179773||Non-cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
10142143|NCT04180150|Experimental|TQ-A3334 combined with entecavir|Subjects receive TQ-A3334 (1.2 mg QW) and entecavir (0.5 mg qd) in 24 weeks
10142144|NCT04180150|Placebo Comparator|Placebo combined with entecavir|Subjects receive placebo (0 mg QW) and entecavir (0.5 mg qd) in 24 weeks
10142145|NCT04179903|Active Comparator|Gym Trainer|Physical Activity program is performed in a group in a gym (Gym Group Training-GGT), with activity sessions conducted by a trainer graduated in Science and Techniques of Preventive and Adapted Physical Activity
10142146|NCT04179903|Active Comparator|Individual Home|Physical Activity program is performed at home individually (Individual Home Training-IHT), without the supervision of a trainer during the exercise session.
10142147|NCT04180137|Experimental|Surgical treatment with subsequent pharmacotherapy|
10142148|NCT04180137|Other|Isolated surgical treatment|
10142149|NCT04179877|Experimental|Individual placement and support|Group of patients receiving IPS to increase workforce participation.
10142150|NCT04179877|No Intervention|Control|Group of patients receiving treatment as usual.
10184778|NCT03752203|Experimental|Sodium-Fluorescein Resection|This study will employ the use of sodium fluorescein and an FDA approved operative microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
10184779|NCT03752190|Experimental|Intravenous and intramuscular administration|Subjects will receive intravenous and intramuscular ACTH on different days
10184780|NCT03752164|Experimental|Yoga and Mindfulness|An intervention consisting of one session lasting 30 minutes where a certified yoga instructor teaches the children gentle yoga and mindfulness skills.
10184781|NCT03752138|Experimental|Group 1 Part 1 TK216: Days 1-7|Patients receive TK216 IV continuously on days 1-7 every 21 days.
10184782|NCT03752138|Experimental|Group 2 Part 1 TK216: Days 1-7 and 15-28|Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.
10184783|NCT03752138|Experimental|Part 2 TK216 + Decitabine 10mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
10184784|NCT03752138|Experimental|Part 2 TK216 + Decitabine 20 mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
10184785|NCT03752138|Experimental|Expansion Phase: TK216 + Decitabine|All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.
10184786|NCT03752125|Experimental|Flavonoid, caffeine|Flavonoid, caffeine capsules
10184787|NCT03752125|Placebo Comparator|Placebo|Placebo capsules
10184788|NCT03752112|Experimental|Cefixime|cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.
10184789|NCT03752112|Other|Benzathine penicillin|To benchmark the performance of benzathine penicillin in the study population being used for cefixime, the investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.
10184790|NCT03752086|Experimental|Greater omentum binding|Bind greater omentum to pancreatic stump after distal pancreatectomy
10184791|NCT03752086|Experimental|Pancreatic stump exposed|pancreatic stump exposed without binding greater omentum after distal pancreatectomy
10184792|NCT03752060|Experimental|Resistance Training Group|These participants will participate in a progressive resistance training program three times per week on non-consecutive days for 16 weeks. During each session, participants will perform the following exercises: supine bench press, lat pulldown, lateral raise, seated row, leg press, leg extension, leg curl, biceps curl, and triceps extension. The exercises will be completed such that upper body and lower body exercises are alternated throughout each session. During the Weeks 1-4 of training, the subjects will complete two sets of 15 repetitions for each exercise at approximately 50% of their one-repetition maximum (1RM). During Weeks 5-8 of training, the subjects will complete three sets of 12 repetitions at approximately 60% 1RM. During Weeks 9-12, the subjects will complete four sets of 12 repetitions at approximately 60% 1RM. During Weeks 13-16 of training, the subjects will complete 4 sets of 10 repetitions at approximately 70% 1RM.
10184793|NCT03752060|Active Comparator|Aerobic Training Group|Women randomized to the AT group will engage in aerobic exercise training that complies with ACSM recommendations10. Specifically, women will complete walking or stationary cycling sessions 5 times per week for 16 weeks. Heart rate data from the pre-intervention VO2peak tests (described below) will be used to estimate each participant's target training heart rate. Like the RT regimen, the AT intervention will be progressive in nature. During the first half of the intervention period, duration will increase by 5 minutes every 2 weeks, from 30 min to 45 min. In the second phase of the intervention, duration will remain constant at 45 min, but intensity will increase from 50% to 65% of heart rate reserve (HRR). Exercise sessions will take place on a treadmill and/or cycle ergometer.
10142151|NCT04179786|Other|Sci-B-Vac™|Single arm study in healthy volunteers who had never been vaccinated with any hepatitis B vaccine and who were seronegative for antibodies to HBsAg, HBc and HBs at baseline.
10142152|NCT04179994|Experimental|Miswak extract-containing toothpaste group|Test group.
10142153|NCT04179994|Active Comparator|Toothpaste containing Potassium Nitrates|Positive control.
10142154|NCT04179994|Placebo Comparator|Placebo group|Toothpaste contains same ingredients of test group except for the active ingredient as negative control.
10142155|NCT04180007|Experimental|Neoadjuvant arm|Patients receive Apatinib orally qd up to 12 wk.
10142156|NCT04179916|Experimental|Healthy volunteers|Participants between 21 and 25 years, the Faculty of Physical Education and Physiotherapy of the Opole University of Technology Students
10142157|NCT04179747|Experimental|Group A|The cognitive behavior psychotherapy was administered to participants in this treatment arm.
10142158|NCT04179747|Active Comparator|Control Group|This group received the administration of pharmacotherapy (PDE5i) for treatment of Erectile Dysfunction.
10142159|NCT04180033|Other|Colonoscopy surveillance in TC survivors|TC survivors treated with platinum-based chemotherapy will be invited to undergo a colonoscopy surveillance.
10142160|NCT04179942|Active Comparator|Patients|full night PSG (polysomnogram) was done, fractional exhaled nitric oxide and Hs-CRP were measured
9519688|NCT03284541|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
10142161|NCT04179942|Placebo Comparator|control|CRP level was measured
10142162|NCT04179708|Experimental|pain neuroscience education|
10142163|NCT04179708|Active Comparator|Conventional education|"patient receiving a classical education on spinal physiology and ergonomics"
10142164|NCT04179695|Experimental|consultation with Parkinsun|
10142165|NCT04179695|Active Comparator|consultation as usual without Parkinsun|
10142166|NCT04179682|Active Comparator|4-week 2-hours/day CIMT program|a 4-week 2-hours/day constraint program, total 40 hours CIMT, in preschool education.
10142167|NCT04179682|Active Comparator|2-week 4-hours/day CIMT program|one was a 2-week 4-hours/day constraint program, total 40 hours CIMT, in preschool education.
10142168|NCT04179604|Experimental|Levosimemdam|Levosimendan 2.5 mg / ml concentrate for solution for infusion. A 5 ml vial contains 12.5 mg of levosimendan. The concentrate is a clear solution, yellow or orange, for dilution before administration. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
10142169|NCT04179604|Placebo Comparator|Placebo|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
10142170|NCT04179656|Experimental|Pyrotinib Treatment|This arm for HER2-postive solid tumor
10142171|NCT04179552|Experimental|PAAG-OA|All subjects receive treatment with PAAG-OA
10142172|NCT04179643|Experimental|3 x 10e13vg NAN-101|Intracoronary Infusion of NAN-101 at 3 x 10e13vg up to 4 subjects
10142173|NCT04179643|Experimental|1 x 10e14vg NAN-101|Intracoronary Infusion of NAN-101 1 x 10e14vg up to 4 subjects
10142174|NCT04179643|Experimental|3 x 10e14 vg NAN-101|Intracoronary Infusion of NAN-101 3 x 10e14 vg up to 4 subjects
10142175|NCT04179630|Experimental|Aldafermin (NGM282)|Administered by subcutaneous injection
10142176|NCT04179500|Experimental|Study Participants|Participants will receive bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg once daily (BPaMZ) for 26 weeks.
10142177|NCT04179383|Other|Patient|"Patient presenting a Reversible Cerebral Vasoconstriction Syndrome (RCVS) :~Questionnaires about anxiety, depression ;~Constitution of a biobank (if specific consent) at inclusion and at 3 months"
10142178|NCT04179383|Other|Volunteers|"Volunteers admitted for a non neurological or non vascular pathology or healthy volunteers accompanying a patient :~Questionnaires about anxiety, depression ;~Constitution of a blood biobank (if specific consent)"
10142179|NCT04179578|Active Comparator|Crura|Closure of the diaphragmatic hiatus by a running suture alone
10142180|NCT04179578|Active Comparator|Crura and lateral release|Closure of the diaphragmatic hiatus by a running suture and an incision of 4 cm of the left diaphragm (lateral release)
10142181|NCT04179526|Experimental|Transdiagnostic Internet-delivered REBT|Protocol is based on Rational Emotive Therapy (Ellis, 1962, 1994), structured in 8 modules delivered over 6 weeks (Module 1- Introduction and psychoeducation about emotions, Module 2 - Psychoeducation anxiety and depression, Module 3 - Relaxation, Module 4 - Negative patterns of thinking and cognitive restructuring, Module 5 - Problem solving, Module 6 - Exposure and Behavioral activation, Module 7 - Positive emotions and Module 8 - Gaining maintenance)
10142182|NCT04179526|No Intervention|Waitlist|Participants in the control group will complete pre-treatment and post-treatment assessments. After participants in the experimental group complete post-treatment assessment, they will receive the intervention.
10142183|NCT04179669|Experimental|IBI306|Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
10142184|NCT04179669|Experimental|placebo|Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
10142185|NCT04179435|Other|Tourette syndrome|Patients with Tourette syndrome aged 13 - 18 y.o. Interventions : Brain scans, cognitive testing, TMS measures
10142186|NCT04179435|Other|Controls|Controls matched to Tourette syndrome group nterventions : Brain scans, cognitive testing, TMS measures
9519689|NCT03284541|Active Comparator|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
10142187|NCT04179513|Experimental|GB224 10mg|GB224 10mg
10142188|NCT04179513|Experimental|GB224 20mg|GB224 20mg
9970310|NCT01298908|Other|Foam sclerotherapy|Ultrasound guided foam sclerotherapy
10142189|NCT04179617|Experimental|Preferred nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 5% nicotine content pod (their preferred pod)
10142190|NCT04179617|Experimental|Low nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 3% nicotine content pod (non-preferred pod)
10142191|NCT04179487||Pregnant Patients with Suspected PE|Pregnant Patients with Suspected pulmonary embolism undergoing low dose CT pulmonary angiogram
10142192|NCT04179201||IBD with CDI|Inflammatory bowel disease with clostridium difficile infection
10142193|NCT04179201||IBD without CDI|Inflammatory bowel disease without clostridium difficile infection
10142194|NCT04179214|Experimental|Group I Experimental: thoracic manipulation|The experimental group will receive thoracic manipulation along with conventional pt protocol.
10142195|NCT04179214|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol
10142196|NCT04179227||Observational (focus group)|Participants attend a focus group session and review printed copies of planned posts for the to-be-developed Facebook intervention over 90 minutes to 2 hours.
10142197|NCT04179318||low risk|BCT Score <4
9519690|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
10142198|NCT04179318||high risk|BCT Score ≥4
10142199|NCT04179305|Experimental|Oncolo_GIST Arm|Physicians assigned to this arm will receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with an Oncolo-GIST trained physician.
10142200|NCT04179305|Placebo Comparator|Usual Care Arm|Physicians assigned to this arm will not receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with a physician that was not trained with the Oncolo-GIST intervention.
10142201|NCT04179279||Pilot|
10142202|NCT04179279||Pivotal|
10142203|NCT04179344||Integrated e-healthcare services (IeHS) web-based app|This usability study is conducted under 3 steps: IeHS simulation, user experience survey using SUS questionnaire, and qualitative study through the in-depth interview.
10142204|NCT04179253|Other|Unexplained infertility|"The patient was placed in the dorsal lithotomy position. Normal saline was used for uterine distension connected to the inflow channel on the sheath with intravenous tubing. The tip of the hysteroscope was positioned in the vaginal introitus, the labia being slightly separated with fingers. The vagina was distended with saline.~The uterine cavity was systematically explored by rotating the fore-oblique scope in order to identify any anomaly in the uterine walls and/or the right and left tubal ostia. At this stage it was crucially important to avoid lateral movements as much as possible to reduce patient discomfort to a minimum. After that, the scope was removed Finally the evaluation and the data that had been found were written in details by the surgeon. Operative intervention was done if needed. Any complication in the form of pain, bleeding, vasovagal attack and perforation, were registered in the patient sheet."
10142205|NCT04179292|Experimental|Physiotherapy Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist for 3 sessions per week. On the other days, it will be implemented as an 8-week home program with 5 sessions per week.
10142206|NCT04179292|Experimental|Home Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients as home program. Motivation will be provided by contacting by phone / call once a week for follow-up.
10142207|NCT04179071|Experimental|Savolitinib|Subjects will receive single dose of 600mg savolitinib after a high-fat, high-calorie meal.
10142208|NCT04179071|Experimental|Savolitinib + Famotidine|Subjects will receive savolitinib 600mg single dose after high-fat, high-calorie meal and after 1.5 hours (Part A) or 5.5 hours (Part B) of famotidine 40mg dose. Famotidine will be administered after an overnight fast of at least 8 hours with approximately 240 mL of water.
10142209|NCT04179188||Bariatric OSA Group|Bariatric surgery plannified intervention patient with obstructive sleep Apnéa
10142210|NCT04179188||Bariatric without OSA Group|Bariatric surgery plannified intervention patient without obstructive sleep Apnéa
10142211|NCT04179240|Experimental|audio and animated cartoon questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with audio and animated cartoon questionnaire. The animation was an 8-minute cartoon video divided into different parts according to different questions. The first part of the animation was the introduction of biospecific nonspecimen specimen and our survey, while the other parts showed the content of the questionnaire about donating biospecific nonspecimen specimen in a vivid way. The background music built a relaxed and pleasant atmosphere, and some cartoon pictures were made into question options to simplify the understanding and data analysis.
10142212|NCT04179240|No Intervention|text questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
10142213|NCT04179240|Other|Parent group|After a brief introduction to our survey, participants(parent) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
10142214|NCT04178967|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W."
10142215|NCT04178967|Experimental|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W."
10142216|NCT04178967|Experimental|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebikizumab injection."
10142217|NCT04178967|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):~Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
10142218|NCT04178863|Active Comparator|lataprost|latanoprost use
10142219|NCT04178863|Active Comparator|timolol|timolol group
10142220|NCT04179123|Experimental|Healthy|Conventional and customised PAP interfaces
10142221|NCT04179123|Experimental|Patients|Conventional and customised PAP interfaces
10142222|NCT04179045|Experimental|Bioheart|Subjects have CAD with one or two de novo native coronary artery lesions and will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System. There will be only one arm in this study.
10142223|NCT04178928|Active Comparator|group A|patiWill receive L-T4 treatment at a dose 1 µg/kg/day for 12 weeks. And the dose will be titrated every 4 weeksents with SCH will be subjected to clinical, laboratory and imaging assessment and
10142224|NCT04178928|No Intervention|Group B|.pWill not receive treatment.atients with SCH will be subjected to clinical, laboratory and imaging assessment and
10142225|NCT04179006|Active Comparator|LF chocolate + antidepressant(s)|Participants with LF chocolate add-on to their antidepressants regimen.
10142226|NCT04179006|Active Comparator|Erinacine A-enriched Hericium chocolate + antidepressant(s)|Participants with Erinacine A-enriched Hericium chocolate add-on to their antidepressants regimen.
10142227|NCT04179006|Placebo Comparator|Plain chocolate + antidepressant(s)|Participants with plain chocolate add-on to their antidepressants regimen.
10142228|NCT04179539|Experimental|Intervention|"Patients with suspected acute PE undergo CTPA and V/Q PET/CT imaging within 24 hours. V/Q PET/CT images are not used for patients management.~After completion of inclusion, central readings will be independently conducted:~CTPA will be interpreted by two radiologists, blinded to the results of any clinical information or imaging test results. The results of this interpretation will be used as a reference standard.~V/Q PET/CT will be interpreted by two independant nuclear medicine physicians, blinded to the results of any clinical information or imaging test results (including the reference standard)."
10142229|NCT04179058||IPAF patients|IPAF definition according to 2015 ERS/ATS criteria
10142230|NCT04179058||non-IPAF patients|
10142231|NCT04178941|Experimental|Intervention (Single Arm)|The intervention is a combined educational outreach and audit and feedback strategy that includes providing the hospital's own continuous pulse oximetry use data back to them on a weekly basis. The data will be accompanied by staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
10142232|NCT04178980|Active Comparator|case|
10142233|NCT04178980|Placebo Comparator|control|
10142234|NCT04179136|Active Comparator|High enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
10142235|NCT04179136|Placebo Comparator|High enterolactone producer's (Control)|Placebo treatment matching intervention
10142236|NCT04179136|Active Comparator|Low enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
10142237|NCT04179136|Placebo Comparator|Low enterolactone producer's (Control)|Placebo treatment matching intervention
10142238|NCT04179331|Experimental|Neurotensin|
10142239|NCT04179331|Experimental|Saline|
10142240|NCT04179084|Experimental|fruquintinib + Sintilimab|
10142241|NCT04178811|Active Comparator|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia
10142242|NCT04178811|Active Comparator|Prostatic Uretheral Lift|Use of Holmium Prostatic Uretheral Lift in Management of Benign Prostatic Hyperplasia
10142243|NCT04178902|Experimental|Part A: ABBV-467 Dose Escalation|ABBV-467 administered by intravenous (IV) infusion at various doses until a recommended phase 2 dose is determined.
10142244|NCT04178902|Experimental|Part B: ABBV-467 Dose Expansion|ABBV-467 administered by intravenous (IV) infusion at recommended phase 2 dose as identified in Part A.
10142245|NCT04178850|Experimental|GB242|3mg/kg
10142246|NCT04178850|Active Comparator|Infliximab|3mg/kg
10142247|NCT04178616|Other|systemic sclerosis patients population|All the patients with systemic sclerosis disease followed in day-care in a tertiary hospital are eligible to be enrolled in the study.
10142248|NCT04178876|Experimental|Aspiration and Sclerotherapy of endometriomas|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
10142249|NCT04178876|Active Comparator|laparoscopic stripping technique|cystectomy of endometriomas during laparoscopy
10142250|NCT04178759|Active Comparator|Control|Patients with benign liver disease, who undergo liver resection
10142251|NCT04178759|Experimental|Experimental|Patients with liver metastases and received chemotherapy, who undergo liver resection
10142252|NCT04178655|Experimental|Tranexamic Acid Treatment|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
10142253|NCT04178655|Placebo Comparator|Placebo|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
10142254|NCT04178707|Other|Intervention|Using microdialysis the patients inner enviorment of the anal fistula will be measured - levels of lactate, glucose and pyruvate.
10142255|NCT04178577|Experimental|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
10142256|NCT04178694|Experimental|non-invasive ventilation|All subjects will be submitted to non-invasive ventilation with different settings. During the whole period indirect calorimetry will be performed and haemodynamic parameters will be monitored using a non-invasive device. Reversed combined RPE scale will be asked on a regular base.
10142257|NCT04178499||smokers|active smokers
10142258|NCT04178499||non-smokers|never smokers
10142259|NCT04178915||Patients with severe bacterial infections|
10142260|NCT04178785|Active Comparator|REMIFENATIL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
10142261|NCT04178785|No Intervention|FENTANYL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
10142262|NCT04178733|Experimental|LY3493269 - Subcutaneous (SC)|LY3493269 administered SC.
10142263|NCT04178733|Placebo Comparator|Placebo - SC|Placebo administered SC.
10142264|NCT04178733|Experimental|LY3493269 - Intravenous (IV)|LY3493269 administered IV.
10142265|NCT04178746||IVH subjects in the Hyper-Acute Phase|The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in approximately 20 subjects with intracerebral hemorrhages utilizing the Artemis Neuro Evacuation Device in the hyper-acute phase. For the purposes of this registry, the hyper-acute phase as defined by initiation of the MIS procedure no longer than 12 hours from initial NCCT scans and no longer than 18 hours since time patients last known well.
10142266|NCT04178668|Experimental|20-40 years old|33 patients between 20 and 40 years old
10142267|NCT04178668|Experimental|70-90 years old|33 patients between 70 and 90 years old
10142268|NCT04178525|Experimental|Arm A (Experimental group|ChitoCare gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
10142269|NCT04178525|Placebo Comparator|Arm B (Control group)|Placebo gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
10142270|NCT04178642|Experimental|(experimental group)|Evaluating the efficacy of an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin-Lipiodol (experimental group)
10142271|NCT04178642|Active Comparator|(standard group)|The absence of adjuvant treatment (standard group).
10142272|NCT04178343|Experimental|Group A|Meningeal Metastases, with or without brain metastases
10142273|NCT04178564|Experimental|Intervention Group|Intervention group will receive 47 sessions of group CS and participate in 3 evaluation sessions. The CS program will last 1 year and each group CS session will last approximately 60 minutes.
10142274|NCT04178330|Experimental|Group A|patients with multiple brain metastases (no less than 3 lesions) ,who have not recived whole brain radiotheray (WBRT).
10142275|NCT04178304|Experimental|G1 patients receive prolotherapy|Intra and extra articular dextrose 25%
10142276|NCT04178356|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proprioceptive neuromuscular facilitation techniques will be applied for 4 weeks.
10142277|NCT04178356|Active Comparator|Control Group|Conservative treatment of low back pain will be applied for 4 weeks.
10142278|NCT04178369|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proximal and distal tibiofibular joint manipulations will be applied for 6 weeks.
10142279|NCT04178369|Active Comparator|Control Group|All participants were given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept (conservative treatment) for 5 days a week, 45 minutes each.
10142280|NCT04178486|Experimental|Amnesia|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions to experience amnesia for the food pictures they had just seen.
10142281|NCT04178486|Experimental|Cognitive Rehearsal|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a future where they will control their eating behaviors.
10142282|NCT04178486|Experimental|Memory Substitution|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a past where they have always controlled their eating behaviors.
10142283|NCT04178486|Placebo Comparator|Control|Hypnosis formed from only hypnotic induction (an adapted version from Barber Suggestibility Scale).
10142284|NCT04178382|Experimental|experiment group|Combined detection of PCR and CRISPR/Cas12a in alveolar lavage fluid to guide early target adjustment of antibiotics
10142285|NCT04178382|No Intervention|control group|Guide the target adjustment of antibiotics according to traditional microbiological detection methods
9970311|NCT01298934|Experimental|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
10142286|NCT04178395|Experimental|real tDCS group|Patients allocated to the real tDCS group (11 patients) received one daily session of bihemispheric transcranial direct stimulation and repetitive peripheral stimulation for 5 consecutive days.
10142287|NCT04178395|Sham Comparator|sham group|Patients allocated to the sham tDCS group (9 patients) received sham tDCS + rPNS also daily, for 5 consecutive days.
10142288|NCT04178239||Chronic Fatigue|MFI score >53 points
10142289|NCT04178239||No Chronic Fatigue|MFI score < 54 points
10142290|NCT04178408||Cases|Cases of inflammatory bowel disease
10142291|NCT04178408||Controls|Two controls per case. 1. Sibling or other second degree relative of similar age. 2. neighbourhood control matched for age
10142292|NCT04178291|Experimental|Conventional debridement and air polishing|All participants will receive full mouth EPAP as an adjunct to RSD using ultrasonic scalers and Gracey currettes. The EPAP procedure will be performed using the Air-Flow Master R (EMS) equipment. For supragingival biofilm removal, the Air-Flow handpiece will be used, while the Perio-Flow handpiece with a disposable nozzle will be used for subgingival debridement at sites with PPD ≥ 5mm. No time limit is applicable for supragingival air polishing. However, for subgingival debridement, the nozzle will be inserted for 5 seconds into each pocket, and moved vertically up and down. Gracey currettes will be used at sites with PPD ≥ 5mm.
10142293|NCT04178291|Active Comparator|Conventional debridement|All participants will receive full mouth RSD using ultrasonic scalers and Gracey currettes. Gracey currettes will be used at sites with PPD ≥ 5mm.
10142294|NCT04178681|Experimental|V-A-C|"Order of administration:~100% vegetable fat blend~100% Anhydrous Milk Fat (AMF)~100% Cream (AMF + milk fat globular membranes)"
10142295|NCT04178681|Experimental|V-C-A|"Order of administration:~100% vegetable fat blend~100% Cream (AMF + milk fat globular membranes)~100% Anhydrous Milk Fat (AMF)"
10142296|NCT04178681|Experimental|A-V-C|"Order of administration:~100% Anhydrous Milk Fat (AMF)~100% vegetable fat blend~100% Cream (AMF + milk fat globular membranes)"
10142297|NCT04178681|Experimental|A-C-V|"Order of administration:~100% Anhydrous Milk Fat (AMF)~100% Cream (AMF + milk fat globular membranes)~100% vegetable fat blend"
10142298|NCT04178681|Experimental|C-A-V|"Order of administration:~100% Cream (AMF + milk fat globular membranes)~100% Anhydrous Milk Fat (AMF)~100% vegetable fat blend"
9970312|NCT01298947|Active Comparator|Laser atherectomy and drug-coated balloon|Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries
9970313|NCT01298947|Active Comparator|Drug eluting Ballon PTA|Paclitaxel-coated balloon angioplasty
10142299|NCT04178681|Experimental|C-V-A|"Order of administration:~100% Cream (AMF + milk fat globular membranes)~100% vegetable fat blend~100% Anhydrous Milk Fat (AMF)"
10142300|NCT04178421|Experimental|Experimental Group|A computerized eye -tracking program training the eye gaze fixation with the target to improve impulse control and sustained attention of children with special needs
10142301|NCT04178421|Placebo Comparator|Control Group|Computerized program
10142302|NCT04178226|No Intervention|Control|conventional therapy (NSAIDs and OCP)
10142303|NCT04178226|Experimental|Manual Acupuncture|manual acupuncture therpy
10142304|NCT04178226|Experimental|Laser Acupuncture|laser acupuncture therapy
10142305|NCT04178512|Active Comparator|group Dexamethasone|Patients will receive 8 mg of dexamethasone(2ml) in addition to 2ml of hyperbaric bupivacaine 0.5% (total volume 4 ml) intrathecal injection.
10142306|NCT04178512|Active Comparator|group Fentanyl|patients will receive 20 microgram fentanyl(diluted in sterile normal saline0.9% to 2ml)in addition to 2ml of hyperbaric bupivacaine 0.5%(total volume 4 ml) intrathecal injection.
10142307|NCT04178512|Active Comparator|group Control|patients will receive 2ml of sterile normal saline0.9% in addition to 2ml of hyperbaric bupivacaine o.5% (total volume 4 ml) intrathecal injection.
10142308|NCT04178447|Experimental|Group 1: ESRD subjects not on dialysis or severe RI|subjects with eGFR <15 mL/min/1.73 m2) or (eGFR 15 to <30 mL/min/1.73 m2)
10142309|NCT04178447|Experimental|Group 2: normal renal function|subjects with eGFR ≥90 mL/min/1.73 m2
10142310|NCT04178447|Experimental|Group 3: moderate RI|subjects with eGFR 30 to <60 mL/min/1.73 m2
10142311|NCT04178447|Experimental|Group 4: mild RI|subjects with eGFR 60 to <90 mL/min/1.73 m2
10142312|NCT04178148|Experimental|BestDose|Therapeutic drug optimization of amikacin using the BestDose software algorithm
10142313|NCT04178148|No Intervention|Control|
10142314|NCT04178018|Experimental|Transvaginal photoacoustic imaging/ultrasound|"Baseline transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging for all participants enrolled~Once the surgeon has surgically removed the ovary(ies), they will be imaged with the photoacoustic imaging/ultrasound~For the exploratory outcome measure for high risk participants (approximately 50 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally at 6 months, 12 months, 18 months, 24 months, and at the time of surgery~For the exploratory outcome measure for high risk participants (approximately 10 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally every 2 weeks at follicular phase and at the luteal phase for 3 months"
10142315|NCT04178278|Experimental|Shuttle walking test group|Patients will performed shultte walking test.
10142316|NCT04178278|Active Comparator|Exercise stress test group|Patients will performed exercise stress test.
10142317|NCT04178278|Active Comparator|6 minutes walking test group|Patients will performed 6 minutes walking test.
10142318|NCT04178200||1.5 ml Dose|For retrobulbar anesthesia, 1.5 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
10142319|NCT04178200||3 ml Dose|For retrobulbar anesthesia, 3 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
10142320|NCT04178265|Experimental|Electroacupuncture group|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of three times per week for four weeks, for a total of twelve times.~Acupoint selection: needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints."
10142321|NCT04178265|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of three times per week for four weeks, for a total of twelve times.
10142322|NCT04178252|Active Comparator|standard drug|Standard treatment of primary headache with 10 mg metoclopramide IV in 150 ml saline given over 10 minutes
10142323|NCT04178252|Active Comparator|drug mask|Standard treatment plus eye mask
9970314|NCT01298960|Experimental|rGH Group|
9970315|NCT01298960|No Intervention|Non rGH group|
9970316|NCT01298973|Experimental|Saline|One group will receive Saline to irrigate the wound
9970317|NCT01298973|Experimental|Viscoat|One group will receive Viscoat to close the surgical wound
10142324|NCT04178252|Active Comparator|drug headset|Standard treatment plus headset
9669343|NCT02879136|Active Comparator|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
9519695|NCT03284489||ICU patients|Patients with pancreatitis
10142325|NCT04178252|Active Comparator|drug mask headset|Standard treatment plus headset plus eye mask
10142326|NCT04178473|Active Comparator|total abdominal hysterectomy|Total abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
10142327|NCT04178473|Active Comparator|subtotal abdominal hysterectomy|subtotal abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
10142328|NCT04177927|Experimental|endtidalcarbondioxide monitoring group|The patients performed gastrointestinal endoscopy will be monitored with Capnostream 20p / Coviden for etCO2 (End tidal CO2), RR (Respitarory rate), SpO2 and PR (heart rate).
10142329|NCT04177927|Active Comparator|Control Group|Rutine monitorization will be performed to control group of patients.
10142330|NCT04178161|Experimental|Treated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.~Treatment side receives laser treatment of the sweat glands."
10142331|NCT04178161|No Intervention|Untreated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.~Control side is untreated."
10142332|NCT04177888|Experimental|Experimental group|Experimental group with 45 participants, received hot pack, which was a single-use pack filled with magnesium sulfate and water, squeezed between the hands to activate the warming effect, applied to the lower back area for 30 minutes followed by 10 minutes rest then again applied for 30 minutes. This procedure was repeated till delivery.
10142333|NCT04177888|No Intervention|Control group|Control group with 46 participants received the hospital routine care that included Entonox inhalation as optional labor pain management.
10184794|NCT03752060|No Intervention|Control Group|The control group will complete all baseline and post-testing, but will not complete any training for the 16 weeks between the baseline and post-testing sessions. These participants will also be instructed to maintain their current dietary and physical activity habits (see Lifestyle Controls section). All participants in the control group will also be provided an opportunity to come to the laboratory for two weeks after they have completed the study to receive instruction regarding resistance and/or aerobic training exercise prescription, and to complete supervised resistance and/or aerobic exercise training.
10184795|NCT03752021||Laboring Subjects|Subjects with a planned cesarean delivery who labor prior to their scheduled date or those who are in labor and require an unplanned but non-emergent cesarean delivery. These subjects will be approached upon admission to the study facility by the researcher for potential enrollment to allow adequate time to consider participation, ask questions, provide consent, and prior to procedure (Myometrial Sampling).
10184796|NCT03752021||Non Laboring Subjects|Subjects with a planned cesarean delivery will be approached by the researcher during prenatal visits or at the study facilities prior to planned procedure (Myometrial Sampling)
10184797|NCT03752008|Experimental|Active Play (AP)|This arm received the Active Play curriculum intervention (described in following section).
10184798|NCT03752008|Experimental|Outdoor Play (OP)|This arm received the Outdoor Play curriculum intervention (described in following section).
10184799|NCT03751995|No Intervention|Control|Participants from medical centers assigned to the control arm will receive usual care.
9827474|NCT02457247|Experimental|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
10184800|NCT03751995|Experimental|Intervention|Participants from medical centers assigned to the intervention arm will receive access to their choice of a mindfulness app or a webinar-based mindfulness course for 6 weeks.
10184801|NCT03751982|Active Comparator|Open-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is not synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
10184802|NCT03751982|Experimental|Closed-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
10184803|NCT03751969|Experimental|HSK3486|"0.4 mg/kg of HSK3486 emulsion injection (containing [14C] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg)~."
10184804|NCT03751956|Experimental|HSK3486|0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection
10184805|NCT03751943|Other|NanoFuse® PL Gutter|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) within one posterolateral gutter (unilateral)
10184806|NCT03751930||Patients with Autism Spectre Disorders|Taken biological samples on patients with Autism Spectre Disorders
10184807|NCT03751930||Healthy volunteers|Taken biological samples on patients healthy volunteers
9669344|NCT02877134|Experimental|Part I : Placebo|Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI <150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22.
10184808|NCT03751917||APL patients|The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
10184809|NCT03751904|Other|AcoustiCare|Single Arm
10184810|NCT03751891|Experimental|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
9669345|NCT02877134|Experimental|Part I : JNJ-64304500|Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22.
9519696|NCT03284476||ICU patients|Collection of medical data of Patients with peritonitis (nosocomial or community-acquired) or Patients with post-operative peritonitis
10142334|NCT04178057|Experimental|GB222 3mg/kg|GB222 3mg/kg
10142335|NCT04178057|Experimental|GB222 5mg/kg|GB222 5mg/kg
10142336|NCT04178057|Experimental|GB222 7.5mg/kg|GB222 7.5mg/kg
10142337|NCT04178057|Experimental|GB222 10mg/kg|GB222 10mg/kg
10142338|NCT04178083||Laparoscopic Sacrohysteropexy,|"Under general anesthesia,laparoscopic approach is used to enter the abdomen.Following this, visceral peritoneum is held with forceps from the point where the sacro-uterine ligaments adhere to the uterus.~cut with unipolar scissors to the sacrouterin ligaments approximately 2-4 cm in the midline a transverse incision is made and the posterior wall of the cervix is reached. Approx. 10-15 x2 cm polypropylene mesh 5 mm trocar is inserted into the abdomen with the help of grasper and one end three points with 2/0 non-absorbable prolene sutures in the midline cervix Intracorporeal suture technique.~After the sacral promontorium on peritona about 2 The transverse incision is made to the normal anatomical position and the appropriate mesh length is determined and the other end is fixed to the area prepared on the sacral promontorium at 3 points with 2-0 prolene. Bleeding reperitonization according to intracorporeal suture technique with 2/0 vicry"
10142339|NCT04178083||Modified Laparoscopic Lateral Suspension|A 10 cm diameter trocar is passed through a 1 cm infraumbical incision. In addition, two 5 mm diameter trocar are placed on 4 cm on both sides of the spinal iliac crest, and a 5 mm diameter trocar is placed laterally in the rectus muscle at the left lateral level of the umbilicus. A Prolene network of 25 cm in length is prepared. Dissection of the uterine cavity is performed to expose a mustache. The bottom of the web is secured by suturing the web in the midline and sides of the web with 2-0 prolene. The left and right modified lateral ports are then removed by moving under the bottom of the planet with the help of the planet until the isthmus reaches the bottom of the round ligament. The lateral ports are again slid onto the mesh, placed and sutured with peritoneal 2-0 vicryil, the mesh ends are cut at the skin level and the procedure is terminated.
10142340|NCT04178083||Laparoscopic Pectopexy|"First, the peritoneal layer on the top and side of the bladder opens parallel to the round ligament toward the right pelvic sidewall.~The iliopectineal ligament is then located under the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medially of the outer iliac vein.~iliopectineal (Cooper) ligament exposing a segment of approximately 3-4 cm is formed.~After completion of the dissections, the ends of the mesh are sutured to both iliopectineal ligaments by intracorporeal suture using nonabsorbable sutures. The middle of the net is fixed with three sutures to the lower anterior segment of the uterus. The peritoneum on the mesh is sutured with an absorbable suture material."
10142341|NCT04177966|Experimental|women watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term The day before surgery the women will watch a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation
10142342|NCT04177966|Placebo Comparator|women not watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term Women will receive general information about the surgery as part of informed consent, without watching a pre- prepared film.
10142343|NCT04177836|Experimental|MIndfulness|This arm was developed to increase attention towards and acceptance of current experiences.
10142344|NCT04177836|Active Comparator|Active Control|This arm is a relaxation-based active treatment comparison intervention, developed to parallel the structure of the mindfulness intervention without the attention towards or acceptance of present experiences.
10142345|NCT04177979|Experimental|Near assisted learning group|Participants in this arm were supervised by the trained peer-instructors.
10142346|NCT04177979|No Intervention|Self directed learning group|Participants in this arm were practicing independently. They were not supervised by any instructors.
10142347|NCT04178070|Experimental|GB224 2mg|single dose
10142348|NCT04178070|Experimental|GB224 5mg|single dose
10142349|NCT04178070|Experimental|GB224 10mg|single dose
10142350|NCT04178070|Experimental|GB224 15mg|single dose
10142351|NCT04178070|Experimental|GB224 20mg|single dose
10142352|NCT04178070|Experimental|GB224 30mg|single dose
10142353|NCT04178070|Placebo Comparator|Placebo 2mg|single dose
10142354|NCT04178070|Placebo Comparator|Placebo 5mg|single dose
10142355|NCT04178070|Placebo Comparator|Placebo 10mg|single dose
10142356|NCT04178070|Placebo Comparator|Placebo 15mg|single dose
10142357|NCT04178070|Placebo Comparator|Placebo 20mg|single dose
10142358|NCT04178070|Placebo Comparator|Placebo 30mg|single dose
10142359|NCT04177875|Experimental|Chemoradiation and pd-1|Subjects in Arm A receive 2 cycles of Docetaxel /Albumin-bound Paclitaxel + Cisplatin, for neoadjuvant therapy Neoadjuvant radiotherapy for 40Gy/20F
9827475|NCT02457260|Experimental|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
10142360|NCT04177615|Experimental|Thromboectomy and rTPA|use thromboectomy and rtpa for patient with basilar artery occlusion stroke in 24 hour
10142361|NCT04177615|No Intervention|rTPA( recombinant tissue plasminogen activator )|use rtpa for patient with basilar artery occlusion stroke in 24 hour
10142362|NCT04177641||low grade squamous intraepithelial lesion(LGSIL)|low grade squamous intraepithelial lesion(LGSIL) n=100
10142363|NCT04177641||high grade squamous intraepithelial lesion(HGSIL)|high grade squamous intraepithelial lesion(HGSIL) n=100
10142364|NCT04177641||Healthy controls|Healthy volunteers n=100
10142365|NCT04177849|Active Comparator|Anterior Cervical Decompression and Fusion (ACDF)|Patients entered into this arm are treated via an anterior approach with disk excision, root canal decompression and fusion of the affected segment with a cage and plate.
10142366|NCT04177849|Experimental|Posterior Foraminotomy (PF)|Patients entered into this arm are treated via a posterior approach through intermuscular planes. The root canal is decompressed by burring the medial third of the facet joint. No fusion is performed.
10142367|NCT04177732|Other|Healthy peri-implant status|Patient with healthy peri-implant status
10142368|NCT04177732|Other|Presence of peri-implant diseases|Patients with presence of peri-implant diseases
10142369|NCT04177667|Active Comparator|Proxeed arm|Subjects received 2 packets per day for 6 months of supplement (1000 mg of L-carnitine, 725 mg of fumarate, 500 mg of acetyl-L-carnitine, 1000 mg of fructose, 50 mg of citric acid, 50 µg of selenium, 20 mg of coenzyme Q10, 90 mg of vitamin C, 10 mg of zinc, 200 µg of folic acid and 1.5 µg of vitamin B12)
10142370|NCT04177667|Placebo Comparator|Placebo arm|Subjects received 2 packets per day for 6 months of placebo
10142371|NCT04177563|Experimental|a group of ten students with high physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
10142372|NCT04177563|Experimental|a group of eight students with moderate physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
10142373|NCT04178109|Active Comparator|Group A|"Group A was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group A was given the oral combination dexketoprofen/tramadole (25mg/75mg) 2h after surgery every 8h for 72h."
10142374|NCT04178109|Placebo Comparator|Group B|"Group B was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group B received postoperative analgesia with intravenous tramadole 75mg and paracetamol 1g every 8h with the first dose beginning 2h after the end of the surgery. For 72h"
10142375|NCT04177745|Experimental|Hot Application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
10142376|NCT04177745|Experimental|Cold Application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
10142377|NCT04177745|No Intervention|Standard Practice|The standard practice of the clinic was made. Accordingly, the researcher performed the vein assessment after the participants filled out the questionnaire, and then inserted the 20-G catheter into the inner surface of their forearm without any application. Afterwards, she assessed the pain and anxiety levels of the patients twice before and after the catheter insertion procedure.
10142378|NCT04177784|Experimental|Intervention (I)|This arm was randomized to a 20 min video that emphasized information about factors other than individual behaviors that influence weight, weight loss and ability to maintain weight. It also indirectly addressed weight bias by explaining how to have conversation about weight and health with a patient with obesity that is free of biases.
10142379|NCT04177784|Active Comparator|Weight Control (C1)|This arm was randomized to a 20 min video that emphasized the controllable aspects of weight and gave dietitians an overview of a tool to help plan and monitor weight loss.
10142380|NCT04177784|Placebo Comparator|Weight Neutral Control (C2)|The arm was randomized to a 20 min video about the role dietitians play in society, that made no mention of weight or obesity.
10142381|NCT04177719|Experimental|Oxytocin|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
10142382|NCT04177719|Placebo Comparator|Placebo|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
10142383|NCT04178044|Experimental|GB223-group 1|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg,single dose administration; 2 subjects receive placebo.
10142384|NCT04178044|Experimental|GB223-group 2|21mg/kg
10142385|NCT04178044|Experimental|GB223-group 3|63mg/kg
10142386|NCT04178044|Experimental|GB223-group 4|119mg/kg
10142387|NCT04178044|Experimental|GB223-group 5|140mg/kg
10142388|NCT04177602|Experimental|Trifluridine/tipiracil based radiotherapy|Trifluridine/tipiracil based chemoradiotherapy (CRT)
10142389|NCT04177602|Active Comparator|standard calibration arm (internal control)|capecitabine based chemoradiotherapy
10142390|NCT04177537||Pre-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work with traditional therapies selected from one rehabilitation facility
10142391|NCT04177537||Post-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies selected from one rehabilitation facility
10142392|NCT04177472|Experimental|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
10142393|NCT04177472|No Intervention|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
10142394|NCT04177576||Patients with myeloproliferative neoplasms (MPN)|Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
9970318|NCT01298986|Active Comparator|Pulmonary Vein Isolation|Patients who have paroxysmal or persistent atrial fibrillation but whose left atrium is < /= 5.0
10142395|NCT04177498|Experimental|Treatment (rigosertib sodium)|Patients receive rigosertib sodium either oral or IV over a 52 week period. Patients will take oral rigosertib continuously for a total of three weeks, every four-week cycle (three weeks on, one week off drug). For IV, rigosertib is administered as a 72-hr continuous infusion on Days 1, 2 and 3 of a 2-week cycle for the first eight 2-week cycles, then on Days 1, 2 and 3 of a 4-week cycle thereafter.
10142396|NCT04177290|Experimental|sintilimab (M1b) 200mg|
10142397|NCT04177290|Active Comparator|sintilimab (approved) 200mg|
10142398|NCT04177342|Active Comparator|fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
10142399|NCT04177342|Experimental|oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
10142400|NCT04177628|Experimental|Arm A: Shared decision making|Patients will be informed by a doctor randomized to practice shared decision making and use the in-consultation PtDA during the consultation on adjuvant radiotherapy.
10142401|NCT04177628|No Intervention|Arm B: Usual practice|Patients will be informed by a doctor randomized to inform about adjuvant radiotherapy according to usual practice.
10142402|NCT04177173|Experimental|Simvastatin & Methotrexate|Methotrexate 10 mg once a week per oral for 6 months and Statins (Simvastatin) 20 mg once a day per oral
10142403|NCT04177173|Active Comparator|Methotrexate|Methotrexate 10 mg once a week for 6 months
10142404|NCT04177368||assess nutrition with regular dialysis|This study aims to assess the growth and the nutritional status in children with end-stage kidney disease on regular hemodialysis to define the degree of malnutrition , predict and quantify the risk for complications deriving from impaired nutritional status .Giving them theragran 60ml ,twice daily for 3 month.
10142405|NCT04177446|Placebo Comparator|control group|Patients will be given basic energy intake according to their weight, and will be extra maltodextrin as the placebo
10142406|NCT04177446|Experimental|intervention group|Patients will be given basic energy intake according to their weight, and will be extra protein intake
10142407|NCT04177147|Experimental|Clinical decision support via alert tool|Clinicians received access to the electronic alert tool, which automatically displayed patients' risk of hypoglycemia.
10142408|NCT04177147|No Intervention|Usual care|Clinicians did not receive access to the electronic alert tool.
10142409|NCT04177407|Experimental|BPF group|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
10142410|NCT04177407|No Intervention|control group|Regarding to the pelvic peritoneum reconstruction, in control group, the pelvic peritoneum will be closed with running suturing. If not possible, the peritoneum covering the surface of the bladder will be secured on the anterior surface of the sacrum with nonabsorbable sutures at the level where the anatomic structure obliterates the pelvic entrance. If neither method was feasible, the pelvic peritoneum defect will be left unclosed.
10142411|NCT04177459|Experimental|Health promoting dialogue in addition to treatment as usual|Health promoting dialogues in addition to follow-up from primary and secondary health care, and from schools, which is individually customized due to fatigue and other symptoms present.
10142412|NCT04177459|Active Comparator|Treatment as usual|Follow-up from primary and secondary health care, and from Schools, which is individually customized due to fatigue and other symptoms present..
10142413|NCT04177420|Experimental|Experiment Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night.
9519697|NCT03284463|Active Comparator|Glibenclamide|Glibenclamide Tablets
9519698|NCT03284463|Placebo Comparator|Placebo|Placebo for Glibenclamide
9519699|NCT03284450|Experimental|Dance performance fitness test (DPFT)|
9827476|NCT02457260|Experimental|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
10142414|NCT04177420|Placebo Comparator|Control Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night. the FIR-C mattress and the FIR-C abdominal pad is malfunction and it can not produce the FIR-C.
10142415|NCT04177056|Experimental|Stereotactic Body Radiotherapy|High dose SBRT to lesion(s) of interest.
10142416|NCT04177433|Experimental|Corticosteroid Injection|Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
10142417|NCT04177433|Placebo Comparator|Saline|Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
10142418|NCT04177069||Visucomplex Plus monotherapy|Patients with early dry AMD will be treated with Visucomplex Plus monotherapy.
10142419|NCT04177069||anti-VEGF drug plus Visucomplex Plus|Dry or wet AMD patients under treatment with a stable dose of an anti-VEGF drug, Visucomplex Plus will be added-on, upon physician decision.
10142420|NCT04177017|Experimental|Experimental group|The experimental group is the one that participates in the intervention
10142421|NCT04177017|No Intervention|Control group|The control group belonged to the same school but did not participate in the intervention. Instead, they continued with regular curricular classes
10142422|NCT04177186|Experimental|strength training group|ST group only strength training will be provided.
10142423|NCT04177186|Experimental|strength training with botulinum toxin|BT-ST group, strength training will be provided after the administering Botulinum toxin into the muscle belly guided under Ultra sound imaging.
10142424|NCT04177485|Experimental|Standard of Care + SMS text reminders|Standard of Care + SMS text reminders to be sent to caregivers for each of their subsequent vaccination visits, as per the EPI schedule (Penta2/OPV2/PCV2, Penta3/OPV3/PCV3, and MCV)
10142425|NCT04177485|No Intervention|Standard of Care|*Standard of care was defined as the health worker providing vaccination cards (home based records) to caregivers, as available, and providing verbal instruction of when to return for the next visit.
10142426|NCT04176991|Experimental|CTI-1601|
10142427|NCT04176991|Placebo Comparator|Placebo|
10142428|NCT04177004|Experimental|Group A (conditioning, goat milk, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
10142429|NCT04177004|Active Comparator|Group B (conditioning, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
10142430|NCT04177030|Experimental|Group A-Morning First|Within the first week of the study, Group A will consume fruits and vegetables within time-restriction morning window (9am-12pm). Following washout week, Group A will consume fruits and vegetables within time-restriction night window (7pm-10pm) for one week.
10142431|NCT04177030|Experimental|Group B-Night First|Within the first week of the study, Group B will consume fruits and vegetables within time-restriction night window (7pm-10pm). Following washout week, Group B will consume fruits and vegetables within time-restriction morning window (9am-12pm) for one week.
10142432|NCT04177303|Active Comparator|Metformin|Patients will continue with their standard insulin therapy and will additionally receive orally metformin 2gr/day.
10142433|NCT04177303|Placebo Comparator|Placebo|Patients will continue with their standard insulin therapy and will additionally receive placebo
10142434|NCT04176952|Experimental|FOLFOX-A|"FOLFOX A arm (14-day cycle)~nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)~Patients will also receive daily G-CSF as primary prophylaxis against neutropenic events for all cycles. This should be given as per local policy for chemotherapy regimens given every 14 days e.g. it may be started on day 4 for 7 days (preparation and dose should be given as per local policy)."
10142435|NCT04176952|Active Comparator|Abraxane and Gemcitabine|"Nab-Paclitaxel + Gemcitabine (AG) arm (28-day cycle)~nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
10142436|NCT04177043|Other|Screening|
10142437|NCT04177225||Patients with normal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their normal left ventricular diastolic function.
10142438|NCT04177225||Patients with abnormal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their abnormal left ventricular diastolic function.
10142439|NCT04176900|Experimental|Alternating 3D boluses|Both rigid and flexible 3D printed boluses made for each patient. Each is used on alternate days during radiation therapy.
10142440|NCT04176822|Experimental|Educational Animated Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched an educational animated movie through VR Goggles. The educational animated movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
10184811|NCT03751891|Active Comparator|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_A which will be fitted to the participants individual Hearing loss.
10142441|NCT04176822|Experimental|Documentary Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched a documentary movie through VR Goggles. The documentary movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
10142442|NCT04176822|No Intervention|Control Group|No intervention was made, pain and fear levels were measured using scales only.
10142443|NCT04176926||Group 1: SR|Group 1: Subjects in the sinus rhythm (SR) cohort should not have any history of atrial fibrillation and should not be in atrial fibrillation or other atrial arrhythmia at the time of enrollment based on the screening ECG.
10142444|NCT04176926||Group 2: AF|Group 2: Subjects in the atrial fibrillation (AF) cohort must have a known history of AF and must be in AF at the time of enrollment based on the screening ECG.
10142445|NCT04177082|Experimental|Pulsed 6mW/cm2|6mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 30 minute total treatment time
10142446|NCT04177082|Experimental|Pulsed 4mW/cm2|4mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 45 minute total treatment time
10142447|NCT04176835|Experimental|oxytocin|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
10142448|NCT04176835|Placebo Comparator|Placebo|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
10142449|NCT04176796|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
10142450|NCT04176796|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
10142451|NCT04176809|Experimental|Interventional arm|The intervention will consist in an electronic measurement of HRQoL before each consultation with delivery scores to clinicians, who can discuss it with patients and coupled with therapeutic information. Patients will complete the EORTC-Quality of Life Questionnaire (QLQ)-C30 and the EORTC-QLQ-Breast (BR) 23 questionnaires using the CHES software before their consultation, via a touch pad or from their home via a secure web portal. Therapeutic information will consist on workshops on various themes. Only attendance Workshop 1 will be required, other workshops will be optional. The aim of workshop 1 is to inform patients about their ET and treatment benefits. Two additional optional workshops on nutrition (Workshop 2) and fatigue (Workshop 3) will be offered. This workshops will be collective. Every month, a letter encouraging patients to regularly take their medication will be sent. This letter will also include some tips on how to deal with some particular side effects of ET.
10142452|NCT04176809|No Intervention|Control arm|Participants in the control arm will receive standard care. They will not undergo digital HRQoL collection, and therapeutic information workshops will not be proposed.
10142453|NCT04176939|Experimental|HZ/su Group|Eligible participants who had a complete 2-dose HZ/su vaccination course in the primary study (NCT02058589) will be enrolled in this extension study, to receive 2 doses of HZ/su vaccine- first dose at Month 24 and second dose at Month 25 and will be followed up until the study end.
10142454|NCT04176861|Experimental|Home based intervention|Participants using hBET technology at home (all participants).
10142455|NCT04177160|Experimental|SCD subjects|Patients were diagnosed with subjective cognition decline and referred by neurologists.
10142456|NCT04177160|Experimental|Healthy controls|Voluntary healthy elderly recruited from the community.
10142457|NCT04177095|Experimental|Belatacept treated patients|Renal transplant recipients treated with a combination of belatacept and any of the following: mycophenolate, sirolimus, everolimus and prednisone
10142458|NCT04176731|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm
10142459|NCT04176757|Experimental|ZN-c5|
10142460|NCT04176744|Experimental|Magnetic Phrenic Nerve Stimulation|Each participant will be tested with 4 different stimulation setups (coils and stimulator) on 3 different days.
10142461|NCT04176666|Experimental|Intervention group receiving NettOpp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
10142462|NCT04176666|No Intervention|Control group|The control group will receive the intervention after study completion.
10142463|NCT04176653|Placebo Comparator|Placebo|
10142464|NCT04176653|Experimental|0.3 mg/kg|
10142465|NCT04176653|Experimental|1.0 mg/kg|
10142466|NCT04176653|Experimental|3.0 mg/kg|
10142467|NCT04176653|Experimental|10.0 mg/kg|
10142468|NCT04176887|Experimental|Levetiracetam|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
10142469|NCT04176887|Active Comparator|Phenytoin|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
10142470|NCT04176978|Experimental|T2T + statin|Patient in this arm will receive treat-to-target strategy with rousavastin 20mg
10142471|NCT04176978|Active Comparator|T2T only|Patient in this arm will receive treat-to-target strategy only.
10142472|NCT04176770|Experimental|ESP group|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
10142473|NCT04176770|Experimental|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
10142474|NCT04176354||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
10142475|NCT04176354||Palbociclib + Letrozole|Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
10142476|NCT04176354||Letrozole|Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
10142477|NCT04176588|Experimental|Experimental: Etrasimod 2mg|2mg/tablet, administratered orally, once daily
10142478|NCT04176588|Placebo Comparator|Placebo Comparator: Placebo|matching tablet, administratered orally, once daily
10142479|NCT04176588|Experimental|Etrasimod 2mg (optional open-label extension period)|2mg/tablet, administratered orally, once daily
10142480|NCT04176510|Experimental|Patient Centered Medical Home (PCMH) plus Health Coach|A health coaching intervention that employs a positive affect/self-affirmation intervention to help motivate patients to succeed at implementing self-management by setting life goals, in addition to the usual care provided for patients with multiple chronic diseases by the The Patient-Centered Medical Home (PCMH).
10142481|NCT04176510|No Intervention|Patient Centered Medical Home (PCMH)|Usual care provided for patients with multiple chronic diseases by the Patient-Centered Medical Home (PCMH).
10142482|NCT04176341|Other|Intervention group|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
10142483|NCT04176341|No Intervention|Control group|chronic pain patient consulting in Lyon University Hospital who will receive usual care.
10142484|NCT04176237|Experimental|Intervention|Schools receive 3 one hour lessons on sun safety, followed by a 1 hour UV dosimtery laboratory session.
10142485|NCT04176237|No Intervention|Control|Schools receive 3 one hour lessons on sun safety.
10142486|NCT04176237|No Intervention|Observation|Schools do not receive any lessons.
10142487|NCT04176224|Experimental|MT-1186|Patients receive the edaravone oral suspension.
10142488|NCT04176263|Experimental|SBT|The SBT group will receive a 4-week split-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
10142489|NCT04176263|Active Comparator|TBT|The TBT group will receive a 4-week tied-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
10142490|NCT04176276||Patients with Type2 Diabetes|200 patients with type 2 diabetes consecutively enrolled among those referring to our Diabetes outpatient clinic.
10142491|NCT04176276||Patients without Type2 Diabetes|100 patients without diabetes among those referring to our outpatient clinic most of them affected by hypercholesterolemia, obesity or CV disease.
10142492|NCT04176536|Experimental|All participants|
10142493|NCT04176315|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty autonomously
10142494|NCT04176315|Experimental|ReHub Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty but use the telerehabilitation platform ReHub to do the exercises at home and to have their progress monitored.
10142495|NCT04176289|Active Comparator|PPI-guided pain therapy|At the end of anesthesia a PPI targeted opioid pain therapy will be performed by gradual administration of piritramid in 3 mg steps up to a PPI score ≤ 3.
10142496|NCT04176289|No Intervention|Non-PPI-guided pain therapy|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
10142497|NCT04176484||Survey|Women, 18 years of age or older, who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be given a handout (attached) by clinic staff during routine pre-op counseling informing them that they may be called and asked to participate in a research survey. Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview. Participation will be voluntary and all data collected will be recorded without any identifiers.
10142498|NCT04176484||Operating Room Feasibility|A list of women 25 or older who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be generated to include MRN, procedure date, and pocedure type. A medical record review will be undertaken of these women and we will collect information about conditions that would facilitate or hinder the ability to perform a salpingectomy. No patient interaction will occur by the study team and all data will be de-identified at the time of collection.
10142499|NCT04176471|Experimental|Therapeutic Hypothermia|Therapeutic hypothermia will be achieved using a servo-controlled temperature regulating blanket that is approved for use in neonates and is currently used for the treatment of neonates with moderate-severe HIE. The goal target temperature is 33.5°C ± 0.5°C for 72 hours and the subject will then be rewarmed at a rate of 0.5°C per hour to a goal of 36.5°C.
10142500|NCT04176471|Active Comparator|Normothermia|Normothermia will be achieved using a servo-controlled temperature regulating blanket with the temperature goal of 36.5-37.3°C for 72 hours.
10142501|NCT04176393|Experimental|Ivosidenib (CS3010) tablet|Ivosidenib (CS3010) tablet
10184812|NCT03751891|Active Comparator|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_B which will be fitted to the participants individual Hearing loss.
9519700|NCT03284450|Active Comparator|Sport specific repeated sprints (SSRS)|
10142502|NCT04176107|Other|Study group- video+questionnaire|"The study group will be exposed to a video at admission to an elective cesarean delivery. The video will have information regarding the admission, pre-operation preparation and post- operation recovery.~All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate the impact of exposure to informative video before caesarean delivery on anxiety and stress measured by State-Trait Anxiety Inventory (STAI)."
10142503|NCT04176107|No Intervention|Control group- questionnaire only|All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate anxiety and stress measured by State-Trait Anxiety Inventory (STAI) without intervention.
10142504|NCT04176367|Experimental|Test: Nicergoline manufactured in China|
10142505|NCT04176367|Active Comparator|Reference: Nicergoline manufactured in Italy|
10142506|NCT04176120|Experimental|TTAX01|TTAX01 plus standard care
10142507|NCT04176120|Other|Control|Standard Care alone
10142508|NCT04176016|Experimental|Single Study Arm, no competitor|
10142509|NCT04175990|Experimental|Progestogen|Oral Dydrogesterone 10mg tds was given from day 1 of menses till day of trigger
10142510|NCT04175990|No Intervention|standard combine minimal stimulation protocol|Oral clomiphene citrate 100mg daily given from day 1 till day 10 of menses with additional gonadotrophin (Menopur 225mg daily) from day 3 of menses till trigger day
10142511|NCT04176042|Experimental|Track 1|"Subjects will be randomized to one of two 4-week tracks.~Track 1 (intervention + follow-up) will consist of the following:~Subjects will be randomized to one of two 4-week tracks. Track 1 (intervention + follow-up) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention participants will complete a baseline questionnaire battery consisting of measures including demographics, medical history and sleep. After completion, a 2-hour educational presentation will take place with a question-and-answer session. Participants will then complete post-intervention questionnaires to assess immediate impact of the session on knowledge, beliefs and practices. After 4 weeks, Track 1 participants will be contacted and will be asked to re-complete all baseline questionnaires (see above), in order to evaluate changes over 4 weeks."
10142512|NCT04176042|Active Comparator|Track 2|"Subjects will be randomized to one of two 4-week tracks. Track 2 (wait list + intervention) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention for Track 1 participants will complete the same baseline questionnaire battery.~An identical intervention session, scheduled 4 weeks into the future. At that time, an identical procedure to the other track will be followed, including the pretest questionnaires, 2-hour session, and post-session assessment. No additional 4-week follow-up will be performed."
10142513|NCT04176185|Experimental|Active|HDM SLIT-tablet once daily for approximately 24 weeks
10142514|NCT04176185|Placebo Comparator|Placebo|Placebo tablet once daily for approximately 24 weeks
10142515|NCT04176328|Experimental|Cystic Fibrosis patients treated with Teicoplanin|Hospitalized male and female patients aged ≥ 18 years, suffering of Cystic Fibrosis.
10142516|NCT04176055|Experimental|HALO|
10142517|NCT04176523||Methylmalonic_acidemia|Patients with confirmed diagnosis of methylmalonic acidemia, and treated with carglumic acid, at any dose form, any dosage,
10142518|NCT04176523||Propionic_Acidemia|Patients with confirmed diagnosis of propionic acidemia, and treated with carglumic acid, at any dose
10142519|NCT04176068|Experimental|Combined microfocused ultrasound and calcium hydroxylapatite|One-time intense microfocused ultrasound with calcium hydroxylapatite injection to one anterior lower thigh with option for additional filler injection at 6 weeks, 12 weeks, and 24 weeks. Optional combined treatment of the opposite lower anterior thigh at week 24 with no further follow up.
10142520|NCT04176159|Experimental|Motor imagery and task-oriented training group|Two modules. A first module of motor imagery. A second module of task-oriented training and the incorporation of collective activities.
10142521|NCT04176159|No Intervention|Usual school routines group|Children continue with the usual school routine. Once the study is completed and the corresponding measurements have been made, the subjects included in this group will be subjected to the same program detailed in the intervention, to not deprive them of their benefits.
10142522|NCT04175860|Experimental|Intervention group|"Consists of a series of non-pharmacological preventive interventions that will focus on the - transition-discharge-hospital program including individualized non-pharmacological interventions such as dyad characterization, competency assessment, risk assessment, inherent program strategies, and monitoring.~The intervention or program  Hospital Discharge Plan to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes an educational session and weekly telephone follow-up according to the patient's risk characterization."
10142523|NCT04175860|No Intervention|Control group|This group of patients-family caregivers will be carried out the discharge activities that are regularly developed in the second level institution and recorded in a check-sheet and field diary.
10142524|NCT04176146|Experimental|Nudge Letter|Participants receive a letter that highlights their performance vs. peer organizations on up to seven care delivery practices featured in the National Survey of Healthcare Organizations and Systems (NSHOS). The letter includes a link to access technical assistance resources and is sent alongside the participant's NSHOS respondent report.
10142525|NCT04176146|No Intervention|Control Letter|Participants receive a letter with a link to technical assistance resources; the letter is sent alongside the participant's NSHOS survey respondent report.
10142526|NCT04176094|Experimental|16 hour schedule|All residents assigned to an ICU randomized to a 16h overnight schedule will complete 16h overnight calls not preceded by an 8h daytime shift.
10142527|NCT04176094|Active Comparator|24 hour schedule|All residents assigned to an ICU randomized to a 24h overnight schedule will complete 24h shifts when scheduled for overnight calls (8h daytime shift followed by a 16h overnight call).
10142528|NCT04176003||Patients with CPPD|
10142529|NCT04176003||Healthcare professionals working with CPPD patients|
10142530|NCT04176003||Stakeholders working on behalf of CPPD patients|
9519701|NCT03284437|No Intervention|Usual Care|Usual medical care provided to patients in the ICU.
10142531|NCT04175938|Active Comparator|Subjects with Fuch's Endothelial Dystrophy|Persons with a diagnosis of Fuch's Endothelial Dystrophy will wear a contact lens in an affected eye for three hours.
10142532|NCT04175938|Other|Subjects with healthy eyes|Persons with healthy eyes will wear a contact lens in one eye for three hours.
10142533|NCT04175925|Experimental|Part A: BMS-986322|
10142534|NCT04175925|Experimental|Part B: BMS-986322 Placebo|
10142535|NCT04175925|Experimental|Part C: BMS-986322 with famotidine|
10184813|NCT03751878|Experimental|Intervention arm|Evaluation of reporting inconsistencies between the CONSORT checklist and the information reported in the manuscript. Feedback is provided to authors.
10184814|NCT03751878|Other|Control arm|Standard peer review process.
10184815|NCT03751865|Experimental|CBT group|This intervention aims for distress reduction, symptom coping, and life quality enhancement. It is a gender-specific CBT tailor-made for the at-risk population. The intervention is delivered by a registered clinical psychologist.
10184816|NCT03751865|Active Comparator|Psychoeducation group|The content of the psycho-education program will be related to healthy living content and mental health knowledge, such as food hygiene, psychological well-being, knowledge about psychosis and common mental disorder and food nutrition. In addition, a weekly call to remind the subject about healthy living will also be provided to the subjects. The intervention is delivered by a registered social worker.
10184817|NCT03751852|Experimental|Exercise coaching group|This intervention is an integration of aerobic exercise, yoga, mindfulness and exercise coaching. Exercise class and coaching will be provided weekly in the first 8 weeks. In the next 8 week, exercise class will be provided weekly while exercise coaching will be provided bi-weekly. The exercise class includes aerobic exercise coached by a well-trained intervention officer, and the yoga and mindfulness coached by a certified yoga instructor. The exercise coaching session followed by some stretching and aerobic exercise session. Both motivational coaching and aerobic exercise will be coached by a well-trained intervention officer.
10184818|NCT03751852|Active Comparator|Psychoeducation group|This group is similar with the exercise coaching group while exercise coaching session will be substituted by psychoeducation session.
10184819|NCT03751839|Experimental|Diagnostic|The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.
10184820|NCT03751826|Experimental|Incentivised network delivery HIV-ST|Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
10184821|NCT03751826|Experimental|Peer Navigator distributed HIV-ST|Peer navigators will directly distribute HIV-ST kits to females aged 18-24 years over a period of six months. Each person recruited will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV-ST. The packs include referral slips with information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
10184822|NCT03751826|Active Comparator|Standard of care|Peer navigators will encourage females aged 18-24 years to test for HIV at clinics, and link to services/care. Each female aged 18-24 approached by a peer navigator will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. They will then be given a referral slip for HIV testing through the clinic. The referral slips include information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
10184823|NCT03751813|Placebo Comparator|Placebo|placebo supplement
10184824|NCT03751813|Experimental|Supplement|actual supplement
10184825|NCT03751787|Experimental|cranial osteopathy|The group will receive treatment with osteopathic cranial osteopathy
10184826|NCT03751787|Placebo Comparator|comfort massage|The group will benefit from a placebo manipulation by an osteopathic student who has not yet been trained in cranial osteopathy.
10184827|NCT03751761|Experimental|durvalumab, tremelimumab, paclitaxel|
10184828|NCT03751748|Sham Comparator|Control arm|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
10184829|NCT03751748|Experimental|AFR arm|Implantation of Occlutech atrial flow regulator (AFR) device
10184830|NCT03751735|Experimental|Dose 1|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up
10184831|NCT03751696|Experimental|Group coaching|There will be a total of 4 sessions of group coaching intervention within 8 weeks. Each session is in a group of 5-6 women and lasts for approximately 1-1.5 hours. The sessions will be conducted by experienced social workers online.
10184832|NCT03751696|Active Comparator|SMS Self-help tips|The participants in the control group will receive four self-help tips on mental well-being on the same schedule as the group coaching group.
10184833|NCT03751670|Experimental|PR+conventional treatment|Patients will be treated with daily medication prescribed by the physician. Additionally, patients will receive 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). PR will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training, education and psychosocial support.
10184834|NCT03751670|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician.
9516819|NCT03311971|Experimental|Virtual reality glasses|Patient undergoing conventional analgesic therapy after total knee replacement and treated with virtual glasses
9516820|NCT03311958|Experimental|Nivolumab|
10142536|NCT04175782|Experimental|ERAS group|A standardized ERAS protocol is applied to the ERAS group based on the latest guidelines. Smoking and alcohol consumption is stopped 4 weeks before the surgery. Preoperative anemia is corrected with intravenous iron supplementation. Prolonged fasting, bowel preparation, and premedication are avoided in this group. Clear fluids are allowed up to 2 h and solids rich in carbohydrate up to 6 h hours prior to induction of anesthesia. Warmed up intravenous fluids are administered to maintain normothermia intraoperatively. This group of subjects receives general anesthesia. Volume and salt overload and drain usage are avoided to the utmost. Intravenous paracetamol is administered for postoperative analgesia before the completion of the surgical procedure. Nasogastric tube placement is avoided and catheters are removed as soon as possible. Nonopioid oral analgesics and NSAIDs are utilized for postoperative pain medication.
10142537|NCT04175782|No Intervention|Control|This group will receive conventional pre-and postoperative care.
10142538|NCT04175951|Active Comparator|Tecnis Eyhance|Tecnis Eyhance hydrophobic IOL is a monofocal IOL with added advantage of slightly better unaided intermediate vision at 60 cms.
10142539|NCT04175951|Active Comparator|Rayner RayOne|Rayner Rayone is a monofocal hydrophilic IOL which is not intended to give better unaided or near vision.
10142540|NCT04175769|Experimental|Experimental intervention|Standard intervention of chemotherapy, immunotherapy or combination of immunotherapy and chemotherapy, plus the experimental intervention nutritional product.
10142541|NCT04175769|Placebo Comparator|Non-experimental intervention|Standard intervention of chemotherapy, immunotherapy or combination of immunotherapy and chemotherapy, plus the non-experimental intervention placebo product.
10142542|NCT04175977|Experimental|Aliviado Dementia Care-Hospice Edition|A multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
10142543|NCT04175977|Active Comparator|Control phase|PWD subjects will receive usual care as provided by their hospice agency during the control phase
10142544|NCT04175652|Experimental|Laughter yoga group, group doing laughter yoga|The duration of the laughter yoga was 30 minutes and a total of 16 sessions were performed on a twice-weekly basis.
10142545|NCT04175652|No Intervention|No laughter yoga group, group not doing laughter yoga|
10142546|NCT04175743|Experimental|200 mg CT-044 HCl or Placebo|200 mg of CT-044 HCl administered every 8 hours vs placebo
10142547|NCT04175743|Experimental|400 mg CT-044 HCl or Placebo|400 mg of CT-044 HCl administered every 8 hours vs placebo
10142548|NCT04175743|Experimental|600 mg CT-044 HCl or Placebo|600 mg of CT-044 HCl administered every 8 hours vs placebo
10142549|NCT04175795|Experimental|Dashboard group|The intervention group will receive their personal profile via this e-mail along with instructions on goal-setting and tips to improve brain health.
10142550|NCT04175795|No Intervention|No Dashboard group|The control group will receive only the goal-setting instructions and tips.
10142551|NCT04175873|No Intervention|Group C|Control group.
10142552|NCT04175873|Experimental|Group M|Music group.Preoperative 1 hour and during the operation of Classical Turkish Music (Acemaşiran makam) listening group
10142553|NCT04175899|Experimental|POCCP (Pharmacist-led Oral Chemo Care Program)|"Intervention Group :~Subjects undergo structured intensified pharmaceutical care program (POCCP) led by oncology experienced pharmacist (run alongside oncologist patient review at the clinic or daycare) in addition to Current Standard Best Care (SBC)"
10142554|NCT04175899|No Intervention|SBC (Current Standard Best Care)|"Control Group :~Subjects undergo usual procedure which is Current Standard Best Care (SBC) for oral chemotherapy treatment which includes pre-chemotherapy review by doctor and prescribing of chemotherapy and supportive medications according to patient's chemotherapy protocol at each visit. Subsequently the patients will collect their prescribed oral medications at the ambulatory pharmacy counter according to the standard procedure of medication dispensing which includes prescription screening, medication filling, double checking, dispensing and counselling at the pharmacy counter as per usual practice of pharmaceutical care of patients."
10142555|NCT04175717|Experimental|physiotherapy-led follow-up programme|
10142556|NCT04175704|Other|Cohort 1|0.2 mg/kg UB-221 or placebo
10142557|NCT04175704|Other|Cohort2|0.6 mg/kg UB-221 or placebo
10142558|NCT04175704|Other|Cohort 3|2 mg/kg UB-221 or placebo
10142559|NCT04175704|Other|Cohort 4|6 mg/kg UB-221 or placebo
10142560|NCT04175496|Experimental|Test Foods|Blueberry Cake, Snack with Cheese and spicy Crackers will be used as test foods.
10142561|NCT04175496|Experimental|Reference Food|Glucose solution will use as reference food.
10142562|NCT04175535|Other|The experimental group|PPECD was performed in the experimental group
10142563|NCT04175535|Other|control group|ACDF was performed in the control group
10142564|NCT04175522|Experimental|Experimental|Investigational product(IP)
10142565|NCT04175561|Experimental|Intervention|Participants in the intervention arm will be given a green prescription (gardening activities).
10142566|NCT04175561|No Intervention|Control|Participants in the control arm will not be given the intervention.
10142567|NCT04175587|Experimental|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Induction: a) RIF: 60 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR; Consolidation: a) RIF: 60 mg/kg daily, in a 4-week on 4-week off regimen for four cycles in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles
10142568|NCT04175587|Other|Arsenic trioxide Plus Retinoic Acid|Induction: a) Arsenic trioxide: 0·15 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR Consolidation: a) Arsenic trioxide: 0.15mg/kg daily, in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles Expected Efficacy: Oral RIF plus ATRA is not inferior to intravenous arsenic trioxide plus ATRA for achieving 2-year EFS.
10142569|NCT04175418|Experimental|Supervised Exercise Program Group|Participants in the supervised exercise group were included to a program that consisted of 16 individual physiotherapist supervised sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
10142570|NCT04175418|Experimental|Online Education Program Group|Participants in the online education group were included to a program that consisted of 16 online sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
10142571|NCT04175249|Experimental|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
10142572|NCT04175405|Experimental|Right side of the maxilla|The 635-nm laser parameters; dose: 10J per point (20J/cm2), time: 100 sec per point, 2 points (irradiation on a buccal, and a palatal side of the alveolus/implant), the total energy per session 20J.
10142573|NCT04175405|No Intervention|Left side of the maxilla|
10142574|NCT04175327||CardioCel group|Patients who require repair of cardiac and vascular defects including intracardiac defects; septal defects, valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing
10142575|NCT04175223|Experimental|probiotics|probiotic administration
10142576|NCT04175223|No Intervention|without probiotic|no change from the usual care
10142577|NCT04175470|Experimental|Arm A: Discontinue treatment after first treatment cycle|
10142578|NCT04175470|Experimental|Arm B: Continue treatment until progression|
10142579|NCT04175379|Experimental|group 40|In group 40, target PaCO2 is 40 during surgery
10142580|NCT04175379|Experimental|group 50|In group 50, target PaCO2 is 50 during surgery
10142581|NCT04175379|Experimental|group 60|In group 60, target PaCO2 is 60 during surgery
10142582|NCT04175366|Experimental|Shared Decision Making|Intervention with Shared Decision Making procedure regarding decision on planning of care and treatment before discharge.
10142583|NCT04175366|No Intervention|Care as usual|Discharge planning as usual.
10142584|NCT04175457|Experimental|e-cigarette inhalation with nicotine|inhalation of e-cigarette vapor with nicotine for 30 minutes.
10142585|NCT04175457|Active Comparator|e-cigarette inhalation without nicotine|inhalation of e-cigarette vapor without nicotine for 30 minutes.
10142586|NCT04175132|Experimental|Healthy subjects|
10142587|NCT04175132|Experimental|PD patients|
10142588|NCT04175288|Experimental|Ultrasound, manual therapy and exercise|This group will receive Ultrasound, manual therapy and exercise
10142589|NCT04175288|Active Comparator|manual therapy and exercise|This group will receive manual therapy and exercise
10142590|NCT04175197||Study Cohort|Subjects with symptoms of intermittent claudication and/or critical limb ischemia (Rutherford Class 2-3-4-5-6) with angiographic evidence of femoropopliteal-below-the-knee arterial occlusion or stenosis
10142591|NCT04175301|Experimental|Hydrogen|Five times per day for 6 weeks subjects will dissolve a hydrogen generating tablet into water and drink the effervescent water. Dissolving one tablet in 250 mL of water will achieve a saturating hydrogen concentration of approximately 1.6 ppm.
10142592|NCT04175301|Placebo Comparator|Placebo|Five times per day for 6 weeks subjects will dissolve an placebo tablet into water and drink the effervescent water. The effervescent placebo tablet does not generate hydrogen-enriched water.
10142593|NCT04175210|Experimental|ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
10142594|NCT04175210|Experimental|ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
10142595|NCT04175314||Case -|Patient presenting one or more periodontal recession more than 1mm of height
10142596|NCT04175314||Control-|Patient presenting no periodontal recession or recession of less than 1 mm of height
10142597|NCT04175548||surgery for a pertrochanteric fracture|Patients having had surgery for a pertrochanteric fracture at the CHU Brugmann Hospital between January 2013 and May 2019.
9827477|NCT02457260|Experimental|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
10142598|NCT04175171|Experimental|GB221|Coprelotamab Injection, 8mg/kg, single dose
10142599|NCT04175171|Active Comparator|Herceptin|Trastuzumab Injection, 8mg/kg, single dose
10142600|NCT04175093||Mild persistent asthma|• Group I, patients with mild persistent asthma.
10142601|NCT04175093||Moderate persistent asthma|• Group II, patients with moderate persistent asthma.
10142602|NCT04175093||Severe persistent asthma|• Group III ,patients with severe persistent asthma.
10142603|NCT04175158|Experimental|GB222|1mg/kg
10142604|NCT04175158|Active Comparator|Bevacizumab|1mg/kg
10142605|NCT04175353|Experimental|Dairy snack|Drink high in milk protein, 250 ml
10142606|NCT04175353|Active Comparator|Orange juice|Regular orange juice, 250 ml
10142607|NCT04175353|Experimental|Berry snack 1|Bilberry-blackcurrant purée, 139 g
10142608|NCT04175353|Experimental|Berry snack 2|Lingonberry purée, 122 g
10142609|NCT04175353|Active Comparator|Berry soup|Bilberry soup, 250 ml
10142610|NCT04174937|Experimental|Potentiator of antibiotics (PA)|Potenciator of antibiotics (PA) , albumin complex of tetraiodid was given per os, single and multiple doses for the different periods (but not exceeding 14 days)
10142611|NCT04174937|Placebo Comparator|Patients taking placebo PA|Placebo without any active pharmaceutical ingredients was given per os dosed for the patients in same periods of time as per experimental group, single and multiple doses for the different periods (but not exceeding 14 days)
9516821|NCT03311945|Experimental|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
10142612|NCT04174963|Experimental|eToke + TPsy|All participants will receive the intervention (eToke+TPsy). The intervention consists of eToke (a brief computerized intervention that uses motivational enhancement therapy to improve readiness to decrease cannabis use and increase motivation to engage in substance use treatment) AND 6-8 interactive text messages regarding cannabis use reduction over 4 weeks . Text messages will contain written content, and queries, as well as links to publicly available websites and YouTube videos.
10142613|NCT04175067||Endometrium cancer|stage I endometrium cancer n=57
10142614|NCT04175067||Healthy controls|Healthy volunteers n=60
10142615|NCT04174729|Experimental|Hand strength|"The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength. The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength.~In the first session, the volunteers performed the movements 3 times in each device of daily living activities with the right limb, with a 1-minute rest interval between the 3 measurements. The entire procedure performed in the session was repeated again after 30 minutes to verify the reliability and reproducibility of the Intra-evaluator test. The Inter-rater test was repeated after 7 days by the second rater to analyze reliability between the rater."
10142616|NCT04174911|Experimental|BOL-DP-o-08|BOL-DP-o-08
10142617|NCT04174911|Placebo Comparator|Placebo|Placebo
10142618|NCT04174924||Phakic intraocular lens (pIOL) explantation|Patients with pIOLs where a combined pIOL explantation and cataract surgery is needed.
10142619|NCT04174924||Cataract extraction|Healthy control group of patients scheduled for regular cataract surgery without comorbidities affecting an immune response.
10142620|NCT04174690|Experimental|Balance|Volunteers aged from 18 years to over 60 years were selected without compromise. The tests were performed in a single session lasting 1 hour where the volunteers will do the tests on the force platform.
10142621|NCT04175028|Other|ADHD|Patients with ADHD.
10142622|NCT04175028|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
10142623|NCT04175015|Experimental|Experimental|Participants will be randomised to eat an orange coloured smartie©
10142624|NCT04175015|Active Comparator|Control Group|Participants will be randomised to eat a pink coloured smartie ©
10142625|NCT04174768|Experimental|Bariatric surgery patients|Bariatric patients undergoing sleeve gastrectomy or Roux-en-Y gastric bypass
10142626|NCT04175054|Active Comparator|Low Intensity Group|Less than 40% Heart Rate Reserve
10142627|NCT04175054|Experimental|Vigorous Intensity Group|More than 60% Heart Rate Reserve
10142628|NCT04175002||Anovulatory PCOS women with a BMI greater than 27|
10142629|NCT04175002||Anovulatory PCOS women with a BMI lower than 25|
10142630|NCT04175002||Healthy fertile women with a BMI greater than 27|
10142631|NCT04175002||Healthy fertile women with a BMI lower than 25|
10142632|NCT04174846|Active Comparator|Treatment of SAM children with RUTF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with standard ready-to-use therapeutic food (RUTF)
10142633|NCT04174846|Experimental|Treatment of SAM children with RUSF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with ready-to-use-supplementary food (RUSF)
10142634|NCT04174950|Active Comparator|control group|Routine perioperative nursing intervention
10142635|NCT04174950|Experimental|experimental group|Perioperative ERAS Based Nursing Model
10142636|NCT04174898|Experimental|Treatment Population|100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours
10142637|NCT04174885|Other|AF epicardial ablation|Patient with persistent AF will receive an epicardial ablation.
10142638|NCT04174872|Other|Dexmedetomidine|It has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
10142639|NCT04174872|Other|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
10142640|NCT04174755|Experimental|Semaglutide 0.25/0.5/1 mg plus standard of care|
10142641|NCT04174755|Other|Standard of care alone|
10142642|NCT04174820||Retrospective Low-Grade Glioma|Inclusion of patients with Low-Grade Glioma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
10142643|NCT04174820||Retrospective Medulloblastoma|Inclusion of patients with Medulloblastoma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
10142644|NCT04174820||Prospective patients|Inclusion of prospective patients with an indication to surgery of a Posterior Fossa Tumor, with evaluation of post-operative mutism and then one year after the end of mutism, an evaluation with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
10142645|NCT04174820||Control patients|Inclusion of patients without Posterior Fossa Tumor, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
10142646|NCT04174703|Experimental|Self-compassionate letter-writing intervention|An online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks
10142647|NCT04174703|No Intervention|Control condition|
10142648|NCT04175041|Other|ADHD|Patients with ADHD.
10142649|NCT04175041|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
10142650|NCT04174781|Experimental|TACE-DEB in combination with Sintilimab Injection|Treatment will be divided into 4-week cycles from the starting date of TACE-DEB. The first TACE-DEB session and Sintilimab Injection will be initiated simultaneously. The repetition of TACE-DEB procedures will be initiated on demand according to tumour response assessment. Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression for up to one years.
10142651|NCT04174807||Cohort|
10142652|NCT04174599|Experimental|F-627|Subjects will receive F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
10142653|NCT04174599|Active Comparator|GRAN®|Subjects will receive GRAN® [5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 ×109/L] on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
10142654|NCT04174976||Wall hernia repair|"All patients admitted for wall hernia repair with mesh between 28/12/2017 and 28/12/2020.~."
10142655|NCT04174573|Experimental|Group therapy only (GTO)|Patients in GTO group will receive structured group therapy programme
10142656|NCT04174573|Experimental|Group therapy with tDCS (GT-tDCS)|Patients in this group will receive group therapy along-with tDCS intervention
10142657|NCT04174339|Experimental|camrelizumab plus apatinib and POF|Participants will receive camrelizumab in combination with apatinib plus POF until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10142658|NCT04174248|Experimental|Experimental group|Experimental group with BCSMS App using
10142659|NCT04174248|No Intervention|Control group|Control group without BCSMS App using
10142660|NCT04174378||GnRH agonist with progestogen support|
10142661|NCT04174378||progestogen support only|
10142662|NCT04174391|Experimental|Mediterranean diet supplemented with extra-virgin olive oil|
10142663|NCT04174391|Active Comparator|Low-fat diet|
10142664|NCT04174547||Clonal hematopoiesis (AIM 1)|"The investigators will analyze the genomic features of clonal dominance and ineffective hematopoiesis in elderly subjects enrolled in two population-based studies: Health and Anemia study [Haematologica 2010;95:1849], and Monzino 80-plus study [BMC Neurol.2011;11:54, validation cohort]. Overall in 5000 subjects aged >65y peripheral blood samples (in some cases collected at different time points) will be available for biological investigations."
10142665|NCT04174547||Innovative predictive models in MDS (AIM2)|"The investigators will base on large retrospectove adult MDS population with comprehensive genomic and clinical data available within EuroBloodNet network (data on 3000 patients will be available), to accurately predict clinical outcomes in MDS at individual-patient level.~The investigators plan to define 2 homogenous clinical cohorts (learning and testing cohort at 2:1 ratio) in order to define distinct patterns and genetic groups within MDS and to independently validate their predictive value."
10142666|NCT04174547||Predictive biomarkers in MDS (AIM3)|The investigators will analyze MDS patients enrolled in prospective clinical trials conducted within the EuroBloodNet network. Overall 350 patients treated with azacitidine from prospective studies (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study) will be available for biological investigations to define biomarkers associated with clinical response. Validation of biomarkers will then be performed in an independent cohort including 320 patients (AZA-PLUS trial). In all these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been systematically performed, providing a unique resource to be investigated within this proposal.
10142667|NCT04174365|Experimental|Brexpiprazole|
10142668|NCT04174365|Placebo Comparator|Placebo|No Intervention
10142669|NCT04174404|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Circumcision which is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
10142670|NCT04174404|Active Comparator|Control group|The participants in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care.
10142671|NCT04174287|Experimental|F-18-AV45|F-18-AV45 imaging
10142672|NCT04174456|Experimental|Olmesartan group|olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month
10142673|NCT04174456|Active Comparator|Valsartan group|valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month
10142674|NCT04174352|Experimental|Tamoxifen Dose Levels|"Three participants will be enrolled to each dose level of oral tamoxifen (n = 12)~Dose Level 1 = 20 mg daily Dose Level 2 = 80 mg daily Dose Level 3 = 160 mg daily Dose Level 4 = 200 mg daily~Tamoxifen should be started within 14 days of the FES-PET/CT scan, at least 24 hours after FES injection. Participants will continue tamoxifen therapy until there is radiologic or clinical evidence of progressive disease or drug intolerance."
9669346|NCT02877134|Experimental|Part II : Placebo|"Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in CDAI or CDAI <150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 150 mg SC at Week 12 and then JNJ-64304500 75 mg at Weeks 14, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive placebo up to 52 weeks (for a total of up to 72 weeks of placebo in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ- 64304500. Participants receiving placebo during the LTE will stop receiving placebo."
9669347|NCT02877134|Experimental|Part II : JNJ-64304500 High Dose|"JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 high dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
10142675|NCT04174300|Experimental|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
10142676|NCT04174417|Active Comparator|systolic blood pressure (SBP)|Systolic blood pressure (SBP) for group 1 patients 80-90 mmHg
10142677|NCT04174417|Active Comparator|mean blood pressure (MBP)|Mean blood pressure (MBP) for group 2 patients 50-65 mmHg
10142678|NCT04174209|Experimental|Cohort 1|70 patients are involved and will perform the three conditions.
10142679|NCT04174586|Experimental|cord blood group|standard induction and consolidation chemotherapy with cord blood microtransplantation
10142680|NCT04174261|Experimental|Ticagrelor - Remote Ischemic Preconditioning|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
10142681|NCT04174261|Other|Ticagrelor - Control|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. BP-cuff uninflated around the non-dominant arm
10142682|NCT04174261|Active Comparator|Clopidogrel - Remote Ischemic Preconditioning|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
10142683|NCT04174261|Other|Clopidogrel - Control|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. BP-cuff uninflated around the non-dominant arm
10142684|NCT04174274||positive|ventilator-associated pneumonia-developed group followed by mechanical ventilation
10142685|NCT04174274||negative|not ventilator-associated pneumonia-developed group followed by mechanical ventilation
10142686|NCT04174482|Experimental|flat foot patients|20 patients recruited consecutively and candidates for surgery to correct the adult flat foot according to the Grice technique.
10142687|NCT04174430||mild to moderate bronchiolitis|Bronchiolistis patients without Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks, Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency and Neurologic disease
10142688|NCT04174183|Experimental|Prevena (right side) - Dry dressing (left side)|
10142689|NCT04174183|Experimental|Prevena (left side) - Dry dressing (right side)|
10142690|NCT04174560|Experimental|Cohort 1|Single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
10142691|NCT04174560|Experimental|Cohort 2|Single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
10142692|NCT04174560|Experimental|Cohort 3|Single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
10142693|NCT04174495||Obese patients followed at Nancy University Hospital|
10142694|NCT04173871|Experimental|Intervention|Intervention group
10142695|NCT04173871|No Intervention|Control|Control group
10142696|NCT04174014|Experimental|Recruitment manoeuvre|"Volume control (VC) ventilation mode with a tidal volume of 6 mL/kg of ideal body weight~P/V tool assessment~Baseline measurements~CT scan of chest without EIT belt~Re-establishment of EIT belt, continuous EIT and transpulmonary pressure measurement during the recruitment and de-recruitment manoeuvre.~increment phase:~constant volume settings~increasing PEEP with 4 cmH2O following each 10 consecutive controlled breath until reaching a peak pressure of 40 cmH2O~decrement phase:~constant volume settings~decreasing PEEP with 4 cmH2O following each 10 consecutive controlled breath not lower than 2 cmH20 from target PEEP~target PEEP level is defined where the end-expiratory transpulmonary pressure is 0-1 cmH2O~P/V recruitment with target end-PEEP level~Removal of EIT belt, CT scan of chest~Continuous EIT and transpulmonary pressure measurement with the initial FiO2 and the new PEEP settings"
10142697|NCT04174066||SNLGM|70 patients with an SNLGM
10142698|NCT04174066||primary FSH|74 with a primary FSH
10142699|NCT04173845|Experimental|Tianqi Pingchan Granule group|Tianqi Pingchan Granule were manufactured according to Good Manufacturing Practice (GMP) by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. , granule, twice a day, for six months.
10142700|NCT04173845|Placebo Comparator|Tianqi Pingchan Granule Placebo group|placebo, granule, twice a day, for six months.
10142701|NCT04173832|Experimental|Tianqi Pingchan Granule Combined With Amantadine|
10142702|NCT04173832|Placebo Comparator|placebo Combined With Amantadine|
10142703|NCT04173910||LPEC/Sellick ultrasound|
10142704|NCT04174326|Experimental|Intervention group|A weekly 2 hour CBT for chronic pain group intervention for a duration of 6 weeks
10142705|NCT04174326|No Intervention|Delayed intervention group|A waiting list for CBT for chronic pain group intervention.
10142706|NCT04174131|Experimental|Treatment A (right) B (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
10142707|NCT04174131|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
10142708|NCT04174001||Neuro group|"Patients who meet the following criteria:~18 years of age or younger~diagnosed with one or more of the following neurological disorders: moyamoya disease, congenital anomalies of the brain, hypoxic-ischemic encephalopathy, brain tumor, Chiari malformation, epilepsy and stroke~planned for any surgical procedures that require general anesthesia~planned to receive intraoperative and/or postoperative invasive arterial blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or are scheduled for a cardiac procedure will be excluded."
10142709|NCT04174001||Control group|"Patients who meet the following criteria:~18 years of age or younger-planned for any surgical procedures that require general anesthesia~planned postoperative invasive blood pressure monitoring~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or have symptoms of neurological disorders will be excluded."
10187764|NCT03722849|Experimental|Healthy control participant|"Twenty-five (25) appropriately age and sex matched healthy non-smoking individuals will be recruited as the comparison group.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of ATP (0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo fMRI for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
10142710|NCT04173884|Active Comparator|Live Surgical Peer Coaching|Coaches will facilitate an initial, individual, introductory phone call with participants prior to the first formal coaching session. The objective of this call is to develop rapport, explore each other's background, experience, and motivation for participation in the program, set overall goals for the program, set specific goals for the first coaching session, develop an action plan including identification of the key characteristics of the first case for review, and develop a timeline and plan for meetings. Peer coaching sessions will be scheduled at three national meetings that are commonly attended by ACHQC surgeons. In advance of each meeting, participants will record and upload a self-selected video to a secure server maintained by the study team, and coaches will have the opportunity to review the video if they wish to prepare. A live coaching session will be organized at the meeting where the coaches and participants will have parallel one-hour coaching sessions.
10142711|NCT04173884|Active Comparator|Asynchronous Video-based Constructive Feedback|There will be no real-time interpersonal contact between coaches and participants in this arm. Participants will upload their self-selected procedural video to the video review platform, together with a short description of the case and any specific questions. The coach will review the video within one week of its posting and provide time-stamped feedback on the video platform. Participants will then review the coach's feedback within one week with the ability to respond to the comments. The coach and participant will continue communication via the internet-based review platform until no further comments are made by either party. Coach-participant dyads are expected to review three videos during the 6 month intervention period.
10142712|NCT04173884|Active Comparator|Wait-List Control|One-third of participants will be randomized to an intervention, but wait-listed to provide a control group. These surgeons will submit two videos for technical skill evaluation during each of the baseline and follow-up periods, and ACHQC data will be tracked for short-term outcomes prior to their crossover to the intervention for long-term follow-up. Selecting the control group using the identical sampling frame of ACHQC surgeons participating in the interventions affords the opportunity for a comparable group with outcome metrics recorded systematically.
10142713|NCT04173858||Experimental|Patients with confirmed opioid-induced constipation diagnosis and inadequate response to laxatives.
10142714|NCT04173962|Experimental|Ketamine group|One 0.5mg/kg intravenous dose of ketamine
10142715|NCT04173962|Active Comparator|Midazolam group|One 0.045mg/kg intravenous dose of midazolam
10142716|NCT04173897|Experimental|Intervention arm|12 weeks access to LIBERATE online supportive intervention (dose not specified) including symptom monitoring questionnaire component, with questionnaire results integrated within electronic medical records for clinician review.
10142717|NCT04173897|No Intervention|Waiting list control arm|Care and support as usual; no access to intervention. Placed on waiting list to receive intervention following study completion.
10184835|NCT03751644|Experimental|Electrical stimulation|After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
10184836|NCT03751644|No Intervention|Placebo|Patients will not submitted to electrical stimulation.
10184837|NCT03751618|Experimental|Capsular suture|Capsular suture at the end of hip arthroscopy
10184838|NCT03751618|Active Comparator|No capsular suture|No capsular suture at the end of hip arthroscopy
10184839|NCT03751592|Experimental|Chlorogenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
10184840|NCT03751566|Active Comparator|Regimen A|Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.
10184841|NCT03751566|Experimental|Regimen B|Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.
10184842|NCT03751540||OSTAP|Data of patients (performed oblique subcostal transversus abdominis plane-OSTAP- block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
10184843|NCT03751540||SIPB plus rectus sheath block|Data of patients (performed serratus intercostal plane block-SIPB- plus rectus sheath block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
10184844|NCT03751527|Experimental|ZENFLEX stent Group|subjects applying ZENFLEX peripheral stent system
10184845|NCT03751514|Experimental|Phase A - SI|"Phase A aims to determine a 'standard inoculum' dose (SI), which results in safe colonisation of 70% of volunteers.~The SI will be identified in a dose escalating or de-escalating experiment commencing at 10-3 colony forming units B. pertussis administered intranasally. Each group of volunteers will be inoculated at half log-fold increasing/decreasing doses until the endpoint is reached. The experiment will be continued until the SI yields 10 subjects who are colonised at day 14.~Intervention to be administered: Bordetella Pertussis B1917"
10184846|NCT03751514|Experimental|Phase B Inoculum|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence. The final protocol for phase B will be presented as a protocol amendment, it will be based on the SI and colonisation period identified in Phase A.~The SI determined in phase A will be used for all volunteers and eradication therapy will be given after the colonisation period based on the data of phase A. Approximately 30 individuals will receive the intranasal SI and will be treated with azithromycin for three days at the end of the colonisation period.~Intervention to be administered: Bordetella Pertussis B1917"
10184847|NCT03751514|Experimental|Phase B Sham|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence.~Approximately 15 individuals will not receive the Bordetella Pertussis B1917, instead they will be given an intranasal sham of sterile saline and will be treated with azithromycin 500mg for three days at the end of the 'colonisation' period."
10142718|NCT04174170|Experimental|Brexpiprazole + Sertraline|3 pills: Fixed dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
10142719|NCT04174170|Experimental|Sertraline|3 pills: Fixed dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
10142720|NCT04174170|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
10142721|NCT04174053|Experimental|Temperature measurement|"enteric capsule will be ingested every 24 hours during aplasia. Temperature measurement will be made continuously during aplasia.~In parallel, auricular temperature will be measure every 4 hours during aplasia."
10142722|NCT04174040|No Intervention|Control 1|Applied any intervention.
10142723|NCT04174040|Active Comparator|Control 2|Gross's Process of Emotion Regulation Model interventions applied.
10142724|NCT04174040|Active Comparator|Control 3|Musical rhythm interventions applied.
10142725|NCT04174040|Experimental|Experimental|Musical rhythm integrated Gross's Process of Emotion Regulation Model interventions applied.
10142726|NCT04173988|Experimental|alloCART-19|"For the very first patient, the initial dose could be administered via one or three intravenous infusions within 1 to 5 days. Starting from the second patient, the investigator will decide whether to use single or multiple alloCART-19 infusions, based on the treatment experience at previous dose level(s) and the patient's baseline disease burdens.~A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before alloCART-19 infusion."
10142727|NCT04174118|Experimental|belcesiran|Healthy volunteers will be administered a single dose of belcesiran.
10142728|NCT04174118|Placebo Comparator|Placebo|Healthy volunteers will be administered a single dose of matching placebo.
10142729|NCT04173936||Tai Chi|All participants enrolled in a 12 week community-based tai chi program.
10142730|NCT04174144||TLIF group|Participants with degenerative spondylolysthesis who underwent a single-level TLIF procedure.
10142731|NCT04173819|Experimental|Group 1|Single Agent, abdominal subcutaneous injection, 10:2 ratio for Ab:placebo
10142732|NCT04173819|Experimental|Group 2|Single agent, abdominal subcutaneous injection 10:2 ratio for Ab:placebo
10142733|NCT04173819|Experimental|Group 3|Single agent intravenous injection 10:2 ratio for Ab:placebo
10142734|NCT04173819|Experimental|Group 4|Single agent intravenous injection 10:2 ratio for Ab:placebo
10142735|NCT04173819|Experimental|Group 5|Combined agent intravenous injection 10:2 ratio for Ab:placebo
10142736|NCT04173819|Experimental|Group 6|Subcutaneous injection combined ratio 1 with loading dose 30:3 ratio of Ab:Placebo
10142737|NCT04173819|Experimental|Group 7|Subcutaneous injection in abdomen combined ratio 2 with loading dose 30:3 ratio of Ab:Placebo
10142738|NCT04173819|Experimental|Group 8|Subcutaneous injection in abdomen combined ratio 3 with loading dose 30:3 ratio of Ab:Placebo
10142739|NCT04173819|Experimental|Group 9|Subcutaneous injection in abdomen combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
10142740|NCT04173819|Experimental|Group 10|Subcutaneous injection in arm combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
10142741|NCT04173806|Experimental|Facebook group|"Participants will be included in an online classroom through a closed group of Facebook to receive an asynchronous course of telemedicine."
10142742|NCT04173806|Active Comparator|Control group|In this group the participants are exposed to the same course of telemedicine but on the Moodle educational platform.
10142743|NCT04173793|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
10142744|NCT04173793|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
10142745|NCT04173793|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
10142746|NCT04173793|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
10142747|NCT04173793|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
10142748|NCT04173767|Experimental|HFNC|
10142749|NCT04173780|Experimental|Atropine 0.01%|
10142750|NCT04173780|Placebo Comparator|Placebo|
10142751|NCT04173416|Experimental|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.~The specific components of YORS will be refined and adapted based on feedback from interviews and focus groups with various stakeholders. However, the basic framework outlined above is expected to persists."
10142752|NCT04173416|No Intervention|Treatment As Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, contingency management, and home delivery of medication. This often includes a referral and warm hand off to intensive outpatient SUD services and/or mental health care.
10142753|NCT04173403|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;
10142754|NCT04173481|Experimental|Rood's Group|Rood's sensory motor training along with CIMT
10142755|NCT04173481|Active Comparator|Conventional Physical Therapy Group|Conventional Physical Therapy including Proprioceptive Neuromuscular Facilitation technique.
10142756|NCT04173468|Active Comparator|MWM Group|This group will receive Mobilization with Movement (MWM) i.e. straight leg raised with traction,Tibial Gliding
10142757|NCT04173468|Active Comparator|Mulligan Taping Group|This group will receive Mulligan knee taping
10142758|NCT04173689|Active Comparator|Inspiratuar muscle training group|This group will be given inspiratory muscle training (IMT) at home for 15 minutes twice a day for 7 days a week with the resh Threshold IMT 'device. In the IMT group, the initial training intensity will be determined by measuring the maximal inspiratory muscle strength (MRP) with the intraoral pressure measuring device, 30% of the measured MRP value will be started at the first evaluation and the new training intensity will be determined by calculating 30% of the measured value by repeating the MRP measurement every week.
10142759|NCT04173689|Active Comparator|Exercise group|This group will perform upper extremity and trunk exercises combined with breathing exercises at home for 7 days, twice a day for 15 minutes. Patients in both groups will perform a single 15-minute session once a week at the hospital under the supervision of a physiotherapist.
10142760|NCT04173624|Experimental|Endosonography|Endosonography is endoscopic method to diagnose pancreatic and biliary disorders. Participants randomized to this arm will undergo diagnostic endosonography under propofol sedation in supervision of trained anesthesiologists. If choledocholithiasis is diagnosed on endosonography, patient will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
10142761|NCT04173624|Experimental|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for diagnosis of pancreatic and biliary disorders. Participants randomized to this arm will undergo MRCP. If choledocholithiasis is diagnosed on MRCP, participants will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
10142762|NCT04173455|Experimental|HZ-A-018|"In the dose-escalation part, the 3+3 design will be applied. If the subject does not have a DLT during the first 28-day cycle, those who with stable or remission of disease may continue to receive treatment until disease progression, intolerable toxicity or the subject no longer benefits.~In the dose-expansion part, HZ-A-018 will be administered for several 28-day cycles until disease progression, intolerable toxicity or the subject no longer benefits."
10142763|NCT04173598|Experimental|Intervention Group|An intervention group consisting of a dyad (patient + family carer) benefiting in addition to the usual treatment from the intervention for the family carer.
10142764|NCT04173598|Active Comparator|Control Group|A group consisting of a dyad (patient + caregiver) with usual care (control group)
10142765|NCT04173585|Experimental|Bortezomib-Gemtuzumab Ozogamicin Treatment|"one cycle of combined chemotherapy:~Bortezomib (1.3 mg/m2) sc on day 1 and 3. Dose will be given 3 hours prior to Cytarabine on day 1 and 3~Cytarabine (1g/m² twice daily) iv over 3 hours on day 1, 2 and 3 Gemtuzumab Ozogamicin (3 mg/m²,up to a maximum of one 5 mg vial) iv over 2 hours on day 1 after first dose of Cytarabine and day 4~Pegfilgrastim 6 mg sc on day 8 (optional)"
10142766|NCT04173390|Experimental|pregabalin|
10142767|NCT04173390|Placebo Comparator|placebo|
10142768|NCT04173637|Experimental|AK101 45mg every 8 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 8 weeks
10142769|NCT04173637|Experimental|AK101 45mg - every 12 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 12 weeks
10142770|NCT04173637|Experimental|AK101 90mg - every 8 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 8 weeks
10142771|NCT04173637|Experimental|AK101 90mg -every 12 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 12 weeks
10142772|NCT04173637|Experimental|AK101 135mg -every 8 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 8 weeks
10142773|NCT04173637|Experimental|AK101 135mg -every 12 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 12 weeks
10142774|NCT04173637|Placebo Comparator|Placebo to AK101|Placebo on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously at Week 12, 16 and then every 12 weeks
10142775|NCT04173728|Experimental|young and normal weight|20 subjects aged 20-29 years with normal body weight(18.5≤BMI<24), male:female = 1:1
10142776|NCT04173728|Experimental|normal weight|40 subjects aged 30-70 years with normal body weight(18.5≤BMI<24), male:female = 1:1
10142777|NCT04173728|Experimental|overweight or obesity|40 subjects aged 30-70 years with overweight or obesity (BMI≥24), male:female = 1:1
10142778|NCT04173728|Experimental|Mets|20 objects with Mets, male:female = 1:1
10142779|NCT04173715||General Group|All those who are over 65 years old and capable of walking by themselves.
10142780|NCT04173715||Low Physical Function Status Group.|All those who present a low physical function status will be included in this group.
10142781|NCT04173715||Medium Physical Function Status Group.|All those who present a medium physical function status will be included in this group.
10142782|NCT04173715||High Physical Function Status Group.|All those who present a high physical function status will be included in this group.
10142783|NCT04173507|Experimental|Treatment (talazoparib, avelumab)|Patients receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10142784|NCT04173442||Cohort 1: Dupilumab-Exposed Cohort|Pregnant women with approved indications exposed to dupilumab during pregnancy
10142785|NCT04173442||Cohort 2: Disease-Matched Comparison Cohort|Pregnant women with approved indications not exposed to dupilumab during pregnancy
10142786|NCT04173442||Cohort 3: Healthy Comparison Cohort|Pregnant women who are not diagnosed with any dupilumab-approved indications, and not exposed to dupilumab during pregnancy
10142787|NCT04173611|Experimental|EXPAREL®|For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).
10187765|NCT03722823|Active Comparator|Group 1: Healthy|Match-controlled healthy subjects with normal hepatic function
10142788|NCT04173611|Active Comparator|Bupivacaine|In each cohort, subjects randomized to the bupivacaine arm will receive 15mg of plain bupivacaine HCL (the equivalent of 13.3mg bupivacaine base) providing a 1:1 reference to the starting dose level chosen for EXPAREL®.
10142789|NCT04173611|Active Comparator|Placebo|Subjects in the placebo arm will receive normal saline intrathecal injection
10142790|NCT04173676|Experimental|use of indocyanine green|submucosal injection of ICG is by gastroscopy on the superior and inferior edge of the esophageal tumor,Dose of 0.5mg
10142791|NCT04173663|Experimental|ASSIST intervention group|This group will attend the 12 sessions of the ASSIST training program (one 2-hour session per week for 12 weeks).
10142792|NCT04173663|Other|Written materials only control group|This group will receive the ASSIST curriculum and written materials developed for the program but will not attend the in-person sessions.
10142793|NCT04173364|Experimental|Experimental group : ropivacaine 0.1%|Interscalene block for arthroscopic shoulder surgery with small volume of low concentration (0.1%) of ropivacaine
10142794|NCT04173364|Active Comparator|control group : ropivacaine 0.5%|Interscalene block for arthroscopic shoulder surgery with small volume of standard concentration (0.5%) of ropivacaine
10142795|NCT04173351|Experimental|Intervention|Pregnant women in intervention group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Date of the next antenatal follow-up of the participants in the intervention group was recorded and they were given an appointment for the antenatal education. Women, whose date of next antenatal follow-up was unknown, were asked to inform the researchers about their appointment. Following the antenatal follow-up, the pregnant women in the intervention group were given an antenatal childbirth education and an educational brochure after the education. Also, provided telephone counseling to the intervention group one week after the education. Participants in the intervention group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
10142796|NCT04173351|No Intervention|Control|Pregnant women in control group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Participants in the control group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
10142797|NCT04173325|Experimental|Nivolumab and Irinotecan|Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)
10142798|NCT04173234|Experimental|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
10142799|NCT04173234|Active Comparator|Control Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 5 days a week.
10142800|NCT04172935|Experimental|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal working distance as measured before intervention.
10142801|NCT04172935|No Intervention|Control Group|Will be deferred to receive spectacles as above, after the 4 weeks evaluation period.
10142802|NCT04173299||Early Tips|Patients wtih early tips for Acute esophageal variceal bleeding
10142803|NCT04173299||stantard treatment|patients with standard treatment (medical + endoscopic) for Acute esophageal variceal bleeding
10142804|NCT04173208|Experimental|Fecal microbial transplant|The participants of the experimental arm will receive an oral fecal microbial transplant after delivery
10142805|NCT04173208|Placebo Comparator|Placebo group|The participants of the placebo arm will receive an oral placebo after delivery
10142806|NCT04172948|Experimental|Virtual reality arm|This arm will receive diaphragmatic breathing teaching by a medical professional and virtual reality module that teaches diaphragmatic breathing. This arm will be sent home with the virtual reality equipment and practice this breathing technique through the virtual reality module for 8 weeks.
10142807|NCT04172948|Placebo Comparator|Control|This arm will receive diaphragmatic breathing teaching by a medical professional only. They will practice this breathing technique with a paper handout of diaphragmatic breathing technique instructions for 8 weeks.
10142808|NCT04173039|Other|Controls|Patients with psoriasis and without psoriatic arthritis.
10142809|NCT04173039|Other|Cases|Patients with psoriatic arthritis and with personal or familial psoriasis.
10142810|NCT04172961|Experimental|Nanomicellular Cyclosporine 0.09 prior to surgery|50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
10142811|NCT04172961|Active Comparator|Lifitegrast 5.0%|50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery
10142812|NCT04172987|Experimental|Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)|EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)
10142813|NCT04172987|Experimental|EE/NGM + Tirzepatide (Period 2)|"EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)~Tirzepatide administered by subcutaneous injection (SC)."
10142814|NCT04173078|Experimental|Computerized Distress Intolerance Intervention|Two, 1-hour computerized sessions that include psychoeducation about emotional avoidance, idiographic emotional exposure, and construction of idiographic implementation intentions to practice distress tolerance skills outside of session.
10142815|NCT04173078|Placebo Comparator|Computerized Healthy Behaviors Intervention|Two, 1-hour computerized sessions that focus on psychoeducation about the importance of a healthy lifestyle.
10142816|NCT04173052|Experimental|Infertile Males|It represents the participants, all the participants in the study are infertile.
10142817|NCT04172974|Experimental|Treatment for depression and anxiety|Treatment
10142818|NCT04172974|Other|Usual care|Usual Care
10142819|NCT04173221|Experimental|Intervention|
10142820|NCT04173221|Other|Control|
10142821|NCT04173130|Experimental|Injection of botulinum toxin with investigational device|
10142822|NCT04173286||short term antibiotics|< 7 days
10142823|NCT04173286||long terms antibiotics|> 7 days
10142824|NCT04173143|Experimental|Group 1|This group will receive Cranio cervical flexion training with pressure biofeedback protocol.
10142825|NCT04173143|Active Comparator|Group 2|This group will receive Cranio cervical flexion training without pressure biofeedback protocol
10142826|NCT04173156|Experimental|Oscillating Chitosan Device|The brush bristles of the test device (Labrida BioClean®, LABRIDA AS, Oslo, Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed, thus not causing harm to the tissues.surrounding the tooth. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
10142827|NCT04173156|Active Comparator|Regular Curettes|Standard non surgical treatment of active periodontal disease includes supra and subgingival scaling and root planing with periodontal medical grade Gracey system steel curettes
10142828|NCT04172922|Experimental|Open label, topical sirolimus arm|Single arm, open label study of1% sirolimus ointment applied to affected area twice daily for the first four weeks followed by once daily for 5 months.
10142829|NCT04172896|Active Comparator|Intraperitoneal Group|Vaginal intraperitoneal uterosacral ligament suspension group
10142830|NCT04172896|Active Comparator|Extraperitoneal Group|Vaginal extraperitoneal uterosacral ligament suspension group
10142831|NCT04172623|Experimental|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
10142832|NCT04172623|Active Comparator|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
10142833|NCT04172727|Active Comparator|ultrasound guided transversalis fascia plane block|20 mL of 0.25% bupivacaine
10142834|NCT04172727|Placebo Comparator|ultrasound guided sham block|20 mL of saline
10142835|NCT04172649|Experimental|Acu Arm|press tack needle acupuncture (ACU) and routine postoperative analgesic care
10142836|NCT04172649|Sham Comparator|SHAM Arm|press tack placebo acupressure (SHAM) and routine postoperative analgesic care
10142837|NCT04172649|No Intervention|CONTROL Arm|Patients in the control group will receive only routine postoperative analgesic care
10142838|NCT04172597|Experimental|Poziotinib|"Cohort 1: Patients that have HER2-positive or HER2-negative breast cancer with HER2 activating mutations~Cohort 2: Patients that have colorectal cancer with HER2 activating mutations~Cohort 3: Patients that have solid tumors (except NSCLC, breast cancer, or colorectal cancer) with HER2 activating mutations~Cohort 4: Patients that have high-grade glioma with EGFR activating mutations~Cohort 5:Patients that have solid tumors (except NSCLC or high-grade glioma) with EGFR activating mutations"
10142839|NCT04172792|Active Comparator|high-caloric fatty diet|intake of 405 kcal (45g fat) per day in addition to normal food intake
10142840|NCT04172792|Experimental|ultra-high-caloric fatty diet|intake of 810 kcal (90g fat) per day in addition to normal food intake
10142841|NCT04172792|Experimental|ultra-high-caloric carbohydrate-rich diet|intake of 900 kcal (111.4g carbohydrate, 34.9g fat, 36.0g protein) in addition to normal food intake
10142842|NCT04172792|No Intervention|control|normal food intake (no intervention)
10142843|NCT04172818|Experimental|Patients with diary|Evaluation the psychological impact of a diary on the patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives.
10142844|NCT04172753|Experimental|Rectal and anal cancer|In this arm patients with rectal and anal cancer are recruited.
10142845|NCT04172753|Experimental|Prostate cancer|In this arm patients with prostate cancer are recruited.
10142846|NCT04172753|Experimental|Head and neck cancer|In this arm patients with head and neck cancers are recruited.
10142847|NCT04172753|Experimental|Esophageal cancer|In this arm patients with esophageal cancer are recruited.
10142848|NCT04172753|Experimental|Breast Cancer|In this arm patients with breast cancer are recruited.
10142849|NCT04172753|Experimental|Central nervous system tutors|In this arm patients with tumors of the central nervous system are recruited.
10142850|NCT04172753|Experimental|Palliative treatments|In this arm patients with palliative treatments are recruited.
10142851|NCT04172753|Experimental|Other|In this arm patients with other tumors are recruited.
10142852|NCT04172753|Experimental|Imaging only|In this arm patients receive only imaging on the MR-Linac
10142853|NCT04172883|No Intervention|Control arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the standard device setting or MINERVA setting ( control arm)
10142854|NCT04172883|Active Comparator|Treatment arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the reduced sequence programming ( treatment arm)
10142855|NCT04172571|Experimental|AK105 and anlotinib|
10142856|NCT04172493|Experimental|Diagnostic|Patients undergo standard of care white light endoscopy (WLE) and hyperspectral endoscopy (HySE) during routine colonoscopy procedure.
10142857|NCT04172844|Experimental|Pevonedistat Dose Escalation|This study uses a varied 3 + 3 design. Three patients will be started at a dose of 10 mg/m^2 days 1, 3 and 5. If no DLTs are observed in the first 3 participants, then a new cohort will be enrolled at the next planned dose level of 15 mg/m^2 days 1, 3 and 5. If two out of three subjects experience a DLT, then they will de-escalate one dose level. If one subject in three experiences a DLT, then expand up to three subjects at 20 mg/m^2 day 1, 3 and 5. If two out of six subjects experience a DLT, de-escalate one level. All subjects will receive Azacitidine and Venetoclax at the indicated dosages and timing.
10142858|NCT04172844|Experimental|Dose Expansion Phase|Patients will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase.
10187766|NCT03722823|Experimental|Group 2: Mild Hepatic Impairment|Subjects with Mild hepatic impairment (Child-Pugh Class A, score of 5 or 6)
10142859|NCT04172831|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
10142860|NCT04172831|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
10142861|NCT04172428||Healthy volunteers|Young healthy volunteers between the ages of 18-55.
10142862|NCT04172870||Group I|Healthy group ( No generalised periodontitis and no CAD)
10142863|NCT04172870||Group II|Generalised periodontitis patients without CAD
10142864|NCT04172870||Group III|CAD patients without generalised periodontitis
10142865|NCT04172870||Group IV|Generalised periodontitis with CAD
10142866|NCT04172415||Retrospective cohort|Patients that received procedural sedation in a community Emergency Department.
10142867|NCT04172688|Placebo Comparator|Placebo|Two 3.3g doses/day (12 kcal/dose) of maltodextrin
10142868|NCT04172688|Experimental|Prebiotic|Two 8g doses/day (12 kcal/dose) of oligofructose-enriched inulin
10142869|NCT04172519|Experimental|Group A|Patients who before prostate cancer surgery will receive: psychological consultation, nursing consultation, physiotherapy consultation and intervention (4 visits which will be implemented pelvic floor muscle training). Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Then, 6 months after the surgery, there will also be a physiotherapy consultation.
10142870|NCT04172519|Experimental|Group B|Patients who will receive: psychological consultation, nursing consultation, physiotherapy consultation before prostate cancer surgery. Subsequently, patients will have the procedure performed laparoscopic radical prostatectomy, immediately after which they receive psychological consultation, nursing consultation. The physiotherapist consultation will be two weeks after the surgery, during which the physiotherapist will provide an instruction pelvic floor muscle training. Patients do the exercises themselves at home according to the instructions, 3 times a day for 3 months). Physiotherapeutic consultation 6 months after surgery.
10142871|NCT04172519|Experimental|Group C|Patients who will not receive any intervention before prostate cancer surgery. Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Physiotherapeutic consultation 6 months after surgery.
10142872|NCT04172519|No Intervention|Group D|Control group, patients after radical laparoscopic prostatectomy, without additional interventions
10142873|NCT04172662|Experimental|Music therapy group|Receive Music therapy in addition to standard treatment
10142874|NCT04172662|No Intervention|Control group|Receive standard treatment
10142875|NCT04172779|Experimental|Erlotinib treatment|
10142876|NCT04172337|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display FOP labels on any products.
10142877|NCT04172337|Experimental|HCS-only|Arm 2 (termed HCS-only) displayed the HCS on eligible products, crossed referenced via the Health Promotion Board's HCS database (https://www.hpb.gov.sg/food-beverage/healthier-choice-symbol). Out of the 4,177 products available on NUSMart, 311 (7·45%) carried the HCS. This was comprised of 150 foods and 161 beverages.
10142878|NCT04172337|Experimental|HCS+PAE|Arm 3 displayed the HCS on eligible products as in Arm 2 and the PAE label on all products (termed HCS+PAE). PAE was calculated as the minutes required to burn off the calories of a single serving for a 73 kg person jogging at 8 km per hour.
10142879|NCT04172740|Experimental|Treatment|
10142880|NCT04172506|Experimental|AK105|AK105 200 mg, every 2 weeks
10142881|NCT04172350|Experimental|Intervention group: iCareBreast plus routine care|Participants in the intervention group will receive the routine care provided by the hospital (the same as the control group) plus the iCareBreast mobile app, which provides i) pre-surgery education and instructions; ii) post-surgery education, instructions, and recovery plan; iii) positive psychological support; and iv) social support. The total intervention period is 29 days (14 days before surgery, operation day, and 14 days after the surgery).
10142882|NCT04172350|Active Comparator|Control group: Routine care|Participants in the control group will only receive routine care provided by the attending Hospital. Participants being allocated to the control group may freely use the Internet to search for information regarding breast cancer but will not be granted to access the iCareBreast app.
10142883|NCT04172298|Placebo Comparator|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
10142884|NCT04172298|Experimental|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
10142885|NCT04172298|Experimental|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
10142886|NCT04172454|Experimental|AK104|AK104 in subjects with advanced melanoma and other selected advanced solid tumor including PD-1/PD-L1 relapsed/refractory tumors)
10142887|NCT04172363|No Intervention|Standard Care|Octenisept will be used as standard care antiseptic for dressing change
10142888|NCT04172363|Experimental|Resistance testing|Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results
10142889|NCT04172376|Experimental|Minimally invasive puncture aspiration plus rt-PA|
10142890|NCT04172376|Active Comparator|Conservative medical treatment|
10142891|NCT04172207||Results of study groups.|
10187767|NCT03722823|Experimental|Group 3: Moderate Hepatic Impairment|Subjects with Moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9)
10142892|NCT04172311|Experimental|Modified Atkins Diet|"Modified Atkins Diet administration~Carbohydrates will be restricted to 10 grams per day.~Recipes will be provided to be prepared from easy home available foods, to have 2.5 gram per meal. Along with this, a list of carbohydrate free foods will be provided.~Fats intake will be actively encouraged. Protein intake will be unrestricted.~Medications will be changed to carbohydrate free preparations.~A multivitamin and calcium supplementation will be added."
10142893|NCT04172311|Active Comparator|Levetiracetam|Levetiracetam will be started at a dose of 10 mg/kg/day in two divided doses and increased to 20 mg/kg/day after 1 week. Syrups will be used in children younger than 5 years of age, and tablets will be used in children > 5 years of age. Further dose titration will be done as per the seizure control, in 10 mg/kg/day increments in 2 weekly intervals, to a maximum of 60mg/kg/day.
10142894|NCT04172220|Experimental|PECS + Opioid-free GA|Loco-regional anesthesia with PEC I and serratus plane block with an echoguided technique and opioid-free general anesthesia
10142895|NCT04172220|Active Comparator|GA|General anesthesia
10142896|NCT04172233|Experimental|Phase I: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0 and 4 by subcutaneous injection
10142897|NCT04172233|Experimental|Phase I: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0 and 4 by subcutaneous injection
10142898|NCT04172233|Experimental|Phase I: AK101 270 mg|Biological: AK101 AK101 270 mg on Week 0 and 4 by subcutaneous injection
10142899|NCT04172233|Placebo Comparator|Phase I: Placebo|Biological: Placebo Placebo on Week 0 and 4 by subcutaneous injection
10142900|NCT04172233|Experimental|Phase II: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0, 4 and 16 by subcutaneous injection
10142901|NCT04172233|Experimental|Phase II: AK101 90 mg|Biological: AK101 AK101 90 mg on Week 0, 4 and 16 by subcutaneous injection
10142902|NCT04172233|Experimental|Phase II: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0, 4 and 16 by subcutaneous injection
10142903|NCT04172233|Placebo Comparator|Phase II: Placebo to AK101|Drug: Placebo Placebo on Week 1 and 4 by subcutaneous injection, and then AK101 on Week 12 16 by subcutaneous injection
10142904|NCT04172285|Experimental|Physical activity group|
10142905|NCT04172285|Experimental|Physical activity and supplementation group|
10142906|NCT04172285|Experimental|Control group|
10142907|NCT04172129||NANOS|NANOS™ Neck Preserving Hip Stem
10142908|NCT04172064||377patients evaluated by MPS and DSE|
10142909|NCT04172181||UCBT-SCID-Case|SCID patients who underwent cord blood stem cell transplantation.The only curative therapy for SCID is allogeneic hematopoietic stem cell transplantation.
10142910|NCT04172272|Active Comparator|Systemic multimodal analgesia only|"In the first group, patients will receive intravenous, systemic, multimodal analgesia: paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
10142911|NCT04172272|Experimental|TAP block only|In the second group there will be patients in who will be given the TAP block. The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacaine in 40 ml bilaterally. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
10142912|NCT04172272|Experimental|Combined TAP block with systemic multimodal analgesia|In the third group there will be patients who will be treated with TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
10142913|NCT04172259|Experimental|ACH-TH|Doxorubicin liposome（PLD）35 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Docetaxel（DOC）75 mg/m2 every 3 weeks
10142914|NCT04172259|Active Comparator|EC-TH|Epirubicin（EPI）90 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Docetaxel（DOC）75 mg/m2 every 3 weeks
10142915|NCT04172051|Experimental|Experimental Group|"Subjects will be admitted into the Tony Robbins event for free, or receive a voucher for an event in the future. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
10142916|NCT04172051|No Intervention|Control Group|"The control group will be asked to engage in gratitude journaling every day for a month. The control group will NOT attend the event. This exercise will take 10 minutes to complete. The subject will write down three things that went well each day and provide an explanation about why they went well. This will be written down in a journal. The subjects will follow these instructions:~Give the event a title (e.g., co-worker complimented my work on a project)~In the space below, write down exactly what happened in as much detail as possible, including what you did or said, and if other people were involved, what they did or said.~Include how this event made you feel at the time and how this event made you feel later (including now, as you remember it)."
10142917|NCT04172051|Active Comparator|Motivated Experimental Group|"The Motivated Experimental Group (M Experimental) will consist of participants who registered and paid for Tony Robbins Date with Destiny (DWD). They are chosen as the motivated experimental as they will be paying full price for the event. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
10142918|NCT04171947|Experimental|Matuzalem|Tea extract vaginal ovule daily for 7 consecutive days
10142919|NCT04171947|Sham Comparator|Vehicle|Polyethylene glycol vaginal ovule daily for 7 consecutive days
10142920|NCT04171908|Active Comparator|Conventional therapy|Conventional Physical therapy for the upper limb
10142921|NCT04171908|Experimental|Nintendo Switch Joy-Con plus conventional therapy|Conventional Physical therapy for the upper limb plus Nintendo Switch Joy-Con
10142922|NCT04172142||Control group|Healthy individuals of similar age and sex who meet the inclusion criteria
10142923|NCT04172142||Pectus Excavatum|Individuals with pectus excavatum that meet the inclusion criteria
10142924|NCT04172142||Pectus Carinatum|Individuals with pectus excavatum that meet the inclusion criteria
10142925|NCT04171986|Experimental|Test Group|
10142926|NCT04172168||Heart rupture|Include left ventricular free-wall ruptrue after AMI
10142927|NCT04172168||Non heart rupture|AMI with non heart rupture
10142928|NCT04171921|Active Comparator|Robotic ventral hernia repair|
10142929|NCT04171921|Active Comparator|Open ventral hernia repair|
10142930|NCT04171778|Experimental|Intervention|Subjects in this arm will immediately begin a whole-food, plant-based nutrition program consisting of weekly educational group meetings and prepared meals delivered to the subjects' homes for the first 12 weeks followed by monthly educational group meetings for an additional 6 months.
10142931|NCT04171778|Other|Wait List Control|Subjects in this arm will continue their usual care as directed by their nephrologist for 12 weeks before starting the same whole-food, plant-based nutrition program as the intervention arm subjects.
10142932|NCT04172116||long pouch RYGB|Patients with the variation of a long and narrow pouch (hypothesis: slower transit of food)
10142933|NCT04172116||short pouch RYGB|Patients with the variation of a short and wide pouch (hypothesis: faster pouch emptying as compared with long and narrow pouch)
10184848|NCT03751501|Experimental|Experimental Group|Indocyanine green-Guided Targeted Laser photocoagulation combines routine procedures, that are, the detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT. Indocyanine green-Guided Targeted Laser photocoagulation is administered in combination with anti VEGF treatment
10184849|NCT03751501|Sham Comparator|Control Group|Sham laser is administered at randomization visit and repeated if needed 3 month later in combination with anti VEGF treatment
10184850|NCT03751488|Experimental|LY03010 351mg|LY03010 at 351 mg
10184851|NCT03751488|Experimental|LY03010 156 mg|LY03010 at 156 mg
10184852|NCT03751488|Experimental|LY03010 117mg|LY03010 at 117mg
10184853|NCT03751488|Active Comparator|INVEGA SUSTENNA|INVEGA SUSTENNA 156mg
10184854|NCT03751475|Experimental|OptiMA|The enrolled subjects will follow the nutritional Optima strategy.
10184855|NCT03751475|Active Comparator|Control|The enrolled subjects will follow the standard nutritional protocol currently in use in the Democratic Republic of Congo
10184856|NCT03751462|Experimental|Pseudoexfoliation syndrome|Patients with pseudoexfoliation syndrome or traumatic cataract will be examined using the Purkinjemeter device concerning IOL wobble, tilt and decentration
10184857|NCT03751436|Experimental|Treatment (venetoclax, enzalutamide)|Patients receive venetoclax PO QD and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10184858|NCT03751423|Active Comparator|PO Morphine & IV Placebo|One third of study participants will be randomized to this local standard of care arm.
10184859|NCT03751423|Active Comparator|IV Fentanyl & PO Placebo|One third of study participants will be randomized to this current gold standard of care arm.
10184860|NCT03751423|Experimental|IV Ketamine & PO Placebo|One third of study participants will be randomized to this experimental arm.
10184861|NCT03751384|Experimental|Capsules|Dietary Supplement: Möllers Omega-3 Ekstra Sterk
10184862|NCT03751384|Active Comparator|Drink|Dietary Supplement: Nutrifriend Cachexia
10184863|NCT03751371|Experimental|Walking Training with the HWA Device|Training with HWA device
10184864|NCT03751371|Other|Usual Care|Usual Care
10184865|NCT03751358|Experimental|Unilateral Erector spinae plane block|Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging
10184866|NCT03751345|No Intervention|Treatment As Usual (TAU)|The TAU condition consists of the standard treatment elements offered to all Gateway (study site) patients, and will be received by patients in both the PW and the TAU-only condition. TAU services during the adolescent's treatment are typically eclectic and mainly entail meeting with the adolescent alone to provide support and psychoeducation, with occasional family therapy sessions. Medication management is offered as needed.
10184867|NCT03751345|Experimental|Parenting Wisely (PW)|In addition to TAU services, the PW arm includes in-person sessions where parents complete computer-administered PW sessions, in-person session including therapist coaching to reinforce PW material and personalize treatment by applying PW skills to individual issues, and access to PW material remotely so parents can access information and skills from home as needed.
10184868|NCT03751332|Other|Conversion from either CSA or TAC|Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily. In patients treated with ciclosporin A, the initial dose will be 0.1 - 0.12 mg tacrolimus MR4 per kg of body weight per day with oral morning administration. In patients who are already treated with Prograf, the conversion to Advagraf will be performed in a 1:1 ratio.
10184869|NCT03751319|Active Comparator|Standard Emergency Care + CGA|Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
10184870|NCT03751319|No Intervention|Standard Emergency Care|Standard Care is provided for the acute condition as usual by the ED personnel.
10184871|NCT03751306|Active Comparator|Control-Cardiorespiratory Rehabilitation|These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
10184872|NCT03751306|Placebo Comparator|Transcranial Photobiomodulation Placebo|In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
10184873|NCT03751306|Experimental|Transcranial Photobiomodulation|In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
10184874|NCT03751293|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
10184875|NCT03751267|Experimental|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
10142934|NCT04171791|Experimental|ABT-199 (Venetoclax)|Patients with Cutaneous T Cell Lymphoma (CTCL) will receive ABT-199 (Venetoclax).
10142935|NCT04171661|Experimental|SASS|SASS applied on chronic skin wounds as skin graft
10142936|NCT04171596|Experimental|Primary care coordination|
10142937|NCT04171648|Experimental|Roasted Peanut Group 1|Arm 1 is the arm of participants that will receive the roasted peanut treatment first and then will crossover to the boiled peanut treatment.
10142938|NCT04171648|Experimental|Boiled Peanut Group 1|Arm 2 is the arm of participants that will receive the boiled peanut treatment first then will crossover to the roasted peanut treatment.
9827478|NCT02457325|Experimental|Surgery With 2% Articaine first, then Surgery With 4%Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
10142939|NCT04171726|Experimental|Edoxaban|treatment with edoxaban
10142940|NCT04171973|Other|Driving an electric wheelchair in real condition|In order to be able to evaluate the feasibility of virtual reality driving training, the driving performance will be evaluated on the same 3 standardized circuits: for the control group, 3 circuits of test of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
10142941|NCT04171973|Experimental|Driving an electric wheelchair in virtual condition|In order to be able to evaluate the feasibility of driving training in virtual reality, the driving performance will be evaluated on the same 3 standardized circuits: for the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
10142942|NCT04171622|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenvatinib PO daily on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
10142943|NCT04171817|No Intervention|Control|Dog-handler teams will follow established hospital and therapy dog program guidelines for infection control with no changes for eight sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
10142944|NCT04171817|Experimental|CHX Intervention A|"Dog-handler teams will follow a modified protocol for infection control, with Treatment A first for four sessions, and cross-over to Treatment B for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.~Treatment A consists of a pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine) within 24 hours prior to the session, and wiping with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival at the session and every 20 minutes during the session, or between participants if the flow of participants is structured in a way that allows this (such as visits from one room to the next to visit individual patients)."
10142945|NCT04171817|Experimental|CHX Intervention B|"Dog-handler teams will follow a modified protocol for infection control, with Treatment B first for four sessions, and cross-over to Treatment A for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.~Treatment B will consist of the same pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine), with a single wipe with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival. This treatment will depend on the residual activity of chlorhexidine throughout the visit."
10142946|NCT04171687|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
10142947|NCT04171687|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and Tegoprazan 50mg tablet once daily for 7 days
10142948|NCT04171687|Experimental|Clopidogrel 75 mg + RAPA113|Oral administration of clopidogrel 75 mg tablet and RAPA113 tablet once daily for 7 days
10142949|NCT04171843|Experimental|PBCAR269A at Dose Level 1 (Cohort A)|The starting dose of PBCAR269A will be 6 x 10^5 CAR T cells/kg body weight.
10142950|NCT04171843|Experimental|PBCAR269A at Dose Level 2|2 × 10^6 CAR T cells/kg body weight.
10142951|NCT04171843|Experimental|PBCAR269A at Dose Level 3|6 × 10^6 CAR T cells/kg body weight.
10142952|NCT04171843|Experimental|PBCAR269A at Dose Level 2 (Cohort B)|2 × 10^6 CAR T cells/kg body weight.
10142953|NCT04171843|Experimental|PBCAR269A at Dose Level 1 (Cohort B)|6 x 10^5 CAR T cells/kg body weight.
9970319|NCT01298986|Experimental|Hybrid procedure for patients with a left atrium < /= 5.0 cm|A combined procedure where the cardiac surgeon will place the ablation lesions on top of the heart and the electrophysiologist will place the lesions inside the heart. 3D mapping with be used to guide the procedure. The left atrial appendage will be surgically managed.
9970320|NCT01298986|Active Comparator|Cox Maze Procedure|All lesions of the Cox Maze procedure will be completed as originally described by Dr. James Cox using crypthermia. Patients will be randomized if there left atrium is >5.0 cm but < 6.1 cm and are experiencing paroxysmal or persistent atrial fibrillation
9970321|NCT01298986|Experimental|Hybrid Procedure|A collaborative approach between electrophysiologist and surgeons for patients with a left atrium <5.0 cm and < 6.1 cm where the surgeon will epicardially place the ablation lesions and the electrophysiologist will place the lesion lines endocardially. 3D mapping will be used and the left atrial appendage will be surgically managed.
9970322|NCT01299051|Active Comparator|Steps to Health|Steps to Health worksite weight management program at Duke.
9970323|NCT01299051|Experimental|Steps to Health Plus!|Steps to Health Plus! worksite weight management program at Duke. Also known as Pathways to Change.
9970324|NCT01299051|No Intervention|Observational Comparison|Observational comparison group consisting of employees who are eligible for the study but do not take part will also be used in analyses (approximately 1500 subjects).
9970325|NCT01299064||Buddhist Clergy and Laypersons|
9970326|NCT01299142|Experimental|FGI-101-1A6|Intervention: Drug-FGI-101-1A6
9516822|NCT03311932|Active Comparator|Cortef® Tablets - fasted|Single dose of 20mg Cortef® Tablets - fasted arm
9516823|NCT03311932|Experimental|Infacort® - fasted|Single dose of 20mg Infacort® - fasted arm
9970327|NCT01299142|Placebo Comparator|Placebo|Intervention: Drug-Placebo
9970328|NCT01299155|Experimental|ReSTOR +3|Bilateral implantation of a ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1
10142954|NCT04171843|Experimental|PBCAR269A at Dose Level 3 (Cohort B)|6 × 10^6 CAR T cells/kg body weight.
10142955|NCT04171479||Manual|Subjects who underwent epicardial mapping and/or ablation using a manual technique will comprise this group.
10142956|NCT04171479||Remote Magnetic Navigation|Subjects who underwent epicardial mapping and/or ablation using a remote magnetic technique (using Stereotaxis Niobe system) will comprise this group.
10142957|NCT04172090|Other|Control|2 consecutive days of standardised daily levels of moderate physical activity (PAL=1.85 reflecting their habitual levels), and matched energy (food) intake
10142958|NCT04172090|Experimental|SIT+E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst maintaining the level of food intake prescribed in the Control trial, thus creating a positive energy balance
10142959|NCT04172090|Experimental|SIT=E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst reducing food intake to match the reduction in energy expenditure induced by inactivity, thus maintaining energy balance
10142960|NCT04171713|Experimental|Grup 1|MBHP protocol + TAU
10142961|NCT04171713|Experimental|Grup 2|ABCT protocol + TAU
10142962|NCT04171713|Active Comparator|Grup 3|TAU
10142963|NCT04171609|Experimental|Cancer survivors|Adult survivors of any kind of cancer (except for minor skin cancer) are eligible to participate
10142964|NCT04171401||Participants post stroke|Severly affected patients in the subacute phase post stroke that are unable to walk without the help of one or two therapists to assist for balance and weight-carrying. Participants were able to sit independently for two minutes. Participants post stroke performed limits of stability testing in sitting, and tests for trunk control and functional balance.
10142965|NCT04171401||Healthy controls|Healthy control subjects who matched patients post stroke for age and gender, and had no limitations to perform measurements. Healthy controls performed limits of stability measurements and a clinical measurements for balance.
10142966|NCT04171388|Placebo Comparator|Routine care: Placebo|"In all pregnancies presenting at all centers, routine antenatal care will be strengthened:~Provision of iron-folic acid and tetanus toxoid vaccine~Screening for anemia and blood pressure~Screening/treatment of HIV, syphilis, malaria, tuberculosis~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
10142967|NCT04171388|Experimental|Routine care: Azithromycin|Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later.
10142968|NCT04171388|Experimental|Routine care: Enhanced Infection Management Package (EIMP)|At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrhea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment.
10142969|NCT04171388|Experimental|Enhanced Nutrition Package (ENP): Placebo|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
10142970|NCT04171388|Experimental|ENP: Azithromycin|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.~Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
10142971|NCT04171388|Experimental|ENP: EIMP|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.~At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrohea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment."
10142972|NCT04171752|Experimental|Young Adults|Single oral dose of elafibranor 120mg
10142973|NCT04171752|Experimental|Elderly|Single oral dose of elafibranor 120mg
10142974|NCT04171362|Experimental|Migraine group|The study included patients diagnosed by migraine according to International Headache Community criteria with18-65 years of age followed by routine controls and who were volunteered
10142975|NCT04171362|Active Comparator|Control group|The study included patients diagnosed by migraine according to International Headache Community criteria with 8-65 years of age followed by routine controls and were volunteered
10142976|NCT04171427|Other|Lithium liposome and placebo A|• Group A : 4 patients; Lithium liposome 1 application / day (evening) on target lesions on one side of the body, placebo 1 application / day (evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
10142977|NCT04171427|Other|Lithium liposome and placebo B|Group B : 4 patients; Liposomal Lithium 2 applications / day (morning and evening) on target lesions on one side of the body, placebo 2 applications / day (morning and evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
10142978|NCT04171427|Other|Lithium liposome and placebo C|Groupe C : 4 patients; Lithium liposome 2 applications / day (morning and evening) on one side, placebo 2 applications / day (morning and evening) on contralateral target lesions.
10142979|NCT04171739|Other|Cohort A|Itraconazole DDI
10142980|NCT04171739|Other|Cohort B|Rifampicin DDI
10142981|NCT04171674|Experimental|Patients treated with high-dose ceftobiprole|
10142982|NCT04171583||mucoid S. aureus|CF patients with mucoid S. aureus
10142983|NCT04171583||non-mucoid S. aureus|CF patients with non-mucoid S. aureus
10142984|NCT04171570|Other|Distal Transradial Access|Distal Transradial Access
10142985|NCT04171570|Other|Conventional Transradial Access|Conventional Transradial Access
10142986|NCT04171531|Active Comparator|Botox A® injection|A dose of 100 units of Botulinum toxin A will be injected into the bladder. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
10184876|NCT03751267|No Intervention|Wait-list control|This group of patients will receive Tuina (massage) 4 weeks after baseline assessments.
10142987|NCT04171531|Active Comparator|Mid-urethral sling|Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
10142988|NCT04171557||Patients with diabetes at the baseline assessement in EPIC|Self-reported and confirmed diabetes (validated by a second source (at least 1), including repeated self-report, contact with physician, linkage to register later point, intake of diabetes medicine, registration of diabetic chiropody, baseline glycated hemoglobin>=6.0%, five annual blood glucose measurements or two blood glucose measurements per year for five consecutive years) cases were included in the analyses. No information is available to distinguish between type 1 and type 2 diabetes across the population but type 1 is rare by comparison.
10142989|NCT04171336|Experimental|Animal-assisted group therapy|
10142990|NCT04171245|Experimental|Experimental|One minute laughter prescription 3x a day Tracking sleep using equipment
10142991|NCT04171245|Active Comparator|Control|Tracking sleep using equipment
10142992|NCT04171089|Experimental|Child-Safety Plan Intervention|A Child Safety Plan to prevent suicidal behavior will be developed with the children and their parents. The parents and child will complete feasibility and acceptability questionnaires.
10142993|NCT04171466|Active Comparator|Broad Spectrum Antibiotic Therapy + Microbial Consortia|
10142994|NCT04171466|Placebo Comparator|Broad Spectrum Antibiotic Therapy + Placebo|
10142995|NCT04171466|Active Comparator|No Antibiotic Therapy + Microbial Consortia|
10142996|NCT04171466|Placebo Comparator|No Antibiotic Therapy + Placebo|
10142997|NCT04171180|Active Comparator|Controlled group|Controlled group: budesonide/formoterol(SYM) 160/4.5ug 1 inhalation bid* 3 months (n=250).
10142998|NCT04171180|Experimental|Study group|Study group: SYM 160/4.5ug 2 inhalation bid* 3 months (n=250).
10142999|NCT04171154|Experimental|Expectation|Participants are asked to think of three strength which have helped them in prior stressful events. They then have to think of ways how these strength may help them in future stressful situations, i.e. a test in this experiment.
10143000|NCT04171154|Experimental|Acceptance|Participants listen to an audio-instruction on cognitive defusion. They shall observe the thoughts and feelings of stress and, with the help of the instruction, distance themselves from it.
10143001|NCT04171154|No Intervention|Control|Participants wait for the stress-test to start.
10143002|NCT04171232|Active Comparator|Balance It (Group 1)|Children with spastic hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Balance It group. Each subject in first group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
10143003|NCT04171232|Active Comparator|Bubble Pop (Group 2)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Bubble Pop group. Each subject in second group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
10143004|NCT04171232|Active Comparator|Scoop'd (Group 3)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Scoop'd group. Each subject in third group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance
10143005|NCT04171271|Experimental|Activating kinesthetic motor imagery training|
10143006|NCT04171271|Active Comparator|Relaxing kinesthetic motor imagery training|
10143007|NCT04171271|No Intervention|Control (no specific intervention)|
10143008|NCT04171193|Experimental|ISO|Patients not taking oral medications for depression. They will receive the study intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes.
10143009|NCT04171193|Experimental|ISOAD|Patients in treatment with oral medications for depression, will receive intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes
10143010|NCT04171193|Experimental|ISOPOT|Patients that where from ISO arm, that did not respond to intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes They will now, start taking sertraline as oral medication for depression to asset the enhancement of oral treatment after Isoflurane challenge.
10143011|NCT04171349|Active Comparator|Group A|Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%
10143012|NCT04171349|Experimental|Group AD|Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).
10143013|NCT04171284|Experimental|SCT-I10A plus Docetaxel|SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles
10143014|NCT04171284|Active Comparator|Placebo puls docetaxel|Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles
10143015|NCT04171284|Experimental|Maintenance therapy of SCT-I10A|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
10143016|NCT04171284|Placebo Comparator|Maintenance therapy of Placebo|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
10143017|NCT04171206|Experimental|Free From Abuse|This is a brief internet-delivered intervention designed to boost participants' ability to recognise abusive behaviour, reduce acceptance of myths related to domestic violence and IPV, as well as decrease abuse perpetration and victimisation.
10143018|NCT04171206|Placebo Comparator|Technology and crime|This is a brief internet-delivered placebo intervention designed to inform participants about how the development of technology could affect crime.
10143019|NCT04171050|Active Comparator|Group 1: Local Anesthesia|Standard of care with local anesthesia used during surgery
10143020|NCT04171050|Active Comparator|Group 2: Local Anesthesia plus Pudendal Nerve Block|Pudendal Nerve Block (PNB) in addition to local anesthesia used during surgery
10143021|NCT04171076|Experimental|Intervention|Intervention: non-invasive spinal cord stimulation
10143022|NCT04171505||vaccinated women|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.~Women who sign informed consent.~Patients with negative results in the first post-surgery control.~Patients who have received HPV vaccination and provide vaccination card."
10143023|NCT04171505||non vaccinated woman|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.~Women who sign informed consent.~Patients with negative results in the first post-surgery control.~Patients who have NOT received HPV vaccination and provide vaccination card."
10143024|NCT04170933|Experimental|Magnetic recanalization|The subjects in this group will be treated by magnetic recanalization
10143025|NCT04170777||Arm A|The CBCT imaging involved for Arm A is considered part of the study treatment. Pre and post treatment images will be acquired of the patient treated on Perfexion Gamma Knife using the 'Leksell Coordinate Frame'.
10143026|NCT04170777||Arm B|Arm B will be undergoing standard treatment on Gamma Knife Perfexion for Stereotactic Radiosurgery using the 'relocatable mask'. Patients with lesions that are >3 cm at the largest diameter will be treated with the relocatable mask for which a hypo fractionated approach may be beneficial.
10143027|NCT04171011|Experimental|Nerve Stimulation|Participants will undergo brief NVB stimulation during the esophagectomy procedure.
10143028|NCT04170725|Experimental|Patients and Healthy volunteers|Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
10143029|NCT04170855|Other|Furosemide Injection|"Patients with diuretic resistance:~The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). Fluid overload is defined as the presence of at least two of the following clinical features:~Peripheral or sacral oedema~Jugular venous distension ≥ 7 cm~Radiographic pulmonary oedema or pleural effusion~Enlarged liver or ascites~Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea~Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter >2.5 cm and/or failure to collapse at least 50% with sharp inspiration"
10143030|NCT04170842|Experimental|Music intervention|"The music intervention used in the study will be a patient selected list of songs or other music delivered to the participant by passive listening via in-ear or on-ear headphones. They will be given the choice of using their own personal headphones or use a pair provided by the hospital. If choosing to use a hospital device, the earphones provided will be disposable to minimise infection risk from re-use.~Patient preferred music has shown to be more effective than preselected, or prescriptive music. Prescriptive music, if not of the patient's preference, could cause further discomfort, distress or anxiety. Therefore, investigators will use streaming services to provide a bank of music containing a wide range of music and genres to suit the majority of music preferences. Music will also be curated based on feedback from age-appropriate sources to identify common and popular music in the target participant age group."
10143031|NCT04170842|No Intervention|Control|Wound dressing procedure conducted according to clinical practice
10143032|NCT04170751|Experimental|group N|In group N, 16 mcg / cc of norepinephrine was infused to patients.
10143033|NCT04170751|Experimental|group V|In group V, 0.4 unit / cc of vasopressin was infused to patients.
10143034|NCT04171219|Experimental|Treatment (talabostat, pembrolizumab)|Patients receive talabostat PO BID on days 1-14 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10143035|NCT04170868|Other|Video 1|Ten-day exposure to one of two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
10143036|NCT04170868|No Intervention|Video 1 Washout|Ten-day washout period between access to the first and second videos.
10143037|NCT04170868|Other|Video 2|Ten-day exposure to the second of the two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
10143038|NCT04170816|Active Comparator|DN plus KT group|"DN plus KT therapy is going to be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy is going to be applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.~Kinesio Taping Application: Tapes is going to be left on the patient's body for 5 days."
10143039|NCT04170816|Active Comparator|DN group|DN will be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy was applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.
10143040|NCT04170959|No Intervention|A: Observational arm|Radiotherapy as per standard of care without metformin, no additional biomarkers/imaging will be performed
10143041|NCT04170959|Other|B: Control arm|Radiotherapy as per standard of care without metformin, with additional biomarkers/imaging
10143042|NCT04170959|Active Comparator|C: Interventional arm|Radiotherapy as per standard of care with metformin, with additional biomarkers/imaging
10143043|NCT04170595|Experimental|GB221,2mg/kg|Coprelotamab Injection, 2 mg/kg, Single dose,
10143044|NCT04170595|Experimental|GB221,6mg/kg|Coprelotamab Injection, 6 mg/kg, Single dose,
10143045|NCT04170595|Active Comparator|Herceptin,6mg/kg|Trastuzumab Injection, 6 mg/kg, Single dose,
10143046|NCT04170595|Experimental|GB221,8mg/kg|Coprelotamab Injection, 8 mg/kg, Single dose,
10143047|NCT04170595|Experimental|GB221+ Capecitabine|Multiple dose groups
10143048|NCT04170595|Active Comparator|Herceptin+Capecitabine|Multiple dose groups
10143049|NCT04170803|Experimental|True Dry Needling|"Active duty DoD beneficiaries, with shoulder pain will be recruited from Army Medical Department Center and School (AMEDDC&S) and the Brooke Army Medical Center (BAMC) Outpatient Physical Therapy Clinic who meet inclusion and exclusion criteria. The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the infraspinatus muscle using FDA approved (FDA regulation # 880.5580) disposable 0.25 x 40 mm stainless steel Seirin J-type needles (Seirin, Japan). Each shoulder will undergo this treatment. Each needle insertion will last approximately 2-3 seconds using the sparrow pecking (in and out) technique to the depth of the scapula at 3 locations in the infraspinatus muscle on the affected (painful) side. When detectable, the needle insertion will specifically target palpably painful and/or taut bands of tissue. Immediately after use, all needles will be disposed of in approved sharps containers."
10143050|NCT04170803|Sham Comparator|Sham Dry Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a blunted instrument in a needling guide tube against the skin. The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in previous studies performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants..
10143051|NCT04170712||Surgical or High Risk|Patients with confirmed diagnosis of ovarian cancer or suspicious mass or who have a family history or genetic mutation that puts them at high risk fro ovarian cancer.
10143052|NCT04170530|Experimental|mFOLFOXIRI|patients received FOLFOXIRI alone for 6 cycles before surgery.
10143053|NCT04170790|Experimental|Healthy volunteer|Day 1: Sildenafil 50 mg single dose Day 2-Day 8: Washout period Day 9-12: Saxagliptin 5 mg Once/day Day 13: Sildenafil 50 mg+ Saxagliptin 5 mg
10143054|NCT04170881||CHILDREN|Children from involved daycares (Paris region)
10143055|NCT04170881||WORKERS|workers in involved daycares (Paris region)
10143056|NCT04170829|Experimental|Group 1 (n=6)|will be administered ChAdOx1 MERS: 5 x 109 vp ChAdOx1 MERS
10143057|NCT04170829|Experimental|Group 2 (n=9)|will be administered ChAdOx1 MERS: 2.5 x 1010 vp ChAdOx1 MERS
10143058|NCT04170829|Experimental|Group 3 (n=9)|will be administered ChAdOx1 MERS: 5 x 1010 vp ChAdOx1 MERS
10143059|NCT04170634||Patients with bone metastases at risk of fracture|Adult patients with tumor osteolytic bone lesions located in proximal femur and/or vertebrae secondary to a myeloma or a breast, lung (NSCL: Non-Small Cell Lung), bladder, thyroid or kidney cancer. The target vertebrae or femur has to be naïve of localized treatment (interventional radiology - cementoplasty, cryotherapy, radiofrequency…). Previous exposure to systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) and bone treatments are allowed if administered for less than 3 months.
10143060|NCT04170426|Experimental|Phase 1 ARM 0|9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1
10143061|NCT04170426|Active Comparator|Phase 2 ARM 1|30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a
10143062|NCT04170426|Placebo Comparator|Phase 2 ARM 2|15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a
10143063|NCT04170699|Experimental|PECS 1 Block|40 patients who had PECS 1 block for peroperative analgesia in port-a-cath replacement. All patients will receive IV Midazolam (0.05mg/kg) premedication. Standard monitorization of EKG, non- invasive blood pressure and pulseoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the intervention and in the supine positon the PECS 1 block will be done. 10 % povidone - iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done as a single injection of local anaesthetic between pectoralis major and pectoralis minor muscles at the level of the 3rd rib to anaesthetise the lateral and medial pectoral nerves. The USG probe will be replaced inferior to the clavicle. Identify the pectoralis muscles with the axillary artery and axillary vein on sonography. The brachial plexus should be visible underneath. After confirmation with 20 mL %0.25 bupivacaine will be administered.
10143064|NCT04170699|Experimental|Infiltrative Anesthesia|40 patients who had port-cath replacement will receive infiltrative anesthesia.
10143065|NCT04170387|Experimental|Relaxometer fibromyalgia cases|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
10143066|NCT04170387|Active Comparator|Relaxometer controls|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
10143067|NCT04170439|Other|clomiphene plus metformin plus N acetyle cysteine|Women who will receive clomiphene citrate plus metformin plus n acetyle cysteine
10143068|NCT04170439|Other|clomiphene plus metformin plus chromium|Women who will receive clomiphene plus metformin plus chromium
10143069|NCT04170439|Other|clomiphen citrate plus metformin|Women who will receive clomiphene plus metformin
9516824|NCT03311932|Active Comparator|Cortef® Tablets - fed|Single dose of 20mg Cortef® Tablets - fed arm
9516825|NCT03311932|Experimental|Infacort® - fed|Single dose of 20mg Infacort® - fed arm
9516826|NCT03311906|Experimental|Test side|Scaling and Root Planing 0.8% Hyaluronic acid gel
9516827|NCT03311906|Active Comparator|Control Side|Scaling and Root Planing
10143070|NCT04170452||Chronic Hepatitis Delta patients|Patients infected with delta virus
10143071|NCT04170322|Experimental|thin pvc gasrtric calibration tube|thin pvc gastric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy.
10143072|NCT04170322|Active Comparator|thick silicone gastric calibration tube|thick silicone gastrric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy
10143073|NCT04170569|Experimental|Experimental Group|Yoga program was applied.
10143074|NCT04170569|No Intervention|Control Group|No yoga program.
10143075|NCT04170504|Experimental|Qing Re Huo Xue (QRHX) plus methotrexate (MTX)|QRHX XXmg bid and methotrexate (MTX) 10 mg once a week for 24 weeks
10143076|NCT04170504|Active Comparator|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)
10143077|NCT04170608|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
10143078|NCT04170335||Bariatric surgery group|Women older than age 40 and younger than age 74 undergoing primary bariatric surgery and having a BMI of ≥35 will be enrolled in this study. Pre operative and postoperative mammograms, inflammatory markers and breast cancer risk scores will be compared.
10143079|NCT04170114|Experimental|Cystic Fibrosis|Children with cystic fibrosis
10143080|NCT04170114|Experimental|Bronchiectasis|Children with bronchiectasis
10143081|NCT04170270|Experimental|oral omeprazole|oral omeprazole in bleeding peptic ulcer after endoscopic therapy 40 mg twice daily for 72 hours
10143082|NCT04170270|Active Comparator|intravenous omeprazole|intravenous omeprazole in bleeding peptic ulcer after endoscopic therapy as continuous infusion at rate of 8 mg/hour for 72 hours
10143083|NCT04170127|Experimental|Right side of the maxilla|the right side of the maxilla
10143084|NCT04170127|No Intervention|Left side of the maxilla|left side of the maxilla
10143085|NCT04170257|Experimental|Opportunistic screening cohort|This opportunistic screening cohort is constructed among patients aged 45-69 years who undergo endoscopic examinations at the endoscopy center in any of the five hospitals included in this study. Enrolled participants are requested to complete a computer aided one-on-one questionnaire regarding demographic factors, smoking and alcohol drinking status, dietary habits，digestive tract symptoms and family history of ESCC. Then experienced endoscopists will perform the upper gastrointestinal endoscopic examination for each participant, and the entire esophagus will be visually examined with the white light, NBI and iodine staining endoscopic examination.
10143086|NCT04170179|Experimental|Systemic chemotherapy plus lenvatinib and toripalimab|Systemic chemotherapy of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
10143087|NCT04170413||CeVUS Urodynamic|patients undergoing urodynamic study with CeVUS
10143088|NCT04170049|Experimental|Behavioral: The sensory stimulative activity interventions|
10143089|NCT04170166|Active Comparator|Anterolateral Approach|The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach
10143090|NCT04170166|Active Comparator|Posterior Approach|The randomised group of patients receiving the subacromial steroid injection via a posterior approach
10143091|NCT04170192||UCBT-IBD-Case|Very early onset IBD patients who underwent Cord Blood Stem Cell Transplantation.
10143092|NCT04170465|Experimental|Metformin group|Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
10143093|NCT04170465|Active Comparator|Control group|Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)
10143094|NCT04170309||With medical condition of interest|"Participants treated with ceftobiprole with at least one of the following conditions:~Renal Insufficiency~Hepatic Insufficiency~Immunosuppression"
10143095|NCT04170309||Without medical condition of interest|"Patients treated with ceftobiprole without any of the following conditions:~Renal Insufficiency~Hepatic Insufficiency~Immunosuppression"
10143096|NCT04170101|Experimental|a continuous deep NMB (group A)|after 0,6 mg/kg LBW Rocuronium for intubation Rocuronium is given in a continuous infusion starting at 1 mg/kg/h and adapted to keep PTC below 5 and note.
10143097|NCT04170101|Placebo Comparator|non deep NMB (group B)|after 0,6 mg/kg LBW Rocuronium for intubation no extra NMB is given and depth is measured by TOF/PTC to note depth.
10143098|NCT04170491|No Intervention|control|The standard medical care (Control) group will receive sequential portable EEGs, performed according to clinical demand. These patients usually have 2 recordings of 20-30 minutes each within 24 or 48 hours. The studies include baseline recoding and recording after auditory, tactile and nociceptive stimulation. The EEGs will be visually reviewed and reported within 4 hours after the recording completion by a Consultant Clinical Neurophysiologist or other doctor with equivalent qualifications.
10143099|NCT04170491|Experimental|cEEG|The treatment (cEEG) group will have cEEG applied within 12 hours of RSE diagnosis, which will continue until 24 hours after cessation of clinical and electrical seizure activity. Reactivity testing with auditory, tactile and nociceptive stimulation will be repeated at least once daily. The cEEG will be visually interpreted twice daily by a Consultant Clinical Neurophysiologist and the results will be communicated within two hours of their completion to the treating clinical team.
10143100|NCT04170036||Protein supplement group|The group of subjects who use protein supplements at least for the preceding three months
10143101|NCT04170036||Control group|The group of subjects who never used protein supplements
10143102|NCT04169984|Active Comparator|Myofunctional Therapy|This therapy consists of the practice of isotonic, isokinetic and isometric exercises that improve mobility and coordination and increase the muscular strength of the orofacial structures that contribute to the obstructive sleep apnea etiopathogenesis.
10143103|NCT04169984|Placebo Comparator|Placebo|The placebo group will be instructed in simulation exercises that do not alter the function or morphology of the upper airway.
10143104|NCT04170088|Experimental|Tranexamic acid|"Left side of face of each participant was selected for intradermal Tranexamic acid injections.~generic name : Tranexamic acid Dose : 4mg / ml tranexamc acid diluted with 0.9 % normal saline Frequency : every 2 weekly total 6 doses. Duration : 6 months"
10143105|NCT04170088|Experimental|0.9% Normal saline|Right side of face of each participant was selected for intradermal normal saline injections generic name : Normal Saline Dose : 0.9 % Normal Saline Dose : Frequency : every 2 weekly total 6 doses. Duration : 6 months
10143106|NCT04170010||Conservatively managed group|Individuals with conservatively managed obesity
10143107|NCT04170010||Surgically managed group|Individuals with a past history of bariatric surgery (Roux-en-Y gastric bypass/Sleeve gastrectomy) for the management of obesity
10143108|NCT04169945|Experimental|Ultrasonic instrumentation and Air Polishing|All participants will receive full mouth conventional ultrasonic subgingival debridement, followed by air-polishing with erythritol powder which include activating device for 5 seconds of each surface (Petersilka 2003). Subsequently, Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm. Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm
10143109|NCT04169945|Active Comparator|Ultrasonic instrumentation|All participants will receive full mouth conventional ultrasonic subgingival debridement only. No time limit (Flemmig 2012), until dental surfaces feel smooth.
10143110|NCT04169867||Healthy Volunteers|This cohort will consist of 1000 healthy volunteers from Poland.
10143111|NCT04169867||Melanoma|This cohort will consist of 160 patients with melanoma.
10143112|NCT04169711|Experimental|ARO-HIF2|
10143113|NCT04169971|Experimental|Music group|Will receive music during the operation conducted under spinal anaesthesia
10143114|NCT04169971|No Intervention|Control group|Will not receive music during the operation conducted under spinal anaesthesia
10143115|NCT04169815||ED Setting|An acute HF population enrolled at the emergency department. Testing of clinical samples will be performed with the Access natriuretic peptide assay.
10143116|NCT04169750|Experimental|Exergames|
10143117|NCT04169750|Active Comparator|Adaptive COGNI-TRAcK|
10143118|NCT04169750|Sham Comparator|Sham COGNI-TRAcK|
10143119|NCT04169854|Experimental|Lidocaine Patch|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked Lidocaine 5% patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
10143120|NCT04169854|Placebo Comparator|Placebo|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked placebo patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
10184877|NCT03751254|Experimental|Myopic patients|In myopic patients with axial length over 25.0 mm during surgery of the first eye the Stellaris platform will be used and during surgery of the second eye the Stellaris Elite platform will be used
10184878|NCT03751241|Experimental|Intraocular lens types|Patients with different types of IOLs (EROV, monofocal, minimonovision) are tested for their reading quality using the EyeTracker device
10184879|NCT03751228|Experimental|BMS-986165 taste evaluation|BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners
10184880|NCT03751215|Experimental|Monofocal IOL|Patients will be implanted with two different monofocal lenses (Clareon and AcrySof) during cataract surgery
10184881|NCT03751202|Experimental|Test product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
10184882|NCT03751202|Active Comparator|Reference product|ADVAIR DISKUS® 500/50
10184883|NCT03751176|Experimental|FOLFIRI + panitumumab|"Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
10184884|NCT03751176|Active Comparator|FOLFIRI|"Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
10184885|NCT03751163|Active Comparator|Study|Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
10184886|NCT03751163|Placebo Comparator|Control|Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
10184887|NCT03751150|No Intervention|Control|Normal training, no intervention
10184888|NCT03751150|Experimental|Intervention INT|The intervention consists of an exercise program developed by a team specialised in orthopaedics, physiotherapy and biomechanics, based on the results from a recent prospective study in Gothenburg, Sweden. The exercises included cover muscle control training for the core, abductors, quadriceps and foot pronators, as well as foamrolling for the abductors, quadriceps, hamstrings, calf muscles and gluteal muscles. The runners will be instructed to perform the training program twice a week for the entire intervention period.
10184889|NCT03751111|Experimental|Naloxone|Naloxone at an sublingual dose of 40 mg daily will be given to each subject.
10184890|NCT03751111|Placebo Comparator|Placebo|Sublingual placebo will be given to each subject.
10184891|NCT03751085|Experimental|AW frame|AW frame biopsy
10184892|NCT03751072||Relapse/Refractory|
10184893|NCT03751072||MRD positive|
10187768|NCT03722823|Experimental|Group 4: Severe Hepatic Impairment|Subjects with Severe hepatic impairment (Child-Pugh Class C, score of 10 to 14)
10187769|NCT03722771|Experimental|lavender oil group (A)|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to surgery.~Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)"
10187770|NCT03722771|Sham Comparator|control group (B)|No application of lavender oil, prior to surgery. Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)
10187771|NCT03722758|Active Comparator|Spectrum TPH3, tooth restoration|Restoration with micro hybrid resin composite
10143121|NCT04169685||with dexmedetomidine|Drugs provided moderate sedation during procedure including dexmedetomidine
10143122|NCT04169685||without dexmedetomidine|Drugs provided moderate sedation during procedure without dexmedetomidine
10143123|NCT04169841|Experimental|GUIDE2REPAIR patients|olaparib + immunotherapy (durvalumab + tremelimumab) during 4 months followed by durvalumab alone as maintenance in patients with solid cancer and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.
10143124|NCT04169893|Placebo Comparator|Arm Title: Placebo (fasting)|fasting
10143125|NCT04169893|Placebo Comparator|Placebo (feeding)|after meal
10143126|NCT04169893|Experimental|TS-142, 1 mg|fasting
10143127|NCT04169893|Experimental|TS-142, 3 mg|fasting
10143128|NCT04169893|Experimental|TS-142, 10 mg (fasting)|fasting
10143129|NCT04169893|Experimental|TS-142, 10 mg (feeding)|after meal
10143130|NCT04169893|Experimental|TS-142, 30 mg|fasting
10143131|NCT04169724|Experimental|Calm|Participants will be asked to download the Calm app on their smartphone. Participants will then receive an email containing login credentials to access the Calm app. Once they receive this email and they receive their study start date, they will be asked to meditate for at least 10 minutes a day for 8 weeks. This prescription mimics how a new, paying member would use the app. Participants in the intervention group will be emailed weekly reminders.
10143132|NCT04169724|No Intervention|Waitlist|Participants randomized to the control group will be asked to maintain their normal routine for 8 weeks and to avoid using the Calm meditation app.
10143133|NCT04169932|Experimental|CD20 CAR-T|
10143134|NCT04169919|Active Comparator|Modified method|Povidone Iodine
10143135|NCT04169919|Active Comparator|Ordinary method|normal saline
10143136|NCT04169997|Experimental|IMP4297|The starting dose is 100mg QD
10143137|NCT04169997|Placebo Comparator|Placebos|The starting dose is 100mg QD
10143138|NCT04169802||Normal subjects|Age ≥ 50 years, Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye.
10143139|NCT04169802||Subjects with neovascular AMD|Age ≥ 50 years, History of neovascular age-related macular degeneration, in the study eye, Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye.
10143140|NCT04169906|Placebo Comparator|Placebo|
10143141|NCT04169906|Experimental|TS-142 10 mg|
10143142|NCT04169906|Experimental|TS-142 20 mg|
10143143|NCT04169906|Experimental|TS-142 30 mg|
10143144|NCT04169776|Experimental|Steroid Sensitive Frequently-Relapsing Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid sensitive frequently relapsing idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and the level of proteinuria before and while using taVNS therapy.
10143145|NCT04169776|Experimental|Steroid Resistant Idiopathic Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
10143146|NCT04169620|Experimental|variable aquatic Ai Chi|"The 15 patients assigned to the aquatic therapy group (experimental group) received 20 twice-weekly sessions in total, during the same period of time as the control group. These 20 sessions consisted of group sessions lasting 45-minutes.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
10143147|NCT04169620|Placebo Comparator|variable dry land|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
10143148|NCT04169646|Other|Intervention|Multi-component intervention
10143149|NCT04169646|Other|Control|Control
10143150|NCT04169659|Experimental|Kyphoplasty with Titanium spheres|Patients treated with kyphoplasty with baloons and insertion of titanium microspheres inside the body vertebra.
10143151|NCT04169659|Active Comparator|Kyphoplasty with Polymethylmethacrilate|Patients treated with Kyphoplasty with baloons and insertion of Polymethylmetacrylate inside the body vertebra.
10143152|NCT04169880|Experimental|HILT Group|HILT Group (n=15)
10143153|NCT04169880|Experimental|HILT & EXERCISE Group|HILT&Exercise Group (n=15)
10143154|NCT04169789|Active Comparator|L. reuteri Low Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E8 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total dose of either 1x10E9 L.reuteri CFU and 400 IU of cholecalciferol per day.
10143155|NCT04169789|Active Comparator|L. reuteri High Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day.
10143156|NCT04169789|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 24 months.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day.
10184894|NCT03751059|Active Comparator|NSAID|Bromfenac 0.07% Oph Susp: used from one week post-op to three months post-op
10184895|NCT03751059|Active Comparator|Steroid|Dexamethasone: used from one week post-op to three months post-op
10143157|NCT04169607|Experimental|individualized PEEP|"Basic ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.~Randomization: Subsequently patient was randomized, the PEEP was then maintained (individualized PEEP arm) until extubation.~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
10143158|NCT04169607|Active Comparator|PEEP 8|"Bacis ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.~Randomization: Subsequently patient was randomized , the PEEP was then reduced to 8cm H2O (PEEP8 arm) until extubation.~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
10143159|NCT04169672|Experimental|Surufatinib & Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
10143160|NCT04169672|Experimental|Surufatinib|Surufatinib 300mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
10143161|NCT04169295|Experimental|Intervention group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's, and couple's personalized IVF-prognosis
10143162|NCT04169295|Sham Comparator|Control group|At the time of their fresh embryo transfer couples will receive a document with a photo of their transferred embryo(s) and the number of cryopreserved embryos.
10143163|NCT04169308|Experimental|Experimental: Restylane-L® Filler injection|
10143164|NCT04169399|Experimental|Toripalimab plus SBRT|Participants received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Participants recevied Stereotactic body radiotherapy. Radiotherapy dose was 36 ~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
10143165|NCT04169568||OI manuel cuff BP|Patients with diagnosis of Osteogenesis Imperfecta from ages 1 to 35 who are admitted to our institution to the inpatient, non-ICU setting, following orthopedic surgery for lower extremity realignment and IM rodding
10143166|NCT04169763|Experimental|Treatment (nelfinavir, cisplatin, EBRT)|Patients receive nelfinavir PO BID for up to 8 weeks. Starting week 2, patients also receive cisplatin IV over 60-90 minutes once weekly during weeks 2-8. Patients undergo EBRT for 5 consecutive days between weeks 2-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
10143167|NCT04169412||Resuscitation Failure, High PCO Level, High RIPK3 Level|"Resuscitation failure was defined as lactate level ≥2 mmol/L or lactate reduction <20% hour-4 after initial sepsis recognition.~High PCO level was defined as PCO level ≥ cut off point.~High RIPK3 level was defined as PCO level ≥ cut off point."
10143168|NCT04169412||Resuscitation Success, Low PCO Level, Low RIPK3 Level|"Resuscitation success was defined as lactate level <2 mmol/L or lactate reduction ≥20% hour-4 after initial sepsis recognition.~Low PCO level was defined as PCO level < cut off point.~Low RIPK3 level was defined as PCO level < cut off point."
10143169|NCT04169256|Experimental|HYR-PB21 & Placebo|
10143170|NCT04169256|Active Comparator|Liposome Bupivacaine & Placebo|
10143171|NCT04169425||Group 1|patients who underwent to laparoscopic TME, with elective diverting ileostomy for rectal cancer
10143172|NCT04169425||Group 2|patients who underwent to laparoscopic TME, without elective diverting ileostomy for rectal cancer
10143173|NCT04169386|Experimental|AK102 75mg|AK102 75mg
10143174|NCT04169386|Experimental|AK102 150mg|AK102 150mg
10143175|NCT04169386|Experimental|AK102 300mg|AK102 300mg
10143176|NCT04169386|Experimental|AK102 500mg|AK102 500mg
10143177|NCT04169386|Placebo Comparator|Placebo|Matching placebo
10143178|NCT04169347|Other|Active|This is an open label study single arm
10143179|NCT04169178|Experimental|HLX55, dose finding stage, advanced solid tumor|Participants will receive HLX55 at assign dose level, e.g. 2.5, 5, 15 and 25 mg/kg every three weeks followed by a 21-day DLT observation period.
9827479|NCT02457325|Experimental|Surgery With 4%Articaine first, then Surgery With 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
10143180|NCT04169178|Experimental|HLX55, dose expansion stage, gastric cancer|Participants diagnosed with gastric cancer with will receive HLX55 in recommended phase 2 dose (RP2D) every three weeks.
9516828|NCT03311893|Active Comparator|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
9827480|NCT02457403|Experimental|ROTEM|Transfusion guided by ROTEM during OLT
10143181|NCT04169178|Experimental|HLX55, dose expansion stage, NSCLC|Participants diagnosed with non-small cell lung cancer (NSCLC) with will receive HLX55 in RP2D every three weeks.
10143182|NCT04169178|Experimental|HLX55, dose expansion stage, colorectal cancer|Participants diagnosed with colorectal cancer (CRC) with will receive HLX55 in RP2D every three weeks.
10143183|NCT04169178|Experimental|HLX55, dose expansion stage, other solid cancer|Participants diagnosed with other solid cancer with will receive HLX55 in RP2D every three weeks.
10143184|NCT04169334|No Intervention|Control group|Group receiving care as usual
10143185|NCT04169334|Experimental|Intervention group|Intervention group receiving a standardized preventive program (5 days at the Obstetric department)
10143186|NCT04169217|No Intervention|Control arm|This arm will not be in the prehabilitation group- as is current standard practice
10143187|NCT04169217|Active Comparator|Group 2|This arm will be subject to a one off prehabilitation workshop and provided with a prehab booklet
10143188|NCT04169217|Experimental|Group 3- Mentored group|This arm will be subject to a one off workshop and provided with a prehab booklet- and additional mentoring by means of 1. an educational app, 2. push notifications,3. weekly communication with physiotherapy team member.
10143189|NCT04169321|Experimental|Single Arm|All participants will receive a mass dose of 40 μg or less of [68Ga]-NOTA-hGZP (radioactivity dose of 3 mCi to 15 mCi) and have a PET scan.
9970329|NCT01299155|Active Comparator|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) Model
9970330|NCT01299168||Kidney Transplant Biopsies for Cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).
9970331|NCT01299181|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
10143190|NCT04169282|Experimental|nPEP Recipients|Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration
10143191|NCT04169126|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
10143192|NCT04169360|Experimental|ANS-6637|ANS-6637 600mg once daily for 12 weeks
10143193|NCT04169360|Placebo Comparator|Placebo arm|Placebo 600 mg once daily for 12 weeks
10143194|NCT04169087||General anesthesia|Patients undergoing general anesthesia
10143195|NCT04169464|Other|group I|A group of HCV infected patients treated with DAA therapy including Sofospovir
10143196|NCT04169555|Experimental|Ultrasound|
10143197|NCT04169555|Other|Standard care|
10143198|NCT04169230|Experimental|Citalopram|Single acute oral dose 20 mg Citalopram (tablet encapsulated in opaque capsule)
10143199|NCT04169230|Placebo Comparator|Placebo|Single acute oral dose Lactose Placebo (tablet encapsulated in opaque capsule)
10143200|NCT04169269|Active Comparator|Enoxaparin|enoxaparin injectable, 40 milligram subcutaneous injection daily for 20 days
10143201|NCT04169269|Active Comparator|Rivaroxaban|rivaroxaban oral 10 milligram tablet daily for 20 days
10143202|NCT04169139|Active Comparator|MIST - minimally invasive surgical therapy|"Beginning with the papilla preservation technique (Takei et al), further improved by Cortellini et al (1995) and combined with minimally invasive approaches (Harrel et al 1995), MIST, using minimally invasive surgical approaches and micro-surgery instruments, has evolved into a decision tree guideline for treating periodontitis based on periodontal pocket morphology and papilla width/ interdental space (Cortellini P, Tonetti MS (2007) J Clin Periodontol;34(1):87-93)."
10143203|NCT04169139|Experimental|REPaiR - laser periodontal therapy|The REPaiR regimen is a step-by-step protocol for using the Waterlase Express Er,Cr:YSGG laser for periodontitis. The protocol steps and associated laser delivery is controlled by a computer interface that dictates laser tip, energy and associated air and water mixes. Like MIST, REPaiR uses a set, decision tree approach for periodontal therapy, with prescribed steps and laser settings to quantify and standardize treatment. Potential clinical benefit, as with MIST, are not only effective periodontal therapy with reduced recession compared with traditional surgical approaches, but also reduced patient morbidity (Arnabat-Domínguez et al (2010). Lasers Med Sci;25(3):459-64).
10143204|NCT04168996|Experimental|rib fracture patients group|Individualized discharge planning in rib fracture patients with different severity of lung injury
10143205|NCT04168996|No Intervention|Control group|Patients included in control group received standard conservative treatment during hospitalization
10143206|NCT04168931|Experimental|Interventional|Use of trastuzumab combination chemotherapy in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue but positive in CTC.
10143207|NCT04168749||local compounding group|the first 100 preterm babies born as from January 1 2015 with a birth weight between 1250-2000g that received at least 10 days of TPN.
10143208|NCT04168749||Numeta G13 group|the first 100 preterm babies as from January 1 2017 with a birth weight between 1250-2000g that received at least 10 days of TPN
10143209|NCT04169152||Internal hemorrhoids and rectal prolapse|Participants were treated with Cap-assisted endoscopic sclerotherapy (CAES).
10143210|NCT04168697|Experimental|Controls|Control subjects undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
10143211|NCT04168697|Experimental|BAD|Patients with bipolar affective disorder (BAD) undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
10187772|NCT03722758|Active Comparator|Riva LC, restorative material|Restoration with resin-modified glass ionomer cement
9970332|NCT01299181|Placebo Comparator|Placebo|Placebo
9970333|NCT01299194|Active Comparator|ATORVASTATIN|Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
9970334|NCT01299194|Placebo Comparator|PLACEBO|Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily
9970335|NCT01299207||CAD treated with Xience stents|Patients with CAD who undergo successful stenting with the Xience drug-eluting stent will represent the patient population.
9970336|NCT01299233||control group|age matched healthy controls
9970337|NCT01299233||Glaucoma|patients with diagnosis of primary open angle glaucoma
9970338|NCT01299246|Experimental|improving self-care|
9970339|NCT01299259|Experimental|Text Message Reminders|Subjects randomized to the the intervention group will receive a total of 4 text messages on days 2 through 5 to remind them to schedule and attend a PCP follow-up appointment
9970340|NCT01299259|No Intervention|Control Group|The control group will not receive any additional reminders to follow-up with PCP.
9970341|NCT01299298|Experimental|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
9970342|NCT01299298|Placebo Comparator|placebo|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
10143212|NCT04168840||Patient undergoing general anesthesia with intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway
10143213|NCT04168879|Active Comparator|bupivacaine group|
10143214|NCT04168879|Placebo Comparator|saline group|
10143215|NCT04169035|Experimental|Odon device|The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assiste vaginal birth. Odon trained practitioner available to assist the birth.
10143216|NCT04169035|Active Comparator|Forceps or ventouse|"The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assisted vaginal birth.~The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth."
10143217|NCT04169048|Experimental|Intervention group (BPD)|Participants (N=60) receive the weekly conducted intervention (group training for mothers with BPD) over the period of 12 weeks (12 sessions). Assessments of each participant: T0 (pre-intervention), T1 (post-intervention) and follow-up (6 months after T1).
10143218|NCT04169048|No Intervention|waiting control group (BPD)|Members of this group (N=60) receive no intervention but treatment as usual (TAU). After completing all assessment points (T0, T1, T2), they can receive the intervention of the intervention group (group training).
10143219|NCT04169048|No Intervention|clinical control group (AD/MDD)|Mothers with anxiety and/or depression (N=60) receive no intervention. Assessment point only T0.
10143220|NCT04169048|No Intervention|healthy control group|Mothers with no actual mental disorder (N=60) receive no intervention.# Assessment points T0, T1, T2.
10143221|NCT04168905|Experimental|Active arm|After receiving standard treatment and AOTI Inc. TWO2 topical oxygen therapy equipment training, patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
10143222|NCT04168905|Placebo Comparator|Controlled arm|patients receive standard treatment.
10143223|NCT04168944|Experimental|lenvatinib group|Participants are given the same anti-rejection therapy as the control group after liver transplantation. 1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mgor 12 mg orally once a day. The initial dose was 8 mgor 12 mg orally once a day.
10143224|NCT04168944|Placebo Comparator|Placebo group|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
10143225|NCT04168814||Oncology patients (Immunotherapy alone or in combination))|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: PD1, PDL1 inhibitors. At least 12 weeks of treatment."
10143226|NCT04168814||Oncology Patients (Chemo-Radiotherapy group).|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).~Patients under active treatment either in combination with chemotherapy or radiotherapy. At least 12 weeks of treatment."
10143227|NCT04168970||PSGB group|MD will perform PSGB using Lidocaine. The PGSB will be performed after the administration of the 4th shock if the 3rd shock was unsuccessful in restoring a stable perfusing rhythm, considering all the shocks administered both by an AED or by manual defibrillator. PSGB will be performed after all the actions provided in the ACLS algorithm and which are considered useful in the clinical situation (intubation and ventilation, administration of iv/io adrenaline, amiodarone or lidocaine, use of mechanical chest compression, etc.).
10143228|NCT04168970||Control group|Historical cohort of patients with the same OHCA characteristics (first shockable rhythm and who received more than 4 shocks) enrolled in the Cardiac Arrest Registry of the Province of Pavia
10143229|NCT04168918|Experimental|Group Psychological Intervention|One topic will be discussed at each of the six sessions using some principles from cognitive behavioral therapy and psychoeducation.
10143230|NCT04168918|No Intervention|Treatment-as-usual|Participants will receive their usual care which involves being seen by a mental health professional (psychologist, psychiatrist/resident in psychiatry, or mental health nurse).
10143231|NCT04168658|Experimental|Physical activity and education intervention|
10143232|NCT04168658|Active Comparator|Education intervention|
10143233|NCT04168762|Experimental|TUMS and Sham Group|During the subjects two visits they will receive a TUMS stimulation and a sham (placebo) stimulation at both visits.
10143234|NCT04168762|Experimental|TUMS or Sham Group|During the subjects first of two visits they will receive either a TUMS stimulation or a sham (placebo) stimulation and at the second visit they will receive the other.
10143235|NCT04168827||Relatives of severe traumatized child|Relatives of a child who has been hospitalized in intensive care of Necker hospital following a severe trauma
9970343|NCT01299311|No Intervention|Inactivity|4 days of inactivity, mainly sitting
10143236|NCT04168723|Experimental|Group A-MD1003|Group A=32 subjects Placebo for MD1003 on Day -1. Daily dose of 1200 mg of MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Day 9
10143237|NCT04168723|Active Comparator|Group B-Moxifloxacin|"Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.~Subgroup B1: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Moxifloxacin 400 mg on Day 1 and Placebo for moxifloxacin on Day 9 Subgroup B2: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Moxifloxacin 400 mg on Day 9"
10143238|NCT04168671|Other|Asthma|Asthma and symptomatic during exercise
10143239|NCT04168671|Other|Severe asthma|Severe asthma and symptomatic during exercise
10143240|NCT04168801|Experimental|Early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, if he did not have them, then receives diet indicated between 16 and 24 hours after admission.
9970344|NCT01299311|Active Comparator|NEAT|4 days of NEAT (everyday activities)
9970345|NCT01299311|Active Comparator|Exercise|4 days of inactivity combined with 1 hour of exercise
10143241|NCT04168801|Active Comparator|Usual oral refeeding|usual oral refeeding (UOR) Once the attending physician decided according to his clinical judgment to restart the oral feeding
10143242|NCT04168645|Experimental|Presence of SUD with CBT|Patients diagnosed with SUD who are randomly assigned to receive CBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
10143243|NCT04168645|No Intervention|Presence of SUD with TAU|Patients diagnosed with SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
10143244|NCT04168645|Experimental|Absence of SUD with CBT|Patients without SUD who are randomly assigned to receive CBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
9970346|NCT01299324|Experimental|BMAC Infusion|Infusion of autologous bone marrow aspirate concentrated nucleated sells into the coronary sinus
9970347|NCT01299324|No Intervention|Control|Standard of care only. No infusion
10143245|NCT04168645|No Intervention|Absence of SUD with TAU|Patients without SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
10143246|NCT04168853|Other|Roller pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Maquet® for the roller pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
10143247|NCT04168853|Other|Centrifugal pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Sorin® for the centrifugal pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
10143248|NCT04168866|Experimental|Surgery|Patients who choose operations will have surgery performed to remove the appendix laparoscopically, through 3 or 4 small incisions. All patients in the operative group will receive standard perioperative antibiotics. They will also have the abscess(es) drained during the same surgery if there is one present. In some cases, the operation may be too difficult to perform laparoscopically, so an open appendectomy will be performed, involving a longer incision to remove the appendix. In some cases, both laparoscopic and open are performed. The surgeon may also choose to remove a section of the intestine with the appendix or perform additional procedures.
10143249|NCT04168866|Active Comparator|Non-operative management|If a patient chooses non-operative management and if an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
10143250|NCT04168788|Other|Nephrobalstoma or ALL|Pateints treated for a nephrobalstoma or ALL in childhood or adolescence
10143251|NCT04169022|Experimental|AML patients at diagnosis|AML patients at diagnosis (except AML3)
10143252|NCT04169022|Experimental|AML patients at relapse|AML patients at relapse after chemotherapy, targeted therapy or allograft
10143253|NCT04168619||Transient elastography (TE)|All patients who had MTX taken
10143254|NCT04168619||Two dimensional shear wave elastography (2D SWE)|For patients who has cumulative more than 3.5g methotrexate
10143255|NCT04168619||Liver biopsy|For patients who has cumulative more than 3.5g methotrexate and had 2D SWE done
10143256|NCT04168515||Patient|
10143257|NCT04168515||Caregiver|
10143258|NCT04168515||Healthcare provider|
10143259|NCT04168450|Other|WiSAT Passive|This arm is composed of participants who meet their activity threshold over the 4-week period.
10143260|NCT04168450|Other|WiSAT Active|This arm is composed of participants who do not meet their activity threshold over the 4-week period.
10143261|NCT04168554||Phase 1 and Phase 2|"20 patients studied in the emergency room with a pediatrician not presen in the ER performing the telemedicine examination from a distance (ie an office down the hall) followed directly by a face-to-face~20 patients included in the general practitioners office, telemedicine is performed from within the hospital to the GPs office.~Patient is then still referred to the hospital in order to check whether the telemedicine and face-to-face examination are somewhat similarce physical examination"
10143262|NCT04168359|Experimental|Semi-barbed Sutures Localization Group|Patients with pulmonary nodules requiring CT-guided puncture positioning before thoracoscopic surgery
10143263|NCT04168463|Experimental|Immediate Intervention|This cluster of four homes will receive robot animals immediately at commencement of the eight month trial.
10143264|NCT04168463|Other|Delayed Intervention|This cluster of four homes will receive robot animals four months after commencement of the 8 month trial. The four months without robots will serve as a control period.
10143265|NCT04168541|Active Comparator|Oral Nutrition Supplement A|Product containing calories from carbohydrate, protein, and fat
10143266|NCT04168541|Active Comparator|Oral Nutrition Supplement B|Product containing calories from carbohydrate, protein, and fat
10143267|NCT04168541|Active Comparator|Oral Nutrition Supplement C|Product containing calories from carbohydrate, protein, and fat
10143268|NCT04168541|Active Comparator|Oral Nutrition Supplement D|Product containing calories from carbohydrate, protein, and fat
10143269|NCT04168541|Active Comparator|Oral Nutrition Supplement E|Product containing calories from carbohydrate, protein, and fat
9970348|NCT01299337||placebo|Subjects will be randomized either receiving T3 or placebo.
10143270|NCT04168541|Active Comparator|Oral Nutrition Supplement F|Product containing calories from carbohydrate, protein, and fat
10143271|NCT04168489|Active Comparator|active rTMS|
10143272|NCT04168489|Sham Comparator|sham rTMS|
10143273|NCT04168398|Experimental|Plavix 75mg and juspirin 81 mg therapy|Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.
10143274|NCT04168398|Experimental|Eliquis 2.5mg and juspirin 81 mg therapy):|Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin (juspirin) 81 mg.
10143275|NCT04168476|Experimental|Treatment group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:~Visual Analogue Scale~Range of movement~Hand grip strength. After a first assessment, scapula mobilization techniques were performed and participants reassessed."
10143276|NCT04168476|Placebo Comparator|Control group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:~Visual Analogue Scale~Range of movement~Hand grip strength. The procedure was a contralateral calcaneus abduction and adduction mobilization technique was carried out."
10143277|NCT04168593|Sham Comparator|A- Placebo|Sham Acupuncture and Sham Cupping
10143278|NCT04168593|Active Comparator|B -Cupping|Sham Acupuncture and Real Cupping
10143279|NCT04168593|Active Comparator|C - Acupuncture|Real Acupuncture and Sham Cupping
10143280|NCT04168593|Active Comparator|D - Acupuncture + Cupping|Real Acupuncture and Real Cupping
10143281|NCT04168281|Experimental|PCI- free after response to radical chemoradiotherapy|Patients with no metastases will be followed-up with MRI: at the qualifying visit before MRI-1, and then every 6 months +/- 2 weeks), the patients will have a cognitive examination performed using dedicated neuropsychological tests and QoL assessment using the QLQ-C30 questionnaire. The tests will be conducted in the following order: California verbal learning test (CVLT) with a delay of 15 min, Color connection test (CTT), CVLT (after delay), Benton visual memory test (BNRT), Verbal fluency test by the certified psychologist.
10143282|NCT04168164|Experimental|Ai Chi|Ai Chi aquatic therapy Dry land therapy
10143283|NCT04168203|Experimental|Extended Duration Thromboprophylaxis|apixaban 2.5 mg orally twice daily for a duration of 12 months
10143284|NCT04168203|Placebo Comparator|Control|oral placebo for a duration of 12 months
10143285|NCT04168177|Active Comparator|control group|
10143286|NCT04168177|Active Comparator|ESP Group|
10143287|NCT04168294||sedation group|Patients undergo sedative esophagogastroduodenoscopy (EGD) and are intravenous injected propofol in bolus
10143288|NCT04168294||control group|patients undergo conventional EGD
10143289|NCT04168086|Experimental|Right Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to motor area of the right cerebellum prior to completing a motor learning task.
10143290|NCT04168086|Experimental|Non-Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to a non-motor area of the right cerebellum prior to completing a motor learning task.
10143291|NCT04168086|Sham Comparator|Control|Participants will have the Focused Ultrasound transducer placed on their neck without stimulation as a Sham present prior to completing a motor learning task.
10143292|NCT04168190|Experimental|Phase 1: pPCV-1|Single intramuscular (IM) 0.5 mL vaccination on Day 1
10143293|NCT04168190|Experimental|Phase 1: pPCV-2|Single IM 1.0 mL vaccination on Day 1
10143294|NCT04168190|Active Comparator|Phase 1: Pneumovax™23|Single IM 0.5 mL vaccination on Day 1
10143295|NCT04168190|Experimental|Phase 2: pPCV|Single IM vaccination on Day 1 at dose to be determined.
10143296|NCT04168190|Active Comparator|Phase 2: Pneumovax™23|Single IM 0.5 mL vaccination on Day 1
10143297|NCT04168437|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report.
10143298|NCT04168437|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report following completion of the study.
10143299|NCT04168307|Experimental|Ankle trainer device|The patients were instructed in the use of a new spring loaded ankle trainer
10143300|NCT04168307|Active Comparator|Conventional physiotherapy|The patients were instructed in passive stretching exercises by the use of a non-elastic band
10143301|NCT04168047|Other|Healthy volunteers|
10143302|NCT04168047|Other|Patients with insomnia|
10143303|NCT04168047|Other|Patients with irritable bowel syndrome|
10143304|NCT04168047|Experimental|Patients with irritable bowel syndrome and insomnia|
10143305|NCT04168151|Experimental|hypoxic group|hypoxic patients (hypoxic index less than 250)
10143306|NCT04168138|Experimental|Newly diagnosed AML in elderly patient|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when WBC>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
10143307|NCT04168229|Experimental|ITE Hearing Aid|The subjects will wear the ITE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
10143308|NCT04168229|Active Comparator|BTE Hearing Aid|The subjects will wear the BTE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
9516829|NCT03311893|Placebo Comparator|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
9516830|NCT03311880|Experimental|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
9516831|NCT03311867|Active Comparator|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
9516832|NCT03311867|Active Comparator|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
10143309|NCT04168255|Other|Retinal detachment|Retinal detachment with proliferative vitreoretinopathy and inferior breaks
10143310|NCT04168411|Experimental|Symptomatic treatment group|The patients were allocated to wear a double layered elasticated bandage for treatment 5th metatarsal base fractures (Zone 1).
10143311|NCT04168411|Active Comparator|Cast group|The patients were given a below-knee cast for treatment 5th metatarsal base fractures (Zone 1).
10143312|NCT04168346|Experimental|Intervention|IV-iron substitution: The intravenous iron formulation used in the study is ferric carboxymaltose and it will be administered two to four weeks before the surgery, aiming at four weeks. The dose of intravenous iron will be calculated according to the weight and haemoglobin level of the patients, however so that all the patients receive minimum 1000mg iv iron and the maximum dose is 20 mg/kg per day.
10143313|NCT04168346|Placebo Comparator|Placebo|Placebo is NaCl 0.9% solution, which is administrated in the same way as the study drug
10143314|NCT04168099|Experimental|Cefotaxime|Cefotaxime intravenous
10143315|NCT04168099|Active Comparator|Gemifloxacin|Oral Gemifloxacin
10143316|NCT04167878|Experimental|ACDF with 3D printed biodegradable cervical fusion cage|A resorbable cervical interbody cage made of PCL-TCP.
10143317|NCT04167878|Active Comparator|ACDF with PEEK cage|A structural PEEK cage with autologous bone.
10184896|NCT03751046|Experimental|Intervention group. Trial-Based Cognitive Therapy|Participants with therapeutic failure. Fourteen sessions of psychotherapy in group format, using Trial-Based Cognitive Therapy. Frequency: Bi-weekly meetings for seven months. Intervention arm comprises 10 psychotherapy groups with five participants in each group.
10184897|NCT03751046|Experimental|Control group. Standard healthcare.|Participants with therapeutic failure, receiving standard healthcare in the HIV/AIDS Program, which includes at least half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each). The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV.
10184898|NCT03751033|Experimental|BSS and DisCoVisc|Following lens removal and removal of all OVD from the anterior chamber during cataract surgery, the chamber will be filled with BSS and the main incision hydrated with BSS. Intraoperative aberrometry, using the Optiwave® Refractive Analysis with VerifEye+ (ORA), will be performed, and the results of aphakic refraction and suggested IOL power will be recorded in triplicate. Immediately following, the BSS will be replaced with DisCoVisc; and, triplicate readings will be measured under the same conditions.
10184899|NCT03750942|Experimental|Adhesix® monofilament polypropylene mesh (Bard Davol) group|The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
10184900|NCT03750942|No Intervention|Control group|The control group will not receive a mesh and the stoma will be created according local protocol.
10184901|NCT03750929|No Intervention|Non physical exercises|Patients will not be submmitted to combined acute physical exercises (strength and aerobic)
10184902|NCT03750929|Experimental|Physical exercises|Patients will be submmitted to combined acute physical exercises (strength and aerobic) that consist on: supine, paddling, leg press 45º, knee extensor, flexor knee (two sets of 15 to 20 repetitions, with loads between 30% and 40% of a maximum repetition, with 30 seconds of interval). We will perform in the first exercise for upper and lower limbs, for heating, after starting the training where 4 series of 8 to 12 maximum repetitions will be performed, using the load between 70% and 80% of 1 maximum repetitions, already evaluated. The recovery between sets will be 90 seconds and between exercises will be 120 seconds.
10184903|NCT03750916|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1) Drug: Anlotinib Hydrochloride plus Docetaxel
10184904|NCT03750864|Experimental|ACT-LCS Therapy|Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
10184905|NCT03750851|Placebo Comparator|GPlacebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
10184906|NCT03750851|Experimental|GCPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
10184907|NCT03750851|Experimental|GLaser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
10184908|NCT03750851|Experimental|GLaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
10184909|NCT03750838|Experimental|Text Messaging Intervention Group|Participants in the TM Intervention condition will be provided a predetermined number of messages per week (based partially on responses from Phase 2 focus group) for 6 weeks delivered on Thursdays, Fridays, and Saturdays, which are the most common days of the week that heavy drinking occurs as well as other days and times that focus group participants indicated would be the most helpful.
10184910|NCT03750838|Active Comparator|Active Control|Participants in the attention only control condition will receive a series of TM based on nutritional data on the same schedule as those in the TM intervention and will complete a 6 week post-intervention assessment as well as all follow-ups.
10184911|NCT03750812|Active Comparator|Highly fit older adults - Exercise|This will receive an aerobic exercise intervention
9827481|NCT02457403|Active Comparator|Conventional|Transfusion guided by conventional labs
10143318|NCT04168125|Experimental|Tilapia skin|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a tilapia skin as an occlusive biological dressing for palatal wound healing.~Device: Tilapia skin. A xenogeneic collagen dressing will be placed over palate wound and stabilized with sutures during the healing process."
10143319|NCT04168125|Active Comparator|Surgical Wound Dressing|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a surgical wound dressing as a mechanical protection during palatal wound healing.~Device: Surgical wound dressing A surgical wound dressing will be placed over palate wound during the healing process to provide mechanical protection."
9669348|NCT02877134|Experimental|Part II : JNJ-64304500 Middle Dose|"JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 middle dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
9827482|NCT02457520|Experimental|Single treatment arm|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
9827483|NCT02457546|Experimental|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
10143320|NCT04167774|Experimental|Camrelizumab +nb-Paclitaxel|Participants receive Camrelizumab 200mg(3mg/kg for underweight patients) iv and nb-Paclitaxel 260mg/m2 iv every 3 weeks until disease progression or unacceptable toxicity
10143321|NCT04168021|No Intervention|Group 90 individuals, baseline assessment before intervention|Baseline Cognitive status assessment
10143322|NCT04168021|Experimental|Remote ischemic condition of the brain|Intermittent claudication induction on a daily basis for 1 month
10143323|NCT04168021|No Intervention|Late cognitive assessment|Late cognitive status assessment 6 months later
10143324|NCT04168333|Active Comparator|T101 Group|"The study will consist of 2 cohorts:~Single Dose (SD) Cohort:~9 chronic hepatitis B patients will be enrolled and be divided into 3 groups, with 3 patients in each group.~Multiple Dose (MD) Cohort:~18 chronic hepatitis B patients will be enrolled and be divided into 2 groups, with 9 patients in each group."
10143325|NCT04168333|Placebo Comparator|Placebo Group|"The study will consist of 2 cohorts:~Single Dose (SD) Cohort:~3 chronic hepatitis B patients will be enrolled in this group.~Multiple Dose (MD) Cohort:~6 chronic hepatitis B patients will be enrolled in this group."
10143326|NCT04167852|Experimental|Treatment group|Subject to receive daily short message service (SMS) text message with a link to a mindfulness intervention.
10143327|NCT04167852|Experimental|Text group|Subject to receive daily text message but without the link to the mindfulness intervention.
10143328|NCT04167852|No Intervention|Standard of Care group|Subject will not receive any text message reminders or the mindfulness meditation intervention.
10143329|NCT04167995|Active Comparator|Patient with attention deficit hyperactive disorser|patients (n=40) will receive probiotic preparation once daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
10143330|NCT04167995|No Intervention|ADHD not receiving probiotics|ADHD patient (40) not receiving probiotics
10143331|NCT04167735|Active Comparator|Hearing Aid without Reverberation Canceller (no_RevC)|Hearing Aid without Reverberation Canceller (RevC)
10143332|NCT04167735|Experimental|: Hearing Aid Reverberation Canceller enabled (RevC_1)|Hearing Aid Reverberation Canceller enabled (RevC_1)
10143333|NCT04167800|No Intervention|Control group|All patients will be instructed to wear the device for 23 weeks for 12 weeks after being instructed on how to use the appropriate compression orthosis. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
10143334|NCT04167800|Active Comparator|Exercise Group|In addition to the applications to the first group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PC. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
10143335|NCT04167865|No Intervention|Control group|All patients will be instructed to wear the device for 1 hours for 12 weeks after being instructed on how to use the vacuum bell. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
10143336|NCT04167865|Active Comparator|Exercise Group|In addition to the applications to the control group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PE. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
10143337|NCT04167631|Other|Multiparametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) using multi-parametric MRI.
10143338|NCT04167982|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid(ALA) cream for 30min. A repeat treatment was administered once weekly for a maximum of 5 times. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and after treatment.
10143339|NCT04167982|Active Comparator|conventional-dose isotretinoin group|Patients in the conventional-dose isotretinoin group were given oral isotretinoin 0.5 mg/kg daily for 6 months, and the cumulative dose was 90 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
10143340|NCT04167982|Active Comparator|low-dose isotretinoin group|Patients in the low-dose isotretinoin group were given oral isotretinoin 0.2 mg/kg daily for 6 months, and the cumulative dose was 36 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
10143341|NCT04167605||Breast cancer metastatic to bone|No direct intervention(s) will be administer to the patients. We will use the sample (slides) recovered from the surgery on primary tumor (breast cancer responsible for metastatic disease).
10143342|NCT04167605||Bone metastasis|No direct intervention(s) will be administer to the patients. Waste material will be analysed for the expression of specific proteins
10143343|NCT04167709|Experimental|Allocated CHS nurses|Primary and secondary baseline data are collected from the allocated CHS nurses before the study starts. The CHS nurses are then given the educational intervention and afterwards primary and secondary outcomes are collected again.
10143344|NCT04167475|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
10143345|NCT04167475|Placebo Comparator|Placebo capsule|The participants consume one placebo capsule a day for 8 weeks
10143346|NCT04167956|Experimental|ultrasound combined with CT guided|ultrasound combined with CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
10143347|NCT04167956|Sham Comparator|CT guided|CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
10143348|NCT04167657|Experimental|Arm1|Sintilimab monotherapy every 3 weeks, after a radiation targeting a single location no less than dose 30Gy/5f.
10143349|NCT04168034|Experimental|Experimental: iParent2Parent Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 2 to 3 months
10143350|NCT04168034|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iParent2Parent program
10143351|NCT04167488|Experimental|Actigraphic measurement|
10143352|NCT04167410|No Intervention|control group|We did not perform any intervention on the patients in the control group. These patients received routine glycaemia control and healthcare provided to diabetic patients undergoing surgical intervention in the department of general surgery.After receiving written informed consent, the first part of the data collection form on the socio-demographic and disease characteristics of the patients were completed face-to-face. The BG levels of the patients and the medications and insulin used for glycaemic control were recorded one night before surgery. The anxiety levels of the patients were evaluated on the morning of surgery using State-Trait Anxiety Inventory . The second part of the data collection form , which included information on glycaemic management, glycaemia levels and the medications and insulin used on the morning of surgery and during surgery, intensive care stay and the clinical period, was filled in by the nurse on the monitoring and anaesthesia forms.
10143353|NCT04167410|Experimental|intervention group|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. management was conducted by nurses in line with the protocol. Data on glycaemic management of the intervention group was similar to the control group.the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protoco
10143354|NCT04167397|Experimental|Single training|Initial training individually
10143355|NCT04167397|Experimental|Dyad training|Initial training in groups of 2
9669349|NCT02877134|Experimental|Part II : JNJ-64304500 Low Dose|"JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 low dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
9694663|NCT04786834|Active Comparator|Traditional training group|Trainees in the Traditional trained group will be trained according to the traditional approach of 'See one, do one, teach one' principle. Trainees will have an e-learning didactic component (specifically on the anatomy & physiology of the procedure, clinical aspects of the procedure, published evidence etc) which they must complete before training by a procedure expert. On completion of the e-learning module they will complete a summative assessment of their knowledge. They will then be shown how and then trained to suture and tie knots using the robot. The VUA will be demonstrated initially by an expert and who will then proctor the trainees in the same technique for repeated training trials., i.e., repeated practice for a period of time matched to the PBP group.
10143356|NCT04167397|Experimental|Triad training|Initial training in groups of 3
10143357|NCT04167397|Experimental|Tetrad training|Initial training in groups of 4
10143358|NCT04167566|Other|Intervention Communities|All participants confirmed using rapid diagnostic test (RDTs) to be carrying the malaria parasite will be treated using artemisinin combination therapy (ACT) following the Ghana National Malaria Treatment Guidelines and followed up on days 1, 2, 3 during treatment as DOTs (Directly observed therapy) and on day 7 post treatment. The research team together with Community volunteers will be provided the treatment guidelines which specify the dosage for each treatment regimen. Participants who receive the treatment will be observed for five minutes to ensure that they retain the drug. Those who vomit within this period will have the treatment repeated.
10143359|NCT04167553|Experimental|HM15136|
10143360|NCT04167553|Placebo Comparator|Placebo|
10143361|NCT04167384|Experimental|Hard nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
9826110|NCT02408068|Active Comparator|Immediate release hydrocortisone: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
10143362|NCT04167384|Experimental|Soft nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
10143363|NCT04167644||Unfavorable outcome|80 patients with poor outcome were classified according to mRS score after discharge (mRS range from 3 up to 6).
10143364|NCT04167644||Favorable outcome|70 patients with better outcome were classified according to mRS score after discharge (mRS range from 0 up to 2) .
10143365|NCT04167722||Obese patients|BMI > 25
10143366|NCT04167722||Lean patients|BMI < or = 25
10143367|NCT04167306|Experimental|1) Varenicline + Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Investigational medicinal product (IMP) 2: Bupropion SR 150 mg
10143368|NCT04167306|Experimental|2) Varenicline + Placebo for Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Placebo capsule for IMP 2 (bupropion)
10143369|NCT04167306|Experimental|3) Bupropion + Placebo for Varenicline|Investigational medicinal product (IMP) 2: Bupropion SR 150 mg and Placebo capsule for IMP 1 (varenicline)
10143370|NCT04167306|Placebo Comparator|4) Placebo for Varenicline + Placebo for Bupropion|Placebo capsule for IMP 1 (varenicline) and Placebo capsule for IMP 2 (bupropion)
10143371|NCT04167696|Experimental|Dose Escalation Dose Level 1|"in case of no dose limiting toxicity (DLT) and no replacement of patients, 3 consecutive patients at the dose of 1x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
10143372|NCT04167696|Experimental|Dose Escalation Dose Level 2|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 3x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
10143373|NCT04167696|Experimental|Dose Escalation Dose Level 3|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 1x10e9 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
10143374|NCT04167319||Paclitaxel|Patients scheduled to receive paclitaxel as part of their standard treatment
10143375|NCT04167319||Oxaliplatin|Patients scheduled to receive oxaliplatin as part of their standard treatment
10143376|NCT04167592|Active Comparator|Benzydamine Hydrochloride Group|Subjects who were allocated in benzydamine group would gargle with 15 of ml benzydamine hydrochloride 0.15% before sedation started.
10143377|NCT04167592|Placebo Comparator|Control Group|Subjects who were allocated in control group would gargle with 15 ml of water before sedation started.
10143378|NCT04167501||Non exposed|Women born between 1972 and 1982 who were not exposed to HPV vaccination
10143379|NCT04167501||exposed|Women born between 1983 and 1993 who were potentially exposed to HPV vaccination
10143380|NCT04167449|Active Comparator|Hydroponic Red Ginseng|
10143381|NCT04167449|Active Comparator|Conventional White Ginseng|
10143382|NCT04167449|Placebo Comparator|Placebo|
10143383|NCT04167293|Experimental|SBRT + PD-1 Arm|Patients assigned to this arm will receive SBRT followed by sintilimab. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
10143384|NCT04167293|Other|SBRT Arm|Patients assigned to this arm will receive SBRT alone. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
10143385|NCT04167527|Experimental|Immediate mechanical thrombectomy(iMT)|Treatment initiation within 8 hours of symptom onset. Arterial puncture and revascularization will be performed using EmboTrap II Retriever. The procedure will be completed within two hours of arterial access.
10143386|NCT04167527|Active Comparator|Initial medical management (iMM)|Standard medical therapy based on current AHA (American Heart Association) guidelines. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.
10143387|NCT04167241||Patients submitted to right pneumonectomy or bi-lobectomy|Consecutive, elective surgical patients submitted to right pneumonectomy or bi-lobectomy
10143388|NCT04167202|Experimental|Hydrogen-rich water|Six 30-min ankle baths with hydrogen-rich water (one hydrotherapy every 4 hours)
10143389|NCT04167202|Active Comparator|RICE protocol for acute injury|RICE protocol include: (1) rest, (2) ice packs every 20 min every 3 hours (total of 8 sessions), (3) compression with elastic bandage for 24 h, and (4) leg elevation at all possible times of the injured area above the level of the heart
9827484|NCT02457546|Active Comparator|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
9827485|NCT02457611|Experimental|LDV/SOF|LDV/SOF FDC for 6 weeks
10143390|NCT04167137|Experimental|Arm 1: SYNB1891 Monotherapy|SYNB1891 is to be administered as an intratumoral injection in up to four 21-day cycles of escalating doses on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-4. The starting dose of SYNB1891 in the first cohort will be 1 × 10^6 live cells and will be increased in approximately 3-fold increments in subsequent cohorts until MTD determination. A de-escalation dose of 3 × 10^5 live cells is available if the starting dose is deemed not tolerable. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 on day 1 of each cycle for up to 24 months after initial dose of study treatment.
10143391|NCT04167137|Experimental|Arm 2: SYNB1891 in Combination with Atezolizumab|Once the MTD has been established in Arm 1, dosing of SYNB1891 will begin in Arm 2 at a 10-fold lower dose than the Arm 1 maximum tolerated dose (MTD) and will be increased in approximately 3-fold increments in subsequent cohorts until recommended Phase 2 dose (RP2D) determination. SYNB1891 is to be administered in the same manner and frequency as Arm 1. Atezolizumab will be administered in accordance with its recommended dose and schedule (1200 mg IV every 3 weeks) on day 1 of each of the 4 planned cycles. On days when atezolizumab and SYNB1891 are both administered, SYNB1891 will be administered first, followed by at least 1 hour of observation prior to the atezolizumab infusion. Combination doses will not be escalated above the SYNB1891 single-agent MTD established in Arm 1. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 and atezolizumab on day 1 of each cycle for up to 24 months after initial dose of study treatment.
10143392|NCT04167228||CRE infected patients treated with ceftazidime-avibactam|Patients with infections caused by carbapenem resistant enterobacteria treated with ceftazidime-avibactam
10143393|NCT04167228||CRE infected patients treated with best available treatment|Patients with infections caused by carbapenem resistant enterobacteria treated with the best available treatment
10143394|NCT04167215|Experimental|perforator flap augmentation|Doppler probe is used to locate perforating vessels from the superior gluteal artery. . Flaps or lumbar artery flap will be designed to allow deepithelialization and dissection laterally to medially to identify the perforator . then sketolization is performed A gluteal pocket will then create for the augmentation flaps by undermining in a plane just superficial to the gluteal muscle extending to within 5 cm of the inferior gluteal crease. The deepithelialized flaps will then transpose inferomedially , and tacked to the fascia with several sutures.to be used as autologus buttock augmentation flap
10143395|NCT04167215|Experimental|fat injection|liposuction is performed firstly to parts where excess fat is exist and we will prepare the aspirated fat for injection as a graft in subcutaneous tissue of the buttock regoin
10143396|NCT04167280|Active Comparator|Ipratropium bromide|20mcg bronchodilator inhaler
10143397|NCT04167280|Placebo Comparator|placebo|matching bronchodilator inhaler
10143398|NCT04167059|Experimental|Waitlist-Control Group|The 'waitlist control' group will receive the 12-week non-intervention period first, followed by 12 week intervention period.
10143399|NCT04167059|Experimental|Immediate Treatment|The 'immediate treatment' group will receive the 12-week intervention period first, followed by 12 week non-intervention period.
10143400|NCT04167683||Cohort 1 - Patients referred to myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
10143401|NCT04167683||Cohort 2 - Patients referred to non myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
10143402|NCT04167267|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
10143403|NCT04167267|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
10143404|NCT04167046||Control|Patients in this group did not receive an erector spinae block. Data are obtained retrospectively (years 2017 and 2018).
10143405|NCT04167046||Erector spinae block|Patients in this group receive an erector spinae block. Data will be obtained prospectively.
10143406|NCT04166968|Sham Comparator|Control Group|neuromotor training and placebo stimulation
10143407|NCT04166968|Experimental|Group 1|neuromotor training and cathodal stimulation over the unaffected hemisphere
10143408|NCT04166968|Experimental|Group 2|neuromotor training and anodal stimulation over the affected hemisphere
10143409|NCT04167085|Experimental|Doxycycline, then Placebo|Doxycycline for a period of 2 months followed by a 1-month washout period, and then placebo for a further 2 months period followed by a 1-month washout period.
10143410|NCT04167085|Experimental|Placebo, then Doxycycline|Placebo for a period of 2 months followed by a 1-month washout period, and then Doxycycline for a further 2 months period followed by a 1-month washout period.
9669350|NCT02877134|Experimental|Part II : Ustekinumab|"Participants will receive tiered doses of Ustekinumab 260 mg (weight <=55 kg), Ustekinumab 390 mg (weight >55 kg and <=85 kg), Ustekinumab 520 mg (weight >85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive Ustekinumab up to 52 weeks (for a total of up to 72 weeks of Ustekinumab in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving Ustekinumab during the LTE will stop receiving study drug and will have a final safety follow-up visit after the last dose of study drug. However, participants receiving Ustekinumab in countries where Ustekinumab is not commercially available or approved for adult Crohn's disease were continued to receive Ustekinumab in the LTE."
10143411|NCT04167111|Active Comparator|Vitamin D 4000|At baseline, if subjects 25(OH)D levels are 12-19.9, they will be started on 4000 IU per day.
10143412|NCT04167111|Active Comparator|Vitamin D 2400|At baseline, if subjects 25(OH)D levels are 20-30, they will be started on 2400 IU per day.
10143413|NCT04167098|Experimental|Platelet-Rich Plasma|
10143414|NCT04167098|Active Comparator|Corticosteroid|
10143415|NCT04167098|Placebo Comparator|0.9% saline|
10143416|NCT04167254|Experimental|Sit Down and Play|
10143417|NCT04167254|No Intervention|Usual Care|
10143418|NCT04167124|Experimental|multi-sensor lifestyle intervention|
10143419|NCT04166721|Experimental|DKN-01 and atezolizumab|"DKN-01 is an intravenous medication which will be given at a variable dose during the Phase IIA safety run in phase of the trial (150mg, 300mg or 600mg IV q14d).~During the Phase IIB efficacy phase of the trial patients will be treated with DKN-01 at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.~Atezolizumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 840mg on the first day of a two week cycle. (Day 1 q 14d) from cycle 2 onwards.~In the first cycle of treatment, patients will be treated with only DKN-01, and following this they will be treated with both DKN-01 and atezolizumab"
10143420|NCT04166695|Experimental|Monolithic / facially veneered zirconia|Participants receive one monolithic / facially veneered zirconia fixed partial denture.
10143421|NCT04166695|Other|Completely veneered CoCr|Control group. Participants receive one completely veneered metal ceramic fixed partial denture.
10143422|NCT04167072|Experimental|Scheduled removal|This group involves patients who will have the LAMS removed immediately after all the stones have been cleared from the gallbladder
10143423|NCT04167072|Active Comparator|Observation|This group involves patients who will be followed closely for 1 year after all the stones have been removed from the gallbladder. These patients will keep the stent in place for 1 year and at that time the patients will be offered removal of the stent.
10143424|NCT04166734|Other|Initial safety cohort|Patients will receive an initial dose of pembrolizumab in week 1 dosed at 200 mg. They will then receive SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
10143425|NCT04166734|Other|Expansion cohort|An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at 200 mg in week 1. This will be followed in by SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
10143426|NCT04166747|Experimental|Intervention Group|The participants in this group will receive virtual reality based intervention for 15 minutes at a time, twice in a week for six weeks.
10143427|NCT04166747|No Intervention|Control Group|The participants in this group will not receive virtual reality based intervention for six weeks.
10143428|NCT04166890|Experimental|NS Lower right molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
10143429|NCT04166890|Active Comparator|SD Lower Left molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
10143430|NCT04166890|Experimental|NS Lower left molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
10143431|NCT04166890|Active Comparator|SD Lower right molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
10143432|NCT04166877|Experimental|Magnesium Group|The magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours.
10143433|NCT04166877|Placebo Comparator|Control Group|The control arm will receive the same volume and rate of saline as if they were in the experimental group.
10143434|NCT04166825|Active Comparator|Long protocol|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day
10143435|NCT04166825|Active Comparator|Short protocol|Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg
10143436|NCT04166825|Active Comparator|Clomiphene citrate|Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle
10143437|NCT04166825|Active Comparator|Letrozole|Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle
10143438|NCT04166825|Active Comparator|Gonadotropins|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).
10143439|NCT04166604|Experimental|trifluridine/tipiracil|35mg/m² BID (PER OS) (one cycle every 4 weeks)
10143440|NCT04166617|Active Comparator|Conventional therapy|Conventional physical therapy for upper limb in stroke patients
10143441|NCT04166617|Experimental|Leap motion plus conventional therapy|Leap motion plus conventional physical therapy for upper limb in stroke patients
10143442|NCT04166955|Experimental|(Intervention)|Participants will be provided with weekly messages including information for promoting physical activity.
10143443|NCT04166955|No Intervention|(Control)|Participants will be evaluated without providing any intervention.
10143444|NCT04166799|Experimental|Mepitel Film Arm|Patients randomized to the Mepitel Film arm will receive the film for the entire duration of their radiation treatment and will be worn up to 2 weeks after completion of radiotherapy.
10143445|NCT04166799|No Intervention|Standard of Care Arm|Patients randomized to the Standard of Care arm will be instructed to use the institutional standard of care skin treatments for the entire duration of their radiation treatment and up to 2 weeks after completion of radiotherapy.
10143446|NCT04166526||Group 1: Typically developing children|Participants of this group will not have a diagnosis of SCD. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
10143447|NCT04166526||Group 2: Children with SCD not receiving treatment|Participants of this group have a diagnosis of SCD, but do not receive chronic transfusions, gene therapy or bone marrow transplants. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
10143448|NCT04166526||Group 3: Children with SCD who have undergone gene therapy|Participants of this group have a diagnosis of SCD and have had gene therapy at least one month prior to enrollment. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
10143449|NCT04166526||Group 4: Children with SCD who have chronic transfusions|Participants of this group have a diagnosis of SCD and receive chronic transfusions. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
10143450|NCT04167007|Active Comparator|Group I|Gemcitabine at 1000 mg/m²
10143451|NCT04167007|Active Comparator|Group II|Oxaliplatin at 85 mg/m² ; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) and 5-FU 2400 mg/m²
10143452|NCT04166786|Experimental|Testosterone + Ethanol|Subjects receive a 3-day treatment with testosterone in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
10143453|NCT04166786|Other|Testosterone placebo + Ethanol|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
10143454|NCT04166786|Other|Testosterone + Ethanol placebo|Subjects receive a 3-day treatment with testosterone in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
10143455|NCT04166786|Placebo Comparator|Testosterone placebo + Ethanol placebo|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
10143456|NCT04166812||patients with early COPD|diagnosis according to current GOLD recommendations
10143457|NCT04166812||patients at risk for COPD|no current diagnosis according to GOLD recommendations, but at risk for COPD
10143458|NCT04167150|Active Comparator|Dose 1|Participants consume 8 fl oz of tart cherry juice per day.
10143459|NCT04167150|Experimental|Dose 2|Participants consume 2 x 8 fl oz of tart cherry juice per day.
10143460|NCT04166864|Experimental|SCC-Determined TMS|
10143461|NCT04166422|Active Comparator|Conventional group|Conventional rehabilitation treatment
10143462|NCT04166422|Experimental|Experimental group|Virtual reality plus conventional rehabilitation treatment
10143463|NCT04166760|Active Comparator|WHE (regular whey protein)|Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
10143464|NCT04166760|Experimental|speWHE (specific whey protein compound)|Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
10143465|NCT04166656|Other|Arm A : Trumenba®: Standard vaccination|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
10143466|NCT04166656|Other|Arm B:Bexsero®: standard vaccination regimen|Two doses of 0.5 ml each at one month intervals
10143467|NCT04166656|Other|Arm C : Bexsero® Innovative vaccine strategy|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
10143468|NCT04166448||Group 1: High risk IUGR patients|EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile, EPF or PA<3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),
10143469|NCT04166448||Group 2: Low risk IUGR patients|EPF et PA>20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)
10143470|NCT04166578||Mydrane group|Patients were randomly selected to the group receiving intracameral 0.2 ml Mydrane (a solution of 1% lidocaine and 0.025% of adrenaline ) during phacoemulsification.
10143471|NCT04166578||Reference group|Patients were randomly selected to the group receiving intracameral a combination of intracameral solution of lignocaine 1% and adrenalin 0.025% (0.2 ml) during phacoemulsification.
10143472|NCT04166396|Experimental|A: Cystic fibrosis|Patients with CF will be randomly assigned to resveratrol or placebo.
10143473|NCT04166396|Experimental|A: Healthy Controls|Healthy controls will be randomly assigned to resveratrol or placebo
10143474|NCT04166396|Experimental|B: Cystic Fibrosis|Patients with CF will be randomly assigned to NR or placebo.
10143475|NCT04166396|Experimental|B: Healthy Controls|Healthy controls will be randomly assigned to NR or placebo
10143476|NCT04166838|Experimental|CD19 UCAR-T|
10143477|NCT04166916|Active Comparator|Slow waves enhancing acoustic stimulation|During non-rapid eye movement (NREM) sleep, acoustic stimuli will be played to increase slow wave amplitude.
10143478|NCT04166916|Sham Comparator|SHAM: no application of acoustic stimuli|During NREM sleep no acoustic stimuli will be played.
10143479|NCT04166916|Active Comparator|Slow waves decreasing acoustic stimulation|During NREM sleep acoustic stimuli will be played to decrease/modulate slow waves amplitude in a dose-dependent way (e.g. less pronounced than arm 1).
10143480|NCT04166682|Placebo Comparator|Control Group|Routine care
10143481|NCT04166682|Experimental|Interventional Group|Home-based cardiac rehabilitation
10143482|NCT04166474|Experimental|Dolutegravir|
10143483|NCT04166565|Experimental|Daratumumab/bortezomib/cyclophospamide/dexamethasone (daraVCD)|"Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.~Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.~Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
10143484|NCT04166370|Active Comparator|Standard of Practice|Current Standard of Practice
10143485|NCT04166370|Experimental|Strengthened Services and Social Behavioral Change (SBCC)|Increase referrals to health services, strengthen health services, and provide enhanced social and behavior change communication (SBCC)
10143486|NCT04166370|Experimental|Strengthened Services and SBCC plus Conditional Cash Transfer|Increase referrals to health services, strengthenhealth services, provide enhanced SBCC, as well as cash transfers that are conditional on a mother attending antenatal care (ANC) and monthly nutrition education SBCC group sessions.
10184912|NCT03750812|Active Comparator|Poorly fit older adults - Exercise|This arm will receive an aerobic exercise intervention
10184913|NCT03750812|Active Comparator|Highly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
10143487|NCT04166136|Active Comparator|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
10143488|NCT04166136|Active Comparator|Transition from the Rearfoot to the Forefoot and Midfoot|"Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. The participants will receive verbal command Try to touch first with the middle region of the foot on the treadmill. In the last four sessions, feedback will be gradually removed. At the end of each session, participants will be asked a question about the naturalness of running the new foot touch pattern on the ground. A scale from 0 to 10 will be used, where 0 means very difficult to perform and 10 indicates easy pattern. The perception of pain will also be evaluated with the numerical scale of pain of 11 points (0 to 10), where 0 means no pain and 10 the greatest pain possible."
10143489|NCT04166136|Active Comparator|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
10143490|NCT04166305||Drug responders|60 patients are drug responders
10143491|NCT04166305||Drug resistant|60 patients are drug resistant
10143492|NCT04166305||The control|The control consists of 60 Age and gender matched healthy individual with negative past and family history of epilepsy and febrile convulsion.
10143493|NCT04166058|Active Comparator|72 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
10143494|NCT04166058|Active Comparator|145 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
10143495|NCT04166058|Active Comparator|290 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
9970349|NCT01299350|No Intervention|Usual|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged according to routine clinical practice based on symptoms, physical examination and other data that the cardiologist deems appropriate, except for Nt-proBNP.
9970350|NCT01299350|Experimental|Nt-proBNP guided|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
9970351|NCT01299363|No Intervention|No dilator use|
9970352|NCT01299363|Active Comparator|Dilator use|Women randomized to vaginal dilators will be given instructions to perform softening exercises from postoperative weeks 4 to 8
9970353|NCT01299402|Experimental|Soulera Herbal Blend|
10143496|NCT04166344|Experimental|Intervention Group|Participants in the IG will be given free access to the HappyAir platform during a 6-month period. This platform combines online/offline content to help patients with chronic respiratory diseases monitor their symptoms and improve self-management. In addition to tailored information on their condition, participants will be encouraged to fill in daily data on their physical activity levels, symptomatology, use of rescue medication and mood. In children under 12 years, parents or caregivers will fill in this information. Patients will be asked to record their peak expiratory flow using an electronic peak flow meter twice daily and to fulfil the Asthma Control Questionnaire once a week. They will also have a device connected to their inhaler to record adherence to the medical treatment and will get daily reminders in their smartphones. Every patient will be assigned a respiratory coach who will monitor patient during the study and whom the patients can contact at any time.
10143497|NCT04166344|No Intervention|Control Group|Subjects in the CG will receive standard care consisting of periodic visitations at the Allergology or Paediatric Pulmonology Unit in their respective hospitals every 4 - 8 weeks according to their physician's criteria. In addition, patients and caregivers in both groups will receive one educational session regarding the correct use of their inhalers.
10184914|NCT03750812|Active Comparator|Poorly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
10184915|NCT03750812|Active Comparator|Highly fit older adults - TV|This arm will sit at rest and watch television
10184916|NCT03750812|Active Comparator|Poorly fit older adults - TV|This arm will sit at rest and watch television
10184917|NCT03750812|Active Comparator|Highly fit young adults - TV|This arm will sit at rest and watch television
9970354|NCT01299402|Placebo Comparator|Placebo Blend|
9970355|NCT01299415|Experimental|ASA404 + Fluvoxamine|ASA404 + Fluvoxamine (Core Phase), ASA404 + either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination (Extension Phase)
9970356|NCT01299428|Active Comparator|cerebral oxygenation|
9970357|NCT01299441||OLT patients intubated with ECOM ETT|Patients undergoing liver transplantation and intubated with ECOM endotracheal tube (ETT).
9970358|NCT01299467|Experimental|Dose 1 (0.5 hours)|
9970359|NCT01299467|Experimental|Dose 1 (8 hours)|
9970360|NCT01299467|Placebo Comparator|Dose 1 (placebo)|
9970361|NCT01299467|Experimental|Dose 2 (0.5 hr)|
9970362|NCT01299467|Experimental|Dose 2 (8 hours)|
9970363|NCT01299467|Placebo Comparator|Dose 2 (placebo)|
10143498|NCT04166357||Respiratory and autonomic complications of GBS|"Early detection of respiratory failure is among the main challenges raised by the management of GBS. Careful monitoring by an experienced team of nurses and physicians is crucial. The classic signs of respiratory failure occur late, and the early manifestations consist only of tachypnea, tachycardia, air hunger, broken sentences, and a need to pause between sentences; later, use of the accessory respiratory muscles, paradoxical breathing, and orthopnea indicate severe diaphragmatic weakness.~Autonomic dysfunction occurred in the affected patients, including cardiac arrhythmia, hypertension or hypotension, ileus, and urinary retention."
10143499|NCT04165980|Sham Comparator|Sham transcranial direct current stimulation (sham tDCS)|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
10143500|NCT04165980|Active Comparator|Active transcranial direct current stimulation (activetDCS)|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
10143501|NCT04166006|Experimental|Experimental|"7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by Interleukin (IL) - 2 (IL-2), at a dose of 3 Million Units (MU), given by subcutaneous injection daily for five days (days 3-7). This constitutes a treatment cycle.~Treatment cycles are repeated every 28 days up to a maximum of six cycles."
10143502|NCT04166279|Experimental|Single rehabilitative Treatment|Patients treated within single rehabilitative protocol
10143503|NCT04166279|Experimental|Group rehabilitative Treatment|Patients treated within group rehabilitative protocol
10143504|NCT04166175|Active Comparator|group 1 botox group|48 patients subjected to 80 IU botox injection under GAin lithotomy position in the 5,7,11, and 1 O'clock positions
10143505|NCT04166175|Active Comparator|group 2 lateral sphincterotomy group|48 patients subjected to lateral internal sphincterotomy under GAin lithotomy position
10143506|NCT04166110|Active Comparator|Physician's prescription|Antibiotic treatment duration according to physician, following the French national guidelines: 7 to 14 days.
10143507|NCT04166110|Experimental|Duration according to stability|"Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%).~Minimum of duration of antibiotic treatment: 3 days."
10143508|NCT04166084|Active Comparator|Control Group|Patients in this group will receive active ROM exercises, 10 repeats X 3 times a day, 5 days a week for 6 weeks. All exercises will be performed at home .
10143509|NCT04166084|Experimental|Training group|I addition to active ROM exercises, patients in this group will also receive trunk stabilization exercises training for 45 minutes, 2 times a week for 6 weeks. All exercises sessions will be supervised by a physiotherapist in a clinic per week.
10143510|NCT04166292|Experimental|Treated face|The device will be injected on V1 (D0) in the cheekbones (upper part of the cheek) for all subjects and in the chin for 20 subjects minimum and if needed (optional areas) in the temple, and facial oval (mandibular angle and border). A touch-up is possible in one or several of these areas on V2 (M1). Optional treated areas will be at the discretion of subjects and injectors.
10143511|NCT04166201|Other|modified chevrel technique|hernioplasty done with double mesh modification of chevrels technique
10143512|NCT04166253|No Intervention|Control group|Control group of breast cancer patients will receive adjuvant AC chemotherapy
10143513|NCT04166253|Experimental|Vitamin D group|Intervention group of breast cancer patients will receive adjuvant AC chemotherapy in addition to vitamin D (alfacalcidol 0.5 mcg orally once daily
10184918|NCT03750812|Active Comparator|Poorly fit young adults - TV|This arm will sit at rest and watch television
10184919|NCT03750799|Experimental|Experimental group|Whole body vibration was applied on the right lower extremity.
10184920|NCT03750799|Sham Comparator|Sham group|Unlike the experimental group, sham vibration was applied to the control group.
10184921|NCT03750773|Active Comparator|Subjects receiving gabapentin drug|Administration of Gabapentin 600mg orally every 8 hours. Women will receive gabapentin for a total of 48 hours after cesarean
10184922|NCT03750773|Placebo Comparator|Subjects receiving placebo oral capsule|Administration of identical placebo capsule orally every 8 hours. Women will receive placebo for 48 hours after cesarean
10184923|NCT03750760|Active Comparator|Alirocumab (enhanced care)|"Alirocumab (150 mg) administered by subcutaneous injection, every two weeks for 7 weeks.~Atorvastatin (80 mg), oral administration daily."
10184924|NCT03750760|Active Comparator|Atorvastatin (standard care)|Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
10184925|NCT03750734||Idiopathic bronchiectasis|Idiopathic bronchiectasis participants
10184926|NCT03750734||Healthy volunteers|Healthy volunteers
10184927|NCT03750721||Role of rifampin in staphylococcal PJI|retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (< 1 month) PJI treated with DAIR in 2011-2016 period
10184928|NCT03750708|Other|Ara® KOLIBREE toothbrush|The Ara® KOLIBREE tooth brush is given to the child at the usual consultation one month before alveolar bone graft.
10184929|NCT03750708|No Intervention|Without Ara® KOLIBREE tooth brush|Usual consultation one month before alveolar bone graft.
10184930|NCT03750669|Experimental|Neoadjuvant Chemotherapy|Patients receive the sequential neoadjuvant chemotherapy of AG regimen (nab-paclitaxel plus gemcitabine) and mFOLFIRINOX before resection.
10184931|NCT03750669|No Intervention|control|Patients receive surgical treatment without any neoadjuvant treatments.
10184932|NCT03750656|Active Comparator|Hyoscyamine|Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort
10184933|NCT03750656|Active Comparator|Tamsulosin|0.4 mg tab orally daily
10184934|NCT03750643|Experimental|LY3454738 - Part A|Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants
9970364|NCT01299493|Experimental|Interventional|Access to systems-level interventions to increase colorectal cancer screening.
10143514|NCT04166045|Sham Comparator|Sham|Treatment at the bicep location
10143515|NCT04166045|Active Comparator|Verum|Treatment at the hand location
10143516|NCT04166188|Experimental|Cadavers|"20ml of 0.01% methylene blue solution (50mg of methylene blue diluted in 0.9% saline 500ml) will be injected, simulating the LESP block technique: injection between the transverse process of the fourth lumbar vertebra (L4) and the erector muscle of the underlying spine.~The injection will be performed with a Quincke 20G 100-150mm ultrasound-guided needle with a low-frequency curvilinear transducer (4-8 MHz - SonoSite) in the plane between the transverse process of L4 and the spinal erector muscle, bilaterally in each cadaver. by the same operator.~After injection of the solution the cadavers will be submitted to posterior lumbar region dissection by an anatomist and analyzed the dispersion and impregnation of the blue solution. The anatomical structures with the dye dispersion will be photographed and stored."
10143517|NCT04165967|Experimental|Tumor-infiltrating lymphocyte product (TIL) transfer|The TIL product will be produced from excised tumor lesions from the patient. Expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to Patient at Day 0.
10143518|NCT04165876|Active Comparator|Primary motor cortex|
10143519|NCT04165876|Active Comparator|Dorsolateral prefrontal cortex|
10143520|NCT04165876|Active Comparator|Multi-modal stimulation (DLPFC+M1)|
10143521|NCT04165876|Sham Comparator|Sham-stimulation|
10143522|NCT04166318|Active Comparator|Arm A (standard-dose chemoradiation)|Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
10143523|NCT04166318|Experimental|Arm B (de-intensified chemoradiation)|Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
10143524|NCT04165681|Experimental|Limbix Spark|A 5 week mobile + virtual reality CBT-based program
10143525|NCT04165577|Experimental|OCD, Active TMS|Participants with OCD who receive active rTMS
10143526|NCT04165577|Sham Comparator|OCD, Sham TMS|Participants with OCD who receive sham rTMS
10143527|NCT04165577|Other|Healthy Control, Active TMS|Healthy control participants who receive active rTMS
10143528|NCT04165577|Other|Healthy Control, Sham TMS|Healthy control participants who receive sham rTMS
10143529|NCT04165590|Experimental|Blood-stage infection of P.vivax|This is a single arm study that is planed to enroll 60 patients with advanced malignant solid tumor and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
9970365|NCT01299493|No Intervention|Usual Care|Practices will receive access to intervention components after outcomes data collection is complete.
10143530|NCT04165707|Experimental|Keyto intervention arm|Keyto device + app
10143531|NCT04165707|Active Comparator|Weight Watchers comparator arm|Weight Watchers app
10143532|NCT04165902|Experimental|steroid plus hyaluronic acid|steroid plus hyaluronic acid injection, one time per week, for 3 weeks
10143533|NCT04165902|Active Comparator|dextrose plus hyaluronic acid|dextrose plus hyaluronic acid injection, one time per week, for 3 weeks
10143534|NCT04165668||Dispatched lay responders|Nearby mobile phone located and dispatched lay responders who reached the place of the suspected OHCA before EMS and first responders (fire and police services).
10143535|NCT04165668||Non-dispatched lay responders|Nearby mobile phone located lay responders who have neither actively, nor technically responded due to either human or technical factors.
10143536|NCT04165538|Experimental|TEG group|
10143537|NCT04165538|No Intervention|Non-TEG group|
10143538|NCT04165850|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
10143539|NCT04165837|Experimental|Active|
10143540|NCT04165837|Placebo Comparator|Placebo|
10143541|NCT04165811|Experimental|Aerobic Dance based Exercise|The exercise program will be administered 60 minutes, 2 days a week for 8 weeks. The exercise program will be created by physiotherapists as a group exercise program.
10143542|NCT04165811|Experimental|Counseling of physical activity|Physical activity counseling is aimed at increasing the physical activity levels of the individuals who are waiting for bariatric surgery in the preoperative period.
10143543|NCT04165785|Experimental|OPT IPL followed by MGX|"Subjects in the experimental arm will receive OPT IPL followed by MGX: OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.~Interventions:~Device: IPL Procedure: MGX"
10143544|NCT04165785|Sham Comparator|Sham OPT IPL followed by MGX|"Subjects in the sham comparator arm will receive Sham OPT IPL followed by MGX: Sham OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.~Interventions:~Device: Sham IPL Procedure: MGX"
10143545|NCT04165603|Active Comparator|5mg/kg of ICG, 24h before surgery|5mg/kg of indocyanine green, intravenously injection 24 hours before surgery
10143546|NCT04165603|Experimental|1mg/kg of ICG, 24h before surgery|1mg/kg of indocyanine green, intravenously injection 24 hours before surgery
10143547|NCT04165603|Experimental|5mg/kg of ICG, 48h before surgery|5mg/kg of indocyanine green, intravenously injection 48 hours before surgery
10143548|NCT04165603|Experimental|1mg/kg of ICG, 48h before surgery|1mg/kg of indocyanine green, intravenously injection 48 hours before surgery
10184935|NCT03750643|Placebo Comparator|Placebo - Part A|Placebo administered IV to healthy participants
10143549|NCT04165486|Experimental|BIIB101 Low Dose|Participants will be administered BIIB101 low dose and matching placebo via intrathecal (IT) injection at regular intervals.
10143550|NCT04165486|Experimental|BIIB101 Medium Dose|Participants will be administered BIIB101 medium dose and matching placebo via IT injection at regular intervals.
10143551|NCT04165486|Experimental|BIIB101 High Dose|Participants will be administered BIIB101 high dose and matching placebo via IT injection at regular intervals.
10143552|NCT04165655|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 10-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 10-weeks. The activity sessions will include semi-structures free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
10143553|NCT04165655|No Intervention|Waitlist control group|Participants in this group will not receive the 10-week group based activity intervention throughout the duration of this study. Participants will be able to participate in the 10-week activity intervention once this research has ended.
10143554|NCT04165421|Experimental|Family intervention group|The intervention starts with a two hour group session for AF-patients and family members designed by the PhD student and the project nurses based on clinical guidelines of AF-management and theory from multifamily group intervention. Project nurses who are also Nurse specialists will facilitate knowledge to patients and family members about AF and how to support self-management in their daily living. Furthermore the (Family focused nursing) FFN intervention will consist of 3 -5 Family Strength Orientated Therapeutic Conversations (FAM-SOTC) accordingly to the needs of patient and the family. The FAM-SOTC conversations will be used as health promoting conversations and a way to enhance family health and psychological resilense
10143555|NCT04165421|No Intervention|Control group|"The control group will receive conventional care and treatment according to guidelines.~Conventional care is characterized by ad hoc management as per usual standards of clinical care (with access to routine medical care, hospital care, and pharmacotherapy)."
10143556|NCT04165473|Experimental|Intervention Group|In a 6-module course, with four 3-day modules and two 5-day modules in the timeframe of one year, participants learn ways to strengthen their personal resources to establish effective social relationships and to develop skills as a social being. In between the module courses, the participants take 5 single sessions with an instructed trainer and document 10 conversations/social situations where they successfully applied the new skills.
10143557|NCT04165473|No Intervention|Intervention Group - Close Relationship|Individuals having a close relationship to participants of the Intervention Group
10143558|NCT04165473|No Intervention|Control Group|Individuals matched to the participants of the Intervention Group
10143559|NCT04165473|No Intervention|Control Group - Close Relationship|Individuals having a close relationship to participants of the Control Group
10143560|NCT04165551|Experimental|Probiotic|Volunteers will take 1 capsule per day containing 6x109 cfu of Lactobacillus BSL_PS71 in maltodextrin.
10143561|NCT04165551|Placebo Comparator|Placebo|Volunteers will take 1 capsule per day containing maltodextrin.
10143562|NCT04165512|Experimental|stellate ganglion block in breast cancer related lymphedema|US-guided stellat ganglion block will be applied to the patients with breast cancer related lymphedema twice at two-week intervals.
10143563|NCT04165460|Experimental|"A Intervention"|Psychoeducation, Relaxation, Cognitive Reestructuring and Problem Solving
10143564|NCT04165460|Active Comparator|"B Intervention"|Psychoeducation, Relaxation
10143565|NCT04165629||Aspirin responders|On impedance aggregometry- Multiplate analyzer, if ASPI < 600 or ASPI/TRAP < 0.5
10143566|NCT04165629||Aspirin non-responders|On impedance aggregometry- Multiplate analyzer, if ASPI > 600 or ASPI/TRAP > 0.5
10143567|NCT04165629||Clopidogrel responders|On impedance aggregometry- Multiplate analyzer, if ADP < 500 or ADP/TRAP < 0.5
10143568|NCT04165629||Clopidogrel non-responders|On impedance aggregometry- Multiplate analyzer, if ADP > 500 or ADP/TRAP > 0.5
10143569|NCT04165447|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display the label on any products.
10143570|NCT04165447|Experimental|Within-category labeling|Arm 2 displayed the label on the 20% of products that were lowest in calories per serving within each product category (termed Within-category Labeling, WC).
10143571|NCT04165447|Experimental|Across-category labeling|Arm 3 displayed the label on the 20% of all products that were lowest in calories per serving (termed Across-category Labeling, AC).
10143572|NCT04165304|No Intervention|control|the range of products offered by the vending machines remains unchanged
10143573|NCT04165304|Other|Intervention group 1|vending machines will be re-equipped to contain 60% drinks containing a maximum of 6.7g sugar/100ml, 20% drinks containing more than 6.7g sugar/100ml and 20% water
9519702|NCT03284437|Experimental|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
9519703|NCT03284372|Experimental|Intervention 1|Text Message Only
9519704|NCT03284372|Experimental|Intervention 2, Incentive|Text message + Incentive
9519705|NCT03284372|No Intervention|Cohort|For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19. The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
9519706|NCT03284372|No Intervention|Control|The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
10143574|NCT04165304|Other|Intervention group 2|In the second intervention group, the vending machines offer 80% water and 20% products with a maximum of 6.7g sugar/100ml.
10143575|NCT04165525|Active Comparator|HelixAR Electrosurgical Generator (HEG)|Argon gas and high frequency electrical current ablation device
10143576|NCT04165525|Active Comparator|Conventional Electrosurgical Coagulation (CEC) Systems|Standard Bovie electrosugical device without argon gas
10184936|NCT03750643|Experimental|LY3454738 - Part B|LY3454738 administered IV to healthy participants
9519707|NCT03284372|No Intervention|Adolescent Allergy Advisors|We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language. These advisors will not be part of the cohort multiple randomized controlled trial.
9826111|NCT02408068|Active Comparator|Chronocort: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
10143577|NCT04165499|Experimental|Combination of Plant Extracts (BSL_EP026)|Volunteers will take 1 capsule twice daily with the combination of the plant extracts (BSL_EP026).
10143578|NCT04165499|Placebo Comparator|Control|Volunteers will take 1 capsule twice daily with maltodextrin.
10143579|NCT04165434|Experimental|Experimental|Untrained unilateral transtibial amputees who underwent the assessment and recommended training.
10143580|NCT04165434|No Intervention|Control|Untrained unilateral transtibial amputees who after the evaluation were not included for the recommended training.
10143581|NCT04165395|No Intervention|Control group|The control group will receive the standard of care adopted at Hôpital du Sacré-Coeur de Montréal in terms of pressure ulcers prevention in the SCI population.
10143582|NCT04165395|Experimental|Intervention group|In addition to undergoing the identical standard-of-care as the control group, all patients in this group will receive a prophylactic five-layer foam dressing placed directly on the sacral area and a Heelmedix boot installed alternately on both legs
10143583|NCT04165252||Term Birth|Delivery between 37-41 weeks of gestation
10143584|NCT04165252||Preterm birth|Delivery between 24-37 weeks of gestation
10143585|NCT04165265|Experimental|Responders and Partial/non-responders|"The definition of responders to glucocorticoids is: Bowel movements ≤ 3/day without blood and normalization of CRP. In the study, this is supported by CC.~The definition of non-responders is: Bowel movements > 8/day or 3-8/day and CRP > 45 mg/l. The decision if the patient is a non-responder is supported by CC.~Questionnaires in CC and FC analysis with CalproSmart are performed every day until discharge or when classified as green in CC. After discharge questionnaires in CC and FC analysis are performed once every week in the following 7 weeks and a final registration at week 52. In case of disease relapse between week 7 and 52 registration in CC and FC analysis are performed on demand. Fecal samples for future use (biobank) and FC Elisa as well as blood samples are done before administration of IFX (week 2 and 6). At follow-up (week 52) it is considered whether the patient underwent colectomy or not."
10143586|NCT04165330|Experimental|AL3818 plus nivolumab|"Part 1: All participants will be assigned to receive AL3818 capsules orally, once daily at sequential deescalating doses (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (on Day 1 and Day 15) for a single 21-day cycle. Participants may continue study treatment at the AL3818 cohort dose at investigator discretion.~Part 2: All participants will receive AL3818 capsules orally, once daily at the RP2D determined from Part 1 (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (every 2 weeks starting on Cycle 1, Day 1) in 21-day cycles, for up to 24 cycles of total AL3818 therapy."
10143587|NCT04165382|Other|Pre-implementation study group|Preterm infants receiving NIV before the implementation of the guideline
10143588|NCT04165382|Other|Post-implementation study group|Preterm infants receiving NIV after the implementation of the guideline
10143589|NCT04165369||Patients with extended surgical exposures|Patients with extended surgical exposures requiring postoperative observation.
10143590|NCT04165005|Experimental|decentering group|"MBSR focused on a decentering component (i.e. individuals observe their feelings and thoughts as ephemeral events, with no reactivity, alongside with acceptance)."
10143591|NCT04165005|Experimental|guided imagery group|a group practicing in guided imagery sessions.
10143592|NCT04165005|No Intervention|control group|usual care group
10143593|NCT04165356|Experimental|Mouth-rinse with clorhexidine|Mouth-rinse with 0.12% clorhexidine + tooth brushing twice daily
10143594|NCT04165356|Active Comparator|Mouth-rinse with bicarbonate isotonic solution|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate + tooth brushing twice daily
10143595|NCT04165278|Experimental|Hyperthermic baths|On the first, third and fifth day of the first week, each subject will take the Hyperthermic Baths (HTB) at the same time. They will receive subjective measures before and after HTB. In the second week, no subjects accepted any intervention. On the fifteenth, seventeenth and nineteenth days of the third week, these subjects will receive two subjective measures without HTB in the same environment and scoring time as the experimental group.
10143596|NCT04165291|Experimental|F4C|Participants randomized to the Fathers for Change (F4C) program.
10143597|NCT04165291|Active Comparator|BIP|Participants randomized to the Batterer Intervention Program (BIP).
10143598|NCT04165226|Active Comparator|Low level light therapy (LLLT)|Low level light therapy using 808/915 nm infra red diode laser
10143599|NCT04165226|Active Comparator|Fractional CO2|Fractional carbon dioxide laser 10600 nm
9519708|NCT03284346|Experimental|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
9826112|NCT02408120|Active Comparator|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >140 mg/dL.
10143600|NCT04165226|Active Comparator|Combined fractional CO2 and LLLT|Combined fractional CO2 laser and low level light therapy
10184937|NCT03750643|Placebo Comparator|Placebo - Part B|Placebo administered IV to healthy participants
10184938|NCT03750643|Experimental|LY3454738 - Part C|LY3454738 administered IV to participants with atopic dermatitis (AD)
10184939|NCT03750643|Placebo Comparator|Placebo - Part C|Placebo administered IV to participants with AD
10184940|NCT03750617|Experimental|pre-endoscopic screening risk assessment|
10143601|NCT04165213|Experimental|Online training site|"Ten participating Trinity PACE Organizations will participate via webinar in a brief orientation/ training to the study and project logistics. Next, Trinity Health PACE organizations will be randomized into two groups using the re-randomization procedures described in the paragraph below; 5 PACE organizations will serve as the control site in which training will be provided via the traditional high intensity face-to-face.; 5 PACE organizations will serve as the comparison and be trained through the online training site. Prior to randomization, we will carefully examine PACE organizations on important variables such as size, location (urban; rural) percent of persons with dementia, and staff: participant ratio. In each site, one occupational therapist (OT) and one nurse (RN) will be trained (e.g., 5 OTs and 5 RNs in traditional sites; 5 OTS and 5 RNS in online training sites for a total of 10 OTs and 10 RNs or 20 health providers)."
10143602|NCT04165213|Experimental|COPE-PACE participant outcomes with online training|The efficacy of the COPE program training on PACE participant outcomes by type of COPE training will be evaluated in this arm. Each of the PACE organizations will enroll 5 persons with dementia and their caregivers in the study. This will yield 50 family dyads or 100 subjects (25 dyads in traditional training sites and 25 dyads in online training sites). Dyads will be followed for 4 months. Non-inferiority analysis will be used to assess whether dyads will yield the same or better outcomes regardless of how PACE staff were trained.
10143603|NCT04165044|Active Comparator|L-PRF+CAF|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap
10143604|NCT04165044|Active Comparator|CTG+CAF|Connective Tissue graft plus Coronally Advanced Flap
10143605|NCT04165174|Experimental|PAS|PD-1:240mg,ivdrip,Q3W,begin with SBRT Apatinib:250mg,po,QD,begin with SBRT SBRT:6-10Gy/F,5-8F
10143606|NCT04165187|Experimental|BAT+Home exercise program|The patients in this group will participate in BAT for 3 days a week for 6 weeks in addition to home exercise program.
10143607|NCT04165187|Active Comparator|Home exercise program|The patients in the control group will perform home exercise program, two times a day, 7 days a week for 6 weeks.
10143608|NCT04165200|Active Comparator|Patients receiving FMT capsules and ART|"ART Start at week 0 non-stop.~FMT. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
10143609|NCT04165200|Placebo Comparator|Patients receiving placebo capsules|"ART Start at week 0 non-stop.~Placebo capsules. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
10143610|NCT04165057|Active Comparator|Group OMT|Optimal muscle tension management
10143611|NCT04165057|No Intervention|Group Control|Conventional anesthetic management
10143612|NCT04164927|Active Comparator|Kinesio Taping|Lymphatic correction method is applied via Kinesiotaping depending on the size of the leg two or three fan-cut tape was applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Certified Kinesio Tape practitioner applied Kinesiotaping on the second day (day 2) post-surgery and once a week.
10143613|NCT04164927|Active Comparator|Manual Lymphatic Drainage|A standardized 30-minute manual lymphatic drainage (MLD) treatment is applied to MLD group. On the second day (day 2) post-surgery, patients allocated to the MLD group underwent a standardized 30 minute MLD treatment on the operated limb by an experienced remedial massage therapist trained in delivering MLD.
10143614|NCT04164927|No Intervention|Control|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
10143615|NCT04164953|Experimental|Dupuytren's|Surgical intervention as second-line surgery for the treatment of Dupuytren's disease.
10143616|NCT04164862|Active Comparator|use ACCUVEIN AV400|Device to facilitate cannulation of the great saphenous vein at the ankle in infants
10143617|NCT04164862|Active Comparator|ULTRASOUND GUIDED CANNULATION|Ultrasound cannulation of the great saphenous vein in infants
10143618|NCT04164992|Experimental|not resectable pancreatic cancer patients|Patients with not-resectable pancreatic adenocarcinoma will be treated with endoscopic ultrasound radio frequency ablation
10143619|NCT04164940||Age 21-30|Patients aged 21-30 when admitted to hospital and receiving brief alcohol intervention
10143620|NCT04164940||Age 31-40|Patients aged 31-40 when admitted to hospital and receiving brief alcohol intervention
10143621|NCT04164940||Age 41-50|Patients aged 41-50 when admitted to hospital and receiving brief alcohol intervention
10143622|NCT04164940||Age 51-60|Patients aged 51-60 when admitted to hospital and receiving brief alcohol intervention
10143623|NCT04164940||Age 61-70|Patients aged 61-70 when admitted to hospital and receiving brief alcohol intervention
10143624|NCT04164940||Age 71-80|Patients aged 71-80 when admitted to hospital and receiving brief alcohol intervention
10143625|NCT04164940||Age 81 and older|Patients aged 81 and older when admitted to hospital and receiving brief alcohol intervention
10143626|NCT04164914|Experimental|Healthy subjects|Prebiotic administration
10184941|NCT03750617|No Intervention|routine screening|
10143627|NCT04164810|Experimental|Hydrotherapy|Hydrotherapy intervention will receive the treatment for 9 weeks (2 days per week) , resulting in a total of 18 sessions of Hydrotherapy. Each session will be held for a duration of 45 minutes to 1 hour.
10143628|NCT04164810|Active Comparator|Physical therapy|Physical therapy inthervention will have 18 standard physical therapy treatment sessions during 9 weeks. Each session will be held for a duration of 45 minutes to 1 hour.
10143629|NCT04164836|No Intervention|control group|nose selection will be done by random table
10143630|NCT04164836|Experimental|rhinoscope group|nose selection will be done by rhinoscopy
10143631|NCT04164628|Experimental|Experimental Group: quality of life assessment|Women's quality of life will be evaluated.
10143632|NCT04164511||Patients with post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy and receiving 2 daily ice creams for 2 weeks after surgery. Standard analgesic therapy available.
10143633|NCT04164511||Patients without post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy, not receiving any ice cream for 2 weeks after surgery. Standard analgesic therapy available.
10143634|NCT04164485|Experimental|Functional collagen scaffold transplantation|
10143635|NCT04164485|Experimental|Autologous adipose cell transplantation|
9669351|NCT02875314|Experimental|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
10143636|NCT04164498|Experimental|Music exposure|will be exposed to music to investigate effects on preventing noise Adverse effects
10143637|NCT04164498|No Intervention|Control|no exposure to music
10143638|NCT04164784|Experimental|therapeutic monitoring|"Based on the dietary habits from guidelines, the patients will be instructed to adjust the diet according to the ambulatory glucose profile (AGP) and the recorded log monitored by the continuous glucose monitoring system, thereby implementingtherapeutic monitoring."
10143639|NCT04164784|No Intervention|The control group|Patients will be given the basic diet, lifestyle instructions according guidelines.
10143640|NCT04164823|Experimental|Medical Taping|"Medical taping will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).~Patients will be taped for four days. It will start at the beginning of pain associated to the menstruation."
10143641|NCT04164823|Active Comparator|Analgesic self-medication (OTC)|"Participants will use the usual analgesic self-treatment for primary dysmenorrhea.It will start at the beginning of pain associated to the menstruation.~They will note the treatment indicating the analgesic and the dosage in a calendar."
10143642|NCT04164563|No Intervention|Control|Standard CAM boot treatment without Even-Up device.
10143643|NCT04164563|Experimental|Study|CAM boot treatment with Even-Up for contralateral extremity.
10143644|NCT04164615|Experimental|GB221+ Capecitabine tablets|test drug+capecitabine
10143645|NCT04164615|Placebo Comparator|Placebo control + capecitabine tablets|placebo+capecitabine
10143646|NCT04164524||Group; A|Open technique Hernioplasty for abdominal hernia in which 160 mg Gentamycin spray applied over the mesh
10143647|NCT04164524||Group; B|Open technique Hernioplasty for abdominal hernia in which no Gentamycin spray applied over the mesh
10143648|NCT04164797|Experimental|treatment group|endostar : 7.5mg/m2/d,continuous infusion for 5 days in week 1、3、5、7, chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
10143649|NCT04164797|Active Comparator|control group|chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
10143650|NCT04164446|Placebo Comparator|Placebo|Two capsules containing starch and glucose, once per day, 60 days duration
10143651|NCT04164446|Active Comparator|Oil Palm Phenolics 250 mg|One capsule 250 mg active compound (OPP) and one capsule containing starch and glucose, once per day, 60 days duration
10143652|NCT04164446|Active Comparator|Oil Palm Phenolics 1000 mg|One capsule containing 1000 mg active compound (OPP) and one capsule starch and glucose, once per day, 60 days duration
10143653|NCT04164446|Active Comparator|Oil Palm Phenolics 2000 mg|Two capsules, 1000 mg active compound (OPP) each, once per day, 60 days duration
9970366|NCT01299506||Trabectedin|The administration of chemotherapy regimen with trabectedin will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
9970367|NCT01299506||Conventional care|This includes other palliative chemotherapy or biological therapy or best supportive care.
9970368|NCT01299519|Experimental|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
9970369|NCT01299519|Active Comparator|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
9970370|NCT01299532|Experimental|Macrolane VRF30|
9970371|NCT01299545||a single group of patients -200 expected|polyarthrite rhumatoid patients
9970372|NCT01299558|Other|Treatment period 1|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
9970373|NCT01299558|Other|Treatment Period 2|Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
9970374|NCT01299558|Other|Treatment Period 3|Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
9970375|NCT01299597|Experimental|Cohort 1: Atorvastatin|single dose session with Atorvastatin with PK samples collected up to 72h post dose, then 14 days repeat dose session with SB649868 with Atorvastatin single dose co-administered on day 8 (same time as SB649868) and on day 12 (2 hours before SB649868).
10143654|NCT04164771|Experimental|Moringa Group|Participants will receive 5-7g of moringa diet daily for 6 weeks.
10143655|NCT04164771|Experimental|Aerobic training Group|Participants will receive 5-7g of moringa diet daily and will do 30 minutes of aerobic training daily for 6 weeks.
10143656|NCT04164771|Experimental|Moringa and Aerobic training|Participants will do 30 minutes of aerobic training daily for 6 weeks
10143657|NCT04164771|No Intervention|Control Group (T4)|Participants will not recieve any treatment
10143658|NCT04164589|Placebo Comparator|Control|The Neuro-Adaptative Regulation will be carried out in the regime of switched off power supply in vulvo-perineal and sacral area.
10143659|NCT04164589|Experimental|Experimental|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacarl area.
10143660|NCT04164654|Experimental|Experimental-Immediate Access to the Nod app|The experimental group will have immediate access to all content in the Nod app and will be free to engage with it as much or as little as they like for four weeks. They will retain access to the Nod app for an additional four weeks.
10143661|NCT04164654|Other|Waitlist Control-Delayed Access to the Nod app|The waitlist control group will have full access to the Nod app approximately four weeks after the experimental group gains access.
10143662|NCT04164745|Experimental|Experimental: Anlotinib plus Pembrolizumab|
10143663|NCT04164706|Experimental|HumiGard (plus standard care)|HumiGard device will be used to provide warmed humidified CO2 for insufflation during laparoscopic surgery. The device will be used alongside standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.
10143664|NCT04164706|Sham Comparator|Standard Care (with sham HumiGard device).|"Patients will receive standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.~A sham HumiGard device will be used in the standard care arm. This will be the same HumiGard device as is in the intervention arm. However, the sham device will be turned off so that the gas delivered to the peritoneal cavity for insufflation is not heated or humidified. The sham device will deliver CO2 (as is the case for current standard practice in the hospital) through the HumiGard tubing. The sham device will look and sound the same as the active intervention arm where the HumiGard device is switched on and is delivering warm, humidified CO2 to the peritoneal cavity."
10143665|NCT04164459|Experimental|Xalost S|
10143666|NCT04164459|Active Comparator|Xalatan|
10143667|NCT04164459|Active Comparator|Taflotan-S|
10143668|NCT04164719|Experimental|Treatment A|TNX-102 SL 2.8 mg, under fasting conditions
10143669|NCT04164719|Experimental|Treatment B|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fasting conditions
10143670|NCT04164719|Experimental|Treatment C|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fed conditions
10143671|NCT04164693|Experimental|anticoagulant therapy group|during hospitalization, patients began to use low molecular weight heparin subcutaneously after arteriovenous fistula operation, once or twice a day, 4000iu-8000iu a day. After discharge, the patients took warfarin sodium tablets orally, 1.25mg on dialysis day, 2.5mg on non dialysis day, for a total course of 4 weeks.
10143672|NCT04164693|Other|non anticoagulant therapy group|no anticoagulant was used after operation, but both groups could take antiplatelet drugs.
10143673|NCT04164680||Patients with disorders of consciousness|
10143674|NCT04164667|Active Comparator|Self-Guided|Participant's do not receive text message direction from the VA Annie Text Messaging System. Participant's create their own method for accomplishing app-based exercise and mindfulness practice without detailed instructions.
10143675|NCT04164667|Experimental|Directed Messaging|Participant's receive text message directions from the ANNIE VA messaging system. The directed messaging system provides text message details of the participant's app-based meditation and exercise instructions.
10143676|NCT04164290|Active Comparator|treatment group 1|Jiashen tablet, 0.47g, oral, once a day
10143677|NCT04164290|Active Comparator|treatment group 2|Jiashen tablet, 0.94g, oral, once a day
10143678|NCT04164290|Active Comparator|treatment group 3|Jiashen tablet,1.88g, oral, once a day
10143679|NCT04164290|Active Comparator|treatment group 4|Jiashen tablet,2.82g, oral, once a day
10143680|NCT04164290|Active Comparator|treatment group 5|Jiashen tablet,3.76g, oral, once a day
10143681|NCT04164290|Active Comparator|treatment group 6|Jiashen tablet,4.23g, oral, once a day
10143682|NCT04164290|Placebo Comparator|control group 1|Jiashen placebo tablet,0.47g, oral, once a day
10143683|NCT04164290|Placebo Comparator|control group 2|Jiashen placebo tablet,0.94g, oral, once a day
10143684|NCT04164290|Placebo Comparator|control group 3|Jiashen placebo tablet,1.88g, oral, once a day
10143685|NCT04164290|Placebo Comparator|control group 4|Jiashen placebo tablet,2.82g, oral, once a day
10143686|NCT04164290|Placebo Comparator|control group 5|Jiashen placebo tablet,3.76g, oral, once a day
10143687|NCT04164290|Placebo Comparator|control group 6|Jiashen placebo tablet,4.23g, oral, once a day
10143688|NCT04164238|Experimental|Arm A|Toripalimab 240mg IV, every 3 weeks;
10143689|NCT04164238|Experimental|Arm B|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Carboplatin AUC 5, IV, Q3W
10143690|NCT04164238|Experimental|Arm C|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Cisplatin 25mg/m^2 IV,d1-d3, Q3W; 5-FU 3000mg/m^2 CIV 72h, Q3W
10143691|NCT04164212|Other|open label|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
10143692|NCT04164160|Experimental|integrated-care-model benefiting group|Chronic patients whose clinical and social data will be added in the integrated care model application software.
10143693|NCT04164355||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months
10143694|NCT04164355||Control Group|Healthy controls without previous surgery of radical prostatectomy.
10187773|NCT03722745|Experimental|Study group 1|Juvenile offenders will attend 4-session Trauma Affect Regulation: Guide for Education & Treatment (TARGET) groups led by one or two juvenile staff members
10143695|NCT04164433|Experimental|Workplace-based HIV Self-Testing|"i. Explain the procedure of conducting HIVST & interpret HIV self- test result to the user.~ii. Demonstrate how to perform the self-test and how to interpret the self-test result.~iii. Provide appointment card including information on linkage for HIV prevention services and further testing for diagnosis among those with a reactive self-test. Participants with a non-reactive self-test will be referred to HIV prevention services.~iv. Provide a toll free number for continued consultation"
10143696|NCT04164433|No Intervention|Workplace-based standard HIV Testing Services (HTS)|Standard of care following the HIV testing algorithm .
10143697|NCT04164420|Experimental|Oral neuromuscular training and orofacial sensory-vibration|Intensive training with oral neuromuscular training and orofacial sensory-vibration stimulation for 5 weeks. The oral neuromuscular training is performed three times per session, and three times daily before eating. Regarding the orofacial sensory-vibration stimulation, the instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal by using a toothbrush.
10143698|NCT04164420|Active Comparator|Orofacial sensory-vibration stimulation|Orofacial sensory-vibration stimulation by using an electrical toothbrush for five weeks. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
10143699|NCT04164368|Experimental|R2-CHOP|Lenalidomide combined with rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone
10143700|NCT04164108|Experimental|Intermittent feed participants|Patients admitted to medical ICU #1 (of 2 at our hospital) will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
10143701|NCT04164108|No Intervention|Control participants|Patients admitted to the medical ICU #2 (of 2 at our hospital) will receive usual care.
10143702|NCT04164381|Experimental|Robotic assisted intervention|Upper limb robotic therapy using a set of robotic and sensor based devices and exercises specifically selected to train cognitive functions.
10143703|NCT04164342|Experimental|Single ARM|This is an observational study, all patients will be followed at 3, 6 and 12 months by phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done).
10143704|NCT04164394|Placebo Comparator|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
10143705|NCT04164394|Experimental|Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
10143706|NCT04164251|Experimental|Inpatient screening mammography for non-adherent and high risk|All non-adherent women were offered inpatient screening mammography during hospitalization
10143707|NCT04164329||Exposed group|The exposed group will be composed by the patients that undergo CRT/ICD implantation (general anesthesia).
10143708|NCT04164329||Not exposed group|The non-exposed group, or control group, will be composed by the patients undergo PM implantation (without anesthesia)
10143709|NCT04164264|Experimental|Intravenous Propofol Infusion|Quantification of the dose of propofol required to produce loss of consciousness and apnea.
10143710|NCT04164095|Experimental|lappg|
10143711|NCT04164095|Active Comparator|ladgbi|
10143712|NCT04164056|Experimental|stimulation on the hippocampus|deep brain stimulation on the hippocampus
10143713|NCT04164056|Active Comparator|stimulation on the anterior nucleus of the thalamus|deep brain stimulation on the anterior nucleus of the thalamus
10143714|NCT04164147|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
10143715|NCT04164147|Active Comparator|Persona MC Retained PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Retained PCL prosthesis
10143716|NCT04164147|Active Comparator|Persona MC Sacrificed PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Sacrificed PCL prosthesis
10143717|NCT04163939|Experimental|Collar|This group will wear a cervical collar for at least 30 minutes per day, 5 out of 7 days of the week
10143718|NCT04163939|Placebo Comparator|Control|This group will not wear the cervical collar
10184942|NCT03750604|Active Comparator|patients with OAB|"Patients were asked to fill (OABSS) for more accurate evaluation of bothersome degree. Waist Circumference is evaluated. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to CT detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
10184943|NCT03750604|Placebo Comparator|normal variants healthy without symptoms|"WC is evaluated crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL. And in males:VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
10187774|NCT03722745|Active Comparator|study group 2|Juvenile offenders will receive treatment-as-usual (TAU).
10187775|NCT03722732|Active Comparator|Open pancreaticoduedenectomy|will include all the patients who will undergo open pancreaticoduodenectomy
10187776|NCT03722732|Active Comparator|Laparoscopic pancreaticoduodenectomy|will include all the patients undergoing laparoscopic pancreaticoduodenectomy
9519709|NCT03284346|Active Comparator|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
9519710|NCT03284333|Experimental|other|no arm
10143719|NCT04163965|Other|Patients having a pacemaker|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology. Simultaneously standard routine ECG measurements will take place.
10143720|NCT04163848||Desflurane|desflurane administration based on a BIS index kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator and its econometer for an optimized fresh gas flow as low as the O2 consumption allows
10143721|NCT04163848||Sevoflurane|sevoflurane administration based on a BIS kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator with a fixed fresh gas flow of 2L/min as requested in the gas monography
10143722|NCT04163835|Experimental|Low-dose Group|The intervention is half-dose of Wenxin Granules (1/2 normal dose).
10143723|NCT04163835|Experimental|Medium-dose Group|The intervention is medium-dose of Wenxin Granules (normal dose).
10143724|NCT04163835|Experimental|High-dose Group|The intervention is twice-dose of Wenxin Granules (twice normal dose).
10143725|NCT04163835|Placebo Comparator|Placebo Group|The intervention is a placebo.
10143726|NCT04163861||1|"31 patients diagnosed as heart failure with preserved ejection fraction per ESC guidelines 2016 on the basis of history, clinical examination and investigations presenting to the department of cardiology, BSMMU were selected inclusion criteria~Patients with regional wall motion abnormality in 2D echocardiography.~Patients with moderate to severe valvular heart diseases.~Patients with prosthetic valves and pacemakers.~Patients with congenital heart diseases.~Patients currently having arrhythmia such as atrial fibrillation on ECG screening during enrollment of patient.~Patients with poor echo window.~Patients who were not interested to take part in the study."
10143727|NCT04163861||2|31 normal healthy control subjects of similar age and sex of HFpEF subjects were taken. Normal echocardiograms will be defined as normal LV size and geometry, normal LVEF >55%). patients are free from cardiovascular diseases.
10143728|NCT04164043|Experimental|Recreational Therapy Wellness Recovery Program Group|All participants will enter a baseline data collection period for two weeks. They will then participate in a 12-week community-based Recreational Therapy (RT) Wellness Recovery Program (WRP) for individuals with Parkinson's disease (WRP).
10143729|NCT04163978|Experimental|Nitric oxide releasing solution (NOSi)|DailyTopical sinus irrigation delivery of 240mL NOSi
10143730|NCT04163978|Active Comparator|Budesonide -saline|Daily Topical sinus irrigation delivery of 240 mL of 1 mg Budesonide-saline
10143731|NCT04164017|Experimental|EUS-guided FNB with syringe suction|
10143732|NCT04164017|Active Comparator|EUS-guided FNB without syringe suction|
10143733|NCT04164030|Active Comparator|Nutrition Education Control|An evidence-based nutrition program entitled Eating Smart Being Active. Delivered in a group: Meets weekly for 2 hours for 9 weeks.
10143734|NCT04164030|Experimental|Nutrition Education +OT+Yoga|9 week group that meets twice a week for two hours each. Group occupational therapy and group yoga will be added to the nutrition program.
10143735|NCT04163653||Fontan Group|Fontan patients operated at the two centres between 1991 and 2014.
10143736|NCT04163653||Healthy Control Group|Age, gender and weight matched healthy controls.
10143737|NCT04163770|Experimental|performance of pacemaker at time of implantation|
10143738|NCT04163770|Experimental|performance of pacemaker 6 months after implantation|
9519711|NCT03284307|Experimental|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
9826113|NCT02408120|Active Comparator|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >260 mg/dL.
10143739|NCT04164004|Experimental|Early Implementation of Health Status Measurement|Patients in the early implementation arm will undergo KCCQ-12 assessment of patient-reported heart failure health status at each heart failure clinic visit beginning at the start of the trial. Assessment results will be available to clinicians when making treatment decisions during each clinic visit.
10143740|NCT04164004|Active Comparator|Delayed Implementation of Health Status Measurement|Patients in the delayed implementation will start receiving the KCCQ-12 assessment at each clinic visit beginning one year after randomization.
9528306|NCT03212014|Experimental|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
9826114|NCT02408198|Experimental|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
10143741|NCT04163783|Experimental|Arm A|Subjects will be administered a single oral dose of 320 mg of [14C]-BGB-3111
10143742|NCT04163679|Experimental|Vaginal Preparation|In addition to standard care, subjects will undergo vaginal preparation (VP). A VP kit includes sponge sticks and sponges soaked in a povidone-iodine 10% solution.
10143743|NCT04163679|Sham Comparator|Standard Infection Procedures|The very staff will follow hospital protocols for the cesarean delivery. The subject and the infant will be provided care in accordance with current medical standards and be discharged at the discretion of the attending physician.
10143744|NCT04163913|Experimental|Cirvo Device|The CirvoTM device (Figure 1) is a lightweight, mobile, active, intermittent leg compression device placed on the calf of the leg, using hook and loop (e.g. Velcro) straps in the similar manner as commercially available intermittent leg compression devices The system utilizes an electro-mechanical drive system to intermittently compress the calf from the ankle toward the knee for a duration and compression level prescribed by the physician. The level of compression delivered by the CirvoTM therapy will be in the same range as existing devices which corresponds to the type of pressure applied by a blood pressure cuff.
10143745|NCT04163913|Active Comparator|ActiveCare DVT|A commercially available device was previously used to assess patient satisfaction with compression therapy for DVT prophylaxis as per standard of care.
10187777|NCT03722719|Experimental|Group I (the Knack)|
9528307|NCT03212014|Experimental|POWER|Participants in this group would be treated with POWER for three months
9528308|NCT03212014|Active Comparator|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
9826115|NCT02408198|No Intervention|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
10143746|NCT04163796|Experimental|UPnRIDE Training|During each session, heart rate (HR), blood pressure (BP), total session time, time in standing posture, count of sit-to-stand positioning, total distance of overground movement, and rating of perceived exertion (Borg scale) for mobility skills will be monitored. At all study visits during the training period, participants will be asked to answer general health questions about the occurrence of any pressure ulcers or infections.
10143747|NCT04163510|Experimental|Reading Intervention Group|A group of parents and their children will participate in this single arm, pre-/post-intervention study. This 10-week study will include 10 sets of parents of low-reading elementary school children, recruited from Harlem Grown Community Center. Intervention will be implemented in a 9-week period, with data collection during the first intervention week and one week post-intervention. Three large-group sessions will be held in a central location (at Harlem Grown Community Center), to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. The reading program will help parents identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading.
10143748|NCT04163536|Active Comparator|cortisteroids arm|
10143749|NCT04163536|Placebo Comparator|placebo arm|
10143750|NCT04163757|Placebo Comparator|placebo|
10143751|NCT04163757|Active Comparator|crocin|
10143752|NCT04163497|Experimental|Diary reading|
10143753|NCT04163497|No Intervention|No diary reading|
10143754|NCT04163341|Experimental|CETA protocol|
10143755|NCT04163341|No Intervention|Enhanced Usual Care|
10143756|NCT04163523|Experimental|Treatment Sequence 1|5 Subjects received Period 1- 320 mg BGB-3111 administered after an overnight fast; Period 2- 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 3 - Day 15: 320 mg BGB-3111 administered after Low Fat/Calorie Meal
10143757|NCT04163523|Experimental|Treatment Sequence 2|5 Subjects received Period 1 - Day 1: 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 2- Day 8: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 3- Day 15: 320 mg BGB-3111 administered after an overnight fast
10143758|NCT04163523|Experimental|Treatment Sequence 3|Approximately 5 Subjects receive Period 1-Day 1: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 2-Day 8: 320 mg BGB-3111 administered after an overnight fast; Period 3- Day 15: 320 mg BGB-3111 administered after High Fat/Calorie Meal
10143759|NCT04163666|Experimental|Mirror therapy group|The mirror therapy group will receive a treatment based on this therapy, combined with task-oriented motor learning.
10143760|NCT04163666|Experimental|Cognitive therapeutic exercise group|The cognitive therapeutic exercise group will receive a treatment based on this therapy, combined with task-oriented motor learning.
10143761|NCT04163666|No Intervention|Control Group|No additional intervention with the participants of this group will be completed.
10143762|NCT04163575|Experimental|experimental:1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
10143763|NCT04163575|Experimental|experimental:2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
10143764|NCT04163575|Experimental|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
10143765|NCT04163705||Gram negative|"The presence of one or more positive samples will be considered positive blood cultures.~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
10143766|NCT04163705||Gram positive|"The presence of one or more positive samples will be considered positive blood cultures.~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
10143767|NCT04163549|Experimental|Safe at Home Cycle 1|The experimental arm will receive the Safe at Home program which is a community-based discussion group series aiming to prevent and respond to intimate partner violence and child maltreatment in conflict-affected communities. It includes once weekly, single-sex discussion groups with coupled men and women and once monthly family discussion groups with couples and children. During the weekly sessions men and women reflect critically and engage in dialogue related to gender, power, and privilege, learn about the causes and consequence of violence against women and children and gain skills in stress management, psychosocial support and positive parenting strategies. Family sessions focus on improving relationship quality and shared decision-making among partners and participation of children in family decision-making.
10143768|NCT04163549|No Intervention|Safe at Home Cycle 2|During the period of the study, this group will not receive an intervention. Rather, this arm will receive the Safe at Home program after endline data collection is completed for a waitlisted group.
10143769|NCT04163692|Experimental|Exercise Group|Progressive relaxation exercises (PRE) as 1 day supervised and 3 days home based program in a week, for 6 weeks
10143770|NCT04163692|No Intervention|Control Group|Information was provided about pain and its treatment and the importance of relaxing exercises without any intervention, up to 6 weeks.
10143771|NCT04163562|Experimental|INP20 (Oral Immunotherapy)|
10143772|NCT04163562|Placebo Comparator|Placebo|
10143773|NCT04163263|Experimental|Cohorts 1-3: BOS-356|Twice daily application of BOS-356 0.1%, 0.4%, and 0.7% gel in Cohorts 1, 2, and 3, respectively
10143774|NCT04163263|Placebo Comparator|Cohorts 1-3: Vehicle|Twice daily application of vehicle gel
9826116|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
10187778|NCT03722719|Active Comparator|Group II (PFMT)|
10143775|NCT04163263|Experimental|Cohort 4: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
10143776|NCT04163263|Placebo Comparator|Cohort 4: Vehicle|Twice daily application of vehicle gel
10143777|NCT04163263|Experimental|Cohort 5: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
10143778|NCT04163263|Placebo Comparator|Cohort 5: Vehicle|Twice daily application of vehicle gel
10143779|NCT04163445|Active Comparator|Depuy Attune|Subjects will have been implanted with the Depuy Attune PCR TKA
10143780|NCT04163445|Active Comparator|MicroPort Medial Pivot|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
10143781|NCT04163198|Experimental|Insufflation optimisation|Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.
10143782|NCT04163198|Experimental|Exsufflation optimisation|Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF
10143783|NCT04163211||Group 1|Patients with complicated appendicitis who had a drain inserted
10143784|NCT04163211||Group 2|Patients with complicated appendicitis who did not have a drain inserted
10143785|NCT04163419|Experimental|Arm A (treatment)|Tanezumab 10 mg SC administered on day 1 and Day 57 (± 4 days)
10143786|NCT04163419|Placebo Comparator|Arm B (placebo then treatment)|Placebo SC (to match tanezumab SC) administered on Day 1 and tanezumab 10 mg SC on Day 57 (± 4 days)
10143787|NCT04163822||group with typical imaging changes in early stages|the BPD infants with typical BPD radiographic changes within the first 14 days after birht, including fibrosis and cyst.
9826117|NCT02408445|Experimental|Testosterone treatment|Testosterone cypionate (200 mg/ml) intramuscular injection
10143788|NCT04163822||group with typical imaging changes in late stages|the BPD infants with typical BPD radiographic changes after 14 days of birht, including fibrosis and cyst.
10143789|NCT04163822||group without typical imaging changes|the infants meet the diagnosis criteria of BPD at postmenstrual age of 36weeks, but lack of typical radiographic changes.
10143790|NCT04163471||VasoStat|Randomized to use of VasoStat radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
10143791|NCT04163471||TR Band|Randomized to use of TR Band radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
10143792|NCT04163458|Experimental|MENOPUR liquid|MENOPUR liquid (including placebo to MENOPUR powder) initiated at a fixed dose of 225 international units (IU) for first five stimulation days. From stimulation Day 6, dosing can be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose will be 450 IU/day and the minimum dose will be 75 IU/day. The dosing can continue for a maximum of 20 days.
10143793|NCT04163458|Active Comparator|MENOPUR powder|MENOPUR powder (including placebo to MENOPUR liquid) initiated at a fixed dose of 225 IU for first five stimulation days. From stimulation Day 6, dosing can be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose will be 450 IU/day and the minimum dose will be 75 IU/day. The dosing can continue for a maximum of 20 days.
10143794|NCT04163250||Patients with ACS undergoing cardiac catheterization|"Adults with moderate / high risk acute coronary syndrome undergoing coronary intervention.~The sample will be selected consecutively, including patients admitted to the Cardiac Coronary Unit and who require a radiological test with intra-arterial IC administration, for diagnostic or diagnostic / therapeutic purposes"
10143795|NCT04163146|Experimental|Healthy children and adolescents|Healthy children and adolescents aged 6 to 18 years (N=100) for the assessment of normal PEF and FEV1 variability.
10143796|NCT04163146|Experimental|Asthmatic children and adolescents|Children and adolescents aged 6 to 18 years with diagnosed asthma (N=100) for the assessment of PEF and FEV1 variability in asthmatics.
10143797|NCT04163354|Active Comparator|NaF varnish|Application of a 5% NaF varnish (Duraphat, Colgate-Palmolive Ltd, Waltrop, Germany) on the occlusal surfaces of primary second molars and all other teeth, every 3 months during the study period;
10143798|NCT04163354|Experimental|GI sealant|Glass ionomer sealant (GC Fuji VII® (pink)) on all primary second molars included in the studies, with no further repair/replacement of the sealant
10143799|NCT04163276||Group 1|20 patients without anomaly of brain metabolism
10143800|NCT04163276||Group 2|20 patients with Alzheimer's disease
10143801|NCT04163367|Active Comparator|Intervention as usual|The social services standard process for families reported for violence or abuse towards children. The standard process always includes a formal investigation of the suspected violence/abuse. The investigation may or may not result in voluntary or mandatory interventions, such as family support or parent training.
10143802|NCT04163367|Experimental|Intervention as usual + Safer Kids|The procedure in this arm is exactly the same as in the active comparator arm (i.e., investigation that may be followed by interventions). In addition, the general parent training program Safer Kids is offered during the investigation to all participants in this arm.
10143803|NCT04163380|Experimental|Early Follicular Phase (EFP)|
10143804|NCT04163380|Experimental|Late Follicular Phase (LFP)|
10143805|NCT04163380|Experimental|Early Luteal Phase (ELP)|
10143806|NCT04163380|Experimental|Late Luteal Phase (LLP)|
10143807|NCT04163302|Experimental|CD19+ Lymphoma|This study is to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with Relapsed/Refractory B Cell Lymphoma.
10143808|NCT04163588|Active Comparator|Standard therapy|intravenous loop diuretics as recommended by current guidelines plus placebo
10143809|NCT04163588|Experimental|SNB|loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
10143810|NCT04163068||Interview with researcher|All participants will participate in an interview with a researcher
10143811|NCT04163029||preoperative oral care|
10187779|NCT03722719|Active Comparator|Group III (the Knack + PFMT)|
10187780|NCT03722706|Experimental|Handbook|handbook provided as an adjunct to standard AD management with a healthcare provider at BCH
10187781|NCT03722706|No Intervention|Control|standard management alone
9669352|NCT02875314|Experimental|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
9826118|NCT02408445|No Intervention|No treatment|Subjects will not receive any testosterone during the study period.
9970376|NCT01299597|Experimental|Cohort 2: Simvastatin|single dose session with Simvastatin with PK samples collected up to 24h post dose, then 14 days repeat dose session with SB649868 with Simvastatin single dose co-administered on day 12 (same time as SB649868) and on day 14 (2 hours before SB649868).
9970377|NCT01299623|Active Comparator|Evidential Group|Participants in this group will receive education about breast cancer prevention and specific information about African American women and breast cancer risk.
9970378|NCT01299623|Active Comparator|Non-Evidential Group|Participants in this group will receive general information about breast cancer prevention without anything specific to African American women.
9970379|NCT01299636|Experimental|PM060184|
9970380|NCT01299649||Non-contrast echocardiography|Non-contrast echocardiography
9970381|NCT01299649||Contrast Echocardiography|Contrast Echocardiography
9970382|NCT01299662|Experimental|Poly ICLC|One 1.6 mg subcutaneous injection of the adjuvant, poly ICLC, in the upper arm.
9970383|NCT01299675||Chronic Performance|Subjects enrolled prior to or within 30 days post implant of SureScan pacing system. In office follow-up visits required every 6 months.
9970384|NCT01299675||Multiple MRI Scan Characterization|Subject enrolled into study at the time of MRI Scan indication. Subject followed per clinic standard of care.
9970385|NCT01299701|Experimental|ASA404|
9970386|NCT01299740|Other|Control Group|Treatment as usual
9970387|NCT01299740|Experimental|Research Group|Participation in the DBT skills group
9970388|NCT01299779|Active Comparator|PEG-ELS|
9970389|NCT01299779|Active Comparator|PEG-SD|
9970390|NCT01299792||one arm; neurogenic bladder dysfunction|evaluation of the clinical utility of bladder wall thickness as a diagnostic tool in patients with spinal cord injury
9970391|NCT01299818||spinal surgery|patients who undergo spinal surgery
9970392|NCT01299831|Experimental|72 hour fast|
9970393|NCT01299831|Experimental|12 hours fast|
9970394|NCT01299831|Experimental|12 hour fast, growth hormone bolus|
9970395|NCT01299831|Experimental|72 hour fast, inhibition of lipolysis|
9970396|NCT01299844|No Intervention|Standard Care|
9970397|NCT01299844|Experimental|Diabetes Peer Counseling|
9970398|NCT01299870|Active Comparator|AED treatment plus placebo|
9970399|NCT01299870|Experimental|Keishibukuryogan|
9970400|NCT01299883|Active Comparator|Cancer and CVD Education|Participants receive education about both cancer and CVD risk factors and their relationship to dietary and physical activity health behaviors.
9970401|NCT01299883|Active Comparator|CVD Education|Participants receive education about CVD risk factors and their relationship to dietary and physical activity health behaviors.
9826119|NCT02408484|Experimental|Octafibrin|Plasma-derived fibrinogen concentrate
9970402|NCT01299922|Experimental|cyclosporine+mycophenolic acid+prednison|Triple therapy
9970403|NCT01299922|Active Comparator|mycophenolic acid + prednison|Mycophenolic acid+prednison 106 weeks
9970404|NCT01299948|Active Comparator|prednisolone|5 mg prednisolone per os daily administration
9970405|NCT01299948|Placebo Comparator|placebo|The placebo is designed to the equal look like the study medication.
9970406|NCT01299974|Other|Parents and Residents in Session|Parents and Residents in Session
9970407|NCT01299987|Experimental|Intraoperative radiotherapy|single arm with intraoperative radiotherapy
9970408|NCT01300000|Active Comparator|Human Milk|ad lib
9970409|NCT01300000|Active Comparator|Milk based standard infant formula|ad lib
9970410|NCT01300000|Experimental|Milk based investigational infant formula|ad lib
9970411|NCT01300026|Experimental|Part II Dose Expansion|Dose selected from Part I dose exploration
9970412|NCT01300026|Experimental|Part I Dose Exploration|The AMG 319 doses proposed for this study are 25, 50, 100, 200, 300 and 400 mg administered by mouth once daily.
9970413|NCT01300039||Antibiotics for H. pylori|Patients who underwent upper endoscopy and were found to have H. pylori, and were then to be treated with antibiotics for eradication of H. pylori
9970414|NCT01300039||Control group, no H. pylori|Patients who underwent upper endoscopy and found to not have H. pylori, and then would not receive antibiotics
9970415|NCT01300078|Experimental|MF101 10 grams/day|
9970416|NCT01300078|Experimental|MF101 15 grams/day|
9970417|NCT01300104|Experimental|Exercise and whole grain rye|
9970418|NCT01300104|Active Comparator|No prescriptions|
9970419|NCT01300117||with extracorporeal circulation|Patients undergoing cardiac surgery with the use of an extracorporeal circulation
9970420|NCT01300117||without extracorporeal circulation|Patients undergoing cardiac surgery without the use of extracorporeal circulation (OPCAB)
9970421|NCT01300130|Experimental|low docosahexaenoic acid formula|
9970422|NCT01300130|Experimental|medium docosahexaenoic acid formula|
9970423|NCT01300130|Experimental|high docosahexaenoic acid formula|
9970424|NCT01300130|Active Comparator|human milk|
9970425|NCT01300156|Experimental|ESHAOx arm|Patients who are planned to be treated with ESHAOx chemotherapy
9970426|NCT01300169|Experimental|CAMS--Collaborative Driver-Treatment|"The Collaborative Assessment and Management of Suicidality (CAMS) is a suicide-specific clinical intervention that targets and treats patient-defined suicidal drivers over the course of clinical care."
10143812|NCT04163315|Experimental|dMRI, fMRI and electrocorticography|With this exploratory pilot study, the investigator propose a multimodal evaluation of the structural and functional connectivity of patients with brain tumours, in order to better understand the tumor-induced lesion mechanisms on brain connectivity as well as the brain plasticity mechanisms that the brain develops to maintain a level of overall function neurological. The investigator hope to obtain multimodal brain mapping of locally brain-damaged patients, with a view to improving onco-functional neurosurgical practices.
10143813|NCT04163120|Experimental|Intervention|In this single arm study subjects follow a low calorie mediterranean ketogenci diet
10143814|NCT04163172|Active Comparator|Elbow hemiarthroplasty|The Latitude anatomical hemiarthroplasty (WRIGHT -Memphis, Tennessee) for distal humeral fractures.
10143815|NCT04163172|Active Comparator|Open reduction and internal fixation|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States) for distal humeral fractures.
10143816|NCT04162951|Experimental|Ordinary approach group|The patients in this group will receive ordinary ultrasound-guided thoracic paravertebral block. by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
10143817|NCT04162951|Experimental|Retro-laminar approach group|The patients in this group will be receive real ultrasound-guided Retrolaminar thoracic paravertebral block by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
10143818|NCT04163133|Experimental|two days delay of trigger group|Two days later of trigger than regular trigger timing day (three follicles reach 17mm) .
10143819|NCT04163133|No Intervention|regular trigger group|regular trigger timing when three follicles reach 17mm bilateral.
10143820|NCT04162912|Experimental|Experimental group|Participants in the experimental group will receive a MotivationaI Interviewing tailored ACP programme.
10143821|NCT04162912|No Intervention|Control group|The participants in the control group will receive usual care offered by the palliative care team under study and its affiliated day care centres, home care team and outpatient clinics.
10143822|NCT04163055|No Intervention|Standard of Care|Wounds will be assessed using the Clinical Signs and Symptoms Checklist (CSSC). After initial assessment, a white-light (WL) photo will be taken of the wound. The wound bed will be prepared as indicated by clinical staff based on standard of care (SoC), including irrigation and debridement. A second WL image will be taken and a swab/biopsy will be obtained from the wound. Wounds will be dressed based on SoC.
10143823|NCT04163055|Experimental|Autofluorescence guided Standard of Care|Wounds will be assessed by autofluorescence (AF)-guided SoC. A baseline WL and AF photo will be taken of the wound. AF images will guide SoC including targeted debridement of areas of bacterial growth (AF+) and targeted sampling in areas of residual bacterial growth post-debridement. If no bacterial AF is detected, sample will be obtained from the wound center by curettage technique. If AF is detected, AF-guided debridement will be repeated and additional images will be obtained until 1) no AF is detected or 2) further debridement is not medically advised. After wound bed preparation, a second set of WL and AF images will be taken. Wounds will be dressed as per SoC. At all visits, samples will be sent for microbiology analysis. At 6- and 12-week visits (or any other scheduled visits in between), microbiology reports will be shared with clinicians if they were not collected outside of SoC.
10143824|NCT04162977|Experimental|High-risk youth|The 23-item Substance Use Risk Profile Scale (SURPS) will be used to identify high-risk adolescents who enter the intervention trial. Adolescents who score high on one of SURPS subscales (i.e., high-risk youth) will be invited to participate in two group-based intervention sessions which target their dominant personality profile. The criterion for high scores on SURPS personality traits are determined based on norms from high-risk adolescents in the same age range who participated in previous trials on personality-targeted interventions.
10143825|NCT04163237|Experimental|PD-1 & Sorafenib|
10143826|NCT04163237|Other|Sorafenib|
10143827|NCT04163094|Experimental|Treatment arm|Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.
10143828|NCT04163081|Experimental|Quit Card Intervention (QCI)|Study intervention group.
10143829|NCT04163081|No Intervention|Usual Care (UC)|Study control group.
10143830|NCT04162990|Experimental|Lifestyle remodeling|
10143831|NCT04162990|Active Comparator|Does Comparator: regular treatment|
10143832|NCT04162587||1)Patients with significant carotid stenosis only|Patients with significant carotid stenosis without intracranial stenosis.
10143833|NCT04162587||2) Patients with carotid and intracranial stenosis.|Patients with carotid and intracranial stenosis.
10143834|NCT04162587||3) Patients with lone intracranial stenosis.|Patients with lone intracranial stenosis.
10143835|NCT04162587||4) Patients with no significant stenosis|Patients with no significant carotid or intracranial stenosis.
10143836|NCT04162691||Malignant thymoma|
10143837|NCT04162691||Benign thymoma|
10143838|NCT04162626|Experimental|Intervention|Supportive home visits by public health nurses to new parents from 28 weeks in pregnancy until the child is two years.
10143839|NCT04162626|Other|Control|Follow up as usual at the Child health center
10143840|NCT04162678||Diagnostic (blood collection via fluid biopsy, lab analysis)|Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.
10143841|NCT04162743|Active Comparator|Trazodone|take trazodone 100mg hs
10143842|NCT04162743|Placebo Comparator|Placebo|take placebo pill hs
10143843|NCT04162639|Experimental|One donor|Participants will receive skin allograft from 1 distinct cadavers.
10143844|NCT04162639|Experimental|Two donors|Participants will receive skin allograft from 2 distinct cadavers.
10143845|NCT04162639|Experimental|Three donors|Participants will receive skin allograft from 3 distinct cadavers.
10143846|NCT04162639|No Intervention|Control|Participants will be burned patients with wounds that do not require skin allografts, but are instead reconstructed with their own skin (skin autografts) in a single stage.
10143847|NCT04162834|Experimental|Papaverine group|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
10143848|NCT04162834|Active Comparator|Normal saline group|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
10143849|NCT04162821|Experimental|60mg group|
10143850|NCT04162821|Experimental|90mg group|
10143851|NCT04162821|Experimental|120mg group|
10143852|NCT04162873|Experimental|Celecoxib Arm|Patients receive celecoxib PO or via feeding tube BID starting 5 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
10143853|NCT04162873|Placebo Comparator|Placebo Arm|Patients receive placebo PO or via feeding tube BID starting 5 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
10143854|NCT04162886|Experimental|Exercise Group|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
10143855|NCT04162886|No Intervention|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
10143856|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
10143857|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
10143858|NCT04162899|Active Comparator|Placebo Comparator: Placebo|Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.
10143859|NCT04162860|Experimental|minimally invasive esophagectomy with preemptive ENP|Patients will undergo a standard total minimally invasive transthoracic Ivor Lewis esophagectomy with preemptive ENP. After completion of the esophago-gastric anastomosis, an Eso-SPONGE® system will be inserted via an intraoperative gastroscopy. ENP will be carried out upon completion of the esophago-gastrostomy, but no later than 12 hours after the surgical intervention. Postoperatively, secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg. ENP will remain for 4 days and will be monitored with clinical parameters.
10143860|NCT04162860|No Intervention|Standard minimally invasive esophagectomy|Patients in the control group will undergo a standard minimally invasive transthoracic Ivor Lewis esophagectomy without preemptive ENP.
10143861|NCT04162535|Experimental|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
10143862|NCT04162535|Experimental|Total intravenous anesthesia|Patients will receive a general anesthesia with Propofol as anesthetic agent
10143863|NCT04162535|Experimental|Total intravenous anesthesia and Lidocaine|Patients will receive a general anesthesia with Propofol as anesthetic agent and will also receive a fully lidocaine infusion according to the lidocaine protocol
10143864|NCT04162535|No Intervention|Placebo|10 presumed healthy volunteers that have donated 10 ml of venous blood for serum comparison
10143865|NCT04162717|Experimental|The Effect of Telephone Symptom Triage Protocols|"Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles.~Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later."
10143866|NCT04162717|No Intervention|Control group|The control group received standard nursing care applied at the hospital
10143867|NCT04162522|Active Comparator|escitalopram (10-20 mg)|"Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as responders or non-responders. Responders will continue on escitalopram until the study endpoint (16 weeks)."
10143868|NCT04162522|Active Comparator|brexpiprazole (0.5-2 mg)|"At week 8, participants classified as non-responders will be given 8 weeks of brexpiprazole as add-on treatment to escitalopram."
10143869|NCT04162574||BEGIN Case|Enrolled participants with BN/BED will participate in a 30-day observational study.
10143870|NCT04162613||Patients with ACL reconstruction in Lund and Umeå|Persons who have suffered a unilateral anterior cruciate ligament injury treated with reconstruction
10143871|NCT04162249||Conventional ablation (CONTROL GROUP)|"Pulmonary veins ablation.~Anterior aspect: power 30 W, catheter dragging (30 s per point).~Posterior aspect: point-by-point ablation using 30 W/30 s applications. If esophageal temperature measured with two independent esophageal probes exceeded 49 ºC radiofrequency settings were modified to 20 W/ 60 s and the number of radiofrequency applications minimized in areas with esophageal temperature rise.~Al procedures were performed with continuos intracardiac echo image and esophageal temperature monitoring."
10143872|NCT04162249||High-power and short-duration ablation|"Pulmonary veins ablation.~Subgroup 50W: power 50 W, application duration ≤ 30 s, target lesion index: LSI ≥ 5 or Ablation Index ≥ 350 (posterior wall) or ≥400 (anterior wall).~Subgroup 60W: power 60 W, application duration 7-10 s, contact force ≥5 g.~Subgroup 70W: power 70 W, application duration 9 s, contact force ≥5 g.~Intracardiac echo was not used. Esophageal temperature probes were used only in 6 patients in the subgroup 50W."
10143873|NCT04162379|Other|Prospective quizi-pre-post oral predensolone|single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mgs for 3 successive dosing every 4th day then stop the drug totally).
9519712|NCT03284294|Placebo Comparator|Placebo|Oral placebo daily for 8 weeks
9970427|NCT01300169|Active Comparator|Enhanced Care as Usual--E-CAU|This control group treatment will reflect current clinical practices for treating suicidal soldiers in the research site setting. These are providers were on site clinicians who provided care according to their usual and customary practices for working with suicidal risk within outpatient care.
9970428|NCT01300182|Experimental|Whole body vibration therapy|Whole body vibration therapy on top of conventional physiotherapy treatment.
10143874|NCT04162509|Experimental|Exposure|The experimental intervention in the experimental group consists of six 30-minutes AR exposures as home training (total duration in AR: 3 hours) within two weeks.
10143875|NCT04162509|No Intervention|Control|The control group will not receive any active treatment (untreated comparison group).
10143876|NCT04162418|Other|Intervention|Treatment with Temporary Spur Stent System and a commercially available, limus-base, drug coated balloon
10143877|NCT04162496|Experimental|Treatment with Restylane Refyne Group 1|Treat right side with Restylane Refyne with a cannula and left side with a needle
10143878|NCT04162496|Experimental|Treatment with Restylane Refyne Group 2|Treat left side with Restylane Refyne with a cannula and right side with a needle
10143879|NCT04162392|Experimental|Experimental group|
10143880|NCT04162392|Active Comparator|Control group|
10143881|NCT04162197|Experimental|Experimental 1: Gait Group (GG)|Gait Group (GG) will perform, in addition to conventional therapy, gait training using only an end effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 12 sessions/month. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/ h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
10143882|NCT04162197|Experimental|Experimental 2: Balance Group (GHG)|Balance Group (GHG) will receive, in addition to conventional therapy, a combined robotic treatment program with the same end-effector robotic system and a robotic proprioceptive platform, 3 times/week for 12 sessions/month. The time of the single session (45 minutes) is dived in gait training and balance training. The balance training will consist in static and dynamic exercises during sitting and standing position, dual-task exercises and exercises aimed to improve trunk control.
10143883|NCT04162288|Experimental|Online training on SDM in prenatal screening|
10143884|NCT04162288|Placebo Comparator|Online training on prenatal screening|
10143885|NCT04162171|Experimental|Imaging & SBRT Treatment for Ventricular Tachycardia|
10143886|NCT04162444||Cohort 1|We will study safety, clinical and hemodynamic efficacy of the method of the aortic valve reconstruction with autopericardium in children with aortic valve disease.
10143887|NCT04162301|Experimental|CS3002 CDK4/6 inhibitor|
10143888|NCT04162431||non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
10143889|NCT04162431||hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
10143890|NCT04162431||squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
10143891|NCT04162431||reactive|patients diagnosed with a reactive (non-cancerous) lymph node
10143892|NCT04162431||other|none of the above. Other cancer and non-cancer conditions
10143893|NCT04162132||DynamiCare group|Patients at Morgan Street location of BrightView who were given the DynamiCare smartphone app.
10143894|NCT04162132||Non-DynamiCare group|Patients at Colerain location of BrightView who were not given the DynamiCare smartphone app.
9970429|NCT01300182|Active Comparator|Control|Conventional post-operative physical therapy rehabilitation exercises.
10143895|NCT04162327|Experimental|Ia stage - IBI315 Dose escalation|
10143896|NCT04162327|Experimental|Ib stage - IBI315 monotherapy|
10143897|NCT04162353|Experimental|BCMA-CD19 cCAR|Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg
10143898|NCT04162366|Experimental|Aprocitentan 25 mg|
10143899|NCT04162366|Experimental|Placebo|
10143900|NCT04162366|Experimental|Aprocitentan 25 mg or Placebo|
10143901|NCT04162405||Patients with tinnitus and hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold >30 dB
10143902|NCT04162405||Patients with tinnitus without hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold <30 dB
10143903|NCT04162340|Experimental|CD4 CAR T cells|Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg
10143904|NCT04162236||High Risk of Preeclampsia|"Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they meet the following criteria:~1)High risk for preeclampsia according to first trimester screening (maternal risk factors, blood preassure, PPAP-A, mean pulsatility index (PIm) of the uterine arteries (UtA) at 11.0 to 13.6 weeks of gestation (n=280).~Women in this group will be subdivided in cases and controls according to the later development of preeclampsia:~cases: women developing PE (estimated n=40)~controls: women not developing PE (estimated n=240)"
10143905|NCT04162236||Patients with Preeclampsia|Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they develop PE. Inclusion criteria: Patients presented with clinical signs and symptoms of preeclampsia (N=60).
10143906|NCT04162236||Control group|Healthy pregnant women with at low risk PE screening at 11.0 to 13.6 weeks of gestation (n=100).
10184944|NCT03750591||Integrative Korean medicine treatment group|"Observation of pain, function, quality of life, satisfaction, and adverse events in inpatients with lumbar intervertebral disc herniation hospitalized at 4 Korean medicine hospitals~Interventions:~Drug: Herbal medicine Procedure/Surgery: Chuna manual therapy Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s)"
10184945|NCT03750578|Experimental|Virtual Reality Group|Patients in this group will be offered virtual reality distraction through the use of OR in addition to standard of care.
10184946|NCT03750578|No Intervention|Standard of care group|Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse.
10184947|NCT03750565|Experimental|Cohort 1|Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
9970430|NCT01300195||lung cancer surgery|Patients undergoing video-assisted thoracic surgery
9970431|NCT01300221||Group 1|Subjects who are healthy normal children.
10143907|NCT04162262|Experimental|Stretching, Strengthening, and IASTM|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. This group will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
10143908|NCT04162262|Active Comparator|Strengthening and Stretching|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. To equalize visit time with the Stretching, Strengthening, and IASTM group, subjects will perform 15 minutes of self-paced bicycle riding at the beginning of each session. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
10143909|NCT04162262|Other|Pain-free Comparison Group|The third group is a pain-free comparison group. This group will come to the laboratory once. They will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. These measurements will be compared to the same measures from the Stretching, Strengthening, and IASTM group to examine outcome measure differences in those with and without plantar fasciopathy following a single IASTM treatment.
10143910|NCT04162119|Experimental|multiple myeloma|This study is to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with Relapsed/Refractory Multiple Myeloma.
10143911|NCT04162145|Active Comparator|Active Device|Patients in the Active Device arm will receive placement of an active BRIDGE device.
10143912|NCT04162145|Sham Comparator|Sham Device|Patients in the Sham Device arm will receive placement of an inactive, or sham, BRIDGE device. The inactive device will be identical in appearance to the active device but will have no electrical current.
10143913|NCT04162093|Experimental|single trough|
10143914|NCT04162158|Experimental|Targeted drug combined with allogeneic NK cell treatment group|In addition to traditional symptomatic supportive treatment, Sorafenib, regolfinib or levabinib will be administered in combination with allogeneic NK cells (3 cycles).
10143915|NCT04162158|No Intervention|Targeted drug treatment group|Sorafenib, regolfinib or levabinib will be administered in addition to traditional symptomatic supportive care.
10143916|NCT04162106|Active Comparator|Ultravision™ System|Smoke management during laparoscopic cholecystectomy performed with the Ultravision™ System
10143917|NCT04162106|Active Comparator|Airseal® iFS|Smoke management during laparoscopic cholecsystectomy performed with the Airseal® iFS
10143918|NCT04162028|Experimental|Nebulized Ketamine|sub-dissociative dose ketamine administered prehospitally via breath-actuated nebulizer at 1.0 mg/kg for patients with acute pain
10143919|NCT04162314|Experimental|Experimental|This group received combination of mycelium extract of Ganoderma lucidum capsule containing 180 mg Beta-1,3/1,6-D-Glucan with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
10143920|NCT04162314|Placebo Comparator|Control|This group received combination of placebo capsules with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
10143921|NCT04162223|Experimental|Subcutaneous Fat Vaccine Injection|Subcutaneous fat Hepatitis B vaccine injections on Days 0, 28, and 180.
10143922|NCT04162223|Experimental|Intramuscular Vaccine Injection|Intramuscular Hepatitis B vaccine injections on Days 0, 28, and 180.
10143923|NCT04162002|Experimental|Restylane® Lyft Filler Injection|
10143924|NCT04162457|Experimental|Stevia beverage|Participants receive 4 study beverages in the 4 imaging sessions in randomised and counterbalanced order.
10143925|NCT04162457|Experimental|Glucose beverage|330 ml of water with glucose (equal sweetness with the stevia beverage)
10143926|NCT04162457|Experimental|Maltodextrin beverage|330 ml of water with maltodextrin (equal amount of calories as the glucose beverage)
10143927|NCT04162457|Placebo Comparator|Water|330 ml water
10143928|NCT04161820|Experimental|Education and telephone follow ups based on the CCM|"After the pre-tests (self-management, quality of life and patient satisfaction were assessed by scales at the first interview), the patients were given discharge training with a booklet prepared based on the Chronic Care Model (CCM) and containing information and recommendations on self-management strategies during their stay in the hospital (0 months). Trainings were performed in a single session and in the patient room at the clinic, not to exceed 45-50 minutes. The patients who were included in the intervention group were followed up by phone on the 7th day, 15th day, 1st month and 2nd month after discharge. Patients were referred to the hospital in unexpected / unpredictable situations during the three-month period.~Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later."
10143929|NCT04161976|Experimental|LY900027|LY900027 administered to participants with type 1 diabetes mellitus (T1DM) using continuous subcutaneous insulin infusion (CSII) in one of two dosing periods.
10143930|NCT04161976|Active Comparator|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII in one of two dosing periods.
10143931|NCT04161963||Phaco|tandard ultrasound phacoemulsification cataract surgery
10143932|NCT04161963||FLACS|femtolaser assisted cataract surgery
10143933|NCT04161963||phaco+MIGS|combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery
10143934|NCT04161937|Experimental|Behavioural Intervention|Half of the randomly selected participants will get behavioural intervention based on Diabetes Prevention Program module.The behavioural intervention classed will be administered by trained nurse weekly for 16 weeks.After completion of behavioural intervention both the experimental and control arm will get cafeteria intervention.
10143935|NCT04161937|Experimental|Control|Half of the participants will act as a control and will not receive any form of behavioural intervention.
10143936|NCT04161872|Active Comparator|Uricemin|
10143937|NCT04161872|Placebo Comparator|Placebo|
10143938|NCT04161768|Active Comparator|Norfloxacin|Norfloxacin 400 mg daily
10143939|NCT04161768|Experimental|Norfloxacin and Itopride|Norfloxacin 400 mg daily and Itopride 50 mg three times daily.
9970432|NCT01300221||Group 2|Subjects who have congenital heart disease.
10143940|NCT04161638|Experimental|High Blood Pressure|Ambulatory BP measurement was used to confirm the laboratory BP group classification according to the European Society of Hypertension. Participants were placed in the high blood pressure (HBP) group if they met any of the following criteria: 1) 19-hour average systolic BP/diastolic BP (SBP/DBP) > 130/80 mmHg, 2) daytime (awake) average SBP/DBP > 135/85 mmHg, or 3) nighttime (sleep) average SBP/DBP > 120/70 mmHg.
10143941|NCT04161638|Experimental|Normal Blood Pressure|Participants were placed in the normal BP (NBP) group if they met all of the following criteria: 1) 19-hour average SBP/DBP < 130/80 mmHg, 2) daytime (awake) average SBP/DBP < 135/85 mmHg, and 3) night-time (asleep) average SBP/DBP <120/70 mmHg.
10143942|NCT04161833|Experimental|OPERA|Women receiving adjuvant aromates-inhibitor with arhtralgia grade ≥ 1 (CTACAE 4.03)
10143943|NCT04161924||X-ray imaging with physical grid using conventional processing|
10143944|NCT04161924||X-ray without physical grid using conventional processing|
10143945|NCT04161924||X-ray imaging without physical grid using experimental SimGrid|
10143946|NCT04161625|Experimental|Safe Step - digital exercise program|"All included participants will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.~Additional support to promote reach and exercise adherence will be provided in the format of technical support and try-out group exercises throughout the recruitment period."
10143947|NCT04161794|Experimental|Intervention group|2 g EPA/DHA via fish oil daily Regular dietary counselling Twice weekly strength and cardiovascular exercise
10143948|NCT04161794|No Intervention|Historical control group|Standard of Care
10143949|NCT04161690|Active Comparator|Group IV|Dexketoprofen 50mg is given intravenous 10 min before the start of the surgery. Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
10143950|NCT04161690|Active Comparator|Group Periarticular|Dexketoprofen 50mg is given as part of the local infiltration analgesia with 300mg ropivacaine. Local infiltration analgesia is proceeded by the orthopedic surgeon.
10143951|NCT04161690|Placebo Comparator|Group P|Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
10143952|NCT04161703|Experimental|focused ultrasound, diet and exercises|
10143953|NCT04161703|Experimental|diet and exercises|
10143954|NCT04161664|Experimental|neo adjuvant Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
10143955|NCT04161846|Experimental|Virtual World Program|Participants take part in a group training delivered using a virtual world approach.
10143956|NCT04161846|Active Comparator|In Person Program|Participants take part in a group training delivered using an in person approach.
10143957|NCT04161651|Experimental|single arm|
10143958|NCT04161729|Active Comparator|Magnesium sulfate|Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
10143959|NCT04161729|Placebo Comparator|Isotonic solution 0.9%|Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.
10143960|NCT04161573||TBI group|15 people in this group. Each should be post TBI for 6 months.
10143961|NCT04161573||Control group to TBI|15 people in this group. Their gender and age accord with TBI group.
10143962|NCT04161573||Aging group 1- 20 to 39|Normal people whose age range from 20 to 39.
10143963|NCT04161573||Aging group 2- 40 to 59|Normal people whose age range from 40 to 59.
10143964|NCT04161573||Aging group 3- above 60|Normal people whose age are above 60.
10143965|NCT04161508|Experimental|Sugammadex|sugammadex 2 mg/ Kg for the reversal of neuromuscular blockade at the end of surgery
10143966|NCT04161508|Active Comparator|Neostigmine|neostigmine 50 mcg/Kg + glycopyrrolate 10 mcg/kg for the reversal of neuromuscular blockade at the end of surgery
10143967|NCT04161521|Other|Placenta Accreta patients|of 60 pregnant female diagnosed as placenta previa accreta recuirted from Obstetrics and Gynecology Department , Menoufia University Hospital.
10143968|NCT04161560|Experimental|use of the cetuximab-IRDye800|four groups : control group, 1% dose group (1% of therapeutic dose; 2.5 Mg/m2) and 10% dose groups (10%of therapeutic dose ;25mg/m2) and 25% dose group (25%of therapeutic dose; 62.5mg/m2)
10143969|NCT04161547|Experimental|Cohort A1: CSPCHA115 100 mg|"CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
10143970|NCT04161547|Experimental|Cohort A2: CSPCHA115 200 mg|"CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
10143971|NCT04161547|Experimental|Cohort A3: CSPCHA115 400 mg|"CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
10143972|NCT04161547|Experimental|Cohort A4: CSPCHA115 600 mg|"CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
10143973|NCT04161417|Other|Biopsy Material Required for Registration|The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer
10143974|NCT04161222|Experimental|Experimental group|The control group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
10143975|NCT04161222|Experimental|Control group|The control group will perform a typical warm-up of competitive football.
10143976|NCT04161482|Experimental|Cohort One|A bi-phasic delivery over 5 hours
10143977|NCT04161482|Experimental|Cohort 2a|Continuous infusion over 2 hours
10143978|NCT04161482|Experimental|Cohort 2b|Bi-phasic delivery over 2 hours
10143979|NCT04161482|Experimental|Cohort 3|Continuous infusion over 1 hour.
9970433|NCT01300221||Group 3|Subjects who have sickle cell disease
9970434|NCT01300221||Group 4|Subjects who have Duchenne muscular dystrophy
9970435|NCT01300221||Group 5|Patients who have Marfan syndrome and other aortic disease
9970436|NCT01300273|Experimental|Ketosteril|
9970437|NCT01300299|Experimental|All subjects|Subjects will receive chemotherapy after stereotactic body radiation therapy.
9970438|NCT01300312|Experimental|1|
9970439|NCT01300312|Active Comparator|2|
9970440|NCT01300325|Placebo Comparator|0.9% saline|patients receive every 6 hours the nebulized 0.9% saline (placebo comparator) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
9970441|NCT01300325|No Intervention|3% hypertonic saline|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
9970442|NCT01300364|Placebo Comparator|sugar pill|
9970443|NCT01300364|Active Comparator|reboxetine (NRI)|
9970444|NCT01300364|Active Comparator|citalopram (SSRI)|
9970445|NCT01300377|Active Comparator|Bupivacaine / Lidocaine|Lidocaine/Bupivacaine mixture - 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
9970446|NCT01300377|Active Comparator|Lidocaine|Lidocaine - 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
9970447|NCT01300390||End-stage liver disease pre-transplant|Patients with end-stage liver disease (non-fulminant) awaiting liver transplant
9970448|NCT01300403|Experimental|FLUTTER|Since this was a crossover study, all patients performed all interventions in a randomized order.
9970449|NCT01300403|Experimental|ELTGOL|Since this was a crossover study, all patients performed all interventions in a randomized order.
9970450|NCT01300403|Active Comparator|CONTROL|Since this was a crossover study, all patients performed all interventions in a randomized order.
9970451|NCT01300416||With Gastro-Intestinal (GI) symptoms|
9970452|NCT01300416||Without GI symptoms|
9970453|NCT01300429||patients with Non Small Cell Lung cancer|This is a protocol to obtain and/or analyze tissue specimens of patients with NSCLC harboring an activating ALK inversion or translocation that have had a previous clinical response to tyrosine kinase inhibitor therapy and subsequently experience progressive disease. The tissue will be used to identify changes in the ALK gene that are acquired during treatment with an ALK TKI and may account for acquired resistance.
9970454|NCT01300442|Experimental|Control|The transcutaneous electrical diaphragmatic stimulation will be applied in healthy and COPD subjects.
9970455|NCT01300442|Experimental|Chronic Obstructive Pulmonary Disease|The intervention will be the TEDS in patients with Chronic Obstructive Pulmonary Disease (COPD)
10143980|NCT04161482|Experimental|Cohort 4|Continuous infusion over 30 minutes.
9970456|NCT01300468|Experimental|Dose-escalation|
9970457|NCT01300520|No Intervention|Target Tape|Including target tape in the procedure
9970458|NCT01300520|Other|Control|Without target tape in the procedure
9970459|NCT01300585|Other|MRI|All patients on study will undergo an MRI of the breast(s).
9970460|NCT01300611|Experimental|TXA127 300 mcg/kg/day|Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
9970461|NCT01300611|Experimental|TXA127 1000 mcg/kg/day|Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
9970462|NCT01300637|Active Comparator|metformin|metformin intervention group
9970463|NCT01300637|Placebo Comparator|placebo|placebo-controlled
9970464|NCT01300663||post-surgery symptom experience|women with vulvar intraephitelial neoplasia or vulvar cancer
9970465|NCT01300676|Active Comparator|Tualang Honey|Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
10143981|NCT04161339|Experimental|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
10143982|NCT04161339|Placebo Comparator|Placebo|
10143983|NCT04161196|Active Comparator|patients with post - tonsillectomy suturing tonsil pillars|
9970466|NCT01300676|No Intervention|Group 2|Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
9970467|NCT01300702||lung cancer surgery|Patients undergoing thoracotomy for lung cancer
9970468|NCT01300715|Active Comparator|MBRF|
9970469|NCT01300754|Active Comparator|Dextrose|
9970470|NCT01300754|Active Comparator|Lidocaine|
9970471|NCT01300754|Active Comparator|Usual Care|
9970472|NCT01300780|Active Comparator|Experimental|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
9977031|NCT01357369||Ondansetron/Cefazolin treatment|Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
10143984|NCT04161196|Placebo Comparator|patients without post - tonsillectomy suturing tonsil pillars|
10143985|NCT04161170|No Intervention|Control A|no intervention conventional diabetes treatment and clinic visit every 3 months
10143986|NCT04161170|Active Comparator|Intervention B|apply digital integrated healthcare platform clinic visit every 3 months
10143987|NCT04161170|Experimental|Intervention C|apply digital integrated healthcare platform, CGMS, and medical team monitoring, and education clinic visit every 3 months
10143988|NCT04161235||Treatment|Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
10143989|NCT04161469|Other|Group 1|Patients diagnosed with anal fistula treated by laser closure of the tract
10143990|NCT04161469|Other|Group 2|Patients diagnosed with anal fistula treated by laser closure of the tract with an additional surgical technique as the closure of the internal orifice with a purse-string suture using 2-0 polyglactin
10143991|NCT04161287||SBRT with TACE|
10143992|NCT04161287||SBRT alone|
10143993|NCT04161274|Active Comparator|Traditional method: Electrosurgery|"Local anaesthesia and excision with a scalpel connected to the electric current, according to the voltage. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
10143994|NCT04161274|Active Comparator|Traditional method: Cryotherapy|"Application of liquid nitrogen to cause freezing. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
10143995|NCT04161274|Active Comparator|Traditional method: Silver nitrate|"Excision is made with the scissors and a rod is applied containing silver nitrate with caustic power on the wound.~Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
10143996|NCT04161274|Experimental|Moist healing environment|"Excision is made with the scissors, afterwards pressure, clorhexidine and a hydrocolloid dressing when the skin is dry.~Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
10143997|NCT04161443|Experimental|Experimental|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.~i. MET Quadratus lumborum ii. Ultrasound iii. Gluteus medius exercises iv. Hamstring stretch Posture advice and home exercise program"
10143998|NCT04161443|Active Comparator|Comparator|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.~i. Ultrasound ii.Gluteus medius exercises iii.Hamstring stretch"
10143999|NCT04161300|Active Comparator|Foam Rolling Group (FR)|
10144000|NCT04161300|Active Comparator|Orthopaedic Manual Physical Therapy Group (OMPT)|
10144001|NCT04161300|Other|Control Group (CG)|
10144002|NCT04161313||Cystic fibrosis|children with cystic fibrosis
10144003|NCT04161313||primary ciliary dyskinesia|children with primary ciliary dyskinesia
10144004|NCT04161313||healthy controls|Age-matched healthy volunteers
10144005|NCT04161261|Experimental|IntraOperative Group|The intra-operative group consists of patients who have met criteria for cochlear implants. We monitor the facial nerve EMG intraoperatively in all patients, and often get some facial nerve activation when we are testing the implant intraoperatively when we are looking to see if we are getting any hearing nerve responses from electrical stimulation of the implant. We will also measure the facial nerve responses for some other charge-balanced pulse shapes, which are asymmetric and in which either the positive or negative charge is expected to stimulate the nerve. We will only measure these for two electrodes, not for all 12-22 electrodes They will be then invited back post operatively for a second testing during a standard of care visit post switch on for other pulse shapes.
9519713|NCT03284294|Active Comparator|Vitamin D|Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
10144006|NCT04161261|Experimental|PostOperative Group|The post-operative group, are patients who are actually having facial nerve stimulation on one or more electrodes, and for whom these electrodes are turned down so much they can't hear very well, or are actually turned off because of the facial nerve stimulation. For these patients, we will slowly increase the current levels on the offending electrodes (maximum of two) until they get some facial nerve twitching, and then turn down the current until they do not have stimulation any more. We will do this for all pulse shapes and determine which shape produces the greatest loudness without stimulating the facial nerve. This will be the only testing session for the second group.
10144007|NCT04161378||RHB-SG 01|Patients with early mobilization (< 2 days after the onset of symptoms)
10144008|NCT04161378||RHB-SG 02|Patients with delayed mobilization after AMI (>2 days after the onset of symptoms)
10144009|NCT04161365|Experimental|Urethral stricture patients|Patients suffering from urethral stricture are treated with direct visual internal urethrotomy (DVIU). Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
10144010|NCT04161430|Experimental|DRBP108|Phase A (Weeks 1-24): DBPR108 100mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
10144011|NCT04161430|Active Comparator|Sitagliptin|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
10144012|NCT04161430|Placebo Comparator|Placebo|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
10144013|NCT04161404|Experimental|Period 1|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
10144014|NCT04161404|Experimental|Period 2|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
10144015|NCT04161404|Experimental|Period 3|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
9519714|NCT03284281|Experimental|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
9519715|NCT03284281|Placebo Comparator|Control arm|No stimulation will be performed.
9970473|NCT01300780|Placebo Comparator|placebo group|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
9970474|NCT01300806||myHERO SBIRT|
9970475|NCT01300806||clinician administered SBIRT|
9977032|NCT01357382|No Intervention|low fat diet|replace high fat, energy dense foods with foods rich in whole grains, fruits and vegetables. The macronutrient distribution of this diet will be approximately 55% carbohydrate, 15% protein and 30% fat. Individuals will also be instructed to reduce sodium intake to < 2300 mg / day and in individuals with hypertension, < 1500 mg / day.
9977033|NCT01357382|Experimental|low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' to increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
9977034|NCT01357408||REVEAL XT device|Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications>
9977035|NCT01357421|Experimental|TT301|Investigational drug TT301
9977036|NCT01357421|Placebo Comparator|Placebo|Normal saline
9977037|NCT01357434||Adolescents|Participants 12-21 years old.
9977038|NCT01357447|Experimental|Dornase alfa (Pulmozyme)|Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.
9977039|NCT01357447|Placebo Comparator|Saline|Normal saline 0.9% solution
9977040|NCT01357486|Experimental|A|patients receiving sorafenib 400 mg - twice a day
9977041|NCT01357486|Experimental|B|patients receiving pravastatin 40 mg - once a day
9977042|NCT01357486|Experimental|C|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
9977043|NCT01357486|Other|D|patients receiving best supportive care
9977044|NCT01357499||control group|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg but without inflating the cuff and without stimulating the muscle. Now 25 minutes will have to pass by before beginning the coronary angioplasty.
9977045|NCT01357499||intervention group 1|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. There will be no electrical muscle stimulation in this group.
9977046|NCT01357499||intervention group 2|A Blood pressure cuff and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle
9977047|NCT01357538|Active Comparator|Posiformin 2 %|Eye ointment applied to the eye lid
9977048|NCT01357538|Placebo Comparator|Placebo|corresponding vehicle, eye ointment applied to the eye lid
9977049|NCT01357603|Experimental|Glaritus arm|Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
9977050|NCT01357603|Active Comparator|Lantus arm|Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
9977051|NCT01357681|Experimental|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
9977052|NCT01357681|Placebo Comparator|Placebo|Placebo
9977053|NCT01357694|Experimental|psychotherapeutic contacts|
9977054|NCT01357694|No Intervention|control group|
9977055|NCT01357707||West Syndrome (idiopathic)|Patients with idiopathic infantile seizures
9977056|NCT01357733|Other|Interim FDG PET/CT|Single arm study with diagnostic imaging study as the intervention.
9977057|NCT01357759|Experimental|Escalating doses of MORAb-022|Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
9977058|NCT01357759|Placebo Comparator|Placebo|Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
9977059|NCT01357798|Active Comparator|Btx-A: Active Comparator|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
9977060|NCT01357798|Placebo Comparator|Placebo Comparator|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
9977061|NCT01357811|Active Comparator|digoxin|
9977062|NCT01357811|Experimental|eliglustat with digoxin|
9977063|NCT01357824||Patients admitted for elective surgery|The patient admitted for elective surgery can be included, and will both the case and control, as we intubate the same patient twice, with and without Sellick´s maneuver.
9977064|NCT01357837|Placebo Comparator|Matching Placebo|Once daily oral administration of matching placebo for 4 weeks.
9977065|NCT01357837|Experimental|75 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
9977066|NCT01357837|Experimental|200 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
9977067|NCT01357837|Experimental|400 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
9977068|NCT01357863||Patients on second line treatment|Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
10144016|NCT04161209|Experimental|Drug: Citalopram|20mg oral dose of citalopram (tablet encapsulated in opaque capsule)
10144017|NCT04161209|Placebo Comparator|Placebo|Lactose placebo (tablet encapsulated in opaque capsule)
10144018|NCT04161092|Other|Liver transplantation + best alternative care|"Patients subjected to Ltx will during the waiting time receive individualized chemotherapy, with the aim to avoid side effect that make them not transplantable.~If possible, patients randomized to Ltx should be treated within 12 weeks after randomization.~If the patients progress systemically they will be treated with best alternative care.~If they progress only within the liver they continue to be transplantable until they are deemed technically not transplantable by the transplant surgeon."
10144019|NCT04161092|Other|Best alternative care|The treating physician will together with the patient decide the treatment.
10144020|NCT04161105|Experimental|Rectus femoris dry needling group|The rectus femoris dry needling group will have their strength assessed. They will then receive one treatment of dry needling to a trigger point in their rectus femoris muscle. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
10144021|NCT04161105|Experimental|Gluteus maximus dry needling group|The gluteus maximus dry needling group will have their strength assessed. They will then receive one treatment of dry needling to trigger points in their gluteus maximus muscle only. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
10144022|NCT04161105|No Intervention|Control|This group will receive no intervention. They will have their strength assessed at baseline and 24, 48 & 72 hour follow-up
10144023|NCT04161014|Other|Treatment Arm|Nintedanib 150mg twice daily for 3 years
10144024|NCT04161053|Active Comparator|Rifaximin|550 mg Rifaximin tablets twice daily for six months.
10144025|NCT04161053|Experimental|Nitazoxanide|500 mg Nitazoxanide tablets twice daily for six months.
10144026|NCT04161001|Experimental|Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe
10144027|NCT04161001|Placebo Comparator|Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan and Rosuvastatin, Ezetimibe
10144028|NCT04161001|Placebo Comparator|Amlodpine, Olmesartan|co-administration of Olmesartan, Amlodipine
10144029|NCT04160936|Active Comparator|study group ,infiltration with 0.25% ropivacaine post-op|At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin
10144030|NCT04160936|No Intervention|control group , no anesthesia infiltration post-op|
10144031|NCT04161027|Experimental|Pregabalin|
10144032|NCT04161027|Placebo Comparator|Placebo|
10144033|NCT04160806|Active Comparator|Active Group|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
10144034|NCT04160806|Sham Comparator|Sham Group|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
9970476|NCT01300832|Experimental|Duplex scan|Subjects undergo preoperative and post-operative duplex scanning of the lower extremities
10144035|NCT04160962||lappg|
10144036|NCT04160962||ladgbi|
10144037|NCT04160884|Active Comparator|A|0.6mg/kg of ICG, iv
10144038|NCT04160884|Experimental|B|0.2mg/kg of ICG, iv
10144039|NCT04160754|Experimental|MBRP|The experimental group will receive treatment as usual plus eight Mindfulness based relapse prevention (MBRP) therapy sessions.
10144040|NCT04160754|Active Comparator|Control (CTL)|The CTL group will receive treatment as usual plus information on the neurobiology of addiction and healthy behaviors.
10144041|NCT04160767|Active Comparator|Probiotic|
10144042|NCT04160767|Placebo Comparator|Placebo|
10144043|NCT04160858|Experimental|Exercise Condition|The intervention is a personalized exercise prescription based on the International Scientific Spinal Cord Injury (SCI) Exercise Guidelines. Participants begin at the Starting Level guideline: 20 min aerobic exercise, 2x/wk, at 70% of heart rate reserve (or a Borg Continuous Ratio 0-10 rating of 6), & 3 sets of 10 repetitions of strengthening exercises (each major functioning muscle group at 50-80% of 1-rep max), 2x/wk. Participants will gradually increase aerobic exercise to 30 min, 3x/wk (i.e. the Advanced Level guideline). Exercise implementation will be supported by a fitness trainer and an exercise counsellor with SCI-specific training and experience.
10144044|NCT04160858|Active Comparator|Wait-list Control|Control participants will not get an exercise prescription. They will be asked to refrain from lifestyle changes for 6 mos. After the 6-month waitlist period, Controls will receive the same resources as Exercisers.
10144045|NCT04160741|Experimental|Hot environment with radiation|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
10144046|NCT04160741|Experimental|Hot environment without radiation|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
10144047|NCT04160741|Experimental|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
10144048|NCT04160741|Active Comparator|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
10144049|NCT04160871|Experimental|Family Connections|Experimental group
10144050|NCT04160871|Active Comparator|Treatment As Usual|Control group
10184948|NCT03750565|Experimental|Cohort 2|Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
10184949|NCT03750565|Experimental|Cohort 3|Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
10144051|NCT04160819|Experimental|individualized nutritional intervention programs (iNIPs)|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs. Anthropometry (i.e., body mass index, limb circumference, and subcutaneous fat thickness), blood parameters (i.e., albumin and total lymphocyte count), hospital stay, Mini-Nutritional Assessment-Short Form (MNA-SF) score, target daily calorie intake, total calorie intake adherence rate, and three-major-nutrient intake were assessed during hospitalization and 3 and 6 months after discharge. Both groups received regular follow-up through phone calls. Furthermore, the rate of readmission resulting from pneumonia was recorded after discharge.
10144052|NCT04160819|No Intervention|standard care (SC) group|SC group was only provided standard nutritional supplements according to the Kaohsiung Chang Gung Memorial Hospital Nutrition Department, and patients' family members were not provided dietary advice.
10144053|NCT04160897||ETV cohort|CHB patients with entecavir naive treatment
10144054|NCT04160897||TDF cohort|CHB patients with naive tenofovir disopropyl naive treatment
10144055|NCT04160702|Experimental|Motivate-The-Bystander|Participants assigned to the MTB condition arm.
10144056|NCT04160702|No Intervention|Assessment only control condition|Participants assigned to the assessment only condition arm.
10144057|NCT04160637||Patients with post-thyroidectomy hypocalcemia|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
10144058|NCT04160637||Patients without post-thyroidectomy hypocalcemia|Patients without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
10144059|NCT04160728|Experimental|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
10144060|NCT04160728|Experimental|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work.
10144061|NCT04160728|Experimental|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts.
10144062|NCT04160728|Experimental|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
10144063|NCT04160728|Sham Comparator|Business as usual scenario|No interference with the usual work day of the participants.
10144064|NCT04160728|Sham Comparator|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment.
10144065|NCT04160949||Patients|Patients who have been diagnosed with Fatty Liver.
10144066|NCT04160598|Placebo Comparator|Placebo group|bolus 50 ml nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
10144067|NCT04160598|Experimental|IV Mg ++ group|continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate.
10144068|NCT04160650|Experimental|Educational nursing intervention|"Patients in experimental group receive standard care and one-hour educational session. Patients are provided knowledge of~healthy diet~malnutrition, its prevalence and consequences for patients with CRC undergoing CT~side effects impairing nutrition intake during CT treatment.~prevention and self-care methods of the side effects Teach-back is used to verify participants' understanding. Empowering effect is confirmed by using active listening and asking patients' individual side effects, self-care strategies and need of additional knowledge in the beginning of the session and supporting patients' self-care methods when they have been applicable and effective. Additional knowledge of each theme is offered. To reinforce the intervention effect patients receive after the first CT a self-monitoring diary including assessment of side effects prevalence and intensity (NRS 0-10) before and after the self-care strategies. They return diaries by the 5th cycle of CT."
10144069|NCT04160650|No Intervention|Standard care|"Patients in control group receive standard care, information of~general CT induced side effects and their self-care; nausea, diarrhoea, obstipation and sores in the mouth, peripheral neuropathy symptoms, local venous irritation, heart symptoms, mucous and skin irritation~side-effects' self-monitoring, fluid intake, medication dose changes, effect of CT~weight control~taste alteration~cold sensitivity~variable diet~dietary supplements~available dietitian services~They receive a self-monitoring diary, which includes only side effects and their intensity (NRS 0-10)."
10144070|NCT04160624|Active Comparator|Non-ECLS GROUP|For AS/R patients with normal EF, only TAVR was performed
10144071|NCT04160624|Experimental|ECLS GROUP|For AS/R patients with low EF, TAVR under ECLS-assisted was performed
10144072|NCT04160689|Active Comparator|Group 1|Anyridge (Mega'Gen, Korea) 5° conical internal hexed connection
10144073|NCT04160689|Active Comparator|Group 2|Core (Bioimplant, Italy) 35° conical internal hexed connection (screw-vent style)
10144074|NCT04160390||Arm I (biospecimen collection)|Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
10144075|NCT04160390||Arm II (biospecimen collection)|Patients undergo collection of blood prior to transplant and on days 0, 3, and 4. Patients also undergo collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
10144076|NCT04160676|Active Comparator|Group I|"The patients in this group will be managed only according to the surviving sepsis campaign 2016 and the surviving sepsis campaign bundle 2018 update.~The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline I.V / 6 h, 5 ml normal saline I.V / 12 h."
10184950|NCT03750565|Experimental|Cohort 4|Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
10184951|NCT03750552|Experimental|ampreloxetine|Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.
10144077|NCT04160676|Experimental|Group II|The patients will receive the conventional therapy of sepsis and combined therapy of hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5 gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12 h This combined therapy will be given for 4 days or to the time of discharge if the admission period is less than 4 days
10144078|NCT04160403|Experimental|factors ( SES,age, sex,severity) and progress|the relation between progress in gross motor functions
10144079|NCT04160416|Experimental|mXELOXIRI|"Induction therapy is followed by the maintenance therapy. Induction treatment: XELOXIRI+CET/BEV Administered for 6 cycles (a maximum of 8 cycles).Bevacizumab (BEV): 5mg/kg (d.i.v.); Cetuximab 500mg/sq.m (d.i.v.)；Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) Irinotecan (IRI):135 mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-10) Administered every 2 weeks.~Maintenance treatment: CAP+CET/BEV. The following CAP+BEV/CET therapy will be repeated in 2-week cycles."
10144080|NCT04160273|Experimental|Diagnosis and follow-up arm|"Patients are informed during the 9th month pregnancy consultation consultation at Angers University Hospital by the midwife or obstetrician in charge of the consultation. They are included in the 48 hours following the delivery after their hospitalization in the maternity ward.~During hospitalization, socio-demographic and medical data are collected and the IDP scale is completed before returning home.~Follow-up at one month and one year is carried out by the investigators by means of a telephone call during which the patient answers the PCL-S questionnaire. Also collected during this call are information on the physical and mental state of the patient, the state of health of her newborn and the progress of the return home.~Patients are considered at high risk of PTSD if they have a PCL-S score ≥ 44 at 1 month. A consultation with a psychiatrist is offered to these patients at risk of PTSD in order to make the diagnosis and offer them appropriate care if necessary."
10144081|NCT04160520|Experimental|Pramipexole and half-standard dose of morphine|0.25 mg oral tablet of pramipexole in combination with 0.05mg/kg of IV morphine
10144082|NCT04160520|Active Comparator|Standard dose of morphine and placebo|0.1mg/kg of IV morphine in combination with a placebo pill
10144083|NCT04160793|Other|Genital Nerve Stimulation|Stimulation of the DNP
10144084|NCT04160247|Active Comparator|Angulated screw-retained crown|Restorations are connected to the implants by angulated screw channel system
10144085|NCT04160247|Placebo Comparator|Cemented crown|Restorations are cemented onto the implant abutment
10144086|NCT04160572|Experimental|Morning-evening sleep schedule|
10144087|NCT04160572|Active Comparator|Evening-morning sleep schedule|
10144088|NCT04160312|Experimental|Mitopure™ (Proprietary Urolithin A)|Fruit flavored food sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
10144089|NCT04160312|Experimental|Pomegranate Juice|100% Pomegranate juice equivalent to a glass of juice
10144090|NCT04160559|Placebo Comparator|Control group|chemotherapy plus water
10144091|NCT04160559|Experimental|Test group|chemotherapy plus green tea
10144092|NCT04160286||ECT (Work Package 1)|Group of patients receiving ECT during their hospitalization.
10144093|NCT04160286||Non-ECT (Work Package 1)|Group of patients not receiving ECT during their hospitalization.
10144094|NCT04160286||Work Package 2|Group of discharged patients who during their hospitalization received ECT. At the time of assessment, the discharged patients received their last session of ECT six months ago.
10144095|NCT04160780|Experimental|L-PRF as sole graft material|lateral sinus augmentation using L-PRF as sole graft material
10144096|NCT04160780|Experimental|xenograft as sole graft material|lateral sinus augmentation using xenograft as sole graft material
10144097|NCT04160780|Experimental|Xenograft mixed with L-PRF as graft material|lateral sinus augmentation using L-PRF mixed with xenograft as graft material
10144098|NCT04160481|Active Comparator|Tomato extract|
10144099|NCT04160481|Placebo Comparator|Placebo|
10144100|NCT04160611|Experimental|Premedication with Midazolam|Patients will be randomly divided into two groups, control and midazolam. The midazolam group will receive midazolam premedication in such a way that 7.5mg midazolam will be taken orally 30 minutes before the aspiration procedure. Because midazolam causes sedation, the woman will be monitored by midazolam after medical premedication to avoid possible complications and will not be allowed to get out of bed on her own for 30 minutes. After 30 min, all women, both test and control group, will begin aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
10144101|NCT04160611|No Intervention|No Premedication with Midazolam|Women in the control group will undergo aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
10144102|NCT04160299|Experimental|Dance-based exergaming|This will be an intervention-based study with single-group design, where participants will receive VR-based dance training for ten weeks. An anticipated 20 participants with a diagnosis of mild cognitive deficits will be recruited for initial screening
10184952|NCT03750552|Placebo Comparator|Placebo|Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.
10184953|NCT03750539|Active Comparator|Standard Treatment|External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
10184954|NCT03750539|Experimental|hypofractionated treatment|External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
10184955|NCT03750526|Experimental|rTMS and AR group|Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
10144103|NCT04160208||IUI - Insemination|Males of couples undergoing their first IUI treatment
9970477|NCT01300845|Active Comparator|Humidification|
9519716|NCT03284255|Experimental|study group|in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
9970478|NCT01300845|Experimental|No Humidification|
9970479|NCT01300871||Postmenopausal Women on Endocrine Therapy|Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
9970480|NCT01300884||healthy volunteers|
9970481|NCT01300884||patients with fecal incontinence|
9970482|NCT01300884||patients with constipation|
9970483|NCT01300897||Healthy Volunteer|healthy volunteers will serve as controls. In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potentials will be measured.
9970484|NCT01300897||Constipated patients|Patients with chronic constipation and rectal hypersensitivity or hyposensitivity and/or dyssynergic defecation.In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potential will be measured
9970485|NCT01300910|Active Comparator|1|One group of men will undergo a circumcision using the Shang Ring and men are to return for regular follow-up visits to evaluate pain and wound healing. . The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 60 days.
9970486|NCT01300910|Active Comparator|2|One group of men will undergo a conventional circumcision using a WHO recommended surgical technique, either the forceps-guided method or the dorsal slit method. Men are to return for regular follow-up visits to evaluate pain and wound healing, with the last scheduled follow-up visit at 60 days.
9970487|NCT01300936||patients with abdominal wall hernias|
9970488|NCT01300962|Experimental|BYL719 ARM B|Treatment with BYL719 and Capecitabine
9970489|NCT01300962|Experimental|BKM120 ARM A|Treatment with BKM120 and capecitabine
9970490|NCT01300962|Experimental|ARM C|BKM 120 plus capecitabine plus trastuzumab
9970491|NCT01300962|Experimental|ARM D|BKM120 plus capecitabine plus lapatinib
9970492|NCT01300975|Experimental|Intralesional antimony|3 intralesional injections of antimony at D1, D3 and D7
9970493|NCT01300975|Active Comparator|Cryotherapy|Liquid nitrogen until freezing at DF1 and D14
9970494|NCT01300975|Placebo Comparator|Topical cream|topical treatment 3 times a day during 21 days with an emollient cream
9970495|NCT01300988|Active Comparator|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
9970496|NCT01300988|Placebo Comparator|Placebo|Aprepitant (Emend®) placebo for 14 days
9970497|NCT01301040|Active Comparator|Epirubicin/Cyclophosphamide|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles
9970498|NCT01301040|Active Comparator|docetaxel/cyclophosphamide|Treatment Arm 2: TC - docetaxel (Taxotere) (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
9970499|NCT01301053|Other|Current UVA intensive care insulin protocol without brakes|Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days and uses the current UVA intensive care insulin for insulin management for 12 hours.
9970500|NCT01301053|Active Comparator|Current UVA intensive care insulin protocol with brakes|"Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days. Uses the current UVA intensive care insulin protocol for insulin management for 12 hours with the addition of brakes that reduce insulin administration based on continuous glucose monitoring data between hourly reference glucose data."
9970501|NCT01301105|Placebo Comparator|Health Enhancement Program (HEP)|Intervention designed to be effective and structurally equivalent to Mindfulness Based Stress Reduction (MBSR) but without a mindfulness component. Designed as an active control for MBSR to isolate mindfulness as an active ingredient.
10144104|NCT04160208||IVF - In vitro fertilisation|Males of couples undergoing their first IVF treatment. Including males of couples who have had previous IUI treatments.
10144105|NCT04160208||ICSI - Micro Insemination|Males of couples undergoing their first ICSI treatment. Including males of couples who have had previous IUI treatments.
9970502|NCT01301105|Active Comparator|Mindfulness Based Stress Reduction (MBSR)|
9970503|NCT01301131|Experimental|Probiotic|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
9970504|NCT01301131|No Intervention|control|
9970505|NCT01301196|Experimental|Behaviour change|Attendance at 3-h workshop
9970506|NCT01301209||treatment|patients undergoing treatment
9970507|NCT01301222|Experimental|octreotide|octreotide arm 100mcg for 5 days. control has no octreotide
9970508|NCT01301235||Subjects with mitochondrial disease|
9970509|NCT01301248|Active Comparator|Radiotherapy/Cisplatin(GroupA)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)
9970510|NCT01301248|Experimental|Radiotherapy/Cisplatin/Cetuximab(GroupB)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
9970511|NCT01301261|Active Comparator|sugammadex 2 mg/kg|2 mg/kg of sugammadex are given when a response of two counts of train of four are present
9970512|NCT01301261|Active Comparator|4 mg/kg of sugammadex|4 mg/kg of sugammadex are given when a posttetanic count 1-3 appears
9970513|NCT01301261|Active Comparator|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg are given three minutes after the injection of cis-atracurium
9970514|NCT01301287|Experimental|Chlorella|
9970515|NCT01301300|Active Comparator|Glenbrook Hospital|Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
9970516|NCT01301300|Active Comparator|Evanston, Highland Park, Skokie Hospitals|"Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.~Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)"
9970517|NCT01301313|Experimental|Levosimendan|
9970518|NCT01301313|Active Comparator|Conventional intensified inotropic treatment|
10144106|NCT04160195|Active Comparator|1/Conditioning chemotherapy plus Chimeric Antigen Receptors (CAR) T-cells dose escalation|All participants will be receiving escalating dose of Anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) CAR T cells/kg + conditioning chemotherapy
10144107|NCT04160195|Active Comparator|2/Conditioning chemotherapy plus Chimeric Antigen Receptors (CAR) T-cells expansion phase|Maximum tolerated dose (MTD) dose of Anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) CAR T cells/kg + Conditioning chemotherapy
10144108|NCT04160351|Experimental|MCO Dialyser|12 treatments (4 weeks) with Medium Cut-Off Dialyzer
10144109|NCT04160351|Active Comparator|High Flux Dialyser|12 treatments (4 weeks) with High Flux Dialyzer
10144110|NCT04160143|Experimental|SBRT followed by pulmonary metastasectomy|SBRT+Surgery
10144111|NCT04159883|Experimental|app|For the App group, we installed the app from the store in their smart phone or tablets, made their account using the same email they use in their smart phone store. the participant was informed if they cannot follow the animated image in the app, they can re-launch the program and start to follow.
10144112|NCT04159883|Active Comparator|paper|For the paper group, the participants were provided with a hard copy of the exercise program; we gave one paper of all nine exercises.
10144113|NCT04160182|Experimental|Energy Conservation Work Simplification Education|The intervention will be delivered online by an occupational therapist. The intervention consists of 6 weekly sessions; each session will be 45 minutes long. The focus of the intervention is to teach breast cancer survivors strategies to manage their fatigue.
10144114|NCT04159961|Experimental|GroupA|Inject the Drug into submental fat and abdominal fat via subcutaneous
10144115|NCT04159961|Experimental|GroupB|Inject the Drug into submental fat and abdominal fat via subcutaneous
10144116|NCT04159961|Experimental|GroupC|Inject the Drug into submental fat and abdominal fat via subcutaneous
10144117|NCT04160039|Experimental|Cycle Ergometry + Standard PT/OT|
10144118|NCT04160039|No Intervention|Standard PT/OT alone|
10144119|NCT04160234||Elderly patient|Preoperative elderly patients, who are planned for a surgical intervention
10144120|NCT04160026|Active Comparator|IPTp-SP|Arm 1. Standard single-day stat course of quality-assured SP (Fansidar ®) of 3 tablets (500 mg of sulphadoxine and 25 mg of pyrimethamine). SP given monthly
10144121|NCT04160026|Experimental|IPTp-DP|Arm 2. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy). DP given monthly
10144122|NCT04160026|Experimental|IPTp-DP Plus|Arm 3. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy) plus targeted information for health providers.
10144123|NCT04159870|Experimental|Intervention Group|Rifaximin 1200 mg/day in 3 doses
10144124|NCT04159870|Active Comparator|Control Group|Norfloxacin 400 mg/day in one dose
10144125|NCT04160117|Experimental|Intervention|Colchicine 0.6 mg p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
10144126|NCT04160117|Placebo Comparator|Control|Matching placebo p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
10144127|NCT04159844|Active Comparator|Short stretch bandage|Application with 50% overlap in combinaison with wading
10144128|NCT04159844|Active Comparator|Multi componant bandage|Application with 50% overlap
10144129|NCT04159844|Active Comparator|Short stretch bandage bis|Application with 50% overlap in combinaison with wading
10144130|NCT04159831|Experimental|400,000 U LTI-01|400,000 U LTI-01 qd x 3 days administered intrapleurally
10144131|NCT04159831|Experimental|800,000 U LTI-01|800,000 U LTI-01 qd x 3 days administered intrapleurally
9669353|NCT02875314|Experimental|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
9669354|NCT02875132|Experimental|pembrolizumab|
9826120|NCT02408523|Experimental|Lacosamide|"Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects >= 50 kg.~Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30 kg.)~Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to < 50 kg.)"
9970519|NCT01301326|Experimental|subthreshold laser treatment|
10144132|NCT04159831|Experimental|1,200,000 U LTI-01|1,200,000 U LTI-01 qd x 3 days administered intrapleurally
10144133|NCT04159831|Placebo Comparator|Placebo|placebo (normal saline) 6ml qd x 3 days administered intrapleurally
9970520|NCT01301326|Active Comparator|threshold laser treatment|
10144134|NCT04159792||stroke|Those with standard treatment as usual.
10144135|NCT04160156||Type 1 diabetes|Subjects attending metabolic clinic who were suggested to use long term sensor due to persistent hyperglycemia and hypoglycemia
10144136|NCT04159987|Experimental|Spinal muscular atrophy patient|
10144137|NCT04159935|Experimental|iLux® treatment|The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.
10144138|NCT04159935|Experimental|Delayed iLux® treatment|Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.
10144139|NCT04160130|Experimental|SAPIEN 3 or SAPIEN 3 Ultra|Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems.
10144140|NCT04160130|Active Comparator|any surgical bioprosthetic aortic valve|Any commercially available surgical bioprosthetic valve
10144141|NCT04159948|Placebo Comparator|Water|Patients will be allowed to drink water up to 2 hours before their caesarean section.
10144142|NCT04159948|Active Comparator|Carbohydrate drink|Patients will be allowed to drink a designated carbohydrate drink up to 2 hours before their caesarean section.
10144143|NCT04159948|Active Comparator|Apple juice|Patients will be allowed to drink apple juice up to 2 hours before their caesarean section.
10144144|NCT04160104||Training cohort|This cohort was used to establish the bowel preparation score (BPS).
10144145|NCT04160104||Validation cohort|This cohort was used to verify the bowel preparation score (BPS).
10144146|NCT04159922||Type 2 diabetic patients with foot wounds|
10144147|NCT04159662|Experimental|Cognitive Intervention|
10144148|NCT04159662|Active Comparator|Active Control Intervention|
10144149|NCT04159623|Experimental|Belk Device|With Belk Device
10144150|NCT04159623|Other|Standard Rehabilitative treatment|With the standard rehabilitative treatment
10144151|NCT04159675||control patients|Patients with idiopathic craniosynostosis
10144152|NCT04159675||HR patients|Patients with craniosynostosis due to HR
10144153|NCT04159896|Experimental|Treatment (ESK981, nivolumab)|Patients receive ESK981 PO QD for 5 consecutive days per week, followed by a 2-day break. Patients also receive nivolumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10144154|NCT04159636|No Intervention|Fasting group|Participants will be remained fasted until surgery
10144155|NCT04159636|Experimental|Carbohydrate group|Participants will be allowed to drink carbohydrate beverage before 2 hours of surgery
10144156|NCT04159649|Experimental|letrozole, gonadotropins and fixed GnRH antagonist|letrozole (2.5 mg) will be given from the second day of the cycle and for 5 days, gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF (interventional group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
10144157|NCT04159649|Active Comparator|gonadotropins and fixed GnRH antagonist (control group).|gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF(control group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
10144158|NCT04159766|Active Comparator|NLY01 (2.5 mg)|
10144159|NCT04159766|Active Comparator|NLY01 (5.0 mg)|
10144160|NCT04159766|Active Comparator|NLY01 (10 mg)|
10144161|NCT04159766|Placebo Comparator|Placebo|
10144162|NCT04160013|Experimental|Discipline education|Education about discipline using the Play Nicely program (www.playnicely.org).
10144163|NCT04160013|Placebo Comparator|Cavity prevention|Education about cavity prevention using a 2 page handout.
10144164|NCT04159701|Experimental|LY3454738|500 milligram (mg) LY3454738 administered intravenously (IV).
10144165|NCT04159701|Placebo Comparator|Placebo|Placebo administered IV.
10144166|NCT04160000|Active Comparator|Phase 1 Catheter Ablation|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They randomly assigned to catheter ablation as one arm. They will undergo a catheter ablation procedure within 14 days of randomization. This procedure will include isolation of all four pulmonary veins in the antrum using catheter delivered radiofrequency current, cryothermal or laser ablation energy with standard FDA approved ablation catheter systems used in atrial fibrillation ablation. Patients will be monitored for a minimum period of 9 months after the catheter ablation intervention.
10144167|NCT04160000|Active Comparator|Phase 1 Antiarrhythmic drug therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They will be randomly assigned to antiarrhythmic drug therapy for Rate or Rhythm control in this arm. They will undergo drug dose titration within 14 days of randomization. . Patients will be monitored for a minimum period of 9 months after the AAD therapy initiation
9970521|NCT01301339||failed and passed physical fitness test|520 subjects who have failed their Air Force physical fitness test and 520 volunteers who have passed their physical fitness test both within the last 6 months
9970522|NCT01301352|No Intervention|Nasojejunal feeding (control)|
10144168|NCT04160000|Active Comparator|Phase 2 Guided Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to insertion of an implantable hemodynamic monitor in this arm and heart failure therapy guided by wireless hemodynamic monitoring. Patients will be monitored for a minimum period of 9 months after the implantable hemodynamic monitor insertion on guided drug therapy
10144169|NCT04160000|Active Comparator|Phase 2 Empiric Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to heart failure management with empirical selection of heart failure therapy. Patients will be monitored for a minimum period of 9 months after the initiation of empirically selected heart failure drug therapy
10144170|NCT04159545||Participants treated with DAAs|"Participants identified through the standard pathway of care as receiving Direct-Acting Antiviral (DAA) drugs to treat chronic hepatitis C with a history of problematic substance use.~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
10184956|NCT03750526|Active Comparator|Sham rTMS and AR group|Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
10184957|NCT03750526|Active Comparator|AR group|Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
10184958|NCT03750526|Active Comparator|Conventional physiotherapy group|Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
9970523|NCT01301352|Experimental|Nasogastric feeding (intervention)|
10144171|NCT04159545||Control Group|"Participants identified through the standard pathway of care as having HCV positive antibodies who spontaneously clear the infection.~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
10144172|NCT04159467|Active Comparator|Group 1- diet therapy (control)|Control group undergoing a low calorie diet will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and after 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
10144173|NCT04159467|Experimental|Grupo 2 - low calorie diet + PFMT (experimental)|"Experimental group will receive supervised pelvic floor muscle training additionally to a low calorie diet. Women will be instructed to perform daily pelvic floor muscle training at home. 4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The 4 sets will be performed in 2 different positions (sitting and standing). Twice a month (once every 15 days), they will receive a supervised session using the same protocol described above except for the position that will be only sitting and standing. In addition, they will be instructed to perform the the knack maneuver."
10144174|NCT04159610|Experimental|WO 3970|Formulation containing WO 3970 for topical application
10144175|NCT04159610|Active Comparator|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
10144176|NCT04159558|Experimental|experimental hypertension|The subjects with Hypertension will be trained in the use of the personalized help tool and will use it during a period of 3 months.
10144177|NCT04159558|Experimental|experimental diabetes|The subjects with Diabetes will be trained in the use of the personalized help tool and will use it during a period of 3 months.
10144178|NCT04159558|Experimental|experimental heart failure|The subjects with Heart failure will be trained in the use of the personalized help tool and will use it during a period of 3 months.
10144179|NCT04159558|Experimental|experimental copd|The subjects with COPD will be trained in the use of the personalized help tool and will use it during a period of 3 months.
10144180|NCT04159558|Experimental|experimental asthma|The subjects with Asthma will be trained in the use of the personalized help tool and will use it during a period of 3 months.
10144181|NCT04159558|Experimental|experimental obesity|The subjects with Obesity will be trained in the use of the personalized help tool and will use it during a period of 3 months.
10144182|NCT04159584|Experimental|Enrolled Subject|All subjects will undergo the medical music intervention.
10144183|NCT04159727|Experimental|IBD or PD patients|20 patients suffering from IBD 10 patients suffering from PD
10144184|NCT04159727|Active Comparator|Asymptomatic subjects|30 asymptomatic subjects matched to patients on age, sexe and BMI
10144185|NCT04159311|Active Comparator|Treated group|"The treated group will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3."
10144186|NCT04159311|Sham Comparator|Untreated group|"The untreated group will have 4 sessions of only testing osteopathy (M0, M1, M2, M3)."
10144187|NCT04159298|Experimental|Intervention|Intervention group who will undergo the Top Spin 360 study protocol.
10144188|NCT04159298|No Intervention|Traditional|Control group who undergo traditional usual clinical care comprised of bi-weekly physiotherapy sessions and home-based exercise programs.
10144189|NCT04159389|No Intervention|traditional teaching|theoretical courses and procedural simulation on airway management during rapid sequence induction
10144190|NCT04159389|Experimental|Mental visualization|traditional teaching completed by mental visualization : theoretical courses and procedural simulation on airway management during rapid sequence induction + mental visualization (theoretical courses, audioguide for individual practice and experience sharing session)
10144191|NCT04159454|Experimental|PITA Participants|"All patients in the study are part of the PITA arm, where PITA will be on for Weeks 0-8, and off from Weeks 8-12."
10144192|NCT04159493|Placebo Comparator|Placebo|"Subjects will be randomized to placebo.~Placebo, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
10144193|NCT04159493|Active Comparator|Ovestin|"Subjects will be randomized or assigned to varying doses of Ovestin (500, 50, 25, 12.5, 10, 5, 2.5, 0.5, 0.25 mcg) as determined by the dose de-escalation constraints specified in the protocol.~Active, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
10144194|NCT04159116|Experimental|Suctioned Prior to Endoscope|This group will be suctioned prophylactically after sedation but prior to introduction of endoscope.
9519717|NCT03284255|Active Comparator|control group|in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
9970524|NCT01301378|Active Comparator|KeraSys Tissue Patch Graft|20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
10144195|NCT04159116|Other|Standard of Care|This group will be suctioned by anesthesia providers when clinically indicated by copious secretions, coughing, choking or desaturation.
10144196|NCT04159285|Experimental|Group CBT|15-week group CBT with a focus on improvement of social interactions by cognitive re-modelling and role plays. Patients may simultaneously receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
10144197|NCT04159285|Experimental|Treatment as Usual|Patients may receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
10144198|NCT04159532|Experimental|Monoglyceride (MAG)|Group A will receive the omega-3 fatty acids in monoglyceride formulation (MAG). Subjects will receive 1.5g per day of MAG-EPA/MAG-DHA in a proportion of 460:200 for 12 consecutive weeks.
10144199|NCT04159532|Active Comparator|Triglyceride (TG)|Group B will receive the omega-3 fatty acids in triglyceride formulation (TG). Subjects will receive 1.5g per day of TG-EPA/TG-DHA in a proportion of 460:200 for 12 consecutive weeks.
10184959|NCT03750513|Experimental|Treatment (LET optimized IMPT)|Patients receive LET optimized IMPT for up to 6 weeks.
10144200|NCT04159532|Active Comparator|Ethyl Ester(EE)|Group C will receive the omega-3 fatty acids in Ethyl ester formulation (EE). Subjects will receive 1.5g per day of EE-EPA/EE-DHA in a proportion of 460:200 for 12 consecutive weeks.
10144201|NCT04159064||Minimal Invasive Extracorporeal Circulation(MIECC)|"Monitoring coagulation using thromboelastometry and platelet function using impedance aggregometry. Samples at the following phases:~Time 0: Baseline, upon arrival at the operation room (samples for thromboelastometry and impedance aggregometry), Time 2: after aortic cross clamp off (only sample for thromboelastometry), Time 2': 20 minutes post protamine administration (only sample for impedance aggregometry )."
10144202|NCT04159025|Experimental|Endobronchial ultrasound guided miniforceps biopsy|"Standard of care convex-probe endobronchial ultrasound and transbronchial needle aspiration followed by rapid on-site evaluation. If evaluation yields a diagnosis of nonsmall cell lung cancer then EBUS-MFB will be performed.~With the EBUS bronchoscope, 6 needle punctures will be made into the targeted lymph node with the 22 gauge aspiration needle. The needle will be removed and the 1mm miniforceps will be passed through the working channel of the EBUS-bronchoscope into the targeted lymph node through the puncture site made using the 22 gauge needle using continuous endobronchial ultrasound guidance. The miniforceps will be used to obtain a core biopsy of the targeted lymph node - 8 core biopsies will be obtained from each targeted lymph node using this technique"
10144203|NCT04159233|Other|Adapted 'Brief Behavioral Therapy for Insomnia' (BBTI)|All participants will receive the same intervention in this pilot study.
10144204|NCT04159168|Experimental|Arm 1: R61 FAST|Individuals in this Arm will receive the FAST intervention, as described in the Intervention section of the Clinical Trials form below, with a focus on demonstrating target (facial affect sensitivity) engagement.
10144205|NCT04159168|No Intervention|Arm 2: R61 No-Treatment Control|Individuals in this Arm will not receive any intervention.
10144206|NCT04159168|Experimental|Arm 3: R33 FAST|Individuals randomized this Arm of the R33 phase will receive the FAST intervention, with the aim of replicating FAST target engagement (as demonstrated in the R61 phase) with a new high-CU sample, and to evaluate the FAST intervention in comparison to an active control condition (Arm 4, implicit eye gaze training).
10144207|NCT04159168|Active Comparator|Arm 4: R33 Active Control|Individuals in this Arm will receive the active control component, which is an implicit gaze training intervention.
10144208|NCT04159181|Experimental|Day A|After an overnight fast participants will receive an oral solution of lactulose (20g lactulose/200mL water).
10144209|NCT04159181|Experimental|Day B|After an overnight fast participants will drink 200mL of water
10144210|NCT04159181|Experimental|Day C|After an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).
10144211|NCT04159363|Experimental|Intervention group|Participants in the intervention group will receive an interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage) in addition to routine care provided by the respective hospitals.
10144212|NCT04159363|No Intervention|Control group|Participants in the control group will receive routine care provided by the respective hospitals . The routine care includes normal consultation with their attending physician, information concerning treatment plans, such as surgical procedures and its associated risks, preoperative preparations and postoperative care, treatment after discharge and/or subsequent adjunct therapy if required.
10144213|NCT04159090|Experimental|Prostate cancer patients|
10144214|NCT04159246||Sovaldi group|patients with a documented diagnosis of chronic hepatitis C , normal renal functions And Rheumatoid factor tests (to exclude Purtscher like retinopathy as a rare presentation of cryoglobuinemia which considered one of extra hepatic manifestations of HCV)
10144215|NCT04159155|Experimental|Early Stage Cohort - Arm A|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles
10144216|NCT04159155|Experimental|Early Stage Cohort - Arm B1|"External beam radiotherapy, 5 days per week, for 4-5 weeks~Cisplatin intravenously, on the first and fourth week of radiotherapy.~Brachytherapy will be given if needed Then~Carboplatin, intravenously, once every 3 weeks for 4 cycles~Paclitaxel, intravenously, once every 3 weeks for 4 cycles"
10144217|NCT04159155|Experimental|Advanced Stage Cohort Arm C|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles
10144218|NCT04159155|Experimental|Advanced Stage Cohort Arm D1|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles Then Niraparib daily continuous dosing for 28 day cycles
10144219|NCT04159155|No Intervention|Exploratory Cohort|Observation on Standard of care
10144220|NCT04159376|Experimental|Bone Metastases Patients|
10144221|NCT04159142|Experimental|Nab-paclitaxel + Carboplatin|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
10144222|NCT04159142|Experimental|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
10144223|NCT04159077|Experimental|Tamsulosin Hydrochloride (HCL)|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of tamsulosin HCL to be started 3 days prior to their date of surgery.
10144224|NCT04159077|Placebo Comparator|Placebo|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of placebo to be started 3 days prior to their date of surgery.
10144225|NCT04158934||Haemophilia A Group|Participants with haemophilia A in the study will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national summary of product characteristics (SmPC).
10144226|NCT04158947|Experimental|T-DM1 + Afatinib|"Trastuzumab emtansine (T-DM1) : 3.6 mg/kg IV Day 1 every 21 days.~Afatinib: the highest dose of Afatinib with T-DM1 found in Phase I, po every day"
10144227|NCT04158947|Active Comparator|T-DM1|Trastuzumab emtansine (T-DM1) :3.6 mg/kg IV Day 1 every 21 days.
10144228|NCT04159324|Experimental|StroCare treatment group|Optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
10144229|NCT04159324|No Intervention|control group|routine aftercare stroke treatment
10144230|NCT04158999||Mother milk|Step 1: Mothers who meet the sample selection criteria will be informed about the scope of the study and their written and verbal consent will be obtained. Data collection form will be applied to mothers who accept to participate in the study by using face to face interview technique. Mothers and newborns will be weighed and 4 ml breast milk sample will be taken from the mother for manual milking.
10144231|NCT04159207||A Longitudinal Study of Inflammatory Pathways in Depression|We target to recruit 80 patients with Major Depression Disorder diagnosis and 80 patients with Major Depression Disorder with suicidal behavior.
10144232|NCT04159012|Experimental|Active transcranial direct current stimulation|Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
10144233|NCT04159012|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
10144234|NCT04158973|Experimental|VTE prophylaxis based on bleeding risk assessment|Patients will undergo a bleeding risk assessment to determine their entering VTE prophylaxis. Low bleeding risk patients will have once daily sc LMWH prophylaxis. Intermediate bleeding risk patients will have q 12 h sc low dose unfractionated heparin prophylaxis. High bleeding risk patients will have mechanical prophylaxis. Assigned prophylaxis can be interrupted as clinical judgement requires, e.g., for peri-procedural reasons. When patients are discharged, if they have low risk of bleeding at the time of discharge, whatever their bleeding risk assessment at the time of randomization, will begin 5 mg rivaroxaban prophylaxis (two 2.5 mg tablets) once daily with food, starting on the day of discharge, for 15 days.
10144235|NCT04158973|Active Comparator|Routine VTE prophylaxis in local clinical practice|VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge.
10144236|NCT04159038|Experimental|Immediate Intervention Group|Parents in the immediate intervention arm sign a study consent that is integrated into the WIC Referral Form. They also complete a brief demographic survey. No consent is necessary in the delayed intervention arm as only aggregate information will be reported to the study team by EI/ECSE. EI/ECSE referrals are tracked from clinics in both arms for 6 months in ecWeb. At the end of the data collection period, the study team will meet to refine the intervention based on the experience with the immediate intervention group. Qualitative Interviews will take place with WIC staff, parents who indicate interest, EI/ECSE staff, and primary care providers during and after the post-intervention data collection period.
10144237|NCT04159038|Other|Delayed Intervention Group|6 months after the immediate intervention group receives their training, the delayed intervention group will receive the training. Prior to implementation of the training in the delayed intervention group, the study team will meet with the Stakeholder Advisory Board. It will review interim results and consider the efficacy of the intervention as a whole. Based on actual use patterns and stakeholder feedback, the investigators will make improvements to the intervention prior to implementing it in the delayed intervention group.
10144238|NCT04159259|Experimental|Diet intervention|All participants will stay weight stable while undergoing 3 phases of a dietary intervention
10144239|NCT04159194|Active Comparator|Normal CHO|
10144240|NCT04159194|Experimental|High CHO|
10144241|NCT04158921|Other|The Control:Diabetes mobile app for Diabetes self-management.|This is a single arm open label pilot clinical trial that will assess patient-reported blood glucose levels before and after using the Control:Diabetes mobile app.
10144242|NCT04158739|Experimental|Treatment (cytarabine, flotetuzumab)|Patients receive cytarabine IT on days -6 to 0 prior to cycle 1. Patients may receive additional doses of cytarabine on day 1 of subsequent cycles per physician discretion. Patients also receive flotetuzumab IV continuously for 28 days. Treatment repeats every 29 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
10144243|NCT04158661||Tmin-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG~age ≥ 18 years~thymectomy ≥ three years"
10144244|NCT04158661||T0-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG~a very long disease history OR~age ≥ 18 years~rejecting a thymectomy or have contraindications for thymectomy"
10144245|NCT04158661||"MGTX-group (historical control group)"|"from MGTX-trial (Randomized Trial of Thymectomy in Myasthenia Gravis)"
10144246|NCT04158674|Experimental|Levosimendan|
10144247|NCT04158674|Sham Comparator|Placebo|
10144248|NCT04158778|Experimental|MDMA assisted Psychotherapy|All participants receive 2 sessions of MDMA-assisted psychotherapy
10144249|NCT04158791||EMM-I|Group with an intact IS/OS junction
10144250|NCT04158791||EMM-D|Group with a disrupted IS/OS junction
10144251|NCT04158596|Experimental|Treatment|The applied therapeutic vibrations generated by an acoustic coil have a defined sweeping frequency range.
10144252|NCT04158596|Active Comparator|Control|A control device with a different vibration pattern will be used as comparator intervention
10144253|NCT04158609||Group 1|Pregnant women with CPR value below 1, based on Doppler indices assessment
10144254|NCT04158609||Group 2|Pregnant women with CPR value equal to or above 1, based on Doppler indices assessment
9970525|NCT01301378|Active Comparator|Tutoplast tissue patch graft|20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft
9970526|NCT01301404|No Intervention|control|patient receive nothing
9970527|NCT01301404|Experimental|carbohydrate drink|10%carbohydrate drink
10144255|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 1)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered intravenously (IV).
10144256|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 2)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered IV.
10144257|NCT04158700|Experimental|LY3200882 and Pembrolizumab Expansion|Participants with urothelial carcinoma, non-small cell lung cancer, or hepatocellular carcinoma: LY3200882 administered orally twice in combination with pembrolizumab administered IV.
10144258|NCT04158908|Experimental|Oncolo_GIST Arm|Patients in this arm will receive care from a clinician that received the Oncolo-GIST Version 1.0 intervention training.
10144259|NCT04158544||Checkpoint Inhibitors|Patients with metastatic melanoma receiving systemic therapy with checkpoint inhibitors
10144260|NCT04158544||Kinase Inhibitors|Patients with metastatic melanoma receiving systemic therapy with kinase inhibitors
10144261|NCT04158843|Experimental|Radical local treatment|Radical resection is performed, and the cutting edge is negative, or radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy). Systemic endocrine therapy and targeted therapy are allowed after radical local therapy. However, whether systemic chemotherapy should be used is determined by clinicians according to clinical experience or guidelines.
10144262|NCT04158843|Active Comparator|Palliative treatment|No radical surgical resection or radical surgical resection or radiotherapy is performed in this group. But palliative internal fixation or radiotherapy for pain relief is permitted. Moreover, systemic chemotherapy, endocrine therapy and targeted therapy are allowed.
10144263|NCT04158817|Experimental|Experimental Arm|All Prostate cancer patients recruited to the study will be administered 2.11 MBq/kg of 68Ga-THP-PSMA in a single dose injection.
10144264|NCT04159051|Experimental|Combined regional hyperthermia and salvage radiotherapy|
10144265|NCT04158765||Infertile men|Men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
10144266|NCT04158622|Experimental|Pneumatic Retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy + laser/cryotherapy
10144267|NCT04158622|Experimental|Pars Plana Vitrectomy|Patients with retinal detachment allocated to pars plana vitrectomy + laser/cryotherapy
10144268|NCT04158960|No Intervention|Control|Control period; no equine-assisted activities or brain-building activities occurred
10144269|NCT04158960|Active Comparator|Equine-assisted activities period|Period in which only equine-assisted activities were performed
10144270|NCT04158960|No Intervention|Washout|Washout period; no equine-assisted activities or brain-building activities occurred
10144271|NCT04158960|Experimental|GaitWay period|Period in which both equine-assisted activities and brain-building activities were performed
10144272|NCT04158531|Experimental|REC2Stim|Use electrocorticography (ECoG)-based seizure detection and cortical network stimulation upon seizure onset detection.
10144273|NCT04158713|Placebo Comparator|CTX-alone|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly placebo-DP, given as a fixed dose of 3 placebo-DP tablets daily for three days until delivery.
10144274|NCT04158713|Experimental|CTX-DP|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly DP, given as a fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery.
10144275|NCT04158830|Other|Group 1 - ACOG recommended dose|oral dose: 81 mg aspirin daily; designated by odd number assignment [1-001, 1-003, 1-005, etc. to 899]
10144276|NCT04158830|Active Comparator|Group 2 - Comparison Dose|oral dose: 162 mg aspirin daily; designated by even number assignment [2-002, 2-004, 2-006, etc. to 900]
10144277|NCT04158856|Experimental|Experimental Arm|adjuvant Pyrotinib plus Trastuzumab
10144278|NCT04158518|Experimental|Toxicities reduced treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).
10144279|NCT04158518|Active Comparator|Conventional treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by concurrent cisplatin chemotherapy with standard radiation dose when responses to induction chemotherapy are less than 50% Partial Response(PR).
10144280|NCT04158505||non-interventional study|
10144281|NCT04158414|Experimental|Different types of cancer Patients|Lymphoma,Nasopharyngeal Cancer; Esophageal Cancer, Cervical cancer; Hepatobiliary and pancreatic cancer; Sarcoma; Prostate Cancer
10144282|NCT04158479||Pulmonary Support|ECMO support for acute respiratory failure, ARDS
10144283|NCT04158479||Cardiac Support|ECMO support for heart failure, cardiogenic shock
10144284|NCT04158479||Extracorporeal Cardiopulmonary Resuscitation|ECMO support for cardia arrest
10144285|NCT04158076|Experimental|Co-administered of AD-2071 and AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2073(Telmisartan/Amlodipine) for 8 weeks."
10144286|NCT04158076|Active Comparator|Co-administered of AD-2071 and AD-2072|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2072(Telmisartan) for 8 weeks."
10144287|NCT04158076|Active Comparator|AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2073(Telmisartan/Amlodipine) for 8 weeks."
10144288|NCT04158102|Experimental|20 mg single dose cohort|Subjects would receive a 20 mg single dose of EXPAREL®
10144289|NCT04158193|Experimental|Acupuncture group|Subjects in the acupuncture group are given acupuncture treatment.
10144290|NCT04158193|Experimental|Sham acupuncture control group|Subjects in the sham acupuncture control group are given non-acupoint shallow acupuncture.
10184960|NCT03750500|Experimental|Experimental|Participants included in this arm will benefit from a 12-week exercise program using the novel biofeedback rehabilitation device, under remote monitoring from a physical therapist
10184961|NCT03750500|Placebo Comparator|Standard of Care|Patients included in this arm will benefit from the standard of care currently in place in the Primary Care facility: education on risk factors for falls, medication review, visual and auditory acuity screening.
10144291|NCT04158115|Experimental|Entire Spinal Mobilization|Entire Spinal Mobilization( All spinal segment from Co-C1to L5-S1 Moist heat. Soft tissue Mobilization Exercises. (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
10144292|NCT04158115|Active Comparator|Segmental Mobilization|Segmental Mobilization. (All lumbar segment from L1-L2 to L5-S1) Moist heat. Soft tissue Mobilization Exercises (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
10144293|NCT04158167|Other|oxytocin|All subjects will receive both oxytocin and placebo in a counterbalanced design
10144294|NCT04158362|Experimental|Standard Chemotherapy regimen|"* Paclitaxel: administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle.~OR~* Capecitabine: given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks."
10144295|NCT04158362|Experimental|Standard Endocrine therapy (ET) regimen + Abemaciclib|"* Letrozole: continuous orally administration of 2.5 mg/day (1 tablet/day) OR anastrozole continuous orally administration of 1 mg/day (1 tablet/day) in combination with oral abemaciclib 150 mg (BID: twice a day) continuous for patients NSAI naïve or relapsing >1 year after the end of adjuvant ET.~OR~* Fulvestrant: 500 mg intramuscular on D1-D15-D29 (loading dose). Then 500 mg every 28 days (maintenance dose) with oral abemaciclib 150 mg BID continuous for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.~For women with a non-menopausal status at inclusion, a concomitant Luteinizing hormone-releasing hormone (LH-RH) agonist will be administered in combination with ET every 28 days. The LH-RH agonist drug to be used will be left to the investigator's choice."
10144296|NCT04158401||Control group|Pregnant patients between 12w0d and 22w0d who present for prenatal care.
10144297|NCT04158401||Cerclage group A|Patients who present for a history-indicated cerclage placement.
10144298|NCT04158401||Cerclage group B|Patients who present for an ultrasound-indicated cerclage placement.
10144299|NCT04158401||Cerclage group C|Patients who present for an exam-indicated cerclage placement.
10144300|NCT04158050||anti-IL5/IL5R-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IL5/IL5R
10144301|NCT04158050||anti-IgE-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IgE-therapy
10144302|NCT04158271|Experimental|Prone Position|Evaluation of Techniques for tracheal tube Exchange in prone position
10144303|NCT04158271|Experimental|Laryngeal tube|Evaluation of Techniques for tracheal tube Exchange in patients with laryngeal tube (LT)
10144304|NCT04158271|Experimental|Endotracheal tube Leackage|Evaluation of Techniques for tracheal tube Exchange in critical care patients with a endotracheal tube and a high leackage
10144305|NCT04158453|Active Comparator|AUT00201|
10144306|NCT04158453|Placebo Comparator|Placebo|
10144307|NCT04158232|Active Comparator|Blood clotting protocol for pulp regeneration|pulp regeneration for mature teeth using blood clotting protocol
10144308|NCT04158232|Experimental|platelet rich fibrin for pulp regeneration|pulp regeneration for mature teeth using platelet rich fibrin (PRF)
10144309|NCT04158388|Experimental|EXPERIMENTAL DIET GROUP|
10144310|NCT04158388|Other|CONTROL GROUP|
10144311|NCT04158388|Experimental|EXPERIMENTAL MASSAGE GROUP|That group received moderate pressure digital manual therapy.
10144312|NCT04158388|Experimental|EXPERIMENTAL PLACEBO GROUP|That group was treated with a US (in off mode) without conductive gel. Placebo group.
10144313|NCT04158336|Experimental|Single Agent Dose Escalation and Expansion|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
10144314|NCT04158349|Experimental|Dose Level 0|Dose Level 0: 85 mg/m2 Oxaliplatin IP every 2 weeks
10144315|NCT04158349|Experimental|Dose Level 1|Dose Level 1: 95 mg/m2 Oxaliplatin IP every 2 weeks
10144316|NCT04158349|Experimental|Dose Level 2|Dose Level 2: 105 mg/m2 Oxaliplation IP every 2 weeks
10144317|NCT04157868|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
10144318|NCT04157868|Placebo Comparator|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
10144319|NCT04157946||Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
10144320|NCT04157946||Non-Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
10144321|NCT04157803|Other|Patient cohort|Patients with polyps> 5mm with suspicion of tubular, tubulovillious or serrated adenomas, found during a videcolonoscopy.
10144322|NCT04157764|Experimental|APD|
10144323|NCT04157959|Experimental|SHR4640|SHR4640 dose1 Oral Tablet Day1~Day14 qd,Febuxostat dose2 Oral Tablet Day8 and Day14 qd.
10144324|NCT04157959|Experimental|Febuxostat|Febuxostat dose2 Oral Tablet Day1 and Day14 qd, SHR4640 dose1 Oral Tablet Day8~Day14 qd.
10144325|NCT04157751|Experimental|Empagliflozin|
10144326|NCT04157751|Placebo Comparator|Placebo|
10144327|NCT04158063|Experimental|Dual Task Training (DTT)|
10144328|NCT04158063|Active Comparator|Single Mobility Training (SMT)|
10144329|NCT04157816|Experimental|Digital Training (DGT)|Participants allocated to this arm receive a low-intensity digital program accessible by smart phone app for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
10144330|NCT04157816|Experimental|Digital Training with Coaching Support (DGT+)|Participants allocated to this arm receive a high-intensity digital program accessible by smart phone app augmented with weekly telephone coaching support for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
10144331|NCT04157816|Active Comparator|Face-to-Face Training|Participants allocated to this arm receive a traditional classroom-based (face-to-face) program hosted in community settings for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
9519718|NCT03284216|Other|Normal glycemia + exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
10144332|NCT04158206|Experimental|Maternal voice|The mother's voice recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group were explored maternal voice, which start from 3 minutes before the procedure, once a day and for three consecutive days.And then recorded the process by the camera, uploaded to YouTube within 24 hours and sent to their mother.
10144333|NCT04158206|No Intervention|control group|When the premature infants undergoing heel lance procedure, the control group were under routine care.And then recorded the process by the camera for three consecutive days, uploaded to YouTube within 24 hours and sent to their mother.
10144334|NCT04157972|Active Comparator|SIMEOX|Participants will have to perform 20 minutes of SIMEOX. Passive exhalation is required using the SIMEOX, starting from tidal volume and going until achieving residual volume.
10144335|NCT04157972|Active Comparator|PEP|Participants will have to perform 20 minutes of PEP. Active exhalation is required using a PEP device, starting from tidal volume and going until achieving residual volume.
10144336|NCT04157998|Placebo Comparator|control|patient receive 10 ml normal saline intravenous
10144337|NCT04157998|Active Comparator|metoclopramide group|"patient receive 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.~intravenous"
10144338|NCT04157907||Patients with borderline personality disorder|Patients with borderline personality disorder included in the MBT program
10144339|NCT04157933|Experimental|A-1a|Part A, Arm 1 (active), Dose 1 (009-A1)
10144340|NCT04157933|Experimental|A-2a|Part A, Arm 2 (active), Dose 2 (009-A2)
10144341|NCT04157933|Experimental|A-3a|Part A, Arm 3 (active), Dose 3 (009-A3)
10144342|NCT04157933|Placebo Comparator|A-0p|Part A, placebo comparator in all 3 arms, placebo dose (009-A0)
10144343|NCT04157933|Experimental|B-1 (009-B3 -> 009-B0)|Crossover (active to placebo)
10144344|NCT04157933|Experimental|B-1 (009-B0 -> 009-B3)|Crossover (placebo to active)
10144345|NCT04157829|Experimental|Scintilling lamp- Classic lamp|
10144346|NCT04157829|Experimental|Classic lamp- Scintilling lamp|
10144347|NCT04157842|Experimental|total hip replacement with subtrochanteral osteotomy|subtrochanteral osteotomy is applied during total hip replacement
10144348|NCT04157842|Sham Comparator|total hip replacement with no osteotomy|no osteotomy is applied during total hip replacement.
10144349|NCT04157777|Experimental|massage|Among women who applied to Maternity Hospital 350 pregnant women were assigned to massage group. Participants in massage group filled out an information form including socio-demographic characteristics. Perineum massage with olive oil in the second period of delivery was performed to massage group.In massage group when they progressed to full dilatation of the cervix, the midwife inserted two fingers inside vagina and using a sweeping motion gently stretched the perineum with lubricant 5 up to 10 minutes, in and between mother's pushing in the second stage of labour.
10144350|NCT04157777|Experimental|control|Among women who applied to Maternity Hospital 350 pregnant women were assigned to control group. Participants in control group filled out an information form including socio-demographic characteristics.And, no other interventions except for applications performed routinely in the delivery room were done.In control group just Ritgen Maneuver was applied. At last, we com-pared the rate of intact perineum, episiotomy and laceration, mean duration of the second stage of labor and Apgar score in 1 and 5 minutes be-tween two groups.
10144351|NCT04157712|Experimental|Cohort A Capsule - Fasted|ALZ-801 171 mg or matching placebo once daily Day 1, ALZ-801 171 mg or matching placebo twice daily Days 2-7, ALZ-801 256.5 mg or matching placebo once daily Days 8-14
10144352|NCT04157712|Experimental|Cohort B Capsule - Fasted|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 or matching placebo mg twice daily Days 2-7, ALZ-801 340 mg or matching placebo once daily Days 8-14
10144353|NCT04157712|Experimental|Cohort C Capsule - Fed|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 mg or matching placebo twice daily Days 2-7, ALZ-801 340 mg or matching placebo twice daily Days 8-13, ALZ-801 340 mg or matching placebo once daily Day 14
10144354|NCT04157712|Experimental|Cohort D Tablet - Fed|ALZ-801 265 mg or matching placebo once daily Day 1, ALZ-801 265 mg or matching placebo twice daily Days 2-6, ALZ-801 265 mg or matching placebo once daily Day 7
10144355|NCT04157452||proximal ureteral stone patient|
10144356|NCT04157686|Experimental|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL.
10144357|NCT04157686|Experimental|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL.
10144358|NCT04157686|Experimental|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 will be injected into the LCL.
10144359|NCT04157439|Active Comparator|Control Group|Hot fermentation, Sustain pressure on trigger point, Self-stretches
10144360|NCT04157439|Experimental|Experimental Group|Integrated Neuromuscular Inhibition Technique Post isometric stretch (MET) Strain counter strain
9970528|NCT01301417||ColonRing™|Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice
10144361|NCT04157530|Sham Comparator|sham group|15 subjects with seeds of wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
10144362|NCT04157530|Experimental|acupuncture group|15 subjects with acupuncture applied to Qingming and Qiuhou with Der-qi
10144363|NCT04157530|Experimental|Electroacupuncture group|15 subjects wth acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi
10144364|NCT04157374|Experimental|EXPERIMENTAL GROUP|AOT and Active exercises
10144365|NCT04157374|Active Comparator|Control group|Active exercises
9970529|NCT01301430|Experimental|H-1 parvovirus (H-1PV)|
10144366|NCT04157582|Experimental|Study group|will consist of 20 hemiparetic patients and will receive Pilates training in addition to conventional physical therapy program consists of (manual stretching exercises, Strengthening Exercises and Wobble board training ) for 18 sessions every other day for one and half month , 3 sessions /week ,each session for 1.30 hours (40 minutes for pilates then 10 minutes rest then 40 minutes conventional physical therapy).
10144367|NCT04157582|Experimental|Control group|will consist of 20 hemiparetic patients and will receive conventional physical therapy program only same as group I for 18 sessions every other day for one and half month, 3 sessions /week, each session for (40 minutes ).
10144368|NCT04157491|Experimental|anlotinib and anti PD-1 antibody|
10144369|NCT04157647|Active Comparator|CytoSorb|Patients assigned to this arm group will receive hemadsorption witbhCytoSorb during the surgery and in the next 24 hours after surgery.
10144370|NCT04157647|Sham Comparator|Control|Patients assigned to this arm group will undergo to a normal CPB without the use of any hemoadsorption system.
10144371|NCT04157634|Experimental|Prognostication model|In a prospective cohort of children hospitalized in a PICU, development of a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
10144372|NCT04157387|Experimental|Cyriax inferior capsular stretching + Manual Therapy|"Cyriax inferior capsular stretching~+ Electrotherapy Manual therapy : Kaltenborn grade 1 and 2 Mobilization~Active ROM exercises :~Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction"
10144373|NCT04157387|Active Comparator|Manual Therapy|Analgesic short-wave diathermy Manual Therapy: Kalternbon grade 1 and 2 Mobilization :, Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction.
10144374|NCT04157621|Active Comparator|Active taVNS|
10144375|NCT04157621|Sham Comparator|Sham Stimulation|
10144376|NCT04157660|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
10144377|NCT04157660|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
10144378|NCT04157504|Experimental|Experimental Group: Physical Function|Forty patients with burn injury will be evaluated in this study. Lower extremity function, functional capacity, functional mobility, quality of life an scar tissue will be evaluated.
10144379|NCT04157608|Active Comparator|Habitual Prosthesis|Participant's existing baseline prescribed prosthesis
10144380|NCT04157608|Experimental|e-MIP|Experimental ankle-foot prosthesis
10144381|NCT04157556|Experimental|Group of athletes|Age: 18-35 Gender: Male Basketball, volleyball, handball players who have been training regularly for at least last 3 months.
10144382|NCT04157556|Experimental|Group of sedentary people|Age: 18-35 Gender: Male Individuals with similar physical characteristics to the group of athletes and who have not exercise regularly for at least last 3 months.
10144383|NCT04157478|Experimental|Radiation therapy, Temozolomide and anlotinib|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
10144384|NCT04157478|Active Comparator|Radiation therapy and temozolomide|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).
10144385|NCT04157543|Experimental|electroacupuncture|electroacupuncture at points after surgery
10144386|NCT04157543|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
10144387|NCT04157543|No Intervention|Control group|only injection painkiller were used before surgery
10144388|NCT04157218|Active Comparator|Treatment with HIFU and immediately after insertion of threads|
10144389|NCT04157218|Active Comparator|Treatment with HIFU and 6 months later insertion of theads|
10144390|NCT04157218|Active Comparator|Treatment with lifting threads alone|
10144391|NCT04157166|Other|group 1 in pair week|In pair week, patients will inclued in group1: the conventional recording followed by complementary images SPECT/CT, will be realized in first intention and the procedure of recording in camera VERITON will be recorderd in second intention
10144392|NCT04157166|Other|group 2 in odd week|in odd week, patients will inclued in group2: the procedure of recording of 25 minutes in camera VERITON-CT ™, will be realized in first intention and the procedure of conventional recording followed by complementary images SPECT/CT will be recorded in second intention
9970530|NCT01301443|Experimental|Subretinally Injected RetinoStat|Subretinally injected RetinoStat
10144393|NCT04157231|No Intervention|Usual Care|Usual care to be provided to patients as per hospital guidelines for 3 months
10144394|NCT04157231|Other|Intervention arm|"The intervention consists of training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. This intervention will run for 3 months.~Refresher training will be given monthly during the intervention."
10144395|NCT04157205|Experimental|Test arm|All patients. Single arm study
10144396|NCT04157270||Patients with acute ischemic stroke|Patients with acute ischemic stroke secondary to intracranial large vessel occlusion (LVO)
10144397|NCT04157699|Experimental|QL-007 100 mg QD + TDF|QL-007 tablet 100 mg QD was combined with TDF tablet 300mg
10144398|NCT04157699|Experimental|QL-007 200 mg QD + TDF|QL-007 tablets 200 mg QD were combined with TDF tablet 300mg
10144399|NCT04157699|Experimental|QL-007 400 mg QD+ TDF|QL-007 tablets 400 mg QD were combined with TDF tablet 300mg
10144400|NCT04157699|Experimental|QL-007 200 mg BID+ TDF|QL007 tablets 200 mg BID were combined with TDF tablet 300mg
10144401|NCT04157699|Active Comparator|TDF monotherapy|TDF tablet 300mg
10144402|NCT04157023|Other|Medical Students|Simulator training of 7 patient cases adapted to medical students.
10144403|NCT04157023|Other|Ophthalmologist|Simulator training of 7 patient cases adapted to ophthalmologists.
10144404|NCT04157023|Other|Neurologist/Neurosurgeon/Neonatologist|Simulator training of 7 patient cases adapted to neurologists, neurosurgeons and neonatologists.
10144405|NCT04157192|Active Comparator|Patients receiving real acupuncture treatment|Treatment with needle insertion
10144406|NCT04157192|Sham Comparator|Patients receiving sham acupuncture treatment|Treatment without needle insertion
9970531|NCT01301469|Experimental|1|6% HES 130/0.42 in plasma adapted Ringer's solution (balanced solution)
9970532|NCT01301469|Active Comparator|2|HES 130/0.4 in a saline solution
9970533|NCT01301482|Experimental|battlefield auricular acupuncture|
9970534|NCT01301482|No Intervention|placebo|
9970535|NCT01301495|Experimental|HANAROSTENT covered Esophageal Stent|
9970536|NCT01301521|Experimental|Cinnulin PF|Will take (by mouth) 2 gelatin capsules that contains 1 gram (2-500 mg capsules) water-soluble cinnamon extract (Cinnulin PF) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
9970537|NCT01301521|Placebo Comparator|Placebo|Will take (by mouth) 2 placebo capsules (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
9970538|NCT01301534||T-Con|1. Nurse initiated Telephone Consult (T-Con)
9970539|NCT01301534||Mail-Out|2. Mail-0ut Letter to the patient
9970540|NCT01301534||Education|3. Provider, Nurse and Technician Education with point-of-care patient referrals , Exam Room Flyer
9970541|NCT01301534||Control group|4. Control group (i.e. usual care)
9970542|NCT01301560|Experimental|Radiosurgery arm|Radiosurgery before palliative chemotherapy
9970543|NCT01301560|No Intervention|Observation arm|No radiotherapy or local treatment until specific symptoms or sign developed
9970544|NCT01301573||rAAV-GAD Treated Subjects|rAAV-GAD treated subjects who are being observed for long-term effects of the gene therapy product which they received from participating in a previous clinical study.
9970545|NCT01301586|Active Comparator|Oral antibiotic plus soy extract|
9970546|NCT01301586|Active Comparator|Oral antibiotic|
9970547|NCT01301599|Experimental|combination group|combination therapy of alpha blocker and 5-alpha-reductase inhibitor medication
9970548|NCT01301599|Active Comparator|alpha blocker group|alpha blocker monotherapy
9970549|NCT01301599|Active Comparator|5 ARI group|5 alpha-reductase inhibitor group
9970550|NCT01301612|Active Comparator|Radiation therapy and Cisplatin|Cisplatin, 40 mg/m2, IV - Weekly doses for 6 weeks Pelvic radiation therapy, 45 Gy External, Fractions of 1.8 Gy per day, 5 days a week Dose boosts,15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week Brachytherapy (if indicaed), 40 Gy at spot A(low dose rate), Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A, (high dose rate) Intracavitary,4 fractions of 7.0 Gy once or twice a week.
9970551|NCT01301612|Experimental|Nimotuzumab and|"Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks.~Nimotuzumab, 200 mg, Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes, Weekly doses for 14 weeks.~Pelvic radiation therapy, 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts, 15 Gy ± 5%, External,Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week~Brachytherapy (In case there is indication, should it be performed, not to be longer than the expected 70 days for the entire radiation therapy), 40 Gy at spot A (low dose rate) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks 28 Gy at spot A (high dose rate), Intracavitary, 4 fractions of 7.0 Gy once or twice a week."
9970552|NCT01301651|Experimental|virtual reality balance training|balance board training with virtual reality intervention
9970553|NCT01301651|Experimental|conventional balance training|physical therapy conventional balance training
9970554|NCT01301651|No Intervention|control group|No physical therapy
9970555|NCT01301677|Active Comparator|Hydrocortisone|
9970556|NCT01301677|Experimental|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
9970557|NCT01301677|Experimental|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
9970558|NCT01301690||Neck masses|Neck mass received US and US-FNA
9970559|NCT01301703|Active Comparator|Tdap vaccination|Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)
9970560|NCT01301716|Experimental|A|
9970561|NCT01301716|Experimental|B|
9970562|NCT01301716|Experimental|C|
9970563|NCT01301755||1|
9970564|NCT01301768|Experimental|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
9970565|NCT01301768|No Intervention|Usual care|Women in the control group receive the usual care during the pregnancy
9970566|NCT01301807|Experimental|Treatment (carfilzomib, panobinostat)|Participants receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 and panobinostat PO QD on days 1, 3, 5, 8, 10, and 12 of each course. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each course. If the disease becomes worse, participants can receive carfilzomib on the original dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).
9970567|NCT01301820|Other|ARM A|maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
9970568|NCT01301820|Other|ARM B|maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
9970569|NCT01301846||Wheelchair users|People who have a wheelchair for home and community use.
9970570|NCT01301859|Active Comparator|TIP Adherence Intervention|The TIP program is a brief, individualized intervention designed as an adjunct to pharmacotherapy for depression prescribed by a primary care physician. The key to the intervention is the involvement of the older adult in creating an adherence strategy tailored to his/her barriers and needs.
9970571|NCT01301859|Placebo Comparator|Usual Care|Treatment as usual in a primary care setting
9970572|NCT01301872|Other|1|All patients meet ALI/less severe ARDS criteria
9970573|NCT01301885||Endometriosis|Women (19-48 years of age) with surgically confirmed endometriosis.
9970574|NCT01301885||Healthy women|Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation
10144407|NCT04157049||Alpha-1 Diagnosed Individuals|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
10144408|NCT04157049||Carriers of Alpha-1|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
10144409|NCT04157114|Active Comparator|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
10144410|NCT04157114|Placebo Comparator|Placebo|Subjects will receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
10144411|NCT04157257|Experimental|QL-007 +TDF|QL-007 200 mg BID +TDF 300 mg QD
10144412|NCT04157257|Experimental|QL-007 +Entecavir|QL-007 200 mg BID +Entecavir 0.5 mg QD
10144413|NCT04157257|Active Comparator|TDF monotherapy|TDF tablet 300 mg QD
10144414|NCT04157257|Active Comparator|Entecavir monotherapy|Entecavir tablet 0.5 mg QD
10144415|NCT04156971|Experimental|Intervention Group|stage-based lifestyle modification intervention and fish oil supplement (omega-3). Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring' Participants in the intervention group were also given fish oil capsules containing n-3 LCPUFA (DHA and EPA) for a duration of 16 weeks. The participants were required to consume two fish oil capsules, providing 1320 mg n-3 LCPUFA (792 mg EPA, 20:5n-3 and 528 mg DHA, 22:6n-3), and 6 IU vitamin E (D-alpha tocopherol) daily. The EPA and DHA ratio was 1.5:1.
10144416|NCT04156971|Other|Control Group|Only received Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring'
10144417|NCT04156841||performed SLNB using a single mapping agent|
10144418|NCT04156841||performed SLNB by combination of blue dye and radiotracer|
10144419|NCT04156841||underwent SLN surgery receiving neoadjuvant chemotherapy|
10144420|NCT04156841||underwent SLN surgery not receiving neoadjuvant chemotherapy|
10144421|NCT04156984|Other|Study arm|Subjects treated with optimized dose of golimumab, irrespective of weight: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4 weeks. In case of disease flare: discontinuation of drug.
10144422|NCT04156984|Other|Control arm|"Subjects treated according to current European Label (2019) based on body weight:~<80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 50 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): dose optimization to 100 mg sc q4wk starting at week 6 or at any time during first year.~≥80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): discontinuation of drug."
10144423|NCT04157140|Experimental|Anlotinib+ TACE+ RFA|Anlotinib+ TACE+ RFA
10144424|NCT04157244|Experimental|Experimental: Tailored Music|4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet.
10144425|NCT04157244|No Intervention|4-week Wait-list control|4-week wait-list control (Note: participants will be crossed over to 4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet)
10144426|NCT04156932|Active Comparator|OUC|Origin uterine artery closure
10144427|NCT04156932|Active Comparator|IUC|Cervical-isthmic uterine artery closure
10144428|NCT04157283||Group 1|60 male patients
10144429|NCT04157283||Group 2|60 female patients
10144430|NCT04156724|Experimental|HV|6MWT with helmet ventilation
9970575|NCT01301898|Experimental|GC1111_0.5mg/kg|
10144431|NCT04156724|No Intervention|Control|6MWT alone according to ATS guideline
10144432|NCT04157010|Experimental|TCZ monotherapy|Tocilizumab (TCZ) monotherapy 8mg/kg 4-weekly for a total of 48 weeks.
10144433|NCT04157010|Experimental|TCZ+MTX combination therapy|Tocilizumab (TCZ) and methotrexate (MTX) combination therapy 8mg/kg 4-weekly for a total of 48 weeks.
10144434|NCT04157062|Experimental|Study Group|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive excitatory rTMS with a stimulation frequency of 10 Hz or higher.
10144435|NCT04156958|Other|Fruquintinib Arm|Fruquintinib, 5 mg once daily for 21 days, followed by 7 days off (28 days/cycle) treatment until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
10144436|NCT04157036|Experimental|800mg Ibuprofen|Subject will take 800mg of Ibuprofen 45 minutes prior to anesthetic delivery.
10144437|NCT04157036|Experimental|40mg Methylprednisolone|Subject will take 40mg of Methylprednisolone 45 minutes prior to anesthetic delivery.
10144438|NCT04156906|Experimental|D+ RH genotype matched Red Blood Cell Transfusion|Investigators will provide one red cell unit of D+ RH genotype matched RBCs at the first transfusion study visit. The remainder of units will be provided per clinical standard of care, i.e. D-, CEK-matched, and negative for all other antigens the patient is alloimmunized against. If laboratory monitoring shows no reappearance of anti-D and no signs of increased red cell hemolysis, the patient will receive one unit of D+ RH genotype matched RBCs at the 2nd transfusion study visit, and if tolerated, D+ red cell exposures will increase by one unit per study visit until all units required are D+.
10144439|NCT04156685|Experimental|PartA, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
10144440|NCT04156685|Experimental|PartA, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
10144441|NCT04156685|Experimental|PartB, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
10144442|NCT04156685|Experimental|PartB, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
9970576|NCT01301898|Experimental|GC1111_1.0mg/kg|
9970577|NCT01301898|Active Comparator|Elaprase_0.5mg/kg|
9970578|NCT01301911|Experimental|Cipatinib|Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.
10144443|NCT04157127|Experimental|Autologous DC Vaccine Cohort 1|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 1:~st vaccine - 0.5 million cells~nd vaccine - 1 million cells~rd vaccine - 2 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
10144444|NCT04157127|Experimental|Autologous DC Vaccine Cohort 2|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 2:~st vaccine - 1 million cells~nd vaccine - 2 million cells~rd vaccine - 4 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
10144445|NCT04157127|Experimental|Autologous DC Vaccine Cohort 3|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 3:~st vaccine - 2 million cells~nd vaccine - 4 million cells~rd vaccine - 8 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
10144446|NCT04157127|Experimental|Autologous DC Vaccine Cohort 4|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 4:~st vaccine - 6 million cells~nd vaccine - 6 million cells~rd vaccine - 6 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
10144447|NCT04157127|Experimental|Autologous DC Vaccine Cohort 5|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 5:~st vaccine - 7 million cells~nd vaccine - 7 million cells~rd vaccine - 7 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
10144448|NCT04157127|Experimental|Autologous DC Vaccine Cohort 6|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 6:~st vaccine - 8 million cells~nd vaccine - 8 million cells~rd vaccine - 8 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
10144449|NCT04156776|Experimental|Group A (MET)|Muscle Energy Technique Conventional Treatment
10144450|NCT04156776|Experimental|Group B (AIS)|Active Isolated Stretching Conventional Treatment
10144451|NCT04156750|Experimental|LY3556050 (Part A)|LY3556050 administered orally.
10144452|NCT04156750|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
10144453|NCT04156750|Other|Iohexol (Part B)|Iohexol given intravenously (IV). (Part B is optional.)
10144454|NCT04156750|Other|Metformin (Part B)|Metformin given orally. (Part B is optional.)
10144455|NCT04156750|Experimental|LY3556050+ Iohexol (Part B)|Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)
9669355|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
10144456|NCT04156750|Experimental|LY3556050 + Metformin (Part B)|Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)
10144457|NCT04156945|Experimental|Intervention I: behavioural intervention|Participants will receive the behavioural Intervention in addition to standard of care.
10144458|NCT04156945|Experimental|Intervention II: home-based testing intervention|Participants will receive the home-based testing intervention in addition to standard of care.
10144459|NCT04156945|Experimental|Intervention III: combined intervention|Participants will receive the behavioural intervention and the home-based testing intervention in addition to standard of care.
10144460|NCT04156737|Experimental|Investigational Lens|TECNIS Symfony plus IOL Model ZHR00V
10144461|NCT04156737|Active Comparator|Control Lens|Trifocal Intraocular Lens
10144462|NCT04156568|Experimental|6INH Group|10mg/kg 6INH were used in this group.
10144463|NCT04156568|Experimental|3INH+RFT group|3INH+RFTwere used in this grroup.
10144464|NCT04156711|Experimental|Remote Ischemic Preconditioning|Remote ischemic preconditioning is carried out before the induction of general anesthesia. All four cycles will be completed before general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg (if systolic blood pressures exceeds 185 mmHg, the cuff will be inflated to at least 15 mmHg above the systolic blood pressure) resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia, the cuff is deflated, and the limb is reperfused for 5 minutes. This cycle is repeated 4 times. Pulse oximetry is performed on the RIPC limb to make sure that the blood flow is completely interrupted during ischemia
10144465|NCT04156711|No Intervention|Control|Will receive no intervention, but will go through same tests at the same time-points (endothelial function measured by reactive hyperemia index, blood samples, Heart rate variability and questionaires)
10144466|NCT04156555|Experimental|Study drug|
10144467|NCT04156542|No Intervention|Control|In this school, we collected data throughout the entire study without implementing any intervention.
10144468|NCT04156542|Experimental|5-week Intervention with Post-intervention Data Collection|In this school, we collected baseline data for 5 weeks, implemented the intervention for five weeks, then removed the intervention and collected post-intervention data for five weeks.
10144469|NCT04156542|Experimental|Implement intervention for 15 weeks|In this school, we implemented the intervention on January 11, 2016, the day the study began.
10144470|NCT04156542|Experimental|Implement intervention for 12 weeks|In this school, we collected baseline data for three weeks and then implemented the intervention for the remaining twelve weeks.
10144471|NCT04156542|Experimental|Implement intervention for 9 weeks|In this school, we collected baseline data for six weeks and then implemented the intervention for the remaining nine weeks.
10144472|NCT04156542|Experimental|Implement intervention for 6 weeks|In this school, we collected baseline data for nine weeks and then implemented the intervention for the remaining six weeks.
10144473|NCT04156529|Experimental|ESU position|Firstly, the semi-elevated supine position was given to participants during tube feeding
10144474|NCT04156529|Experimental|ESRL position|Firstly, the semi-elevated right lateral position was given to participants during tube feeding
10144475|NCT04156815|Active Comparator|1,565nm NAFL only group|Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas. A facial sheet mask (skin repair dressing, Panion & BF Biotech Inc, Zhuhai, China) was used to clean the face after laser treatment, and the face was cooled by air cooler for 10 minutes. The patients received three treatment sessions with a 6-week interval between each session.
10144476|NCT04156815|Active Comparator|Oral isotretinoin only group|Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
10144477|NCT04156815|Active Comparator|Double therapy group|The patients first received 2-4 weeks of oral isotretinoin medication (1mg/kg/d), followed by 1565nm M22-ResurFx NAFL treatment. Subjects were then given isotretinoin with a dosage of 0.5 mg/kg/d for the next 12-14 weeks. Laser treatment parameters and procedures were as same as in the group one above.
10144478|NCT04156815|Experimental|Triple therapy group|The patients received the same treatments as the subjects in group (3) with additional PBT. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
10144479|NCT04156516|Experimental|HEART|sexual health intervention that focuses on communication skills
10144480|NCT04156516|Active Comparator|HealthyMinds|Attention-matched control: Growth mindset intervention
10144481|NCT04156919|Experimental|Playful condition|Children in the playful and non-playful conditions will receive the fooya! intervention but will be varied in the psychological state of playfulness. Children in the playful condition will play a health game called fooya! Drawing on the playfulness literature, we will manipulate four dimensions of play. First, to manipulate the voluntariness of tasks, children in the playful condition will be asked/invited to participate in the study. Second, to manipulate adult presence, there will be little to no teacher involvement in the playful condition. Third, to manipulate the timing of the activity, children in the playful condition will be given an option to play anytime, including after school hours. Fourth, to manipulate the goal perception, the children in the playful condition will be told that their activity is not graded-i.e., autotelic.
9519719|NCT03284216|Experimental|Steady-state hyperglycemia + exercise|Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
9970579|NCT01301924|Active Comparator|High dose|High dose: 20 days of 20 mg/kg/day meglumine antimoniate
10144482|NCT04156919|Experimental|Non-playful condition|As mentioned earlier, we will manipulate four dimensions of play. First, participation will be mandatory for children in the non-playful condition. Second, teacher presence will be more salient in this condition. Third, children in the non-playful condition will participate during school hours. Fourth, the children in the non-playful condition will be told that their activity is graded.
10144483|NCT04156919|Active Comparator|Control condition|Children in the control condition will play a video game unrelated to diet and lifestyle called Wordsearch.
10144484|NCT04156867|Experimental|simple discectomy|traditional simple discectomy
10144485|NCT04156425|Experimental|escitalopram + golimumab|Patients will be treated with escitalopram from the minimum dosage and golimumab according to direction for use.
10144486|NCT04156425|Experimental|escitalopram + calcium tablet|Patients will be treated with escitalopram from the minimum dosage and calcium tablet according to direction for use.
10144487|NCT04156425|Active Comparator|escitalopram|Patients will be treated with escitalopram from the minimum dosage.
10144488|NCT04156503|Experimental|Test fat: Palm olein|One high fat muffin will be serves together with a glass of low fat milk shake.
10144489|NCT04156503|Experimental|Test fat: Lard|One high fat muffin will be serves together with a glass of low fat milk shake.
10144490|NCT04156477|Experimental|Ketone ester|Intake of a ketogenic drink.
10144491|NCT04156477|Active Comparator|Isocaloric and -volumetric glucose drink|Intake of a taste matched glucogenic drink.
10144492|NCT04156477|Placebo Comparator|Isovolumetric tap water drink|Intake of a taste matched tap water drink.
10144493|NCT04156451|Active Comparator|Central Venous Pressure 8 - 10 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 8-12 mmHg is reached
10144494|NCT04156451|Experimental|Central Venous Pressure 0 - 4 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 0-4 mmHg is reached
9669356|NCT02847364|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum starting morning of post-operative day 1 until the first bowel movement.
9669357|NCT02847364|No Intervention|Control group|These patients will not be offered any food/beverage orally. Patients will be asked not to eat or chew anything till the first bowel movement.
9669358|NCT02843035|Experimental|Open label (OL) venglustat|Administered once a day orally for up to approximately 8.7 years. Patients will continue their usual dose of Cerezyme during Part 1, Part 2 and Part 3. There is no administration of Cerezyme in Part 4 unless administrated as rescue treatment.
9970580|NCT01301924|Experimental|Low dose|Low dose: 30 days of 5 mg/kg/day meglumine antimoniate
9970581|NCT01301937|Active Comparator|High continuous dose|Meglumine antimoniate 20 mg/kg/day for 30 continuous days
9970582|NCT01301937|Active Comparator|Low continuous dose|Meglumine antimoniate 5 mg/kg/day for up to 120 continuous days according to clinical cure
9970583|NCT01301989|Placebo Comparator|Sleep Education Control|"The control group receives a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers (in English and Spanish)."
9970584|NCT01301989|Experimental|Sleep Counselor Intervention|"The sleep counselor visits are to assess the family's understanding of their child's sleep problems; help parents recognize the child's sleep deficiency; discuss how sleep problems affect behavior, learning, and health; and reassure parents that the sleep counselor can help them with these problems.~Additionally, sleep counselors: review parent's sleep goals to monitor changes to the child's bedtime routine and sleep environment; help them solve problems with implementation; provide positive feedback to help the parent recognize success; and help parents set additional goals for improving sleep."
9970585|NCT01302002|Experimental|Metformin Pre-Surgery|Patients will take metformin twice a day for three weeks prior surgery
9970586|NCT01302015|Experimental|RNL-Vascostem®|drug name and ingredients : RNL-Vascostem[Autologous adipose tissue derived mesenchymal stem cells] dosage : Intramuscular infusion, 5 x 10e6 cells/kg
9970587|NCT01302028|Active Comparator|Healthy volunteers with normal renal function|Oral
9970588|NCT01302028|Experimental|T2DM patient with normal renal function|Oral
9970589|NCT01302028|Experimental|T2DM patient with mild renal impairment|Oral
9970590|NCT01302028|Experimental|T2DM patient with moderate renal impairment|Oral
9970591|NCT01302028|Experimental|T2DM patient with severe renal impairment|Oral
9970592|NCT01302093|Experimental|Experimental Tablet|A single 100 mg dose of an experimental Racecadotril Film-Coated Tablet (FCT)
9970593|NCT01302093|Active Comparator|Marketed Capsule|A single 100 mg dose of a marketed Racecadotril capsule
9970594|NCT01302106|Experimental|Arm 1|Clofarabine combined with low dose Ara-C
9970595|NCT01302145|Experimental|ASP1941 + metformin|Oral
9970596|NCT01302145|Placebo Comparator|Placebo + metformin|Oral
10144495|NCT04156464|Active Comparator|Phenobarbital based treatment|"The phenobarbital group will undergo management with a phenobarbital based treatment protocol with additional symptom triggered therapies.~On day 1, the phenobarbital group receive a loading dose of phenobarbital intravenous 10mg/kg (actual body weight) with a maximum dose of 1 g/100 mL~On day 2 of study protocol, and no sooner than 12 hours after loading dose, phenobarbital 64.8 mg is administered every 12 hours for two doses.~On day 3 of study protocol, patients will receive phenobarbital 32.4 mg every 12 hours for two doses.~On day 4 of study protocol, patients will receive phenobarbital 32.4 mg once, to be given 24 hours after last scheduled dose.~Throughout the 4 day protocol, the patient will have phenobarbital 65 mg every 6 hours as needed available either IM or IV, starting no sooner than 30 minutes after the loading dose."
10184962|NCT03750487|Experimental|e-screening & brief intervention (e-SBI)|A two-session (20 minutes each) computer-delivered screening and brief motivational intervention targeting alcohol and drug use. Computerized screening is conducted using the ASSIST. Session 1 of the BI includes personalized feedback, readiness to change interventions, and goal setting around substance use. Session 2 will contain motivational content reinforcing engagement in home visiting and information around other challenges mothers may experience including tobacco use, postpartum depression, and intimate partner violence.
9826121|NCT02408523|Placebo Comparator|Placebo|"Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects >= 50kg.~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30kg.)~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to < 50kg.)"
9826122|NCT02408692|Active Comparator|Normal BMI ECx1|5 normal weight women (BMI<25 kg/m2) taking 1.5mg LNG
9826123|NCT02408692|Active Comparator|Obese BMI ECx1|5 obese women (BMI >30 kg/m2) taking 1.5mg LNG
9826124|NCT02408692|Active Comparator|Obese BMI ECx2|5 obese women (BMI >30 kg/m2) taking 3mg LNG
9826125|NCT02408796|Experimental|OTO-201|6 mg OTO-201
10144496|NCT04156464|Active Comparator|Lorazepam based treatment|"The lorazepam group will undergo management with a lorazepam based treatment protocol with additional symptom triggered therapies.~On Day 1, the lorazepam group will be started on scheduled lorazepam 4 mg every 6 hours~After day 1, the scheduled lorazepam dose will be modified based on the total lorazepam requirements from the previous day and divided into 4-6 doses.~A lorazepam infusion, at physician discretion, will be available at any point if the dose of scheduled and PRN lorazepam being given is too high or frequent to effectively be administered.~Once symptoms are well controlled on lorazepam based therapy, the total dose given over the past 24 hours will be calculated and weaned by approximately 10-20% per day when clinically appropriate.~Throughout the entire protocol, 2-4 mg lorazepam IV q 30 minutes PRN will be available for a goal CIWA <6 or RASS -1 to 0."
10144497|NCT04156607|Experimental|Kinesio taping group (KT)|"Kinesio taping applied to plantar soles of these children with Down Syndrome. Epidermis-Dermis-Fascia technique was used for providing sensory input from soles.~The application was performed on both feet."
10144498|NCT04156607|Sham Comparator|Sham taping group (ST)|A random taping was performed using Kinesio tape but without using Kinesiotaping techniques for sham taping. The application was performed on both feet
10144499|NCT04156607|No Intervention|Healty control group|This group took no intervention but all balance assessments once.
10144500|NCT04156373|Experimental|Fuerte|This group will receive the Fuerte prevention program over the span of six to eight weeks.
10144501|NCT04156373|No Intervention|Delayed waitlist control|This group will be the delayed waitlist control group. They will not receive the Fuerte prevention program until the following semester.
10144502|NCT04156412|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
10144503|NCT04156061|No Intervention|ASSIGN score|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.~Patients randomised to standard care with ASSIGN score alone (n=200) will be invited back approximately 6 months after baseline assessment. The detailed questionnaire, breath test, blood pressure monitoring, and 2-week activity monitor will be repeated. Bloods will be retaken to look at change in lipid levels and HbA1c where appropriate - no more than 30mls will be required."
10144504|NCT04156061|Active Comparator|CTCA - visual report|"Those in the CTCA group will be further randomised into review with or without CT images.~The review WITH images (VISUAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
10144505|NCT04156061|Active Comparator|CTCA - verbal report|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.~Those in the CTCA group will be further randomised into review with or without CT images.~The review WITHOUT images (VERBAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
10144506|NCT04156204|Experimental|Adolescent and Young Adult (AYA) Kidney Transplant Recipients|AYA kidney transplant recipients will receive a Medication Event Monitoring System (MEMS) in the form of a medication bottle and cap system and once daily tacrolimus XR 1-10mg
10144507|NCT04156386|Active Comparator|Animal Protein|
10144508|NCT04156386|Active Comparator|Vegan Protein|
10144509|NCT04156386|Placebo Comparator|Placebo|
10184963|NCT03750487|Sham Comparator|Control|The control group will receive a similar 2-session brief motivational intervention. Session 1 focuses on nutrition and healthy eating, session 2 focuses on exercising while pregnant or in the postpartum period.
10184964|NCT03750474|Experimental|patient with chronic low back pain|magnetic resonance elastography and shear wave elastography of the back muscles
10184965|NCT03750474|Other|healthy controls|magnetic resonance elastography and shear wave elastography of the back muscles
10184966|NCT03750448|Active Comparator|Telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
10144510|NCT04156282|Active Comparator|classical closure.|In this group, the rectus sheath closure will be done by simple running continuous sutures with the knots beneath the subcutaneous layer.
10144511|NCT04156282|Active Comparator|knot burial technique|The surgeon holds the left angle of the rectus sheath incision with an Allis. Using (Polyglactin 910) suture,The needle is taken from the inside outward on the upper edge.The needle is then taken lateral to the Allis and brought back into the wound by taking it through the inferior edge from outside to inside . A square knot is tied with three or four throws. The needle is then taken out of the wound through the upper edge and continuous running stitches . As the right angle is approached, the angle is held with an Allis. the suture, will be taken through the lower edge, is brought outside the wound and passed between the blades of a closed Allis before taking it inside out on the upper edge. One more bite is taken but this time just lateral to the Allis holding the angle, and the needle is brought back into the wound and to the outside between the edges of the rectus sheath. Using the loop of polyglactin held with the Allis , an Aberdeen knot is tied after removing the Allis.
10144512|NCT04156269|Experimental|BCMA-CD33 cCAR T cells|BCMA-CS1 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-BCMA and CS1 CARs
10144513|NCT04156321|Experimental|Intervention|Group I (intervention) will receive 150 gm of Sajna shak/bora (Moringa) added with 25 gm concenstrated dal with 100 gm of rice as mid-morning snack in selected school 5 times a week for 6 months
10144514|NCT04156321|No Intervention|Control arm|Group II (Control) will rice, concenstrated dal and potato vaji. Both groups will receive calorie matched meal (411 kcal)
10144515|NCT04156256|Experimental|CD123-CD33 cCAR T cells|C123-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs
10144516|NCT04156308|Experimental|Combined exercises+OMT weekly|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions with a weekly frequency (with + -2 days of margin: between 5 and 9 days)."
10144517|NCT04156308|Experimental|Combined exercises+OMT once every 3 weeks|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions at the rate of one session every 3 weeks (with + -2 days of margin: between 19-23 days)."
10144518|NCT04156308|Experimental|Combined exercises|This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality.
10144519|NCT04156347|Experimental|Phase I Open Label Study|Phase I Single Arm
10144520|NCT04156113|Experimental|Athletes Group|"The athletes group will be composed of healthy, non obese (body mass index < 30), male basketball, volleyball and handball players aged between 18 and 35 years who have been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
10144521|NCT04156113|Experimental|Sedentary Group|"The sedentary group will be composed of healthy, non obese (body mass index < 30), male aged between 18 and 35 years who have not been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
10144522|NCT04156139|Active Comparator|Control group|NPPV treatment for patients will be performed for patients immediately after extubation in control group.
10144523|NCT04156139|Experimental|intervention group|HFNC treatment will be performed for patients immediately after extubation in the intervention group.
10144524|NCT04156035|Experimental|Lamotrigine + Ketamine|Pretreatment with lamotrigine will occur 2 hours before the ketamine infusion
10144525|NCT04156035|Experimental|Placebo + Ketamine|Pretreatment with placebo will occur 2 hours before the ketamine infusion
10144526|NCT04156035|Placebo Comparator|Placebo + Placebo|Pretreatment with placebo will occur 2 hours before the placebo infusion
10144527|NCT04156074|Experimental|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
10144528|NCT04156074|Active Comparator|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
10144529|NCT04156074|Placebo Comparator|Placebo coconut oil emulsion drink|30 mL placebo drink consumed daily for 4 weeks
10144530|NCT04156074|Active Comparator|Vitamin D supplement (20 mcg/day)|Vitamin D supplement consumed daily for 4 weeks
10144531|NCT04156009|Experimental|Treatment (+aromatherapy) group|
10144532|NCT04156009|Sham Comparator|Control (-aromatherapy) group|
10144533|NCT04156243|Experimental|CD19 CARvac T cells|CD19 CARvac T cells transduced with a lentiviral vector to express
10144534|NCT04156152|Active Comparator|Grupo I|16 patients
10144535|NCT04156152|Active Comparator|Grupo II|16 patients
10144536|NCT04156178|Experimental|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD20 and CD19 CARs
10144537|NCT04156087|Experimental|MIMIPAC|Intervention: MIS-MWA plus immunotherapy using the combination of durvalumab with tremelimumab
10144538|NCT04155827|Experimental|SIT for males|
10144539|NCT04155827|Experimental|SIT for females|
10144540|NCT04155814|Experimental|Iron Sucrose Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
10144541|NCT04155814|Active Comparator|Venofer Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
10144542|NCT04155866||Healthy participants|Measurement of lower-limb muscle activation from healthy participants.
10144543|NCT04155866||Chronic Stroke Survivors|Measurement of lower-limb muscle activation from chronic stroke survivors
10144544|NCT04155905|Active Comparator|group A fistulotomy group|35 patients with simple anal fistula subjected to fistulotomy
10144545|NCT04155905|Active Comparator|group B marsupialization group|35 patients with simple anal fistula subjected to fistulotomy and marsupialization of fistulotomy wound
10144546|NCT04155957|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty and perform a daily 5-exercise plan autonomously.
10144547|NCT04155957|Experimental|ReHub Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty but use the telerehabilitation platform ReHub to do the exercises in their rehabilitation plan at home and to have their progress monitored.
10144548|NCT04155775||Best Practice Alert|Platelet transfusion orders for patients with a recent platelet count exceeding 50,000 per microliter (50k/uL) will trigger an alert in the electronic health record that displays current guidelines for platelet transfusion. The alert will allow providers to bypass the recommendation and continue with platelet ordering by selecting a clinical acknowledgement / exception to recommendation.Exclusions will be built into the alert to avoid triggering in operative or procedural settings, for neurosurgery providers, or patients on anti-platelet medications.
10144549|NCT04155775||No Best Practice Alert|For this group, no visible best practice alert will activate in the electronic health record for platelet transfusion orders and recent counts above 50k/uL.
10144550|NCT04155879|No Intervention|Control Group|Cardioversion without treatment with Colchicine
10144551|NCT04155879|Active Comparator|Treatment group|This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months
10144552|NCT04155970|Experimental|Manual Therapy Arm|The group will receive manual therapy, as well as an evidence-informed home management booklet.
10144553|NCT04155970|Experimental|Non-Manual Therapy Arm|The group will receive an evidence-informed home management booklet only.
10144554|NCT04155983|Active Comparator|High ACB|In the pre-operative cohort, the adductor canal block is administered by anesthesia staff immediately prior to patient transport to the operating room. The thigh is prepped with cholorhexidine at the midpoint between the anterior superior iliac spine and the patella and sterile drapes are applied. An ultrasound probe is then used to localize the adductor canal and confirm that the femoral artery, femoral vein and saphenous nerve can be visualized deep to the sartorious. The probe is moved proximally or distally until the neurovascular bundle is centered under the sartorius. A 20cc syringe with a blunt tip 1.5in 18ga needle is then used to inject 15cc of 0.5% ropivocaine. Following this, the wound is prepped and draped in usual sterile fashion for the arthroplasty procedure.
10144555|NCT04155983|Active Comparator|Low ACB|Surgeon Administered Group In the intra-operative cohort, the block will be administered after the final components are in place and cement debris is removed. The knee joint is irrigated with dilute hibiclens or betadine followed by pulsatile lavage per institutional protocol. A blunt tip 1.5in 18ga needle was then used to administer 15cc of 0.5% ropivocaine.. The location of the saphenous nerve as it exits the adductor canal will be estimated to be 1.5x the TEA proximal to the medial epicondyle in men and 1.3x the TEA proximal in women as described by Kavolus et al. The 60cc of the anesthetic will then injected through the vastus medialis musculature in a field extending from 1cm proximal to one cm distal to the assumed location of the nerve with the needle directed in from 20° to 45° medial. The wound is then irrigated pulsatile lavage one final time and closed in layered fashion.
10144556|NCT04155632|Experimental|N-acetylcysteine + Theta Burst Stimulation|
10144557|NCT04155632|Sham Comparator|N-acetylcysteine + Sham Theta Burst Stimulation|
10144558|NCT04155632|Placebo Comparator|Placebo + Theta Burst Stimulation|
10144559|NCT04155632|No Intervention|Placebo + Sham Theta Burst Stimulation|
10144560|NCT04155658|Experimental|Experimental SMFP Toothpaste|Toothpaste containing 1450ppm SMFP with additional calcium and phosphate
10144561|NCT04155658|Active Comparator|SMFP Toothpaste|Toothpaste containing 1450ppm SMFP
10144562|NCT04155658|Placebo Comparator|Negative control toothpaste|Toothpaste with no fluoride
10144563|NCT04155645|Experimental|Cohort 1|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 1 injection (8 subjects) or matching placebo (3 subjects).
10144564|NCT04155645|Experimental|Cohort 2|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 2 injection (8 subjects) or matching placebo (3 subjects).
10144565|NCT04155645|Experimental|Cohort 3|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 3 injection (8 subjects) or matching placebo (3 subjects).
10144566|NCT04155931||body temperature measurement|The investigators planned to perform prospectively in 80 children with ASA I according to the American Society of Anesthesia (ASA) Anesthesia Risk Scale between 6 months and 7 years of age in both sexes who underwent inguinal hernia, undescended testes and hydrocele surgery
10144567|NCT04155918|Experimental|AR882/FBX|
10144568|NCT04155918|Experimental|AR882/ALLO|
10144569|NCT04155801|Experimental|Salix Probiotic Blend|Participants will receive a Salix Probiotic Blend capsule orally once a day for 30 days.
10144570|NCT04155697|Active Comparator|Hand washing with soap for thirdhand smoke removal|
10144571|NCT04155697|Active Comparator|Ethyl alcohol-based sanitizer for thirdhand smoke removal|
10144572|NCT04155606|Active Comparator|Interventional Therapy|Neurosurgery or Endovascular procedure
10144573|NCT04155606|No Intervention|Conservative Management|Monitoring with pharmacological therapy if need arises.
10144574|NCT04155762|Experimental|Intervention|Both suspension systems were applied consecutively to the participants. Initially, participants used the Pin Suspension System (PSS) for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period. They then employed the Vacuum-Assisted Suspension System (VASS) for three months after a similar training period.
10144575|NCT04155619|Active Comparator|No change in eating or light exposure habits|
10144576|NCT04155619|Experimental|Early Time-Restricted Feeding|
10144577|NCT04155619|Experimental|Timed Light Therapy|
10144578|NCT04155619|Experimental|Early Time-Restricted Feeding and Timed Light Therapy|
10144579|NCT04155736|Experimental|Renew with coaching|Users will be assigned a study staff member as a support person who is notified when the user engages with the app or if they have not engaged for 7 days. Support persons are provided with psychoeducation material including information about how to be an effective support person for the user and direct messaging capacity to respond to app notifications about user engagement (e.g., user earned X points, user achieved a new level).
10144580|NCT04155736|Active Comparator|Renew without coaching|"Same as Renew with coaching except that the users will not be assigned a study staff member as a support person."
10144581|NCT04155736|No Intervention|Wait list|No intervention is provided
10144582|NCT04155671|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
10144583|NCT04155671|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
10144584|NCT04155372|Experimental|30min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 30 min.
10144585|NCT04155372|Experimental|60min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 60 min.
10144586|NCT04155372|Experimental|90min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 90 min.
10144587|NCT04155255|No Intervention|Control|Age-matched overweight and obese students were selected from control schools. The students participated in their usual health and physical education classes plus any other curriculum activities provided by the school.
10144588|NCT04155255|Experimental|Intervention|Overweight and obese students were recruited from intervention schools. Students underwent MyBFF@school intervention programme that consisted of physical activity, nutrition and psychological modules for the duration of 6 months. MyBFF@school intervention programme were conducted by trained personnel that were stationed full-time at each intervention school.
10144589|NCT04155177||begining of curriculum|trainees in obstetrics and gynecology who have achieved less than 2 years of their hole curriculum
10144590|NCT04155177||mid curriculum|trainees in obstetrics and gynecology who have achieved at least 2 years and less than 4 years of their hole curriculum
10144591|NCT04155177||Advanced|trainees in obstetrics and gynecology who have achieved at least 4 years of their hole curriculm
10144592|NCT04155320|Active Comparator|Group A|Subjects are encouraged to disclose their HIV status to their partner(s) with or without a counselor present (Options 1 & 2).
10144593|NCT04155320|Experimental|Group B|Subjects may choose to notify their partners themselves, with or without a counselor present (Options 1 & 2), or choose to have one or more partners notified anonymously by project staff (Option 3).
9519720|NCT03284216|Experimental|Fluctuating hyperglycemia + exercise|Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.
9519721|NCT03284216|No Intervention|Normal glycemia, no exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.
9519722|NCT03284203|Experimental|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
9519723|NCT03284190||ASDH Copenhagen, Denmark|
10144594|NCT04155281||suspicion of intoxication|New Psychoactive Substances research in urine
10144595|NCT04155242|Experimental|Study group|As part of the post RFA treatment follow up patients will receive a Cytosponge test followed by an endoscopy with NBI magnification and biopsies. Four endoscopies will be performed during 2 years of active follow up together with up to 2 Cytosponge procedures. Molecular biomarkers including a methylation panel on DNA and immunohistochemical markers on formalin fixed paraffin embedded samples obtained during the examinations will be assessed. Patients will be then followed up for up to 3 years with standard endoscopy to assess for relapse of Barrett's oesophagus/IM/dysplasia.
10144596|NCT04155554|Experimental|Bictegravir/emtricitabine/tenofovir alafenamide|Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD
10144597|NCT04155554|Active Comparator|Dolutegravir/lamivudine/abacavir|Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD
10184967|NCT03750448|Active Comparator|No intervention|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
9519724|NCT03284190||ASDH Odense, Denmark|
9519725|NCT03284190||ASDH Århus, Denmark|
9519726|NCT03284190||ASDH Ålborg, Denmark|
9519727|NCT03284190||ASDH Lund, Sweden|
9519728|NCT03284190||ASDH Linköping, Sweden|
9519729|NCT03284190||ASDH Gothenburg, Sweden|
9519730|NCT03284190||ASDH Stockholm, Sweden|
9519731|NCT03284190||ASDH Uppsala, Sweden|
9519732|NCT03284190||ASDH Umeå, Sweden|
9519733|NCT03284177|Experimental|C13-CAC|
9519734|NCT03284164|Experimental|Healthy Subjects|Healthy Subjects matched to RI subjects Tenofovir Exalidex (TXL)
9519735|NCT03284164|Experimental|Severe RI|Severe Renal Impairment subjects Tenofovir Exalidex (TXL)
10144598|NCT04155346|Experimental|Facility-based prehabilitation (FBP)|"Exercise~Three supervised exercise training sessions of aerobic and resistance exercises. Includes high-intensity interval aerobic training and whole-body resistance exercises (60 min/session)~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a Registered Dietitian (60 min/session)~Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a psychologist (60 min/session)"
10144599|NCT04155346|Experimental|Home-based prehabilitation (HBP)|"Exercise~Three unsupervised, home-based exercise training sessions of aerobic and resistance exercises. Includes continuous moderate-intensity aerobic training and whole-body resistance exercises (60 min/session)~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist~Nutrition~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a Registered Dietitian (60 min/session)~Participants will also receive 20g of protein supplementation daily~Stress management and behavioural support~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery~All sessions will conducted by a psychologist (60 min/session)"
10144600|NCT04155346|No Intervention|Usual Care|- This group will receive no additional intervention from the routine care.
10144601|NCT04155385|Active Comparator|Measurement-only|Patients will complete weekly measures of treatment progress and goals; however, the information from these measures will not be shared with clinicians or patients.
10144602|NCT04155385|Experimental|Measurement and feedback|Patients will complete weekly measures of treatment progress and goals; the information from these measures will be shared with clinicians.
10144603|NCT04155528|Experimental|Study group|The intervention group will receive routine hospital care alongside 30 minutes of music therapy per day for three consecutive days. The music therapy will be initiated on the second day postoperatively. The assessment of baseline data and the music therapy will be applied at least three hours after analgesics administration.
10144604|NCT04155528|No Intervention|Control group|Patients in the control group will receive routine hospital care only.
10144605|NCT04155515|Other|Non-cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
10144606|NCT04155515|Other|Cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
10144607|NCT04155463|Experimental|Organic Diet|Participants will be allowed to order one week's worth of food from a grocery store website (capped by price), with the restriction that they may only order foods certified by the US Department of Agriculture (USDA) as organically grown. This food will be delivered to the researcher's laboratory, packaged, and delivered to each participants' home. Participants will log their food intake using a custom food diary phone app provided by the study.
10144608|NCT04155463|Experimental|Conventional Diet|Participants will be allowed to order one week's worth of food from a grocery store website (capped by price), with the restriction that they may only order foods NOT certified by the USDA as organically grown. This food will be delivered to the researcher's laboratory, packaged, and delivered to each participants' home. Participants will log their food intake using a custom food diary phone app provided by the study.
10144609|NCT04155229|Experimental|Null setting, forced entry|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at -blank-. This setting required the prescriber to enter a quantity in order to write a prescription."
10144610|NCT04155229|Experimental|5 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 5."
10144611|NCT04155229|Experimental|10 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 10."
10144612|NCT04155229|Experimental|15 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 15."
10144613|NCT04155229|Active Comparator|Status quo default setting|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at the status quo value for each site (20 for site 1, 12 for site 2)."
10144614|NCT04155268|Experimental|Floatation-REST|Participants will float in a shallow pool of water with about 1000 pounds of epsom salt, in a light and sound attenuated device, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
10144615|NCT04155268|Active Comparator|Dark Room|Participants will lay on an air mattress in a dark and quiet room, with reduced environmental stimulation, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
10144616|NCT04155190|Experimental|Patidegib Topical Gel, 2%|Participants will be randomized (1:1) to receive Patidegib Topical Gel, 2% for 9 months
10144617|NCT04155190|Active Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized (1:1) to receive Patidegib Topical Gel, Vehicle for 9 months
10144618|NCT04155476|Experimental|Nitroglycerin exposure|
10144619|NCT04155476|Placebo Comparator|Non-Nitroglycerin exposure|
10144620|NCT04155307|Experimental|Detection of anismus in patients with distal constipation|
10144621|NCT04155151|Experimental|Single Arm|6 Minute Walking Test
10144622|NCT04154852|Experimental|TNF-antagonist|Adalimumab, 40 mg, 2-weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
10144623|NCT04154852|Active Comparator|Placebo + MTX|Placebo, 2 weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
10144624|NCT04154813|Experimental|Topiramate group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is topiramate group.During this group the initial dose of 25mg/day is rapidly increased to the target dose (100mg/day) or below the maximum tolerable dose if the patient can tolerate it.
10144625|NCT04154813|Experimental|Fluoxetine+DBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+DBT group. Group cognitive behavioral therapy was performed while fluoxetine was maintained. Target dose of fluoxetine is 60mg/day.Treatment was divided into three stages: the initial stage, the main stage and the end stage. The treatment was conducted once a week for a total of 12 times, followed by maintenance treatment for 6 months.
10144626|NCT04154813|Experimental|Fluoxetine+CBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+CBT group.Target dose of fluoxetine is 60mg/day. DBT therapy was performed while the original fluoxetine dose was maintained.The core treatment stage was 1 time per week, 12 times in total, and 6 months of maintenance treatment followed.
10144627|NCT04154969|Experimental|intervention|daily physiotherapy session as part of the rehab plan, which includes 10 minutes of vestibular exercize.
10144628|NCT04154969|Active Comparator|control|daily physiotherapy session as part of the rehab plan
10144629|NCT04154982|Experimental|Pharmacological treatment|Patients are treated with NAC prior to carrying out CAP.
10144630|NCT04154982|No Intervention|Standard procedure|Patients are not treated with NAC. No placebo treatment is performed.
10144631|NCT04155073|Experimental|COPD/smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking, quitting smoking, and respiratory symptoms, 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit, and if needed, 3) a home spirometry test with instructions on how to video themselves completing a lung functioning test via the device within an additional e-visit.
10144632|NCT04155073|Active Comparator|Treatment as Usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
10144633|NCT04154995||Long-term ICU patients|Patients with a ICU length of stay of at least 48 hours.
10144634|NCT04155112|Active Comparator|Exercise|Participants randomized to exercise will receive exercise sessions of 50 minutes twice weekly for 4 weeks led by experienced exercise instructors, thereafter once weekly with an instructor and twice weekly without an instructor (up to 6 month)
10144635|NCT04155112|Active Comparator|Mediterranean diet|Participants randomized to dietary group will be counseled by experienced dietitians to follow the Mediterranean diet with Nordic modifications with follow up sessions at biweekly intevals to reinforce changes (up to 6 month)
10144636|NCT04154865|Experimental|Enrolled, eligible|Single arm for eligible subjects
10144637|NCT04154748|Experimental|APC 90W / PPI 120mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
10144638|NCT04154748|Active Comparator|APC 90W / PPI 40mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
10144639|NCT04154748|Active Comparator|APC 60 W/ PPI 120mg|treatment with standard-power argon plasma coagulation (60 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
10144640|NCT04155008|Active Comparator|Patients with fair to good appetite|The patients with fair-good appetite (score on CNAQ more than 24) will not receive any pharmacological agents and will receive nutrition intervention alone.
10144641|NCT04155008|Experimental|Patients with poor to fair appetite|The patients with poor-fair appetite (score on CNAQ less than 24) will be provided nutrition intervention by the Registered Dietitian and then put into one of three pharmacological groups.
10144642|NCT04155125|Experimental|efepoetin alfa|"Route of administration: Subcutaneous Injection.~The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period."
10144643|NCT04155125|Placebo Comparator|Mircera|"Route of administration: Subcutaneous Injection.~The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL."
10144644|NCT04155086|Experimental|Exposed group (patient with an autoimmunise disease)|Any patient with an autoimmune disease followed at one of the 14 centres who wants to be screened for T21.
10144645|NCT04155086|Other|Non Exposed group (patient without an autoimmunise disease)|
10144646|NCT04155138|Other|Naida Hearing Aid|"Adults (> 18 years of age)~Unilaterally implanted with an Advanced Bionics implant (CII or later)~At least six months of CI use experience~Limited bimodal benefit as perceived by the recipient and/or the clinician~Participants may or may not currently be using a hearing aid in the unimplanted ear.~Open set performance with current device configuration:~≥40% AzBio sentence score in quiet (S0)~If currently bimodal:~Hearing aid ear only CNC score <50%~AzBio Scores bimodal benefit <15%~Unaided audiometric threshold of ≤100 dBHL up to 500 Hz~Ability and willingness to participate in multiple sets of open speech testing (and chronically evaluate HA and CROS benefit)"
10144647|NCT04155138|Other|Naida CROS Device|The same cohort will cross over to each arm.
10144648|NCT04154930|Experimental|Treatment|"Restylane-L® injected with optional touch at 1 month and optional retreatment at 12 months~,"
10144649|NCT04154930|No Intervention|No Treatment Control|No treatment control with optional treatment at 12 months
10144650|NCT04155099|Experimental|High dose|Capsules of active drug will be supplied in 8-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
10144651|NCT04155099|Experimental|Low dose|Capsules of active drug will be supplied in 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
10144652|NCT04155099|Placebo Comparator|pill quantity-matched Placebo|Capsules of inactive compound will be supplied in 8- or 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
10144653|NCT04154917|Experimental|Experimental|HOME will be delivered by a community-based OT, who will be involved in the hospital discharge planning, trained by the PI. The HOME intervention comprises 4 phases: Phase 1 (in hospital): The clinician will focus on building a rapport with the patient and family members. Information will be gathered about the participant's home environment and functional ability. Phase 2 (± 5 days prior to expected discharge): Clinician will conduct a pre-discharge home assessment with patient and family to evaluate the environment, identify potential problems, and suggest appropriate ways to address them. Phase 3 (<1 week after discharge): Post-discharge home assessment will be conducted to provide additional in-home training and follow up on any of the patient's unmet needs. Phase 4 (2-4 weeks post-discharge): Follow-up telephone calls will be made to provide ongoing support to participant and family and encourage self-problem solving and independence.
10144654|NCT04154917|No Intervention|Usual care|Usual care group will receive the customary discharge planning assessment by a different clinician (OT). During this assessment, according to usual care, information regarding the participants' ability to perform activities of daily living and regarding their home environment is gathered and used to plan for discharge. Usual care group will not receive an OT home assessment as this is not part of usual care. If the clinician identifies a potential need for assistive equipment and home modification needs, patients will be referred to community-based homecare services as is the current practice, and a home visit may be performed following discharge, typically after an lengthy wait (weeks, months) for service.
10144655|NCT04154735|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with fludarabine, cyclophosphamide, mesna, and alemtuzumab. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant until engraftment. Rifaximin and tacrolimus will be administered for 6 and 12 months, respectively, beginning one day before the infusion of stem cells.
10144656|NCT04154722|Experimental|meropenum and azithromycin group|inj meropenum 20mg/kg/dose I/v in 3 divided doses and syp azithromycin 20mg/kg/day in 2 divided doses.
10144657|NCT04154722|Active Comparator|meropenum group|inj meropenum 20mg/kg/dose I/v in 3 divided doses
10144658|NCT04154540|Experimental|demyelinating hereditary neuropathy|adult patients with demyelinating hereditary neuropathy type CMT 1A.
10144659|NCT04154540|Experimental|demyelinating inflammatory neuropathy|adult patients with acquired demyelinating inflammatory neuropathy.
10144660|NCT04154449||Control group.|
10144661|NCT04154449||Surgical group Received intranasal insulin.|
10144662|NCT04154449||Surgical group Received placebo.|
10144663|NCT04154462|No Intervention|No intervention|The VAMC sites randomized to the comparison arm will not have medical scribes introduced into emergency departments or specialty clinics.
10144664|NCT04154462|Experimental|Treatment|The VAMC sites randomized to the treatment arm are each expected to have four medical scribes, with two being VA employees and two being contractors, introduced into emergency departments or specialty clinics to assist providers during patient encounters.
10144665|NCT04154566|Experimental|the study group|Group (A) the study group received aerobic exercise in addition to selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
10144666|NCT04154566|No Intervention|the control group|group (B) the control group received the same selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment only.
10144667|NCT04154592|Experimental|Experimental Group|In addition to the conservative treatment of the control group, humeral head depressor muscle co-activation training will be applied for 14 weeks.
10144668|NCT04154592|Active Comparator|Control Group|The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., & Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).
10144669|NCT04154709|Experimental|CTA101|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
10144670|NCT04154527||postpartum women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz) curved linear array ultrasound transducer was used (LOGIQe Ultrasound,General Electric Healthcare, USA) with the ultrasound unit set in B mode."
10184968|NCT03750448|Active Comparator|Unsupervised rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
10184969|NCT03750435|Experimental|Ablation for AF or left-sided AT|The patient will be admitted in hospital as for a standard ablation procedure and discharged the next day. The procedure will be carried out without using fluoroscopy and relying on the visualization of the electroanatomical mapping system.
10144671|NCT04154527||nulliparous women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz)curved linear array ultrasound transducer was used (LOGIQe Ultrasound,GE eneral Electric Healthcare, USA) with the ultrasound unit set in B mode."
10144672|NCT04154696|Experimental|Normothermic perfusion of a graft|
10144673|NCT04154657|Experimental|biventricular conductance catheter|patients with indication for invasive assessment receive right and left heart catheter and parallel biventricular conductance catheter at rest and stress
10144674|NCT04154215|Experimental|Dementia with Lewy Body (DLB) patients|
10144675|NCT04154501|Placebo Comparator|Cohort 1 Placebo|Oral Placebo Capsule
10144676|NCT04154501|Experimental|Cohort 1 Drug|25 mg Oral Capsule
10144677|NCT04154501|Placebo Comparator|Cohort 2 Placebo|Oral Placebo Capsule
10144678|NCT04154501|Experimental|Cohort 2 Drug|50 mg Oral Capsule
10144679|NCT04154501|Placebo Comparator|Cohort 3 Placebo|Oral Placebo Capsule
10144680|NCT04154501|Experimental|Cohort 3 Drug|100 mg Oral Capsule
10144681|NCT04154501|Placebo Comparator|Cohort 4 Placebo|Oral Placebo Capsule
10144682|NCT04154501|Experimental|Cohort 4 Drug|300 mg Oral Capsule
9669359|NCT02780648|Experimental|Stereotactic Body Radiation|Patients will receive 5 fractions of 5 Gy or 6.6 Gy (dose depending upon whether or not they have received prior radiation therapy to the pancreatic region) delivered over a five-day period.
10144683|NCT04154501|Placebo Comparator|Cohort 5 Placebo|Oral Placebo Capsule
10144684|NCT04154501|Experimental|Cohort 5 Drug|450 mg Oral Capsule
10144685|NCT04154501|Placebo Comparator|Cohort 6 Placebo|Oral Placebo Capsule
9519736|NCT03284138|Active Comparator|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
9826126|NCT02408965|Experimental|methergine|Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
10144686|NCT04154501|Experimental|Cohort 6 Drug|600 mg Oral Capsule
10144687|NCT04154501|Placebo Comparator|Cohort 7 Placebo|Oral Placebo Capsule
10144688|NCT04154501|Experimental|Cohort 7 Drug|800 mg Oral Capsule
9826127|NCT02408965|Placebo Comparator|saline placebo|Placebo group saline single injection when manual cervical dilation begins the day before the procedure
10144689|NCT04154501|Placebo Comparator|Cohort 9 Placebo|Oral Placebo Capsule
10144690|NCT04154501|Experimental|Cohort 9 Drug|1000 mg Oral Capsule
10144691|NCT04154501|Experimental|Cohort 8 Fasted|Participant will take 300 mg Oral Capsule in a fasting state, and then fed state.
10144692|NCT04154501|Experimental|Cohort 8 Fed|Participant will take 300 mg Oral Capsule in a fed state, and then fasting state.
10144693|NCT04154254|Experimental|Dementia Patients|
10144694|NCT04154579|Experimental|HeRe We Arts|This is an 8 week, arts-based session that includes educational & experiential components. Topics include: Introduction to Arts & Health; Music, Well-Being, & Resilience; Movement & Physical Activity; Art & Well-Being; Writing & Communication/Self-Expression; Theater & Socialization; Art Appreciation & a Healthy Brain; & Summary/Integration of the Arts into Daily Lives.
10144695|NCT04154579|Active Comparator|HeRe We Ed (Health Education Group)|This is an 8 week, non-arts-based health education session that includes educational & some experiential components. Topics include: Introduction to Health, Resilience, & Well-Being; Nutrition & Healthy Eating; Exercise, Chair Yoga, & Sleep; Mental Health, Stress Management, & Life Satisfaction; Holistic Approaches: Wellness, Integrative Medicine, & Complementary & Alternative Medicine; Chronic Illnesses & Chronic Pain; Health & Behaviors; Summary & Navigating the Healthcare System.
10144696|NCT04154228|Experimental|Lymphoma Patients|
10144697|NCT04154176||POD CAM Nu-DESC|Patients undergoing surgery under general anesthesia assessed for POD with CAM and Nu-DESC
10144698|NCT04154514|Experimental|Delivering FES to stroke survivors|"In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. We are going to employ the wearable to deliver personalized muscle-synergy-based FES stimulations to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors as they walk on a treadmill for gait rehabilitation. We hypothesized that the subject will essentially be walking with his/her abnormal muscle pattern superimposed with the artificially introduced normal muscle pattern coming from FES."
9519737|NCT03284138|Sham Comparator|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
9519738|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
9519739|NCT03284112|Placebo Comparator|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
9519740|NCT03284112|Experimental|Intervention|School population with the Old SCHOOL Hip-Hop program.
9519741|NCT03284099|Experimental|intervention|ACEIs or ARBs will be switch to be taken before bedtime
10144699|NCT04154137||Patients undergoing digestive endoscopy|"All the patients, age ranged from 18 to 90 years, referred to Digestive Endoscopy Outpatients Clinic of the Department of Gastroenterology of the University Hospital Paolo Giaccone of Palermo, Italy"
10144700|NCT04154436|Experimental|Sodium Bicarbonate (NaHCO3) Plus Solution|15 cc of Sodium Bicarbonate (NaHCO3) plus Solution will be sprayed on left or right side of the patient's face based on randomisation
10144701|NCT04154436|Placebo Comparator|Water (H2O)|15 cc of Water (H2O) will be sprayed on the left or right side of the patient's face based on randomisation
10144702|NCT04154670|Experimental|Normal kidney function|MGTA-145 single dose
10144703|NCT04154670|Experimental|Mild decrease in GFR|MGTA-145 single dose
10144704|NCT04154670|Experimental|Moderate decrease in GFR|MGTA-145 single dose
9519742|NCT03284099|Active Comparator|control|ACEIs or ARBs will be taken in the morning as usual
9970597|NCT01302171|Experimental|Peripheral|Half the patients will be randomised to the non-interventional part of the trial. In this subgroup of patients will be randomised 1:1 to 5 day course of subcutaneous placebo injections or a 5 day course of G-CSF(Granocyte™) subcutaneous injections
10144705|NCT04154202|Experimental|Bone inaction patients|Three months or more post joint replacement, or post tibial ORIF, or last surgical intervention adult patients suspected of bone infection and or mechanical loosening.
10144706|NCT04154475|Experimental|yogurt diet|yogurt-diet (-500 kcal/day, 500 g yogurt, high calcium)
10144707|NCT04154475|Active Comparator|dairy diet|dairy diet: -500 kcal/day, high calcium, 500 g non-yogurt dairy products
10144708|NCT04154475|Active Comparator|standard diet|standard diet: -500 kcal/day, low calcium, 500 g soya-yogurt
10144709|NCT04154267|Experimental|Intervention|In addition to the routine evaluation commonly carried-out at this post-transplant period, protocol biopsies will be performed at the 10th-week post-transplantation in high-risk transplant recipients. Biopsy fragments will be evaluated for tissue immune aggression (mainly cellular and antibody-mediated rejections) and other conditions such as infections, particularly polyomavirus and cytomegalovirus and medication toxicities.
10144710|NCT04154267|No Intervention|Control|Patients will only undergo routine noninvasive evaluation at this post-transplant period
10144711|NCT04154319|Active Comparator|HPV Vaccination|Mothers participated in educational/behavior change sessions to promote HPV vaccination among their 9-12 year old daughters
10144712|NCT04154319|Active Comparator|Healthy Eating|Mothers and daughters participated in educational/behavior change sessions to promote healthy eating and appropriate nutrition label interpretation
10144713|NCT04154345|Experimental|Painful exercises|The pain allowed during exercises ranges between 4 and 7 on NPRS (Numeric Pain Rating Scale)
10144714|NCT04154358|Experimental|HPV Testing|Will perform HPV testing with self-collected specimen
10184970|NCT03750422|Active Comparator|Stratacel|medical grade silicone gel following Picoway Laser treatment
10184971|NCT03750422|Sham Comparator|Vehicle|Clear ultrasound gel following Picoway Laser treatment
10184972|NCT03750409|Active Comparator|Helmet Active Device|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
10184973|NCT03750409|Sham Comparator|Helmet Sham|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
10184974|NCT03750396|Experimental|Endocrine and local treatments|"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.~Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.~Local treatments for metastatic lesions will be added in this group.~Local treatments include modalities described below:~i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation"
10184975|NCT03750383|Experimental|EDP-938 and cyclosporine interaction (Part 1)|
10184976|NCT03750383|Experimental|EDP-938 and prednisone interaction (Part 2)|
10184977|NCT03750357|Experimental|Primary Relief v 2.0 with Paracetamol|Group A will be treated with Primary Relief v 2.0(1 - 100Hz) sweep stimulation with increase in power of the stimulation for fixed interval of time.
10184978|NCT03750357|No Intervention|Only Paracetamol|Group B will be treated with paracetamol drug.
10184979|NCT03750344|Experimental|ChroniSense Polso Respiratory Rate|
10184980|NCT03750305|Active Comparator|psychoeducation/TAU|TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,
10184981|NCT03750305|Experimental|imCT intervention|For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).
10184982|NCT03750266||Congenital Diaphragmatic Hernia referred for fetal MRA|
10184983|NCT03750253|Other|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy to relieve pain after arthroscopy for osteochondral lesions of talus
10184984|NCT03750240|Experimental|12 Triple Negative Breast Cancer Patients|scanned 4 times to assess breast cancer response to NACT with the proposed method.
10184985|NCT03750214|Experimental|Biop Coplposcopy System|Biop Colposcopy system procedure
10184986|NCT03750201|Experimental|Direct Selective Trabeculoplasty|Treatment by the investigational device.
10184987|NCT03750201|Active Comparator|Selective Trabeculoplasty|Treatment by the comparator device.
10184988|NCT03750162|Experimental|Passive Ultrasonic irrigation|Irrigation solution was ultrasonically activated in the canal for 1 minute by using IrriSafe tip coupled to an ultrasonic device with VDW Ultra .
10184989|NCT03750162|Experimental|Manuel dynamic activation|Irrigation solution was activated with a well-fitting a ProtaperNext X3 gutta-percha point placed to working length was then moved in push - pull motions at a rate of 100 strokes/per minute
10184990|NCT03750162|Experimental|Photodynamic Therapy|Root canal was filled by 0.5 mL of 0.01% methylene blue (MB) solution for 5 minutes, then radiated by the light supply of a diode laser AMD picasso with a wavelength of 810 nm for 40 seconds (0.2 W).
10184991|NCT03750149|Experimental|Ophthalmologic Disease|Patients with glaucoma, AMD, diabetic maculopathy, epiretinal membranes, and healthy patients will undergo a reading analysis using the EyeTracker
9519743|NCT03284086|Other|paraplegic|Well-trained participants with a spinal cord injury (<Th1) were included in this group.
9519744|NCT03284086|Other|able bodied|Upper-body trained, able-bodied participants were included in this group.
10144715|NCT04154306|Placebo Comparator|Placebo|
10144716|NCT04154306|Experimental|Red clover|
10144717|NCT04154241|Experimental|neuroendocrine tumor Patients|A cohort of patients that were diagnosed with NET using biopsy.
10144718|NCT04154397|No Intervention|error-enhancing feedback|The project of the first arm was to investigate how visualized error size affects postural training effect of the elderly, with a particular focus on error amplification strategy to optimize training benefits for postural training that favors the use of feedback mechanism on postural control and error correction. All participants were randomly assigned into the control and error amplification groups. The control group was trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. For the error amplification group, they were trained with the same postural paradigm, except that the visual guidance was virtually manipulated so that the participants visually perceived twice of the execution errors during stabilometer stance. We contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
10144719|NCT04154397|Experimental|positive cerebellar transcranial stimulation|The project of the second arm was to investigate the training benefits of using combined cerebellar transcranial direct current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance.They were randomly assigned into the control (traditional error amplification)and cerebellar transcranial direct current stimulation groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
10144720|NCT04154397|Experimental|sham cerebellar transcranial stimulation|The project of the third arm was to investigate the training benefits of using combined cerebellar transcranial random current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance. All participants were randomly assigned into the control (sham stimulation) and cerebellar transcranial random current stimulation and visual error amplification (ES) groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
10144721|NCT04154280|Experimental|prostate cancer Patients|patients over the age of 18 with diagnosed prostate cancer at different stages of the disease.
10144722|NCT04154293|Placebo Comparator|Vehicle Ointment (Control)|Topical, BID (Twice daily)
10144723|NCT04154293|Experimental|TMB-001 Ointment, 0.05%|Topical, BID ( twice daily)
10144724|NCT04154293|Experimental|TMB-001 Ointment, 0.1%|Topical, BID (Twice daily)
10144725|NCT04154085|Experimental|Study Group|This study only has one arm; all patients receive the treatment intervention.
10144726|NCT04154098|Experimental|NO-OA-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
9977069|NCT01357863||Patients on third or more lines treatment|Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
10144727|NCT04154098|Experimental|NO-MA-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
10144728|NCT04154098|Experimental|OA-NO-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
10144729|NCT04154098|Experimental|OA-MA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
10144730|NCT04154098|Experimental|MA-NO-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
10144731|NCT04154098|Experimental|MA-OA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
10144732|NCT04154124|Experimental|Rectal Cancer Patients|
10144733|NCT04153968|Experimental|Phase 1|Determination absorption and bioconversion kinetics of [13C14]β-cryptoxanthin and provide external validation for single-sample prediction methods.
10144734|NCT04153968|Experimental|Phase 2|Test the bioefficacy of provitamin A carotenoids (pVACs) in maize by comparing a high β-cryptoxanthin:β-carotene (βCX:βC) variety to a low βCX:βC variety in combination with external [13C]-labelled pVACs.
10144735|NCT04153955|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after undergoing thrombectomy per usual care
10144736|NCT04153955|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after undergoing thrombectomy per usual care
10144737|NCT04154007||Adult Patients who met the diagnosis of ARDS|ARDS patients were followed for the development of AKI during their ICU stay
10144738|NCT04153994|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique.
10144739|NCT04153994|No Intervention|Erector Spinae Plane Blockade Control - Standard of Care|Patients will receive the standard of care for pediatric scoliosis surgery including multi-modal opioid pain management. If the patient declines to consent to enrollment into the randomized study, patients may still participate by allowing prospective data and samples collection/analysis with respect to perioperative choice.
10144740|NCT04153773||Group 1|60 Patient
10144741|NCT04153773||Group 2|30 Control subject
10184992|NCT03750136|Experimental|high-dose furosemide & hypertonic saline|furosemide i.v., 3% NaCl
10184993|NCT03750136|Active Comparator|high-dose furosemide|furosemide i.v.
10144742|NCT04153747|Active Comparator|Conventional ablation|"Point-by-point catheter-based pulmonary veins isolation using convencional radiofrequency parameters.~Anterior aspect of pulmonary veins: 40 W, temperature limit 45 ºC, irrigation 17-30 ml/min; objective LSI>=6 or Ablation index >=500.~Posterior aspect of pulmonary veins: 20-40 W, temperature limit 45 ºC, irrigation 17-3 ml/min; objective LSI>=5 or Ablation index >=350."
10144743|NCT04153747|Experimental|High-power and short-duration ablation|Point-by-point catheter-based pulmonary veins isolation using high-power and short duration radiofrequency: 70 W, duration per application 9-10 s (initial ramp 2-3 s according to the technical characterictics of radiofrequency sources), temperature limit 45 ºC, irrigation 17 ml/min, contac-force > 5 g.
10144744|NCT04153721|Experimental|Digital Solution|The proposed digital solution aims to improve the patient's preparation for his colorectal surgery and follow his rehabilitation after surgery, by reinforcing his compliance with existing protocols and enriching it with complementary practices
10144745|NCT04153916|Other|Single use and continuous use|"Patients with a continuous unilateral facial paralysis that underwent an operation for facial reanimation will be enrolled at least one year after the operation according to review of medical records of the Department of plastic surgery.~Patients with temporary unilateral facial paralysis secondary to Bell's palsy as was identified in the admission to the Hospital Department of Plastic Surgery or to the Department of Ear, Nose and Throat."
9970598|NCT01302171|Experimental|Interventional arm|In the subgroup of the interventional arm patients will be randomised 1:1 to receive a 5 day course of subcutaneous G-CSF (Granocyte™) injections and bone marrow aspiration at day 5, they will then receive either stem cells or placebo via intracoronary injection
9970599|NCT01302184|Experimental|Experimental Group|Lokomat®
9970600|NCT01302184|Active Comparator|Control Group|Treadmill training
9970601|NCT01302210||Intervention|Active surveillance testing for MRSA and decolonization of positive subjects
10144746|NCT04153942|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after receiving IV thrombolysis therapy per usual care
10144747|NCT04153942|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after receiving IV thrombolysis therapy per usual care
10144748|NCT04153890|Experimental|FamPALcare|Standard Care plus FamPALcare
10144749|NCT04153890|No Intervention|Standard Care|The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines.
10144750|NCT04154059|Experimental|Intervention Group|Patients will receive a physical therapy intervention three times per week, for 8 weeks.
10144751|NCT04154059|No Intervention|Control Group|Patients will not receive any exercise treatment but they will keep their recommended clinical treatment.
10144752|NCT04153981|Experimental|Insulin Glargine|Insulin glargine administered subcutaneously (SC).
10144753|NCT04153903||Patients with intermediate lesions|Imaging cohort will be performed invasive angiography and optical coherence tomography (or Coronary CT angiography) with FFR(Fractional Flow Reserve) values of the intermediate lesions (50-70% stenosis)
10144754|NCT04154033|No Intervention|Arm A: Circadian Rhythm of Itch|For the study arm A, to evaluate circadian rhythm of itching, patients will record for 7 days 6 times daily in a booklet the itch intensity on a visual analog scale (VAS) scale. These time points for itch intensity recording will be hours after time of awakening (AW), so they will be AW+2h, AW+4h, AW+6h, AW+8h, AW+10h, AW+12h. Patients are to document all their pruritus attacks at these time points. On day 8 the investigators will collect suction blisters (4-5 10mm blisters) at these 6 time points from unaffected skin on the trunk. For this purpose, the investigators will use the commercially available 47mm orifice plate (Electronic Diversities, Finksburg MD, USA) with 4-5 x10mm openings for each time point and use the 4-5 1mm blister roofs for harvesting.
10144755|NCT04154033|Experimental|Arm B: Topical Naltrexone Cream|Patients will start with placebo in week 2 and move on to naltrexone treatment in week 3. There will be a wash-in phase during week 1. Following week 2 and week 3, at visits 3 and 4, patients will be asked for the area where they are experiencing most intense itch and the investigators will take suction blisters from that area before any treatment. They will be told to bring the medication they have been using and they will apply this topically. After an hour, another suction blister will be taken from the same area. This will ensure the study is still blinded as neither the physician or the participant will know whether the medication was a placebo or not. Participants may apply their topical treatment as often as he wishes.
10144756|NCT04154033|Placebo Comparator|Arm C: Placebo Cream|Patients will start with naltrexone treatment in week 2 and move on to placebo treatment in week 3. Other than this, all procedures will be the same as in study arm B.
10144757|NCT04153825|Active Comparator|Active TENS Group|Ten sessions of active conventional TENS and hydrocollator hot-pack.
10144758|NCT04153825|Active Comparator|Active IFC Group|Ten sessions of active interferential current and hydrocollator hot-pack.
10144759|NCT04153825|Sham Comparator|Sham TENS Group|Ten sessions of sham TENS and hydrocollator hot-pack.
10144760|NCT04153825|Sham Comparator|Sham IFC Group|Ten sessions of sham IFC and hydrocollator hot-pack.
10144761|NCT04153669|No Intervention|Control|This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
10144762|NCT04153669|Experimental|Exercise-No NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions."
10144763|NCT04153669|Experimental|Exercise-NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions. Additionally, this group will receive neuromuscular electrical stimulation (NMES) concomitant to the strength training."
10144764|NCT04153695|Experimental|Experimental|To listen flamenco music during 30 minuts per day, during 2 weks
10144765|NCT04153695|No Intervention|Control|No intervention
10144766|NCT04153682|Active Comparator|Antimicrobial stewardship (= AMS)|Management of HAP according to current practice, including intervention of the AMS team.
9970602|NCT01302210||control|Usual standard of care
10144767|NCT04153682|Experimental|Antimicrobial Stewardship + Rapid Diagnostic Testing|Management of HAP including rapid diagnostic testing (FA-PP) and intervention of the AMS team.
10144768|NCT04153656|Other|Nurses|Subjects will be asked to commit to reading and studying Spiritual Flow.
10144769|NCT04153786|Experimental|Cohort|Pacemakers will be programmed to BiV pacing, left ventricular (LV) pacing, right ventricular (RV) pacing and no pacing for five minutes each. LVAD flow will be recorded every thirty seconds for five minutes with each setting. Once the interventions have been completed, all pacemakers will be returned to their original setting.
10144770|NCT04153851|Other|neurectomy of nasopalatine nerve|"Prophylactic preoperative antibiotic will be administered prior to surgery.~Oral disinfection will be performed before surgery.~Labial infiltration anesthesia and nasopalatine nerve block anasthesia.~The nasopalatine foramen will be exposed after reflection of a palatal and buccal flap.~Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal.~Dental implant will be inserted in the central incisor location."
10144771|NCT04153708|Experimental|Retrieval by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
10144772|NCT04153708|Active Comparator|Retrieval by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
10144773|NCT04153838||Children|A group of 'typically' developing children (aged between 6 years and 16 years 11 months) from the general paediatric population will be recruited; with the sample distributed evenly across 6 age bands (i.e. ages 6-7 years, 8-9 years, 10-11 years, 12-13 years, 14-15 years, and 16 years+).
10144774|NCT04153864|Experimental|Non-specialist|Trained nurses or midwives with general health care professional skills (as assessed during recruitment) with no previous experience delivering psychological treatments implementing a brief, manualized behavioral activation treatment
10144775|NCT04153864|Active Comparator|Specialist|Psychiatrists, psychologists and social workers with experience in treating perinatal mental illness and a minimum of 5 years of experience delivering psychological treatments delivering a brief, manualized behavioral activation treatment
10144776|NCT04153864|Experimental|Telemedicine|A brief, manualized behavioral activation treatment delivered over Zoom in Toronto, via the UNC TelePsychiatry Program in Chapel Hill, and via Zoom in Chicago
10144777|NCT04153864|Active Comparator|In-Person|A brief, manualized behavioral activation treatment delivered in-person held at participating clinical care sites within UToronto, UNC and NorthShore Chicago
10144778|NCT04153513|Experimental|Lanolin|
10144779|NCT04153513|Active Comparator|Mother's milk|
10144780|NCT04153630|Experimental|Haploidentical MSCs derived from bone marrow|Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
10144781|NCT04153487|Experimental|ASTRALI Group|ASTRALI (AScorbic acid in TRALI) group (n=40)
10144782|NCT04153487|Placebo Comparator|Control Group|Control group (n=40)
10144783|NCT04153617|Placebo Comparator|Control honey|"Orange blossom honey.~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.~Short term trial: 20g/day in a single day."
10144784|NCT04153617|Experimental|Modified honey with soluble fiber and polyphenols|"Honey modified with soluble fiber and polyphenols~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.~Short term trial: 20g/day in a single day."
10144785|NCT04153526||Surgical Cohort|Surgical Cohort: Patients offered surgery, with or without adjuvant chemotherapy.
10144786|NCT04153526||Non Surgical Cohort|Non-Surgical Cohort: Stage I/II/IIIB patients undergoing radical radiotherapy (with or without chemotherapy) or stereotactic ablative radiotherapy (SABR).
10144787|NCT04153734|Experimental|Immunotherapy plus chemotherapy|Combination of CDDP at 75 mg/m2 (day 1) or CBDCA at Area Under the Curve=6 (AUC=6) (day 1) + PEM at 500 mg/m2 (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, CBDCA at AUC=6 (day 1) + nab-PTX at 100 mg/m2 (days 1, 8, and 15) will be administered at 3-week intervals. If there is no progression after the 4th course of induction therapy, it will be switched to maintenance therapy. For maintenance therapy, the combination of PEM at 500 mg/m2 (day 1) + Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
10144788|NCT04153799|Experimental|EGFR CAR-T|Group: 3 dose levels
10144789|NCT04153357|Active Comparator|intubation time airtraq|intubation time of Airtraq
10144790|NCT04153357|Active Comparator|intubation time glidescope|intubation time of glidescope
10144791|NCT04153357|Active Comparator|intubation time of c-mac|intubation time of c-mac
10144792|NCT04153461|Active Comparator|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
9519745|NCT03284073|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from a live donor
9970603|NCT01302223||Minor Burns|Total burn surface area less than 5% of second and third degree.
10144793|NCT04153461|Active Comparator|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
10144794|NCT04153370|Active Comparator|intubation time airtraq|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
10144795|NCT04153370|Active Comparator|intubation time glidescope|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
10144796|NCT04153370|Active Comparator|intubation time c-mac|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
10184994|NCT03750123||Kawasaki Disease (KD)|Children 5 years after Kawasaki Disease
9519746|NCT03284060|Experimental|Cognitive remediation program|
9977070|NCT01357876|Other|Type two diabetics|Type two diabetics
10184995|NCT03750123||Healthy controls (HC)|Age- and sexmatched healthy siblings of children after Kawasaki Disease
10144797|NCT04153201|Experimental|Hydroxychloroquine|Patients with primary antiphospholipid syndrome started on hydroxychloroquine while continuing standard care (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents, depending on primary APS subgroup)
10144798|NCT04153201|No Intervention|Standard care|Patients with primary antiphospholipid syndrome continuing standard care only (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents
10144799|NCT04153175|Active Comparator|CT-010 Active Therapy|Subjects in the active comparator arm will have been randomized to receive active therapy through the implanted drug delivery system through the 3-month blinded period.
10144800|NCT04153175|Placebo Comparator|Placebo|Subjects in the placebo comparator arm will have been randomized to receive placebo therapy through the implanted drug delivery system for the 3-month blinded period.
10144801|NCT04153383||TMAD|Tissue motion annular displacement (TMAD) transesophageal echocardiography
10144802|NCT04153162|Experimental|Stereotactic body radiation therapy|In patients with HCM and refractory symptoms from LVOTO, stereotactic body radiation therapy will be delivered locally to relieve symptoms
10144803|NCT04153253|Active Comparator|Group I|Intravitreal injection of Aflibercept followed by panretinal photocoagulation.
10144804|NCT04153253|Active Comparator|Group II: Early vitrectomy.|Early vitrectomy.
10144805|NCT04153123|Experimental|Lidocaine with epinephrine|Peribulbar anesthesia with lidocaine and epinephrine
10144806|NCT04153123|No Intervention|Lidocaine without epinephrine|Peribulbar anesthesia with lidocaine
10144807|NCT04153344||Infrared hyperreflective area|Patients with neurofibromatosis type 1 and with infrared hyperreflective areas
10144808|NCT04153344||No infrared hyperreflective areas|Patients with neurofibromatosis type 1 and with no infrared hyperreflective areas
10144809|NCT04153344||Controls|Patients with no neurofibromatosis type 1
10144810|NCT04153266||Patients with oral epithelial dysplasia|"INCLUSION CRITERIA~These include:~Adults aged 18 or above at the time of the screening visit.~Good command of English language both written and spoken [this is necessary as questionnaires are in English and cannot be translated unless through a cross-cultural validation study].~Being able to consent.~Diagnosed with OED as per current standard diagnostic criteria.~No concurrent malignancy in the head and neck or elsewhere."
10144811|NCT04153500|No Intervention|Traditional Methodology|A professor/lecturer of anatomy will carry out the session in the control group. The traditional (40 minutes total) will consist of 30 minutes of lecture (75% out of the total time), where female pelvic floor will be presented throughout theory and images. In the 2nd part, during 10 min (25%), participants will review anatomical drawings /atlases.
10144812|NCT04153500|Experimental|Pelvic+ method|The second researcher will carry out the session in the intervention group. The interventional session (40 minutes total) will consist of two parts: The 1st one is a lecture of 10 minutes (25% out of the total time) on female pelvic floor anatomy. In the 2nd part, during 30 min (75%), participants, in small groups of 4 people, will assemble the female pelvic floor interactive model, following the indications suggested by the second researcher. Pelvic+ is supported by an assembling manual that participants will be allowed to use.
10144813|NCT04153448||Bronchiectasis|Children with bronchiectasis
10144814|NCT04153448||Healthy Controls|Age-matched healthy volunteers
10144815|NCT04153331|Experimental|Patients admitted to emergency department with medical cause|Patient included in emergency with a nasal swab
10144816|NCT04153214|Experimental|Cycling workstation|Participants will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 6 months
10144817|NCT04153214|Placebo Comparator|control|Daily activities unchanged during 3 months. Then they will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 3 months.
10144818|NCT04153474|Active Comparator|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
10144819|NCT04153474|Active Comparator|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
10144820|NCT04153240|Experimental|Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'THERAPY' mode (ie. vibration feedback will be given in response to supine position)
10144821|NCT04153240|Sham Comparator|Sham Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'MONITOR' mode (ie. no vibration feedback will be given)
10144822|NCT04153110|Experimental|Real tDCS - Real tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
10144823|NCT04153110|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks).
10144824|NCT04153097||pembrolizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with pembrolizumab
10144825|NCT04153084||High volume electrolytes Polyethylene Glycol (PEG 4000) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using high volume electrolytes PEG (Bohm solution®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
10144826|NCT04153084||Low volume electrolytes PEG (PEG 3350) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using low volume electrolytes PEG (Movicol®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
10144827|NCT04153084||Sodium picosulfate cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using sodium picosulfate (Picoprep®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
10144828|NCT04153071|Experimental|Unipolar microplasma RF treatment|Single cutaneous unipolar microplasma RF treatment, with variable treatment parameters
10144829|NCT04153045|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
10144830|NCT04153045|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
10184996|NCT03750110|Active Comparator|Usual Care|Smoking Cessation NICE PH48 Guidelines
10144831|NCT04153058|Experimental|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
10144832|NCT04153058|Active Comparator|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
10144833|NCT04152655|Active Comparator|Group 1: idebenone|Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
10144834|NCT04152655|Placebo Comparator|Group 2: placebo|Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
10144835|NCT04152694|Other|Ceftaroline in CRRT|Ceftaroline levels measured in patients receiving continuous renal replacement therapy
10144836|NCT04152876||Cases|Patients with rare disease
10144837|NCT04152876||controls|Healthy parents and relatives
10144838|NCT04152668|Active Comparator|Titanium curette and ultrasonic.|Control implants will be debrided with titanium curette and ultrasonic device without time limit.
10144839|NCT04152668|Experimental|Titanium curette, ultrasonic and air-polishing.|Test implants will be treated with titanium curette, ultrasonic device and a specially designed nozzle mounted on a hand piece (Perio-Flow) connected to an airflow unit also without time limit.
10144840|NCT04152720|Active Comparator|Prevention of infection Foley catheter|
10144841|NCT04152720|Active Comparator|Conventional Foley catheter|
10144842|NCT04152902||PULL-DOWN HELLER-DOR|The PD-HD procedure aimed to restore the vertical axis of the intraabdominal portion of the oesophagus as much as possible. In brief, before performing the myotomy and the anterior fundoplication according to Dor, at least 6 cm of the mediastinal oesophagus was fully isolated; two or more U intramuscular stitches were applied on the curling of the right side of the oesophagus, pulled down and rotated towards the right side of the gastro-oesophageal junction. The PD-HD operation was performed under manometric control
10144843|NCT04152902||OESOPHAGECTOMY|OE was performed with open technique, or recently, with a minimally invasive technique. The stomach was always the oesophageal substitute, and the oesophagogastric anastomosis was preferably located at the thoracic dome or at the neck to minimize the risk of postoperative reflux oesophagitis or cancer growth in the residual dilated oesophagus
10144844|NCT04152681|Experimental|Assigned Interventions|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
10144845|NCT04152759|Experimental|BAT2506 injection|50mg ；subcutaneous injection
10144846|NCT04152759|Active Comparator|Sinponi(EU-licensed)|50mg ；subcutaneous injection
10144847|NCT04152928|Experimental|Neuroendocrine Tumors Patients|Patients with confirmed NET
10144848|NCT04152746||Adenoid group|Periostin levels in the adenoid group
10144849|NCT04152746||Control Group|Periostin levels in the control group
9970604|NCT01302223||Major Burns.|Total Burn Surface Area more than 25% of second and third degree, and less than 50%.
10144850|NCT04152811|Active Comparator|Waitlist 1|usual diabetes care
10144851|NCT04152811|Experimental|Intervention 1|6-weeks of cooking matters for diabetes classes
10144852|NCT04152811|Active Comparator|Waitlist 2|usual diabetes care
10144853|NCT04152811|Experimental|Intervention 2|6-weeks of cooking matters for diabetes classes
10144854|NCT04153032|Experimental|DTZ arm|The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.
10144855|NCT04153032|Experimental|MEBO arm|The second group of patients will apply topical DTZ ointment peri-anally 3 times daily for 6 weeks.
10144856|NCT04153032|Experimental|MEBO and DTZ arm|The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
10144857|NCT04152889|Experimental|Camrelizumab+chemotherapy|
10144858|NCT04153019|Other|Cancer cachexia|Psycho-educational session: 3 weekly face-to-face consultations between a dyads (patients-caregivers) and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
10144859|NCT04153006||Chest pain patients|"Patients who are admitted to the cardiac ED because of chest pain for ruling out acute coronary syndrome by troponin analysis are eligible for participation.~Troponin analysis will be performed according to standard protocol (0-1h protocol). From every included patient capillary blood samples and an extra venous blood sample will be drawn to evaluate HS cTnI levels obtained with the POC instrument and central laboratory (CL)."
10144860|NCT04152850|Experimental|Lifestyle Medicine Group|
10144861|NCT04152850|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
10144862|NCT04152733|No Intervention|Control group|Children in the control group receive oxygen via conventional nasal cannula during deep sedation. Oxygen flow is determined to set the fraction of inspired oxygen of 50%.
10144863|NCT04152733|Experimental|High flow (HF) group|Children in the HF group receive oxygen via high flow nasal cannula during deep sedation. Fraction of inspired oxygen is set to 50%.
10144864|NCT04152993|Experimental|RNS group|This study consists in only one arm. In this arm, the patients will undergo the placement of the RNS implant and the subsequent RNS programming to optimize the PTSD symptoms.
10144865|NCT04152772|Active Comparator|Active during extinction learning / Sham during consolidation|Active tDCS stimulation will be applied during the extinction learning phase. Sham tDCS stimulation will be applied during the consolidation phase.
9519747|NCT03284008|Experimental|Manual manoeuver + stretching|Patients will receive a manual manoeuver treatment and education to perform stretching exercises at home.
9970605|NCT01302236|Experimental|Eplerenone|
10144866|NCT04152772|Active Comparator|Sham during extinction learning / Active during consolidation|Sham tDCS stimulation will be applied during the extinction learning phase. Active tDCS stimulation will be applied during the consolidation phase
10144867|NCT04152772|Sham Comparator|Sham during extinction learning / Sham during consolidation|Sham tDCS stimulation will be applied during both the extinction learning phase and the consolidation phase.
10144868|NCT04152837|Experimental|Lixivaptan|Lixivaptan oral capsules, 100-200 mg twice daily
10144869|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 3 hours.|This is a dose optimization study, different dosages will be tested, the lowest dosage that will be tested is 2,5 mg/kg/h for 3 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
10144870|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 6 hours|The second lowest dosage that will be tested is 2,5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
10144871|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 6 hours.|The third lowest dosage, is the start dosage and the dosage that is already used in other clinical studies: 5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
10144872|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 12 hours.|The fourth dosage that is tested is 5 mg/kg/h for 12 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease..
10144873|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 18 hours.|The fifth dosage that is tested is 5 mg/kg/h for 18 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
10144874|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 24 hours.|The sixth dosage that is tested is 5 mg/kg/h for 24 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
10144875|NCT04152577|Experimental|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
10144876|NCT04152577|Active Comparator|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
10144877|NCT04152564|Active Comparator|levo-bupivacaine continuous epidural infusion [CEI])|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered.
9970606|NCT01302262||Healthy smokers|Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.
10144878|NCT04152564|Active Comparator|Levo-bupivacaine continuous preperitoneal infusion [CPI]),|At the end of surgery and after the closure of the peritoneal layer, the preperitoneal catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing. Thereafter, a 20 ml bolus of L-bupivacaine 0.25% will be administered through the catheter and then a continuous fixed-rate infusion of L-bupivacaine 0.25% will be delivered.
10144879|NCT04152447|No Intervention|Standard of care|This arm describes the standard protocol used to aid in orthopedic recovery.
10144880|NCT04152447|Active Comparator|VR device|Patients randomly assigned to the experimental arm of the study were provided an Oculus Go™ device for the duration of their hospitalization. The device featured a headset with a 1280 x 1440, 60 Hz refresh rate LCD display, spatial audio (via built-in speakers; headphones were not provided or used to our knowledge, despite compatibility) and the ability to track 3 degrees of rotational freedom; it was compatible with glasses and included a soft, adjustable strap for optimal, user-based fit. A single controller, capable of recognizing hand motion, pointing, and clicking was also included.
10144881|NCT04152434||Reduction in monthly migraine days all cohorts at 4 months|Migraineurs with 15-30 headache days per month at baseline were clustered in 3 categories. Failure of Erenumab was defined as no improvement in the frequency of monthly headache days. Group I: no preventive therapy, prior to the start of Erenumab. (No botox cohort). Group II: on Botulinum Toxin A (Botox), prior to the add on therapy with Erenumab. (Botox cohort).Group III: on an oral preventive drug, prior to the add on therapy with Erenumab. (No Botox cohort)
10144882|NCT04152434||Selection of elegible paitients|A total of 158 patients were involved in this study. 118 patients (75%), received Erenumab 140 mg., and 40 patients (25%) received 70 mg. In the Botox cohort, of 650 patients, 90 (13%) patients were eligible. In the no Botox cohort, 533 patients, 83 (15%) patients were eligible.
10144883|NCT04152434||Rate of adverse events related to Erenumab|72 adverse events were experienced during the 4 months of treatment, mostly with the 140 mg. dose. The most frequent were: constipation 34%, fatigue 19%, itching 7.5%, muscle cramps 6.3%, increased headache 4.4%, rhinitis 4.4%, injection site discomfort 3.7%, lack of energy 3.1%
10144884|NCT04152512||Whole Cohort|Whole cohort administration of questionnaire at 7 times
10144885|NCT04152538||healthy subjects|Healthy subjects matched with TKA patients
10144886|NCT04152538||TKA patients|age greater than 18 years old and a recent TKA.
10144887|NCT04152525|Experimental|experimental group|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
10144888|NCT04152525|No Intervention|control group|Routine care
10144889|NCT04152629|Experimental|FOQUEST adults|adult (≥18 years or older) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg, or 100 mg/day)
10144890|NCT04152629|Active Comparator|VYVANSE adults|adult (≥18 years or older) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
10144891|NCT04152629|Experimental|FOQUEST pediatric|pediatric (6 to 17 years old) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg or 70 mg/day)
10144892|NCT04152629|Active Comparator|VYVANSE pediatric|pediatric (6 to 17 years old) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
10144893|NCT04152291|Experimental|E-EPA-diet group|All the study participants will receive the same treatment. 3.9g of E-EPA in capsules, which include 75µg of D3-vitamin, daily for 30 days.
10144894|NCT04152707|Experimental|Splendor X|
10144895|NCT04152603|No Intervention|Control|Individuals in this arm will go through the partner study's standard recruitment and consent process
10144896|NCT04152603|Experimental|Intervention|Individuals in this arm will be exposed to our intervention during the partner study's recruitment and consent process
10144897|NCT04152369|Active Comparator|24 hour prophylaxis|In this group patients received a AMP for the day of the procedure
10144898|NCT04152369|Active Comparator|72 hour prophylaxis|In this group patients received a AMP one day prior, on the day of the procedure and the following day.
10144899|NCT04152616|Experimental|Optitrack®|Instrumental evaluation of posture
10144900|NCT04152460|Active Comparator|Thermo-Viscous preheated bulk fill resin composite|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
10144901|NCT04152460|Placebo Comparator|Conventional Bulk Fill resin Composite|GrandioSo X-tra (Voco,Cuxhaven
10184997|NCT03750110|Active Comparator|Intervention|Smoking Cessation NICE PH48 Guidelines plus personalised feedback from Lung Scan
10184998|NCT03750097|Experimental|Walking protocol|Walking for 250 steps with comfortable walking velocity (CWV), slow walking velocity (SWV: CWV - 20%) and fast walking velocity (FWV: CWV + 20%) with sufficient rest between conditions.
10184999|NCT03750071|Experimental|VXM01/Avelumab|Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
10185000|NCT03750058|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
10185001|NCT03750045|Experimental|Experimental group|For the tests, the volunteers used the access device (Leap Motion) and a computer that were previously installed. The intervention was composed by 8 sessions of 15 minutes each, where the volunteers used a virtual environment attached it to a Leap Motion, which is a sensor that allows to capture the movements that are produced by the hands and reproduce them in a computer through a 3D virtual environment in order to stimulate the execution of their finer movements. The strength (Jamar) and motor coordination (wooden box) evaluations were made in the first, fourth and eighth sessions with the objective of checking the gain progression or not of motion coordination and grip strength.
10185002|NCT03750032|Experimental|Stapler appendectomy|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using a stapler.
10185003|NCT03750032|Experimental|Endoloop|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using endoloop.
10185004|NCT03750032|Experimental|Hem-O-Lock|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using Hem-O-Lock.
10185005|NCT03750019|Experimental|Satisfying rehearsal|Participants completed the satisfying rehearsal task where they rehearsed the satisfying aspects of the lunchtime meal.
10185006|NCT03750019|Experimental|Dissatisfying rehearsal|Participants completed the dissatisfying rehearsal task where they rehearsed the dissatisfying aspects of the lunchtime meal.
10185007|NCT03750019|Active Comparator|Neutral rehearsal|Participants completed the neutral rehearsal task where they rehearsed their journey to campus that day.
10185008|NCT03749993|Other|Screening Arm|Screening
10185009|NCT03749954||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
10185010|NCT03749915|Active Comparator|Comparator: Ametop only|Ametop Gel applied as sole topical anesthetic.
10185011|NCT03749915|Experimental|Intervention: Pain Ease Cold Spray|Pain Ease Cold spray applied immediately before IV insertion, as an adjunct to Ametop Gel.
10185012|NCT03749902|Other|Oxytocin infusion|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
10185013|NCT03749902|Other|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
10185014|NCT03749889|Experimental|100 g carbs|100 grams of carbohydrate allowance for the day
10185015|NCT03749889|Active Comparator|MyPlate|Carbohydrate suggestions based on standard MyPlate. 45-65% kcal intake from carbs.
10144902|NCT04152798|Active Comparator|ProGrip™ mesh repair|Laparoscopic hiatal hernia repair with ProGrip™ mesh
10144903|NCT04152798|Active Comparator|Primary crural repair|Primary posterior crura repair
10144904|NCT04152421|Experimental|Software user|
10144905|NCT04152330|Other|Comparison between intervention and control group|"Subjects will be randomized to two groups, intervention group (IG) and Control group (CG). Each GI Parents-Baby dyad will receive 4 interventions, which will take place at predetermined dates (at 30 days, 3 months, 6 months, and 9 months) with groups of up to 5 pairs of participants. Parents is understood to be a generalist nomenclature and will be considered as parent, parent or primary caregiver.~CG subjects will receive standard guidelines from the pediatric and pediatric cardiology outpatient clinic."
10144906|NCT04152109|Other|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, an average of 8 weeks.
10144907|NCT04152109|Sham Comparator|Laying on of hands without Spiritual connection subgroup|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, an average of 8 weeks.
10144908|NCT04152109|Experimental|"Laying on of hands by Spiritual connection Passe subgroup"|"The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist pass. Patients remain in the supine bed blindfolded for 5 minutes, an average of 8 weeks."
10144909|NCT04152317|Experimental|Misoprostol 200mcg|In this group, the participants will receive 200mcg of misoprostol, single dose, via the vaginal route.
10144910|NCT04152317|Active Comparator|Misoprostol 800mcg|In this group, the participants will receive 800mcg of misoprostol, single dose, via the vaginal route.
10144911|NCT04152122||Intermittent exotropia group|Intermittent exotropia group
10144912|NCT04152122||Normal group|Normal group
10144913|NCT04152356||PD-1|
10144914|NCT04152356||Sorafenib|
10144915|NCT04152304|Experimental|Feasibility of the SINEX for treatment of shoulder instability|Feasibility of the SINEX program for treatment and evaluation of of traumatic anterior shoulder instability eligible for surgery
10144916|NCT04152226|Active Comparator|Cohort 1|Cohort 1 low dose of J. lividum
10144917|NCT04152226|Active Comparator|Cohort 2|Cohort 2 medium dose of J. lividum
10144918|NCT04152226|Active Comparator|Cohort 3|Cohort 3 - high dose of J. Lividum
10144919|NCT04152148|Experimental|500mg BAT4306F|3 weeks of a cycle
10144920|NCT04152148|Experimental|750mg BAT4306F|3 weeks of a cycle
10144921|NCT04152148|Experimental|900mg BAT4306F|3 weeks of a cycle
10144922|NCT04152148|Experimental|1000mg BAT4306F|3 weeks of a cycle
10144923|NCT04152408|Experimental|FiberSense System|6 diabetic patients will wear a FiberSense system at the upper arm for up to 30 days. and a comparator CGM system at the abdomen (replaced every 7 days).
10144924|NCT04152395||Metabolic group|Patients with metabolic syndrome undergoing EVAR
10144925|NCT04152395||Control group|Patients without metabolic syndrome undergoing EVAR
10144926|NCT04152278||study group|The study group included 300 women presenting with unexplained spontaneous miscarriage or missed abortion during the first and early second trimester of pregnancy (8-16 weeks gestational age). The included women aged 18 to 45 years old.
10144927|NCT04152278||control group|The control group included 300 women with normal pregnancy, recruited from women attending the antenatal clinic of gestational age 8-16 weeks. The included women aged 18 to 45 years old.
10144928|NCT04152265|Other|No Intervention: Current screening practice.|Patients will be asked to complete the Food Frequency Questionnaire (FFQ) and the questionnaire about The World Health Organization Quality Of Life (WHOQOL-BREF), also and will be collected the demographic and anthropometric data
10144929|NCT04152265|Experimental|Experimental: Sequential screening strategy|People aged between 50-65, will take part in the study. Patients, which will take in a screening colonoscopy, will be divided into two groups according to the result obtained. The first group, will be constitute the patients with a positive test result, while the second group (control) will be constitute the patients with the negative test result. In addition, from the Subjects the samples of blood and faeces will be collected.
10144930|NCT04152005||Control|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
10144931|NCT04152005||Periodontitis|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
10144932|NCT04152005||Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
10144933|NCT04152005||Periodontitis+Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
10144934|NCT04152044||Liver biopsy, Visceral and subcutaneous obesity|Those with histology and LFT's and quantificaiton of obesity
10144935|NCT04152161|Experimental|Bacille Calmette Guerin (BCG) group|
10144936|NCT04152161|Placebo Comparator|Placebo group|
10144937|NCT04152096|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
10144938|NCT04152096|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
10144939|NCT04152187|Experimental|Inspiratory muscle training (IMT)|Patients will receive IMT for 30 min (15x2), 7 times per week for 8 weeks using inspiratory muscle trainer device (PowerBreathe). During training, patients will be instructed to maintain diaphragmatic breathing. Inspiratory load will be set at 40-60% of maximum inspiratory pressure. Each week, six training sessions will be held at home and a training session will be supervised with physiotherapist.
9519748|NCT03284008|Active Comparator|stretching exercise|Patients will receive education to perform stretching exercises at home.
10144940|NCT04152187|No Intervention|Control|No additional intervention
9519749|NCT03283995||cardiogenic shock without SCA|
9519750|NCT03283995||cardiogenic shock with SCA|
10144941|NCT04152070||Community-dwelling older adults|Community-dwelling older adults living in the Valencia region (Spain).
10144942|NCT04152057|Experimental|Pyrotinib Combined With Albumin Paclitaxel and Trastuzumab|"Preoperative~-Drug: Pyrotinib Maleate Tablets combined with Albumin Paclitaxel and Trastuzumab.~Surgery:Subjects should be evaluated by tumor-enhanced MRI combined with mammary gland ultrasound during the preoperative neoadjuvant administration, and evaluated every 2 cycles. The subjects who were evaluated for CR and PR for the first time should be confirmed after at least 4 weeks. The confirmed tumor assessment cannot change the previously fixed examination time point.~Postoperative~Drug: Epirubicin hydrochloride combined with Cyclophosphamide~At the same time, according to the recommendation of the clinician, choose whether to accept the same anti-HER2 treatment plan before surgery. For patients with tumors positive for estrogen receptor (ER) and/or progesterone receptor (PR), endocrine therapy should be given at the end of adjuvant chemotherapy, and if there is clinical indication at the end of adjuvant chemotherapy, radiotherapy should be given."
10144943|NCT04151797|Experimental|Medication therapy management|Medication therapy management by pharmacist-led medication review
10144944|NCT04151823|Experimental|Postbiotic &vitamin D3, lifestyle intervention.|Postbiotics will be given at the dose of 80 mg/day (2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN; immunofos from Lactobacillus paracasei CNCM I-5220). 2 mL of product will give 1600 UI/die of VIT D3. Healthy living habits will be encouraged at t0, t1 and t2 visit.
10144945|NCT04151836|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity 30 minutes of exercise in week 1-4,40 minutes of exercise in 5-8 weeks,50 minutes in the 9-12 week,three times weekly in three month.We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 65%-70% of the target Maximal heart rate(HRmax).
10144946|NCT04151836|No Intervention|control group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
10144947|NCT04151849||GLP-1 receptor agonist treatment|Patients starting treatment with any molecule belonging to the class of GLP-1 receptor agonist.
10144948|NCT04151849||SGLT-2 inhibitor treatment|Patients starting treatment with any molecule belonging to the class of SGLT-2 inhibitors.
10144949|NCT04151680|Experimental|Intermittent anticoagulation|Patients will be given anticoagulation if continuous electrocardiographic monitoring will detect an atrial fibrillation episode lasting more than an hour
10144950|NCT04151680|Experimental|Chronic anticoagulation|Patients will be given chronic oral anticoagulation regardless findings at continuous electrocardiographic monitoring
10144951|NCT04151654|Other|assessment1|İt is assessment study. Assessment1 was evaluated for all test with and without footwear.
10144952|NCT04151758|Experimental|Docosahexaenoic Acid Supplementation, lifestyle intervention|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day. Physical activity and healthy eating habits will be encouraged.
10144953|NCT04151862|Active Comparator|tight eye bandage|Both eyes will be operated at two separate sessions. In the first session the first 25 patients will be bandaged postoperatively with tight eye bandage patching.
10144954|NCT04151862|Active Comparator|therapeutic contact lenses (TCL)|Both eyes will be operated at two separate sessions. In the second session the 25 patients will be bandaged postoperatively with therapeutic contact lenses (TCL).
10144955|NCT04151810|Experimental|anti-EGFR monoclonal antibody|"Single-dose Phase:This is a dose-escalation trial, all participants will receive treatment with CDP1. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.~Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;~Multi-dose Phase:Multiple administrations of three Cohorts of subjects were followed by continuous administration of CDP1."
10144956|NCT04151784||Pulmonary Group|Pulmonary Group who have evidence of pulmonary diseases
10144957|NCT04151784||Healthy Control|Health Group who have no evidence of pulmonary diseases
10144958|NCT04151693|Experimental|Research group CFS|"Research treatment for patients with CFS (diagnosed G 93.3). CBT- based group therapy~8 sessions in 4 months. n=35-40 patients~Special focus on autonomic nervous system and how it affects the individual (hyperarousal, cognitive disabilities) Psychoeducation and tasks (for example abdominal respiration and mindfulness) learning new coping skills Stress management in every day life"
10144959|NCT04151693|Experimental|Control group CFS|"Control group~6 sessions in 3 months n=35-40 patients~Health, lifestyle and wellbeing counselling (sleep, nutrition, performance)"
10144960|NCT04151706|Experimental|fTBI/Thiotepa/fludarabine|Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide.
10144961|NCT04151472|Experimental|90mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 30mg table by mouth, three times a day for next 3 months
10144962|NCT04151472|Experimental|270mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 90mg table by mouth, three times a day for next 3 months
10144963|NCT04151472|Placebo Comparator|Placebo|Placebo by mouth, three times a day for 4 months
10144964|NCT04151745|Other|study group|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
10144965|NCT04151602||PWUD with active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with active TB disease
10144966|NCT04151602||PWUD with no active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with no active TB disease
10144967|NCT04151602||non-PWUD with active TB|People who do not use meth/mandrax who have active TB disease
10144968|NCT04151719|Experimental|MNTX 450 mg QD|Participants will receive methylnaltrexone bromide (MNTX) 450 milligrams (mg) (3 tablets of 150 mg each) once daily (QD) orally. Treatment will continue until participant's death or early withdrawal from the study or study termination by the sponsor.
9519751|NCT03283995||SCA,|
9519752|NCT03283995||acute left heart failure with severe alteration of LVEF|
10144969|NCT04151641|Experimental|Sequence 1|
10144970|NCT04151641|Experimental|Sequence 2|
10144971|NCT04151459|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy on severe obesity PCOS patients
10144972|NCT04151589|Experimental|Interventional Site|"The process below will be allocated in Interventional Sites:~At each interventional sites, implementing full assessment of current emergency work flow of acute ischemic stroke patients who eligible for endovascular treatment. All interventional sites would undergo assessment in order to form a baseline.~Drafting intervention approaches based on the assessment results of all interventional sites. These approaches are executable, reproducible, and measurable.~Emergency work flow management APP would be installed on smartphones of designated personnel at each interventional sites.~Both intervention approaches and APP would be incorporated with original work flow at each interventional site.~Training sessions would be held in interventional sites or online every 3 month once the patient enrolment begin.~Outcome data would be analysed and dispatched every 3 month for each interventional sites."
10144973|NCT04151589|No Intervention|Control Site|The control site would not undergo any emergency work flow modification for acute ischemic stroke patients who eligible for endovascular treatment.
10144974|NCT04151407|Experimental|601 dose level 1 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
10144975|NCT04151407|Experimental|601 dose level 2 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once
10144976|NCT04151407|Experimental|601 dose level 3 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once
10144977|NCT04151407|Experimental|601 dose level 4 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
10144978|NCT04151407|Experimental|601 dose level 5 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(3.75mg), Vitreous injection, injection once;
10144979|NCT04151407|Experimental|601 dose level 6 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously.
10144980|NCT04151407|Experimental|601 dose level 7 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously.
10144981|NCT04151615||Patients|Treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation
10144982|NCT04151576|Experimental|Experimental|The patients received medical treatment. The intervention: An aromatic oil mixture (lavender and peppermint) was massaged for 15 minutes on the temple and root of the neck of the patients, and this application continued for three weeks
10144983|NCT04151576|No Intervention|Control|The patients received only medical treatment
10144984|NCT04151355|Experimental|Atorvastatin group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) in addittion to atorvastatin (20 mg once daily)
10144985|NCT04151355|No Intervention|Control group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks)
10144986|NCT04152174|Experimental|Combined extracorporeal blood purification|CRRT with CVVHDF mode plus treatment with CytSorb adsorber
10144987|NCT04152174|Active Comparator|Control|CRRT with CVVHDF mode
10144988|NCT04152590|Experimental|Uincare|Exercise using Uincare
10144989|NCT04151511|Other|Continuous Thoracic Epidural|Continuous Thoracic Epidural Analgesia for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
10144990|NCT04151511|Experimental|Continuous Erector Spinae Plane Block|Continuous Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
10144991|NCT04151498|Experimental|Intervention Group|This group will complete an HIV health reengagement intervention on a mobile van, in addition to a pre- and post-intervention qualitative interview.
10144992|NCT04151498|Other|Usual Care Reengagement Group|This group will complete a qualitative interview about barriers and facilitators to HIV care.
10144993|NCT04151498|No Intervention|Non-enrolling Group|This group will not be enrolled in the intervention, and will include de-identified data from clinic patients referred to bridge counselors during the study time period that do not participate in the intervention.
10144994|NCT04151381|Placebo Comparator|the control group|the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .
10144995|NCT04151381|Active Comparator|Amiophylline (2mg)|Aminophylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia
10144996|NCT04151381|Active Comparator|Aminophylline(4mg)|Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
10144997|NCT04151537|Active Comparator|Intervention|The intervention group is provided with a PA tracker that enables self-monitoring of PA and are instructed to obtain a personalized PA goal on a weekly basis.
10144998|NCT04151537|Active Comparator|Control|The control group is recommended to follow national PA guidelines, which can be considered as the 'intervention' offered to the public.
10144999|NCT04151771|Experimental|LL-BFRT group|Participants randomised into intervention group are attending pulmonary rehabilitation in which strengthening exercises of the lower limb are performed using LL-BFRT.
9970607|NCT01302275|Experimental|oxcarbazepine|Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
10145000|NCT04151771|Active Comparator|Usual pulmonary rehabilitation group|Participants randomised into control group are attending usual pulmonary rehabilitation as established.
10145001|NCT04151342||Prospective|Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR exon 20, ROS1, and BRAF, from participating sites/cancer centres across Canada.
9970608|NCT01302275|Placebo Comparator|placebo|
9970609|NCT01302314|Experimental|cognitive rehabilitation|
9970610|NCT01302340|Active Comparator|Delta-THC|THC will be administered twice daily during three consecutive days per treatment block(0.75 or 1.5 mg twice daily)
9970611|NCT01302340|Placebo Comparator|placebo|Placebo will be administered twice daily during three consecutive days per treatment block.
9970612|NCT01302353|Experimental|Arm 1 (0.0024 ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0024ml/kg.
9970613|NCT01302353|Experimental|Arm 2 (0.006ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.006ml/kg.
9970614|NCT01302353|Experimental|Arm 3 (0.012ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.012ml/kg.
9970615|NCT01302353|Experimental|Arm 4 (0.02ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.02ml/kg.
9970616|NCT01302353|Experimental|Arm 5 (0.0301ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0301ml/kg.
9970617|NCT01302353|Experimental|Arm 6 (0.0391ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0391ml/kg.
9970618|NCT01302353|Experimental|Arm 7 (0.0508ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0508ml/kg.
9970619|NCT01302353|Experimental|Arm 8 (0.066ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.066ml/kg.
9970620|NCT01302353|Experimental|Arm 9 (0.0859ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0859ml/kg.
9970621|NCT01302353|Experimental|Arm 10 (0.1116ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1116ml/kg.
9970622|NCT01302353|Experimental|Arm 11 (0.1451ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1451ml/kg.
9970623|NCT01302353|Experimental|Arm 12 (0.1886ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1886ml/kg.
9970624|NCT01302353|Experimental|Arm 13 (0.2452ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.2452ml/kg.
9970625|NCT01302353|Experimental|Arm 14 (0.3188ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.3188ml/kg.
9970626|NCT01302353|Experimental|Arm 15 (0.4144ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.4144ml/kg.
9970627|NCT01302353|Experimental|Arm 16 (0.5387ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.5387ml/kg.
9970628|NCT01302405|Experimental|PRI-724|
9970629|NCT01302431|Experimental|Nurse-Led Manualised Telephone support|Participants assigned to this arm of the study will receive 4 nurse-led telephone support calls over a three month time-frame
9970630|NCT01302431|No Intervention|Usual care|Participants randomised to this arm of the study will receive their usual care which comprises caregivers calling nurse specialists when they needs advice and support
9970631|NCT01302457||Healthy Same Subjects|The control group will be 19 years or older and be randomly picked from from volunteer staff at Saint Elizabeth Regional Medical Center. This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects
9970632|NCT01302457||Health Volunteers|"The control group will be 19 years or older and be randomly picked from volunteer staff at Saint Elizabeth Regional Medical Center.~DESIGN This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects"
9970633|NCT01302470|Active Comparator|Robotic placement of CS lead|CS leads placed epicardially in the area of increased dyssynchrony as demonstrated by low dose dobutamine stress testing.
9970634|NCT01302470|Active Comparator|Transvenous placement of CS lead|CS lead will be placed transvenously
9970635|NCT01302496|Experimental|TriMix-DC and Ipilimumab|
9970636|NCT01302509|Active Comparator|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
9970637|NCT01302535|Active Comparator|Yoga group with supervision/trainer|
9970638|NCT01302535|Active Comparator|Yoga at home|
9970639|NCT01302535|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention groups.
10145002|NCT04151342||Retrospective|Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR exon 20, ROS1, and BRAF, from participating sites/cancer centres across Canada.
10145003|NCT04151342||Comparator group|All cancer patients without rare molecular alterations in their tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy.
10145004|NCT04151420||Adult IBD patients|
9970640|NCT01302561|Placebo Comparator|Sugar Pill|
9970641|NCT01302561|Experimental|Galactooligosaccharide 5 g|
9970642|NCT01302574|Placebo Comparator|mixed liquid meal|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate
9970643|NCT01302574|Active Comparator|mixed liquid meal + lactisole|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate + 450 ppm lactisole
9970644|NCT01302587||Albuterol MDI|All participants in this study will receive an albuterol MDI inhaler.
10145005|NCT04151368|Experimental|Robotic Nipple Sparing Mastectomy Arm|Patient cohort undergoing nipple sparing mastectomy with use of robotic dissection.
10145006|NCT04151329|Experimental|2.4mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box, 2.4mg/kg IV infusions
10145007|NCT04151329|Experimental|3.6mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box,3.6mg/kg IV infusions
10145008|NCT04151433|Active Comparator|The combined technique|First step consisting of stripping the cyst wall for 80% of the surface, followed by a second step consisting of ablation of the remaining 20% cyst surface.
10145009|NCT04151433|Active Comparator|CO2 laser vaporization only|CO2 laser vaporization only of the complete inner cystic wall after drainage of the cyst content, irrigation and inspection of its inner wall. Ablation of the inner cyst wall using the CO2 laser (Lumenis). Power settings of 30-55W for CO2 laser beam and 6-10W for CO2 fibre are used. The laser should be on the ablate function to widen the beam (e.g. Surgitouch modus). The laser should be applied in Surgitouch modus so that it can ablate the cyst surface while preserving the underlying healthy tissue.
10145010|NCT04151212|Experimental|BAT5906 injection|Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.
10145011|NCT04151238|Experimental|Exercise intervention|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home. Data on training at home and other items of physical activity is recorded in a diary.
10145012|NCT04151316|Experimental|vertical group|
10145013|NCT04151316|Experimental|horizontal group|
10145014|NCT04151303||Cerclage 1|Time to delivery after cerclage removal Between 36-36.6 weeks' gestation - group 1
10145015|NCT04151303||Cerclage 2|Time to delivery after cerclage removal Between 37-37.6 weeks' gestation - group 2
10145016|NCT04151303||Cerclage 3|Between 38-38.6 weeks' gestation - group 3
9970645|NCT01302600|Experimental|Olesoxime|100 patients in this arm. liquid suspension
10145017|NCT04151303||Cerclage 4|Time to delivery after cerclage removal Beyond 39 weeks' gestation - group 4
10145018|NCT04151199|No Intervention|No Intervention Control|The control group does not engage in any exercise during acute testing protocol.
10145019|NCT04151199|Active Comparator|Endurance Exercise|Participants randomized to ET first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
10145020|NCT04150952|Experimental|HRV-Group|Athletes will train according to their basal HRV scores. If the resting HRV is higher tan their basal HRV, they will perform a high or moderate intensity training. If the resting HRV is lower, they will perform a low intensity training. If the resting HRV still lower, they will rest. They will not accumulate two or more days of high-moderate intensity training, nor two or more days of rest.
10145021|NCT04150952|Active Comparator|TRAD-Group|Athletes will train according to their trainer plan. Training will not be guided by their basal HRV scores.
10145022|NCT04151069||At home group|Participants with allergy to tree nuts who follow the introduction procedure A (at home)
10145023|NCT04151069||At the hospital group|Participants with allergy to tree nuts who follow the introduction procedure B (at the hospital)
10145024|NCT04151069||Control group|Participants with allergy to tree nuts who follow strict avoidance of the offending nuts.
10145025|NCT04151095|Experimental|BFR|
10145026|NCT04151095|Experimental|CTL|
10145027|NCT04150809||Patients|Patients who have been diagnosed with ALS.
10145028|NCT04151056||Patients without social determinant of health|"Patients without any of the five selected social determinants of health / Patients without any of the five selected social diagnosis. Patient with a registered diagnostic  Health check (Z00.00)"
10145029|NCT04151056||"Patients with the social determinantstressful work hours"|"Patients with the selected social determinant of health. Patients with a registered diagnostic stressful work hours  (Z56.3)"
10145030|NCT04151056||"Patients with the social determinant of health living alone"|"Patients with the select social determinant of health . Patients with the selected social determinant of health . Patients with a registered diagnostic  living alone problems (Z60.2)"
10145031|NCT04151056||"Patients with the social determinant of health acculturation"|"Patients with the selected social determinant of health. Patients with a registered diagnostic difficulty acculturation  (Z60.3)"
10145032|NCT04151056||"Patients with the social determinant near surrounding"|"Patients with the selected social determinant of health. Patients with a registered diagnostic other specific problems related to the nearest surroundings (Z63.8)"
10145033|NCT04151056||"Patients with the social determinant unemployment"|"Patients with the selected social determinant of health. Patients with a registered diagnostic unemployment not specified (Z56.0)"
10145034|NCT04151147|Experimental|CGF application in the extraction socket|Partially impacted third molar was extracted with the help of straight elevator and third molar forceps. After extraction, any remains of the dental follicle were removed and the extraction sockets were irrigated with 60 mL of sterile saline. CGF fibrin gel was then randomly placed into one socket and wound closure was completed with silk suture.
10145035|NCT04151147|Experimental|non-CGF application in the extraction socket|Opposite side of the patient was considered as the control. After extraction of the third molar, dental follicle were removed and to prevent the flap laceration, bone contouring was also performed under sterile saline irrigation. Finally, wound closure was completed with silk suture.
10145036|NCT04151030|Experimental|Endoscopic-PEG|"The patients who are unable to undergo an endoscopic pull PEG placement, will undergo an Endoscopic introducer style Direct-PEG procedure at the time of the index endoscopy"
10145037|NCT04151030|Active Comparator|IR-PEG|Patients who underwent PEG placement by interventional radiology (IR-PEG).
10145038|NCT04151004|Experimental|Patient group|Incremental cycling test to volitional exhaustion. Constant load cycling test to volitional exhaustion. Respiratory and leg muscle endurance test to volitional exhaustion. Three respiratory muscle training interventions.
10145039|NCT04151004|Active Comparator|Control group|The control group executes the same tests as the patient group.
10145040|NCT04151160||Case Subjects|Infants with hemodynamically significant congenital heart disease.
10145041|NCT04151160||Control Subjects|Healthy infants with no heart disease or non-hemodynamically significant congenital heart disease.
9970646|NCT01302600|Placebo Comparator|Placebo|50 patients enrolled in this arm. liquid suspension
10145042|NCT04150835|Experimental|Xingnaojing|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
10145043|NCT04150835|Placebo Comparator|Placebo|Subjects will receive intravenously administered Xingnaojing placebo, combined with guidelines-based standard care.
10145044|NCT04151186|Experimental|TM4SF1 and EpCAM positive CAR-T cells for solid tumors|The present study is proposed to study advanced malignant solid tumors in adults, and the three escalating doses, namely, 2.0~2.5. 4.0~5.0 and 8.0~10.0 (×10 ^6/kg), will be given.
10145045|NCT04151173|Experimental|aspiration/electrocoagulation|
10145046|NCT04151173|Active Comparator|cystectomy|
10145047|NCT04150978|Active Comparator|5% Dextrose|the parenteral formulation as prescribed by the intensive care specialist
10145048|NCT04150978|Experimental|High Protein Polymeric Formula|"Procedure :~The daily calorie and protein prescriptions were calculated from standard recommendations (calories 25-30 kcal/kg/d, proteins 1.2-2 g/kg/d)~Administered as boluses via a nasogastric tube. A total of 5 aliquots were administered at 4-hourly intervals in a daily feeding period of 24 hours, with the participant positioned 30° head-up."
10145049|NCT04150978|Experimental|Oligomeric Formula|Similar to the High Protein Polymeric Formula Procedure
10145050|NCT04151043|Other|Verbal suggestion|
10145051|NCT04151043|Other|No suggestion|
10145052|NCT04150848|Experimental|Goal Focused Emotion-Regulation Therapy (GET)|GET is a 6-session intervention delivered over 8 weeks to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses. GET has an emphasis on goal navigation skill building. This includes work on goal setting with a focus on assessing progress toward achieving specific, realistic, and measurable goals. Emotion regulation components include basic cognitive restructuring skills, cognitive distancing, and coping efficacy skills (matching the correct coping skill to specific circumstances).
10145053|NCT04150848|Active Comparator|Individual Supportive Psychotherapy (ISP)|"ISP includes 6-sessions of individual supportive psychotherapy and includes components of genuineness, unconditional positive regard, and empathic understanding through reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis. ISP emphasizes maintaining focus on the cancer experience, supporting participants in the here and now, fostering expression of emotion and discussion of difficult topics, and creating a sense of being understood."
10145054|NCT04150965|Active Comparator|Arm A - Elotuzumab|Patients receive Elotuzumab in combination with pomalidomide and dexamethasone. Arm A begings in Phase 2 portion.
10145055|NCT04150965|Experimental|Arm B - Anti LAG-3 Single Agent|Patients receive Anti-LAG-3 as a single agent for 1 Cycle in Phase 1 portion.
10145056|NCT04150965|Experimental|Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-LAG-3 in combination with pomalidomide and dexamethasone.
10145057|NCT04150965|Experimental|Arm C - Anti-TIGIT Single Agent|Patients receive Anti-TIGIT as a single agent for 1 Cycle in Phase 1 portion.
10145058|NCT04150965|Experimental|ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-TIGIT in combination with pomalidomide and dexamethasone.
10145059|NCT04151277|Experimental|FOLFOX-A|"nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first)~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1~Folinic acid: 350 mg flat dose, IV over 2 hours, day 1~5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours (or 48 hours as per standard practice))"
10145060|NCT04151277|Active Comparator|Abraxane and Gemcitabine|"nab-paclitaxel: 125 mg/m2 IV over 30 minutes, day 1, 8, and 15 (administered first)~Gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 (immediately following nab-paclitaxel)"
10145061|NCT04150939|Experimental|Treatment (cryoablation)|Beginning 1 week prior to the next scheduled standard of care immunotherapy infusion, patients undergo core biopsy of the lesion to be ablated and a non-ablated lesion and also undergo cryoablation. Patients undergo a mandatory second core biopsy of the non-ablated lesion at 4 weeks after cryoablation.
10145062|NCT04150926|Experimental|Black currant puree|Black currant puree
10145063|NCT04150926|Active Comparator|Black currant-quinoa product|Black currant-quinoa product
10145064|NCT04150926|Active Comparator|Quinoa base|Quinoa base is used for the black currant-quinoa product.
10145065|NCT04150926|No Intervention|Liquid with glucose, fructose and sucrose|Liquid with glucose, fructose and sucrose
10145066|NCT04151121|Experimental|Intervention|The participants will receive MBCT (Mindfulness-Based Cognitive Therapy) as 2-hourly sessions over 8-weeks including a 6-hour session at the end of 6th week. The MBCT will be adapted for chest pain.
10145067|NCT04151121|No Intervention|Control group|These participants will continue to receive any treatment (or no treatment) by their primary care physicians.
10145068|NCT04150575|Experimental|HLX10|HLX10+albumin-bound paclitaxel
10145069|NCT04150718|Experimental|Subjects with Major Depressive Disorder|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine is they meet criteria for MDD.
10145070|NCT04150718|Active Comparator|Control|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine they do not meet criteria for MDD.
10145071|NCT04150666|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 2.0 to 2.5 L of water per day (depending on sex), in addition to usual consumed beverages, for 3 months
10145072|NCT04150666|No Intervention|Control|
10145073|NCT04150484|Other|interventional group|dietary intervention, physical exercise and mindfulness
10145074|NCT04150484|No Intervention|control group|Group without any intervention.
10145075|NCT04150614|Active Comparator|Arm 1|ARM 1 -transdermal granisetron plus intravenous dexamethasone
10145076|NCT04150614|Active Comparator|ARM 2|ARM 2 -intravenous ondansetron plus intravenous dexamethasone
10145077|NCT04150627|Active Comparator|deep breathing|
10145078|NCT04150627|No Intervention|normal breathing|
10145079|NCT04150601|Active Comparator|Spontaneous slow vital capacity|Participants will have to perform a slow vital capacity according to the guidelines, from total lung capacity to residual volume
9970647|NCT01302613|Other|arm one|RT + Chemo + surgery
10145080|NCT04150601|Active Comparator|SIMEOX|Participants will have to perform a passive exhalation using the SIMEOX, starting from total lung capacity and going until achieving residual volume
10145081|NCT04150601|Active Comparator|PEP|Participants will have to perform an active exhalation using a PEP device, starting from total lung capacity and going until achieving residual volume
10145082|NCT04150679|Active Comparator|group I retrospective non access loop|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy without access loop
10145083|NCT04150679|Active Comparator|GROUP II access loop group|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy with duodenojejunostomy access loop
10145084|NCT04150549|Placebo Comparator|Autologous Transplants|
10145085|NCT04150549|Active Comparator|Allogeneic Transplants|
10145086|NCT04150653||AAA patients|"All patients enrolled in phase 1 will undergo:~Multiphase scan CT~Non-invasive vascular ultrasound elastography by ultrasound (NIVE)"
10145087|NCT04150458|Experimental|Fluorocholine PET/CT|The sole study-specific procedure is a single 18F-fluorocholine positron emission tomography / computed tomography (PET/CT). Subjects will receive 9 mCi 18F-fluorocholine IV, 5 to 120 minutes prior to PET/CT. 18F-fluorocholine PET/CT studies will be performed on hybrid PET/CT scanners which combine a dedicated, full-ring PET scanner with a multi-slice spiral CT scanner.
10145088|NCT04150640|Experimental|Cohort 1: HER2 Negative|Participants in Cohort 1 (HER2-negative) will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
10145089|NCT04150640|Experimental|Cohort 2: HER2 Positive|Participants in Cohort 2 (HER2-positive)will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
10145090|NCT04150445|Experimental|Internet treatment for overweight and obese patients|The intervention is a treatment of overweight and obesity based on cognitive behavioural therapy provided via the Internet. The treatment lasts for six months and comprises 12 treatment modules. The patient works with each module for two weeks. The modules conclude with one or more exercise tasks to be performed before the next module is activated. The patient has written contact with the therapist via the Internet platform.
10145091|NCT04150588||Good reaction to Efrin test|
10145092|NCT04150588||Unsatisfied reaction to Efrin test|
10145093|NCT04150744|Experimental|RFA plus carrizumab|
10145094|NCT04150744|Placebo Comparator|carrizumab|
10145095|NCT04150562|Experimental|1- Experimental Treatment: Safety Run-in|IL-15 by CIV infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 4 cycles) with avelumab by IV infusion at a dose of 800mg on Day 8 and 22 of each cycle
10145096|NCT04150562|Experimental|2-Experimental Treatment: Doe Expansion|IL-15 by CIV infusion at 4 mcg/kg/day on days 1-5 of each 28- day cycle (max 4 cycles) with avelumab by IV infusion at a dose of 800mg on Day 8 and 22 of each cycle
10185016|NCT03749876|Active Comparator|Study Group 1|Study Group 1 will begin the first treatment period with the provided Unfiltered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Filtered Cigarette intervention for two weeks.
10185017|NCT03749876|Experimental|Study Group 2|Study Group 2 will begin the first treatment period with the provided Filtered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Unfiltered Cigarette intervention for two weeks.
10185018|NCT03749863|Experimental|Serial PRP injections|This arm will receive experimental intervention of serial monthly platelet-rich plasma (PRP) injections to a unilateral vocal fold mucosa for a total of 4 injections.
10185019|NCT03749850|Experimental|Study treatment|"LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide~Single arm study"
10185020|NCT03749837|Experimental|C- MAC VS|Intubation with C- MAC VS
10185021|NCT03749837|Active Comparator|Video Endoscope|Intubation with standard fiberoptic scope
10185022|NCT03749824|Experimental|Omega-3|Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure.
10185023|NCT03749824|Placebo Comparator|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
10185024|NCT03749811|Experimental|Pupillometry group|A group of participants who receive remifentanil infusion under pupillometry monitoring.
10185025|NCT03749811|No Intervention|Conventional group|A group of participants who receive remifentanil infusion without pupillometry monitoring; their analgesic dose is mainly determined via hemodyamic change.
10185026|NCT03749798|Experimental|Intraoperative wavefront measurement|Patients will be measured with an intraoperative wavefront device during cataract surgery
10185027|NCT03749785|Active Comparator|Regular carbohydrate feeding|Ingestion of 75 g sucrose, given in regular doses for the first 75 minutes of exercise during a time to exhaustion run
10185028|NCT03749785|Active Comparator|Single carbohydrate bolus|Ingestion of 75 g sucrose, given in a single bolus after 75 minutes of exercise, during a time to exhaustion run
10185029|NCT03749772|Experimental|Cognitive|The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
10185030|NCT03749772|No Intervention|Control|As a control group, we used nutrition education sessions of approximately the same duration (30 min) where we simply reinforced the knowledge that was already provided during the sessions with the patient, such as concepts about the balanced diet, nutrient composition and micronutrients, etc. The objective of this control group was to avoid the effect of time with the researcher.
10185031|NCT03749759|Experimental|Biofeedback measurement|A Biofeedback measurement will be done during cataract surgery of both eyes
9970648|NCT01302626||1: Surgery alone or combined with (chemo)radiotherapy|"Fresh frozen tumor tissue and normal tissue;~Recording of clinical characteristics, imaging, surgery features.~After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery"
9970649|NCT01302626||2: Radiotherapy alone|"(including stereotactic radiotherapy)~Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features;~Day 8-12 (during RT): Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
9970650|NCT01302626||3: Sequential chemotherapy and radiotherapy|"Day -30 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
9970651|NCT01302626||4: Concurrent chemoradiotherapy with induction chemotherapy|"Day -30 until-18 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
9970652|NCT01302626||5: Concurrent chemoradiotherapy without induction chemotherapy|"Day 0 (before start CRT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, chemotherapy features, and radiotherapy features.~Day 8-12 (during CRT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
9970653|NCT01302626||6: Stage IV lungcancer, any systemic therapy & supportive care|"Day 0:~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, surgery or any systemic (MoAb) features.~After treatment: FU at 2-3 weeks post treatment, 3,6,12,24 and 36 months post-treatment"
9826128|NCT02409277|Experimental|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
9826129|NCT02409277|Experimental|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
9826130|NCT02409277|No Intervention|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
9970654|NCT01302639|Experimental|EGCG and resveratrol|
9970655|NCT01302639|Experimental|EGCG, resveratrol and genistein|
9970656|NCT01302639|Placebo Comparator|placebo|
9970657|NCT01302652||GH deficient after acromegaly cure (on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment.
9970658|NCT01302652||GH deficient after acromegaly cure (not on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment.
9970659|NCT01302717|Active Comparator|Right ventricular pacing|
9970660|NCT01302717|Experimental|Left ventricular pacing|
9970661|NCT01302769|Experimental|battlefield auricular acupuncture|battlefield auricular acupuncture
9970662|NCT01302769|No Intervention|placebo|
9970663|NCT01302795|Experimental|Canakinumab|Canakinumab s.c. 150-300mg Week 0, (2), 8
9970664|NCT01302821|Experimental|Radiotherapy|AMT positron emission tomography with integrated computed tomography (PET/CT)scanning in metastatic breast cancer patients to identify tumors with increased AMT uptake due to up-regulated IDO expression.
9970665|NCT01302873|Experimental|BGG492|
9970666|NCT01302873|Placebo Comparator|Placebo|
9970667|NCT01302925|Experimental|PEP005 Gel 0.05%/2 days|Subjects will be exposed to investigational product for 2 consecutive days.
9970668|NCT01302925|Experimental|PEP005 Gel 0.015%/3 days|Subjects will be exposed to investigational product for 3 consecutive days.
9970669|NCT01302951|Experimental|Moxifloxacin|Moxifloxacin 400 mg i.v.
9970670|NCT01302951|No Intervention|No drug|2 Patients were included as controls- no MXF given
9970671|NCT01302977|Experimental|Fetal intervention|Composed of fetuses that undergo to fetal tracheal occlusion at 26-28 weeks.
9970672|NCT01302977|No Intervention|Control|Composed of fetuses that do not undergo fetal intervention
9970673|NCT01302990|Experimental|5 micrograms H1 VLP|
9970674|NCT01302990|Experimental|13 micrograms H1 VLP|
9970675|NCT01302990|Experimental|28 micrograms H1 VLP|
9970676|NCT01302990|Active Comparator|45 micrograms Fluzone|
9970677|NCT01302990|Placebo Comparator|Placebo|
10185032|NCT03749733|Experimental|Test Product|"Participants will receive a single film-coated tablet of the test formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
9826131|NCT02409329|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
10145097|NCT04150536|Experimental|Lidocaine Topical System with Moderate Exercise (Treatment A)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. Subjects are instructed to exercise 30 minutes on an exercise bicycle, achieving at heart rate of approximately 108 bpm. Exercise is performed after 2.5 hours, 5.5 hours, and 8.5 hours after topical system application.
10145098|NCT04150536|Experimental|Lidocaine Topical System with Heat Applied (Treatment B)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. A heating pad is applied for 20 minutes at 2.5, 5.5, and 8.5 hours after the product is applied.
10145099|NCT04150536|Experimental|Lidocaine Topical System under normal conditions (Treatment C)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. No heat application or exercise is performed during this period.
10145100|NCT04150432|Experimental|propofol|propofol general anesthesia, exhaled measurement of propofol
10145101|NCT04150731|Experimental|Breast cancer and FES|Only one arm: All included are patients with disseminated breast cancer and all have an experimental FES-PET/CT done
10145102|NCT04150757|No Intervention|Standard Analgesia|"Patients receiving no intervention will receive no intranasal ketamine while awaiting intravenous line placement for parenteral pain control."
10145103|NCT04150757|Active Comparator|Intranasal Ketamine + Standard Analgesia|Enrolled patients will receive one dose of Intranasal Ketamine dosed at 1mg/kg (Ketamine 500mg/10 mL solution) after triage while waiting for IV placement (max 50mg).
10145104|NCT04150406|Active Comparator|Flexofytol|2 capsules containing 42mg of curcumin will be administered twice a day for a duration of 4 months.
10145105|NCT04150406|Placebo Comparator|Placebo|2 capsules of the placebo, identical in appearance to Flexofytol, will be administeres twice a day for a duration of 4 months.
10145106|NCT04150237||Novices|Medical students
10145107|NCT04150237||Intermediates|Endoscopy (EGD) assisting nurses. No prior self-performed endoscopies
10145108|NCT04150237||Experienced|Medical doctors in medical Gastroenterology or surgery, who have self-performed more than 500 EGD
10145109|NCT04150211|Active Comparator|Exten(d)|Subjects have to take Exten(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
10145110|NCT04150211|Placebo Comparator|Placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
10145111|NCT04150367||Study group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
10145112|NCT04150367||Control group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
10145113|NCT04150172|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
10145114|NCT04150172|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
10145115|NCT04150003|Experimental|Pulmonary Rehabilitation program|10-weeks structured exercise-based intervention protocol on the restoration of lung blood flow after an acute PE
10145116|NCT04150003|Active Comparator|Usual care|Protocolized usual care for patient suffering PE
10145117|NCT04149938|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
10145118|NCT04149938|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.
10145119|NCT04150016|Experimental|Firehawk implantation|22 subjects will be enrolled to receive Firehawk™ sirolimus target-eluting stent(s).
10145120|NCT04150016|Active Comparator|XIENCE implantation|22 subjects will be enrolled to receive XIENCE™ everolimus target-eluting stent(s).
10145121|NCT04149951|Experimental|Active|Randomized to active device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
9970678|NCT01303016|Experimental|Nutrition supplement|Receives a month's supply of the nutrition supplement, Chispuditos, in addition to a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month.
10145122|NCT04149951|Placebo Comparator|Control|Randomized to sham device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
10145123|NCT04150120|Active Comparator|Reconstructive paediatric surgery (Area I)|The overall incidence of congenital malformations in the gastrointestinal and urinary tract needing surgical interventions is about 1:1000 (Swedish national malformation registers) with a morbidity during childhood about 20-60%. Advanced paediatric surgery for the diagnosis Hirschsprung's disease, anorectal malformations, bladder extrophy, congenital diaphragmal hernia, and esophageal atresia is from July 2018 only performed at two NCSM in Sweden. The NCSM at Skåne University Hospital (SUS) in Lund forms one context. The quality of postoperative care is of immense importance both for short and long-term outcome. Legal guardians describe their situation after leaving the hospital as extremely stressful as they have not only to take responsibility for their new-born child but also of surgical wounds, medications, treatments, and special nutritional needs.
10145124|NCT04150120|Active Comparator|Congenital heart disease (Area II)|In Sweden, about 8-10 in 1000 children per year are born with congenital heart disease (CHD). CHD is a birth defect that leads to frequent hospitalisation, long hospital stays, and extreme anxiety for parents (18). In Sweden, paediatric heart surgery is concentrated to two NCSM of which one is situated at SUS, Lund where 250-300 children have cardiac surgery every year. Children with complicated CHD require contact and follow-up visits for a long time after the heart surgery and many families have to travel long for surgery (for example from Iceland), postoperative care and follow-up visits. Telemedicine after reconstructive cardiac surgery in children is shown to be feasible, although challenging and reduced unscheduled visits.
10145125|NCT04150120|Active Comparator|Preterm born (Area III)|Most prematurely born children grow up to be healthy, but as a group, they are at a greater risk of developing cognitive, emotional and behavioural problems. Every year 7% of all children are born prematurely (gestational age of less than 37 weeks) and the numbers of preterm births are rising in Sweden as well as internationally. Preterm births often involve long hospitalisations for children and parents, and discharge from the hospital often means a difficult transition for parents in both short and long-term perspectives. Traditionally, communication with parents following discharge has been through home visits or telephone calls. By communicating through digital technology, it may be possible to improve the support to parents and thereby make the transition from hospital to home less stressful.
10145126|NCT04150120|Active Comparator|Paediatric oncology (Area IV)|For children with cancer, treatment and follow-up at home is common. At the same time, families wish to minimize the negative impact on family members' social and everyday life. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care and regular follow-up in their home with an increased need for education as well as clinical management support. At present, there are no, or limited, professional outreach support to support them and their families. Communication with parents following discharge has been through e-mail and/ or telephone calls. By communicating through digital technology, it may be possible to improve the support to children and parents.
10145127|NCT04150120|Active Comparator|Intravenous infusion therapy at home (Area V)|For children with LTI administration of intravenous infusion therapy at home is an increasingly important area. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care in their home with an increased need for educational as well as clinical management support during home infusion therapy. At present, children and adolescents with LTI at the University Hospital of Copenhagen receive home infusion therapy by a portable pump with no assistance from an outreaching team to support them and their families.
10145128|NCT04150120|Active Comparator|Children with cerebral palsy (VI)|Cerebral palsy (CP) is the most common physical disability in childhood. Approximately 2-2.5/1000 children have CP with affected muscle tone, movement and motor skills, often accompanied by pain, epilepsy and intellectual, communicational and behavioural impairment. Early detection is challenging but important for minimizing the consequences from neurodevelopmental impairment by an early and right treatment. General Movement Assessment (GMA), an observational method for classification of spontaneous movements in young infants, is currently the most accurate method for early identification of CP. Video recordings are taken with a standardised video set-up in the hospitals regular follow-up clinics when the child is 10 to 20 weeks post-term age. Performing video recordings at home by the parents at a time, which suits the family and the child, would optimize the chances for a successful recording.
10145129|NCT04150185||live liver donors|Live liver donors undergoing donor hepatectomy
10145130|NCT04150159|Experimental|Fasting Mimicking Diet (FMD) Arm|The ProLon® FMD diet is made up of nut bars, dehydrated soups, tea, olives, kale crackers, electrolyte beverages, and a chocolate crisp bar consumed for 5 days every 30 days for 4 months.
10145131|NCT04150159|Active Comparator|Mediterranean Diet Arm|"The Mediterranean diet is based on the traditional foods that people used to eat in countries like Italy and Greece in the 1960s.~Eat every day: vegetables, fruits, nuts, seeds, legumes, potatoes, whole grains, breads, yogurt, dairy, fish/seafood, herbs, spices and extra virgin olive oil.~Eat three or fewer servings each week: poultry, eggs, cheese.~Eat two or fewer servings each week: red meat, potatoes.~Eat two or fewer servings each week: sweets, sodas, processed meat, refined grains, refined oils and other highly processed foods."
10145132|NCT04150198|Experimental|Patients with Alzheimer (<65 years) (AD-Y)|15 patients with a diagnostic of MA-J
10145133|NCT04150198|Experimental|Patients with posterior Cortical Atrophy (PCA)|15 patients with a diagnostic of PCA
10145134|NCT04150198|Active Comparator|Control|15 controls
10145135|NCT04150055|Experimental|Intervention|Everyone in the study will get Mindfulness Coach and an orientation session. Mindfulness Coach is a self-guided mHealth intervention designed to help individuals learn MT, an evidence-based treatment to enhance health, wellness and mental health. The intervention will be introduced during 1 in-person session by a trained research assistant with 1-2 booster instructional phone call at 7 and 14-days to ensure that the participant knows how and is encouraged to use the app. The participant will also be provided with a laminated card that provides the basic instructions. We will encourage the participant to use Mindfulness Coach weekly for 8 weeks, or more if desired, as this treatment dose is commensurate with most in-person MT psychotherapy treatment protocols.
10145136|NCT04150315||Coronary bypass with DM type 2|
10145137|NCT04150315||Coronary bypass without DM type 2|
10145138|NCT04150146|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
10145139|NCT04150146|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
10145140|NCT04149873|Placebo Comparator|Control group|Control group' has the treatment with [Physical chest care ]
10145141|NCT04149873|Placebo Comparator|Experimental group-A|'Experimental group-A' has the treatment with [Mechanical-Insufflation- Exsufflation]
10145142|NCT04149873|Experimental|Experimental group-B|'Experimental group-B' has the treatment with [Mechanical-Insufflation- Exsufflation] and [Physical chest care]
10145143|NCT04150094|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training without stimulus.
10145144|NCT04150094|Experimental|Pelvic floor muscle training + intravaginal vibratory stimulus|Pelvic floor muscle training with intravaginal vibratory stimulation.
10145145|NCT04149886|Experimental|Ablation group(Ablation+pacemaker)|"The cardioneuroablation will be performed under conscious sedation. After 3-dimensional endocardial surface of the LA and pulmonary veins have been constructed by Ensite system, the GP sites can be located in LA；High frequecy stimulation（HFS）will be used to conform if there is a positive vagal response at each GP site. The upper limits of power and temperature will be set to 30-40 W and 43-60°C, respectively. And if no vagal response been induced during ablation, radiofrequency will be delivered for 30 seconds and stopped in this site. The end point of the ablation procedure will be that no vagal response could be induced by repeat HFS.~After ablation of GPs, the participants will receive permanent pacemaker implantation(see arm of control group)."
10145146|NCT04149886|Sham Comparator|Control group(only pacemaker)|The control group only treated with permanent pacemaker without cardioneuroablation.The participants will receive permanent pacemaker implantation, the pacemaker placement will be done in accordance with standards at each center. All implanted pacemakers are provided two manufacturers (St. Jude Medical or Medtronics), His bundle pacing will be recommended in patients with a LVEF between 35%-45%. After placement of permanent pacemaker, the participants will be followed-up at 1 week, 3,6,12 months. After the permanent pacemaker implantation, the rate response function should be turned off and low pacing rate should be set at 60bpm uniformly in all the eligible participants.
10145147|NCT04150107|Experimental|Treatment A|Treatment A is 24 mg (16 mg + 8 mg capsules) Once Daily (QD) at Bedtime of ORMD-0801
10145148|NCT04150107|Experimental|Treatment B|Treatment B is 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
10145149|NCT04149522|Active Comparator|Medial Breast Tissue|Women assigned to the medial breast tissue arm, will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the medial breast tissue by clinically trained staff on day 1 of radiotherapy, the lateral segment will not be covered. The treatment area is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to the skin, then the paper frame is removed. Multiple sheets of non-overlapping film will be used to adequately cover the treatment area. During course of radiotherapy, new film may be applied by clinically trained staff in the event the film no longer adheres to the skin or comes off. Replacement of the film may be done as often as necessary. If there are signs of infection (e.g. redness, feeling warm or swollen), film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or clinically trained staff.
10145150|NCT04149522|Active Comparator|Lateral Breast Tissue|Women assigned to the lateral breast tissue arm will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the lateral breast tissue only, by trained staff on day 1 of radiotherapy. The in-field ipsilateral axilla will be included with lateral breast segment to extent necessary to cover breast or chest wall only. The skin is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to skin and paper frame is removed. Multiple sheets of non-overlapping film will be used to cover the treatment area. During course of therapy, new film may be applied as often as necessary, by trained staff if film no longer adheres to skin or comes off. If there are signs of infection (e.g. redness, feeling warm or swollen), the film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or trained staff.
10145151|NCT04149743|No Intervention|Randomized Standard of Care|Standard of Care
10145152|NCT04149743|Active Comparator|Randomized Standard of Care with HEMOTAG|Standard of Care with HEMOTAG
10145153|NCT04149561||Cerebral Palsy|100 patients over 2 years of age with a diagnosis of cerebral palsy will be included in the study. Demographic information form prepared for the study in terms of demographic information such as age, gender, clinical type of cerebral palsy, drugs used, comorbid diseases will be completed. Communication Function Classification System and Functional Communication Classification System will be used to evaluate patients' communication skills. In addition, patients; The Gross Motor Function Classification System for cerebral palsy and based on child-initiated movements with emphasis on sitting, displacement and mobility, and to hold objects during the daily activities of children with cerebral palsy. The Manual Ability Classification System, which classifies how they use their hands, will also be completed.
10145154|NCT04149847|Experimental|Nylon darn repair|a nylon #1 suture to be used to reconstruct the posterior inguinal wall
10145155|NCT04149847|Experimental|polypropylene mesh repair|a commercially available 7.5cm x 15cm sheet of polypropylene mesh to be trimmed to fit the posterior inguinal wall
10145156|NCT04149483|Experimental|Atorvastatin|Atorvastatin tablets, 20mg once a day, for six months.
10145157|NCT04149483|Placebo Comparator|Placebo|Same color and size coated tablet, 20mg once a day, for six months.
10145158|NCT04149808|Active Comparator|Xeroform Control|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with xeroform dressing, which is the standard of care.
10145159|NCT04149808|Experimental|Mepilex Ag Intervention|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with Mepilex Ag; the product being tested.
10145160|NCT04149678|Experimental|Treatment Group A - Ozanimod|Subjects will receive a single oral dose of ozanimod 0.46 mg
10145161|NCT04149678|Experimental|Treatment Group B - Ozanimod plus Cyclosporine|Subjects will receive a single oral dose of ozanimod 0.46 mg plus a single oral dose of cyclosporine 600 mg
10145162|NCT04149496|Experimental|All|Patients requiring IVF treatment with PCOS or a PCO pattern in their ovaries who wish to undertake IVM (as a variant of their IVF procedure)
10145163|NCT04149795||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
10145164|NCT04149769|Other|Interventional|Walking in an exoskeleton within the home and community.
10145165|NCT04149756||overweight or obese adults|overweight or obese adults who participate the trial (NCT03675191)
10145166|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution A and Exercise|"Subject baseline HR, BP, EKG recorded.~Subject will ingest sucrose (150g):~30 min later, subject will exercise on a treadmill~Subjects will return each week to repeat the above procedures with a different test solution."
10145167|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution B and Exercise|"Subject baseline HR, BP, ECG recorded.~Subject will ingest sucrose (150g); caffeine (400 mg)~30 min later, subject will exercise on a treadmill~Subjects will return each week to repeat the above procedures with a different test solution."
10145168|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C and Exercise|"Subject baseline HR, BP, ECG recorded.~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)~30 min later, subject will exercise on a treadmill"
10145169|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C|"Subject baseline HR, BP, ECG recorded.~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)"
10145170|NCT04149639|Experimental|NeuroQ|Directions: take 2 capsules at the same time daily
10145171|NCT04149613||Colorectal Cancer Patients|Newly diagnosed stage IV colorectal cancer patients
10145172|NCT04149613||Controls|cancer free
10145173|NCT04149548||pregnant diabetic women|Fetal Ultrasound to diabetic pregnant women
10145174|NCT04149548||non diabetic pregnant women|Fetal ultrasound to non diabetic pregnant women
10145175|NCT04149834|Active Comparator|Modified Minimally Invasive Surgical Technique|Comparator: Modified Minimally Invasive Surgical Technique The defect will be gained through the tiny buccal triangular ﬂap: from the buccal 'window' the soft tissue ﬁlling the defect (i.e. the so-called granulation tissue) will be sharply dissected from the papillary supra-crestal connective tissue and from the bony walls with a micro-blade and will be removed with a mini-curette (The soft tissue will be sharply dissected from the osseous defect)
10145176|NCT04149834|Other|Non- incised papilla surgical approach|intervention: Non- incised papilla surgical approach Apical horizontal incision on the buccal mucosa, as far as possible from the interdental papillae and marginal KT will be performed. Soft tissue will be reflected apico-coronally by a full-thickness flap showing the granulation tissue filling the bony defect after exposing the coronal limit of the intra-bony component of the defect, while the marginal tissue will be kept unaltered.
10145177|NCT04149652|Other|Patients with COPD or fibrosis|Subjects, enrolled on either an inpatient or outpatient basis, with stable COPD or fibrosis documented by anamnestic, imaging and functional tests. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
10145178|NCT04149652|Other|Smokers with no signs of COPD|Subjects with an active smoking habit or a personal history of hard smoking dating back to maximum 5 years before, without clinical and functional signs of COPD. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
10145179|NCT04149652|Other|Healthy non-smoking volunteers|Healthy volunteers who have never smoked and who have no clinical or functional sign of COPD or other respiratory diseases. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
10145180|NCT04149600||Bicuspid aortic valve|We wish to investigate the etiology of calcific aortic valve disease, and aortic dilation or aneurysm in patients with a bicuspid aortic valve undergoing aortic valve replacement or aortic surgery.
10145181|NCT04149600||Tricuspid aortic valve|Data and samples will be compared using a control group comprised of patients with a tricuspid aortic valve undergoing aortic surgery.
10145182|NCT04149626|Active Comparator|Group A|Dexmedetomidine sedation
10145183|NCT04149626|Active Comparator|Group B|Midazolam sedation
10145184|NCT04149626|Active Comparator|Group C|Remifentanil sedation
10145185|NCT04149509||Exposed|Infants born ≥ 37 weeks gestation with second or third trimester opioid exposure as determined by maternal urine toxicology screen at delivery; maternal history; and/or infant urine, meconium, or umbilical cord toxicology screen.
10145186|NCT04149509||Unexposed - Controls|Infants born ≥ 37 weeks gestation with no antenatal drug exposure as determined by maternal urine toxicology screen at delivery and/or maternal history. We will match control infants to exposed infants based on Clinical Site and up to 60 days after the date of birth of the exposed infant , recruiting 1 control for every other exposed infant at each site.
10145187|NCT04149457|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
10145188|NCT04149457|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
10145189|NCT04149470|Experimental|Omeprazole|Participants will receive high dose PPI therapy (Omeprazole 20mg twice daily) and will be evaluated for histological improvement.
10145190|NCT04149444|Experimental|ARM 1|"Dose escalation cohort - First 10 patients enrolled on study.~Trifluridine/Tipiracil 30mg/m2 - to start, if no significant dose limiting side effects the dose will be increased to 35mg/m2 for the duration of the trial.~After first 10 patients enrolled on study - Trifluridine/Tipiracil 35mg/m2~Each cycle is 28 days. Two doses per day during days 1-5 with a two day rest for days 6 and 7. Then two doses per day for days 8-12, followed by a rest period for days 13-28 with the next cycle starting the day after day 28."
10145191|NCT04149366||group 1 (Wrapround retainer)|
10145192|NCT04149366||Group 2 (Essix retainer 1mm)|
10145193|NCT04149366||Group 3 (Essix retainer 1.5 mm)|
10145194|NCT04149366||Group 3 (Essix retainer 2mm)|
10145195|NCT04149262|Active Comparator|Fiasp/Novorapid|4 weeks on Fiasp® then crossover to 4 weeks on NovoRapid® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
10145196|NCT04149262|Active Comparator|Novorapid/Fiasp|4 weeks on NovoRapid® then crossover to 4 weeks on Fiasp® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
10145197|NCT04149119|Experimental|Intervention arm|ATSB+LLINs+Standard Care for Malaria case management
10145198|NCT04149119|No Intervention|Standard arm or arm 2|LLINs+Standard Care for MalarIA case management
10145199|NCT04149431|Active Comparator|Derinat|nasal drops
10145200|NCT04149431|Placebo Comparator|Placebo|nasal drops
10145201|NCT04149379|Experimental|Treatment group|One group of 6 patients undergoing 20 sessions of hyperbaric therapy at table 14/90.
10145202|NCT04149249|Experimental|Experimental: Intervention Group (CONNECT)|Patients complete CONNECT, the Video Doctor over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.
10145203|NCT04149249|Active Comparator|Control Group|"Patients complete CONNECT assessment only over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.~Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources."
10145204|NCT04149223|No Intervention|Control|Current practice at baseline, routine cirrhosis care.
10145205|NCT04149223|Experimental|Intervention|Use of a standardized cirrhosis order set.
10145206|NCT04149223|Active Comparator|Intervention + EMR|Use of a standardized cirrhosis order set embedded within an electronic medical record.
10145207|NCT04149275|Experimental|Cabozantinib + Nivolumab + Ipilimumab|All recurrent carcinosarcomas
10145208|NCT04148950|Experimental|Kinesio Taping|Kinesio Taping group consisted of 29 patients with CVD. Kinesio Taping was applied once a week for a period of 4 weeks. Closed Fan and Closed Basketweave techniques were applied according to the clinical manifestations, intensity of symptoms, and the needs for the areas to be taped. Basketweave technique was used generally for the thigh, and the areas rich in lymph nodes while closed fan technique was used for cruris, and regions of less severe venous reflux or obstruction. Kinesio Taping was slowly removed by the patient 4 days after the application to prevent any allergic reactions. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
10145209|NCT04148950|Active Comparator|Compression Stockings|Compression stockings group consisted of 29 patients with CVD. Patients were recommended medium pressure (23-32 mmHg) compression stockings by the physician. Knee high or thigh high compression stockings were given according to the level of symptoms and signs. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
10145210|NCT04148976|Placebo Comparator|Placebo (P)|The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
10145211|NCT04148976|Experimental|Dietary Portfolio (DP)|The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
10145212|NCT04148963|Experimental|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
10145213|NCT04148963|Placebo Comparator|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
10145214|NCT04149327|Experimental|Antibiotics group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days plus a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
10145215|NCT04149327|Active Comparator|Control group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
9669360|NCT02750566|Experimental|Osteopathic Manipulative Treatment|A board certified NMM/OMM or FP/OMM physician will perform an osteopathic structural exam and osteopathic treatment for a 30 minute session. The investigators will follow a generalized protocol for diagnosis and treatment of the head, neck, spine, rib cage, and pelvis. The following techniques will be included in the treatment protocol, OA (Occipitoatlantal) decompression, V-Spread, venous sinus drainage, balanced membranous tension (BMT), cranial lifts, CV4, and a mix of balanced ligamentous tension (BLT), muscle energy techniques, facilitated positional release, articulatory techniques (ART), high-velocity low-amplitude, and counterstrain to address any somatic dysfunctions.
10185033|NCT03749733|Active Comparator|Reference Product|"Participants will receive a single film-coated tablet of the marketed reference formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
9669361|NCT02750566|Active Comparator|Counseling|"For the control group, an investigator will complete a 30-minute counseling session with the subject. The focus of discussion will be from the CDC's What to expect after a concussion article. Other resources that will also be used come from the American Academy of Family Physicians (AAFP), FamilyDoctor.org, and the Brain Care Center. Each counseling session will follow the same protocol. The counseling session will provide subject with similar face-to-face time with the OMT arm."
9669362|NCT02741323|Experimental|Arm 1: Maraviroc (MVC)|Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
9669363|NCT02741323|Placebo Comparator|Arm 2: Placebo|Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
10145216|NCT04149392|Experimental|CGM intervention|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge which will be downloaded at their outpatient follow up clinic visit 6-14 days later. At the follow-up visit medications may be modified based on downloaded glucose data. During the already scheduled post-discharge follow up appointment the CGM sensor data will be downloaded by clinic staff. The diabetes medications will be reconciled and the downloaded data will be reviewed with the patient. Based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
10145217|NCT04148989|No Intervention|Pre-implementation usual care (intervention site)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the intervention hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
10145218|NCT04148989|Experimental|Code Sepsis post-implementation (intervention site)|Adult patients age ≥18 years presenting to the ED of the intervention hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
10145219|NCT04148989|No Intervention|Pre-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
10145220|NCT04148989|No Intervention|Post-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
10145221|NCT04149067||Dapagliflozin cohort|Patients diagnosed with type 2 diabetes that started dapagliflozin treatment at least 6 months before the beginning of the study.
10145222|NCT04149067||Sitagliptin cohort|Patients diagnosed with type 2 diabetes that started sitagliptin treatment at least 6 months before the beginning of the study.
10145223|NCT04149340|Other|Sufentanil sedation|3 microgram of Sufentanil IV
10145224|NCT04149340|Placebo Comparator|Placebo sedation|1 ml de NaCl 0,9%
10145225|NCT04149340|Other|Multimodal sedation|Clonidine, sufantil, midazolam, dihydrobenzperidol, ketamine
10145226|NCT04149106|Active Comparator|Standard|The Mali National Malaria Control program has initiated SMC for children less than 5 years since 2016 (countrywide) with SPAQ. This standard care will not change in this arm
10145227|NCT04149106|Active Comparator|SMC with SPAQ extended to older children|Within this arm, SMC with SPAQ will be extended to children 5-9 years old
10145228|NCT04149106|Active Comparator|SMC with DHAPQ|Children less than 10 years within this arm will received Dihydroartemisin piperaquin for SMC instead of SPAQ
10145229|NCT04149015|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles
10145230|NCT04148924||Patients|Anyone who is hospitalized in the palliative care service of the Lyon Sud Hospital Center.
10145231|NCT04148924||Doctors|Doctors taking care of patients in the study will be solicited by the research nurse or a study investigator.
10145232|NCT04148924||Nurses|Nurses taking care of patients in the study will be solicited by the research nurse or a study investigator.
10145233|NCT04148924||Caregivers|Caregivers taking care of patients in the study will be solicited by the research nurse or a study investigator.
10145234|NCT04149158|Placebo Comparator|Placebo|
10145235|NCT04149158|Experimental|Verum|Sinetrol® Xpur
10145236|NCT04149171|Experimental|conventional treatment|red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC)
10145237|NCT04149171|Active Comparator|conventional treatment added to Crystalloids and TXA|administration of Crystalloids and TXA
10145238|NCT04149132||Patients without sepsis|Patients admitted and hospitalized for infections without sepsis and for other reasons in departments of Internal Medicine and Intensive Care Units
10145239|NCT04149080|Experimental|SIM Group|Alveolar socket post-extraction filled with Simvastatin covered with polypropylene membrane
9970679|NCT01303016|No Intervention|Control|Receives a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month. Participants in the control group will receive the nutrition supplement, Chispuditos, for one year after the study is complete.
10145240|NCT04149080|Placebo Comparator|Control Group|Alveolar socket post-extraction covered with polypropylene membrane
10145241|NCT04148742|Experimental|daily dose of DZD9008|daily dose of DZD9008
10145242|NCT04148898|Experimental|osimertinb group|Osimertinib 80 mg oral daily
10145243|NCT04148898|Experimental|osimertinb combined with bevacizumab group|"Osimertinib 80 mg oral daily;~.bevacizumab 7.5 mg/kg intravenous every 3 weeks"
10145244|NCT04148768|Active Comparator|Inferential therapy|Interferential therapy will be given using 4 electrode methods. The 'medium frequency' currents (medium frequency in electromedical terms is usually considered to be 1KHz-100KHz). These medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross & they literally interfere with each other. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation. Pre-Post Y balance test will be used after 4 sessions to measure the improvement in balance in the population
10145245|NCT04148768|Active Comparator|Shortwave diathermy|4 sessions of treatment will be given to the participants with SWD. Pre-post Y balance test will be used to measure balance in the population
10145246|NCT04148755||Elastography guided FNA|Those patients are going to have EUS elastography guided FNA
10145247|NCT04148755||EUS. FNA|From records we are going to compare them with patients who had EUS without elastography guided FNA
9970680|NCT01303029|Active Comparator|Control|Gemcitabine+erlotinib
10145248|NCT04148807|Experimental|Progressive walking program with gait retraining|Participant will receive 8 gait-retraining intervention sessions.
10145249|NCT04148807|Active Comparator|Progressive walking program|Participant receives 8 sessions of a graded walking program.
10145250|NCT04148885|Experimental|nab-paclitaxel + Carboplatin|nab-paclitaxel at 260 mg/m^2 on days 1; Carboplatin AUG=5, d1, 21 days in one cycle, 3 cycles in total
10145251|NCT04148820|Experimental|Once daily drug administration|Patients will be given cardiovascular drugs once daily
10145252|NCT04148820|Experimental|Twice daily drug administration|Patients will be given cardiovascular drugs twice daily
10145253|NCT04148833|Experimental|LDE-Paclitaxel|Paclitaxel carried by a lipid nanoparticle (LDE-Paclitaxel)
10145254|NCT04148833|Placebo Comparator|LDE-Placebo|Lipid nanoparticle (LDE)
10145255|NCT04148794|Experimental|Intervention group|Participants who join the class of eALS
10145256|NCT04148456|Other|Aortoiliac occlusive disease|This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
10145257|NCT04148781|Experimental|Fampridine-SR|Fampridine-SR 10 mg Orally Twice Daily for 8 weeks.
10145258|NCT04148469|Experimental|dry needling and TENS|A dry needling treatment was performed on trapezius trigger point number 2, and just after thar, a TENS curretn was applied. Patients will be reassed on fourth day after treatment.
10145259|NCT04148469|Placebo Comparator|Placebo|A placebo dry needling was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
10145260|NCT04148469|Experimental|dry needling|A dry needling treatment was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
10145261|NCT04148547|Experimental|transcranial direct current stimulation|
10145262|NCT04148547|Placebo Comparator|Sham transcranial direct current stimulation|
10145263|NCT04148586|Experimental|One week Whole Breast Irradiation|WBI: 27 Gy/5 fractions/1 week. 5.4 Gy /fraction ± boost to tumor bed 5.4 Gy/ 1 fraction, 2 days after the end of WBI.
10145264|NCT04148586|Experimental|Once weekly Whole Breast Irradiation|WBI: 28.5 Gy/ 5 fractions/ 5 weeks. 5.7 Gy/fraction ± boost to tumor bed 5.7 Gy/ 1 fraction, one week after the end of WBI. WBI is given on the same day each week.
10145265|NCT04148586|Active Comparator|3 weeks Whole Breast Irradiation|WBI: 40.05 Gy/ 15 fractions/ 3 weeks. 2.67 Gy/ fraction ± boost to tumor bed 10 Gy/ 4 fraction / 4 days after the end of WBI
10145266|NCT04148482|Active Comparator|Genotype of interest group|Individuals with desired genetic susceptibility will receive a standardized and an election meal in a full-day clinic visit.
10145267|NCT04148482|Placebo Comparator|Control|Individuals without genotype of interest (i.e., carrying the opposite genotype) will receive a standardized and an election meal in a full-day clinic visit.
10145268|NCT04148508|Experimental|Tailored Emotional Competence|Self-help Tailored Emotional Competence delivered via mobile app
10145269|NCT04148508|Active Comparator|Cognitive-behavioural Approach|Self-help cognitive-behavioural approach delivered via mobile app
10145270|NCT04148508|Placebo Comparator|Self-monitoring|Self-help self-monitoring delivered via mobile app
10145271|NCT04148599|Active Comparator|dexmedetomidine|dexmedetomidine ( precedex) infusion will be administered preoperatively and continued intraoperatively
10145272|NCT04148599|Active Comparator|lidocaine|Lidocaine (Xylocaine) infusion will be administered preoperatively and continued intraoperatively
9519753|NCT03283982|Active Comparator|Robotic IPOM|Robotic Ventral Hernia Repair with IPOM: The da Vinci® Surgical System robotic platform (Intuitive Surgical, Inc.) will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
9970681|NCT01303029|Experimental|Experimental|Gemcitabine+erlotinib+capecitabine
10145273|NCT04148599|Placebo Comparator|placebo|saline infusion will be administered preoperatively and continued intraoperatively
10145274|NCT04148690|Experimental|Group ANC Intervention|Clinics in the group ANC intervention arm offer group Antenatal Care to women who present for their initial visit prior to 24 weeks provided that they intend to remain in the area for the duration of the pregnancy, and agree to participate in GANC. Women not enrolled in group ANC will receive standard ANC per ministry of health protocols.
9970682|NCT01303042|Experimental|Insulin lispro mix 50/50|
9970683|NCT01303055|Experimental|Alogliptin|Alogliptin 25 mg
9970684|NCT01303055|Active Comparator|Metformin|Metformin 750 mg
10145275|NCT04148690|Active Comparator|Routine ANC|Clinics will offer only standard ANC per ministry of health protocols.
10145276|NCT04148716||patients|recruitement of 9 patients
10145277|NCT04148716||control|recruitement of 9 control person
10145278|NCT04148859|Experimental|pregnant women|women who have to undergo amnioreduction due to TTTS
10145279|NCT04148404|Active Comparator|Group NT|1.Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).
10145280|NCT04148404|Active Comparator|Group HT|2.Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
10145281|NCT04148378||Patients|Patients who have been diagnosed with colorectal cancer.
10145282|NCT04148703|Experimental|Active group|in-office follow-up at 30 days post-implantation and after by remote monitoring (daily) without scheduled in-office follow-up during the study period (48 months). A remote FU will be planned every 9 months.
10145283|NCT04148703|Active Comparator|Control group|The patients randomized in the control group will be followed accordingto the guidelines; i.e. with an in-office follow-up at 30 days post-implantation and after followed with in-office follow-ups according to clinical practice.
10145284|NCT04148872|Active Comparator|Neuromuscular Retraining Therapy|Neuromuscular retraining therapy alone for four months, with botulinum toxin injection added during an additional four month period.
10145285|NCT04148872|Active Comparator|Chemodenervation|Ipsilateral chemodenervation with botulinum toxin injections alone for four months (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin, Merz), with neuromuscular retraining therapy added for an additional four months.
10185034|NCT03749720|Other|Cervical cancer patients|Baseline- and follow-up blood samples are collected from the cervical cancer patients at time of diagnosis and during treatment and clinical follow-up. HPV DNA is measured in these samples.
10145286|NCT04148729|Active Comparator|bupivacaine+lidocaine|15 ml bupivacaine+ 5 ml lidocaine will use for USG guided ESP block under general anaesthesia with Sevuflurane and remifentanil. This block will perform at the T10 level bilaterally after induction of anaesthesia at the prone position. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with 11-point numerical rating scale. If the score over 4 points, rescue analgesic 0.4 mg/kg meperidine will be apply intravenously.
10145287|NCT04148729|Sham Comparator|saline|In this group, the same volume saline will apply to the block region. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with 11-point numerical rating scale. If the score over 4 points, rescue analgesic 0.4 mg/kg meperidine will be apply intravenously.
10145288|NCT04148846|Active Comparator|Clinical treatment - old protocol|In group I, patients will receive clinical treatment according to the institution's old protocol for post dural puncture headache.
10145289|NCT04148846|Active Comparator|Clinical treatment - new protocol|In group II, patients will receive clinical treatment, according to the new protocol of the institution.
10145290|NCT04148846|Experimental|Sphenopalatine block|In group III patients will receive clinical treatment, according to the new protocol of the institution, associated with sphenopalatine block.
10145291|NCT04148339||Patients|Patients with Elevated Cholesterol
10145292|NCT04148248||Patients|Patients with a diagnosis of chronic constipation
10145293|NCT04148261|Active Comparator|Healthy Arm, CORT + EPI, then PLB + EPI|Healthy participant will receive cortisol pill and epinephrine infusion
10145294|NCT04148261|Active Comparator|Healthy Arm, PLB + EPI, then CORT + EPI|Healthy participant will receive placebo pill and epinephrine infusion
10145295|NCT04148261|Experimental|Depression Arm, CORT + EPI, then PLB + EPI|Depressed participant will receive cortisol pill and epinephrine infusion
10145296|NCT04148261|Experimental|Depression Arm, PLB + EPI, then CORT + EPI|Depressed participant will receive placebo pill and epinephrine infusion
10145297|NCT04148664|Active Comparator|Standard Catheter Settings|Group 1 - Standard RF ablation settings
10145298|NCT04148664|Experimental|High Power Short Duration (HPSD)|Group 2 - High power short duration RF
10145299|NCT04148677||Protoves M1® syrup|A combination of two alkaloid, Protopine and Nuciferine
10145300|NCT04148677||No treatment|Patients will not receive a treatment
10145301|NCT04148443|Experimental|3 minutes period of preoxygenation|3 minutes of preoxygenation : participants in this group will receive 3 minutes of preoxygenation before intubation
10145302|NCT04148443|Experimental|5 minutes period of preoxygenation|5 minutes of preoxygenation: participants in this group will receive 5 minutes of preoxygenation before intubation
10145303|NCT04148053||Active TB|"Subjects met the following:~Either Pulmonary or Extra-pulmonary tuberculosis patients~TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen."
10145304|NCT04148053||Latent TB|"Subjects met the following:~TB Contact in history.~Chest X-ray suggestive of non-TB.~without any symptoms suggestive of TB.~TST and/or IGRA positive."
10145305|NCT04147975||Patients Suspected of Bloodstream Infection|No intervention(s) to be administered.
10145306|NCT04148196|No Intervention|Control group|older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.
10145307|NCT04148196|Experimental|Experimental group|Intervention group: older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.The researcher will perform 16 sessions of progressive relaxation exercises twice a week for 8 weeks. Each PMR exercise was conducted under the guidance of the researcher. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate and blood pressure.
10145308|NCT04148326||Patients|Patients who have been diagnosed with Parkinson's Disease
9970685|NCT01303081|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
10145309|NCT04148274||Patients|Patients with Ulcerative Colitis diagnosis
10145310|NCT04148183|Experimental|Metformin Group|Metformin (850 mg/day) treatment was administered for 8 weeks
10145311|NCT04148183|Experimental|Rosiglitazone Group|Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
10145312|NCT04148183|Placebo Comparator|Placebo Group|Placebo treatment was administered for 8 weeks
10145313|NCT04147936|Active Comparator|AXA1665 29.4g|Dietary Supplement: AXA1665 Amino acids, food study
10145314|NCT04147936|Active Comparator|AXA1665 53.9 g|Dietary Supplement: AXA1665 Amino acids, food study
10145315|NCT04147936|Placebo Comparator|Placebo 29.4 g|Dietary Supplement: Placebo
10145316|NCT04148209|Experimental|Treatment|Participants receiving PF-07081532
10145317|NCT04148209|Placebo Comparator|Placebo|Participants receiving Placebo
10145318|NCT04147923|Active Comparator|Floradapt Mature Immune Defense|A multivitamin will also be consumed.
10145319|NCT04147923|Placebo Comparator|Placebo|A multivitamin will also be consumed.
10145320|NCT04148235||Patients|Patients who have been diagnosed with Celiac Disease
10145321|NCT04148612|Experimental|Opti-Me|Patients in this group will be treated based on the Opti-Me algorithm recommended treatment.
10145322|NCT04148612|No Intervention|Randomization|Patients in this group will be treated by random assignment of treatment.
10145323|NCT04148222||Patients|Patients who have been diagnosed with Lyme Disease
10145324|NCT04148066|Other|Osimertinib and Crizotinib|"Osimertinib will be administered according to label: 80 mg once daily.~Crizotinib will only be prescribed upon detection of MET amplification using ctDNA. Crizotinib will be administered according to label: 250 mg bi-daily."
10145325|NCT04147949|Experimental|AV-101|1440 mg of L-4-chlorokynurenine administered twice a day orally
10145326|NCT04147949|Placebo Comparator|Placebo|Matching capsules of placebo
10145327|NCT04147962||Patients with dry eye disease with meibomian gland dysfunction|"Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations).~- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light"
10145328|NCT04148313||Patients|Patients with diagnosis of Multiple Sclerosis.
10145329|NCT04148014|Experimental|Adjunctive Emotion Regulation Skills Training|Participants will receive a 5 session once a week group emotion regulation skills training adjacent to treatment as usual provided by the eating disorder unit at the child and adolescent psychiatric clinic, Linköping, Sweden.
10145330|NCT04147910|Experimental|KW-6356|Single oral dose of carbon-14-KW-6356.
10145331|NCT04148118|Experimental|NE+50µg rPA - sprayer|
10145332|NCT04148118|Experimental|NE+50µg rPA - pipette|
10145333|NCT04148118|Experimental|NE+100µg rPA - sprayer|
10145334|NCT04148118|Experimental|NE+100µg rPA - pipette|
10145335|NCT04148118|Placebo Comparator|Saline - sprayer|
10145336|NCT04148118|Placebo Comparator|Saline - pipette|
10145337|NCT04148118|Active Comparator|BioThrax - SC|
10145338|NCT04148040|Experimental|G-POEM for infantile hypertrophic pyloric stenosis|The procedure includes four steps: a) a transversal mucosal incision was performed at the proximal antrum. b) a submucosal longitudinal tunnel was created across the pyloric ring. c) full-thickness pyloromyotomy was performed, with a little extension of the antrum. After pyloromyotomy, an ultrathin gastroscope was used to inspect the mucosa and pyloric outlet. d) after careful hemostasis, the mucosal entry was closed by clips.
10145339|NCT04147897|Active Comparator|Internal Facilitation|mHealth specialist is a trained clinician embedded in the clinical team offering the mHealth intervention, FOCUS.
10145340|NCT04147897|Active Comparator|External Facilitation|mHealth specialist is a trained clinician external to the clinical team offering the mHealth intervention, FOCUS.
10145341|NCT04147637|Experimental|FSL-M|FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
10145342|NCT04147637|Active Comparator|FSL-A|FreeStyle Libre alone
10145343|NCT04147572|Experimental|Inhaler A, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type A
10145344|NCT04147572|Experimental|Inhaler B, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type B
10145345|NCT04147572|Placebo Comparator|Reference product, Spiriva modified HandiHaler|Placebo Spiriva, hard capsule inhaled via modified HandiHaler device
10145346|NCT04147572|Experimental|Substudy Test product Placebo Tiotropium Easyhaler|The substudy subjects will demonstrate the use of the inhaler.
10145347|NCT04147572|Placebo Comparator|Substudy Reference product Placebo Spiriva® HandiHaler|The substudy subjects will demonstrate the use of the inhaler.
10145348|NCT04147585|Experimental|Intervention Arm|Three cycles of a 5-day Intermittent Reduced Calorie Diet
10145349|NCT04147585|No Intervention|Control Arm|Regular Diet
10145350|NCT04147702|Experimental|Experimental Group: Balance analysis|fifty dancers will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
10145351|NCT04147702|Active Comparator|Control Group:Balance Analysis|fifty healthy subjects will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
10145352|NCT04147780||Primary vulvar cancer, tumor ≥ 4cm|"Patients with primary squamous cell vulvar cancer, unifocal tumor ≥ 4cm:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
9519754|NCT03283982|Active Comparator|Laparoscopic IPOM|Laparoscopic Ventral Hernia Repair with IPOM: The standard laparoscopic platform will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
10145353|NCT04147780||Primary vulvar cancer, multifocal tumor|"Patients with primary squamous cell vulvar cancer, multifocal tumor:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
10145354|NCT04147780||Local recurrence after vulvar cancer, no earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier without treatment of the groins or solely sentinel node biopsy:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
10145355|NCT04147780||Local recurrence after vulvar cancer, earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier treatment of the groins by lymphadenectomy and / or (chemo-)radiation:~Sentinel node biopsy if detectable, otherwise no groin treatment"
10145356|NCT04147741|Experimental|Pre-Workout Supplement|A 60 g dose of a commercially available pre-workout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine 1 g, yerba mate 0.3 g and caffeine 0.4 g. With 250 ml of water.
10145357|NCT04147741|Placebo Comparator|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 250 ml of water.
10145358|NCT04147806|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
10145359|NCT04147806|Experimental|IGRT 24 Gy single dose|single fraction IGRT at a prescription dose of 24 Gy
10145360|NCT04147793||Controls|patients attneding for surgery with no known bladder disease
10145361|NCT04147793||Overactice sphincter|those with evidence of dysfunctional voiding
10145362|NCT04147793||Underactive sphincter|those with genuine stress incontinence
10145363|NCT04147598|Experimental|Low Fat Diet (LFD) to Standard American Diet (SAD)|Week 1 to 4 participants will receive a LFD followed by a washout period of 2 weeks and then week 6 to 10 SAD.
10145364|NCT04147598|Experimental|SAD to LFD|Week 1 to 4 participants will receive a SAD followed by a washout period of 2 weeks and then week 6 to 10 LFD.
10145365|NCT04148170|Active Comparator|classic intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with metal probe and then intubation with bicanlicular silicon tube.
10145366|NCT04148170|Active Comparator|endodiathermy probe|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
10145367|NCT04147754||Epidural anesthesia|At physician discretion (observational study)
9519755|NCT03283969|Placebo Comparator|Control Powder|Isocaloric powder
9519756|NCT03283969|Experimental|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
10145368|NCT04147754||Intrathecal morphine|At physician discretion (observational study)
10145369|NCT04147754||Erector spinae block|At physician discretion (observational study)
10145370|NCT04147767|Experimental|Phytosterols Arm|"The investigational food product Cholesterol Reducing Strawberry Yogurt Drink (Tesco) is a strawberry yogurt drink with added plant sterols. A 100g bottle (one serving) of cholesterol lowering strawberry yogurt drink contains 2g of free plant sterols. The magnitude of the effect given by this enriched food product, providing a daily intake of 1,5-2,4 g plant sterols/stanols, refers to the lowering/reducing blood cholesterol effects in the range 7 % to 10 % within 2 to 3 weeks of treatment, as specified by Commission Regulation (EU) 384/2010 of 05/05/2010.~The dietary intervention will consist in 8 weeks consumption of PSS enriched Yogurt Drink, which provide a daily PSS intake of 3.4g/100g bottle plant sterols ester equivalent to 2g/100g bottle of free plant sterols."
10145371|NCT04147767|Placebo Comparator|Placebo Arm|"The investigational food product Low Fat Strawberry Yogurt Drinks (Morrisons) is a strawberry flavoured yogurt drink with sweetener and sugar, vitamin C, B6 and D, British milk.~Placebo intervention consists in 8 weeks consumption of PSS non-enriched Yogurt Drinks. The placebo intervention is needed for the study design chosen (randomized double-blind placebo-controlled cross-over clinical trial). Placebo will be used in order to determine the efficacy of PSS intervention, comparing the effects of the two compounds (PSS and placebo) in the same experimental conditions and then avoiding bias."
10145372|NCT04147845|Experimental|Fractional Carbon dioxide laser and triamcinolone acetonide|"Group I:Fractional Carbon dioxide laser (CO2 Laser) and triamcinolone acetonide (TrA; 10 mg/ ml) (14, 15) The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
10145373|NCT04147845|Experimental|Microneedling with Dermapen and triamcinolone acetonide|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~Triamcinolone acetonide in concentration of 10 mg/ml (0.1 ml containing 1 mg of triamcinolone) will be applied on each lesion twice, before and after performing microneedling.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
10145374|NCT04147845|Experimental|Fractional Carbon dioxide laser and Platelet-rich plasma|"The same laser parameters as group I will be used, followed by application of freshly prepared PRP. The applied PRP will be spread over the whole affected area.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
10145375|NCT04147845|Experimental|Microneedling with Dermapen and Platelet-rich plasma|"Microneedling using dermapen is performed as Group II. Microneedling is preceeded and followed by intermittent application of freshly prepared PRP. The applied PRP will be spread over the whole affected area and again rolled till pinpoint bleeding points are noticed.~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
10145376|NCT04147728|Experimental|SRS Combination With Anlotinib|Stereotactic Radiosurgery Combination With Anlotinib
10145377|NCT04147624|Experimental|Treatment Group|Participants in the treatment group will receive 125 mL of Souvenaid taken by mouth, once daily, for 6 consecutive months.
10145378|NCT04147624|Placebo Comparator|Placebo Group|Participants in the treatment group will receive 125 mL of iso-caloric placebo taken by mouth, once daily, for 6 consecutive months.
10145379|NCT04147871|Active Comparator|ADV7103 1.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
10145380|NCT04147871|Active Comparator|ADV7103 3.0 mEq/Kg/day|Patients receive ADV7103 twice a day.
10145381|NCT04147871|Active Comparator|ADV7103 4.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
10145382|NCT04147871|Placebo Comparator|Placebo|Patients receive placebo twice a day.
10145383|NCT04147676||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study.~The specimens will be tested with~Roche cobas MTB - for the detection of Mycobacterium tuberculosis complex~Roche cobas MTB-RIF/INH - all specimens that are Mycobacterium tuberculosis complex positive will be reflexed to the Roche cobas MTB-RIF/INH test for the detection of resistance to rifampicin and isoniazid~Hain FluoroType MTBDR - for the detection of Mycobacterium tuberculosis complex and the detection of resistance to rifampicin and isoniazid"
10145384|NCT04147429|No Intervention|Usual care|Newborns randomized to the usual care group will receive standard education about safe sleep practices, measuring temperatures and newborn feeding needs. This information will be accompanied by printed instructions that will be added to the family's discharge instructions. This reflects current practice in the Duke Hospital Newborn Nursery.
10185035|NCT03749707|Other|SLNs from early-stage cervical cancer patients|Tissue from SLNs removed from early-stage cervical cancer patients are analyzed for HPV.
10145385|NCT04147429|Experimental|Intervention|In addition to usual care, families randomized to the intervention group will receive an early literacy intervention, delivered by a trained research assistant. To ensure intervention and delivery fidelity, the PI will meet with research assistants at bi-weekly intervals to review procedures and perform structured observations of intervention delivery.
10145386|NCT04147286|Active Comparator|Atorvastatin (Arm B)|12 weeks of 40 mg atorvastatin therapy per os daily
10145387|NCT04147286|Placebo Comparator|Placebo (Arm C)|Identical placebo tablet is taken per os daily
10145388|NCT04147468|Active Comparator|Virtual Reality Gaming Intervention|A newly developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child, will be used. The research team will loan the system to the family. The child will be asked to move their arms to 'pop' as many virtual objects as possible with the focus on outwards, upwards, and across midline.
10145389|NCT04147468|Experimental|Functional Strength Training|Children will receive repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises which are designed to move their arms.
10145390|NCT04147208|Experimental|Combination group|Subjects will receive 96 weeks of GLS4+RTV+ETV.
10145391|NCT04147208|Active Comparator|Entecavir monotherapy|Subjects received 96 weeks of entecavir treatment
10145392|NCT04147377|Experimental|PD with FOG|Patients with Parkinson's disease who complain of freezing of gait
10145393|NCT04147520|Active Comparator|Brief Motivational Interview|Single-session in person conversation focusing on risks associated with alcohol use.
10145394|NCT04147520|No Intervention|Natural History Control|No contact.
10145395|NCT04147507|Experimental|Music Therapy|
9970686|NCT01303081|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
10145396|NCT04147507|Other|Control|Life style Modification.
10145397|NCT04147273|Other|Evaluation of CGM compared with standard measurements|Two products were studied: white bread (Butter Toast®, Golden Toast, Wittenberg, Germany) and whole grain bread (1688 Mehrkorn®, Harry-Brot, Schenefeld, Germany). One portion (containing 50 g digestible carbohydrates) was eaten immediately before the beginning of the test in the morning after an overnight fast of at least 10 h. Before testing, participants ate as usual on the previous day without a standard meal and refrained from consuming alcohol and exercising for 72 h. A 200-ml glucose drink (Accu-Chek Dextrose O.G.-T. Saft®, Roche Diabetes Care, Mannheim, Germany), containing also 50 g of carbohydrates, was used as the reference product.
10145398|NCT04147481|Experimental|Group Abdominal Nerve Block|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
10145399|NCT04147481|Placebo Comparator|Group control|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.9% saline.
10145400|NCT04147390|Active Comparator|usage mycophenolate mofetil|
10145401|NCT04147390|Active Comparator|usage tacrolimus|
10145402|NCT04147533|Experimental|initially treated patients|The dose of tyrosin kinase inhibitors (imatinib, or nilotinib, or dasatinib) in patients meeting all of the inclusion criteria and none of the exclusion criteria will be reduced in two consequent steps, during the first 6 months after study entry by 50%, during the second 6 months by 50% again; the medication is discontinued then and the patients are followed each month in the first 6 months after withdrawal, each 1,5 month in the next 6 months, and each 3 months in the next 12 months.
10145403|NCT04147104|Active Comparator|Standard-of-care plus invasive mechanical ventilation|Invasive mechanical ventilation for lung support and to facilitate exhalation via an endotracheal tube o tracheotomy.
10145404|NCT04147104|Experimental|ECCO2R plus invasive mechanical ventilation|Low-flow ECCO2R adjunct to standard-of-care and invasive mechanical ventilation.
10145405|NCT04147182|Experimental|Patient with low grade TCC|"Patients of 18 years or older able to sign informed consent~A previous diagnosis of low grade bladder cancer~A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography) showing normal upper urinary tract in the 12 months prior to inclusion~Serum creatinine levels ≤ 2.0 mg/dl~Serum sodium levels <146 mg/ml~Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months~Patient is candidate for TURBT"
10145406|NCT04147091|Experimental|domestic nanohydroxyapatite gel ApaCare & Repair|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
10145407|NCT04147091|Experimental|in-office ozone therapy OzonyTron|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
10145408|NCT04147091|Experimental|both remineralizing gel and ozone therapy|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
10145409|NCT04147260|Experimental|BI 730357 low dose|
10145410|NCT04147260|Active Comparator|Ciprofloxacin|
10145411|NCT04147260|Experimental|BI 730357 high dose|
10145412|NCT04147260|Placebo Comparator|Placebo|
10145413|NCT04147299||HFrEF|Heart Failure with Reduced Ejection Fraction
10145414|NCT04147299||HFpEF|Heart Failure with Preserved Ejection Fraction
10145415|NCT04147299||Elite Athletes|Endurance athletes
10145416|NCT04147312|Experimental|Treatment group|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles
10145417|NCT04147312|Placebo Comparator|control group|Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
10145418|NCT04147026|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from rheumatoid arthritis. Prescription of an original or biosimilar biotherapy (rituximab, adalimumab, abatacept) is possible.
10145419|NCT04147026|Active Comparator|Current practice|Prescription of biotherapy without the SinnoTest® software which corresponds to current practice (all biotherapies).
10185036|NCT03749642|Experimental|trazodone/gabapentin 2.5/25 mg|One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
9519757|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
9970687|NCT01303081|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
9970688|NCT01303081|Experimental|Chosen Deposits|Same as USUAL CARE, plus financial incentive as follows: participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine or anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
9970689|NCT01303081|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
9970690|NCT01303094|Other|Continuation of Trabectedin|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
9970691|NCT01303094|Other|"Drug holiday therapy"|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge
9970692|NCT01303107|Active Comparator|bupivacaine S50:R50|3 ml subarachnoid block
9970693|NCT01303107|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
9970694|NCT01303120|Active Comparator|Femoral Nerve Block|
9970695|NCT01303120|Active Comparator|Combined Nerve Blocks|
9970696|NCT01303120|Active Comparator|Patient-controlled analgesia|
9970697|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/-)|We will be recruiting healthy adults with Down syndrome ages 30 and over. Participants cannot have a diagnosis of dementia.
9970698|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/+)|
9970699|NCT01303133||Adults with Down Syndrome ages 30+ (PiB+/+)|
9970700|NCT01303146|Experimental|Enzyme replacement therapy|intravenous infusion 100U/kg every other week for 18 months
9970701|NCT01303185||Experimental Group|
9970702|NCT01303185||Control Group|
9970703|NCT01303198|Active Comparator|CPAP|Use of CPAP as treatment for sleep apnea
9970704|NCT01303198|Active Comparator|APAP|Use of APAP as treatment for sleep apnea
9970705|NCT01303211||serogroup A meningococcal disease|Cases of serogroup A meningococcal disease
9970706|NCT01303211||Community controls|Healthy members of the community controls matched with cases for age, sex and place of residence
9970707|NCT01303211||Hospital controls|Patients admitted to the hospital with an acute illness other than meningitis or septicemia
9970708|NCT01303250|Experimental|Group 1|A balanced hydroxyethyl starch 130/0.4 will be used
9970709|NCT01303250|Active Comparator|Group 2|A balanced crystalloid will be used
9970710|NCT01303263|Other|Intervention Group|Residents Randomized to Receive Educational Intervention
9970711|NCT01303263|No Intervention|Control Group|Residents randomized not to receive a teaching intervention.
9970712|NCT01303276||Anti-VEGF group|Patients who are clinically indicated for the intravitreal injection of ranibizumab
9970713|NCT01303276||Age-matched controls|Group of healthy participants who will be age and gender matched
9970714|NCT01303289|Experimental|Group 1|The group 1 will receive the experimental product T-Diet plus Standard for 3 months.
9970715|NCT01303289|Active Comparator|Group 2|The group 2 will receive the control product Jevity (Abbott Laboratories) for 3 months.
9970716|NCT01303302|Active Comparator|GCM stimulation|The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
9970717|NCT01303302|Sham Comparator|Device off|The TANTALUS System is implanted but is off
10185037|NCT03749642|Experimental|trazodone/gabapentin 5/50 mg|One capsule, three times a day, for 8 weeks.
9519758|NCT03283943|Experimental|Durvalumab and focal radiotherapy|Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
9970718|NCT01303315|Other|GLP-1 receptor agonist therapy|Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c < 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.
9970719|NCT01303315|Experimental|GLP-1 receptor agonist and TANTALUS|Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c > 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period
9970720|NCT01303315|Active Comparator|Subjects on TANTALUS therapy only|Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system
9970721|NCT01303328|Experimental|Treatment group|
9970722|NCT01303328|Placebo Comparator|Placebo group|
9970723|NCT01303354|Experimental|DXM 4 mg|Dexamethasone 4 mg
9970724|NCT01303354|Experimental|DXM 8 mg|Dexamethasone 8 mg
9970725|NCT01303354|Experimental|DXM 12 mg|Dexamethasone 12 mg
9970726|NCT01303367||antipsychotic agents|
9970727|NCT01303367||non-antipsychotic agents|
10185038|NCT03749642|Experimental|trazodone/gabapentin 10/100 mg|One capsule, three times a day, for 8 weeks.
10185039|NCT03749642|Placebo Comparator|placebo|Two capsules, three times a day, for 8 weeks.
9970728|NCT01303393||Surgery for colorectal cancer|Patients that had surgery for colorectal cancer without receiving a stoma, and their next of kin.
9970729|NCT01303432|Experimental|Mobilee yogurt|Subjects eating daily on yogurt supplemented with Mobilee
9970730|NCT01303432|Placebo Comparator|Placebo yogurt|Subjects receiving daily a standard yogurt
9970731|NCT01303458|Experimental|Intervention arm|Study subjects will receive the Basic Needs Surveillance (BNS) intervention.
9970732|NCT01303458|No Intervention|Control arm|Study subjects in the control arm will receive the standard of care.
9970733|NCT01303471|Experimental|opioïd|Different levels of remifentanyl of each group during nociceptive stimulation
9970734|NCT01303484|Placebo Comparator|MDn|Maltodextrin
9970735|NCT01303484|Active Comparator|B-GOS|Prebiotic
9970736|NCT01303497|Other|Arm A : Paclitaxel|administration of paclitaxel drug during cycle of 28 days (6 cycles Max) + blood sample on day 1, 8, 15, 29 and 57
9970737|NCT01303497|Other|Arm B : Paclitaxel + Bevacizumab|"administration of paclitaxel drug during per cycle of 28 days (6 cycles Max) + Bevacizumab every two weeks during paclitaxel cycles then every 3 weeks during P cycles until disease progression or inacceptable toxicity~+ blood sample on day 1, 8, 15, 29 and 57"
9970738|NCT01303536|Experimental|obsessive compulsive disorder|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
9970739|NCT01303549|Experimental|Anidulafungin|Anidulafungin IV once a day: initial dose 200 mg/day, following doses 100 mg/day.
9970740|NCT01303549|Active Comparator|Liposomal Amphotericin B|Liposomal amphotericin B once a day: 3 mg/kg/day
9970741|NCT01303562|Placebo Comparator|Placebo muffin made with no whole grains|
9970742|NCT01303562|Active Comparator|Test muffin made with whole oats|
9970743|NCT01303562|Active Comparator|Test muffin made with whole barley|
9970744|NCT01303575|Experimental|HIV, STI, and Pregnancy Prevention Curriculum|
9970745|NCT01303575|Active Comparator|Control curricula: Science Education|No sexual health elements
10185040|NCT03749642|Active Comparator|Gabapentin|"according to the following scheduling dosage regimen:~100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);~300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);~400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);~300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2)."
10185041|NCT03749603|Experimental|TIBAY meter|Non-invasive measurement of red blood cell Zinc Protoporphyrin (ZnPP/haem ratio-µmol/mol haem) fluorescence in the microcirculation of the lower lip.
9970746|NCT01303588|No Intervention|Waiting Group|
9970747|NCT01303588|Active Comparator|Qigong|
9970748|NCT01303588|Active Comparator|Yoga|
9970749|NCT01303601|Experimental|olanzapine|
9970750|NCT01303601|Placebo Comparator|placebo|
9970751|NCT01303614|Active Comparator|Lidocaine-Prilocaine cream|
9970752|NCT01303614|Placebo Comparator|Placebo|purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
9970753|NCT01303640|Active Comparator|Biolimus-eluting stent|Biolimus-eluting stent
9970754|NCT01303640|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent
9970755|NCT01303666|Active Comparator|TI of the knee|
9970756|NCT01303666|Active Comparator|Intra-articular CSI|
9970757|NCT01303679|Active Comparator|paclitaxel-bevacizumab|Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
9970758|NCT01303679|Experimental|exemestane-bevacizumab|exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks
9970759|NCT01303692||A|Total of 250 prostate cancer patients receiving GnRH agonist
9970760|NCT01303692||B|Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
9970761|NCT01303705|Experimental|Cyclophosphamide - Cohort 1|Cyclophosphamide 300 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
9970762|NCT01303705|Experimental|Cyclophosphamide - Cohort 2|Cyclophosphamide 600 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
9970763|NCT01303705|Experimental|Cyclophosphamide - Cohort 3|Cyclophosphamide 900 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
9970764|NCT01303718|Experimental|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
9970765|NCT01303718|Active Comparator|Standard of Care|Usual care (no CardioFit System implant)
9970766|NCT01303731|Active Comparator|Standard dose Marcaine Spinal 0.5% Heavy|Standard group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml).
9970767|NCT01303731|Experimental|Minidose of Marcaine Spinal 0.5% Heavy|Minidose group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
9970768|NCT01303757|Experimental|Low glycemic load diet|Low glycemic load diet
9970769|NCT01303757|Active Comparator|Low fat diet|Low fat diet
9970770|NCT01303770|Experimental|Cognitive intervention group|Cognitive rehabilitation program designed to be tested in this study
9970771|NCT01303770|Active Comparator|Control group|
9970772|NCT01303796|Experimental|Sapacitabine-decitabine alternating|Arm A sapacitabine administered in alternating cycles with decitabine
9970773|NCT01303796|Active Comparator|Decitabine|Arm C Decitabine
9977071|NCT01357902|Experimental|Lamictal|Chinese healthy male subjects were randomized to receive single dose of either 5 mg lamotrigine dispersible/chewable tablets or 25mg compressed/standard tablets.
9977072|NCT01357928||Healthy Volunteers|
10145420|NCT04146987|Active Comparator|Open rotator cuff repair|Patients will be positioned in a beach chair position with the affected limb pending off the table, allowing manipulation and full range of motion range. After asepsis, antisepsis and placement of sterile surgical fields, anterolateral incision will be made in the shoulder in question; the deltoid muscle belly will be gently divided along its fibers until exposure of the subdeltoid / subacromial bursa, which will be partially excised for exposure of the subacromial space and rotator cuff tendons. After mobilization and release of the ruptured tendons and debridement of the rotator cuff footprint, the tendon repair to the bone will be performed using 5.5m metal anchors, according to the preference and technique chosen by the surgeon. In all cases, the release of the coracoacromial ligament and acromioplasty will be performed.
10145421|NCT04146987|Active Comparator|Arthroscopic rotator cuff repair|The patients will be positioned in lateral decubitus position, with the arm to be operated attached to a skin traction device, which trough a traction post and 07 kg, will maintain the shoulder in the following position: abduction of 30 to 60 and flexion of 20 to 30 degrees. After asepsis, antisepsis and placement of impermeable sterile surgical fields, a posterolateral incision will be made in the shoulder for optic introduction, with a 50 mmHg pressure pump and a 0.90 flow, and inspection of the GU joint. After joint inspection, the optic will be introduced into the subacromial space with detachment of the subacromial and subdeltoid. Using shaver blades, partial bursectomy will be performed as well as debridement of the rotator cuff footprint. The tendon will then be reinserted to the bone using metallic 5.5mm anchors. After tendon repair, the coracoacromomial ligament will be released, as well as acromioplasty.
10145422|NCT04147156|Active Comparator|Epley's Maneuver|Treatment of posterior canal BPPV with Epley's maneuver in the ROTUNDUM-chair.
10145423|NCT04147156|Experimental|Semont Maneuver|Treatment of posterior canal BPPV with the Semont maneuver in the ROTUNDUM-chair.
10145424|NCT04147156|Active Comparator|360 degree vertical rotation|Treatment of posterior canal BPPV with a 360 degree vertical rotation in the ROTUNDUM-chair.
10145425|NCT04147169||Dying patients|Dying patients admitted to the Intensive Care Unit who are approaching end-of-life.
10145426|NCT04146818|Experimental|Adapted Tango Dancing arm|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months)
10145427|NCT04146818|Placebo Comparator|Control arm|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
10145428|NCT04146883|Experimental|Post procedural antibiotics treatment|This group was treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin) and post procedural oral prophylactic antibiotics
10145429|NCT04146883|No Intervention|Pre procedural antibiotics treatment only|This group was only treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin).
10145430|NCT04146766|Experimental|eHealth|Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
10145431|NCT04146766|Experimental|wait list control|wait list control for 3 months and then Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
10145432|NCT04146779|Experimental|Video and Written Yoga Instruction|Videos and written instructions on Hatha yoga will be provided
10145433|NCT04146779|Experimental|Video, Written Yoga Instruction Plus Guided Yoga Sessions|Videos and written instructions on Hatha yoga and instructor guided session on Hatha yoga will be provided
10145434|NCT04147117|Experimental|Pessary Group|"A pessary certified is inserted through the vagina with the woman in recumbent position and is placed around the cervix.~Correct placement of the pessary is assessed by ultrasound. Patients on the pessary group are specially awarded about adverse symptoms and the need of immediate report in case of pain, bleeding and symptomatic contractions.~The pessary is not removed when symptoms of infection occur after pessary insertion, but appropriate treatment is given.~The pessary is removed at 37 weeks of pregnancy. Indications for pessary removal before 37 weeks are: active vaginal bleeding, premature labor not responding to tocolysis or severe patient discomfort."
10145435|NCT04147117|No Intervention|Control group|Current management for the follow-up of these women in the PBPC.
10145436|NCT04146714|Experimental|Substance use screening|Participants complete a substance use questionnaire (=intervention).
10145437|NCT04146714|Active Comparator|Physical activity screening|Participants complete a physical activity questionnaire (=control).
10145438|NCT04147078|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times
10145439|NCT04146792|Experimental|body acceptance program|
10145440|NCT04146792|Active Comparator|writing creativity program|
10145441|NCT04146948||COPD group|No intervention 40 years or older, clinical diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease stages I to IV)
10145442|NCT04146948||healthy group|40 years or older, not with the clinical diagnosis of COPD
10145443|NCT04147416|Experimental|HSK3486|
10145444|NCT04147416|Active Comparator|Propofol|
10185042|NCT03749590|Experimental|Magnesium|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate)."
10145445|NCT04146740|Experimental|Structured Exercise Group|"Structured Exercise Group will receive medical and dietary interventions like insulin plus structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min The combination of Stabilization exercise (10 repetitions) and PFM training ( 20 repetitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repeatitions) alongwith deep breathing exercises.~Life style modification with postural guidance and back care would also be followed.~Exercise dosage would be twice a week for 05 weeks while exercise duration will be 45 to 50 min session under Physio supervision and home plan of 10 min exercise daily. Total 150 min per week. Data will be recorded at baseline then after treatment of 5 weeks."
10145446|NCT04146740|Active Comparator|Control Group|Control Group will receive no structured exercise regime only the group will be receiving medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist due to ethical concerns and their outcomes will be observed at the baseline and then after 05 weeks.
10145447|NCT04146727||ICU Duration|The total study duration is determined by their length of stay in the ICU.
10145448|NCT04146727||Transplant through 1 month at Home|Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.
10145449|NCT04146857|Placebo Comparator|Normoxia|20.9% oxygen
10145450|NCT04146857|Active Comparator|Hypoxia 1|15.0% oxygen
10145451|NCT04146857|Active Comparator|Hypoxia 2|12.8% oxygen
10145452|NCT04147065|Experimental|7-day triple therapy and 7-day bismuth quadruple therapy|7-day triple therapy is consisted of proton pump inhibitor (PPI), amoxicillin and clarithromycin for seven days 7-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for seven days
10145453|NCT04147065|Active Comparator|14-day triple therapy and 14-day bismuth quadruple therapy|14-day triple therapy is consisted of PPI, amoxicillin and clarithromycin for fourteen days 14-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for fourteen days
10145454|NCT04146701||Acute heart failure|All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
10145455|NCT04146701||STEMI|All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
10145456|NCT04146701||NSTEMI|All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
10145457|NCT04146701||Ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
10145458|NCT04146701||Non-ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
10145459|NCT04146701||Sepsis|All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
10145460|NCT04146701||Healthy controls|Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
10145461|NCT04146688|Active Comparator|Patients with neurodegenerative disease|Patients with neurodegenerative disease (AD or related disease)
10145462|NCT04146688|Active Comparator|People with no neuropathological disease|
10145463|NCT04146831|Experimental|Sintilimab|Sintilimab is administered in this arm.
10145464|NCT04146805|Experimental|Part 1SAD/Part 2 MAD:Active Treatment(BLD-0409)|For each cohort in both study parts, 6 subjects will be randomized to active (BLD-0409). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s)
10145465|NCT04146805|Placebo Comparator|Part 1SAD/Part 2 MAD:Control(Matched Placebo)|For each cohort in both study parts, 2 subjects will be randomized to control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
10145466|NCT04146454|Experimental|Smartphone-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with a smartphone-based wearable telerehabilitation system.
10145467|NCT04146454|No Intervention|Paper-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with typical paper-based instructions.
10145468|NCT04146285|Experimental|BAT4406F|
10145469|NCT04146311|Active Comparator|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) is injected into the left infrapatellar fat pad.
10145470|NCT04146311|Placebo Comparator|Isotonic saline|A bolus injection (0.25 ml) of isotonic saline (0.9 %) is injected into the left infrapatellar fat pad.
10145471|NCT04146311|Experimental|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
10145472|NCT04146636|Other|Diagnostic Test: e-LIFT|only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
10145473|NCT04146610|Experimental|Dp303c|Multiple dose grouping
10145474|NCT04146623|Placebo Comparator|Normal Saline Placebo|Saline (0.9%)
10145475|NCT04146623|Experimental|CodaVax-H1N1|Live-attenuated influenza vaccine
10145476|NCT04146415|Experimental|Cardiac amyloidosis patients|
10145477|NCT04146675|Experimental|TRICOT JERSEY VANISE DOUBLE FACE|
10145478|NCT04146675|Placebo Comparator|TRICOT JERSEY SIMPLE|
10185043|NCT03749590|Placebo Comparator|Placebo (NaCl 0,9%)|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~To each infusion 10 ml NaCl 0.9% (Placebo) will be added ."
9516833|NCT03311828|Experimental|Diagnostic (Copper 64Cu-DOTA-daratumumab, PET)|Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
9516834|NCT03311802||1|
9970774|NCT01303809|Active Comparator|ERAS|The perioperative management of the patients in this arm will be according to a fast-track protocol designed by the investigators. The preoperative component of this program is the same as routine practice. Intraoperative and postoperative components which are different to routine practice are as described in the intervention section. This protocol is based on current literature regarding Enhanced Recovery After Surgery (ERAS).
9970775|NCT01303809|No Intervention|non ERAS|The perioperative management of patients in this arm will be according to routine practice currently implemented at our institution.
9970776|NCT01303822|Experimental|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
9970777|NCT01303848||Healthy probands|Healthy probands, age between 18 and 40 years
9970778|NCT01303874|Experimental|Combination Therapy|Methotrexate & Etanercept
9970779|NCT01303874|Placebo Comparator|Single-agent therapy|Methotrexate (MTX)
9970780|NCT01303887|Active Comparator|R-CVP|Repeated every 21 days for up to 8 cycles with response assessment after 4 cycles. Responders (PR/CR) after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
9970781|NCT01303887|Experimental|R-FC|Repeated every 21 days for 4 cycles. Responders (PR/CR) after 4 cycles will receive 4 further cycles of Rituximab only. Responders after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
9970782|NCT01303913||Walking desaturation group|COPD patients that at the end of 6MWT have SO2 nadir <88-90%
9970783|NCT01303913||Walking No-desaturation group|COPD patients that at the end of 6MWT have SO2 nadir >88-90%
9970784|NCT01303926|Active Comparator|Cisplatin and Pemetrexed|
9970785|NCT01303926|Active Comparator|Carboplatin paclitaxel bevacizumab|
9970786|NCT01303952|Experimental|Eculizumab|
9970787|NCT01303978|Experimental|APD421 starting dose|
9970788|NCT01303991|Experimental|Hexvix PDT|
9970789|NCT01304004|Experimental|Experimental drinking yogurt|
9970790|NCT01304004|Placebo Comparator|Placebo drinking yogurt|
9970791|NCT01304017|Experimental|Virtual Reality Therapy|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing.
9970792|NCT01304017|Active Comparator|Traditional Therapy|The traditional therapy will include exercises for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
9970793|NCT01304030|Experimental|Experimental Group|The experimental group receives Empathy Training. The control Group receives residency training as usual
9970794|NCT01304030|Active Comparator|Control Group|The control group receives residency training as usual
9970795|NCT01304056||Critically ill patients|Patients that are treated in intensive care unit and given ventilatory therapy.
9970796|NCT01304056||Interventional volunteer group|Healthy volunteers
9970797|NCT01304069|Placebo Comparator|Placebo|
9970798|NCT01304069|Active Comparator|Selecoxib|
9970799|NCT01304069|Active Comparator|Etoricoxib|
9970800|NCT01304095|Active Comparator|Ranolazine|Ranolazine in addition to standard of care medical therapy
9970801|NCT01304095|No Intervention|Standard of Care|
9970802|NCT01304108|Experimental|Order Set|"Insertion of VTE-P Order Set tollgate in all active admission and transfer orders."
9970803|NCT01304108|Experimental|Clinical Decision Support Pop-up|Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
9970804|NCT01304108|Active Comparator|Usual Care|Usual care, without the experimental additions
9970805|NCT01304121|Experimental|Bioactive glass|Resorbable bioactive glass granules
9970806|NCT01304134|Experimental|Oxycodone i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
9970807|NCT01304134|Active Comparator|Morphine i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
9970808|NCT01304160|Experimental|strereotactic radiotherapy, gemcitabine|stereotactic radiotherapy (30Gray in 5 fractions) followed by gemcitabine
9970809|NCT01304186|Experimental|Tailored Information|Participants in this arm receive the computer-based tailored information application that focuses on improving health literacy related to treatment of HIV infection.
9970810|NCT01304199||Adult Cancer Survivors|"Intervention:~Behavioural:~Questionnaires for patient/family caregiver interview"
9970811|NCT01304212|Active Comparator|femoral block|
9970812|NCT01304212|Experimental|local infiltration + femoral nerve block|Combination of local infiltration with drugs and femoral nerve block
9970813|NCT01304212|Active Comparator|several drugs local infiltration|
9970814|NCT01304225|Active Comparator|100ms single-shot|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
9970815|NCT01304225|Experimental|20ms multiple-shot|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
9970816|NCT01304225|Experimental|20ms multiple-shot, barely visible|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
9970817|NCT01304251|Active Comparator|Short-term fasting|short term fasting (i.e. 24 hours before and 24 hours after administration of chemotherapy) in 20 breast cancer patients
9970818|NCT01304251|Placebo Comparator|Healthy nutrition|20 breast cancer patients eat according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy.
9970819|NCT01304264||combination topical glaucoma treatment|timolol or dorzolamide add on latanoprost monotherapy
9970820|NCT01304290|No Intervention|Control|
9970821|NCT01304290|Experimental|Glucose/Insulin Clamp|
9970822|NCT01304303|Experimental|SPARC1023 I|
9970823|NCT01304303|Experimental|SPARC1023 II|
9970824|NCT01304316|Experimental|Kovacaine Nasal Spray|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 6 sprays of 0.1 mL - total of 18 mg tetracaine HCl and 0.3 mg oxymetazoline HCl followed by 12 sprays of 0.1 mL - total of 36 mg tetracaine HCl and 0.6 mg oxymetazoline HCl
9970825|NCT01304342|Active Comparator|Remifentanil|Remifentanil 1 microgram/kg/h along with propofol infusion
9970826|NCT01304342|Active Comparator|Fentanyl|Fentanyl 200 micrograms intranasally
9970827|NCT01304342|Placebo Comparator|Normal saline|Normal saline intravenously and intranasally
9977073|NCT01357941||Prior VTE minor transient risk factor|Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
9977074|NCT01357941||Prior VTE major transient risk factor|Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
9977075|NCT01357954|Experimental|Targeted Training|
9977076|NCT01357954|Other|Control|
9977077|NCT01357967|Experimental|Seroquel XR adjunctive|"The quetiapine XR adjunct group will be titrated up to 300mg. Initial dosing will begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments will be able to be made upwards or downwards within the recommended dose range of 50mg to 300mg depending upon the clinical response and tolerance of the patient. Seroquel XR will be administered daily in the evening.~The dosage of SSRIs will be maintained as low (es-citalopram 5mg, paxil CR 6.25mg, fluoxetine 10mg, and sertraline 25mg)."
9977078|NCT01357967|Active Comparator|SSRI monotherapy|active comparator
9977079|NCT01357993|Experimental|001|JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
9977080|NCT01358006|Experimental|001|JNJ-40411813 Cohort 1: Type=2 to 3 unit=mg number=200 to 300 form=capsule route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.,JNJ-40411813 Cohort 2: Type=up to 7 unit=mg number=up to 700 mg form=capsule route=oral use. Capsule(s) taken in the fed state.
9977081|NCT01358019|Experimental|LY2523355|
9977082|NCT01358032|Experimental|Cognitive behavioral program|an in-home cognitive behavioral program on managing concerns about falling and associated activity avoidance in frail community-dwelling older people facilitated by trained community nurses.
9977083|NCT01358032|No Intervention|Control group|no program, only care as usual
9977084|NCT01358045|Active Comparator|Solaraze|
9977085|NCT01358045|Active Comparator|Solaraze + Silkis|
9977086|NCT01358045|Active Comparator|Silkis|
9977087|NCT01358045|No Intervention|No treatment|
9977088|NCT01358058|Experimental|Proton radiation therapy|Single arm study delivering fractionated proton therapy over 6 week (54-59.4 Gy(RBE))
9977089|NCT01358071|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
9977090|NCT01358071|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
9977091|NCT01358084|Experimental|Arm A: NGR-hTNF + Best Supportive Care|NGR-hTNF + Best Supportive Care
9977092|NCT01358084|Placebo Comparator|Arm B: Placebo + Best Supportive Care|Placebo + Best Supportive Care
9977093|NCT01358097||Patients with HPV positive tumors|
9977094|NCT01358097||Patients with HPV negative tumors|
9977095|NCT01358097||Control|
9977096|NCT01358110|Experimental|Early palliative care consultation|Early palliative care consultation for ED patients with advanced cancer.
9977097|NCT01358110|Other|Care as usual|Care as usual, may or may not receive palliative care consultation
9977098|NCT01358136||Hemithyroidectomy|Patients with benign nontoxic goiter who have an indication for hemithyroidectomy
9977099|NCT01358149|Placebo Comparator|placebo|cocoa-based food 1
9977100|NCT01358149|Active Comparator|Treatment 1|cocoa-based food 2
9977101|NCT01358162|Experimental|SQ109|300 mg of SQ109, orally, given daily for 14 consecutive days
9977102|NCT01358162|Placebo Comparator|Placebo|Placebo given orally, daily for 14 consecutive days
9977103|NCT01358188||Gaucher disease group|Subjects will include individuals with GD
9977104|NCT01358188||Control group|Controls will include healthy individuals and individuals with primary immune dysfunction
9977105|NCT01358214||Patients treated with a surgical mesh|This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected
9977106|NCT01358214||Intended to be treated with a mesh|This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.
9977107|NCT01358214||Non-symptomatic Population|This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.
9977108|NCT01358227|Experimental|PR104|
9977109|NCT01358240|Experimental|Econazole Nitrate Foam 1%|Study medication
9977110|NCT01358240|Placebo Comparator|Vehicle Foam|Placebo medication
9977111|NCT01358240|Active Comparator|Econazole Nitrate Cream 1%|Econazole Nitrate Cream 1%
9977112|NCT01358240|Sham Comparator|Placebo Cream|Placebo Cream
9977113|NCT01358253|Active Comparator|HyperCVAD|"Consolidation:~HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9."
9977114|NCT01358253|Experimental|R-HyperCVAD|"Consolidation:~R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12."
9977115|NCT01358279|Experimental|migraine|
9977116|NCT01358292|Experimental|Semi-extended surgical technique|The experimental technique for implanting an intramedullary tibia nail is with the knee in 10-20 degrees of flexion.
9977117|NCT01358292|Active Comparator|Standard Surgical Technique|The standard surgical technique in intramedullary tibia nailing is with the knee in almost 90 degrees of flexion.
9977118|NCT01358305|Active Comparator|Whey Protein Isolate|
10145479|NCT04146220|Experimental|Low dose group|Prednisolone 0.5 mg/kg/day
10145480|NCT04146220|Active Comparator|High dose group|Prednisolone 1 mg/kg/day
10145481|NCT04146402|Experimental|SCT-I10A + Chemotherapy|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
10145482|NCT04146402|Active Comparator|Placebo + Chemotherapy|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
10145483|NCT04146168||VenaSeal|Complete closure of previously treated veins will be assessed via ultrasound
10145484|NCT04146480|Experimental|Cardiac amyloidosis patients|
10145485|NCT04146376||Non-Corrector|Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
10145486|NCT04146376||Corrector|Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
10145487|NCT04146181|Experimental|SCT-I10A|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
10145488|NCT04146207|Experimental|combination therapy|"Experimental: combination therapy There is only 1 arm. Combination therapy arm includes SHR0302 and Prednisone~Prednisone 1mg/kg/d po，At the same time give SHR0302 QDpo；"
10145489|NCT04146506||Male|Static Muscle stretching exercises of the knee flexors
10145490|NCT04146506||Female|Static Muscle stretching exercises of the knee flexors
10145491|NCT04146337|Experimental|Fecal microbiota transplantation (FMT)|FMT regimen: Patients will be given capsulized FMT 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
10145492|NCT04146337|No Intervention|Control|Routine follow-up
10145493|NCT04146363|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W."
10145494|NCT04146363|Experimental|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W."
9826132|NCT02409329|Experimental|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
10145495|NCT04146363|Experimental|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebrikizumab injection."
10145496|NCT04146363|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):~Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
10145497|NCT04146493||Vascular surgery group|Patients which are given unfractionated heparin during their vascular surgery.
10145498|NCT04146493||Thromboprophylaxis group|Patients which are given low molecular heparins as a thrombosprofylax after major surgery
10145499|NCT04146493||Cardiothoracic surgery|Patients which are given high dose unfractionated heparin during their open heart surgey
10145500|NCT04146428|Experimental|clinician-mediated JASPER|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
10145501|NCT04146428|Experimental|parent-mediated JASPER|This group will consist of the therapist assisting the parent implement JASPER on the child twice a week.
10145502|NCT04146532|Placebo Comparator|Placebo|Single dose of a 500mg placebo tablet.
10145503|NCT04146532|Active Comparator|Aspirin 500MG|Single dose of a 500 mg aspirin tablet.
10145504|NCT04146350|No Intervention|Control|
10145505|NCT04146350|Active Comparator|PPV+/-Cat|
10145506|NCT04146350|Active Comparator|PPV+/-Cat+Gas|
10145507|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Gas|
10145508|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Oil|
10145509|NCT04146350|Active Comparator|PSR|
10145510|NCT04146350|Active Comparator|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|
10145511|NCT04146350|Active Comparator|Gas|
10145512|NCT04146558|Experimental|Internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
10145513|NCT04146558|Active Comparator|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
10145514|NCT04146584|Experimental|Sofwave Treatment|In this arm (single) patients would be treated twice with Sofwave on the face and/or submental and neck.
10145515|NCT04146519|Experimental|Study group|Autologous MMSC
10145516|NCT04146519|Placebo Comparator|control group|
10145517|NCT04146597|Experimental|Neural mobilization|The intervention is always performed after Jiu Jitsu practice and at the training site itself. Neural mobilization consisted of the execution of a sciatic nerve sliding technique in three sets of one minute for each lower limb with an interval of one minute between sets, twice a week, for five consecutive weeks, totaling 10 interventions (Garber et al., 2011). The order of the first lower limb to be submitted to the intervention is not standardized, being at the discretion of the subjects.
9826133|NCT02409329|Active Comparator|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
9970828|NCT01304355||Controls|Healthy Control Subjects
9970829|NCT01304355||IBS Group|Subjects diagnosed with IBS
9970830|NCT01304368|Active Comparator|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
9970831|NCT01304368|No Intervention|Waiting list|Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
9970832|NCT01304381|Experimental|Integrated care|Multidisciplinary approach and collaboration between specialist palliative and heart failure (HF) caregivers in a shared structured person-centred and identity-promoting homecare
9970833|NCT01304381|No Intervention|control|Usual care is performed for the control group
9528309|NCT03211897||Haloperidol 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
9826134|NCT02409459|Experimental|Injectafer|15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
9970834|NCT01304394|Other|parenteral nutrition solution|
9970835|NCT01304433||1|hydroxyethyl starch (HES) 130/0.42
10145518|NCT04146233|Other|Orange Juice without pulp|Drink orange juice without pulp and have gastric ultrasound performed 2 hours later
10145519|NCT04146233|Other|Orange juice with pulp|Drink orange juice with pulp and have gastric ultrasound performed 2 hours later
10145520|NCT04146155|Experimental|Liraglutide+standard-of-care treatment|Intervention: Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies.
10145521|NCT04146155|Active Comparator|standard-of-care treatment|standard-of-care treatment with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
9970836|NCT01304446|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
9970837|NCT01304472|Experimental|Prasugrel|Prasugrel 10mg per day
9970838|NCT01304472|Active Comparator|Clopidogrel|
9970839|NCT01304485|Experimental|Sodium Acetate C11 PET Imaging|
9970840|NCT01304537|Experimental|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 40 mg/kg throughout the study.
9977119|NCT01358305|Experimental|Protein Blend (soy, whey and casein)|
10145522|NCT04146259||group A|Control
10145523|NCT04146259||Group B|Post-surgical hypoparathyroidism
10145524|NCT04146246||Adult|Adults aged 18 years or older. Collect whole blood sample via venous/arterial puncture and, where possible, finger stick.
10145525|NCT04146246||Neonate|Neonates gestational age >35 weeks or older. Collect whole blood sample via heel prick or, where an in dwelling line already exists, via arterial/umbilical draw.
10145526|NCT04145973||recurrence and metastasis|breast cancer patients with recurrence and metastasis after surgery
10145527|NCT04145856|Placebo Comparator|Placebo|- Control arm
10145528|NCT04145856|Experimental|Probiotic|- Arm with active probiotic alone
10145529|NCT04145856|Experimental|Probiotic + Antispasmodic/Antifoam|- Arm with active probiotic combined to antispasmodic/antifoam drug
10145530|NCT04145869|Experimental|Fluorescent cholangiography|Intraoperative fluorescent cholangiography using an intravenous injection of 5mg Indocyanine green
10145531|NCT04145869|Active Comparator|X-ray cholangiography|Intraoperative X-ray cholangiography using an intraductal (cystic duct) injection of Iohexol
10145532|NCT04145947||triple negative breast cancer|triple negative breast cancer patients with age ≤ 60 years old
10145533|NCT04145752|Experimental|Nurse-led femoral nerve block|"Trained nurses in ED provide ultrasound guided single-shot femoral nerve block shortly after (at arrival emergency department) the patient is diagnosed with a hip fracture.~Drug: Ropivacaine 3 mg/kg, single-shot"
10145534|NCT04145752|Active Comparator|Standard of care|Nurses do not provide ultrasound guided single-shot FNB and the patient follows the standard of care course.
10145535|NCT04146038|Experimental|Treatment (salsalate, decitabine, azacitidine, venetoclax)|"CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.~CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
10145536|NCT04146129|Experimental|CDX-0159|Eligible subjects will receive a single dose of CDX-0159
10145537|NCT04146129|Placebo Comparator|Normal saline|Subjects assigned to receive placebo will receive a single dose of normal saline
10145538|NCT04145999|Experimental|PRP + PBM group|This group will receive both PRP application and photobiomodulation.
9826135|NCT02409459|Placebo Comparator|Placebo|15 cc of Normal Saline IV push at 2 ml/minute
10145539|NCT04145999|Experimental|PRP + placebo PBM|This group will receive PRP application and placebo photobiomodulation.
10145540|NCT04145999|Experimental|PBM + placebo PRP|This group will receive placebo PRP application with a saline solution and active photobiomodulation.
10145541|NCT04145986||young ladies|Young ladies≤ 35 years old.
10145542|NCT04146116|Experimental|Nasal povidone-iodine|Intranasal povidone-iodine (PDI PROFEND) will be applied to the patients' noses before orthopedic trauma surgery and after surgery. This intranasal povidone-iodine was developed under the Tentative Final Monograph for Health-Care Antiseptic Drug Products 21 CFR Parts 333 and 369 (Docket # 75N-183H), Federal Register Volume 59, Number 116, Friday, June 17, 1994, Proposed Rules. However, the product need not be controlled like a pharmaceutical drug. The product may be stored and controlled similarly to an iodine or alcohol skin preparation product.
10145543|NCT04146012|Active Comparator|Early Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation.
10145544|NCT04146012|Active Comparator|Normal Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU.
10145545|NCT04146025|Experimental|Nature Coach Intervention|The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.
10145546|NCT04146025|No Intervention|Control Group|Education only
10145547|NCT04145960||Lymph node metastasis|Axillary lymph node metastasis ≥ 4 Lymph nodes
10145548|NCT04146103|Experimental|Experimental arm|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally, for 3 months.
10145549|NCT04145778||Patient|
10145550|NCT04145778||Control|
10145551|NCT04146090|Active Comparator|Low-pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
10145552|NCT04146090|Placebo Comparator|Standard pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
10145553|NCT04145882|Active Comparator|No additional osteotomy|
10145554|NCT04145882|Experimental|varisation osteotomy addition|
10145555|NCT04145882|Experimental|supination osteotomy addition|
10145556|NCT04145882|Experimental|both (varisation + supination) osteotomies addition.|
10145557|NCT04145596|Active Comparator|Compensated Chronic Liver Disease (Child-Pugh A)|
10145558|NCT04145596|Active Comparator|Decompensated Chronic Liver Disease (Child-Pugh B)|
10145559|NCT04145596|Active Comparator|healthy volunteers（Normal liver functions）|
10145560|NCT04145609|Experimental|Intensified care|Experimental: Multidisciplinary team (MDT) care + Acute kidney disease (AKD) clinic Participants randomized to this arm will receive multidisciplinary team (MDT) care by a specialized medical team which is composed of nephrologist, pharmacist and dietitian. Besides intensified care, participants of this arm receive evaluation of biochemical and physiological renal function more frequently. In order to provide seamless care of this group, post-discharge acute kidney disease (AKD) clinic will also be arranged for them. Clinic visits consist of evaluation of renal function, reconciliation of medication and steering necessity of renal replacement therapy.
10145561|NCT04145609|No Intervention|Usual care|No intervention: Usual care Participants randomized to this arm will receive usual care according to the medical decisions of principal care physician. Nephrologist consultation and nephrology outpatient clinic follow-up will be allowed. However, this group of patient will not have access to MDT care and AKD clinic.
10145562|NCT04145726||Patients undergoing esophageal resection|All patients undergoing esophageal resection will be included and tested if frail or non-frail. Which means there is no intervention
10145563|NCT04145908|Active Comparator|preperitoneal mesh|patients underwent preperitoneal mesh mesh placement
10145564|NCT04145908|Active Comparator|onlay mesh|patients underwent preperitoneal mesh mesh placement
10145565|NCT04145583|Experimental|HSK3486|0.4 mg/kg
10145566|NCT04145583|Experimental|voriconazole , HSK3486|400 or 200 mg; 0.4 mg/kg
10145567|NCT04145570|Experimental|Erlotinib HCl 150 mg|Crossover
10145568|NCT04145570|Active Comparator|Tarceva® 150 mg|Crossover
10145569|NCT04145791|No Intervention|No Ice|Patients will receive standard postoperative pain control methods as defined by the participating institution
10145570|NCT04145791|Experimental|Ice|Patients will receive ice packs to the abdomen, in addition to standard postoperative pain control methods as defined by the participating institution
10145571|NCT04145934|Experimental|training|The subjects receive the ADSTEP intervention
10145572|NCT04145934|No Intervention|waitlist|These subjects receive two brochures on fall prevention and walking aid selection, and a letter is sent to their care provider informing them that the subject has reported falling. Subjects in this group will be offered the ADSTEP intervention once their study participation is complete.
10145573|NCT04145817|Experimental|genetic counselling|Genetic counselling (PRS for risk estimation) and questionnaires in the participating Cancer Genetic Clinics for healthy woman relative of a person first tested in the family (index case) who received a positive genetic test result or a negative non-informative test result
10145574|NCT04145830|Experimental|Ultrasound Cyclo Plasty (UCP)|Ultrasound Cyclo Plasty (UCP) using focused ultrasound
9970841|NCT01304537|Experimental|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 60 mg/kg throughout the study.
10145575|NCT04145492|Active Comparator|Vitamin K2 group|15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.
10145576|NCT04145492|Active Comparator|Cholecalciferol group|15 patients will take 10 ug of vitamin inactive vitamin D daily in addition to the standard therapy for 4 months.
10145577|NCT04145492|Active Comparator|Vitamin K2 and Cholecalciferol group|15 patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D to daily in addition to the standard therapy for 4 months.
10145578|NCT04145492|No Intervention|Control group|15 patients will take the standard therapy.
10145579|NCT04145921|Experimental|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
10145580|NCT04145921|Active Comparator|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
10145581|NCT04145687|Active Comparator|Metformin|
10145582|NCT04145687|Placebo Comparator|Placebo|
10145583|NCT04145557|Placebo Comparator|skaling root planing|
10145584|NCT04145557|Active Comparator|skaling root planing and diode laser|
10145585|NCT04145544|Experimental|Treatment arm|"Procedure will be performed under general anaesthesia. The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use the ArtiFascia® patch. Implantation of the ArtiFascia® will be according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Detailed instructions are in the instructions for use.~Post operation the subject will stay at the hospital according to site standards and physician discretion."
10145586|NCT04145544|Active Comparator|Control|"Same procedure as for the treatment arm but using a commercial suturable dural substitute.~Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use."
10145587|NCT04145739|Experimental|Mastectomy group|Patients undergoing mastectomy
10145588|NCT04145739|Experimental|Quadrantectomy group|Patients undergoing quadrantectomy
10145589|NCT04145518|Active Comparator|Naproxen/Placebo Crossover|"Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill. Randomization with a block size only known by the statistician, will be programmed to be allocated out of REDcap.~Our clinical research pharmacy will provide naproxen and an identical looking placebo in containers with codes only known to the statistician to provide a double-blinded experimental design.~On a subsequent episode of menstrual pain (1-2 months later), participants will receive the opposite treatment and undergo the exact same assessments."
10145590|NCT04145518|Placebo Comparator|Placebo/Naproxen Crossover|Participants will receive placebo first in this arm.
10145591|NCT04145661|Experimental|DR group|Participants who have cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
10145592|NCT04145661|Experimental|No DR group|Participants who have no cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
10145593|NCT04145713|Experimental|Probiotic group|
10145594|NCT04145713|Placebo Comparator|Placebo group|
10145595|NCT04145674|Active Comparator|25 mg d-Methadone|25 mg d-Methadone Tablet and one 0 mg Placebo Tablet
10145596|NCT04145674|Experimental|50 mg d-Methadone|2 x 25 mg d-Methadone Tablet
10145597|NCT04145674|Placebo Comparator|Placebo|2 x Non-active substance Tablet
10145598|NCT04145193|Active Comparator|Control Arm (mFOLFOX6)|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
10145599|NCT04145193|Experimental|Durvalumab|Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
10145600|NCT04145193|Experimental|Oleclumab|Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)
10145601|NCT04145193|Experimental|Monalizumab|Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)
10145602|NCT04145258|Other|WHO TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
10145603|NCT04145258|Other|WHO TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
10145604|NCT04145258|Other|Intensified TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
10145605|NCT04145258|Other|Intensified TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
10145606|NCT04145206||experimental group|the experimental group is characterized by the practice of flamenco dance
10145607|NCT04145206||control group|not practice of flamenco dance
10145608|NCT04145440|Experimental|MOR202|9 doses of MOR202 will be administered as an intravenous infusion over 6 treatment cycles at 28-days each. Dosing occurs weekly in cycle 1 (C1) and every four weeks in cycles 2-6.
10145609|NCT04145167||Medical Treatment|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication.
10145610|NCT04145167||Percutaneous intervention|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team.
10145611|NCT04145167||Surgical treatment|This group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision.
10145612|NCT04145310|Experimental|Arm A|
10145613|NCT04145310|Placebo Comparator|Arm B|
10145614|NCT04145102|No Intervention|negative control|restoration will applied without any treatment
10145615|NCT04145102|Experimental|hesperidine|hesperidine will be applied for remaining caries then restoration will be applied
10145616|NCT04145102|Experimental|propolis|propolis will be applied for remaining caries then restoration will be applied
10145617|NCT04145102|Experimental|silver diamine fluoride|silver diamine fluoride will be applied for remaining caries then restoration will be applied
10145618|NCT04145375|Experimental|Experimental: ZEN003694 in Combination with Enzalutamide|Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide
10145619|NCT04145180|Experimental|Manual Therapy|Manual Therapy-based intervention
9970842|NCT01304537|Experimental|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 80 mg/kg throughout the study.
9970843|NCT01304563|Active Comparator|IM15|15 mcg TIV 2010/2011 influenza vaccine delivered via intramuscular injection (control)
9970844|NCT01304563|Active Comparator|ID1|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
9970845|NCT01304563|Active Comparator|ID2|Higher low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
9970846|NCT01304563|Active Comparator|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device
9970847|NCT01304576|Experimental|patient with right parietal lesions|
9970848|NCT01304576|Active Comparator|patient with left parietal lesions|
9970849|NCT01304602|Experimental|Irinotecan + BKM120|Irinotecan + BKM120 at the assigned cohort dose level.
9970850|NCT01304615|Active Comparator|Web-Based|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a life skills training program. Life skills training topics include stress management, coping with change, time management, and thoughts and emotions in weight control.
9970851|NCT01304615|Experimental|Web-Based plus Culinary Training|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a hands-on culinary skills training program designed to increase food purchasing and meal self-preparation and consumption of meals low in energy density.
9970852|NCT01304628|Experimental|PL-3994 (4 escalating doses)|
9970853|NCT01304628|Placebo Comparator|Placebo|
9970854|NCT01304654||ALI/ARDS oncologic patients|Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
9970855|NCT01304719|Experimental|Computer Assisted home visitation|Home visitation with computer modules added
9970856|NCT01304719|Experimental|Home Visitation TAU|Home Visitation Treatment as Usual
9970857|NCT01304719|No Intervention|Community Referral|Community Referral
9970858|NCT01304745|Experimental|Physical traning in group|
9970859|NCT01304745|Experimental|Educational and counselling group|
9970860|NCT01304745|No Intervention|Control group|
9970861|NCT01304758|Experimental|ExAblate Treatment|
9970862|NCT01304771|Active Comparator|Synbiotic AKSB|Participants (healthy > 65 year old persons) will be randomized to take the synbiotic AKSB. All participants will also receive inactivated trivalent Influenza vaccine while being on the AKSB. We will assess safety of the AKSB in this setting. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus and probiotic strain enterococcus. We will also assess influenza vaccine response in patients on AKSB
9970863|NCT01304771|Placebo Comparator|Talc Placebo|Participants (healthy > 65 year old persons) will be randomized to take the placebo. All participants will also receive inactivated trivalent Influenza vaccine while being on the placebo. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus. We will also assess influenza vaccine response in patients on placebo.
9970864|NCT01304784|Experimental|Arm 1|"Regimen follows a 3-week treatment cycle.~Cisplatin 80mg/m2 given on day 1 by IV infusion over two hours every three weeks.~Capecitabine 1000 mg/m2 given orally twice daily for fourteen days each 3-week cycle.~Up to six 3-week cycles of Cisplatin and Capecitabine to be administered. Trastuzumab given as 8 mg/kg loading dose at week 1 over 90 minutes followed by 6 mg/kg every 3 weeks over 30-90 minutes.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Trastuzumab (every 3 weeks) and MM-111 (weekly) will continue until disease progression, unacceptable toxicity, or withdrawal of consent."
9970865|NCT01304784|Experimental|Arm 2|"Regiment follows a 4-week treatment cycle.~The following Lapatinib and Trastuzumab regimen will be given in combination with MM-111 in the following order:~Trastuzumab 4 mg/kg loading dose week 1 over 90 minutes~Followed by Trastuzumab 2 mg/kg weekly thereafter~Lapatinib 1000 mg by mouth (PO) daily~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
9970866|NCT01304784|Experimental|Arm 3|"Regimen follows a 4-week treatment cycle Paclitaxel dosing should begin first dose on cycle 1 day 1. Paclitaxel will be administered at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab will be administered via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
9970867|NCT01304784|Experimental|Arm 4|"4-week treatment cycle. Lapatinib given orally. Paclitaxel dosing on cycle 1 day 1. Paclitaxel given at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab given via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 given over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
9977120|NCT01358318|Placebo Comparator|Control|
9977121|NCT01358318|Experimental|Soy Protein|
9977122|NCT01358318|Experimental|Soy Fiber|
10145620|NCT04145180|No Intervention|Control|Patients waiting list
9977123|NCT01358318|Experimental|Soy Protein and Soy Fiber|
9977124|NCT01358344|Experimental|Standard Percentage|
9977125|NCT01358344|Experimental|High Percentage|
9977126|NCT01358396||HBA1c|
10145621|NCT04145089|Active Comparator|C-Mac intubation|Intubation with C-MAC video laryngoscopy
10145622|NCT04145089|Active Comparator|Glidescope intubation|Intubation with Glidescope video laryngoscopy
10145623|NCT04145245|Experimental|Intervention or group a|Diabetic neuropathy patients with antidiabetic therapy in addition with l-carnitine supplementation
10145624|NCT04145245|Placebo Comparator|Placebo or group b|Diabetic neuropathy patients with antidiabetic treatment in addition with placebo
10145625|NCT04145154|Experimental|Plasma|Subjects to whom platelet rich plasma is applied
10145626|NCT04145154|No Intervention|Advanced cure|Subjects to whom advanced healing is performed
10145627|NCT04145336|Active Comparator|5cm PDS group|All patients in this group receive 5cm 5-Fr PDS.
10145628|NCT04145336|Experimental|7cm PDS group|All patients in this group receive 7cm 5-Fr PDS.
10145629|NCT04145128|Experimental|AG-881|Participants will receive AG-881 10 mg, tablet orally, once in Period 1 followed by AG-881 50 mg, tablet orally, once in Period 2. Period 1 and Period 2 will be separated by a washout period of 20 days between doses.
10145630|NCT04145323|Experimental|ICG microangiography for necrotic tissue determination|During flap procedure, the study area of the patient will be imaged with a white light digital camera prior to a 5 mg dose of ICG as per FDA approved protocol for use of SPY device in microangiography. Following ICG injection, the study area will undergo fluorescence imaging using the SPY system to obtain microangiography perfusion data (baseline imaging - Standard of Care). During the standard postoperative evaluation (approximately 4 hours after baseline) and 24 hours after baseline, the study area will undergo repeat digital photography and fluorescence imaging using SPY for necrosis avid detection of ICG (Research only session). This evaluation with digital photography and fluorescence imaging will continue every 24 hours for the first 3 days after surgery or one day prior to discharge(Research only session).
10145631|NCT04145232||NSCLC|This cohort will consist of 30 patients with non-small cell lung cancer (NSCLC).
10185044|NCT03749577|Experimental|L-citrulline|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
10185045|NCT03749577|Experimental|Beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
10185046|NCT03749577|Placebo Comparator|L-citrulline placebo|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
10185047|NCT03749577|Placebo Comparator|Denitrated beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
10185048|NCT03749564|Experimental|SMT Only|All patients receive 2 SMT sessions in the first week.
10185049|NCT03749564|Experimental|SMT extended|All patients receive 2 SMT sessions in the first week. This arm also involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
10185050|NCT03749564|Experimental|SMT with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm receives 6 additional sessions of activation exercises."
10185051|NCT03749564|Experimental|SMT with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additional sessions of mobilizing exercise."
10185052|NCT03749564|Experimental|SMT with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additions sessions including both activation and mobilizing exercises."
10185053|NCT03749564|Experimental|SMT extended with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and mobilizing exercises."
10185054|NCT03749564|Experimental|SMT extended with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and activation exercises."
10185055|NCT03749564|Experimental|SMT extended with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including SMT, activation and mobilizing exercises."
10185056|NCT03749551||Participants|diagnostic test - patients serving as their own controls
9826136|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
10185057|NCT03749538|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: three times, once per day.
10185058|NCT03749538|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session.
10185059|NCT03749525|Placebo Comparator|placebo group|5% GS solution
10185060|NCT03749525|Active Comparator|control group|shenfu injection
10185061|NCT03749512||Observational Group|Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
10185062|NCT03749486|Experimental|ArcScan|High resolution immersion ultrasound measurement before Cataract surgery
10185063|NCT03749473|Active Comparator|Control|Participants receive a daily message with their step count on the prior day to serve as an active control for 24 weeks (daily performance feedback). No other interventions during the 24-week study
10185064|NCT03749473|Experimental|Choice + Immediate|Participants choose a step goal between 1000-3000 steps greater than their baseline (choice). They are asked to reach their full step goal upon intervention start (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
9970868|NCT01304784|Experimental|Arm 5|"Docetaxel, trastuzumab and MM-111 3-week treatment cycles with therapies given in the following order: 1) docetaxel, 2) trastuzumab, and 3) MM-111~Docetaxel given as an IV infusion over 60 minutes every three weeks. The infusion should be prepared as directed in the Docetaxel package insert and any institutional guidelines. All patients receiving Docetaxel should be pre-medicated as per the local institutional guidelines.~The first dose of trastuzumab is a loading dose of 8 mg/kg administered over 90 minutes followed by every three week dosing at 6 mg/kg over 60 minutes via IV infusion.~The first dose of MM-111 given over 90 minutes followed by 3 week dosing over 60 minutes in the absence of infusion-related reactions"
9970869|NCT01304797|Experimental|MM-302|
9970870|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab|
9970871|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab q3w|
9970872|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab and Cyclophosphamide|
9970873|NCT01304810||NicVAX|NicVAX vaccine
9970874|NCT01304810||Placebo vaccine|Placebo vaccine
9970875|NCT01304823|Active Comparator|glucose|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
9970876|NCT01304823|Active Comparator|glucose + lactisole|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
9970877|NCT01304823|Active Comparator|mixed liquid meal|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
9970878|NCT01304823|Active Comparator|mixed liquid meal + lactisole|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
9970879|NCT01304823|Placebo Comparator|saline + lactisole|saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole
9970880|NCT01304836|Active Comparator|10 Days of Steroids|Advagraf + Basiliximab + MMF + Steroids (10 days)
9970881|NCT01304836|Experimental|Optional Steroid bolus only|Advagraf + Basiliximab + MMF + Steroids (bolus only)
9970882|NCT01304849|Experimental|Primary|Patients with aHL will receive 2 cycles of ABVD and undergo interim PET-2 scan- those with positive scans will receive 4 additional cycles of Esc BEACOPP while those with negative scans will receive 4 additional cycles of ABVD.
9970883|NCT01304888|Experimental|Food basket w/o nutrition education|
9970884|NCT01304888|Experimental|Food basket + nutrition education|
9970885|NCT01304888|Experimental|Control|
9970886|NCT01304888|Experimental|Cash + health and nutrition education|
9970887|NCT01304901|Active Comparator|1-Montelukast|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
9970888|NCT01304901|Placebo Comparator|2- Placebo|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
9970889|NCT01304914||Healthy, term-delivered babies|
9970890|NCT01304927|Active Comparator|Cholecalciferol + calcium|Group of intervention: Each man will receive 300,000 IU (7500 ug) Cholecalciferol (VD3) orally once after blood and semen sampling and performed DXA scan. Thereafter they will receive VD tablets of 1,400 IU (35 ug) + 500 mg calcium daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of 1400 IU VD3 + 500 mg calcium. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
9970891|NCT01304927|Placebo Comparator|placebo|Group receiving placebo: Each man will receive placebo oral mixture once after blood- and semen sampling and performed DXA scan. Thereafter they will receive placebo tablets daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of placebo. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
9970892|NCT01304953|Placebo Comparator|P+P|
9970893|NCT01304953|Experimental|P+T|
9970894|NCT01304953|Placebo Comparator|S+P|
9970895|NCT01304953|Experimental|S+T|
9970896|NCT01304979|No Intervention|Usual care alone|Subjects receive usual care alone before and after spine fusion surgery
9970897|NCT01304979|Experimental|Active Intervention|Acupuncture therapies, ear seeds, acupuncture treatment and gua sha, designed to reduce pain and facilitate recovery for low back spine fusion patients.
9970898|NCT01304979|Sham Comparator|Control Arm|Indirect therapies with same encounter time and timing as direct care group.
9970899|NCT01304992|Experimental|Lupin Protein|Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)
9970900|NCT01304992|Active Comparator|Reference protein|Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)
9970901|NCT01304992|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
9970902|NCT01305005||patients with active-fluidics system|patients who underwent phacoemulsification surgery using active-fluidics system
9970903|NCT01305005||patients with gravity-fluidics system.|patients who underwent phacoemulsification surgery using gravity-fluidics system
9970904|NCT01305018|Experimental|Exercise and BCAA|
9970905|NCT01305018|Experimental|Exercise and Leucine|
9970906|NCT01305018|Placebo Comparator|Exercise and Placebo|
9970907|NCT01305031|Experimental|Room air|Initiation of resuscitation with 21% Oxygen, adjustments to the inspired oxygen concentration (increased 10%) will be made every 60 seconds for infants to achieve a target SpO2 range of 85-92%
9970908|NCT01305031|Active Comparator|100% Oxygen|Initiation of resuscitation with 100% Oxygen and achieve oxygen saturation in the preset limits 85-92%
9970909|NCT01305057|Experimental|Evaluation of P-IP on hydration and barrier function|Effects of P-IP on improvement of skin hydration and TEWL were examined.
9970910|NCT01305070|Active Comparator|Standart balloon angioplasty|Admiral Xtreme, Invatec
9970911|NCT01305070|Active Comparator|Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec
9970912|NCT01305083|Active Comparator|Udenafil|Active Ingredient
9970913|NCT01305083|Placebo Comparator|Placebo|Placebo
10145632|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent will be placed (usually the standard of care)
10145633|NCT04145063|Active Comparator|uncomplicated ureteroscopic lithotripsy without US|Following uncomplicated uretroscopic lithotripsy no uretric stent will be placed
10145634|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US-string|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent with an extraxtion string will be placed
10145635|NCT04145050|Experimental|Carbohydrate Dose: 0 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
10145636|NCT04145050|Experimental|Carbohydrate Dose: 30 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
10145637|NCT04145050|Experimental|Carbohydrate Dose: 60 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
10145638|NCT04144855|Experimental|TQB3474 injection|Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.
10145639|NCT04144842|Experimental|ATOR-1017|ATOR-1017 administered by intravenous infusions every 3 weeks until confirmed progressive disease, clear clinical deterioration, unacceptable toxicity or withdrawal of consent
10145640|NCT04144777|Experimental|Treatment|Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.
10145641|NCT04144777|No Intervention|Placebo|Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.
10145642|NCT04144907|Experimental|Phenylalanine intake|
10145643|NCT04144790||ADHD+RLS|Twelve participants between the ages of 5 and 18 years with a clinical diagnosis of either RLS or ADHD, and iron deficiency.
10145644|NCT04144868|Experimental|Experimental: NBO group|"For eligible patients into the group of cerebral hemorrhage,Low-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours.~Regular treatment is based on associated guidelines for ICH ."
10145645|NCT04144868|No Intervention|Control group|"Low-flow oxygen is delivered through the facemask at a rate of 2 L/min, once a hour, every 4 hours.~Regular treatment is based on associated guidelines for ICH ."
10145646|NCT04144946||Healthy control group (CTRL)|Sports active individuals with no history of patellar tendinopathy.
10145647|NCT04144946||Early tendinopathy group (ET)|Sports active individuals with clinical signs of early tendinopathy and debut of symptoms within 90 days.
10145648|NCT04144946||Chronic tendinopathy group (CT)|Sports active individuals with clinical signs of tendinopathy and duration of symptoms >90 days.
10145649|NCT04144816||Passive Birth Cohort|"This will be a multicenter, prospective, observational cohort study conducted across the Lyon Public hospital maternity (HFME : Hospital for women, mother and children, Croix-Rousse, Lyon-Sud) recruited from the general population.~Infants born between October 2019 and march 2020. At birth the remains (after diagnosis use) of cord blood samples will be store. Groups of RSVh cases and control will be class at one year of age using the hospital data (RSV must be confirmed by RT-PCR). Parents will be informed of the protocol. If enrolled available hospital data will be use and RSV serology testing perform on the store blood cordon."
10145650|NCT04144764|Experimental|Workplace-based exercise group|
10145651|NCT04144764|Sham Comparator|Control group|
10145652|NCT04144920|Other|Block 1|Participants in this arm performed the conditions in this order: CS, HFLD, LFHD
10145653|NCT04144920|Other|Block 2|Participants in this arm performed the conditions in this order: CS, LFHD, HFLD
10145654|NCT04144920|Other|Block 3|Participants in this arm performed the conditions in this order: HFLD, CS, LFHD
10145655|NCT04144920|Other|Block 4|Participants in this arm performed the conditions in this order: HFLD, LFHD, CS
10145656|NCT04144920|Other|Block 5|Participants in this arm performed the conditions in this order: LFHD, CS, HFLD
10145657|NCT04144920|Other|Block 6|Participants in this arm performed the conditions in this order: LFHD, HFLD, CS
10145658|NCT04144881|Experimental|coronary computed tomography|
10145659|NCT04144881|No Intervention|conservative (ischemia-guided) management|
10145660|NCT04144972|Active Comparator|Active DBS|Chronic brain recordings and stimulation with bilateral implantations in pain-related brain regions. All participants will participate in active DBS, blinded to the participant.
10145661|NCT04144972|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. brain recordings will remain active during this period. All participants will participate in inactive DBS, blinded to the participant.
10145662|NCT04144803||Cerebral desaturation group|absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
10145663|NCT04144803||Control group|no absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
10145664|NCT04144985|Active Comparator|Eyelid Speculum|Eyelid retraction was performed with an eyelid speculum.
10145665|NCT04144985|Experimental|Cotton Tipped Applicator|Eyelid retraction was performed with the cotton tipped applicator eyelid retraction technique.
10145666|NCT04144985|Experimental|Unimanual Eyelid Retraction|Eyelid retraction was performed with the unimanual eyelid retraction method.
10145667|NCT04144712|Experimental|High Dose arm|subjects will receive the high dose of the drug
10145668|NCT04144712|Active Comparator|low dose arm|subject will receive low dose of the drug
10145669|NCT04144933|Experimental|Opioid-free General Anesthesia (OFA)|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis.
10145670|NCT04144933|Active Comparator|Traditional Opioid-containing General Anesthesia (TOA)|Opioid-sparing preoperative medications, Opioid-containing pre-intubation medications, Opioid-containing maintenance medications, postoperative nausea and vomiting prophylaxis.
9826137|NCT02409667|Experimental|Secukinumab 300mg in PASI 90 responders (longer intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.
9826138|NCT02409667|Experimental|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
9970914|NCT01305096|Experimental|Yoga group|Participants in this group will take part in six to eight weeks of yoga classes. The classes will be held once a week and each class will be approximately one hour long. The classes will consist of yoga inversions, sun salutations and other yoga postures with deep breathing.
9970915|NCT01305096|No Intervention|Control group|Matched control
9970916|NCT01305109|Experimental|Oral Rotavirus Vaccine 116E (ORV 116E)|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5 mL at 4 week intervals
9970917|NCT01305109|Placebo Comparator|Placebo|3 doses of 0.5 mL at 4 week intervals
9970918|NCT01305122|Other|OMS grade II glioma|neurocognitive tests
9970919|NCT01305135|Experimental|azacitidine 75mg/m²/d + idarubicin 5mg/m²/d|"phase I : palier 1 have 10 patients and palier 2 have to 10 patients.~palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)"
9970920|NCT01305135|Experimental|Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d|palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)
9970921|NCT01305148|Experimental|Randomized - Genetic|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
9970922|NCT01305148|No Intervention|Randomized - Clinical|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
9970923|NCT01305148|Experimental|Registry|Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
9970924|NCT01305174|Active Comparator|Balloon expandable stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted"
9970925|NCT01305174|Active Comparator|Selfexpanding stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter."
9970926|NCT01305187|Experimental|Hyaluronic Acid Filler - Medical Device|
9970927|NCT01305226|Experimental|Test - THR-100|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
9970928|NCT01305226|Active Comparator|Streptokinase|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
9970929|NCT01305278|No Intervention|Control|No Wii balance gaming undertaken
9970930|NCT01305278|Active Comparator|Wii during vestibular rehab only|To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
9970931|NCT01305278|Active Comparator|Wii whilst on waiting list and rehab|Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.
9970932|NCT01305291|Placebo Comparator|tea only without fibersol-2|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects (11).~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to after the treatments."
9970933|NCT01305291|Active Comparator|tea only with fibersol-2 (10 g)|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to and after the treatments.~Ingredient only test will be done without the meal to determine independent effects of Fibersol-2."
10145671|NCT04144725||Suspected coronary artery disease|Patients hospitalized for suspected acute coronary syndrome who are referred to CCTA or patients referred to CCTA from outpatient clinics for evaluation of stable coronary artery disease.
10145672|NCT04144686|Active Comparator|Group A|Vestibular participants undertaking a single-task vestibular rehabilitation
10145673|NCT04144686|Experimental|Group B|Vestibular participants undertaking a dual-task vestibular rehabilitation
10145674|NCT04144621||Normal SDF|Couples with male partners having SDF lower than 20% using TUNEL assay
9826139|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.
9970934|NCT01305291|Placebo Comparator|tea without fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
9970935|NCT01305291|Experimental|tea with 5 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
9970936|NCT01305291|Experimental|tea with 10 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
9970937|NCT01305304||1|"15 healthy male veteran runners (marathon, triathlon, orienteering) aged between 40 and 65 years with a history of competitive running at a national level during a period of at least 5 years, implicating normally a runner career with at least 50km per week over more than 10 years"
9970938|NCT01305304||2|15 healthy male volunteers, matched for age and bmi, without a history of competitive physical exercise (i.e. sedentary controls)
9970939|NCT01305317|Experimental|lipitor|atorvastatin 20mg daily
9970940|NCT01305343||Surgical treatment|This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity.
10145675|NCT04144621||Abnormal SDF|Couples with male partners having SDF greater than 20% using TUNEL assay
10145676|NCT04144660||Cardiogenic Shock Treated with ECMO|This cohort of participants required clinical intervention with ECMO for treatment of their index cardiogenic shock episode while pregnant or post delivery of their infant.
10145677|NCT04144595||Low plasma glucose|This group will be formed by women with low plasma glucose: fasting plasma glucose (<10th percentile, <65 mg/dL), 1 or 2-hour low plasma glucose results after OGTT.
10145678|NCT04144595||Normal plasma glucose|This group will be formed by women with normal plasma glucose: fasting plasma glucose ( ≥10th percentile, ≥65 mg/dL but < 92 mg/dL), 1 or 2-hour normal glucose (< 180 mg/dL and 153 mg/dL, respectively) results after OGTT.
10145679|NCT04144452|Active Comparator|Patient Education Session|Educational session will be given twice a day for three months. Individualized instructional booklet about back care for each patient will be designed, reviewed and finalized by operating surgeons according to the needs of patients.
10145680|NCT04144452|Experimental|Therapeutic exercises plus educational sessions|Trunk and lower musculature strength and endurance training will be performed twice a week for three months. Therapeutic exercises incorporating mat exercises will be performed. Progression will be made according to patient status.
10145681|NCT04144634|Experimental|Intervention/Strengthening|
10145682|NCT04144634|Sham Comparator|Control/Stretching|
10145683|NCT04144556|Experimental|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
10145684|NCT04144556|Active Comparator|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
10145685|NCT04144491|Experimental|Yoghurt|Yoghurt, containing Lactobacillus rhamnosus yoba 2012, Streptococcus thermophilus C104, whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence.
10145686|NCT04144491|Placebo Comparator|Custard|Custard, containing whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence, 4% modified corn starch.
10145687|NCT04144335|Active Comparator|Group 1: N-803 and bNAbs Only|Group 1 will receive only N-803 and the bNAbs; they will not receive the haNK™ cells
9970941|NCT01305382||Heart Transplant Cohort|This group consist of transplant subjects within 10 years of heart transplant
9970942|NCT01305382||Heart Failure Sub group|Consist of subjects with advanced heart failure (NYHA class III and IV)
9970943|NCT01305382||Healthy Volunteer|This groups consist of healthy individuals
9970944|NCT01305395|Experimental|Early Intervention Arm|Initiate sirolimus within 6 months of heart transplant
10145688|NCT04144335|Experimental|Group 2: N-803 and bNAbs with haNK™ Cells|The protocol for Group 2 will be identical to the one followed by Group 1, except that they will receive haNK™ cells on the same day as each dose of N-803.
10145689|NCT04144439|No Intervention|Before treatment|no intervention
10145690|NCT04144439|Active Comparator|After treatment|GABA
9970945|NCT01305395|Experimental|Late Intervention Arm: Group 2A|Initiate sirolimus after CAV is diagnosed by angiogram
9970946|NCT01305395|Experimental|Retrospective Arm: Angiogram group|Start sirolimus after CAV diagnosed is by angiogram
9519759|NCT03283917|Experimental|Treatment (daratumumab, ixazomib, dexamethasone)|Participants receive daratumumab IV over 3.5-6.5 hours on days 1, 8, 15, and 22 of courses 1-2, on days 1 and 15 of courses 3-6, and on day 1 of courses 7-12. Participants also receive ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unaccepted toxicity.
9519760|NCT03283904|Experimental|Multicomponent PA intervention|Intervention schools will adopt a multicomponent intervention by integrating physical activities into different parts of the school day
9970947|NCT01305395|Experimental|Late Intervention Arm: Group 2B|Start sirolimus after CAV is diagnosed by IVUS
9970948|NCT01305395|Experimental|Retrospective Arm: Intravascular Ultrasound|Sirolimus after CAV is diagnosed by IVUS
9970949|NCT01305434|Other|Placebo then mulberry leaf|These patients receive placebo for two weeks, then 1 week washout, then two weeks of mulberry leaf extract.
9970950|NCT01305434|Other|Mulberry leaf then placebo|These patients receive mulberry leaf extract for two weeks, then 1 week washout, then two weeks of placebo.
9970951|NCT01305447|Experimental|Exercise Maintenance|"Randomization and Group-Mediated Cognitive Behavioural therapy (GMCB) sessions will begin on week 8 of the program. Topics of self-regulation related to exercise (Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the GMCB principles on how to maintain exercise behavior."
9970952|NCT01305447|Experimental|Ex. Maintenance + relapse prevention|"The same topics of self-regulation related to exercise maintenance(Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the Group-Mediated Cognitive Behavioural therapy (GMCB) principles on how to maintain exercise behavior.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
9970953|NCT01305447|Active Comparator|relapse prevention|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
9970954|NCT01305447|Active Comparator|Contact Control|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time."
9970955|NCT01305486||XenMatrix|
9970956|NCT01305512|Experimental|SPARC1028|
9970957|NCT01305525||Spinal Cord Stimulation|
9970958|NCT01305551|Experimental|Treatment A-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fasted state.
9970959|NCT01305551|Experimental|Treatment B-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fasted state.
9970960|NCT01305551|Experimental|Treatment C-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fed state.
9970961|NCT01305551|Experimental|Treatment D-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fed state.
9970962|NCT01305590|Other|Survey|"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
9970963|NCT01305603|Active Comparator|Dual TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness.
9970964|NCT01305603|Active Comparator|Classical (or single) TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness
9970965|NCT01305616|Active Comparator|Group 1, glaucoma and cataract|Group1 were those patients with visually significant cataract (less than grade 2) and mild to moderate open angle glaucoma
9970966|NCT01305616|Sham Comparator|Group2, cataract patients|This group included those patients with visually significant cataract and normal other eye examination.
9970967|NCT01305629|Experimental|Intervention Condition|Twelve sessions of spiritual self schema counseling, adapted to target target medication adherence and substance use.
9970968|NCT01305629|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition.
9970969|NCT01305642|Experimental|Individualized fortification of breast milk|
9970970|NCT01305668||Emphysema phenotype|
9970971|NCT01305668||No-Emphysema phenotype|
9970972|NCT01305681|Active Comparator|LoFric® catheters|LoFric® catheters during clean intermittent catheterization will be compared to non-LoFric® catheters during clean intermittent catheterization
9970973|NCT01305694|Experimental|MSC|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia.
9519761|NCT03283891|Experimental|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
10145691|NCT04144374|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 5 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
10145692|NCT04144374|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
10145693|NCT04144361|Experimental|sleeve without plication|sleeve gastrectomy on bougie 36 without plication
10145694|NCT04144361|Active Comparator|sleeve with plication|sleeve gastrectomy on bougie 42 without plication
10145695|NCT04144647|Experimental|Healthy adults 18-80 years old|Healthy adults 18-80 years old
10145696|NCT04144426|Experimental|Normal diet then modified diet|Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM. Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.
10145697|NCT04144426|Experimental|Modified diet then normal diet.|Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM.
10145698|NCT04144296|Other|Study Arm|All patient will be included in this arm
10145699|NCT04144309|Active Comparator|True acupuncture group|12 sessions of acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
10145700|NCT04144309|Placebo Comparator|Sham acupuncture group|12 sessions of sham acupuncture treatment (SE+SA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
10145701|NCT04144244|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips will be used when preparing sperm of male partner and IUI will be made with separated sperm
10145702|NCT04144244|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and IUI will be made with separated sperm
10145703|NCT04144478|Experimental|experimental|Web based education intervention
10145704|NCT04144478|No Intervention|No intervention|Normal polyclinics application
10145705|NCT04144387|Experimental|Test group|Each patient included in the study will be followed for 5 years
10145706|NCT04144257|Experimental|Subjects diagnosed with Multiple Sclerosis (MS)|We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing multiple sclerosis and 6 with secondary progressive multiple sclerosis).
10145707|NCT04144504|Active Comparator|Plastic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given balloon dilatation and plastic stenting for treatment.
10145708|NCT04144504|Active Comparator|Retrievable metallic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given retrievable metallic stenting for treatment.
10145709|NCT04144218|Placebo Comparator|Control group|
10145710|NCT04144218|Experimental|Experimental group|
10145711|NCT04144400|Experimental|BRAVE Group|The BRAVE program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of quiet ego characteristics. The BRAVE intervention (delivered over four weeks) will ask study participants to use the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
10145712|NCT04144400|Active Comparator|Time Management Group|The time management program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of time management characteristics. The time management intervention (delivered over four weeks) will ask study participants to use the time management version of the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
10145713|NCT04144543|Experimental|White Noise|"The white noise used in our study is a fragment called Bebeğiniz ağlamasın-2 from Kolik album of Buzuki Orhan Osman, which was used in similar studies (Balci, 2006; Karakoc & Turker, 2014; Kucukoglu et al., 2016).Since the white noise is a continuously monotonous sound, which is in the form of a hum, it resembles the sounds in mother's womb (Balci, 2006)."
10145714|NCT04144543|Experimental|Facilitated Tucking|Facilitated tucking is the procedure of holding the baby's arms and legs in a flexed position close to the midline of the torso, and the baby is able to move his/her extremities during this procedure (Caglayan, 2011).
10145715|NCT04144543|Experimental|White Noise+Facilitated Tucking|Both applications performed together.
10145716|NCT04144673|Experimental|Investigational Product|
10145717|NCT04144673|Placebo Comparator|Placebo|
10145718|NCT04144699||Wheezing 3~11months|Patient has wheezing, age 3 to 11 months
10145719|NCT04144699||Wheezing 12~23months|Patient has wheezing, age 12 to 23 months
10145720|NCT04144699||Wheezing 24~35months|Patient has wheezing, age 24 to 35 months
10145721|NCT04144699||Wheezing 36~107months|Patient has wheezing, age 36 to 107 months
10145722|NCT04144699||No wheezing 3~11months|Patient do not have wheezing, age 3 to 11 months
10145723|NCT04144699||No wheezing 12~23months|Patient do not have wheezing, age 12 to 23 months
10145724|NCT04144699||No wheezing 24~35months|Patient do not have wheezing, age 24 to 35 months
10145725|NCT04144699||No wheezing 36~107months|Patient do not have wheezing, age 36 to 107 months
10145726|NCT04144413|Experimental|Period 1 Open-label Ikervis|Period 1 for all patients: IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Baseline for the first 12 months of treatment.
10145727|NCT04144413|Experimental|Period 2 Masked Ikervis|"Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
10145728|NCT04144413|Other|Period 2 Masked Vehicle|"Other: Vehicle Comparator. Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~Vehicle. Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
10145729|NCT04144231|No Intervention|Treatment-as-usual (TAU)|Treatment-as-usual (TAU) delivered by psychiatrists and psychiatric nurses in HUS Psychiatry Outpatient Clinic for Psychosis. Participants who randomized to TAU -group, may receive medication for insomnia, but they will not received CBT-I. Treatment-as-usual is included in all intervention groups.
10145730|NCT04144231|Experimental|Internet-Based Cognitive Behavioral Therapy for Insomnia|"TAU and Internet-Based Cognitive Behavioral Therapy for Insomnia (iCBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I): There will be seven manualized sessions, conducted at intervals of either every one or two weeks.~HUS iCBT-I, is based on the same theoretical model of insomnia as described in Morin 2003 and Edinger 2015- and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. iCBT-I consists of psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.~During the therapy, the therapist monitors progress at least once a week, sends messages to the participant, and answers any treatment-related questions. The aim of the feedback is to comment on exercises, clarify intervention and motivate the patient to persist the in carrying out the treatment and the requested behavioral changes."
10145731|NCT04144231|Experimental|Cognitive Behavioral Group Therapy for Insomnia|TAU and Cognitive Behavioral Group Therapy for Insomnia (GCBT-I): There will be six 90-minute manualized sessions, conducted at intervals of either one or two weeks. One booster session will be conducted one month after the treatment. Each group will have 4-8 people. The content of the CBT-I group is based on CBT for insomnia (as described above) and a previously published insomnia treatment manual for psychotic patients (Waters 2017).To ensuring the rights, safety and wellbeing of participants during the COVID-19 (Coronavirus) pandemic, we produce GCBT-I via internet.
10145732|NCT04144829|Active Comparator|HIFU|3 cycles of HIFU treatment in 6-week intervals
10145733|NCT04144829|Active Comparator|Fibrin|3 cycles of platelet-rich fibrin injection treatment in 6-week intervals
10145734|NCT04144270||Included patients|One-arm study. All included patients will have muscle mass and muscle function evaluated
10145735|NCT04144465|Active Comparator|NORADRENALIN|NORADRENALINE INFUSION
10145736|NCT04144465|Active Comparator|PHENYLEPHRINE|PHENYLEPHRINE INFUSION
10145737|NCT04143971|Placebo Comparator|Continiuous Low calorie diets|Low calorie diet with daily calorie restriction
10145738|NCT04143971|Active Comparator|Intermittent Fasting|Intermittent fasting every other day, in which daily calorie intake will be up to 30% of required calorie.
10145739|NCT04144075|Experimental|Mindful Self-Compassion|Protocolized training program in mindfulness and self-compassion skills.
10145740|NCT04144075|Active Comparator|Cognitive Behaviour Therapy Group|A control intervention designed to develop a control group suitable for comparison with experimental groups receiving interventions based on mindfulness and compassion.
10145741|NCT04144075|Placebo Comparator|Treatment as Usual|Es variable según las características clínicas y personales del paciente.
10145742|NCT04143997||PPCM with Diastolic Dysfunction & Normal Systolic Function|The patient population examined will include patients diagnosed with peripartum cardiomyopathy who have diastolic dysfunction and normal systolic function.
10145743|NCT04144205|Experimental|Fraction of inspired oxygen setting change|
10145744|NCT04144114|Experimental|Whey + ProHydrolase®|Subjects received 250mg of ProHydrolase® along with 25g of whey protein mixed in a drink every visit for 4 weeks
10145745|NCT04144114|Active Comparator|Whey|Subjects received 25g whey protein in a drink every visit for 4 weeks
10145746|NCT04144114|Placebo Comparator|Placebo|Subjects received 25g maltodextrin in a drink every visit for 4 weeks
10145747|NCT04144153|Experimental|Opioid Free Anesthesia Group|
10145748|NCT04144153|Active Comparator|Opioid Anesthesia Group|
10145749|NCT04144101|Experimental|Etoricoxib|Etoricoxib 60 mg QD
10145750|NCT04144101|Experimental|Aceclofenac|Aceclofenac 100 mg BID
10145751|NCT04143880|Experimental|experimental group|Progesterone
10145752|NCT04143880|Placebo Comparator|control grou|saline
10145753|NCT04143893||Cardiogenic shock with MCS|Patients with cardiogenic shock who underwent MCS
10145754|NCT04143893||Cardiogenic shock without MCS|Patients with cardiogenic shock who did not undergo MCS
10145755|NCT04144062|Active Comparator|Zirconia crowns|
10145756|NCT04144062|Active Comparator|CAD/CAM crowns|
10145757|NCT04143906|Experimental|Vinorelbine/Carboplatin|Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
10145758|NCT04143906|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
10145759|NCT04144192|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
10145760|NCT04144192|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.
10145761|NCT04144049|Experimental|MT921|1% or 1.5%, subcutaneously administered at most 50 injections per treatment.
10145762|NCT04144049|Placebo Comparator|Placebo|Subcutaneously administered at most 50 injections per treatment.
10145763|NCT04143867|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
10145764|NCT04144036|Experimental|Neihulizumab Dose Escalation, 3 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
10145765|NCT04144036|Experimental|Neihulizumab Dose Escalation, 6 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
10145766|NCT04144036|Experimental|Neihulizumab Dose Escalation, 9 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
10145767|NCT04144036|Experimental|Neihulizumab Dose Expansion|Upon determination of the maximum-tolerated dose, an expansion cohort of 4-7 patients will be enrolled so that a total of 10 patients are enrolled at the potential Phase II dose. This will be done to preliminarily assess efficacy.
10145768|NCT04143802|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
10145769|NCT04143802|Active Comparator|Dulaglutide|Dulaglutide administered SC
10145770|NCT04143802|Placebo Comparator|Placebo|Placebo administered SC
10145771|NCT04143789|Experimental|Tablets to be taken orally daily for 14 of 21 day cycle|AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days
10145772|NCT04143685|Active Comparator|misoprostol|misoprostol 50 mcg tablet by mouth every four hours for maximum dosage of six
10145773|NCT04143685|Active Comparator|oxytocin|Oxytocin 10 IU in 1000 mL Standard solution. Starting with 10 mL/hr infusion rate and increasing by 10mL/hr every 20 minutes until achieving 3-5 regular uterine contractions every 10 minutes (as recorded by cardiotocography)
10145774|NCT04143750|Experimental|[14C]Vicagrel|
10145775|NCT04143620|Other|Neovascular glaucoma|Neovascular glaucoma patients underwent triple procedure
10145776|NCT04143724|Experimental|Cohort 1: 12 to < 18 years - Luspatercept 0.75 mg/kg|Luspatercept 0.75 mg/kg, administered SC once every 21 days (for up to 4 cycles)
10145777|NCT04143724|Experimental|Cohort 2: 12 to < 18 years: Luspatercept 1.0 mg/kg,|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
10145778|NCT04143724|Experimental|Cohort 3 (Expansion Cohort): 12 to <18 years|Luspatercept administered SC once every 21 days (for up to 12 months)
10145779|NCT04143724|Experimental|Cohort 4: 6 to < 12 years: Luspatercept 1.0 mg/kg|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
10145780|NCT04143724|Experimental|Cohort 5: 6 to <12 years: Luspatercept 1.25 mg/kg|Luspatercept 1.25 mg/kg, administered SC once every 21 days (for up to 4 cycles)
10145781|NCT04143633|Experimental|FODMAP diet in Irritable Bowel Syndrome|Patients with IBS will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
10145782|NCT04143633|Experimental|FODMAP diet in Ulcerative Colitis|Patients with UC will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
10145783|NCT04143633|Active Comparator|FODMAP diet in healthy patients|Healthy patients will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
10145784|NCT04143854|Experimental|MBA-P01 24U|Experimental group; Dose: 24U
10145785|NCT04143854|Experimental|MBA-P01 12U|Experimental group; Dose: 12U
10145786|NCT04143854|Placebo Comparator|Placebo|Placebo group; normal saline
10145787|NCT04143763|Active Comparator|Intervention group|receive mobile messages supporting caregivers' psychological well-being, according to the participants' preferences in intervention group.
10145788|NCT04143763|No Intervention|Control group|receive general health information through a mobile message.
9826140|NCT02409680|Active Comparator|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
9970974|NCT01305707|Experimental|C-ECT and Pharmacotherapy|Consolidation treatment with ECT will be considered finished after 9 months of being started, at which time patients will stay only on the pharmacological treatment they already had. The study will be completed within 15 months of patient inclusion (six months after the end of C-ECT). Patient assessment and follow-up will be conducted by participant researchers. Blind rater will conduct clinical and adverse effects ratings. A neuropsychologist will conduct neuropsychological assessments.
9970975|NCT01305707|Active Comparator|Pharmacotherapy|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet.
9970976|NCT01305733|Active Comparator|local infiltration analgesia|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
9970977|NCT01305733|Placebo Comparator|saline injection|The normal saline injection are used in the control group in the same manner than in the RKA group.
9970978|NCT01305746|Experimental|A-623 high dose weekly|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
9970979|NCT01305746|Experimental|A-623 low dose weekly|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
9970980|NCT01305746|Experimental|A-623 high dose every 4 weeks|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
9970981|NCT01305759||YoungTKA|Adults under 60 years who are having primary TKA
9970982|NCT01305759||YOUNGTHA|Adults under 60 years who are having primary THA
9970983|NCT01305759||PAOAarhus|Adults under 60 years who are having primary PAO
9970984|NCT01305798|Experimental|Control Arm|The control arm will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment.
9970985|NCT01305798|Experimental|Active Choice and Default Option Arm|The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email.
9970986|NCT01305798|Experimental|Active Choice Only Arm|The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
9970987|NCT01305837|Experimental|methylprednisolone|all patients will be treated with the active drug methylprednisolone 500 mg in 3 days every month for 60 weeks.
9970988|NCT01305850|Active Comparator|Aliskiren|
9970989|NCT01305850|Active Comparator|Aliskiren plus Losartan|
9970990|NCT01305850|Active Comparator|Enalapril plus Losartan|
9970991|NCT01305850|Placebo Comparator|placebo|
9970992|NCT01305863|Active Comparator|Propaten graft|Untreated Propaten vascular graft
9970993|NCT01305863|Experimental|ASC-Coated ePTFE graft|ASC Coated BARD IMPRA® ePTFE Vascular Graft
9970994|NCT01305876|Experimental|one group with yoga intervention|one group with yoga intervention
9970995|NCT01305889|Experimental|problem solving therapy|subjects will receive 12 weeks of weekly problem solving therapy
9970996|NCT01305889|Experimental|sertraline|12 weeks of sertraline
9970997|NCT01305902|No Intervention|walking recommendations|Participants assigned to this condition will be instructed to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. Each week, they will be congratulated if they walked the target goal on any days, and encouraged to meet the goals for the upcoming week. However, they will not receive any tangible reinforcement for walking. The meetings will be brief (about 15 minutes) and will include discussions and handouts related to the health benefits of walking.
9970998|NCT01305902|Experimental|contingency management for walking|Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
9970999|NCT01305915|No Intervention|Control|participant will receive standard print material
9971000|NCT01305915|Experimental|Intervention|patient will receive standard print material and a single session group psychoeducational intervention (GBOT)
9971001|NCT01305928|Active Comparator|Fax|
9971002|NCT01305928|Experimental|Warm Hand-off|
9971003|NCT01306006|Active Comparator|MV-for-all|Measles vaccine provided to all children aged 9 months -3 years of age
9971004|NCT01306006|No Intervention|National policy|Measles vaccine provided to children aged 9-11 months, if there are sufficient children to open a measles vaccine vial.
9971005|NCT01306097|Experimental|Zinc sulfate|daily zinc supplementation for 3 months. (10mg daily for under 1 years old children and 20mg daily for above 1 years old children)
9977127|NCT01358409|Experimental|Nebivolol|Nebivolol (Bystolic® by Forest/Mylan) is a third-generation beta-blocker; it selectively blocks β1-adrenergic receptors and increases peripheral vasodilation.
9977128|NCT01358422||In Patients|
9977129|NCT01358435|Experimental|Wosulin 70/30|Wosulin 70N /30R is a recombinant Human Insulin with 30 % Regular Insulin Human Neutral and 70% Isophane Insulin, 600 nmol/ml, 100 IU/ml.
9977130|NCT01358435|Active Comparator|Novolin 70/30|Novolin 70/30 is a Recombinant Human Insulin with 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection
9977131|NCT01358448|No Intervention|Newsletter|
9977132|NCT01358448|Experimental|Growth Monitoring|
9977133|NCT01358448|Experimental|Growth Monitoring plus Family-based Behavioral Counseling|
9826141|NCT02409680|Placebo Comparator|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
9971006|NCT01306123|Experimental|Nascobal nasal spray (cyanocobalamin USP)|One single administration of intranasal cyanocobalamin (initially)
9971007|NCT01306123|Active Comparator|Vitamin B12-ratiopharm N, injection solution|One single injection of IM cyanocobalamin (initially)
9971008|NCT01306136|Experimental|Prolonged Exposure|
9971009|NCT01306136|Active Comparator|Usual care|
9971010|NCT01306188||Breast cancer|Metastatic breast cancer
9971011|NCT01306188||Lung cancer|Metastatic lung cancer
9971012|NCT01306227|Placebo Comparator|water|Oral treatment with water for 6 weeks
9971013|NCT01306227|Experimental|L-Thyroxine|Oral treatment with L-Thyroxine for 6 weeks
9971014|NCT01306240|Experimental|Early strategy|Intratracheal poractant alpha (Curosurf®) after tracheal intubation
9971015|NCT01306240|Active Comparator|Delayed strategy|Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 > 60%
9971016|NCT01306266|Active Comparator|rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo
9971017|NCT01306266|Placebo Comparator|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg
9971018|NCT01306279||Cystic Fibrosis, infection|Cystic Fibrosis patients with an infective exacerbation
10145789|NCT04143737|Other|Intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
10145790|NCT04143737|No Intervention|Control|22 women participated in the control group. They were recruited from a community center in the old city of Jerusalem and did not receive any intervention. Baseline data was collected.
10145791|NCT04143841|Active Comparator|Single treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
9971019|NCT01306318|Experimental|1|
9971020|NCT01306318|Active Comparator|2|
9971021|NCT01306344||Patients|Heterogeneous groups of patients (age, gender)
9971022|NCT01306344||Nurses|Heterogeneous groups of nurses (age, gender, working experience)
9971023|NCT01306344||Physicians|Heterogeneous groups of physicians (age, gender, working experience)
9971024|NCT01306357||Zomacton® with Zomajet® needle-free device|Zomacton® 4 mg delivered by percutaneous transjection (needle-free) using the Zomajet® 2 Vision device or Zomacton® 10 mg delivered by percutaneous transjection (needle-free) using the Zomajet® Vision X needle-free device.
9971025|NCT01306370|Experimental|Tranexamic acid|Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
9971026|NCT01306370|Experimental|Fibrin glue BSTC|It is homologous fibrin glue from a single blood donor.
9971027|NCT01306370|Experimental|Tissucol|It is fibrin glue commercialized from multiple donors.
9971028|NCT01306370|Other|Habitual haemostasis|Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
9971029|NCT01306383|Active Comparator|SODIS Bottles given|Caregivers in the intervention group were given two 2-litre plastic bottles. Bottle was filled with available water and placed in direct sunlight for a minimum of 6 hours. Water was consumed the next day while second bottle was being consumed.
9971030|NCT01306383|Active Comparator|Usual practices|Caregivers in this group were asked to maintain their usual practices regarding drinking water so that disease rates could be compared with the SODIS arm
9971031|NCT01306396|Other|Intervention group|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
9971032|NCT01306396|No Intervention|Control group|"Families participating in the control group are given only one dietary counseling based on the references of the DGE at the beginning of the study if they wish."
9971033|NCT01306409|Experimental|A|Sequential application of different ESA
9971034|NCT01306422|Placebo Comparator|Stage 2: Placebo|Placebo product, twice-daily, 65 minutes before breakfast and dinner
9971035|NCT01306422|Active Comparator|Stage 2: H.g.PE 1110 mg b.d.|Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
9971036|NCT01306422|Placebo Comparator|Stage 1: placebo, breakfast & dinner|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
9971037|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/dinner|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
9971038|NCT01306422|Placebo Comparator|stage 1: Placebo breakfast/lunch|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
9971039|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/lunch|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
9971040|NCT01306435|Experimental|Laser Group|
9971041|NCT01306435|Placebo Comparator|Placebo Group|
9971042|NCT01306448|Experimental|vibrating capsule|
9971043|NCT01306461|Active Comparator|Timolol and Tafluprost|Concomitant administration of preservative-free timolol and tafluprost eye drops
9971044|NCT01306461|Experimental|Fixed Dose Combination of tafluprost and timolol|Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
9971045|NCT01306474||Prednisone|profess to convinced 1-1.5mg/Kg.d
9971046|NCT01306474||methotrexate to band prednisone|profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d
9971047|NCT01306487||Macular hole patients|The patients who underwent vitreous surgery for idiopathic macular hole.
9971048|NCT01306500|Experimental|Gastric lavage Group|In neonates randomized to intervention Group (gastric lavage group) gastric lavage was done in the labor room after initial stabilization
10145792|NCT04143841|Sham Comparator|Single sham treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
10145793|NCT04143555||endoscopic submucosal injection of indocyanine green|
10145794|NCT04143464|Experimental|Intervention group|"The participants in this group will receive group kyphosis-specific exercise classes given by the certified physical trainer and kyphosis-specific exercise videos.~The intervention arrangement is:~Group learning and practice: a 1-hour kyphosis-specific exercise training session will be provided two times in the first week,~Weekly follow-up: a 1-hour kyphosis-specific exercise will be conducted with reinforcement of learning and remedial teaching by a certified physical trainer once a week for five consecutive weeks after the group learning and practice,~Self-practice: the participant will following the kyphosis-specific exercise videos doing self-practice every day for the whole intervention period lasting six weeks."
10145795|NCT04143464|No Intervention|Control group|No special arrangement
10145796|NCT04143568||Control|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
10145797|NCT04143568||Periodontitis|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
10145798|NCT04143672|Experimental|study group|"The following tests will be performed on the study subjects.~Pain catastrophizing scale~Hospital Anxiety and Depression scale-Anxiety Subscale (HADS-A)~Pain sensitivity questionnaire~Pain pressure threshold using electronic digital pressure algometer"
10145799|NCT04143828|Experimental|Mobile Mindfulness Programme|The mobile mindfulness program is delivered via a mobile application.
10145800|NCT04143828|No Intervention|Wait-list control condition|When assigned to the control condition, participants will be wait-listed for 3 months during the study. After the final assessment participants will receive access to the mobile mindfulness program.
10145801|NCT04143581|Experimental|IMP|
10145802|NCT04143607|Experimental|ASK120067+ placebo Gefitinib|ASK120067 (160 mg or 80 mg orally, twice daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
10145803|NCT04143607|Active Comparator|Gefitinib + placebo ASK120067|Gefitinib (250 mg orally, once daily) plus placebo ASK120067 (160 mg or 80 mg orally, twice daily), in accordance with the randomization schedule. Following objective disease progression according to RECIST1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label ASK120067 (crossover to active ASK120067).
10145804|NCT04143451|Active Comparator|IQ|"Year 1: a single dose ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream~Year 2: randomised into 3 subgroups. Group IQ1: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream Group IQ2: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IQ3: ID normal saline vaccination with pre-treatment of the injected skin with imiquimod (Aldara) cream.~Year 3: IQ1 and IQ2 same treatment as second year. IQ3 same as first year."
10145805|NCT04143451|Active Comparator|IM|"Year 1: a single dose IM QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: randomised into 3 subgroups. Group IM1: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IM2: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream. Group IM3: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: IM1 and IM2 same treatment as second year. IM3 same as first year."
9971049|NCT01306500|No Intervention|No gastric lavage|Neonates randomized to 'No gastric lavage group' will receive supportive treatment as per standard unit protocol.
10145806|NCT04143451|Active Comparator|HD|"Year 1: a single high-dose IM TIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: Group HD1: IM QIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream. Group HD2: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: Group HD1 same treatment as second year. HD2 same as first year."
10145807|NCT04143698|Active Comparator|Disposable (single-use) duodenoscope|This group will be using the disposable (single-use) duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
9971050|NCT01306513|Experimental|cells|
9971051|NCT01306526||Moderate to Severe OSA|
9971052|NCT01306539|Experimental|Deep Brain Stimulation|Parkinson's patients with deep brain stimulation in the subthalamic nucleus.
9971053|NCT01306552|Active Comparator|Student-intervention only group|"Schools randomized to intervention only (arm 1) will agree to visit the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?).~One school class of students will visit the parcours once during a school day. The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
10145808|NCT04143698|Active Comparator|Reusable duodenoscope|This group will be using the reusable duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
10145809|NCT04143542|Experimental|Groups Q|"In abdominal surgeries, USG guided Quadratus Lumborum 2 blocks are performed for postoperative analgesia. For this purpose, Quadratus Lumborum Block 2 (QLB 2) are frequently used blocks.~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
10145810|NCT04143542|Experimental|Groups T|"In abdominal surgeries, USG guided TAP blocks are performed for postoperative analgesia. For this purpose, TAP blocks are frequently used blocks.~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
10145811|NCT04143542|No Intervention|Groups C|There was no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg, and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with the target of EtCO2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC). Anesthesia will be discontinued and tracheal extubation will be done once the patient fulfills the extubation criteria.Tramadol 100 mg i.v. Before 15 min end of surgery. The patient control analgesia device will administer all patients.
10145812|NCT04143529|Experimental|Personalized acceptance-based mindfulness exercise|The purpose of this study is to identify whether a brief 60-second acceptance based mindfulness intervention at specific time points will reduce state trait anxiety, Mini-Mental Adjustment to Cancer Scale score, pain intensity, distress, anxiety, depression and anger
10145813|NCT04143529|Placebo Comparator|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 second at specific timepoints.
10145814|NCT04143646|Active Comparator|Web-based prevention program|"Patients after myocardial infarction participate in a 12-months program with telemetric risk factor control, e-learning and E-Mail/App-contacts.~In a substudy patients are further randomly assigned to disclosure of genetic risk vs. no disclosure."
10145815|NCT04143646|No Intervention|Usual Care|Patients after myocardial infarction are treated following the standard of care (clinical practice as offered by general practitioners, cardiologists, etc.).
10145816|NCT04143425||Received bevacizumab treatment|Recurrent glioblastoma patients with received anti-angiogenic treatment
10145817|NCT04143815|Experimental|MBA-P01 30U|Experimental group, Dose: 30U
10145818|NCT04143815|Experimental|MBA-P01 20U|Experimental group, Dose: 20U
10145819|NCT04143815|Experimental|MBA-P01 10U|Experimental group, Dose: 10U
10145820|NCT04143815|Placebo Comparator|Placebo|Placebo group, Normal saline
10145821|NCT04143334||RAAB survey|We will examine 3700 Chaonan County residents aged 50 years and older, selected via a clustered, randomized sampling with probability proportional to size (PPS). The cluster will be at the village level, 50 subjects aged 50 years and older will be examined in each cluster includes Visual acuity, torch light, and fundus review, the major cause of blindness or visual impairment will be determined.
10145822|NCT04143334||conventional survey|All the recruited participants underwent ophthalmic examination according to the RAAB protocol and then 60% of them were re-examined with instruments in a mobile eye clinic set up in a village center on the same day. Examination in the mobile clinic included standardized visual acuity (VA) tests using logarithm of the minimum angle resolution charts, refraction, slit-lamp biomicroscopy, and dilated fundal examination with a binocular indirect ophthalmoscope.
10145823|NCT04143269|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the GammaCore device (ElectroCore LLC)
10145824|NCT04143269|Sham Comparator|Sham Treatment|Inactive sham vagus nerve stimulation applied by the GammaCore sham device (ElectroCore LLC)
10145825|NCT04143347||Community Hospitals - CH|Patients with head injury managed at Community Hospitals
9519762|NCT03283891|No Intervention|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
10145826|NCT04143347||Level 1 Trauma Center - L1TC|Patients with head injury presenting to level 1 trauma center directly
10145827|NCT04143347||Transfer|Patients with head injury presenting at a community hospital but then getting transferred to the level 1 trauma center
10145828|NCT04143321|Experimental|empagliflozin|following a two-week washout and complete SAQ and exercise tolerance test patients gave 25 mg empagloflozin and therafter SAQ and ETT was done
9528310|NCT03211897||Ziprasidone 20mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
10145829|NCT04143321|Placebo Comparator|No drug|following a two-week washout and complete SAQ and exercise tolerance test patients gave placebo and therafter SAQ and ETT was done
10145830|NCT04143399|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
10145831|NCT04143399|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
10145832|NCT04143217|Experimental|Open-Label Treatment|SPN-812 Open-Label Treatment 200mg to 600mg SPN-812 once daily for up to 156 weeks
10145833|NCT04143490|Experimental|UC Patients|Patient group
10145834|NCT04143490|Active Comparator|Healthy controls|Control group
10145835|NCT04143230|Active Comparator|Extended Screening Tool (EST)|The SIAARTI/NCCN (EST) screening tool is, in fact, an instrument validated by many scientific societies, but it is very articulated and its compilation is too much time-consuming.
10145836|NCT04143230|Experimental|Simplified Screening Tool (SST)|The Simplified Screening Tool (SST) has been created through a statistical process in order to include all the critical variables, with the advantage of being shorter and therefore easier to administer in a routinely use.
10145837|NCT04143048||The construction of Gene detection technology flow|At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored. It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).
10145838|NCT04143048||Establishment of non-invasive gene testing technology process|In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors. About 50 patients were planned to be enrolled. Peripheral blood was collected once for each patient and the blood volume was 10mL. Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion . DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.
10145839|NCT04143048||Prospective cohort (double-blind recommended)|Peripheral blood of about 150 patients was collected once and the blood volume was 10mL . Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion. Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm. DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients.
10145840|NCT04143438|Experimental|Undergoing EOS 3D imaging|Patients with patello-femoral instability will undergo EOS 3D Imaging protocol before and after undergoing corrective surgery
10145841|NCT04143165|Active Comparator|Epidural block|Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
10145842|NCT04143165|No Intervention|control group|patients did not receive injection
10145843|NCT04143009|Experimental|Adapted Friendship Bench (AFB)|35 women seeking ANC services at Mitundu Clinic in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Adapted Friendship Bench intervention from date of enrollment through 6 months post-partum.
10145844|NCT04143009|Experimental|Enhanced Friendship Bench (EFB)|35 women seeking ANC services at Lumbadzi Clinic in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Enhanced Friendship Bench intervention from date of enrollment through 6 months post-partum.
10145845|NCT04143009|Active Comparator|Enhanced Standard Care (ESC)|35 women seeking ANC services at Nathenje Clinic will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will received the Enhanced Standard Care intervention from date of enrollment through 6 months post-partum.
10145846|NCT04143360|Experimental|New Closed Drainage Device|We further improve the new closed thoracic drainage system by changing the material of drainage tube, adding external fixator control valve and increasing the gas flow monitoring kit for special patients, and apply it in clinical practice.
10145847|NCT04143360|Experimental|Traditional Closed Drainage Device|We use traditional closed drainage devices for patients with hemothorax and pneumothorax.
10145848|NCT04143022|Active Comparator|group A (acupuncture press needle)|Group A subjects first receive acupuncture press needle treatment at acupoint of Jin's 3-tongue point and EX-HN25. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
10145849|NCT04143022|Active Comparator|group B (acupuncture press needle)|Group B subjects first receive acupuncture press needle treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of Jin's 3-tongue point and EX-HN25. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
10145850|NCT04143178|Experimental|Expressive Writing Group|Writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the disease, the transplant, and their best expectations after the operation.
10145851|NCT04143178|Other|Control Group|The control group participant has been asked to describe an objects in their room, in a neutral way, without mentioning emotions or feelings,for 3 consecutive days, 20 minutes each day.
10145852|NCT04143152||Diagnostic/prognostic cohort|Patients being evaluated for a potential pancreatic abnormality or for potential treatment for pancreatic adenocarcinoma.
10145853|NCT04143152||Surveillance Cohort|Patients who are being monitored for recurrence following surgical or medical treatment for pancreatic adenocarcinoma
10145854|NCT04143087||Withdrawal TKIs|
10145855|NCT04143087||halve TKIs|
10145856|NCT04143308|Experimental|Simultaneous training of walking and cognitive group|"Wearable technology (fitness wristband & App)~SWATCH system (App & controller)~3 times a week (30 mins/ each time)~Lasts for 12 weeks~Simultaneous walking and cognitive training"
10145857|NCT04143308|Active Comparator|Cognitive training group|"Wearable technology (fitness wristband & App)~SWATCH system (App)~3 times a week (30 mins/ each time)~Lasts for 12 weeks~Cognitive training while sitting"
10145858|NCT04143308|Active Comparator|Treatment as usual group|1. Keep treatment as usual group at health care system.
10145859|NCT04143256|Experimental|Group I|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco
10145860|NCT04143256|Experimental|Group II|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint
10145861|NCT04143256|Experimental|Group III|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol
10145862|NCT04143256|Experimental|Group IV|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango
10145863|NCT04143256|Experimental|Group V|Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)
10145864|NCT04143256|Experimental|Group VI|Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)
10145865|NCT04143412|Active Comparator|Tritace (Ramipril)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day. Full doses will be reached by forced titration after 4 weeks
10145866|NCT04143412|Active Comparator|Eraloner (Eplerenone)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day. Full doses will be reached by forced titration after 4 weeks
10145867|NCT04143412|Active Comparator|Tritace/Eraloner (Ramipril/Eplerenone)combination therapy|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace/Eraloner (Ramipril 10 mg / Eplerenone 50 mg ) / day. Full doses will be reached by forced titration after 4 weeks
10145868|NCT04143113|No Intervention|Usual Care (n=20)|Control: general information about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
10145869|NCT04143113|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
10145870|NCT04143191|Active Comparator|Sorafenib|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.
10145871|NCT04143191|Experimental|Sorafenib plus TACE|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. TACE will be performed on the fourth day after randomization. If any drug related adverse event occurred, the dosage will be reduced.
10145872|NCT04143074|Other|intervention|multidisciplinary intervention arm - behavioral intervention by physician, dietician, psychologist and physical activity trainer
10145873|NCT04142996|Active Comparator|Unilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
10145874|NCT04142996|Active Comparator|Bilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC and continuous TBS (cTBS) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
10145875|NCT04142996|Active Comparator|Maintenance Phase: Fixed|The fixed protocol will consist of two sessions per week for the first month, followed by a weekly TBS session for two months, biweekly sessions for two months and a monthly session for the last month (total of 21 sessions over 6 months).
10145876|NCT04142996|Active Comparator|Maintenance Phase: Flexible|The flexible maintenance protocol will be based on symptom emergence. Participants will receive a fixed TBS (2x/week) schedule for the first month. For the following months (2-6), they will come in for an assessment (HRSD-17) to determine how many TBS sessions (0, 1, or 2) they receive on a flexible basis.
10145877|NCT04142970|Active Comparator|Mild renal impairment|Mild renal impairment (eGFR: 60-89 mL/min/1.73 m^2)
10145878|NCT04142970|Active Comparator|Moderate renal impairment|Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m^2)
10145879|NCT04142970|Active Comparator|Subjects with normal renal functions|Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m^2)
10185065|NCT03749473|Experimental|Choice + Gradual|Participants are asked to choose a step goal between 1000-3000 steps greater than their baseline (choice). They will be asked to increase their step goal by even increments of 12.5% each week for the 8 weeks of the ramp-up period (gradual). After the 8-week ramp-up period, they will be asked to maintain the step goal for the study. They may change their goal within the range at anytime. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
10185066|NCT03749473|Experimental|Assigned + Immediate|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to reach their full step goal as soon as the intervention begins (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
10185067|NCT03749473|Experimental|Assigned + Gradual|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to achieve their step goal of 2000 steps incrementally over the 8 weeks of the ramp-up period (gradual). After the first 8 weeks, they will be asked to maintain their full step goal of 2000 for the the study. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
10185068|NCT03749408|Active Comparator|bupivacaine plus mannitol|0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
10185069|NCT03749408|Experimental|bupivacaine alone|0.5% bupivacaine with 1:200,000epinephrine alone
10185070|NCT03749395|Active Comparator|Erector Spinae Plane Block group|"The Erector Spinae Plane block will be done as follow,the patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.~All patients will receive general anesthesia as described in conventional group"
10185071|NCT03749395|No Intervention|Conventional group|"Nothing will be injected~All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCo2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC), 0.5μg/kg fentanyl will be given intraoperative when either heart rate or Non Invasive Blood Pressure report an increase by more than 20% of the basal records. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria."
10185072|NCT03749382|Experimental|Intervention Neutral instructions|Appearance based intervention group delivered with neutral instructions from the investigator alongside general stop smoking intervention leaflet.
10185073|NCT03749382|Experimental|Intervention Additional instructions|Appearance based intervention group delivered with neutral instructions with additional reassuring messages from the investigator alongside general stop smoking intervention leaflet.
9669374|NCT02279095|Experimental|Palovarotene dose level 1 (completed)|Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).
10145880|NCT04142931|Active Comparator|filtration of 2X PV|filtration of 2X PV through the ImmunicomAIAC
10145881|NCT04142931|Active Comparator|filtration of 2X PV combined with Nivolumab 240mg|filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
10145882|NCT04142957||Focus Groups|"The investigators will invite 13-15 participants to attend the focus groups, of which it is expected that 10-12 to attend. Participants will be asked to bring a smart phone. An Informed Consent Form will be signed by the participant and a delegated researcher before the focus groups begin.~The current generation of COPD Pal will be downloaded onto the participants' own smart phones (see Appendix 1 for current screenshots of app), participants will then be explained the purpose of the app, and asked to interact with it for 15-60 minutes, as required.~A semi-structured focus group will then be conducted with the participants to facilitate conversation and discussion regarding COPD Pal. Once introductions have been completed, questions will be asked relating to the usability and acceptability of COPD Pal (see the Interview Schedule, Appendix 2). The focus group will last 30-60 minutes, as required."
10145883|NCT04142554|Experimental|Single Arm: Parsaclisib ( Dose De-Escalation )|Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days.
10145884|NCT04142606||Control Group (Group 1)|Having prenatal ultrasound screening without detected abnormality
10145885|NCT04142606||Non Optimal Ultrasound Scan Group (Group 2)|Having an ultrasound examination without abnormality detected but in whom ultrasound examination is not optimal (poor technical conditions, multiple pregnancies, obese patients)
10145886|NCT04142606||Malformation Group (Group 3)|Standardized prenatal screening with ultrasound examination finding an isolated anomaly that does not currently constitute a commonly accepted indication of fetal MRI
10145887|NCT04142606||TOP Group (Group 4)|A medical termination of pregnancy, (TOP), in addition to a fetopathological examination (virtopsy)
10145888|NCT04142541|Experimental|Carotid artery stenting with Neuroguard IEP System|To evaluate the safety and feasibility of the Neuroguard IEP System when used in patients with clinically significant carotid artery stenosis requiring revascularization.
10145889|NCT04142879||Non-Interventional Centers|"Cohort A: Viz Subjects Initially Presenting to a Non-Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a non- interventional center.~Cohort B: Subjects Initially Presenting to a Non-Interventional Center The standard of care group will be comprised of subjects randomized to not have Viz notification and who initially present to a non-interventional center."
10145890|NCT04142879||Interventional Centers|"Cohort C: Viz Subjects Initially Presenting to an Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a interventional center.~Cohort D: Subjects Initially Presenting to a Interventional Center The standard of group will be comprised of subjects randomized to not have Viz notification and who initially present to an interventional center."
10145891|NCT04142840|Experimental|Dexmedetomidine Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the dexmedetomidine group will be infused with a single dose of 0.7ug/kg dexmedetomidine."
10145892|NCT04142840|Active Comparator|Propofol Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the propofol group will be infused with a single dose of 0.5mg/kg propofol."
10145893|NCT04142762|Experimental|Cohort 1: ABI-H2158 + Itraconazole|Oral ABI-H2158 on Days 1 and 9; oral itraconazole once-daily (QD) on Days 6 through 13
10145894|NCT04142762|Experimental|Cohort 2: ABI-H2158 + Rifampin|Oral ABI-H2158 on Days 1 and 12; oral rifampin QD on Days 6 through 16
10145895|NCT04142762|Experimental|Cohort 3: ABI-H2158 + Esomeprazole|Oral ABI-H2158 on Days 1 and 11; oral esomeprazole QD on Days 6 through 11
10145896|NCT04142762|Experimental|Cohort 4: ABI-H2158 + Midazolam|Oral midazolam on Days 1 and 11; oral ABI-H2158 QD on Days 2 through 11
10145897|NCT04142762|Experimental|Cohort 5: ABI-H2158 + Oral Contraceptive|Cycle 1: active oral contraceptive (ethinyl estradiol/levonorgestrel) QD on Days 1 through 21 and oral placebo QD on Days 22 through 28; Cycle 2: active oral contraceptive QD on Days 1 through 21, oral placebo QD on Days 22 through 26, and oral ABI-H2158 QD on Days 11 through 24
10145898|NCT04142775||intracranial hemorrhage (ICH)|ARDS patients treated with ECMO developing ICH
9669375|NCT02279095|Experimental|Palovarotene dose level 2|Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
10145899|NCT04142775||no intracranial hemorrhage|ARDS patients treated with ECMO not developing ICH
10145900|NCT04142671|Experimental|Individualised Gait Modification Intervention|"Patients will carry out several walking trials to test the efficacy of an individualised gait modification intervention.~Pre-intervention over ground walking, pre-intervention treadmill walking, intervention treadmill walking with real-time biofeedback on their knee loading, intervention treadmill walking with no feedback, and post-intervention over ground walking."
10145901|NCT04142827|Experimental|Therapy with high flow humidification|The patients will be activated after enrollment with myAirvo2 device at home for 6 months before first observations
10145902|NCT04142827|No Intervention|Therapy with usual care|The patients will be under usual care for observational
10145903|NCT04142801|Experimental|MeMo group|MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
10145904|NCT04142801|Placebo Comparator|Control group|Regular follow up at the memory center without cognitive training
9971054|NCT01306552|Active Comparator|Multi-component intervention|Schools randomized to the student-parent intervention arm also will agree to visit the KARUNA e.V. smoking prevention parcours. In addition, the schools will agree to have one parents' night presented by trained health coaches informing parents about smoking prevention topics in youth during the school year. Trained health coaches will give an evaluated smoking prevention presentation for parents at the parents' nights at the end of the first school year. Also, participating parents will receive information about successful ways to prevent smoking and promote smoking cessation in their children once by mail.
9971055|NCT01306552|Active Comparator|Control Group|Schools randomized to the control school will be offered to participate in the nutrition and exercise prevention program offered by KARUNA e.V. during the 2-year study.
10145905|NCT04142853|Experimental|Persons with MS, dance group|
10145906|NCT04142853|Active Comparator|Persons with MS, art group|
10145907|NCT04142710|Experimental|Follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements.
10145908|NCT04142710|No Intervention|Standard clinical care|Participants in this arm receive standard clinical care in accordance with their medinal needs.
10145909|NCT04142710|Experimental|Non-randomized follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements. This arm is not randomized, but otherwise identical to the randomized experimental arm.
10145910|NCT04142749|Active Comparator|Oltipraz|Oltipraz 30mg
9971056|NCT01306565|Active Comparator|High dose atorvastatin|Three 80mg daily doses of atorvastatin
10145911|NCT04142749|Placebo Comparator|Placebo|Placebo 30mg
10145912|NCT04142528||Parkinson's Disease|Smartwatch-based sensor assessment of PD symptoms during standard care
10145913|NCT04142489|Other|UV and biopsy|"Minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= 6.4 photoproducts, and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure."
10145914|NCT04142333|Other|GIA Access|All patients consented to this study will be given access to the GIA technology to share with their family members.
10145915|NCT04142346|No Intervention|Uninterrupted sitting|Participants remained seated throughout 7 hours. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
10145916|NCT04142346|Experimental|Sitting + moderate intensity breaks|Participants were instructed to sit throughout 7 hours, while interrupting the sitting position every 30 minutes to perform 2 minutes of moderate-intensity physical activity. The breaks consisted of walk up and down stairs and squats. Each person performed these exercise alternately. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
10145917|NCT04142359||Cohort A: CIS (either study)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
10145918|NCT04142359||Cohort B: High-Grade Ta/T1 Papillary Disease (either study)|Patients with histologically confirmed presence of BCG-unresponsive high-grade Ta/T1 papillary disease
10145919|NCT04142359||Cohort C: CIS (QUILT-3.032)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
10145920|NCT04142463|No Intervention|Before-group|This arm comprises patients who are recruited in phase 3 of the study, i.e. before the implementation of the care pathway. It is intended that patients included in phase 3 serve as a control-group for patients included in phase 6.
10145921|NCT04142463|Experimental|After-group|This arm comprises patients who are recruited in phase 6 of the study, i.e. after the implementation of the care pathway.
10145922|NCT04142138|Experimental|nutrition implementation|Volunteers with prehypertension, but otherwise healthy, will complete a screening visit, then be admitted to the In-Patient Unit for fourteen (14) days. Participants will be admitted for 5 days during the week and then go on pass for 2 weekend days each week with packed DASH diet meals. During hospitalization we will: 1) collect samples of blood and urine daily 2) monitor blood pressure, weight and pulse twice daily 3) collect 24-hour urine, twice during the period of two weeks 4) serve participants a menu based on DASH principles, namely low in sodium and high in potassium.
10145923|NCT04142151|Active Comparator|SanchiTongshu group|"Drug: SanchiTongshu The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.~Drug: Aspirin or Clopidogrel"
9528311|NCT03211897||Olanzapine 10mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
10145924|NCT04142151|Placebo Comparator|SanchiTongshu Placebo group|"Drug: placebo of Sanchitongshu The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).~Drug: Aspirin or Clopidogrel"
10145925|NCT04142112|Experimental|Ohana IVF Sperm Preparation Kit|Samples in the Ohana IVF Sperm Preparation Kit group will undergo product-specific multistep processing in the lab prior to insemination.
10145926|NCT04142112|Active Comparator|Standard IVF Preparation Kit|Samples in the Standard IVF Sperm Preparation Kit group will undergo traditional processing in the lab prior to insemination.
10145927|NCT04142229|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
10145928|NCT04142229|Active Comparator|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
10145929|NCT04142476|Experimental|Pharmaceutical Interview|Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance
10145930|NCT04142060|Experimental|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously
10145931|NCT04142190||ELONVA|Patients stimulated with Elonva
10145932|NCT04142190||PUREGON|Patients stimulated with Puregon
10145933|NCT04141995|Experimental|Treatment|Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.
10145934|NCT04142008|Experimental|Walk with Me app|
10145935|NCT04142099|Experimental|skin to skin contact 60 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.~Observe the time of newborn spent in suctioning the maternal nipple in 60 minutes of skin to skin contact.~No intervention or forced neonatal suction."
10145936|NCT04142099|Active Comparator|skin to skin contact 20 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.~Observe the time of newborn spent in suctioning the maternal nipple in 20 minutes of skin to skin contact.~No intervention or forced neonatal suction."
9971057|NCT01306565|Experimental|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
9971058|NCT01306578|Active Comparator|IVIG group|20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
9971059|NCT01306578|Active Comparator|Plasma Exchange|21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
10145937|NCT04141969|Active Comparator|RLP|ReaLife+
10145938|NCT04141969|Placebo Comparator|Inert|Inert brown powder to look similar to RLP
10145939|NCT04141969|No Intervention|Control|Not given RLP or the placebo
10145940|NCT04142047||HIV|Participants (ages 60 and above) with HIV
10145941|NCT04142047||Control|Participants (ages 60 and above) without HIV
10145942|NCT04142411|Experimental|Insulin and Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin and 20 mg of Sodium Hyaluronate
10145943|NCT04142411|Active Comparator|Insulin Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin
10145944|NCT04142411|Active Comparator|Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 20 mg of Sodium Hyaluronate
10145945|NCT04141891|Experimental|Driving Decision Aid|Web-based Driving Decision Aid
10145946|NCT04141891|Active Comparator|Older Drivers Website|National Institute on Aging (NIA) Older Drivers website
10145947|NCT04141943|Experimental|VR|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality
9971060|NCT01306591|Active Comparator|Bevacizumab 1|
10145948|NCT04141943|No Intervention|Printed document|The patients who are allocated to the Printed document arm will receive information about radiotherapy via printed document.
10145949|NCT04141826|Experimental|Hydrolysed whey|Hydrolysed whey
10145950|NCT04141826|Active Comparator|Intact whey|Intact whey
10145951|NCT04141826|Placebo Comparator|Caseinate|Caseinate
10145952|NCT04141722|Experimental|Sleep|
10145953|NCT04141722|Experimental|Wake|
10145954|NCT04141735||patients from September 2016 to September 2018|all patients underwent allogeneic hematopoietic stem cell transplantation
10145955|NCT04141709|Experimental|local ablative radiotherapy|The therapy is performed for all patients in the intervention arm using high-dose radiation therapy, either as conventional fractional irradiation with 2 Gy/fraction up to a total dose of 50 Gy or as hypofractional irradiation with a single dose of 10 Gy up to a total dose of 30 Gy.
10145956|NCT04141709|No Intervention|Observational group|"Effectiveness is measured as the rate in patients with PSA progression one year after randomization (defined as PSA nadir after randomization +2 ng/ml).~There is a 2:1 randomization between intervention and observation group."
10145957|NCT04141839|Other|Control|Delayed intervention: baseline and 3-month assessment prior to receiving the Safer Bars training.
10145958|NCT04141839|Experimental|Intervention|This arm with consist of bars randomized to have the Safer Bars training on their premises attended by all their liquor serving staff with assessment directly before and after training (pre/post), and at 3 and 6 months post-training follow-up.
10145959|NCT04141904|Experimental|Tofacitinib|Tofacitinib 5mg capsule twice a day for 7-10 days
10145960|NCT04141904|Placebo Comparator|Placebo|Placebo capsule twice a day for 7-10 days
10145961|NCT04141787|Active Comparator|Ceftriaxone|Ceftriaxone 2g IV q24hvia Gravity (or q12h in the case of CNS infections) Duration dependent on site of infection, determined by treating infectious diseases (ID) clinicians based on accepted clinical guidelines.
9971061|NCT01306591|Active Comparator|Bevacizumab 2|
9971062|NCT01306604||Observation|Patients from the first day of life with Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease
9971063|NCT01306630|Other|tivozanib + capecitabine|
10145962|NCT04141787|Active Comparator|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Usual Antibiotics to treat methicillin-susceptible Staphylococcal infections~Cloxacillin 2g IV q4h via Pump (dose adjusted for renal function)~Cefazolin 2g IV q8h via Preloaded Syringe (dose adjusted for renal function)~Daptomycin 6-10mg/kg IV daily via Gravity (dose will be determined based on the severity of infection as per discretion of the ID clinician and in accordance with most recent evidence)~Duration dependent on site of infection, determined by treating infectious diseases clinicians based on accepted clinical guidelines."
10145963|NCT04141917|No Intervention|Standard influenza surveillance|Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
10145964|NCT04141917|Active Comparator|Point-of-care molecular testing and treatment of influenza|Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A & B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .
10145965|NCT04141670|Experimental|Low dose group|Experimental: Low dose group Group of three participants who are treated with a low dose of S48168 (ARM210) for 28 days.
9669376|NCT02279095|Experimental|Palovarotene dose level 3|Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
10145966|NCT04141670|Experimental|High dose group|Experimental: High dose group Group of seven participants who are treated with a high dose of S48168 (ARM210) for 28 days.
10145967|NCT04141540|Other|"Groupe Twin 1"|Twin 1 with psychotic symptoms (PANSS +) Molecular analyses 1
10145968|NCT04141540|Other|"Groupe Twin 2"|Twin 2 without psychotic symptoms (PANSS +) Molecular analyses 2
10145969|NCT04141566||PCPC|pseudocontinent perineal colostomy using shmidt technique for perineal reconstruction after abdominoperineal resection
10145970|NCT04141566||PLIC|Permanenet left iliac colostomy , the standard technique after abdominoperineal resection and primary closure of the perineal wound
10145971|NCT04141605||SherpaPak CTS Patients|Patients whose donor heart was transported with the SherpaPak CTS
10145972|NCT04141605||Standard Transport Patients|Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years
10145973|NCT04141462|Experimental|Patients with a a constitutional genetic alteration|one genetic consultation and one blood test
10145974|NCT04141371|Active Comparator|Molar Sodium Lactate|
10145975|NCT04141371|Placebo Comparator|physiological serum|
10145976|NCT04141527||Primiparous women|82 primiparous obstetrical patients given intrathecal sufentanil for labor pain.
10145977|NCT04141527||Multiparous women|82 multiparous obstetrical patients given intrathecal sufentanil for labor pain.
10145978|NCT04141384|Other|General rehabilitation+Modular Interactive Tiles System, MITS|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment. In the experimental group, external stimulation (MITS) was added, and the training time was 65 minutes. Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
10145979|NCT04141384|No Intervention|General rehabilitation|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment.In the control group, each training time was 45 minutes.Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
10145980|NCT04141514|Experimental|intervention group|therapeutic fasting
10145981|NCT04141514|No Intervention|control group|usual alimentation
10145982|NCT04141436|Experimental|Intervention|Intervention Based on Hypnofertility
10145983|NCT04141436|Active Comparator|Control|Routine clinical procedure
10145984|NCT04141358||Study group|Patients with end-stage renal disease who will undergo arteriovenous fistula (AVF) surgery will be recruited and follow-up them up to 6 weeks or until the AVF become suitable for hemodialysis.
10145985|NCT04141501|Placebo Comparator|Control: Placebo|30 Patients will receive placebo
10145986|NCT04141501|Active Comparator|Intervention: Psilocybin|30 Patients will receive psilocybin
10145987|NCT04141449|Experimental|Potlako intervention|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation~Community-led cancer symptom awareness campaign to educate residents on methods and importance of early detection of cancer~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer.~Cross-sectional community-facing activities partnered with longitudinal clinic-based targeted educational program~Remote phone/SMS-based cancer suspect navigation program to support and expedite evaluation for symptoms/signs of possible cancer."
10145988|NCT04141449|Active Comparator|Enhanced Care|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation.~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer."
10145989|NCT04141488|Experimental|Experimantel Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own. The experimantel group was given strengthening exercises of the upper trapezoidal, middle trapezoidal and serratus anterior muscles with extra scapula muscles.
9528312|NCT03211897||Midazolam 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
9971064|NCT01306669|Active Comparator|Trivalent influenza vaccine|Single dose administration of trivalent influenza vaccine prior to onset of influenza season
10145990|NCT04141488|Other|Control Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own.
10145991|NCT04141332||Group 1|80 Patient
10145992|NCT04141332||Group 2|80 Control subject
10145993|NCT04141553|Active Comparator|Diltiazem IV push|In the standard IV push group, diltiazem will be administered at a dose of 0.25 mg/kg, to a max dose of 25 mg, over 2 minutes. At time 0, these participants will also receive 30 mg of immediate release oral diltiazem. After 15 minutes, if adequate rate control of <110 BPM has not been achieved, an additional dose 0.35 mg/kg to a max dose of 35 mg will be administered. In order to maintain the blind, the control group will also receive 50 mL of 0.9% NS IV over 20 minutes.
10145994|NCT04141553|Active Comparator|Diltiazem IV Slow Infusion|In the slow infusion group, 50 mg of diltiazem will be diluted in 50 mL of 0.9% NS and infused over 20 minutes. Similar the other group, these participants will also receive 30 mg of immediate release oral diltiazem. In order to maintain the blind, this slow infusion group will receive the equivalent volume of IV 0.9% NS over 2 minutes as a placebo.
10145995|NCT04141293|Experimental|Eligible patients|
10145996|NCT04141241|Experimental|Low Dose PH100: 800mg/day|"PH100 (Ecklonia cava Phlorotannin) 200mg/tablet~PH100 2 tablets (400mg) and Placebo 2 tablets BID during 12wks"
10145997|NCT04141241|Experimental|High Dose PH100: 1600mg/day|- PH100 4 tablets (800mg) BID during 12wks
10145998|NCT04141241|Placebo Comparator|Placebo|"Placebo 200mg/tablet~Placebo 4 tablets BID during 12wks"
10145999|NCT04141319|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
10146000|NCT04141319|Active Comparator|The control group|In the control group, preoperative peri-incisional scalp infiltration will be performed using 30ml of 60 mg ropivacaine and 0.1mg epinephrine.
10146001|NCT04141176|Experimental|Spiri+|new CPAP device
10146002|NCT04141345||Heart failure with chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
10146003|NCT04141345||Heart failure without chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. HF patients who did not have chronic lung disease were assigned as a non-CLD group.
10146004|NCT04141397||POG patients|Patients enrolled in POG who initiated WGTA between July 2014 and December 2017
10146005|NCT04141397||Usual care controls|Matched controls who received usual care and were diagnosed with metastatic cancer prior to December 2017
10146006|NCT04141163|Experimental|Metformin|Subjects randomized to metformin will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
10146007|NCT04141163|Placebo Comparator|Placebo|Subjects randomized to placebo will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
10146008|NCT04141254|Experimental|Debriefing|"a standardized follow-up visit at one month associated with debriefing and enhanced educative component"
10146009|NCT04141254|Other|Without debriefing|"a standardized follow-up visit at one month alone (i.e.; without debriefing and educative component)"
10146010|NCT04140877|Other|Visu OD, Control OS|Contralateral eye study
10146011|NCT04140877|Other|Control OD, Visu OS|Contralateral eye study
10146012|NCT04140994|Active Comparator|Intermittent theta burst stimulation|"Volunteers will be submitted to non-invasive parietal stimulation before a mirror drawing task.~A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver interrmittent bursts of bipolar magnetic pulses exerting an excitation on the underlying brain tissue (iTBS). The stimulation coil will be placed over the parietal cortex. Stimulation consisted of a burst of three pulses administered at 50Hz, repeated at a frequency of 5Hz, delivered in 2 s trains followed by an 8 s interval for a total of 600 pulses12. Stimulation intensity was set at 70% of RMT.~Each session will consist of two spaced neuronavigated iTBS applications, separated by 15 minutes."
9669377|NCT02279095|Experimental|Palovarotene dose level 4|All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
10146013|NCT04140994|Sham Comparator|Sham intermittent theta burst stimulation|For sham iTBS, the protocol is the same, except the sham coil produces no magnetic field.
10146014|NCT04140981||group 1|difficult intubation according to antropometric measurements
10146015|NCT04140981||group 2|not difficult intubation according to antropometric measurements
9971065|NCT01306669|Placebo Comparator|Normal saline|
10146016|NCT04140981||group 3|difficult intubation according to ultrasound measurements
10146017|NCT04140981||group 4|not difficult intubation according to ultrasound measurements
10146018|NCT04141475|Active Comparator|Alpha-Lipoic Acid group|
10146019|NCT04141475|Placebo Comparator|placebo group|
10146020|NCT04141189|Experimental|weekly|weekly fetal surveillance
10146021|NCT04141189|Active Comparator|bi-weekly (twice-weekly)|bi-weekly fetal surveillance
10146022|NCT04141111|Experimental|CGM intervention|Underwent intervention defined by the intermittent use of a continuous glucose monitoring (CGM) device.
10146023|NCT04140955|Experimental|Tapering plan and telephone counselling|Patients receive an individually customized tapering plan at discharge and telephone counselling 5-7 days after discharge.
10146024|NCT04140955|No Intervention|Control group|Patients receive standard care and treatment, i.e. no tapering plan or telephone counselling.
10146025|NCT04140838|Experimental|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
10146026|NCT04140838|Experimental|TAU + Behavioral Activation Therapy for Depression (BATD)|Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.
10146027|NCT04140838|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
10146028|NCT04140929|Experimental|Intervention group|In the intervention group, a range of clinical parameters are recorded and the dentists prepares an individual oral hygiene and care recommendation, based on the Oral Health Tool Box. The Box is also used for instructing the dental assistants and the nursing staff for each patient individually. It is then determined when and how the dental assistants re-evaluates the oral hygiene and care process and reinstructs and remotivates the nursing staff. If the examination reveals a need for dental treatment (possibly requiring referral and transport), this will be communicated to the nursing staff. The dental assistant will further receive a training in communication, enabling them in reinstruction and remotivation. Dentists and dental assistants will further receive a training in geriatric dentistry by the State Commissioner of the German Society for Geriatric Dentistry.
10146029|NCT04140929|No Intervention|Control group|In the control group, the residents receive care as usual. This includes the recording of the same parameters are recorded as in intervention group, a standardized form is filled out and handed over to the nursing staff. As in the case of Intervention group, the nursing staff is informed in the event of a need for treatment. No further measures are applied.
10146030|NCT04141033|Other|saliva neopterin levels|assessment of saliva neopterin levels in pre and post-menopausal women
10146031|NCT04141033|Other|GCF neopterin levels|assessment of GCF neopterin levels in pre and post-menopausal women
10146032|NCT04141124|Sham Comparator|Control|5 minutes of reading fictitious biological medical results that are almost normal and unrelated to the upcoming scenario. This condition reflects a likely activity in relation to other patients in charge, pending an announced critical situation.
9971066|NCT01306682|Active Comparator|Trivalent Influenza vaccine|0.5ml of TIV will be administered into deltoid muscle of non dominant arm
10146033|NCT04141124|Active Comparator|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
10146034|NCT04141124|Experimental|Breathing exercise combined with HRV|5 minutes of relaxing breathing, guided by a computer helping to follow inspiration and expiration and coupled with direct biological feedback on HRV.
10146035|NCT04140786|Experimental|Daily IV Gentamicin|Once daily (for 24 days) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
10146036|NCT04140786|Experimental|Biweekly IV Gentamicin|Twice weekly (for 3 months or 24 total) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
10146037|NCT04140916|Experimental|Midline catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
10146038|NCT04140916|Active Comparator|PICC-line catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
10146039|NCT04140812|Active Comparator|Term infants (≥37+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
10146040|NCT04140812|Experimental|Preterm infants (≤32+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
10146041|NCT04141098|Experimental|Total Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
10146042|NCT04140851|Experimental|overweight/obesity diet intervention group|Dietary fiber intervention
10146043|NCT04140851|Placebo Comparator|overweight/obese normal diet group|Normal diet
10146044|NCT04140851|No Intervention|healthy control group|Healthy people
10146045|NCT04140747||non-pregnant women|Samples will be collected from 30 healthy, non-pregnant women in the reproductive age: blood, urine, stool, saliva, oral swabs, vaginal swabs
10146046|NCT04140747||pregnant women delivering vaginally|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; cord blood, colostrum, meconium, infant oral swabs"
10146047|NCT04140747||pregnant women undergoing C-section|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; amniotic fluid, cord blood, colostrum, meconium, infant oral swabs"
10146048|NCT04140760|Active Comparator|Probiotic|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid probiotic (Symprove) daily following manufacturers guidelines for a period of 12 weeks."
10146049|NCT04140760|Placebo Comparator|Placebo|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.~Participants will take the liquid placebo daily for a period of 12 weeks following the same guidelines as for the probiotic."
10146050|NCT04140656|Active Comparator|Plantar sensitive exercise group|Plantar sensitive exercises:
10146051|NCT04140656|Active Comparator|Textured insole group|Textured insole group
10146052|NCT04140578|Experimental|Antibiotic|Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
9971067|NCT01306682|Placebo Comparator|Normal saline|0.5ml of normal saline administered into deltoid muscle of non dominant arm
9971068|NCT01306695|Experimental|NYUCI|New York University Caregiver Intervention (NYUCI) in addition to community-based case management using community health workers: The first component consists of two individual and four family counseling sessions that include relatives suggested by the caregiver.
10146053|NCT04140578|No Intervention|Control|Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
10146054|NCT04140643|Experimental|Ozone therapy|Oral hygiene instructions given by dental hygienist and home daily use of ozonated water delivering system.
10146055|NCT04140643|Active Comparator|Only oral hygiene instructions|Oral hygiene instructions given by dental hygienist.
10146056|NCT04140487|Experimental|Treatment (azacitidine, venetoclax, gilteritinib)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles, and gilteritinib PO QD on days 1-28. Treatment of azacytidine and venetoclax repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Cycles of gilteritinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10146057|NCT04140448||UWFA-RVO-ME|Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab
10146058|NCT04140474|Experimental|Archimedes procedure|All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure.
10146059|NCT04140513|Experimental|Diagnostic (dPET)|Patients receive fludeoxyglucose F-18 via injection and undergo dPET over 20 minutes after standard of care computed tomography (CT) imaging (week -2), after receiving 20-26 Gy and 40-46 Gy of radiation (weeks 3 and 5), and 3 months after completion of treatment. Patients with concern for residual disease may receive an additional dPET 6 months after treatment.
10185074|NCT03749382|No Intervention|Control|Neutral task plus the general stop smoking intervention in the form of a leaflet, administered by the investigator.
10185075|NCT03749369|Active Comparator|SRP plus salvadora persica root|Subjects receiving salvadora gel in addition to scaling and root planing
10185076|NCT03749369|Placebo Comparator|SRP only|Subjects receiving scaling and root planing only
10185077|NCT03749356|Experimental|Once-Daily Tacrolimus|One arm: TacroBell SR Cap.
10185078|NCT03749317|Experimental|Treatment|IVIEW-1201; four times per day (QID) for 7 days
10185079|NCT03749317|Placebo Comparator|Placebo|Placebo; four times per day (QID) for 7 days
10185080|NCT03749304|Experimental|ANI monitor|
10187782|NCT03722680|Experimental|Riluzole|The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
10187783|NCT03722680|Placebo Comparator|Placebo|Posology, administration and duration of treatment will be equivalent to riluzole group.
10187784|NCT03722667|Placebo Comparator|Technology-Based Component|A Technology-based interventions comprised of three technolgy components accessible via smartphone to support self-managing hypertension.
10187785|NCT03722667|Experimental|TechSupport|A Technology-based interventions comprised of three technolgy components plus positive psychological training accessible by smartphone to support self-managing hypertension.
10187786|NCT03722654|Experimental|MTFS|MTFS-I Installation
10187787|NCT03722654|No Intervention|Control|
10187788|NCT03722641|Placebo Comparator|Bread reference|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread.
10187789|NCT03722641|Experimental|Product 1: Milk|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on milk.
9519763|NCT03283865|Experimental|Ultrasound|"The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure.~All study participants will have ultrasound used for caudal block."
9519764|NCT03283839|Other|Temporomandibular disorder|
10187790|NCT03722641|Experimental|Product 2: Full fat milk + oat|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on full fat milk and oat with high fiber content.
9519765|NCT03283839|Other|Without temporomandibular disorder|
9669378|NCT02196844|Experimental|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
10146060|NCT04140461|Experimental|Trial|Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks
10146061|NCT04140461|Active Comparator|Control|Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks
10146062|NCT04140591|Placebo Comparator|Proton-pump inhibitor|PPI: Pariet EC 20 mg/QDAC
10146063|NCT04140591|Active Comparator|Propranolol+Proton-pump inhibitor|"Propranolol:~Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)~PPI: Pariet EC 20 mg/QDAC"
10146064|NCT04140669||Fetal Surgery Procedures|All pregnant women with a fetus diagnosed with a fetal abnormality and planning to undergo a fetal surgical procedure will be included in this single arm of the study.
10146065|NCT04140630||E-cigarette users and bystanders|Households with one e-cigarette user (adult (18 years old and above); e-cigarette exclusive user for at least 1 month; daily use of e-cigarettes inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of any tobacco products or e-cigarettes) and one bystander cohabiting with the user
10146066|NCT04140630||Conventional cigarette smokers and bystanders|Households with one smoker (adult (18 years old and above; manufactured cigarette exclusive smoker for at least 6 months; daily smoking inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the smoker
10146067|NCT04140630||Heated tobacco product users and bystanders|Households with one user of the heated tobacco product, HTP (adult (18 years old and above; • HTP exclusive user for at least 1 month; daily use of HTP inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the user
10146068|NCT04140630||Non-smokers and non-users (control)|Smoke free households (participants should be adult (18 years old and above), non e-cigarette user (never or former e-cigarette user >1 month), non-user of any kind of tobacco product (never or former user >1 month), and other household members should not be users of tobacco products or e-cigarettes
10146069|NCT04140695|Experimental|Tradipitant|Oral Capsule
10146070|NCT04140695|Placebo Comparator|Placebo|Oral Capsule
10146071|NCT04140617|Experimental|E-cigarette aerosol exposure in a room|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a 25 m3 room.
10146072|NCT04140617|Experimental|E-cigarette aerosol exposure in a car|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a car.
10146073|NCT04140422|Experimental|Hyperosmolar Eye Drops|5% sodium chloride eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
10146074|NCT04140422|Placebo Comparator|Lubricating Eye Drops|Lubricating eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
10146075|NCT04140435||TTNB group|Patients with PCLs suitable for biopsy.
10146076|NCT04140409|Experimental|Treatment|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
10146077|NCT04140383||Group 1, patients aged 85 years and older|75 eyes of 75 patients (39 female, 36 male) Mean age: 86,8 ± 1,8 years
10146078|NCT04140383||Group 2, patients aged 65 and 85 years|77 eyes of 77 patients (34 female, 43 male) Mean age:73,3 ± 5,2 years
10146079|NCT04140682|Experimental|PAV+ mode|Weaning with PAV+ mode
10146080|NCT04140682|Active Comparator|PSV mode|Weaning with PSV mode
10146081|NCT04140318|Experimental|treatment|combination therapy of PD-1 and chemotherapy including: sintilimab 200mg iv, 30-60min, q3w; nab-paclitaxel 125mg/m2, iv, d1,d8, q3w
10146082|NCT04140123|Experimental|ZSP1601-Dose 1|ZSP1601-50mg once daily
10146083|NCT04140123|Experimental|ZSP1601-Dose 2|ZSP1601-50mg twice daily
10146084|NCT04140123|Experimental|ZSP1601-Dose 3|ZSP1601-100mg once daily
10146085|NCT04140123|Placebo Comparator|Placebo|Placebo
10146086|NCT04140006|Active Comparator|Alendronate Gel (ALN)|After preparation, 0.05 ml of the gel containing 100 µg of ALN will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
10146087|NCT04140006|Active Comparator|Bone Morphogenic Protein Gel (BMP)|After preparation, 0.05 ml of the gel containing 100 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
10146088|NCT04140006|Active Comparator|Mixture Gel of ALN and BMP|After preparation, 0.05 ml of mixture gel containing 50 µg of ALN and 50 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
10146089|NCT04140006|Sham Comparator|Control|After preparation, the fixture will be inserted without topical application of any medication (20 fixtures)
10146090|NCT04139928|Experimental|Picometer-ionic form of magnesium chloride|
10146091|NCT04139928|Active Comparator|Magnesium citrate or magnesium oxide|
10146092|NCT04139928|Placebo Comparator|Placebo|
10146093|NCT04140292|Experimental|Vitamin D3 + Photodynamic therapy (PDT)|Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
10146094|NCT04139954||Rheumatoid arthritis and Spondyloarthritis|Patients using Biological or Targeted Synthetic DMARDs
10146095|NCT04139915|Experimental|10 mg daily RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 16 weeks
10146096|NCT04139915|Placebo Comparator|Placebo|Oral matching placebo once daily for 16 weeks
10146097|NCT04139941||Individuals with known or unknown HCV status|
10146098|NCT04140149||Participants|Adults who have made a suicide attempt in the past 3 months who have been referred to, and enrolled in, the Living with Hope class.
10146099|NCT04140058|Active Comparator|group O4|Patients received 4mg ondansetron.
9971069|NCT01306695|Other|CHW Intervention|Community-based case management using community health workers (CHWs): The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6.
10146100|NCT04140058|Active Comparator|group O6|Patients received 6mg ondansetron.
10146101|NCT04140058|Placebo Comparator|group C|Patients received normal saline.
10146102|NCT04140019||NSTEMI|
10146103|NCT04140253|Active Comparator|Standard Duloxetine treatment|Peroral treatment with duloxetine at a dose of 40 mg twice a day
10146104|NCT04140253|Experimental|Standard Duloxetine treatment with PFMT|Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
10146105|NCT04140188|Active Comparator|Axilla no touch|Volunteer patients who did not underwent to SLNB or axillary lymph node dissection during previous NSM
10146106|NCT04140188|Active Comparator|Axilla with previous SLNB|Volunteer patients who has underwent to SLNB but not axillary lymph node dissection during previous NSM
10146107|NCT04140136|Active Comparator|Treatment group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients.The investigational product is to be administered twice daily, at a dose of 400mg per day.
10146108|NCT04140136|Placebo Comparator|Placebo group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients. The placebo is similar in appearance but does not contain tocotrienols and consist of palm oil.
10146109|NCT04140201|Active Comparator|Receive oral hypoglycemic +omega 3|Eicosapentanoic acid + standard treatment
10146110|NCT04140201|Active Comparator|Receive oral hypoglycemic +statin|Simvastatin + standard treatment
10146111|NCT04140201|Active Comparator|Receive oral hypoglycemic +fibrate|Fenofibrate +standard treatment
10146112|NCT04140201|No Intervention|Receive oral hypoglycemic only|Standard treatment only
10146113|NCT04140032|Experimental|Intervention group|Centers in the group will participate in the A-B-C Healthy Me/Soy Saludable multi- component nutrition and physical activity preschool intervention.
10146114|NCT04140032|No Intervention|Control group|"Preschools in the group will continue with usual care practices. Control group preschools will receive intervention materials and accompanying instructions after follow-up measures are collected for each cohort."
10146115|NCT04140097||COPD patients with acute exacerbation|
10146116|NCT04140097||COPD patients without acute exacerbation|
10146117|NCT04140084|No Intervention|Translation, Redesign and Rapid prototyping with clinicians|This step includes a translation of the tools (English to French) and a redesign work of the original tools. Then, the study will include clinicians (at least 20) from two healthcare settings (CHU Sainte-Justine, and the CISSS-CA (Hotel-Dieu de Levis). After a presentation of the two tools during the Emergency Physicians' departmental meetings, the written comments about the prototype version will be collected. A revision of the prototypes is scheduled at the end of this step.
10146118|NCT04140084|No Intervention|Rapid prototyping with patients|This step will include the assessment of the tools by patients (or parents of patients) that have had a previous mTBI at the CISSS-CA (Hotel-Dieu de Levis). The comments about the adult and pediatric prototypes (5 adult patients, 5 parents of pediatric patients) will be collected through interviews. A revision of the prototypes is scheduled at the end of this step.
10146119|NCT04140084|Experimental|Real-life clinical meetings|This step will include a presentation of the tools to 5 emergency physicians so that they can use the tools with patients (5 adults, 5 parents of pediatric patients) in a realistic setting to identify any problems of use. The clinicians and patients that had used the tools during the clinical encounters will be then met during cognitive interviews to collect their comments on the tools and to address any usability issues. A final revision of the prototypes is scheduled at the end of this step.
10146120|NCT04140084|No Intervention|Training session developement|This step includes the development of a training session on how to perform SDM with patients facing the decision to undergo head CTs for mTBI and about how to use our newly developed decision aids in this clinical setting. The content of the training session will be adapted to the needs, goals, strengths and limitations observed during the focus groups (departmental meetings) exploring health professionals' barriers to using a decision aid about head CTs in mTBI. The expertise of SAVIE (www.savie.ca) in producing online and interactive elearning programs will be mobilized in order to produce a training program that will integrate the content the investigators will have identified as the main skills, knowledge and competencies needing development among our health professionals to stimulate the use of SDM and our decision aids. SAVIE will produce a virtual elearning program adaptable to all media (PC, mobile device, tablet) and different health professionals.
10146121|NCT04140084|No Intervention|Retrospective analysis|This step will retrospectively analyze the medical records of traumatic brain injury adult patients (adult, 350, Hotel-Dieu de Levis) and pediatric patients (406, CHU de Sainte-Justine and Hotel-Dieu de Levis)) randomly selected throughout the year preceding this study in each of the two centers to determine the rate of head CT ordering, the head CT result and the appropriateness of having ordered the head CT based on the CCHR and PECARN criteria. One reviewer will judge the appropriateness of having done a CT scan according to the CCHR and PECARN criteria based on a structured extraction form that will previously be approved by the study's steering committee. To ensure validity, 10% of the analysis will be reviewed by an expert. The reviewer will look at prehospital data collection, triage information, physician's notes, nursing notes and head CT requisition form information to determine if any of the clinical decision rule criteria are present.
10185081|NCT03749291|Experimental|Obemat2.0 Intervention Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
9971070|NCT01306708|Active Comparator|nimesulide|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral non-steroidal anti-inflammatory (nimesulide 100 mg, twice per day, for 14 days);
10146122|NCT04139980|Experimental|Virtual Reality supported therapy|"The Virtual Reality (VR) interface will be used during patients stay at the rehabilitation center. A research employee will install the VR system in the patient's room. Participants will be comfortable sitting while in VR session. Each interface consists of a head mounted display (HMD) allowing participants to see their arms and legs represented in the virtual environment. Participants will be able to control their virtual legs using hand controllers, which will allow them to walk through several virtual environments and gather points (no additional gaming elements are included)."
9971071|NCT01306721|Active Comparator|FEX 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)"
9971072|NCT01306721|Experimental|FEX 60 mg/PSE 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination~Double-blind treatment period:~1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)"
9971073|NCT01306721|Experimental|FEX 60 mg/PSE 120 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg"
9971074|NCT01306734||Gradient cooling group|Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
9971075|NCT01306734||Crash cooling group|Study group receiving rapid cooling using extracorporeal circulation. The protocol for rapid cooling is using routinely in the department and is not an experimental procedure. When cooling, the investigators aim for maximal difference in temperature between the heater-cooler unit of the ECC-machine.
10146123|NCT04139811|Other|non-ILM peeling group|vitrectomy without ILM peeling is done to all cases
10146124|NCT04139811|Other|ILM peeling group|vitrectomy with ILM peeling is done to all cases
10146125|NCT04139889||normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
10146126|NCT04139889||non-malignant lesions|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of non-malignant lesions after intravenous injecting 10% fluorescein.
10146127|NCT04139889||malignant lesions|pCLE images of malignant lesions were associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
10146128|NCT04139746|Active Comparator|Scleral Buckling|Scleral Buckling represents the gold standard for retinal detachment in young phakic patients.
10146129|NCT04139746|Experimental|Drainage-Injection-Pneumoretinopexy|Drainage-Injection-Pneumoretinopexy is a modified pneumatic retinopexy technique, in which, before injecting the gas, the drainage of the subretinal fluid is performed with a simultaneous injection of balanced salt solution (BSS) in the vitreous chamber.
10146130|NCT04140045|Experimental|Hypohydrated|Participants will be required to restrict their water intake during cycling in the heat (90-120 minutes at 35°C), in order to achieve a body mass loss of approximately 3%.
10146131|NCT04140045|Experimental|Euhydrated|Participants will be provided with water intake that matches their sweat losses during cycling in the heat (90-120 minutes at 35°C)
10146132|NCT04140240|Experimental|İntervention group|Experimental: İntervention group
10146133|NCT04140240|No Intervention|Control group|Control group: No intervention
10146134|NCT04139733|Experimental|Prone group|"Prone position within 6 hours after randomization.~Prone position for at least conservative hours per days during a minimum of 5 days."
10146135|NCT04139733|Other|Supine group|1. Supine group on ECMO.
10146136|NCT04139694|Experimental|Cinnamon with Food Plan|Group of ladies who will undergo testing, receive dietary intervention, and take cinnamon supplements.
10146137|NCT04139694|Active Comparator|Food Plan Only|Group of ladies who will undergo testing, receive dietary intervention, but will not get cinnamon supplements.
10146138|NCT04139759|Experimental|hand massage group|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
10146139|NCT04139759|Experimental|Foot massages group|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
10146140|NCT04139759|No Intervention|control group|The patients in the control group (n = 28) were not administered except nursing interventions in the HD unit.
10146141|NCT04139720|Experimental|e-book|e-book learning mode of sexual harassment prevention training
10146142|NCT04139720|No Intervention|audio-visual and booklet|sexual harassment prevention audio-visual and booklet learning mode
10146143|NCT04139824|Experimental|Cohort|Period 1: LC350189 200mg (QD) Day 1~ Day 4, Period 2: Naproxen 500 mg (BID) Day 8 ~ Day 12 , Period 3 : LC350189 200mg (QD) + Naproxen 500 mg (BID) Day 13~19
10146144|NCT04139707|Experimental|Caring4Dementia Group|The experimental group will receive Careing4Dementia downloadable on their smartphone or tablet. Caring4Dementia will tell and show caregivers of a person living with dementia how to 1) manage difficult behaviors, 2) deal with refusal, 3) deal with tensions and 4) manage work-life demands. The app is self-administered and self-paced and contains surveys referring to the outcome measurements tools used in the study. The intervention will be for 30 days without any restriction or limitation in terms of timing, location or frequency of use.
10146145|NCT04139707|Active Comparator|White Paper Group|The White Paper group will receive a white paper on the principles of communicating efficiently with persons living with dementia.
10146146|NCT04139707|No Intervention|Control Goup|The control group will not receive any intervention.
10146147|NCT04139668|Experimental|Vivitrol + MET/CBT|All participants will receive three 4ml doses of extended-release naltrexone 380mg (Vivitrol), administered by intramuscular injection. Three injections will be administered to each participant; one injection every 4 weeks for 12 weeks of treatment. In addition, all participants will receive weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy for 12 weeks.
10146148|NCT04139863|Other|aMMP-8 chairside test|Test group. The aMMP-8 chairside mouth rinse test is performed for the test group.It identifies adolescents with poor oral hygiene at risk for subclinical periodontitis without detectable and visible manifestations of the illness, such as periodontal deepened pockets.
10146149|NCT04139863|No Intervention|No test|The other group is control group. No test administered.
10146150|NCT04139525|Experimental|unfractionated heparin and 8% trisodium citrate|Unfractionated heparin and 8% trisodium citrate.
10146151|NCT04139850||Korean chronic hepatitis B patients cohort|Korean patients with chronic hepatitis B with or without antiviral therapy on a regular follow-up in tertially medical institution
10146152|NCT04139603|Active Comparator|Lumbopelvic kinesio taping (LPKT)|Two I-shaped kinesio tapes in 40 cm length will be applied bilaterally, beginning from 5 cm below the spina iliaca posterior superiors (SIPSs) to the level of the 12th costae, in maximum trunk flexion position, on the paravertebral muscles, by inhibition technique of muscle correction techniques. The tapes will be placed with no tension at 5 cm of both ends, and with 15-25% tension in between. In addition, an extra I-shaped tape will be placed perpendicullar to these tapes with the ligament correction technique, while the pregnant women are in the vertical upright position, at the level of the sacroiliac joints, starting with a tensile strength of 75-100% from the middle, and then with no tension at two ends.
10146153|NCT04139603|Experimental|Abdominal supported lumbopelvic kinesio taping (ALPKT)|An abdominal support tape will be added to the LPKT. In order to reduce the tension of the uterus ligaments, and to help perception of the normal elasticity of the target tissues, ligament technique will be used. The middle part of an I-shaped tape will be placed to the midpoint of the lower abdomen, and then will be progressed laterally and above with 50% tension.
10146154|NCT04139603|Placebo Comparator|Placebo taping|A Micropore™ surgical plaster of the same color with KT will be applied with no tension, as described in the LPKT technique.
10146155|NCT04139772|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
10146156|NCT04139772|Experimental|Abiraterone or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
10146157|NCT04139512|Other|guided surgery|test group, using a full digital workflow procedure
10146158|NCT04139512|Other|conventional technic|free- hand technic to place implant
10146159|NCT04139499||Adults with OSA|Adults with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
10146160|NCT04139499||Children with OSA|Children with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
10146161|NCT04139499||Adult control|Adult without any obstruction at four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent a control.
10146162|NCT04139499||Children control|Children exam will be done for all the participants. Subject without obstruction represent a control.
10146163|NCT04139460|Active Comparator|CRT-D|Implantation of cardiac resynchronization therapy with a defibrillator (CRT-D)
10146164|NCT04139460|Active Comparator|CRT-P|Implantation of cardiac resynchronization therapy pacemaker (CRT-P)
10146165|NCT04139382|Experimental|Intervention|Telephone Consultation for women requesting abortion
10146166|NCT04139382|Active Comparator|Control|Face-to-face consultation for women requesting abortion
10146167|NCT04139473|Active Comparator|Hepaticojejunostomy|Patients undergo right lobe living donor liver transplantation will receive hepaticojejunostomy
10146168|NCT04139473|Active Comparator|Duct-to-duct anastomosis|Patients undergo right lobe living donor liver transplantation will receive duct-to-duct anastomosis
10146169|NCT04139395|Experimental|Diagnostic 68Ga-Citrate PET/MRI Imaging|Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.
10146170|NCT04139629|Other|antibody positive (CAT+)|patients found positive for one of the assayed antichlamydial antibodies
10146171|NCT04139629|Other|antibody negative (CAT-)|women with negative antichlamydia antibody test
10146172|NCT04139590|Placebo Comparator|Visual Analogue Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Visual Analogue Scale."
10146173|NCT04139590|Active Comparator|Visual Analogue Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Visual Analogue Scale."
10146174|NCT04139590|Placebo Comparator|Numeric Rating Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Numeric Rating Scale."
10146175|NCT04139590|Active Comparator|Numeric Rating Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Numeric Rating Scale."
10185082|NCT03749291|Active Comparator|Control Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
9519766|NCT03283800|Experimental|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
10146176|NCT04139681|Experimental|A. Vogels Sore Throat Lozenges|Each patients receives 1 glass containing 20 A.Vogel Sore Throat lozenges at inclusion visit 1. They first suck under supervision in the study centre one Vogel Sore Throat lozenge and document every 15 minutes the pain 90 minutes. Patients will receive the rest of the bottle still containing 19 Vogel Sore Throat lozenges and have to take them for 4 days (5 lozenges per day, throughout the day) and record tonsillitis pain.
10146177|NCT04139408|Experimental|Disposable Pulmonary Surgical Marker|Locate the pulmonary nodules with Disposable Pulmonary Surgical Marker before VATS.
10146178|NCT04139551||1XXX Denono PD|Newly diagnosed unmedicated PD patients
10146179|NCT04139551||2XXX Mild /Moderate PD|Early to moderate stage PD patients well controlled on medication(typically fewer than 8 years since diagnosis)
10146180|NCT04139551||3XXX Advanced PD|Advanced PD patients (typically greater than 8 years duration)
10146181|NCT04139551||4XXX DBS patients|PD patients with deep brain stimulation systems
10146182|NCT04139551||5XXX PSP patients|PSP patients
10146183|NCT04139551||6XXX Healthy Controls|Age-frequency matched healthy controls
10146184|NCT04139785|Experimental|Intervention|Guided Cognitive Behavioural Therapy based app
10146185|NCT04139785|No Intervention|Care as usual|Care as usual
10146186|NCT04139356|Experimental|Patients with rest O2 desaturation|Patient will undergo an experimental protocol consisting of 10 deep inspirations to measure and characterize changes on pulse-oxymetry values
10146187|NCT04139330|Experimental|NPC-06 (high dose)|Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.
10146188|NCT04139330|Experimental|NPC-06 (low dose)|Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes
10146189|NCT04139330|Placebo Comparator|NPC-06 (placebo)|Infuse NPC-06 (placebo) over 12 minutes or 18 minutes
10146190|NCT04139577|Experimental|Fecal Microbiota Transplant (FMT) FOR HIGH-RISK ACUTE GVHD|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~this research study for up to 6 months. You may receive up to 2 cycles of the study treatment.~- Fecal Microbiota Transplant ( FMT)- Oral Study Drug, predetermined dosage and timings, up to 2 cycles.~One cycle of treatment consists of one induction week of FMT followed by three weeks of maintenance FMT.~The maintenance weeks happen for 3 weeks after the induction week.~All doses will be administered in the clinic.~A second cycle of treatment as deemed appropriate"
10146191|NCT04139421|Active Comparator|Urban Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in urban green space.
10146192|NCT04139421|Experimental|Rural Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in rural green space.
10146193|NCT04139642||Group AB|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
10146194|NCT04139642||Group BA|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
10146195|NCT04139031||Fluid loading group|Mechanically ventilated patients with low tidal volume in the intensive care unit whom clinician decided to provide fluid for correction of hypovolemia
10146196|NCT04139044|Experimental|Stable Ankle Training Group (SG)|Balance Exercise Training for Only The Stable Ankle
10146197|NCT04139044|Experimental|Unstable Ankle Training Group (UG)|Balance Exercise Training for Only The Unstable Ankle
10146198|NCT04139044|No Intervention|Control Group (CG)|No balance exercise training
10146199|NCT04139057|Experimental|EBV TCR-T|EBV-specific TCR-T cell with anti-PD1 auto-secreted element
10146200|NCT04139226|Experimental|Administration of CC-11050|Part 1: Single Ascending Dose Part 2: drug-drug interaction/ food effect (DDI/FE)
10146201|NCT04139213|Active Comparator|Usual care|usual medication assisted treatment for maintenance care of opioid use disorder
10146202|NCT04139213|Experimental|Pharmacy MAT|pharmacy-based medication assisted treatment for maintenance care of opioid use disorder
10146203|NCT04139135|Experimental|HLX10|HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase
10146204|NCT04139135|Placebo Comparator|Placebo|Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
10146205|NCT04138966||Patients undergoing general anesthesia|Patients are monitored with Nol-Index, skin conductance, and antinociception-index
10146206|NCT04138979||Control group|20 healthy volunteers were included in the healthy control group
10146207|NCT04138979||Disease group|First chemotherapy for breast cancer
10146208|NCT04138992|Experimental|study group A|"bevacizumab combined with neoadjuvant chemotherapy and concurrent chemoradiotherapy：~bevacizumab combined with neoadjuvant chemotherapy for 2 cycles: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; Docetaxel 75mg/m2, intravenous injection，once three week;~bevacizumab combined with concurrent chemoradiotherapy: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor"
10185083|NCT03749239|Experimental|Effects of collagen protein.|Non-hydrolized collagen protein
9971076|NCT01306747|Experimental|Chronic Pain Self-Management|
10146209|NCT04138992|Experimental|study group B|study arm: bevacizumab combined with concurrent chemoradiotherapy： Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
10146210|NCT04138992|Active Comparator|control|standard concurrent chemoradiotherapy: DDP 40mg/m2, intravenous injection，once a week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
10146211|NCT04139187|Experimental|Experimental|Individuals randomized to experimental group.
10146212|NCT04139187|No Intervention|No Intervention Control|Individuals without quadriceps dominance randomized to no intervention group.
9519767|NCT03283800|Placebo Comparator|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
9519768|NCT03283748|Experimental|Measurement of Motor Movements|Wearable Accelerometer Sensors manufactured by leading manufacturers will be given to the participants to be worn around hands and legs. These sensors will be used to measure accelerations which will be impacted by the motor movements.
10146213|NCT04139070|Experimental|Treátment group|8 patients are expected to be included in this study. The patients will be treated once with bleomycin in combination with elektroporation
10146214|NCT04139174||adolescent group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).~measurements will be done on the radiograph using digital software."
10146215|NCT04139174||adult group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).~measurements will be done on the radiograph using digital software."
10146216|NCT04139239||Patients with disorders of consciousness|
10146217|NCT04138914|Experimental|Focal Cryotherapy|Focal Cryotherapy using 2 freeze-thaw cycles
10146218|NCT04139161|Experimental|Q-Factor Intervention|Participants will progress through three increasing Q-Factors for each cycling workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated.
10146219|NCT04139083||TVM group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with TVM
10146220|NCT04139083||LSC mesh suspension group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with LSC mesh suspension
10146221|NCT04139148|Active Comparator|True tDCS Combined With CCAT|Ture transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including drug knowledge every week, self-evaluation every two weeks and outpatient follow-up reminder every four weeks.
10146222|NCT04139148|Sham Comparator|Sham tDCS Combined With CCAT|Sham transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including only outpatient follow-up reminder every four weeks.
10146223|NCT04139148|No Intervention|Control group|During the treatment, the participants in control group only received treatment such as education of psychology, health and judicature, physical training as well as vocational training as usual in the compulsory rehabilitation center.
10146224|NCT04139291|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema
10146225|NCT04139005|Experimental|Awareness-Connection|
10146226|NCT04139005|Experimental|Awareness-Insight|
10146227|NCT04139005|No Intervention|Wait list|
10146228|NCT04139265||Hospitalized patients aged 65 and over|- Patients aged 65 and over hospitalized in the department of Internal Medicine and Geriatry
10146229|NCT04138901|Experimental|Group T|Patients receiving bilateral subcostal TAP block.
10146230|NCT04138901|No Intervention|Group C|Patients not receiving bilateral subcostal TAP block.
10146231|NCT04138940|Experimental|Distributed, Short Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 5 sentence-long script.
10146232|NCT04138940|Experimental|Distributed, Long Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 10 sentence-long script.
10146233|NCT04138940|Experimental|Massed, Short Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 5 sentence-long script.
10146234|NCT04138940|Experimental|Massed, Long Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 10 sentence-long script.
10146235|NCT04138745||Control|Historical control patients that are matched to the surgery type
9519769|NCT03283735|Experimental|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
9519770|NCT03283735|No Intervention|Control|This will be the control group.
10146236|NCT04138745||Experimental|After the practice change of TTP was initiated, the future pediatric patients were put into a database.
10146237|NCT04138732|Experimental|Intervention treatment group|This arm will receive the intervention treatment aimed to help improve their health behaviors. Interventions will include nutrition workshops and personal consultation for employees at risk, environmental intervention that includes brief exercise session prior to weekly meetings, placement of sports equipment in the department, and pedometer program, and stress reduction workshops. Healthy options will be demarcated in the hospital cafeteria.
10146238|NCT04138732|Other|Control group|This arm will be the control group and not receive the intervention treatment aimed to help improve their health behaviors.Once completing their time as the control group, they will continue into another phase of the trial and receive the intervention treatment.
9519771|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI >40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
9971077|NCT01306747|No Intervention|Control group|
10146239|NCT04138784|Experimental|Comprehensive Rehabilitation program|19 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks individualized comprehensive rehabilitation program administered once a day.
10146240|NCT04138784|Experimental|Aquatic training|18 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks hydrotherapy intervention once a day.
10146241|NCT04138654|Experimental|Normal nitrite levels|Processed meat products enriched with natural compounds will contain normal nitrite levels.
10146242|NCT04138654|Experimental|Reduced nitrite levels|Processed meat products enriched with natural compounds will contain reduced nitrite levels
10146243|NCT04138628|Experimental|ctDNA screening arm|Flat dose 1200 mg Atezolizumab every three weeks for up to 13 months
10146244|NCT04138667|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema who will undergo complex decongestive therapy
10146245|NCT04138862|Active Comparator|Sensory Matched/Unlabelled|Sensory-matched covert calorie reduction, unlabelled
10146246|NCT04138862|Experimental|Sensory Matched/Labelled|Sensory-matched explicit calorie reduction, labelled
10146247|NCT04138862|Experimental|Sensory Reduced/Labelled|Sensory-reduced explicit calorie reduction, labelled
10146248|NCT04138862|Experimental|Sensory Enhanced/Labelled|Sensory-enhanced explicit calorie reduction, labelled
10146249|NCT04138849|Experimental|BBT-877 Low Dose|
10146250|NCT04138849|Experimental|BBT-877 Mid Dose|
10146251|NCT04138849|Experimental|BBT-877 High Dose|
10146252|NCT04138849|Placebo Comparator|Placebo|
10146253|NCT04138524|Experimental|interventional|All the participants will received the full SAFIR. SAFIR is composed with 5 core components: 1) assessment of the family, 2) emotional support, 3) information, 4) family engagement, 5) care coordination. Each family will participate in 3 structured family meetings, with a follow-up at 30 days. During each meeting, every core component will be delivered but their dose will be adapted following the priorities of the families.
10185084|NCT03749226|Active Comparator|AZLI group|Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator
10185085|NCT03749226|No Intervention|Control group|Patients assigned to control group will no receive any intervention for heavy Gram negative colonization
10185086|NCT03749213|Experimental|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
10185087|NCT03749200|Experimental|Obemat2.0 Intervention Group|Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
10185088|NCT03749200|Active Comparator|Control Group|Control Intervention: regular practise in primary care (11 individual monthly visits) Duration: 12 months (+3 months). Setting: Primary care centers. Providers: standard pediatritians and nurses Children and their families receive the usual recommendations conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity. At visits, the family receive explanations about carrying out a balanced diet, divided into 5 meals, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports regular practise is recommended. Monthly visits are organized in which weight and height are measured and compliance with advice is reviewed.
10185089|NCT03749174|Active Comparator|Long acting anesthetic block/plaster|Intervention 1: Blockade will be given supraclavicularly with Long acting local Anesthetic (n=30) combined with post operative plaster immobilization.
10185090|NCT03749174|Active Comparator|Short acting anesthetic block/plaster|Intervention 2: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) combined with plaster immobilisation postoperatively
10185091|NCT03749174|Active Comparator|Short acting anesthetic block/orthotic|Intervention 3: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) and combined with orthosis for postoperative immobilisation
10185092|NCT03749174|Active Comparator|General Anesthesia and plaster|Intervention 4: General anesthesia wil be administered for surgical procedure combined with postoperative plaster immobilisation (n=30),
10185093|NCT03749161|Experimental|Lentis comfort|Patient will receive the low-add multifocal IOL during cataract surgery
10185094|NCT03749161|Experimental|Lentis L-313|Patient will receive the monofocal IOL Lentis L-313 during cataract surgery
10185095|NCT03749096|Active Comparator|Intravenous immunoglobulin|IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).
10185096|NCT03749096|Placebo Comparator|Placebo|
10185097|NCT03749083||Tumor Sequencing|"Quality of life assessments will be collected using The Functional Assessment of Cancer Therapy- Colorectal~Blood for circulating tumor DNA will be collected"
10185098|NCT03749044|Experimental|Patient Educational Tool|At the baseline visit, after having responded to the questionnaire, participants in the education arm will be given the patient educational tool.
10185099|NCT03749044|No Intervention|Standard of Care|Subjects in the standard of care arm will not receive the patient educational tool. If participants ask specific questions on pregnancy complications and/or preeclampsia, the clinicians will provide relevant information as they judge appropriate, but without handing out the patient educational tool.
10185100|NCT03749031|Placebo Comparator|Orange juice only|16 oz. orange juice per day for 4 weeks
10185101|NCT03749031|Experimental|orange juice + orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
10185102|NCT03749031|Placebo Comparator|Apple juice only|16 oz. apple juice per day for 4 weeks
10146254|NCT04138420||Patients receiving Bevacizumab|Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.
10146255|NCT04138381|Other|selinexor as a single agent and in combination with imatinib|"This is a single-arm, two-cohort, open label phase Ib/II trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of:~Cohort A: an initial escalation phase (Ib) evaluating increasing doses of selinexor in combination with fixed doses of imatinib administered in repeated 28-day cycles in advanced/metastatic, imatinib-resistant GIST patients, followed by en expansion phase (II) testing for safety and preliminary evidence of antitumor activity~Cohort B: single-agent, fixed selinexor dose in the same target population"
10146256|NCT04138459||Qualitative exploration|Ten community mental health service users will be interviewed with their most important mental health worker to explore how recovery orientation of services affects roles and collaboration.
10146257|NCT04138563||Case|Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
10146258|NCT04138563||Control|Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years
9971078|NCT01306760|Experimental|Ketamine|Ketamine used as the anaesthetic during ECT.
10146259|NCT04138589||CF patients aged 6-18 years homozygeous for delta F508|CF patients aged 6-18 years homozygeous for delta F508 starting with lumacaftor/ ivacaftor or tezacaftor/ ivacaftor
10146260|NCT04138693|Experimental|Cohort 1: 2 x 2.0 g G-PUR® oral suspension|
10146261|NCT04138693|Experimental|Cohort 2: 1 x 2.0 g G-PUR® oral suspension|
10146262|NCT04138693|Placebo Comparator|Cohort 3: Placebo oral suspension|
10146263|NCT04138888|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in Period 1 and a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10146264|NCT04138888|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in Period 1 and a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10146265|NCT04138602|Active Comparator|Emsella Chair Active Treatment with Dietary Counseling|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%. During the visit the subject will also receive dietary counseling.
10146266|NCT04138602|Placebo Comparator|Emsella Sham Treatment with Dietary Counseling|Sham subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power). During the visit the subject will also receive dietary counseling.
10146267|NCT04138836|Experimental|Midazolam|
10146268|NCT04138836|Experimental|Itraconazole|
10146269|NCT04138836|Experimental|Esomeprazole|
10146270|NCT04138719|Experimental|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
10146271|NCT04138719|Active Comparator|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；
10146272|NCT04138511|Experimental|Experimental group (ECOFISIO)|Ecofisio Group received the ECOFISIO mobile application after students had received theoretical-practical lessons about ultrasound skills in sports pathologies areas, to study the subject.
10146273|NCT04138511|No Intervention|Control Group|Students received theoretical-practical lessons about ultrasound skills in sports pathologies areas and used traditional study models, to study the subject
10146274|NCT04138368|Experimental|dyadic treatment|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
10146275|NCT04138368|Active Comparator|supportive treatment|mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
10146276|NCT04138277|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
10146277|NCT04138355|Experimental|Extracorporeal shock wave therapy group|. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
9971079|NCT01306760|Active Comparator|Propofol|Propofol, the standard anaesthetic, used during ECT.
9971080|NCT01306773|Active Comparator|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma
10146278|NCT04138355|No Intervention|conventional manual therapy|the same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy.
10146279|NCT04138407|Experimental|Intervention|
10146280|NCT04138407|Other|Control|Usual rehabilitation exercise
10146281|NCT04138290|Experimental|Predictix Antidepressant Software tool|Predictix Antidepressant Software tool will be used when prescribed with a medication for their MDD, by their treating physician.
10146282|NCT04138342|Active Comparator|Quantum dots nanoparticles group|A group of female volunteers infected with breast cancer will receive topical Quantum dots in different dosage forms.
10146283|NCT04138342|Placebo Comparator|Topical approved placebo cream|A group of female volunteers infected with breast cancer will receive placebo cream as a negative control.
10146284|NCT04138446|Experimental|200-3000|Day 1: 200m (above sea level) asl Day 2: 3000m asl
10146285|NCT04138446|Experimental|3000-200|Day 1: 3000m asl Day 2: 200m asl
10146286|NCT04138446|Experimental|200-5000|Day 1: 200m asl Day 2: 5000m asl
10146287|NCT04138446|Experimental|5000-200|Day 1: 5000m asl Day 2: 200m asl
10146288|NCT04138446|Experimental|3000-5000|Day 1: 3000m asl Day 2: 5000m asl
10146289|NCT04138446|Active Comparator|5000-3000|Day 1: 5000m asl Day 2: 3000m asl
10146290|NCT04138329|Active Comparator|Lichtenstein Technique|In this arm the inguinal hernia repair was made with the Lichtenstein technique by surgeons with experience in this kind of plasty using the conventional polypropylene mesh.
10146291|NCT04138329|Experimental|Onstep Technique|In this arm the inguinal hernia repair was made with the Onstep technique by one surgeon with experience using the Bard's 3DMAX mesh.
10146292|NCT04138225||Healthy|Healthy participants are those without IBS, IBD or any other gastrointestinal disorder
10146293|NCT04138225||Irritable bowel syndrome (IBS)|Participants with Rome IV diagnosed IBS
10146294|NCT04138225||Inflammatory bowel disease (IBD)|Patients with IBD - either ulcerative colitis (UC) or Crohn's disease (CD)
10146295|NCT04138303|Experimental|Exercise Only Group (EX)|Participants will only receive the exercise protocol without nutrition education or counseling and instructed to continue to consume their regular diet.
10146296|NCT04138303|Experimental|Exercise with CR-LC Group|Participants will receive the exercise protocol and CR-LC Diet regimen.
10146297|NCT04138303|Experimental|Exercise with Ancestral Diet (AD) Group|Participants will receive the exercise protocol and AD regimen.
10146298|NCT04138771|Experimental|Eligible patients for AI test|Device: an artificial intelligence system for postoperative management of cataract patients. These patients are enrolled in primary healthcare units and the AI clinic at Zhongshan Ophthalmic Center.
10146299|NCT04138472|Experimental|Dexmedetomidine|Group A patients receive intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
10146300|NCT04138472|Experimental|Fentanyl|Group B receives intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
10146301|NCT04138472|Experimental|Lidocaine|Group C patients receives intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
10146302|NCT04138264|Active Comparator|Peroperative counseling|
10146303|NCT04138264|No Intervention|No preoperative counseling|
10146304|NCT04138485|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
10146305|NCT04138485|Placebo Comparator|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
10146306|NCT04138537|Other|Acromegaly group|CCCRC test and OB volume results
10146307|NCT04138537|Other|Control Group|CCCRC test and OB volume results
10146308|NCT04138251|Experimental|Treatment|Oral empaglifozin 5 mg 1x/day, increase up to 10 mg 1x/day if no 25% decrease of blood1,5-anhydroglucitol level
10146309|NCT04137978|Active Comparator|ADV7103|"Patients receive ADV7103 twice a day at optimal dose. Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.~Other Names:~• Potassium Citrate and Potassium Bicarbonate"
10146310|NCT04137978|Active Comparator|Standard of care comparator|Alkalinising treatment (SoC) taken at the usual dose and frequency
10146311|NCT04137991|Experimental|Nol-Guided Analgesia Group|In the Nol-Guided Analgesia Group remifentanil effect site concentration will be adapted to maintain the NOL-index between 10 and 25 throughout the anesthetic.
10146312|NCT04137991|Active Comparator|Standard Analgesia Group|Remifentanil titration in the Standard Analgesia Group will be left at the anesthesiologists discretion (i.e., guided by heart rate, blood pressure, and experience).
10146313|NCT04138095|Other|Virtual Reality|As this is a within subject design, participants will act as their own control. Participants will have access to their baseline opioids and benzodiazepines for pain and anxiety. Every second day they will have access to virtual reality as an adjunct to their opioids and benzodiazepines to manage their symptoms
10146314|NCT04137952|Experimental|deterministic visual error gain|"Day1(Pretest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min~Day2 to Day5:~Exp.group:27 times of posture tracking with high visual error gain.~Control group:27 times of posture training with normal visual error gain.~Day6 (Posttest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min"
10146315|NCT04137952|Experimental|stochastic visual noise|"Day1(Pretest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min~Day2 to Day5:~Exp.group A:27 times of posture training with posture tracking signal-to-noise ratio=2:1.~Exp.group B:27 times of posture training with posture tracking signal-to-noise ratio=4:1.~Control group:27 times of posture training with normal visual error gain.~Day6(Posttest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min"
10185103|NCT03749031|Experimental|Apple Juice + Apple Pomace|16 oz. apple juice + apple Pomace per day for 4 weeks
10187791|NCT03722641|Experimental|Product 3: Skim milk + oat, high fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with high fiber content.
10187792|NCT03722641|Experimental|Product 4: Skim milk + oat, low fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with low fiber content.
10146316|NCT04137952|Experimental|intermittent visual gain|"Day1 (Pretest):~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec.~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec~air pillow stance, 8 times/1 min~Day2 (training section):~Exp. group:Posture tracking with wearing flash glasses (low frequency with opaque ratio 50%), 12 times/45 sec.~Control group:Posture tracking with wearing flash glasses (clear), 12 times/45 sec.~Day3 (Posttest):~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec~air pillow stance, 8 times/1 min"
10146317|NCT04138147|Active Comparator|Superficial cervical plexus with auriculotemporal nerve blocks|
10146318|NCT04138147|Experimental|Cervical retrolaminar with auriculotemporal nerve blocks|
10146319|NCT04138030|Active Comparator|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
10146320|NCT04138030|Active Comparator|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
10146321|NCT04138186|Experimental|2.0g G-PUR® capsules|
10146322|NCT04138186|Placebo Comparator|Placebo capsules|
9826142|NCT02409719|Active Comparator|Control - Verbal information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
10146323|NCT04138160|Experimental|5:2 intermittent energy restriction|The 5:2 intermittent energy restriction (IER) of 70% restriction (~600 kcal) delivered for two non-consecutive days/week and no restriction (so sufficient energy to meet the requirement of participants) on the other 5 days/week.
10146324|NCT04138160|Other|Continuous energy restriction|The continuous energy restriction (CER) of 20% restriction below the estimated requirement of participants (~1600 kcal) 7 days/week.
10146325|NCT04137861|Active Comparator|Mineral Trioxide Aggregate (MTA)|Root repair material
10146326|NCT04137861|Experimental|bioceramics|Root repair material
10146327|NCT04138108|Experimental|Experimental Group|Two sessions of psychoeducation were given to the parents in the experimental group.
10146328|NCT04138108|No Intervention|Control Group|The parents in the control group did not undergo any intervention and the children of the parents in this group continued their current treatment plans.
10146329|NCT04138004|Experimental|2-L PEG with LB|"PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes (sodium sulfate, sodium hydrogen carbonate, sodium chloride, and potassium chloride) and is taken by diluting one sachet into 2-L of plain water. The patients were instructed to take 250 mL every 15 min untill the entire solution was consumed.~In this group (2-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 9.00 pm and the remaining dose was given in the morning at about 5.00 to 6.00 am on the procedure day. And these patients, one 24 mcg tablet of LB was given 2 hours before PEG ingestion (at 6.00 pm of the pre-procedure day)."
10146330|NCT04138004|Active Comparator|4-L PEG|In this group (4-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 10.00 pm and the remaining dose was given in the morning at about 5.00 to 7.00 am on the procedure day.
10146331|NCT04138121|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
10146332|NCT04138082|Experimental|High-dB Environment|While performing the spinal anesthesia, the participants were exposed to a pre-recorded soundtrack of one of the investigators' operating rooms while the anesthesiology team was performing a spinal anesthesia. It included instruments noise and discussion but alarms, pulse oximetry and discussion with the patient were removed. The level of the soundtrack was set to be at 70 dB with peaks up to 100 dB, this level was recorded for every participant with Iphone™ application SoundMeter X 10.3 by Faber Acoustical, which has been both choosed in accordance with similar studies. The average noise was measured using the LEq value on a ''A'' scale (dB(A)) which correlate with frequencies perceived by the human ear. Speakers where placed at each corner of the room. Since literature describe that noise can initially enhance performance but is a transitory effect, the investigators decided to expose the experimental group to the maximum level of noise without any gradation.
10146333|NCT04138082|No Intervention|Low-dB Environment|The control group performed the same spinal anesthesia simulation scenario but without any soundtrack. The ambient noise in the room was recorded with the same method for each participant.
10146334|NCT04138069|Experimental|PLB+Aerobic Bicycling|Pursed Lip Breathing + Aerobic Bicycling
10146335|NCT04138069|Active Comparator|Aerobic Bicycling|Only Aerobic bicycling
10146336|NCT04138238||Supraflex Cruz Sirolimus-eluting Stent|
10146337|NCT04137939|No Intervention|Control group|Ctrl group is instructed to maintain their original daily life
10146338|NCT04137939|Experimental|Smart Exercise group|SE group are instructed to perform one session of upper extremity ergometer and one session of lower extremity ergometer in a week, 30 minute per session, lasting for 12 weeks.
10146339|NCT04138212|Active Comparator|Chemotherapy group|Patients in this group will receive neoadjuvant chemotherapy.
10146340|NCT04138212|Experimental|Chemoradiation group|Patients in this group will receive neoadjuvant chemoradiation therapy.
10146341|NCT04137926|Experimental|Alzheimer's disease|
10146342|NCT04137926|Experimental|MCI due to AD|
9971081|NCT01306773|Active Comparator|Oral Oseltamivir alone|Oseltamivir 75mg bid during ICU hospitalization
10146343|NCT04137926|Experimental|Normal Elderly|
10146344|NCT04137848|Experimental|Experimental|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
9971082|NCT01306786|Active Comparator|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
10146345|NCT04137848|Sham Comparator|Control|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
10146346|NCT04137913|Experimental|Music Group|Individuals in the music group will complete two assessment visit (pre-intervention and post-intervention). After their baseline visit, they will participate in a 6-week group music class, scheduled for 2 hours a day, 3 days a week. The daily music workshops will be led by a musician associated with the Rice Shepherd School of Music. Each week will be carefully scaled in difficulty, with the workshops becoming progressively more sophisticated. For instance, the first week's listening will focus on short and more familiar works such as instrumental etudes and folk songs. Gradually, the instructor will build towards symphonic movements, as well as more unfamiliar and experimental music. The course will culminate in creating a final composition.
10146347|NCT04137913|No Intervention|Non-music group|Individuals in the non-music group will complete two assessment visits separated by 2-3 months. They will be asked not to participate in any other music-related courses during the time they are enrolled in the study. At the end of participation, participants will be given resources to seek out music classes.
10146348|NCT04137874|Experimental|eSTROKE|
10146349|NCT04137874|Active Comparator|Control|Conventional prehospital care
10146350|NCT04137835|Experimental|Showmotion|"Performing an analysis requires the positioning of sensors on the patient's skin in predetermined positions, according to the related protocols. Each sensor positioned on patient's skin provides both raw data (accelerometer, magnetometer, gyroscope) and the orientation matrix, representing the orientation of the local System of Reference (SoR) with respect to a fixed SoR. A proprietary sensor-fusion algorithm allows provides an accurate estimate of the orientation, as assessed by stereo-photogrammetric system-based testing.~Data from each sensor are sampled at 50 Hz and transferred wirelessly to a laptop with a proprietary software that processes the data according to the biomechanical model chosen for the analysis."
10146351|NCT04137640|Other|endocrine group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into endocrine group.
9669379|NCT02196844|Experimental|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
10146352|NCT04137640|Other|chemotherapy group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into chemotherapy group
10146353|NCT04137536|Experimental|Pancreatic Adenocarcinoma|Participants have metastatic pancreatic cancer who have received at least first line chemotherapy and have disease progression during or within 6 months of treatment.
10146354|NCT04137549||Nocturnal controlled hypertension|Nocturnal blood pressure was controlled under 120/70 mmHg after aggressive anti-hypertensive therapy.
10146355|NCT04137549||Nocturnal uncontrolled hypertension|Nocturnal blood pressure was still over 120/70 mmHg after aggressive anti-hypertensive therapy.
10146356|NCT04137718||Rare driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation positive.
10146357|NCT04137718||Rare driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction(PCR)panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation negative.
10146358|NCT04137744|Active Comparator|ARM preservation ALND|ARM +ve LN PRESERVED , ALND COMPLETED LATER ON
10146359|NCT04137744|Active Comparator|conventional ALND|ARM +VE NODES MARKED AND TAKEN WITH ALND
10146360|NCT04137614|Placebo Comparator|Digital substraction angiography|
10146361|NCT04137614|Experimental|Drug-coated balloon|
10146362|NCT04137679|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
10146363|NCT04137679|Active Comparator|Neoadjuvant Radiochemotherapy followed by surgery|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
10146364|NCT04137575|Experimental|ConquerFear-Group|ConquerFear-Group is a psychological intervention developed specifically for fear of cancer recurrence
10146365|NCT04137575|Placebo Comparator|Relaxation Training|The Relaxation Training serves as a placebo comparator and is not developed specifically to target fear of cancer recurrence.
10146366|NCT04137588||Group A|antiangiogenesis 7.5mg/Kg q3w+pemetrexed 500mg/m2 q3w+ platinum 75mg/m2 q3w
10146367|NCT04137588||Group B|immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
10146368|NCT04137588||Group C|antiangiogenesis 7.5mg/Kg q3w+immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
9826143|NCT02409719|Experimental|Study - Verbal information, Booklet & Schedule.|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
9971083|NCT01306786|Active Comparator|Triple Therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
9971084|NCT01306799||Barrett's Esophagus, Erosive Esophagitis, GERD|
9971085|NCT01306838|Experimental|Treatment|The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
10146369|NCT04137445|Experimental|Study Provided Diet|A group of complementary foods provided to participants by researchers.
10146370|NCT04137445|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
10146371|NCT04137809|Experimental|Robot Group|1-arm study where eligible volunteers will undergo robotic testing for safety, comfort, and fit.
9971086|NCT01306838|Active Comparator|Control Group|Routine care
9826144|NCT02409732|Experimental|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
10146372|NCT04137653|Experimental|nab-Paclitaxel group|749 patients will be assigned into nab-Paclitaxel group.
10146373|NCT04137653|Active Comparator|paclitaxel group|749 patients will be assigned into paclitaxel group
10146374|NCT04137497||Patients with disorders of consciousness|
10146375|NCT04137497||Patients with unresponsive wakefulness syndrome|
10146376|NCT04137497||Patients with minimally conscious state|
10146377|NCT04137432|Experimental|Oxytocin (24 IU)|Intranasal administration of 24 international units (IU) of oxytocin (OT) 30 minutes before the start of four intervention sessions
10146378|NCT04137432|Placebo Comparator|Placebo|Intranasal administration of a placebo spray 30 minutes before the start of four intervention sessions
10146379|NCT04137419|Experimental|ProlacSan|Patient will get ProlacSan lozenges after nonsurgical treatment of periodontitis.
10146380|NCT04137419|Placebo Comparator|Placebo|Patients will get placebo lozenges after nonsurgical periodontal treatment
10146381|NCT04137250|Active Comparator|Hamstring|It is the group in which the hamstrings are surgically removed to be used as an autograft for the reconstruction of the anterior cruciate ligament. The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament.
10146382|NCT04137250|Experimental|Quadriceps tendon|It is the group in which a portion of the quadriceps tendon will be surgically removed for later use as an autograft for the reconstruction of the anterior cruciate ligament. The intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
10146383|NCT04137094|Experimental|PHCI with HIV/HCV counselor|A persuasive health communication intervention will be performed by a community HIV/HCV test counselor
10146384|NCT04137094|Experimental|PHCI with ED Medical Staff|A persuasive health communication intervention will be performed by ED medical staff
10146385|NCT04137406||T1 tumor with lymph node metastasis|patients with T1 tumor and lymphnode positive
10146386|NCT04137406||T2 or T3 tumor with lymph node negative|patients with T2 or T3,lymph node negative
10146387|NCT04137081|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
10146388|NCT04137159|Experimental|FES rowing|Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.
10146389|NCT04137159|No Intervention|Wait list|During the 12-week treatment as usual program, subjects will not participate in FES-rowing.
10146390|NCT04137198|No Intervention|control|classic analgetic protocol
10146391|NCT04137198|Experimental|intervention|intranasal Sufentanil
10146392|NCT04137185|Experimental|rhTSH|Phase 1: 0.9mgx1d、0.9mgx2d、1.8mgx1d、1.8mgx2d, intramuscularly (IM) ; Phase 2: patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the Phase 1.
10146393|NCT04137172|Experimental|group1|underwent laparoscopic IPOM hernioplasty without repair
10146394|NCT04137172|Experimental|group2|underwent laparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS
10146395|NCT04137172|Experimental|group3|underwent laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0
10146396|NCT04137328|Experimental|liraglutide group|Mecobalamin tablets (0.5mg/day, oral) and liraglutide (0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection) were used for 3 months.
10146397|NCT04137328|Active Comparator|control group|Take Mecobalamin (0.5mg/day, oral), add or adjust insulin (when basic insulin is preferred for those who do not use insulin, if insulin has been used, adjust the dose or program according to the condition, inject subcutaneously) for 3 months.
9971087|NCT01306851|Active Comparator|Fibrin glue|
9519772|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI<28 , Systemically healthy, taking no prescribed medication
9971088|NCT01306864|Experimental|Hemospray Treatment|Hemospray Kit
9971089|NCT01306903|Experimental|MECC|Minimal extracorporeal circuit
10146398|NCT04137211|Experimental|Prolonged sitting with social break|
10146399|NCT04137211|Experimental|Prolonged sitting with walk break|
10146400|NCT04137211|Experimental|Prolonged sitting with simple resistance activities|
10146401|NCT04137146|Experimental|Sacral Nerve Stimulation|Intervention: Sacral nerve Stimulation Stimulation sites：S3 Postoperative study visits lasted approximately 3 hours and were conducted in 3 months.
10146402|NCT04137146|No Intervention|No SNS Intervention|
10146403|NCT04137393|Experimental|Salvadora persica|"brush teeth with Salvadora persica Miswak"
10146404|NCT04137393|Active Comparator|tooth brush|brush with fluoridated tooth paste
10146405|NCT04137263|Experimental|Treatment|Subjects will receive dose formulation for treatment of melasma
10146406|NCT04137276|Experimental|vitamin C and thiamine|patients who received intravenous vitamin C and thiamine
10146407|NCT04137276|Active Comparator|thiamine|patients who received thiamine
10146408|NCT04137302|Active Comparator|Topical hydrocortisone administration|dermal cream (twice a day, 2.5 g of cream, 1% hydrocortisone during 5 days)
10146409|NCT04137302|Active Comparator|Systemic hydrocortisone administration|tablets (once a day, 50 mg, morning, during 50 days)
10146410|NCT04137016|Experimental|HIV-subjects with APP|HIV-infected patients using the App + standard clinical management (SCM)
10146411|NCT04137016|No Intervention|Control group|HIV-infected patients, who only receive Standard Clinical Management (without the App)
10146412|NCT04137341|Experimental|Tablet A|A single oral 300-mg dose of GLPG1972 in fasted state
10146413|NCT04137341|Experimental|Tablet B|A single oral 300-mg dose of GLPG1972 in fasted state
10146414|NCT04137341|Experimental|Tablet C|A single oral 300-mg dose of GLPG1972 in fasted state
10146415|NCT04137341|Experimental|Food effect|selected tablet B or C under fed conditions
10146416|NCT04137042|Active Comparator|Saline|intraoperative fluid therapy by using 0.9% saline
10146417|NCT04137042|Experimental|Balanced crystalloid|intraoperative fluid therapy by using balanced crystalloid
10146418|NCT04137380|Experimental|Mirikizumab - Intravenous (IV)|Mirikizumab administered IV
10146419|NCT04137380|Placebo Comparator|Placebo - IV|Placebo administered IV
10146420|NCT04137380|Experimental|Mirikizumab - Subcutaneous (SC)|Mirikizumab administered SC
10146421|NCT04137380|Placebo Comparator|Placebo - SC|Placebo administered SC
10146422|NCT04137055|Experimental|ZSP0678-10mg (single dose)-Cohort 1|ZSP0678/Placebo 10mg
10146423|NCT04137055|Experimental|ZSP0678-30mg (single dose)-Cohort 2|ZSP0678/Placebo 30 mg Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.
10146424|NCT04137055|Experimental|ZSP0678-60mg (single dose)-Cohort 3|ZSP0678/Placebo 60mg Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.
10146425|NCT04137055|Experimental|ZSP0678-120mg (single dose)-Cohort 4|ZSP0678/Placebo 120mg Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.
10146426|NCT04137055|Experimental|ZSP0678-180mg (single dose)-Cohort 5|ZSP0678/Placebo 180mg Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.
10146427|NCT04137055|Experimental|ZSP0678-240mg (single dose)-Cohort 6|ZSP0678/Placebo 240mg Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.
10146428|NCT04137055|Experimental|ZSP0678-320mg (single dose)-Cohort 7|ZSP0678/Placebo 320mg Enrollment into Cohort 7 will begin upon assurance of safety for Cohort 6.
10146429|NCT04137055|Experimental|ZSP0678 (food effect)-Cohort FE|"Period 1: Group A and Group B receive ZSP0678/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2: Group A and Group B receive ZSP0678/Placebo under the fed or fasting condition ,respectively on Day8.~Enrollment into Cohort FE will begin upon assurance of safety for Cohort 4."
10146430|NCT04137055|Experimental|ZSP0678 Dose1 (multiple doses)-Cohort 8|ZSP0678/Placebo Dose1 will be administrated according to the results of Cohort 2&3
10146431|NCT04137055|Experimental|ZSP0678 Dose2 (multiple doses)-Cohort 9|ZSP0678/Placebo Dose2 will be administrated according to the results of Cohort 3&4
10146432|NCT04137055|Experimental|ZSP0678 Dose3 (multiple doses)-Cohort 10|ZSP0678/Placebo Dose3 will be administrated according to the results of Cohort 4&5
10146433|NCT04137029|Experimental|smoking|Healthy smoking volunteers
10146434|NCT04137029|Experimental|non-smoking|Healthy non-smoking volunteers
9519773|NCT03283631|Experimental|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
9971090|NCT01306903|Placebo Comparator|MOPS|
9971091|NCT01306903|Placebo Comparator|Super MOPS|
9971092|NCT01306916||Group 1 of 1|diagnosis of primary and secondary hyperparathyroidism scheduled to undergo parathyroid resection.
10146435|NCT04137003|Experimental|Rouge et Or program|Rouge et Or program group follow a detailed program that they do on their own. It is made of three cycles of four weeks each. Every cycle contains 3 training sessions by week with a minimum of 24 hours between sessions. The training volume is modulated for every cycle and every week. Each training sessions is made of 6 warm-up exercises followed by 6 training exercises. The exercises are a mix of strengthening, endurance, plyometric, neuromuscular control and dynamic stability. The exercises change every month with a progressively increasing difficulty towards the end to mimic return to sport demands.
10146436|NCT04137003|Active Comparator|CHU intervention guide|CHU intervention guide group follow the standard CHU protocol. At three months post-surgery, the protocol suggests progressing the exercises without precisely suggesting exercise, parameter or frequency.
10146437|NCT04136886|Active Comparator|IMRT and concurrent cisplatin|IMRT and concurrent cisplatin to treat T3/T4 locally recurrent NPC patients. Cisplatin 100mg/M2 is to give D1,D22 of IMRT for 2 cycles. IMRT is to give GTV 60Gy in 27 fraction
10146438|NCT04136886|Experimental|IMRT alone|IMRT alone to treat T3/T4 locally recurrent NPC patients. IMRT is to give 60Gy in 27 fraction
10146439|NCT04136847|Experimental|Hand Aging|Microneedling treatment of the dorsum of the hands
10146440|NCT04136860||Conservative management|Patients refused to accept any interventional treatment or patients were not suitable for any interventional treatment.
10146441|NCT04136860||Microsurgical resection|All microsurgical procedures were performed with intraoperative neuronavigation, ultrasonography, indocyanine fluorescence angiography (ICG), continuous monitoring of electroencephalogram and somatosensory evoked potential.
10146442|NCT04136860||Embolization|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Multi-stage embolization and target embolization were widely used within the embolization. Onyx was the main embolization material.
10146443|NCT04136860||Embolization+Radiosurgery|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Radiosurgery management was recommended for the residual lesions about 3 months after the embolization if necessary.
10187793|NCT03722628||HCC with TTT|Blood sample from all HCC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
10146444|NCT04136860||Single-stage hybrid surgery|Hybrid surgery is a new surgical strategy defined as single-stage combined microsurgical resection and embolization in which embolization is performed firstly on the deep feeding artery, aneurysm, AVF, and meningeal arteries involved in blood supply of the nidus, and then, the microsurgical resection was performed immediately. Intraoperative angiography was performed repeatedly before the skull was closed, confirming complete occlusion of the malformation.
10146445|NCT04136873|Active Comparator|Part A: 5 mg QD CVL-231|Oral Dose
10146446|NCT04136873|Placebo Comparator|Part A: 5 mg QD Placebo|Matching Placebo; Oral Dose
10146447|NCT04136873|Active Comparator|Part A: 10 mg QD CVL-231|Oral Dose
10146448|NCT04136873|Placebo Comparator|Part A: 10 mg QD Placebo|Matching Placebo; Oral Dose
10146449|NCT04136873|Active Comparator|Part A: 20 mg QD CVL-231|Oral Dose
10146450|NCT04136873|Placebo Comparator|Part A: 20 mg QD Placebo|Matching Placebo; Oral Dose
10146451|NCT04136873|Active Comparator|Part A: 5-10-20 mg BID CVL-231|Oral Dose
10146452|NCT04136873|Placebo Comparator|Part A: 5-10-20 mg BID Placebo|Matching Placebo; Oral Dose
10146453|NCT04136873|Active Comparator|Part A: 30 mg QD CVL-231|Oral Dose
10146454|NCT04136873|Placebo Comparator|Part A: 30 mg QD Placebo|Matching Placebo; Oral Dose
10146455|NCT04136873|Active Comparator|Part B 30 mg QD CVL-231|Oral Dose
10146456|NCT04136873|Placebo Comparator|Part B 30 mg QD Placebo|Matching Placebo; Oral Dose
9826145|NCT02409784|Experimental|Ketogenic diet|"Pre/Post TEP study with a 4 days ketogenic diet (KD).~Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet~Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet"
10146457|NCT04136873|Active Comparator|Part B 20 mg BID CVL-231|Oral Dose
10146458|NCT04136873|Placebo Comparator|Part B 20 mg BID Placebo|
10146459|NCT04136691|Experimental|simulation training|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed. In the research, the application of burn patient scenario was performed only with the intervention group.
10146460|NCT04136691|No Intervention|Control|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed.
10146461|NCT04136704||Sleeve Gastrectomy in Pediatric Patients|Laparoscopic Sleeve Gastrectomy will be offered as an adjuvant to a multidisciplinary family-based program that focuses on nutrition, physical activity, and behavioral counseling.
10146462|NCT04136704||Sleeve Gastrectomy in Adult Patients|This comparison group will be composed of adult patients who undergo sleeve gastrectomy
10146463|NCT04136769|Experimental|Intervention|"After trial enrolment, patients undergo visceral debranching.~After visceral debranching, patients proceed to neoadjuvant chemotherapy. The therapy as such is not a formal part of the trial protocol. The specific chemotherapy regimen and its duration are decided individually by treating physicians.~Tumor resection should be performed two to four weeks after completion of chemotherapy. Prior to resection, re-staging and verification of vascular reconstruction patency are carried out. The specific procedure for tumor resection and intestinal tract reconstruction is at the choice of the treating surgeon. It should follow oncological principles and aim at complete removal of the tumor and regional lymph nodes. Usually, resection will be done as pancreatoduodenectomy with or without distal gastrectomy (Whipple's procedure or pylorus-preserving Whipple's procedure), distal pancreatectomy with splenectomy, or total pancreatectomy with splenectomy."
10146464|NCT04136821|Placebo Comparator|Placebo|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
10146465|NCT04136821|Experimental|Oceanix™|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
10146466|NCT04136834|Experimental|Pegtomarginase (PT01)|To determine the MTD of PT01 based on the toxicity observed during Cycle 1 of the Dose Escalation Phase and to investigate the safety and tolerability of PT01 when administered intravenously(IV) to subjects with advanced malignancies
10146467|NCT04136613|Experimental|Post placental intra uterine device insertion|There was immediate post-partum insertion of CuT 380 A intrauterine device after delivery of placenta during cesarean delivery. To overcome the considerable expulsion rate in the previous studies, we stabilize the IUD in place at the fundus be an absorbable suture; vicryl 0 that was introduced through the fundus, held the needle with sponge holder that was introduce up the fundus and taken out the vicryl through the lower uterine inscion, cutting the needle, hold the vicryl around the the T arm of the IUD and withdrawn back to be placed inside the fundus. Before closing the uterine incision, the threads were placed in the lower uterine segment, then the uterine incision was then closed routinely.
10146468|NCT04136951|Experimental|Experimental phase|The PREVENT recommendation about patient homecare priority will be shared in homecare referral communication with the homecare intake coordinators. Homecare intake coordinators will be instructed to prioritize high risk patients for care.
10185104|NCT03749018|Experimental|Treatment (nivolumab, DA-REPOCH)|Patients receive rituximab IV and nivolumab IV over 60 minutes on day 1. Patients also receive etoposide, vincristine sulfate and doxorubicin hydrochloride IV continuously over 96 hours, cyclophosphamide IV bolus, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After course 6, patients receive nivolumab IV over 60 minutes on day 1 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10185105|NCT03748940|Placebo Comparator|Part A: Placebo|Placebo administered subcutaneously (SC)
10185106|NCT03748940|Experimental|Part A: LY3074828|LY3074828 administered SC
10185107|NCT03748940|Placebo Comparator|Part B: Placebo|Placebo administered SC
9826146|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|FDG PET scan,T1-weight MRI and blood were obtained for each participant
9971093|NCT01306955|Active Comparator|methylprednisolone|patients who received methylprednisolone
9971094|NCT01306955|Placebo Comparator|dextrose water 5%|patients who received dextrose water 5% as placebo
10146469|NCT04136938||Intervention group (social marketing campaign)|People aged 60 and over will be included. They will receive a social marketing campaign.
10146470|NCT04136938||Control group|People aged 60 and over will be included.
10146471|NCT04136743|Active Comparator|Corticosteroid|Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg [triamcinolone acetonide]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.
10146472|NCT04136743|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle.
10146473|NCT04136795||Conventional surgery|Patients having had esophageal atresia (type III, long gap excluded) repair by conventional surgery (right thoracotomy) or patients having had minimally invasive surgery converted to thoracotomy between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
10146474|NCT04136795||Minimally invasive surgery|Patients having had esophageal atresia (type III, long gap excluded) repair through minimally invasive surgery between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
10146475|NCT04136782|Experimental|Trial group|55 cases of triple-negative breast cancer will be assigned into a trial group.
10146476|NCT04136782|Active Comparator|Control group|55 cases of triple-negative breast cancer will be assigned into a control group.
10146477|NCT04136964||Patients group|Patients who have pain located in the anatomical region of the neck for more than three months due to mechanical causes; with or without radiation to the head, trunk, and upper limbs. Posteriorly, pain may be present in the neck region from the superior nuchal line to the spine of the scapula and the side region down to the superior border of the clavicle and the suprasternal notch.
10146478|NCT04136535|Experimental|Pemetrexed and Carboplatin with Anlotinib|Pemetrexed and Carboplatin with Anlotinib
9826147|NCT02409927|Other|Healthy participant|Each participant undergo 7 metabolic day, separate by at least 3 days, where they received a different dietary supplement on each day: control (no supplement), MCT oil 10g, MCT oil 20g, MCT oil 30g (provided from pure MCT oil), MCT homogenate 10g, MCT homogenate 20g, MCT homogenate 30g (provided by a 10% MCT homogenate emulsion)
9826148|NCT02410018|Experimental|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
9826149|NCT02410018|Experimental|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
10146479|NCT04136535|Active Comparator|Pemetrexed and Carboplatin without Anlotinib|Pemetrexed and Carboplatin without Anlotinib
10146480|NCT04136717|Other|COPD patients|Patients with acute exacerbation of COPD and respiratory acidosis under oxygen therapy.
10146481|NCT04136717|Other|Bariatric surgery patients|Obese patients after gastric surgery under CPAP.
10146482|NCT04136522|Active Comparator|conventional|The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). We will identify and isolate superior mesenteric vein (SMV) before pancreatic resection. The surgeon will dissect tissue around superior mesenteric artery (SMA) and uncinate process of pancreas along the SMA.
10146483|NCT04136522|Experimental|total mesopancreas excision with arterial first approach|The patients who included this group will undergo PD or PPPD including total pancreatic mesopancreas excision and superior mesenteric artery approach. Before pancreatic transection, the surgeon will isolate superior mesenteric vein (SMV) and superior mesenteric artery (SMA). And the surgeon will dissect nerve plexus and lymph node around SMA. inferior pancreaticoduodenal artery (IPDA) and first jejunal artery will be identified and the surgeon will ligate according to surgical margin. Anastomosis will be performed as usual manners.
10146484|NCT04136509|Experimental|allograft|The filler used in sinus floor elevation is albumin impregnated allograft.
10146485|NCT04136509|Experimental|xenograft|The filler used in sinus floor elevation is anorganic bovine bone mineral.
10146486|NCT04136678|Experimental|treadmill back walking training|15 minutes conventional walking training, 15 minutes of treadmill back walking training, 15-minute treadmill forward walking training
10146487|NCT04136561|Experimental|CVC and Midline Catheter|Existing standard of care CVC. Midline catheter placed within 24 hours of CVC placement.
10146488|NCT04136561|No Intervention|CVC|Standard of care CVC: case-matched controls using baseline data.
10146489|NCT04136340|Active Comparator|In-person follow-up|Due to the COVID-19 pandemic, patients originally randomized to the in-person group received telemedicine visits. Thus, the researchers will expand our sample for these interviews to include patients who have completed at least 2 telemedicine follow-up visits whether they were originally randomized to the in-person group or the home telemedicine group.
10146490|NCT04136340|Experimental|Home Telemedicine follow-up|
10146491|NCT04136925||"runner participating of the Grand Raid"|
10146492|NCT04136639|Experimental|Miswak|Miswak sticks used twice daily, every 12 hours, for three months.
9826150|NCT02410161|Experimental|4 week ALA treatment|Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
9826151|NCT02410200|Experimental|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
9971095|NCT01306981|Experimental|Ranibizumab|
10146493|NCT04136639|Experimental|Grape Seed Extract|Grape seed extract 6.5% mouthwash used twice daily, every 12 hours, for three months.
10146494|NCT04136639|Active Comparator|Fluoride Mouthwash|0.05% fluoride mouthwash used twice daily, every 12 hours, for three months.
10146495|NCT04136483|Experimental|CBT-I|
10146496|NCT04136652|Placebo Comparator|Sham|The women are randomized, by a computer program, to a sham laser-treatment with the laser not active.
10146497|NCT04136652|Active Comparator|Laser|The women are randomized, by a computer program, to a vaginal CO2 laser-treatment with 30 w.
10185108|NCT03748940|Experimental|Part B: LY3074828|LY3074828 administered SC
10185109|NCT03748940|Experimental|Part B: LY900021|LY900021 (LY3074828 + LY9999QS) administered SC
9669380|NCT02196844|Experimental|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
9669381|NCT02178436|Experimental|Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)|Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9669382|NCT02178436|Experimental|Group II: Phase II Group I (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
10146498|NCT04136587|Active Comparator|Healthy Controls|"Inclusion criteria:~Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss~Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia~Exclusion criteria:~Diagnosis of IBD or any other inflammatory condition of the small and large intestine~Diagnosis of irritable bowel syndrome (IBS)~Autoimmune disorders~Obesity (BMI> 30)~Regular intake of NSAIDs (> 2 tablets/ week), immunosuppressants~Intake of antibiotics within the last 3 months~Intestinal infection by enteric pathogens~Probiotic therapy"
10146499|NCT04136587|Active Comparator|Crohn's disease|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~Colonoscopy indicated by routine clinical care~Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
10146500|NCT04136587|Active Comparator|Ulcerative Colitis|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~Colonoscopy indicated by routine clinical care~Established diagnosis of ulcerative colitis (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
10146501|NCT04136587|Active Comparator|Colorectal carcinoma|"Inclusion criteria:~• Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is confirmed later by histology~Exclusion criteria:~• None"
10146502|NCT04136587|Active Comparator|Colitis/Enteritis of other origin|"Inclusion criteria:~Diagnosis of intestinal inflammation at endoscopy or histology~E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; graft versus host disease (GVHD); NSAID colitis; Colitis of unknown cause~Exclusion criteria:~• None"
10146503|NCT04136431|Experimental|Intervention group|
9971096|NCT01306981|Placebo Comparator|Saline|
10146504|NCT04136431|Placebo Comparator|Control group|
10146505|NCT04136496|Active Comparator|Ink placed before chemotherapy (Study A)|In Study A, 0.5 mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy
10146506|NCT04136496|Active Comparator|Ink placed after chemotherapy (Study B)|In Study B, 0.5 mL of Black Eye Ink will be placed before neoadjuvant therapy
10146507|NCT04136418|Active Comparator|Usual care|Patients currently self-manage their condition using antibiotics and steroids when their disease symptoms match the criteria in information provided by a clinician
10146508|NCT04136418|Experimental|Mobile App device|Patients enter their health status onto an App which is relayed to the healthcare team, who can then provide further information or clinical intervention should they so choose
10146509|NCT04136470||NSCLC|This cohort will consist of 100 patients with non-small cell lung cancer (NSCLC).
10146510|NCT04136470||MEL|This cohort will consist of 30 patients with melanoma (MEL).
10146511|NCT04136392||Eligible Patients|The population to be enrolled in this study includes patients whose intended treatment is to receive mechanical circulatory support with the ABIOMED, Inc. hemodynamic support devices per the treating physician's discretion and best practices.
10146512|NCT04136600|Experimental|EGFR antibody arm|Participants received a dose of 500 mg/m2 Cetuximab iv on Day 1 of cycle every 3 weeks, or 400mg Nimotuzumab on Day 1 of cycle, every week, until disease progression. 12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
10146513|NCT04136600|Placebo Comparator|Placebo arm|12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
10146514|NCT04136314|Experimental|Gain-Frame Survey [A]|
10146515|NCT04136314|Experimental|Loss-Frame Survey [B]|
10146516|NCT04136327|Experimental|GLPG1972 oral and [14C]-GLPG1972 IV|GLPG1972 film-coated tablet followed by [14C]-GLPG1972 solution for infusion
10146517|NCT04136327|Experimental|[14C]-GLPG1972 oral solution|[14C]-GLPG1972 oral solution
10146518|NCT04136236||esophageal mucosal lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
10185110|NCT03748914|Experimental|Intervention Group|Milking the cut umbilical cord once towards the Infant at a speed of 10cm/second.
9826152|NCT02410213|Experimental|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
9971097|NCT01306994||Syndrome Group|Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3
10146519|NCT04136301|Experimental|Informative video arm|"Nuliparus women admitted to an induction will be exposed to informative video with data regarding labor and possible obstetric emergencies such as cesarean delivery.~All patients will answer the State-Trait Anxiety Inventory (STAI) before and after intervention"
10146520|NCT04136301|No Intervention|control arm|no intervention. All patients will answer the State-Trait Anxiety Inventory (STAI) before and after delivery.
10146521|NCT04136132|Experimental|Biological collection|"Biological collection~For all the patients include in the study :~blood and tissue samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database"
10146522|NCT04136249|No Intervention|Control chimiotherapeutic arm|Standard care as comparaison procedure that includes chemotherapy
10146523|NCT04136249|Experimental|Physical over-activity|The procedure under study which includes a re-training mixing EMS and EXC with a nutrition adapted to the needs related to the physical over-activity following the chemotherapy
10146524|NCT04136106||Low-dose IL-2 group|Patients in this group were treated with low-dose IL-2 combined with corticosteroid and immunosuppressor, and low-dose IL-2 is defined as 100IU subcutaneously every other day for two weeks, followed by two-week break, as one treatment cycle, and at least three cycles.
10146525|NCT04136106||Non IL-2 group|Patients in this group were only treated with corticosteroid and immunosuppressor,
10146526|NCT04136041|Experimental|Smartphone Application|Participants watch a video using the Smartphone Application displaying positive word stimuli.
10146527|NCT04136041|No Intervention|No Intervention|No Intervention.
10146528|NCT04136067|Experimental|NNC0268-0965|Participants will receive NNC0268-0965
10146529|NCT04136067|Active Comparator|Insulin glargine|Participants will receive insulin glargine
10146530|NCT04136028|Experimental|intervention/treatment|Anakinra (Kineret)
10146531|NCT04136093|Experimental|the MED|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the MED group
10146532|NCT04136093|Experimental|the DASH|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the DASH group
10146533|NCT04136093|Experimental|The control group|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the control group.
10146534|NCT04136119||healthcare professionals|doctors, pharmacists and dieticians who are involved in prescribing vitamins and micronutrients to critically ill patients
10146535|NCT04135846|Experimental|doxazosin|16 mg, or maximum tolerated dose (MTD)
10146536|NCT04135846|Placebo Comparator|placebo|matching placebo
10146537|NCT04135872||hypoalbuminemia|hypoalbuminemia was classified as serum albumin level (SAL) <35g/L
10146538|NCT04135872||normal albumin level|patients with serum albumin level (SAL) of 35g/L or higher
10146539|NCT04136080|Other|chronic hypertension group|septic patients with chronic hypertension
10146540|NCT04136080|Other|denying chronic hypertension group|septic patients without chronic hypertension
10146541|NCT04136015||Dasatinib group|
10146542|NCT04136015||Imatinib group|
10146543|NCT04135898|Experimental|SIBP-04|
10146544|NCT04135898|Active Comparator|Bevacizumab|
10146545|NCT04135885|Experimental|Intervention group|Intervention group: patients took 7 days of folic acid tablets before surgery (0.3mg/d for children aged 1-3, 0.4mg/d for children aged 4~5 years, dissolved in 20ml brown sugar water.)
10146546|NCT04135885|Experimental|Placebo group|Placebo group: The patient received the same dose of brown sugar water for 7 days before surgery. Folic acid dose selection is based on the maximum daily intake of children（tolerable upper intake levels，UL）
9971098|NCT01306994||Control Group|Healthy individuals
10146547|NCT04135924|Active Comparator|walking nordic and respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will be submitted to respiratory muscle training (TMR) associated with the Nordic walking(NC) training .
10146548|NCT04135924|Active Comparator|walking nordic group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to Nordic walking training.
10146549|NCT04135924|Active Comparator|respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to respiratory muscle training protocol.
10146550|NCT04135833|Experimental|Itraconazole and BPI-7711|BPI-7711 alone followed by BPI-7711 +Itraconazole, followed by Itraconazole alone.
10146551|NCT04135833|Experimental|Rifampicin and BPI-7711|BPI-7711 alone followed by BPI-7711 +Rifampicin, followed by Rifampicin alone.
10146552|NCT04135820|Experimental|Fasted|BPI-7711 following a period of fasting
10146553|NCT04135820|Experimental|High-fat meal|BPI-7711 following a high-fat meal.
10146554|NCT04135664|Active Comparator|Patients undergoing adjuvant esophagectomy|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients randomized into undergoing adjvant esophagectomy."
10146555|NCT04135664|Experimental|Patients undergoing adjuvant chemoradiation|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients randomized into undergoing adjvant chemoradiation."
10146556|NCT04135664|Active Comparator|Prospective registry of patients that cannot be randomized|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients cannot be randomized into undergoing adjvant esophagectomy or chemoradiaton.~This arm includes patients undergoing adjuvant esophagectomy; adjuvant chemoradiation and active surveillance."
10146557|NCT04135625|Active Comparator|Full Intervention|The full intervention group will receive three egg laying chickens that will be presented as a gift to the child by their religious leader (imam or priest) during a gifting ceremony, as well as Integrated nutrition and agricultural (INA) education training sessions.
10146558|NCT04135625|Active Comparator|Education Only|The education only intervention group will receive 3 chickens given in manner similar to animal distribution programs and the INA training sessions.
10146559|NCT04135625|No Intervention|Control|The control group will receive no chickens gifted and no INA training sessions.
10146560|NCT04135651|Experimental|Paralaryngeal pressure|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
10146561|NCT04135651|Active Comparator|Cricoid pressure|During the induction of anesthesia, cricoid pressure is applied by 30N force with three fingers.
10146562|NCT04135807|Experimental|Microdevice|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Patients with newly found supratentorial lesions, or patients previously diagnosed with supratentorial gliomas at time of recurrence, whose treatment plan includes partial or total resection surgery as a component of standard-of-care treatment will be included.~- Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~-- The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs microdoses for intratumor release of the following 8 approved drugs: Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
10146563|NCT04135755||vertebral compression fracture|No drugs intervention
10146564|NCT04135755||older adult without spinal deformity|No drugs intervention
10146565|NCT04135755||young adults|No drugs intervention
10146566|NCT04135638|Other|Cover Group (CG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.~In the Cover Group the ILM flap will be folded as a single layer to bridge tissue dehiscence during air-fluid exchange. All eyes will recive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
10146567|NCT04135638|Other|Fill Group (FG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.~In the Fill Group, multiple layers of ILM will be deliberately folded within the loss of tissue before air-fluid exchange. All eyes will receive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
10146568|NCT04135742|Experimental|active tACS+ Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
10146569|NCT04135742|Sham Comparator|sham tACS+Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min."
10146570|NCT04135742|Sham Comparator|active tACS+ sham Cognitive Training group|"Subjects will watch neutral pictures on iPad for a period of 3 months, 24 times, twice a week for 20 minutes each time.~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
10146571|NCT04135716|Experimental|Exposed group|Patients will receive colonoscopy with assistance of Endo.Angel
10146572|NCT04135716|Sham Comparator|Non-exposed group|Patients will receive colonoscopy without assistance of Endo.Angel
10146573|NCT04135599|Active Comparator|real tDCS|Participants received 1.5mA tDCS for 20 minutes in 10 consecutive days.
10146574|NCT04135599|Sham Comparator|sham tDCS|Participants received sham tDCS for 20 minutes in 10 consecutive days.
10146575|NCT04135677|Active Comparator|low-dosage group|rivaroxaban 10mg qd for for 3 months and continued DAPT for 6 months.
10146576|NCT04135677|Active Comparator|high-dosage group|rivaroxaban 20mg qd for for 3 months and continued DAPT for 6 months.
10146577|NCT04135677|Active Comparator|DAPT group|asprin 100mg qd together clopidogrel 75mg for 6 months
10146578|NCT04135781|Experimental|AS|Arm A：nab paclitaxel （120mg/m2；iv；d1，8）+S-1 （<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）Q3W；up to eight cycles
10146579|NCT04135781|Active Comparator|XELOX|Arm B：Capetabine（1000 mg/m2 po, d1-14 bid ）+ Oxaliplatin（130mg/m2 , iv, d1）Q3W；up to eight cycles
10146580|NCT04135430||Survey|Practice of an updated questionnaire at D0, D2 and D7
10146581|NCT04135443|Experimental|3T Tune in! Turn on! Turn up!|The intervention is a mobile app delivered sexual health promotion program designed specifically for young black men who have sex with men or who are attracted to men. The mobile app will include more than 30 interactive activities including resource maps, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) content, and communication forums. The app helps participants to become clearer about what they do/don't want to do sexually, to communicate their choices. It also focuses on ways to increase healthy relationships, enhance sexual experience if having sex while reducing HIV/STI risk. The intervention/app is intended to be used regularly (e.g., two times per week) during the 90 day active participation period.
10146582|NCT04135443|Active Comparator|General Health App|Participants will download a general health mobile app (focused on promoting drinking water). The control mobile app is intended to be used regularly during the 90 day active participation period.
9519774|NCT03283618|No Intervention|Control Group|The control group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) as well as caloric and step goals, but no health coaching. They will complete the same pre- and post-intervention measurements and consultations with the medical doctor and registered dietitian.
10146583|NCT04135287|Experimental|Arm 1|Treatment with GLP-1 RA
10146584|NCT04135547|Experimental|intra-osseous access, IO at the humeral site|the OHCA patients receiving IO at the humeral site by paramedics in the field
10146585|NCT04135547|Active Comparator|intravenous access; IV at the upper limb|the OHCA patients receiving IV at the upper limb by paramedics in the field
10146586|NCT04135508|Experimental|BAT1406|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
10146587|NCT04135508|Active Comparator|Humira|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
10146588|NCT04135313|Experimental|Neoadjuvant chemotherapy|Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy
10146589|NCT04135313|Active Comparator|Chemoradiotherpy|Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.
10146590|NCT04135339|Experimental|Group A. Eccentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
10146591|NCT04135339|Experimental|Group B. Concentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
10146592|NCT04135339|Experimental|Group C. Isometric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
10146593|NCT04135339|No Intervention|Group D. Control.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
10146594|NCT04135586|Experimental|Exercise|The patients in this arm will follow an exercise program for 24 weeks (i.e., during neo-adjuvant treatment), with two sessions per week including both aerobic and resistance training. Exercise intensity will range between 65% and 100% of the maximum score in the scale of Rated Perceived Exertion (RPE).
10146595|NCT04135586|Other|Control|The patients follow their usual habits as well as a Yoga program. They will also receive educational sessions on the benefits of regular physical activity (brisk walking).
10146596|NCT04135365||Pediatric T1D|A sample of 20 children with Type 1 Diabetes and their caregivers will be asked to stay after their diabetes clinic appointment to complete enrollment, or they may choose to come back for a study visit. Trained study staff will describe the study in detail to interested families. They will be encouraged to ask questions before giving consent. After obtaining informed consent/assent, children and caregivers will schedule time for a neurocognitive assessment and neuroimaging assessment. Children and caregivers will complete assessments again approximately 12 months later.
10146597|NCT04135365||Comparison|Children with no known chronic medical conditions or intellectual disability will undergo the same procedure listed for the Pediatric T1D group
10146598|NCT04135378|Experimental|student- ascorbic acid|Student that have presentation given ascorbic acid ( 500 mg per day) for one week before presentation .
10146599|NCT04135378|Placebo Comparator|Control- ascorbic acid like|ascorbic acid like placebo for one week before presentation
10146600|NCT04135690|Experimental|HAIC plus toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Toripalimab 240mg intravenously every 3 weeks.
10146601|NCT04135690|Active Comparator|HAIC plus sorafenib|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Sorafenib 400mg twice daily (Bid) oral dosing.
10146602|NCT04135404||Pulmonary Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; pulmonary group are those who have reported any pulmonary diseases and they will be included in this study as pulmonary group.
10146603|NCT04135404||Control Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; The control group are subjects without pulmonary diseases and they will be included as (control group).
10146604|NCT04135469|Active Comparator|Referral for tax preparation|Participants will be given contact information on financial services, including all the free tax preparation services in the city, including Boston Medical Center.
10146605|NCT04135469|Experimental|BMC tax preparation|A navigator will help the participants with using free tax preparation services located at Boston Medical Center or a service located elsewhere in the city.
10146606|NCT04135391|Experimental|Pre- and Post- exercise training effects|All recruited subjects received aerobic exercise training (HIIT or MICT). VO2peak, cardiac output (CO), bilateral frontal cortex blood volume (∆[THb]), oxyhemoglobin (∆[O2Hb]) and deoxyhemoglobin (∆[HHb]), ventilation efficiency, serum brain-derived neurotrophic factor (BDNF) levels, cognitive and life quality questionnaire, percentage of neuroblastic cell bearing neurites (% neurites), and cell fluorescent staining were examined before and after interventions.
10146607|NCT04135261|Experimental|Part 1: Dose escalation|"QW - up to 4 (28 day) cycles of treatment (treatment administered 1x weekly) or Q3W - up to 6 (21 day) cycles of treatment (treatment administered 1x q3w)~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee."
10146608|NCT04135261|Experimental|Part 2: Dose expansion|Treatment administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) established in Part 1, in specific tumor cohorts - Melanoma, HCC and RCC.
10146609|NCT04135482||CD|patients with severe crohn's disease
10146610|NCT04135274||Sepsis group|
10146611|NCT04135274||Non Sepsis group|
10185111|NCT03748914|Active Comparator|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
10185112|NCT03748888|Experimental|Exercise group|An antenatal physical activity (APA) programme will be designed for participants in the exercise group.
10185113|NCT03748888|No Intervention|Control Group|Sedentary participants.
10185114|NCT03748875|Experimental|Intervention group|an 8-session mindfulness-based relapse prevention program
9977134|NCT01358461||Patients with vagal syncopes|Patients with vagal syncopes (n=120 : 60 adults & 60 children)
10185115|NCT03748875|No Intervention|Control group|treatment as usual
10146612|NCT04135612|Experimental|Smartphone group|"application installed to their smartphones. This application will be in Hebrew language, simple to use, and specifically designed to the needs of the current study.~Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles. In addition, patients will be encouraged to use the platform to ask questions and receive immediate answers regarding any aspect lactation. As per the study protocol, medical treatment will only be initiated in a formal clinic appointment and not via the application."
10146613|NCT04135612|No Intervention|Control group|The routine prenatal care provided by our institute includes lactation consulting during the 48-72 hour postpartum hospitalization.
10146614|NCT04135560|Experimental|Part A Cohort 1 (1% Body Surface Area)|Each participant in this cohort will receive both PF-07038124 0.06% and vehicle applied to the skin (1% Body Surface Area)
10146615|NCT04135560|Experimental|Part B Cohort 1 (10% Body Surface Area)|
10146616|NCT04135560|Experimental|Part B Cohort 2 (10% Body Surface Area)|
10146617|NCT04135560|Experimental|Part B Cohort 3 (10% Body Surface Area)|
10146618|NCT04135560|Experimental|Part B Cohort 4 (10% Body Surface Area)|
10146619|NCT04135560|Experimental|Part B Cohort 5 (20% Body Surface Area)|
10146620|NCT04135560|Experimental|Part B Cohort 6 (10% Body Surface Area)|Optional cohort of Japanese participants
10146621|NCT04135183|Experimental|Comprehensive evaluation group|The effectiveness of initial treatment and the next treatment plan were determined based on the CAP guidelines of Chinese Thoracic Society (CTS) or Infectious Diseases Society of America/American Thoracic Society(IDSA/ATS). The evaluation process was independently evaluated and documented by at least two clinicians. In case of disagreement, the final determination shall vote on the majority of votes.
10146622|NCT04135183|Experimental|PSI evaluation group|The changes of PSI scores and serum CRP were used to evaluate the therapeutic effects. If both PSI scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of PSI scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both PSI scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
10146623|NCT04135183|Experimental|Expand-CURB evaluation group|The changes of Expand-CURB scores and serum CRP were used to evaluate the therapeutic effects. If both Expand-CURB scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of Expand-CURB scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both Expand-CURB scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
10146624|NCT04135183|No Intervention|Prospective observational group|Patients' Expand-CURB scores, PSI scores and serum CRP before and after 3-5 days of initial treatment will be recorded. And the initial treatment, whether the initial treatment was changed 3-5 days of initial treatment and the final outcomes (ICU admission, 30-day mortality, average length of stay) will be recorded.
10146625|NCT04135170|Experimental|Plain bone cement|
10146626|NCT04135170|Active Comparator|Antibiotic loaded bone cement|
10146627|NCT04135456|Experimental|Low dose group|0.5g/kg of 20% mannitol administered at skin incision.
10146628|NCT04135456|Experimental|Medium dose group|1.0g/kg of 20% mannitol administered at skin incision.
9519775|NCT03283618|Experimental|Video Conference-based Health Coaching|The video conference-based health coaching group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) meet the medical doctor at baseline and at 12 weeks via the Amwell® app using their smartphone. The participants will receive health coaching by meeting weekly (12 times) with the registered dietitian (RD) to discuss behavior modification, exercise, and nutrition goals.
10146629|NCT04135456|Experimental|High dose group|1.5g/kg of 20% mannitol administered at skin incision.
10146630|NCT04135326|Experimental|Supportive care (tDCS)|Patients undergo tDCS QD over 20 minutes 5 days each week (Monday-Friday) for 3 weeks.
10146631|NCT04135768|Experimental|Treatment|Participants who will undergo both volar locking plate fixation of the distal radius and the study procedure (wrist joint haematoma washout)
10146632|NCT04135768|Placebo Comparator|Placebo|Participants who will undergo volar locking plate fixation of the distal radius only
10146633|NCT04135534|Active Comparator|group A|mutonpain 0.05 mg/kg
10146634|NCT04135534|Active Comparator|Group B|mutonpain 0.1 mg/kg
10146635|NCT04135534|Active Comparator|Group C|mutonpain 0.2 mg/kg
10146636|NCT04134884|Experimental|ASTX727 + Talazoparib|
10146637|NCT04134858|Experimental|The health coaching group|The experimental group (n = 52) consisted of frequent attenders who had chosen the health-coaching program. The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
10146638|NCT04134858|No Intervention|The control group|The control group consisted of 58 frequent attenders. They, along with the experimental group, received the usual care regarding their health problems from the physicians and nurses at the primary healthcare centres if they needed it. The usual care for frequent attenders included assessment for the need of treatment, physical examination, problem assessment, laboratory and X-ray tests, medical advice and patient support and education during their visits.
10146639|NCT04134975|Experimental|Scanner Group|lumbar spine surgical procedure with guided pedicle screw placement coupled with intraoperative scanning (BODYTOM, Samsung).
10146640|NCT04134975|Active Comparator|fluoroscopy group|lumbar spinal surgery with pedicle screw placement guided by fluoroscopy, a fluoroscopic control being performed with each set screw.
9519776|NCT03283592|Experimental|Rank-Heat Plot|The intervention group will receive an online survey to evaluate their interpretation of the results from the NMA with a rank-heat plot including results from 2 outcomes that were selected by our knowledge users (#injurious falls, #fractures).
10146641|NCT04135053|Experimental|Challenge|Challenge participants will inoculated intranasallly with reconstituted lyophilised Neisseria lactamica (lyoNlac). The initial dose will be 10^5 colony-forming units (CFU) and will be escalated or de-escalated by 1/2 - 1 log depending upon the proportion of volunteers colonies with viable N. lactamica.
10146642|NCT04134949|Experimental|CBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
10146643|NCT04134949|Experimental|MCBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
9971099|NCT01307072||Never-treated group|The patients who had no previous ophthalmic examination until the first visit when vitreous surgery was prescribed
9971100|NCT01307072||The non-compliant group|The patients with a history of missing ophthalmic examination over a one year period
9971101|NCT01307072||The compliant group|The patients who had ophthalmic examinations at least once a year
9971102|NCT01307085|Experimental|preconditioning|Adult patients undergoing elective pulmonary lobectomy were received a remote ischemic preconditioning group after induction of anaesthesia.
9971103|NCT01307085|No Intervention|conventional|Adult patients undergoing pulmonary lobectomy were received no treatment after induction of anaesthesia.
9971104|NCT01307124|Active Comparator|standard dose|Arm 1:LPV/r Standard dose BW 25-35 kg 300/75 mg BW >35-50 kg 400/100 mg
9971105|NCT01307124|Experimental|low dose|Arm 2:Low dose BW 25-35 kg 200/50 mg BW >35-50 kg 300/75 mg
9971106|NCT01307137|Experimental|Telehealth (TAP)|
9971107|NCT01307137|Experimental|Peer-led care (PC)|
9971108|NCT01307150||Before and after treatment|SCORAD of each patient before and after treatment.
9971109|NCT01307176|Experimental|Home exercise program|Balance and walking exercise program
9971110|NCT01307189|Active Comparator|Tiotropium|
9971111|NCT01307189|Placebo Comparator|Placebo|
10146644|NCT04135235||TAF group|take propofol fumarate for Maternal and child blockade treatment
10146645|NCT04135235||TDF group|take difenofurate fumarate for Maternal and child blockade treatment
10146646|NCT04134923||[11C] Pittsburgh Compound-B (PIB)|Using [11C] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.
10146647|NCT04134819||Vaginally Delivered Babies- No antibiotic treatment|Adult healthy pregnant females (in total 400) as well as their infants will be recruited. It is expected 67% of babies will be vaginally delivered and that 60% will not have antibiotic treatment during pregnancy. This will be up to 161 mother/infant dyads.
10146648|NCT04134819||Vaginally Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 67% of babies will be vaginally delivered and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 107 mother/infant dyads.
10146649|NCT04134819||C-section Delivered Babies- No antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by C section and that 60% will not have antibiotic treatment during pregnancy. This will be up to 80 mother/infant dyads All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
10146650|NCT04134819||C-section Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by c section and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 52 mother/infant dyads .All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
10146651|NCT04135144|Active Comparator|Group 1 (printed materials),|Group 1 was given home exercise method with printed materials
10146652|NCT04135144|Active Comparator|Group 2 (video phone reminder)|Group 2 was given exercise with home exercise method with video phone reminder
10146653|NCT04135131|Experimental|PILATES MAT EXERCISE EFFECT ON LOW BACK PAIN|Patients were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. The evaluations were made at the beginning and end of the treatment. Outcome parameters were VAS, Oswestry Disability Index, Qubec Disability Scale, Short Form-36, Beck Depression Questionnaire, sit and reach, Modified Schöber and sit up tests. Multifidus and abdominal muscle thickness were measured by ultrasound image
9519777|NCT03283592|Active Comparator|SUCRA (surface under the cumulative ranking) Plot|The control group will receive an online survey to evaluate their interpretation of the results from the NMA with the SUCRA plots including results from the same 2 outcomes that will be presented to the intervention group (i.e., #injurious falls, #fractures).
9519778|NCT03283579||Pregnant women|
9971112|NCT01307202|Experimental|Gabapentin|Gabapentin 600 mg will be given per oral two hours preoperatively and 200 mg three times daily after surgery (600 mg/day).
9971113|NCT01307202|Placebo Comparator|Placebo|Placebo will match the the gabapentin pill and will be given orally.
9971114|NCT01307215|Experimental|20mLs of 0.5% ropivacaine per side|
9971115|NCT01307215|Experimental|30mLs of 0.33% ropivacaine per side|
9971116|NCT01307215|Experimental|40mLs of 0.25% ropivacaine per side|
9971117|NCT01307228|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~database (Health Systems Evidence) access;~monthly e-mail alerts; and~full-text article availability."
9971118|NCT01307228|Active Comparator|Self-serve evidence service|"Participants allocated to the self-serve evidence service will receive only database access, which is already publicly available at www.healthsystemsevidence.org"
9971119|NCT01307241||one cohort|Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
9971120|NCT01307254||Non alcoholic fatty liver disease|
9971121|NCT01307254||control|
9971122|NCT01307280|Experimental|Basic HEALTH|Participants received the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
9971123|NCT01307280|Experimental|Interactive Internet|Intervention intensity increased in RCT2, which included bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments.
9971124|NCT01307280|Experimental|Behavioral Counseling|RCT3 included bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
9971125|NCT01307293|Experimental|Cognitive Behavior Therapy|6-12 sessions of Cognitive Behavior Therapy to address PTSD symptoms and parenting issues related to premature infants.
9971126|NCT01307293|No Intervention|Placebo comparison|Education regarding NICU parenting issues.
9971127|NCT01307332|Experimental|MabCampath-1h|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
9971128|NCT01307345|No Intervention|Monitoring Alone|Research assistants will phone or text participants and request videorecordings of breathalyzer samples up to 21 times per week. Participants will receive compensation for each valid videorecording that occurs within the requested one-hour time frame, and bonus compensation each time all requested videorecordings are submitted within the timeframe over a 7-day period, and/or if >90% of prompts are returned over the study period.
9971129|NCT01307345|Experimental|Monitoring plus contingency management for abstinence|Participants assigned to this condition will receive the same monitoring schedule outlined above, plus the same payment for compliance. In addition, they will receive contingent reinforcement for submission of videorecordings that demonstrate negative breath alcohol samples. For each sample submitted that reads below the cut point, participants will receive vouchers for payment.
9971130|NCT01307358|Experimental|Manual Toothbrush + Sonicare Interproximal Cleaning Prototype|Manual Toothbrush + Sonicare Interproximal (IP) Cleaning Prototype
9971131|NCT01307358|Active Comparator|Manual Toothbrush|Manual Toothbrush
9971132|NCT01307358|Active Comparator|Manual Toothbrush + Floss|Manual Toothbrush + Floss
9971133|NCT01307358|Active Comparator|Manual Toothbrush + Waterpik Ultra Water Flosser|Manual Toothbrush + Waterpik Ultra Water Flosser
9971134|NCT01307371||Diabetes|Patients with diabetes.
9971135|NCT01307371||non-diabetes|Patients without diabetes.
9971136|NCT01307384||Continuum Acetabular System|Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System
9971137|NCT01307410||with CAD|Patients with hypertension and dyslipidemia with prior CAD
9971138|NCT01307410||without CAD|Patients with hypertension and dyslipidemia without prior CAD
9971139|NCT01307436|Experimental|Group A|Epaxal + concomitant administration of DTPaHibIPV, MMR, OPV
9971140|NCT01307436|Experimental|Group B|Epaxal, with administration of DTPaHibIPV, MMR, OPV one month later
9971141|NCT01307436|Active Comparator|Group C|Havrix 720 + concomitant administration of DTPaHibIPV, MMR
9971142|NCT01307475||Proband Group|Patients identified with FSS or a related condition
9971143|NCT01307475||Family Group|Persons who are genetically or legally related to a person with FSS or related condition
9971144|NCT01307475||Other Affected Individuals Group|Persons who have had significant and meaningful contact with a person with FSS or related condition but do not qualify for family group enrolment
9971145|NCT01307488|Experimental|ATV/r+3TC|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
9971146|NCT01307488|Active Comparator|ATV/r+2 NRTIs|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
9971147|NCT01307540|Experimental|Active light therapy|oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
9971148|NCT01307540|Placebo Comparator|Inactive light therapy|Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
9971149|NCT01307553||PCS Group|
9971150|NCT01307566|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP)
9971151|NCT01307605|Active Comparator|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
10185116|NCT03748862||Cases|"Patients who were receiving high-dose, long-term opioid therapy at study entry and achieved a sustained taper during the follow-up period.~A Taper Plan is a plan to reduce or discontinue use of opioids discussed with the primary care provider. Evidence of a taper plan is found in the prescription notes or medical encounter notes in the electronic health record."
9971152|NCT01307605|Active Comparator|Rituximab plus Lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
9971153|NCT01307644|Experimental|Web-based only (WO) weight intervention|A comprehensive lifestyle modification intervention for healthy eating and activity delivered by web only to facilitate Phase I weight loss (weekly messages baseline to 6 months), Phase 2 guided weight loss and weight maintenance (bi-weekly hot topics news, 6-18 months) and Phase 3 self-managed weight maintenance (6 monthly and 3 bi-monthly new content, 18-30 months).
9971154|NCT01307644|Experimental|WO & peer-led discussion board (WD)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with peer-lead discussion board. A peer leader will facilitate the asynchronous discussion group. The primary purpose of this group is to provide support, increase self-efficacy (role modeling by successful women and leader) and discuss progress toward goals.
9971155|NCT01307644|Experimental|WO & professional email counseling (WE)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with professional email-counseling by experienced counselor who will review women's web-logs of eating, activity, weight and goal-setting on web-site and send e-mail feedback.
9971156|NCT01307657|Other|clopidogrel 600 mg loading dose|
9971157|NCT01307683|Active Comparator|Mindful Moms|Based on the Mindful Motherhood Training (developed by Cassandra Vieten, PhD), Mindfulness-Based-Eating and Awareness Training (MB-EAT) (developed by Jean Kristeller, PhD), and other mindfulness- and acceptance-based interventions
10146654|NCT04135131|Placebo Comparator|HOME EXERCISE|The exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises. Patients were asked to perform three sets of exercises (10 repetitions) for three times a week for 8 weeks. Exercise training was provided by a physiotherapist. Patients were also provided an illustrated exercise brochure along with an exercise diary to record the number of days on which exercise was performed. They were followed up by phone calls every 2 weeks
10146655|NCT04134897|Experimental|Neoadjuvant chemotherapy|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery within 2 weeks. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 8-10 weeks. After surgery patients receive 4 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
10146656|NCT04134897|Active Comparator|Neoadjuvant radiotherapy|Patients will receive 5x5 Gy radiotherapy and then surgery following 6-8 weeks. After surgery patients receive 8 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
10146657|NCT04135040|Experimental|Lysine metabolic availability|Lysine metabolism from pure amino acids and cereal foods in children.
10185117|NCT03748862||Controls|Patients who were receiving high-dose, long-term opioid therapy at study entry and didn't achieve a sustained taper during the follow-up period.
10185118|NCT03748849||Low back pain group|Males and females who have had low back pain lasting between 12 weeks - 5 years without any other health problems (physical or psychological). Following baseline measurements, all subjects are offered individualized physiotherapy. The interventions mainly consist of exercises targeting their functional limitations. These are supplemented by a thorough explanation of their pain condition. This is done within the boundaries of the current understanding of musculoskeletal pain. This is supplemented with encouragement to do regular exercise and with manual therapy if needed/indicated.
10185119|NCT03748849||Control group|"Healthy males and females who have no current musculoskeletal pain problem (specific to the low back and/or in general). Likewise, they cannot have a previous history of on-going musculoskeletal pain. On-going pain is defined as a condition that limited their function for 3 months or more.~Participants in the control group take part in the baseline measurement and then another measurement after 6-8 weeks"
10185120|NCT03748836|Active Comparator|Single Ascending Dose ALPN-101|
10185121|NCT03748836|Placebo Comparator|Single Dose Placebo|
10185122|NCT03748836|Active Comparator|Multiple Ascending Dose ALPN-101|
10185123|NCT03748836|Placebo Comparator|Multiple Dose Placebo|
10185124|NCT03748797|Experimental|Exercise group|8-week moderate intensity exercise training under supervision
9519781|NCT03283475|No Intervention|control group|"- Control group will include 60 adult individuals between 18 and 35 years old who have body mass index (BMI) between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences."
9519782|NCT03283475|Active Comparator|patient group|"- Patient group will include 30 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.~After assessment, one of the following techniques will be selected:-~Liposuction only.~thigh lift.~Liposuction assisted thigh lift."
10185125|NCT03748797|No Intervention|Control group|No supervised exercise training given. Participants were advised to continue their routine daily activities and self exercises if they have
10185126|NCT03748745|Experimental|Cohort A|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
10185127|NCT03748745|Experimental|Cohort B|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
10185128|NCT03748719|Experimental|Stereotactic Body Radiation Therapy, followed by Prostatectomy|Patients will receive 6 Gy per day of Stereotactic Body Radiation Therapy (SBRT) per day for 5 days, followed by prostatectomy in 3 weeks.
10185129|NCT03748693||POP Group|Women with POP undergoing surgery in our OB/GYN department.
10185130|NCT03748693||Non-POP Group|Women undergoing hysterectomy for other indications.
10185131|NCT03748667||Patients with colorectal polyps|Patients with non-pedunculated type 0 lesions in Paris classification (not obvious cancers) larger than 10 mm
10185132|NCT03748654|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset
10185133|NCT03748628|Experimental|Single arm EDP-305|
10185134|NCT03748615|Experimental|Computer Guided ridge splitting in posterior mandible|fabrication of a computer aided surgical guide and performing ridge splitting in posterior mandible using piezosurgery
10185135|NCT03748602|Experimental|TOD|Thoracic Outlet Decompression (TOD)
10185136|NCT03748602|No Intervention|Conservative therapy|Physiotherapy and pain relief
10185137|NCT03748589|Experimental|airway type 1|The children weighed between 2-5kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1
10185138|NCT03748589|Experimental|airway type 1.5|The children weighed between 5-12kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1.5
10185139|NCT03748589|Experimental|airway type 2|The children weighed between 10-25kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2
9519783|NCT03283462|Active Comparator|AMAZ-02|
10185140|NCT03748589|Experimental|airway type 2.5|The children weighed between 25-35kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2.5
9519784|NCT03283462|Placebo Comparator|Placebo|
9519785|NCT03283410|Experimental|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
10146658|NCT04134871|Experimental|Intervention group|Participants randomised to the intervention group will be invited to attend a group education session where they will be given a step counter and activity diary, they will be invited to weekly group walks and fortnightly coaching 1-1 sessions aimed at setting and reviewing goals to increase physical activity and reduce sedentary behaviour
10146659|NCT04134871|No Intervention|Control group|Participants randomised to the control group will be given an information leaflet about being more active during a one-off 1-1 consultation.
9669383|NCT02178436|Experimental|GroupIII: Phase II Group II (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9971158|NCT01307683|No Intervention|Comparison Group|Usual prenatal care
9971159|NCT01307722|Experimental|Patients under LA distensibility-guiding management|The management of guide group will be adjusted by LA distensibility, including the adjustments of inotropic agents, diuretics, beta-blocker, ACEI, and AIIB.
9971160|NCT01307722|No Intervention|patients under conservative monitor and management|This group will be treated by conventional management and traditional echocardiography can be performed as in-charge doctor request. Renal function will be checked 1 time per 3 months.
10146660|NCT04135196|Experimental|Low Magnitude|voluntary forearm compression by leaning onto the palm of the hand with low target strain
10146661|NCT04135196|Experimental|High Magnitude|voluntary forearm compression by leaning onto the palm of the hand with high target strain
9971161|NCT01307735||Myocarditis negative on CMR|Patients with suspected myocarditis referred for CMR and not fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
9971162|NCT01307735||Myocarditis positive on CMR|Patients with suspected myocarditis referred for CMR and fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
9971163|NCT01307761||Patients with thyroid nodule received US-FNA exam|Patients with thyroid nodules which underwent head and neck ultrasound(US) examination and US-FNA cytology at Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan. No patient included in this series had a previous diagnosis of thyroid malignancy before US exam.
9971164|NCT01307826|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
9971165|NCT01307826|Active Comparator|classical massage|In this group of patients 10 classical massage sessions were applied
9971166|NCT01307839|Active Comparator|5% lidocaine patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
9971167|NCT01307839|Placebo Comparator|placebo patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
9971168|NCT01307852|Experimental|In Vivo Dosimetry|Modified endorectal device capable of real-time dose measurement during prostate radiation therapy
9971169|NCT01307865|Experimental|Sculptra Aesthetic|Patients receiving Sculptra Aesthetic
9971170|NCT01307878|Experimental|arm A|chemotherapy ± targeted therapy before resection of primary colorectal cancer
9971171|NCT01307878|No Intervention|arm B|resected the primary colorectal cancer and then given chemotherapy ± targeted therapy
9971172|NCT01307904|Active Comparator|dates|Each healthy and diabetic subjects received 50 grams equivalent of carbohydrates of the tested dates, On five separate days.
9971173|NCT01307904|Active Comparator|sugar|Each healthy and diabetic subjects received 50 grams of glucose
9971174|NCT01307917|Experimental|healthy controls high flavonoid|20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement
9971175|NCT01307917|Active Comparator|healthy controls low flavonoid|20 healthy adolescents (12-21 years old) receiving the placebo
9971176|NCT01307917|Experimental|T1DM or T2DM high flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement
9669384|NCT02163525|Active Comparator|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
9971177|NCT01307917|Active Comparator|T1DM or T2DM low flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo
9977135|NCT01358461||Subjects controls without vagal syncopes|Subjects controls without vagal syncopes (n=120:60 adults & 60 children
9977136|NCT01358474||PD Subjects|Subjects diagnosed with Parkinson's disease (PD)
9977137|NCT01358474||At-risk for PD|Subjects at-risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations)
9977138|NCT01358474||Healthy Controls|Healthy volunteers
9977139|NCT01358487|Active Comparator|Online self-help mood management course|Online self-help mood management course based on cognitive behavioral therapy and social cognitive theory, plus automated online follow ups using email reminders and incentives for completing follow-ups
9977140|NCT01358487|Experimental|Online self-help course plus live follow-up if needed|Intervention and automated follow ups with incentives as in the active comparator condition. The experimental procedure is adding live phone follow-ups if participant does not complete online assessment surveys at 1, 3, and 6 months in response to automated emails.
9977141|NCT01358500|Experimental|Fentanyl|
9977142|NCT01358513||Control Patients|Patients with normal aortic valves
9977143|NCT01358513||Aortic sclerosis|To undergo PET imaging and follow up with CT and echo for 2 years
9977144|NCT01358513||Mild Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
9977145|NCT01358513||Moderate Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
9977146|NCT01358513||Severe aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
9977147|NCT01358539|Experimental|Pain education|Patients receiving pain education
9977148|NCT01358539|No Intervention|No Pain education|Control group, patients receiving no pain education
9977149|NCT01358552||Néevo®/NéevoDHA®|Subjects who have been prescribed Néevo/NéevoDHA® daily.
9977150|NCT01358565|Active Comparator|Mild and Moderate Hepatic Dysfunction|Patients with mild and moderate hepatic dysfunction
10146662|NCT04135196|Experimental|Low Rate|"voluntary forearm compression by leaning onto the palm of the hand with low strain rate (task performed slowly and evenly)"
10146663|NCT04135196|Experimental|High Rate|"voluntary forearm compression by leaning onto the palm of the hand with high strain rate (task performed as quickly as possible, with a bump)"
10146664|NCT04135196|No Intervention|Control|observation only
10146665|NCT04135001|Experimental|HBM Training|
10146666|NCT04135001|Placebo Comparator|Placebo Training|
10146667|NCT04134988|Experimental|Medimoov|Bi-weekly 35-minute sessions of an adaptated physical activity administered by a psychomotor therapist for 8 weeks.
10146668|NCT04134988|Active Comparator|Standard rehabilitation|Bi-weekly 35-minute sessions of the standard psychomotor therapy for 8 weeks.
10146669|NCT04135157|Experimental|PECS II or ESP|PECS II or ESP block are performed 30 minutes before general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
10146670|NCT04135157|Active Comparator|Control|In the control group, patients will have only general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
10146671|NCT04135027||CD group|no interventions
10146672|NCT04134962||Ankel surgery group|Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.
10146673|NCT04134962||control foot group|"Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.~Will be retained only results of normal aligment FAO"
10146674|NCT04135209||Healthy controls|Healthy individuals of age-matched
10146675|NCT04135209||Myopic patients|Patients with myopia who meet the inclusion criteria
10146676|NCT04135105||Normal hearing group|Right-handed, normal hearing, no reported neurological disorders
10146677|NCT04135014|Placebo Comparator|Midazolam|Patients were assigned to receive oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
10146678|NCT04135014|Experimental|Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 2ug/kg approximately 30-40 minutes before surgery using a computer-generated random number table.
10146679|NCT04135014|Experimental|Midazolam and Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 1ug.kg-1 and oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
10146680|NCT04134806||Young Adults|Neurologically healthy young adults between ages 18 and 40
10146681|NCT04134806||Older Adults|Neurologically healthy older adults between ages 60 and 85
10146682|NCT04134806||Mild Cognitive Impairment/Mild Dementia|Older adults between ages 60 and 85 with Mild Cognitive Impairment or Mild Dementia
10146683|NCT04134611|Active Comparator|Knee arthroscopy with Hyaluronic acid injection|Those patients who received hyaluronic acid injection
10146684|NCT04134611|Active Comparator|Knee arthroscopy without Hyaluronic acid injection|Knee arthroscopy who did not Hyaluronic acid injection
10146685|NCT04134546|Experimental|group with biliary injury|group for Early versus late intervention after biliary tract injury post cholecystectomy
10146686|NCT04134624|Active Comparator|Prehospital intervention|All subjects enrolled in this study will receive a sepsis intervention bundle in the prehospital setting, including blood cultures, IV fluids, and antibiotics. These patients will be compared to historical controls.
10146687|NCT04134624|No Intervention|Control arm|Historical controls without prehospital sepsis intervention.
10146688|NCT04134676|Experimental|Conditioned Medium Group|"In this group, the subjects will use Conditioned Medium topical therapy for 2 weeks The Conditioned Medium gel will be applied to the wound and closed by transparent dressing.~The evaluation and dressing replacement will be done every week for 2 weeks."
10146689|NCT04134793||Sinus group|Six-month follow-up, by holter ECG record，the patients keep normal sinus after atrial fibrillation radiofrequency ablation.
10146690|NCT04134793||atrial fibrillation recurrence group|Six-month follow-up, by holter ECG record，the patients again suffer from atrial fibrillation after atrial fibrillation radiofrequency ablation.
10146691|NCT04134650|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5mg + metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
10146692|NCT04134650|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
10146693|NCT04134702|Experimental|Acupuncture|30 patients will receive acupuncture additionally to standard pharmacological therapy of postoperative pain
10146694|NCT04134702|No Intervention|No intervention|30 patients will receive just standard pharmacological therapy of postoperative pain
10146695|NCT04134780||Breast Characterization|
10146696|NCT04134715|Experimental|PF-06826647 alone then OC alone then OC+PF-06826647|In Period 1 (Period 1 is 2 days), participants will receive a single dose of PF-06826647 600 mg on Day 1. Period 2 (Period 2 is 14 days) will immediately follow Period 1 without any washout. In Period 2, the participants will receive OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet, orally starting from Period 2 Day 1 until Period 3-Day 16 (Period 3 is 17 Days). Period 3 will immediately follow Period 2 with no washout. In Period 3 on Day 1, the participants will receive a single dose of PF-06826647 600 mg. On Day 2 in Period 3, PF-06826647 will not be dosed. From Day 3, the participants will receive PF-06826647 600 mg QD for 14 days followed by OC in the form of 1 PORTIA (EE and LN) or equivalent tablet.
10146697|NCT04134468|Experimental|Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine|Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days.
10185141|NCT03748576|Experimental|Mobile technologies group|m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.
9669385|NCT02163525|Active Comparator|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
9669386|NCT02135484|Experimental|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
9669387|NCT02107638|Experimental|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
9971178|NCT01307943|Experimental|Mindfulness Based Stress Reduction|"Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat at the completion of the eight sessions to review and consolidate experience with the various mindfulness practices. The MBSR concepts and techniques will emphasize portability. Participants will be encouraged to find moments throughout their day in which to practice the techniques. The language used to describe mindfulness practices will be accessible to youth. Mindfulness concepts will be linked with tag phrases like breathing break, autopilot, and choice points. Homework will emphasize experiential, concrete tasks (notice five new things today; eat one meal mindfully this week)."
9971179|NCT01307943|Active Comparator|Usual Care|The control group will be youth receiving therapies and programs already used at the site. The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
9971180|NCT01307969|Experimental|Anesthetic efficacy|Local anesthetics were injected at the apex of the maxillary right canine.
9971181|NCT01307982|Active Comparator|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
9971182|NCT01307982|Active Comparator|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
9971183|NCT01307995||GDM|Patients with Gestational Diabetes Mellitus found during pregnancy by means of 75g OGTT
9971184|NCT01307995||NGT|Pregnant patients with normal glucose tolerance as observed in 75g OGTT
9971185|NCT01308021|Experimental|gpASIT400|gpASIT+TM 400 µg
9971186|NCT01308021|Experimental|gpASIT800|gpASIT+TM 800 µg
9971187|NCT01308021|Placebo Comparator|Placebo|
9971188|NCT01308047|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
9971189|NCT01308047|Active Comparator|bupivacaine (S50:R50)|3 ml subarachnoid block
9971190|NCT01308073||EMIC 2 dialysis|Patients on ICU requiring dialysis for acute renal insufficiency
9971191|NCT01308086|Active Comparator|FOLFOX 4 - 6months or XELOX -6months|
9971192|NCT01308086|Experimental|FOLFOX4 -3months or XELOX -3months|
9971193|NCT01308099||POTS & Controls|"Participants will have a physical prior to the study day and collect urine for 24 hours.~On the study day the following procedures take place:~After blood samples taken (about 2 tbsp), the subject will lie down. A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The arm blood pressure cuff will be inflated 60 points above the highest number on your normal blood pressure for five minutes. The blood pressure and forearm blood flow will be recorded. At the end of 5 minutes, the cuff will be released and the measurements of blood pressure and calf blood flow will be repeated. The brachial artery diameter and flow will be measured at baseline, during cuff inflation and for 3 minutes after deflation.~The study lasts about 2 hours."
9971194|NCT01308112|Experimental|Supplemental iron|
9971195|NCT01308112|Placebo Comparator|Placebo|
9971196|NCT01308138|Experimental|ExerciseTr|
9971197|NCT01308138|Experimental|Remote ischemic preconditioning group|
9971198|NCT01308138|No Intervention|Control patient group|
9971199|NCT01308151|Experimental|Experimental Arm|Culturally Adapted Manualised Cognitive Behavioral Therapy (CBT) Sessions will be offered weekly in the first month and then fortnightly.
9971200|NCT01308151|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
9971201|NCT01308164|Experimental|MD logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
9971202|NCT01308164|No Intervention|Control Group|Regular treatment, no change will be made in the insulin pump setting during the study (unless there is a medical need or any safety concern) Only segment 2 of the study, which is conducted as RCT (randomized controlled trial) , will include control group
9971203|NCT01308177|Placebo Comparator|PPI+placebo|
9971204|NCT01308177|Active Comparator|PPI+ES|
9971205|NCT01308203|Experimental|Extended release niacin /laropiprant|The patients will be randomized to one of two arms. The intervention is with the extended release niacin laropiprant combination, that is an add on of the usual medication that the primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
9971206|NCT01308203|Placebo Comparator|placebo|The patients will received placebo added to the usual therapy their primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
9971207|NCT01308216|Experimental|Transcranial low level laser therapy|Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
9971208|NCT01308216|Active Comparator|Control|The patients undergoing only a standard rehabilitation program based on therapeutic exercises.
9971209|NCT01308229|Experimental|Nile PAX®|
9971210|NCT01308242|Experimental|Treatment|Patients enrolled will receive Renvela for a 3 month time frame.
9971211|NCT01308255|Experimental|Infliximab Arm|For those randomised to the infliximab arm, infliximab will be administered at a dose of 3mg/kg according to the standard treatment protocol.
9977151|NCT01358565|Active Comparator|Healthy Volunteers|Healthy volunteers
10146698|NCT04134494|Experimental|Intervention|Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart
10146699|NCT04134585||People aged 60|People aged 60 and over who had refused to participate in fall prevention workshops will be included. They will have semi-structured interviews.
10146700|NCT04134559|Experimental|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a dose of 2mg/kg/dose (max: 200mg) with 21 consecutive days defined as a treatment cycle.
10146701|NCT04134754|Other|Respiratory physiology testing|Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.
10146702|NCT04134403|Experimental|Arm 1: Intervention|Arm will be those that are randomized to receive usual care plus hydrocortisone, thiamine and ascorbic acid.
10146703|NCT04134403|No Intervention|Arm 2: Usual care|Arm will be those that are randomized to receive usual care alone.
10146704|NCT04134416|Experimental|Anodal transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive 10 20-minute sessions while receiving REGIAplus (online). Group 1 will receive active stimulation (anodal stimulation, A-tDCS).The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
10146705|NCT04134416|Sham Comparator|Sham transcranial direct current stimulation|Group 2 will receive sham stimulation (S-tDCS). In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the assay.
10146706|NCT04134377|Experimental|Protein Food Snack|Provide a high protein food snack the first 2 weeks of each month for 6 months. Each participant will receive an 8 ounce food snack after dialysis for a total of 6 food snacks for each month.
10146707|NCT04134182|Experimental|Nivolumab + Ipilimumab|Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.
10146708|NCT04134364|No Intervention|control|no medication after gastric biopsy
10146709|NCT04134364|Experimental|treatment|oral administration of sodium alginate (LaminaG) after gastric biopsy
10146710|NCT04134520||Generally healthy subjects with no known cancer disorder|
10146711|NCT04134520||Subjects with a pathological diagnosis of cancer|
9971212|NCT01308255|Placebo Comparator|Steroid/Placebo Arm|Patients randomised to this arm will receive an IV infusion of 250mg methylprednisolone at week 0 & those without an adequate clinical response after 26 wks will receive additional steroid as IM methylprednisolone 120mg. Patients on this arm will receive an IV placebo infusion of 250ml of 9mg/l NaCl.
9971213|NCT01308281|Experimental|PCI with IVUS guidance|PCI(percutaneous coronary intervention) with IVUS(IntraVascular UltraSound) group
9971214|NCT01308281|Active Comparator|PCI without IVUS guidance|PCI(percutaneous coronary intervention) group
10146712|NCT04134130|Other|GnRH antagonist + FSH + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks.~After 3 weeks: 1000 mg testosterone once."
10146713|NCT04134130|Other|GnRH antagonist + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany).~After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once."
10146714|NCT04134273|Experimental|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
10146715|NCT04134273|Active Comparator|Clindamycin Phosphate Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
10146716|NCT04134273|Placebo Comparator|Vehicle of the test product|Placebo (vehicle of the test product), applied to the face twice a day for 84 days.
10146717|NCT04134117|Experimental|Tisagenlecleucel|"Study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits.~- Tisagenlecleucel will be administered intravenously as a one-time rapid infusion predetermined dose following lymphodepleting chemotherapy."
10146718|NCT04134247|Experimental|PD-1 combined with chemotherapy|21 days every cycle, assessment after 3-cycle
10146719|NCT04134247|Active Comparator|chemotherapy|21 days every cycle, assessment after 3-cycle
10146720|NCT04134741|Experimental|Kinetic Control Group|"The players participated in the classic training and for 4 weeks (3 times a week) underwent the Kinetic Control neuromuscular training with assistance of a physical therapist.~The duration of one training was 20-30 minutes."
10146721|NCT04134741|No Intervention|Traditional Training Group|Players participated in the classic training.
9971215|NCT01308307|Experimental|one arm|
9971216|NCT01308320|Placebo Comparator|saline|control group
9971217|NCT01308320|Active Comparator|F1 group|F1 group : fentanyl 1 mcg/kg
9971218|NCT01308320|Active Comparator|F1.5 group|F1.5 group : fentanyl 1.5 mcg/kg
9971219|NCT01308320|Active Comparator|F2 group|F2 group : fentanyl 2 mcg/kg
10146722|NCT04134312|Experimental|MVA-BN-Brachyury IV|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
10146723|NCT04134039|Experimental|Polyurethane (PU) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
10146724|NCT04134039|Experimental|Natural Rubber Latex (NRL) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
10146725|NCT04134598|Experimental|Partial Breast Irradiation (PBI)|Partial Breast Irradiation (PBI)
10146726|NCT04134598|Active Comparator|Endocrine Therapy (ET)|Endocrine Therapy (ET)
10146727|NCT04134156|Active Comparator|Sleeve gastrectomy|5-port standard sleeve gastrectomy was conducted
10146728|NCT04134156|Active Comparator|one anastomosis gastric bypass|5-port standard one-anastomosis gastric bypass was performed
10146729|NCT04134078|Experimental|inhaled nitric oxide|Inhaled Nitric Oxide at 40 ppm will be administered in adults who suffer in hospital cardiac arrest. The administration of inhaled nitric oxide at 40 ppm will be provided upto 24 hours once ROSC is achieved.
10146730|NCT04134065|Placebo Comparator|Control group|The physical properties such as appearance, size, color, dosage form, weight, taste and odor of placebo should be as much as possible as the test drug, but should not contain the Vitamin D (such as tablets containing lactose).
10146731|NCT04134065|Experimental|Vitamin D group|Liquid cholecalciferol supplementation (OsteVit DTM, Key Pharmaceuticals, Macquarie Park, NSW, Australia), supplied in 50 mL bottles (5000 units in 1 mL)
10146732|NCT04134104||Bowel, Bladder, and Sexual Dysfunction group|Out of 38 patients included for surgery 12 were excluded due to poor follow up and those patients who underwent upfront surgery. Only 26 patients were included in the study. There were 20 (76.9%) males and 6 (23.1%) females respectively. The mean age of the patient was 43.577yrs (26-75) and mean BMI was 20.78. The number of patients that underwent LAR was 24 (92.30%) and those who underwent APR were 2( 7.6%) after neoadjuvant chemoradiotherapy respectively.
10146733|NCT04134052|Experimental|ketamine sedation|Sedation will be performed with ketamine dose 5-20mcg / kg / min in infusion with 100 ml Na Cl solution 0.9% during surgery
9971220|NCT01308333||XLHED children|
9971221|NCT01308333||XLHED adults|
10146734|NCT04134052|Active Comparator|midazolam sedation|Sedation will be performed with midazolam dose 5 - 35mcg / kg / hr in infusion with 100 ml Na Cl solution 0.9% during surgery
10146735|NCT04134143|Experimental|Cohort 1: One Application|Participants enrolled in Cohort 1 received one application of experimental skin tissue during the first part of this trial (NCT02657876)
10146736|NCT04134143|Experimental|Cohort 2: Up to Five Applications|Participants enrolled in Cohort 2 may receive up to 5 applications of experimental skin tissue as required for wound healing
10146737|NCT04134143|Experimental|Cohort 3: Up to Ten Applications|Participants enrolled in Cohort 3 may receive up to 10 applications of experimental skin tissue as required for wound healing
10146738|NCT04133961|Experimental|Group A (Phenylephrine)|Phenylephrine infusion started immediately after administration of spinal block
10146739|NCT04133961|Placebo Comparator|Group B (Saline)|Normal saline infusion started immediately after administration of spinal block
10146740|NCT04134026|Experimental|HIF-PHI|HIF-PHI will be dosed orally three times a week.
10146741|NCT04134026|Active Comparator|Epoetin alfa|Epoetin alfa wull be disoensed per the package insert or the country-specific product labeling.
10146742|NCT04133974|No Intervention|Methadone|The subjects take methadone as usual.
10146743|NCT04133974|Experimental|Methadone-10min-Extinction|The subjects were given extinction training 10 min following methadone administration.
10146744|NCT04133974|Sham Comparator|Methadone-6h-Extinction|The subjects were given extinction training 6h following methadone administration.
10146745|NCT04133987|Experimental|Tetravalent live attenuated dengue vaccine admixture TV005|Tetravalent live attenuated dengue vaccine admixture TV005
9519786|NCT03283397|Experimental|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
10146746|NCT04133987|Placebo Comparator|placebo|Plasma-Lyte A
10146747|NCT04134195|Experimental|Real transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of real transcranial direct current stimulation over two distinct brain areas.
10146748|NCT04134195|Experimental|Sham transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of sham transcranial direct current stimulation over two distinct brain areas.
10146749|NCT04133896||Group 1 Male|group 1 (22 lean men),
10146750|NCT04133896||Group 2 Male|group 2 (22 class I obese men),
10146751|NCT04133896||Group 3 Male|group 3 (22class II obese men),
10146752|NCT04133896||Group 4 Male|group 4 (22 class III obese men).
10146753|NCT04133896||Group 1 Female|group 1 (22 lean women),
10146754|NCT04133896||Group 2 Female|group 2 (22 class I obese women),
10146755|NCT04133896||Group 3 Female|group 3 (22 class II obese women),
9971222|NCT01308333||Control children|
9971223|NCT01308333||Control adults|
9971224|NCT01308346|Experimental|Bioresorbable Vascular Scaffold (BVS)|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
9977152|NCT01358591|Sham Comparator|Control Breakfast|Normal calcium breakfast.
10146756|NCT04133896||Group 4 Female|group 4 (22 class III obese women).
10146757|NCT04133883|Other|Haemophilia A patients|Treated on-demand or prophylaxis with any Factor VIII (FVIII) product, plasma derived or recombinant (conventional or extended-half life) FVIII, according to routine clinical practice.
10146758|NCT04133831|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
10146759|NCT04133831|Experimental|Condition 2: Combined plus Total|Participants randomized to Condition 2 will view combined transplant survival and total survival outcome information when making a choice between the two hospitals.
9971225|NCT01308346|Active Comparator|XIENCE V® or XIENCE PRIME®|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) or XIENCE PRIME®
9971226|NCT01308359|Experimental|glucose 5%|glucose 5%
9971227|NCT01308359|Active Comparator|saline|saline
9971228|NCT01308372||1|For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
9971229|NCT01308385||Patients with pectus excavatum|
9971230|NCT01308411|Experimental|50% reduction in ICS dose|All patients will reduce their inhaled corticosteroid dose by 50%
9971231|NCT01308437|Experimental|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
9971232|NCT01308437|Active Comparator|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
9971233|NCT01308489|Experimental|Arm I (posterior spinal tumor resection)|Patients undergo posterior spinal tumor resection on day 0.
9971234|NCT01308489|Experimental|Arm II (anterior and posterior spinal tumor resection)|Patients undergo anterior and posterior tumor resection on day 0.
9971235|NCT01308502|Experimental|Probe|Children with airway obstruction
9971236|NCT01308515|Other|Posterior Stabilized|Patients who received a PS (Posterior Stabilized) Tibial Bearing.
9971237|NCT01308515|Other|Anterior Stablized|Patients who received an AS (Anterior Stabilized) Tibial Bearing
9971238|NCT01308528|Experimental|Sodium enoxaparin|Endocris - 40 mg/0,4mL
9971239|NCT01308528|Experimental|sodium enoxaparin Clexane|Clexane - 40 mg/ 0,4mL
9971240|NCT01308541|Active Comparator|LUSEDRA (arm 1)|
9971241|NCT01308541|Active Comparator|LUSEDRA (arm 2)|
9971242|NCT01308541|Active Comparator|Propofol (arm 3)|
9971243|NCT01308554|Placebo Comparator|Sterile normal saline|Control group will receive sterile normal saline in the block
9971244|NCT01308554|Active Comparator|Marcaine|Study group will receive a bilateral TAP block using 20 ml of Marcaine 2,5 mg/ml on each side.
9971245|NCT01308593|Active Comparator|Juvederm XC|Juvederm XC
9971246|NCT01308593|Active Comparator|Botox|Medication used to block neuromuscular transmission
9971247|NCT01308606|Experimental|001|TMC435 gelatin capsule Single intake of one 150-mg capsule without food
9971248|NCT01308606|Experimental|002|TMC435 HPMC capsule Single intake of one 150-mg capsule without food
9971249|NCT01308606|Experimental|003|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
9971250|NCT01308606|Experimental|004|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
9971251|NCT01308606|Experimental|005|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
9971252|NCT01308632|Experimental|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
9971253|NCT01308658|Experimental|001|Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
9971254|NCT01308658|Experimental|002|ritonavir 100-mg once daily on Day 1 to Day 5
9971255|NCT01308671|Active Comparator|varenicline|On 3 day after received clopidogrel 75mg/day, Varenicline group will be administered with varenicline 0.5mg Qd,after 3 days, 0.5mg Bid,after 7days,1mg Bid .And received counseling and psychosocial support.
9971256|NCT01308671|Other|Blank|Blank group will be only administered with Counseling and psychosocial support,beside antiplatelet etc.conventional therapy for 14 days.
9971257|NCT01308684|Experimental|1|
9971258|NCT01308684|Experimental|2|
9971259|NCT01308697|Active Comparator|Operative|Operative intervention
9971260|NCT01308697|Active Comparator|Non Operative Treatment|Non Operative management
9971261|NCT01308723|Experimental|Part I|
9971262|NCT01308723|Experimental|Part II (A)|
9971263|NCT01308723|Active Comparator|Part II (B)|
9971264|NCT01308775|Active Comparator|SIS.NET, Routine Follow up|
9971265|NCT01308801|Experimental|active rTMS + rehabilitation exercise|14 weeks of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
9971266|NCT01308801|Placebo Comparator|placebo rTMS + rehabilitation exercise|14 weeks of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
9971267|NCT01308827||Children with suspected pneumococcal invasive disease|
9971268|NCT01308866|No Intervention|Control|Usual care
9971269|NCT01308866|Experimental|Intervention|Intervention arm using a share-decision tool for cardiovascular patients
9971270|NCT01308879|Experimental|Weekly feedback|After clinical questionnaires are entered into the system (CFStm), an automated online report is available weekly to clinicians in the experimental group that shows current mental health status of youths, alerts, and trends over time based on youth, caregiver, and clinician responses. Reports also show some clinical data on caregivers.
9971271|NCT01308879|Other|No feedback|Clinicians in the control group do not have access to weekly feedback. Instead, they receive reports every 90 days after the youth is enrolled in CFStm. Because the average duration of CFS enrollment was 3.8 months, many youths would have been discharged before the first 90-day report became available three months after treatment start. Thus, we considered the 90-day feedback group to be essentially a no-feedback group.
9971272|NCT01308892|Active Comparator|High flavaonol chocolate|
9971273|NCT01308892|Placebo Comparator|Low flavanol chocolate|
9977153|NCT01358591|Experimental|High calcium breakfast|High calcium breakfast.
10146760|NCT04133831|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
10146761|NCT04133831|Experimental|Condition 4: Stratified plus Total|Participants randomized to Condition 4 will view stratified transplant survival and total survival outcome information when making a choice between the two hospitals.
10146762|NCT04133831|Experimental|Condition 5: Total only|Participants randomized to Condition 5 will view only total survival outcome information when making a choice between the two hospitals.
10146763|NCT04134533||Oral Feeding Group|Children with cerebral palsy who fed orally according to the Functional Oral Intake Scale
10146764|NCT04134533||Non-Oral Feeding Group|Children with cerebral palsy who fed non-orally according to the Functional Oral Intake Scale.
10146765|NCT04134637|Experimental|PIFB group|"For carrying out PIFB bilaterally the skin on either side of the sternum will be prepared with povidone iodine solution. Then a linear ultrasound probe will be placed on the right and left sides at 2 cm from the sternal body.~A 22 gauge, 4 inch needle will be advanced until contacting the 4th costal cartilage following the lower edge of US probe, directing the tip from the bottom of the sternum and positioning the needle tip between the pectoralis major and the external intercostal muscles. Group A will receive twenty milliliters of a solution of 0.25% bupivacaine plus epinephrine (5 mcg/ml). Boluses of 5 ml are introduced to perform hydrodissection of the interfascial plane."
10146766|NCT04134637|No Intervention|control group|the block will not be given
10146767|NCT04133571|No Intervention|Control group|Control group: using normal saline for bladder irrigation
10146768|NCT04133571|Experimental|Study group|Study group: using 0.05% Lidocaine normal saline solution for bladder irrigation
10146769|NCT04134169||Rheumatoid arthritis|
10146770|NCT04134299|Experimental|AXA4010|AXA4010
10146771|NCT04133584|Experimental|Group 1 EV71 +SIV|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV) simultaneously with 28 days apart
10146772|NCT04133584|Active Comparator|Group 2 EV71|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) with 28 days apart
10146773|NCT04133584|Active Comparator|Group 3 SIV|Give 2 doses of seasonal influenza vaccine(SIV) simultaneously with 28 days apart
10146774|NCT04133857|Active Comparator|Group A|undergo HIIT first then SSMIT protocol
10146775|NCT04133857|Active Comparator|Group B|undergo SSMIT first then HIIT protocol
10146776|NCT04133844||Extracorporeal membrane oxygenation|
10146777|NCT04133597|Experimental|Interventional|Two experimental steps: baseline skin conductance measurements (step 1, three minutes) and measurements of SC after social media stimulation with Line messages or calls (step 2, three minutes). With a 5-minute rest period after these two steps completed, then each participant fill out questionnaires for assessing anxiety and problematic smartphone use.
10146778|NCT04133818||Multidisciplinary program.|Patients with subacute or chronic LBP for whom first-line treatments had failed but for whom an intensive multidisciplinary rehabilitation program was not indicated.
10146779|NCT04133714|Experimental|multi-channel tDCS|"In the multi-channel tDCS stimulation group, a 1:4 (anode: cathode) approach was applied, with the central anode placed in the left dorsolateral prefrontal cortex (dlPFC) (reference 10-20 standard lead EEG), and the remaining cathode distributed around the central electrode.~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
10146780|NCT04133714|Experimental|single-channel tDCS|"The anode electrode of the single-channel tDCS stimulation group was placed in the left dlPFC, and the cathode electrode was placed in the right orbital forehead.~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
10146781|NCT04133714|Sham Comparator|sham stimulation|The shame stimulation group had only 30 seconds of up and down stimulation, with no intermediate stimulation.
10146782|NCT04133610|Experimental|Self-sampling device in media|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using self-sampling device in STM media. HPV will be detected by hybridization technique.
10146783|NCT04133610|Experimental|Dry self-sampling device|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using dry self-sampling device. HPV will be detected by hybridization and PCR techniques.
10146784|NCT04133727|Experimental|Intervention|Intervention group will wear a simulation suit in which will mimic the physical limitations experienced by older adults. In addition, they will participate in a polypharmacy workshop which allows them to communicate with older adults
10146785|NCT04133727|Active Comparator|Control|This group will participate in a polypharmacy workshop which allows them to communicate with older adults
10146786|NCT04133753|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
10146787|NCT04133753|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
10146788|NCT04133766|Experimental|Community-Based Nutrition Package|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
10146789|NCT04133766|No Intervention|Standard of care|Current standard of existing community health services.
10146790|NCT04133740|Active Comparator|Standard regime|Supplementary oxygen is given according to the standard regime with a fraction of inspired oxygen (FiO2) of at least 0.60 during mechanical ventilation and 3 liter/minute or more after weaning from the ventilator in the intensive care unit (ICU).
10146791|NCT04133740|Active Comparator|Oxygenation targeting|Supplementary oxygen is given to achieve a partial pressure of arterial oxygen (PaO2) within the normal range defined as 10-12 kPa (75-120 mmHg) during surgery and in the ICU.
10185142|NCT03748576|No Intervention|control group|Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.
10146792|NCT04133779||Group A (MS)|"Age 18-55 years;~Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS;~Course of the disease: RR-SP-PP-CIS;~Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS;~Not in clinical relapse (at least 30 days after the last clinical relapse);~Subjects treated or non-treated with immunomodulatory and immunosupressive drugs;~Signature of the informed consent."
10146793|NCT04133779||Group B (HC)|"Age 18-55 years;~Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC);~Signature of the informed consent.~The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study, or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres."
10146794|NCT04133779||Group C (OND)|"Aged 18-55 years;~Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy.~Signature of the informed consent."
10146795|NCT04133779||Group D (ONDi)|"Age 18-55 years;~subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases;~Signature of the informed consent."
10146796|NCT04133649|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
10146797|NCT04133493|Placebo Comparator|Standard of Care Group|Fibracol Dressing covered with gauze and wrapped with kerlix and wrap. Change 3Xper week
10146798|NCT04133493|Active Comparator|Intervention Group|Kerecis affixed with steri-strips, cover with gauze and change one per week .
10146799|NCT04133662|Experimental|Group 1|Restricted sleep condition first, longer sleep condition second
10146800|NCT04133662|Experimental|Group 2|Longer sleep condition first, restricted sleep condition second
10146801|NCT04133389|Experimental|Growth Mindset of Personality|Experimental intervention
10146802|NCT04133389|Placebo Comparator|Growth Mindset of Athletic Ability|Control intervention
10146803|NCT04133428||Sacubitril-Valsartan cohort|Patients with severe systolic disfunction (left ventricle ejection fraction<40%) heart failure that remain functional class II, III or IV after at least 3 months of optimal treatment and after being evaluated by the cardiologist by doing an echocardiography, blood test and clinical evaluation, start Sacubitril-Valsartan treatment.
10146804|NCT04133350|Experimental|Active Patient Engagement|All patients are enrolled into the Active Patient Engagement (APE) arm. This arm will receive the APE intervention.
10146805|NCT04133155||nab-P + GEM|Nab-paclitaxel plus gemcitabine
10146806|NCT04133181|Experimental|Guided endodontic surgery|Use of a 3D surgical guide in endodontic surgery
10146807|NCT04133181|Placebo Comparator|Conventional endodontic surgery|Use of a mock guide in endodontic surgery
10146808|NCT04133311|Active Comparator|DE-130A|Instillation of one drop, once daily in the evening (9 pm ±1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
10146809|NCT04133311|Active Comparator|Xalatan®|Instillation of one drop, once daily in the evening (9 pm ± 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
10146810|NCT04133337|Experimental|Apatinib Combined With SHR-1210 Injection|"Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery.~Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion.~Surgery:~The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose."
10146811|NCT04133454|Experimental|subjects treated with LGT|subjects will be treated with a single dose of LGT (AAV-hTERT)
10146812|NCT04133506||acute eczema|acute eczema patients with eczema <72 hours no drugs
10146813|NCT04133506||chronic eczema|chronic eczema with eczema > 72 hours no drugs
10146814|NCT04133506||allergic contact dermatitis|allergic contact dermatitis with a clear allergen identified no drugs
10146815|NCT04133506||psoriasis patients|patients with plaque psoriasis no drugs
10146816|NCT04133506||healthy volunteers|dithranol or DNCB (used to induce irritant or allergic eczema used safely in similar research studies for decades) aspirin to half the group to assess the effects on downstream mediators
10146817|NCT04133194|Experimental|1600 mg Asacol (mesalazine)|1600 mg mesalazine (Asacol) treatment regimen (1 tablet per day) for a year
10146818|NCT04133194|Active Comparator|800 mg Asacol (mesalazine)|800 mg mesalazine (Asacol) treatment regimen (3 tablets per day) for a year
10146819|NCT04133259|Experimental|HLX10, in patients with CHB|HLX10: 1 mg/kg at 0, 4th, 8th week (maximum 3 doses). Concomitant antiviral medications: take Nucleoside/nucleotide analogues (NAs) starting from at least 2 weeks before the first dose of HLX10 until 12 weeks after the last dose of HLX10 infusion.
10146820|NCT04133298|Active Comparator|Tunneling with laser de-epithelized gingival graft.|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
10146821|NCT04133298|Active Comparator|Tunnelingwith subepithelial connective tissue graft.|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid.
10146822|NCT04133142|No Intervention|Medical treatment|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation"
10185143|NCT03748563|Experimental|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
9519787|NCT03283397|Active Comparator|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
9971274|NCT01308905|Experimental|FLT-PET|"Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment.~Low risk patients: observation only.~Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection.~High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin.~PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection)."
9971275|NCT01308931||Tubal ligation|Patients who elect to have tubal ligation
9971276|NCT01308931||Essure|Group that elects to have Essure placement
9971277|NCT01308931||Levonorgestrel IUD|Patients that elect to have a levonorgestrel intra-uterine device placement
9971278|NCT01308944|Experimental|Arm 1|"Propranolol 40mg po orally twice daily to begin at least 48 hours prior to surgical debulking. This will ideally be titrated in order to maintain a heart rate between 60 and 80 without hypotension.~After surgery, the patient will resume the propranolol once tolerating clear liquids in the hospital and will remain on them until completion of chemotherapy.~After completion of chemotherapy, the patient will be weaned off the medication over the following two weeks."
9971279|NCT01308957|Experimental|Long chain omega-3 fatty acids|
9971280|NCT01308957|Placebo Comparator|Corn oil|
9971281|NCT01308957|No Intervention|Young healthy controls|Young subjects' muscle mass and physical function will be evaluated once (i.e., during baseline testing only). The data in young subjects will be used to determine the magnitude of the aging-induced decline in muscle mass and physical function in the older subjects prior to starting the interventions.
9971282|NCT01308970|Experimental|Stress Management Group 1|
9971283|NCT01308970|Experimental|Stress Management Group 2|
9971284|NCT01308970|Experimental|Stress Management Group 3|
9971285|NCT01308983|Other|Amiloride|
9971286|NCT01308996|Experimental|INFUSE® Bone Graft|
9971287|NCT01308996|Active Comparator|Autogenous bone graft|
9971288|NCT01309009|Experimental|Nepadutant High Dose|
9971289|NCT01309009|Experimental|Nepadutant Low Dose|
9971290|NCT01309009|Placebo Comparator|Placebo|
9971291|NCT01309035|Active Comparator|With Tourniquet|Total Knee Arthroplasty. Surgery performed during use of a tourniquet.
9971292|NCT01309035|Experimental|Without Tourniquet|Total Knee Arthroplasty. Surgery performed without use of a tourniquet.
9971293|NCT01309048|Experimental|Patients with painful bone metastasis|Patients with bone metastasis causing pain
9971294|NCT01309074|Experimental|Pregabalin|Pregabalin is an antiepileptic medication which has been found in double blind placebo controlled trials to be effective and safe in the treatment of primary generalized anxiety disorder. It has an indication for the treatment of this condition in Europe & Canada but not in the US.
9971295|NCT01309074|Active Comparator|Sertraline|Sertraline is an SSRI found to be an effective treatment of generalized anxiety disorder in controlled trials. It does not have an indication for this in this country.
9971296|NCT01309113|Placebo Comparator|Placebo of VAC BNO 1095|1 tablet of placebo in the morning, 1 tablet of placebo in the evening
9971297|NCT01309113|Active Comparator|10 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of placebo in the evening
9971298|NCT01309113|Active Comparator|20 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of VAC BNO 1095 10 mg in the evening
9971299|NCT01309126|Experimental|Arm 1: Imprime PGG + cetuximab|Biological/Vaccine + Drug
9971300|NCT01309126|Active Comparator|Arm 2: cetuximab|Drug
9971301|NCT01309139|Experimental|Treatment A: Tiotropium medium dose|Oral inhalation daily for 21 days
9971302|NCT01309139|Experimental|Treatment A: BI 54903 high dose|Oral inhalation daily for 21 days
9971303|NCT01309139|Experimental|Treatment B: Tiotropium medium dose|Oral inhalation daily for 21 days
9971304|NCT01309139|Experimental|Treatment C: BI 54903 high dose|Oral inhalation daily for 21 days
9971305|NCT01309178|Active Comparator|Amitriptyline|After the experience with the treatment of 18 CF-patients phase IIa study), the medication will be therefore 25 mg daily in two doses (2 x 12,5 mg). Because of a higher rate of side effects (tiredness, dry mucous membrane) the higher dose of 50 mg (2 x 25 mg) is not chosen first, but will be adapted after 2 weeks of treatment.
9971306|NCT01309178|Placebo Comparator|Mannite|The placebo will be given 25 mg daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
9971307|NCT01309217|Active Comparator|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. See below for a complete description.
9971308|NCT01309217|Experimental|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
9971309|NCT01309256||R-robot group|retrospective robot group
9971310|NCT01309256||P-robot group|prospective robot group
9971311|NCT01309256||P-laparoscopic group|prospective laparoscopic group
9971312|NCT01309295||Cohort|
9971313|NCT01309321|Experimental|Perinatal Handwashing Intervention Arm|
9971314|NCT01309321|Active Comparator|Neonatal Health Promotion|
9971315|NCT01309373||001|Patient assessment 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
9971316|NCT01309399|Active Comparator|teriparatide|six weeks of teriparatide
10146823|NCT04133142|Experimental|Early block Single|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment
10146824|NCT04133142|Experimental|Early Repeated block|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery.
10146825|NCT04133142|Experimental|Late block single|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day at day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block . Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment"
10146826|NCT04133142|Experimental|late block repeated|"Patients receive the standard medical medication for herpes pain~Oral administration of Gabapentin~300 mg/d on day 1 and 2~600 mg/d on day 3 and 4 if pain persists~900 mg/d on day 5 and 6 if pain persists~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation At day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery."
10146827|NCT04133116|Experimental|LY3471851|LY3471851 administered by subcutaneous (SC) injection.
10146828|NCT04133116|Placebo Comparator|Placebo|Placebo administered by SC injection.
10146829|NCT04133480|Experimental|GWP42003-P|For the first 7 days of the treatment period, participants are to take GWP42003-P at a dose of 5 milligrams per kilogram per day (mg/kg/day), administered as 2 equally divided doses (i.e., 2.5 mg/kg in the morning and 2.5 mg/kg in the evening). On Day 8, participants are to increase the dose to 10 mg/kg/day, administered as 2 equally divided doses (i.e., 5 mg/kg in the morning and 5 mg/kg in the evening). The 10 mg/kg/day dose should be maintained for the remainder of the treatment period; however, per labeling, investigators may increase the dose to a maximum of 20 mg/kg/day if clinically warranted by titrating an additional 5 mg/kg/day each week until reaching the maximum dose. GWP42003-P will be taken b.i.d. (morning and evening).
10146830|NCT04133246|Other|Group arm|Includes subjects enrolled in focus groups
10146831|NCT04133246|Other|Interview arm|Includes subjects with individual interviews
10146832|NCT04133467||Group SB|Scalp block performed with Levobupivacaine 0.125% (total dose 2 mg/kg) in combination with intraoperative intravenous acetaminophen (15 mg/kg if body weight >10Kg, 7 mg/kg if body weight < 10 kg).
10146833|NCT04133467||Group ST|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg
10146834|NCT04133129|Experimental|LV-High Intensity Interval Training|2 x 4 minutes at 85%-95% of Heart rate max.
10146835|NCT04133129|Experimental|Moderate Intensity Continuous Training|1 x 45 minutes at 65%-75% of Heart rate max.
10146836|NCT04133129|No Intervention|Control Group|They will not be prescribed any training and will be asked to continue with their normal lifestyle.
10146837|NCT04133103|No Intervention|First ambulation at 24 hours after operation|
10146838|NCT04133103|Experimental|First ambulation at 4 hours after operation|
10146839|NCT04132752|Experimental|Intervention|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
9826153|NCT02410252|Experimental|iThermonitor|Participants are asked to use the iThermonitor device for two weeks to monitor their temperature. Participants are asked to wear the device for as many hours as they can but at a minimum to wear while sleeping.
9826154|NCT02410278|Experimental|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
10146840|NCT04132752|No Intervention|Control|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
10146841|NCT04133090|Active Comparator|Autogenous block bone graft|Surgical site as control group was treated with autogenous block bone graft. Augmentation site was covered with a mixture of particulate allograft and leukocyte and platelet-rich fibrin (L-PRF) membrane.
10185144|NCT03748550|No Intervention|Control|Participants will receive standard of care treatment for their breast cancer.
9669388|NCT02107638|Active Comparator|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
9826155|NCT02410278|Experimental|DMF plus placebo|DMF as described in the USPI plus matched placebo
9971317|NCT01309399|Placebo Comparator|placebo|placebo identical in appearance to teriparatide
9971318|NCT01309412|Experimental|Siltuximab|Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
9971319|NCT01309425|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 25mg TRF single oral dose
9826156|NCT02410291|Experimental|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
10146842|NCT04133090|Active Comparator|i-PRF enriched allograft material+screw tent pole technique|Surgical site as test group was treated with injectable platelet rich-fibrin (i-PRF) enriched allograft material. To avoid soft tissue collapse, screws were used. Augmentation site was covered with leukocyte and platelet-rich fibrin (L-PRF) membrane.
10146843|NCT04132856|Experimental|Intervention Group|The Intervention group will receive the services of the Psychosocial Navigator (PSN) monthly for the full 12 months of the study. At baseline, the PSN will provide the health care providers (HCPs) and family with recommendations for mapping and triaging of resources to levels of psychosocial risk (PAT: Universal, Targeted, Clinical) and level of depression and anxiety (mild, moderate, and high mental health problems; as determined by the standardized norms for the measures). This information will be summarized in the Communication Summary Profile and shared with the treating team (oncologist, nurse, and Social Worker, core psychosocial staff involved in the child's care) and family within 48 hours of completion. The PSN will conduct follow-up psychosocial screenings on a monthly basis, using the Distress Thermometer for children and caregivers. Results of the monthly assessments and recommended resources will also be communicated to the caregiver/parent and treating team of the youth.
10146844|NCT04132856|No Intervention|Treatment as Usual Group|Current psychosocial care services will be accessible to Treatment as Usual Group (e.g., social work, child life, psychology, art and music therapy, and psychiatry).
10146845|NCT04132791|Other|aspirin after awakening + placebo before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study."
10146846|NCT04132791|Experimental|placebo after awakening +aspirin before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study."
10185145|NCT03748550|Experimental|Exercise|Participants will receive standard of care treatment for their breast cancer plus be given a 12-week home based aerobic exercise program.
10185146|NCT03748537|Experimental|Hydrocortisone|Hydrocortisone will be administered intravenously at 200 mg every 24 hours for 5 days, then tapered to a 50 mg intravenous bolus every 12 hours for days 6 to 8 and 50 mg every 24 hours for days 9 to 11, and then stopped.
10185147|NCT03748537|No Intervention|No Hydrocortisone|In control group, patient will not receive any corticosteroids for seven day after inclusion.
10185148|NCT03748524|Experimental|Single Influenza Vaccine|Single Influenza Vaccine,Quadrivalent
10185149|NCT03748511||fatty liver disease 0-1F|20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
10185150|NCT03748511||fatty liver disease 2F|20 patients with liver disease, fibrosis stage 2F.
10185151|NCT03748511||fatty liver disease 3-4F|20 patients with advanced liver disease, fibrosis stage 3-4F.
10185152|NCT03748498|Experimental|laser group|Low level laser was applied for 60 second per tooth using Nd-YAG laser.
10185153|NCT03748498|Placebo Comparator|placebo group|The same procedures as in the laser group were performed, been completed but the laser was not activated in this group.
10185154|NCT03748459||Permanent suture|Subjects will have skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
10185155|NCT03748459||Resorbable suture|Subjects will have skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty
10185156|NCT03748446|Active Comparator|X-TAU (xenon)|"Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug.~- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)"
10185157|NCT03748446|Placebo Comparator|N-TAU (nitrogen-placebo)|Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
10185158|NCT03748420|No Intervention|Usual Care|Basic clinical decision support alone
10185159|NCT03748420|Experimental|ReachOut Adherence intervention|Adherence-enhanced clinical decision support plus pharmacist-based adherence outreach
10185160|NCT03748407|Other|dosages in Healthy volunteers|"Only one arm : healthy volunteer blood donors. Performing a blood test for the determination of parameters that explore thyroid status : only once.~Absence of other healthy volunteers group all healthy volunteers have a blood test performed in the same way."
10185161|NCT03748394|Experimental|Work-directed rehabilitation|Work-directed, person-centered plan using modules of occupational therapy and physical therapy
10185162|NCT03748394|Active Comparator|Physical activity|Physical activity according to national health recommendations
10185163|NCT03748381|Experimental|Trifocal IOL|The patients will receive two different diffractive trifocal IOLs in each eye (AT Lisa tri vs. Rayner trifocal) during cataract surgery
10185164|NCT03748368|Active Comparator|Cataract presentation|Cataract presentation prior to surgery
10185165|NCT03748368|Placebo Comparator|Placebo presentation|Placebo presentation prior to surgery
10185166|NCT03748355|Other|Pharmacogenetic Analysis|A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
10185167|NCT03748303|Experimental|Allo IM cohort|Allopregnanolone 4-18mg IM, weekly, for 12 weeks.
10185168|NCT03748290|Experimental|People with a SCI who will receive Lyrica 75mg for 12 weeks|
10185169|NCT03748290|Placebo Comparator|People with a SCI who will receive Placebo for 12 weeks|
10146847|NCT04132739|No Intervention|Control|
10146848|NCT04132739|Experimental|Exercise only|
10146849|NCT04132739|Experimental|Diet only|
10146850|NCT04132739|Experimental|Diet + Exercise|
10146851|NCT04132869|Experimental|Experimental Group|In Spring of 2020, all 6th graders in Wave 1 intervention schools (6 schools), which include 561 total 6th graders, will be invited to participate the intervention. Those in the experimental group will complete all measures according to the timeline. Those not in the experimental group will also complete the intervention, but will not participate in measurements. In Fall 2020 all 6th graders who attend the Wave 2 intervention schools (schools that were the control schools in Spring), will be invited to participate the intervention. Those in the experimental group will complete all measures on schedule. *Note these activities were delay due to schools shutting down in March 2020 because of COVID-19
10146852|NCT04132869|No Intervention|Control group|Wave 1 comparison schools (2 Schools) have a total of 267 6th graders. Students will be invited to join the comparison group. and will have measurements taken at baseline and 6 months. Wave 2 comparison schools (3 Schools) have a total of 363 6th graders adn will be invited to join the comparison group and will have measurements taken at baseline and 6 months. These students will continue with their normal activities as usual.*Note these activities were delay due to schools shutting down in March 2020 because of COVID-19
10146853|NCT04132908|Experimental|Sclerocarya birrea|
10146854|NCT04132908|Placebo Comparator|Placebo|
10146855|NCT04132921||Patients with AKI|Patients with AKI after joint replacement
10146856|NCT04132921||Patients without AKI|Patients without AKI after joint replacement
10146857|NCT04132843|Experimental|Diagnostic (MRI, gadobutrol, gadobenate dimeglumine)|Within 21 days before standard of care chemotherapy and/or radiation therapy, patients undergo an MRI scan for the first set of images. Patients then receive either gadobutrol or gadobenate dimeglumine IV and undergo an MRI for the second set of images. All MRI scans take a total of 60 minutes to complete. Patients then repeat the MRI scans 120 days after standard of care chemotherapy and/or radiation therapy.
10146858|NCT04133025|Active Comparator|Conventional vestibular rehabilitation|Conventional vestibular rehabilitation
10146859|NCT04133025|Active Comparator|Vestibular rehabilitation with software|
10146860|NCT04132778|Experimental|Intervention - Asthmatuner|Asthmatuner (Medituner AB, Stockholm, Sweden) is a CE-marked cloud-computing-based system with a healthcare interface and a downloadable patient app (Android or iOS).The intended use of Asthmatuner is to automate asthma self-management by letting patients register symptoms and measure forced expiratory volume in one second (FEV1) with a Bluetooth spirometer (MIR, SmartOne). The patient then receives immediate feedback on the status of symptom control (controlled, partly controlled or uncontrolled), and a treatment recommendation, with an image of the correct inhaler or other type of medication and the dose. Symptom control is quantified based on lung function; litre to percentage of personalised best FEV1, using a cut-off ≤80% and symptoms during the last week based on four questions: 1) need for rescue medication more than twice due to asthma symptoms, 2) any daytime symptoms, 3) nocturnal symptoms/awakenings, and 4) limitation in physical activities.
9669389|NCT02090530||Advanced Cancer Patients|Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
10146861|NCT04132778|No Intervention|Control group - Traditional asthma management|Traditional self-management is defined as all other types of non-digital asthma management. This could be treatment plan written on paper or by oral communication to patient/caregiver on asthma treatment.
10146862|NCT04133051|Active Comparator|Quadratus Lumborum Block|17 cases will be subjected to bilateral Ultrasound-guided Quadratus lumborum block through bilateral catheter insertion for perioperative analgesia.
10146863|NCT04133051|Active Comparator|Epidural Analgesia|17 cases will be subjected to epidural catheter insertion for perioperative analgesia (as a control group).
10146864|NCT04133064|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 10 or more cigarettes per day
10146865|NCT04132830||HIV-Exposed Uninfected Dyads|Mothers who had HIV during pregnancy and their HIV-negative young adult offspring
10146866|NCT04132830||HIV-Unexposed Uninfected Dyads|Mothers and young adults without HIV
10146867|NCT04132765||Patients with cerebral palsy|Patients with cerebral palsy at between the ages of 4-16 years and at Gross Motor Function Classification Levels of 3,4,5
10146868|NCT04132401|Experimental|family medicine physicians|Retina reading
10146869|NCT04132401|Experimental|retina specialists|Retina reading (gold standard)
10146870|NCT04132440||Observational (questionnaire, interview)|Patients and physicians complete a questionnaire over 5 minutes and an interview over 30-45 minutes about thoughts on NAFLD, including what they know about NAFLD and its diagnosis, management, and monitoring, and other thoughts on NAFLD.
10146871|NCT04132518|Experimental|Treatment Group|Each subject assigned to Treatment Group will receive up to 4 injection sessions with 5(±1) weeks intervals.
10146872|NCT04132518|No Intervention|Control Group|Subjects assigned to the Control Group will not receive treatment during the study.
10146873|NCT04132583|Experimental|First Deflox®, Then Cataflam DD®|Participants received single oral dose of Deflox® 50 milligrams (mg) tablet in Treatment Period 1 followed by a single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between the Treatment Periods 1 and 2.
10146874|NCT04132583|Experimental|First Cataflam DD®, Then Deflox®|Participants received single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 1 followed by single oral dose of Deflox® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between Treatment Periods 1 and 2.
10146875|NCT04132700|Experimental|ICU Patients|Patients admitted to the ICU will be monitored using the Q-NRG for up to 30 mins.
10146876|NCT04132622|Experimental|Experimental therapy group|Besides Traditional therapy，patients in this group will also receive thyroid replacement therapy.
10146877|NCT04132622|Sham Comparator|Traditional therapy group|Patients in Standard therapy group will receive treatments according to guideline worldwide.
10146878|NCT04132479|Experimental|Sequential therapy|Sequential Clarithromycin + Amoxycillin + Tinidazole + rabeprazole by mouth (Both amoxycillin 1000mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days, followed by clarithromycin 500 mg every 12 hours, tinidazole 500mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days)
10146879|NCT04132479|Active Comparator|Concomitant therapy|Concomitant clarithromycin 500mg every 12 hours + amoxycillin 1000mg every 12 hours + tinidazole 500mg every 12 hours + rabeprazole 20mg every 12 hours (all drugs by mouth for 14 days).
10146880|NCT04132674|Other|B/F/TAF|Switching participants who are currently on multi-tablet HIV antiretroviral therapy, including multi-tablet regimens and/or two drug combinations (dual therapy) to one oral tablet of B/F/TAF once-daily for 72 weeks
10146881|NCT04132505|Experimental|Treatment (binimetinib, hydroxychloroquine)|Patients receive binimetinib PO BID and hydroxychloroquine PO BID on days 1-14. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10146882|NCT04132661|Experimental|bisacodyl|5 mg bisacodyl, one tablet once
10146883|NCT04132661|Placebo Comparator|placebo|placebo, one tablet once
10146884|NCT04132726|Experimental|Test|Experimental group which employed with massage treatment
10146885|NCT04132726|Placebo Comparator|Placebo|Placebo group which employed with non-effective treatment
10146886|NCT04132726|No Intervention|Control|no treatment
10146887|NCT04132713||Control group|20 healthy volunteers were included in the healthy control group
10146888|NCT04132713||Disease group|30 patients with advanced breast cancer developed hand-foot syndrome after capecitabine administration
10146889|NCT04132687|Other|autologous blood patch|autologoust blood patch therapy
10146890|NCT04132596|Experimental|Motor Complete Tetraplegia|C4-T1 American Spinal Injuries Association (ASIA) Impairment Scale Classification A or B spinal cord injury tscs with activity based therapy intervention
10146891|NCT04132596|Experimental|Motor Complete Paraplegia|T2-12 ASIA Impairment Scale A or B spinal cord injury tscs with activity based therapy intervention
10146892|NCT04132596|Experimental|Motor incomplete SCI|C4-T12 ASIA Impairment Scale C or D spinal cord injury tscs with activity based therapy intervention
10146893|NCT04132635|Experimental|artificial dermis with growth factor|
10146894|NCT04132635|Experimental|artificial dermis only|
10146895|NCT04132609|Active Comparator|Cognitive Bias Intervention|Complete cognitive bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
10146896|NCT04132609|Placebo Comparator|Control|Complete standard attentional bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
10146897|NCT04132648|Experimental|Curcumin|Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials
10146898|NCT04132648|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
10146899|NCT04132531||Normal weight control|Individuals who are generally healthy and have a body mass index less than 25 kg/m^2.
10146900|NCT04132531||Bariatric Surgery Group|Individuals electing to undergo bariatric surgery (generally with a body mass index between 35 and 40 kg/m^2 with an additional co-morbidity such as type 2 diabetes, or individuals with a body mass index greater than 40 kg/m^2) and who are willing to participate for 2 visits, one before and one after surgery. The intervention in this group is bariatric surgery.
10146901|NCT04132570|Experimental|Budesonide 256 mcg per Day (Treatment A)|Participants will self-administer 2 nasal sprays of Budesonide (64 microgram [mcg]/spray) in each nostril once daily (every morning) up to 10 +\- 3 Days.
10146902|NCT04132570|Placebo Comparator|Placebo (Treatment B)|Participants will self-administer 2 nasal sprays of matching placebo in each nostril once daily (in the morning) up to 10 +\- 3 Days.
9669390|NCT02088333|Experimental|mCRC intervention|intervention arm
9669391|NCT02088333|Placebo Comparator|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
10146903|NCT04132349|Experimental|Ullipristal Acetate|Women with symptomatic uterine fibroids will be treated with 5 mg UPA / day in 3 months
10146904|NCT04132557||Cohort 1 (Target): Methylphenidate Monotherapy|Participants will be analyzed for Attention Deficit Hyperactive Disorder (ADHD) who are new users of methylphenidate monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
10146905|NCT04132557||Cohort 2 (Comparator [C]): Lisdexamfetamine Monotherapy|Participants will be analyzed for ADHD who are new users of lisdexamfetamine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
10146906|NCT04132557||Cohort 3 (C): Atomoxetine Monotherapy|Participants will be analyzed for ADHD who are new users of atomoxetine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
10146907|NCT04132557||Cohort 4 (C):Amphetamine/Dextroamphetamine Combo Therapy|Participants will be analyzed for ADHD who are new users of amphetamine/dextroamphetamine combo therapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
10146908|NCT04132323|Active Comparator|hypertonic glucose|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 75% glucose, with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
10146909|NCT04132323|Active Comparator|0.05% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 0.05% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
10146910|NCT04132323|Active Comparator|0.1% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 0.1% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
10185170|NCT03748277|Experimental|Minimally invasive fusion|Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
10185171|NCT03748277|Active Comparator|Open Fusion|Bilateral decompression, open fusion + screw fixation
10146911|NCT04132323|Active Comparator|0.15% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 0.15% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
10146912|NCT04132310||MINT Participants|Up to 60 MINT maternal participant are linked with 60 infant participants, and 60 partner participants.
10146913|NCT04132297|Experimental|Virtual Asthma Academy Training + Telehealth Visit Group|Participants will receive the Asthma Academy Training virtually. One week after the virtual training, participants will be scheduled to complete a Telehealth visit via zoom through their smart phones or computers.
10146914|NCT04132297|Experimental|Virtual Asthma Academy Training|Participants will receive the virtual Asthma Academy Training via zoom through their smart phones or computers.
10146915|NCT04132167|Experimental|training group|perturbation balance training
10146916|NCT04132167|Active Comparator|control group|traditional physical therapy that including strengthening and stretching
10146917|NCT04132063||Generic levetiracetam|
9528201|NCT03212846|Experimental|Treatment group|Children will receive hippotherapy by a licensed physical therapist. Before riding, stretching and warming exercises of the adductor muscles will be performed. Later, the patient will be seated astride with the therapist behind. In any case, the participant had no control of the horse. Therapist will be responsible for correctly positioning the subject on the horse, but no position changes or active intervention of the subject with the therapist will be made. This positioning consists on achieving the optimal body alignment with neutral pelvis.
10146918|NCT04132037||patient with multiple sclerosis|At each visit, inclusion, 6 weeks, 6 months, 12 months, and 24 months, the clinical and urinary data will be recorded and the ISC frequency , ISC discontinuation and adherence scale will be evaluated
9971320|NCT01309425|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50mg TRF single oral dose
9971321|NCT01309425|Experimental|003|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
10146919|NCT04132089|No Intervention|Control|This was the control group for the messaging component of the study (push notifications). These participants only received the mobile health application called capABILITY without messages.
10146920|NCT04132089|Other|Facilitator Message Group|This group of participants received the mobile health application called capABILITY and received three facilitator messages per week. Facilitator messages are designed to help people who lack ability to do something.
10146921|NCT04132089|Other|Spark Trigger Group|This group of participants received the mobile health application called capABILITY and received three spark messages per week. Spark messages are designed to help people who lack ability to do something.
10146922|NCT04132128|Experimental|study|6 meetings with a dietician diabetes educator assimilating simple CC tool
10146923|NCT04132128|Other|control|meeting with dietician as needed with regular education of CC
10146924|NCT04132011|Active Comparator|Shortened interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals less than every 12 hours.
10146925|NCT04132011|Active Comparator|Standard interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals every 12 hours
10146926|NCT04132024|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
10146927|NCT04132284|Experimental|DBT IOP plus DBT PI|Standard Dialectical Behavior Therapy (DBT) delivered in the context of an intensive outpatient program (DBT IOP) for adolescents plus an 8-10 session DBT-based parenting intervention (DBT PI)
10146928|NCT04132284|Active Comparator|DBT IOP alone|No parenting intervention provided beyond what is part of the DBT IOP treatment as usual.
10146929|NCT04132102|Experimental|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
10146930|NCT04131985|Experimental|Erector spina block|"After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).~All anesthesia procedure will be the same as control group"
10146931|NCT04131985|No Intervention|Control|There were no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1-2μg/kg, propofol 2 - 4 mg/kg and rocuronium 0.6 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCO2≈ 35-40 mmHg. Anesthesia was maintained using remifentanil 0.05-0.1 mcg/kg/min and propofol 80-100 mcg/kg/min via total intravenous micro pump until the surgery was completed. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria.Tramadol 100 mg i.v. will be used before 15 min end of surgery and 20 mL of 25% bupivacaine will be infiltrated to the trochar sites at the end of the surgery. Patient control analgesia device will administer all patients.
10146932|NCT04132271|Experimental|Personalized diet|Personalized diet during the swallowing rehabilitation
10146933|NCT04132271|Active Comparator|Control|Nutritional recommendations during the swallowing rehabilitation
9971322|NCT01309425|Experimental|004|tapentadol (CG5503) ER two 100-mg TRF 200mg TRF single oral dose
9971323|NCT01309438|Experimental|Normal renal function|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
9971324|NCT01309438|Experimental|Mild renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
10146934|NCT04132154||No Warming|Patients in this group were treated according to our institution's old protocol and did not receive any warming intervention during the surgical procedure.
10146935|NCT04132154||Active Warming|This group will include the patients treated after the implementation of the S3 Guidelines for prevention of hypothermia. For this purpose convective warming through an underbody blanket was used during the surgical procedure
10146936|NCT04131842|Experimental|ExFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive external focus of attention visual feedback.
10146937|NCT04131842|Experimental|ExFOCUS Auditory|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive auditory feedback.
10146938|NCT04131842|Experimental|InFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive internal focus of attention visual feedback via video.
10146939|NCT04131842|Active Comparator|NoFeedback|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and receive no feedback.
10146940|NCT04131816|Experimental|HeartHome Intervention|Participants will be in the HeartHome program for a total of 12 weeks.
10146941|NCT04131816|No Intervention|Control|De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation
10146942|NCT04131686||Control sites|Group of patients receiving standard treatment for symptomatic acute rhinosinusitis
10146943|NCT04131686||Test sites|Group of patients receiving NAC inhalation in addition to standard treatment for symptomatic acute rhinosinusitis
10146944|NCT04132245|Experimental|obesity prevention|Families were randomized to an obesity prevention intervention arm or a general health control arm.
10146945|NCT04132245|Experimental|behavioral intervention|there are two arms in this study. An active intervention arm and a control arm
10146946|NCT04131803|Experimental|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
10146947|NCT04131803|Experimental|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
10146948|NCT04131712|No Intervention|Ambulatory Control|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. Atrophy will not be induced and massage intervention will not be applied.
10146949|NCT04131712|Sham Comparator|Ambulatory Massage|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. No atrophy induction. Four massage treatments will be applied every other day until the end of the study.
10146950|NCT04131712|No Intervention|Immobilization Control|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Massage intervention will not be applied.
10146951|NCT04131712|Experimental|Immobilization Massage|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Four massage treatments will be applied every other day until the end of the study.
10146952|NCT04131829|No Intervention|Healthy Controls|The healthy control group will be an age matched sample of unmedicated healthy adults who will be recruited and imaged once at baseline and the data compared with that of OCD subjects at baseline.
10146953|NCT04131829|Experimental|OCD Group|The OCD group will comprise of unmedicated individuals with clinically significant OCD symptoms. OCD Subjects will be randomized, double-blind, to receive immediate or delayed (by 6 weeks as a placebo lead-in) pharmacotherapy.
9519788|NCT03283358|Experimental|Person-centered follow up|The intervention program is a person-centered health promotion program led by a nurse and consists of two telephone calls (15 minutes each) at two weeks and nine months after surgical treatment for Intermittent Claudication and three visits (45 - 60 min) at six weeks, six months and one year after treatment. The program includes a baseline assessment, an individual plan for self-care and educational information about Intermittent Claudication, received treatment and secondary prevention (medication and modifiable risk factors). The purpose is to enhance self-care in terms of adherence to medication and to recommended changes of lifestyle.
10146954|NCT04131777||Roll-in|Initial patients enrolled until optimal RF algorithm is determined
10146955|NCT04131777||Optimized|Patients treated using optimal RF algorithm
10146956|NCT04131946|Experimental|Community Intervention Group/Arm 1|"Community navigators will work with local businesses (barber shop, hair salon) to identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT.~Community navigators will attend community events to post the informational flyer and provide education about CRC to community members. At these events, they will identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT."
10185172|NCT03748251|Experimental|Short fermented pizza|the patients ate a pizza that fermented for 8 hours
10185173|NCT03748251|Experimental|Long fermented pizza|the patients ate a pizza that fermented for 24 hours
10185174|NCT03748238|Experimental|Injury group|Endometrial injury with hysteroscopy
10185175|NCT03748238|No Intervention|Control group|No hysteroscopy
10185176|NCT03748212|Active Comparator|Group 1|D935 Cap. 1T
10185177|NCT03748212|Experimental|Group 2|CKD-385 Tab. 1T
10146957|NCT04131946|No Intervention|Standard of Care (Control) Arm 2|"These procedures are a detailed summary of the existing lay navigation program at Mile Square Health Center (MSHC). These procedures are unrelated to our research, except to demonstrate how the existing navigation program from which we will obtain deidentified data works.~Lay clinic navigator use clinic schedules and walk-ins to identify and screen eligible participants within the Englewood MSHC. The navigator engages with each potential participant using standard scripted language. For interested patients, the navigator documents interest and FIT dispensing as appropriate, and assists the patient in obtaining and returning their FIT.~Lay clinic navigators attend community events as normally scheduled to provide community-based health education and referral to the MSHC. At these events, they identify and screen eligible community members within the Englewood community area."
10146958|NCT04131868|Experimental|Extended sleep opportunity|
10146959|NCT04131868|Active Comparator|Typical sleep opportunity|
10146960|NCT04131699||pediatric thoracoscopic group|record hemodynamic changes and cardiac output at different intrathoracic pressures ( insufflation pressures 4, 5, 6 mmHg)
10146961|NCT04131790|Experimental|Tele-Behavioral Activation|Manualized Behavioral Activation (BA) protocol delivered via videoconferencing by a trained BA interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist guides participants in learning BA skills, focusing on strategies to decrease barriers to social connectedness (e.g., limited mobility, inadequate caregiving resources).
10146962|NCT04131790|Active Comparator|Tele-Friendly Visiting|Friendly Visitor (FV) calls delivered via videoconferencing by a trained FV interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist provides social support to participants through good listening and provision of genuine regard.
10146963|NCT04131855|Active Comparator|Pumice prophylaxis.|Will receive pumice prophylaxis in a slurry of plain pumice and water for 5 seconds per tooth using a rubber cup in a slow contra-angle handpiece. The teeth involved will then be washed and dried prior to using the self etch primer.
10146964|NCT04131855|Experimental|No pumice prophylaxis.|Will not receive pumice prophylaxis. Teeth will be washed and dried before using the self etch primer.
10146965|NCT04131920||Phase 1 and 2|10 male patients with severe Hemophilia A from the Washington Center for Bleeding Disorders
10146966|NCT04131920||Phase 3|20 subjects who are also participating in the EmiMSKUS study
10146967|NCT04131894|No Intervention|Control|Extraction sockets with spontaneous healing (16 sockets).
10146968|NCT04131894|Active Comparator|Dentin|Extraction sockets were filled with undemineralized autogenous dentin graft (20 sockets).
10146969|NCT04131894|Active Comparator|Dentin+PRF|Extraction sockets were filled with mixture of undemineralized autogenous dentin graft and platelet rich fibrin (PRF) (21 sockets).
10146970|NCT04131621|Experimental|Nivolumab/Ipilimumab|
10146971|NCT04131725||Cardiac Function Monitoring|Subjects will wear Cardiac Performance System (CPS) non-invasive device for brief periods during procedures including assessment by Pulmonary Artery Catheter (PAC) methods.
10146972|NCT04131764||Optic neuritis diagnosis only|Patients who have a diagnosis of optic neuritis, without a diagnosis of MS or NMOSD.
10146973|NCT04131764||ON and multiple sclerosis|Patients who have a diagnosis of optic neuritis AND multiple sclerosis.
10146974|NCT04131764||ON and NMOSD|Patients who have a diagnosis of optic neuritis and neuromyelitis optica spectrum disorder.
10146975|NCT04131634|Experimental|SAbR 6 measurable lesions|PD-L1 assessment on biopsy of metastatic site (biopsy will be performed if no prior metastasis sample available)
10146976|NCT04131660|Experimental|AVAPS-AE mode|A volume targeted pressure support ventilation mode
9669392|NCT02086604|Experimental|Starting Dose (brentuximab vedotin & lenalidomide)|"Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
9826157|NCT02410291|No Intervention|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
10146977|NCT04131660|Active Comparator|S/T mode|A pressure support ventilation mode
10146978|NCT04131478||Cases|Cachectic lung, pancreas, or colon cancer patients.
10146979|NCT04131478||Control|Non- cachectic lung, pancreas, or colon cancer patients.
10146980|NCT04131569||ESBL-E fecal carriers|Patients with a positive ESBL-E fecal carriage according to routine screening
10146981|NCT04131569||non ESBL-E fecal carriers|Patients without positive ESBL-E fecal carriage according to routine screening
10146982|NCT04131608||diabetic foot ulcer (1and2)with iron defic|"50 diabetic patients with diabetic foot ulcer grade (1and2) with iron deficiency anemia will be applied TO~cbc~ferritin~HBA1C~ankle brachial index by duplex"
10146983|NCT04131608||diabetic foot ulcer grade(1and2)without iron deficiency anemia|"50 patients with diabetic foot ulcer grade (1and2) without iron deficiency anemia will be applied to~CBC~Ferritin,~HBA1C~ankle brachial index by duplex"
10146984|NCT04131543|Experimental|Cabozantinib|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
10146985|NCT04131348|Other|CSG|patients underwent open CST (component separation group or CSG)
9669393|NCT02086604|Experimental|Dose Level 1 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
9669394|NCT02086604|Experimental|Dose Level 2 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
10146986|NCT04131348|Other|BTG|patients with preoperative BT administration and following open RSR (botulinum toxin group or BTG).
10146987|NCT04131465|Experimental|Home HIV self-testing|Fieldworkers will visit potential participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing.
10146988|NCT04131465|Experimental|Home HIV rapid testing|Fieldworkers will visit potential participants in their homes and offer home-based HIV rapid testing and counselling.
10146989|NCT04131465|Experimental|Home HIV self-testing and rapid testing|Fieldworkers will visit participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing as well as home-based HIV rapid testing and counselling.
10146990|NCT04131387|Experimental|Test Group|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
10146991|NCT04131387|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
10146992|NCT04131530||Colon mucosa observed by pCLE|pCLE is used to evaluate the inflammation activity in different parts of the colon mucosa
10146993|NCT04131595|Experimental|MVA-BN-WEV Dose 1|Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.
10146994|NCT04131595|Experimental|MVA-BN-WEV Dose 2|Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL
10146995|NCT04131595|Experimental|MVA-BN-WEV Dose 3|Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL
10146996|NCT04131582|Experimental|Empagliflozin + linagliptin + metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5 mg + metformin 850 mg every 12 hours and empagliflozin 12.5 mg + metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
10146997|NCT04131582|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the complete dose. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
10146998|NCT04131491|Other|Patients with Mild Cognitive Impairment (MCI) due to AD|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, magnetic resonance imaging (MRI), blood sample with deep genetic profiling and Apolipoprotein E (APOE) determination.
10146999|NCT04131491|Other|Healthy volunteers|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, MRI, blood sample with deep genetic profiling and APOE determination.
10147000|NCT04131101|Experimental|Community Organizing|All tenants in three TCHC buildings will be invited to participate in a survey on their building conditions at baseline, 6 months and 12 months. Once baseline data collection is complete, there will be a community organizing campaign involving tenants to advocate for improved building conditions.
10147001|NCT04131257|Experimental|Continuum of care|Trained diabetes nurses will provide continuum of care to the participants that includes: conducting community awareness campaigns, screening programs, linkage to clinical care, community follow-up counseling and support for individuals with diabetes, and prevention programs for individuals with pre-diabetes.
10147002|NCT04131257|Active Comparator|Usual care|The control group will receive usual diabetic care without the nurse coordination and supervision as in the intervention group.
10147003|NCT04131374|Experimental|Virtual Reality Intervention|Virtual Reality Intervention: Each Person Living with Dementia-caregiver dyad will receive 10 weekly sessions of tailored reminiscence therapy delivered via virtual reality. Each session will last for a period of 15-30 minutes.
10147004|NCT04131283|Experimental|Epinephrine effect throught keratinized ginigva|1 mg/ml epniephrine vs physiologocal saline
10147005|NCT04131283|Experimental|Epinephrine effect throught gingival sulcular epithelium|1 mg/ml epniephrine vs physiologocal saline
10147006|NCT04131153|Other|Conventional radiofrequency ablation group|Conventional radiofrequency ablation procedures
10147007|NCT04131153|Experimental|Three-step radiofrequency ablation group|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
10147008|NCT04131400||Patients with Inherited Retinal Dystrophy|known patients with a diagnosis of inherited retinal dystrophy (IRD) will be recruited to identify the type of IRD diagnosis. The comprehensive ophthalmic examinations and retinal imaging will be performed. Additionally, blood sample of all participants and their family members will be kept in our bio- bank for genetic testing.
9669395|NCT02055560||PK-Guided Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was monitored and optimized using PK-guided dose adjustment.
9669396|NCT02055560||BSA Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was done according to body surface area (BSA) and no PK monitoring was performed.
9826158|NCT02410382|Placebo Comparator|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
9826159|NCT02410382|Active Comparator|Arm 2 Dexamethasone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
10147009|NCT04131452||Fresh embryo transfers|those undergoing fresh embryo transfer
10147010|NCT04131452||Frozen embryo transfers|those undergoing frozen embriyo transfer
10185178|NCT03748199|Experimental|POL6014|multiple ascending doses: 80, 160 and 40 mg once or twice daily
10147011|NCT04131309|Experimental|Daratumumab|"Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter.~Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone."
9971325|NCT01309438|Experimental|Moderate renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
10147012|NCT04131361|Active Comparator|Crystalloid -control group:|
10147013|NCT04131361|Experimental|Colloid- study group:|
10147014|NCT04131231|Experimental|microparticles packaging methotrexate (MPs-MTX) group|"Patients are first treated with microparticles packaging methotrexate (MPs-MTX) via intrapleural infusion four times on day5,6,7,8 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.~MPs-MTX: 5 U of MPs-MTX containing a total dose of more than 25μg of MTX dissolving in 50ml of physiological saline solution"
10147015|NCT04131231|Active Comparator|recombinant human interleukin-2(rhIL-2) group|"Patients are first treated with rhIL-2 via intrapleural infusion three times on day5,8,11 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.~rhIL-2: 2 million IU of rhIL-2 dissolving in 50ml of physiological saline solution"
10147016|NCT04131075||Study group|Patients with CAD undergoing FFR-guided revascularisation. FFR, coronary flow reserve (CFR) and the index of hyperemic microvascular resistance (HMR) will be measured with the Doppler guidewire (Combowire, Volcano - Philips corporation) under steady state hyperemia.
10147017|NCT04131270|Experimental|Planning + Education|"3 education sessions + 1 planning session (integrated into the 3rd education session); delivered face-to-face over 3 weeks (after the baseline measurement), individually.~Planning: The planning materials and forms have sections: (a) instructions of what should be included in a good plan (the when, where, and how components), (b) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties) will be formed. After forming the plans individually, experimenters will discuss the plans with the participants."
10147018|NCT04131270|Active Comparator|Education|"3 education sessions; delivered face-to-face over 3 weeks (after the baseline measurement), individually.~The education includes extended physical activity and sedentary behavior education using participant-educator discussions and printed materials."
10147019|NCT04131205||Minimal Hepatic Encephalopathy|Patients with hyperammonemia and minimal hepatic encephalopathy
10147020|NCT04131205||Control|Healthy controls
10147021|NCT04131218|Experimental|Obese group|n=8, 25≤BMI≤39.9kg/m²
10147022|NCT04131218|Experimental|Morbidly obese group|n=8, BMI≥40kg/m²
10147023|NCT04131322|Experimental|switch-cohort|Adalimumab biosimilar
10147024|NCT04131322|Active Comparator|non-switchcohort|Adalimumab original
10147025|NCT04131335|Experimental|Experimental Arm|Experimental arm receives lubricant eye-drops (phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vitamins A and E (AEONTM Repair) to be administered four times a day for 6 weeks following cataract surgery (in addition to the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks).
10147026|NCT04131335|Active Comparator|Control Arm|The control arm group receive the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks after cataract surgery.
10147027|NCT04131192|Experimental|z650 and Gemcitabine|Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles
10185179|NCT03748199|Placebo Comparator|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
10185180|NCT03748173|Experimental|Treatment|Subjects randomized to the aerosol surfactant evaluation will occur at the end of 60 minutes, with the aerosol continued if the bronchiolitis score is > 4 or there has been less than a 2-point improvement in the bronchiolitis score. Similar evaluation will be performed, if necessary, at 30-minute intervals (maximum 2 hours) with stoppage of the aerosol for an improved bronchiolitis score (≤ 4 or 2-point improvement) at any of the time points. The aerosol would be stopped at any time for significant sustained deterioration in clinical status or any serious adverse event felt related to the treatment. Retreatment can be given at > 4 but < 24 hours if the initial response was positive and there has been subsequent deterioration.
10185181|NCT03748173|No Intervention|Usual Care|The only difference in care between treatment and usual care will be treatment with up to two doses of aerosolized Infasurf®.
10185182|NCT03748160|No Intervention|Control|There is no intervention (letter) in the control arm. There is no control arm in the city of Espoo. 1/3 of subjects in all other municipalities are assigned to the control arm.
10185183|NCT03748160|Active Comparator|Mailing|This treatment arm consists of a standard letter reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
10185184|NCT03748160|Active Comparator|Herd|This treatment arm consists of a letter that highlights the herd immunity effects of vaccination and reminds elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
10185185|NCT03748147|Active Comparator|Control|Standard of care, misoprostol 25 mcg po every four hours
10185186|NCT03748147|Experimental|Intervention|Misoprostol 50 mcg po every four hours
10185187|NCT03748121|Experimental|Pranayama assisted Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|To prepare patients for the TF-CBT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-CBT units.
10185188|NCT03748121|Active Comparator|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Patients wait for 10 TF-CBT units and then are offered to learn pranayama.
10185189|NCT03748108|Experimental|lidocaine|A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
10147028|NCT04131049|Experimental|Carbohydrate Counting|The insulin doses of the breakfasts were calculated according to carbohydrate counting.
10147029|NCT04131049|Experimental|Food Insulin Index|The insulin doses of the breakfasts were calculated according to food insulin index.
10147030|NCT04130958|Experimental|MDD and Active iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving active iTBS-TMS.
10147031|NCT04130958|Experimental|BPD and Active iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving active iTBS-TMS.
10147032|NCT04130958|Sham Comparator|MDD and Sham iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving sham iTBS-TMS.
9971326|NCT01309477|Experimental|ADVAGRAF|All subjects in the study will take the Tacrolimus Sustained-release Capsules (ADVAGRAF) orally at the basis of low dose prednisone treatment
10147033|NCT04130958|Sham Comparator|BPD and Sham iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving sham iTBS-TMS.
10147034|NCT04131023|Experimental|Metabolic Tracking|Metabolism (indirect calorimetry) tracking was performed
10147035|NCT04131023|No Intervention|Standard Care|Metabolic (indirect calorimetry tracking was not performed
10147036|NCT04130880||Children with cerebral palsy|Children with CP who aged between 18 months and 6 years will be evaluated.
10147037|NCT04130880||Children with typical development|Children with typical development who aged between 18 months and 6 years will be evaluated.
10147038|NCT04130698|Experimental|Distress Tolerance|"Treatment rationale: RAs will explain that there are 3 (not 2 as in the control) key factors that maintain smoking behavior and excess weight: 1) learned habits, 2) the addictive properties of smoking and food, and 3) a way to manage distress. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address all 3 key factors. This condition includes both key factors in the control but introduces the third key factor distress tolerance (DT). Toward that end, modules will include: a values discussion; experiential avoidance; distress tolerance; and mindfulness-based ways to manage distress.~Module 1: Orientation & ACT; Module 2: Avoidance; Module 3: Cognitive Fusion vs. Defusion; Module 4: Self-As-Context; Module 5: Present-Moment-Awareness; and Module 6: Values and Committed Action."
10147039|NCT04130698|Active Comparator|Active Health Control|"Treatment rationale: RAs will explain that there are 2 key factors that maintain smoking behavior and excess weight: 1) learned habits and 2) the addictive properties of smoking and food. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address both key factors. Toward that end, modules will include standard treatment on: the dangers of smoking, excess weight, unhealthy diets and sedentariness; the importance of healthy behaviors; and relaxation exercises to manage stress. These are all key aspects of standard treatment for smoking cessation and weight loss.~Module 1: Orientation and Health; Module 2: Game Plan; Module 3: Stress and Coping Strategies; Module 4: Physical Activity; Module 5: Changes in Activities, Habits and Lifestyle; and Module 6: Long-Term Rewards."
10147040|NCT04130815|Active Comparator|Slow/Deep/Large|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration
10147041|NCT04130815|Active Comparator|Slow/Deep/Small|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
10147042|NCT04130815|Active Comparator|Fast/Shallow/Large|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration.
10147043|NCT04130815|Active Comparator|Fast/Shallow/Small|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
10147044|NCT04130750|Active Comparator|treatment of physician's choice|Patients in this arm will receive neoadjuvant chemotherapy according physician's choice.
10147045|NCT04130750|Experimental|treatment of drug screening|Patients in this arm will receive neoadjuvant chemotherapy according results of drug screening vitro.
10147046|NCT04130633|Placebo Comparator|Placebo|Placebo (5mL distilled water)
10147047|NCT04130633|Experimental|Vaporized high THC alone|25mg of vaporized pure THC
10147048|NCT04130633|Experimental|Vaporized low alpha-pinene|0.5mg of vaporized alpha-pinene
10147049|NCT04130633|Experimental|Vaporized high alpha-pinene|5mg of vaporized alpha-pinene
10147050|NCT04130633|Experimental|Vaporized high THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 25mg vaporized THC
10147051|NCT04130633|Experimental|Vaporized high THC and high alpha-pinene|5mg of vaporized alpha-pinene with 25mg vaporized THC
10147052|NCT04130633|Experimental|Vaporized low THC alone|10mg of vaporized pure THC
10147053|NCT04130633|Experimental|Vaporized low THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 10mg vaporized THC
10147054|NCT04130633|Experimental|Vaporized low THC and high alpha-pinene|5mg of vaporized alpha-pinene with 10mg vaporized THC
9971327|NCT01309490|Experimental|Ribavirin, nucleoside analog|
10147055|NCT04130763|Experimental|FMT Capsule in Combination with Anti-PD-1 Therapy|
10147056|NCT04130984|Experimental|Group IO|Intraosseous assess will be established in group IO, using EZ-IO for drug or fuild resuscitation. Proximal tibia is the insertion site,locating at 1 cm medial tibial tuberosity. IO access should be retained for less than 1 day, and venous access should be established as soon as possible after winning rescue time to continue treatment. Other treatment measures refer to 2015 AHA guidelines.
10147057|NCT04130984|No Intervention|Group IV|Intravenous access will be established in group IV, choosing any available peripheral venous for the administration of drugs or fluids.The antecubital vein is the preferred choice. If failed, the next catheterization plan will be determined by the physician in charge of the scene.Other treatment measures also refer to 2015 AHA guidelines.
10147058|NCT04130841|Experimental|Spontaneous ILM peeling|
10147059|NCT04130841|Active Comparator|Active ILM peeling|
10147060|NCT04130841|No Intervention|No ILM peeling|
10147061|NCT04130594|Experimental|phase 1, vaccine half dose|half dose of BVRS-GamVac vaccine single administration
10147062|NCT04130594|Experimental|phase 1, vaccine full dose|full dose of BVRS-GamVac vaccine single administration
10147063|NCT04130594|Experimental|phase 2, vaccine selected dose|selected dose of BVRS-GamVac vaccine single administration
10147064|NCT04130594|Placebo Comparator|phase 2, placebo|placebo single administration
10147065|NCT04131010|Experimental|SpyGlass Pancreatoscopy|ERP with direct pancreatoscopy
10147066|NCT04130867||Group A: Swallow Therapy Oropharyngeal Strengthening|"Participants receiving any standard of care swallow therapy with oropharyngeal strengthening as the primary goal~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post -therapy)"
10147067|NCT04130867||Group B: Surgical Treatment Esophageal Sphincter|"Participants receiving surgical treatment for relief of upper esophageal sphincter outlet obstruction.~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post therapy)"
10147068|NCT04130867||Group C: Healthy Controls|Healthy controls (n=50) will also undergo data collection at parallel time points, without completion of a treatment paradigm.
10147069|NCT04130789||patients with sepsis (cases)|patients who developed or were admitted with sepsis to the ICU (cases)
10147070|NCT04130789||patients without sepsis (controls)|patients who did not develop sepsis (controls).
10147071|NCT04130607|Experimental|Analytical|Students will receive brief instruction in probability, sensitivity, specificity, and likelihood ratios, with distributions and calculations. Pretest and posttest probabilities will be computed for two cases for each of the three conditions listed above.
10147072|NCT04130607|Active Comparator|Experiential|"Students will receive a brief instruction conceptually discussing sensitivity and specificity (e.g. a sensitive test will be positive at even low levels of disease. However, this can lead to a number of false positive errors, when the test is positive even when there is no disease. As a result, it is most useful for ruling out a diagnosis). They will then work through a total of 30 cases, 10 for each condition, in blocked sequence. For each brief written case they will be asked for a probability of diagnosis after the clinical information is presented. The test result will then be given and they will be asked for a post-test probability. Their estimate will be compared to the computed value based on published estimates of sensitivity and specificity and feedback provided."
10147073|NCT04130607|Placebo Comparator|No Explicit Instruction or Examples|Students will receive 3 passages from a clinical text related to each of the 3 conditions in the study and asked to study them for 15 min each.
10147074|NCT04130672|Other|Hot saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 50 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 50 ° C saline irrigation was applied.
10147075|NCT04130672|Other|Cold saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 22 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 22 ° C saline irrigation was applied.
10147076|NCT04130945|Active Comparator|group 1|patients with erector spine plane block
10147077|NCT04130945|No Intervention|group 2|patients without erector spine plane block
10147078|NCT04130724||Ketogenic diet|Subjects consuming either a ketogenic (<30g carbohydrate per day) or a low-carb (<100g carbohydrate per day) diet.
10147079|NCT04130724||High-carbohydrate diet|Subjects consuming a high carbohydrate (>100g carbohydrate per day) diet.
10147080|NCT04130646|Active Comparator|Active taVNS, Active TMS|
10147081|NCT04130646|Sham Comparator|Sham taVNS, Active TMS|
10147082|NCT04130646|Sham Comparator|Active taVNS, Sham TMS|
10147083|NCT04130646|Sham Comparator|Sham taVNS, Sham TMS|
10147084|NCT04130581|Experimental|TMS|Six 30-pulse trains of 20 Hz repetitive Transcranial Magnetic Stimulation to left primary motor cortex hand area, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
9669397|NCT02050113|Experimental|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft. custom made device or arch branch device.
10147085|NCT04130581|Sham Comparator|Sham|Six 30-pulse trains of 20 Hz repetitive sham Transcranial Magnetic Stimulation above, but not in contact with, the head, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
10147086|NCT04130464|Experimental|Ropivacaine|Subjects will receive a continuous intraperitoneal infusion of ropivacaine
10147087|NCT04130464|Experimental|Ropivacaine + Ketorolac|Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac
9971328|NCT01309503||Normal hearing|Children and adults
9971329|NCT01309503||Unilateral hearing loss|
10147088|NCT04130464|Placebo Comparator|Normal Saline|Subjects will receive a continuous intraperitoneal infusion of normal saline
10147089|NCT04130373||Women receiving autologous fat grafting|Women who received breast reconstruction and autologous fat grafting.
10147090|NCT04130373||Control|Women who received breast reconstruction only.
10147091|NCT04130451|Active Comparator|Pre pleurodesis Procedure Fever Pulse rate Respiratory rate Pa|Pre pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procedure 24 hours before 16 hours before 8 hours before
10147092|NCT04130451|Active Comparator|After Pleurodesis procedure Fever Pulse rate Respiratory rate|Post pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procdure 24 hours before 16 hours before 8 hours before
10147093|NCT04130399|Experimental|Preoperative Chemotherapy + SBRT|"Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines.~After 6 cycles of neoadjuvant therapy are completed, patients will undergo imaging with pancreatic protocol CT and PET-MRI to assess disease status . Patients without evidence of disease progression at the end of 6 cycles of neoadjuvant treatment will proceed to SBRT followed by surgical resection.~Following surgery, patients will receive an additional 6 cycles of FOLFIRINOX chemotherapy."
10147094|NCT04130295|Experimental|Wearable intensive nerve stimulation|The device will be worn on the upper calf with each session of stimulation lasting 60 minutes after which the device will turn off for 60 minutes before turning back on. Participants will be instructed to wear the device for 5 hours a day in order to receive three one our sessions of stimulation.
10147095|NCT04130386|Experimental|Motivational Interviewing|Participants assigned to this arm will complete three MI sessions over 10 weeks.
10147096|NCT04130386|Active Comparator|E-education|The e-education group receives three educational modules lasting approximately 10 minutes each over a period of 10 weeks.
10147097|NCT04130438|Active Comparator|Beta Blocker (nebivolol)|
10147098|NCT04130438|Active Comparator|Calcium Channel Blocker (diltiazem)|
9826160|NCT02410629|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
10147099|NCT04130438|Placebo Comparator|Placebo|
10147100|NCT04130412|Active Comparator|Open release of lateral retinaculae|This group was treated by open release of lateral retinaculae after diagnosis of lateral compression syndrome by arthroscopy
10147101|NCT04130412|Active Comparator|Arthroscopic release of lateral retinaculae|This group was treated by arthroscopic release
10147102|NCT04130256|Experimental|Active Reminders|43 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will provide daily medication reminders for participants to take their pill.
10147103|NCT04130256|Experimental|Passive Adherence Monitoring|42 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will not provide medication reminders and will only track medication use.
10147104|NCT04130477|Experimental|Clear aligners with tunnel attachment|Participants will receive traditional clear aligner therapy with virtual set up and will be supplemented by virtually planned tunnel attachments which will be threaded by a light Nickel-Titanium wire
10147105|NCT04130477|Active Comparator|Clear aligners|Participants will receive traditional clear aligner therapy with virtual set up
10147106|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to horizontal|horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
10147107|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to vertical|horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
10147108|NCT04130360|Experimental|Problem-solving|
10147109|NCT04130360|No Intervention|Control|
10147110|NCT04130139||residents|obstetrics and gynecology residents from France with or without previous experience in oocyte pick up
10147111|NCT04130178|Active Comparator|Bupivacine injected|Half ml of Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was injected through a 27G needle at the level of the volar proximal digital crease of the 2nd and 3rd PIP on each side of the selected joint.
10147112|NCT04130178|Placebo Comparator|Control group|Saline was injected subcutaneously in the 2nd and 3rd PIP on each side of the selected joint.
9519789|NCT03283358|No Intervention|Standard follow up|Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
10147113|NCT04130282|Experimental|Group 1|8 volunteers receiving 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
10147114|NCT04130308|Experimental|ACL-R|
10147115|NCT04130308|No Intervention|Control|
10147116|NCT04130230|Experimental|Neostigmine group|This arm will receive -in addition to standard therapy for sepsis and septic shock-Neostigmine methylsulfate ampoule diluted in normal saline, and administered as continuous infusion for five days. The rate of infusion is 0.2 mg/hr.
10147117|NCT04130230|Placebo Comparator|Standard group|This arm will receive the standard therapy for sepsis and septic shock only and followed for five days.
10147118|NCT04130126|No Intervention|Warm showers|Participants in the warm showers condition are instructed to continue their normal warm showers throughout the study
9519790|NCT03283345|Active Comparator|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
9826161|NCT02410629|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
9971330|NCT01309503||Severe hearing loss high frequencies|
9519791|NCT03283345|Active Comparator|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
9971331|NCT01309503||Adult CI users|Unilateral and bilateral CI
10147119|NCT04130126|Experimental|Cold showers|Participants in the cold showers condition will be asked to take cold showers over a time period of 3 months
9519792|NCT03283293|Experimental|Target volume delineation after NACT|
9971332|NCT01309503||Bilateral CI users|"Children and adults~Sequential CIs~Simultaneous CIs"
10147120|NCT04130152|Experimental|Palbociclib + Letrozole|"Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.~If the patient is pre-menopausal, ovarian suppression with luteinizing hormone-releasing hormone (LHRH) analogues (ie, triptorelin 3.75 mg intra-muscular (IM) or Goserelin 3,6 mg SC) must be initiated at least 2 weeks before palbociclib plus letrozole administration."
10147121|NCT04129957||Patients who underwent placement of dental implants|The study only includes one cohort. That is the patients who underwent placement of dental implants at baseline.
10147122|NCT04130269||Patients with MCI|Patients with myocardial infarction (STEMI/NSTEMI) aged 19-90
10147123|NCT04130243||Congenital Heart disease|In patients with (a history of) pressure- and/or volume loaded right ventricle due to congenital heart disease extra blood will be withdrawn for a blood test; serumbiomarker
10147124|NCT04130243||Pulmonary Arterial Hypertension|In patients with (a history of) pressure- and/or volume loaded right ventricle due to pulmonary arterial hypertension extra blood will be withdrawn for a blood test; serumbiomarker
10147125|NCT04130217|No Intervention|Control group|patients will be intraoperatively mechanically ventilated without PEEP nor RM.
10147126|NCT04130217|Experimental|PEEP Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
9826162|NCT02410707|Experimental|Nitrous Oxide Arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
10147127|NCT04130217|Experimental|PEEP and RM Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
10147128|NCT04130087|Experimental|Selegiline Group|27 healthy participants who will be administered a single 10mg tablet of selegiline hydrochloride.
10147129|NCT04130087|Placebo Comparator|Placebo Group|27 healthy participants who will be administered a single lactose tablet (placebo)
10147130|NCT04130009|Active Comparator|TKA with tourniquet|This group was treated by TKA with the use of tourniquet
10147131|NCT04130009|Active Comparator|TKA without tourniquet|This group was treated by TKA without tourniquet
10147132|NCT04130100|Experimental|Low Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of low dose of mesenchymal stem cells.
9519793|NCT03283280|Experimental|Short fiber RC|Short fiber reinforced resin composite restoration (Ever X Posterior, Gc Europe) that is used in high stress bearing areas as direct onlay restoration.
9519794|NCT03283280|Active Comparator|Nanohybrid RC|Nanohybrid resin composite (GrandioSO, VOCO GmbH Germany ) that can be used to make indirect restorations in posterior teeth.
9971333|NCT01309516|Experimental|Complex Intervention (LTP-TH)|The 12 sessions of complex intervention (LTP-TH) will be delivered to mothers.
10147133|NCT04130100|Experimental|High Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of high dose of mesenchymal stem cells.
10147134|NCT04130100|Active Comparator|Sodium Hyaluronate|Patients receiving intraarticular injection of Sodium Hyaluronate
10147135|NCT04129866|Experimental|M-IBM|M-IBM is based on a slightly modified version of the word sentence association paradigm focused on words and sentences related to common concerns among those with elevated anxiety sensitivity cognitive concerns (i.e., losing control of mental processes).
10147136|NCT04129866|Placebo Comparator|Control IBM|Control-IBM is identical to M-IBM except that the sentence that follows the cue word is not related to an anxious-threat interpretation of the cue word.
10147137|NCT04129814|Experimental|test group|Non-surgical periodontal treatment consisted of oral hygiene instructions (OHI), single session full-mouth scaling and root planing (SRP)
10147138|NCT04129814|No Intervention|control group|no periodontal treatment was performed during the follow-up period in the control group.
10147139|NCT04129762|Experimental|Diet without NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
10147140|NCT04129762|Active Comparator|Diet with NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS
10147141|NCT04129762|Experimental|Diet without NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
10147142|NCT04129762|Active Comparator|Diet with NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS
10147143|NCT04129658||Intervention|The patients are registered at PHCCs who agreed to participate into the study, the patients have provided an informed consent. The PHCCs (seventeen according to the power calculation) will receive an educational outreach visit by a cardiologist, discussing evidence-based treatment. The physician will decide afterwords if the treatment will be adjusted. Blood samples and electrocardiography will be collected before the intervention, data from the EMR will be collected before and after the intervention.
10147144|NCT04129658||Control|The control group will be the rest of the patients with heart failure in Southern Sweden. Data from the regional data base on medication and heath care consumption will be collected at base line and 6 and 12 months after.
10147145|NCT04129684|Experimental|Test group|SRP+BioGaia Prodentis oil drops and lozenges
10147146|NCT04129684|Placebo Comparator|Control group|SRP+subgingival delivery of placebo and placebo lozenges
10147147|NCT04129879|Experimental|1|all patients treated by conventional bare eye technique and then the use of methylene blue contrast technique to visualize endometriotic lesions perioperatively
10147148|NCT04129632|Other|IEPF intervention|Survey respondent voluntary decides to do a 4 weeks mindfulness intervention
10147149|NCT04129788|Experimental|bisacodyl|bisacodyl 5mg tablet, once a day on three consecutive days
9519795|NCT03283267|Experimental|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
10147150|NCT04129788|Placebo Comparator|placebo|tablet, once a day on three consecutive days
10147151|NCT04129983|Experimental|Prednisone acetate + somatosensory stimulation|Prednisone acetate 1 mg/kg body weight * 7 days and somatosensory stimulation 30 days were given to sudden deafness patients.
10147152|NCT04129983|Experimental|Prednisone acetate + hyperbaric oxygen|Prednisone acetate 1mg / kg body weight * 7 days and hyperbaric oxygen 15 days were given to sudden deafness patients.
10147153|NCT04130061|Experimental|Randomized|
10147154|NCT04130061|No Intervention|Control|
10147155|NCT04129918|Experimental|experimental group|ear plugs and eye mask for 3 successive nights
10147156|NCT04129918|No Intervention|control group|without ear plugs and eye mask
10147157|NCT04129853|Experimental|Crossover|Performing a sit to stand with the Cyberlegs Xleg and comparing with their current prosthesis.
10147158|NCT04129853|Experimental|Case study|Comparing the cyberlegs xleg with other devices.
10147159|NCT04129697|Active Comparator|Dexamethasone|
10147160|NCT04129697|Active Comparator|Methylprednisolone|
10147161|NCT04130321|Experimental|Camu camu|
10147162|NCT04130321|Placebo Comparator|Placebo|
10185190|NCT03748108|Placebo Comparator|Placebo|A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.
10147163|NCT04129801||Prospective analysis|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).~Evaluation of Muscle Strength was used The Biodex Multi-joint System 3 dynamometer (Biodex Medical Systems, Inc., Shirley, New York, USA) to measure isokinetic extension (Ext) and flexion (Flex) MVC torques for both legs."
10147164|NCT04129736|Other|Teriflunomide 14 mg tablets|Single arm
10147165|NCT04129710|Experimental|I-MRE|"Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
10147166|NCT04129710|Experimental|L-MRE|"Oral lenalidomide 25mg/day (starting dose) between days 4 and 24 of each cycle for six cycles.Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
10147167|NCT04129710|Active Comparator|MRE|"Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.~Rituximab 375 mg/m2 conventional infusion d1.~Etoposide 250 mg/m2 over 3 hours on day3.~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.~Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time will be randomly allocated to the Experimental groups."
10147168|NCT04129892|Experimental|Course participants|Students that enroll in the Resilience-based course during their Bachelor of science or Bachelor of social studies.
10147169|NCT04129892|No Intervention|Control group- no intervention|Students in their Bachelor of science or Bachelor of social studies that did not attend the course, but agreed to fill out the study questionnaires.
10147170|NCT04129749||Real-Time Analysis Interactive Lab|walk spontaneously or at prescribed speeds of cerebral palsy patient to a standstill in a virtual and secure virtual reality environment.
10147171|NCT04129593|Experimental|Self Awakening|Participant will intend to wake up at a specific time before going to bed.
10147172|NCT04129593|Experimental|Snooze|Participant will set multiple alarms before bed to wake at a specific time.
10147173|NCT04129606|Other|TURBT|Transurethral resection of bladder tumour
10147174|NCT04129580|Experimental|Treatment-As-Usual (TAU) + reSET-O|Participants randomly assigned to this arm will receive their TAU alongside the use of the app, reSET-O.
10147175|NCT04129580|No Intervention|TAU only|Participants randomly assigned to this arm will receive their TAU only (no use of the app, reSET-O).
10147176|NCT04129359|Experimental|FamilieTrivsel|Enhanced care as usual in general practice plus training in the use of the online mentalisation programme
10147177|NCT04129359|Active Comparator|control|Enhanced care as usual in general practice
10147178|NCT04129476|Experimental|Cooperative Education Program|We explore the effects of a cooperative education program based on precede-proceed model during pregnancy on preventing postpartum depression.
10147179|NCT04129476|No Intervention|Control|We provide routine care for these people during pregnancy
10147180|NCT04129281|Other|Surgery|Surgery
10147181|NCT04129281|No Intervention|Active surveillance|Follow up
10147182|NCT04129463|Active Comparator|SST with Iris incarceration|infants that underwent SST with iris incarceration procedure
10147183|NCT04129463|Active Comparator|Conventional trabeculotomy|infants that underwent Conventional trabeculotomy
10147184|NCT04129450|Experimental|Mindfulness Pain Program + Usual PCP Care|Participants will undergo 8 weekly 90 minute sessions of Mindfulness-Based Stress Reduction in addition to receiving usual PCP care for chronic lower back pain.
10147185|NCT04129450|Active Comparator|Usual PCP Care|Participants will receive usual PCP care for chronic lower back pain.
10147186|NCT04129372|Experimental|New Foods Take Time|"Head Start classrooms will receive New Foods Take Time, a series of five interactive weekly lessons designed to promote children's willingness to try new foods, particularly fruits and vegetables. Lessons will be delivered by nutrition educations. Children will also receive three tastings per week of the new foods discussed during the lessons."
10147187|NCT04129385|No Intervention|Group S|Control group (Group S: 54 patients); this group will undergo the standard laparoscopic procedure (the procedure is done in Trendelenburg position). While in Trendelenburg position and prior to wound closure and with laparoscopic port valves open, the patient's abdomen will be passively deflated. The patients will be placed in supine head up position in the post anesthesia care unit (PACU).
10147188|NCT04129385|Experimental|Group T|Intervention group (Group T: 54 patients); the patients will be subject to the same maneuver as in arm 1 prior to wound closure but will be positioned in a 20 degree Trendelenburg position once fully awake and cooperative in the PACU and will remain in this position for the first 24 hours post operatively, even after they are transferred to their rooms on the American University of Beirut Medical Center (AUBMC) floors. The maximum time allowed in a straight-up position will be three 15-minute intervals over a 24-hour period (the first interval being a clear fluids intake at 12 hours postoperatively).
10147189|NCT04129333|Experimental|Hypnosis group|A hypnosis group with standard care during the invasive procedure according to the usual practice of the care team and setting up a hypnotic accompaniment by an nurse trained beforehand and dedicated throughout the gesture. The hypnosis session will end at the same time as the invasive procedure.
10147190|NCT04129333|Placebo Comparator|Control group|A control group with standard care during the invasive procedure according to the usual practice of the care team.
10147191|NCT04129424|Experimental|Type 1 diabetes mellitus_7-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147192|NCT04129424|Experimental|Type 1 diabetes mellitus_14-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
9826163|NCT02410772|Active Comparator|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
9827679|NCT02464657|Experimental|Ph 1 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
10147193|NCT04129424|Experimental|Type 1 diabetes mellitus_28-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147194|NCT04129424|Experimental|Type 2 diabetes mellitus_7-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147195|NCT04129424|Experimental|Type 2 diabetes mellitus_14-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147196|NCT04129424|Experimental|Type 2 diabetes mellitus_28-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147197|NCT04129424|Experimental|Gestational diabetes mellitus_7-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147198|NCT04129424|Experimental|Gestational diabetes mellitus_14-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147199|NCT04129424|Experimental|Gestational diabetes mellitus_28-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147200|NCT04129424|Experimental|Pregestational diabetes mellitus_7-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147201|NCT04129424|Experimental|Pregestational diabetes mellitus_14-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147202|NCT04129424|Experimental|Pregestational diabetes mellitus_28-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147203|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _7-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147204|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _14-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147205|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _28-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147206|NCT04129424|Experimental|Diabetes patients in perioperative period _7-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147207|NCT04129424|Experimental|Diabetes patients in perioperative period _14-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147208|NCT04129424|Experimental|Diabetes patients in perioperative period _28-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
10147209|NCT04129255|Other|OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)|OCT LAR is already registered By FDA for USA, by EMA for Europe and , also, by AIFA for Italy.
10147210|NCT04129489|Experimental|Sintetic Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day
10147211|NCT04129307|Experimental|Motor Imagery|
10147212|NCT04129307|Experimental|Double time Motor imagery|
10147213|NCT04129307|Active Comparator|Action observation|
10147214|NCT04129567|Experimental|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
9528202|NCT03212846|No Intervention|Control group|Children will receive the conventional treatment, based on physiotherapy related techniques, such as neurodevelopmental treatment (twice a week).
10147215|NCT04129567|Experimental|Dry air|Delivering dry air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
10147216|NCT04129567|Placebo Comparator|Humidified air|Delivering humidified air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
10147217|NCT04129567|Active Comparator|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
10147218|NCT04129268|Other|No exercise control|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
10147219|NCT04129268|Experimental|175kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
10147220|NCT04129268|Experimental|350kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
10147221|NCT04129268|Experimental|700kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
10147222|NCT04129541|Active Comparator|SDD|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
10147223|NCT04129541|Active Comparator|OH|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
10147224|NCT04129190|Experimental|Single|
10147225|NCT04129515|Experimental|PHASE 1: NovoTTF-200A + PEMBROLIZUMAB|"The Phase I portion of the study will have a 3 + 3 design and consist of one cohort treated~NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
10147226|NCT04129515|Experimental|PHASE 2: NovoTTF-200A + PEMBROLIZUMAB|"NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
10147227|NCT04129164|Experimental|VIB4920 Dose 1 in Population 1|Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
10147228|NCT04129164|Placebo Comparator|Placebo in Population 1|Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
10147229|NCT04129164|Experimental|VIB4920 Dose 1 in Population 2|Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
9826164|NCT02410772|Experimental|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
9971334|NCT01309516|No Intervention|Control group|Control group will receive standard postnatal follow-up.
9519796|NCT03283267|Experimental|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
9519797|NCT03283228||CD11b and CD56 markers|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
10147230|NCT04129164|Placebo Comparator|Placebo in Population 2|Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
10147231|NCT04129203|Experimental|Trial arm|Mechanical thrombectomy using Versi Retriever
10147232|NCT04128995|Active Comparator|Bariatric Surgery|
10147233|NCT04128995|Active Comparator|Medical Therapy|
10147234|NCT04128891|Experimental|Sacubitril/Valsartan|30 participants to be administered Sacubitril/Valsartan (Entresto) tablets, minimum dose of 49/51mg or maximum dose of 97/103 mg twice daily for the duration of the study (two years).
10147235|NCT04128891|Active Comparator|Valsartan|30 participants to be administered Valsartan tablets, minimum dose 80 mg or maximum dose of 160 mg twice daily for the duration of the study (two years).
10147236|NCT04128852|Other|MagnetOs Putty|MagnetOs Putty will be applied according to the latest Instructions For Use (IFU) approved in Europe. Specifically, MagnetOs Putty will be used as bone void filler.
10147237|NCT04128787|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.
10147238|NCT04128787|Experimental|Treatment Sequence BCAD|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 then Treatment A in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
10147239|NCT04128787|Experimental|Treatment Sequence CABD|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 then Treatment B in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
10147240|NCT04128904|Active Comparator|Standard in vitro fertilisation (IVF)|"Oocytes are fertilised with standard IVF. For details please see Project Description."
10147241|NCT04128904|Active Comparator|Intracytoplasmic sperm injection (ICSI)|"Oocytes are fertilised with ICSI. For details please see Project Description."
10147242|NCT04128800|Experimental|Apatinib and S-1 group|
10185191|NCT03748082|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
10185192|NCT03748082|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
10185193|NCT03748056|Experimental|Targeted incentives arm|The interventions received by the experimental group include: 1) weekly emails with targeted coupons for healthier products, 2) weekly emails with targeted nutrition education, and 3) and a nominal discount on grocery purchases for using their loyalty card
10185194|NCT03748056|Active Comparator|Usual care arm|"The interventions included under usual care include 1) untargeted nutrition education, 2) occasional untargeted coupons for healthier products, and 3) a nominal discount on their grocery purchases for using their loyalty card. These interventions are only received by participants randomized to the usual care arm (rather than the entire population of shoppers), and will allow for testing whether targeting discounts and nutrition education improves the diet quality of purchases in comparison to untargeted approaches."
10185195|NCT03748043|Experimental|lactoferrin+ferric hydroxide polymaltose|lactoferrin 100 mg /day plus ferric hydroxide polymaltose 6 mg /kilogram body wight for 3 months
10185196|NCT03748043|Experimental|ferric hydroxide polymaltose|6 mg /kilogram body wight of ferric hydroxide poly maltose per day for 3 months
10185197|NCT03748030||Confirmed Left-Sided Breast Cancer|T1/T2 N0, T1/T2 N1, T3/T4 and/or N2/N3 Left-Sided Breast Cancer Patients receiving standard radiation therapy will receive PET/MRI, ECG/EKG, and bloodwork before, within a month, and within a year post treatment.
10185198|NCT03748017|Placebo Comparator|Placebo-Control Supplement|12 participants will receive a placebo-control supplement per daily oral feeding.
10185199|NCT03748017|Active Comparator|Streptococcus-Containing Probiotic Supplement|12 participants will receive a powdered probiotic containing 7.77 billion colony-forming units (CFU) of L. acidophilus, 8.25 billion CFU of B. lactis, and 2 billion CFU of S. salivarius bacteriocin-like inhibitory substance (BLIS) K12 per daily oral feeding.
10185200|NCT03748004|Experimental|Adults living in the DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
9519798|NCT03283228||Haematological parameters in cases of adult AML|Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
10185201|NCT03748004|Placebo Comparator|Individuals 19 yrs or older settled in DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
9528203|NCT03212651|Experimental|Patients with MIBC (Muscle Invasive Bladder Cancer)|Cisplatinum-ineligible patients with muscle-invasive bladder cancer
10147243|NCT04129008|Experimental|Indobufen|
10147244|NCT04129008|Active Comparator|Aspirin|
10147245|NCT04129112||Patients without body movements|Patient who, under general anesthesia without curare agents, during surgery has no body movements
10147246|NCT04129112||Patients with body movements|Patient who, under general anesthesia without curare agents, during surgery has any body movements that are no reflexes movements
10147247|NCT04129099|Experimental|CAR-T treatment group|The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.
10147248|NCT04128813|Active Comparator|Vertical whole body vibration platform.|Use of a rotational whole body vibration platform.
10147249|NCT04128813|Active Comparator|Rotational whole body vibration platform|Use of a rotational whole body vibration platform.
10147250|NCT04128813|No Intervention|Control group|No intervention.
10147251|NCT04128826|Experimental|Partial Range of Motion (PROM)|
10147252|NCT04128826|Experimental|Full Range of Motion (FROM)|
10147253|NCT04128826|No Intervention|Control (CON)|
10147254|NCT04128878||Atrial Fibrillation Cohort|Adult patients with known or new diagnosis of either paroxysmal or persistent atrial fibrillation seen at the electrophysiology outpatient clinic and admitted to the electrophysiology service for initiation of anti-arrhythmic medications (dofetilide or sotalol).
10147255|NCT04128930|Experimental|Fixed CPAP titration at home|"Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:~After 3 nights: median obstructive AHI<5/h: decrease pressure with 2 cmH2O; median obstructive AHI>5/h: increase with 2cmH2O~After 7 nights: median obstructive AHI>5/h of 4 nights after last adaptation: increase with 2 cmH2O"
10147256|NCT04128930|Active Comparator|APAP titration at home|Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.
10147257|NCT04128917|Experimental|Tegoprazan 50 mg|Tegoprazan 50 mg Triple Therapy
10147258|NCT04128917|Experimental|Tegoprazan 100 mg|Tegoprazan 100 mg Triple Therapy
10147259|NCT04128917|Active Comparator|RAPAE01|RAPAE01 Triple Therapy
10147260|NCT04129021|Experimental|High-resolution retinal imaging through adaptive optics|High-resolution retinal imaging through adaptive optics, full field OCT and holographic systems
10147261|NCT04128982||Videolaryngoscopy|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
10147262|NCT04129034|Experimental|Treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
10147263|NCT04129047|Experimental|Omnichroma (one shade universal) composite by Tokuyama|class V cavities will be made under isolation. Omnichroma (one shade universal) composite by Tokuyama will be placed according to guidelines.
10147264|NCT04129047|Active Comparator|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA)|class V cavities will be made under isolation. A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA) will be placed according to guidelines.
10147265|NCT04128709|Experimental|Neurogenic Bladder Patient|Patients with neurogenic bladder
10147266|NCT04128748|Experimental|Treatment (CPX-351, quizartinib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3 and 5 and quizartinib PO on days 6-19. Patients who do not respond to treatment during cycle 1 receive CPX-351 IV on days 1 and 3 and quixartinib PO on days 6-19 during cycle 2. Treatment repeats every 28 days for up 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive CPX-351 over 90 minutes on days 1 and 3 and quizartinib PO on days 4-28 of cycle 1. Treatment with CPX-351 repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive quizartinib PO on days 1-28 in the absence of disease progression or unacceptable toxicity."
10147267|NCT04128462|Experimental|MNK6105 + SoC|"Participants will receive standard of care (SoC), along with MNK-6105 delivered by continuous intravenous (IV) infusion as follows:~Loading dose: 20 g infused over 6 hours~Intermediate dose: 15 g infused over 18 hours~Maintenance dose: 15 g infused over 24 hours for up to 4 days"
10147268|NCT04128462|Placebo Comparator|Placebo + SoC|Participants will receive SoC, along with continuous IV infusion of matching placebo for 5 days.
9826165|NCT02410772|Experimental|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg"
10147269|NCT04128605|Experimental|Intervention: Suprascapular nerve block (SSNB)|SSNB performed by skilled interventionist who is not blinded for safety reason. 5 mls of Bupivacaine, 5 mls Lidocaine and 10 mls of saline.
10147270|NCT04128605|Active Comparator|Control: Intraarticular shoulder steroid injection (IAS)|"IAS performed by skilled interventionist who is blinded on patient's initial measurement.~40 mg of Triamcenolone Acetate + 2 ml of Lidocaine 1%"
10147271|NCT04128618|Experimental|Active NMES|
10147272|NCT04128618|Sham Comparator|Modified NMES sham|
10147273|NCT04128683|Experimental|Healthy Controls|Healthy Control Subjects
10147274|NCT04128683|Experimental|Anorexia Nervosa|Anorexia Nervosa Subjects
10147275|NCT04128488||Transgender women without HIV|
10147276|NCT04128488||Transgender women with HIV|
10147277|NCT04128202|Active Comparator|Sunnyside|An online intervention to better manage mood during and after pregnancy.
10147278|NCT04128202|Experimental|Sunnyside Plus|An online intervention to better manage mood and promote and support breastfeeding during and after pregnancy.
10147279|NCT04128345||SBN arm|We will evaluate the feasibility of using an integrated navigation system incorporating pre-operative MRI and intraoperative ultrasound images
10147280|NCT04128332|Other|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) delivering 35Gy in five fractions (7Gy/fraction) over 5 days.
10147281|NCT04128410||T1|At 5 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147282|NCT04128410||T2|At 10 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147283|NCT04128410||T3|At 15 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147284|NCT04128410||T4|At 20 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147285|NCT04128410||T5|At 25 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147286|NCT04128410||T6|At 30 minutes after flurbiprofen axetil injected intravenously, 14 patients' samples were required to be collected,including 7 younger patients
10147287|NCT04128410||T7|At 35 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147288|NCT04128410||T8|At 40 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147289|NCT04128410||T9|At 45 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
10147290|NCT04128410||T10|At 50 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
9971335|NCT01309529||thoracic surg, epidural, urine retention|
9826166|NCT02410798|Experimental|TransLoc electrode|Electrode placement
10147291|NCT04128384|Other|EPS arm|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR
10147292|NCT04128254|Experimental|Apixaban|
10147293|NCT04128254|Placebo Comparator|Placebo|
10147294|NCT04128267|Experimental|Response to Pain|Brain's response to pain using magnetic resonance imaging (MRI)
10147295|NCT04128540|Other|Control group|This group will receive fentanyl infusion only
10147296|NCT04128540|Active Comparator|ESPB group|This group will receive fentanyl infusion plus Ultrasound guided ESPB
10147297|NCT04128397|Experimental|traditional stimulation site transcranial magnetic stimulation（TMS）|arm:experimental:perform TMS to patients for 5days ,3times a day(0 minute ,15 minute ,60 minute ).The Globus Pallidus internus (GPi) is the traditional stimulation site .
10147298|NCT04128397|Experimental|precise stimulation site TMS|arm:experimental:perform TMS to patients for 5days ,3times a day(0 minute ,15 minute ,60 minute ).The stimulation site include left supplementary motor area, right supplementary motor area, left primary motor area, right primary motor area , left superior parietal lobule, right superior parietal lobule.
10147299|NCT04128592|Other|Wheezing|
10147300|NCT04128592|Other|Rattling|
10147301|NCT04128306|Experimental|Patient group|"A total of 120 patients with brain tumors will be divided into our two groups, divided as follows:~In the group Pre-Per, 20 patients will be included by localization of electrical stimulation (60 patients in total). A patient who would be stimulable in two different areas could be included in two different groups.~In the group Pre-End, the subjects will be distributed by localization of the brain tumor, by lobe. A total of 20 participants will be included per lobe, corresponding to the frontal, temporal or parietal lobes (as a reminder, a tumor in the occipital lobe is an exclusion criterion), for a total of 60 participants"
10147302|NCT04128306|Active Comparator|Control group|A maximum of 120 healthy matched sex and age subjects with patients will also be included
10147303|NCT04128553|Experimental|Intervention motivational interview group|Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.
10147304|NCT04128553|No Intervention|Control|The control group will be pre-tested and post-tested and the average number of steps will be calculated with a pedometer.
10147305|NCT04128501|Experimental|Treatment (azacitidine, venetoclax)|Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
10147306|NCT04128280|Experimental|Test Group|Test group: Patients will receive a surgery: transurethral dilation of prostate with a columnar balloon
10147307|NCT04128280|Active Comparator|Control Group|Control group: Patients will receive a surgery: transurethral incision of bladder neck.
10147308|NCT04128358|Experimental|Group on high dose dexamethasone, cyclosporin and rituximab|Egyptian patients with idiopathic thrombocytopenic purpura on high dose dexamethasone together with cyclosporine and rituximab.
10147309|NCT04128358|Active Comparator|Group on steroids only|Egyptian patients with idiopathic thrombocytopenic purpura on parenteral or oral steroids.
10147310|NCT04128358|Placebo Comparator|Placebo group|Egyptian normal healthy volunteers who share on the President Initiative (100 Million Health).
10147311|NCT04128449|Experimental|docosahexaenoic acid|1,66 grams/24 hours (5 dragees)
10147312|NCT04128449|Placebo Comparator|Placebo|sunflower oil (5 dragees)
9826167|NCT02410811||Age Stratum A|"Age 6 to 13.99 years~Cardiac magnetic resonance imaging (CMR)"
9826168|NCT02410811||Age Stratum B|"Age 14 to 20.99 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
9971336|NCT01309542|Experimental|DVS|
9971337|NCT01309568||Investigational testing|Pending the outcome of culture, the subject may be treated with an approved antiviral medication at the doctors discretion.
9971338|NCT01309594|Experimental|Hematopoietic stem cell transplantation|Extraction of bone marrow cells from HIV positive patients with advanced liver cirrhosis and transplant their bone marrow back into the patients
9971339|NCT01309607|Experimental|Pre-operative Therapy|Neoadjuvant paclitaxel/carboplatin/lapatinib x 12 weeks
9971340|NCT01309620|Placebo Comparator|Placebo|
10147313|NCT04128228|Other|Alcohol use disorder|All patients with alcohol use disorder will receive the same 8 week outpatient treatment.
10147314|NCT04128228|No Intervention|Controls|Control participants with and without early trauma will receive baseline assessment and no outpatient treatment.
10147315|NCT04128163|Experimental|QL1206|"QL1206 injection (60mg:1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
10147316|NCT04128163|Placebo Comparator|Placebo|"placebo injection (1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
10147317|NCT04128176|Experimental|Rituximab combined with Omalizumab|All patients will receive daily doxycycline, nicotinamide, and high-potency topical steroids. Additionally, all patients will receive rituximab combined with omalizumab.
10147318|NCT04128137|Experimental|fludrocortisone|FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.
10147319|NCT04128137|Placebo Comparator|Placebo|placebo of flucortac and same diagram of administration
10147320|NCT04128072|Experimental|Mogamulizumab + Total Skin Electron Beam Therapy (TSEB)|"Treatment with mogamulizumab will be continued until disease progression or the occurrence of another withdrawal criterion as specified in the protocol.~TSEB will start 28 days after mogamulizumab cycle 2 day 1 at a dose of 12 Gy in 8 fractions over two weeks (4 fractions per week)."
10147321|NCT04128085|Experimental|TQB3804|TQB3804 tablet administered orally , once daily in 28-day cycle.
10147322|NCT04127773||NEX group|oro gastric tube placement using NEX insertion length predictor
10147323|NCT04127773||NEMU group|oro gastric tube placement using NEMU insertion length predictor
10147324|NCT04127747|Active Comparator|Standard dose group|
10147325|NCT04127747|Experimental|Individualized dose group|
10147326|NCT04127799|Experimental|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
10147327|NCT04127799|Active Comparator|Subjects with AF conventional treatment|Subjects with AF via conventional clinic visit according to the latest relevant guidelines
10147328|NCT04127812|Experimental|Savor the Flavor|"The Savor the Flavor curriculum is a series of five interactive lessons designed to teach children how to savor foods and slow down while eating by focusing on the sensory experience of eating. The intervention also teaches attention control techniques so that children are better able to delay consumption of high energy, low nutrition foods, when appropriate, as well as general mindfulness practices (e.g. breathing exercises). Lessons are delivered in the Head Start classroom by a nutrition educator."
10147329|NCT04127851|Experimental|Sodium Hyaluronate 0.15%|
10147330|NCT04127851|Active Comparator|Cyclosporin 0.05%|
10147331|NCT04127851|Other|Combination therapy|
10147332|NCT04127890|Experimental|Intervention Arm|1.5 L of ELO Water to be drunk daily for 24 weeks
10147333|NCT04127890|Placebo Comparator|Control Arm|1.5 L of placebo bottled drinking water to be drunk daily for 24 weeks
10147334|NCT04127942|Experimental|platelet-rich plasma injection|1cc platelet-rich plasma(PRP) injection in the superior temporomandibular disk joint space by ultrasound guidance.
10147335|NCT04127942|Placebo Comparator|normal saline injection|1cc normal saline injection in the superior temporomandibular disk joint space by ultrasound guidance.
10147336|NCT04127877|Experimental|CHRONIC HEMODIALYSIS PATIENTS, NICAS-ASSISTED MONITORING|Chronic hemodialysis patients, NICAS-assisted monitored
10147337|NCT04127877|No Intervention|Control hemodialysis patients|Chronic hemodialysis patients, conventional clinical care and monitoring.
10147338|NCT04128020|Experimental|Nivolumab|Nivolumab: 0.3, 0.5, or 1.0 mg/kg IV, days 1 & 15
10147339|NCT04128020|Experimental|Nivolumab + Azacitidine|Azacitidine 8,16, 24 mg/m^2, days 1-5 Nivolumab @MTD (1.0 mg/kg or lower), days 8 & 15
10147340|NCT04128033|Experimental|puncture of the RP6 point|The acupuncturist midwife, who does not perform the delivery herself, punctures the RP6 point at the time of the expulsive efforts.
10147341|NCT04128033|Placebo Comparator|puncture of the placebo point|The acupuncturist midwife, who does not perform the delivery herself, punctures the placebo point at the time of the expulsive efforts.
10147342|NCT04128111||Acute Exacerbation|Exacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e. they represent a change from the patient's usual status that is sufficient to require a change in treatment.
10147343|NCT04128111||Non-acute exacerbation|Non-acute exacerbation of asthma includes chronic remission and clinical delays.Clinical remission stage refers to an absence of wheezing, chest tightness, cough and other symptoms for more than 1 year.Chronic duration refers to that symptoms, such as wheezing, chest tightness, cough and so on, attack at different frequency and different degrees every week.
10147344|NCT04128111||Healthy Volunteer|Health is not only the absence of disease or infirmity, but also a state of physical, mental, and social perfection.
10147345|NCT04127994|Experimental|3 meals|"Patients with type 2 diabetes will be submitted to a 3 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
10147346|NCT04127994|Experimental|6 meals|"Patients with type 2 diabetes will be submitted to a 6 meal regimen for 3 months.~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
10147347|NCT04128046|Experimental|PRFM|Hemi-face injected with PRFM. PRFM was produced from 9 mL of blood (Healeon Medical, Inc).
10147348|NCT04128046|Placebo Comparator|Saline|Hemi-face injected with saline.
10147349|NCT04127929|Active Comparator|Glass carbomer|
9971341|NCT01309620|Experimental|Zinc supplement|
10147350|NCT04127929|Active Comparator|Tokuyama Estelite Posterior|
10185202|NCT03747978|Experimental|Perindopril and Amlodipine|Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
10147351|NCT04127955|Experimental|Intervention|"Quasi-experimental design with one-group, pre-post test~A nurse-led Theory of Planned Behavior based Physical Activity intervention consists of five component. These are a health education, a group walking, an individually tailored counseling session grounded on motivational interview technique, having the individuals keep track their physical activity levels with a pedometer, and use of physical activity pamphlet and posters as a reminder was planned. This intervention will be completed in eight weeks."
10147352|NCT04127760|No Intervention|control|Follow-up at several time frames
10147353|NCT04127760|Experimental|treatment|Radiotherapy would be carried out. Follow-up at the same time frames as the control arm
10147354|NCT04127903|Experimental|the Length of Right Main Stem Bronchus >=15mm|
10147355|NCT04127903|Experimental|the Length of Right Main Stem Bronchus <15mm|
10147356|NCT04128124||self-extubation|patients receiving invasive mechanical ventilation who develops an episode of self-removal (voluntary) of the endotracheal tube. Excluding those accidentally removed.
10147357|NCT04128124||spontaneous breathing trial|patients who, according to the attending physician, are clinically ready to initiate and begin a protocolized test (acording to the institutions or unit) to evaluate the readiness to be liberated from mechanical ventilation.
10147358|NCT04127721|Experimental|Prevention (itacitinib, busulfan, fludarabine, ASCT)|"CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor)."
10147359|NCT04127708|Placebo Comparator|sham acupuncture|Ten acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
10147360|NCT04127708|Active Comparator|acupuncture|en acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
10147361|NCT04127370|Experimental|Obese Patients With NAFALD Undergoing Bariatric Surgeries|
10147362|NCT04127513|Experimental|12% AMMONIUM LACTATE|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 12% ammonium lactate. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
10147363|NCT04127513|Active Comparator|10% UREA|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 10% urea. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
10147364|NCT04127422||Study group|"Patients presenting with current symptoms related to the breast. Adult females aged 18-39 years presenting to the breast outpatient clinic with either mastalgia, nodularity and/or discharge.~A questionnaire, physical examination and bilateral breast ultrasonography will be obtained for all patients.~A- The questionnaire will contain the following items:~symptoms related to the breast.~other medical history.~menstrual history.~obstetric history.~rapid screener for beverages and fast food consumption.~rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~breast tender point(s).~breast nodularity.~nipple discharge.~weight, height, body mass index (BMI).~C- bilateral breast ultrasonography for all patients.~D- breast biopsy when clinically indicated as per hospital policy."
10147365|NCT04127422||Control group|"Age-matched healthy volunteers with no current medical conditions. Adult females aged 18-39 years with no current breast problems. These healthy volunteers will be asked to complete the same questionnaire as per the Study group and have anthropometric measure.~A- The questionnaire will contain the following items:~other medical history.~menstrual history.~obstetric history.~rapid screener for beverages and fast food consumption.~rapid screener for vegetables and fruit consumption.~B- Physical examination will specifically records the following:~1- weight, height, body mass index (BMI)."
10147366|NCT04127383|Experimental|ABCC-tool|The intervention group will use the ABCC-tool during consultation with their healthcare provider. Healthcare providers in the intervention group will receive a short instructional film about the ABCC-tool before the start of the study. Additionally, healthcare providers from 12 practices will be invited for interviews, evaluating the context and process of implementation.
10147367|NCT04127383|No Intervention|Usual care|The control group will receive usual care, and healthcare providers will not be instructed
10147368|NCT04128059|Experimental|phase 1, component 1|component 1 of vaccine
10147369|NCT04128059|Experimental|phase 1, half dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in half dose
10147370|NCT04128059|Experimental|phase 1, full dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in full dose
10147371|NCT04128059|Experimental|phase 2, selected dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in selected dose
9669398|NCT02028884|Experimental|Satralizumab + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
10147372|NCT04128059|Placebo Comparator|phase 2, placebo|vaccination with placebo with an interval of 21 days
10147373|NCT04127448|Experimental|Exergaming Training Group|Training was given using X-box 360 Kinect.
9826169|NCT02410811||Age Stratum C|"Age ≥21 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
10147374|NCT04127448|Active Comparator|Aerobic Exercise Group|Session using treadmill (model no TMX58 220).
10147375|NCT04127552||Patients with non-functioning adrenal adenoma|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels lower than 50 nmol/L
10147376|NCT04127552||Patients with pACS receiving conservative management|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving conservative management
10147377|NCT04127552||Patients with pACS receiving adrenalectomy|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving adrenalectomy according to the 2016 European Society of Endocrinology guidelines
10147378|NCT04127552||Healthy controls|Patients without adrenal masses
10147379|NCT04127396|Experimental|lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
10147380|NCT04127396|Active Comparator|Sorafenib and TACE|Patients in Sorafenib + TACE group will take oral sorafenib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
10147381|NCT04127474||Group I|25 Generalized chronic periodontitis subjects without coronary heart disease.
10147382|NCT04127474||Group II|25 Generalized chronic periodontitis subjects diagnosed with coronary heart disease.
10147383|NCT04127474||Group III|25 Periodontally healthy subjects diagnosed with coronary heart disease.
10147384|NCT04127487||Periodontitis group|35 Generalized chronic periodontitis subjects without coronary heart diseases
10147385|NCT04127487||periodontitis with CAD group|35 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease
10147386|NCT04127617|Experimental|Osteopathic Manipulative Treatment|the treatment group will receive 5 osteopathic manipulative treatment. The treatment will last 45 - 60 minutes with the following frequency: the subjects will receive 3 OMT on a weekly basis, the two following twice weekly. The osteopathic treatment protocol will therefore last 7 weeks. Each individual patient will be taken in charge by two operators during the entire duration of the study.
10147387|NCT04127617|Active Comparator|Nursing Care|The conventional treatment consists in educational nursing care.
10147388|NCT04127643||S-ICD patients|patients who have received the EMBLEM S-ICD system
9977154|NCT01358617||Biomarker analysis|Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique.
10147389|NCT04127604|Experimental|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
10147390|NCT04127604|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
10147391|NCT04127669|Experimental|Arm A|Active substance treatment with OSU6162. Starting dose for all patients in the OSU6162 treatment group is 15 mg BID. The dose is taken orally as one circular coated tablet of 15 mg together with a light meal in the morning and one tablet around lunch unless otherwise agreed upon. In order to aim at optimal dosing of OSU6162, some flexibility is allowed. The investigators are able to modify the dose for individual patients based on how well the treatment is tolerated and how well the patients respond to it. In the case where there is no clear response, the dose can be increased to maximally 30 mg BID (intermediate dosage is allowed) after 4 weeks of treatment; it is also possible to decrease the dose to a lower level (even below 15 mg BID) if a higher dose is not tolerated and/or there is a perceived weakened therapeutic effect with the higher dose. All dose changes will be performed while retaining the blind.
10147392|NCT04127669|Placebo Comparator|Arm B|Placebo treatment. Starting dose for all patients in the placebo group is one circular coated tablet (with identical appearance to active treatment tablets 15 mg) taken BID, according to the same schedule as active treatment. The dose may be increased or decreased in the same manner as for active treatment.
10147393|NCT04127526|Active Comparator|Baseline Period of 2 weeks|2 participants will be randomly allocated to a baseline of 2 weeks before commencing CONNECT intervention.
10147394|NCT04127526|Active Comparator|Baseline Period of 3 weeks|2 participants will be randomly allocated to a baseline of 3 weeks before commencing CONNECT intervention.
10147395|NCT04127526|Active Comparator|Baseline Period of 4 weeks|2 participants will be randomly allocated to a baseline of 4 weeks before commencing CONNECT intervention.
10147396|NCT04127409|Placebo Comparator|Control Chicken-meat & Control Eggs|Participants will be provided with control chicken-meat and control eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three control eggs/week, for 6 months.
10147397|NCT04127409|Experimental|Control Chicken-meat & Omega-3 Eggs|Participants will be provided with control chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three omega-3-enriched eggs/week, for 6 months.
10147398|NCT04127409|Experimental|Omega-3 Chicken-meat & Control Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and control eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three control eggs/week, for 6 months.
10147399|NCT04127409|Experimental|Omega-3 Chicken-meat & Omega-3 Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three omega-3-PUFA enriched eggs/week, for 6 months.
10147400|NCT04127591||myocardial infarction group|Patients admitted with the diagnosis of myocardial infarction.
10147401|NCT04127591||Blank control group|Patients admitted without the diagnosis of myocardial infarction.
10147402|NCT04127500|Experimental|DEX group|use DEX
10147403|NCT04127500|No Intervention|control group|use placebo
10147404|NCT04127357|Other|A - Control|Brushing with 1450 ppm fluoride toothpaste.
10147405|NCT04127357|Experimental|B - Test|Resin sealing (FluroShield, Dentsply, Brazil).
10147406|NCT04127435||High-Dose-Rate 192Ir Brachytherapy|"All patients underwent computed tomography (CT) 3-5 days before surgery. The collimation is 2.5 mm and CT Planning System.~Delineation of the gross tumor volume (GTV) and adjacent organs at risk (OARs);~Determination of the needle tract of the implanted insertion direction, distribution, and depth. Then calculation of the dose distribution of the target volume and OARs.~Depending on B-TPS data, we establish a digital model for the individual template.~Local anesthesia or intraspinal anesthesia was induced in all patients. The three-dimensional printing noncoplanar templates (3D-PNCT) was placed on the surface of the treatment area of the patient. The 3D-PNCT was aligned accurately with the outer-contour features. Through the guide hole of the 3D-PNCT, we inserted to pre-planned depths.~Delineation of the GTV and design planning .~Connect the source tube and 192Ir high dose rate interorganizational brinotherapy~At the end pressed to stop bleeding."
10147407|NCT04127461|Active Comparator|Open vessel harvesting|Arm 1 is the conventional procedure
10147408|NCT04127461|Experimental|Medtronic endoscope|Arm 2 - is the minimally invasive procedure
10147409|NCT04127630||mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
10147410|NCT04127344|Experimental|Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients randomised to a music therapy intervention will receive an individualised music therapy intervention."
10147411|NCT04127344|No Intervention|Non-Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.~Patients allocated to Non-Music Therapy Intervention received standard treatment."
10147412|NCT04127084|Experimental|normal albuminuria|baseline urinary albumin creatinine ratio [UACR]< 30 mg/g
10147413|NCT04127084|Experimental|moderately increased albuminuria|baseline UACR 30~300 mg/g
10147414|NCT04127084|Experimental|severely increased albuminuria|baseline UACR>300mg/g
10147415|NCT04127084|No Intervention|blank Comparator|normal participant
10147416|NCT04126980||ED group|The ED group who had less than 72 hours of hospitalization (including the preparation period which commonly took approximately 1 day) for the surgery.
10147417|NCT04126980||Comparison group|The comparison group who were hospitalized for more than 72 hours but less than 12 days.
10147418|NCT04126928|Other|Participant|Each participant will go through (i) screening using DMFT and PUFA, (ii) orthopantomography assessment using PAI, and (iii) comprehensive clinical examination to derive pulpal and periapical diagnoses
10147419|NCT04127071|Active Comparator|Surgical I&D Procedure|The abscess cavity will be evaluated thoroughly with ultrasonography. The site will be prepared and draped. The skin surface will be infiltrated with local anesthetic with a 25-gauge needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Incision of the skin surface with a number 11-blade scalpel will be performed over the largest area of infection; the incision will be extended into the abscess cavity. A blunt instrument will then be used to break up internal loculations if present. Repeated instrumentation through the initial incision or extension of the original incision will be performed if needed. Lastly, iodoform packing will be inserted through the incision into the cavity. The decision to send the abscess contents for microbiological culture and susceptibility analysis will be at the discretion of the treating clinician.
10147420|NCT04127071|Experimental|Ultrasound-guided Needle Aspiration Procedure|The abscess cavity will be evaluated thoroughly with US. The site will be prepared and draped. The skin surface and anticipated needle track will be infiltrated with local anesthetic with a 25g needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Under direct US-guided visualization, a 14g 2in steel needle attached to a 40mL syringe will be advanced into the abscess cavity with manual negative pressure. The needle tract will be extended obliquely 2-3 cm between the skin and abscess to prevent fistulization. Purulent material will be aspirated until no further purulence can be aspirated. Multiple aspiration attempts on the initial visit will be permitted to maximally drain the abscess cavity. Additionally, irrigation of the abscess cavity with sterile saline will be permitted to break up internal loculations if present, as has reported previously for trunk and breast abscesses.
10147421|NCT04126941||Teriparatide|Patients with hypoparathyroidism treated by teriparatide
10147422|NCT04127292|Experimental|Emotional Self Awareness Group (Clinician participants)|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
10147423|NCT04127292|No Intervention|Emotional Self Awareness Group (Patient participants)|Patients provided care by clinicians trained in ESA
10147424|NCT04127292|Sham Comparator|Control Group (Clinician participants)|The Control group CPs will engage in the same two VHI scenarios and will complete the TRQ-SF in response to each scenario without receiving the ESA feedback
10147425|NCT04127292|No Intervention|Control Group (Patient participants)|Patients provided care by clinicians not receiving ESA feedback
10147426|NCT04127058|Other|CYP2D6 non-poor metabolizers|titrated up to 24 mg daily (12 mg b.i.d.)
10147427|NCT04127058|Other|CYP2D6 poor metabolizers|titrated up to 12 mg daily (6 mg b.i.d.)
10185203|NCT03747978|Active Comparator|Perindopril-Indapamide|Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks
10185204|NCT03747965|Experimental|Mesothelin-directed CAR-T cells infusion|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation."
10147428|NCT04127318|Experimental|Pedaling Group|During their 30 minute immunotherapy infusions, participants will pedal using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. A research personnel will monitor the patient's heart rate, blood pressure, and RPE at baseline and every 10 minutes throughout the pedaling session. Participants will also have treatment response biomarkers gathered at baseline and before and within 10 minutes of completing their first and fourth immunotherapy infusions. Lastly, participants will complete both a physical activity questionnaire and a quality of life questionnaire at baseline and following their fourth treatment.
10147429|NCT04127019|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
10147430|NCT04127019|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
10147431|NCT04127019|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).
10147432|NCT04127279|Experimental|Enriched Cream|The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.
10147433|NCT04127279|Active Comparator|Placebo Cream|Cream devoid of essential oils, self-administered
10185205|NCT03747913|Experimental|Antioxidative Supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
10185206|NCT03747900|Experimental|BTX-A|Patients underwent 200 U BTX-A injections in biceps brachii muscle.
10185207|NCT03747900|Active Comparator|BTX-A+Dry needling|Dry needling was administered for 4 times in total after the BTX-A injection.
10185208|NCT03747874|Other|past medical history of sudden hearing loss|sleep examination and ventilatory polygraphy device for 1 night
10185209|NCT03747861|Other|Arm for HRV monitoring|For monitoring HRV each subject will put Wristband for registration of ECG RR intervals for one hand, SenceBand in the left wrist and Holter monitor electrodes will be placed in standard configurations places.
10185210|NCT03747822|Active Comparator|autogenous fat|autogenous fat augmentation in deficient chin will be harvested from lower abdomen,inner or outer thigh
10185211|NCT03747822|Active Comparator|PEEK|Will use onlay PEEK augmentation in deficient chin.Virtual planning will be done using mimics software. A virtual osteotomy of the chin will be performed at the inferior border of the mandible same alignments as sliding genioplasty, then segmentation of the chin area will be done and according to the soft tissue analysis adjustment will be performed.
10185212|NCT03747822|Other|Osseous sliding genioplasty|Under general anesthesia, the preparation and the incision line will be performed same as PEEK augmentation .After complete exposure of the bone repositioning of the chin will be performed. Finally fixation will be obtained using x shape titanium plate.
10185213|NCT03747809||Patients with CIEDs having Remote Monitoring|
10185214|NCT03747809||Patients with CIEDs having no Remote Monitoring|
10185215|NCT03747796|Active Comparator|supine position|The children will be in the supine position after ingestion of a standard volume of clear fluid.
10185216|NCT03747796|Experimental|Semi-sitting position|The children will be in the semi-sitting position after ingestion of a standard volume of clear fluid.
10185217|NCT03747783||Survival Group|status from radical operation to follow-up
10185218|NCT03747783||Non-Survival Group|status from radical operation to follow-up
10185219|NCT03747770|No Intervention|Cross-sectional baseline survey|This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students
10185220|NCT03747770|Active Comparator|Single Dose HPV vaccination|Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
10185221|NCT03747770|Active Comparator|Two-dose HPV vaccination|Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
10185222|NCT03747770|No Intervention|Cross-sectional survey at Year 2|This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students
10185223|NCT03747770|No Intervention|Cross-sectional survey at Year 4|Cross-sectional survey at Year 4 post vaccination
10185224|NCT03747744|Experimental|CD1c (BDCA-1)+ myDC|CD1c (BDCA-1)+ myDC
10185225|NCT03747731||Resistive Index and Peep Titration|"Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney.~Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level.~The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period."
10185226|NCT03747718|Experimental|Fecal Microbiota Follow up Enemas|In this arm subjects will receive 3 fecal microbiota transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
10185227|NCT03747718|Placebo Comparator|Placebo Enemas|In this arm subjects will receive 3 placebo transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
10185228|NCT03747692|Experimental|study group|patient put in dorsal postion , insertion of a speculum , sterilization of the cervix then intracervical injection of 5 ml mepicaine hydrochloride a local anasthetic as Carbocaine3%54 mg at site 3 and 9 using a 10 cm syringe
10185229|NCT03747692|Placebo Comparator|control group|patient receives one tablet of NSAIDs (diclofenac sodium 50 mg )15 minutes before procedure then 5 ml of normal saline will be injected intracervical using 10 cm syringe then wait for 5 minutes before the procedure
10147434|NCT04126967|Other|allo-PBSCT patients with no NGS text|
10147435|NCT04127045||IMN-Group|Patients treated with intramedullary nailing
10147436|NCT04127045||HA-Group|Patients treated with Hemiarthroplasty
10147437|NCT04127097|Experimental|cartoon group|
10147438|NCT04127097|No Intervention|control group|
10147439|NCT04126902||late-onset preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
10147440|NCT04126902||Control|The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
10147441|NCT04126993|Experimental|Camrelizumab+ Apatinib test group|Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
10147442|NCT04126993|Active Comparator|Apatinib single drug control group|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
10147443|NCT04126954||Cinacalcet|Patients with primary or secondary hyperPTH resulting from phosphocalcic pathology treated by cinacalcet
10147444|NCT04127227|Experimental|Sintilimab With P-GemOx|Sintilimab, 200mg, d1, intravenous drip; pegaspargase, 2000U/m2, d1, intravenous drip; gemcitabine, 1000mg/m2, d1,d8, intravenous drip; oxaliplatin, 130mg/m2, d1, intravenous drip; All patients received up to 6 treatment cycles of 21 days. Stage IV patients with localized disease will be treated with consolidative RT. Patients with CR or PR will receive Sintilimab maintenance therapy.
10147445|NCT04127305||VA ECMO|Patients will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
10147446|NCT04127305||VA EMCO + RRT|Patients with RRT will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
10147447|NCT04127305||VV ECMO|Patients will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
10147448|NCT04127305||VV ECMO + RRT|Patients with RRT will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
10147449|NCT04127305||Control|Patients will be included within 24-48h after start of an antiinfective therapy
10147450|NCT04127149|Experimental|Group with ultrasound|The first group consists of nine general practitioners having received a brief training on the use of ultrasound scanners in general practice. The general practitioner includes all adult patients who are consulting for one of the 8 medical conditions studied and perform an ultrasound scan. Two weeks later, he/she calls each patient to collect the necessary data.
10147451|NCT04127149|No Intervention|Group without ultrasound|The second group consists of nine general practitioners. Each physician includes all adult patients who are consulting for one of the 8 medical conditions studied and performs a standard consultation. Two weeks later, he/she calls each patient to collect the necessary data.
10147452|NCT04127136|Experimental|Study Group|The cases were analyzed for the change in the severity of binge eating disorder in the program. The data collection was performed via socio-demographic information form, binge eating disorder evaluation (BEDE) form, and progress record forms. BEDE was a structured form exclusively using DSM-5 BED diagnosis and the severity criteria. Progress record form included weekly session content that was administered by a physician, dietitian, psychologist, and the physiotherapist and the monthly individual meetings data. BEDE and progress record forms were applied before the trainings that focuses on cognitive change and repeated every four weeks for 20 weeks. The patients were planned to receive 80 hours of training by the physician, dietitian, psychologist, and the physiotherapist.
10147453|NCT04127032|Experimental|Tailored ICBT for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
10147454|NCT04126876|Experimental|Tilsotolimod (IMO-2125)|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
10147455|NCT04126876|Placebo Comparator|Placebo|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
10147456|NCT04126837|Other|Patient admitted for Ankle and foot injuries|Diagnosis and treatment of Ankle and foot injuries by an accelerated nursing branch in emergency department
10147457|NCT04126785|Placebo Comparator|Control without exercise in heated water-based|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the xiphoid process level for 30 min.
10147458|NCT04126785|Experimental|High Intensity Interval Exercise in Heated Water|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
10147459|NCT04126785|Experimental|Continuous Moderate Exercise in Heated Water|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light) level of RPE.
10147460|NCT04126577||Patients with suspected peritonitis|Secondary peritonitis, sepsis and endotoxemia
10147461|NCT04126811|Experimental|Apatinib and Chemotherapy Test Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
10147462|NCT04126811|Active Comparator|Apatinib Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
10185230|NCT03747679|Experimental|A- Bosutinib in water|200 Mg of bosutinib (50 mg capsule x4) in Water solution
10147463|NCT04126811|Active Comparator|Chemotherapy Group|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
9826170|NCT02410811||Age Stratum D|"Age ≥6 years.~Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at <3 years of age, and for which there has been no interruption of therapy for >6 consecutive months since the initiation of disease-modifying therapy.~Cardiac magnetic resonance imaging (CMR)"
9826171|NCT02410824|Experimental|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
9826172|NCT02410824|Active Comparator|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
10147464|NCT04126798||Healthy adults|Standardization and collecting normative age-related data for cognitive and motor single tasks, as well as cognitive-motor dual-tasks
10147465|NCT04126798||Bilateral vestibulopathy|Validation of cognitive and motor single tasks, as well as cognitive-motor dual-tasks
10147466|NCT04126798||Unilateral vestibular impairment|Cross-sectional study on cognitive and motor single tasks, as well as cognitive-motor dual-tasks, in persons with unilateral vestibular impairment
10147467|NCT04126642|Other|Assessment only group|Standard care + Daily ecological momentary assessments (EMAs)
10147468|NCT04126642|Experimental|Intervention group|"Intervention group will receive same measures and interventions as the assessment only group AND will receive messaging that is tailored to patient responses on EMAs. When participants provide a pattern of responses that are suggestive of heightened emotional distress, they will receive feedback and/or a prompt to complete one of the self-management exercise. The app will prompt participants to complete a brief educational video on relaxation strategies and guided relaxation exercises. Participants will have access to: 1) a Help me Cope button in the app that contains links to evidenced-based self-management techniques, and 2) a Contact Counselor button that will send a secure email to a study psychologist requesting a call. Participants will receive a coping focused message at the completion of the Report Distress EMAs. Participants can access these on demand intervention components and review them at any time in addition to receiving the tailored intervention messages."
10147469|NCT04127253|Experimental|transcranial direct current plus Brain training tools|20 minutes of transcranial direct current stimulation along with the application of motor imagery and action observation
10147470|NCT04127253|Placebo Comparator|Placebo transcranial direct current plus Brain training tools|A placebo intervention of direct transcranial stimulation being active during 15 seconds and then it will be turned off the rest of the time until 20 minutes. This group will also carry out the training of action observation and motor imagery.
10147471|NCT04127253|Sham Comparator|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
10147472|NCT04127240|Experimental|Meat assignment in DASH intervention|Participants consumed 3 ounces of red meat per day as a part of the DASH diet.
10147473|NCT04127240|Experimental|Meat allocation in DASH intervention|Participants consumed 6 ounces of red meat per day as a part of the DASH diet.
10147474|NCT04126668|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast
10147475|NCT04126668|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast
10147476|NCT04127201|Experimental|Online intervention, en_línea|Participants will be provided with a username and a password to acess to a website. en_línea program is an online adaptation of the LEARN program. The five treatment areas are: Lifestyle, Exercise, Attitudes, Relationships and Nutrition. We have designed and developed a website (www.programaenlinea.org) with 17 weekly treatment sessions and an exclusive mobile application for self-recording.
10147477|NCT04127201|Active Comparator|Standard group therapy|Participants in this arm will received a 10 sessions of standard primary care group therapy. Sessions 1 and 2 will be weekly and sessions from 3 to 10 will be biweekly. Sessions, between 8 and 10 participants, will be conducted by a specialized psychologist and they will last 90 minutes. Treatment areas will be the same as en_línea, beginning with nutrition and exercise and a progressive incorporation of the other topics. Material to work at home and self-recording will be provided in paper.
10147478|NCT04127201|No Intervention|Control group|Participants in the control group only will receive a biweekly newsletter by email without feedback. They will be provided with material and instructions to self-record their daily meals and exercise. The newsletter only will content basic information about nutrition and exercise.
10147479|NCT04126707|Experimental|[14C] HQP1351|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of [14C] HQP1351 to healthy Chinese male subjects.
10147480|NCT04126772||Active MS patients|10 MS patients with an active lesion of 0,5 cm diameter
10147481|NCT04126772||Healthy controls|20 healthy controls
10147482|NCT04126772||SPMS patients|10 SPMS patients
10147483|NCT04126629||Normotensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the normotensive group. Every attempt will be made to stratify both groups equally between second and third trimesters.
10147484|NCT04126629||Hypertensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the hypertensive group.Every attempt will be made to stratify both groups equally between second and third trimesters.
10147485|NCT04126434|Sham Comparator|no masking|not wearing facemask
10147486|NCT04126434|Active Comparator|masking|wearing facemask
10185231|NCT03747679|Experimental|B- bosutinib in sorbitol|200 Mg of bosutinib sorbitol base in water solution
9971342|NCT01309633|Experimental|Arm A|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
9971343|NCT01309633|Experimental|Arm B|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
10147487|NCT04126512||Bedside ligation|Infants admitted to St. Orsola-Malpighi Hospital (SOM) NICU had their PDA ligated at bedside, with a timing of surgery dependent on the time schedule of the surgeons and anaesthesiologists.
10147488|NCT04126512||Referred to specialist paediatric cardiac surgery centre|Due to the unavailability of local cardiac surgery, infants admitted to the Cambridge University Hospital (CUH) NICU were referred to specialist paediatric cardiac surgical centres, where PDA ligation was performed. In these cases, the surgical timing depended on both bed availability at the referral centre and the availability of the neonatal transfer team.
10147489|NCT04126564|Experimental|IEO Intervention Group|The Group 1 is the active study group which receives the online mindfulness intervention first.
9669399|NCT02028884|Placebo Comparator|Placebo + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
9669400|NCT01983774|Placebo Comparator|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
10147490|NCT04126564|Active Comparator|Control Group|Group 2 will be asked to read a book or journal of their choice for first 30 days, and then recieve online mindfulness intervention (IEO).
10147491|NCT04126759|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.
10147492|NCT04126655|Experimental|Arfolitixorin.|Drug: Arfolitixorin Drug: 5-FU Per operative i.v. bolus injection of Arfolitixorin in combination with 5-FU
10147493|NCT04126655|Active Comparator|Calciumfolinate.|Drug: Calciumfolinate Drug: 5-FU Per operative i.v. bolus injection of Calciumfolinate in combination with 5-FU
10147494|NCT04126421|Active Comparator|E1 Vitamin E infused HXLPE|E1 Vitamin E infused highly cross-linked polyethylene (HXLPE)
10147495|NCT04126421|Active Comparator|Marathon HXLPE|Marathon highly cross-linked polyethylene (HXLPE)
10147496|NCT04126694|Experimental|CBT with smartphone application|12 weeks of CBT with SenseSupport smartphone application
10147497|NCT04126681|Experimental|HQP1351 therapy cohort|HQP1351 40 mg, taken orally once every other day of a 28-day cycle
10147498|NCT04126681|Active Comparator|Best Available Therapy (BAT) cohort|Best available therapy (BAT) will be selected by the investigator for each participant.
10147499|NCT04126616|Experimental|patients with COPD and PH|
10147500|NCT04126616|Active Comparator|patients with COPD without PH|
10147501|NCT04126616|Active Comparator|healthy subjects|
9669401|NCT01983774|Active Comparator|Esomeprazole|Esomeprazole 40mg twice daily
9669402|NCT01974206|Experimental|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
9669403|NCT01974206|Placebo Comparator|Placebo|Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
9669404|NCT01970865|Experimental|PF-06463922|
9826173|NCT02410967|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
10147502|NCT04126460|Experimental|Toripalimab|Injection; dosage form: 6ml: 240mg; frequency: 240mgQ3W; duration: 17cycles (12 months) or randomization to the date of the first documented progression
10147503|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Elderly|
10147504|NCT04126330|Placebo Comparator|Placebo- Elderly|
10147505|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Obese|
10147506|NCT04126330|Placebo Comparator|Placebo- Obese|
10147507|NCT04126369|Experimental|mindfulness intervention|12 mindfulness sessions for 3 months (1 session per week)
10147508|NCT04126369|Active Comparator|Psycho educative programme|12 psycho educative sessions for 3 months (1 session per week)
10147509|NCT04126382|Active Comparator|INSURE|Intubate-Surfactant-Extubate(INSURE) technique is a Important treatment in premature infants with RDS.
10147510|NCT04126382|Experimental|LISA|Less invasive surfactant administration(LISA) technique is a Important treatment in premature infants with RDS.
10147511|NCT04126720|Active Comparator|vitamin E|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and Vitamin E capsule (Vitamin E 400: 400 mg vitamin E capsules - Pharopharmaceuticles) daily.
10147512|NCT04126720|Placebo Comparator|Placebo|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and placebo capsule daily
9669405|NCT01970865|Other|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
9669406|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
9669407|NCT01703520||Male Finasteride Users|Male finasteride users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
9971344|NCT01309633|Experimental|Arm C|Arm C Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
10147513|NCT04126148||Age matched Healthy participants (150)|Healthy Participants Age: > 40y No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system
10147514|NCT04126148||Coronary Artery Disease (CAD) Patients (200)|Coronary Artery Disease (CAD) Patients Age > 18 y Patients with an Indication for invasive coronary angiography based on symptoms and a test positive for inducible coronary ischemia, or previous coronary angiography.
10147515|NCT04126304||Common cold|A cold is a clinical diagnosis.Complaints may include a stuffy nose, sore throat, cough and headache.Objective signs are rare, but may include fever, enlarged anterior cervical lymph nodes, nasal mucosa and oropharyngeal erythema, and nasal mucus.
10147516|NCT04126304||acute bronchitis|In 2011, the European society of respiratory diseases (ERS) defined acute disease in patients with non-chronic lung disease. Symptoms include cough, with or without expectoration of phlegm, and other symptoms and signs may indicate lower respiratory tract infection and cannot be explained by other diseases (e.g., sinusitis, asthma).The main symptoms of acute bronchitis are cough, may be accompanied by fever, fatigue, asthma and dyspnea.
10147517|NCT04126304||Post-infection cough|The definition in the 2013 guidelines for diagnosis and treatment of chronic cough in Chinese children: cough refers to a recent history of respiratory tract infection;The cough lasted > for 4 weeks, presenting an irritating dry cough or a little white phlegm.Chest x - ray examination showed no abnormality or only increased lung veins.The pulmonary ventilation function was normal, or presented transient high airway response.Coughs are usually self-limited, and other diagnoses should be considered if the cough is more than 8 weeks old.In addition to other causes of chronic cough.
10147518|NCT04126304||community-acquired pneumonia|According to the 2019 guidelines for the diagnosis and treatment of community-acquired pneumonia in children, it is defined as infectious pneumonia developed outside the hospital (community), including pneumonia developed after admission due to infection of pathogens with a clear incubation period outside the hospital (community).
9826174|NCT02410967|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
10147519|NCT04126291|Experimental|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived change in self-efficacy/ confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
10147520|NCT04126239||Participant suffering from obesity|Patient, male or female, over 18 and under 70 years old Patient group with a Body Mass Index (BMI) greater than or equal to 30 kg / m2
10147521|NCT04126239||healthy volunteer|
10147522|NCT04126161|Active Comparator|CT|Patients have standard of care CT prior to primary hip replacement
10147523|NCT04126161|Experimental|Ultrasound|Patients have ultrasound scans together with standard of care CT prior to primary hip replacement
10147524|NCT04126252|Experimental|Group A|This arm received pharmacotherapy for erectile dysfunction.
10147525|NCT04126252|Experimental|Group B|This arm received cognitive behavior psychotherapy for erectile dysfunction.
10147526|NCT04126252|Experimental|Group C|This arm received combined treatment approach.
10147527|NCT04126252|Placebo Comparator|Group D|This arm acted as a control group and received placebo or no intervention.
10147528|NCT04126226|Experimental|Study group|
10147529|NCT04126226|No Intervention|Control Group|
10147530|NCT04126408|Sham Comparator|Sham arm|gammaCore sham device which will not provide stimulation of the vagus nerve
10147531|NCT04126408|Active Comparator|Treatment group|Active gammaCore device that supplies non-invasive stimulation of the cervical branch of the Vagus nerve
10147532|NCT04126265|No Intervention|Routine colonoscopy group|The patient underwent routine colonoscopy.
10147533|NCT04126265|Experimental|Artificial intelligence assisted colonoscopy group|The real-time automatic polyp detection system was used to assist the endoscopist.
10147534|NCT04126044|Active Comparator|Reference: bevacizumab - EU|
10147535|NCT04126044|Experimental|Test: PF-06439535 (CN)|
10147536|NCT04125823|Experimental|Video game-based physical activity training|
10147537|NCT04125823|Active Comparator|Conventional physiotherapy program|
10147538|NCT04125797|Active Comparator|Adhesive 1|This arm investigates one type of silicone adhesive (3M2475P) on adult female skin.
10147539|NCT04125797|Active Comparator|Adhesive 2|This arm investigates one type of silicone adhesive (RX1449P) on adult female skin.
9971345|NCT01309633|Experimental|Arm D|Arm D Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
10147540|NCT04125797|Active Comparator|Adhesive 3|This arm investigates one type of silicone adhesive (PS-1243) on adult female skin.
10147541|NCT04125940|Placebo Comparator|Placebo-controlled Arm|Placebo - 12oz water with food coloring
10147542|NCT04125940|Active Comparator|1 serving Resync Arm|12oz water + 7.5g Resync
10147543|NCT04125940|Active Comparator|2 servings Resync Arm|12oz water + 15g Resync
10147544|NCT04125940|Active Comparator|1 servings Resync+Collagen Arm|12oz water + 17g collagen + 2g Resync + 1g Carbohydrates
10147545|NCT04125862|Other|Fibrous Dysplasia/McCune-Albright Syndrome|20, Fibrous Dysplasia/McCune-Albright Syndrome Patients with or without pain
10147546|NCT04125862|Other|Healthy Controls|20, matched healthy controls
10185232|NCT03747679|Experimental|C- - bosutinib mannitol|200 Mg of bosutinib powder mannitol base in water solution
10185233|NCT03747679|Experimental|D - bosutinib in mannitol low sweet|200 Mg of bosutinib mannitol low sweet solution
10147547|NCT04125901|Experimental|Pain Neuroscience Education and Exercise|Participants will received an 8-week intervention consisting of exercise and pain neuroscience education. Pain neuroscience education will be conducted in line with international guidelines and will address the following topics: pain neurophysiology, nociception and nociceptive pathways, inhibition and spinal cord stimulation, peripheral and central sensitization, nervous system plasticity and the impact of variables such as stress, anxiety, sleep and exercise on pain behavior. Exercise will be performed in accordance with international guidelines for chronic NP. Motor control, endurance and strengthening exercises will be performed for the neck and scapulo-thoracic region.
10147548|NCT04125901|Other|Exercise|Participants will received an 8-week intervention consisting of exercise. The exercise performed in this group will be the same as in the intervention group and will follow the same international guidelines for chronic NP.
10147549|NCT04125992|Experimental|Distal Radial|Patients who undergo coronary catheterization by accessing the distal radial artery in the snuff-box of the hand.
10147550|NCT04125992|Active Comparator|Forearm Radial|Patients who undergo conventional coronary catheterization by accessing the forearm radial artery.
10147551|NCT04125979|Experimental|Preservation of pulmonary vagus nerve|Preservation of pulmonary branches of vagus nerve in minimally invasive surgery for lung cancer
10147552|NCT04125979|Experimental|No pulmonary vagus nerve preservation|In minimally invasive surgery for lung cancer, the pulmonary branches of vagus nerve were severed
10147553|NCT04125953|Experimental|Intervention|A 3 week intervention with Andullation will be performed, 3 times a week for 20 minutes after completion of the radiotherapy session
10147554|NCT04125953|Placebo Comparator|Control|This group will follow the same intervention protocol, but without the application of the Andullation technology
10147555|NCT04125927|Experimental|Open-label arm|
10147556|NCT04125810|Experimental|Probiotic|Probiotic
10147557|NCT04125810|Placebo Comparator|Placebo|Placebo
10147558|NCT04125875||Patients with cirrhosis of esophageal varices|
10147559|NCT04125875||Patients with gastric polyps|
10147560|NCT04125628|Experimental|Exercise with cooling|Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise training session involved head cooling and neck wraps. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
10147561|NCT04125628|Active Comparator|Exercise without cooling|10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise session performed without cooling. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
10147562|NCT04125888||AIT Cohort|Allergic rhinitis patients with and without asthma treated with AIT
10147563|NCT04125888||Control Cohort|Allergic rhinitis patients with and without asthma not treated with AIT
10147564|NCT04125719|Experimental|Primay PD-1 resistance|Cohort 1 will include 15 patients who progressed within 3 months (primary resistance) of starting PD-1 therapy
10147565|NCT04125719|Experimental|Secondary PD-1 resistance|Cohort 2 will include 15 patients who progressed after at least 3 months of PD-1 therapy
10147566|NCT04125576||Burn patients|The subjects complaine of severe neuropathic pain that is rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
10147567|NCT04125576||Healthy controls|age and sex matched healthy controls
10147568|NCT04125563|Placebo Comparator|Placebo capsules|Soft gel capsules with placebo: Sorbitol and colorant.
10147569|NCT04125563|Active Comparator|Active substance - oral capsaicin in soft gel capsules|"This is a phase 2 clinical study in humans for therapeutic use of Capsicum oleoresin - (capsaicin) in CIC. The study has a randomised, double-blind and cross-over design. During 4 weeks the participants take either active capsules (Capsicum oleoresin), or matching placebo capsules. This period follows by 2 weeks of wash out and then another 4 weeks with active capsules or placebo in accordance with the trial profile below."
10147570|NCT04125511|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
10147571|NCT04125654|Experimental|Patients with ascites enrolled for mNGS testing|Patients with ascites will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective clinical documents).
10147572|NCT04125732|Experimental|AdVEGFXC1 at 1x10^9 vp|
10147573|NCT04125732|Experimental|AdVEGFXC1 at 1x10^10 vp|
10147574|NCT04125732|Experimental|AdVEGFXC1 at 4x10^10 vp|
10147575|NCT04125732|Experimental|AdVEGFXC1 at 1x10^11 vp|
10147576|NCT04125537||Dialysis Centers|Dialysis Center staff participating in the collaborative learning activities. These staff then implement the best practices for seriously ill patients in their setting via quality improvement activities around identifying seriously ill patients, shared-decision making/advanced care planning, palliative dialysis and dialysis withdrawal.
10147577|NCT04125537||Chronic Kidney Disease Clinics|Chronic Kidney Disease Clinic staff participating in the collaborative learning activities. These staff then implement the best practices for seriously ill patients in their setting via quality improvement activities around identifying seriously ill patients, shared-decision making/advanced care planning, and medical management without dialysis.
10147578|NCT04125706|Experimental|Mincycline hydrochloride 2% oral gel|Minocycline will be delivered locally in the periodontal pocket.
10147579|NCT04125706|Experimental|Metronidazole hylcate 0.75 % oral gel|Metronidazole gel will be delivered locally in the periodontal pocket.
10185234|NCT03747679|Experimental|E- - bosutinib in mannitol high sweet|200 Mg of bosutinib High % sweet mannitol solution
10147580|NCT04125680|Other|ESL Health Literacy Classes|The program will last 8 weeks with classes held online during evening hours. The curriculum will focus on using pedagogies for health literacy as a practice. Assessments will be administered pre-post intervention.
10147581|NCT04125329|Experimental|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
10147582|NCT04125264|Experimental|Intense therapeutic Ultrasound|"During the trial two applications of 1000 pulses each one (day one and day thirty) will be applied. Pulse regulation could be modified from 4 to 5 joules depending the presence or not of pain.~Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching."
10147583|NCT04125264|No Intervention|Control group|Non ITU application. Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching.
10147584|NCT04125641||Elxaban group|AF patients taking Elxaban
10147585|NCT04125407|Experimental|Interventional|"Experimental group will receive one customized pair of sensorimotor foot orthoses (insoles).~Intervention: Other: Sensorimotor foot orthoses with any other supplementary treatment."
10147586|NCT04125407|No Intervention|Control|Control group will receive neither orthotic nor other supplementary intervention.
10147587|NCT04125355|Placebo Comparator|Placebo|Placebo control
10147588|NCT04125355|Experimental|Reflexology|foot reflexology
10147589|NCT04125589|Experimental|Speaking Activity and Talking Activity|Participants will engage in a speaking activity first and a talking activity second.
10147590|NCT04125589|Experimental|Talking Activity and Speaking Activity|Participants will engage in a talking activity first and a speaking activity second.
10147591|NCT04125381||Exposed to high Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with high Arsenic concentration in drinking water, were enrolled
10147592|NCT04125381||Exposed to low Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with low Arsenic concentration in drinking water, were enrolled
10147593|NCT04125433|Experimental|Medicaid Emergency Department High Utilizers|"This Arm will include the following individuals~Up to 400 Adults age 18 to 65~New York State Medicaid Managed Care Members~Have utilized emergency department services 6 or more times in a 12-month period~Have been assigned to the Pilot Project by their Medicaid Managed Care Plan"
10147594|NCT04125446||Cancer in pregnancy chemo treated|Patients that received at least one of the following treatments: Carboplatin, Cisplatin, Cyclophosphamide, Paclitaxel and/or anthracyclines, the latter being the most given type of CT during pregnancy
10147595|NCT04125446||Cancer in Pregnancy not chemo treated|Women who were not treated with CT during pregnancy, including those who were solely surgically treated or did not receive any treatment during pregnancy, will be included in the CT-unexposed control arm
10147596|NCT04125446||healthy pregnancies|A group of healthy pregnant women without cancer will form the second control group
9971346|NCT01309698|Experimental|Treatment Sequence 1|
9971347|NCT01309698|Experimental|Treatment Sequence 2|
10147597|NCT04125615|Experimental|Protected Non-Clinical Time|Protected non-clinical time
10147598|NCT04125615|No Intervention|Control Period|No protected non-clinical time
10147599|NCT04125602|Experimental|High fat low carbohydrate diet|
10147600|NCT04125602|Experimental|Low fat high carbohydrate diet|
10147601|NCT04125394|Experimental|NaCl 5%|Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days.
10147602|NCT04125303|Experimental|Intervention Group|Based on NANDA diagnosis recommendations, entertainment-sector workers were asked to record their perceptions and the meaning of their substance-use problem in a diary. The intervention was subsequently designed based on brief motivational psychoeducational therapy (BMPT).
10147603|NCT04125849|Active Comparator|Thoraco-laparoscopic esophagectomy|Treated by thoraco-laparoscopic esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
10147604|NCT04125849|Active Comparator|Mediastinoscopy-assisted transhiatal esophagectomy|Treated by mediastinoscopy-assisted transhiatal esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
10147605|NCT04125199|Experimental|experimental group|
10147606|NCT04125199|Placebo Comparator|control group|
10147607|NCT04125056|Experimental|test group|Hydronidone capsules (Specification: 30 mg / capsule）
10147608|NCT04125056|Placebo Comparator|Control group|Hydronidone capsules (Specification: 15 mg / capsule）
10147609|NCT04125004|Experimental|virtual reality|Patients will use virtual reality headset during procedure
10147610|NCT04125004|No Intervention|general anesthesia|Patients will undergo general anesthesia for their procedure
9971348|NCT01309698|Experimental|Treatment Sequence 3|
9971349|NCT01309698|Experimental|Treatment Sequence 4|
9971350|NCT01309698|Experimental|Treatment Sequence 5|
10147611|NCT04125017|Other|effect of using LASER pulse|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
10147612|NCT04125017|Other|Micro-needle Technique|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
10147613|NCT04125082|Other|Type 2 Diabetics|"Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks. Participants will attend study visits at Day 0, Weeks 1, 2, 3, 4, 8, 12 and 16, where insulin titration may be performed based on CGM readings. Participants will receive instruction in carbohydrate counting and corrective insulin dose adjustments.~Participants will wear CMG throughout the study.~At final study visit, CGM system will be collected. A1c, FEV1 and Quality of Life Questionnaires will be collected. Pregnancy test will be collected for all females of child-bearing potential. Participants will be transitioned back to Multiple Daily Injections plus basal or may choose to continue on commercial Afrezza® inhaled insulin plus basal"
10147614|NCT04124991|Experimental|Yttrium-90 Microspheres in Combination with Durvalumab|Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD. TARE will be performed 1-2 weeks (7 to 14 days) before the first dose of durvalumab and a maximum of 2 more times during the treatment period, per Investigator discretion. If additional TARE is performed, the interval between additional TARE treatments and administration of durvalumab should be at least 1 week.
10185235|NCT03747679|Experimental|F- - bosutinib low flavour|Taste assessment of 200 Mg of bosutinib low % Flavour
10185236|NCT03747679|Experimental|G- bosutinib high flavour|Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
10185237|NCT03747679|Experimental|H- - bosutinib capsules in low sweet|Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
10185238|NCT03747679|Experimental|I - bosutinib capsules high sweet|200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
10185239|NCT03747679|Experimental|J- - bosutinib capsules low flavour|Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
10185240|NCT03747679|Experimental|K - bosutinib capsules high flavour|Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
10185241|NCT03747679|Experimental|L - bosutinib capsules applesauce|200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
10185242|NCT03747679|Experimental|M - bosutinib capsules full fat yougurt|200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
10185243|NCT03747679|Experimental|N - bosutinib capsules in water (retest)|200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
10185244|NCT03747666|Experimental|Locking miniplate|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
10185245|NCT03747666|Experimental|Non-locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 two non-locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
10185246|NCT03747653||Arm 1|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.
10185247|NCT03747653||Arm 2|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.
10185248|NCT03747614|Experimental|Dry eye group|The recruitment of subjects met the criteria of DEWS. Each subject received treatment based on increasing severity according to the expert consensus for the treatment of DE inflammation. For moderate levels of severity, topical anti-inflammatory agents (0.1% Fluorometholone) were administered twice daily and then gradually less frequently until inflammation was controlled. For severe DE, the approach was similar to that of the moderate level but with an increased concentration and treatment frequency of the anti-inflammatory agents (0.1% Fluorometholone, 4 times daily). Topical 0.05% tacrolimus twice daily when DE was extremely severe. Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
10185249|NCT03747614|Experimental|Control group|Normal health subject without drug intervention, Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
10185250|NCT03747601|Experimental|Temporal Interference (TI) Stimulation|Temporal Interference stimulation applied to the head via standard electrodes
10185251|NCT03747588|Experimental|Laparoscopic Pancreaticoduodenectomy|LPD
10185252|NCT03747588|Placebo Comparator|Open Pancreaticoduodenectomy|OPD
9971351|NCT01309698|Experimental|Treatment Sequence 6|
9971352|NCT01309711||HIE|Moderate of severe neonatal encephalopathy
10185253|NCT03747562|Experimental|Experimental group|"Patients randomised to the experimental group will receive a prescription for a gabapentin starting dose of 100 mg three times a day (ter in die, t.i.d) /day per orally, additional to the analgesics according to standard local practices.~Gabapentin dosage may be gradually increased based on individual patient response and tolerability, and as per standard practice in accordance with the drug label. The dose can be further increased in 300 mg/day increments (dose increments of 50% - 100%) every two to three days, up to a maximum dose of 3600 mg/day. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of two weeks, and to reach 3600 mg/day is a total of three weeks."
10185254|NCT03747562|Placebo Comparator|Control group|Patients randomised to the control group will receive a prescription for a matching placebo. The starting dose will be the same as in the experimental group (100 mg three times a day per orally), additional to the analgesics according to standard local practices. Placebo can optionally follow the same dose scheme as described in the experimental arm.
9971353|NCT01309724|No Intervention|Control|No measurements are made on the control group.
10185255|NCT03747549|Experimental|Acupuncture and Home Exercise|Acupuncture and home exercise.
10185256|NCT03747549|Active Comparator|Home Exercise Alone|The prescribed home exercise program alone.
10185257|NCT03747536|Experimental|Intervention|ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
9669408|NCT01703520||Male Finasteride Non-users|Country-matched male finasteride non-users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
9971354|NCT01309724|Experimental|USCOM|Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
9971355|NCT01309750||C. diff|Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
9977155|NCT01358643|Other|P90X + Sparkpeople|"For six weeks of the study participants will use the P90X tools and for the other six weeks participants will use Sparkpeople tools.~Sparkpeople is a web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight.~P90X is A DVD based home exercise program that guides the participant through a daily exercise routine."
10147615|NCT04125108|Experimental|pulmonary rehabilitation group|The experimental group was to participate in a 12-week pulmonary rehabilitation program supplemented with an individualized and supervised exercise-training program.
10147616|NCT04125108|No Intervention|control group|The control group was to participate in a 12-week conventional rehabilitation program.
10147617|NCT04125147|Experimental|Montage Bone Hemostat|Use of Montage Settable Resorbable Hemostatic bone putty on the cut surfaces of bleeding bone at the osteotomy site
10147618|NCT04125147|No Intervention|Standard of Care: No bone hemostat|Use of no bone hemostat on the cut surfaces of bleeding bone at the osteotomy site
10147619|NCT04124978|Experimental|Intervention group|prospective, single armed, single centre trial study using the MyTAP device on a daily basis for a period of 3 months
10147620|NCT04125121|Active Comparator|Sevoflurane-Propofol|"Session one: Sevoflurane as maintenance anaesthetic during general anaesthesia.~Session two: Propofol as maintenance anaesthetic during general anaesthesia."
10147621|NCT04125121|Active Comparator|Propofol-Sevoflurane|"Session one: Propofol as maintenance anaesthetic during general anaesthesia.~Session two: Sevoflurane as maintenance anaesthetic during general anaesthesia."
10147622|NCT04125160||Type 2 diabetes and peritoneal dialysis|Case group with type 2 diabetes undergoing peritoneal dialysis for at least 3 months.
10147623|NCT04125160||Type 2 diabetes and eGFR above 60ml/min|Control group with type 2 diabetes and no nephropathy (defined as eGFR above 60ml/min and UACR below 300mg/g).
10147624|NCT04124679|Experimental|TAES group|In TEAS group, an experienced acupuncturist performed 30 minutes of TEAS treatment at the HT7 (Shenmen) and Neiguan (PC6) acupoints on bilateral side, which were identiﬁed in accordance with the TCM anatomic localizations on the first night before surgery by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no.: SDZ-II; Suzhou Medical Appliances Co. Ltd, Suzhou, China). And after surgery, ST36 (Zusanli) and LI4 (Hegu) acupoints were added for the effect of relieving postoperative complications. 30 minutes of TEAS treatment was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints on the first three nights after surgery
10147625|NCT04124679|No Intervention|Control group|Patients in the control group were attached the gel electrodes at the sham acupoints
10147626|NCT04124705|Experimental|Armour® Thyroid|Oral administration
10147627|NCT04124705|Active Comparator|Synthetic T4|Oral administration
10147628|NCT04124627|Experimental|Single arm study|Ultrasound plus radiographic guidance
10147629|NCT04124848||Somali Descent|Study participants who are of Somali origin.
10147630|NCT04124848||Non-Somali Descent|Study participants who are not of Somali origin.
10147631|NCT04124744|Experimental|Intervention|Will receive the Health Champion intervention
10147632|NCT04124744|Active Comparator|Control|Treatment as usual
10147633|NCT04124783|Experimental|Cooling Bolero|
9971356|NCT01309763|Active Comparator|AFFITOPE AD03|s.c. injection
10147634|NCT04124614|Experimental|Brexpiprazole + Sertraline|3 pills: Dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
10147635|NCT04124614|Experimental|Sertraline|3 pills: Dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
10147636|NCT04124614|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
10147637|NCT04124900||patients at prostate cancer risk diagnosed|"The study is composed of one single subject cohort. After risk evaluation, prostate biopsies will be performed for diagnostic purposes on all recruited patients. The cases are sorted into two groups after diagnosis:~Group 1: patients at prostate cancer risk diagnosed with significant prostate cancer after prostatic biopsy (Gleason >6).~Group 2: patients at prostate cancer risk diagnosed free of cancer after prostate biopsy. There will be a subdivision within this group in patients without significant prostate cancer ( No cancer o Non-significant prostate cancer (Gleason ≤6))."
10147638|NCT04124822|No Intervention|control|group 1 , is no intervention group in which root canal procedure will be done without drug as ideal protocol .
10147639|NCT04124822|Experimental|Piroxicam|group 2 is given Piroxicam 20 mg half an hour before root canal treatment to manage post operative pain.
10147640|NCT04124822|Experimental|Prednisolone|group 3 is given Prednisolone 20mg half an hour before root canal treatment to manage post operative pain.
10147641|NCT04124887|Active Comparator|Sodium fluoride|Duraphat Varnish containing 5% Sodium fluoride
10147642|NCT04124887|Experimental|Tricalcium phosphate|Clinpro™ White Varnish containing 5% NaF with TCP
10147643|NCT04124887|Experimental|Xylitol-coated calcium and phosphate|Embrace ™ Varnish containing 5% NaF with CXP
10147644|NCT04124887|Experimental|Casein phosphopeptide amorphous calcium phosphate|MI Varnish containing 5% NaF with CPP-ACP
10147645|NCT04124640||treatment group|The study population will be women between 45 and 65 years old, both ages included, who present a decrease in sexual desire or arousal
10147646|NCT04124939|Active Comparator|10 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 10 cc of sterile saline for the purpose of 10 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
10147647|NCT04124939|Active Comparator|20 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 20 cc of sterile saline for the purpose of 20 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
9971357|NCT01309763|Experimental|AFFITOPE AD03 + Alum|s.c. injection
9971358|NCT01309776|Experimental|Tianeptine|
10147648|NCT04124913|Experimental|Dydrogesterone|
10147649|NCT04124913|Active Comparator|Vaginal progesterone|
10147650|NCT04124731|Experimental|Sintilimab plus anlotinib|Sintilimab and anlotinib combination therapy
10147651|NCT04124731|Active Comparator|Control|Standard platinum-based chemotherapy
10147652|NCT04124796|Experimental|target subjects|"target subjects patients are expected, corresponding to the average population received each year for a CBCa in the unit."
10147653|NCT04124796|Active Comparator|health care team|the health care team managing these patients
10147654|NCT04124926|Experimental|Healing Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
10147655|NCT04124926|Active Comparator|Healing Phase: Lansoprazole 30 mg|Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
10147656|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 10 mg|Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
10147657|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
10147658|NCT04124926|Active Comparator|Maintenance Phase: Lansoprazole 15 mg|Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.
9971359|NCT01309776|Active Comparator|Escitalopram|
9971360|NCT01309789|Experimental|1|Sequential
10147659|NCT04124965|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
10147660|NCT04124965|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
9971361|NCT01309789|Experimental|2|Combination
9971362|NCT01309789|Experimental|3 Brentuximab vedotin/CH-P|Combination
10147661|NCT04124718||high caries experience|80 adults will be allowed in the high caries experience group according to DMFT index DMFT>13.9
10147662|NCT04124718||low caries experience|80 adults will be allowed in the high caries experience group according toDMFT index DMFT≤4
10147663|NCT04124666|Experimental|Granulocytes infusion only|Fresh, non-irradiated granulocytes from ABO, Rh, CMV compatible, unrelated donors; bioactivity of anti-cancer ability meets the criteria.
10147664|NCT04124809|Experimental|Study group (artificially laser-collapsed blastocysts)|laser was used as an intervention before blastocyst vitrification to assist rapid blastocyst collapse with vitrification
10147665|NCT04124809|No Intervention|& control group (blastocysts were vitrified, no laser collapse|blastocyst were vitrified without laser assisted collapse
10147666|NCT04124757|No Intervention|Standard neuromuscular blockade|Subjects will receive regular rocuronium induction dose, followed by bolus foses of 10 mg in case of insufficient conditions
10147667|NCT04124757|Experimental|Deep neuromuscular block|Subjects will receive high dose rocuronium induction dose followed by continuous rocuronium administration, to achieve a depth of neuromuscular block of 1-2 twitches post tetanic count
10147668|NCT04124224||Unidos Participants|In the Unidos intervention the county/community-based CHWs will: 1) support and connect participants to health promotion resources; 2) provide individual and group-based support guided by a novel framework for understanding Latino's health advantages, the sociocultural resiliency model; and, 3) leverage community resources to help individuals address SDH-related needs.
10147669|NCT04124224||Non-Unidos Participants: Comparison Group|Using propensity score matching, the investigators will use the medical records of Unidos participants and the electronic health record comparison group to compare health outcomes.
10147670|NCT04124549|Sham Comparator|Stand of Care|Patients in the control group received usual care with sham exercise.
10147671|NCT04124549|Experimental|Combined Exercise|The intervention was a 24-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours. Each exercise lasted about 40 minutes.
10147672|NCT04124198|Experimental|Transoral robotic surgery (TORS)|
10147673|NCT04124198|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|"Patients with clinical T1N0 stage are offered accelerated radiotherapy to 66 Gy/33fractions with concurrent nimorazole.~Patients with clinical T2N0 stage are offered either accelerated radiotherapy to 66 Gy/33fractions with the option of weekly cisplatin to fit patients or hyper-fractionated accelerated radiotherapy to 76 Gy/56fractions both with concurrent nimorazole.~Patients with clinical T1-T2, N1 stage are offered accelerated radiotherapy to 66 Gy/33 fractions and nimorazole with the addition of concurrent weekly cisplatin 40 mg/sqm to fit patients."
10147674|NCT04124211|Experimental|FMT Arm|10 Participants will be enrolled in this arm to receive FMT treatment
10147675|NCT04124354|Experimental|Immediate Experimental Group|Participants will immediately begin an experimental supervised moderate-intensity treadmill walking intervention program.
10147676|NCT04124354|No Intervention|Delayed Intervention Control Group|Participants will be asked to maintain their usual physical activity during the initial 8-week intervention period but will undergo all data collection procedures. Following the initial intervention period, these participants will be given the option to complete the 8-week intervention, with identical data collection procedures employed.
9971363|NCT01309815||Cancer in elderly people|other
9971364|NCT01309854|Experimental|pioglitazone|
9971365|NCT01309854|Experimental|pioglitazone and fostamatinib|
9971366|NCT01309958||intervention|design instruments and test feasibility of an intervention aimed at increasing the proportion on non-invasive treatment for early caries
9971367|NCT01309971||Questionable occlusal lesions|
9971368|NCT01309984|Active Comparator|arm 1|
9971369|NCT01309984|Active Comparator|arm 2|
9971370|NCT01310023||Static Cohort|HIV-uninfected children < 12 years of age at the time of enrollment, born of HIV-infected mothers
9971371|NCT01310023||Dynamic Cohort|HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
10147677|NCT04124328|Active Comparator|ALINE only group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria
10185258|NCT03747536|Placebo Comparator|Placebo|normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
10147678|NCT04124328|Active Comparator|VoM group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria and vein of Marshall (VoM) ethanol infusion
10147679|NCT04124458|Active Comparator|Pulsed Radiofrequency Ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
10147680|NCT04124458|Active Comparator|Bilateral Occipital Nerve Block|In this arm all steps are the same as other arm, except the generator will not be on and patient will have pain relief by injecting numbing medications beside the sensory nerves.
10147681|NCT04124302|Active Comparator|IPF|Total meal bolus will consist of insulin for carbohydrates (IC) and insulin for proteins and fats (IPF) based on individual insulin-to-carbohydrate ratio (ICR). Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
10147682|NCT04124302|Experimental|30%IC|Total meal bolus will consist of insulin for carbohydrates (IC) calculated based on individual insulin-to-carbohydrate ratio (ICR) and insulin for proteins and fats (IPF) estimated as 30% of IC. Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
10147683|NCT04124289||Pain post surgery|Patients who have completed surgery will be assessed with three types of pain scales. A new pain scale, a functional pain scale (FPS), will be compared to two pain scales that are routinely used: the FACES pain scale and the numeric rating scale (NRS).
10147684|NCT04124367|Active Comparator|Verum|
10147685|NCT04124367|Placebo Comparator|Control|
10147686|NCT04124380|Experimental|Imaginal Exposure First, then Alcohol Skills|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. After imaginal exposure, alcohol skills targeting alcohol misuse after sexual assault.
10147687|NCT04124380|Experimental|Alcohol Skills First, then Imaginal Exposure|Alcohol skills targeting alcohol misuse after sexual assault. After alcohol skills training, imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault.
10147688|NCT04124380|Active Comparator|Supportive Counseling/Telehealth|Internet-based intervention focusing on providing support.
10147689|NCT04124380|Experimental|Alcohol Skills First, no additional treatment|Alcohol skills targeting alcohol misuse after sexual assault only. No additional treatment.
10147690|NCT04124380|Experimental|Imaginal Exposure First, no additional treatment|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. No additional treatment.
10147691|NCT04124419|Experimental|Treatment Arm|Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
10147692|NCT04124445|Active Comparator|Pulsed Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine with Maximum allowable temperature 50° rotation: 90.; Pulse rate: 3 Hz; pulse duration: 50 ms; 3 minutes
10147693|NCT04124445|Active Comparator|Continuous Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine, burn will be made at 80° for 60 seconds.
10147694|NCT04124406||Adults Prescribed Cologuard|Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.
10147695|NCT04124484|Experimental|50mg group|Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.
10147696|NCT04124484|Experimental|100mg group|Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.
10147697|NCT04124484|Experimental|200mg group|Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.
10147698|NCT04124484|Placebo Comparator|placebo group|Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg
10147699|NCT04124432|Experimental|Active cannabis without nicotine|Smoked cannabis containing 10mg THC + No nicotine/tobacco
10147700|NCT04124432|Experimental|Active cannabis with own brand cigarettes|Smoked cannabis containing 10mg THC + ad-libitum use of preferred brand cigarettes
10147701|NCT04124432|Experimental|Active cannabis with low nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
10147702|NCT04124432|Experimental|Active cannabis with high nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
10147703|NCT04124432|Experimental|placebo cannabis with own brand cigarettes|Smoked placebo cannabis + ad-libitum use of preferred brand cigarettes
10147704|NCT04124432|Experimental|Placebo cannabis with low nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
10147705|NCT04124432|Experimental|Placebo cannabis with high nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
10147706|NCT04124276|Experimental|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day) for 6 weeks
10147707|NCT04124276|Placebo Comparator|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
10147708|NCT04124510|Experimental|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
10147709|NCT04124263|Experimental|Medication Time Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
10147710|NCT04124263|Experimental|Educational Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
10147711|NCT04124172|Active Comparator|Real rTMS|"rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). M1 is defined like the hot spot to elucidated a motor evoked potential in the Abductor Pollicis Brevis (APB) muscle of the contralateral hand. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
10147712|NCT04124172|Sham Comparator|Sham rTMS|"Sham rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). Investigators will make the simulation disconnecting the coil but keeping its position during the same time as the real one. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
10147713|NCT04124029||Younger mild Traumatic Brain Injury|mTBI subjects aged 30-59 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the Test of Memory Malingering (TOMM) and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
10147714|NCT04124029||Older mild Traumatic Brain Injury|mTBI subjects aged 60- 90 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
10147715|NCT04124029||moderate Traumatic Brain Injury|TBI control subjects, age-, education- and sex-matched with mTBI subjects (aged 30-90) will be recruited who have a physician diagnosis of 1 or more moderate TBI episodes (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). Moderate TBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
10147716|NCT04124029||Mild Cognitive Impairment (MCI)|MCI control subjects, age-, education- and sex-matched with older mTBI subjects (aged 60-90) will be recruited if they meet diagnostic criteria for MCI (without a history of TBI) based on the judgement of a behavioral neurologist following the 2011 MCI criteria. Specifically, subjects will test in the impaired range on one or more cognitive domains on neuropsychological testing and will not have impairments in function (i.e. will not meet diagnostic criteria for dementia). MCI subjects will be matched for their Montreal Cognitive Assessment (MoCA) score with older mTBI subjects. Of note, subjects with MCI may or may not meet diagnostic criteria for MCI due to AD. The intent of this control group is to recruit a broad range of MCI subjects without TBI as controls for subjects with cognitive impairment who have a history of mTBI.
10147717|NCT04124029||Younger Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with younger mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
10147718|NCT04124029||Older Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with older mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
10147719|NCT04124003|Experimental|rosuvastatin + BMS-963272|
10147720|NCT04124016|Experimental|Inulin|Inulin_ extract of chicory fermentable fiber
10147721|NCT04124016|Experimental|green tea extract|green tea extract_rich in tri-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursor)
10147722|NCT04124016|Experimental|grape seed|grape seed extract - rich in di-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursors)
10147723|NCT04124016|Experimental|grape seed exctract|grape seed extract - rich in di-hydroxylated flavan-3-ol oligomers (1 mmol of PVL precursors)
10147724|NCT04124107|Experimental|Prostate biopsy with 68Ga-PSMA PET/MRI|Both targeted biopsy and 12-core systematic biopsy with positive 68Ga-PSMA PET/MRI
10147725|NCT04123860|Experimental|buccal fat pad|will undergo sinus lifting using intralift technique then placement of buccal fat pad followed by immediate implant placement.
10147726|NCT04123860|Active Comparator|prf|will undergo sinus lifting using intralift technique the prpration of PRF and immediate implant placement.
10147727|NCT04123951|Experimental|Home-based Exercise|Patients in this arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
10147728|NCT04123951|No Intervention|Control|"In this arm patients will continue 'as normal' with daily activities.~Patients in this arm will be offered the exercise intervention once they have completed post 12 week assessments."
10147729|NCT04123808|Experimental|IpsiHand Treatment|All participants will receive treatment with IpsiHand device
10147730|NCT04124094|Experimental|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg|Test Product
10147731|NCT04124094|Active Comparator|SERETIDE DISKUS 100/50|reference Product
10147732|NCT04123847|Experimental|Stand, Step and Voluntary Training|
10147733|NCT04123821|Experimental|Group A|
10147734|NCT04123821|No Intervention|Group B|
10147735|NCT04123990|Experimental|IBD|
10147736|NCT04123834|Experimental|implantless Arthroscopic ACL reconstruction|implantless Arthroscopic ACL reconstruction using press-fit femoral technique
10147737|NCT04123834|Experimental|Arthroscopic ACL reconstruction with implant|ACL reconstruction with implant (hamstring autograft fixed with bioscrew and endo-button)
9669409|NCT01703520||Men with Breast Cancer|Breast cancer cases among men aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
10147738|NCT04124068|Experimental|GLO Science Professional Chairside Teeth Whitening|
10147739|NCT04124068|Experimental|GLO Science Professional At-Home Teeth Whitening Device|
10147740|NCT04124068|Experimental|GLO Brilliant At-Home Teeth Whitening Device|
10147741|NCT04124068|Experimental|GLO Lit At-Home Teeth Whitening Device|
10147742|NCT04124068|Experimental|GLO Lit Whitening GLO Vials|
10147743|NCT04124081|Experimental|Drug group|
10147744|NCT04123912|Experimental|KT-FMPT group|
10147745|NCT04123912|Placebo Comparator|Control group|
10147746|NCT04123899|Experimental|IGAD→GSTD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
10147747|NCT04123899|Experimental|GSTD→IGAD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
10147748|NCT04124146||Patients with Surgery more than 10 years|Patients with surgery for spinal lumbar stenosis between 2006 and 2008 will be purposed to participate to the study.
10147749|NCT04123925|Experimental|Nivolumab|Patients will receive nivolumab at a flat dosage of 240 mg every two weeks on Day -28 and Day-14 (+/- one day) prior to planned surgery on Day 0 or up to +7 days
10147750|NCT04123782|Active Comparator|Group A (F-ESWT group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.12 mJ/mm2 per session)
10147751|NCT04123782|Placebo Comparator|Group B (placebo group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.01 mJ/mm2 per session)
10147752|NCT04124055|Experimental|Therapeutic drug monitoring (TDM)|Therapeutic drug monitoring (TDM) based on Saliva and Dried blood spot samples
10147753|NCT04123431||ACE Acetabular Cup System with XLPE Liner|
10147754|NCT04123431||ACE Acetabular Cup System with Ceramic Liner|
10147755|NCT04123431||ACE Acetabular Cup System with Dual Mobility Insert|
10147756|NCT04123769|Experimental|Drug group|
10147757|NCT04123587|Experimental|Sulfonylurea-dependent|Sulfonylurea is replaced by alternative oral hypoglycemic agent.
10147758|NCT04123483|Experimental|EnBrace HR for Acute Treatment of PMS and MRMD|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 weeks. Participants are currently experiencing clinically significant MRMD symptoms, defined as a ≥ 30% increase in the total Daily Record of Severity of Problems Scale (DRSP) score from the mid-follicular phase (average of DRSP scores for days 6-10) to the late-luteal phase (average of DRSP scores for last 5 days prior to menstrual bleeding).
10147759|NCT04123678||All|Patients attending a Medical Photography facility with at least 1 suspicious skin lesion will be approached to participate in the study. Participants will have an additional macro and dermoscopic image of each suspicious skin lesions suitable for photography. Photographs will be taken by a healthcare professional using an iPhone XR smart phone camera with a DL1 dermoscopic lens attachment. The images will be encrypted and electronically transmitted to Skin Analytics' cloud servers for analysis by DERM. The suspected diagnosis determined by DERM will be compared with dermatologist review and histologically confirmed diagnosis, where obtained. Healthcare resource utilization information and patient satisfaction data will also be collected
10147760|NCT04123522||anterior cervical spine surgery|The patients will be enrolled for elective anterior cervical spine surgery.
9971372|NCT01310023||Reference Cohort|HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
9971373|NCT01310023||Young Adult Cohort|Former Dynamic and Static Cohort participants ≥ 18 years of age.
10147761|NCT04123522||posterior cervical spine surgery|The patients will be enrolled for elective postieor cervical spine surgery
10147762|NCT04123717|Active Comparator|Arm1 - IV Ibuprofen|Patients will receive IV Ibuprofen 10 mg/kg to a maximum of 400 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with 100 ml normal saline.
10147763|NCT04123717|Active Comparator|Arm 2 -IV Paracetamol|Patients will receive 15 mg/kg IV Paracetamol to a maximum of 1000 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with normal saline.
10147764|NCT04123717|Active Comparator|Arm 3- Both IV Paracetamol and IV Ibuprofen|Patients will receive an infusion of both IV Paracetamol and IV Ibuprofen. They will initially receive IV Ibuprofen and the IV catheter will then be flushed with 10 ml of normal saline, and the patient will receive IV Paracetamol
10147765|NCT04123717|Active Comparator|Arm 4 -PO Brufen|Patients will receive PO ibuprofen given as a 100mg/5ml syrup or 200 mg tablets to a maximum of 400 mg. The treating nurse will ask the parental preference to use syrup or tablets. If they vomit the medication within 15 minutes of administration, another full dose will be administered.
10147766|NCT04123704|Experimental|Sitravatinib|Sitravatinib 120 mg daily
10147767|NCT04123652|Other|Lidocaine and ketamine infusion|
10147768|NCT04123743|Experimental|Experimental Group|The experimental group will be given topical cream containing Trigonella foenum-graceum extract, Wardah brand facial wash, and Parasol sunscreen SPF 33.
10147769|NCT04123743|Placebo Comparator|Control Group|The control / placebo group will be given placebo topical cream, Wardah brand facial wash, and Parasol sunscreen SPF 33
10147770|NCT04123730|Active Comparator|Fixed dose oxygen|O2Matic deliver the usual fixed-dose oxygen treatment during walking.
10147771|NCT04123730|Experimental|Automated oxygen titration|O2Matic deliver a variable oxygen dosage set at an SpO2-target of 90 to 94 % and a O2-flow of 0 - 15 liters/min during walking.
10147772|NCT04123392|Experimental|Decitabine + BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, Decitabine +BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
9971374|NCT01310049|Experimental|LP0058 oral solution (0.050 mg/mL)|LEO 32731
9971375|NCT01310049|Experimental|LP0058 oral solution (0.200 mg/mL)|LEO 32731
9971376|NCT01310049|Placebo Comparator|LP0058 oral solution (placebo)|Placebo
9971377|NCT01310049|Experimental|LP0058 capsule 1-120 mg|LEO 32731
9971378|NCT01310049|Placebo Comparator|LP0058 capsule (placebo)|Placebo
10147773|NCT04123392|Active Comparator|BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
10147774|NCT04123340|Experimental|Additional intraprocedural CT-scan|Additional intraprocedural CT-scan
10147775|NCT04123119|Experimental|Rotarix Arm|
10147776|NCT04123028||eosinophilic COPD patient|COPD patient with blood eosinophil equal or > 300 cells/µL
10147777|NCT04123028||non-eosinophilic COPD patient|COPD patient with blood eosinophil < 300 cells/µL
10147778|NCT04123288|Experimental|Test drug formulation|Test drug 60 mg single dose
10147779|NCT04123288|Active Comparator|Reference drug formulation|60 mg single dose
10147780|NCT04123106|Experimental|ESP block|Ultrasound-guided, performed below erector spinae plane (ropivacaine 0.5% 20 mL each side).
10147781|NCT04123106|Active Comparator|Wound infiltration|Ropivacaine 0.5% 20-40 mL, performed by surgeon.
10147782|NCT04122989|Experimental|MS-SUPPORT|Group receives access to an online shared decision making tool (an interactive decision aid) for multiple sclerosis.
10147783|NCT04122989|No Intervention|Control|Usual care
10147784|NCT04123210|Experimental|Vitamin A supplement|Subjects receive a vitamin A supplement containing 175 or 525 micrograms of vitamin A as retinyl palmitate daily
10147785|NCT04123210|Placebo Comparator|Placebo|Subjects receive an oil placebo containing no vitamin A
10147786|NCT04123301|Active Comparator|Active TBS Arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
10147787|NCT04123301|Sham Comparator|Sham TBS Arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
10147788|NCT04123002|Experimental|Interventional group|Miswak chewing sticks would be provided to the participants and they would be explained the method of use
10147789|NCT04123002|No Intervention|Comparison group|They would use only tooth brush and paste
10147790|NCT04123041|Experimental|Virginia Tobacco|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Virginia Tobacco ENDS, JUUL 3% Virginia Tobacco ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
10147791|NCT04123041|Experimental|Mint|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mint ENDS, JUUL 3% Mint ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
10147792|NCT04123041|Experimental|Menthol|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Menthol ENDS, JUUL 3% Menthol ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
10147793|NCT04123041|Experimental|Mango|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mango ENDS, JUUL 3% Mango ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
10147794|NCT04123145|Experimental|CDK-ND|
10147795|NCT04123158||WHITE|If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
10147796|NCT04123158||GREEN|"Patients will be assessed by a Green Card to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics.~If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form will be fulfilled in order to check the presence of the criteria described in the Orange Card~In case of negative Orange Criteria (no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of positive Orange Criteria the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately."
10147797|NCT04123158||ORANGE|- If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 30 days and triaged to surgery (to be performed within 60 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled Histology of the target myometrial lesion will be considered as the gold standard parameter.
10147798|NCT04123249|Experimental|Group Propofol|In the Group P, propofol 4-6 mg/kg/h and remifentanil 0.2μg/kg/min were infused by intravenous pump separately for assisted sedation and assisted analgesia.
10147799|NCT04123249|Experimental|Group Sevoflurane|sevoflurane (concentration: 2%-3%, mixed with 50% air and 50% oxygen to keep the minimum alveolar concentration (MAC) at 1.0-1.1) was inhaled to maintain assisted sedation, and remifentanil 0.2 μg/kg/min was infused by intravenous pump for assisted analgesia.
10147800|NCT04123236||Oral Health Impact Profile|To evaluate the Oral Health-related Quality of Life, Turkish version of Oral Health Impact Profile-14 was used. Responses were made on a scale 0 (never), 1(hardly ever), 2 (occasionally), 3 (fairly often),and 4 (very often).Oral Health-related Quality of Life impairment was characterized by the Oral Health Impact Profile-14 summary score (the sum of all 14 items, potential range 0-56). Higher Oral Health Impact Profile-14 scores mean worse Oral Health-related Quality of Life and vice versa.
10147801|NCT04123236||Helkimo's anamnestic dysfunction index|As a method based on patient feedback for the determination of the degree of temporomandibular disorders, anamnestic index was used. For this purpose eight questions were asked to the patients that includes answers as 'yes' or 'no'. (Table 2) The analyses of the questionnaire was done according to anamnestic scale as 0: no symptoms; I: mild symptoms (sensation of the jaw fatigue, jaw stiffness, and temporomandibular joint sounds as clicking or crepitus) and II:severe symptoms (included one or more of the following: Difficulty in the mouth opening, jaw locking, mandible dislocation and its painful movement and painful temporomandibular joint region and/or masticatory muscles)
10147802|NCT04123236||Visual analog scale (VAS) for facial pain:|Facial pain was measured by asking the patients if they had had any pain during last 12 months and made them mark the intensity of the pain on a visual analog scale which had the anchor points at the left (no pain) and right (worse pain) ends of a 10 cm horizontal line. The analyses of the facial pain was done as fallowing: if the patient marked no facial pain the Visual analog scale value was accepted as 0 and if the patient marked any level of facial pain Visual analog scale value was accepted as 1.
10147803|NCT04123236||Helkimo's clinical dysfunction index (DI):|Maximum opening of mandible, deviation during opening, dysfunction of temporomandibular joint, pain in the temporomandibular joint and pain in the masticatory muscles was evaluated
10185259|NCT03747523|Experimental|Healthy Group|40 Healthy individuals will receive a single dose of ergocalciferol (200,000 units)
10147804|NCT04123223|Experimental|Restorative CR Intervention|The restorative remediation intervention will consist of a target of 50 hours (5 hours per week, 1 hour per day, over 3 months) of a sequence of computerized cognitive exercises designed to improve cognitive function through repeated drill-and-practice of exercises largely focused on attention, working memory and verbal episodic memory. Cognitive deficits will be directly targeted by these exercises. Exercises will be started at individually determined levels of difficulty at which each client will be successful, e.g., 80% accuracy. Task difficulty will be increased as performance improves.
10147805|NCT04123223|Experimental|Strategy CR Intervention|Participants in this intervention will be treated for 24 hours (2 hours per week, one day per week over 3 months) with Compensatory Cognitive Training (CCT). The therapy targets four cognitive domains: (a) prospective memory, (b) attention and vigilance, (c) learning and memory, and (d) executive function. The program is a group-based intervention that teaches strategies via interactive, game-like activities to maintain interest and enhance motivation and engagement.
10147806|NCT04123223|Placebo Comparator|Computer Games|Three months of 1-hour, 5-times per week, client-selected computer games.
10185260|NCT03747523|Experimental|ADTKD-MUC1 Group|40 individuals with ADTKD-MUC1 (Autosomal Dominant Tubulo-Interstitial Kidney Disease- a rare disease caused by mutation in MUC1) will receive a single dose of ergocalciferol (200,000 units)
10185261|NCT03747510|Experimental|CarpX Device|Transverse carpal ligament release with CarpX Device
10185262|NCT03747471|Experimental|Experimental Arm|Intervention: Diabetic Conversation Map x 4 Sessions
10185263|NCT03747471|No Intervention|Control Arm|No intervention
10185264|NCT03747445||Roux-en-Y gastric bypass patients|severely obese non-diabetic adult female patients scheduled for RYGB
10185265|NCT03747445||Normal weight controls|normal weight healthy non-diabetic adult females
10185266|NCT03747445||Obese controls|Severely obese non-diabetic adult female patients not scheduled for RYGB
10185267|NCT03747432|Experimental|Propofol|Conscious sedation with propofol during the TAVR procedure (anticipated around 2 hours), dosage: 0,5-2,5 mg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
10185268|NCT03747432|Experimental|Dexmedetomidine|Conscious sedation with dexmedetomidine during the TAVR procedure (anticipated around 2 hours), dosage: bolus of 0,5 mcg/kg during 10 minutes, then continuous infusion of 0,2-1 mcg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
10185269|NCT03747406|Experimental|ESP group|The patient rolled to his side, the level between T9 and T10 identified using ultrasound. An 8-14 MHz curved array probe (Siemens ACUSON X300 Ultrasound System) will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced inplane until contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration confirmed. The same procedure will be repeated in the contralateral side.
10185270|NCT03747406|Experimental|TAP group|The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
10185271|NCT03747406|No Intervention|opioid group|will receive intravenous morphine with general anesthesia and total opioid consumption will be calculated
10185272|NCT03747393|Active Comparator|DoD/VA CPG Core Set|The standard core set of interventions recommended by the DoD/VA clinical practice guidelines for non-surgical management of knee OA.
10185273|NCT03747393|Experimental|DoD/VA CPG Core Set + PT|In addition to DoD/VA clinical practice guidelines, patients will be referred to physical therapy (PT). Physical therapy will consist of evidence-based interventions that can be provided by a PT (exercise, manual therapy, education).
10185274|NCT03747367|No Intervention|Baseline|8 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab. Repeated for visit 1 and visit 2.
10185275|NCT03747367|Experimental|Insufficient Sleep|3 days with 3 hour sleep opportunities in lab, immediately following baseline on both visit 1 and visit 2.
10185276|NCT03747354|Active Comparator|complete blood count|blood samples will be taken from patient and complete blood count is done early morning
10185277|NCT03747354|Active Comparator|erythrocyte sedimentation rate|blood samples will be taken from patient and erythrocyte sedimentation rate is done
10185278|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine Low|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=low dose buprenorphine + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
10185279|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine High|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=high dose buprenorphine + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
10185280|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine Low-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=low dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
10187794|NCT03722628||HCC without TTT|Blood sample from all HCC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
9971379|NCT01310088|Experimental|Lifestyle counseling|Treatment protocol The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
10147807|NCT04123080|Experimental|EBL group|Removal of large long-stalked pedunculated colonic polyps using band ligations
10147808|NCT04123132||Patients with metabolic syndrome|
10147809|NCT04123132||Healthy controls|
10147810|NCT04123171||The Three Villages Cohort|Individuals aged 60 years or more identified by means of door-to-door surveys, living in Atahualpa, El Tambo, and Prosperidad. Individuals will be interviewed with validated field instruments, and there will be invited for the practice of complementary exams to recognize markers of aterosclerosis and cerebral small vessel disease.
10147811|NCT04122963|Active Comparator|High power group|The experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds).
10147812|NCT04122963|Active Comparator|Standard group|The control group will receive AF ablation according to the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds)
10147813|NCT04122937||Ovarian cancer|Patients affected by ovarian cancer will be stratified according to BRCA1 and BRCA2 mutational status.
10147814|NCT04122937||Colon cancer|Patients affected by colon cancer will be similarly stratified according to BRAF and KRAS mutational status and to the presence of low-grade or high-grade microsatellite instability (MSI).
10147815|NCT04122885||CRS and HIPEC|Cyroreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
10147816|NCT04122885||PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy (if CRS and HIPEC not possible)
10147817|NCT04122846|Experimental|Treatment (Emotional Awareness and Expression Therapy)|Internet-based Emotional Awareness and Expression Therapy
10147818|NCT04122911|Experimental|Temozolomide|Temozolomide 75mg/m2 metronomic schedule: one week on/one week off in a cycle of 28 days
10147819|NCT04122768|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
10147820|NCT04122768|Sham Comparator|Sham coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application.
10147821|NCT04122599|Other|Melatonin versus standard care|Melatonin is tested versus standard care
10147822|NCT04122872||Patients with bone or soft tissue sarcomas or carcinosarcomas|Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone [GCTB], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
10147823|NCT04122664|Active Comparator|RayOne® Hydrophilic lens 600C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophilic lens 600C
9669410|NCT01703520||Men without Breast Cancer|Country- and age-matched controls: men without breast cancer aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
9669411|NCT01654159|Placebo Comparator|Monofocal|"Monofocal IOL Implant~Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
10147824|NCT04122664|Active Comparator|RayOne® Hydrophobic lens 800C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophobic lens 800C
10147825|NCT04122859|Active Comparator|Zip Skin Closure Device|The device is a class IIa device as per Annex II of the MDD 93/42EEC, as amended by Directive 2007/47/EEC. A CE-mark was affixed in 2014. The Zip device adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives. A combination of acrylic and hydrocolloid adhesives is used to provide a skin-friendly environment while providing the necessary tack to maintain skin adhesion during a maximum wear time of 14 days. In addition to the pressure-sensitive adhesives, the device's closure and force distribution components are made up of polyurethane monofilm, polyethylene tape, polyester and nylon.
10147826|NCT04122859|Active Comparator|Standard of Care Sutures|Conventional sutures used for laceration repair
10147827|NCT04122547|Active Comparator|Roflumilast|Roflumilast 500 microgram one tab oral per day
10147828|NCT04122547|Placebo Comparator|Placebo|One tablet oral per day
10147829|NCT04122716|Active Comparator|Liraglutide + exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
10147830|NCT04122716|Other|Liraglutide + non-exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
10147831|NCT04122716|Other|Placebo + exercise|"Placebo: 3mg/day sc.~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
10147832|NCT04122716|No Intervention|Placebo + non-exercise|"Placebo: 3mg/day sc.~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
10147833|NCT04122703|Experimental|Percutaneous tibial nerve stimulation (PTNS)|The patients in the PTNS group will receive 1 PTNS treatments per week for 12 weeks.
10147834|NCT04122703|Sham Comparator|Transcutaneous electrical nerve stimulation (TENS)|The patients in the Sham group will receive one sham (TENS) treatment per week for 12 weeks
10187795|NCT03722628||LC with TTT|Blood sample from all LC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
10147835|NCT04122651|Experimental|Experimental Arm|Patients will be receiving a toric intraocular lens with either a 2.00 or 4.00 diopter (D) correction, depending on the degree of pre-operative astigmatism, and the astigmatic refractive error will be refined with the use of adjunctive limbal relaxing incisions LRIs and/or off axis rotation of the toric IOL (based on a standardized protocol) so the full amount of corneal astigmatism can be targeted for correction for each patient.
10147836|NCT04122651|Active Comparator|Control Arm|The patient will receive a toric intraocular lens individually tailored to and ordered for each patients' precise degree of corneal astigmatism.
10147837|NCT04122417||Control Group|"The mothers and infants in the experimental and control groups were assigned to the groups by randomization method. Therapeutic touch didn't apllied to control group.~Babies in the control group who took care practices in accordance with normal hospital procedures."
10147838|NCT04122417||Yakson Group|"The touch method was taught to the mothers in the Yakson group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~In yakson method, mother's fingers are closed, and she should touch in a way that does not apply excessive pressure. The method is applied for a total of 15 minutes in three cycles. First 5 minutes is resting the hand, 5 minutes is gentle caressing, and another 5 minutes of resting the hand."
10147839|NCT04122417||Gentle Human Touch Group|"The touch method was taught to the mothers in the Gentle Human Touch group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~Mother slowly places one hand on the baby's hand and the other over pelvic cavity, covering the waist and hips of the baby.~The touch is preserved for 15 minutes. In order to ensure equal touch for the duration of gentle human touch, the mother sits on a stool and her elbows have to be at the same level with baby's bed"
10147840|NCT04122742||Patients with RSTS|
10147841|NCT04122521||Glioma|Patients suspected of glioma
10147842|NCT04122573||Acute chest pain|The population in this study are characterized by acute chest pain as the first symptom for consultation within 24 hours.
10147843|NCT04122560|Experimental|Obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
10147844|NCT04122560|Active Comparator|Non-obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
10147845|NCT04122495|Experimental|Probiotic|Bifidobacterium lactis M8 at 10 log CFU/day for 4 weeks
10147846|NCT04122495|Placebo Comparator|Placebo|Intervention consists of daily administration of 1g of maltodextrin, administered daily for 4-weeks
10147847|NCT04122807|Active Comparator|Mapping|Standard treatment involving ablation of the slow pathway with cryotherapy
10147848|NCT04122807|Experimental|Ablation|Mapping and ablation of the retrograde fast pathway with cryotherapy
10147849|NCT04122430||GCT treated with first line chemotherapy|"Men with disseminated Germ Cell Tumours-GCT (AJCC Stage IS, 2, or 3) and have received first line chemotherapy with curative intent for disseminated GCT~."
10147850|NCT04122781|Experimental|with novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation and novel K-wire fixation devices
10147851|NCT04122781|Active Comparator|without novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation
10147852|NCT04122365|Experimental|Interventional group|Chest Wall Mobilization Program
10147853|NCT04122365|Other|Control Group|Routine limbs exercises and education
10147854|NCT04122586|No Intervention|health control group|
10147855|NCT04122586|Experimental|Tongxieyaofang granule group|
10147856|NCT04122404|Other|Intervention|"Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture) + Intervention~Intervention: LF-LAM is made available at the study site for the clinical staff to use; Training of clinical staff in national TB guidelines and LF-LAM use together with staff from the National TB Programme in Ghana"
10147857|NCT04122404|No Intervention|Standard of care|Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture)
10147858|NCT04122378|Experimental|Treatment Arm|Acupuncture will be provided up to once daily for one or more days till the day of discharge or 5 days, whichever occurs first. Patients will continue to receive their standard pain management regime including IV opioids, ketorolac and fluids. Minimum number of sessions received by the acupuncture group will be one.
10147859|NCT04122378|No Intervention|Control Arm|Standard of care for SCD patients who are hospitalized for acute pain and typically includes IV opioids, ketorolac and fluids.
10147860|NCT04122820|Other|Presence of HV-Labile|Presence of vertical heterophoria labile with proprioceptive Maddox
10147861|NCT04122820|Other|Absence of HV-Labile|Presence of stable vertical heterophoria or stable orthophoria with proprioceptive Maddox
10147862|NCT04122326|Experimental|Posture Sequence|Participants will complete computer work on a provided monitor and keyboard for two hours. During the first hour, the research personnel will alter the workstation every ten minutes to test various different postures of the neck, shoulder, arms, and trunk. The sequence will include 3 seated postures and 3 standing postures. At the end of the first hour, the participant will be instructed to adjust the workstation independently and continue to work for 60 minutes for an observational session.
10147863|NCT04121988||Denoising MRI group|Patients suspected of Cushing disease undergoing deep learning based denoising MRI
10147864|NCT04122027|Active Comparator|Control|Patients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.
10147865|NCT04122027|Active Comparator|Intervention|Patients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.
10147866|NCT04122014|Experimental|Control group|Usual daily activities
10147867|NCT04122014|Experimental|Training group|Each subject will participate in 2 sessions each week during 3 months.
10147868|NCT04122001|Experimental|Active HD-tDCS+word intervention then Sham+word intervention|Participants will receive active HD-tDCS + Word List Learning Intervention (WordLLI) and then receive Sham + WordLLI after a three-month washout period.
10147869|NCT04122001|Experimental|Sham+word intervention then active HD-tDCS+word intervention|Participants will receive Sham + Word List Learning Intervention (WordLLI) and then active HD-tDCS + WordLLI after a three-month washout period.
10147870|NCT04122144|Experimental|Intervention|ENHANCED-SPS intervention implemented
10147871|NCT04122144|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV care visits at the health facilities include ART card documentation as required, general/routine counseling, and adherence counseling to the non suppressors, ART drug supply based on the clinicians prescription and laboratory monitoring.
10147872|NCT04122118|Experimental|Hearth services research (pharmacist-led education)|"PHASE I: Patients' medical records are reviewed.~PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider."
9971380|NCT01310088|No Intervention|Control|Healthy age and gender matched control subjects. Recruited from school visits.
10147873|NCT04121923|Experimental|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG) will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. There will be no separate arm to test a different device.
10147874|NCT04122352|Experimental|Exercises + ischemic compression group|volunteer patients with temporomandibular joint dysfunction with trigger points
10147875|NCT04122352|Other|Exercises group|volunteer patients with temporomandibular joint dysfunction with trigger points
9971381|NCT01310101|Experimental|Ofatumumab plus dexamethasone|
9971382|NCT01310140||Major Depressive Disorder|
9971383|NCT01310140||Major Depressive Disorder with Psychotic Features|
10147876|NCT04122183|Experimental|Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation) and asked to complete the iManage Program. Six months after the screening participants will be asked if they visited an audiologist.
9669412|NCT01654159|Experimental|Multifocal|"Multifocal IOL~Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
9669413|NCT01654159|Experimental|Toric|"Toric IOL~Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
10147877|NCT04122183|No Intervention|Delayed Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation). Six months after the screening participants will be asked if they visited an audiologist and they will be given the opportunity to complete the iManage Program.
10147878|NCT04122391||control|team will work in OR with volume of 85 dB
10147879|NCT04122391||intervention|team will work in OR with volume of 100 dB
10147880|NCT04122066||respiratory symptoms reported in studied patients|If Sofosbuvir\Daclatasvir regimen has respiratory side effects or not and the factors increase incidence of respiratory complications
10147881|NCT04122105|Experimental|intervention|sildenafil administration perioperative to renal transplant
10147882|NCT04122105|Active Comparator|control|renal transplant recipients
10147883|NCT04122222|Active Comparator|Hemodialysis|ESRD patients treated by hemodialysis
9669416|NCT01572493|Experimental|Arm A1 (Dose Escalation, 10-day Dosing)|MTD determination in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
9669417|NCT01572493|Experimental|Arm A2 (Dose Expansion, 10-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
9669418|NCT01572493|Experimental|Arm B1 (Dose Escalation, 5-day Dosing)|MTD determination in subjects with metastatic unresectable cancers receiving rhIL-15 IV for 5 consecutive days
9669419|NCT01572493|Experimental|Arm B2 (Dose Expansion, 5-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 5 consecutive days
9669420|NCT01554410|Experimental|IMRT/Cisplatin/Gemcitabine|All patients get IMRT with concurrent cisplatin & gemcitabine, with the dose of gemcitabine varying according to cohort
9669421|NCT01550237|Experimental|radiotherapy daily reduced|radiotherapy, with daily CT position verification and reduced safety margins
9971384|NCT01310153|Active Comparator|Prone Positioning|Newly born infant placed in prone position (face up) for the first 30 60 seconds of life after delivery by Cesarean birth.
9971385|NCT01310153|Active Comparator|Supine Positioning|newly born infant placed in supine position (face down) for the first 30 60 seconds of life after delivery by Cesarean birth.
9971386|NCT01310166|Experimental|Fingolimod|
9971387|NCT01310192|Experimental|1|Investigational Imaging Device
9971388|NCT01310205||Hepatitis C treatment|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
9971389|NCT01310205||non cirrhotic subjects|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
10147884|NCT04122222|Active Comparator|Hemodiafiltration|ESRD patients treated by on-line hemodiafiltration
10147885|NCT04122209|Experimental|HIIE-First|60-min of exercise split into; firstly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest). Secondly 30-min of continuous exercise (50% peak maximal oxygen uptake).
10147886|NCT04122209|Experimental|Continuous-First|60-min of exercise split into; firstly 30-min of continuous exercise (50% peak maximal oxygen uptake). Secondly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest)
10147887|NCT04122092||MM patients have curative effect at least VGPR|We will detect cfDNA CIN of multiple myeloma patients who have the curative effect at least very good partial response (VGPR) after front line therapy, and then monitoring cfDNA CIN every two treatment cycles or every three months during follow up，the result will be compared with bone marrow aspiration MFC.
10147888|NCT04122248||M6-C|Subjects treated with an M6-C device
10147889|NCT04122248||ACDF|Subjects treated with Anterior Cervical Discectomy and Fusion (ACDF)
10147890|NCT04121975|Experimental|Chemoradiotherapy|"Radiation:~Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.~Drug: Endostar 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.~Drug: Cisplatin 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29."
10147891|NCT04122040|Active Comparator|roxithromycin|roxithromycin 300 mg oral per day
10147892|NCT04122040|Placebo Comparator|placebo|placebo one tablet per day
10147893|NCT04122235|Experimental|Intervention arm|New follow-up model
10147894|NCT04122235|No Intervention|Control arm|Usual care
10147895|NCT04122300|Experimental|Euphrasia arm|Euphrasia eye drops® (Weleda AG, Arlesheim) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
10147896|NCT04122300|Placebo Comparator|Placebo arm|Placebo (0.9% NaCl) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
10147897|NCT04121962|Experimental|Peer Mentor|Peer Mentor Training is 5 groups with a 30 day reunion session. This condition is focused on training participants with communication skills to promote HIV and STI home-based testing and treatment and pre-exposure prophylaxis (PrEP) to individuals in their social networks. Participants will also learn how to use the Star website to request home-based testing kits. Peer Mentor training is conducted by a two health educators. The sessions are held once a week and will last approximately 90 minutes.
10147898|NCT04121962|Active Comparator|Control|Participants will receive information on how to use the website to request at-home test kits
10147899|NCT04121910|Experimental|Savolitinib and/or Itraconazole|Treatment Period 1: Single administration of savolitinib (200 mg) will occur on Study Day 1 after a high-fat, high-calorie breakfast followed by PK sampling for 48 hours Treatment Period 2: Itraconazole will be administered (200 mg BID) on Study Day 15, and (200 mg QD) on Study Days 16 and 17, 1 hour before breakfast (and before dinner, when applicable) Treatment Period 3: A single combination of itraconazole (200 mg) 1 hour before breakfast + savolitinib (200 mg) after a high-fat, high-calorie breakfast on Study Day 18, and a single dose of itraconazole (200 mg) on Study Day 19, 1 hour before breakfast
10147900|NCT04121832|Experimental|Case|"25 people with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio Hospital. All patients over the age of 18 will be included.~Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Patients with cognitive difficulties and / or diagnoses of intellectual disability and male patients will not be included in the study. In addiction to standard therapies, the sample will be treated with 10 sessions of biofeedback training."
10147901|NCT04121832|Active Comparator|Controls|25 women with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio. All patients over the age of 18 will be included. Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Moreover, patients with cognitive difficulties and / or diagnoses of mental retardation and male patients will not be included in the study. The sample will be treated only with standard therapies without the use of biofeedback training
10147902|NCT04121884|Experimental|ART Treatment|A broad patient representation of male and female adults; aged > 18 years; English speaking; and significant clinical symptoms of any of the following conditions: PTSD, Depression, ASD, Complicated Grief, and Alcohol Abuse.
10147903|NCT04121767|Experimental|Edoxaban group|patients prescribed edoxaban after thoracoscopic ablation during window period to prevent stroke
10147904|NCT04121767|Active Comparator|Warfarin group|patients prescribed warfarin after thoracoscopic ablation during window period to prevent stroke
10147905|NCT04121741|Active Comparator|Singing intervention 1|Instructional sing-a-long video. A video series will be created and recorded for the purposes of the study. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
10147906|NCT04121741|Active Comparator|Singing intervention 2|In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
10147907|NCT04121741|Sham Comparator|Control/sham intervention|"Subjects will have a 30-minute period of rest sitting upright (as they would be positioned for the singing interventions). This arm is meant to isolate the specific effects of the treatment rather than the potential incidental effects related to the research setting and measurements. During this time, subjects will undergo hearing testing. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after the 30 minute rest."
10147908|NCT04121806|Experimental|Ulcerative colitis patients with mild to moderate activity|Participants will be followed for 14 days on their traditional diet followed by an 8 week intervention with the specially designed and provided treatment diet.
10147909|NCT04121689|Experimental|Milk Protein Concentrate|Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-[ring-2H5]phenylalanine and L-[1-13C]leucine tracer infusions, and ingested 38 g of L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein concentrate
10147910|NCT04121663|Experimental|Full seam anchor|
10147911|NCT04121663|Active Comparator|Polyether ether ketone bone anchor|
10187796|NCT03722628||LC without TTT|Blood sample from all LC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
9669422|NCT01550237|Active Comparator|radiotherapy weekly standard|radiotherapy, with weekly orthogonal position verification and standard safety margins
9669423|NCT01499888|Experimental|Allogeneic Non-Myeloablative Stem Cell Transplantation|The transplant regimen will consist of alemtuzumab 1mg/kg divided over five days, 300 cGy TBI, followed by sirolimus dosed for a target serum trough level of 10- 15 ng/mL.
9669424|NCT01405066|Experimental|Dose Reports and Educational Seminar|
9669425|NCT01204684|Experimental|Tumor Lysate-pulsed DC vaccination|Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
9669426|NCT01204684|Experimental|Tumor lysate-pulsed DC vaccination+0.2% resiquimod.|Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
9669427|NCT01204684|Experimental|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.|Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).
10147912|NCT04121637|Experimental|Aerobic exercise+Frenkel coordination Study group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set. Following this, an aerobic exercise of 30 minutes will be performed on the bicycle ergometer with electronic brake. Subjects will be advised not to do any exercise two days before or on that day and to eat only a light meal at least two hours before the test. The intensity of the exercise will be adjusted based on maximum oxygen consumption (VO2 max) specific to each individual.
10147913|NCT04121637|Active Comparator|Frenkel coordination exercise group - Control group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set.
10147914|NCT04121611|Experimental|Optical coherence tomography confirmed residual thrombus|Early antithrombotics
10147915|NCT04121611|No Intervention|Optical coherence tomography confirmed no residual thrombus|Best medical management
10147916|NCT04121520||Observational|At time of consent and within the same day of HVPG measurement, participants will be asked to complete a pre-operative assessment. Relevant statistics will be recorded during the HVPG procedure. Post-operative complication will also be collected and the satisfaction survey will be conducted.
10147917|NCT04121702|Active Comparator|PEP-H|Physical exercise program at a hospital
10147918|NCT04121702|Experimental|PEP-PSC|Physical exercise program with tele-monitoring in a public sport centre
10147919|NCT04121728|Other|Group Ginkgo-Placebo|Cross-over design: In Group Ginkgo-Placebo participants are allocated first to the IMP Symfona® during 6 months and after 2 months of wash-out period are allocated to the placebo for 6 months.
10147920|NCT04121728|Other|Group Placebo-Ginkgo|Cross-over design:In Group Placebo-Ginkgo participants are allocated first to the placebo during 6 months and after 2 months of wash-out period are allocated the IMP Symfona® for 6 months.
10147921|NCT04121793||Parkinson's Disease|Parkinson's Disease patients
10147922|NCT04121819|Experimental|AraC|cytarabine 100mg/m2 d1-5 subcutaneous
10147923|NCT04121481|Placebo Comparator|Placebo|Approximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
10147924|NCT04121481|Active Comparator|Treatment Group|Approximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
10147925|NCT04121715|Active Comparator|standard medication|"standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
10147926|NCT04121715|Experimental|standard medication+fastigial nucleus stimulation|"fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.~standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
10147927|NCT04121494|Experimental|Group A|BCG-vaccinated, 1x10^9 vp, aerosol
10147928|NCT04121494|Experimental|Group B|BCG-vaccinated, 5x10^9 vp, aerosol
10147929|NCT04121494|Experimental|Group C|BCG-vaccinated, 1x10^10 vp, aerosol
10147930|NCT04121494|Experimental|Group D|BCG-vaccinated, highest tolerated dose aerosol + placebo IM; Randomized with Group E, blind
10147931|NCT04121494|Experimental|Group E|BCG-vaccinated, highest tolerated dose IM + placebo aerosol; Randomized with Group D, blind
10147932|NCT04121494|Experimental|Group F|BCG-non vaccinated, highest tolerated dose, aerosol
10147933|NCT04121780|Experimental|Growth Hormone|Norditropin® (somatropin [rDNA origin] injection) via FlexPro® 30 mg / 3ml strength auto-injector pens (Novo Nordisk Inc).
10147934|NCT04121780|Placebo Comparator|Saline|Saline-placebo via auto-injector pens (Haselmeier Inc).
10147935|NCT04121507|Experimental|alloSCT|defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)
10147936|NCT04121845|Active Comparator|Treatment group|Coronary sinus reducer implantation through right internal jugular vein.
10147937|NCT04121845|Sham Comparator|Sham group|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
10147938|NCT04121858|Experimental|Brain Safe App|1)Brain Safe App provides conversation starters for older adult patients on target anticholinergics. The conversation starters assist the patient to have discussions with their physicians regarding reduction in exposure to prescription anticholinergics. 2) Provides anticholinergic risk assessment.
9669428|NCT00867191|Placebo Comparator|1|Placebo, 1 tablet daily, per os
9669429|NCT00867191|Active Comparator|2|Desloratadine, one 5 mg tablet daily, per os
9669430|NCT00835094|Experimental|Morning|
9669431|NCT00835094|Experimental|Evening|
9669432|NCT00834119|Experimental|Mometasone furoate|
9669433|NCT00834119|Experimental|Mometasone furoate plus an oral antihistamine|
9669434|NCT00805584|Experimental|Arm 1|
9669435|NCT00795522|Experimental|Arm 1|Desloratadine
9669436|NCT00795158|Experimental|Arm 1|
10147939|NCT04121858|Sham Comparator|Attention Control App|1) Attention Control App provides a medication list for older patients to use but lacks the conversation starters for patient to use with there physicians aimed at reduction in exposure to prescription anticholinergics.2) No anticholinergic risk assessment.
10147940|NCT04121585||SL-PLUS™ hydroxylapatite coated cement free hip stem|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
10147941|NCT04121533|Placebo Comparator|Placebo|Matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
10147942|NCT04121533|Experimental|Vitamin D|Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
10147943|NCT04121533|Experimental|Vitamin D, glucosamine sulfate, and omega-3 fatty acids|Vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids). Supplements taken daily for 84 days (12 weeks).
10147944|NCT04121442|Experimental|Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor|Patients will receive specified dose of Isunakinra as monotherapy for three weeks, followed by combination with a PD-(L)1 inhibitor
10147945|NCT04121273|Experimental|CAR-T cells|CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.
10147946|NCT04121156|Active Comparator|2 milli Amp dose of HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
10147947|NCT04121156|Sham Comparator|Sham (placebo) dose of HD-tDCS treatment|Sham (placebo) dose of HD-tDCS treatment for 20 minutes, for 5 consecutive twice daily sessions
10147948|NCT04121364|Experimental|Tetranite|All patients enrolled in study will receive the dental adhesive with a dental implant. The robustness of the dental implant stability will be assessed at various time points.
10147949|NCT04121208|Active Comparator|Active drug: JNJ-40346527|"A single initial randomisation site will be set up for Part 1 that will assign participants to JNJ-40346527 300 mg Bis in die - twice a day (BID) or placebo in a 2:1 ratio.~A second randomisation site will be setup for Part 2 depending on which scenario is adopted.~Either a Part 2, Scenario 1 site will assign participants to JNJ-40346527 150 mg BID, JNJ-40346527 50 mg BID or placebo in a 2:2:1 ratio or a Part 2, Scenario 2 site will assign participants to JNJ-40346527 150-50 mg BID or placebo in a 2:1 ratio."
10147950|NCT04121208|Placebo Comparator|Placebo|Non-active study drug
10147951|NCT04121195|Other|Dose escalation sequence (all participants)|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
10147952|NCT04121247|Experimental|Experimental: Parents in Chad will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
10147953|NCT04121247|Experimental|Experimental: Parents in Turkey will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
10147954|NCT04121143|Active Comparator|Treatment group A|SHR-1314 low dose short intervals of subcutaneous injection
10147955|NCT04121143|Active Comparator|Treatment group B|SHR-1314 high dose long intervals of subcutaneous injection
10147956|NCT04121143|Active Comparator|Treatment group C|SHR-1314 high dose short intervals of subcutaneous injection
10147957|NCT04121143|Placebo Comparator|Placebo group|Placebo was subcutaneously injected into the 16 weeks turnover SHR-1314 subcutaneous injection
10147958|NCT04121416|Experimental|Oxycodone group|
10147959|NCT04121416|Experimental|Sufentanil group|
10147960|NCT04121039|Experimental|Apatinib plus POF|Participants will receive apatinib in combination with POF,total 9-12 cycles.Then receive apatinib plus S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10147961|NCT04121039|Active Comparator|POF|Participants will receive POF,total 9-12 cycles.Then receive S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10147962|NCT04121338|Experimental|Test group|10 patients with presumptive diagnosis of dysautonomia with chronic nausea, vomiting and food intolerance
10147963|NCT04121403|Active Comparator|Rituximab|Biosimilar rituximab concentrate for solution for infusion
10147964|NCT04121403|Active Comparator|Cladribine|Mavenclad oral cladribine tablets
9971390|NCT01310218|Other|extended postoperative dressing|Bulky dressing for 2 weeks
9971391|NCT01310218|Other|short postoperative dressing|2 day bulky dressing followed by bandaid.
9669437|NCT00794846|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9669438|NCT00794846|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9669439|NCT00794768|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
10147965|NCT04121390||Newborn Parenting Class|New Mother who attended the Newborn Parenting Class
10147966|NCT04121390||New Mothers|New Mothers who expressed interest, but did not attend the Newborn Parenting Class
10147967|NCT04121104|Experimental|SCS off|
10147968|NCT04121104|Experimental|SCS on|
10147969|NCT04121377|Experimental|Resistance exercise program|Early resistance exercise sessions and home program
10147970|NCT04121091|Experimental|Pramipexole|
10147971|NCT04120948|Experimental|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
10147972|NCT04120948|Active Comparator|Tongue scraper|tongue scraping
10187797|NCT03722628||Healthy control|MMP1-genotype polymorphism will be applied on those healthy people to detect which type of mutation occur in healthy rather than diseased.
10147973|NCT04120792|Experimental|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
10147974|NCT04120792|Active Comparator|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
10147975|NCT04120792|Active Comparator|Cognitive training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
10147976|NCT04120792|Active Comparator|Neutral Video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
10147977|NCT04121130|Active Comparator|Group A (F-ESWT Group)|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
10147978|NCT04121130|Placebo Comparator|Group B (sham F-ESWT):|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
10185281|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine High-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=high dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
10185282|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Low|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=low dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
10185283|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Mid|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=mid dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
10185284|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine High|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=high dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
10187798|NCT03722602|Experimental|Rehabilitation group|Patients with stroke receiving standard inpatient rehabilitation for five weeks
10187799|NCT03722589|Active Comparator|Flublok (Recombinant)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
10187800|NCT03722589|Active Comparator|Flucelvax (Cell-based)|Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
10187801|NCT03722589|Active Comparator|Fluarix (Egg-based)|Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
10187802|NCT03722589|Active Comparator|Fluzone (Egg-based)|Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
10187803|NCT03722589|Active Comparator|Fluzone (Egg-based) High-Dose|Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain
10187804|NCT03722563|Active Comparator|TLHS|total laparoscopic hysterectomy with sacrocolpopexy will be performed
10187805|NCT03722563|Experimental|TLHLS|total laparoscopic hysterectomy with lateral suspension will be performed
10187806|NCT03722537|Active Comparator|Ligament Reconstruction Tendon Interposition (LRTI)|Selected randomly, 100 patients will receive this treatment. During the LRTI (standard of care procedure), the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
10187807|NCT03722537|Experimental|Osteochondral Allograft|Selected randomly,100 patients will receive this treatment. In this procedure, the arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface, known as the 'Cartibend©' .
10187808|NCT03722498|Experimental|HAIC of FOLFOX|Hepatic arterial infusion chemotherapy with oxaliplatin, leucovorin, and 5-fluorouracil
10187809|NCT03722498|Active Comparator|Sorafenib|Sorafenib 400 mg orally twice a day
10187810|NCT03722485|Experimental|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|V.A.C. VeraFlo Cleanse Choice Dressing, V.A.C.Ulta Therapy Unit and saline solution
10187811|NCT03722485|Active Comparator|Collagenase Ointment|Collagenase Ointment
10187812|NCT03722472|Experimental|Single-vial ID93 + GLA-SE|Single-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
10187813|NCT03722472|Active Comparator|Two-vial ID93 + GLA-SE|Two-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
10187814|NCT03722433|Experimental|probiotic plus 14-day sequential therapy|D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
10187815|NCT03722433|Placebo Comparator|placebo plus 14-day sequential therapy|D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
10187816|NCT03722420|Experimental|Radotinib 300mg|Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
10187817|NCT03722420|Active Comparator|Imatinib 400mg|Oral administration of Imatinib 400mg QD (400mg/day) for 12months
10187818|NCT03722394|Experimental|Pain Neuroscience Education|Subjects received a 15-minute verbal, one-on-one Pain Neuroscience Education (PNE) session
10147979|NCT04120883|Experimental|HCQ treatment 1|In treatment arm 1, the dose of study drug will be 4 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
10147980|NCT04120883|Experimental|HCQ treatment 2|In treatment arm 2, the dose of the study drug will be 5 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
9971392|NCT01310244|Experimental|Single arm, open label|"At the study entry each patient will receive a dose level assignment which will include a specific dose level and the dose of IV belinostat in mg/m2 to be administered during the study treatment.~Belinostat will be infused over 30 minutes once daily on Days 1-5 of each 21-day cycle. On Day 3, the infusion of belinostat must be completed at least 1 hour prior to the start of the paclitaxel infusion. Dose of belinostat will be assigned at study entry. The same dose and level will remain throughout the entire study for each patient and no dose adjustment will be allowed, except due to toxicity."
9971393|NCT01310257||Knee osteoarthritis|Patients will have osteoarthritis (OA) of the knee defined and scored radiologically in Study 1. Patients in Study 2 will also have OA of the knee, but a clinical diagnosis will suffice. All patients will report knee pain.
9971394|NCT01310270|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation
9971395|NCT01310270|Placebo Comparator|Placebo|
9971396|NCT01310283|No Intervention|control group|Conventional pediatric dental care.
9971397|NCT01310296|Other|Radiolabeled Lofexidine Oral Solution|Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.
10147981|NCT04121117||Tobacco detoxication cohort|Patients appointed in a tobacco detoxication consultation
10147982|NCT04120779|Experimental|The EMPOWER-SUSTAIN e-Health Intervention|The EMPOWER-SUSTAIN intervention is a multifaceted chronic disease management strategies based on the Chronic Care Model (CCM) and persuasive technology (PT) theory. It consists of training physicians and patients to use the EMPOWER-SUSTAIN web-based self-management intervention mobile apps, strengthening patient-physician relationship and reinforcing the use of relevant clinical practice guidelines for management and prescribing.
10147983|NCT04120779|No Intervention|Control|The control group will continue to receive usual care at the university primary care clinic. They will be given the EMPOWER-SUSTAIN Global CV Risks Self-Management Booklet©, as this is considered as usual care at the university primary care clinic. The EMPOWER-SUSTAIN web-based self-management tool will be made available to the control group at the end of the study. During the course of the study, there will be no limit to the number of clinic visits that a patient is allowed to make in either the intervention or control groups.
10147984|NCT04120987|Active Comparator|Lifitegrast|One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.
10147985|NCT04120987|No Intervention|Control|No treatment
10147986|NCT04120753|Experimental|1|
10147987|NCT04120753|Experimental|2|
10147988|NCT04120753|Active Comparator|3|
10147989|NCT04121052|Experimental|Treatment Sequence 1|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147990|NCT04121052|Experimental|Treatment Sequence 2|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147991|NCT04121052|Experimental|Treatment Sequence 3|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147992|NCT04121052|Experimental|Treatment Sequence 4|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147993|NCT04121052|Experimental|Treatment Sequence 5|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147994|NCT04121052|Experimental|Treatment Sequence 6|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10185285|NCT03747315||Familial Mediterranean Fever (patients)|Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)
9971398|NCT01310296|Experimental|Lofexidine Intravenous Solution|Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.
10147995|NCT04121052|Experimental|Treatment Sequence 7|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147996|NCT04121052|Experimental|Treatment Sequence 8|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147997|NCT04121052|Experimental|Treatment Sequence 9|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147998|NCT04121052|Experimental|Treatment Sequence 10|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10147999|NCT04121052|Experimental|Treatment Sequence 11|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10148000|NCT04121052|Experimental|Treatment Sequence 12|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions ( low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10148001|NCT04121052|Experimental|Treatment Sequence 13|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10148002|NCT04121052|Experimental|Treatment Sequence 14|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10148003|NCT04121052|Experimental|Treatment Sequence 15|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
10148004|NCT04121052|Experimental|Treatment Sequence 16|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
9971399|NCT01310309||EXecutive Registry|A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).
10148005|NCT04121221|Experimental|GA Depot|Monthly IM injection
10148006|NCT04121221|Placebo Comparator|Placebo|Monthly IM injection
10148007|NCT04120818||SIOL group|aphakic children diagnosed with congenital cataract who underwent secondary IOL implantation
10148008|NCT04120818||PIOL group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and primary IOL implantation
10148009|NCT04121065||Relapsing MS patients|Single Arm: Relapsing Multiple Sclerosis patients ADA SNPs and other biomarkers analyses in blood samples.
10148010|NCT04120896|Experimental|Karate group|
10148011|NCT04120896|Active Comparator|Kung Fu group|
10148012|NCT04121169|Other|Adults subjects with CDI receiving 10g a day|5 g twice a day for 10 - 14 days
10148013|NCT04121169|Other|Adults subjects with CDI receiving 20g a day|10 g twice a day for 10 - 14 days
10148014|NCT04121169|Other|Adults subjects with CDI receiving 40 g a day|20 g twice a day for 10 - 14 days
10148015|NCT04121013|Active Comparator|Mothership|Acute stroke patients with suspected large vessel occlusion will be directly transferred to the nearest transportation to the endovascular center
9669440|NCT00794768|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9971400|NCT01310322|Experimental|1|AZD5423 iv
9971401|NCT01310322|Experimental|2|AZD5423 inhalation, Spira
10148016|NCT04121013|No Intervention|drip'n'ship|Acute stroke patients with suspected large vessel occlusion will be transferred to the closest local stroke centre or telemedicine hub as done with the current stroke protocol
10148017|NCT04120844|Experimental|Intervention|Patients in the intervention group (n=117) received a four-session PEP in small groups over one month by trained nurses and doctors.
10148018|NCT04120844|Placebo Comparator|Control|The control group (n=108) received the traditional lecture-style health education on Diabetes Mellitus.
10148019|NCT04120857|No Intervention|Educational Control Group|Education provided for optional use
10148020|NCT04120857|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly
10148021|NCT04121000|Experimental|Erector Spinae Block for VATS Group|40 patients who had VATS will receive erector spinae block for postoperative pain management. All patients will receive IV Midazolam (0.05mg/kg) premediacation. Standard monitorization of EKG, non- invasive blood pressure and pulsoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the induction and in the prone positon the ESB procedure will be done. 10 % povidon- iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done at the 8th thoracic vertebra line. The USG probe will be replaced 2-3 cm lateral to the spinous process in sagittal plane. When the erector spinae muscle is identified in the USG the needle will be guided caudally.0.5-1 ml local anesthetics will be given in order to confirm the needle is in the right place. After confirmation with 20 mL %0.25 bupivacaine the procedure will be performed.
10148022|NCT04121000|Experimental|Patient - Controlled Analgesia for VATS Group|40 patients who had VATS will receive IV PCA for postoperative analgesia managemnet.
10148023|NCT04120974|Experimental|Optimal insulin injection|Study subjects will receive personal training from the Investigator on how to optimally inject insulin to treat their Diabetes Mellitus. In addition, each subject receives instruction how to use a web-based platform with online video training modules on optimal injection technique.
10148024|NCT04120805|Experimental|Group 1 (Hemostatic Agents Plus +)|
10148025|NCT04120805|Active Comparator|Group 2 (Hemostatic Agents Negative -)|No Hemostatic Agent
10148026|NCT04120935||Cohort of CRC patients|Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.
10148027|NCT04120922|Other|calcium carbonate|"Calcium based P-binder - calcium carbonate: Typical dose is 500mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
10148028|NCT04120922|Other|sevelamer carbonate|"Calcium (Ca) free P-binder - sevelamer carbonate: Typical dose is 800mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
10148029|NCT04120831|Experimental|Rituximab + Abatacept + MTX|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
10148030|NCT04120831|Active Comparator|Rituximab + MTX (standard of care)|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
10148031|NCT04120961|Experimental|prolonged continuous use of bivalirudine|A total of 165 patients are assigned to group with prolonged continuous use of bivalirudin after randomization schedule.
10148032|NCT04120961|Other|bivalirudin use during ePCI|A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.
10148033|NCT04120649||endomterial cancer|All patients visiting the clinic at Women Health Hospital who having endometrial carcinoma with their diagnosis based on investigations (tumor marker ) , imaging, histopathology will have surgical staging consisted of total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
10148034|NCT04120636|Experimental|Phase I open label study|"Drug: Episcleral Celecoxib~Other Names:~Sequestered, Transscleral, Controlled-Release Celecoxib~Sustained Release Transscleral Celecoxib"
10148035|NCT04120623|Experimental|Dapagliflozin combined with CSII|Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.
10148036|NCT04120623|Active Comparator|CSII alone|Aspart infused by CSII alone as glucose lowering therapy.
10148037|NCT04120571|Experimental|experimental|Sleep Audiological Intervention Device (SleepAID)
10148038|NCT04120571|Sham Comparator|control|no sound
10148039|NCT04120662|Active Comparator|Group A: Surgery group|Surgical procedure according to the injury type
10148040|NCT04120662|Active Comparator|Goup B: Shockwave group|3 weekly sessions of Focused Shock Wave Treatment (F-ESWT), using an electrohydraulic device set to an energy flux density (EFD) of 0.21 mJ/mm2 and 2000 impulses
10148041|NCT04120675|Experimental|Experimental group|"Experimental Group 20 patients on Early Harvest Extra Virgin Olive Oil Aluminum bottle with 500 ml of early harvest extra virgin olive oil (3 tablespoons per day).~Dietary Supplement: Early Harvest Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
9519799|NCT03283202|Experimental|Avadomide (CC-122) plus R-CHOP-21|Avadomide (CC-122) by mouth (PO) at varying dose levels (Ph 1) on Days 1 through 5 and Days 8 through 12 plus Rituxan 375 mg/m2 by intravenous (IV) infusion, cyclophosphamide 750mg/m2 by IV infusion, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 (max is 2.0 mg) IV and 100 mg PO prednisone/prednisolone on Days 1 through 5 of each 21-day treatment cycles for up to 6 total treatment cycles (approximately 18 weeks or 4 months)
9971402|NCT01310322|Experimental|3|AZD5423 inhalation I-neb
9971403|NCT01310322|Experimental|4|AZD5423 oral
10148042|NCT04120675|Active Comparator|Control group|10 patients will not receive treatment with Extra Virgin Olive Oil
10148043|NCT04120376|Experimental|Counseling Intervention|All participants will receive contraception counseling.
10148044|NCT04120363|Placebo Comparator|Placebo|single intramuscular injection of 3 mL sesame oil solution on Day 8
10148045|NCT04120363|Experimental|Testosterone|single intramuscular injection of 750 mg testosterone undecanoate on Day 8
10148046|NCT04120428|Experimental|Experimental protocol|24-week aquatic exercise training program
10148047|NCT04120428|No Intervention|Control protocol|Maintain lifestyle routine as usual
10148048|NCT04120311|Experimental|Phase I open label study|"Drug: Episcleral Dexamethasone Sequestered Transscleral, Controlled-Release Dexamethasone~Other Names:~• Sustained Release Transscleral Dexamethasone"
10148049|NCT04120441|Experimental|Group mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
10148050|NCT04120441|No Intervention|Routine care/control|Study participants randomized to control will receive information about community resources. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
10148051|NCT04120506|Experimental|Rapid infusion of Vpriv|: Infusions at Baseline and during step-wise rate increases and End-of-study will be performed in the Shaare Zedek Medical Center (SZMC) by the Study Nurse who will monitor vital signs (see below) for a total of 8 visits at SZMC. Home therapy will be approved if the patient so desires for 5 infusions in Phase 1 and for the first 5 infusions in Phase 3. All routine hematological and biochemical tests will be performed in the SZMC clinical labs. Abdominal quantitative MR Imaging (MRI) for spleen and liver volumes will be performed at SZMC
10148052|NCT04120324||Eligible & Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty and is discharged home on the day of surgery.
10148053|NCT04120324||Eligible but NOT Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty but is NOT discharged home on the same day as the surgery, and remains in hospital for a minimum of one night following surgery. Reasons for not being discharged same day include potential problems related to Surgery (eg. complication), Anesthesia (eg. prolonged effect), or patient factors (egs. pain, nausea, mobility difficulties, etc.).
10148054|NCT04120324||Not Eligible for Discharge Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and/or Anesthesia deems the patient to NOT be eligible for Same Day Discharge. The patient undergoes Primary Single Joint Total Hip Arthroplasty and remains for a minimum of one overnight in hospital following hip replacement surgery.
10148055|NCT04120389|Experimental|BCL group|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)
10148056|NCT04120389|Active Comparator|control group|
10148057|NCT04120259|Active Comparator|Group 1|Intervention: Metformin Tablet oral 750 mg OD
10148058|NCT04120259|Experimental|Group 2|Intervention: Metformin 750 mg oral plus 2 tablespoons of apple cider vinegar OD
10148059|NCT04120350|Experimental|R2-MTX-LEN|"Phase Ib：Experimental arm will be treated with R2-MTX regimen for 6 cycles as initiate induction, the dose of lenalidomide was escalated from 15mg， 20mg， 25mg to test DLT by 3+3 design, meanwhile the dose of rituximab and methotrexate is fixed. If the patients achieved CR or PR by MRI and CSF evaluation, they processed to lenalidomide maintenance for 2 years.~Phase II: the patients will be treated by fixed dose of R2-MTX regimen (established lenalidomide dose from phase Ib study) for 6 cycles. the efficiency evaluation will be performed every 2 cycles, the patients who achieved CR or PR will finish the total 6 cycles of induction therapy, then begin the stage of lenalidomide maintenance for 2 years. Follow-ups should be taken for 5 years."
10148060|NCT04120519|Experimental|TCD|thalidomide 100mg qn cyclophosphamide 300mg/m2 d1,8,15 dexamethasone 40mg d1,8,15,22
10148061|NCT04120415|Experimental|Vaccine and Vedolizumab infusion|"Vaccine:~The vaccine is MVA HIV-B which is a solution of HIV MVA vectors in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)."
10148062|NCT04120415|Experimental|Placebo vaccine and Vedolizumab infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)"
10148063|NCT04120415|Placebo Comparator|Placebo vaccine and placebo infusion|"Placebo vaccine:~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).~Placebo infusion:~Sodium Chloride (NaCl) 0.9% administered as an intravenous infusion (255ml)"
10148064|NCT04120688|Active Comparator|Effect on surgery|Duration of surgery, degree of manipulation of the transplant
10148065|NCT04120688|Active Comparator|Success of transplantation|Normal eruption and root development of the transplant
10148066|NCT04120532|Experimental|Education group|
10148067|NCT04120532|No Intervention|Usual care group|
10148068|NCT04120337|Experimental|RemovAid Device + lidocaine patch|Test device with lidocaine patch for local anesthesia
10148069|NCT04120337|Experimental|RemovAid Device + lidocaine injection|Test device with lidocaine injection for local anesthesia
10148070|NCT04120337|Active Comparator|Standard removal technique + lidocaine injection|Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia
10148071|NCT04120194|Experimental|NanoFlu|NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
10148072|NCT04120194|Active Comparator|Fluzone Quadrivalent|Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
10148073|NCT04120207|Experimental|Home-based Pilates|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
10148074|NCT04120207|Other|Delayed-Start Control|Participants randomized to Delayed-start will be instructed to maintain their pre-intervention physical activity levels during the trial and will be contacted by the lead researcher by email or telephone to ensure timely completion of the on-line outcome assessments at biweekly intervals. Following the 8-week intervention, Delayed start participants will be provided with the Pilates DVD for their own use, but no data will be collected. For both groups, participants who experience a relapse will be immediately withdrawn from the study, which will be recorded by the lead researcher.
10148075|NCT04120103|Experimental|Doll therapy|"Experimental: Doll Therapy Intervention A total of 30 patients were included in the study. All patients that meet the study inclusion criteria will be included in the study The patients in the intervention group will have Doll therapy for 60 days and weekly patient visits. The study will be started with control group patients. At the beginning of the study and after 60 days, Introductory Information Form, Mini Standard Mini Mental Test and Cohen-Mansfield Agitation Inventory will be applied to patients in intervention and control groups for data collection. Dementia patients will be given a baby, patients will be followed for two months. There will be monitoring once a week."
10148076|NCT04120103|Active Comparator|Routine nursing care|"The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.~There was no intervention other than routine care. The patients were followed up for two months.The patients were followed up for two months.Data collection forms were applied at the beginning, first and second months of the study."
10148077|NCT04119921|Active Comparator|usage of topical ketorolac in group1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
10148078|NCT04119921|Active Comparator|usage of artificial tear in group 2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
10148079|NCT04119921|Active Comparator|usage of artificial tear in group 1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval
10148080|NCT04119921|Active Comparator|usage of topical ketorolac in group2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval
10148081|NCT04119908|Experimental|Patients with haemorrhagic disease|Patients with von Willebrand disease or Patients with Glanzmann Thrombasthenia
10148082|NCT04119908|Other|Control group|Patients with moderate or severe hemophilia A or women carrying the hemophilia gene
9519800|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
9519801|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
10148083|NCT04120090|Active Comparator|Low dose|
9971404|NCT01310335|Experimental|Training|The whole-body vibration (WBV) training
9971405|NCT01310348|Placebo Comparator|Very low magnitude vibration|Very low magnitude vibration
9971406|NCT01310348|Experimental|Training|The whole-body vibration (WBV) training
10148084|NCT04120090|Experimental|High dose|
10148085|NCT04120077|Placebo Comparator|DSME + placebo supplement (group 1)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects be instructed to consume two capsules (canola oil soft-gels) per day in the morning and two capsules per day in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
10185286|NCT03747315||Control group (patients)|Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.
10185287|NCT03747315||Healthy donors|Patients without symptoms (anonymous blood donors)
10185288|NCT03747302|Experimental|HPV Messaging|Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
9669441|NCT00794599|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9826175|NCT02411084|Experimental|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
9519802|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
10148086|NCT04120077|Experimental|DSME + DVS supplement (group 2)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (canola oil placebo) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
10148087|NCT04120077|Experimental|DSME + DVS supplement + omega-3 supplement (group 3)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (EyePromise EZTears) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
10148088|NCT04120064|Experimental|Large bolus|
10148089|NCT04120064|Active Comparator|Standard|
10148090|NCT04119934||Control - None|A retrospective chart review will assess physician behaviour (rates of smoking cessation counselling and prescription of smoking cessation pharmacotherapy) in the one-year pre-intervention period.
9826176|NCT02411084|Active Comparator|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
9826177|NCT02411110|Experimental|LiRIS® (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
9826178|NCT02411110|Other|LiRIS Placebo (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment period 1: Matching placebo device to LiRIS inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
9826179|NCT02411201|Experimental|DOTAREM|
10148091|NCT04119934||Intervention - Smoking cessation infographic|Throughout the intervention period, the personalized smoking cessation infographic will be provided to physicians (for eligible patients). Chart review will be conducted for the patient's physician within a three-month window of receiving the infographic to assess outcomes.
10148092|NCT04120142|Experimental|IMT goup|Inspiratory muscle training + aerobic exercice
10148093|NCT04120142|Active Comparator|Control group|aerobic exercice
10148094|NCT04119999|Active Comparator|CPAP|Continuous Positive Airway Pressure
10148095|NCT04119999|Experimental|MAD|Mandibular Advancement Device
10148096|NCT04120181||Control|The control group consists of 13 age- and gender-matched subjects who underwent CI surgery but showed no complications. The members of the control group were selected based on hospital records.
10148097|NCT04119856|Other|Intervention group|"Affiliation with outgoing lung team~Instructions and teaching by the outgoing lung team.~Needs-based consultation at Dept. of Respiratory Diseases and Allergy.~Contact to the outgoing lung team in case of exacerbation of COPD."
10148098|NCT04119856|No Intervention|Control group|"The usual practice~Scheduled consultations at Dept. of Respiratory Diseases and Allergy.~Contact to GP/doctor on call in case of exacerbation of COPD."
10148099|NCT04119752|Active Comparator|Curcumin powder|Curcumin powder - 10g
10148100|NCT04119752|Placebo Comparator|Placebo ( curcumin depleted)|Placebo- sucralose -1g
10148101|NCT04119778|Experimental|Aerobic Exercise|The exercise intervention will last 16 weeks, comprised of home-based exercise with weekly telephone counselling to encourage participants to continue to exercise, supplemented with 8 supervised exercise sessions (2 sessions per month). Each session will last for an hour. The supervised exercise sessions will be provided by professional exercise specialists twice in the first week in each month throughout the intervention period, an hour each time. Exercise trainers will lead the classes. Each class will include both aerobic exercise and resistance exercise. They are encouraged to do aerobic exercise for at least 150 min weekly at a moderate intensity level, as well as perform resistance exercises alternate day. Participants are also provided an exercise diary, containing details of their weekly prescribed exercises and the scales they have to refer to.
10148102|NCT04119778|Experimental|Tai chi|Our tai-chi classes will be based on a 16-form tai-chi exercise set. The classes will run twice a week for 16 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 16 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
9971407|NCT01310361|Experimental|Amoxicillin|Once-daily Therapy for Streptococcal Pharyngitis With Amoxicillin
9519803|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
9971408|NCT01310361|Active Comparator|Benzathin Penicillin G|Once-daily Therapy for Streptococcal Pharyngitis With Intramuscular Benzathin Penicillin G
10148103|NCT04119778|No Intervention|Self Management Group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 16 weeks and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
10148104|NCT04119791|Experimental|Wild rice|Participants will consume one serving of the test food containing wild rice every day over 28 days.
10148105|NCT04119895|Experimental|NMES and exercise|Neuromuscular electrical stimulation and core stabilization exercise
10148106|NCT04119895|Sham Comparator|Sham NMES and exercise|Sham neuromuscular electrical stimulation and core stabilization exercise
10148107|NCT04119947|Experimental|SY-009 dose 1|A single dose of SY-009 (0.5-40mg) taken orally.
10148108|NCT04119947|Experimental|SY-009 dose 2|A single dose of SY-009 (0.5-40mg) taken orally.
10148109|NCT04119947|Experimental|SY-009 dose 3|A single dose of SY-009 (0.5-40mg) taken orally.
10148110|NCT04119947|Experimental|SY-009 dose 4|A single dose of SY-009 (0.5-40mg) taken orally.
10148111|NCT04119947|Experimental|SY-009 dose 5|A single dose of SY-009 (0.5-40mg) taken orally.
10148112|NCT04119947|Experimental|SY-009 dose 6|A single dose of SY-009 (0.5-40mg) taken orally.
10148113|NCT04119947|Placebo Comparator|SY-009 matching placebo|from 2-40mg
10148114|NCT04119726|Other|Control Group|The control group will receive a simplified tool including only the education message. The methodology will ensure that potential confounders by differences in nonspecific support and attention could be adjusted. Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behavior. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
10148115|NCT04119726|Experimental|Intervention Group|The intervention group will receive a complete social medial tool (web-based application ) installed on mobile phones including general education about coronary disease、personalized reminders and internet-based counseling. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
10148116|NCT04119882||Positive for ischaemia|Blood test for 121 patients with confirmed cardiac ischemic event
10148117|NCT04119882||Negative for ischaemia|Blood test for 283 patients with no cardiac ischemic event
10148118|NCT04119869|Experimental|iaya Smart Phone Application|"Pre-study evaluation~Access to the smartphone intervention over the course of 12 weeks~Post-study evaluation and interview"
10148119|NCT04120051|Experimental|Fermented canola-seaweed supplement|Ingredients: Canola meal, seaweed, wheat, glucose, Vitamin D and lactic acid bacteria
10148120|NCT04120051|Placebo Comparator|Placebo|Ingredients: Rye flour, water, iodized salt, brown sugar
10148121|NCT04119622|Experimental|XELOX combined with Toripalimab|
10148122|NCT04119817|Experimental|Mucosave® capsules|60 healthy volunteers taking 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day after dinner before going to bed.
10148123|NCT04119817|Placebo Comparator|Placebo|40 healthy volunteers taking capsules of placebo for a period of 8 weeks, once a day after dinner before going to bed.
10148124|NCT04120129|Experimental|TMS treatment|participants receive TMS treatment
9519804|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
9519805|NCT03283189||Group 6|Liberal follow-up of pregnancy
9519806|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
10148125|NCT04120129|Sham Comparator|sham TMS|participants receive control TMS treatment
10148126|NCT04120129|No Intervention|non intervention|control group
10148127|NCT04119700|Active Comparator|Muco-muscular endorectal advancement flap|After fistulectomy a muco-muscular endorectal advancement flap is mobilised and fixed to anoderma
10148128|NCT04119700|Experimental|Primary sphincter reconstruction|After fistulectomy the defect in anal sphincters is closed
10148129|NCT04119648|Experimental|CAMS-4Kids|Participants will receive up to 10 sessions of CAMS-4Kids
10148130|NCT04119557|Experimental|LY3471851|LY3471851 administered subcutaneously (SC)
10148131|NCT04119557|Placebo Comparator|Placebo|Placebo administered SC
10148132|NCT04120272||Delirium group|Group of patients with postoperative delirium
10148133|NCT04120272||Non delirium group|Group of patients without postoperative delirium
10148134|NCT04119570|No Intervention|No intervention|Participants will have their clinic visit as per usual care.
10148135|NCT04119570|Active Comparator|CKD Report Card|Participants will receive the CKD Report Card prior to the clinic visit.
9519807|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
9971409|NCT01310387|Experimental|active pain management|active pain management (APM) by specialized nurses for cancer pain
10148136|NCT04119440|Experimental|Low Dose|Vaccination with 2x10^7 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
10148137|NCT04119440|Experimental|High Dose|Vaccination with 2x10^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
10148138|NCT04119440|Placebo Comparator|Placebo|Injection with placebo. Injections will be administered at days 0, 28 or 56, and 336.
10148139|NCT04119388|Experimental|Adapted sports practice|patients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.
10148140|NCT04119349|Experimental|Counseling|Women are given extra 15-minute counseling on the pros and cons of all different methods for prenatal testing including no testing at all
10148141|NCT04119349|No Intervention|Standard care|Women receiving standard care by means of counseling
10148142|NCT04119583|Experimental|U-shape Automatic Electric Toothbrush|
10148143|NCT04119583|Active Comparator|Usual home toothbrushing procedure|
10148144|NCT04119583|No Intervention|No toothbrushing|
10148145|NCT04119583|Active Comparator|Conventional Electric Toothbrush|
10148146|NCT04119661|Experimental|Max-i-Probe|
10148147|NCT04119661|Active Comparator|NaviTip|
10148148|NCT04119674|Experimental|Arm|Experimental: arm Biological: Anlotinib Drug: Temozolomide Radiotherapy:2.0 Gy/fraction ×30 fractions Monday to Friday total dose of 60Gy
10148149|NCT04119401|Active Comparator|doppler-guided|ligation of hemorrhoidal arteries with doppler guidance
10148150|NCT04119401|Experimental|finger-guided group|ligation of hemorrhoidal arteries without doppler guidance but with finger detection
10148151|NCT04119596||Diagnosed Parkinson's disease|Patients with incident Parkinson's disease
10148152|NCT04119596||Control|Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria
10148153|NCT04119466|Experimental|Protrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
10148154|NCT04119466|Experimental|Extrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
10148155|NCT04119518|Other|Healthy and hypertensive subjects|Subjects will be enrolled to be monitored for 24 hours via: the non-occlusive CSEM Pulse Watch, and a gold standard oscillometric device (Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM.
10148156|NCT04119427|Experimental|Test Group|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
10148157|NCT04119427|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
10148158|NCT04119492|Experimental|CO-OP Treatment Group|Participants in the treatment group will receive occupational therapy once weekly for 10 weeks using the published protocol for the CO-OP approach.
10148159|NCT04119492|No Intervention|Waitlist Control Group|Participants in the waitlist control group not receive CO-OP intervention during this time. They will receive their CO-OP intervention 12 weeks after their baseline assessment.
10148160|NCT04119297|Active Comparator|Control|Routine care (Irregular cold application or gauze bandages wetted with isotonic solution or once daily heparinoid cream application) of the clinic was applied.
10148161|NCT04119297|Experimental|Cold application|Cold application was applied for three days after craniotomy.
10148162|NCT04119297|Experimental|Heparinoid group|Heparinoid cream was applied for three days after craniotomy
10148163|NCT04119739|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
10148164|NCT04119739|Active Comparator|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
9826180|NCT02411292|Experimental|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
9826181|NCT02411396||Patients With SCD|Patients treated for uncomplicated VOC in ICs and EDs.
10148165|NCT04119739|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
10148166|NCT04119102|Experimental|Open Label Duobrii|Duobrii QD
10148167|NCT04119180|Experimental|Sedation|The child receives sedatives approved for use in an outpatient setting, directed by a doctor, to accomplish the dental treatment.
10148168|NCT04119180|Other|Control|The child does not receive sedatives. As s/he exhibits negative behavior for the dental procedure, s/he will be restrained by a family member and dental team.
10148169|NCT04118946|Active Comparator|intravesical instillation|Intravesical instillation of platelet enriched plasma every week for 6 weeks
10148170|NCT04118946|Active Comparator|submucosal injection|submucosal injectionof platelet enriched plasma
10148171|NCT04119076|Experimental|Intervention Group|Teacher delivered a 10 minute classroom-based physical activity on school days for eight weeks.
10148172|NCT04119076|Other|Control Group|Children in the control schools continued with their usual school routine
10148173|NCT04119245|Experimental|study group|"after induction of general anesthesia, a proper size of Igel will be inserted after compelete muscle relaxation. In order to confirm proper positioning of the I-gel,a fiberoptic bronchoscope will be pass through the device and pushed forward up to1 cm proximal to it to obtain a glottic view, leak airway pressure test will be done.~Afterwards the same patient will be placed in the lateral decubitus position ,confirmation of I-gel position using fiberoptic bronchoscope will be done and recorded.The leak air way pressure test will be done as previously done in supine position and recorded.~The patient will be returned to supine position."
10148174|NCT04119258||Psychiatric patients|Psychiatric outpatient care patients with major depressive disorder, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, or illness anxiety disorder who have just completed cognitive-behavioral therapy.
9971410|NCT01310426||anal sphincter damage|After assessing women after vaginal delivery, a comparison will be made between those with anal sphincter damage and those women without.
10148175|NCT04118920|Experimental|Topical insulin|Patients will receive topical insulin eye drops.
10148176|NCT04118972|Experimental|Functionality Mirror Exposure & Journal|"A text-based functionality gratitude journaling prompt three times weekly paired with three weeks of weekly functionality-based guided mirror exposure sessions in the lab (the IM FAB program)"
10148177|NCT04118972|Active Comparator|Pure Mirror Exposure & Gratitude Journal|Thrice weekly generic (non body-focused) gratitude text prompts and pure mirror exposure in the lab. Participants are not given instructions on how to examine body parts, only instructed to examine the same specific body parts as the Functionality group to control specifically for impacts of the body functionality focus.
10148178|NCT04118972|No Intervention|Assessment only control|Assessments at Week 1, Week 3, and 1- and 4-month follow-ups, identical to those received by participants in the active condition
10148179|NCT04118933|Experimental|MSI-H advanced colorectal cancer|
10148180|NCT04119154|Experimental|Standard diagnosis and CEM platform|Participants will receive standard diagnostic approach and assessment by CEM platform
10185289|NCT03747302|Other|Control Message|Subjects are randomized to receive one of five messages about electronic cigarettes.
9669442|NCT00794599|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9826182|NCT02411448|Experimental|Ramucirumab + Erlotinib|"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met.~Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
10185290|NCT03747289|Experimental|weight bearing group|performing exercises in a weight bearing posture
10185291|NCT03747289|Active Comparator|non-weight bearing group|performing exercises in a non- weight bearing posture
10185292|NCT03747276|Other|Clinical Trial Kiosk|
10185293|NCT03747263|Experimental|Individual Freeze-Catheter ablation|"The individualized time-to-effect protocol utilizing the AFA-Pro applies a freeze-cycle until documentation of PVI based on continuous real-time recordings from the Achieve catheter inside the PV. After documentation of PVI the freeze-cycle is prolonged for additional 90 seconds. If no PVI is achieved after 90 seconds or a temperature of -<30° is not reached after 40 seconds the freeze cycle is stopped, the cryoballoon will be repositioned to possibly achieve a better position. Afterwards the freeze-cycle will be restarted. If no real-time PV signal recording can be obtained, a standard freeze-cycle of 180 seconds is applied. No bonus-freeze-cycle is applied in this protocol."
10185294|NCT03747263|Active Comparator|Fixed Freeze-Catheter ablation|The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
10185295|NCT03747250|Experimental|Videolaryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of videolaryngoscope
10185296|NCT03747250|Active Comparator|Direct laryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of direct laryngoscopy
10185297|NCT03747237|Experimental|1. method, Edema measurement methods|"The surgeon will measure from three different places on the patient's face with the help of a paper ruler to measure the edema.~Tragus-Pogonion Tragus-Labial Comissura Angulus Mandible-Latheral Cantus Measurements will be made preoperative, postoperative 2. and 7. days and saved as milimetre."
10185298|NCT03747237|No Intervention|2. method, Edema measurement methods|Patients will be given edema scale.With the help of the edema scale, the patients will be evaluated the edema by themselves. When the patient stand in front of the mirror, they will be assessed the edema on their face. And a value between 0 and 5 will be pointed on the scale postoperative 2. and 7. days.
10185299|NCT03747224|Experimental|ARO-ANG3|
10185300|NCT03747224|Placebo Comparator|Placebo|
10185301|NCT03747211|Experimental|Aerobic exercise intervention|Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
10185302|NCT03747211|No Intervention|Control group|No intervention for 12 weeks
10185303|NCT03747198|Experimental|methylsulfonylmethane|Subjects will be given 2 g/day of methylsulfonylmethane (MSM). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points (ovulation, menstruation).
10185304|NCT03747198|Placebo Comparator|Placebo|Subjects will be given 2 g/day placebo (rice flour). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points as the intervention arm (ovulation, menstruation).
10185305|NCT03747185|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
10185306|NCT03747185|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
10185307|NCT03747133|Experimental|Stereotactic Ablative Radiotherapy|Adult patients with Kidney mass (either primary or metastasis) amenable to SABR
10185308|NCT03747094|Active Comparator|Fentanyl group|
9669443|NCT00794495|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9669444|NCT00794495|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9669445|NCT00794248|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9826183|NCT02411448|Placebo Comparator|Placebo + Erlotinib|"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met."
10185309|NCT03747094|Experimental|Ketamine group|
10185310|NCT03747081|Experimental|Rivoroxaban|Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
10185311|NCT03747081|Active Comparator|warfarin|Patients would be administered Warfarin with overlap of Enoxaparine utill INR adjust to 2-3 then enoxaparine will disconstinue.it would be given once a day.The total duration of Warfarin would be 3 months
10185312|NCT03747068||anti-TNF|UC patients treated with maintenance anti-TNF therapy who underwent IPAA surgery
10185313|NCT03747068||CONTROL GROUP|UC patients who were not exposed to anti-TNF therapy
10185314|NCT03747055|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
10148181|NCT04119232|No Intervention|Control|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
10148182|NCT04119232|Experimental|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
10148183|NCT04119141|Active Comparator|Standard Arm|the first acquisition will be carried out without a tin filter in supine position and the second with tin filter in procubitus.
10148184|NCT04119141|Experimental|Tin filter Arm|the first acquisition will be carried out with tin filter in supine position and the second without tin filter in procubitus.
10148185|NCT04119336|Experimental|Nivolumab and Ixazomib|"- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle.~Oral:~Ixazomib given weekly on days 1, 8, 15~Dexamethasone given weekly during cycle~Infused:~Nivolumab given once per cycle~Cyclophosphamide given on days 1, 8, 15 during cycle"
10148186|NCT04119037|Experimental|Group I (cordotomy)|Patients undergo a cordotomy over 1-2 hours.
10148187|NCT04119037|Sham Comparator|Group II (morphine, fake cordotomy)|Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours.
10148188|NCT04118855|Experimental|Neoadjuvant arm|Patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.
10148189|NCT04119310|Experimental|Lumbar thrust-mobilization|The investigator will perform a lumbar thrust-mobilization with the subject in right and then left sidelying position
10148190|NCT04119310|Sham Comparator|Sham-mobilization|No lumbar-thrust mobilization will be performed. Subject will receive simple passive inter-vertebral range of motion.
10148191|NCT04119219|Active Comparator|Ranibizumab|Arm 1
10148192|NCT04119219|Active Comparator|Aflibercept|Arm 2
10148193|NCT04119128|Active Comparator|Active tDCS|Patients in this group will receive 5 active sessions of low-intensity transcranial electrical stimulation for 20 minutes.
10148194|NCT04119128|Sham Comparator|Sham tDCS|Patients in this group will receive 5 sessions of sham transcranial electrical stimulation for 20 minutes.
10148195|NCT04118985|Active Comparator|Self-implementation|Individuals randomized to this group will be given all the materials about cognitive compensations techniques and brain health behavior guidelines and encouraged to implement those on their own.
10148196|NCT04118985|Experimental|Health-behavior intervention|Individuals randomized to this group will attend 10 weekly classes designed to provide information about cognitive compensation techniques and brain health behaviors as well as interventional support to implement those recommendations with homework and follow-up classes.
10148197|NCT04119011|Experimental|Probiotic|Probiotic in powder form containing lactobacillus and bifidobacterium strains, sugar, milk powder and flavoring, taken 2 sachets daily for 3 months
9971411|NCT01310439||ADHD adolescents and adults|30 adolescents and adults diagnosed with Combined-subtype AD/HD
9971412|NCT01310452|Active Comparator|neutral protamine insulin, metformin|NPH insulin once daily plus oral metformin twice or thrice daily during 26 weeks
10148198|NCT04119011|Placebo Comparator|Placebo|Placebo in powder form containing sugar, milk powder, flavoring, taken 2 sachets daily for 3 months
10148199|NCT04118881|Experimental|treatment group|The treatment group was given intradermal needling at ear acupoints: cardia (CO3), stomach (CO4), sympathetic (HX4)
10148200|NCT04118881|Sham Comparator|control group|The control group was given intradermal needling at ear acupoints: spiral area (HX7 and HX8).
10148201|NCT04118816||Control|Healthy subjects, 7-75 y/o
10148202|NCT04118816||Study|7-75 y/o, diagnosed with Prader-Willi syndrome.
10148203|NCT04118842|Experimental|Savolitinib and/or Rifampicin|Treatment Period 1 consists of 16 days starting with admission on Study Day -1, followed by a single dose administration of savolitinib on Day 1, followed by a washout period of at least 14 days. Subjects will be discharged from the Study Centre on Study Day 3, after the last PK sample is collected Treatment Period 2 consists of 6 days, starting with admission on Study Day 14, followed by QD dose administrations of rifampicin for 5 consecutive days (Study Day 15 to Study Day 19) Treatment Period 3 consists of 4 days, starting immediately after Treatment Period 2, comprising of a single dose administration of savolitinib on Study Day 20 and QD dose administration of rifampicin on Study Day 20 and Study Day 21. Subjects will be discharged from the Study Centre on Study Day 22, after the last PK sample is collected
10148204|NCT04118647|Experimental|Wu-Chu-Yu tang|
10148205|NCT04118725|Experimental|Muscular explorations|Pulmonary function test and diaphragmatic electromyography
9971413|NCT01310452|Experimental|insulin detemir, metformin|Insulin detemir once daily plus oral metformin twice or thrice daily during 26 weeks
9971414|NCT01310465|Experimental|Experimental group|Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.
9971415|NCT01310465|Placebo Comparator|Placebo Comparator|Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.
9971416|NCT01310478|Experimental|Endostar combined with mFOLFOX6|
9971417|NCT01310491|No Intervention|Usual Care|
9971418|NCT01310504|Active Comparator|Non peritoneal dialysis patient|
9971419|NCT01310504|Active Comparator|Peritoneal dialysis patient|
9971420|NCT01310517||Radial Coronary Angiography|The subjects enrolled in this study will be adults referred for radial coronary angiography with left ventriculography for clinical indications.
10148206|NCT04118634||Group with PE|"The criteria for confirmation of PE are:~PE on spiral computed tomography (CT) proximal deep vein thrombosis on ultrasound (US) thromboembolic events objectively confirmed during the follow up"
10148207|NCT04118634||Group without PE|"The criteria for exclusion of PE are:~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up low and moderate clinical probability and negative CT and negative follow up high clinical probability and negative CT, US and follow up."
10185315|NCT03747055|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
10185316|NCT03747029||Patients with hyperparathyroidism|Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
10148208|NCT04118582||Prospective analisys|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).~Evaluation of RMR For the evaluation of the RMR, the values of VO2 and VCO2 will be collected by the indirect calorimetry (IC) method using the Ultima CPX metabolic analyzer (MedGraphics, USA), calibrated with each test."
10148209|NCT04118751||parents of preterm babies (born before 37 weeks of pregnancy|
10148210|NCT04118751||parents of full-term babies (over 37 weeks of pregnancy)|
10148211|NCT04118907|Experimental|acoustic stimulation|Pink noise in both ears is given to tinnitus patients. The pink noise is removed by notch filter from tinnitus frequencies that are 20 decibel higher than the threshold.
10148212|NCT04118907|Experimental|somatic stimulation|Three stimulation points were selected for each ear of tinnitus patients, namely ear door (CN.V), auditory Palace (CN.VII) and Yifeng (C2/3). The stimulation intensity should be needle-sensed.
9669446|NCT00794248|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9669447|NCT00783354|Active Comparator|Continuous Treatment|
10148213|NCT04118907|Experimental|vestibular stimulation|The patient sat on a rotating chair with sinusoidal harmonic acceleration and rotated without causing the greatest frequency of discomfort.
10148214|NCT04118907|Experimental|acoustic + somatic stimulation|Combination of auditory and somatic stimulation for tinnitus patients
10148215|NCT04118907|Experimental|acoustic + vestibular stimulation|Combination of auditory and vestibular stimulation for tinnitus patients
10148216|NCT04118907|Experimental|acoustic + somatic + vestibular stimulation|Combination of auditory stimulation, somatic stimulation and vestibular stimulation for tinnitus patients
10148217|NCT04118829|Experimental|Group one|The Group 1 patients will be taking PER up to 14 days following surgical intervention as per discretion of the treating neurosurgeon.
10148218|NCT04118829|Experimental|Group Two|The Group 2 patients will be taking PER as part of their maintenance AED regimen and will continue on the same maintenance dosage postoperatively.
10148219|NCT04118673|No Intervention|Control (Standard Care)|Standard care during consultations. Advice and guidance offered by clinicians verbally and sometimes the addition of leaflets or a referral.
10148220|NCT04118673|Experimental|Intervention (Standard Care plus Lifestyle prescription - LRx)|Standard care during consultations with the addition of a physical lifestyle prescription. Advice and guidance will be offered by clinicians verbally, whilst being supported with a lifestyle prescription and a possible referral if required.
10148221|NCT04118868|Experimental|All participants|Pembrolizumab administered intralymphatically using the Sofusa® DoseConnect™device
10148222|NCT04118686|Experimental|Experimental group|The group receives CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)
10148223|NCT04118686|Sham Comparator|Control group|The group receives CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)
10148224|NCT04118790||Minor Stroke patients|"Clinical Assessment~MRI scan session"
10148225|NCT04118790||TIA patients|"Clinical Assessment~MRI scan session"
10148226|NCT04118790||Healthy Controls|MRI scan session
10148227|NCT04118556|Experimental|Decidua Stroma Cells (DSC)|"Placenta derived decidua stroma cells (DSC). In the first phase I part, two different dose levels will be used, 1x10^6/kg and 3x10^6/kg. Two doses, one week apart, will be given. The decision to proceed to the next dose level will depend on results observed at the previous dose level.~The dose in the randomized part will be based on the findings in the phase I part. In the Phase II study all patients will receive 2 doses, one week apart. Depending on response, up to 6 doses in total may be given. Additional doses (beyond the first 2 doses) may be given one week apart until response."
10148228|NCT04118556|Active Comparator|Best Available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
10148229|NCT04118517|Experimental|test meal|The study comprises one arm of 12 healthy Jamaican male and female adults with normal body mass inex, aged 20 to 45 years, receiving a test meal containing the common bean that was intrinsically labelled with deuterium .
10148230|NCT04118530||Hematopoietic Stem Cell Transplant (HSCT) Patients|- Patients with incidence of AF/AFL in the first 30 days of transplant
10148231|NCT04118699|Experimental|Rifaximin|Two tablets of the investigational product per dosing (400 mg of rifaximin) are orally administered 3 times daily for 4 weeks.
10148232|NCT04118699|Placebo Comparator|Placebo|Two tablets of the placebo are orally administered 3 times daily for 4 weeks.
10148233|NCT04118543|Experimental|Intervention Group|The intervention group will take part in three 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
10148234|NCT04118543|Sham Comparator|Sham-Exercise Group|The shame-exercise group will complete three sham exercise group sessions per week for eight weeks (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
10148235|NCT04118491|Sham Comparator|sham1st|40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
10185317|NCT03747029||Patients with hypoparathyroidism|"Patients aged between 18-90 years old with diagnosed hypoparathyroidism. No intervention is provided.~."
10185318|NCT03747029||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~No intervention is provided."
9669448|NCT00783354|Experimental|PRN regimen|
9669449|NCT00783237|Experimental|Mometasone Furoate Nasal Spray|
10148236|NCT04118491|Active Comparator|sham second|"iii. We will divide the subjects into two groups of five. One group will receive 40 Hyperbaric Oxygen (HBO2) treatments (100% oxygen at twice normal air pressure (2 ATA)) followed by 40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.~iv. Neurological and psychologic assessments will be done prior to starting treatments, after the first block of 40 and again after the second block of 40."
10148237|NCT04118777|Active Comparator|0.2 % Ropivacaine|An ON-Q pain pump will be placed into the pelvic cavity and 0.2% Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr.
10148238|NCT04118777|Placebo Comparator|Saline|An ON-Q pain pump will be placed into the pelvic cavity and saline will be continuously administered intraperitoneally at a rate of 6 mL/hr
10148239|NCT04118465|Active Comparator|ECV with Full urinary bladder|ECV with Full urinary bladder
10148240|NCT04118465|Active Comparator|ECV with empty urinary bladder|ECV with empty urinary bladder
10148241|NCT04118452|Experimental|Intervention + Usual Care + Developmental Screening Results|Intervention group families will receive usual care and developmental screening results will be shared with each child's primary care provider. In addition, they will be connected via telephone to 2-1-1 prior to their scheduled well-child visit for the telephone-based early childhood development care coordination intervention.
10148242|NCT04118452|No Intervention|Usual Care + Developmental Screening Results|This group will receive usual care. In addition, developmental screening results will be shared with each child's primary care provider.
10148243|NCT04118478|Experimental|Multi-component phased training program|"The intervention of the program consists of conducting a multi-component training in a neighborhood unit.~The intervention will consist of the realization of a multi-component program in a training center adapted for the elderly. The duration of the program will be 27 weeks with a frequency of two weekly sessions and an intervention duration of 45 to 60 minutes"
9971421|NCT01310530|Experimental|Partial Breast Proton Therapy|Two weeks of daily proton therapy delivered to the lumpectomy site.
10148244|NCT04118478|No Intervention|CONTROL|Older people assigned to the GC do not do any training programming. Only attend the measurement dates.
10148245|NCT04118374|Experimental|Standard Carb Diet then Low Carb Diet|
10148246|NCT04118374|Experimental|Low Carb Diet then Standard Carb Diet|
10148247|NCT04118413|Experimental|Erector spinae plane block|Erector spinae plane block will be administrated to this group at end of the surgery under spinal anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively and sheduled paracetamol will be given.
10148248|NCT04118413|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine and sheduled paracetamol. No block will be performed.
10148249|NCT04118426||Radiotherapy group|Patients receiving radiotherapy after surgery for brain tumor
10148250|NCT04118426||No radiotherapy group|Patients NOT receiving radiotherapy after surgery for brain tumor
10148251|NCT04118439|Experimental|Motor Imaginery|Patients allocated in this arm will recieve a training on the first day after recruitment on a motor imaginery task and will be asked to do the task every day during 30 days until they start the usual care. Then after the physical therapy treatment with a pragmatic perspective will be meassured just inthe last session, after 1 month an.d after 3 moths of the treatment for the follow up
10148252|NCT04118439|No Intervention|Control Group|Patients allocated in this arm will be meassured at the start, again after 30 days and at the end of the physical therapy usual care with a pragmatic perspective. Then will be meassured again after 1 and 3 months.
10148253|NCT04118296|Experimental|Intervention|Intervention will be given in the form of the use of anti-acne combination creams that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
10148254|NCT04118153|Experimental|Abatacept|Abatacept will be given by a subcutaneous (SC) formulation weekly for three months.
10148255|NCT04118309|Experimental|High-intensity interval training|Three sessions of high-intensity interval training per week for nine weeks. Following a three minute warm up, a session contained twenty minutes of alternating between a sprint (80% of maximum workload, 90-95% of maximum heart rate) and active rest (30% of maximum workload) at a one minute to one minute ratio. Every session ended with a two and a half minute cool down.
10148256|NCT04118309|Placebo Comparator|Placebo exercise group|No changes in physical activity behaviour occurred (already engaging in less than 150 minutes per week, instructed to maintain their current inactivity). They were told they needed to stay inactive since they were part of an 'acute' exercise group, aiming to see how long the effects of their baseline maximal exercise test would last. Thus, the cover story gave them the impression they were also in an exercise group, as oppose to a non-exercise control group.
10148257|NCT04118400||Experimental: NIN-NAVA|"Premature>30weeks with respiratory distress~PI to determine eligibility or exclusion~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization~PI will not be blinded to the intervention (not feasible)~Place the catheter to optimize position~ABG or VBG to be obtained at 2 hrs. post NIV-NAVA~NIV-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
10148258|NCT04118400||Active Comparator: Nasal CPAP or NIMV|"Premature>30weeks with respiratory distress~PI to determine eligibility or exclusion~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization~PI will not be blinded to the intervention (not feasible)~Place the catheter to optimize position~ABG or VBG to be obtained at 2 hrs. post Nasal CPAP or NIMV~NCPAP or NIMV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
10148259|NCT04118335|Experimental|Intervention Group|The individuals in the intervention group were asked to gargle with 5 ml black mulberry syrup three times a day after meals and wait average one minute in the mouth and then swallow, in addition to the standard practice of the clinic. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. The patients were followed for 15 days. The 15-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
10148260|NCT04118335|No Intervention|Control Group|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
10148261|NCT04117867||Intraoperative hypotension|
10148262|NCT04118257|Experimental|Fruit Juice|Participants consumed 2 bottles of 100% fruit juice daily for 3 weeks.
10148263|NCT04118257|Experimental|Soda|Participants consumed 2 cans of caffeine-free Coca Cola daily for 3 weeks.
10148264|NCT04118257|Other|Water|Participants consumed 2 bottles of water daily for 3 weeks.
10148265|NCT04118179||Suspected Sepsis Group|Participants suspected of potential to develop sepsis recruited at the emergency department.
10148266|NCT04118179||Surgical Group|Participants undergoing non-emergency scheduled surgery, including ear/nose and throat cases, orthopaedic surgery of the major joints including hip, knee, ankle, shoulder, and wrist.
10148267|NCT04118179||Healthy Group|Healthy participants
10148268|NCT04118101|Active Comparator|ESPB group|A total of 25 ml bupivacaine 0.5% willbe injected into the ESP.
10148269|NCT04118101|Placebo Comparator|Control group|The ESPB will not be performed.
9826184|NCT02411448|Experimental|Ramucirumab + Gefitinib or Osimertinib|"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.~Ramucirumab and gefitinib administered during period 1.~Ramucirumab and osimertinib administered during period 2."
9826185|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
10148270|NCT04117971||Staff members|Staff members in different clinical departments at Faculty of Dentistry, Cairo University.
10148271|NCT04117971||PhD students|PhD candidates in different clinical departments at Faculty of Dentistry, Cairo University.
10148272|NCT04117971||Master's students|Master's candidates in in different clinical departments at Faculty of Dentistry, Cairo University.
10148273|NCT04117828|Active Comparator|Control|50 g of glucose will be given to the individuals
10148274|NCT04117828|Experimental|1st Intervention group|50 g of Aseel dates will be given to the individuals
10148275|NCT04117828|Experimental|2nd Intervention group|50 g of Ajwa dates will be given to the individuals
10148276|NCT04117828|Experimental|3rd Intervention group|50 g of Karbala dates will be given to the individuals
10148277|NCT04118127|Experimental|2mg conventional tablet, once-weekly tablets|
9826186|NCT02411461||Healthy siblings|Control group
10148278|NCT04117906|Experimental|STAGE course|
10148279|NCT04117906|No Intervention|Wait-list control|The wait-list control group will receive access to the STAGE course after the trial is complete.
10148280|NCT04117919|Experimental|chinese medicine medicated bath|we used the leaf of paper mulberry as chinese medicine medicated bath. Two packs per day ,and the period of treatment will be two month.
10148281|NCT04117919|Active Comparator|control group|Topical steroids
10148282|NCT04118114|Experimental|PRL3-ZUMAB Monotherapy|
9669450|NCT00783237|Placebo Comparator|Placebo Nasal Spray|
9826187|NCT02411461||Obese patients|Control group
9826188|NCT02411539|Experimental|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
9826189|NCT02411539|Experimental|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
10148283|NCT04117880|Experimental|Ataluren|Ataluren Oral suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).
10148284|NCT04117893|Experimental|Duloxetine combined with intra-articular injection|
10148285|NCT04117893|Active Comparator|Intra-articular injection|
10148286|NCT04117841||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
10148287|NCT04117841||Arm II: Prior treatment at centre|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
10148288|NCT04117841||Arm III: Prior treatment at outside centre|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
10148289|NCT04117776||Patients|Patient benefiting during the same hospitalization of the loss or the gain of a central venous catheter.
10148290|NCT04117685||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
10148291|NCT04117685||Arm II: Prior treatment at center|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
10148292|NCT04117685||Arm III: Prior treatment at outside center|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
10148293|NCT04117750|Active Comparator|intervention group|55 female patients with PCO
10148294|NCT04117750|Placebo Comparator|non -intervention group|40 female patients with PCO and 50 healthy women matched to PCOS women as regard age and ethnic origin.
10148295|NCT04117698|Experimental|Antitubercular treatment and local corticosteroid therapy|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~associated with a treatment similar to the control group."
10148296|NCT04117698|No Intervention|Local Corticosteroid Therapy Only|"Treatment of Ocular Inflammation by Local Corticosteroid Therapy Only comprising:~Dexamethasone (DEXAFREE® eye drops) at an attack dose for one week (4 to 6 drops / d maximum and if severe inflammation 1 drop / hour) then decrease and stop over 3 weeks, with relay by fluorometholone (Flucon®) for 2 months maximum. The modalities of the decrease of the local steroids are left to the ophthalmologists own judgment. Maximum total duration of 3 months.~Mydriatic (tropicamide) 1gx3 / d if necessary.~Neosynephrine 5% if posterior synechiae.~Atropine (Alcon 0.3%) if pain."
10185319|NCT03747016|Experimental|High energy 2|In the second step, the experimental group (Group E2) was given high energy digestible food 300ml before the time of gastric emptying found in the first step before surgery.
10148297|NCT04117789|Experimental|Therapist-guided ICBT for depression|"Participants will receive internet-delivered CBT with therapist support. The treatment consists of 8 online chapters with interactive features as videos and illustrations, delivered over a maximum of 10 weeks. The treatment has the main focus on behavioral activation.~The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The parent program also consists of eight chapters, including psychoeducation about depression and how to support their adolescent in treatment.~The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support."
10148298|NCT04117789|Experimental|Self-guided ICBT for depression|The self-guided ICBT for depression is identical to the therapist-guided ICBT intervention, however without the therapist support. To ensure patient-safety, there will be clear instructions to the patients and primary caregivers how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
10148299|NCT04117789|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both. The content of TAU and the treatment techniques used, will be monitored.
10148300|NCT04118322|Experimental|intervention group|The patients in the intervention group applied peppermint oil (3%) on lips three times a day, during the five days following chemotherapy administration, in addition to the standard antiemetic treatments. The data were collected using a Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching (INVR), Visual Analog Scale (VAS) Patient Nausea Severity Follow-up Form, Patient Watch Chart, and Oil Application Protocol. Besides, patients in the intervention group were questioned thoughts associated with peppermint oil application using individual in-depth interview method.
9826190|NCT02411565|Active Comparator|Fermented Wheat Germ Extract (FWGE)|FWGE administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
10148301|NCT04118322|No Intervention|control group|The control group underwent only the routine treatment.
10148302|NCT04117737|Experimental|Intervention|Single-arm
10148303|NCT04117542||Overweight/Obesity Control|Adolescents who have overweight/obesity, but do not report loss of control eating.
10148304|NCT04117542||Overweight/Obesity Experimental|Adolescents who have overweight/obesity, and report loss of control eating.
10148305|NCT04118075|Experimental|PT-CY-FK +/- ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
10148306|NCT04117529|Experimental|Experimental Arm|Pemphigus or other autoimmune diseases.
10148307|NCT04117464|Experimental|Behavioral activation therapy|Behavioral activation therapy was applied following the protocol designed by Martell, Dimidjian & Herman-Dunn (2013).
10148308|NCT04117464|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment therapy was applied following the protocol designed by Hayes, Strosahl & Wilson, (2011).
10148309|NCT04117464|Experimental|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy was applied following the protocol designed by Barlow, Allen and Choate (2004).
10148310|NCT04117464|Other|Wait List Group|Participants at Wait List Group will be evaluated pre-post and 3, 6, 9 and 12 months follow up periods, like experimental groups.
10148311|NCT04117633|Active Comparator|Mesh Rectopexy|Using Laparoscopy
10148312|NCT04117633|Active Comparator|Suture Rectopexy|Using Laparoscopy
10148313|NCT04117646||Patients|Patients of 2 and 12 years of age with chronic rhinosinusitis.
10148314|NCT04117646||Controls|Subjects of 2 and 12 years of age without chronic rhinosinusitis.
10148315|NCT04117477|Experimental|Xylitol wipes|
10148316|NCT04117477|Placebo Comparator|Placebo wipes|
10148317|NCT04117659|Experimental|Phosphodiesterase-5 inhibitor withdrawal|In this single arm pretreatment with an oral phosphodiesterase-5 inhibitor will be discontinued
10148318|NCT04117555||Control|Diagnostic Test: Pupillometry
10148319|NCT04117555||Parkinson patients|Diagnostic Test: Pupillometry
10148320|NCT04117386||Primary pterygium group|Participants who was diagnosed with primary pterygium
9826191|NCT02411565|Placebo Comparator|Placebo Administration|Placebo administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
10148321|NCT04117386||Secondary pterygium group|Participants who was diagnosed with secondary pterygium
10148322|NCT04117386||Healthy participants as control group|Participants who have no pterygium and other inflammation disease in eyes
10148323|NCT04117282|Active Comparator|control group|15 children received the regular exercise program including classical gait training for diplegic children (30 minutes exercises + 30 minutes gait training)
10148324|NCT04117282|Experimental|study group|15 diplegic child received the same exercise program including the use of the antigravity shoes for gait training (30 minutes exercises + 30 minutes gait training)
9826192|NCT02411578|Experimental|G-Pen Mini™ (glucagon injection)|"Participants are to check blood glucose (BG) with study meter once their continuous glucose monitor (CGM) reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using mini-dose glucagon for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
10148325|NCT04117399|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
10148326|NCT04117399|Active Comparator|Control group|aerobic exercice
10148327|NCT04117451|Sham Comparator|Chlorhexidine|Chlorhexidine mouthwash will be provided to participants for a week to rinse the mouth twice a day.
10148328|NCT04117451|Experimental|Propolis|Propolis mouthwash will be provided to participants for a week to rinse the mouth twice a day.
10148329|NCT04117061|No Intervention|Control|Patient gets usual diagnostic path: after inconclusive ultrasound is refered to CT scan.
10148330|NCT04117061|Active Comparator|Observation|Patient after inconclusive primary evaluation is observed in emergency room for 8-12 hours and after the clinical evaluation, laboratory results and ultrasound examination is repeated.
9971422|NCT01310543|Experimental|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
9971423|NCT01310543|No Intervention|Comparison|Girls in the comparison group will continue with their normal afternoon of schooling, which is missed by girls attending the T&T intervention for the 20 weeks of their attendance.
9971424|NCT01310556||coronary artery disease|patients with coronary artery disease
9971425|NCT01310595|Experimental|Manual mobilization on cervical spine|Manual mobilization given on cervical spine with infra-red therapy and self exercise and advice pamphlet.
9971426|NCT01310595|Active Comparator|Infra-red radiation therapy|Infra-red radiation therapy with self exercise pamphlet given to patients with chronic mechanical neck pain.
9971427|NCT01310608|Experimental|A-View|
9971428|NCT01310608|No Intervention|No A-View|
9971429|NCT01310621|No Intervention|No Lavage|Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward. The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
9971430|NCT01310621|Experimental|Surfactant Lavage|The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds. Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine. The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube. Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by > 5% of the prelavage value. The same shall be resumed once prelavage oxygen saturation has been restored. The infant's bed will now be moved back to horizontal position. Once the neonate is STABLE, suctioning will be again repeated. The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
9971431|NCT01310634|Experimental|Comprehensive intervention|Parents of hospitalized neonates received Comprehensive intervention program.
9971432|NCT01310634|Other|Conventional treatment|Usual educational program
9971433|NCT01310647|Experimental|Testosterone|Transdermal testosterone (20µg/day) from day 24 of the previous cycle until day 2 of the ICSI cycle
9971434|NCT01310647|Experimental|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
9971435|NCT01310647|Experimental|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI~Estradiol valerate 4 mg/day during 10 days, starting the second day of the cycle prior to the ICSI cycle."
9971436|NCT01310660||Nulliparous|
9971437|NCT01310673|Active Comparator|Allopurinol|
9971438|NCT01310673|Placebo Comparator|Placebo|
9971439|NCT01310686||Wet AMD Non-Responders to Anti-VEGF|
9971440|NCT01310712|Experimental|oxybutynin|patients will receive in the end of the treatment, 10 mg of oxybutynin a day
9971441|NCT01310712|Placebo Comparator|Placebo|Placebo
9971442|NCT01310738|Active Comparator|Meglumine antimoniate|Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
9971443|NCT01310738|Experimental|Liposomal Amphotericin B|Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
9971444|NCT01310738|Experimental|Amphotericin B|Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
9971445|NCT01310738|Experimental|Combination therapy|Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.
9971446|NCT01310751|Experimental|iloprost nebuliser solusion|50 ng/kg/min
9971447|NCT01310751|Placebo Comparator|distilled water|2ml
9971448|NCT01310764|Sham Comparator|Mitomycin C|Those with trabeculectomy and intraoperative application of mitomycin C.
9971449|NCT01310764|Active Comparator|Bevacizumab|Those with trabeculectomy and adjunctive intraoperative subconjunctival injection of bevacizumab.
9971450|NCT01310816|Active Comparator|IPI-926|IPI-926
9971451|NCT01310816|Placebo Comparator|Sugar Pill|Placebo Arm, sugar pill
9971452|NCT01310829||Virtual Reality|Board-eligible or board-certified genetic counselors and students evaluate a virtual reality-based intervention using questionnaires and physiological measurements.
9971453|NCT01310842||Pilot Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 5 in-person counseling sessions.
9971454|NCT01310842||Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 7 in-person counseling sessions.
9971455|NCT01310881|Experimental|Dose 1|
9971456|NCT01310881|Experimental|Dose 2|
9971457|NCT01310881|Experimental|Dose 3|
9971458|NCT01310881|Experimental|Dose 4|
9971459|NCT01310881|Experimental|Dose 5|
9971460|NCT01310881|Experimental|Dose 6|
9971461|NCT01310881|Experimental|Dose 7|
9971462|NCT01310894|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
9971463|NCT01310894|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have low-risk prostate cancer
9971464|NCT01310907||sinus node dysfunction|
9971465|NCT01310907||Atrioventricular block|
9971466|NCT01310907||control|
9971467|NCT01310920||sick sinus syndrome|
9971468|NCT01310920||control|
9971469|NCT01310933||Kikuchi's disease|
9971470|NCT01310933||Malignant lymphoma|
9971471|NCT01310998|Experimental|schizophrenic disorder|
9971472|NCT01310998|Experimental|other psychotic disorder|
9971473|NCT01310998|Experimental|no mental disorder|
10148331|NCT04117035|Placebo Comparator|Control arm|Standard care
10148332|NCT04117035|Experimental|Intervention|
10148333|NCT04117022|Experimental|supplemented arm|Each subject will receive DVS formula, 2 softgels per day for 6 months.
10148334|NCT04117139|Other|Study Group|In addition to other standard imaging modalities in the fast track cancer program, included patients will have a PET/MRI done.
10148335|NCT04117178|Active Comparator|Standard of care|Participants allocated to this arm follow the usual routines of the out patient dementia clinic but are requested to have the serum level of the prescribed drug measured after 12 month. Also, CYP2D6, BcHE K and APOe4 status will be determined after 12 months.
10148336|NCT04117178|Experimental|Intervention arm|Participants allocated to this arm follow are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention arm not experiencing side effects will have their treatment adjusted after 6 months based upon serum level of the drug in question.
10148337|NCT04116957|Other|Time 1|First two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
10148338|NCT04116957|Other|Time 2|Second two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
10148339|NCT04117217||Central venous lines|Patients having a central venous catheter placed at Banner University Medical Center, University of Arizona
10148340|NCT04117217||Cardiac catheterization|Patients undergoing a cardiac catheterization procedure done at Banner University Medical Center, University of Arizona
10148341|NCT04117334||Bracing AIS patients|These are patients undergoing brace treatment for AIS
10148342|NCT04117269|Experimental|External shoe lift|Those patients allocated in the experimental group will be supplemented with a external shoe lift in the contralateral limb in their conventional shoes to compensate the differences with the affected foot (using a offloading device to active ulcer).
9971474|NCT01311076|Experimental|TAK-329 50 mg|
9971475|NCT01311076|Experimental|TAK-329 200 mg|
10148343|NCT04117269|No Intervention|Standard of care|Those patients allocated in the control group will not be supplemented, they will be treated with a standard of care treatment.
10148344|NCT04117256|Active Comparator|Transcranial Stimulation|Transcranial stimulation on the primary motor cortex (M1) with anode located on the point C3 (10/20 EEG system), and the cathode on contralateral supraorbital zone.
10148345|NCT04117256|Active Comparator|Suboccipital Stimulation|Suboccipital stimulation with anode located at the upper cervical level and cathode was placed on the lateral part of right shoulder.
10148346|NCT04117009|Experimental|Remifentanil 2 ng/mL|Following baseline echocardiographic evaluation, Remifentanil (ultiva at a concentration of 20 micg/ml) infusion will be started at a rate to reach a target plasma level of 2 ng/mL. A target Controlled Infusion pump will be used to infuse the study drug. Once the target drug concentration is reached (which is expected to reach around 10-15 minutes), the final echocardiographic examination will be performed.
10148347|NCT04117009|Experimental|Baseline|Baseline transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure and study drug infusion begins.
10148348|NCT04116970|Experimental|Diagnostic (bronchoscopy with EBUS-TBNA with/without vacuum)|Patients undergo bronchoscopy with EBUS-TBUA first without and then with applied vacuum.
10148349|NCT04116983||All patients|Recruited participants will be attending a dermatology clinic with at least one skin lesion where there is a suspicion of skin cancer. All suspicious lesions suitable for photographing will be photographed six times in a single visit. A macro and dermoscopic image of each lesion will be captured by three different mobile phones: an iPhone, a Samsung and a Nokia smart phone, without (macro image) or with (dermoscopic image) a Dermlite DL1 lens attached. Dermoscopic images of healthy skin will also be captured by each camera. Images of the lesions will be analysed by DERM. The DERM results for lesions biopsied will be compared to the biopsy result; the DERM results for lesions not biopsied will be compared to the clinical assessment.
10148350|NCT04117243|Active Comparator|Tranexamic group|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision).
10148351|NCT04117243|Active Comparator|Misoprostol group|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision.
10148352|NCT04117243|Active Comparator|oxytocin only group|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby
10148353|NCT04117048|Experimental|At home INR measurement with LabPad®|All at home INR measurements will be performed with the LabPad® point-of-care
9826193|NCT02411578|Active Comparator|Glucose Tabs|"Participants are to check their blood glucose (BG) with study meter once their continuous glucose meter reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using oral glucose tablets for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
9971476|NCT01311076|Active Comparator|Insulin 0.2 U/kg|
9971477|NCT01311076|Placebo Comparator|Placebo|
10148354|NCT04117204|Experimental|Fruits and Vegetables|This group will receive a prescribed amount of free fruits and vegetables (F&V) for 6 weeks of pick-up at a farm stand or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 6 weeks with minimal contact.
10148355|NCT04117204|No Intervention|Wait List Control|This group will not receive a prescribed amount of free fruits and vegetables (F&V) for 12 weeks. They will serve as the control group. After 12 weeks of control and data comparisons, they will be given 12 weeks of vouchers with minimal contact.
10185320|NCT03747016|Active Comparator|Glucose 2|In the second step, Group G2 is given 5% glucose injection 300ml before the time of gastric emptying found in the first step before surgery.
10187819|NCT03722368|Experimental|RCHC|Participation in the Resilience and Coping of the Healthcare Community Intervention.
10148356|NCT04117074|Experimental|Arm 1: Thoracic Epidural Analgesia with bupivicaine|Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter [mL] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
10148357|NCT04117074|Experimental|Arm 2: Surgical Site Infiltration with Liposomal Bupivacaine|Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
10148358|NCT04117191|Experimental|Tryptophan loading|All participants are introduced to receive tryptophan loading test.
10148359|NCT04116944|Experimental|Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults with analogue-Generalized Anxiety Disorder
10148360|NCT04116944|Other|Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
10148361|NCT04116944|Experimental|Non-Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults without analogue-Generalized Anxiety Disorder
10148362|NCT04116944|Other|Non-Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
10148363|NCT04117165|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from chronic inflammatory rheumatism, in particular, rheumatoid arthritis. Prescription of bDMARD or their biosimilars is possible.
10148364|NCT04117165|Active Comparator|Patient Current care|Current care of patients with rheumatoid arthritis, based on the recommendations of the French Society of Rheumatology. Prescription of bDMARD or their biosimilars is possible.
9669451|NCT00783133|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
9669452|NCT00783133|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
10148365|NCT04116892|Active Comparator|the peeling group|the internal limiting membrane was discarded
9971478|NCT01311089||Robotic thyroidectomy group|Robotic thyroidectomy group is the patient group who underwent robot-assisted endoscopic thyroid surgery using a gasless, trans-axillary approach.
9971479|NCT01311089||conventional open thyroidectomy group|Conventional open thyroidectomy group is th patient group who underwent thyroid surgery via neck incision.
10148366|NCT04116892|Experimental|the Cover group|the internal limiting membrane was peeled centripetally all the way up to the MH rim and the hinged ILM flap folded upside-down on top of the MH in order to bridge the entire retinal defect with a single layer.
10148367|NCT04116892|Experimental|the Fill group|"the internal limiting membrane was folded in multiple layers and deliberately stuffed or packed within the MH defect using a forceps."
10148368|NCT04116762|Experimental|Intervention|Placement of TissuePatchDS-P™ at time of operation. No surgical drain is used.
10148369|NCT04116762|Active Comparator|Control|No use of TissuePatchDS-P™. Wound is closed with a surgical drain (Surgeon's choice) in situ.
10148370|NCT04116775|Experimental|Treatment|"INITIAL TREATMENT PHASE: Patients progressing on enzalutamide will receive 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy.~ASSESSMENT PHASE: After completion of the initial treatment phase, patients will have their disease assessed by tumor imaging. Patients who respond to treatment will become stool donors to patients who do not respond. Non-responders will move on to the retreatment phase.~RETREATMENT PHASE: Non-responders will undergo a fecal transplant and be retreated with 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for an additional 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy."
9977780|NCT01365169|Experimental|Arm II (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
10148371|NCT04116723|Experimental|Flexible brace|The design of the flexible brace incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) artificial hinge bone for the strategical application and fixation of corrective panel, 3) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
9669453|NCT00779636|Experimental|Desloratadine 10 mg|
9669454|NCT00779636|Placebo Comparator|Placebo|
9669455|NCT00763529|Experimental|Arm 1|
9669456|NCT00763529|Active Comparator|Arm 2|
9669457|NCT00757562|Experimental|DL|Desloratadine syrup once daily
9669458|NCT00757562|Placebo Comparator|Placebo|placebo syrup once daily
9669459|NCT00751075|Active Comparator|1|MFNS once daily
9669460|NCT00751075|Experimental|2|MFNS twice daily
9669461|NCT00751075|Active Comparator|3|Amoxicillin
9669462|NCT00751075|Placebo Comparator|4|Placebo
9669463|NCT00750750|Active Comparator|1|MFNS once daily
9669464|NCT00750750|Experimental|2|MFNS twice daily
9669465|NCT00750750|Active Comparator|3|Amoxicillin
9669466|NCT00750750|Placebo Comparator|4|Placebo
9669467|NCT00731185|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
10148372|NCT04116606|Active Comparator|Active JNJ-54175446|JNJ-54175446 is an unlicensed drug currently being developed by Janssen Pharmaceuticals. The drug is presented in oral capsules, each capsule containing 50 mg of JNJ-54175446. Participants will be asked to self-administer one capsule daily for 8 weeks.
10148373|NCT04116606|Placebo Comparator|Matching placebo|
10148374|NCT04116931|Experimental|clopidogrel-600 mg-12h|clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
10148375|NCT04116931|Experimental|clopidogrel-600 mg-24h|clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
10148376|NCT04116931|Experimental|clopidogrel-75 mg-12h|clopidogrel 75 mg maintenance dose(MD) 12 hours after the last MD of ticagrelor
10148377|NCT04116931|Experimental|clopidogrel-75 mg-24h|clopidogrel 75 mg maintenance dose（MD) 24 hours after the last MD of ticagrelor
10148378|NCT04116476|Experimental|Moderate Hepatic Impairment|
10148379|NCT04116476|Experimental|Normal Healthy Matches|
10148380|NCT04116476|Experimental|Mild Hepatic Impairment|
10148381|NCT04116424|Experimental|nurse training of the patient|
10148382|NCT04116424|Active Comparator|simple information of the patient by neurologist|
10148383|NCT04116554|Active Comparator|intervention group (A)|which will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block by injection of 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side.
10148384|NCT04116554|Sham Comparator|control group (B)|which will have sham block bilaterally by injection of 20 ml of 0.9%saline will be injected on each side.
10148385|NCT04116385||Cancer surgery patients|Adult subjects (18 years or older) undergoing an oncologic surgical procedure.
10148386|NCT04116801|Experimental|Fluorescence arm|fluorescence guided microsurgical resection (under 560 nm filter) in addition to the usual techniques, after iv injection of 200 mg (i.e. 3-4 mg/kg) of fluorescein sodium at the time of skin incision.
10148387|NCT04116801|Active Comparator|Standard excision|microsurgical resection with usual techniques
10148388|NCT04116905|Experimental|Intensive Lifestyle Intervention|Participants in the intensive lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain a 15% weight loss.
10148389|NCT04116905|Active Comparator|Conventional Treatment|The conventional treatment arm provides group sessions on metabolic syndrome management and social support, aimed at a 5% weight loss.
10148390|NCT04116697|Experimental|Acupuncture with Anti-Emetics|
10148391|NCT04116697|Experimental|Aromatherapy with Anti-Emetics|
10148392|NCT04116697|No Intervention|Control Group|
10148393|NCT04116463|Experimental|CDSMP|Chronic Disease Self-Management Program (CDSMP) - a 6-week, group-based behavioral intervention delivered in a 2.5 hour session each week by a trained facilitator.
10148394|NCT04116463|Active Comparator|Financial Self-Management|Financial self-management course delivered in 3 modules, with a delivery time of approximately 1 hour per module.
10148395|NCT04116632|Experimental|BMS-963272 or Placebo once daily (QD)|
10148396|NCT04116632|Experimental|BMS-963272 or Placebo every 12 hours (Q12H)|
10148397|NCT04116632|Experimental|BMS-963272 or Placebo every 8 hours (Q8H)|
10148398|NCT04116450|Other|primary congenital glaucoma|Glaucolight illuminated microcatheter trabeculotomy in primary congenital glaucoma
10148399|NCT04116580||Allergic patients to raw apple and birch|Single-group studies about 28 patients allergic to birch and no longer eating raw rosaceae for at least 6 months. Patients brought back into contact with this family of fruits via the raw golden apple according to an Ultra-Rush protocol.
9669468|NCT00731185|Placebo Comparator|Placebo|Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning
10148400|NCT04116528|Other|Ketamine|Every eligible participant will receive 0.5mg/kg IV given over 40 minutes
10148401|NCT04116528|Active Comparator|Buprenorphine or Placebo|Buprenorphine or placebo once daily for 4 weeks
10148402|NCT04116372|Experimental|Empty Nest Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
10148403|NCT04116372|Experimental|Retirement Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
10148404|NCT04116372|No Intervention|Empty Nest Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
10148405|NCT04116372|No Intervention|Retirement Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
10148406|NCT04116827||Tamoxifen group|Pre-menopausal breast cancer patients who underwent proper surgical treatment, chemotherapy, or radiation therapy, and are scheduled for application of tamoxifen and goserelin
10148407|NCT04116346|No Intervention|Fasting group|Fasting for both solids and fluids for up to 6 hours pre-procedure
10148408|NCT04116346|Experimental|Non Fasting group|Usual meal on the day of the procedure and allowed to drink as usual
10185321|NCT03747016|Placebo Comparator|Normal saline 2|In the second step, Group N2 is given normal saline 300ml before the time of gastric emptying found in the first step before surgery.
10148409|NCT04116411|Placebo Comparator|Placebo|Patients will receive placebo tablets with similar appearance as the active drug. Patients receive two 450 mg tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg tablet once daily for an additional 22.5 months; a total treatment time of 24 months.
10148410|NCT04116411|Active Comparator|Valganciclovir|Patients will receive valganciclovir tablets with similar appearance as the placebo tablets. Patients receive two 450 mg valganciclovir tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg valganciclovir tablets once daily for an additional 22.5 months; a total treatment time of 24 months.
9669469|NCT00653835|Experimental|Ezetimibe + Simvastatin|
10148411|NCT04116359|Experimental|Non-BRD4 exploratory cohort (molibresib, cisplatin, etoposide)|Patients receive molibresib besylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive molibresib besylate, etoposide phosphate and cisplatin as in Phase I and II Cohort at the discretion of the principal investigator.
10148412|NCT04116359|Experimental|Phase I and II cohort (molibresib, etoposide, cisplatin)|Patients receive molibresib besylate PO QD on days 1-14 (may switch to days 1-21 after completion of etoposide and cisplatin cycles). Patients also receive etoposide phosphate IV over 60 minutes on days 1-3 and cisplatin IV over 60 minutes on day 1 of cycles 1-4. Treatments repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of cycle 4, patients may receive etoposide phosphate and cisplatin for up to 8 cycles total in the absence of disease progression or unacceptable toxicity at the investigator's discretion.
10148413|NCT04116333|Experimental|ML + ETI|Intubation with using endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
10148414|NCT04116333|Active Comparator|ML|Intubation with using the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
10148415|NCT04116216|Active Comparator|High frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
10148416|NCT04116216|Active Comparator|Low frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
10148417|NCT04116216|Sham Comparator|Sham rTMS + physical therapy|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
10148418|NCT04116177|Active Comparator|Standard Stimulation|Standard stimulation using contact 3-6 to achieve best therapeutic stimulation
10148419|NCT04116177|Experimental|Flexible stimulation|Flexible stimulation using all available stimulation strategies provided by the VerciseTM system including stimulation of contacts 1-8 and variable pulse width and frequency.
10148420|NCT04116229||Normal-weight|Participants who have a body mass index within the normal-weight category.
10148421|NCT04116229||Obese|Participants who have a body mass index within the obese category.
9669470|NCT00653835|Active Comparator|Simvastatin|
10148422|NCT04116151|Experimental|Intervention group|Local administration of the Alantel (R) cream on the affected skin
10148423|NCT04116151|Placebo Comparator|Control group|Local administration of the Placebo cream on the affected skin
10148424|NCT04115982|Experimental|Cholecalciferol|Cholecalciferol (Vitamin D3) 100 000 IU/2 mL
10148425|NCT04115982|Placebo Comparator|Placebo|Placebo of Cholecalciferol (Vitamine D3) 100 000 IU/2 mL
10148426|NCT04116281|Experimental|Supervised group|Supervised group
10148427|NCT04116281|Other|No supervised group|Control group
10148428|NCT04116307|Experimental|Polymethylsiloxane|Polymethylsiloxane (Enterosgel) is given 3 x 10 g for the initial two days, and 3 x 5 g for the next three days.
10148429|NCT04116307|Active Comparator|Lactobacillus reuteri|Probiotic Lactobacillus reuteri (BioGaia) is given 3 x 20 drops (which means 3 x 400,000.000 CFU) per day for five days.
10148430|NCT04116255|Experimental|exercises group|exercises group apply regular therapeutic home exercises programme
9669471|NCT00653796|Experimental|Ezetimibe + Atorvastatin|
9669472|NCT00653796|Active Comparator|Atorvastatin|
9669473|NCT00651404|Experimental|Ezetimibe|
9669474|NCT00651404|Placebo Comparator|Placebo|
9669475|NCT00651391|Experimental|Ezetimibe + Simvastatin|
9669476|NCT00651391|Active Comparator|Simvastatin|
9669477|NCT00651391|Placebo Comparator|Placebo|
9669478|NCT00651144|Experimental|Ezetimibe + Rosuvastatin|
10148431|NCT04116255|Experimental|splint group|splint group use mandibular oral occlusal splint
10148432|NCT04116190|Experimental|Telerehabilitation (TR)|Shortened inpatient rehabilitation mixed with home-based telerehabilitation.
10148433|NCT04116190|Experimental|Conventional rehabilitation (CR)|Traditional inpatient rehabilitation
10148434|NCT04116294|No Intervention|Before|Standard of care for informatic prescription.
10148435|NCT04116294|Active Comparator|After|Computer-assisted prescription for radiological procedure
10148436|NCT04116164|Experimental|Dosimetry and targeting|"Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively.~In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point"
10185322|NCT03747016|No Intervention|Control 2|In the second step, the control group (Group C2) was not given any diet before surgery.
10148437|NCT04116034|Experimental|DSR|Up to 10 subjects will be treated with alfapump DSR system for a total treatment period of 59 days post-implantation
10148438|NCT04115943|Experimental|Experimental Group|The experimental group (EG) will be submitted to a clinical method considered the gold standard for the treatment of neck pain together with a tongue muscle release protocol.
10148439|NCT04115943|Active Comparator|Control Group|The control group (CG) will only receive the gold standard method for the treatment of neck pain.
10148440|NCT04115904|Experimental|Post-endodontic Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg takena week after. Incidence of flare ups after a single vsmultiple visits root canal treatments.
10148441|NCT04115904|Experimental|Acute pain|Acetaminophen 325 mg for Acute pain. Taken secondday after. Incidence of Post operative pain after rootcanal treatment in one vs two visits
10148442|NCT04116008|Active Comparator|Erector Spinae Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
10148443|NCT04116008|Active Comparator|Subcostal Abdominis Plane Block|Ultrasound-guided bilateral STAP block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
10148444|NCT04116125|Placebo Comparator|Sentinel lymph node biopsy|Perform conventional sentinel lymph biopsy
10148445|NCT04116125|Experimental|Adjuvant radiation without Sentinel lymph node biopsy|Perform radiotherapy instead of sentinel lymph node biopsy
10148446|NCT04116320|Experimental|Cohort 1, primary regimen (Regimen 1a)|FUSA therapy and standard of care PD-1 blockade. FUSA therapy will be administered on day 8.
10148447|NCT04116320|Experimental|Cohort 1, secondary regimen (Regimen 2a)|FUSA therapy will be administered on day 8.
10148448|NCT04116320|Experimental|Cohort 2, primary regimen (Regimen 1b)|FUSA therapy, standard of care PD-1 blockade, and imiquimod. FUSA therapy will be administered on day 1.
10148449|NCT04116320|Experimental|Cohort 2, secondary regimen (Regimen 2b)|FUSA therapy and imiquimod. FUSA therapy will be administered on day 1.
10148450|NCT04116021|Active Comparator|PECS block|Ultrasound-guided pectoral nerve block with bupivacaine 0.5 % 30 mL before surgical incision
10148451|NCT04116021|Active Comparator|Wound infiltration|Wound infiltration with bupivacaine 0.5 % 30 mL at the end of surgery
10148452|NCT04116138|Experimental|Salovum|Salovum®, an egg powder enriched for anti secretory factor.
10148453|NCT04115917|Experimental|Schocket Scleral Depressor|Scleral Depression with Schocket Scleral Depressor
10148454|NCT04115917|Active Comparator|Cotton Tipped Applicator|Scleral Depression with Cotton Tipped Applicator
10148455|NCT04116086|Other|PSMA PET-CT exam|Ga 68 -PSMA PET/CT scanning will be performed using a combined PET/CT protocol with a 16-detector-row helical CT scanner (Philips Gemini GXL). This scanner allows simultaneous acquisition of up to 45 transaxial PET images with interslice spacing of 5 mm in one bed position and provides an image from the vertex to the thigh in about 10 bed positions. The use of (68)Ga-PSMA HBED-CC results in a relatively low radiation exposure, delivering organ doses that are comparable to those of other (68)Ga-labelled PSMA-inhibitors used for PET-imaging. Total effective dose is lower than for other PET-agents used for prostate cancer imaging (e.g. (11) C- and (18) F-Choline).
10148456|NCT04116060|Experimental|Nitrate|Dietary nitrate dissolved in water (0,12 mmol sodium-nitrate/kgBW/day) Dietary Supplement: Dietary nitrate 200 ml tab water with 0,12 mmol/kgBW sodium-nitrate
10148457|NCT04116060|Placebo Comparator|Control|Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day) Dietary Supplement: Dietary sodium-chloride 200 ml tab water with 0,12 mmol/kgBW sodium-chloride
10148458|NCT04116203|Other|Fish Oil|Fish oil capsules 1200mg 6 tablets/day 12 weeks
10148459|NCT04116203|Other|Metformin|Metformin tablets (500 mg) 2/day 12 weeks
10148460|NCT04116203|Other|Fish Oil and Metformin|Combo of other 2 arms
10148461|NCT04115592|Experimental|Liquid oil type 1|Cocoa butter (CB)
10148462|NCT04115592|Experimental|Solid oil type 1|Cocoa butter oleogel (CBOG)
10148463|NCT04115592|Experimental|Liquid oil type 2|Sal seed oil (SL)
10148464|NCT04115592|Experimental|Solid oil type 2|Sal seed oleogel (SLOG)
10148465|NCT04115826|Placebo Comparator|Extracorporeal Shock-Wave Lithotripsy|Stone localization will first be performed by obtaining high-quality plain films of the pancreatic area in left and right oblique positions using a two-dimensional radiologic targeting system.Depending on the stone localization, ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
10148466|NCT04115826|Active Comparator|Per-oral Pancreatoscopy-guided Lithotripsy|Standard ERP will be performed to cannulate the PD, perform pancreatic sphincterotomy, and stricture dilation as necessary. A pancreatoscope (Spyglass Digital System, Boston Scientific, Marlborough, MA) will then be inserted through the duodenoscope into the PD. For PPL, electrical pulses will be delivered through an aqueous medium by EHL or LL with the probe tip in contact with or 1-2mm away from the stone. Settings for EHL (1.9F fiber; Autolith, Northgate Technologies, Elgin, IL) are 10-20 pulses/second with a power of 50-100; and for LL (200, 272, or 365 micrometer fiber, Versa Pulse Power Suite 20-W Holmium laser, New Star, Roseville, CA) ranging from 0.8 - 2.5 Joules with a frequency of 8-15Hz and power of 9-30 W. A maximum of 1 hour of intraductal lithotripsy will be allowed to reduce performance bias.
10148467|NCT04115670|Experimental|specific intervention (experimental)|Specific intervention (experimental). The intervention group will carry out 3 sessions of specific pain education + 15 sessions of physical training.
10148468|NCT04115670|Active Comparator|control group (no intervention)|NO intervention
10148469|NCT04115553|Experimental|idiopathic intracranial hypertension|patients with idiopathic intracranial hypertension
10148470|NCT04115553|Sham Comparator|healthy subjects|Healthy subjects
10148471|NCT04115540|Experimental|TENS penile nerve stimulation group|"The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to prime their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use)."
10148472|NCT04115722||Agroup of IBD patients in activity|
10148473|NCT04115722||Normal controlled group|
10148474|NCT04115878|Active Comparator|High dose ato-oxy|
10148475|NCT04115878|Active Comparator|Low dose ato-oxy|
10148476|NCT04115852||CON|Healthy Controls
10148477|NCT04115852||BED|Patients with Binge-Eating-Disorder
9669479|NCT00651144|Active Comparator|Ezetimibe|
10148478|NCT04115891|Experimental|Lavender oil group|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to tooth extractions.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale 2 (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
10148479|NCT04115891|Sham Comparator|Control group|"No application prior to interventions. No lavender oil inhalation.~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
10148480|NCT04115657|Experimental|Starch 1|Tapioca starch
10148481|NCT04115657|Experimental|Starch 2|High amylose
10148482|NCT04115657|Experimental|Starch 3|Kithul flour
10148483|NCT04115657|Experimental|Starch 4|Sago flour
10148484|NCT04115657|Experimental|Sugar 1|Pure palatinose
10148485|NCT04115657|Experimental|Sugar 2|Blend of sucrose and palatinose
10148486|NCT04115709|Experimental|Intervention: Device attached with advice activated|Beacon Caresystem device will be attached to the patients and its ventilator advice will be activated.
10148487|NCT04115709|Active Comparator|Control: standard care with device attached without advice|Beacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated.
10148488|NCT04115813|Experimental|Intervention Arm|The intervention arm participants received the Project YES! intervention for the first phase and then after midline data collection went into a maintenance phase.
10148489|NCT04115813|Other|Comparison Arm|The comparison arm was a usual care arm during the first phase (and primary analysis). After midline data collection the comparison arm began receiving the Project YES! intervention.
10148490|NCT04115683|Experimental|Intervention Group|
10148491|NCT04115683|Active Comparator|Control Group|
10148492|NCT04115579|Experimental|Biscuit 1 Control|Consumption of control biscuit for breakfast and afternoon snack and impact on postprandial glucose and insulin
10148493|NCT04115579|Experimental|Biscuit 2 Test|Consumption of test biscuit for breakfast and afternoon snack on postprandial glucose and insulin
10148494|NCT04115618|Experimental|SIB|Simultaneous integrated boost intensity-modulated chemoradiotherapy
10148495|NCT04115748|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
10148496|NCT04115748|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg + PTM adalimumab for up to 16 weeks.
10148497|NCT04115748|Active Comparator|Adalimumab (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + adalimumab 40 mg injection for up to 16 weeks.
10148498|NCT04115748|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
10148499|NCT04115748|Experimental|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 2 years.
9669480|NCT00651144|Active Comparator|Rosuvastatin|
9669481|NCT00651144|Placebo Comparator|Placebo|
9669482|NCT00651014|Experimental|Ezetimibe|
9669483|NCT00651014|Placebo Comparator|Placebo|
9669484|NCT00650689|Experimental|Ezetimibe + Atorvastatin|
9669485|NCT00650689|Active Comparator|Atorvastatin|
10148500|NCT04115748|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 2 years.
10148501|NCT04115800|Experimental|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
10148502|NCT04115800|Placebo Comparator|Liposomal|Subconjunctival liposomal injections in patients with conventional treatments and moderate and severe dry eye disease
10148503|NCT04115423||Tocilizumab initiators|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving tocilizumab at least once from January 2013 to December 2018. Tocilizumab initiators are required to have no record of tocilizumab within 1 year prior to the first prescription of tocilizumab.
10148504|NCT04115423||Tumor necrosis factor inhibitors (TNFi) users|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving TNFi at least once from January 2013 to December 2018. TNFi users will be patients who had no record of tocilizumab and given specific TNFi during 1 year before the first prescription of TNFi.
10148505|NCT04115514|Experimental|Active treatment|Liothyronine Sodium (T3), 5-10-25-50µg instilled directly into the airways in a total volume of 10 ml (T3+0.9% sodium chloride). Progressive dosing every 24 hours for total 96 hours.
10148506|NCT04115514|No Intervention|Control arm|Standard of Care
10148507|NCT04115631|Experimental|Arm A (bendamustine, rituximab, cytarabine)|Patients receive bendamustine IV on days 1 and 2 and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive rituximab IV on day 1 and cytarabine IV every Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
10185323|NCT03747016|Experimental|High energy 1|In the first step,The experimental group (Group E1) is treated with high energy digestible food 300ml.
10148508|NCT04115631|Experimental|Arm B (acalabrutinib, bendamustine, rituximab, cytarabine)|Patients receive PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive acalabrutinib PO BID on days 1-7 and 22-28, rituximab IV on day 1, and cytarabine IV Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
10148509|NCT04115631|Experimental|Arm C (acalabrutinib, bendamustine, rituximab)|Patients receive acalabrutinib PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
10148510|NCT04115436||stroke (+)|Patients experiencing thromboembolic events following a brief discontinuation of anticoagulant or having thrombus on the LAA occlusion device
10148511|NCT04115436||No-stroke|Patients remaining stroke-free months after discontinuation of anticoagulants
10148512|NCT04115449|Experimental|Dexa group|"Spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Than manintance dose of dexmedetomidine will be titrated from (0.2- 0.6 mcg /kg/ min) according to the patient discomfort.~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale. Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
10148513|NCT04115449|Placebo Comparator|Control group|"Normal Saline as a placebo will be infused over a period of ten minutes then spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Then the placebo will be titrated according to patient discomfort.~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale.Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
10148514|NCT04115410||PD-1 inhibitor|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received PD-1 inhibitors as a second line treatment from cytotoxic chemotherapy or as a third line for those received tyrosine kinase inhibitors as a first line, from August 2017 (the first month PD-1 inhibitors were reimbursed in South Korea) to September 2018.
10148515|NCT04115410||Chemotherapy Drugs, Cancer|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received cytotoxic chemotherapy or tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) from August 2017 to September 2018. Each patient switching to PD-1 inhibitor will be matched to three reference standard chemotherapy users.
10148516|NCT04115462|Active Comparator|Morphine|Each participant will receive a single dose of 20 mg morphine tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
10148517|NCT04115462|Placebo Comparator|Placebo|Each participant will receive a single dose of an identical placebo tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
10148518|NCT04115501|Experimental|Restrictive Oxygen|The restrictive oxygen patients' Fraction of Inspired Oxygen (FiO2) will be set at a minimum of 0.3 to maintain their oxygen saturations (SpO2) greater than or equal to 95% intraoperatively. During CPB a blended air/oxygen mixture will be titrated to arterial blood gas analysis with aim of maintenance of PaO2 between 100 and 150 mmHg. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
10148519|NCT04115501|No Intervention|Liberal Oxygen|The liberal oxygen group will consist of subjects exposed to a Fraction of Inspired Oxygen (FiO2) set at 1.0 throughout the intraoperative period, including during cardiopulmonary bypass. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
10148520|NCT04115475|Active Comparator|Healthy Volunteers (HV)|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
10148521|NCT04115475|Experimental|Spinal Muscular Atrophy (SMA) patients|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
10148522|NCT04115397|Experimental|Bisphophonate|Zolendronic acid, one infusion iv
10148523|NCT04115397|Placebo Comparator|Placebo|Placebo, one infusion iv
10148524|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Pancreatic|SMART will be administered per each individual disease site standards
10148525|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Renal|SMART will be administered per each individual disease site standards
10148526|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Lung|SMART will be administered per each individual disease site standards
10148527|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-ADRENAL METASTASES|SMART will be administered per each individual disease site standards
10148528|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-LIVER METASTASES|SMART will be administered per each individual disease site standards
9669486|NCT00650663|Experimental|Ezetimibe + Simvastatin|
9669487|NCT00650663|Active Comparator|Simvastatin|
10148529|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- METACHRONOUS OLIGOMETASTATIC NODES|SMART will be administered per each individual disease site standards
10148530|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- OLIGOPROGRESSIVE OLIGOMETASTATIC NODES/SOFT TISSUE|SMART will be administered per each individual disease site standards
10148531|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SYNCHRONOUS OLIGOMETASTATIC NODES/SOFT TISSUE METASTASES|SMART will be administered per each individual disease site standards
9977156|NCT01358643|Other|P90X + BodyMedia Fit|"For six weeks participants will use the P90X tools and for the other six weeks participants will use the BodyMedia Fit Device.~P90X is a DVD based home exercise program that guides the participant through a daily exercise routine.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress."
10148532|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE CANCER|SMART will be administered per each individual disease site standards
10148533|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BORDERLINE RESECTABLE PANCREAS|SMART will be administered per each individual disease site standards
9669488|NCT00589420|Experimental|Phase II|All patients received sorafenib 200 mg bid daily and docetaxel 75 mg/m2 every 3 weeks
10148534|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BRAIN METASTASIS|SMART will be administered per each individual disease site standards
10148535|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- MESOTHELIOMA|SMART will be administered per each individual disease site standards
10148536|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE BOOST|SMART will be administered per each individual disease site standards
10148537|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PELVIC RE-IRRADIATION|SMART will be administered per each individual disease site standards
10148538|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SPINE|SMART will be administered per each individual disease site standards
10148539|NCT04115202||posterior spinal approach group|Lumbar arthrodesis performed by a posterior spinal approach.
10148540|NCT04115202||anterior spinal approach group|Lumbar arthrodesis performed by a anterior spinal approach.
10148541|NCT04115930||Patient|Fatigue, cognition and quality of life measurements with different kind of tests and forms. EDSS and SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
10148542|NCT04115930||Control|Healthy volunteers. Fatigue, cognition and quality of life measurements with different kind of tests and forms. SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
10148543|NCT04115189||Patients with Metastatic RCC|Patients diagnosed with metastatic RCC with clear cell histology who switched from a 4/2 schedule to a 2/1 schedule of sunitinib in first-line metastatic treatment between January 1, 2014 and June 30, 2018
10148544|NCT04115332|Experimental|Interventional|"EEG Recording The one-channel EEG sensor was recorded from Cz with linked-ear reference based on the International 10-20 system. EEG signals were recorded using BioGraph Infiniti software (Version 6.0.4, n.d.) with a band-pass between 1-30 Hz. The sample rate was 256 Hz with 60-Hz notch filters, and the electrode impedances were lower than 5 kΩ.~A lead II electrocardiogram (ECG) was collected for 5 minutes at baseline using the ProComp InfinitiTM system (Thought Technology Ltd., Montreal, Canada), which was installed on a laptop. A sampling rate of 2,048/second was set in order to acquire real-time interbeat intervals."
10148545|NCT04115215|Experimental|Arm 1|Physical exercise (PE)
9669489|NCT00552097|Experimental|EZ/Simva|
9669490|NCT00552097|Placebo Comparator|Placebo/Simva|
10148546|NCT04115215|Experimental|Arm 2|Transcranial current stimulation (tCS)
10148547|NCT04115215|Active Comparator|Control|Educational sessions on healthy aging
10148548|NCT04115306|Experimental|PMD-026|Oral PMD-026 (dose: 25 - 1000 mg), given daily until disease progression or unacceptable toxicity
10148549|NCT04115111|Experimental|Durvalumab arm|"Patients will receive Durvalumab at the dose and regimens described above every 4 weeks until evidence of disease progression or occurrence of unacceptable toxicity.~Patients who show evidence of disease progression but appear to tolerate Durvalumab well, for whom no other treatment options exist and who, at the judgement of the investigator, may still enjoy clinical benefit, will be classified as failures and offered the possibility to continue treatment with extended follow up."
10148550|NCT04115163|Experimental|Treatment (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10148551|NCT04114942|Experimental|Constant Coach|Randomized to have coach during didactic training and internship.
10148552|NCT04114942|Experimental|Internship Only Coach|Randomized to have coach during internship only.
10148553|NCT04114942|Experimental|Never Coach|Randomized to never have coach.
10148554|NCT04115137||Women with pelvic congestion syndrome|Women older than 18 years At least 1 birth Present symptoms
10148555|NCT04115046||Treatment Arm|Consecutive, eligible patients reporting for an ultrasound and liver biopsy for evaluation of fibrosis will be enrolled. Each subject will undergo both procedures (FibroScan and EUS with SW Elastography).
10148556|NCT04114903||Study A|Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users.
10148557|NCT04114903||Study B|Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity.
10148558|NCT04115020|Experimental|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
10148559|NCT04115020|Experimental|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
10148560|NCT04114994||Alzheimer's Disease|
10148561|NCT04114994||Mild Cognitive Impairment|
10148562|NCT04114994||Frontotemporal Dementia|
10148563|NCT04114994||Vascular Dementia|
10148564|NCT04114994||Parkinson Disease|
10148565|NCT04114994||Traumatic Brain Injury (TBI)|
10148566|NCT04114994||Multiple Sclerosis|
10148567|NCT04114994||No diagnosis|
9971480|NCT01311115|Experimental|Group commitment contracts|"In addition to education and counseling, the intervention includes the following components:~Each participant is encouraged to deposit his cigarette money on a weekly basis, to be returned only if the smoker quits successfully within three months.~The project gives a series of two matching contributions of 150 baht each to participants who meet certain deposit requirements.~Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
9971481|NCT01311115|Active Comparator|Education and counseling|Participants in this group receive educational pamphlets about quitting smoking and one-time, group counseling from a nurse trained in smoking cessation counseling.
9971482|NCT01311128||Heart rate and blood pressure determination|All subjects have the same conditions (T-line, blood pressure cuff, and radial artery catheter), in order to compare them within-subjects.
10148568|NCT04114864|Experimental|Experimental|This arm will be receiving the 7 ME-WE sessions psycho-educational intervention. The experimental group will involve a blended approach with 'face to face' meetings in three European partner countries and online sessions (via a ME-WE mobile app) and a purely 'f2f' approach in a further three European partner countries.
10148569|NCT04114864|Placebo Comparator|Control|The control-group will be a wait-list, receiving relaxation exercises during waiting.
10148570|NCT04115085|Experimental|Hand therapy|9 weeks of standard hand therapy including two 20 min slots per week.
10148571|NCT04115085|Experimental|Therapeutic ultrasound|9 weeks of standard ultra sound therapy including two 10 min slots per week.
10148572|NCT04115085|Experimental|Combined hand therapy and therapeutic ultrasound|9 weeks of standard hand therapy plus therapeutic ultrasound including two 30 min slots per week.
10185324|NCT03747016|Active Comparator|Glucose1|In the first step, Group G1 is given 5% glucose injection 300ml
10185325|NCT03747016|Placebo Comparator|Normal saline 1|In the first step, Group N1 is given normal saline 300ml.
10185326|NCT03747003||HIV-infected male patients|Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided
10185327|NCT03746977|Active Comparator|energy restriction and protein supplementation|Energy restriction of 500 kcal/d and total Protein Uptake (including Supplementation) of 1.2 g/kg body mass/d
10185328|NCT03746977|Active Comparator|Energy restriction, walking and protein|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d) and total protein uptake (including supplementation) of 1.5 g/kg body mass/d
9827680|NCT02464657|Experimental|Ph 2 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase II dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
10185329|NCT03746977|Active Comparator|Energy restriction, walking, protein and WB-EMS|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d), total protein uptake (including supplementation) of 1.5 g/kg body mass/d and WB-EMS application 1,5x 20 min/week
10185330|NCT03746938|Experimental|VB-C01|Surgical technique: Via left lateral thoracotomy, the heart is lifted and supported on two deep pericardial points with 4-0 or 5-0 Prolene double arrmed suture. Each suture is passed through the reinforced frame of the collagen membrane containing the stem cells (VB-C01) and then tied, while the upper part of the patch is held with forceps. After securing the lower part of the pericardial layer, the heart is allowed to slowly recover its position with the pericardial cavity while the collagen membrane is mobilized to cover all of the target area. If necessary, some sutures can be used to fix the patch VB-C01 to the epicardial surface of the heart. Each suture is likewise passed through the reinforced frame of the membrane.
10185331|NCT03746925|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
10185332|NCT03746925|Experimental|SuperPATH|SuperPATH approach surgery to replace the hip.
10185333|NCT03746886||Breast-feeding women|A single breast-milk sample will be collected from 20 women who breast-feed their child (0-6 months old).
10185334|NCT03746847||Patients with Suspected Cardiac Sarcoidosis|patients with biopsy proven or suspected sarcoidosis (based on standard clinical imaging findings).
10185335|NCT03746834|Experimental|Treatment arm|Patients are given NASHA/Dx as a perianal injection
10185336|NCT03746821|Other|Biotin|Volunteers to take biotin suppliment
10185337|NCT03746808|Placebo Comparator|EMA only|Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are receiving shelter-based treatment.
10185338|NCT03746808|Active Comparator|EMA + App/Treatment Messages|Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
10185339|NCT03746795|No Intervention|Standard spirometry|Standard spirometry measurement with a pneumotachograph alone.
9669491|NCT00370890|Experimental|A|Adjuvant chemotherapy and then clinical follow-up and surveillance
10185340|NCT03746795|Experimental|EIT alone|Spirometric examinations realized using the EIT
10185341|NCT03746795|Experimental|Simultaneous standard spirometry and EIT|Simultaneous measurement by spirometer and EIT
10185342|NCT03746782||ACS using clopidogrel + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin
10185343|NCT03746782||ACS using ticagrelor + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin
10185344|NCT03746782||Healthy Donors|Apixaban combined with blood specimens (in vitro) from healthy participants
10185345|NCT03746743||Preterm neonates|Neonates born between 32 and 37 weeks gestation
10148573|NCT04115072|Active Comparator|A - Single dose og PZQ|Single dose of Praziquantel 40 mg/kg Standard treatment of schistosomiasis as recommended by WHO
10148574|NCT04115072|Experimental|B - Five doses of PZQ|"Five doses of Praziquantel~1 x 40 mg/kg Praziquantel after enrollment in the study plus two single doses (40 mg/kg) after 12 and 24 hours after the first treatment~1 x 40 mg/kg Praziquantel five weeks following the 1st dose~1 x 40 mg/kg Praziquantel ten weeks following the 1st dose"
10148575|NCT04114968||Intervention group|Eligible women residing in the Central Denmark Region will be assigned to intervention group. Women in the intervention group receive an invitation for HPV-based cervical cancer screening by attending either 1) GP-based screening or 2) HPV self-sampling. The self-sampling kit includes the dry Evalyn brush self-sampling device (Rovers Medical Devices B.V, Oss, Netherlands), written and picture-based user instructions on how to collect and mail the self-sample, and a prestamped return envelope addressed to the Department of Pathology, Randers Regional Hospital.
10148576|NCT04114968||Control group|Eligible women residing in the other five Danish regions (North, Central, South, Zealand and Capital ) will be assigned to control group. Women in the control group will receive usual care, which for 65-69 year-old women is opportunistic cervical cancer screening at the GP
10148577|NCT04115007|Experimental|Arm A|Standard of care + Stereotactic Body Radiotherapy to oligometastases
10148578|NCT04115007|Active Comparator|Arm B|Standard of care
10148579|NCT04114929|Experimental|Threshold-Based|Patients will be prescribed exercise based on ventilatory thresholds from a maximal cardiopulmonary exercise test
10148580|NCT04114929|Active Comparator|Standard Care|Patients will be prescribed exercise based on standard guidelines
10148581|NCT04114799|Active Comparator|Group A invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid bolus will be applied in case of protocol defined hypotension according to the value of systolic pressure variation SPV (Aisys GE). The value of SPV (tidal volume 6 ml/kg) above 8% will be used to predict fluid responsiveness. In case of fluid responsiveness, bolus of 2ml/kg of Plasmalyte will be given within 10 minutes. Boluses will be repeated in hypotensive patients if fluid responsiveness persists. Norepinephrine will be used in hypotensive patients without predicted fluid responsiveness.
10148582|NCT04114799|Experimental|Group B non-invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid management and the use of norepinephrine will follow a protocol based on the values of cardiac index level, systemic vascular resistance and systolic volume variation (SVV) (ClearSight, Edwards).
10148583|NCT04114786|Experimental|3D-printed mask|Patients will undergo the standard CT SIM, and MR SIM necessary for radiation therapy, creating the masks from the MRIs. Prior to the start of their treatment, patients will have an additional CT scan with the 3D printed mask to confirm safety and treatment accuracy. Patients will then proceed with their standard radiation therapy, immobilized with the mask.The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
9519808|NCT03283163|Experimental|Chronic Pain//PTSD group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
10148584|NCT04114786|Active Comparator|Control group|Control group that will be treated with the standard thermoplastic mask, as a comparison measure. The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
10148585|NCT04114773|Experimental|SCARF|"The participants will take part in a rehabilitation intervention focused on the physical, mental, and social consequences of cardiac arrest with an overarching theme of managing fatigue. This will consist of:~a 5-day residential rehabilitation stay~followed by a 12 week home-based programme including one telephone call by a member of the clinical rehabilitation team,~after the 12 week home intervention there will be a further 2-day rehabilitation stay."
10148586|NCT04114955|Active Comparator|Intervention|Intervention condition comprised of two components designed to address intersectional stigma: 1) a group-level, peer-led intervention and 2) an individual-level peer navigation program to increase uptake of HIV testing and PrEP.
10148587|NCT04114955|Other|Wait-list control|Control participants will receive the intervention after a one-year waiting period.
10148588|NCT04115124|Experimental|E-PAR Arm|Exposed to media, information and communication technology through ethnographic participatory action research.
10185346|NCT03746743||Fullterm neonates|Neonates born at or after 37 weeks gestation
10185347|NCT03746717|Experimental|Prineo|Skin closure with Dermabond Prineo occlusive wound closure system
10185348|NCT03746717|Active Comparator|Staples|Skin closure with staples
9971483|NCT01311141|Experimental|Doripenem i.v.|no comparator, PK study
9971484|NCT01311167|Experimental|Dexamethasone|
9669492|NCT00370890|No Intervention|B|Clinical follow-up and surveillance only
9971485|NCT01311167|Placebo Comparator|Placebo|
9971486|NCT01311180|Experimental|Sensoril®|
9971487|NCT01311180|Placebo Comparator|Placebo|
9971488|NCT01311193|Experimental|light therapy|Morning bright light treatment (at 8000 lux for 40min, daily during 3 weeks)
9669493|NCT00144924|Experimental|laparoscopic pyloromyotomy|
9669494|NCT00144924|Active Comparator|open pyloromyotomy|
9971489|NCT01311206|Experimental|PBFR|Partial Blood Flow Restriction (PBFR) during Low-Intensity Exercise.
9971490|NCT01311206|Active Comparator|PBFR control|Low-Intensity Exercise without partial blood flow restriction.
9971491|NCT01311219|Active Comparator|No surgery|Non-operative Treatment
9971492|NCT01311219|Active Comparator|Plate fixation|Operative Treatment-Plate fixation
9971493|NCT01311219|Active Comparator|Intramedullary pinning|Operative Treatment-Intramedullary Pinning
9971494|NCT01311232||Case|Patients with HBV reactivation
9971495|NCT01311232||Control|Patients without HBV reactivation
9971496|NCT01311245|Experimental|Stage-tailored|At baseline and three months later
9971497|NCT01311245|Experimental|Non-stage-tailored|At baseline and three months later
10148589|NCT04114825|Experimental|RV001V|Total of 12 SC vaccinations with RV001V. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
10148590|NCT04114825|Placebo Comparator|Placebo|Total of 12 SC vaccinations with placebo. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
10148591|NCT04114604|Experimental|Spinal Cord Injury|Adults who have sustained a spinal cord injury at the cervical or upper thoracic level (T6 or higher). Participants will swallow 20% w/v barium (E-Z-Paque) thickened to different consistencies using starch or xanthan-gum based food thickeners.
10148592|NCT04114578||Neonatal profile|ECHO in first 24 hours of life - ideally ECHO at Day 3-5 of life ECHO at 2-3 weeks of life or before discharge (whichever comes first) Data collected at each echocardiography: blood pressure at beginning of ECHO, pre and post-ductal saturation, respiratory support, use of inotropes and dosages, use of iNO and dosage and last blood gas
10148593|NCT04114578||Infant profile ( 4 month and/or 9 month)|Echocardiography Age and stage questionnaires CAT/CLAMS assessment
10148594|NCT04114578||Pediatric profile 3, 5 and/or 8years|Echocardiography Age and stage questionnaires CAT/CLAMS assessment Results from 18 months PMA Bailey will be retrieved
10148595|NCT04114578||Pre-adolescent/adolescent profile 11,14 and/or 17 years|Echocardiography Pediatric Quality of Life inventory survey
10148596|NCT04114591||LARS symptoms|Patient suffering from LARS as identified through LARS questionnaire
10148597|NCT04114591||No LARS symptoms|Absence of LARS symptoms
9971498|NCT01311245|No Intervention|Control group|Assessment only
10148598|NCT04114617|Experimental|Healthy Adults|"Participants will be asked to swallow a series of up to 54 liquid stimuli: a) liquid barium (different brands and concentrations); b) a 20% w/v concentration liquid barium thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; c) lemon-flavored water thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; and/or d) foods representative of minced and moist, soft-and-bite-sized or regular consistency."
10148599|NCT04114643|Active Comparator|Prothrombin Complex Concentrate|
10148600|NCT04114643|Active Comparator|Frozen Plasma|
10148601|NCT04114487|No Intervention|control 1|The control 1 group will not be subjected to any application except education.
10148602|NCT04114487|Active Comparator|control 2|The control 2 group will be the control group and will be taken to the balance training in addition to normal education.
10148603|NCT04114487|Experimental|intervention|In theintervention group, dual task balance training will be applied within the scope of cognitive rehabilitation.
10148604|NCT04114630|Experimental|erenumab|Solution for s.c injection. Prefilled autoinjector
10148605|NCT04114734|Experimental|Park Rx|Participants will be given a park prescription as part of their treatment plan
10148606|NCT04114734|No Intervention|No Park Rx|Usual care only
9827681|NCT02464917|Experimental|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
9971499|NCT01311271|Sham Comparator|Sham rTMS-Sham rTMS|Sham rTMS for 2 weeks
10148607|NCT04114916|Experimental|Apigenin, luteonin, grapefruit extract and citrolive|One capsules a day. It will be consumed at breakfast for eight weeks.
10148608|NCT04114916|Placebo Comparator|maltodextrina|One capsules a day. It will be consumed at breakfast for eight weeks.
10148609|NCT04114708|Other|ACLR|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
10148610|NCT04114708|Other|ACLR with lateral extra-articular tenodesis|All LETs will be performed in a standardized fashion using the modified Lameire technique.
10148611|NCT04114760|Active Comparator|Group A : defibrillator ECG to patchy-type ECG|"Group A subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using defibrillator which contain 12-lead ECG checking function. And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using patchy-type wireless device.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
10148612|NCT04114760|Experimental|Group B : patchy-type ECG to defibrillator ECG|"Group B subject will performing ECG examination to a mock patient in the ambulance.~First ECG performance will be using patchy-type wireless device.~And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using defibrillator which contain 12-lead ECG checking function.~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
10148613|NCT04114331|Experimental|Manual therapy and exercise|"The intervention (3 times a week for 4 weeks, for a total of 12 sessions) consisted primarily of manual therapy (soft tissue and joint mobilization) followed by therapeutic exercises (muscular control and coordination).~Manual therapy:~Joint mobilizations (Grades I-V) to cervical spine, thoracic spine and ribs Soft tissue mobilization to the pectoralis, scaleni, upper traps, thoracolumbar fascia, erector spinae, and suboccipital musculature~Therapeutic exercises:~Strengthening of mid and lower traps, lats, glut med, and glut max. Active & passive stretching of thoracic and lumbar rotation, hip flexors, and plantarflexors.~The treating therapists agreed on a protocol with treatment individualized to each patient."
10148614|NCT04114201|Experimental|PSI|Patients received TKA using patient-specific Instrumentation.
10148615|NCT04114201|Active Comparator|Conventional|Patients received TKA conventional Instrumentation.
10148616|NCT04114448|Experimental|Therapeutic exercise|Patients will be trained to perform a therapeutic exercise intervention protocol. The program will be based on active physical activity including strength, balance an coordination exercises, among others. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
9971500|NCT01311271|Experimental|Sham rTMS-Real rTMS|Sham rTMS in the first week and real rTMS in the second week
9971501|NCT01311271|Experimental|Real rTMS-Real rTMS|Real rTMS for 2 weeks
10148617|NCT04114448|Active Comparator|Usual care|Patients will be instructed to perform an usual care physical therapy intervention protocol. Participants in this group will be told to undergo gentle self-performed joint mobilization and stretching exercises. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
10148618|NCT04114305||Intervention|HIV-infected pregnant women enrolled in ECD program implemented by m2m program; women followed during pregnancy and 18 months post-partum with their infants.
10148619|NCT04114305||Control|HIV-infected pregnant women receiving routine care in clinics without ECD program; women followed during pregnancy and 18 months post-partum with their infants.
10148620|NCT04114526|Experimental|Community Health Advisor 4-step Program|
10148621|NCT04114435||Neonatal profile|"Echocardiography at:~7 to 10 days of chronological age~35 to 37 weeks post-menstrual age (PMA = corrected age);~39 to 44 weeks PMA; Term equivalent"
10148622|NCT04114435||Infant profile ( between 4 months and 9 months)|"Echocardiography~Ages & stages questionnaires CAT/CLAMS assessment"
10148623|NCT04114435||Pediatric profile (36 months and 5 years)|"Echocardiography~Ages & stages questionnaires CAT/CLAMS assessment~Results from 18 months PMA Bayley will be retrieved Figure 1: Premature population - Groups Recruited simultaneously"
10148624|NCT04114357|Experimental|Intervention Group|This arm will consume the supplement daily for 4 weeks.
10148625|NCT04114357|No Intervention|Control Group|This arm will not receive the supplement for 4 weeks.
10148626|NCT04114461|Experimental|HL-TOF tab. 5mg|Tofacitinib freebase
10148627|NCT04114461|Active Comparator|Xeljanz tab. 5mg|Tofacitinib citrate (5mg as tofacitinib)
10148628|NCT04114396||Severe asthma|Untreated by anti-IL5 treatment for severe asthma at point of recruitment. To be prescribed anti-IL5 as part of their treatment following consent. Note: Anti-IL5 treatment is prescribed as per agreed multidisciplinary team meeting, outside of the decision to enrol the patient on the study, and is administered by the clinical team as part of the patient's clinical care outside of the research study.
10148629|NCT04114396||Healthy control|Control group without respiratory condition
10148630|NCT04114253||Liver transplant patients|Adult patients undergoing deceased donor liver transplantation.
10148631|NCT04114188|Experimental|Antithymocyte Immunoglobulin (Rabbit)|rATG induction on day 0 & 1 post op
9519809|NCT03283163|Active Comparator|Trauma-exposed healthy control group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
10148632|NCT04114279|Experimental|Laparoscopic Duodenal Atresia Repair|All participants will attempt a laparoscopic duodenal atresia repair on the synthetic high fidelity simulator.
10148633|NCT04114318|Experimental|Cognitive-Cycling|Dual-task cognitive-cycling training; cognitive and cycling training simultaneously
10148634|NCT04114318|Active Comparator|Cycling|Single-task cycling training; stationary bicycle exercise training
10148635|NCT04114175|Active Comparator|Control Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
10148636|NCT04114175|Experimental|Spinal Stabilization Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
10148637|NCT04114513|Placebo Comparator|Maltodextrin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
10148638|NCT04114513|Experimental|Inulin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
10148639|NCT04114513|Experimental|Pectin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
9519810|NCT03283150|Active Comparator|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
9519811|NCT03283150|Active Comparator|Propofol|Propofol will be administered to subjects during MER.
9519812|NCT03283150|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
10148640|NCT04114513|Experimental|Beta-glucan|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
9669495|NCT04231565|Active Comparator|TAF group|50 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long.
9669496|NCT04231565|No Intervention|Observation group|50 patients would not receive treatment from baseline to life-long.
10148641|NCT04114513|Experimental|Galactooligosaccharides|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
10148642|NCT04114071|Experimental|Physical Activity intervention group|Older overweight or obese Black women who participate in the physical activity intervention group will receive a daily text message from the TOSS study for 12 weeks, a Fitbit device plus have access to the Fitbit community option on their Fitbit app as an opportunity for virtual peer support. They will also receive an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention.
10187820|NCT03722368|Experimental|RCHC+|Participation in the Resilience and Coping of the Healthcare Community Intervention, support groups and one on one counseling.
10187821|NCT03722368|Other|Waitlist Control|This group will receive treatment as usual and will be offered services once the study is complete.
10148643|NCT04114071|Active Comparator|Control group|The control will only receive a weekly neutral text message during the 12-week intervention. For this project, a neutral text message is defined as a message that only provides facts about a topic.They will also receive a Fitbit device, an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention
10148644|NCT04114422|Experimental|Seven-day preoperative exercise training program|All patients will undergo to seven-day preoperative exercise training program that includes aerobic and resistance exercises
9971502|NCT01311284|Active Comparator|Macintosh|
9971503|NCT01311284|Active Comparator|Mcgrath|
9971504|NCT01311284|Active Comparator|Airtraq Nasotracheal|
9971505|NCT01311297||Perioperative ovarian cancer patients|
10148645|NCT04114149|Active Comparator|TENS (transcutaneous electrical nerve stimulation)|High frequency, high intensity TENS treatment. Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
10148646|NCT04114149|Active Comparator|Conventional treatment with iv opioid|Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
10148647|NCT04114149|No Intervention|Control|Patients who report postoperative pain intensity according to NRS (numeric rating scale) < 3 during the time spent in post-anesthesia care unit.
10148648|NCT04114084||A. patients with MGUS and sleep apnea|
10148649|NCT04114084||B. patients with MGUS and no sleep apnea|
9971506|NCT01311297||Pregnant patients|
9971507|NCT01311297||Female healthy volunteers|
9971508|NCT01311310|Experimental|remote ischemic preconditioning|
9971509|NCT01311323|Experimental|PCI with DES implantation|Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
9971510|NCT01311323|Active Comparator|CABG|Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
9971511|NCT01311336|Active Comparator|Loratadine|Loratadine 10 mg once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
9827682|NCT02464917|No Intervention|Room air|This control arm will receive no supplemental oxygen
9971512|NCT01311336|Placebo Comparator|Placebo|Placebo once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
9971513|NCT01311349||1|A listing of all isolates meeting the inclusion criteria will be maintained.
9971514|NCT01311375|Experimental|w3 supplement + capsule CA-D|Mor DHA :w3 supp will be given to this group + capsule Ca(500 mg)-D(200 micro gram)
9971515|NCT01311375|Placebo Comparator|placebo+ CA-D|placebo in the same color,shape,size
9971516|NCT01311401||Rehania village (Kfar Rehania)|Circassian community
9971517|NCT01311401||Kama village (Kfar Kama )|Circassian community
9971518|NCT01311414|Experimental|cafedrine/theodrenalin|
9971519|NCT01311427|Active Comparator|Group education|The control condition received standard group education, which met in small groups two times weekly for 60 minutes over 12 weeks.
9971520|NCT01311427|Experimental|8-form Yang-style Tai chi program|This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
9971521|NCT01311440|Experimental|Modified Atkins diet treatment|12 weeks of Modified Atkins diet treatment, recording seizures
9971522|NCT01311440|No Intervention|No intervention|12 weeks seizure record
10148650|NCT04114084||C. patients with MM and sleep apnea|
10148651|NCT04114084||D. patients with MM and no sleep apnea|
10148652|NCT04114240||Xybilun: mild erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with mild ED (score IIEF-6 between 22 and 25) and begin treatment at 50 mg
9977157|NCT01358643|Other|BodyMedia Fit + Sparkpeople|"For six weeks participants will use the BodyMedia Fit devise and for the other six weeks participants will use the Sparkpeople program.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress.~Sparkpeople is A web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight"
9977158|NCT01358656|Active Comparator|Single Bundle Reconstruction|Subjects will undergo single bundle acl reconstruction
9977159|NCT01358656|Active Comparator|Double bundle reconstruction|Subjects will undergo double bundle acl reconstruction
9977160|NCT01358747|Active Comparator|Standard arm|Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 4 cycles. A PET will be performed after 2 cycles of chemotherapy (PET2) with no decisional value, and after 4 cycles with decisional value. Consolidation treatment: depends on the reviewed PET4 result. In case of PET4 negative result, patient will received 2 additional cycles of BEACOPPesc, whatever the result of the PET2. In case of PET4 positive, the patient will be considered in treatment failure and proposed to a salvage therapy after pathologic confirmation of failure by biopsy of the hypermetabolic residual mass when possible.
10148653|NCT04114240||Xybilun: moderate erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with moderate ED (score IIEF-6 between 11 and 21) and begin treatment at 50 mg
10148654|NCT04114240||Xybilun: severe erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with severe ED (score between 6 and 10) and begin treatment at 50 mg
10148655|NCT04114240||Xybilun switch|Substitution dose to dose of previous treatment by Xybilun whatever the severity of ED.
10148656|NCT04113850|Experimental|Sitting|Subjects will undergo acoustic startle testing in the sitting position.
10148657|NCT04113850|Experimental|Standing|Subjects will undergo acoustic startle testing in the standing position.
10187822|NCT03722355|Active Comparator|Arm 1: Conventional RT + Carmustine|Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles
9971523|NCT01311466|Experimental|Liver transplantation|The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
9971524|NCT01311479|Active Comparator|Osteopathic Manipulation|"Patients will be evaluated and examined by an Osteopathic physician. This examination will consist of full osteopathic structural exam, and a focused examination of the sacroiliac joint and the surrounding musculature.~Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction."
9971525|NCT01311479|Active Comparator|Massage Therapy|Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
9971526|NCT01311492|Placebo Comparator|Healthy Lifestyle Program|The purpose of the healthy lifestyle group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest.
10148658|NCT04113824|Experimental|trapezius motion style acupuncture treatment|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
10148659|NCT04113824|Active Comparator|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
10148660|NCT04114123||Longitudinal|The researchers will be evaluating baseline indicators of wanting salience and liking between 2 and 6 month olds, with the goal of following up with these families at 24 months and beyond by reviewing the dyads' medical charts. The researchers will also examine direct and indirect associations between reward-driven eating, and maternal and infant characteristics and infant weight-for-length.
10148661|NCT04114123||Cross-sectional|The researchers will as the mother to answer questionnaires and participate in up to two video taped behavioral protocols when the infant is 6 months old.
10148662|NCT04113837|Experimental|verum|"The food range is comprised of:~sausages (1100 g per week / exchange of saturated fatty acids by long-chain unsaturated omega-3 fatty acids from fish oil (Maris Oil ED0222N rich in docosahexaenoic acid (DHA)), partially exchange of fat by plant protein (sesame)), eggs (3 eggs per week / 2 µg vitamin D per egg), 100 g mushrooms per day (5 µg Vitamin D/d), one bread per week (5 µg Vitamin D/d), bread rolls (16 g dietary fibers/d), 100 ml ice cream per week (exchange of sugar by xylitol), 3x 70 g pasta per week (3 x 10 g dietary fibers per week)"
10148663|NCT04113837|Active Comparator|control|In the placebo period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), eggs, mushrooms, bread, bread rolls, ice cream and pasta) with traditional nutrient profile.
10148664|NCT04113772|Active Comparator|Orfandin .5 mgm/kg mgm bid|Two participant will receive .5 mgm/kg mgm of orfadin
10148665|NCT04113772|Experimental|Nitinosine .5 mgm/kg bid|Two participant will receive .5 mgm/kg of nitinosine
10148666|NCT04113980|Experimental|music group|The children in the groups were distracted by listening music 2 minutes before venipuncture, until the process was over.
10148667|NCT04113980|Experimental|kaleidescope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
10148668|NCT04113980|Experimental|video group|The children in the groups were distracted by watching cartoon 2 minutes before the blood collection, until the process was over.
9971527|NCT01311492|Active Comparator|Physical Activity Intervention|The physical activity program includes aerobic, strenth, flexibility and balance training.
9971528|NCT01311518|Placebo Comparator|Placebo|
9971529|NCT01311518|Active Comparator|Drug: Thymosin Beta 4 injectable|
9971530|NCT01311531|Active Comparator|TriMed fragment-specific fixation|
9971531|NCT01311531|Active Comparator|TriMed volar locking plate|
9971532|NCT01311570|Experimental|Buprenorphine|
9971533|NCT01311583|Active Comparator|usual care plus Teach Back intervention|Trained nurses will provide Teach Back to the intervention group. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
10148669|NCT04113980|No Intervention|control group|No intervention was made to children in the control group
10148670|NCT04113863|Active Comparator|ARM A - Anastrozole|Anastrozole at the dosage of 1 mg/die. Treatment will last 28 days
10148671|NCT04113863|Experimental|ARM B - Anastrozole + ATRA|Anastrozole at the dosage of 1mg/die in combination with ATRA at the total dosage of 45mg/m2/die (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
10148672|NCT04113954|Experimental|Leg 1 ACB + low dose SNB-PF|Right leg and 0.375% mepivacaine popliteal fossa-sciatic
10148673|NCT04113954|Experimental|Leg 1 ACB + high dose SNB-PF|Right leg and 1.5% mepivacaine popliteal fossa-sciatic
10148674|NCT04113954|Experimental|Leg 2 ACB + low dose SNB-PF|Left leg and 0.375% mepivacaine popliteal fossa-sciatic
10148675|NCT04113954|Experimental|Leg 2 ACB + high dose SNB-PF|Left leg and 1.5% mepivacaine popliteal fossa-sciatic
10148676|NCT04113954|Experimental|Leg 1 ACB only|Right leg and 1.5% mepivacaine ACB
10148677|NCT04113954|Experimental|Leg 2 ACB only|Left leg and 1.5% mepivacaine ACB
10148678|NCT04114019||Stress urinary incontinence|Women suffering from stress urinary incontinence
10148679|NCT04113915||Group 1|Group of ITP patients received triple therapy
10148680|NCT04113915||Group 2|Group of ITP patients received steroids
10148681|NCT04113915||Group 3|Normal control group
10148682|NCT04113889|Active Comparator|Combination therapy group|Arm 1: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)
10148683|NCT04113889|Placebo Comparator|Standard therapy group|Arm 2: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Placebo
10148684|NCT04113928|Experimental|Broccoli & mustard seed soup|200ml acute feed
10148685|NCT04113928|Active Comparator|Broccoli soup|200ml acute feed
10148686|NCT04113902|Experimental|intervention group|Health education is given intervention group and 12 weeks follow up.
10148687|NCT04113902|No Intervention|control group|Control group takes standard health care and 12 weeks follow up.
10148688|NCT04114097|Experimental|Betamethasone-17-valerat + placebo ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid (Betnovate, betamethasone dipropionate ointment 0.1%) and placebo"
10148689|NCT04114097|Active Comparator|Tacrolimus ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor (Protopic, tacrolimus ointment 0.1%)"
10148690|NCT04113967|Experimental|Biodanza Group|The biodanza program will consist of 12 sessions, one per week, during three months. Each session will last approximately 60 minutes and an introductory phase (10-15 minutes) and an experience phase (45 minutes) will be divided. It involves moving / dancing according to the suggestions of the monitor and the rhythm of the music.
10148691|NCT04113967|No Intervention|Treatment as usual Group|The control group will continue with its usual treatment and activities, without suffering any alteration. A measurement of the groups (control group and biodanza group) will be carried out before the start and after the end of the sessions.
10148692|NCT04113941|Experimental|Neuronox®|Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites
10148693|NCT04113941|Placebo Comparator|Placebo|Normal saline, same volume with Experimental arm
10148694|NCT04113993|Experimental|Oral Bazedoxifene|Oral Bazedoxifene dosed at 40 mg daily
10148695|NCT04113993|Placebo Comparator|Placebo|Identically packaged placebo capsule daily
10148696|NCT04113798|Experimental|Moderate Intensity Exercise|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction
10148697|NCT04113798|Active Comparator|Control|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction
10148698|NCT04114045|Experimental|Whey protein|Whey protein isolate
10148699|NCT04114045|Active Comparator|Isoenergetic control - Carbohydrate|Carbohydrate or maltodextrin
10148700|NCT04114045|Placebo Comparator|Placebo control - Water|Water - chocolate flavoured
10148701|NCT04113668|Experimental|Arm A: Single Dose (BMS-986165)|
10148702|NCT04113668|Experimental|Arm B:Diflunisal and Single Dose (BMS-986165)|
10148703|NCT04113486||Renal cancer group|Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
10148704|NCT04113486||Urothiasis group|Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100.
10148705|NCT04113486||Renal cysts group|Patients which imaging studies have found renal cysts (simple or complex) about 100.
10148706|NCT04113486||Liver cancer group|Patients which imaging studies have found hepatic mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
10148707|NCT04113473|Experimental|Yoga Group|Experimental group received individualised yoga therapy twice a week for an hour for 12-weeks.
10148708|NCT04113473|No Intervention|Control Group|Control group were given education session and continued on usual care for 12-weeks.
10148709|NCT04113564|Experimental|IV remimazolam|IV remimazolam administration of 0.025 mg/kg body weight
10148710|NCT04113564|Experimental|Oral remimazolam|Oral remimazolam Administration of 0.14 mg/kg Body weight
9669497|NCT04215003|Active Comparator|A|6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.
9669498|NCT04215003|Experimental|B|2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery
9669499|NCT04215003|Experimental|CL1|If patients were HR+ and HER2- without PI3K-AKT pathway mutation
10148711|NCT04113551||Cohort T1: Methylphenidate (MPH) (Concerta)|Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
10148712|NCT04113551||Cohort T2: MPH (Ritalin)|Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
10148713|NCT04113551||Cohort T3: MPH (Concerta and Ritalin)|Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.
10148714|NCT04113551||Cohort T4: Atomoxetine (ATO)|Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
10148715|NCT04113551||Cohort T5: Guanfacine (GFC)|Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
9669500|NCT04215003|Experimental|CL2|If patients were HR+ and HER2- with PI3K-AKT pathway mutation
9669501|NCT04215003|Experimental|CLH1|If patients were HR+ and HER2+ without PI3K-AKT pathway mutation
9669502|NCT04215003|Experimental|CLH2|If patients were HR+ and HER2+ with PI3K-AKT pathway mutation
10148716|NCT04113551||Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
10148717|NCT04113551||Cohort T7: MPH (Concerta or Ritalin)|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior. These are the first exposure to any MPH among the participants with who had some exposure to MPH.
10148718|NCT04113551||Cohort T8: MPH (Concerta) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
10148719|NCT04113551||Cohort T9: MPH (Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
10148720|NCT04113551||Cohort T10: ATO All Exposures|Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
10148721|NCT04113551||Cohort T11: GFC All Exposures|Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
10148722|NCT04113551||Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
10148723|NCT04113551||Cohort T13: MPH (Concerta or Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
10148724|NCT04113551||Cohort T14: MPH (Concerta and Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.
10148725|NCT04113590|Experimental|Transvaginal cholecystectomy under laparoscopic guidance|The removal of the gallbladder through several small incisions using a camera to see is called laparoscopic cholecystectomy. This study is being done to evaluate whether cholecystectomy can be performed through a natural orifice (the vagina) with minimal laparoscopic assistance (only one abdominal trocar versus four in the routine laparoscopic cholecystectomy).
10148726|NCT04113460|Experimental|Yoga Group|The yoga group received the 8-week yoga sessions at work setting once a week by trained teacher followed by self practices.
10148727|NCT04113460|No Intervention|Control Group|Participants had one introductory session on proper physical position and stretching exercises to be practiced daily during work.
9662366|NCT04537364||pediatric patients with CAKUT|"This cohort is composed of pediatric children diagnosed of CAKUT from Shanghai peri-conceptional parent-offspring cohort (SPCC) clinic research related outpatient and high-risk newborns referral outpatient, and those who are enrolled in nephrology department and urinary surgery department with CAKUT diagnosis.~By diagnostic tests for predicting renal parenchymal damage in this cohort, data of kidney images, urinary biomarkers and disease genes can be collected."
10148728|NCT04113512|Experimental|Yoga Nasal Irrigation Group|Saline nasal irrigation using neti pot was practiced.
10148729|NCT04113512|No Intervention|Wait list Control group|Group was given usual pain medication. After trial period, they were offered the intervention.
10148730|NCT04113369|Sham Comparator|TENS group|30 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training program, patients will receive 30 minutes of conventional antalgic TENS (100 Hz) program as controls with electrostimulation device to the non-paretic wrist flexors.
10148731|NCT04113369|Active Comparator|EMS group|0 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training, the patients will receive 20 minutes of electrical stimulation to their non-paretic forearm upon wrist flexors by an intermittent maximum strength program (6 seconds of contraction, 10 seconds of rest) along with 5 minutes of pre and post warm-up with the same device.
10148732|NCT04113629|Other|Sofosbuvir/Daclatasvir|standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir
10148733|NCT04113642||single group|healthy subjects
10148734|NCT04113356||ST-Elevation Myocardial Infarction|Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
10148735|NCT04113655||acellular pertussis vaccine|Antibody persistence at 2 years after a single dose vaccination of Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel (comparator vaccine) administered in parent protocol TDA202
10148736|NCT04113707|Experimental|Motor Lab|Group A will receive 20 minutes of motor lab intervention daily.
10148737|NCT04113707|No Intervention|Standard of Care|Group B will receive standard of care which will be 20 minutes of reading per day.
10148738|NCT04113239||Diagnosed Type 2 Diabetes Mellitus|Patients with incident type 2 diabetes mellitus
10148739|NCT04113239||Control|Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria
10148740|NCT04113265|Experimental|SUNEKOS ® Body|The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated 3 more times with an interval of 1 week (T2i, T3i and T4i).
10148741|NCT04113577||geriatric inpatients with neurocognitive disorder|usability assessment after 30 minutes to test the app
10148742|NCT04113577||unformal cargivers|usability assessment after 30 minutes to test the app with their relatives
10148743|NCT04113577||health professionals|usablity assessment after the enrollement of all patients and unformal caregivers
10148744|NCT04113603|Experimental|A_Single bolus|Single bolus computed tomography urography (CTU)
10148745|NCT04113603|Experimental|B_Split bolus|Split bolus computed tomography urography (CTU)
10148746|NCT04113538|Active Comparator|Standard|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed by an injection every 8 weeks until the end of the study
10148747|NCT04113538|Experimental|Treat and Extend|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed and, until the end of the study, retreatment interval based on disease stability
10148748|NCT04113174||SAIL databank|Anonymised records from around 5 million people in Wales, with linked primary care, ED attendance, hospital admissions, outpatient data, social care, Welsh Care Homes Dataset, and ONS mortality data. SAIL includes eFI summary scores and individual components.
10148749|NCT04113174||ResearchOne|Nationally representative, de-identified data from around 6 million primary care electronic health records on the TPP SystmOne clinical system. ResearchOne includes eFI summary scores and individual components.
10148750|NCT04113174||Leeds Data Model|Anonymised, linked primary, secondary, community and social care data from 810,000 patients across 108 practices in Leeds, including eFI summary scores and individual components.
9971534|NCT01311583|No Intervention|usual care|"All participants will experience the current practice of discharge teaching: daily interaction with the interdisciplinary team members via rounds, counseling on diet and medications with a dietician and pharmacist when referred, view the Heart Failure Discharge Video, and receive a Congestive Heart Failure education package which includes the Heart and Stroke Managing Congestive Heart Failure booklet."
9971535|NCT01311596||No icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the first 2 weeks of the study period~Lab -Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the first 2 weeks of the study period"
9971536|NCT01311596||Icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the last 2 weeks of the study period~Lab - Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the last 2 weeks of the study period"
9971537|NCT01311609|Experimental|Systane|Systane Lubricant Eye Drops
10148751|NCT04113174||CARE75+|National prospective cohort study (n≈1,200) collecting detailed sociodemographic information, frailty measures (including eFI scores), simple instruments suitable for use in primary care (e.g. gait speed, timed-up-and-go test; activities of daily living; informal care; loneliness), and key outcomes at six, 12, 24 and 48 months. CARE75+ is a very rich dataset that provides a highly efficient method to investigate how simple instruments might augment eFI performance.
10148752|NCT04113291|Experimental|DASH diet group|Participants randomized to receive the DASH diet will be prescribed an isocaloric DASH diet using meals (lunch, dinner, snacks) prepared by a Clinical Research Metabolic Kitchen under the direction of a registered dietician. Participants will prepare their own breakfast from a menu. The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
10148753|NCT04113291|Active Comparator|Attention Control Group|Participants randomized to attention control will continue their usual diet, but they will be instructed to limit their sodium intake to 2300 mg/day. They will be requested and voluntarily agree to not make additional diet or exercise changes during the 12-week study.
10148754|NCT04113226|Active Comparator|classical rituximab-based chemotherapy|Rituximab-based physician's choice chemotherapy
10148755|NCT04113226|Experimental|rituximab plus lenalidomide|Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression.
10148756|NCT04113109|Experimental|placebo, icatibant, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
10148757|NCT04113109|Experimental|placebo, icatibant, icatibant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
10148758|NCT04113109|Experimental|icatibant, placebo, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
10148759|NCT04113109|Experimental|icatibant, placebo, icatibant placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
10148760|NCT04113148||Healthy volunteer|Physiological measurements from heel over 60 minute period
10148761|NCT04113148||At risk of Pressure Ulcer|Physiological measurements from heel over 60 minute period
9662367|NCT04535141|Experimental|Olanzapine Arm|Olanzapine 5mg tablet with chemotherapy, and 3 days after
9662368|NCT04535141|Placebo Comparator|Placebo Arm|
9669503|NCT04215003|Experimental|CH1|If patients were HR- and HER2+ without PI3K-AKT pathway mutation
9971538|NCT01311622|Experimental|warfarin|
9971539|NCT01311622|Experimental|warfarin and fostamatinib|
9971540|NCT01311635|Experimental|Treatment A|
9971541|NCT01311635|Experimental|Treatment B|
9971542|NCT01311635|Experimental|Treatment C|
9971543|NCT01311635|Experimental|Treatment D|
10148762|NCT04113148||Confirmed Catefory I Pressure Ulcer|Physiological measurements from heel over 60 minute period
10148763|NCT04113148||Suspected Deep Tissue Injury|Physiological measurements from heel over 60 minute period
10148764|NCT04113122|Experimental|Cross-sectional study:|Testicular cancer survivors who were treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and who were extensively phenotypically mapped within two longitudinal trials (15,16) will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.
10148765|NCT04113122|Experimental|Longitudinal study - chemotherapy group|"Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited in the longitudinal part of this study. Study participation involves four study visits:~Visit 1: before start of chemotherapy Visit 2:before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy"
10148766|NCT04113122|Other|Longitudinal study - stage I control group|"Patients with stage I testicular cancer will serve as control group with three study visits:~Visit 1: at time of orchidectomy Visit 2: one month Visit 3: one year after orchidectomy"
10148767|NCT04113343|Active Comparator|Treatment A: remimazolam|Oral administration of 360 mg remimazolam
10148768|NCT04113343|Experimental|Treatment B: remimazolam + 5% v/v alcohol|Oral administration of 360 mg remimazolam and 5% v/v alcohol
10148769|NCT04113343|Experimental|Treatment C: remimazolam + 15% v/v alcohol|Oral administration of 360 mg remimazolam + 15% v/v alcohol
10148770|NCT04113343|Experimental|Treatment D: remimazolam + 40% v/v alcohol|Oral administration of 360 mg remimazolam + 40% v/v alcohol
10148771|NCT04113343|Placebo Comparator|Treatment E: placebo + 40% v/v alcohol|Oral administration of Placebo + 40% v/v alcohol
10148772|NCT04113005|Experimental|Desmopressin|Aim to evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment.
10148773|NCT04113681|Experimental|Geniculate Artery Embolization Arm|Single-arm prospective study of geniculate artery embolization for symptomatic knee osteoarthritis
10148774|NCT04112914|No Intervention|Education as usual|Participants receive education/healthcare provider communication as usual during their visit to the ED for concussion care.
10148775|NCT04112914|Experimental|New education|Participants receive the newly developed educational toolkit
10148776|NCT04113213|No Intervention|Control|Standard care during consultations.
10148777|NCT04113213|Experimental|Intervention|Standard care during consultations with the addition of a physical lifestyle prescription.
10148778|NCT04113031|Experimental|Flywheel group|The players allocated to the flywheel group will perform six weeks of squat resistance exercise using a flywheel device.
9661861|NCT03862729||Early minimally invasive surgery group|For patients in minimally invasive surgery group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
10148779|NCT04113031|Experimental|Barbell free weight group|The players allocated to the barbell free weight group will perform six weeks of squat resistance exercise using a an olympic barbell and free weight of high loads.
10148780|NCT04113031|Active Comparator|Control|All players in all three groups (including control group) will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (~one weekly match).
10148781|NCT04112901||People with trans-femoral amputation or knee dis-articulation|include individuals with unilateral transfemoral amputation or knee disarticulation, with ≤ K2 mobility grade OR SIGAM grade D or below; i.e. able to walk ≤ 50 meters on level ground, who have been users of either microprocessor-controlled knee or non-microprocessor-controlled knee joint for at least 6 months prior to the recruitment date.
10148782|NCT04113070||Overweight and obesity group|"Children with BMI cutoff points greater than 25.0 or 30.0 at 18 years old were defined overweight or obesity according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.~Willingness to comply with study requirements"
10148783|NCT04113070||Non-overweight group|"Children with BMI smaller than 25.0 at 18 years old were defined non-overweight according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.~Willingness to comply with study requirements"
10148784|NCT04113135|Experimental|Journaling, meditations, education, yoga intervention Arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post testing will take approximately 45 minutes to one hour. Session 1 for all participants will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The intervention sessions (2-6) for the experimental group participants consist will include a group discussion of the objectives for the week, 20-30 minutes of education and journaling (Attachment B), 45-60 minutes of PA consisting of various yoga poses followed by SMART goal setting and guided relaxation..
9971544|NCT01311700|Active Comparator|Early metoprolol initiation strategy|
9971545|NCT01311700|No Intervention|Delayed metoprolol initiation strategy|
9971546|NCT01311739|Experimental|10 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
10185349|NCT03746691|Experimental|Citalopram, 20 mg, IV|After placement of a high resolution impedance manometry catheter (transnasally), citalopram will be administered IV over 30 minutes (20 mg in 100ml saline). Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
10148785|NCT04113135|Active Comparator|Journaling, meditation, education arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post-testing will take approximately 45 minutes to one hour. Session 1 for all participants (control and experimental) will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The control group will participate in a 45-60 minute session for weeks 2-6 consisting of goal setting to facilitate behavior change, education on MS, and meditation. Session 7 will conclude the study with reassessment of all outcome measurements as listed above.
10185350|NCT03746691|Placebo Comparator|Placebo, IV|After placement of a high resolution impedance manometry catheter (transnasally), placebo (saline 100ml) will be administered IV over 30 minutes. Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
10185351|NCT03746678||C-Care Mobile Application|
10185352|NCT03746665|Experimental|meningococcal serogroup A conjugate|mothers will be vaccinated with meningococcal serogroup A conjugate vaccine between 28 - 34 weeks gestation
10185353|NCT03746665|No Intervention|control|serological samples from 100 control mother-infant pairs already recruited as part of the PROPEL trial, (SCC1433), NCT02628886
10185354|NCT03746652|Experimental|DId|Daratumumab, Ixazomib, Dexamethasone
10185355|NCT03746639|Active Comparator|therapeutic ultrasound group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy and therapeutic ultrasound over the paravertebral low back region.
10185356|NCT03746639|Other|therapeutic ultrasound untreated group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy over the paravertebral low back region.Therapeutic ultrasound will not be applied to this group.
10185357|NCT03746626||Hospice 1|Strathcarron Hospice, Scotland. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
10185358|NCT03746626||Hospice 2|Arthur Rank Hospice, England. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
10185359|NCT03746626||Hospice 3|All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
10185360|NCT03746613|Experimental|Minimally invasive robotic cochlear implantation with HEARO|
10185361|NCT03746574|Experimental|Intervention Clinics|Participants in the intervention clinics experienced a 12 session compassion curriculum intevention offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
10185362|NCT03746574|No Intervention|Control Clinics|Completed baseline, end of curriculum, and 6 month follow up survey. Otherwise no intervention
9662369|NCT04530630|Experimental|Biktarvy|Participants receive a Biktarvy tablet orally once daily with or without food.
10185363|NCT03746561||spinal stenosis|Spinal stenosis is a narrowing of the spaces within your spine, which can put pressure on the nerves that travel through the spine. Spinal stenosis occurs most often in the lower back and the neck.
10185364|NCT03746548|Other|CM-ADHEAR|First patients use the Contact Mini (conventional bone conduction device used with a soft band or headband) then ADHEAR (adhesive bone conduction device)
10185365|NCT03746548|Other|ADHEAR - CM|First patients use ADHEAR (adhesive bone conduction device) then CM (conventional bone conduction device used with a soft band or headband)
10185366|NCT03746522|Experimental|Setmelanotide|Dosage form: Subcutaneous injection Dosage: 3 mg Frequency: daily
10185367|NCT03746522|Placebo Comparator|Placebo|Dosage form: Subcutaneous injection Dosage: 3 mg equivalent volume Frequency: daily
10185368|NCT03746496||pre-hospital emergency patients|Patient in a need of an IO-access. Patient in a need of point-of-care laboratory analysis. Over 18 years. Alive (no Cardiac arrest.)
10185369|NCT03746470|Experimental|insertion preserving|ACL reconstruction preserving insertion
10185370|NCT03746470|Active Comparator|insertion detaching|ACL reconstruction detaching insertion
9669504|NCT04215003|Experimental|CH2|If patients were HR- and HER2+ with PI3K-AKT pathway mutation
9669505|NCT04215003|Experimental|CT1|If patients were HR- and HER2- with LAR subtype
10185371|NCT03746457|No Intervention|Control ART Center|Control arm with no intervention throughout the course of the study
10185372|NCT03746457|Active Comparator|Control and Cycle 3 integrated package|Control arm in Cycles 1 and 2 and in Cycle three converts to experimental
10185373|NCT03746457|Experimental|GI + CA + IC|Receives one alternative sequence of three interventions
10185374|NCT03746457|Experimental|IC + GI + CA|Receives a second alternative sequence of three interventions
10185375|NCT03746457|Experimental|CA + IC + GI|Receives a third alternative sequence of three interventions
10185376|NCT03746444|Active Comparator|General Anesthesia|"The patients in this group will undergo unilateral total knee arthroplasty under general anesthesia. Following vascular access and monitorization (non-invasive blood pressure, saturation, electrocardiography).~Epidural chateterisation will be performed and test dose will be applied. Induction will be carried out using propofol (3mg/kg), fentanyl (1cmg/kg) and rocuronium (0.6 mg/kg). Maintenance will be carried out using sevoflurane (%2-3) and 50-50% mixture of nitrous oxide and oxygen. Epidural analgesia will be initiated after the end surgery."
10185377|NCT03746444|Active Comparator|Regional Anesthesia|The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
10185378|NCT03746418|Placebo Comparator|Group I|received 20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.
10148786|NCT04112966|Experimental|Early Manual Lymph Drainage|14 sessions of manual lymphatic drainage technique in the three months following surgery and received health education on the prevention of lymphedema.
10148787|NCT04112966|Other|Health education for lymphedema prevention|Only the health education for lymphedema prevention.
10148788|NCT04112940|Experimental|Adults with oropharyngeal cancer|Adult participants who have completed radiation therapy for oropharyngeal cancer within the past 3 months will undergo a swallowing x-ray study in which they will swallow up to 15 liquid stimuli prepared to different consistencies using starch and gum based thickeners.
9971547|NCT01311739|Experimental|5 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
9971548|NCT01311739|Active Comparator|5 mg Oral Cyanocobalamin|A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
9971549|NCT01311739|Active Comparator|1 mg Intravenous Cyanocobalamin|A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
9971550|NCT01311765|Active Comparator|8 day-antibiotherapy|Duration of antibiotic therapy limited to 8 days: Antibiotics received for up to 8 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit
10148789|NCT04113096|Experimental|Breast Cancer Stage IV|Stage IV Breast Cancer: Dibenzyl trisulphide capsules (20mg once daily)/6 months
10148790|NCT04113096|Experimental|Colon Cancer Stage IV|Stage IV Colon Cancer:Dibenzyl trisulphide capsules (20 mg one daily for 6 months
10148791|NCT04113096|Experimental|Cervical Cancer Stage IV|Stage IV Cancer of the Cervix: Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
10148792|NCT04113096|Experimental|Cancer of the Prostate Stage IV|Stage IV Prostate cancer:Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
10148793|NCT04112810|Experimental|Tildrakizumab|Tildrakizumab (IluymaTM) is a humanized monoclonal antibody that specifically binds to the IL-23p19 subunit of IL-23 to neutralize its function.
10148794|NCT04112979|Experimental|Auditory stimulation 1 (Music)|45 deciBel Sensation Level (dB SL), normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
10148795|NCT04112979|Experimental|Auditory stimulation 2 (Mother's lap)|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
10148796|NCT04112979|Experimental|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 deciBel (dB)
10148797|NCT04112979|No Intervention|No stimulation|Current standard of care
9661862|NCT03862729||conventional treatment group|Eligible patients not accepting early minimally invasive surgery are classified as the conventional treatment group. Conventional treatment includes medical treatment and conventional craniotomy. According to the intention-to-treat principle, patients treated by minimally invasive surgery beyond the 24 hours interval after ICH onset are also classified as conventional treatment group.
10148798|NCT04112771||Penehyclidine group|Penehyclindine hydrochloride was administered before anesthesia induction.
10148799|NCT04112771||Placebo group|Penehyclindine hydrochloride was not administered before anesthesia induction.
10148800|NCT04112836||Normal nutritional status|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of 24-30 points.
10148801|NCT04112836||Malnourished|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of fewer than 17 points.
10148802|NCT04112563|Active Comparator|WLI-LCI group|a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI
10148803|NCT04112563|Active Comparator|LCI-WLI group|a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)
10148804|NCT04112875|Active Comparator|L-arginine|L-arginine supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
10148805|NCT04112875|Placebo Comparator|Maltodextrin|Maltodextrin supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
10148806|NCT04112862|Experimental|Intervention|three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.
10148807|NCT04112680|Experimental|Intervention group 1|Audio messages in this group are focussed on providing a Plausible Alternative to the misinformation
10148808|NCT04112680|Experimental|Intervention group 2|Audio messages in this group focus on Avoiding the Misinformation and instead only provide the correct information
10148809|NCT04112680|Placebo Comparator|Control group|Audio messages in this control group are on a different topic
10148810|NCT04112927||OSA Participants|"Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.~Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study."
10148811|NCT04112927||Healthy Controls|"Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders.~Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording.~Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent."
10148812|NCT04112823|Active Comparator|Dexamethasone 4mg|Dexamethasone 4mg, administered intravenously
10148813|NCT04112823|Active Comparator|Dexamethasone 16mg|Dexamethasone 16mg, administered intravenously
10148814|NCT04112719||Control arm/pregnant patients at term|Control arm where the term pregnant patient will be lying on the bed at 45 degrees.
10148815|NCT04112719||Experimental/Supine|Term pregnant patient will be positioned in supine. Changes in hemodynamics will be measured.
10148816|NCT04112719||Experimental/15 degrees lateral tilt|Term pregnant patient will be positioned at 15 degrees in lateral tilt. Changes in hemodynamics will be measured.
10148817|NCT04112719||Experimental/30 degrees lateral tilt|Term pregnant patient will be positioned at 30 degrees in lateral tilt. Changes in hemodynamics will be measured.
10148818|NCT04112615||Patients and/or carers|Patients and/or their nominated carers come in to give feedback on the device and the system as a whole, from usability to design.
10148819|NCT04112615||Healthcare professionals|Healthcare professionals come in to give feedback on the device and the system, from what results they would like to see and their concerns about patients using it.
10148820|NCT04112550|Active Comparator|Methadone|This cohort will receive oral methadone 15mg po tablet pre-operatively
10148821|NCT04112550|Active Comparator|Oxycodone|This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
10148822|NCT04112758|Experimental|Exercise group|The group will receive twice a week for 5 week
10148823|NCT04112758|No Intervention|Control group|The group will be maintained their normal after school activities
10148824|NCT04112732|Experimental|Multivitamin|1 multivitamin tablet administered by mouth daily for 12 weeks, to be taken with main meal.
10148825|NCT04112732|Placebo Comparator|Placebo|1 placebo tablet administered by mouth daily for 12 weeks, to be taken with main meal.
10148826|NCT04112745|Experimental|Experimental group|
10148827|NCT04112745|Placebo Comparator|Control group|
10148828|NCT04112667||Normal Macular Health|>=60 years old with no macular disease
10148829|NCT04112667||Early Macular Degeneration|>=60 years old with early age-related macular degeneration
10148830|NCT04112667||Young Normals|20-30 years old with normal macular health
10148831|NCT04112329|Experimental|Exergaming|Will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks
10148832|NCT04112329|No Intervention|Control|Asked to continue with their normal daily routine
10148833|NCT04112888|Experimental|Collagen group|"Patients will receive 3 to 5 infiltrations of collagen on the scar once a week.~Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes."
10148834|NCT04112888|Active Comparator|Control group|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes.
10148835|NCT04112485|Other|Open discectomy|This group of patients are treated by open discectomy
10148836|NCT04112485|Other|Microdiscectomy|This group of patients are treated by Microdiscectomy
10148837|NCT04112472|Experimental|Examination of participants|Examination of participants by means of the investigational device as well as the comparative devices.
10148838|NCT04112212|Experimental|IV administration of vedolizumab-800CW|The tracer will be intraveniously administrered 2 or 3 days before the colonoscopy procedure (with the near infrared fluorescence endoscopy platform).
10148839|NCT04112186|Experimental|Behavioral group therapy 1|8-weeks of group therapy
10148840|NCT04112186|Active Comparator|Behavioral group therapy 2|8-weeks of group therapy
10148841|NCT04112368|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
10148842|NCT04112368|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
10148843|NCT04112251|Placebo Comparator|Placebo|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg oral placebo capsule (Cornstarch) every 12 hours for 12 weeks.
10148844|NCT04112251|Experimental|Supplement|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg capsule every 12 hours (100 mg / day of epicatechin) for 12 weeks.
10148845|NCT04112407|Experimental|Control|Standard preparation of the surgical site without P. acnes pretreatment
10148846|NCT04112407|Experimental|BPO Group|Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry.
10148847|NCT04112407|Experimental|BPO and Phototherapy|2 days of benzoyl peroxide washes and 3 treatments of blue light phototherapy. Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry. The blue light phototherapy is administered to the shoulder for 3 minutes on three occasions; 2 days before, the day before surgery and in the preoperative area by the patient.
10148848|NCT04112225|Active Comparator|Positive affect condition|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
10185379|NCT03746418|Active Comparator|Group II|received 20 ml of 0.25% bupivacaine with supplementation of 1 mL containing 100µg dexmedetomidine bilaterally
10185380|NCT03746392|Experimental|Jumpstart Intervention|
10185381|NCT03746392|No Intervention|Usual Care|
10148849|NCT04112225|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
9519813|NCT03283124|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
10148850|NCT04112082|Experimental|Home-Based Neurofeedback Training|
10148851|NCT04112082|Active Comparator|Treatment as Usual|
10148852|NCT04112056|Experimental|Study formula|The infants recruited are provided with the study formula named NAN Comfort producted by Nestle Deutschland AG, Werk Biessenhofen containing moderately hydrolyzed protein and low lactose for free during study, and asked to drink the study formula more than half of the total diet daily.
10148853|NCT04112420|Other|Group A|200 Participants more than 60 yrs old having Trans-esophageal Echocardiography examination upon admission to ICU
10148854|NCT04112264|Experimental|Monopolar radiofrequency ablation|Patients will receive ultrasound-guided monopolar radiofrequency ablation
10148855|NCT04112264|Active Comparator|Bipolar radiofrequency ablation|Patients will receive ultrasound-guided bipolar radiofrequency ablation
10148856|NCT04112017|Experimental|YVOIRE Y-Solution 360|Maximum 5 ml including touch-up
10148857|NCT04112017|No Intervention|No-treatment|No-treatment. At 12 weeks after the assessment, treatment maximum 5 ml including touch-up
10148858|NCT04112316|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
10148859|NCT04112316|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
10148860|NCT04112147|Experimental|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
10148861|NCT04112147|Experimental|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
10148862|NCT04112147|Placebo Comparator|Placebo oral capsule|Patients will receive 12-week of 50mg BID Antroquinonol placebo
10148863|NCT04112043|Active Comparator|NR plus Walking Exercise|
10148864|NCT04112043|Active Comparator|Walking Exercise plus Placebo|
10148865|NCT04112043|Active Comparator|NR Alone|
10148866|NCT04112121|Experimental|Patients Meeting the Chaplain at the Bedside|First meeting with the chaplain, coupled with biblical readings at the bedside.
10148867|NCT04112121|Experimental|Patients Meeting the Chaplain at the Chapel|First meeting with the chaplain, coupled with biblical readings at the hospital's chapel
10148868|NCT04112121|No Intervention|Patients Not Meeting the Chaplain|In the control group we enrolled patients whose diagnoses and number of days in the hospital was similar to the intervention groups (covariate-adaptive, blocked, stratified randomization method).
10148869|NCT04112498|Experimental|nivolumab + relatlimab + rHuPH20|
10148870|NCT04112446|Experimental|Study Treatment|4 mg [14C]-saroglitazar magnesium (approximately 100 μCi) oral suspension
10148871|NCT04112108||mitral stenosis post percutaneous mitral commissurotomy(PTMC)|successful PTMC after follow up
10148872|NCT04111991|Active Comparator|Usual Care|Usual care in the NCH Complex Concussion Clinic
10148873|NCT04111991|Experimental|Usual Care + C-STEP|Usual care in the NCH Complex Concussion Clinic, plus 4 weekly sessions of C-STEP
10148874|NCT04112004||Liver Transplant Recipients|All elective liver transplant recipients done between study period
10148875|NCT04112173|Experimental|Intervention|perturbation-based balance training
10148876|NCT04112394|Experimental|ESP Group|In addition to routine standard perioperative and postoperative analgesia protocol patients will receive a single shot of local anesthetic injection at the erector spinae plane.
10148877|NCT04112394|Other|Control|Patients will receive standard perioperative and postoperative analgesia protocol.
10148878|NCT04111900|Experimental|Sleep/Circadian Friendly|initiation of sleep/circadian rhythm friendly intervention the first night spent in MICU after enrollment until patient transfers/discharges, ceases participation, or meets exclusion criteria.
10148879|NCT04111900|No Intervention|Usual Care|Usual care within intensive care unit
10148880|NCT04111679|Experimental|Music|During laparoscopic task performance; participants will wear a noise cancelling headphone that plays music that is chosen by the participant.
10148881|NCT04111679|No Intervention|No music|During laparoscopic task performance; participants will wear a noise cancelling headphone that does not play music.
10148882|NCT04111653|Experimental|Single arm|Healthy volunteers
10148883|NCT04111731|Active Comparator|Group one|Cryoballoon pulmonary vein isolation
10148884|NCT04111731|Active Comparator|Group two|Radiofrequency pulmonary vein isolation
10148885|NCT04111718|Experimental|Viewing of preparation|The patient will be in the room for the preparation of the PRP and will receive a description of the centrifuge process from the physician administering the injection.
10148886|NCT04111718|Sham Comparator|Blinded to preparation|The patient will leave the room after their blood is drawn and will not view the preparation of the PRP, and will also not receive a description of the centrifuge process.
10148887|NCT04111835|No Intervention|Conventional exfoliative cytology/LBC|"According to current Polish guidelines:~ASC-US: repeat Pap testing in 6 months - current standard protocol~LSIL - repeat Pap testing in 6 months or refer for colposcopy (by the decision of cytologist) - current standard protocol~ASC-H and higher and all glandular lesions - refer for colposcopy - current standard protocol~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~If screening cytology is negative -> rescreening after 3 years."
9971551|NCT01311765|No Intervention|15 day-antibiotherapy|Antibiotics received for up to15 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit corresponding to usual practice and recommendations
9971552|NCT01311778|Placebo Comparator|Placebo|Subjects will receive placebo
9971553|NCT01311778|Experimental|CBD 400 mg|Subjects will receive 400 mg CBD
9971554|NCT01311778|Experimental|CBD 800mg|Subjects will receive 800 mg CBD
9971555|NCT01311791|Experimental|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure.
9971556|NCT01311791|Active Comparator|Standard Medical Therapy|as per protocol
9971557|NCT01311804|Experimental|periarticular parecoxib sodium|patients will be given periarticular parecoxib sodium injection
9971558|NCT01311804|Active Comparator|intravenous parecoxib sodium|intravenous parecoxib sodium will be given during total knee arthroplasty
9971559|NCT01311817|Placebo Comparator|Saline Patch|1mL saline applied to the vaccine patch
9971560|NCT01311817|Experimental|Bacteria plus CT|0.95mL bacterial vector plus 0.05mL cholera toxin
9971561|NCT01311830|Active Comparator|Telephone Counseling|
9971562|NCT01311830|Placebo Comparator|Written Materials|
9971563|NCT01311856||Standard Arm (mail/telephone)|
9971564|NCT01311856||Internet Arm|
10148888|NCT04111835|Experimental|hrHPV molecular testing|"hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative -> The CINtec PLUS Cytology and The QIASURE methylation test~The CINtec PLUS Cytology Positive -> colposcopy Negative -> rescreen in 3 years~The QIASURE methylation test Positive -> colposcopy Negative -> rescreen in 3 years~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.~HPV-negative - rescreen in 5 years"
9971565|NCT01311869|Active Comparator|EGCG ( Green Tea extract)|40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
9971566|NCT01311869|Placebo Comparator|Brown Rice pills|40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months
9971567|NCT01311882|Experimental|MK-4305 40 mg|Day 1 and Day 8- 4 x 10 mg MK-4305 and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305
9971568|NCT01311882|Experimental|MK-4305 20 mg|Day 1 and Day 8- 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo
9971569|NCT01311882|Active Comparator|Zopiclone 7.5 mg|Day 1 and Day 8- 1 x 7.5 mg zopiclone and 4 x 10 mg MK-4305 matching placebo; Days 2-7- 4 x 10 mg MK-4305 matching placebo
9971570|NCT01311882|Placebo Comparator|Placebo|Day 1 and Day 8- 4 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305 matching placebo
9971571|NCT01311908||Surgery, Roux-en-Y , reflux esophagitis|Patients with roux-en-Y reconstruction (study group)
9971572|NCT01311908||surgery, traditional gastrojejunostomy|Traditional gastrojejunostomy reconstruction (control group).
9971573|NCT01311934||HBV-infected|
9971574|NCT01311934||HCV-infected|
9971575|NCT01311960|Experimental|bevacizumab eye drop|
9971576|NCT01311960|Experimental|placebo normal saline eye drop|
9971577|NCT01311973||Renal Function Group #1|Creatinine clearance > 90 mL/min
9971578|NCT01311973||Renal Function Group #2|Creatinine clearance 60-69 mL/min
9971579|NCT01311973||Renal Function Group #3|Creatinine clearance 50-59 mL/min
9971580|NCT01311973||Renal Function Group #4|Creatinine clearance 40-49 mL/min
9971581|NCT01311973||Renal Function Group #5|Creatinine clearance 30-39 mL/min
9971582|NCT01311973||Renal Function Group #6|Creatinine clearance 20-29 mL/min
9971583|NCT01311973||Renal Function Group #7|Creatinine clearance < 20 mL/min (not on dialysis)
9971584|NCT01311986||Patients with atopic dermatitis|
9971585|NCT01311986||Patients with nummular eczema|
9971586|NCT01311986||Normal control|
9971587|NCT01311999||IGRA-positive group|The subjects who have positive results of interferon-gamma release assay
9971588|NCT01311999||IGRA-negative group|The subjects who have negative results of interferon-gamma release assay
9971589|NCT01312012|Experimental|The effectiveness and feasibility, using antiviral therapy|Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels > 10^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
9971590|NCT01312012|No Intervention|Control|Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
9971591|NCT01312025|Placebo Comparator|conventional laparoscopic cholecystectomy|
9971592|NCT01312025|Active Comparator|modified laparoscopic cholecystectomy|
9971593|NCT01312051||Protocol 1|Healthy, overweight 11 to 17 year old black and white adolescents
9971594|NCT01312051||Protocol 2|Healthy, normal-weight 11 to 17 year old black and white adolescents
9971595|NCT01312051||Protocol 3|Healthy, normal-weight 8 to 12 year old black and white adolescents
9971596|NCT01312051||Protocol 4|Healthy, overweight 11 to 17 year old black and white adolescents
9971597|NCT01312064|Active Comparator|rituximab and everolimus|Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
9971598|NCT01312064|Active Comparator|thymoglobulin and tacrolimus|The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.
10148889|NCT04111640|Experimental|Experimental group|A computer-supported cognitive training for the training of logical-executive and working-memory functions (CoRe software)
10148890|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
10148891|NCT04111822|Active Comparator|Conventional treatment of septic shock|Conventional treatment of septic shock according to current management guidelines
10148892|NCT04111822|Experimental|Current management plus ascorbic acyd,thiamine and vitamin C|"Conventional treatment of septic shock according to current management guidelines associated with:~i. Hydrocortisone 50 mg every 6 hours for 7 days or until discharge from the ICU with subsequent withdrawal in descending pattern for 3 days ii. Vitamin C (ascorbic acid) 1.5 gr diluted in 100 ml of 5% SG every 6 hours for 4 days (16 doses) iii. Thiamine 200 mg diluted in 100 ml of SG 5% or SF 0.9% every 12 hours for 4 days iv. Measurement of vitamin C levels prior to administration of the first dose of vitamin C"
10148893|NCT04111744|Experimental|Training Group|Preoperative Exercise Training Optimal medical therapy,
10148894|NCT04111744|Other|Control Group|Optimal medical therapy, inactive control group
10148895|NCT04111913|Experimental|anlotinib and chemoradiotherapy|"anlotinib: 12 mg, po, qd, on day1-14 of a 21 days cycle; anlotinib will be administrated to 2 cycles for induction before the 2 cycles of chemoradiation and anlotinib will be administrated up to 1year or disease progression for maintenance treatment.~EP regimen: cisplatin 50mg/m2, d1, 8, 29, 36; etoposide 50mg/m2, d1~5, d29~33. Radiotherapy program: 2 Gy / time / d, 5 d / week;PTV radiotherapy 60~66Gy/30~33 times/6~7 weeks."
10148896|NCT04111783|Experimental|POU ultrasound intervention test group|The experimental group used POU protocol ultrasound to perform a heart scan and a standard scan, a large vascular scan under the xiphoid, a body cavity scan, a standard section, and a lung scan in 10 minutes. Comprehensive preoperative circulation and assessment of systemic conditions, and guided intraoperative anesthesia management with assessment results.
10148897|NCT04111783|No Intervention|Control group|the anesthesiologist performed according to the existing preoperative evaluation program and existing experience, and guided the anesthesia management with the evaluation results.
10148898|NCT04111770|Experimental|IVUS guided PCI|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
10148899|NCT04111770|Active Comparator|QCA guided PCI|QCA will be used to determine lesion characteristics
10148900|NCT04111796|Experimental|group in nature|they participate in nature based-program during work hours
10148901|NCT04111796|No Intervention|control group|they participate don't in nature based-program during work hours and perform their normal work schedule
10148902|NCT04111562|Other|polymethyl methacrylate Cranioplasty|The Cranioplastic kit used (Teknimed, Biomaterials Innovation, Gentafix 1 ®, France) a biocompatible material that is composed of powder and liquid form of polymethyl methacrylate.
10148903|NCT04111809||intravenous biphosphonate|Patients treated with intravenous bisphosphonate until 12 months in routine care
10148904|NCT04111614|Experimental|Arm 1|Single dose of 5 mL tofacitinib oral solution on Day 1 of Period 1 and Singe dose of 5 mg tofacitinib tablet on Day 1 of Period 2
10148905|NCT04111614|Experimental|Arm 2|Single dose of 5 mg tofacitinib tablet on Day 1 of Period 1 and Singe dose of 5 mL tofacitinib oral solution on Day 1 of Period 2
10148906|NCT04111523|Experimental|SY-007 dose 1|The study will be intiated in healthy subjects at a 1mg dose. Six subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 2:1.
10148907|NCT04111523|Experimental|SY-007 dose 2|The study will be intiated in healthy subjects at a 4mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
10148908|NCT04111523|Experimental|SY-007 dose 3|The study will be intiated in healthy subjects at a 10mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
9826194|NCT02411591|Experimental|Necitumumab + Abemaciclib|"Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.~Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met."
9826195|NCT02411747|Experimental|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
10148909|NCT04111523|Experimental|SY-007 dose 4|The study will be intiated in healthy subjects at a 20mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
9519814|NCT03283124|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
10148910|NCT04111523|Experimental|SY-007 dose 5|The study will be intiated in healthy subjects at a 30mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
10148911|NCT04111523|Experimental|SY-007 dose 6|The study will be intiated in healthy subjects at a 45mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
10185382|NCT03746366|Experimental|Alcohol use disorders|[C-11]Pittsburgh Compound B (PiB) PET scan
10185383|NCT03746366|Experimental|Healthy controls|[C-11]Pittsburgh Compound B (PiB) PET scan
10185384|NCT03746353|Experimental|Early closure of ileostomy|Early clousure of ileostomy before 30 days
10185385|NCT03746353|Active Comparator|Conventional closure of ileostomy|Conventional closure of ileostomy after 30 days
10185386|NCT03746340||Anesthetic|Sevoflurane Group Propofol Group
10185387|NCT03746327|Experimental|Sivextro arm|200 mg milligram per day during 4 weeks
10148912|NCT04111887|Experimental|Change Ahead|Each of the 6 weekly 1-hour sessions begins with a voluntary commitment to actively participate and to try something new in the upcoming week; includes a section devoted to selecting and publicly committing to one change focused on reducing negative/increasing positive cognitions and one change focused on increasing pleasant activities; and ends with home practice assignments. Additional exercises designed to increase dissonance induction include (a) group discussions for changing conditions, (b) roleplays to generate quick comebacks to written negative thoughts provided by other group members, (c) in-session writing exercises on the benefits of doing fun activities, (d) discussion of methods for creating internal and external accountability for positive change, (e) home practice assignment of engaging in actions to help someone else' mood, (f) writing a letter to my future self about positive intentions, and (g) providing positive feedback to other group members at the last session.
10148913|NCT04111887|Active Comparator|Blues Program|The 6 weekly 1-hour sessions begin with a review of concepts and (after Session 1) review of past home practice assignments; all sessions conclude with home practice assignments. Each session has a portion devoted to thought identification/recording and cognitive restructuring and a portion devoted to increased involvement in pleasant activities. We use motivational enhancement exercises to maximize willingness to use the new skills, behavioral techniques to reinforce use of the new skills, and group activities to foster feelings of group cohesion.
10148914|NCT04111887|Placebo Comparator|Brochure control|"NIMH brochure that describes major depression and recommends treatment for depressed youth (Let's Talk About Depression NIH Pub. 01-4162), as well as information about local treatment options."
10148915|NCT04111575|Experimental|music therapy group 1|The mothers in the experimental group 1 received music therapy for 30 minutes a day.They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
10148916|NCT04111575|Experimental|music therapy group 2|The mothers in the experimental group 1 received music therapy for 30 minutes twice a day. They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
10148917|NCT04111575|No Intervention|control group|the control group were made to rest in bed for 30 minutes a day for two consecutive days, considering the first day after the C-section as the beginning day.
10148918|NCT04111484|Active Comparator|Adrenomedullin|Will received 19.9 picomol/kg/min of adrenomedullin over 20 min
10148919|NCT04111484|Placebo Comparator|Saline|Saline
9826196|NCT02411747|Active Comparator|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
10148920|NCT04111471|Placebo Comparator|Placebo Arm|20 patients will receive 5.6 g of placebo product (maltodextrin) daily for a total of 21 days (7 days before and until 2 weeks after transplant)
10148921|NCT04111471|Experimental|Prebiotic (Inulin) Arm|20 patients will receive 10 g of inulin product daily for a total of 21 days (7 days before and until 2 weeks after transplant)
10148922|NCT04111432|Experimental|Group I-EV71 and EPI vaccines Concomitant administration|EV71 Vaccine (intramuscular injection,0.5ml,first dose)/measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and EV71 Vaccine (intramuscular injection, 0.5ml,second dose)/ encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
10148923|NCT04111432|Active Comparator|Group II-EPI vaccine only Single injection of EPI vaccine:|measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
10148924|NCT04111432|Active Comparator|Group III-EV71 vaccine only EV71 Vaccine only|the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 andday 30 respectively
10148925|NCT04111341|Experimental|TCM Gan-Lu-Yin (GLY)|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
10148926|NCT04111341|Placebo Comparator|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
10148927|NCT04111328|Experimental|sufentanil administration intravenously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
10148928|NCT04111328|Experimental|sufentanil administration subcutaneously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
10148929|NCT04111328|Experimental|hydromorphone administration intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
10148930|NCT04111328|Experimental|hydromorphone administration subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
10148931|NCT04111328|Experimental|sufentanil and dexmedetomidine intravenously|The dose of sufentanil, dexmedetomidine,for patient-controlled analgesia is 3.0μg/Kg, dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
10148932|NCT04111328|Experimental|sufentanil and dexmedetomidine subcutaneously|The dose of sufentanil ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
10185388|NCT03746288|Experimental|Treatment Group|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
9519815|NCT03283111|Experimental|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
9826197|NCT02411916|Experimental|intervention cases|patient receiving misoprostol
9519816|NCT03283072|Sham Comparator|Sham|normoxia for 2 minutes, normoxia 1 minute x 8 using hypoxicator
9826198|NCT02411916|No Intervention|controls|patients not receiving misoprostol
10148933|NCT04111328|Experimental|hydromorphone and dexmedetomidine intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5ml/h, PCA dose 1ml, locking time 15 min.
10148934|NCT04111328|Experimental|hydromorphone and dexmedetomidine subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5ml/h, PCA dose 1 ml, locking time 15 min.
10148935|NCT04111198||coronary artery disease in diabetic and non diabetic patients|
10148936|NCT04111159|Experimental|HSK3486|Subjects < 65 years old:0.4mg/kg/0.15mg/kg;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
10148937|NCT04111159|Active Comparator|Propofol|Subjects < 65 years old:2mg/kg/0.75mg/kg;Subjects≥ 65 years old:75% of the dose for subjects < 65 years old.
10148938|NCT04111315|Active Comparator|metamizole + educational intervention|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
10148939|NCT04111315|Active Comparator|metamizole + standard care|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
10148940|NCT04111315|Active Comparator|ibuprofen + educational intervention|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
10148941|NCT04111315|Active Comparator|ibuprofen + standard care|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
10148942|NCT04111302|Experimental|IV-PCA|use IV-PCA for postoperative pain
10148943|NCT04111302|Experimental|IV-dezocine|use IV-dezocine for postoperative pain
10148944|NCT04111302|Experimental|IV-PCA+AA|use IV-PCA and AA for postoperative pain
10148945|NCT04111302|Experimental|IV-dezocine+AA|use IV-dezocine and AA for postoperative pain
10148946|NCT04111406|Other|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
10148947|NCT04111406|Experimental|Protocol based|Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based
10148948|NCT04111133|Experimental|Carvedilol + Ivabradine|
10148949|NCT04111133|Active Comparator|Carvedilol|
10148950|NCT04111848|Experimental|ketamine group : group (k)|-Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour
10148951|NCT04111848|Experimental|ketamine and magnesium group: group (KM)|- Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
10148952|NCT04111081|Experimental|Auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
10148953|NCT04111081|Sham Comparator|Sham auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
10148954|NCT04111120||Cirrhosis with variceal bleeding|Coagulation factor assays and heparinase treated SONOCLOT at Days 0,3, and 7
10148955|NCT04111120||Cirrhosis without Bleeding|Control group of 25 subjects
10148956|NCT04111029||Unresectable HCC undergoing locoregional therapy|Patients with unresectable HCC who have no curative option like tumour ablation, resection or transplantation and are being taken for locoregional therapy will be recruited
10148957|NCT04111367|Experimental|Genotype 2 and 6 Subjects|Genotype 2 and 6 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12
9669506|NCT04211831|Experimental|Cohort 1: URO-902 24 mg; Placebo|Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
10148958|NCT04111367|Experimental|Genotype 3 Subjects|Genotype 3 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 24
10148959|NCT04111445|Experimental|ADG116|
10185389|NCT03746288|Active Comparator|Control Group|The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.
10185390|NCT03746275||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Europe, Asia, Latin America and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid to prevent atherothrombotic events
9519817|NCT03283072|Experimental|Trubower|15 bouts of hypoxia for 1 minute, normoxic 1 minute using hypoxicator
9669507|NCT04211831|Experimental|Cohort 2: URO-902 48 mg; Placebo|Participants will receive either a single treatment of URO-902 48 mg or matching placebo.
10148960|NCT04111250|Experimental|Crestal sinus lift using iRasie implant|"Device: iRaise Sinus Lift implant (Maxillent, Herzliya, Israel). Procedure: crestal sinus lift augmentation.~We tested crestal versus lateral approach to the sinus. Crestal approach is made by a novel device (iRaise, implant system). Lateral approach is made conventionally with gold standard procedure (lateral approach).~The iRaise Sinus Lift implant is made of Titanium-6 Aluminum-4 Vanadium alloy, have a surface treated with grit blasting using an apatitic calcium phosphate media, followed by acid etching, and have an internal hexagon connection. Implants have an internal l-shape channel to allow saline and graft passage.~This implants system is made to perform crestal sinus lift procedure at the same time of the implant placement using the same device. After implant site preparation and initial implant placement, the hydraulic system is connected to the implant to allow the injection of saline and then graft the material. Then, the implant, is inserted for its full length."
10148961|NCT04111250|Active Comparator|Lateral sinus lift|"Conventional procedure.~Lateral approach to the sinus was made following the conventional procedure.~A window on the lateral wall of the sinus is performed according to a conventional surgical lateral approach to the sinus cavity. Graft materials is filled inside the sinus cavity. Finally, iSure implants [Maxillent] are placed, and flap is sutured."
10148962|NCT04110951|Experimental|Pranayama group|Kapalbhati, Ujjayi and Anuloma-Viloma pranayama techniques were applied to the experimental group. Within this scope, a three days of applied training program was prepared and a guide involving the steps of Pranayama breathing technique was formed. The patients in of pranayama group were trained by the researcher who had yoga trainer certificate. After completing three days of training and observations regarding their accomplishment of applications properly, a pranayama breathing technique video showing how the pranayama breathing technique is done with its details was downloaded to their smartphones and a guide including the application steps was distributed to the patients. The patients were required to apply pranayama technique, in company with the video, 20 min every day and a month in total.
10148963|NCT04110951|Active Comparator|Relaxation group|As there was not placebo breathing control treatment appropriate to yoga breathing technique, relaxation technique was decided to apply in the second group to equalize psychological effects of the treatment. Progressive relaxation technique was taught to the relaxation group during the same training span.A three days of applied training program and Relaxation Technique Application Guide, including steps of progressive relaxation technique, were prepared within this scope. After completing three days of training and observations regarding their accomplishment of applications properly, a relaxing music to listen during applications and a training video involving progressive relaxation directives were downloaded to smartphones of the patients. Also, Relaxation Technique Application Guide involving application steps were distributed to the patients. The patients were required to apply relaxation technique, in company with the video, 20 min every day and a month in total.
10148964|NCT04110964|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
10148965|NCT04111354|Active Comparator|Short-term (4-hours) immobilization.|Short-term (4-hours) immobilization after primary pacemaker implantation.
10148966|NCT04111354|Active Comparator|Long-term (16-24 hours) immobilization.|Long-term (16-24 hours) immobilization after primary pacemaker implantation.
10148967|NCT04111016||Participants able to access the intervention|These group sessions will be delivered by government health workers, and include behavioral recommendations about responsive stimulation, nutrition, water, sanitation and hygiene, lead poisoning prevention, and maternal mental health. Pregnancy groups and caregiver-child groups will be held separately, and mothers and caregivers who attend sessions will receive simple toys and books to use during some of the intervention sessions, which they will be permitted to take home with them. In addition, mothers and caregivers who attend intervention sessions will receive 30 sachets containing 1 gm multiple micronutrient powder (MNP) per month. Beginning as soon as pregnancy is confirmed, health workers will facilitate pregnant women in receiving the Iron and Folic acid supplements already provided by the Government of Bangladesh and will continue the supplementation up to three months post-partum period.
10148968|NCT04111003|Experimental|SFRC direct filling|Restoration of endodontically treated tooth Endodontically treated molars are restored with direct composite restorations, using a short-FRC base filling.
10148969|NCT04111003|Active Comparator|CEREC endocrown|Restoration of endodontically treated tooth Endodontically treated molars are restored with indirect ceramic CAD/CAM restorations.
10148970|NCT04110912||Cardiac arrest|Ischaemic heart disease is the leading cause of death worldwide. However, this is a registry and no interventions are taking place
10148971|NCT04110912||Trauma|Worldwide, trauma is the number one cause of death and disability in people younger than 40 and confirmed for Canada as well for those under the age of 45. However, this is a registry and no interventions are taking place
10148972|NCT04110912||Sepsis|Sepsis is a clinical syndrome that results from dysregulation of the inflammatory response to severe infection. However, this is a registry and no interventions are taking place
10148973|NCT04110912||Stroke|Stroke is the second leading cause of death worldwide, and the leading cause of chronic disability. However, this is a registry and no interventions are taking place
10148974|NCT04110847|Active Comparator|TCM OA1|"JING CEIH SHERN YUAN EXTRACT PILL CHUANG SONG ZONG 3 TABLET For 2 Times per day"
10148975|NCT04110847|Placebo Comparator|Placebo|Placebo 3 TABLET For 2 Times per day
10148976|NCT04110782||Radium223|
10148977|NCT04110795||Cases|Atypical Femur fracture cases
10148978|NCT04110795||Control|matched to AFF cases by race, age, length of ART use
10148979|NCT04110925|Other|MDS patients|All Canadian MDS patients on the MDS-database to be included.
10148980|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
10148981|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+ Nefopam and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and Nefopam 120 mg intravenously were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
10148982|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
10148983|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+Opioid delayed release and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and 20 mg of opioid delayed release (Oxycodone) were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
10148984|NCT04110756|Experimental|ChangeGradients|100 adolescents will be enrolled in the CHANGEGRADIENTS intervention.
10148985|NCT04110756|No Intervention|Comparison, non-intervention condition|100 participants will not participate in the ChangeGradients intervention, and will continue to have treatment as usual at the clinic.
10185391|NCT03746249|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10185392|NCT03746223|Experimental|R2-R/IV-MTX（methotrexate）|experimental arm will be treated rituximab plus lenalidomide (R2) regimen for 6 cycles and followed by lenalidomide maintenance for 2 years, meanwhile intravitreal methotrexate will be given as protocol
10185393|NCT03746197|Experimental|Project EVO Multi- Treatment|Treatment group receives video game device treatment. Participant plays the game for 30 minutes a day, at least five days a week for four weeks.
10185394|NCT03746197|No Intervention|Control|No contact control
10185395|NCT03746171||Patients with rectosigmoid colonic polyps|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
10185396|NCT03746158|Experimental|Curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
10185397|NCT03746145|Experimental|Bifidobacterium longum 1714|Participants consume one 2g sachet containing 10e11 colony-forming units Bifidobacterium longum 1714 strain with maltodextrin and magnesium stearate on a daily basis over 1 year.
10185398|NCT03746145|Experimental|Placebo|Participants consume one 2g placebo sachet containing maltodextrin and magnesium stearate.
10185399|NCT03746132|Active Comparator|Transdermal Continuous Oxygen Therapy|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the Treatment arm which provides Transdermal Continuous Oxygen Treatment (TCOT) (as delivered by EPIFLO device), in addition to standard of care for the surgical wound
10185400|NCT03746132|No Intervention|Control|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the control arm which provides standard of care for the surgical wound.
9977781|NCT01365169|Experimental|Arm III (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.
10185401|NCT03746119|Active Comparator|Nicotine-free e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine-free vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
10185402|NCT03746119|Active Comparator|Nicotine e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine containing vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
10185403|NCT03746106|Active Comparator|Thiamine only|5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
10185404|NCT03746106|Experimental|Trimethporim + thiamine combination|5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
10185405|NCT03746106|Experimental|Metformin + thiamine combination|5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.
10185406|NCT03746093|Placebo Comparator|Control Group|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
10185407|NCT03746093|Experimental|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
10185408|NCT03746067|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
10185409|NCT03746067|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, the 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
10185410|NCT03746054|Experimental|active prevention|optimal medical treatment
10185411|NCT03746054|Sham Comparator|usual clinical practice|usual clinical practice in each center
9519818|NCT03283072|Experimental|Hayes|15 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
9519819|NCT03283072|Experimental|Tester|8 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
10185412|NCT03745989|Experimental|MK-8353 and Selumetinib Dose Escalation|Starting Dose (Dose Level [DL] 1): MK-8353 + selumetinib
10148986|NCT04110899|Experimental|Different paratracheal force|Esophageal occlusion is assessed by inserting an esophageal stethoscope under different paratracheal forces.
9971599|NCT01312077|Experimental|Levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine, and will receive peri- and intraarticular surgical site infiltration during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure and this will be left in situ in the wound. The catheter will be sited under the fascia lata exiting antero-superior to the incision. A bacterial filter will be attached and it will be connected to an elastomeric pump which will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
10148987|NCT04110873|Experimental|Antroquinonol capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
10148988|NCT04110873|Experimental|Antroquinonol capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
10148989|NCT04110873|Placebo Comparator|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
10148990|NCT04110717|Experimental|Active Device Group|25 subjects randomised to receive active device use plus lifestyle intervention for 3 months.
10148991|NCT04110717|Placebo Comparator|Control Device Group|25 subjects randomised to receive control device use plus lifestyle intervention for 3 months.
10148992|NCT04110730|Experimental|3D Prostheses Users|Children with unilateral congenital upper-limb reductions
9827486|NCT02457637||Acute-on-Chronic Liver Disease Inpatient|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients; and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT>3NL(normal level),AST>3NL or TB>2NL within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection gastrointestinal bleeding or jaundice(TB>5NL)within 1 month before enrollment)].~Standary therapy"
10148993|NCT04110730|Active Comparator|Typically Developing Children|Age- and sex-matched control group of typically developing children.
10148994|NCT04110834|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
10148995|NCT04110834|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
10148996|NCT04110834|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to assure that the results obtained from other arms are only due to the effects of the active ingredient in the prepared gel.
10148997|NCT04110860|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
10148998|NCT04110860|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
9971600|NCT01312077|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.2 mg).
9971601|NCT01312090|Active Comparator|Conventional weight loss treatment group|Eating and physical activity counseling and behavioral therapy for weight loss.
10148999|NCT04110860|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
10149000|NCT04110808|Active Comparator|Nitroglycerine|Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
10149001|NCT04110808|Other|Phentolamine|Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
10149002|NCT04110769|Experimental|Responders|"The investigator will administer neoadjuvant chemotherapy After neoadjuvant chemotherapy, multidisciplinary team will decide to surgery or continuing chemotherapy based on following imaging studies and tumor markers.~The patients who undergo surgery after neoadjuvant chemotherapy will be included responders."
10149003|NCT04110769|Active Comparator|Non-responders|The patients who show cancer progression even after neoadjuvant chemotherapy will be classify with non-responder. And the investigator will change palliative chemotherapy.
10149004|NCT04110977|Experimental|Standard Care supported by a Reminder App (Arm A)|Treatment with Standard Care supported by a Reminder App, starting at the beginning of radiotherapy.
10149005|NCT04110977|Active Comparator|Standard Care alone (Arm B)|Treatment with Standard Care alone, starting at the beginning of radiotherapy.
10149006|NCT04110678|Active Comparator|NeuroEPO|The dose of NeuroEPO was a vial with a dose of 1 mL/1mg administered intra-nasally for five consecutive weeks.
10149007|NCT04110678|Placebo Comparator|Placebo|The dose of placebo was a vial with a dose of 1 mL/1mg of an intranasal inert solution administered intra-nasally for five consecutive weeks.
10149008|NCT04110652|Active Comparator|patient|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.(20-22) in addition to pulmonary rehabilitation program.
10149009|NCT04110652|Placebo Comparator|control group|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.
10149010|NCT04110886|Experimental|HSK21542 single ascending doses|
10149011|NCT04110886|Placebo Comparator|Placebo single dose|
10149012|NCT04110639|Active Comparator|Validation Group|A validation group of 10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
9971602|NCT01312090|Experimental|Cryo group|"Eating and physical activity counseling and behavioral therapy for weight loss will be provided to all subjects.~The subjects in the cryo group will be given whole-body cryotherapy 1-3 times a week for the 4-month-treatment period"
10149013|NCT04110639|Experimental|Study Group|A study group of 20 patients with displaced femoral neck fracture patients (Garden 2-4) treated with open or closed reduction and internal fixation
10149014|NCT04111380|Experimental|Nab-paclitaxel and Cisplatin|cisplatin and nab-paclitaxel: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
10149015|NCT04111289|Active Comparator|Patient received upstream high bolus dose of tirofiban|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
10149016|NCT04111289|Active Comparator|Patients did not receive upstream high bolus dose of tirofiban|Patient receive tirofiban downstream selectively according to operator discretion
10149017|NCT04110704|Active Comparator|Transvaginal cerclage|
10149018|NCT04110704|No Intervention|Active monitoring|
10149019|NCT04110548|Experimental|HCs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the emotion regulation task on the computer.
10149020|NCT04110548|Experimental|IGDs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on.They are instructed to complete the emotion regulation task on the computer.
10149021|NCT04110548|Experimental|IGDs on Craving Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the craving regulation task on the computer.
10149022|NCT04111055|Experimental|Closed-loop group|The MAP of the patient will be managed by the CLV system to avoid hypotension. The MAP target selected in the closed-loop system will be the patient's MAP target ( same target as patient's MAP value preoperatively). Then the closed-loop system will have to adjust norepinephrine infusion rate to keep that MAP value within 10% of patient's target.
10149023|NCT04111237|Active Comparator|Two Finger|two finger method for performing chest compressions
10149024|NCT04111237|Experimental|Two Thumb Technique|Two Thumb Technique
10149025|NCT04110379|Experimental|Virtual Reality (VR)|Child behavior management will be done using virtual reality glasses distraction (Remax Fantasy Land virtual reality glasses (Schenzen Remax Co.,Ltd))
10149026|NCT04110379|Active Comparator|Conventional Behavior Management|Child behavior management will be done using conventional behavior management techniques
10149027|NCT04110353|Active Comparator|Conservative dressings|Use of simple dressings on wound post operatively - to be placed at end of operation
10149028|NCT04110353|Active Comparator|Prevena dressing|Use of Prevena(KCI) dressing on wound post operatively - to be placed at end of operation
10149029|NCT04110353|Active Comparator|ciVAC dressing|Use of closed incision VAC (vacuum assisted closure) dressing on wound post operatively - to be placed at end of operation
10149030|NCT04110483|Active Comparator|TURBT|A step-by-step resection of a tumor. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
10149031|NCT04110483|Experimental|Tm-fiber ERBT|A circumferential incision around the tumor is made in the visually intact bladder mucosa. After that, the incision is continued deeper into the muscular layer. Than the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers.
10149032|NCT04110535|Experimental|Remimazolam 5 mg|IV administration of remimazolam 5 mg
9669508|NCT04192006|Active Comparator|Conventional|Jig-based procedure
9971603|NCT01312103|Experimental|Internet Based Safety Decision Aid|
9971604|NCT01312103|Active Comparator|Control Website|
10149033|NCT04110535|Experimental|Remimazolam 10 mg|IV administration of remimazolam 10 mg
10149034|NCT04110535|Active Comparator|Midazolam 2.5 mg|IV administration of midazolam 2.5 mg
10149035|NCT04110535|Active Comparator|Midazolam 5 mg|IV administration of midazolam 5 mg
10149036|NCT04110535|Placebo Comparator|Placebo|Saline injection
10149037|NCT04110418|Active Comparator|Methylene Blue group (Group MB)|"Methylene Blue is supplied in 1 ml or 10 mL single-dose ampules. Each 1 mL ampule contains 10 mg of methylene blue as a clear dark blue solution~Any unused product or waste material should be disposed of in accordance with local practice,~For administration to be diluted before use in a solution of 50 mL 5% Dextrose in Water (D5W) in order to avoid local pain, particularly in the paediatric population. Use the diluted solution immediately after preparation.~Do not mix with sodium chloride 9 mg/mL (0.9%) solution for injection, because it has been demonstrated that chloride reduces the solubility of methylene blue."
10149038|NCT04110418|Placebo Comparator|Terlipressin Group (Group TP )|"The active substance is terlipressin acetate. Each ampoule contains~1 mg of terlipressin acetate in 8.5 ml solution for injection. This is equivalent to 0.12 mg terlipressin acetate per ml.~The powder is to be dissolved in the enclosed solvent and slowly administered intravenously. Further dilution up to 10 ml with sterile isotonic sodium chloride solution is possible.~Store in a refrigerator at 2-8˚C.~Keep the ampoules in the outer carton in order to protect from light"
10149039|NCT04110600|Active Comparator|Coffee group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia And will have 100 ml of coffee after 2,4 and 6 hours~Then outcomes will be assessed as per time frame"
10149040|NCT04110600|Active Comparator|Pepper mint oil group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia This group will have 100 ml of pepper mint oil After 2,4 and 6 hours~Then outcomes will be assessed as per time frame"
10149041|NCT04110587|Placebo Comparator|arthroscopy|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.
10149042|NCT04110587|Active Comparator|arthroscopy plus hyaluronic Acid|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative. An hyaluronic acid injection of 1 mL (Durolane®, 20 mg / mL, Zambon, Barcelona, Spain) at the end of arthroscopy that was only performed in this arm.
10149043|NCT04110626||Expériences Animées Programme|The Expériences Animées programme involves supervised short movies and talks with secondary school and high school pupils about the use of psychoactive substances.
10149044|NCT04110561|Other|Spinal Cord Injury patients with motor complete paralysis|
10149045|NCT04110132|Active Comparator|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Patient will have hemorrhoidectomy."
9669509|NCT04192006|Experimental|Robotic arm-assist|Mako robotic-arm assist based procedure
10149046|NCT04110132|Placebo Comparator|Ganglion impar block with Saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Patient will have hemorrhoidectomy.
10149047|NCT04110041|Experimental|Moderate Intensity|Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
10149048|NCT04110041|Experimental|High Intensity|Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
10149049|NCT04110470|Active Comparator|Control Group|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
10149050|NCT04110470|Experimental|Treatment Group|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
10149051|NCT04110002|Experimental|Injury Prevention Program|Those allocated to the injury prevention program will be instructed on the program, the added exercises, and the additional time commitment.
10149052|NCT04110002|No Intervention|Control|The control group will practice and perform with no change to pre-existing years' standard operating practice.
10149053|NCT04110184||active systemic lupus erythematosus|
10149054|NCT04110184||inactive systemic lupus erythematosus|
10149055|NCT04110067||1|SMILE - Correction of eyes with myopia of more than -7.75 D
10149056|NCT04110015||Neurology patients|Any patients with neurological disorders
10149057|NCT04110015||Glaucoma patients|Any patients with chronic open angle and chronic angle closure glaucoma of all stages
10149058|NCT04110015||Retina patients|Any patients with known retinal conditions
10149059|NCT04110028|Experimental|Nicotinamide riboside 250 mg|One capsule of 250 mg each morning for three months
10149060|NCT04110028|Experimental|Nicotinamide riboside 500 mg|One capsule of 250 mg each morning and afternoon for three months
10149061|NCT04110028|Experimental|Nicotinamide riboside 1000 mg|Two capsules of 250 mg each morning and afternoon for three months
10149062|NCT04110028|Experimental|Nicotinamide riboside 2000 mg|Four capsules of 250 mg each morning and afternoon for three months
10149063|NCT04110028|Placebo Comparator|Placebo for 250 mg nicotinamide riboside|One capsule each morning for three months
10149064|NCT04110028|Placebo Comparator|Placebo for 500 mg nicotinamide riboside|One capsule each morning and afternoon for three months
9971605|NCT01312116|Experimental|Internet-delivered CBT|Active treatment: Internet-delivered Cognitive Behavior Therapy, 8 weeks treatment, guided self-help
10149065|NCT04110028|Placebo Comparator|Placebo for 1000 mg nicotinamide riboside|Two capsules each morning and afternoon for three months
10149066|NCT04110028|Placebo Comparator|Placebo for 2000 mg nicotinamide riboside|Four capsules each morning and afternoon for three months
10149067|NCT04110392|Experimental|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
10149068|NCT04110405|Experimental|Stepped Care|To assess the effectiveness of the stepped care model with 420 women who have depression and potential co-occurring anxiety, recruited from 12 primary care clinics in Tajikistan.
10149069|NCT04110405|Active Comparator|Standard of Care plus Healthy Lifestyle|To compare standard of care plus healthy lifestyle materials with 210 women recruited from 6 primary care clinics in Tajikistan.
10185413|NCT03745976||Group 1|a new long-term total articular prosthesis follow-up strategy by simple questionnaire and radiography (questionnaire and Xray for all patients)
9669510|NCT04191993|Experimental|Direct Superior Approach (DSA)|Direct superior incision during surgery
9669511|NCT04191993|Active Comparator|Posterior Approach (PA)|Posterior approach incision during surgery
10149070|NCT04110210|Active Comparator|Group A(Ultrasound guided ESP block after indtiucon of GA).|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
10149071|NCT04110210|Active Comparator|Group B(GA with conventional analgesia)|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
10149072|NCT04110301|Experimental|MIL62 + Lenalidomide|MIL62 plus Lenalidomide
10149073|NCT04110288||Uncoated Balloon Treatment|Patients treated for PAD with balloon angioplasty, without use of stent.
10149074|NCT04110288||Bare Metal Stent Treatment|Patients treated for PAD with implantation of bare metal stent.
10149075|NCT04110288||Paclitaxel Coated Balloon|Patients treated for PAD with drug coated balloon angioplasty, without use of stent.
10149076|NCT04110288||Paclitaxel Eluting Stent|Patients treated for PAD with implantation of Paclitaxel DES.
9827487|NCT02457728|Experimental|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
9827488|NCT02457793|Experimental|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
10149077|NCT04110223||non-smell cell lung cancer (NSCLC)|Advanced NSCLC patients receiving radiotherapy or chemo-radiotherapy
10149078|NCT04110223||Rectal cancer|Rectal cancer patients receiving neoadjuvant radiotherapy or chemo-radiotherapy
10149079|NCT04110223||Smell cell lung cancer (SCLC)|SCLC patients receiving radiotherapy or chemo-radiotherapy
10149080|NCT04110223||Esophageal cancer|Esophageal cancer patients receiving radiotherapy or chemo-radiotherapy
10149081|NCT04110223||Cervical cancer|Cervical cancer patients receiving radiotherapy or chemo-radiotherapy
10149082|NCT04110223||Liver cancer|Liver cancer atients receiving radiotherapy or chemo-radiotherapy
10149083|NCT04109989|Experimental|HominisTM Surgical System|Gynecological surgical procedure will be performed with the HominisTM Surgical System
10149084|NCT04110340|Active Comparator|Ciprofloxacin Arm|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
10149085|NCT04110340|Other|Control arm|"Control arm adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those who cannot take it orally) for an additional 7 days.~Control arm children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who start taking intravenous ciprofloxacin may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
10149086|NCT04110275|Experimental|low dose group|"Recombinant human tissue-type plasminogen activator derivative(rPA) for injection: 18 mg, Intravenous injection for 2 minutes or more.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
10149087|NCT04110275|Experimental|high dose group|"Recombinant human tissue-type plasminogen activator derivative (rPA) for injection: the first injection of 18 mg rPA is pushed slowly for 2 minutes or more,the second injection of 9mg rtPA is pushed for 1 minute or more.The interval between the two injections should be controlled accurately about 30 minutes.~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
10149088|NCT04110275|Active Comparator|comparative group|Recombinant tissue plasminogen activator for injection: continuous intravenous injection for 2 hours.
10149089|NCT04110093|Experimental|Immunotherapy Combination treatment|All colorectal cancer patients received regorafenib plus PD-1 inhibitor
10149090|NCT04110119|Active Comparator|Control: Drug-Only Group|Patients with acute lower-back pain who have undergone routine conventional drug treatment at the first visit to the emergency department (49 patients). The drug treatment consists of analgesic-anti-inflammatory (diclophenac sodium 75 mg IM) and myorelaxant (thiocolchicoside 4 mg IM), administered only once.
10149091|NCT04110119|Experimental|Case: Drug and Chiropractic Group|Patients, who received chiropractic treatment immediately after the conventional drug treatment as in the control group (49 patients). The chiropractic treatment consists of high speed and low amplitude spinal manipulation techniques, applied only once.
10187823|NCT03722355|Experimental|Arm 2: Hyperfractionated RT + Carmustine|Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles
10187824|NCT03722342|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
10187825|NCT03722329|Experimental|SB12|SB12 (proposed eculizumab biosimilar)
9519820|NCT03283059|Experimental|Octohydroaminoacridine Succinate Tablet|Octohydroaminoacridine Succinate Tablet 4mg P.O. tid
9519821|NCT03283059|Active Comparator|Aricept|Aricept 5mg/day P.O.
10149092|NCT04109807|Experimental|6 hour Filtered Air (FA) followed by O3 exposure|For the first exposure session, participants are exposed to filtered air (FA) for 6 hours. For the second exposure session, the same participant will be exposed to ozone for 6 hours. The ozone levels will start at 0.06ppm increasing to 0.08 ppm in the first hour and holding there for an hour, decreasing to 0.06ppm over the next hour and holding for an hour, increasing back to .08 over the next hour and holding there until the exposure is complete (a total of 6 hours).
9971606|NCT01312116|Experimental|Internet-delivered PDT|Active treatment: Internet-delivered Psychodynamic Therapy Active treatment: Internet-delivered Psychodynamic Therapy, 8 weeks treatment, guided self-help
9971607|NCT01312116|No Intervention|Control condition|Wait-list condition, received treatment 3 months after initial treatment period
10149093|NCT04109807|Experimental|6 hour O3 exposure followed by FA exposure|For the first exposure session, a participant will be exposed to ozone for 6 hours. The ozone levels will start at 0.06ppm increasing to 0.08 ppm in the first hour and holding there for an hour, decreasing to 0.06ppm over the next hour and holding for an hour, increasing back to .08 over the next hour and holding there until the exposure is complete (a total of 6 hours). For the second exposure session, the same participant will be exposed to FA for 6 hours.
10149094|NCT04109768|Experimental|Hands on Nutrition Education|Nutrition and activity intervention to improve behaviors pre to post
10149095|NCT04109872||Mantle cell lymphoma treated with lenalidomide cohort|Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.
10149096|NCT04109742|Active Comparator|Curcumin 500mg capsules|Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
10149097|NCT04109742|Active Comparator|Curcumin 1000mg capsules|Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
10149098|NCT04109742|Placebo Comparator|Placebo curcumin capsules|Dose will be matching placebo capsules daily, orally for 24 weeks
10149099|NCT04109781|Other|Patients with Lumbar disc herniation|Patients with lumbar disc herniation with no response to conservative treatment and were treated with Microdiscectomy
10149100|NCT04109664||antral preservation|The patients were grouped according to the distance of gastric division as Antral preservation group (6cm from pylorus)
9971608|NCT01312142||patients with difficult weaning|
10149101|NCT04109664||Antral resection|The patients were grouped according to the distance of gastric division as Antral preservation group (2 cm from pylorus)
10149102|NCT04109638|Active Comparator|Active PEMF Group|Participants will have a 1 in 2 chance to get the active treatment device post-operatively. The device will be attached to the post-operative dressing. The device is an Endonovo SofPulse that emits a pulsed electromagnetic field (PEMF). Single blind randomization.
10149103|NCT04109638|Sham Comparator|Placebo PEMF Group|Participants will have a 1 in 2 chance to get the placebo treatment device post-operatively. The device will be attached to the post-operative dressing. The Endonovo SofPulse placebo device does not emit a pulsed electromagnetic field (PEMF). Single blind randomization.
10149104|NCT04109599|Experimental|PlaySmart|Adolescents, boys and girls, aged 16-19 will participate in the pilot testing of the adapted game.
10149105|NCT04109859|Experimental|Methylene blue group|Before the anesthesia was intubated, the patients in the methylene blue group were given a 2 mg/Kg methylene blue 50 ml intravenously for 10 min; continuous constant speed pumping methylene blue(0.5mg/Kg/h).
9519822|NCT03283059|Placebo Comparator|Placebo|Placebo P.O. tid
9971609|NCT01312155||Patients undergoing general anesthesia|
9971610|NCT01312168|No Intervention|Healthy non-OSA control|
9971611|NCT01312168|Experimental|OSA receiving therapeutic CPAP|
9971612|NCT01312168|Sham Comparator|OSA receiving subtherapeutic CPAP|
9971613|NCT01312194|Experimental|One vist group|All patients included in this treatment group will receive the complete endodontic treatment in a single visit.
9971614|NCT01312194|Active Comparator|Two-vist group|All patients included in this treatment group will receive treatment in two visits. The first will be done chemo mechanical root canal preparation, the placement of the intracanal medication the basis of calcium hydroxide and coronal sealing. Ten to twelve days later, this medication is removed and the root canal will be permanently filled.
10149106|NCT04109859|Placebo Comparator|Placebo group|Before the anesthesia was intubated, the placebo group was given 50 ml of normal saline for 10 min.continuous constant speed pumpingnormal saline (10ml/h).
10149107|NCT04109651|Experimental|Nursing İntervention|Intervention: Other: Nursing intervention
10149108|NCT04109651|Other|No Intervention: Control Group|Receive routine nursing care
10149109|NCT04109898|No Intervention|standard I-gel insertion technique|Investigator will apply the recommended (standard) I-gel insertion technique in patients
10149110|NCT04109898|Experimental|Modified I-gel insertion technique|Investigator will apply the modified (interventional) I-gel insertion technique in patients
10149111|NCT04109937|No Intervention|Surgery Alone|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction but will not receive any post-operative radiation therapy.
10149112|NCT04109937|Active Comparator|Surgery and Post-Operative Radiation Therapy|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction and will receive any post-operative radiation therapy.
10149113|NCT04109924|Experimental|Treatment (irinotecan, bevacizumab, TAS-102)|Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 10 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10149114|NCT04109963|Active Comparator|RIC once per day|RIC performed once a day on one arm. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
10149115|NCT04109963|Active Comparator|RIC twice per day|RIC performed twice a day on one arm, approximately 12 hours apart. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
9519823|NCT03283046|Experimental|Nivolumab + Ipilimumab + Dexamethasone + Lenalidomide|"The first 4 study cycles are 21 days long, and all remaining cycles are 28 days long.~On Day 1 of Cycles 1-4, Nivolumab by vein over 60 minutes. Thirty (30)minutes after Nivolumab, Ipilimumab given by vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, Nivolumab given by vein over 60 minutes.~Lenalidomide tablets take by mouth on Days 1-14 of Cycles 1-4 and on Days 1-21 of Cycles 5 and beyond. Dexamethasone tablets taken by mouth on Days 1, 8, and 15 of Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.~For participants who are eligible for autologous stem cell transplant, those who achieve at least a partial response after at least 4 cycles of initial therapy will be eligible for:~EITHER Stem cell collection and storage OR Stem cell collection and autologous stem cell transplantation."
9519824|NCT03283020|Active Comparator|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
9519825|NCT03283020|Active Comparator|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
9519826|NCT03283007|Experimental|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
9519827|NCT03283007|Placebo Comparator|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
9519828|NCT03282994|Experimental|Treatment with cryotherapy|Dermal Cooling System
9519829|NCT03282968|Experimental|Experimental|Regular neurophysiotherapy plus REWIRE exercises
9971615|NCT01312259|Active Comparator|Interstim Parameter Frequency 14 HZ|Subjects in this arm will receive 14 Hx as their frequency for the first three months. For the second 3 months, these patients will receive 40 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
9971616|NCT01312259|Experimental|Interstim Parameter Frequency 40 HZ|Subjects in this arm will receive 40 Hz as their frequency for the first three months. For the second 3 months, these patients will receive 14 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
9971617|NCT01312285|Placebo Comparator|Placebo|
9971618|NCT01312285|Experimental|Resonator Device|
9971619|NCT01312298|Experimental|General Anesthesia|Patients allocated to this arm will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml in a Target Controlled Infusion (TCI)
9971620|NCT01312298|Active Comparator|Regional anesthesia|Patients will receive intrathecal anesthesia
9971621|NCT01312311|Experimental|weekly docetaxel and cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
9971622|NCT01312324|Experimental|neoadjuvant chemotherapy|3 cycles of docetaxel/cisplatin before operation
9971623|NCT01312337|Experimental|Iressa for EGFR wild group|salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients
9971624|NCT01312350|Active Comparator|CCRT only arm|no neoadjuvant chemotherapy before definitive CCRT
9971625|NCT01312350|Experimental|neoadjuvant chemotherapy arm|2 cycles of TPF chemotherapy before definitive CCRT
9971626|NCT01312402|Active Comparator|Topical Brinzolamide (Azopt)|ophthalmic drop given three times a day
9971627|NCT01312402|Placebo Comparator|placebo ophthalmic drop in 5 mL solution|masked non-active eye drop (absence of Brinzolamide)
9971628|NCT01312415|Experimental|levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine (17.5 or 15 mg) without morphine, and will receive peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% at 8am the following morning.
9971629|NCT01312415|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
9971630|NCT01312441|Experimental|Ergocalciferol|Ergocalciferol 50,000 IU by mouth once weekly for 6 months
9971631|NCT01312441|Placebo Comparator|Placebo|Placebo by mouth once weekly for 6 months
9971632|NCT01312480|Other|Intervention Group|The smoking cessation intervention is a Public Health Services-approved intervention based on the 5A's Model, which includes (1) Ask if the patient smokes, (2) Advise every patient to quit, (3) Assess readiness to quit, (4) Assist in quitting and finding services and (5) Arrange for cessation services and follow up. Practitioners will complete a 5A checklist for each patient in this arm.
9971633|NCT01312480|Other|Control Group|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
9971634|NCT01312506||Subjects undergoing a craniotomy|This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
9971635|NCT01312506||Metastases, no craniotomy|These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
9971636|NCT01312506||Healthy Volunteers|Subjects who do not have known melanoma or metastases.
9971637|NCT01312532|Other|fixed-bearing|fixed-bearing device is a kind of prosthesis
9971638|NCT01312532|Other|mobile-bearing|mobile-bearing device is a kind of prosthesis
9971639|NCT01312545|Experimental|local made implant (3DP)|Enucleation and local made implant (3DP) insertion
9971640|NCT01312545|Experimental|imported implant (Medpor)|Enucleation and imported implant (Medpor) insertion
10149116|NCT04109833||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation without antibiotic treatment in the first week of life
10149117|NCT04109833||ABT in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation with antibiotic treatment in the first week of life
10149118|NCT04109625|Experimental|Non-immunized Hepatitis B|subjects non-immunized against hepatitis B (naive)
10149119|NCT04109625|Experimental|Vaccine Hepatitis B|subjects vaccinated against hepatitis B
10149120|NCT04109625|Experimental|Old or cured Hepatitis B|subjects with hepatitis B (old or cured)
10149121|NCT04109625|Experimental|Ongoing Hepatitis B|subjects with hepatitis B (ongoing)
10149122|NCT04109794|Active Comparator|E-CTG|Envelope connective tissue graft
10149123|NCT04109794|Active Comparator|SCAF|Semilunar connective tissue graft
10149124|NCT04109755|Experimental|Experimental|Short Course Radiation Therapy (5 x 5 Gy in 1 week, SCRT) with 4 injections of Pembrolizumab starting on the first day of radiotherapy and surgery
10149125|NCT04109326|Experimental|Adapted Physical Activity and Dietetique|tailored PA program associated with individual nutritional counseling whilst hospitalization and at home during the 26-week duration of adjuvant treatment
10149126|NCT04109326|No Intervention|Control|Standard of care
9971641|NCT01312558|Experimental|Prudent diet group|Participants follow CPAP therapy, a prudent diet while receiving counselling to increase their physical activity.
10149127|NCT04109313|Experimental|LOU064|Participants will be asked to take selected dose of LOU064 twice daily for 52 weeks
10149128|NCT04109573|Experimental|Anorectal function post anal laser|"Intervention:~Device: laser"
10149129|NCT04109261||Palbociclib treatment|
10149130|NCT04109339|No Intervention|group 1 with no oxytocin|
9826199|NCT02411929|Experimental|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. The 14^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. Both the unlabeled and 14^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
10149131|NCT04109339|Experimental|group 2 with oxytocin 10 U IM + oxytocin 10 U IV|
10149132|NCT04109339|Experimental|group 3 with oxytocin 20 U IM + oxytocin 0 U IV|
10149133|NCT04109339|Experimental|group 4 with oxytocin 0 U IM + oxytocin 20 U IV|
10149134|NCT04109378|Active Comparator|Patients operated with conventional laparoscopic technique|Patients operated with conventional laparoscopic technique for colorectal DIE
10149135|NCT04109378|Active Comparator|Patients operated with NOSE laparoscopic technique|Patients operated with NOSE technique for colorectal DIE
10149136|NCT04109287|Experimental|Two ultrasound scans and activation of NMES device|Participants will have their leg scanned using an ultrasound machine, before being asked to use the REVITIVE® device for 30 minutes. Their leg will then be scanned again.
10149137|NCT04109508|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
10149138|NCT04109508|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
10149139|NCT04109508|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
10149140|NCT04109508|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
10149141|NCT04109508|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
10149142|NCT04109508|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
10149143|NCT04109300|Experimental|preemptive screening|prospective HLADQA1*05A>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
10149144|NCT04109300|Active Comparator|standard of care|administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1*05A>G genotyping will be performed retrospectively.
10149145|NCT04109495|Other|Smart phone application(NOOM)|
10149146|NCT04109495|Other|Non-user|
10149147|NCT04109209|Active Comparator|Usual Care Group|"60 Participants will be randomized to receive usual care for caregivers of patients with malignant brain tumors~Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
10149148|NCT04109209|Experimental|Psychosocial Intervention Group|"60 Participants of caregivers of patients with malignant brain tumors will be randomized into the psychosocial intervention arm~Caregivers assigned to the intervention arm will receive usual care and the psychosocial intervention. The intervention entails six one-on-one sessions with an interventionist (psychologist or social worker)~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
9826200|NCT02412098|Experimental|Moderate Hepatic Impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
10149149|NCT04109534|Placebo Comparator|Placebo|Placebo comparator 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Placebo Comparator
10149150|NCT04109534|Active Comparator|Verum|PUFAS: 2640 mg of middle-chain and polyunsaturated fatty acids 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Active Comparator
9826201|NCT02412098|Experimental|Severe Hepatic Impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
10149151|NCT04109417|Experimental|osteotomy filled with PRP-gel and covered with PRP-biomembrane|the defect was filled with the previously activated autologous Platelet-rich plasma (PRP) gel and its supernatant. The site was then externally covered with the prepared bio-membrane composed of activated PRP which acted as an adjunct to the mucoperiosteal flap to stimulate tissue regeneration
10149152|NCT04109417|Sham Comparator|osteotomy site left empty|osteotomy site following the surgical intervention was left empty
10149153|NCT04109235|Active Comparator|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
10149154|NCT04109235|Experimental|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
10149155|NCT04108910||Traditional Urine Culture|Patients treated based upon traditional urine culture
10149156|NCT04108910||Guidance PCR/Pooled Sensitivity|Patients treated based upon multiplex UTI PCR/pooled sensitivity results
10149157|NCT04108923|Active Comparator|Ligasure ( group A)|
10149158|NCT04108923|Active Comparator|Conventional vessel ligation (group B)|
10149159|NCT04108897|Experimental|Doxycycline 40mg/day|Doxycycline 40mg will be administered once a day per oral for 28 days.
10149160|NCT04108897|Experimental|Doxycycline 50mg/day|Doxycycline 50mg will be administered once a day per oral for 28 days.
10149161|NCT04108897|Experimental|Doxycycline 100mg/day|Doxycycline 100mg will be administered once a day per oral for 28 days.
10149162|NCT04108897|Experimental|Doxycycline 200mg/day|Doxycycline 100mg will be administered twice a day per oral for 28 days.
10149163|NCT04108897|Experimental|Topical ivermectin(1%)|Topical ivermectin will be applied once a day for 28 days.
10149164|NCT04108897|No Intervention|Control|No intervention will be performed.
10149165|NCT04109092|Experimental|Dose Escalation: NMIBC And BCG Unresponsive NMIBC|
10149166|NCT04109092|Experimental|Dose Expansion: CIS With/Without Ta or T1|
10149167|NCT04109092|Experimental|Dose Expansion: High-grade Ta or T1, Without CIS|
10149168|NCT04108884|Experimental|App Group|In the app group, if an episode of arrhythmia is detected with the app, the local investigator will contact the respective patient to schedule an appointment for a 14 day Holter ECG.
10149169|NCT04108884|Other|Standard Care Group|The control group will perform the same measurements as the intervention group, with the only difference that a cumulated Portable Document Format (PDF) report is provided after 6 months instead of the immediate feedback in the app group.
10149170|NCT04108949|Experimental|Tuning in to Kids|Eight weekly two-hour sessions delivered in groups of up to six parents.
10149171|NCT04108949|Active Comparator|Treatment as usual|Treatment as usual, may consist of any psychosocial intervention the therapist sees fit, which is the type of intervention the participants ordinarily receives in the participating clinics. No limit on number of sessions or format of delivery.
10149172|NCT04109105||NHS-PEG coated collagen patch cohort|Patients diagnosed of colon adenocarcinoma that have ileocolic anastomosis after undergoing a laparoscopic right hemicolectomy surgery.
10149173|NCT04109183|Experimental|Active Comparator: FNC 2 mg+ TDF+EFV|
10149174|NCT04109183|Experimental|Active Comparator: FNC 3 mg+ TDF+EFV|
10149175|NCT04109183|Experimental|Active Comparator: FNC 4 mg+ TDF+EFV|
10149176|NCT04109183|Experimental|Postive Comparator: 3TC+ TDF+EFV|
10149177|NCT04109196|Experimental|Intensive 5-day Cognitive Processing Therapy for PTSD|Participants who are eligible for and enrolled in the study will receive a 5-day CPT treatment for PTSD. All participants will be asked to complete clinician-rated and self-report assessments at multiple time points during the study. Participants will also be asked to provide fecal and saliva samples as part of the study, however, they may opt out of biological sample collection.
10149178|NCT04108871|Experimental|Transperineal Prostate Biopsy|The biopsy needed is inserted to the prostate through the perineal skin, with the assistance of an access system device known as PrecisionPoint. It utilises a single access needle cannula mounted directly on to the ultrasound probe, which acts as an access point traversing through the perineal skin. 4 - 5 cores are obtained from the anterior, mid and posterior zone of each side of the prostate.
10149179|NCT04108871|Active Comparator|Transrectal Prostate Biopsy|The biopsy needle penetrates through the bowel (rectum) to the prostate to obtain 12 cores of prostate tissues from the lateral and medial base, midzone and apex of each side of the prostate (1 core each).
10149180|NCT04108832|Experimental|TCM OA2|TCM OA2 3G BID FOR 8 WEEKS
10149181|NCT04108832|Placebo Comparator|PLACEBO|PLACEBO
10149182|NCT04109131|Other|CNS metastases from solid tumours|"The study will be organised on three time-periods based on the time of the 1st CNS event:~Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event"
10149183|NCT04108780||CBD exploration with T-tube|repair of CBD after CBD exploration over T-tube
10149184|NCT04108780||CBD exploration with primary repair|primary repair of CBD after CBD exploration
10149185|NCT04108936||Peritoneal Carcinomatosis|Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies
10149186|NCT04108936||Control group|Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis
10149187|NCT04109170||Dry Eye Group|This group of subjects were diagnosed with dry eye.
10149188|NCT04109170||Normal Control Group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
10149189|NCT04108793|Experimental|Intervention Arm|The Intervention group will be given a program of progressive balance and lower limb strengthening exercises twice a week for 3 months. All exercises will include 5 minutes warm-up exercises. The lower limb extensor muscle groups (hip & knee extensors and ankle plantar flexors) will be targeted with exercises designed to enhance postural control (i.e. balance) and muscle strength. The balance exercises include standing with a decreased base of support, forwards and sideways stepping/walking, and graded reaching activities in standing. Strengthening exercises will include sit-to-stand, forward and lateral step-ups onto a small block, semi squats and heel raises in standing. Standard principles governing frequency, volume, duration, intensity and progression of exercise will be applied. Cueing strategies will be used to reduce freezing. T
10149190|NCT04108793|No Intervention|Control Arm|The control arm will receive the usual standard postoperative rehabilitation after a bipolar hemiarthroplasty/ total hip arthroplasty which will include in hospital rehabilitation and a maximum of 5 visits postoperatively
10149191|NCT04108845|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine, 0.5 ml/dose
10185414|NCT03745963|Experimental|Skin-to-skin contact|"Infants will be placed in full ventral skin-to-skin with their mother at least fifteen minutes prior to heel lance to allow time to settle and recover following transfer. Positioning will be determined based on individual maternal preference in order to optimize comfort as well as facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Skin to skin contact will continue until the procedure is completed.~In addition, infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) during SSC. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
10185415|NCT03745963|Active Comparator|24% Oral sucrose|"Infants will be placed in a cot or in an incubator, depending on their gestational age, for the duration of the blood collection. Administration of 0.12mls (0.04mls per drop) of 24 percent oral sucrose will occur two minutes prior to the heel lance.~The infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
10185416|NCT03745950|Experimental|Olaparib|"The Olaparib arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST (Response evaluation criteria in solid tumors) as assessed by the investigator, or unacceptable toxicity"
10185417|NCT03745950|Placebo Comparator|Placebo|"The placebo arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST as assessed by the investigator, or unacceptable toxicity"
10185418|NCT03745911|Experimental|Paclitaxel plus TAK-228|"Paclitaxel will be given on days 1, 8, and 15 of each 28 day cycle intravenously (every Monday or first day of business week if holiday), the day before the first TAK-228 dose. It should be given over approximately one hour.~TAK-228 will be given orally on Days 2-4, 9-11, 16-18 and 23-25 of each 28-day cycle."
10185419|NCT03745898|Active Comparator|Nocturnal Oxygen Therapy|Active nocturnal oxygen therapy
10185420|NCT03745898|Sham Comparator|Sham Nocturnal Oxygen Therapy|Sham nocturnal oxygen therapy (room air)
10185421|NCT03745885|Experimental|0.15mg Supaglutide or placebo|0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
9826202|NCT02412098|Experimental|Mild Hepatic Impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
9971642|NCT01312558|Experimental|Mediterranean diet group|Participants follow CPAP therapy, Mediterranean diet, while receiving counselling to increase their physical activity.
10185422|NCT03745885|Experimental|0.375mg Supaglutide or placebo|0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
10185423|NCT03745885|Experimental|0.75mg Supaglutide or placebo|0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
10185424|NCT03745885|Experimental|1.5mg Supaglutide or placebo|1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
10185425|NCT03745885|Experimental|3.0mg Supaglutide or placebo|3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
10185426|NCT03745872|Experimental|Testing|This is a preventative study model. All students who choose to participate will receive a pre and post test regarding their sun exposure behaviors and knowledge on sun exposure risk.
10185427|NCT03745846|Experimental|Composite Gel Containing Black Raspberry|Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
10185428|NCT03745846|Placebo Comparator|Composite Gel Containing Black Raspberry-placebo|Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
10185429|NCT03745833|Experimental|Intervention|Participants will be shown a brief VR-based mindfulness intervention after meals.
9669512|NCT04189445|Experimental|Futibatinib (Cohort A)|Advanced or metastatic solid tumors harboring FGFR1-4 rearrangements
9669513|NCT04189445|Experimental|Futibatinib (Cohort B)|Advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification
10185430|NCT03745807|Experimental|Combination|NKTR-214 + nivolumab
10185431|NCT03745781|Experimental|open-label placebo|open-label placebo
9971643|NCT01312571|Active Comparator|Cognitive behavior therapy via the internet|Cognitive behavior therapy via the internet with therapist support.
9669514|NCT04189445|Experimental|Futibatinib (Cohort C)|Myeloid or lymphoid neoplasm harboring FGFR1 rearrangement
9826203|NCT02412111|Experimental|Ivacaftor (Run-in Period)|Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
10149192|NCT04108806|Experimental|Endovascular therapy|Outcome of endovascular therapy on PAC
10149193|NCT04108975|Active Comparator|Rectus muscle reapproximation group|Rectus muscle reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures
10149194|NCT04108975|Active Comparator|Rectus muscle non reapproximation group|No rectus muscle reapproximation will be done based on the fact that rectus muscle can regain its position
10149195|NCT04109157|Other|Study population|Women who had fulfilled the standardization of terminology of lower urinary function from ICS were diagnosed as urodynamic stress incontinence (USI) after urodynamic study (UDS) and enrolled for analysis in this study.
9826204|NCT02412111|Experimental|VX-661 + Ivacaftor (Active comparator period)|VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
10149196|NCT04108767||Health students enrolled in the 3rd year at the University Cla|Health students enrolled in the 3rd year at the University Claude Bernard Lyon 1, aged over 18 years.
10149197|NCT04108754||Diagnosis of AIT|Patients in the neurovascular unit of the Neurological Hospital of Lyon between 01/01/2016 and 30/12/2017 with a probable diagnosis of AIT and having an MRI within 7 days of TIA.
10149198|NCT04108741|Experimental|treadmill training with augmented reality dual tasking|
9971644|NCT01312571|Active Comparator|Attentional retraining|Attentional retraining as described by Nader Amir.
9971645|NCT01312584|Placebo Comparator|Non alkalised High Flavanol|Non-alkalised high flavanol cocoa drink containing 1745 mg of total flavanols
10149199|NCT04108741|Experimental|treadmill training with random number generation dual tasking|
9826205|NCT02412111|Active Comparator|Ivacaftor monotherapy (Active comparator period)|Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
10149200|NCT04108741|Active Comparator|treadmill training|
9826206|NCT02412228|Experimental|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
10149201|NCT04108533|Experimental|Text-Based Support|"Text-Based Support - Women randomized to this arm will receive text-based support via the Way to Health platform as described below.~Supportive texts - Encouraging text messages with prompts to ask questions will be sent twice weekly during the first four weeks postpartum and once weekly thereafter for the remaining two weeks of the program~Inquiry texts - Questions regarding infant feeding with prompts to answer will be sent three times weekly during the first two weeks postpartum and twice weekly thereafter for the remaining 4 weeks of the program.~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.~Women in this group will also have the option to send a text with a question or concern at any time during the study. Weekdays from 8am to 5 pm these will be fielded by a trained obstetrician. If a text is received after-hours or on the weekend, women will be instructed to reach out to their primary OBGYN provider."
10149202|NCT04108533|No Intervention|Usual Care|"Usual care - Women randomized to this arm will receive usual postpartum care with the following exceptions:~Inquiry texts- Questions regarding infant feeding with prompts to answer will be sent once weekly for all 6 weeks of the program.~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.~Women in this group will be directed to their physician with any questions or concerns during the study period."
10149203|NCT04108715|Active Comparator|ESPB GROUP|Erector spina plane block group
10149204|NCT04108715|Active Comparator|SAPB group|Deep Serratus anterior plane block group
10149205|NCT04108494|Experimental|Experimental group|D2 radical gastrectomy with partial omentectomy
9826207|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 1b Adult Population|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
10149206|NCT04108494|No Intervention|Control group|D2 radical gastrectomy with total omentectom
10149207|NCT04108468|Experimental|Golimumab & Methotrexate|
9971646|NCT01312584|Active Comparator|Alkalised high Flavanol|Alkalised high flavanol cocoa drink (medium alkalisation) containing 410 mg of total flavanols
9971647|NCT01312584|Active Comparator|Alkalised Low Flavanol|Alkalised low flavanol cocoa drink (heavily alkalised) containing 1.26 mg of total flavanols
10149208|NCT04108468|Active Comparator|Methotrexate|
10149209|NCT04108403|Experimental|Pain Inducing Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
10149210|NCT04108403|Active Comparator|Pain Inducing Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
10149211|NCT04108403|Active Comparator|Pain Free Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
10149212|NCT04108403|Active Comparator|Pain Free Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
10185432|NCT03745781|No Intervention|treatment as usual|
10149213|NCT04108611|Experimental|systemic lupus in activity|Sixty systemic lupus patients in activity will receive conventional therapy (47 patient as cases 1) and immunadsortion (13 patients as cases 2) will be provided to the non responders
10149214|NCT04108611|Other|Control group 30 subjects|controls 1 (20 healthy volunteers, controls 2 (10 patients with glomerular diseases other than lupus) will do routine laboratory investigations
10149215|NCT04108585||HFO group|HFO therapy
10149216|NCT04108585||CPAP group|CPAP therapy
10149217|NCT04108507|Experimental|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP)operation
10149218|NCT04108507|No Intervention|without posterior branch block of spinal nerve|without posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
10149219|NCT04108520|Experimental|Intervention Group|Exercises on respiratory muscle, 3 times per week, 1 hour peer day
10149220|NCT04108676|Experimental|single arm|Drug: Fluzoparib Drug: Omeprazole
10149221|NCT04108377|Experimental|Roflumilast|Roflumilast 500mcg by mouth, once daily, for 70 days (10 weeks).
10149222|NCT04108377|Placebo Comparator|Placebo|Placebo by mouth, once daily, for 70 days (10 weeks).
10149223|NCT04108572|Experimental|Infant feeding intervention|The intervention will be delivered to parents by practice nurses and/or GPs in MPHC at each of the vaccination visits, prior to administration of the vaccination. These vaccination visits take place at 2, 4, 6, 12 and 13 months. This intervention consists of 1) verbally delivered pre-specified infant feeding messages, and 2) provision of additional infant-feeding resources including an information leaflet, a magnet, an infant bib and access to an informational website.
9519830|NCT03282968|Active Comparator|Control|Regular neurophysiotherapy plus standing balance exercises
10149224|NCT04108702|Experimental|VR heart|
10149225|NCT04108702|Sham Comparator|VR control|
10149226|NCT04108702|Active Comparator|Standard control|
10149227|NCT04108455||With Diabetes|Pregnant women with diabetes - either diagnosed beforehand or diagnosed during gestation
10149228|NCT04108455||Controls|Biobank samples will be obtained from similar age/BMI/ethnicity women who do not have evidence of diabetes.
10149229|NCT04108650|Experimental|Fit & Strong! group|The experimental group (23 participants) was enrolled in the intervention, the Fit & Strong! program. The program consists in 24 sessions each divided in two parts. The first part is the exercise component (60 minutes) and the second is the educational component (30 minutes). The program was provided in two classes, the first class took place from October to December 2017 and the second class took place from October to November 2018. The experimental group was enrolled in the intervention (8 weeks).
10149230|NCT04108650|No Intervention|Control group|To participants in the control group (8 participants) were offered the possibility of enrolling in the program the following year after posttest measurement for both the intervention and control groups was complete.
10149231|NCT04108390|Experimental|Intervention group|Individuals for this group will be treat with a dry needling intervention at the gluteus medius trigger point.
10149232|NCT04108390|Active Comparator|Control group|Individuals for this group will be treat with a dry needling technique at 1,5 cm from the trigger point (not in the trigger point).
10149233|NCT04108663|Sham Comparator|Sham|Sham tDCS (ramp up and ramp down of electrical current before as well as after task performance to elicit physical sensations similar to verum tDCS)
10149234|NCT04108663|Active Comparator|L1A|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: anodal"
10149235|NCT04108663|Active Comparator|R1A|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: anodal"
10149236|NCT04108663|Active Comparator|L2A|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: anodal"
10149237|NCT04108663|Active Comparator|R2A|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: anodal"
9661863|NCT03861897|Experimental|Intervention KRP-NI + KM|Realization of Non instrumental pleural chest physiotherapy and Mobilization physiotherapy sessions (KRP-NI)
9971648|NCT01312597|Experimental|Fruit beverage|
10149238|NCT04108663|Active Comparator|L1C|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: cathodal"
10149239|NCT04108663|Active Comparator|R1C|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: cathodal"
10149240|NCT04108663|Active Comparator|L2C|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: cathodal"
10149241|NCT04108663|Active Comparator|R2C|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: cathodal"
10149242|NCT04108689|Experimental|I-ACT|I-ACT is short for Internet-Acceptance and Commitment Training
10149243|NCT04108442|Active Comparator|Traditional|
10149244|NCT04108442|Experimental|Virtual|
10149245|NCT04108598||Adults presenting with SSNHL|Adults presenting with SSNHL to NHS
10149246|NCT04108624|Experimental|MRD2STOP ARM|
10149247|NCT04108637|Experimental|penicillin allergy assessment pathway|"Those in the PAAP intervention arm will complete stage 2&3 of the PAAP pathway:~Stage-2 assessed for skin testing (ST) and ST done or straight to stage 3~Stage-3 oral challenge test (OCT) All completing PAAP will receive a letter from the immunology clinic giving the results of the test. Also, patients who have tested negative will receive the Post-test Intervention Booklet and Patient Intervention Card Materials.~Additionally, all participants in the PAAP arm will be called by the trial team at days 4-6 and 28-30 post testing to collect safety data. During the call at days 28-30 patients will complete the patient questionnaire on allergy beliefs.~Practices will be informed of the test result and instructed to update the participant's electronic health records accordingly."
10149248|NCT04108637|No Intervention|Control Arm|The usual care arm receive no intervention but will be followed up as per intervention arm with monitoring of any symptoms following an antibiotic prescription.
10185433|NCT03745768|Experimental|Active iTBS Treatment|Intermittent theta burst stimulation to the dorsolateral prefrontal cortex
10149249|NCT04108559|Experimental|Kinesiologic Tape Group|After the routine impacted third molar surgery, the kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. Kinesiologic tape will be removed on the second postoperative day, and all sutures on will be removed on 7. postoperative day.
10149250|NCT04108559|Experimental|Surgical Drain Group|After routine impacted third molar surgery, plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa.
10149251|NCT04108559|Placebo Comparator|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
10149252|NCT04108364|Experimental|VoiceAdapt Intervention|PWA who train with VoiceAdapt app
10149253|NCT04108364|No Intervention|No Intervention|PWA who are on the waitlist and not training with VoiceAdapt app
10149254|NCT04108351|Experimental|Zopiclone|
10149255|NCT04108351|Placebo Comparator|Placebo|
10149256|NCT04108728|Experimental|HIV exposed children during pregnancy|children born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language
10149257|NCT04108728|Other|control children|children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.
10149258|NCT04108338||CCRT-randomized clinical trial|Trial patients receiving CCRT
10149259|NCT04108338||CCRT-real-world database|Patients receiving CCRT from real-world database
10149260|NCT04108338||IC+CCRT-randomized clinical trial|Trial patients receiving IC+CCRT
10149261|NCT04108338||IC+CCRT-real-world database|Patients receiving IC+CCRT from real-world database
10149262|NCT04108325|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
10149263|NCT04108247|Experimental|Abiraterone+SHR3162|
10149264|NCT04108234|Experimental|Treatment group A|HR071603,nasal spray,dose escalation.
10149265|NCT04108234|Placebo Comparator|Treatment group B|Placebo, nasal spray
10149266|NCT04108260|Experimental|Single arm_Idelvion treated|
10149267|NCT04108312||Autism Spectrum Disorders|
10149268|NCT04108312||Typical Control|
9971649|NCT01312597|Experimental|Control beverage|
9971650|NCT01312610|Experimental|High flavonone orange juice drink|
9971651|NCT01312610|Placebo Comparator|Control orange juice drink|Juice drink matched for sugar content
9971652|NCT01312623|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
10149269|NCT04108299|Placebo Comparator|wait-list control|Standard of care
10149270|NCT04108299|Experimental|SMS intervention|The SMS group will receive brief lifestyle counseling videos via SMS links. At the end of the study, the wait-list control group will be provided the opportunity to receive the counseling videos.
10149271|NCT04107974|Experimental|Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. Two T-fasteners are inserted into the stomach approximately 4cm apart. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate. The gastropexy/T-fastener sutures are cut after one week.
10149272|NCT04107974|Experimental|Non-Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate.
10149273|NCT04108117||Robotic nipple sparing mastectomy group/RNSM|"Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.~The estimated sample size for this arm is 300 cases."
10185434|NCT03745768|Sham Comparator|Sham Stimulation|Sham stimulation to the dorsolateral prefrontal cortex.
9971653|NCT01312623|No Intervention|Control|No ischemic preconditioning
9971654|NCT01312636||A|
10185435|NCT03745742|Other|control|standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.
10185436|NCT03745742|Experimental|study strategy|individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).
9661864|NCT03861897|Active Comparator|Control KM|Realization of mobilization physiotherapy sessions (KM)
9971655|NCT01312649|Experimental|Arm 1|Healthy volunteers
9971656|NCT01312649|Experimental|Arm 2|Schizophrenia with history of delusions of control
9971657|NCT01312649|Experimental|Arm 3|Schizophrenia without history of delusions of control
9971658|NCT01312649|Experimental|Arm 4|Bipolar disorders
9971659|NCT01312649|Active Comparator|Arm 5|Matched healthy controls
9971660|NCT01312662||normal ophthalmological status|
9971661|NCT01312662||opacity of the refractive media|
9971662|NCT01312662||maculopathy|
9971663|NCT01312662||optic neuropathy|
9971664|NCT01312662||chiasmal and postchiasmal visual pathway pathologies|
10149274|NCT04108117||Conventional nipple sparing mastectomy group/CNSM|"Cases or Patients who underwent conventional nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Conventional nipple-sparing mastectomy should not be performed using robotic or endoscopic surgical systems. Axillary or lateral incisions that are similar to incisions in robotic nipple-sparing mastectomy are not allowed. Other than axillary or lateral incisions can be performed for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with nipple-sparing mastectomy without immediate reconstruction are excluded.~The estimated sample size for this arm is 300 cases."
10149275|NCT04107987|Active Comparator|Reglicemi|Reglicemi is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
10149276|NCT04107987|Placebo Comparator|Placebo|Placebo
10149277|NCT04107883|Experimental|control group|Do not perform plasma transfusion during operation.
10149278|NCT04107883|Experimental|anhapetic group|Perform plasma transfusion during anhapetic phase.
10149279|NCT04107883|Experimental|neohepatic group|Perform plasma transfusion during neohepatic phase.
10149280|NCT04108078|Experimental|Intervention|This arm consists of 1) MSM who receive the intervention (not wait listed) and healthcare facility staff who work at health facilities that have been chosen for the intervention.
9971665|NCT01312662||amblyopia (deprivation)|
10149281|NCT04108078|No Intervention|Wait listed|Participants in this arm (MSM and staff at health facilities that were wait listed) will complete assessments, but will receive the intervention after the experimental arm of the study.
10149282|NCT04108273|Experimental|OST Intervention|
10149283|NCT04108273|Other|Waitlist|
9971666|NCT01312662||amblyopia (strabism)|
10149284|NCT04108013|Experimental|SHR-1210+Carboplatin+Paclitaxel-albumin|Subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
10149285|NCT04108013|Active Comparator|Carboplatin+Paclitaxel-albumin|Subject will receive carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
10149286|NCT04107831|Experimental|Pulmonary rehabilitation|Participants who are participating in a 6-week pulmonary rehabilitation program are enrolled in the study.
10149287|NCT04107870|Experimental|Virtual Reality Exposure Therapy|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
10149288|NCT04107870|Active Comparator|Psychomotor Therapy|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
10149289|NCT04107922|Active Comparator|Glicoset|Glicoset is a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
10149290|NCT04107922|Placebo Comparator|Placebo|
10149291|NCT04108130|No Intervention|Usual Care|Patients in this arm will receive usual anesthetic and postoperative care as provided in each site.
9971667|NCT01312688|Other|Standard hemodynamic therapy|Standard hemodynamic therapy currently accepted in our ICU
10149292|NCT04108130|Experimental|Intervention|This arm will receive the bundle of interventions.
10149293|NCT04107909|Other|3 ports|3port operation
10149294|NCT04107909|Other|4 port|4 port operation
10149295|NCT04108286|Experimental|TEST/CONTROL|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
10149296|NCT04108286|Experimental|CONTROL/TEST|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
10149297|NCT04108169|Active Comparator|Active Comparator|
10149298|NCT04108169|No Intervention|Sham Comparator|
10149299|NCT04107844||Athletes without concussion|We follow the athletes in terms of injuries and make a baseline test each season.
10149300|NCT04107844||Athletes suffering a concussion|We follow the athletes in terms of injuries and make a baseline test each season and when they suffer a concussion, then we follow them with the same test as at baseline every 14th day for 3 months, after that they will get enrolled in another study.
10149301|NCT04107896|Experimental|Silodosin|8 mg daily by mouth, 12 weeks
9661865|NCT03830619||lung cancer patients|
9661866|NCT03830619||normol volunteers|
9661867|NCT03815916|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
9661868|NCT03815916|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
9971668|NCT01312688|Experimental|Early Goal Directed Hemodynamic Therapy|Early Goal Directed Hemodynamic Therapy according to the Surviving Sepsis Campaign Guidelines
9971669|NCT01312701||cancer patients|as described patietns with solid cancer about to be treated with anticancer therapies
9971670|NCT01312701||control group|normal populations who domated blood for further use
9971671|NCT01312714|Active Comparator|Cholecalciferol|
9971672|NCT01312714|Placebo Comparator|Placebo|
9971673|NCT01312727|Other|HTIN|HTIN
10149302|NCT04107896|Active Comparator|Tamsulosin|0.4 mg daily by mouth, 12 weeks
10149303|NCT04107805|Experimental|Part 1: Dose Group 1|
10149304|NCT04107805|Experimental|Part 1: Dose Group 2|
10149305|NCT04107805|Experimental|Part 1: Dose Group 3|
10149306|NCT04107805|Experimental|Part 1: Dose Group 4|
10149307|NCT04107805|Experimental|Part 1: Dose Group 5|
10149308|NCT04107805|Placebo Comparator|Part 1: Placebo|
10149309|NCT04107805|Experimental|Part 1: Dose Group 6|
10149310|NCT04107805|Experimental|Part 2: Dose Group 1|
10149311|NCT04107805|Experimental|Part 2: Dose Group 2|
10149312|NCT04107805|Experimental|Part 2: Placebo|
10185437|NCT03745716|Experimental|Experimental arm: APR-246 + azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
10187826|NCT03722329|Active Comparator|EU Soliris|EU sourced Soliris (eculizumab)
10149313|NCT04107753|Experimental|Intervention: Brief counseling based on the 5As model|The intervention group received a brief counseling based on the 5As model. It mainly consists of the following steps: ask, advice, asses, assist, arrange. It is performed by the nurse who take clinical care of the patient. The patients receive an information card about the Smoke cessation center's (CTT) and the patients who agree are contacted by the CTT's staff.
10149314|NCT04107753|No Intervention|Control group|"No other intervention than the usual care (range between the not mentioning the subject at all, to a general advice to quit without bringing any evidence or any structured counseling)."
10149315|NCT04107740|Experimental|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
10149316|NCT04107740|Placebo Comparator|Placebo (0mg Taltirelin Hydrate)|BID for 24 weeks
10149317|NCT04107636|Experimental|Assigned Interventions|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location. After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
10149318|NCT04108143|Experimental|Intervention|MonitorMe device
10149319|NCT04108000|Experimental|SPIRIT-Dementia|Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
10149320|NCT04108000|Active Comparator|Usual Care|Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
10149321|NCT04107792|Experimental|Experimental|Parents of children with sensory processing issues who attend Workshop 1
10149322|NCT04107792|No Intervention|Waitlist Control|parents of children with sensory processing issues who attend Workshop 2
10149323|NCT04107428|Active Comparator|Somatostatin|
10149324|NCT04107428|Placebo Comparator|Placebo|
10149325|NCT04107779|Experimental|JUUL 5% Virginia Tobacco ENDS|JUUL 5% Virginia Tobacco flavored ENDS product [6 days] in confinement.
10149326|NCT04107779|Experimental|JUUL 3% Virginia Tobacco ENDS|JUUL 3% Virginia Tobacco flavored ENDS product [6 days] in confinement.
10149327|NCT04107779|Experimental|JUUL 5% Mint ENDS|JUUL 5% Mint flavored ENDS product [6 days] in confinement.
10149328|NCT04107779|Experimental|JUUL 3% Mint ENDS|JUUL 3% Mint flavored ENDS product [6 days] in confinement.
10149329|NCT04107779|Experimental|JUUL 5% Menthol ENDS|JUUL 5% Menthol flavored ENDS product [6 days] in confinement.
10149330|NCT04107779|Experimental|JUUL 3% Menthol ENDS|JUUL 3% Menthol flavored ENDS product [6 days] in confinement.
10149331|NCT04107779|Experimental|JUUL 5% Mango ENDS|JUUL 5% Mango flavored ENDS product [6 days] in confinement.
10149332|NCT04107779|Experimental|JUUL 3% Mango ENDS|JUUL 3% Mango flavored ENDS product [6 days] in confinement.
10149333|NCT04107779|Experimental|Dual-use of JUUL 5% and UB of Combustible Cigarette|JUUL 5% Virginia Tobacco, Mint, Menthol, or Mango flavored ENDS product and usual brand of combustible cigarette [6 days] in confinement.
10149334|NCT04107779|Active Comparator|UB of Combustible Cigarette|Usual brand combustible cigarette [6 days] in confinement.
10149335|NCT04107779|Other|Tobacco/Nicotine Abstention|Smoking abstention (no smoking) [6 days] in confinement.
10149336|NCT04107558|Experimental|Painful stimuli with Hypnosis and Virtual Reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes. This session takes place under hypnosis
9661869|NCT03815916|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
9661870|NCT03815916|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10149337|NCT04107558|No Intervention|Painful stimuli without Hypnosis and Virtual reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes.
10149338|NCT04107506|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
10149339|NCT04107506|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
10149340|NCT04107454|Active Comparator|Active group|The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
10149341|NCT04107454|Placebo Comparator|Placebo group|Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
10149342|NCT04107571||Cohort|
10149343|NCT04107337|Experimental|Experimental group|Experimental group (N=10): this group will conduct a vocal work session based on semi-occluded vocal-tract exercises with a straw.
10149344|NCT04107337|Other|Control group|Control group (N=10): the second group acting as control group will perform a vocal work session based on open mouth exercices (vocalizations).
10149345|NCT04107519|Experimental|Immediate GRIT (ImT) training intervention|
10149346|NCT04107519|No Intervention|Delayed Training (DeT) control|
9971674|NCT01312792|Experimental|Modified IMCI guideline|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
9971675|NCT01312792|Active Comparator|Current IMCI guideline|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
9971676|NCT01312831|Experimental|Oral Eligen® B12|Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.
9971677|NCT01312831|Active Comparator|IM B12|Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.
9971678|NCT01312870|Experimental|postoperative nutritional supplements|postoperative nutritional supplements in addition to standard hospital diet
9971679|NCT01312870|Placebo Comparator|standard hospital diet|patients receiving standard hospital diet
9971680|NCT01312883|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
9971681|NCT01312883|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
9971682|NCT01312935|Experimental|Heparin and PMX-60056|
9971683|NCT01312987|Experimental|Nutrition intervention|Receives a month's supply of the nutrition supplement, Plumpy'doz®, in addition to food voucher for each month. Participants were also allowed to attend monthly educational sessions.
9971684|NCT01312987|No Intervention|Control|Receives food vouchers each month.
9971685|NCT01313000||Autologous fat transfer|
9971686|NCT01313013|Experimental|intervention|question prompt sheet
9971687|NCT01313013|No Intervention|control|no question prompt sheet
9971688|NCT01313026|Active Comparator|PNE first|patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
9971689|NCT01313026|Active Comparator|TAI first|Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
9971690|NCT01313052|Experimental|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
9971691|NCT01313052|Active Comparator|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
9971692|NCT01313065|Experimental|VX15/2503|VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.
9971693|NCT01313104|Experimental|Screening|See Detailed Description
9971694|NCT01313130||blast-related TBI|100 active duty US military personnel identified clinically as having suffered blast-related TBI
9971695|NCT01313130||non-blast-related TBI|100 active duty US military personnel identified clinically as having suffered non-blast-related TBI. TBI caused by other mechanisms such as motor vehicle crashes, falls, struck by blunt objects etc.
9971696|NCT01313130||other blast-related injuries|100 active duty US military personnel with blast-exposure and other blast-related injuries but no clinical evidence of TBI
9971697|NCT01313130||other non-blast injuries|100 active duty US military personnel with other non-blast injuries and no clinical evidence of TBI
9971698|NCT01313143|Experimental|AOP200704, infusion|
9971699|NCT01313143|Active Comparator|Esmolol, infusion|
9971700|NCT01313169|Experimental|EMR reminder|EMR reminder
10149347|NCT04107597|Experimental|Core stabilization exercises|Patients with CLBP who practice core stabilization exercises
10149348|NCT04107597|Experimental|Core stabilization exercises and paced breathing training|Patients with CLBP who practice core stabilization exercises combined with paced breathing training
10149349|NCT04107597|Experimental|Myofascial trigger point release|Patients with CLBP who receive myofascial trigger point release therapy
9971701|NCT01313169|Experimental|EMR reminder + Panel management|EMR reminder + Panel manager
9971702|NCT01313169|No Intervention|Control|Control
9971703|NCT01313234|Experimental|Education|Educational theory based intervention and systematic daily pain assessment
9971704|NCT01313234|No Intervention|Control|Control group with care as usual
9971705|NCT01313247|Placebo Comparator|Placebo pills|Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily
9971706|NCT01313247|Active Comparator|oral paracetamol 4 g daily|Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily
9971707|NCT01313260||Epilepsy patients|Epilepsy patients selected before undergoing intracranial EEG recordings
9971708|NCT01313260||control group|Healthy volunteers
9971709|NCT01313325|Experimental|Treatment group|Children between 5-17 years who have balance deficits related to any movement disorder (preferably neuromuscular)
9977782|NCT01365169|Experimental|Arm IV (cancer survivors that are current/former smokers)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
10149350|NCT04107597|Experimental|Myofascial trigger point release and paced breathing training|Patients with CLBP who receive myofascial trigger point release therapy combined with paced breathing training
10149351|NCT04107441|Experimental|Part 1 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg, 10 mg, 20 mg or 40 mg AX-8 twice daily (8 hours apart, i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of treatment periods 1, 2, 3 or 4, respectively.
10149352|NCT04107441|Experimental|Part 2 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg AX-8 and one ODT with 40 mg AX-8 8 hours later (i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of the treatment period.
10149353|NCT04107688|Experimental|PROP non-taster subjects|This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
10149354|NCT04107688|Experimental|PROP super-taster subjects|This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
10149355|NCT04107532|Other|Virtual Reality Therapy for Acrophobia|There were a total of 5 treatments in the VR treatment group, followed by cliffs, cliffs, cliffs, single-plank bridges, and high-altitude rescues. The difficulty of the scene increased in turn. The frequency of treatment twice a week, about 30 minutes each time, fills in the motion sickness questionnaire before and after each treatment to understand the safety of VR treatment. In the course of treatment, physiological data such as skin electricity, skin temperature, heart rate, and blood volume were measured, and the state of the subjects was objectively evaluated. At the same time, every two minutes, participants were asked about sud values and recorded.
10149356|NCT04107532|Other|Imagination Exposure Therapy for Acrophobia|The imaginary exposure treatment program is to convert the five scenes of VR exposure treatment through language, guide the subjects through the guidance language, guide the subjects to expose, and achieve the purpose of adaptation. Both treatment groups were required to collect scales and nuclear magnetic data before, after and after six months of follow-up.
10149357|NCT04107714|Experimental|Intervention (STC)|"Study participants randomized to the experimental group receive the intervention (STC). STC is a peer-led and web-based group intervention containing four two-hour sessions within four weeks plus an additional booster session one month later.~Fidelity to manual is rated in each session by study staff."
10149358|NCT04107714|No Intervention|No intervention|Participants randomized to the control group do not receive the group program but get the accompanying workbook at the end of the study.
10149359|NCT04107545|Experimental|athletes|48 elite athletes, 24 men and 24 women, experiencing regular weight cycling.
10149360|NCT04107649|Other|Arm1|Participants in this arm receive usual post-operative care and complete all basic study activities, which include: attending 2 in-clinic visits at designated time-points, wearing and returning waist-worn activity trackers at 5 time points over two years, and completing 6 study surveys.
10149361|NCT04107649|Experimental|Arm2|Participants in this arm receive usual post-operative care, complete all basic study activities, receive the wrist-based activity tracker intervention, and receive regular calls from study personnel about improving their general well being.
10149362|NCT04107649|Experimental|Arm3|Participants in this arm receive usual post-operative care, complete all basic study activities, and receive the TAC(MI)+FI and wrist-based activity tracker interventions.
10149363|NCT04107376|Experimental|Retroviewing endoscopy (RVE)|Withdrawal in every colonic segment with SFV (standard forward view) followed by another withdrawal with the retroviewing endoscope. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
10149364|NCT04107376|Active Comparator|standard forward viewing endoscopy (SFVE)|Withdrawal in every colonic segment with SFV followed by another withdrawal with SFV. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
10149365|NCT04107389|Active Comparator|Intervention Group|Receives Art Therapy assessment and intervention
10149366|NCT04107389|Active Comparator|Wait List Control Group|Added to wait list to receive intervention at a later date, participant is made aware of this
9971710|NCT01313338||Acute coronary syndrome|
9971711|NCT01313364|Experimental|All subjects to self-administer 4 IM injections|Subjects will be recruited and stratified into BMI groups: <18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and >30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
9971712|NCT01313377|Experimental|ARM A: Gemox 85|Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)
9971713|NCT01313377|Other|ARM B:|Observation until progression or death
9971714|NCT01313429|Experimental|1|tumor cell vaccine administered with chemotherapy
9827489|NCT02457793|Experimental|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
9971715|NCT01313468|Experimental|4 x 4 Interval|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
9971716|NCT01313468|Experimental|1 4 minutes interval|1 x 4 minutes intervals at 90-95% of HR max
9971717|NCT01313468|Experimental|Moderate continuous Training|47 minutes of Moderate continuous Training
9971718|NCT01313481|Experimental|Group exercise|Otago exercise performed in groups
9971719|NCT01313481|Active Comparator|Home exercise|Otago exercise performed as home exercise
9971720|NCT01313533|Active Comparator|Lactated Ringers Solution with Arginine|100 ml of LRS with arginine
9971721|NCT01313533|Placebo Comparator|Lactated Ringers Solution|Lactated ringers solution
9971722|NCT01313546|Active Comparator|quadriceps|quadriceps muscular contraction
9971723|NCT01313546|Active Comparator|sartorius|stimulation of sartorius muscle through femoral nerve
9971724|NCT01313585||IPDA salbutamol MDI|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
9971725|NCT01313585||IPDA salbutamol EB|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
9971726|NCT01313585||IPDI salbutamol EB|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
9971727|NCT01313585||IPDI salbutamol MDI|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
9971728|NCT01313598|Experimental|GLPG0187|GLPG0187 for infusion
10149367|NCT04107480|Experimental|Intervention|Patients in the intervention groups will be referred to one of the participating neurosurgical centers, for surgical consultation. After this consultation, the patient may choose to continue with surgery or not.
10149368|NCT04107480|Active Comparator|Standard care|Patients in the standard care groups will receive treatment as usual as described by the US Endocrine Society.
10149369|NCT04107415|Experimental|Yoga group|group doing yoga
10149370|NCT04107415|No Intervention|No yoga group|group not doing yoga
10149371|NCT04107363|Experimental|Experimental group:|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes.~After the oropharyngeal aspiration was completed, the patient's position was changed."
10149372|NCT04107363|Other|Control group|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
10149373|NCT04107350|Experimental|whole body vibration on|vibration machine on combined with conventional physical therapy
10149374|NCT04107350|Sham Comparator|whole body vibration off|vibration machine off combined with conventional physical therapy
10149375|NCT04107402|Experimental|Septic shock|Septic shock Patients admitted to the ICU
10149376|NCT04107402|Other|Control group|Patients recruited at the central lab of the hospital, with matched age, gender and comorbidities
10149377|NCT04107402|Experimental|Covid-19|Covid-19 patients admitted to the ICU for Acute Respiratory Distress Syndrom with PaO2/FiO2 < 200
10149378|NCT04107324|Other|PVE (Portal vein embolisation)|Standard of care when FLR is small.
9519831|NCT03282942|Experimental|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
9669515|NCT04171518||Catalys Precision Laser System|Cataract Surgery with use of Catalys Precision Laser System
9669516|NCT04147247|Experimental|BI 905681|
9827490|NCT02457793|Experimental|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
10149379|NCT04107324|Experimental|ARAPS (Portal vein embolisation and associating RFA)|Experimental arm with PVE combined with RFA to induce accelerated liver hypertrophy.
10149380|NCT04107025|Experimental|Intervention|As part of the intervention, along with legal opinions, advise and support, participants were provided counselling support during their time to help survivors with trauma of legal proceedings.
10149381|NCT04107025|No Intervention|Usual Care|Participants were scheduled for legal consultancy only.
10149382|NCT04106908||Eqwilate|
10149383|NCT04106999|Placebo Comparator|Placebo|Normal Saline will be infused as per the protocol
10149384|NCT04106999|Experimental|Intervention group|Dexmedetomidine will be infused as per the protocol
10149385|NCT04107155|Experimental|Weight Management Program|Dietary Supplement: Saffron extract and Gynostemma extract with hesperidin and a handout with suggestions for healthy eating and overall health
10149386|NCT04107155|Placebo Comparator|Placebo|Placebo and handout with suggestions for healthy eating and overall health
9669517|NCT04141761|Experimental|Treatment Group|
9669518|NCT04141761|Placebo Comparator|Placebo Group|
9669519|NCT04124185||Patients with Achromatopsia|
9669520|NCT04123444|Experimental|Iloprost|Patients randomized to active treatment (n=190 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
9669521|NCT04123444|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n=190 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
9669522|NCT04116502|Experimental|A- Ruxolitinib|Treatment with Ruxolitinib
9971729|NCT01313611|Experimental|Rituximab + bendamustine|
10149387|NCT04106895||Fibryga|
10149388|NCT04107181|Experimental|Patient surveillance|The introducer will be used during annual Pap smears for cervical cancer screening.
10149389|NCT04107181|Experimental|Healthy Volunteers|There will be 2 types of healthy volunteers recruited to participate in this arm. The home study is to determine ease of use/feasibility of the introducer. The other group of healthy volunteers will be interviewed only. The goal of this study is to better understand how to improve women's health through learning about women's perceptions of their reproductive anatomy, specifically the cervix, comfort in discussing reproductive health topics with providers, and thoughts on two tools used to see the cervix.
10149390|NCT04107064|Experimental|Neurodiversity at Work (NaW) Group|Individuals in this group will receive a 6-week Autism at Work pre-employment training. Upon onboarding, each individual will be supported by a team manager, a team buddy, a peer mentor, a job/life skills coach, a vocational rehabilitation counselor, and a personal counselor. Ongoing support for members of support circles will be provided during the 12 weeks immediately after onboarding.
10149391|NCT04107064|Experimental|Neurodiversity at Work - Delayed Start (NaW-DS)|Participants in this group will receive typical orientation for neurotypical employees after onboarding. The support of peer mentor, job/life skills coach, vocational rehabilitation counselor, and a personal counselor will start 6 months after onboarding. Managers, co-workers, team buddies and mentors for all recruited and hired employees in both groups will receive the same specialized training to enhance their abilities to work with individuals with ASD.
10149392|NCT04107207|Active Comparator|Kombucha Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
10149393|NCT04107207|Placebo Comparator|Placebo Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
10149394|NCT04107090|Experimental|US guided lung recruitment|Group A: it included 22 patients on whom the recruitment manoeuvre was applied guided by lung ultrasonography.
10149395|NCT04107090|Other|Non US guided lung recruitment|Group B: it included 22 patients on whom the recruitment maneuver was not ultrasound guided. This is considered the control group.
10185438|NCT03745716|Experimental|Control arm: Azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
10185439|NCT03745703|Experimental|MOCHA|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
10185440|NCT03745703|Experimental|"MOCHA+, Stories Matter"|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
10185441|NCT03745703|No Intervention|Wait-list control|There is no intervention to be administered during the 12-week wait-list control period
10185442|NCT03745677|Experimental|Phase I|Each study site has selected 1-2 units ideally suited for initial implementation of the Advanced and Integrated MicroSystems (AIMS) interventions (Phase I Implementation) and 1-2 units for later implementation of AIMS interventions (Phase II Implementation). During Implementation Phase I, AIMS interventions were implemented on the initial, phase I Implementation units. The phase II units serve as control units during phase I.
10185443|NCT03745677|Experimental|Phase II|During Implementation Phase II, Advanced and Integrated MicroSystems (AIMS) interventions are being implemented on additional, phase II implementation units, leveraging lessons learned during phase I.
10185444|NCT03745664|Active Comparator|Treatment group|"Methylprednisolone Sodium Succinate (20mg/ml) will be given at the dose of 40 mg/day (20 mg x 2/day).~The treatment will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days)."
10185445|NCT03745664|Placebo Comparator|Placebo group|Saline Solution for Injection will be given ath the dose of 2 ml/day. The treatment placebo will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days).
10185446|NCT03745625|Experimental|HSK3486|First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,
10185447|NCT03745625|Active Comparator|Propofol|First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h
10185448|NCT03745599|Experimental|Diclofenac|Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
10185449|NCT03745599|Experimental|Flurbiprofen|Flurbiprofen group, which received flurbiprofen 100 mg capsules and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
10185450|NCT03745599|Experimental|Benzydamine|Benzydamine group, which received benzydamine 0.045 g, 30 mL oral sprays (Tantum Verde) and placebo capsules. Placebo capsules contained starch.
10185451|NCT03745586|Experimental|All study participants|
10185452|NCT03745573|Experimental|Empateach Intervention|All teachers in intervention schools will be invited to participate. Participants in the intervention condition will receive Empateach, a 10-week group intervention. Groups meet 14 times for 1-1.5 hour length sessions, which are led by peers. The aim of the Empateach intervention is to improve 'student and teacher well-being; self-regulation; teacher classroom management and teacher's use of positive discipline techniques. The intervention uses cognitive behavioural therapy techniques to change negative thought and behaviour patterns related to corporal punishment. The teachers receive information on alternatives to corporal punishment, planning exercises and reinforcement SMS, and because the intervention is in a group setting, social support to change their behaviours. They discuss their experiences and challenges in group sessions.
10185453|NCT03745573|No Intervention|Wait-list control|Teachers in wait-list control schools will receive no specific interventions related to violence prevention during the study, but will receive the intervention after the study is over if it is shown to be effective (pending donor funding).
10185454|NCT03745508|Active Comparator|Caffeinated Coffee (200 mg caffeine)|~200 mg of caffeine from instant coffee
10185455|NCT03745508|Active Comparator|Caffeinated Coffee (400 mg caffeine)|~400 mg of caffeine from instant coffee
10185456|NCT03745508|Placebo Comparator|Decaffeinated Coffee|Decaffeinated instant coffee
10185457|NCT03745482|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following application of the mobilisations outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
10185458|NCT03745482|No Intervention|Control|"The control condition will consist of the participant lying prone on a plinth for the same time if takes for intervention to be applied approximately 10 minutes.~Following the control condition outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
10185459|NCT03745469||Young-age group|Patient between the age of 18 and 30 years old, with a confirmed diagnosis of chronic mechanical neck pain
10185460|NCT03745469||Middle-age group|Patients between 30 and 60 years old, with a confirmed diagnosis of chronic mechanical neck pain.
10185461|NCT03745456||Subarachnoid Hemorrhage patients|Patients with severe subarachnoid hemorrhage (Hunt and Hess 4-5, Fisher 3-4) will be included initially in the first 6 hours after the onset of symptoms.
10187827|NCT03722329|Active Comparator|US Soliris|US sourced Soliris (eculizumab)
9971730|NCT01313689|Experimental|Ofatumumab|Biological
10149396|NCT04107194|Experimental|Tailored therapy|"Clarithromycin-sensitive strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~Clarithromycin-resistant and tetracycline-sensitive strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)~Clarithromycin- and tetracycline-resistant and levofloxacin-sensitive strain (10 day- therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Levofloxacin 500 mg bid (tablet)~Clarithromycin-, tetracycline- and levofloxacin-resistant strain (10 day-therapy):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Rifabutin 150 mg bid (tablet)"
10149397|NCT04107194|Active Comparator|Empiric therapy|"Either one of the two following 10-day regimens (according to physician's decision):~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)"
10149398|NCT04107220|Other|one arm|One arm study patients where NT-proBNP and BNP tests will be monitored.
10149399|NCT04107259||Patient with diabetes|60 newly diagnosed type 2 diabetes
10149400|NCT04107259||Control|60 non-diabetic control subjects
10149401|NCT04107272|Experimental|Experimental group|Real rTMS
10149402|NCT04107272|Sham Comparator|Control group|Sham rTMS
10149403|NCT04107142|Experimental|CAR-T Cell Therapy Group|"One arm study consisting of 3 + 3 dose escalation study design ranging from 3 x 10^8 - 3 x 10^9 cells CAR-γδ T cell.~Each cycle of therapy will consist of 4 intravenous infusions, given 7 days apart."
10149404|NCT04107233|Experimental|Intervention|Audit and feedback directed at family physicians, including reports a one-on-one meeting.
10149405|NCT04107233|No Intervention|Control|Usual care; may receive the intervention at the end of the study if successful
10149406|NCT04107103|Experimental|Single Arm|A single-arm combining nivolumab with pemetrexed
10149407|NCT04106947||Patients with Hirschsprung and anorectal malformation|Patients with Hirschsprung and anorectal malformation living in Norway
10149408|NCT04106882|Experimental|Arm 1: Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
10149409|NCT04106882|Experimental|Arm 2: Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
10149410|NCT04106882|Experimental|Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
10149411|NCT04106869|Active Comparator|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
10149412|NCT04106869|Placebo Comparator|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 ( 40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
10149413|NCT04106830||NMOSD|Patients with neuromyelitis optica spectrum disorders
10149414|NCT04106830||Multiple sclerosis(MS)|Patients with multiple sclerosis
10149415|NCT04106830||Health control(HC)|Healthy people without any neuroinflammation disease
10149416|NCT04106609|Experimental|Exercise Group|Patients will complete a 60-minute exercise session once per week for 12 weeks. The exercise sessions will be individualized to the patient's needs and fitness level by a trainer. A patient will work with the same trainer throughout the study, who will plan the patient's individualized exercise regimen, and who will provide one-on-one supervision for the duration of each 60-minute session. Each 60-minute session will include cardiovascular, strength, and flexibility training. The intensity level for the aerobic exercise ranges from 30-45% of the individual's predicted VO2max, controlled by heart monitors and lasting 30 min. Strength training will involve a full body workout, with emphasis on all major muscle groups and employing machines, free weights, and resistance tubing. Patients will complete 3 sets of 10 repetitions for each strength exercise. Flexibility training will involve static stretching of all major muscle groups for 15-20 seconds at the completion of each workout.
10149417|NCT04106609|Active Comparator|Control Group|The control group will receive the current standard of care, which includes a resource guide with various options available to the cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
10149418|NCT04106752|Active Comparator|meal followed by caffeine|A standardized meal consisting of 2 slices of toast bread, organic peanut butter and jam was given to the participant. One and a half hours later, the participant ingested a caffeinated drink (3 mg per kg body weight of caffeine powder dissolved in water). After 30 mins, resting EE was measured using FM for 15 min while seated on the comfortable seat, and then for 5 min while seated on a cycle ergometer. Participants were then asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively. During cycling, EE was being measured using the FM, HR was monitored and rating of perceived exertion (RPE) was recorded in the last minute of every load cycle.
10149419|NCT04106752|Active Comparator|Caffeine followed by meal|Caffeine was given to the participant. After 1.5 hours the standardized meal was given followed by the same protocol mentioned above.
10149420|NCT04106752|Active Comparator|caffeine only|Caffeine will be given to the participant. 2 hours later the same protocol mentioned above will be applied
10149421|NCT04106752|Active Comparator|Meal only|A standardized meal will be given to the participant. 2 hours later the same protocol mentioned above will be applied.
10149422|NCT04106752|Active Comparator|meal plus caffeine|A standardized meal + a caffeinated drink (3 mg/kg of body weight of caffeine powder dissolved in water) will be given to the participant. 2 hours later resting EE is measured using a facemask (FM) for 10 min while seated on a cycle ergometer . The participant will be asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively.
10149423|NCT04107012|Experimental|Clear Aligner|Group 1 treated with clear aligners
9971731|NCT01313689|Active Comparator|Physicians' Choice|Physicians' choice of treatment
10149424|NCT04107012|Active Comparator|Fixed appliance|Group 2 treated with conventional fixed appliances
10149425|NCT04106921|Experimental|Universal Health Coverage Mode|The NGOs Muso and Medic Mobile have partnered to develop Universal Health Coverage Mode, a smartphone app tool that provides visual cues to help CHWs track the quantity of household visits they have conducted at each household in a given month.
10149426|NCT04106921|No Intervention|Work as usual|For the control arm, all households within the CHW's household list in the app will have the same appearance. There will be no visual differentiation between households on the list to indicate the frequency of home visits.
10149427|NCT04106765||: epileptic LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom~Evaluated items:~Number of seizures~Type of seizures~Presence of EEG abnormalities~Presence of IRM abnormalities~Time before cognitive disorders"
10149428|NCT04106765||cognitive LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom~Evaluated items:~Presence of EEG abnormalities~Presence of IRM abnormalities~Time before epileptic seizures"
10149429|NCT04106700|Experimental|Apixaban (single arm)|
10149430|NCT04106687|Active Comparator|Caudal Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided caudal block wil performe with bupivacaine 1 ml/kg as 0.25%.
10149431|NCT04106687|Active Comparator|Sacral Erector Spinae Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided sacral erector spinae block wil performe with bupivacaine 1 ml/kg as 0.25%.
10149432|NCT04106791|Experimental|Closed-loop|Pilot study: one single group of 10 ICU patients.
10149433|NCT04106622||Wolff Parkinson White patients|"The investigators will decide the location of the AP by:~- Invasively: if the patient is subjected to (EPS)~• There are different locations of AP To assess whether the AP is of high risk or not, for all patients the Antegrade refractory period of the APAERP of the AP will be determined by one of the following ways: ( AERP) is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval (SPERRI) during spontaneous or induced AF.~The AERP and the risk category of the AP according to its value, will be recorded in relation to the site of the AP determined in every case and compared between different accessory Locations to see whether some of these positions are more liable to be of higher risk or there is no differerence between different positions."
9519832|NCT03282942|No Intervention|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
10149434|NCT04106674|No Intervention|Non-surgical|No surgery
10149435|NCT04106674|Active Comparator|Surgical|Surgeons preference
10149436|NCT04106427|Experimental|cTBS plus SCRT|10 daily sessions of continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
10149437|NCT04106427|Placebo Comparator|Placebo plus SCRT|10 daily sessions of placebo continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
10149438|NCT04106427|Sham Comparator|Sham SCRT|16 sessions of sham social cognitive remediation therapy (SCRT) twice per week over an eight week period. Participants will engage in non-effective group activities
9519833|NCT03282929|Experimental|Part 1 Group 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.
10149439|NCT04106661|Experimental|Tai Chi Intervention 1|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
10149440|NCT04106661|Experimental|Tai Chi Intervention 2|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
10149441|NCT04106466|Experimental|Deep Brain Stimulation (DBS)|Open label active Deep Brain Stimulation (DBS)
10149442|NCT04106557|Experimental|OV101 once daily (weight-based dosing) Other Name:Gaboxadol|OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration
10149443|NCT04106557|Placebo Comparator|Placebo once daily|Matching placebo,oral, provided once daily at bedtime for 12 week duration
10149444|NCT04106778|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
10149445|NCT04106778|Experimental|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
9519834|NCT03282929|Experimental|Part 2 group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
10149446|NCT04106635|Experimental|PP group|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
9826208|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
10149447|NCT04106635|Active Comparator|CP group|During the induction of anesthesia, cricoid pressure is applied by 30N force with three finger.
10149448|NCT04106505|Experimental|Biofeedback|The treatment comprises an app containing biofeedback training, instructions for self-delivery and a headache diary. The treatment utilizes these functionalities by a push-reminder in the app to complete a daily headache diary entry and a biofeedback session of 10 minutes duration daily. Prior to commencing treatment participants will be given basic information on the rationale behind biofeedback treatment, given instructions on how to use the equipment and software and instructions on how to complete a biofeedback session. The biofeedback is based on wireless sensors measuring muscle tension, finger temperature and heart rate.
10149449|NCT04106505|Sham Comparator|Sham-biofeedback|Sham-biofeedback will be made by disrupting the connection between input of physiological parameters and the feedback. Thus, the feedback will simply be displayed as positive feedback occurring at random intervals throughout the sessions. The looks and contents of the normal app and the sham-app will be completely similar. The participants being allocated to the sham-goup will also use exactly the same sensor setup as the biofeedback group. The only difference between the two arms/interventions is the internal software algorithm, which will be inaccessible to the user. All participants in both groups will be given the same information and instructions.
10149450|NCT04106596||Patients with antibodies against LGI1|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
10149451|NCT04106596||Patients with antibodies against CASPR2|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
10149452|NCT04106596||Patients with antibodies against GAD|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
10149453|NCT04106726|Experimental|Test: Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply cream to the affected areas of the face once daily for 12 weeks.
10149454|NCT04106726|Active Comparator|Reference: Soolantra® cream, 1%|Manufactured by Galderma Laboratories, L.P.; Apply cream to the affected areas of the face once daily for 12 weeks.
10149455|NCT04106726|Placebo Comparator|Placebo: Placebo for Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply to the affected areas of the face once daily for 12 weeks.
10149456|NCT04106843|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30 minutes every 8-16 weeks. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
10149457|NCT04106440|Experimental|Application Use|Participants will be asked to use applications to track food intake, carbohydrate counts, insulin delivered, and blood sugar values and share the data with the study team.
10149458|NCT04106440|No Intervention|Standard of Care|The control group will receive usual care during their hospitalizations at the time of diabetes diagnosis, and during the time between hospital discharge and first visit to the UCD Pediatric Diabetes clinic.
10149459|NCT04106713|Experimental|Individual Therapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
10185462|NCT03745443|Experimental|Intervention group|Intervention: increase and decrease positive end-expiratory pressure. PEEP titration: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11 ventilation was maintained on PEEP 11 for 2 minutes.Then, PEEP was reduced by 2 for every 5 breaths to 5.Total time to titrate was 5 minutes.
10185463|NCT03745443|No Intervention|Control|Ventilation with PEEP 3 during anesthesia and surgery
9827491|NCT02457793|Experimental|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
9519835|NCT03282929|Experimental|Part 2 Group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
9669523|NCT04116502|Active Comparator|B- Hydroxycarbamide OR Interferon A|Best Available Therapy (BAT), Treatment with hydroxycarbamide OR Interferon A
9669524|NCT04116047|Active Comparator|Arm 1 (control): chemoradiotherapy|Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.
9971732|NCT01313702|Experimental|polipillV1|poli pill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
9971733|NCT01313702|Experimental|polipillV2|Polipill versão2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
9971734|NCT01313702|Active Comparator|usual care|
10149460|NCT04106713|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven [behaviours] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing [behavioural] and emotional awareness, and situational and interoceptive exposure to emotion cues."
10149461|NCT04106713|Experimental|Group CBT|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
10149462|NCT04106713|No Intervention|Delayed Waitlist|Participants in the Waitlist group will be recruited from those referred for psychotherapy and who are not assigned to either group or iCBT and not planned for psychotherapy at IMH for 8 weeks or more from the point of consent.
10149463|NCT04106713|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group are individuals who are not assigned to psychotherapy at IMH. They will be recruited from outpatient services and emergency services at IMH.
10149464|NCT04106453|Experimental|navigated microwave ablation|microwave ablation is performed laparoscopically with navigation
10149465|NCT04106453|Active Comparator|ultrasound guided microwave ablation|microwave ablation is performed laparoscopically with ultrasound guidance
10149466|NCT04106401|Experimental|hypoxia & confinement|Participants exposed to high-altitude hypoxia and confinement during a one-year stay at Concordia station, Antarctica (3200 m)
10149467|NCT04106401|Active Comparator|confinement|Participants exposed to confinement during a one-year stay at Dumont d'Urville station, Antarctica (sea level)
10149468|NCT04106375|Experimental|Intervention Group|Women with a history of depression and no other mental health disorders undergoing Mindfulness Based Cognitive Therapy.
10149469|NCT04106375|No Intervention|Control|Healthy women with no prior history of depression or other mental health disorders as a control group for time-repetition effects on brain activity and task performance
10149470|NCT04106336|No Intervention|non cannabis addict|30 non cannabis addict will be control group
10149471|NCT04106336|Active Comparator|cannabis addict|30 cannabis addict will undergo rTMS
10149472|NCT04106362|Active Comparator|Arm I (radiation therapy, cisplatin)|Beginning on day 0, patients undergo radiation therapy over 6 weeks for a total of 35 fractions. Patients also receive cisplatin IV over 1-2 hours on days 0 and 21.
10149473|NCT04106362|Experimental|Arm II (cetuximab, radiation therapy, cisplatin)|Patients receive cetuximab IV over 120 minutes 5-7 days prior to start of radiation therapy and then IV over 60 minutes weekly on Monday or Tuesday for 7 weeks. Patients also undergo radiation therapy and receive cisplatin as in Arm I.
10149474|NCT04105985|Experimental|Kovanaze Nasal Spray (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
10149475|NCT04105985|Active Comparator|Articaine Injections (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
10149476|NCT04106180|Experimental|SBRT + sintilimab + GM-CSF|
10149477|NCT04105959|Experimental|RIST4721 300mg|RIST4721 as once-daily 300mg oral solution for 6 days with a placebo crossover.
10149478|NCT04105959|Experimental|RIST4721 150mg|RIST4721 as once-daily 150mg oral solution for 6 days with a placebo crossover.
10149479|NCT04106011||Patients with Neuropathic Pain|
10149480|NCT04106037||Legionnaires' disease|All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.
10149481|NCT04106128|Experimental|ultrasound examination|Assess the prevalence of acute diaphragmatic dysfunction by ultrasound
10149482|NCT04106206|Experimental|LY3372689|LY3372689 administered orally
10149483|NCT04106206|Placebo Comparator|Placebo|Placebo administered orally
10149484|NCT04106050|Experimental|Part A: BIIB095 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 1 capsules from Day 1 to Day 8.
9827492|NCT02457793|Experimental|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
10149485|NCT04106050|Experimental|Part A: BIIB095 Dose 2|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 2 capsules from Day 1 to Day 8.
10149486|NCT04106050|Experimental|Part A: BIIB095 Dose 3|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 3 capsules from Day 1 to Day 8.
9519836|NCT03282929|Experimental|Part 2 Group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
10149487|NCT04106050|Placebo Comparator|Part A: BIIB095 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB095 capsules from Day 1 to Day 8.
10149488|NCT04106050|Active Comparator|Part A: Lidocaine|Healthy participants and participants with DPN will receive single injection of lidocaine for partial nerve conduction block and single injection of lidocaine for skin infiltration on Day 8.
10149489|NCT04106050|Experimental|Part B: BIIB074 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB074 Dose 1 tablets from Day 1 to Day 8.
10149490|NCT04106050|Placebo Comparator|Part B: BIIB074 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB074 tablets from Day 1 to Day 8.
10149491|NCT04106102|Active Comparator|Transcramial Direct current stimulation|Implement of Transcramial Direct current stimulation
10149492|NCT04106102|Placebo Comparator|Placebo|
9971735|NCT01313715|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 children aged 13-60 months old on day0,28
9971736|NCT01313715|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 children aged 13-60 months old on day0,28
10149493|NCT04106271|Experimental|Experimental group|dyadic pain management program will be accessible by the intervention group
10149494|NCT04106271|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
10149495|NCT04106310|Active Comparator|Theranova|Patients will be receiving hemodialysis using Theranova dialyzer. The other hemodialysis parameters are kept the same.
10149496|NCT04106310|Active Comparator|High-flux|Patients will be receiving hemodialysis using a high-flux dialyzer. The other hemodialysis parameters are kept the same
10149497|NCT04106076|Experimental|Dose escalation|Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.
10149498|NCT04106141|Other|control group|
9669525|NCT04116047|Experimental|Arm 3: Dose-escalated chemoradiotherapy|Dose-escalated chemoradiotherapy using intensity modulated radiotherapy (IMRT) 64Gy in 25F + Cisplatin 100mg/m2 day 1 of week 1 and of week 5 or weekly 40mg/m2. Neck dissection as indicated by clinical and radiological assessment at 3-months post-treatment.
10149499|NCT04106141|Active Comparator|intervention group|
10149500|NCT04105946|Active Comparator|OFA Group|patients undergoing FESS under opiod free anesthesia
10149501|NCT04105946|Active Comparator|TIVA Group|patients undergoing FESS under total intravenous anesthesia
10149502|NCT04106245|Experimental|Supportive care (PACK health coach, survey)|Patients are contacted once weekly by a health coach by text message, phone call, email, or a mobile application, for 3 months. The total time interacting with the health coach is about 3.5-4.5 hours across the study. Patients also complete surveys over 30 minutes each time at baseline and every 30 days for 3 months.
10149503|NCT04106297|Experimental|GLPG3970 SAD|Single doses of GLPG3970 at up to 6 dose levels in ascending order
10149504|NCT04106297|Placebo Comparator|Placebo SAD|Single doses of placebo
9669526|NCT04116047|Experimental|Arm 5: Durvalumab + Arm 1|One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months
10149505|NCT04106297|Experimental|GLPG3970 MAD|Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days
10149506|NCT04106297|Placebo Comparator|Placebo MAD|Multiple doses of placebo
9669527|NCT04109014|Other|FASTLANE II Group|Participants will participate in the FASTLANE II Intervention. Counseling sessions will focus on: 1) depressive symptoms, 2) methamphetamine use, and 3) sexual risk behaviors. Three sessions will be devoted to each topic area. Trained staff will use a client-centered approach and develop a goal for each area alongside the participant. Counseling sessions will remain confidential and will not be audio recorded.
9669528|NCT04095845|Active Comparator|CO THA|Computerised tomography based planning of conventional total hip arthroplasty
9669529|NCT04095845|Experimental|Mako THA|Mako robotic-arm assisted total hip arthroplasty
9669530|NCT04095637|Experimental|Mako medial UKA|Mako medial unicondylar knee arthroplasty
10149507|NCT04106297|Experimental|GLPG3970 FE-rBA|Single dose of GLPG3970 in fed and fasted state
10149508|NCT04106297|Experimental|GLPG3970 FE|Single dose of GLPG3970 in fed and fasted state
10149509|NCT04106297|Experimental|GLPG3970 in psoriasis subjects|
10149510|NCT04106297|Experimental|Placebo in psoriasis subjects|
10149511|NCT04105725|Experimental|BMI+Substance-Free Activity Session|Two 50-minute text messaging sessions that discuss alcohol use and experiences related to alcohol use, as well as the individual's college, career, and personal goals. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that return to the individual's goals and progress.
10149512|NCT04105725|Active Comparator|Alcohol + Nutrition Education Session|Two 50-minute text messaging sessions the provide information on alcohol and nutrition. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that provide additional information and review previous information about alcohol use and nutrition.
10149513|NCT04105673||Shaken Baby Syndrome|Realization of a clinical examination and survey on children with a past history of a Shaken Baby Syndrome
10149514|NCT04105920|Experimental|hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
10149515|NCT04105920|Active Comparator|Conventional brachytherapy|Patients included in this arm will have the conventional brachytherapy.
9669531|NCT04095637|Active Comparator|Oxford media UKA|Oxford unicompartmental knee arthroplasty with navigation control
9827493|NCT02457793|Experimental|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
9971737|NCT01313715|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 children aged 13-60 months old on day0,28
9971738|NCT01313715|Experimental|160U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 infants aged 6-12 months old on day0,28
10149516|NCT04105764|Active Comparator|DEEP BLOCK|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
10149517|NCT04105764|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
10149518|NCT04105634|Experimental|Inflammation group|Patient diagnosed with Cardiac Amyloidosis
10149519|NCT04105634|Experimental|Amyloid group|Patient diagnosed with Cardiac Amyloidosis
10149520|NCT04105608|Experimental|HFV meal|A vegetarian meal high in dietary carbohydrate and fiber
10149521|NCT04105608|Active Comparator|MED meal|A Mediterranean-like meal
10149522|NCT04105686|Active Comparator|Control Infant Formula|Milk-based study product
10149523|NCT04105686|Experimental|Experimental Infant Formula|Milk-based study product with oligosaccharides
10149524|NCT04105686|No Intervention|Reference Group|Human milk-fed group
9971739|NCT01313715|Experimental|320U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 infants aged 6-12 months old on day0,28
9827494|NCT02457819|Experimental|Dasotraline|Dasotraline 2, 4, 6 mg
9971740|NCT01313715|Experimental|640U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 infants aged 6-12 months old on day0,28
9971741|NCT01313715|Placebo Comparator|0/0.5ml placebo in children|0/0.5ml placebo in 45 children aged 13-60 months old on day0,28
9971742|NCT01313715|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 45 infants aged 6-12 months old on day0,28
9971743|NCT01313741|Experimental|Single arm shoulder arthroplasty|
10149525|NCT04105647|Experimental|Experimental group|Patients in the experimental group will receive a face-to-face group session and a package of healthy lifestyle instant messages, including lifestyle-integrated exercise and physical activity.
10149526|NCT04105647|Placebo Comparator|Control group|The control group will receive a face-to-face group session and a package of healthy lifestyle instant messages, but not related to lifestyle-integrated exercise and physical activity.
10149527|NCT04105829|Experimental|Tooth color measurement|Tooth color changes between times (before retainer bonding, after retainer bonding, in 1 month, 3 months, 6 months and a year)
10149528|NCT04105777||Standard Low Glucose Parenteral Nutrition using Eurotubes®|Patients receive standard PN reduced in glucose in Eurotubes®.
10149529|NCT04105777||Standard Parenteral Nutrition using Eurotubes®.|Patients receive standard PN in Eurotubes®.
10149530|NCT04105777||Standard Parenteral Nutrition using 2/3-chamber bags|Patients receive PN according to the routine used by the participating site.
10149531|NCT04105933|Experimental|CS-CBT|Culturally sensitive-CBT intervention was comprised of 16 sessions of cognitive behavioral therapy focused on culturally-specific beliefs and attitude.
9827495|NCT02457897|Experimental|Patients with insulin receptor mutation|
9971744|NCT01313754|Other|Vicryl|These patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive the vicryl material on the left.
9971745|NCT01313754|Experimental|Dermabond|The patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive dermabond skin glue on the left
10149532|NCT04105933|Active Comparator|CBT|CBT intervention was comprised of 16 sessions of cognitive behavioral therapy.
10149533|NCT04105907|Experimental|Partial root canal treatment with the Sonendo GentleWave|
10149534|NCT04105595||ASD patients|
10149535|NCT04105595||PFO patients|
10149536|NCT04105842|Experimental|Delfilcon A|All study participants will be refit with Delfilcon A (Dailies Total 1) lenses which they will wear for 1 month.
10149537|NCT04105881||Full term labor|Measured by flow cytometry and ELUSA
10149538|NCT04105881||Preterm labor|Measured by flow cytometry and ELISA
10149539|NCT04105881||Control|For comparison
10149540|NCT04105556|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.~Care was given when the child and his / her parents applied to the outpatient clinic for anesthesia consultation on the working day before the operation, and care was continued in the day surgery unit. On the 1st and 3rd days after discharge, the researcher provided tele-monitoring and consultancy services. In addition, communication with the parents was maintained at all times as needed. Care was terminated on the 10th day after discharge. The time of the study was approximately 12-14 days for each child and his / her parents.~Nursing care consists of 3 types of comfort-oriented care interventions. These interventions;~Standard maintenance interventions,~Emotional focused comfort care interventions,~Cognitive and functional comfort care interventions."
10149541|NCT04105556|No Intervention|Routine hospital schedule|"The researcher sincerely answered all questions asked by the control group during the perioperative period.~After the post-discharge post-tests, the control group was given a gift of medal of courage, a story book and a training booklet prepared for the parents after the policlinic control on the 10th postoperative day, and the training was given to the intervention group."
10149542|NCT04105569|Experimental|Healthy Volunteers|Enrolled subjects will be included in an experimental gingivitis model (SIBO) for 21 days and use an acrylic stent fabricated before and dispensed at the baseline appointment
10149543|NCT04105582|Experimental|Neo-antigen pulsed Dendritic cell|Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)
10149544|NCT04105374|Active Comparator|Arm I (surgery, radiation therapy, temozolomide)|Beginning on week 5 following standard of care surgery, patients undergo radiation therapy over 30 fractions 5 days per week for up to 6 weeks, and receive temozolomide PO QD for up to 49 days. At the discretion of treating physician, patients may also receive novoTTF-100A (Optune) device 0-7 weeks following radiation and temozolomide treatment. One month following completion of radiation therapy, patients continue to receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
10185464|NCT03745417|Experimental|UCMSCs group|Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks.
10149545|NCT04105374|Experimental|Arm II (Toca 511, Toca FC, radiation therapy, temozolomide)|Patients receive vocimagene amiretrorepvec via intracranial injection during surgery on day 1. Beginning on week 5 following surgery, patients receive extended release flucytosine PO TID for 7 consecutive days every 7 weeks. Patients also undergo radiation therapy and receive temozolomide as in arm I. After completion of radiation therapy and at the discretion of the treating physician, patients may continue to receive extended release flucytosine PO TID for 7 consecutive days every 8 weeks in the absence of disease progression or unacceptable toxicity.
10149546|NCT04105361|Experimental|Study group|We will do posterior nasal neurectomy in patients with allergic rhinitis after FESS in one side of the nose
10149547|NCT04105361|Experimental|Control group|We will do FESS only in the other side of the nose
9971746|NCT01313793|Experimental|Sequence 1|Subjects will receive clinical formulation (treatment A) followed by commercializable formulation (treatment B).
9971747|NCT01313793|Experimental|Sequence 2|Subjects will receive commercializable formulation (treatment B) followed by clinical formulation (treatment A).
9971748|NCT01313806|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
9971749|NCT01313806|Placebo Comparator|Placebo|
9827496|NCT02458092|Experimental|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant given intramuscularly in the deltoid muscle of the non-dominant arm.
9971750|NCT01313819|Active Comparator|Group 1|Give IV amantadine first then IV placebo(normal saline) drug
9971751|NCT01313819|Active Comparator|Group 2|Give IV placebo drug first then IV amantadine
9971752|NCT01313832|Experimental|remote ischemic preconditioning|
9971753|NCT01313845|Active Comparator|amantadine|administration of intravenous amantadine sulfate 200mg/500ml/bottle 1 bottle infusion over 3 hours, twice a day for consecutive 5 days
10149548|NCT04105348||IBD with DM|
10149549|NCT04105348||IBD without DM|
10149550|NCT04105426|Active Comparator|Antioxidants|This arm of patients received one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
10149551|NCT04105426|Placebo Comparator|Placebo|This arm of patients received placebo for 3 months.
9669532|NCT04092179|Experimental|Venetoclax and Enadisenib|"Enasidenib and venetoclax will be taken by mouth (orally), once a day, every day, continuously.~Every 28-day period will be called a cycle. Participants will start venetoclax alone on Cycle 1 Day 1 and continue the study drug alone until Day 15. On Day 15, participants will take enasidenib and venetoclax together and will continue to take the combination of study drugs until intolerable side effects or disease worsening."
9669533|NCT04092153|Active Comparator|Mechanically aligned|Neutral limb alignment irrespective of the patient's native knee anatomy and joint mechanics
9669534|NCT04092153|Experimental|Functionally aligned|Restore the patient's own pre-arthritic knee anatomy
9669535|NCT04090515|Experimental|Project Health|Project Health has three aims: 1) encourage participants to explore the costs of obesity, an unhealthy diet, and sedentary behavior and the benefits of physical fitness, a healthy diet, and regular exercise; 2) help participants gradually reduce caloric intake and increase physical activity, such that the participant reaches energy balance (i.e., is not eating more calories than they need); and 3) reduce attitudinal and behavioral risk factors for eating disorders and obesity. The intervention will be administered in Spanish.
9669536|NCT04090515|Placebo Comparator|Educational Video Control|The educational video control condition will include an educational video series on obesity in Spanish.
9669537|NCT04078828|Active Comparator|PR|
9669538|NCT04078828|Active Comparator|Non-PR|
9669539|NCT04050293|Experimental|SPN-538|Patients will be treated with SPN-538 as a single dose once a day
9669540|NCT04050293|Placebo Comparator|Placebo|Patients will be treated with Placebo once a day
9827497|NCT02458092|Experimental|Rabies Vaccine Rabipur|Rabies Vaccine Rabipur given intramuscularly in the deltoid muscle of the non-dominant arm.
10149552|NCT04105491||Aligner Patients|Patients who decided to be treated with Invisalign® aligners
9971754|NCT01313845|Placebo Comparator|placebo|administration of 0.9% sodium chloride 500ml/bottle 1 bottle infusion over 3 hours twice a day for consecutive 5 days
9971755|NCT01313871||All Participants|Adults with a confirmed diagnosis of rheumatoid arthritis
9971756|NCT01313949|No Intervention|Usual Care|A total of 90 patients with diabetes will be recruited. Thirty will be selected for the training course and the other 60 will be compared as controls. These controls will receive their usual diabetes care.
10149553|NCT04105387|No Intervention|Control Group|Tracheostomy change at day 7
10149554|NCT04105387|Experimental|Treatment Group|Tracheostomy change at day 4
10149555|NCT04105140|Experimental|male oxytocin group|male subjects with oxytocin treatment
10149556|NCT04105140|Placebo Comparator|male placebo group|male subjects with placebo treatment
10149557|NCT04105504|Experimental|Glutathione Group|Subjects were randomised to receive Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
10149558|NCT04105504|Placebo Comparator|Placebo Group|Subjects were randomised to receive Placebo capsules, which were identical in appearance and packaged in identical-looking containers with the Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
9971757|NCT01313949|Experimental|Peer leader training|"Peer leaders are people with diabetes who had volunteered to undertake an extensive program of training. The purpose of this training is to make them effective in the provision of support and advice to their peers on a one-to-one basis via telecommunication.~These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors."
10149559|NCT04105231|Experimental|Cannabidiol|"Cannabidiol (Epidiolex®) (oral suspension)100 mg/ml dosed as 3 ml in the morning for 4 days, then increased to 3 ml in the morning and 3 ml in the evening, equivalent to CBD 300 mg BID, with a total treatment duration of 7 weeks.~AND Risperione placebo, encapsulated tablet."
9669541|NCT04046900|Active Comparator|Vaginal microbiome transplant|Women in this group will be randomized to receive two doses of vaginal fluid from a healthy donor
10149560|NCT04105231|Active Comparator|Risperidone|"Risperidone (encapsulated tablet) dosed as 2 mg in the morning for 4 days, then increased with 2 mg in the morning and 2 mg in the evening, with a total treatment duration of 7 weeks~AND Cannabidiol placebo, oral suspension"
10149561|NCT04105816|Placebo Comparator|Adult Healthy Controls|Subjects included in part I of this study will be healthy adult volunteers with no known musculoskeletal injury. Exclusion criteria will be those with identified musculoskeletal injury, non-English speaking persons, and women who are pregnant.
10149562|NCT04105816|Experimental|Adult ACL Reconstruction Patients|Subjects included in part II of the study will be adult volunteers undergoing anterior cruciate ligament reconstruction at the University of Iowa. Exclusion criteria will be non-English speaking persons, women who are pregnant, patients undergoing multi-ligament repair, patients undergoing ACL reconstruction revision, patients undergoing concomitant cartilage or meniscal repair procedures, and patients undergoing bilateral ACL reconstructions.
10149563|NCT04105244|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post-enrollment plus the current standard of care, whereby caregivers phone their healthcare providers when they have questions or concerns
10149564|NCT04105244|Experimental|Resourcefulness Training Intervention©|The Resourcefulness Training© arm will receive (a) individually tailored instruction on personal and social resourcefulness skills via the Resourcefulness Video and intervention nurse, (b) journal-writing instruction to describe resourcefulness application, (c) access to the study website with videotape vignettes and Resourcefulness Video, and (d) boosters at 2 and 4 months post-enrollment that will include reinforcement of skills learned and additional journal writing.
10149565|NCT04105205|Experimental|Apramycin injection in escalating doses|Apramycin, solution for infusion.
10149566|NCT04105205|Placebo Comparator|Placebo|Physiological saline, solution for infusion.
10149567|NCT04105790|Experimental|Participants|Participants in class-based mental health intervention.
10149568|NCT04105478|Experimental|Un-cemented Comprehensive Nano stemless shoulder arthroplasty|"By using a stemless humeral component stem-related complications can be reduced. Furthermore, the canal preserving design may also facilitate further surgery should the need of a revision prosthesis arise.~Currently, little is known about the results of the stemless design. The initial results have been promising, but as with the stemmed design migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
10149569|NCT04105478|Active Comparator|Un-cemented Comprehensive stemmed total shoulder arthroplasty|A design with a metal stem in the humeral bone canal is currently regarded as the best treatment option, but complications related to the stem including humeral fractures can have devastating consequences.
10149570|NCT04105322|Experimental|Kinesio Taping on Abdominal Muscles|
10149571|NCT04105322|Experimental|Kinesio Taping on Back Muscles|
10149572|NCT04105322|No Intervention|Control|
10149573|NCT04105166|Experimental|RP-L301|RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
10149574|NCT04105465|No Intervention|Surgery without trial (PJ) device|All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein.
10149575|NCT04105465|Active Comparator|Surgery with trial (PJ) device|Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.
10149576|NCT04105192|Experimental|experimental group (Lippia citriodora + sabdariffa)|"Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days."
10149577|NCT04105192|Placebo Comparator|control group Placebo (sucrose)|Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg or Placebo (sucrose) Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days.
10149578|NCT04105257|Other|All patients|All patients seen at emergency with acute neurological deficit will be assessed if eligible to CTP/MRI
10149579|NCT04105309|Experimental|Implementation Intention (IMP)|"Following review of a psychoeducational packet regarding making changes for weight loss, all participants were assigned five dietary goals (e.g. avoiding high-fat foods, eating five servings of fruits and vegetables a day) and a goal to weight daily. Participants in the IMP condition formed an implementation intention for each of the goals at the baseline session. Two examples of implementation intentions were provided for each goal as a model. Participants thought about how they would best be able to achieve the outlined goals in their life on a daily basis (goal-aligned behavior), as well as when, where, and how they would initiate these new behaviors (retrieval cue). Participants then created and wrote down a unique implementation intention for each of the goals using the sentence structure If/When I _______, then I will ______. No repetitions or combinations of implementation intentions were allowed for standardization across participants."
10185465|NCT03745404|Experimental|Lido-Patch (Open-label Run-in Phase)|All participants applied up to 3 Lido-Patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area). Patches were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
9669542|NCT04046900|Placebo Comparator|Saline placebo|Women in this group will be randomized to receive two doses of sterile saline
9971758|NCT01313962|Experimental|Flufirvitide-3|
9971759|NCT01313962|Placebo Comparator|Placebo|
9971760|NCT01313975||1|Patients with non-traumatic subarachnoid hemorrhage
9971761|NCT01313975||2|Patients with severe traumatic brain injury
10149580|NCT04105309|Experimental|Enhanced Implementation Intention (IMP+)|Participants completed all tasks of the IMP group and additionally, individuals in the IMP+ condition received fluency training and text message reminders. Fluency training occurred weekly using an online survey tool. On fluency training days, participants received a survey link via email, which consisted of six multiple-choice questions for participant's unique implementation intentions. Participants had to correctly identify their matching goal-aligned behavior among three distractor behaviors as quickly as possible and were given corrective feedback if they chose incorrectly. Text messages containing all six implementation intentions as well as goal reminders that were obtained by asking participants to write down their reasons for wanting to lose weight were sent on four days each week of the intervention (16 days total). At baseline, participants chose how text messages were bundled and when they were sent. Text schedules stayed constant across the study.
10149581|NCT04105309|Active Comparator|Goal Intentions (GOL)|Participants in the GOL condition were assigned the five dietary goals and the daily weighing goal. No additional intervention was given.
10149582|NCT04105179|Experimental|Implant Groups|Group will receive the Smith & Nephew Journey II knee implant or the Zimmer NexGen LPS-Flex knee implant
9669543|NCT04044872|Experimental|Single Arm:Diagnosing Cardiotoxicity when on Radiation therapy|
10149583|NCT04105179|No Intervention|Healthy Control Group|Control group that will not be undergoing a total knee arthroplasty
9669544|NCT04038099|Placebo Comparator|Water Based Lubricating Jelly|5ml of Water Based Lubricating Jelly
10149584|NCT04105283|Experimental|Tc99m-MAA|"Tc99m-MAA will be administered by selective or supra-selective arterial injection via the bronchial artery or branches thereof.~Administration will occur over a period of 30-240 seconds"
10149585|NCT04105127|Active Comparator|Anterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the palatal surfaces of central upper incisors
10149586|NCT04105127|Active Comparator|Posterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the occlusal surfaces of first or second upper/lower molars
10149587|NCT04105036||45-54 years of age|Divided into two subgroups: individuals who are and are not socially deprived
10149588|NCT04105036||54-64 years of age|Divided into two subgroups: individuals who are and are not socially deprived
10149589|NCT04105036||65-74 years of age|Divided into two subgroups: individuals who are and are not socially deprived
10149590|NCT04105036||75-85 years of age|Divided into two subgroups: individuals who are and are not socially deprived
10185466|NCT03745404|Experimental|Lido-Patch (Double-blind Phase)|Up to 3 patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
10185467|NCT03745404|Placebo Comparator|Placebo Patch (Double-blind Phase)|Up to 3 placebo plasters per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
9669545|NCT04038099|Active Comparator|Lidocaine 2% Jelly|5ml of Lidocaine 2% Jelly
9669546|NCT04036968|Experimental|5 outpatient sessions|This is a within-subject study so all session procedures will be identical, however the specific medications provided as part of the double-blinded study medications may change during each session. During each session, which will last up to 8 hours a day and will be conducted on an outpatient basis, participants will be asked to complete standardized pain testing procedures, as well as questionnaires about how participants are feeling and to complete cognitive tasks.
10185468|NCT03745391|Active Comparator|MULTIMODAL MAGNETIC RESONANCE (MR)|Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
10185469|NCT03745391|Active Comparator|MULTIMODAL COMPUTED TOMOGRAPHY (CT)|Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
9669547|NCT04034420|Experimental|Online training|To receive self-paced online training and learning materials
9669548|NCT04029597|Experimental|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the Remote Patient Monitoring System.
9669549|NCT04027114|Experimental|Behavioural Physical Activity (PA) intervention|
9669550|NCT04027114|No Intervention|Wait list control|
9669551|NCT04019314|Experimental|Subjects with know chronic systolic heart failure|Subjects with know chronic systolic heart failure (LVEF<50%) admitted to SMH Heart Failure Medical Service for decompensated HF with clinical findings of volume overload requiring advanced diuretic therapy intervention and management will receive daily blood draws and quantitative blood volume analysis
9669552|NCT04015648|Experimental|Group 1|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^9 vp vaccination intramuscularly.
9669553|NCT04015648|Experimental|Group 2|Volunteers will receive standalone dose of ChAdOx1 Zika 2.5 x 10^10 vp vaccination intramuscularly.
9669554|NCT04015648|Experimental|Group 3|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^10 vp vaccination intramuscularly.
9669555|NCT04001101|Active Comparator|RT and Anti-PD-1|"In the pembrolizumab + RT arm, pembrolizumab will be started on study within 7 days (+/- 7 days) of start of RT.~Pembrolizumab will be given as standard of care in both arms"
9669556|NCT04001101|Placebo Comparator|Anti-PD-1|anti-PD-1 therapy alone Pembrolizumab will be given as standard of care in both arms
10149591|NCT04105101|Experimental|Prototype exoskeleon|The experimental trial will be performed with the prototype exoskeleton
9669557|NCT03991832|Experimental|Cohort A: IDH mutated glioma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
10149592|NCT04105101|Experimental|Skel-Ex|The experimental protocol will be performed with the commercially available Skel-Ex 360 (Skel-Ex, Rotterdam, The Netherlands)
10149593|NCT04105101|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
10149594|NCT04105023|Experimental|genistein|Genistein capsules of 25 mg each, 50mg/day
10149595|NCT04105023|Placebo Comparator|placebo|Maltodextrin capsules, administered orally once every 12 hours
10149596|NCT04105296|Experimental|EKSO+ES|6 months of exoskeleton training with spinal cord epidural stimulation.
10149597|NCT04104997|Experimental|The A group in 5% GLH8NDE|Three times administration both eyes, each 1 drop in Korean
10149598|NCT04104997|Placebo Comparator|The A group in placebo|Three times administration both eyes, each 1 drop in Korean
10149599|NCT04104997|Experimental|The B group in 5% GLH8NDE|Six administration both eyes, each 1 drop in Korean
10149600|NCT04104997|Placebo Comparator|The B group in placebo|Six administration both eyes, each 1 drop in Korean
10149601|NCT04104997|Experimental|The C group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Korean
10149602|NCT04104997|Placebo Comparator|The C group in placebo|Six administration both eyes, each 2 drop in Korean
10149603|NCT04104997|Experimental|The D group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Caucasian
10149604|NCT04104997|Placebo Comparator|The D group in placebo|Six administration both eyes, each 2 drop in Caucasian
10149605|NCT04104919|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the brivoligide treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
10149606|NCT04104919|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal administration of placebo while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
10149607|NCT04104893|Experimental|Single Arm|This is a single-arm, open-label study of the checkpoint inhibitor, pembrolizumab, in Veterans with mCRPC who have progressed on at least 1 prior novel androgen receptor (AR) signaling inhibitor, inclusive of abiraterone acetate, enzalutamide, apalutamide, and darolutamide. In addition to progressive mCRPC, a patient must have a somatic tumor mutation characterized by dMMR or CDK12-/- detected by next generation sequencing (NGS). Patients enrolled in this study will be treated with pembrolizumab at the FDA approved dosage of 200 mg intravenously every 3 weeks (21 days) until disease progression or unacceptable toxicity. During study, patients will maintain a castrate level of testosterone, = 50 ng/dL by ongoing treatment with a GnRH analogue or prior bilateral orchiectomy. Prior to initiating treatment with pembrolizumab, patients will undergo a baseline biopsy of a metastatic lesion. An additional biopsy of a metastatic lesion at the time of progression will be encouraged as well.
10149608|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Itopride|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
10149609|NCT04104867|Placebo Comparator|Colonoscopy preparation by PEG-EL with Placebo|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
10149610|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Domperidone|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
10149611|NCT04104945|Experimental|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
10149612|NCT04104906|Experimental|motor control training|8-week exercise program, twice a week, with motor control training
10149613|NCT04104906|Active Comparator|exercises|8-week exercise program, twice a week.
10149614|NCT04104971||with complications|children who did liver transplantation and develop complications
10149615|NCT04104971||without complications|children who did liver transplantation and do not develop complications
10149616|NCT04104841|Experimental|Behaviorally Enhancing Adolescents' Mood in Schools (BEAMS)|8-session modified behavioral activation program
10149617|NCT04104841|Active Comparator|Usual Care|Referrals to usual care
9519837|NCT03282929|Experimental|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
9669558|NCT03991832|Experimental|Cohort B: IDH mutated cholangiocarcinoma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
9669559|NCT03991832|Experimental|Cohort C: Other IDH mutated solid tumors|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
10149618|NCT04104711|Experimental|Home visits+Health education group|"Home visits were paid 3 times at 3-month intervals. After the home visits started, reminder messages supporting the home visit process were sent at two-week intervals.~Nursing interventions were applied in accordance with the subscales of the Health Belief Model by taking into account the individual differences of the participants and were performed within the scope of the basic dimensions of diabetes management such as nutrition, exercise, medication management, oral care and foot care. In addition, the importance of annual monitoring of HBA1c, blood lipid, albumin/ creatinine levels, fundus examination, blood pressure monitoring, sleep hygiene, avoidance of smoking and alcohol was also explained."
10149619|NCT04104711|No Intervention|No nursing intervention group|"The participants in the control group who have standart care by other health services were contacted 3 times at 3-month intervals through telephone calls, and were applied the data collection tools only. They have no nursing intervention by the researcher.~At the end of the study, for ethical statement the participants in the control group were given health training and the training booklet was distributed to them."
10149620|NCT04104958||Group 1|"Group 1 (n=50): women (age 20-40year) with PCOS who are diagnosed according to the criteria of the Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003), which require two of the following 3 manifestations:~oligo- or anovulation,~clinical and/or biochemical signs of hyperandrogenism (> 2.08 nmol/l),~polycystic ovaries on ultrasound examination (the presence of ≥12 follicles measuring 2-9 mm in diameter and/or ovarian volume > 10 cm)"
10149621|NCT04104958||Group 2|Group 2 (n=50): women (age 20-40 year) with male factor infertility.
10149622|NCT04104984|Experimental|control group not follow NICE guide lines|All pregnant women who fulfil the same inclusion criteria, exclusion criteria, diagnoses established as short cervix , and do not managed according to NICE guide lines will be treated and managed according to their units as a control group.
10149623|NCT04104984|Experimental|study group follow NICE guide lines|- All pregnant women will attend hospital between 14-24 weeks and fulfil inclusion and exclusion criteria will be approached for possibility to be included in the study . and will be managed according NICE guide lines
10149624|NCT04104607|Experimental|CC-1 therapy|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation. In case of clinical benefit, additional cycles with a total of up to six are possible.
10149625|NCT04104633|Other|Patients with breast or colorectal cancer|10 patients with invasive breast carcinoma, not otherwise specified (NOS) (Stade I to III) and 10 patients with invasive colorectal adenocarcinoma (Stade I to III)
10149626|NCT04104542|Experimental|Mindfulness MTHM|online mindfulness based stress reduction training
10149627|NCT04104542|Experimental|Mindfulness JBSA|online mindfulness based stress reduction training
10149628|NCT04104542|Sham Comparator|Healthy Lifestyle MTHM|online healthy lifestyle training
9519838|NCT03282903||Crohn's disease patients|1550 Crohn's disease patients who are symptomatically controlled.
9519839|NCT03282903||Ulcerative Colitis patients|1550 Ulcerative Colitis patients who are symptomatically controlled.
9669560|NCT03977896|Experimental|11C-MET PET/MRI|
9826209|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 2 Adult Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
10149629|NCT04104542|Sham Comparator|Healthy Lifestyle JBSA|online healthy lifestyle training
10149630|NCT04104477|Active Comparator|CMC OA Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
10149631|NCT04104477|Active Comparator|Age-Matched Control Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
10149632|NCT04104594|Experimental|patients with chronic rhinosinusitis with nasal polyps|
10149633|NCT04104594|Other|Patients with an indication for septoplasty = control group|
10149634|NCT04104698||Study Group (MDD with SIs)|25 Egyptian patients diagnosed with major depression (with suicidal ideations)
10149635|NCT04104698||Control group (MDD without SIs)|25 Egyptian patients diagnosed with major depression (without suicidal ideations)
10149636|NCT04104880|Experimental|Continuous Positive Airway Pressure (CPAP) group|Three-month CPAP use
10149637|NCT04104724|Experimental|Self-help|Immediate access to self-help materials
10149638|NCT04104724|No Intervention|Control|Wait-list control - treatment as usual (no intervention)
10149639|NCT04104932||Surgical group|Patients with isolated minor rib fractures received surgical stabilization.
10149640|NCT04104932||Conservative group|Patients with isolated minor rib fractures received conservative treatment, such as NSAIDs.
10149641|NCT04104659||MK 6240|
10149642|NCT04104581|Placebo Comparator|Control|Volunteers will consume a diet in which all grain foods are made from refined grains.
10149643|NCT04104581|Experimental|Low Whole Grain Oat Diet|Volunteers will consume a diet with a low level of whole grain oat incorporated into some of the foods.
10149644|NCT04104581|Experimental|High Whole Grain Oat Diet|Volunteers will consume a diet with a high level of whole grain oat incorporated into some of the foods.
10149645|NCT04104581|Experimental|Low Whole Grain Wheat Diet|Volunteers will consume a diet with a low level of whole grain wheat incorporated into some of the foods.
10149646|NCT04104581|Experimental|High Whole Grain Wheat Diet|Volunteers will consume a diet with a high level of whole grain wheat incorporated into some of the foods.
10149647|NCT04104737|Experimental|Spire Medical Health Tag|Spire Medical Health Tag is worn by all subjects The study is open label
10149648|NCT04104815|Experimental|Experimental Thickener|Powder thickener
10149649|NCT04104503|Experimental|Part A|
10149650|NCT04104503|Experimental|Part B group 1|"Treatment period 1: Fasted + iv;~Treatment period 2: Fasted;~Treatment period 3: High-fat meal"
10149651|NCT04104503|Experimental|Part B group 2|"Treatment period 1: High-fat meal;~Treatment period 2: Fasted + iv;~Treatment period 3: Fasted"
10149652|NCT04104503|Experimental|Part B group 3|"Treatment period 1: Fasted;~Treatment period 2: High-fat meal;~Treatment period 3: Fasted + iv"
9826210|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Adult Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
10149653|NCT04104789|Experimental|Kovanaze Nasal Spray (General Practice)|Adults who require restorations in the maxillary teeth that would need local anesthesia
10149654|NCT04104789|Active Comparator|Articaine Injections (General Practice|Adults who require restorations in the maxillary teeth that would need local anesthesia
10149655|NCT04104568|Experimental|iSupport for dementia - European-Portuguese version|Access, for 3 months, to an online self-help training and support program: iSupport for dementia - European-Portuguese version. The e-program offers information, skills training and support for informal caregivers of people with dementia. It comprises five modules, including twenty-three lessons on dementia and caregiver support. In line with good practices on digital engagement, the education plan can be personalized by the caregiver. This means that it can be adjusted to the person's availability and lessons can be selected according to particular needs. Each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques including psycho-education, behavioral activation, cognitive reframing, relaxation and antecedent-behavior-consequence (ABC) analysis.
10149656|NCT04104568|Active Comparator|Education-only e-book|The control group will receive a minimal education-only intervention, consisting on an e-book. The manual contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
10149657|NCT04104386|Experimental|Disclosure of Telomere Length Arm|Telomere Length results were provided (personal value, means, and standard deviation of the group), and categorized as 'short' telomere length (bottom quartile) and 'not short' (above the bottom quartile) based on age related norms available from research literature.
10149658|NCT04104386|No Intervention|Non-Disclosure|Telomere Length results were not provided.
10149659|NCT04104204|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.1 mg, A sham subcutaneous injection of 0.5 ml normal saline at inguinal area
10149660|NCT04104204|Experimental|Ultrasound guided supra-inguinal fascia iliaca block|0.25% bupivacaine 40 ml
10149661|NCT04104113|Experimental|XBYRT decoction|Participants assigned to receive the modifed Xiang Bei Yang Rong Tang granules
10149662|NCT04104113|Placebo Comparator|Placebo|Participants assigned to receive placebo (contains 5% of XBYRT) granules
9826211|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
10149663|NCT04104399|Experimental|XC101-D13H|single dose
10149664|NCT04104399|Placebo Comparator|Placebo|single dose
10149665|NCT04104230||Individuals Affected With Pancreatic Cancer|Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
10149666|NCT04104230||Individuals Affected with Related Cancer|Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
10149667|NCT04104230||Individuals Affected With Pancreatic Neoplasm|Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
10149668|NCT04104230||High-Risk Individuals|Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
10149669|NCT04104230||Healthy Controls|Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
9826212|NCT02412371|Experimental|Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
9971762|NCT01313988|Active Comparator|Dose 1|Spread that contains plant sterols and fish oil
9971763|NCT01313988|Active Comparator|Dose 2|Spread that contains plant sterols and fish oil
10149670|NCT04104217||patients|Participate in 30-60 minute interviews after each music therapy session.
10149671|NCT04104217||caregivers|Participate in 30-60 minute interviews after each music therapy session (ideally within 3 days).
10149672|NCT04104217||nurses|Participate in 10-15 minute interviews after initial music therapy session.
10149673|NCT04104217||music therapists|Music therapist will notify the researcher if he/she has provided music therapy for a patient who is identified as having delirium. Music therapists will also be interviewed about the clinical process after initial and follow up music sessions.
10149674|NCT04104295|Experimental|Ultrasound following X-ray|An ultrasound scan of the abdomen within 2 hours of the routine X-ray will be performed by a physician blinded to the X-ray results.
10149675|NCT04104126|Active Comparator|Standard of Care Physical Therapy|Patients with Achilles injury are prescribed PT for their treatment, therefore physical therapy is a standard of care treatment for patients with tendon pathology.
10149676|NCT04104126|Experimental|Blood flow restriction (BFR) therapy|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff.
10149677|NCT04104269||Mechanical Complications|Include free wall ventricular rupture and ventricular septal rupture
10149678|NCT04104269||Non-Mechanical Complications|Mechanical complications were not included in patients with AMI
10149679|NCT04104360|Experimental|Galacto-oligosacchardies|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
10149680|NCT04104360|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin three times daily for four weeks
10149681|NCT04104438|Active Comparator|Basiliximab with Delayed TAC|"Basiliximab~Dose #1: 20mg IV within 2 hours of transplant~Dose #2: 20mg IV Post-operative day #4~Tacrolimus (with basiliximab induction) o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to six months: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol~Post-operative taper:~Post-op day 1- methylprednisolone 50mg IVP Q6H~Post-op day 2- methylprednisolone 40mg IVP Q6H~Post-op day 3- methylprednisolone 30mg IVP Q6H~Post-op day 4- methylprednisolone 20mg IVP Q6H~Post-op day 5- methylprednisolone 20mg IVP Q12H~Post-op day 6- methylprednisolone 10mg IVP Q12H until taking PO, then change to: prednisone 20mg PO QAM"
10149682|NCT04104438|Active Comparator|Basliximab, Delayed TAC with Everolimus|"Basiliximab~Tacrolimus (with basiliximab induction)~o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to POD 30: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL~Mycophenolate mofetil o 1000 mg po bid up to POD 30: reduce mycophenolate mofetil following achievement of steady state everolimus (POD 35) as clinically indicated~Corticosteroids (SOC): Per UCLA protocol~Everolimus (delayed)~o Add by POD 30: 1 mg po bid and adjusted to maintain whole blood trough concentrations of 3-8 ng/ml."
10149683|NCT04104438|No Intervention|Control: standard TAC with steroids and MMF|"Tacrolimus (without basiliximab induction)~Beginning day #1 post-transplant to six months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 5-12ng/mL~Six months to one year: maintain whole blood trough concentration of 5-10ng/mL~Mycophenolate mofetil~o 1000 mg po bid~Corticosteroids (SOC): Per UCLA protocol"
10149684|NCT04104191|Experimental|L-1000AF System|Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation
10149685|NCT04104087|Experimental|deepithelializ free gingival graft|performing tunneling technique with deepithelialized free gingival graft in treating RT2 gingival recession
10149686|NCT04104087|Active Comparator|subepithelial connective tissue graft|performing tunneling technique with sub epithelial connective tissue graft in treating RT2 gingival recession
9826213|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
10149687|NCT04104074|Experimental|Radiotherapy Plus Sintilimab|HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.
10149688|NCT04104152|Experimental|ENDS 2.4% nicotine|Subjects will be assigned to one of four flavors variants of 2.4% ENDS products based on their preferred UB flavor.
10149689|NCT04104152|Experimental|ENDS 5.0% nicotine|Subjects will be assigned to one of four flavors variants of 5.0% ENDS products based on their preferred UB flavor.
10149690|NCT04104256|Experimental|Alert 1|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
10149691|NCT04104256|Experimental|Alert 2|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
10149692|NCT04104256|Experimental|Alert 3|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
10149693|NCT04104256|Experimental|Control|Pre-op clinic physicians will not receive interventions and perform duties as usual.
10149694|NCT04104035||BCR-ABL-positive hematopoiesis|Patients with BCR-ABL-positive hematopoiesis (newly diagnosed CML patients, CML patients with leukocytosis, CML patients without a hematological and/or cytogenetic and/or molecular response, CML patients whose BCR-ABL status becomes negative and then positive) will be included.
9971764|NCT01313988|Active Comparator|Dose 3|Spread that contains plant sterols and fish oil
9971765|NCT01313988|Placebo Comparator|Placebo|Placebo spread
10149695|NCT04104035||BCR-ABL activity inhibition under TKI|Patients with CML with BCR-ABL activity inhibition under TKI therapy (patients with MMR and/or deeper response) will be included.
10149696|NCT04104243|Experimental|Power-Up|Participants randomized to this arm will undergo 16 classes tailored for men, that discuss food choices, physical activity, and managing stress over 6 months, which are called the core, and 6 classes over the following 6 months, which is called the maintenance phase.
10149697|NCT04104243|No Intervention|Standard NDPP (National Diabetes Prevention Program)|Participants randomized to this arm will undergo 16 mixed gender classes that discuss food choices, physical activity, and managing stress over 6 months which are called the core and 6 classes over the following 6 months which is called the maintenance phase.
10149698|NCT04104347|Experimental|Metacognitive training (MCT)|
10149699|NCT04104347|Active Comparator|Support group|
10149700|NCT04104334|Active Comparator|"Monitored group M (optimized controlled anesthesia)"|"Patients in the Monitored group M, the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume."
10149701|NCT04104334|Active Comparator|"Control group C (standard of care anesthesia)"|"Patients in the Control group C will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100."
10149702|NCT04104009|Experimental|Interventional group|"In the exam group there will be group training for four meetings of one hour each.~After completing the training program with the test group, a break of 5 weeks will follow, during which a new test and control group will be formed. The procedure will be carried out until the estimated sample size (99 subjects per group) is met."
10149703|NCT04104009|Active Comparator|Control group|In the control group there will not be any group training.
10149704|NCT04104022|No Intervention|OAT as usual|Those randomized to OAT as usual will continue to receive standard buprenorphine or methadone treatment and complete assessments of PTSD symptom severity, psychosocial functioning and drug use at intake and Study Weeks 4, 8, and 12.
10149705|NCT04104022|Active Comparator|OAT+PET|In addition to receiving OAT and completing monthly assessments, OAT+PET participants will receive 12 weekly PET sessions with a trained therapist.
10149706|NCT04104022|Experimental|OAT+PET+|OAT+PET+ participants will receive the procedures for the OAT+PET group plus monetary incentives contingent upon completion of PET sessions
10149707|NCT04103866|Experimental|Pressure Offloading Innersole System|Use of Juvederm Voluma in the foot for fat pad restoration
10149708|NCT04103671|Experimental|Group A|Prompt panretinal photocoagulation
10149709|NCT04103671|Experimental|Group B|Micro-invasive Pars-plana vitrectomy
10149710|NCT04103684|Experimental|Patients will receive steroid pulse therapy|
10149711|NCT04103684|Active Comparator|Patients will receive low dose steroids|
10149712|NCT04103736|Experimental|Beet Juice Supplement|A single, acute dose of Beet It Sport Shot containing ~12.6mmol naturally occurring dietary nitrates.
10149713|NCT04103736|Placebo Comparator|Placebo juice|A single, acute dose of nitrate-depleted Beet It Sport Shot
10149714|NCT04103801|Experimental|Sucrose group|This group received the 2 ml of sweet solution (sucrose)
10149715|NCT04103801|Placebo Comparator|Water group|This group received the 2 ml of water
10149716|NCT04103983|Active Comparator|Sensory Retraining Interactive Device|The interactive device is a sensory retraining device. A pad consisting of twelve equally spaced electrodes is placed over the residual limb. This pad is connected to a handheld device which delivers an electrical current to the electrodes. The type of electrical current is similar to a TENS device. The device stimulates the skin via one of the electrodes, with either a single, or a rapid burst of pulse(s). The device touch screen then presents the questions, Which electrode (location) was stimulated? Was a single continuous or a rapid burst of pulses given (stimulation type)? The user responds via the screen and is told if they are correct. If correct, a new stimulus is delivered (different location and type) and the process repeated. If incorrect, the user is informed of the correct response, the same stimulation (location and type) is repeated once before moving onto to a new stimulus.
10149717|NCT04103983|Active Comparator|Sensory Retraining Non-Interactive Device|The non-interactive device is physically visually identical to the interactive device. There is no interaction required with this device i.e. there is no Q&A element, feedback nor response dependent progression.
10149718|NCT04103814|Active Comparator|Mg-CBDa cream|Subjects in this group will receive the active Mg-CBDa (magnesium-cannabidiolic acid) for topical treatment of hallux valgus or hallux rigidus.
10149719|NCT04103814|Placebo Comparator|Placebo cream|Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
10149720|NCT04103723||patients with premedication|Patients receiving preoperative premedication with midazolam before surgery.
10149721|NCT04103723||patients without premedication|Patients without preoperative premedication before surgery.
10149722|NCT04103762|Experimental|indocyanine green|During the surgery, intraoperative cholangiography using indocyanine green will be performed
10149723|NCT04103762|Active Comparator|standard cpo|"During the surgery, intraoperative cholangiography using a contrast product gold standard will be performed"
10149724|NCT04103827||old patients|"During the first 24 hours of the hospitalisation in the equiped room and before the presentation of the device, A first series of questions will be asked a priori to the patients. Patient will freely use Le Qoos during all his hospitalisation. After this use, a survey concerning the usability of Le Qoos will be administered to the patient, during the 48 hours before his discharge from hospital."
10149725|NCT04103827||relatives / unformal caregivers|"Before the presentation of the device, a first series of questions will be asked a priori to the unformal caregiver. Unformal caregiver will freely use Le Qoos during the hospitalization of his relative. After this use, a survey concerning the usability of Le Qoos will be administered to the unformal caregivers, 48 hours before the discharge of his hospitalized relative from hospital."
9971766|NCT01313988|Active Comparator|Control|Spread that contains plant sterols
10149726|NCT04103827||profesional caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Le Qoos will be administered to professional caregivers."
10149727|NCT04103658|No Intervention|Standard of care (control)|This will be the standard of care group. The excision of the non-melanoma skin cancer will be based on standard visual inspection with 4-6mm margins.
10149728|NCT04103658|Experimental|NIR heating|This will be the NIR heating group, where the excision of the non-melanoma skin cancer will be based on the lesion margins based on the application of near-infrared radiation (with 4-6mm margins).
10149729|NCT04103853|Experimental|Proxalutamide|"Stage one - Dose climbing:~Each dose cohort will assess toxicity within the 35 days following the first dose of GT0918.~Stage two- the expansion cohort :~30 patients will be enrolled to the 200mg cohort . 15 patients will be enrolled to the 300mg cohort."
10149730|NCT04103502||MicroPort Medial Pivot|Subjects will have been implanted with the MicroPort Medial Pivot TKA
10149731|NCT04103502||DePuy Attune|Subjects will have been implanted with the DePuy Attune PCR TKA
9971767|NCT01314027|Experimental|neoadjuvant + adjuvant chemotherapy|neoadjuvant chemotherapy is based on gemcitabine/oxaliplatin adjuvant therapy is based on gemcitabine
9971768|NCT01314027|Active Comparator|adjuvant chemotherapy|adjuvant therapy is based on gemcitabine
9971769|NCT01314040|Other|Run in|
9971770|NCT01314040|Experimental|High meat protein diet|
10149732|NCT04103775|Experimental|Cognitive Remediation|Cognitive Remediation comprises of six exercises supplied by BrainHQ by Posit Science Corporation: Sound Sweeps (targets auditory processing speed): Two successive frequency-modulated tone sweeps are presented and participants indicate whether the frequency increased or decreased within each tone: Fine Tuning (targets auditory perception and processing speed): Participants indicate which one of two confusable syllables were presented; Syllable Stacks (targets auditory memory); Users report the order of presented syllables in a serial memory span task; Memory Grid (targets auditory memory); Participants match identical cards representing syllables; To do List Training (targets auditory memory): Participants see a g rid of everyday items (e.g., plant, carrots, shovel) and select the items in accordance with spoken instructions; Rhythm Recall (target auditory memory): Participants recreate auditory melodies
10149733|NCT04103775|Active Comparator|Active Control|Active Control Comprises six exercises also supplied by Post Science Corporation: A Maze Race, Reversi, Bricks Breaking Hex, Word Search II, Bricks Squasher II, and CircloO. These are all common computer games freely offered online.
10149734|NCT04103944|Experimental|Osteonecrotic Repair Device|A biphasic osteochrondral composite method to support the regeneration of articular cartilage in vivo. With its concept that could be securely installed by press-fit without additional fixation, this approach can present an alternative to perform graft harvest and implantation in a single surgery.
10149735|NCT04103944|Active Comparator|Core Decompression|Core decompression is a common surgical procedure that aims to improve vascular inflow by decreasing intraosseous pressure in the femoral head. It is performed that involves removing a cylindrical core of bone from the proximal femur.
10149736|NCT04103606|Experimental|immediate-use App group (iApp group)|Participants in the iApp group start using the app immediately (Time 0; T0) for 16 consecutive days (until Time 1; T1).
9669561|NCT03971591|Experimental|Immediate Lifestyle program|The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
10149737|NCT04103606|Active Comparator|delayed-use App group (dApp)|Participants in the dApp group start using the app at Time 1 (T1; 16 days after the iApp group) and use the app for the following 16 days (Time 2; T2).
10149738|NCT04103905|Experimental|MIL62|
10149739|NCT04103918|Other|Jalucomplex® 2|Jalucomplex® 2 (Linear Hyaluronic Acid) Injection: follow the instruction for use
10149740|NCT04103541|Experimental|IP-Colombia|
10149741|NCT04103541|No Intervention|Waitlist control|
10149742|NCT04103697|Experimental|4xCapOx|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery. The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
10149743|NCT04103697|Active Comparator|Surgery|Patients will receive standard surgery for rectal cancer with partial or total mesorectal excision (based on exact tumor location and surgeons discretion). The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
10149744|NCT04103424|No Intervention|Pre-training Metabolic Study Visit|Participants will first complete a pre-training metabolic study visit.
10149745|NCT04103424|Experimental|Post-training Metabolic Study Visit|Participants will complete a second, identical metabolic study visit following 2-weeks of exercise training.
10149746|NCT04103528|Other|morning group(from 8:00 to 12:00)|
10149747|NCT04103528|Other|afternoon group(from 14:00 to 18:00)|
10149748|NCT04103463|Experimental|Interactive stepping exercise group|
9971771|NCT01314040|Experimental|High dairy protein diet|
10149749|NCT04103463|Active Comparator|Home exercise group|
10149750|NCT04103489|Experimental|HELLP Syndrome at less than 30 weeks gestation|Women diagnosed with HELLP syndrome at 23-30 weeks gestation will receive eculizumab.
10149751|NCT04103840||Severe alcohol- associated hepatitis|Severe alcohol associated hepatitis as defined by probable/ conformed National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria
9669562|NCT03971591|Other|Waitlist Control|In the waitlist control arm, the men will not receive any intervention for 16-weeks. After the 16-week assessment, men randomized to this arm will crossover to the intervention arm.
9669563|NCT03967470|Placebo Comparator|Placebo arm|Placebo spray used during one month
10149752|NCT04103840||Control|Apparently healthy Family controls
10149753|NCT04103476|Experimental|BZA/CE|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
10149754|NCT04103476|Placebo Comparator|Placebo|Oral matching placebo
9669564|NCT03967470|Active Comparator|Treatment arm|Bacteria spray used during one month
9669565|NCT03965741||Men with Prostate Cancer (PCa)|
9669566|NCT03965741||Men without PCa|
9971772|NCT01314040|Experimental|High grain protein diet|
9971773|NCT01314066|Experimental|Bevacizumab 5 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
10149755|NCT04103060|Experimental|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily
10149756|NCT04103060|Placebo Comparator|Vehicle gel|Vehicle gel applied topically twice daily
10149757|NCT04103164|Experimental|Cutera® excel V laser arm|After the PWS is be divided into five equal portions, four of those portions treated once with a different laser fluence using the multiple-pass approach (2 J/cm² vs 4 J/cm² vs 6 J/cm² vs 8 J/cm²), and one of the portions treated with single-pass approach at 8 J/cm²
10149758|NCT04103008||Group A|single coronary artery lesion
10149759|NCT04103008||Group B|multiple coronary artery lesions
10149760|NCT04103268||Sepsis|
10149761|NCT04103268||Control|
10149762|NCT04103411|Experimental|High Intensity Interval Training (HIIT)|For the twelve weeks of intervention, participants will have three training sessions per week. Each session will be done on a cycle ergometer and will last approximately 40 minutes. Participants will be supervised by certified kinesiologists and their training programs will be revised every four weeks.
10149763|NCT04103411|Active Comparator|HydroChloroThiazide|For this group, participants have to take a diuretic (12,5 mg of Hydrochlorothiazide) daily prescribed by the doctor of this study, for twelve weeks. Participants should also maintain the same lifestyle habits that they had before the study.
10149764|NCT04103307|No Intervention|Control: Standard of care|Participants in the control group will receive standard-of-care CRRT prescriptions, and have the returning venous blood warmed with an external blood warmer to a temperature of 37°C. The blood warmer temperature will be adjusted by the CRRT nurse as per usual practice to maintain normothermia.
10149765|NCT04103307|Experimental|Intervention: Cooling|Participants in the intervention group will receive standard of care CRRT prescriptions and have the blood warmer set to 35.5°C, as long as the nasopharyngeal temperature remains above 35.5°C.
9669567|NCT03961438|Active Comparator|Group A|HIV-uninfected participants
10149766|NCT04103151||Febrile infants|Febrile Infants less than 3 months presenting to the emergency department with a temperature of ≥ 38oC.
10149767|NCT04103151||Afebrile infants|Afebrile Infants less than 3 months presenting to the emergency department
10149768|NCT04103398|Experimental|Transarterial chemoembolization combined with sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
10149769|NCT04103398|Active Comparator|Transarterial chemoembolization alone|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
10149770|NCT04103047||SAD group|Adult surgical patients who are due to undergo general anaesthesia and requiring SAD insertion will be identified on the day of surgery.
10149771|NCT04103437||recreational runners|Recreational runners (minimum of 2 running session and 20km of total mileage per week), with seasonal best on half-marathon comprised between 1h20' and 2h00'. Age > 18 and < 60 years. Free from musculoskeletal injuries from at least three months.
9669568|NCT03961438|Active Comparator|Group B|HIV-uninfected participants
9669569|NCT03945812||Granulocyte Colony Stimulating Factor Arm|"Women in this group will receive G-CSF with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
10149772|NCT04103125|Other|Janesse|Janesse® 20 (Cross-linked Hyaluronic Acid) Injection: follow the instruction for use
10149773|NCT04103203|No Intervention|New diagnostic results NOT available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.
10149774|NCT04103203|Experimental|New diagnostic results available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.
10149775|NCT04103229|Experimental|10 ml sterile distilled water|The indwelling urinary catheterization was inflated with 10 ml sterile distilled water (SDW) of the balloon.
9669570|NCT03945812||Platelet Rich Plasma Arm|"Women in this group will receive PRP with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
10149776|NCT04103229|Experimental|15 ml sterile distilled water|The indwelling urinary catheterization was inflated with 15 ml sterile distilled water (SDW) of the balloon.
10149777|NCT04103229|Experimental|10 ml 0.9% sodium chloride (NaCL)|The indwelling urinary catheterization was inflated with 10 ml 0.9% sodium chloride (NaCL) of the balloon.
10149778|NCT04103229|Experimental|15 ml 0.9% sodium chloride (NaCL)|The IUC was inflated with 15 ml 0.9% sodium chloride (NaCL) of the balloon.
10149779|NCT04103255|Experimental|High frequency and intensive prevention|"High frequency and intensive prevention program -~Goal management training (Ariane Giguere-Rancourt et al., 2018) - is a home-based approach for PD patients with Mild Cognitive Impairment (MCI)~Physiotherapy~Rhythmic Music Gymnastic~Speech therapy"
10149780|NCT04103255|No Intervention|Control group (Stepped-wedge trial)|Best Medical Treatment
10149781|NCT04103294|Experimental|cowpea variety #1|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
10149782|NCT04103294|Experimental|cowpea variety #2|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
9669571|NCT03945812||Saline|"Women in this group will receive saline with conventional hormonal therapy:~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
9971774|NCT01314066|Experimental|Bevacizumab at 10 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
10149783|NCT04103021|Experimental|Port-a-cath|Ultrasound guided Port-a-cath insertion
10149784|NCT04103372|Active Comparator|Low risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 0. (Margin Clear >0mm from the diathermy margin and Sm1/2 or Haggitt 1/2/3) Six monthly follow up from date of surgery.
10149785|NCT04103372|Active Comparator|Moderate Risk - RT&Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to receive radiotherapy (RT) and regular surveillance, with 3 monthly follow-up from the date of surgery.
10149786|NCT04103372|Active Comparator|Moderate Risk - Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to surveillance arm with regular surveillance, with 3 monthly follow-up from the date of surgery.
10149787|NCT04103372|Active Comparator|High Risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of >2. (Margin positive - 0mm to the diathermy margin, Margin positive/or unassessable due to piecemeal removal - 0mm to the tumour margin, Sm3 or Haggitt 4, Poorly differentiated/mucinous, LVI, T2) Patient is considered for surgery, receives radiotherapy and surveillance, with 3 monthly follow-up from date of surgery.
10149788|NCT04103372|Active Comparator|TME (Total mesorectal excision) Surgery|For patients where it is considered technically feasible to do LE but MR staged<1mm muscularis preserved, or it is considered not feasible to perform a local excision. Patients undergo TME surgery. Pathology assessment on sample with confirmation of adenocarcinoma. Patient receives 6 monthly follow-up from date of surgery.
10149789|NCT04103346|Active Comparator|air filtration with hepa filter|air purifier used is the Holmes HAP8650B-NU-1 with the hepa filter inserted.
10149790|NCT04103346|Sham Comparator|air filtration with hepa filter removed|sham comparator uses the Holmes HAP8650B-NU-1 air purifier to be operated with the filter removed.
10149791|NCT04103112|No Intervention|Standard clinical care|Standard clinical care (anticoagulation) with no graduated compression stocking
10149792|NCT04103112|Experimental|Graduated compression stocking and standard clinical care|A graduated compression stocking and the standard clinical care (anticoagulation)
10149793|NCT04103086|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol). All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
10149794|NCT04103086|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
10149795|NCT04102995|Experimental|Sepranolone (UC1010) low dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
10149796|NCT04102995|Experimental|Sepranolone (UC1010) high dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
10149797|NCT04102995|Placebo Comparator|Placebo|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
10149798|NCT04102683|Experimental|Intervention Group|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
10149799|NCT04102683|No Intervention|Control Group|
10149800|NCT04102891|Experimental|Study arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the Flemish food-based dietary guidelines. Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
10149801|NCT04102891|No Intervention|Control arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the guidelines from the newly developed microbiota modulation diet (MMD). Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
9669572|NCT03923504|Active Comparator|Physical Activity Intervention (PAI)|Tailored multi-level physical activity intervention (PAI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
9971775|NCT01314066|Placebo Comparator|Placebo|In addition to receiving the best standard supportive care for both diagnosis and treatment for individuals diagnosed with severe sepsis, they will receive an IV saline solution.
9971776|NCT01314092|Experimental|Group 1|Low dose group
9971777|NCT01314092|Experimental|Group 2|high dose group
9971778|NCT01314131|Experimental|Intervention group|
10149802|NCT04102982|Active Comparator|Microwave ablation plus camrelizumab group|Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
10149803|NCT04102982|Placebo Comparator|Camrelizumab group|Patients in the group are treated with camrelizumab alone.
10149804|NCT04102852|Experimental|LGG regular dose|Patients taking LGG 1.2 × 10^10 CFU/day, 2 capsules a day, for 1 month
10149805|NCT04102852|Experimental|LGG double dose|Patients taking LGG 2.4 × 10^10 CFU/day, 4 capsules a day, for 1 month
10149806|NCT04102722|Experimental|Single Arm|All enrolled subjects will undergo breast cancer screening with mammography and the MUST device
10149807|NCT04102696|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
10149808|NCT04102696|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
10149809|NCT04102631|Experimental|exposed group|patients will receive colonoscopy with assistance of Endo.Angel
10149810|NCT04102631|Sham Comparator|non-exposed group|patients will receive colonoscopy without assistance of Endo.Angel
10149811|NCT04102605|Experimental|Nunap Vision|Nunap Vision , 5 days a week for 12 weeks
10149812|NCT04102605|Sham Comparator|Nunap Vision-C|Nunap Vision-C, 5 days a week for 12 weeks
10149813|NCT04102748|Active Comparator|Conventional|
10149814|NCT04102748|Active Comparator|I-incision|
10149815|NCT04102748|Active Comparator|M-flap|
9971779|NCT01314144|Experimental|Bupivacaine|Patients will receive intraoperative wound soakage with 20ml of 0.5% bupivacaine with adrenaline by the surgeon before closure and receive a continuous infusion of 4ml/hr of 0.2% bupivacaine delivered by an elastomeric pump the catheter of which will be placed by the surgeon in the wound before closure. Postoperative anlagesia will be provided with oxycodone, paracetamol and diclofenac.
9971780|NCT01314144|No Intervention|Control|Patients will receive morphine up to 0.1mg/kg intraoperatively. Postoperative analgesia will be provided with oxycodone, paracetamol and diclofenac.
10149816|NCT04102878|Active Comparator|Transcutaneous anaesthetic|
10149817|NCT04102878|Active Comparator|Transconjunctival anaesthetic|
10149818|NCT04102670|Experimental|Treatment|Subjects will receive a combination of Ultherapy, Xeomin, Beletero Balance, Dilute Radiesse and Neocutis MicroFirm Face and Neck Cream
10149819|NCT04102800|Other|Treatment|Benralizumab 30mg by subcutaneous injection, 18 months treatment for the first 75 participants enrolled, 12 months treatment for participants 76-150
10149820|NCT04102969|Experimental|Intervention group|"Intervention group will be instructed by an interventionist who is qualified in stress management and relaxation will perform the Benson relaxation technique to the intervention group to perform the Benson relaxation technique two times a day for 10 minutes during the study period ( two months).~Training session of the technique will be repeated if necessary over one or two sessions until the interventionist confirm that the participants acquired sufficient skills. A total of two hours will be scheduled for each session and will be coordinated with the nursing manager of the hemodialysis department."
9669573|NCT03923504|Active Comparator|Healthy Living Control Group|Healthy living intervention (HLI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
9669574|NCT03920007|Experimental|SAR439483|SAR439483 single dose according to an ascending dose design (dose escalation phase) or SAR439483 single dose (dose expansion phase)
9971781|NCT01314157|Experimental|Physiotherapy treatment technique|"Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with technical isostretching and the other group is control group."
9971782|NCT01314170|No Intervention|Susanna Implant|Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.
9971783|NCT01314183|Active Comparator|exercise|Subjects in this arm receive 12 exercise sessions in 9 weeks.
10149821|NCT04102969|Other|Control Group|A qualified nutritionist will run out a nutrition package session for hemodialysis patients in the control group. This nutrition package session will be for one session for one hour.
10149822|NCT04102943|Experimental|Tacrolimus1|Tacrolimus tablet Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
10149823|NCT04102943|Active Comparator|Tacrolimus2|Tacrolimus Cap Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
10149824|NCT04102657|Experimental|Intermittent Fasting with Left Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
10149825|NCT04102657|Experimental|Intermittent Fasting with Right Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
10149826|NCT04102657|Experimental|Free-living Diet with Left Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
10149827|NCT04102657|Experimental|Free-living Diet with Right Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
10149828|NCT04102761|Placebo Comparator|Trigger Point Needling|The first group will receive a deep trigger point injection of saline into deep tissue.
10149829|NCT04102761|Active Comparator|Platelet Rich Plasma Injection|The Platelet Rich Plasma group will receive an injection of approximately 1-2 mL of Platelet Rich Plasma into the painful disc/discs.
9971784|NCT01314183|Active Comparator|exercise + manual therapy|Subjects in this group receive exercise combined with manual therapy techniques for 12 sessions in 9 weeks.
10149830|NCT04102761|Active Comparator|Bone Marrow Aspirate Injection|The third group will receive an injection of approximately 1-2 mL of Bone Marrow Concentrate into the painful disc/discs.
10149831|NCT04102592|Experimental|Intervention Group|Participants in this arm receive Lesu (baby wrap) treated with 0.5% permethrin
10149832|NCT04102592|Placebo Comparator|Control Group|Participants in this arm receive Lesu (baby wrap) soaked with water only to mimic re-treatment and mask allotment
10149833|NCT04102787|Experimental|experimental group|Experimental group who received the Cardiac educational program and will be applied for Coronary Artery Disease patients, and measure the level of knowledge and satisfaction in pre and post test.
10149834|NCT04102787|No Intervention|control group|Control group who received the usual care and measure the level of knowledge and satisfaction in pre and post test.
9661871|NCT03812263|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
10149835|NCT04102917||QFR group|915 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, acute myocardial infarction with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
10149836|NCT04102774|Experimental|myAIRVO2|Patients will receive a myAIRVO2 at home over-night with humidifier on top of standard therapy for bronchiectasis according to international guidelines (ERS 2017).
10149837|NCT04102774|No Intervention|Control|Patients will receive standard therapy for bronchiectasis according to international guidelines (ERS 2017).
10149838|NCT04102930||Retrospective|A patient who has a diagnosis of GCA or PMR
10149839|NCT04102930||Prospective|Patient with suspected GCA and PMR
10149840|NCT04102293|Experimental|Rotary instrumentation using MM files 1|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
10149841|NCT04102293|Active Comparator|Manual instrumentation using K-files 1|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
10149842|NCT04102293|Experimental|Rotary instrumentation using MM files 2|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Disposable syringe technique.
10149843|NCT04102293|Active Comparator|Manual instrumentation using K-files 2|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Disposable syringe technique
9971785|NCT01314183|Experimental|exercise + booster|subjects in this arm will receive exercise sessions delivered with booster sessions (8 sessions in the first 9 weeks, 2 sessions at 5 months, 1 session at 8 months, and 1 session at 11 months).
10149844|NCT04102553|Experimental|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
10149845|NCT04102553|Active Comparator|F-18-Fluorocholine|Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.
10149846|NCT04102332||Before arm|usual infusion practices (neutral solvent-purged infusers)
10149847|NCT04102332||After arm|Safe Infusion Device
10149848|NCT04102267|Experimental|Liposomal bupivacaine injection (Group 1)|Liposomal bupivacaine 266 mg via injection
10149849|NCT04102267|Experimental|Bupivacaine HCl continuous infusion (Group 2)|Bupivacaine HCl 300 mg via continuous infusion
9971786|NCT01314183|Experimental|exercise + manual therapy + booster|Subjects in this arm will receive exercise combined with manual therapy techniques and booster sessions.
10149850|NCT04102527||Patients|Patients with Terminal Chronic Kidney Disease undergoing Peritoneal Dialysis for at least three months in stable condition
10149851|NCT04102358||Single injection|Patients who received an infraclavicular block with a single injection technique were included in Group-S.
10149852|NCT04102358||Triple injection|Patients who received an infraclavicular block with a triple injection technique were included in Group-T.
10149853|NCT04102488|Experimental|6-step hygiene technique, application time of 30 seconds|
9661872|NCT03810859|Experimental|All patients|Blood sample
9661873|NCT03805581|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
9661874|NCT03796481||Cases|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) with comorbid insomnia
10149854|NCT04102488|Experimental|6-step hygiene technique, application time of 15 seconds|
9661875|NCT03796481||Controls|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) without comorbid insomnia
9661876|NCT03791593|Experimental|Experimental group|The patient will receive evolocumab 420 mg/month on top of guideline-driven medical treatment
9661877|NCT03791593|No Intervention|Control group|The patient will continue guideline-driven medical treatment
9661878|NCT03784118|Experimental|Children|Children who are followed up after arterial catheterization for evaluation of complications, using ultrasonography
9661879|NCT03739723|No Intervention|Control Arm|Programs will continue to conduct normal educational activities.
9661880|NCT03739723|Experimental|Intervention Arm|The intent of the intervention arm is to provide programs with data and resources to inform and improve surgical learning environments and resident wellness.
10149855|NCT04102488|Experimental|3-step hygiene technique, application time of 30 seconds|
10149856|NCT04102488|Experimental|3-step hygiene technique, application time of 15 seconds|
10149857|NCT04102384|No Intervention|Control Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using an electronically link sent via email. Additionally, participants will be asked to fill out one survey once a week during the study period.
10185470|NCT03745378||Cases|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.
9669575|NCT03913845|Experimental|0.5% lidocaine with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
10149858|NCT04102384|Experimental|Intervention Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using the e-PRO app. Additionally, participants will be asked to fill out one survey once a week during the study period. A subgroup of these participants will be asked to complete an additional interview to collect more information on their experiences using the mobile app.
9971787|NCT01314196|Active Comparator|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers
10149859|NCT04102462|Experimental|Multiple rising dose part|
10149860|NCT04102462|Experimental|Midazolam part|
10149861|NCT04102397|Experimental|Standard plus Vojta therapy (SVT)|The physiotherapist's hands produce the activation with no need for medication or external equipment, thus guaranteeing the patient's safety.this therapy is able to change pathological patterns to painless patterns that reduce the use of energy caused by movement difficulty. The end result is to facilitate movement without strain.
10149862|NCT04102397|Active Comparator|Standard therapy (ST)|It consists of one or more of the following procedures: transcutaneous electrical nerve stimulation (TENS), ultrasound therapy, kinesiotherapy, and cryotherapy.
10149863|NCT04102410|Experimental|Experimental group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program composed of two 2 training strategies.
10149864|NCT04102410|Sham Comparator|Control group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program of usual practice.
9971788|NCT01314196|Experimental|progressive resistance training biceps|therapeutic exercises for the shoulder and scapula stabilizers and biceps resistance training.
9971789|NCT01314209|Experimental|dexmedetomidine|
10149865|NCT04102514|Other|Real-time Group Video|
10149866|NCT04102514|Other|Enhanced Usual Care|
10149867|NCT04102449|Other|Treatment with Apremilast|"Single group:~Apremilast will be prescribed according to the patient information leaflet, i.e.:~Dosage form: Oral pill Dosage and Frequency: First 6 days titration phase, followed by 30mg twice daily (in case of kidney problems 30mg once daily in the morning). Treatment duration at the discretion of the treating physician."
10149868|NCT04102215|Experimental|ARCI25|Robot assited Cochlear implant surgery.
10149869|NCT04102566|No Intervention|Standard of care arm|"The standard of care group will group will receive the following regimen while inpatient:~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~Acetaminophen 1000mg every 8 hours standing~Oxycodone 5mg PO every 4 hours as needed pain~Phenazopyridine 100mg TID as needed for urinary burning~Senna 1 tab every 12 hours~Miralax 17g powder once daily as needed for constipation~The standard of care group will get the following prescriptions on discharge:~Oxycodone 5mg every 4 hours as needed pain - 15 tabs~Acetaminophen 1000mg every 8 hours standing for two days then as needed~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~Senna 1 tab every 12 hours - 10 tabs"
10149870|NCT04102566|Experimental|Multi-modal group|"The multi-modal group will receive the following regimen while inpatient:~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours~Acetaminophen 1000mg every 8 hours standing~Ibuprofen 600mg every 6 hours standing~Oxycodone 5mg PO every 4 hours as needed pain~Phenazopyridine 100mg TID as needed for urinary burning~Senna 1 tab every 12 hours~Miralax 17g powder once daily as needed for constipation~Patient Education (Figures 2 & 3)~The multi-modal group will receive the following prescriptions on discharge:~Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs~Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs~Senna 1 tab every 12 hours - 10 tabs"
10149871|NCT04102176|Active Comparator|Continue nucleos(t)ide analogue|patients will be given open label tenofovir alafenamide
10149872|NCT04102176|Experimental|Stopping nucleos(t)ide analogue|patients will stop nucleos(t)ide therapy (such as entecavir, tenofovir, lamivudine or adefovir)
10149873|NCT04102202|Experimental|BOL-DP-o-05|
10149874|NCT04102202|Placebo Comparator|Placebo|
10149875|NCT04101864|Experimental|Electromagnetic navigation|In the study group acetabular components in total hip arthroplasty will be placed with the help of electromagnetic image-less navigation system. Reference plane will be anterior pelvic plane.
10149876|NCT04101864|Active Comparator|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
10149877|NCT04102306||Temporomandibular disorder group (TMD)|"Patients with temporomandibular disorder coming at the Cabinet Saint Alexandre for orofacial rehabilitation.~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a rehabilitation session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next rehabilitation session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 45 days).~Questionnaires were performed during the course of the patient rehabilitation that was instructed not to perform imagined movement during the interval."
10149878|NCT04102306||Control healthy group (CTL)|"Healthy individuals with no temporomandibular disorder (i.e., no orofacial medical consultation or rehabilitation) aged-matched and gender-matched to TMD group.~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 8 days).~Questionnaires were performed with no additional rehabilitation and participants were instructed not to perform imagined movement during the interval."
10149879|NCT04101968||GBA-PD|People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
10149880|NCT04101968||Asymptomatic GBA|Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.
10149881|NCT04102085||Mothers under 30|no intervention will be administered
10149882|NCT04101942|Experimental|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in the experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours on weekdays
10149883|NCT04101942|No Intervention|Control condition (assessment only)|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 7 weeks.
10149884|NCT04101981||healthy subjects|10 subjects
10149885|NCT04101981||oncological patients|10 subjects
10149886|NCT04102137||3|Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines
10149887|NCT04101929|Experimental|Experimental: Apatinib + S-1+ Irinotecan|Apatinib: 250mg po qd； S-1 capsule: According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle; Irinotecan: According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks.
10149888|NCT04102072|Experimental|Trendelenburg Maneuver|The Trendelenburg position is a common treatment in medicine.It is used either as a diagnostic tool to assess fluid loading response or as a therapeutic maneuver pending fluid resuscitation.With the advantage of autotransfusion readily available,the Trendelenburg position is used for expected instantaneous effect on cardiovascular performance.
10149889|NCT04102072|Experimental|dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
10149890|NCT04101994|Experimental|VCT and real rTMS|In virtual cycling training and intermittent theta burst stimulation group (VCT + iTBS group), they received VCT and iTBS (80% of active motor threshold) on affected hemisphere.
10149891|NCT04101994|Experimental|VCT and sham rTMS|In virtual cycling training and sham theta burst stimulation group (VCT + iTBS group), they received VCT and sham TBS stimulation.
10149892|NCT04101994|Experimental|real rTMS|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
10149893|NCT04101994|Sham Comparator|sham rTMS|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
10149894|NCT04101994|Experimental|VCT and real TES|In virtual cycling training and transcranial electric stimulation group (VCT + TES group), they received TES stimulation over motor cortex.
10149895|NCT04101994|Experimental|VCT and sham TES|In virtual cycling training and sham transcranial electric stimulation group (VCT + sham TES group), they received VCT and sham TES stimulation.
10149896|NCT04101994|Experimental|real TES|In transcranial electric stimulation group (TES group), they received TES stimulation over motor cortex.
10149897|NCT04101994|Sham Comparator|sham TES|In sham transcranial electric stimulation group (sham TES group), they received sham TES stimulation.
10149898|NCT04102501|Experimental|RT001|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
10149899|NCT04102501|Placebo Comparator|Placebo|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
9826214|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
9971790|NCT01314248||children weighing 10 to 15 kg|
9971791|NCT01314274|Experimental|bevacizumab|submucosal intranasal bevacizumab on day 0
9971792|NCT01314274|Placebo Comparator|placebo|0.9% NaCl intranasal submucosal on day 0
9971793|NCT01314300|Experimental|Efficacy of Lidocaine 5% plaster|Treatment of pain by Lidocaine 5% plaster
10149900|NCT04102124|Experimental|SHR3680+SHR3162|Participants will receive SHR3680 combined with SHR3162 orally
10149901|NCT04102124|Experimental|SHR3680+SHR3162(Placebo)|Participants will receive SHR3680 combined with SHR3162(Placebo) orally
10149902|NCT04102124|Placebo Comparator|SHR3680(Placebo)+SHR3162(Placebo)|Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally
10149903|NCT04101825|Experimental|Auralya|Auralya® 25 (Cross-linked Hyaluronic Acid) Injection
10149904|NCT04101838|Active Comparator|Fluzone Younger|10 adults 18-50 years old, will receive a single dose of the Fluzone influenza vaccine each year for two sequential years
10149905|NCT04101838|Active Comparator|Flucelvax|10 adults 18-50 years old, will receive a single dose of the Flucelvax influenza vaccine each year for two sequential years
10149906|NCT04101838|Active Comparator|Fluzone Older|10 adults 65-80 years old, will receive a single dose of the Fluzone influenza vaccine
10149907|NCT04101838|Active Comparator|Fluzone High Dose|10 adults 65-80 years old, will receive a single dose of the Fluzone High-Dose influenza vaccine
10149908|NCT04101838|Active Comparator|Fluad|10 adults 65-80 years old, will receive a single dose of the Fluad influenza vaccine
10149909|NCT04101812|Experimental|Experimental group|Experimental group Pegylated liposomal doxorubicin 40mg/m2 iv every 3 weeks, for 3 cycles; PD-1 every 3 weeks, for 3 cycles.
10149910|NCT04101812|Active Comparator|Control group|PD-1 every 3 weeks, for 6 cycles.
10149911|NCT04101539|Active Comparator|Standard Ablation (PVI)|Patients in this arm will receive standard ablation for atrial fibrillation (wide-area circumferential ablation to achieve pulmonary vein isolation [PVI]).
10149912|NCT04101539|Experimental|OPTIMA Ablation|Patients in this arm will receive standard PVI ablation and supplemental ablation of reentrant driver sites identified by OPTIMA analysis as sites likely supportive of persistent atrial fibrillation.
9669576|NCT03913845|Active Comparator|Normal saline with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
10149913|NCT04101604||Patients with VKH, BD, DR, AMD, or PCV|Collection of blood samples and clinical information from patients with VKH, BD, DR, AMD, or PCV
10149914|NCT04101604||Healthy subjects|Collection of blood samples and clinical information
10149915|NCT04101500|Placebo Comparator|AECOPD(P+C1)|Placebo Tablets(P) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
10149916|NCT04101500|Experimental|AECOPD(C1+C2)|Compound Sodium Chlolate and Aminophylline Tablets(C2) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
10149917|NCT04101552|Experimental|grafted versus graft less socket shield technique|
10149918|NCT04101799|Experimental|Intervention|Participating in the For our children's sake intervention, 10 group sessions, 2 hours each
10149919|NCT04101799|Active Comparator|Control|Participating in everyday activities that may include parenting activities in the control prisons
10149920|NCT04101734||Double Lumen Endotracheal Tube|Group of patients intubated with Double Lumen Endotracheal Tube.
10149921|NCT04101734||Double Lumen Video Endotracheal Tube|Group of patients intubated with Double Lumen Video Endotracheal Tube.
10149922|NCT04101474|Active Comparator|Ketamine group|half of participants will take ketamine
10149923|NCT04101474|No Intervention|Placebo group|the other half of participants will not take any drugs
10149924|NCT04101773|Other|Rubber Band Ligation (RBL)|RBL is generallya simple, inexpensive procedure. It entails a ligation of haemorrhoids using rubber bands. In RBL, a disposable suction device applies a rubber band at least 2 cm proximal to the dentate line at the base of each haemorrhoidal cushion by using an anoscope. The banding process causes necrosis of the banded tissue and slough. The resultant inflammatory reaction causes refixation of the mucosa to the underlying tissue, helping to eliminate haemorrhoidal prolapse.The end result is a return of the haemorrhoidal cushions to a more normal size and configuration, with resolution of haemorrhoidal symptoms.
10149925|NCT04101773|Other|Sutured mucopexy|A sutured mucopexy is an operation performed under general anaesthesia. At 4 cm proximal of the dentate line, a Z- shaped stitch through the rectal wall is placed and then at the upper level of the haemorrhoidal tissue, pulling up the prolapsing haemorrhoid high into the anal canal.
10149926|NCT04101773|Other|Haemorrhoidectomy|Haemorrhoidectomy involves excision of the haemorrhoidal tissue. An elliptical incision is made in the external haemorrhoidal tissue extending proximally through the dentate line to the upper limit of the haemorrhoids. The base of the haemorrhoidal complex is ligated and the haemorrhoid is excised.
10149927|NCT04101695|Active Comparator|sham tDCS- washout period- anodal tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds. At least 7 days of washout period is in between two tDCS. For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA."
10149928|NCT04101695|Active Comparator|anodal tDCS- washout period- sham tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.~For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA. At least 7 days of washout period is in between two tDCS. For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds."
10149929|NCT04101682|Active Comparator|Single Shot|Patients will receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine
10149930|NCT04101682|Active Comparator|Continuous Block|Patients will have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will have a set flow rate over the next couple days
10149931|NCT04101669|Experimental|EndoBarrier|Patients in ARM 1, will receive an upper endoscopy and will be treated with the EndoBarrier Liner
10149932|NCT04101669|Sham Comparator|Sham|Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the EndoBarrier Liner.
10149933|NCT04101578||Ocular MG|Patients with autoimmune MG whose symptoms restricted to extraocular muscles
10149934|NCT04101578||Generalized MG|Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
10149935|NCT04101656||Experimental: APBI (Accelerated Partial Breast Irradiation)|APBI 28 Gy in 5 fractions of 5.6 Gy, using external radiotherapy with modulated intensity technique (IMRT)
10149936|NCT04101708|Experimental|high dose dual group|Patients in high dose dual group will receive lansoprazole (Takepron) 30mg po qid, amoxicillin 750mg po qid for 14d
10149937|NCT04101708|Active Comparator|half-dose clarithromycin-containing bismuth quadruple group|Patients in half-dose clarithromycin-containing bismuth quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 250mg po bid for 14d
10149938|NCT04101760|Experimental|Study group|Patients in study group accept prophylactic treatment of long-acting granulocyte colony stimulating factor
10149939|NCT04101760|Active Comparator|Control group|Patients in control group accept regular or prophylactic treatment of short-acting granulocyte colony stimulating factor according to current guidelines
10149940|NCT04101435|Experimental|Group A|Aged 3 to 8 years old vaccine naïve subject (without prior seasonal influenza vaccine exposure)
10149941|NCT04101435|Active Comparator|Group B|Aged 3 to 8 years old vaccine non-naïve subject (with prior seasonal influenza vaccine exposure)
10149942|NCT04101435|Experimental|Group C|Aged 9 to 17 years old subject
10149943|NCT04101448||Group A|COPD patients with bronchiectasis
10149944|NCT04101448||Group B|COPD patients without bronchiectasis
10149945|NCT04101370|Experimental|Bosentan|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
10149946|NCT04101370|Active Comparator|Tracleer®|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
10149947|NCT04101409|Experimental|DAs group|Shared decision making using decision aids
10149948|NCT04101409|No Intervention|Control group|Standard oral explanation guided with booklets
9971794|NCT01314326||Perimetric Glaucoma (PG)|Patients with clinically confirmed abnormal VF and glaucomatous ONH or NFL defect
10149949|NCT04101084|Experimental|Rocking chair therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
9826215|NCT02412371|Active Comparator|Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
10149950|NCT04101097||training group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
10149951|NCT04101097||validation group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
10149952|NCT04101032|Experimental|eBEfree|eBEfree is a ICT-delivery version of BEfree - eBEfree that comprises 12 online sessions, based on mindfulness,values and compassion components for women with Binge Eating.
10149953|NCT04101032|No Intervention|Waiting List|Participants will remain in a waiting list. After 12 weeks, they will be offered the same intervention.
10149954|NCT04101227|Experimental|Treatment Arm|AD04 (ondansetron)
10149955|NCT04101227|Placebo Comparator|Placebo Arm|Matching Placebo
10149956|NCT04101214|Experimental|Dry needling|One session of dry needling technique will be applied by a physiotherapist specialized in the technique. Dry needling technique will be performed in the muscle of the lower limb whose MMAS score is >1 by locating a sensitive point within a taut band. After that, a thin needle (0,32x40mm) is introduced directly into those muscle that present spasticity, decide by the clinician expert.
10149957|NCT04101214|Sham Comparator|Sham Dry needling|A physiotherapist specialized in dry needling technique will use a sham needle in order to simulate the active intervention. Sham acupuncture uses non-penetrating needles.The palpation and evaluation of the spastic muscle will be exactly the same that in the active group.
10149958|NCT04101201|Other|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
10149959|NCT04101201|Placebo Comparator|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
10149960|NCT04101136|Active Comparator|Atorvastatin 20 mg|Study pharmacist will make code (A and B) for atorvastatin and placebo, then save the code in safe place. Pharmacist will record each subject as participant received A or B intervention.
10149961|NCT04101136|Placebo Comparator|Placebo 20 mg|The placebo tablets will be prepared by Cipto Mangunkusumo hospital pharmacist, were composed of starch and were similar to atorvastatin tablets in size, shape, and colour.
10149962|NCT04101123||Children and adolescents with cancer|Children and adolescents between 10-18 years with newly diagnosed leukemia, brain tumors, and sarcomas
10149963|NCT04101305||Localised prostate cancer|Patients diagnosed with prostate cancer of moderate estimated risk suitable for and scheduled for prostatectomy with gland evacuation
10149964|NCT04101305||Stage 3 prostate cancer|Patients with diagnosed stage 3 prostate cancer
10149965|NCT04101305||Stage 4 prostate cancer|Patients with diagnosed stage 4 prostate cancer
10149966|NCT04101305||Healthy controls|Age-matched healthy individuals free from diagnosed cancer, but with benign inflammatory prostatitis or other benign urological condition
10149967|NCT04100993||Patient group|60 participants ≥16 years of age with a confirmed diagnosis of a childhood-onset NMD
10149968|NCT04100993||Exploratory reference group|20 healthy adults ≥16 years of age
10149969|NCT04101279|Experimental|Midurethral synthetic tape with tension control mechanism|
10149970|NCT04101279|Active Comparator|midurethral tension free tape|
10149971|NCT04101318|Experimental|New Stoma Baseplate with Protective Layer|New Stoma baseplate with Protective layer
10149972|NCT04101318|Active Comparator|Standard of Care|1-piece and 2-piece stoma devices already on the market.
10149973|NCT04101266|Active Comparator|Interscalene nerve block|preoperative interscalene nerve block to be applied with ultrasound guidance.
10149974|NCT04101266|Active Comparator|suprascapular and infraclavicular nerve block|preoperative suprascapular and infraclavicular nerve block to be with ultrasound guidance
10149975|NCT04101344|Experimental|Fiber-blend|All participants will receive a two fiber-blend snack and then a four fiber-blend snack. Stool, blood, and urine will be monitored for changes throughout the study.
10149976|NCT04101162|Other|liver biopsy|
10149977|NCT04101162|Other|ATI|
10149978|NCT04101175||Request for abortion|Patient in first trimester of pregnancy in request for abortion
10185471|NCT03745378||Controls|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.
10149979|NCT04100720|Experimental|Cardiovalve Transfemoral Tricuspid Valve|Replacement (Implant) delivered through a transfemoral access
10149980|NCT04100850|Experimental|Aquatic Exercises|Aquatic Exercises (AE) are water aerobics exercises and resistance exercises, classes will be supervised by a Physical Educator, in collective sessions of up to 30 people per class, twice a week, lasting 50 minutes, for two months.
10149981|NCT04100850|Active Comparator|Watsu|The Watsu (water shiatsu) will be applied by a physical therapist, in individual sessions, twice a week, lasting 50 minutes, for two months in a warn pool (± 34°C). Watsu in particular prescribes transition of movements, once they are instituted, the therapist can create and adapt according to the limitations and restrictions that are encountered.
10149982|NCT04100850|No Intervention|Control|The control group will not receive any of these treatments (aquatic exercises and Watsu).
9971795|NCT01314326||Glaucoma Suspects and Pre-Perimetric Glaucoma (GSPPG) Group|Patients who are at high risk to develop perimetric glaucoma
10149983|NCT04101019|Placebo Comparator|Control|The patient will undergo the SPGB block with saline.
10149984|NCT04101019|Active Comparator|Active drug|The patient will undergo the SPGB block with the active drug which will include 10% lidocaine diluted to 5%.
10149985|NCT04100980||Chronic UTI|Patients who have been diagnosed with chronic urinary tract infections (UTI).
10149986|NCT04100876||primary ITP patients .|60 primary ITP patients .
10149987|NCT04100876||healthy subjects .|30 healthy age and sex matched control subjects .
9971796|NCT01314326||Normal Group|Volunteers with healthy eyes
9971797|NCT01314339|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
10149988|NCT04100759|Experimental|Non-Smokers|Subjects administer one tablet of sildenafil 50 mg
10149989|NCT04100759|Experimental|Cigarette Smokers|Subjects administer one tablet of sildenafil 50mg
10149990|NCT04100759|Experimental|Cannabis Smokers|Subjects administer one tablet of sildenafil 50mg
10149991|NCT04100863||Individuals with Autism|Individuals who have been diagnosed with autism
10149992|NCT04100707|Experimental|Operated|Genicular block will aply to the patients with knee pain who was operated before
10149993|NCT04100707|Sham Comparator|Nonoperated|Genicular block will aply to the patients with knee pain who wasn't operated before
10149994|NCT04100772|Experimental|vaccine 1A|Subjects received one dose of PCV13i at 18 to 49 years old
10149995|NCT04100772|Experimental|vaccine 2A|Subjects received one dose of PCV13i at 50 years old and above
10149996|NCT04100772|Experimental|vaccine 3A|Subjects received one dose of PCV13i at 6 to 17 years old
10149997|NCT04100772|Experimental|vaccine 4A|Subjects received one dose of PCV13i at 2 to 5 years old
10149998|NCT04100772|Experimental|vaccine 5A|Subjects received two doses of PCV13i at 7 months to 2 years old
10149999|NCT04100772|Experimental|vaccine 6A|Subjects received three doses of PCV13i at 3,4,5 months of age
10150000|NCT04100772|Experimental|vaccine 7A|Subjects received three doses of PCV13i at 2,4,6 months of age
10150001|NCT04100772|Active Comparator|vaccine 7B|Subjects received three doses of PCV13 at 2,4,6 months of age
10150002|NCT04100668|Experimental|Data collection|Comparing radial arterial line, Sensifree's Alpha sensor and PPG sensor pressure waveforms
10150003|NCT04100785|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|The iCBT programme comprised of 6 online modules, delivered over 4 weeks, with 3 face-to-face sessions provided by a clinician.The face-to-face sessions were conducted at week 1, 3 and 4. The objectives of the face-to-face sessions was for participants to discuss with the clinician about the application of the content of the modules and the active therapeutic interventions were all found in the online modules.
10150004|NCT04100785|No Intervention|Delayed Wait-list control|The delayed wait-list control did not receive any therapy interventions for 4 weeks from the pre-treatment assessment and from the fifth week onwards, they received the same intervention as the iCBT experimental group.
10150005|NCT04100655|Experimental|GM-CSF|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.~3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice."
10150006|NCT04100655|Experimental|Control|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.~After hysteroscopy examination, nothing was applied to the uterine cavity."
9971798|NCT01314339|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
9971799|NCT01314352|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
9971800|NCT01314352|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
9971801|NCT01314378|Active Comparator|Cognitive-Behavioral Therapy|
9971802|NCT01314378|Experimental|Mindfulness Training|
9971803|NCT01314404||KAP/WTP study population|"The participants will range in age from 12 to 50 and will be selected randomly. The study population will be representative of the following categories: men, women, adolescent boys, and adolescent girls.~As our study seeks to take a broad-based view of knowledge related to cervical cancer and HPV, our study population is necessarily wide-ranging. Adolescent boys and girls will be between the ages of 12 and 18; men and women will be older than 18, with at least one child that falls within the adolescent age range."
10150007|NCT04100915||Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Patients diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
10150008|NCT04101383|Experimental|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
10150009|NCT04101383|Active Comparator|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
10150010|NCT04100889||Alzheimer's disease patients|Patients who have been diagnosed with Alzheimer's disease
10150011|NCT04100824|Experimental|Bupivacaine 0.5%|patient will take stellate ganglion block 10 ml bupivacaine 0.5% and nimodipine
10150012|NCT04100824|Active Comparator|Nimodipine|patient will take nimodipine 60 mg every 4 h.
10150013|NCT04100681|Active Comparator|Active FlowOx™|The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
10150014|NCT04100681|Sham Comparator|Sham FlowOx™ (Placebo)|The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
10150015|NCT04100941|Experimental|standard suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the standard suction technique with 10ml negative pressure
10150016|NCT04100941|Experimental|slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
10150017|NCT04100941|Experimental|wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
10150018|NCT04100642|Active Comparator|1% Hemay808 apply to 25%BSA|8 subjects use 1% Hemay808
10150019|NCT04100642|Experimental|3% Hemay808 apply to 25%BSA|8 subjects use 3% Hemay808
10150020|NCT04100642|Experimental|3% Hemay808 apply to 55%BSA|6 subjects use 3% Hemay808
10150021|NCT04100642|Experimental|7% Hemay808 apply to 25%BSA|8 subjects use 7% Hemay808
10150022|NCT04100642|Placebo Comparator|placebo apply to 25%BSA|6 subjects use placebo apply to 25%BSA
10150023|NCT04100642|Placebo Comparator|placebo apply to 55%BSA|2 subjects use placebo apply to 55%BSA
10150024|NCT04100603||Patients with CDI|Patients who are infected with C. diff
10150025|NCT04100304|Other|patient under going liver resection|
10150026|NCT04100330|Experimental|Ficlatuzumab with HiDAC|Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.
10150027|NCT04100330|Active Comparator|HiDAC alone|Cytarabine 2 g/m2 IV per day on Days 1 through 6
10150028|NCT04100356|Experimental|Normal diet|The group ingests normal diet, recommended by the health authorities
10150029|NCT04100356|Experimental|LCHF diet|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat
9977783|NCT01365169|Experimental|PCS (pancreatic surgery patients)|Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.
10150030|NCT04100356|Experimental|Normal diet + exercise|The group ingests normal diet, recommended by the health authorities in addition to exercise program 3x week.
10150031|NCT04100356|Experimental|LCHF diet + exercise|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat, in addition to exercise program 3x week.
10150032|NCT04100629|Placebo Comparator|Control Group|The control group will receive medical facts and are not meant to support newly licensed nurses and are not known to affect stress, resilience, perceived social support, or Intention To Leave one's job.
9826216|NCT02412436|Experimental|Arm A: Depot medroxyprogesterone acetate|At study entry/week 0, participants received depot medroxyprogesterone acetate (DMPA) 150 mg administered intramuscularly as a single dose and co-administered with rifampicin (RIF) and efavirenz (EFV).
9826217|NCT02412488|Experimental|Out of CathLab setting|Out of cathlab insertion
10150033|NCT04100629|Experimental|Experimental Group|Texts sent to the experimental group will be based on nurturant support messages and are intended to decrease stress, Intention To Leave, increase resilience, and perceived sense of support.
10150034|NCT04100252||Group 1 (Women with AFI<5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI<5 were enrolled in the Group 1.
10150035|NCT04100252||Group 2 (Women with AFI≥5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI≥5 were enrolled in the Group 2.
10150036|NCT04100512|Active Comparator|Incentive spirometry|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
10150037|NCT04100512|Experimental|Oscillating Positive Expiratory Pressure Device|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
10150038|NCT04100473|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.
10150039|NCT04100473|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection.
10150040|NCT04100226|Experimental|Interstitial lung patients with low vitamin D|Arm 1:(interventional group): interstitial lung diseases patients with low vitamine D will receive Vitamin D supplementation in form of Vitamin D3 (1.25(OH)2 cholecalciferol) in dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for deficient vitamin D level patients and every month for 3 months for insufficient vitamin D level patients beside ca supplementation in form ca carbonate 600 mg oral capsule once daily for 3 months for all patients in addition to current treatment.
9826218|NCT02412501|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent
9826219|NCT02412631|Placebo Comparator|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
9826220|NCT02412631|Experimental|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
9826221|NCT02412644|Active Comparator|Apremilast + apremilast|apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
10150041|NCT04100226|No Intervention|interstitial lung diseases patients with low vitamin D|Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive their current treatment only without vitamin D supplementation.
10150042|NCT04100265|Experimental|Panel 1 - High risk for postoperative ileus|Intervention in patients at high risk to develop prolonged postoperative ileus. Monitoring postoperative gastric motility for 2 consecutive days in patients who require preventive placement of a nasogastric feeding tube due to a high risk to develop postoperative ileus. Allowing to explore associations between gastric motility and general clinical evolution.
10150043|NCT04100265|Experimental|Panel 2 - Postoperative ileus arm with investigational device|Intervention in a population of patients with clinical signs of postoperative ileus, requiring a nasogastric feeding tube for symptom relief. The investigational medical device will be applied. Allowing to explore the association of gastric motility and clinical signs of postoperative ileus in an enriched population with true postoperative ileus.
10150044|NCT04100265|No Intervention|Panel 3 - Postoperative ileus arm with standard of care|Standard of care control group of patients with clinical signs of postoperative ileus requiring a standard nasogastric feeding tube for symptom relief. Symptoms will be surveyed as control group to assess safety and tolerability of the investigational medical device.
10150045|NCT04100447|Experimental|Treatment Arm|All subjects will receive 1 dose of study drug (split into 2 administrations), over the 12 hours prior to surgery.
10150046|NCT04100460|Experimental|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
10150047|NCT04100460|Experimental|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
10150048|NCT04100460|Placebo Comparator|Control - No Arabinoxylan (Maltodextrin)|Participants are given no Arabinoxylan
10150049|NCT04100616||Obsese individuals|Patients with a BMI greater than or equal to 30
10150050|NCT04100213|Experimental|TSST|
10150051|NCT04100434|Experimental|the evolocumab plus statin therapy|Patients with ACS are treated with atorvastatin (20mg) daily and evolocumab (140 mg) every two weeks throughout the study period
10150052|NCT04100434|No Intervention|the statin alone therapy|Patients with ACS are treated with atorvastatin (20mg) daily throughout the study period.
10150053|NCT04100486||Healthy, Able-Bodied Individuals|This study will only enroll healthy, able-bodied individuals.
10150054|NCT04100278|No Intervention|Traditional therapy group|All patients in this group will be given routine diabetes management, including lifestyle education, health guidance, monitoring blood sugar guidance and drug adjustment.
10150055|NCT04100278|Active Comparator|Shared Care group|The patients download the Shared Care mobile application and connect with the smart-glucometer Bg1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
10150056|NCT04100538|Experimental|Intervention group|The intervention group will receive the technology-assisted program by health coach twice a week during the 10-week treatment period. The health coach will be an experienced master-prepared nurse who has extensive and in-depth knowledge about fibromyalgia and has previously worked in direct contact with patients with fibromyalgia in a research project.
10150057|NCT04100538|No Intervention|control group|The control group will receive technology-assisted informational support twice a week during the 10-week treatment period. Each technology-assisted informational support will last for approximately 10-30 min consisting of 15-min questions-and-answers regarding the educational materials and 15-min debriefing.
10150058|NCT04100564|Active Comparator|Standard airway method arm|Standard airway management strategy
10150059|NCT04100564|Experimental|Supraglottic airway method arm|Supraglottic first airway management strategy
10150060|NCT04100382|Experimental|Laser and SLA implants|Surgical placement of short implants in maxillary posterior teeth with Laser surface treated and SLA surface treated dental implants
10150061|NCT04100525|Active Comparator|Standard Care|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant received a copy of this report in the mail and a call from the psychologist to go over test findings and recommendations.
10150062|NCT04100525|Experimental|Experimental Treatment|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant then receives in-person feedback (and a copy of the report at this visit) and two calls from a care-coordinator research nurse at approximately 1 and 6 months post feedback, who asks participant whether they completed recommendations and assist participant in completing recommendations where possible (i.e., help find a provider, explanation of importance of completing recommendations, etc).
10150063|NCT04100291|Active Comparator|FMT|Faecal microbiota transplantation
10150064|NCT04100291|Placebo Comparator|Placebo|Placebo mixture
10150065|NCT04100239|Experimental|Intervention Arm|Open continuous recruitment of participants to trial where all participants begin the study as 'control participants' and at regular 'steps' participants are allocated to next available intervention group and cross from the control to the intervention condition, until all groups have completed the intervention.
9826222|NCT02412644|Placebo Comparator|apremilast + placebo|apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks
10150066|NCT04100590|Experimental|Active Cannabis|In this session, the participant will smoke two-thirds of one active cannabis cigarette (7% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
9826223|NCT02412657|Experimental|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
9669577|NCT03903939|Experimental|Iloprost|Patients randomized to active treatment (n = 110 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first
9826224|NCT02412657|Experimental|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
10150067|NCT04100590|Placebo Comparator|Placebo Cannabis|In this session, the participant will smoke two-thirds of one inactive placebo cannabis cigarette (0% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
9977784|NCT01365169|Experimental|TAPS (Technological Approach to Performance Status)|Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.
10150068|NCT04100187|Experimental|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
10150069|NCT04099784||Freeze-only|Children born from freeze-only group and frozen embryo transfer
10150070|NCT04099784||Fresh|Children born from fresh embryo transfer
10150071|NCT04099966|Experimental|alpha beta cell depletion|Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.
10150072|NCT04099979||Psoriasis patients|Patients who have been diagnosed with Psoriasis
10150073|NCT04100161|Experimental|Protein supplementation|20g protein supplementation twice daily for 3 months
10150074|NCT04100161|Active Comparator|Carbohydrate supplementation|20g maltodextrin supplementation twice daily for 3 months
10150075|NCT04099953|Experimental|dialysis patients|Dialysis patients were evaluated by objective diagnostic tests.
10150076|NCT04099953|Experimental|Control group|Healthy individuals
10150077|NCT04099940|Experimental|Virtual Reality Avatar Therapy (VRAT)|In the VRAT, patients with schizophrenia and acoustic hallucinations design a visual and auditory recreation (avatar) of the entity to which they attribute their hallucinations. Working with a therapist over the course of several sessions, participants change the avatar from controlling to benevolent.
10150078|NCT04099940|Active Comparator|Assertiveness Training Program (ATP)|The ATP is a transdiagnostic cognitive behavioural treatment programme, which aims to increase self-confidence and social competence in patients with a psychiatric disorder.
10150079|NCT04100005||Crohn's disease|Patients who have been diagnosed with Crohn's disease
9669578|NCT03903939|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n= 110 patients) will receive continuous infusion of isotonic saline (equal volume) for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
9826225|NCT02412657|Placebo Comparator|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
10150080|NCT04099992|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
10150081|NCT04099992|Active Comparator|Health enhancement program (HEP)|Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions with a day-long retreat.
10150082|NCT04099992|Experimental|MBSR+tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD) ."
10150083|NCT04099992|Active Comparator|MBSR+sham-tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Sham stimulation will be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
10150084|NCT04099992|Experimental|HEP+tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator (a registered dietician) in a group setting for 8 weekly 2.5-hour sessions.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD)."
10150085|NCT04099992|Active Comparator|HEP+sham-tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions.~Sham stimulation is be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency (0.1 Hz) biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
10150086|NCT04099862||ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
10150087|NCT04099862||EUS-BD|Endoscopic UltraSound Biliary Drainage
9977785|NCT01365182|Other|BF+SUPPORT|
9977786|NCT01365182|Other|BF+PHONE|
9977787|NCT01365182|No Intervention|Usual Care|
9977788|NCT01365208||advanced nasopharyngeal carcinoma|
10150088|NCT04100083|Active Comparator|Group 1|Patients taking 50mg Spironolactone
10150089|NCT04100083|Active Comparator|Group 2|Patients taking 100mg Spironolactone
10150090|NCT04100083|Active Comparator|Group 3|Patients taking 200mg Spironolactone
10150091|NCT04100057|Experimental|Cognitive Behavioral Therapy for Insomina (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
10150092|NCT04100057|Active Comparator|Desensitization Therapy for Insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
10150093|NCT04100122||Cutaneous only|Cutaneous and mucosal involvement only; generalized hives, pruritus or flushing, swollen lips-tongue-uvula (n=15)
10150094|NCT04100122||Wheat anaphylaxis sIgElo|Anaphylaxis (using the clinical diagnostic criteria according to World Allergy Organization; WAO 2011) with specific Immunoglobulin E (sIgE) to wheat <100 kUA/L (n=15)
10150095|NCT04100122||Wheat anaphylaxis sIgEhi|Anaphylaxis (using the clinical diagnostic criteria according to World Allergy Organization; WAO 2011) with specific Immunoglobulin E (sIgE) to wheat ≥100 kUA/L (n=15)
10150096|NCT04100122||Wheat tolerant|Patients with confirmed IgE-mediated wheat allergy for more than 12 months, and a negative oral food challenge (OFC) result to wheat during the past 12 months will be include as a control group (n=15)
10150097|NCT04100031|Experimental|BCL group|
10150098|NCT04100031|Active Comparator|control group|
10150099|NCT04099758|Experimental|Mindfulness of the breath meditation|10 minute mindfulness of the breath meditation practice delivered online via audio-recording.
10150100|NCT04099758|Placebo Comparator|Audio-recording control|10 minute non-fiction audio-recording delivered online
10150101|NCT04099771|Experimental|Ketamine|A total of 20 patients identified as having suicidal ideation will receive ketamine at 0.5mg/kg infused intravenously over 40 minutes.
10150102|NCT04099550|Active Comparator|SMBG with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The control group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
10150103|NCT04099550|Experimental|RT-CGM with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.
10150104|NCT04099563|Experimental|PF-04965842|Following an overnight fast for at least 10 hours, participants will receive PF-04965842 oral single dose of 200 mg (2 × 100 mg tablets) on Day 1, at approximately 08:00 am plus or minus 2 hours in the morning. On Days 3 to 8, participants will receive PF-04965842 oral dose of 200 mg (2 × 100 mg tablets) QD in the morning at approximately similar clock hour as on Day 1. On Day 3 and Day 6-8, the dosing of PF-04965842 will be after collection of pre-dose blood samples (under fasted condition for at least 10 hours). On Day 8, the dosing will be under fasted condition at approximately 8:00 am plus or minus 2 hours in the morning.
10150105|NCT04099706|Experimental|Intervention - Fat grafting|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the intervention group, the fat will be purified using decanting and injected into the painful areas of skin.
10150106|NCT04099706|Sham Comparator|Control - Saline|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the control group, the fat will be discarded and saline will be injected into the painful areas of skin.
10150107|NCT04099576|Experimental|Physiotherapy plus Education|The experimental group received a three-week program consisting of 15 sessions of physiotherapy and six sessions of therapeutic neuroscience education.
9977789|NCT01365221|Experimental|Patients who have received loading dose of clopidogrel|
10150108|NCT04099576|Active Comparator|Control group|The control group received a three-week program consisting of 15 sessions of physiotherapy alone. .
10150109|NCT04099615||Endovascular urgent stroke treatment group|Patients between 18 and 85 years old who have and acute cerebral stroke due to a demonstrated occlusion in the anterior circulation (M1 or M2 segment of middle cerebral artery with or without ipsilateral internal carotid artery (ICA), that undergo endovascular acute therapy fulfilling all inclusion criteria and with non exclusion criteria for that treatment. We also exclude patient with well-documented history of neuromuscular disorders, stroke or central nervous system tumors that could interfere in the SEPs assessment.
10150110|NCT04099472|Placebo Comparator|Control Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. The intervention group will also receive the same pamphlet.
10150111|NCT04099472|Experimental|Intervention Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. Additionally, they will receive delirium education on prevention and management of delirium.
9977790|NCT01365221|Active Comparator|Patients who have not received loading dose of clopidogrel|
9977791|NCT01365234|Experimental|20066 Lead|Non-randomized study. Intervention: Device: Pacing Lead
9971804|NCT01314404||Prevalence study population|"We plan to identify and recruit women diagnosed with cervical cancer who are being treated by a doctor from the department of gynecology of the Hospital Gabriel Touré in Bamako, Mali. These patients will have been previously identified and diagnosed by clinical exam by an obstetrician-gynecologist at Gabriel Touré, and will have been identified as surgical candidates by a doctor.~The subject has expressed a willingness to have a biopsy or other gynecological operation and have a doctor collect tissue samples during a standard medical appointment, has agreed to have blood drawn, was older than 18, and has the capacity to give informed consent."
9971805|NCT01314456|Experimental|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
9971806|NCT01314469||Patients with intermediate uveitis|
9971807|NCT01314482|Experimental|Minocycline|
9971808|NCT01314495|Active Comparator|Abatacept|Abatacept administered as a 30 minute intravenous infusion
9971809|NCT01314495|Placebo Comparator|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
9971810|NCT01314508|Other|All patients will be treated with IGF-1 factors|Patients will serve as their own control.
9971811|NCT01314560|Experimental|1|experimental
9971812|NCT01314573|Experimental|Interval maximal exercise|Interval exercise involving repeated Wingate tests (30s durations of maximal exercise on a cycle ergometer).
9971813|NCT01314573|Experimental|Continuous maximal exercise|Continuous exercise of maximal exertion that has been work matched to an initial bout of interval exercise of 4 x 30s of maximal exercise. This exercise is performed on a cycle ergometer.
9971814|NCT01314586|Placebo Comparator|placebo|placebo pill, diet counseling to comply with NCEP Step I diet
9971815|NCT01314586|Experimental|150 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks
9971816|NCT01314586|Experimental|300 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks
9971817|NCT01314599|Experimental|Arm 1|PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
9971818|NCT01314612|Experimental|Group Intervention|Subjects randomly assigned to this arm of the study will receive the 9-week insomnia and nightmare intervention group once per week for 90 minutes in addition to continuing treatment as usual with medical and mental health providers.
9971819|NCT01314612|No Intervention|Treatment as Usual|This group is randomly assigned to receive only treatment as usual and does not receive the active intervention of the insomnia and nightmare group treatment. This treatment will be made available to these members once the study is completed
9971820|NCT01314625||one arm|
9971821|NCT01314638||Single group|Single group, Identical investigations for all subjects
9971822|NCT01314651|Experimental|Sleep Management|Instructions in stimulus control and sleep restriction.
9971823|NCT01314651|Sham Comparator|Lifestyle Modification|Instructions to change general lifestyle habits (maintain consistent liquid consumption, range of motion exercises, etc.)
9971824|NCT01314677|Experimental|Group A (FDG PET/CT between RT fractions 5-6)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
9971825|NCT01314677|Experimental|Group B (FDG PET/CT between RT fractions 10-11)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
9971826|NCT01314677|Experimental|Group C (FDG PET/CT between RT fractions 15-16)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
9971827|NCT01314729|Active Comparator|Fiber-reinforced-composite retainer|
9971828|NCT01314729|Active Comparator|composite-wire retainer|
9971829|NCT01314755|Experimental|immune-enhancing feed IMPACT|immune-enhancing feed IMPACT
9971830|NCT01314755|Active Comparator|control arm|iso-nitrogenous, iso-caloric control feed
9971831|NCT01314768|Active Comparator|Brief intervention|Behavioural brief intervention delivered by GP
9971832|NCT01314768|Placebo Comparator|Business as usual|Business as usual according to individual GP
9971833|NCT01314768|Other|Chronic headache control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
9971834|NCT01314768|Other|Population control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
9971835|NCT01314781|Experimental|solifenacin 5mg, PFMT and WBVT|Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
9971836|NCT01314781|Active Comparator|solifenacin 5mg|Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
9971837|NCT01314807||patients with COPD|patients who were defined as COPD, based on post-bronchodilator spirometry (GOLD criteria). Patients will have at least 10 pack years
9971838|NCT01314807||smoking controls|patients with at least 10 pack years who have no COPD (based on post-bronchodilator spirometry)
9971839|NCT01314807||non-smoking controls|patients with < 1 pack year who have no COPD (based on post-bronchodilator spirometry)
9971840|NCT01314820|Active Comparator|normal saline injection|20 cc normal saline injection into the knee joint
9971841|NCT01314820|Sham Comparator|sham injection|knee injection without saline
9971842|NCT01314833|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
9977792|NCT01365247|Experimental|COPE|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
9971843|NCT01314833|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
9971844|NCT01314833|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)
9971845|NCT01314846||Control Group|sequential culture system
9971846|NCT01314846||Co-culture system|
9971847|NCT01314859|Experimental|Nifedipine|"Oral Treatment with Nifedipine capsules (10 mg)~Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~Maximum Duration of the treatment: 48 hours."
9971848|NCT01314859|Active Comparator|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)~Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~Maximum Duration of the treatment: 48 hours."
9971849|NCT01314885|Experimental|PF-03715455|
9971850|NCT01314885|Experimental|PH-797804|
9971851|NCT01314885|Placebo Comparator|Placebo for PF-03715455|
9971852|NCT01314885|Placebo Comparator|Placebo for PH-797804|
9971853|NCT01314898|Experimental|Treatment|
9971854|NCT01314924|Experimental|Responders|Patients who present an increase in flow-mediated dilation of brachial artery.
9971855|NCT01314924|Experimental|Non responders|Patients who do not present an increase in flow-mediated dilation of brachial artery.
9971856|NCT01314937|Experimental|Deworming at 12 months of age|
9971857|NCT01314937|Experimental|Deworming at 18 months of age|
9971858|NCT01314937|Experimental|Deworming at 12 and 18 months of age|
9971859|NCT01314937|Placebo Comparator|Usual care|
9971860|NCT01314950|Active Comparator|Best practices primary care|Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
9971861|NCT01314950|Experimental|Home based occupational therapy|The intervention group receives all of the components of best practice primary care in addition to a home-based intervention designed to slow functional decline.
9971862|NCT01314976|Experimental|Metronidazole|Active treatment.
9971863|NCT01314976|Placebo Comparator|Placebo|Passive treatment.
9971864|NCT01314989|Active Comparator|Cyproheptadine|Cross-over study
9971865|NCT01314989|Placebo Comparator|Sugar pill|Cross-over study
9971866|NCT01315015|Experimental|Contrast enhanced breast MRI|The additional MRI will take place biennially after the regular screening mammogram for a study period of 6 years.
9971867|NCT01315015|No Intervention|Regular breast cancer screening|No further follow-up until next scheduled screening examination two years later (according to the current Dutch guideline).
9971868|NCT01315041|Active Comparator|"Pi medicine"|
9971869|NCT01315041|Placebo Comparator|Placebo|
9971870|NCT01315054|Other|Control arm|Using currently practiced methadone dosage prescription methods
9971871|NCT01315054|Experimental|MMT provider dosage training|Intensive health care provider training on prescribing methadone dosage based on national guidelines
9971872|NCT01315054|Experimental|MMT provider dosage training/counseling|Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .
9971873|NCT01315080||Saline|Percutaneous drainage and saline solution irrigation
9971874|NCT01315080||Triamcinolone|Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
9971875|NCT01315093|Experimental|Heparin, Low-Molecular-Weight group|LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
9971876|NCT01315093|Active Comparator|Non Heparin, Low-Molecular-Weight group|IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
9971877|NCT01315171|Experimental|Medium chain supplemented diet|Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
9971878|NCT01315171|No Intervention|Standard group|Subjects will continue with a standard western diabetes diet.
9971879|NCT01315184|Experimental|Recovery Line Support System|Patients assigned to the Recovery Line Support System will be trained on the system and provided 24-hr access to the system for a four week period, provided with a Recovery notebook, and given reminder calls to contact the system.
9971880|NCT01315184|No Intervention|Treatment as Usual|Patients assigned to the TAU condition will receive any services provided by their buprenorphine provider and any additional services that their provider refers or recommends that patients attend. No additional services will be provided by the study.
9971881|NCT01315197|Experimental|massage|The massage Anma has Japanese origin and a protocol was used with smoothing, kneading and pressure points on the bladder meridian.
9977161|NCT01358747|Experimental|Experimental arm|"Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 2 cycles followed by a PET scan (PET2).~After PET2 central review:~In case of positive PET2, the induction treatment will be completed by 2 additional cycles of BEACOPPesc~In case of negative PET2, the induction treatment will be completed by 2 cycles of ABVD delivered every 4 weeks. The first cycle of ABVD will start at day 21 of the second cycle of BEACOPPesc.~Consolidation treatment: depends on the reviewed PET4 result In case of PET4 negative result, consolidation treatment will depends on PET2 results:~If PET2 was positive, patient will received 2 additional cycles of BEACOPPesc delivered every 3 weeks~If PET2 was negative, patient will received 2 additional cycles of ABVD delivered every 4 weeks In case of PET4 positive, the patient will be considered as treatment failure."
9977162|NCT01358773|Other|Lifestyle counseling|Obese adolescents are encouraged to improve their lifestyle
9977163|NCT01358786|No Intervention|no quilting sutures but drains|
9977164|NCT01358786|Experimental|quilting sutures and drains|
9977165|NCT01358786|Experimental|quilting sutures but no drains|
9977793|NCT01365247|Active Comparator|RPT|Relapse Prevention Therapy
10150112|NCT04099602|Experimental|Massage group|Twice a day after the birth of the baby was massaged by the researcher for 5 days. Bilirubin levels were measured twice daily by the transcutaneous bilirubin meter before the morning massage and 2 hours after the evening massage for 5 days. In the morning (between 07:00-09:00 am) and in the evening (between 19:00-21:00 pm) twice a day, 15-20 minutes baby massage was applied.
10150113|NCT04099602|No Intervention|Control group|The control group who were administered standard care and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
10150114|NCT04100070|Other|Standard monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls.~Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)"
10150115|NCT04100070|Other|Intensive monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study.~Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits)."
10150116|NCT04099641|Experimental|bavituximab and pembrolizumab|Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks
10150117|NCT04099732|Experimental|Part 1: Reference 1 followed by Test 1|Reference 1 - Rosuvastatin. Test 1 - Rosuvastatin + BI 1358894
10150118|NCT04099732|Experimental|Part 2: Reference 2 followed by Test 2|Reference 2 - Dabigatran etexilate. Test 2 - Dabigatran etexilate + BI 1358894
9826226|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 3 mg|Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
9826227|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 4 mg|Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
9826228|NCT02412722|Experimental|Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2|Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
10150119|NCT04099680|Active Comparator|Partial-thickness bed preparation|Partial-thickness bed preparation for free gingival graft procedure.
10150120|NCT04099680|Experimental|Full-thickness bed preparation|Full-thickness bed preparation with bone screw placement for anchoring the sutures.
10150121|NCT04099654|Experimental|Core-Stabilization Exercise|
10150122|NCT04099654|Experimental|Counseling of physical activity|
10150123|NCT04099810|Other|Patients undergoing Cardiac MRI|Patients scheduled to undergo cardiac magnetic resonance for clinical reason will be asked if they are willing to undergo additional non invasive testing (three-dimensional echocardiography) which will take about 15-20 minutes
10150124|NCT04099745|Experimental|CGM（continuous glucose monitoring）|Each diabetic patient received three CGM tests within 14 days of FGM monitoring, on days 1-3, 6-9 and 12-14, respectively.
10150125|NCT04099745|Experimental|FGM（Flash glucose monitoring）|Each diabetic patient received one FGM test for 14 days.
10150126|NCT04099433|Experimental|Oral Bacteriotherapy Arm|Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria). Probiotic sachets are indistinguishable from placebo
10150127|NCT04099433|Placebo Comparator|Placebo Arm|Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day). Placebo sachets are indistinguishable from probiotic
10150128|NCT04099927|Experimental|SHR0410|Experimental: SHR0410 dose escalation.
10150129|NCT04099420||Italian university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
10150130|NCT04099420||Spanish university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
10150131|NCT04099394|Experimental|Behavioral Health|Ten behavioral health classes.
10150132|NCT04099394|Active Comparator|Health Education|Ten health education classes covering healthy aging.
10150133|NCT04099407|Experimental|Antifibrotic plus standard of care treatment|Prolonged release pirfenidone formulation in combination with standard of care treatment.
10150134|NCT04099381|Experimental|Group 1 Low HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or less HLA compatibility degree in A, B, DRB1 loci will be used.
10150135|NCT04099381|Experimental|Group 2 High HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or more HLA compatibility degree in A, B, DRB1 loci will be used.
10150136|NCT04099381|Other|Group 3 Control|Patients with standard therapy as a control group.
9977794|NCT01365247|Active Comparator|Active Monitoring Control Group|
9977795|NCT01365260|Experimental|MM-II|
10150137|NCT04099017|Experimental|Mulligan mobilization group|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~Mulligan joint mobilization in Non-weight bearing (NWB):~Knee strengthening~Kinesiotaping"
10150138|NCT04099017|Experimental|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Trunk stabilization i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~Iv. lateral step up:~Knee strengthening i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~Kinesiotaping:"
10150139|NCT04099017|Other|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Knee strengthening i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~Kinesio-taping:"
10150140|NCT04099043|Experimental|Continuous Monitoring|Single Arm, Randomized
9971882|NCT01315223|No Intervention|Conventional treatment CHF patients|One hundred and fifty patients with CHF will be treated according to current guidelines (conventional treatment).
9971883|NCT01315223|Experimental|Lung impedence-guided treatment|
9971884|NCT01315262|Active Comparator|Viagra 100 mg daily|
9971885|NCT01315262|Active Comparator|Viagra 100mg on demand|
9971886|NCT01315275|Experimental|Ranibizumab|
9971887|NCT01315288|Other|Video presentation|
9971888|NCT01315301|Active Comparator|Arm-A|Immediate Treatment Group
9971889|NCT01315301|Active Comparator|Arm-B|Deferred Treatment Group-1
9971890|NCT01315301|Active Comparator|Arm-C|Deferred Treatment Group-2
9971891|NCT01315314|No Intervention|conventional PDF (Stay safe)|
9971892|NCT01315314|Active Comparator|low GDP PDF (Balance)|
9971893|NCT01315327|Experimental|Omega-3 Fatty Acids|Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.
9971894|NCT01315327|Placebo Comparator|Placebo|Olive oil placebo, looks and tastes identical to active intervention.
9971895|NCT01315340|Experimental|Glaucoma Patients|
9971896|NCT01315340|Active Comparator|Control subjects|
9971897|NCT01315353|Experimental|Arm A: Immediate cryotherapy (HPV test-and-treat)|Participants in Arm A (HPV test-and-treat) had cervical cryotherapy at entry. Post entry, participants in Arm A were seen at regular intervals for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP.
9971898|NCT01315353|Experimental|Arm B: cytology-based strategy|Participants in Arm B followed a cytology-based management plan involving three steps- cytology, colposcopy with directed biopsies, and LEEP (as needed).
9971899|NCT01315353|Experimental|Arm C : Ineligible for randomization to Arm A or B|Participants were eligible for Arm C under the conditions noted in the inclusion criteria. Participants in Arm C had colposcopy and directed biopsies at entry. If CIN2+ was found by biopsy, then LEEP was performed and a follow-up visit 26 weeks after these procedures was scheduled for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP. After the week 26 visit, Arm C participants went off study.
9971900|NCT01315366|Active Comparator|High dose vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a supplement of vitamin D3 EuroD (20,000 IU/wk) for one year.
9971901|NCT01315366|Placebo Comparator|Low dose Vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a weekly placebo (EURO D Placebo) supplement for one year.
9971902|NCT01315379||PTSD without TBI|"children and adolescents with a diagnosis of PTSD and without head injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
9971903|NCT01315379||PTSD with m-TBI|"children and adolescents with a diagnosis of PTSD and a diagnosis of mild traumatic brain injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
9971904|NCT01315418|Active Comparator|1 = Tested product|
9971905|NCT01315418|Sham Comparator|2 = Control product|
9971906|NCT01315431|Experimental|Tesetaxel-capecitabine|
9971907|NCT01315444|Active Comparator|PPI abrupt cessation|Abrupt cessation
9971908|NCT01315444|Active Comparator|PPI gradual step down cessation|Gradual cessation
9971909|NCT01315457||Alemtuzumab|Patients treated with alemtuzumab
9971910|NCT01315470|Experimental|neupogen|
9971911|NCT01315470|No Intervention|no intervantion|
9971912|NCT01315483|Experimental|Low fat, high carb weight loss diet|Ornish-like weight loss dietary pattern
9971913|NCT01315483|Experimental|Low carb, high fat weight loss diet|South-Beach-like weight loss diet pattern
9971914|NCT01315483|No Intervention|Control|Usual care
9971915|NCT01315496|Experimental|Imunoglobulin G|The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
9971916|NCT01315496|Placebo Comparator|Placebo control|The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
9971917|NCT01315522|Active Comparator|ComVi stent|ComVi stent (Niti-S stent, ComVi type, Taewoong Medical Inc, Korea)
9971918|NCT01315522|Active Comparator|Uncovered SEMS|uncovered nitinol metal stent (HANAROSTENT, M.I. Tech Co., Ltd., Korea)
9971919|NCT01315535||Fast Titration|
9971920|NCT01315535||Regular Titration|
9971921|NCT01315535||Fast Tritation Including Mandibular Exercises|
9971922|NCT01315535||Regular Tritation Including Mandibular Exercises|
9971923|NCT01315548||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histologicalconfirmation
9971924|NCT01315548||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
9971925|NCT01315561|Experimental|acupuncture|MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
9971926|NCT01315561|Active Comparator|injections of diclofenac|the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
9971927|NCT01315587|Active Comparator|intermittent theta burst stimulation|
9971928|NCT01315587|Active Comparator|repetitive Transcranial Magnetic Stimulation|
9971929|NCT01315587|Placebo Comparator|Sham TMS|
9971930|NCT01315613||Acute pancreatitis|Patients admitted in our institution for an episode of acute pancreatitis
9971931|NCT01315626||Immediately preceding intervention|3 months immediately before the education event. Charts of patients with a primary respiratory complaint will be reviewed so evaluate if they 1) have experienced 3 or more suppurative respiratory infections and 2) have required 3 or more courses of antibiotic therapy for respiratory infection over the period of one year. 4) Whether or not they underwent a HRCT, and if so, and 5) Were the patients diagnosed with BE.
9977166|NCT01358812|Experimental|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
10150141|NCT04099238||Subjects with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018
10150142|NCT04099238||NVAF patients with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018 and had a diagnosis of NVAF prior to ischemic stroke (Subgroup)
10150143|NCT04099069|Placebo Comparator|trachial intubation|patient was insert trachial intubation with normal frequency jet ventilation
10150144|NCT04099069|Experimental|rigid bronchoscopy|patient was insert trachial intubation with high frequency jet ventilation
10150145|NCT04099082||Cases|eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months
10150146|NCT04099082||Controls|eligible patients free of 10% FEV1 decline at 2 months
10150147|NCT04099368|Experimental|Auditory|Group receives training on listening to musical pitch differences between sounds as the first component of a crossover trial. The intervention is the listening exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
10150148|NCT04099368|Active Comparator|Visual|Group receives training on visual differences between objects on a computer screen as the first component of a crossover trial. This is a control measure for the auditory training exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
10150149|NCT04099316|Experimental|Older adults|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
10150150|NCT04099316|Experimental|Older adults-Control|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
10150151|NCT04099316|No Intervention|No intervention|Metabolic diseases, Hypertension (150/90mmHg), Myocardial infarction within 6 months. Fractures within 6 months.
10150152|NCT04099303|Experimental|Vaccine 1A|Subjects received one dose of DTaP aged 4 to 6 years.
10150153|NCT04099303|Active Comparator|Vaccine 1B|Subjects received one dose of DT aged 4 to 6 years.
10150154|NCT04099303|Experimental|Vaccine 2A|Subjects received one dose of DTcP aged 18 to 24 months.
10150155|NCT04099303|Active Comparator|Vaccine 2B|Subjects received one dose of DTaP aged 18 to 24 months.
10150156|NCT04099303|Experimental|Vaccine 3A|Subjects received three doses of DTcP at 3,4,5 months of age.
10150157|NCT04099303|Active Comparator|Vaccine 3B|Subjects received three doses of DTaP at 3,4,5 months of age.
10150158|NCT04099303|Active Comparator|Vaccine 3C|Subjects received three doses of DTaP-IPV-Hib at 3,4,5 months of age.
10150159|NCT04099303|Experimental|Vaccine 4A|Subjects received three doses of DTcP at 2,3,4 months of age.
10150160|NCT04099303|Active Comparator|Vaccine 4B|Subjects received three doses of DTaP-IPV-Hib at 2,3,4 months of age.
10150161|NCT04099303|Experimental|Vaccine 4C|Subjects received three doses of DTcP at 2,4,6 months of age.
10150162|NCT04098939||Healthy participants|Participants without any known cardiac or pulmonary disease.
10150163|NCT04098939||Heart disease participants|Participants with heart disease.
10150164|NCT04098939||Lung disease participants|Participants with lung disease.
10150165|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN0|Lymph node negative breast cancer
10150166|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN1|Lymph node positive breast cancer
10150167|NCT04099186|Experimental|hydro-mechanical pulmonary embolism fragmentation|Those patients will undergo catheter directed fragmentation followed by injection of 100 ml of heparinized saline via power injector
9977167|NCT01358838|Active Comparator|laser|
10150168|NCT04099186|No Intervention|thrombolytic treated arm|patients with high risk and intermediate high risk PE who received thrombolysis as only treatment modality
10150169|NCT04099212||Cases|Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
10150170|NCT04099121|Other|Patients with Pelvic Organ Prolapse|Patients who meet the inclusion criteria will be recruited. Ultrasound images of the pelvic floor and vaginal cavity will be analyzed to predict pessary size and type. This will be compared against the pessary size and type being used already by the patient.
10185472|NCT03745365|Experimental|sleeve gastrectomy|"The greater omentum is divided 5 cm from the pylorus with an energy device. The antral pouch is measured 2-6cm from the pylorus along greater curve as risk benefit ratio is best within these limits.~Devascularization is continued up the greater curve of the stomach to the short gastric vessels with the help of the assistant who maintains traction and exposure during this process. Eventually, one reaches the left crus which is an important landmark of dissection. We selectively explore the hiatus of the symptomatic and endoscopically proven hiatus hernia , and the hernia should be reduced and repaired."
10185473|NCT03745365|Experimental|sleeve gastrectomy with loop bipartition|Sleeve gastrectomy is performed first, then a loop gastro-ileostomy 200-250 cm from doudeno-jejunal junction was created at the dependent part of the antrum with 2 layers of with stapler but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastro-ileostomy. The staple line and anastomosis was tested with methylene blue. A drain is inserted.
10185474|NCT03745313|Experimental|Treatment|Treatment with the Edwards PASCAL Transcatheter Valve Repair System
10185475|NCT03745300|Active Comparator|GROUP 1|Scaling and root planing (SRP) followed by 1.2% atorvastatin gel local drug delivery
10185476|NCT03745300|Active Comparator|GROUP 2|Scaling and root planing (SRP) followed by 1.2% simvastatin gel local drug delivery
10185477|NCT03745300|Placebo Comparator|GROUP 3|Scaling and root planing (SRP) followed by placebo gel local drug delivery
10185478|NCT03745274|Experimental|GHB04L1|GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
10185479|NCT03745274|Placebo Comparator|Placebo|Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.
10150171|NCT04099147||ETHON|Subjects from the general population identified in the ETHON
10150172|NCT04099147||HEPAmet|Subjects belonging to the Spanish registry of NAFLD (HEPAmet)
10150173|NCT04098991||Participants with primary hypothyroidism|All participants will receive the same treatment (levothyroxine, a synthetic T4 hormone replacement) at a dose that will be titrated using serum thyrotropin (TSH) levels as a goal, according to the American Thyroid Association Task Force recommendations
9971932|NCT01315626||3 months after educational event|3 months immediately after the education event. An active assessment will be preformed as per the proposed diagnostic algorithm (attachment B) Patients that meet all criteria in the algorithm are considered at risk for bronchiectasis and based on these criteria, physicians will be encouraged to order HRCT, and the number/ proportion of patients identified with BE will be noted and compared to the other time periods.
9971933|NCT01315626||Seasonal prior year|As respiratory illnesses are commonly seasonal, an assessment of rate of Bronchiectasis diagnosis during the months of Period 2 in the year prior to the educational intervention will also be assessed as described in Period 1
9971934|NCT01315652|Experimental|Auto DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
10150174|NCT04099056|Active Comparator|Participants with Major Depressive Disorder (MDD)|Participants with MDD will complete computer tasks while receiving TMS.
10150175|NCT04099056|Active Comparator|Healthy Control|Participants without MDD will complete computer tasks while receiving TMS.
10150176|NCT04098978|Experimental|Pharmacist Drug Therapy Management|
10150177|NCT04098965|Experimental|Experimental|Physical Therapy Techniques
10150178|NCT04098965|Other|Control|physician treatment
10150179|NCT04098861|Experimental|once daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day."
10150180|NCT04098861|Experimental|twice daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.~For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day."
10150181|NCT04098757||Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
10150182|NCT04098757||acupuncture|2 sessions a week, for a total of 10 (5 weeks), performed by the same operator, repeatable if necessary, after a therapeutic interval of at least one month. Each session lasts about 20-30 minutes per patient. Tewa J Type sterile disposable needles, coated, with a Chinese-style copper wire handle, with a guide tube, of 22x13 mm (CJ 2213) and 30x25 mm (CJ 3025) will be used. Acupuncture will be carried out by same trained operator.
10150183|NCT04098887|Experimental|Lattice stereotactic body radiation therapy|Patients with up to 10 chondrosarcoma lesions will undergo radiotherapy to all sites of disease. For lesions less than 4.5 cm, traditional SBRT will be used. For sites 4.5 cm or greater, Lattice SBRT will be used. For Lattice SBRT, radiotherapy will be prescribed to 20 Gy in 5 fractions delivered every other day with a LATTICE simultaneous integrated boost (SIB) to 66.7 Gy in 5 fractions.
10150184|NCT04098770|Experimental|Conventional treatment plus Allogeneic Adoptive Immune Therapy|Participants will receive conventional treatment (anti-opportunistic infections, cART and other treatments) plus a dose (2-3 times) of Allogeneic Adoptive Immune Therapy
10150185|NCT04098770|No Intervention|Conventional treatment|Without Allogeneic Adoptive Immune Therapy but conventional treatment (anti-opportunistic infections , cART and other treatments) should be received
9971935|NCT01315652|Active Comparator|Comorbidities treatment|
9971936|NCT01315691|Experimental|Arikace™|Liposomal amikacin for inhalation
9971937|NCT01315691|Placebo Comparator|Placebo|Placebo for liposomal amikacin for inhalation
9971938|NCT01315704||Group 1|Patients with Mild Cognitive Impairment
9971939|NCT01315704||Group 2|Patients with Mild Alzheimer's disease or related disorders
9971940|NCT01315704||Group 3|Patients with Moderate Alzheimer's disease or related disorders
9971941|NCT01315717||Group 1|Healthy subjects
9971942|NCT01315717||Group 2|Patients with Mild Cognitive Impairment
9971943|NCT01315717||Group 3|Patients with Mild AD
9971944|NCT01315717||Group 4|Patients with Moderate AD
9971945|NCT01315730|Experimental|Device: Tactile Stimulation|"A new medical grade device (FDA - category exempt) has been newly designed and built at the University of Mississippi within the departments of Communication Sciences & Disorders, Exercise Science, and Computer and Electrical Engineering. The device records either sound waves (via a small standard microphone) or three dimensional accelerometer data from the throat of a stuttering subject. This data is digitally signal processed, and fed back to the user in the form of a small vibrating disk/film that can be held between the fingers or mounted on the skin. This feedback data does not require the subject to attend to the incoming signal."
9971946|NCT01315743|Experimental|Intervention|
9971947|NCT01315756|No Intervention|Control group|Treatment as usual.
9971948|NCT01315756|Experimental|Few Touch Application (FTA)|"This arm will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user."
9971949|NCT01315756|Experimental|FTA and health counseling|This arm will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via sms from the diabetes nurse which is based on the patient's initiative (via sms). In addition, the diabetes nurse will call the patients three times during this period and discuss progress.
9971950|NCT01315769||non pregnant nulliparous|Group 1
9971951|NCT01315769||primiparous women|Group 2
10150186|NCT04098705|No Intervention|Pre-intervention|Pre-intervention period
10150187|NCT04098705|Experimental|Post-intervention|Post-intervention period
9669579|NCT03870438|Experimental|Intervention|"Children infected with HIV-1 will be referred to the National Programme for confirmed HIV diagnosis and immediate ART.~For children that are not HIV-1 infected, the results on the mother's viral load will guide the next steps:~Mothers with a detectable plasma viral load (≥ 1000 copies/mL): their children will be initiated on lamivudine oral solution.~Mothers with an undetectable viral loads (<1000 copies/mL): their children will not be initiated on lamivudine oral solution at 6-8 weeks of age. However, additional monitoring on the viral load of the mother and the diagnosis of the child will take place at 6 months: If the maternal plasmatic viral load is ≥ 1000 copies/mL, the child will be initiated on lamivudine oral solution."
9826229|NCT02412722|Experimental|Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2|Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
10150188|NCT04098562|Experimental|Treatment|0.5 mg/mL LL-37 cream, administered twice a week for 4 weeks
10150189|NCT04098562|Placebo Comparator|Placebo|Placebo cream, administered twice a week for 4 weeks
10150190|NCT04098653|Experimental|Decitabine + BUCY|For myeloid tumors undergoing allo-HSCT, Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
10150191|NCT04098653|Active Comparator|BUCY|For myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
9971952|NCT01315782||Multi-organ failure|Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
9971953|NCT01315795|Experimental|Symptomatic polycystic liver disease (PCLD) patients|Symptomatic polycystic liver disease (PCLD) patients
10150192|NCT04098874|Experimental|Bupropion|Participants randomized to extended-release bupropion. Once-daily
10150193|NCT04098874|Placebo Comparator|Placebo|Participants randomized to placebo. Once-daily
10150194|NCT04098614|Experimental|Recovery Coach Intervention|"Experimental: Recovery Coach Intervention Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR)~- Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants."
10150195|NCT04098614|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
10150196|NCT04098601|Experimental|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
10150197|NCT04098601|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
10150198|NCT04098692|Experimental|Single-Arm: Derazantinib (Part 1 and Part 2)|"Part 1: 300 mg Derazantinib oral administration followed by 100 μg [14C]-Derazantinib intravenous microdose~Part 2: 300 mg [14C]-Derazantinib oral administration"
10150199|NCT04098588|Experimental|BEAST|There are 3 parts to BEAST. Part 1 involves the Behavioral Nudge technique using previously collected injunctive and descriptive norms from a National Guard sample. Soldiers will be given a customized feedback form that shows norms relevant to the target behavior they selected. The soldier will be given a chance to ask any follow-up questions. Part 2 of the intervention focuses on the principle of targeting others, considering how a change would impact those closest to them. Part 3 will utilize the Reciprocal Concessions procedure combined with the Reducing Barriers technique.
10150200|NCT04098588|Active Comparator|Descriptive Feedback|This condition will involve a presentation of descriptive data based on the soldiers' tests scores and an opportunity to ask any follow-up questions. This process is a component of some behavioral change interventions (e.g., motivational interviewing); therefore this should be a more useful control condition (mirroring parts 1 and 2 of the active condition) versus a more passive or waitlist control condition. Participants in the control condition will also be given standard referral information to the USM Psychology Clinic (mirroring part 3 of the active condition).
10150201|NCT04098536|Experimental|Diesel Exposure|
10150202|NCT04098536|Placebo Comparator|Filtered Air Exposure|
10150203|NCT04098627|Experimental|Intervention|Once weekly 30-minute long group laughter therapy session for 8 weeks while patients are on dialysis
10150204|NCT04098627|No Intervention|Usual Care|Usual care
9971954|NCT01315808||Low risk group|Patients will be stratified based on risk factors significantly contributing to diabetes type 2.
9971955|NCT01315808||Intermediate risk group|
9971956|NCT01315808||High risk group|
10150205|NCT04098510|Experimental|MitoQ|Subjects ingest 160 mg of MitoQ
9971957|NCT01315821|Experimental|Saccharomyces boulardii|Saccharomyces boulardii 5 million unit/day for 3 months
9971958|NCT01315821|Placebo Comparator|control|Placebo- for 3 months
10150206|NCT04098640|Other|FMI|FoundationOne CDx will be performed using archival tumor tissue
10150207|NCT04098523|Other|Epidemiologic screening|All subjects are screened by duplex ultrasound for abdominal aortic aneurysm (AAA) and carotid artery stenosis (CAS). A questionnaire is completed to obtain information on demographic information, risk factors as well as prior treatment for AAA or CAS and current medication. No treatment is given.
10150208|NCT04098718|Other|PO open label prednisolone (in low blood eosinophils)|Standard care Prednisolone 30mg given daily for 5 days to treat an exacerbation.
10150209|NCT04098718|Experimental|Benralizumab SC + PO placebo|Benralizumab as a single 100mg sub cut injection and oral placebo tablet daily for 5 days
10150210|NCT04098718|Experimental|Benralizumab SC + PO prednisolone|Benralizumab as a single 100mg sub cut injection and oral prednisolone 30mg daily for 5 days
10150211|NCT04098718|Active Comparator|Placebo SC + PO prednisolone|Placebo sub cut injection and oral prednisolone 30mg daily for 5 days.
10150212|NCT04098796|Experimental|Experimental: Anti-PD-1 antibody＋XELOX|Every patient will receive anti-PD-1 antibody (200 mg intravenous drip every 3 weeks) and XELOX regimen chemotherapy (Oxaliplatin 130 mg/m2, intravenous drip, d1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14;every 21 days). Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years. XELOX will be administered 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
10150213|NCT04098913|Experimental|Reduced screen-based media use|Reducing recreational screen-based media use for a period of 2 weeks.
10150214|NCT04098913|No Intervention|Control group|Participants are asked to continue their habitual screen-based media use.
10150215|NCT04098783|Experimental|Nursing interventions (home visit and health education) group|Nursing interventions group: Home visit, health education At the Intervention group; the researcher made pretest (baseline measurements) before the nursing interventions at the first home visit. The researcher offered education and guide about prevention of lymphedema after the baseline measurements at the first home visit. Second and third home visits were made three and six months after the first visit. At the second and the third home visits, the measurements were repeated, and the nursing interventions were maintained in the direction of the patients' individual needs.
10150216|NCT04098783|No Intervention|No Nursing interventions group|No Nursing interventions group; the researcher administered the pretests at first home visit. The measurements were repeated in the third and sixth months after the first home visit. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
10150217|NCT04098549|Experimental|Rapid-Slow|"This arm will begin with intervention rapid (rapid rate of fall in plasma glucose) for the first study visit and proceed to intervention slow (slow rate of fall in plasma glucose) for the second study visit."
10150218|NCT04098549|Experimental|Slow-Rapid|"This arm will begin with intervention slow (slow rate of fall in plasma glucose) for the first study visit and proceed to intervention rapid (rapid rate of fall in plasma glucose) for the second study visit."
10150219|NCT04098354|Active Comparator|home-based BP telemonitoring|The intervention is a working prototype of a home BP telemonitoring system whereby a patient pushes a single button on a home BP monitor to initiate measurement, and data are auto-transmitted via Bluetooth to an Android smartphone and relayed to a secured web portal for review. Patients will receive a validated electronic upper arm oscillometric BP device (A&D Ltd. UA-651BLE; San Jose, CA) and an Android smartphone. Patients will take four measurements daily for 1 week. If BP is uncontrolled (high or low), this 1-week protocol will be followed each month until BP is in the therapeutic range. Once controlled, the 1-week protocol will be repeated every 3 months. Teletransmitted BP readings will be summarized within the health portal using telemonitoring software to the study case manager, who will also review telemonitored health portal BP summaries, make protocol-based therapeutic adjustments and send summaries to participants' PCPs to inform them of treatment changes.
10150220|NCT04098354|Placebo Comparator|usual care|For the control arm (usual standard care), participants' home BP series mean, trends, and individual readings will be sent via secure electronic medical records (EMR) to their PCP along with a 1-page summary of Canadian guidelines for BP thresholds, targets, and treatments relevant for CKD.
10150221|NCT04098263|Active Comparator|Part B: Cohort 1|300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days
10150222|NCT04098263|Active Comparator|Part B: Cohort 2|1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days
9826230|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 20 mg|Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
9826231|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 30 mg|Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
9826232|NCT02412761|Active Comparator|Amlodipine, then HCTZ, then Lisinopril|Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
9971959|NCT01315834||Couples coping with CHD|The target group will be 127 male patients and their partners. The couples will be recruited during the patients' first hospitalization for ACS. The participants will complete questionnaires during the hospitalization and again six months later. The patients will also be asked to be weighed and have their blood drawn and at the six-month follow-up for measurement of blood Cholesterol level. Relevant data will be obtained from their medical files.
9971960|NCT01315834||control group|The control group will be 100 couples who are not coping with a life threatening illness. The couples will complete self report questionnaires at one point of time.
9971961|NCT01315860||Pregnant Females|Pregnant females in their second or third trimester that meet the inclusion and exclusion criteria.
9977168|NCT01358838|No Intervention|no laser|
9977169|NCT01358851|Experimental|1|Drug Las41005
9977170|NCT01358851|Other|2|Cryotherapy
9977171|NCT01358890|Experimental|B|Subjects will be supplied with low carbohydrate diet for 12 weeks.
10150223|NCT04098263|Active Comparator|Part B: Cohort 3|3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days
10150224|NCT04098263|Other|Part A|3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally
10150225|NCT04098432|Experimental|Arm 1|4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks
10150226|NCT04098302|Active Comparator|dutasteride|two 0.5 mg capsules of dutasteride daily
10150227|NCT04098302|Placebo Comparator|placebo capsule|inactive placebo matched in appearance with dutasteride capsules
10150228|NCT04098159|Experimental|ESRD Patients have functioning or failing VAs (AVFs or AVGs).|
10150229|NCT04098471|Experimental|single transanal loca excision|
10150230|NCT04098471|Experimental|transanal local excision following radiotherapy|
10150231|NCT04098471|Experimental|total mesorectal excision|
10150232|NCT04098341|Other|Screening|All eligible migrants will be offered opt-out IGRA blood test to screen for for latent Tuberculosis infection
10150233|NCT04098367|Experimental|VIVITY|VIVITY IOL implanted in the eye during cataract surgery
10150234|NCT04098367|Active Comparator|SYMFONY|SYMFONY IOL implanted in the eye during cataract surgery
10150235|NCT04098367|Active Comparator|AT LARA|AT LARA implanted in the eye during cataract surgery
10150236|NCT04098289||Hysteroscopic septum resection without in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with natural conception (without the use of in vitro fertilization techniques).
10150237|NCT04098289||Hysteroscopic septum resection with in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
10150238|NCT04098289||Natural conception, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with natural conception (without in vitro fertilization techniques).
10150239|NCT04098289||In vitro fertilization, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
10150240|NCT04098380|Active Comparator|Small bite|The needle bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
10150241|NCT04098380|Active Comparator|Large bite|The needle bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
10150242|NCT04098419|Experimental|Williams Implementation|
10150243|NCT04098419|Experimental|Pittsburg Implementation|
10150244|NCT04098107|Experimental|Throwing Device Phase 1|During Phase 1, subjects that have been recruited, consented, and enrolled will come to the biomechanics laboratory for throwing performance housed at the University of Pennsylvania (Human Motion Laboratory) on the day of their appointment. Subjects will be asked to wear the prototype device during a simulated baseball game (approximately 30-45 pitches), and then will perform a set of other baseball-specific movements while fitted with infrared markers for throwing analysis. This data will be used to develop and refine the algorithm for the prototype.
10150245|NCT04098081|Experimental|galeterone|galeterone orally once daily
9977172|NCT01358890|Experimental|A|Subjects will be supplied with calories restricted diet for 12 weeks
9977173|NCT01358903|Experimental|A|
10150246|NCT04098081|Experimental|galeterone+gemcitabine|daily dose galeterone and weekly dose of gemcitabine
9977174|NCT01358903|Experimental|B|
10150247|NCT04098003|Experimental|Rosuvastatin|rosuvastatin 20 mg daily for eight weeks
10150248|NCT04098003|Placebo Comparator|Placebo|placebo daily for eight weeks
10150249|NCT04097990|Other|healthy participants|healthy participants
10150250|NCT04097990|Other|hypertriglyceridemia without prior pancreatit|
10150251|NCT04097990|Other|hypertriglyceridemia and at least one case of|
10150252|NCT04097808|Experimental|collagen peptide bovine high molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
10150253|NCT04097808|Experimental|collagen peptide bovine low molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
10150254|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 1|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 1
10150255|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 2|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 2
10150256|NCT04097808|Experimental|collagen peptide fish low molecular weight-Water|source: fish; standardized to 10 g provided as single dose. Orally applied in water.
10150257|NCT04097808|Experimental|collagen peptide porcine low molecular weight-Water|source: porcine; standardized to 10 g provided as single dose. Orally applied in water.
10150258|NCT04097756|Experimental|Part1：dose escalation|The investigational product for this study is LX-039 tablets,which can be administered orally. 6~8 ascending dose level until MTD and the specification included 50 mg, 100 mg, 200 mg, 400 mg, 600 mg , 800 mg,1050 mg and 1400 mg. LX-039 tablets will be administered in a therapeutic cycle of 28 days once a day orally. The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
10150259|NCT04097756|Experimental|Part 2：dose expansion|2~3 selected tolerable dose will be selected according to the tolerance and FES PET results of dose escalation phase.The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
10150260|NCT04097795||Prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which offer prehabilitation.
10150261|NCT04097795||No prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which do not offer prehabilitation.
10150262|NCT04097951|Experimental|Montelukast|
10150263|NCT04097951|Experimental|Bepotastine|
10150264|NCT04097951|Experimental|Montelukast + Bepotastine|
10150265|NCT04097977|Experimental|Intervention: RENEW in a psychiatric ward|Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group that will form the basis of real user involvement.
10150266|NCT04097977|No Intervention|Conventional clinical practice in a psychiatric standard ward|The comparison group patients were admitted to a standard psychiatric ward that offered conventional care.
10150267|NCT04097899||Group A in preimplementation phase|Patient and antibiotic related data were collected to calculate and define; ventilator associated pneumonia incidence, mean ventilation days and mean length of stay, antibiotic selection, antibiotic cost, antibiotic susceptibility pattern, antibiotic consumption.
9971962|NCT01315886|Experimental|SL Fentanyl conversion|"Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication~Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes."
9971963|NCT01315899|Experimental|ORM-12471 30mg|
9971964|NCT01315899|Placebo Comparator|placebo|
10150268|NCT04097899||Group B in postimplementation phase|The appropriateness of antibiotic use (selection, initiation, duration & time of discontinuation) before and after implementing the educational program was compared, calculation of the change in the ventilator associated pneumonia incidence & length of ICU stay, calculation of the change in the rate of antibiotic resistance and calculation of the cost change of antibiotics used after implementing the educational program.
10150269|NCT04097860|Experimental|Intervention group|Will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
10150270|NCT04097860|No Intervention|Control group|Will only be sent text messages that include the same general lactation information sent to the treatment group
10150271|NCT04097678|Experimental|Retained Sponge Group|Just prior to imaging, the surgeon will purposely place a sponge in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
10150272|NCT04097678|No Intervention|No Retained Sponge Group|No sponge will be placed in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
10150273|NCT04097782|No Intervention|Control Group|"Prior to the study, primiparous pregnant women presented to the outpatient clinic for routine pregnancy control were introduced with free prenatal education classes and they were invited to participate in the study.~Primiparous women who volunteered to participate in the study and met the inclusion criteria were included in the study and they formed the experimental and control group. Control group did not receive antenatal education and they received prenatal care service routinely provided at the polyclinics of the same hospital."
10150274|NCT04097782|Experimental|Experimental Group|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
10150275|NCT04098042||Scaffold|"Patients receiving during PCI the implantation of at least one Magnesium Made Bioresorbable Scaffold Magmaris"
10150276|NCT04097925|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 16 weeks
10150277|NCT04097834||PrEP Prescription at Enrollment|
10150278|NCT04097834||No PrEP Prescription at Enrollment|
9661881|NCT03732950|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab intravenously IV on day 1. Courses repeat every 3 weeks for up to 35 courses (2 years) in the absence of disease progression or unacceptable toxicity.
9971965|NCT01315899|Experimental|ORM-12471 100mg|
10150279|NCT04097691||on subcutaneous glucose|this group was on subcutaneous glucose 0.5 ml per site around subcutaneous nerves in the foot region both on palm and sole.which is repeated every 2 weeks for 2 months.
10150280|NCT04097691||control(not receiving treatment)|the second group is considered as control.received no treatment.
10150281|NCT04097886|Experimental|Morning Exercise Group|Participants perform moderate exercise in the morning.
10150282|NCT04097886|Experimental|Evening Exercise Group|Participants perform moderate exercise in the evening.
10150283|NCT04097769|Other|HX009|Study treatment: HX009 administered every 2 weeks (14 [±1] days) via intravenous infusion.
9661882|NCT03710265|Experimental|SHR-1701|
9661883|NCT03667404|Experimental|Resistant Maltodextrin|Resistant maltodextrin (RM) powder 25 g during days 1-7 and 50g during days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
10150284|NCT04097938|Experimental|GLPG3667 SAD|Single doses of GLPG3667 at up to 6 dose levels in ascending order
10150285|NCT04097938|Placebo Comparator|Placebo SAD|Single doses of placebo
10150286|NCT04097938|Experimental|GLPG3667 MAD|Multiple doses of GLPG3667 at up to 3 dose levels in ascending order, daily for 13 days
10150287|NCT04097938|Placebo Comparator|Placebo MAD|Multiple doses of placebo
10150288|NCT04097938|Experimental|GLPG3667 FE fasted|Single dose of GLPG3667 in fasted state
10150289|NCT04097938|Experimental|GLPG3667 FE fed|Single dose of GLPG3667 in fed state
10150290|NCT04097938|Experimental|GLPG3667 oral suspension rBA-FE fed|Single dose of GLPG3667 oral suspension in fed state
10150291|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fasted|Single dose of GLPG3667 capsules in fasted state
10150292|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fed|Single dose of GLPG3667 capsules in fed state
10150293|NCT04097587|Other|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
10150294|NCT04097743|Experimental|Coping statement|Daily practice of pain coping statements for 7 days
10150295|NCT04097743|No Intervention|Control|No instruction about pain coping statement.
10150296|NCT04097613|Experimental|Betadine Treatment|Study subjects will use betadine saline sinus rinse for period of 6 weeks.
10150297|NCT04097496|Experimental|Act Out! Intervention|Eligible classrooms will be randomized to attend a 1-hour ACT OUT! interactive, semi-improvisational psychodrama performance. The ACT OUT! intervention is an established theater program (https://www.claudemcnealproductions.com/act-out-ensemble/). The ACT OUT! production will include three to five vignettes paired with moderated discussions between the audience and the actors, the latter who will remain partly in character for the duration of the intervention. Vignettes will be different for each grade level included in the study (4th, 7th, and 10th). Public documentation of the guidelines for the ACT OUT! intervention will be made available as a supplemental file attached to the primary outcomes paper for the study.
10150298|NCT04097496|No Intervention|Control|Classrooms randomized to this arm will continue with their school day as normal, except that they will complete the data collection tools.
10150299|NCT04097483|Experimental|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention, centered on motivational interviewing and cognitive behavioural therapy for adherence and depression.
10150300|NCT04097483|No Intervention|Control group|Control group with treatment as usual (TAU).
10150301|NCT04097600|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
10150302|NCT04097600|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
10150303|NCT04097600|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
10150304|NCT04097600|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
10150305|NCT04097600|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
10150306|NCT04097600|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
10150307|NCT04097431|Experimental|Precursors as Response Chain or Class|The precursor behavior occurs as a part of a sequence, or for the same maintaining variable, leading up to the severe problem behavior.
10150308|NCT04097405|Active Comparator|D-0120 Dose Ascending Cohorts 1-4|D-0120 dose daily for up to 7 days.
10150309|NCT04097405|Placebo Comparator|Placebo Dose Ascending Cohorts 1-4|Placebo dose daily for up to 7 days
10150310|NCT04097405|Experimental|D-0120/Uric Acid Lowering Agent Cohort 6|D-0120 in combination with a uric acid lowering agent for up to 7 days of combination therapy
10150311|NCT04097522|Active Comparator|real neurofeedback|Participants receive neurofeedback from a region of the brain thought to be associated with increasing pain resilience
10150312|NCT04097522|Sham Comparator|sham neurofeedback|Participants receive neurofeedback from a region of the brain thought to be unrelated with increasing pain resilience
10150313|NCT04097574|Active Comparator|NPO-13 0.8%|Low dose
10150314|NCT04097574|Active Comparator|NPO-13 1.6%|High dose
10150315|NCT04097574|Placebo Comparator|NPO-13 0%|Placebo
10150316|NCT04097652|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
9977796|NCT01365260|Active Comparator|DurolaneTM|hyaluronic acid
10150317|NCT04098029|Experimental|Group 1 Low HLA compatibility|The patients in the first group will receive two CBU of low-level HLA matched infusions within a 6-month interval. The low-level match is 3 or less HLA compatibility degree by A, B, DRB1 loci.
10150318|NCT04098029|Experimental|Group 2 High HLA compatibility|The patients in the second group will receive two CBU of high-level HLA matched infusions within a 6-month interval. The high-level match is 4 or more HLA compatibility degree by A, B, DRB1 loci.
10150319|NCT04098029|Other|Standard therapy|Patients with standard therapy as a control group
10150320|NCT04097353|Experimental|Harvesting Hope for Kids (HH4K)|Eight weekly, 60-minute sessions at a university-based farm with booster sessions. Learning is structured around fun activities to provide information about the impact of cancer treatment on children's health, as well as the importance of nutrition and physical activity in survivorship. Each session is manualized and devoted to education, a behavioral strategy applied toward a weekly goal, a cooking demonstration/taste testing, and harvesting produce from the survivor garden. Modules are offered in a group format with families together.
10150321|NCT04097353|Sham Comparator|Surviving Strong for Kids (SS4K)|Families assigned to enhanced usual care (SS4K) group will receive education in the form of standardized guidelines for nutrition and physical activity for survivors of childhood cancer. In a one-hour session, they will learn about the impact of cancer treatment on health and the importance of nutrition and physical activity for survivors. Families will receive websites for other educational resources. They will not have access to harvesting, remote coaching, the web portal, or behavioral training to address their child's nutrition or activity.
10150322|NCT04097444|Experimental|Step 1 (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1.~[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
10150323|NCT04097444|Experimental|Step 2 Arm A (FOLFOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: FOLFOXIRI+BEV] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks."
10150324|NCT04097444|Experimental|Step 2 Arm B (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1.~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
10150325|NCT04097665||patients with expanded flaps|Patients will undergo tissue expansion. When the expanded flaps are harvested and transplanted, ICGA will be conducted intraoperatively. Meanwhile, the possible area of necrosis will be marked according to clinical experience. And then this area will be further divided into perfusion units (1*1 square centimeter for each). The center of each perfusion unit will be marked as observation point, of which the fluorescence value will be recorded. After 1 week's follow-up postoperatively, the flap tissue will be determined by superimposing digital photography over ICGA imaging results, and the outcome of each observation point will be recorded. By analyzing the fluorescence value and outcome of each observation point, a cut-off point can be further identified to achieve both higher positive and negative predictive value, improving the utility and accuracy of ICGA in predicting the postoperative skin viability of expanded flaps.
10150326|NCT04097548|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care.
9971966|NCT01315925||Newly disgnosed AML|Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and not eligible for intensive chemotherapy. Since this is a non-interventional study, therapeutic strategies remains related to local guidelines. Will be treated as cases all patients with acute leukemia in first induction developing an Invasive Fungal Infection according to international EORTC criteria for possible/probable/proven infections. Patients who do not develop the infection will be used as a control group.
10150327|NCT04097548|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care.
10150328|NCT04097288|Experimental|Single dose citalopram|A blinded single dose 40 mg citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
10150329|NCT04097288|Active Comparator|Single dose reboxetine|A blinded single dose 8 mg reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
9669580|NCT03870438|No Intervention|Control|Routine Option B+ national guidelines including HIV-1 plasmatic viral load testing will be adhered to. Visits will take place at 6-8 weeks, 6 and 12 months post-partum to collect samples from the mother for the analysis of viral load results at 12 months. In addition, at 6-8 weeks, 6 and 12 months post-partum, POC tests will be done for the diagnosis of HIV-1 in their infants (by HIV-1 DNA PCR) and results will be shared within 2 hours. Children infected with HIV-1 will be referred to the National Programme for confirmed diagnosis and immediate ART.
10150330|NCT04097288|Placebo Comparator|Single dose placebo citalopram|A blinded single dose visually identical placebo pill to citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
10150331|NCT04097288|Placebo Comparator|Single dose placebo reboxetine|A blinded single dose visually identical placebo pill to reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
10150332|NCT04097509|Experimental|autologous fibrin glue (AFG) group|In the test groups, polymerized AFG was applied to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
10150333|NCT04097509|Experimental|injectable platelet rich fibrin (i-PRF) group|In the test groups, polymerized i-PRF was applied to the donor area. Donor palate was closed with sterile aluminum foil and periodontal pack.
10150334|NCT04097509|Placebo Comparator|Control Group|In the control group, only moist sterile tamponade was applied following graft removal to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
10150335|NCT04097093||Study 62005-STBSG patients treated with imatinib > 10 years|
10150336|NCT04097171|Experimental|High Carbohydrate Diet|Participants will consume a high carbohydrate diet (65-75% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
9669581|NCT03852667|No Intervention|Control|No intervention between the two test sessions
9669582|NCT03852667|Active Comparator|Pain Neuroscience Education|Two sessions (30 min) of Pain Neuroscience Education
9669583|NCT03852667|Experimental|Pain neuroscience education - exercise|2 sessions of PNE and 5 sessions of exercise therapy.
9669584|NCT03845374|Experimental|Conventional Antibiotics+ Hyper-CL™ lens|Conventional treatment with topical Antibiotics+ Hyper-CL™ lens
9669585|NCT03845374|No Intervention|Conventional Antibiotics|Conventional treatment with topical Antibiotics
9669586|NCT03834363|Active Comparator|Morphine capsules and Placebo patch|Morphine retard 10 mg twice daily Placebo patch, change every three days.
9669587|NCT03834363|Experimental|Placebo capsules and Fentanyl patch|Placebo capsules twice daily Fentanyl patch 12 mcg/hr, change every three days
9669588|NCT03834363|Placebo Comparator|Placebo capsules and Placebo patch|Placebo capsules twice daily Placebo patch, change every three days
10150337|NCT04097171|Experimental|Ketogenic Diet|Participants will consume a low carbohydrate diet (<5-10% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
10150338|NCT04097418|Experimental|Aerobic training in healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
10150339|NCT04097418|Active Comparator|Conventional motor training of healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
10150340|NCT04097418|Experimental|Aerobic training in MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
10150341|NCT04097418|Active Comparator|Conventional motor training of MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
10150342|NCT04097626|Experimental|experimental|This group will receive nutrition education during the first week of the study. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
10150343|NCT04097626|Active Comparator|control|This group will receive no nutrition education. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
10150344|NCT04097392|Experimental|Diaphragm biofeedback reeducation plus inspiratory training|
10150345|NCT04097392|Active Comparator|Isolated high-intensity inspiratory muscle training|
10150346|NCT04097366|No Intervention|Standard of Care|Control arm, no supplementary imaging is given. Participants have mammographic screening 3-yearly as per current standard of are.
10150347|NCT04097366|Active Comparator|Abbreviated MRI (ABB-MRI)|Supplementary imaging with abbreviated MRI at study entry and 18 months after baseline mammogram.
10150348|NCT04097366|Active Comparator|Automated Breast Ultrasound (ABUS)|Supplementary imaging with automated breast ultrasound at study entry and 18 months after baseline mammogram.
10150349|NCT04097366|Active Comparator|Contrast Enhanced Mammography (CESM)|Supplementary imaging with contrast enhanced spectral mammography at study entry and 18 months after baseline mammogram.
10150350|NCT04097197|Experimental|Patients receiving information|Patients in the experimental arm will receive a brief educational intervention if they initially refuse flu vaccination. The intervention was designed towards the most common barriers to flu vaccination that were found after a brief review of the literature. After the intervention, patients will be asked again whether or not they wish to receive the flu vaccine.
10150351|NCT04097015|Experimental|Treatment|The treatment or intervention is the use of NI-ES using a signal generator, Alpha-Stim M, with an Ocular Interface connected to one channel and a Spinal Interface to the other channel. The treatment is done at home for 40 minutes at a time, twice a day. The upper lids of the closed eyes are treated for 10 minutes and the lower lids of the closed eyes are treated for 10 minutes, alternated throughout the treatment time. The Spinal Interface is placed above the SCI for 40 minutes. The entire procedure is repeated for another 40 minutes for a second time. The participant will treat himself at home.
10150352|NCT04097132||ischemic stroke patients|all patient admitted with acute ischemic stroke either their ECG was AF or sinus rythm
10150353|NCT04097080|Experimental|NBTX-001|30% medical grade xenon/70% Oxygen
10150354|NCT04097080|Placebo Comparator|Standard of Care|Reconstituted air
10150355|NCT04097457|Experimental|Parent mediated intervention (PMI) group|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. The protocol is administered to groups of 4 families.
10150356|NCT04097457|Experimental|Waitlist control|Families will be recruited and will fill out measure for 3 months prior to participation and will then join the active intervention
10150357|NCT04097457|Experimental|Individual|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. In this arm the protocol is administered individually to families.
10150358|NCT04097314|Experimental|Zibotentan|
10150359|NCT04097314|Placebo Comparator|Placebo|
10150360|NCT04096937||Appalachian adults|Adults in Appalachia invested in well-being of youth.
10150361|NCT04096937||Appalachian youth|Youth from 7th through 12th grade.
10150362|NCT04096950|Experimental|MT-3921|Intravenous, single dose
10150363|NCT04096768|Experimental|Dexmedetomidine + Ketamine|
10150364|NCT04096768|Placebo Comparator|Dexmedetomidine + Placebo|
10150365|NCT04097275||Participants with an Inborn Error of Metabolism|
10150366|NCT04096885||InSurg cohort|Patients who undergo elective or emergency surgery at the Department of Visceral Surgery and Medicine, Inselspital, Bern, who gave informed consent.
10185480|NCT03745261|Experimental|YCC capsule+conventional medicine|Patients in this group will be given Yong Chong Cao (YCC) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD,which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
10185481|NCT03745261|Experimental|BL capsule + conventional medicine|Patients in this group will be given Bailing (BL) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD, which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
10185482|NCT03745248|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
9971967|NCT01315938|Other|Active treatment|Abatacept will be administered intravenously at a dose based on body weight at the screening visit (baseline): participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
9971968|NCT01315938|Other|Delayed-onset treatment|Abatacept will be administered intravenously at a dose based on body weight at 3 months: participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
9971969|NCT01315951|Experimental|Petroleum Jelly|Every patient will be applying petroleum jelly to the affected areas per protocol.
10185483|NCT03745248|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
10185484|NCT03745235|Experimental|"Mindfulness group"|
10185485|NCT03745235|Other|Control group|Treatment as Usual
10185486|NCT03745209|Experimental|Ultrasound-guided peripheral IV.|Ultrasound-guided peripheral IV cannulation
10185487|NCT03745209|No Intervention|Traditional landmark technique|Traditional landmark technique
10185488|NCT03745196|Experimental|PC945|PC945 5mg once-daily, nebulized
10185489|NCT03745196|Placebo Comparator|Placebo|Placebo, nebulized
10185490|NCT03745183|Experimental|Senna alata leaf decoction|The participants were instructed to take a bath once a day using a syndet bar and to towel dry their skin before applying the akapulko decoction. Fresh decoction was prepared by the patients every day. After a bath, the patient applied the fresh cooled decoction by hand on the whole body especially on the affected areas and left it to dry. Approximately one glassful (350ml) of akapulko decoction should be consumed for one whole body application. The total duration of daily application should be 4 weeks (28 days +3) until the next outcome assessment.The patients were given illustrated, laminated instructional materials and a tabulated checklist of instructions on how to prepare and apply the decoction which served as a monitoring sheet of each patient.
10185491|NCT03745170|Experimental|Sintilimab+ Oxaliplatin +capecitabine|
10185492|NCT03745170|Active Comparator|placebo +Oxaliplatin + Capecitabine|
10185493|NCT03745157||Patients with Type 2 Diabetes requiring insulin therapy|Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)
10185494|NCT03745131||Pre-exposure prophylaxis recipients|40 healthcare workers who provide specialist medical care to patients with monkeypox and who received vaccine as pre-exposure prophylaxis.
10185495|NCT03745131||Post-exposure prophylaxis recipients|40 healthcare workers who received vaccine as post-exposure prophylaxis following monkeypox-exposure risk assessments.
10185496|NCT03745131||Control Group 1|20 healthcare workers who provided specialist medical care to patients with monkeypox but declined the offer of vaccine as pre-exposure prophylaxis.
10185497|NCT03745131||Control Group 2|Healthcare workers not involved in the care of, and have not had known exposure to, patients with monkeypox and, therefore, were not offered vaccine.
10185498|NCT03745105|Experimental|dexamethasone|Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)
10185499|NCT03745105|Experimental|piroxicam|Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)
9971970|NCT01315964|Active Comparator|plant stanol ester|3 grams of plant stanol esters per day in a margarine product as part of daily diet for 6 months
9971971|NCT01315964|Placebo Comparator|Placebo|a margarine product as part of daily diet, which is not containing plant stanol esters
10185500|NCT03745105|Active Comparator|Mepivacaine HCL|Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)
10185501|NCT03745040|Experimental|Group A: Exparel|"Standard of Care plus Liposomal bupivacaine (Exparel®). Dosage: Exparel® 20 mL single use vial, 1.3% (13.3 mg/mL), Maximum dose of 266 mg (20 mL).~Frequency: Single intraoperative administration"
10185502|NCT03745040|No Intervention|Group B: No Exparel|Standard of Care
10185503|NCT03745027|Experimental|In vitro fertilization|Paients undergoing in vitro fertilization with Gonadotropin-releasing Hormone agonist. Follicular fluid sialic acid levels will be measured.
10185504|NCT03745014|Active Comparator|Pheno|
10150367|NCT04096989|No Intervention|Control group|Routine care.
10150368|NCT04096989|Experimental|Experimental group|The participants accept TCM regimen-based lifestyle mobile health application intervention.
10150369|NCT04096989|Sham Comparator|Sham comparator group|The participants accept mobile health application intervention.
9826233|NCT02412761|Active Comparator|Amlodipine, then Lisinopril, then HCTZ|Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
10150370|NCT04097028|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1 and trifluridine and tipiracil hydrochloride PO BID on days 1-5. Treatment repeats every 14 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care chemoradiation therapy followed by surgery.
10150371|NCT04096651|Other|PSP Classic|"15 patients with a classical form of PSP are recruited to realize all the tests of the multimodal approach."
10150372|NCT04096651|Other|Caribbean PSP|"15 patients with a Caribbean PSP are recruited to realize all the tests of the multimodal approach."
10150373|NCT04096651|Other|Healthy controls|15 persons with no PSP are recruited to realize all the tests of the multimodal approach.
10150374|NCT04096976||Hospital survival|
10150375|NCT04096976||No hospital survival|
10150376|NCT04096599|Experimental|Test group|
10150377|NCT04096599|Active Comparator|Control group|
10150378|NCT04096612|Experimental|Orbital decompression combined MPT|Orbital decompression was performed by the same doctor with rich clinical experience. MPT should be implemented in the patients with obvious thyroid disorder before orbital decompression surgery which should only be performed when thyroid function was stabilized. The surgery was performed under general anesthesia. An arcuate incision was made in the skin 2 mm below the lower eyelid margin, and the tissue under the incision were separated to the periorbita and orbital septum. Part of the medial orbital wall, inferior orbital wall and partial tissue of ethmoidal sinus were removed, and an appropriate amount of adipose tissue was excised. MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
10150379|NCT04096612|Experimental|Separate MPT|MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
10150380|NCT04096664|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
10150381|NCT04096664|No Intervention|Control|Usual care
10150382|NCT04096742|Experimental|Altreno|tretinoin 0.05% lotion (Altreno)
10150383|NCT04096742|Sham Comparator|Vehicle|Vehicle lotion not containing tretinoin
10150384|NCT04096638|Experimental|Part 1a: Monotherapy Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses (0.3-14 SB 11285 µg/Kg)
10150385|NCT04096638|Experimental|Part 1b: PD-L1 Combination Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses (0.3-3.0 SB 11285 µg/Kg) plus 1680mg every 4 weeks (Q4W) atezolizumab
10150386|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort A)|"Cohort A: Patients with Melanoma~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
9971972|NCT01315990|Experimental|FOLFIRI + Cetuximab|
9971973|NCT01316003||Normal subjects|Thirty-seven eyes of 37 individuals without eye diseases
9971974|NCT01316016|Experimental|Rose hip|
10150387|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort B)|"Cohort B: Patients with HNSCC~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
10150388|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort C)|"Cohort C: Patients with tumor types other then Cohort A and B (Naïve or relapsed refractory to anti PD-1/PD-L1)~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
10150389|NCT04096833|Experimental|Intervention Group|Participants use as a distracting measure Virtual Reality glasses during the vaccination.
10150390|NCT04096833|No Intervention|Control Group|Participants use usual non-virtual distracting measures during the vaccination.
10150391|NCT04096755||DVT group|40 patients with a confirmed deep venous thrombosis (DVT) on Duplex ultrasound will be recruited into this group. All patients will have serum and urine samples for analysis.
10150392|NCT04096755||Control Group|40 volunteers without a DVT will be recruited for the control group. They will have urine and serum samples taken for analysis.
10150393|NCT04096729||patients who have consulted and need compression therapy using|1) age from 18 to 75 years; 2) compression therapy prescribed by a phlebologist. The exclusion criterion is hearing impairment, which could interfere with a telephone questionnaires.
10150394|NCT04097041|Active Comparator|Surgical Arm|Surgery arm - patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).Patient has routine follow up - H&P, 2 weeks after surgery and then H&P, Audiometry and Tympanometry over 12 months post surgery (3rd month, 6th month and 12th month).
10150395|NCT04097041|Active Comparator|Non-Surgery|"Non surgery arm - patient has audiological consult and fitting of masking device.~The Patient has a routine follow up - H&P, 2 weeks after masking fitting and then H&P, Audiometry, Tympanometry over 12 months (3rd month, 6th month and 12th month). Patient cross over to change arms, at 6 months, if they have no resolution of symptoms."
10150396|NCT04096911|Experimental|Sintilimab and HPV Vaccine|Sintilimab 200 mg intravenously every 3 weeks ，3 doses of quadrivalent HPV vaccine intramuscularly at day 1,60,180
10150397|NCT04096924|Experimental|Treatment Group|Experimental group is allocated to use novel interventional guidewire for the echocardiography guided percutaneous interventions for ASD.
10150398|NCT04096924|Active Comparator|Control Group|Control Group is allocated to use Cook lunderquist guidewire for the echocardiography guided percutaneous interventions for ASD.
10150399|NCT04096690|Experimental|Anti-PD-1 antibody plus pegaspargase|Participants will receive induction treatment for six cycles of Anti-PD-1 antibody plus pegaspargase (21-day cycle) and Anti-PD-1 antibody monotherapy maintenance treatment for about 2 years (21-cycle)
10150400|NCT04096378|Experimental|EMBRace Intervention Group|Over 13 weeks, participants will engage in a pretest (week 1) 5 weekly sessions (weeks 2-6), a posttest (week 7) and a follow-up (week 13). The intervention (Engaging, Managing, and Bonding through Race: EMBRace) seeks to reduce racial trauma for both youth and caregivers and increase family functioning via psychoeducation and therapy.
10150401|NCT04096378|Other|EMBRace Waitlist Group|Participants will wait for thirteen weeks without receiving EMBRace or alternative therapeutic sessions. The waitlist group will subsequently become the intervention group with the opportunity to participate in the EMBRace intervention protocol above.
10150402|NCT04096625|Experimental|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
10150403|NCT04096625|Sham Comparator|Sham tDCS|Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
10150404|NCT04096534|Experimental|Normotonic partial nephrectomy|Performing a partial nephrectomy under normal body blood pressure
10150405|NCT04096534|Active Comparator|Hypotonic partial nephrectomy|Performing a partial nephrectomy under hypotonic body blood pressure
9971975|NCT01316029||laying-on-of-hands|44,587 Japanese volunteers with/without illness, who were interested in receiving laying-on-of-hands
10150406|NCT04096508|Experimental|Group A|Patients sit comfortably in a chair for 20 min listening classic music before the procedure.
10150407|NCT04096508|Experimental|Group B|Patients sit comfortably in a chair for 20 min listening popular music before the procedure.
10150408|NCT04096508|No Intervention|Control group|Patients sit comfortably in a chair for 20 min without music listening before the procedure.
10150409|NCT04096339|Active Comparator|EGD followed by Colonoscopy|Randomized to group Esophagogastroduodenoscopy followed by Colonoscopy
10150410|NCT04096339|Active Comparator|Colonoscopy followed by EGD|Randomized to group Colonoscopy followed by Esophagogastroduodenoscopy
10150411|NCT04096677||hysteroscopy repair|patients with post cesarean scar defect
10150412|NCT04096677||transvaginal repair|patients with post cesarean scar defect
10150413|NCT04096352|Experimental|Indirect+Direct method|"Indirect method: one session of information on voice function and voice hygiene.~Direct method: three sessions of voice training using virtual reality simulations over a course of 3 weeks."
10150414|NCT04096352|Active Comparator|Indirect method|Indirect method: one session of information on voice function and voice hygiene.
10150415|NCT04096274|Experimental|LOCI (Intervention)|Agencies in the intervention group will receive leadership training and coaching in addition to training and technical assistance to implement the digital measurement based care system.
10150416|NCT04096274|Placebo Comparator|Implementation As Usual (Control)|Agencies in the control group will receive web-based leadership training in addition to training and technical assistance to implement the digital measurement based care system.
10150417|NCT04096391|Active Comparator|Intrathecal Drug Delivery System|Subjects randomized to the Intrathecal Drug Delivery System group will be implanted with the Prometra System under sterile technique in accordance with the Instructions for Use. The pump will be filled at the time of implantation with the prescribed medication.
10150418|NCT04096391|Active Comparator|Conventional Medical Management|Subjects randomized to the Conventional Medical Management group will continue with the standard of care procedures.
10150419|NCT04096287|Experimental|PNT001|Single escalating doses of intravenous PNT001 administered as a 30 minute infusion at doses of 33mg, 100mg, 300mg, 900mg, 2700mg, and as a 60 minute infusion at 4000 mg
10150420|NCT04096287|Placebo Comparator|Placebo|Single intravenous dose of vehicle administered as a 30 minute infusion up to 2700 mg and as a 60 minute infusion at 4000 mg
9669589|NCT03806283||Cohort 1 no Preeclampsia|Cohort 1: 26 mothers with no diagnosis of preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
9971976|NCT01316068|Experimental|sequencial use of sulodexide|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.
10150421|NCT04096404|No Intervention|Control|no advice
10150422|NCT04096404|Active Comparator|Non genetic personalised advice|dietary and physical activity advice based on reported dietary intake and physical activity
10150423|NCT04096404|Experimental|Genotype- based personalised advice|dietary and physical activity advice based on genotype, reported dietary intake and physical activity
10150424|NCT04096469|Experimental|Motivational Interviewing|The intervention group received a guidance regarding their diet and physical activity using the motivational interviewing strategy to improve adherence to healthy behaviors. Participants received a guide with a motivational interviewing approach, which served as the basis for the interview process. The objectives in the intervention group were to consume four vegetables and two fruits a day, seven days a week, increase fiber consumption to more than 30 g daily, reduce fat consumption to no more 20% of the total energy consumed, decrease the consumption of sugary drinks and increase protein intake. Another goal was to increase the number of steps to 4,000 additional steps to those who have already walked.
10150425|NCT04096469|Active Comparator|Traditional Education|The comparison group received a guide on medical care and nutrition with a traditional educational approach. The indication was to read and learn about the health-related topics included in the booklet that was given to them. These participants were visited in the same way as the intervention group to answer questions and monitor participation throughout the intervention.
9971977|NCT01316068|Active Comparator|oral use of sulodexide|Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks
9971978|NCT01316081|Experimental|Antioxidant Group|500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
9971979|NCT01316081|Placebo Comparator|Placebo Group|identical appearing placebo supplements
10150426|NCT04096222||Active pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactuve disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
10150427|NCT04096222||Inactive pemphigus vulgaris subjects|Subjects with the diagnosis of pemphigus and with active or inactuve disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 34 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Biometric data
10150428|NCT04096222||Healthy subjects|Healthy subjects will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) Demographic data will be documented, 2) biometric data, 3) A 34 ml blood sample will be taken
10150429|NCT04096430|Experimental|ENGAGE approach (child-oriented goal-setting)|Therapists will receive training on our principles-based goal setting approach and strategies in the goal setting toolbox. Training will include an overview of tools and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS) and the Pediatric Activity Card Sort (PACS). In addition, we will provide training on Goal Attainment Scaling and administration of the Canadian Occupational Performance Measure (COPM). We will introduce simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
10150430|NCT04096430|No Intervention|Usual care|The control group will comprise of usual care.
10150431|NCT04096209|Experimental|Graft-less and grafting using xenograft and autograft|Extraction of badly decayed teeth with immediate implant placement using graft-less and grafting using autogenous bone and xenograft between the implant and labial socket bone
10150432|NCT04096235|Experimental|RAM Cannula|
10150433|NCT04096196|Experimental|Game intervention group|Participants assigned to the intervention group will be given a manual containing instructions to play the Safe City game. A research assistant will provide a briefing session on the game in each participating school. A unique username and password set will be created for each user to log in the game. This login information will be provided to the student participants in a sealed envelope after the briefing session. The participants will be instructed to play the game as many times as desired within a 4-week time frame. The players ranked in the top 20 will receive a reward in the form of book coupon after the intervention ends.
9971980|NCT01316094|Experimental|ASP group|oral
9971981|NCT01316094|Placebo Comparator|placebo group|oral
10150434|NCT04096196|Active Comparator|"Health education (control) group"|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
10150435|NCT04096261||Healthy controls|Healthy controls recruited through public advertisement.
10150436|NCT04096261||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement
10150437|NCT04096261||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
10150438|NCT04096261||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
10150439|NCT04096261||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
10150440|NCT04096157|Experimental|Isavuconazonium sulfate IV solution then capsules|Participants will first receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 2.
10185505|NCT03745014|Active Comparator|Standard of Care|
9669590|NCT03806283||Cohort 2 mild or severe Preeclampsia|Cohort 2: 26 mothers with diagnosis of mild or severe preeclampsia during pregnancy (13 male, 13 female neonate) Omental Biopsy and placental collection will be performed
9826234|NCT02412761|Active Comparator|HCTZ, then Amlodipine, then Lisinopril|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
10185506|NCT03745001|Experimental|Single dose study part|there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
9826235|NCT02412761|Active Comparator|HCTZ, then Lisinopril, then Amlodipine|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
9971982|NCT01316107|Experimental|ASP group|Concomitant administration of ASP1941 and nateglinide
9977175|NCT01358916|No Intervention|Usual information policy|No specific intervention
9977176|NCT01358916|Other|Antibiotic therapy guidelines|
9977177|NCT01358929|Experimental|1|
10150441|NCT04096157|Experimental|Isavuconazonium sulfate capsules then IV solution|Participants will first receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 2.
10150442|NCT04096144|Experimental|Neostigmine|This is the standard Neuromuscular reversal drug that has been in standard care for the past thirty years. Dose: -Neostigmine: 0.03-0.07 mg/kg by intravenous route.
9971983|NCT01316120|Experimental|HPV Dry first|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
10150443|NCT04096144|Experimental|Sugammadex|"Used for Neuromuscular reversal; Sugammadex is devoid of the parasympathetic effects caused by Neostigmine.~Dose: -Sugammadex: 2-4 mg/kg (4 mg/kg if no twitch responses after initial stimulation), intravenous route."
10150444|NCT04096131||SURGERY|subjects with early DME undergoing cataract surgery
10150445|NCT04096131||OBSERVATION|subjects with early DME
10150446|NCT04095949|Experimental|Artichokes|1 day of artichokes intake
10150447|NCT04095962|Experimental|Experimental Group|Training protocol will be held for 6 months, twice per week/ 60 min per sessions.
10150448|NCT04095962|No Intervention|Control Group|Participants in the control group will receive monthly sessions regarding physical activity and health related topics as a complement to standard care. No specific exercise intervention will be conducted for this group.
10150449|NCT04095884||Urinary Tract Infection|"Inclusion criteria (one from the list below):~Positive leukocytes, positive nitrites on dipstick~Negative leukocytes, Positive nitrites on dipstick~Positive leukocytes, negative nitrites, plus bacteriuria on microscopy~Positive leukocytes, negative nitrities plus no bacteriuria, only pyuria on microscopy PLUS clinical features e.g. fever, pain on urination, offensive smelling urine.~Exclusion criteria (one from the list below):~1. No evidence of UTI on dipstick"
10150450|NCT04095884||Upper respiratory tract infection|"Inclusion criteria (one from the list below)::~Evidence of nasal discharge AND/OR~Inflammation throat/ tonsils on direct examination AND/OR~Inflammation of middle or outer ear on direct examination~History of fever AND history of stridor/ barking cough~History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e sore throat/ cough~Exclusion criteria (one from the list below)::~Foreign body inserted in either nose/ ear~Traumatic perforation of ear drum~Allergic rhinitis i.e. good contact history~Evidence of LRTI"
10150451|NCT04095884||Lower respiratory tract infection|"Inclusion criteria (one from the list below):~Focal signs on auscultation of the chest i.e crepitations/ wheeze/ reduced air entry~Fever > 38.5C AND chest recessions AND/OR raised respiratory rate~Radiological evidence of LRTI~Exclusion criteria (one from the list below):~1. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever"
10150452|NCT04095884||Diarrhoea/ gastroenteritis|"Inclusion criteria (one from the list below):~Abrupt onset of 3 or more loose/liquid stools/ day~Ova, cysts, parasites identified on stool microscopy PLUS symptomatic diarrhoea,and/ or fever and/or vomiting~Fever AND vomiting WITHOUT other source of fever i.e UTI/LRTI/URTI~Exclusion criteria (one from the list below):~Normal breast milk stool~Neurological cause of vomiting"
10150453|NCT04096183|Other|Ventilation of healthy volunteers|
10150454|NCT04096014|Active Comparator|Ensure Enlive|
10150455|NCT04096014|Placebo Comparator|Standard of Care|
10150456|NCT04095754|Other|Group I (control group)|Patients will be positioned supine.
10150457|NCT04095754|Experimental|Group II|patients will be positioned 10° anti-trendelenburg position.
10150458|NCT04095754|Experimental|Group III|patients will be positioned 20° anti-trendelenburg position.
10150459|NCT04095715||Children and adults with unexplained hemorrhagic syndrome|Patients with spontaneous or induced hemorrhagic manifestations who are present for a consultation to investigate a thrombopathy or during follow-up consultations as part of their usual care.
10150460|NCT04095728|Experimental|Investigational Product|
10150461|NCT04095728|Placebo Comparator|Placebo|
10150462|NCT04095819|Experimental|Middle Meningeal Artery Embolization|Middle Meningeal Artery Embolization
10150463|NCT04095819|Active Comparator|Traditional Surgery|Craniotomy/Burr hole
10150464|NCT04095897||conventional analgesic therapy|Patient underwent mastectomy with conventional analgesic therapy
10150465|NCT04095897||Pecs II block|Patient underwent mastectomy with conventional analgesic therapy with pre induction Pecs II block
10150466|NCT04095910|Experimental|Planet Nutrition program|multidisciplinary school- based program
10150467|NCT04095910|No Intervention|Control Group|Normal curricular classes
10150468|NCT04096105|Experimental|CC-93538 in Japanese subjects|Twenty-four Japanese subjects will be randomized into 1 of 2 dose levels in a 1:1 fashion so that 12 subjects will receive a 180 mg or 360 mg dose via SC injection.
10150469|NCT04096105|Experimental|Administration of CC-93538 in Caucasian subjects|Twenty-four Caucasian subjects will be matched to Japanese subjects by weight (± 20%) and receive a 180 mg or 360 mg dose via SC injection
10150470|NCT04095767|Experimental|Treatment arm|The thrombectomy in eligible patients will be carried out by making use of the device under investigation.
10150471|NCT04095936|Experimental|AMG531|
10150472|NCT04095988|Experimental|Verum-AMR|Patients receiving Verum-Allogeneic Microbiota Reconstitution via gastroscopy
10150473|NCT04095988|Placebo Comparator|Placebo-AMR|Patients receiving Placebo(Saline)-Infusion via gastroscopy
10150474|NCT04096053|Experimental|TEACHH|The training workshop is designed as a 3-hour session for care providers. The training will be delivered by trans women. During this training, we plan to have providers: 1) discuss human rights for trans women; 2) teach providers about common words with which to discuss gender identity and expression, and develop a basic understanding of trans healthcare, HIV prevention, and HIV treatment, and how these types of healthcare affect trans women living with and affected by HIV; 3) discuss what it means to be trans-affirming in their work and how they can make their organizations more trans- affirming; and 4) have participants complete a case study to apply what they have learned to practice. These case studies will address issues affecting trans women who are immigrants/newcomers, trans women who are living with HIV, and trans women who experience other vulnerabilities.
10150475|NCT04096027|Experimental|Early administration|Cabergoline administered the day before egg collection.
10150476|NCT04096027|Experimental|Late administration|Cabergoline administered after egg collection.
10150477|NCT04095832||Parturients with preeclampsia|Parturients who were diagnosed with preeclampsia
10150478|NCT04095832||Healthy parturients|Healthy full-term parturients
10150479|NCT04095481||Obalon NTS|Patients who commercially purchased the NTS Compatible Obalon Balloon System
10150480|NCT04095533||Sepsis|"Starting at admission to ICU, patients admitted to a mixed medical-surgical ICU will be assessed every second day to determine their muscle size as measured by ultrasound, and their muscle strength as measured clinically using the Medical Research Council strength assessment at the bedside.~One-time Measures:~Illness severity as measured by the SOFA score within the first 24 hours of admission.~duration of mechanical ventilation~duration of stay in the ICU~duration of stay in the hospital"
10150481|NCT04095702|Experimental|Weighted Pacifier|Patient will receive a weighted pacifier for 48 hours of their stay in the NICU.
10150482|NCT04095702|Placebo Comparator|Non-Weighted Pacifier|Patient will receive a standard non-weighted pacifier for 48 hours of their stay in the NICU.
10150483|NCT04095780|Experimental|Advanced oral hygiene care programme|Patients with stroke will receive the advanced oral hygiene care programme (AOHCP) comprising powered tooth brushing and mouth rinsing with chlorhexidine (with a supply of standardized power tooth brushes, mouth rinse, tooth paste and oral hygiene instruction).
10150484|NCT04095780|Experimental|Oral hygiene instruction|Patients with stroke will only receive the oral hygiene instruction.
10150485|NCT04095650|Experimental|Intervention|Participants will engage in a 7-week chronic pain self-management program.
10150486|NCT04095585||Patients presenting with WBS and ASD|patients with WBS and ASD. The diagnosis of WBS was confirmed by fluorescent in situ hybridization. All patients met formal ASD criteria.
10150487|NCT04095611|Experimental|SPAIRE|hemiarthroplasty surgery, the muscle-sparing modification of the posterior approach (SPAIRE).
10150488|NCT04095611|Active Comparator|LATERAL|hemiarthroplasty surgery, the standard lateral approach
10150489|NCT04095624|Experimental|Opioid Taper Group|Patients randomized to the taper group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive a scheduled tapering protocol, with a goal of 10-15% reduction in their weekly opioid use, along with weekly phone calls from a study coordinator assessing their ability to taper and pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
10150490|NCT04095624|Active Comparator|Control Group|Patients randomized to the control group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive no recommendation or guidance in their preoperative opioid pain medication use, but will received weekly phone calls from a study coordinator assessing their preoperative pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
10150491|NCT04095195||Familial pancreatic cancer relatives|
10150492|NCT04095195||Peutz-Jeghers syndrome|
10150493|NCT04095195||BRCA 1/2, PALB2, p16 mutations with familiarity for PC|Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC
10150494|NCT04095195||Lynch syndrome with familiarity for pancreatic cancer|
10150495|NCT04095195||FAMMM syndrome|
10150496|NCT04095195||Hereditary and genetic pancreatitis|
10150497|NCT04095234|Experimental|Acupuncture|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
10150498|NCT04095234|Active Comparator|Massage|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
10150499|NCT04095312|Experimental|pancreaticobiliary disease|10 pancreaticobiliary disease cases
10150500|NCT04095312|Experimental|Urinary tract disease|13 urinary tract disease cases
9977178|NCT01358929|Placebo Comparator|2|
10150501|NCT04095312|Experimental|Colon disease|10 colon disease cases
10150502|NCT04095338|Active Comparator|control group|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks
10150503|NCT04095338|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks.
10150504|NCT04095338|Experimental|robotic treadmill arm|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks.
9977179|NCT01358942||Cohort|
10150505|NCT04095390|Experimental|Arm A|Hormone receptor positive,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Letrozole until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10150506|NCT04095390|Experimental|Arm B|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Capecitabine until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10150507|NCT04095390|Experimental|Arm C|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10150508|NCT04095468||Resectable rectal cancer|
10150509|NCT04095468||Rectal cancer with threatened mesorectal fascia|
10150510|NCT04095507|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
10150511|NCT04095455|Active Comparator|pectoral nerves block group|modified pectoral nerves block was performed on the side of surgery
9519840|NCT03282890|Experimental|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
9971984|NCT01316120|Experimental|HPV standard transport medium|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
9971985|NCT01316133|Experimental|Tacrolimus group|Oral
9971986|NCT01316172|Experimental|5 Cs|Educational intervention
9971987|NCT01316172|No Intervention|Control|
9971988|NCT01316185|Experimental|Group 1|Low Dose for 28 days: n=4
9971989|NCT01316185|Experimental|Group 2|High Dose for 28 days; n=4
9971990|NCT01316198|Experimental|Lutein and zeaxanthin|
9971991|NCT01316198|Experimental|Placebo|
9971992|NCT01316237|Other|Cohort 1|(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2) 50 mg GS-6620 or placebo QD in the morning with food [total daily dose (TDD) = 50 mg] for 5 days
9971993|NCT01316237|Other|Cohort 2|"(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS-6620 or placebo QD in the morning with food (TDD = 100 mg) for 5 days"
9971994|NCT01316237|Other|Cohort 3|"Cohort 3 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning with food (TDD = 300 mg) for 5 days"
9971995|NCT01316237|Other|Cohort 4|"Cohort 4 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS 6620 or placebo QD in the morning without food (TDD = 100 mg) for 5 days"
9971996|NCT01316237|Other|Cohort 5|"Cohort 5 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning without food (TDD = 300 mg) for 5 days"
9971997|NCT01316237|Other|Cohort 6|"Cohort 6 (N = 10, genotype 2 or genotype 3): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo QD in the morning without food (TDD = 900 mg) for 5 days"
9971998|NCT01316237|Other|Cohort 7|"Cohort 7 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~450 mg GS 6620 or placebo, administered BID with food (TDD = 900 mg) for 5 days"
9971999|NCT01316237|Other|Cohort 9|"Cohort 9 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo BID in the with food (TDD = 1800 mg) for 5 days"
9972000|NCT01316237|Other|Cohort 11|"Cohort 11 (N = 10, genotype 1 : (Active drug: 8, Matching Placebo: 2)~Up to 450 mg GS-6620 or placebo as an oral solution, BID, 12 hours apart in the fasted state, 2 hours after a meal (up to TDD = up to 900 mg) for 5 days."
9972001|NCT01316328||BC patients after SSPBI|breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery
9661884|NCT03667404|Placebo Comparator|Maltodextrin|Maltodextrin 25g for days 1-7 and 50 g for days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
9972002|NCT01316354|Experimental|Beta-glucan|Bread with purified beta-glucan
9972003|NCT01316354|Experimental|Rye kernels|Rye bread with kernels
9972004|NCT01316354|Experimental|White bread|White bread
9972005|NCT01316354|Experimental|Arabinoxylan|Bread with Purified arabinoxylan
9972006|NCT01316367|Active Comparator|Conventional Health Promotion Education (CHPE).|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
9972007|NCT01316367|Experimental|PRECEDE HPE model|
9972008|NCT01316393|Experimental|XER2020|mucoprotective product
9972009|NCT01316393|Active Comparator|Saliva Natura|salivary substitute
9972010|NCT01316393|Placebo Comparator|XER2020 placebo|
9972011|NCT01316406|Experimental|ATH008 cream 3%|ATH008 cream 3%
9972012|NCT01316406|Experimental|ATH008 cream 8%|ATH008 cream 8%
9972013|NCT01316406|Placebo Comparator|ATH008 cream placebo|ATH008 cream placebo
9972014|NCT01316432|Experimental|SQ Bolus Cenderitide|
9972015|NCT01316432|Experimental|SQ Infusion Cenderitide|24 hour SQ infusion of cenderitide
9972016|NCT01316432|Placebo Comparator|Placebo|24 hrs of SQ placebo infusion
9972017|NCT01316445|Experimental|nasal Midazolam|3 mg of the standard IV solution of midazolam (5 mg/mL) was given via a metered-dose nasal sprayer (6 sprays × 0.1 ml/spray, or 6 × 0.5 mg/spray) divided between the two nostrils within 1-2 min. During the EEG, vital signs (blood oxygen saturation, blood pressure, pulse and respiratory rate) were monitored and a nurse and a physician were available at all times. Subjects were monitored for 2 hours after administration of midazolam to ensure adequate recovery from sedation.
9972018|NCT01316458|Experimental|imatinib mesylate|
9972019|NCT01316471|Experimental|Online Behavioral Intervention|In addition to standard medical care, children and parents in the online behavioral intervention will receive access to the full web-based program including education about chronic pain, training in behavioral and cognitive coping skills, instruction in increasing activity participation, and education about pain behaviors and parental operant strategies using an engaging, interactive format on the Internet.
9972020|NCT01316471|Active Comparator|Online Patient Education|The Online Patient Education group will serve as an attention control condition. In addition to standard medical care, children and parents will be provided with access to a modified version of the study website that will provide information from publicly available educational websites about pediatric chronic pain management.
10150512|NCT04095455|Active Comparator|Ktamine plus Magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump
10150513|NCT04095455|Active Comparator|Control Group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo
10150514|NCT04095182|Experimental|Zebinix 400mg|
9972021|NCT01316484||No Treatment|Adult subjects with diabetes mellitus and a diagnosis of gastroparesis
10150515|NCT04095182|Placebo Comparator|Placebo for Zebinix 400mg|
10150516|NCT04095182|Experimental|Zebinix 800mg|
10150517|NCT04095182|Placebo Comparator|Placebo for Zebinix 800mg|
10150518|NCT04095182|Experimental|Zebinix 1600mg|
10150519|NCT04095182|Placebo Comparator|Placebo for Zebinix 1600mg|
10150520|NCT04095299|Active Comparator|A: Standard chemoradiotherapy|50.4 Gy to the tumor and elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays.
10150521|NCT04095299|Experimental|B: High-dose radiotherapy|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays
10150522|NCT04095325|Active Comparator|transversus abdominis plane block|Group 1 (n: 50): those who underwent TAP block after induction of propofol atropine and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
10150523|NCT04095325|Active Comparator|erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
10150524|NCT04094987|Experimental|Quadratus Lumborum block|We will use the ultrasound guided anterior Quadratus Lumborum Block.A peripheral nerve block catheter will be placed between the quadratus lumborum muscle and the psoas muscle with ultrasound
10150525|NCT04094896|Experimental|Arm A: TCHP|docetaxel/carboplatin/trastuzumab/Pertuzumab
10150526|NCT04094896|Active Comparator|Arm B: EC-THP|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab
10150527|NCT04095169||axSpA|Patients with low back pain ≥three months who a) fulfilled the ASAS definition for a positive MRI scan of sacroiliac joints (definite inflammation) or b) were HLA-B27 positive with at least one concomitant clinical spondyloarthritis feature.
10150528|NCT04095169||non-axSpA|Patients with a) positive MRI according to the ASAS definition, but no additional clinical spondyloarthritis features, or b) positive HLA-B27 and one clinical spondyloarthritis feature.
10150529|NCT04095169||Controls|Patients with non-specific low back pain without spondyloarthritis-related features and negative MRI SIJ.
10150530|NCT04094831|Active Comparator|Intervention arm|Intervention group (Health education through CKD campaign and mHealth) technology
10150531|NCT04094831|Active Comparator|Control|No intervention
10150532|NCT04094948|Experimental|clenbuterol|The initial dose of clenbuterol will be 40 mcg per oral each morning for one week, followed by 40 mcg twice per day (BID) for the next 5 weeks until Week 6. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5 weeks until the Week 12 visit. If 80 mcg BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
10150533|NCT04094948|Placebo Comparator|placebo|Initially, one capsule each morning for one week, followed by one capsule BID for the next 5 weeks until Week 6. If tolerated, the dose will be increased to two capsules each morning and 1 capsule each evening for one week, followed by two capsules BID for the next 5 weeks until the Week 12 visit. If two capsules BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
10150534|NCT04094922|Experimental|Intervention|Free access to the Swedish PTSD Coach smartphone app for three months.
9826236|NCT02412761|Active Comparator|Lisinopril, then Amlodipine, then HCTZ|Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
10150535|NCT04094922|No Intervention|Waitlist|Delayed access to the Swedish PTSD Coach smartphone app. Access is given after post-intervention data collection at three months.
10150536|NCT04095000|Experimental|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
10150537|NCT04095000|Active Comparator|Treatment As Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
10150538|NCT04095013|Experimental|Group BF|hyperbaric Bupivacaine 10mg with fentanyl 10micrograms
9972022|NCT01316497|Experimental|Remote ischemic preconditioning (RIPC)|See intervention description
9972023|NCT01316497|Placebo Comparator|Control|
10150539|NCT04095013|Experimental|Group BD|hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
10150540|NCT04095065|Experimental|itMatters|Participants will have access to content focused on general knowledge and injunctive and descriptive norms for a period up to 3 weeks.
10150541|NCT04095065|Experimental|itMatters and itMatters Sexual Violence Prevention|Participants will have access to content focused on general knowledge and injunctive and descriptive norms related to alcohol use and sex. Additionally, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
10150542|NCT04095065|Experimental|itMatters Well-being and itMatters Sexual Violence Prevention|Participants will have access to content focused on basic information related to sleep wellness and time management. In Addition, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
10150543|NCT04095065|Experimental|itMatters Well-being|Participants will have access to content focused on basic information related to sleep wellness and time management. This content will be available for a period up to 3 weeks.
10150544|NCT04094779|Active Comparator|Usual relational care|Isolate the patient from the group of other patients in order to propose to him a a relationship dual with the caregiver to the aim to calm the agitation
10150545|NCT04094779|Experimental|"Flash activity breath of fresh air"|Isolate the patient from the group of other patients in order to propose to him in a relationship dual with the caregiver a physical activity outside the service that promotes relaxation by focusing his attention to the environment during 15 minutes
10150546|NCT04094805|Active Comparator|Rocaltrol Combining HD-DXM|Rocaltrol 0.25 μg once per day, 1 month; HD-DXM (orally at 40 mg daily for 4d )
10150547|NCT04094805|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
10150548|NCT04094909|Experimental|Rh-endostatin + chemotherapy+Pembrolizumab|The subjects are 186, including Squamous and Non-Squamous NSCLC. Squamous NSCLC receives rh-endostatin at a dose of 15mg/m2 for 5 days and 200 mg of pembrolizumab at day 1 in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. all the patients with squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and [nab]-paclitaxel (100mg/m2) for the first 4 cycles. For non-squamous NSCLC, rh-endostatin at dose of 15mg/m2 for 5 days, 200 mg of pembrolizumab at day 1 and pemetrexed (500mg/m2,d1) are given in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. Non-squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and pemetrexed (500mg/m2,d1) for the first 4 cycles.
10150549|NCT04095130||Healthy subjects|those without a condition
10150550|NCT04095130||Psoriasis patients|those with a condition
10150551|NCT04094740|Experimental|Needle-free Jet Injector|Subjects will be instructed to use a needle-free syringe to inject insulin during the study period. The dosage and frequency of insulin are determined by the responsible physician according to the patient's condition.
10150552|NCT04094740|No Intervention|Conventional Insulin Pen|Patients allocated to the control group will be instructed to use conventional insulin pens to inject insulin. Except for the syringe, all of them are the same as the experimental group.
9519841|NCT03282890|No Intervention|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
9977797|NCT01365286|Active Comparator|Ivabradine-Placebo|
10150553|NCT04094740|No Intervention|Routine Care|Subjects can receive the education provided by health-care professionals and training in the outpatient department and inpatient departments.
10150554|NCT04094727|Experimental|Presumptive treatment and enhanced vector control|"For all eligible HRPs in intervention areas, after obtaining informed consent, presumptive treatment for malaria will be carried out using artemether-lumefantrine (AL) at two time points.~Enhanced vector control activities will include: (1) a mop up indoor residual spraying (IRS) campaign and (2) distribution of long-lasting insecticide-treated nets (LLINs) and/or vector control packs with topical repellent.~The intervention arm will also receive the standard of care in Namibia."
10150555|NCT04094727|No Intervention|Standard of care|The control arm will receive the standard of care in Namibia: passive case detection through health facilities and health extension workers, routine indoor residual spraying (IRS), and reactive case detection (RACD) accompanied by reactive IRS.
10150556|NCT04094857|Experimental|HBN-1 Plus Standard of Care|Subjects will receive an intravenous loading dose of HBN-1 followed by a 12 hour maintenance infusion plus standard of care targeted temperature management
10150557|NCT04094857|No Intervention|Standard of Care|Subjects will receive standard of care targeted temperature management only
10185507|NCT03745001|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
10185508|NCT03744988||control group|serum androgen levels will be measured in 25 normotensive pregnant women
10185509|NCT03744988||mild preeclampsia|serum androgen levels will be measured in 25 mild preeclamptic patients
10185510|NCT03744988||severe preeclampsia|serum androgen levels will be measured in 25 severe preeclamptic patients
10185511|NCT03744949|Experimental|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
10185512|NCT03744949|Experimental|Remifentnil dose 1 ug/kg|Remifentanil will be given (dosage of 1.0 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
10185513|NCT03744949|Experimental|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
10185514|NCT03744949|Experimental|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
10150558|NCT04094766|Experimental|BLLCAR-L10D treatment group|In BLLCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 2.0×10^6 CAR-T cells/kg.
10150559|NCT04094584|Experimental|Multimodal Intervention|"The intervention is multimodal and consists of:~Intramuscular injections of 380mg extended-release Naltrexone, given once monthly for 6 months.~Case Management services~Access to telemedicine counseling services to be used as needed by study participants."
10150560|NCT04094571|Experimental|Healthy Individuals and those with Movement Disorders|Participants will perform the FES cycling protocol along with the FES angle protocol.
10150561|NCT04094649|Sham Comparator|Sham vs Active Stimulation Positions|Adults with Diabetes Mellitus Type 2 (DMT2) will be recruited and randomized to active uVNS or sham across two sessions according to a 2x2 crossover design. Sham uVNS will be delivered with the same stimulation parameters as active uVNS, but will be targeted to the left sternocleidomastoid muscle ~2 cm away from the vagus nerve.
10150562|NCT04094649|Active Comparator|Active uVNS|Active stimulations will be targeted with the ultrasound beam of the DECIMA device .Active uVNS will be delivered to the left cervical vagus nerve following the OGTT through the 60-min time point.
10150563|NCT04094597|Placebo Comparator|placebo|saline is given orally in dose of 2 ml per day for one month
10150564|NCT04094597|Active Comparator|lacoferrin|Pravotin is given orally 100 mg per sachet dissolved in 5 ml water given for one month
10150565|NCT04094636|No Intervention|No intervention: Control|Control group
10150566|NCT04094636|Experimental|In-bed cycling|Supervised in-bed cycling
10150567|NCT04094636|Experimental|Exercise booklet|Supervised physical training with exercises from exercise booklet
10150568|NCT04094454|Experimental|Tampon with extended vaginal dilatation|Patients in arm A will use a special tampon with extended vaginal dilatation during radiotherapy
10150569|NCT04094454|Active Comparator|Commercially available tampon|Patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
10150570|NCT04094532|Active Comparator|ultrasound guided transverse thoracic muscle plane block|
10150571|NCT04094532|Sham Comparator|ultrasound guided sham block|
9972024|NCT01316536|Experimental|With Music|This randomized group will receive music
10150572|NCT04094467|Experimental|Study group|"the antagonist protocol group where they will do intra-cytoplasmic injection using classical antagonist protocol"
10150573|NCT04094467|Active Comparator|control group|"agonist stop/antagonist protocol group where they will receive mid luteal agonist in the preceding intra-cytoplasmic injection cycle before starting classical antagonist protocol"
10150574|NCT04094493|Experimental|A1|vit D + no hypocalcemia
10150575|NCT04094493|Experimental|A2|Vit D + hypocalcemia
10150576|NCT04094493|No Intervention|B1|NO vit D + no hypocalcemia
10150577|NCT04094493|No Intervention|B2|NO vit D + hypocalcemia
10150578|NCT04094701|Placebo Comparator|Control Group|"Control Group will receive the following pain medication regimen:~- Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
10150579|NCT04094701|Experimental|Experimental Group - Opioid Reduced|"Experimental - opioid reduced: 50% less oxycodone relative to control group~Tylenol extra strength (1000 mg, three times daily for 10 days following surgery)~Gabapentin (300 mg at night for 10 days following surgery)~Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills~The following non-opioid medications are standard of care at our practice following hip arthroscopy and, thus, will be prescribed to patients regardless of the group they are randomized to: aspirin (325 mg, two times daily for 30 days) and Indocin (75 mg extended release, one time daily for 10 days)."
10150580|NCT04094623|Experimental|NSSI-DBT|Dialectical behavior therapy, 2 hours every week for 13 weeks.
10150581|NCT04094623|Active Comparator|NSSI-SSGT|Social support group therapy, 2 hours every week for 13 weeks.
10150582|NCT04094350|Experimental|ACF with a seed-and-recruit model|Active case finding with a seed-and-recruit model to be implemented by KHANA. Target group: key populations for TB (people living with HIV, TB contacts, people with diabetes, people who use/inject drugs) and presumptive TB cases
10150583|NCT04094350|Experimental|ACF targeting household and neighborhood contacts|Active case finding targeting household and neighborhood contacts to be implemented by CENAT. Target group: household contacts, immediate neighbors of people diagnosed with TB in the last 2 years, and other presumptive TB cases
10150584|NCT04094350|Experimental|ACF targeting the older population|Active case finding targeting the older population (people aged 55 and older) using mobile screening units to be implemented by CATA. Target group: elderly above age of 55 and other presumptive TB cases
10150585|NCT04094350|No Intervention|Passive case finding|Passive case finding strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
10150586|NCT04094376|Other|Day group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00)
9972025|NCT01316536|Placebo Comparator|Control Arm|Will not receive music but will receive audio loop of recorded ICU sounds
9977798|NCT01365286|Active Comparator|Placebo-Ivabradine|
10150587|NCT04094376|Other|Night group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
10150588|NCT04094337|Experimental|Internet-assisted treatment|The intervention group will receive internet-assisted treatment comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
10150589|NCT04094337|No Intervention|Control group|The control group will receive treatment as usual, which is no specific treatment. The control group can however use the general health system as they like.
10150590|NCT04094363|Experimental|Product usage order ABCD|Subjects will use each of the 4 products (ABCD) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
10150591|NCT04094363|Experimental|Product usage order BDAC|Subjects will use each of the 4 products (BDAC) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
10150592|NCT04094363|Experimental|Product usage order CADB|Subjects will use each of the 4 products (CADB) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
10150593|NCT04094363|Experimental|Product usage order DCBA|Subjects will use each of the 4 products (DCBA) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
10150594|NCT04094389|Experimental|Orthotic continuous wear group|Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance.
10150595|NCT04094389|Experimental|Orthotic wear during waking hours only group|Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping.
10150596|NCT04094389|Experimental|Orthotic wear only while sleeping group|In the night-wear group, participants will be told to wear their orthosis only at night.
10150597|NCT04094324||Children and youth at obesity clinic|Children 11-18 who are patients at obesity clinics in region Skåne SUS.
10150598|NCT04094324||Children and youth at a pediatric gastrointestinal clinic|Children 11-18 who are patients at a gastrointestinal clinic i region Skåne SUS.
9826237|NCT02412761|Active Comparator|Lisinopril, then HCTZ, then Amlodipine|Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
10150599|NCT04094480|Active Comparator|endoloop ligation|securing appendicular base with endoloops
10150600|NCT04094480|Active Comparator|non absorbable polymeric clips|securing appendicular base with non absorbable polymeric clips
10150601|NCT04094129|Placebo Comparator|Placebo|Subjects received two placebo sachets per day
10150602|NCT04094129|Experimental|Probiotic|Subjects received two Wismemo sachets with 1x10^10 cfu/day
10150603|NCT04094233|Experimental|Beetroot Extract|Capsule containing 600mg of beetroot extract.
10150604|NCT04094233|Experimental|Placebo|Capsule containing 600mg of starch.
10150605|NCT04094272||Chronic hepatitis C participants|Participants with a newly started DAA medication for HCV infection were included in the study.
9826238|NCT02412852|Placebo Comparator|Placebo|One placebo tablet administered twice daily for 12 weeks.
9826239|NCT02412852|Active Comparator|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
10150606|NCT04094428||Intensive care unit patient|All intensive care unit patients staying for at least 72 hours on the ICU and patients dying within 72 hours
10150607|NCT04093960|Experimental|escitalopram plus128|escitalopram (10 mg daily) plus PS128(a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily)
10150608|NCT04093960|Active Comparator|escitalopram|10 mg/d of escitalopram
10150609|NCT04094077|Experimental|Aguix + Stereotactic Radiation|
10150610|NCT04093908||multi-center validation cohort|We collect retrospective data from several international centers containing preoperative variables (demographical and clinical) and postoperative outcome (UPDRS II, III, IV) one year postoperatively, and merge these data to one validation cohort.
10150611|NCT04093973||MAC subjects|Outpatients with moderate to severe mitral annular calcification on echocardiogram who are able to perform supine bicycle exercise.
10150612|NCT04093973||Controls|Sex matched individuals who are within 5 years of age of the paired MAC subject and who have the same left ventricular wall thickness as measured by echocardiography.
9519842|NCT03282877|Experimental|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
9826240|NCT02412852|Placebo Comparator|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
9826241|NCT02412852|Active Comparator|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
10150613|NCT04094116|Active Comparator|ear wax syringing with pre ear oil treatment|patients in Fanling Family Medicine Centre with ear wax will be given ear oil one week before performing ear syringing.
10150614|NCT04094116|Sham Comparator|ear wax syringing without pre ear oil treatment|Patients in Wong Siu Ching Clinic and Tai Po Clinic who are found to have ear wax after physical examination will have ear syringing done, without pre-ear oil application.
10150615|NCT04093999||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction with additional sensory nerve coaptation.
9519843|NCT03282877|No Intervention|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
9972026|NCT01316549||Inpatient Pediatric Bone Marrow Transplant Recipients|All patients enrolled in this study will be located on the inpatient pediatric bone marrow transplant unit at University of California, San Francisco Benioff Children's Hospital.
9972027|NCT01316562||Group 1|Healthy controls
10150616|NCT04093999||Noninnervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction without sensory nerve coaptation.
10150617|NCT04094220|Experimental|Lateral lumbar interbody fusion|Patients in this group received lateral lumbar interbody fusion alone. Patients who suffered residual neurologic symptoms postoperatively will received conservative treatment for at least 3 months.Patients were considered to have unsuccessful indirect decompression if they had less than 20% improvement according to the Oswestry Disability Index (ODI) by 3 months postoperatively.
10150618|NCT04094220|Experimental|Lateral lumbar interbody fusion plus posterior decompression|Patients in this group received lateral lumbar interbody fusion plus posterior decompression.
10150619|NCT04094168|Experimental|Del Nido Cardioplegia solution|1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed.
10150620|NCT04094168|Active Comparator|Cold blood Cardioplegia solution|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.
10150621|NCT04094090|Experimental|Pulsed, accelerated|4 mW, 10 sec on, 10 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
10150622|NCT04094090|Experimental|Pusled, accelerated|8 mW, 10 sec on, 10 sec off, 11.25 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
10150623|NCT04094025|Experimental|dATS patch|dATS, placebo and saline will be administered simultaneously
10150624|NCT04094142|Experimental|Treatment arm|"Acalabrutinib is provided as hard gelatin capsules for oral administration. Acalabrutinib 100 mg will be administered approximately every 12 hours from day 1 to day 28 Rituximab is provided as single-use vials for intravenous administration only. Rituximab 375 mg/m2 will be administered on day 1.~Lenalidomide is provided as opaque hard capsules for oral administration. Lenalidomide 20 mg will be administered once daily from day 1 to day 21"
10150625|NCT04094155|Experimental|Retinal fundoscopy|Retinal vascular analysis by retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
10150626|NCT04094038|Experimental|Intervention|Intradialytic parenteral nutrition three times weekly during 16 weeks
10150627|NCT04094038|Placebo Comparator|Placebo|5% glucose three times weekly during 16 weeks
10150628|NCT04093895|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept® drug administration
10150629|NCT04093804|Active Comparator|32mm Glenosphere|The control group will receive the standard 32mm glenosphere.
10150630|NCT04093804|Experimental|36mm Glenosphere|The experimental group will receive a 36mm glenosphere.
10150631|NCT04093791|Experimental|"Collective Intervention G"|"HAPPY MAMA intervention will follow the following steps: listening and establishing relationship phases; analysis of the problems; definition of the problem and the goal of intervention.~The duration will be of 3.5 hours in one day and the intervention will happen in Sapienza University of Rome, in a group of 15 women.~This group fill in an on line questtionarie for four times, the first before the intervention."
10150632|NCT04093791|Experimental|"Individual Intervention I"|"The same intervention of G group (HAPPY MAMA), but at individual level and the intervention will happen at the participants' house.~This group fill in an on line questtionarie for four times, the first before the intervention."
10150633|NCT04093791|No Intervention|"Control group C"|The women from this group will not receive any intervention. This group fill in an on-line questtionarie for four times.
10150634|NCT04093778|Experimental|SDA intervention|Low dose high frequency training of all health workers in maternity and pediatric ward and dissemination of a Safe Delivery Application
10150635|NCT04093830|Experimental|pre-lingually deafened children with cochlear implant|pre-lingually deafened children with cochlear implant who continuously used bimodal hearing.
10150636|NCT04093518|Active Comparator|Active Comparator|Estradiol 200µg
10150637|NCT04093518|Placebo Comparator|Placebo Comparator|Placebo
10150638|NCT04093622||Genetically engineered NK Cell - treated|Long term follow-up of subjects who have received lentivirus-mediated genetically engineered NK Cells.
10150639|NCT04093505|Experimental|GO147_G|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
10150640|NCT04093505|Placebo Comparator|GO147_P|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
10150641|NCT04093505|Experimental|GO1_G|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
10150642|NCT04093505|Placebo Comparator|GO1_P|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
10150643|NCT04093531|Experimental|Ustekinumab|All subjects will receive an intravenous loading dose of 6 mg/kg at their baseline visit. 650mg acetaminophen and 60mg allegra will be given as premedication to the infusion. All patients will receive 90mg ustekinumab by a subcutaneous injection at all subsequent dosing visits. Subcutaneous injections do not require any premedication. Drug will be administered by qualified personnel.
10150644|NCT04093609||cases|
10150645|NCT04093609||control|
9972028|NCT01316562||Group 2|Patients with an Alzheimer's disease or related disorders
9972029|NCT01316588|Experimental|Plastic adesive drape|Intraoperative: Plastic adhesive drape on the chest and bare skin on the leg
10150646|NCT04093713|Other|participants|participants are subjected to a novel technique to block the inferior alveolar nerve depending on extraoral landmarks
10150647|NCT04093544|Active Comparator|Standard Stimulation|Participants will receive stimulation using the best contact combination in ring mode.
10150648|NCT04093544|Experimental|Directional Stimulation|Participants will receive stimulation using the best segmented (steered) contacts.
10150649|NCT04093635||Group I|Those patients that will be treated by NPWT.
10150650|NCT04093635||Group II|Those patients will be treated with standard saline moist wound care and dressing.
10150651|NCT04093583|Active Comparator|Simple suture|
10150652|NCT04093583|Experimental|PRGF-Endoret|
10150653|NCT04093687|Experimental|Intervention Arm|"The intervention will consist of one training session, focusing on technical and non-technical aspects identified in the study Phase I (according to the evaluation questionnaire). The training will be conducted by a team consisting of (i) supervisors (researchers) and (ii) teachers experienced in the previous trial (Train-Colonoscopy-Leaders course - TCL; this methodology has already been evaluated (citation)). There will be 7 trainees per session: 1 under-, 4 average and 2 overperformers.~The training session will be divided into two parts: theoretical and practical. During the first, theoretical part of the training, the body of research on the phenomenon of colonoscopy pain will be presented. The second, practical part of the training, will consist of a one-day session of 7 colonoscopies.~Each average and underperforming endoscopist who underwent training in the randomized phase will receive a written, customized feedback on his/her performance during the training session."
10150654|NCT04093687|No Intervention|Control Arm|The endoscopists in the control arm will not be informed about participation in the study and will receive only tailored feedback on adjusted painful colonoscopy rate (practice as usual). They will receive a reminder, that dedicated report on painful colonoscopy rate is provided in the Polish Colonoscopy Screening Program database and they will be monitored for endpoints through Polish Colonoscopy Screening Program database.
10150655|NCT04093440|Other|Observation|lifestyle modification: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
10150656|NCT04093674|Experimental|Clinical evaluation|Clinical periodontal parameters
10150657|NCT04093674|Experimental|Laser Doppler Flowmetry|Laser Doppler Flowmetry evaluation
10150658|NCT04093674|Experimental|Patient centered outcomes|Pain and discomfort/ Esthetics
10150659|NCT04093453|Placebo Comparator|Placebo + Fasting|Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
10150660|NCT04093453|Placebo Comparator|Placebo + Exercise|Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.
10150661|NCT04093453|Placebo Comparator|Placebo + Post-prandial|Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.
10150662|NCT04093453|Experimental|Propionate and Fasting|Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
10150663|NCT04093453|Experimental|Propionate and Exercise|Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.
10150664|NCT04093453|Experimental|Propionate and Post-prandial|Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.
10150665|NCT04093427|Active Comparator|softSTOPP active|
10150666|NCT04093427|No Intervention|softSTOPP inactive|
10150667|NCT04093817||on pump CABG|patients under going CABG with cardiopulmonary bypass machine
10150668|NCT04093817||off pump CABG|patients under going CABG without cardiopulmonary bypass machine
10150669|NCT04093726|Experimental|lollipop|
10150670|NCT04093726|No Intervention|control|
10150671|NCT04093648|Experimental|TEGAR T cells + Fludarabine and Cytoxan|GPC3-CAR (TEGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
10150672|NCT04093557|Active Comparator|Orton Score Cohort - High|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they score highly, they will receive an extended GoLytely bowel prep."
10150673|NCT04093557|Placebo Comparator|Prospective Orton Score Cohort - Low|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they do not score highly, they will receive a standard GoLytely (or Suprep) bowel prep."
9826242|NCT02412878|Experimental|Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone|"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
10150674|NCT04093557|Other|Retrospective Cohort (before Orton Score)|
10150675|NCT04093479||BMI, oxytocin|Repeteadly blood samples will be taken
10150676|NCT04093180|Experimental|Experimental group|Experimental group undergoing treatment course according to INRS
10150677|NCT04093180|Other|Control group|Wait-list delayed intervention. Control group continues usual activity and care while staying in the waiting list.
10150678|NCT04093089|Experimental|Test Group|
10150679|NCT04093089|Placebo Comparator|Control Group|
10150680|NCT04093193|Experimental|Debridement group|Patients receive routine post-operative debridement at their Day 6, 30 and 60 follow up appointments.
10150681|NCT04093193|No Intervention|Non Debridement Group|Patients will not receive debridement at any follow up visit after surgery. They will continue with saline irrigation.
10150682|NCT04093284|Experimental|Group A|The needle-free jet injector Continuous insulin therapy for 9 days, then changed to conventional insulin pen therapy for 9 days
9972030|NCT01316588|Experimental|Microbial Sealant|Intraoperative: Microbial Sealant on the leg and bare skin on the chest
9977180|NCT01358955|Active Comparator|Group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
10150683|NCT04093284|Experimental|Group B|The conventional insulin pen therapy for 9 days, then changed to needle-free jet injector Continuous insulin therapy for 9 days
10150684|NCT04093154|Experimental|Virtual Reality|Standard Care + VR VR applications introduced to the child or adolescent by the researcher before the procedure. Three VR applications were used in this study; riding a rollercoaster (Rilix VR), swimming with marine animals in underwater world (Ocean Rift) and exploring the forest though the eyes of woodland species (In the eyes of animal). Children/adolescent chose one of these three applications. When the child is ready for the procedure, the researcher started the application by wearing virtual glasses to the child/adolescent. VR intervention was started 2-3 min before the procedure and continued until the procedure was completed.
10150685|NCT04093154|No Intervention|Control|Standart Care Control group children did not receive any distraction techniques.
10150686|NCT04093141|Experimental|Intervention|
10150687|NCT04093102||cases|cases with obsrtuctive sleep apnea
10150688|NCT04093102||control|cases without obstructive sleep apnea.
10150689|NCT04093206|Experimental|EpiCor and Vitamin C|EpiCor (90mg/5ml) and Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
10150690|NCT04093206|Active Comparator|Vitamin C|Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
9669591|NCT03799341|Experimental|Tangible Prize-Based Contingency Management (TangiblePBCM)|For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.
9669592|NCT03799341|Experimental|Voucher Prize-Based Contingency Management (VoucherPBCM)|For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).
9669593|NCT03799341|Active Comparator|Treatment As Usual (TAU)|Participants in all arms will be engaged with TAU outpatient substance use services and will be recommended to participate in at least two outpatient group and/or individual psychotherapy encounters per week. Participants assigned to the TAU only arm will be asked to engage with recommended outpatient treatment services for 12-weeks (as described above) but will not receive adjunctive PBCM during this time period. Participants in the TAU arm will additionally be asked to provide urine specimens on a twice-weekly basis for lab-based urinalysis. However, these participants will not interact with a CM provider or receive contingent reinforcement based on urinalysis results.
9669594|NCT03792958|Experimental|CM082|CM082 tablet
9669595|NCT03782350|Experimental|Tranexamic Acid Dosage 1|A bolus of 30 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 16 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 2 mg/kg.
9669596|NCT03782350|Active Comparator|Tranexamic Acid Dosage 2|A bolus of 10 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 2 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 1 mg/kg.
10150691|NCT04093128|Experimental|adults aged 19-57|adults aged 19-57 years old living in Amman Jordan, body mass index between 19-57
10150692|NCT04093219|Experimental|IV Acetaminophen|1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
10150693|NCT04093219|Placebo Comparator|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
10150694|NCT04093063|Experimental|Intervention Group|Subjects in the intervention group were tasked with building a micro-stellated icosahedron using a detailed instruction manual. They were each provided with a dissecting microscope and necessary materials to complete the task at home at their leisure. They were given two weeks to complete the task. They were asked to return for a second in-person meeting two weeks.
10150695|NCT04093063|No Intervention|Control Group|Subjects in the non-intervention control group were not given any task or any materials. They were asked to return for a second in-person meeting in two weeks.
10150696|NCT04093271|Experimental|Randomized to consume Rest-ZZZ, comparator, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Rest-ZZZ dietary supplement in Study Period 1, Comparator (Diphenhydramine HCl) in Study Period 2, and Placebo in Study Period 3.
10150697|NCT04093271|Experimental|Randomized to consume comparator, placebo, then Rest-ZZZ|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Comparator (Diphenhydramine HCl) in Study Period 1, Placebo in Study Period 2, and the Dietary Supplement, Rest-ZZZ in Study Period 3.
10150698|NCT04093271|Experimental|Randomized to consume placebo, Rest-ZZZ, then comparator|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Dietary Supplement, Rest-ZZZ in Study Period 2, and Comparator (Diphenhydramine HCl) in Study Period 3.
10150699|NCT04093115|Experimental|CX1106|CX1106 740 mg/m2 as a 24-hour continuous infusion for 5 days every 3 weeks (3 weeks/cycle, 4-6 cycles)
10150700|NCT04093401|No Intervention|Control|Subjects will be assigned to the control arm if their subject ID is an odd number. Control arm subjects will not receive counseling for individualized risk assessment for developing a second basal cell carcinoma.
10150701|NCT04093401|Experimental|Individualized risk assessment|Subjects will be assigned to the intervention arm (i.e., informed of their individualized risk assessment) if their subject ID is an even number. Subjects in the intervention arm will be informed of their estimated 1-year, 3-year, and 5-year risk of developing a second basal cell carcinoma.
10150702|NCT04093050|Experimental|TT Genotype|
10150703|NCT04093050|Experimental|AA/AT Genotype|
10150704|NCT04093245|No Intervention|Phase I-A (Local project set-up)|An executive committee will oversee the entire project. This committee, led by the nominated PI and Director of Nursing, will meet every 4 weeks during this four-year project. The team may include, depending on the hospital site: an administrator, the ED Director, the ED Head nurse, a community and/or hospital-based geriatric nurse specialist, an ED physician, a hospitalist, a geriatrician, a family physician, a home care nurse/coordinator, an inpatient unit manager, the research coordinator, and a local patient/caregiver. Each local team will be responsible for selecting and implementing the ACE intervention(s) best suiting their milieu, and will include locally identified champions to lead the local implementation.
9669597|NCT03782168||Placental Abruption|Mother-infant dyads with suspected or confirmed diagnosis of placental abruption
9669598|NCT03782168||Phenotypically-matched controlled group|Healthy mother-infant dyads admitted for delivery
9669599|NCT03767933|Active Comparator|Non-Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo, both administered once during the study at the time of recruitment.
9669600|NCT03767933|Experimental|Non-Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg), both administered once during the study at the time of recruitment.
9977181|NCT01358955|Active Comparator|Home-based cognitive intervention|The participants will do their homework for 30 minutes every business days for 12 weeks.
10150705|NCT04093245|Experimental|Phase I-B (Implementation):|The investigators will implement the context-adapted ACE program with the support of administrators and local implementation teams who will have the responsibility to roll out the different elements of the intervention within their respective hospitals. It may include a series of systematic pre-discharge, post-discharge and across transitions period interventions for eligible patients: 1) a GEM nurse to support patients during the post-discharge transition period, 2) pre- and post-hospitalization medication list reconciliation, 3) systematic discharge summaries given to patients and/or caregiver, and sent to their family physician, 4) a planned follow-up appointment with their family physician, 5) a systematic follow-up phone call, 6) access to wiki-based patient-oriented KT tools, 7) access to a community-based telemonitoring service.
10150706|NCT04093245|Experimental|Phase IC (Study description)|Results from each center will be analysed over time. Guided by previous work in healthcare governance, the investigators will analyze the impact of the sequential interventions within the context of a major health reform in Quebec aiming at implementing an integrated health system and within the PI program's overall goal of creating a Learning Health System. This will be accomplished by conducting a comparative case study across the four study sites to compare the barriers, facilitators and local solutions implemented to gain a better understanding about how the ACE program could eventually be scaled up elsewhere.
10150707|NCT04093375|Experimental|Radical Prostatectomy|Patients with locally advanced prostate adenocarcinoma receives Radical Prostatectomy with or without enlarged lymph node dissection
10150708|NCT04093375|Active Comparator|Radical Radiotherapy|Patients with locally advanced prostate adenocarcinoma receives Radical Radiotherapy with adjuvant androgen deprivation therapy
10150709|NCT04092920|Experimental|laser and SLA implants|extraction of badly broken maxillary and mandibular teeth with immediate implant placement using laser surface treated and SLA surface treated dental implants
10150710|NCT04092959|Experimental|Walking group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
10150711|NCT04092959|Experimental|Chinese Square Dancing group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
10150712|NCT04092959|Experimental|Control group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
10150713|NCT04092712|Experimental|Investigational Product|[14C]-CTP-543
10150714|NCT04092972|Experimental|Atherectomy|Atherectomy and drug-coated balloon (DCB)
10150715|NCT04092972|Active Comparator|Standard care|Standard care with predilation (POBA) and DCB
10150716|NCT04092998|Experimental|Thermocautery VS scalpel circumcision|Thermocautery circumcision in comparison to circumcision with traditional scalpel
10150717|NCT04092751|Experimental|Treatment A|Single oral 20-mg dose of PRA on Day 1 AM
10150718|NCT04092751|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later.
10150719|NCT04092738|Experimental|Intervention Group|"In the intervention group, subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2. In addition, participants will be provided with an external movement sensor that will be linked to the Walk@WalkApp-Diab for Android and iOS. This App will monitor the time participants spend sitting, walking and standing during working hours. It will also provide participants with strategies to sit less and move more at work throughout 13 weeks. This mHealth intervention aims to change occupational sitting by replacing desk-based activities by active tasks."
10150720|NCT04092738|No Intervention|Control Group|Subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2.
10150721|NCT04092660|Experimental|Intervention Care Group|"The Intervention care group will receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard. Additionally, they will also receive special support in the form of behaviour change interventions. The behavior change interventions consist of motivational interviewing, will be shown a video highlighting the negative consequences of sleep apnoea.~Booster calls at week 3,6, 18 and 12 for verbal encouragement and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life."
10150722|NCT04092660|Active Comparator|Standardized Care Group|"The standardized care group will only receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard along with routine care and will be called for follow up at 3rd and 6th month of treatment to assess their use and to resolve any technical problems with the device.~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life at the initial visit and subsequent follow-up."
10150723|NCT04092725|Experimental|Treatment A|Single oral 150-mg dose of DAB on Day 1 AM.
10150724|NCT04092725|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
9669601|NCT03767933|Active Comparator|Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
9977182|NCT01358955|No Intervention|Wait list Control|They will participate in cognitive intervention after ending this study.
10150725|NCT04093037|Experimental|Patient with dry eye disease|"Patient with dry eye disease will be included. They will have:~Time #1: LacryDiag examination without dye~Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score~Time #3: Standard Break-Up Time (SBUT)~Time #4: Schirmer test~Satisfaction questionnaire to the patient"
10150726|NCT04092803|No Intervention|GA for LP|Patients who decline to undergo an LP with VR will be asked if they would be willing to participate by answering questionnaires specific to their pre procedure anxiety. This will include questionnaires 2 and 3 from above. The investigators will also plan to collect vital sign data if they agree to participate in that capacity.
10150727|NCT04092803|Experimental|VR for LP|"The patients in this study will be presented the opportunity to use VR instead of undergo GA for a LP. Patients who agree to undergo an LP with VR will be assessed by a certified child life specialist (CCLS) to determine whether the patient is an appropriate candidate for using VR.The system includes a VR headset with VR software already loaded in to it. The VR software to be used is either a game called Pebbles the Penguin or SpacePups (Weightless Studios)."
10150728|NCT04092985||Patients suspected with Cardiac Arrhythmia|iECG + 12-lead ECG recording in patients suspected with any type of cardiac arrhythmias at the time of recruitment
9977183|NCT01359020|Experimental|Ibuprofen|10 milligram per kilo, oral administration
9977184|NCT01359020|Active Comparator|Acetaminophen|10 milligram per kilo, oral administration
10150729|NCT04092868||cardiac surgery with extracorporeal circulation|"during the operation~Intervention Blood sample :~- Choay Heparin (pharmacokinetic) concentration: t = 5, 15, 30 minutes after the start of the heparin injection + t = 5, 30, 60 minutes after the start of extracorporeal circulation~protamine dosage: t = 2, 5, 8, 10 and 15 min after protamine injection~anti-X activity t = 0 before administration and at time 2, 5, 8, 10 and 15 min then at time 1, 3, 5, 6 and 7 hours after protamine injection~thrombin generation test (TGT) activity (thrombinography) : t = 2, 5, 8, 10 and 15 min after protamine injection"
10150730|NCT04092881|Active Comparator|Short pulsed Nd-YAG laser treatment side|"Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) (Fotona XP®) laser is a successful therapeutic modality and is characterized by its safe profile compared to other lasers.~Short pulsed Nd-YAG laser (Fotona XP® Accelera mode) results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections."
10150731|NCT04092881|Active Comparator|Fractional ablative CO2 laser treatment side|"Carbon dioxide (CO2) (Deka SmartXide DOT®) laser is one of the well-tolerated therapeutic modalities used for treatment of different skin disorders including striae alba.~CO2 laser targets mainly water content in both epidermis and dermis causing vaporization of target cells.~Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in striae distensae."
10150732|NCT04092543||Stroke patients|All patients diagnosed with a stroke are collected in the database.
10150733|NCT04092634|Experimental|Dual mobility|Patients in this group will receive a dual mobility hip implant
10150734|NCT04092634|Active Comparator|Single bearing, traditional hip implant|Patients in this group will receive a traditional, single-bearing hip implant.
10150735|NCT04092556|Active Comparator|tDCS (M1)|The participants will be submit to tDCS applied over the motor cortex (M1)
10150736|NCT04092556|Active Comparator|tDCS (Cerebellar cortex)|The participants will be submit to tDCS applied over the cerebellar cortex
10150737|NCT04092556|Sham Comparator|Sham stimulation|The participants will be submit to sham stimulation
10150738|NCT04092621|Experimental|Rhythm-control strategy|The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.
10150739|NCT04092621|Active Comparator|Rate-control strategy|At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.
10185515|NCT03744923|Active Comparator|Transmuscular QLB group|Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall Then, scan dorsally keeping the transverse orientation until observing that the transverse abdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia The needle (20G spinal needle) is inserted in-plane from posterior to anterior and the tip of the needle is advanced towards then through the QL muscle, penetrating the ventral proper fascia of the QL muscle. The target site for injection is the plane between quadratus lumborum and psoas major. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together.
9977185|NCT01359020|Active Comparator|Dipyrone|10 milligram per kilo, oral administration
10150740|NCT04092517|Active Comparator|Control Corn Soya Diet|Control Corn Soya Diet will be prepared to a formulation for Corn Soya Blend (SUPER CEREAL) product adopted by the WFP as complementary food for children over than 6 months.
10150741|NCT04092517|Experimental|Test Corn Moringa Diet|Test Corn Moringa Diet will be prepared to the same formulation as Corn Soya Blend, but the Soya content will be replaced with Moringa and no micronutrient premix will be added.
10150742|NCT04092647|Experimental|ashwagandha|Ashwagandha
10150743|NCT04092647|Placebo Comparator|placebo|Placebo
10150744|NCT04092439|Experimental|Watermelon juice|100% watermelon juice
10150745|NCT04092439|Placebo Comparator|Placebo|Fructose matched control
10150746|NCT04092426||patients with keratoconus|"patients with keratoconus attending refractive surgery centers in Assiut will be subjected to the following :-~Full history and clinical evaluation.~collection of individual data ( residency , occupation , special habbit , chronic illness )~Analysis of results to assess prevelance of keratoconus and its distribution geographically in Assiut"
10150747|NCT04092491||1 blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~2 PAXgene RNA tubes of 2 ml each~1 dry tube for creatinine and IgA assay~1 tube of NFs (5ml)"
10150748|NCT04092608|Active Comparator|Low CVP group (restrictive group)|"Standard practice: the goal is to keep the CVP < 7 mmHg during surgery.~Baseline of crystalloid of 2ml/kg/h max in all patients.~EV 1000 monitoring device (Edwards Lifesciences, Irvine, USA) will be used but values will be blinded to the anesthesiologist in charge of the patient.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~Additionnal fluid administration is given to the patient at the end of the surgery (standard practice)~UPi is blinded in all groups"
10150749|NCT04092608|Experimental|GDFT group|"The goal is to keep stroke volume variation below 13% during surgery with mini fluid challenge of 100 ml of balanced crystalloid using the monitoring device (Edwards Lifesciences, Irvine, USA). Of course, the values will not be blinded to the anesthesiologist in charge of the patient.~All patients have a baseline crystalloid: 2ml/kg/h and mini fluid challenges per 100 ml as described above.~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion~UPi is blinded in all groups"
10150750|NCT04092595|Experimental|PF-06651600 and Rosuvastatin|Period 1 is 4 days in length. On Day 1 of Period 1 participants will receive a single dose of Rosuvastatin 10 mg given as a tablet orally. Period 2 is 11 days in length and will immediately follow Period 1 with no washout. In Period 2, participants will be dosed with oral 200 mg PF-06651600 once-daily (QD) for 7 days. On Day 8 of Period 2, a single dose of 10 mg Rosuvastatin oral tablet will be administered following administration of the 200-mg dose of PF-06651600. Dosing with oral 200 mg PF-06651600 QD will continue until Day 10 of Period 2.
10150751|NCT04092699|Other|patient|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
10150752|NCT04092699|Other|skulls|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
10150753|NCT04092322||Patients with subacute chronic stroke|Patients with subacute chronic stroke between the ages of 40-80
10150754|NCT04092387|Experimental|RC 1 only|Research cigarettes #1
10150755|NCT04092387|Experimental|RC 2 only|Research Cigarettes #2
10150756|NCT04092387|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
10150757|NCT04092387|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
10150758|NCT04092478||Traditional Sitting Position|We are going to use the Traditional Sitting Position on each patients.
10150759|NCT04092478||Lateral Decubitis Position|We are going to use the Lateral Decubitis Position on each patients.
10150760|NCT04092478||Abdominal Crunch Position|We are going to use the Abdominal Crunch Position on each patients.
10150761|NCT04092140||diabetic complaining of neuropathy or not|using of ultrasound in examination and nerve conduction study
10150762|NCT04092140||carpal tunnel syndrome|using of ultrasound in examination and nerve conduction study
10150763|NCT04092127||premature infants (<32 weeks of Gestation Age)|premature babies (<32 weeks of Gestation Age) to be screened with RetCam for retinopathy of prematurity and who will be filmed during the screening procedure to evaluate pain with the PIPP score (Premature Infant Pain Profile)
10150764|NCT04092114|Other|Control|Receives Standard of Care (SOC) services established in accordance with the South African Department of Health (DoH) PrEP (Pre-exposure Prophylaxis) guidelines.
10150765|NCT04092114|Experimental|CHARISMA Intervention|"Receives SOC (Standard of care) per control arm plus provider-administration of HEART (HEAlthy Relationship Assessment Tool) and provider-administration of CHARISMA (the Community Health clinic model for Agency in Relationships and Safer Microbicide Adherence) counseling modules, as applicable:~Module A: General Partner Communication and Relationship Skills~Module B: Partner Disclosure and Communication around PrEP Use~Module C: Responding to Intimate Partner Violence and Safety Planning"
10150766|NCT04092296|Experimental|resin infiltration|resin infiltrant (Icon product, DMG, Hamburg,Germany)
10150767|NCT04092296|Active Comparator|remineralization|
10150768|NCT04092569|Active Comparator|Intervention group|Pre-medical consultation structured diabetes self-care education programme
9516835|NCT03311789|Experimental|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
10150769|NCT04092569|No Intervention|Control group|Usual care
10150770|NCT04092400||Micro-Invasive Glaucoma Surgical devices|Patients implanted With Micro-invasive Glaucoma Surgical (MIGS) devices at the National University Hospital, Singapore
10150771|NCT04092374|Experimental|Case arm|
10150772|NCT04092205|Experimental|Experimental: Treatment|28 days treatment with NBMI 600 mg/day
10150773|NCT04092361||anisometropic amblyopia|
10150774|NCT04092361||strabismic amblyopia|
10150775|NCT04092361||deprivational amblyopia|
10150776|NCT04092023|Other|Control group|Participants in control group will be received usual care. They will be gone through yearly DM complication screening. A screening report and information sheet on general DM management will be issued to participants. Therapeutic goals will be set and further conventional health care education intervention will be referred.
10150777|NCT04092023|Other|Intervention group|The interventions are designed to address the seven key self-management behaviours identified by the Association of American Diabetes Educations: (1) healthy eating, (2) being active, (3) monitoring, (4) taking medication, (5) problem solving, (6) reducing risk, and (7) healthy coping. In addition, the Chronic Care Model elements of self-management support and patient centered-care approach is embraced during the intervention process. The nursing care components provided to participants will be included (a) self-care management knowledge, (b) skill-based learning and problem solving, (c) participants' participation and engagement, (d) participants' in goal setting, and (e) coordinate care, involve participants to make decision.
10150778|NCT04092309|Other|ACE group|patients after bone marrow transplantation will be treated with ACE inhibitor
10150779|NCT04092309|Other|Sacubitril Valsartan group|patients after bone marrow transplantation will be treated with sacubitril valsartan
10150780|NCT04092309|Other|Control group|patients after bone marrow transplantation will be treated neither with ACE i nor with sacubitril valsartan
10150781|NCT04092036||Unstable patients|Patients on mechanical ventilation, 18 years or older and developing hypotension (Mean arterial blood pressure) <65 mmHg
9519844|NCT03282864|Active Comparator|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
9519845|NCT03282864|Placebo Comparator|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
9519846|NCT03282851|Experimental|MSB11456|
10150782|NCT04092049|Experimental|lollipop|
10150783|NCT04092049|No Intervention|control|
10150784|NCT04091971|Experimental|Depressed adults with current MDD|Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.
10150785|NCT04092088|Active Comparator|tDCS-r+TENS-r|Real transcranial direct current stimulation (tDCS-r) + real transcutaneous electrical nerve stimulation (TENS-r)
10150786|NCT04092088|Experimental|tDCS-r+TENS-s|Real transcranial direct current stimulation (tDCS-r) + sham transcutaneous electrical nerve stimulation (TENS-s)
10150787|NCT04092088|Experimental|tDCS-s+TENS-r|Sham transcranial direct current stimulation (tDCS-s) + real transcutaneous electrical nerve stimulation (TENS-r)
10150788|NCT04092088|Sham Comparator|tDCS-s+TENS-s|Sham transcranial direct current stimulation (tDCS-s) + sham transcutaneous electrical nerve stimulation (TENS-s)
10150789|NCT04092231||1|Thirty children were between two and five years of age at the time of implantation. All were congenital pre-linguistically bilateral profound sensorineural hearing loss. Reports about basic audiological evaluation which included air and bone conduction thresholds, speech audiometry for all the study group before the implantation were obtained. They had limited benefit from consistent use of hearing aid amplification and enrolled in a rehabilitation program focused on oral communication. they underwent unilateral CI with CI experience ranged from 6 months and above.
10150790|NCT04091906|Experimental|Healthy donor|
10150791|NCT04092075|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
10150792|NCT04092075|Sham Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
10150793|NCT04092101|Experimental|RC 1 only|Research Cigarettes #1
10150794|NCT04092101|Experimental|RC 2 only|Research Cigarettes #2
10150795|NCT04092101|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
10150796|NCT04092101|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
10150797|NCT04091919||ASD group|Isolated ostium Secundum ASD patients who are involving in this study have been already selected for intervention before the starting time of the study. The ASD patients who will be scheduled for transcatheter closure have either haemodynamically significant shunt fraction (Qp/Qs > 1.5) or echocardiographic signs of right heart dilation or RV volume overload and pulmonary hypertension related symptoms. 2-D TTE derived Tissue Doppler and Strain Imaging will be done for all patients at baseline, 24 hours and 1-3 month post-procedure. Correlation between the device size and echocardiographic variables will be performed. Comparison between the results of the 2D-TTE derived Strain Imaging procedures will be done between baseline data and those obtained one day after the procedure and at one month follow up.
10150798|NCT04091919||Controlled group|Age matched controlled subjects without ASD
10150799|NCT04091880|Experimental|experimental group|378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
9669602|NCT03767933|Experimental|Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg) + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
10150800|NCT04091880|Active Comparator|control group A|378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
9669603|NCT03767933|Experimental|Opioid Trial: Arm 3|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone (0.05mg/kg, maximum 5 mg), all administered once during the study at the time of recruitment.
9669604|NCT03754127|Experimental|Active group|tDCS
9519847|NCT03282851|Active Comparator|US-licensed Actemra|
9519848|NCT03282851|Active Comparator|EU-approved RoActemra|
9519849|NCT03282838|Experimental|DFN-15 (fasted)|
9519850|NCT03282838|Experimental|DFN-15 (fed)|
9519851|NCT03282838|Experimental|Comparator (fed)|
9669605|NCT03754127|Sham Comparator|Sham group|Sham tDCS
10150801|NCT04091880|Active Comparator|control group B|378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).
10150802|NCT04091997||endometriosis|laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay
10150803|NCT04091997||control|diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay
10150804|NCT04091854||HMS5552 treatment|
10150805|NCT04091815|Active Comparator|I group - general anaesthesia|General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), opioids (fentanyl and morphine), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture.
10150806|NCT04091815|Experimental|II group - combined - spinal and general anaesthesia|"Spinal anesthesia: L3-4 interspace, 27G needle, bupivacaine hyperbaric, 16 mg, morphine sulfate 0.1% - 0.1ml.~General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture."
10150807|NCT04091945|Active Comparator|LT3001 Drug Product|
10150808|NCT04091945|Placebo Comparator|Placebo|
10150809|NCT04091698|Active Comparator|topical Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
10150810|NCT04091698|Placebo Comparator|topical corticosteroid|will receive topical corticosteroid (kenacort A Orabase: triamcinolone acetonide 0.1%5gram adhesive paste - dermapharm), 4 times daily for 3months.
10150811|NCT04091789|Experimental|Test Article|Subjects will take Pure Femme sublingual tablets as directed, one tablet 2 days before, one tablet 1 day before, and then up to 3 tablets per day for 3 days (72 hours) during menstruation.
10150812|NCT04091802|Experimental|single layer of L-PRF|single layer of L-PRF will be put in the vertical incision
10150813|NCT04091802|Experimental|multiple layers of L-PRF|multiple layers of L-PRF will be put in the vertical incision
10150814|NCT04091711|Experimental|ReX-C intervention|Subjects use ReX-C to receive oral oncolytic medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
10150815|NCT04091932|Experimental|Pembrolizumab treatment|Pembrolizumab dosage form:100mg/4ml dosage:2mg/kg weight frequency: once per 4 weeks duration:12 weeks
10150816|NCT04091737|Experimental|CSL200|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
10150817|NCT04091958|Experimental|Post-tumourectomy reconstruction with myo-glandular flap.|Standard tumourectomy followed by reconstruction with myo-glandular flap.
10150818|NCT04092062|Experimental|Treatment - ToothWave brush|Subjects using the Silk'n ToothWave, Radio frequency (RF)-utilizing toothbrush.
10150819|NCT04092062|Sham Comparator|Control - powered toothbrush|Subjects using a regular ADA-Accepted Powered Toothbrush, no RF
10150820|NCT04091620|Experimental|Transanal Total Mesorectal Excision|For transanal total mesorectal excision, a two team approach will be adopted. One surgical team will be performing the abdominal phase dissection using standard laparoscopic approach, while the other will be simultaneously performing the transanal dissection and total mesorectal excision in a 'down-to-up' fashion using laparoscopic instruments.
10150821|NCT04091620|Active Comparator|Robotic Total Mesorectal Excision|For robotic total mesorectal excision, a fully robotic approach will be adopted. Left-sided colonic mobilization, division of lymphovascular pedicle, and 'top-to-down' total mesorectal excision will be performed using the robotic platform.
10150822|NCT04091841|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
10150823|NCT04091841|Placebo Comparator|Carbo Mass|Control patients will be received protein diet (1.2 g/kg/day) and Carbo Mass for 1 month after surgery.
10150824|NCT04091594|Experimental|Flexible orthotic|Sensory input flexible ankle foot orthotic (SIAFO) with appropriate lycra garments
10150825|NCT04091594|Active Comparator|Standard of care|Standard of care solid ankle foot orthotic (AFO)
10150826|NCT04091763|Experimental|Polidocanol foam sclerotherapy|"Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the microbubbles of the foam did not disintegrate);~Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;~Patients treated in a maximum of 3 sessions at 3 weeks intervals;~Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;~In each session more than one hemorrhoid cushion could be treated."
9519852|NCT03282825|Experimental|Decitabine|"A standard 3+3 trial design will be used for Decitabine dose escalation cohorts.~The number of cohorts is three. The subjects will be administered Decitabine on every seven days in a 28day cycle and Decitabine is sequential administered with Paclitaxel.~Cohort 1: Decitabine 15mg/m2, Cohort 2: Decitabine 20mg/m2, Cohort 3: Decitabine 25mg/m2"
9519853|NCT03282812||cases|
9669606|NCT03753490|Other|ABC score guided therapy|Individual treatment recommendations based on the ABC-scores for stroke and bleeding.
10150827|NCT04091763|Experimental|Rubber band ligation|"Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;~A maximum of 3 sessions of ligation at 3-week intervals were performed;~More than 1 band per session could be applied."
9519854|NCT03282812||controls|
9669607|NCT03753490|Other|Standard care|Management according to local practice, national and international guidelines.
9977799|NCT01365312|Experimental|Ethanol|Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.
10150828|NCT04091581|Experimental|Assessment|Instill eye drop and perform followup assessments
10150829|NCT04091438|Experimental|TAK-925 Dose A + Placebo|TAK-925 Dose A, 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by TAK-925 placebo-matching 9-hour IV infusion once on Day 3, Treatment Period 2.
10150830|NCT04091438|Placebo Comparator|Placebo + TAK-925 Dose A|TAK-925 placebo-matching 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by, TAK-925 Dose A, 9-hour IV infusion once on Day 3, Treatment Period 2.
10150831|NCT04091516|Other|Low-fat plant-based diet|For 12 weeks, participants will follow a diet comprised of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
10150832|NCT04091334|Experimental|Serial ultrasound group|"Will received standard care and monitoring and in addition, have focused ultrasound examination of the heart and the lungs done twice.~The investigator is supposed to titrate the treatment according to the findings on the ultrasound examinations."
10150833|NCT04091334|Active Comparator|Standard care group|Standard care and monitoring.
10150834|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 75 mg/M2 per day|75 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
10150835|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 150 mg/M2 per day|150 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
10150836|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 200 mg/M2 per day|200 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
10150837|NCT04091633|Active Comparator|School Mental Health Program-Conventional (cSMHP)|The teachers of schools randomized to control arm will receive training in World Health Organization (WHO) School Mental Health Program (SMHP) by mental health experts at WHO collaborating center for mental health research and training, Institute of Psychiatry. The training of teachers will consist of a mix of both didactic and interactive training methodologies in the form of a workshop. The workshop will consist of lectures/presentations, incorporating group discussions/activities. Through didactic methods, teachers will be taught basic theoretical knowledge related to mental health in schools. Training will be followed by monthly supervision meeting of teachers for 9-months.
10150838|NCT04091633|Experimental|Enhanced-School Mental Health Program (eSMHP)|The teachers of schools randomized to intervention arm will receive online training in adapted version of School Mental Health Program. The online training in adapted School Mental Health Program consists of 4-5 hour, self-paced online training course for teachers. The teachers will register themselves in the online course in the form of a group of 4-5 teachers from each school. The teachers will complete the online training course in a group, with interactive group activities and role plays. Progress to the next module in the online training is conditional upon completion of post-module mental health literacy quiz. A certificate of training completion in adapted SMHP shall be awarded to those teachers who complete the post-test. Teachers will be supported online and in-person by the trainers who are trained in SMHP in monthly supervision meeting of teachers for 9-months.
10150839|NCT04091425|Experimental|TAK-925 Dose A|TAK-925 dose A intravenous (IV) infusion in each treatment sequence (crossover design).
10150840|NCT04091425|Experimental|TAK-925 Dose B|TAK-925 dose B IV infusion in each treatment sequence (cross over design).
10150841|NCT04091425|Placebo Comparator|Placebo|TAK-925 placebo-matching IV infusion in each treatment sequence (crossover design).
10150842|NCT04091529|Experimental|Radiofrequency myolysis of uterine fibroids|54 premenopausal participants with symptomatic uterine myomas
10150843|NCT04091269|Placebo Comparator|PSV-10%|PSV mode using E5 ventilator with fixed flow trigger and Esense 10%
10150844|NCT04091269|Placebo Comparator|PVS-30%|PSV mode using E5 ventilator with fixed flow trigger and Esense 30%
10150845|NCT04091269|Placebo Comparator|PSV-50%|PSV mode using E5 ventilator with fixed flow trigger and Esense 50%
10150846|NCT04091269|Experimental|PSV-auto|PSV mode using automatic adjustmen of inspiratory triger and cycling-off based on waveform
10150847|NCT04091269|Active Comparator|PSV-neuro|NAVA mode using NAVA level of 15 cmH2O/uV and pressure limit function to simulated EAdi triggered PSV.
10150848|NCT04091373|Experimental|Sequence 1|100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15
10150849|NCT04091373|Experimental|Sequence 2|100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15
10150850|NCT04091373|Experimental|Sequence 3|100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15
10150851|NCT04091373|Experimental|Sequence 4|100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15
10150852|NCT04091373|Experimental|Sequence 5|100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15
10150853|NCT04091373|Experimental|Sequence 6|100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15
10150854|NCT04091490|Experimental|Patients with relapsed/refractory Hodgkin's lymphoma|A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma
10150855|NCT04091412|Experimental|Long-term administration of Butylphthalide Soft Capsules|In addition to standard secondary preventive drugs, such as atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets, patients in this group take Butylphthalide Soft Capsules orally, 0.2g per serving, three times a day for one year.
9977800|NCT01365312|Placebo Comparator|Heparinized saline|Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.
10150856|NCT04091412|No Intervention|Standard secondary prevention group|patients in this group take atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets as standard secondary prevention.
10150857|NCT04091399|Experimental|Patient cohort|Patients suffered from alveolar osteitis and treated using a Stomatological tamponade Contipro, composed of the Hyaluronic acid and Octenidine dihydrochloride. Firstly, the extraction wound had been irrigated with 2 ml of 3% solution of H2O2 to disinfect the site and then flushed by 2 ml of Aqua pro injectione to clear any remaining debris. After, the tested drug was applied into the extraction wound. This procedure was repeated on a daily basis for a maximum of 7 days or until the pain subsided below 20 mm and remained there for at least 2 days.
10150858|NCT04091360|Experimental|Experimental dose 1 - 100ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 1; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.~No. of Puffs per Inhaler = 2; Total Dose = 100ug; Inhaler No.1 = 50ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
10150859|NCT04091360|Experimental|Experimental dose 2 - 300ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 2; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.~No. of Puffs per Inhaler = 2; Total Dose = 300ug; Inhaler No.1 = 150ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
10150860|NCT04091360|Experimental|Experimental dose 3 - 1000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 3; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.~No. of Puffs per Inhaler = 2; Total Dose = 1000ug; Inhaler No.1 = 500ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
10150861|NCT04091360|Experimental|Experimental dose 4 - 3000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 4; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.~No. of Puffs per Inhaler = 2; Total Dose = 3000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug"
10150862|NCT04091360|Experimental|Experimental dose 5 - 6000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 5; each patient will be instructed to take four puffs (inhalations) from each of Inhalers 1 through 3, for a total of twelve inhalations.~No. of Puffs per Inhaler = 4; Total Dose = 6000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug"
10150863|NCT04091360|Placebo Comparator|Placebo comparator - placebo|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 6; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.~No. of Puffs per Inhaler = 2; Total Dose = Placebo; Inhaler No.1 = Placebo; Inhaler No.2 = Placebo; Inhaler No.3 = Placebo"
10150864|NCT04091256|Experimental|Clinical trials with a single arm|: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
10150865|NCT04091139|Experimental|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
10150866|NCT04091139|Active Comparator|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
10150867|NCT04091204|Experimental|Olaparib|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
10150868|NCT04091243|Experimental|Romosozumab|Romosozumab (210mg) subcutaneously every month for 12 doses
10150869|NCT04091243|Active Comparator|Denosumab|Denosumab subcutaneously (60mg) every 6 months for 2 doses
10150870|NCT04091542|Experimental|FiO2 group 1|FiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
10150871|NCT04091542|Experimental|FiO2 group 2|FiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
10150872|NCT04091542|Experimental|Duration 1|In duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
10150873|NCT04091542|Experimental|Duration 2|In duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
10150874|NCT04091542|Experimental|respiratory rate 1|In the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
9669608|NCT03753412||ICUAW ECMO group|The physical and psychological effects of ICUAW on patients receiving extracorporeal membrane oxygenation for severe cardiorespiratory failure will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
10150875|NCT04091542|Experimental|respiratory rate 2|In the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
10150876|NCT04091542|Experimental|Position 1|The position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
10150877|NCT04091542|Experimental|Position 2|The position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
9669609|NCT03753373|Experimental|Acupuncture and Home Exercise|Acupuncture plus the prescribed home exercise program
9669610|NCT03753373|Active Comparator|Home Exercise Only|The prescribed home exercise program alone
10150878|NCT04091230|Experimental|novel needle|TRUSbx using the 18 gauge (G) 25 centimeter(cm) novel needle with 19 millimeter (mm) sample notch and a new actuator. 12 biopsies / patient.
10150879|NCT04091230|Active Comparator|standard tru cut needle|TRUSbx using a standard tru cut biopsy needle (Mermaid Medical M-biopsy 18G 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator ( Moller Medical Blue RBG-1000-10-1000). 12 biopsies/ patient.
10150880|NCT04091100|Active Comparator|electroacupuncture|The individuals in the electroacupuncture group were administered the therapy by a certified acupuncturist. Two Shenlong acupuncture needles were inserted in each of the trapezius and levator scapulae muscles at intervals of 0-3 mm and clips were attached to their ends. Afterwards, an electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes.
10150881|NCT04091100|Active Comparator|myofascial release|Firstly, longitudinal stretching was done with forearm to the muscles in the person's neck in order to relax. Afterwards, the researcher placed one hand under the person's head and placed their fingertips on the muscles under the occipital bone in the neck area. The researcher applied lateral flexion to the neck with one hand while placing the other hand on the trapezius and levator scapulae muscles and then stretched the muscles with friction massage. After this step, the participant's neck was guided back into a neutral position and the pinching technique was applied to the muscles. During the administration of therapies, the trigger points on muscles were identified and friction was applied to these sites until a loosening could be felt. The myofascial release sessions concluded with the administration of the friction massage technique once again to the muscles.
10150882|NCT04091074|Active Comparator|aspirin + ticagrelor before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + ticagrelor 90mg for 15 days before carotid stenting
10150883|NCT04091074|Active Comparator|aspirin + clopidogrel before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + clopidogrel 75 mg for 15 days before carotid stenting
10150884|NCT04091178|Experimental|VITAMIN D SUPPLEMENTATION ARM|"On day 1 of every chemotherapy cycle, the patient will be receive an oral solution of vitamin D (UVEDOSE/calciferol).~In parallel,a calcium supplementation is prescribed."
10150885|NCT04090996|Experimental|DT patients|
10150886|NCT04091191|Active Comparator|Specialized nutraceutical|Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
10150887|NCT04091191|Placebo Comparator|Placebo|Identical placebo formulated without active ingredients in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
10150888|NCT04091152||old patients|"Patient will freely use Ardoiz during their hospitalisation for a maximum of 9 days.~After this use, a survey concerning the usability of Ardoiz will be administered to the patient, before their discharge from hospital."
10150889|NCT04091152||relatives / unformal caregivers|"Unformal caregivers will freely use Ardoiz during the hospitalization of their relatives and a maximum of 9 days.~After this use, a survey concerning the usability of Ardoiz will be administered to the unformal caregivers, before the discharge of their hospitalized relatives from hospital."
10150890|NCT04091152||profesionnal caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Ardoiz will be administered to professional caregivers."
10150891|NCT04091009|Active Comparator|Continue Group|Those who continue taking their standard dose of buprenorphine before, during and after surgery.
9977186|NCT01359033||MINAP cohort|The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
10150892|NCT04091009|Active Comparator|Reduce Group|Those who are placed on a lower dose of buprenorphine starting one day before surgery and during the time period after surgery until the pain from the surgery has decreased. Once the pain from the surgery has decreased, you will be put back on your full dose of buprenorphine.
10150893|NCT04090944|Active Comparator|1st group (group B)|"The LMA LarySeal Multiple will be inserted using the blind technique which involves holding the LMA like a pen guided into the pharynx with the index finger of the operator at the junction of the tube and the bowl, with the operator at the head of the patient and the LMA facing caudally.~The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
10150894|NCT04090944|Active Comparator|2nd group:(group U)|"The LMA LarySeal Multiple will be inserted under the guide of B-mode US on the anterior neck . Transverse scans , Sagittal view and Parasagittal view.~-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
10150895|NCT04090983|Active Comparator|Cognitive-behavioral therapy (Hesslinger protocol)|
10150896|NCT04090983|Experimental|Cognitive-behavioral therapy (CADDI protocol)|
10150897|NCT04090814|Experimental|Movement-Evoked Pain during TENS treatment|Participants performed several physical tasks while using the HeatTens device (HV-F311-E). During these tasks, participants needed to rate their pain.
10150898|NCT04090814|No Intervention|Movement-Evoked Pain|Participants performed several physical tasks during with their pain was assessed.
10150899|NCT04090879|Experimental|RC 1 only|Research Cigarettes #1
10150900|NCT04090879|Experimental|RC 2 only|Research Cigarettes #2
10150901|NCT04090879|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
10150902|NCT04090879|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
10150903|NCT04090827|No Intervention|Control/ iheartchange Only|Access to the iHeartChange website only
10150904|NCT04090827|Experimental|Intervention|Nurse-led transition intervention and access to the iHeartChange website
10150905|NCT04090892||Persons with spasticity 4.0-20.11 years|Study personnel are not carrying out the surgical intervention but are assessing the outcomes of the surgery on gait and motor function.
9977801|NCT01365325|Experimental|handled echocardiography|home monitoring care program based on clinical and electrocardiographic evaluations and periodical handled echocardiographic examinations
10150906|NCT04090762|No Intervention|Control|Women in the control arm will complete the baseline and follow up surveys but will not receive any intervention.
10150907|NCT04090762|Active Comparator|Risk information only|Women in the risk only arm who exhibit characteristics associated with a greater risk of a poor birth outcome will be informed that they possess these characteristics. Risk characteristics (identified from the medical and epidemiological literature) include age, prior pregnancy and birth history (e.g., previous stillbirth).
10150908|NCT04090762|Active Comparator|Conditional Cash Transfer only|Women in this arm will be eligible to receive conditional cash transfers. To receive the transfer, pregnant women must attend prenatal care and give birth in a health facility.
10150909|NCT04090762|Active Comparator|Conditional Cash Transfer and risk information|Women in this arm will be provided with risk information at the time of baseline survey administration AND be eligible to receive conditional cash transfers, pending attendance at prenatal care and delivery at a health facility.
10150910|NCT04090697|Experimental|Oxandrolone Cohort 1|Participants randomized to Oxandrolone Cohort 1 will receive 0.1mg/kg of oxandrolone suspended in a multi-chain triglyceride (MCT) oil buccally twice per day.
10150911|NCT04090697|No Intervention|Standard of Care|Participants randomized to standard of care will receive the standard therapies provided at the institution at which they are being treated. Control subjects will receive standard therapy with no placebo and no oxandrolone.
10150912|NCT04090736|Experimental|Arm A: Pevonedistat plus Azacitidine|Pevonedistat 20 mg/m2 IV on days 1, 3, and 5 plus Azacitidine 75 mg/m2 subcutaneous administered on a 5-on/2-off [weekend]/2-on schedule in 28-day cycles (intravenous Azacitidine can be administered for any patients who have non-tolerated local reactions)
10150913|NCT04090736|Active Comparator|Arm B: Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle (intravenous azacitidine can be administered for any patients who have non-tolerated local reactions)
10150914|NCT04090931|Experimental|Heat-Activated Nickel-Titanium Archwires|"Heat-activated NiTi (HANT) Group (TruFlex™ Thermal Nickel-Titanium, Ortho Technology, USA):~0.014-inch HANT~0.016-inch HANT"
10150915|NCT04090931|Experimental|Superelastic Nickel-Titanium Archwires|"Superelastic NiTi (SENT) Group (TruFlex™ Nickel-Titanium, Ortho Technology, USA):~0.014-inch SENT~0.016-inch SENT"
10150916|NCT04090788|Experimental|dried bitter-gourd supplements|2.4 gram per day for 4 weeks
10150917|NCT04090788|Active Comparator|dried cucumber supplements|2.4 gram per day for 4 weeks
10150918|NCT04090723|Experimental|Computer-delivered brief alcohol intervention (CBI-CC)|Participants will be offered only the Computer-delivered brief alcohol intervention with peer navigation from beginning of study to the end.
10150919|NCT04090619||Observational (questionnaires)|Participants complete 8 questionnaires about appetite, quality of life, symptoms, history of weight loss, nutritional status, body image, and nutritional support over 30 minutes.
10150920|NCT04090632|Experimental|closed kineTic chain upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
10150921|NCT04090801|Active Comparator|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|Group A applied topical minoxidil 5% in 90% ethanol and 5% propylene glycol
10150922|NCT04090801|Active Comparator|Topical minoxidil 5% in pure ethanol alone|Group B applied topical minoxidil 5% in pure ethanol alone
10150923|NCT04090801|Placebo Comparator|Placebo|Group C applied pure ethanol (placebo)
10150924|NCT04090671|Active Comparator|COPD Exacerbation|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
10150925|NCT04090671|Active Comparator|CHF|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
10150926|NCT04090671|Active Comparator|COPD|In stable state of COPD, the questionnaire MDP will be administered once during a routine control visit at the hospital or the medical practice.
10150927|NCT04090671|Active Comparator|OSA|The questionnaire MDP will be administered once during the first visit in the sleep laboratory.
10150928|NCT04090437|Active Comparator|Group1 - PVI first step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~PVI as first step~Remap to assess any change in activation~Ablate all rotors (API) in LA until SR or DCCV~Deployment of RA CTI line and demonstration of bidirectional block"
10150929|NCT04090437|Active Comparator|Group2 - PVI last step|"Catheter ablation procedure:~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)~Ablate all rotors (API) in LA until SR or DCCV~Remap to assess any change in activation~PVI as last step even when SR achieved earlier~Deployment of RA CTI line and demonstration of bidirectional block"
10150930|NCT04090593|Experimental|Educational Module Intervention|Intervention arm patients receive educational mobile module related to chronic condition that contributed to reason for admission.
10150931|NCT04090593|No Intervention|Hospital Practice Control|Control arm patients receive current, standard practice as related to patient education in the hospital (this does not include an educational mobile module).
10150932|NCT04090554|Other|Cytosponge™|Single intervention arm of feasibility study
10150933|NCT04090606||FTC Method|
10150934|NCT04090606||Massachusetts Method|
10150935|NCT04090606||Health Canada Intense Method|
10150936|NCT04090385|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
10150937|NCT04090385|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
10150938|NCT04090385|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over left primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
10150939|NCT04090320|Experimental|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
10150940|NCT04090853|Other|Patient Treatment Group|Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.
10150941|NCT04090580|Experimental|Daily dosage of dapagliflozin and metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 10 mg dapagliflozin and 2000 mg metformin for 12 weeks
9972031|NCT01316627|Experimental|Crooked Mirror Externalization Therapy|"Of recent, the crooked mirror externalization therapy, developed by Dr. Eda Gorbis, has been put to use with much success (Gorbis 2004). This method involves the use of crooked or fun house mirrors made from highly reflective surfaces that can be bent in different directions, which distort and exaggerate the patient's perceived defects (Gorbis 2005). In turn, this process externalizes or reverses the patient's internalized distorted body image, and allows the patient to habituate to the reflection of the imagined defect that is even more distorted than the internalized image (Rosen et al. 1995)."
9972032|NCT01316627|Active Comparator|Mirror Retraining Method|"In treating BDD, the cognitive-behavioral technique, mirror retraining, uses ordinary and/or magnifying mirrors to amplify the supposed defect, which teaches patients to see their appearance in a more holistic way. Since BDD patients tend to only focus on their perceived flaws when looking in the mirror, and tend to think about their flaws in negative terms, in mirror retraining, patients learn how to change their negative evaluations of their appearance into more objective and nonjudgmental descriptions. Generally, this method is designed to intentionally exaggerate anxiety regarding appearance concerns through exposures with mirrors. However, using exclusively ordinary and/or magnifying mirrors does not address the internal distorted image that many patients with BDD experience (Rosen et al. 1995, Osman et al. 2004, Veale 2004)."
9972033|NCT01316653|Active Comparator|GROW Smarter|Library based program to promote early literacy
9972034|NCT01316653|Experimental|GROW Healthier|Healthy lifestyle intervention focused on building healthy lifestyle skills for preschool children and participating parents and building new social networks between the intervention group members.
9972035|NCT01316666||Neurogenic Hypotension|Patients with neurogenic hypotension, which includes those with Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA) and Parkinson Disease (PD)
9972036|NCT01316679||group A|Patients with known HCC
9972037|NCT01316679||Group B|Patients with liver disease but no HCC
9972038|NCT01316679||Group C|Control; patients with no known liver disease or HCC
9972039|NCT01316718|Experimental|Mesalazine Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
9972040|NCT01316718|Placebo Comparator|Placebo Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
9972041|NCT01316731|Experimental|Exercise|
9972042|NCT01316757|Experimental|Treatment|Patients receive cetuximab IV over 60 minutes, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9972043|NCT01316809|Experimental|A|Surgical arm
9972044|NCT01316809|Experimental|B|Non-surgical arm
9972045|NCT01316822|Experimental|ARRY-382|
9972046|NCT01316835||Type 2 Diabetes Mellitus, No treatment|
9972047|NCT01316848|Experimental|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
9972048|NCT01316848|Experimental|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
9972049|NCT01316861|Experimental|EMS Acarbose|
9972050|NCT01316861|Active Comparator|Bayer Acarbose|
9972051|NCT01316874|Experimental|AD32 (valrubicin)|800mg, once weekly for 6 weeks
9972052|NCT01316952||LabRx database Oct. 1st 2004 to Sep. 30th 2009|The study cohort from which cases and controls are drawn is all subjects in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009.
9972053|NCT01316965|Experimental|multifaceted prevention program|
9972054|NCT01316965|No Intervention|usual care|
9972055|NCT01316978|Experimental|Experimental|Experimental Ibuprofen
9972056|NCT01316978|Active Comparator|Nurofen|Nurofen Meltlets Orodispersible Tablet
9972057|NCT01316978|Active Comparator|Motrin|Junior Strength Motrin Chewable Tablet
9977187|NCT01359033||RIKS-HIA cohort|The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.
9977188|NCT01359059|Active Comparator|IV-PCA (Patient-controlled analgesia) morphine|
9977189|NCT01359059|Active Comparator|Patient controlled epidural analgesia (PCEA) fentanyl|
9977190|NCT01359072|Experimental|Immediate Intervention Treatment|
9977191|NCT01359072|Experimental|Wait list|
9977192|NCT01359085|Active Comparator|Pregabalin|
9977193|NCT01359085|Active Comparator|ISBPB|Interscalene brachial plexus block
9977194|NCT01359098|Active Comparator|Ciprodex Otic Suspension|Ciprodex Sterile Otic Solution (Alcon, Inc.)
9977195|NCT01359098|Experimental|Ciprodexa Otic Foam|Ciprodexa Otic Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone otic foam)
9977196|NCT01359124||Water Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a water-based treadmill.
9977197|NCT01359124||Land Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a land-based treadmill.
9977198|NCT01359124||Exercise Cycle|These subjects will participate in three monitored exercise sessions per week for 8 weeks using an upright exercise cycle.
9977199|NCT01359137|Experimental|Probation as usual|Routine supervision with no deferred jail condition.
9977200|NCT01359137|Experimental|Deferred jail|Discretionary deferred jail in response to violations of probation conditions.
9977201|NCT01359137|Experimental|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) which uses non-discretionary brief jail sanctions for probation violations.
9977202|NCT01359163|Active Comparator|Femulen commercial tablets|
9977203|NCT01359163|Experimental|Femulen reformulated tablets|
9972058|NCT01316991|Active Comparator|Chewing gum|Subject will chew gum at defined intervals
10150942|NCT04090580|Experimental|Daily dosage of metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 2000 mg metformin for 12 weeks
10150943|NCT04090307|Experimental|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
10150944|NCT04090307|No Intervention|Traditional Prenatal Care|Subjects randomized to routine care will receive their prenatal care with their primary obstetric provider. Patients are seen for 10-15 minutes every four weeks until 28 weeks' gestation, every two weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits focus on routine screening tests and prenatal care. Traditional care participants will receive a phone call once a month, until 28 weeks gestation, from a nurse practitioner to check-in on pregnancy goals, healthy eating, and exercise. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
10150945|NCT04090294|Experimental|Roflumilast -non roflumilast|"35 patients will receive Roflumilast for three months and improvement regarding dyspnea scales , Pulmonary function Test , Six minutes walking test and bronchectasis severity index (FACED) score pre and post therapy will be assessed.~patients will receive Roflumilast 500 Mcg. Tablet Once daily for Three months and then base line assessment will be repeated to evaluate improvement."
10150946|NCT04090463|Experimental|IORT group|"Intraoperative administration of 10 to 20 Gy after surgery or as an in situ treatment in case resection will not be performed"
10150947|NCT04090372|Active Comparator|Control group|Control group will be assessed by standard preop planning using implants templates.
10150948|NCT04090372|Active Comparator|TraumaCad Group|TraumaCad Group will be assessed by preop planning using Traumacad
10150949|NCT04090359|Experimental|Dual Mobility|If patients are randomized to the dual mobility cohort, they will receive a dual mobility prosthesis at the surgeon's discretion. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
10150950|NCT04090359|Active Comparator|Conventional, Single-bearing hip implant|If patients are randomized to the conventional, single bearing cohort, surgeons will use their preferred implant design at their discretion using a 36 or 40mm head, depending on the diameter of the cup and manufacturer specifications. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
10150951|NCT04090268|Experimental|Children with malignant hemopathies|Children with malignant hemopathies attending a precision exercise training
10150952|NCT04090268|No Intervention|Healthy children|Healthy children
10150953|NCT04090281|Other|Precision medicine implementation|Patients will receive a precision medicine approach, incorporating both CYP2C19 genotyping and platelet reactivity phenotyping, to guide dual antiplatelet therapy selection for patients with ACS, post PCI and followed over a 12 month period.
10150954|NCT04090255|Experimental|Ultrasonographic guided renal access|The use of ultrasound to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
10150955|NCT04090255|Experimental|Fluoroscopic guided renal access|The use of fluoroscopy to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
10150956|NCT04090138|Active Comparator|Setria performance blend|l-citrulline + glutathione
9972059|NCT01316991|Placebo Comparator|No Gum|No chewing gum will be provided to subject
9972060|NCT01317069|Experimental|Fluorouracil implant|
10150957|NCT04090138|Placebo Comparator|Placebo|
10150958|NCT04090112|Experimental|the study group (Group A)|Patients received four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
10150959|NCT04090112|Active Comparator|Comparator group (Group B)|Patients received 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
10150960|NCT04090086|Experimental|Treatment Sequence 1: Treatment ABC|Participants will receive Treatment A (JNJ-53718678 once daily for 7 days) in Treatment Period 1, followed by Treatment B (JNJ-64417184 once daily for 7 days) in Treatment Period 2, followed by Treatment C (JNJ-53718678 once daily + JNJ-64417184 once daily for 7 days) in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
10150961|NCT04090086|Experimental|Treatment Sequence 2: Treatment BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
10150962|NCT04090086|Experimental|Treatment Sequence 3: Treatment CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
10150963|NCT04090086|Experimental|Treatment Sequence 4: Treatment ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
10150964|NCT04090086|Experimental|Treatment Sequence 5: Treatment BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
9972061|NCT01317108|No Intervention|A|Low uPA/PAI-1: Observation
9972062|NCT01317108|No Intervention|B2|High uPA/PAI-1: Observation
9972063|NCT01317108|No Intervention|B3|High uPA/PAI-1: refused randomization
9972064|NCT01317108|Active Comparator|B1|High uPA/PAi-1: CMF chemotherapy
9977204|NCT01359176||Healthy volunteers|
9977802|NCT01365325|Active Comparator|home monitoring program|home monitoring care program based on clinical and electrocardiographic evaluations
10150965|NCT04090086|Experimental|Treatment Sequence 6: Treatment CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
10150966|NCT04090216||Addict patients|patients with substance use disorders presented with STEMI & undergoing Primary PCI
10150967|NCT04090216||Non Addict patients|patients without substance use disorders presented with STEMI & undergoing Primary PCI
10150968|NCT04090840|Experimental|Intermittent Fasting|Patients will follow intermittent fasting for 16 hours with time restricted eating during an 8 hour window. The subjects are also advised to minimize sugar intake to <15g per serving.
10150969|NCT04090541|No Intervention|Control|Tests were applied with any taping.
10150970|NCT04090541|Sham Comparator|Sham Taping|In ST stage; medical purpose, hypoallergenic OctaCare® Rigid Transparent Plaster was applied as a rigid tape. This tape is also used under rigid tapes for protecting the skin. In this study investigators didn't prefer extra rigid tape on the plaster because that was very light and less sensitive material to our knowledge so it suited our aim of placebo control.
10150971|NCT04090541|Experimental|Kinesiology Taping|In KT stage; the original Kinesio Tex® Tape Classic was applied as a kinesiology tape. In this study, investigators applied the tape with muscle activation technique and paper of tension (it was declared %10) according to Kenzo Kase's Kinesio Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
10150972|NCT04090541|Experimental|Biomechanical Taping|In BT stage; Dynamic Tape® was applied as a biomechanical tape. In this study, investigators applied the tape with offload technique and paper of tension according to Ryan Kendrick's Biomechanical Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
10150973|NCT04090151||Austrian HIV Cohort Study (AHIVCOS)|
10150974|NCT04090151||The Australian HIV Observational Database (AHOD)|
10150975|NCT04090151||CHU Saint-Pierre|
10150976|NCT04090151||University Hospital Cologne|
10150977|NCT04090151||The EuroSIDA cohort|
10150978|NCT04090151||Frankfurt HIV Cohort Study|
10150979|NCT04090151||Georgian National AIDS Health Information System (AIDS HIS)|
10150980|NCT04090151||Modena HIV Cohort|
9972065|NCT01317121||Subjects at risk for psychosis|Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany. Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
10150981|NCT04090151||San Raffaele Scientific Institute|
10150982|NCT04090151||Swiss HIV Cohort Study (SHCS)|
9972066|NCT01317121||Patients with a first episode of schizophrenia|Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany. All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
9972067|NCT01317121||Healthy control subjects|Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany. They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
9972068|NCT01317134|Active Comparator|Therapy-naive|"This group consists of patients with a newly diagnosed PH (Class I or IV). First blood sampling takes place before initiation of PH therapy (0 months), the following measurements will be performed after 3, 6, 9 and 12 months under specific therapy.~Initiation of standard therapy is performed directly after baseline visit / study inclusion. No special study medication will be used.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood Test"
9977803|NCT01365338|Placebo Comparator|Placebo|Participants will receive placebo as a single oral dose.
10150983|NCT04090151||Royal Free HIV Cohort Study|
10150984|NCT04090151||The ATHENA national observational HIV cohort|ATHENA: AIDS Therapy Evaluation in the Netherlands
10150985|NCT04090151||Nice HIV Cohort|
10150986|NCT04090151||Italian Cohort Naive Antiretrovirals (ICONA)|
10150987|NCT04090151||PISCIS Cohort Study|
10150988|NCT04090151||Swedish InfCare HIV Cohort|
10150989|NCT04090151||Bonn University Hospital|
10150990|NCT04089956||Extubation Success|extubation Success which defined as no need for need for ventilatory support after extubation using tracheal intubation or non-invasive mechanical ventilation during ICU stay
10150991|NCT04089956||Extubation Failure|Extubation Failure was defined as need for any ventilatory support after fist extubation during ICU stay or tracheostomy befor any extubation attempt.
10150992|NCT04090047|Experimental|PF-06700841 and Itraconazole|This fixed sequence, 2-period arm will consist of two treatments. Participants will receive a single oral dose of 30 milligrams (mg) PF-06700841 on Day 1 in Period 1. On Days 1-7 in Period 2, Itraconazole 200mg will be administered once daily(QD). On Day 4 of Period 2, co-administration of Itraconazole 200 mg and 30 mg PF-06700841 tablets will occur.
10150993|NCT04089839||CP-CML participants initiating dasatinib|
10150994|NCT04090008|Active Comparator|PRP gel|PRP gel was applied to the ulcer twice per week after preparation and then the ulcer was covered with Vaseline gauze, few layers of sterile gauze and crepe bandage.
10150995|NCT04090008|Active Comparator|Saline dressing|daily dressing of the ulcer with normal saline was done
10150996|NCT04089995||Coats + and LCC syndrome|
10150997|NCT04090021|Experimental|Genotypic resistance-guided triple therapy|"In the group of genotypic resistance-guided triple therapy, a molecular assay based on DNA-strip technology was used to determine the genotypic resistance of H. Pylori to clarithromycin (23SrRNA mutations) and fluoroquinolones (gyrA mutations) from gastric biopsy specimens. According to 23SrRNA and gyrA mutational analyses, a 7-day tailored triple therapy therapy was given as follows:~Wild-type 23SrRNA: Clarithromycin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d.~23SrRNA mutated/wild-type gyrA: Levofloxacin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and levofloxacin 500 mg b.i.d.~23SrRNA mutated/gyrA mutated: Rifabutin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g t.i.d. and rifabutin 150 mg b.i.d."
9972069|NCT01317134|Active Comparator|Under therapy|"This group consists of patients under ERA monotherapy at timepoint of inclusion. Observation period is one year to detect intraindividual changes in endothelial dysfunction measured by L-arginine/NO-metabolites after 0, 3, 6, 9 and 12 months under investigation.~Specific PAH therapy has been started prior to the study for medical reasons and will be continued throughout.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood"
9972070|NCT01317134|Active Comparator|Healthy controls|This group consists of healthy individuals. Sex and age matching is intended. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood
9972071|NCT01317147||Gastric bypass patients|
9972072|NCT01317173||Progressive disease|Serum creatinin level rise more than 2 times
10150998|NCT04090021|Active Comparator|Empirical concomitant therapy|In the empirical concomitant group, patients received esomeprazole 40mg, amoxicillin 1gr, clarithromycin 500mg and metronidazole 500mg, all b.i.d., for 10-14 days.
10150999|NCT04089670|Active Comparator|Online Acceptance and Commitment Therapy Intervention|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Each module has a practice assignment at the end with the goal of having the participant engage in the material over the next week. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls, one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. During the call the clinical student will be able to help troubleshoot any technical difficulties being experienced, as well as clarify any questions about the material being taught in the intervention."
10151000|NCT04089670|No Intervention|Control|Participants in this arm of the study will complete the same sleep diaries and questionnaires at the same time points as the intervention group, but will not be administered the intervention modules and will not receive any phone coaching. When they have completed the 1-month follow-up they will be offered the intervention.
10151001|NCT04089696|Experimental|ExSpiron|10 patients with ALS
10151002|NCT04089657|Experimental|Apatinib+Sintilimab|Apatinib 500mg qd p.o and Sintilimab 200mg intravenously on day 1 every 3 weeks until disease progression or intolerable toxicity or patients withdrawal of consent
10151003|NCT04089709|Experimental|Study arm|Patients randomized to this group will be provided exercises to perform with the uninjured arm once daily for 3 months.
10151004|NCT04089709|No Intervention|Control arm|"Patients randomized to this group will not be provided exercises for the well-arm and will be managed according to the current standard of care."
10151005|NCT04089722|Other|Open-Label: Deoxycholic Acid Injections|Deoxycholic Acid Injections (dose strength: 2 mg/cm2) via subcutaneous injections into posterior and/or anterior axillary roll adiposity. Patients will receive 10 mL or less (≤100 mg) of study drug per treatment administered in 0.2-mL injections with a 30-gauge, 0.5-in needle attached to a 1-mL syringe at 1.0-cm spacing using a customized grid. Up to 6 treatments (30 ± 7 days apart) will be permitted, but fewer can be allowed because of efficacy (insufficient BSF to inject, patient satisfaction with treatment) or safety/tolerability concerns.
10151006|NCT04089813||Metformin|Patients use metformin to control blood sugar
10151007|NCT04089813||Insulin|Patients use Insulin to control blood sugar
10151008|NCT04090073|Experimental|Electroacupuncture Plus Fast-track Perioperative Program|Patients who are randomized to the intervention arm will receive Electroacupuncture combined with Fast-track program. Each session of Electroacupuncture will last for 20 minutes. The patients will undergo one session of Electroacupuncture daily from day 1 till day 4, or until the time when the primary outcome has occurred, whichever is earlier.
10151009|NCT04090073|Active Comparator|Fast-track Perioperative Program|Patients who are randomized to the control arm will receive Fast-track program alone.
10151010|NCT04089774|Experimental|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
10151011|NCT04089774|No Intervention|Kiné|Standard physiotherapy treatment, at least 20 sessions, renewed at least once, spread over 12 months
10151012|NCT04089800|Experimental|Intervention|For 9 months, each of the 40 women in the intervention condition will use their phones to access the multimedia-based antenatal videos and audios tailored to their pregnancy stages. Participants will use the prototype until six weeks after giving birth. The intervention implementation is estimated to take 9 months including a 6 weeks follow-up after delivery, which implies that the implementation will be completed by November/ December 2019. The investigators will install the final prototype on a phone and give each participant in the intervention group a phone with a prototype installed, and explain how it works. Women will get support in resolving technical issues that may arise with the application between March and May 2019.
10151013|NCT04089800|No Intervention|Control|The 40 women in the control condition will receive the usual standard care of antenatal check-up and counselling but no multimedia intervention.
10187828|NCT03722316|Experimental|MCI/Mild Dementia|"Twenty participants will be allocated to this arm if they demonstrate mild impairments in cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
9972073|NCT01317173||Non-progressive disease|Serum creatinin level rise less than 2 times
9972074|NCT01317186||Group I|Stage 2 Non-diabetic Chronic Kidney Disease
9972075|NCT01317186||Group II|Stage 3 Non-diabetic Chronic Kidney Disease
9972076|NCT01317186||Group III|Stage 4 Non-diabetic Chronic Kidney Disease
9972077|NCT01317225|Experimental|17 α hydroxyprogesterone caproate|17α-Hydroxyprogesterone caproate.
9972078|NCT01317225|Placebo Comparator|Placebo|Saline solution.
9972079|NCT01317238|Experimental|CJ Vaccination arm|healthy vaccinia-experienced volunteers who received CJ smallpox vaccine
10151014|NCT04089852|Experimental|Inhaled nitrous oxide anesthesia|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The treatment group will receive inhaled N2O/O2. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2. N2O/O2 will be administered per Boston Children's Hospital (BCH) N2O sedation protocol. Prior to speculum placement, treatment group participants will receive the inhaled gas until minimal sedation is achieved per BCH sedation guidelines, such that the patient is cooperative, oriented, and tranquil. Inhaled N2O will be administered throughout the duration of the procedure."
10151015|NCT04089852|Placebo Comparator|Inhaled oxygen placebo|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The control group will receive inhaled O2 alone. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered throughout the duration of the procedure."
10151016|NCT04089904|Experimental|ARM 1|
10151017|NCT04089748||Patients enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
10151018|NCT04089748||Patients from St Louis cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
10151019|NCT04089631|Experimental|Chemotherapy|"Capecitabine mono or Capecitabine/Oxaliplatin as investigator choice:~Patients who are positive for postoperative ctDNA (ctDNApos) and not microsatellite instable are randomized (2:1) to adjuvant chemotherapy with capecitabine or to follow up.~Capecitabine 2 x 1250 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days). Patients with a GFR between 30 and 50 ml/min start with capecitabine dose of 2 x 1000 mg/m^2. Treatment duration: 8 cycles (approx. 6 months)~Capecitabine, if combined with Oxaliplatin (investigator choice):~If the investigation decides to add oxaliplatin, the following schedule should be used:~[Oxaliplatin 130 mg/m^2 i.v. (2 hours on d1)] Capecitabine 2 x 1000 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days) Treatment duration: 4 or 8 cycles (approx. 3 or 6 months)"
9972080|NCT01317251|Experimental|Control diet|Diet without dairy products
9972081|NCT01317251|Experimental|Milk diet|Diet with a high content of milk
10151020|NCT04089631|No Intervention|Follow-up|Patients negative for postoperative ctDNA (ctDNAneg) are randomized (1:4) to follow-up within CIRCULATE or to routine follow up outside the Trial protocol.
10151021|NCT04089618|Experimental|Baseline 10 Days|10 days baseline before intervention starts.
10151022|NCT04089618|Experimental|Baseline 17 Days|17 days baseline before intervention starts.
10151023|NCT04089618|Experimental|Baseline 24 Days|24 days baseline before intervention starts.
10151024|NCT04089787|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
10151025|NCT04089787|Active Comparator|Control group|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
9826243|NCT02412878|Experimental|Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone|"Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
10151026|NCT04089683||Doctors|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
10151027|NCT04089683||Nurses|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
10151028|NCT04089683||OT Technicians|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
10151029|NCT04089683||House keeping staff and cleaners|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
10151030|NCT04089488||Observational (respond to surveys, medical record review)|Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
9972082|NCT01317251|Experimental|Cheese diet|Diet with a high content of cheese
10151031|NCT04089644|Active Comparator|manual group|Hypotension will be corrected by manual infusion of norepinephrine
10151032|NCT04089644|Experimental|closed-loop group|Hypotension will be corrected by closed-loop control of norepinephrine infusion
10151033|NCT04089462|Other|"1. Five sessions per period - Two sessions per period"|
10151034|NCT04089462|Other|"2. Two sessions per period - Five sessions per period"|
10151035|NCT04089501||Inflammatory Bowel Disease (IBD)|Subjects will be asked to provide a stool sample (if no colonoscopy is to be performed) or if clinically indicated, a colonoscopy will be performed per standard medical routine. During colonoscopy, stool will be collected for analysis and 3 additional biopsies will be taken each from the ileum and colon for research purposes. Alternatively, subjects who are undergoing intestinal and/or colonic resection will provide stool prior to surgery and a portion of their pathology specimens will be used for research purposes following complete pathologic evaluation.
10151036|NCT04089501||Subjects not affected by IBD (Control Group)|Results of subjects with IBD will be compared to subjects in the control group.
9972083|NCT01317264|Placebo Comparator|Placebo milk drink|
9972084|NCT01317264|Experimental|Millk drink with oat β-glucan|
9972085|NCT01317264|Experimental|Milk drink with barley β-glucan|
9972086|NCT01317264|Experimental|Milk drink with mutant-barley β-glucan|
9972087|NCT01317290|Experimental|linseed oil; young|ALA rich linseed oil to younger subjects (18-35 years)
9972088|NCT01317290|Experimental|linseed oil; older|ALA rich linseed oil to older, normalweight subjects (BMI <25, age 49-69 years)
10151037|NCT04089605|Experimental|intravitreal dexamethasone implant|The eyes undergo dexamethasone intravitreal implant 0.7 mg injections at baseline and every 3 or 4 months thereafter. Dexamethasone implants are re-injected in minimal 3-month interval if macular edema persisted or recurred with CFT more than 350 μm or manifestation of apparent submacular fluid and/or intramacular cysts. If DME subside with CFT less than 350 μm without accompanying fluid and cysts, repeated injection is mandatory in maximal 4-month interval.
10151038|NCT04089605|Active Comparator|intravitreal ranibizumab|As for intravitreal ranibizumab 0.5 mg (IVR), we use OCT-guided treat-and-extend protocol for DME treatment after modifying the settings of TREX-DME study.4 The regimen include 3 monthly loading doses then extending the treatment injection interval one month more if CFT less than 350 μm without obvious submacular fluid and intramacular cysts. The injection interval shorten one month if CFT more than 350 μm or presence of obvious fluid and/or cysts. The patients are intentionally injected at most every 3 months even DME not existing.
10151039|NCT04089436||patients with encephalitis|children above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar
10151040|NCT04089410|Active Comparator|Hyperthermic Fitness Treatment|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the HFT.
10151041|NCT04089410|Placebo Comparator|Attenuated heating|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the placebo-HFT.
10151042|NCT04089371||Arm A Total Shoulder Arthroplasty / Hemiarthroplasty|Total Shoulder Arthroplasty (TSA) Humeral & Glenoid components as a Hemiarthroplasty or Total Shoulder Replacement.
10151043|NCT04089371||Arm B Reverse Shoulder Arthroplasty|Reverse Shoulder Arthroplasty (RSA) Humeral & Glenoid Components as a primary, fracture or revision total shoulder replacement
10151044|NCT04089592|Experimental|Dex Group|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
10151045|NCT04089592|Experimental|Fent Group|intravenous fentanyl at 2mcg/kg in 100ml saline
10151046|NCT04089878|Experimental|PARTO/BRTO + SMT|PARTO/BRTO with SMT will be given.
10151047|NCT04089878|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
10151048|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
10151049|NCT04089384|Active Comparator|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
10151050|NCT04089384|Placebo Comparator|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment
10151051|NCT04089540|Experimental|Study group: New intubation method|In the new intubation method the respirator is connected to the tube prior to insertion into the mouth (oral intubation) or into the nose (nasopharyngeal intubation). Therefore an oxygen flow is already administered via the tube during the intubation process.
10151052|NCT04089540|Other|Control group: Conventional intubation|In the control group the respirator is connected to the tube and ventilation is started after the insertion of the tube into the trachea. Therefore there is no oxygen flow administered during the intubation process.
10151053|NCT04089345|Experimental|Open label ustekinumab|All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48. All subjects will receive concomitant antibiotic treatment with ciprofloxacin or metronidazole from baseline through Week 4. Intravenous induction doses will be 260mg for patients <55kg, 390mg for patients between 55 and 85kg, and 520mg for patients with a body weight >85 kg.
10151054|NCT04089397|Experimental|Light therapy group|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis (at home, for patients dialyzing the afternoon, or during dialysis for patients dialyzing in the morning)
10151055|NCT04089397|No Intervention|Control group|Usual care, without light therapy
10151056|NCT04089228|Experimental|Kinesiotape Group and INIT|Kinesiotaping and Integrated Neuromuscular Inhibition Technique (KT + INIT )
10151057|NCT04089228|Active Comparator|INIT Group|Integrated Neuromuscular Inhibition Technique (INIT)
10151058|NCT04089319|Experimental|Acupuncture + mindfulness|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen to a 15-minute mindfulness recording followed by music for 30 minutes. Acupuncture needles will then be removed.
10151059|NCT04089319|Other|Acupuncture control|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen music for 45 minutes. Acupuncture needles will then be removed.
10151060|NCT04089254|Active Comparator|Inpatient Psychiatry|Child and adolescent inpatient treatment
10151061|NCT04089254|Active Comparator|Outpatient Crisis Intervention Clinic|OCIC is outpatient crisis intervention clinic
10151062|NCT04089280|Experimental|Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: Sanprobi Barrier-multispecies probiotic product, 2,5 x10 9 cfu/gram or placebo, cross-over design
10151063|NCT04089280|Placebo Comparator|carrier material of Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: placebo comparator (carrier material of Sanprobi Barrier-multispecies probiotic product , not containing bacterial strains,similar appearance as the probiotic, cross-over design
10151064|NCT04089163|Experimental|Sequential Dose Cohorts|Doses of Toca 511 will be evaluated in sequential cohorts. Toca 511 will be administered as a single intravesical instillation. Following Toca 511 administration, Toca FC will be administered orally at a dose of 220 mg/kg/day for 7 days every 6 weeks.
10151065|NCT04089124|Other|repair using General anesthesia ( control group)|Surgery repair zone 2 under GA
10151066|NCT04089124|Other|repair using Walant|Surgery repair zone 2 under WALANT
9826244|NCT02412956|No Intervention|Control|pamphlet
10151067|NCT04089215|Experimental|JWCAR029 treatment|JWCAR029 be administrated in two dose level
10151068|NCT04089241|Experimental|all cohort|Patients will perform CTA 1 months after the EVAR procedure. Following CTA, an ultrasound examination which will include a 3D reconstruction and CEUS will be performed using SONOVIEW contrast agent. The dimensions and volume of the aorta will be compared to the measurements in CTA using the fusion method. In the case of endoleak type 1 or 3 the patient will be urgently refered to endovascular repair . In the case of endoleak type 2 or a normal exam the patient will undergo another fused exam with CEUS at 6 month . In the case of endoleak type 2 with a growth of more than 1 cm in the aneurysm diameter , the patient will be refered to endovascular repair. In the case of a normal exam or an endoleak type 2 with a shrinkage of 1 cm or more ,the patient will undergo another fused exam with CEUS at 12 months. At any case of a new endoleak type 1 or 3 the patient will undergo CTA.
10151069|NCT04089189|Experimental|IMP4297|100 subjects to receive IM4297 orally.
10151070|NCT04089267|Experimental|experimental group 1|rhTPO injection7500 U ;one time a day; 14 times of administration
10151071|NCT04089267|Experimental|experimental group 2|rhTPO injection15000 U;one time a day;14 times of administration
10151072|NCT04089267|Experimental|experimental group 3|rhTPO injection15000 U;1 time every other day, 7 times;
10151073|NCT04089267|Experimental|experimental group 4|rhTPO injection30000 U；1 time every other day, 7 times;
10151074|NCT04089072|Experimental|Control group|Patients in the control group will have phenylephrine infusion starting at 50 mcg/min and titrated to maintain a MAP >65 mmHg as a third line vasopressor. Maximum dose of Phenylephrine is 300 mcg/min.
10151075|NCT04089072|Experimental|Intervention group|Patients enrolled in the intervention group will receive 2 mg/kg IBW (Ideal Body Weight) bolus, given over 15 mins, of ProvayBlue® followed by a concomitant infusion at 2 mg/kg/hr (IBW) mixed in D5W, which will continue for 24 hours. ProvayBlue® ( Methylene Blue) will be used as the third-line vasopressor.
10151076|NCT04089111|Experimental|1.1. ASV, MV target 100%|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
10151077|NCT04089111|Active Comparator|1.2. Volume control, MV target %100|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3 Ventilation frequency will be adjusted to reach the same volume target calculated in arm1.
10151078|NCT04089111|Experimental|2.1. ASV, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
10151079|NCT04089111|Active Comparator|2.2. Volume control, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3. Ventilation frequency will be adjusted to reach the target PaCO2 level
10151080|NCT04089176|Active Comparator|protocal A|Carbetocin versus placebo
10151081|NCT04089176|Active Comparator|protocal B|Oxytocin versus placebo
10151082|NCT04088877|Experimental|Exercise and Art Sculpting Class|Participants will take part in a twelve week exercise program twice per week as well as an eight week art sculpting class once a week.
10151083|NCT04088812|Placebo Comparator|Placebo meat derivative + Placebo satiating compound|60 g Placebo meat derivative 25 g Placebo satiating compound
9669611|NCT03749499|No Intervention|Usual Care|Participants randomized to usual care will receive preprinted discharge instructions on HTN and a 48-72-hour referral to our FQHC (or other community health center if pre-assigned though Illinois Medicaid) to schedule their follow-up appointment (current standard of care)
10151084|NCT04088812|Experimental|Placebo meat derivative + Satiating compound|60 g Placebo meat derivative 25 g Satiating compound
10151085|NCT04088812|Experimental|Experimental meat derivative + Placebo satiating control|60 g Experimental meat derivative 25 g Placebo satiating compound
10151086|NCT04089007|Experimental|SOmNI intervention group|"Participants will receive an iPhone with the SOmNI app and will be instructed to move their bedtime earlier by 5 minutes (from their average baseline week bedtime) on each school night (Sunday to Thursday). Participants will also be given sleep hygiene information related to the embedded features of the SOmNI app. A research assistant will help the participant to enter the appropriate goal bedtime in the SOmNI app and orient them to the features of the SOmNI app. Participants will also be instructed to aim for <1 hour difference between school night and weekend bedtimes and wake times (i.e. avoid staying up late and sleeping in on weekends).~The SOmNI application will allow the user to graphically track sleep behaviour across the four-week intervention period as recorded by the wearable sensor (e.g. bedtimes, wake times, amount of sleep achieved will all be displayed in the app)."
10151087|NCT04089007|Active Comparator|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
10151088|NCT04089020|Experimental|Psychosocial intervention|Text messaging and health coaching over the telephone to address goal setting, monitoring, motivation, problem solving, and related skills, delivered over 6 weeks.
10151089|NCT04089033||Primary Retinal Detachment 1|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pneumatic Retinopexy
10151090|NCT04089033||Primary Retinal Detachment 2|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pars Plana Vitrectomy
10151091|NCT04088929|Experimental|CBD for Treatment of Diabetic Neuropathic Pain|Patients are instructed to take 3 total tablets a day, under the tongue, six hours apart for three weeks. Patients are to enter their pain scale score into the smartphone app as instructed during the initial site visit. Patients are to enter into the notes section of the app any additional information such as side effects (positive or negative), medication changes.
10151092|NCT04088695|Experimental|Intervention|The arm exposed to the intervention video
10151093|NCT04088695|Active Comparator|Control|The control group exposed an informative text.
10151094|NCT04088851|Experimental|Metformin - T2D|Patients with type-2 diabetes and from their GP described Metformin Therapy (1 g per day) will undergo MRS and PINTA measurement.
9826245|NCT02412956|Experimental|Intervention (text)|SmokefreeMOM text messaging program
9972089|NCT01317290|Experimental|linseed oil older, overweight|ALA-rich linseed oil to older, normalweight subjects (BMI >25, age 49-69 years)
10151095|NCT04088851|Placebo Comparator|No Metformin - T2D|Patients with type-2 diabetes and from their GP described Metformin Therapy (1 g per day) will pause the medication for 2 weeks and undergo MRS and PINTA measurement. After their visit they will continue the anti-diabetic treatment according to the GP's presription.
10151096|NCT04088851|No Intervention|No Metformin - Healthy Controls|Healhy controlls will undergo the MRS and PINTA measurments, matched in BMI and age.
10151097|NCT04088838||Patients undergoing abdominal surgery|All adult patients undergoing elective abdominal surgery are eligible. Abdominal surgery includes each operation in which the peritoneal cavity is openen, i.e. laparotomy or laparoscopy.
10151098|NCT04088747||Fibromyalgia|Patients who display symptoms and have a history of Fibromyalgia, between 20-65 years of age.
10151099|NCT04088747||Healthy Controls|Age-matched, healthy controls, between 20-65 years of age who present no signs of chronic pain.
10151100|NCT04088760|Experimental|TCRαβ+/CD19+ depleted HSCT|
10151101|NCT04088942|Experimental|High-intensity group|"Will receive high-intensity intervention, which is a combination of pharmacological (varenicline) and behavioural support, described later."
10151102|NCT04088942|Active Comparator|Low-intensity group|Encouraged to quit smoking via own doctor and is prescribed varenicline.
10151103|NCT04088656|Experimental|Hypertension Systems Analysis and Improvement|Eight (8) health facilities will receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
10151104|NCT04088656|No Intervention|Control|Eight (8) health facilities will not receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
10151105|NCT04088721|Experimental|AD17002 20μg|Intranasal weekly dosing of AD17002 for three times
10151106|NCT04088721|Experimental|AD17002 40μg|Intranasal weekly dosing of AD17002 for three times
10151107|NCT04088721|Experimental|AD17002 60μg|Intranasal weekly dosing of AD17002 for three times
10151108|NCT04088721|Placebo Comparator|Placebo|Intranasal weekly dosing (placebo) for three times
10151109|NCT04088617|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
10151110|NCT04088617|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
10151111|NCT04088669|Experimental|Intervention group|A home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist.
10151112|NCT04088669|Active Comparator|Control group|A training session about the disease and the correct inhaler use, booklets that include breathing exercises and aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks.
10151113|NCT04088682||All hospitals|"All hospitals will take the treatment quality improvement strategies and tools into implementation.~Intervention: Behavioral: Quality improvement strategies and tools"
10151114|NCT04088643|Experimental|tACS group|NEXALIN ADI transcranial alternating current stimulator
10151115|NCT04088643|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
10151116|NCT04088773||Aim 1 Crohn Disease participants (B2 phenotype)|Crohn's Disease participants scheduled for ileal small bowel resection; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
10151117|NCT04088773||Aim 2 Crohn Disease participants (B1 phenotype)|Crohn's Disease participants with uncomplicated small bowel disease; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
10151118|NCT04088773||Aim 2 Healthy Controls|No intervention; observational only; collection of blood, stool, and completion of Gastrointestinal Symptoms Rating Scale
10151119|NCT04088903|Experimental|Daratumumab infusion|"Participants will receive an intravenous infusion of daratumumab weekly for 8 doses and then every other week for 2 doses.~For this dose-escalation study, the initial patients will receive a 2 mg/kg dose of daratumumab. In subsequent patients, the dose will be uptitrated to 16 mg/kg as tolerated.~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
10151120|NCT04088487|Experimental|Experimental group|Participants gain access to the internet intervention after the baseline measurement (pre-test).
10151121|NCT04088487|Other|Waitlist control group|Participants gain access to the internet intervention 8 weeks after the baseline measurement (pre-test).
10151122|NCT04088344|Placebo Comparator|Isocaloric diet (7 days)|Protocole A
10151123|NCT04088344|Experimental|Hypercaloric diet enriched with carbohydrate food (7 days)|Protocole B
10151124|NCT04088604|Experimental|LY01610-Dose Escalation|The starting dose was 30 mg/m2 IV and the subsequent dose was increased according to the protocol of 60 mg/m2, 90 mg/m2, 120 mg/m2, 150 mg/m2, 180mg/m2. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
10151125|NCT04088604|Experimental|LY01610-Dose Extension|According to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 were further evaluated in 6 - 8 patients. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
10151126|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Escalation|"Dose Escalation:~Based on the results of the first stage, three doses of low, medium and high doses were selected in combination with a fixed dose of 5-Fu to determine the DLT, MTD, PK characteristics and the preliminary efficacy. 5-Fu, 400mg/m2 will be administered intravenously on days 1, followed by 600 mg/m2 given as a 22-hour continuous infusion on day 1 and 2, every 2 weeks."
10151127|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Extension|"Similarly, according to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 combined with a fixed dose of 5-Fu were further evaluated in additional 6 - 8 patients.~In dose escalation and dose extension stages, both LY01610 and fixed dose 5-Fu will be given once every 2 weeks."
10151128|NCT04088604|Active Comparator|Hydrochloride Injection- pharmacokinetics comparative study|After receiving the MTD of LY01610, another 8 subjects were enrolled and given Irinotecan Hydrochloride Injection（captol ®） (180mg/m2) once every 2 weeks. Upon completion of the pharmacokinetics study, the sponsor will continue to provide the study drug treatment free of charge, and the researcher will conduct treatment and examination according to the subject's situation, without collecting any safety and efficacy data of the subject.
10151129|NCT04088422||B-cell lymphoma|
10151130|NCT04088526|Experimental|intervention group|Through the effective intervention of risk factors for death in patients with dialysis, the effect of mortality of peri-dialysis patients was observed.
10151131|NCT04088461|Experimental|Linagliptin + Metformin and lifestyle|Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.
10151132|NCT04088461|Active Comparator|Metformin|Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.
10151133|NCT04088474|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.
10151134|NCT04088474|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
10151135|NCT04088448|Placebo Comparator|Control group|Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
10151136|NCT04088448|Experimental|Metformin group|Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks
10151137|NCT04088292|Active Comparator|USAT + low dose thrombolysis|UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization
10151138|NCT04088292|Active Comparator|Low dose thrombolysis|Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).
10151139|NCT04088292|No Intervention|Heparin alone|UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)
10151140|NCT04088227|Active Comparator|Control Group|The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
10151141|NCT04088227|Experimental|Experimental Group|The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee. At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection. A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).
10185516|NCT03744923|Active Comparator|unilateral posterior TAP block group|"under ultrasonographic guidance,the probe will be positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid-axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, the block was performed with the 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydro visualization of needle-tip position and confirming its correct positioning. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together."
9972090|NCT01317290|Experimental|olive oil|n3-PUFA free control oil to normalweight subjects (BMI <25)
9972091|NCT01317303|Experimental|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
10185517|NCT03744923|No Intervention|control group|the patients will not receive any blocks
9972092|NCT01317303|Experimental|cTBS-PAS|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
9972093|NCT01317303|Experimental|iTBS|190 seconds of intermittent theta-burst stimulation
9972094|NCT01317303|Experimental|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
9972095|NCT01317329|Other|Clinically prescribed CPAP therapy|Clinically prescribed CPAP therapy
10185518|NCT03744897|Experimental|Hypnotic analgesia|"Intervention:~- Subjects will receive hypnotic analgesia"
10185519|NCT03744897|Experimental|a-tDCS|"Intervention: transcranial direct current stimulation - tDCS~active tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current:2 milliamps~time: 20 minutes"
10185520|NCT03744897|Sham Comparator|s-tDCS|"Sham comparator: transcranial direct current stimulation - tDCS~sham tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current: 0 milliamps~time: 20 minutes"
10185521|NCT03744897|Experimental|Hypnotic analgesia + a-tDCS|"Intervention:~hypnotic analgesia~active tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current:2 milliamps~time: 20 minutes"
10185522|NCT03744884|Experimental|CP intervention group|Force efforts with haptic feedback in virtual reality for participants with CP.
10185523|NCT03744884|No Intervention|CP control group|Regular activity control group, for participants with CP.
10185524|NCT03744884|Experimental|TD intervention group|Force efforts haptic feedback in virtual reality. The intervention will be the same as the CP intervention group but for typically developing participants.
10185525|NCT03744884|No Intervention|TD control group|Regular activity control group, same as CP no intervention group, but for typically developing participants.
10185526|NCT03744871|Active Comparator|Respirator|Open label use of N95 respirators (worn outdoors) (active limb, n=100)
10185527|NCT03744871|No Intervention|No intervention|No respirators will be worn by the control group (control limb, n=100)
10151142|NCT04088058|Experimental|GXHPC1|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
10151143|NCT04088383|Other|Amnios™ RT|
10151144|NCT04088383|Placebo Comparator|Saline|
9972096|NCT01317342|Active Comparator|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour
9972097|NCT01317342|No Intervention|Control group: no intervention|Conventional cold storage (IGL-1)
9826246|NCT02412956|Experimental|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
10151145|NCT04088097|Experimental|Cognitive-Behavioral Therapy|Adapted Cognitive-Behavioral Therapy (CBT) for adolescents with binge eating or loss-of-control eating.
10151146|NCT04088097|Other|Control Condition|Educational materials related to adolescent health and nutrition.
10151147|NCT04088214|Experimental|ArtDSTP|Arthroscopic lateral soft tissue release
10151148|NCT04088266|Other|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA® sublingual film 16 mg buprenorphine with 4 mg naloxone
10151149|NCT04088253|Experimental|cirrhotic patient|cirrhotic patient with umbilical hernia to be operated
10151150|NCT04088149|Experimental|GXNPC1|"There are 2 dose levels Cohort 1: Low dose (1 ± 0.1 × 10^8 GXNPC1) of IPs will be administered in parallel.~Cohort 2: High dose (2 ± 0.2 × 10^8 GXNPC1) of IPs will be administered sequentially."
10151151|NCT04087993|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
10151152|NCT04087993|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
10151153|NCT04087993|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
10151154|NCT04088162|No Intervention|Standard Dressing|In case of Control group. After Ileostomy closure skin will be closed by 6 to 8 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures, and sterile standard dressing will be placed.
10151155|NCT04088162|Experimental|Postoperative NPWT dressing|"In case of NPWT group. After Ileostomy closure skin will be closed by 3 or 4 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures. Between them small sponge tongues 1x 0,5x2 cm were placed and over whole incision an NANOVA (KCI USA) negative pressure dressing will be placed. In control group first dressing change was made in 48 hours after operation and then every day until suture removal at 7 postoperative day. In NPWT group NANOVA dressing was taken out at 72 hours. 3 steri-streps were placed between sutures and standard sterile dressing was placed. After it dressing was changed every 24 hours until suture removal at 7 postoperative day."
10151156|NCT04088032|Experimental|Active|Experimental treatment
10151157|NCT04088201|Experimental|Measuring glucose|Measuring glucose from interstitial fluid
10151158|NCT04088045|Experimental|Receiving PRP injections or PRP plus neural prolotherapy|"This experiment compares the effect of injecting PRP alone into the knee joint and pes anserinus complex with when dextrose solution is also injected to the genicular nerves.~The injection of dextrose solution is to decrease the inflammation of the genicular nerves, hoping to further effectively alleviate the knee pain condition. Therefore, upon the conclusion of this study, we can see whether the inclusion of dextrose injection in addition to PRP treatment can really be effective in treating patients with more severe degrees of knee OA."
10151159|NCT04088175|Experimental|Group 1 - Virginia Tobacco and Menthol|Subjects randomized to Group 1 will use JUUL ENDS Virginia Tobacco and Menthol flavors
10151160|NCT04088175|Experimental|Group 2 - Mint and Mango|Subjects randomized to Group 2 will use JUUL ENDS Mint and Mango flavors
10151161|NCT04088240|Experimental|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (~980 mg DPA, 380 mg EPA, 1720 mg DHA)
10151162|NCT04088240|Active Comparator|n-3 control|4 g/d n-3 control (~980 oleic acid, 380 mg EPA, 1720 mg DHA)
10151163|NCT04088240|Placebo Comparator|Placebo|"4 g/d placebo control (light olive oil)"
10151164|NCT04087915||High risk coronary artery disease|Participants with high risk coronary artery disease.
9826247|NCT02412982|No Intervention|Serum anti-Xa >= 0.1 IU/mL|Patients with serum anti-Xa level >= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
10151165|NCT04088084|Experimental|standard of care+palmitoylethanolamide|PEA was supplemented for 3 months to the standard of care (SOC, topical IOP lowering med)
10151166|NCT04088084|No Intervention|standard of care|patients were only on topical IOP lowering therapy (SOC)
10151167|NCT04088019||Observational cohort group|"Subjects: idiopathic uveitis with IGRA positive.~Examinations:~Clinical improvement examinations at day 0, second week, week 8, month 3, month 6 and month 12.~Blood sampling at day 0, second week, month 6 for analysing type 1 IFN gene expression scoring using RT-qPCR methods."
10151168|NCT04088110|Experimental|Pyrotinib and trastuzumab plus aromatase inhibito|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10151169|NCT04087824|Experimental|AI monitoring colonoscopy|Patients in this group go through colonoscopy under the AI monitoring device.
10151170|NCT04087837|Experimental|bougie group|The bougie group: The end of the endotracheal tube was guided to the glottis using the endotracheal tube in the bougie mode under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
10151171|NCT04087837|Experimental|Nasogastric(NG) tube group|NG tube group: The end of the endotracheal tube is guided to the glottis by using the endotracheal tube in the nasogastric tube under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
10151172|NCT04087837|No Intervention|control group|Control group: The general anesthesia method of placing the endotracheal tube through the nasal cavity is used to guide the tip of the endotracheal tube to the glottis under the direct view of the electronic imaging laryngoscope.
10151173|NCT04087954|Experimental|Intervention vs control|
10151174|NCT04087954|No Intervention|Control|
10151175|NCT04087707|Experimental|Step 1;TS-142|
10151176|NCT04087707|Experimental|Step 2;TS-142|
10151177|NCT04087707|Placebo Comparator|Step 2;Placebo|
10151178|NCT04087746|Active Comparator|AFLIBERCEPT|Intra-vitreal injection of AFLIBERCEPT
10151179|NCT04087746|Active Comparator|RANIBIZUMAB|Intra-vitreal injection of RANIBIZUMAB
10151180|NCT04088006|Experimental|Treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area treated
10151181|NCT04088006|No Intervention|Non-treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area non-treated
10151182|NCT04087928|Experimental|Group Flexors (A)|Group A was treated by applying FMV to the flexor muscles of the upper limb (brachial biceps and carpal flexors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
10151183|NCT04087928|Experimental|Group Extensors (B)|Group b was treated by applying FMV to the extensors muscles of the upper limb (triceps brachial and carpus extensors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
10151184|NCT04087941|Placebo Comparator|Placebo|
10151185|NCT04087941|Experimental|VM-202|
10151186|NCT04087967|Experimental|Decitabine combined with HAAG|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
10151187|NCT04087967|Active Comparator|IA Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
10151188|NCT04087577|Experimental|experimental group|conventional physical therapy with mirror therapy
10151189|NCT04087577|Active Comparator|control group|conventional physical therapy
10151190|NCT04087863||Atopic Dermatitis|
10151191|NCT04087538||Patients treated using troponin T|
10151192|NCT04087538||Patients treated using troponin I|
10151193|NCT04087590|Experimental|PT003 treatment|
10151194|NCT04087551|Experimental|Developing the list of items for BRFES|Two groups of six community-dwelling older adults will participate in a focus group session. Each focus group session will begin with a trained facilitator using a session guide welcoming the participants and introducing the participants in the group. The session will adopt a nominal group method which includes silent generation of ideas, sharing of an idea in a 'round robin' fashion, group discussion to clarify ideas and then completing the session with anonymous voting to include items into a list of items to be included in the Balance Recovery Falls-Efficacy Scale (BRFES).
10151195|NCT04087499|Sham Comparator|regular medication treatment|regular medication treatment
10151196|NCT04087499|Experimental|acupuncture and regular medication treatment|acupuncture and regular medication treatment
10151197|NCT04087850|Experimental|Making Socially Accepting Inclusive Classrooms (MOSAIC)|
10151198|NCT04087850|No Intervention|Typical Practice Control|
10151199|NCT04087733|Experimental|GROUP / TREATED EYE|OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.
10151200|NCT04087733|No Intervention|GROUP / CONTROL EYE|Saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
10151201|NCT04087460|Experimental|Low-dose Group A|Subjects received three doses of PBPV with 20μg each antigen
9972098|NCT01317355||cancer patients|in and out patients of 5 German university hospitals currently undergoing cancer treatment
9972099|NCT01317368|Active Comparator|TAP block|"TAP block with Ropivacaine~Wound infiltration with Saline"
9519857|NCT03282786|Active Comparator|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
9519858|NCT03282786|No Intervention|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
9972100|NCT01317368|Active Comparator|Wound infiltration|"TAP block with Saline.~Wound infiltration with Ropivacaine."
9972101|NCT01317368|Placebo Comparator|Placebo|"TAP block with Saline.~Wound infiltration with Saline."
9972102|NCT01317381||ICU patients|Admitted patients to the ICU
9972103|NCT01317420|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every three weeks, monotherapy
9972104|NCT01317433|Experimental|Arm A|Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
9972105|NCT01317433|Active Comparator|Arm B|Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.
9972106|NCT01317446|Experimental|amine fluoride/stannous fluoride|Amine fluoride/stannous fluoride mouthrinse in addition to mechanical oral hygiene
10151202|NCT04087460|Placebo Comparator|Low-dose Group B|Subjects received three doses of placebo
10151203|NCT04087460|Experimental|Middle-dose Group A|Subjects received three doses of PBPV with 50μg each antigen
10151204|NCT04087460|Placebo Comparator|Middle-dose Group B|Subjects received three doses of placebo
10151205|NCT04087460|Experimental|High-dose Group A|Subjects received three doses of PBPV with 100μg each antigen
10151206|NCT04087460|Placebo Comparator|High-dose Group B|Subjects received three doses of placebo
10151207|NCT04087434||Retrospective|retrospective review of 300 records of patients following concussive diagnosis to track recovery and adherence to progressive return to activity recommendations.
10151208|NCT04087434||Prospective|300 prospective patients enrolled following concussive diagnosis to track recovery, clinical diagnosis and brain gauge performance.
10151209|NCT04087434||Control Group|75-100 Healthy Controls recruited by Fort Bragg to assess performance in a healthy population for brain gauge performance.
10151210|NCT04087447||Thyroidectomy group|patient undergoing thyroidectomy for simple nodular goiter
10151211|NCT04087525|Experimental|Sequence 1|Period 1 : Fasted state + HIP1701, Period 2 : Fasted state + HGP1809
10151212|NCT04087525|Experimental|Sequence 2|Period 1 : Fasted state + HGP1809, Period 2 : Fasted state + HIP1701
10151213|NCT04087629|Experimental|CTCL group|Patients with CTCL being treated with mechlorethamine gel will receive StrataCTX® gel.
9972107|NCT01317446|No Intervention|No rinsing|Mechanical oral hygiene only
9972108|NCT01317459|Experimental|Lifestyle counselling|
9972109|NCT01317459|Experimental|No intervention|Care as usual
9972110|NCT01317485|Experimental|Purulent peritonitis|"Patients with purulent peritonitis are randomised at a 2:1:1 ratio between~Laparoscopic lavage and drainage~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
9972111|NCT01317485|Experimental|Fecal peritonitis or overt perforation|"Patients with fecal peritonitis or an overt perforation are randomised between~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
10151214|NCT04087629|Experimental|Skin Toxicity group|Patients with skin toxicity secondary to chemo/immunotherapy will receive StrataCTX® gel.
10151215|NCT04087668|Other|Monitored Anesthesia Care|Patients in this arm will undergo an ERCP using monitored anesthesia care (MAC) with propofol based deep sedation.
10151216|NCT04087668|Other|General Anesthesia|Patients in this arm will receive standard general anesthesia with neuromuscular blockade.
10151217|NCT04087668|Other|General Anesthesia Without Neuromuscular Blockade|Patients in this arm will receive nasotracheal intubation without neuromuscular blockade.
10151218|NCT04087694|Other|Open|Open laminectomy and posterior stabilization with pedicle screws for symptomatic lumbar spine stenosis
10151219|NCT04087694|Other|Microscope|Microscopically done decompression of lumbar spine stenosis who are symptomatic
10151220|NCT04087655|Experimental|Exercise training|Eight weeks of interval exercise training
10151221|NCT04087616|Experimental|CBIT|ICBIT. Intervention delivered through an internet platform called Managing children's' tics (www.cbteamathome.co.il), based on CBIT protocol (Woods et al., 2008) adapted to an online parent-guided self-help format.
10151222|NCT04087616|Placebo Comparator|Waiting List|Participants initially assigned to the wait list receive no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants receive ICBIT.
10151223|NCT04087603|Experimental|Weekend Morning Bright Light & Early Bedtime|"Assigned a set sleep schedule for 2 weeks~Receives evening time management goals to help facilitate scheduled bedtime~Receives morning bright light from 2 light boxes (Phillips EnergyLights) on two weekend mornings."
10151224|NCT04087603|No Intervention|Healthy Control|- Sleep as usual at home for 2 weeks
10151225|NCT04087811||Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) - Interspinous Spacer
10151226|NCT04087759|Experimental|Treatment Sequence BAE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
10151227|NCT04087759|Experimental|Treatment Sequence CAF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet II under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
10151228|NCT04087759|Experimental|Treatment Sequence DAG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
10151229|NCT04087759|Experimental|Treatment Sequence ABE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
10151230|NCT04087759|Experimental|Treatment Sequence ACF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 2, thereafter will receive bedaquiline oral test tablet 2 under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
9972112|NCT01317498|Placebo Comparator|Standard Monitoring|The patients in the standard monitoring arm will receive routine laboratory monitoring as provided to all patients in public HIV clinics in Vietnam, including CD4 count, complete blood count, and liver functions tests every 6 months.
9972113|NCT01317498|Active Comparator|Virological Monitoring|The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
9972114|NCT01317511|Experimental|Protein|Protein drink
9972115|NCT01317511|Placebo Comparator|Placebo|water
9972116|NCT01317524|Experimental|Homogenized Milk|900 mL homogenized milk is consumed within a mixed meal
9972117|NCT01317524|Experimental|Unhomogenized Milk|900 mL unhomogenized milk is consumed within a mixed meal
9972118|NCT01317524|Experimental|Skimmed Milk|900 mL skimmed milk and 44 g of butter are consumed within a mixed meal
9972119|NCT01317537|Experimental|Received personal health record|received personal health record access
9972120|NCT01317537|No Intervention|No personal health record|did not receive personal health record
9972121|NCT01317563|Active Comparator|Antioxidant arm|Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)
9972122|NCT01317563|Placebo Comparator|Placebo arm|two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)
9972123|NCT01317576|Experimental|Healthy control|This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
10151231|NCT04087759|Experimental|Treatment Sequence ADG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
10151232|NCT04087408|No Intervention|control group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~Trigger will be done using HCG followed by OPU 36 h later.~Retrieved oocytes will be fertilized by ICSI.~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6 - Blood sampling will be performed for progesterone 7 days after OPU.~7-Quantative BHCG will be performed 14 days after OPU."
10151233|NCT04087408|Active Comparator|study group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~Trigger will be done using HCG followed by OPU 36 h later.~Retrieved oocytes will be fertilized by ICSI.~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~GnRH agonist 0.1 mg will be given 6 days after OPU.~Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~Quantative BHCG will be performed 14 days after OPU."
10151234|NCT04087421|Experimental|Transanal irrigation|Participants receiving TAI will irrigate once/day with stepwise volumes; 1. month 150 ml, 2. month 300 ml, and 3. month 500 ml.
10151235|NCT04087421|Active Comparator|Glycerol suppositories|Participants treated with glycerol suppositories will administer one glycerol suppository once/day.
10151236|NCT04087291|Active Comparator|Phase 1: Low Dose (1-5 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a low dose (1-5 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
10151237|NCT04087291|Active Comparator|Phase 1: Higher Dose (8-12 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a higher dose (8-12 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
10151238|NCT04087291|Active Comparator|Phase 2: CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive chiropractic chronic pain management (CCPM) consisting of scheduled monthly chiropractic care for 10 months.
10151239|NCT04087291|No Intervention|Phase 2: No CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive no CCPM in which they will receive no chiropractic care for 10 months.
10151240|NCT04087239||Pregnant women from >20 weeks gestation|1,200 pregnant women (600 HIV infected mothers and 600 HIV uninfected controls) at least 20 weeks gestation were enrolled from January 2016 to June 2019. Participants are being followed as mother-baby pairs at birth, within 10 days of life 6, 10, 14 24, 48, 72 and 96 weeks of age. At each visit clinical examinations are being used to assess health and the impact of environmental factors. In addition, questionnaires are administered and bio-samples for laboratory tests. The design of the study is non-interventional cohort but participants are being offered advice regarding health and hygiene.
9977804|NCT01365338|Experimental|Cohort 1|Participants will receive 0.075 milligrams (mg) of PF-04958242 as a single oral dose.
10151241|NCT04087304|No Intervention|Low Risk Group|
10151242|NCT04087304|No Intervention|Mild Risk Group|
10151243|NCT04087304|Active Comparator|Moderate Risk Group|
10151244|NCT04087304|Active Comparator|High Risk Group|
10185528|NCT03744858||Group A - Participants with CVD|Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
9519859|NCT03282786|Active Comparator|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
9519860|NCT03282786|No Intervention|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
9519861|NCT03282773|Experimental|Deferred stent implantation|Drug-eluting stents are implanted 4-10 days after primary angiography and restoration of blood flow in left main coroanry artery in a secondary PCI
9519862|NCT03282773|Active Comparator|Immediate stent implantation|Drug-eluting stents are implanted immediately after primary angiography and restoration of blood flow in left main coroanry artery
9519863|NCT03282760|Experimental|Human Neural Stem Cells Suspension|Intraventricular injections of Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10,16 or 24 millions)
9519864|NCT03282734|Experimental|The smart rehab group|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for 4 weeks
9519865|NCT03282734|Active Comparator|The control group|Conventional home rehabilitation exercise education for 4 weeks
9519866|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
9669612|NCT03749499|Active Comparator|Educational and Empowerment Intervention|"Participants receive:~HTN Educational Video about high BP, how it is diagnosed, and importance of treatment to prevent secondary complications.~Visual Echocardiogram Image Clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change behavior and improve their BP.~Mobile Health and Remote BP monitoring- participants receive an FDA-approved home blood pressure monitoring (HBPM) kit that includes the Nokia wireless BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.~A Post-Acute Care HTN Transition consultation (PACHT-c) with a clinical pharmacist or advanced practice nurse (APN)."
9519867|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
10151245|NCT04087213|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
10151246|NCT04087382|Active Comparator|Intervention group|it included 32 patients with acute ischemic stroke beyond the time of window (more than 6 hours) assigned to mechanical thrombectomy) plus the conventional treatment (Aspirin 150 mg and atorvastatin 40 mg).
10151247|NCT04087382|Other|non-intervention group|it included 25 patients with acute ischemic stroke beyond the time of window (more than 6 hours) who received medical treatment (Aspirin 150 mg and atorvastatin 40 mg).
10151248|NCT04087356||RMD+ Patients|Age-related macular degeneration patients with reticular macular disease
10151249|NCT04087356||RMD- Patients|Age-related macular degeneration patients without reticular macular disease
10151250|NCT04087369|Experimental|Bundled NCD WHO PEN Intervention|Mixed-methods type 2 hybrid effectiveness-implementation study to evaluate an integrated NCD care management intervention
9669613|NCT03744936|Experimental|DA4Afib|Developing a tool to use during the encounter
9669614|NCT03734731|Other|Objective Nerve Conduction testing|Therapy of chronic pain and swelling with Monochromatic Infrared Photo Energy (MIRE) in combination with Transcutaneous Electrical Nerve Stimulation (TENS) and Cannabis or Opioids, to determine which treatment is deemed as the most successful, through objective nerve conduction testing with Neural Scan or AXON-II testing systems. Other types of therapies may be introduced during comparison reviews.
10151251|NCT04087174|Experimental|Part A1: Capivasertib + enzalutamide|From day 1 to day 28 of this study treatment, patients will continuously enroll on a starting dose of capivasertib in combination with 160 mg enzalutamide.
10151252|NCT04087174|Experimental|Part A1: Capivasertib dose level 1 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+1 along with 160 mg enzalutamide.
10151253|NCT04087174|Experimental|Part A1: Capivasertib dose level 2 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+2 along with 160 mg enzalutamide.
10151254|NCT04087174|Experimental|Part A2: Capivasertib + abiraterone|Patients will continuously enroll on a starting dose of capivasertib in combination with 1000 mg abiraterone.
10151255|NCT04087174|Experimental|Part B1: Capivasertib + enzalutamide|This optional expansion will treat patients at the recommended dose regimen of capivasertib and enzalutamide.
10151256|NCT04087174|Experimental|Part B2: Capivasertib + abiraterone|This optional expansion will treat patients at the recommended dose regimen of capivasertib and abiraterone.
10151257|NCT04087044|Experimental|Vestibular dysfunction|66 patients: 30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine
10151258|NCT04087044|Other|Control|120 aged matched controls
10151259|NCT04086979|Experimental|Parental Friendship Coaching (PFC)|
10151260|NCT04086979|Active Comparator|Coping with ADHD through Relationships and Education (CARE)|
10151261|NCT04087135|Experimental|participant LD|
10151262|NCT04087135|Experimental|participant VL|
10151263|NCT04087135|Experimental|participant VLS|
10151264|NCT04087187|Experimental|Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
9669615|NCT03722095|Active Comparator|active tDCS + active iTBS|Participants will receive 20 minutes of active tDCS, during the last 7 minutes active iTBS will be applied.
9669616|NCT03722095|Sham Comparator|sham tDCS + active iTBS|Participants will receive 20 minutes of sham tDCS, during the last 7 minutes active iTBS will be applied.
9972124|NCT01317576|Experimental|Non-alcoholic fatty liver disease|This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
10151265|NCT04087187|Experimental|Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
10151266|NCT04087187|Experimental|Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
10151267|NCT04087187|Experimental|Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
10151268|NCT04087187|Experimental|Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
10151269|NCT04087187|Experimental|Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.~Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
10151270|NCT04087005|Experimental|Hominis placental pharmacopuncture|The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.
10185529|NCT03744858||Group B - Healthy Participants|Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
10151271|NCT04087005|Active Comparator|Transcutaneous electrical nerve stimulation|The control group will receive 2 sessions/week of TENS for 5 weeks. A high-frequency, low-intensity stimulus of 50-100Hz and up to 15mA will be used, such that the patients feel a current but do not feel pain. At each treatment visit, a physiotherapist will administer the treatment to the bilateral temporomandibular joint for 15 minutes. Both centres will use the same TENS device-a BioTron-DX (D.M.C, Osan, South Korea).
10151272|NCT04087109|Experimental|Intervention: MedSafer|In the intervention phase, the MedSafer feature will become accessible in MED e-care for the physicians, pharmacists and nurses. This feature will provide health care professionals with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. During the intervention phase, all patients will receive the educational (EMPOWER) brochures as applicable to the medications they are taking (PPI, sedative-hypnotic, antihistamine, antipsychotic, sulfonylurea, NSAID, opioid/narcotic).
10151273|NCT04087109|No Intervention|Control: Baseline (no MedSafer)|During the control phase, the MedSafer application programming interface will not be accessible to the caretakers at the aged care facilities (ACF). This serves to obtain baseline deprescribing levels for each ACF.
10151274|NCT04086901|Experimental|Dose escalation Arm|Chemo-radiotherapy with radiotherapy dose escalation based on Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG/PET) scans
10151275|NCT04086901|No Intervention|Standard|Standard chemo-radiotherapy
10151276|NCT04086940|Active Comparator|esmolol(breviblock) group|Patients in group E received a loading dose of esmolol(breviblock) 1 mg/kg in 50 ml isotonic saline over 30 minutes before induction of anesthesia, then followed by an infusion of esmolol 10 µg/kg/min until the end of the surgery.
10151277|NCT04086940|Active Comparator|non esmolol group|Patients in group N received 50 ml of isotonic saline over 30 min, followed by an infusion of isotonic saline at same rate of group E till the end of the surgery.
10151278|NCT04087083|Experimental|technological intervention arm|Twenty technological treatment sessions divided into 3 training sessions per week for 7 weeks.
10151279|NCT04087083|Active Comparator|Control arm|Twenty traditional treatment sessions divided into 3 training sessions per week for 7 weeks.
10151280|NCT04086927|No Intervention|Control Group|Patients will not receive compression dressing
10151281|NCT04086927|Experimental|Experimental Group|Patients will receive compression dressing
10151282|NCT04087031|Active Comparator|control arm|Ten traditional treatment sessions divided into 2 training sessions per week for 5 weeks
10151283|NCT04087031|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
10151284|NCT04087031|Experimental|robotic treadmill arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
10151285|NCT04087265|Other|Study Population (All Participants)|Patients who are referring for scheduled screening colonoscopy
10151286|NCT04087226|Active Comparator|Conventional Retraction Cord|
10151287|NCT04087226|Experimental|PTFE Retraction Cord|
9972125|NCT01317576|Experimental|Type 2 diabetes patients|This group will exist of patients that suffer from type 2 diabetes
9972126|NCT01317589|Active Comparator|fentanyl|active pain treatment with fentanyl patch
9972127|NCT01317589|Experimental|methadone|active pain treatment with methadone
9972128|NCT01317628|Other|Lifestyle counseling|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
9972129|NCT01317654||Survivors of TBM trial 2001-2005|
9972130|NCT01317680|Active Comparator|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
9972131|NCT01317680|Placebo Comparator|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy.
9972132|NCT01317693|Experimental|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
9972133|NCT01317706|Active Comparator|Bishop score|
9972134|NCT01317706|Active Comparator|transvaginal ultrasound|
9972135|NCT01317719||Distal Biceps Ruptures|
10151288|NCT04086953|Experimental|Chronic Respiratory Disease Group|"Each patient receive the same intervention : 4 visits with different exercise tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2) Specific measures for COPD subjects : Respiratory Functional Assessment and Dyspnea questionnaire"
10151289|NCT04086953|Experimental|Cardiovascular diseases Group|"Each patient receive the same intervention : 4 visits with different tests.~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle,, questionnaires and accelerometer)~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)~Visit 4 : Reproducibility of the WTLT (WTLT x2)"
10185530|NCT03744845|No Intervention|Control group|Usual anesthetic care.
9972136|NCT01317732|Experimental|MOTIONPOD (TM)|
9972137|NCT01317745|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
9972138|NCT01317745|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
10151290|NCT04087252|Experimental|vaccinated group|Neoantigen vaccination will be performed with 6 doses in total, once per week
10151291|NCT04086914|No Intervention|Non nerve block|Receives no nerve block
10151292|NCT04086914|Experimental|Nerve block|Receives nerve block
10151293|NCT04087070||biosignal derived blood pressure|"Blood pressure is measured by an automated oscillometric device or arterial waveform from IntelliVue MX800 Bedside patient monitor (Philips Healthcare, Amsterdam, Netherlands).~Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~PAT(time between R peak of ECG and beginning of the pulse of PPG)~PEP(time between R peak of ECG and peak of accelerometer signal)~PTT(PAT-PEP)"
10151294|NCT04086992|No Intervention|Control Group|This group will continue to receive standard care for ACTH monitoring and follow-up with includes blood pressure by the patient's PCP while on therapy, a one week nursing follow-up phone call, and a two-week EEG and Neurology appointment.
10151295|NCT04086992|Experimental|Intervention Group|This group will be provided remote monitoring technology where they will be able to monitor blood pressure at home. In addition, they will receive a nurse-led telemedicine visit at one week and three weeks of therapy. Like the control group, they will still receive a two-week EEG and Neurology appointment.
10151296|NCT04087317|Experimental|Fixed time interval group.|Once the patient will arrive at the maternity ward the patient will receive paracetamol 1 gram and a tablet of ibuprofen 400 mg. Six hours after patient arrival and every 6 hours the patient will receive a tablet of paracetamol 500 mg and a tablet of ibuprofen 400 mg.
10151297|NCT04087317|Experimental|'On-demand' group.|Patients allocated to this group will receive the same medications in the same combinations and order as described in the 'fixed time interval' group protocol, patients in this group will receive pain treatment only following demand, and the time intervals described above will be considered as the minimal time for giving the next combination of drugs.
10151298|NCT04086836||Patient suffering a late stroke after TAVR|All patients suffering a stroke after TAVR will be studied
10151299|NCT04086654|Other|International Trauma Interview (ITI)|
10151300|NCT04086615|Experimental|NMES and exercise supplemented with high BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The High BFR group will have the pressure set at 80% of limb occlusion pressure."
10151301|NCT04086615|Sham Comparator|NMES and exercise supplemented with low BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The Low BFR group will have the pressure set at 20 mmHg."
10151302|NCT04086706||Consecutive Patients with complete colonoscopy|Inclusion criteria were as follows: Patients older than 18 years, with a complete colonoscopy, for CRC screening or post-polypectomy surveillance or diagnostic assessment. Exclusion criteria precluded patients with previous colectomy or an abdominal surgery in the last 6 months, patients with polyposis syndromes or inflammatory bowel diseases and if they were unfit for polypectomy or the polyp specimen was not retrieved for histology.
10151303|NCT04086537||BMPR2-mutation carriers|Patients affected by pulmonary arterial hypertension (PAH) with already determined BMPR2 mutation status (hereditary PAH, HPAH) or patients with idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted positive for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
10151304|NCT04086537||non-BMPR2 mutation carriers|Patients affected by Pulmonary arterial hypertension (PAH) who resulted negative at the routinely-performed (according to current guidelines) BMPR2 analysis (Idiopathic PAH, IPAH) or patients with Idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted negative for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
10151305|NCT04086537||healthy controls|Healthy controls free of heart and lung disease or any comorbidities affecting iron metabolism. This control group will be age and gender matched to non-BMPR2 mutation carriers.
10151306|NCT04086771|Experimental|Intervention Group (Navigation)|Participants will be contacted by CHAs by phone one week after giving informed consent and completion of the baseline survey. CHAs will contact participants once a week for up to 10 weeks (a maximum of 10 attempts or until a clinic appointment is made, whichever comes first). Using the TIMS© message library, the CHAs will engage participants in conversations about breast and cervical cancer screening and navigate the participants to overcome any barriers to screening and motivate them to make a clinic appointment. Personal messages from mothers to daughters and vice versa and screening reminder notecards will be sent at 12-months (T3). At 18-months (T4), CHAs will follow-up with navigation group participants who reported completing a mammogram during the navigation process. Screening completion will be measured by self-report and confirmed via medical record check.
10185531|NCT03744845|Experimental|Virtual Reality Intervention Group|Virtual Reality Distraction
10151307|NCT04086771|Placebo Comparator|Control Group (Information only)|Participants will be mailed an informational brochure on mammography and Pap testing one week after enrollment into the study. At 3-months post enrollment, CHAs will conduct a follow-up phone call with each participant to assess mammogram and/or Pap testing completion (primary outcomes). At 12-months (T3) post enrollment, CHAs will contact all control group participants by phone to confirm a scheduled appointment or screening completion. For those who completed a mammogram within the 12 months since enrollment, generic screening reminder notecards will be sent by mail. At 18-months (T4), CHAs will follow-up with those control group participants who reported scheduling a mammogram, Pap smear, or both at the 12-month (T3) time point.
10151308|NCT04086719|Experimental|BMS- 986185 + Pyrimethamine|
10151309|NCT04086719|Experimental|BMS-986185|
10151310|NCT04086498|Experimental|ketogenic-mediterranean diet with phytoextracts|The KEMEPHY diet (Paoli et al., 2011) is a mediterranean calorie-controlled ketogenic protocol (about 900 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg). Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (Lodi et al., 2016).
10151311|NCT04086498|Active Comparator|Ketogenic Diet|The KD is a protocol in which all foods containing carbohydrate are excluded, whereas meat, eggs, fish, ham, green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants can be eat without any limit. This protocol allows the use of oil, lemon juice (2 tbs/day), spices and aromatic herbs with a limitation of the use of saturated fats like butter, margarine and lard. Coffee, tea and herbal tea could be sweetened with sweeteners
10151312|NCT04086498|Active Comparator|Mediterranean Diet|The MD is a balanced calorie-controlled diet. The calorie intake was 1200 Kcal/day of which 15% were proteins, 60% carbohydrates and 25% fat. In this protocol was highlighted the use of the typical ingredients of the mediterranean tradition, such as extravirgin olive oil, vegetables, fruits, fish, lean meat and whole grain cereals.
10151313|NCT04086797|Experimental|IQP-AE-103|2 capsules after 3 main meals per day (total 1980 mg)
10151314|NCT04086797|Placebo Comparator|Placebo|2 capsules after 3 main meals per day
10151315|NCT04086459|Active Comparator|Active repetitive transcranial magnetic stimulation|
10151316|NCT04086459|Sham Comparator|Sham repetitive transcranial magnetic stimulation|
10151317|NCT04086459|No Intervention|No repetitive transcranial magnetic stimulation|
10151318|NCT04086823|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 48 sites in the submental fat (0.05/0.1mL per site):~Up to 120mg administered at 48 sites in a volume of 0.05 ml at each injection site (total injected volume 2.4mL)~Up to 240 mg administered at 48 sites in a volume of 1 ml at each injection site (total volume injected 4.8mL)"
9826248|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 40 mg q12h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
10151319|NCT04086823|Placebo Comparator|Vehicle|"Subject receive a single-treatment injection. Multiple injections of the Placebo are administered at 48 sites (0.05/0.1mL per site) into the submental fat.~Up to a total of 2.4 mL will be injected for placebo subjects enrolled during cohort 1.~Up to a total of 4.8 mL will be injected for placebo subjects enrolled during cohort 2."
10151320|NCT04086875|Experimental|Phase 1 (focus groups)|Participants attend focus groups on adherence to hormone therapy.
10151321|NCT04086875|Experimental|Phase II Group 1 (text messages)|Participants receive text messages twice weekly for 6 months to remind and motivate participants about AHT adherence.
10151322|NCT04086875|Active Comparator|Phase II Group II (usual care)|Participants receive usual care.
10151323|NCT04086394|Experimental|PECS Block|Group who was randomly selected to receive the intraoperative nerve block.
10151324|NCT04086394|Sham Comparator|Control|Patient who was randomly selected not to receive intraoperative nerve block
10151325|NCT04086524|Experimental|Binocular cartoon treatment at home|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL at home. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
10151326|NCT04086524|Active Comparator|Control group|"Participants will patch for 2 hours every day at home. After 2 weeks, they will be given the option to crossover to the teratment group for an additional 2 weeks (total of 4 weeks). Patching is a common treatment for amblyopia, often considered the golden standard. It is the most common comparison as a control group in amblyopia and vision therapy literature."
10151327|NCT04086524|Experimental|Binocular cartoon treatment in office|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL in office. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
10151328|NCT04086563|Experimental|Action observation|The patients will observe a 25 minutes clip of neurodynamic exercises of the hand.
10151329|NCT04086563|Experimental|Mirror Therapy|With a mirror glasses, the patients will execute neurodynamic movements of their non-dominant hand during 25 minutes.
10151330|NCT04086563|Active Comparator|Strength Training|Strength protocol for the dominant hand.
10151331|NCT04086563|Experimental|Neurodynamic exercise|Active neurodynamic exercises for the dominant hand.
10151332|NCT04086602|Experimental|Single Ascending Dose|Once daily oral IZD334 or Placebo
10151333|NCT04086602|Experimental|Multiple Ascending Dose|Once or twice daily oral IZD334 or Placebo
10151334|NCT04086368|Active Comparator|The Synthes Pediatric LCP Plate System|Open osteotomy and osteofixation with the pediatric LCP hip plate
10151335|NCT04086368|Experimental|The adolescent Lateral Femoral Nail|Percutaneous osteotomy and intramedullary nailing
10151336|NCT04086628||Asthmatic children vaccinated|
10151337|NCT04086628||Asthmatic children unvaccinated|
10151338|NCT04086420|Experimental|Mindfulness|Delivered through an audio-recording consisting of a single meditation exercise that lasted for 30 minutes
10151339|NCT04086420|Active Comparator|Heart-Rate|Given a heart rate monitor and instructed to use it to determine the intensity of their exercise
10151340|NCT04086810|Experimental|DCCR|25 - 450 mg DCCR
10151341|NCT04086342|Active Comparator|CHI-902|Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
10151342|NCT04086342|Placebo Comparator|Placebo|Study subjects will enter a titration phase of 1 week with a daily oral dose of 150 mg (50 mg three times daily) of matching placebo. Then, daily dose of 300 mg of matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
10151343|NCT04086355|Experimental|Effect of electrical stimulation on dysphagia in cp|the study group that was treated by selected oromotor exercise program in addition to neuromuscular electrical stimulation, Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
10151344|NCT04086355|Experimental|effect of oromotor exercise on dysphagia in cp|the control group was treated by the same oromotor exercise program in addition to placebo effect of neuromuscular electrical stimulation. Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
10151345|NCT04086667|Experimental|Pain group|"The segment on the lower back marked as most painful"
10151346|NCT04086667|Experimental|Stiff group|"The segment on the lower back marked as most stiff"
10151347|NCT04086108|Experimental|Tomato|Single oral administration
10151348|NCT04086108|Experimental|GABA supplement|Single oral administration
10151349|NCT04086108|Experimental|Glutamate supplement|Single oral administration
10151350|NCT04086108|No Intervention|Placebo|Single oral administration, same volume of water that is distributed in the other arms
10151351|NCT04086160|Experimental|schizophrenia- tDCS|
10151352|NCT04086160|Sham Comparator|schizophrenia- sham|
10151353|NCT04086160|Experimental|at risk- tDCS|
10151354|NCT04086160|Sham Comparator|at risk- sham|
10151355|NCT04086160|Experimental|healthy controls for schizophrenia- tDCS|
10151356|NCT04086160|Sham Comparator|healthy controls for schizophrenia- sham|
10151357|NCT04086160|Experimental|healthy controls for at risk- tDCS|
10151358|NCT04086160|Sham Comparator|healthy controls for at risk- sham|
10151359|NCT04086173|Experimental|Study group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of probiotics for 16 weeks. Probiotics (LACTIPAN®) include 2.5 billion CFU of 6 different strains of live microorganisms, such as Lactobacillus acidophilus (1.0 x 109 CFU), Lactobacillus casei (1.0 x 109 CFU), Lactobacillus rhamnosus (4.4 x 108 CFU), Lactobacillus plantarum (1.76 x 108 CFU), Bifidobacterium infantis (2.76 x 107 CFU), Streptococcus thermophilus (6.66 x 105 CFU) and 50 mg of oligofructose enriched inulin.
10151360|NCT04086173|Placebo Comparator|Control group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of placebo for 16 weeks. Placebo presentation will have the same aspect as those of the probiotic treatment.
10151361|NCT04086303|Experimental|young handball players|The first group was named young players (n = 19; age = 18.05 ± 2.58 years, body mass index = 22.0 ± 2.21 kg, sport participation ≤ 10 years)
10151362|NCT04086303|Active Comparator|adult handball players|The second group was named old players (n =23; age = 28,91 ± 3.39 years, body mass index = 22.20 ± 2.75 kg, sport participation ≥ 11 years).
10151363|NCT04086381|Active Comparator|Intervention|Oral injestion of 20 grams of creatine monohydrate daily
10151364|NCT04086381|Placebo Comparator|Placebo|Oral injestion of 20 grams of cellulose daily
10151365|NCT04086277|Experimental|Women in labor with continuous intrapartum support|Continuous intrapartum support was based on three basic aspects: 1) emotional support, 2) physical support and comfort measures and 3) information and advice.
10151366|NCT04086277|No Intervention|Women in labor without continuous intrapartum support.|The no intervention group received the usual obstetric care, without continuous intrapartum support.
10151367|NCT04086290|Experimental|RARP + SBRT + ADT|Radical prostatectomy + extended pelvic lymph node dissection according to EAU guidelines followed by stereotactic body radiotherapy to osseous lesions with six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
10151368|NCT04086264|Experimental|Regimen A|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 on Days 1 to 7 of a 28 day cycle. Cycle 1 azaciditine dose in subsequent cohorts may be reduced.
10151369|NCT04086264|Experimental|Regimen B|IMGN632, administered intravenously on Day 7 of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on the day 3 up to Day 21 of a 21 day cycle. Alternate schedules with reduced venetoclax administration may be explored.
10151370|NCT04086264|Experimental|Regimen C|IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 35-75 mg/m2 given for Days 1 to 7 of a 28 day cycle and venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on Day 3 up to Day 28 of a 28 day cycle. Alternate schedules with reduced venetoclax administration or reduced azacitidine dose or administration may be explored.
10151371|NCT04086264|Experimental|Regimen D|IMGN632, administered intravenously on Day 1 of a 21 day cycle at 0.045 mg/kg, as a monotherapy for Fit and Unfit MRD+ patients
10151372|NCT04086251|Experimental|Gaido Intervention|All patients enrolled in the study will participate in the Gaido Intervention, which entails wearing the Biovotion Everion continuously and take blood pressure and oral temperature spot checks per clinician orders. Patients will also be responsible for filling out PRO surveys and any surveys that trigger as a result of their vital signs falling outside of tailored thresholds.
10151373|NCT04086134|Experimental|Intervention fruit products 1|Three servings of fruit products per day for 4 weeks.
9826249|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 30 mg q8h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours
10151374|NCT04086134|Experimental|Intervention fruit products 2|Three servings of fruit products per day for 4 weeks.
10151375|NCT04086134|Placebo Comparator|Control fruit products|Three servings of control fruit products per day for 4 weeks.
10151376|NCT04086316||Depression Group|Naturally cycling women with a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
10151377|NCT04086316||Healthy Group|Naturally cycling women without a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
10151378|NCT04085991|Experimental|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses
10151379|NCT04086043|Experimental|Endovascular Denervation|
10151380|NCT04085952|Experimental|anterior colporrhaphy with dermal graft|Patients randomized to this arm underwent anterior colporrhaphy with dermal graft augmentation (ARUCS) during their surgery for pelvic organ prolapse.
10151381|NCT04085952|Active Comparator|anterior colporrhaphy suture based|Patients randomized to this arm underwent anterior colporrhaphy with suture based repair (native tissue) during their surgery for pelvic organ prolapse. This is and was the most common practice for anterior colporrhaphy.
10151382|NCT04086186|Active Comparator|Adductor Canal Block Group|Standard method for peri-operative pain control. Adductor canal block is performed by anesthesiologist prior to surgery.
10151383|NCT04086186|Experimental|Liposomal Bupivacaine Group|Experimental method for peri-operative pain control. Liposomal bupivacaine peri-articular injection is performed by surgeon during surgery.
10151384|NCT04086238|Other|Formulation A Fasted|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
10151385|NCT04086238|Experimental|Formulation A Fed|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
10151386|NCT04086238|Other|Formulation B Fasted|EPI01 Formulation B (slow reelase): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
9972139|NCT01317745|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus Novartis MF59 adjuvant
10151387|NCT04086238|Experimental|Formulation B Fed|EPI01 Formulation B (slow release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
10151388|NCT04086238|Other|Formulation C Fasted|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
10151389|NCT04086238|Experimental|Formulation C Fed|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
10151390|NCT04086199||Anterior discectomy|The discectomy is made by an anterior muscle sparring approach (extraperitoneal).
10151391|NCT04086199||Posterior discectomy|The discectomy is made by a posterior approach (posterior midline incision).
10151392|NCT04085926|Experimental|Sealed shoe|"Therapeutic footwear including off-the-shelf therapeutic shoes and custom-made insoles. The shoe on the ulcerated foot is sealed, i.e., made irremovable, with a plastic band."
10151393|NCT04085926|Active Comparator|Total contact cast|A irremovable custom-made total Contact cast enclosing the foot and shin
10151394|NCT04086095|Experimental|Intervention Group|Surfactant administration will be done via videolaryngoscopy and the application aid Neofact in neonates with respiratory distress syndrome and airway support with CPAP. Alveofact is used as Surfactant in its standard dosage of 100 mg / kg
10151395|NCT04086069|Experimental|Standard Training+Sit-to-stand trainer|Training using a sit-to-stand trainer device in addition to standard training of standing-up with the help of a physiotherapist
10151396|NCT04086069|No Intervention|Standard Training|Standard training of standing-up with the help of a physiotherapist
10151397|NCT04086004|Experimental|Group I Experimental Motor Imagery|Motor imagery practice
10151398|NCT04086004|Experimental|Group II Dual Task Training|Dual-task balance training
10151399|NCT04085874|Experimental|FBR group|weekly home visit and monthly group meeting for 12 weeks
10151400|NCT04085874|Active Comparator|non-FBR group|once nutrition counseling from standard health care services
10151401|NCT04085965|Experimental|CAMP|Children randomized to CAMP were enrolled in the Boys and Girls Club Camp in one of two low-income Rhode Island communities in summer 2017 or 2018 for 7-weeks in 2017 and 8-weeks in 2018 due to a delayed end to the 2017 school year (i.e. snow days). Camp was offered daily from 8:30 to 4:30.
10151402|NCT04085965|No Intervention|Summer As Usual|Children randomized to the SAU group were asked to experience an unstructured summer as otherwise planned by their parent / guardian. They agreed to not attend structured summer programming (i.e. camp, summer school, or day care) for more than one week over the summer so as to provide an inactive control group for comparison to those in CAMP.
10151403|NCT04085822|Experimental|Multiple Abdominal Injections|Ten injections per patient: 7 of SMA-001 and 3 of control device.
10151404|NCT04085913|Active Comparator|Current Practice|Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.
10151405|NCT04085913|Experimental|Bupivicaine HCL|Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
10151406|NCT04085913|Experimental|Exparel Injection|Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
9826250|NCT02412982|No Intervention|Serum anti-Xa < 0.1 IU/mL|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
9972140|NCT01317745|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus Novartis MF59 adjuvant
9972141|NCT01317745|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus Novartis MF59 adjuvant
10151407|NCT04085848|Experimental|Groupe intervention|Usual care and music therapy
10151408|NCT04085848|No Intervention|Groupe contrôle|Usual care
10151409|NCT04085549|Experimental|Berry Oil Cream|Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
10151410|NCT04085549|No Intervention|Control|Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.
10151411|NCT04085549|Active Comparator|Reference cream|A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
10151412|NCT04085692|Experimental|Intervention|"The intervention group begins LDHF dispatcher training with one introduction week followed by twelve weeks of LDHF training.~During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs."
10151413|NCT04085692|No Intervention|Comparison|During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs.
10151414|NCT04085562|Experimental|Amlodipine|Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.
10151415|NCT04085562|Experimental|Bisoprolol|Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.
10151416|NCT04085861|Experimental|Dancers|Recruited group of professional dancers from the Norwegian University of dance
10151417|NCT04085861|No Intervention|Control|Recruited group of professional art students from the Oslo Academy of the Arts (Norway)
10151418|NCT04085861|Experimental|Dance teachers|Recruited group of dance teachers from the Norwegian University of dance
10151419|NCT04085744|No Intervention|control group|In this group any drug will be applied on the cuff of the intubation tube
10151420|NCT04085744|Active Comparator|lidocaine group|10% lidocaine spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
10151421|NCT04085744|Active Comparator|steroid group|mometasone furoate spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
10151422|NCT04085484||Infants born between 1 Feb 2010 and 18 Feb 2012|Infants born between 1 February 2010 and 18 February 2012, before the concentrated PN regime was implemented (Original PN group: n = 81).
10151423|NCT04085484||Infants born between 19 Feb 2012 and 30 Sep 2013|Infants born between 19 February 2012 and 30 September 2013, after the concentrated PN regime was implemented (Concentrated PN group: n = 53).
10151424|NCT04085783|Experimental|endometrial PRP|In study group (75 patients), intrauterine infusion of PRP was done 48 hrs. before ET. PRP was prepared from autologous blood and it was made by using two steps centrifuge process. All Blastocyst transfers were performed under ultrasound guidance by one expert gynecologist with infertility fellowship. ET was performed according to American Society for Reproductive Medicine (ASRM) guidelines 2013 (Two or three embryos for each participant). On PRP infusion day, 17.5 ml of peripheral venous blood was drawn into a syringe that contains 2.5 ml of Acid Citrate and centrifuged immediately at 1200 rpm for 12 min to separate red blood cells, then plasma was centrifuged again at 3300 rpm for 7 min to obtain PRP that contained platelet 4-5 times more than peripheral blood. 0.5- 1 ml of PRP was infused into the uterine cavity with embryo transfer catheter (Wallace - Smiths, UK). On the other side, No PRP was done in control group. Pregnancy tests were done 12 days after ET.
10151425|NCT04085666|Experimental|1st Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
10151426|NCT04085666|Experimental|2nd Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
10151427|NCT04085510|Experimental|Contrast-enhanced mammogram|All women will receive both 3D mammography and contrast-enhanced mammography for breast cancer screening; the order of interpretation will vary for each of two radiologists
10151428|NCT04085770|Experimental|Alfacalcidol|Patients allocated to the alfacalcidol group received 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay.
10151429|NCT04085770|No Intervention|Control|Control group were exposed to the same conditions as the treatment group except they were not given one-alfacalcidol.
10151430|NCT04085757|Experimental|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
10151431|NCT04085757|Active Comparator|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablets(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
10151432|NCT04085575|Active Comparator|tranexamic acid - The G1 group|The G1 group received 1 g of intra-articular tranexamic acid (TXA). The G1 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
9826251|NCT02413008|Experimental|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
9972142|NCT01317745|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
10151433|NCT04085575|Active Comparator|tranexamic acid - The G2 group|The G2 group received 2 g of intra-articular tranexamic acid (TXA). The G2 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
10151434|NCT04085523|Other|TransCon CNP 6 mcg|TransCon CNP 6 mcg CNP/kg or placebo mimicking TransCon CNP 6 mcg delivered once weekly by subcutaneous injection
10151435|NCT04085523|Other|TransCon CNP 20 mcg|TransCon CNP 20 mcg CNP/kg or placebo mimicking TransCon CNP 20 mcg delivered once weekly by subcutaneous injection
10151436|NCT04085523|Other|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection
10151437|NCT04085523|Other|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
10151438|NCT04085523|Other|TransCon CNP >100 mcg|TransCon CNP >100 mcg CNP/kg delivered once weekly by subcutaneous injection (to be determined after completion of 100 mcg cohort)
10151439|NCT04085679||MMU active group|Subjects residing in nursing homes where the MMU care model has already been implemented
10151440|NCT04085679||MMU control group|Subjects residing in nursing homes where the MMU care model has not yet been implemented (ED visits performed in case of urgent clinical situations)
10151441|NCT04085497|Experimental|Treatment|KT was applied once a week, 6 times in total. Exercises were performed for all patients for 5 weeks 5 days a week, 3 sets 15 repetitions each day.
10151442|NCT04085497|Placebo Comparator|Group 2|The exercise program included quadriceps set exercise, straight leg lifting, mini squat, stretching to hamstring and gastrosoleus muscle groups.
10151443|NCT04085809|Experimental|Left Leg: AmLactin® Rapid Relief / Right Leg: No Treatment|AmLactin® Rapid Relief, BID application for 14 days on left leg and no treatment on right leg
10151444|NCT04085809|Experimental|Left Leg: No Treatment / Right Leg: AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days on right leg and no treatment on left leg
10151445|NCT04085536|Other|Chronic maxillary sinusitis(for more than 12 weeks)|Patients for whom chronic maxillary sinusitis will be diagnosed in the first ENT consultation, will then be seen in a stomatology consultation to determine whether or not a dental cause is objective.
10151446|NCT04085627|Experimental|T Test|Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
10151447|NCT04085627|Active Comparator|R Reference|Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
10151448|NCT04085393|Active Comparator|GERSC for patients receiving highly emetogenic chemotherapy|Participants will receive GERSC, and two other standard antiemetics prior to chemotherapy
10151449|NCT04085393|Active Comparator|GERSC on patients receiving moderately emetogenic chemotherapy|Participants will receive GERSC and one other standard antiemetic prior to chemotherapy
9669617|NCT03718221|Active Comparator|Usual Care FIT Screening Strategy|"Mailed outreach invitation to complete FIT include: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage). Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion. Centralized processes to promote guideline-based follow-up."
9669618|NCT03718221|Experimental|GeoMail FIT Screening Strategy|The experimental arm differs from the active comparator in one way: patients living in treated ZIP codes will receive the mailed outreach at the same time.
10151450|NCT04085640|Experimental|Obturator nerve block with Ropivacaine|Obturator nerve block will be performed before general anesthesia as descripted by Nielsen (RAPM, 2019). A linear transducer will be oriented in the transverse plane and placed in the inguinal crease. The tail of the transducer will be tilted distal in order to visualize the pectineus muscle (medial to the femoral vessels) at its insertion at the superior pubic ramus superficial to the external obturator muscle. An 80 mm nerve block needlewill be inserted in-plane from the lateral end of the transducer and advanced until the tip of the needle will be inside the interfascial plane between the pectineus and the obturator externus muscles. 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
10151451|NCT04085640|Sham Comparator|Obturator nerve block with isotonic salin|The same procedure will be performed and 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles
10151452|NCT04085406|Experimental|Active Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label period) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
10151453|NCT04085406|Sham Comparator|Sham Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label phase) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
10151454|NCT04085094||1. Healthy and pre-menopausal women without CKD|"A total of 45 healthy and pre-menopausal women (<50 years old) will be recruited. Thirty of them are not on oral anticonception; 15 will be examined at each visit during their follicular phase, 15 during their luteal phase. Fifteen are on oral contraception.~Three visits will take place:~V1: after 5 days of a high salt diet (adding 6g of salt/day on top of regular diet), patients will undergo renal ultrasound (Doppler and CEUS), renal functional MRI (BOLD and phase contrast) and Na23 muscle and skin MRI.~V2: after 5 days of low salt diet (dietary instructions), the same exams mentioned above will be repeated~V3: renal CEUS will be performed before and after an oral protein load (1g/kg) or after SL nitroglycerin (0.2mg).~The day before each visit, a 24h urine collection will be performed in order to measure renal salt excretion."
10151455|NCT04085094||2. Pre-menopausal women with CKD|A total of 30 women with CKD will be recruited and undergo the same visits as outlined above
10151456|NCT04085094||3. Post-menopausal women without CKD|Fifteen post-menopausal women will undergo the same exams as outlined above
10151457|NCT04085094||4. Healthy men|A total of thirty age-and sex-matched men (15 below and 15 above 50 years old) will undergo the same exams as above.
10151458|NCT04085094||5.Men with CKD|Fifteen men with CKD will undergo the same exams as outlined above
10151459|NCT04085302|Experimental|All subjects|
10151460|NCT04085159|Experimental|CART/CTL/DCvac cells to treat cancer|
10151461|NCT04085354|Placebo Comparator|Placebo|Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
10151462|NCT04085354|Active Comparator|Dapoxetine|Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
10151463|NCT04085354|Active Comparator|Dapoxetine and folic acid.|Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
10151464|NCT04085354|Active Comparator|Dapoxetine and vitamin B12|Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
10151465|NCT04085211||Inflammatory Bowel Disease|Patients with an established diagnosis of ulcerative colitis or Crohn's Disease who require either a flexible sigmoidoscopy or colonoscopy as part of routine care (e.g. surveillance or staging disease activity)
10151466|NCT04085211||Patients with symptoms of gastro-oesophageal reflux disease|Patients with symptoms of gastro-oesophageal reflux disease requiring a gastroscopy as part of routine clinical care.
9826252|NCT02413008|Placebo Comparator|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
10151467|NCT04085211||Atrophic gastritis|Patients with known or suspected atrophic gastritis that require a gastroscopy to either confirm the diagnosis or surveillance for pre-cancerous changes.
10151468|NCT04085211||Neuroendocrine Tumours|Patients with an established history of gastric neuroendocrine tumours requiring surveillance
10151469|NCT04085198|Active Comparator|No-touch technique with the application of light physics rules|This procedure will be performed by the gynecologists who are familiar to the rules of the 'lights physics' and are currently 'lights physics' rules in their clinical practice. The brightness or darkness of the tissue which reflects the distance between the light source and the surrounding tissue will be used to find the correct route from the vagina introitus to the uterine cavity.
9972143|NCT01317758|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
9972144|NCT01317758|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
10151470|NCT04085198|Placebo Comparator|Control|Patients in this arm of the study protocol will receive standard hysteroscopy with 'no-touch' technique without the utilization of the 'lights physics' rules. The gynecologist performing this procedure will find their route from the vagina introitus to the uterine cavity by the identification of the anatomical structures on their way.
10151471|NCT04085185|Experimental|Phase Ia Dose-Escalation Stage:IBI110|Participants will be treated with escalating doses of IBI110 to determine the MTD.
9972145|NCT01317758|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
9972146|NCT01317758|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus GSK AS03 adjuvant
10151472|NCT04085185|Experimental|Phase Ia Expansion Stage:IBI110|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in different cancer types.
10151473|NCT04085185|Experimental|Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab|Participants will be treated with escalating doses of IBI110 in combination with a fixed dose of Sintilimab to determine the MTD.
10151474|NCT04085185|Experimental|Phase Ib Expansion Stage:IBI110+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in combination with Sintilimab in different cancer types.
10151475|NCT04085172|Experimental|Part A: Guanfacine hydrochloride (TAK-503)|Participants randomized to TAK-503 will receive initial dose of 1 milligram (mg), and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet once daily (QD) for 52 weeks.
9972147|NCT01317758|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus GSK AS03 adjuvant
9972148|NCT01317758|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus GSK AS03 adjuvant
9972149|NCT01317771||Proximal Biceps Tendon Tenodesis|
10151476|NCT04085172|Active Comparator|Part A: Atomoxetine hydrochloride|Participants who weigh less than (<) 70 kilograms (kg) at baseline will receive active Atomoxetine hydrochloride capsule orally at an initial dose of 0.5 milligram per kilogram (mg/kg) which may be increased to the target dose of 1.2 mg/kg oral capsule QD during the treatment of 52 weeks. Permitted doses of Atomoxetine hydrochloride capsule will be 10, 18, 25, 40, 60, and 80 mg QD. Participants who weigh >= 70 kg at baseline will receive Atomoxetine hydrochloride at an initial dose of 40 mg oral capsule QD which may be increased to 80 mg and then to 100 mg for 52 weeks. The total dose for participants who weigh >= 70 kg at baseline will not exceed 100 mg.
10151477|NCT04085172|Placebo Comparator|Part A: Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg tablet of placebo matched to TAK-503 and aged 13 to 17 years will receive 5 to 7 mg tablets of placebo matched to TAK-503 orally QD for first 18 weeks. Participants who weigh < 70 kg at baseline will receive placebo matched to Atomoxetine hydrochloride oral capsule at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg QD oral capsule during the treatment of first 18 weeks. Permitted doses of placebo matched to Atomoxetine hydrochloride will be 10, 18, 25, 40, 60, and 80 mg QD and participants who weigh >= 70 kg will receive placebo matched to Atomoxetine hydrochloride at an initial dose of 40 mg QD capsule orally which may be increased to 80 mg and then to 100 mg.
9972150|NCT01317784|Experimental|All tests.|Choose from all 16 possible tests.
9972151|NCT01317784|Active Comparator|HIV/HCV|Choice of 10 different HIV and hepatitis C tests in the bundle.
9826253|NCT02413034|Placebo Comparator|Control group|no antibiotic prophylaxis group
9972152|NCT01317784|Active Comparator|HIV/Syphilis|Choice of 7 different tests for HIV and syphilis.
9972153|NCT01317784|Active Comparator|HIV only|Choice of 4 rapid tests for HIV only.
9972154|NCT01317810||Subjects with Overactive Bladder (OAB)|Combination of new OAB subjects and existing subjects on OAB medication
9972155|NCT01317823|Active Comparator|Bishop score|
9972156|NCT01317823|Active Comparator|transvaginal ultrasound|
9972157|NCT01317836||Patients having pancreatic cystic lesion|
10151478|NCT04085172|Experimental|Part B: Guanfacine hydrochloride (TAK-503)|Participants from Part A roll over into Part B, where participants received placebo in Part A will roll over after first 18 weeks and participants received TAK-503 or atomoxetine will roll over after 52 weeks of Part A. During Part B all the participants will receive TAK-503 at an initial dose of 1 mg, and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg TAK-503 oral tablet QD for 52 weeks of Part B.
10151479|NCT04085068||Study group (group A):|15 women take cranioscaral treatment
10151480|NCT04085068||control group (group B):|shame group
10151481|NCT04085081|Experimental|Supportive care (coaching call, motivational messages)|Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement.
10151482|NCT04085120|Experimental|Ropivacaine/dexamethasone group|3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
10151483|NCT04085120|Experimental|10% lignocaine injection group|4 ml of 10% lignocaine
10151484|NCT04085224|Active Comparator|1|
10151485|NCT04085224|Experimental|2|
9826254|NCT02413034|Active Comparator|Study group cefazolin|Classical antibiotic prophylaxis
10151486|NCT04085224|Experimental|3|
10151487|NCT04085250|Experimental|Nivolumab Consolidation|Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
10151488|NCT04085250|Active Comparator|Observation|Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
10151489|NCT04085315|Experimental|Dose Escalation (Closed to Enrollment)|Patients will continue to receive osimertinib 80 mg PO daily as part of standard of care therapy during screening and study treatments. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose will be 30 mg twice daily (dose level 1). All patients at a given dose level must complete the DLT period before any additional cohorts can be opened.
10151490|NCT04085315|Experimental|Dose Expansion: Cohort A|Stage IV EGFR-mutant NSCLC currently receiving and progressing on osimertinib who have received no more than one additional line of systemic cancer therapy other than osimertinib (e.g., chemotherapy +/- immunotherapy, amivantamab +/- Lazertinib) for metastatic disease. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
10151491|NCT04085315|Experimental|Dose Expansion: Cohort B|Stage IV EGFR-mutant NSCLC patients who are currently receiving first line osimertinib treatment and have received at least 3 months, but no more than 6 months, of osimertinib with a best response of PR or SD. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
10151492|NCT04085419|Active Comparator|denosumab|denosumab 60 mg subcutaneously every 6 months
10151493|NCT04085419|Active Comparator|zoledronic acid|zoledronic acid 5 mg intravenously once a year
10151494|NCT04085263|Sham Comparator|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
10151495|NCT04085263|Experimental|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
10151496|NCT04085237|Experimental|Ultrasound-guided continuous ESP block with opioid PCA|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. The patient's skin will be anesthetized with 2% lidocaine. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg) followed by insertion of the echo catheter system under direct vision 2-3 cm beyond the needle tip.
10151497|NCT04085237|Sham Comparator|Ultrasound-guided sham block and catheter with opioid PCA|The exact same procedure as the experimental group will be followed, substituting saline for local anesthetic at the same amounts and rate. As with the ESP group, the patients will have PCA initiated postoperatively in the PACU at the same doses.
10151498|NCT04085055|Active Comparator|22 Gauge FNB Needle - ProCore|The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.
10151499|NCT04085055|Active Comparator|22 Gauge FNB Needle - Acquire|The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.
10151500|NCT04085055|Active Comparator|22 Gauge FNB Needle - SharkCore|The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.
10151501|NCT04085055|Active Comparator|22 Gauge FNB needle - EZ Shot 3 Plus|The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.
9826255|NCT02413151|Experimental|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
10151502|NCT04085016||meibography of statin group|patients with regular HMG CoA reductase inhibitor (statin) treatment
10151503|NCT04085016||meibography of non-statin group|patients with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy
10151504|NCT04085003||Intact abdominal aortic aneurysm|
10151505|NCT04085003||Ruptured abdominal aortic aneurysm|
9826256|NCT02413151|Active Comparator|Control|Regular lifestyle
10151506|NCT04085107||243 PwMCI|
10151507|NCT04084977||Sydenam Chorea (SC)|individuals with SC
10151508|NCT04084977||tonsilitis|children with tonsilitis in the past 3 months
10151509|NCT04084977||control|children wit no tonsilitis
10151510|NCT04084834|Experimental|Intervention group|Participants allocated to the intervention group will be familiarized with exercise intensity levels (heart rate and Borg RPE) during the assessment at Diakonhjemmet Hospital. Further, the patients will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital. Thereafter, the participants will get access to a web-based exercise program and guided to choose the appropriate exercise-level. Weekly, based on the individual progression, all participants will receive an exercise program by email consisting of individually tailored exercise sessions and motivational messages. At the end of each week, the participants complete an electronic exercise diary for monitoring adherence. All participants will be offered the possibility to seek peer-support; however, if preferred they may also follow the exercise program by themselves.
10151511|NCT04084652|Experimental|Mycoprotein|Mycoprotein in its full food matrix
10151512|NCT04084652|Experimental|Protein Isolated from Mycoprotein|Protein from mycoprotein isolated from the food matrix
10151513|NCT04084938|Active Comparator|Prostate operation|You will have a surgery to remove the prostate gland. The surgery will be done during general anesthesia. If your prostate gland is small the surgery will be done through a catheter into the penis. If your prostate gland is large the surgery will be through an incision in your lower abdomen.
10151514|NCT04084938|Active Comparator|Prostate artery embolization|The embolization is done in the Department of Radiology. There will be placement of a catheter into the artery in one of the groins during local anesthesia. Through this catheter small particles will be injected into the arteries of the prostate gland. When finished, the hole in the artery will be closed.
10151515|NCT04084639|Experimental|Ingestion of 20g Mycoprotein Drink|Milkshake containing 20g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
9972158|NCT01317849|Experimental|vitamin supplements|
9972159|NCT01317849|Placebo Comparator|Placebo|
9972160|NCT01317862|Active Comparator|Transcervical foley catheter|
10151516|NCT04084639|Experimental|Ingestion of 40g Mycoprotein Drink|Milkshake containing 40g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
10151517|NCT04084639|Placebo Comparator|Ingestion of Isocaloric Control Drink|Milkshake containing 250ml full-fat milk, 50g glucose, 19g dried skim milk and 9g full-fat dried milk
10151518|NCT04084873|Experimental|Experimental PBrE|Participants are exposed to several words of emotional contents (positive, and negative). The differences between these words will allow the regulation and counter regulation of emotional processes (Schwager y Rothermund, 2013). The words are related to clinical and personal characteristics of the patients and they will promote an emotional identification that improve the emotional regulation (Kashdan, Barret y McKnight, 2015).
10151519|NCT04084873|Placebo Comparator|Control PBrE|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
10151520|NCT04084873|Other|Control|Participants do not receive the intervention.
10151521|NCT04084899||Continuous Positive Airway Pressure|Patient treated with continuous positive airway pressure
10151522|NCT04084912|Active Comparator|Dexamethasone group|this group will receive one ampoule Intravenous injection of Dexamethasone Sodium Phosphate 2 ml . 8 mg once by the anesthesiologist immediately before skin incision
10151523|NCT04084912|Placebo Comparator|Placebo group|this group will receive one ampoule Intravenous injection of Saline once by the anesthesiologist immediately before skin incision
10151524|NCT04084756|Experimental|Couples Crisis Response Plan|
10151525|NCT04084756|Active Comparator|Mental Health Education|
10151526|NCT04084743|Experimental|Virtual reality training and Dual task intervention|Cognitive and motor Dual-task intervention and virtual reality training intervention in patients with Parkinson's disease
10151527|NCT04084743|Active Comparator|Conventional physiotherapy and Dual task intervention|The dual-task intervention without virtual reality training intervention in patients with Parkinson's disease
10151528|NCT04084691|Experimental|Single Arm|Every patient will undergo every combination of physical exercise/meal type (3x3 combinations), one following the other. Each combination is replicated three times.
10151529|NCT04084665|Experimental|Intervention|Guselkumab 200mg q4 weekly
9972161|NCT01317862|Active Comparator|Prostaglandins|
9972162|NCT01317888|Experimental|Treated with MAB-425|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections.
9972163|NCT01317914|Experimental|Dietary instruction on Gluten Free Diet|
9972164|NCT01317927|Experimental|Warfarin, Belinostat|Warfarin 5 mg po will be given on Day -14 and Day 3. Belinostat 1000 mg/m² will be given as a 30 minute IV infusion on Days 1 - 5
9972165|NCT01317966||rhIL-11Combinating Low-dose Rituximab|"rhIL-11 (interleukin-11, Juheli) 50 mcg/kg subcutaneously daily for 14 days~Rituximab 100mcg weekly for 4 weeks"
9972166|NCT01317979||Diabetes group I|metabolic surgery, laparoscopicly
9972167|NCT01317992|Experimental|Ibudilast|To receive ibudilast 40mg twice daily for 8 weeks.
9972168|NCT01317992|Placebo Comparator|Placebo|To receive placebo twice daily for 8 weeks.
9972169|NCT01318005|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
9972170|NCT01318005|Active Comparator|Ovcon® 35|Ovcon® 35 is an oral contraceptive that contains less progestin.
9972171|NCT01318005|Active Comparator|Microgestin Fe® 1/20|is an oral contraceptive that contains less estrogen.
9972172|NCT01318031|Experimental|DDI|
9972173|NCT01318044|Active Comparator|Propofol group: propofol|
9972174|NCT01318044|Active Comparator|Thiopental group: thiopental|
9972175|NCT01318057||Wild-Type|Wild-Type are those individuals who were non-carriers of any functional (loss-of-function)variant in CYP2C9 and/or VKORC1 genes
10151530|NCT04084808|Experimental|Maple Syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
10151531|NCT04084808|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
10151532|NCT04084808|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
10151533|NCT04084808|Active Comparator|Sports drink|A commercial sports drink of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
10151534|NCT04084808|Placebo Comparator|Water|A solution containing stevia (sugar substitute) labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
10151535|NCT04084847|Active Comparator|Barberry|Daily consumption of barberry in powder form.
10151536|NCT04084847|Placebo Comparator|placebo|Daily consumption of placebo powder.
10151537|NCT04084782||Onychomycosis group|Subjects in this group suffer from onychomycosis of the toenail, who chose to self treat by purchasing the product from an online platform.
10151538|NCT04084795|Active Comparator|EMDR plus MtCS|MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
10151539|NCT04084795|Placebo Comparator|EMDR plus sham-MtCS|Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
10151540|NCT04084795|No Intervention|Treatment as Usual|Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry. The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.
10151541|NCT04084587|Experimental|Treated Group|"Group A: 15 patients rehabilitated with Retimax Vision Trainer, 10 consecutive sessions of 8 minutes each, performed twice a week in the best eye.~Exams performed before and after treatment:~BCVA (ETDRS)~Reading speed (MNREAD)~Contrast sensitivity (Pelli-Robson)~Microperimetry and analysis of fixation (OCT-SLO OPTOS)~QoL (VFQ-25)"
10151542|NCT04084587|No Intervention|Control Group|"Group B: 9 patients control group without rehabilitation.~Exams performed twice, at the same time interval elapsed for the treated group:~BCVA (ETDRS)~Reading speed (MNREAD)~Contrast sensitivity (Pelli-Robson)~QoL (VFQ-25)"
10151543|NCT04084561|Experimental|HRHA|High Risk, High Ancestry
10151544|NCT04084561|Experimental|LRLA|Low Risk, Low Ancestry
9669619|NCT03714399||ICUAW group|The physical and psychological effects of ICUAW on patients undergoing aortic valvular surgery will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
9669620|NCT03703323|Experimental|Rotative thromboelastometry analysis|Evaluation of diagnostic properties of coagulation by rotative thromboelastometry in patient with digestive hemorrhage in predictive value of mortality.
9669621|NCT03702842|Experimental|Immediate effects|All participants will complete 2 sessions of walking with tsDCS separated by at least 72 hours. The only difference between sessions will be the dosage of stimulation (higher or lower dosage tsDCS using the Soterix Medical tsDCS stimulator). During each session, participants will be asked to walk for up to 30 minutes on a treadmill while the stimulation is delivered. Assessments will be completed before and after the bout of treadmill walking.
9669622|NCT03702842|Experimental|Interventional effects: Higher dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the higher dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the higher dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
9826257|NCT02413203|Experimental|Celecoxib|Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.
9826258|NCT02413203|Placebo Comparator|Placebo|Oral administration of a single placebo pill.
10151545|NCT04084561|Experimental|HRLA|High Risk, Low Ancestry
10151546|NCT04084561|Experimental|LRHA|Low Risk, High Ancestry
10151547|NCT04084600|Experimental|Intervention Group|Once a week for 6 consecutive weeks, this group will receive a manual therapy protocol with an approach based on Taylor et al., 1990; Schleip et al., 2012; Bienfait, 1999 and Myers, 2016, lasting 20 minutes, focused on the upper quadrant homolateral to the surgery. Shortly thereafter, this group will participate in a kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
10151548|NCT04084600|Sham Comparator|Sham Group|Once a week for 6 consecutive weeks, this group will receive a soft and shallow traditional massage, lasting 20 minutes. Shortly thereafter, this group will participate to the same kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
10151549|NCT04084535|Active Comparator|High intensity interval training|It will apply a HIIT program for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
10151550|NCT04084535|Active Comparator|Inspiratory muscle training|It will apply an inspiratory muscle training for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
10151551|NCT04084496|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
10151552|NCT04084119|Experimental|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
10151553|NCT04084119|Active Comparator|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
10151554|NCT04084158|Experimental|Toripalimab+chemoradiation|"Induction immunotherapy: Toripalimab injection (JS001) 3mg/kg IV q 14 days x 2 cycles.~Concurrent Chemoradiotherapy: Starting within 4 weeks after the first cycle induction immunotherapy. carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or paclitaxel liposome 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation and adjuvant therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles.~Adjuvant immunotherapy:Toripalimab injection (JS001) 3mg/kg IV q 14 days up to 1 year."
10151555|NCT04084158|Active Comparator|chemoradiation|"Concurrent Chemoradiotherapy: carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or Liposome paclitaxel 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation therapy.~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles."
10185532|NCT03744832|Experimental|Point of Care Testing|"Point of care testing using the Alere i™ Strep A assay for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. If test is positive, patients will be started on antibiotics prior to discharge from the ED. If test is negative, patients will not be started on antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
10185533|NCT03744832|Active Comparator|Standard Care|"Conventional testing using a standard bacterial throat culture for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. Patients will be discharged with a post-dated prescription and will be contacted in approximately 3 days if their culture results are positive to fill/take the antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
10185534|NCT03744806||treated with intravitreal bevacizumab.|
10185535|NCT03744806||control group|
10185536|NCT03744767|Experimental|Single treatment arm|
10185537|NCT03744754||Women with endometriosis|Women with endometriosis disease aged 18-36 years, with appropriate endometriosis diagnosis, based on transvaginal sonography, magnetic resonance imaging and/or previous surgery.Ovarian reserve was assessed by antral follicle counting (AFC) and measurement of serum anti-Mullerian hormone (AMH) levels Enrolled after preservation fertility procedure (vitrification of mature oocytes)
10185538|NCT03744702|Experimental|Treatment|All patients will receive ascorbic acid as this is a pilot study.
9826259|NCT02413229|Experimental|DSXS1411|DSXS applied once a day for a total of 28 days.
9826260|NCT02413229|Placebo Comparator|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
10185539|NCT03744689|Active Comparator|Erector Spinae Plane Block|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks"
10185540|NCT03744689|Sham Comparator|Control Group|Sham block will be done with serum physiologic.
10185541|NCT03744663|Active Comparator|Suboxone® SL|Patients assigned to this group will continue with their already established dose of Suboxone ® SL films for 24 weeks along with weekly therapy.
10185542|NCT03744663|Experimental|Sublocade®|Patients assigned to the Sublocade® group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy.
10185543|NCT03744650|Experimental|"Care4Heart programme"|The single group pretest and repeated posttest longitudinal study design is adopted in the main study. All the recruited participants received the study intervention
10185544|NCT03744611|Experimental|CE|CE capsule administered orally twice daily for 12 weeks.
10185545|NCT03744611|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for 12 weeks.
10185546|NCT03744559|Experimental|R-E (Retrieval Extinction) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a lab-based smoking-related cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the R-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
10185547|NCT03744559|Experimental|R-E (Retrieval Extinction) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a smoking-related cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
10151556|NCT04084106|Experimental|phenoximethylpenicillin|phenoximethylpenicillin, tablet, 1 g 3 times daily for 5 days.
10151557|NCT04084106|Active Comparator|amoxicillin|amoxicillin, tablet, 500 mg 3 times daily for 5 days.
10151558|NCT04084106|Active Comparator|amoxicillin-clavulanic acid|amoxicillin-clavulanic acid tablet, 500/125 mg 3 times daily for 5 days.
10151559|NCT04084106|No Intervention|No intervention|No intervention
10151560|NCT04084236|Active Comparator|Active TENS|
10151561|NCT04084236|Sham Comparator|Sham TENS|
10151562|NCT04084171|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia.
10151563|NCT04084223|Experimental|Active RA patients group|"64 active RA patients (DAS28>3,2 AND presence of ≥2 US synovitis with Power-Doppler≥2) with an inadequate response to methotrexate (MTX) starting a treatment with JAKi (tofacitinib ou baricitinib) will be evaluated at baseline, 1, 3 and 6 months in 5 centres.~A clinical joint assessment will be performed and CRP will be tested to calculate DAS28-CRP. Several PROs will be completed: RAPID3, HAQ, pain, and patient global assessment of disease activity on a VAS.~An US exam on 40 joints and 12 tendons will be performed by an independent investigator, looking for synovitis and tenosynovitis with B-Mode and Power Doppler. A Global US score (GLOESS) will be collected at each visit."
9826261|NCT02413255|Placebo Comparator|Part 1 Cohort 1-9: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1.
10151564|NCT04084301|No Intervention|Normal CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.4 L/min/m2 throughout the CPB period.
10151565|NCT04084301|Experimental|High CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.9 L/min/m2 throughout the CPB period.
10151566|NCT04084431|Active Comparator|WBRT (10 x 2 Gy) + OSC|Whole brain radiotherapy will be applied with a total dose of 20 Gy in 10 fractions (single dose of 2 Gy). OSC as needed.
10151567|NCT04084431|Experimental|Optimal Supportive Care (OSC) alone|Symptomatic treatment including steroids, pain medication, nutritional support, etc
10151568|NCT04084249|Experimental|ctDNA guided surveillance|ctDNA analysis will be performed every 4 months postoperatively (4, 8, 12, 16, 20 and 24). At time of first positive ctDNA, patients undergo a whole-body FDG-PET/CT-scan for radiological assessment and a colonoscopy. If the initial assessment is without evidence of recurrence, patients will be offered high-intensive radiological surveillance with FDG-PET/CT-scans every 3 months, until recurrence detection or 21 months has passed. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C). At every FDG-PET/CT-scans the patients also complete the FCRI questionnaire.
10151569|NCT04084249|No Intervention|Standard Danish follow-up program|Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).
10151570|NCT04084340|Experimental|Anodal tDCS + Exercises therapies|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA"
10151571|NCT04084340|Sham Comparator|Sham tDCS + Exercises therapies|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA"
10151572|NCT04084275|Experimental|experimental group|Levine's conservation model was used as the theoretical framework for this study. A literature review was used to determine the contents of the intervention program. A nursing care program which consisted of 8 sessions, the first of which was at the hospital and the others at the homes of puerpera and which were held at different times and lasted 12 weeks in total, based on Levine's Conservation Model was provided to the women in the intervention group. Each session lasted approximately 60-120 minutes, according to the educational and practical contents.The puerpera were given trainings on different subjects based on the module during each session. For these trainings, the investigators prepared, in the light of the literature data, leaflets containing information about breastfeeding, personal hygiene, fatigue, nutrition and pilates exercises
10151573|NCT04084275|No Intervention|control group|The puerpera in the control group received only the standard nursing care given after birth. Standard nursing care contain solely breastfeeding training. The puerpera in the control group were visited before they were discharged from the hospital to obtain their contact information and to administer them the pretest. A home visit at the end of postpartum month 3 was also planned and they were administered the posttest. After collecting the posttest data, the trainings given to the women in the intervention group on nutrition, sleep, fatigue and pilates exercises were also given to the women in the control group in consideration of the ethical dimension of the study; they were actively trained on pilates exercises by the investigator and the relevant leaflets were given to them by the end of their trainings.
10151574|NCT04084132|Experimental|Early re-valving|60 patients who are assigned to early re-valving undergo pulmonary valve replacement within 3 months from randomization.
10151575|NCT04084132|Experimental|Later re-valving|60 patients who are assigned to later re-valving undergo pulmonary valve replacement when the current European guideline criteria are met.
10151576|NCT04084457|Placebo Comparator|Placebo|Matched for macronutrients, micronutrients and fibre
10151577|NCT04084457|Active Comparator|Wild Blueberry Powder|Formulation of a 100% blueberry (freeze-dried whole fruit) drink
10185548|NCT03744559|Other|NR-E (No R-E) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a lab-based non-smoking or neutral cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the NR-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
9826262|NCT02413255|Experimental|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 mg, solution, orally once on Day 1.
9972176|NCT01318057||Carriers|Those patients who were identified as having any functional CYP2C9 and/or VKORC1 polymorphism
10151578|NCT04084288|Experimental|Postoperative Acupuncture|"Neuraxial anesthesia (spinal or combined spinal epidural (CSE) with up to 4cc mepivacaine 1.5%) and 2 blocks for postoperative pain (IPACK and adductor canal peripheral nerve blocks). Sedation will be provided. Tranexemic acid (TXA) will be dosed per surgeon request.~A certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed. If an epidural is placed, it may be redosed with lidocaine as needed (up to 100mg total) and will be removed prior to transfer to the recovery room.~A periarticular injection (PAI) will be placed by the surgeon during the surgery (timing at the discretion of the surgeon)"
10151579|NCT04084405|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
10151580|NCT04084405|Active Comparator|Control group|aerobic exercice
10151581|NCT04084353||Delivered women|Maternal and perinatal outcomes will be collected prospectively on all patients that deliver in Government Medical College (GMC) Hospital before, during and after the training over the study period (8 months) in order to evaluate the impact of the training.
10151582|NCT04084197|Experimental|Sequence 1|Period 1 : Fasted state + HIP1402, Period 2 : Fasted state + HIP1801
10151583|NCT04084197|Experimental|Sequence 2|Period 1 : Fasted state + HIP1801, Period 2 : Fasted state + HIP1402
10151584|NCT04084197|Experimental|Sequence 3|High fat diet + HIP1402, Period 2 : High fat diet + HIP1801
10151585|NCT04084197|Experimental|Sequence 4|High fat diet + HIP1801, Period 2 : High fat diet + HIP1402
10151586|NCT04084093|Experimental|Surfactant Gel|
10151587|NCT04084184|Experimental|Sequence 1|Period 1 : Fasted state + HGP1812, Period 2 : Fasted state + HGP1602
10151588|NCT04084184|Experimental|Sequence 2|Period 1 :Fasted state + HGP1602, Period 2 : Fasted state + HGP1812
10151589|NCT04083846|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
10151590|NCT04083846|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
10151591|NCT04083846|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
10151592|NCT04083846|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
10151593|NCT04083846|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
9669623|NCT03702842|Active Comparator|Interventional effects: Lower dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the lower dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the lower dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
10151594|NCT04083846|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
10151595|NCT04084418|Experimental|Control diet followed by VLCHF diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~Phase 2 (6 weeks): Control diet (50% of energy from carbohydrates)~Phase 3 (4 weeks): Washout period~Phase 4 (6 weeks): VLCHF diet (10% of energy from carbohydrates)"
10151596|NCT04084418|Experimental|VLCHF diet followed by Control diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet~Phase 2 (6 weeks): VLCHF diet (10% of energy from carbohydrates)~Phase 3 (4 weeks): Washout period~Phase 4 (6 weeks): Control diet (50% of energy from carbohydrates)"
10151597|NCT04083989||Multimodal treatment for AN|Adolescent patients with AN attending an integrative medicine-based inpatient treatment program
9972177|NCT01318096|Experimental|A:Raltegravir + tenofovir+lamivudine|
10151598|NCT04083989||Healthy controls|Healthy volunteers assessed once to collect comparative data
10151599|NCT04083898|Experimental|Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
10151600|NCT04083898|Experimental|Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
10151601|NCT04083898|Experimental|Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
10151602|NCT04083898|Experimental|Phase II: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
9972178|NCT01318096|Active Comparator|B:Efavirenz+tenofovir+lamivudine|
9972179|NCT01318148|Experimental|Caspofungin|
10151603|NCT04083794|Other|Laboratory based assessments|The current study has no arms; it is a cross-sectional assessment where all participants will undergo the same procedures.
10151604|NCT04083937|Active Comparator|70.0/ 2.0 Gray (RBE)|Normofractionated radiotherapy with photons (70.0/ 2.0 Gray)
10151605|NCT04083937|Experimental|57.0/ 3.0 Gray (RBE)|Hypofractionated radiotherapy with photons (57.0/ 3.0 Gray)
10151606|NCT04083937|Experimental|57.0/ 3.0 (RBE)|Hypofractionated radiotherapy with protons (57.0/ 3.0 Gray relative biological effectiveness [RBE]).
10151607|NCT04083911|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in elderly newly diagnosed AML patients.
10151608|NCT04083807|Experimental|TISSEEL Lyo|Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System.
10151609|NCT04083807|Active Comparator|Manual compression with surgical gauze pads|Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line.
9519868|NCT03282708|Experimental|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
10151610|NCT04084002||Patients with subacute chronic stroke|Patients with subacute chronic stroke
10151611|NCT04084002||Control group|Healthy control group age and sex matched
10151612|NCT04083872|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
10151613|NCT04083872|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
10151614|NCT04084041|Experimental|Device|Device group
10151615|NCT04084041|Active Comparator|Conventional chest physiotherapy|Control group
10151616|NCT04083768|Placebo Comparator|Supine group|After the patient completes the spinal anesthesia, the cesarean section is completed in the supine position.
10151617|NCT04083768|Active Comparator|15° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 15°, and the cesarean section was completed using the supine position after the skin was cut.
10151618|NCT04083768|Active Comparator|30° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 30°, and the cesarean section was completed using the supine position after the skin was cut.
10151619|NCT04083690|Active Comparator|Standard CRT Programming, then ECG CRT Optimization|The control arm patients will have standard CRT programming for the first 6 months, and then will be reprogrammed based on the ECG CRT optimization information for the following 6 months
10151620|NCT04083690|Experimental|ECG CRT Optimization|The experimental arm patients will have CRT device reprogrammed based on the ECG CRT optimization information for 12 months.
10151621|NCT04083833|Experimental|Treatment Arm|(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)
10151622|NCT04083833|Placebo Comparator|Control|"Treatment D:~(Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo~Treatment E:~(Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment F:~(Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment G:~(Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment H:~(Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment I:~(Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin"
10151623|NCT04083924|Experimental|Basic cardiac ultrasound training|Single group education intervention study. No control group. Pre-post educational outcomes only.
10151624|NCT04083755|Active Comparator|Line A|One dose of Ferric carboxymaltose (1000mg) intravenous. Duration of administration 15 minutes.
10151625|NCT04083755|Other|Line B|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
10151626|NCT04083482|Experimental|Septic patients require CVVH|continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
10151627|NCT04083599|Experimental|GEN1042 monotherapy dose escalation (phase 1a)|• All NON-CNS solid tumors
10151628|NCT04083599|Experimental|GEN1042 monotherapy expansion (phase 2a)|"NSCLC~Melanoma~CRC"
10151629|NCT04083599|Experimental|Combination safety run-in (phase 1b) for NSCLC, HNSCC and Melanoma|"1L NSCLC~1L HNSCC~1L Melanoma"
10151630|NCT04083599|Experimental|Combination safety run-in (phase 1b) for HNSCC|• 1L HNSCC
9519869|NCT03282708|No Intervention|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
9519870|NCT03282669|Active Comparator|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
9519871|NCT03282669|Active Comparator|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
9519872|NCT03282643|Experimental|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
10151631|NCT04083599|Experimental|Combination safety run-in (phase 1b) for PDAC|• 1L PDAC
10151632|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for Melanoma|• 1L Melanoma
10151633|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for NSCLC|• 1L NSCLC
10151634|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab|• 1L HNSCC
10151635|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for HNSCC with pembrolizumab + chemotherapy|• 1L HNSCC
10151636|NCT04083599|Experimental|Combination therapy expansion (phase 2b) for PDAC|• 1L PDAC
10151637|NCT04083729|Active Comparator|Patients with persistent pulmonary hypertension|Patients with persistent pulmonary hypertension after balloon mitral comisseruotomy
10151638|NCT04083729|Active Comparator|Patients without persistent pulmonary hypertension|Patients without persistent pulmonary hypertension after balloon mitral comisseruotomy
10151639|NCT04083716|Experimental|Group 1|ABI-H2158 Reference Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation after a high-fat meal on Day 15 (Period 3)
10151640|NCT04083716|Experimental|Group 2|ABI-H2158 Test Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation after a high-fat meal on Day 8 (Period 2), then ABI-H2158 Reference Formulation in a fasting state on Day 15 (Period 3)
10151641|NCT04083716|Experimental|Group 3|ABI-H2158 Test Formulation after a high-fat meal on Day 1 (Period 1), then ABI-H2158 Reference Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation in a fasting state on Day 15 (Period 3)
10151642|NCT04083638||Group 1|Control group
10151643|NCT04083638||Group 2|Feeding will not stop during the transfusion
10151644|NCT04083651|Experimental|Methylnaltrexone Bromide (MNTX)|Participants will receive methylnaltrexone bromide (MNTX) 450 mg (3 tablets of 150 mg each) QD orally. If the initial interim analysis suggests a lack of efficacy, subsequent participants will receive 450 mg MNTX twice daily (BID) or three times daily (TID). Treatment will continue until participant's death or early withdrawal from study or study completion at Day 168.
10151645|NCT04083651|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX until participant's death or early withdrawal from study or study completion at Day 168.
10151646|NCT04083378|Active Comparator|Arm I (standard of care ablation)|Patients undergo standard of care ablation.
10151647|NCT04083378|Experimental|Arm II (standard of care ablation, software-aided imaging)|Patients undergo standard of care ablation with software-aided imaging (Morfeus).
10151648|NCT04083417|Active Comparator|Phenoxymethylpenicillin group|Patients randomized to oral phenoxymethylpenicillin 1000 mg three times daily for ten days
10151649|NCT04083417|Experimental|No antibiotic treatment group|Patients randomized to no antibiotic treatment
10151650|NCT04083664||Control healthy subjects without anemia.|"Adults > 18 years.~Age and sex matched.~No active infection or inflammation."
10151651|NCT04083664||ESRD with Hgb <11 g/dl.|"Adults > 18 years.~ESRD patients on regular hemodialysis.~Hgb < 11g/dl.~No apparent infection or inflammation."
10151652|NCT04083664||ESRD with Hgb ≥ 11 g/dl|"Adults > 18 years.~ESRD patients on regular hemodialysis.~Hgb ≥ 11g/dl.~No apparent infection or inflammation."
10151653|NCT04083612|Other|Standard of care - ixekizumab|Patient will continue to receive ixekizumab according to standard of care dosing regimen, i.e. loading dose first (160 mg) at week 0; 80 mg every 2 weeks until week 12, then 80 mg every 4 weeks
10151654|NCT04083625|Experimental|carbetocin|100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
10151655|NCT04083625|Placebo Comparator|placebo|10 cm syringe normal saline IV given just before skin incision of myomectomy.
10151656|NCT04083443||Patients with blood stream infections|Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment. There will be an additional blood sampling for these patients, which is the only intervention in the study.
10151657|NCT04083547||HIPEC group|All patients undergoing HIPEC will asked to join this prospective study.
10151658|NCT04083677||Control GROUP|healthy adult fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
10151659|NCT04083677||trauma GROUP|trauma patients fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
10151660|NCT04083703|Experimental|Simple lumbar discectomy|
10151661|NCT04083703|Experimental|Lumbar discectomy with inter vertebral cage|
10151662|NCT04083248|Experimental|Feasibility group|"Intervention components:~Personalized group diabetes education.~Fitbit Charge 3 wrist activity monitor for real-time monitoring of steps, active minutes and heart rate. The Fitbit will be used by the women to set activity goals, self-assess their progress and aid in motivation to be more active.~Freestyle Libre (Abbott Labs, Alameda, CA) Personal CGM (FDA approved). The Libre CGM will be used to self-monitor glucose goals and monitor the real-time effects of activity and eating choices by the women.~Final guided interview for study acceptability and feasibility. The interviews will be audiotaped, transcribed. Thematic content analyses will be performed."
10151663|NCT04083144|Active Comparator|Deep rTMS active + Varenicline|Participants undergoing deep rTMS (active) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
9972180|NCT01318161|Experimental|Epidural anesthesia and analgesia|
9972181|NCT01318161|Active Comparator|Patient controlled analgesia|
10151664|NCT04083144|Sham Comparator|Deep rTMS sham + Varenicline|Participants undergoing deep rTMS (sham) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
10151665|NCT04083352|Experimental|6-week ketone supplementation|Participants took a ketomax ketone salt supplementation for 6-weeks. They took 2 servings per day.
10151666|NCT04083352|Placebo Comparator|6-week placebo supplement|Participants took a placebo supplement for 6-weeks. The placebo was calorie, sodium, and flavor-matched to the experimental supplement.
10151667|NCT04083105|Experimental|30% Nitrous Oxide with Midazolam|30 percent nitrous oxide/70 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
9972182|NCT01318187|Experimental|Paracetamol|
10151668|NCT04083105|Experimental|70% Nitrous Oxide with Midazolam|70 percent nitrous oxide/30 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
10151669|NCT04083157|Experimental|Intradermal hepatitis B vaccine with imiquimod|Subjects in the study arm will receive 20 mcg intradermal Engerix-B at two separate sites (10 mcg/0.5 ml) with topical imiquimod ointment pre-treatment 5 minutes before injection.
10151670|NCT04083157|Active Comparator|Intramuscular hepatitis B vaccine with aqueous cream|Subjects in the control arm will receive 20 mcg intramuscular Engerix-B at two separate sites (10 mcg/ 0.5 ml) with topical placebo aqueous cream pretreatment 5 minutes before injection.
10151671|NCT04083209|Experimental|Counseling group|"Patients randomized into the counseling group will be given a 1-2 minute presentation over the risks of opioid pain medications during their preoperative visit."
9972183|NCT01318187|Active Comparator|Morphine|
9972184|NCT01318200|Active Comparator|Transarterial Chemoembolization|
9972185|NCT01318200|Active Comparator|CyberKnife SBRT|
9977805|NCT01365338|Experimental|Cohort 2|Participants will receive 0.15 mg of PF-04958242 as a single oral dose.
10151672|NCT04083209|No Intervention|Control group|The control group will undergo the standard preoperative evaluation by the senior author without any additional formal opioid counseling.
10151673|NCT04083313|Active Comparator|Endoloop|Patients in which appendiceal stump was ligated using Endoloop
10151674|NCT04083313|Active Comparator|Endostapler|Patients in which appendiceal stump was ligated using Endostapler
10151675|NCT04083313|Active Comparator|Endoclip|Patients in which appendiceal stump was ligated using Endoclip
10151676|NCT04083222|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRx administered subcutaneously once-weekly for 8 weeks
10151677|NCT04083222|Placebo Comparator|Placebo|Placebo matching solution administered subcutaneously once-weekly for 8 weeks
10151678|NCT04083469|Experimental|Peer-Led Peer-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated the peer-leader.
10151679|NCT04083469|Other|Adult-Led Intervention|The e-cigarette intervention program will be administered to students by an adult educator.
10151680|NCT04083469|Other|Peer-Led Non-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated a different peer-leader.
10151681|NCT04083560|Experimental|Intervention group|Group A Intervention: 360 pregnant women will receive 250 mcg of B-12 daily orally from 1st trimester to 6 months postpartum
10151682|NCT04083560|Active Comparator|Control group|Group B- Control: 360 pregnant women will receive 50 mcg of B-12 daily orally from 1st trimester to 6 months post partum
10151683|NCT04083521|Experimental|Treatment|Subjects received a once daily dose of Bacillus subtilis DE111® 1x10^9 CFU for 90-days.
10151684|NCT04083521|No Intervention|Placebo|Subjects received a once daily dose of maltodextrin for 90-days.
10151685|NCT04083053|Experimental|Perianal Exam First|Perianal exam that is a part of anal cancer screening will be performed prior to the intraanal portion of the exam (high-resolution anoscopy with biopsy).
10151686|NCT04083053|Experimental|Perianal Exam Last|Perianal exam that is a part of anal cancer screening will be performed after the intraanal portion of the exam (high-resolution anoscopy with biopsy).
10151687|NCT04083040|Other|TAVI patients|Patient undergone TAVI
10151688|NCT04083261||High daily dose users|Total Cannabinoid Daily Dose greater than 50 mg
10151689|NCT04083261||Control|"Users that represent the median dose between high daily dose users and low daily dose users taking between 11-21 mg"
10151690|NCT04083261||Low daily dose users|Total Cannabinoid Daily Dose less than 10 mg
10151691|NCT04083066|Experimental|Rituximab combined with formoterol, pemetrexed, dexamethasone|Rituximab 375mg/m2D0 is soluble in 0.9% NS, concentration 1mg/ml, micro pump is pumped for 4h Fotemustine 100mg/m2 D1 dissolved in 250mL 0.9% NS, intravenously for 1h, protected from light Pemetrexed 600mg/m2 D1 dissolved in 100ml 0.9% NS, intravenously 1h Dexamethasone 40mg D1-5 Dissolved in 100 ml 5% GS, intravenously (21 days is a cycle)
10151692|NCT04083118||Bicuspid aortic valve|80 patients with bicuspid aortic valve with or without an aortic aneurysm
10151693|NCT04083118||controls|20 healthy volunteer controls age and sex matched to 20 of the bicuspid aortic valve patients
10151694|NCT04083235|Experimental|Irinotecan liposome injection + Oxaliplatin + 5-FU/LV|Irinotecan liposome injection, oxaliplatin, 5 FU/LV, will be administered on Days 1 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
9519873|NCT03282643|Experimental|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
9519874|NCT03282643|Active Comparator|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
10151695|NCT04083235|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel and gemcitabine will be administered on Days 1, 8 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
10151696|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths:5-6mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
10151697|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths≥7mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
10151698|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths:5-6mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
10151699|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths≥7mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
10151700|NCT04082975|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
10151701|NCT04082975|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
9669624|NCT03695146|Experimental|Paced breathing|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.
9977806|NCT01365351||Growth hormone|Children with growth hormone deficiency
10151702|NCT04083079|Experimental|PEG-rhG-CSF cohort|"PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once.~Dosage: 6mg for weight ≥45kg，3mg for weight <45kg, subcutaneous injection"
10151703|NCT04083079|Experimental|rhG-CSF cohort|"rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10^9/L.~rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10^9/L.~Dosage: 5μg/kg/d, subcutaneous injection"
10151704|NCT04083001|Experimental|OTR4132MD|"one medical device (10mL) of one of the 5 available concentrations (20 μg/mL, 50 μg/mL, 100 μg/mL, 150 μg/mL, 200 μg/mL) will be administrated as a one shot-dose to the patient.~The respective total dose of OTR4132 received by a patient will be one of the following: 0,20 mg, 0,50 mg, 1 mg, 1,5 mg and 2 mg."
10151705|NCT04082962|Experimental|Treatment Group|Participants receiving dexamethasone implant.
10151706|NCT04082962|No Intervention|Non-treatment group (control)|Participants not receiving dexamethasone implant.
10151707|NCT04082832|Active Comparator|Cu(II)ATSM|Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
9977807|NCT01365364|Active Comparator|PLM group|Individuals with increased periodic leg movement index (>5)
10151708|NCT04082832|Placebo Comparator|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
10151709|NCT04082988|Other|Nivolumab|"Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation"
10151710|NCT04082897|Experimental|Combination of Obinutuzumab, Atezolizumab and Venetoclax|"Obinutuzumab will be administered iv from cycle 1 to cycle 8 :~cycle1: 100 mg iv (day 1) and 900 mg iv (day 2) 1000mg iv (day 8 and day 15)~Cycle 2-8: 1000 mg iv on day 1~Atezolizumab will be administered iv at 1.200 mg fixed dose from C1 to C18:~Cycles 1: day 2~Cycle 2-18: day 1~Venetoclax will start from day 15 of cycle 1 on a weekly ramp-up basis:~week 1: 20 mg (from day 15 cycle 1) week 2: 50 mg (from day 1 to day 7 cycle 2) week 3: 100 mg (from day 8 to day 14 cycle 2) week 4 200 mg (from day 15 to day 21 cycle 2) week 5: 400 mg (from day 1 cycle 3) venetoclax will be thereafter continued until day 21 of cycle 35"
10151711|NCT04082884|Experimental|Very Low Carbohydrate Diet|Participants will follow a high protein very low carbohydrate diet (VLCD) for 2 weeks. This will be 11% of caloric intake from carbohydrates, 54% of calories from protein, and 35% of calories from fat. Immediately following this, participants will follow a high protein very low carbohydrate diet (VLCD) which will be 11% of caloric intake from carbohydrates, 23% of calories from protein, and 66% of calories from fat.
9977808|NCT01365364|Active Comparator|Non-PLM group|Individuals with PLM index <5
10151712|NCT04082845|Experimental|Experimental Group|The experimental group will be educated via a website that was created by the researchers.
10151713|NCT04082845|No Intervention|Control Group|The control group will take rutin patient care.
10151714|NCT04082650|Experimental|Vitamin D|Participants in the intervention group will be treated with vitamin D 4000IU (800IU per pill, take five pills once each day) per day for around 12 weeks (till the triggering day).
10151715|NCT04082650|Placebo Comparator|Placebo|Participants in the control group will be treated with equal amount of placebo tablets per day for the same duration.
10151716|NCT04082715|Experimental|carbidopa/levodopa+celecoxib|carbidopa/levodopa+celecoxib treatments will be effective.
10151717|NCT04082715|Placebo Comparator|placebo1+celecoxib|A placebo comparator for carbidopa/levodopa+celecoxib .
10151718|NCT04082715|Placebo Comparator|placebo1+placebo2|A placebo comparator for carbidopa/levodopa+celecoxib and placebo1+celecoxib.
10151719|NCT04082741|Experimental|Monotherapy SAD BMS-986318 or Placebo|Single Ascending Dose (SAD)
10151720|NCT04082741|Experimental|Monotherapy MAD BMS-986318 or Placebo|Multiple Ascending Dose (MAD)
10151721|NCT04082858|Experimental|Ketamine|Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
10151722|NCT04082858|Active Comparator|Midazolam|Participants will receive twice-weekly infusions of midazolam at 0.045mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
10151723|NCT04082793|Experimental|Photobiomodulation group|Low-level laser therapy will be given to the PTMB group along with mandibular mobilization and stabilization exercises
10151724|NCT04082793|Experimental|Sonophoresis group|Ultrasonic massage with diclofenac gel will be given to the sonophoresis group along with mandibular mobilization and stabilization exercises
10151725|NCT04082871|Active Comparator|Intervention|"All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist.~A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied.~If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist."
10151726|NCT04082871|Active Comparator|Control|"Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations.~After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist"
10151727|NCT04082923|Other|Gastric bypass operated patients|Two test days in a randomized, patient-blinded, cross-over design
10151728|NCT04082923|Other|Gastric sleeve operated patients|Two test days in a randomized, patient-blinded, cross-over design
10151729|NCT04082923|Other|Control arm|Two test days in a randomized, patient-blinded, cross-over design
10151730|NCT04082702|Experimental|Faith-enhanced DPP|A total of six churches were randomized to this arm that included 119 participants and received 10-month DPP with faith components.
9977809|NCT01365377|Experimental|Booklet|Referent member of the family is designated to receive a written detailed information on Critical care.
9977810|NCT01365377|No Intervention|No booklet|daily information to the family is given as usual.
10151731|NCT04082702|Active Comparator|Standard DPP|A total of five churches were randomized to this arm that included 102 participants who received the standard DPP on the church settings.
10151732|NCT04082624|Active Comparator|Nutrition condition|Received nutrition information such as the comparison of nutritional information between orange juice and soda pop. Received intervention following measurements at baseline, week 4, and week 8.
10151733|NCT04082624|Experimental|Affective condition|Learned about the affective benefits (e.g., less depression) of reduced office sitting time through taking active breaks. Received intervention following measurements at baseline, week 4, and week 8.
10151734|NCT04082624|Experimental|Instrumental condition|Learned about instrumental benefits such as the relationship between sitting and cardiovascular disease and absenteeism at work. Received intervention following measurements at baseline, week 4, and week 8.
9669625|NCT03695146|Active Comparator|Relaxing music|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.
9669626|NCT03695146|No Intervention|No intervention|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.
10151735|NCT04082624|Experimental|Self-regulation condition|Learned how to self-monitor their sedentary behavior and active breaks. They also learned how to create prompts/cues (e.g., sticky note reminder), problem solve to overcome barriers, action plan (i.e., specifying when, where, and how to do the behavior), and set goals in order to be less sedentary according to SMART (i.e., specific, measurable, attainable, relevant, time-oriented) principles. Received intervention following measurements at baseline, week 4, and week 8.
10151736|NCT04082806|Experimental|healthy controls|
10151737|NCT04082806|Experimental|Major Depressive Disorder|
10151738|NCT04082767|Active Comparator|Dexmedetomidine|
10151739|NCT04082767|Active Comparator|Midazolam|
10151740|NCT04082598|Experimental|Tooth extraction and antibiotic treatment|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days
9669627|NCT03691714|Experimental|Durvalumab and Cetuximab|Durvalumab 500mg as a 120-minute intravenous infusion every two weeks. Cetuximab 400mg/m2 IV loading dose followed by weekly Cetuximab 250mg/m2 IV Treatment with Durvalumab continues until progression and Cetuximab may continue as maintenance
9669628|NCT03661333|Experimental|Adolescents with bipolar disorder|40 adolescents aged 13 to 19 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
9669629|NCT03659604|Experimental|Experimental with tailored feedback|'SmartLife' with tailored feedback: School classes will receive the developed 'SmartLife' intervention with tailored feedback, that is based on data from a sensors that is integrated in a T-shirt.
10151741|NCT04082598|Experimental|tooth extraction and antibiotic treatment + dietary supplement|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days
10151742|NCT04082598|No Intervention|Tooth extraction|tooth extraction without antibiotics and/or Bifidobacterium longum and Lactoferrin
10151743|NCT04082351|Active Comparator|Magnalife|the group of patients receiving the nanotechnology structured water
10151744|NCT04082351|Placebo Comparator|Ordinary water|the group of patients receiving ordinary water
10151745|NCT04082559|Other|Antibiotic treatment|"Patients with active disease will be randomized and will receive a prescription for one of two antibiotic regimens.~Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks~Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks"
10151746|NCT04082559|Other|Combination therapy (Antibiotics + diet)|"Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks.~Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks."
10151747|NCT04082559|Other|Nutritional prevention|"Patients in clinical remission will be recruited to a dietary prevention study.~Mediterranean diet~Control- based on the American Dietetic Association recommendations for patients with IBD~Personalized nutrition group- based on prior results from study- NCT02858557"
10151748|NCT04082325|Experimental|Part A Lu AF88434 or Placebo|6 cohorts (cohort A1 to A6) with 9 subjects in each cohort. In each cohort 6 subjects will receive single doses of Lu AF88434 and 3 subjects will receive placebo
10151749|NCT04082325|Experimental|Part B1 Lu AF88434 Fed-Fasting-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B1. The treatment sequence for Group B1 is: Fed-Fasting-Fasting. 14C-spiked dose (Lu AF99723) will be given in the last treatment sequence.
9669630|NCT03659604|Active Comparator|Active control without tailored feedback|'SmartLife' without tailored feedback: School classes will receive the developed 'SmartLife' intervention without tailored feedback.
10151750|NCT04082325|Experimental|Part B2 Lu AF88434 Fasting-Fed-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B2. The treatment sequence for Group B2 is: Fasting-Fed-Fasting. 14C-spiked dose (Lu AF99722) will be given in the last treatment sequence.
10151751|NCT04082325|Experimental|Part B3 Lu AF88434 Fasting-Fasting-Fed|4 subjects will receive an identical oral dose of Lu AF88434 in Group B3. The treatment sequence for Group B3 is: Fasting-Fasting-Fed.
10151752|NCT04082286|Experimental|Radioimmunotherapy|Children affected by high risk malignant disorders will be receiving increasing infused activity of a radio-immune conjugated antibody as part of their conditioning regimen prior to alleogeneic stem cell transplantation
10151753|NCT04082234|Experimental|Integrated Individualized Behavioral Parent Training|Partnering to Achieve School Success (PASS) is a personalized, enhanced behavioral intervention for ADHD that includes evidence-based behavior therapy strategies and enhancements to promote family engagement in treatment, team-based care, and high quality therapy. Caregivers engage in up to 12 sessions with a behavioral health provider over the course of 16 weeks that are specifically tailored to caregiver goals and values.
9669631|NCT03659604|Other|Passive control|School classes will not receive any intervention, thus no game.
9669632|NCT03640624|Experimental|Intervention|Multidisciplinary treatment
9669633|NCT03640624|Active Comparator|Control|Treatment as usual
9669634|NCT03636282|Experimental|Hockey FIT Program (Immediate Delivery)|Hockey FIT Program: A gender-sensitized, weight loss and healthy lifestyle program that engages men using the power of being a sports fan.
10151754|NCT04082234|Active Comparator|Treatment as Usual|The control condition will be TAU informed by AAP guidelines for managing ADHD and facilitated by electronic practice supports, which have been successfully incorporated into the electronic health record (EHR) to guide primary care providers (PCPs) in implementing ADHD guidelines. At CHOP, PCPs across the primary care network were invited to participate in a distance learning, quality improvement initiative to promote implementation of AAP guidelines,including strategies to educate families about ADHD and evidence-based treatments, engage families in shared decision making, titrate medication, and monitor treatment effects. The five practices participating in this study participated in that project.
10151755|NCT04082338|Experimental|VPN Toolkit+TM|The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application) format.
10151756|NCT04082338|Active Comparator|Text Messages|Receive TM respectively once a week for 5 weeks for every 6 months in the 18-month study period
10151757|NCT04082312||Group 1|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + with KDIGO stage 3 AKI
10151758|NCT04082312||Group 2|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + without KDIGO stage 3 AKI and alive at D10
10151759|NCT04082312||Group 3|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + died before D10 without KDIGO stage 3 AKI
10151760|NCT04082507||Non_adherent plcenta|placenta separated within 15 minutes after delivery of fetus
10151761|NCT04082507||Adherent placenta|placenta dosenot separated within 15 minutes after delivery of fetus
10151762|NCT04082299||Pregnant women|pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
10151763|NCT04082299||Non pregnant women|Non pregnant women expected to be vaccinate with Tdap vaccine
10151764|NCT04082390|Experimental|RELEASE Supplement|
10151765|NCT04082390|Placebo Comparator|Placebo|
10185549|NCT03744559|Other|NR-E (No R-E) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a non-smoking or neutral cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
10185550|NCT03744533|Experimental|head-down position treatment|
10185551|NCT03744533|Active Comparator|guideline-based treatment|
10185552|NCT03744520|Experimental|ESP block group|The patients who had paravertebral interfacial plane block for postoperative analgesia
10185553|NCT03744455||End of training|Anesthesia residents at the end of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
9669635|NCT03636282|No Intervention|Wait-List Control (Delayed Delivery)|No intervention for 12 months. After 12 months, Hockey FIT program is offered.
9669636|NCT03636256|Experimental|Non-Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL and additional Induction (6 weekly NanoDoce intravesical instillations, followed by 6 weeks of rest) and Maintenance (3 weekly NanoDoce intravesical instillations, followed by 9 weeks of rest) instillations at 2.0 or 3.0 mg/mL.
9669637|NCT03636256|Experimental|Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL. Subjects will then go on to receive institutional standard of care.
9669638|NCT03635515|Active Comparator|Standard Protocol (Control) Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
9826263|NCT02413255|Experimental|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
9826264|NCT02413255|Experimental|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
9826265|NCT02413255|Experimental|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
10185554|NCT03744455||Begin of training|Anesthesia residents at the begin of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
10185555|NCT03744442|Active Comparator|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
10185556|NCT03744442|Active Comparator|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
10185557|NCT03744442|Active Comparator|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
10185558|NCT03744416|Experimental|Intervention group|Counseling based on Epstein's active decision making on birth plan
10185559|NCT03744416|No Intervention|Control group|The standard midwife's advice on birth plan during prenatal care.
10185560|NCT03744390|Experimental|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.
10185561|NCT03744364|Active Comparator|Misoprostol|Group of women allocated to misoprostol induction.
10151766|NCT04082494|No Intervention|Regular Treatment|"No intervention is planned for the first period. Baseline treatment assesment."
10151767|NCT04082494|Experimental|Music|Optional music via internet and noise canceling headphones will be offered.
10151768|NCT04082494|Experimental|Music and Beverages|Additionally to the offered optional music via internet and noise canceling headphones, there will be beverages optionally offered (with and without sugar, warm or cold).
10151769|NCT04082403|Active Comparator|Pre SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway
10151770|NCT04082403|Experimental|Post SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway after receiving SALAD training
10151771|NCT04082546||Surgical unroofing|Refractory angina to medical treatment (beta-blockers or calcium channels blockers)
10151772|NCT04082546||Medical treatment|Responders to medical treatment for angina relief
10151773|NCT04082260||De novo patients with alemtuzumab|De novo patients prior and after alemtuzumab treatment initiation
10151774|NCT04082260||Alemtuzumab treatment|Patients under alemtuzumab treatment
10151775|NCT04082260||Extended alemtuzumab treatment|Patients requiring more than two alemtuzumab infusions
10151776|NCT04082273|Experimental|Femtosecond Laser for Cataract Surgery|Capsulotomy, lens fragmentation and Clear Corneal Incisions with FEMTO LDV Z8, followed by ultrasound phacoemulsification and IOL implantation.
10151777|NCT04082273|Active Comparator|Conventional Cataract Surgery|Clear Corneal Incisions, conventional capsulorhexis and ultrasound phacoemulsification and IOL implantation. Control treatment where the clear corneal incisions and capsulorhexis are performed manually and the lens fragmentation is performed with the phacoemulsification device.
10151778|NCT04082208|Experimental|Intervention Group|High Flow nasal cannula (HF)
10151779|NCT04082208|Active Comparator|Standar Care Group|Standar Care: low flow device (LF)
10151780|NCT04082182|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIX4-LUNG autologous DC vaccine
10151781|NCT04082195|Experimental|Fooya mobile game|An arm that receives a mobile-app-based treatment.
10151782|NCT04082195|Active Comparator|Uno board game|An arm that receives a non mobile-app-based treatment.
10151783|NCT04082247|Experimental|Experimental group|The education and training of early childhood educators (developed by the researchers) and their intervention on children.
10151784|NCT04082247|No Intervention|Control group|Receive the standard care.
10151785|NCT04082156|Active Comparator|Active TENS|
10151786|NCT04082156|Sham Comparator|Sham TENS|
10151787|NCT04082052|Experimental|Single Session Intervention for Self-Dislike|A 30-45 minute intervention delivered in a web browser that focuses on reducing self-dislike using facts about the brain, testimonials from peers, and writing exercises.
10151788|NCT04082052|Placebo Comparator|Single Session Intervention for Feelings Disclosure|A 30-45 minute intervention delivered in a web browser that focuses on encouraging feelings disclosure using facts about the brain, testimonials from peers, and writing exercises.
10151789|NCT04082065|Active Comparator|conventional physical therapy|Myofacial release Stretching of hamstring and Piriformis
10151790|NCT04082065|Experimental|cyriax lumber manipulation group|Myofacial Release stretching of hamstrings and Piriformis Cyriax Lumbar Manipulation Techniques
10151791|NCT04082026|Experimental|Early Adolescent Skills for Emotions (EASE)|EASE has four core features: Seven group sessions for young adolescents and three for their caregivers; Delivered by non-specialists; Trans-diagnostic: addressing depression, anxiety, distress, and other problems as defined by the young people themselves; and Designed for young people and their caregivers in low- and middle-income countries living in communities affected by adversity.
10151792|NCT04082026|Placebo Comparator|Enhanced Treatment As Usual (ETAU)|The Enhanced Treatment as Usual (ETAU) consisted of a single psychoeducation individual session, jointly for eligible adolescents and their caregivers, that included information on: (i) the results of the screening; (ii) self-care strategies; and, (iii) seeking services from local health or community services offering psychosocial / mental health care support.
10151793|NCT04082039|Active Comparator|1-channel PCA|Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
10151794|NCT04082039|Experimental|2-channel PCA|Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
10151795|NCT04082130|Experimental|(XCM)+(CAF)|"Surgical protocol for test treatment with CAF + XCM:~After local anesthetizing the recipient site,CAF elevation will be done using (De Sanctis & Zucchelli 2007) design.Horizontal incisions will be done at the recession site,another two slightly divergent vertical incisions will be done at the end of previous incisions extending to the mucogingival junction.The resulting flap will be split thickness in the surgical papillae area,then will be full thickness exposing 3-4 mm of the bone apically of the dehiscence and after that it will be split thickness in the apical direction,all the muscle insertions will be eliminated,the root surface will be prepared by curettes and chemically treated with 24% EDTA gel.De-epithelialization of the interdental papillae will be done.The XCM will be trimmed and fix onto the root surface 1-2mm coronally of the CEJ using absorbable sutures,and the flap will be coronally advanced to fully cover the XCM and then sutured to the de-epithelialized papillae."
10151796|NCT04082130|Active Comparator|(SCTG)+(CAF)|"The surgical protocol in the control group will be identical with test group protocol with these exceptions:~The entire flap will be elevated as split thickness instead of split-full-split thickness flap.~A SCTG harvested from the palate will be used to cover the exposed denuded root surface in lieu of placement of XCM in the test group. And absorbable sutures will be used to stabilize it 2 mm coronally from the CEJ.~As in the test group the mucosal flap will coronally advanced to completely cover the SCTG then sutured to the de-epithelialized papillae."
10151797|NCT04081948|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
10151798|NCT04081948|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
10151799|NCT04081727|Experimental|Test Article - Zip-stitch(TM) Clips|Zip-stitch(TM) clips for vaginal cuff closure during laparoscopic hysterectomy
10151800|NCT04081727|Other|Reference Group - V-Loc Barbed Suture|Will not be comparative against the test article, but will be performed for reference and safety.
10151801|NCT04081974||Minimally invasive cardiac surgery|All consecutive patients presenting for minimally invasive cardiac surgery will be screened for participation to the study.
10151802|NCT04082117|Other|Open Label|Educational genetic counseling video
10151803|NCT04081844|Experimental|Fixed-Sequence|Period 1: Fasted state+HCP1306, Period 2: Fasted state+HGP0904+HGP0608, Period 3: Fasted state+HCP1306+HGP0904+HGP0608
10151804|NCT04081857|Experimental|Sequence 1|Period 1 : Fasted state + HGP1810 Period 2 : Fasted state + HCP1704
10151805|NCT04081857|Experimental|Sequence 2|Period 1 : Fasted state + HCP1704 Period 2 : Fasted state + HGP1810
10151806|NCT04082143|Experimental|Implant with prophylactic allograft|
10151807|NCT04082143|Active Comparator|Implant without prophylactic allograft|
10151808|NCT04081909|Active Comparator|Opioid Based Anesthesia(OBA)|
10151809|NCT04081909|Experimental|Opioid Free Anesthesia(OFA)|
10151810|NCT04081922|Experimental|Regional analgesia using erector spinae plane block|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. Then, regional analgesia is performed for additional analgesia; ultrasound guided erector spinae plane block is performed using 0.25% ropivacaine (total 1 ml/kg) bilaterally. Plasma concentration of ropivacaine at baseline, and 5, 10, 20, 30, 60, 120 minutes after ropivacaine injection will be measured.
10151811|NCT04081922|No Intervention|Control|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. No regional block is performed.
10151812|NCT04082000|Experimental|BOL-DP-o-04|
10151813|NCT04082000|Placebo Comparator|Placebo|
10151814|NCT04081753|Experimental|TMD Group|Temperature Monitoring Device Group - The interventional group, who will be given the temperature monitoring device and will be monitored remotely.
9977811|NCT01365390||Cohort A|Subjects aged < 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).
9977812|NCT01365403|Experimental|Single Arm|
10151815|NCT04081753|No Intervention|Historic cohort Group|Historic cohort group will be enrolled from medical record
10151816|NCT04081883|Experimental|Biosensor algorithm|The biosensor DIABLO algorithm is compared to Continuous Glucose Monitoring Systems (CGMS) utilisation.
10151817|NCT04081935|Experimental|Reduce pain and fair|To determine whether the virtual reality as a distracting intervention could reduce pain and fear in school-age children receiving intravenous injections at an emergency department.
10151818|NCT04081935|No Intervention|Compared|Normal treatment
10151819|NCT04081506|Experimental|Group A|Individualized care
10151820|NCT04081506|No Intervention|Group B|Conventional care
10151821|NCT04081519|Active Comparator|DLPFC-DLPFC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over DLPFC
10151822|NCT04081519|Experimental|DLPFC-LPC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over LPC
10151823|NCT04081519|Sham Comparator|DLPFC-SHAM|15 sessions of active rTMS over DLPFC + 15 sessions of sham rTMS over DLPFC or LPC
10151824|NCT04081532|Active Comparator|Surgical treatment|
10151825|NCT04081532|No Intervention|No surgical treatment|
10151826|NCT04081441|Experimental|Inyenyeri clean cookstove/fuel|A tier 4 clean Mimi-moto cookstove/pellet system
10151827|NCT04081441|Experimental|I-ACT behavioral empowerment intervention|A culturally adapted 2-day personal empowerment workshop (based on the Individual, Agency-Centered Training (I-ACT) to women and modified, condensed 1-day training for their male partners, if applicable
10151828|NCT04081441|Experimental|Cookstove and I-ACT empowerment|Access to both the clean cookstove system and I-ACT empowerment training
10151829|NCT04081441|Other|I-ACT Waitlisted control|These households include those that were offered cookstoves after 6 months (from baseline) and are waitlisted to receive the I-ACT intervention
10151830|NCT04081545|Active Comparator|Control Goup A- Opioid-based regimen|"Preop - Multimodals unless contraindicated~Induction~Fentanyl (50mcg IV)~Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)~Propofol 2-3mg/kg IV bolus~Neuromuscular blockade per Anesthesiology team discretion~Maintenance~Sevoflurane~Neuromuscular blockade at discretion of anesthesiology team~May use fentanyl to treat SBP or HR > 20% of baseline~Emergence~Neuromuscular reversal, dosed according to Virginia Mason protocol~May titrate fentanyl per anesthesiology team throughout the case.~Patient extubated and brought to PACU~PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
10151831|NCT04081545|Experimental|Experimental Group B- Opioid-free regimen|"Preop - Multimodals unless contraindicated~Induction~Dexmedetomidine 1mcg/kg IV bolus over 10 minutes using IBW~Lidocaine 1.5mg/kg IV bolus using IBW~Propofol 2-3mg/kg IV bolus~Neuromuscular blockade per Anesthesiology team discretion~Ketamine 0.5mg/kg IV bolus (based on IBW)~Maintenance~Sevoflurane~Dexmedetomidine 0.4 mcg/kg/hr IV infusion using IBW (may titrate based on patient response between 0.3-0.5mcg/kg/hr)~Lidocaine 2mg/kg/hr IV infusion using IBW~May use esmolol as needed to treat SBP or HR > 20% of baseline~Neuromuscular blockade at the discretion of anesthesiology team~Emergence~Dexmedetomidine infusion turned off during laparoscopic desufflation~Lidocaine infusion turned off at skin closure~Neuromuscular reversal, dosed according to VM protocol~Pt extubated and brought to PACU~PACU opioid orders per anesthesiology team~Post-operative Nausea/Vomiting Prophylaxis~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
10185562|NCT03744364|Active Comparator|Dinoprostone|Group of women allocated to dinoprostone induction.
10185563|NCT03744351|Other|Healthy volunteer|"45 subjects~A single visit"
10185564|NCT03744351|Other|Clinically Isolated Syndrome|• 35 subjects
9972186|NCT01318213||Intervention Arm|The intervention will consist of wearing gloves and gowns for all patient contact in the ICUs that are randomized to receive the intervention. During the intervention phases of the study, all healthcare workers (nurses, physicians, nurse extenders, respiratory therapists, social workers etc.) in the intervention group will be required to wear gloves and gowns for patient contact and when entering any patient room. In essence, healthcare workers will apply the CDC Contact Precautions guidelines for ALL patients.
9519875|NCT03282630|Experimental|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
9519876|NCT03282630|Sham Comparator|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
10151832|NCT04081766|Active Comparator|SUGAR Handshake|"Participants assigned to the intervention group will receive an individualised, pharmacist-led patient counselling session (SUGAR Handshake package) at the inclusion visit.~Participants will also receive a pictogram with the main instructions for easy recall of the counselling contents.~They will also receive a glucometer and test strips with a demonstration on proper use, to measure their fasting blood glucose levels on a daily basis for 12 weeks.~At week 6, participants will receive a phone call to reinforce the intervention and to remind them of the study protocol. For the qualitative evaluation of the intervention, a number of participants are interviewed and asked questions through the sixth week-phone call.~Additionally, participants in this group will be provided with the usual care that is normally provided in the outpatient clinics at King Abdullah University Hospital."
9519877|NCT03282617|Experimental|locally recurrent or metastatic nasopharyngeal cancer|This cohort consists of patients with metastatic or locally recurrent NPC who have received systemic concurrent chemotherapy and have a favourable response of stable disease, partial or complete response. As up to 30% of these patients will suffer from relapse within 5 months of completion of chemotherapy, following definitive treatment, y, and treatment with CD137L-DC-EBV-VAX may activate T cell response against the tumor and prolong time to progression.
9519878|NCT03282617|Experimental|stage 4 locally advanced nasopharyngeal cancer|This cohort consists of patients with stage 4 locally advanced patients (N2 and N3 disease, and/or T4 disease) who are treated definitely with chemoradiation with curative intent, but who have a high risk of distant relapse. Treatment with CD137L-DC-EBV-VAX may activate antitumor T cell responses and prolong time to relapse.
9519879|NCT03282604||male|
9519880|NCT03282604||female|
9977813|NCT01365429|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the XPS™ with Steen Solution™ and undergone ex-vivo lung perfusion before being transplanted.
10151833|NCT04081766|No Intervention|Control|"Participants within this group will receive the usual care provided by the health care professionals in the outpatient clinics at King Abdullah University Hospital.~They will also be provided with instructions on hypoglycemia diagnosis, and treatment and a demonstration on glucometer use at the inclusion visit. They will be asked to measure their fasting blood glucose level daily for 12 weeks.~Participants will receive a phone call at week 6 of the inclusion visit to remind them of measuring blood glucose levels and documenting hypoglycemic episodes on the diaries., plus a counselling session about hypoglycaemia recognition and treatment at the inclusion visit.~For the qualitative evaluation of the study, a number of participants will be interviewed and asked questions through the sixth week-phone call."
10151834|NCT04081454||Children with chronic pain|
10151835|NCT04081454||Caregivers of children with chronic pain|
10151836|NCT04081805|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
10151837|NCT04081805|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcroablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
10151838|NCT04081805|Active Comparator|Promestriene|The patient will use intravaginal promestriene, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube to verify the correct use.
9519881|NCT03282578|Active Comparator|Sternalock 360 sternal plating system|use of the SternaLock 360 system to close the sternum: 3 plates with 3 bands and measured screw length to engage but not penetrate the posterior sternal cortex, used to close the sternum
9519882|NCT03282578|Active Comparator|Sternal wires|"Stainless steel sternal wires applied in a figure of 8 configuration to close the sternum"
9519883|NCT03282552|Active Comparator|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
9519884|NCT03282552|Active Comparator|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
9826266|NCT02413255|Experimental|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
9977814|NCT01365429|No Intervention|Control Group|Control Group are those recipient lung transplant patients that receive donor lungs via conventional transplant.
10185565|NCT03744351|Other|Non-MS patients with neurological inflammatory disease|• 30 subjects
10185566|NCT03744351|Other|MS patients (remitting or progressive untreated)|"30 untreated remittent patients~30 progressive untreated patients"
10185567|NCT03744338||Group 1|
9977815|NCT01365442||Consenting, eligible participants|All consenting eligible participants in the study area will receive the oral cholera vaccine
10151839|NCT04081870||ICSI cases|All women underwent long agonist protocol for controlled ovarian hyperstimulation The GnRH agonist was started in the previous mid-luteal phase . After the confirmation of pituitary down regulation , the HMG ampoules were started by 225 IU/day . During the follow up of overstimulation, the doses were adjusted according to the response of patient. All women underwent serial TVS until at least three dominant follicles were reached in every woman. When the dominant follicles reached 18-20 mm, HCG 10000 was administered. Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration. The luteal phase was supported by progesterone 300 mg per day . Five days following ovum pick up, the embryos were transferred at the blastocyst stage.
10151840|NCT04081467|Experimental|bed rest condition|Bed rest condition without any additional intervention
10151841|NCT04081688|Experimental|Treatment (varlilumab, atezolizumab, SBRT)|Patients receive varlilumab IV over 90 minutes and atezolizumab IV over 30-60 minutes every cycle. Cycles repeat every 21 days for up to 1 year (18 cycles) in the absence of disease progression or unacceptable toxicity. Between cycle 1 and 2, patients also receive SBRT.
10151842|NCT04081493|Experimental|Group 1 (BFRE)|Low-load blood flow restricted exercise 3/weekly for 8 weeks before TKR 10-min warm-up followed by unilateral leg press and unilateral knee extension
10151843|NCT04081493|No Intervention|Group 2 (CON)|No training before TKR
9519885|NCT03282552|No Intervention|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.~In this group all patients will receive the usual standard of care, with no other interventions included"
10151844|NCT04081558|Experimental|Electronic follow-up|
9519886|NCT03282539||LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents.
10151845|NCT04081662|Experimental|compACT Intervention|"At every time-point of the study, participants will complete self-reports of stress, (as measured by the PSS-4) distress (as measured by the PHQ-2), and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
10151846|NCT04081389|Experimental|CKM weeks 1-3, doxorubicin, cyclophosphamide)|Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
10151847|NCT04081597|Experimental|STAR-101|Doses in two of three crossover periods
10151848|NCT04081597|Placebo Comparator|Placebo|Matching placebo in one of three periods
10151849|NCT04081415||Group with FPIES|Not yet healed children with FPIES
10151850|NCT04081376|Experimental|Treatment group|Subjects receive a single-dose treatment.Urine samples will be collected after administration (8 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-60h, 60-72h post-administration).
10151851|NCT04081623||Clinic|This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP)
10151852|NCT04081623||Labor and Delivery|This group is in active labor.
10151853|NCT04081402|Experimental|HU-014 Inj|
10151854|NCT04081402|Active Comparator|Botox Inj|
10151855|NCT04081701||Meningioma|Cohort of 30 subjects with meningioma.
10151856|NCT04081701||Non-Meningioma|"Cohort of 60 subjects with non-meningioma:~(esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma and SSTR-positive tumors metastatic to the brain)"
10151857|NCT04081480|Other|Valacyclovir oral solution|Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.
10151858|NCT04081129||ICU patients with early mobilization|
10151859|NCT04081194||case group, Melanoma Patients|"15 patients of with Melanoma, Age between 40 and 90 years.~-Withdrawal of Blood sample, Isolation of Exosomes:~Bradford protein assay And Qubit protein assay.~Bioanalyzer.~Real time PCR."
10151860|NCT04081194||control group|"10 Persons without Melanoma, age > 40 years~-Withdrawal of Blood sample, Isolation of Exosomes:~Bradford protein assay And Qubit protein assay.~Bioanalyzer.~Real time PCR."
10151861|NCT04081246|Experimental|Modified en bloc resection|For patients undergoing modified en bloc resection, piecemeal resection of the exophytic part of the bladder tumour will be performed, followed by en bloc resection of the tumour base.
10151862|NCT04081272||G6PD-normal|Donated blood from G6PD-normal subjects
9519887|NCT03282539||LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
9519888|NCT03282526|Experimental|Whole body plethysmography|
9519889|NCT03282526|Active Comparator|spirometery|
10151863|NCT04081272||G6PD-deficient|Donated blood from G6PD-deficient subjects
10151864|NCT04081168|Active Comparator|Stereotactic Body Radiotherapy|Patients included will undergo Stereotactic Body Radiotherapy (SBRT) of hepatic metastases.
10151865|NCT04081168|Active Comparator|Microwave Ablation|Patients included will undergo Microwave Ablation (MWA) of hepatic metastases.
9826267|NCT02413255|Experimental|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
9977816|NCT01365520|Experimental|N8|
9977817|NCT01365533|Active Comparator|Roflumilast|
9977818|NCT01365533|Placebo Comparator|Placebo|
10151866|NCT04081012|Experimental|N-acetyl Cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before endarterectomy or balloon angioplasty.
10151867|NCT04081012|Placebo Comparator|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals. All study medications will be prepared by the Pharmacology department, which is not involved in patient care; the name of the medication and dose of the original ampule will be erased and also an identification label will be placed with the name, registration number, bed number, date and will be indifferent for groups with the same type of ampoule, with the same type of labeling
10151868|NCT04081025||Adults|Age Groups 35, 50, 65, 75 and 85
10151869|NCT04081077|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
10151870|NCT04081077|Experimental|Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
10151871|NCT04081077|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
10151872|NCT04081064|Experimental|Non-obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >18.5 and <30.0 kg/m2
10151873|NCT04081064|Experimental|Obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >30.0 to <40.0 kg/m2
10151874|NCT04081116|Experimental|MI-E testing symmetric settings|Symmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
10151875|NCT04081116|Experimental|MI-E testing assymetric settings|Asymmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
10151876|NCT04081116|Sham Comparator|Settings in use|Settings in use is one of 3 different settings that will be tested on the same day but in randomized order
10151877|NCT04080973|Experimental|osteopenic patients|patients with a kidney stone and osteopenic changes.
10151878|NCT04081090|Experimental|Brain HQ adaptive Cognitive Therapy Modules|Brain HQ licensed modules that adapt to each individuals unique strengths and weaknesses to address deficits and improve neuroplasticity.
10151879|NCT04081090|Active Comparator|Brain HQ Active Control Modules|Participants in this arm will complete puzzles such as crossword puzzles, Sudoku, etc.
9826268|NCT02413255|Experimental|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
10151880|NCT04081103|Experimental|NEXAGON High Dose Concentration|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
10151881|NCT04081103|Experimental|NEXAGON Low Dose Concentration|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
10151882|NCT04081103|Placebo Comparator|NEXAGON Vehicle|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
10151883|NCT04081207|Experimental|AAC-LaRc|all participants receive the experimental treatment
10151884|NCT04081259|Experimental|Arm B: Dose Escalation LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients with inhibitors for fungal prophylaxis/treatment
10151885|NCT04081259|Experimental|Arm A: Dose Expansion LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients without inhibitors for fungal prophylaxis/treatment
10151886|NCT04081311|Experimental|water flosser|patient will be provided with Waterpik Water Flosser and instructed to water floss around the implant once a day, preferably at nighttime
10151887|NCT04081311|Active Comparator|dental floss|patient will be instructed to floss with TePe Bridge and Implant Floss once a day, preferably at nighttime
10151888|NCT04081181|Experimental|CT_ guided percutaneous microwave ablation|The procedure will be done under anaesthesia by interventional radiologist
10151889|NCT04080921|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
9826269|NCT02413255|Experimental|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
9977819|NCT01365559|Experimental|Group A: Carfilzomib & Non-IMiD containing regimen|Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
9826270|NCT02413255|Experimental|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.
10151890|NCT04081051|Experimental|Intervention|Diagnostic algorithm( paper and electronic) utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change training for healthcare workers
9669639|NCT03635515|Active Comparator|Gentlewave Treatment Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed through working length verification. For the Gentlewave treatment group, each canal will be shaped to a canal size of 20.06 and to 0.5 - 1mm short of the apical terminus. An occlusal platform will be prepared using the Kool-dam material recommended by Sonendo. The Gentlewave system will be held on the tooth by the clinician and will cycle through five minutes of 3% sodium hypochlorite, two minutes of 8% EDTA, and a final rinse of distilled water. Canals will be obturated with root canal sealer and gutta-percha. The same VAS scale from pretreatment to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.
10151891|NCT04081051|No Intervention|control|Standard of care practices for acute febrile illness
10151892|NCT04080934|Experimental|Experimental Group|In the experimental group, patients allocated to the swimming/experimental group will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum. They will be asked to undergo a range of motion (ROM) assessment by a registered kinesiologist, as well as a few short questionnaires administered over the phone by a research assistant, once at the onset of the intervention and once a month for 3 months during the intervention.
10151893|NCT04080934|No Intervention|Control Group|The control group will include patients who receive standard of care. This includes the recommendation to undertake exercise and physiotherapy; however, no formal exercise program will be provided. In the control group, participants will be asked to answer a few short questionnaires administered over the phone by a research assistant once per month for 4 months.
10151894|NCT04080609|Experimental|Sequential arm|Dorzagliatin was administered single dose; after wash-out, rifampicin was dosed continuously for 9 days, with Dorzagliatin dosed simultaneously on day 8.
10151895|NCT04080661|Experimental|Standard of care - secukinumab|Patients will continue to receive secukinumab according to the standard dosing schedule: subcutaneous injections once a week for 5 weeks, then every 4 weeks (300 mg).
10151896|NCT04080908|Experimental|Ferumoxytol injection treatment|
10151897|NCT04080674||Parkinson's disease|30 participants
10151898|NCT04080674||Essential Tremor|10 participants
10151899|NCT04080674||Dystonia|20 participants
10151900|NCT04080687||Fallers|The patients who had fallen during the 6 months prior to the study onset
10151901|NCT04080687||Non-fallers|The patients who had not fallen during the 6 months prior to the study onset
10151902|NCT04080596|Experimental|Sequential arm|Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11.
10151903|NCT04080648|Other|Standard of case - guselkumab|Patients will continue to receive guselkumab according to the standard dosing schedule; subcutaneous injection of 100 mg at weeks 0 and 4 and then every 8 weeks
10151904|NCT04080635|Experimental|Standard of care - brodalumab|Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.
10151905|NCT04080453||Septic shock|Plasma of 100 patients presenting a septic shock will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
10151906|NCT04080453||Systemic Inflammatory Response Syndrome|Plasma of 100 patient presenting a systemic inflammatory response syndrome = SIRS will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
10151907|NCT04080518|Active Comparator|Experimental|Dapagliflozin, 10mg, oral dose, once every day
10151908|NCT04080518|Placebo Comparator|Control|Matching placebo for dapagliflozin, oral dose, once every day
10151909|NCT04080726|Experimental|HIP1601+HGP1705 Placebo|HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks
10151910|NCT04080726|Experimental|HGP1705+HIP1601 Placebo|HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks
9669640|NCT03617263|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium once daily in the morning before breakfast
10151911|NCT04080401|Experimental|Fun-Knee Mobile Application|Participants will use a mobile application paired to a knee sleeve with embedded inclinometer sensors. The sensor system will compute knee movement, and feed towards game-based rehabilitation exercises for Total Knee Arthroplasty rehabilitation. game-based and supported on mobile device running on Android or Inter-network Operating System platforms. The mobile apps is able to capture the angle and position data from the two inclinometers on smart knee sleeve.
10151912|NCT04080401|Active Comparator|Conventional Exercise Brochures|Participants will be guided to do their Total Knee Arthroplasty rehabilitation exercises using conventional, paper-based exercise brochures.
10151913|NCT04080830||Acute ischemic stroke/transient ischemic attack (TIA) with AF|patients with Acute ischemic stroke/TIA and Atrial fibrillation (observational -no intervention)
10151914|NCT04080492||Inherited Cardiac Disease|Patients being seen for the first time at the Cleveland Clinic for Hypertrophic Cardiomyopathy or Thoracic Aortic Aneurysm.
10151915|NCT04080492||Non-inherited Cardiac Disease|Patients being seen for the first time at the Cleveland Clinic for Radiation-Induced Heart Disease.
10151916|NCT04080817|Experimental|Neolexon Therapy|
10151917|NCT04080817|Active Comparator|Standard logopedic therapy|
9519890|NCT03282513|Experimental|Cohort 1A: Mild Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)"
10151918|NCT04080570|Experimental|Remote Visit|After an initial physical in-home visit, the physician will see home hospitalized patients by facilitated video each day.
10151919|NCT04080570|No Intervention|In-Home Visit|The physician will see home hospitalized patients physically in their homes each day, as is usual care.
10185568|NCT03744325|Active Comparator|Hen's egg OIT|Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
10151920|NCT04080739|Experimental|Experimental Group|US-guided ipsilateral sciatic nerve block for fibula free flap patients utilizing ropivacaine 0.2% at 2-8 cc/hr for fibula free flap patients; US-guided infraclavicular brachial plexus nerve block for forearm free lap patients utilizing ropivacaine 0.2% at 2-8cc/hr for forearm free flap patients.
10151921|NCT04080739|No Intervention|Control Group|No regional anesthetic of any kind during the surgical procedure.
10151922|NCT04080440|Active Comparator|Standard of care|Clinicians decide whether to extubate or not following their ICU protocol
10151923|NCT04080440|Experimental|Extubation readiness clinical score|Clinicians decide whether to extubate or not following the extubation readiness clinical score
10151924|NCT04080466|Experimental|Cam Group|This group will consist of patients that are scheduled for surgery to undergo cam resection by hip arthroscopy.
10151925|NCT04080466|Active Comparator|Control Group|This group will consist of a matched cohort of control participants.
10151926|NCT04080375|Experimental|dinoprostone 3 mg|patients will take 1 tablet of vaginal dinoprostone 1 hour before the surgery
10151927|NCT04080375|Placebo Comparator|placebo|patients will take 1 tablet of placebo 1 hour before the surgery
10151928|NCT04080388|Active Comparator|Control Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The control group (half of the patients) will be discharged without additional intervention.
10151929|NCT04080388|Active Comparator|Interventional Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The interventional group (half of the patients) will continue anti-congestive treatment while hospitalized until achieving a suitable level of decongestion.
10151930|NCT04080414|Experimental|Home-based high-intensity interval training|
10151931|NCT04080414|Active Comparator|Home-based moderate-intensity continuous exercise|
10151932|NCT04080479|Experimental|Bolus enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding. The study subjects will undergo the following interventions:~Quadriceps Muscle Layer Fitness measurement~Muscle Strength measurement~Acute Physiology and Chronic Health Evaluation~Sequential Organ Failure Assessment~Nutritional Risk Screening~Energy and Protein Intake"
10151933|NCT04080479|Experimental|Continuous enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding.~The study subjects will undergo the following interventions:~Quadriceps Muscle Layer Fitness measurement~Muscle Strength measurement~Acute Physiology and Chronic Health Evaluation~Sequential Organ Failure Assessment~Nutritional Risk Screening~Energy and Protein Intake"
10151934|NCT04080713|Experimental|Budesonide|
10151935|NCT04080765|Experimental|HIV-ASSIST + DHHS arm|Decision-making support for ARV selection through DHHS guidelines in conjunction with HIV-ASSIST
10151936|NCT04080765|Active Comparator|DHHS-alone arm|Decision-making support for ARV selection through DHHS guidelines alone
10185569|NCT03744325|No Intervention|Hen's egg avoidance|Hen's egg is avoidance diet is continued.
10185570|NCT03744312|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
10185571|NCT03744312|Active Comparator|No cognitive impairment|Healthy Controls
10185572|NCT03744299|Other|Intervention|Patients and caregivers are asked to complete a questionnaire
9519891|NCT03282513|Active Comparator|Cohort 1B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
9519892|NCT03282513|Experimental|Cohort 2A: Moderate Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)"
10185573|NCT03744247|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10185574|NCT03744247|Active Comparator|Lenvatinib alone|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received placebo intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
9519893|NCT03282513|Active Comparator|Cohort 2B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
10185575|NCT03744234|Experimental|Platelet-Rich Plasma Injection|Autologous injection of platelet-rich plasma (PRP) in the sacroiliac joint
10185576|NCT03744234|Active Comparator|Steroid Injection|Steroid injection in the sacroiliac joint
10185577|NCT03744221|Experimental|Corn protein|Corn protein powder
10185578|NCT03744221|Experimental|Bovine plasma protein|Bovine plasma protein powder
10185579|NCT03744221|Active Comparator|control benchmark protein Whey|Whey protein powder
10185580|NCT03744208|Experimental|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
10185581|NCT03744195|Experimental|Group I Experimental Kinesotaping|Application of kinesotaping along with conventional treatment
10185582|NCT03744195|Active Comparator|Group II conventional training group|Application of conventional treatment
10185583|NCT03744182|Experimental|HM15211|
10185584|NCT03744182|Placebo Comparator|Placebo|
10185585|NCT03744169||Children with acute respiratory failure|Point-of-care lung ultrasound on admission to the PICU to determine the cause of respiratory failure.
10151937|NCT04080622|Placebo Comparator|Placebo|Usual care
10151938|NCT04080622|Active Comparator|Selenium|Usual care + selenium 300 µg/day (IV infusion)
10151939|NCT04080557||AAA patients that went to the ICU postoperatively|An retrospective cohort study was conducted that included all patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
10151940|NCT04080206|Experimental|188-0551 Spray|Investigational Topical Spray Product
10151941|NCT04080206|Active Comparator|Reference Listed Drug (RLD)|FDA Approved Topical Cream
10151942|NCT04080193|Experimental|Intervention Group|The study will be a Smartphone-based interventional trial. To assess the effectiveness of the intervention weight- and eating-related behavior and cognitive and emotional responding as well as body-weight will be assessed using questionnaires and ecological momentary assessment (EMA) for one week at a pre- (T0), post- (T1) and two follow-up-assessments after six (T2) and 12 months (T3).
10151943|NCT04080193|No Intervention|Control Group|Members of the control group will participate at each assessment. During the intervention phase they will receive treatment as usual.
10151944|NCT04080362|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral vavle repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
10151945|NCT04080349|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
10151946|NCT04080349|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
10151947|NCT04080349|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
10151948|NCT04080323|Experimental|dinoprostone 3 mg|60 minutes before the surgery 3 mg of dinoprostone inserted vaginally
10151949|NCT04080323|Placebo Comparator|placebo|60 minutes before the surgery 1 tablet of placebo inserted vaginally
10151950|NCT04080336|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
10151951|NCT04080336|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
10151952|NCT04080336|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
10151953|NCT04080778|Experimental|MST|
10151954|NCT04080778|Active Comparator|ECT|
10151955|NCT04080102|Experimental|High intensity interval training (HIIT)|
10151956|NCT04080102|Experimental|Essential Amino Acid Supplement|
10151957|NCT04080102|Experimental|High intensity interval training + Essential Amino Acid|
9669641|NCT03617263|Placebo Comparator|Placebo|Placebo tablet once daily in the morning before breakfast
10151958|NCT04080102|No Intervention|Control|
10151959|NCT04080310|Active Comparator|combination therapy group|The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.
9519894|NCT03282500|Experimental|Mindfulness Based Cognitive Therapy|In the experimental condition, participants will receive 12 sessions including the instruction of mindfulness skills and cognitive behavioral therapy.
9669642|NCT03616964|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9669643|NCT03616964|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9669644|NCT03616964|Placebo Comparator|Placebo|Placebo administered orally.
10151960|NCT04080310|Other|intensive statin group|The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.
10151961|NCT04080219||Normal|Patients with Oxygen desaturation index <5
10151962|NCT04080219||Sleep-disordered breathing|Patients with Oxygen desaturation index ≥5
10151963|NCT04079998|Experimental|Procellera® dressing|The Procellera® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use.
10151964|NCT04079998|Active Comparator|Standard of Care|The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.
10151965|NCT04080869|Experimental|retinyl palmitate ethosomes arm|All patients will be instructed to apply a thin film of the new formula on one side of the face
10151966|NCT04080869|Active Comparator|tretinoin arm|All patients will be instructed to apply a thin film of topical retinoid cream on the other side of the face
10151967|NCT04080258|Experimental|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMTh). Patients in the OMTh group will receive 5 Osteopathic manipulative therapies: the first at baseline, the second after 1 week, the third after 3 weeks, and then 2 more treatments on a monthly basis. The protocol will last for three months.
10151968|NCT04080258|Sham Comparator|Light Touch Therapy|Participants to the LTT group will receive the protocol at the same date of the OMTh group.
10151969|NCT04079946|Active Comparator|patients for whom Complete mesocolic excision will be done|
10151970|NCT04079946|Active Comparator|patients had conventional surgery before|
10151971|NCT04080063|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
10151972|NCT04079933|No Intervention|Group 1: Continue Smoking|Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks
10151973|NCT04079933|Experimental|Group 2: OTDN|Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint) also under ad libitum conditions
10185586|NCT03744143|Other|Group A (vaginal technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through vaginal technique
10185587|NCT03744143|Other|Group B (laparoscopic technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through laparoscopic technique. Closure of the vagina with a transverse suture or a longitudinal suture.
10185588|NCT03744130|Experimental|patients with UC|"Patients with endoscopically proven UC with various extents of disease activity.~Diagnostic Test: Contrast-enhanced Ultrasound"
9977820|NCT01365559|Experimental|Group B: Carfilzomib & IMiD containing regimen.|Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
10151974|NCT04080089||Case group|Children over the age of 6 who came to the outpatient clinic of our hospital received the informed consent of the parents, and then included in the case group, conducted a self-made sleep questionnaire, established a file, and monitored the sleep on the Mofeh Time Sleep Apnea Monitor. The results were uploaded to the cloud system for analysis. 50 children with OSAHS were screened. Voluntary participation in the study; ability to complete all tests as well as magnetic resonance studies. Exclusion criteria: 1 mental retardation, generalized developmental disorders, severe physical and endocrine diseases, neurological diseases and other mental disorders; 2 visual and auditory diseases affecting the processing of cognitive information. 3 Psychiatric drugs were used in January.
10151975|NCT04080089||Control group|Children in the same age group of children with health checkups were screened for sleep and questionnaires without sleep. After receiving parental informed consent, 30 children were included in the control group. Exclusion criteria: 1 mental retardation, generalized developmental disorder, learning disabilities, conduct Disorders, severe physical and endocrine diseases, neurological diseases and other mental illnesses. 2 There are visual and auditory diseases that affect the processing of cognitive information.
10151976|NCT04080128|Other|Contact lens|Depending upon the study lens proven to be the most effective in the BLINK Study, this contact lens will be used for the first two years of the study. The last year of the study, all subjects will be wearing single vision contact lenses.
10151977|NCT04079972|Experimental|personalized lifestyle intervention|to provide personalized lifestyle guidance for weight loss through SNP testing
10151978|NCT04079972|Active Comparator|general lifestyle intervention|to provide general lifestyle guidance for weight loss
10151979|NCT04079985|Experimental|Experimental Group|"The experimental Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus. The experimental group also underwent AAT. We conducted a total of 12 weekly sessions of 60 minutes each with 10 participants."
10151980|NCT04079985|Active Comparator|Control Group|"The Control Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus without the presence of the therapy dog."
9519895|NCT03282500|No Intervention|Psychoeducation on brain injury and treatment|In the control condition, participants will receive 12 sessions on the psychoeducation of brain injuries, outcomes, treatment, and support.
10151981|NCT04079894||LSS Participants|Patients with lumbar spinal stenosis
10151982|NCT04079894||Healthy Participants|Healthy Participants
10151983|NCT04080141||PD+|Subjects with personality disorder
10151984|NCT04080141||PD-|Subjects without personality disorder
10151985|NCT04080050||RGX-501|Study participants who have received RGX-501 gene therapy in a separate parent trial
10151986|NCT04080037|Experimental|Study Participants|All eligible and consented participants will be asked complete a multiple-choice opioid assessment based on the latest CDC opioid guidelines, then care for 6 online QualityIQ patient simulations and receive feedback on their care decisions. They will then all complete an other multiple-choice assessment at the conclusion of the study.
10151987|NCT04080076|Active Comparator|ACTHar gel combined with Tacrolimus|ACTH gel 80 units 2er week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks
10151988|NCT04080076|Active Comparator|ACTHar gel|ACTHar gel 80 units 2 er week for 52 weeks
10151989|NCT04079959||women who are undergoing frozen embryo transfer|endometrial biopsy will be done one cycle before the frozen embryo transfer
10151990|NCT04080154|Experimental|Anlotinib|Anlotinib p.o., qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
10151991|NCT04079855|Experimental|Diet composition 1|A diet with a specified macronutrient composition different from arms 2, 3, and 4.
10151992|NCT04079855|Experimental|Diet composition 2|A diet with a specified macronutrient composition different from arms 1, 3, and 4.
10151993|NCT04079855|Experimental|Diet composition 3|A diet with a specified macronutrient composition different from arms 1, 2, and 4.
10151994|NCT04079855|Experimental|Diet composition 4|A diet with a specified macronutrient composition different from arms 1, 2, and 3 based on the current information about the US macronutrient composition.
10151995|NCT04079699|Experimental|Liquid Biopsy|"Experimental arm where the liquid biopsy decides whether to perform an prostate biopsy or not"
10151996|NCT04079699|Other|Standard Biopsy|Standard arm, where every patient receives a standard prostate biopsy
10151997|NCT04079595|Experimental|Open-faced head immonbilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with openings for the face
10151998|NCT04079595|Active Comparator|Closed-face head immobilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with the face closed
9519896|NCT03282487|No Intervention|Conventional immediate release hydrocortisone|
9977821|NCT01365572|Active Comparator|Xience V, drug-eluting stent|randomized implantation for DES restenotic lesion
10151999|NCT04079517|Experimental|Tamoxifen 10mg|Randomised dose of daily oral Tamoxifen 10mg, for 180 days
10152000|NCT04079517|Active Comparator|Tamoxifen 20mg|Randomised dose of daily oral Tamoxifen 20mg, for 180 days
10152001|NCT04079686|Experimental|Cephazolin|Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
10152002|NCT04079686|Placebo Comparator|Sterile saline|Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
10152003|NCT04079582|Experimental|Higher dialysate magnesium|
10152004|NCT04079582|Active Comparator|Lower dialysate magnesium|
10152005|NCT04079647||Patient with endocrinopathy after immunotherapy|Patient with endocrinopathy after immunotherapy
10152006|NCT04079491||dental hygienists|all dental hygienists members in the trade union for dental hygienists
10152007|NCT04079556|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
10152008|NCT04079777||Clinical diagnosis of severe acute pancreatitis|"1, with typical clinical manifestations, such as abdominal pain or nausea and vomiting, accompanied by epigastric tenderness or peritoneal irritation.~2. Pancreatin content in serum, urine or abdominal cavity puncture fluid increases.~3. Image examination (ultrasound, CT) showed pancreatic inflammation or pancreatic inflammation seen by surgery or confirmed by autopsy pathology.~4, can except other similar clinical manifestations of lesions."
10152009|NCT04079777||mtDNA|"Mitochondrial DNA is the genetic material in mitochondria. Mitochondria can produce energy (ATP) for cells, which is a special form of ribonucleic acid found in mitochondria of cells. Mitochondria are organelles that provide energy (ATP) to cells. There are usually many DNA molecules in a mitochondria.~They carry their own DNA--mtDNA, and mutations in these genes can cause mitochondrial diseases. Although the symptoms of the disease are changeable, organs that consume more energy, such as brain, muscle and heart, are usually affected. Since mitochondria are transmitted through egg cells, related diseases will be inherited from the mother."
10152010|NCT04079543|Other|Strict NPO|NPO after midnight. No solids or liquids after midnight.
10152011|NCT04079543|Other|Liberal NPO|No solids after midnight. Clear liquids up to 2 hours prior to surgery.
10152012|NCT04080011|Experimental|NP-PWD application|All patients enrolled into the study will have the negative pressure- platform wound device applied to their surgical incision.
10152013|NCT04079764||active surveillance|Patient with Bosniak III or IV lesion that decide to be followed under active surveillance
10152014|NCT04079764||Surgery|Patient with Bosniak III or IV lesion that decide to undergo a definitive treatment such as surgery
10152015|NCT04079569|Experimental|Tobacco|"Participants will receive education delivered by a lay health worker on Quit Smoking For a Healthy Family. Participants will receive written information on nutrition and physical activity."
10152016|NCT04079569|Active Comparator|Healthy Living|"In this comparison arm, participants will receive education delivered by the lay health worker about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
10152017|NCT04079660||Surgical patients|Diabetic patients scheduled to undergo non-cardiac surgery
10152018|NCT04079725|Experimental|Experimental : Infants with primary congenital glaucoma|
10152019|NCT04079608|Experimental|FLASH curriculum|Students who will receive the FLASH high school curriculum.
10152020|NCT04079608|Active Comparator|Sexual Health Education for Adolescents|Students will receive a five-session knowledge-based sexual health curriculum designed for classroom settings.
10152021|NCT04079530|Experimental|Treatment A|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
10152022|NCT04079530|Experimental|Treatment B|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
10152023|NCT04079530|Experimental|Treatment C|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
10152024|NCT04079530|Experimental|Treatment D|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
10152025|NCT04079530|Experimental|Treatment E|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
10152026|NCT04079530|Experimental|Treatment F|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
10152027|NCT04079530|Experimental|Treatment G|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
10152028|NCT04079530|Experimental|Treatment H|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
10152029|NCT04079530|Experimental|Treatment I|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
10152030|NCT04079530|Experimental|Treatment J|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
10152031|NCT04079530|Experimental|Treatment K|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
10152032|NCT04079530|Experimental|Treatment L|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
10152033|NCT04079413|Experimental|GP40071|Subcutaneous (SC), before meals intake, up to Week 26
10152034|NCT04079413|Active Comparator|NovoRapid® Penfill®|Subcutaneous (SC), before meals intake, up to Week 26
10152035|NCT04079478||AI|Artificial Intelligence colonoscopy
10152036|NCT04079478||Control|White light colonoscopy
10152037|NCT04079439|Other|Intervention|Tailored e-heath support for physical activity with a focus on communication and rewards, using commercial accelerometers for measurements
10152038|NCT04079439|No Intervention|Control group|Standard care
10152039|NCT04079309|No Intervention|No Intervention|No mist will be diffused into the environment.
10152040|NCT04079309|Active Comparator|Lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
10152041|NCT04079309|Active Comparator|Orange|0,3 ml orange oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
10152042|NCT04079179|Experimental|Patients < 30 years with recurrent LCH (Grp1)|Children and young adults (<30 years) with recurrent active LCH lesions (may also have LCH-ND).
10152043|NCT04079179|Experimental|Patients of any age with LCH-ND (Grp2)|Patients of any age with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.
10152044|NCT04079179|Experimental|Patients <30 years with other histiocytic disorders (Grp3)|Newly diagnosed or relapsed/refractory children and young adults (<30 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.
10152045|NCT04079179|Experimental|Patients ≥ 30 years with LCH/histiocytic disorders (Grp4)|Adults (≥30 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).
10152046|NCT04079361|Other|Pregnancy complication|Intervention: blood samples
10152047|NCT04079192|Experimental|Biolimus A9™ Drug Coated Balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Biolimus A9™ Drug Coated Balloon
10152048|NCT04079192|Active Comparator|Sequent ® Please Paclitaxel coated balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Sequent ® Please Paclitaxel coated balloon
10152049|NCT04079322|Experimental|Exercise|During the exercise arm, volunteers will complete a planned workout, as prescribed by the coach. The workout will be designed to be strenuous and induce an inflammatory response.
10152050|NCT04079322|Experimental|Rest|"The rest arm will be coordinated with a planned non-workout day, as prescribed by the coach, where volunteers are either scheduled to not run or go for an easy recovery run (<6 miles at a self-described easy pace) later in the afternoon."
10152051|NCT04079231|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
10152052|NCT04079231|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
10152053|NCT04079153|Active Comparator|25% of maximal mandibular advancement|25% of maximal mandibular advancement of individual protrusion range
10152054|NCT04079153|Active Comparator|50% of maximal mandibular advancement|50% of maximal mandibular advancement of individual protrusion range
10152055|NCT04079270|Experimental|Personalized algorithm-based diet|The intervention arm will be an 'algorithm-based' arm in which patients will receive personally tailored dietary recommendations, based on their microbiome, and other clinical data such as blood tests and lifestyle features.
10152056|NCT04079270|Active Comparator|standard Mediterranean low-fat diet|The control arm will receive nutritional recommendations according to the standard Israeli dietary approach Mediterranean-style low-fat diet.
10152057|NCT04079205|Experimental|Home rehabilitation using Wearable Device|Home rehabilitation using Wearable Device(exoRehab)
10152058|NCT04079205|Active Comparator|Control|Standard home rehabilitation program
10152059|NCT04079374|Experimental|Etanercept|Patients receive Etanercept in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
10152060|NCT04079374|Active Comparator|Enbrel|Patients receive Enbrel in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
10152061|NCT04079283||Monotherapy|Patients who has received mono-therapy of immune checkpoint inhibitor.
10152062|NCT04079283||Combined therapy|Patients who has received immune checkpoint inhibitor combining chemotherapy.
10152063|NCT04079257||Patients with paroxysmal nocturnal hemoglobinuria|Patients are already treated with eculizumab. The only intervention is the collection of extra blood samples to measure peak concentrations of eculizumab
10152064|NCT04079101|Experimental|BIIB104 0.15 mg|Participants will receive multiple oral doses of BIIB104 0.15 mg capsules twice daily (BID) for 9 days, with an additional dose occurring in the morning on Day 10.
10152065|NCT04079101|Experimental|BIIB104 0.5 mg|Participants will receive multiple oral doses of BIIB104 0.5 mg capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
10152066|NCT04079101|Experimental|Placebo|Participants will receive multiple oral doses of placebo-matched BIIB104 capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
10152067|NCT04079023||Obese|30 obese patients (12 M/ 18 F) with a mean BMI of 46 candidate to SG Alcohol drink mean volume: 158 Ml administered in 10 minutes
9972187|NCT01318213||Non-intervention - Usual Standard of Care|The non-intervention units will follow their present standard of care. For all of these units, this will consist of healthcare workers following Contact Precautions (gloves and gowns) only for patients known to have antibiotic-resistant bacteria such as VRE and MRSA based on previous admission clinical and surveillance cultures or clinical cultures from the present admission. This represents on average 20-25% of patients on Contact Precautions. For the rest of the patients standard precautions will be followed.
9669645|NCT03614572|Experimental|Group MI|The structure and content of the active intervention programme will be developed and adopted on the basis of previous research on sleep educational programme and motivational interviewing techniques. The whole treatment package consists of 4 sessions of group therapy (n=6-8) followed by 3 week daily text reminders.
9669646|NCT03614572|No Intervention|Control group|Control group will no receive any intervention
10152068|NCT04079010|Placebo Comparator|Control|Participants will adhere to resistance training protocol.
9669647|NCT03588260||Idiopathic pulmonary fibrosis|The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic.
9669648|NCT03588260||Healthy subjects|The healthy adults without additional disease
10152069|NCT04079010|Active Comparator|BFR (blood flow restriction)|Participants will adhere to resistance training protocol, while also applying a blood flow restriction cuff during resistance training.
10152070|NCT04079010|Active Comparator|BFR (blood flow restriction), plus Arginine|Participants will adhere to resistance training protocol, apply a blood flow restriction cuff during resistance training, and will take the clinically safe dose of arginine prior to training sessions.
10152071|NCT04079088|Placebo Comparator|Placebo|Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
10152072|NCT04079088|Experimental|BIIB061 Dose 1|Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
10152073|NCT04079088|Experimental|BIIB061 Dose 2|Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
10152074|NCT04079088|Experimental|BIIB061 Dose 3|Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
9519897|NCT03282487|Active Comparator|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
9669649|NCT03581981|Experimental|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
9826271|NCT02413255|Placebo Comparator|Part 2 Cohort 1-6: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.
10152075|NCT04079140|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
10152076|NCT04079140|Placebo Comparator|placebo|one tablet of placebo self-administered by the patient 12 hours before IUD insertion.
10152077|NCT04079049|Experimental|Surgical intervention|Surgical and oncological treatment
10152078|NCT04079049|Active Comparator|Control|Oncological treatment
9519898|NCT03282487|No Intervention|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
9519899|NCT03282474|Experimental|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
9669650|NCT03581981|Active Comparator|Treatment as Usual (TAU)|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
9669651|NCT03578965|Experimental|Arm 1: Antibiotic prophylaxis prior to skin incision|-Women randomized to prophylactic antibiotics will receive a cefazolin as per ACOG guidelines.
10152079|NCT04079166|Experimental|SCIB1|SCIB1 administered using the TDS-IM v2.0 device
10152080|NCT04079075|Experimental|Non-pharmacological intervention|"Non-pharmacological strategy, implemented in groups of 10 participants, over 10 consecutive months, based on five different interventions:~cognitive training, physical activity; nutrition education; adaption to memory loss; detection and correction of hearing impairment."
10152081|NCT04078984||Experimental|Experimental group is composed by patients that enter the weaning phase following a moderate to severe Acute Respiratory Distress Syndrome (ARDS) equiped with a nasogastric allowing measures of Electrical Activity of diaphragm (EAdi) will be included. Driving Pressure will be measured following the method used by Bellani et al. A weaning test will be conducted daily.
10152082|NCT04078997||PCV13-vaccinated,15-24 months of age|"Recruitment for carriage surveillance (primary endpoint) will take place at randomly selected households within each of the catchment areas (zones) of the 20 selected health centers.~Sampling: Random sampling from populations will occur preferentially around the health centers and not from the population on the zonal interfaces. Researchers will designate two geographic sampling areas within each zone around each health center that allows a buffer against zonal borders. If the recruitment target within first sampling area is not met, sampling will move into the second area."
10152083|NCT04078997||PCV13-vaccinated, 5-10 years of age|"Six schools will be selected: three located centrally in each of the 3+0 zones, and three in the 2+1 zones.~Sampling: Children will be randomly chosen and recruited from each school. NP swab collection will occur during two surveys, starting 21 and 34 months after the switch to 2+11.~Mapping analysis from our current surveillance activities shows good clustering of recruited children living around the school, suggesting limited movement and thus low risk of contamination between zones with different vaccination schedules."
10152084|NCT04078997||PCV13-unvaccinated HIV-infected adults on ART 18 - 40 years of|"Adults will be recruited from the Queen Elizabeth Central Hospital (QECH), Lighthouse ART clinic in Blantyre.~Sampling: Mapping analysis from current surveillance activities shows good distribution throughout the Blantyre area, suggesting it is possible to achieve balance between those adults residing in 2+1 vs 3+0 areas. Sample collection will be on a rolling basis throughout the study period, starting 18 months after switch to 2+1."
10152085|NCT04078997||PCV13-vaccinated, 9 months of age|"Recruitment will take place at vaccination centers.~Sampling: A convenience sample of NP swabs will be collected at the 9-month (measles-1) visit. Sample collection will occur 9 months after the switch to 2+1 schedule."
10152086|NCT04078971|Experimental|Ketogenic diet|Ketogenic diet: less than 30 g/day of carbohydrate. Subjects can eat beef, veal, poultry, fish, raw and cooked vegetables without restriction, cold cuts such as dried beef, eggs and seasoned cheese (parmesan), ketogenic pasta (selected with a ketogenic ratio of 4:1), fruits with the lowest glycemic index (blueberry, raspberry), raw nuts and seeds, ghee butter, plant oils and fats from avocado, coconut and olives
10152087|NCT04078971|Active Comparator|Western diet|The western diet (WD) is composed mainly of whole cereals (spelt, rye, oat) and pseudo-cereals (buckwheat, quinoa, amaranth), whole grain pasta, potatoes, meet, fish, vegetables, fruit, legumes, olive oil, milk and red wine (at most 1 glass per day). It ensure a constant energy and macronutrient balance: protein 1.8g x Kg-1 x body weight-1 x day-1, (30%), fats 20-25% and carbohydrate 50-55%.
10152088|NCT04078958|Experimental|Salmon fishmeal|5 g fishmeal in capsules, single oral dose
10152089|NCT04078958|Active Comparator|Whey|5 g whey in capsules, single oral dose
10152090|NCT04078763|Experimental|visual-auditory feedback|Patients included in this arm will follow the rehabilitation protocol with visual-auditory feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
10152091|NCT04078763|Experimental|visual feedback|Patients included in this arm will follow the rehabilitation protocol with visual feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
9972188|NCT01318226|Placebo Comparator|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
9972189|NCT01318226|Experimental|ATx08-001 2.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.
10152092|NCT04078854|Experimental|Foot amputation, sexual health|Group 1, Experimental arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations plus sexual health
10152093|NCT04078854|Active Comparator|Foot amputation, no sexual health|Group 2, Control arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations, with no mention about sexual health
10152094|NCT04078646|Experimental|Dietary intervention|Intervention with test meal only
10152095|NCT04078646|Experimental|Dietary intervention 2|Intervention with test meal and whey protein isolate (30 g)
9661885|NCT03662776||retinoblastoma survivors treated with enucleation|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
9977822|NCT01365572|Active Comparator|Endeavor Resolute, drug-eluting stent|randomized implantation for DES restenotic lesion
10152096|NCT04078646|Experimental|Dietary intervention 3|Intervention with test meal and soy protein (30 g)
9519900|NCT03282461|Experimental|ABY-029|Between 3-9 patients will be administered ABY-029 as a single intravenous injection approximately 1-3 hours prior to surgery.
10152097|NCT04078633|Experimental|Normal Liquid Soap (250mL)|A normal hygiene kit will be distributed to the households. In addition, a liquid soap will be added to see the impact of having a liquid soap for hand washing on hygiene behaviors.
10152098|NCT04078633|Experimental|Bar soap (250gram)|A normal hygiene kit will be distributed to the households. In addition, a nice bar soap will be added to see the impact of having a nicer bar soap for hand washing on hygiene behaviors.
10152099|NCT04078633|Experimental|Mirror (50x30cm)|A normal hygiene kit will be distributed to the households. In addition, a mirror will be added to see the impact of having a mirror by the handwashing stand on handwashing behaviour. The mirror will have a plastic edge and be 30x 50cm in size.
10152100|NCT04078633|No Intervention|Control|A normal hygiene kit will be distributed to the households. No additional interventions will be given.
10152101|NCT04078633|Experimental|Nurture story for hygiene promotion|Hygiene promoters will share a story of being a good parent through teaching their children to do hand washing with soap at critical times. A story about a good mother who every day reminds her child to wash her/his hands before eating or preparing food and after going to the toilet will be shared with participants. The story ends with the child growing up healthy, happy and with a good education. This story if belived to increae handwashing with soap in the household/
10152102|NCT04078633|Experimental|Comfort story for hygiene promotion|Hygiene promoters will deliver hygiene promotion through an activity that provoke the feeling of comfort by having clean hands. Hygiene promoters will deliver this intervention to up to 5 neighbor households at the time, sharing a story about a family that keeps good hygiene behaviors and therefore are clean, healthy and happy. This story is believed to encourage families to increase handwashing with soap in the household.
10152103|NCT04078633|No Intervention|Education session for hygiene promotion|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
10152104|NCT04078633|Experimental|Hygiene Promotion Activity - Disgust|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will use 5 buckets of clean water and place them in front of households. They will then ask a member of one of the households to rinse their hands in the first bucket. Some dirt will come of their hands. Then the participant rinses their hands again in bucket number 2, then 3 and then 4. Before the 5th bucket the participant receives a bar of soap to use when they rinse their hand. When they do the water will have a dirty colour as the dirt comes of their hands. This activity is believed to encourage handwashing with soap.
10152105|NCT04078633|Experimental|Hygiene Promotion Activity - Comfort|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will bring some food oil and ask participants to cover their hands in food oil. They will then ask the participants to cover their hands in turmeric powder. The participants will then be asked to wash their hands with water only. This will have little effect on the cleanliness of their hands. Then participants will be given a bar of soap. The participants will then be asked to wash their hands again. This will leave their hands nice comfortable and clean. They will experience the comfort of clean hands and the activity hope to increase regular handwashing.
10152106|NCT04078633|No Intervention|Education Hygiene Promotion Activity|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
10152107|NCT04078750|Sham Comparator|Phase I. Control group|"The standard of care will be provided to the control group pre- and post-transplant. This does not involve any direct pre-transplant assessment of medication adherence or risk factors for non-adherence.~Tacrolimus capsules will be dispensed in Medication Event Monitoring System (MEMS) caps for 3 months post-transplant for the purpose of measuring adherence after transplantation.~Patients will be asked to complete Basel Assessment of Adherence to Immunosuppressive Medication instrument (BAASIS) questionnaire and Long-term Medication Behaviour Self-efficacy Scale at 3 months after transplantation."
10152108|NCT04078750|Experimental|Phase II. Intervention group|Patients will be given lactose containing white- and yellow-colored gelatin capsules stored in (MEMS®) bottles for a 1-month adherence trial. Yellow-colored gelatin capsules represent tacrolimus 0.5mg capsules while white-colored gelatin capsules represent tacrolimus 1mg capsules. MEMS® is designed to record the date/time of opening and closure of the drug vial. Patients will be asked to take a certain dose and expected to remove the correct number of white and yellow capsules from respective vial at the correct time each day. Phone calls will be made to patients to change the 'dose' at various times throughout the month to mimic the frequent need to make tacrolimus dosing changes early post-transplant.Pill count and MEMS record will be reviewed at the end of the 1-month trial period to assess adherence. Patients will also undergo health literacy, cognition testing, self-efficacy tests, with a customized post-transplant plan.
10152109|NCT04078724|Active Comparator|Normal subject without 5-HTP|Subjects with normal cognition will be randomly assigned to not consuming 5-HTP.
10152110|NCT04078724|Experimental|Normal subject with 5-HTP|Subjects with normal cognition will be randomly assigned to consuming 100 mg of 5-HTP.
10152111|NCT04078685|Active Comparator|CONVENTIONAL group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a standard (non-contact-force sensing) ablation catheter
9519901|NCT03282448|Experimental|Family therapy|Adolescent mothers and their family members will receive a total of 10 weekly, 30-minute, video-based family therapy sessions.
9519902|NCT03282448|No Intervention|Historical comparison group|The Edinburgh Postnatal Depression Scale scores of adolescent mothers in the intervention group will be compared to those of adolescent mothers, who were previously enrolled in the home visiting programs, at the same time points.
9519903|NCT03282435|Experimental|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
10152112|NCT04078685|Experimental|CONTACT-FORCE group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a Contact-Force-sensing ablation catheter
10152113|NCT04078776||Lean Individuals|waist circumference ≤94 cm (men) and 80 cm (women) and BMI ≥ 21.0 kg/m2
9972190|NCT01318226|Experimental|ATx08-001 7.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
10152114|NCT04078776||Obese Individuals|waist circumference ≥102cm (men) and 88 cm (women) and BMI ≥ 30.0kg/m2
10152115|NCT04078711|Experimental|losartan & qianyangyuyin|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Chinese Medicine (Qianyangyuyin granule) 20g by mouth, bid for 6 months.
10152116|NCT04078711|Placebo Comparator|Losartan & Placebo|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Qianyangyuyin placebo 20g by mouth, bid for 6 months.
9972191|NCT01318239|Experimental|Standard Chemotherapy with Avastin|
9972192|NCT01318239|Active Comparator|Standard Chemotherapy only|
10152117|NCT04078802|Experimental|VNOTES ARM|treatment of Vaginal prolapse with VNOTES surgery and apical suspension to the uterosacral ligaments.
10152118|NCT04078802|Experimental|Vaginal hysterectomy Arm|treatment of Vaginal prolapse with classic vaginal hysterectomy surgery and apical suspension to the uterosacral ligaments.
10152119|NCT04078581|Experimental|healthy controls|Questionnaire and fecal sample collection
10152120|NCT04078659|Experimental|Propofol infusion|Patients received intravenous Propofol infusion
10152121|NCT04078659|Experimental|Magnesium Sulfate infusion|Patients received intravenous Magnesium Sulfate infusion
10152122|NCT04078880|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus ascorbic acid, other than the standard of care.
10152123|NCT04078880|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
10152124|NCT04078867||DeVega|The DeVega repair is performed when the patient had minimal annular dilation and lower severity of pulmonary hypertension
10152125|NCT04078867||MC3 ring|MC3 ring annuloplasty is performed in patients with severe tricuspid annular dilation and severe pulmonary hypertension
10152126|NCT04078919|Active Comparator|Low calorie diets with nuts|Low calorie diet in which 20 percent of daily calories will be provided from nuts
10152127|NCT04078919|Placebo Comparator|Low calorie diet|Low calorie diet
10152128|NCT04078607|Experimental|Distraction|Distraction during eating using the Rapid Visual Information Processing task as the distraction
10152129|NCT04078607|Placebo Comparator|Control|No distraction during eating
10152130|NCT04078841|Active Comparator|ReaLife+ (RLP)|Dietary Supplement: ReaLife+ (RLP) RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids
10152131|NCT04078841|Placebo Comparator|Inert Brown Powder|"Brown powder~Inert brown powder to look similar to RLP"
10152132|NCT04078841|No Intervention|Control|Control
10152133|NCT04078217|Experimental|Jintronix|Jintronix Rehabilitation System uses Microsoft Kinect cameras to track patient's movements in 3D during exercises. They are programmed as games that are visualized on a TV and for which performance feedback is provided to the participant. Individualized asynchronous supervised home-base exercise program using the Jintronix System, 3 times/week for 12 weeks (36 sessions). A trained kinesiologist will install the system and supervise the exercise program, in person and remotely.
10152134|NCT04078217|Active Comparator|Control|Participants in this group will follow an individualized non-supervised home-based exercise program (booklet format). The exercise program will include 3 sessions per week for 12 consecutive weeks, as for Jintronix group. Actually, all movements of the booklet program are selected to match the exercise-games of the technology (similar movement, muscles engagement, etc.). A trained kinesiologist will explain and supervise the exercise program for the first sessions. The communication frequence will be the same as the Jintronix group.
10152135|NCT04078438|Experimental|neurofeedback augmentation group|The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol was determined considering the patient's main symptoms. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.
9519904|NCT03282435|Active Comparator|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
9519905|NCT03282422|Experimental|Intervention group|Upper-limb splint and home-based protocol in specific tasks
9669652|NCT03578965|No Intervention|Arm 1: No antibiotic prophylaxis prior to skin incision|-Women randomized to no antibiotic prophylaxis will not receive any antibiotics prior to skin incision.
9669653|NCT03559400|Experimental|gentamicin injection at fracture site|Subjects with an open tibia fracture who receive gentamicin in saline solution administered after closure at the time of initial debridement.
9972193|NCT01318265|Experimental|Arm1|
9972194|NCT01318291|Placebo Comparator|Control|
9972195|NCT01318291|Experimental|CCRI Group|
10152136|NCT04078438|Active Comparator|medication-only (treatment as usual, TAU) group|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.
10152137|NCT04078438|No Intervention|healthy controls|The healthy controls provided blood samples using the same procedure at baseline only.
10152138|NCT04078399|Experimental|patients with recurrence after allogeneic transplantat|One arm
10152139|NCT04078464|Experimental|Acute Physical Activity + Mindfulness training|20 minutes of walking on a treadmill at a moderate pace while listening to a pre-recorded guided mindfulness meditation.
10152140|NCT04078464|Experimental|Mindfulness training|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 20 minutes.
10152141|NCT04078464|Experimental|Acute Physical Activity|20 minutes of walking on a treadmill at a moderate pace.
9669654|NCT03559400|Placebo Comparator|placebo saline injection at fracture site|Subjects with an open tibia fracture who receive placebo saline solution administered after closure at the time of initial debridement.
9669655|NCT03558087|Experimental|Gemcitabine, Cisplatin and Nivolumab|Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with > cTa status will undergo cystectomy.
10152142|NCT04078282|Experimental|Active treatment group|Patients will meet in a joint consultation with their family physician and a psychiatrist for evaluation. Then it follows three treatment sessions with the family physician before a new joint consultation with the psychiatrist. The intervention ends with three more treatment sessions with the family physician.
10152143|NCT04078282|Active Comparator|Control group|Patients belonging to family physicians who constitute the control group will be assessed and given treatment according to usual care. This may include treatment by the family physician, medication, referrals to specialized care.
10152144|NCT04078425|Experimental|HF with preserved EF|50patients of heart failure with preserved ejection fration will receive anti.failure treatment(lanoxin,beta blocker,diuretics) for one month with follow up echocardiography before and after
10152145|NCT04078425|Experimental|HF with preserved EF recive eplernone|50 patients with heart failure with preserved ejection frationnwill receive traditional anti-failure treatment in addition to aldosterone antagonist (Eplernone) with follow up echocardiography and aldosterone level before and after
10152146|NCT04078477|Experimental|Lateral tilt bed|Special lateral tilt bed.
10152147|NCT04078477|No Intervention|Body positioning|Standard NICU preventive strategy
10152148|NCT04078451|Experimental|the experimental group|"The experimental group operated by the left side of laparoscopic cholecystectomy preserving the main cystic artery.~The operation area of cystic artery dissection is moved from the traditional triangular area to the gallbladder neck plane, away from the hepatic duct and hepatic portal.Only the superficial and even more minute branches of the cystic artery were isolated and coagulated."
10152149|NCT04078451|No Intervention|the control group|treated with conventional laparoscopic cholecystectomy cutting the cystic artery
10185589|NCT03744130|Experimental|patients with CD|Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound
10185590|NCT03744117|Experimental|Intervention Arm|There is a single arm in this study. All patients will be assigned to receive the intervention, which is a palliative care consultation delivered by telemedicine.
10185591|NCT03744104|Experimental|Quadrivalent influenza vaccine|Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)
9669658|NCT03519984|Experimental|Arm A (sEPHB4-HSA, cytarabine)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and cytarabine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9669659|NCT03519984|Experimental|Arm B (sEPHB4-HSA, vincristine liposomal)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and vincristine liposomal IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
10185592|NCT03744104|Active Comparator|Trivalent influenza vaccine A|Trivalent influenza vaccine (containing B/Victoria lineage)
10185593|NCT03744104|Active Comparator|Trivalent influenza vaccine B|Trivalent influenza vaccine (containing B/Yamagata lineage)
9669660|NCT03518073|Experimental|LY3303560 Dose 1|LY3303560 administered intravenously (IV).
9669661|NCT03518073|Experimental|LY3303560 Dose 2|LY3303560 administered IV.
10185594|NCT03744091|Active Comparator|10 mg P1|10 mg of P1 will be administered and compared with an active dose of 20 mg P1 on crossover
10185595|NCT03744091|Active Comparator|20 mg P1|20 mg of P1 will be administered and compared with an active dose of 10 mg P1 on crossover
10185596|NCT03744078|Active Comparator|PGE2 with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
10185597|NCT03744078|No Intervention|PGE2 vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
10185598|NCT03744065|Active Comparator|Lumbar plexus block|Patients randomized to receive an ultrasound-guided lumbar plexus block
10185599|NCT03744065|Experimental|Suprainguinal fascia iliaca block|Patients randomized to receive an ultrasound-guided suprainguinal fascia iliaca block
10185600|NCT03744052|Experimental|Adult Participants|Messages regarding physical activity will be texted to participants.
10185601|NCT03744000|Placebo Comparator|Immediate stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate stenting group.
10185602|NCT03744000|Active Comparator|Deferred stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred for 3-7 days in the deferred stenting group.
9669662|NCT03518073|Placebo Comparator|Placebo|Placebo administered IV.
9669663|NCT03479203|Experimental|Healthy, Non-Smokers|Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)
9669664|NCT03439917|Experimental|Carnitine and Meal Replacement Drink|2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
9669665|NCT03439917|Placebo Comparator|Placebo and Meal Replacement Drink|2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
9669666|NCT03437928|Experimental|Directional Deep Brain Stimulation|
9826272|NCT02413255|Experimental|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
10185603|NCT03743987|Sham Comparator|control group|Apical resection group. Only root resection was applied without any other interventions (like prf or mta)
10185604|NCT03743987|Experimental|MTA group|Root resection was applied and MTA was inserted through the apical foramen
10185605|NCT03743987|Experimental|PRF group|Root resection was applied and PRF was placed to the surgically prepared area
9669667|NCT03423589|Experimental|VSL#3|Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
10152150|NCT04078256|Experimental|Experimental group|Group will carry out the proprioceptive exercise program during 8 weeks at the begining of the season
9669668|NCT03407833||Obese, surgery|Obese subjects recruited from the Center for Surgical Weight loss who are undergoing weight loss surgery as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at surgical visits.
9972196|NCT01318304||Pregnant, HIV- negative|This cohort has completed accrual as of 12/28/11.
10152151|NCT04078256|Placebo Comparator|Control group|Control group will continue with their usual training routine
10152152|NCT04078230|Experimental|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
10152153|NCT04078230|No Intervention|Regional LymphAdenectomy|Regional lymph node dissection for intrahepatic cholangiocarcinoma included station 12.
10152154|NCT04078542||Chronic cough|Subject complaining cough from at least 8 weeks
10152155|NCT04078243||CardioMEMS HF System|Eligible patients will be recruited and will attend for the implantation in line with standard of care procedures. The patient's details will be uploaded to the CardioMEMS HF system, enabling remote monitoring of their heart failure device. The patient will also be given a Fitbit activity monitor and set up with an account that is accessible to patient and physician to allowing activity to be monitored. The research team will be able to continuously monitor data remotely from the CardioMEMS HF system and Fitbit platform.
10152156|NCT04078269|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIXNEO-LUNG autologous DC vaccine
10152157|NCT04078321|Experimental|Single case design|Single case studies
10152158|NCT04078932|Experimental|Intervention|Cohort of residents trained in the conversation script who will utilize the script at pediatric clinic visits. Will evaluate baseline feelings of comfort and self-efficacy prior to being trained in the script (pre-intervention measures). After being trained in the conversation script (the intervention), the following will be measured (post-intervention measures): frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
9972197|NCT01318304||Pregnant, HIV-positive|
9972198|NCT01318304||Non-pregnant, HIV-negative|This cohort has completed accrual as of 12/28/11.
10152159|NCT04078932|No Intervention|Control|Cohort of residents at another clinical site with a similar community demographic make-up who do not receive the intervention. In the control group, we will measure frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
9972199|NCT01318304||Non-pregnant, HIV-positive|This cohort has completed accrual as of 12/28/11.
10152160|NCT04078529|Experimental|Intervention group|This group will complete a 5 day falls prevention training programme, followed by a 12 week home exercise programme, then a repeat 5 day training intervention.
10152161|NCT04078529|Active Comparator|Comparison group[|This group will complete the home exercise programme only.
10152162|NCT04078204|Experimental|Butylphthalide Soft Capsules|Two Butylphthalide soft capsules will be taken three times a day before meals.
10152163|NCT04078204|Placebo Comparator|Placebo Soft Capsules|Two placebo soft capsules will be taken three times a day before meals.
10152164|NCT04078308|Experimental|Mesenchymal Stem Cells Transplantation|The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells
10152165|NCT04078308|Placebo Comparator|Placebo|The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)
10152166|NCT04078334|Experimental|Group 1|PATH Tool : Prescription of exercise programs at discharge
10152167|NCT04078334|Experimental|Group 2|PATH 2.0 Tool : Prescription of exercise programs during hospitalization and discharge
10152168|NCT04078334|Experimental|Group 3|MATCH tool: Prescription of physical exercise programs during hospitalization
10152169|NCT04078334|No Intervention|Group 4|Control group: Usual care by the clinical teams
10152170|NCT04078893|No Intervention|control group|
10152171|NCT04078893|Experimental|on need group|
10152172|NCT04078893|Experimental|communication group|
9972200|NCT01318343||Treatment Group 1|Eight (8) subjects will receive one (1) treatment with the eZ8 Large Applicator.
9972201|NCT01318343||Treatment Group 2|Eight (8) subjects will receive two (2) treatments two (2) months apart with the eZ8 Large Applicator.
9977823|NCT01365598|Placebo Comparator|Placebo|Non-active drug
10152173|NCT04078594|Experimental|Experimental wards|Active sepsis e-alert
10152174|NCT04078594|No Intervention|Contol wards|"Masked sepsis e-alert.~The wards will have masked sepsis e-alert."
10152175|NCT04078347||Successful Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
10152176|NCT04078347||Failed Paravertebral block|Pinprick test was evaluated at 20 min after Paravertebral block. Pinprick sensation was assessed using a 22-gauge short bevel needle from T2 to T10 at midclavicular line bilaterally . Pinprick response was recorded quantitatively as 1 (sensation) or 0 (no sensation/numb). Successful block was defined as the pinprick score was 0 at 20 min after block. Otherwise, it was defined as a failed block.
10152177|NCT04078165|Experimental|Zero-Gravity|In this group, the operator uses the Zero-Gravity protection system
10152178|NCT04078165|Active Comparator|Conventional|In this group, the operator uses conventional radiation protection
10152179|NCT04078503||Case|All patients aspected to stay in ICU for at least 3 days who will develop delirium
9826273|NCT02413255|Experimental|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
10152180|NCT04078503||Control|All patients aspected to stay in ICU for at least 3 days who will not develop delirium (1:1 matched with the controls with a propensity score method).
10152181|NCT04078074|Experimental|Maxillary OSS|
10152182|NCT04078074|Experimental|Mandibular OSS|
10152183|NCT04078074|Experimental|Modified farrar splint|
10152184|NCT04078048|Experimental|Vitamin C Group|Tablet Vitamin C 500 mg Once a day
10152185|NCT04078048|Experimental|Vitamin E Group|Tablet Vitamin E 600 I U Twice daily
10152186|NCT04078048|Placebo Comparator|Placebo Group|Capsule Paraffin oil 500 mg Once a day
10152187|NCT04077853|Experimental|study group|women will be given 17-OHPC 250 mg intra-muscular at admission and every 7 days thereafter in addition to other conservative measures of early-onset PE
10152188|NCT04077853|No Intervention|control group|No intervention will be given apart from the usual conservative measures of early-onset PE
10152189|NCT04077775||Study group (group A):|"Study group (group ) Diagnostic Test: Study group (group A)24 women who have cyclic CPP~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
10152190|NCT04077775||Study group(group B):|"included 20 women who have non-cyclic CPP and the other 16 women of the participants were normal I)~Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately. In contrast, the woman was in a standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer~Diagnostic Test: Study group (group A)"
10152191|NCT04077775||Control group (group C):|"16 women of the participants were normal and considered the control group~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
10152192|NCT04078100||group A|underwent mitral valve surgery through transseptal approach.
10152193|NCT04078100||group B|underwent mitral valve surgery through conventional left atrial approach.
10152194|NCT04078035|Experimental|Socio-evaluative Speech Stress, then Control|Participants will attend two laboratory sessions. At the first session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated. At the second session, participants will rest quietly for the same period as the speech task, in the absence of the stressor.
10152195|NCT04078035|Experimental|Control, then Socio-Evaluative Speech Stress|Participants will attend two laboratory sessions. At the first session, participants will rest quietly for 5 minutes. At the second session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated.
10152196|NCT04077827|Experimental|Total intravenous anesthesia|"The patients will recieve intravenous anesthesia (propofol-remifentanyl)~Recommended dosage:~Propofol: Induction dosage 1,5-2,5 mg/kg Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
10152197|NCT04077827|Experimental|volatile anesthesia|"The patients will recieve volatile anesthesia (desflurane-remifentanyl)~Recommended dosage:~Desflurane dosage 6-7 MAC Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
10152198|NCT04077957|Experimental|Group 1. Experimental|Etanercept 50mg per week plus conventional synthetic DMARDs(csDMARDs, methotrexate 10mg per week, sulfasalazine 2.25g per day, hydroxychloroquine 0.2g per day) for 4 weeks when in high disease activity; etanercept 50mg per week plus csDMARDs for 2 weeks and continue with csDMARDs only for 2 weeks when in low disease activity; csDMARDs only for 4 weeks when in disease remission status.
10152199|NCT04077957|Active Comparator|Group 2. Positive Control|Etanercept 50mg per week for first 12 weeks; etanercept 50mg per ten days for second 12 weeks; etanercept 25mg per week for next 12 weeks; etanercept 25mg per two week for next 12 weeks.
10152200|NCT04077879|Experimental|Single ascending dose of ASP1617|This is composed of 5 sequential cohorts (cohorts 1.1 to 1.5). Participants (6-9 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of ASP1617 under fasting conditions.
10152201|NCT04077879|Placebo Comparator|Single ascending dose of Placebo|Participants (2-3 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of matching placebo under fasting conditions.
10152202|NCT04077879|Experimental|Single dose of ASP1617 (Food Effect)|Participants (6 Japanese and 3 non-Asian) will receive a single dose of ASP1617 with a high-fat meal. Dosing of the Food Effect cohort will commence after having established the safety and tolerability of the dose tested in cohort 1.4.
10152203|NCT04077879|Experimental|Multiple ascending dose of ASP1617|"This is composed of 3 sequential cohorts (cohorts 2.1 and 2.3). Participants (9 for each cohort, consisting of only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohorts 2.2 and 2.3) will receive ASP1617 for 14 consecutive days at the same dose level.~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
10152204|NCT04077879|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort, consisting of either only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohort 2.2 and 2.3) will receive matching Placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.3.
10152205|NCT04077892|Experimental|combination of budesonide and montelukast|receive treatment with either a combination of budesonide (Rhinorcort Astra Zeneca AB), 1 spray per nostril twice daily (total 256 μg/d) and 10mg oral montelukast tablet (Merck Sharp & Dohme Australia Pty Ltd) in the evening for 14 days (BD+MNT treatment group)
10152206|NCT04077892|Active Comparator|only intranasal budesonide|treatment with only intranasal budesonide 1 spray per nostril twice daily for 14 days (BD treatment group)
10152207|NCT04077996|Active Comparator|Peritonitis treatment with one exchange in CAPD|This group will receive peritonitis treatment with one exchange on Continuous Ambulatory Peritoneal Dialysis per day. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines; adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
10152208|NCT04077996|Experimental|Peritonitis treatment placed in APD|This group will receive peritonitis treatment placed in Automated Peritoneal Dialysis. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days); adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
10152209|NCT04078360|Experimental|Mobile-based intervention (AMBIT)|This arm will receive a mobile based program delivered over messages/IVR calls.
9826274|NCT02413255|Experimental|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
9519906|NCT03282422|Active Comparator|Control group|Home-based protocol in specific tasks
9519907|NCT03282396|Experimental|Treatment (ibrutinib)|Participants receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for 5 years in the absence of disease progression or unacceptable toxicity.
10152210|NCT04078360|Active Comparator|Face-to-face counselling|This arm will receive a brief counselling session from a trained health worker.
10152211|NCT04078360|Active Comparator|Active control|This arm will receive an educational BI leaflet.
10152212|NCT04077801||Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
10152213|NCT04077801||Control group (group B):|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
10152214|NCT04078113|Experimental|Experimental group|Every patient will be subjected to a measured stimulus with a power selected in phase 1 (X mA) and pupillary dilatation will be measured by pupillometry. In those patients showing pupillary size variation over the limit for insufficient analgesia estimated in phase 1 for tracheal suction, additional analgesia will be provided before tracheal suction. In those patients without pain detected by pupillometry, additional anlagesia won´t be provided. In both cases Pupillometry, BPS and ESCID will be measured during tracheal suction to determine whether the patient is in pain or not.
9519908|NCT03282370|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
9519909|NCT03282370|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
9519910|NCT03282344|Experimental|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
9826275|NCT02413255|Experimental|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
10152215|NCT04078113|No Intervention|Control group|"Before tracheal suction and due to medical decision, analgesia following current clinical practice would be administered prophylactically.~Pupillometry, BPS and ESCID will be measured during tracheal suction to determinate whether the patient is in pain or not."
10152216|NCT04077970|Experimental|Intrauterine flushing follicular fluid|Women underwent intrauterine flushing with follicular fluid plus granulosa cells
10152217|NCT04077970|No Intervention|Without intrauterine flushing with follicular fluid|Women without intrauterine flushing with follicular fluid
10152218|NCT04078139|Experimental|The MP/RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 40mg methylprednisolone, plus 10ml saline;
10152219|NCT04078139|Active Comparator|The RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10ml saline;
10152220|NCT04077788||Study group (group A):|It consisted of fifteen subjects who received muscle energy technique (Mitchell relaxation osteopathic technique). Two sessions per cycle for three cycles before menstruation by one week and after the end of menstruation by one week. In addition to their medical treatment non-steroidal anti-inflammatory drugs (NIAIDS).
10152221|NCT04077788||control group (group B):|It consisted of fifteen subjects who took their medical treatment only (non-steroidal anti-inflammatory drugs (NIAIDS)).
10152222|NCT04077866|Active Comparator|Temozolomide alone|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
10152223|NCT04077866|Experimental|Temozolomide + B7-H3 CAR-T|"Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.~The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide treatment in the cycles of B7-H3 CAR-T treatment will be stopped."
10152224|NCT04077983|Experimental|combined therapy using nab-paclitaxel and gemcitabine chemo|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~Three weeks is a course of treatment with a total of 4 courses."
10152225|NCT04077814|Active Comparator|ShamtDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Sham Transcranial direct brain stimulation (tDCS)
10152226|NCT04077814|Experimental|tDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Transcranial direct brain stimulation (tDCS)
10152227|NCT04078022|Experimental|Cohort 1: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
10152228|NCT04078022|Experimental|Cohort 2: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
10152229|NCT04078022|Experimental|Cohort 3: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
10152230|NCT04078022|Experimental|Cohort 4: Shigella Vaccine Only, No Challenge|All volunteers receive the investigational Shigella vaccine (n=12). No Shigella challenge.
10152231|NCT04078009|Experimental|Aquagen (Starts with Aquagen and finish with Grazax)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
10152232|NCT04078009|Experimental|Grazax (Starts with Grazax and finish with Aquagen)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
10152233|NCT04077905|Experimental|DEP regimen|pegylated liposomal doxorubicin, etoposide and methylprednisolone administered in 2 week cycles for 2 cycles
10152234|NCT04077762|Active Comparator|Radial access|Radial access for cardiac catheterization. Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
10152235|NCT04077762|Active Comparator|State-of-the-art femoral access|Femoral access for cardiac catheterization. Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
10152236|NCT04077749|Experimental|Probiotic|
10152237|NCT04077749|Placebo Comparator|Placebo|
10152238|NCT04077918|Active Comparator|Plant protein diet|18 g of plant protein diet added every day for 3 months , and after washout for 1 month, 18 g of animal protein diet added every day for 3 months
10152239|NCT04077918|Active Comparator|Animal protein diet|18 g of animal protein diet added every day for 3 months, and after washout for 1 month, 18 g of plant protein diet added every day for 3 months
10152240|NCT04077736|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
10152241|NCT04078087||Non obese|"Non obese (whether normal weight or overweight) = Group NO"
10152242|NCT04078087||Obese|"obese = Group O"
10152243|NCT04077931|Experimental|Aerobic exercises|She asked to start walking with the speed of the machine was adjusted at 0.8 km/hour, so her resting pulse rate increases, then we increased the speed by 0.2 km/hour gradually every 2 minute (to give a time for adjustment of heart rate) till reaching our target heart rate (not less than 60% and not more than 75% of target heart rate). So the intensity of exercises can be increase or decrease only by changing the speed of treadmill according to target heart rate [13]
10152244|NCT04077931|Experimental|Deep breathing exercises|Technique of breathing exercises: Regular aerobic exercises in a form breathing exercises included duration of 30 min. at 40-70% VO2 max. performed 2-3 per week. Each woman practiced deep breathing exercises 30 min. in the of form (diaphragmatic breathing exercises, 15 min. and lateral costal breathing exercises 15 min.) 3 times per week for 12 weeks.
10152245|NCT04077944||Preterm prelabor rupture of membranes|"The diagnosis of Preterm prelabor rupture of membranes was made in the case of apparent spontaneous leakage of AF from the cervical canal during sterile speculum inspection before the onset of active labor at 37 weeks of pregnancy. The study population consisted of 55 women with a singleton pregnancy who were diagnosed with pP-ROM between 24+0 and 36+6 weeks of gestation.~The Amnisure test (AmniSure International LLC, Boston, MA) was used when there was inconclusive results to confirm the final diagnosis. The gestational age was determined by calculation from the last menstrual period and supported by the ultrasonography measurements at the first trimester of gestation."
10152246|NCT04077944||Control|The control cases were recruited from the healthy pregnant women with a gestational age-matched cohort who admitted for routine obstetric care to our outpatient clinic. Sixty healthy pregnant women who delivered at term were included in the study as the control group.
10152247|NCT04077502|Active Comparator|stimulated group|The group stimulated by real coil of rTMS.
10152248|NCT04077502|Sham Comparator|controle group|The group stimulated by sham coil of rTMS.
10152249|NCT04077333|Experimental|MISA group|minimal invasive surfactant administration group
9826276|NCT02413255|Experimental|Part 2 Cohort 5: TAK-020 45 mg|TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
10152250|NCT04077333|No Intervention|EISA group|conventional treatment: endotracheal intubation surfactant administration group
10152251|NCT04077346|Experimental|Transcutaneous Spinal Stimulation- Acute and with Training.|"For Aim 1: Participants will receive transcutaneous stimulation (TcStim) in supine or side lying position at a single or multi site spinal levels to produce stepping/locomotor activity in lower limbs.~For Aim 2: TcStim will be delivered while participants are stepping on a computerized treadmill with an overhead partial body weight support (BWS) system and while stepping overground.~For Aim 3: Participants will first receive a combination of Activity-based locomotor training (AB-LT)+TcStim for 60 sessions."
10152252|NCT04077554||Study group|women and men with excess body mass
10152253|NCT04077554||Control group|women and men with proper body mass
10152254|NCT04077489|Other|MT|Macular thickness
10152255|NCT04077515|Active Comparator|high blood concentration group|The blood concentration is maintained at 10-15ng/ml (not including 10ng/ml).
10152256|NCT04077515|Experimental|low blood concentration group|The blood concentration is maintained at 7-10ng/ml (including 10ng/ml).
10152257|NCT04077411||Children with severe TBI|Children with severe Traumatic Brain Injury
10152258|NCT04077385|Experimental|Retrieval Extinction (R-E) Training Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the R-E training group will observe 5-min of high calorie pictorial food cues during retrieval which will purportedly retrieve cue-reward associative memories. This will be followed by 60-min of extinction training to high calorie food cues. The R-E training group will only differ from the extinction control group in regards to the 5-min exposure to high calorie food cues prior to the 60-min of extinction training to high calorie food cues."
10152259|NCT04077385|Active Comparator|Extinction Control Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the extinction control group will observe 5-min of non-food-related cues (e.g., pictures of office supplies, tools) during retrieval, which will purportedly avoid retrieval of the food cue-reward associative memories that are targeted in the R-E training group. The 5-min of exposure to non-food-related cues will be followed by the same 60-min of extinction training to high calorie food cues that the R-E training group receives."
10152260|NCT04077580|Experimental|Methenamine hippurate|Tablets containing 1 g methenamine hippurate, dosage 1 tablet morning and evening.
10152261|NCT04077580|Placebo Comparator|Placebo|Placebo tablets containing 1 g of lactose, with identical size, shape and stamps
10152262|NCT04077684|Placebo Comparator|Placebo|placebo s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
10152263|NCT04077684|Active Comparator|IL-2 at 0.2MIU|0.2 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
10152264|NCT04077684|Active Comparator|IL-2 at 0.5MIU|0.5 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
10152265|NCT04077684|Active Comparator|IL-2 at 1.0MIU|1.0 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
10152266|NCT04077476|Active Comparator|Online Yoga|Participants in both groups will follow a prescription of classes the research team (including a 200-hour yoga instructor) developed, and is safe and appropriate for this study population. The yoga prescription will be based on the prescription used in the current R34 study (see reference for description), and modified based on results (i.e., participant feedback). Participants will be given instructions about how to use the online yoga class platform (Udaya) during the intake appointment.
10152267|NCT04077476|Experimental|Online Yoga + Facebook|"In addition to what is described above, participants will be provided instructions on how to join the private Facebook group. The Facebook group will be an informal platform where participants can connect with other people in the online + SN group to share their experiences with yoga as it relates to their stillbirths. Current social media intervention research suggests careful consideration must be given to the intervention. The current intervention will be designed based on results of focus groups asking stillbirth moms who have completed an online yoga intervention what they would find helpful in a Facebook intervention. For instance, preferences included having a moderator, rules about what they can post (e.g., no rainbow babies), and discussion about both stillbirth and life in general."
10152268|NCT04077398|Experimental|low volume High concentration group|1.Low Volume: 30 subjects randomized to Low Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,75% ropivacaine x 15 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
10152269|NCT04077398|Experimental|high volume low concentration|2.High Volume: 30 subjects randomized to High Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,375% ropivacaine x 30 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
10152270|NCT04077645|Experimental|Sun salutations|Sun salutations, breathing exercises, and relaxation, at a low to moderate intensity, for 30 minutes.
10152271|NCT04077645|Active Comparator|Aerobic exercise|Walking on a treadmill at low to moderate intensity for 30 minutes.
10152272|NCT04077645|Other|Seated rest (attentional control)|Watching educational videos for 30 minutes.
10152273|NCT04077632|Experimental|tDCS (anodal)|Real transcranial direct current stimulation tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
10152274|NCT04077632|Sham Comparator|tDCS (sham)|Sham transcranial direct current stimulation tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
10152275|NCT04077658|Experimental|HeartMath|
10152276|NCT04077658|Active Comparator|Waitlist Control|
9826277|NCT02413255|Experimental|Part 2 Cohort 6: TAK-020 60 mg|TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
10152277|NCT04077697||ITBA group|ITBA group is : invasive tracheobronchitis aspergillosis form.
10152278|NCT04077697||IPA without tracheobronchial involvement|IPA group is : invasive pulmonary aspergillosis without tracheobronchial involvement
10152279|NCT04077606|Active Comparator|ceramo-metallic crown|ceramo-metallic crown preparation
10152280|NCT04077606|Active Comparator|monolithic zirconia crown|monolithic zirconia crown preparation
10152281|NCT04077307|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are three planned dose cohorts. Patients will be given every second day dosing.
10152282|NCT04077320|Experimental|Memory Self-Efficacy Training|
10152283|NCT04077320|Active Comparator|General Education Group|
10152284|NCT04077294||Preoperative BNP used for cardiac risk stratification|Cohort of patients recruited in the pre-admission clinic who qualified for, and underwent, preoperative BNP screening according to CCS guidelines.
10152285|NCT04077294||Preoperative BNP not used for cardiac risk stratification|Cohort of patients from patient care database (SPOR) who qualified for preoperative BNP screening according to CCS guidelines, but did not receive screening due to surgery occurring before the implementation of the CCS guidelines.
10152286|NCT04077281|Experimental|Intervention Arm|Clinical Pharmacology specialist team approach starting in hospital and following up with the patient at home using telemedicine and detailed communication with them, their caregiver, family physician, community pharmacist and other specialists.
10152287|NCT04077281|No Intervention|Control Arm (Usual care)|Patients will receive a best possible medication history (BPMH) as do the intervention patients, then usual care by their primary team.
10152288|NCT04077567|Experimental|TS-152 30mg SC|TS-152 30mg subcutaneously (SC) every 4 weeks
10152289|NCT04077567|Experimental|TS-152 80mg SC|TS-152 80mg subcutaneously (SC) every 4 weeks
10152290|NCT04077450|No Intervention|Modified Waitlist Control Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. Two weeks later, participants will be asked to complete post-intervention data collection (T2), which consists of a questionnaire and heart rate variability assessment. After the completion of data collection, participants will be offered the online heart-focused breathing intervention.
10152291|NCT04077450|Experimental|Intervention Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. These participants will receive an online heart-focused breathing intervention. Participants will be asked to practice their breathing skills while monitoring their heart rate variability using the Welltory app on their smart device for the following two weeks. Participants will be instructed to maintain a log to record the date and time of each practice session. Research staff will make biweekly reminder calls to participants. After the two-week period, participants will complete post-intervention data collection (T2), which includes a questionnaire and HRV assessment.
10152292|NCT04077060|Experimental|NIPT|Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.
10152293|NCT04077060|Other|Combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
10152294|NCT04077242|Active Comparator|"Parryscope-group"|"In these patients, Fallopian tube patency is assessed using the Parryscope technique. A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed."
9519911|NCT03282344|Experimental|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
9519912|NCT03282331|Experimental|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
9519913|NCT03282331|Other|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
9519914|NCT03282331|Other|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
9519915|NCT03282318|Experimental|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
10152295|NCT04077242|Active Comparator|"Tubal flow-group"|"In these patients, Fallopian tube patency is assessed using the flow technique. a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
10152296|NCT04076930||ACEI/ARB users|
10152297|NCT04076930||ACEI/ARB non-users|
10152298|NCT04077047|Other|Intervention pilot|
10152299|NCT04077034|Experimental|Experimental group|Probiotic DE111®
10152300|NCT04077034|Placebo Comparator|Control group|Placebo
10152301|NCT04077021|Experimental|Part 1: Dose Escalation|CCW702 is administered subcutaneously with ascending dose levels to determine maximal tolerated dose (MTD).
9519916|NCT03282318|Placebo Comparator|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
9519917|NCT03282292|Experimental|Jugular|CVC insertion in the left or right internal jugular vein
9519918|NCT03282292|Active Comparator|Femoral|CVC insertion in the right or left femoral vein
9519919|NCT03282279||TVOR population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all transvaginal oocyte retrieval procedures performed between 1996 and October 2016.
9519920|NCT03282214|Experimental|Self-management energy conservation|Thai women with breast cancer randomized to the group will receive four sessions approximately every three weeks with the PI. The women will be instructed on how to do a self-management energy conservation program.
9519921|NCT03282214|No Intervention|Control|The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
9519922|NCT03282201||Transfused|Patients in whom blood transfusion is used
9519923|NCT03282201||Nontransfused|Patients in whom blood transfusion is not used
9519924|NCT03282188|Experimental|GROUP A (Reovirus only)|Group A patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus is given. Group A patients will then receive only 1 cycle of treatment which will comprise of reovirus only at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days.
9519925|NCT03282188|Experimental|GROUP B (Reovirus plus GM-CSF)|Group B patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus plus GM-CSF is given. Group B patients will be given a subcutaneous injection of GM-CSF (50mcg/day) for 3 days, followed by only 1 cycle of treatment which will comprise of reovirus at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days
9519926|NCT03282175|Experimental|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
9519927|NCT03282175|Experimental|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
9519928|NCT03282175|Active Comparator|Control group|Participants allocated to control group did not receive any placebo or treatment.
9519929|NCT03282162|Experimental|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
9519930|NCT03282162|Experimental|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
9519931|NCT03282149|Experimental|Dose 1|Lowest trial dose of XT-150
9519932|NCT03282149|Experimental|Dose 2|Second, escalating dose of XT-150
10152302|NCT04077021|Experimental|Part 2: Dose Expansion|CCW702 is administered subcutaneously at the recommended phase 2 dose (RP2D). Different dosing regimens will be compared.
10152303|NCT04077190|Experimental|adipose-derived stem cell injection|Ultrasound guided injection of 5cc adipose derived stem cells
10152304|NCT04077190|Active Comparator|cortisone injection|Ultrasound guided injection of cortisone
10152305|NCT04077203|Sham Comparator|Control|Those receiving no visual feedback because the handheld device monitor will be occluded with black tape (the control group).
10152306|NCT04077203|Experimental|Test|Those receiving the ability to visualize their glucose levels via the handheld device (the biofeedback group).
9519933|NCT03282149|Experimental|Dose 3|Third, escalating dose of XT-150
9519934|NCT03282149|Placebo Comparator|Saline placebo|2 of 8 participants in each cohort will randomly be assigned to placebo
9519935|NCT03282136|Active Comparator|incretin arm|T2DM with HF treated by CRTd participants will be assigned prospectively to an intervention (incretin therapy plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
9519936|NCT03282136|Placebo Comparator|conventional hypoglycemic drug arm|T2DM with HF treated by CRTd participants will be assigned prospectively to placebo comparator (placebo plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
9519937|NCT03282110|Experimental|ta-VNS & Electro-acupuncture|"Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months~Other:Electro-acupuncture:3 times per week, once every other day for two months"
9519938|NCT03282110|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
9519939|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
9519940|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
9977824|NCT01365598|Experimental|Low dose primaquine (PQ1)|Lowest experimental dose of primaquine base: 0.1mg/kg
10152307|NCT04077216|Experimental|Group A|Initially received the test meal with EVOO, then on crossover, received the meal without EVOO
10152308|NCT04077216|No Intervention|Group B|Initially received the test meal without EVOO, then on crossover, received the meal without EVOO
10152309|NCT04077151|No Intervention|Standard of Care|PrEP prescribed with no intervention
10152310|NCT04077151|Experimental|Intervention Recipients|PrEP Demonstration Project intervention will be given
10152311|NCT04076995|Experimental|High Water intake|High water intake of 3.0 L/day in males and 2.0 L/day in females
10152312|NCT04076995|Active Comparator|Low Water Intake|Low water intake of 0.5 L/day in males and 0.4 L/day
10152313|NCT04076865|Experimental|EMLA|
10152314|NCT04077112|Active Comparator|traditional PCIT|once a week parent training
10152315|NCT04077112|Experimental|intensive PCIT|every day for two weeks parent training
10152316|NCT04077177|No Intervention|Assessment Only|
10152317|NCT04077177|Experimental|Intervention|
10152318|NCT04077255|Experimental|anti-EGFR|Participants will receive GC-1118 in combination with weekly paclitaxel.
10152319|NCT04077164||Individuals with Chronic Pain|Individuals who identify as having a chronic musculoskeletal pain condition.
10152320|NCT04077164||Partners|Partners (e.g., life partner, spouse, or significant other) of the individual with the chronic musculoskeletal pain condition.
10152321|NCT04076969|Experimental|Integrated Educational Session|The anemic pregnant women in the study group received an integrated health education in one session. The educational session was steered as 40-minutes session in a personalized manner. The educational session content included; disease specific information, effect of anemia on maternal and neonatal outcome, management possibilities, the effectiveness, benefits and disadvantages of treatment options, identify diet rich with iron, false dietary habits prevent iron absorption and the balanced diet and meals.
10152322|NCT04076969|Other|Routine follow up|Routine follow up
10152323|NCT04076943|Experimental|Roxadustat (FG-4592)|
10152324|NCT04076982|Experimental|mung bean|daily oral administration of protein supplement
10152325|NCT04076982|Placebo Comparator|biscuit|daily oral administration of control supplement
10152326|NCT04077008|Other|Bilaterally Obstructed Kidneys by benign cause|
10152327|NCT04077008|Other|Bilaterally Obstructed Kidneys by malignant cause|
10152328|NCT04077125||Cirrhosis no MHE|Patients with liver cirrhosis without signs of minimal hepatic encephalopathy
10152329|NCT04077125||Cirrhosis MHE|Patients with liver cirrhosis with minimal hepatic encephalopathy
10152330|NCT04077125||Controls|Healhty subjects
10152331|NCT04077229|Experimental|Intervention|A total of 28 intervention text messages (1/day for 4 weeks) will be sent to participants following the baseline self-report assessment. After each message is sent, participants will receive a second text message asking them to rate the utility of the message. Following the 4-week intervention, participants will complete the same self-report assessments as in the baseline assessment (via phone) and will provide feedback about the program. Finally, 4 weeks later (at 8 weeks), participants will repeat the self-report questionnaires by phone.
10152332|NCT04076891|Active Comparator|Cohort 1 - Dercum's disease|Nodule size - diameter (cm) 2-2.9 3-3.9 4-8 Total Dose of RZL-012 (mg) 10 15 20 Dose per NOAEL* 1/25th 1/18.75th 1/12.5th Number of Injections 2 3 4
10152333|NCT04076891|Active Comparator|Cohort 2 - Lipedema|Total Dose RZL-012 (mg) 60 80 Dose per NOAEL* 1/4.688 1/3.125 Number of Injections 12 16
10152334|NCT04076878|Experimental|Intervention in a Mechanism and a Clinical substudy|"Mechanism substudy: 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo). Patients and datacollectors were blinded in terms of the randomised order of the treatment at each of the 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo).~Clinical substudy: Use of the fitted and individually set body suit, Mollii, in the home setting for 6 weeks"
10152335|NCT04076839|Experimental|Goal Management Training (GMT)|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Participants assigned to this group will attend 9 weeks of GMT group sessions, each 2 hours in length, occurring once per week.
10152336|NCT04076839|No Intervention|Wait-list Control|Following baseline testing, participants randomly assigned to the wait-list control group will have no intervention during the 9 weeks that the GMT group attends their group sessions. Following the completion of the GMT group intervention, the wait-list control will attend a a testing session, and subsequently, a 3 month follow-up testing session, the results of which will be compared to those of the GMT group. This group will then be offered a complimentary 9-week GMT program once the final testing session is complete. Again, during these sessions participants will be required to complete questionnaires every third session in order to monitor their progress and symptoms. Following the completion of the complimentary 9-week GMT program, individuals in the WLC will complete post-intervention testing
10152337|NCT04076631||Hepatocellular Carcinoma|Patients with hepatocellular carcinoma undergo open hepatectomy.
10152338|NCT04076670|No Intervention|Control group|Group pf participants that received usual psychological attention.
10152339|NCT04076670|Experimental|Experimental group|Group of participants that received usual psychological attention plus the structured psychological intervention prosed in the study.
10185606|NCT03743987|Experimental|MTA + PRF group|Root resection was applied. MTA was inserted through the apical foramen and PRF was placed to the surgically prepared area
10185607|NCT03743974|Active Comparator|Interscalene block|Site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled of extra-plexus injection of the mixture posterior to the C6 root
10185608|NCT03743974|Experimental|Supraclavicular block|"Site of injection for SCB was superficial and lateral to the trunks of the brachial plexus, and not directly deep inside the corner pocket zone, with neurostimulation control and visualization of the lung"
9519941|NCT03282058|Experimental|Silastic Stent|"At the time of surgery, if the patient is identified in the silastic stent arm, dressing of the septal donor site with silastic stents will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely."
10185609|NCT03743961||Group A : control group|"Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients with 14 Questions) and QoL EORTC Q30 (Quality Qf Life with 30 Questions)~for patients with G8 score > 14/17"
10185610|NCT03743961||Group B : geriatric intervention group|Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients) and QoL (Quality Qf Life) EORTC Q30 for patients with G8 score ≤14/17 ( in this arm there is two groups : patient who received geriatric intervention before treatment initiation (group A) and group of patient did not received geriatric intervention before treatment initiation( group B))
10185611|NCT03743948|Experimental|Expectant couple at risk of transmitting a monogenic disease.|Expectant couple (pregnant woman from 9 weeks of gestation and spouse) at risk of transmitting a monogenic disease among the genes included in the trusight one expanded sequencing kit (Illumina).
10152340|NCT04076735|Experimental|Distal femoral replacement (DFR)|"Distal femoral replacement will be performed by excising the distal portion of the femur (up to two thirds) and replacing with a prosthesis incorporating a hinged total knee replacement.~Surgical approach and implant selection will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in arthroplasty."
10152341|NCT04076735|Active Comparator|Surgical Fixation (ORIF)|Surgical fixation of the distal femoral fracture will be performed with the goals of obtaining and maintaining anatomic reduction and stable fixation of the distal portion of the femur. Surgical approach and implant selection for the surgical fixation (ORIF) will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in trauma of the knee.
10152342|NCT04076423|Experimental|Experimental arm:|they will take 1 tablet (50 mg BIC + 200 mg FTC + 25 mg TAF), orally, once a day, from the moment of randomization.
10152343|NCT04076423|Active Comparator|Comparator arm|they will take 1 tablet of 50 mg of DTG orally, once a day + 1 tablet of 300 mg of 3TC orally, once a day, from the randomization moment.
10152344|NCT04076722|Experimental|Stress reactivity weight stigma|This study arm received a stress reactivity paradigm that involved weight stigma content in the form of an evaluated speech task.
10152345|NCT04076722|Active Comparator|Stress reactivity non-weight stigma.|This study arm received a stress reactivity paradigm that involved non-weight stigma content in the form of an evaluated speech task.
10152346|NCT04076436||Fosfomycin cohort:|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous fosfomycin
10152347|NCT04076436||Quinolones or beta-lactams cohort|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous quinolones or beta-lactams.
10152348|NCT04076709|No Intervention|Standard Care|
10152349|NCT04076709|Experimental|Goal directed anesthesia|Deep neuromuscular blockade (post tetanic count 1-2 twitches) and nociception guided anaesthesia
10152350|NCT04076449||Cerebral Cavernous Malformation with Epilepsy|Patients with cerebral cavernous malformation and associated with epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
10152351|NCT04076449||Cerebral Cavernous Malformation without Epilepsy|Patients with cerebral cavernous malformation but without epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
10152352|NCT04076696|Experimental|Scatter corrected s-DCT|The study scan, s-DCT and correction scan, will be performed within two weeks of the patient's clinical evaluations by chest CT and x-ray. The study scan may be done within 2 weeks prior or two weeks following standard of care imaging. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the standard of care (SOC) imaging and the s-DCT. All patients will have a breath held s-DCT scan in an anterior-posterior direction.
10152353|NCT04076826|Experimental|Protocol A (Dexmedetomidine)|Dexmedetomidine will be administered in accordance with hospital standard operating procedures (SOP).
10152354|NCT04076826|Active Comparator|Protocol B (Propofol / Midazolam)|Propofol and/or Midazolam will be administered in accordance with hospital standard operating procedures (SOP).
10152355|NCT04076800|Experimental|Acupuncture|
10152356|NCT04076800|Sham Comparator|Sham acupuncture|
10152357|NCT04076527||Group 1 - Incomplete Responder|"Primary Incomplete Responder: PBC patients demonstrating an insufficient response to the standard therapy with ursodeoxycholic acid (UDCA) after a minimum of 12 months of treatment (Paris II criteria).~Secondary Incomplete Responder: PBC patients demonstrating a satisfactory initial response to UDCA after a minimum of 12 months of treatment (Paris II criteria) followed by a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment."
10152358|NCT04076527||Group 2 - Responder|PBC patients demonstrating a satisfactory initial and contin-ued response to UDCA after a minimum of 12 months of treatment (Paris II criteria) without a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment.
10152359|NCT04076527||Group 3|Patients newly diagnosed for PBC receiving an approved PBC therapy for the first time. Patients are considered to be newly diagnosed if the initial diagnosis took place no later than six months prior to inclusion into the study.
10152360|NCT04076488|Experimental|Dividat FIT: Computer based exercise|Tablet based interactive physical training.
10152361|NCT04076501|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
10152362|NCT04076501|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
10152363|NCT04076319|Other|CAPABLE|CAPABLE Intervention
10152364|NCT04076553|Active Comparator|CBT + ICT|"Participants randomized to the ICT condition will complete a computerized ICT training at home during the first 4 weeks of treatment and ICT boosters following their treatment sessions during weeks 5-12."
10152365|NCT04076553|Sham Comparator|CBT + sham|"Participants randomized to the sham condition will complete a computerized sham ICT training at home during the first 4 weeks of treatment and sham ICT boosters following their treatment sessions during weeks 5-12. The shame will contain the same proportion of food as non-food but no inhibitory training component."
10152366|NCT04076345||Bacterial group|Newborns or infants less dans 3 months old with fever and positive bacterial sample.
10152367|NCT04076345||Viral group|Newborns or infants less dans 3 months old with fever and positive viral sample.
10152368|NCT04076345||Negatives Microbiological samples|Newborns or infants less dans 3 months old with fever and negatives microbiological samples.
10152369|NCT04076306|Other|iSTEP Feasibility Study Protocol|All participants will be asked to undergo the entire protocol: iSTEP exercise test, 10 metre incremental shuttle walk test, myometry, accelerometry and Haemophilia Joint Health Score.
10152370|NCT04076514||patients with node negative papillary thyroid carcinoma|
10152371|NCT04076475|Experimental|electrical stimulation|receive daily NMES for 30 min/session for 10 days.
10152372|NCT04076475|Sham Comparator|Control|receive similar electrical stimulation (ES) procedure as those in the intervention group but with ES machine power off.
10185612|NCT03743922|Experimental|Oral calciferol group|Subjects will receive oral calciferol 20,000 iu per week during pregnancy until delivered
10152373|NCT04076397|Other|lipofilling group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~Make EVA (evaluation of the pain),~Complete DASH questionnaire~Complete DN4 questionnaire~Patients in the lipofilling group will also have:~the repair of the last dressing during the consultation at J15~Ablation of any threads~Control of the digital and abdominal scar~Making a photo of their finger at V1 and M6"
10152374|NCT04076397|Other|desensitization group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:~Make EVA (evaluation of the pain),~Complete DASH questionnaire~Complete DN4 questionnaire"
10152375|NCT04076410|Experimental|5 Lenses|"The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).~Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).~Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK)."
10152376|NCT04076371|Experimental|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
10152377|NCT04076371|Placebo Comparator|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
10152378|NCT04076371|Experimental|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
10152379|NCT04076371|Placebo Comparator|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
10152380|NCT04076371|Experimental|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
10152381|NCT04076371|Placebo Comparator|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
10152382|NCT04076371|Experimental|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
10152383|NCT04076371|Placebo Comparator|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
10152384|NCT04076774|Experimental|Wondaleaf female condom|Participants will be provided with 5 Wondaleaf condoms first at enrolment and switched to 5 FC2 condoms at the first follow up visit
10152385|NCT04076774|Active Comparator|FC2 Female condom|Participants will be provided with 5 FC2 condoms first at enrolment and switched to 5 Wondaleaf condoms at the first follow up visit
10152386|NCT04076683|Experimental|Algorithm (arm A)|Frequency and volume for apherisis proposed by algorithm and validated by the physician
10152387|NCT04076683|No Intervention|Usual care (arm C)|Frequency and volume for apherisis only decided by the physician (usual care)
10152388|NCT04076085|Active Comparator|Unsupported Upper extremity exercise|Specially designed unsupported Arm exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
10152389|NCT04076085|Active Comparator|Lower extremity exercise|Specially designed Lower extremity exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
10152390|NCT04076085|No Intervention|Control|Here no active intervention will be given only standard care as prescribed by the hospital will be given
10152391|NCT04076098|Experimental|Minocycline|Minocycline gel
10152392|NCT04076098|Placebo Comparator|Placebo|Similar gel without the active agent
10152393|NCT04076254|Experimental|albumin|albumin 5%
10152394|NCT04076254|Active Comparator|fluid|Ringer Lactate
10152395|NCT04076033|Experimental|ECF ESPIRAL|The volunteer is submitted to four-layer spiral functional compressive bandage, then performs Taylor's Jebsen manual function test with comprehensive functional bandage (ECF).
10152396|NCT04076033|Experimental|ECF OITO|The volunteer is submitted to functional compressive bandage in eight with four layers, then performs the Taylor Jebsen manual function test with the comprehensive functional bandage (ECF).
10152397|NCT04076241|Experimental|Combined intervention|Combined intervention group consisted of 16 pulmonary arterial hypertension (PAH) patients. Three different yoga breathing exercises were applied after osteopathic manipulative treatment (OMT). This combined intervention was applied 2 times a week for a period of 8 weeks with a total of 16 training sessions. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
10152398|NCT04076241|Active Comparator|Osteopathic manipulative treatment|OMT group consisted of 16 PAH patients. Six different OMT techniques were applied 2 times a week for a period of 8 weeks with a total of 16 sessions. The same osteopathic manipulative treatment techniques applied to combined intervention group were used for this study group. There remained a 3-workday gap between two sessions. Patients in this group were thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
10152399|NCT04076241|No Intervention|Control|Control group also consisted of 16 PAH patients and serves as the controls. No interventions were applied for the patients in this group. Similar with the patients in other two groups, pharmacological treatment of the patients in this group continued and they were advised for using their medication properly, Patients in this group were also thought about pathophysiology of PAH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
10152400|NCT04076267||Patients with cancer|
10152401|NCT04076293|Experimental|HM15912|
10152402|NCT04076293|Placebo Comparator|Placebo|
10152403|NCT04076163|No Intervention|control group|group of students participating to a face-to-face learning
10152404|NCT04076163|Other|intervention group|group of students using serious game
10152405|NCT04076189|Experimental|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
10152406|NCT04076189|Active Comparator|No endotracheal suctioning|Procedure includes: Initiation of positive pressure ventilation without endotracheal suctioning
10152407|NCT04076137|Experimental|Targeted T-cell|This study is a pre-phase I immunotherapy trial in 10 people with malignant solid tumor consisting of 9 infusions of bispecific antibody armed anti-CD3-Actibated T cells(ATC) to determine safety, maximum tolerated dose (MTD), technical feasibility, immune responses.
10152408|NCT04076228||Pembrolizumab|Chinese lung cancer patients who will receive pembrolizumab will be enrolled in this study. Clinically, the treatment course of pembrolizumab is depended on the efficacy, but average cycle is about 3-4 weeks and patient will receive 6 treatment courses.
10152409|NCT04076215|Experimental|Pariticapnts with PTSD|
10152410|NCT04076215|Experimental|Pariticapnts without PTSD (controls)|
10152411|NCT04075968||group 1|exercise group; 6 weeks, twice a week, 30 minutes physical group exercises and 30 minutes general cognitive function exercises will be applied as groups.
10152412|NCT04075968||group 2|control group; patients will be given physical and cognitive home exercise program individually.
10152413|NCT04075942|Other|Atrophic Anterior Maxillary Ridges participants|Using customized Xenograft bone shell with equal mixture of autogenous and xenograft particulate bone as a graft with the modified cortical shell technique, with atrophic anterior maxilla with less than 5 mm Bucco-lingual
10152414|NCT04075877|Experimental|FOCUS|"Participants will complete a baseline survey battery and learn about The Hero's Journey. Starting at hospital discharge for 10 days, they will do the following: 1) identify which stage of The Hero's Journey they are experiencing; 2) take a picture of something good and write a caption describing the picture and provide advice; and 3) take a picture of something difficult or challenging during the day and write a caption for the photo and provide advice.~Daily text messages will remind participants to take the photographs, write the advice captions, upload both to the server, as well as to take a very brief daily survey. At the conclusion of day 10, participants will be asked to review their photos and captions and provide final advice in the form of a letter to other adolescents with SCD or cancer. Finally, they will complete a post-intervention battery."
9826278|NCT02413294|Experimental|Bright Light Intervention|Before the bright light intervention is initiated (and during the intervention), participants will wear two wrist bands which measure sleep quality and activity levels- the Fitbit and actigraphy watches. These will be worn for two weeks to assess individuals' baseline levels of sleep quality and will continue to be worn during the intervention. Following the baseline period, the re-timer glasses will be introduced and worn for a period of 30 to 50 minutes a day for two weeks.
10152415|NCT04075877|No Intervention|Control|"In a 30-min visit (in person or virtual) with adolescents during hospitalizations, we will have participants complete a baseline survey battery.~Daily text messages will remind participants to take a very brief daily survey. At the conclusion of day 10, participants will complete a post-intervention battery."
10152416|NCT04076358|Experimental|Tab-CBI|The Tab-CBI group receives a tablet preloaded with the Tab-CBI application and an accelerometer. During the study period, the participants have four weekly educational sessions plus one booster session by the research assistant through a videoconferencing tool. The educational modules were developed based on the principles of cognitive behavioral therapy. The key elements of the modules include activity-pacing, adjustment of goal-setting to the current physical condition, setting priorities and structured planning of a simple walking activity and time off, and cognitive restructuring of activity demands (see attached, outline of education modules).
10152417|NCT04076358|No Intervention|Usual Care|The usual care group receives Arthritis related fatigue management which are currently offered to the participants at the recruitment sites. Participant are also instructed to maintain usual activity during the study period. The control group participants also receive an accelerometer to count steps, but without a tablet.
10152418|NCT04076124|Experimental|Active rTMS-DLPFC|This active group will receive high-frequency repetitive TMS stimulation.
10152419|NCT04076124|Experimental|Active iTBS-DLPFC|This active group will receive intermittent theta-burst TMS stimulation.
10152420|NCT04076124|Sham Comparator|Sham TBS-DLPFC or Sham rTMS-DLPFC|Patients in the sham group will receive the same iTBS or rTMS parameter stimulation, performing by a sham coil.
10152421|NCT04076007|Active Comparator|Active|Nitrate rich beetroot juice (7.5 mmol nitrate in 250mls beetroot juice) once daily.
10152422|NCT04076007|Placebo Comparator|Placebo|Nitrate depleted beetroot juice (0.002 mmol nitrate in 250 ml beetroot juice) once daily.
10152423|NCT04075890|Active Comparator|Healthy subjects|
10152424|NCT04075890|Active Comparator|OCD subjects|
10152425|NCT04076332|No Intervention|Controlled group|Standard oral explanation with booklet
10152426|NCT04076332|Experimental|Decision aid group|Shared decision making using decision aid
10152427|NCT04075903|Experimental|Intervention|"Storytelling A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
10152428|NCT04075903|No Intervention|Control|Usual Care
10152429|NCT04076202|Experimental|Cementless Vanguard DD RP|Patients receiving a total knee prosthesis
9977825|NCT01365598|Experimental|Intermediate dose primaquine (PQ2)|Intermediate experimental dose of primaquine base: 0.4mg/kg
10152430|NCT04076176|Active Comparator|L-amino Acids|"The specific amount and timing of L-amino acid consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
10152431|NCT04076176|Experimental|PKU Sphere|"The specific amount and timing of PKU sphere consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
10152432|NCT04075955|Experimental|Study treatment group|Olanzapine in combination with ondansetron and dexamethasone
10152433|NCT04075955|Active Comparator|Standard treatment group|Aprepitant in combination with ondansetron and dexamethasone
10152434|NCT04075734|Experimental|RCT Intervention|The intervention consists of (1) online self-management educational modules and (2) weekly peer mentor calls to facilitate engagement with the modules and offer specialized support over approximately six weeks.
10152435|NCT04075734|No Intervention|RCT Usual Care|Participants receive usual care.
10185613|NCT03743922|Placebo Comparator|oral placebo group|Subjects will receive oral placebo 1 tab per week during pregnancy until delivered
10152436|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001). The group gathered for a one-hour session once a week for 18 weeks.
10152437|NCT04075786||Gynecologists|Gynecologists in active clinical practice and resident (in training) gynecologists.
10152438|NCT04075773|Experimental|Religious Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported religious identity. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
10152439|NCT04075773|Sham Comparator|Age Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported age. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
10152440|NCT04075851||Hashimoto or Grave's disease patients in treatment|Draw 10 ml venous blood
10152441|NCT04075851||Hashimoto or Grave's disease patients on initial treatment|10 ml of venous blood was extracted every month for three months
10152442|NCT04075851||Pregnant woman with Hashimoto or Grave's disease|10 ml venous blood was extracted every month to postpartum for 6 months
10152443|NCT04075851||Healthy crowd|Draw 10 ml venous blood
10152444|NCT04075799|Experimental|training|8 weeks using stair climbing with a frequency of thrice a week. For the first week of the stair training exercise program subjects will meet at UNM's Teaching Education Building (Stair Case 2). The following 7 weeks subjects can perform the exercise program at a staircase most convenient to them and approved by the research team. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will be comprised of 6-12 x 30-seconds bout of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. After the exercise session the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks.
10152445|NCT04075721|Experimental|Part A (Dose Escalation): M3258|
10152446|NCT04075721|Experimental|Part B (Dose Expansion): M3258|
10152447|NCT04075929|Other|4x8 min|4x8-min intervals with 2-min recovery periods. The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x8-min = 32 min
9977826|NCT01365598|Active Comparator|Reference dose primaquine (PQ-R)|WHO-recommended dose of primaquine base: 0.75mg/kg
10152448|NCT04075929|Other|4x(8x40/20s)|4x(12x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group:4x(12x40/20-sec) = 32 min if the 20-sec recovery is not included in the total time of HIT
10152449|NCT04075929|Other|4x(12x40/20s)|4x(8x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x(8x40/20-sec) = 32 min if the 20-sec recovery is included in the total time of HIT
10152450|NCT04075760|Experimental|EUS-guided combined therapy|Patients with endoscopic and EUS documented GOV II and IGV I will be included. Procedure will be performed under general anesthesia using a linear array therapeuthic echoendoscope, coils and cyanoacrylate will be injected within the feeder vessel under EUS and fluroscopic guidance.
10152451|NCT04075760|Placebo Comparator|Beta Blocker (Propranolol)|o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose will be increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication will be attempted if cessation of the medication did not result in improvement of the reported side-effect.
10152452|NCT04075539|Experimental|Home-based cycling program associated to usual care|
10152453|NCT04075539|Other|Outpatient physiotherapy|
10152454|NCT04075500|No Intervention|Arm 1|Control arm, 24-h Holter monitoring
10152455|NCT04075500|Other|Arm 2|Interventional arms, prolonged cardiac monitoring
10152456|NCT04075552|Experimental|Participants|Participants are students from a specialized school for children with autism.
10152457|NCT04075461|Experimental|Undisplaced FNF + Arthroplasty|Arthroplasty is the typical surgery for a displaced femoral neck fracture
10152458|NCT04075461|Active Comparator|Undisplaced FNF + Internal fixation|Internal fixation is the typical surgery for an undisplaced femoral neck fracture
10152459|NCT04075565|Active Comparator|Simulated altitude|The participants are exposed to simulated altitude in a normobaric situation.
10152460|NCT04075565|Experimental|Terrestrial altitude|The participants are exposed to terrestrial altitude in a hypobaric situation.
10152461|NCT04075565|No Intervention|Control|the participants are exposed to a normoxic and normobaric environment.
10152462|NCT04075578||female with urinary incontinence|Female ≥ 18 years, suffers from urinary incontinence by idiopathic overactive bladder, inadequately treated by 2 anticholinergic medicines during a period of 3 months for each of them or stopped for intolerance or adverse events
10152463|NCT04075357|No Intervention|Control|The patients underwent conventional CTS surgery
10152464|NCT04075357|Experimental|Experimental|The patients underwent conventional CTS surgery and transplantation of amniotic membrane
10152465|NCT04075656|Experimental|UrApp|Participants randomized to this study arm will use the UrApp mobile application for one year, in addition to receiving the standard of care.
10152466|NCT04075656|Active Comparator|Standard of Care|Participants randomized to this study arm will use receive the standard of care for one year.
10152467|NCT04075617|Experimental|intervention group|electronic habit reminder will fabricated to treat thumb/finger sucking habit containing two parts: acrylic part specially fabricated for the child finger/thumb connected to the reminder in the shape of wrist watch.
10152468|NCT04075617|Active Comparator|control group|palatal crib will be cemented after impression taking and fabrication
10152469|NCT04075643|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
10152470|NCT04075643|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
10152471|NCT04075474|Experimental|silver diamine fluoride|38% silver diamine fluoride
10152472|NCT04075474|Active Comparator|sodium fluoride|5% sodium fluoride
10152473|NCT04075344|Experimental|Experimental RCHEs staff|Experimental RCHEs staff will received a multimodal ICP regarding the NG tube feeding. Knowledge and skills of NG tube feeding will be measured before and after the multimodal ICP. In addition, 10 fingertips of RCHEs staff, enteral milk and NG tube hubs of residents will be taken for bacterial counts before and after the intervnetion.
10152474|NCT04075344|No Intervention|Control RCHEs staff|No multimodal ICP will be offered to the staff of control RCHEs.
10152475|NCT04075370||Single arm study|In this feasibility study, longitudinal mixed methods will be used to measure cognitive function and symptoms by objective tests, interviews, and biomarker assay in adults with brain cancer over time: prior to radiation (XRT; T1), 2-weeks post-XRT (T2), 2-3 months post-XRT (T3).
10152476|NCT04075305||Brain cancer|
10152477|NCT04075305||Lung cancer|
10152478|NCT04075305||Esophageal cancer|
9972202|NCT01318343||Treatment Group 3|Four (4) subjects will receive one (1) treatment, six (6) months after the previous treatment with the eZ App 8 large applicator to the abdomen. This is the same applicator that is being evaluated in this study. These subjects have been treated on-site at the Laser & Skin Surgery Center of New York by the study doctor.
9972203|NCT01318369|Experimental|Namisol|Namisol (dronabinol) single dose 8 mg
9972204|NCT01318369|Active Comparator|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
10152479|NCT04075305||Breast Cancer|
10152480|NCT04075305||Head and Neck Cancer|
10152481|NCT04075305||Pancreatic cancer|
10152482|NCT04075305||Gynecological cancer|
10152483|NCT04075305||Rectal cancer|
10152484|NCT04075305||Prostate cancer|
10152485|NCT04075305||Bladder cancer|
10152486|NCT04075305||Oligometastases|
10152487|NCT04075305||Liver cancer|
10152488|NCT04075305||Other types of cancer|
10152489|NCT04075162||Low charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)
10152490|NCT04075162||No charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at no charge
10152491|NCT04075123||CPAP GROUP|Suggested PEEP range 5-10 cmH2O; Minimum required PEEP WILL BE 8 cm water (7 cm water if using bubble CPAP); Maximum allowable† PEEP: 12 cmH2O
10152492|NCT04075123||NIPPV GROUP|Suggested Ranges: PIP 12 to 24 cm water; PEEP 5 to 10 cm water; Rates 20-40 bpm; iTime 0.4-1.0 seconds; Minimum required settings on NIPPV: PEEP 8 cm water; Difference of pressure 6 cm water; Rate 20 bpm; Maximum allowable settings: PEEP 10 cm water; PIP 24 cm water; Rate 60 bpm
10152493|NCT04075227|Experimental|0.2% loteprednol etabonate|This group was treated with subconjunctival 5-FU injection and topical 0.2% loteprednol etabonate every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
10152494|NCT04075227|Active Comparator|0.1% dexamethasone|This group was treated with subconjunctival 5-FU injection and topical 0.1% dexamethasone (CD-oph) every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
10152495|NCT04075032|Experimental|Pomegranate extract-1|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks
10152496|NCT04075032|Placebo Comparator|Placebo-1|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks
10152497|NCT04075032|Placebo Comparator|Placebo-2|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks. This arm is the previous PE-1 after crossover and one month of wash-out
10152498|NCT04075032|Experimental|Pomegranate extract-2|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks. This arm is the previous PLA-1 after crossover and one month of wash-out.
10152499|NCT04075214|Sham Comparator|delayed-active tAN|
10152500|NCT04075214|Experimental|active tAN|
10152501|NCT04075058|Experimental|Study|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 34Gy in 10 fractions over 2 weeks.
10152502|NCT04075058|Active Comparator|Control|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 35Gy in 15 fractions over 3 weeks
10152503|NCT04075045|No Intervention|"Group A. Standard Care (Control)"|Does not receive Wellth app.
10152504|NCT04075045|Experimental|"Group B. Wellth App (Treatment 1)"|Receives Wellth app without additional financial rewards tied to adherence.
10152505|NCT04075045|Experimental|"Group C. Wellth App (Treatment 2) with targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at local pharmacies for using the app to track adherence.
10152506|NCT04075045|Experimental|"Group D. Wellth App (Treatment 3) with non-targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at many stores for using the app to track adherence.
10152507|NCT04075019|Experimental|full intervention|students assigned to intervention classrooms in grades 1 through 4 and who remained in schools assigned to the intervention condition in grades 5 or 6
10152508|NCT04075019|Experimental|late intervention|students in intervention classrooms in grades 5 and 6 only
10152509|NCT04075019|Experimental|parent-training only|students whose parents were offered parent training only when their children were in grades 5 and 6 and no other intervention
10152510|NCT04075019|No Intervention|control|students in schools assigned to receive no intervention in grades 5 and 6 and who were not in intervention classrooms in grades 1 through 4
10152511|NCT04075422||Prospective cohort|64 patients treated with Bezlotoxumab
10152512|NCT04075422||Retrospective Cohort (Control)|All the first episodes diagnosed in each participating sites during the previous year that meet the inclusion criteria
10152513|NCT04075006|Experimental|Ketamine Group|adjunct low dose continuous infusion ketamine in addition to the standard of care. Ketamine will be given at a fixed infusion rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
10152514|NCT04075006|No Intervention|Control Group|Standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC sedation and analgesia protocol.
10152515|NCT04075448|Experimental|Control - 50g Walnut|Control condition followed by experimental condition.
10152516|NCT04075448|Experimental|50 g Walnut - Control|Experimental condition followed by control condition.
10152517|NCT04075149|Experimental|Spironolactone|16 weeks without medication, then 16 weeks with medication, then 12 months without medication; spironolactone 50 mg tablets: 50-100 mg orally twice daily (1.7-3.3 mg/kg/24 hr)
10152518|NCT04075175|Experimental|S315 human monoclonal antibody|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo (0.9% Sodium Chloride)) with escalation of a fixed dose of S315
10152519|NCT04075175|Placebo Comparator|0.9% sodium chloride (NaCl)|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo(0.9% Sodium Chloride)) with escalation of a fixed dose of S315
10152520|NCT04075240|Active Comparator|THA-control arm|Total Hip Arthroplasty: 5 days of rivaroxaban, followed by 30 days of aspirin
10152521|NCT04075240|Experimental|THA-study arm|Total Hip Arthroplasty: 35 days of aspirin
10152522|NCT04075240|Active Comparator|TKA-control arm|Total Knee Arthroplasty: 5 days of rivaroxaban, followed by 9 days of aspirin
10152523|NCT04075240|Experimental|TKA-study arm|Total Knee Arthroplasty: 14 days of aspirin
10152524|NCT04074915|Placebo Comparator|Placebo rinse|Normal saline
10152525|NCT04074915|Experimental|Chlorhexidine mouth rinse|Chlorhexidine mouth rinse
10152526|NCT04074915|Experimental|Test group|Chamomile mouth rinse
10152527|NCT04075097|Experimental|Aerobic exercise|44 minutes of moderate intensity walking on a treadmill.
10152528|NCT04075097|Experimental|Yoga|44 minutes of Iyengar yoga.
10152529|NCT04075188|Experimental|Combined therapy|Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.
10152530|NCT04075071|Experimental|TCIT-U|Four teachers from two Head Start classrooms will be assigned to Teacher-Child Interaction Training - Universal (TCIT-U). TCIT-U occurs in two phases (6 weeks per phase): Child-Directed Interaction (CDI; focusing on relationship building) and Teacher-Directed Interaction (TDI; focusing on managing behavior problems). The TCIT-U Trainer (a licensed clinical child psychologist) will provide teachers with group didactic sessions (6 hours per phase) and individualized live coaching in their classrooms (20 minutes, once per week). Strategies include the use of PRIDE skills (Praise, Reflection, Imitation, Behavior Description, and Enthusiasm) or specific verbalizations that promote warm, responsive interactions, as well as classroom-appropriate behavior modification strategies which include using effective commands, prompts, natural consequences, differential social attention, and a modified time-out appropriate for use in a classroom.
10152531|NCT04075071|No Intervention|Usual Care|Four teachers from 2 PreK Counts classrooms will be assigned to the Usual Care (UC) group. They will continue their existing behavioral management strategies and techniques. Teachers will report on specific training in and use of other behavior management and social-emotional learning programs at baseline. At the conclusion of the study, UC teachers and staff will be offered didactic training in TCIT-U principles and strategies.
10152532|NCT04075604|Experimental|Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)|
10152533|NCT04075604|Experimental|Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ|
10152534|NCT04075604|Active Comparator|Arm C: Palbociclib+ANZ|
10152535|NCT04074980|Experimental|Venous only|One venous whole blood draw will be performed into two anti-coagulated collection tubes
10152536|NCT04074980|Experimental|Fingerstick and Venous|One finger-stick sample of capillary blood (~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of INR on the LumiraDx Instrument. One further fingerstick sample is then obtained (~10µl/sample) from a separate finger for immediate measurement of INR on the Coaguchek PRO. From each patient, one venous whole blood draw will also be performed into two anti-coagulated collection tubes.
10152537|NCT04075201|Experimental|Adults-Experimental group|One dose of investigational vaccine
10152538|NCT04075201|Experimental|Children-Experimental group|One dose of investigational vaccine
10152539|NCT04075201|Active Comparator|Children-Control group|One dose of control vaccine
10152540|NCT04075201|Experimental|Neonates-Experimenatal group|Three doses of investigational vaccine
10152541|NCT04075201|Active Comparator|Neonates-Control group|Three doses of control vaccine
10152542|NCT04074954||Cataracts present, no surgery|Adult patients undergoing bilateral cataract surgery
10152543|NCT04074954||Cataracts present, yes surgery|adult patients who have cataracts but are not undergoing cataract surgery
10152544|NCT04074889|Active Comparator|Group A|Patients will be given Lactobacillus & Bifidobacterium containing probiotics [Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg], to be taken 1 sachet twice daily for 6 months.
10152545|NCT04074889|Placebo Comparator|Group B|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 6 months.
10152546|NCT04074876||patients with femur fracture|"Group is composed of patients more of 65 years of age with femur fracture undergoing urgent orthopedic surgery.~During normal pre-operative evaluation and classification based on principal scores and laboratory data, patients will be subjected to bedside pulmonary ultrasound.~Pulmonary ultrasound will evaluate the presence of one of four patterns (normal pattern, isolated B lines, coalescent B lines and consolidation) defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient.~These patients will be later subjected to spinal anaesthesia and orthopedic surgery.~They will be follow for evaluation of MACE (major adverse cardiovascular events: atrial fibrillation, flutter, acute heart failure and non-fatal acute myocardial infarction)"
10185614|NCT03743896|No Intervention|Control group|No intervention
10185615|NCT03743896|Experimental|Test group|single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)
10152547|NCT04074850||TBI group|"A cohort of patients admitted to UZ Leuven from 1999 to 2019 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.~Inclusion criteria will be: ≥ 65 years old at the time of the accident, admitted to UZ Leuven from 1999 and 2019, all injury severities, classified by the Glasgow Coma Scale (GCS) (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven in a different period from 1999-2019, diagnosis of other neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology before the TBI, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
10152548|NCT04074811|Sham Comparator|Sham rTMS|Sham rTMS will be applied over the left dorsolateral prefrontal cortex using a sham figure of 8 coil (within-subject crossover). Sham rTMS will consist of the same auditory and tactile stimuli as the active condition, but does not induce an electromagnetic field and does not affect cortical excitability.
10152549|NCT04074811|Active Comparator|Active rTMS|Active rTMS will be applied over the left dorsolateral prefrontal cortex using an active figure of 8 coil (within-subject crossover). In the active rTMS condition, the investigators will use high-frequency (10Hz) dorsolateral prefrontal cortex (dlPFC) stimulation with intensity of 110% of resting motor threshold. rTMS will consist of 120 trains with 50 stimuli per train (i.e. 5-sec long at 10 Hz) and 10-sec intertrain interval for a total of 6000 pulses. The entire protocol will last 30 min (120 trains with 5-sec on/10-sec off).
10152550|NCT04074746|Experimental|Treatment (AFM13-NK, AFM13)|Patients receive two cycles of standard of care fludarabine IV over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -4 to -2, AFM13-NK IV over 30 minutes on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.
10185616|NCT03743883||Low-dose ASA cohort|A person is identified as newly exposed to low-dose ASA, he/she will become member of new user low-dose ASA cohort and that date will be the start date for outcome follow-up.
10185617|NCT03743883||Comparison unexposed cohort|When a member of new user low-dose ASA cohort is confirmed, one comparison member will be confirmed also from the source population not yet censored on that day (start date) and with the same distribution of matching factors (age, sex, time interval since entry date and number of PCP visits in the year prior to start date) of its low-dose ASA pair with the only difference of being free of ASA on start date.
10185618|NCT03743870||levobupivacaine cohort|125 pregnant patients that will have to undergo spinal anesthesia with Levobupivacaine for elective caesarean section.
10185619|NCT03743870||bupivacaine cohort|Historical control group made of 125 patients underwent spinal anesthesia with Bupivacaine for elective cesarean section during the period between April 2017 and April 2018.
10185620|NCT03743857|Experimental|Manual Therapy|6 sessions of ankle manual therapy
10185621|NCT03743857|No Intervention|Control|No intervention
10185622|NCT03743844|Experimental|Compassion-focused psychoeducation group|Receiving 2-hours of group-based in-person psychoeducational sessions weekly for 6-weeks.
10185623|NCT03743844|No Intervention|Control group|Weight management treatment as usual
10185624|NCT03743831|Other|orotracheal intubation direct|
9972205|NCT01318395|Active Comparator|Aliskiren|
9972206|NCT01318395|Placebo Comparator|Placebo|
10185625|NCT03743831|Other|orotracheal intubation indirect|
10185626|NCT03743818|Experimental|dry needling|dry needling in trigger point in vastus medialis of quadriceps
10185627|NCT03743818|Active Comparator|standardized treatment protocol|in the standardized treatment protocol the investigators including ultrasound, tens, and isometric quadriceps contractions
10185628|NCT03743818|Active Comparator|hialuronic acid|infiltration of hyaluronic acid in the affected knee
10185629|NCT03743805|Experimental|Reversal drugs|Flumazenil and naloxone
10185630|NCT03743792|Experimental|Active|Freeze-dried red raspberry powder (25 g) in active breakfast meal
10185631|NCT03743792|Placebo Comparator|Placebo|Placebo breakfast
10185632|NCT03743779||Intervention|Participants enrolled in Mastering Diabetes.
10185633|NCT03743740|Experimental|Group 1|"first, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.~then, exercises will be suspended for 4 weeks. then, patients will undergo home based program 3 days per week for 6 weeks."
10185634|NCT03743740|Experimental|Group 2|first, patients will undergo home based program 3 days per week for 6 weeks. then, exercises will be suspended for 4 weeks. then, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
10185635|NCT03743727|Experimental|Combined Therapy LDV and SOF|
10185636|NCT03743714|Experimental|males|healthy, sedentary males
10185637|NCT03743714|Experimental|females|healthy, sedentary females
10185638|NCT03743701|Active Comparator|Transrectal ultrasound in В-mode|
10185639|NCT03743701|Experimental|Transrectal ultrasound examination using three-di|
9972207|NCT01318421|Experimental|ELND002|ELND002 sc injection
9972208|NCT01318447|Experimental|CyberKnife SBRT|
9972209|NCT01318460|Active Comparator|Levosimendan|Patients treated with prophylactic administration of levosimendan
9972210|NCT01318460|Placebo Comparator|Placebo group|Patients managed with placebo administration
9972211|NCT01318473|Other|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
9972212|NCT01318525|Experimental|ALF-5755|
9972213|NCT01318525|Placebo Comparator|Saline solution (0.9% NaCl)|
9972214|NCT01318551|Experimental|Arm 1|
9972215|NCT01318551|Experimental|Arm 2|
9972216|NCT01318551|Experimental|Arm 3|
10185640|NCT03743688||Influenza Vaccine Recipients (ccIIV-4)|All participants will receive one dose of FDA-approved inactivated influenza vaccine (Flucelvax Quadrivalent) via intramuscular injection (0.5 mL) as part of their standard of care.
10185641|NCT03743675|Experimental|Diet-Induced Weight Loss|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period.
10185642|NCT03743675|Experimental|Exercise Training|Subjects in this arm will undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
10152551|NCT04074733||Patients with fractures|
10152552|NCT04074837|Placebo Comparator|Placebo|Placebo liquid suspension.
10152553|NCT04074837|Active Comparator|NNI-362, 10 mg|NNI-362 at 10 mg in liquid suspension
9972217|NCT01318564||Group 1: Unit-dose - Pill Bottle|Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
9972218|NCT01318564||Group 2: Pill Bottle - Unit Dose|Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
10152554|NCT04074837|Active Comparator|NNI-362, 20 mg|NNI-362 at 20 mg in liquid suspension
10152555|NCT04074837|Active Comparator|NNI-362, 60 mg|NNI-362 at 60 mg in liquid suspension
10152556|NCT04074837|Active Comparator|NNI-362, 120 mg|NNI-362 at 120 mg in liquid suspension
10152557|NCT04074798|Active Comparator|Patients with low back pain|
10152558|NCT04074798|Sham Comparator|Healthy controls|
9826279|NCT02413320|Active Comparator|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
9826280|NCT02413320|Active Comparator|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
9826281|NCT02413333|Other|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
10152559|NCT04074473|Placebo Comparator|Propranolol alone|TPropranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
10152560|NCT04074473|Active Comparator|Esophageal variceal ligation alone|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
10152561|NCT04074473|Experimental|Esophageal variceal ligation(DC inderal after EV eradication)|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
10152562|NCT04074473|No Intervention|Propranolol(Keep BB after EV eradication)|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
10152563|NCT04074603|Experimental|Group A|needle-free before needle
10152564|NCT04074603|Experimental|Group B|needlebefore needle-free
10152565|NCT04074694|No Intervention|Watchfull waiting|
10152566|NCT04074694|Active Comparator|Interventional|
9826282|NCT02413333|Other|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
9826283|NCT02413346|Experimental|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
9826284|NCT02413346|Experimental|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
9826285|NCT02413372|Experimental|Treatment Group A: BMS-986036|Administered as specified on specified days
10152567|NCT04074564|Experimental|A group|MASCT-I A+PD1 antibody+Apatinib combination therapy
10152568|NCT04074564|Experimental|B group|MASCT-I B+PD1 antibody+Apatinib combination therapy
10152569|NCT04074577|Active Comparator|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. The first colonoscopy will be performed without automated polyp detection software (standard technique) followed immediately by another colonoscopy with automated polyp detection software (combination technique).
10152570|NCT04074577|Active Comparator|Combination +followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. In this arm, the first colonoscopy with be performed with automated polyp detection software (combination technique) followed immediately by another colonoscopy without automated polyp detection software (standard technique)
10152571|NCT04074460|Active Comparator|Propofol (TIVA)|Propofol-based total intravenous anaesthesia
10152572|NCT04074460|Active Comparator|Volatile|Volatile-based (isoflurane, sevoflurane or desflurane) general anaesthesia
10152573|NCT04074551|Experimental|Experimental|HCP1701
10152574|NCT04074551|Active Comparator|Active Comparator 1|HGP0904, HGP0608
10152575|NCT04074551|Active Comparator|Active Comparator 2|HGP0608, HCP1306
10152576|NCT04074642|No Intervention|Non compressive adenoma|Optical Coherence Tomography Angiography without surgery
10152577|NCT04074642|Experimental|Compressive adenoma|Optical Coherence Tomography Angiography before and after neurosurgery
10152578|NCT04074655|Experimental|Intervention Arm|Participants of the study will play the driving simulator daily (5 days/week) for 15-20 minutes/day over a period of 2 consecutive weeks.
10152579|NCT04074720|Other|Standard of Care|patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab
10152580|NCT04074499||Group-1|"The patients were classified based on the frequency of falls in the last 12 months.~Group-1 consists of COPD patients whose have at least one fall (fallers)"
10152581|NCT04074499||Group-2|"The patients were classified based on the frequency of falls in the last 12 months.~Group-2 consists of COPD patients whose have no history of falls (non-fallers)."
10152582|NCT04074369||Pulmonary Tuberculosis Suspects|Individuals with suspected TB infection
10152583|NCT04074356|Active Comparator|Healthy Controls|Healthy volunteers with no known gastrointestinal complications will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
10152584|NCT04074356|Active Comparator|Achalasia subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of achalasia will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
10152585|NCT04074356|Active Comparator|Hypercontractile/spastic disorder subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of hypercontractile/spastic disorder will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
10152586|NCT04074421|Active Comparator|Rifaximin group|Repeating treatment of Rifaximin
10152587|NCT04074421|Sham Comparator|Probiotics group|Sequential treatment of probiotics called Bacillus subtilis and Enterococcus faecium
10152588|NCT04074421|Placebo Comparator|Placebo group|Placebo control group
10152589|NCT04074707|Experimental|oral iron supplementation|Participants go through 3 cycles of oral iron Supplementation (daily dosing, alternate-day dosing, every third-day dosing)
10152590|NCT04074200||Open Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using an open surgical approach.
10152591|NCT04074200||Laparoscopic Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a laparoscopic surgical approach.
10152592|NCT04074200||Robotic-assisted Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a robotic-assisted surgical approach.
9826286|NCT02413372|Experimental|Treatment Group B: BMS-986036|Administered as specified on specified days
9826287|NCT02413372|Placebo Comparator|Treatment Group C: Placebo|Administered as specified on specified days
10152593|NCT04074252|Active Comparator|Lofstrand Crutches|This group is given a set of Lofstrand crutches.
10152594|NCT04074252|Active Comparator|Axillary Crutches|This group is given a set of axillary crutches.
9669669|NCT03407833||Obese, nonsurgery|Obese subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
10152595|NCT04074031|Experimental|minimally invasive method for performing thalamotomy|We will study patients with essential tremor with significant disability despite well-conducted drug therapy who have a contraindication to deep brain stimulation or who refuse treatment. In this population, unilateral thalamotomy of Vim by radiosurgery is already considered a valid indication and performed routinely with proven efficacy and morbidity deemed acceptable. It is therefore the population of choice to evaluate for the first time in France the efficacy and safety of a new, minimally invasive method for performing thalamotomy: targeted ultrasound thermal injury at high intensity. This same population will also make it possible to study, for the first time in humans in this indication, the potential of neuromodulation by low frequency low frequency ultrasound beams to improve the guidance before the lesion is achieved.
10152596|NCT04074018|Experimental|Experimental group|Self-rehabilitation guided program with investigator PMR specialist
10152597|NCT04074018|Active Comparator|Control group|Conventional rehabilitation with a speech therapist or physiotherapist specialized in facial rehabilitation
10152598|NCT04073914|Active Comparator|Intervention|Type 1 Teamwork program
10152599|NCT04073914|No Intervention|Control|Standard of care
10152600|NCT04073901|Experimental|Endocrown|Adhesive monoblock restoration for pulpotomized primary molars
10152601|NCT04073901|Active Comparator|Zirconia crowns|Prefabricated primary full coverage crown
10152602|NCT04074239|Experimental|Video triage|The sick child will be triaged on video by the operator.
9826288|NCT02413398|Experimental|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
9826289|NCT02413398|Placebo Comparator|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
10152603|NCT04074239|No Intervention|Telephone triage|The sick child will be triaged solely on telephone by the operator.
10152604|NCT04074213||Haematologic malignancies with clozapine|Cases reported in the World Health Organization (WHO) database of patients treated by Clozapine, with a chronology compatible with the drug toxicity
10152605|NCT04074434||All Participants|
9516836|NCT03311750|Experimental|Panitumumab|On day 1 of each cycle patients will receive panitumumab followed by 5-fluorouracil and leucovorin in combination with either irinotecan (FOLFIRI regimen) or oxaliplatin (FOLFOX regimen) or followed by irinotecan monotherapy. This treatment will be repeated every 2 weeks for FOLFIRI and FOLFOX regimens and every 3 weeks for irinotecan monotherapy.
9516837|NCT03311737|Experimental|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
9826290|NCT02413463|Active Comparator|Augmented recession|The medial rectus muscle will be exposed and hooked through a limbal approach. The muscle will then be secured with 6-0 polyglactin sutures. The medial rectus muscles will then be recessed using standard tables with the surgical dose targeting the average of the largest and smallest angles
9826291|NCT02413463|Active Comparator|Faden|Medial rectus muscle recession will be performed as described above with the surgical dose targeting the smallest pre-operative angle. The muscle will then fixated to the sclera using 6/0 polyester sutures placed in a mattress like with the anterior and the posterior sutures passing through both the edge of muscle and the sclera 12 mm and 14 mm from the muscle insertion, respectively.
10152606|NCT04074070||Psoriasis with and without musculoskeletal complains|psoriasis with and without musculoskeletal complains
10152607|NCT04074070||Healthy individuals|
10152608|NCT04074070||Psoriatic arthritis|
10152609|NCT04073953|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15mg of RPQ every day for 5 days. Cohort 2 will receive 22.5 mg of RPQ every day for five days.
10152610|NCT04073953|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15mg of SPQ every day for 5 days. Cohort 2 will receive 22.5 mg of SPQ every day for five days.
10152611|NCT04073953|Placebo Comparator|Placebo|Cohort 1 will receive placebo capsules every day for 5 days. Cohort 2 will receive placebo capsules every day for five days.
10152612|NCT04074317|Experimental|PRAM9|Xeris pramlintide + insulin co-formulation
10152613|NCT04074317|Experimental|Regular Insulin + Pramlintide|Humulin® + Symlin® pen as separate injections
10152614|NCT04074317|Active Comparator|Regular Insulin|Humulin®
10152615|NCT04073940|Experimental|Targeted Ballet Program|A 16-week (32 sessions of 1 hour each) ballet-based intervention targeted to improve motor function in persons with multiple sclerosis.
10152616|NCT04073849|Active Comparator|Cohort A|EPOGEN® (epoetin alfa) Study Drug Epoetin Alfa (EPOGEN®) 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
10152617|NCT04073849|Sham Comparator|Cohort B|Saline 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
10152618|NCT04074382||Prospective Cohort|Prospective cohort (Phase 1, and Phase 2 Group A: explained in detailed description earlier) We will recruit and consent patients on the ward in the first few weeks following their admission for major trauma when the consultant in charge of their care feels that they are physically and emotionally/mentally ready and appropriate to take part in the study. A member of the research team will ask whether they want to take part in the study and offer them the participant information sheet. If happy to take part, the patient will have an account set up on the online questionnaire service we will be using called QTool. The consent form will be completed online at baseline along with the initial baseline PROM questionnaires. This group of people will then be sent reminders at 3, 6, 9 and 12 months to complete follow-up questionnaires, up to 28 days before or after these timepoints. They will then enter Phase 2 (Group A).
10152619|NCT04074382||Retrospective Cohort|"Retrospective cohort (Phase 1/2):~Patients between 1 to 10 years following their major trauma will be identified using a database. We will randomly select which of these patients to include in our study, using computer software, to reduce selection bias, and those selected will be sent a recruitment pack in the post. We have calculated that we need at least 320 patients in the retrospective cohort to show any important changes.~This group of patients will only complete the questionnaires once in phase 1, and once per year up to 10 years after their trauma in phase 2 (Group B)."
10152620|NCT04074057|Other|Control arm|the control group will undergo a conventional weekly CR programme lasting 8-12 sessions. Components of each session will include warm up, aerobic training, resistance exercises and cool down. Patients are encouraged to continue their home exercises, exercising another 2 times a week at home and record down using an activity diary. The importance of CR programme and exercise advice will be explained and reinforced by the CR Physiotherapist. The submaximal exercise test and a body composition analysis will be repeated on the final assessment. Every week research coordinator will call the subject to remind them to exercise.
10152621|NCT04074057|Other|Intervention arm|"During the initial assessment, the importance of CR and regular exercise will be explained and reinforced by CR physiotherapist. A research assistant will teach the patient how to use Heart Track. The patient will then bring Heart Track home to continue their CR program. Patient will then undergo the whole CR programme to exercise for 3 times a day for 8-12 weeks using Heart Track. Each Heart Track session will include warm up, aerobic training, resistance exercises and cool down (same as the traditional CR session). After 8-12 weeks, patient will be called back to the clinic by the research assistant to complete the final assessment (sub-maximal exercise test and a body composition analysis) with the blinded assessor. Every week research coordinator will call the subject to remind them to exercise."
10152622|NCT04073758|Sham Comparator|Remifentanil group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted Minimal Alveolar Concentration (MAC). As explained above, remifentanil is infused with Target Controlled Infusion pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Remifentanil is usually infused with the effect site concentration of 2.0 to 6.0 ng/ml during general anesthesia. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, remifentanil infusion will be stopped.
10152623|NCT04073758|Active Comparator|Dexmedetomidine group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration). As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.
9972219|NCT01318590|Experimental|Celiac bloc|The experimental arm will consist of the fractional injection on both sides of the celiac trunk, via EUS, of a local anesthetic (10 ml of Bupivacaine 0.5% (gr / ml)) and an injection of steroids (Triamcinolone 40 mg). In this group antibiotic prophylaxis will be administered after administration of sedation (Cephazolin 1gr IV or Gentamycin).
10152624|NCT04073797|Experimental|Stable CVD - treatment|Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor
10152625|NCT04073797|Placebo Comparator|Stable CVD - placebo control|Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control
10152626|NCT04073797|Experimental|HeFH - treatment|HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor
10152627|NCT04073797|Placebo Comparator|HeFH - placebo control|HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control
10152628|NCT04073693|Active Comparator|BRCA|They were in treatment with BRCA and standard treatment based on nutritional intervention and physical exercise.
10152629|NCT04073693|Placebo Comparator|Placebo|They only were on standard treatment based on nutritional intervention and physical exercise.
10152630|NCT04073745|Experimental|Treatment (SBRT)|Beginning at least 2 weeks after surgical resection, patients undergo 1 fraction (or 5 fractions every other day if R2 resection of central tumor) of SBRT.
9826292|NCT02413489|Experimental|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
9826293|NCT02413580|Experimental|IGIV-C Treatment|In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
10152631|NCT04073550|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
10152632|NCT04073550|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
10152633|NCT04073654|Active Comparator|SA Implants|Dental implant with sandblasted and Acid-etched (SA) surface
10152634|NCT04073654|Experimental|SOI Implants|Same dental implant with sandblasted and Acid-etched surface modified with pH buffering agent
10152635|NCT04073537|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
10152636|NCT04073537|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m^2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
9826294|NCT02413593|Experimental|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
9972220|NCT01318590|Sham Comparator|Conservative treatment|Subject will undergo standard EUS without any additional interventions.
10152637|NCT04073719|Experimental|Apple Cider Vinegar + Coconut Water|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
10152638|NCT04073719|Experimental|Apple Cider Vinegar + Citric Soda|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
10152639|NCT04073719|Experimental|Apple Cider Vinegar + Lemonade|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
10152640|NCT04073719|Experimental|Coconut Water + Apple Cider Vinegar|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
10152641|NCT04073719|Experimental|Coconut Water + Citric Soda|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
10152642|NCT04073719|Experimental|Coconut Water + Lemonade|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
10152643|NCT04073719|Experimental|Citric Soda + Apple Cider Vinegar|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
10152644|NCT04073719|Experimental|Citric Soda + Coconut Water|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
10152645|NCT04073719|Experimental|Citric Soda + Lemonade|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
10152646|NCT04073719|Experimental|Lemonade + Apple Cider Vinegar|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
10152647|NCT04073719|Experimental|Lemonade + Coconut Water|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
10152648|NCT04073719|Experimental|Lemonade + Citric Soda|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
10152649|NCT04073602|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
10152650|NCT04073641||Survey population|Adults with type 1 and type 2 diabetes and caregivers of people with diabetes including parents of children and young people with diabetes.
10152651|NCT04073576|Experimental|AHCL|Advanced Hybrid Closed Loop
9826295|NCT02413684|Other|Asthma Patients|Patient engagement toolkit
9972221|NCT01318616|Experimental|Training group|
10152652|NCT04073576|Active Comparator|SAP+PLGM|Sensor Augmented Pump with Predictive Low Glucose Monitoring
10152653|NCT04073706|Experimental|TH BSO with SNB|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG) (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.
10152654|NCT04073706|Active Comparator|TH BSO without retroperitoneal node dissection|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age) wish to retain their ovaries a BSO may be omitted.
10152655|NCT04073524|Experimental|Nature-Body-Mind-Community (NBMC) + treatment as usual|9 weeks of nature-based therapy (Nature-Body-Mind-Community (NBMC)) treatment as usual
10152656|NCT04073524|Other|Treatment as usual|Treatment as usual
10152657|NCT04073628|Active Comparator|Active Lighting intervention|The active lighting intervention will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, the intervention will allow us to: (1) use a light source that will stimulate the circadian system and (2) provide the participants with options as to how the light treatment will be delivered
10152658|NCT04073628|Placebo Comparator|Control Lighting Intervention|The control lighting intervention will consist of low levels of a warm light source designed not to impact the circadian system.
10152659|NCT04073485|Other|Microwave ablation|The uterine fibroid will be identified and located with ultrasonography. A microwave electrode appropriate for the size of target lesion is placed into the target lesion under ultrasound guidance. Appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
10152660|NCT04073771||Cohort study|Patients with septic shock undergoing continuous renal replacement therapy
10152661|NCT04073511|Experimental|Eungyosan|Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
10152662|NCT04073511|Experimental|Samsoeum|3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
9669670|NCT03407833||Lean control|Lean control subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
10152663|NCT04073511|Placebo Comparator|Placebo|Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
9519942|NCT03282058|No Intervention|No Stent|"At the time of surgery, if the patient is identified in the no silastic stent arm, dressing of the septal donor site without the stent will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely - this is currently the standard of care."
9519943|NCT03282045|Experimental|Lysobact Complete Sprey|"Lysobact Complete Sprey~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride."
9519944|NCT03282045|Active Comparator|Tantum Verde® Spray|"Tantum Verde® Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose."
9519945|NCT03282045|Active Comparator|Pharyngal® Oromucosal Spray|"Pharyngal® Oromucosal Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride."
9519946|NCT03282045|Placebo Comparator|Placebo|"Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times."
9669671|NCT03407833||Liver transplant|Lean or obese subjects who are undergoing liver transplantation as part of their standard of care. Excised liver tissue will be collected the day of procedure.
9669672|NCT03392064|Experimental|AMG 119 Treatment|AMG 119 administered as a one-time intravenous infusion at different cell dose levels
10152664|NCT04073680|Experimental|Serabelisib|"Part 1 is dose escalation of Serabelisib Cohort 1 = 600mg; Cohort 2 = 900mg; Cohort 3 = 1200mg~Part 2 is expansion of mutational cohorts with selected dose as follows:~Cohort 4 = PIK3CA-mutated breast cancer; Cohort 5 = PIK3CA-mutated Non breast cancer; Cohort 6 = KRAS mutated"
10152665|NCT04073459|Experimental|L dose of Hexavalent|Low dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
10152666|NCT04073459|Experimental|M dose of Hexavalent|Middle dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
10152667|NCT04073459|Experimental|H dose of Hexavalent|High dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib).
10152668|NCT04073459|Active Comparator|Pentavalent+IPV|Co-administration of EupentaTM Inj and Imovax Polio
10152669|NCT04073355|Experimental|Physical Activity|Smartphone-delivered physical activity intervention
10152670|NCT04073173|Experimental|LISA-analgesic|Less Invasive Surfactant Administration (LISA) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
10152671|NCT04073173|Experimental|LISA-no analgesic|Less Invasive Surfactant Administration (LISA) without an analgesic drug.
10152672|NCT04073173|Experimental|INSURE-analgesic|INtubation-SURfactant-Extubation (INSURE) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
10152673|NCT04073173|Experimental|INSURE-no analgesic|INSURE without an analgesic drug.
10152674|NCT04074408|Experimental|Cohort 1|low dose hUMSCs or high dose hUMSCs
10152675|NCT04074408|Experimental|Cohort 2|best dose of hUMSCs (from cohort 1) or placebo
9972222|NCT01318655|Experimental|NKTR-118|
10152676|NCT04074265|Active Comparator|Pain injection|This group will be injected with a cocktail totaling 40mL (20mL on each side) that will be composed of ropivicaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), ketorolac 30mg/mL (0.5mg/kg).
10152677|NCT04074265|Placebo Comparator|Normal saline|The control group will receive an injection of 40mL of 0.9% sodium chloride solution.
10152678|NCT04073251|Experimental|KalobaTuss children|KalobaTuss children syrup 5 ml for 4 times a day supplied for 8 consecutive days.
10152679|NCT04073251|Placebo Comparator|Placebo|Placebo syrup 5 ml for 4 times a day supplied for 8 consecutive days.
10152680|NCT04073277|Experimental|SCF-N-treated needle acupuncture|For each participant, one hand was randomly assigned to the experimental group with SCF-N-treated needle acupuncture .
10152681|NCT04073277|Sham Comparator|untreated needle acupuncture|The other hand of participant in experimental group was assigned to the control group with untreated needle acupuncture.
10152682|NCT04073264|Experimental|monofilament|monofilament absorbable suture
10152683|NCT04073264|Active Comparator|polifilament|synthetic absorbable braided (polifilament) suture
10152684|NCT04073121|Experimental|Luminor DCB and Angiolite DES|Study Devices
10152685|NCT04073160|Experimental|Decipher Bladder test subtype non-basal|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype non-basal
10152686|NCT04073160|Experimental|Decipher Bladder test subtype basal and cisplatin-ineligible|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype basal and the subject is cisplatin-ineligible
10152687|NCT04073381|Experimental|Prehabiliation Program|100 subjects between the ages of 18 and 90, who have GI cancer and will undergo surgery will be recruited for this study ad participate in the prescribed prehabilitation exercise and nutrition program.
10152688|NCT04073134|Active Comparator|Evolocumab|Participants will receive evolocumab 140 mg subcutaneous injections once every 2 weeks.
10152689|NCT04073134|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injections once every 2 weeks.
10152690|NCT04073329||Plain x ray|measurement the accuracy of post operative reduction by Matta method
10152691|NCT04073329||CT|measure the accuracy of reduction by Verbeek method
10152692|NCT04073589|Experimental|Treatment A|Single SC injection of Dose A
10152693|NCT04073589|Experimental|Treatment B|Single SC injection of Dose B
10152694|NCT04073589|Experimental|Treatment C|Single SC injection of Dose C
10152695|NCT04073589|Experimental|Treatment D|Single SC injection of Dose D
10152696|NCT04073095|Active Comparator|Group T = mTLIP block group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
10152697|NCT04073095|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
10152698|NCT04073095|No Intervention|Group C = Control group|Patients in control group will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
10152699|NCT04074122||Symptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
9826296|NCT02413879|Experimental|Treatment Group|All study subjects will be treated using the CleanCision device.
9826297|NCT02413918|Experimental|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
10152700|NCT04074122||Asymptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
10152701|NCT04074122||Healthy controls|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
10152702|NCT04073927|Active Comparator|Sodium butyrate|3.6 g sodium butyrate. 6 capsules twice daily for 12 weeks.
10152703|NCT04073927|Placebo Comparator|Placebo|Placebo. 6 capsules twice daily for 12 weeks.
10152704|NCT04073316|Experimental|"Intervention group"|
10152705|NCT04073316|Active Comparator|"Control group"|
10152706|NCT04073342||Surgical Necrotizing enterocolitis|Cases of preterm infants with necrotizing enterocolitis need surgical intervention
10152707|NCT04073342||Non Necrotizing enterocolitis|babies with intestinal operations for non necrotizing enterocolitis pathologies like congenital intestinal obstruction.
10152708|NCT04073212|Experimental|Intervention 1 DN+HSLE|Patients in the intervention 1 Dry Needling (DN)+heavy Slow Load Exercise (HSLE) group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon followed by DN, HSLE and a standardized shoulder strengthening exercise program.
10152709|NCT04073212|Active Comparator|Intervention 2 Control|"Patients in the control group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon and a standardized exercise program. Dry needling nor heavy slow load exercise will not be integrated into the control plan of care."
10152710|NCT04073303|Active Comparator|Botulinum Toxin Type A (BOTOX®)|Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments
9972223|NCT01318655|Placebo Comparator|Placebo|
9972224|NCT01318668|Experimental|Nicotine vaccination|18 week treatment with Nicvax
10152711|NCT04073303|Placebo Comparator|Placebo|Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter
10152712|NCT04073199|Active Comparator|Long Lever Group|This arm receive the protocolized treatment along with the long passive stretch of the Teres Major in Long Lever with the patient in supine position.
10152713|NCT04073199|Active Comparator|Short Lever Group|This arm receive the protocolized treatment along with the short lever stretch according to the Orthopaedic Manual Therapy of the Teres Major.
10152714|NCT04073199|No Intervention|Control Group|only receive the protocolized physiotherapy treatment for the Subacromial syndrome that is applied in the Rehabilitation Service, without the addition of any additional stretch technique.
10152715|NCT04073888|Other|Single arm|Men with Fabry Disease
10152716|NCT04073056|Active Comparator|Quadratus Lumborum II Group|The QL 2 group will receive 15 mL bupivacaine 0.25% on both sides for a total of 30 mL once the surgery is done but prior to extubation under ultrasound guidance.
10152717|NCT04073056|Active Comparator|Conventional Therapy|Conventional therapy consists of the injection of 30 mL of bupivacaine 0.25% directly into the incision sites by the surgeon at the end of the procedure.
10152718|NCT04072926|Experimental|PDT+/BIOROOT|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with BioRoot in combination with guttapercha points.
10152719|NCT04072926|Experimental|PUI/BIOROOT|This arm will only get PUI (passive ultrasound irrigation) with 2,5ml of 2,5% sodium hypochlorite, then 2ml of 15% EDTA which will be activated for 60seconds (EndoUltra MicroMega, France) and finally 2,5ml of 2,5% of sodium hypochlorite will be also activated for 30 seconds. Root canal filling in combination with BioRoot and guttapercha points.
10152720|NCT04072926|Active Comparator|PDT+/AH+|Photodynamic therapy will bi conducted with diode laser (660nm, 100mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with AH+ epoxy based cement in combination with guttapercha points.
9669673|NCT03386942|Experimental|MORAb-202|"Part 1 (Dose-escalation): The initial dose level of MORAb-202 will be 0.3 milligrams per kilogram (mg/kg) every 3 weeks in the first cohort with 1 participant for dose-limiting toxicity (DLT) evaluation. DLTs will be evaluated in successive dose level cohorts with a single participant until a drug-related Grade 2 or higher toxicity is observed. If such a toxicity is observed, the cohort will be expanded to enroll a total of 3 participants.~Part 2 (Treatment Phase): MORAb-202 will be administered every 3 weeks during the treatment phase at the dose determined in Part 1 until participants meet any of the criteria for discontinuation. Criteria for discontinuation include: withdrawal of consent, major protocol violations, unable to continue due to adverse events, pregnancy, progressive disease, Investigator decision, or infusion reactions."
9972225|NCT01318681|Experimental|Pollen provocation with systemic treatment|Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution
10152721|NCT04072926|Active Comparator|PUI/AH+|This arm will only get PUI (passive ultrasound irrigation) in combination with AH+ epoxy based cement and guttapercha points.
9519947|NCT03282032|Experimental|One-lung ventilation|Before surgical incision, 2-min of OLV followed by 2-min of TLV (1 cycle) is performed for 5 cycles.
9519948|NCT03282032|No Intervention|Two-lung ventilation|Maintain two-lung ventilation until surgical incision
10152722|NCT04072796||Case group|Case group reported urinary complaints
10152723|NCT04072796||Control group|Control group did not have any urinary complaints.
10152724|NCT04072692|No Intervention|1st part: The gliding properties of the tendons|No intervention. Subjects are measured by ultrasound under 5 different postures of the hand for forty minutes.
10152725|NCT04072692|No Intervention|1st part: The gliding properties of the median nerve|No intervention. Subjects are measured by ultrasound under under 6 different postures of the wrist and hand and 5 different movement patterns of the wrist and hand for forty minutes.
10152726|NCT04072692|Experimental|2nd part: New hybrid rehabilitation strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times hybrid rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
10152727|NCT04072692|Experimental|2nd part: Traditional strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.~For post-test, the same procedure is repeated again after completing all training.~For follow-up, the same procedure is repeated again 6 months after completing all training.~After pre-test, 8 times traditional rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
10152728|NCT04072692|No Intervention|3rd part: The effect of carpal tunnel release|"No intervention. The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~For post-test, subjects perform the functional assessment of both hands one week after carpal tunnel release surgery. It takes 20 minutes.~For first follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands two month after carpal tunnel release surgery. It takes 40 minutes."
10152729|NCT04072692|Experimental|3rd part: Wearable anti-bowstringing orthosis (WABO)|"The program includes pre-test, post-test and two times follow-up tests.~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.~Subjects wear WABO in the morning and a splint at night within a week after carpal tunnel release surgery.~For post-test, subjects perform the functional assessment of both hands with and without wearing WABO and a splint one week after carpal tunnel release surgery. It takes 40 minutes.~From the third weeks after carpal tunnel release surgery, subjects wear WABO only in the morning.~For first follow-up, the same procedure in pre-test is repeated again one month after carpal tunnel release surgery. It takes 40 minutes.~For second follow-up, the same procedure in pre-test is repeated again two month after carpal tunnel release surgery."
9519949|NCT03282019|Experimental|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
9519950|NCT03282019|Active Comparator|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
9519951|NCT03282006|Experimental|Pivmecillinam|Patients treated with pivmecillinam
9519952|NCT03281993||CPAP-AT|After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.
9519953|NCT03281980|Experimental|Intervention (UCT+HE+PS)|The participants of this arm will receive UCT and HE along with psychosocial stimulation (PS)
9519954|NCT03281980|Sham Comparator|Government Intervention (UCT+HE)|The participants of this arm will receive only UCT and HE
9519955|NCT03281980|No Intervention|Comparison|
9519956|NCT03281967|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
10152730|NCT04072874|Active Comparator|Régimen 1|"Regimen 1: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 4 weeks.~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
10152731|NCT04072874|Active Comparator|Régimen 2|"Regimen 2: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 6 weeks.~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
9972226|NCT01318681|Experimental|Pollen provocation with topical treatment|treatment with 25ug fluticasone furoate after a nasal pollen challenge
9972227|NCT01318681|Placebo Comparator|placebo treatment after pollen challenge|Placebo treatment after a nasal challenge with pollen solution
10152732|NCT04072718|Other|Single arm|
10152733|NCT04072653|Experimental|Observation group( SLNB is spared)|In the second stage, sentinel lymph node biopsy will be spared in the patients with negative preoperative axillary assessment.
10152734|NCT04072640|Experimental|voriconazole treatment|induction treatment with Voriconazole 200mg bid (IV) + 5FC (100mg/kg/d) for 14 days, consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
10152735|NCT04072640|Active Comparator|amphotericin treatment (0.7-1.0mg/kg/d)|Induction treatment with amphotericin B 0.7-1.0mg/kg/d + 5FC (100mg/kg/d) for 14 days,consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
10152736|NCT04072640|Experimental|amphotericin B treatment (0.4-0.5mg/kg/d)|Induction treatment with amphotericin B 0.4-0.5mg/kg/d + 5FC (100mg/kg/d) for 28 days, consolidation treatment with fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
10152737|NCT04073017|Experimental|Enterade|Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
10152738|NCT04073017|Experimental|Experimental|Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
10152739|NCT04072770|Experimental|Pea|Mashed potatoes meal containing pea protein isolate intrinsically labelled with 15N and 2H
10152740|NCT04072770|Active Comparator|Casein|Mashed potatoes meal containing casein isolate intrinsically labelled with 15N and 2H
10152741|NCT04072913|Other|Control group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
10152742|NCT04072913|Other|Low grade lesion group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
10152743|NCT04072913|Other|High grade lesions group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
10152744|NCT04072913|Other|Cancer group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
10152745|NCT04072965|Experimental|Cross eduacation of balance|10 females with Chronic Ankle Instability will receive balance training for the non affected side for a six weeks
10152746|NCT04072965|Experimental|Traditional training|10 females with Chronic Ankle Instability will receive balance training for the affected side for a six weeks
10152747|NCT04072965|No Intervention|control|balance of 15 females with Chronic Ankle Instability will be assessed before and after six weeks of no intervention
9972228|NCT01318681|No Intervention|control condition|A placebo drug is administered after a sham nasal challenge with a pollen solution
10152748|NCT04072679|Experimental|Sintilimab+IBI305|Sintilimab: 200mg (D1, q3w） IBI305: 7.5mg/kg or 15mg/kg (D1, q3w）
10152749|NCT04072900|Experimental|Intervention/Treatment|"Personalized NeoAntigen Cancer Vaccine- Neo-Vac-Mn (peptides + rhGM-CSF+anti-PD1+Imiquimod 5% Topical Cream)~NeoAntigen peptides:4 x 2 mg the total peptides given on days 84，87，91，98，105，133，and 161~Anti-PD-1 Toripalimab: 3mg/kg, ivgtt, Q2w~rhGM-CSF: 3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160~Imiquimod 5% Topical Cream:topical application on the injection site 6 hours before each NeoAntigen peptides injection"
10152750|NCT04072666|Experimental|ASSIP plus SPP|Participants in the ASSIP group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the ASSIP psychological intervention where they will receive three therapy sessions followed by regular ongoing contact through individually focused letters sent over 24 months.
9972229|NCT01318720|Experimental|Manipulation|The experimental group is receiving thoracic spine thrust manipulation and cervical spine non-thrust manipulation.
9972230|NCT01318746||Healthy group|15 persons with normal renal function
9972231|NCT01318746||Renal failure|15 persons with renal failure (GFR < 60 ml/min)
9972232|NCT01318772||Fluoroscopy and Angiography Procedure|Patient that have been scheduled for routine diagnostic fluoroscopy and angiography procedures by their physician.
9972233|NCT01318785|Active Comparator|Compression ArmsleevesType A|Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387
9972234|NCT01318785|Active Comparator|Compression Armsleeves Type B|Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387
9977205|NCT01359189|Experimental|Suspected Primary Prostate Cancer|Patients with suspected prostate cancer will be evaluated for initial proof of concept and feasibility of a scintigraphic rectal probe (ProxiScanTM) utilizing a PSMA receptor radiopharmaceutical (ProstaScint®). To explore the adjunctive benefit/feasibility of PSMA distribution in the normal prostate versus prostate cancer gland utilizing TRUS and CT/SPECT hybrid imaging, biopsy negative patients will be considered as normal controls. This is an exploratory, open label trial and randomization is not required. Subject blinding is not needed and investigator blinding in not possible.
9977206|NCT01359202|Active Comparator|Niastase RT|Niastase RT 80ug/kg IV bolus
9977207|NCT01359202|Placebo Comparator|Placebo|saline IV bolus
10152751|NCT04072666|Experimental|CBT plus SPP|Participants in the CBT group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the CBT psychological intervention where they will receive five CBT 60-minute individual sessions.
10185643|NCT03743675|Experimental|Diet Plus Exercise|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period. They will simultaneously undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
10152752|NCT04072666|Active Comparator|SPP alone|"The Suicide Prevention Pathway (SPP) comprises seven steps:~i) Initial screening - persons experiencing suicide ideation and who may also have a history of, or recent, suicide attempt, are placed on the pathway; ii) Assessment of suicide risk iii) Formulation of suicide risk (based on a prevention oriented approach) iv) Safety planning (collaboratively developed with the client) and Counselling on access to lethal means v) Structured follow-up (within 24-48 hrs); vi) Transition of care plan; and vii) Caring contacts - ongoing contact/support for the person for the next 2 years (through personalised letters or phone texts)."
10152753|NCT04072731||thyroid cancer|the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.
9669674|NCT03363893|Experimental|Module 1 Part A|Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). This module includes a cohort expansion of participants with breast cancer who provide paired biopsy samples.
9669675|NCT03363893|Experimental|Module 1 Part B|"Participants with advanced solid tumours that may include, but is not limited to, triple negative breast cancer (TNBC), castrate-resistant prostate cancer (CRPC), small cell lung cancer (SCLC) or ovarian cancer, will receive CT7001 (samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.~To date Module 1 Part B Arm has recruited a cohort of CRPC participants."
10152754|NCT04072731||the adjacent thyroid tissues|the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.
9977208|NCT01359215||Treatment|Children who received an anesthetic prior to age 2
10152755|NCT04072978||Intraocular lens implantation: AC IOL|"Patients who are scheduled to undergo AC IOL (anterior chamber intraocular lens) implantation for any of the following indications:~primary or secondary aphakia~primary or secondary lens subluxation or dislocation"
10152756|NCT04072978||Intraocular lens implantation: SF IOL|"Patients who are scheduled to undergo SF IOL (scleral fixated intraocular lens) implantation for any of the following indications:~primary or secondary aphakia~primary or secondary lens subluxation or dislocation"
9826298|NCT02413996|Experimental|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS) in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
10152757|NCT04072939||Single arm|dilated fundus exam
10152758|NCT04072757|Active Comparator|Intervention Group|The cooking skill building/nutrition education workshops will be led by a multidisciplinary team comprised of: a chef/instructor, a nutritionist and/or registered dietitian, MD and/or Preventive Medicine Resident, and Yale-Griffin Prevention Research Center staff. The cooking/nutrition education workshop sessions will be approximately 45 minutes and will: include a plant forward approach to healthy eating; integrate nutrition and health-related information and cooking instruction (i.e. knife skills, equipment use); show participants how to prepare meals that are simple, nutritious, affordable, and delicious; provide recipes and nutrition information aimed at improving dietary intake and health status; and provide an enjoyable program that participants will look forward to attending. Fruit and vegetable prescription vouchers will be redeemed at ShopRite grocery stores (Ansonia and Shelton locations) and Griffin Hospital's farmers market, where redemption will be tracked.
10152759|NCT04072757|Placebo Comparator|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
10152760|NCT04072705||1. Poor and intermediate metabolizer group|Poor and intermediate metabolizer group: acute ischemic stroke patients with poor and intermediate metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
10152761|NCT04072705||2. Extensive metabolizer group|Extensive metabolizer group: acute ischemic stroke patients with Extensive metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
10185644|NCT03743675|No Intervention|Control|Subjects in this group will be asked to maintain their habitual physical activity, and will received counseling regarding a healthy, weight-maintenance diet.
10185645|NCT03743649|Experimental|Group I (haloperidol, placebo)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
10185646|NCT03743649|Experimental|Group II (lorazepam, placebo)|Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
10185647|NCT03743649|Experimental|Group III (haloperidol, lorazepam)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.
10185648|NCT03743649|Experimental|Group IV (placebo, lorazepam)|Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.
10185649|NCT03743623|Experimental|Treatment Group|Study treatment with Neurocytotron, which is a device is designed to generate a controlled beam of electromagnetic waves of certain frequencies in the presence of a magnetic field with pre-determined strength.
10185650|NCT03743623|Placebo Comparator|Placebo Group|The placebo control is a mock treatment in which a subject will go through the same procedures as subjects assigned to the treatment group, only without being actually exposed to electromagnetic waves and magnetic fields.
9669676|NCT03363893|Experimental|Module 1 Part B-1 TNBC Expansion|Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
9826299|NCT02413996|Active Comparator|traditional rehabilitation|exercise therapy through a traditional rehabilitation training in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
9826300|NCT02414204|Active Comparator|Sildenafil|20 mg twice a day orally
9977209|NCT01359215||Control|Children who have never been anesthetized
10152762|NCT04072601|Experimental|Atorvastatin|Atorvastatin 10-20 mg for 18 months of treatment. Start dose is 10 mg, adjusted to 20 mg after 15-30 days if no sideeffects occurs.
10152763|NCT04072601|Placebo Comparator|Control|Placebo of atorvastatin 10 mg, 1-2 tablets for 18 months of treatment. Start dose is 1 tablet (10 mg placebo), adjusted to 2 tablets (20 mg placebo) after 15-30 days if no side effects occurs.
10152764|NCT04072562|Experimental|AZD7594 0.7 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 0.7 mg, delivered dose 1 inhalation
10152765|NCT04072562|Experimental|AZD7594 1.6 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 1.6 mg, delivered dose 1 inhalation
10152766|NCT04072562|Active Comparator|AZD7594 720 μg|The study subjects will receive AZD7594 via DPI: 0.72 mg, delivered dose (792 µg nominal dose) 1 inhalation
10152767|NCT04072484|No Intervention|Room Air|The reduced oxygen breathing device will be set to deliver room air. (i.e., no oxygen is removed from the gas mixture. The subject will perform CPR while breathing through mask and tubing that is connected to the device.
10152768|NCT04072484|Experimental|Hypoxia|The reduced oxygen breathing device will be set to deliver a gas mixture with15% oxygen. (Equivalent to the partial pressure of oxygen at 2,438 meters.) The subject will perform CPR while breathing through mask and tubing that is connected to the device.
10152769|NCT04072536|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
10152770|NCT04072536|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
9669677|NCT03363893|Experimental|Module 2 Part A|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.
10152771|NCT04072406|Active Comparator|Arm I: Usual Care|"Participants assigned to usual care will receive a packet of instructions with information about how to complete weekly surveys via a link that will be emailed to them~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
10152772|NCT04072406|Experimental|Arm II: Mindfulness Meditation|"Participants will listen to mindfulness meditations daily over the course of three weeks.~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
10152773|NCT04072315|Experimental|PLN-74809 Dose Level 1|PLN-74809 Dose Level 1
10152774|NCT04072315|Experimental|PLN-74809 Dose Level 2|PLN-74809 Dose Level 2
10152775|NCT04072315|Experimental|PLN-74809 Dose Level 3|PLN-74809 Dose Level 3
10152776|NCT04072315|Experimental|PLN-74809 Dose Level 4|PLN-74809 Dose Level 4
9977210|NCT01359228|Experimental|Rifaximin|rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
10152777|NCT04072341|Experimental|Propolis Period|Hemodialysis patients will be under regular treatment of their comorbidities and using Propolis.
10152778|NCT04072341|Experimental|Control Period|Hemodialysis patients will be under regular treatment of their comorbidities, but without using Propolis.
10152779|NCT04072497|Experimental|Zoster vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
10152780|NCT04072497|Active Comparator|Varicella vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=3.3 LgPFU per dose)
10152781|NCT04072497|Placebo Comparator|Placebo|Placebo with no live virus
10152782|NCT04072263|Experimental|Cohort 1|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x."
10152783|NCT04072263|Experimental|Cohort 2|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x, plus~Interferon Alpha 2A (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total."
9669678|NCT03363893|Experimental|Module 2 Part B|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will be randomized to receive CT7001 (samuraciclib) or matching placebo as oral monotherapy at the dose determined in Module 2 Part A, in combination with fulvestrant.
9669679|NCT03363893|Experimental|Module 2 Part C|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer who were enrolled to the placebo arm in Module 2 Part B will, on progression of disease, receive CT7001 (samuraciclib) oral monotherapy in combination with fulvestrant.
9977211|NCT01359228|Placebo Comparator|sugar pill|Placebo 1 tablet three times a day for 14 days.
10152784|NCT04072211|Other|Vaccine arm|Engerix-B vaccine will be administered. This arm will include all those at risk of hepatitis B virus infection
10152785|NCT04072471||Zurampic®|Patients exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) (lesinurad+XOI)
10152786|NCT04072471||Control group: xanthine oxidase inhibitor monotherapy|Patients exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat).
10152787|NCT04072510|Experimental|Case: Self-esteem group + Treatment as Usual|"Self-esteem group is based on a cognitive behavioral model of low self-esteem addressing thoughts, feelings and behaviour. The self-esteem group is designed to be administered in 6 weekly sessions.~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.Treatment as usual occurred alongside the self-esteem group."
10152788|NCT04072510|Active Comparator|Control: Treatment as Usual Only|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
10185651|NCT03743597|Experimental|SOCKNLEG|"Group of participant who will conduct the examinations first with the SOCKNLEG compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
9972235|NCT01318798||Patients with post-operative ARF|"Patients developing acute renal failure (ARF) following liver surgery~ARF was defined according to the RIFLE criteria as an absolute increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more than 1.5 times the pre-operative baseline value within 48 hours after surgery, or a reduction of urinary output less than 0.5 ml/kg/h for at least 6 hrs."
9669680|NCT03363893|Experimental|Module 4|Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
9669681|NCT03363893|Experimental|Module 6|Participants with advanced solid malignancies will receive CT7001 (samuraciclib) and a new enteric capsule CT7001 (EC) (samuraciclib) oral monotherapy in a randomized, single blind, balanced, two treatment two period, two sequence crossover with one wash out period in between, followed by once daily continuous dosing.
9669682|NCT03287778|Active Comparator|Pyridoxine|Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.
9669683|NCT03287778|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
9669684|NCT03277170|Experimental|High-dose Montelukast Oral Granules|30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
9669685|NCT03277170|Placebo Comparator|Placebo|Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
9669686|NCT03271372|Experimental|Arm I (avelumab)|Patients receive avelumab IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
9826301|NCT02414204|Placebo Comparator|Placebo|Placebo twice a day orally
9669687|NCT03271372|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
9669688|NCT03253627|Experimental|MBSR|Mindfulness-Based Stress Reduction
9669689|NCT03253627|Active Comparator|HEP|Health Enhancement Program
9669690|NCT03249532|Active Comparator|standard hemodialysis|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
9669691|NCT03249532|Active Comparator|cool hemodialysis|prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
9669692|NCT03249532|Active Comparator|low volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
9669693|NCT03249532|Active Comparator|high volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
9669694|NCT03243786|Active Comparator|"12-week Stay on Track intervention"|The study intervention includes three personal exercise training sessions, three dietary counseling sessions, use of a physical activity tracking device, and approximately three weekly text messaging
9669695|NCT03243786|Active Comparator|12-week self-guided control|The self guided group does not receive the study intervention, but is offered a Nutrition and wellness guide at the end of 6 months
9669696|NCT03238196|Experimental|Escalation|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
9669697|NCT03238196|Experimental|Expansion|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
9669698|NCT03191916|Experimental|Experimental group|The experimental group will receive 2 milliamps of anodal transcranial direct current stimulation for 20 minutes daily for 5 days.
9669699|NCT03191916|Sham Comparator|Sham group|The sham group will be connected to the anodal transcranial direct current stimulation device daily for 5 days. During the 20 minute sessions, the participant will only receive stimulation for a 30-second ramp up period, at which point the stimulation will be discontinued for the remainder of the time.
9669700|NCT03187288|Experimental|CFI-400945|CFI-400945 will be given by mouth at 64,96,128,160,192 or 224 mg/day, everyday until intolerable side effects or disease progression.
9669701|NCT03106701|Experimental|Ablation|Radiofrequency epicardial ablation
9669702|NCT03055403|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
9826302|NCT02414243|Experimental|New Amino Acid formula|New Amino-Acid based Infant Formula
9669703|NCT03055403|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
9669704|NCT03042962||Patients with dystonia|Patients with dystonia (spasmodic dysphonia, singer's dystonia, writer's cramp, musician's focal hand dystonia) will undergo MRI of the brain and blood draw.
9972236|NCT01318798||Patients without post-operative ARF|Patients with normal kidney function (without acute renal failure (ARF)) following liver surgery
9826303|NCT02414243|Active Comparator|Control formula|Commercially available Amino Acid Formula
9826304|NCT02414633||Humira|Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
9826305|NCT02414828|Placebo Comparator|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
9826306|NCT02414828|Experimental|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
9972237|NCT01318824|Placebo Comparator|I=NIPPV|This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment.
9972238|NCT01318824|Experimental|II=BiPAP|This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
9972239|NCT01318837|Experimental|sofilenacin group|
9972240|NCT01318837|No Intervention|control group|age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once
9669705|NCT03042962||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
10152789|NCT04072549|Experimental|Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
10152790|NCT04072549|No Intervention|Comparison/Control|The children in the control group will be children enrolled in the same schools as those randomized to receive summer programming. The comparison/control group will not receive a voucher to attend a summer camp.
10152791|NCT04072419||enhanced recovery after surgery group|"weaning mechanical ventilation after surgery (less than 48h),~no post-operative chest tube and urinary catheterization)~Establishment of early feeding (D3 post-operative)"
10152792|NCT04072419||control group|"the time of mechanical ventilation after surgery is more than 48 hours~routine postoperative indwelling chest tube and urinary catheterization)~Establishment of feeding after D3 post-operative"
10152793|NCT04072367|Other|Active Treatment Group|NeVa Stent Retrievers
10152794|NCT04072367|Other|Control Device|Solitare Stent Retrievers
10152795|NCT04072185|Experimental|Physical activity group|
10152796|NCT04072185|No Intervention|Control group|
10152797|NCT04072146|Experimental|OC-01 (varenicline) nasal spray|
10152798|NCT04072146|Active Comparator|Chantix®|
10152799|NCT04072068|Experimental|Edoxaban|edoxaban 60 mg daily
10152800|NCT04072198|Experimental|FOLFOXIRI/Bevacizumab + Nivolumab|Bevacizumab 5 mg/m2 Nivolumab 240 mg Irinotecan 165 mg/m2 iv (max 8 cycles) Oxaliplatin + leucovorin 200 mg/m2 (max 8 cycles) Fluorouracil 3200 mg/m2 (max 8 cycles)
10152801|NCT04072094|Experimental|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
10152802|NCT04072094|Active Comparator|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
10152803|NCT04071886|Experimental|Mindfulness-Based Training|Participants in the Mindfulness-Based Training arm will receive 2 weeks of Mindfulness-Based Training for at least 30 minutes every day.
9972241|NCT01318850|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes and Reeder, 2005)
9972242|NCT01318850|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
9972243|NCT01318850|Other|Healthy Controls|Healthy controls
9972244|NCT01318889|Experimental|normal saline|mouth wash of normal saline ,three times a day, 10 cc each time
10152804|NCT04071886|Active Comparator|Relaxation Training|Participants in the Relaxation Training arm will receive 2 weeks of Relaxation Training for at least 30 minutes every day.
10152805|NCT04071834||Diabetes mellitus group|Diabetic patients undergoing spinal anesthesia for lower extremity surgery
10152806|NCT04071834||Non-diabetic group|Non-diabetic patients undergoing spinal anesthesia for lower extremity surgery
10152807|NCT04072172|Experimental|Female with leg spider veins|Females at the age of 20 to 45 not known diabetics or hypertensive complaining of leg spider veins.
9972245|NCT01318928|Placebo Comparator|Periodontal intervention, sugar pill|Group 1: metronidazole + mechanical treatment in one day, Group 2: Placebo + mechanical treatment in one day Group 3: metronidazole + mechanical treatment on day 1 and 21 Group 4: Placebo + mechanical treatment on day 1 and 21
10152808|NCT04072055||MOTO medial|Patients suitable fulfilling the standard criteria for the implantation of unicondylar implant.
10152809|NCT04072133|Experimental|Meditative Movement Intervention|Participants will complete the following components of baseline (T1) data collection: demographics, biometric measurements, a heart rate variability assessment, and questionnaires. Participants will be asked to provide six saliva samples via passive drool to measure cortisol levels. Participants will be assigned into hour-long meditative movement (MM) classes for eight weeks total. Participants will be asked to practice their MM skills at home for at least 30 minutes most days per week. The study will distribute hard-copy movement manuals and DVD instruction videos for guidance. Participants will be asked to provide a log of all dates and lengths of their at-home practice. After the eighth class, participants will return for post-intervention (T2) data collection, consisting of biometric measurements, a heart rate variability assessment, and questionnaires. Participants will provide six more saliva samples via passive drool method.
10152810|NCT04071795|Experimental|Opt Out|Training and Academic Detailing
10152811|NCT04071795|Experimental|Opt In|Training and Academic Detailing
10152812|NCT04072029||Cataract - FECD|Eyes with FECD undergoing cataract surgery
10152813|NCT04071951|Experimental|Pharmacist Arm|Pharmacist-Led Medication Reconciliation, Regimen Review, and Adherence and Literacy Assessment and Counseling
10152814|NCT04071951|No Intervention|Usual Care|Patients in this study will receive usual care. Clinically-indicated services, including pharmacist services, may be provided to control group patients.
9516838|NCT03311737|Active Comparator|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
9669706|NCT03029403|Experimental|Dose Escalation|Patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
9972246|NCT01318941||Ranibizumab|
9972247|NCT01318954||Subjects on allergen immunotherapy|Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved.
10152815|NCT04072003||IVUS-guided PCI|In this group, intravascular ultrasound(IVUS) in addition to coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
9669707|NCT03029403|Experimental|Dose Expansion - Cohort A|Patients with platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
9669708|NCT03029403|Experimental|Dose Expansion - Cohort B|Patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
9669709|NCT03029403|Experimental|Dose Expansion - Cohort C|Patients with recurrent advanced epithelial ovarian, fallopian tube and primary peritoneal patients with uncommon tumor histologies, including clear cell, mucinous and low grade serous or low grade endometrioid ovarian subtypes.
9669710|NCT02940288|Experimental|Intervention|Participants will be randomized to receive bilateral auricular acupuncture for postoperative pain.
10152816|NCT04072003||CAG-guided PCI|In this group, coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
10152817|NCT04071873|Experimental|Point-of-care HIV testing (intervention)|Participants will be offered voluntary point-of-care HIV testing during a traditional healer visit.
10152818|NCT04071873|Active Comparator|Education on community HIV resources (control)|Participants will be offered education regarding HIV testing and community resources during a traditional healer visit.
10152819|NCT04072081|Experimental|Drug-coated ballon|Treatment of in suit coronary lesions with drug-coated balloon
10152820|NCT04072081|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
9669711|NCT02940288|Sham Comparator|Control|Participants will be randomized to receive bilateral sham acupuncture.
10152821|NCT04071938|Active Comparator|Intervention group|"Physicians: 10 GPs from 10 practices who treat patient with Spinal cord injury (SCI) and 10 SCI specialists.~Patients: 270 people with SCI within 25 minutes vehicle driving distance to the GP practices will be in the intervention group"
10152822|NCT04071938|No Intervention|Control group|"Physicians: 20 GPs who treat patient with SCI will not receive any intervention. They will be completing the questionnaire (DOC) and assessed for satisfaction with collaboration with the SCI specialist.~Patients: 210 people with spinal cord injury outside the catchment area of the intervention group will be receiving usual care (no intervention)"
9669712|NCT02910726|Experimental|Sentinel Lymph Node Biopsy|This is a single-center clinical trial to evaluate non-inferiority of ICG-guided SLN biopsy compared with the gold standard TcL-guided SLN biopsy in pediatric patients with solid tumors. Each patient will undergo TcL, consistent with the standard of care, but the surgeon will be blinded to the results preoperatively. Intraoperatively, ICG injection and transdermal lymphography will be used to identify the draining nodal basin and the position of the sentinel nodes. ICG transdermal lymphography will be considered successful if SLNs can be visualized on near-infrared imaging. After the transdermal lymphography results have been recorded, the surgeon will be unblinded to the TcL mapping.
9669713|NCT02897479|Experimental|Savolitinib|Pulmonary Sarcomatoid Carcinomas
9972248|NCT01318980|Experimental|Period 1 Cohort 1 - GSK2190915 100mg|Period 1 - GSK2190915 100mg tablet.
10152823|NCT04071743|Active Comparator|Treatment|Treatment and Prevention with active gammacore device(vagus nerve stimulator)
10152824|NCT04071743|Sham Comparator|Sham|Treatment and Prevention with sham gammacore device(vagus nerve stimulator)
10152825|NCT04071990|Active Comparator|Family-based cognitive behavioral group therapy (FB-CBGT)|One family member of each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session.
10152826|NCT04071990|Placebo Comparator|Cognitive-behavioral group therapy (CBGT) without family|Each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session., without the involvement of family members.
10152827|NCT04071899||Patients|patients with RBD
10152828|NCT04071899||Bedpartners|Subjects which are the bedpartners of patients with RBD
10152829|NCT04071756|Experimental|Topical Tazarotene 0.1% Gel Plus BPS|"Pharmacy teaching call~DFCI approved teaching sheets will be provided~20% urea applied to the palms and soles in the morning + tazarotene 0.1% gel, applied to the palms and soles nightly"
10152830|NCT04071756|Placebo Comparator|Placebo Gel Plus BPS|"A substance that has no therapeutic effect, used as a control in testing new drugs~Pharmacy teaching call~DFCI approved teaching sheets will be provided~20% urea applied to the palms and soles in the morning with placebo gel applied in the evening."
10152831|NCT04071717|Experimental|NIRS group|Participants with obesity, 12 sessions of NIRS feedback
10152832|NCT04071717|Sham Comparator|Sham NIRS group|Participants with obesity, 12 sessions of sham NIRS feedback
10152833|NCT04071717|Other|Healthy control group|Healthy participants, 12 sessions of NIRS feedback
10152834|NCT04072328|Experimental|Propofol alone|Participants who receive propofol alone during sedative endoscopy.
10152835|NCT04072328|Active Comparator|Midazolam with propofol|Participants who receive midazolam + propofol during sedative endoscopy.
10152836|NCT04071600|Placebo Comparator|Placebo|Type two trauma patients randomly assigned to be administered the vehicle (water) with Kurve intranasal device once and followed for up to 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
10152837|NCT04071600|Active Comparator|Neuropeptide Y|The individuals in this arm will be randomly assigned to be administered intranasal NPY with Kurve intranasal device once and will be followed for at least 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
10152838|NCT04071600|No Intervention|Control|The individuals in this arm will be randomly assigned and treated the same as the other arms but with no intervention.
10152839|NCT04071964||Groupe 1|Patients with colorectal cancer undergoing resection with anastomosis
10152840|NCT04071964||Groupe 2|Patients with colorectal cancer undergoing resection without anastomosis (Abdominoperineal resection)
10152841|NCT04071964||Groupe 3|"Patients with rectal cancer without surgery (Watch and wait)"
10152842|NCT04071964||Groupe 4|Control group consisting of patients who do not have surgical pathologies of the colon and rectum
10152843|NCT04072302|Experimental|KAF156 800 mg pre-challenge|Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
10152844|NCT04072302|Placebo Comparator|Placebo 800 mg pre-challenge|Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
10152845|NCT04072302|Experimental|KAF156 800 mg post-challenge|Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
10152846|NCT04072302|Placebo Comparator|Placebo 800 mg post-challenge|Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
9669714|NCT02762669|No Intervention|Control (no oxytocin) + No recovery|A control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. No recovery time.
9826307|NCT02414828|Experimental|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
10152847|NCT04072302|Experimental|KAF156 300 mg post-challenge|Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
10152848|NCT04072302|Placebo Comparator|Placebo 300 mg post-challenge|Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
9972249|NCT01318980|Experimental|Period 1 Cohort 2 - GSK2190915 100mg plus microtracer|Period 1 - GSK2190915 100mg tablet plus [14C] radiolabelled GSK2190915 microtracer solution.
10152849|NCT04072302|Experimental|KAF156 100 mg post-challenge|Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
10152850|NCT04072302|Placebo Comparator|Placebo 100 mg post-challenge|Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
10152851|NCT04072302|Experimental|KAF156 20 mg post-challenge|Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
10152852|NCT04072302|Placebo Comparator|Placebo 20 mg post-challenge|Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
10152853|NCT04072302|Experimental|KAF156 50 mg post-challenge|Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
10152854|NCT04072302|Placebo Comparator|Placebo 50 mg post-challenge|Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
9669715|NCT02762669|Active Comparator|Continuous oxytocin + No recovery|10-5M oxytocin for 2 hours. No recovery time.
10152855|NCT04071509|Experimental|Percutaneous Lung Biopsy|
10152856|NCT04071665|Experimental|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion for treatment of scoliosis
9516839|NCT03311711|Experimental|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
9669716|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes.
9972250|NCT01318980|Experimental|Period 2 GSK2190915 100mg to proximal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule.
9972251|NCT01318980|Experimental|Period 3 GSK2190915 100 mg to distal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule.
9972252|NCT01318980|Experimental|Period 4 - GSK 100mg enteric-coated tablet|100mg enteric-coated GSK2190915 coated tablet.
9972253|NCT01318993|Experimental|GSK1605786A|500 milligrams twice daily
9972254|NCT01319006|Experimental|GSK1278863A 100mg (X90=13um)|single dose
9972255|NCT01319006|Experimental|GSK1278863A 100mg (x90=29Um)|single dose
9972256|NCT01319006|Experimental|GSK1278863 100mg (X90=41um)|single dose
9972257|NCT01319019|Experimental|GSK961081 100 mcg QD|
9972258|NCT01319019|Experimental|GSK961081 100mcg BD|
9972259|NCT01319019|Experimental|GSK961081 200mcg QD|
9972260|NCT01319019|Experimental|GSK961081 400mcg QD|
9972261|NCT01319019|Experimental|GSK961081 400mcg BD|
9972262|NCT01319019|Experimental|GSK961081 800mcg QD|
9972263|NCT01319019|Active Comparator|Salmeterol 50mcg BD|
9972264|NCT01319019|Placebo Comparator|Placebo|
9972265|NCT01319032||I. Top-level swimmers|
9972266|NCT01319032||II. Control|Other swimmers
9972267|NCT01319058|Active Comparator|Electrocautery tonsillectomy|Children undergoing tonsillectomy and adenoidectomy for obstructive sleep apnea
9972268|NCT01319058|Active Comparator|Debrider tonsillotomy|Children undergoing debrider tonsillotomy + adenoidectomy for obstructive sleep apnea.
10152857|NCT04071665|Active Comparator|transforaminal lumbar interbody fusion|transforaminal lumbar interbody fusion
10152858|NCT04071691||Active LVV|Patients with active LVV
10152859|NCT04071691||Stable LVV|Patients with inactive LVV
10152860|NCT04071769|Experimental|Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
10152861|NCT04071821|Experimental|A: Test under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
10152862|NCT04071821|Active Comparator|B: Reference under Fasted Condition|Reference: Single oral dose of cetirizine HCl oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
10152863|NCT04071821|Experimental|C: Test under Fed Condition|Test: Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
10152864|NCT04071821|Experimental|D: Test under Fasted Condition with No Water|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with no water, under fasted conditions
10152865|NCT04071821|Experimental|E: Test Swallowed Whole with Water, under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
10152866|NCT04071678||A: Model A|Mode A was silent mode, back-to-back with endoscopic physicians to simultaneously display endoscopic images and record video, but did not interfere with the operation of endoscopic physicians.After the operation, the AI model automatically generates an endoscopy report, which is compared with the official report given by the endoscopy doctor in the endoscopy system. If the difference is large, video verification shall be played back immediately or endoscopic examination shall be performed again before the patient wakes up
10152867|NCT04071678||B: Model B|Mode B is a delayed reminder mode. If the lesion is found during the operation, it is required to be moved to the middle of the visual field within 5 seconds. If the lesion has been detected by the AI model (the lesion has been circled in the picture), but the doctor does not move the lesion to the middle of the visual field within 5 seconds, the AI system will give an alarm prompt
10152868|NCT04071678||C: Model C|Mode C is a real-time reminder mode, which is an alarm prompt when the focus is captured in the visual field.
10152869|NCT04071483|Experimental|Moderate stenosis|Moderate cervical neural foraminal stenosis is narrowest width of the neural foramen was >50% of the width of the width of the extraforaminal nerve root at the level of the anterior margin of the superior articular process.
10152870|NCT04071483|Active Comparator|Severe stenosis|Severe cervical neural foraminal stenosis is narrowest width of the neural foramen was ≤50% of the extraforaminal nerve root width
10152871|NCT04071639|Experimental|Group 1|Mild to moderate HD patients receive medicine treatment with different doses of Deutetrabenazine(Austedo), Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Zoloft should be taken 50mg once in the morning and Risperidone 1mg once at night. Deutetrabenazine(Austedo) should be taken 6mg once a day, or increase dose according to AUSTEDO® tablets Prescribing Information. Idebenone should be taken 30mg three times a day. Study drug can be taken irrespective of meals. Duration:5 years.
10152872|NCT04071639|Experimental|Group 2|Mild to moderate HD patients receive medicine treatment with different doses of Haloperidol, Risperidone, Zoloft+Idebenone, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Haloperidol should be taken 0.5mg~1mg three times a day. The administration of Zoloft, Risperidone and Idebenone are same as group 1. Study drug can be taken irrespective of meals. Duration:5 years.
10152873|NCT04071574|Active Comparator|"Protocol A"|"Protocol with gonadotropins alone without agonist or antagonist:~Gonadotropin treatment begins after spontaneous menses. The gonadotropins (e.g. Menopur, 150-225IU) are injected daily from D2/3 of the cycle (Gonadotropin dose varies based on the follicular response). The moment to trigger ovulation by administration of HCG (e.g. Ovitrelle or Pregnyl, 10.000IU) is determined by monitoring ovulation (folliculogenesis) approximately 14 days after gonadotropins regimen and the presence of at least 3 follicles with 18 mm sizes and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
10152874|NCT04071574|Active Comparator|"Protocol B"|"Short GnRH agonist protocol:~For the short GnRH agonist protocol, the administration of gonadotropins begins at the same time as that of the agonist, which makes it possible to take advantage of the action of endogenous gonadotropins released by the flare-up effect of the agonist. A low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg/day)) is administered in parallel to gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
10152875|NCT04071574|Active Comparator|"Protocol C"|"Multiple-dose antagonist protocol:~For the GnRH antagonist protocol, a low dose of GnRH antagonist (0.25 mg/day) is administered. The protocol starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU). 36 h after HCG triggering, the mature oocytes are retrieved."
10152876|NCT04071574|Active Comparator|"Protocol D"|"Long GnRH agonist protocol:~For the long GnRH agonist protocol, a low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg)) is administered on cycle-day 21 followed by gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 after menses (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm. 36 h after HCG triggering, the mature oocytes are retrieved."
9519957|NCT03281954|Placebo Comparator|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
9519958|NCT03281954|Experimental|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
9669717|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes.
9826308|NCT02414828|Experimental|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
9516840|NCT03311711|Experimental|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
9516841|NCT03311711|Active Comparator|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
9519959|NCT03281941|Other|Patients without BT|
10152877|NCT04071574|Active Comparator|"Protocol E"|"Combined GnRH antagonist and agonist protocol:~For the combined protocol, it starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till GnRH agonist injection (e.g., triptorelin (Decapeptyl 0.1mg/day)). 36 h after agonist injection, the mature oocytes are retrieved."
10152878|NCT04071561||Non-conversion|In 13 patients, 14 posterior retroperitoneal adrenalectomy procedures were successfully completed and form the non-conversion group
10152879|NCT04071561||Conversion|Conversion to lateral transperitoneal adrenalectomy was necessary in 1 patient after starting posterior retroperitoneal adrenalectomy.
10152880|NCT04071730|Experimental|Immulina Dietary Supplementation|Immulina Dietary Supplementation - 200 mg capsules; 800 mg/day; 2 (200 mg) capsules given by mouth in the morning and 2 (200 mg) capsules given by mouth in the evening for 4 weeks duration
10152881|NCT04071730|Placebo Comparator|Placebo|Placebo - inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 4 weeks duration
10152882|NCT04071522||LBP|110 literate Turkish speaking patients suffering from low back pain (LBP) for over 3 months, within the age range 18-65 were included in the study.
9669718|NCT02762669|Active Comparator|Control (no oxytocin) + No recovery + 10-7 oxytocin|A second control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. After 2 hours, the solution will be drained from the organ baths, and replaced with fresh PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
9669719|NCT02762669|Active Comparator|Continuous oxytocin + No recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
10152883|NCT04071548|Experimental|HIIT Exercise|All individuals recruited in exercise portion will be on an active exercise intervention
10152884|NCT04071444|Experimental|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
9826309|NCT02414841|Active Comparator|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
10152885|NCT04071444|No Intervention|Control group|The control group (CG) received routine care.
10152886|NCT04071431|No Intervention|Control|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
10152887|NCT04071431|Experimental|Risk shown|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are known by the endoscopists before and during the endoscopy."
10152888|NCT04071418||I-125 Seeds Implantation|All the enrolled patients were treated with CT-guided radioactive I-125 seeds implantation assisted by 3D printing template. Prescription dose 140-160gy.
10152889|NCT04071262|Experimental|Abemaciclib + Abiraterone Acetate + Prednisolone|Abemaciclib, abiraterone acetate and prednisolone given orally.
10152890|NCT04071210|Experimental|Experimental|Probiotic tablets (containing a mix of Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307, 1*10(9) CFU) 2 times/day for 12 weeks
10152891|NCT04071210|Placebo Comparator|Placebo Comparator|Placebo tablets 2 times/day for 12 weeks
10152892|NCT04071197|Experimental|Gastrostomy-biliary tube|The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
10152893|NCT04071197|Experimental|Other biliary diversion modalities|The control group will include those cases with other modalities of therapy as external biliary diversion, internal biliary diversion, and nasobiliary tube
10152894|NCT04071353||Interferon combined with ribavirin group|Interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) in patients with chronic hepatitis C, collect basic data before antiviral therapy, and during the PR antiretroviral treatment period, Follow-up was performed every 3-6 months in March, June, September, December, DAAs antiviral treatment during January, March, and withdrawal follow-up, and clinical biochemistry, HCV RNA, and serological markers were used during follow-up ( anti-HCV), AFP and liver imaging (liver ultrasound) examination.
9519960|NCT03281941|Other|Post BT|
9826310|NCT02414841|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation
9826311|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 200 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
10152895|NCT04071353||DAAs treatment group|Patients with chronic hepatitis C treated with direct acting antivirals (DAAs), collect basic data before antiviral therapy, and during the period of PR antiviral treatment, January, March, June, September, December Follow-up was performed every 3-6 months during January, March, and withdrawal follow-up during DAAs antiviral therapy. Clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP, and liver imaging were performed at follow-up. Liver ultrasound) check.
10152896|NCT04071327||Pulmonary arterial hypertension (PAH)|Patients with newly diagnosed or established PAH, within 6 months of first outpatient visit to a PH Care Center
10152897|NCT04071327||Chronic thromboembolic pulmonary hypertension (CTEPH)|Patients with newly diagnosed or established CTEPH, within 6 months of first outpatient visit to a PH Care Center
10152898|NCT04071327||Group 3 PH due to Developmental Lung Disease|Pediatric patients with newly diagnosed or established Group 3 PH due to developmental lung disease, within 6 months of first outpatient visit to a PH Care Center.
9669720|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
9669721|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
10152899|NCT04071093|Other|Telemonitoring|
10152900|NCT04071093|No Intervention|Usual Care|
10152901|NCT04071314||Cystic fibrosis|Children diagnosed with cystic fibrosis. Children aged between 0 and 18 years.
9972269|NCT01319058|Active Comparator|Laser tonsillotomy|Children undergoing laser tonsillotomy + adenoidectomy for obstructive sleep apnea.
9972270|NCT01319071||Top-level athletes|
10152902|NCT04071314||Hirschsprung's disease|Children diagnosed with Hirschsprung's disease. Children aged between 0 and 18 years.
10152903|NCT04071314||Obstructive sleep apnoea|Children diagnosed with obstructive sleep apnoea. Children aged between 0 and 18 years.
9972271|NCT01319071||Control group|
9669722|NCT02759458|Experimental|Healicoil|Patients that met the inclusion criteria who were randomly selected to receive the Healicoil anchor for their rotator cuff repair.
10152904|NCT04071314||Healthy controls|Children free of any chronic health condition. Children aged between 0 and 18 years.
9669723|NCT02759458|Active Comparator|Twinfix|Patients that met the inclusion criteria who were randomly selected to not receive the Healicoil anchor for their rotator cuff repair.
10152905|NCT04071275|Active Comparator|Mirror therapy|Subjects will be asked to perform specific movements (using the unaffected limb while watching its mirrored reflection for 20 minutes per day, for 10 treatment days, completed during two weeks (every weekday, excluding weekends)
10152906|NCT04071275|Sham Comparator|Mirror therapy + sham tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, a sham tDCS treatment will be applied.
9669724|NCT02755103|Experimental|Women receiving MBRP plus TAU|Women will receive the Mindfulness Based Relapse Prevention (MBRP) plus treatment as usual (TAU less trauma focused group).
9669725|NCT02755103|No Intervention|Women receiving TAU|Women will only receive treatment as usual (TAU less trauma focused group).
10152907|NCT04071275|Experimental|Mirror therapy + active tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, an active tDCS treatment will be applied.
10152908|NCT04071054||Hemodialysis patients|
10152909|NCT04071080|Experimental|100mg Fluorescein disodium|100mg Fluorescein disodium will be mixed with 500mL of Gatorade and taken orally by the participant
10152910|NCT04071080|Placebo Comparator|Placebo|500mL of Gatorade taken orally by the participant
10152911|NCT04070924|Active Comparator|Conventional post-operative bulky soft tissue dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal~Postoperative: Non-opioid medications only; Conventional post-operative bulky soft tissue dressing (Xeroform, 4x4s, Webril, Ace Wrap; Worn until first postoperative visit)"
10152912|NCT04070924|Experimental|Bandaid post-operative dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal~Postoperative: Non-opioid medications only; Bandaid over incision (Patient given an edema glove to wear starting post-operative day 1; Dressing change be changed post-operative day 2 and as needed after that)"
10152913|NCT04070950||Single group|Interview of patients with cancer of the cervix or uterine body, or ovary between the time of diagnosis and 3 months after the end of their last cancer treatment (not the object of the study).
10152914|NCT04070976|Active Comparator|Standard treatment|Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A.
10152915|NCT04070976|Experimental|Experimental treatment|Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.
10152916|NCT04071106|Active Comparator|Turmeric Extract group|10 psoriasis patients receiving turmeric based ointment levigated in glycerin twice daily and assessed for response and side effects weekly for 12 weeks
9669726|NCT02731508|Experimental|True stimulation|True repetitive bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, daily 20 minutes for 20 sessions
9669727|NCT02731508|Sham Comparator|Sham stimulation|Repetitive bihemispheric transcranial direct current stimulation, as the experimental stimulation condition but only for 120 seconds
9972272|NCT01319084||ARMES group|Surgeons who watch Tilepro program before da Vinci Robotic Surgery.
9972273|NCT01319084||normal group|Surgeons who do not watch Tilepro program before da Vinci Robotic Surgery.
9972274|NCT01319097|Other|Sorbion Sachet S|Subject will evaluate Sorbion Sachet S dressing for 4 weeks.
9972275|NCT01319123|Other|wound dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers.
9669728|NCT02716948|Experimental|Treatment (nivolumab, stereotactic radiosurgery)|Patients receive nivolumab IV over 60 minutes on day 1. Patients then undergo stereotactic radiosurgery on day 8 per standard of care. Courses with nivolumab repeats every 14 days in the absence of disease progression or unacceptable toxicity.
9972276|NCT01319149||No treatment|Patient records would be extracted from the electronic health record system of Southwest Regional Wound Care Center and placed in a separate bin.
10152917|NCT04071106|Active Comparator|Turmeric extract + olive oil group|10 psoriasis patients receiving turmeric extract levigated in olive oil instead of glycerin. The ointment will be applied twice daily for 12 weeks & will be assessed weekly
10152918|NCT04071106|Placebo Comparator|Petrolatum group|10 Psoriasis patients will receive the base of the therapeutic ointment which is the petrolatum. Patients will apply it twice daily and will be assessed weekly clinically and dermoscopically for 12 weeks
10152919|NCT04071106|Active Comparator|NBUVB group|10 Psoriasis patients will receive two sessions of NBUVB weekly for 12 weeks and will be assessed weekly clinically and with dermoscope.
10152920|NCT04071106|Active Comparator|Established ttt group|10 Psoriasis patients will receive topical betamethasone dipropionate or calcipotriol cream twice daily for 12 weeks and will be assessed on weekly basis clinically and by dermoscope
10152921|NCT04071184|Experimental|Dose cohorts|"Part 1 (dose escalation): 3+3 design will be used. Alofanib (dose levels of 50, 100, 165, 250, 350 mg/m2) will be given i.v. daily (1-5 days on, 6-7 days off, every week) till progression or unacceptable toxicity.~Part 2 (dose expansion): Afterwards the dosing regimen identified in Part 1 will be evaluated in a single-arm study focused on clinical efficacy."
10152922|NCT04071067||Emergency Clinical County Hospital Group|
10152923|NCT04071067||Municipal Clinical Hospital Group|
10152924|NCT04070911|Experimental|patients in the water group|water group: Patients in the water group were performed oral water after their accession to PACU.
10152925|NCT04070911|Experimental|patients in the ice group|ice group, Patients in the ice group were performed oral ice popsicle after their accession to PACU.
10152926|NCT04070911|No Intervention|no intervention group|control group, the control group patients have performed rutin treatment and care without any other intervention
10152927|NCT04071028|Active Comparator|Footbath group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes,"
10152928|NCT04071028|No Intervention|Control group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
10152929|NCT04070963||Cohort|We propose a prospective, observational single-centre pilot study in the PAC (SGH), on participants aged 21 years and above. A HbA1c test will be added to their routine preoperative blood tests. The incidence of newly-diagnosed DM/pre-diabetes (HbA1c ≥6.1%) and poorly controlled DM (HbA1c ≥ 8%), demographic details and presence of significant comorbidities will be analysed.
9669729|NCT02705924|Experimental|Psychoeducational intervention|group participating to the first psychoeducational intervention: it consists in a week-end session in a SPA center including several conferences about HBOC familial risk, cancer prevention, prophylactic possibilities (surgery), recommendations about nutrition and physical activity a risk modulators, assisted medical procreation and embryo selection, social support...). Besides conferences, Moreno role games and group sharing are organized under the supervision of a psychotherapist.
10152930|NCT04070742|Experimental|FMX-101|
10152931|NCT04070781|Experimental|Itacitinib + Tocilizumab|"A dose de-escalation design will be used to identify the MTD of both itacitinib and tocilizumab when given in combination. The following two levels will be tested with at least 6 patients per dose:~Dose level 1: Itacitinib 200 mg daily + tocilizumab 8mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Starting dose level~Dose level -1: Itacitinib 200 mg daily + tocilizumab 4mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Dose De-escalation level~Itacitinib will be given daily in 28-day long cycles, tocilizumab will be given every 4 weeks in 28-day cycles."
10152932|NCT04070781|Experimental|Dose Expansion|Once the MTD is determined, an additional 10 patients as an expansion cohort to further define the safety profile of the combination and estimate its response rate.
10152933|NCT04070755|Experimental|FMX-101|
10152934|NCT04070872|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
10152935|NCT04070872|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
10152936|NCT04070846|Experimental|[14C] LC350189|Single oral dose
10185652|NCT03743597|Active Comparator|Sigvaris COTTON|"Group of participant who will conduct the examinations first with the Sigvaris COTTON compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
10185653|NCT03743584|Experimental|Targeted temperature management at 33°C|Cooling and temperature control at 33°C, according to the study protocol of the TTM2-trial
9519961|NCT03281928|Experimental|Low Sodium plus Potassium Citrate|
9669730|NCT02705924|Other|Waiting list|delayed intervention: group participating to the second psychoeducational intervention (6 months later). Intervention is same as in the intervention arm but it is delayed. Because questionnaires are completed before this second intervention in both arms and allocation to arms are randomized, it represents an adequate control group.
9669731|NCT02681237|Experimental|Cediranib and Olaparib|"Cediranib will be given by mouth, at a dose of 20 mg, once a day, everyday.~Olaparib will given by mouth, at a dose of 300 mg, twice a day, every day."
9669732|NCT02604108|Experimental|Physical Exercise|Physical Exercise: Participants will receive training and health messages on positive psychology and healthy living style focusing on physical activity.
10185654|NCT03743584|Active Comparator|Standard care, early treatment of fever|Standard of care and normothermia. If temperature 37,8 °C or above use of device for temperature control.
10152937|NCT04071041|Experimental|Standard care plus albumin|"Patients will receive human albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.~Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team."
10152938|NCT04071041|No Intervention|Standard care alone|Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team.
10152939|NCT04071002|Active Comparator|surgical group|distal radius fractures that treated volar plate
10152940|NCT04071002|Active Comparator|conservative group|distal radius fractures that treated plaster of paris
10152941|NCT04071288||laparoscopic burch colposuspension|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing laparoscopic burch colposuspension
10152942|NCT04071288||mid urethral sling operations|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing mid-urethral sling operations
10152943|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fasting)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fasting condition
10152944|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fed)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fed condition
9669733|NCT02604108|Experimental|Healthy Diet|Healthy Diet: Participants will receive training and health messages on positive psychology and healthy living style focusing on healthy diet.
9669734|NCT02541435||conventional radiotherapy|450 breast cancer patients treated with conventional radiotherapy with or without anthracyclines and/or trastuzumab during 2007-2012
10152945|NCT04070833|Active Comparator|Vitamin D + fish oil|
10152946|NCT04070833|Active Comparator|Vitamin D + fish oil placebo|
10152947|NCT04070833|Active Comparator|Vitamin D placebo + fish oil|
10152948|NCT04070833|Placebo Comparator|Vitamin D placebo + fish oil placebo|
10152949|NCT04070677|Experimental|Ziverel arm|Patients included will receive treatment with ZIVEREL®, initially 10 mL every 8 hours, 30 minutes after meals, to avoid physical entrainment by food, during a minimum of 8 weeks, recruited during a period of 12 months. The treatment will be indicated when the patient develops a radiation-induced esophagitis of degree ≥ 2.
9669735|NCT02541435||breath controlled radiotherapy|350 breast cancer patients treated with laser assisted breath controlled radiotherapy with or without anthracyclines and/or trastuzumab during 2015-2017
10152950|NCT04070937||study group|all patients at least 18 years of age who present bilateral vestibulopathy on vestibular investigations according to the Barany criteria
9519962|NCT03281928|Placebo Comparator|Low Sodium plus placebo|
9972277|NCT01319162||Women with PCOS|All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
9519963|NCT03281928|Experimental|High Sodium plus Potassium Citrate|
9669736|NCT02541435||controls|per participating patient 2 age-matched female controls from the HUNT-3 population (total 800)
9669737|NCT02431897|Experimental|Estrogen Cream|
9669738|NCT02431897|Placebo Comparator|Placebo Cream|
9972278|NCT01319162||Women without PCOS|All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
10152951|NCT04070937||control group|DFNA9 patients carrying the p.P51S mutation in COCH gene presenting bilateral vestibulopathy according to the Barany criteria
10152952|NCT04070690|Other|Intervention-Control group|"In this group, the participants will receive intervention for 2 months first, followed by a wash-out period of 1 month and control for 2 months.~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients)."
10152953|NCT04070690|Other|Control-Intervention group|"In this group, the participants will receive control for 2 months first, followed by a wash-out period of 1 month and intervention for 2 months.~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients).~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements."
9972279|NCT01319175|Experimental|Training group|
9972280|NCT01319188|Active Comparator|0.5 mg of ranibizumab|
9972281|NCT01319188|Active Comparator|injection + photodynamic therapy|
9972282|NCT01319188|Sham Comparator|Sham injection|
9972283|NCT01319201||Impaired glucose regulation|This group of subjects was diagnosed as impaired glucose regulation using oral glucose tolerance test.
10152954|NCT04070625||Communication book group|Speech therapy with communication book
10152955|NCT04070625||Control group|Simple speech therapy
10152956|NCT04070586||4DCBCT images|4DCBCT images are acquired and assessed offline.
10152957|NCT04070729|Placebo Comparator|Negative control|Placebo gel
10152958|NCT04070729|Experimental|Test group 1|Hyaluronic acid gel
10152959|NCT04070729|Experimental|Test group 2|injectable prf
10152960|NCT04070716|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
10152961|NCT04070716|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
10185655|NCT03743571|Active Comparator|anodal tDCS during exposure|anodal transcranial direct current stimulation (2mA) will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
10185656|NCT03743571|Sham Comparator|sham tDCS during exposure|sham transcranial direct current stimulation will be applied over EEG coordinate FpZ during exposure therapy at a level that provides the physical sensations of tDCS but which is non-therapeutic
10185657|NCT03743558|Experimental|children with adenoamygdala hypertrophy|
10185658|NCT03743545|Active Comparator|conventional drilling with irrigation|
10185659|NCT03743545|Experimental|low speed without irrigation|
9972284|NCT01319201||Type 2 diabetes|This group of subjects was diagnosed as type 2 diabetes using oral glucose tolerance test.
9972285|NCT01319201||Normal glucose regulation|This group of subjects was considered normal regarding glucose metabolism using oral glucose tolerance test.
9972286|NCT01319214|Experimental|Inderal, neutral cues|
9972287|NCT01319214|Experimental|Inderal, drug cues|
9972288|NCT01319214|Experimental|Placebo, neutral cues|
9972289|NCT01319214|Experimental|Placebo, drug cues|
9972290|NCT01319227|Experimental|Hip Arthroplasty, ultra-short stem, conventional cup|Hip replacement with a hydroxy-apatite covered ultra-short uncemented femoral stem and a conventional uncemented acetabular cup with hydroxy-apatite covered porous coating and a moderately cross-linked polyethylene cup liner
9972291|NCT01319227|Experimental|Hip Arthroplasty, conventional stem, trabecular-titanium cup|Hip replacement with an uncemented tapered femoral stem and an uncemented acetabular cup with trabecular-Titanium backside and E-vitamin-treated polyethylene cup liner
9972292|NCT01319240|Experimental|IDegLira|
9972293|NCT01319240|Active Comparator|IDeg|
9972294|NCT01319240|Active Comparator|Lira|
10185660|NCT03743519|Placebo Comparator|Placebo|
10185661|NCT03743519|Experimental|Cherry juice|
10185662|NCT03743506|Experimental|Volunteers without motor abnormalities.|The test was performed in a single, 30-minute session. The test is divided into two phases, with feedback and no feedback from the system. The order of phases was randomized. In each phase the volunteer will remain balanced on the wobble board for 15 seconds under the conditions of the phase. This test is repeated 3 times with a 30 seconds rest between them, then the next phase is performed. With feedback the volunteer can observe the system responses. Without feedback the volunteer can not observe the response of the system.
10187829|NCT03722316|Active Comparator|Healthy Older Adults|"Participants are allocated to this arm if they demonstrate healthy cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
10187830|NCT03722303|Active Comparator|Steroid Injection|Subjects with CTS will receive steroid injection.
10187831|NCT03722303|Experimental|Fat Injection|Subjects with CTS will receive fat injection.
10187832|NCT03722290|Experimental|Metformin|Metformin 500mg twice a day per os for 9 weeks
10187833|NCT03722277|Experimental|Variable load training|"The participants will be training two times per week in 10 weeks. Training will consist of variable load training in knee flexion- and extension.~Training will be based on symptoms in isometric strength at five different angles of flexion- and extension."
10187834|NCT03722277|Active Comparator|Conventional strength training|The participants will be training two times per week in 10 weeks. Training will consist of a training programme consisting of strength training with rubber bands for hip and knee.
10187835|NCT03722251|Experimental|Glucose Beverage|50 g of glucose in solution
10187836|NCT03722251|Experimental|Control Beverage|Sucralose in solution
9519964|NCT03281928|Placebo Comparator|High Sodium plus placebo|
9972295|NCT01319253||Cayston Only Cohort|This cohort will be on a previously established medication regiment of Cayston inhaled antibiotic alternating regimen every other month.
9972296|NCT01319253||Tobi Only Cohort|This Cohort will be on a previously established medication regiment that includes Tobi inhaled antibiotic regimen alternating every other month.
9972297|NCT01319253||Cayston and Tobi Cohort|This Cohort will be on a previously established medication regiment that includes Cayston and Tobi inhaled antibiotic alternating every other month
9972298|NCT01319266|Experimental|Normal Renal Function|Subjects with normal renal function
10187837|NCT03722251|Experimental|Glucose beverage and active video game playing|50 g of glucose in solution and 30 min of active video game playing
10187838|NCT03722251|Experimental|Control Beverage and active video game playing|Sucralose in solution and 30 min of active video game playing
10187839|NCT03722225|Experimental|Descriptive, single arm, interventional study|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
10187840|NCT03722212|Other|Patients for METAglut1|"The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.~Already diagnosed patients are included retrospectively."
10187841|NCT03722199|Experimental|Healthy persons|In this interventional study the investigators ask the patient (healthy persons) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
10152962|NCT04070612||children with autoimmune haemolytic anemia|A blood sample of 2 times 2 to 5 ml additional maximum
10152963|NCT04070612||Children with Evans syndrome|A blood sample of 2 times 2 to 5 ml additional maximum
10152964|NCT04070612||Children with Immune thrombocytopenic purpura|A blood sample of 2 times 2 to 5 ml additional maximum
9972299|NCT01319266|Experimental|Mild Renal Impairment|Subjects with mild renal impairment (defined by an estimated creatinine clearance of > 50 and up to 80 mL/min)
9972300|NCT01319266|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment (defined by an estimated creatinine clearance of 30-50 mL/min)
9972301|NCT01319266|Experimental|Severe Renal Impairment|Subjects with severe renal impairment (defined by an estimated creatinine clearance of less than 30 mL/min)
10152965|NCT04070560|Active Comparator|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table Other Name: Immediate clamping
9972302|NCT01319266|Experimental|End Stage Renal Disease (ESRD)|Subjects with ESRD (defined as being on hemodialysis for at least 6 months prior to enrollment and be receiving standard in-center dialysis treatments three times a week)
9972303|NCT01319279|Experimental|Normal Hepatic Function|Intervention Drug: Hydrocodone bitartrate extended-release tablet
9972304|NCT01319279|Experimental|Moderate Hepatic Impairment|Intervention Drug: Hydrocodone bitartrate extended-release tablet
9972305|NCT01319292||Asthma children|children with asthma symptoms through screening
9972306|NCT01319292||normal children|children without symptoms of asthma
9972307|NCT01319305||BREATHE I participatants|
9972308|NCT01319331|Experimental|Alpha-1 Antitrypsin (AAT, Aralast NP)|Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
9972309|NCT01319344|Experimental|Eplerenone|
9972310|NCT01319357|Placebo Comparator|Placebo|Placebo
9972311|NCT01319357|Active Comparator|Saxagliptin|saxagliptin 5 mg/day during 6 weeks
9972312|NCT01319370|Placebo Comparator|vehicle of 5% Minoxidl topical foam|vehicel foam in twice daily application in temple and vertex region
9972313|NCT01319370|Active Comparator|5% Minoxidil topical foam|5% Minoxidil topical in twice daily application in temple and vertex region
9972314|NCT01319409|Experimental|Anatomic Double-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic double-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will be split into 2 strands, 1 to recreate the posterolateral (PL) bundle, the other to recreate the anteromedial (AM) bundle of the ACL. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft will be placed in tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle will be fixed with the knee in full extension and the AM bundle will be fixed with the knee at 45 degrees of flexion.
9972315|NCT01319409|Active Comparator|Anatomic Single-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic single-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will not be split. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free end of the graft will be placed in single tunnel located in the center of the tibial ACL insertion site. The graft will be fixed with the knee at 10 20 20 degrees of flexion.
9972316|NCT01319435|Other|Pharmacokinetics of ciprofloxacin|Patients receiving ciprofloxacin following clinical decision by attending physician
9972317|NCT01319448|Active Comparator|Daily proguanil|Standard policy of a supply of proguanil tablets to be taken daily
9972318|NCT01319448|Experimental|IPT with MQ+AS bimonthly|Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
9972319|NCT01319448|Experimental|IPT with SP+AQ bimonthly|IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
9972320|NCT01319461|Placebo Comparator|sterile normal saline injection|
9972321|NCT01319461|Experimental|Hyalgan injection|
9972322|NCT01319474|Other|Ultrasound for suspected DVT|Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
9972323|NCT01319487|Experimental|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
9972324|NCT01319487|Experimental|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
9972325|NCT01319487|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
9972326|NCT01319513|Experimental|protein feeding|Participants will complete 2 trials in a cross-over fashion in which they will consume whey protein either as a single bolus or as 10 small divided doses
9972327|NCT01319578|Active Comparator|Chewing Arm 1|
9972328|NCT01319578|Placebo Comparator|Chewing Arm 2|
9972329|NCT01319578|Active Comparator|Chewing Arm 3|
9972330|NCT01319578|Active Comparator|Chewing Arm 4|
9972331|NCT01319591||CNS lymphoma patients|
9972332|NCT01319604|Experimental|Study device during 3 hours|
9972333|NCT01319604|Experimental|Study device during 6 hours|
9972334|NCT01319604|Experimental|Study device during 9 hours|
9972335|NCT01319604|Experimental|Study device during 12 hours|
9972336|NCT01319604|Experimental|Study device during 15 hours|
9972337|NCT01319604|Experimental|Study device during 18 hours|
9972338|NCT01319604|Experimental|Study device during 21 hours|
10152966|NCT04070560|Active Comparator|Intact cord (≥ 180 seconds) resuscitation|"If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother~Other Names:~Late cord clamping Deferred cord clamping Optimal cord clamping"
10152967|NCT04070599|Experimental|Single arm|Study of lymphocyte subpopulations, cytokine assays, identification of autoantibodies, study of CD40 platelet ligand, thrombopoietin assay
10152968|NCT04070495|Experimental|Clarithromycin|
10152969|NCT04070495|Experimental|Rifampicin|
10185663|NCT03743480|No Intervention|standard care|Patients in this arm will receive standard hematological care and palliative care on demand
9972339|NCT01319604|Experimental|Study device during 24 hours|
9972340|NCT01319604|Active Comparator|Tonometric assessment during 24 hours|
9972341|NCT01319630||Normal Saline|patients with severe sepsis/septic shock randomized to receive 1500 cc of Normal saline bolus as the resuscitation fluid.
9972342|NCT01319630||Albumin|patients with severe sepsis/septic shock randomized to receive 500 cc of Albumin 5% bolus as the resuscitation fluid.
9972343|NCT01319630||HES|patients with severe sepsis/septic shock randomized to receive 500 cc of Hydroxyethyl starch (HES 130kD) bolus as the resuscitation fluid.
9972344|NCT01319643|Experimental|Oxygenation, rigorous normal|Patients admitted in intensive care unit for 3 days. Administration of the lowest inspiratory fraction dose of oxygen to maintain oxygen peripheral saturation (SpO2) between 94 and 98% or an arterial partial pressure of oxygen (PaO2) between 70 and 100 mmHg. No oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
9972345|NCT01319643|No Intervention|Oxygen, free conventional|Patients admitted in intensive care units for 3 days. Administration of oxygen inspiratory fractions to maintain SpO2 over 97%, up to a PaO2 of 150 mmHg. Oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
9972346|NCT01319656|Active Comparator|Group A|Intervention group(n = 163)
9972347|NCT01319656|Active Comparator|Group B|Delayed intervention (n = 163)
9972348|NCT01319656|No Intervention|Group C|No intervention group (n = 163)
9972349|NCT01319669|Experimental|Treatment group|rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.
9972350|NCT01319669|Active Comparator|Control group|15000U of rhTPO(recombinant human thrombopoietin) is given subcutaneously 6 to 24 hours within the end of chemotherapy cycle, that is, the 8th day for 3 consecutive days (d9 to d11)
9972351|NCT01319682|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
10152970|NCT04070274|Experimental|New surgery platform for calcaneal surgery|"The lateral position surgical platform for calcaneus surgery is designed with a bottom board, mats in front and at back of calf and thigh, and two sizes of cover plates, using tunnel principle according to physiological curve of lower limbs."
10152971|NCT04070274|Experimental|Traditional lateral platform|"The traditional lateral position makes the surgery platform bread-shaped arch surface by using medical mats and putting lower limbs superimpose on each other"
10152972|NCT04070417|Experimental|Treatment Group|Lifestyle Medicine Group
10152973|NCT04070417|No Intervention|CAU Group|Care-As-Usual Group
10152974|NCT04070196|Other|Leucocyte testing|The PD effluent will be sent to the laboratory for leucocyte testing for patients presented with suspected PD peritonitis.
10152975|NCT04070521|Experimental|Observational EEG Monitoring|
10152976|NCT04070547|Experimental|Early tVNS|First 2 weeks this group will receive transcutaneous vagal nerve stimulation 4 hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28) without any intervention. Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
9519965|NCT03281915||high inguinal approch|Patients undergoing high inguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
9972352|NCT01319682|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
9972353|NCT01319695|Experimental|corifollitropin alfa|
9972354|NCT01319695|Active Comparator|recombinant follicle stimulating hormone (FSH)|150-300 IU of FSH for ovarian stimulation in women undergoing IVF
9972355|NCT01319708|Experimental|mild ovarian stimulation|100 mg CC by day 2 till 6, plus antagonist plus gonadotrophin 150-200IO until HCG triggering
9972356|NCT01319708|Active Comparator|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses using a GnRH agonist long protocol
9972357|NCT01319734|Experimental|Vitamin C supplementation plus oral hypoglycemic agents arm|This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
9519966|NCT03281915||subinguinal approch|Patients undergoing subinguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
9972358|NCT01319734|Active Comparator|Type 2DM patients receiving oral hypoglycemic agents alone|this group is the control group who receive oral hypoglycemic agents alone
9972359|NCT01319747|Active Comparator|Percutaneous therapy|
9972360|NCT01319747|Active Comparator|VATS therapy|
9972361|NCT01319786|Other|Low- polyphenol diet|
9972362|NCT01319786|Active Comparator|High-polyphenol diet|
9972363|NCT01319838|Experimental|isotretinoin prolongation|Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
9972364|NCT01319864|Experimental|Plerixafor, Dose Escalation|Dose escalation of plerixafor administered intravenously in combination with IV cytarabine and IV etoposide in pediatric patients wtih relapsed/refractory AML/ALL.
9972365|NCT01319890||Right Colectomy for colonic tumors|The group of patients enrolled will be patients with biopsy proven right colon tumors, both benign and malignant. These patients will then be subdivided into those having conventional laparoscopic right colectomy and SILS right colectomy
9972366|NCT01319942||Unresectable hepatoma|Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
9972367|NCT01319955|Experimental|Influenza vaccine (trivalent inactivated vaccine)|
9972368|NCT01319955|Active Comparator|Inactivated polio vaccine|
10152977|NCT04070547|Experimental|Early Sham|First 2 weeks this group will receive sham stimulation 4hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
10152978|NCT04070547|Experimental|Late tVNS|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive transcutaneous vagal nerve stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
10152979|NCT04070547|Experimental|Late Sham|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive sham stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
10152980|NCT04070469|Experimental|Patient reveiving amoxycillin|all patient included in this study
10152981|NCT04070391|Experimental|vitamin B6|One pill (100 mg) ingested daily for 4 weeks.
10152982|NCT04070391|Placebo Comparator|control|One vinegar pill ingested daily for 4 weeks
10152983|NCT04070222||Natural labour group|
10152984|NCT04070222||Cesarean scar group|
10152985|NCT04070222||Cesarean with diverticulum (PCSD) group|
10152986|NCT04070235|Experimental|SH229/DCV 400mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg once daily and DCV tablets 60 mg once daily QD (n=40) for 12weeks
10152987|NCT04070235|Experimental|SH229/DCV 600mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 600 mg once daily and DCV tablets 60 mg once daily (n=40).
10152988|NCT04070235|Experimental|SH229/DCV 800mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 800 mg once daily and DCV tablets 60 mg once daily (n=40).
10152989|NCT04070235|Experimental|SH229/DCV|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg,600 mg or 800 mg once daily and DCV tablets 60 mg once daily
10152990|NCT04070482||HIV-exposed uninfected infants|These are children to women who are living with HIV but who are not infected with the virus (HIV PCR results at 6 weeks is negative)
10152991|NCT04070482||HIV-unexposed uninfected infants|These are children born to women who are not infected with HIV
10152992|NCT04070248||Group 1|50 HIV-seropositive with spirometry confirmed COPD
10152993|NCT04070248||Group 2|50 HIV-seropositive without COPD
9972369|NCT01319968||Postpartum patients|100 postpartum women attending the clinic for their postpartum visit will be evaluated for vaginal atrophy, vaginal symptoms and dyspareunia.
10152994|NCT04070248||Group 3|50 HIV-seronegative with spirometry confirmed COPD
10152995|NCT04070248||Group 4|50 HIV-seronegative without COPD
10152996|NCT04070118||patients with previous cesarean section|presenting to the emergency department with pain, previous cesarean section; Patients measured niche thickness before operation
9972370|NCT01319981|Experimental|Hyper-CMAD + Rituximab|Odd Courses 1, 3, 5, 7: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 1 & 3; Imatinib oral 600 mg days 1-14 Course 1 then continuously; Cyclophosphamide 300 mg/m2 IV every; 12 hours for 6 doses; Mesna 600 mg/m2/day IV Days 1-3; Doxorubicin 50 mg/m2 IV CVC Day 4; VSLI 2.25 mg/M2 IV Day 1 & 8; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 µg/kg/day; Dexamethasone 40 mg IV or P.O. daily days 1-4 and days 11-14 +/- 3 days.
9972371|NCT01319981|Experimental|Hyper-CVAD|Courses 2, 4, 6, 8: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 2 & 4; Imatinib oral 600 mg; Methotrexate 200 mg/m2 IV over 2 hours followed by 8-0- mg/m2 over 22 hours on Day 1; Solu-Medrol 40 mg IV hours approximately every 12 hours +/- 2 hours for 6 doses days 1-3 +/- 3 days; Decadron 40 mg IV or orally 4 times Days 1-4; Ara-C 3 gm/m2 IV every 2 hours, 4 doses on Days 2-3; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 mg/kg/day.
9972372|NCT01320007|Experimental|Group 1: Optivol Group|
9972373|NCT01320007|Active Comparator|Group 2: Optivol alarm muted|
9972374|NCT01320020|Experimental|catumaxomab|
9972375|NCT01320046||Patients with urinary incontinence|Patients attending the urogynecological clinic for urinary incontinence-100 patients. In this group we will recruit patients with UI, and will assess co-existence of VCD
9972376|NCT01320046||Patients with vulvar contact dermatitis|Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100 patients). In this group we will recruit patients with VCD, and will assess co-existence of UI.
9972377|NCT01320046||Age matched control group|"Patients attending the general clinic for annual checkup, which will be matched for age with the two other groups (200 patients).~These patients will be evaluated for symptoms of UI and VCD"
10152997|NCT04070261||User|
10152998|NCT04070144|Experimental|IQ-Tip|At most four lumbar punctures with Injeq IQ-Tip(tm) system per participant
10152999|NCT04070079|Other|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Dosed orally, once daily with or without food.
10153000|NCT04070092||TBI group|"A cohort of patients admitted to UZ Leuven from 2019 to 2023 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.~Inclusion criteria will be: ≥ 65 years old, admitted to UZ Leuven between 2019 and 2023 due to TBI, all injury severities (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven before 2019, diagnose of neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
10153001|NCT04070092||Control group|"A cohort of healthy volunteers with similar demographic characteristics will be recruited as a control group.~Inclusion criteria will be: ≥ 65 years old and having signed the informed consent to participate in the study.~Exclusion criteria will be: < 65 years old, diagnose of neurodegenerative diseases, cognitive and motor disturbances caused by any pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
10153002|NCT04070430|Active Comparator|2 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
10153003|NCT04070430|Active Comparator|4 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
10185664|NCT03743480|Experimental|early palliative care|early palliative care: patients in this arm will receive integrated palliative care
10185665|NCT03743467||Control group|Health subjects
10185666|NCT03743467||PD patients Hoehn Yahr 1|Patients with Hoehn Yahr stage 1
10185667|NCT03743467||PD patients Hoehn Yahr 2-3|Patients with Hoehn Yahr stage 2 and 3
10153004|NCT04070066|Experimental|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
10153005|NCT04070066|Active Comparator|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
10153006|NCT04070001|Active Comparator|Ibuprofen group|Ibuprofen group received 1-dose 400-mg Ibuprofen 1 hour before elastomeric separator placement
10153007|NCT04070001|Active Comparator|Laser group|Laser groups received a single irradiation of low-level laser immediately after elastomeric separator placement.
9972378|NCT01320059|Experimental|Imaging with 18F-PEG6-IPQA|Radioactive injection given by vein before multiple (3) PET scans.
9669761|NCT02114450|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with the H2 lower limb powered exoskeleton. They will perform walking and other lower limb exercises (as applicable) while wearing the H2 lower limb powered exoskeleton. Training will involve 3 sessions per week for 4 weeks, each lasting about 1.5 hours.
9669762|NCT02114450|Active Comparator|Supervised motor practice|Participants in this group will perform walking and other lower limb exercises (as applicable) under the supervision of a research physical therapist. Training will be for 3 sessions per week for 4 weeks, each session lasting about 1.5 hours.
9669763|NCT01832181||Metformin|
9669764|NCT01832181||Control|
9826312|NCT02414854|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
10153008|NCT04070001|Placebo Comparator|Control group|Control group received placebo lactose tablets 1 hour before elastomeric separator placement.
9972379|NCT01320098|Experimental|Home-Based Parenting Program|
10153009|NCT04069975||No sedation|The group of patients who did endoscopies without sedation.
10153010|NCT04069975||Sedation|The group of patients who did endoscopies with sedation.
10153011|NCT04069988|No Intervention|Control group|The control group (CG) received routine care and was required to physical activity for thirty minutes
10153012|NCT04069988|Experimental|Baduanjin program|The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks ; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
10153013|NCT04069949|Experimental|sorafenib plus toripalimab|"Stage I：Subjects (n=3) in cohort A received oral sorafenib (400 mg qd), in combination with intravenous toripalimab (240 mg d1, q3w). Subjects (n=3) in cohort B received oral sorafenib (400 mg bid) and the administration of toripalimab is consistent with cohort A. If dose-limiting toxicity (DLT) does not occur within 42 days of the first administration, the dose is escalated.~Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39."
10153014|NCT04070209|Experimental|Darolutamide (BAY1841788)+ SBRT|"CRPC subjects will receive LHRH agonist in combination with the new generation of hormonal therapy Darolutamide (300mg).~Subjects who progress on LHRH + Darolutamide and develop oligometastases will receive SBRT"
10153015|NCT04069962|No Intervention|Control group|Patients in the control group will receive CGA coordinated by the oncology team as standard of care, including geriatric recommendations for interventions communicated to the treating physician (eg. referral to the social worker, psychologist, dietician).
10153016|NCT04069962|Experimental|Intervention group|Patients in the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching.
10153017|NCT04069936|Experimental|MILs™ - NSCLC plus nivolumab with or without tadalafil|Locally advanced and unresectable and metastatic NSCLC subjects previously treated with anti-programmed cell death-1 (PD-1) will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil.
10153018|NCT04069884|Active Comparator|Arm I (Clinical high-risk, RecurIndex low-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
9669765|NCT01641107|Experimental|Ponatinib|
9669766|NCT01230879|Experimental|60 - 70 years old|EFR and TDM
9669767|NCT01230879|Experimental|71 - 80 years old|EFR and TDM
9669768|NCT01230879|Experimental|81 - 95 years old|EFR and TDM
9669769|NCT00967863|Experimental|Arm I|Patients undergo 80 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
9669770|NCT00967863|Experimental|Arm II|Patients undergo 70 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
9669771|NCT00858078||Previously referred|Previously-enrolled subjects from NCI Protocol 01-C-0009
9972380|NCT01320098|Experimental|Clinic-Based Parenting Program|
9972381|NCT01320098|Other|Wait-List Control Group|
9972382|NCT01320111|Active Comparator|Arm 1: PA|patient is treated with paclitaxel only
9972383|NCT01320111|Experimental|Arm 2: PASO|patient is treated with paclitaxel AND sorafenib
10153019|NCT04069884|Experimental|Arm II (Clinical high-risk, RecurIndex low-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
9972384|NCT01320124||osteoarthritis, total knee arthroplasty|The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
10153020|NCT04069884|Active Comparator|Arm III (Clinical low-risk, RecurIndex high-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
10153021|NCT04069884|Experimental|Arm IV (Clinical low-risk, RecurIndex high-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
10153022|NCT04069676||Autism Spectrum Condition (ASC)|Adults males and females with a formal autism diagnosis, without intellectual disability
10153023|NCT04069676||Typically developped (TD)|Adults males and females without any neurodevelopemental issue (or health issue which could impaired task performances)
10153024|NCT04069546|Experimental|AIS-RIC|RIC is a physical strategy performed through cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times. This group of patients received regular therapy of acute ischemic stroke plus unilateral arm of RIC intervention.
10153025|NCT04069546|No Intervention|AIS|This group of patients received regular therapy of acute ischemic stroke.
10153026|NCT04069871|Active Comparator|TENS|
10153027|NCT04069871|Sham Comparator|Control|
10153028|NCT04069572|Experimental|Vibrotactile Stimulation|
10153029|NCT04069572|Sham Comparator|Sham Stimulation|
10153030|NCT04069845||liposomal doxorubicin treatment|intravenous liposomal doxorubicin
10153031|NCT04069806|Experimental|Preoperative oral carbohydrate load|6 hours for solid food and 2 hours for liquids + oral carbohydrate preparation 2 hours prior to surgery.
10153032|NCT04069806|No Intervention|Standard preoperative fasting|6 hours for solid food and 2 hours for liquids.
10153033|NCT04069858|Experimental|Baracle|Chronic hepatitis B patients who swiched to Baracle® 1 mg from Baraclude® 1 mg treatment as mono- or combination therapy after the development of antiviral resistance to nucleos(t)ide analogues
10153034|NCT04069832|Other|Intervention|SINGLE-SESSION CONSULTATION
10153035|NCT04069793|Active Comparator|Home Trial Condition A|Subject will use a pattern recognition controlled prosthesis that includes a powered wrist rotation, passive wrist flexion/extension, and a single DOF powered hand.
10153036|NCT04069793|Experimental|Home Trial Condition B|Subject will use at pattern recognition controlled prosthesis that includes a powered wrist rotation, powered flexion/extension and a single DOF powered hand.
9519967|NCT03281902||Ancillary-Correlative (genetic profile analysis)|Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model.
9519968|NCT03281889|Experimental|Proton Radiotherapy|"Patients will be treated with Proton Beam once daily 5 days per week.~Doses will be prescribed such that maximum possible coverage is achieved"
9669772|NCT00858078||Self-referred|Self-referred women at increased familial risk of breast and ovarian cancer were recruited through an hereditary breast/ovarian cancer advocacy group
9669773|NCT00843037|Experimental|Open label - Sunitinib|Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break
9669774|NCT00546598|Other|Duraloc Option COC Hip|
9669775|NCT00054964|Experimental|Albuterol HFA-BOI|
9669776|NCT00054964|Active Comparator|Albuterol HFA-MDI|
9669777|NCT00045201|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9669778|NCT05073796|Experimental|Interventional arm|Participants will receive the intervention as descibed in the respective section.
9669779|NCT05073731|Experimental|Synchronized Telerehabilitation|Physical activity training aiming to increase hand/arm function and fine motor function will be applied via videoconference for 8 weeks, 2 days a week, in 45-60 minute sessions.
9669780|NCT05073731|Active Comparator|Asynchronous Telerehabilitation|Exercise videos and exercise tracking form will be sent.
9669781|NCT05073770|Experimental|N64|"Based on the penis girth measurements, eligible participants will be assigned to two groups:~Group 1: The couples who will test the 64 mm plain condom (n=25).~The test condom has the following specifications throughout the study:~The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm."
9669782|NCT05073770|Experimental|N69|"Based on the penis girth measurements, eligible participants will be assigned to two groups:~Group 2: The couples who will test the 69 mm plain condom (n=25).~The test condom has the following specifications throughout the study:~The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
9669783|NCT05073757||Orthognatic surgery|Orthognathic surgery patients, adults or minors whose bone maturity is sufficient according to the investigator.
9669784|NCT05073640|Active Comparator|Pentoxifylline|Pentoxifylline (Oxopurin 400 mg)
9669785|NCT05073640|Placebo Comparator|Placebo|Placebo (105 mg Lactose and 510 mg Dextrose)
10153037|NCT04069533|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
10153038|NCT04069650||None-malnutrition|normal nutritionnal status
10185668|NCT03743454||Men|
10185669|NCT03743454||Women|
10185670|NCT03743441|Active Comparator|Exercise + Cryotherapy + LLLT|
10185671|NCT03743441|Sham Comparator|Exercise + Cryotherapy + Sham LLLT|
10153039|NCT04069650||Malnutrition|"weight loss was superior to 5% in the past month;~a weight loss was superior to 10% in the past 6 months;~a BMI was inferior to 18,5 kg/m² (if age inferior to 70 years old) or inferior to 21 kg/m² (if age superior to > 70 years old) - a serum albumin level inferior to 30g/L (if age inferior to 70 years old) or inferior to <35g/L (if age superior to 70 years old)."
9972385|NCT01320124||contracture post arthroplasty|A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
9972386|NCT01320176|Experimental|Group A|Subjects received dose A of the investigational HIV vaccine
10153040|NCT04069611|Experimental|Test Group|Subjects in the test group will receive scaling and root planing, plus the take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
10153041|NCT04069611|Placebo Comparator|Control Group|Subjects assigned to the placebo group will receive scaling and root planing, and will take lozenges exactly like the test ones but without bacteria.
10153042|NCT04069754|Experimental|Adapted Passport to Freedom Intervention Arm|The intervention consists of 5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections
10153043|NCT04069780|Active Comparator|Study group I : Intravitreal injection|A single intravitreal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
10153044|NCT04069780|Active Comparator|Study group II: Suprachoroidal injection of full dose|A single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
10153045|NCT04069780|Active Comparator|Study group III : Suprachoroidal injection of half dose|They will receive a single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 2 mg / 0.1 ml.
10153046|NCT04069741|Other|Usual care, no depression|Participants without symptoms of depression who have the opportunity to use a Decision Aid but otherwise receive Usual care
10153047|NCT04069741|Other|Usual care, depression|Participants with symptoms of depression who are randomized to receive Usual care (in addition to the Decision Aid)
10153048|NCT04069741|Active Comparator|Toolkit, depression|Participants with symptoms of depression who are randomized to receive the Toolkit intervention in addition to Usual care
10153049|NCT04069689|Experimental|EPX-100|Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)
9669786|NCT05073666||pulmonary embolism|Patients with a recent pulmonary embolism event will be followed for 6 months and will benefit of routine tests (Lung scintigraphy, venous echo doppler, d- dimers measurement) in order to determine chronic thrombo-embolic disease prevalence and its risk factors.
9694664|NCT04786834|Experimental|Proficiency based progression (PBP) training group: a new training methodology|Participants in the PBP trained group will follow the exact same e-learning didactic course as the Traditional trained group but the PBP group will be required to pass a test of procedure knowledge before continuing to the surgical training. Their knowledge will be assessed in a formative and summative fashion. After their initial VUA assessment, procedure-specific and validated procedure metrics will be used to teach the students the steps of the procedure, as well as the correct (and incorrect) way to perform the procedure. The metrics will be used to give them performance feedback with specific advice on how they might improve their performance, i.e., deliberate practice.
9694665|NCT04786743|Experimental|non-urgent endoscopy group|undergo endoscopy between 6 and 24 hours after gastroenterological consultation
10153050|NCT04069689|Placebo Comparator|Placebo|Single and multiple doses of 20, 40, 80mg of placebo
10153051|NCT04069728|Other|Standard clinic appointment|Patients who undergo a routine clinic outpatient appointment using standard explanation of their fistula with words, diagrams and MRI images, as per Consultant preference
9694666|NCT04786743|Other|urgent endoscopy group|undergo endoscopy within 6 hours after gastroenterological consultation
9694667|NCT04786535|Active Comparator|Hemodiafiltration|
9694668|NCT04786535|Experimental|Expanded hemodialysis|
9519969|NCT03281837|Experimental|Group 1: Hymovis plus Physical Exercise Program (PEP)|Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)
9694669|NCT04786535|Experimental|Conventional high-flux hemodialysis|
9972387|NCT01320176|Experimental|Group B|Subjects received dose B of the investigational HIV vaccine
9972388|NCT01320189|Experimental|Protein intake of 5 energy percent|
10153052|NCT04069728|Experimental|Clinic appointment with 3D model|Patients who undergo a routine clinic outpatient appointment using a 3D printed model to assist explanation of their fistula
10153053|NCT04069559|Experimental|Intervention Group|Intervention contain education and application about refugees health.
10153054|NCT04069559|No Intervention|Control Group|Students of control group performed routine public health nursing practices.
10153055|NCT04069481|Experimental|Dance intervention|Participants will receive a 1-hour group dance class twice a week for 12 weeks. Classes will include a seated warm up, dance exercises in standing, dance activities moving across the floor, throughout the space and conclude with a bow exercise. Music and dance styles will vary and personal preference of participants will also be taken into account.
10153056|NCT04069481|Active Comparator|Exercise and mindfulness meditation|Participants will receive a 1-hour group exercise class twice a week for 12 weeks. Classes will include resistance training exercises with resistance bands, stretching and range of motion exercises in seated and standing positions. Classes will also include mindfulness exercises. During active exercises music will be played and personal preference of participant will be taken into account.
10153057|NCT04069494||patients|People diagnosed with advanced lung cancer and scheduled to receive palliative RT will be invited to participate between 1st July 2019 and 31st January 2020.
10153058|NCT04069494||care giver|Patients' family caregivers will also be invited to participate
10153059|NCT04069234|Experimental|Ticagrelor|ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily
10153060|NCT04069234|Active Comparator|Clopidogrel|clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily
10153061|NCT04069169|Experimental|Intravenous lidocaine|1% preservative free lidocaine 10 mg/ml in 0.9% NaCl
10153062|NCT04069169|Placebo Comparator|Intravenous saline control|0.9% sodium chloride, also known as normal saline
10153063|NCT04069377||Manuel chest compression|Manuel chest compressions will be handled by human efforts.
10153064|NCT04069377||Mechanical chest compression|In the study, chest compression in the mechanical cardiopulmonary resuscitation group was performed with the Lund University Cardiopulmonary Assist System (LUCAS) Chest Compression System (LUCAS 2).
9669787|NCT05073523|Other|Meal A|Diet: meal proportion 1
9669788|NCT05073523|Other|Meal B|Diet: meal proportion 2
9519970|NCT03281837|Other|Group 2: Physical Exercise Program (PEP) alone alone|Specified designed Physical Exercise Program (PEP) not combined with any other intervention
9669789|NCT05073523|Other|Meal C|Diet: meal proportion 3
9669790|NCT05073406|Experimental|Hypobaric normoxia|Altitude exposure in hypobaric normoxic condition
9519971|NCT03281837|Other|Group 3: Cross-Over group|Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.
9669791|NCT05073406|Sham Comparator|Hypobaric hypoxia|Altitude exposure in hypobaric hypoxic condition
9669792|NCT05073380|Experimental|Control|Outdoor play is an essential component of childhood development, including supporting children's cognitive, physical, emotional, and social growth. Currently, the YMCA early learning and child care centres (ELCCs) host children within childcare settings, with outdoor playtime governed by institutional regulations.
10153065|NCT04069208|Experimental|IA14|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
10153066|NCT04069351|Experimental|Overfeeding Plus Resistance Training Arm|6-week overfeeding plus resistance training arm
10153067|NCT04069338|Active Comparator|Device Storz Modulith SLX-F2|Patients receive standard of care treatment for their urolithiasis using the Device Storz Modulith SLX-F2
10153068|NCT04069338|Active Comparator|Dornier Delta III Treatment|Patients receive standard of care treatment for their urolithiasis using the Dornier Delta III lithotripter
9669793|NCT05073380|Sham Comparator|Intervention|"The PRO-ECO intervention to increase the quality of outdoor play involves four primary components:~Modifying YMCA GV's outdoor play policies The ELCC policy on outdoor play requirements and procedures will be modified in conjunction with YMCA management.~ECE training ECEs will undergo training delivered by YMCA of Southwestern Ontario that includes the importance of outdoor risky play, along with other online training tools along with resources on supporting outdoor play. There will also be ongoing as-needed supportive training and mentorship provided by YMCA senior managers and research team, along with peer mentorship and support.~ELCC outdoor space modification This includes designing and implementing tailored modifications for each centre's outdoor play space developed by landscape architecture students.~Parent engagement We will host parent-engagement events and opportunities to increase knowledge of the importance of outdoor play."
9669794|NCT05073744|Experimental|Tumor ablation using nalbuphine for pain control and anaesthesia|Nalbuphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
9519972|NCT03281811|Experimental|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
9669795|NCT05073744|Active Comparator|Tumor ablation using morphine for pain control and anaesthesia|Morphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
9669796|NCT05073276|Active Comparator|Non-weightbearing for the first six weeks after surgery|Not weightbearing after surgery
9669797|NCT05073276|Experimental|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
9972389|NCT01320189|Experimental|Protein intake of 15 energy percent|
10153069|NCT04069182|Other|Behavioral Activation Therapy|Psychological intervention
10153070|NCT04069130|Experimental|BIA 5|single oral dose of 400 mg as an oral capsule
10153071|NCT04069195|Active Comparator|DHA supplement|Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
10153072|NCT04069195|Placebo Comparator|corn oil: Soybean oil placebo|Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery.
10153073|NCT04069091|Experimental|CBT intervention|Participants in the CBT intervention arm will undergo standard antenatal care and the 'Enjoy your Bump' online self-help intervention employing elements of cognitive behavioral therapy (CBT)
10153074|NCT04069091|No Intervention|Standard care|Participants in the Standard Care arm will undergo standard antenatal care.
10153075|NCT04069390|Experimental|Cardioskin-Neuronaute|
10153076|NCT04069325|Experimental|simiaowan 6g + febuxostat 40mg|
9669798|NCT05073289|Experimental|SAPC|SAPC is a acronmy that defines Sandplay activity in psychiatry clinic
9669799|NCT05073289|Active Comparator|Control Group|
9972390|NCT01320189|Experimental|Protein intake of 30 energy percent|
10153077|NCT04069325|Placebo Comparator|placebo 6g + febuxostat 40mg|
10153078|NCT04069416||Group I|175 patients who fall within the Milan criteria.
10153079|NCT04069416||Group II|36 patients who fall within up-to-7 criteria
10153080|NCT04069416||Group III|30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).
9669800|NCT05073263|Active Comparator|Partial weight -bearing for the first six weeks after surgery|Partial weightbearing will be defined as 40% of the patient's body weight.
10153081|NCT04069455|Experimental|EPRO group|Clinical usual care plus ePRO App self-management online during postoperative adjuvant chemotherapy
10153082|NCT04069455|No Intervention|Control group|Clinical usual care during postoperative adjuvant chemotherapy
10153083|NCT04069403|Experimental|Intervention Arm- Automated Reports|Receives automated reports on prescription patterns monthly
10153084|NCT04069403|No Intervention|Control Arm: Usual clinical education and feedback|Receive no reports
10153085|NCT04069429|Experimental|Healthy Controls|7 controls (subjects without GI symptoms and known GI disease), subjects will receive the radiopharmaceutical agent orally
10153086|NCT04069429|Experimental|Eosinophilic Esophagitis Patients|10 patients with diagnosed EoE (greater than 15 eosinophils per HPF) on esophageal biopsy will be included as the diseased population, subjects will receive the radiopharmaceutical agent orally
10153087|NCT04069286|Experimental|Treated Group|in which dry Aroeira extract (Schinus terebinthifolius raddi, 640mg / tablet) will be administered + amoxicillin 500mg 2 tablets + clarithromycin, 500mg 1 tablet given twice daily (12/12 hours).
10153088|NCT04069286|Active Comparator|Control Group|in which 1 tablet of 20mg of omeprazole will be administered + amoxicillin 2 tablets of 500mg + clarithromycin, 1 tablet of 500mg administered twice daily (12/12 hours).
9669801|NCT05073263|Experimental|Full weight -bearing for the first six weeks after surgery|If the patient is randomized to the full weightbearing group, the patient will be instructed about acceptable exercises and activities.
9669802|NCT05073211|Experimental|SJW-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
10153089|NCT04069442||cDC-1 positive|cDC-1 positive patients according to RNAseq and in situ analysis
10153090|NCT04069442||cDC-1 negative|cDC-1 negative patients according to RNAseq and in situ analysis
10153091|NCT04069078|Active Comparator|Hyoscine butylbromide|
10153092|NCT04069078|Placebo Comparator|Control|
10153093|NCT04069260|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
9669803|NCT05073211|Active Comparator|IAA-PDT|Participants were randomized to receive either the SJW extract or IAA on each split-face. The SJW extract (DR-Light complexTM; Genicos Co., Ltd, Cheongju, Korea) consisted of 70% 1, 3-butylene glycol, and 0.1% hypericin as active ingredients. After cleansing the face gently, participants applied 1.5 ml of 0.5% SJW extract on one half of the face and 1.5 ml of 0.015% IAA (AC gel®; Wellskin, Seoul, Korea) on the other half of the face for 10 minutes under occlusion.
9669804|NCT05073198|Experimental|Experiment|Giving educational brochures about testicular cancer and Testicular Self-Examination to the students in the experimental group
10153094|NCT04069065|Experimental|Conversion to Once-daily Tacrolimus|Conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) at least one year after liver transplantation
10153095|NCT04069052|Experimental|Inhaled Nitric Oxide|Inhaled nitric oxide administered throughout 4 min exercise protocol at 800 ppm.
10153096|NCT04069052|Placebo Comparator|Placebo|Inhaled room air administered throughout 4 min exercise protocol at FiO2 = 0.21.
10153097|NCT04068714||Endovascular repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through endovascular repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
10153098|NCT04068714||Open repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through open repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
9519973|NCT03281798|Experimental|Fetuses with LUTO|Performance of ultrasound-guided, percutaneous fetal cystoscopy with the Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set
9669805|NCT05073198|No Intervention|Control|No intervention
9669806|NCT05073159|Active Comparator|0 degree Head-of-Bed (HOB) position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
9669807|NCT05073159|Active Comparator|Elevated (30-degree or more) head-of-bed|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
9669808|NCT05073094|Experimental|Esmolol|1 mg/kg (max. 100 mg) as a bolus before aortic cross-clamping and 2 mg/kg (max. 200 mg) in the cardioplegia solution
9669809|NCT05073094|Placebo Comparator|Placebo|Equivalent volume of saline as a bolus before aortic cross-clamping and in the cardioplegic solution
10153099|NCT04068766|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
9694671|NCT04786561||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years or older were invated to participate in HUNT 4 70+
9972391|NCT01320228|Placebo Comparator|Control|Alli treatment plus placebo (rice flour)
10153100|NCT04068766|Placebo Comparator|Paracervical block with normal saline|ck with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
10153101|NCT04068974|Experimental|Test group|Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
10153102|NCT04068844|Experimental|Central HFpEF whole body exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to whole body cycle training.
10153103|NCT04068844|Experimental|Central HFpEF isolated single leg exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to isolated single leg training.
9669810|NCT05073081|Experimental|Prehabilitation|The 8-week prehabilitation program will be delivered online using synchronous and asynchronous sessions delivered by either a physiotherapist, chiropractor or kinesiologist. There will be 4 individual exercises sessions delivered synchronously using Zoom or Physitrack in which motivational interviewing and graded activity exercises will be conducted. Participants will also be asked to exercise at least 3 times a week using the asynchronous exercise videos. The exercises will be individualized on participants functional ability and personal goals identified at baseline, with a focus on muscle strengthening, stretching, improving spinal flexibility and stability. There will be a booster session at 6-weeks post-op. Participants will also undergo 5 group educational sessions, which will provide information regarding: goal setting, pain education, self-management, pacing, post-operative expectations, exercise recommendations, and information regarding their upcoming surgery.
9669811|NCT05073081|Active Comparator|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice. This generally consists of one session with an anesthesiologist, a nurse and access to our online videos.
9972392|NCT01320228|Experimental|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
9972393|NCT01320228|Experimental|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
10153104|NCT04068844|Experimental|Peripheral HFpEF whole body exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to whole body cycle training.
10153105|NCT04068844|Experimental|Peripheral HFpEF isolated single leg exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to isolated single leg training.
10153106|NCT04068987||Healthy Volunteers|"Healthy volunteers~Recruited from the public~Patients who have scheduled imaging scans for non-cardiac reasons and without a prior history or suspected history of cardiac disease"
10153107|NCT04068987||Children undergoing clinically indicated cardiac MRI|Patients who are scheduled to have a clinically indicated cardiac MRI
10153108|NCT04069013|Active Comparator|Standard PCNL|Patients receive a standard PCNL procedure using a 24 fr tract
10153109|NCT04069013|Active Comparator|Mini-PCNL|Patients receive a mini-PCNL procedure using a 16 fr tract
10153110|NCT04068792|Other|Part 1-Observational Phase|Participants will not receive any intervention in the observation phase. All infants will be closely monitored for early signs and symptoms of Respiratory Syncytial Virus (RSV) disease using a mobile RSV application on the parent/caregiver's mobile phone, upon an alert, the RSV will be tested, if RSV negative participants (RSV [-] diagnosed at site) will return to the pre-diagnostic phase and RSV positive participants (RSV [+] diagnosed at site) can be enrolled in the interventional stage of the study after obtaining informed consent for the interventional stage at that time. RSV (+) participants whose parent(s)/caregiver(s) do not consent for enrollment in the interventional stage and participants who are screening failures in the interventional stage will enter the post-diagnostic phase of the observational stage (hospitalized or outpatients).
9972394|NCT01320228|Experimental|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
9972395|NCT01320241|Active Comparator|novel radiation stent|"Patients undergo placement of a novel biliary stent loaded with 125I seeds on day 1.~Intervention: Device: self-expandable 125I radioactive seeds-loaded-stent"
10153111|NCT04068792|Experimental|Part 2-Interventional Phase|Participants will be randomized to receive either JNJ-53718678 (for Age Group 1 (greater than or equal to [>=] 28 days and less than [<] 3 months): 2.5 milligram per kilogram [mg/kg]; for Age Group 2 (>=3 and <6 months): 3 mg/kg and for Age Group 3 (>=6 months): 4.5 mg/kg) or placebo (Age Group 1, 2 and 3) twice daily for 7 days.
9972396|NCT01320241|Experimental|conventional stent|"Patients undergo placement of a conventional nitinol SEMS on day1.~Intervention: Device: self-expandable biliary nitinol alloys stent"
9972397|NCT01320254|Experimental|Cisplatin, Gemcitabine and Panitumumab|Experimental Arm with cisplatin 25mg/sq.m. at day 1 + 8, gemcitabine 1000mg/ sq.m.at day 1 + 8 and panitumumab 9mg/kg BW at day 1. Cycle will be repeated every 3 weeks.
10153112|NCT04068857|Experimental|rTMS|
10153113|NCT04068857|Sham Comparator|Sham|
10153114|NCT04068870|Experimental|Contraceptive management program|
10153115|NCT04068870|No Intervention|Usual care|
10153116|NCT04068883|Experimental|Collar group|group of athletes that will wear the collar device
10153117|NCT04068883|No Intervention|Non Collar group|group of athletes that will not wear the collar device
10153118|NCT04068675|Experimental|Group counseling arm|There is only one(1) arm in this study. All patients that enroll in the study will receive the group counseling intervention and be compared to historical controls.
10153119|NCT04068584|Experimental|Complete Smart Angel|Smat Angel application with artificial intelligence
10153120|NCT04068584|Experimental|Basic Smart Angel|Smat Angel application without artificial intelligence
10153121|NCT04068584|No Intervention|Control|
10153122|NCT04068805|Active Comparator|Positive affect condition|Participants use Happify and have the option to use a diabetes-specific track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
10153123|NCT04068805|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
10185672|NCT03743428|Experimental|Apatinib-FOLFIRI|Apatinib Mesylate Tablets 250mg po qd Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
9519974|NCT03281785|Active Comparator|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
10185673|NCT03743428|Active Comparator|Bevacizumab-FOLFIRI|Bevacizumab Injection 5mg/kg IV,day 1 Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
10153124|NCT04068922|Experimental|Resilience Intervention|Participants will initially complete a baseline assessment assessing study eligibility. The Resilience intervention consists of seven weekly 1.5-hour group sessions guided by trained clinicians. Due to the COVID-19 pandemic, these group session may be conducted through Zoom. Skills and content will be directed toward improving pain management by enhancing positive emotions, setting goals, learning to live a life according to one's values, and boosting self-confidence in one's ability to manage pain. Self-administered activities include the identification of personal strengths, pleasant activity scheduling, expressing gratitude, values clarification, mindfulness practice, goal setting, positive reappraisal, and noting positive events.
10153125|NCT04068948|Active Comparator|Midazolam, Hydroxyzine, Meperidine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, Hydroxyzine 1.0mg/kg, and Meperidine 1.5mg/kg prior to their dental procedure.
10153126|NCT04068948|Experimental|Midazolam, Hydroxyzine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, and Hydroxyzine 1.0mg/kg prior to their dental procedure.
9669812|NCT05073055|Active Comparator|Group SA|Group 1 (SE) (n = 35): patients undergoing spinal anesthesia of patients in our hospital to do unilateral inguinal hernia operation. Block application and the times when the sensory block reaches the T10 level are recorded. Surgery is allowed in patients who develop sensory block at the T10 level. During our study, no changes will be made to the procedure described above, which is standardized during our study, only patient data will be recorded observationally. Patients who do not have sufficient sensory block to start the procedure despite waiting 10 minutes will be registered and excluded from the study and additional anesthesia will be applied.
9669813|NCT05073055|Active Comparator|Group ESP+TA|Group 2 (Errector spina block + TA) (n = 35): 2% lidocaine hydrochloride (10 mg / ml) 15 ml, 0.5% bupivacaine hydrochloride (20 mg / ml) 15 ml, serum 8.4% Sodium Bicarbonate 5 ml to be used for each patient before the operation in order to apply the erectile spina block block with tumescent anesthesia. Adding adrenaline tartrate (5 μg / mL) to 5 ml with saline, a total of 40 ml of mixture was prepared. Hydrodissection was achieved using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle on the Transverse Process of L1. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
9669814|NCT05073029|Active Comparator|standard care group|3-month course of individually selected nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
9669815|NCT05073029|Experimental|intervention group|additionally to previous group recieved treatment with synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103) and vitamin D3 - 2000 IU. The students were instructed to take vitamin D3 and synbiotic sachets twice a day for 3 months.
9669816|NCT05072925|Active Comparator|Combustible Cigarette|The usual brand of combustible cigarette smoked by study subjects, with a minimum Federal Trade Commission tar yield of 8mg
9669817|NCT05072925|Experimental|BIDI Stick ENDS Arctic flavor|BIDI Stick ENDS containing 6% nicotine and Arctic flavor
9669818|NCT05072925|Experimental|BIDI Stick ENDS Classic flavor|BIDI Stick ENDS containing 6% nicotine and Classic flavor
10153127|NCT04069000|Active Comparator|Regular grade 3 classrooms|Students in this condition will participate in the regular grade 3 program. Educators will use their usual teaching methods to meet educational outcomes, including standards for social-emotional learning.
10153128|NCT04069000|Experimental|First time MindUP participants|Students in this condition will participate in MindUP for the first time. Their classroom teachers will receive training and implement the program during the school year.
10153129|NCT04069000|Experimental|Repeat MindUP participants|Students in this condition are in schools where MindUP has been implemented since they were in kindergarten (although some students may not have participated in those first three years, depending on when they moved to the school). Their classroom teachers will receive training and implement the program during the school year.
10153130|NCT04068662|Experimental|Pregnant Moms' Empowerment Program|Five session group therapy program covering safety planning, resilience and coping, infant care and parenting.
10153131|NCT04068662|Active Comparator|Nondirective Support Group|Five session nondirective support group with two co-leaders who assist in facilitating open discussion on women's self-identified discussion topics.
10153132|NCT04068701|Experimental|MaNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
10153133|NCT04068701|Sham Comparator|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
10153134|NCT04068610|Active Comparator|Control Arm (FOLFOX + Bevacuzimab)|Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only. Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle)
10185674|NCT03743389|Experimental|12G pigtail catheter|
9669819|NCT05072925|Experimental|BIDI Stick ENDS Zest flavor|BIDI Stick ENDS containing 6% nicotine and Zest flavor
9669820|NCT05072925|Experimental|BIDI Stick ENDS Regal flavour|BIDI Stick ENDS containing 6% nicotine and Regal flavor
10185675|NCT03743389|Active Comparator|16F chest tube|
10185676|NCT03743376|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
9669821|NCT05072925|Experimental|BIDI Stick ENDS Winter flavour|BIDI Stick ENDS containing 6% nicotine and Winter flavor
9519975|NCT03281785|Active Comparator|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
9669822|NCT05072925|Experimental|BIDI Stick ENDS Solar flavor|BIDI Stick ENDS containing 6% nicotine and Solar flavor
9669823|NCT05072925|Active Comparator|JUUL ENDS Virginia Tobacco flavor|JUUL ENDS containing 5% nicotine and Virginia Tobacco flavor
9669824|NCT05072938|Active Comparator|Nizatidine Monotherapy|Nizatidine Monotherapy
9669825|NCT05072938|Experimental|Rebamipide/Nizatidine Combination Therapy|Rebamipide/Nizatidine Combination Therapy
9694672|NCT04786561||HUNT4 70+ Trondheim|All inhabitants of one district in Trondheim 70 years or older were invated to participate in HUNT 4 70+
10153135|NCT04068610|Experimental|Exp. Arm (FOLFOX + Bevacuzimab + Durvalumab + Oleclumab)|"Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only.~Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle) Durvalumab 1500 mg IV Q4W Oleclumab 3000mg IV Q2W x 4 then Q4W"
10153136|NCT04068649|Experimental|Arm I (palliative RT)|Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
10153137|NCT04068649|Experimental|Arm II (SBRT)|Patients undergo single fraction SBRT.
10153138|NCT04068558|Experimental|VNI-NAVA/sNIPPV|Ventilation of the child non-invasive ventilation (VNI) NAVA then sNIPPV
10153139|NCT04068558|Experimental|sNIPPV/VNI-NAVA|Ventilation of the child sNIPPV then non-invasive ventilation (VNI) NAVA
10153140|NCT04068935|Experimental|Buddy taping|Buddy taping of the fractured finger to ist neighbouring uninjured finger.
10153141|NCT04068935|Active Comparator|splint immobilization|A forearm-based palmar Hand Splint in an intrinsic plus Position, enclosing all fingers without the thumb.
10153142|NCT04068623||Triple negative breast cancer|
10153143|NCT04068441||Regular treatment|
10153144|NCT04068441||Treatment interruption|
9972398|NCT01320254|Active Comparator|Cisplatin and Gemcitabine|Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
9669826|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with platelet rich plasm|patients with chronic shoulder pain injected with platelet rich plasm ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
10185677|NCT03743376|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
10185678|NCT03743376|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
9669827|NCT05072899|Experimental|25 patient with chronic shoulder pain injected with Hyaluronic acid|patients with chronic shoulder pain injected with Hyaluronic acid ultrasound guided, assessment done on initial visit and follow up after 4weeks and 6month using (VAS, CS, SPADI)
9972399|NCT01320267|Experimental|SILS right hemicolectomy|Single arm with intervention only.
10185679|NCT03743363|Experimental|Exergame 3/week|The group does active training for 8 weeks after not training.
10185680|NCT03743363|Experimental|Exergame 2/week|The group does active training for 8 weeks after not training.
10185681|NCT03743363|Experimental|Healthy control / Exergame 1/week|In the first 8 week-long only control group, The group will do 1 training/week for the next 8 weeks.
9519976|NCT03281785|Active Comparator|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
9669828|NCT05072860|Experimental|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid or placebo
9669829|NCT05072860|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
9669830|NCT05072873|Experimental|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
9669831|NCT05072873|Placebo Comparator|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
9669832|NCT05072782|Other|Status quo arm|"If the patient received no prophylactic therapy after resection, no treatments will be started.~If the patient received a prophylactic therapy after resection, the same will be continued at the same dose."
9972400|NCT01320280|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
9972401|NCT01320306||Subarachnoid hemorrhage|A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
9972402|NCT01320306||Prophylactic surgical treatment of un-ruptured aneurysms|A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
10185682|NCT03743324||BR group|Breast reconstruction without radiation therapy
10185683|NCT03743324||Immediate BR +post-op radiation|Immediate breast reconstruction followed by surgical site radiation therapy
10185684|NCT03743324||Radiation +delayed BR|previous post-mastectomy radiation followed by delayed breast reconstruction
10185685|NCT03743298|Experimental|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
10185686|NCT03743285|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
10185687|NCT03743272||Liver condition|Participants who have a history of of liver disease
10185688|NCT03743272||Healthy volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
10185689|NCT03743259|Experimental|LuminoMark inj. 0.1mL|Injection LuminoMark inj. 0.1mL once in this study.
10185690|NCT03743259|Experimental|LuminoMark inj. 0.2mL|Injection LuminoMark inj. 0.2mL once in this study.
10185691|NCT03743259|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
10185692|NCT03743246|Experimental|Administration of JCAR017|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
10185693|NCT03743233|Active Comparator|Hand file instrumentation|
10185694|NCT03743233|Active Comparator|Reciprocating instrumentation|
10185695|NCT03743207|Experimental|Room temperature|All of the infants in neonatal intensive care units are used to be fed with milk at 22-24°C which is close to room temperature.
10185696|NCT03743207|Experimental|Warmer temperature|The investigators decided to feed the infants in this group with warmer milk at to examine the effects of feeding temperature.
9669833|NCT05072782|Experimental|Therapy escalation arm|Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.
9669834|NCT05072834||Cohort A|children with chronic malnutrition who do not respond to adequate supplemental feeding will undergo Upper Gastrointestinal Endoscopy
10153145|NCT04068454|Active Comparator|classical rehabilitation group|
10153146|NCT04068454|Experimental|virtual reality group|
10153147|NCT04068402|Experimental|Treatment|
10153148|NCT04068506|Experimental|Group A|Gabapentin 600 mg Tab
10153149|NCT04068506|Active Comparator|Group B|Paracetamol 1000 mg Tab
9972403|NCT01320306||Conservative treatment|A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
9972404|NCT01320306||Control group of healthy subjects|Control group of healthy subjects
10153150|NCT04068519|Experimental|Tislelizumab|Tislelizumab will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
10153151|NCT04068740||Mitral valve disease|
9662370|NCT04530149|Active Comparator|serratus anterior plane block group|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where either the bupivicaine injected. After the injection, the needle is taken out.
10153152|NCT04068740||Aortic valve disease|
10153153|NCT04068337||Hemiarch|Patients with Freestyle aortic root implantation receiving a hemiarch replacement by open anastomosis technique with axillary cannulation and antegrade cerebral perfusion
10153154|NCT04068337||Non-Hemiarch|Patients with Freestyle aortic root implantation without hemiarch replacement with normal systemic perfusion
10153155|NCT04068272|Experimental|Treatment|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
10153156|NCT04068272|Placebo Comparator|Placebo|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
10153157|NCT04068571|Active Comparator|I-PUSH intervention sites|Clusters with I-PUSH intervention
10153158|NCT04068571|No Intervention|No I-PUSH intervention sites|Clusters with no I-PUSH intervention
10153159|NCT04068493|Experimental|Dissonance-based obesity intervention|Participants in this arm will receive Enhanced Project Health.
10153160|NCT04068493|No Intervention|Assessment Only|Participants in this arm will only complete the baseline assessment and 2 month assessment. They will not receive Enhanced Project Health.
10153161|NCT04068090||Patients with CIPN|Patients with peripheral neuropathy after treatment with taxanes
10153162|NCT04068090||Patients without CIPN|Patients treated with taxanes and don't develop will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age, tumor stage, chemotherapy regimen or total taxane dosage
10153163|NCT04068467|Experimental|Active|Instructed to download the app and use the app daily for 30 days.
10153164|NCT04068467|Active Comparator|Waitlist Control|Waitlist control.
10153165|NCT04068480||Capsule endoscopy|Patient refered for small bowel capsule endoscopy in conventional indication.
10153166|NCT04068532|Placebo Comparator|Placebo|Participants will receive matching placebo to BIIB104 on Days 1-4 in treatment periods 1 or 2.
10153167|NCT04068532|Experimental|BIIB104|Participants will receive BIIB104 on Days 1-4 in treatment periods 1 or 2.
9662371|NCT04530149|Placebo Comparator|Placeoo injection group|The injection of normal saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where saline is injected. After the injection, the needle is taken out.
10153168|NCT04068376|Active Comparator|Control group (C-GR)|Control group of an aerobic-balance-stretching exercise program led by a coach for 24 weeks (C-GR).
10153169|NCT04068376|Experimental|T1-GR training sessions by health professional|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health professional with a nursing background previously certified to coach SSE trainings by the Institute of Square-Stepping Exercise in Mie, Japan (Chief Tomohiro Okura and Overseas Director Professor Ryosuke Shigematsu).
10153170|NCT04068376|Experimental|T2-GR older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
10153171|NCT04068129||Burma|Patients from remote Burma clinic
10153172|NCT04068129||Alaska|Patients in pediatric ophthalmology clinic
10153173|NCT04068025|No Intervention|No Intervention: Control group|Patients in the control group were given usual care by a health professional who was not involved in the study and who worked in the Department of Urology. After the end of the study, the patients in the control group were also given structured bladder training similar to the patients in the intervention group.
9662372|NCT04529902||Tumor necrosis factor inhibitors|Reference group
9662373|NCT04529902||Abatacept|Exposure group
9662374|NCT04521712|Experimental|Postpartum GDM|Women with GDM diagnosed early (< 20 weeks gestation) or with routine 3rd trimester screening (>=24 weeks) will be enrolled in this longitudinal study. All enrolled women will complete a oral glucose tolerance test and wear a continuous glucose monitor for 10 days at the 3 designated study time points (0-4 days, 4-6 weeks, and 6 months after delivery).
9662375|NCT04514367|Experimental|ANX005|IV
9662376|NCT04504383|Experimental|PN-943 450 mg BID|Oral administration of PN-943 450 mg BID
9662377|NCT04504383|Experimental|PN-943 150 mg BID|Oral administration of PN-943 150 mg BID
9662378|NCT04504383|Placebo Comparator|Placebo BID|Oral administration of matching placebo
9669835|NCT05072834||Cohort B|Children 6 months to 24 months old who are undergoing Upper Gastrointestinal endoscopy for any appropriate indication
9669836|NCT05072821|Experimental|Botulinum Toxin type A injection side|The Botulinum Toxin type A will be injected into the dermal layer before skin closure in keloid excision surgery. The concentration of Botulinum Toxin type A is 100 units in 2 mL and dosage is 8 units/cm. The maximal dose is 100 units for each participant.
9669837|NCT05072821|Placebo Comparator|0.9% saline injection side|The 0.9% saline will be injected into the dermal layer before skin closure in keloid excision surgery. The dosage is 0.16 mL/cm.
9972405|NCT01320319|Placebo Comparator|Placebo|
9972406|NCT01320319|Experimental|Nutritional Supplementation with EPA|This arm will receive the nutritional supplementation of EPA 960mg Three times a day.
9972407|NCT01320332|Experimental|ASP3291 low dose|
9972408|NCT01320332|Experimental|ASP3291 high dose|
9972409|NCT01320332|Placebo Comparator|Placebo|
10153174|NCT04068025|Active Comparator|the IMB model|Structured bladder training was applied to the patients in the intervention group via the IMB model.
10153175|NCT04068207|Experimental|Minocycline|Tablets Minocycline 100mg po per day for 24 weeks
10153176|NCT04068220|Other|Intraoperative FVEPs monitoring|adult patients admitted to TOH - Civic Campus, for chiasmal or pre-chiasmal lesions undergoing a first time minimally invasive endoscopic skull base surgery.
10153177|NCT04068077||Experimental|Patients with amyloidosis and other indistinguishable diseases
10153178|NCT04068350||Single arm|The evaluation at 3 months of the postoperative pain will be carried out without the information collected in preoperative and immediate postoperative.
10153179|NCT04068064|Experimental|EABM training group|about 40 individuals with IGD will be randomly assigned to the EABM training group
10153180|NCT04068064|Placebo Comparator|Control training group|about another 40 individuals with IGD will be randomly assigned to the control training group
10153181|NCT04068116|Experimental|Postconditioning in primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention with post-conditioning by making 4 cycles of repeated occlusion & re-perfusion 30-second each by inflation/deflation of an appropriately sized PTCA (per-cutaneous trans-luminal coronary angioplasty) balloon
10153182|NCT04068116|Active Comparator|Primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention without post-conditioning
10153183|NCT04068246|Placebo Comparator|Control group|patients will receive the standard therapy (methotrexate) plus placebo tablets
10153184|NCT04068246|Experimental|Metformin group|patients will receive the standard therapy plus 1 g metformin daily.
10153185|NCT04068259|Experimental|Cohort 1, Dose 1 of PBI-4547 or Placebo|Dose 1 of PBI-4547 or matching Placebo tablets by mouth
10153186|NCT04068259|Experimental|Cohort 2, Dose 2 of PBI-4547 or Placebo|Dose 2 of PBI-4547 or matching Placebo tablets by mouth
10153187|NCT04068259|Experimental|Cohort 3, Dose 3 of PBI-4547 or Placebo|Dose 3 of PBI-4547 or matching Placebo tablets by mouth
10153188|NCT04068259|Experimental|Cohort 4, Dose 4 of PBI-4547 or Placebo|Dose 4 of PBI-4547 or matching Placebo tablets by mouth
10153189|NCT04068259|Experimental|Cohort 5, Dose 5 of PBI-4547 or Placebo|Dose 5 of PBI-4547 or matching Placebo tablets by mouth
10153190|NCT04068233|Experimental|Eligible patients - pacing mode sequence 1|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-synchronous pacing mode first, then AV-dyssynchronous pacing mode.
10153191|NCT04068233|Experimental|Eligible patients - pacing mode sequence 2|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-dyssynchronous pacing mode first, then AV-synchronous pacing mode.
10153192|NCT04068324|No Intervention|8 hours fasting group|Routine preoperative fasting group undergoes 8 hours of fasting before the operation.
10153193|NCT04068324|Experimental|Clear liquid group|"30 pediatric patients drink 3ml/kg 1 hour before the surgery. Although clear liquid suggests any drinks that do not contain any solid ingredients, but in this study we define clear liquid as water."
9669838|NCT05072769|Experimental|Experimental group|After the fetus and placenta are born, feeding 100 gr (5-6 pieces) dates to the experimental group
9669839|NCT05072769|No Intervention|Control group|The group that was not attempted any intervention in the postpartum period
9669840|NCT05072756||Gynecologists|Brazilian gynecologists who agreed to participate and answered the questionnaire
9669841|NCT05072665|Experimental|PATIENT WITH Irritable Bowel Syndrome|"2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. after the fluorescein injection.~A first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped"
9694673|NCT04786652|Experimental|Assessment of fluid responsiveness|
9694674|NCT04786977||VIPN Patients|
9694675|NCT04786977||Healthy Volunteers|
9694676|NCT04786431||Controls, CVD, IS, SLE|"Control (n = 85) were taken from the population of the Coimbra and Lisbon, Portugal, regions. They satisfied the criterion that they had never had any CVD- or SLE-related health complaints.~The CVD patients (n = 238) were divided into 6 groups. CVD1 (n = 61) contains individuals who went to the hospital with chest pain but had no indicators for stable angina pectoris, unstable angina pectoris or myocardial infarction.~Acute ischemic stroke (IS) (n = 21) were patients admitted at the emergency room of the Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, who suffered from acute ischemic stroke.~The SLE cohort (n = 104) were patients from Hospital Dr. Fernando Fonseca, Amadora, Portugal."
9694677|NCT04786509||ECG sensor|All subjects performed shuttle run (SR), Cooper 2400 m (C), and 100 m sprint test (S), once wearing the sensor attached to self-adhesive skin electrodes, additionally fixed with self-adhesive tapes, and secondly with the sensor attached to Polar belt and strapped around the chests.
9826313|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 300 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
10153194|NCT04068324|Experimental|Carbohydrate containing liquid group|"Other 30 pediatric patients drink 3ml/kg of carbohydrate containing fluid 1 hour before the surgery. The product name we have is NoNPO from NewCare (South Korean company). This fluid does not contain any solid ingredients, so consuming the fluid does not exceed Nil per Os time needed before the surgery."
10153195|NCT04068285|Active Comparator|High intensity interval exercise|"Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.~exercise"
10153196|NCT04068285|Active Comparator|Moderate intensity continuous exercise|"Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.~exercise"
10153197|NCT04068285|No Intervention|No Intervention: Control group|The participants with type 2 Diabetes mellitus in the control group will make stretching exercise at home
9972410|NCT01320345|Experimental|Fenofibrate|145 mg tablet of fenofibrate administered daily for 36 months.
10153198|NCT04067934|Experimental|Jumping exercise|High-impact exercise intervention: 3 sessions per week for four weeks Each session will consist of three jumping-based exercises, performed for three sets of various repetitions, following a progressive protocol with increasing volume/intensity.
10153199|NCT04067986|Other|Camrelizumab + Apatinib|Camrelizumab + Apatinib
10153200|NCT04067999||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
10153201|NCT04067791|Experimental|Prolonged-Release melatonin then Immediate-release melatonin|
10153202|NCT04067791|Experimental|Immediate-Release Melatonin then Prolonged-Release Melatonin|
10153203|NCT04067817|Experimental|norepinephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, norepinephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered
10153204|NCT04067817|Experimental|phenylephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, phenylephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered.
10153205|NCT04067583||Physicians with recent aflibercept experience|Ophthalmologists who have prescribed and/or administered aflibercept in the past 6 months
10153206|NCT04067700|Other|Coronary perfusion PET/CT patients|
10153207|NCT04067804|No Intervention|Usual Care|Standard school disciplinary practices.
10153208|NCT04067804|Experimental|Dynamic Adaptation Process|Using the Dynamic Adaptation Process, specialist coordinators will convene and lead Implementation Resource Teams (IRTs). With the assistance of expert trainers and coaches, the coordinator-led IRTs will then engage in an iterative process of assessment and planning to build school capacity and implement restorative practices to reduce adverse student outcomes related to discipline.
10153209|NCT04067765|Experimental|Alcohol Cue|Alcohol cue exposure in scanner
10153210|NCT04067765|Active Comparator|Neutral Cue|Neutral cue exposure in scanner
10153211|NCT04067687|No Intervention|Control|No palliative home visit intervention
10153212|NCT04067687|Experimental|Intervention|Palliative home visit intervention
10153213|NCT04067908|Experimental|woman giving birth prematurely|Proteome: by liquid chromatography coupled with tandem mass spectrometry. Fibronectin: by vaginal sampling. Ultrasound of the cervix. Cytokines: ELISA kit of a panel of several cytokines.
10153214|NCT04067869|Experimental|Single arm|Patient with confirmed HIV-1 infection
10153215|NCT04067895||human bone graft screw|human bone graft screws will be used during the epiphysiodesis
10153216|NCT04067843|Experimental|Photodynamic treatment|Skin microbiome after photodynamic treatment before and after skin antisepsis
10153217|NCT04067856|Active Comparator|Bevacizumab|Intravitreal injection of 1.25mg/0.05cc bevacizumab
10153218|NCT04067856|Active Comparator|Dexamethasone implant|Intravitreal injection of 0.7mg dexamethasone implant
10153219|NCT04067882||Cervix cancer|Women older than 18 years with histopathological diagnosis of cervical cancer clinical stage I2-IVA, candidates to receive standard treatment with chemotherapy followed by brachytherapy.
10153220|NCT04067947|Experimental|XG005|XG005 in 4 dose levels
10153221|NCT04067947|Placebo Comparator|Placebo|Placebo in all cohort
10153222|NCT04067531|Other|treatment of BV|all patients be treated with first Deqularum then with clindamycin Cream,
10153223|NCT04067596|Experimental|epiphysiodesis|The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).
10153224|NCT04067570|Experimental|SBRT post operative|"Stereotactic Body Radiotherapy (SBRT) 30 Gy in 5 fractions, once weekly to prostate bed~/ - 25 Gy in 5 fractions, once weekly simultaneously to pelvic lymph nodes~/ - 6-24 months of androgen deprivation therapy (ADT)"
10153225|NCT04067544|Other|Acupuncture Treatment|All patients receive 10 acupuncture treatments over the course of 8 weeks.
10153226|NCT04067258||Beta-Thalassemia group|Patients suffering from beta thalassemia major or intermedia will be included in this group
10153227|NCT04067258||Control group|Healthy age and sex matched volunteers will be included in this group
10153228|NCT04067232|Experimental|Patients with posttraumatic forearm impairment|All patients with a one-sided posttraumatic impairment of forearm pro- and/or supination at least 3 months after injury
10153229|NCT04067414|Experimental|BZ019 treatment|Subjects will receive lymphodepleting chemotherapy of fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion. A 3×3 dose escalation design of BZ019 will be adopted.
10153230|NCT04067362|Placebo Comparator|no fiber|Breakfast with hot chocolate with no fiber
10153231|NCT04067362|Experimental|chicory root flour|Breakfast with hot chocolate with chicory root flour
10153232|NCT04067362|Experimental|chicory root fiber supplement|Breakfast with hot chocolate with chicory root fiber supplement
10153233|NCT04067518|Experimental|Pegaspargase arm|
9669842|NCT05072691||Patients with Multiple sclerosis and Optic Neuritis|Patients ≥ 18 year-old at the time of enrollment, with newly diagnosed multiple sclerosis according to 2017 McDonald diagnostic criteria Patients ≥ 18 year-old at the time of enrollment with first episode of optic neuritis, fulfilling or not (i.e. CIS, clinically isolated syndrome) 2017 McDonald diagnostic criteria for multiple sclerosis
10153234|NCT04067323|Placebo Comparator|LCT consumption|20g soy oil (containing mainly long chain triglycerides - LCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
10153235|NCT04067323|Experimental|MCT consumption|20g MCT oil (containing 100% MCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
10153236|NCT04067245|Other|Tetrasodium EDTA cathether lock solution|There is only one arm in this study where home parenteral nutrition patients who meet the inclusion criteria will receive tetrasodium EDTA catheter lock solution.
10153237|NCT04067193||old geriatric inpatients|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes)
10153238|NCT04067193||unformal caregivers|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes) by their relative
9972411|NCT01320345|Placebo Comparator|Placebo|Inert lactose tablet (otherwise matching active) administered daily for 36 months.
9669843|NCT05072691||Patients with non-inflammatory neurologic diseases (NIND)|Patients ≥ 18 year-old with suspected non-inflammatory neurologic diseases (such as Alzheimer disease, intracranial hypertension, etc) receiving routine diagnostic lumbar puncture
9826314|NCT02414854|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
9972412|NCT01320358|Experimental|ECMPS-IEM|
9972413|NCT01320371||Barbed sutures|Barbed sutures are self-anchoring, requiring no knots for wound closure.
9972414|NCT01320371||Knotted sutures|Knotted sutures used for traditional surgical closures.
9972415|NCT01320384|Active Comparator|O2 conventional : standard low flow therapy|in order to obtain a SpO2>92%
10153239|NCT04067193||professional caregivers|usability assessment after the possible use of the device (PARADE CONNECT shoes) by 40 hospitalzed old patients in the geriatrics ward
10153240|NCT04067453||Patients undergoing fatiguing protocol|patient consulting for anorectal manometry in order to explore anorectal disorders with a voluntary command on external anal sphincter
10153241|NCT04067154|Experimental|ALPE-TAC|ARDS patients on mechanical ventilation. Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O to evaluate potential for recruitment and measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
9972416|NCT01320384|Experimental|O2-HNF : high flow nasal oxygen therapy|set between 30 to 50 l/min,adjusted in order to obtain a SpO2 >92%.
10153242|NCT04067375||Pregnant women, HPA-1a positive|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a positive.
10153243|NCT04067375||Pregnant women, HPA-1a negative with HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and have formed anti-HPA-1a alloantibodies.
10153244|NCT04067375||Pregnant women, HPA-1a negative without HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and did not have formed anti-HPA-1a alloantibodies.
10153245|NCT04067440||Patients|Subjects to undergo surgery including opening of the jejunum with non-inflammative condition.
10153246|NCT04067349|Active Comparator|laparoscopic liver resection|Patients undergoing laparoscopic liver resection
10153247|NCT04067349|Active Comparator|open liver resection|Patients undergoing open liver resection
10153248|NCT04067206|Experimental|Recorded mothers' voice group.|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
10153249|NCT04067206|Experimental|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
10153250|NCT04067206|Experimental|MiniMuffs|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
10153251|NCT04067206|No Intervention|Control Group|The control group who were administered standard care.
9972417|NCT01320384|Experimental|O2-HFN/NPPV|cycling of NIV and O2-HDN
9972418|NCT01320397|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
9972419|NCT01320397|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
9669844|NCT05072691||Patients with other inflammatory neurologic diseases (IND)|Patients ≥ 18 year-old with suspected inflammatory neurologic diseases other than multiple sclerosis (such as inflammatory peripheral neuropathies, meningitis, neuromyelitis optica spectrum disorders, etc) receiving routine diagnostic lumbar puncture
9669845|NCT05072587|Active Comparator|Group A - Standard ADA dietary guidelines (SADA)|Participants in this group will be given prepared meals based on standard ADA dietary guidelines for 12 weeks.
9669846|NCT05072587|Experimental|Group B - Plant Based ADA diet with no oxysterols (PB-ADAØ).|Participants in this group will be given prepared meals based on ADA guidelines but with no dietary cholesterol oxides/oxysterols - Plant-based ADA diet
10153252|NCT04067115|Experimental|Trabectedin and Irinotecan|Trabectedin will be delivered by infusion on day 1 followed by 2 doses on irinotecan delivered by infusion for one hour on day 2 and day 4 of 21 day cycles. Some patients will receive an 18F-FLT Imaging scan prior to the first administration of trabectedin and once after administration of trabectedin.
10153253|NCT04067128|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach called patients three times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
9669849|NCT05072418||Children with dyslexia|
10153254|NCT04067128|No Intervention|Usual care arm|Patients assigned to usual care had access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
9669850|NCT05072418||Non-dyslexic children|
10153255|NCT04067466|Experimental|Fiber product|Fiber product: Inulin, maltodextrin, gum guar, plum powder
10153256|NCT04067466|Placebo Comparator|Control product|Maltodextrin, plum powder
10153257|NCT04067505|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg twice daily for three weeks, then 20mg oral once daily after operation.
9972420|NCT01320397|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
9972421|NCT01320397|Experimental|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
9972422|NCT01320423|Other|surgery|
10153258|NCT04067505|Active Comparator|Warfarin/Nadroparin|Participants will receive nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 6 months.
10153259|NCT04067492|Experimental|RPH - 4 mg|Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.
10153260|NCT04067492|Experimental|RPH - 20 mg|Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.
10153261|NCT04067492|Experimental|RPH - 40 mg|Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.
9972423|NCT01320436|Active Comparator|Treatments arm|Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
9669851|NCT05072405|Other|simvastatin 20 mg (Zocor®, MSD)|simvastatin 20 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases.
9669852|NCT05072405|Other|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given on 3 occasions: 1. without herbs; 2. with green tea extract containing EGCG 800 mg once daily for 14 days before statin dosing; 3. with soy isoflavones extract containing isoflavones 120 mg once daily for 14 days before statin dosing, with at least 4-week washout period between phases
9972424|NCT01320436|Placebo Comparator|Control arm|Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.
9972425|NCT01320449|Placebo Comparator|No training + placebo|10 young men being investigated with 10 weeks apart. The will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
9972426|NCT01320449|Active Comparator|No training + EPO|10 young men being investigated with 10 weeks apart. During the 10 weeks participants will receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-mas tests will be obtained during the 10 weeks.
9972427|NCT01320449|Active Comparator|Training + placebo|10 young men will be trained for 10 weeks and investigated before and after. They will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
10153262|NCT04067492|Experimental|RPH - 80 mg|Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.
10153263|NCT04067492|Experimental|RPH - 160 mg|Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)
10153264|NCT04067492|Active Comparator|Voltaren® (diclofenac)|Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)
10153265|NCT04067180|Experimental|Haplo SCT|Allogeneic stem cell transplantation with a haplo-identical family donor graft.
10153266|NCT04067180|Active Comparator|URD SCT|Allogeneic stem cell transplantation with a matched unrelated donor graft.
10185697|NCT03743181||intervention|will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
10185698|NCT03743181||control|will received standard care by physician in attendance
10185699|NCT03743168|Experimental|Intermittent stretching protocol|Intermittent stretching protocol including five sets at 1 minute and 15 second rest.
10153267|NCT04067297|No Intervention|Control Arm|The 14 communities that are in the control arm of the trial will receive usual standard of care. The usual standard of care will follow clinical daily practice patterns provided by family physicians in Ontario for CVD prevention. This follows the periodic standard of care provided by Canadian cholesterol, hypertension, and diabetes best practice guideline recommendations utilized based on each physician's clinical judgement, physical assessment, and discretion. Patients also typically have access to existing cardiovascular prevention materials offered online through publicly available websites.
10153268|NCT04067297|Experimental|Intervention Arm|The 14 communities that are in the intervention arm of the trial will receive a multicomponent intervention that provides both physicians and patients with access to a 'toolbox' of lipid management resources. The components planned for the 'toolbox' are all evidence-based interventions and chosen after consultations with Canadian family physicians and implementation science experts based on their potential for scalability to the entire population, cost and practicality. Online tools will be used and the trial will leverage pre-existing implementation initiatives (e.g., newsletters, listservs) wherever possible to minimize study costs and increase accessibility.
10153269|NCT04067167|Sham Comparator|WB-EMS (Sham-intervention)|Low-theshold WB-EMS combined with nutritional therapy
10153270|NCT04067167|Experimental|WB-EMS|WB-EMS combined with nutritional therapy
10153271|NCT04067167|Experimental|Free WB-EMS|WB-EMS using a mobile System combined with nutritional therapy
10153272|NCT04067167|Experimental|Flexi Band Resistance Training|Flexi band resistance Training combined with nutritional therapy
10153273|NCT04067076||Students of IEMS of Mexico City|Students currently enrolled in the academic year 2019-2020 from the 24 IEMS centers of Mexico City
10153274|NCT04066972|Experimental|Single arm|
10153275|NCT04067219|Experimental|Single arm|HIV-1 infected patients
9669853|NCT05072522|Experimental|SKLB1028|"Dose-escalation stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles, in three doses beginning at 200 mg and rising to 400 mg.~Cohort-expansion stage: Patients will receive SKLB1028 capsules orally once daily (QD) in continuous 28-day cycles at selected dose as per the results of dose-escalation stage."
9669854|NCT05072392|Experimental|Foley-assisted|"The tip of the nasal endotracheal tube will be telescoped onto a 16g Foley catheter. If a ballooned catheter is used then the inflation port may be cut off prior to use. The catheter tip is then fed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. The catheter is then removed from the tip of the nasal endotracheal tube through the mouth and disposed of. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may opt to use the other side nare.~Following this, the anesthetist will complete the rest of the intubation as usual."
9669855|NCT05072392|No Intervention|Control|"The endotracheal tube is passed through the pre-selected primary nare, until the tip of the endotracheal tube is in the oropharynx. If the nasal endotracheal tube is inappropriately sized, a half size above or below may be used. If difficult to pass, the anesthetist may choose to use the other side nare.~Following this, the anesthetist will complete the rest of the intubation as usual."
9669856|NCT05072457|Experimental|Experimental|The Roger microphone will be used in conjunction with Audeo P hearing aid to test localization
9669857|NCT05072470|Experimental|Roger Microphone|Participants will be using a Roger microphone transmitter and hearing aid receiver to complete speech in noise task
10153276|NCT04066985|Experimental|Growth Mindset Intervention|"Includes one online, single-session program, the Growth Mindset Program. The 30-minute, self-administered youth program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
10153277|NCT04066985|Experimental|Self-Kindness Intervention|Includes one online, single-session program, the Self-Kindness Program. The 30-minute, self-administered youth program includes: An introduction to the science behind why adolescents might think disliking themselves is necessary for success and thus fear self-compassion; Scientific evidence and testimonials from other teens that being self-compassionate actually predicts being more successful socially and academically; Evidence-based tips for overcoming common, fear of self-compassion based obstacles to self-compassion in day to day life; And an exercise in which youths write notes to younger students, using scientific information to explain the benefits of using self-kindness.
9669858|NCT05072327|Experimental|Mohs surgery conbind with cryotherapy|patients in this group received both Mohs surgery and cryotherapy.
9669859|NCT05072327|Active Comparator|Mohs surgery|patients in this group received only Mohs surgery.
10153278|NCT04066985|Active Comparator|Supportive Therapy Intervention|Includes one online, single-session active comparator program, the Supportive Therapy Intervention. The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. The 30-minute, self-administered control group program includes: vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family; the same number of reading and writing activities as the web-based growth mindset intervention. However, the only goals of the ST intervention are to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs.
10153279|NCT04067024|Active Comparator|Local anesthesia by the surgeon (LAS)|Local infiltration (ropivacaine 3,75 mg/ml) by surgeon
9694678|NCT04786288|Experimental|Aromatherapy|"22 elderly participants received M technique hand massage that lasted for 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the hand massage.~Intervention: massage with lavender essential oil mixed in a carrier oil"
10153280|NCT04067024|Experimental|Regional anesthesia group (LRA):|By ultrasound, a pecs block I associated with a supraclavicular nerf block is performed. (Ropivacaine 3,75 mg/ml)
10153281|NCT04067102|Experimental|Nab-paclitaxel Based Regimens|
10153282|NCT04067102|Active Comparator|Paclitaxel Based Regimens|
10185700|NCT03743168|Experimental|Continuous stretch|2 minutes continuous stretch
10153283|NCT04067037|Experimental|Camrelizumab Combined With AVD regimen|Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen：AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
10153284|NCT04067063||Milpa Alta inhabitants|Population among 15 and 70 years old
9669860|NCT05072353|Experimental|Treatment|DFU Patients are subjected to digital or transmetatarsal amputation. The treatment is provided during the amputation surgical session according to the SEFFI technique. The SEFFICARE® system (SEFFILINE S.r.l., Via delle Lame, 98, 40122 Bologna, Italy) is a disposable commercially available device. The device is provided in a sterile bag without any drugs. The SEFFI is a 5-step technique meaning preparation, anesthesia, harvesting, washing, and fluidification. The resulting tissue (2.5 mL per syringe) is ready for grafting. The stumps are closed by primary intention following adipose tissue injection.
10153285|NCT04066803|Experimental|MTX group with folic acid|the group with optimal MTX dose (gradually increased from 0 to 12weeks，appropriate folic acid，and stable original other DMARDs
10153286|NCT04066803|Active Comparator|control group without folic acid|the group with stable MTX 10mg/w dose and maximum DMARDs doses（graduallly increased from 0 to 12 weeks）without folic acid
10153287|NCT04067089|Experimental|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
9972428|NCT01320449|Active Comparator|Training + EPO|10 young men will be investigated with 10 weeks apart. During the ten weeks they will train 3 times a week and receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
9972429|NCT01320462|Experimental|Smoking cessation group|Counselling, Pharmacotherapy and Smokers Help Line
10153288|NCT04067089|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
10153289|NCT04066946|Experimental|Group 1 = Intervention group|Standard of care (hydration + silicone gel sheet) + Microcurrent
10153290|NCT04066946|Active Comparator|Group 2 = Control Group|Standard of care (hydration + silicone gel sheet)
9669861|NCT05072249||lay person provided with take home naloxone|Naloxone all forms
9669862|NCT05072431|Experimental|Experimental group|The participants in the experimental group received the 3D VR training program.
9669863|NCT05072431|No Intervention|Control group|The control group did not receive any intervention.
9669864|NCT05072275||Subjects receiving care from Scripps Health physicians in Cardiology and Primary Care|A confidential data request will be submitted to screen the Scripps Health EHR system for individuals meeting study inclusion criteria and having seen a participating study physician in the past two years.
9669865|NCT05072288|Experimental|Remote activity program|Activity program based on objective evaluation. Possibility of 35 different programs primarily targeting impairments (lower limb, upper limb or balanced)
9669866|NCT05072314|Active Comparator|Lidocaine|2% Lidocaine infusion intra-operative and 10% Lidocaine infusion post-operative.
9669867|NCT05072314|Placebo Comparator|Placebo|0.9% Saline infusion intra-operative and 0.9% Saline infusion post-operative.
10153291|NCT04066777|Other|Hypertrophic obstructive cardiomyopathy|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
10153292|NCT04066738|Other|Patients with myocardial scar|Patient with previous STEMI resulting in myocardial scar, elected to CRT implant
10153293|NCT04066790|Experimental|Pyrotinib in combination with nab-paclitaxel|Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
10153294|NCT04066790|Active Comparator|Trastuzumab in combination with nab-paclitaxel|Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
10153295|NCT04066699||Localization|Electromagnetic navigation (EMN) guided percutaneous localization of suspicious lung lesion(s).
9669868|NCT05071989|Experimental|Sleep education group do not supported with social media reminders|Sleep education do not supported with social media reminders
9669869|NCT05071989|Experimental|Sleep education group supported with social media reminders|Sleep education group supported with social media reminders
9669870|NCT05071989|No Intervention|Control group|No intervention was made in the control group.
10153296|NCT04066764|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg oral twice daily for 3 weeks after operation, later rivaroxaban 20mg oral once daily until 3 months after the filter is retrieved.
10153297|NCT04066764|Active Comparator|Warfarin/ Nadroparin|Participants will receive Nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 3 months after the filter is retrieved.
10153298|NCT04066998|Experimental|Conjunctivitis|Patients treated with Dupilumab with conjunctivitis
9669871|NCT05071924|Experimental|PLH Teens Original|The original in-person PLH programme is delivered by community-based workers in low-resource settings. Implementation occurs in a group-based format with both joint parent and teen sessions (10 sessions) and separate parent and teen sessions (4 sessions).
9972430|NCT01320462|Other|Control group|Brief informatin about quitting and smokers help line
9972431|NCT01320475|Experimental|iv Ketamine|Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)
9972432|NCT01320475|Active Comparator|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
9972433|NCT01320501|Experimental|Erlotinib|150 mg PO daily
9972434|NCT01320514||Fibrin Sealant (Artiss)|
10153299|NCT04066998|Other|No conjunctivitis|Patients treated with Dupilumab and showing no signs of ocular involvement
10153300|NCT04066842||1 - Controls|Control Healthy controls
10153301|NCT04066842||2 - SSc|SSc Systemic Sclerosis
10153302|NCT04066842||3 - Cardiovascular|Cardiovascular Cardiovascular disease
10153303|NCT04066842||4 - SSc+Periodontitis|SSc+ Periodontitis Systemic Sclerosis with Periodontitis
10153304|NCT04066712|Experimental|A: Normal (control) renal function|
9669872|NCT05071924|Experimental|PLH Teens Hybrid|The hybrid delivery of PLH Teens consists of 8 sessions delivered to parents via WhatsApp (ParentChat-Teens) and 4 sessions delivered to parents and adolescents in person.
9669873|NCT05072223|Experimental|Group A|
10153305|NCT04066712|Experimental|B: Mild impairment renal function|
10153306|NCT04066712|Experimental|C: Moderate impairment renal function|
10153307|NCT04066712|Experimental|D: Severe impairment renal function|
10153308|NCT04066894|Experimental|Supportive Care (sacral nerve stimulator)|Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
10153309|NCT04066881|Experimental|Group A|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Truvada (0-26 weeks)"
10153310|NCT04066881|Experimental|Group B|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Truvada (0-26 weeks)"
10153311|NCT04066881|Placebo Comparator|Group C:|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Truvada (0-26 weeks)"
9669874|NCT05072223|Active Comparator|Group B|
9669875|NCT05072002||pregnant women with low back pain|
10153312|NCT04066881|Active Comparator|Group D|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Descovy (0-26 weeks)"
10153313|NCT04066881|Experimental|Group E|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Descovy (0-26 weeks)"
10153314|NCT04066881|Placebo Comparator|Group G|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Descovy (0-26 weeks)"
10153315|NCT04066920|Experimental|IBER treatment arm|This is the only arm in a single-arm phase II study.
10153316|NCT04066582||Experimental|Suspected skin inflammations or skin tumors
9669876|NCT05071885|Experimental|Game-based Exercise program|"Each exercise session would last 45 minutes and supervised by study staff at First Step Wellness center you will be shown how to handle and move the joystick and how to play a group of computer games. The game activities will require you to move the joystick at various speeds, movement' amplitudes and in different directions. Each game will be played for 2-3 minutes.~A variety of therapy handles of different shapes and sizes have been produced that Snap-On to joystick handle. These are designed to practice a broad range of manual dexterity skills involving the thumb, fingers, wrist and elbow, o Different games will also be used to vary the movement types and precision levels. To note you will be able to choose the types of movement exercises and games to use."
10153317|NCT04066530|Experimental|AD-203|
10153318|NCT04066530|Active Comparator|Mucosta tab.|
10153319|NCT04066595|Experimental|Experimental (cohorts 1 and 2)|Cohort 1 will consist of patients who have been pre-treated with checkpoint inhibitors only (2nd line setting for cabozantinib). Cohort 2 will consist of patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (3rd line setting for cabozantinib). Both cohorts receive the same treatment.
10153320|NCT04066517|Experimental|Open Label|Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.
10185701|NCT03743155|Experimental|treatment with mesenchymal stem cells|xerostomy using mesenchymal stem cells adult autologous bone marrow
10185702|NCT03743142||Patients with AAA|Patients with AAA are eligible for participation and study screening. They will receive, once included, an endovascular repair of the AAA
10185703|NCT03743129|Experimental|Anlotinib|Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).
10185704|NCT03743129|No Intervention|Blank|No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).
10185705|NCT03743103|Experimental|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
10185706|NCT03743103|Active Comparator|Nitroprusside, Sodium|0.5 mcg / kg / min every 3 minutes until reaching the pressure target
10185707|NCT03743090||CABG with ECC|Group of patients for whom CABG was performed under ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
10185708|NCT03743090||CABG without ECC|Group of patients for whom CABG was performed without ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
9694679|NCT04786288|Placebo Comparator|Placebo|"odourless baby oil was used for the application of the M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.~Intervention: other: massage with no fragrance baby oil"
10153321|NCT04066543|Active Comparator|TACE group|Device: Transcatheter arterial chemoembolization(TACE)
10153322|NCT04066543|Experimental|TACE+Anlotinib group|Device: Transcatheter arterial chemoembolization Drug: Anlotinib Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
10153323|NCT04066556||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
10153324|NCT04066621|Experimental|CRO-SBT|Ceftriaxone Sodium and Sulbactam Sodium for Injection(2:1)
9669877|NCT05071885|Active Comparator|Range of motion and Strength Exercise program.|"This will involve stretching, range of motion and strength exercises as set out by training staff at the First Step Wellness center.~On completion of the ten week exercise program, you will be invited to take part in a 30-minute interview to discuss the experiences you had on receiving the specific hand exercise program. The whole interview session will be audio taped. Your identity will be protected and your privacy will be maintained. All the information discussed and shared during the interview will be kept confidential and safely protected."
9669878|NCT05072106|Active Comparator|Single agent lurbinectedin cycle|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
9972435|NCT01320527|Experimental|Nutriceutical formulation|Nutritional supplement
9669879|NCT05072106|Active Comparator|Bosentan co-administration cycle|"Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).~Lurbinectedin: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1 in first three patients. Dose for remaining five patients will depend on PK and safety outcomes in first three patients."
10153325|NCT04066569|Active Comparator|OGTT Tests and Placebo Test|Patients with acromegaly
10153326|NCT04066569|Active Comparator|OGTT Tests|age and sex matched healthy volunteers
10153327|NCT04066478|Experimental|Teatment|75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation
10153328|NCT04066478|Placebo Comparator|Comaprator|75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation
10153329|NCT04066452||Single-group studies|"Patients will be informed about the study and their written informed consent will be requested.~Once included in the study:~A series of clinical, analytical and echocardiographic parameters will be collected and measured~Will be performed:~Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP)~Analytical to rule out monoclonal protein:~Proteinogram and serum immunoglobulins.~Light chains free in serum -Freelite-~Immunofixation in serum and urine.~The number of readmissions, emergency visits and mortality in the following 12 months will be recorded to compare the readmission and mortality rates in one year of patients with and without CA.~The prescribed pre- and post-diagnostic treatments will be described, according to clinical practice (without intervention).~No intervention, whether diagnostic or follow-up, that is not the usual clinical practice will be applied to patients."
10153330|NCT04066322||system treatment|Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
9669880|NCT05071794|Active Comparator|Group A|Subhypnotic dose of propofol, 0.5mg/kg, 10 - 15 min before end of surgery
9669881|NCT05071794|Placebo Comparator|Group B|Normal saline 0.9%, 10 mL , 10 - 15 min before end of surgery
10153331|NCT04066322||system treatment and Surgery|Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.
10153332|NCT04066179|Experimental|Prednisolone+G-CSF|Prednisolone 40 mg/day for initial 7 days G-CSF300 microgram daily for 7 days
10153333|NCT04066179|Active Comparator|Prednisolone|Prednisolone 40 mg/day for 7 days
10153334|NCT04066179|Experimental|Granulocytes-Colony Stimulating Factor|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
9669882|NCT05071443|Experimental|Negative pressure wound therapy (NPWT)|Negative pressure wound therapy (NPWT): an NPWT device will be applied hermetically from randomization to skin grafting.
9669883|NCT05071443|Active Comparator|Conventional dressing|Conventional dressing will be performed from randomization to skin grafting. The dressings will be performed following usual procedures of investigating centers
9669884|NCT05071495|Experimental|Intervention group|
9669885|NCT05071495|No Intervention|Control group|
10153335|NCT04066296|Active Comparator|Liposomal Bupivicaine|Treatment with liposomal bupivicaine
10153336|NCT04066296|Active Comparator|Standard Local Anesthestic|Treatment with Standard Local Anesthestic
9972436|NCT01320527|Placebo Comparator|Placebo 1|
9972437|NCT01320527|Placebo Comparator|Placebo 2|
10153337|NCT04066257|Active Comparator|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg twice daily for 7 days
10153338|NCT04066257|Active Comparator|Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
10153339|NCT04066257|Active Comparator|MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
10153340|NCT04066231|Experimental|VIPUN GMS|Single arm study.
10153341|NCT04066114|Experimental|lulizumab pegol + novel ISR|lulizumab pegol + novel ISR: lulizumab pegol plus immunosuppressive regimen (anti-thymocyte globulin (rabbit), steroids,) belatacept, tocilizumab, and everolimus)
10153342|NCT04066166||Subjects|Healthy
10153343|NCT04066127|Experimental|Non-ischemic heart preservation (NIHP)|Non-ischemic hypothermic perfusion (NIHP): The donor heart is preserved using a portable heart-lung machine. The device perfuse the heart continuously with a a new preservation solution at a temperature of 8°C.
10153344|NCT04066127|Other|Standard cold storage (SCS)|Standard cold static storage (SCS): The donor heart is preserved using a standard crystalloid cardioplegia. The heart is in then storage i a transport box containing ice to keep the temperature around 4-8°C. The device does not perfuse the heart.
10185709|NCT03743077|Experimental|Individuals with spinal cord injury|Volunteers will participate in the the spinal mobility fitness training program which includes exercise training with inspiratory muscle training.
10153345|NCT04066192|Placebo Comparator|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
10153346|NCT04066192|Active Comparator|BREX 2mg|The BREX 2mg group will start at the same dose at the BREX 4mg group and titrate up at the same rate, so the BREX 2mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, and 2mg on day 5, to reach its final 2mg dose for day 5-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
10153347|NCT04066192|Active Comparator|BREX 4mg|The BREX 4mg group will start at the same dose as the BREX 2mg group and titrate up at the same rate, so the BREX 4mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, 2mg on day 5-6, and 4mg on day 7 to reach its final 4mg dose for days 7-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
10153348|NCT04066465||Proton Therapy|Patients receive proton Radio(chemo)therapy according to clinical standard. Proton Treatment is indicated BEFORE inclusion into the trial ans is not part of the trial. Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases. In addition to the treatment parameters of the radio(chemo)therapy protocol, further radiation doses to brain substructures and organs at risk are documented.
10153349|NCT04066465||No Radiotherapy - Surgical only group|"Patients are included AFTER surgery of their brain tumour and receive no radiotherapy due to their disease (i.e. according to clinical standard). This Treatment is not part of the trial, but stratifies the Patient in this second Group.~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
9694680|NCT04786288|No Intervention|Control|Participants in this group didn't receive any type of intervention from the researcher except the routine hospital management.
9972438|NCT01320540||Breast Center Patients|Patients newly diagnosed with breast cancer who did or did not have genetic testing (retrospectively and prospectively).
9972439|NCT01320540||Staff from the Lynn Sage Comprehensive Breast Cancer Center|Members of the Northwestern staff to include but not limited the Lynn Sage Comprehensive Breast Cancer Center and/or Breast Cancer Genetics Program provider staff (including physicians, nurses, schedulers, physician assistants and/or genetic counselors).
9972440|NCT01320579|Experimental|Group 2 Cis-UCA 5% emulsion cream|
10153350|NCT04066465||Control Group|"Healthy kids are recruited as Standard Group.~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
10153351|NCT04066101||high caries risk|100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)
10153352|NCT04066101||low caries risk|100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)
10153353|NCT04065945||Couples undergoing ART treatment|Couples in reproductive age undergoing ART treatment in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
9661886|NCT03662776||retinoblastoma survivors treated with intra-arteria chemo|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
9661887|NCT03645122|Experimental|Physiology|Different neural elements will be stimulated and evoked potentials will be recorded via electromyography. Metrics used to quantify evoked potentials will be used to infer changes in physiological functioning of the nervous system.
10153354|NCT04065945||Couples getting pregnant naturally|Couples who get pregnant naturally and want to deliver the babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
10153355|NCT04066660|Experimental|Treatment & Oligo Fucoidan|4.4 g Oligo Fucoidan powder by six months, BID
9972441|NCT01320579|Placebo Comparator|Group 3 Placebo cis-UCA emulsion cream|
10153356|NCT04066660|Placebo Comparator|Treatment & Placebo|4.4 g Placebo powder by six months, BID
10153357|NCT04065815|Experimental|Resistance Training (RT)|Individualized, protein-rich nutritional therapy combined with resistance training
10153358|NCT04065815|Experimental|WB-EMS|Individualized, protein-rich nutritional therapy combined with whole-body electromyostimulation (WB-EMS)
9661888|NCT03645122|Experimental|Behavior|A visuomotor task will be performed and force signals will be recorded. Metrics used to quantify force signals will be used to infer changes in control processes governing movement.
9661889|NCT03644277|Experimental|Massed practice training with dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
9662379|NCT04486118|Active Comparator|CA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
9972442|NCT01320579|Active Comparator|Group 4 Protopic® 0.1% ointment|
9972443|NCT01320579|Experimental|Group 1 Cis-UCA 2.5% emulsion cream|
10153359|NCT04065815|Experimental|High-intensity interval training (HIIT)|Individualized, protein-rich nutritional therapy combined with high-intensity interval training (HIIT)
10153360|NCT04065815|Experimental|Combined HIIT and Resistance Training (Combi)|Individualized, protein-rich nutritional therapy combined with a combined high-intensity interval training (HIIT) and resistance training
10153361|NCT04066088|Sham Comparator|Placebo|
10153362|NCT04066088|Experimental|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
10153363|NCT04065880|Active Comparator|TachoSil®|TachoSil® is a collagen sponge coated with the human coagulation factors fibrinogen and thrombin.
9669886|NCT05071521|Active Comparator|Eating disorders prevention|"The Body Project. The Body Project is a dissonance-based eating disorders prevention programme. It is a manualised evidence-based programme that targets eating pathology and body image dissatisfaction in young women. The objective of the programme is to create cognitive dissonance to encourage participants to decrease pursuing ideal-thinness. It includes group discussion, written and behavioural exercises and role-play to achieve cognitive dissonance (Stice, Rohde, & Shaw, 2013). It involves four group sessions for an hour each in consecutive weeks. At the beginning of each meeting, the facilitator reinforces voluntary commitment. Homework is explained and given at the end of each meeting and reviewed at the beginning of the following meeting.~References:~Stice, E., Rohde, P., Shaw, H. (2013). The body project a dissonance-based eating disorders prevention intervention (updated edition). New York: Oxford University Press."
9669887|NCT05071521|Sham Comparator|Healthy eating education|"The control group were asked to read educational material in Arabic about healthy nutrition and active lifestyle from the Saudi branch of the World Obesity Federation (Kayl Association for Combatting Obesity, 2021). The material includes information about body mass index; easy ways to measure food units without a scale; benefits of working out; means to adopt healthier daily habits; and healthier food alternatives. The material was chosen because it was designed to be easy to understand by any individual.~References:~Kayl Association for Combatting Obesity. (2021). Kayl association for combatting obesity. Retrieved from https://www.kayl.org.sa"
9669888|NCT05071547|Experimental|Internet-delivered acceptance and commitment therapy addition|The IACT addition supplies participants with weekly educational material and additional exercises in line with live IRPR, although enriched with multimedia. Participants will have access to their rehabilitation content via the web-site and can practice in their homes in-between live sessions of IRPR.
10153364|NCT04065880|Active Comparator|Neoveil®|Neoveil® sheet made of polyglycolic acid (PGA). It is a biodegradable, thermoplastic and non-antigenic polymer.
10153365|NCT04065997||Patients implanted with HVAD System|Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.
10153366|NCT04066010|No Intervention|Control|
10153367|NCT04066010|Other|Intervention|Mobile application intervention
10153368|NCT04065854|No Intervention|Control|The control group will receive standard brief falls assessment and advice.
9669889|NCT05071547|Active Comparator|Interdisciplinary pain rehabilitation program|A 6-week long multimodal treatment including approximately 108 hours on site, focusing on return to work. Psychologists, physicians, physiotherapists (PT) and occupational therapists (OT) give synchronized treatments with a CBT/ACT approach.
10153369|NCT04065854|Active Comparator|Intervention|Therapy intervention.
10153370|NCT04065906|Experimental|NIRS group|Children with ADHD, 12 sessions of NIRS feedback, for two sessions per week.
9669890|NCT05071573|Experimental|Intervention arm|"Quality improvement package Identification of a viral load champion whose role will include tracing and recalling patients who need further assessments of their VL or switch to second-line regimen.~QIP to address process and clinic impediments to VLM as well as training in antiretroviral treatment monitoring guidelines Training in the use of enhanced TIER.Net technology developed as part of the trial and how to access reports on the dashboard system.~Augmentation of TIER.Net with a dashboard system VL results will be imported into TIER.Net daily from the National Health Laboratory Service which will be linked to patients in TIER.Net based on multiple exclusive and linked deterministic rules using a combination of variables such as name, surname, sex, date of birth, date of visit, NHLS lab number, facility and folder number. The information contained in TIER.Net will be used to develop a dashboard which summarises viral load data at individual and clinic level."
10153371|NCT04065906|Other|Drug group|Children with ADHD, 6 weeks' treatment of either methylphenidate or tomoxetine
10153372|NCT04065906|Other|Control group|Healthy children, 12 sessions of NIRS feedback, for two sessions per week.
10153373|NCT04065958|Experimental|Yoga-mindfulness|Yoga-mindfulness program consisting of movements/postures (asanas), breathing practices, relaxation practices and meditation practices, together with brief talks on yoga-based coping strategies. The intervention starts with a introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks, with home assignments for about 30 minutes per day, four days per week.
10153374|NCT04065958|Active Comparator|Patient education and physiotherapy|Patient education program consisting of lectures on topics related to inflammatory arthritis and pain together with mild physiotherapy. The interventions starts with an introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks. Each session consists of a lecture and a program of instructed physiotherapy. Besides the weekly sessions, home assignments consisting of 30 minutes of walking, are performed four days per week.
10153375|NCT04066023|Experimental|C213 1.9 mg|C213, 1.9 mg administered as one 1.9 mg patch and one placebo patch
10153376|NCT04066023|Experimental|C213 3.8mg|C213 3.8 mg administered as two 1.9 mg patches
10153377|NCT04066023|Placebo Comparator|Placebo|Placebo microneedle system administered as two placebo patches
10153378|NCT04065919|Active Comparator|Exparel|"administration of liposomal bupivacaine 266mg/20mL+ 40 mL bupivacaine 0.25% bupivacaine~."
10153379|NCT04065919|Active Comparator|Standard of Therapy|administration of 0.25% bupivacaine with epinephrine at 1cc/kg total dose
10153380|NCT04066075|Experimental|Telerehabilitation with low vision provider|
9669891|NCT05071573|No Intervention|Control arm|Viral load results are manually captured on to the TIER.Net system with filing of the paper results in patients' clinical notes for nurses' review during routine appointments. This is used to produce a monthly enrolment and quarterly cohort reports for the central monitoring of the ART programme.
10153381|NCT04066075|Experimental|Telerehabilitation w/ low vision provider plus tele-extender|
10153382|NCT04066075|Active Comparator|Usual Care (active control)|
10153383|NCT04065932|Experimental|BMS-985165-01 prototype formulation 1|
10153384|NCT04065932|Experimental|BMS-986165 Tablet|
10153385|NCT04065932|Experimental|BMS-985165-01 prototype formulation 2|
10153386|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3|
9669892|NCT05071482|Experimental|flumatinib arm|600 mg QD oral administration, fasting (2 hours before administration and 1 hour after administration).
9669893|NCT05071482|Active Comparator|imatinib arm|600 mg QD oral administration, with a meal
9669894|NCT05071703|Experimental|Trilaciclib, carboplatin, etoposide, Topotecan|Trilaciclib plus Carboplatin combined with Etoposide OR Topotecan (ES-SCLC patients)
9669895|NCT05071417|Experimental|Semaglutide|Patients on semaglutide
10153387|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3 or 4|
10153388|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3, 4 or 5|
9669896|NCT05071638|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion. Cell dose for all patients was targeted at 5×107 cells per kilogram.
10153389|NCT04065594|Experimental|PRP dressing|
10153390|NCT04065594|Experimental|conventional ordinary dressing|
10153391|NCT04065646|Experimental|Intervention|The intervention group will receive daily text messages with information on: (i) HMM stop locations and schedule; (ii) information on HMM weekly produce specials and sales; (iii) motivational messages encouraging use of the HMM; and (iv) links to produce coupons that they can exchange at HMM- $5 coupons received weekly for the four-week texting period.
9669897|NCT05071638|No Intervention|control group|The control group received standardized treatment without special treatment.
9669898|NCT05071391||Obese|Obese patients undergoing Roux-en-Y gastric bypass
9972444|NCT01320592|Experimental|PD0332991 and Paclitaxel|PD0332991 in combination with weekly paclitaxel at a fixed dose of 80 mg/m2
9972445|NCT01320605|Experimental|Weekly HP802247 treatment|
10153392|NCT04065646|No Intervention|Control|The control group will receive the same dosage of daily text messages covering free activities taking place at the Hartford Public Library and other community locations. The control group will not receive incentive coupons.
9826315|NCT02414932|Experimental|Ketamine|Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate >110/minute or systolic/diastolic blood pressure (BP) >180/100 or >20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
9972446|NCT01320644||vaginal mesh placement|
10153393|NCT04065698|Experimental|RV521|Three single 200 mg oral doses of RV521 administered on Day 1, Day 5 and Day 9 as either the drug in capsule (1 dosing occasion) or the dry powder blend dispersed in water (2 dosing occasions)
9669899|NCT05071508||Preterm Infants|Premature infants (born between 25 and 34 + 6 weeks gestational age) admitted to the University of Minnesota Masonic Children's Hospital NICU
9669900|NCT05071820|Experimental|Mobile application program|
9669901|NCT05071820|Active Comparator|Traditional program|
9669902|NCT05071781|Active Comparator|Cortisol releasing hormone group|HVs will start with CRH infusion.
9669903|NCT05071781|Placebo Comparator|Placebo (sodium choride) group|HVs will start with NaCl 0.9% (placebo) infusion
9669904|NCT05071378|Experimental|Intervention Group|This arm will be enrolled in the intervention prior to any data collection
9669905|NCT05071378|No Intervention|Wait listed control|This arm will receive the intervention after all study data is collected
9669906|NCT05071352|Experimental|Nefopam group|"Adjunct continuous infusion of nefopam plus standard of care in ICU for assessment and management of pain, sedation, and delirium.~Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours."
9669907|NCT05071352|Placebo Comparator|Control group|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
9669908|NCT05071235|Placebo Comparator|CG (control group) + dressing|The group will receive placebo LLLT (low-level laser therapy) application associated with Helianthus annuus oil dressing.
9972447|NCT01320657|Active Comparator|InOvation C|Active Self-ligating Bracket
9972448|NCT01320657|Placebo Comparator|Ovation|Conventional Bracket
9972449|NCT01320657|Experimental|Damon Q|Self-ligating bracket
9972450|NCT01320696|Experimental|Cohort 1|50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
10153394|NCT04065672|Experimental|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
10153395|NCT04065412|Active Comparator|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed to localize the cricothyroid membrane
10153396|NCT04065412|Experimental|Modified laryngeal handshake technique|The modified laryngeal handshake is performed to localize the cricothyroid membrane
10153397|NCT04065529|Experimental|Gelatin tannate (GT)|Gelatin tannate (GT)
10153398|NCT04065529|Placebo Comparator|Placebo|Placebo
10153399|NCT04065568|Experimental|Intervention group|The patient will receive conventional out patient rehabilitation after discharge to the home after stroke. In addition an individualized training program with gamified excercises for motor function will be set and followed up by clincians using video communication, as part of the DISKO-tool. Patients are instructed to train self sufficiently 5 days a week and will be supervised by the treating physiotherapist. The intervention will last for 6 weeks.
10153400|NCT04065568|No Intervention|Control group|Conventional rehabilitation in primary care after discharge to the home after stroke.
10153401|NCT04065724|Other|Physical training resistance and aerobic|Physical training as resistance and aerobic training
10153402|NCT04065451|Experimental|Epinephrine|Epinephrine in the submucosal injection fluid (1:200,000)
9669909|NCT05071235|Active Comparator|LG1 (LLLT group 1) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
9972451|NCT01320696|Experimental|Cohort 2|After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
9972452|NCT01320709|Experimental|Arm 1|
9972453|NCT01320709|Experimental|Arm 2|
10153403|NCT04065451|No Intervention|No epinephrine|Submucosal injection fluid without epinephrine
10153404|NCT04065633|Experimental|Part A sequence 1|
10153405|NCT04065633|Experimental|Part A sequence 2|
10153406|NCT04065633|Experimental|Part B sequence 1|
10153407|NCT04065633|Experimental|Part B sequence 2|
10153408|NCT04065737|Experimental|Sintilimab|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: 8cycles (6 months) or randomization to the date of the first documented oral cancer incidence
10153409|NCT04065776|Experimental|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
10153410|NCT04065581|Experimental|Treatment A-washout-treatment B|Subject will receive a single oral dose of acarbose/metformin FDC (Treatment A, 50 mg acarbose/500 mg metformin) in period 1, followed by a single oral dose of 50mg acarbose and 500mg metformin as loose combination (Treatment B) in period 2. Washout interval between 2 treatment periods was at least 7 days.
10153411|NCT04065581|Experimental|Treatment B-washout-treatment A|Subject will receive a single oral dose of 50 mg acarbose and 500 mg metformin as loose combination (Treatment B) in period 1, followed by a single oral dose of acarbose/metformin FDC (Treatment A, 50mg acarbose/500 mg metformin) in period 2. Washout interval between 2 treatment periods was at least 7 days.
10153412|NCT04065555|Experimental|CIVO Microdose Injection of TAK-981, Cetuximab, and Avelumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one day (Cohort 1) or three days (Cohort 2) prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-981, cetuximab, avelumab, TAK-981 combined with cetuximab, or TAK-981 combined with avelumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node. Approximately six patients will be assigned to each time point cohort. Cohort assignment is not sequential and will be selected by the Investigator based on clinic logistics and patient scheduling. Should one cohort fill in advance of the other, sites will be directed by Presage to enroll patients into the second cohort only.
10153413|NCT04065490|Experimental|PBM Treatment|The Valeda™ Light Delivery System
10153414|NCT04065490|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System non-effective treatment
9669910|NCT05071235|Active Comparator|LG2 (LLLT group 2) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
10153415|NCT04065503|Experimental|Healthy Adults|Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.
10153416|NCT04065685|Active Comparator|CG|control group receiving the usual care, the standardized information on anticipated directives
10153417|NCT04065685|Active Comparator|IG p+r|intervention group with patients and her/his relative
9669911|NCT05071235|Active Comparator|LG3 (LLLT group 3) + dressing|The group will receive application of LLLT (low-level laser therapy) Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
9669912|NCT05071339|Experimental|Participants|"Patients treated at the IVF unit at Shamir Medical Center planned for an antagonist cycle will undergo blood test and US exam at day 2-3 of their menstrual cycle. Patients will be recruited if a leading follicle 10-13 is shown in the presence of E2 > 200-350 pmol/L.~Patients will start GnRH antagonist injections [Cetrotide (cetrolix) or Orgalutran (ganirelix) - depending on their primary prescription] for 3-5 days intervention."
9972454|NCT01320709|Placebo Comparator|Arm 3|
9972455|NCT01320709|Experimental|Arm 4|
9972456|NCT01320748|Experimental|Dual Processing|
10153418|NCT04065685|Active Comparator|IG p|intervention group with patients without relative
10153419|NCT04065373|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored a common peripheral IV site over a 24 hour observation period.
10153420|NCT04065477|Experimental|Experimental|The experimental group will receive treatment program designed to train strategic cognitive functions. Sessions will last 50 minutes and take place twice per week for 16 weeks.
10153421|NCT04065477|No Intervention|Control group|"The control group will receive no active treatment and will be treated as a no-contact control group."
10153422|NCT04065230||TAF antiviral therapy group|
10153423|NCT04065399|Experimental|Experimental: SNDX-5613|"Phase 1:~Oral SNDX-5613; sequential cohorts of escalating dose levels of SNDX-5613 to identify the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D). Patients will be enrolled in one of three dose-escalation arms:~Arm A: Patients not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/ inducers.~Arm B: Patients receiving strong cytochrome P450 3A4 inhibitors for antifungal prophylaxis.~Arm C: Patients receiving SNDX-5613 and cobicistat.~Phase 2:~Oral SNDX-5613; Following the determination of the RP2D in Phase 1, 3 indication-specific expansion cohorts will be enrolled as follows:~Cohort 2A: Patients with MLLr acute lymphoblastic leukemia (ALL)/mixed phenotype acute leukemia (MPAL).~Cohort 2B: Patients with MLLr AML.~Cohort 2C: Patients with NPM1c AML."
10153424|NCT04065711|Experimental|RAP Treatment|Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.
10153425|NCT04065165|Experimental|Experimental arm|Lanreotide 120 mg q4w Telotristat Ethyl 250 mg TID
10153426|NCT04065165|Placebo Comparator|Control arm|Lanreotide 120 mg q4w Placebo TID
10153427|NCT04065243|Active Comparator|Control group|Subjects in this group will have a daily energy intake equivalent of 100 % of their calculated normal daily energy intake.
10153428|NCT04065243|Experimental|Overfed group|Subjects in this group will have a daily energy intake equivalent of 150 % of their calculated normal daily energy intake.
10153429|NCT04065126|Experimental|Physical activity Intervention|This arm receives ten two-hour group sessions with physical activity and psycho-educational components, held by a physiotherapist over a period of ten weeks.
10153430|NCT04065126|Active Comparator|Brief Psycho-education|This arm receives two brief lectures of psycho-education held by a physiotherapist.
10153431|NCT04065308|Experimental|Experimental arm|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~dexamethasone :40mg/day D1-4, intravenous~cyclophosphamide: 400mg/m2 D1-4, intravenous~etoposide: 40mg/m2 D1-4, intravenous~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
10153432|NCT04065282|Experimental|neoadjuvant therapy with Sintilimab plus Xelox|3 cycles of neoadjuvant therapy: Sintilimab iv d1 Q3W, Oxaliplatin 130mg/m2 iv d1 Q3W, and Capecitabine 1000mg/m2 po Bid d1-14 Q3W
10153433|NCT04065360|Experimental|Cognitive behavioural family intervention|
10153434|NCT04065360|Active Comparator|Usual group psychoeducation|
9669913|NCT05070884||non respondants of neo treatment|those patients with no response or partial response when administered with Chemotherapy prior to sugery
9669914|NCT05070936|Other|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backwards both open and closed eyes, and walking on tandem both open and closed eyes. Exercise program was applied for 8 weeks. Patients were observed in the hospital every two weeks. The exercises given in the session were given as home exercises, 3 times a day, for 10 repetitions.
10153435|NCT04065178||Level of Activity|Level of activity for all patients admitting to the inpatient neurological rehabilitation unit.
10153436|NCT04065217|Other|Iraqi patients with face hemangioma|Diode laser 980-nm in the diseased group only while we no need the comparator group because we compared between lesion before and after. The administration of laser is scheduled to start treatment. Patients will take laser therapy as a 12 session at two week-interval. In case of intolerance, session number reduction by 10, 8, 6, 4 allowed. Adherence to treatment will be assessed at each interval for undesired side effects or complications. The intervention should continue also after complete session, or during temporary interval withdrawal due to reached maximal cumulative response or side effects from laser therapy.
10153437|NCT04064866|Experimental|PRP/Hemocyte Autograft Intervention Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to active condition will have exactly 3 cc of hemocyte autograft placed in a 3 cc syringe. The syringe barrels and tubing were covered with opaque tape so that the injector was blinded to the contents. 1-2 cc of PRP was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
10153438|NCT04064866|Placebo Comparator|Placebo Control Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to placebo condition will have exactly 3 cc of saline placed in a 3 cc syringe. 1-2 cc of saline was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
9669915|NCT05070897||Population A|18 to 64 years old
10153439|NCT04064905|Experimental|mRNA-1893|
10153440|NCT04064905|Placebo Comparator|Placebo|0.9% sodium chloride
10153441|NCT04065152|Experimental|oncolytic immunotherapy|Talimogene laherparepvec Dose: 10^6 pfu/ml at week 1 then 10^8/ml at week 4 and every 2 weeks (up to 4ml for each injection) Route: intralesional injection Duration of treatment: 6 months (12 cycles)
10153442|NCT04065269|Experimental|1A: AZD6738|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with single agent AZD6738.
10153443|NCT04065269|Experimental|1B: AZD6738 + olaparib|"In second stage of trial, opening of this cohort depends on response rate in cohort 1A during first stage of trial.~Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with AZD6738 in combination with olaparib."
10153444|NCT04065269|Experimental|2: AZD6738 + olaparib|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with NO loss of ARID1A expression treated with AZD6738 in combination with olaparib.
10153445|NCT04065269|Experimental|3: AZD6738 + olaparib|Women with other rare relapsed gynaecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status, treated with AZD6738 in combination with olaparib.
10153446|NCT04065256|Experimental|Personalized music intervention group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. A total treatment dosage of 560 minutes is required.
10185710|NCT03743025|Experimental|Dulaglutide Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
9669916|NCT05070897||Population B|65 years old and more
9669917|NCT05070910|Experimental|NDT|Therapy will be provided 2 days to 4 days per week for one-hour sessions
9669918|NCT05070871|Active Comparator|Hydrolyzed Collagen type II|10 capsules daily of hydrolyzed collagen (CH) type II is taken per orally. Each capsule contains ~500 mg of CH. Once or twice daily dosing. Duration: 6 months.
9972457|NCT01320748|Active Comparator|Relapse Prevention|
10153447|NCT04065256|Experimental|Personalized music plus earplug group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. In addition, using earplug during night time sleep. The music intervention total treatment dosage of 560 minutes is required.
10153448|NCT04065256|No Intervention|Control group|The control group involves neither music intervention nor using earplug at night.
10153449|NCT04065295|Experimental|Single Rising Dose Part|
10153450|NCT04065295|Experimental|Bioavailability Part|
10153451|NCT04064970||PASS Cohort|
10153452|NCT04065061|Experimental|Experimental|Erinacine A-enriched Hericium Erinaceus Mycelia dietary supplement from week 0 to week 49.
10153453|NCT04065061|Placebo Comparator|Placebo|Placebo dietary supplement from week 0 to week 49.
10153454|NCT04064879|Experimental|Deployment of AD-SVF|Administration of autologous adipose derived SVF
10153455|NCT04065139|Active Comparator|Control Arm|
10153456|NCT04065139|Experimental|Experimental Arm : PIPAC|
10153457|NCT04064944|Experimental|Immunoadsorption group|patients' blood purification treatment protocal is Protain A Immunoadsorption method.
10153458|NCT04064944|Experimental|Plasma exchange group|patients' blood purification treatment protocal is Plasma exchange method.
10153459|NCT04065035|Active Comparator|Topical Firming Body Moisturizer|Oil-in-water emulsion base containing emollients, botanical extracts, peptides, antioxidants, prebiotics, and modified theophylline ingredients.
10153460|NCT04065035|Placebo Comparator|Placebo Moisturizer|Oil-in-water emulsion base containing emollients.
10153461|NCT04065009|Placebo Comparator|Placebo|Normal saline administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
10153462|NCT04065009|Experimental|Experimental|Local anesthetic (ropivacaine) administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
10153463|NCT04065113|Experimental|Embolization Only|Medically managed patient receives middle meningeal artery embolization
10153464|NCT04065113|Experimental|Embolization + Evacuation|Participant receives standard of care evacuation and then undergoes MMA embolization
10153465|NCT04065113|No Intervention|Medical Management|Historical control of medically managed patients
10153466|NCT04065113|Active Comparator|Surgical Patients|Historical control of patients receiving standard surgery alone
10153467|NCT04064840|Active Comparator|IVF: dual trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
10153468|NCT04064840|Placebo Comparator|IVF: hCG trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
10153469|NCT04064840|Active Comparator|FET: agonist|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
10153470|NCT04064840|Placebo Comparator|FET: control|On the day of FET, normal saline will be injected subcutaneously.
10153471|NCT04064996|Active Comparator|Group A|Routine rehabilitation program patient education
10153472|NCT04064996|Experimental|Group B|Routine rehabilitation program + foot exercise training
10153473|NCT04064775|Experimental|Smart snacking intervention|In intervention 2 participants took part in a 4-week intervention on Instagram. Participants saw images of fictitious peers' snacks or beverages three times per week, and saw snack information images three times per week. Peer snack images were posted on days 2,4 and 6 of each week, and snack information images were posted on days 1,3 and 5 of each week. Images were posted between 10-11am each day. Participants also completed quizzes related to snacking at the end of weeks 1-3. Participants completed a survey at baseline and intervention end to assess their ideal portion sizes to allow for examination of the effectiveness of the intervention.
10153474|NCT04064775|No Intervention|Control|Participants in the control received no intervention. They completed the questionnaires at the end of weeks 1, 2 and 3, and also completed the surveys at baseline and intervention end.
10153475|NCT04065191|Experimental|High-intensity interval training|High-intensity interval training
9669919|NCT05070871|Placebo Comparator|Maltodextrin|10 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once or twice daily dosing. Duration: 6 months.
9669920|NCT05070871|Experimental|Unhydrolyzed Collagen type II (Salmon bone meal)|10 capsules daily of salmon bone meal enriched with vitamin D3 is taken per orally. Each capsule contains 300 mg of maltodextrin, 200 mg of salmon bone meal (10 capsules = 2000 mg salmon bone meal = 340 mg elemental calcium in the form of microcrystalline hydroxyapatite), and 4 micrograms of vitamin D3 (10 capsules = 40 micrograms of vitamin D3 = 1600 IU).
9669921|NCT05070962||Clinical population|having experienced repeated and prolonged traumatic exposure
9669922|NCT05070962||General population|Student volunteers from the University of Lille
9972458|NCT01320761|Experimental|Group 1A|"Left side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
10153476|NCT04065100|Experimental|Study group|Maternal PCOS
10153477|NCT04065100|Active Comparator|Comaprator|Non-PCOS pregnant women
10153478|NCT04064619|Active Comparator|sudden stopping|patients were followed up after 1 and 3 months from stopping the drug,
10153479|NCT04064619|Experimental|Weaning|patients were followed up after 1and 3 months from the end of gradual weaning
10153480|NCT04064762|Experimental|Vagus Nerve Stimulation + Prolonged Exposure Therapy|Study treatment is vagus nerve stimulation (VNS) delivered during Prolonged Exposure Therapy.
10153481|NCT04064632|Experimental|RPV +DRV/cobi|The experimental receives rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day) since randomization.
10153482|NCT04064632|Active Comparator|baseline therapy (CAR)|The control arm continues the baseline therapy (CAR) based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day).
10153483|NCT04064515||Cervical Cancer|Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.
10153484|NCT04064515||Control|Participants without a history of cervical cancer or high grade pre-cancer of the cervix
10153485|NCT04064710|Other|Allograft Tissue|Allograft tissue product for patients with painful vertebral compression fractures
9669923|NCT05071105|Experimental|40Gy/5fx|The starting dose level will be 8Gy x 5 fractions, i.e., 40 Gy/5 nonconsecutive once-daily fractions.
9669924|NCT05071105|Experimental|42.5Gy/5fx|The intermediate dose level will be 8.5Gy x 5 fractions, i.e. 42.5Gy/5 nonconsecutive once-daily fractions.
10153486|NCT04064723|Active Comparator|Stem components|Randomization between two stem components. LCU or Corail stem.
10153487|NCT04064723|Active Comparator|Cup components|Randomization between two cup components. DeltaTT or Pinnacle cup.
10153488|NCT04064645|Experimental|Respiratory rate accuracy measurement|
10153489|NCT04064788|Experimental|Consecutive mCIMT group|6 hours / day, 10 consecutive days, 60 hours mKZHT + 2 days 45 minutes / day traditional physiotherapy
10153490|NCT04064788|Experimental|Intermittent mCIMT group|6 hours / day 2 days a week 5 weeks, a total of 60 hours mKZHT + 2 days 45 min / day traditional physiotherapy
10153491|NCT04064788|Active Comparator|Traditional physiotherapy control group|45 min / day, 2 days a week traditional physiotherapy
10153492|NCT04064658|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in Sham RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
9669925|NCT05071105|Experimental|45Gy/5fx|The higher dose level will be 9Gy x 5 fractions, i.e. 45Gy/5 nonconsecutive once-daily fractions
9669926|NCT05071066|Experimental|Group-based ADHD+ Treatment|"This randomized controlled trial (RCT) will run in multi-sites including 5 non-governmental organizations (NGOs) in Hong Kong. Core treatment components are developed by an expert group comprised of psychiatrists and clinical psychologists including internet use/addiction intervention, cognitive training, etc.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months."
9669927|NCT05071066|Other|wait-list control group|For participants in the waiting list control group, they will receive 1-3 hours psychoeducation during the 3 months wait period. Appropriate intervention will be offered after the treatment group.
10153493|NCT04064658|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.~Procedure: Encephaloduroarteriosynangiosis"
9669928|NCT05071001|Experimental|A|
9669929|NCT05071001|Experimental|B|
9669930|NCT05071118|Active Comparator|pregabalin group|Two hours before surgery, the pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery.
9669931|NCT05071118|Active Comparator|placebo group|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
9669932|NCT05071222|Experimental|ARTEGENE drug product|Autologous purified CD34+ cells transduced with a self-inactivated lentiviral vector, expressing the DCLRE1C gene (alias Artemis)
9669933|NCT05071157||anorexia nervosa|girls between 12 and 18 years old with behavioral eating disorder characterized by a drastic reduction in intakes resulting in weight loss and a BMI ≤ 17.5 kg / m2. Anorexia can be restrictive pure or associated with bulimia
9669934|NCT05071157||obesity|girls between 12 and 18 years old with a BMI projecting ≥ 30 kg / m2 at the age of 18 (IOTF C30).
9669935|NCT05071157||normal weight|girls between 12 and 18 years old without BMI abnormality, without eating disorders, without serious medical pathology
9669936|NCT05071092|Experimental|Intervention group|The intervention will consist of personalized guidance from a dietician focussing on improving adherence to the Dutch dietary guidelines.
10153494|NCT04064463|Active Comparator|Control Group|Standard care
10153495|NCT04064463|Experimental|Experimental Group|Standard care plus contingency management
9669937|NCT05071092|No Intervention|Usual care group|The usual care group will not receive any special guidance regarding healthy nutrition, but will have access to their care team as usual.
9669938|NCT05070832|Experimental|Hyperthermia Group|The neoadjuvant therapy is hyperthermia combined with concurrent radiochemotherapy for this group.
9669939|NCT05070832|No Intervention|Non-hyperthermia group|The neoadjuvant treatment is concurrent radiochemotherapy, which is standard treatment for LARC according to the guidelines.
9669940|NCT05070819|Experimental|Cardiac surgery patients|"After admission to OR and arterial catheter is placed the pro-ANP probe is obtained.~After anesthesia induction, trachea intubation before Teboul' test pro-ANP is obtained~At the end of Teboul' test when lower limbs are lifted~30 minutes of CPB~End of CPB~End of volume transtion from CPB circuit to patient~Before Teboul' test at the end of surgery~End of Teboul' test when lower limbs are lifted"
9669941|NCT05070507|Experimental|Enzyme containing lozenge|
9669942|NCT05070507|Placebo Comparator|Placebo lozenge|
9669943|NCT05070416|Experimental|Crowns self-adhesively cemented|Group 1 receives crowns with an occlusal thickness of 1.5 mm and luted with a self-adhesive, self-curing resin cement (SpeedCem Plus, Ivoclar Vivadent AG).
10153496|NCT04064281|Experimental|the healthy Cantonese diet|Based on the typical Cantonese diet, the healthy Cantonese diet is developed according to the DASH diet and the balanced dietary pattern of the Chinese Dietary Guidelines 2016. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set to achieve the healthy goal. Compared with the typical Cantonese diet, the healthy Cantonese diet is increased in fruit, vegetables, low-fat dairy products, whole grains, nuts and seeds, and reduced in salt, oil and sweets.
10153497|NCT04064281|Placebo Comparator|the typical Cantonese diet|The typical Cantonese diet is a diet of what many Cantonese eat. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set at the average dietary intake levels in Guangdong.
10153498|NCT04064268|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
10153499|NCT04064268|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
9669944|NCT05070416|Experimental|Crowns adhesively luted|Group 2 receives crowns with an occlusal thickness of 1.2 mm delivered with a dual-curing resin cement (Variolink Esthetic (DC),Ivoclar Vivadent AG).
9669945|NCT05070676|Experimental|Lateral cephalometric radiographs of pre-adolescent patients (8-13) years old.|
10153500|NCT04064268|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
10153501|NCT04064320|Experimental|Intervention group|Received lullaby intervention and usual care
10153502|NCT04064320|No Intervention|Control group|No intervention other than usual care
10185711|NCT03743025|Placebo Comparator|Placebo Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
10185712|NCT03743012|Experimental|Integrated cardiac rehabilitation|Participants enrolled in integrated cardiac rehabilitation plus usual care
9669946|NCT05070377|Experimental|Intervention|The ActTeens Program will include interventions in three different context: (1) structured physical activity sessions by physical education (school), (2) self-monitoring plus goal setting by pedometer (out-of-school), and (3) healthy lifestyle guidance (social support). The structured PA will be developed in PE lessons, twice a week, with twenty-minute each lesson (40 min·week) To promote active behavior out-of-school will be used a pedometer plus goals setting where each adolescent of the intervention group will receive their own goal (based on the number of steps measured in the baseline week) outlining the goals to achieve weekly. To improve healthy behavior will be sent by WhatsApp® messages about healthy eating and regular PA for the intervention and parents groups.
9669947|NCT05070377|No Intervention|Control|The control group participated in usual practice (regularly scheduled PE and postcurricular school sport) for the duration of the intervention .
10185713|NCT03743012|Active Comparator|Usual Care|Participants receiving usual care only
9669948|NCT05070468|Active Comparator|Group A|Prescribing Vaginally Dexamethasone tablets to the Group A
9669949|NCT05070468|Placebo Comparator|Group B|Prescribing Vaginally placebo tablets to the Group B
9669950|NCT05070611|Experimental|Recurrent chalazia with IPL-MGX|The patients whose lesions had failed to respond to warm compresses and antibiotic and steroid treatment underwent incision and curettage. One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid. After removal of the ultrasound gel, meibomian gland expression (MGX) was performed with forceps-shaped meibomian gland compressor.
10185714|NCT03742999|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
10185715|NCT03742999|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
9669951|NCT05070598|Experimental|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab Q3W d1 Pyrotinib d1-21 Nab-paclitaxel Q3W d1 Tegafur d1-14
9669952|NCT05070260|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
10185716|NCT03742999|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
9669953|NCT05070260|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
9669954|NCT05070182||Patients with brain damage|"ICU patients with brain damage (due to cardiac arrest, intracranial hemorrhage or traumatic brain injury). and GCS upon entry <=8.~All patients will be examined with a transcranial doppler (TCD) and a metabolic computer (for the measurements of REE) After the final diagnosis the patients' characteristics will be compared according to if they were brain dead or not"
10185717|NCT03742960|Experimental|Behavioral Sleep Restriction|Participants will be required to go to sleep half an hour later than their usual bedtime. Wake up time will be determined via their usual wake time.
9669955|NCT05070195|Experimental|The DDI of SKLB1028 and Midazolam|Eligible subjects received a single dose of Midazolam 15 mg on Day 1, and took a single dose of Midazolam 15 mg and a single dose of SKLB1028 150 mg with dosing interval of 0.5 h on Day 3.
9694681|NCT04786418|Active Comparator|Control group|Participants will be given standard advice about healthy eating, physical activity and management of weight during the study visit, in line with current NHS practice. There will be a total of 9 study visits for this group.
10185718|NCT03742947|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
9972459|NCT01320761|Experimental|Group 1B|"Right side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
10185719|NCT03742947|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL)
10185720|NCT03742934|Experimental|Formula group|short peptide formula prior to capsule endoscopy
10185721|NCT03742934|Other|Control group|regular liquid diet
10185722|NCT03742921||Relapsed or Refractory T-Cell Lymphoma patients with Istodax|Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
10185723|NCT03742908|No Intervention|saline control|Implant immersion with 100 ml sterile saline (0.9%) for 10 minutes; Breast pocket irrigation (IRRI) with 100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards. No antibiotics is used.
10185724|NCT03742908|Experimental|Cefazolin/clindamycin immersion|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI) with100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards
10185725|NCT03742908|Experimental|Cefazolin/clindamycin immersion+ IRRI|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI): breast pocket is irrigated with100ml type III Anerdian plus 200mg cefazolin in 100 ml sterile saline (0.9%) for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead of cefazolin
10153503|NCT04064216||Robot assisted laparoscopic surgery|This group will be consisted of patients that will undergo robot assisted laparoscopic surgery for benign gynecologic disorders
10153504|NCT04064216||Conventional laparoscopic surgery|This group will be consisted of patients that will undergo conventional laparoscopic surgery for benign gynecologic disorders
10153505|NCT04064502||volunteers|273 adult volunteers ranging from 18-78 years old
10153506|NCT04064489|No Intervention|neutral|No specific instructions for prescribing prophylaxis or not
10153507|NCT04064489|Active Comparator|TRIPscore|calculation of the TRIPcast score and prescription of prophylactic or not according to the result (score > or = 7 : treatment (low molecular weight heparin or fondaparinux); score < 7 : no treatment)
10153508|NCT04064424|Experimental|Prevention Advertisement|Participants will be exposed to prevention videos and images through Facebook Advertising
10153509|NCT04064424|Active Comparator|No Advertisement|No prevention videos and images will be shown through Facebook Advertising
9669956|NCT05070234||short stature children born small for gestational age|This group was defined as a group of children whose birth weight and/or birth length equal or less than -2 SD for sex and gestational age, and who had failed to catch up in growth, remaining short after 2 years old.
9669957|NCT05069883|Experimental|Oral Steroid|In this group oral steroids were given after Direct vision internal urethrotomy
9669958|NCT05069883|Placebo Comparator|No Oral Steroids|In this group no oral steroids were given after Direct vision internal urethrotomy
9669959|NCT05070026|Experimental|uni-portal VATS group|
9669960|NCT05070026|Experimental|three port VATS group|
10153510|NCT04064554|Experimental|MicronJet600|BCG vaccination with MicronJet600
9669961|NCT05070221|Experimental|Arm A|Patients histologically confirmed mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
10153511|NCT04064554|Active Comparator|Conventional needle|BCG vaccination with conventional needle
10153512|NCT04064541|Other|Virtual Visit|"At the baseline visit patients will complete an in-clinic baseline visit consisting of Medical Hx review, NYHA assessment, Questionnaires (EQ-5D-5L, KCCQ, Frailty Index for Elders & Mini Cog) and Functional Assessments (Timed Up & Go and 6MWT). Patients will also receive virtual visit training and complete an in-clinic virtual visit consisting of the previously stated functional assessments.~All follow-up visits will occur via virtual distance health visits. These f/u visits will occur at Day 7and Day 14 At the initiation of each distance health f/u visit the patient's current state of health will be assessed as well as NYHA. Patient Questionnaires(EQ-5D-5L, KCCQ & Frailty Index) and Functional Assessments(Timed Up & Go and 6MWT) will be completed."
10153513|NCT04064255|Active Comparator|Case: Practical Body Image + Treatment as Usual|"The Case arm involves Practical Body Image + treatment as usual.~Practical Body Image is based on a cognitive behavioural model of body image addressing thoughts, feelings, behaviours and misperceptions. PBI is designed to be administered over 10 weeks (6 weekly sessions over 6 weeks, followed by 8 twice weekly sessions over 4 weeks).~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
10153514|NCT04064255|No Intervention|Control: Treatment as Usual Only|"Control arm involves treatment as usual only.~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
10153515|NCT04064567|Active Comparator|Enhanced Standard of Care|PrEP education and referral to a community-based PrEP provider (enhanced standard of care)
9972460|NCT01320761|Experimental|Group 2A|"Left side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
9669962|NCT05070221|Experimental|Arm B|Patients histologically confirmed non-mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).
9669963|NCT05069870|Experimental|The DDI of SKLB1028 and Itraconazole|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Itraconazole 200 mg twice-daily on Day 8 and 200 mg once-daily on Day 9 through Day 18, and took a single dose of SKLB1028 100 mg on Day 11.
9669964|NCT05069870|Experimental|The DDI of SKLB1028 and Gemfibrozil|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1, then took Gemfibrozil 600 mg twice-daily on Day 8 through Day 19, and took a single dose of SKLB1028 100 mg on Day 12.
9669965|NCT05069870|Experimental|The DDI of SKLB1028 and Rifampicin|Eligible subjects received a single dose of SKLB1028 150 mg on Day 1, then took Rifampicin 600 mg once-daily on Day 8 through Day22, and took a single dose of SKLB1028 150 mg on Day 15.
9972461|NCT01320761|Experimental|Group 2B|"Right side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
9972462|NCT01320787|Experimental|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
9972463|NCT01320800|Active Comparator|Expert-led CBT|Expert SASS is the Skills for Academic and Social Success protocol delivered by a postdoctoral fellows.
10153516|NCT04064567|Experimental|Community Health Worker Involved Enhanced Standard of Care|PrEP education, referral to a community-based PrEP provider, and referral to a CHW who will facilitate access to community-based PrEP and other healthcare and social-support services.
10153517|NCT04064385|Experimental|Intervention|FES cycle training will be performed on the RT300 FES cycle ideally 3 times per week for 6 weeks, each session lasting up to 90 minutes. Electrical stimulation will be delivered through up to 12 independent channels each delivering up to 140 mA current on the following muscles (both on the right and left leg): quadriceps, femoral biceps and gluteus, gastrocnemius and tibialis anterior. Abdominal and back extensor muscles may also be stimulated if the participant presents with neurological trunk weakness (SCI above T6). The FES unit will stimulate the muscles that extend the hip (gluteals), flex the knee (hamstrings) and extend the knee (quadriceps) in the correct order to bring about a cycling motion. The feet and lower legs of the participants will be strapped into the pedals and the wheelchair will be coupled in a rigid manner with the training device.
10185726|NCT03742882|Experimental|Administration of CC-90001|Single oral dose of 200 mg of CC-90001
10153518|NCT04064385|No Intervention|Control|Participants in the control group will receive usual care, consistent with standard NHS care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting approximately 90 minutes. Physiotherapists provide one to one function-oriented physiotherapy session to improve balance, muscle strength and transfer skills.
10153519|NCT04064229|Experimental|Infiltrated Tissue|The ivWatch Model 400 SmartTouch and fiber optic sensors monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
9669966|NCT05070052|Experimental|Group CBT|9 group sessions lasting 75-90 minutes each. CBT starts with psychoeducation about emotions, their primary functions, and how our emotions can affect the way we think and behave. They next learn about behavioral strategies that can help them manage or overcome difficult emotions. Group members also complete gradual exposure exercises, which involve engaging with activities that elicit negative emotions. Finally, group members are taught cognitive skills to help them cope with difficult/stressful thoughts.
9669967|NCT05070052|Experimental|Group MBCT|9 group sessions lasting 75-90 minutes each. The focus of sessions 1 through 4 will be learning to bring greater awareness to the present moment, on purpose, and nonjudgmentally. Appropriate responding is the focus of sessions 5 through 8. All skills are reviewed in session 9.
9669968|NCT05070000||US|Ultrasound
9669969|NCT05070000||CT|Computed tomography
10153520|NCT04064398|Active Comparator|Routine aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
9669970|NCT05070000||US after CT|Ultrasound after Computed tomography
9669971|NCT05070130||dPR and FFR|Subjects with aortic stenosis who are considered for TAVR will undergo a physiological assessment and prediction of ischemic coronary lesions pre- and post-TAVR by using Opsens non-hyperemic dPR and/or Opsens FFR
9669972|NCT05069766|Experimental|BioXmark™|
9669973|NCT05069909|Active Comparator|Conventional technique|The group of patients who received dentures fabricated with conventional technique first
9669974|NCT05069909|Active Comparator|Simplified technique|The group of patients who received dentures fabricated with simplified technique first
10153521|NCT04064398|No Intervention|No aspiration of gastric residuals|Infants will not have routine aspiration of gastric contents prior to each feeding.
10153522|NCT04064333|Experimental|Slow-Stream Expiratory Muscle Strength Training|The therapy protocol consists of 12 sets of five breaths through the EMST150 device per week, in sessions of three or four sets (15 or 20 breaths). A typical schedule might be one 15 breath session four days per week, or one 20 breath session three days per week.
9669975|NCT05069987|Experimental|VR-immersion|
9669976|NCT05069987|No Intervention|Non-VR control|
9669977|NCT05070104|Experimental|Single Arm|CPI-613 mFFX Bevacizumab
9669978|NCT05069584|Experimental|transperineal biopsy|The strategy evaluated is based on performing targeted and systematized prostate biopsies performed by the transperineal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
9669979|NCT05069584|Active Comparator|transrectal biopsy|The comparison strategy is based on performing targeted and systematized prostate biopsies performed by the transrectal route. Biopsy must be performed as part of the usual treatment for prostate cancer diagnosis.
9669980|NCT05069558|Experimental|Investigational PFO Closure Device|PFO closure with the study Occlutech Flex II PFO device.
10153523|NCT04064203|Experimental|Totally pancreatectomized patients|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
10153524|NCT04064203|Experimental|Healthy controls|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
10153525|NCT04064372|Experimental|Mindful Response to Adversity|"The treatment condition will be trained in techniques designed to teach a mindful approach to adversity. These techniques will include: normalizing, attention, equanimity, non-judgment, de-centering, accepting of experiences, and impermanence. Participants will be instructed on the mindset, asked to write about an instance of non-judgment and share with a partner, and then guided through a short training designed to practice each skill."
9669981|NCT05069558|Active Comparator|Standard of Care PFO Closure Device|PFO closure with either of the standard of care PFO occlusion devices; Amplatzer PFO Occluder or the Gore Cardioform PFO Occluder.
10153526|NCT04064372|Active Comparator|Strength-based approach to adversity|The control condition will be trained in techniques designed to teach a typical narrative self-analysis / strengths-based approach to adversity. These techniques will include: choosing the best approach, minimizing stress, and identifying and enhancing personal strengths. Participants will be instructed on the mindset, asked to write about an instance of personal strength and share with a partner, and then guided through a short training designed to practice each skill.
10153527|NCT04064190|Experimental|Vactosertib+Durvalumab|Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.
10153528|NCT04064112|Experimental|S-BLR|For S-BLR, the lower horn of the LR is recessed based on near exodeviation and the upper horn is recessed based on distant exodeviation.
10153529|NCT04064112|Active Comparator|C-BLR|For C-BLR, the LR is recessed based on distant exodeviation.
10153530|NCT04064125|Experimental|FMX-101|
10153531|NCT04064177||Babies (24-42 weeks)|All babies born between 24 and 42 weeks
10153532|NCT04064177||Preterm infants|Preterm infants with fetal growth restriction
10153533|NCT04063826|Other|PET MRI Scan|Imaging scan of the liver
10153534|NCT04063956|Experimental|Cognitive training group|Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 4 x 40 minutes per week, for 12 weeks.
10153535|NCT04063956|Active Comparator|Active-control group|Fixed, primary difficulty level tasks. 4 x 40 minutes per week, for 12 weeks.
9669982|NCT05069779|Experimental|Diazepam|Oral
10153536|NCT04064021|Experimental|Acupuncture|Acupuncture 12 sessions over 6 week to be given to pateints
10153537|NCT04064138|Active Comparator|Peritoneal block|patients will receive peritoneal block as an adjuvant analgesic technique.
9972464|NCT01320800|Experimental|School Counselor-led CBT|"School Counselor SASS is the Skills for Academic and Social Success protocol delivered by School Counselors.~Intervention: Behavioral: Skills for Social and Academic Success"
9669983|NCT05069779|Placebo Comparator|Placebo|Oral
9669984|NCT05069454|Active Comparator|Exposure group|Healthcare workers vaccinated by any of the available COVID19 vaccine;
9669985|NCT05069454|Active Comparator|Control group|Have not received any doses of any form of COVID-19 vaccine
10153538|NCT04064138|Active Comparator|Ultrasound guided erector spinae plane block|Patients will receive ultrasound guided erector spinae plane block
9669986|NCT05069363|Experimental|Intervention Group|All participants in this feasibility trial will receive a course of whole-body photobiomodulation therapy (18 sessions over 6 weeks)
9669987|NCT05069480|Active Comparator|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was one hour and few minutes rest in between. The first part included: reflex inhibiting patterns, strengthening activities, stretching exercises, and postural reactions exercises. The second part included: arm-reaching tasks, arm-hand tasks, hand manipulative tasks for the more affected upper limb through performing functional tasks of daily living activities.~The traditional intervention was carried out three sessions per week for twelve successive weeks."
9694682|NCT04786418|Experimental|Low-calorie diet intervention group|Participants will received a special diet involving 25 regular visits and intensive management. Participants will be given a supply of especially formulated soups and shakes, a special diet in a form of powder that need to be mixed with 200 ml water.
9972465|NCT01320800|Active Comparator|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors. Intervention: Behavioral: Skills for Life
9972466|NCT01320813|Experimental|Robot arm|Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
9972467|NCT01320813|Active Comparator|Open surgery|Patients in this arm will have a thyroidectomy using an open surgical technique.
10153539|NCT04064047|Active Comparator|External Anal application - 5 minutes exposure|Anal application of lidocaine cream 5% for 5 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
10153540|NCT04064047|Active Comparator|External Anal application - 10 minutes exposure|Anal application of lidocaine cream 5% for 10 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
10153541|NCT04064047|Active Comparator|External Anal application - 20 minutes exposure|Anal application of lidocaine cream 5% for 20 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
10153542|NCT04064047|Active Comparator|External Anal plus intrarectal - 5 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 5 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
10153543|NCT04064047|Active Comparator|External Anal plus intrarectal - 10 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 10 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
10153544|NCT04064047|Active Comparator|External Anal plus intrarectal - 20 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 20 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
10153545|NCT04064047|Sham Comparator|Control group|No anal application of lidocaine cream prior to probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
10153546|NCT04064034|Experimental|Subjects with pancreas cancer|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
10153547|NCT04064034|Experimental|Subjects with non-cancerous disorders|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
10153548|NCT04064034|Experimental|Subjects with pancreas cyst|Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
10153549|NCT04063943|Experimental|Sidus Stem-Free Total Shoulder|This arm will include all subjects who are implanted with the Sidus Stem-Free Total Shoulder Arthroplasty System
10153550|NCT04064099|Experimental|Rugby Players|Rugby player will be given custom-fitted mouthguards to be worn for 6-month
10153551|NCT04063891|Placebo Comparator|Placebo-Controlled|Placebo group will have placebo treatment by standing on the LMHFV platform for 20 minutes/day
10153552|NCT04063891|Experimental|Vibration Group|Vibration group is treated with LMHFV at 35Hz, 0.3g, for 20 minutes/day, 5 times/week
10153553|NCT04064073|Experimental|1|
10153554|NCT04064073|Experimental|2|
10153555|NCT04064073|Experimental|3|
10153556|NCT04064892|Experimental|Exercise Intervention|Participants will receive a 12-week, individually-tailored, video conference-based physical activity intervention
10153557|NCT04065022|Experimental|Head stimulation|Each subject will be stimulated at two different days. One day with the presence of topical anesthetic cream on the scalp above the MC and in the other day with absence of the anesthetic cream. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex. Each subject follows three sessions of 12 min length each day. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
10185727|NCT03742869||Patients with HPV integration|The HPV integration status will be checked by GWAS.
10185728|NCT03742869||Patients without HPV integration|The HPV integration status will be checked by GWAS.
10185729|NCT03742843||Group of adenomyosis|Patients with adenomyosis with or without endometriosis
9519977|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
9519978|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
10153558|NCT04065022|Experimental|Arm stimulation|Each subject will be stimulated on only one day. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 2*1 gel-filled cup-electrodes is placed over the contralateral arm. Each subject follows three sessions of 12 min length. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
10153559|NCT04063917|Experimental|Sequence 1|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device ON for the first half and OFF for the second half."
10153560|NCT04063917|Experimental|Sequence 2|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device OFF for the first half and ON for the second half"
10153561|NCT04064008||Primary Total Hip Arthroplasty|Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem
10153562|NCT04063904|Experimental|Mifepristone and misoprostol|Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
10153563|NCT04064060|Experimental|ACE-536|Luspatercept will be administered as a subcutaneous (SC) injection to subjects by the study staff at the clinical site and administration will be documented in the subject's source record.
10153564|NCT04063865|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
10153565|NCT04063865|Experimental|Study Arm|Everolimus monotherapy maintenance immunosuppression
10153566|NCT04063722|Experimental|Modified Benelli Procedure|point x refers to the point where the nipple areola complex should be placed at 18 cm from the mid clavicular line. line A is marked above and medial to the areola and a second radial line above it and parallel to it passing in the point (X) was made and named line B. The ends of this line is curved to approximate and connect to both ends of the line A . two incisions were made on the lines A and B . Next, the whole thickness of the excess skin between line A and the line B was excised (Simon classification 2A, 2B and 3) and subcutaneous mastectomy was done and sent to histopathology. Later on, bleeding control was done by good hemostasis and suction drain was put in its proper site. Finally subcuticular suturing was done by approximation of two incisions using Nylon 3/0. Lastly, sterile pressure dressing was placed.
10153567|NCT04063722|Active Comparator|webester procedure|periareolar incision with excision of the breast tissue
10153568|NCT04063761|Experimental|Esophageal Cooling|Single arm study: Patients receive the Attune Medical Esophageal Heat Transfer Device
9519979|NCT03281759|Active Comparator|Active Coil Helmet|The patients will undergo 18 sessions (627 nm, 70 mW/cm2, 10 J/cm2) at four points of the frontal and parietal region for 30 s each, totaling 120 s three times per week for 6 weeks, lasting 30 minutes of transcranial LED stimulation.
10153569|NCT04063787|Experimental|Fist Assist device (all subjects)|"All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure."
10153570|NCT04063748|Experimental|Experimental|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
10153571|NCT04063748|Placebo Comparator|Placebo|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
10153572|NCT04063735|Experimental|Experimental group|supplement was given for 3 months.
9519980|NCT03281759|Placebo Comparator|Inactive Coil Helmet|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions.
10153573|NCT04063735|Placebo Comparator|Placebo group|Placebo was given for 3 months.
10185730|NCT03742843||Group of endometriosis|Patients with endometriosis without adenomyosis
9662380|NCT04486118|Placebo Comparator|nonCA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
9662381|NCT04485767|Experimental|Progressive Resistance Training Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend structured progressive resistance exercise training sessions 2 times/week for six months.
9662382|NCT04485767|Active Comparator|Flexibility and Balance Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend flexibility and balance exercises training sessions 2 times/week for six months.
9662383|NCT04469855||Ozempic®|Japanese people with type 2 diabetes being treated in normal clinical practice conditions
9662384|NCT04465344|Experimental|IOL implantation experimental|Experimental arm: Trifocal intraocular lens Isatis TF
10153574|NCT04063813|Experimental|40 minute up trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree incline and at 75% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
10153575|NCT04063813|Experimental|40 minute down trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree decline and at 45% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
10153576|NCT04063813|Experimental|Two 20 minute up trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 75% of maximal effort, the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h..Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
10153577|NCT04063813|Experimental|Two 20 min down trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 45% of maximal effort , the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
9972468|NCT01320839||Stroke|People who have had a stroke and have an ankle-foot orthosis.
9972469|NCT01320852|Active Comparator|Milan Criteria|Patients meeting the Milan Criteria
9972470|NCT01320852|Other|No Milan Criteria|Patients not meeting the Milan Criteria
10153578|NCT04063813|Active Comparator|Sedentary trial|No exercise day with isocaloric meals provided at 7:00, 13:00. and 19:00 h.
10153579|NCT04063930|Active Comparator|Lokelma|"Sodium zirconium cyclosilicate Lokelma® 5 g, powder (Astra Zeneca)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
10153580|NCT04063930|Placebo Comparator|Placebo|"Matching placebo (indistinguishable from the active comparator)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
10153581|NCT04064151|Experimental|"My Guide (psychoeducation & self-management program)"|Smartphone-based program plus standard clinical care.
10153582|NCT04064151|No Intervention|Standard Medical Care|Standard clinical care with no smartphone intervention.
10153583|NCT04063774|Experimental|Dengue diagnostic algorithm|single arm of consecutive enrolled subjects with fever in whom the dengue diagnostic algorithms were applied by study physician and blood sample taken for hemogram and dengue reference tests (gold standard)
10153584|NCT04063683|Experimental|Anlotinib with chemotherapy|
10153585|NCT04063618|Experimental|Osteopathic Manipulative Therapy (OMT) Treatment Group|Initial concussion treatment will involve OMT in addition to standard of care treatment. The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles and joints are moved using techniques that include stretching, gentle pressure, and resistance.
10153586|NCT04063618|Active Comparator|Standard of care concussion treatment group|Standard of care concussion treatment without OMT
10153587|NCT04063605|Experimental|Clinical Pilates|Participants in this group will receive twice a week, total 8 weeks of clinical pilates exercise program. Each session will take 45 minutes.
10153588|NCT04063605|Active Comparator|Classic Physiotherapy|Participants in this group will receive twice a week, total 8 weeks of classic physiotherapy exercise program. Each session will take 45 minutes.
9972471|NCT01320865||Subjects with PAH treated with nilotinib|
9972472|NCT01320878|Active Comparator|iloprost low dose group|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
9972473|NCT01320878|Active Comparator|iloprost high dose group|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
9662385|NCT04465344|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens Isatis
9972474|NCT01320878|Placebo Comparator|placebo group|distilled water 2 ml per session
10153589|NCT04063527|Active Comparator|Standard therapy|combination of paclitaxel and carboplatin
10153590|NCT04063527|No Intervention|Observation|Observation
10153591|NCT04063475|Experimental|cyanoacrylate beside sutures for FGG fixation|butyl cyanoacrylate
10153592|NCT04063540|Other|placebo-amiloride|Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.
10153593|NCT04063540|Other|amiloride -placebo|Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.
10185731|NCT03742843||Group of control|Patients without adenomyosis or endometriosis
9662386|NCT04460235|Other|Vaccination|All patients will be vaccinated according to national guidelines
9662387|NCT04433013|Experimental|Treatment group|
9662388|NCT04433013|Placebo Comparator|Control group|
9662389|NCT04427280||Arm A|Suspected acute COVID-19 infection
9662390|NCT04427280||Arm B|Asymptomatic patients with no clinical suspicion of COVID-19
9662391|NCT04373954|Experimental|Forgiveness Therapy|6-month Forgiveness Therapy; Participants meet once per week, in group setting.
9662392|NCT04373954|Active Comparator|Carey Guides|6-month Carey Guides; Participants meet once per week, in group setting.
9662393|NCT04370301|Experimental|Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)|"JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.~CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1.~TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.~GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is > 1,500/mm^3."
9662394|NCT04353128|Experimental|Melatonin|2 mg of melatonin orally before bedtime for 12 weeks
9662395|NCT04353128|Placebo Comparator|Placebo|Identically looking placebo orally before bedtime for 12 weeks
9662396|NCT04347811|Experimental|Death Cafe Arm|Participants undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
9972475|NCT01320891|Experimental|balanced|arm in which the subjects received only balanced solutions
10153594|NCT04063423||hemodialysis study session|"4h hemodialysis session using standard polysulphone dialyzer and Nikkiso dialysis monitors~Minimal dose of unfractionated heparin (UFH) with loading dose 500IE and maintenance 500IE/h, stopped 60 minutes before session end in case of AVF use.~Standard bicarbonate-based ultrapure dialysate. Na, K, Ca, bicarbonate concentrations according to the patient's routine dialysis prescription.~The blood flow rate maximized as per routine nursing care.~Dialysate flow rate fixed at 500 ml/min.~Dialysate temperature between 35.5°C and 36.5°C.~Ultrafiltration according to patient's dry weight and supported ultrafiltration rate.~At the end of the dialysis session the blood will be returned (100ml/min) to the patient."
10153595|NCT04063267|Experimental|E cigarettes|
9669988|NCT05069480|Experimental|Experimental Group|"Participants of the experimental group have received two hours treatment program that included three parts, the first and the second parts were similar to that applied for participants in the control group for one hour followed by few minutes rest, then the third part was applied for one hour. The third part included a virtual reality intervention program by using virtual reality equipment to simulate a range of upper limb tasks related to arm-hand activities and hand manipulative tasks through using different games and soft-wares.~The treatment program for the experimental group was carried out three sessions per week for twelve successive weeks."
9826316|NCT02414932|Active Comparator|Midazolam|Midazolam (0.045 mg/kg; Roche Products Ireland Ltd) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered.
9972476|NCT01320891|Experimental|not balanced|arm in which the subjects received only not balanced solutions that means only normal saline and colloid dissolved in normal saline
9972477|NCT01320904|Placebo Comparator|Closed Kinetic Chain and NMES placebo|"During the stimulation period the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.~We used a 10-channel electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings."
10153596|NCT04063267|Active Comparator|Nicotine Replacement Therapy|
10153597|NCT04063449|Experimental|Experimental:group A|endostar,210 mg,CIV 72h,d1-d3; sintilimab,200mg,IV,d1; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar plus sintilimab for maintenance therapy until PD or intolerable toxicity ;
9972478|NCT01320904|Other|Closed Kinetic Chain Group|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
9972479|NCT01320917|Active Comparator|LNG-IUS|Insertion of a LNG-IUS device
9826317|NCT02414958|Experimental|Empagliflozin low dose|Empagliflozin tablets once daily
9826318|NCT02414958|Experimental|Empagliflozin high dose|Empagliflozin tablets once daily
9826319|NCT02414958|Placebo Comparator|Placebo|Placebo tablets matching empagliflozin once daily
9826320|NCT02415127|Experimental|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
9972480|NCT01320917|Placebo Comparator|Cu-IUD|Insertion of a Cu-IUD
9972481|NCT01320930|Active Comparator|Pulmonary rehabilitation|A standardized 7 week rehabilitation program, including physical training and education.
9972482|NCT01320930|Placebo Comparator|Control|Conventional care
10153598|NCT04063449|Active Comparator|control:group B|endostar,210 mg,CIV 72h,d1-d3; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar for maintenance therapy until PD or intolerable toxicity ;
10153599|NCT04063332||GROUP A|Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
9826321|NCT02415127|Placebo Comparator|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
9972483|NCT01320956|Experimental|Hypnosis|"Pre operative nurse consultation and Hypnosis:~will have hypnosis"
9972484|NCT01320956|Active Comparator|Control|"Pre operative nurse consultation:~usual nurse consultation without hypnosis"
9972485|NCT01320969|Experimental|Mindfulness-Based Stress Reduction course|an eight week mindfulness-based stress reduction course
9972486|NCT01320969|No Intervention|Waitlist group|waitlist group
9972487|NCT01320982|Active Comparator|minocycline|minocycline
9972488|NCT01320982|Active Comparator|pramipexole|pramipexole
9972489|NCT01320982|Active Comparator|acetylsalicylic acid|acetylsalicylic acid
9972490|NCT01320982|Placebo Comparator|Placebo|Placebo
9972491|NCT01320995|Experimental|Experimental arm|In this arm, perineal ultrasound is used directly after delivery in order to hypothetically better detect anal lesions.
9972492|NCT01320995|No Intervention|Standard arm|No perineal ultrasound immediately after delivery.
9972493|NCT01321021|Experimental|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan, Diphenhydramine
10153600|NCT04063332||GROUP B|Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
10153601|NCT04063332||GROUP C|Patients with sepsis as defined by the Sepsis-3 classification criteria3
10185732|NCT03742817|Experimental|Sweet-Flavor 4.5% Nicotine (Salt)|Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.
10153602|NCT04063293|Experimental|PRP injection|PRP is prepared using a special device (VS-400, Genesis Comp, Korea). For each application a kit (e+ PRP, Genesis Comp, Korea) will be used. 18 cc of venous blood will be collected from the patient into the syringe with 2 cc of anticoagulant, and will be gently inverted. The sample will be slowly injected into the e+ PRP kit. The kit will be centrifuged under 1,500G for 4 minutes, which will separate the blood components into 3 different layers. The rot at the top of the kit will be pressed until the bottom of the piston will touch the red blood cell layer, and the rot will be turned clockwise to close it. The cap will be opened and the small syringe will be connected to the cap for extracting PRP. The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound
10153603|NCT04063631||1/Birth cohort|Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.
10153604|NCT04063631||2/mild wheezers and controls|Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls
10153605|NCT04063631||3/pre-school aged severe wheezers|50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.
10153606|NCT04063631||4/school aged severe asthmatics|50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.
10153607|NCT04063345|Experimental|IVUS-guided PCI|Percutaneous intervention under IVUS-guidance
10153608|NCT04063345|Active Comparator|Angiography-guided PCI|Percutaneous intervention under angiograhy-guidance only
10153609|NCT04063319|Experimental|High-fidelity simulation|The participants in the intervention group will receive an high-fidelity simulation intervention
10153610|NCT04063319|No Intervention|Control|The participants in the control group will not receive any instructional intervention
10153611|NCT04063358|Experimental|Lucentis injected Pre-operatively|Lucentis injected 2 weeks before cataract surgery
10153612|NCT04063358|Active Comparator|Lucentis injected intra-operatively|Lucentis injected during the course of the surgery by cataract surgeon.
10153613|NCT04063358|Experimental|Lucentis injected post-operatively|Lucentis injected 2 weeks after cataract surgery
10153614|NCT04063254|Experimental|High-Dose Stereotactic Radiotherapy|
10153615|NCT04063254|Active Comparator|Standard-Dose Stereotactic Radiotherapy|
10153616|NCT04063462|Experimental|Cohort 1|Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC
10153617|NCT04063462|Experimental|Cohort 2|Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC
10153618|NCT04063501||Advanced stage unresectable Non-Small Cell Lung Cancer|Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
9972494|NCT01321034|Other|Niacin/Laropiprant|Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study
10153619|NCT04063592|Experimental|Intervention|Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures
10153620|NCT04063553|Other|Intervention arm|Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.
9972495|NCT01321047|Active Comparator|Propofol group|the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV).
10153621|NCT04063553|Other|Control arm|The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given
10153622|NCT04063514|Experimental|Focused Ultrasound|The ultrasound treatment will last either 1 hour or 20 minutes total time for the DWL device or Brainsonix Focused Ultrasound Device, respectively.
10153623|NCT04063098|Other|All participants|Participants scheduled for endoscopic sleeve gastroplasty
10153624|NCT04063137|Active Comparator|Anthocyanin fortified bread|White bread is fortified with a 25% (w/w) black rice anthocyanin extract. Extract fortification is 4% w/w of bread flour.
10153625|NCT04063137|Placebo Comparator|White bread|
10153626|NCT04063228|Active Comparator|Standard of care|
10153627|NCT04063228|Active Comparator|Simple Skill Group|
10153628|NCT04063150|Active Comparator|IPV at 14 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 14 weeks and 9 months of age.
10153629|NCT04063150|Active Comparator|IPV at 6 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 6 weeks and 9 months of age.
10153630|NCT04063150|Active Comparator|fIPV ID at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
10153631|NCT04063150|Active Comparator|fIPV ID at 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
10153632|NCT04063150|Active Comparator|fIPV IM at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
10153633|NCT04063150|Active Comparator|fIPV 0.1mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
10153634|NCT04063150|Active Comparator|fIPV 0.2mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.2 mL) of IPV at 14 weeks and 9 months of age.
10153635|NCT04063644|Experimental|Vis Glyc Neo|"Vis glyc eye drops is administered.~Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate"
10153636|NCT04063644|Active Comparator|physiological saline solution|Physiological saline solution ALVITA is administered.
10185733|NCT03742817|Placebo Comparator|Sweet-Flavor 0 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.
10153637|NCT04062968|Experimental|Video education|"Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit."
10153638|NCT04062968|No Intervention|Usual care|Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing).
10153639|NCT04062929||Intervention|The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
10153640|NCT04063189|Experimental|First Relapsed Multiple Myeloma|
10153641|NCT04063072|No Intervention|Usual care|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to current hospital clinical practice.
10153642|NCT04063072|Experimental|ERAS protocol|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to ERAS protocol.
10153643|NCT04063163|Experimental|A|HLX 10+chemotherapy (Carboplatin-Etoposide)
10153644|NCT04063163|Placebo Comparator|B|Placebo+chemotherapy (Carboplatin-Etoposide)
10153645|NCT04062773|Experimental|TRF|Eating restricted to between midday and 6pm.
10153646|NCT04062773|Placebo Comparator|Normal timing of food intake.|Eating between 8am and 11pm.
10153647|NCT04063397||Preeclampsia|40 patients diagnosed with preeclampsia with or without severe features
10153648|NCT04063397||Control|20 Control group of patients without hypertensive disorders of pregnancy
10153649|NCT04063436|Experimental|Experimental|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
10153650|NCT04062994||Intervention Group|All patients scheduled for surgery at a UCLA site in the one year period after go-live
10153651|NCT04062838|Experimental|Prolotherapy|Injection of 20% dextrose (50 % dextrose diluted with 0.5% lidocaine) into the rotator cuff tendinous insertions as well as into the tear. All injections are performed under ultrasound.
10153652|NCT04063046|Active Comparator|General anesthesia|General anesthesia involving intubation or supraglottic airway device insertion
10153653|NCT04063046|Experimental|peripheral nerve block|popliteal sciatic nerve block
10153654|NCT04063124|Experimental|Intermittent D+Q|Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
10153655|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for initiation and follow-up of the ketogenic diet
10153656|NCT04063020||Reconstructive plastic surgery procedure|Minors with ear aplasia and initiating a reconstructive plastic surgery procedure
10153657|NCT04062747|Active Comparator|I-gel LMA|After standard anesthesia i-Gel was placed into the patient.
10153658|NCT04062747|Active Comparator|Ambu Aura-i|After standard anesthesia Ambu Aura-i was placed into the patient.
10153659|NCT04062760|Active Comparator|Standard diuretic therapy (SDT)|Furosemide +/- spironolactone or potassium canrenoate
10153660|NCT04062760|Experimental|Early sequential nephron blockade (ESNB)|Furosemide + metolazone + acetazolamide +/- spironolactone or potassium canrenoate
10153661|NCT04062890|Active Comparator|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 1-7), 1000 mg twice daily for 7 days (days 8-14), 1500 mg twice daily for 10 days (days 15-24), 1000 mg twice daily for 7 days (days 25-31), 500 mg twice daily for 7 days (days 32-38).
10153662|NCT04062890|Placebo Comparator|Placebo|Placebo - Pill, 1 pill twice daily for 7 days (days 1-7), 2 pills twice daily for 7 days (days 8-14), 3 pills twice daily for 10 days (days 15-24), 2 pills twice daily for 7 days (days 25-31), 1 pill twice daily for 7 days (days 32-38).
10153663|NCT04063059|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based in-person group sessions and telephone counseling intervention designed for African American women who are overweight or obese.
10153664|NCT04063059|No Intervention|Control|Usual care
9662397|NCT04347811|No Intervention|Control Arm|Participants do not undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
9662398|NCT04346524||microbiome sampling|pregnant women with type 1 diabetes
9662399|NCT04340076|Experimental|Dose reduction|Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.
9662400|NCT04340076|Active Comparator|Normal dose|Patients will continue treatment with the normal/maintenance dose of the biologicals.
9662401|NCT04325880|Placebo Comparator|Placebo arm|Patients in this arm will receive a placebo formula
9662402|NCT04325880|Active Comparator|Mirabegron arm|Patients in this arm will receive Mirabegrone 50 mg once daily
9662403|NCT04325880|Active Comparator|Tamsulosin arm|Patients in this arm will receive tamsulosin o.4 mg once daily
9662404|NCT04325880|Active Comparator|Solifenacin arm|Patients in this arm will receive solifenacin 10 mg once daily
9662405|NCT04323137|No Intervention|Control|This group receives no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
10153665|NCT04062916||women with endometriosis|65 women whose main symptom was pain and who did not respond to medical treatment and underwent endometriosis surgery
9669989|NCT05069688|Experimental|Dolutegravir PK during standard and high-dose rifampicin|This is a single arm study: all patients are started on HIV/TB cotreatment considered standard of care and then for two weeks (study weeks 20-21) high-dose rifampicin is given during which safety and pharmacokinetics are examined.
9669990|NCT05069415|Active Comparator|Emmetropia|The target refraction for both eyes will be emmetropia (± 0.25 D).
10153666|NCT04062903|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed.
9669991|NCT05069415|Experimental|Mini monovision|The target refraction for the dominant eye will be plano (± 0.25 D) and for the non-dominant eye between -0.75D ±0.15.
9669992|NCT05069506|Experimental|Glucose as reference food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9669993|NCT05069506|Experimental|Goat milk as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9694683|NCT04786223|Other|C-11 ER176 PET/CT|C-11 ER176 is an investigational radiopharmaceutical that will be produced under cGMP in the Mayo Clinic Cyclotron Facility. The imaging agent (C-11 ER176) will be administered on an outpatient basis. It will be administered at a single time IV prior to the PET imaging.
9977212|NCT01359241|Experimental|closed-loop insulin delivery|Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
9977213|NCT01359241|Active Comparator|Usual diabetes treatment regimen|Usual non-insulin glucose-lowering medications
9977214|NCT01359267|Experimental|Imaging|
10153667|NCT04062903|Active Comparator|Delayed Appointment|Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
10153668|NCT04062942||DDD patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.
10153669|NCT04063033|Experimental|IV Iron treatment|Patients will be administered IV Iron for 3-5 days. 125 mg per day.
10153670|NCT04063033|No Intervention|No IV Iron treatment|Patients will receive standard treatment for heart failure without IV Iron.
10153671|NCT04062682|No Intervention|Controls|No changes in dietary habits
10153672|NCT04062682|Experimental|Healthy Diet|Changes in dietary habits only
10185734|NCT03742817|Experimental|Sweet-Flavor 6 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.
10185735|NCT03742817|Active Comparator|Usual e-Cigarette|Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.
10185736|NCT03742804|Experimental|G100 injections|All patients will receive 6 intratumoral G100 injections alone over 5 weeks. There will be a 4-week break for restaging. Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
10185737|NCT03742791|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
10185738|NCT03742791|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
10185739|NCT03742778|Experimental|Incentivizing reflection|"Participants will receive three texts each week asking a question to reflect on their latest workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you felt right after your last workout? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
10185740|NCT03742778|Experimental|Incentivizing Exercise|"Participants will receive three texts each week asking a question for them to reflect on. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you are feeling now? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
10185741|NCT03742765|Experimental|Incentivizing Planning|Participants will receive three texts each week asking a question to help plan for the next workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout).
10185742|NCT03742765|Experimental|Incentivizing Exercise|Participants will receive three texts each week asking a question about their workout. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout).
10153673|NCT04063111|Active Comparator|group A|Group A will be treated with vacuum assistant closure
10153674|NCT04063111|Active Comparator|group B|Group B will be treated with conventional dressing
10153675|NCT04062955|Experimental|Prevention (dietary intervention)|"DIETARY INTERVENTION: Participants receive dietary counseling with a dietitian in person or via telephone to support adherence to a diet based on the AHEI guidelines once weekly for up to 12 weeks.~DXA ONLY STUDY: Participants undergo DXA scan for breast density measurement at baseline and at 12 weeks."
10153676|NCT04062487|Experimental|Lumbar pedicle screws implantation of traditional procedure|traditional method of lumbar pedicle screws implantation
10153677|NCT04062695|Active Comparator|Tofacitinib|5 mg oral BID
10153678|NCT04062695|Placebo Comparator|Placebo|matching Placebo BID
10153679|NCT04062721|Experimental|Chemotherapy + RFA + in situ immunotherapy|Patients with non-resectable CRC liver-only metastases.
10153680|NCT04062656|Experimental|B - Nivolumab|"Responders~6 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 postoperative cycles nivolumab (i.v., 240mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 additional cycles nivolumab (i.v., 240mg, q2w)+FLOT (i.v., 240mg, q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480 mg, q4w)"
10153681|NCT04062656|Experimental|D - Nivolumab + relatlimab|"Responders~6 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 postoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 additional cycles nivolumab (i.v.,240 mg, q2w)+FLOT (i.v.,q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
9669994|NCT05069506|Experimental|Goat milk and currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9669995|NCT05069506|Experimental|Currants as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9694684|NCT04786340|Placebo Comparator|Placebo: 4 mL of matching placebo topical solution.|The placebo solution contains the same ingredients as the active solution with the exception of the active WST-057. It is dispensed with a pump to deliver 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
10153682|NCT04062396|Active Comparator|Eurosets REMOWELL 2 oxygenator|
10153683|NCT04062396|Active Comparator|LivaNova INSPIRE oxygenator|
10153684|NCT04062383|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
10153685|NCT04062643||Patients with obesity|Obesity in those with BMI ≥30 kg/m2
10153686|NCT04062643||Patients without obesity|Normal weight was considered in the patients with BMI <30 kg/m2
10153687|NCT04062435|Experimental|Interventional Group|"Peschke®TE 0.25 % application in the INFERIOR FORNIX~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
10153688|NCT04062435|Active Comparator|Control Group|"Peschke®TE 0.25 % application on the CORNEA~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
10153689|NCT04062331|Placebo Comparator|Placebo group|This group will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) without any frequency (device doesn't running; it means, device turned off) but the same duration of sessions.
10153690|NCT04062331|Experimental|Group under TMS 1 Hertz treatment|1 Hertz group (1 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 1 Hertz.
10153691|NCT04062331|Experimental|Group under TMS 5 Hertz treatment|5 Hertz group (5 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 5 Hertz .
10153692|NCT04062526|Experimental|Patient with Parkinson Disease|"Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment."
10153693|NCT04062526|Experimental|Healthy Control|Subject must be a Healthy.
10153694|NCT04062500||Patients with heart failure|patients treated in the hospital for acute heart failure in China
10153695|NCT04062253||HCV or HIV negative|Individuals who test negative for HCV or HIV are given information regarding ways of transmission.
10153696|NCT04062253||HCV and HIV positive|Individuals with a positive test for HCV o HIV are offered delivery or accompaniment to specialist health care.
10153697|NCT04062474|Experimental|Epidural Intervention with Steroids|Epidural Intervention with Steroids
10153698|NCT04062461|Experimental|self-care promotion|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
9826322|NCT02415244||Age 0 - 18|TEE visualization of the spinal cords in patients age between 0 - 18
9669996|NCT05069506|Experimental|Sultanina raisins as test food|Twelve healthy, normal-weight subjects (male: 4, female: 8) after 10-14 hr fast, consumed 25g available carbohydrate from glucose, three times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from a) goat milk yogurt, b) goat milk yogurt and currants, c) currants, d) sultanina raisins, one time each, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9694685|NCT04786340|Experimental|WST-057 active: 4 mL of WST-057 (4%; 146 mg of pirenzepine free base monohydrate) topical solution|The WST-057 is the active topical solution and contains pirenzepine free base monohydrate. It is dispensed with a pump to deliver (with 4 pumps) 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
10153699|NCT04062461|Active Comparator|Control group|routinely management in the HF. Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
10153700|NCT04062175|Active Comparator|cephalosporin arm|72 women will receive single antibiotic chemotheraby first generation cephalosporin (cefazolin) 2 gm iv within 30 minutes before skin incision
10153701|NCT04062175|Active Comparator|cephalosporin +azithromycin arm|72 women will receive combined antibiotic chemotherapy azithromycin (Azrolid) 1 gm single oral dose 2 hours before cesarean delivery + cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
10153702|NCT04062240||Additional BIS sensor|Many providers caring for cardiovascular surgical patients utilizes BIS monitoring to gauge depth of anesthesia. The current practice involves placement of the BIS sensor on the patient's forehead per the manufacturer's recommendation on arrival to the operating room. The intervention in this study will add an additional BIS sensor to the patient's forehead. After syncing the two monitors for time, and ensuring appropriate skin contact and signal quality of both sensors, BIS monitoring will commence. BIS readings will be available every 12 seconds during the duration of the study, yielding up to 240 points of comparison per enrolled patient.
10153703|NCT04062604||Femur fracture|Stabilization of femur fracture according to the AO fundation guidelines
10153704|NCT04062604||Hip alloplasty|Endoprothesis
10153705|NCT04062604||Knee alloplasty|Endoprothesis
10153706|NCT04062604||Knee arthroscopy|Resection of the meniscus lesion or anterior cruciatus ligamentum reconstruction
10153707|NCT04062149|Active Comparator|Control Group|The control group will be the group where the participants receive only their normal physiotherapy treatment.
10153708|NCT04062149|Experimental|Experimental Group|The experimental group will be the group where participants receive physiotherapy aimed at improving their ability to stand on their weaker leg alongside their normal physiotherapy treatment.
10153709|NCT04062578|Experimental|CD Oliver|Female first team players of the club that plays in the National Second Division league.
10153710|NCT04062578|Active Comparator|SD Huesca|Female first team players who play in the Aragonese Territorial First league
10153711|NCT04062513|Experimental|Olfactive stimulation intervention with familiarization|Participants will receive the olfactive stimulation intervention with mothers' milk odor during a previous period of nine hours and during heel prick. Sucrose will be also administered during heel prick.
10153712|NCT04062513|Experimental|Olfactive stimulation intervention|Participants will receive the olfactive stimulation intervention with mothers' milk odor during heel prick only. Sucrose will be also administered during heel prick.
10153713|NCT04062513|Other|Standard care|In the control arm, participants will receive the standard care for pain which is sucrose administration.
10153714|NCT04062318|Experimental|Tactile detection task with online TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over somatosensory cortex during the tactile detection task.
10153715|NCT04062318|Active Comparator|Tactile detection task with online control TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over a control brain region during the tactile detection task. This control condition is intended to mimic the peripheral (e.g. cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
10153716|NCT04062123|Experimental|Dexmedetomidine|Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
10153717|NCT04062123|Experimental|Propofol|Subjects in this group will receive propofol during the drug portion of the experiment.
10153718|NCT04062123|Experimental|Fentanyl|Subjects in this group will receive fentanyl during the drug portion of the experiment.
10153719|NCT04062591|Active Comparator|piroxicam|piroxicam group who received induction with piroxicam(0.4mg/kg) IM
10153720|NCT04062591|Sham Comparator|placebo|saline IM in the same dose of piroxicam
10153721|NCT04062344||Short oral drug provocation test|Minors performing a short (1-4 days) drug provocation test
10153722|NCT04062344||Prolonged oral drug provocation test|Minors performing a prolonged (5-8 days)drug provocation test
10153723|NCT04062565|Experimental|Experimental|Treprostinil and Riociguat
10153724|NCT04062136|Experimental|Stem cell transplantation|1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation
10153725|NCT04062201|Experimental|Study Strategy|
10153726|NCT04062201|Active Comparator|Control Strategy|
10153727|NCT04062370|Experimental|1+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 1 time ( month 1), and then IVR is required if central macular thickness (CMT) greater than 300 μm during the follow-up observation (Pro re nata, PRN, means if necessary).~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
9694686|NCT04786587||Pregnant woman|
10153728|NCT04062370|Active Comparator|3+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 3 consecutive times ( months 1, 2 and 3 ),and then IVR is required if CMT greater than 300 μm during the follow-up observation (PRN).~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
9669997|NCT05069506|Experimental|Goat milk as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
10153729|NCT04062305|Experimental|Diagnostic (nTMS, sensory testing)|Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.
10153730|NCT04062357|Active Comparator|lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
10153731|NCT04062357|Placebo Comparator|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks (One to two applications (1-2 ml) of alcohol 70% sprays).
10153732|NCT04062110|Active Comparator|Long plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with long plaster casts (above-elbow, Long plaster casts).
10153733|NCT04062110|Active Comparator|Short plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with short plaster casts (below-elbow, Short plaster casts)
10153734|NCT04062162|Active Comparator|Interventional group|Walking football training
10153735|NCT04062162|No Intervention|Control group|Usual care
9669998|NCT05069506|Experimental|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) were offered a standardized breakfast and 2h after consumed one of the two preloads (goat milk yogurt and milk with lactic acid) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
9669999|NCT05069428|Experimental|ramelteon|ramelteon 8 mg crushed tablet daily at 20:30
10153736|NCT04062214|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
10153737|NCT04062214|No Intervention|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
10153738|NCT04061837|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
10153739|NCT04061993|Experimental|Intervention Group OBV|Intervention Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
9670000|NCT05069428|Placebo Comparator|placebo|placebo powder equivalent grams at 20:30
10153740|NCT04061993|Active Comparator|Control Group OBV|Control Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
9670001|NCT05069467|Experimental|Acupuncture|Licensed acupuncturists with more than 5 years of experience will be responsible for administering interventions three times per week for 6 weeks. The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling. Acupuncture was defined as targeting the 10 bilateral acupuncture points: Xinshu (BL15), Shenshu (BL23), Zhongliao (BL33), Sanyinjiao (SP6), Yinlingquan (SP9). The needle will be left in place for 30 minutes with brief manipulation at the beginning, middle, and end of therapy.
9670002|NCT05069467|Sham Comparator|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
9670003|NCT05069467|No Intervention|Usual Care|Patients receiving usual care received neither acupuncture nor sham acupuncture. After the 6-week assessment, patients will be offered the option to receive acupuncture treatment as the acupuncture group.
9670004|NCT05069493||Tension-free|Hiatal hernia repair by tension-free mesh closure
9670005|NCT05069493||Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
9670006|NCT05069324||Acromegaly patients not adequately controlled by any kind of SSAs monotherapy|Acromegaly patients not adequately controlled by any kind of SSAs monotherapy, requiring PEG in combination with SSAs or PEG monotherapy
9670007|NCT05069324||Acromegaly patients adequately controlled by medical treatment|Acromegaly patients adequately controlled by medical treatment, by any kind of SSAs or by PEG
10153741|NCT04061993|Experimental|Intervention Group SBNM|Intervention Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
10153742|NCT04061993|Active Comparator|Control Group SBNM|Control Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
10153743|NCT04061824|Experimental|Patients with fixed-dose combination of 2 drugs|Medication for hypertension and dyslipidemia in these group was fixed-dose combination of 2 drugs
10153744|NCT04061824|Active Comparator|Patients with 2 separated drugs|Medication for hypertension and dyslipidemia in these group was 2 separated drugs for each disease.
10153745|NCT04061785|Active Comparator|Participants in 12 week Judo Inspired Exercise program|"The subjects will participate in a 12 week judo inspired training program (45 minute sessions once a week) with the specific aim to increase physical qualities related to falls and injuries during falls.~The subjects will be tested before and after the 12 week period"
10153746|NCT04061785|No Intervention|Control Group|The subjects will go about their normal life for 12 weeks without any intervention. The persons will be tested before and after the 12 week period.
10153747|NCT04061772|Experimental|BCHEP|Bortezomib：1.3mg/m2, intravenous drip, d1,d8, every 3 weeks； Etoposide：100mg/m2,intravenous drip, d1-3, every 3 weeks； Cyclophosphamide：750mg/m2,intravenous drip, d1, every 3 weeks； Pharmorubicin：75mg/m2,intravenous drip, d1,every 3 weeks； Prednisone：100mg,tablet by mouth, d1-5, every 3 weeks.
10153748|NCT04061928|Experimental|Combination of toripalimab with preoperative chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive toripalimab and combined with preoperative chemoradiotherapy and operation.~generic name：PD-1 dosage form：Injection dosage：240mg (6ml) frequency：every 3 weeks duration：4 times before operation and 4 times after operation"
10153749|NCT04061733|Experimental|Experimental|Subjects who will receive an injection of the hydrogel
10153750|NCT04061876|Experimental|Ruxolitinib combined with Corticosteroids|Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone: 1mg/kg/d , iv or iv gtt for at leas 5 days, then taper according to the clinical response.
9670008|NCT05069311|Experimental|Hysterectomy|Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria
10153751|NCT04061876|Active Comparator|Corticosteroids|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
9670009|NCT05069298|Experimental|INTERVENTION|Silibinin (A) for three months, with an administration regimen of 3 oral doses of 300 mg per day, before each main meal.
9972496|NCT01321047|Active Comparator|BPS group|the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.
9972497|NCT01321060|Active Comparator|Conservative treatment|Conservative treatment group with only drugs.
9972498|NCT01321060|Experimental|Continuous catheter drainage|Once the diameter of the fluid collection is more than 6cm, continuous catheter drainage will be applied.
9972499|NCT01321060|Experimental|Repeated aspiration|Once the diameter of the fluid collection is more than 6cm, aspiration is applied and draw the tube out immediately after aspiration.
9972500|NCT01321086|Active Comparator|Motivational Interviewing|Motivational Interviewing (MI) is an effective counseling method in individuals who are less ready to change their behavior. 9 MI sessions will be conducted over the course of the six month intervention.
10153752|NCT04062084|Experimental|Multifunctional Cataract-assisted Retractor|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
9670010|NCT05069298|Placebo Comparator|CONTROL|Similar treatment regimen, but with a placebo.
10153753|NCT04062084|Experimental|Capsule Retractor|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
10153754|NCT04061811||HF (heart failure)|Patients with end stage renal disease requiring dialysis with reduced or preserved ejection fraction.
10153755|NCT04061811||Control|Patients with end stage renal disease requiring dialysis without HF.
10153756|NCT04062019|Experimental|interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 once every other day, for 3 months.
10153757|NCT04062045|Experimental|Group A - Local anesthetic group|Group A will receive a continuous infusion of ropivacaine 0,2% 5ml/h and intermittent boluses of the same local anesthetic 15ml/4h through the erector spinae catheter.
10153758|NCT04062045|Placebo Comparator|Group B - Placebo group|Group B will receive a continuous infusion of 0,9% saline 5ml/h and intermittent boluses of the same fluid 15ml/4h through the erector spinae catheter.
10153759|NCT04061798|Experimental|ACT guided heparinization|Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
10153760|NCT04061798|Active Comparator|5 000 IU of heparin|A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Depending on that ACT value near the end of surgery, the local protamine can be given to neutralize the effect of heparin. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.
10153761|NCT04061863|Experimental|ER+/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
10153762|NCT04061863|Experimental|ER-/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
10153763|NCT04061759|Active Comparator|Soft tissue mobilization&stabilization exercises|"The following manual therapy techniques will be applied:~Soft Tissue Mobilization;~Pretzel Maneuvers;~Pelvis Backward-Distraction;~Trunk Rotation;~Multifidus Mobilization; and~Piriformis Transverse Friction Massage"
10153764|NCT04061759|Active Comparator|Kinesiotape&stabilization exercises|The Kinesio® Taping muscle technique, with 10-25% of the stretch of the tape, will be applied to the sacrospinalis, quadratus lumborum, gluteus medius/maximus and piriformis muscles, based on the the weakness that patient's muscles had. Factors interfering with tape adhesion, such as sweat or hair, will be removed before the application. The tape can stay in place for 3-5 days due to its water resistant and breathable properties
10153765|NCT04061759|Active Comparator|Stabilization exercises|The core stabilization exercise treatment program consisted of the following exercises: a posterior pelvic tilt exercise, lower abdominal muscle isometric strengthening, hip adductor muscle isometric strengthening, lumbar stabilization exercises with a Swiss ball, upper and lower abdominal muscle strengthening exercises with a Swiss ball, oblique abdominal muscle strengthening exercises with a Swiss ball, quadratus lumborum muscle stretching with a Swiss ball, back extensor muscle strengthening exercises with a Swiss ball, a slump exercise (sciatic nerve stretching), lumbar lordosis exercises with a Swiss ball, bridge exercises with a Swiss ball, single leg bridge exercises on a Swiss ball, posture exercises, push-up exercises with a Swiss ball, and squat exercises with a Swiss ball
10153766|NCT04061759|Active Comparator|Reflex therapy&Stabilization exercises|Mobilization of each vertebra and pulls were applied from the medial side of the toe to the medial malleolus and to the heel by hand or with the help of an apparatus, including the cervical, thoracic and lumbar spine reflex zones. Finally, the procedure was finished by making a V-shaped maneuver with a thumb in the direction of spinal nerve exits.
10153767|NCT04062006|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
10153768|NCT04061668|Other|single needle path PECS I and II block group(|The probe is placed inferior to the clavicle . A probe and needle is introduced with in-plane technique . The US is placed below outer third of the clavicle showing pectoralis major and minor muscles then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles is visualised . The US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle is inserted from caudal to cranial using an inclined manner, 15mL of bupivacaine 0.25% is put between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject 15 ml of bupivacaine in thel plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection will be visualized .
10153769|NCT04061668|Sham Comparator|double needle path PECS I and II block group|The probe will be placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles are visualised, then the needle is inserted in plane with probe and 15mL of bupivacaine are put into between pectoralis muscles. In the second puncture , the US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles are identified , the needle will be inserted in plane with the probe from caudal to cranial , 15mL of bupivacaine will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
10153770|NCT04061681|Experimental|Behavioral Intervention (BIPAMS)|Participants will complete a 16-week behavioral intervention to increase physical activity levels.
10153771|NCT04061681|No Intervention|Waitlist Control|Participants will have 16-weeks of no intervention or interaction.
9972501|NCT01321086|Active Comparator|PACE|Patient-centered Assessment and Counseling for Exercise (PACE) is a protocol that targets known modifiable determinants of behavior change to motivate participants to increase their physical activity (walking).
10153772|NCT04061551|Experimental|EC Clinic Support|Whole of practice interventions delivery through nurse-led model
10153773|NCT04061525||Patients with coronary bifurcation lesions|Patients from 18 to 90-years old with coronary bifurcation lesions with significant >50% diameter stenosis artery scheduled for intervention of the main vessel (Medina types: 1x1, x11, 111)
10153774|NCT04061395|Experimental|Guselkumab|Guselkumab 200 mg Q4W; subcutaneous injections; duration of 16 weeks.
10153775|NCT04061304|Experimental|Active rTMS (Anorexia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the anorexia group will receive low-frequency treatment (1 Hz, 60 second cycles, 30 second inter-train interval, 20 trains, 1200 total pulses) at 120% of the resting motor threshold to the orbitofrontal cortex"
10153776|NCT04061304|Experimental|Active rTMS (Bulimia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).~For the second session each day the patients in the bulimia group will receive high-frequency (10 Hz, 5 second cycles, 50 pulses, 25 second inter-train interval, 60 trains, 3000 total) at 120% of the resting motor threshold treatment to the left dorsomedial prefrontal cortex"
10153777|NCT04061304|Sham Comparator|Sham rTMS (Anorexia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Anorexia Nervosa group however their will be no actual brain stimulation.
10153778|NCT04061304|Sham Comparator|Sham rTMS (Bulimia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Bulimia Nervosa group however their will be no actual brain stimulation.
10153779|NCT04061408|Experimental|FSRT|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
10153780|NCT04061512|Active Comparator|DRC Arm|The DRC arm (chemotherapy) is the control arm and consists of rituximab, cyclophosphamide and dexamethasone. It is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.
9826323|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
9670011|NCT05069025|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
9972502|NCT01321086|No Intervention|Control|
9972503|NCT01321099|Experimental|NaFeEDTA|
9972504|NCT01321099|Experimental|Phatase|
9972505|NCT01321099|Experimental|Vitamin C|
9972506|NCT01321112|Experimental|Conversion arm|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
9972507|NCT01321125|Experimental|Whole group of 30 volunteers|The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and two controls.
9972508|NCT01321125|Experimental|test group of substantivity|The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City)
9972509|NCT01321138|Active Comparator|Femoral nerve block|Continuous femoral nerve block with bolus of ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2 % 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 30 patients.
9972510|NCT01321138|Placebo Comparator|PCA morphine|Patients with iv morphine with self administration with a PCA-system, associated with paracetamol and ibuprofen.
9972511|NCT01321164|Active Comparator|Fumaric acid esters|Fumaric acid esters monotherapy
9972512|NCT01321164|Experimental|fumaric acid esters plus narrow band UVB|Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
9972513|NCT01321190||Low Back Pain|Individuals who experience bothersome low back pain.
9972514|NCT01321190||Headache|Individuals who experience bothersome headaches.
9972515|NCT01321190||Fibromyalgia|Individuals who experience bothersome fibromyalgia-related pain.
9972516|NCT01321203||Group-A, use of air;|
9972517|NCT01321203||Group-B use of CO2|
9670012|NCT05069025|Other|non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
9670013|NCT05069272|Active Comparator|Intervention|Synergistic combination of Bakuchiol and Ethyl Linoleate
9670014|NCT05069272|Placebo Comparator|Vehicle|No active ingredients
9670015|NCT05069064|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
9972518|NCT01321216||Hospitalized Gastroenteritis|Children under 5 years of age hospitalized with gastroenteritis
9972519|NCT01321229||With sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission Diagnosis and medical care by a sleeping disorder qualified specialist
9972520|NCT01321229||Without sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission
9972521|NCT01321242||achieving resting HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
9972522|NCT01321242||non-achieving HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
9972523|NCT01321255|Experimental|FDC Fixed Dose Combination|
9972524|NCT01321255|Active Comparator|Conventional treatment|
9972525|NCT01321268|Experimental|dietary supplement for cellulite|PUFA, resveratrol, lycopene, beta carotene, lutein
9972526|NCT01321268|Active Comparator|Control|Vitamin E
9972527|NCT01321281|Experimental|AquaCal|Osteoarthritis and healthy volunteers
9972528|NCT01321281|Active Comparator|AquaPT|Osteoarthritis
9972529|NCT01321294|Active Comparator|Nissen fundoplication|
9972530|NCT01321294|Active Comparator|Toupet fundoplication|
9972531|NCT01321307||Sorend|Group no. 1 shall receive Sorend following diagnosis of aphtostomatitis or mucositis.
9972532|NCT01321307||Sorend placebo|Group no. 2 shall receive Sorend placebo following diagnosis of aphtostomatitis or mucositis.
9972533|NCT01321320|Experimental|Active stimulation|This group will receive active muscle stimulation for 1 week to the quadriceps muscle - the leg will be randomly assigned.
9972534|NCT01321333|Experimental|HuCNS-SC cells|Single dose intramedullary administration of HuCNS-SC cells
9972535|NCT01321346|Experimental|Leukemia Patients|Patients with ALL and AML will be treated in one arm of the study.
9972536|NCT01321346|Experimental|Lymphoma Patients|Patients with NHL or HD will be treated in one arm of the study.
9972537|NCT01321398||Critically Ill patients receiving HFO|
9972538|NCT01321411||1. ARDS/COPD|Critically ill patients with either ARDS or COPD weaning from mechanical ventilation.
9972539|NCT01321411||2. Healthy Volunteers|
9972540|NCT01321424||Aqueous Dificiency Dry Eye|20 Participants
9972541|NCT01321424||Meibomian Gland Disease Dry Eye|20 Participants
9972542|NCT01321424||Normal Eye|20 Participants
9972543|NCT01321450||Group A|Preparation with Harmonic WAVE
9972544|NCT01321450||Group B|Preparation with conventional modalities
9972545|NCT01321489|Experimental|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
9972546|NCT01321489|Active Comparator|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
9972547|NCT01321528||IBSR Intervention group|30 nurses in the geriatric departments in TASMC
9972548|NCT01321567||Rabeprazole Sodium|
9972549|NCT01321580|Experimental|Group A|
9972550|NCT01321593||hemoglobin determination|emergency unit patients
9972551|NCT01321619|Experimental|Varicell|Drug A(Varicell) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
9972552|NCT01321619|Experimental|Placebo daflon (Drug D)|Drug D (Placebo Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
9972553|NCT01321658|Experimental|Geriatric intervention|
9972554|NCT01321658|No Intervention|Control|
9972555|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
9972556|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, fasted|
9972557|NCT01321671|Other|Pregabalin immediate release, 300 mg|
9972558|NCT01321762||1|Pregnant Women with singleton pregnancy
9972559|NCT01321775|Experimental|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|
9972560|NCT01321788||STUDY GROUP|will receive the study drug Innohep ® for 14 days
9972561|NCT01321788||CONTROL|The group that will receive placebo for 14 days
9972562|NCT01321801|Active Comparator|Pregabalin|Preoperative administration of pregabalin 600mg to patients undergo laparoscopic cholecystectomy.Patients receive oral Pregabalin 300 mg the night before the surgery, and another one dose of 300 mg 1 hour prior to surgery
9972563|NCT01321801|Placebo Comparator|Placebo|Preoperative administration of placebo to patients undergo laparoscopic cholecystectomy.Patients receive oral Placebo the night before the surgery, and another one dose 1 hour prior to surgery.
9972564|NCT01321814|Experimental|Cognitive behavioural therapy (CBT)|Patients receiving 6 sessions of CBT conducted by a licensed psychologist. Sessions include psychoeducation, exposure treatment, behavioral activation and applied relaxation.
9972565|NCT01321814|No Intervention|Waiting list|Patient waits for CBT treatment for 6 months.
9972566|NCT01321827|Experimental|Itraconazole group|Itraconazole 200 mg BD for 4 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
9972567|NCT01321827|Active Comparator|Glucocorticoid group|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
9972568|NCT01321840|Experimental|Treatment|This group will be treated with SART.
9972569|NCT01321840|No Intervention|No treatment|This group will not be treated with SART but will regularly be examined by a gynecologist to detect sudden aggravation of the disease.
9972570|NCT01321853|Experimental|Machine and NCC|Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
9972571|NCT01321853|Experimental|Medplanner and NCC|Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
9972572|NCT01321853|No Intervention|Usual Care Group|Admitted post home health care with no intervention.
9972573|NCT01321866|Experimental|Experimental arm|Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
9972574|NCT01321866|Active Comparator|Standard arm|Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.
10153781|NCT04061512|Experimental|RI Arm|The RI arm (chemotherapy free) arm will be using the drug ibrutinib, which in combination with rituximab (RI) will be the experimental arm.
9972575|NCT01321892||Squamous cell carcinoma|Patients included in this study will be receiving surgical treatment for their biopsy-proven squamous cell carcinoma.
9972576|NCT01321905|Experimental|Ergocalciferol|"Patients younger than 16 years of age are administered 35,000 IU ergocalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU ergocalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
9972577|NCT01321905|Experimental|Cholecalciferol|"Patients younger than 16 years of age are administered 35,000 IU cholecalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU cholecalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
9972578|NCT01321905|No Intervention|Control|Patients continue their ordinary vitamin supplementation without getting extra vitamin D supplements.
9972579|NCT01321918|Other|Case subjects|
9972580|NCT01321918|Other|Control subjects|
9972581|NCT01321931|Experimental|NRT 60|A 6 mg dose of an experimental Nicotine Replacement Therapy (NRT) given every hour for 11 hours, with a 36-hour washout between visits
9972582|NCT01321931|Active Comparator|NFG 60|A 4 mg dose of a marketed Nicotine Fruit Gum (NFG) given every hour for 11 hours, with a 36-hour washout between visits
9972583|NCT01321931|Experimental|NRT 90|A 6 mg dose of NRT given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
9972584|NCT01321931|Active Comparator|NFG 90|A 4 mg dose of NFG given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
9972585|NCT01321931|Active Comparator|NIQ 60|A 4 mg dose of marketed nicotine mint lozenge (NIQ), given every hour for 11 hours, with a 36-hour washout between visits
9972586|NCT01321944|No Intervention|Usual clinical care|Usual clinical care provided by health care system
9972587|NCT01321944|Experimental|DTS intervention|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
10153782|NCT04061460|Other|non smokers|patient who never smoked
9670016|NCT05069064|Other|non-music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
9670017|NCT05068960|Experimental|Study group|The study group will receive an interscalene block consisting of 10 mL 0.5% bupivacaine and 10 mL of liposomal bupivacaine [133mg].
10153783|NCT04061460|Other|former smoker|patient who smoked in the past
10153784|NCT04061460|Other|smoker|patient who still smoke
10153785|NCT04061642|Experimental|Clinical Decision Aid|
10153786|NCT04061655|Active Comparator|iron therapy group|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
10153787|NCT04061655|Placebo Comparator|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
10153788|NCT04061369|Experimental|Meal 1|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
9670018|NCT05068960|Active Comparator|Control group|The control group will receive an interscalene block consisting of 20 mL of 0.5%bupivacaine alone.
9670019|NCT05069168||LVEFrecovery|patient who shows improvement of left ventricular systolic function
9670020|NCT05069168||Non LVEF recovery|patient who don't show improvement of left ventricular systolic function
9670021|NCT05069194||COPD|Patients with chronic obstructive pulmonary disease
10153789|NCT04061369|Experimental|Meal 2|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
10153790|NCT04061369|Experimental|Meal 3|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
10153791|NCT04061369|Experimental|Meal 4|"A liquid meal, similar to a smoothie, that is high (60% of energy) in fat calories."
9670022|NCT05069194||High Risk|People who do not suffer from COPD, but have high risk factor for COPD.
9670023|NCT05069194||Health|People who do not suffer from COPD and do not have a high risk factor for COPD either.
9670024|NCT05069181|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
9670025|NCT05069181|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
9670026|NCT05069181|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
9670027|NCT05069077|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
10153792|NCT04061447|Experimental|susceptibility-guided therapy|In the group of the empirical triple therapy, patients received rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
10153793|NCT04061447|Active Comparator|empirical clarithromycin-based triple therapy|In the group of gastric juice susceptibility-guided therapy, the eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
10153794|NCT04061265|Active Comparator|Lidocaine 2% group|lidocaine hydrochloride 2% and epinephrine 1:100000 (Lignospan® standard, 1.7ml, SEPTODONT Ltd)
10153795|NCT04061265|Experimental|Articaine 4%|articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)
10153796|NCT04061629||Group C|Size of the cuffed ETT based on the Cole formula = (Age/4) + 4.
9670028|NCT05069077|Other|non-music group|Participants in the non-music group will undergo diagnostic outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
10153797|NCT04061629||Group D|size of the cuffed ETT based on the Duracher formula = (Age/4) + 3 + 0.5 mm.
10153798|NCT04061629||Group K|size of the cuffed ETT based on the Khine formula = (Age/4) + 3.
10153799|NCT04061538|Experimental|Zinc sulfate|Zinc sulfate 20 mg by mouth, once a day for 10 days
10153800|NCT04061538|Placebo Comparator|Placebo|Placebo tablet, once a day for 10 days
9826324|NCT02415400|Active Comparator|Apixaban|5 mg or 2.5 mg Apixaban tablets orally twice per day
10153801|NCT04061616|Experimental|Participants|All the participants volunteer to participate to the study that were included.
10153802|NCT04061473|Placebo Comparator|Pancreatectomized + Placebo|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 placebo tablets will be administered orally."
10153803|NCT04061473|Active Comparator|Pancreatectomized + DPP-4 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 DPP4-inhibitor tablets will be administered orally."
10153804|NCT04061473|Active Comparator|Pancreatectomized + SGLT-2 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 SGLT-2 tablets will be administred orally."
10153805|NCT04061473|Placebo Comparator|Healthy + Placebo|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
9972588|NCT01321957|Active Comparator|FOLFOX+Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
9972589|NCT01321957|Experimental|FOLFOX+Bevacizumab+Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
10153806|NCT04061473|Active Comparator|Healthy + DPP-4 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
9670029|NCT05068947|Experimental|Study drug: GV101|50 mg or 200 mg tablets totaling to 50mg, 100 mg, 200 mg, 400 mg tablets will be administered once orally to subjects in the treatment group, cohort 1 to 4. 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the treatment group, cohort 5 to 7.
9670030|NCT05068947|Placebo Comparator|Placebo|Matched placebo control 50 mg or 200 mg tablets totaling to 50mg, 100 mg, 200 mg, 400 mg tablets will be administered once orally to subjects in the control group, cohort 1 to 4. Matched placebo control 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the control group, cohort 5 to 7.
9670031|NCT05069103|Experimental|Intervention|"Similar to the original TWIST trial, patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~At least one image of their surgical wound(s).~Patients will receive automated requests via notifications asking to complete the online tool over the 30-day period (every 3 days +/- 1 day), however they may also complete the online form whenever wished."
9670032|NCT05069246|Experimental|Group 1 / Nigella Sativa oil / NS|"Group 1- Nigella Sativa (NS) N. sativa oil (Al-Hussan Food Products Factory, Riyadh, Kingdom of Saudi Arabia), which was brought from the local market in Riyadh.~Each participant was given a 3 weeks supply of oil, and a sterile plastic 15ml graduated measuring cap. They were asked to measure 5ml of oil into the cap and add 5ml of normal drinking water to this and rinse their mouth for 3mins with this solution and spit it out at the end. This was done morning and evening for 14 days.~Group 1: Maintained adequate plaque control levels using mechanical methods + N.sativa oil (5ml oil + 5ml water) pulling for 3 mins twice daily in the morning and at night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
9694687|NCT04786392|Active Comparator|Lutein supplement|"Supplement containing 5 mg powdered lutein, capsule filler microcrystalline cellulose.~To be administered once."
9972590|NCT01321970|Other|Severe coronary artery disease|Patients in this group have coronary artery disease with a stenosis of >70%.
10153807|NCT04061473|Active Comparator|Healthy + SGLT-2 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
10153808|NCT04061278|Experimental|4 Cycles of Neoadjuvant Chemotherapy With Radiotherapy|Four cycles of neoadjuvant chemotherapy combined with radical radiotherapy
10153809|NCT04061278|Active Comparator|3cycles of Neoadjuvant Chemotherapy With chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy
10153810|NCT04061200|Active Comparator|Semaglutide 1,34 mg/ml|Semaglutide 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
10153811|NCT04061200|Placebo Comparator|Placebo 1,34 mg/ml|Placebo 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
10153812|NCT04060992|Experimental|Early Follicular Phase|Women enrolled will be anywhere from cycle day 1 through 5 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
10153813|NCT04060992|Active Comparator|Late Follicular Phase|Women enrolled will be anywhere from cycle day 8 through 13 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
10153814|NCT04060992|Active Comparator|Luteal Phase|Women enrolled will be anywhere from cycle day 21 through cycle day 26 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
10153815|NCT04061044|Experimental|Treatment|
10153816|NCT04061161|Active Comparator|Tiotropium respimat|Tiotropium respimat 2.5mcg two actuations once daily
10153817|NCT04061161|Placebo Comparator|Placebo respimat|Placebo respimat two actuations once daily
10153818|NCT04061174|Experimental|Shoulder stabilization exercise and office exercise training|Shoulder stabilization exercises will be given to the experimental group participants individually during 8 weeks. Exercises will be done 3 times a week and each exercise will be performed with 10 repetitions, 3 sets and 60-90 seconds rest between sets. Also experimental group participants will do office exercise training that given to other group participants.
10153819|NCT04061174|Experimental|Office exercise training|"Office-based stretching exercises will be given to other group 3 sets will be applied by waiting 15 seconds for increasing range of motion of back, shoulder and neck joints.~In addition, isometric exercises and scapula stabilization exercises will be given to strengthen the shoulder muscles and participants will do these exercises 3 times a week and once a day in 10 repetitions (10-15 seconds) and 3 sets. Each set will be given a rest of 60-90 seconds. Total time will be 10-15 minutes.Office exercise training will last a total of 8 weeks."
10153820|NCT04060888|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
10153821|NCT04060888|Placebo Comparator|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
10153822|NCT04061122||EX + / ECTS +|Patients suffering COPD exacerbation in last 7 days; active tobacco smokers
9670033|NCT05069246|Active Comparator|Group 2 / Chlorohexidine / CHX|"Group 2- Chlorohexidine (CHX).~Chlorohexidine (Middle East Pharmaceutical Industries Ltd, Riyadh, Kingdom of Saudi Arabia).~Each participant was given a 3 week supply of chlorohexidine. They were asked to use 10ml of CHX morning and evening, rinsing their mouth for 3 mins and then spit it out at the end. This was done morning and evening for 14 days.~Group2: maintained adequate plaque control levels using mechanical methods + chlorohexidine rinse twice daily 10ml in the morning and at the night (after brushing/breakfast in the morning, and after brushing and before sleeping at night).~Unified oral hygiene instructions and instructions for each intervention were provided to all participants."
9670034|NCT05068986|Other|single arm intervention|
9694688|NCT04786392|Experimental|Blended food beverage|Blended food beverage containing 5 mg lutein from baby spinach. To be administered/consumed once.
9826325|NCT02415400|Active Comparator|Vitamin K Antagonist|VKA tablets orally once daily
10153823|NCT04061122||EX - / ECTS +|Patients without COPD exacerbation in last 6 months; active tobacco smokers
10153824|NCT04061122||EX + / ECTS -|Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier
10153825|NCT04061122||EX - / ECTS -|Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier
10153826|NCT04061005|Active Comparator|Hot snare polypectomy (HSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). According to the randomized group, patients with HSP group were treated with HSP to excise 5-15 mm colorectal polyps. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopist carefully observed the edge of the resection to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
10153827|NCT04061005|Experimental|Cold snare polypectomy (CSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). After randomization, patients in the CSP group will be treated with CSP to remove colorectal polyps of 10-15 mm size. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopic surgeon carefully observed the resection margin to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
10153828|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 1|Participants in the first cohort will receive the CCSH Interventions for Teams during the fall session (first intervention period).
10153829|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 2|Participants in the second cohort will receive the CCSH Interventions for Teams during the spring session (second intervention period).
10153830|NCT04061057|Experimental|IV lidocaine|Perioperative IV lidocaine infusion
10153831|NCT04061057|Placebo Comparator|Normal saline|Perioperative IV normal saline infusion
10153832|NCT04060875||Feasibility group|First phase group will involve piloting a novel virtual reality treatment for chronic pain to investigate feasibility and safety with a smaller number of patients
10153833|NCT04061109|Experimental|Prophylactic therapy|Subjects received Recombinant Human Coagulation FVIII for prophylactic therapy with 25 - 35 IU/kg injection once every other day or three times per week for 6 months.
10153834|NCT04061239|Experimental|CPX-351 Arm|"CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.~The treatment includes up to 2 cycles of induction as follows:~1 x CPX-351 1st induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1, 3, and 5~1 x CPX-351 2nd induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1 and 3~Each induction cycle will last 28 days. Depending on the type and extent of response as well as toxicity, the patient may continue on to consolidation therapy after induction or be discontinued from the treatment phase and transferred directly to alloHCT, if applicable. CPX-351 consolidation is with daunorubicin 29 mg/m² and cytarabine 65 mg/m² in liposomes on days 1 and 3. For patients < 60 years up to 3 consolidation cycles and for patients ≥ 60 years up to 2 consolidation cycles are allowed."
10153835|NCT04061239|Other|CCR Arm|"The conventional care regimens (CCR) arm has 2 options according to the discretion of the investigator:~conventional 7+3 cytarabine/daunorubicin chemotherapy regimen~treatment with s.c. Azacitidine"
10153836|NCT04060966|Experimental|Cold - Pressor Task|
10153837|NCT04061083|Experimental|Continuous Endotracheal Cuff Pressure Control|Continuous endotracheal cuff pressure control using smart cuff manager during the first 48 hours of intubation in the intensive care unit
10153838|NCT04061083|Experimental|Intermittent Endotracheal Cuff Pressure Control|Intermittent cuff pressure control through manual manometer measurement performed 3 times per day during the first 48 hours of intubation in the intensive care unit
10153839|NCT04061083|No Intervention|Standard Care|ET cuff pressure control will be provided with pilot balloon fingers during the first 48 hours of intubation in the intensive care unit
10153840|NCT04061096|Active Comparator|MIH-effected carious first permanent molar teeth|MIH-effected carious permanent first molar teeth were well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
10153841|NCT04061096|Active Comparator|not MIH-effected carious first permanent molar teeth|The carious not MIH-effected teeth were only carious without any hypomineralize areas and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
9670035|NCT05069220|Experimental|18F-MFBG PET/CT in neuroendocrine malignancies|Each patient receive a single intravenous injection of 18F-MFBG 148-444 MBq (4- 12mCi) and undergo PET/CT scan at 60-90 min post-injection. All patients should have a routine clinical 131I-MIBG scintigraphy (planar and/or SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.
9670036|NCT05069285|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian)
9670037|NCT05069285|Active Comparator|Sleep hygiene advice|A sheet of paper with standard sleep hygiene advice
10153842|NCT04061096|Placebo Comparator|MIH-effected non-carious first permanent molar teeth|MIH-effected teeth were carious permanent first molar teeth with well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and did not have any sign of caries.
9670038|NCT05069233||UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
10153843|NCT04061096|Placebo Comparator|not MIH-effected non-carious first permanent molar teeth|not any signs of being caries or hypomineralization.
10153844|NCT04060914|Experimental|Ticagrelor(90mg)|
10153845|NCT04060914|Experimental|Ticagrelor(90/60mg)|
9670039|NCT05068895||Group1|Volunteers with normal glucose tolerance.
9670040|NCT05068895||Group2|type 2 diabetic patients without microvascular (retinopathy, nephropathy or neuropathy) or macrovascular (coronary, cerebrovascular or lower extremity arterial disease) complications.
10153846|NCT04060914|Active Comparator|Clopidogrel(75mg)|
10153847|NCT04060771|Experimental|Group P|During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
9670041|NCT05068895||Group3|type 2 diabetic patients with lower extremity artery disease diagnosed through the measurement of ABI (the ratio of ankle-to-brachial systolic blood pressure).
10153848|NCT04060771|Active Comparator|Group D|During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
10153849|NCT04061070|Sham Comparator|No Intervention with the mix threalose plus polyphenols|The patients allocated in this arm will not treated with a mix of threalose plus polyphenols
9670042|NCT05068622||patients with nasogastric tube before surgery|
9670043|NCT05068622||patients without nasogastric tube before surgery|
10153850|NCT04061070|Active Comparator|Intervention with the mix threalose plus polyhenols|The patients allocated in this arm will treated with a mix of threalose plus polyphenols
10153851|NCT04060940|Experimental|Emotion Regulation Therapy: 8-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 8-session version of ERT will receive 8 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-5 will be 1 hour long, sessions 6 and 7 will be 1.5 hours long, and session 8 will be one hour long, resulting in a total required time commitment of 9 hours over the course of 8 weeks.
10153852|NCT04060940|Experimental|Emotion Regulation Therapy: 16-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 16-session version of ERT will receive 16 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-9 will be 1 hour long, sessions 10-13 will be 1.5 hours long, and sessions 14-16 will be 1 hour long, resulting in a total required time commitment of 18 hours over the course of 16 weeks.
9670044|NCT05068557|Active Comparator|Intervention group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with fish oil (3 capsules daily. Containing EPA+DHA: 1.8 g). (n=40)
9670045|NCT05068557|Placebo Comparator|Control group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with chia/linseed oil (3 capsules daily. Containing ALA 1.6 g). (n=40)
10153853|NCT04060667|Experimental|Intervention|
10153854|NCT04060667|No Intervention|control|
10153855|NCT04061213||Patients with symptomatic severe aortic stenosis|Elderly patients referred for TAVR evaluation
10153856|NCT04060732||Flash Glucose Monitoring Device|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid used by Diabetes Mellitus type 1 patients."
9670046|NCT05068583||Osteosarcoma|
9670047|NCT05068583||Ewing Sarcoma|
9670048|NCT05068583||Rhabdomyosarcoma|
9670049|NCT05068583||Synovial Sarcoma|
10185743|NCT03742752|Experimental|Enteral Nutrition (EN)|"To demonstrate the superiority of EN versus TPN in the treatment of postoperative upper GI anastomotic leak (PUGIAL) after upper GI surgery (including esophageal, gastric, duodenal, pancreatic and obesity surgery).~Patients will be randomized to receive EN through jejunostomy or nasojejunal tube until oral diet covering at least 60% of their daily requirement"
10185744|NCT03742752|Active Comparator|Parenteral Nutrition (TPN)|Patients will be randomized to receive TPN through central venous access, piccline or totally implantable venous access port tube until oral diet covering at least 60% of their daily requirement
10185745|NCT03742726|Experimental|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
9670050|NCT05068583||Non-Rhabdomyosarcoma Soft Tissue Sarcoma|
9670051|NCT05068583||Hepatic Tumors|
9670052|NCT05068583||Renal Tumors|
9670053|NCT05068583||Thyroid Tumors|
9670054|NCT05068583||Germ Cell Tumors|
9670055|NCT05068583||Healthy Volunteers|
9670056|NCT05068739|Experimental|PA-EMR (Partial ampullary endoscopic mucosal resection)|Partial ampullary endoscopic mucosal resection
9670057|NCT05068739|Active Comparator|NKF(Needle knife fistulotomy)|Needle knife fistulotomy
9670058|NCT05068713|Experimental|Hihg Target Mean Arterial Pressure|Target of mean arterial pressure of 85-90 mmHg in ther first 24h after liver transplant.
9694689|NCT04786392|Experimental|Whole food|Consumption of 5 mg of lutein from baby spinach. To be administered/consumed once.
10185746|NCT03742713|Experimental|CPC634 (CriPec® docetaxel)|CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2
10185747|NCT03742700|Experimental|T-smokers|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
10185748|NCT03742700|Experimental|E-smokers|E-smokers were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
9670059|NCT05068713|Active Comparator|Low Target Mean Arterial Pressure|Target of mean arterial pressure of 65-70 mmHg in ther first 24h after liver transplant.
9670060|NCT05068609||Cohort 1|Participants with squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab
9670061|NCT05068492||Training cohort|
9670062|NCT05068492||Validation cohort|
9972591|NCT01321970|Other|Coronary artery disease|Patients in this group have coronary artery disease with stenosis < 70%.
9972592|NCT01321996|Other|68Ga-DOTANOC PET/CT in patients with IPF and NSIP|one arm study: all patients were studied by 68Ga-DOTANOC PET/CT
9972593|NCT01322061|Active Comparator|Vitamin C|
9972594|NCT01322061|Placebo Comparator|mirinda|
9972595|NCT01322074||Total knee arthroplasty|Patients operated with elective, unilateral total knee arthroplasty.
9972596|NCT01322087|Experimental|Nutritional intervention|
9972597|NCT01322113||Na+, K+-ATPase/DLC system in BD|Bipolar patients in the various phases of the disease.
9972598|NCT01322126|Experimental|ultrasound ,without ultrasound|ultrasound group will be passed the neuraxial anesthesia with ultrasound,the secoud group will be passed the neuraxial anesthesia without ultrasound .
9977215|NCT01359280|Experimental|Adherence Counseling + Text Messages|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
9977216|NCT01359280|Experimental|Adherence Counseling Only|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building.
9977217|NCT01359280|Placebo Comparator|General Health Counseling Only|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building.
9977218|NCT01359280|Placebo Comparator|General Health Messages + Text Messages|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
9977219|NCT01359319|Experimental|650 mg (single dose only)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
9977220|NCT01359319|Experimental|1,950 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
9977221|NCT01359319|Experimental|2,925 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
9977222|NCT01359319|Experimental|4,875 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
9977223|NCT01359319|Experimental|6,000 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
9977224|NCT01359332|Experimental|hypothermia|
9977225|NCT01359332|No Intervention|control|
9977226|NCT01359345|Experimental|A|The patients with renal failure in whom Gadollinume has being used
9977227|NCT01359384||affected patients|25 patients suffering from severe immune deficiency under immunoglobulin therapy
9977228|NCT01359384||non-affected patients|25 matched controls not suffering from severe immune deficiency
9977229|NCT01359397|Active Comparator|Herceptin -|
9977230|NCT01359397|Experimental|Herceptin +|
9977231|NCT01359423|Experimental|long coverage|Primary long full coverage stenting
9977232|NCT01359423|Active Comparator|short spot|primary short spot stenting
9977233|NCT01359436|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
9977234|NCT01359462|Experimental|Tolvaptan 15mg tablet|
10153857|NCT04061148|Other|Non-Depressed Controls|"Volunteers who have screened by a clinical psychiatrist, to exclude depression and other major psychiatric and neurocognitive disorders.~They will undergo NIRSIT testing to measure frontal blood oxygenation up to 3 times, with an interval of 3 weeks between each measurement."
10185749|NCT03742700|Experimental|T/E-smokers|T/E-smokers (dual users) were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
9670063|NCT05068492||Test cohort|
9694690|NCT04786314|Experimental|Hot Water Application Group|Pregnant women will apply hot water to their legs before going to sleep for a week, depending on the groups they are in.
9977235|NCT01359475|Experimental|Acetal crown|Clinical performance of acetal crowns for treatment of primary molars
9977236|NCT01359488|Experimental|VRS-317 Safety Arm 1|"VRS-317 Single injection SC of dose level 1 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
9977237|NCT01359488|Experimental|VRS-317 Safety Arm 2|"VRS-317 Single injection SC of dose level 2 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
9972599|NCT01322139|Placebo Comparator|High dose placebo and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
9972600|NCT01322139|Active Comparator|Low dose Sativex and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily) + 16 or 28 placebo sprays (8 or 14 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
9972601|NCT01322139|Active Comparator|High dose Sativex and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
10153858|NCT04061148|Active Comparator|Depressed Patients|Patients diagnosed with Major Depressive Disorder by a clinical psychiatrist. They will undergo NIRSIT testing to measure frontal blood oxygenation up to 5 times, with an interval of 3 weeks between each measurement, over the course of their clinical therapy for Major Depressive Disorder.
10153859|NCT04060953|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report.
10153860|NCT04060953|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report following completion of the study.
9670064|NCT05068531||Observational|We plan to recruit up to 100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.
9670065|NCT05068804|Experimental|cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
9670066|NCT05068804|Placebo Comparator|Control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
9670067|NCT05068817|Experimental|Pilates mat exercises|one hour Pilates exercises with 10 min warm up and 5-10 min cooling down
9670068|NCT05068817|Experimental|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit
10153861|NCT04060979|Experimental|Group 1- NO treatment- dose 1|Will comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
10153862|NCT04060979|Experimental|Group 2- NO treatment- dose 2|Will comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
10153863|NCT04060979|Other|Group 3- Control treatment|Will comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.
9670069|NCT05068817|Active Comparator|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program
9670070|NCT05068765|No Intervention|control group|Once enrolled and consent is documented, eligible subject's will participate in the study for approximately six months.
9670071|NCT05068765|Experimental|communication skills psychoeducation|Communication skills focused psychoeducation group will be given a communication skills-focused psychoeducation program for eight weeks, one session per week, for a total of eight sessions. The number of sessions was planned with reference to the study in which the effect of the psychoeducation program on general health and communication skills in caregivers of individuals with schizophrenia was investigated.Session groups will be formed from a single session of 60-90 minutes for each topic.
9670072|NCT05068765|Experimental|general psychoeducation|General psychoeducation group will be given a general psychoeducation program for four weeks, one session per week, in total. Session groups will be formed from a single session of 60-90 minutes for each topic.
9670073|NCT05068869|Other|Dignio Digital Remote Care intervention group|Participants will receive the MyDignio app for individualized follow-up for 12 months.
9670074|NCT05068869|Other|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
9670075|NCT05068648|Active Comparator|MWC Configuration 1|"standard upholstery back that promotes posterior pelvic tilt set at or below cushion level and 1 above inferior angle"
9670076|NCT05068648|Active Comparator|MWC Configuration 2|active contour back positioned with seat gap and with free scapulae
10153864|NCT04060706||Prostate Cancer|Adults suitable for radical image-guided radiotherapy for their Prostate cancer, approximately 170 patients Components from RTOG, LENT SOM(A), RMH symptom scale and UCLA PCI (prostate cancer index) questionnaires will be used.
9519981|NCT03281746|Active Comparator|Group I (standard prevention education)|Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
9519982|NCT03281746|Experimental|Group II (standard and one-on-one education, consultation)|Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.
9670077|NCT05068648|Active Comparator|MWC Configuration 3|active contour back positioned with seat gap and with blocked scapulae
9670078|NCT05068648|Active Comparator|MWC Configuration 4|deep contour back positioned with seat gap and with free scapulae
9670079|NCT05068648|Active Comparator|MWC Configuration 5|deep contour back positioned without seat gap and with free scapulae
9972602|NCT01322139|Active Comparator|High dose placebo and single oral moxifloxacin 400 mg tablet|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
9972603|NCT01322152|Experimental|wXELIRI regimen|
10153865|NCT04060706||Head & Neck Cancer|Adults suitable for radical image-guided radiotherapy for their Head & Neck cancer, approximately 140 patients. Components from CTCAE v3, LENT SOM(A), EORTC QLQ H+N35 & Modified xerostomia questionnaires will be used.
9670080|NCT05068843|Active Comparator|Arthroscopic partial meniscectomy|"In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy (APM) within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.~Other Names:~APM meniscal surgery surgery"
9670081|NCT05068843|Other|Physical therapy|The physical therapy program consisted of a physical therapist-led incremental exercise program containing of coordination/balance, closed kinetic chain strengths and cardiovascular exercises (see Appendix 1). The program was designed for 8 weeks with a total of 16 treatment sessions, each with a duration of 30 minutes. All 16 sessions were reimbursed. If knee symptoms persisted following the physical therapy program (e.g., knee pain, limitations in daily activities or mechanical dysfunction ), the patient could attend additional physical therapy sessions (not reimbursed by the study) or have meniscal surgery, depending on a shared decision after consultation with their orthopaedic surgeon.
10153866|NCT04060706||Central Nervous System Tumours|Adults suitable for radical image-guided radiotherapy for their CNS tumour, as many patients recruited as possible. Components from RTOG, LENT SOM(A), Folstein mini mental state examination & Generalised activites of daily living scale (G-ADL) questionnaires will be used.
9670082|NCT05068830|Experimental|Exercised plasma (ExPlas)|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 ExPlas transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
9670083|NCT05068830|Active Comparator|Octaplasma|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 Octaplasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
10153867|NCT04060706||Lung Cancer|Adults suitable for radical image-guided radiotherapy for their Lung cancer, as many patients recruited as possible. Components from RTOG & LENT SOM(A) questionnaires will be used.
10153868|NCT04060797|Experimental|endovascular denervation|endovascular denervation
10153869|NCT04060836|Experimental|group A|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse reference drug Xyntha (group A), then experimental drug (group B). All participants who completed the study will enter the prophylaxis group study.
10153870|NCT04060836|Experimental|group B|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse experimental drug (group B), then reference drug Xyntha (group A). All participants who completed the study will enter the prophylaxis group study.
10153871|NCT04060693|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 30 days of home-based measurement, scheduled within a 40 days' time frame. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed within 3 minutes after the BG measurement using the thenar of the right hand of the subject.
9519983|NCT03281694|Other|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
9670084|NCT05068830|Placebo Comparator|Saline|Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods)
9670085|NCT05068245|No Intervention|Routine pain control|The routine pain control group will receive instructions to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants.
10153872|NCT04060810|Other|grey zone hydrocephalic patients|MR CSF flowmetry CT brain Ventriculoperitoneal shunt
10153873|NCT04060719|Experimental|Reference (Period 1) - BI 894416 alone|Reference (Period 1) followed by Test (Period 2)
10153874|NCT04060719|Experimental|Test (Period 2) - BI 894416 + Rifampicin|
9972604|NCT01322191|Experimental|1|Random assignment to a single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
10153875|NCT04060576|Experimental|Group A treated with a 16-gauge needle|Group A is intervened on the gastrocnemius muscle with a 16-gauge needle.
10153876|NCT04060576|Experimental|Group B treated with a 25-gauge needle|Group B is intervened on the gastrocnemius muscle with a 25-gauge needle.
10153877|NCT04060576|Experimental|Group C treated with a 32-gauge needle|Group C is intervened on the gastrocnemius muscle with a 32-gauge needle.
10153878|NCT04060745|Experimental|Cooling|Participants will be cooled using an individualized cooling protocol with a water-perfused vest for two hours while resting. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
10153879|NCT04060745|Experimental|Thermoneutrality|Participants will rest for one hours. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
9972605|NCT01322204|Experimental|1|Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
9972606|NCT01322217||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at sites newly participating in ATN III and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
9972607|NCT01322230|Experimental|Control|Screen shots with voiceover and no interactivity
9972608|NCT01322230|Experimental|WISEMD Original|Learner control of pacing through multi-media content
9972609|NCT01322230|Experimental|Social Networking|social networking features (Forum and Social Presence)
9972610|NCT01322230|Experimental|Social Networking plus Emotional Design|Social networking features plus user interface enhancements
9972611|NCT01322243|Other|Dietary Intervention: Fasted State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission.
9670086|NCT05068245|Experimental|Routine pain control plus music|Patients randomized to receive music in addition to routine pain control measures, will be instructed to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants. Preselected classical music will be played for this group throughout the procedure.
10153880|NCT04060602|Experimental|Personalized Feedback and Education|This arm is provided personalized feedback concerning their cannabis use in addition to educational materials about risky cannabis use.
10153881|NCT04060602|Active Comparator|Education|This arm is provided educational materials about risky cannabis use.
10153882|NCT04060615|Other|Patients with chronic total occlusion of the coronary artery|In each patient before the PCI procedure, the investigators will assess myocardial viability, functional parameters of collateral blood vessels, and quality of life. 24h and 6 months after the procedure these parameters will be reevaluated as well as functional parameters of the treated coronary artery.
9670087|NCT05068180|Experimental|Neuroleptanalgesia group|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
9670088|NCT05068180|Placebo Comparator|Control group|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
9670089|NCT05068375||Thrombotic group|Non-critically COVID-19 patients with unusual thrombotic events
9670090|NCT05068375||Non-thrombotic group|Non-critically COVID-19 patients without thrombotic events
9826326|NCT02415400|Placebo Comparator|Acetylsalicylic acid film coated tablet|81 mg Acetylsalicylic acid film coated tablet orally once daily
9826327|NCT02415400|Placebo Comparator|Placebo matching Acetylsalicylic acid film coated tablet|Placebo matching Acetylsalicylic acid film coated tablet once daily
9670091|NCT05068349|Experimental|A group of patients with ischemic stroke were treated with butylphthalide injection and capsules|Patients eligible for inclusion and exclusion are only divided into one group, no controls or other.
9670092|NCT05068050|Experimental|Experimental group|This arm will be provided by horse-assisted therapy interventions.
9670093|NCT05068050|Active Comparator|Control group|This arm will be provided by the physical exercise interventions.
10153883|NCT04060212|Experimental|All Participants|All participant will eat 6 meals of tuna fish. All participants will take a prebiotic dietary supplement.
10153884|NCT04060186|Active Comparator|Balloninflation Group|Patient who will perform a balloninflation after operation
10153885|NCT04060186|Sham Comparator|Conservative Group|Patient without performing a balloninflation
10153886|NCT04060368|Experimental|ESG Stitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
10153887|NCT04060368|Active Comparator|LSG + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
10153888|NCT04060303|Active Comparator|ENRICH-US Implementation- early|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
10185750|NCT03742700|Placebo Comparator|Control subjects|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
10185751|NCT03742687|Experimental|A:Large target volume|The target volume for radiotherapy treatment volume is considered too large for a standard treatment of 66Gy in 33 fractions, considering the expected normal tissue toxicity with a standard treatment plan. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
10185752|NCT03742687|Experimental|B:Fragile patient|The patient is too fragile for standard long-course radiotherapy with 66 Gy. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
10185753|NCT03742674||Cohort patients post stroke|
9670094|NCT05068414||Patients with atrial fibrillation|
9670095|NCT05068362|Other|Implant|Use of Medpor implant in auricle reconstruction in microtia
9670096|NCT05068323|Other|Epilepsy|Newly diagnosed epileptic patients
9670097|NCT05068323|Sham Comparator|Control|healthy subjects
9670098|NCT05068453|Experimental|OH2+HX-008+RT|Patients will get OH2 （once every two weeks）and HX-008 (once every three weeks)and radiotherapy (totally 3 times).
9670099|NCT05067738|Other|Discharge|Phase 1-Patients will continue to be admitted after their surgery as is the current practice. Phase 2-Patients will have their chest tube removed once they meet chest tube removal criteria and will be discharged home once they meet discharge criteria.
9670100|NCT05067881||Pneumohematocele|Patients with SARS CoV-2 diagnosis and PHC on imaging studies
9670101|NCT05067907||Control|COVID-19 ICU-admitted patients that did not received physiotherapy interventions during ICU stay.
9670102|NCT05067907||Physiotherapy|COVID-19 ICU-admitted patients that received physiotherapy interventions during ICU stay.
9670103|NCT05067699||Patients|recurrent pityriasis versicolor
9826328|NCT02415439|Experimental|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
9826329|NCT02415439|Experimental|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
9826330|NCT02415439|Experimental|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
9826331|NCT02415439|Experimental|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
10153889|NCT04060303|Active Comparator|ENRICH-US Implementation- mid|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
10153890|NCT04060303|Active Comparator|ENRICH-US Implementation- late|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
10153891|NCT04060381||Fetuses of normal weight women|Fetuses of normal pregnancies of normal weight mothers are included from gestational week 37
10153892|NCT04060381||Fetuses of severely obese women|Fetuses of normal pregnancies of severly obese mothers are included from gestational week 37
10153893|NCT04060381||New-borns in need of blood transfusion|Neonates mainly receive blood due to blood loss, often because of repeated blood sampling
10153894|NCT04060381||New-borns in need for closure of the arterial duct|Neonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct.
10153895|NCT04060381||New-borns in need of treatment with catecholamines|Neonates are mainly treated with epinephrine, nor epinephrine or atropine due to compromised cardiovascular function or hypotension.
9670104|NCT05067699||Controls|Healthy age and sex matched
9670105|NCT05067686||Mental Health Professionals|
9670106|NCT05067686||Non Mental Health Professionals|
9670107|NCT05067712|Active Comparator|Open Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposed with the Open Technique followed by the Orthodontic Treatment phase
10153896|NCT04060225|Experimental|Participants|Participants will be asked to participate in a single arm study with three phases (washout phase, abstinence phase, and exposure phase). These participants will first be asked to abstain from drinking any caffeinated food or beverages for 72 hours (known as the washout phase). Following the first phase, participants will then wear a blood pressure cuff to collect diastolic and systolic blood pressure for 24 hours (abstinence phase) wherein they will be asked to refrain from caffeinated products. Participants will then drink the coffee intervention and collect blood pressure measurements for 24 hours (exposure phase).
10153897|NCT04060472|Experimental|albumin-bound paclitaxel + oxaliplatin|
10153898|NCT04060329|No Intervention|Phase 1|Usual care
10153899|NCT04060329|Experimental|Phase 2|Usual care + coopeRATE Prompt intervention
10153900|NCT04060329|Other|Clinicians|After Phase 2, clinicians will be asked about their experiences with, and views about, the coopeRATE Prompt intervention.
10153901|NCT04060563|Sham Comparator|Sham (fake) microcurrent therapy|Sham (fake) microcurrent therapy (placing the microcurrent pads on the patient and turning the microcurrent box on placebo mode )
9972612|NCT01322243|Other|Dietary Intervention: Fed State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission
9972613|NCT01322256|Experimental|Included patients|"Patients included in the study according to stated inclusion and exclusion criteria~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork"
10153902|NCT04060563|Experimental|Frequency specific microcurrent therapy|Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8),
10153903|NCT04060498|Experimental|Mindfulness intervention|This arm consists of seven weekly-session mindfulness-based intervention for psychosis (MBI-p). The MBI-p is a protocol-based, low intensity intervention developed to help patients achieve a greater sense of peace and calmness, and facilitates participants in handling everyday stress and conflicts.
10153904|NCT04060498|Placebo Comparator|Psychoeducation intervention|This arm consists of seven weekly-sessions of psychoeducation. Topics to be discussed in the sessions include the signs and symptoms of psychosis, aetiology of psychosis, as well as pharmacological and non-pharmacological interventions.
9670108|NCT05067712|Active Comparator|Closed Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposure with the Closed technique followed by the Orthodontic Treatment phase.
9670109|NCT05067959||IBD patients|patients with IBD (Chron's disease, Ulcerative colitis, IBD-Unspecify). patients will be divided into two sub-groups: IBD patients on anti-TNF therapy IBD patients on any other therapy
9670110|NCT05067959||Controls|healthy volunteers
9670111|NCT05067608|Active Comparator|Control arm|"Subjects in the control arm will receive normal pooled platelets for all of their transfusion within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
9972614|NCT01322282|Experimental|ODT with Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
9972615|NCT01322282|Experimental|ODT Without Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
9972616|NCT01322282|Active Comparator|FCT with Water|Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
9972617|NCT01322308|Placebo Comparator|sugar pill|tablet similar to comparator
9972618|NCT01322308|Active Comparator|pioglitazone|30 mg tablets QD (taken once daily)
9972619|NCT01322321|Experimental|ACZ885|
9972620|NCT01322321|Placebo Comparator|Placebo|
9972621|NCT01322334|Experimental|Singing exercises|
10153905|NCT04060433|Experimental|ROCKETLAUNCH project|Intensive treatment program with focusing on the implementation of evidence based family therapy
10153906|NCT04060459|Experimental|Treatment plan|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
10153907|NCT04060407|Experimental|Advanced Melanoma|Patients with advanced melanoma.
10153908|NCT04060537||Research|Patients with Renal Cell Carcinoma who have had previous systemic treatment, with adequate tissue samples and radiological data
10153909|NCT04060277|Experimental|Arm I (letermovir, Triplex)|Patients receive letermovir per SOC on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine IM on days 100 and 128 post-HCT.
10153910|NCT04060277|Active Comparator|Arm II (letermovir, placebo)|Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
9670112|NCT05067608|Experimental|Treatment arm|"Subjects in the treatment arm will receive thawed cryopreserved pooled platelets for all of their transfusions (except for unplanned or urgent platelet transfusions outside stipulated periods when thawed cryopreserved platelets are unavailable) within a single thrombocytopenic period. If subjects participate in the study for more than one thrombocytopenic period, they will automatically be enrolled in the opposing arm for their second thrombocytopenic period."
9670113|NCT05067660|Active Comparator|Cohort A - Standard-of-care template-based salvage radiotherapy|Study participants in cohort A undergo template-based salvage radiotherapy according to current standard-of-care protocol. Dose fractionations include dose of 70/2 Gy in the prostatic bed, 50/2 Gy in the pelvic lymph node area and 45/1,8 Gy in the para-aortic lymph node. To the PSMA PET-CT positive lymph nodes, a boost dose will be considered depending on the anatomic site and will be delivered with a simultaneous integrated boost technique (SIB). The typical boost dose to PSMA PET-CT positive lymph nodes is 57,5/2,3 Gy, respecting normal tissue constraints. The dose to PSMA PET-CT positive areas in the prostatic bed is 74-78/2 Gy.
10153911|NCT04060238||Normal colour vision|Normal trichromopsia
10153912|NCT04060238||Inherited red blindness|Protanopia
10153913|NCT04060264|Experimental|BCD-148|"14 participants in BCD-148 group. During the main period (first 27 weeks), test product BCD-148 will be administered as 25- to 45-minute intravenous infusions.~After Week 27 BCD-148 900 mg will be administered biweekly as maintenance therapy."
10153914|NCT04060264|Active Comparator|Soliris|"14 participants in Soliris group. During the main period (first 27 weeks), Soliris® will be administered as 25- to 45-minute intravenous infusions.~After Week 27, patients be switched to BCD-148 900 mg biweekly as maintenance therapy."
9670114|NCT05067660|Experimental|Cohort B - PSMA PET CT-targeted stereotactic ablative radiotherapy|Study participants in cohort B undergo stereotactic ablative radiotherapy, targeted only to PSMA PET-CT-positive areas judged to be suspicious of prostate cancer metastasis by nuclear medicine physician. Dose fractionations in the experimental arm vary from 24/8 Gy to 30/10 Gy in PSMA PET-CT positive lymph nodes in pelvic or para-aortic areas. PSMA PET-CT positive areas in the prostatic bed receive a dose of 35/7 Gy.
9670115|NCT05067530|Experimental|CDK4/6 inhibitor alone: Palbociclib (IMP)|Palbociclib alone (125 mg orally (PO) per day, days 1-14)
9670116|NCT05067530|Active Comparator|Chemotherapy alone: Paclitaxel|Paclitaxel alone (80 mg/m^2 intravenously (IV), day 1, 8, 15 and 22)
9670117|NCT05067530|Experimental|CDK4/6 inhibitor + chemotherapy: Paclitaxel + Palbociclib|Paclitaxel (80 mg/m^2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
9670118|NCT05067530|Active Comparator|Chemotherapy alone: Carboplatin|Carboplatin alone (area under the curve (AUC) 2 IV, day 1, 8, 15 and 22)
10153915|NCT04060511|Experimental|HS-10342|Each subject will receive a single dose(C0) of HS-10342 and then repeat doses(C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
10153916|NCT04060550||Normal controls|No history of skin disease and atopy
9670119|NCT05067530|Experimental|CDK4/6 inhibitor + chemotherapy: Carboplatin + Palbociclib|Carboplatin (AUC 2 IV, day 1, 8, 15 and 22) + Palbociclib (125 mg PO per day, days 1-21)
10153917|NCT04060550||ADEH-|Atopic dermatitis without a history of eczema herpeticum
10153918|NCT04060550||ADEH+|Atopic dermatitis with a history of eczema herpeticum
10153919|NCT04060173|Experimental|Treatment with ABP-671|Three sequential dose escalation cohorts of ABP-671 administered orally for 10 days.
9670120|NCT05067413|Sham Comparator|Total mesorectal excision approach|Patients of the control group who are to receive the traditional approach-- total mesorectal excision approach to transect the distal rectum are assigned into this arm.
9670121|NCT05067413|Experimental|Transanterior obturator nerve gateway approach|Patients of the experimental group who are to receive the novel approach-- transanterior obturator nerve gateway approach to transect the distal rectum are assigned into this arm.
10153920|NCT04060173|Placebo Comparator|Treatment with placebo|Three sequential dose escalation cohorts of ABP-671 matching placebo administered orally for 10 days.
10153921|NCT04060147|Experimental|CILO 30 mg|Participants will receive escalating doses of CILO 30 mg, 60 mg, and 100 mg.
10153922|NCT04059770|Experimental|single dose of L-AmB|single IV dose of 10 mg/kg of L-AmB on day 1;
10153923|NCT04059770|Experimental|2 doses of L-AmB|IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
10153924|NCT04059770|Active Comparator|2 weeks of L-AmB|IV dose of 3 mg/kg of L-AmB for 2 weeks.
10153925|NCT04060004|Other|Control group|Electrotherapy + therapeutic exercise
10153926|NCT04060004|Experimental|Experimental group 1|Electrotherapy + therapeutic exercise + dry needling
10153927|NCT04060004|Placebo Comparator|Experimental group 2|Electrotherapy + therapeutic exercise + sham dry needling
10153928|NCT04059952||Unipolar Depression|Patients diagnosed with Major Depressive Disorder.
10153929|NCT04059952||Bipolar Depression|Patients diagnosed with Bipolar I or II.
10153930|NCT04059952||Healthy Control|Patients without psychiatric diagnoses.
10153931|NCT04060043|Experimental|Goserelin acetate Injection|Pepti 10.8mg is a generic formulation of Zoladex® 10.8mg, with the same ingredients (active and excipients), the same formulation, the same dosage, the same size and route of administration.
10153932|NCT04060095||β1-adrenergic antagonists|Patients who have been treated for more than 3 months with β1-adrenergic antagonists
10153933|NCT04059796|Experimental|Study Eye|Study device in conjunction with an approved monofocal or toric IOL after cataract extraction
10153934|NCT04059796|Active Comparator|Control Eye|approved monofocal or toric IOL after cataract extraction
10153935|NCT04059848|Experimental|tDCS combined with NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
9670122|NCT05067387|Placebo Comparator|Placebo|Oral placebo; sesame and MCT oil
9670123|NCT05067387|Experimental|20 mg THC|THC suspended in sesame oil
9670124|NCT05067387|Experimental|20 mg CBD|CBD suspended in MCT oil
9670125|NCT05067387|Experimental|20 mg THC + 20 mg CBD|THC and CBD in sesame and MCT oil
10153936|NCT04059848|Active Comparator|tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
10153937|NCT04059848|Sham Comparator|sham tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional sham tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
10153938|NCT04059809|No Intervention|Usual Care|The control group will have usual care according to the orientation of the radiation therapy faculty responsible for the radiotherapy treatment the PBM device will be switched off
10153939|NCT04059809|Experimental|Photobiomodulation (PBM)|Additionally to the usual care, the patients will receive the PBM. Treatment will be done twice a week.
10153940|NCT04060017|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
10153941|NCT04060017|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
10153942|NCT04059939|Experimental|Reading Plus Attention Control|
10153943|NCT04059939|Experimental|Reading Plus Anxiety|
10153944|NCT04059939|Active Comparator|BAU|
9670126|NCT05067517|Active Comparator|Nintedanib|Nintedanib 150 mg administered PO twice daily
9670127|NCT05067517|Placebo Comparator|Placebo|Placebo administered PO twice daily
9670128|NCT05067218|Active Comparator|buzzy device (intervention)|The wings of buzzy device will be kept frozen and once the child is ready, the frozen wing will be attached to the device and Buzzy will be placed extra-orally above the area/cheek where local anesthetic is to be delivered.
10153945|NCT04059887|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administrated every 3 week cycle
10153946|NCT04059835|Active Comparator|standard|Standard bra, soft
9670129|NCT05067218|Experimental|Conventinal anasthesia ( control )|"The site of injection will be dried then topical anesthetic gel of 20% benzocaine (Dharma Ophal-S) will be applied. The duration of application of gel will be 1 minute.~Local anesthetic solution will be delivered using a standard aspirating syringe with 27-gauge, 21 mm short needles."
9670130|NCT05067322|Experimental|Minecraft|This group played the video game under development in Minecraft
9670131|NCT05067322|Placebo Comparator|Control|This group played another game.
9670132|NCT05067153|Experimental|Intervention|Intervention group (n=50, anticipated) receives 30 days postoperative treatment with 5000 IE LMWH daily.
9670133|NCT05067153|Active Comparator|Control|Control group (n=50, anticipated) receives standard 10 days postoperative treatment with 5000 IE LMWH daily.
10153947|NCT04059835|Experimental|compression bra|experimental bra, compression and stabile
10153948|NCT04059900|Experimental|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
10153949|NCT04059900|Placebo Comparator|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
10185754|NCT03742661|Experimental|Treatment Group|SPEAC System
9662406|NCT04323137|Experimental|High risk only|This group receives messages telling them they have been identified to be at high risk for flu complications without specifying how or why the health system believes this to be the case.
9662407|NCT04323137|Experimental|High risk based on medical records|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records.
9662408|NCT04323137|Experimental|High risk based on algorithm|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by an AI/ML system.
9662409|NCT04314635|Active Comparator|TAU comparison group|TAU includes standard care modules (psychoeducation, coping, safety planning, problem solving, healthy lifestyle) administered to the teen while they are hospitalized on the inpatient unit. All teens, as part of TAU, also receive skills groups, individual treatment, and family planning meetings. All TAU families will receive a referral to an outpatient provider (standard care procedure) plus referral to specialized CHR case management services.
9662410|NCT04314635|Experimental|Brief intervention group|TAU + experimental intervention. The experimental group will receive all services provided to the TAU group (described above) and, additionally, the experimental intervention.The intervention includes 1 individual session for each teen and parent and 2 family sessions (focused on psychoeducation and motivational enhancement) with both the teen and parent, delivered during hospitalization (~45-60 minutes per session).
9662411|NCT04312490|Experimental|patients|all patients with myocarditis
9662412|NCT04287088|No Intervention|Control|After IMPROD bpMRI all men undergo prostate biopsies. In men with Likert scores of 1-2, TRUS guided systematic biopsies are performed. In men with Likert 3-5 score, in addition to systematic biopsies, two targeted biopsies are taken from each lesion (up to two lesions).
9662413|NCT04287088|Experimental|Intervention|After IMPROD bpMRI prostate biopsies are performed according to shared decision-making by the treating urologist and the patient. If biopsies are to be performed, in men with IMPROD bpMRI likert scores of 1-2, 12-core systematic TRUS guided biopsies are performed and in men with Likert 3-5 score lesions systematic biopsies are performed and two targeted biopsies are taken from each lesion (up to two lesions). If biopsies are not performed, men are referred for a PSA follow-up.
10153950|NCT04059913|Other|Part 1 (2 arms) and Part 2|The purpose of Part 1 is to evaluate difference between low and standard weight-based doses and Part 2 is to evaluate the difference among dosing frequencies
10153951|NCT04059913|Other|Part 1|"Part 1:~Arm Type: Other~Arm Title: Low weight-based dosing~Arm 1: Low weight-based dosing~Arm Description: Subjects in this arm will receive roxadustat 70 mg three times a week (TIW) for body weight < 60 kg or 100 mg TIW for body weight ≥ 60 kg~Arm Type: Other~Arm Title: Standard weight-based dosing~Arm 2: Standard weight-based dosing~Arm Description: Subjects in this arm will receive roxadustat 100 mg TIW for body weight < 60 kg or 120 mg TIW for body weight ≥ 60 kg"
9670134|NCT05067296||Cesarean section niche and patients with abnormal uterine bleeding|Observation by Tvs
9670135|NCT05067296||Abnormal uterine bleeding in patients without Cesarean section niche|Observation by Tvs
9670136|NCT05067114||Observational Cohort|Screening, detection, and referral for atrial fibrillation
9694691|NCT04786314|Experimental|Cold Water Application Group|Pregnant women will apply cold water to their legs before going to sleep for a week, depending on the groups they are in.
9694692|NCT04786314|No Intervention|Control Group|There will be no intervention other than routine follow-up and maintenance.
9694693|NCT04786405|Experimental|Mindfulness Meditation|Participants in this arm will complete five, 20-minute mindfulness meditation sessions delivered over consecutive days.
10153952|NCT04059913|Other|Part 2|"Part 2:~Arm Type: Other~Arm Title: Roxadustat~Arm Description: Subjects in this arm will receive roxadustat at different dose frequencies"
10153953|NCT04060069||Before pneumoperitoneum|Fluid administration
9694694|NCT04786405|Active Comparator|Clinical Hypnosis|Participants in this arm will complete five, 20-minute clinical hypnosis sessions delivered over consecutive days.
9694695|NCT04786496|Experimental|ITP+SA Wise intervention (Incremental Theory of Personality Intervention with Self-affirmations)|Wise intervention (based on ITP and SA) consisting on several tasks to be completed individually. 30 minutes
9694696|NCT04786496|Experimental|ITP Wise intervention (Incremental Theory of Personality Intervention)|Wise intervention (based on ITP) consisting on several tasks to be completed individually. 30 minutes
9694697|NCT04786496|Other|Control Intervention|Educational intervention (about heritage conservation) consisting on several tasks to be completed individually. 30 minutes
9694698|NCT04786483|Experimental|Laughter Therapy group|All students enrolled in the laughter therapy group will receive a total of 10 sessions of laughter therapy, 60 minutes, 2 days a week.
9694699|NCT04786483|No Intervention|Control|No attempt will be made to students in this group.
10153954|NCT04059978|Active Comparator|CBD + Remifentanil|CBD 1600 mg p.o. + Remifentanil 0.1 µg/kg/min i.v. for 30 min
10153955|NCT04059978|Placebo Comparator|Placebo + Remifentanil|Placebo p.o + Remifentanil 0.1 µg/kg/min i.v. for 30 min
9694700|NCT04786327|Placebo Comparator|treated by using Minimally invasive flap only.|7 sites treated with Minimally invasive flap only
9694701|NCT04786327|Experimental|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of platelet rich fibrin graft
9694702|NCT04786327|Experimental|MIST with root conditioning (EDTA) and GEM 21S .|7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of growth factor enhanced matrix GEM21S
9694703|NCT04786470|Active Comparator|Local Anaesthetic Infusion|
9694704|NCT04786470|Sham Comparator|Saline Infusion|
9972622|NCT01322373||Healthy control subjects (HC)|Subjects who met criteria as healthy control subjects and completed Orasi Protocol ADG-08-01.
10153956|NCT04059744|Experimental|Experimental arm|"Device: Fun-Knee Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
10153957|NCT04059874|Experimental|donafenib tablets 1|This is the dose group was given once a day. donafenib tablets 1 100mg qd dose group
10153958|NCT04059874|Experimental|donafenib tablets 2|This is the dose group was given twice a day. donafenib tablets 2 100mg bid dose group
10153959|NCT04060030|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
10153960|NCT04060030|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
10185755|NCT03742661|No Intervention|Standard of Care|Standard of Care
10185756|NCT03742648|Active Comparator|Control physiotherapy group|Basic standard medical and nursing care along with standard chest physiotherapy involving steam inhalation and nebulization for 15-20 minutes and 10-15 cycles of incentive spirometry twice daily
9694705|NCT04786145|Active Comparator|Cryoneurolysis|40 patients are randomized to receive one treatment of cryoneurolysis on the facet joints of three lumbar level corresponding to their facet joint pain generator
9694706|NCT04786145|Active Comparator|Radiofrequency ablation|40 patients are randomized to receive one treatment of radiofrequency ablation on the facet joints of three lumbar level corresponding to their facet joint pain generator
9694707|NCT04786145|Sham Comparator|Placebo|40 patients are randomized to receive sham treatment. Subjected to similar procedures as cryoneurolysis and radiofrequency ablation, but without active treatment.
9972623|NCT01322373||Alzheimer's disease subjects (AD)|Subjects with a diagnosis of DAT according to DSM-IV-TR criteria who completed Orasi Protocol ADG-08-01.
9977238|NCT01359488|Experimental|VRS-317 Safety Arm 3|"VRS-317 Single injection SC of dose level 3 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
9977239|NCT01359488|Experimental|VRS-317 Safety Arm 4|"VRS-317 Two injections SC of dose level 4 (based on 90 kg patient)~Placebo Two SC injection Dose matched to treatment volume"
9972624|NCT01322399|Experimental|Structural Integration plus usual care|Each subject in this arm will receive ten Structural Integration treatments at intervals of between one and three weeks, and will also receive usual care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
9972625|NCT01322399|Active Comparator|Usual care|Each subject in this arm will receive care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
9972626|NCT01322412||Arm A : physical activity program|Arm A : physical activity program (aerobic and strength training) during the 27 weeks of treatment (chemotherapy and radiotherapy) and conventional follow-up during 27 weeks
10153961|NCT04059692|Experimental|Cervical manipulation intervention|"To perform the evaluation and detect the cervical vertebral level with mobility restriction, with the patient in supine position, a cervical examination is carried out to determine the mobility restriction, both in flexo-extension, as in inclination and rotation. To check the level of restriction, the post-anterior sliding test is performed.~The manipulation is performed following the criteria of thrust manipulations. A maximum of 3 manipulations are applied in total per subject, one for each level (high level C1-C2, medium level C3-C6, and low level C7), if necessary."
10153962|NCT04059692|Placebo Comparator|Placebo intervention|This group will receive 15 minutes of sham techniques in a supine position over the stretcher. First, a series of short-time and no pressure contact with physiotherapist´s hands is performed in several points of head and shoulders for 10 minutes. Subsequently, light touch is applied on standardized anatomic areas, for 2 minutes each time.
10153963|NCT04059718|Experimental|Treatment|Treatment arm will be enrolled in the SCI Thrive Peer-Led Online Self-Management program and will take part in the next available group session.
10153964|NCT04059718|No Intervention|Wait-list Control|Wait-list control arm will only complete assessments during the 6 week group period. Subjects will be offered a place in the SCI Thrive Peer-Led Online Self-Management program after 6 weeks and completing the assessments.
10153965|NCT04059679|Active Comparator|EC aspirin (81mg qd)|
10153966|NCT04059679|Experimental|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)|
10153967|NCT04059666|Active Comparator|Control|
10153968|NCT04059666|Experimental|Investigational|
10153969|NCT04059666|No Intervention|Mother's-own Breast Milk|
10153970|NCT04059341|Experimental|Active LI-ESWT|Active group receives five sessions of low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG.
10153971|NCT04059341|Sham Comparator|Sham|Sham group receives five sessions of sham low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG with a shockwave absorbing adapter.
10153972|NCT04059445|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
10153973|NCT04059445|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
10153974|NCT04059653|Experimental|Electrical stimulation|Neuromuscular electrical stimulation treatment
10153975|NCT04059653|Active Comparator|Treatment As Usual|Usual GP treatment
10153976|NCT04059731|Experimental|Surmimed®OPD Drink|Normocaloric oligomeric-hyperprotein supplement
10153977|NCT04059731|Active Comparator|Atempero® or Impact®|Inmunonutrition
10153978|NCT04059471|Active Comparator|Standard Dose|Yellow fever vaccine, Institut Pasteur, standard dose as release by manufacturer will be administered subcutaneously once.
10153979|NCT04059471|Experimental|Fractional dose (1000 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 1000IU/dose and administered subcutaneously once.
10153980|NCT04059471|Experimental|Fractional dose (500 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 500IU/dose and administered once.
10153981|NCT04059471|Experimental|Fractional dose (250 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 250IU/dose and administered once.
10153982|NCT04059367|Experimental|NNC9204-1177 and cocktail of approved drugs|
10153983|NCT04059380||Patients with Hypoparathyroidism|Patients with Post-Surgical or Autoimmune Chronic Hypoparathyroidism requiring daily calcium and calcitriol therapy
10153984|NCT04059380||Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by hypoparathyroidism
10185757|NCT03742648|Experimental|Experimental physiotherapy group|Basic standard medical and nursing care along with chest physiotherapy involving any of the deep breathing exercises as per patients ease with 5-10 repetitions each, twice daily
9662414|NCT04275791|Experimental|hierarchized|Structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
9662415|NCT04275791|No Intervention|all-or-nothing|Structured regional health organization, composed of non-hierarchical trauma centers at different levels according to their capacity to receive severe trauma victims (all-or-nothing type).
9662416|NCT04263350|Experimental|Treatment A:Fixed- dose combination mini-tablet|
9662417|NCT04263350|Experimental|Treatment B: Separate products taken at the same time|
9662418|NCT04243759|Experimental|Control App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
10153985|NCT04059510||Screening for GBS|Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic STI screen according to local usual practice. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection.
9670137|NCT05067309||Missed abortion received letrozole then misoprostol|
9670138|NCT05067309||Missed abortion received misoprostol alone|
9670139|NCT05067361|Experimental|Experimental Group|
9670140|NCT05067361|Active Comparator|Active control Group|
9670141|NCT05066932||Familial Hypercholesterolemia and hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and hyperTriglyceridemia
9670142|NCT05066932||Familial Hypercholesterolemia without hyperTriglyceridemia|Patients with Familial Hypercholesterolemia and without hyperTriglyceridemia
9670143|NCT05067023|Experimental|MRI scan|All participants will undergo 1 DCE-MRI scan before surgery or puncture.
9670144|NCT05067062|Active Comparator|new zealand blackcurrant extract|Capsules will be take daily or every other day.
10153986|NCT04059510||Sampling method optimisation|"If a woman is deemed to meet all inclusion criteria and no exclusion criteria following screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent (optional) for participation in a focus group at the end of the study. 100 eligible women will be recruited on to this part of the study (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site (UK and Uganda).~The sampling study will last for 12 weeks and samples collected include:~A self-taken low vaginal swab~A self-taken rectal swab~Menstrual cup fluid~Serum sample~Urine pregnancy tests"
10153987|NCT04059510||Focus groups|"In the UK investigators will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional.~Women may opt out of the focus groups at any time but remain in the sampling study if they choose.~In Uganda, the investigator will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders.The investigator will explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples."
10153988|NCT04059419|Experimental|Experimental|30 Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
10153989|NCT04059419|Active Comparator|Control|Should remain under geriatric care after randomization.
10153990|NCT04059575|Experimental|PERFORMANCE PLUS|performance plus better than GOLD TEX
10153991|NCT04059575|Active Comparator|GOLD TEX|GOLD TEX better than performance plus
9670145|NCT05067062|Placebo Comparator|control|no capsules will be provided.
9670146|NCT05067049|Experimental|Connected EORTC-C30 arm (quality of life questionnaires on pad, phone,...)|The patients in this arm will have connected mobile app at home and they will regularly fill questionnaires. There are two different questionnaires : one with 14 questions about patient's quality of life and about the evolution of his surgical scar. One with 9 questions only about quality of life. They will also have meetings with physicians.
9670147|NCT05067049|Other|No QoL online follow-up arm|The patient haven't any questionnaires to fill at home. This is the normal management of the pathology. They only have different meeting with the specialist,as usual.
9670148|NCT05067205|Sham Comparator|open release|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using open carpal tunnel release method with duration of 6 months estimated.
9670149|NCT05067205|Experimental|mini CTS releaser|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using mini CTS releaser method with duration of 6 months estimated.
9670150|NCT05067192||Parkinson's Disease|Patients with Parkinson's Disease. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
9670151|NCT05067192||Dementia with Lewy Bodies|Patients with Dementia with Lewy Bodies. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
9670152|NCT05067192||Multiple System Atrophy|Patients with Multiple System Atrophy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
9670153|NCT05067192||Corticobasal Syndrome|Patients with Corticobasal Syndrome. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
9670154|NCT05067192||Progressive Supranuclear Palsy|Patients with Progressive Supranuclear Palsy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
9670155|NCT05067192||Healthy controls|Healthy contols. Contols will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
10153992|NCT04059497|Experimental|Exercise group|The exercise group will receive a 10-minute exercise intervention.
10153993|NCT04059497|Experimental|Healthy diet group|The healthy diet group (control) will receive a 10-minute healthy-diet intervention.
10153994|NCT04059276||Patients with stroke|
10153995|NCT04059276||Healthy subjects|
10153996|NCT04059315||Retrospective cross sectional study|"This is an Epidemiological observational analytic study where the subjects sustained with oral and maxillofacial trauma will be divided into the two-time-frame;~1st, retrospective study between 1 June 2011 to 31 May 2019"
10153997|NCT04059315||Prospective cohort study|2nd prospective study on 1 June 2019 to 1 June 2021.
9694708|NCT04786379|Experimental|Patients with confirmed septic arthritis of the native knee|
9826332|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
10153998|NCT04059627|Experimental|Experimental arm|"Participants were introduced to Heart-Track mobile app system and its navigational characteristics with standardised instructions. Each participant then performed a self-directed Cardiac rehabilitation session using the app."
9670156|NCT05066971|Experimental|Participants in gradual self-adjustment rate control medication|Patients receive a weekly simplified version of the information transmitted by the HM system. In the first 3 months, using that information, the physician changes or not the rate control medication posology (i.e. if the mean heart rate is 60bpm, betablocker dose is cut to half, and another heart rate evaluation is done a week later, and if heart rate is now 120bpm the dose is increased to a 3/4 of the initial dose, and so on). After those three initial months where physician guide titration, the patient is allowed to make self-adjustment of their medication accordingly to the information received (i.e. increasing or decreasing their rate control medication depending on heart rates and activity hours per day.
9670157|NCT05066958|Experimental|boost anti-viral immunity after T-cell depleted HSCT|
9670158|NCT05066906|Experimental|Use of Identifor and Companion+referral to employment agencies|This group will use the Identifor tool and Companion app for a period of 6 months. They will also receive standard referral to employment agencies.
10153999|NCT04059354|Experimental|Speech therapy|Direct speech therapy will be provided for a 12 week period with up to three one-hour sessions per week.
10154000|NCT04059536||Roxwood Anchoring Catheters|Participants will be treated for an index procedure using Roxwood Medical device(s) as prescribed by the Investigator SOC on Day 0. All devices will be used in accordance with the Instructions for Use (IFU). Participants are to be administered SOC acetylsalicylic acid (ASA) and/or anti-platelet medications orally per physician discretion prior to the index procedure. Administration of an intravenous injection of heparin during the index procedure will also be at the discretion of the Investigator per Institutional SOC.
10154001|NCT04059289||Intraocular lens type I|Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA)
10154002|NCT04059289||Intraocular lens type II|Clareon IOL (Alcon Pharma. Freiburg/FRG)
9670159|NCT05066906|Active Comparator|Referral to employment agencies|This group will not use the Identifor tool and Companion app. They will only receive standard referral to employment agencies.
10154003|NCT04059458|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
10154004|NCT04059458|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
10154005|NCT04059614|Active Comparator|"High flow nasal cannula (HFNC)"|"HFNC group: those who receive high-flow nasal cannula therapy"
10154006|NCT04059614|Experimental|conventional oxygen therapy (COT)|COT group: those who receive conventional oxygen therapy group
9670160|NCT05066841|Experimental|CM group|
9670161|NCT05066841|Placebo Comparator|placebo group|
9670162|NCT05066542|Active Comparator|NDPP Standard of Care SOC|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
9670163|NCT05066542|Experimental|NDPP + Basketball (BB)|Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30-minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and bi-weekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
9670164|NCT05066763||People with Parkinson's disease|
9670165|NCT05066711||ACP System|
9670166|NCT05066750|Experimental|Mindful breathing video|Participants watch a 10 minute mindful breathing video
9670167|NCT05066750|Active Comparator|Control video|Participants watch a 10 minute control video
9670168|NCT05066724|Experimental|Centanafadine|400 mg total daily dose Centanafadine Sustained Release (SR)
9670169|NCT05066776||Patients with Pulmonary Nodule|Patients at high-risk of lung cancer found to have a pulmonary nodule 6-20 mm in size.
9670170|NCT05066802|Experimental|modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42~46h continuous infusion, every other week for 6 cycles (12 weeks).
9670171|NCT05066789|Active Comparator|Biodegradable Polymer DES|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use Orsiro Mission stent during the index procedure."
9972627|NCT01322412||Arm B : conventional management|Arm B : conventional management during and after treatment
10154007|NCT04059601||Patients with acute cholecystitis|All patients with acute cholecystitis are included in the study cohort during year 2019. MRCP and IOC will be performed to all patients whenever feasible.
10154008|NCT04059523|Experimental|S6G5T-3|topical cream
10154009|NCT04059523|Active Comparator|Retin-A® 0.1% Cream|topical cream
10154010|NCT04059328||Physicians in Haiti|7 OBGYN physicians underwent a laparoscopic training and simulation course and then were proctored as they performed 3 in vivo cases using a check list to help the participants remember all the steps of laparoscopic set-up.
10154011|NCT04059224|Experimental|Arm A: advanced BRAF V600 wild-type/NRAS-mutant melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
10154012|NCT04059224|Experimental|Arm B: advanced BRAF V600 wild-type/NRAS wild-type melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
10154013|NCT04059042|Experimental|Music|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear music.~The musical selections will be professional recordings of instrumental Classical music selected by the researcher. All participants will hear the same pieces in the same order. Instrumentation ranges from piano solo to full orchestra, but they are without lyrics or heavy percussion. Pitch ranges across the pieces, but is standard across participants and not controlled by either the participant or the researcher. Tempo for all of the pieces is slow (~60 beats per minute). The pieces are in either major keys or minor keys, but all consist primarily of consonant harmonies and sustained melodic phrases. Participants will control the volume to their individual comfort level."
10154014|NCT04059042|Placebo Comparator|Nature Sounds|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear nature sounds.~Professional recordings of nature sounds selected by the researcher without added music will be used as the active placebo control condition. All participants will hear the same recording. This active control condition will allow for non-musical analgesic effects, such as distraction, to be controlled in the experimental design. Participants will control the volume to their individual comfort level."
10154015|NCT04059081|Experimental|GC chemotherapy|"Before administration of GC chemotherapy, all patients must undergo pretreatment bone marrow biopsy. The pretreatment BM biopsy must include at least 1 long core biopsy samples and 10 cc of aspirate.~Obinutuzumab 1000mg fixed dose will be administered intravenously (Day 1,8,15 for cycle 1 and D1 for subsequent cycles). Chlorambucil 0.5mg/kg will be administered orally (D1,15 for all cycles).~28 days are considered as one cycle, and cycles will be repeated every 4-weeks for a total of 6 cycles."
10154016|NCT04059133|Experimental|LiESWT arm|"For SUI: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.~For OAB: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°, and the applicator was gently placed on suprapubic skin area over the bladder dome and bilateral bladder walls with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually."
10154017|NCT04059133|Sham Comparator|Sham arm|"For SUI: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.~For OAB: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). The applicator was gently placed on the suprapubic skin area over the bladder dome (1000 pulses) and bilateral bladder walls (each side 1000 pulses). The probe was placed on the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°."
9670172|NCT05066789|Active Comparator|12-month DAPT|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive 12-month DAPT of aspirin (100mg once daily) plus prasugrel (10mg once daily)."
9670173|NCT05066789|Experimental|Polymer-free DCS|"Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio.~This group will use BioFreedom Ultra stent during the index procedure."
9670174|NCT05066789|Experimental|Prasugrel monotherapy|"Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study.~This group will receive aspirin (100mg once daily) plus prasugrel (10mg once daily) for 1 month and thereafter prasugrel (10mg once daily) alone."
10154018|NCT04059120|Experimental|Experimental group|The physical load will be organized as follows: The experimental group (EG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with specific stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
10154019|NCT04059120|Active Comparator|Control group|The physical load will be organized as follows: The control group (CG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with single or general stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
10154020|NCT04059198|Experimental|Arm 1 - Inarigivir Soproxil Daily|Inarigivir Soproxil Alone 400 mg Inarigivir daily for 12 weeks followed by 400 mg daily in combination with TAF 25 mg daily for 12 weeks
10154021|NCT04059198|Experimental|Arm 2 - Inarigivir Soproxil 3 Times Weekly|400 mg Inarigivir 3 times weekly for 12 weeks followed by 400 mg 3 times weekly in combination with TAF 25 mg daily for 12 weeks
9670175|NCT05066828|Active Comparator|conventional obturator|Participants received conventional obturator one piece
9670176|NCT05066828|Experimental|sectional obturator|two pieces obturators connected by magnet attachments
9826333|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
9826334|NCT02415439|Experimental|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
10154022|NCT04059198|Experimental|Arm 3 - Inarigivir Soproxil and TAF Daily|400 mg Inarigivir daily in combination with TAF 25 mg daily for 24 weeks
9670177|NCT05066568|Other|Sequence of interventions starting with tDCS as the first intervention|"Week 1 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 4 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes.~Week 5 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes"
10154023|NCT04058899|Active Comparator|, Dexmedetomidine group(DEX group)|dexmedetomidine group (DEX)group who will receive 0.5 µg/kg dexmedetomidine diluted in 50 ml of normal saline 0.9% to be given by IV infusion over 10 minutes after induction of anesthesa then 5ml of 0.9% normal saline IV ,
10154024|NCT04058899|Active Comparator|Nalbuphine group(NAL group)|nalbuphine group (NAL)group will receive IV infusion of 50 ml of 0,9%normal saline by IV infusion over 10 minutes then 0.1mg/kg nalbuphine diluted in 5ml of 0.9%normal saline IV after induction of anesthesia.
10154025|NCT04058938|Active Comparator|Control|The control group received standard of care, including standard patient counseling from the surgical teams.
10154026|NCT04058938|Experimental|Intervention|In conjunction with oncologic psychology and plastic surgery, an instrument was developed to be provided as a single-paged paper handout to the intervention group. The instrument included information about expectations for pain control, information about the pain scale, and examples of opioid and adjunct medications which may be used as part of a multi-modal approach to pain control during the perioperative period.
9694709|NCT04786080|Experimental|Parent Positive|This is an app developed for use on a smartphone providing a flexible digital space where parents can get support and advice to help them manage their children's behaviour. The app will be free and parents will be able to access the information when needed and in the order they choose. Parents in the intervention group will receive access during the immediate post-randomisation period.
9694710|NCT04786080|No Intervention|Follow-Up as Usual|FAU was selected as a comparator because of the pragmatic nature of the trial. Individuals randomised to FAU will receive no intervention for the first 10 weeks while the data for baseline (T1), T2 and T3 are collected. They will then be given access to all three zones of the app.
9972628|NCT01322438|Experimental|Arm 1|
10154027|NCT04058964|Experimental|Treatment (pembrolizumab, PEGPH20)|Patients receive pembrolizumab IV over 10 minutes on day 1 and pegylated recombinant human hyaluronidase PH20 SC on days 1, 8, and 15. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
10154028|NCT04058977|Experimental|Power training|Randomized to early power training with standardized exercise progression plus standard of care
10154029|NCT04058977|No Intervention|Standard of Care|Standard of care
10154030|NCT04059107|Experimental|Prosthetic Device|3D Printed Myoelectric Prosthetic Device
10154031|NCT04058912||PATİENCE GROUP|"To be in the range of 18-40 years~Patients with an operation indication with >=5 cm endometrioma~Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)~Patients who will be followed for IVF cycle due to infertility"
10154032|NCT04058912||PATİENCE-CONTROL GROUP|"To be in the range of 18-40 years~Patients with operation plan due to non-endometrioma ovarian pathologies~Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)~Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic"
10154033|NCT04058951|Placebo Comparator|High Animal Protein Diet (HAPD)|Consuming a diet high in protein primarily from animal origin.
10154034|NCT04058951|Experimental|High Plant Protein Diet (HPPD)|Consuming a diet high in protein exclusive from plant origin.
10154035|NCT04059029||Morbidly obese patients with NAFLD|Morbidly obese patient with Nonalcoholic fatty liver disease. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance. The diagnosis of NASH would be made histologically.
10154036|NCT04059172|Active Comparator|Ibuprofen|one 200 mg tablet of ibuprofen and 2 placebo tablets
10154037|NCT04059172|Experimental|Ibuprofen and acetaminophen|one 200 mg table of ibuprofen and two 325 mg tablets of acetaminophen
10154038|NCT04059172|Placebo Comparator|Placebo|3 tablets of tableting compounds with no active ingredients
10154039|NCT04059146|Experimental|Pain Education + Exercise|"The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain.~All participants will receive the same progressive Achilles tendon loading exercise program."
9519984|NCT03281681|Experimental|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
10154040|NCT04059146|Active Comparator|Standard Education + Exercise|"The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage.~All participants will receive the same progressive Achilles tendon loading exercise program."
10185758|NCT03742622|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions
10185759|NCT03742609|No Intervention|Information only|provision of written information regarding consequences of using a hearing aid and not using a hearing. For example using a hearing aid will improve ability to hear others.
9826335|NCT02415439|Placebo Comparator|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
9972629|NCT01322451|Experimental|Single oral dose, single capsule|
9972630|NCT01322451|Experimental|Single oral dose, two capsules|
10154041|NCT04058847|Experimental|Intervention|Use of Your Heart Forecast and an e-mail follow up-program.
10154042|NCT04058847|No Intervention|Control|The control group uses standard regime (business as usual).
10154043|NCT04058860|Other|Study Patients|Patients undergoing open heart surgery with minimal invasive extracorporeal circulation (MiECC) according to accepted indications
10154044|NCT04058821|Experimental|Adults with traumatic brachial plexus injuries|Participants will have two MRI scans before surgery (to find out the best time to scan), then two after surgery (at 6 and 12 months).
10154045|NCT04058522|Experimental|Group Physiotherapy|1 class per week for 6 weeks (30 min length) aiming for 5-10 participants per class. Classes included advice on the nature of the condition and exercises for scapulo-humeral mobility, scapulo-humeral stability and specific rotator cuff rehabilitation exercises
9972631|NCT01322464|Experimental|Group 1 Fasted-Fed|"4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.~Followed by 4 sprays daily in fasted state."
9972632|NCT01322464|Experimental|Group 1 Fed-Fasted|"4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.~Followed by 4 sprays daily in fasted state."
9972633|NCT01322464|Experimental|Group 2|2 sprays Sativex daily in fasted state.
10154046|NCT04058522|Active Comparator|Routine Physiotherapy|Individual physiotherapy sessions: 6 sessions weekly (30 min) for 6 weeks. Treatment was based on evidence-based guidelines for the treatment of shoulder impingement (CSP 2005) and consisted of mobilisation techniques, supervised exercises and stretches.
10154047|NCT04058574|Active Comparator|ACL|"Intervention Group ACL: 30 patient, athletes, with ACL deficiency candidate to a surgical ACL reconstruction"
10154048|NCT04058574|Placebo Comparator|Control|Control Group: 15 healthy volunteers, athletes.
10154049|NCT04058678|Sham Comparator|CONTROL|"A control group composed of women with normal ovarian reserve (30 to 45 yerras old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Note that the term normal ovarian reserve referred to older women indicates women that still have follicles in their ovaries -and thus, normal AMH values-, even though the number may be lower tan at a younger age or the quality of oocytes may be lower tan in younger women. In other words, women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve."
10154050|NCT04058678|Experimental|EXPERIMENTAL|A group of women with diminished ovarian reserve that will take an inactive substance has been included to avoik biases and to set the fertility base line for women with compromised ovarian reserve.
10154051|NCT04058730|Experimental|LRYGBP|"Laparoscopic Roux en Y Gastric by pass surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic RYGB is primarily a restrictive procedure with a small element of malabsorption.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge."
10154052|NCT04058730|Experimental|LSG|Laparoscopic Sleeve Gastrectomy surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic Sleeve Gastrectomy is a pure restrictive procedure. Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge
10154053|NCT04058730|Experimental|SMM|"Standard Medical Management will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Standard Medical management will be as per the recommendation of ADA 2010 guidelines.~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients 1 month, 3 months, 12 months and 24 months post consult"
10154054|NCT04058457||STN DBS|Patients planned to undergo deep brain stimulation of the subthalamic nucleus
10154055|NCT04058457||GPi DBS|Patients planned to undergo deep brain stimulation of the globus pallidus interna
9972634|NCT01322464|Experimental|Group 3|8 sprays sativex daily in fasted state.
10154056|NCT04058457||VIM DBS|Patients planned to undergo deep brain stimulation of the ventral intermediate nucleus of thalamus.
10154057|NCT04058548|Experimental|6MWT and STS|All participates will receive 6MWT and STS test
10154058|NCT04058496||1|Coronary artery bypass surgery off-pump (n=20)
9519985|NCT03281655|Experimental|Vulvovaginal atrophy|Postmenopausal sexually active women affected by vulvovaginal atrophy undergoing treatment (15 days, 1 application per day) with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
9972635|NCT01322477||Hepatocellular Carcinoma|Patients with advanced HCC
9972636|NCT01322503|Experimental|Norovirus Challenge|
9972637|NCT01322503|Experimental|Norovirus challenge|
10154059|NCT04058496||2|Coronary artery bypass surgery on-pump (n=20)
10154060|NCT04058496||3|Coronary artery bypass surgery plus valve surgery (n=20)
9519986|NCT03281629|Active Comparator|Active TMS stimulation|Real active rTMS stimulation.
9826336|NCT02415439|Experimental|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
9826337|NCT02415439|Experimental|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
9826338|NCT02415439|Experimental|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
9826339|NCT02415439|Experimental|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
9972638|NCT01322620||A|
9972639|NCT01322646|Active Comparator|Driver Training|Driver Education Program Practice driving on a driving simulator Provision of the CarChipPro to the family
9972640|NCT01322646|Experimental|STEER Program|Driver Education STEER Program
9972641|NCT01322659|Active Comparator|Helmet NPPV|Weaning from mechanical ventilation with noninvasive positive pressure ventilation (NPPV)delivered by means of the helmet
10154061|NCT04058717|Experimental|NNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
9670178|NCT05066568|Other|Sequence of interventions starting with Hypnosis as the first intervention|"Week 1 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 4 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes~Week 5 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes."
9670179|NCT05066516|Experimental|Period 1: Individual components (ICs), period 2: FCDP|Period 1: Individual components (ICs), period 2: FCDP
9670180|NCT05066516|Experimental|Period 1: FCDP, period 2: ICs|Period 1: FCDP, period 2: ICs
9670181|NCT05066893|Active Comparator|standard of care|standard of care will be given as per usual care
9670182|NCT05066893|Experimental|intensive monitoring|intensive monitoring every week will be given to participants
9670183|NCT05066581|No Intervention|Philips band|It is a medical device that collects, among other things, movement data by means of an accelerometer, from which it accelerometer, from which it estimates the total time of sleep (TTS) and wakefulness, and waking time, also offering the efficiency of the same (time asleep in relation to time in bed). time in bed). In addition, it collects data not related to sleep, such as energy expenditure (in kilocalories), energy expenditure (in kilocalories) (in kilocalories), heart rate, and daily activity (in steps), among others.
9670184|NCT05066581|Active Comparator|Philips Band + Live chat|In the Intervention group, in addition to having the philips band, the subjects will interact through the live chat system that they will have to download to their mobile phones. This live chat offers the possibility to consult in real time, thus initiating a process of relationship between researcher/subject.
10154062|NCT04058717|Experimental|NNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.
9670185|NCT05066633|Placebo Comparator|Control Group|Matching placebo will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
9670186|NCT05066633|Experimental|Treatment Group|Metoprolol succinate will be supplied by the sponsor in child-proof bottles containing dividable tablets with the following dosage of 25mg of IMP and 100mg of IMP. The drug will be administered orally at singular daily doses ranging from 0.75 to 4.5 mg/kg over a Double-Blind Treatment Period (DBTP) of up to 60 months or less dependently on the time of enrolment. The Treatment Period will begin with up to 12-weeks long Up-titration Phase, during which the dose will be gradually escalated. If patient presents with signs and symptoms of intolerance the dose may be temporarily or permanently downgraded at the discretion of the clinician. The up titration ends with reaching maximal tolerated dose level or at a dose corresponding to 4.5 mg/kg.
9670187|NCT05066594||Transoral incisionless fundoplication with EsophyX device (EndoGastric Solutions)|Patients treated by transoral incisionless fundoplication (TIF) using the EsophyX device (EndoGastric Solutions) for gastro-esophageal reflux disease will be enrolled in the registry and clinically followed-up for 5 years from the date of TIF procedure.
9670188|NCT05066607|Experimental|Single-stage|"Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and Dexamethasone 10-20 mg weekly on days 1, 8, 15 and 22.~Each cycle will be of 28 days duration. During cycle 1, Isatuximab will be administered weekly on days 1, 8, 15, and 22 then days 1 and 15 in subsequent cycles from cycle 2 to 9 or 12.~For each individual patient, the treatment period will be 12 months, unless CR at the completion of 9 cycles, disease progression or unacceptable toxicity occurs. The duration of follow-up for overall survival will be 1 year after the last patient enters overall survival follow-up."
9826340|NCT02415439|Placebo Comparator|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
9826341|NCT02415556|Experimental|Type 2 Diabetes Mellitus - Insulin|40 IU of regular human insulin once daily over 24 weeks
10154063|NCT04058717|Experimental|VLNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
9826342|NCT02415556|Placebo Comparator|Type 2 Diabetes Mellitus - Placebo|Intranasal sterile saline once daily over 24 weeks
10154064|NCT04058717|Experimental|VLNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid
10154065|NCT04058444|Experimental|ERAS Group|Perioperative management follows the ERAS (Enhanced Recovery After Surgery) protocol
10154066|NCT04058444|Experimental|Control Group|Perioperative management follows the conventional program
9519987|NCT03281629|Sham Comparator|Sham TMS stimulation|Sham repetitive TMS stimulation.
9519988|NCT03281616|Active Comparator|Diet and Physical Activity Recording|
9519989|NCT03281616|Active Comparator|Diet and No Physical Activity Recording|
10154067|NCT04058600|Experimental|Virtual Reality|The patients will be exposed to a virtual reality software that simulates the environment of the hospital, from admission to the operating room and the recovery room.
10154068|NCT04058600|No Intervention|Control|Patients in this group are not exposed preoperatively to the virtual reality software and are given the standard therapy and cares for their disease.
9670189|NCT05066620|Experimental|Intervention group|Chinese herbal medicine FYTF-919: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
9670190|NCT05066620|Placebo Comparator|Control group|Placebo treatment: Oral liquid 33ml TID (or patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)
9670191|NCT05066854|Experimental|Integron research|"Empirical antibiotic treatment chosen based on the results of the integron search:~when PCR is negative, patients will receive SXT (30 mg/kg/j of sulfamethoxazole and 6 mg/kg/j of trimethoprim)~when PCR is positive or uninterpretable for integrons, patients will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
9670192|NCT05066854|Other|Usual practice|Empirical antibiotic treatment based on the usual practice of each center according to the GPIG guidelines.
9670193|NCT05066425|Experimental|Soluble Corn Fiber|22g Soluble Corn Fiber/day for 4 weeks
9670194|NCT05066425|Placebo Comparator|Maltodextrin|22g Maltodextrin/day for 4 weeks
9670195|NCT05066438||Antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed AND must have received standardized counselling on and practiced antenatal hand expression for a minimum of 10 days beginning no earlier than 36 weeks gestational age.
9670196|NCT05066438||No antenatal hand expression - intention to exclusively breastfeed|Eligible participants in this group intend to exclusively breastfeed but have NOT received any standardized counselling on antenatal hand expression and have not practiced antenatal hand expression OR have practiced antenatal hand expression but for less than 10 days.
9670197|NCT05066360|Other|participants with epilepsy|healthy, menstruating females between 12-18 ages
9670198|NCT05066360|Other|healthy participants|epileptic, menstruating females between 12-18 ages
9670199|NCT05066139|No Intervention|Arm A Standard of care|"Patients will receive standard care before treatment initiation (i.e. geriatric assessment only).~Geriatric assessment includes: Mini Mental State Examination ; mini-Geriatric Depression Scale (mini-GDS) ; Body Mass Index (BMI) calculation ; Mini Nutritional Assessment (MNA) ; Time up and Go ; Cumulative Illness Rating Scale - Geriatric (CIRS-G) ; Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) questionnaires."
9670200|NCT05066139|Experimental|Arm B Multidisciplinary EPODIG program|Patients will undergo the same geriatric assessment as in Arm A plus EPODIG-G program before treatment initiation.
9670201|NCT05066126|Experimental|High-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a high-mixed presentation of content.
9670202|NCT05066126|Experimental|Low-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a low-mixed presentation of content.
10154069|NCT04058743|Active Comparator|TKA with standard cobalt chromium components|Patients randomized to this group will receive the standard cobalt chromium components in their total knee arthroplasty
10154070|NCT04058743|Experimental|TKA with nickel free components|Patients randomized to this group will receive nickel free components in their total knee arthroplasty
10154071|NCT04058613|Experimental|Albumin|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
10154072|NCT04058613|Placebo Comparator|Placebo|Placebo
10154073|NCT04058587|Experimental|Simmitinib tablet|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
10154074|NCT04058431|Experimental|Osteopathic group|Treatment will be compromised of 8 weeks of standard care plus OMT. Each physician will maintain the same patient at recurring sessions. Osteopathic treatment is performed for 30 minutes and the techniques applied are highly individualized to the patient needs (i.e., techniques are selected based on structure/function, and techniques change over time based on treatment response). In an effort to standardize treatment, we will limit the study protocol to the following designated techniques: facilitated positional release treatment, high velocity low amplitude treatment, articulatory treatment, strain-counterstrain, muscle energy treatment, myofascial release treatment, soft tissue treatment.
10154075|NCT04058808|Experimental|Participants with Atrial Fibrillation attending the clinic.|
10154076|NCT04058704|Experimental|Early intervention|Icotinib is administered orally three times per day. Radiation therapy (SRS/ WBRT/ HA-WBRT/SMART) start in 1 month since take icotinib orally.
10154077|NCT04058704|Experimental|Late intervention|Icotinib is administered orally three times per day. Until emerge the progression of the disease, then is given radiation therapy (SRS/WBRT/HA-WBRT/SMART)
10154078|NCT04058418||Familial breast cancer risk assessment services in England|All familial breast cancer risk assessment services in England
10154079|NCT04058223||PPH/DST|Patients underwent hemorrhoidopexy by PPH or DST stapler.
10154080|NCT04058119|Experimental|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates)
10154081|NCT04058119|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the Functional Training Program after the experimental period (6 months).
10154082|NCT04058275||Control|Deployed to 1990-1991 Persian Gulf War Do not meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] Good general medical and psychiatric health
9670203|NCT05066126|Experimental|High-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a high-mixed presentation of content.
9670204|NCT05066126|Experimental|Low-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a low-mixed presentation of content.
9826343|NCT02415556|Experimental|Control - Insulin|40 IU of regular human insulin once daily over 24 weeks
10154083|NCT04058275||Gulf War Illness|Deployed to 1990-1991 Persian Gulf War Meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] plus Center for Disease Control criteria for Chronic Multisymptom Illness (CMI) [Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, Noah DL, Barrett DH, Randall B, Herwaldt BL, Mawle AC, Reeves WC. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998 Sep 16;280(11):981-8. PubMed PMID: 9749480.]
10154084|NCT04058483|Active Comparator|HIP First|Participants randomized to perform the in-person hypnotizability test first. This will be followed within 1 week with the by-phone rHIP test performed by a second, randomly-assigned investigator.
10154085|NCT04058483|Active Comparator|rHIP First|Participants randomized to perform the by-phone hypnotizability test first. This will be followed within 1 week with the in-peron HIP test performed by a second, randomly-assigned investigator.
10154086|NCT04058236|Experimental|human albumin 5%|10 patients with pancreatic cancer will receive human albumin 5% in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
10154087|NCT04058236|Active Comparator|gelofusine|10 patients with pancreatic cancer will receive gelofusine in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
10154088|NCT04058145|Experimental|Pembrolizumab+AMD3100 q3w|"Pembrolizumab is administered intravenously on day 1 of each cycle~AMD3 100 is administered via injection subcutaneously on day 1 of each cycle"
10154089|NCT04058145|Experimental|Pembrolizumab+AMD3100 weekly|"Pembrolizumab is administered intravenously on day 1 of each cycle~AMD3 100 is administered via injection subcutaneously on a weekly basis"
10154090|NCT04058145|Experimental|Pembrolizumab+AMD3100|"Pembrolizumab is administered intravenously~AMD3 100 is administered via injection subcutaneously"
10154091|NCT04058288||Stroke|People suffering from upper-limb motor dysfunction due to stroke
9670205|NCT05066256|Experimental|Fluid responsive test|Measure cardiac output, inferior vena cava (IVC) diameter variation and LV diastolic function (E/e') baseline Fluid challenge Measure cardiac output, IVC diameter variation and LV diastolic function (E/e') after fluid challenge
9670206|NCT05066152|Experimental|Probiotic|For 8 weeks of interventional period, the patient received 10 probiotic drops (1x1010 Cfu LGG) once daily at breakfast.
9670207|NCT05066152|Placebo Comparator|Placebo|For 8 weeks of interventional period, the patient received 10 probiotic drops (placebo) once daily at breakfast.
10154092|NCT04058314|Experimental|Study Eye|Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction
10154093|NCT04058314|Active Comparator|Control Eye|control eyes will received an approved monofocal or toric IOL after cataract extraction
9670208|NCT05066282||Participants with past PTSD who received IMP in the main study|
9670209|NCT05066477|Active Comparator|CalGo (Salmon bone meal)|4 capsules daily of CalGo (salmon bone meal enriched with Vitamin D3) is taken per orally. Each capsule contains ~500 mg of salmon bone meal (380 mg calcium, 200 mg phosphorus, 500 mg native collagen type 2), and 10 micrograms of vitamin D3 (400 IU). Once daily dosing. Duration: 2 years.
9670210|NCT05066477|Placebo Comparator|Maltodextrin|4 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once daily dosing. Duration: 2 years.
10154094|NCT04058249|Experimental|Right DLPFC aiTBS stimulation|
10154095|NCT04058340|Active Comparator|lactizole-placebo|A group of patients who will receive 3ml lactizole solution (150ppm) in nebulization twice a day for 4 weeks , and then for the next 4 weeks they will receive 2 times a day 3ml 0.9% NaCl solution in nebulization
10154096|NCT04058340|Active Comparator|placebo-lactizole|A group of patients who will receive 2 times a day for 4 weeks (0.9% NaCl solution in nebulization) for 4 weeks and will receive 3ml of lactizole solution (150ppm) in nebulization 2 times a day for 4 weeks
10154097|NCT04058509|Experimental|focused shockwave therapy|3 sessions of shock wave treatment.(Focused Shockwave Therapy).
10154098|NCT04058106||A patient who need the spine surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for spine surgery
10154099|NCT04058301|No Intervention|Handout|Participants receive a generic handout about resources in Boston
10154100|NCT04058301|Experimental|Text message|Participants receive a generic handout about resources in Boston and a text message with a geographically proximate resource
10154101|NCT04058327||MHE group|Patients whose MHE test are positive
10154102|NCT04058327||no HE group|Patients whose MHE test are negative
10154103|NCT04058327||overt HE group|2/3/4 HE patients
10154104|NCT04058379|Experimental|CT scan|During this study each patient will have 3 CT scans : D0, D1 and D3. A daily follow up during first seven days in ICU, then a follow up at D28 if still in hospital, and a phone call at M6 for neurological outcome
10154105|NCT04058262|Experimental|Meditation presential|
10154106|NCT04058262|Experimental|Reiki|
10154107|NCT04058262|Experimental|Meditation (app)|
10154108|NCT04058262|Placebo Comparator|round of conversation|
10154109|NCT04058132|Other|Group 1: acute/subacute Traumatic Brain Injury|Any gender, age 18-55 years who have had a traumatic brain injury within 30 days
10154110|NCT04058132|Other|Group 2: Non-TBI healthy control (HC)|Any gender, age 18-55 years with no history of traumatic brain injury
10154111|NCT04058171||LSS group|Participants with a diagnosis of lumbar spinal stenosis
10154112|NCT04058171||PAD group|Participants with a diagnosis of peripheral artery disease
10154113|NCT04058171||LBP group|Participants with a diagnosis of non specific low back pain
10154114|NCT04058093|Experimental|Functional Training Program|"Functional training program (FTP) will last for 6 months and will include:~Functional training sessions (each 45-minutes long, twice a week);~Group nutrition counseling (each 90-minutes long, in three different moments throughout the intervention: week 1, 12 and 20)."
9670211|NCT05066113|Experimental|Healthy Participants|Electrothermolysis treatment using varying levels of RF energies
9670212|NCT05066334|Experimental|Active Arm|"Two procedures:~Bone marrow harvesting from the posterior superior iliac crest region~Single injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control"
10154115|NCT04058093|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the FTP after the experimental period (6 months).
10154116|NCT04057755|Experimental|Botulinum toxin A vs placebo|50 Allergan units (diluted in 0,5 ml sterile NaCl) or 0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
10154117|NCT04057755|Active Comparator|Botulinum toxin A|50 Allergan units (diluted in 0,5 ml sterile NaCl) will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
10154118|NCT04057755|Placebo Comparator|NaCl|0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance and volume will be repeated after 3 months.
10154119|NCT04057950|Active Comparator|treating shampoo|treating shampoo (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo) 1144628 D cosmetic product
10154120|NCT04057950|Placebo Comparator|vehicle|1144781 cosmetic product
9670213|NCT05066334|Sham Comparator|Sham Procedure|"Two sham procedures:~Simulated bone marrow harvesting without insertion into the posterior iliac crest region~Simulated injection under only local anaesthesia without disc injection and without placebo injection."
9670214|NCT05066061|Active Comparator|standard|Only use local anesthetic cream
9670215|NCT05066061|Experimental|anxiolytic gas|Use local anesthetic cream and anesthetic and anxiolytic gas
10154121|NCT04057846|Active Comparator|Double pigtail|Plastic stent group EUS-guided drainage shall be performed as follows: a) Puncture of WON with a 19 GA Access needle (Cook Medical), b) aspiration of fluid in WON for microbiological assessment, c) insertion of guidewire (0.035 inch, 450 cm, Dreamwire (Boston Scientific), d) creation of transmural tract with needle knife over the guidewire, e) dilatation of tract to a diameter of 15 mm with dilation balloon (EZDilate, Olympus), f) insertion of two 7-Fr/6 cm double pigtail stents and a 7-Fr naso-cystic irrigation catheter.
10154122|NCT04057846|Experimental|Lumen apposing metal stent|LAMS shall be the Hot AXIOS stent with electrocautery-enhanced delivery system (Boston Scientific). The stent is a through-the-scope, fully covered, self-expandable metal stents with a diameter of 20 mm and a length of 10 mm. Before placement of the LAMS, the WON shall be punctured with a 19 GA Access needle (Cook Medical) and fluid in WON aspirated for microbiological assessment. Thereafter the LAMS shall be placed as follows: After directly puncturing the WON using the electrocautery tip (without the use of a guidewire to assist in stent insertion), the delivery catheter is advanced into the WON and the distal flange is deployed under EUS-guidance. The proximal flange is then released under EUS guidance or endoscopic view. After placement of the LAMS, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS.
9670216|NCT05066061|Experimental|virtual reality|Use local anesthetic cream and virtual reality mask
9670217|NCT05066412|Experimental|Arm 1|Prophylactic CD45RA-depleted DLI
9670218|NCT05066373|Experimental|EDP1815 capsule A (fasted)|In part 1 period 1, 12 healthy volunteers will receive a single dose of EDP1815 capsule A, dosed in the fasted state
9670219|NCT05066373|Experimental|EDP1815 capsule B (fasted)|In part 1 period 2, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fasted state
9670220|NCT05066373|Experimental|EDP1815 tablet (fasted)|In part 1 period 3, 12 healthy volunteers will receive a single dose of EDP1815 tablet, dosed in the fasted state
9670221|NCT05066373|Experimental|EDP1815 capsule B (fed)|In part 1 period 4, 12 healthy volunteers will receive a single dose of EDP1815 capsule B, dosed in the fed state
9826344|NCT02415556|Placebo Comparator|Control - Placebo|Intranasal sterile saline once daily over 24 weeks
10154123|NCT04058015||adult patients with thoracoabdominal injuries|adult patients with moderate to severe thoracoabdominal injuries
10154124|NCT04057963|Experimental|Conventional plus Functional Inspiratory Muscle Training Group|Conventional program plus functional inspiratory muscle training will be carried out three sessions per week during the six weeks. The content of the program will be the same as for the conventional group. Additional functional inspiratory muscle training will be began with 50% of the maximal inspiratory pressure value in a specific device and it will be progressed 5% every week according to the tolerance.
10154125|NCT04057963|Active Comparator|Conventional Physiotherapy Program|Conventional program will be carried out three sessions per week during the six weeks. Cervical mobilization techniques (glidings-grade 2) of cyriax will be applied in the direction of lateral flexion and rotation. Stretching exercises, craniovertebral flexion exercise and scapulothoracic strengthening exercises will be performed.
10154126|NCT04058080|Experimental|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6 degrees Celsius, 40% humidity). The class opened with a deep breathing exercise and continued with 50 minutes of standing asanas and 40 minutes of floor-based asanas, including a quick, forceful breathing exercise to finish. All but the last asana (i.e., spine-twisting) were performed twice. Savasana, which is a restorative and relaxation posture, was performed between asanas throughout the floor series and at the end of class. The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
10154127|NCT04058080|Active Comparator|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Selecting these classes was done in consultation with the general manager of the YMCA, who was familiar with each class type. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration.
10154128|NCT04058080|No Intervention|Waitlist|Waitlisted individuals were not able to access yoga or exercise classes throughout the intervention period but participated in the rest of the study protocol. Following the post-treatment assessment, they received access to the class type of their choosing.
10154129|NCT04058041|Experimental|Neural mobilization|passive mobilization of the median nerve by the therapist following by an active movement of the fingers of the pathology hand
10154130|NCT04058041|Active Comparator|Surgery|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will teach home exercises (no neural exercises) to the patients.
9670222|NCT05066347|No Intervention|Usual care|Patients randomized to usual care will receive all care as prescribed by the discharging physician and there will be no study specific interventions. The current usual care varies from no outpatient monitoring to short-term Holter monitoring (24 hours to 72 hours).
9670223|NCT05066347|Experimental|Prolonged 24/7 live outpatient cardiac rhythm monitoring|Patients randomized to the intervention arm will receive 24/7 live cardiac rhythm monitoring for 15 days. If a patient is randomized to the intervention arm and was prescribed outpatient cardiac monitoring such as Holter monitor, this will be replaced by the 24/7 live monitoring and will be applied either prior or within 24 hours of discharge from the ED.
9670224|NCT05066178|Experimental|CAS Treatment for MV ASD|Participants will receive CAS treatment, modified for minimally verbal children with autism
9670225|NCT05066243||focus group|15 service users for focus group
9670226|NCT05066243||questionnaire|150 patients to test questionnaire
9670227|NCT05066048||The appendectomy group|
9670228|NCT05066048||Colorectal cancer group|
9670229|NCT05066048||Normal group|
9670230|NCT05065788||2020 Lockdown period|Patients who access to Ophthalmological emergency service during lockdown period in 2020
9670231|NCT05065788||2019|Patients who access to Ophthalmological emergency service in 2019 definite periods
10154131|NCT04058041|Active Comparator|Surgery and Neural mobilization|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will perform mobilizations of the median nerve just like the experimental group.
10154132|NCT04057781|No Intervention|Control|
10154133|NCT04057781|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment every 2 weeks for 6 weeks (weeks 0, 2, 4, 6).~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
9670232|NCT05065684||rhBMP-2 and rhBMP-7|patients who have been treated with rhBMP-2 or rhBMP-7 for long bone non-union or acute fractures
9670233|NCT05065684||No-BMP|patients who have been treated with standart care, i.e. non-union resection and autologous bone graft
9670234|NCT05065762||Phase 1|Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria
9670235|NCT05065762||Phase 2|Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan
9670236|NCT05065814|Other|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus patients who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
9670237|NCT05065814|Other|Systemic sclerosis group|Demographic information of systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
10154134|NCT04057781|Active Comparator|Dry Needling with Intramuscular ES (DNES)|"Subjects will receive dry needling treatment with electrical stimulation every 2 weeks for 6 weeks (week 0, 2, 4, 6)~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
10154135|NCT04057911|Experimental|Real NIBS|In Real NIBS arm, active Noninvasive brain stimulation (NIBS) will be given for 20 mins.
10154136|NCT04057911|Sham Comparator|Sham NIBS|In Sham NIBS arm, sham Noninvasive brain stimulation (NIBS) will be given for 20 mins.
10154137|NCT04058054|Experimental|KeraStat® Cream|KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.
10154138|NCT04058054|Experimental|KeraStat® Gel|KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.
10154139|NCT04058054|Experimental|Biafine|Wound dressing for management of partial and full thickness wounds.
10154140|NCT04058054|Active Comparator|Histamine|Histamine is provided as a solution of histamine base (6.0 mg/mL).
10154141|NCT04058054|Sham Comparator|Saline|Saline (sterile) is provided as a 0.9% NaCl solution.
10154142|NCT04057638|Experimental|Treatment group|There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
10154143|NCT04058002|Experimental|Experimental|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.
10154144|NCT04058002|Active Comparator|Control group|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.
10154145|NCT04057989||Battlefield Injury with ketamine treatment|Patients who received ketamine infusions to treat pain from January 2007 to December 2013.
10154146|NCT04057885|Experimental|Device Arm|A prospective series of 10 patients will receive sensor-guided TKA using the this special Orthosensor™ VERASENSE™ Knee System assisted surgery for optimization of soft tissue balance
10154147|NCT04057885|Active Comparator|Standard of Care|10 patients will receive standard of care. Prior to cementing final implants, VERASENSE will be utilized with the standard of care group with the surgeon blinded to the data.
10154148|NCT04057690||MCA ischemia without malignant edema|MCA ischemia without malignant edema
10154149|NCT04057690||MCA ischemia with malignant edema|MCA ischemia without malignant edema w/o surgical treatment
9670238|NCT05065814|Other|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
9670239|NCT05065658||Critically-ill COVID-19 patients receiving posaconazole prophylaxis|
9670240|NCT05065658||Critically-ill COVID-19 patients without antifungal prophylaxis|
9670241|NCT05065840|Experimental|4 Pillars Program|Patients at study clinics who consent to have their HPV vaccination history verified with the Georgia Registry of Immunization Transactions and Services (GRITS).
9670242|NCT05065840|No Intervention|Adjacent time-period Control Group|The background HPV update rate among PLWH will be obtained by using the electronic medical record (EMR) and GRITS to identify HPV vaccination uptake 18 months prior to the intervention. These data are collected retrospectively and no study participants are prospectively assigned to this study arm.
9670243|NCT05065671|Experimental|Tolcapone|Tolcapone 100 mg by mouth once
9670244|NCT05065671|Experimental|Duloxetine|Duloxetine 30 mg by mouth once
9670245|NCT05065905|Experimental|Interferon|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU alternated with Interal® (interferon alpha) 3,000,000 IU every other day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
9670246|NCT05065905|Experimental|Interferon daily|"All participants receive subcutaneous interferon-gamma (Ingaron®) 500,000 IU given with Interal® (interferon alpha) 3,000,000 IU every day~Interventions:~Drug: Ingaron® Drug: Interal® Drug: Antituberculosis complex therapy"
9670247|NCT05065905|No Intervention|Control|"All participants receive only basic antimicrobial treatment~Interventions:~Drug: Antituberculosis complex therapy"
9670248|NCT05066035|Active Comparator|Neostigmine|"The Group N (Neostigmine) (n=48), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
9670249|NCT05066035|Active Comparator|Neostigmine and Sugammadex|"In Group N+S (Neostigmine+Sugammadex) (n=50), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. After a three-minute waiting period, the study investigators administered an intravenous bolus half-dose of 1 mg/kg of sugammadex after the standard reversal dose.~A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio < 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes."
9670250|NCT05065632||Groupe 1|[1-15[
9670251|NCT05065632||Group 2|[15- 30[
10154150|NCT04057729|Experimental|Arm 1 （IMP4297 100mg, Fasted-Fed）|Period 1: Fasted control → Period 2: Fed control
10154151|NCT04057729|Experimental|Arm 2（IMP4297 100mg, Fed- Fasted）|Period 1: Fed control → Period 2: Fasted control
10154152|NCT04057794|Active Comparator|Site-Based Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.
9670252|NCT05065632||Group 3|[30-45[
9670253|NCT05065632||Group 4|[45-60[
9670254|NCT05065632||Group 5|60+
9670255|NCT05065645|Active Comparator|APN01|Angiotensin Converting Enzyme 2: 1.25 mg/ml, 2.5 mg/ml or 5 mg/ml
9670256|NCT05065645|Placebo Comparator|NaCl|Sodium Chloride: 0.9% NaCl solution
9670257|NCT05065996||Different 4D flow MRI parameters in aortic dilatation and controls|Patients with aortic dilatation (n=20) scheduled for aortic MRI and healthy controls (n=20) without aortic dilatation. One time aortic MRI with 4D flow imaging.
9670258|NCT05065996||Value of aortic 4D flow MRI parameters to predict aortic dilatation in 5 years follow up|Patients with aortic dilatation (n=100) scheduled for aortic MRI follow up in Kuopio University Hospital. Aortic 4D flow MRI will be done yearly for 5 years and flow parameters predicting aortic dilatation will be analysed.
9670259|NCT05065996||Histology, molecular biology and genetics behind aortic dilatation|Patients scheduled for aortic operation (n=20+100) in Kuopio University Hospital. Aortic tissue samples and blood will be collected for analysis and compared to 4D flow MRI parameters. Control samples will be collected from healthy organ donors (n=5+5) operated in Kuopio University Hospital.
10154153|NCT04057794|Active Comparator|Centralized Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.
10154154|NCT04057625|Other|lung ultrasound|using lung ultrasound in diagnosis and follow up of vap measuring the largest area of consolidation according to intercostal space and the direction of the probe
10154155|NCT04057495|Placebo Comparator|no mango intake|No mango consumption on the study visit
10154156|NCT04057495|Experimental|white bread with same amount of calorie as mango|White bread consumption on the study visit
10154157|NCT04057495|Experimental|mango consumption|mango consumption on the study visit
10154158|NCT04057612||Pediatric participants|"Participants' temperature measured at 2 places at the same time~Esophagus~Skin near to carotid artery"
10154159|NCT04057534|Experimental|CB-CRT AUD group|experimental group AUD: patients receive standard clinical therapy and an add-on chess based - cognitive remediation treatment (CB-CRT)
10154160|NCT04057534|Active Comparator|Control group AUD|control group: patients with AUD receive standard clinical therapy
10154161|NCT04057534|Experimental|CB-CRT TUD group|experimental group TUD: patients receive standard smoking cessation therapy and an add-on CB-CRT
9670260|NCT05065593|Experimental|Face-to-Face Training Group|"After completing all assessments, the intervention group will participate in face-to-face exercise training with a physiotherapist for 3 days for 4 months.~In the first week, patients will be taught body awareness; parameters of correct loading on the muscle will be explained and the limits of safe exercise will be drawn. At the beginning and end of all exercises, there will be short-term active stretching and relaxation exercises performed by the patient as a warm-up and cool-down period. In the first 4 weeks, it is planned to increase the physical fitness levels of individuals with progressive resistance exercises and to make them suitable for aerobic loading. For each patient, the PRE, resistance will be increased from 60% to 80% for as long as the person can. At the end of the 1st month, the time allocated to resistance exercise training will be reduced and until the end of the 4th month, an increasing intensity aerobic exercise training will be given on the stationary bike."
9670261|NCT05065593|Active Comparator|Home-Based Control Group|After the patients assigned to the control group are evaluated by the physiotherapist with field tests and scales for physical functions, the patients will be informed about the importance of lifestyle changes in disease management, gait training will be given to increase their physical activity level and participants will be asked to follow a 45-minute walking program every day within their own means. All patients in the control group will be followed up regularly and their activity levels will be questioned in interim evaluations by asking them to keep a weekly physical activity diary.
9670262|NCT05065931||Before|before CDSS on-line
10154162|NCT04057534|Active Comparator|Control group TUD|control group: patients with TUD receive standard smoking cessation therapy
10154163|NCT04057365|Experimental|DKN 01 and Nivolumab Safety Run in|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
10154164|NCT04057365|Experimental|DKN 01 and Nivolumab|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
9670263|NCT05065931||After|after CDSS on-line
9670264|NCT05065281|Experimental|Education|Participants that have undergone the educational intervention
9670265|NCT05065281|No Intervention|Waitlist|Participants still waiting to cross over to intervention arm
10154165|NCT04057430|Active Comparator|String floss|
10154166|NCT04057430|Experimental|Gumchucks floss|
10154167|NCT04057547|Experimental|Experimental group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
10154168|NCT04057547|Active Comparator|Control group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
10154169|NCT04057378|Active Comparator|0.5 ms pulse width stimulus|Electroconvulsive therapy initiated with 0.5 ms pulse width stimulus
10154170|NCT04057378|Active Comparator|1.0 ms pulse width stimulus|Electroconvulsive therapy initiated with 1.0 ms pulse width stimulus
10154171|NCT04057313|Active Comparator|Group 1|Group 1 will receive 80 cc of coffee in the dialysis session
10154172|NCT04057313|Placebo Comparator|Group 2|Group 2 will receive 80 cc of decaffeinated coffee in the dialysis session
10154173|NCT04057456|Placebo Comparator|Placebo diet and placebo capsules|Participants taking the placebo diet and capsules
10154174|NCT04057456|Active Comparator|Placebo diet and Nabilone capsules|Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.
10154175|NCT04057456|Active Comparator|Anti-inflammatory diet and placebo capsules|This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc).
10154176|NCT04057456|Active Comparator|Anti-inflammatory diet and Nabilone capsules|"Capsules will be 0.5mg nabilone. Participants will take up to 8 capsules per day for a maximum dose of 4mg of nabilone per day.~This meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc)."
10154177|NCT04057274|Experimental|Exercise assessment|The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise.
10154178|NCT04057274|No Intervention|Resting assessment|The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest.
10154179|NCT04057352|Other|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
10154180|NCT04057443|Experimental|Intervention group|Patients in the intervention group will follow the standard treatment and follow-uo according to the clinical protocol of the institution and will participate in an intervention program with physical exercise and nutritional support during the period in which they are receiving oncological treatment or for a maximum period of 6 months.
10154181|NCT04057443|Active Comparator|Control group|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
10154182|NCT04057521|Experimental|CHECK Program|Participants were offered enrollment into CHECK care coordination services.
10154183|NCT04057521|Active Comparator|Comparison Group|Participants were not offered enrollment into CHECK.
10154184|NCT04057261|Active Comparator|Liraglutide|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen.
10154185|NCT04057261|Placebo Comparator|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
9670266|NCT05065307|Experimental|Video game in Virtual reality|The study subject will be playing a video game during the venipuncture, in virtual reality
9670267|NCT05065307|Active Comparator|Video game on a tablet|The study subject will be playing a video game during the venipuncture, on a tablet
9670268|NCT05065346|Experimental|DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
9670269|NCT05065138|Experimental|After receiving standardized training on Helicobacter pylori eradication|After the gastroenterologists receive standardized training to eradicate Helicobacter pylori, they recruit Helicobacter pylori-positive patients for treatment.
9670270|NCT05065138|No Intervention|Before receiving standardized training on Helicobacter pylori eradication|Gastroenterologists recruited patients with Helicobacter pylori positive for treatment before receiving standardized training on Helicobacter pylori eradication.
9519990|NCT03281603|Experimental|CAD/CAM complete denture|"First intervention: Constructing complete denture by CAD/CAM technology utilizing milling technique.~Second intervention:Constructing complete denture CAD/CAM technology utilizing 3D printing technique"
9826345|NCT02415595|Experimental|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
9670271|NCT05065580|Active Comparator|Pre test|
9670272|NCT05065580|Active Comparator|Post test|
10154186|NCT04057417|Experimental|Urban Trail Expansion|Neighbourhoods within 400m to 800m of a neely built greenway, defined as a multi-use concrete/asphalt trail that was >4km in length)
10154187|NCT04057417|No Intervention|Control|Neighbourhoods that are located beyond 400 to 800m of a newly built greenway
10154188|NCT04057300|Experimental|Ticagrelor 90mg|Ticagrelor: 180 mg loading dose followed by 90 mg BID. Aspirin: 325 loading dose followed by 81 mg daily.
9670273|NCT05065112|Active Comparator|PVI only|Patients in this arm will undergo only standard pulmonary veins isolation with radiofrequency (RF) energy to treat their AF.
9670274|NCT05065112|Experimental|PVI + IM|Patients in this arm will undergo standard wide area circumferential pulmonary veins isolation along with radiofrequency energy and additional RF ablation guided by individualised mapping with Cartofinder to treat their AF.
10154189|NCT04057300|Active Comparator|Clopidogrel 75mg|Clopidogrel: 300 mg loading dose followed by 75 mg daily. Aspirin: 325 loading dose followed by 81 mg daily.
10154190|NCT04057326|Active Comparator|Oryz-Aspergillus Enzyme and Pancreatin Tablet Arm|Oryz-Aspergillus Enzyme and Pancreatin Tablet ,2 tablets/time, 3 times daily. Study drug will be administered orally.
9670275|NCT05065164|Experimental|dnosumab|Desuzumab 60 mg subcutaneously /6 months, twice a year
9670276|NCT05065164|Placebo Comparator|placebo control|Placebo subcutaneous injection /6 months, twice a year
10154191|NCT04057326|Placebo Comparator|Placebo Arm|Placebo,2 tablets/time, 3 timesdaily. Study drug will be administered orally.
10154192|NCT04057508|Active Comparator|Stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order .
9670277|NCT05065177|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated mumps vaccine;"
9670278|NCT05065177|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated mumps vaccine;"
9670279|NCT05065229|Experimental|A|Right foot no.520 Left foot no.521
9670280|NCT05065229|Experimental|B|Right foot no.521 Left foot no.520
10154193|NCT04057508|Sham Comparator|Sham stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order.
9670281|NCT05065567|Active Comparator|haloperidol|
9670282|NCT05065567|Active Comparator|droperidol|
9670283|NCT05065528|Placebo Comparator|Control|
9670284|NCT05065528|Experimental|Intervention|
9670285|NCT05064696|Active Comparator|Group 1 (Control group)|Surgical wound will be covered with the standard non-stick gauze dressing.
9670286|NCT05064696|Experimental|Group 2 (Treatment group)|Surgical wound will be covered with the PICO dressing.
9670287|NCT05064969|Experimental|Single-arm non-randomised|This study includes a baseline assessment, a 9-week (with the possibility of extension to 12 weeks) blended intervention period, a post-intervention assessment, and two follow-ups at 3 and 6 months. Informal caregivers of people with dementia (with at least 18-year-old) with no restriction in terms of sex, educational level, or ethnic background will be included.
9670288|NCT05064917||Children with suspected cow's milk allergy|
9670289|NCT05064995||Patients|Patients with the Diagnosis of a Bipolar Disorder
9670290|NCT05064995||Healthy Controls|Individuals with no diagnosis of Bipolar Disorder
9670291|NCT05064930|Active Comparator|Bifidobacterium lactis|Probiotic formula contains 5x109 Bifidobacterium lactis Nordbiotic™ BI040 colony forming units (CFU)/capsule
9670292|NCT05064930|Active Comparator|Bacillus coagulans|Probiotic formula contains 2x109 Bacillus coagulans Nordbiotic™BC300 colony forming units (CFU)/capsule
9670293|NCT05064930|Placebo Comparator|Maltodextrin|Maltodextrin (starch hydrolisate) as a compound presents in probiotic formula.
10154194|NCT04057586|Experimental|Nonintubated|Nonintubated thoracoscopic surgery
9670294|NCT05064839|Experimental|Bony scintigraphy|Bony scintigraphy within 1 to 4 months after inclusion
9670295|NCT05064852||Surufatinib|Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.
9670296|NCT05065021|Experimental|Initial/Cohort C|Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.
9670297|NCT05065021|Experimental|Cohort A|"Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
9972642|NCT01322659|Sham Comparator|ETT IMV|Weaning from mechanical ventilation with standard invasive mechanical ventilation (IMV) delivered by means of the endotracheal tube (ETT)
10154195|NCT04057586|Active Comparator|Intubated|Intubated thoracoscopic surgery
10154196|NCT04057222||Patients included|"Patient with multiple sclerosis and anorectal symptoms, with indication to realize a anorectal manometry, age > 18~A first record of rectal sensory function will be at strong desire to void. A second record will be after void. Rectal sensory function records consist on an anorectal manometry with 3 measures of external anal sphincter resting pressure, 5 measures of RAIR, 1 measure of perception, constant sensation to need to defecate and maximum tolerable threshold volumes."
10154197|NCT04056936||Infants diagnosed with a tongue-tie and a frenotomy|If a tongue-tie is present at the routine newborn examination, the infant can be included in the study. If the infant also has breastfeeding problems and there is a decreased tongue mobility and poor sucking ability, the pediatrician may find indication for frenotomy. If the frenotomy is performed before discharge the infant is included in this group. All Mother-infant dyads will get breastfeeding support.
10154198|NCT04056936||Infants diagnosed with a tongue-tie and no frenotomy|The infants that are recruited to the tongue-tie cohort that do not receive treatment before discharge. The pediatrician evaluates that the tongue tie does not cause any functional problems and no treatment is performed before discharge. All Mother-infant dyads will get breastfeeding support.
10154199|NCT04056936||All infants born in Telemark and Vestfold Counties|All the infants born in the study period that will contribute to the prevalence study.
10154200|NCT04056923|Experimental|3D-printed template-guided(3D-G)|Intraoperative 3D-G methylene blue dye marking in the operating room
10154201|NCT04056923|Active Comparator|CT-guided(CT-G)|Preoperative localization is performed by CT-G indocyanine green marking in the radiology department
10154202|NCT04057144|Experimental|ACT with mindfulness|4-hour weekly session of acceptance and commitment therapy (ACT) with mindfulness exercises during 8 weeks in groups of 8
9670298|NCT05065021|Experimental|Cohort B|"Paclitaxel, by vein (intravenously), once a week. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.~Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards."
9670299|NCT05064748|Experimental|Treatment Cohort|
9670300|NCT05064891||Stroke patients|
9670301|NCT05064891||Participants without stroke|
9694711|NCT04786132|Experimental|Dual Task (proprioception, balance and cognitive) training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
9694712|NCT04786132|Active Comparator|Proprioception and balance training|"The control group training protocol is the same as the experimental group, whit the same duration and the same sessions, the unique difference is that there was no music included in the sessions, and therefore cognitive ability was not worked.~The sessions were carried out by the main researcher who controlled the technique of the exercises and motivated the participant."
9694713|NCT04785729|Experimental|almonertinib|
9694714|NCT04785755|Active Comparator|Group I|The control group (n=15) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
9694715|NCT04785755|Experimental|Group II|The hypertonic saline solution (HSS) group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the start of the study to the end of the study) with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
9694716|NCT04785755|Experimental|Group III|The etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
9694717|NCT04785755|Experimental|Group IV|The hypertonic saline solution (HSS) + Etilefrine group (n=25) received oral standard diuretic therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg100mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study), with hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days, and etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
10154203|NCT04057144|Experimental|ACT without mindfulness|4-hour weekly acceptance and commitment therapy (ACT) without mindfulness exercises during 8 weeks in groups of 8
10154204|NCT04057144|Active Comparator|Education program|Self-management education program during 8 weeks in groups of 8.
10154205|NCT04056949|Other|IBI308 + Paclitaxel/Albumin-Bound Paclitaxel|IBI308 Combined with Albumin-Bound Paclitaxe
9972643|NCT01322685||Health Group|
10154206|NCT04056897|Experimental|BCD-132, 125 mg|72 patients
10154207|NCT04056897|Experimental|BCD-132, 500 mg|72 patients
10154208|NCT04056897|Active Comparator|Teriflunomide|72 patients
10154209|NCT04056897|Placebo Comparator|Placebo|54 patients
10154210|NCT04056988|Experimental|Acute spinal cord injury patients to undergo contrast-enhanced|"Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.~A hand-held intraoperative ultrasound probe will be used to collect sagittal images of the spinal cord centered above the spinal cord injury. A bolus IV injection of DEFINITY® contrast agent (1.5ml DEFINITY®/8.5ml saline) will be given. Continuous imaging will be obtained to record contrast inflow and washout."
10154211|NCT04057014|Active Comparator|Extraction Only|Immediate extraction of infected tooth without antibiotic prescription.
9670302|NCT05064904|Active Comparator|never received RAAS blockers or multidiscipline consultation before AKI.|The enrollees assigned to the control group should not receive RAAS blockers or AKD consultation at least in 180 days after index discharge. In addition, these multidiscipline consultation and administration of RAAS blockers are continuing, and results regarding them remain masked. All patients provided written informed consent.
10154212|NCT04057014|Experimental|Average Dose Antibiotic|Average dose antibiotic therapy(25 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 10 days and receive tooth extraction on day 10 (25 patients). (*given the average weight of a 12 year old is 45 kilos, we do not expect that we will reach the maximum dose in this group)
10154213|NCT04057014|Experimental|High Dose Antibiotic|High dose antibiotic therapy (45 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 5 days and receive tooth extraction on day 10 (25 patients)
9670303|NCT05064904|Active Comparator|had received RAAS blockers and multidiscipline consultation before AKI.|"All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.~Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D)."
10154214|NCT04057196|Experimental|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 12 weeks.
10154215|NCT04057053|Experimental|Netarsudil use|Patient eye undergoes cataract surgery + DWEK, immediately after surgery Netarsudil 0.02% ophthalmic 1 drop daily is used in the operative eye until corneal clearance is documented.
9670306|NCT05064462||All the patients included in the study|50 patients, at least 18 years old, first heart transplant
9694718|NCT04785742|Experimental|20 exon (20INS) mutation|
9694719|NCT04785742|Experimental|Rare mutations except for 20INS|
9694720|NCT04785833|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
10154216|NCT04057053|Active Comparator|Standard of care + possible rescue drop|Patient eye undergoes cataract surgery + DWEK, no Netarsudil is used after surgery, if cornea is not cleared in time for first eye Netarsudil 0.02% ophthalmic 1 drop dailyadded daily as possible rescue drop and time to corneal clearance is documented
9519991|NCT03281603|Active Comparator|Conventional complete denture|Constructing complete denture by conventional technique of denture processing
10154217|NCT04057027|Experimental|Delayed Cord Clamping for 30 seconds|Infants whose umbilical cord clamping will be delayed for 30 secs.
10154218|NCT04057027|Experimental|Delayed Cord Clamping for 60 seconds|Infants whose umbilical cord clamping will be delayed for 60 secs.
10154219|NCT04057027|Experimental|Umbilical Cord Milking|Infants whose umbilical cord will be clamped after milking from the distance of 20 cm from mother's side to the baby for 3-4 times.
10154220|NCT04056975|Experimental|single arm|A-319 dosage: 0.05, 0.15, 0.03, 0.06, 0.12, 0.18, 0.24 μg/kg
10154221|NCT04056819|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack.
10154222|NCT04057066|Experimental|Intervention|Participants receive physical activity counseling as well as an individualized exercise plan.
10154223|NCT04057209|Active Comparator|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|Transoral CO2-Laser Microsurgical Cordectomy defined by European Laryngological Society (Remacle M, Eckel HE, Antonelli A, et al. Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol. 2000;257(4):227-231.)
10154224|NCT04057209|Experimental|Arm B: Single Vocal Cord Irradiation (SVCI)|Single Vocal Cord Irradiation defined by Kwa et al. and Al-Mamgani et al. (Kwa SLS, Al-Mamgani A, Osman SOS, Gangsaas A, Levendag PC, Heijmen BJM. Inter- and Intrafraction Target Motion in Highly Focused Single Vocal Cord Irradiation of T1a Larynx Cancer Patients. Int J Radiat Oncol Biol Phys. 2015;93(1):190-195. Al-Mamgani A, Kwa SLS, Tans L, et al. Single Vocal Cord Irradiation: Image Guided Intensity Modulated Hypofractionated Radiation Therapy for T1a Glottic Cancer: Early Clinical Results. Int J Radiat Oncol Biol Phys. 2015;93(2):337-343.)
10154225|NCT04056806|Experimental|Group A|receiving terlipressin 2mg bolus on enrollment followed by 1mg per 6 hours. Both Terlipressin infusion and Ceftriaxone continue till 48 hours after endoscopic therapy
10154226|NCT04056806|Active Comparator|Gruoup B|receiving terlipressin 2mg bolus instituted on enrollment followed by 1mg per 6 hours. Ceftriaxone 1gm intravenously dose of ceftriaxone 1gm at 24 h interval. Both Terlipressin infusion and Ceftriaxone continue till 5 days after endoscopic therapy.
10154227|NCT04056884|Active Comparator|SIBS intervention|SIBS intervention is a 5-session group intervention for siblings and parents of children with chronic illness. Sessions 1-3 are delivered in one day, and sessions 4-5 are delivered in one day one week later.
10154228|NCT04056884|No Intervention|Waitlist|Waitlist is 12 week of no intervention/usual care
10185760|NCT03742609|Active Comparator|Physical reminder only|provision of written information regarding consequences of using a hearing aid and not using a hearing and physical reminder to use a hearing aid. For example, a hearing aid box as a physical reminder to use the hearing aids.
10185761|NCT03742609|Active Comparator|Behaviour Plan only|provision of written information regarding consequences of using a hearing aid and not using a hearing and creation of behaviour plan to use a hearing aid. For example, when and where to use the hearing aids.
9519992|NCT03281551|Experimental|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
9519993|NCT03281499|Experimental|da Vinci Surgical System Model IS4000|Transoral robotic surgery, followed by tailored radiotherapy
10154229|NCT04056871||Fried Frailty Phenotype|This group of patients will be assess by using 5 characteristics of Frailty which are weight loss, weakness, exhaustion, low activity and physical fitness of the patients. Patients classify as frail will have more than 3 criteria, intermediate or pre-frail will be 1 or 2 criteria present and robust will not have criteria.
10154230|NCT04056871||Groningen Frailty Index|GFI is a simple questionnaire consisting of 15 items which are classified into 8 groups, consistent of 4 domains of functioning. A score of 4 or more indicates a higher risk for frailty and possible delirium.
10154231|NCT04057170|Experimental|mulligan method|Mulligan mobilization with mowement method every three days for six weeks
10154232|NCT04057170|Experimental|accelerated protocol|accelerated rehabilitation protocol every three days for six weeks
9670307|NCT05064475||Recurrent breast cancer patients with elevated tumor markers|PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer cells by using 18F-FDG. Its ability to identify tumor recurrence before detection of morphologic changes in conventional imaging reflecting its importance in detecting BC recurrence in asymptomatic patients with high tumor markers and negative results of radiological imaging. 18F-FDG PET/CT is frequently used for BC evaluation. However, data on its value in evaluating BC recurrence in patients with elevated tumor markers are limited and unclear
9670308|NCT05064436|Experimental|Part A - Healthy Participants|
9670309|NCT05064436|Experimental|Part B - Participants with MS|
9670310|NCT05064566||caries diagnosis|diagnostic accuracy of clinical visual examination (ICDAS II), digital intraoral radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), by examining third molar teeth in comparison to gold standard micro-CT images.
9670311|NCT05064527||Patients|"OCD (ICD-10 F42) as the primary or secondary diagnosis, verified with a semi-structured psychopathological interview using Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-PL).~CY-BOCS > 7: mild (8-15), moderate (16-23), severe (24-31), extreme (32-40)~A psychiatrist determined that the child is eligible for care within psychiatry for their primary diagnosis.~Patient is age 8 through 17 years (both inclusive)."
9670312|NCT05064527||Controls|"Ages 8 through 17 years (both inclusive).~Sex and age (+/- 3months) matched to an included patient."
9826346|NCT02415595|Experimental|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
10154233|NCT04057118|Experimental|SKI-O-703 100 mg|
10154234|NCT04057118|Experimental|SKI-O-703 200 mg|
10154235|NCT04057118|Experimental|SKI-O-703 400 mg|
10154236|NCT04057118|Placebo Comparator|Placebo|
10154237|NCT04057092|Experimental|Intervention group|Eligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total.
10154238|NCT04056832|Experimental|Single Strip Pericardium|Aortic Valve Replacement using single strip of patient's autologous pericardium
10154239|NCT04056832|Active Comparator|Mechanical Prosthetic Valve|Aortic Valve Replacement using mechanical prosthetic valve
10154240|NCT04057079|Experimental|Anugel|"In this arm, after the surgery a hydrogel impregnated sponge will be placed in the rectum.~The patient is evaluated after the operation and the following day when the sponge is removed.~A hydrogel impregnated foam pad is applied on the surface of the wound the following 5 days.~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
10154241|NCT04057079|Active Comparator|Sponge|"Currently used treatment method i.e. insertion of gelatine sponge in to the rectum post operation.~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
10154242|NCT04056845|Experimental|Knee brace group|Patients in this group will receive a valgus knee brace (Medex K39-OA Corrector), to be worn for at least four hours a day, during the study period, on top of the presrciption of physiotherapy and oral analgesic (diclofenac and panadol).
10154243|NCT04056845|Active Comparator|Control Group|Patients in this group will receive physiotherapy and oral analgesic (diclofenac and panadol).
10154244|NCT04056533|Experimental|CMV CTLs|1x10^5 CMV-CTLs/kg
10154245|NCT04056637|No Intervention|Group 1: Standard of Care|Participants will be asked to complete follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider.
10154246|NCT04056637|Experimental|Group 2: Flexible Follow-Up|Participants will be offered three follow-up options, including: 1) follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider; 2) repeat serum beta-hCG testing; 3) repeat multi-level pregnancy test strategy
10154247|NCT04056559|Experimental|SIngle arm|The research is based on a population of men and women practicing a sport at risk of oral trauma.
10154248|NCT04056507||ITP group|On frozen spleens of already splenectomized adult ITP patients.
10154249|NCT04056507||Control group|On frozen control spleens from patients who had a splenectomy at the Bordeaux University Hospital following a road accident.
10154250|NCT04056572|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally, twice daily.
10154251|NCT04056650|Active Comparator|Single caffeinated beverage/supplement|
10154252|NCT04056650|Active Comparator|Combination caffeine and L-theanine|
10154253|NCT04056728|Experimental|Eupenta Inj.|
9519994|NCT03281486|Experimental|HA formulation Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
9670313|NCT05064527||Caregivers of Patients|Parent or guardian of patient with OCD
9670314|NCT05064527||Caregivers of Controls|Parent or guardian of control participant
9670315|NCT05064189|No Intervention|Group 1|15 patients will be included in group 1 (no additional treatment)
9670316|NCT05064189|Experimental|Group 2|15 patients will be in group 2 (treatment directly after cataract surgery in the surgical theatre)
10154254|NCT04056793|Experimental|Parturients in situation of dystocia|Positioning of the parturients in an optimized birthing position
10154255|NCT04056754|Experimental|Abiraterone acetate group|Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
10154256|NCT04056754|Placebo Comparator|Placebo group|Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
10154257|NCT04056338||Delirium|Patients with delirium as assessed by the bedside nurse using Confusion Assessment Method for the ICU.
9670317|NCT05064189|Experimental|Group 3|15 patients will receive treatment after local anaesthesia (pre-operatively) and directly after cataract surgery (group 3)
9670318|NCT05064631|Experimental|Active intervention|Oral Broncho-Vaxom (3.5mg) administered daily for 10 days per month for 24 months
9670319|NCT05064631|Placebo Comparator|Placebo control|Matched placebo administered daily for 10 days per month for 24 months
9670320|NCT05064579||Patients with asthma|Children and adolescents aged 8 to 17 years old with a doctor's diagnosis of asthma and controller asthma treatment
9670321|NCT05064579||Holders of parental authority|Holders of parental authority of patients with asthma described in group A
9670322|NCT05064579||Doctors|Doctors caring for patients with asthma described in group A
9670323|NCT05064501||Asthma and COVID19 infection|Asthma and COVID19 infection
9670324|NCT05064501||Asthma without COVID19 infection|Asthma and COVID19 infection
9670325|NCT05064111||All subjects|The experimental conditions will include a standard prostate biopsy using an FDA-approved ultrasound machine with application of the experimental (non-FDA approved) image fusion software.
9670326|NCT05064124||CADDIE|Participants will have a colonoscopy with the assistance of the CADDIE device characterisation AI system
9670327|NCT05064124||Control group|Participants will have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system
10154258|NCT04056338||Non-delirium|Patients without delirium.
10154259|NCT04056351|Other|Cohort of 50 enrolled patients|The following visits will be performed: direct post-OP, 3 weeks, 6 weeks, 3 months and 6 months after surgery. Surgical details will be assessed from the surgical notes. Medical images will be collected according to the standard of care. A post-OP CT scan will also be acquired when the treating surgeon requests it as per standard of care, or additionally, as a study specific imaging procedure for the rest of the participants. Patient activity will be estimated based on various factors, including questionnaires on demographics, activity level, comorbidity score and contralateral grip strength. The actual post-OP shoulder activity will be measured by motion tracking by means of sensors attached to upper arm of the treated side and on the chest for 6 weeks and by grip strength assessed at the treated arm at week 6. Fixation failure status will be determined 6 months post-OP. Imaging and details regarding the fixation failure event will be sent to ARI.
10154260|NCT04056429|Experimental|BHA|Subjects treated with BHA + standard of care
10154261|NCT04056429|No Intervention|Control|Subjects treated as per standard of care
10154262|NCT04056455|Experimental|Severe Renal Impairment (RI): Mobocertinib 80 mg|Mobocertinib 80 milligram (mg), capsule, orally, a single dose on Day 1.
10154263|NCT04056455|Experimental|Normal Renal Function: Mobocertinib 80 mg|Mobocertinib 80 mg, capsule, orally, a single dose on Day 1.
10154264|NCT04056442|Experimental|Cannabidiol|300 mg Cannabidiol (synthetic form) Olive Oil Solution, 5%
10154265|NCT04056442|Placebo Comparator|Placebo|Olive Oil Solution
10154266|NCT04056260|Experimental|ICG injection|ICG 0.5mg/ml x 0.5ml x 4 sites
10154267|NCT04056325|Experimental|Phase 2a - Arm A|2 mg Moxidectin at day 0 administered orally
10154268|NCT04056325|Experimental|Phase 2a - Arm B|4 mg Moxidectin at day 0 administered orally
9670328|NCT05064618|Experimental|Phase I study; 3+3 Design|"Phase I study; single-center, open-label, uncontrolled, dose-finding study~MIKE-1 (AM80, Tamibarotene) After the DLT assessment period, if there is no evidence of disease progression or unacceptable toxicity to the patient according to RECIST v1.1, the investigational drug in each dose group will continue to be administered orally twice daily after breakfast and dinner for up to 24 weeks.The dose of the study drug will not be reduced or increased in the same subject.~6 mg dose group (level 1).~8 mg dose group (level 2).~4 mg group (level 0). To be considered when two or more cases of DLT occur at level 1.~GEM/nab-PTX (Phase I / II study) GEM (1000mg/m2) and nab-PTX (125mg/m2) will be administered intravenously."
9670329|NCT05064618|Experimental|Phase II study; Single-centre, open-label, single arm, uncontrolled study.|The dose of MIKE-1 will be fixed at the clinically recommended dose determined in Phase I. MIKE-1 will be administered orally twice daily after breakfast and dinner, and treatment will be continued until the occurrence of intolerable toxicity or disease progression, up to a maximum of six courses, to confirm efficacy and safety (tolerability).
9670330|NCT05064215||injection behind NAC|in 7 breasts dye was injected behind the nipple areola complex before breast reduction
9670331|NCT05064215||Injection into lateral upper quadrant|in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction
9670332|NCT05064215||injection into medial upper quadrant|in 2 breasts dye was injected into upper medial glandular tissue before breast reduction
9694721|NCT04785963|Experimental|Music with Suggestion|Active condition where participants will be provided with recordings of pre-determined music in addition to recorded suggestions instructing the participant on how to listen to the music.
9694722|NCT04785963|Active Comparator|Music|Control group where participants will be provided recordings of pre-determined music
10154269|NCT04056325|Experimental|Phase 2a - Arm C|6 mg Moxidectin at day 0 administered orally
10154270|NCT04056325|Experimental|Phase 2a - Arm D|8 mg Moxidectin at day 0 administered orally
10154271|NCT04056325|Experimental|Phase 2a - Arm E|10 mg Moxidectin at day 0 administered orally
10154272|NCT04056325|Experimental|Phase 2a - Arm F|12 mg Moxidectin at day 0 administered orally
10154273|NCT04056325|Placebo Comparator|Phase 2a - Arm G|matching Placebo tablet(s) at day 0 administered orally
10154274|NCT04056325|Experimental|Phase 2b - Arm A|the recommended dose moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) at day 0 administered orally
10154275|NCT04056325|Active Comparator|Phase 2b - Arm B|200 µg/kg ivermectin at day 0 administered orally
9670333|NCT05064020||Polypharmacy|"Polypharmacy: patient is using five or more medications will be considered polypharmacy.~Subjects having polypharmacy condition with taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
9519995|NCT03281486|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
9670334|NCT05064020||Nonpolypharmacy|"Nonpolypharmacy: patient is using less than five medications will be considered nonpolypharmacy~Nonpolypharmacy Subjects taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
9670335|NCT05064033|Experimental|GROUP A|Pragmatic Set of intervention and posterior capsular stretch
9670336|NCT05064033|Active Comparator|GROUP B|Pragmatic Set of intervention and Sleeper Stretch
9670337|NCT05063877|Placebo Comparator|Placebo|"Matched placebo control 10 mg capsule or 20 mg capsules totaling to 10 mg, 20 mg, 40mg or 60 mg will be administered once daily orally for 12 weeks with the option for open-label extension.~Intervention: Drug: Placebo"
9670338|NCT05063877|Experimental|Study drug EQU-001|"10mg capsules or 20 mg EQU-001 capsules totally 10 mg, 20 mg, 40 mg, 60 mg will be administered once orally daily to active-treatment subjects for 12-weeks with the option for open-label extension.~Intervention: Drug : EQU-001"
9670339|NCT05064228|Experimental|m-ReACT app condition|Participants will download the m-ReACT app on their mobile phones and will be asked to engage with the app for a period of 12 weeks.
9670340|NCT05064228|Active Comparator|Brief Advice|Participants will be given a one time brief informational session on the importance of engaging in substance-free activity while in AUD treatment.
9670341|NCT05064072|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
10154276|NCT04056325|Placebo Comparator|Phase 2b - Arm P|matching Placebo tablet(s) at day 0 administered orally
9670342|NCT05064072|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube
9670343|NCT05064072|Active Comparator|Silk plaster|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube
10154277|NCT04056676|Active Comparator|Intraoperative modified PEC block only|Intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
10154278|NCT04056676|Experimental|Adding preoperative thoracic paravertebral nerve block|Preoperative thoracic paravertebral nerve block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug and intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
10154279|NCT04056663|Experimental|Health-Circuit mobile application|"The intervention contemplates. (i) management of unexpected events; and, (ii) empowering the patient to improve self-efficacy.~Users of the intervention arm will have the Health-Circuit mobile application, which will offer them the possibility of contacting the case managers to notify a health event at any time and that this can be resolved by their health professionals through Health -Circuit. The improvement of the patient's self-efficacy for the management of their health problems through the use of Health-Circuit is considered through the virtual visits of follow-up with the manager, the possibility of interacting with the manager and the consultation of the shared documents reminders of the action plan agreed with the patient."
9826347|NCT02415595|Experimental|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
10154280|NCT04056663|No Intervention|Conventional treatment|Patients assigned to this group will follow conventional treatment. Once the three months have passed, we will contact you again to ask the pertinent questions.
10154281|NCT04056598||Moderate to severe acne vulgaris|Determined by the acne severity grade of IGA 2 and above
10154282|NCT04056598||Mild acne vulgaris|Determined by the severity grade of IGA <2
10154283|NCT04056585|Experimental|Brachial plexus block with intermittent pneumatic compression|Hand and forearm surgery is performed after axillary brachial plexus block with intermittent pneumatic compression for 3 minutes.
10154284|NCT04056585|Placebo Comparator|Brachial plexus block|Hand and forearm surgery is performed after axillary brachial plexus block only.
9670344|NCT05063838|Experimental|Pharmacogenomic group|The perioperative (anesthetic and postoperative pain management) plan for each patient will be determined preoperatively by the treating anesthesia team. Thereafter, the pharmacogenomic results of the patient will be released and a personalised anesthetic plan formulated based on international pharmacogenomic guidelines. The treating anesthesia team will then modify the perioperative care plan based on the patients' pharmacogenomic results and the international pharmacogenomic guidelines.
9670345|NCT05063838|No Intervention|Control group|Perioperative care will be managed according to current 'standard care' practice at Peter MacCallum Cancer Centre.
9670346|NCT05063890|Experimental|Muscle Specific MET|
9670347|NCT05063890|Experimental|Movement specific MET|
9670348|NCT05063799|Experimental|a case included pulmonary rehabilitation program|
9670349|NCT05063721|Experimental|Intra-arterial delivery of autologous MABs|Autologous mesoangioblasts (MABs) will be intra-arterially delivered to lower leg of participant
9670350|NCT05063721|No Intervention|No intervention|intra-subject control
9826348|NCT02415595|Active Comparator|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
9972644|NCT01322685||Tuberculosis Group|Tuberculosis or lung cancer group
10154285|NCT04056780||Septic group|The septic group will be considered as patients that fulfill the 2018 ICM definition of PJI.
10154286|NCT04056780||Aseptic group|The aseptic group will be considered as patients that don't fulfill the 2018 ICM definition of PJI.
9519996|NCT03281473|Experimental|Arms A|Strategy 1 - Washout period - Strategy 2
10154287|NCT04056312|Experimental|Group memory retraining|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
9972645|NCT01322698||The study population|The target population includes patients in ICUs at the Nîmes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils > 500/mm3) at risk of developing invasive candidiasis.
10154288|NCT04056312|Placebo Comparator|Placebo|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
10154289|NCT04056715||HCM Group|Eligible HCM subjects will be monitored for arrhythmias with a 2-week ECG patch.
10154290|NCT04056234||Rheumatoid arthritis group|Patients with rheumatoid arthritis
9670351|NCT05063760|Experimental|TGCT patients - exercise|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
9670352|NCT05063760|No Intervention|TGCT patients - nonexercising controls|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
10154291|NCT04056234||Control group|Patients with osteoarthritis / joint effusion.
9670353|NCT05063708|Sham Comparator|Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|"Traditional dysphagia therapy (TDT) involved orofacial, lingual, and laryngeal motor exercises and compensatory swallowing strategies included various modifications of head, neck, and body postures and adjustment of food/liquid temperature, viscosity, and volume. The choice of specific strategies was based on the FEES findings and the clinical swallowing examination. The rehabilitative treatment will be administered in the 8 centers taking part to the study. The electrodes in this sham group will be placed in the same positions as the active treatment, with a current between 3 and 5 mA (average of 3.5 mA) current unable to perform muscle contraction. Every MS patient will be received 16 sessions of TDT according to their degree of dysphagia, contemporary associated with Sham neuromuscular electrostimulation two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks"
9670354|NCT05063708|Experimental|traditional dysphagia therapy plus Neuromuscular electrostimulation|Every MS patient will be treated with traditional dysphagia therapy, associated with an active neuromuscular electrostimulation. The amplitude will be increased until the subject will feel a 'grabbing sensation' which corresponded to muscular contraction. This will be the amplitude used for the therapy. This process will be repeated for the second channel of the stimulator. The typical electrical stimulus is at 80 Hz and at 300 microsec, and it will be adapted to avoid annoying stimulus to the patients. During therapy, both channels will be active. Every MS patient will be received 16 sessions of traditional dysphagia therapy according to their degree of dysphagia, contemporary associated with neuromuscular electrostimulation , according to our previous experiences, two 30-min treatment a day, separated by a rest period of at least 45 minutes for four consecutive days per week, within a period of 4 weeks.
9670355|NCT05063968|Experimental|Part A - Single Ascending Dose (SAD) phase: Experimental|
9670356|NCT05063968|Placebo Comparator|Part A - Single Ascending Dose (SAD) phase:Placebo|
9670357|NCT05063968|Experimental|Part B - Food Effect (FE) phase: Experimental 1|
9670358|NCT05063968|Experimental|Part B - Food Effect (FE) phase: Experimental 2|
9670359|NCT05063968|Experimental|Part C - multiple ascending dose (MAD) phase: Experimental|
9670360|NCT05063968|Placebo Comparator|Part C - multiple ascending dose (MAD) phase:Placebo|
9670361|NCT05063630|Experimental|Medical treatment plus intracranial stenting (MT plus IS)|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
9670362|NCT05063630|Active Comparator|Medical treatment alone (MT)|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
9670363|NCT05063695||Epidural|Patients who underwent Nuss procedure under epidural protocol (between January and December of 2019)
9670364|NCT05063695||ESP|Patients who underwent Nuss procedure using ESP catheter protocol (June 2020 to April 2021)
10154292|NCT04056702||Prescribed triple combination|A group of 60 people with CF who are clinically prescribed elexacaftor-tezacaftor-ivacaftor and have chronic sinusitis
9670366|NCT05063955||Chronic Heart Failure|Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
9670367|NCT05063955||Controls|Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.
9519997|NCT03281473|Experimental|Arms B|Strategy 2 - Washout period - Strategy 1
9670368|NCT05063578|Experimental|Participant|
9670369|NCT05063929|Experimental|Fruits|Participants will receive 2 cup eq fruits per day
10154293|NCT04056702||Not eligible for modulators|A group of 10 patients with two class I/II mutations who are ineligible for elexacaftor-tezacaftor-ivacaftor based on their genotype and have chronic sinusitis.
10154294|NCT04056741|Experimental|Surfactant administered via supraglottic administration device|Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.
10154295|NCT04056286|Experimental|Healthy + Whey|Healthy (overnight fast)
10154296|NCT04056286|Experimental|Catabolic + Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
10154297|NCT04056286|Experimental|Catabolic + 3-OHB / Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
9519998|NCT03281460|Experimental|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
10154298|NCT04056221|Experimental|acupuncture|Acupuncture at the selected points.
10154299|NCT04056221|Sham Comparator|Sham acupuncture|Similar appearance to conventional acupuncture, however, without needles skin penetration.
10154300|NCT04056364||Asthma|Asthma patients will be diagnosed according to a clinical history of wheezing, cough, chest tightness or shortness of breath, as well as the presence of BHR (cumulative dose caus¬ing a 20% decrease in FEV1), based on the GINA guidelines. None of them had a history of COPD, or previous doctor-diagnosed ACO. All subjects had not used any oral or/and inhaled corticosteroid (ICS) in the previous 12 weeks. The included patients with asthma had initial diagnosis and were under uncontrolled stage.
9670370|NCT05063929|Other|Fruit restriction|Participants will receive 1/2 cup eq fruits per day
10154301|NCT04056364||COPD|COPD patients were diagnosed according to the GOLD criterion, which included a post-bronchodilator spirometry to confirm airflow obstruction (FEV1 to forced vital capacity ratio [FEV1/FVC] ,70%), in a clinical context (dyspnea, chronic cough or sputum production, and a history of expo¬sure to risk factors for the disease). They had received a COPD diagnosis at least 1 year before the study. None of them had a history of asthma. All subjects had not used any oral or/and ICS in the previous 4 weeks. The included COPD patients had exacerbations. The GOLD stage of COPD was defined according to the 2019 recommendations of GOLD.
9670371|NCT05063747||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 is defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis U07.1 in the nationwide Swedish intensive care registry.
9670372|NCT05063747||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up not including patients in the COVID-19 ICU cohort. COVID-19 is defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
9670373|NCT05063747||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. ICU and hospital admitted COVID-19 patients are not included.
9670374|NCT05063864|Experimental|Nursing Support Program|the group that applied the nursing support program
9670375|NCT05063864|No Intervention|No Nursing Support Program|the group that did not receive a nursing support program
9670376|NCT05063773|Experimental|Group 1|
9670377|NCT05063773|No Intervention|Group 2|
9670378|NCT05063474||PAD: Peripheral Artery Disease|People with Peripheral Artery Disease (PAD). No intervention given, observation and assessment only
9826349|NCT02415608|Experimental|Ibrutinib 420 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
9826350|NCT02415608|Experimental|Ibrutinib 560 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
9670379|NCT05063474||PLL+PAD: People with Limb Loss and Peripheral Artery Disease|People with Lower-Limb Loss (PLL) and Peripheral Artery Disease (PAD) No intervention given, observation and assessment only
9670380|NCT05063682|Experimental|Treatment|Patients receive EGFRvIII -CAR T cells intracerebroventricular over 15 minutes on day 1. Patients may receive additional cycles based on the persistence of the cells.
9670381|NCT05063383||PCOS|"Oligomenorrhea/amenorrhea~Clinical androgen excess or biochemical androgen excess~Polycystic ovary showed by gynecological ultrasound"
9670382|NCT05063383||NOPCOS|not meet Rotterdam standards
9670383|NCT05063513|Experimental|Transplant arm|Experimental arm will undergo mobilisation with cyclophosphamide (CY) 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
9670384|NCT05063513|Active Comparator|Rituximab arm|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
9670385|NCT05063669|Experimental|Cognitive Occupational Therapy|Occupational therapy applications were carried out 40 minutes, twice a week (one individual session and one group intervention session) and total of 8 weeks. In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
9670386|NCT05063669|No Intervention|Control|No intervention was performed in this group.
9670387|NCT05063487||Recent HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test recent on the rapid test for recent infection (RTRI).
9826351|NCT02415842||H1N1_AS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42.
10154302|NCT04056364||ACO|ACO will be diagnosed by two steps: the first step is the identification of a history of chronic airway disease, i.e., chronic or recurrent cough, sputum production, wheezing, or repeated acute lower respiratory tract infections. In the second step, the features of asthma and those of COPD that best describe the patients
10154303|NCT04056195|Experimental|SKI-O-703 200 mg|2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks
10154304|NCT04056195|Experimental|SKI-O-703 400 mg|4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks
9826352|NCT02415842||H1N1_NAS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study -Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42
9826353|NCT02415842||H5N1_AS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21
9826354|NCT02415842||H5N1_NAS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21.
9977240|NCT01359488|Experimental|VRS-317 Safety Arm 5|"VRS-317 Two injections SC of dose level 5 (based on 90 kg patient)~Placebo Two SC injections Dose Volume matched to active treatment volume"
10154305|NCT04056195|Placebo Comparator|Placebo|4 capsules of placebo during 12 weeks
10154306|NCT04056065|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
9670388|NCT05063487||Long-Term HIV Infection|Persons ≥15 years of age who are newly-diagnosed with HIV, consent to participate in case-based surveillance and recency testing and test long-term on the rapid test for recent infection (RTRI).
9670389|NCT05063409|Active Comparator|1:1 Ratio of FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:1 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
9670390|NCT05063409|Active Comparator|1:4 Ratio FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
9670391|NCT05063422|Experimental|Mild Resorption of mandibular ridge|Loss of upto 1/3 of original vertical height
9670392|NCT05063422|Experimental|Moderate Resorption of mandibular ridge|2. Moderate Resorption: Loss of upto 1/3 to 2/3 of original vertical height
10154307|NCT04056065|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
10154308|NCT04056052|Sham Comparator|Home Activity Only|Over the 8-week project, families were asked to try eight different vegetable recipes from a choice of 12. All family members could participate in the home activities as the families wished. Families were also asked to complete a weekly recipe cooking tracking sheet.
9670393|NCT05063422|Experimental|Severe Resorption of mandibular ridge|3. Severe Resorption: Loss of 2/3 or more of original vertical height
9670394|NCT05063110|Experimental|Treatment arm|300 mg of ITACITINIB will be administrated per os every day for 30 days, dose with reduction to 200 mg per safety is allowed if AEs are observed or if co-administered a strong CYP3A inhibitor
9670395|NCT05063188|Active Comparator|Control group|
9670396|NCT05063188|Experimental|Intervention group|
9972646|NCT01322711|Active Comparator|Atorvastatin|"Each day accordingly to randomization patients allocated to Atorvastatin received a pill of 40 mg of atorvastatin. In diabetic patients the concomitant aspirin treatment include a previous 30 days treatment with 100 mg daily of aspirin.~All patients followed the diet used in the placebo group."
9972647|NCT01322711|Placebo Comparator|Diet|Low-fat diet with mean macronutrient profiles that were close to the present Adult Treatment Panel III guidelines (7% energy from saturated fat and, 200 mg dietary cholesterol per day)
9670399|NCT05063526||Group B|"40 patients who are mechanically ventilated due to pulmonary disease at respiratory ICU had their diagnosis as follows: 21 (53%) had COPD, 8 (20%) had asthma, 5 (13%) had bronchiectasis, 5 (13%) had pneumonia and~1 (3%) had viral influenza H1N1. Out of group B patients, 11 patients (13.75%) had failed weaning, of which 6 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 3 patients were re-intubated and 2 patients died."
10154309|NCT04056052|Active Comparator|Home Activity + cooking Workshop|The 8-week cooking workshop condition incorporated all of the home activities previously described, however, this cohort also participated in two, two-hour cooking workshops held at a local cooking school.
9670400|NCT05063526||Group A|40 patients on mechanical ventilation due to non-pulmonary disease at respiratory ICU had their diagnosis as follows: 24 (60%) had congestive heart failure, 4 (10%) had diabetes mellitus, 4 (10%) had sepsis other than pneumonia, 2 (5%) had epilepsy, 2 (5%) had embolic hemiplegia, and 4 (10%) had chronic renal failure. Out of group A patient, 9 patients (11.25%) had failed weaning of which 4 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 2 patients were reintubated and 3 patients died.
10154310|NCT04056039|Active Comparator|"Atorvastatin"|"-Changes of troponin I in rheumatoid arthritis with atorvastatin 40 mg orally every 24 hours for four weeks"
10154311|NCT04056039|Active Comparator|"Colchicine"|"Changes of troponin I in rheumatoid arthritis with colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks"
10154312|NCT04055870||Undergone EUS-guided liver biopsy at MDMC|Undergone EUS-guided liver biopsy at MDMC
10154313|NCT04055974|Experimental|BeAMom|Low-risk (LR) women will receive a web-based intervention for the promotion of maternal mental health (the Be a Mom program). In addition, women will receive postpartum treatment as usually performed in primary care settings (TAU).
9670401|NCT05063526||control group.|40 patients Chronic obstructive pulmonary disease (COPD) from Outpatient Clinic
9670402|NCT05063058|Experimental|Molecular guided therapy|
9670403|NCT05063266|Active Comparator|Group A|Deep Breathing exercise
9670404|NCT05063266|Experimental|Group B|Inspiratory Muscle Training
9670405|NCT05063279|Experimental|Resistance training group|Participants in two age groups will receive moderate (three sets of per exercise per session) and low-volume (one set of resistance per session) training allocated to either right or left upper- and lower extremities. A total of 24 sessions will be performed over 10-12 weeks.
9670406|NCT05063279|No Intervention|Negative control group|A negative control group is included in the study which will not receive any resistance training.
9670407|NCT05062967||HAOD Cohort|"This cohort includes patients with acute hepatitis of unknown origin, meaning its origin could not be determined after screening of (at least) HAV, HAB, HAC, HAE, Epstein-Barr virus and cytomegalovirus. Patients will be recruited in 17 centres nationwide.~The research group will receive a 1mL plasma / serum sample from each patient to study the presence of Ortho-C infection"
9519999|NCT03281460|Active Comparator|without any morcellation bag|without any morcellation bag
9520000|NCT03281447|Experimental|Nurse navigation|Coherent navigation and support from a family-centred viewpoint throughout the cancer trajectory, despite the individual patient's affiliation to any department.
9670408|NCT05062967||OrthoC-Tx Cohort|This cohort includes liver or kidney transplant patients under follow-up. The research group will receive a 1mL plasma / serum sample every year from each patient to study the presence of Ortho-C infection
9670409|NCT05062967||Ortho-CoRIS Cohort|"This cohort includes VIH positive patients who are in follow-up by the Spanish Network of AIDS Research.~The research group will receive a plasma / serum sample every year from each patient to study the presence of Ortho-C infection."
9670410|NCT05062967||TrazHE Cohort|"This cohort includes patients whose clinical picture is compatible with HAE infection.~The presence of Ortho-C infection will be studied in patients with positive IgM for HAE and absence of RNA-HAE."
9670411|NCT05062967||Ortho-C-Rodent Cohort|This cohort includes wild rats. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in wild rats (Ortho-C's main reservoir).
9670412|NCT05062967||Ortho-C-Domestic Rodent Cohort|This cohort includes domestic rats and mustelids. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in domestic rats and mustelids.
9670413|NCT05062967||Ortho-C-Carnivore Cohort|"This cohort includes 236 wild carnivores that feed off rodents. Carnivores' cause of death is they were run over.~Feces, liver and serum samples will be taken to study the transmission of Ortho-C."
9670414|NCT05063240|Experimental|Mobile phone text messaging plus prospective motivational interviewing|Experimental: Text messaging-motivational interviewing. Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding the infants. Participants will be asked to respond within 48 hours, indicating no problem or a problem with breastfeeding that requires help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, and 10. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
9670415|NCT05063240|Active Comparator|Standard infant feeding counselling|Standard infant feeding counselling as part of routine primary healthcare practice
9670416|NCT05063292|No Intervention|Control group|Patients covered with a 41 centigrade degrees double layered cotton cloth
9670417|NCT05063292|Experimental|Prewarmed group|Patients receive active prewarming with an air forced blanket ( full body blanket) 30 minutes prior to the operation
10154314|NCT04055974|No Intervention|Control|Low-risk (LR) women will receive postpartum treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
9670418|NCT05063214||Ultrasound assessment|Muscle ultrasound evaluation
9670419|NCT05063253|Experimental|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once weekly.
9670420|NCT05063253|Experimental|TG103, 22.5 mg|TG103 (22.5 mg) will be administered via subcutaneous injection once weekly.
10154315|NCT04055896|No Intervention|Control Group|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
10154316|NCT04055896|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making) Pause of medication and clinical monitoring"
9670421|NCT05063253|Experimental|TG103, 30 mg|TG103 (30 mg) will be administered via subcutaneous injection once weekly.
9670422|NCT05063253|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection once weekly.
10154317|NCT04055948|No Intervention|Control - Standard of Care|- All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
10154318|NCT04055948|Experimental|Intervention|"All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)~Three in-person, one-on-one teaching sessions with the caregiver during radiation treatments, followed by a telephone booster contact 2 weeks post-treatment."
9670423|NCT05063318|Active Comparator|Sequence TR|"Sequence 1 (TR)~Cycle 1: Itraconazole + lurbinectedin 0.8 mg/m²~Cycle 2: Lurbinectedin alone 3.2 mg/m²~Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)~PART A The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m². In Part A, all patients will receive itraconazole plus lurbinectedin in Cycle 1 and lurbinectedin alone in Cycles 2 and 3 (this last cycle being optional).~PART B Randomization will apply for study Part B only. In Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A. In Part B, patients will be randomly assigned to the corresponding sequences."
9670424|NCT05063318|Active Comparator|Sequence RT|"Sequence 2 (RT):~Cycle 1: Lurbinectedin alone 3.2 mg/m²~Cycle 2: Itraconazole + lurbinectedin 0.8 mg/m²~Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)"
9670425|NCT05062941|Active Comparator|Control group|Conventional therapy (CT) was applied to all participants. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS) in conventional mode, 5 minutes of ultrasound (1.5 W/cm2, 1 MHz), 20 minutes of interference current with vacuum electrodes (80 Hz pulse frequency, 1/1 rectangular spectrum), and exercises (all exercises were applied as 1 set of 10 repetitions in each direction: Codman exercises (3-directions), wand exercises (4-directions), exercises using the shoulder wheel (2-directions), exercises with exercise band (5-directions), exercises on the finger ladder (1 set of 10 repetitions in both directions); and shoulder capsule stretching exercises performed (1 set of 12 repetitions) by asking the subjects to wait 20 seconds where the tension was felt).
9670426|NCT05062941|Active Comparator|Study group|"Same conventional therapy (CT) that was applied to control group was also applied to all participants in this group. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and the same exercises.~In addition to the CT program, only study group has received HILT (BTL 6000, BTL Industries, Inc., USA) application to the shoulder area (analgesic mode, 25 Hz,10 W, 12 j/cm2) for 2 minutes."
10154319|NCT04055883|Experimental|DA-1229 5mg|Oral administration of DA-1229 5mg tablet once a day
10154320|NCT04055883|Experimental|DA-1229 10mg|Oral administration of DA-1229 10mg tablet once a day
10154321|NCT04055883|Placebo Comparator|DA-1229 Placebo|Oral administration of DA-1229 Placebo tablet once a day
10154322|NCT04056091|Experimental|Back rub stimulation|
10154323|NCT04056091|Active Comparator|Foot flicks stimulation|
9972648|NCT01322724|Active Comparator|Warm water|Body temperature (95-100 degrees F) water
10154324|NCT04056156|No Intervention|Control|Standard of care (no specific intervention)
9670427|NCT05063071|Experimental|TAF monotherapy without HBIG|The standard dose of TAF 25mg daily was used. TAF can be used on the first day after orthotopic liver transplantation. No HBIG was used before, during, or after transplantation; and therapeutic vaccination was not routinely used.
9670428|NCT05062902|Active Comparator|Template Injection|For the standard template injection, 200 units of BoNT diluted in 6mL of preservative saline will be prepared. 1/4 of the prepared BoNT solution will be administered to each of the pubococcygeus and puborectalis muscle at 5 and 7 o'clock position, respectively. The index finger will be used for palpation as the 20-gauge spinal needle with a trumpet guide (i.e. paracervical block kit) piercing through the vaginal mucosa to the intended muscle groups. The syringe will be withdrawn before each injection to avoid intravascular injection.
9670429|NCT05062902|Experimental|Guided Injection|For the guided injection, pelvic floor injections (total of 4) will be made to the pubococcygeus and puborectalis muscles each, at NMJ locations (1.5 ml per site), at patient-specific locations and depths identified from vaginal HD-sEMG recordings. NMJ mappings will be generated for each participant. The channel locations will provide angle measurements for each NMJ. The device will calculate these parameters based on acquired HD-sEMG. The index finger will be used for palpation and guidance of injection needle through the vaginal mucosa to the defined injection sites. The BoNT dosage with respect to the total 200 units administered to each site will be patient specific, determined as the ratio of the resting average resting root-mean square (RMS) value of a specific region divided by the total average resting RMS.
9670430|NCT05062720|Experimental|Local consolidative therapy (LCT) + systemic therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
9670431|NCT05062720|Active Comparator|Systemic therapy alone|Appropriate second-line systemic therapy, as defined in the NCCN guidelines will be used during study treatment (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). The choice of specific regimen will be left to the discretion of the treating oncologist but cannot include other experimental or investigational treatment. Sample appropriate systemic therapies include FOLFOX or FOLFIRI with a biologic agent such as an anti-angiogenic antibody or anti-EGFR antibody.
9670432|NCT05062681|Active Comparator|Dexamethasone group|Patients will receive dexamethasone 8 mg q12hours
10154325|NCT04056156|Experimental|Level 1: Online dissemination of the HIV screening advice|General practitioners included at the first level receive the HIV-testing advice through a personal electronic mail by their local GP-organization coordinator containing an information message with the printer-friendly screening advice attached. The message also provides a link to the website of the Flemish umbrella organization for GPs (https://domusmedica.be), where the tool is available for download for all Flemish GPs. A reminder is sent out to all participants after 13 months.
10154326|NCT04056156|Experimental|Level 2: additional group-level training session|At the second intervention level, GPs first receive intervention condition 1 and additionally the face-to-face group-level training session. These sessions are organized as part of regular 'continuous medical education' provided by the GP organizations ('quality circles') at their usual venues and are organized a few months after receiving intervention level 1. A reminder of the advice is sent out 13 months after the initiation of intervention level 1.
10154327|NCT04055987|Experimental|Congenitally deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of consonant-vowel-consonant (CVC) combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
9670433|NCT05062681|Experimental|methylprednisolone group|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
9670434|NCT05062564|Experimental|LipiFlow group|Single preoperative treatment with the thermal pulsation system LipiFlow within two months before cataract surgery
9670435|NCT05062564|Active Comparator|Control group|Eyelid warm compresses plus eyelid massage twice a day for the preoperative month
9670436|NCT05062551|Experimental|intervetion group|50 patients complained of post-menstrual bleeding with confirmed presence of isthmocele. After written consent, the patient will be subjected to three steps hysteroscopic resection of an isthmocele by removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
10154328|NCT04055987|Experimental|Adventitiously deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of CVC combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
10154329|NCT04055831||GD1 subjects with no bone complications|1. GD1 subjects with no bone complications (n=10)
9670437|NCT05062954|Experimental|Polyphenol-rich cranberry extract supplement standardized in PACs|Supplementation with polyphenol-rich cranberry extract standardized in PACs (1 capsule / day)
9670438|NCT05062954|Placebo Comparator|Placebo supplement|Supplementation with placebo (1 capsule / day)
10154330|NCT04055831||GD1 patients with mild bone complication|2. GD1 subjects with mild bone complications
10154331|NCT04055831||GD1 with severe bone complications|3. GD1 subjects with severe bone complications
9670439|NCT05062486|Experimental|Resveratrol, Quercetin, Curcumin (RQC)|Resveratrol (100mg BID), Quercetin (120mg BID), Curcumin (1000mg BID); 24 months
9670440|NCT05062486|Active Comparator|Curcumin|Curcumin (1000mg BID); 24 months
9670441|NCT05062499|Active Comparator|Active TENS|electrical stimulation
9670442|NCT05062499|Sham Comparator|Sham TENS|no stimulation
9977241|NCT01359501|Experimental|Chinese medical treatment|
10154332|NCT04055831||No bone disease|Controls with no known bone disease (n=10)
10154333|NCT04056143||Dabigatran|Subjects who are receiving long-term Dabigatran for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
9520001|NCT03281447|Active Comparator|Current care coordination|Department-specific coordination and answers to questions from a patient-centred viewpoint.
9670443|NCT05062395||Observational (diet, FDG PET CT)|Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive FDG then undergo PET CT.
9670444|NCT05062434|Experimental|Intervention Arm|VA cardiac electrophysiologists receiving the intervention
9972649|NCT01322724|Experimental|Cool water|Room temperature (68-73 degrees F) water
9972650|NCT01322737|Experimental|SUMO Tissue Access and Resection System|
9972651|NCT01322750||With CTCs|Those individuals whom are identified with CTCs
9972652|NCT01322750||Without CTCs|Those individuals whom present and did not have CTCs
9972653|NCT01322776|Experimental|Bortezomib,Fludarabine,Cyclophosphamide|
9972654|NCT01322789|Experimental|Intravenous mesenchymal stem cell|This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart
9972655|NCT01322802|Experimental|Treatment (pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine)|Patients receive pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine ID monthly for 3 months.
9972656|NCT01322828|Active Comparator|Single incision repair of distal bicep tendon rupture|In this treatment arm patients will have a single incision technique used to repair their distal bicep tendon rupture
9972657|NCT01322828|Active Comparator|Double incision repair of distal bicep tendon rupture|In this treatment arm, patients will have a double incision technique used to repair their distal bicep tendon rupture.
9972658|NCT01322854|Experimental|IMRT + integrated boost|28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost
9972659|NCT01322854|Other|Conventional RT + sequential boost|Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy
9972660|NCT01322867|Active Comparator|Reference Drug|
9972661|NCT01322867|Active Comparator|Test Drug|
9972662|NCT01322880|Other|Control Arm|The project, administered by the International Rescue Committee (IRC), involved 25 village savings and loans association (VSLA) groups across the province. The VSLA groups initially formed through local members of the community designated as community based facilitators (CBF).
9972663|NCT01322880|Experimental|Treatment Group|"Half of the VSLA participants were invited to participate in an additional set of discussion groups to be attended along with their spouse. All participants were informed that due to space constraints, only half of the members would be able to attend. In each VSLA, individuals drew numbers from a bag or hat, and those with winning slips were the ones who entered the discussion groups with spouses."
9972664|NCT01322893||Blood sampling.|Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
9972665|NCT01322906|Other|Group A|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
9972666|NCT01322919|Experimental|Myopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a myopic condition of the eye in conjunction with a presbyopic condition
9972667|NCT01322919|Experimental|Hyperopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a hyperopic condition of the eye in conjunction with a presbyopic condition
9972668|NCT01322958||At Risk of Ectopic Pregnancy|Women who present to the emergency department at UCSF who are at risk of ectopic pregnancy.
9972669|NCT01322984|Active Comparator|Normal controls|Normal children and youths
9972670|NCT01322984|Experimental|ASD|Children and youths diagnosed with autism spectrum disorder (ASD)
9972671|NCT01322997|Experimental|Myomo + RTP|This group will be administered a regimen comprised of repetitive task specific practice (RTP) in conjunction with use of the robotic brace described elsewhere in this record.
9972672|NCT01322997|Active Comparator|Myomo|Patients in this group will only be administered the robotic brace described elsewhere in this record.
9972673|NCT01322997|Active Comparator|RTP only|Patients in this group will be administered repetitive task specific practice (RTP), emphasizing use of their affected arms during performance of valued, functional tasks.
9972674|NCT01323036|Experimental|Krill Oil|
9520002|NCT03281434|Active Comparator|Collagen peptide|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides
9670445|NCT05062382|Experimental|Complementary feeding program|Promotion of two main products: 1) Cerifam, a fortified complementary food popular in Ethiopia, and 2) eggs.
9972675|NCT01323036|Experimental|Fish Oil|
9972676|NCT01323049|Active Comparator|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia in this group
9972677|NCT01323049|Active Comparator|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia in this group
9972678|NCT01323062|Other|Single-arm trial|Single-arm trial
9972679|NCT01323075||Renal insufficiency group|Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis. These patients do not have diabetes.
9972680|NCT01323075||Diabetic group|These patients have diabetes, but not renal insufficiency.
9972681|NCT01323075||Non-exposed group|These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
9972682|NCT01323088|Other|Control|Standard care control (no-exercise)
9972683|NCT01323088|Active Comparator|Aerobic Exercise|
9972684|NCT01323088|Active Comparator|Resistance Exercise|
9972685|NCT01323101|Sham Comparator|Control|No doxycycline
9972686|NCT01323101|Experimental|Doxycycline|
9972687|NCT01323114|Active Comparator|Medical Control Group|Control group of patients who will receive conventional medical treatment for type 2 diabetes, along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
9972688|NCT01323114|Experimental|Surgical Treatment Group|Experimental group in which patients will undergo the laparoscopic duodenal bypass procedure along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
9972689|NCT01323127||Chronic back pain|This group of patients has had chronic back pain for longer than 3 months.
9670446|NCT05062382|No Intervention|Comparison|Comparison arm with no program
9670447|NCT05062525||Immunotherapy|
9826355|NCT02415842||H9N2_AS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed study Q-PAN H9N2-001 (116358) (A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
9972690|NCT01323127||Non chronic back pain|This group of patients is hospitalized for cardio physical therapy, and has no lumbar-pelvic complications. Patients are selected from the hospitalized population according to age, sex, and BMI in order to match chronic back pain patients.
9972691|NCT01323166||Excision of the levator muscle|The abdominal part of the operation is performed as an TME and the perineal part of the operation is performed with the intent to get a cylindrical specimen thus removing part of or the entire levator muscle with the specimen
9972692|NCT01323166||Traditional perineal operation|The abdominal part of the operation performed as a TME. The perineal operation performed with the intent of removing the tumour with CRM free of tumour and the levator left in place
9972693|NCT01323179||Strong opioids|Patients taking strong opioids preoperatively
9520003|NCT03281434|Experimental|Whey protein|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
9670448|NCT05062525||Non-Immunotherapy|
9972694|NCT01323179||Weak opioids|Patients taking weak opioids preoperatively
9972695|NCT01323179||Opioid native|Patients not taking opioids preoperatively
9972696|NCT01323231|Experimental|Communities in Schools Services|Communities in Schools services include case management, mental health services, mentorship services, after school programs, and academic assistance.
9972697|NCT01323244|Experimental|TMC435|TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
9972698|NCT01323257|Experimental|001|TMC435 150 mg capsule once daily for 7 days (Trt A C D)
9972699|NCT01323257|Experimental|002|erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
9972700|NCT01323257|Experimental|003|erythromycin 500 mg tablets three times a day for 7 days (Trt C)
9972701|NCT01323257|Experimental|004|TMC435 50 mg capsule once daily for 7 days (Trt F)
9972702|NCT01323257|Experimental|005|Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
9972703|NCT01323257|Experimental|006|Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
9972704|NCT01323283|Active Comparator|Omega-3 supplementation|50 % of all included children will be randomized to this arm and administered capsules containing an omega-3 fatty acid composition.
9972705|NCT01323283|Placebo Comparator|Placebo|50 % of included children will be randomized to this arm and will be administered placebo capsules for the 15 week intervention.
9972706|NCT01323296|Active Comparator|Ferumoxytol|Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.
9972707|NCT01323296|No Intervention|Control|Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.
9972708|NCT01323348|Experimental|Diabetes Educational Intervention|Study participants in the intervention group will receive a diabetes management educational intervention at baseline and at follow-up visits. For those on an annual follow-up schedule, educational intervention will take place at baseline and 12 months. For those whose standard care involves more frequent, than annual, visits the educational intervention will take place no more than once every 12 weeks.
9972709|NCT01323348|No Intervention|Standard Care|Usual care
9972710|NCT01323361|No Intervention|Non-immunosupressed|Normal population
9972711|NCT01323374|Experimental|Droxidopa 200mg TID|
9972712|NCT01323374|Experimental|Droxidopa 400mg TID|
9972713|NCT01323374|Experimental|Droxidopa 600mg TID|
9972714|NCT01323374|Active Comparator|Carbidopa 25mg TID|
9972715|NCT01323374|Active Comparator|Carbidopa 50 mg TID|
9972716|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/25mg TID|
9972717|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/25mg TID|
9972718|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/25mg TID|
9972719|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/50mg TID|
9972720|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/50mg TID|
9972721|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/50mg TID|
9670449|NCT05062122||vibration group|Hand skills will be evaluated before and after the 10-minute vibration application.
9670450|NCT05062122||kinesiology tape group|Manual dexterity will be evaluated before and after kinesiology tape application.
9670451|NCT05062122||control group|Manual dexterity will be evaluated before and after conventional physiotherapy.
9670452|NCT05062252|Experimental|Mirror group|Mirror Medacta Shoulder System
9670453|NCT05062252|Active Comparator|Historical Control group|Total shoulder arthroplasty system
9670454|NCT05062187||Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
9670455|NCT05062187||Healthy Individual|Proprioception on balance and gait functions in healthy individuals
9670456|NCT05062304||Fluticasone furoate-vilanterol|Reference group
9670457|NCT05062304||Fluticasone furoate-umeclidinium-vilanterol|Exposure group
9972722|NCT01323374|Placebo Comparator|Placebo TID|
9972723|NCT01323400|Experimental|Pazopanib|"Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.~Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed."
9972724|NCT01323400|Other|Best supportive care|Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
9972725|NCT01323413||stroke|acute ischemic stroke patients
9972726|NCT01323426|Experimental|periurethral injection|Periurethral injection of autologous muscle fibers
9977242|NCT01359501|Placebo Comparator|Placebo|
9670458|NCT05062512||Participants living with and without neurodegenerative diseases|No intervention
9670459|NCT05062148|No Intervention|Standard of Care|Subjects will follow the standard of care, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
9670460|NCT05062148|Active Comparator|Float-REST|Subjects will do Flotation Restricted Environmental Stimulation Therapy, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
9670461|NCT05062148|Active Comparator|Photobiomodulation|Subjects will do photobiomodulation, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
9670462|NCT05062265|Active Comparator|Tight Rope Fixation|
9670463|NCT05062265|Active Comparator|tight rope fixation w/ AITFL repair augmentation with an internal brace|
9670464|NCT05062239|Active Comparator|Continuance|Continuance prior statin therapy.
9670465|NCT05062239|Experimental|Discontinuance|Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
9670466|NCT05062226|Experimental|GMP-based products|GMP-based nutritional protein substitutes for the dietary management of PKU and TYR
9670467|NCT05062096|Other|Group 1: BRAF-mutated metastatic patients treated with 1st line targeted therapy|BRAF-mutated metastatic patients treated with 1st line targeted therapy
9670468|NCT05062096|Other|Group 2: Metastatic patients treated with 1st line immunotherapy|Metastatic patients treated with 1st line immunotherapy
9670469|NCT05062096|Other|Group 3: BRAF-mutated patients treated with adjuvant targeted therapy|BRAF-mutated patients treated with adjuvant targeted therapy
9670470|NCT05062096|Other|Group 4: Patients treated with adjuvant immunotherapy|Patients treated with adjuvant immunotherapy
9670471|NCT05062161|Experimental|Sleep Hygiene/Extension Intervention|Participants with short sleep duration will receive a 60-minute educational session on sleep hygiene/extension. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts and/or complete questionnaires about sleep. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
9670472|NCT05062161|Active Comparator|Control Condition|Participants with short sleep duration will receive a 60-minute educational session on sleep physiology. Over an 8-week period, participants will receive weekly phone or Zoom video calls from the Educational Research Coordinator to review additional materials including handouts. Participants will undergo sleep tracking/monitoring during the 8-week period, and repeat BP/heart rate monitoring for 24 hours after the 8-week period.
9670473|NCT05062005|Other|Induction Chemotherapy+Chemoradiotherapy|
9670474|NCT05062005|Other|Chemoradiotherapy|
10154334|NCT04056143||Rivaroxaban|Subjects who are receiving long-term Rivaroxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
10154335|NCT04056143||Apixaban|Subjects who are receiving long-term Apixaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
10154336|NCT04056143||Edoxaban|Subjects who are receiving long-term Edoxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
9670475|NCT05061914|Active Comparator|pericardiocentesis|vitally unstable patients with tamponading pericardial effusion undergone percutaneous gradual drainage by a central venous catheter
9670476|NCT05061914|Active Comparator|subxiphoiodal drainage|drainage of the pericardial effusion through a subxiphoidal midline incision
9670477|NCT05061914|Active Comparator|thoracotomy|encysted and undiagnosed pericardial effusion drainage through anterior thoracotomy performing a pericardiopleural window and take a pericardial biopsy
9670478|NCT05061914|Active Comparator|VATS drainage|encysted and undiagnosed pericardial effusion drainage through VATS that permits performing a pericardiopleural window and take a pericardial biopsy with minimal incisions
10154337|NCT04056130|Experimental|Cohort SAD1|9 Subjects for SAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
9670479|NCT05061771|Active Comparator|nomacopan (rVA576)|"PART A:~High dose nomacopan (standard complement ablating doses on Day 1 followed by 45 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd~or~Low dose nomacopan (standard complement ablating doses on Day 1 followed by 15 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS~PART B:~Nomacopan (standard complement ablating doses on Day 1 followed by to be confirmed mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd"
9670480|NCT05061771|Placebo Comparator|Placebo|"PART A:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 45mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~or~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 15mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~PART B:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of active dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd"
9670481|NCT05061732|Experimental|RBCL|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levofloxacin 0.5 g qd for 14 days
9670482|NCT05061732|Experimental|RBLM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levofloxacin 0.5 g bid for 14 days
9670483|NCT05061732|Experimental|RBCM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
9670484|NCT05061732|Experimental|RA|Rabeprazole 20 mg bid, and Amoxicillin 1.0 g tid for 14 days
9670485|NCT05061732|Experimental|RAB|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, and Amoxicillin 1.0 g tid for 14 days
9670486|NCT05061732|Experimental|RAM|Rabeprazole 20 mg bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
9670487|NCT05061732|Experimental|RBAM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
9670488|NCT05061732|Experimental|RBAM4|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g tid for 14 days
9977243|NCT01359514|Active Comparator|Duloxetine|
10154338|NCT04056130|Experimental|Cohort SAD2|9 Subjects for SAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
10154339|NCT04056130|Experimental|Cohort MAD1|9 Subjects for MAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
9670489|NCT05061732|Experimental|RBDM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
9670490|NCT05061732|Active Comparator|RBTM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and tetracycline 0.5 g qid for 14 days
9670491|NCT05061784||MEN-1 patients who underwent routine thymectomy during parathyroidecotmy|A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.
9670492|NCT05061797|Active Comparator|Active Study Product|An energy beverage formulated to improve the thermogenic (calorie burning) impact in humans via caffeine and ingredients for overall metabolic wellness.
9670493|NCT05061797|Placebo Comparator|Placebo|A carbonated soft-drink with the same appearance, aroma, and flavor as the active study product
9670494|NCT05061901|Other|Sequence TR|19 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9670495|NCT05061901|Other|Sequence RT|19 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Zestril® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Lisinopril (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10154340|NCT04056130|Experimental|Cohort MAD2|9 Subjects for MAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
10154341|NCT04056117|Experimental|NA (Non-adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the non-adjuvanted investigational product
9694723|NCT04785963|Active Comparator|Pain Information|Non-arts group receiving structured attention and standard care
9694724|NCT04785885||Transcatheter Aortic Valve Replacement|Patients receive 100U/Kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
9694725|NCT04785885||Cardiac Valve Annuloplasty|Patients receive 300U/kg of IV heparin. An arterial sample activated clotting time (ACT) will be checked by iStat and hemochron
9694726|NCT04785846||Single Group|Adult patients with coronary artery disease undergoing percutaneous coronary intervention on vessels with a diameter less than or equal to 2.5 mm.
9694727|NCT04786041||underwent Appendectomy during march-april of 2019|all patients who underwent Appendectomy during the period of march-april of 2019
9694728|NCT04786041||underwent Appendectomy during march-april of 2020 (during covid pandemic)|all patients who underwent Appendectomy during the period of march-april of 2020 (during the COVID19 pandemic lockdown)
10154342|NCT04056117|Experimental|A (adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the adjuvanted investigational product
10154343|NCT04056117|Experimental|NA (Non-adjuvanted) - low dose -infants|Infants receive 3 low doses of the non-adjuvanted investigational product
10154344|NCT04056117|Experimental|A (adjuvanted) - low dose - infants|Infants receive 3 low doses of the adjuvanted investigational product
9694729|NCT04785872|Experimental|Intervention group|
10154345|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the non-adjuvanted investigational product
9694730|NCT04785872|No Intervention|Control group|
9977244|NCT01359514|Active Comparator|Pregabalin|
9694732|NCT04786054|Active Comparator|Group BED|Those who are diagnosed with having Binge Eating disorder. These individuals qualified after the questionnaire was administered.
9694733|NCT04786054|No Intervention|Group Non-BED|Those who are not diagnosed with having Binge Eating disorder
9694734|NCT04785859||Moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, with the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
9694735|NCT04785859||no moderate-severe bronchopulmonary dysplasia|Neonates of less than 30 weeks´ gestation, born at any of the study centers, or transferred from other centers in the first 24 hours of life, without the diagnosis of moderate-severe bronchopulmonary dysplasia at 36 weeks' postmenstrual age.
9694736|NCT04785976||Surgical clipping|
9694737|NCT04785976||Endovascular coiling|
9694738|NCT04785768|Experimental|PCA with continuous + bolus dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours;（2）PCA hydromorphone with continuous infusion where dose/h was the total equianalgesic over the previous 24h divided by 24 and bolus dosage for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h；lockout time = 10 minutes；（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
9977245|NCT01359527||Hip Resurfacing|
9977246|NCT01359527||Total Hip Arthroplasty|
10154346|NCT04056117|Experimental|A (adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the adjuvanted investigational product
10154347|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - children|Children receive 3 medium doses of the non-adjuvanted investigational product
10154348|NCT04056117|Experimental|A (adjuvanted) - medium dose - children|Children receive 3 medium doses of the adjuvanted investigational product
10154349|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose-adults|Adults receive 2 medium doses of the non-adjuvanted investigational product
10154350|NCT04056117|Experimental|A (adjuvanted) - medium dose - adults|Adults receive 2 medium doses of the adjuvanted investigational product
10154351|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - infants|Infants receive 3 high doses of the non-adjuvanted investigational product
9670496|NCT05061459||Group1:|28 control
10154352|NCT04056117|Experimental|A (adjuvanted) - high dose - infants|Infants receive 3 high doses of the adjuvanted investigational product
10154353|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - children|Chilldren receive 3 high doses of the non-adjuvanted investigational product
10154354|NCT04056117|Experimental|A (adjuvanted) - high dose - children|Chilldren receive 3 high doses of the adjuvanted investigational product
9670497|NCT05061459||Group 2:|68 T2DM patients
10154355|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - adults|Adults receive 2 high doses of the non-adjuvanted investigational product
9670498|NCT05061511||Healthy gingival tissue|healthy patients with absence of gingivitis (full-mouth bleeding score <10%), no history of periodontal disease, having ≥20 teeth, and ≤1 tooth with interdental clinical attachment loss.
9670499|NCT05061511||Periodontitis patients|patients with stage III or IV periodontitis, which means that these patients would have deep periodontal lesions that extend at least to the mid portion of the roots and whose management is complicated by the presence of intrabony defects, furcation involvement, history of periodontal tooth loss and localized ridge defects.
9670500|NCT05061511||Peri-implantitis patients|patients affected by peri-implantitis, defined as radiographic evidence of bone loss ≥3 mm and probing pocket depth ≥6 mm around implants in conjunction with bleeding on probing; or defined as bleeding and/or suppuration on probing, increased probing pocket depth from a previous examination and loss of peri-implant bone.
10154356|NCT04056117|Experimental|A (adjuvanted) - high dose - adults|Adults receive 2 high doses of the adjuvanted investigational product
9670501|NCT05061615||acne vulgaris patients|
9670502|NCT05061407||Paediatric surgical patients|All patients < 18 years old, admitted to participating hospitals during the study period who undergo elective and non-elective surgery
9670503|NCT05061329||Normal individuals|no sino-nasal disease - no upper airway allergies - no intra nasal medication - normal sense of smell
9670504|NCT05061329||COVID-19 positive patient|
9670505|NCT05061329||Post-COVID-19 patients|Previous COVID-19 positive patients with prolonged olfactory dysfunction
9670506|NCT05061329||Patients with chronic rhinosinusitis with and without nasal polyps|
9670507|NCT05061329||Patients with smell loss|
9670508|NCT05061836|Experimental|Dextrose0|Acetate Ringer's solution
9670509|NCT05061836|Experimental|Dextrose1|1.25%dextrose equivalence
9670510|NCT05061836|Experimental|Dextrose2|2.5%dextrose equivalence
9670511|NCT05061836|Active Comparator|Dextrose5|5%dextrose
9670512|NCT05061628|Experimental|JS006 as Monotherapy|"JS006 as Monotherapy dose-escalation：5 proposed dose levels（18mg, 60mg, 180mg, 600mg, 1800mg).~JS006 as Monotherapy dose-extension：1 or 2 proposed dose levels, to be determined."
9670513|NCT05061628|Experimental|JS006 in combination with Toripalimab|"JS006 in combination with Toripalimab dose-escalation：2 or 3 proposed dose levels, to be determined.~JS006 in combination with Toripalimab dose-extension：1 or 2 proposed dose levels, to be determined.~JS006 in combination with Toripalimab indications expansion: 2 to 4 specific tumor types are selected for indication expansion after the combination dose-expansion is completed."
9670514|NCT05061745|Active Comparator|Guided Meditation VR for Wellness|Selected modules of commercially available meditation VR
9670515|NCT05061745|Active Comparator|Accelerated Transcranial Magnetic Stimulation: Treatment A|Intermittent theta-burst over dlPFC
9670516|NCT05061745|Active Comparator|Accelerated Transcranial Magnetic Stimulation: Treatment B|Intermittent theta-primed 10Hz over mPFC
9670517|NCT05061602||Diabetic Group|The patients were included if they were of 18 years or older, with a diagnosis of diabetes mellitus for more than three years.
9670518|NCT05061602||NonDiabetic Group|The healthy age-matched control group was included.
9670519|NCT05061381|Experimental|A Lust for Life Schools Programme Group|A Lust for Life programme will be delivered to primary school pupils by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
9670520|NCT05061381|No Intervention|Waiting list control group|Participants will be placed on a sixteen-week waiting list for the programme.
9670521|NCT05061576|Active Comparator|Standard of care|Oral advice on exercise from a physician.
9670522|NCT05061576|Experimental|Active intervention|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
10154357|NCT04056117|Experimental|MenACWY-Placebo|Adults receive one administration of MenACWY followed by one placebo administration
10154358|NCT04056117|Other|Rabies|Children receive three administrations of Rabies
9670523|NCT05061225|Experimental|Intervention|Participants invited to the private Facebook group
9670524|NCT05061225|No Intervention|Waiting list|Waiting list. Will be invited to Facebook group after finalising the study and will receive same intervention.
9670525|NCT05061277|Experimental|Recifercept|A 300 mg single subcutaneous (SC) dose of recifercept for the treatment phase of study
9670526|NCT05061641|Active Comparator|progesterone 200mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 200mg
9670527|NCT05061641|Experimental|progesterone 400mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 400mg
9670528|NCT05061641|Experimental|progesterone 600mg|Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 600mg
9670529|NCT05061342||Cancer Patients|Those with cancer.
9670530|NCT05061342||Normal (non cancer) controls|Those without cancer.
10154359|NCT04056117|Other|MenACWY-DTaP|Infants receive two administrations of MenACWY followed by DTaP administration
10154360|NCT04055935|Experimental|full thickness mucoperiosteal flap|A full thickness mucoperiosteal flap (FTMPF) was reflected on FTMPF side at the maxillary canine/premolar region by the same surgeon for all patients following the same procedures.
10154361|NCT04055935|Experimental|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length
10154362|NCT04055935|No Intervention|Control for Full thickness mucoperiosteal flap|Control for Full thickness mucoperiosteal flap, in which canine retraction was done in a conventional method
9670536|NCT05061121|Experimental|sustained natural apophyseal glides|Investigate the short- and mid-term effects of Mulligan's SNAGs on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
10154363|NCT04055935|No Intervention|control for Low level laser therapy group|Control for Low level laser therapy , in which canine retraction was done in a conventional method
10154364|NCT04055857||NIID|NIID patients
9670537|NCT05061121|Experimental|Myofascial release|Investigate the short- and mid-term effects of Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
9670538|NCT05061121|Experimental|sustained natural apophyseal glides in addition to myofascial release|Investigate the short- and mid-term effects of Mulligan's SNAGs combined with Myofascial release on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
9670539|NCT05061147|Experimental|Max-40279-01 in combination with Azacitidine (AZA)|"This is an open-label Phase Ib/II clinical study. The study will be conducted in two parts:~Part I: Phase Ib dose escalation. Participants receive Max-40279-01 in combination with azacytidine (AZA), with different dose schedules.~Part II: Phase II dose expansion. Participants divide into positive group and negative group according to whether FLT3 gene mutation occurs, approximately 40 people per group.~All participants receive the recommended dose for Part 2 of Max-40279-01 with azacytidine (AZA)."
9670540|NCT05061264|Experimental|Active infection group|A cohort of 38 patients carrying an active infection (mesh sinus, exposed mesh or enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with PVDF mesh.
9670541|NCT05061264|Active Comparator|Clean control group|A cohort of 38 patients with ventral hernias, and submitted to clean ventral hernia repair with PVDF mesh.
9670542|NCT05061394||Second division football players|Players competing in the third best league in Denmark
10154365|NCT04055857||HC|healthy control
10154366|NCT04056169|Active Comparator|Rosuvastatin|rosuvastatin 20 mg once a day for 6 months
10154367|NCT04056169|Experimental|ezetimibe/rosuvastatin|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
10154368|NCT04056026|Experimental|Fecal Microbiota Transplant|The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
9670543|NCT05061394||"Danmarkserien football players"|Players competing in the fourth best league in Denmark
9670544|NCT05061433|No Intervention|Usual Care|Participants receive standard of care.
9670545|NCT05061433|Experimental|Intervention|"Initial Home Visit: MIH/CP provider team will visit the patient's home at the scheduled time following a specific General Followup Protocol involving 1. Assessment of patient understanding of recent illness and medical therapy including reinforcement of medical adherence, 2. Any other disease-specific concerns, 3. Performance of a home safety evaluation, 4. If patients have concerns relating to their ability to manage their disease process at home, 5. MIH/CP providers and an on-call social worker will provide assistance in the form of on-site, telephone, and electronic referrals or provision of appointments with appropriate services.~Subsequent visits: The MIH/CP team will decide in conjunction with Medical Control and the PMD if further followup is needed, and the most appropriate followup interval., At 30 days from initial hospital discharge, the patient will be discharged from the MIH/CP program in conjunction with the PMD."
9670546|NCT05061069|Experimental|Infants with permanent hearing loss|Each infant with permanent hearing loss in Flanders will be offered a vestibular screening by means of the cVEMP (cervical vestibular evoked myogenic potentials) test to screen for vestibular deficits.
10154369|NCT04056000|Experimental|Exercising following the ingestion of a high-carbohydrate br|60 minutes of cycling, with the ingestion of a high-carbohydrate breakfast and 200 mg of caffeine.
10154370|NCT04056000|Experimental|Exercising following the ingestion of caffeine only|60 minutes of cycling, with the ingestion of 200 mg of caffeine.
10154371|NCT04056000|Experimental|Exercising in the absence of breakfast or caffeine ingestion|60 minutes of cycling, without the ingestion of breakfast, or caffeine.
10154372|NCT04055805||Fondazione Policlinico Universitario A. Gemelli, Roma|Polo Scienze della Salute della Donna e del Bambino
10154373|NCT04055805||Università degli Studi di Pavia|
10154374|NCT04055805||"Università di Napoli Federico II"|
10154375|NCT04055805||Università degli Studi di Siena|
10154376|NCT04055805||Azienda Ospedaliero-Universitaria Careggi Firenze|
10154377|NCT04055805||Fondazione Policlinico Universitario A. Gemelli Roma|U.O.C Chirurgia Senologica
10154378|NCT04055805||Istituto Nazionale dei Tumori di Napoli Fondazione G.Pascale|
10154379|NCT04055779||Induced hypotension and arterial occlusion pressure|The patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=[SBP+10]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
10154380|NCT04055779||induced hypotension and limb occlusion pressure|the patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
10154381|NCT04055792|Experimental|Sintilimab combine with Anlotinib|Sintilimab 200mg intravenously on day 1 and Anlotinib 12mg per os on day 1-14 of each 3-week cycle
9977247|NCT01359540||APEX Modular|APEX Modular Stem group
9977248|NCT01359540||ARC Stem|ARC Stem group
10154382|NCT04055792|Active Comparator|Anlotinib|Anlotinib 12mg per os on day 1-14 of each 3-week cycle
9670547|NCT05061030|Active Comparator|Wharton's jelly derived mesenchymal stromal cells (Protrans)|Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects < 50 kg and 200 million cells to subjects 50-100 kg (>100 kg is an exclusion criterion).
9670548|NCT05061030|Placebo Comparator|Placebo|Placebo (saline) is given intravenously over a period of 20-40 min.
9670549|NCT05060822|Experimental|HEC585 dose A|Drug: HEC585 dose A once daily, up to 24 weeks
9670550|NCT05060822|Experimental|HEC585 dose B|Drug: HEC585 dose B once daily, up to 24 weeks
9670551|NCT05060822|Experimental|HEC585 dose C|Drug: HEC585 dose C once daily, up to 24 weeks
9670552|NCT05060822|Active Comparator|pirfenidone|Drug: pirfenidone three times a day (target dose), up to 24 weeks
9670553|NCT05060822|Placebo Comparator|placebo|Drug: placebo once daily, up to 24 weeks
9670554|NCT05060796|Experimental|EGFR CAR-T|Group: 3 dose levels
9670555|NCT05060809|Experimental|Hemodialysis patient with high level of dp uc-MGP|one hundred and twenty hemodialysis patients with high level of dephosphorylated uc-MGP received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by Kauppila score.In addition, study patients were subjected to an echocardiography at baseline as well as 6 months post vitamin K1 supplementation. Echocardiography was performed by the same operator.
9670556|NCT05060900|Experimental|Hand and Wrist Ligament Reconstruction with Allograft Ligament|Participants will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
9670557|NCT05060848||ADRD|"Participants in the ADRD group will have a score of greater than or equal to 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory.~Subgroups based on sex and race categories will also be examined."
9670558|NCT05060848||Control|Participants in the control group will have a score of less than 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory
9670559|NCT05060952||PJI|Patients with septic arthroplasty failure
9670560|NCT05060952||Aseptic|Patients with aseptic causes of arthroplasty failure
9670561|NCT05061043|Active Comparator|Group A|Routine physical therapy treatment
9670562|NCT05061043|Experimental|Group B:|Routine physical therapy along with orofacial therapy
9670563|NCT05060731|Active Comparator|Oral iron supplementation|Patients randomized to receive oral ferrous sulfate, ca. 200-300 mg every day for 3 months.
9670564|NCT05060731|Active Comparator|Intravenous iron supplementation|Patients randomized to receive one dose of 1000 mg intravenous ferric carboxymaltose.
9670565|NCT05060575|Experimental|EDUTC|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
10154383|NCT04055714|Experimental|Treatment arm|Balloon dilation of the Eustachian Tube(s) with Acclarent Aera Balloon
10154384|NCT04055766||Meningitis/Encephalitis|Patients with clinical signs and symptoms suspected of meningitis/encephalitis
10154385|NCT04055766||Stroke|Patients with clinical signs and symptoms suspected of stroke
10154386|NCT04055766||Headache|Patients with clinical signs and symptoms suspected of headache
10154387|NCT04055766||Vertigo|Patients with clinical signs and symptoms suspected of vertigo
10154388|NCT04055337|Experimental|Flap Sliding|"noninvasive flap sliding technique for managing flap striae following laser in situ keratomileusis (LASIK)."
10154389|NCT04055402|Experimental|EMA group|Participate in the baseline survey, 2-week ecological momentary assessments and a 1-month follow-up survey
10154390|NCT04055402|Active Comparator|Control group|Participate in the baseline survey,and a 1-month follow-up survey
10154391|NCT04055597|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
10154392|NCT04055597|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
10154393|NCT04055363|Experimental|Formula-fed infants|Infants fed exclusively with experimental formula
10154394|NCT04055363|Experimental|Mixed-fed infants|Infants receiving breastmilk and experimental formula
10154395|NCT04055363|No Intervention|Breast-fed infants|Reference group of exclusively breastfed
10154396|NCT04055480|Active Comparator|Closed-loop using standard rapid-acting insulin|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
10154397|NCT04055480|Experimental|Closed-loop using faster insulin aspart|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using faster insulin aspart~The CamAPS FX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
10154398|NCT04055506|Experimental|Combination Therapy|
9670566|NCT05060575|Active Comparator|Control Group|Routine hospital care.
9670567|NCT05060653|Experimental|SBRT followed by surgical stabilization within 48 hours|SBRT and surgical stabilization will be performed within a 24 to 48-hour time window instead of today's standard of care of two weeks between surgical stabilization and conventional radiotherapy.
9670568|NCT05060393|Experimental|Intervention group|Daily use of mindfulness-based mobile application for 30 days.
9670569|NCT05060393|No Intervention|Control group|Treatment as usual
9670570|NCT05060588|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
9670571|NCT05060588|Active Comparator|Valsartan|1 tablet of Valsartan every 24 hours for 6 months
9670572|NCT05060692||LONGCOVID|Patient with Long-COVID Syndrom
9670573|NCT05060692||CONTROLS|Healthy individials
9670574|NCT05060419|Experimental|Meropenem-FL058 (180min infusion)|
9670575|NCT05060419|Active Comparator|Piperacillin-Tazobactan (30min infusion)|
9670576|NCT05060471|Experimental|Intervetional group|Neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and concurrent toripalimab
9972727|NCT01323439||Axium™ MicroFX™ PGLA Treated Subjects|This observational evaluation will evaluate early experience using the Axium™ MicroFX™ PGLA COILS as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ Bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol
10154399|NCT04055493|Experimental|Ribociclib plus ET|Ribociclib 600mg / day over 26 cycles + endocrine treatment of physician´s choice
9670577|NCT05060744|Active Comparator|Intervention (Antacid)|"An Antacid, a CE marked medical device under normal conditions of use.~Sodium alginate (reduces reflux) (250 mg/tablet) Calcium carbonate (reduces acidity) (80 mg/tablet) Magnesium carbonate (reduces acidity) (144 mg/tablet) Hyaluronic acid (mucosal protector) (6.15 mg/tablet) Aloe vera extract without anthraquinones (mucosal protector) (40 mg/tablet)~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
9670578|NCT05060744|Placebo Comparator|Control|"The control will consist of a placebo based on excipients without active ingredients that will be formulated so that the tablet has the same appearance as the test product, with three different colour layers.~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
9670579|NCT05060757|Experimental|colonoscopy|Participants will be patients undergoing colonoscopy
9670580|NCT05060705|Experimental|Efesovir|The patients of experimental arm take study drug Efesovir twice a day as an antiviral therapy in dose 0.125 ml / kg. Daily dose of Efesovir: 0.250 ml / kg. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
9670581|NCT05060705|Active Comparator|Remdesivir|"The patients are treated with the antiviral drug Remdesivir in dose 200 mg intravenously on the 1st day, then by 100 mg intravenously daily for 5 - 10 days, depending on the severity of the disease."
9670582|NCT05060497||Covid patients|Participants who were treated in hospital with laboratory diagnosed Covid-19 requiring high flow oxygen, non invasive ventilation or intubation and have now recovered. They will be recruited 5-7 months post discharge from their local hospital Trust
10154400|NCT04055493|No Intervention|Standard-of-care chemotherapy|Standard-of-care chemotherapy according to the clinical guidelines, e.g., of the Breast Committee of the German Gynecological Oncology Group (AGO), and regional prescribing information depending on patient's needs for 16-24 weeks,
9670583|NCT05060497||Healthy control volunteers|Participants who are otherwise healthy, who have not had Covid-19 infection and are age, gender, BMI and ethnicity matched to patients
9670584|NCT05061056|Experimental|Russian current 10%|Subjects will receive a interventions (Russian Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
9670585|NCT05061056|Experimental|Russian current 20%|Subjects will receive a interventions (Russian Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
9670586|NCT05061056|Experimental|Aussie current 10%|Subjects will receive a interventions (Aussie Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
9670587|NCT05061056|Experimental|Aussie current 20%|Subjects will receive a interventions (Aussie Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
9670588|NCT05060510|No Intervention|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
9670589|NCT05060510|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
9670590|NCT05060406|Experimental|LY06006 60mg|"injection~Interventions:~Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
9670591|NCT05060406|Placebo Comparator|Placebo|"injection~Interventions:~Drug: Placebo； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
9670592|NCT05060367|Experimental|Liposomal multivitamin/mineral condition|Ingestion of novel, liposomal multivitamin/mineral.
9670593|NCT05060367|Active Comparator|Standard multivitamin/mineral condition|Ingestion of standard multivitamin/mineral.
9670594|NCT05060354||MS Kesimpta (ofatumumab)|MS patients treated with Kesimpta (ofatumumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
9670595|NCT05060354||MS Ocrevus (ocrelizumab)|MS patients treated with Ocrevus (ocrelizumab) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
9670596|NCT05060354||MS Gilenya (fingolimod) and Mayzent (siponimod)|MS patients treated with Gilenya (fingolimod) or Mayzent (siponimod) for at least 3 months prior to SARS-CoV2 vaccination (completed regimen) Drug administration n/a, following routine clinical care Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
9670597|NCT05060354||Healthy Control|Individuals with major autoimmune disorders or current treatment with immunosuppressive or immunomodulatory drugs Received SARS-CoV2 vaccination (completed regimen) within 2-6 months of enrollment Blood draws at 2-3 months, 5-6 months, and 11-12 months after enrollment
9670598|NCT05060055|Experimental|Test Group|Customized healing abutment inserted in immediate implant placement in association with the use of a connective tissue graft.
9670599|NCT05060055|Active Comparator|Control Group|Customized healing abutment inserted in immediate implant placement.
9670600|NCT05060185|Other|single arm|the patients will be treated by the trial device
9670601|NCT05060107|Experimental|Experimental group - sEVs|Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.
9670602|NCT05060224|Experimental|Low Level Laser|EasyLaser: Low Level Laser 808 nm and 500 mW. The first four treatments where planned as two treatments per week. The remaining six treatments where planned as once a week.
9670603|NCT05060263|Experimental|Cohort 1|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
9670604|NCT05060263|Experimental|Cohort 2|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
9670605|NCT05060263|Experimental|Cohort 3|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
9670606|NCT05060263|Experimental|Cohort 4|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
9670607|NCT05060263|Experimental|Cohort 5|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
9670608|NCT05060263|Experimental|Cohort 6|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
9670609|NCT05060263|Experimental|Cohort 7|HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.
9670610|NCT05060159|No Intervention|Hemodialysis|Conventional hemodialysis
9670611|NCT05060159|Experimental|Hemofiltration|Postdilutional hemofiltration
9670612|NCT05060146|No Intervention|Standard care|
9670613|NCT05060146|Experimental|Structured medico-pharmaceutical collaboration|
9670614|NCT05060198|Active Comparator|Artemether-lumefantrine (AL)|Participants will be randomized to receive a standard weight-based regimen of artemether-lumefantrine (Coartem®, Novartis Pharmaceuticals Corporation, Missouri, USA). Children in the AL arm received two daily doses (morning and evening) orally, over 3 days (6 doses total at 0, 8, 24, 36, 48, and 60 hours post initial dose, administered with food or milk at the clinic and at home). To promote and evaluate adherence, study staff called parents in the evening to remind them to give the AL dose to the child and to bring the blister pack to the clinic the next day for confirmation.
9670615|NCT05060198|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Participants will be randomized to receive a standard weight-based regimen of dihydroartemisinin-piperaquine (DuoCotexin®; Holley-Cotec Pharmaceuticals, Beijing, China). DP was administered once a day for three days (at 0, 24, and 48 hours, orally).
9670616|NCT05060120||confirmed ovarian torsion|immediately before laparoscopy and 1 day post- operation and four weeks after laparoscopy a panel of serum biomarkers will be tested
9670617|NCT05060120||confirmed non ovarian torsion|immediately before laparoscopy
9670618|NCT05060120||control group|match control Compare healthy controls with patients with or without ovarian torsion as confirmed by laparoscopy
9670619|NCT05059704|Experimental|Circuit Class Training|Patients will participate in a total of 1.5hour/day for 8 weeks with a 1:3 (therapist to patient). The circuit will be divided into 5 specific stations, 5 to 10 minutes for warm-up tasks and 15 to 20 minutes on each station as tailored to the patient's activity level
10185762|NCT03742609|Experimental|Info, Reminder and Plan|provision of written information regarding consequences of using a hearing aid and not using a hearing, physical reminder and creation of behaviour plan to use a hearing aid
9670620|NCT05059704|Active Comparator|Individual Task specific training|Patients will participate in a total of 1.5hour/day for 8 weeks with 1:1 (therapist to patient) ratio. During each session, all patients will perform 5 to 10 minutes warm-up tasks, then practiced the selected tasks for the rest of the time.
9670621|NCT05059691||Observational (transbronchial cryobiopsy)|Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.
9670622|NCT05059821|Experimental|Experimental Personalized Cancer Vaccine|Patients with recurrent HCC after surgical resection and refractory to available line of treatment will receive Personalized peptide based vaccine with autologous heat shock protein 70 and autologous activated monocytes
9670623|NCT05059756|Experimental|Treatment group|PTNS and PFR (twice daily)
9670624|NCT05059756|Experimental|Control group|Sham PTNS and PFR (twice daily)
9826356|NCT02415842||H9N2_NAS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed studyQ-PAN H9N2-001 (116358)(A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
9670625|NCT05059535|Experimental|cryoneurolysis of the saphenous nerve|A cryoneurolysis of the saphenous nerve will be performed between 7 days and 5 days before the knee arthroplasty
9670626|NCT05059535|Experimental|cryoneurolysis of geniculate nerves|A cryoneurolysis of geniculate nerves will be performed between 7 days and 5 days before the knee arthroplasty
9670627|NCT05059535|Placebo Comparator|control|No cryoneurolysis will be performed before the knee arthroplasty
9670628|NCT05059912|Experimental|CD7 positive relapsed or refractory T cell lymphoma|Humanized CD7 CAR-T cells intravenously infused to patient with R/R T-NHL[ at a dose of (0.5- 5)x10^6 CD7 CAR-T cells/kg
9670629|NCT05059587|Experimental|MBA-P01|MBA-P01 will be injected into the GL: initial double-blind treatment on Day 1.
9670630|NCT05059587|Active Comparator|BOTOX®|BOTOX® will be injected into the GL: initial double-blind treatment on Day 1.
9670631|NCT05059574|Experimental|Experimental group|Mothers in this group will begin their baby's first breastfeeding by crawling to the breast.
9670632|NCT05059574|No Intervention|Control group|Mothers in this group will begin their baby's first breastfeeding with biological breastfeeding.
9670633|NCT05059613|Experimental|probiotics group|Use thalidomide in combination with probiotics during radiotherapy and chemotherapy
9670634|NCT05059613|No Intervention|thalidomide group|Thalidomide is used only during radiotherapy and chemotherapy
9670635|NCT05059613|No Intervention|healthy control group|healthy control group
9670636|NCT05059782|Active Comparator|Group A (drug treatment group)|Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
9670637|NCT05059782|Experimental|Group B (radiotherapy group)|IFRT, IMRT or SBRT is applied. Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.
9670638|NCT05059782|Experimental|Group C (radiotherapy + drug group)|Drug therapy is the same as group A; IFRT is the same as group B.
9670639|NCT05059847|No Intervention|Standard Care Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus the World Health Organization recommendation that indicates at least 150 min a week of moderate physical activity, equivalent to walking 30 minutes a day for 5 days at an intensity between 60 and 70% of your maximum heart rate.
9670640|NCT05059847|Active Comparator|Resistance Training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a resistance exercise routine using weights. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
9670641|NCT05059847|Experimental|Cross-training Group|Each patient will receive the standard pharmacological treatment for patients with Acute Lymphoblastic Leukemia based on 3 cycles of chemotherapy (21 days duration per cycle); plus a cross-training routine using implements without any extra weight to improve stability, joint mobility and general strength of the body. An individualized program with exercises supervised by a trainer and basic medical team will be developed for each patient during their hospital stay. Each training routine will have a monthly exercise progression based on intensity, frequency and / or duration.
9670642|NCT05059548||Male Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
9670643|NCT05059548||Female Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
9670644|NCT05059639|Experimental|Almond (2 ounces)|Consume 2 ounces almond daily for 8 weeks
9670645|NCT05059639|Active Comparator|Pretzel|Consume comparative amount of pretzel for 8 weeks
9670646|NCT05059561||Patients group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. According to the Cobb method, individuals with a Cobb angle greater than 10° were diagnosed with Idiopathic Scoliosis. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the study and control groups completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
9670647|NCT05059561||Control group|All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. Healthy individuals who applied for the same examination and met the inclusion criteria were determined as the control group by random sampling method. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the control group completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
9670648|NCT05059496|Experimental|Hamstring stretching with Pressure Biofeedback Unit|Hot pack, Hamstring stretching with Biofeedback unit, TENS
9670649|NCT05059496|Active Comparator|Hamstring stretching with out Pressure Biofeedback Unit|Hot pack, Hamstring stretching without Biofeedback unit, TENS
9670650|NCT05059210|No Intervention|Control|Coach McLungs not yet implemented in practice
9670651|NCT05059210|Active Comparator|Intervention|Coach McLungs Implemented in Practice
9670652|NCT05059730|Active Comparator|Men|Men will belong to one arm
9670653|NCT05059730|Active Comparator|Women (follicular phase)|Women will be allocated in this group during the follicular phase of their menstrual cycle.
10154401|NCT04055623|Experimental|Intravenous infusion of Treg cells + Interleukin-2 injections|For the first six months: T-regulatory cells taken from a participant will be increased in numbers outside the body in a lab and then returned back to the same participant through intravenous (IV) infusions once per month. The participant will also take Interleukin-2 (IL2) injections three times per week.
9670654|NCT05059730|Active Comparator|women (luteal phase)|Women will be allocated in this group during the luteal phase of their menstrual cycle.
9670655|NCT05059366|Experimental|Expert participants randomized to MVG followed by 2VE|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the Manual ventilation grip device (MVG) first followed by the standard 2VE technique alone.
10154402|NCT04055623|Placebo Comparator|Intravenous infusion w/Placebo + matching placebo injections|For the first six months: Participants will receive matching placebo or inactive intravenous (IV) infusions once per month. The participant will also take a matching inactive placebo injection three times per week.
10154403|NCT04055623|Experimental|2nd 6-months Open Label: Treg Infusions + IL-2 injections|For second six months: All participants will receive their own expanded/increased in numbers Treg cells by monthly infusion plus 3 times per week subcutaneous injections of IL-2.
10154404|NCT04055610|Experimental|H-MEX|10 participants with paraplegia will participate in explorative gait training using H-MEX powered exoskeleton.
10154405|NCT04055649|Experimental|Treatment - ONC201 & Paclitaxel|Patients receive ONC201 PO on days 1, 8, 15, and 22 and paclitaxel IV over 1 hour on days 2, 9, and 16. Cycles repeat every 28 days in the absence disease progression or unacceptable toxicity. If paclitaxel must be stopped for any reason, patients may continue on ONC201 alone.
9670656|NCT05059366|Experimental|Expert participants randomized to 2VE followed by MVG|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG).
9670657|NCT05059366|Experimental|Novice participants randomized to MVG followed by 2VE|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) first followed by the standard technique (2VE) alone
9670658|NCT05059366|Experimental|Novice participants randomized to 2VE followed by MVG|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG)
9670659|NCT05059275|Experimental|Modified operation group|Undergo the modified ostium obstruction surgery due to symptomatic TCs.
9972728|NCT01323452||Chronic HBV patients|Patients with chronic hepatitis B Treated for at least 3 months No HIV, HCV or HDV.
9670660|NCT05059418|Active Comparator|Clonazepam|Topical treatment of oral mucosa with a 3-min lozenge tablet with clonazepam (0.5 mg), three times a day.
9670661|NCT05059418|Active Comparator|Capsaicin|Topical treatment of oral mucosa with capsaicin rinsing solution (XXXX IE) for three min three times a day.
9670662|NCT05059418|Placebo Comparator|Placebo|Topical treatment of oral mucosa with rinsing solution without capsaicin for three min three times a day.
9670663|NCT05059288|Experimental|Investigation Mask|Non invasive ventilation mask
9670664|NCT05059028|Active Comparator|Oxytocin massage|
9670665|NCT05059028|Active Comparator|music therapy|
9670666|NCT05059028|No Intervention|control group|
9670667|NCT05059145|Experimental|Chlorhexidine gluconate, 1% vaginal cream|8 ml vaginal cream every night for a week and then prophylactic treatment with 8 ml/week for another 11 weeks
9670668|NCT05059145|Active Comparator|Fluconazole, 150 mg oral capsule|Fluconazole150 mg (oral capsule) every 3 days for the first 3 doses, then prophylactic treatment with 150 mg/week for another 11 weeks
9694739|NCT04785768|Experimental|PCA with bolus-only dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours; (2)PCA hydromorphone with bolus-only where dosage was 10%-20% of the total equianalgesic over the previous 24h administrated as needed;（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
9694740|NCT04785768|Active Comparator|Oral opioid|（1）Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours；(2)Oral sustained-released morphine where total equianalgesic over the previous 24h/2×75% every 12h/day and immediate-release morphine for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h； (3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；(4)The treatment regimen was continued for 7 days.
10154406|NCT04055545|Active Comparator|MICT|
10154407|NCT04055545|Active Comparator|HIIT|
10154408|NCT04055584||Sputum spot|
9694741|NCT04785937|Experimental|Imaging and Biopsy|All patients undergo both liver biopsy and liver imaging (US and MR) to assess the diagnostic performance of imaging compared to histopathological examination in the diagnosis of NASH and fibrosis.
9694742|NCT04785664|Experimental|LLE- Long Live the Elderly!|"The group has been randomized among the Long Live the Elderly! (LLE) clients in two cities: Rome and Naples. The LLE central database includes all the participants to the program in Naples and Rome who have been administered the Functional Geriatric Evaluation (FGE) questionnaire."
9694743|NCT04785664|No Intervention|SoC- Standard of Care|No intervention will be carried out. The control group is selected by randomization from a pool of over-80s followed up by General Practitioners in the same cities who have been available to be involved in the study. Each GP provided a list of patients which 10 names have been selected from by randomization. The total pool consisted of approximately 8500 individuals. The sample was made up of 690 selected patients of which 83 (12.02%) refused to participate in the study.
9694744|NCT04785703||oral lichen planus group|patients with chronic bollus erosive lichen planus
9694745|NCT04785586|Experimental|Individual|"HWC protocol + three individual face-to-face sessions via video"
9694746|NCT04785586|Experimental|Group|"HWC protocol + three face-to-face group sessions via video"
9694747|NCT04785586|Active Comparator|Control|Standard HWC protocol
9694748|NCT04785508|Experimental|treated group|neuromuscolar tape application
9694749|NCT04785508|Active Comparator|control group|antigravity position
9694750|NCT04785547|Experimental|Blincyto|Blincyto is given over a 28-day cycle. Starting day for patients, who are MRD-positive before HSCT is between day +60 and day +100 and for patients, who become MRD-positive post HSCT it is between day +60 and day +360 post HSCT.
9694751|NCT04785417|No Intervention|CONTROL GROUP|received conventional occupational therapy program
9694752|NCT04785417|Experimental|STUDY GROUP|received conventional occupational therapy program in addition to using tablet
9694753|NCT04785443|Experimental|ICG group|Patient receiving 3 intraoperative injections of indocyanine green.
9694754|NCT04785443|Other|Control group|Patient benefiting from the traditional surgical act
9694755|NCT04785599|Experimental|Group EC1: Exercices, informative talk|Group EC1 carried out the conventional prevention program consisting of an informative talk and an exercise program
10154409|NCT04055467|Other|[F18]-ASEM + Contingency Management|PET radiopharmaceutical 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide with incentive payments.
10154410|NCT04055701|Other|dichorionic diamniotic twin pregnancy|rutin examination: the assesment of fetal thymus volume at all cases.
10154411|NCT04055415|Experimental|Intervention group|The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml . Once every week#a total of two times. The Conventional drug therapy（expectorant，bronchodilator） is used.
9694756|NCT04785599|Experimental|Group ECCP2: Exercices, informative talk, compression garment|Group ECCP2 carried out the same program but with the addition of a prophylactic compression garment
9694757|NCT04785157||severe COVID-19 patients with delirium|i) SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF) ii) systemic and central immune response characterization, associated to the assessment of CNS damage biomarkers (peripheral blood and CSF) iii) in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia) iv) structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity) v) multi-domains neurocognitive assessment.
9670669|NCT05058989||Pregnant women who are aged between 18 to 47 years old (childbearing age).|These patients must be willing to be followed up for 1 year and agreeing to give the informed consent. Recruitment period will take up to three months. Follow up period will be conducted at the end of first, second and third trimester and three months after giving birth.
9670670|NCT05059171|Active Comparator|Rotary motion using OneShape single file|File size 25 with a taper of 0.06 was mounted to a 6:1 speed-reduction headpiece powered by X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). The speed and torque were set to 400 rpm and 1 N.cm torque, respectively. In a picking motion without pressure, mechanical preparation began with the first RC two-thirds followed by the next 3 mm followed by the full WL.
9670671|NCT05059171|Active Comparator|Reciprocating motion using WaveOne Gold single file|A Primary file size 25 a taper of 0.07 was installed to pre-programmed reciprocation angles and speed for the WaveOne system handpiece of an endomotor (X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). After ensuring a passive fit of the hand file along the predetermined WL, the RC coronal two-thirds was initially instrumented then followed by the full WL.
9670672|NCT05059106|Experimental|Group 1|Half dose of ChAdOx1 nCoV-19 (AZD1222) ) in a 2-dose schedule with an interval of 8 weeks.
9670673|NCT05059106|Active Comparator|Group 2|Standad dose of ChAdOx1 nCoV-19 (AZD1222) in a 2-dose schedule with an interval of 8 weeks.
9670674|NCT05059444||Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III)|
9670675|NCT05059444||Cohort 2: Non-small cell lung cancer (stage II-III)|
9670676|NCT05059444||Cohort 3: Invasive breast carcinoma with all of the following:|"Clinical stage T1-4/N0-3/M0 at presentation AND~Completed preoperative systemic chemotherapy-containing regimen AND~Underwent definitive surgical resection of the primary tumor AND~Has pathological evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes AND~Hormone receptor and HER2 status are known"
9670677|NCT05059444||Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma|
9670678|NCT05059444||Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III)|
9670679|NCT05059444||Cohort 6: Gastric adenocarcinoma (stage II-III)|
9670680|NCT05059444||Cohort 7: Surgically resected pancreatic adenocarcinoma|
9670681|NCT05059444||Cohort 8: Invasive squamous cell carcinoma of the head and neck|Includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers.
9670682|NCT05059444||Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma|Defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology).
9670683|NCT05059444||Cohort 10: High-risk endometrial carcinoma|Defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology).
9670684|NCT05059444||Cohort 11: High-risk renal cell carcinoma|Defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent.
9670685|NCT05059067||Macintosh blade size 3|Patients intubated using Macintosh blade size 3
9670686|NCT05059067||Macintosh blade size 4|Patients intubated using Macintosh blade size 4
9670687|NCT05058976|Experimental|Romosozumab, then Zoledronic Acid|Monthly dose: 210 mg Romosozumab subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
9670688|NCT05058976|Placebo Comparator|Placebo, then Zoledronic Acid|Monthly dose: placebo saline subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
9670689|NCT05059249|Experimental|Manual Traction|Moist heat packs & TENS for ten minutes followed by Manual Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient.
9670690|NCT05059249|Experimental|Mechanical traction|Moist heat packs & TENS for ten minutes followed by Mechanical Traction and 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions firstly but modified as per the response of the patient
9670691|NCT05058963|Experimental|Mantram repetition program|Weekly 90 minute virtual group therapy sessions for 8 weeks run by two faciliators and will consist of 5-8 participants.
9670692|NCT05059158||Alzheimer's Disease|Patients with a Alzheimer's Disease diagnosis
9670693|NCT05059158||Mild Cognitive Impairment|Patients with a mild cognitive impairment diagnosis
9670694|NCT05059158||Subjective Cognitive Decline|Patients with a subjective cognitive decline diagnosis
9670695|NCT05059392|Experimental|Training for Awareness, Resilience and Action (TARA)|12 weekly sessions, each 90 minutes, up to 14 participants/group. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
9670696|NCT05059054|Experimental|Strengthening group|Strengthening exercise
9670697|NCT05059054|Active Comparator|Insole group|Insole application
9670698|NCT05058677|Experimental|aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution|Treatment will be performed before the endotracheal suctioning
9670699|NCT05058677|Experimental|aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
10154412|NCT04055415|Other|Control group|The Conventional drug therapy（expectorant，bronchodilator） is used with the control group
10154413|NCT04055376|Experimental|Daily exposure to active stimulation|Subjects in this arm will receive daily exposure to active stimulation
10154414|NCT04055376|Sham Comparator|Daily exposure to control stimulation|Subjects in this arm will receive daily exposure to control stimulation
10154415|NCT04055532||Mild Cognitive Impairment|
9670700|NCT05058677|Experimental|Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution|Treatment will be performed before the endotracheal suctioning
9670701|NCT05058677|Experimental|Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
9670702|NCT05058677|Experimental|Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution|Treatment will be performed before the endotracheal suctioning
9670703|NCT05058677|Experimental|Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine|Treatment will be performed before the endotracheal suctioning
9670704|NCT05058729||Cohort 1|Participants with multiple sclerosis (MS) or clinically isolated syndrome (CIS) who are enrolled in MS PATHS under Study 888MS001 and have completed at least one COVID-19 questionnaire administered by a participating healthcare institution.
9670705|NCT05058482|Experimental|Non-adhesive Liquid Embolic System(NALES)|
9670706|NCT05058482|Active Comparator|Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter|
9972729|NCT01323465|Experimental|Sequence 1A|Sativex and rifampicin
9972730|NCT01323465|Experimental|Sequence 1B|Sativex and rifampicin
9972731|NCT01323465|Experimental|Sequence 2C|Sativex and ketoconazole
9670707|NCT05058599||facial videos dataset|facial videos collected from Zhongshan Ophthalmic Center of Sun Yat-sen University.
9670708|NCT05058456|Experimental|Single-arm|
9670709|NCT05058495|Experimental|mobile programme users|Patients will receive and use Mobile Lymphedema Self-Care Support Program application and will receive standart lymphedema education.
9670710|NCT05058495|Active Comparator|control group|Patients who will receive standart lymphedema education
9670711|NCT05058625|Experimental|Needly Group|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
9670712|NCT05058625|Active Comparator|Control Group|Normal volleyball training
9670713|NCT05058521||In-hospital VTE group|In-hospital VTE group includes patients who were with a hospital stay over 3 days and new-onset of VTE during their stay. Patients who presented for VTE were excluded.
9670714|NCT05058521||Negative group|Negative group includes patients who were with a hospital stay over 3 days and did not have a VTE during their hospital stay.
9670715|NCT05058833||Patients with cardiac diastolic dysfunction|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
9670716|NCT05058833||Patients with coronary microcirculatory dysfunction|Patients with coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
9670717|NCT05058586|Active Comparator|Conventional theraphy group|13 patients received twenty sessions of conventional therapy for four weeks
9670718|NCT05058586|Active Comparator|Anti gravity treadmill training|13 patients received twenty sessions of conventional therapy for four weeks and Alter-G training was performed 3 days/week for 4 weeks, with up to 30 min. of training per session.
9670719|NCT05058586|Active Comparator|Underwater walking therapy group|13 patients received twenty sessions of conventional therapy for four weeks and three sessions of aerobic exercise treatment of 45 minutes per week underwater
9670720|NCT05058768||control group|Healthy people served as the control group
9670721|NCT05058768||experimental group|Patients with acute lung injury were treated as the experimental group.
9670722|NCT05058612|Experimental|Midodrine|Midodrine 10 mg PO/NG q8h
9670723|NCT05058612|Placebo Comparator|Placebo|Microcrystalline cellulose PO/NG q8h
10154416|NCT04055532||Alzheimer's Disease|
10154417|NCT04055532||Dementia with Lewy Bodies|
10154418|NCT04055532||Frontotemporal Lobar Dementia|
10154419|NCT04055532||Parkinson's Disease with Dementia|
10154420|NCT04055532||Transient Epileptic Amnesia|
10154421|NCT04055532||Temporal Lobe Epilepsy|
9972732|NCT01323465|Experimental|Sequence 2D|Sativex and ketoconazole
10154422|NCT04055532||Spinocerebellar Ataxia|
10154423|NCT04055532||HIV-Associated Neurocognitive Disorder|
9670724|NCT05058443|Experimental|dnosumab|Desuzumab 60 mg subcutaneously /6 months, twice a year
9670725|NCT05058443|Placebo Comparator|placebo control|Placebo subcutaneously /6 months, twice a year
9670726|NCT05058755|Experimental|TALE regimen|tislelizumab plus azacytidine and lenalidomide
9670727|NCT05058755|Experimental|TEPA regimen|tislelizumab plus etoposide and pegaspargase
9670728|NCT05058534||Very preterm infants born between November 30, 2018 and November 30, 2019|Infants born between November 30, 2018 - November 30, 2019, before implementation of the new multiperfusion neonatal system
10154424|NCT04055532||Amyotrophic Lateral Sclerosis|
9670729|NCT05058534||Very preterm infants born between December 1st, 2019 and December 31st, 2022|Infants born between January 1rst, 2019 - December 31st, 2022, after implementation of the new multiperfusion neonatal system
9670730|NCT05058352|Experimental|HS269|Multiple doses of HS269 tablets
9670731|NCT05058365|Experimental|Intervention group|
9972733|NCT01323465|Experimental|Sequence 3E|Sativex and omeprazole
9972734|NCT01323465|Experimental|Sequence 3F|Sativex and omeprazole
9972735|NCT01323491||routine smokers|would-be non-smokers, no actual nicotine replacement therapy
9972736|NCT01323504|Experimental|Music therapy group|Local care with music
10154425|NCT04055532||Primary Lateral Sclerosis|
10154426|NCT04055285|Experimental|Sympathetic Renal Denervation|Sympathetic Renal Denervation
10154427|NCT04055285|Active Comparator|Conventional treatment with drug therapy|Conventional drug therapy of resistant hypertension
10154428|NCT04055064|Experimental|Intervention|patients received nutrition education and nutritional supplements
10154429|NCT04055064|No Intervention|Control|patients did not receive any intervention
10154430|NCT04054986|Experimental|Breast Cancer|Breast cancer
10154431|NCT04055272|Experimental|Text messaging|Participants in the text messaging intervention arm receive mobile text messages communicating the risks of indoor tanning and motivating cessation on their mobile phones
9670732|NCT05058365|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
9670733|NCT05058144|Experimental|novel alpha glucan|50g novel alpha glucan dissolved in 300ml water
9670734|NCT05058144|Active Comparator|glucose syrup|50g dissolved in 300ml water
9670735|NCT05058144|Active Comparator|Inulin|15g Inulin dissolved in 300ml water
9670736|NCT05058183|Experimental|All participants|All participants
9670737|NCT05058300||Patients with Chest Pain|An unselected patient-population with chest pain in emergency department
9670738|NCT05058235|Experimental|Active Release Technique|Hot pack, TENS, Quadriceps Isometric strengthening, Active Release Technique
9670739|NCT05058235|Active Comparator|Bent leg raise|Hot pack, TENS, Quadriceps Isometric strengthening, Bent leg raise
9670740|NCT05058053|Experimental|Cold application group|"After starting amiodarone treatment, cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals. At all stages of the study, the researcher closely monitored the patients. During the treatment, the development of phlebitis after cold application during the 24-hour infusion was evaluated every 2 hours by the researcher using the Visual Infusion Phlebitis Scale and recorded. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
9670741|NCT05058053|No Intervention|Control group|"the patients who were started on amiodarone infusion were observed for the development of phlebitis, receiving no intervention. During the treatment, phlebitis development was evaluated and recorded by the researcher using the Visual Infusion Phlebitis Scale every 2 hours during the 24-hour infusion. After starting the amiodarone infusion, the patients were observed for the development of phlebitis for 24 hours until the end of the procedure and for 2 hours after the end of the treatment."
9670742|NCT05058066|Active Comparator|Control implant loaded at 6 weeks post-surgery|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
9670743|NCT05058066|Experimental|Test implant loaded at 6 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
9670744|NCT05058066|Experimental|Test implant loaded at 3 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
9670745|NCT05058209|Active Comparator|Arm 1|Triamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous.
9670746|NCT05058209|Active Comparator|Arm 2|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only.
9670747|NCT05058105|Experimental|FL058 500mg and Meropenem 1000mg|"FL058 500mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
9670748|NCT05058105|Experimental|FL058 1000mg and Meropenem 1000mg|"D1~FL058 1000mg(8 subjects) and FL058 Placebo(2 subjects);~D4~Meropenem 1000mg(8 subjects) and Meropenem Placebo(2 subjects);~D7~ D15~FL058 1000mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
9670749|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 120min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
9670750|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 180min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
10154432|NCT04055272|No Intervention|Control|Participants in the control arm receive no intervention
9670751|NCT05058105|Experimental|FL058 2000mg and Meropenem 2000mg|"FL058 2000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
9670752|NCT05057871|Experimental|PEMF+exercise|A total of 20 sessions of pulse electromagnetic field therapy using an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057, Italia), five times a week and once a day for four weeks, were applied to the patients. The patients were then given a daily exercise program once a day by a physiotherapist.
9670753|NCT05057871|Sham Comparator|Sham PEMF+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
9670754|NCT05058027|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 6g prefilled syringe after surgery
9670755|NCT05058027|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
9670756|NCT05057988|Experimental|Empowered Relief|
9670757|NCT05057767|Experimental|Pre-induction Group (I)|will receive intravenous midazolam premedication 2mg in a volume of 3 ml, 15 minutes before induction of anesthesia
9670758|NCT05057767|Experimental|Pre-extubation Group (II)|will receive intravenous midazolam 2mg in a volume of 3 ml 30 minutes before extubation at the end of surgery
10154433|NCT04054960|Experimental|Real tPCS|Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.
10154434|NCT04054960|Sham Comparator|Sham tPCS|Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
10154435|NCT04054960|Active Comparator|Levodopa|Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).
9972737|NCT01323504|No Intervention|control group|Local care without music
9972738|NCT01323543|Experimental|Elaspine™|Impantation of Elaspine™ device
9972739|NCT01323556|Experimental|Exposure with fear augmentation|exposure-based CBT, including interoceptive exposure and in-vivo exposure with fear augmentation by interoceptive exercises (e.g. hyperventilation)
9972740|NCT01323556|Experimental|Exposure without fear augmentation|exposure-based CBT, including interoceptive and in-vivo exposure without fear augmentation during in-vivo exposure
9972741|NCT01323569|Placebo Comparator|Placebo|
9662273|NCT04922593|Active Comparator|INVEGA SUSTENNA treatment group|"INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available. INVEGA SUSTENNA is provided in a prefilled syringe (cyclic-olefin-copolymer) with a plunger stopper and tip cap (bromobutyl rubber).~In SUSTENNA treatment group, all subjects will receive the first dose of 234 mg IM injection in the deltoid muscle on Day 1, and a second dose of 156 mg of IM injection in the deltoid muscle on Day 8, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 148."
9662274|NCT04918888||Overall study population|All new oncologic patients of the outpatient-clinic of the department of radiooncology
9662275|NCT04918888||First dose received (Subpopulation 1)|Patients, who received one or two doses of SARS-CoV-2 vaccine prior to radiotherapy
9662276|NCT04918888||Vaccination during therapy (Subpopulation 2)|Patients, who will receive at least one dose of SARS-CoV-2 vaccine during or up to 6 weeks after radiotherapy
9662277|NCT04903795|Experimental|hEGFRvIII-CD3 (BRiTE) with and without peripheral autologous T-cell (ACT) infusion|Four escalating doses of BRiTE are planned: #1: 57.0 ng/kg, #2: 570.0 ng/kg, #3: 5700.0 ng/kg, and #4: 57000.0 ng/kg. With the second injection of BRiTE, patients will each receive 3 x 10^7 T-cells per kg.
9662278|NCT04892719|Other|Participants who underwent a lung transplant at Duke|Participants will undergo fluoroscopic chest imaging with 4Dx technology software analysis
9662279|NCT04887857|Experimental|CC-486 in combination with Venetoclax|
9662280|NCT04884412|Experimental|PARKEO 2 targeting with asleep deep brain stimulation procedure|Participant with parkeo 2 targeting procedure
9662281|NCT04884412|Active Comparator|Usual DBS procedure|Participant with usual targeting and surgery
9662282|NCT04868409|Active Comparator|Rocuronium group|Rocuronium 1 mg/kg
9662283|NCT04868409|Active Comparator|Suxamethonium group|Suxamethonium 1 mg/kg
9662284|NCT04866199||High-risk colon or bladder surgical patients|Patients who are diagnosed with colon or bladder cancer requiring surgical resection.
9662285|NCT04861155|Experimental|Intervention Arm|The experimental intervention uses the SIVA-P3 system, the prototype of a digital solution aiming to support the diagnostic process in cases of chronic cough. The SIVA-P3 system primarily consists of a wearable audio and movement recorder and a smartphone app for the patient.
9662286|NCT04859972||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County between 2015- 2019, identified by ICD-code K.58.
9662287|NCT04859465|Experimental|Abraxane combined with liposomal doxorubicin|Abraxane combined with liposomal doxorubicin in the treatment of advanced or unresectable angiosarcoma
9662290|NCT04847362|Experimental|Experimental|The mothers in this group will be given telehealth training for 4 weeks.
9662291|NCT04847362|No Intervention|Control|Mothers in this group will not be given telehealth education, they will receive care within the scope of routine care.
9662292|NCT04841070|Experimental|Persistent pulmonary hypertension of the newborn.|Children aged 1 to 5 years who have been hospitalized in pediatric resuscitation service for the treatment of persistent pulmonary hypertension of the newborn.
9662293|NCT04839029|Experimental|Bipolar En bloc TURBT|patient subjected to bipolar Needlescopic En bloc resection of NMIBC
9662294|NCT04839029|Active Comparator|Monopolar En bloc TURBT|patient subjected to Monopolar Needlescopic En bloc resection of NMIBC
9662295|NCT04830774|Other|COVID-19 patients with new-onset AF|Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.
9662296|NCT04829656||Clinical Cohort|Enrolled via the 5 participating clinics at LBDA Research Centers of Excellence.
9662297|NCT04829656||Virtual Cohort|Enrolled via the LBDA.
9662298|NCT04827758|Other|Patients hospitalized in the follow-up care and rehabilitation units|
9662299|NCT04822740|Experimental|Novel strategy|"Inserting the CGMS device with use of the results of the device in real time by the health care team~Insulin infusion according to the same local guidelines for insulin therapy in ACS~Transmission of real-time data to the nurse and use of the alarms of the device~Adaptation of insulin according to blood glucose measured by the CGMS device and according to the same protocol as the conventional arm~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
9662300|NCT04822740|Active Comparator|Conventional strategy|"Inserting the CGMS device without the use of the results by the health care team: blinded CGMS (use of these results only at the end of the participation to analyze the main criterion)~Insulin infusion according to the same local guidelines for insulin therapy in ACS~Adaptation of insulin according to the capillary blood glucose levels performed every hourly if insulin dose change, every 2 hours if stable insulin dose according to local recommendations~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
9662301|NCT04814901|Experimental|Study group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae using FAMM and assessment of success regarding patient satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection.
9662302|NCT04814901|Active Comparator|Comparator group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae and its effect on patient's satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection
9662303|NCT04794218|Experimental|Study Group 1|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^4 or Placebo
9662304|NCT04794218|Experimental|Study Group 2|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
9662305|NCT04794218|Experimental|Study Group 3|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
9670759|NCT05057767|Placebo Comparator|Control Group (III)|will receive 3 ml normal saline 15 minutes before induction of anesthesia plus 3 ml normal saline 30 minutes before extubation at the end of surgery.
9972742|NCT01323569|Experimental|Sativex 4 sprays|
9972743|NCT01323569|Experimental|Sativex 8 sprays|
9972744|NCT01323569|Experimental|Sativex 16 sprays|
9972745|NCT01323569|Active Comparator|Marinol low dose|
9972746|NCT01323569|Active Comparator|Marinol high dose|
9972747|NCT01323608|Placebo Comparator|Placebo|
9972748|NCT01323608|Experimental|Low Vitamin D Group|Subjects in this group will receive the equivalent of 400 IU/day.
10154436|NCT04055194|Active Comparator|Tranexamic acid group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
9662306|NCT04794218|Experimental|Study Group 4|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
9662307|NCT04794218|Experimental|Study Group 5|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^5 or Placebo
9662308|NCT04794218|Experimental|Study Group 6|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^6 or Placebo
9662309|NCT04794218|Experimental|Study Group 7|rVSV∆G-LASV-GPC Vaccine Dosage (pfu) intramuscularly Day 1 2 X 10^7 or Placebo
9662310|NCT04793334||Obese + OSA|"Inclusion Criteria:~Men and women~Ages >= 30-65 years old~BMI 35-40 kg/m2~Scheduled for sleeve gastrectomy (bariatric surgery)~OSA identified by PSG~Exclusion Criteria:~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~Pregnancy~Currently smoking~Any respiratory disorder other than OSA or well controlled asthma~contraindication to MRI"
9662311|NCT04793334||Obese without OSA|"Inclusion Criteria:~Men and women~Ages >= 30-65 years old~BMI 35-40 kg/m2~Scheduled for sleeve gastrectomy (bariatric surgery)~No OSA identified by PSG~Exclusion Criteria:~Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.~Pregnancy~Currently smoking~Any respiratory disorder other than OSA or well controlled asthma~contraindication to MRI"
9662312|NCT04777708|Experimental|Treatment (pembrolizumab, BO-112)|Patients receive pembrolizumab IV over 30 minutes on day 1 of odd number cycles. Patients also receive BO-112 by intratumoral injection on day 1, 8, and 15 of cycle 1, and day 15 of subsequent cycles. Treatment repeats every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
9662313|NCT04777461|Experimental|Group 1|Pilot the structured education in women with PCOS
9662314|NCT04766879|Experimental|Spatial Repellent|Transfluthrin
9662315|NCT04766879|Placebo Comparator|Placebo|Inert ingredients
9662316|NCT04759014||Group 1|21 patients using non-articulated dynamic foot (non-articulating ankle, NAA)
9662317|NCT04759014||Group 2|21 patients using dynamic foot with hydraulic ankle (articulating hydraulic ankle, AHA)
9662318|NCT04752358|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
9662319|NCT04746105|Experimental|TS-142|Period in which subjects received TS-142 10 mg or The night when subjects received TS-142
9662320|NCT04746105|Experimental|Placebo|Period in which subjects received placebo or The night when subjects received matched placebo
9662321|NCT04743206|Experimental|PIAPD-Portable Internal Airway Percussion device|There will be an Inpatient Arm and Outpatient Arm using the Smart One® portable home spirometer
9662322|NCT04743206|Active Comparator|SACD-Standard Airway Clearance device|"There will be an Inpatient Arm and Outpatient Arm using the SACD.~A large majority of patients will be using VEST therapy as their standard of care airway clearance. A few might be using an Intrapulmonary Percussion Device that uses a mechanism different from the device the study will be testing."
9662323|NCT04703816|Experimental|Intervention arm|Physicians in the intervention arm will receive the training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations.
9662324|NCT04703816|No Intervention|Control arm|Physicians in the control group will not receive any specific intervention at this stage.
9662325|NCT04691999|Experimental|Intermittent Fasting|All participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week.
9662326|NCT04691505||Methotrexate|Reference group
9662327|NCT04691505||Hydroxychloroquine|Exposure group
9662330|NCT04678401|Experimental|IS-FREE TREG CRAFT_ENGINEERED HaploHCT|"After meeting eligibility criteria and being enrolled, patients will receive:~Day -15 to -6 prior to hematopoietic stem cell transplant (HSCT), preparatory regimen of radiation and chemotherapy: Total Myeloid and Lymphoid Irradiation (TMLI): Days -15 to -11 prior to HSCT; - Chemotherapy (infusion): Day -10 to day -6 prior to HSCT: Fludarabine (all days), Thiotepa (days -10 and -9) and Cyclophosphamide and Mesna (days -8 and -7)~Day -4 prior to (HSCT), a Treg-enriched donor cell infusion and graft vs host disease (GVHD) assessment~Day -1 prior to (HSCT), a unmodified donor T Cell infusion and (GVHD) assessment~Day of (day 0) (HSCT), CD34+ Haplo Peripheral Blood Stem Cell Infusion/Transplant and (GVHD) assessment~Days 30, 60,100, 180, 365 post hematopoietic stem cell transplant (HSCT), participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD)"
9662331|NCT04653363||1|study1 is the patients who will be assessed by first rater.
9662332|NCT04653363||2|study2 is the patients who will be assessed by second rater.
9662333|NCT04653363||3|Theh are healty peers control patients who will be assessed by first rater.
9662334|NCT04644783|Experimental|Blood test with assays|Ten patients with FPIES exhibiting reactions to 2-3 foods, and up to 10 exhibiting FPIES reactions to 4 or more foods will be recruited.
9662335|NCT04642274|Experimental|ERAS|
9662336|NCT04642274|No Intervention|Control|
9662337|NCT04635826|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
9662338|NCT04635826|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo
9662339|NCT04635826|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
9662340|NCT04635826|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall
9670760|NCT05057754|Experimental|Experimental Group|A total of 50 participants are estimated to be recruited, each completing six conditions in the following order: 1) wrist cooling, 2) wrist heating, 3) exercising, 4) typing, 5) using a mouse, 6) cooking, with an observation of intraneural blood flow assessed with Doppler sonography before and after each condition.
9670761|NCT05058118|Experimental|FL058|a single ascending dose (SAD) of intravenous (IV) FL058(50mg~2000mg)
9670762|NCT05058118|Placebo Comparator|Placebo|FL058 Placebo
9670763|NCT05058170||Renal transplant patients|
9670764|NCT05058079|Active Comparator|Hand-held group|Patients hand will be held by the anesthesia provider during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will have their hand under the folded blanket holding the patient's hand.
9670765|NCT05058079|No Intervention|No hand holding group|No physical contact for comfort or reassurance during the procedure. A folded blanket will be over the patient's hand during the procedure and the anesthesia provider will be next to the patient's hand.
9670766|NCT05057780|Experimental|Intervention Curriculum|The intervention course consisted of 3 hour-long sessions on communication delivered over a 4-month period. It differed from the control course in subject matter and pedagogy. Subject matter focused on specific skills used in communication: reflective listening, responding to emotion, and providing information within a broad range of communication scenarios. In terms of pedagogy, the intervention course was interactive with a focus on skills practice, communication drills, and improvisation to engage learners. The sessions consisted of fifteen minutes of lecture and 45 minutes of skills practice.
9670767|NCT05057780|Active Comparator|Control (Standard) Curriculum|The control course consisted of three hour-long didactic lectures on delivering bad news, discussing prognosis, and talking to patients about pain. The majority of time in these lectures was spent on didactic material. Little, if any, time was spent practicing skills or on interactive skill building. The three parts of the course were delivered over a 4-month period.
9670768|NCT05057793|No Intervention|Standard of care|Multilayer, multicomponent compression intended for the treatment of VLU
9670769|NCT05057793|Active Comparator|Standard of care + geko 12h|Multilayer multicomponent compression intended for the treatment of VLU in conjuction with geko™ therapy 12 hours daily
9670770|NCT05057845|Experimental|Cryoablation in combination with Tislelizumab plus lenvatinib|
9670771|NCT05057598|Experimental|Intervention group on diet and lifestyles|The arm consists to provide survivors with evidence-based recommendations and to promote improved nutrition and physical activity through videos and lectures available on the website (theoretical lectures on preventive strategies, and practical videos on cooking techniques and specific physical exercises).
9670772|NCT05057663|Active Comparator|Bleomycin group|
9670773|NCT05057663|Active Comparator|5-Fluorouracil group|
9670774|NCT05057611|Active Comparator|Usual Care Group (UC)|- Patients allocated to the usual care group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP >65 mmHg, HR (heart rate) <120 beats per minute (BPM), arterial oxygen saturation (SaO2) >94%, Hb > 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
9670775|NCT05057611|Experimental|Capillary-refill time and phenotyping group|"Patients w/normal baseline CRT will be periodically monitored. Patients with abnormal CRT and septic shock will be categorized according to pulse pressure (PP). If <40 mmHg, will go to fluid responsiveness (FR) assessment. FR (-) patients will undergo cardiac echo to rule out significant dysfunction. Fluid boluses will be administered in 30 min intervals and repeated as needed if CRT is still abnormal. Patients with PP ≥40 mmHg will proceed according to diastolic pressure (DAP). If ≥50 mmHg will move to FR assessment. If <50 mmHg NE will be increased for MAP >65 mmHg and DAP ≥50 mmHg w/CRT assessed 1 h after. NE will be increased in 0.1 mcg/k/m increments up to 0.5 mcg/k/m.~If CRT is normal, patients will proceed to periodic monitoring. Patients with persistent abnormal CRT or that reached NE safety limit will proceed directly to echo.~Patients that correct CRT with first tier interventions will not be subjected to obligatory echo but will just proceed to periodic monitoring."
9670776|NCT05057325|Experimental|Wave One Gold|Receporcating single file used for preparation of root canals in primary molars
9670777|NCT05057325|Experimental|One shape|Rotation single file used for preparation of root canals in primary molars
9670778|NCT05057260||Long Covid cohort|Long Covid patients managed in the 10 participating sites
9670779|NCT05057234|Experimental|Simultaneous - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx while tissued-based NGS panel is in progress
9972749|NCT01323608|Experimental|Intermediate Vitamin D group|
10154437|NCT04055194|Placebo Comparator|Placebo group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
10154438|NCT04055181|Active Comparator|rTMS in schizophrenia patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
10154439|NCT04055181|Sham Comparator|rTMS in schizophrenia Controls|In sham rTMS, all procedures were identical to 10Hz Schizophrenia group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
10154440|NCT04055181|Active Comparator|rTMS in major depressive disorders patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
9670780|NCT05057234|Experimental|Simultaneous - no additional testing|Patients undergoing no additional testing while tissue-based NGS panel is in progress
9972750|NCT01323608|Experimental|High Vitamin D Group|
9972751|NCT01323686|Experimental|Imaging guided LV lead placement|
10154441|NCT04055181|Sham Comparator|rTMS in major depressive disorders controls|In sham rTMS, all procedures were identical to 10Hz depression group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
10154442|NCT04054934||Normal Circardian rhythm|Regular night sleep, with at least 7 hours length of sleep.
9670781|NCT05057234|Experimental|Sequential - FoundationOne liquid CDx|Patients undergoing FoundationOne liquid CDx if standard tissue based NGS oncopanel testing identifies no somatic tier 1 variant of strong clinical significance
9670782|NCT05057377||Post-TBI Participants|Over a 2-day period post-TBI adults age 18 years and older, will undergo overground assessments with a questionnaire regarding motivation during day 1, followed by robotic safety-environment assessments during day 2.
9670783|NCT05057650|Experimental|Intervention|Vegan food for 5 weeks: approximately 50 participants volunteered for the intervention.
9670784|NCT05057637||Complete cohort|In all patients included in the study subsequent optical coherence tomography (OCT) measurements will be performed pre and post stent placement.
9670785|NCT05057299||Patients with extramedullary leukemia(eAML) with myeloid neoplasms|
9670786|NCT05057455||ICU patients diagnosed with sepsis or septic shock|compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
9670787|NCT05057286|Experimental|Subjects with gummy smile|The study procedure consisted of recruitment, pre&post-operative photography, gingivoplasty, BTX-A injection, recall visits, and data collecting.
9670788|NCT05057338|Experimental|CoreDISTparticipation|"a) at the MS-OP clinic, in addition to the regular consultations, the patient will have a structured digital conversation with the MS-nurse addressing work related issues and a session with a physiotherapist exploring possibilities for change in balance and walking; b) in the municipality, a physiotherapist will continue exploration of improvements, followed by four weeks of GroupCoreDIST focusing on balance, walking and physical activity and conducted in groups of 3-5 individuals with MS and led by a physiotherapist.~To promote participation in employment, a structured digital meeting between each patient, the MS-nurse, the patient's employer, and the physiotherapist will take place; followed by c) four weeks of outdoor group based exercises and physical activity led by a physiotherapist, complemented with an evaluation form regarding employment and physical activity."
9670789|NCT05057338|Active Comparator|Standard care|The control group will receive the usual consultations at the MS-OP clinic including exploration of possibilities for change in balance and walking together with physiotherapist at the MS-OP clinic. The control group will furthermore follow standard care (their usual follow-up) in the municipality.
9670790|NCT05057351|Experimental|Active ingredient|Isopentenyltheophylline 0.44% + Glycerin 4.56%
9670791|NCT05057351|Placebo Comparator|Placebo|Glycerin 4.56%
9670792|NCT05057507||Atrial fibrillation patients undergoing radiofrequency catheter ablation|Up to 115 patients undergoing radiofrequency catheter ablation will be enrolled.
9670793|NCT05057104||CK-SBRT with TACE group|
9670794|NCT05057104||Conversion hepatectomy after CK-SBRT plus TACE|
9670795|NCT05057065||Hyperlipidemia|"HBsAg(+) patients~TC>5.17mmol/L（200mg/dl）and（or）TG>2.3mmol/L（200mg/dl）"
9670796|NCT05057065||diabetes|"HBsAg(+) patients~FPG>126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h."
9670797|NCT05057065||CHB without metabolic disease|"HBsAg(+) patients~without diabetes/ obesity/hyperlipidemia"
9670798|NCT05057156|Experimental|"application supervised by a psychologist via teleconsultations"|patient have app, and teleconsultation with psychologist
9670799|NCT05057156|Placebo Comparator|"application in total autonomy"|patients have app, they play when they want
9670800|NCT05057156|No Intervention|"control group without using the application"|patients haven't app
10154443|NCT04054934||Reversed circadian rhythm|Night/day circadian clock is opposite, with at least 7 hours length of sleep
10154444|NCT04055259|Experimental|mobile Health and Wellness Coaching|
10154445|NCT04055259|Active Comparator|Usual Care|
9670801|NCT05057208||Vaccinated|COVID Vaccinated
9670802|NCT05057208||Non-vaccinated|COVID Non-vaccinated
9670803|NCT05057078|Experimental|Intervention group|A mindfulness-based stress reduction program will be done once a week for eight weeks
9670804|NCT05057078|No Intervention|Control group|During study process, no application will be made to the control group.
9670805|NCT05056844|Experimental|Diagnostic (CESM, DBT)|Patients receive iodine-based contrast agent IV then undergo CESM over 10-15 minutes. Patients who have not undergone standard of care DBT within 3 months from the study, also undergo DBT.
9670806|NCT05056805|Active Comparator|Arm A (aerobic exercise, nutritional recommendation)|Patients are encouraged to complete at least 30 minutes of moderate intensity aerobic exercise, at least 3 times per week. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Aerobic exercises and nutrition are tracked in the Pt Pal app
9670807|NCT05056805|Experimental|Arm B (aerobic, strength exercise, nutritional recommendation)|Patients complete at least 30 minutes of moderate intensity aerobic exercise (such as brisk walking or stationary bike cycling) at least 3 times per week. Patients also complete strength exercises with resistance tubes/bands at least 2 times per week, with at least 2 sets of 8-15 repetitions of the exercises taught. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Patients also consume a high protein snack/meal/shake (15-25 grams) within 1 hour after any strengthening exercises. Exercise activities and nutrition are tracked in the Pt Pal app.
9670808|NCT05056831|Other|In-Depth Interviews-First|The first interviews with health care providers and clinical stakeholders
10154446|NCT04055090||Subjects who received VM202|
10154447|NCT04055090||Subjects who received Placebo|
10154448|NCT04055129||Birth Control|Hormone levels controlled with subject on birth control pill
10154449|NCT04055129||Non-Birth Control|Hormone (estrogen) levels not controlled but monitored for levels of estrogen at two points in menstrual cycle (Follicular and ovulatory phases)
10154450|NCT04055077|Active Comparator|ASA I/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
10154451|NCT04055077|Active Comparator|ASA II/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
10154452|NCT04055077|Active Comparator|ASA III/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
10154453|NCT04055077|Experimental|ASA I/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
10154454|NCT04055077|Experimental|ASA II/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
10154455|NCT04055077|Experimental|ASA III/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
9670809|NCT05056831|Other|In Depth Interviews-Second|The second interview guide for interviews with rural cancer survivors
9670810|NCT05056948||Control|Original 3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria
9670811|NCT05056948||Test|"3D maxillary teeth model from subjects who fulfill inclusion/exclusion criteria.~The right first molar (FDI number 16) will be removed in the computer and then designed by artificial intelligence (AI) system~AI system will be trained by~different algorithms such as Group 1) Voxel-based; Group 2) View-based; Group 3) Point-based; and Group 4) Fusion methods~Group i) maxillary model only and Group ii) with antagonist model"
9670812|NCT05056935|Experimental|LB1148|active
9670813|NCT05056935|Placebo Comparator|Placebo|placebo
9670814|NCT05056792|Experimental|Participants in this group will receive NMES guided strength training.|NMES guided strength training of the quadriceps femoris muscle for 8 weeks.
9670815|NCT05056792|Sham Comparator|Participants in this group will receive Sham NMES.|Participants in this group will receive Sham NMES guided strength training of the quadriceps femoris muscle for 8 weeks.
9670816|NCT05057039||hypertensive group|SBP >=140mmHg, DBP >=90mmHg, or use of antihypertensive drug
9670817|NCT05057039||normotensive group|SBP <=140mmHg and DBP <=90mmHg without use of antihypertensive drug
9670818|NCT05056909|Active Comparator|Standard of care|CKD care, as routinely provided in the respective nephrology outpatient clinic.
9670819|NCT05056909|Experimental|Intervention|standard of care + Kidney ACTion AI-supported software for chronic kidney disease care.
9670820|NCT05057052|Experimental|Cryoablation in combination with Sintilimab plus regorafenib|
9670821|NCT05056961|Other|Large tidal volumes without respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, without respiratory distress symptoms
9670822|NCT05056961|Other|Large tidal volumes with respiratory distress symptoms|Large tidal volumes (> 10 mL.kg-1 of predicted body weight) despite low pressure support, with respiratory distress symptoms (for example, supra-clavicular and thoracic-abdominal asynchronies...)
9670823|NCT05056701|Experimental|patient with preeclampsia|Patient meeting preeclampsia criteria according to International Society for the Study of Hypertension in Pregnancy (ISSHP) 2018 definitions
9670824|NCT05056688|Experimental|Application of training set to experimental group|Testicular Model BSE/TSE Training Set
9670825|NCT05056688|No Intervention|Control Group|
9670826|NCT05056662||Group 1|Patients with negative invasive functional evaluation
9670827|NCT05056662||Group 2|Patients with positive invasive functional evaluation undergoing PCI
9670828|NCT05056662||Group 3|Patients with positive invasive functional evaluation undergoing PCI and subsequent retest of functional indexes
9670829|NCT05056675|Experimental|PENG block for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of 0.5% ropivacaine iv is injected.
9670830|NCT05056675|Placebo Comparator|Placebo for anterior total hip arthroplasty or surgical hip dislocation|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating theatre, routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance, 20 mL of NaCL 0.9% is injected.
9670831|NCT05056649||Heart Failure Patients with impaired ejection fraction|
9670832|NCT05056740||MS|Patients with a definite MS diagnosis according to the 2017 McDonald criteria
9670833|NCT05056740||Red-flag MS|Patients presenting with clinical, radiological or biological red flags for MS diagnosis who will be ultimately diagnosed as having MS
9670834|NCT05056740||Other CNS autoimmune diseases|Patients with a definite diagnostic of CNS autoimmune disease that is not MS
9670835|NCT05056740||Controls|Patients with a definite diagnostic of non-inflammatory CNS disorder
9670836|NCT05056896|Experimental|Low Dose Aspirin|Participants will be randomly assigned to aspirin group and receive a daily low dose aspirin (81 mg) for the duration of the study up to 12 weeks.
9670837|NCT05056896|Experimental|Placebo|Participants will be randomly assigned to placebo group and receive a daily placebo capsule for the duration of the study up to 12 weeks.
9670838|NCT05056558|Experimental|Baricitinib|Continued SOC together with oral 4 mg Baricitinib from day 1 to day 14
9670839|NCT05056558|Placebo Comparator|Placebo|Continued SOC according as mentioned in operational definition in the protocol
9670840|NCT05056493|Experimental|Clinical Providers|Clinical provider site champions will be invited to participate in web-based quantitative surveys and a semi-structured interview
9670841|NCT05056493|Experimental|Parent/Caregivers|Patient and parent/caregiver subjects from the participating clinic sites will be enrolled. These participants are all adults - parents or caregivers of children and youth with special health care needs (CYSHCN) and adult patients with multiple chronic conditions (MCC) who are already receiving care at Duke Health.
9694758|NCT04785313||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) placed because of temporary contraindication to curative anticoagulation and that was been removed by the radiology department at the University Hospital of Saint-Etienne, between January 1, 2010 and December 31, 2014. All the Inferior Vena Cava Filters (IVCF) were been sent for histological examination.
9694759|NCT04785482||Parents of infants with single ventricle heart disease|All participants
9694760|NCT04785495||Cancer Patients Exposed to Highly Emetogenic Chemotherapy|Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis.
9694761|NCT04785612|Experimental|RSVPreF|A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume
9694762|NCT04785612|Placebo Comparator|Placebo|A single intramuscular injection of Placebo to match active vaccine
9694763|NCT04785404|Experimental|primary skin closure|in this group, skin wound will be primarily closed
9694764|NCT04785404|No Intervention|secondary skin closure|skin will be left open to heal by secondary intention
9694765|NCT04785196|Experimental|APG-115+Toripalimab|
9694766|NCT04785274||SpHb|
9694767|NCT04785274||Control|
9670842|NCT05056480||Parents/caregivers|Parents/caregivers of children <20 years old who received interdisciplinary care coordination within the Pediatric Complex Care Integration (PCCI) program
9670843|NCT05056480||Clinical staff|PCCI care management staff participating in implementation of the PCCI program
9670844|NCT05056571|Experimental|Relaxation exercise|Intensive care nurses will apply 20 minutes of online (zoom meeting) progressive muscle relaxation exercise twice a week, for 8 weeks, for a total of 16 group sessions. In order to support nurses' adaptation to the research, the group counselor will remind the nurses by phone twice a week during the implementation process, and their regular participation in online sessions will be supported.
9670845|NCT05056571|No Intervention|Control|No attempt will be made during the research.
9670846|NCT05056623|Experimental|Dyadic pain management program|The DPM is an 8-week group-based program. The DPM included 4 weeks of center-based, face-to-face activities and 4 weeks digital-based activities delivered via a WhatsApp group.
9670847|NCT05056623|Other|Usual care and pain management pamphlet|The participants in the control group will receive the usual care and a pain management pamphlet.
9670848|NCT05056285||Down syndrome less than four years Group|
9670849|NCT05056610|Experimental|Patients with IBS or FI|Food antigens are added to duodenal mucosa during CLE
9670850|NCT05056610|Experimental|healthy controls|Food antigens are added to duodenal mucosa during CLE
9670851|NCT05056389|Experimental|NIPEX-OXA arm|20 patients treated with NIPEC-OXA after CRS and HIPEC.
9670852|NCT05056181|Experimental|PAI|Participants assigned to the PAI arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will receive conventional medical treatment. They will also participate in 2 weeks of training (12 sessions), plus telematic assistance of a specialized practitioner who will follow them during the post-discharge training sessions for a period of 12 weeks, with 3 workouts per week.
9670853|NCT05056181|No Intervention|TAU|Participants assigned to the TAU arm will receive brief information on the benefits of being more active and will be given information about the best way to training. They will also receive conventional medical treatment.
9670854|NCT05056402|Experimental|9-17y (0,6m)|Subjects who aged 9-17 years old would receive 2 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
9670855|NCT05056402|Experimental|9-17y (0,1,6m)|Subjects who aged 9-17 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
9670856|NCT05056402|Experimental|18-26y (0,1,6m)|Subjects who aged 18-26 years old would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
9670857|NCT05056142|Active Comparator|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL
9670858|NCT05056142|Active Comparator|Spinal Anesthesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
9670859|NCT05056194|Experimental|Valiloxybate|XW10172 Modified Release (MR) Granules for Oral Suspension
9670860|NCT05056194|Placebo Comparator|Placebo|Placebo Granules for Oral Suspension
9670861|NCT05056311|Experimental|Parent Utilization of Decision Aid Website|All enrolled parents will view the decision aid website for as long and as frequently as they wish before the initial visit to the urologist.
9670862|NCT05056415|Active Comparator|Treatment as Usual (TAU)|"In the involved municipalities, TAU mainly consists of short-term efforts, such as Occupational Therapist (OT) prescribing technical aids, often initiated by the housing staff (HS). Daily support provided by HS varies, depending on the approach and commitment of individual staff and the norms that prevail in different housing units, as well as variations between municipalities. Co-planning on long-term rehabilitation efforts does not exist or is weak, and collaboration between OT and HS is, as described by staff from both parties, difficult to achieve.~After a control-period of 6 month, house facilities within the TAU-group will also be offered ELR."
9670863|NCT05056415|Experimental|Everyday Life Rehabilitation (ELR) plus TAU|"ELR is a model for long-term, outreach, and personalized rehabilitation for persons with SPD living in sheltered or supported housing facilities, in close collaboration between resident, OT, and HS.~ELR includes personcentred, motivational-, recovery- and activity-based methods, built on certain process steps. The focus is to promote personal recovery, while targeting meaningful daily activities, through person-driven goals, negotiated expectations, exploration and activity-training in real-life situations, and a maintenance phase. ELR includes a web-based educational package, and devices for reflective collaborative learning.~ELR consists of a weekly session with an OT, followed by regular collaboration with HS, who support the resident on a daily basis, in line with guidance given by the OT and input shared from the HS. The intervention period will last for 6 months.~Prior to the intervention, OT, HS, and HM will partake in web-based training, with associated manuals, and tools."
9670864|NCT05056454|No Intervention|Treatment as usual (TAU, a.k.a. Perinatal Psychiatric Care)|This treatment condition is modelled after the psychiatry-delivered treatment usually provided at the Maternal Outpatient Mental Health Services (MOMS) Clinic associated with the UCLA Westwood OB-GYN Clinic and Department of Psychiatry.
9670865|NCT05056454|Experimental|Screening and Treatment of Anxiety and Depression (STAND)|This treatment condition provides access to a system of care, in which type of treatment is allocated based on presenting symptomatology. Participants will learn their allocation from study staff or participants will create a secure account through STAND to learn about their allocation through the STAND online dashboard. Through their STAND online dashboard, they could also have access to a) their CAT-MH results over time from the start of treatment, b) assessment of their current diet/nutrition and psychoeducation about the relationship between diet/nutrition and mental health, and c) list of additional resources available to them.
9670866|NCT05056428|Experimental|Intervention group|8-week mindfulness program
9670867|NCT05056428|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after experimental group completed the intervention.
9670868|NCT05056519|Experimental|Experimental group|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine
10154456|NCT04055168|Experimental|Cohort 1 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
10154457|NCT04055168|Experimental|Cohort 2 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
10154458|NCT04055168|Experimental|Cohort 3 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 3 of AZD6615 (6 subjects) or matching placebo (2 subjects).
9670869|NCT05056519|Placebo Comparator|Placebo group|Healthy people in placebo group will receive a dose of placebo
9670870|NCT05056597||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
9670871|NCT05056597||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype
9670872|NCT05056597||BN|Participants that meet DSM-V criteria for Bulimia Nervosa.
9670873|NCT05056597||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
9670874|NCT05056337|Experimental|Treatment group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with lenvatinib(8mg/d for BW<60kg and 12mg for BW≥60kg) in combination with toripalimab(240mg iv Q3W) and TACE (on demand). Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the conversion resection rate will be calculated, and patient survival will be assessed.
9670875|NCT05056337|Active Comparator|Control group|Patients with potentially resectable HCC who meet the study inclusion criteria will be treated with TACE alone. Tumor response will be regularly evaluated, data will be collected, and complete surgical resection will be evaluated by an independent review committee, the translational resection rate will be calculated, and patient survival will be assessed.
9670876|NCT05056467|Experimental|IOL|Preeclampsia High-risk Women schedule labor induction at 39 weeks of gestation
9670877|NCT05056467|No Intervention|Expectant Management|Preeclampsia High-risk Women under expectant management
9670878|NCT05056220|Active Comparator|High expected effect: Human Albumin 20% + Standard Medical Treatment|
9670879|NCT05056220|Placebo Comparator|High expected effect: NaCl 0.9% + Standard Medical Treatment|
9670880|NCT05056220|Active Comparator|Low expected effect: Human Albumin 20% + Standard Medical Treatment|
9670881|NCT05056220|Placebo Comparator|Low expected effect: NaCl 0.9% + Standard Medical Treatment|
9670882|NCT05056051|Active Comparator|Post-EET Surveillance Group: WATS-3D samples followed by Forceps biopsies|Sampling will occur with WATS-3D followed by forceps biopsies. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
9670883|NCT05056051|Active Comparator|Post-EET Surveillance Group: Forceps biopsies followed by WATS-3D samples|Sampling will occur with forceps biopsies followed by WATS-3D. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
9670884|NCT05056038|Active Comparator|Lateral Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
9670885|NCT05056038|Active Comparator|Posterior Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the posterior border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bıçakçılar Cooperation, Istanbul, Turkey) according to age and body weight.
9670886|NCT05055804|Experimental|ELG Device Comparison to Whole Blood Testing|Participant will place thumb in the ELG device for scan. Scan generally takes between 1-2 minutes. ELG then displays a readout of both a glucose and A1C reading on the screen of the ELG device.
9670887|NCT05055674|Experimental|Motherly App|Participants in this arm will have access to Motherly, a smartphone app that is designed to promote life habits that have been shown to improve depression and mental health in mothers.
9670888|NCT05055674|Active Comparator|COMVC App|Participants in this arm will have access to COMVC, a smartphone app designed to deliver only psychoeducational content and mental health monitoring.
9670889|NCT05055700|Experimental|Intervention group|This arm will review a mobile app to learn information about prenatal genetic testing before their appointment with maternal-fetal medicine specialists.
9670890|NCT05055700|No Intervention|Control group|This arm will only receive usual care - visit maternal-fetal medicine specialists.
9670891|NCT05055687|Experimental|Part A：FL058|a single ascending dose (SAD) of intravenous (IV) FL058(2500mg~3000mg)
9670892|NCT05055687|Placebo Comparator|Part A：Placebo|FL058 Placebo
9670893|NCT05055687|Experimental|Part B：FL058|a multiple ascending dose (MAD) of intravenous (IV) FL058(500mg~2000mg)
9670894|NCT05055687|Placebo Comparator|Part B：Placebo|FL058 Placebo
9670895|NCT05055648|Active Comparator|Photon Arm|Standard arm with neoadjuvant chemoradiotherapy (nCXT) with photons
9670896|NCT05055648|Experimental|Proton Arm|Experimental arm with neoadjuvant chemoradiotherapy (nCPT) with protons
9972752|NCT01323686|No Intervention|Empiric LV lead placement|LV lead placement using standard clinical routine.
9694768|NCT04785183|Experimental|Melatonin Group|
9694769|NCT04785183|Placebo Comparator|Control Group|
9670899|NCT05056025|Experimental|postbiotics with vitamins|postbiotics (IGENH35.3A) with vitamins (AREDS formulation and recommended daily dose)
9670900|NCT05056025|Placebo Comparator|vitamins|vitamins (AREDS formulation and recommended daily dose)
9670901|NCT05055739|Experimental|SW|Patients undergoing sternal closure with steel wires
9670902|NCT05055739|Experimental|RP|Patients undergoing sternal closure with a rigid plate
9670903|NCT05055882||children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
9670904|NCT05055791|Experimental|Arm 1|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
9670905|NCT05055791|Experimental|Arm 2|Cohort 1-3 dose level 1-3 in subjects with relapsed or refractory haematological malignancies including AML/ALL/CMML/CLL.
9670906|NCT05055817||bloody stool group|bloody stool appear in the hospitalized neonate
9670907|NCT05055817||non-bloody stool group|bloody stool do not appear in the hospitalized neonate
9670908|NCT05055895||early onset deliryum on dementia|It was earlier than The median time of onset of delirium superimposed dementia
9670909|NCT05055895||Delirium on dementia (normal)|It was equal or later than The median time of onset of delirium superimposed dementia
9670910|NCT05055609|Experimental|Open Label|In the dose escalation portion, it is estimated that approximately 12-24 subjects will be enrolled in four dose cohorts. The dose expansion portion will enroll 6-12 subjects.
9670911|NCT05055635|Experimental|Doseescalated pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day.
9670912|NCT05055583|Experimental|Toripalimab in Combination With Platinum-based Chemotherapy|Participants receive totally 3-4 cycles of toripalimab combined with platinum-based chemotherapy neoadjuvant treatment during preoperative period. After the last treatment (Day 21 of Cycle 4), surgery will be performed within 4-6 weeks. Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention was to receive maintenance therapy within 6-12 weeks of the MDT assessment.
9670913|NCT05055518|Experimental|A Phase I, open-labeled multicenter study|APL-102 Capsules
9670914|NCT05055557||ARDS group|"1.85 years≥Age≥18 years. 2.Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O).~3.Diagnosis of ARDS less than 72 hours. 4.Just observation"
9670915|NCT05055557||Critically ill patients without ARDS group|Unstable vital signs, rapid changes in the condition, unstable function of more than two organ systems (excluding the respiratory system), decline or failure, the development of the disease may endanger the life of the patient.
9670916|NCT05055557||healthy adult group|Healthy adults, voluntarily join the study.
9670917|NCT05055310||Normal elderly|normal cognitive group
9670918|NCT05055310||aMCI|amnestic mild cognitive impairment
9670919|NCT05055310||AD|Alzhiemer's disease
9670920|NCT05055414|Experimental|UI030|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
9670921|NCT05055414|Placebo Comparator|Placebo|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
9670922|NCT05055440||Mechanically ventilated patients with COVID-19 in the ICU|Mechanically ventilated patients with COVID-19 admitted to the intensive care unit using sedation and neuromuscular blocker
9670923|NCT05055141|Experimental|Care to Share Poster|"The intervention was an 18x18 poster board with a large blank surface for patients to share information about who they are as people and what is important to them. The Care to Share poster was co-designed with ten medicine inpatients during pilot testing. The goal of the poster was to equip Caregivers with humanizing information about their patients, thereby provoking more genuine empathetic interactions. Based on input from pilot testing, the researcher wrote on the poster for the patient to ensure ease of completion and legibility. The posters were displayed on the wall behind patients' beds, so Caregivers entering the room could easily see the information when facing the patient."
9670924|NCT05055141|No Intervention|Control|Study participants hospitalized on the two control units had no Care to Share poster.
9670925|NCT05055492|No Intervention|Control period|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
9670926|NCT05055492|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
9670927|NCT05055453|Experimental|Experimental Study Group|"It is a prospective study to investigate whether the MyPhonak Junior app can improve speech understanding in children with hearing aids, by evaluating the use of the volume, noise reduction and directional microphone using the MyPhonak Junior App.. The study is linked to randomized patient and test allocation carried out.~Introduction to the MyPhonak Junior app. There are measurements of speech understanding of sentences Carried out in background noise with the Oldenburg sentence test (OLSA). The language test is hard of hearing children and adolescents known from routine clinical practice. Various everyday situations / noise scenarios are played out. Questionnaire (E-HAK, also known from routine) and interview of the children regarding the use of the app in everyday life."
9670928|NCT05055544|Active Comparator|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A)
9670929|NCT05055544|Active Comparator|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
9670930|NCT05055505|No Intervention|control phase|Schools will start in the control phase (SARS-CoV-2 diagnostic testing at an assessment center, primary care office or acute care center) and transition to the intervention phase at a randomly assigned time point over the course of the study.
9972753|NCT01323699|Experimental|Behavioral Therapy|
9972754|NCT01323712|Placebo Comparator|Placebo|
9670931|NCT05055505|Active Comparator|Intervention phase|Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
9670932|NCT05055076||PODEYE TORIC|Adult patients who have undergone cataract surgery with mono- or bilateral implantation of POD EYE TORIC IOL (POD T 49P) and who meet all the inclusion and exclusion criteria will be invited to participate in the study.
9670933|NCT05055219||Group 1: Overweight or Obese Group (visits #1-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight. Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
9670934|NCT05055219||Group 2: Overweight or Obese Group (visits #3-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight, or children and young adults who previously participated in the study (completed visits #1-2 in previous study phase). Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
9670935|NCT05055219||Group 3: Normal Weight Control Group|Children and adolescents who are 8 to 17 years of age, who have do not have risk factors for diabetes such as being overweight or a history of type 2 diabetes in the family. Healthy weight, as defined by a BMI ≥ 5th percentile & < 85th percentile. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
9670936|NCT05055115|Experimental|Balloon Eustachian Tuboplasty|Patients with long-lasting symptoms of ETD, who benefits from tympanostomy tube insertion, will be offered Balloon Eustachian Tuboplasty (BET) of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
9670937|NCT05055245||Patients undergoing assisted reproductive technology|Patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
9670938|NCT05055349|Active Comparator|corneal collagen cross linking and intrastromal corneal keraring segments.|20 eyes will undergo corneal collagen cross linking (epithelium off) 1 month after Femtosecond laser assisted intrastromal corneal keraring segments
9670939|NCT05055349|Active Comparator|toric phakic posterior IOL implantation and corneal collagen cross linking|20 eyes will undergo toric phakic posterior IOL implantation 1 year after corneal collagen cross linking (epithelium off).
9670940|NCT05055284|Experimental|Experimental group|Experimental: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training along with patellar taping
9670941|NCT05055284|Sham Comparator|Control group|No Intervention: Control: Participants in this group will receive Sham EMG-BF guided strength training without patellar taping
9670942|NCT05055388||Group with sepsis complicated with multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with multidrug-resistant bacteria if microbial culture results showed multidrug-resistance.
9670943|NCT05055388||Group with sepsis complicated with none multidrug-resistant bacteria|Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with none multidrug-resistant bacteria if microbial culture results showed none-multidrug-resistance or no positive result of microbial culture.
9670944|NCT05055154|Experimental|Very low calorie diet|Use of very low calorie diet prepared in the hospital
9670945|NCT05055206|Experimental|Lymphatic drainage mapping in patients with oropharynx cancer|"Participants will be given 4 to 6 injections of the radiotracer 99m-Technetium Sulfur Colloid by a needle into one of the veins of the radiotracer around the tumour.~Participants will then have at least 1 or possibly 2 SPECT-CT scans (a special x-ray scan of the body from many angles that are turned into 3-dimensional pictures on a screen)."
9670946|NCT05055232|Experimental|XZP-3621|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
9670947|NCT05054868|Active Comparator|Group 1 (Control group) - Oxycodone only|Subjects randomized to this group will receive oxycodone for postop pain management (standard of care).
9670948|NCT05054868|Experimental|Group 2 (Treatment group) - Oxycodone and Ketorolac|Subjects randomized to this group will receive oxycodone and ketorolac for postop pain management.
9670949|NCT05054959|Experimental|consolidation chemotherapy|"chemoradiation: intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~6 cycles of CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1."
9670950|NCT05054959|Active Comparator|induction chemotherapy|"4 cycles of induction CAPOX chemotherapy. One cycle of CAPOX CT lasts 3 weeks and consists of capecitabine 1000 mg / m2 / 12h per os for 1-14 days and oxaliplatin 130 mg / m2 intravenously in a two-hour infusion on day 1.~Chemoradiation:intensity-modulated irradiation technique with simultaneous integrated boost to the tumor (IMRT-SIB) or with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (VMAT-SIB) to the total tumor dose of 46.2 Gy in T1-3 tumors and 48.4 Gy in T4 tumors in 22 fractions with concomitant CT with capecitabine (dosage: 825 mg / m2 / 12 h per os continuously from the first to the last day of irradiation).~2 cycles of consolidation CAPOX chemotherapy."
9670951|NCT05055167|Experimental|Envafolimab|Elderly NSCLC Patients with high PD-L1 expression
9670952|NCT05054998|Experimental|Diagnostic (fludeoxyglucose F-18, PET/MRI)|Patients receive fludeoxyglucose F-18 IV over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.
9826357|NCT02415842||DQIV_NAS Group|Subjects 18-≤39 years of age (in D-QIV cohort of primary completed study FLU D-QIV-015 (201251) (A/Christchurch/16/2010 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012, B/Brisbane/60/2008)) who were administered 15 µg HA (no AS) of each of 4 strains (total 60 µg HA) at Day 0.
9972755|NCT01323725|Experimental|Team-based financial incentives|Team-based financial incentives
9972756|NCT01323738|No Intervention|Treatment as Ususal|Patients participate in the Treatment as Usual including a non-specific information group.
9972757|NCT01323738|Experimental|Psychoeducation|Intervention group
9972758|NCT01323751|Experimental|Treat Regimen|ACY-1215 Bortezomib Dexamethasone
9972759|NCT01323764|Active Comparator|Radionuclide SPS|Radionuclide Shunt Patency Study
9972760|NCT01323816||Traditional|ICU staffed by a resident, pulmonary fellow and attending
9972761|NCT01323816||Non-Traditional|ICU staffed by Nurse Practitioners as the direct care deliverer, a pulmonary fellow, and an attending
9972762|NCT01323842||rule in renal colic|ED patients with abdominal/flank pain where a diagnosis of renal colic is being considered and undergoing formal imaging while in the ED
9972763|NCT01323881|Experimental|intermittent theta burst stimulation|
9972764|NCT01323881|Placebo Comparator|sham stimulation|
9977249|NCT01359553||Knee pain|Group with knee pain problems referred to an arthroscopy.
9977250|NCT01359579|Experimental|Subjects with mild renal impairment|
9977251|NCT01359579|Experimental|Subjects with moderate renal impairment|
9977252|NCT01359579|Experimental|Subjects with normal renal function|
9977253|NCT01359579|Experimental|Subjects with severe renal impairment|
9977254|NCT01359605|Experimental|varespladib methyl|
9977255|NCT01359618|Experimental|Part A 1|TC-5214
9977256|NCT01359618|Experimental|Part A 2|TC-5214 placebo
9977257|NCT01359618|Experimental|Part B 1|TC-5214 8 mg + moxifloxacin placebo
9977258|NCT01359618|Experimental|Part B 2|TC-5214 supratherapeutic dose + moxifloxacin placebo
9977259|NCT01359618|Active Comparator|Part B 3|TC-5214 placebo + moxifloxacin 400 mg
9977260|NCT01359618|Placebo Comparator|Part B 4|TC-5214 placebo + moxifloxacin placebo
9977261|NCT01359657|Experimental|Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone|
9977262|NCT01359657|Experimental|Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone|
9977263|NCT01359670|Experimental|Tadalafil|
9977264|NCT01359670|Experimental|Sildenafil|
10154459|NCT04055168|Experimental|Cohort 1 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
9977265|NCT01359683|Other|A|This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
9977266|NCT01359696|Experimental|A|
9977267|NCT01359709|Experimental|Contingency Management|
9977268|NCT01359709|Placebo Comparator|Noncontingent control|
9977269|NCT01359722|Experimental|N-Acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
9977270|NCT01359722|Placebo Comparator|Control|This group will receive only the infusion of saline in the same doses and infusion rate.
9977271|NCT01359761|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Post Admission Cognitive Therapy Individual Sessions; Up to Two (2) Inpatient Booster Sessions; Up to Four (4) Telephone Booster Sessions Following Psychiatric Discharge; 12-Months Case Management
9977272|NCT01359761|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services; 12-Months Case Management
9977273|NCT01359774|Other|Healthy volunteers|
9977274|NCT01359774|Other|Huntington patients|
9977275|NCT01359787|Active Comparator|Mapracorat 0.01% Ointment|Lowest concentration
9977276|NCT01359787|Active Comparator|Mapracorat 0.03% Ointment|Middle concentration
9977277|NCT01359787|Active Comparator|Mapracorat 0.1% Ointment|Highest concentration
9977278|NCT01359787|Placebo Comparator|Vehicle without active|
9977279|NCT01359800||Treatment-naive HIV+ subjects|
9977280|NCT01359800||HAART-treated HIV+ subjects|
9977281|NCT01359813|No Intervention|Usual treatment|intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
9977282|NCT01359813|Experimental|Human Albumin|1,5g/kg on first day and 1g/kg on third day.
9977283|NCT01359826|Experimental|Milnacipran|Patients administered milnacipran will receive a dose escalation to 50 mg twice a day over 12 days and continued at this dose until week 6. If tolerated and a 15% improvement in fatigue from baseline is achieved by assessment on the FSS, then patients will continue taking 50 mg twice a day until the end of the study on day 98 (week 14). Otherwise, the dose of milnacipran will be titrated upward to 100 mg twice a day over 12 days and continued at this dose until day 98 (week 14).
9977284|NCT01359826|Placebo Comparator|Placebo|Placebo tablets administered orally twice a day for 14 weeks.
9977285|NCT01359839|Experimental|Relaxation Response Mind Body Intervention|The Relaxation Response (RR) Mind Body Intervention Arm receives the Behavioral: Relaxation Response and Cognitive Behavioral Therapy Intervention which is a RR based Mind Body Group consisting of 1½ hour group classes held weekly for 8 weeks, in a conference room at the health center.
9977827|NCT01365637|Experimental|Cohort 1 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
9977828|NCT01365637|Experimental|Cohort 2 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
9670953|NCT05054972||A|Group of patients in whom the left renal vein was divided for exposure of the aorta.
9670954|NCT05054972||A+|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was present.
9972765|NCT01323907|Experimental|Omegaven|Omegaven IV lipid emulsion administration for infants with life threatening parenteral nutrition associated liver disease
9972766|NCT01323933|Experimental|AB0024|"The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK.~The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in <33% of patients enrolled from Part A."
9972767|NCT01323985|Experimental|GSK2315698|Intravenous infusion single dose
9972768|NCT01324011|Experimental|Family-based intervention|Special intervention (20 weekly group-based sessions) to be compared with a delayed intervention control group.
9972769|NCT01324011|Other|Delayed intervention controls|The delayed intervention controls will continue with usual care (if patients with diabetes)and at the end of the experimental period (6 months), they will receive a 6-session weight loss intervention delivered over a 2 month period.
9972770|NCT01324037|Experimental|clinically suspected upper extremity deep vein thrombosis|Patients with suspected upper extremity DVT
9972771|NCT01324050|Experimental|Internet-based Psychodynamic Therapy|
9972772|NCT01324050|Active Comparator|Internet-delivered therapist support|
9972773|NCT01324089|Active Comparator|Arm 1|Resveratrol 2.5 grams x 1 dose
9972774|NCT01324089|Experimental|Arm 2|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
9972775|NCT01324089|Other|Arm 3|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
9972776|NCT01324180|Experimental|VLPD Regimen|Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.
9972777|NCT01324193|Other|Pre-diaylsis patients|Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
9972778|NCT01324193|Other|Dialysis patients|Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
9972779|NCT01324219|Active Comparator|Staff|
9972780|NCT01324219|Experimental|Resident|
9972781|NCT01324245|Experimental|Enalapril|2.5 mg every 12 hours for two doses
9972782|NCT01324258|Experimental|GSK1120212|Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
9972783|NCT01324258|Experimental|GSK1120212+Gemcitabine|Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
9972784|NCT01324284|Experimental|Lubiprostone|Lubiprostone with PEG solution versus Placebo with PEG solution
9972785|NCT01324284|Placebo Comparator|lubiprostone versus placebo|
9670955|NCT05054972||A-|Subgroup of group A in whom a communicating vein to the left ascending lumbar vein was not present.
9670956|NCT05054972||B|Group of patients in whom the left renal vein was mobilized but not divided for exposure of the aorta.
9972786|NCT01324297||Healthy Control|Caucasian males and females between 19 and 30 years of age.
9972787|NCT01324297||First Episode Psychosis|Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.
9972788|NCT01324336||4-17 years, receiving 6-MP|
9972789|NCT01324362|Active Comparator|Fluticasone propionate|
9972790|NCT01324362|Active Comparator|Fluticasone propionate/salmeterol combination|
9972791|NCT01324375||THA (total hip arthroplasty)|Patients undergoing THA, preoperatively heat tested
10154460|NCT04055168|Experimental|Cohort 2 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
10154461|NCT04054908||Cohort A|Patients treated with oral fluoropyrimidine (Capecitabine (CAP)) as part of standard of care (SOC) chemotherapy
9670957|NCT05055180||HFpEF with pulmonary hypertension|Invasively diagnosed HFpEF and pulmonary hypertension according to current guidelines
9972792|NCT01324427|Experimental|virtual medical visit|"This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a virtual medical visit by patients and health care personnel. During this pilot trial we expect to perform 84 virtual medical visits using telemedicine."
9972793|NCT01324479|Experimental|INC280|
9972794|NCT01324492|Experimental|RAD001|
9972795|NCT01324505|Experimental|One-sequence cross-over arm|
9972796|NCT01324544|Experimental|Buprenorphine IV|Buprenorphine IV
9972797|NCT01324557|Experimental|CSII|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII)
9972798|NCT01324557|No Intervention|MDI|MDI: Control Optimized subcutaneous insulin by multiple daily injections (MDI)
9972799|NCT01324583|Experimental|Arm 1|"Patients will receive cabazitaxel as the dose of corresponded level~1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²"
9972800|NCT01324596|Active Comparator|Arm A: R-CHOP|Participants receive 6 cycles of conventional R-CHOP chemotherapy on a standard 21 day schedule: Rituximab 375mg/m2 intravenous Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous Prednisolone 100mg od orally
9670958|NCT05055180||HFpEF without pulmonary hypertension|Invasively diagnosed HFpEF without pulmonary hypertension according to current guidelines
9670959|NCT05055180||Patients without HFpEF|Patients without invasive evidence of HFpEF
9670960|NCT05055102||Patient with WOVEX bifurcated prosthesis|"Patients who have undergone open abdominal aortic surgery between January 1st, 2013 and December 31, 2017 in Burgundy Dijon Hospital.~Patients who have been treated with a WOVEX bifurcated prosthesis (Wovex® Polyester Vascular Protheses)"
9670961|NCT05054842|Experimental|treatment group A|
9670962|NCT05054842|Placebo Comparator|treatment group B|
9670963|NCT05054855|Experimental|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention.
9670964|NCT05054855|Active Comparator|Abbreviated Treatment|Steps of the Control Condition. Following an inperson session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
9670965|NCT05055193||Preterm infants who received postnatal corticosteroid for bronchopulmonary dysplasia|Corticosteroids used are hydrocortisone (as first-line therapy) and betamethasone (in situations of particular severity)
9670966|NCT05055193||Preterm infants who did not receive postnatal corticosteroid for bronchopulmonary dysplasia|No corticosteroids
9670967|NCT05055089||new-generation bioprostheses|Patients undergoing surgical aortic valve replacement with new-generation bioprostheses
9670968|NCT05055089||traditional bioprosthesis|patients who received a traditional bioprosthesis
9670969|NCT05054933|Other|ultrasound capsule endoscopy examination|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
9670970|NCT05054829|Experimental|PEERS|
9670971|NCT05054829|Other|Controls|
9670972|NCT05054777||oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques
9670973|NCT05054777||conventional breast-conserving surgery|The conventional breast-conserving surgery were performed without any oncoplastic operations
9670974|NCT05054907||Wearable devices + Smartphone|The only arm in the study.
9670975|NCT05054634||Experimental Group (EG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
9670976|NCT05054634||Control Group (CG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
9670977|NCT05054465|Experimental|Pre-transplant consolidation and post-transplant maintnance with navitoclax and venetoclax.|Patients will be treated with VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al. (doi: 10.1158/2159-8290.CD-20-1465) for two 28 day cycles. Following 2 cycles re-staging marrow including MRD assessment and imaging will be followed by alloSCT according to local protocol.Within 90 days from alloSCT patients will be started on VEN and NAV maintenance. For post-alloSCT maintenance a dose escalation scheme based on the BOIN design will be applied with a maximal dose of VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al.
9670978|NCT05054595|Active Comparator|Standard Pain Psychoeducation|
9670979|NCT05054595|Active Comparator|Audio-Recorded Mindfulness-Based Intervention|
9670980|NCT05054595|Experimental|Nurse-Led Mindfulness-Based Intervention|
9670981|NCT05054699|Experimental|MST|Subjects will receive 12-18 sessions of frontal Magnetic Seizure Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
9670982|NCT05054699|Active Comparator|ECT|Subjects will receive 12-18 sessions of bilateral Electroconvulsive Therapy under general anaesthesia, twice a week. Clinical and cognitive measures will be assessed before, during and after the treatment
9670983|NCT05054296|Active Comparator|Group I (education exercise packet, FitBit)|Patients receive general education exercise packet with instruction to exercise regularly for up to 150 minutes weekly. Patients also wear a FitBit daily over 16 weeks.
10154462|NCT04054908||Cohort B|Patients treated with Trifluridine/Tipiracil (TAS-102) including those receiving it in combination with Y-90 radioembolization as part of a clinical trial
10154463|NCT04054908||Cohort C|Patients receiving CAP plus immunotherapy (pembrolizumab) and bevacizumab as part of a clinical trial.
9670984|NCT05054296|Experimental|Group II (exercise program FitBit)|Patients participate in supervised and self-directed exercise sessions over 60 minutes BIW for up to 16 weeks. Patients also wear a FitBit daily over 16 weeks.
9670985|NCT05054608||COVID-19 ICU cohort|All patients, 18 to 63 years old, admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
9670986|NCT05054608||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
10154464|NCT04055220|Experimental|Regorafenib|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
9520004|NCT03281421|Experimental|Group from posterior to anterior (GPA)|Participants in group GPA will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from posterior to anterior. The physiotherapist will be positioned in front the participant's ankle, and a belt will be posicioned above the participant's malleolus and around physiotherapist's pelvis. The therapist applies with belt a anterior slip sustained in the tibia of the participant, while the talus are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
9661890|NCT03644277|Experimental|Massed practice training with Sham dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
9670987|NCT05054608||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
9670988|NCT05054478|Experimental|Experimental Arm|"4 days of dexamethasone. According to local practice, one dose of doxorubicine (30 mg/m2 IV) or cyclophosphamide (750 mg/m2 IV) may also be added~Induction Treatment (4 months): Subject will receive 4 x 28 days cycles of Dara-VRD induction:~Daratumumab sc 1800 mg on D1 D8 D15 D22 for cycle1 & 2 and D1 D15 for cycle 3 & 4 Bortezomib sc 1.3 mg/m2 on D1 D4 D8 D11 for each cycle Lenalidomide po 25 mg on D1 to D21 for each cycle Dexamethasone po 20 mg on D1 D2 D8 D9 D15 D16 D22 D23 for each cycle~High dose melphalan 200mg/m2 as conditioning therapy and first ASCT~First consolidation : 2 cycles of Dara-VRd~Daratumumab 1800 mg s.c D1 D15~Bortezomib 1.3 mg/m2 s.c D1 D8 D15 D22~Lenalidomide 25 mg p.o from D1 to D21~Dexa 20 mg p.o D1 D8 D15 D22~High dose melphalan 200mg/m2 as conditioning therapy and second ASCT Second consolidation : 6 cycles of Dara-VRd (every 2 months for 2 years) Then maintenance: Lenalidomide every 28 days (25 mg from D1 to D21) for 1 year"
9670989|NCT05054673|Experimental|intervention|PALFIQUE universal adhesive (Tokuyama self-cure universal adhesive)
9670990|NCT05054673|Active Comparator|control|3M™ ESPE™ single bond Universal Adhesive
9670991|NCT05054426|Experimental|intravenous MTX|intravenous methotrexate at a dose of 1g/m2 for 4 courses
9670992|NCT05054426|Experimental|intrathecal MTX|intrathecal methotrexate 10mg at a time for 4 courses
9670993|NCT05054647||family caregivers of palliative patients|psychometric questionnaires
9670994|NCT05054660|Experimental|caring chatbot|The investigators will enroll participants aged over 55 in the psychiatric outpatient department. The participants will get a one-month caring chatbot and can interact with the chatbot freely.
9670995|NCT05054205|Experimental|Experimental group|To the experimental group; motivational interview based self-management education was given for 30-45 minutes with groups of 5-8 people, COPD education guide was given, questions were shared with the question-answer method and group interaction was provided. After the self-management education, 3 motivational interviews were conducted 3 days apart with 30-45 minutes.The data were collected in three stages as pre-test, post-test and follow-up (after 30 day).
9670996|NCT05054205|No Intervention|Control group|Normal care was continued in the control group.
9670997|NCT05054283||Length of hospital Stay (normal)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
9670998|NCT05054283||Length of hospital Stay (prolonged)|The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and > 7 days as prolonged LOS.
9670999|NCT05054751|Experimental|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side.The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
9671000|NCT05054751|Placebo Comparator|Placebo+Fulvestrant|"Placebo: The dose of placebo is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
9671001|NCT05054335|Experimental|Supportive care (walking function test, X-ray)|Patients undergo walking function assessment using optical motion capture and bi-plane dynamic X-ray imaging pre- and post-hemipelvectomy.
9694770|NCT04785209||No complication|Thrombolysis in myocardial infarction flow grade III flow after PPCI, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
9972801|NCT01324596|Experimental|Arm B: RB-CHOP|"Participants in this arm will receive 1 cycle of conventional R-CHOP chemotherapy, followed by 5 cycles of R-CHOP:~Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous bortezomib - Intravenous Prednisolone 100mg od orally~."
10154465|NCT04055220|Placebo Comparator|Placebo|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
10154466|NCT04055207|Experimental|VVC|Option to receive VA Video Connect (VVC) delivery of HIV care.
10154467|NCT04055207|No Intervention|Usual Care|All HIV care available at MEDVAMC will be delivered as usual.
10154468|NCT04055142|Active Comparator|Electrocoagulation|This procedure will be implemented following the Standard of Care (SoC) on weeks: 0, 8 and 16 calculated since the day the patient is included into the trial.
10154469|NCT04055142|Experimental|Sinecatechins (10%)|Topical ointment wich contains 2 grams of active principle (sinecatechins 10%) at each administration. It will be taken three times per week during 8 weeks of treatment.
10154470|NCT04055142|Experimental|cidofovir (1%)|Topical ointment wich contains 2 grams of active principle (cidofovir 1%) at each administration. It will be taken three times per week during 8 weeks of treatment.
10154471|NCT04055233|Experimental|Subcutaneous irrigation with 0.04% polyhexanide solution|"Intervention: after closure of abdominal fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml antiseptic solution (0.04% polyhexanide) will be done once for ten minutes.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
10154472|NCT04055233|Active Comparator|Subcutaneous irrigation with NaCl (saline)|"Intervention: after closure of fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml NaCl (saline) will be done once for one minute.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
10185763|NCT03742596|Experimental|Probiotic Formula Capsule|In this intervention arm the patients will receive oral viable capsules of probiotic contain (1*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
10185764|NCT03742596|Other|Control|In this intervention arm, the control arm will receive normal treatment without any probiotic
10185765|NCT03742583|Active Comparator|Square Knot|
10185766|NCT03742583|Active Comparator|Reversing Half-Hitch Alternating Post Knot|
10185767|NCT03742570||CBBDQ|A Questionnaire
10185768|NCT03742557|Active Comparator|Ketamine|"Ketamine 50 MG/ML - at a dose of 0.5 mg/kg IV diluted in 100cc of saline solution 0.9% over 40 minutes.~The intervention will be done twice weekly for 8 weeks."
9662342|NCT04590586|Experimental|Apremilast and standard of care (SoC)|
9662343|NCT04590586|Placebo Comparator|Apremilast placebo and standard of care (SoC)|
9662344|NCT04590586|Experimental|Lanadelumab and standard of care (SoC)|
9662345|NCT04590586|Placebo Comparator|Lanadelumab placebo and standard of care (SoC)|
9662346|NCT04590586|Experimental|Zilucoplan and standard of care (SoC)|
9662347|NCT04590586|Placebo Comparator|Zilucoplan placebo and standard of care (SoC)|
9662348|NCT04589754|Experimental|Sintilimab plus chemotherapy|Adriamycin and ifosfamide combined with sintilimab in the treatment of advanced or unresectable soft tissue sarcoma
9662349|NCT04588025|Active Comparator|Healthy Volunteers|
9662350|NCT04588025|Active Comparator|Pancreatic Cancer Participants|
9662351|NCT04587323||Group 1:|Group 1: COVID-19 + inpatients who did not require mechanical ventilation (25 patients);
9662352|NCT04587323||Group 2:|Group 2: COVID-19 + inpatients who required mechanical ventilation (25 patients).
9662353|NCT04587323||Group 3:|Group 3: COVID-19 + inpatients with no preexisting cardiovascular disease (25 patients)
9662354|NCT04587323||Group 4:|Group 4: COVID-19 + inpatients with preexisting cardiovascular disease (25 patients).
9662355|NCT04576871|Experimental|All Subjects|
9662356|NCT04575428|Experimental|Splanchnic nerve block|
10185769|NCT03742557|Placebo Comparator|Placebo|Saline solution 0.9% over 40 minutes. The intervention will be done twice weekly for 2 weeks, and then patients will receive intervention with ketamine as described above in the Active Comparator.
9662357|NCT04569435|Experimental|ANX005|IV
9662358|NCT04553562|Experimental|Acupuncture group|For acupuncture group, sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads. The participants will be treated three times a week, on alternate days, for 6 successive weeks; 18 sessions for each patient in total.
9662359|NCT04553562|Sham Comparator|Sham acupuncture group|For the sham acupuncture group, aterile adhesive pads will be placed after skin disinfection on the acupoints and needles with a blunt tip will be inserted at the same acupoints in the acupuncture group without penetrating the skin.No manipulation of needles will be conducted. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
9662360|NCT04553562|No Intervention|Waiting list group|For the waiting list group, patients will receive no treatment in the first 6 weeks and will receive the same treatment used in the acupuncture group according to patients' preference.
9662361|NCT04547738||Tuberculosis (TB) index patients|- Patients (older than 5 years) diagnosed with TB before initiation of TB treatment
10185770|NCT03742531|Active Comparator|low dose group|oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
10185771|NCT03742531|Active Comparator|high dose group|oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
10185772|NCT03742492|Experimental|Canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
10154473|NCT04054843||Gestational diabetes mellitus|First trimester pregnancies with gestational diabetes mellitus
10154474|NCT04054843||Control|First trimester healthy pregnancies
10154475|NCT04054869|Experimental|Bio-mechanically correct manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically correct direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
10154476|NCT04054869|Experimental|Bio-mechanically incorrect manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically incorrect direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
10154477|NCT04054882|Experimental|Sabin-IPV and DTaP|234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
10154478|NCT04054882|Active Comparator|Sabin-IPV only|234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
10154479|NCT04054882|Active Comparator|DTaP only|234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
10154480|NCT04054856|Other|Patients with Morbus Parkinson|
10154481|NCT04054856|Other|Healthy Subjects|
10154482|NCT04055038|Experimental|Platinum-based chemotherapy|"This is an experimental arm of this study. Allowed therapeutic options:~Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);~Gemcitabine 1000 mg/m2 d 1, 8 + cisplatin 75 mg/m2 1 every 3 weeks;~Doxorubicin 40-50 mg/m2 d 1 + carboplatin AUC5 or cisplatin 60-75 mg/m2 d 1 every 3 weeks;~Topotecan 0.75 mg/m2 d 1-3 + cisplatin 60-75 mg/m2 or carboplatin AUC 4-5 d 1 every 3 weeks;~Etoposide 100 mg once daily orally d 1-7 + cisplatin 60-75 mg/m2 d1 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
10154483|NCT04055038|Active Comparator|Non-platinum monochemotherapy|"This is a control arm of this study. Allowed therapeutic options:~Paclitaxel 60-80 mg/m2 weekly (or day 1, 8, 15 every 4 weeks schedule);~Gemcitabine 1000 mg/m2 d 1, 8, 15 every 4 weeks;~Doxorubicin 50-60 mg/m2 d 1 every 3 weeks;~Topotecan 1,2-1,5 mg/m2 d 1-5 every 3 weeks;~Etoposide 100 mg once daily orally d 1-10 every 3 weeks.~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
10154484|NCT04054830|Experimental|Topical, preservative-free NSAID|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
10154485|NCT04054830|Active Comparator|Topical, preservative-free steroid|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
10154486|NCT04054830|Experimental|Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee
10154487|NCT04054817|Experimental|Single Arm|
10154488|NCT04054596|Experimental|STEM|The treatment group (TX) will complete 8 sessions of STEM (2 sessions per week for 4 weeks), Sessions are approximately 30-45 minutes long.
10154489|NCT04054596|No Intervention|Controlled|During weeks 2-5, one group will undergo a memory enhancement protocol, used to improve memory functioning in individuals with neurological injuries. The other group will serve as a control group and complete memory exercises with the researcher.
10154490|NCT04054609|Other|FAZA PET/MRI scan|PET/MRI scan using radiotracer 18F-Fluoroazomycin Arabinoside
10154491|NCT04054531|Experimental|KN046 + carboplatin/paclitaxel|KN046 5 mg/kg IV every three weeks (Q3W) +Carboplatin AUC5 IV Q3W x 4 cycles + Paclitaxel 500 mg/m2 IV Q3W x 4 cycles
10154492|NCT04054531|Experimental|KN046 + carboplatin/pemetrexed|KN046 5 mg/kg IV Q3W +Carboplatin AUC5 IV Q3W x 4 cycles + Pemetrexed 500 mg/m2 IV Q3W x 4 cycles
10154493|NCT04054778|Experimental|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
10154494|NCT04054778|Active Comparator|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
10154495|NCT04054687|Experimental|TXA|Research participants in the experimental group will receive one dose of 100mg/mL TXA soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
10154496|NCT04054687|Placebo Comparator|Saline|Research participants in the placebo group will receive one dose of normal saline (0.9%) soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
10154497|NCT04054323|Experimental|Patient Physical Activity Arm|Patients only receive physical activity intervention.
10154498|NCT04054323|Experimental|Dyadic Physical Activity Arm|Patients and caregivers both receive physical activity intervention.
10154499|NCT04054336|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures containing soft drinks by swiping/pulling them towards themselves, whereas pictures with alcoholic content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
10154500|NCT04054336|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon soft drinks by swiping/pulling towards themselves the picture. Pictures containing alcoholic content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
10154501|NCT04054336|Sham Comparator|Control group|This type of active control group receives the instructions to swipe alcohol pictures to the left and soft drink pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
10154502|NCT04054726|Experimental|Real tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
10154503|NCT04054726|Sham Comparator|Sham tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
10154504|NCT04054427|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF
10154505|NCT04054505|Active Comparator|Vitamin A|Rise or fall of Vitamin A after three months
9694771|NCT04785209||No reflow|No reflow phenomenon after pci on STEMI patients, mean platelet volume, lymphocyte ratio, detailed echo within 24 hrs of admission, clinical STEMI risk scores
10154506|NCT04054505|Active Comparator|Vitamin E|Rise or fall of Vitamin E after three months
10154507|NCT04054505|Active Comparator|Vitamin B1|Rise or fall of Vitamin B1 after three months
10154508|NCT04054505|Active Comparator|Vitamin B2|Rise or fall of Vitamin B2 after three months
10154509|NCT04054505|Active Comparator|Vitamin B6|Rise or fall of Vitamin B6 after three months
10154510|NCT04054505|Active Comparator|Vitamin B12|Rise or fall of Vitamin B12 after three months
10154511|NCT04054505|Active Comparator|Vitamin C|Rise or fall of Vitamin C after three months
10154512|NCT04054505|Active Comparator|Vitamin D|Rise or fall of Vitamin D after three months
10154513|NCT04054505|Active Comparator|Calcium|Rise or fall of Calcium after three months
10154514|NCT04054505|Active Comparator|Iron|Rise or fall of Iron after three months
10154515|NCT04054505|No Intervention|IGF1|Rise or fall of IGF1 after three months
10154516|NCT04054505|No Intervention|FT-3|Rise or fall of FT-3 after three months
10154517|NCT04054492|Experimental|sIPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
10154518|NCT04054492|Active Comparator|sIPV+sIPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
10154519|NCT04054492|Active Comparator|sIPV+sIPV+sIPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
10154520|NCT04054466|Experimental|Experimental group|Intervention with counselling designed
10154521|NCT04054466|Other|Control group|Intervention with habitual counselling
10154522|NCT04054453|No Intervention|Pre-intervention|Baseline data on neonatal encephalopathy and epilepsy before the introduction of the care bundle
10154523|NCT04054453|Experimental|Post-intervention|Baseline data on neonatal encephalopathy and epilepsy after the introduction of the care bundle
10154524|NCT04054635|Experimental|Regimen 1|Two applications of silver diamine fluoride (SDF) four months apart, which is the protocol frequency adopted by the Winnipeg Regional Health Authority's (WRHA) Clinical Guideline on SDF.
10154525|NCT04054635|Experimental|Regimen 2|Two applications of silver diamine fluoride (SDF) six months apart (American Dental Association recommendation)
10154526|NCT04054635|Experimental|Regimen 3|Two applications of silver diamine fluoride (SDF) one month apart, which is proposed in the American Academy of Pediatric Dentistry's clinical practice guidelines.
10154527|NCT04054700|Experimental|distal upper rehabilitation robot|experimental group that applied the distal upper rehabilitation robot
10154528|NCT04054700|Other|proximal upper rehabilitation robot|control group that applied the proximal upper rehabilitation robot
10154529|NCT04054583||Residents|Residents living on a special care unit in a long-term care facility. All 60 residents residing in the unit pre- and post-renovation will be eligible, and all will have intermediate or advanced dementia.
10154530|NCT04054583||Family Members|Family members are defined as the key person who supports the resident on a regular basis. This could include a spouse, adult child, adult grandchild, niece or nephew, close friend, former neighbour, or other significant person to the resident.
9694772|NCT04785430||Patients who underwent elective inguinal hernia surgery|Patients who have applied to the general surgery outpatient clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with inguinal hernia and underwent hernia repair surgery.
10154531|NCT04054583||Staff|Staff are the people who work on the special care unit. They may work only briefly or work on the design of the renovations. Types include: managers, nurses, health care aides, recreation facilitators, social worker, occupational therapist, physiotherapist, rehabilitation assistant, speech language pathologist, physicians, designers, and cleaning staff.
10154532|NCT04054414|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
10154533|NCT04054414|Experimental|PMZ-1620|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
10154534|NCT04054479|Experimental|Penehyclidine|Patients in this arm will receive penehyclidine after anesthesia intubation.
9694773|NCT04785430||Patients who underwent emergency inguinal hernia surgery|Patients who have applied to the emergency clinic of Bakırköy Dr Sadi Konuk Training and Research Hospital, diagnosed with incarcerated inguinal hernia and underwent hernia repair surgery.
10154535|NCT04054479|Placebo Comparator|Normal Saline|Patients in this arm will receive normal saline after anesthesia intubation.
10154536|NCT04054518|Experimental|Durvalumab|1500 mg durvalumab (MEDI4736) via IV infusion Q4W <<for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48>> or <<until confirmed disease progression>> unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
10154537|NCT04054544|Experimental|Gluten challenge|Participants will receive a gluten 4 g powder twice daily (BID), for 13 consecutive days
10154538|NCT04054245|Experimental|Treatment (LOXL2 inhibitor PAT-1251)|Patients receive LOXL2 inhibitor PAT-1251 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10154539|NCT04054362|Experimental|With Cisplatin|Paclitaxel Protein bound, Cisplatin, and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
10154540|NCT04054362|Experimental|Without Cisplatin|Paclitaxel Protein bound and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
10154541|NCT04054258|Experimental|App support programme group|In addition to the usual care, the participant and one family member will receive a CHD app and a briefing from a trained research nurse (A). The reason to invite an additional family member to install the app is to ensure that he/she can be informed automatically when the patient presses an icon during a chest pain attack. The patient may be too stressed during an angina attack and may not be able to follow the 'Things to Do List' quickly. In addition, automatic reminders of the individual's medication times and follow-up times will be pre-set in the app for individual use.
10154542|NCT04054258|Active Comparator|Telephone support group|In addition to the above usual care, bi-weekly 20-minute telephone follow-ups will be provided by a trained research nurse (B) for up to 3 months. Patients can ask about related health problems if any. The nurse will address their problem by providing advice or referring them to the ED follow-up clinic. The team has set up a telephone advice guide to support the research nurse in giving phone advice.
10154543|NCT04054284|Experimental|Intervention|Herbal Tea Mixture is consisted of: Vaccinium myrtillus L. folium, Morus nigra L. folium, Phaseolus vulgaris L. pericarpium, Viscum album L. herba, Urtica dioica L. radix, Gentiana lutea L. radix, Taraxacum officinale W. radix, Cichorium intybus L. herba, Teucrium chamaedrys L. herba, Stevia rebaudiana folium.
10154544|NCT04054284|Active Comparator|Control|Herbal Tea Mixture without antidiabetic properties is consisted of: Achillea millefolium L. herba, Teucrium montanum L. herba, Glechoma hederacea L. herba, Eupatorium cannabinum L. herba, Humulus lupulus L. lupulin, Artemisia absinthium L. herba, Salvia officinalis L.
10154545|NCT04054349|Experimental|Low FODMAP Diet Group|The parent/caregiver was given detailed nutrition education by the investigator concerning the low FODMAP diet and was asked to implement for 2 weeks.
10154546|NCT04054349|No Intervention|Control Group (Habitual Diet)|The parent/caregiver was asked to continue their child's usual dietary intake for 2 weeks.
10154547|NCT04054388|Experimental|300 Randomized to re-education group|LINE re-education of colon preparation
10154548|NCT04054388|No Intervention|300 Randomized to control group|education of colon preparation 1 time in hospital
10154549|NCT04054297|Experimental|High GI/SFA diet|Subjects will adhere to a two-week high GI and high SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
10154550|NCT04054297|Experimental|Low GI/SFA diet|Subjects will adhere to a two-week low GI and low SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
10154551|NCT04054232|Experimental|EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to have their primary care physician receive an electronic health record message regarding their high risk of having PAD and a recommendation will be made to have the participant referred for non-invasive testing called Ankle Brachial Index (ABI) testing to confirm diagnosis. For individuals who undergo ABI testing and are confirmed to have PAD, they and their physicians will be provided with American Heart Association Guidelines for the management of PAD. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications.
10154552|NCT04054232|No Intervention|No EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to the control arm and they nor their physicians will be alerted of their status for 6 months. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications. At the end of 6 months of observation, the primary care physician's of control participants will receive the same alert as participants in the intervention arm.
10154553|NCT04054180|Experimental|CPAP S.Box associated with its 3 connected devices|S.BOXTM CPAP associated with its 3 connected devices Each patient will be monitored by a CPAP S.Box, with a Sefam Access application installed on their Smartphone to collect data from 3 connected measuring devices: PROMs, an activity monitor and a blood pressure monitor.
10154554|NCT04054206|Active Comparator|Sequence 1|"Two participants will be randomly assigned to sequence 1 comprising 3 treatments (ER fasted, ER fed, and IR fasted) in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: ER fed Day 15-22: IR fasted"
10154555|NCT04054206|Active Comparator|Sequence 2|Two participants will be randomly assigned to sequence 2 comprising 3 treatments in a crossover design, administered one week apart: Day 1-7: ER fed; Day 8-15: IR fasted; Day 15-22: ER fasted
10154556|NCT04054206|Active Comparator|Sequence 3|"Two participants will be randomly assigned to sequence 3 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fasted; Day 15-22: ER fed"
10154557|NCT04054206|Active Comparator|Sequence 4|"Two participants will be randomly assigned to sequence 4 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: IR fasted; Day 8-15: ER fed; Day 15-22: ER fasted"
10185773|NCT03742492|Placebo Comparator|Canned tuna + soybean oil|Meal containing canned tuna + soybean oil
10154558|NCT04054206|Active Comparator|Sequence 5|"Two participants will be randomly assigned to sequence 5 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fasted; Day 8-15: IR fasted; Day 15-22: ER fed"
10154559|NCT04054206|Active Comparator|Sequence 6|"Two participants will be randomly assigned to sequence 6 comprising 3 treatments in a crossover design, administered one week apart:~Day 1-7: ER fed; Day 8-15: ER fasted; Day 15-22: IR fasted"
10154560|NCT04054739|Experimental|Robot-assisted gait training|experimental group that applied the end-effector robot-assisted gait training
10154561|NCT04054739|Active Comparator|Treadmill gait training|control group that applied the treadmill gait training
10154562|NCT04054024|Active Comparator|Active drug|
10154563|NCT04054024|Placebo Comparator|Placebo|
10154564|NCT04053855||Renal mass patients|"Patients with renal mass requiring surgery (partial or total nephrectomy) will be included.~They will have an urinary sample."
10154565|NCT04053855||Control patients|Control patients (without renal mass) will be included. They will have an urinary sample.
10154566|NCT04054102|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
10154567|NCT04054102|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
10154568|NCT04054037||HBV-ACLF Group|Patients with HBV related acute on chronic liver failure
10154569|NCT04054154|Experimental|Device Feasibility (Millar Mikro-tip catheter, elastography)|Patients scheduled for an ultrasound-guided tumor biopsy undergo stiffness assessment of the tumor with shear wave elastography over 2 minutes and pressure measurements of the tumor using a Millar Mikro-tip catheter before and after the biopsy is collected.
10154570|NCT04053829|Experimental|HOLOBalance|The experimental arm will use the HOLOBalance tele-rehabilitation system to provide the intervention. Participants will be required to use the HOLOBalance system on a daily basis for the duration of the 8 week study. Although participants will have daily interaction with the HOLOBalance system, they will be free to choose when to complete their exercises.
10154571|NCT04053829|Active Comparator|OTAGO Home Exercise Programme|The comparator for this study is the OTAGO home exercise programme. The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. The OTAGO is well-established and is widely used in clinical practice in the UK for the management of older adults who fall or have increased risk for falling. It has been shown to be well tolerated in older adults in community settings with good adherence rates, and reduces falls rate in older adults by 35%, with greatest effects observed in frailer older women
10154572|NCT04053816|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
10154573|NCT04053816|Active Comparator|Tight control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
10154574|NCT04054076|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
10154575|NCT04054076|Experimental|Custom-made insoles soft|Custom-made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate.
9662362|NCT04547738||TB contacts|- Children (5-17 years old), who had contact with TB index patients
9662363|NCT04543071|Experimental|Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel|Participants will receive standard FDA-approved doses of gemcitabine and nab-paclitaxel for pancreas cancer and cemiplimab at the dose that is approved for participants with skin cancer. Participants will also receive motixafortide at a dose that has been deemed safe in previous studies when used in combination with immunotherapy and chemotherapy. If the combination study treatment causes a serious side effect in participants, the study treatment will be modified.
9662364|NCT04539899|Experimental|VR+|For patients in the experimental group, using the virtual reality helmet, the caregiver will position the helmet on the patient when she is placed on the gynecological examination table. He or she will make sure that the patient can see and hear the current sequence. The caregiver can then proceed with the different steps of the IUD insertion. Once the procedure is completed, the caregiver will indicate to the patient that she can remove the headphones.
10154576|NCT04054076|Experimental|Custom-made hard|Custom-made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate.
10154577|NCT04054076|No Intervention|Control group|No intervention with therapeutic insoles and/or shoes.
10154578|NCT04054167|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.
10154579|NCT04053946|Experimental|Next Science|Following amputation, SurgX™ will be applied directly to the surgical incision in the operating room under sterile conditions and covered with SOC dressing. The surgical dressing will not be removed until post-operative day 3, except if deemed necessary by the treating surgeon. At that time, direct application of the BlastX™ to the incision will be placed, then covered with a SOC dressing. BlastX™ will be applied every day and covered with SOC dressing.
10154580|NCT04053946|No Intervention|Control|Post-op SOC dressing as per treating research doctor to include dressing changes post-op day 3 and daily thereafter.
10154581|NCT04054089|Experimental|A|B/F/TAF
10154582|NCT04054089|Active Comparator|B|DTG+3TC
10154583|NCT04054063|Experimental|HSK3486+etomidate|Cohort 1: HSK3486 0.324 mg/kg + etomidate 0.15 mg/kg Cohort 2: HSK3486 0.216 mg/kg + etomidate 0.2 mg/kg Cohort 3: HSK3486 0.432 mg/kg + etomidate 0.1 mg/kg There were an additional 2 cohorts (Cohorts 4 and 5) planned for dose escalation once the optimal ratio of the drug combination was identified from the first 3 cohorts. However, these 2 cohorts were not done as the results of Cohorts 1 to 3 suggested that dose increases would cause higher occurrence of drug-related adverse events (AEs).
10154584|NCT04053959|Experimental|AI Group|Artificial intelligence assisted insulin titration system group
10154585|NCT04053959|Active Comparator|Control Group|Physicians decided insulin titration group
10154586|NCT04053972|Experimental|treatment group|adjuvant lenvatinib
10154587|NCT04053972|No Intervention|control group|no intervention
10154588|NCT04053920|Experimental|Low load|Training at 30-40% one-repetition maximum (1RM)
10154589|NCT04053920|Experimental|High load|Training at 65-75% one-repetition maximum (1RM)
10154590|NCT04054115|Experimental|Treatment Arm|"Baseline cardiac catheterization under GA. (Standard of Care, SOC)~Transfer patient to MRI unit~Baseline MRI~Obtain ABG for pCO2 from existing femoral arterial access.~Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.~MRI phase contrast imaging for flow measurements(SOC).~During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.~Post alprostadil infusion~1ml blood sample taken from existing femoral venous access for prostaglandin level.~Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.~Repeat MRI flow measurements~7.Return to cath lab if further intervention required. 8.Recovery and monitoring for 4 to 6 hours prior to discharge(SOC)."
10154591|NCT04054128|Experimental|Sodium bicarbonate catheter lock group (SBCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with sodium bicarbonate 7.5% Injection.
10154592|NCT04054128|Active Comparator|Heparin catheter lock group (HCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with heparin, 1000 Units/mL injectable solution
10154593|NCT04053933||Patients treated with ESA|
10154594|NCT04053933||Patients treated with 5'azacitidin|
10154595|NCT04053933||Patients treated with deferoxamine|
10154596|NCT04053933||Patients treated with deferasirox|
10154597|NCT04053933||Patients treated with transfusion only|
10154598|NCT04053933||Patients treated with lenalidomide|
10154599|NCT04053933||Patients treated with intensive chemotherapy|
10154600|NCT04053985|Experimental|TAI+lenvatinib group|TAI combine lenvatinib
10154601|NCT04053985|Active Comparator|lenvatinib group|lenvatinib only
9662012|NCT01701986|Experimental|Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)|"PREPARATIVE REGIMEN: Patients receive gemcitabine hydrochloride IV over 40-180 minutes on days -6 and -4, clofarabine IV over 1 hour on days -6 to -3, and busulfan IV over 3 hours on days -6 to -3. Patients with matched unrelated donors also receive antithymocyte globulin IV on days -3 to -1 and patients with CD20-positive disease also receive rituximab IV on days -14, -7, 1, and 8.~TRANSPLANT: Patients undergo allogeneic BMT or PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO beginning on day -2 for up to 6 months and mycophenolate mofetil IV over 2 hours or PO TID beginning day 0."
10154602|NCT04053712|Placebo Comparator|Single-hormone|FiAsp (R) - Saline
10154603|NCT04053712|Active Comparator|Dual-hormone|FiAsp(R) - GlucaGen(R)
10154604|NCT04053686|Experimental|Intervention|The intervention group will aim to regularly break up participants' prolonged sitting time with three-minute incidental movement breaks every half hour at work. Support for behaviour change will include a lecture/workshop, electronic prompts, break logging, team competition, health champions, and email support.
10154605|NCT04053699||Patients undergoing treatment with a VWF-containing product|Patients with type 3, type 2 (except 2N), or severe type 1 VWD undergoing routine on-demand treatment with a VWF-containing product over a period of 6 months
10154606|NCT04053621|Experimental|Experimental group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and thiamine pyrophosphate (weekly dose of 1 gram administered by IV: 25 ml of thiamine pyrophosphate + 250 ml saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
10154607|NCT04053621|Placebo Comparator|Placebo group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and weekly administration of 275 ml of saline solution at a 60-80 drops/minute rate).~Total duration of 12 weeks."
10154608|NCT04053543|Experimental|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
10154609|NCT04053595|Experimental|Estimated Oxygen Extraction|
10154610|NCT04053595|Active Comparator|Dynamic Parameters|
10154611|NCT04053647||Hypoparathyroid patients|Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.
10154612|NCT04053647||Control patients, without hypoparathyroidism|
10154613|NCT04053660|No Intervention|Control|Periodontally healthy group
10154614|NCT04053660|Experimental|Chronic Periodontitis|Patients with chronic periodontitis
10154615|NCT04053777||NIV group|Patients receiving non-invasive ventilation in the hospital or at home
10154616|NCT04053582|Active Comparator|Augmented Mindfulness Training (AMT)|Participants will receive real-time neurofeedback from the PCC during mindfulness practice in the MRI
10154617|NCT04053582|Active Comparator|Sham|Participants will receive an artificial neurofeedback signal during mindfulness practice in the MRI
10154618|NCT04053439||Lymphoma patients >=60 receiving cytotoxic chemotherapy|Lymphoma patients >=60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP.
10154619|NCT04053413|No Intervention|Usual care|Women in this group will undergo usual care and the complete the survey questions on knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean.
10154620|NCT04053413|Active Comparator|Decision Aid|Women in this group will receive a decision aid prior to undergoing counseling by their physician. Following completion of the decision aid and physician counseling, they will complete a series of survey questions to assess their perceptions of their knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean delivery.
10154621|NCT04053218|Active Comparator|Exercise and supplement|Supervised aerobic exercise three times weekly and daily omega-3 supplements
10154622|NCT04053218|Placebo Comparator|Placebo|Olive oil capsules. No supervised exercise but written recommendations for daily physical activity from the American Heart Association
10154623|NCT04053751|Experimental|closed suctioning system|Closed suctioning system will be compared with open suctioning system
10154624|NCT04053751|No Intervention|open suctioning system|The patient will be monitored with closed system for one day and open aspiration system on the other day.
10154625|NCT04053400||Ketamine Group|Active duty military service member injured in theater, AEROVAC-ED out, and received ketamine.
10154626|NCT04053400||Non-Ketamine Comparison Group|Active duty military service member injured in theater, AEROVAC-ED out, and did NOT receive ketamine treatment for pain.
10154627|NCT04053491|Experimental|Axillary block group|Initial bolus will be given and then a perinervous catheter will be inserted by the axillary approach.
10154628|NCT04053491|Experimental|Infraclavicular block group|Initial bolus will be given and then a perinervous catheter will be inserted by the infraclavicular approach.
10154629|NCT04053530|Experimental|3M™ Ketac™ Universal Aplicap™|"3M™ Ketac™ Universal Aplicap™ Glass Ionomer Restorative Clean the cavity preparation with water. Rinse thoroughly and dry. Extrude the mixed ketac universal out of the capsule directly into the prepared cavity with a capsule gun. Please ensure that no air bubbles are included.~It is recommended that the finishing and polishing can be continued after approximately 4 minutes after the start of the mixing or earlier if heat is applied for faster setting. The finishing and polishing can be done immediately after final setting with Extra-Fine, Friction Grip diamonds under water-cooling."
10154630|NCT04053530|Experimental|Filtek™ Bulk Fill Flowable composite|"Filtek™ Bulk Fill Flowable Restorative is the 3M ESPE choice in the bulk fill flowable category.~Selective etching 15-20 s for enamel. The adhesive system (BISCO universal all bond) will be applied following the manufacturer's instructions (apply 2 coats 20 s before curing). Bulk fill flowable composite will be light cured for 40 s using a visible light curing unit."
10154631|NCT04053530|Active Comparator|ketac N100|"Ketac™ Nano Light Curing Glass Ionomer Restorative. Primer will be applied to both enamel and dentinal surfaces for 15 seconds. The prepared tooth surfaces will be wet with the primer for the full application time.~Dispensing two clicks from the Clicker™ Dispenser will provide an adequate amount of material for most restorative filling applications.~It will be placed with a syringe system then will be placed in 2mm increments or less, and light cured after each increment. An LED curing light will cure all shades with a 20 second light exposure.~Finishing Ketac Nano restorative will be polished with conventional finishing and polishing instruments such as a diamond impregnated rubberized polishing system under water spray. A glaze such as Vitremer™ Finishing Gloss will be applied after polishing if desired."
10154632|NCT04053374||DMD treatment naive CIS or RRMS patients|Newly presenting Clinically Isolated Syndrome (CIS) or Relapsing and Remitting Multiple Sclerosis (RRMS) patients not treated before with Disease Modifying Drugs (DMD) Additional analysis of CSF and CSF cells will be performed in this cohort on a voluntary basis.
10154633|NCT04053374||Secondary Progressive Multiple Sclerosis (SPMS)|People with confirmed diagnosis of SPMS
10154634|NCT04053374||Primary Progressive Multiple Sclerosis (PPMS)|People with confirmed diagnosis of PPMS
10154635|NCT04053374||DMD-treated with stable disease|People with Multiple Sclerosis (MS) who are treated with DMD who have had stable disease symptoms for at least 3 months
10154636|NCT04053374||Disease controls|People who undergo lumbar puncture due to clinical suspicion of neurological condition, but brain Magnetic Resonance Imaging (MRI) and CSF examination exclude MS diagnosis.
10154637|NCT04053374||Healthy donors|Age, sex and ethnicity matched healthy donors will also be recruited from university and hospital staff and patient friends after informed consent has been obtained. Healthy donors will be asked to provide a blood sample and demographic information but will NOT be asked to provide CSF samples.
10154638|NCT04053348|Experimental|Intervention|Participants allocated to the intervention group will receive their home-based rehabilitation program using mobile app installed in the mobile device.
10154639|NCT04053348|Active Comparator|Control|Those assigned to the control group will receive the same home-based rehabilitation program but with information and instructions delivered through the use of paper-based handouts.
10154640|NCT04053296||The first pregnancy with PAH group|
10154641|NCT04053296||The second pregnancy with PAH group|
10154642|NCT04053153|Experimental|Use of musical instrument|
10154643|NCT04053153|Sham Comparator|Use of sham musical instrument|
10154644|NCT04053140|Experimental|Routine intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV 1200mg administered every 4 hours.
10154645|NCT04053140|Experimental|Closed-loop control of intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
10154646|NCT04053140|Experimental|Closed-loop control of continuous infusion|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
10154647|NCT04053114||Retrospective cohort|Tissue samples
10154648|NCT04053257|No Intervention|Before intervention|HH opportunities, compliant moments and HAIs recorded before the intervention
10154649|NCT04053257|Active Comparator|After intervention|HH opportunities, compliant moments and HAIs recorded after the intervention
10154650|NCT04053738|No Intervention|Baseline|Participants slept in the anti-snoring bed in the laboratory, but the bed did not provide any intervention
10154651|NCT04053738|Experimental|Anti-snoring Intervention|Participants slept in the anti-snoring bed in the laboratory, and the bed moved the trunk of the participant
10154652|NCT04053036|Experimental|Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive MDMA (1.5 mg/kg)
10154653|NCT04053036|Experimental|MDMA Then Placebo|Participants first receive MDMA (1.5 mg/kg) at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
10154654|NCT04053244|Experimental|treatment|all participants will be assigned to the treatment, consisting of therapist-assisted iCBT.
10154655|NCT04053010|Experimental|group 1|234 subjects; simultaneously administration of Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
10154656|NCT04053010|Active Comparator|group 2|234 subjects; Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
10154657|NCT04053010|Active Comparator|group 3|234 subjects; DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
10185774|NCT03742479|Experimental|Hyaluronic Acid Microinjection|
9662013|NCT01585675||Diagnosis/treatment of lung cancer|Specimen Banking
10154658|NCT04052984|Experimental|Intervention group|Twenty four pares of healthy mothers-newborns, with delayed clamping and immediate skin-to-skin contact after birth by caesarean section
10154659|NCT04052984|No Intervention|Control group|Twenty four pares of healthy mothers-newborns, with early clamping without skin-to-skin contact after birth by caesarean section and newborn attended in radiant warm table
10154660|NCT04052802|Experimental|Bioactive resin (Giomer)|"This group of patients will receive a bioactive resin Beautifil flow plus X (Shofu Dental) for treatment of their demineralized fissures"
10154661|NCT04052802|Experimental|Conventional resin|"This group of patients will receive a conventional resin Filtek Z350xt Flowable composite (3M ESPE) for treatment of their demineralized fissures"
10154662|NCT04052789|Active Comparator|Zirconia single posterior crowns veneered with ceramics|'In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
10154663|NCT04052789|Experimental|BioHpp PEEK single posterior crowns veneered with compos|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
10154664|NCT04052815|Experimental|Diabetes prevention program culturally tailored|Adult females with Hispanic background
10154665|NCT04053179|Experimental|Connected patch validation|
10154666|NCT04052945|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
10154667|NCT04052945|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
10154668|NCT04052919|Experimental|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
10154669|NCT04052932|Placebo Comparator|Placebo|Placebo once a day, orally, for 12 weeks, followed by SHR4640 treatment to 36 weeks
10154670|NCT04052932|Experimental|SHR4640 dose1|SHR4640 dose1 once a day, orally, for 36 weeks
10154671|NCT04052932|Experimental|SHR4640 dose2|SHR4640 dose2 once a day, orally, for 36 weeks
10154672|NCT04052932|Active Comparator|Allopurinol|Allopurinol 300mg (milligram) once a day, Orally, for 36 week
10154673|NCT04053127|Experimental|RAVANS|Electrodes will be placed in the auricle of the left ear. Electrical stimulation to these electrodes will be provided by a current-constant stimulator (Urostim, Schwa-Medico). Stimulation will be gated, with 1-second delay, after peak inhalation (i.e. during exhalation). Respiratory gating for stimulation will require real-time evaluation of the respiratory cycle. The study will use a belt system constructed in-house, and similar to the system used in several previous studies. A pneumatic belt will be placed around the subject's lower thorax. Once electrodes are set up, subjects will be asked to rate stimulation intensity on a NRS of 0 to 10 (0: no sensation, 10: pain detection threshold). Current intensity will be set to achieve moderate to strong (but not painful) sensation, and this current intensity will be used on subsequent stimulation runs.
10154674|NCT04053127|Sham Comparator|non-RAVANS|For sessions randomized to sham stimulation, the electrodes in the ear will remain as described above, but the leads will be disconnected from the stimulator. Subjects will be instructed that for this session they may or may not feel pulsing in their ear, and that the goal is to ensure that the stimulus was not painful.
10154675|NCT04052906|Experimental|Intervention Group|Planned Inhaler Medication Training
10154676|NCT04052906|No Intervention|Control Group|usual care
10185775|NCT03742466|Active Comparator|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
10185776|NCT03742466|Active Comparator|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
10185777|NCT03742453|Experimental|Hepatic nodule group|This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)
10185778|NCT03742401|Active Comparator|Surgery|Surgery
10185779|NCT03742401|Active Comparator|HIFU (Echopulse)|HIFU (Echopulse)
10185780|NCT03742375|Experimental|HPV genotyping|
10185781|NCT03742362|Experimental|Bone marrow fat fraction by MRI|MRI scans of distal radius will be performed to all participants to monitor the fat fraction in bone marrow
10185782|NCT03742336|Experimental|Arm 1|Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.
10185783|NCT03742336|Experimental|Arm 2|Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.
10185784|NCT03742323|Experimental|Idelalisib|
10185785|NCT03742310|Experimental|identical supplement group|"Take vitamin D supplements according to genotype. If the genotype result is high risk, we will give vitamin d 800 international unit(IU)/d, when the result is middle risk, we will give 600 international unit(IU)/d, when the result is low risk, we will give 400 international unit(IU)/d."
10185786|NCT03742310|No Intervention|control group|General dose. Whatever the result is, we all give 400 international unit(IU)/d.
10185787|NCT03742297|Active Comparator|VMP x 9 + Lenalidomida-dexamethasone x 9|Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose
10185788|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethasone regimen|carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle
9662014|NCT01534481|Active Comparator|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
9972802|NCT01324635|Experimental|Arm A (panobinostat, multiple fractions of SBRT)|Patients receive panobinostat PO thrice weekly for 2 weeks and undergo 10 fractions of SBRT over 2 weeks (recurrent gliomas) OR 30 fractions of SBRT over 6 weeks (high grade meningiomas).
9972803|NCT01324635|Experimental|Arm B (panobinostat, stereotactic radiosurgery)|Patients receive panobinostat as in Arm A and undergo a single fraction of stereotactic radiosurgery on day 1 of week 1.
9972804|NCT01324648|Experimental|TG + GP TAU|
9972805|NCT01324648|Experimental|UG + GP TAU|
9972806|NCT01324648|Active Comparator|GP TAU|
9972807|NCT01324661|No Intervention|Control|Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game.
9972808|NCT01324661|Other|Ostracism|Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game.
9972809|NCT01324674|Placebo Comparator|Placebo group|Is the group of subjects that will take placebo
9972810|NCT01324674|Experimental|experimental group|Is the group of subjects that will take Bach´s Flower remedies
9972811|NCT01324713||Males|
9972812|NCT01324713||Females|
9972813|NCT01324739|Active Comparator|B-type natriuretic peptide|the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
9972814|NCT01324739|Placebo Comparator|Placebo|comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo
9972815|NCT01324752|Experimental|PA21 and Losartan with food|
9972816|NCT01324752|Experimental|No PA21; Losartan with food|
9972817|NCT01324752|Experimental|PA21 with food and Losartan 2 hrs later|
9972818|NCT01324765|Experimental|TARGET|12-session affect regulation therapy for PTSD
9972819|NCT01324765|Active Comparator|SGT|12 session supportive group therapy
9972820|NCT01324778|Experimental|A|
9972821|NCT01324778|Active Comparator|B|
9972822|NCT01324791|Active Comparator|laparoscopic antireflux surgery|
9972823|NCT01324791|Active Comparator|endoscopic full-thickness-gastroplication|
9972824|NCT01324804||CABG - subjects|only one group
9972825|NCT01324817||Hopitalized|Patients admitted to the hospital
9972826|NCT01324856|Experimental|Pancreaticogastro anastomosis|
9972827|NCT01324856|Active Comparator|Pancreaticojejuno anastomosis|
9972828|NCT01324869|Experimental|Group A|Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
9972829|NCT01324869|Experimental|Group B|Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
9972830|NCT01324908|Experimental|Treatment (Treg predictor of response to ECP)|Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.
9972831|NCT01324921|Placebo Comparator|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
9662015|NCT01534481|Placebo Comparator|Preterm Formula|Preterm formula determined by center practice
9972832|NCT01324921|Active Comparator|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
9972833|NCT01324921|Experimental|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
9972834|NCT01324934|Active Comparator|Study Group|immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
9972835|NCT01324934|No Intervention|Control Group|immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.
9972836|NCT01324960|Experimental|Ceplene® / IL2 + Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
9972837|NCT01324960|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
9972838|NCT01324973|Experimental|eWellness program|A comprehensive program that delivers web-based, evidence-based weight management; and structured peer supports. The program is designed to meet the needs of individuals with mental illness.
9972839|NCT01324973|No Intervention|Control group|Care as usual
9972840|NCT01324986|Active Comparator|Nissen fundoplication|
9972841|NCT01324986|Active Comparator|Toupet fundoplication|
9972842|NCT01325012|Active Comparator|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle.
9972843|NCT01325012|Active Comparator|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
9972844|NCT01325025|Other|Patients|Patients with a metachromatic leukodystrophy
9972845|NCT01325025|Other|Control|Epileptic population
9972846|NCT01325038|Active Comparator|extra protein supplement|isometric training with addition of extra protein
9972847|NCT01325038|Active Comparator|extra food supplement|isometric exercise with addition of extra food and calories: one fast food meal/day
9972848|NCT01325051|No Intervention|Raltegravir|To test raltegravir to see if it can be detected in gastrointestinal tissue of healthy men.
10154677|NCT04052763||High-risk ACS patients|High-risk ACS patients admitted to the emergency departement witch chest pain.
10154678|NCT04052737|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, the same dosing regimen will be repeated every month for 6 months post randomization.
10154679|NCT04052737|Experimental|PMZ-1620 (sovateltide)|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1 (total dose/day: 0.9 µg/kg body weight), the same dosing regimen will be repeated every month for 6 months post randomization.
10154680|NCT04053192||High-Gradient Aortic Stenosis (HG-AS)|(Pmean >40mmHg, AVA <1cm^2, Vmax >4m/s)
10154681|NCT04053192||Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)|(Pmean <40mmHg, AVA <1cm^2, Vmax <4m/s, EF <50%)
10154682|NCT04053192||Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)|Pmean <40mmHg, AVA <1cm^2, Vmax < 4m/s, EF >50%)
10154683|NCT04052958|Active Comparator|Group 1: Strength Training|Respiratory muscle strength training
10154684|NCT04052958|Active Comparator|Group 2: Endurance Training|Respiratory muscle endurance training
10154685|NCT04052958|No Intervention|Group 3: Control group|no training of respiratory muscles
10154686|NCT04052711|Experimental|FMX-101|
10154687|NCT04052867|Experimental|Lignocaine group|20 patients undergoing elective laparoscopic donor nephrectomy will be given lignocaine infusion as part of the perioperative pain management.
10154688|NCT04052867|Active Comparator|Control group|20 patients undergoing elective laparoscopic donor nephrectomy will be receiving an equivalent volume of normal saline.
10154689|NCT04053205|Experimental|1 Gentuximab+ Paclitaxel|8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
10154690|NCT04053205|Experimental|2 Gentuximab+ Paclitaxel|12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
10154691|NCT04052594|Experimental|LY3475766 - IV|LY3475766 administered intravenously (IV) to participants with dyslipidemia
10154692|NCT04052594|Placebo Comparator|Placebo - IV|Placebo administered IV to participants with dyslipidemia
10154693|NCT04052594|Experimental|LY3475766 - SC|LY3475766 administered subcutaneously (SC) to participants with dyslipidemia
9694774|NCT04785118|Active Comparator|buscopan|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
9826358|NCT02415842||QPAN_C Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered 3.8 µg A/Indonesia/5/05 (H5N1) with AS03A on Day 0; phosphate buffer saline (PBS) preserved with 20 ppm thimerosal on Day 182; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Day 549.
10154694|NCT04052594|Placebo Comparator|Placebo - SC|Placebo administered SC to participants with dyslipidemia
10154695|NCT04052776|Active Comparator|Buspirone|40mg
10154696|NCT04052776|Active Comparator|Levodopa-Carbidopa|400mg/100mg
10154697|NCT04052776|Active Comparator|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
10154698|NCT04052776|Placebo Comparator|Placebo|Mannitol pill
10154699|NCT04052750|No Intervention|The control group|Patients in this group only received medications without daily text message reminder
10154700|NCT04052750|Experimental|The intervention group|Patients in this group received a daily short message service (SMS) reminder when medications were prescribed
10154701|NCT04052633||Cholangiography success|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative success of cholangiography
10154702|NCT04052633||Cholangiography failure|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative failure of cholangiography
10154703|NCT04052672|Active Comparator|Randomized Intervention|The intervention will consist of an exercise intervention, a combination of supervised exercise classes and in home exercises and open label nutritional supplement.
10154704|NCT04052672|No Intervention|Randomized - Control|The control will consist of a single group educational session which will include the discussion of general advice on health, exercise and nutrition as well as open label nutritional supplement
10154705|NCT04052659|Experimental|Treatment (sintilimab,chidamide and azacitidine)|"Sintilimab: 200 mg IV, Q3W, d1~Chidamid: 30 mg PO, BIW, d1, d4~Azacidine: 100 mg SC, Q3W, d1-7"
10154706|NCT04052607|Experimental|Dydrogesterone Suppression|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH.
10154707|NCT04052607|Experimental|Dydrogesterone Suppression with minimal stimulation|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH.
10154708|NCT04052607|Active Comparator|Antagonist Suppression|cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH.
10154709|NCT04052529|Experimental|Intervention|Participants are instructed to use a popular dietary self-monitoring application on their smartphone for one month.
10154710|NCT04052529|No Intervention|Control|Participants are not asked to use the smartphone application.
10154711|NCT04052438||Patients with recurrent abortion.|More than three idiopathic involuntary miscarriages.
10154712|NCT04052438||Patients with implantation failure.|More than three IVF abortions with good quality embryos or more than two abortions in oocyte donation cycles.
9826359|NCT02415842||QPAN5_G Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered PBS preserved with 20 ppm thimerosal on Day 0; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Days 182 and 549.
9826360|NCT02415842||H5N1_VT Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed study H5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received two administrations of the adjuvanted (AS03A) pandemic influenza vaccine (3.8 µg) containing the Vietnam (VT) strain at Day 0 and Month 12.
10154713|NCT04052503|Experimental|Fully Supported Group|Meetings with knowledge broker 6 times over 10 months to design and implement knowledge translation intervention. Intervention consisted of audit and feedback, goal setting, education, reminders, documentation changes, and KB support.
10154714|NCT04052503|Active Comparator|Partially Supported Group|Meetings with knowledge broker 4 times over 10 months to design and partially implement knowledge translation intervention. Group meets 2 additional times without knowledge broker to self implement intervention. Intervention consisted of audit and feedback, goal setting and documentation changes. Group self implemented education and reminders.
10154715|NCT04052412|Experimental|NSCLC with Immunotherapy without radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy without adjuvant radiation therapy
10154716|NCT04052412|Experimental|NSCLC with Immunotherapy with radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy with adjuvant radiation therapy
9671002|NCT05054244||control group|The patients in control group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires: visual analogue scale, McGill Pain questionnaire, Wound Quality of Life Index, Health Quality of Life Questionnaire, Beck depression and Beck anxiety inventory.
9671003|NCT05054244||HBOT group|"The patients in HBOT group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue.~The HBOT sessions will be performed 5 days a week in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires as in control group."
9671004|NCT05054322|No Intervention|Standard Care|Participants will be monitored via video call twice a day without any specific drugs.
9671005|NCT05054322|Experimental|Fluticasone propionate with spacer|Fluticasone propionate 125 mcg with spacer, 4 puffs, twice a day, added to standard care
9671006|NCT05054361||recent onset patients|patients with recently diagnosed type 1 diabetes
9671007|NCT05054361||at risk patients|patients with a high genetic risk type 1 diabetes
9671008|NCT05054361||control subjects|control patients (no risk of type 1 diabetes and no diagnosed type 1 diabetes)
9671009|NCT05054361||control subjects for endoscopy|patients without type 1 diabetes requiring UGI endoscopy for any medical reason
9671010|NCT05054257|Experimental|Autologous CAR19 T lymphocytes|Human Autologous T Lymphocytes Expressing the Chimeric Antigen Receptor Specific to CD19
9694775|NCT04785118|Active Comparator|ondansetron|Patients will receive IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
9694776|NCT04785118|Placebo Comparator|control|Patients will receive 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
9694777|NCT04785131|Experimental|Prune group|Oral contraceptive users will consume 50 grams prunes daily.
9977829|NCT01365637|Experimental|Cohort 3 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
10154717|NCT04052243|Other|All patients|Exercise is added to resting right heart catheterization
10154718|NCT04052321|Experimental|3D scan arm|This is a single arm study. Patients in this arm will receive a 3D scan just prior to, 2 weeks after, as well as 6 and 12 months after Nuss bar removal.
10154719|NCT04052347|Experimental|Shared decision-making with a patient decision-aid|
10154720|NCT04052347|Active Comparator|routine shared decision-making|control group
10154721|NCT04052360|Experimental|Cenerimod / ACT-334441|
10154722|NCT04052360|Placebo Comparator|Matching Placebo|
10154723|NCT04052373|Experimental|Peri-implantitis treatment with implantoplasty|Open flap debridement with implantoplasty treatment
9694778|NCT04785131|No Intervention|Oral contraceptive users|Oral contraceptive users will be monitored throughout the study period.
9694779|NCT04785131|No Intervention|Non oral contraceptive users|Non oral contraceptive users will be monitored throughout the study period.
9694780|NCT04785391||Patients with KDIGO stage 2 or 3 AKI|
9694781|NCT04785235||ACS|Group ACS: Acute Coronary Syndrome
9694782|NCT04785235||Periodontitis|Group P :Periodontitis
9694783|NCT04785534|Experimental|Screening (survey, biomarker analysis, fibroscan)|Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.
9694784|NCT04785560|Active Comparator|Shunt setting 4 (=110 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 4 (110 mm H20), our standard setting.
9694785|NCT04785560|Active Comparator|Shunt setting 8 (=400 mm H20)|Patients randomised to have the Certas Plus valve initial shunt setting post-operatively set to 8 (400 mm H20 a k a virtual off), in practice a closed non-functional shunt.
9694786|NCT04785222|Experimental|DB|Group DB: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
9694787|NCT04785222|Active Comparator|BP|Group BP: Bilateral infraorbital nerve block with 0.5% plain bupivacaine, a volume of 2 ml per side
9694788|NCT04785222|Placebo Comparator|NS|Group NS (control): Bilateral infraorbital nerve block with normal saline 2 ml per side
10154724|NCT04052373|Active Comparator|Peri-implantitis treatment without implantoplasty|Open flap debridement withput implantoplasty treatment
10154725|NCT04052451|Experimental|Major Depression Disorder|MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
10154726|NCT04052451|Experimental|Generalized Anxiety Disorder|MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured
10154727|NCT04052464||endometrium biopsy only|In these cases, only endometrium biopsy is investigated for the selected biomarkers gene expression profile.
10154728|NCT04052464||endometrium lavage followed by endometrium tissue biopsy|In these cases before the endometrium tissue biopsy, an endometrial lavage is performed and from both samples, the selected biomarkers gene expression profile are investigated.
10154729|NCT04052464||serial endometrium lavage followed by endometrium biopsy|In these cases before the endometrium tissue biopsy, at different days endometrial lavage samples are taken. From all samples, the selected biomarkers gene expression profile are investigated.
10154730|NCT04052269|Experimental|eyes with glaucoma|patients with glaucoma will have imaging of retina post administration of Sildenafil or Tadalafil.
10154731|NCT04052269|Other|Healthy (unaffected) eyes|patients with healthy eyes who are already taking Sildenafil or Tadalafil have their imaging of retina post administration of Sildenafil or Tadalafil.
10154732|NCT04052399|Active Comparator|Anodal tDCS|Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
10154733|NCT04052399|Active Comparator|Cathodal tDCS|Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
10154734|NCT04052399|Placebo Comparator|Sham stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
10154735|NCT04052061|Experimental|CD19 t-haNK|CD19 t-haNK will be administered to patients with Diffuse Large B-Cell Lymphoma who have received 2 or more lines of therapy and are ineligible for transplant.
10154736|NCT04052282||Mobile Health App - Healthy Individuals|"Mobile health App - Test~Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants.~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
10154737|NCT04052165|Experimental|Glaucoma drainage device in glaucoma patient|GDD is inserted in glaucoma patients
10154738|NCT04052386|Experimental|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
10154739|NCT04052386|No Intervention|Control|Participants randomized to the control group did not receive any intervention. They were an assessment-only control group.
10154740|NCT04052074|Experimental|Intervention group. Music in palliative patient|Listening to pre-recorded and selected music preferred by the patient, half an hour for 7 days.
10154741|NCT04052074|Sham Comparator|Palliative patient.|Basic therapeutic education repetition performed to all patients through earphones, half, an hour for 7 days.
10154742|NCT04052074|Experimental|Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
10154743|NCT04052074|Sham Comparator|Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
10154744|NCT04052308|Active Comparator|Control group|"Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team.~They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end fo the study; The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end fo the study; Answer EQ-5D-5L at baseline and at the end fo the study."
9671011|NCT05054764||Participants with CLTI and BTK lesions planned for revascularization|The study population will be CLTI patients presenting with lower limb tissue loss (ulcer or gangrene) and BTK lesions who are candidates for revascularization for limb salvage.
10154745|NCT04052308|Experimental|Continuous group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill at 60% of reserve heart rate), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
10154746|NCT04052308|Experimental|Interval group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill with alternating intensity between 50% and 80%) of HR, resulting in an average load of 60% ((50% 2) + 80% 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
10154747|NCT04052217|Other|Control Ring|"Normal intercourse with very thin (less than 0.5cm) ring randomised to either 3, 4 or 5 episodes of intercourse (Phase A)"
10154748|NCT04052217|Experimental|"1 RIng"|"Intercourse wearing a 1 ring. Randomised to either 3, 4, or 5 episodes of intercourse (Phase B)"
9694789|NCT04785248|No Intervention|Controlled group|the routine preoperative disinfection method
9972849|NCT01325077|Experimental|Conventional model, Study model|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
10154749|NCT04052217|Experimental|"1.5 Ring"|"Intercourse wearing a 1.5 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase C)"
10154750|NCT04052217|Experimental|"2 Ring"|"Intercourse with a 2 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase D)"
10154751|NCT04052256||Patients with intermediate coronary lesions|Patients (age ≥ 18 years) who have undergone invasive coronary angiography and have a minimum of one non-treated coronary artery with a measured invasive FFR of 0.81-0.90.
9694790|NCT04785248|Experimental|Three-step disinfection|new developed method of preoperative disinfection
9972850|NCT01325090|Experimental|BOTOX|Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area
9972851|NCT01325090|Placebo Comparator|PLACEBO|Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
9972852|NCT01325103|Experimental|Stem Cell Transplantation|Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation.
9972853|NCT01325116|Active Comparator|Control|Usual post-STEMI care
9972854|NCT01325116|Experimental|Intervention|Recurrent, personalized, educational reminders sent via post on behalf of the interventional cardiologist to the patient and their family physician urging long-term adherence to secondary prevention medications post-STEMI. A copy of the letter will be provided to the patient to take to their pharmacist.
9972855|NCT01325142||ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
9972856|NCT01325142||No ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
9694791|NCT04785521||BM patients|Adult patients carrying new diagnosed BM confirmed by MRI
9694792|NCT04785521||No BM patients|Adult patients carrying extracranial tumor without BM as confirmed by MRI
9972857|NCT01325168|Experimental|study group|32 PTSD patients intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
9972858|NCT01325168|Other|control group|control group - 30 healthy control subjects intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
9972859|NCT01325194|Experimental|CNS prophylaxis|
9972860|NCT01325220|Active Comparator|STX209 5 mg BID|
9972861|NCT01325220|Active Comparator|STX209 10 mg BID|
9972862|NCT01325220|Active Comparator|STX209 10 mg TID|
9972863|NCT01325220|Placebo Comparator|Placebo|
9972864|NCT01325233|Experimental|PG2 Injection|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
9972865|NCT01325233|Placebo Comparator|Placebo|Powder for Injection, 500 ml normal saline, tiw, 2 weeks
9972866|NCT01325259|Experimental|Alzheimer's disease|30 patients suffering from Alzheimer's disease
9972867|NCT01325259|Experimental|Mild Cognitive Impairment|20 patients suffering from Mild Cognitive Impairment
9972868|NCT01325259|Experimental|Control|15 subjects with no cognitive impairment
9972869|NCT01325272||preterm newborn|
9972870|NCT01325272||term newborn|
9972871|NCT01325298|Active Comparator|20 Minute UV-X Light Treatment Duration|"20 Minute UV-X Light Treatment Duration~Note: UV-X is the trademark of Peschke GmbH"
9972872|NCT01325298|Active Comparator|30 Minute UV-X Light Treatment Duration|30 Minute UV-X Light Treatment Duration
9972873|NCT01325324|Other|Study group|Study group
9972874|NCT01325363|Experimental|Schizophrenia|Schizophrenic patients
9972875|NCT01325363|Experimental|Control|Neurotypical subjects
9972876|NCT01325376|No Intervention|Self directed|
9694793|NCT04785521||Benign lesion patients|Adult patients carrying intracranial extra-axial tumor as as confirmed by MRI
9694794|NCT04785170|Experimental|amino acid|"Dose: 1000 mg/day (500 mg/Capsule) Regimen: One capsule after breakfast & one capsule after dinner to be taken with a glass of water.~Duration: 14 Days"
9694795|NCT04785105||patient with isolated SMA stenosis|patient with isolated SMA stenosis on initial scanner
9972877|NCT01325376|Active Comparator|Technology assisted health behavior|The intervention arm will have access to a dynamic online environment with social networking and device data uploads that include activity data, weight data and laboratory data at frequent intervals to nudge optimal health behavior.
9972878|NCT01325389|Experimental|Myo+Mel|Patients are treated with 2g of myo + 3mg of melatonin daily
9972879|NCT01325389|Placebo Comparator|Placebo|
9972880|NCT01325402|Experimental|Part 1 Cohort 1|Patients with mild to moderate Alzheimer's Disease
9972881|NCT01325402|Experimental|Part 1 Cohort 2|Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.
9972882|NCT01325402|Experimental|Part 2|Healthy Volunteers
9972883|NCT01325415|Experimental|A|NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
9972884|NCT01325415|Experimental|B|NKTR-118 150 mg (6x25 mg tablet)
9972885|NCT01325415|Placebo Comparator|C|NKTR-118 placebo (6x placebo tablets)
9972886|NCT01325415|Active Comparator|D|Moxifloxacin (1 x 400 mg tablet)
9972887|NCT01325454||Patients with parapneumonic effusions|Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
9972888|NCT01325480||Patients with heart failure and wide QRS|Patients undergoing a cardiac resynchronization therapy procedure
10154752|NCT04052178|Active Comparator|Repetitive transcranial magnetic stimulation (rtMS)|"Acute repetitive transcranial magnetic stimulation on the pharyngeal sensory cortex. Applied intensity 90% of the resting motor threshold, 1250 pulses at 5 Hz.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
10154753|NCT04052178|Active Comparator|Intrapharyngeal electrical stimulation (PES)|"Intrapharyngeal electrical stimulation applied to an intensity of 75% of the tolerance threshold with 0.2 ms pulses at 5 Hz during 10 min.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
10154754|NCT04052178|Active Comparator|Capsaicin|"100 mL of oral capsaicin solution at a concentration of 10-5M.~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized"
10154755|NCT04052009|Experimental|CT - Group|The conventional training consists of gait training during walking over ground. It includes the standard interventions therapists apply during training over ground. The aim is to achieve as many steps as possible. Three training sessions per week of intensive over ground therapy are planned, and twice a week a therapy with focus of attention isn't walking.
10154756|NCT04052009|Active Comparator|EET - Group|In the end-effector-based training participants undergo gait training in the end-effector device lyra (THERA-trainer). The principle of an end-effector is that the movement is induced at the level of participants feet. Furthermore, participants wear a harness attached to the end-effector lyra for safety purpose and for weight support. Three training sessions per week of intensive over lyra therapy are planned, and twice a week a therapy with focus of attention isn't walking
10154757|NCT04052009|Active Comparator|CETcomb:|The group with the combined training receives 5 sessions of CT and EET each. The pattern of series per week is always either two sessions of CT with one session of EET or vice versa.
10154758|NCT04052152|Experimental|Group A|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W (D1). Sintilimab injection will be administered until disease progressioncor un-tolerable toxicity. Anlotinib will be administered until disease progression. If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again"
10154759|NCT04052100|Active Comparator|Usual care|Patients following the standard preoperative policies of opur institution
10154760|NCT04052100|Experimental|Prehabilitation|Patients following the standard preoperative policies of opur institution and the multimodal prehabilitation program
10154761|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 1|
10154762|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 1|
10154763|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 2|
10154764|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 2|
10154765|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 3|
10154766|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 3|
10154767|NCT04051723|Experimental|The dexamethasone plus ropivacaine group|Patients in the dexamethasone plus ropivacaine group will receive a peri-incisional scalp infiltration with 0.025% dexamethasone and 0.2% ropivacaine and normal saline miscible liquids.
10154768|NCT04051723|Active Comparator|The ropivacaine group|Patients in the ropivacaine group will receive a peri-incisional scalp infiltration with 0.2% ropivacaine and normal saline miscible liquids.
10154769|NCT04051853|Experimental|Sorafenib with midazolam clearance test|"Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
10154770|NCT04051853|Experimental|Sorafenib with CYP cocktail test|"In this subgroup of 15 patients (in the Academic Medical Center Amsterdam), the midazolam test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
10154771|NCT04051827|Experimental|Part A: Midazolam + TAK-788|Midazolam 3 mg, solution, orally, once on Days 1 and 24 and midazolam 1 mg, infusion, intravenously, once on Days 2 and 25 along with TAK-788 160 mg, capsule, orally, once daily from Day 3 through 30 in Cycle 1.
10154772|NCT04051827|Experimental|Part B: TAK-788|TAK-788 160 mg, capsules, orally, once daily in a 28-day treatment cycle from Cycle 2 to Cycle 24, or until progressive disease (PD), intolerable toxicity, or another discontinuation criterion is met, whichever is sooner. Eligible participants from Part A may enter into Part B. Based on the investigator's opinion, if a participant continues to experience clinical benefit, treatment with TAK-788 may be continued after PD.
10154773|NCT04051762||Preterm neonates on HFNC|neonates extubated to HFNC (High flow nasal cannula)
10154774|NCT04051762||Preterm neonates on NCPAP|neonates extubated to NCPAP ( nasal continuous positive airway pressure)
10154775|NCT04051840|Experimental|ClinOleic group|Patients will be grouped to ClinOleic-based lipid parenteral nutrition regimen using ClinOleic or Structolipid-based lipid parenteral nutrition regimen using Structolipid. From day 0 to day 5, patients will not to receive any food or liquid oral or enteral nutrition. The goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid. The weight of patient calculated as ideal body weight. The patients will be allowed water based on the clinical judgment of the Investigator. From day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent is to supply the total calculated daily nutritional requirement with study treatment plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition will be increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.
10154776|NCT04051970|Experimental|Strategy TRI-BI|
10154777|NCT04051970|Active Comparator|Strategy Immediate BI|
10154778|NCT04051931||stable COPD group|include COPD patients with stable state
10154779|NCT04051931||AECOPD group|include COPD patients with acute exacerbation
9972889|NCT01325506||Prostatectomy subjects|
9972890|NCT01325519|No Intervention|no intervention control group|control subjects
9972891|NCT01325519|Experimental|experimental intervention group|video decision aid viewed by subjects
10154780|NCT04051697|No Intervention|Usual Care arm|Participants allocated to the control group will receive their usual care. Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care. Participants in this arm do not receive the self-management intervention (SEA CHANGE).
10154781|NCT04051697|Experimental|Intervention arm|Participants in the intervention group will receive usual care and will be offered access to the self-management intervention (SEA CHANGE). Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care.
10154782|NCT04051749||Patients submitted to VS|
10154783|NCT04051632||Type 1 Diabetes patients treated with the Medtronic 670G|Type 1 Diabetes patients treated with the Medtronic 670G at Boston Childrens Hospital
10154784|NCT04051658|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the motor area (M1) of the affected hemisphere, Cathodal on the contralateral supraorbital area. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
10154785|NCT04051658|Experimental|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hour). Anodal on the supraorbital area of the affected hemisphere, Cathodal on the primary motor area (M1) of the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
10154786|NCT04051658|Experimental|Dual-tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The current intensity is fixed at 1.5 mA and the current will flow continuously. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic.
10154787|NCT04051658|Sham Comparator|Sham-tDCS & PT|Dual transcranial direct current stimulation (tDCS) in sham mode will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hour). Anodal on the affected hemisphere, Cathodal on the unaffected hemisphere. The physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
10154788|NCT04051489||Mobile App|Individuals with symptomatic knee osteoarthritis
10154789|NCT04051424|Active Comparator|ConMed bite block|Standard bite block (Conmed Bite Block; Conmed Corp., Utica NY, USA)
10154790|NCT04051424|Active Comparator|Williams Airway|Williams Airway Intubator (Williams Airway Intubator Ltd, Calgary, Canada)
10154791|NCT04051424|Experimental|McKay airway|A new device that enables maintenance of jaw thrust. (US patent application 16/098,530)
10154792|NCT04051645|Experimental|Breathing through a system with adjustable flow resistance|During the experiment, the volunteers will breathe through ten adjustable flow resistances and their work of breathing will be measured.
9972892|NCT01325545||Cryptogenic stroke|Patients with stroke of unknown cause after comprehensive conventional evaluation
10154793|NCT04051736|Experimental|group 1|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
10154794|NCT04051736|Active Comparator|group 2|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV
10154795|NCT04051671|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
10154796|NCT04051671|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins (sham mode) of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
10154797|NCT04051541|Other|Simulation arm|All patients were entered into the Simulation arm and received 3 pushes of agitated saline via 3 different methods of delivery. All patients received all methods. The order of the methods for each patient was randomized.
10154798|NCT04051528|Experimental|combinatorial training group|Combinatorial training group will have the same procedure with the sequential training group in the first 8 sessions. After that the procedure for sessions from 9th to 16th will be 60 minutes of guiding training.
10154799|NCT04051528|Experimental|sequential training group.|Sequential training group will first undergo aerobic exercise training for 30 minutes followed by 30 minutes of computerized cognitive training. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
10154800|NCT04051580|Experimental|Lactated Ringer's solution|For patients randomized to lactated Ringer's solution (study group), lactated Ringer's solution is used as a base solution for del Nido cardioplegia.
10154801|NCT04051580|Active Comparator|PlasmaLyte-A|For patients randomized to PlasmaLyte-A (control group), PlasmaLyte-A (Baxter Healthcare Corporation, Deerfield, IL, USA) is used as a base solution for del Nido cardioplegia.
9972893|NCT01325545||Stroke of known cause|Patients with stroke of known cause determined by comprehensive conventional evaluation
9972894|NCT01325571|Experimental|tacrolimus group|
9972895|NCT01325571|Placebo Comparator|placebo group|
9662016|NCT01315639|Other|biomarkers, MRI and CSF|"Longitudinal multicenter study including 1300 subjects with amnestic impairment (MCI, n=650 and AD, n=650) derived from the main French national Memory Resources and Research Centers.~Participants will undergo at baseline and every 6 months a neurological examination, a neuropsychological assessment (and an oculomotor examination for those included from Broca Hospital).~Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
9972896|NCT01325597|Experimental|Combined training|Training with functional electrical stimulation added by inspiratory muscle training.
10154802|NCT04051515|Experimental|Intradialysis exercise guided by nursing staff|During 16 weeks subjects will exercise during the hemodialysis session, the exercise will include both aerobic and resistance training. Guidance will be provided by nursing staff
10154803|NCT04051515|Active Comparator|Home-based exercise program|During 16 weeks subjects will exercise on their own at home. A booklet will be provided, with a diary. Instructions to do resistance exercise with intervals of walking will be provided. Initial training will be provided by physiotherapy staff from the hospital.
10154804|NCT04051554|Experimental|Neuromuscular and Proprioceptive Training|Myklebust's training program
10154805|NCT04051554|Active Comparator|Conventional Training|Running, Sprints, Agility training, and Dynamic stretching
10154806|NCT04051476|Experimental|3-g footbath|Footbath with 3g ginger flour per liter of water
10154807|NCT04051476|Experimental|6-g footbath|Footbath with 6g ginger flour per liter of water
10154808|NCT04051476|Experimental|12-g footbath|Footbath with 12g ginger flour per liter of water
10154809|NCT04051476|Placebo Comparator|Warm water footbath|Footbath with warm water only
10154810|NCT04051567|Experimental|LDA group|
10154811|NCT04051567|No Intervention|NC group|
10154812|NCT04051593|Experimental|Treatment|Exercise
10154813|NCT04051437|Experimental|Plasma exchange|The consented patients will receive standard medical management with sessions of single volume plasma exchange with fresh frozen plasma and 5% human albumin.Plasma exchange session will be done on an alternate day to a maximum of 5 procedures.
10154814|NCT04051437|Active Comparator|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections, entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
10154815|NCT04051372||BAL group|"Adult patients with hematology disease under allo-HSCT at any phase of treatment are enrolled according to the following criteria:~lung infiltration detection at computed tomography (CT) scan.~Patients with fever, cough, respiratory symptoms. According to the investigators, the patients fulfilling these criteria undergo BAL as soon as possible"
10154816|NCT04051788|Experimental|Step Aerobics|Step Aerobics Training (120 to 126 foot steps per min)
10154817|NCT04051788|Active Comparator|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling
10154818|NCT04051398|Experimental|Intervention Arm (BI)|The BI participants will initially undergo simple spirometry and a 6-minute walk test and Borg scale application upon admission to the thoracic surgery department. Immediately after the exams, they will undergo a TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes. Immediately after the TENS application, the participants will be submitted to a new spirometry, a new 6-minute walk test and again to the Borg scale.
10154819|NCT04051398|Placebo Comparator|Control Arm (BC)|The BC participants will undergo the same steps as BI, however when applying TENS to these participants investigators will place the electrodes over the points without turning on the device in order to obtain the effect of a placebo.
10154820|NCT04051203|Experimental|Autologous Platelet Rich Plasma Injection|PRP contains high concentrations of platelets, growth factors, and anti-inflammatory molecules.
10154821|NCT04051203|Active Comparator|Standard Treatment|Steroid and anesthetic injection: the clinical standard.
10154822|NCT04051203|Placebo Comparator|Normal Saline|Placebo injection, with no known treatment effects.
10154823|NCT04051190|Experimental|VLED group|Participants will undergo a 10-week VLED.
10154824|NCT04051190|Experimental|Sleeve Gastrectomy group|Participants will undergo standard clinical practice prior to surgery.
10154825|NCT04051190|Experimental|Gatric Bypass group|Participants will undergo standard clinical practice prior to surgery.
10154826|NCT04051164|Experimental|Progressive Muscle Relaxation Technique|Progressive muscle relaxation technique
10154827|NCT04051164|Active Comparator|Conventional treatment|Conventional Treatment: (Strengthening exercises of residual limb, Gait training, Deep Breathing exercise)
10154828|NCT04051255|Experimental|Smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgingival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients has prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
10154829|NCT04051255|Experimental|Non-smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
10154830|NCT04051359|Active Comparator|Standard carbohydrate (200 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the standard carbohydrate (200 g) group.
10154831|NCT04051359|Experimental|Low carbohydrate (130 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the low carbohydrate (130 g) group.
10154832|NCT04051385|Active Comparator|stage II grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage II grade B periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
10154833|NCT04051385|Active Comparator|stage III grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage III grade B periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
10154834|NCT04051385|Active Comparator|gingivitis|"GCF and serum samples were taken before and after treatment from gingivitis patients.~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
10154835|NCT04051385|Placebo Comparator|periodontally healthy|GCF and serum samples were taken at baseline from periodontally healthy individuals.
10154836|NCT04051021|Other|Usual Care|
10154837|NCT04051021|Experimental|Comfort Coach|
10154838|NCT04051008|No Intervention|Group 1 - Control|No intervention - participants will shop in-person as they usually would. Participants will receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
10154839|NCT04051008|Experimental|Group 2 - Online|Participants will utilize online grocery shopping (shopping at a local grocery store via an online platform). Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
10154840|NCT04051008|Experimental|Group 3 - Default|The default intervention will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make recipes from the provided recipe cards, and that they can modify it as they like. Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
10154841|NCT04051307|Experimental|intervention|"Vaccination with:~PD-L1 peptide:~PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL Dose: 100 µg PD-L1 long1 dissolved in DMSO/water - Total volume: 0,5 ml.~Arginase1 peptide:~ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL Dose: 200 µg ARGLong2 dissolved in DMSO/water - Total volume: 0,5 ml.~Both vaccines are given at a treatment. Adjuvant Montanide ISA 51 0,5ml is mixed with the peptides before treatment To be administered every second week - a total of twelve times, with a possibility of additional six treatments."
10154842|NCT04051151|Experimental|Gameification Arm|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game.
10154843|NCT04051151|No Intervention|Education Arm|Participants and partners that randomized to the control group will receive standard of care educational resources on the importance of physical activity in Parkinson's patients.
10154844|NCT04050982|Experimental|AF CARE|Patients will interface with digital application.
10154845|NCT04050982|Active Comparator|Usual Care and Daily Weight|Usual care with daily weight entry
9972897|NCT01325597|Experimental|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
10154846|NCT04051034|Experimental|Omega 3 supplementation|12 weeks: Active: 1.25 g capsules/ [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
10154847|NCT04051034|Experimental|Placebo|12 weeks: Placebo: 1.25 g capsules/ [1.25-gram high oleic safflower oil capsule]with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
10154848|NCT04051177|Experimental|parents living with HIV intervention group|Parents living with HIV in this group received five two-hour parent HIV disclosure intervention, delivered one session per week for five weeks in the clinics where the parents are recruited. The intervention curriculum is modeled after the TRACK program with supplemental materials from TALC.
10154849|NCT04051177|Other|Parents living with HIV control group|"Parents living with HIV in this group received five two-hour nutrition education curriculum in same delivery way. The nutrition curriculum is modeled after the Simply Good Eating: curriculum developed at University of Minnesota."
10154850|NCT04051086|Other|Williams Beuren|Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
10154851|NCT04051086|Other|Micro-duplication 7q11.23|Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
10154852|NCT04051086|Other|Healthy Group|Subjects without cardiovascular and neurological medical history.
10154853|NCT04050943||CRD patients|Patients with chronic pulmonary disease like COPD, asthma, bronchiectasis, and etc.
10154854|NCT04051281|No Intervention|Just under target control|Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing; no letter sent.
10154855|NCT04051281|Experimental|Just under target letter|"Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing: receive a letter informing of this.~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
9972898|NCT01325597|Experimental|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
10154856|NCT04051281|No Intervention|Over target control|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; no letter sent~Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)~Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2)"
10154857|NCT04051281|Experimental|Over target letter|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target (Letter B1)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
10154858|NCT04051281|Experimental|Over target letter with bar chart|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target, including a bar chart showing their prescribing compared to the target (Letter B1)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
10154859|NCT04051281|Active Comparator|Top 20% feedback letter control|"Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on--standard practice--(Letter C1)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
10154860|NCT04051281|Experimental|Top 20% above target letter|"Targeting practices that are currently in the top 20% of prescribers; letters informing them that their prescribing exceeds the new target (Letter C2)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
10154861|NCT04051281|Experimental|Top 20% feedback letter with specific example of patient harm|"Targeting practices that are currently in the top 20% of prescribers~• Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1) Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
10154862|NCT04051047|Experimental|Gemcitabine|Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure. The surgical procedure is standard of care.
10154863|NCT04050852|Experimental|SMA patients receiving nusinersen treatments|
10154864|NCT04051099|Experimental|bilateral cervical plexus block|bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 0.25% bupivacaine 16 mg)
10154865|NCT04051099|Experimental|General anesthesia|General anesthesia with endotracheal intubation under total intravenous anesthesia (TIVA)
10154866|NCT04050878|Experimental|Patient with or without dental prostheses|The patient will be submitted to two facial scans, one with and another without the dental prostheses and the obtained datasets will be compared to assess the differences. Marks will be made in the face to allow for measurements (digital and conventional)
10154867|NCT04050917|Experimental|Real stimulation|The smartwatch produces vibration stimulation.
10154868|NCT04050917|Sham Comparator|No stimulation|The smartwatch produces no vibration.
10154869|NCT04051073|Sham Comparator|Blinded|CNAP monitoring applied, but screen and information not visible to treating anaesthetist
10154870|NCT04051073|Active Comparator|Unblinded|CNAP monitoring applied and available in full to the treating anaesthetist
10154871|NCT04050969|Active Comparator|Atrial Fibrillation (AF) Catheter Ablation-Group A|Participants will undergo catheter ablation using either radiofrequency or cryo-ablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extra-pulmonary sites at the physician's discretion.
10154872|NCT04050969|Experimental|Bariatric surgery prior to AF Catheter Ablation-Group B|"Participants will undergo either a Roux-en-Y gastric bypass or a laparoscopic sleeve gastrectomy. The choice of the procedure will be based on numerous factors including current practice, the surgeon's and participant's choice, BMI, and the presence of certain comorbidities and their severity such as GERD, kidney stones, and past surgical history. Participants will undergo standard preoperative evaluation including dietary consultation and psychological evaluation during the eligibility process.~After bariatric surgery, in addition to routine post-surgical management, patients will follow up with cardiologist prior to AF catheter ablation."
10154873|NCT04050592|Other|Group A, Abrupt Discontinuation|Women in group A will discontinue HT (estradiol, 2 mg daily) abruptly after study week 9 and will continue with placebo for study weeks 10-20.
10154874|NCT04050592|Other|Group B, Tapered Discontinuation|"Women in group B will discontinue HT (estradiol, 2 mg daily) gradually during study weeks 7-9, as follows:~weeks 7-9: 1 mg estradiol daily for 10 days and then 1 mg estradiol every other day for 11 days.~weeks 10-20: placebo"
10154875|NCT04050592|Active Comparator|Group C, Control Group|Women in Group C, the control group, will continue with HT (estradiol, 2 mg daily) throughout the whole study period of 20 weeks.
9662017|NCT01269593|Experimental|PET Imaging Using 124 IPUH71|Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.
9972899|NCT01325597|No Intervention|Control group|No intervention.
10154876|NCT04050748|Placebo Comparator|Early Rehabiliation|6 weeks of non-weight bearing in addition to basic stretching exercises.
9662018|NCT01144520||Normoglycemic|Healthy subjects that do not have diabetes
9662019|NCT01144520||Type II Diabetes (HbA1c <7 or 7%)|Subject that have Type II Diabetes with good glucose control with glycated hemoglobin (HbA1c <7 or 7%)
10154877|NCT04050748|Active Comparator|Accelerated Rehabilitation|Patients will be non-weight bearing for 2 weeks. After 2 weeks patients were transitioned to a boot with two heel wedges and were weight bearing as tolerated. At 4 weeks, patients were transitioned to one wedge, and at 6 weeks patients were weight bearing as tolerated in a flat shoe. Each heel wedge was ¾ inch tall. After 6 weeks, patient's in both groups underwent identical rehab regimens per protocol
10154878|NCT04050904|Experimental|ExpHeart|The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment.
10185789|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethason with daratumumab|Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22. Daratumumab 1800mg SC Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18
10185790|NCT03742284|Other|SoftOx Wound Irrigation Solution|SoftOx Wound Irrigation Solution is Medical Device that will be applied to rinse acute wounds.
10185791|NCT03742258|Experimental|Treatment (R-CHOP, TAK-659)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in course 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
10185792|NCT03742245|Experimental|Olaparib and Vorinostat|"Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat.~Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression."
10185793|NCT03742232|Experimental|PLENVU|PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
10185794|NCT03742232|Active Comparator|SELG-ESSE|SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
10185795|NCT03742219|Experimental|Lifestyle Intervention|Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
10185796|NCT03742206|Experimental|Parasacral|Parasacral Transcutaneous Electrical Stimulation Group: participants in this group will receive two self-adhesive electrodes and will be instructed to position them in the sacral region. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
10185797|NCT03742206|Active Comparator|Posterior Tibial Nerve|Transcutaneous Posterior Tibial Nerve Stimulation Group: participants in this group will receive a neoprene ankle brace that will be connected to the electrostimulator. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
10185798|NCT03742193|Experimental|Apatinib + GD group|Apatinib + GD regimen. For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after. For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles. Apatinib monotherapy is then maintained until 1 year following complete resection.
10185799|NCT03742180|Experimental|intranasal dexmedetomidine|this group is planned for intranasal dexmedetomidine
10185800|NCT03742180|Active Comparator|sublingual ketorolac|this group is planned for sublingual ketorolac
10185801|NCT03742115|Experimental|Etoposide standard group|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
10185802|NCT03742115|Experimental|Etoposide reduction group|Etoposide 150 mg/m2 once a week; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
10185803|NCT03742115|Active Comparator|Corticosteroid group|dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering, with or without IvIG (0.5 g/kg IV, once every 4 weeks)
10185804|NCT03742089||Treatment|Bone Anchored Hearing Surgery using a BHX implant manufactured by Oticon Medical
10185805|NCT03742063||Huvos group I|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade I is 0% to 49%.
9520005|NCT03281421|Active Comparator|Group from anterior to posterior (GAP)|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from anterior to posterior. The physiotherapist will be positioned behind the participant's ankle. An belt will be posicioned above the participant's malleolus and around physiotherapist's trunk. The therapist applies with belt a posterior slip sustained in the tibia of the participant, while the heel and rearfoot are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
10154879|NCT04050644|Experimental|Preservative-free dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preservative-free dexamethasone 0.1% and diclofenac 0.1% eye drops.
10154880|NCT04050644|Active Comparator|Preserved dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preserved dexamethasone 0.1% and diclofenac 0.1% eye drops.
10154881|NCT04050566||Mothers|900 mothers recruited during pregnancy
10154882|NCT04050566||Children|900 children born to the recruited mothers
10154883|NCT04050800|Experimental|Healthy Controls|Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.
10154884|NCT04050670|Experimental|Tirzepatide - Upper Arm|Tirzepatide administered subcutaneously (SC) to the upper arm of healthy participants in one of three study periods.
10154885|NCT04050670|Experimental|Tirzepatide - Thigh|Tirzepatide administered SC to the thigh of healthy participants in one of three study periods.
10154886|NCT04050670|Active Comparator|Tirzepatide - Abdomen|Tirzepatide administered SC to the abdomen of healthy participants in one of three study periods.
10154887|NCT04050579|Other|OPIE in thin inverventricular septum|The Principal Investigator use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated.
10154888|NCT04050631||L&D team|the first responders on L&D floor including : anesthesia, nurses and OBGYN
10154889|NCT04050774|Experimental|Age group 1|6-9 years old
10154890|NCT04050774|Experimental|Age group 2|15-17 years old
10154891|NCT04050774|Experimental|Age group 3|18 - 24 years old
10154892|NCT04050774|Experimental|Age group 4|65-80 years old
10154893|NCT04050813|Experimental|Control|"The program is performed 2 times per week using resistance equipment in a physiotherapy clinic. Each session consists of on 2-legged loaded exercises for hamstring, quadriceps, gluteus maximun and core. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 4 exercises.~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 set of 12-repetition maximum (12RM), in week 1 and 2; 3 set of 10 RM, in week 3 and 4; 4 set of 10RM, in weeks 5 and 6; and 4 set of 8RM, in weeks 7 to 8."
10154894|NCT04050813|Experimental|Intervention|Experimental: Inertial flywheel resistance training The program is performed 2 times per week using resistance equipment in a physiotherapy clinical. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 16 repetition maximum (RM) with moment inertia 0.05 m² from week 1-2, 24 repetition maximum (RM) with moment inertia = 0.10 m² from week 3 to 4. 32 repetition maximum (RM) with moment inertia = 0.10 m² from week 5 to 6 and 32 repetition maximum (RM) with moment inertia = 0.13 m² in a flywheel hamstring curl devise.
10154895|NCT04050839|Experimental|Neuroscience pain education group|Pain neuroscience education in addition medical treatment
10154896|NCT04050839|Active Comparator|Control group|Medical treatment only
10154897|NCT04050826|Experimental|Dermal Pharmacokinetic study|"Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dOFM after topical application of three lidocaine/prilocaine products in 20 participants.~After baseline sampling (1 hour pre-dose) the three lidocaine/prilocaine products will be applied and removed after 3 hours. ISF and blood sampling will be continued for a duration of 12 hours post-dose. Additionally different physical parameters (e.g. TEWL) will be measured."
10154898|NCT04050787|Experimental|D2 Lymphadenectomy including No. 10|lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
10154899|NCT04050787|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy but without No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
10154900|NCT04050514|Experimental|H-MAD, hinge system according to Herbst|"Patients with snoring and OSAS. Therapy with MAD type H-MAD with lateral hinges according to Herbst.~Bite elevation 2 mm interocclusal distance with a lower jaw advancement of 5 mm"
10154901|NCT04050514|Active Comparator|F-MAD, SomnoDent Fusion|Patients with snoring and OSAS,Fusion MAD with sliding side wings (F-MAD). Bite elevation 5 mm interocclusal distance with a lower jaw advancement of 5 mm
10154902|NCT04050488|Active Comparator|Treatment Group|Participants who receive the intervention.
10154903|NCT04050488|Placebo Comparator|Control Group|Participants who receive the placebo.
10154904|NCT04050761||Monotherapy|Participants diagnosed with recurrent or metastatic squamous cell carcinoma of the Head and Neck and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of SCCHN.
9671012|NCT05054101|Experimental|VieCovid2020 smartphone application|The VieCovid2020 smartphone application in add-on to usual psychiatric intervention
10154905|NCT04050930|Experimental|Normal weight, normo-dented|healthy young male presenting a good oral health ad a normal weight
10154906|NCT04050930|Experimental|Obese, normo-dented|healthy young male presenting a first level of obesity, and a good oral health
10154907|NCT04050475|Experimental|PSY-FMD|Subjects randomized in the PSY-FMD group carried out the Functional Therapy protocol over 20 individual sessions, which were scheduled twice a week for the first two months and once a week for the last month (three months total). The treatment program was specifically manualized for treating depression with the aim to increase mood, self-esteem and quality of life. Furthermore, patients followed a Fasting Mimicking Diet (FMD) protocol consisting of 3 cycles of 5 days a month each: the first day of the diet provided 1090 kcal (10% protein, 56% fat, 34% carbohydrate), the days 2-5 were identical in the formulation and provided 725 kcal (9-10% protein, 44-56% fat, 34-47% carbohydrate). Between cycles of FMD the subjects stuck to a free diet. At the end of the treatment all patients were re-tested through the same assessment protocol and the same things was realized at the follow-up (three months later the end of the treatment).
9671013|NCT05054101|Placebo Comparator|Usual psychiatric intervention|Usual psychiatric intervention alone
9671014|NCT05054062|Experimental|Healthy participants|
10154908|NCT04050475|No Intervention|PSY|Subjects randomized into the control group (PSY) completed the same Functional Therapy program without practicing any diet. Specifically, at the end of the nutritional consultation the nutritionist suggested them to keep a food diary without changing their habitual diet style.
10154909|NCT04050735|Experimental|Alcohol, ethyl, moderate dose|0.6 gram ethyl alcohol per kilogram of body weight
10154910|NCT04050735|Placebo Comparator|Placebo|0 gram ethyl alcohol per kilogram of body weight
10154911|NCT04050657|Experimental|Two-week appointment interval group|Orthodontic patients who come to tighten their braces every 2-weeks.
10154912|NCT04050657|Other|Eight-week appointment interval group|Orthodontic patients who come to tighten their braces every every 8-weeks.
10154913|NCT04050891|No Intervention|group GA (general anesthesia)|"After pre-oxygenation general anesthesia was induced using 2mg/kg propofol, 1μg/kg of fentanyl. After loss of consciousness 0.5 mg/kg of atracurium was injected. The endotracheal tube (ETT) was placed and inflated. The patient was mechanically ventilated to adjust end tidal CO2 between 35 and 40mmHg, anesthesia was maintained using 1.2 % isoflurane diluted in 3L of 50 % oxygen mixed with air. Increments of fentanyl (0.5 μg/kg ) and atracurium 10 mg were used whenever required and the hemodynamic values were maintained within 20% of the basal values.~At the end of surgery, residual muscle relaxant was reversed with 50µg/kg neostigmine and 0.02 mg/kg atropine."
10154914|NCT04050891|Active Comparator|group RA (regional anesthesia)|received combined supraclavicular and interscalene block.The mixture of anesthetic suolution was prepared by 20 ml isobaric bupivacaine 0.5% plus 10ml lidocaine 2% plus 10ml normal saline, total volume was 40ml which is devided into 25ml for suraclavicular block and 15ml for intersalene block
10154915|NCT04050345||Colon|Patients who have a diagnosis of large bowel cancer (in the colon) and the cancer is not metastatic.
10154916|NCT04050345||Rectal|Patients who have a diagnosis of large bowel cancer (in the Rectum) and the cancer is not metastatic.
10154917|NCT04050423||Breast Characterization|
10154918|NCT04050384|No Intervention|No vibratory stimulus before or during heel lance|Baseline measurements and readings after vibration alone will be done, but no vibratory stimulus will be provided immediately preceding or during heel lance.
10154919|NCT04050384|Experimental|Vibratory stimulus before and during heel lance|Baseline measurements and readings after vibration alone will be done, as well as a vibratory stimulus that will be provided immediately preceding and during heel lance.
10154920|NCT04050696|Experimental|Treatment (with PT run-in)|Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
10154921|NCT04050228|No Intervention|Standard Neoadjuvant Chemotherapy Monitoring|
10154922|NCT04050228|Experimental|Adaptive Chemotherapy Monitoring|
10154923|NCT04050397|Experimental|Supervised exercise arm|Informational initiation lecture and supervised exercise twice a week for 12 weeks followed by 12 weeks of non-supervised exercise.
10154924|NCT04050397|Active Comparator|Non-supervised exercise arm|Informational initiation lecture and only non-supervised exercise
10154925|NCT04050332|Experimental|Stair Walking|Participants in this arm will engage in four minutes of stair walking while being tracked by radio frequency identification equipment.
10154926|NCT04050332|No Intervention|Control|Participants in this arm will stand in the stairwell for four minutes while being tracked by radio frequency identification equipment.
10154927|NCT04050215|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 3 hours. Patients may be reenrolled in the study, if 68Ga-PSMA-11 PET/CT is performed for subsequent management decision.
10154928|NCT04050241|Experimental|Videolaryngoscope|Anesthetists performing intubation with the Glidescope videolaryngoscope.
10154929|NCT04050241|Experimental|Direct laryngoscope|Anesthetists performing intubation with the Mcintosh laryngoscope.
10154930|NCT04050254|Experimental|Real tDCS + exercise|Transcranial direct current stimulation combined with therapeutic exercise
10154931|NCT04050254|Sham Comparator|Sham tDCS + exercise|Sham transcranial direct current stimulation combined with therapeutic exercise
10154932|NCT04050254|No Intervention|Control|No treatment.
10154933|NCT04050306||Adolescents and young adults|Participants 12-19 years old without chronic diseases.
10154934|NCT04050267|Placebo Comparator|Control group - air|Breathing air with 21 % of oxygen (0% nitrous oxide). Performing cognitive tests as per protocol.
10154935|NCT04050267|Experimental|Intervention Group - 5% nitrous oxide|Breathing 5% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
10154936|NCT04050267|Experimental|Intervention Group - 7% nitrous oxide|Breathing 7% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
10154937|NCT04050267|Experimental|Intervention Group - 10% nitrous oxide|Breathing 10% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
10154938|NCT04050267|Experimental|Intervention Group - 12% nitrous oxide|Breathing 12% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
10154939|NCT04050267|Experimental|Intervention Group - 15% nitrous oxide|Breathing 15% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
10154940|NCT04050267|Experimental|Intervention Group - 20% nitrous oxide|Breathing 20% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
10154941|NCT04050358|Active Comparator|1X dose of NRPT|
10154942|NCT04050358|Placebo Comparator|Placebo|
10154943|NCT04050124|Experimental|Promogran Prisma|Following standard of care split thickness skin grafting, patients randomized to the intervention group will receive Promogan Prisma as the primary contact dressing at the donor grafting site.
10154944|NCT04050124|Active Comparator|Standard of care (SOC) dressings|
10154945|NCT04050176|Experimental|Blinded Hypnotic Medication Taper (BT)|Participants assigned to the Blinded Taper group will not know the medication dose they receive during the Structured Medication Taper (SMT) phase.
10154946|NCT04050176|Active Comparator|Open-Label Hypnotic Medication Taper (OLT)|Participants assigned to the Open-Label Hypnotic Medication Taper group will know the medication dose they receive during the SMT phase.
10154947|NCT04050163|Experimental|Low Dose|
10154948|NCT04050163|Experimental|Intermediate Dose|
10154949|NCT04050163|Experimental|High Dose|
10154950|NCT04049942|Experimental|Prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
10154951|NCT04049942|Experimental|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
10154952|NCT04049838|Active Comparator|lateral transversus abdominis block|patients will take lateral transversus abdominis plan block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
10154953|NCT04049838|Active Comparator|posterior tansversus abodominis plane block|patients will take posterior transversus abdominis plane block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
10154954|NCT04049838|Active Comparator|convential analgesia|conventional analgesia in form of 1 micrograms. Kg-1 fentanyl and paracetamol 15 mg. Kg-1 suppositories
10154955|NCT04050020|Active Comparator|Group A|
10154956|NCT04050020|Placebo Comparator|Group B|
10154957|NCT04050059|Active Comparator|2% Lidocaine group|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited) skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal anesthesia induction.
10154958|NCT04050059|Active Comparator|EMLA cream group|In EMLA (Eutectic Mixture of Local Anesthesia- lidocaine 2.5% and prilocaine 2.5%) cream group, EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
10154959|NCT04050072||Childhood Cancer Survivors (CCSS)|i. PRO-CTCAE-SCC ii.Quality of life assessment
10154960|NCT04050072||St. Jude Life (SJLIFE)|i. PRO-CTCAE-SCC ii. Quality of life assessment iii. Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation
10154961|NCT04050072||Community non-cancer control|i. PRO-CTCAE-SCC ii.Quality of life assessment
10154962|NCT04049916|Active Comparator|Pyronaridine-artesunate (PA)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days.
10154963|NCT04049916|Experimental|PA with single low dose primaquine (PQ)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days, and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
10154964|NCT04049916|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days.
10154965|NCT04049916|Active Comparator|DP with single low dose primaquine (PQ)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days., and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
10154966|NCT04050098|Active Comparator|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
10154967|NCT04050098|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
10154968|NCT04050111|Experimental|SVF injection|"Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.~Interventions:~Procedure: Liposuction Other: SVF isolation Other: Intraarticular administration of autologous SVF"
10154969|NCT04050046|Active Comparator|Real tDCS + CBCT|20 minutes of 2.0mA of tDCS for 5 consecutive days
10154970|NCT04050046|Sham Comparator|Sham + CBCT|Sham stimulation closely imitates reals tDCS 30 second ramp-up / ramp-down
10154971|NCT04049929|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
10154972|NCT04050137|Experimental|Exercise group|Exercise programme 3 times/week.
10154973|NCT04050007|Experimental|1|Preventive initiation of fluid removal
10154974|NCT04050007|Other|2|Curative initiation of fluid removal
10154975|NCT04049955|Experimental|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
10154976|NCT04049747|Experimental|CHRONOS A - Arm 1 (Control)|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]). In patients undergoing radiotherapy a maximum of 6-months neo-adjuvant hormonal therapy will be allowed. In patients undergoing radical prostatectomy, cytoreduction of maximum 6 months with medication will be permissible, provided this is part of local practice.
10154977|NCT04049747|Experimental|CHRONOS A - Arm 2 (Intervention)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second focal therapy session in-field, or a first focal therapy session to an out-of-field progressive or de novo lesion will be allowed as part of the focal therapy intervention.
9671015|NCT05054114|Experimental|Drug: Interferon Gamma|IFN-G administered for 2 10-day courses with a 1-week pause between the courses.
10154978|NCT04049747|Experimental|CHRONOS B - Arm 3 (Control)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second treatment in-field, or a first focal ablation to an out-of-field progressive or de novo lesion will be allowed but will be regarded as failure events for the purpose of CHRONOS-B.
10154979|NCT04049747|Experimental|CHRONOS B - Arm 4 (Intervention):|Neoadjuvant finasteride 5mg once daily for a minimum of 12 weeks followed by focal therapy (as per CHRONOS B control arm).
10154980|NCT04049747|Experimental|CHRONOS B - Arm 5 (Intervention)|Neoadjuvant bicalutamide 50mg once daily therapy for a minimum of 12 weeks followed by focal therapy (as per control arm).
10154981|NCT04049981|Experimental|Facial Engagement|This group will receive a version of Superpower Glass that targets specific areas of social deficits associated with autism.
10154982|NCT04049981|Experimental|Emotion Recognition|This group will receive a version of Superpower Glass that targets different areas of social deficits associated with autism.
10154983|NCT04049890||Parents of children with a chronic disease with no siblings|Parents of children suffering from a chronic disease who has no brother or sister over 3 years of age
10154984|NCT04049890||Parents of children with a chronic disease with siblings|Parents of children suffering from a chronic disease who one or more sibling over the age of 3 years old
10154985|NCT04049617|Experimental|GS-4224|"Dose Escalation (Phase 1b):~Participants will be sequentially enrolled in a dose escalation design to receive GS-4224 starting at 400 mg once a day (QD). Subsequent doses of 700 mg QD, 1000 mg QD, 1500 mg QD, and 1000 mg twice a day (BID) are planned based on the safety and tolerability of each dose level.~Dose Expansion (Phase 2):~Dose expansion will begin when the RP2D has been determined."
10154986|NCT04049968|Experimental|Experimental group|Patients in the experimental group were individually assessed by a mobile health application (APP).
9826361|NCT02415842||H5N1_IN Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed studyH5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received one administration(3.8 µg) of the adjuvanted (AS03A) pandemic influenza vaccine containing the Vietnam (VT) strain at Day 0 and one administration(3.8 µg) of the adjuvanted (AS03A) pandemic vaccine containing the Indonesia (IN) strain at Month 12.
10154987|NCT04049968|Active Comparator|Control group|Patients in the control group were individually assessed by a traditional routine health care and instruction.
10154988|NCT04049812|Active Comparator|Pulsed electromagnetic field (PEMF) treatment Group|Group received routine hot pack, Transcutaneous electrical nerve stimulation (TENS) and PEMF treatment.
10154989|NCT04049812|Sham Comparator|Sham PEMF treatment Group|Group received routine hot pack, TENS and sham PEMF treatment.
10154990|NCT04049734|Active Comparator|patients received the oral losartan|50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis
10154991|NCT04049734|No Intervention|patients didn't receive the oral losartan|50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs
10154992|NCT04049682||Pre Time-change|Daily activity, sleep duration, subjective sleepiness, and response time before change in school start time
10154993|NCT04049682||Post Time-change|Daily activity, sleep duration, subjective sleepiness, and response time after change in school start time
9826362|NCT02415842||H5N1_PAS Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03B) pandemic vaccine with 1.9 µg HA (hemagglutinin) at Days 0 and 21.
10154994|NCT04049721|Active Comparator|Standard of Care without HBO|Intravenous access and fluid resuscitation (standard of care treatment)
10154995|NCT04049721|Experimental|HBO + Standard of Care|Ten daily treatment sessions of HBO at 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks
10154996|NCT04049630|Experimental|LEV 1 mg/kg|Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
10154997|NCT04049630|Experimental|LEV 1,5 mg/kg|Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
10154998|NCT04049630|Experimental|LEV 2,5 mg/kg|Tablet of LEV at 2,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
10154999|NCT04049630|Placebo Comparator|Placebo|Tablets of placebo will be administrated to the participant in single dose only one time.
10155000|NCT04049448|Experimental|ABX464 50 mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)
10155001|NCT04049435||horizontal deficiency anterior maxilla|Using the titanium sheet in augmentation of horizontally deficient anterior maxilla will be efficient, time saving, accurate reconstruction
10155002|NCT04049760|Experimental|migalastat HCl 150 mg|One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.
10155003|NCT04049409|Experimental|CMAB809|
10155004|NCT04049409|Active Comparator|Trastuzumab|
10155005|NCT04049539|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|Within 14-26 days after the start of previous cycle of chemotherapy, patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
10155006|NCT04049565||Procalcitonin|septic patients who will receive Procalcitonin
10155007|NCT04049565||C-Reactive Protein|septic patients who will receive C-Reactive ptotein
10155008|NCT04049487|Active Comparator|Generalized Exercise|General wellness/exercise program designed to replicate a generic wellness program that one would find in a gym setting. Will be led by an exercise instructor.
10155009|NCT04049487|Experimental|Diastasis Specific Exercise|Diastasis specific exercise program incorporating multiple muscle groups and based on research findings of exercises that are shown to be effective for reducing size and impact of diastasis rectus.
10155010|NCT04049591|Active Comparator|Higher Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.
10155011|NCT04049591|Active Comparator|Lower Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.
10155012|NCT04049474|Experimental|Bronchoscopic Cryo-Immunotherapy (BCI)|BCI is performed by advancing a flexible cryoprobe through a bronchoscope to reach a peripheral tumor. The cryoprobe is activated to freeze a portion of the tumor. The cryoprobe is allowed to thaw to prevent removal of lung or airway tissue. The tumor must be located by radial EBUS and a guide sheath placed prior to cryoablation.
10155013|NCT04049461||PDAC Group|Radical operations were performed through central abdominal incisions. The postoperative pathology was pancreatic ductal adenocarcinoma.
10155014|NCT04049461||Benign Group|The abdominal midline incision was performed and the postoperative pathology was benign.
10155015|NCT04049396|Experimental|Berberine|Berberine (6.25 g/day)
10155016|NCT04049396|No Intervention|Control|No intervention
10155017|NCT04049513|Experimental|WZTL002-1 (1928T2z CAR T-cells)|"A starting WZTL-002 dose of 5 × 10^4 CAR T-cells/kg has been selected with four possible dose level cohorts proposed.~Escalation to a higher dose cohort will be based on assessment of dose limiting toxicities to determine safety at a given dose level."
10155018|NCT04049357|Experimental|The intervention group|"If the FIT test is returned and positive the individual can choose either Camera Capsule Endoscopy (CCE) or Optical colonoscopy (OC) as the primary bowel investigation. If OC is chosen, it is performed as standard and the participant outcomes remains analyzed in the intervention group as intention to treat.~If CCE is chosen an out-clinic CCE will be done at one of four regional sites. Overall and segmental bowel preparation grade (Leighton-Rex 1-4) and all pathological findings are reported. If the anal verge is identified without video blackout in the colon the transit is considered complete. Any incomplete CCE investigation will be followed by standard optical endoscopy to the extent needed to investigate the proportion of the colon not visualized by the capsule and remove any detected polyps. If the CCE is complete with complete transit and adequate preparation, individuals with more than two polyps or one polyp over 9 mm will be referred for colonoscopy."
10155019|NCT04049357|No Intervention|The control group|The control group will be invited to screening as usual. The intervention group will be informed that if the fecal test is returned and positive they can either choose to have an initial colon capsule endoscopy, and only colonoscopy if significant findings are made or an initial colonoscopy as usual.
10155020|NCT04049240|Active Comparator|Active Comparator: 18<BMI<30 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
10155021|NCT04049240|Active Comparator|Active Comparator: 30≤BMI<35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
10155022|NCT04049240|Active Comparator|Active Comparator: BMI≥35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
10155023|NCT04049240|Active Comparator|Experimental: 18<BMI<30 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
10155024|NCT04049240|Active Comparator|Experimental: 30≤BMI<35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
10155025|NCT04049240|Active Comparator|Experimental: BMI≥35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
10155026|NCT04049370||"Retrospective data collection of the actual state"|"Retrospective data collection of the actual state 6 months prior to August 2019."
10155027|NCT04049370||Prospective data collection|Prospective data collection after implementation of the quality assurance measure for another 6 months (SOP as clinical decision tool into the electronic database of the CPU).
9520006|NCT03281421|Active Comparator|Group GPA-AP|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense both from posterior to anterior and anterior to posterior. In the group GPA-AP, will be apllied both the procedure described for the group GPA as for the group GAP. To standardized the sequence of mobilization, the first two sets will be performed with slip sense from posterior to anterior, and the last two sets will be performede with slip sense from anterior to posterior.
9520007|NCT03281408||Suspected OSA Patients Undergoing Knee or Hip Arthroplasty|These 100 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered. Troponin testing will be done post-op with other routine blood work.
10155028|NCT04049305|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
10155029|NCT04049305|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
10155030|NCT04049305|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
9520008|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
10155031|NCT04049266|Experimental|KSI-301 5 mg|"Drug: KSI-301 5 mg. KSI-301 5 mg will be administered by intravitreal injection into the study eye at 12, 16, and 20 weeks intervals as specified in the study protocol.~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
10155032|NCT04049266|Active Comparator|Aflibercept 2 mg|"Drug: Aflibercept 2 mg. Aflibercept 2 mg will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
10155033|NCT04049344|Experimental|Combination of decitabine with oxaliplatin treatment|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
9826363|NCT02415842||H5N1_PCN Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered placebo at Days 0 and 21.
10155034|NCT04049318||24 weeks|Subjects who participated in the intervention who have data available at week 24
10155035|NCT04049318||48 weeks|Subjects who participated in the intervention who have data available at week 48
10155036|NCT04049292|Experimental|RTS and rehabilitation tool|Six months after ACLR, athletes will commence a standardized RTS assessment. The athlete will follow a standardized, sport-specific progression protocol designed to increase athletic confidence and trust in the knee during sports. Readiness to return to full, unrestricted practice will be determined based on 7 time-based, load-based, clinical and functional criteria. If the athlete fails any of the criteria, he or she will continue to participate in restricted practice. Depending on which of the specific criteria the athlete fails, a targeted treatment plan will be developed. Standardized protocols for effusion management, knee control and strength training will be triggered if the athlete fails the criteria for knee joint effusion, hopping and muscle strength, respectively. The RTS assessment and development of the targeted treatment plan will be repeated every 2 months until the athlete is cleared to RTS, up to a maximum of 12 months after ACLR.
10155037|NCT04049292|Active Comparator|Usual care|Athletes will receive usual care as determined by their treating health care professional
9972900|NCT01325636|Experimental|CD4 and CD8 T cell|Injection of specific CD4 and CD8 T cell
9972901|NCT01325649||advanced rectal cancer|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low rectal carcinoma, and with cT4 Tumors Arm 1 Long course radiochemotherapy before total mesorectal excision Arm 2 total mesorectal excision without radiochemotherapy
10155038|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
10155039|NCT04049201|Experimental|Group tablet|group T will receive interactive Tablet containing many cartoon's videos 20 minutes before parental separation until the anesthesia induction
10155040|NCT04049201|Active Comparator|Group Midazolam|group Midazolam will receive oral midazolam 0.5 mg/kg (max 20 mg) 20 minutes before the parental separation
10155041|NCT04049253|Experimental|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
10155042|NCT04049253|Placebo Comparator|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
10155043|NCT04048902|Placebo Comparator|Pilates and Shortwave placebo|In this group the patients will receive 20 minutes of short wave placebo application. The equipment will keep the timer on and the intensity will remain at zero. The patient will be informed that the dose is subsensory and therefore there will be no perception of the passage of the short waves through the body.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
10155044|NCT04048902|Active Comparator|Pilates and Shortwave active|In this group the patients will receive 20 minutes of application of the Shortwave Active continuous mode (thermal effect), with vigorous local thermal sensation.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
10155045|NCT04048889|Experimental|Popliteal plexus block and continuous femoral nerve block|
10155046|NCT04048889|Active Comparator|continuous femoral nerve block|
10155047|NCT04049032||In-Person Participants|This group received perinatal OUD treatment in-person.
10155048|NCT04049032||Telemedicine Participants|This group received perinatal OUD treatment via telemedicine.
10155049|NCT04049162|Experimental|Blueberry Plus Exercise (BB-EX)|BB-Ex participants will consume lyophilized blueberry powder, mixed with water (18 grams, equivalent to 3/4ths cup of blueberries) with 2 daily meals (36 g/d blueberry powder total; approx. 1.5 servings/d)
10155050|NCT04049162|Placebo Comparator|Blueberry Placebo Plus Exercise (P-EX)|Participants randomized to P-EX treatment will consume an indistinguishable placebo powder, matched for color, flavor, consistency, and caloric content, in the same manner.
9662020|NCT01144520||Type II Diabetes (HbA1c between 7.1-9)|Subjects with Type II Diabetes with moderate glucose control (HbA1c between 7.1-9)
10155051|NCT04048954||APPLITABAC arm|Use of a smartphone application on screening for complications related to tabagism
10155052|NCT04049149|Other|JADE-PRISM group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
10155053|NCT04049149|Other|JADE group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
10155054|NCT04049188|Experimental|Single-Fraction Palliative RT|Single-Fraction Palliative Radiation Therapy Adminstration
10155055|NCT04049110|Experimental|Dapagliflozin first, placebo second|Dapagliflozin followed by placebo
10155056|NCT04049110|Experimental|Placebo first, Dapagliflozin second|Placebo followed by dapagliflozin
10155057|NCT04049136||Healthy pregnant women with BMI <30|
10155058|NCT04049136||Healthy pregnant women with BMI >=30|
9826364|NCT02415959|Experimental|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
10155059|NCT04048941|Experimental|Verum Acupuncture with Movement|Verum acupuncture along radial side of 2nd metacarpal, following by active movement of previously painful body part x 10 minutes.
10155060|NCT04048941|Active Comparator|Verum Acupuncture without Movement|Verum acupuncture along radial side of 2nd metacarpal, following by laying on examination table x 10 minutes.
9520009|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
10155061|NCT04048941|Sham Comparator|Control Acupuncture with Movement|Sham/control acupuncture at acupoint LI4, following by active movement of previously painful body part x 10 minutes.
10155062|NCT04049227|Experimental|Treatment (letrozole, abemaciclib)|Patients receive letrozole PO QD and abemaciclib PO BID on days 1-14. Patients then undergo standard of care hysterectomy on day 15.
10155063|NCT04049045|Active Comparator|Verum arm|25 mg tablet of empagliflozin once daily for five days
10155064|NCT04049045|Placebo Comparator|Placebo arm|one tablet of the matching Placebo once daily for five days
10155065|NCT04049019|Experimental|Urine collection|"The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.~The child will be asked to perform home recordings for seven days consisting of measurements of diaper weight and first morning voided volume and a two-day frequency-volume chart."
10155066|NCT04049006|Experimental|complex-treatment benefiting group|Participants in the intervention group will receive the complex treatment and the usual clinical practice.
10155067|NCT04049006|No Intervention|complex-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
10155068|NCT04048967|Experimental|Intervention|Preschool staffs will participate in 50 hours of professional development over 7 months focused on promotion of physical activity in the preschool setting. Staffs and investigators will work together to develop models to ensure children receive 60 minutes per day of moderate-to-vigorous physical activity, 90 minutes per week of motor challenging physical activity, 90 minutes per week of cognitively engaging games/play, and 90 minutes per week of physically active learning.
10155069|NCT04048967|No Intervention|Control|Staffs receive no professional development and children will receive standard care.
10155070|NCT04048980|No Intervention|Control Group|Patients with dementia or cognitive impairment and femur fracture receiving the traditional care in traumatology units.
10155071|NCT04048980|Experimental|Experimental Group|Patients with dementia or cognitive impairment and femur fracture receiving an intervention in traumatology units.
10155072|NCT04048928|Experimental|Strength group|Receives maximal strength training
10155073|NCT04048928|No Intervention|Control group|receives no active treatment
10185806|NCT03742063||Huvos group II|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade II is 50% to 89%.
10185807|NCT03742063||Huvos group III|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade III is 90% to 99%.
10185808|NCT03742063||Huvos group IV|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade IV is 100% necrosis.
10185809|NCT03742050|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
10185810|NCT03742050|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention
10185811|NCT03741998|No Intervention|THRIVE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction using jaw-thrust maneuver.
10185812|NCT03741998|Active Comparator|THRIVE with nasopharyngeal airway|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction with nasopharyngeal airway.
10185813|NCT03741985|Placebo Comparator|The handgrip exercise|Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
10185814|NCT03741985|Experimental|The dumbbell exercise|Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
10185815|NCT03741972||Treatment|Patients with diabetes and heart failure that are treated with iSGLT2
10185816|NCT03741959|Experimental|Experimental|The experimental group will undergo three groups of exercises: 1) active self-correction exercises (20 minutes) defined as the best possible trunk alignment the patient can achieved in the three-dimensional planes; 2) passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint and to counteract the evolution of the misalignment; 3) functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks.
10185817|NCT03741959|Active Comparator|Control|The control group will undergo strengthening exercises and gait training as the usual practice in Parkinson Disease. Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks (Bartolo et. al., 2010).
9520010|NCT03281356|Experimental|Intervention Group|
9520011|NCT03281343|Experimental|MI-NAV|A study therapist will deliver a motivational interviewing session with participants while they are incarcerated and serve as a role of patient navigator post-release.
9520012|NCT03281343|Active Comparator|Standard of Care (SOC)|Approximates care currently provided at the prison.
10155074|NCT04048863|Active Comparator|Stage 1 Baseline|Study site to use standard of care PIVC device(s) and procedure(s) on patients.
10155075|NCT04048863|Other|Stage 2 Education|RN education and training in the use of B. Braun PIVC products, devices and procedures.
10155076|NCT04048863|Other|Stage 3 Run-In|Familiarization of study RNs with the B. Braun devices and procedures in a clinical setting.
10155077|NCT04048863|Other|Stage 4 Post-Education|Study site uses B. Braun PIVC device(s) and procedure(s) on patients.
10155078|NCT04048915|Experimental|Long live drama|Primary school students watched an interactive long live drama (90 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
10155079|NCT04048915|Experimental|Short live drama|Primary school students watched an interactive short live drama (60 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
10155080|NCT04048915|No Intervention|Waitlist control|Primary school students received no intervention during the 3-month study period. After the study finished, the students watched either short or long live drama, and DVD with worksheets were distributed to students and they were invited to share with their parents.
10155081|NCT04048811|Experimental|HSK3486|HSK3486 induction + maintenance group
10155082|NCT04048811|Active Comparator|Propofol|Propofol induction + maintenance group
10155083|NCT04048811|Other|Propofol HSK3486|Propofol induction + HSK3486 maintenance group
10155084|NCT04048850||Patients living with HCV +/- HIV|HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use treated with elbasvir/grazoprevir 50-100 mg fixed-dose-combination, 1 tablet by mouth daily, for 12 weeks.
10155085|NCT04048798|Active Comparator|Oxygen therapy via HFNC|Patients who will be applied high frequency nasal cannula before and after surgery
10155086|NCT04048798|Active Comparator|Oxygen therapy via face mask|Patients who will be applied O2 via face mask before and after surgery
10155087|NCT04048772|Experimental|Intervention|Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.
10155088|NCT04048772|Other|Control|Standard of care in vitro fertilization patients at our institution.
10155089|NCT04048434|No Intervention|Standard of care (SOC)|
10155090|NCT04048434|Experimental|Cyotosorb|
10155091|NCT04048785|No Intervention|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
10155092|NCT04048785|Experimental|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
10155093|NCT04048577|Experimental|Dose Interruption|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days) except during the pre-planned dose interruption of 2 consecutive skipped doses.
9972902|NCT01325662||Continuous drip sampling|Sampling at ~0.6 cc / hour (~1.2 cc / 2 hours, or lowest feasible rate given technical requirements and volume requirements for core analytes assays)
9520013|NCT03281330||persons with Multiple Sclerosis|
10155094|NCT04048577|No Intervention|Standard Treatment|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days).
10155095|NCT04048590|No Intervention|Control|Control subjects will receive care at a skilled nursing facility.
10155096|NCT04048590|Active Comparator|Intervention|Intervention subjects will go home from the hospital and receive care from a specialized care team.
10155097|NCT04048603||idiopathic REM sleep behavior disorder|Subjects with the diagnosis of idiopathic REM sleep behavior disorder
10155098|NCT04048603||Controls without iRBD|Healthy controls without the diagnosis of idiopathic REM sleep behavior disorder
10155099|NCT04048525|Experimental|CVVHD with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
10155100|NCT04048525|Active Comparator|CVVH with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
10155101|NCT04048551|No Intervention|No S&D Reduction Training; PrEP and SRH only|Arm 1 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
10155102|NCT04048551|Experimental|No S&D Reduction Training; PrEP and SRH + YWHC|Arm 2 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
10155103|NCT04048551|Active Comparator|S&D Reduction Training; PrEP and SRH only|Arm 3 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
10185818|NCT03741946|Other|Triangle of Sedillot identification using ultrasonography|USG probe placed upright at the top of triangle of Sedillot at cricoid level
10185819|NCT03741933|Experimental|Apremilast|30 mg twice daily to be administered for a period of 6 months
9520014|NCT03281330||Healthy controls|
10155104|NCT04048551|Experimental|S&D Reduction Training; PrEP, SRH + YWHC|Arm 4 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
10155105|NCT04048759|Other|Remote Low|
10155106|NCT04048759|Other|Remote High|
10155107|NCT04048759|Other|Personal Coach|
10155108|NCT04048733|Experimental|Patchy type-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using patchy-type 12-lead ECG device as a doctor's order. This device will be automatically record 12-lead ECG 3 times in 1 minutes at a time by its algorithm."
10155109|NCT04048733|No Intervention|Standard 12-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using standard 12-lead ECG device as a doctor's order. Interns and ECG technicians will perform 12-lead ECG as they perform as usual."
10155110|NCT04048486||CAPA-IVM|Live babies born from CAPA-IVM
10155111|NCT04048486||IVF/ICSI|Live babies born from IVF/ICSI
10155112|NCT04048486||Natural conception|Live babies born from natural conception
10155113|NCT04048720|Experimental|Family Nurture Intervention (FNI)|FNI sessions will be held once a week in the afternoon for eight weeks. Participants will take part in FNI group therapy with their child alongside other mother-child pairs. One to two staff members will lead FNI sessions.
10155114|NCT04048655|Other|Study group|Single arm and everyone gets the same treatment according the protocol
10155115|NCT04048629|Experimental|Point-of-care (POC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At POC facilities, at the first antenatal visit (ANC1), all women enrolled in the intervention cohort will have a blood sample collected for VL which will be tested onsite using an existing POC device. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
10155116|NCT04048629|Active Comparator|Standard of care (SOC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At SOC facilities, at ANC1, all women enrolled in the intervention cohort will have a blood sample collected for VL which will be sent to centralized labs for testing. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
10155117|NCT04048395||Follicular lymphoma arm|The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
10155118|NCT04048707|Active Comparator|Midodrine/Octreotide|This arm will receive standard of care treatment of midodrine, octreotide, and albumin.
10155119|NCT04048707|Experimental|Angiotensin 2|This arm will receive the experimental treatment of angiotensin 2 infusion and albumin.
10155120|NCT04048356|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
9972903|NCT01325662||Intermittent sampling|Sampling at 4 cc every 2 hours (+ 2 cc dead space clearance, total = 6 cc / 2 hours)
10155121|NCT04048356|Active Comparator|Povidone Iodine|Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
10155122|NCT04048057|Experimental|Modarete Intensity Continous Training|
10155123|NCT04048057|Experimental|High Intensity Interval Training I|
10155124|NCT04048057|Experimental|High Intensity Interval Training II|
10155125|NCT04048044|Active Comparator|Telomere length, GigaHz exposure|Measurement of white blood cell telomeres before and yearly for 5 years
10155126|NCT04048265|Experimental|Pain in PD Arm one|This arm will receive a total 5 sessions of TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
10155127|NCT04048265|Sham Comparator|Pain in PD Arm two|This arm will receive a total 5 sessions of sham-TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
10155128|NCT04048135|Experimental|Dose 1|
10155129|NCT04048135|Experimental|Dose 2|
10155130|NCT04048135|Experimental|Dose 3|
10155131|NCT04048135|Experimental|Dose 4|
10155132|NCT04048135|Experimental|Dose 5|
10155133|NCT04048135|Experimental|Dose 6|
10155134|NCT04048135|Placebo Comparator|Placebo|
10155135|NCT04048135|Experimental|Dose 4 Open Label|
10155136|NCT04048369|Experimental|Point-of-care testing arm|for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7.
10155137|NCT04048369|Active Comparator|Core Lab testing arm|for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday)
10155138|NCT04048343|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
10155139|NCT04048096|Placebo Comparator|Placebo|4g/day of mixed vegetable oil supplements
10155140|NCT04048096|Experimental|Krill|4g/day krill oil
10155141|NCT04048291|Experimental|Brisk walking and balance training|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)"
10155142|NCT04048291|Active Comparator|Upper limb exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~Participants practice own upper limb exercise 2-3 times/week (to aim at 150 min of exercise per week)"
9520015|NCT03281239|Experimental|welder/airport agent|No drug and no placebo were used in this study.
9972904|NCT01325675|Experimental|Interval training|Interval training
9972905|NCT01325675|No Intervention|Control|Live as usual
10155143|NCT04047992|Experimental|Exoskeleton Users|All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.
10155144|NCT04048174|Sham Comparator|Saline irrigation|"Each participant performed nasal saline irrigation at 2 periods:~Day -14 to Day 0~Day 14 to Day 28"
10155145|NCT04048174|Experimental|Probiotic lactococcus lactis W136 irrigation|Each participant performed Probiotic lactococcus lactis W136 nasal irrigation from Day 0 to D14
10155146|NCT04048083|Experimental|Patients-MT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training (MT) of reaching to grasp movements
10155147|NCT04048083|Experimental|Patients-CAT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in computer-aided training (CAT) of reaching to grasp movements using virtual environment with visual-feedback.
10155148|NCT04048083|Experimental|Patients-CAMT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training of reaching to grasp movements supplemented by virtual environment (patients that received both types of training).
10155149|NCT04048083|Active Comparator|Healthy-controls|9 Healthy, age and gender-matched subjects, without any kind of training
10155150|NCT04048187|Experimental|Phone Application|
10155151|NCT04048317|Experimental|drug eluting bead trans arterial chemo embolization|the international arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Hepasphere
10155152|NCT04048317|Placebo Comparator|conventional trans arterial chemo embolization|the control arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Lipiodol
10155153|NCT04048226|Placebo Comparator|Control group|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
10155154|NCT04048226|Experimental|Dexmedetomidine-Ketamine group|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
10155155|NCT04048304|Experimental|short antibiotic therapy|3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
10155156|NCT04048304|Active Comparator|long antibiotic therapy|6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
10155157|NCT04048200|Other|Control group|Anesthesia will be induced by fentanyl 1 ug/kg, propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The patients in this group will be connected to a syringe pump before induction of anesthesia that was prepared by anesthesia resident not participating in the study and contain normal saline and adjusted at a rate of 1 ml/kg/hr till the end of the surgery.
10155158|NCT04048200|Experimental|Opioid free anesthesia group|A syringe 50 ml was prepared by anesthesia resident not participating in the study and contain 100 ug of dexmedetomidine (2 ug/ml) and 25 mg ketamine 90.5 mg/ml) and 200 mg lidocaine (4 mg/ml). The syringe will be connected to the patients before induction of anesthesia at a rate of 0.1 ml/kg/hr according to the ideal body weight. Anesthesia will be induced by propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The syringe infusion will be continued till the end of peritoneal manipulation. Patients in this group will receive magnesium sulphate preload at a dose of 40 mg/kg ideal body weight followed by maintenance infusion of 10 mg/kg/hr.
10155159|NCT04048018||Active Tuberculosis Patient|
10155160|NCT04048018||High risk for LTBI Participant|
9972906|NCT01325727|Experimental|Brief computerized feedback|Brief computerized feedback
10155161|NCT04048018||Low risk for prior TB infection Participant|
10155162|NCT04048018||NTM patient|
10155163|NCT04048018||Precision patient|
9671016|NCT05054114|No Intervention|Control: No intervention|Any preventive method including a variety of pharmacologic therapies against COVID-19, alongside the use of antiviral and immunomodulating agents, with the exception of drugs prescribed off-label or for research purposes, and IFN-G as well.
10155164|NCT04048070|Experimental|ERAS with postoperative intravenous Flubiprofen Axetil|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
9972907|NCT01325727|Active Comparator|Resources only|
10155165|NCT04048070|Experimental|ERAS with analgesia pump|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
9972908|NCT01325740|Active Comparator|STX107 10 mg|
9972909|NCT01325740|Placebo Comparator|Placebo|
9972910|NCT01325740|Active Comparator|STX107 30 mg|
9972911|NCT01325753|Experimental|Treatment (cryoablation)|Patients undergo CT-guided CA.
9972912|NCT01325766|Active Comparator|Yoga (immediate start) group|This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks. This group will then continue with home yoga for an additional 8 weeks.
9972913|NCT01325766|Active Comparator|Yoga (waitlist) group|This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
9972914|NCT01325779|Active Comparator|subcutaneous heparin|
9972915|NCT01325779|Active Comparator|subcutaneous enoxaparin|
9826365|NCT02415959|Experimental|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
10155166|NCT04048070|Experimental|Traditional care with Flubiprofen Axetil|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
9520016|NCT03281226|Active Comparator|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
9520017|NCT03281226|Experimental|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
9520018|NCT03281213||Female|
9520019|NCT03281213||Male|
9520020|NCT03281187|Experimental|Nasotestt 5 mg|Participants randomized to this arm must administer one packet of Nasotestt 5 mg in each nostril (3 times a day - T.I.D) for 60 days.
9520021|NCT03281187|Active Comparator|Androgel 50 mg|Participants randomized to this arm must administer one packet of Androgel 50 mg applied once daily to skin of shoulder for 60 days.
9520022|NCT03281187|Placebo Comparator|Androgel Placebo|Participants must administer one packet of Androgel placebo applied once daily to skin of shoulder in addition to an experimental drug for 60 days.
9520023|NCT03281187|Placebo Comparator|Nasotestt Placebo|Participants must administer one packet of Nasotestt Placebo in each nostril (3 times a day - T.I.D) in addition to an experimental drug for 60 days.
9972916|NCT01325818|Active Comparator|1:pravastatin, 2:rosuvastatin|"Active Comparator Drug:pravastatin~Active Comparator Drug:rosuvastatin"
9972917|NCT01325831|Experimental|transcranial magnetic stimluation|
9520024|NCT03281174||EV71 vaccine group|The group which received two doses EV71 vaccine (400U/0.5ml) on day 0,28 in phase III clinical trial.
9520025|NCT03281174||Placebo group|The group which received two doses placebo (0U/0.5ml) on day 0,28 in phase III clinical trial.
9662021|NCT01144520||Type II Diabetes (HbA1c >9%)|Subjects with Type II Diabetes with poor glucose control (HbA1c >9%)
9826366|NCT02415959|Experimental|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
9972918|NCT01325831|Sham Comparator|rTMS_sham|
9972919|NCT01325844|No Intervention|G group|G group = General anesthesia group
9972920|NCT01325844|Experimental|G+E group|G+E group = General anesthesia + epidural anesthesia group
9972921|NCT01325857|Experimental|Group B|Group B = Nerve block group
9972922|NCT01325857|Placebo Comparator|Group L|Group L = Local wound infiltration group
9972923|NCT01325857|Active Comparator|Group C|Group C = Control group
9972924|NCT01325896|Other|All patients are receiving PEG-Intron|
10155167|NCT04048070|Experimental|Traditional care with analgesia pump|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
9972925|NCT01325909|Active Comparator|Exercise|
9972926|NCT01325909|No Intervention|No Exercise|
9972927|NCT01325922|Other|50/50% Tilt|
10155168|NCT04048070|Placebo Comparator|traditional care without postoperative intravenous analgesia.|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Intravenous saline with necessary oral analgesic for postoperative pain management.
10155169|NCT04048161|Experimental|Tacrolimus(Group A)|Tacrolimus: 0.5mg and 1mg; Capsule; 0.05-0.10mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
9972928|NCT01325935|Experimental|Short-term DAPT group|1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
9972929|NCT01325935|No Intervention|Long-term DAPT group|1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
9972930|NCT01325948||Patients with COPD|
9972931|NCT01325987|Placebo Comparator|sugar pill|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
9972932|NCT01325987|Experimental|vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
9972933|NCT01326000|Experimental|KRAS WT A|
9972934|NCT01326000|Active Comparator|KRAS WT B|
9972935|NCT01326000|Experimental|KRAS mutant A|
9972936|NCT01326000|Active Comparator|KRAS mutant B|
9972937|NCT01326013||Blinded, Prospective Arm|Diagnostic accuracy for higher prevalence targets will be evaluated in prospectively collected, anonymized, leftover, stool specimens.
9972938|NCT01326013||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
9972939|NCT01326039|Active Comparator|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
9972940|NCT01326039|Placebo Comparator|saline|perineural isotonic saline 20 ml
9972941|NCT01326052|Experimental|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
10155170|NCT04048161|Experimental|Mycophenolate Mofetil(Group B)|Mycophenolate Mofetil: 250mg; Dispersible tablets; 20~30mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
10155171|NCT04048382|Experimental|Patient Navigation (PN)|This intervention consists of standardized health educational materials and manualized sessions that can be implemented based on a participant's stage in the PrEP continuum. The intervention will utilize bilingual peer lay navigators and also consist of barrier reduction strategies to assist individuals with implementing HIV prevention, including the use of PrEP.
10155172|NCT04048382|Other|Usual Care (UC)|Participants in this condition will receive the CDC's 2-page PrEP Information Sheet in the participant's preferred language (either English or Spanish).
10155173|NCT04048031|Active Comparator|Nutrafol Supplement Capsules|"NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal."
10155174|NCT04048031|Placebo Comparator|Placebo Capsules|The placebo capsules contain no active ingredients. Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
10155175|NCT04048031|Other|Open Label 6 month Extension|"During the 6 month open label extension all 70 subjects will receive NUTRAFOL's Synergen Complex Plus® which is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for the six month extension with a substantial meal."
9662022|NCT01118767|Experimental|Cell phone intervention|Participant receives short text messages
9662023|NCT01118767|No Intervention|Standard of care|Participant receives standard of care support but not short text messages
10155176|NCT04048148|Other|Novel myopia control lenses|This group will be randomized to wear test lenses for 6 months followed by control lenses for 6 months and then test lenses for another 6 months
10155177|NCT04048148|Other|Single vision lenses|This group will be randomized to wear control lenses for 6 months followed by test lenses for 12 months
10155178|NCT04047654||Non vitamin K oral anticoagulants (NOACs)|Patients who were prescribed with apixaban, dabigatran, edoxaban, or rivaroxaban for stroke secondary prevention.
10155179|NCT04047654||Warfarin|Patients who were prescribed with warfarin for stroke secondary prevention.
10155180|NCT04047667||CBCT guided TBCB|Patients with ILD who met the following including criteria from September 2018 to July 2019 were suggested to receive TBCB under CBCT guidance: more than 18 years old, diffuse parenchymal lung diseases without a diagnosis after integration of clinical profile, laboratory tests and HRCT features, FVC more than 50%, DLCO more than 35%, patients without acute exacerbation within one month, patients without bleeding diathesis, anticoagulant therapy, using antiplatelet drugs, patients without pulmonary hypertension, respiratory failure, liver or kidney disfunction, or cardiac insufficiency, PLT more than 50 x 109/L. All included patients signed the informed consent.
10155181|NCT04047615|Experimental|Exercise effects on Behavior|An exercise intervention programme will be implemented 3 times a week for an 8 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will be fun for the students to participate in and will involve aspects of fundamental movement skills.
10155182|NCT04047732|Experimental|Topical KB105|HSV1-TGM1 vector (KB105)
10155183|NCT04047706|Experimental|Cohort I (radiation, temozolomide, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT methylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive temozolomide PO QD, IDO1 inhibitor BMS-986205 PO QD, and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins.~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Within 4 weeks of radiation therapy completion, patients also receive temozolomide PO QD on days 1-5 of cycles 2-6. Cycles repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
10155184|NCT04047706|Experimental|Cohort II (radiation, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT unmethylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive IDO1 inhibitor BMS-986205 PO QD and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Cycles repeats every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins."
10155185|NCT04047940|Experimental|LY900020 Formulation 1|LY900020 Formulation 1 administered orally
10155186|NCT04047940|Experimental|LY900020 Formulation 2|LY900020 Formulation 2 administered orally
10155187|NCT04047940|Experimental|LY900020 Formulation 3|LY900020 Formulation 3 administered orally
10155188|NCT04047940|Active Comparator|Reference Drugs|Metformin XR, atorvastatin, and valsartan administered orally
10155189|NCT04047758|Experimental|Palbociclib + Letrozole group|210 patients will be randomly assigned to receive treatment with palbociclib and letrozole (palbociclib + letrozole group) .
10155190|NCT04047758|Placebo Comparator|Letrozole group|210 patients will be randomly assigned to receive treatment with letrozole (letrozole group).
10155191|NCT04047719||Intent-to-Diagnose Population|All subjects enrolled in the study that have at least one Karius Test with a valid result
10155192|NCT04047641|Experimental|Treatment (idarubicin, cladribine, cytarabine, quizartinib)|"INDUCTION: Patients receive idarubicin Intravenous over 1 hours on days 1-3, cladribine intravenous over 1-2 hours on days 1-5, cytarabine Intravenous over 3 hours on days 1-5 (or days 1-3 for patients over age 60), and quizartinib by mouth daily on days 6-19. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR or CRp after Induction receive idarubicin Intravenous over 1 hours on days 1-2, cladribine Intravenous over 1-2 hours on days 1-3, cytarabine Intravenous over 3 hours on days 1-3, and quizartinib by mouth daily on days 4-28. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve CR or CRi/CRh after Consolidation receive quizartinib by mouth daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
10155193|NCT04047849|Experimental|Antibiotics|This will include those subjects randomized into the treatment arm, receiving the outpatient antibiotic course of azithromycin and amoxicillin prior to re-admission at viability (23 0/7 weeks gestation). They will receive a single, 500mg dose of Azithromycin given prior to discharge to home, followed by 250mg daily for 4 more days, and Amoxicillin 500mg orally TID for 7 days (first dose also being given prior to discharge home).
10155194|NCT04047849|No Intervention|No antibiotics|This will include those subjects randomized into the control arm and will not receive outpatient antibiotics prior to re-admission at viability (23 0/7 weeks gestation).
10155195|NCT04047888||Intervention Group|Mothers and children in this group will have measurements, questionnaire administration. The children will have routine child care at their health center and mothers will have a 60 minute nutrition-based and non-nutrition based educational message
10155196|NCT04047888||Control Group|Mothers and babies will have measurements and questionnaire administration and children will receive routine child care at their health centers. These mothers will receive a non-nutrition based educational message only.
10155197|NCT04047914|Experimental|experimental PDT group|Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 1 minute pre-irradiation time. Irradiations will be performed with a red laser diode (wavelength = 660 nm), 240 seconds and 4-point nostril application (one point on each of the 4 walls).
10155198|NCT04047914|Active Comparator|control mupirocin group|A standard treatment will be performed conventionally with topical mupirocin. Will be performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
10155199|NCT04047901|No Intervention|control group|"A group of patients who will not be trained will be evaluated at baseline (pre) and after 16 weeks.~They are oriented to maintain lifestyle changes"
10155200|NCT04047901|Experimental|Training group|Patients will complete 16 weeks of training including 40 minutes of aerobic training, 15 minutes of resistive exercise and 5 minutes of relaxation.
10155201|NCT04047875|Experimental|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Primolut-Nor® per bleeding episode)
10155202|NCT04047875|Placebo Comparator|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Placebo per bleeding episode)
10155203|NCT04047784|Experimental|Critically Ill Patients|"Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
10155204|NCT04047784|Experimental|Patients undergoing standard of care clinical bronchoscopy|"Patients undergoing clinical bronchoscopy as a part of their standard of care.~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
10155205|NCT04047784|No Intervention|Previously recorded patient media from standard of care clinical bronchoscopy with EBUS|"Patients who underwent a standard of care clinical bronchoscopy with EBUS previously.~Information and media including images and videos that were previously recorded for patients who underwent a standard of care clinical bronchoscopy with EBUS will be available to the study team."
10155206|NCT04047745|Active Comparator|liposomal bupivacaine|
10155207|NCT04047745|Active Comparator|ropivacaine|
10155208|NCT04047927|Experimental|EpiFinder|Eligible subjects will be included to this group to receive an epidural injection of steroids to treat their chronic back pain. The investigational device will be used in conjugation to the standard practice of epidural injections, to assist the investigator to identify the epidural space.
10155209|NCT04047680||SOF-based DAAs|Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks
10155210|NCT04047680||SOF-free DAAs|Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks
10155211|NCT04047537|Other|Experimental: WBF-0011|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
9520026|NCT03281161|Experimental|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
10155212|NCT04047537|Other|Experimental: WBF-0011 (0.2X concentration)|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
10155213|NCT04047537|Other|Placebo|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
10155214|NCT04047576|Experimental|sirolimus group|"Sirolimus: 2 mg/day for the first 3 days and 1 mg/day thereafter. The plasma drug concentration was monitored at 14 days, 12 weeks, and 48 weeks of medication to maintain a plasma drug concentration of 4-15 ug/L.~Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until discontinuation."
10155215|NCT04047576|Active Comparator|corticosteroid group|Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until 5-7.5 mg/d.
10155216|NCT04047797|Experimental|Treatment (ixazomib, rituximab)|Patients receive ixazomib by mouth on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of cycle 1. Beginning in cycle 3, patients receive rituximab Intravenous over 4-8 hours on day 1. Treatment repeats every 28 days up to cycle 12 in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue to receive ixazomib indefinitely in the absence of disease progression or unacceptable toxicity.
10155217|NCT04047524|Other|Prehabilitation|These participants will receive a home based prehabilitation programme for a period of 2-6 weeks prior to surgery and will be provided with a Fitbit Charge 2.
10155218|NCT04047524|Other|Control|These participants will receive a Fitbit Flex and told to continue with their every day activity levels for a period of 2-6 weeks prior to surgery
10155219|NCT04047329||Without post-operative myocardial infarction|Patients without post-operative myocardial infarction after first admission for transurethral resection of the prostate
9671017|NCT05054036|Experimental|MoviPrep|"For MoviPrep, the dose, schedule, and route of administration are as follows:~On the evening prior to the colonoscopy, mix the powder with lukewarm water to a total volume of 32 oz. Drink 8 oz. every 15 minutes until the solution is finished. Drink 16 oz. of clear liquids before bed.~On the morning of the procedure, repeat the above steps and make sure all fluids are consumed at least 2 hours prior to colonoscopy.~Limit food intake to a regular breakfast, light lunch and clear soup or plain yogurt for dinner on the day prior to the colonoscopy (completed at least 1 hour prior to the first MoviPrep dose.~Consume only clear liquids from the start of MoviPrep until after the colonoscopy."
10155220|NCT04047329||With post-operative myocardial infarction|Patients with post-operative myocardial infarction after first admission for transurethral resection of the prostate
10155221|NCT04047498|Experimental|Within-subjects comparison of constant and alternating DBS|
10155222|NCT04047212||Smokers|
10155223|NCT04047212||non-Smokers|
10155224|NCT04047381||Atrial Fibrillation|Turkish patients diagnosed with atrial fibrillation
10155225|NCT04047394|Experimental|PEGylated recombinant candida urate oxidase|Participants will be administered with 2mg, 3mg, 4.5mg, 6mg, 8mg, 10mg once by Intravenous injection. Subjects will be followed for 56 days.
10155226|NCT04047355|Experimental|Group A: Propranolol first|"Participants randomly assigned to this group will receive Propranolol first. After the washout period, they will receive Placebo.~Propranolol will be given in liquid or pill form."
10155227|NCT04047355|Placebo Comparator|Group B: Placebo first|"Participants randomly assigned to this group will receive Placebo first. After the washout period, they will receive Propranolol.~Placebo will look identical to the study drug Propranolol."
10155228|NCT04047459||Patient undergoing prosthetic surgery|Patients undergoing surgery for the insertion of a hip prosthesis or a cruciate ligament reconstruction will be included. On those patients tissue samples collection and cells isolation will be performed
10155229|NCT04047407||Fibromyalgia|
9520027|NCT03281161|Active Comparator|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
9520028|NCT03281148|Experimental|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
9520029|NCT03281148|Active Comparator|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
9694796|NCT04785105||patient with both SMA stenosis and CA or/and IMA stenosis|patient with both SMA stenosis and CA or/and IMA stenosis on initial scanner
9694797|NCT04785079|Experimental|Graston effect medial arch, plantar fascia, and trapezius|Pre and post Graston change in blood flow at the medial arch foot, plantar fascia, and the trapezius region
10155230|NCT04047407||Healthy volunteers|
10155231|NCT04047511|Experimental|Virtual Reality|"Twice a week, for a 4 consecutive weeks:~8 sessions of VRTierOne therapy ( 20 minutes each).~8 sessions of general fitness training (40 minutes each)~8 sessions of psychoeducation (20 minutes each"
10155232|NCT04047511|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each)~8 sessions of psychoeducation (20 minutes each"
10155233|NCT04047277|Experimental|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxztion, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
10155234|NCT04047277|No Intervention|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
10155235|NCT04047446|Experimental|Liposomal bupivacaine & standard bupivacaine|
10155236|NCT04047446|Active Comparator|Standard bupivacaine & dexamethasone|
10155237|NCT04047485||Elderly Female (A)|Female subjects between 65 and 85 years old
10155238|NCT04047485||Great Elderly Female (B)|Female subjects with more than 85 years old
10155239|NCT04047485||Elderly Male (C)|Male subjects between 65 and 81 years old
10155240|NCT04047485||Great Elderly Male (D)|Men subjects with more than 81 years old
10155241|NCT04047134|Experimental|Experimental Group (EG)|The Experimental Group (EG) will observe and execute/repeat Activities of Daily Living (ADL) actions.
10155242|NCT04047134|Active Comparator|Control Group (CG)|The COntrol Group (CG) will observe landscapes and perform the same actions observed by their peers but after verbal instructions.
10187842|NCT03722199|Experimental|Persons with essential hypertension|In this interventional study the investigators ask the patient (persons with essential hypertension) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
9520030|NCT03281135|Other|HPV testing|This is an experimental arm for the primary outcome, 'adherence to the procedures'. In this group self sampling will be done using the Evalyn brush for HPV testing.
10155243|NCT04047173|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
10155244|NCT04047173|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
10155245|NCT04047238|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving Reminiscence Therapy or to a control group receiving treatment as usual. Participants in the intervention group will participate in two Reminiscence Therapy sessions per week for 3 months besides their treatment as usual. The sessions will be based on the Book of Past and Present and they will follow the same protocol in every participant institution.
10155246|NCT04047238|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
10155247|NCT04047147||Enrollment in the Million Hearts CVD Risk Reduction Model|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to participate in the Million Hearts CVD Risk Reduction Model intervention.
10155248|NCT04047147||Enrollment in control provider organizations|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to the control group.
10155249|NCT04046913|Active Comparator|Low food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
10155250|NCT04046913|Placebo Comparator|Habitual food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
10155251|NCT04047225|Experimental|Analgesia Nociceptive Index (ANI)|Using ANI for guiding intraoperative opioid administration.
10155252|NCT04047225|No Intervention|No Analgesia Nociceptive Index (ANI)|Do not use ANI
10155253|NCT04046952|Active Comparator|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
10155254|NCT04046952|Experimental|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
10155255|NCT04047017|Experimental|Test group|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
10155256|NCT04046874|Other|Usual Care|All patients were referred for the study by their General Practitioner (GP). GPs were encouraged to assess and treat their patients as usual and make all the referrals they think are appropriate for their patients.
10155257|NCT04046874|Other|Stratified Model of Care|A subgrouping tool helps guide clinical decision-making about treatment and onward referral (Start Back Screening Tool). Patients in each subgroup (low, medium or high risk of chronicity) are then managed according to a targeted treatment system of increasing complexity.
10155258|NCT04046744|Active Comparator|BAX|
9520031|NCT03281135|No Intervention|Standard care: VIA screening|Control Arm, in which women's are invited to cervical cancer screening as per standard Ethiopian cervical cancer prevention and control guideline. Uptake of screening in this group will be compared with the HPV testing arm group to test for significant differences in adherence.
10155259|NCT04046744|Experimental|BAX-Asso|
10155260|NCT04047186|Experimental|neoadjuvant PD-1 group|receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor
10155261|NCT04047004|Experimental|High-risk gastric cancer patients|The study population of high-risk gastric cancer patients will be offered one session of PIPAC immediately after laparoscopic removal of the stomach.
10155262|NCT04046991|Active Comparator|HD-tDCS+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.
10155263|NCT04046991|Sham Comparator|Sham+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,
10155264|NCT04046861|Active Comparator|Vitamin C|2g vitamin C (ascorbic acid) iv before cardiopulmonary bypass, 2 g vitamin C iv before removing the aortic clamp, 1g vitamin C iv 8 h after aortic clamp removal and every 8 h thereafter(2 times)
10155265|NCT04046861|Placebo Comparator|Placebo (saline)|placebo (saline) iv before cardiopulmonary bypass, placebo before removing the aortic clamp, placebo iv 8 h after aortic clamp removal and every 8 h (2 times)
10155266|NCT04047069|Other|Control|Awareness Training
9520032|NCT03281122|Experimental|Arm A|Specified dose on specified days
9671018|NCT05054036|Active Comparator|GoLYTELY|"For GoLYTELY, the dose, schedule, and route of administrate are as follows:~On the evening prior to the colonoscopy, mix powder with lukewarm water to a total volume of 4 liters. Drink 2 liters of the solution and store the rest in the refrigerator.~Drink the remaining 2 liters on the morning of the procedure.~Limit food intake to a light breakfast on the day prior to the colonoscopy, followed by only clear liquids until the procedure is complete.~Avoid red and purple liquids."
9972942|NCT01326052|Active Comparator|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
9972943|NCT01326078|Experimental|propofol nanoemulsion|3-4 mg/kg of propofol nanoemulsion will be administered by 1mL per 5 seconds, adjustment dose can be given.
9972944|NCT01326078|Active Comparator|propofol lipid emulsion|3-4 mg/kg will be administered by 1 ml per 5 seconds.
9972945|NCT01326091|No Intervention|Standard Positioning|
9972946|NCT01326091|Active Comparator|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
9972947|NCT01326117|Experimental|tadalafil|
9972948|NCT01326130|Active Comparator|Chronic care management 1|Content of chronic care model implemented in territory 1 and level of implementation
9972949|NCT01326130|Active Comparator|Chronic care management 2|Content of chronic care model implemented in territory 2 and level of implementation
9972950|NCT01326130|Active Comparator|Chronic care management 3|Content of chronic care model implemented in territory 3 and level of implementation
9972951|NCT01326130|Active Comparator|Chronic care management 4|Content of chronic care model implemented in territory 4 and level of implementation
9972952|NCT01326130|Active Comparator|Chronic care management 5|Content of chronic care model implemented in territory 5 and level of implementation
9972953|NCT01326130|Active Comparator|Chronic care management 6|Content of chronic care model implemented in territory 6 and level of implementation
9972954|NCT01326143||ORM Narval MRD|
9972955|NCT01326156|Experimental|Avon patellofemoral replacement|Knee arthroplasty with insertion of patellofemoral joint replacement.
9972956|NCT01326156|Active Comparator|PFC Sigma CR total knee replacement|Knee arthroplasty with total (tricompartmental) knee replacement.
9972957|NCT01326169|Active Comparator|Standard care|No intervention
9972958|NCT01326169|Experimental|Counseling|Telephone-delivered counseling
9972959|NCT01326182|Experimental|MAADRE|Group-based intervention combining asthma education and cognitive behavioral treatment for depressive symptoms
9972960|NCT01326182|Active Comparator|MAAS|Group-based treatment combining asthma education and general information regarding child health
9972961|NCT01326195|Experimental|Skills|Cognitive-Behavioral Dating Violence and HIV Prevention Group
9972962|NCT01326195|Active Comparator|Health Promotion|Psycho-educational Dating Violence and HIV Prevention group
9972963|NCT01326208|Experimental|Acute Lung Injury / ARDS|Patient under mechanical suffering from ALI or ARDS
9972964|NCT01326221||1|Single dose of Truvada
9972965|NCT01326234|Active Comparator|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
9972966|NCT01326234|Sham Comparator|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred.
9972967|NCT01326247|No Intervention|0.9% NaCl solution|
10155267|NCT04047069|Experimental|Intervention group|"Awareness Training~Person-Centered Occupational Therapy Intervention"
10155268|NCT04046978|Experimental|Group F|Mos3.1 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
10155269|NCT04046978|Experimental|Group G|Mos3.2 100 ug at Month 0 Mos3.1 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
9972968|NCT01326260||THAM Patients|Patients who were managed with the use of THAM
9972969|NCT01326260||Non-THAM Patients|Patients who did not use THAM but were resuscitated with crystalloids and colloids and may have received sodium bicarbonate for the treatment of acidosis
9972970|NCT01326286||Open Radical Prostatectomy|262
9972971|NCT01326286||Robotic Radical Prostatectomy|1303
9972972|NCT01326286||Intensity-Modulated Radiotherapy|638
9972973|NCT01326286||Interstitial Brachytherapy|171
9972974|NCT01326286||combined EBRT and Brachytherapy|143
9972975|NCT01326286||Active Surveillance|448
9972976|NCT01326286||Various other treatments|300
9972977|NCT01326299|Active Comparator|Nutritional ingredient|Dissolve in water and consume with meal
10155270|NCT04046978|Experimental|Group H|Mos3.3 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.1 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
9520033|NCT03281122|Placebo Comparator|Arm B|Specified dose on specified days
9972978|NCT01326299|Placebo Comparator|Carbohydrate|dissolve in water and consume with meal
9972979|NCT01326299|Experimental|#1 Nutrtitional ingredient + Fiber|Dissolve in water and consume with meal
9972980|NCT01326299|Experimental|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
9972981|NCT01326299|Experimental|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
9972982|NCT01326312|Experimental|GTX 758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
9972983|NCT01326312|Experimental|GTx-758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
9972984|NCT01326312|Active Comparator|Lupron Depot|Luteinizing Hormone Releasing Hormone Agonist
9972985|NCT01326325|Experimental|Ketamine|Ketamine PANFARMA
9972986|NCT01326325|Placebo Comparator|Not Ketamine|NaCl
9972987|NCT01326338|Experimental|Nitazoxanide Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
9972988|NCT01326338|Placebo Comparator|Placebo Suspension|Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years
9972989|NCT01326351|Experimental|Regenerative Injection Therapy|
9972990|NCT01326351|Sham Comparator|Dry needle|
9972991|NCT01326351|Active Comparator|Exercise|
9972992|NCT01326403|Experimental|Group A|Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
9972993|NCT01326403|Experimental|GROUP B|Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
9972994|NCT01326403|Placebo Comparator|GROUP C|A control group will only receive placebo in the emergency room and in the OR.
9972995|NCT01326416|Active Comparator|S: Nutritional Supplementation alone|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
9972996|NCT01326416|Active Comparator|A: Physical Reconditioning alone|Physical reconditioning sessions led by a trainer three times a week for 6 months.
9972997|NCT01326416|Active Comparator|AS: Physical Reconditioning + Nutritional Supplementation|Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
9972998|NCT01326416|No Intervention|C: Lifestyle counseling|Usual advice given in consultation on the need for a balanced diet and regular physical activity
9972999|NCT01326429||Hypernatremia|Patients admitted to the emergency department with a serum sodium exceeding 145 mmol/L.
9973000|NCT01326429||Hyponatremia|Patients admitted to the emergency room with a serum sodium below 135 mmol/L.
9973001|NCT01326442|Experimental|diet only|low glycemic index diet, calorie restricted with exercise 3 times per week.
9973002|NCT01326442|Active Comparator|supplemented|2000 IU vitamin D3 plus 1.8 g EPA + DHA
9973003|NCT01326455|No Intervention|Terumo Control|
9973004|NCT01326455|Active Comparator|Terumo Fast Release|
9973005|NCT01326455|Active Comparator|Clo-Sur P.A.D.|
9973006|NCT01326468|Experimental|Cohort A - Temsirolimus with Cisplatin|Temsirolimus with cisplatin, Erbitux and radiation therapy
9973007|NCT01326468|Experimental|Cohort B - Temsirolimus|Temsirolimus with Erbitux and radiation therapy
9973008|NCT01326494|Active Comparator|Arm 1 Oral Cortico Steroid|A filled prescription will be given to be used upon early onset of symptoms.
9973009|NCT01326494|No Intervention|Usual care for Asthma treatment|monitor the readmission of URTI induced asthma in children over a 12 month period
9973010|NCT01326520|Experimental|Phospholipid enriched dairy product|
9973011|NCT01326520|Placebo Comparator|dairy product|
9973012|NCT01326559|Experimental|Experimental 1|Induction chemotherapy using Docetaxel, Cisplatin and 5-FU for week 1 to week 9 and followed by concurrent chemoradiation plus cetuximab from week 10 to week 16
9973013|NCT01326572||female, male, HIV, lung disease|All participants in the University of Pittsburgh Multicenter AIDS Cohort Study are eligible for this protocol. All participants in the UCSF Women's HIV study are eligible and all Men from the UCLA men's HIV study are eligible
9973014|NCT01326585|Experimental|Dexamethasone|Subjects receive intravenous intraoperative dexamethasone
9973015|NCT01326585|Placebo Comparator|Saline solution|Subjects receive intravenous intraoperative normal saline solution
9973016|NCT01326598||T2DM patients with A1C<7.0%|
9973017|NCT01326611|Active Comparator|Clarithromycine Group: Active Comparator|Drug: Clarithromycin intravenous clarithromycin (10 mg/kg twice a day for 10 days)
9973018|NCT01326611|Placebo Comparator|Placebo Group: Placebo Comparator|Drug: D5W Dose given daily, IV same volume that Clarithromycin would be to equal 10 mg/kg for first 10 days.
10155271|NCT04046978|Experimental|Group I|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug at Months 0, 2 and 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
9973019|NCT01326624||NYHA class III or IV|"Patients with NYHA class III or IV during the past month and one or more of the following:~Hospitalization for cardiac decongestion and stabilization.~Advanced heart failure receiving intravenous diuretics/inotropics in an outpatient clinic.~Awaiting cardiac transplantation"
9973020|NCT01326624||left ventricular ejection fraction ≤ 35%|"Patients with left ventricular ejection fraction ≤ 35% and either one of the following:~Coronary revascularization within 3 calendar months prior to enrollment.~Heart failure of non-ischemic origin diagnosed within 3 calendar months prior to enrollment."
9973021|NCT01326624||Awaiting ICD re-implantation|
9973022|NCT01326624||Acute myocardial infarction|Patients hospitalized with acute myocardial infarction and Killip Class III/IV.
9973023|NCT01326637|Experimental|intervention|Received the intervention: previsit planning phone call with filled out patient overview document & clinician huddle
9973024|NCT01326637|No Intervention|observation|Received usual care
9973025|NCT01326650|Experimental|Vitamin D|daily vitamin D supplement
9973026|NCT01326650|Placebo Comparator|placebo|daily placebo supplement
9973027|NCT01326663|Active Comparator|divalproex sodium|
9973028|NCT01326663|Placebo Comparator|sugar pill|
9973029|NCT01326676|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2.
9973030|NCT01326676|Active Comparator|usual medication|participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
9973031|NCT01326689|Experimental|KW-2246|
9973032|NCT01326689|Placebo Comparator|Placebo|
9973033|NCT01326754|Other|Artemether-lumefantrine|
9973034|NCT01326754|Other|Artesunate-amodiaquine|
9973035|NCT01326754|Other|Dihydroartemisinin-piperaquine|
9973036|NCT01326767|Active Comparator|Paclitaxel dosing according to SmPC|
9671019|NCT05054023|Active Comparator|Piroxicam gel|50g tubes that contained 0.5% piroxicam. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
9671020|NCT05054023|Active Comparator|Soulagel®; Belpharma Tunisia|100g tubes that contained extracts of cinnamon, cloves, cypress, lavender, thyme, peppermint, rosemary, arnica, and camphor. the gel was gently massaged in the injured site for 1 minute, 3 times a day for 7 days.
9671022|NCT05053854|Experimental|177Lu-DOTA-Octreotate + talazoparib|Patients will receive 4 cycles of 177Lu-DOTA-Octreotate every 8 weeks, the last 3 cycles combined with talazoparib on days 2-6 of each cycle.
9671023|NCT05053633||Combined spinal epidural anesthesia|Apply combined spinal epidural anesthesia
9671024|NCT05053984|Experimental|Neuromodulation|This study has only 1 arm and the control group is their baseline data
9973037|NCT01326767|Experimental|Individualized pharmacokinetically driven paclitaxel dosing|In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
9973038|NCT01326806|Experimental|Sex Education + Standard Care|Participating mothers will receive sex education information while their child is having a physical exam.
9973039|NCT01326806|Active Comparator|Hygiene & Nutrition Education + Standard Care|Participating mothers will receive information on hygiene and nutrition while their child is having a physical exam.
9973040|NCT01326806|No Intervention|No Education + Standard Care|Participating mothers who are passive controls will not receive any additional information while their child is having a physical exam.
9973041|NCT01326858|Experimental|Olopatadine, 0.7%|Olopatadine hydrochloride ophthalmic solution, 0.7%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic vehicle and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
9973042|NCT01326858|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
9973043|NCT01326858|Active Comparator|Zaditor|Ketotifen fumarate ophthalmic solution, 0.025%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and olopatadine hydrochloride ophthalmic solution vehicle, Periods 2 and 3, as randomized
9973044|NCT01326871|Experimental|ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)|
9973045|NCT01326871|Experimental|ALT-801 and Gemcitabine (Phase II only)|
9973046|NCT01326884|Other|1|Endovascular Repair
9973047|NCT01326897|Active Comparator|Comparison Group|Comparison group participants will be given health education materials.
9973048|NCT01326897|Experimental|Intervention'|This group will receive the intervention (Healthy Homes/Healthy Families) as described below.
9973049|NCT01326936|Experimental|Unworked VP|Online education using typical virtual patient (VP) approach. Five unworked VPs presented to subjects for study.
9973050|NCT01326936|Experimental|Guided Learning|Online education replaces two unworked VPs in Arm 1 with identical worked example VPs (case studies) for learners to study
9973051|NCT01326949|Active Comparator|ET+NSBB|"Endoscopic treatment(ET)- Endoscopic variceal ligation (EVL)~Non-selective beta blocker(NSBB)-Propranolol.~Anticoagulation(AT)- Heparin followed by warfarin."
9973052|NCT01326949|Active Comparator|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS.
9973053|NCT01326975||EAdi 1|babies in this group will first receive CPAP through IF-CPAP for 30 minutes. After another 45 minutes, they will be switched to HFNC for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
9973054|NCT01326975||EAdi 2|babies in this group will first receive CPAP through HFNC for 30 minutes. After another 45 minutes, they will be switched to IF-CPAP for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
9973055|NCT01326988||Patients requiring spinal anesthesia for lower limb surgery|Patients of at least 18 years of age undergoing spinal anesthesia for elective lower limb surgery will be recruited. Therefore inclusion and exclusion criteria are the same as for traditionally administered spinal anesthesia as below. Additionally we will exclude those patients who are incapable of providing fully informed consent, patients who are currently enrolled in other studies and patients with communication difficulties
9973056|NCT01327014|Placebo Comparator|Placebo group|
9973057|NCT01327014|Experimental|1,200 mg/day of XZK group|
9973058|NCT01327014|Experimental|2,400 mg/day of XZK group|
9671025|NCT05053685||Obstructive Sleep Apnoea (OSA)|Subjects with OSA
9671026|NCT05053685||Elevated Urine Metanephrines|Subjects with elevated metanephrines
9671027|NCT05053581||Patient|
9671028|NCT05053750|Experimental|Paclitaxel|
9671029|NCT05053750|Experimental|Bevacizumab|
9671030|NCT05053594|Experimental|Group N10|Reversal with neostigmine 10 mcg/kg and atropine 5 mcg/kg
9973059|NCT01327027|Experimental|Vasopressin, Arginine, ADH|We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
9973060|NCT01327027|Placebo Comparator|Sterile Salilne|Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
9973061|NCT01327040|Experimental|sensitization duration 1.375h|This group will experience a 1.375h sensitization duration prior to the 12h light exposure
9973062|NCT01327040|Experimental|sensitization duration 5.5h|This group will experience a 5.5h sensitization duration prior to the 12h light exposure
9973063|NCT01327040|Experimental|sensitization duration 22h|This group will experience a 22h sensitization duration prior to the 12h light exposure
9973064|NCT01327040|Experimental|sensitization duration 0.33h|This group will experience a 0.33h sensitization duration prior to the 12h light exposure
9973065|NCT01327066|Experimental|Droxidopa - Therapeutic|Droxidopa 600 mg
9973066|NCT01327066|Experimental|Droxidopa - Supratherapeutic Dose|Droxidopa 2000 mg
9973067|NCT01327066|Placebo Comparator|Placebo|Placebo
9520034|NCT03281096|Experimental|Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years
9520035|NCT03281096|Placebo Comparator|Placebo|identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years
9973068|NCT01327066|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg dose
9973069|NCT01327079|Experimental|Group 1|"Gestational age less than 29 weeks We will substitute for one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
9973070|NCT01327079|Experimental|Group 2|"Gestational age greater then 29 weeks We will substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
9973071|NCT01327092|No Intervention|Literacy Group|Families in the Literacy Group (control group)will receive a program which seeks to promote literacy by providing developmentally appropriate books and other reading-related materials to children and encouraging mothers to develop an interest in reading with their child. After enrollment and randomization, CHIP staff will visit these control group homes, assess the mother's interest in and barriers to reading with her child, council mothers about the importance of literacy and reading books to their child, and children will be given age appropriate books and other materials to promote literacy.
9973072|NCT01327092|Experimental|Injury Intervention Group|Injury Intervention Group: In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq ft) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1 meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years
9973073|NCT01327118|Placebo Comparator|Isoton sodium chloride|
9973074|NCT01327118|Active Comparator|Prostaglandin F2alpha|
9973075|NCT01327144|Experimental|Famciclovir 500mg|1 tablet each 8 hours for 7 days
9973076|NCT01327144|Active Comparator|Aciclovir 400mg|2 tablets of Aciclovir 400 mg each 4 hours for 7 days
9973077|NCT01327170|Active Comparator|Subthreshold diode micropulse laser|Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy
9973078|NCT01327170|Sham Comparator|Sham|Sham group simulating the laser treatment
9973079|NCT01327209||Patients with diabetes|
9973080|NCT01327222|Experimental|bevacizumab|three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
9973081|NCT01327222|No Intervention|control|monthly follow-up
9973082|NCT01327235|Active Comparator|Endostar|
9973083|NCT01327235|Active Comparator|Cisplatin|
9973084|NCT01327235|Experimental|Endostar and Cisplatin|
9973085|NCT01327248||affected patients|20 Patients suffering from bronchiolitis obliterans
9973086|NCT01327248||non-affected patients|20 matched controls not suffering from bronchiolitis obliterans
9520036|NCT03281083|Experimental|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
9520037|NCT03281044|Experimental|FMT group|Patient group receiving active FMT capsules
9520038|NCT03281044|Placebo Comparator|Placebo group|Patient group receiving placebo capsules
9662024|NCT00962884|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
9973087|NCT01327261|Experimental|Levodopa + benserazide (test formulation)|A randomized-sequence, open-label, 2-period crossover study assessing relative bioavailability of two drug products containing the association levodopa + benserazide.
9973088|NCT01327261|Active Comparator|Levodopa + benserazide (reference formulation)|
9973089|NCT01327287||Trauma patients eligible to receive thoracic epidural|Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
9973090|NCT01327287||Control Arm|Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain
9973091|NCT01327326|Active Comparator|TMD patients|"Intervention:~Drug: Naltrexone~Drug: placebo"
9973092|NCT01327326|Active Comparator|Healthy controls|"Intervention:~Drug: Naltrexone~Drug: placebo"
9973093|NCT01327352|Experimental|Oshadi D|"2 dose levels of Oshadi D in 2 food regimen will be administered as following:~Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.~On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration~On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.~On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.~On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast."
9973094|NCT01327365|Experimental|Sheathless group|patient randomized to the sheathless guiding catheter group
9973095|NCT01327365|Active Comparator|Conventional group|patients randomized to the conventional guiding catheter group
9973096|NCT01327378||Dialysis, normal glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min < 7.8 mmol/L
9973097|NCT01327378||Dialysis, impaired glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min 7.7<11.1 mmol/L
9671031|NCT05053594|Experimental|Group N20|Reversal with neostigmine 20 mcg/kg and atropine 10 mcg/kg
9973098|NCT01327378||Control, normal glucose tolerance|Healthy Control subjects, N=10 OGTT,120 min <7.8 mmol/L
9973099|NCT01327391|Active Comparator|On line Hemodiafiltration|Hemodialysis patients treated with on line hemodiafiltration technic
9973100|NCT01327391|Other|hemodialysis|Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers
10155272|NCT04047030||Injured Cohort|Approximately 300 participants treated for a fracture of the tibial plateau, pilon, ankle or calcaneus will be enrolled from METRC civilian trauma centers and military treatment facilities over an 18 month period. Participating centers treat large numbers of severe orthopaedic injuries and have a proven track record for successfully recruiting and retaining participants in prospective studies in orthopaedic trauma. Participants will be enrolled following definitive treatment of their injury.
10155273|NCT04047030||Non-Injured Volunteers|Non-injured adults of similar age and gender distribution will be enrolled at two participating centers (Carolinas Medical Center and Womack Military Medical Center). The sample of non-injured volunteers will exclude individuals with history of lower extremity injury, vascular disease, or who require use of ambulatory aides to walk.
10155274|NCT04047043||Taurine > 30 μmol/L|serum taurine level
10155275|NCT04047043||Taurine 30-20 μmol/L|serum taurine level
9973101|NCT01327404||Depressed|Patients with Major Depressive Disorder
9973102|NCT01327404||Diabetic|Patients with Type 2 Diabetes
9671032|NCT05053594|Experimental|Group N30|Reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
9671033|NCT05053594|Placebo Comparator|Group P|Spontaneous reversal (placebo)
9973103|NCT01327404||Diabetic/Depressed|Patients with both diabetes and major depressive disorder
9973104|NCT01327404||Healthy Controls|
9973105|NCT01327417||Depressed|Patients with Major Depressive Disorder
9973106|NCT01327417||Healthy Controls|
9973107|NCT01327430|Experimental|Phospholipid supplementation|Supplementation of milk phospholipid
9977286|NCT01359852|Experimental|001|"[11C] JNJ-42491293 + JNJ-40411813 Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan,[11C] JNJ-42491293 + JNJ-40411813 Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain,[11C] JNJ-42491293 Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.,[11C] JNJ-42491293 Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection have a 90 minute PET scan and have arterial and venous blood sampling."
9977287|NCT01359865|No Intervention|Lumbar plexus Block|This group will recieve pre-operative lumbar plexus block plus general anesthesia
9977288|NCT01359878|Experimental|Fibrinogen Concentrate|
9977289|NCT01359878|Placebo Comparator|Placebo|Isotonic Saline
9977290|NCT01359891||Cohort 1|"All patients >18 years admitted to the University Hospital Graz, Austria, with positive blood cultures tested in the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz, or the Institute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, are screened for study inclusion. Patients eligible for the study have to have Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Klebsiella pneumoniae or medically relevant fungi / viral pathogens identified as causative pathogen.~The estimated total number of patients included in this first study cohort will be 500."
9977291|NCT01359891||Cohort 2|"All patients >18 years admitted to the University Hospital Graz, Austria, will be screened for study inclusion if the attending emergency department physicians on the very first visit suspects bacteremia/fungemia/sepsis and consecutively orders blood cultures. Patients will be included in this second cohort if these initially taken blood culture turns positive (n=200) or stays negative (n=50) at the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz. As soon as the number of 50 is reached for the control group enrollment will be stopped for this group.~As soon as the proposed number of 250 patients is reached enrolment for this second cohort will be stopped. Patients enrolled in cohort 2 may also be consecutively enrolled in cohort 1."
9977292|NCT01359891||Validation Cohort|To verify the employed Presage™ST2 assay established in our study laboratory for its intended use, a total number of 70 left over plasma samples obtained from septic patients which have prior been tested for sST2 with the same assay at the Department of Laboratory Medicine, Barmherzige Brueder Linz, Austria, will be retested. This cohort therefore serves as a validation cohort.
9977293|NCT01359917||autologous fat transfer|patients received fat transfer for HIV lipodystrophy
9977294|NCT01359917||polylactic acid|treatment with polylactic acid (PLA) for HIV lipodystrophy
9977295|NCT01359917||bio-alcamid|bio-alcamid injections
9977296|NCT01359930|Active Comparator|Naltrexone and Bupropion SR|
9977297|NCT01359930|Placebo Comparator|Placebo|
9977298|NCT01359982|Experimental|RRx-001|
9977299|NCT01360008||Cryo ablation|Patients with first Ablation of atrial fibrillation treated by cryo ablation
9977300|NCT01360008||RF ablation|Patients with first Ablation of atrial fibrillation treated by Radio frequency ablation
9977301|NCT01360034|Experimental|Nifedipine|108 patients will receive nifedipine as tocolytic for 48 hours.
9977302|NCT01360034|Experimental|Indomethacin|108 patients will receive indomethacin as tocolytic for 48 hours.
9977303|NCT01360047||Cases|Cases with nonfatal MI or coronary death
9977304|NCT01360047||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
9977305|NCT01360060||Group N|parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia
9977306|NCT01360060||Group P|parturients who had undergone Cesarean section under the diagnosis of preeclampsia
9977307|NCT01360073||Cases|Cases with nonfatal MI or coronary death
9977308|NCT01360073||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
10155276|NCT04047043||Taurine < 20 μmol/L|serum taurine level
10155277|NCT04046770|Experimental|Double-Chamber Syringe|Intravenous administration of drugs and flushing with the Double-Chamber Syringe
10155278|NCT04046770|Active Comparator|Classical Syringes|Intravenous administration of drugs and flushing with the classical syringe
10185820|NCT03741920|Experimental|Personal KinetiGraph™ (PKG™) +|For subjects in the PKG+ Group, the study MDS will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment. PKG results will be recorded in the PKG Reporting case report form (CRF). The study MDS will complete the MDS-Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures along with the PKG information.
10185821|NCT03741920|Active Comparator|Personal KinetiGraph™ (PKG™) -|For subjects in the PKG- Group (control group), the study Movement Disorder Specialist (MDS) will complete the MDS - Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures. The study Movement Disorder Specialist will be blinded to the PKG information until the second part of the 90-day follow-up visit.
10185822|NCT03741907|Experimental|FAUCS|French Ambulatory C-section
10185823|NCT03741907|Active Comparator|MLC|Gold Standard
10185824|NCT03741894|Placebo Comparator|Primary wound closure|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
10185825|NCT03741894|Experimental|Iodoform and wound closure|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.
10185826|NCT03741894|Experimental|Chlorhexidine and wound closure|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
10185827|NCT03741855|Experimental|Remote-Monitoring Program|Cloud Dx kit with remote-monitoring
10185828|NCT03741855|Experimental|Self-Monitoring Program|Cloud Dx kit with self-monitoring
10185829|NCT03741855|No Intervention|Standard of Care|Participants will not be provided with the Cloud DX kit or an action plan
10185830|NCT03741816|Active Comparator|Biodentine|Indirect pulp capping with Biodentine in mature permanent molars with deep carious lesions and reversible pulpitis
10185831|NCT03741816|Experimental|TheraCal LC|Indirect pulp capping with TheraCal LC in mature permanent molars with deep carious lesions and reversible pulpitis
10185832|NCT03741803|Active Comparator|Delayed cord clamping|
10185833|NCT03741803|Active Comparator|Early cord clamping|
10185834|NCT03741764|Other|Vivosorb|Only arm in study
10185835|NCT03741751|Experimental|active rTMS with computerized cognitive training|Participants will receive 6 sessions of active rTMS followed by a computerized cognitive training session over 2 weeks.
10185836|NCT03741751|Sham Comparator|sham rTMS with computerized cognitive training|Participants will receive 6 sessions of sham rTMS followed by a computerized cognitive training session over 2 weeks.
10185837|NCT03741712|Experimental|SHR2554|Participants will receive SHR2554 orally
10185838|NCT03741712|Experimental|SHR2554+SHR3680|Participants will receive SHR2554 combined with SHR3680 orally
10185839|NCT03741699|Experimental|Arm 1 - experimental group|Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
10185840|NCT03741699|No Intervention|Arm 2 - control (no pre-treatment) group|The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
10185841|NCT03741686|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.
10185842|NCT03741686|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.
9662025|NCT00962884|Sham Comparator|Sham Device|Breathing device similar to active Res-Q-Gard device but with one-way resistance valve removed.
9662026|NCT00962728|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
9662027|NCT00962728|Sham Comparator|Sham Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
10185843|NCT03741673|Experimental|Group I (pre-operative SRS)|Patients undergo SRS within 15 days of randomization followed by surgery within 15 days. Patients may undergo additional SRS if disease returns after treatment.
10185844|NCT03741673|Active Comparator|Group II (post-operative SRS)|Patients undergo surgery within 15 days of randomization followed by standard of care SRS within 30 days. Patients may undergo additional SRS if disease returns after treatment.
10185845|NCT03741660|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
10185846|NCT03741660|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
10187843|NCT03722199|Experimental|Persons with type 2 diabetes|In this interventional study the investigators ask the patient (persons with type 2 diabetes) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
10187844|NCT03722186|Experimental|SHR-1603|Multiple escalating doses of SHR-1603
10187845|NCT03722173|Experimental|All subjects|Period 1:Treatment R (BI 894416 alone) followed by Period 2:Treatment T (BI 894416 + itraconazole)
10187846|NCT03722160|Other|Solo Tympanostomy Tube Device|The Solo Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
10187847|NCT03722147|Experimental|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
10187848|NCT03722134|Experimental|MOCA|The refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
10187849|NCT03722134|Active Comparator|EVLA|The refluxing GSV was treated with endovenous laser ablation.
9662028|NCT00754949|Experimental|1|
9662029|NCT00754949|Active Comparator|2|
9662030|NCT00754949|Active Comparator|3|
9662031|NCT00466531|Experimental|Patients with CLL or indolent B-cell lymphoma|The first stage is a standard 3-step phase I dose escalation trial to assess the safety of 19-28z CAR expressing autologous T cells with or without prior conditioning chemotherapy.Step 1, a cohort of pts will receive the lowest planned dose of 19-28z+ modified T cells. Step 2, a cohort of pts will receive cyclophosphamide conditioning chemotherapy followed by the lowest planned dose of 19-28z+ modified T cells. If less than 33% of pts in the cohort experience unanticipated dose-limiting toxicity,Step 3, a cohort of pts will be treated with the investigator's choice conditioning chemotherapy followed by the higher dose of 19-28z+ modified T cells. If less than 33% of pts in the initial cohort (Step 3) experience unanticipated dose-limiting toxicity, the cohort in Step 3 may be expanded to include up to 15 pts. In Step 3, an additional cohort of Waldenstrom's Macroglobulinemia (WM) pts will be treated with the investigator's choice conditioning chemotherapy followed by 19-28z+ T cells.
9973108|NCT01327443|Other|Weight loss|10% weight loss in 24 weeks time period through nutritional counseling.
9973109|NCT01327443|Active Comparator|Exercise without weight loss|24 weeks under direct supervision.
9973110|NCT01327443|No Intervention|Control|No change in usual exercise levels or food intake.
9973111|NCT01327456|Experimental|Self-Management Intervention|participants who receive the one-on-one self-management intervention
9973112|NCT01327456|No Intervention|Usual Care|group receives no additional education or intervention then they would as usual care of their COPD
9973113|NCT01327469|Experimental|Albendazole 400mg|albendazole, 1 x 400mg
9973114|NCT01327469|Experimental|Albendazole 2 x 400mg|albendazole, 2 x 400mg
9973115|NCT01327469|Experimental|Mebendazole 500mg|mebendazole, 1 x 500mg
9973116|NCT01327469|Experimental|Mebendazole 2 x 500mg|mebendazole, 2x 500mg
10155279|NCT04046783||Group A included subjects without a history of C-section|Group A consisted of 47 women without a prior a history of C-section: 24 controls and 23 subjects who used patch. These latest 23 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
9973117|NCT01327469|Experimental|Pyrantel-oxantel + mebendazole|pyrantel-oxantel (10mg/kg)+ mebendazole (500mg)
9973118|NCT01327534|Experimental|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
9973119|NCT01327534|Active Comparator|clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
9973120|NCT01327586|Experimental|ATM|Advisor-Teller Money Manager
9973121|NCT01327586|Active Comparator|Individual Drug Counseling|
9973122|NCT01327625|Experimental|Azithromycin|Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria
10155280|NCT04046783||group B subjects who had already undergone previous C-section|Group B consisted of 46 women already undergone previous C-section: 22 controls and 24 subjects who used patch. These latest 24 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
10155281|NCT04047095|Experimental|Intervention|"Normal daily meals plus one sachet three times a day of immune nutrients for five days after the surgery.~8 a.m. - normal meal plus one sachet immune nutrients~1 p.m - normal meal plus one sachet immune nutrients 6 p.m. - normal meal plus one sachet immune nutrients"
10155282|NCT04047095|Active Comparator|Control|"Normal daily meals. 8 a.m. - normal meal~1 p.m. - normal meal 6 p.m. - normal meal"
10155283|NCT04046822|Active Comparator|Active drug|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
10155284|NCT04046822|Placebo Comparator|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
10155285|NCT04046796||Healthy twin|
10155286|NCT04046796||Effected Twin|Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.
10155287|NCT04046718|Experimental|electroacupuncture|the study group received electroacupuncture stimulation at different points
10155288|NCT04046718|No Intervention|control group|a control group with no intervention
10155289|NCT04046510|Active Comparator|High doses|the patients of this group recieved conventionnal doses of ocytocin after foetal extraction in C section: 5IU in bolus followed by 15IU in continuous infusion
10155290|NCT04046510|Experimental|Intermediate doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 10IU in continuous infusion
10155291|NCT04046510|Experimental|Low doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 5 IU in continuous infusion
10155292|NCT04046523|Experimental|Healthy Controls|In the first phase of the experiment, 20 healthy controls will test the VO device to determine whether the camera with a CCD or CMOS lens is the most appropriate for use in ICP patients and to synchronize the VO, ECG, PPG, IOP and respiratory signals.
10185847|NCT03741634|Experimental|Intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
10187850|NCT03722134|Active Comparator|RFA|The refluxing GSV was treated with radiofrequency ablation.
9973123|NCT01327664|Experimental|AIN457 300mg s.c every 2 weeks|
9973124|NCT01327729|Active Comparator|YPEG-IFN α-2a one week|this arm will be treated with: YPEG-IFN α-2a 180mcg/ week for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
9973125|NCT01327729|Active Comparator|YPEG-IFN α-2a Ten days|this arm will be treated with: YPEG-IFN α-2a 180mcg/10 days for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
9973126|NCT01327729|Active Comparator|YPEG-IFN α-2a two weeks|"The third group will be treated with:~YPEG-IFN α-2a 180mcg/ 2 weeks for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks."
10155293|NCT04046523|Experimental|Transfer Function Estimation|Subjects in the second phase of the experiment (70 subjects total) will be randomized to either Group A or Group B. We anticipate that 25 adult and 10 pediatric (ages 4-17) patients will participate in each group. Individuals in Group A will have two inter-leaved examinations (1-14 days apart). Data from the first examination will serve for SVP-ICP transfer function estimation and data from the second examination will serve for the intra-group verification for the estimated transfer function.
10155294|NCT04046523|Experimental|Intra-Group Verification|Individuals in Group B will undergo one examination. Data from Group B participants will serve as the inter-group re-test verification of the estimated transfer function.
10155295|NCT04046458|Experimental|EHR Alert|Physician teams will observe the EHR alert as they perform their clinical duties in the EHR.
10155296|NCT04046458|Placebo Comparator|No Alert|Physician teams will perform their clinical duties in the EHR as usual, with no visible alert.
10155297|NCT04046562|Active Comparator|PAW plus standard of care|Each PAW session will include handouts and worksheets to assist with new strategies as well as homework. Strategies taught within PAW will be integrated with the skills taught in weight management. For example, pain diaries will be kept along with food and exercise logs to examine relationships among pain, eating and activity.
10155298|NCT04046562|Placebo Comparator|Pain education plus standard of care|For those randomized into the information-only group, sessions will be delivered in the same manner. Sessions will cover general pediatric pain management but no behavioral or cognitive skills training will be taught.
10155299|NCT04046601|Experimental|Impedance|every resected tissue will measured by an impedance probe
9662032|NCT00406445||carrier LFS family members|96 carrier LFS family members
10155300|NCT04046588|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
10155301|NCT04046588|Other|Healthy control group|This group will include 40 healthy volunteers.
10155302|NCT04046588|Experimental|Healthy intervention group|This study will include 40 healthy adults. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively.
10155303|NCT04046432|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial 1. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101-LAB capsule II) containing 10 billion bacteria per capsule for clinical trial 2.
10155304|NCT04046432|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
9973127|NCT01327755|Experimental|Selenium|
10155305|NCT04046653|Experimental|Study arm 1|Allin capsules (x2) and Sulforaphane capsules (x2) once daily for 4 weeks
10155306|NCT04046653|Experimental|Study arm 2|Allin capsules (x2) and placebo capsules (x2) once daily for 4 weeks
10155307|NCT04046653|Experimental|Study arm 3|Sulforaphane capsules (x2) and placebo capsules (x2) once daily for 4 weeks
10155308|NCT04046653|Placebo Comparator|Study arm 4|Placebo capsules (x4) once daily for 4 weeks
10155309|NCT04046640||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
10155310|NCT04046640||Healthy group|This group will include 40 healthy volunteers.
10155311|NCT04046692||children in hospital school in contact with outside school|children experience school's lesson with the hospital teacher in the school's room or into their bedrooms and the investigator give before/after the lesson 2 questionnaire (PANAS-C and PH-C) and the VAS to evaluate the aim's study. Then, the investigator asks the children to make 2 paintings: one about the hospital school experience (what is for him/her the hospital school) and one about the outside school (what he/she do/did outside during school).
10155312|NCT04046692||children in hospital school NOT in contact with outside school|"it's the same of the previous group (children experiencing hospital school still in contact with outside school); the only difference of this group is that children are not in contact with the outside school."
10155313|NCT04046692||hospital teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
10155314|NCT04046692||outside teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
10155315|NCT04046692||Parents|parents have to answer some questions (qualitative interview)
10155316|NCT04046666|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
10155317|NCT04046666|Other|Healthy group|This group will include 40 healthy volunteers.
10155318|NCT04046666|Other|Healthy intervention group|This group will include 40 healthy volunteers, who will receive moxibustion intervention.
10155319|NCT04046354|Experimental|Group A|The group will use microwave ablation equipment to treat benign thyroid nodules.
10155320|NCT04046354|Active Comparator|Group B|The group will use radiofrequency ablation equipment to treat benign thyroid nodules.
10155321|NCT04046679|Experimental|Bleomycin|Bleomycin Infusion By Tattoo Machine
10155322|NCT04046679|Placebo Comparator|Saline Solution|Saline Infusion by Tattoo Machine
10155323|NCT04046393|Experimental|Traditional Chinese Medicine(TCM) group|nasal irrigation with Traditional herbal medicine(licorice) extract-saline isotonic solution
10155324|NCT04046393|Placebo Comparator|Saline control group|nasal irrigation with saline isotonic solution
10155325|NCT04046380||normal lungs|
10155326|NCT04046380||Acute respiratory distress syndrome (ARDS) group|
10155327|NCT04046198|Experimental|İntervention group|Nurses working at Akdeniz University Hospital became the intervention group. The nurses who accepted to participate in the study were divided into groups of 5-15 people. Pre-test was applied to nurses who accepted the research. Nurses were given 4-hour group trainings. A booklet on the subject prepared by the researchers was given. Three interim interviews were conducted in the subsequent 3-month period. Six separate posters were posted in the clinics. Weekly reminder messages were sent via WhatsApp. At the end of the third month, post-test data were collected from the nurses.
9662033|NCT00406445||non-carrier LFS family members or normal|60 non-carrier LFS family members or normal
9662034|NCT00406445||non-carrier mitochondrial disorder family members or normal controls|20 non-carrier mitochondrial disorder family members or normal controls
9662035|NCT00406445||normal controls for MR spectroscopy study|30 normal controls for MR spectroscopy study
10155328|NCT04046198|Other|Control group|The nurses working in the University of Health Sciences Antalya Training and Research Hospital constituted the control group. Pre-test was applied to nurses who accepted the research. Post test applied 3 months later. A booklet on the subject prepared by the researchers was given after the post test. Group training was conducted to nurses.
10155329|NCT04046120|No Intervention|Heel included|The bandage is made by including the heel as recommended in routine.
10155330|NCT04046120|Experimental|Heel not included|he bandage is made by leaving the heel uncovered.
10155331|NCT04046029|Experimental|Bivalirudin|
10155332|NCT04046029|Active Comparator|Heparin|
10155333|NCT04046705|Experimental|HLA matched haematopoietic stem cell transplantation|Peripheral blood stem cell from matched HLA related donor.
10155334|NCT04046705|Other|Control arm|Best standard care : Patients will receive the best standard care according to their situation and their previous treatment: initiation of Hydroxyurea, continuation or optimization of the dose of Hydroxyurea, initiation or continuation of TP, initiation of a new drug proved to improve SCD and having authorization to use in France.
10155335|NCT04045951|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
10155336|NCT04045951|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
10155337|NCT04046211|Experimental|Hydrogen exposure|The first two patients will be exposed to 2.4% hydrogen gas in medical air via HFNC for 24 hours. The second two patients will be exposed to the same gas for 48 hours. The final 4 patients will be exposed to the same gas for 72 hours.
10155338|NCT04046016|Experimental|Subjects|A total of two subjects were enrolled. Those are breast cancer patients.
10155339|NCT04045886|Experimental|Online Educational Modules group|anesthesia residents are randomized to watch educational videos which is the intervention.
10155340|NCT04045886|Active Comparator|Reading two research papers group|anesthesia residents are randomized to read 2 research papers which is the active comparator
10155341|NCT04046367|Experimental|Intervention|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, with specific training aimed at increasing physical activity, functional capacity and conditioning of the respiratory musculature (prehabilitation by a physiotherapist)
10155342|NCT04046367|Active Comparator|Control|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
10155343|NCT04046055|Sham Comparator|Sham|50% of participants will have a unilateral cerebellar montage with the anode (active electrode) three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode (return electrode) on the ipsilateral cheek. 50% of participants will have a bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned (2 mA) on for the 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
10155344|NCT04046055|Experimental|Unilateral, 2 mA|A unilateral cerebellar montage with the anode three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode on the ipsilateral cheek. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
10155345|NCT04046055|Experimental|Bilateral, 2 mA|Bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
10155346|NCT04046055|Experimental|Unilateral, 4 mA|A unilateral cerebellar montage with the anode three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode on the ipsilateral cheek. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
9520039|NCT03281018|Experimental|Interventional arm|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session (experimental arm): The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
10155347|NCT04046055|Experimental|Bilateral, 4 mA|Bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
10155348|NCT04046094|Experimental|IV Ascorbic Acid|IV Ascorbic Acid 25 grams (g) infused 2 times a week for 4 weeks
10155349|NCT04046289||Low Calcium|low calcium milk of 180 ml, twice daily for 24 weeks
10155350|NCT04046289||Regular Calcium|regular calcium milk of 180 ml, twice daily for 24 weeks
10155351|NCT04046289||Probiotic 1|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
10155352|NCT04046289||Probiotic 2|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
10185848|NCT03741634|No Intervention|No intervention|During the study, participants enrolled at one study location will non receive the Multi-sectoral agricultural intervention. At the end of the study, participants in this arm will be eligible for education in financial management and sustainable farming practices and those who pay the loan down payment will be eligible for a small loan to purchase a human-powered water pump, seeds, fertilizers and, pesticides.
9826367|NCT02415959|Experimental|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
10185849|NCT03741621|Experimental|High Viscosity|viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
9662036|NCT00406445||subjects with mitochondrial disorders|20 subjects with mitochondrial disorders
9662037|NCT00279318||General Population, First Degree Relative|Newborns with high risk HLA in the general population or having a first-degree relative affected with T1DM.
9662038|NCT05132049|Experimental|Sequence A|
10155353|NCT04046146|Experimental|NIR-ICG MRL|We may ask healthy subjects to return for up to four injection sessions for the study. The first injection session will consist of intradermal injection of ICG into the webspaces of the hand as done in our previous studies followed by NIR camera imaging. The second session will consist of intradermal gadolinium injection and intravenous (IV) iron contrast agent followed by MRI imaging approximately 1 week after the first session. The third session will occur at minimum eight weeks later and entail intra-articular ICG injection in order to evaluate drainage via the lymphatics. The MCP joints will be identified in the non-dominant hand and injected with ICG. Approximately one week later, the fourth session will compromise of intra-articular gadolinium injection and IV iron contrast to confirm lymphatic drainage. The MCP joints of the non-dominant hand will again be identified and injected with gadolinium.
10155354|NCT04045977|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
10155355|NCT04045977|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
10155356|NCT04046042|Active Comparator|Conventional exercise time|During 12 months subjects will exercise during the first two hours of the hemodialysis session. A virtual reality exercise program will be implemented
10155357|NCT04046042|Experimental|Experimental group|During 12 months subjects will exercise during the last two hours of the hemodialysis session. A virtual reality exercise program will be implemented
10155358|NCT04046133|Experimental|pembrolizumab|Patients with locally advanced (stage IIIA/B, T3/T4, any N, M0) anal cancer will receive pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT.
10155359|NCT04045873|Experimental|ECMO plus IABP|
10155360|NCT04045873|Experimental|IABP|
10155361|NCT04045860|Experimental|CDT for head and neck lymphedema|Complete Decongestive Therapy
10155362|NCT04045860|Other|Standard of Care for head and neck lymphedema|Observation
10155363|NCT04045899|Active Comparator|ProSeal Laryngeal Mask Airway Group|ProSeal LMA was inserted in 50 patients
10155364|NCT04045899|Experimental|Air-Q LMA Group|Air-Q LMA was inserted in 50 patients
9662039|NCT05132049|Experimental|Sequence B|
10155365|NCT04045899|Experimental|Ambu AuraGain LMA Group|Ambu AuraGain was inserted in 50 patients
10155366|NCT04045925|Experimental|Taïso practice|6 months of biweekly practice Taïso
10155367|NCT04046302|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
10155368|NCT04046302|Placebo Comparator|placebo|one tablet of placebo self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
10155369|NCT04045678|Experimental|LY03003|
10155370|NCT04045678|Placebo Comparator|Placebo|
10155371|NCT04045717|Experimental|Hypo-FLAME 2.0|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
10155372|NCT04045600|Experimental|Mult FCT/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules (mult FCT) to evaluate the effects of mult FCT on renewal, super-resurgence, and reinstatement.
10155373|NCT04045600|Experimental|Mult FCT + Stimulus Fading/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules and stimulus fading (mult FCT + stimulus fading) to evaluate the effects of mult FCT and gradual fading of contextual stimuli on renewal, super-resurgence, and reinstatement.
10155374|NCT04045769|Experimental|Study Treatment 1|Saroglitazar magnesium 4 mg
10155375|NCT04045769|Experimental|Study treatment 2|Saroglitazar magnesium 20 mg
10155376|NCT04045769|Placebo Comparator|Placebo|Placebo
10155377|NCT04045769|Active Comparator|Active Control|Moxifloxacin 400 mg
10155378|NCT04045743|Experimental|Bermekimab (MABp1)|
10155379|NCT04045743|Experimental|Placebo|
9826368|NCT02415959|Active Comparator|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
10155380|NCT04045730|Experimental|Patients with metastatic pancreatic ductal adenocarcinoma|Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma, and all patients must have at least 15 unstained slides of formalin fixed paraffin embedded (FFPE) tumor tissue available or a pre-treatment core needle biopsy will be required as outlined in section 7.1.2.7. All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab in 4-week cycles.
9662365|NCT04539899|No Intervention|VR-|For patients in the control group, without a helmet, the course of the consultation will not be modified.
10155381|NCT04045782|Other|single arm|Adult patients (≥ 18 years of age) with Ulcerative Colitis or Crohn's Disease on maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
10155382|NCT04045756|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
10155383|NCT04045847|Experimental|CD147-CART|CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks
10155384|NCT04045821|Placebo Comparator|Control|Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D&C procedure will be completed.
10155385|NCT04045821|Experimental|Intervention|Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D&C procedure will be completed.
10155386|NCT04045574|Experimental|DAMP1 :|Single arm trial comparing a conventional technique with an experimental one, within the same patient.
10185850|NCT03741621|Experimental|Medium Viscosity|Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
10155387|NCT04045626|Active Comparator|Transepithelial accelerated cross-linking|"Paracel is instilled 1 drop every 1.5 minutes for 4.5 minutes then vibex-xtra is instilled 4 drops at 5.5 minutes followed by 1 drop at 6.5 minutes for a total soak time of 11 minutes followed by ultraviolet-A UVA irradiation with intended irradiance of 45mW/cm2 for 2.4 minutes"
10155388|NCT04045626|Active Comparator|Epithelium-off accelerated cross-linking|"Vibex-rapid is instilled every 2 minutes for 10 minutes followed by ultraviolet-A UVA irradiation of 30 mW/cm2 for 4 minutes"
10155389|NCT04045587||Severe Asthma Participants|Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.
10155390|NCT04045808||CAD(+) group|Participants were included in CAD (+) if they had more than 50% reduction in diameter in one or more major epicardial arteries,
9826369|NCT02415998||TEE|
10155391|NCT04045808||CAD(-) group|patients with less than 50% reduction in epicardial artery diameter were enrolled to CAD (-) group
10155392|NCT04045535|Experimental|Intervention group|Intervention with nurse and patients
10155393|NCT04045535|Active Comparator|Usual care|Usual clinical care based on current clinical practice guidelines.
10155394|NCT04045548|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.
10155395|NCT04045548|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.
10155396|NCT04046185|Experimental|pd-1 inhibitor and progesterone|Toripalimab. 240mg intravenous injection, every 3 weeks, 4 times. Megestrol Acetate Tablets, 160mg, po, once a day.
10155397|NCT04046185|Active Comparator|progesterone|Megestrol Acetate Tablets, 160mg, po, once a day.
10155398|NCT04045327|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
10155399|NCT04045327|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
10155400|NCT04045470|Experimental|Initial Cohort|"Patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma~Mandatory skin biopsy for corollary studies will be obtained~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)"
10155401|NCT04045470|Experimental|Expansion Cohort|"Only patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma who plan to start systemic therapy as part of standard of care~Mandatory skin biopsy for corollary studies will be obtained~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)~Participants will receive standard of care therapy and clinical course followed~Participants will undergo standard of care therapy as previously determined by treating oncologist and/or dermatologist prior to enrollment to study~Participants will not be assigned any treatment intervention"
10155402|NCT04046276|Placebo Comparator|Conventional Physical Therapy|Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months
10155403|NCT04046276|Sham Comparator|Medium Intensity Aerobic exercise (50% VO2 max)|Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
10155404|NCT04046276|Experimental|High Intensity Aerobic exercise|Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
10155405|NCT04045912|Experimental|HIVST + AGYW-Friendly Services|"Drug shops in Arm 1 will implement AGYW-friendly services, including a sexual and reproductive health (SRH) product display, a tablet with SRH videos, and a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discretely request free SRH products. They will also provide HIV self-test (HIVST) kits to AGYW customers for free."
10155406|NCT04045912|Active Comparator|HIVST Only|Drug shops in Arm 2 will provide HIVST kits to AGYW customers for free.
10155407|NCT04045392|Experimental|Mediterranean diet group|Mediterranean diet with calorie restriction below 1,500 kcal per day.
10155408|NCT04045392|No Intervention|Conventional diet group|Conventional diet with calorie restriction below 1,500 kcal per day.
10155409|NCT04046159|Active Comparator|Radiotherapy arm|Radiotherapy for ipsilateral whole breast with 50 Gy/25 fractions or 40.05 Gy/15 fractions
10155410|NCT04046159|Experimental|Tamoxifen arm|Tamoxifen 5 mg QD for 10 years
10155411|NCT04046081|Other|Dichloroacetate|Open label study
10155412|NCT04045418||COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
10155413|NCT04045418||Healthy control group|This group will include 40 healthy volunteers.
10155414|NCT04045418||Healthy intervention group|This group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
10155415|NCT04045236||Non metastatic rectal cancer|Patients receiving the diagnosis of non metastatic rectal cancer and the indication for a curative treatment will be enrolled in the registry. The study population will consist of all the patients enrolled in the participating centres from the start of the rectal cancer registry on.
10155416|NCT04045431|Experimental|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
10155417|NCT04045431|Active Comparator|Synvisc-One|Intra-articular injection with Synvisc-One (hyaluronic acid)
10155418|NCT04045314|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the long-term effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study.
10155419|NCT04045379|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 (carbon dioxide)LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
10155420|NCT04045379|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcro ablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
10155421|NCT04045379|Active Comparator|Estriol|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
10155422|NCT04045457|Other|SIngle arm|Single arm, intervention All recipients were treated with dry needling technique into active myofascial trigger points They received 1 treatment weekly for three weeks.
10155423|NCT04045444|Experimental|women non active young people|women between 18 and 30 years practice less than 1h of physical activity per week
10155424|NCT04045444|Experimental|men non active young people|men between 18 and 30 years practice less than 1h of physical activity per week
10155425|NCT04045444|Experimental|women non active old people|women between 60 and 85 years practice less than 1h of physical activity per week
10155426|NCT04045444|Experimental|men non active old people|men between 60 and 85 years practice less than 1h of physical activity per week
10155427|NCT04045444|Experimental|women active old people|women between 60 and 85 years practice at least 3h of physical activity per week
10155428|NCT04045444|Experimental|men active old people|men between 60 and 85 years practice at least 3h of physical activity per week
10155429|NCT04045444|Experimental|women with parkinson's disease|women between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
10155430|NCT04045444|Experimental|men with parkinson's disease|men between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
10155431|NCT04045275|Experimental|Calm|"The intervention will occur across 8 weeks. During Week 1, it is suggested to intervention participants that they complete 7 days of Calm meditation series (7 meditations, each approximately 10 minutes long, created to help users learn the basics of mindfulness meditations. For the remaining weeks (Week 2- Week 8) intervention participants will be asked to meditate for 10 minutes per day using any of the meditation sessions/features. Throughout the intervention, participants not completing 30 minutes of meditation per week will be sent reminders texts/emails."
10155432|NCT04045275|No Intervention|Control|This group is a wait-list control group who will receive the intervention following the 8-week waiting period. Participants in this condition are instructed not to start meditating before the waiting period. After the 8-week waiting period, waitlist participants will receive the same intervention as described in the Calm Arm.
10155433|NCT04045288|Active Comparator|Standard Implementation|All schools in SWITCH receive training through webinars and an in-person conference to learn about the defining elements and school wellness programming in general. Consistent with the standard implementation, schools were added to the online content management system (CMS) and were given access to an online community of practice (CoP) to interact with other schools / teachers in the study. Schools were provided with resources and program materials (i.e. educational modules, trinkets, posters, etc.) but were given autonomy with regard to how they were used within their school. Weekly updates through the online CMS, the CoP, and via direct email correspondence provided information about the weekly corresponding weekly themes, implementation tips, recommended module activities to incorporate, upcoming evaluation needs, important SWITCH dates, and other program reminders.
10155434|NCT04045288|Experimental|Enhanced Implementation|The 'Enhanced' implementation strategy provided schools with the same training, access and resources as the standard SWITCH implementation along with more personalized, web-based training based on motivational interviewing (MI) techniques and feedback throughout the implementation process. The supplemental support was provided through participation in two online 'checkpoint sessions' that helped schools self-assess their use of the recommended quality elements and setting-specific best practices. The sessions used principles of motivational interviewing (MI) to promote autonomy and motivation for school change through the process. Schools were also provided with information about how to capitalize on support from local 4H program leaders in their county.
10155435|NCT04045509|Other|Group 'young age'|Group 'young age': 18 - 30 years of age; healthy eyes
10155436|NCT04045509|Other|Group 'advanced age'|Group 'advanced age': 50 - 70 years of age; healthy eyes
10155437|NCT04045483|Experimental|VR based cognitive training|Participants perform the VR based cognitive training under the supervision of a research nurse or psychologist for 30 min per session, twice per week, over the 6-week intervention period.
10155438|NCT04045483|No Intervention|Usual care|Participants take some medication for risk factors and cognitive impairment and receive health advice as a usual care.
10155439|NCT04045249|No Intervention|1st Group|Children were treated as per standard CMAM protocols; provided RUTF until MUAC reaches 11.5 cm
10155440|NCT04045249|Experimental|2nd Group (1st Intervention group)|Children were initially provided RUTF until MUAC reach 11 cm then 50 % calories were provided from RUTF and 50% calories from home based food
10155441|NCT04045249|Experimental|3rd Group (2nd Intervention)|Children were initially provided RUTF until MUAC reach 11 cm then 100 % calories provided from home based food
10155442|NCT04045093|Experimental|Dabigatran etexilate|Subjects randomized into this group will be prescribed with either Dabigatran 150mg or Dabigatran 110mg (twice daily) according to creatinine clearance level, twice daily) for stroke prevention.
10155443|NCT04045093|Active Comparator|Warfarin|Subjects randomized into this group will be prescribed with Warfarin with dosage adjustment according to INR level (targeting to INR 2-3) for stroke prevention.
10155444|NCT04045106|Experimental|PNF pattern|"PNF patterns were performed using Dynamic of reversals technique which is characterized as active motion alternating from one direction (agonist) to the opposite (antagonist) without relaxing. The cervical patterns consisted of~Cervical flexion with right rotation followed by extension with left rotation.~Cervical flexion with left rotation followed by extension with right rotation."
10155445|NCT04045106|Experimental|PNF stretching|PNF stretching was done using contract-relax-antagonist contract (CRAC) technique for cervical flexors, extensors, right and left lateral flexors, right rotators and left rotators.
10155446|NCT04045106|Sham Comparator|control|Participants allocated to the control group received ineffective passive ROM.
10155447|NCT04045080|Experimental|AMADEO Training|Twenty PD patients with hand bradykinesia will be treated with the AMADEO® system. They will undergo 15 training sessions, 5 a week for 3 weeks, each session lasting about 60 minutes. During each session, both the hands will be treated using the endeffector in its active and active-assisted modality.
10155448|NCT04045080|Active Comparator|OT training|"Twenty control subjects (PD patients) will be treated with traditional rehabilitation focused on fine hand-finger movement skills. The patients in this group will undergo the same amount of treatment.~Both the groups will be trained with conventional physiotherapy concerning postural, balance and gait."
9694798|NCT04785027|Other|PSORI-CM01 group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
10155449|NCT04045119|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the longterm effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study
10155450|NCT04045197|Experimental|Intervention group|In the intervention group; informed consent forms, Relaxation Focused Nursing Care and routine nursing care in the hospital were performed. Then data collection tools were applied.
10155451|NCT04045197|No Intervention|Control group|Women in the control group received routine nursing care in the hospital and data collection tools were applied at the same hours as the intervention group.
10155452|NCT04044963|Experimental|Exercise Group|All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The exercise intervention is prescribed based on the FITT principle: frequency, intensity, time and type. The 10-point Rating of Perceived Exertion (RPE) scale, which has been well correlated to target HR levels, will be used to monitor exercise intensity levels throughout the intervention, with participants instructed to maintain their intensity level at 3-5 during exercise sessions. Participant progression will be individualized and based on their subjective perceived intensity level using the RPE scale. In person instruction, from a member of the research team with standard first aid and CPR-C training, and an instructional handout and exercise log will be provided, as well as exercise resistance bands to perform resistance exercises.
10155453|NCT04044963|No Intervention|Control Group|This will consist of regular care, which is standard procedure.
10155454|NCT04044976|Experimental|Treated infants|Infants who will receive caffeine in the delivery room.
10155455|NCT04044885|Experimental|Nap|After each night with a 6.5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
10155456|NCT04044885|No Intervention|No nap|After each night with a 8-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead have free time.
10155457|NCT04044755|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
10155458|NCT04044755|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
10155459|NCT04044690|Experimental|IgPro20|human immunoglobulin G administered subcutaneously
9662040|NCT05132023|Experimental|Empagliform|Test drug
10155460|NCT04044690|Placebo Comparator|Placebo|human albumin solution administered subcutaneously
10155461|NCT04044833||intervention|(n=63)
10155462|NCT04044833||control|(n=65)
10155463|NCT04045184||B-FED|Clients of the Birmingham AIDS Outreach Food and Education Delivery (B-FED) program who are also patients at the 1917 Clinic.
10155464|NCT04045184||non B-FED|Patients at the 1917 Clinic who have chosen not to participate in B-FED at this time.
10155465|NCT04044989|Experimental|Root resorption (total)|The resorption cavities on the root surface were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
10155466|NCT04044989|Experimental|Root resorption (local)|The resorption cavities on the root surface (palatal, buccal, distal and mesial root surfaces) were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
10155467|NCT04044820|Active Comparator|Standardized Discharge Prescription|Based on a previous study examining mean number of opioid pills used by patients undergoing elective, unilateral hand and forearm surgery
9973128|NCT01327755|Placebo Comparator|Placebo|
10155468|NCT04044820|No Intervention|Usual Discharge Prescription|Routine standard of care involves prescription for opioids at the discretion of the surgical team
10155469|NCT04045015|Active Comparator|glycyrrhizic acid 1.5 mg/kg body weight|Liqourice corresponding to 1.5 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
10155470|NCT04045015|Active Comparator|glycyrrhizic acid 3.0 mg/kg body weight|Liqourice corresponding to 3.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
10155471|NCT04045015|Active Comparator|glycyrrhizic acid 6.0 mg/kg body weight|Liqourice corresponding to 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
10155472|NCT04045041|Experimental|Treatment group|10 week internet-based acceptance and commitment therapy
10155473|NCT04045041|No Intervention|Control group|Waiting-list control.
10155474|NCT04045054|Other|Intervention|The Link Team follows up with the participants for 6 months after they discharge from the hospital
10185851|NCT03741621|Experimental|Low Viscosity|Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
9662041|NCT05132023|Active Comparator|Synjardy|Reference drug
9662042|NCT05131984||Multiple Sclerosis patients on Ocrelizumab at Brigham and Women's Hospital|All MS patients at the Brigham MS Center who have been diagnosed with relapsing remitting multiple sclerosis (RRMS) or primary progressive multiple sclerosis (PPMS), ages 18 or older, on Ocrelizumab for at least one year and have received at least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg), who have been followed at these institutions for clinical care and brain and/or spinal cord MRI, and who have received Ocrelizumab infusions at these institutions for the duration of the study period.
10155475|NCT04045002|Experimental|Intervention|Intervention group receive 'MyPinkMom' educational intervention delivered through WhatsApp application for 2 weeks and routine antenatal care.
10155476|NCT04045002|No Intervention|Control|Control group receive information on anaemia in pregnancy placed at respondents' antenatal card and routine antenatal care
10155477|NCT04044911|Active Comparator|Tea making followed by stepping|Five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (CogWatch) is followed after a 3-week break by a control condition in which participants receive five 1-hour weekly stepping training sessions.
10155478|NCT04044911|Active Comparator|Stepping followed by tea making|A control condition comprising five 1-hour weekly stepping training sessions is followed after a 3-week break by five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (COgWatch)
10155479|NCT04044625|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
10155480|NCT04044625|Active Comparator|Low-intensity NPPV|The patients will receive low-intensity noninvasive positive pressure ventilation.
10155481|NCT04044638|Experimental|Young Group|"Young women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
10155482|NCT04044638|Experimental|Middle-aged Group|"Middle-aged women women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
10155483|NCT04044677|Experimental|tDSC-active|"The TDCS-active will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend) during the practice of VR games, TDCS-active will be performed with a current of 1 mA and 20 min of duration (20 seconds of ramp-up and ramp-down). The stimulation target will be the M1 area, choosing the more functional side of the participant (C3 or C4).~This group will perform the tDCS-sham after one-month washout."
9520040|NCT03281018|No Intervention|Control (CAT)|CAT is performed in routine care for all patients after the announcement of the illness by a trained nurse, if possible on the same day as the consultation or before the consultation of anesthesia. This is an interview of approximately 45 minutes to listen to the patient, to answer her questions and to re-explain the information delivered to her. The patient will tackle the history of the disease and then the treatment, this time dedicated evolves according to the desire of the patient and her ability to accept the disease. The patient can express her feelings, then the family circle is evoked talking about the resource persons and the future. The purpose of this interview is to obtain the autonomy of the patient by the setting up of supportive care
9671034|NCT05053789|Experimental|Group 1|After enrolment into the study and randomization to the study group (V0) and baseline examinations (V1), patients will receive 1 drop of Lacrimera at the study site and will be instructed to apply one drop of C-NAC into both eyes before bedtime for the following 5 consecutive days and return for a follow-up visit after 7±1 days (V2). Patients will complete a diary describing symptoms during the day, use of Lacrimera and potential side effects until the next visit. If the NEI grading is ≤1 OR the OSDI score <20 at the next visit, treatment with Lacrimera will be discontinued and one further physical follow-up appointment will be arranged, which will take place 28±2 days after the last physical visit.
10155484|NCT04044677|Sham Comparator|tDCS-sham|"The TDCS-sham will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend). However, the electrodes will be positioned at the same sites of the tDCS-active and the device will be switched on for 20 seconds (with ramp-up and ramp-down), giving the children the initial sensation of the 1 mA current, but with no stimulation administered during the rest of the time. This sham protocol is already programmed in the device prior to data collection.~This group will perform the tDCS-active after one-month washout."
10155485|NCT04044651|Experimental|Lenvatinib plus nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w+ lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
10155486|NCT04044651|Active Comparator|Lenvatinib|Lenvatinib 12 mg (or 8 mg) Po once daily
10155487|NCT04044703|Experimental|Model-based vancomycin dosing|Participants will receive model-based intermittent intravenous vancomycin dosing as calculated by the dosing calculator available on a web application. Participants will then have routine therapeutic drug monitoring and linear dose adjustments.
10155488|NCT04044664|Placebo Comparator|Placebo|
10155489|NCT04044664|Experimental|NYX-783 Low Dose|
10155490|NCT04044664|Experimental|NYX-783 High Dose|
10155491|NCT04044391||Intention to Treat: Cardiac Catheterization|All patients meeting inclusion criteria and scheduled to undergo cardiac catheterization will undergo a CardioFlux magnetocardiogram (MCG) to determine presence of patterns which indicate myocardial ischemia.
10155492|NCT04044391||Post Percutaneous Coronary Intervention|All patients found to have significant coronary artery obstruction seen via angiography +/- fractional flow reserve (FFR) or instant wave-free ratio (iFR) and who receive a catheter based intervention will have a post-procedure CardioFlux MCG scan. Follow up over the next 30 and 180 days will be performed to determine if a persistent pattern suggesting residual ischemia will correlate with an increased incidence of major cardiac adverse events (MACE).
9520041|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
9671035|NCT05053789|Active Comparator|Group 2|The study days are conducted in the same way as for the study group. Patients of the control group will receive preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine) for 4 times a day as control.
9671036|NCT05053919|Experimental|SR device group|
9671037|NCT05053919|Placebo Comparator|placebo device group|
9973129|NCT01327768|Experimental|OECs, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.
9973130|NCT01327794||Group 1|Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25[OH]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
9973131|NCT01327807||Cystinsosis patients|Those with a diagnosis of cystinosis.
9973132|NCT01327820||Open aortic aneurysm repair|
9973133|NCT01327820||Endovascular aortic aneurysm repair|
9973134|NCT01327820||Infra-inguinal lower limb revascularisation|
9973135|NCT01327833||Cardiac Arrest|
9973136|NCT01327859|Experimental|Prior Donepezil 5mg|
9973137|NCT01327859|Experimental|Prior Donepezil 10mg|
9973138|NCT01327859|Placebo Comparator|Prior Placebo|
9973139|NCT01327872|Experimental|Treatment A|
9973140|NCT01327872|Experimental|Treatment B|
9973141|NCT01327872|Experimental|Treatment C|
9973142|NCT01327872|Experimental|Treatment D|
9973143|NCT01327898|Experimental|1|empowerment theory-based small group discussion
9973144|NCT01327898|Active Comparator|2|single session individual resilience counseling
9973145|NCT01327911|Experimental|Ciliary Neurotrophic Factor (CNTF)/NT-501|Biological/Vaccine:NT-501 implant
9973146|NCT01327924||Norditropin NordiFlex® users|
9973147|NCT01327937|Active Comparator|Apligraf Group|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
9973148|NCT01327937|Placebo Comparator|Standard of Care Dressing Group|Standard of care dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
9520042|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
9973149|NCT01327950||Superficial Femoral Lesions|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions
9973150|NCT01328015|Active Comparator|Oxybuynin, hyperhidrosis|
9973151|NCT01328015|Placebo Comparator|placebo - sugar pill|
9973152|NCT01328028||Group A|Subjects diagnosed with invasive cervical cancer
9973153|NCT01328067|Active Comparator|Treatment|MR guided Focused Ultrasound
9973154|NCT01328067|Active Comparator|Surgery|Myomectomy
9973155|NCT01328106|Experimental|1|
9973156|NCT01328119|Other|hemodialysis patients|conventional hemodialysis patients
9973157|NCT01328132|Active Comparator|Saline|
9973158|NCT01328132|Experimental|25% albumin|
9520043|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
9973159|NCT01328145|Active Comparator|ASA|
9973160|NCT01328145|Placebo Comparator|Placebo|
9973161|NCT01328171|Experimental|A (FOLFOXIRI + Panitumumab)|FOLFOXIRI + Panitumumab
9973162|NCT01328171|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
9973163|NCT01328197|Experimental|Treovance|
9973164|NCT01328210|Experimental|blood letting|Blood letting was performed immediately after baseline assessment and after 4 weeks. First blood removal consisted of 400ml, second blood removal was tailored according to subsequent serum ferritin levels between 300- 400 ml.
9973165|NCT01328210|No Intervention|waiting list control|This group received no specific treatment but was offered treatment after termination of the 6-week study phase
9973166|NCT01328223||radiotherapy efficacy|"Concurrent stage with RT: sorafenib 400mg twice daily~Maintenance stage after RT: sorafenib 400mg twice daily Treatment can be continued until the occurrence of clinical or radiologic progression, the occurrence of either unacceptable adverse events, death, or any criteria met for removal from the protocol treatment. Basically, minimum maintenance duration of 6 months is recommended, not mandatory."
9973167|NCT01328236|Experimental|V-DD single arm|"INDUCTION THERAPY: V-DD induction therapy for 6 cycles，28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment.~Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,（Specially for IgA type）. Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
9973168|NCT01328262|Experimental|Hemoglobin dose|Intervention: Calculated red blood cell transfusion
9973169|NCT01328262|Active Comparator|Standard treatment|Intervention: Standard red blood cell transfusion
9973170|NCT01328275||1|long-term follow-up of HIV-infected patients on ART
9973171|NCT01328288||1|long-term follow-up of HIV-infected children
9973172|NCT01328301|Experimental|Speed-dependent treadmill training (SDT)|Subjects underwent short interval of walking trials with stepwise increases in the treadmill speed
9973173|NCT01328301|Active Comparator|speed-stable treadmill training|Control subjects received gait training on the treadmill with a steady speed.
9973174|NCT01328340|Active Comparator|High-speed power training|Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
10155493|NCT04044326|Experimental|microwave ablation (MWA)|20 patients with liver cancer, considered for local treatment of liver tumors of size measuring <5 cm and without any signs of extra-hepatic metastasis, will be enrolled to be treated with microwave ablation (MWA)
10155494|NCT04044599|Experimental|Study|THE GROUP THAT WİLL RECİEVE VAGİNAL LACTOBACİLLUS
10155495|NCT04044599|No Intervention|Control|Control group
10155496|NCT04044378|Experimental|Arm A: famitinib and camrelizumab|"In the dose-defining phase I portion, camrelizumab was given at a fixed dose of 200mg Q2W, while the de-escalated 3+3 design was used to detect the recommended dose of famitinib from an initial level of 15mg orally taken daily. Recommended phase 2 dose (RP2D) was defined as the highest dose at which no more than 30% patients experience a DLT in the first two courses.~In the phase II portion, famitinib will be orally taken daily with RP2D together with camrelizumab intravenous infusion at a dose of 200 mg over 30 minutes, once every two weeks (Q2W), 4 weeks (28 days) as one treatment cycle."
10155497|NCT04044378|Active Comparator|Arm B: famitinib alone|Only phase II portion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle.
9520044|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
9826370|NCT02416102|Active Comparator|Healthy non-smokers|10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
10155498|NCT04044378|Experimental|Arm C: Famitinib and Ifofamide|Only phase II protion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle together with ifofamide 1800 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 and 15-17 of each 28-day cycle for a total of 5 cycles.
10155499|NCT04044430|Experimental|Treatment (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days for a maximum of 24 cycles of treatment in the absence of disease progression or unacceptable toxicity.
10155500|NCT04044612|Experimental|Medial Unloader Brace|
10155501|NCT04044508|Active Comparator|Interventional diet|A modified ketogenic diet (with the composition found in the pilot study, 75%fat, 15% protein, 10% carbohydrates)
10155502|NCT04044508|Placebo Comparator|Placebo diet|A placebo diet (over 100 g of carbohydrates per day)
10155503|NCT04044417|Placebo Comparator|open flap debridement only|surgical treatment of periodontal defects
10155504|NCT04044417|Active Comparator|curcumin and simvastatin|open flap debridement followed by application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
10155505|NCT04044417|Active Comparator|EDTA, curcumin and simvastatin|open flap debridement followed by 24% EDTA root surface etching and application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
10155506|NCT04044950|Experimental|Arm 1|Approximately 3x10^8 E7 TCR T cells (based on the number of disease sites the patient has) will be injected on day 0.
10155507|NCT04044547|Experimental|LY03003|
10155508|NCT04044547|Placebo Comparator|Placebo|
10155509|NCT04044404||A on C group|Acute on Chronic Kidney Disease patients
10155510|NCT04044404||functional delayed graft function group|patients with functional delayed graft function(fDGF) after kidney transplantation
10155511|NCT04044404||Normal|without functional kidney injury
10155512|NCT04044573|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
10155513|NCT04044339|Experimental|TD-5202 for SAD (Part A)|6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive TD-5202
10155514|NCT04044339|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive placebo
10155515|NCT04044339|Experimental|TD-5202 for MAD (Part B)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-5202
10155516|NCT04044339|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo.
10155517|NCT04044846|Experimental|The recipients of the home-based physical activity program|Frail OAs will be asked to fill out the Vitality Plus Scale at the beginning of the implementation phase (baseline) by a research assistant over the telephone. At the end of the 6-month implementation phase, the research assistant will administer the survey again (post-intervention).
10155518|NCT04044300|Experimental|Operative|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level.
10155519|NCT04044300|Experimental|Non-operative|Continued pain management and physical therapy
10155520|NCT04044313|Experimental|HAIC plus Lenvatinib and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
10155521|NCT04044287|Active Comparator|Intervention|200 micrograms of Misoprostol applied sublingually together with standard parenteral oxytocic therapy
10155522|NCT04044287|Placebo Comparator|Placebo|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy micrograms of misoprostol
10155523|NCT04044261|Experimental|Study Arm|Single open-label study arm. All participants are enrolled into this arm.
10155524|NCT04043910|Experimental|Single-sided deaf group|30 children will be included in this group
9520045|NCT03280979|Experimental|study group1|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
9520046|NCT03280979|Experimental|study group2|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
9520047|NCT03280940||Dolutegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a dolutegravir containing regimen
10155525|NCT04043910|Active Comparator|Normal hearing group|30 children will be included in this group
10185852|NCT03741608|Active Comparator|Education, BP cuff & training|High blood pressure management education. Home blood pressure measurement
10185853|NCT03741608|Active Comparator|Education only|High blood pressure management education
10155526|NCT04044235|Experimental|PrEP Cohort|AGYW HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.
9671038|NCT05053893|Experimental|New treatment group(Roxadustat combined with Sacubitril Valsartan Sodium Tablets)|Roxadustat(FibroGen, China), 100mg (45-60kg) or 120mg (≥ 60kg) each time, three times a week, orally on an empty stomach in the morning. The initial dose of Sacubitril Valsartan Sodium Tablets(Novartis, China) is 50mg, once a day, taken on an empty stomach in the morning, and gradually titrated from the minimum dose to the maximum tolerated dose.
9826371|NCT02416102|Experimental|Smokers without COPD|10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
10155527|NCT04044235|No Intervention|HIV Incidence|HIV Incidence Cohort: In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence.
10155528|NCT04043845|Experimental|LY3214996+Ibrutinib|"LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle~Ibrutinib will be administered by mouth once daily continuously throughout each treatment cycle."
10155529|NCT04043871||Patients with renal insufficiency|
10155530|NCT04044027|No Intervention|Control Group|
10155531|NCT04044027|Experimental|Intervention Group|
10155532|NCT04043897|Experimental|Drug|Patients will receive open-label rifaximin 550mg tid x 4 weeks.
10155533|NCT04044053|Experimental|Relative Bioavailability|Each participant will receive 400 mg IR, 400 mg MR, and 50 mg MR in the fed state, and 400 mg MR in the fasted state
10155534|NCT04044053|Experimental|Fasted State|Comparison of 400 mg MR in fed and fasted states
10155535|NCT04044014|Active Comparator|Arm A|Left arm: Gellan sheet; Right arm: Mepitel One.
10155536|NCT04044014|Active Comparator|Arm B|Left arm: Mepitel One; Right arm: Gellan sheet.
10155537|NCT04044014|Active Comparator|Arm C|Left arm: Gellan fluid gel; Right arm: Mepitel One.
10155538|NCT04044014|Active Comparator|Arm D|Left arm: Mepitel One; Right arm: Gellan fluid gel.
10155539|NCT04043858|Experimental|Midodrine daily|Midodrine hydrochloride 2.5 mg tab once per day
10155540|NCT04044105|No Intervention|No Education|Patients in this arm receive no education regarding how to dispose of their opiate medication
10155541|NCT04044105|Experimental|Pamphlet education|Patients receive an educational pamphlet only, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment.
10155542|NCT04044105|Experimental|Pamphlet education + texts|Patients receive an educational pamphlet, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment. In addition, 3 automated text messages sent at those same time points.
10155543|NCT04044170|Experimental|Poziotinib|"Cohort 1 : Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC"
10155544|NCT04044131|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
10155545|NCT04044131|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
10155546|NCT04044079|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
10155547|NCT04044079|Active Comparator|misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
10155548|NCT04044079|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
10155549|NCT04044183|Experimental|Active Brains|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
10155550|NCT04044183|Placebo Comparator|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
10155551|NCT04043962|Experimental|Web-based CBT (Web-MAP)|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
10155552|NCT04043975||Patients with metastatic RCC|Patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) with intermediate or poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, who will be treated with Nivolumab + Ipilimumab for the first time
10155553|NCT04044092|Active Comparator|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization, Cervical Spine strengthening exercises
10155554|NCT04044092|Experimental|ELDOA stretching exercise|ELDOA stretching exercise protocol along with Conservative physical therapy
10155555|NCT04044222|Experimental|Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)|Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.
10155556|NCT04044222|Experimental|Treatment (placebo, etoposide, ifosfamide, carboplatin)|Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.
10155557|NCT04044118|Experimental|Caloric Restriction|3-week low calorie diet
10155558|NCT04043884|Experimental|sEmg Biofeedback training|8-week exercise program, twice a week, with emg biofeedback training.
10155559|NCT04043884|Active Comparator|Exercises|8-week exercise program, twice a week.
10155560|NCT04043767||Pediatric patients aged between 1-8 years|Pediatric patients aged between 1-8 years who scheduled for general anesthesia in elective surgery. Additional physical examinations which were including thyromental distances, hyomental distances and neck circumferences, was performed at one day prior surgery. Intubation was done by general anesthesiologist in order to grade the laryngoscopic view.
10155561|NCT04043676|Experimental|Ponatinib Treatment|Patients will be treated with 15 mg/day of ponatinib during 48 weeks. If a patient maintains MR4 throughout the 48 weeks, he/she will be eligible to start the ponatinib TFR phase. If a patient has confirmed loss of MR4 (two consecutive BCR-ABL > 0.01% IS) or loss of MMR (no confirmation needed), he/she will not be eligible for the TFR phase. Instead, he/she will restart imatinib treatment.
10155562|NCT04043429|Experimental|Vision Restoration Training (VRT)|home-based rehabilitation program which applies intense light stimulation via a PC-monitor to areas of residual vision with a duration of 1 hour daily/six days a week, subjects are asked to respond via button press upon appearance of light stimuli without eye movements
10155563|NCT04043429|Active Comparator|Vision Exploration Training (VET)|home-based rehabilitation program to train eye movements upon visual stimuli presented via a PC-monitor with a duration of 1 hour daily/six days a week, subjects are asked to shift their gaze towards targets and respond via button press upon detection of targets
9671039|NCT05053893|Experimental|Traditional treatment group(EPO combined with ACEI or ARB )|Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week; Perindopril tablets (Servier, China), taken on an empty stomach, gradually titrated from the minimum dose to the maximum tolerated dose.
9671040|NCT05053958|No Intervention|using conventional protocol|Patients will receive a pre-operative CBCT examination. Implants will be inserted using freehand drilling protocol. The implants will be placed using flapless technique with the reference of neighboring teeth and 3D radiographic information.
9694799|NCT04785027|Experimental|Gu Ben Hua Yu group|"Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2×10 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.~Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
10155564|NCT04043546|Experimental|Exercise intervention|
10155565|NCT04043520|Experimental|Premenopausal: GnRH antagonist + estradiol|"Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection~Estradiol is a transdermal patch 0.075 mg, applied weekly for 12 weeks"
10155566|NCT04043520|Experimental|Premenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection~Placebo is a transdermal patch, applied weekly for 12 weeks"
10155567|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + estradiol|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Estradiol is a transdermal patch 0.075 mg, applied weekly for 24 weeks"
10155568|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo is a transdermal patch, applied weekly for 24 weeks"
10155569|NCT04043520|Placebo Comparator|Postmenopausal: placebo + placebo|"Placebo (1) is normal saline, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)~Placebo (2) is a transdermal patch, applied weekly for 24 weeks"
10155570|NCT04043819|Experimental|PSC-01|All study participants will receive intraarticular injection of the investigational biological product, PSC-01.
10155571|NCT04043533|Experimental|Exercises Group|
10155572|NCT04043533|No Intervention|Control Group|
10155573|NCT04043806|Experimental|Open-Label Triple Combination|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
10155574|NCT04043572||Participants with Epilepsy|This group comprises pregnant patients with epilepsy who are actively using anti-epileptic drugs
10155575|NCT04043572||Healthy Controls|Healthy volunteers
10155576|NCT04043598|Active Comparator|high sodium infusion fluid|Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
10155577|NCT04043598|Active Comparator|low sodium infusion fluid|Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
10155578|NCT04043611|Active Comparator|Conservative physical therapy management|Tens and hot pack , Soft tissue mobilization , Maitland's Lumbar segmental mobilization, Traction, Neurodynamics, Active Stretching, McKenzie Prone Extension Exercises
10155579|NCT04043611|Experimental|ELDOA|Conservative physical therapy management + ELDOA positions
10155580|NCT04043650|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
10155581|NCT04043702||on topiramate|"topiramate, conviban® group vs no treatment ( control group)."
10155582|NCT04043702||on empagliflozine|"empagliflozine, jardiance® vs no treatment ( control group)."
9520048|NCT03280940||Raltegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a raltegravir containing regimen
10155583|NCT04043702||on topiramate plus empagliflozine|all patients' vs no treatment ( control group).
9520049|NCT03280940||Elvitegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a elvitegravir containing regimen
9520050|NCT03280940||Protease inhibitors treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a protease inhibitors containing regimen
10155584|NCT04043702||no treatment|all patients' vs no treatment ( control group).
10155585|NCT04043455|Experimental|Olorinab low dose (Main Study)|
10155586|NCT04043455|Experimental|Olorinab medium dose (Main Study)|
10155587|NCT04043455|Experimental|Olorinab high dose (Main Study)|
10155588|NCT04043455|Placebo Comparator|Placebo (Main Study)|
9520051|NCT03280927|Experimental|Jublia®|
9520052|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
9520053|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
10155589|NCT04043455|Experimental|Olorinab (Long-Term Extension)|Participants will receive olorinab based on their treatment assignment in the Main Study.
10155590|NCT04043624|Experimental|Lidocaine group|First group (lidocaine group) will include those who receive a intraoperative lidocaine infusion.Induction bolus dose of 1.5 mg/kg body weight ( 30 minutes before incision)followed by a continous lidocaine infusion of 2mg/kg/h，until 1 hours after skin closure.
9520054|NCT03280901|Experimental|Standard HD|HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions
9520055|NCT03280901|Experimental|Thermocontrolled HD|HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions
9520056|NCT03280875|Experimental|healthy volunteers|
9973175|NCT01328340|Active Comparator|Slow-speed strength training|Volunteers randomized into STR will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
9520057|NCT03280862|Active Comparator|Control|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned preferentially in a posterolateral, non-apical position
9520058|NCT03280862|Experimental|Intervention|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned according to the latest electrical activation in the CS
9520059|NCT03280849|Experimental|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
9527680|NCT03217838|Experimental|Group 2 Arm A (AZD2811 Dose 3 + Azacitidine 75 mg/m^2)|Participants with AML and MDS will receive Azacitidine 75 mg/m^2 of body surface area (BSA) by subcutaneous (SC) injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 3 on Days 1 and 4 of each 28-day cycle. Participants will receive the study treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
10155591|NCT04043624|Placebo Comparator|Saline group|The second group（saline group） will include those who receive a intraoperative placebo.The same dosage of saline was given according to the same method of administration in the lidocaine group.
10155592|NCT04043663|Experimental|Virtual reality program group|Virtual reality program based on a virtual reality guided tour registered in the investigator's pediatric OR setting before surgery.
10155593|NCT04043663|Active Comparator|control group|standard perioperative care without virtual reality program
10155594|NCT04043468|Experimental|Improved A&F intervention|Two feedback sessions and four structured focus groups
10155595|NCT04043468|Active Comparator|Standard A&F intervention|Two feedback sessions
10155596|NCT04043338|Experimental|XC130-A10H|XC130-A10H (single dose)
10155597|NCT04043338|Placebo Comparator|Placebo|placebo (single dose)
10155598|NCT04043559||patients with an acute symptomatic infarction|
10155599|NCT04043559||controls with cryptogenic stroke|
10155600|NCT04043754|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
10155601|NCT04043754|Active Comparator|GTR treated patients|"Periodontal surgery with MEMBRANE is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers ; then, ABG will be applied alternatively with MEMBRANE into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositioned and sutures completed by interrupted sutures."
10155602|NCT04043689|Active Comparator|tACS stimulation of the right frontal region|Active tACS stimulation of the right frontal region (around the right FEF, EEG electrode FC2) at a high-beta frequency (30 Hz) with the goal of visibly training EEG recordings, frontal oscillatory activity and right fronto-parietal synchrony (FEF-IPS, or between FC2 and P4 electrodes) in the high-beta band (~ 30 Hz) which facilitates attentional orientation and visual perception in the two visual hemi-fields, but more particularly the targets present on the blind field of vision.
10185854|NCT03741595|Experimental|Single Arm|
10185855|NCT03741582||Control - San Cristobal|"1000 individuals located in an area with no access to the intervention (TransMicable). The control area was defined by a 800-meter buffer around each projected station of the car, San Cristobal was an area with a projected but non financed Cable Car."
10155603|NCT04043689|Active Comparator|tACS stimulation of the occipito-parietal region|Active tACS stimulation of the occipito-parietal posterior contralesional region(around the right IPS, EEG electrode P4), at an alpha frequency (10 Hz) which will induce on the EEG recordings an oscillatory drive in the alpha band ( ~ 10Hz) and an increase in synchrony at this frequency band on the stimulated posterior occipital and parietal lobe (EEG electrodes P4 and 02), but also, by transcallosal push-and-pull phenomena, a desynchronization effect of the contralateral posterior occipital and parietal area (EEG electrodes P3 and 01), which will facilitate attention orientation and target detection in the blind visual field of view.
10155604|NCT04043689|Sham Comparator|TACS stimulation of the right frontal (FEF)|. Condition TACS stimulation of the right frontal (FEF) at a high-beta frequency (30 Hz) for half of the patients and unilateral occipital cortex (right / left) at an alfa frequency (10 Hz) for the other half . This condition will control the possible placebo effects of tACS stimulation and the potential effects of visual field enhancement with repetition of perimetry tests. This condition will also verify the lack of changes in cerebral rhythm activity in the case of an application without effective electrical current.
10155605|NCT04043494|Other|SR I/II: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~maintenance therapy"
10155606|NCT04043494|Experimental|SR I/II: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment Phase (protocol M)~maintenance therapy"
10155607|NCT04043494|Other|SR: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
10155608|NCT04043494|Experimental|SR: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
10155609|NCT04043494|Other|"HR: R1 into Pred and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
10155610|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
10155611|NCT04043494|Experimental|"HR: R1 into Pred and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib*)~HR extra-compartment phase (intensified protocol M)~reintensification phase (protocol II)~maintenance therapy"
10155612|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib*)~HR extra-compartment phase (intensified protocol M)~reintensification phase (protocol II)~maintenance therapy"
10155613|NCT04043715|Other|Comparison of transcutaneous & epidural stimulation|Comparison of transcutaneous vs epidural electrical stimulation
10155614|NCT04043741|Experimental|Dry Needling|Dry needling (04 Sessions) and exercises
10155615|NCT04043741|Active Comparator|Sustain Pressure|sustained pressure and Exercises
10155616|NCT04043780|Experimental|Decompression prototype splint|The patients of this group will wear the decompression prototype splint.
10155617|NCT04043780|Active Comparator|standard splint|The patients of this group will wear a standard splint.
10155618|NCT04043390|Experimental|CRP and Xpert ULTRA MTB/RIF|Scheme 1 will screen all patients for HIV using rapid tests routinely used by the clinics and a rapid CRP. Patients with CRP >10 will be further tested using Xpert ULTRA. Individuals with HIV will undergo an HIV VL using Xpert HIV-1 VL.
10155619|NCT04043390|Experimental|CRP and Molbio Truenat MTB|Scheme 2 will screen individuals for HIV and CRP (as in scheme 1) and patients with CRP >10 will be tested using Molbio Truenat MTB. Individuals with HIV will undergo an HIV VL using Molbio Truenat HIV-VL and individuals with Truenat MTB-positive samples wil be tested with Truenat MTB RIF.
10155620|NCT04043390|No Intervention|standard test Xpert|All patients receiving in scheme 1 and scheme 2 will be tested using the standard tests used in the study context. These are rapid HIV tests, Xpert MTB/RIF and culture.
10155621|NCT04043299|Experimental|Intervention|This arm will receive 100% oxygen at a rate of 10L/min for 15 minutes
10155622|NCT04043299|Active Comparator|Control|This arm will receive medical air (21% oxygen) at a rate of 10 L/min for 15 minutes
10155623|NCT04043364|Experimental|LIVE|A multicomponent intervention focusing on Learning, Innovation, Volunteers and Empowerment organized by a local coordinator.
10155624|NCT04043364|No Intervention|Treatment as usual|Care coordination and facilitation as usual.
10155625|NCT04043273||Whole cohort|The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment
10155626|NCT04043247|Sham Comparator|Control Group|Same as TEAS group but without electrical stimulation
9826372|NCT02416102|Experimental|Ex-smokers with COPD|10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
10155627|NCT04043247|Experimental|TEAS Group|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
10155628|NCT04043182|No Intervention|group control|You will not receive any type of intervention
10155629|NCT04043182|Experimental|treatment group (ultrasound)|Will perform protocols of 10 sessions of ultrasound in the region of abdomen
10155630|NCT04043182|Placebo Comparator|placebo group|It will perform protocols of 10 sessions of ultrasound in the region of abdomen, but the apparatus will be with zero intensities
10185856|NCT03741582||Intervention - Ciudad Bolviar|1000 individuals who live in the area of influence of TransMiCable. The area of influence of TransMiCable was defined by a 800-meter radial buffer around each station of the cable car.
10185857|NCT03741569|Other|parturients (gestational age ≥37 weeks).|
10155631|NCT04043260|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 3 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
10155632|NCT04043000|Experimental|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
10155633|NCT04043000|Placebo Comparator|Placebo|" The placebo without Super 13 Pro & Prebiotics was given three times a day for four weeks."
10155634|NCT04042948|Experimental|Experimental Group|preventive use non-steroidal anti-inflammatory drugs to before the removal of drainage tube
10155635|NCT04042948|No Intervention|Control Group|without any intervention when remove the drainage tube
10155636|NCT04043195|Experimental|Nivolumab + Oxaliplatin|Cohort 1
10155637|NCT04043195|Experimental|Nivolumab + Oxaliplatin + Ipilimumab|Cohort 2
10155638|NCT04042974|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
10155639|NCT04042974|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
10155640|NCT04042896|Experimental|exergame group|"The exergame group performed exercise using the Exer Heart device (D&J Humancare, Seoul, South Korea), which consisted of a running/jumping board and a screen connected to the board. The exercise program Alchemist's Treasure, a running-based exergame, moves the avatar according to the user's motions and was used for the exercise session. Alchemist's Treasure is a game in which the user listens to stimulating music, runs with the avatar, avoiding obstacles, and wins items using the front, back, left, and right sensors on the exercise board. The subject can control the speed of the avatar movement by adjusting the walking or running speed on the board.~This study did not enforce exercise intensity in order to allow patients to enjoy the exergame. Thus, during the training period, the patients exercised at a self-selected pace for 40 minutes per day."
10155641|NCT04042896|Active Comparator|treadmill group|The treadmill group consisted of 40 minutes of walking or jogging at 60-80% of the heart rate (HR) reserve. The exercise intensity was determined using the Karvonen method target HR = [Exercise Intensity × (HRmax - resting HR)] + resting HR. The HR was recorded during each session using an HR monitor (Polar RS400sd; Madison Height, Michigan, USA). The control group was asked to maintain their regular physical activity level for 12 weeks.
10155642|NCT04042896|No Intervention|control group|The control group was asked to maintain their regular physical activity level for 12 weeks.
10155643|NCT04043039|Experimental|FULL THICKNESS PALATAL GRAFT|the full thickness palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
10155644|NCT04043039|Active Comparator|FREE GINGIVAL GRAFT|the Epithelialized Free Gingival Grafts palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
9671041|NCT05053958|Active Comparator|using digital protocol|Patients will receive a pre-operative CBCT examination and optical scan of the oral tissues by intra-oral scanner. Digital Imaging and Communications in Medicine (DICOM) file from the CBCT examination and the Standard Tessellation Language (STL) file from the optical scan will be imported and merged in implant planning software. The virtual implant planning will be performed. The surgical guide and prosthesis are designed according to the virtual plan.
9671042|NCT05053841|No Intervention|Control group|fifteen obese females who received letrozole only
10155645|NCT04042870|Experimental|Joint Loosening Yoga|Yoga Intervention. Dose: 15 minutes, M-F for 4-weeks.
10155646|NCT04042922|Experimental|Exposure to active stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of active stimulation
10155647|NCT04042922|Sham Comparator|Exposure to control stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of control stimulation
10155648|NCT04043052|Active Comparator|Treatment As Usual (TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination
10155649|NCT04043052|Experimental|EMA intervention assocuated to Treatment As Usual (EMA-TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination in addition with Ecological Momentary Assessment (EMA) evaluation.
10155650|NCT04043013|Active Comparator|Mini-Taurus® (Rocky Mountain©) Brackets|"Brackets Mini-Taurus® (Rocky Mountain©) with:~ORTHODONTIC BRACKET PRESCRIPTION Canines 0º First Premolar 0º Second Premolar 0º First Molar 0º"
10155651|NCT04043013|Active Comparator|Smart Clip® SL3 High Torque (3M Unitek©)|"Brackets Smart Clip® SL3 High Torque (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines +6º First Premolar -4º Second Premolar -4º First Molar -14º"
10155652|NCT04043013|Active Comparator|Tip-Edge Plus® (TP Orthodontics©)|"Brackets Tip-Edge Plus® (TP Orthodontics©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines -4º First Premolar -7º Second Premolar -7º First Molar 0º -14º -11º -14º"
10155653|NCT04043013|Active Comparator|Victory® (3M Unitek©)|"Brackets Victory® (3M Unitek©) with:~ORTHODONTIC BRACKET PRESCRIPTION~Canines 0º First Premolar -7º Second Premolar -7º First Molar -14º"
10155654|NCT04043065|Experimental|LEAP-2|Liver-enriched antimicrobial peptide 2
10155655|NCT04043065|Placebo Comparator|Placebo|Saline
10155656|NCT04043078|Other|Exercise|Exercise and respiratory muscle training before surgery
10155657|NCT04042857|Experimental|Next Science|Patients will apply Next Science treatment to the study target hallux nail for 48 weeks daily.
10155658|NCT04043104|Experimental|1 x 1011 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
10155659|NCT04043104|Experimental|3 x 1011 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
10155660|NCT04043104|Experimental|1 x 1012 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
9520060|NCT03280836|No Intervention|Control|We ask that participants in the control arm do not start an exercise program.
9671043|NCT05053841|Active Comparator|metformin group|fifteen obese females who received the same dose of letrozole plus metformin (2000 ± 500) mg daily
9520061|NCT03280836|Experimental|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
9520062|NCT03280810|Experimental|Movement group|patients with schizophrenia (experimental group) have psycho-corporal training once a week, during 1 hour and a half for a period of two months
9520063|NCT03280810|No Intervention|Control group|No intervervention : patients with schizophrenia (comparator group) who don't have psycho-corporal training
10155661|NCT04043104|Experimental|3 x 1012 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
10155662|NCT04042844|Experimental|Active Treatment- BRTX-100|BRTX-100 consists of a population of hypoxic-cultured bone marrow mononuclear cells highly enriched in mesenchymal stem cells from autologous bone marrow with autologous platelet lysate.
10155663|NCT04042844|Placebo Comparator|Saline|Isotonic saline will be used as a control in this study. Drug: saline (0.9% sodium chloride).
10155664|NCT04043117||Clinical Group|Group is composed by 12-19 years adolescents with a tumor (excluding brain tumor). Every patient included in the group complete the assessment including: evaluation of self-esteem (TMA test) and body image (BUT test, I-BICI test and Human Figure Drawing).
10185858|NCT03741504|No Intervention|No micro-osteoperforations (No MOPs)|Canine Distalization without micro-osteoperforations Distalization of the upper canine in working phase with coil spring of 100 gr of force
10185859|NCT03741504|Experimental|Micro-osteoperforations (MOPs)|Canine Distalization with micro-osteoperforations at the start of the distalization Distalization of the upper canine in working phase with coil spring of 100 gr of force
10185860|NCT03741478|Experimental|Metabolic Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility.~This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.~Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.~On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure."
10185861|NCT03741478|Experimental|Cognitive and MRI Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing."
10185862|NCT03741465|Active Comparator|The SFP technique|In the SFP neuraxial positioning technique, fifty participants were planned to sit on the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs hanging freely, forearms on the lap and hand are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
9973176|NCT01328340|No Intervention|Control|Volunteers randomized into CON will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
9973177|NCT01328353|No Intervention|control group|Control group arm follows usual care
9520064|NCT03280771|Experimental|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
9520065|NCT03280771|Active Comparator|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
9520066|NCT03280758|Experimental|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
9671044|NCT05053841|No Intervention|lean group|fifteen non- obese breast cancer females who received letozole for six months, treatment period
9671045|NCT05053802|Experimental|Microwave ablation plus Camrelizumab|Microwave ablation plus Camrelizumab (no more than 16 cycles)
9973178|NCT01328353|Experimental|Intervention group arm 1|Intervention group arm 1 receives aprn/telephone care coordination
9973179|NCT01328353|Experimental|Intervention group arm 2|Intervention group arm 2 receives aprn/telephone/video care coordination
10155665|NCT04043156|Experimental|High-precision RT|Study Arm: 18 x 2.33 Gy of high-precision RT in 3.5 weeks.
10155666|NCT04043130|Experimental|Pulse Treatment App|The treatment app is a web-based mobile health app designed for Black & Latinx women ages 18-20. Through culturally and age-appropriate content, Pulse provides information on birth control, healthy relationships, sexual health, pregnancy, & utilization of clinical services to encourage users to choose effective birth control, seek reproductive health services, and prevent unplanned pregnancies. Users access Pulse autonomously and on their own terms. The app does not require users to follow a specific sequence of content viewed. Participants randomized to the intervention condition are given access to Pulse and receive Multimedia Messaging Service (MMS) messages related to sexual health several times a week for 6 weeks. Participants receive a baseline survey, 6-week follow-up survey, and 6-month follow-up survey via an electronic survey platform (6-month survey only administered to participants recruited between November 2018-March 2019).
10155667|NCT04043130|Active Comparator|Pulse Control App|The control app, also called Pulse, is a web-based mobile health app designed by the study team for young women ages 18-20. Although Pulse control and Pulse treatment apps look and feel similar aesthetically, they contain different content. Pulse control app provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Users access Pulse autonomously, on their own terms, and in their own time and place. The app does not require the user to follow a specific sequence of content viewed; however, all users receive a monetary incentive after completing a baseline survey and registering with the app. Control participants also receive MMS messages related to general health for six weeks. Participants receive a baseline survey and a six-week follow-up which are conducted online via an electronic survey platform.
10155668|NCT04042909|Experimental|Counter Attitudinal Advocacy|Participants in this arm will articulate ways to avoid alcohol-related consequences using self-generated protective strategies and publicly state those strategies.
10155669|NCT04042909|Active Comparator|Personalized Normative Feedback|Participants in this arm will view personalized normative feedback regarding their 1) own drinking quantity and frequency of drinking, 2) perceptions of typical drinking by same-sex students' on campus (i.e., perceived descriptive norms), and 3) actual drinking rates by same-sex students' on campus (i.e., actual descriptive norms).
10155670|NCT04042909|No Intervention|Assessment-only Control|Participants in this arm will not receive any intervention.
10155671|NCT04042883|Active Comparator|ANH|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
10155672|NCT04042883|No Intervention|Control|No intervention
10155673|NCT04042766|Active Comparator|laser treatment|
10155674|NCT04042766|Sham Comparator|sham treatment|
10155675|NCT04043091|Experimental|percutaneous coronary intervention|stable obstructive coronary artery disease (coronary artery stenosis >70%) - percutaneous coronary intervention performed in all diseased segments until 300 mL of contrast reached; preferably with drug eluting stents; along with standard medical therapy
10155676|NCT04043091|No Intervention|standard of care|stable obstructive coronary artery disease (coronary artery stenosis >70%) - no intervention (revascularization), just standard medical therapy
10155677|NCT04042779|Active Comparator|model-based WM training|In order to build the model-based WM training, existing tasks used to assess the different component of the Baddeley's model will be reviewed on their findings according to test-retest reliability and construct validity. For each component - phonological loop, visuospatial sketchpad, episodic buffer and central executive - the task with the highest reliability and validity will be chosen and then build the basis for the computerized training program. This procedure results in a model-based, adaptive, computerized training program for WM.
10155678|NCT04042779|Active Comparator|single-task WM training|"The basis for the single-task training administered to the second group will be the widely used dual-n-back training paradigm suggested by Jaeggi et al. (2008). A complex dual n-back task including a visual and an auditory WM task will be implemented for tablet devices."
10155679|NCT04042779|Active Comparator|multiple-task WM training|Verbal WM tasks - particularly letter span and digit span tasks - and a visuospatial WM task are most commonly used (e.g. Dahlin et al., 2008; Klingberg et al., 2005; Westerberg et al., 2007). Therefore, a multiple-task training including these tasks will be administered to the third group.
10155680|NCT04042779|Sham Comparator|sham intervention|Active control group that as well performs a training, however not based on WM. To exclude the involvement of WM, a motor training will be administered to the control group.
9520067|NCT03280758|No Intervention|Control group|No exercise training.
10155681|NCT04042805|Experimental|Sintilimab Plus Lenvatinib|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus sintilimab 200 mg intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10155682|NCT04042545|Experimental|inhaled THC/CBD (PPP001)|PPP001 (cannabis dosing capsule with THC/CBD) inhalation with a device
10155683|NCT04042545|Placebo Comparator|Placebo|Placebo inhalation with a device
9671046|NCT05053802|Other|Microwave ablation|Microwave ablation
9671047|NCT05053568|Experimental|Intervention group|Live visualised, fluoroscopy-fused, image-guided, left ventricular lead placement on the basis of avoiding scar and targeting late mechanically activated segments.
10155684|NCT04042506|Experimental|Extracranial SBRT and Nivolumab|"Stereotactic body radiation therapy (SBRT) will be given to a single extracranial metastatic site in combination with nivolumab.~Patients will receive nivolumab 480mg intravenously (IV) every 4 weeks (1 cycle = 8 weeks), as well as SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.~Nivolumab will be continued until confirmed progression, unacceptable toxicity, or total of 6 Cycles (whichever occurs first)."
9520068|NCT03280745|Active Comparator|7.3% NaCl (intervention)|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
9671048|NCT05053568|No Intervention|Control group|Empirical standard-of-care left ventricular lead placement, in line with current CRT implantation guidelines with electrical guiding on the basis of Q-LV sense.
10155685|NCT04042454|Experimental|Test Product|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
10155686|NCT04042454|Active Comparator|Control Product|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
10155687|NCT04042389|Experimental|WhatsApp|WhatsApp reminders
10155688|NCT04042389|Experimental|Email|Email reminders
10155689|NCT04042389|Other|Control|No reminder
10155690|NCT04042441||Ryzodeg® as per local practice|Real-world population of patients with Diabetes Mellitus, Type 2 (T2DM), who have been initiated or switched to Ryzodeg® from previous antihyperglycaemic treatment according to local clinical practice.
9671049|NCT05053542||With or without enema before operation|Patients who had received pre-operative bowel preparation(PBP) were identified using electronic medical records. Patients prescribed an enema solution (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before surgery were allocated to the PBP group. Patients who received no PBP were allocated to none PBP group.
10155691|NCT04042428|Experimental|Treatment group|Subjects receive a 14-day treatment. A 450 mL blood sample is extracted 6 hours after the last administration (day 14).
10155692|NCT04042428|No Intervention|Control group|Subjects do not receive any treatment. A 450 mL blood sample is extracted at baseline.
10155693|NCT04042610|Experimental|Intervention: electronic prompt to interrupt sitting time|The intervention will consist of two components: education and an electronic prompt via the iOS application Stand Up and notification through the Amzafit BIP device. The Stand-Up application will generate a prompt every hour during the workday to interrupt sitting time and encourage 2 minutes of physical activity. The intervention group participants will be given verbal and written educational materials on the health benefits of incorporating physical activity throughout their workday as well as the health risks of a sedentary lifestyle. Suggestions and demonstrations of physical activity will be given including but not limited to: use a restroom further away from their workstation, take a brief walk around the office, walk-in place, stretch. In addition, they will record their steps via the Amazfit BIP device and submit their daily step counts for weeks: 1,2,4, 6 and 8.
10155694|NCT04042610|No Intervention|Control Group|The control group will be given an Amazfit BIP device to record their steps. They will submit their daily steps counts for weeks: 1,2,4, 6 and 8.
9671050|NCT05054049|Experimental|Abbott i-stat Allinity|Randomised patients to this arm receive the application of the point of care testing device to provide further diagnostic information to assist clinical decision making.
9671051|NCT05054049|Placebo Comparator|Usual Care|Randomised patients to this arm receive usual care.
10155695|NCT04042597|Experimental|Arm A: anlotinib arm|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
10155696|NCT04042597|Active Comparator|Arm B: imatinib arm|Imatinib was given at dose of 400 mg twice daily continuously
10155697|NCT04042688|Experimental|Treatment group|Patients were randomly allocated to one of two groups during preoperative preparation by computer-generated randomization. Treatment group; IA administration of TXA, control group; no TXA administration
10155698|NCT04042688|No Intervention|Control gorup|
10155699|NCT04042662||Meropenem Failure ( Treatment failure)|
10155700|NCT04042662||Meropenem Success ( Treatment Success)|
10155701|NCT04042519||Healthy control|age - and sex-matched healthy individuals without lung disease
10155702|NCT04042519||Patients with mild and moderate COPD|Grading according to the GOLD guide standards
10155703|NCT04042519||Patients with severe and very severe COPD|Grading according to the GOLD guide standards
10155704|NCT04042519||The severe and very severe COPD group baseline|Severe and very severe COPD patients were in the baseline time group
10155705|NCT04042519||The severe and very severe COPD group six months|Patients with severe and very severe COPD were six months from baseline.
10155706|NCT04042519||The severe and very severe COPD group one year|Patients with severe and very severe COPD were one year from baseline.
10155707|NCT04042558|Experimental|Cohort with Bevacizumab|"4 cycles of induction every 3 weeks with :~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~Pemetrexed 500 mg/m² per IV route~Atezolizumab 1200 mg per IV route~Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles"
10155708|NCT04042558|Experimental|Cohort without Bevacizumab|"4 cycles of induction every 3 weeks with :~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route~Pemetrexed 500 mg/m² per IV route~Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles"
10155709|NCT04042649|No Intervention|pre-intervention|Critically ill patients didn't provide environmental intervention (help sleep cycle, provide comfortable environment)
10155710|NCT04042649|Experimental|post-intervention|After providing environmental intervention for critically ill patients
10155711|NCT04042467|Experimental|Greenlight Plus|"Families will receive the Greenlight intervention plus a health information technology (HIT) intervention aimed at supporting family goal-setting and behavior change.~This design allows us to determine if HIT and the asynchronous support it provides between well-child visits can promote additional behavior change and obesity prevention."
9671052|NCT05053529|Experimental|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
9671053|NCT05053529|Experimental|Constrained induced movement therapy (CIMT)|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
9671054|NCT05053373|Experimental|Electroacupuncture Added to Pelvic Floor Muscle Training|Patients will be in a prone position. Bilateral Zhongliao (BL33) and Huiyangacupoint (BL35) will be identified and punctured by an acupuncturist. The electrodes will be placed on the needle handles, and stimulate for 30 minutes at 50 Hz with a current intensity between 1 to 5 mA. PFMT will be performed 3 sets a day (morning, around noon, and night).
9973180|NCT01328418|Other|Achondroplasia lengthening|
10155712|NCT04042467|Active Comparator|Greenlight|During each of the recommended well child visits from 0-24 months, pediatric residents, trained in clear health communication skills and shared goal-setting, will use the Greenlight Toolkit of low literacy, age- specific, parent education booklets to promote healthy family behaviors and obesity prevention.
10155713|NCT04042675||parkinson group|parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage.
10155714|NCT04042675||Control group|healthy individuals between the ages of 40-75 and without any neurological disorders.
10155715|NCT04042532|Active Comparator|Active group|Active group will receive active stimulation of standard intermittent TBS (iTBS) protocol.
10155716|NCT04042532|Sham Comparator|Sham group|Sham group will receive sham stimulation of the same iTBS protocol with the coil set at 90 to the skull.
10155717|NCT04042532|No Intervention|Cognitively normal control|Cognitively normal controls will be recruited for neuroimaging comparison.
10155718|NCT04042714|Experimental|TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
10155719|NCT04042402|Experimental|Open Label|Open label, monthly subcutaneous injection
9694800|NCT04784884|Experimental|HSI-Pilot|Diagnostic hyperspectral imaging of the bronchus stump or bronchus anastomosis after lung resection and calculating the stump or anastomotic Perfusion measures, respectively
10155720|NCT04042415|No Intervention|Free diet controls|Patients on free diet
10155721|NCT04042415|Experimental|Caloric restriction|Patients will be treated with a mild caloric restriction (15-20% caloric restriction)
10155722|NCT04042415|Experimental|Caloric restriction without cow's milk and gluten|Patients will be treated with a mild caloric restriction (15-20% caloric restriction) with exclusion of cow's milk, its derivatives and gluten
10155723|NCT04042350||CKD patients on dialysis|Data will be analyzed from CKD patients on dialysis that participated in the AURORA study.
10155724|NCT04042363|Experimental|Active Transorbital electrical stimulation|Transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks
10155725|NCT04042363|Sham Comparator|Sham Transorbital stimulation|Sham stimulation - 10 sessions during 2 consecutive weeks
9694801|NCT04784962|No Intervention|Control Arm|Standard rehabilitation care including physiotherapy
9973181|NCT01328470|Active Comparator|clopidogrel 75 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
10155726|NCT04042272||Healthy volunteers|Healthy volunteers group; Kidney donor groups; Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
10155727|NCT04042272||Living kidney graft recipients|Kidney transplant group; Course of the research: Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
10155728|NCT04042246|No Intervention|Control|No intervention is implemented among Control
10155729|NCT04042246|Experimental|Treatment (Educational Information on Vaccination)|Provide general and tailored information on vaccination and vaccination schedule at the end of the baseline survey
10155730|NCT04042233|Active Comparator|IV administration of vancomycin|Standard IV vancomycin administration protocol.
10155731|NCT04042233|Experimental|IO Vancomycin 500mg in 250 mL NS|Experimental Intraosseous administration protocol.
10155732|NCT04041934|Experimental|cohorte 1|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.11
10155733|NCT04041934|Experimental|cohorte 2|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.07
10155734|NCT04041934|Experimental|cohort 3|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.04
10155735|NCT04041908|Experimental|Experimental Product|Drink mix powder
10155736|NCT04041882|Experimental|68Ga-DOTATATE PET/CT|Inject 68Ga-DOTATATE and then perform PET/CT scan
10155737|NCT04042090|Experimental|Intervention group: use of therapeutic virtual reality|Intervention group: use of virtual reality intervention at home over a period of 28 days (with a maximum of 35 days) at least ten minutes a day (excluding day 1, in which the participants should do the entire education module of 25 minutes) and in addition, when participants feel the need. Meanwhile, participant is placed on the waiting list to receive normal chronic pain treatment.
10155738|NCT04042090|No Intervention|Control group: no use of therapeutic virtual reality|Control group: no intervention, patient is waiting to receive normal chronic pain treatment.
10155739|NCT04041895||Alzheimer's Disease|Those individuals who possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
10155740|NCT04041895||Control|Those individuals who do not possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
9694802|NCT04784962|Experimental|Intervention Arm|Standard rehabilitation care including physiotherapy + Adjunctive Neuromuscular Stimulation Device Usage
9520069|NCT03280745|Active Comparator|0.9% NaCl (comparator)|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
9694803|NCT04784832|Placebo Comparator|Sequence 1 - Control|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation No mental training
9694804|NCT04784832|Experimental|Sequence 1 - Training (same Task)|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation Mental training
10155741|NCT04042038|Experimental|CBT|Intensive CBT (20 sessions in 1 month)
10155742|NCT04042038|No Intervention|Waiting-list|Waiting-list
10155743|NCT04042051|Other|Single Arm|This study is a phase Ib open label, single arm, adaptive multi-centre trial. Patients with unresectable locally advanced or metastatic HER2-positive breast cancer who previously received trastuzumab and a taxane, separately or in combination, will be treated with copanlisib (as assigned at registration according to the dose escalation scheme) plus trastuzumab emtansine 3.6mg/kg IV on day 1 of a 21-day cycle.
10155744|NCT04041999|Experimental|Daily Cognition Training Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment."
10155745|NCT04041999|Active Comparator|Traditional Cognitive Stimulation Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.~Tasks are performed to work various cognitive functions."
10155746|NCT04042025|Other|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi|Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene
10155747|NCT04041869|Experimental|MapTrek|
10155748|NCT04041986|Experimental|Site-Finding|Each subject will receive anodal, cathodal, and sham stimulation to both the ipsilesional and contralesional hemispheres in a series of six sessions (one condition per session), each separated by at least two days. During anodal and cathodal tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 mA using a 5x5 cm electrode. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. The participant will complete pre/post language testing at each session in order to determine if the subject is a tDCS responder and if so, which site produces the best transient language improvement in that individual. Subjects who do not respond to tDCS will not be invited to move forward to the treatment phase.
10155749|NCT04041986|Active Comparator|Real tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of real tDCS. During real tDCS sessions, subjects will receive stimulation for 20 minutes at a current of 2.0 mA with a 5x5 cm electrode at their optimal responder site previously determined.
10155750|NCT04041986|Sham Comparator|Sham tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of sham tDCS. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds at the beginning of the sham condition before being extinguished over the course of seconds. Individuals randomized into the sham arm will be offered the option to crossover to real tDCS after their participation is complete.
10155751|NCT04042220||GK + IT|Gamma Knife and immunotherapy
10155752|NCT04042220||GK + IT + GC|Gamma Knife, immunotherapy and glucocorticoids
10155753|NCT04042220||GK only|Gamma Knife without immunotherapy
10155754|NCT04042103|Experimental|Tapinarof (DMVT-505) cream, 1%|Tapinarof (DMVT-505) cream, 1% applied topically once daily
10155755|NCT04042064||Inhalation|Patient anesthetised with Inhalation anesthetic agents.
10155756|NCT04042064||TIVA (total intravenous anesthesia)|Patient anesthetised with total total intravenous anesthesia.
10155757|NCT04042207|Active Comparator|Reference treatment (Open-Loop)|Sensor-augmented pump therapy (SAP) namely the Low Glucose Predictive Suspend system or LGPS and a blinded glucose sensor (Dexcom G6) followed by a 48-week extension period in closed-loop condition
10155758|NCT04042207|Experimental|DBLHU system (Closed-Loop)|DBLHU software (a Model Predictive Control [MPC]-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleido insulin pump followed by a 48-week extension period in closed-loop condition
10155759|NCT04041856|Active Comparator|EKC patients|Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
10155760|NCT04041856|No Intervention|Control group|All patients will undergo observational treatments including artificial tear drop and improving hygiene level
10155761|NCT04042142|Active Comparator|Healthy overweight subjects|MR spectroscopy verified no steatosis
10155762|NCT04042142|Active Comparator|Subjects with non-alcoholic fatty liver disease|MR spectroscopy verified steatosis, no steatohepatitis on liver biopsy
10155763|NCT04042142|Active Comparator|Subjects with non-alcoholic steatohepatitis|MR spectroscopy verified steatosis, steatohepatitis on liver biopsy
10155764|NCT04041960|Experimental|SMG|Brain region targeted with transcranial magnetic stimulation: superamarginal gyrus
10155765|NCT04041960|Experimental|MTG|Brain region targeted with transcranial magnetic stimulation: middle temporal gyrus
10155766|NCT04041960|Active Comparator|Vertex|Brain region targeted with transcranial magnetic stimulation (none associated): Vertex
10155767|NCT04042012|Experimental|Eccentric group|The dancers of this group wil perform a soleus eccentric exercise
10155768|NCT04042012|Experimental|PNE group|"The dancers of this group will receive a PNE treatment, consisting of the application of galvanic current, by ultrasound.~The approach will be performed with a transverse axis with a needle orientation that will depend on the location of the target tissue. The parameters will be 3 mA, 3 seconds, 3 impacts (3: 3: 3). The periodicity will be 1day/7day/21day"
9520070|NCT03280719|Active Comparator|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
10155769|NCT04042012|Experimental|Combined group|The dancers of this group will receive a combined treatment and will be carried out in the same way as the other two groups.
10155770|NCT04041843|Experimental|Abixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
10155771|NCT04041765|Experimental|Treatment Group|IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics
9520071|NCT03280719|Experimental|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
9694805|NCT04784832|Experimental|Sequence 1 - Training (similar task)|Motor task (Pretest and Posttests with a similar task in immediate post test) Transcranial magnetic stimulation Mental training
9694806|NCT04784832|Experimental|Sequence 1 - Training (different task)|Motor task (Pretest and Posttests with a different task in immediate post test) Transcranial magnetic stimulation Mental training
10155772|NCT04041765|Placebo Comparator|Placebo Group|Antibiotics only
10155773|NCT04041635|Experimental|Stimuli Reduction|This group will receive reduced visual and auditory stimuli in addition to usual care during venipuncture. Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
10155774|NCT04041635|Active Comparator|Usual Care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
10155775|NCT04041661|Experimental|Active tDCS plus gait training group|Participants in Active tDCS plus gait training group will execute Active tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
10155776|NCT04041661|Sham Comparator|Sham tDCS plus gait training group|Participants in Sham tDCS plus gait training group will executeSham tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
10155777|NCT04041492|Experimental|Group 1|Vitamin D3 1000UI + Placebo (Calcined Magnesia).
10155778|NCT04041492|Experimental|Group 2|Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
10155779|NCT04041492|Active Comparator|Group 3|Vitamin D3 1000UI + Vitamin K2 100 mcg
10155780|NCT04041544|Active Comparator|SN1011|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
10155781|NCT04041544|Placebo Comparator|SN1011 placebo|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
10155782|NCT04042129||1|gynecologic operations with urologic complications
10155783|NCT04041505|Active Comparator|Breastfeeding|Infant consumes mother's milk directly from the breast.
10155784|NCT04041505|Experimental|Bottle-feeding|Infant consumes mother's expressed milk from a bottle.
10155785|NCT04041518|Other|Intervention|Autotransplantation and intra-operative extraoral apicoectomy of a permanent tooth.
10155786|NCT04041817|Experimental|Trigger increasing steps|"Trigger variations will be performed following increasing steps of 2 L/min every 15 minutes. End expiratory lung volume and lung aeration will be conducted using elecrical impedance tomography. Diaphragmatic motion and thickening will be analyzed by ultrasonography. Work of breathing will be evaluated using gastric and oesophageal pressure measurements.~Measurements will be conducted during the last minute of each step."
10155787|NCT04041752|Experimental|Normal weight|30 healthy normal weight adults will be involved and will realize the three conditions
10155788|NCT04042194|Experimental|Thickened with T-PRF|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and T-PRF was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
10155789|NCT04042194|Active Comparator|Thickened with CTG|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and CTG was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
10155790|NCT04041791|Active Comparator|Benzyl penicillin/ampicillin + gentamicin & IV fluids|"Participants are assigned to receive benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Maintenance fluids will be given as a continuous infusion for at least 24 hours."
10155791|NCT04041791|Experimental|Ceftriaxone and IV fluids|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
10155792|NCT04041791|Experimental|Amoxicillin-clavulanate and IV fluids|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for a minimum of 48 hours and for up to 7 days.~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
10155793|NCT04041791|Experimental|Benzyl penicillin/ampicillin + gentamicin & NG feeds|"Participants are assigned to receive Benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
10155794|NCT04041791|Experimental|Ceftriaxone and NG feeds|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
10155795|NCT04041791|Experimental|Amoxicillin-clavulanic acid and NG feeds|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for up to 7 days.~Nasogastric feeds will be given 3 hourly for at least 24 hours."
10155796|NCT04042181|Placebo Comparator|Placebo|
10155797|NCT04042181|Active Comparator|Bifidobacterium longum|
10155798|NCT04041739||diabetic foot osteomyelitis|"Patients will be subjected to:~1-History taking including duration of diabetes and ulcer . 2 Clinical examination of ulcer , including diagnosis of osteomyelitis 3- Venous blood will be withdrawn to do the following laboratory tests :~HbA1c~erythrocyte sedimentation rate(ESR)~C reactive protein(CRP)~Complete blood culture~Serum urea and creatinine 4-culture and sensitivity test 5-Bone fragments and tissue biopsy from infected ulcers 6-Fundus examination"
10155799|NCT04041622|Other|Endoscopy and biopsy|Participants of the HUNT study with a positive serological assay for celiac disease are invited to attain a diagnostic endoscopy with duodenal biopsies
10155800|NCT04041362|Active Comparator|Arm1 (Standard ART)|Standard ART
10155801|NCT04041362|Experimental|Arm 2 (ART plus UB-421)|ART plus weekly UB-421 IV infusion at 5 mg/kg dose level for 16 weeks
10155802|NCT04041466|Experimental|Atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
10155803|NCT04041466|Experimental|Sinus Rhythm (SR)|Patients diagnosed with SR during reference ECG
10155804|NCT04041466|Experimental|Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
9694807|NCT04784832|Experimental|Sequence 2 - Mental|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
10155805|NCT04041388|Other|Tooth tipping|
10155806|NCT04041193|Experimental|SIDERA^B|Behavioral: telerehabilitation activities Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) 5 sessions/week of an individualized telerehabilitation program at home. The sessions will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by the therapist weekly. Each patient's performed session will be reviewed by the therapist.
10155807|NCT04041193|Active Comparator|usual care|Behavioral: paper and pencil activities as usual rehabilitation at home Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) of a usual rehabilitation program.
10155808|NCT04041336|Experimental|All participants|All participants will have measurements taken. There are no comparators or controls in this feasibility study
10155809|NCT04041271||Nonspecific chronic neck pain (NCNP) group|Subjects with nonspecific chronic neck pain will be included to perform clinical test and assess their jaw kinematics and muscle activation.
10155810|NCT04041271||Control group|Healthy control subjects will be included to compare the differences in jaw kinematics, muscle activation and clinical tests between healthy subjects and subjects with nonspecific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
10155811|NCT04041349|No Intervention|The standard treatment group|The standard treatment group is treated with conventional drugs and cholinesterase inhibitors
10155812|NCT04041349|Experimental|mouse nerve growth factor (mNGF)group|Conventional drugs and cholinesterase inhibitors + mouse nerve growth factor (mNGF) of 20 μg (9000 U)/day for 14 consecutive days by intramuscular injection.
10155813|NCT04041401||Children and their Caregivers|Children following discharge from PICU and their caregivers receiving a storybook intervention.
10155814|NCT04041206||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
10155815|NCT04041206||Healthy group|This group will include 40 healthy volunteers.
10155816|NCT04041427|Experimental|Fasting|Albendazole 400mg will be ingested by study participants with an 8-hour fasting diet.
10155817|NCT04041427|Experimental|High fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with high fat content (40 grams of fat).
10155818|NCT04041427|Experimental|Moderate fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with moderate fat content (15 grams of fat).
10155819|NCT04041154|Experimental|Cognitive Fatigue|We will use a behavioral intervention. Participants will perform a cognitively demanding task, repeatedly, to induce cognitive fatigue.
10155820|NCT04041154|Experimental|Physical Fatigue|We will use a behavioral intervention. Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
10155821|NCT04041154|Experimental|Rewarding Stimuli|We will use a behavioral intervention. Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
9694808|NCT04784832|Experimental|Sequence 2 - Physical|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
9694809|NCT04784832|Sham Comparator|Sequence 3 - Control 1|Mental Training Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
9671055|NCT05053373|Experimental|Sham Electroacupuncture Added to Pelvic Floor Muscle Training|The preparation for the patients will be the same as that for the patients who will receive EA. Whereas, instead of using real acupuncture needles, special designed placebo needles (size 0.30 × 25 mm) with the blunt-head will be used in the PFMT+sham EA group to penetrate the fixed pad to the skin surface but without skin penetration. The same procedure for deqi will be performed as in the PFMT+EA group. A special-designed cable (the intermediate wire of the cable is cut off but the appearance is normal) will be used to connect the electrodes to the electroacupuncture machine. Therefore, the electroacupuncture machine appears to work, but does not actually stimulated acupoints. The sham EA treatment will also be maintained for 30 minutes. PFMT will be performed 3 sets a day (morning, around noon, and night),
9671056|NCT05053698||Initial gas tamponade|Primary vitrectomy and fluid-air exchange with SF6 or C2F6 gas tamponade
10155822|NCT04041167|Active Comparator|Alpha lipoic acid|All patients will be assigned intravenous alpha lipoic acid 600mg within 24 hours of symptom onset. Patients will receive intravenous alpha lipoic acid 600mg/day for one week, followed by an oral pill of alpha lipoic acid 600mg/day for three months.
10155823|NCT04041167|Placebo Comparator|Normal saline|All patients will receive intravenous normal saline within 24 hours of symptom onset.
10155824|NCT04041141||Oral Cancer|Patients receiving curative radiation treatment for an oral cancer.
10155825|NCT04041128|Experimental|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
10155826|NCT04041804|Active Comparator|Every week RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every week until getting the require expansion needed
10155827|NCT04041804|Active Comparator|Every four days RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every four days until getting the require expansion needed
9671057|NCT05053698||Initial silicone oil tamponade|Primary vitrectomy and fluid-air exchange with silicone oil tamponade
9671058|NCT05053698||Relapse treated with gas tamponade|Secondary vitrectomy and fluid-air exchange with SF6 or C2F6 or C3F8 gas tamponade
9671059|NCT05053698||Relapse treated with silicone oil tamponade|Secondary vitrectomy and fluid-air exchange with silicone oil tamponade
10155828|NCT04041648|Placebo Comparator|placebo|placebo group
9671060|NCT05053516|Other|the intervention group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
9671061|NCT05053516|Other|the control group|The intervention group will participate in the training program of this study, while the control group will receive the existing routine training program.
10155829|NCT04041648|Experimental|L606 Liposomal inhalation solution|Liposomal inhalation solution
10155830|NCT04041713|Active Comparator|Rett T|Rett T is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
10155831|NCT04041713|Placebo Comparator|Placebo|Placebo is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
9671062|NCT05053503|Placebo Comparator|Active tAN + placebo|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
10155832|NCT04041245||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
10155833|NCT04041245||Healthy group|This group will include 40 healthy volunteers.
10155834|NCT04041011|Experimental|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|
10155835|NCT04041011|Experimental|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|
10155836|NCT04041011|Experimental|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|
10155837|NCT04041076||Elective Surgical Patients in Tuen Mun Hospital|Patients who received elective surgical operation in Tuen Mun Hospital from 1July 2012 to 30June 2018
10155838|NCT04041115|Active Comparator|Control|personalized nutritional therapy + aerobic exercise
10155839|NCT04041115|Active Comparator|Non-alcoholic Beer|non-alcoholic beer + personalized nutritional therapy + aerobic exercise
10155840|NCT04041089|Experimental|Recognition of objects|Patients will do the therapy in the following order: object location, object manipulation and object recognition
10155841|NCT04041089|Experimental|Location of objects|Patients will do the therapy in the following order: object recognition, object location, and object manipulation
10155842|NCT04041089|Experimental|Manipulation of objects|Patients will do the therapy in the following order: object manipulation, object recognition and object location
10155843|NCT04040985|Other|Legion Primary|Legion Primary TKA
10155844|NCT04041063|Experimental|Nerve transfer + robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
10155845|NCT04041063|Active Comparator|Nerve transfer + delayed robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year + six weeks after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
10155846|NCT04040972|Experimental|Rebalance - Group Compassion Focussed Therapy|
10155847|NCT04041024|Experimental|bulimia nervosa group|Patients with Bulimia Nervosa according to DSM 5 criteria aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right handed.
10155848|NCT04041024|Other|Control group|healthy participants without any history of eating disorder aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right
10155849|NCT04040998|Experimental|CCT+TAU group|The participants in CCT+TAU group received compensatory cognitive training plus treatment as usual. The CCT intervention consisted of two 50-minute sessions each week for 10 weeks
10155850|NCT04040998|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as CCT+TAU group.
10155851|NCT04040881|Experimental|Remote monitoring using Smartphone|Patients will be provided with a Global System for Mobile communications (GSM) accelerometer-equipped Android smartphone (specific model to be decided) with an installed open source, freely available pedometer application (Google Fit, Google, CA, United States) which will record their daily steps. Patients will receive daily calls from a research assistant to document the presence of clinically significant chemotherapy-related toxicity.
10155852|NCT04040868|Other|robot-assisted technique|
10155853|NCT04040868|Other|conventional fluoroscopy-assisted technique|
9973182|NCT01328470|Active Comparator|clopidogrel 150 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
10185863|NCT03741465|Experimental|The ASP technique|In the ASP neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
10185864|NCT03741452|Experimental|Transversalis fascia plane block|The transversalis fascia plane block will be administrated to this group at end of the surgery under general anesthesia. An intravenous patient-controlled analgesia device within tramadol will be given to the patients postoperatively.
10185865|NCT03741452|No Intervention|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with tramadol. No block will be performed.
10185866|NCT03741439|Experimental|Treatment arm|Receives real treatment according to manufactures instructions. 6 sessions of low intensity shockwave treatment with an electromagnetic emitter.
10185867|NCT03741439|Sham Comparator|Sham Arm|Receives sham treatment with same applicator, same sound, same time and number of shocks. But no real energy is delivered.
10185868|NCT03741426|Experimental|Arm 1- Cediranib|Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
10185869|NCT03741426|Experimental|Arm 2- Olaparib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy.
10185870|NCT03741426|Active Comparator|Arm 3- Olaparib and Cediranib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy AND Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
10185871|NCT03741426|Experimental|Arm 4- Durvalumab|Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
10185872|NCT03741426|Active Comparator|Arm 5- Olaparib and Durvalumab|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy. Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
10185873|NCT03741413|Experimental|Gain-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to save their lives. Thank you for your support. were send to donors in this group."
10185874|NCT03741413|Experimental|Loss-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to prevent them from death. Thank you for your support. were send to donors in this group."
10185875|NCT03741413|Experimental|Control SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can donate blood again. Thank you for your support. were send to donors in this group."
10185876|NCT03741413|No Intervention|Control group|Donors in this group were not received SMS reminders.
10185877|NCT03741400|Experimental|Standard Occupational Therapy + Smart Glove|Subjects randomized to this arm will be expected to use the Neofect Rapael Smart Glove for a minimum of 20-30 minutes per day, 5 days per week, in addition to prescribed occupational therapy.
10185878|NCT03741400|No Intervention|Standard Occupational Therapy|Subjects in the control arm will undergo standard of care occupational therapy as prescribed by their care team.
10185879|NCT03741387|Experimental|Gain-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you save his life? Donors in this group will answer the questions about attitude of saving patients' lives."
10185880|NCT03741387|Experimental|Loss-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you prevent him from death? Donors in this group will answer the questions about the attitude of preventing patients from death."
10185881|NCT03741374|Experimental|Minimally-invasive non-surgical therapy|Intrabony defects treated with Minimally-invasive non-surgical therapy (MINST)
10185882|NCT03741361||Anxiety and Depression|Female patients scheduled for hysteroscopic surgery under propofol-based intravenous anesthesia will be recruited in this prospective cohort study.
10185883|NCT03741348|Active Comparator|ES|Erector Spinae Plane Block
10185884|NCT03741348|Placebo Comparator|control|the control group will not receive block
10185885|NCT03741309|Active Comparator|Group I|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
10185886|NCT03741309|Sham Comparator|Group II|dentifrice containing Calcium sodium phosphosilicate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
10185887|NCT03741309|Placebo Comparator|Group III|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks.
10155854|NCT04040855|Experimental|Intervention|Patients in the intervention groups received multi-professional medication reviews. A nurse performed a symptom evaluation, a pharmacist assessed the drug list and made adjustment suggestions and finally a physician took action and performed medication changes.
10155855|NCT04040855|No Intervention|Control|Patients were treated according to the usual routine.
10155856|NCT04040829|Active Comparator|SE + TAU|"Supported education (SE) includes a variety of services ranging from orientation, study strategies or homework help. This intervention is personalized to the need of each patient in terms of services and frequency. Previous to this randomized controlled trial, we conducted interviews with each site that will provide SE. In these interviews, we explored the fidelity of their services to the Individual Placement and Support adapted to education. Information regarding the dosage of SE (frequency, length of session, type of support) will be collected and used as covariates for each participant since intensity treatment can impact outcomes.~Treatment as usual (TAU) consists of medication and routine contact with the clinical team. Patients will continue to receive their standard treatment, but we will collect information regarding the type of medication, the dosage, and all other relevant information and use it as covariate in our analyses."
10155857|NCT04040829|Experimental|CR + SE + TAU|"Cognitive remediation therapy (CR) will be conducted using CIRCuiTS, a computerized program designed to improve cognition (attention, memory, executive functioning) and metacognitive skills. CIRCuiTS has an integrated focus on the transfer of cognitive skills to daily living, using real-world goals and homework to facilitate in vivo use of new strategies, as well as a formulation-based approach, which takes into account the impact of cognitive strengths and difficulties with daily living skills. Each session includes about 4-8 tasks targeting a range of cognitive problems, which become more ecologically valid as the program progresses. The rate of delivery for CIRCuiTS will be two to three sessions per week, for a maximum of 40 sessions. The therapy will be provided entirely online with a therapist, using the platform Zoom.~This arm will include our active control condition : supported education (SE) as well as Treatment as usual (TAU) as previously described."
10155858|NCT04040725|Experimental|Rogaratinib|"Rogaratinib is administered orally twice daily~Rogaratinib is held for 72 hours before cystoscopy/TURBT and if no complications are seen, treatment is resumed 24 hours after the TURBT"
10155859|NCT04040712|Experimental|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
10155860|NCT04040712|Sham Comparator|Sham FMT|Sham fecal microbiota transplantation
10155861|NCT04040686|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99m-Tc-NM-02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection
10155862|NCT04040764|Experimental|Uncemented Tritanium Knee Replacement|30 participants will be randomly allocated to receive an uncemented Tritanium total knee replacement.
10155863|NCT04040764|Active Comparator|Cemented Triathlon Knee Replacement|30 participants will be randomly allocated to receive standard Triathlon cemented total knee replacements.
10155864|NCT04040478||Abdominal|80 patients undergoing surgery for abdominal cancer. Data review for interim analysis will be conducted after the participation of 40 patients to evaluate the requirement for further enrollment.
10155865|NCT04040478||Vascular|20 patients undergoing femoral endarterectomy.
10155866|NCT04040543|Experimental|Daily|Daily supplementation with product containing markers
10155867|NCT04040543|Experimental|Intermittent|Daily supplementation with either the product containing markers or the product not containing markers
10155868|NCT04040543|Placebo Comparator|Control|Daily supplementation with product not containing markers
10155869|NCT04040595|Experimental|Adipocyte measurement|Abdominal fat biopsy
10155870|NCT04040491|Experimental|Newly diagnosed PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
10155871|NCT04040491|Other|Relapse/refractory PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
10155872|NCT04040803|Experimental|10 Hz tACS|"Stimulation will be applied at 10 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~10 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
10155873|NCT04040803|Experimental|20 Hz tACS|"Stimulation will be applied at 20 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~20 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
10155874|NCT04040803|Experimental|70Hz tACS|"Stimulation will be applied at 70 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~70 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
10155875|NCT04040803|Experimental|0.1-640Hz tRNS|"Stimulation will be applied at 0.1-640Hz tRNS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~0.1-640Hz tRNS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
10155876|NCT04040803|Sham Comparator|Sham|"Stimulation will be performed only for 10 s before the fade out, with 20 Hz tACS and an intensity of 1.5 mA (peak to peak).~Sham condition will be applied over pseudo-stimulation of pharyngeal cortex region and contralateral supraorbital region."
10155877|NCT04040296|No Intervention|Usual Care|Kidney Action Team Recommendations will not be delivered to the primary care teams of randomized patients.
9520072|NCT03280719|Experimental|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
10155878|NCT04040296|Experimental|Kidney Action Team Recommendations|Recommendations made by the Kidney Action Team will be delivered to the patient's primary care team within 30 minutes of AKI development.
10155879|NCT04040400|Experimental|Treatment Arm|intraoperative radiotherapy (IORT) arm
10155880|NCT04040322|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
10155881|NCT04040322|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
10155882|NCT04040647||colorectal surgery|50 consecutive patients scheduled to colorectal surgery in an enhanced recovery programme
10155883|NCT04040647||bariatric surgery|50 consecutive patients scheduled to bariatric surgery (gastric by-pass, sleeve gastrectomy) in an enhanced recovery programme
10155884|NCT04040270|Experimental|Live drama+DVD+Worksheets|Primary school students watched an interactive live drama in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
10155885|NCT04040270|Experimental|DVD+Worksheets|Primary school students were given DVD and worksheets and they were asked to watch the DVD and finish the worksheets with their parents. After the study finished, the students watched the live drama.
10155886|NCT04040270|No Intervention|Waitlist control|Primary school students received no intervention during the 4-week study period. After the study finished, the students watched the live drama, and DVD with worksheets were distributed to students and they were encouraged to share with their parents.
10155887|NCT04040465|Active Comparator|Normal Weight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
10155888|NCT04040465|Active Comparator|Normal Weight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
10155889|NCT04040465|Active Comparator|Normal Weight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
10155890|NCT04040465|Active Comparator|Overweight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
10155891|NCT04040465|Active Comparator|Overweight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
10155892|NCT04040465|Active Comparator|Overweight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
10155893|NCT04040465|Active Comparator|Obese/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
10155894|NCT04040465|Active Comparator|Obese/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
10155895|NCT04040465|Active Comparator|Obese/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
10155896|NCT04040556||anesthesia residence|anesthesia residences who currently study in the department of Anesthesia and voluntarily enrolled into the study
10155897|NCT04040387|Experimental|Treatment Arm|Intervention with NightWare Therapeutic System
10155898|NCT04040387|Sham Comparator|Sham Arm|NightWare system set to not provide any interventions
10155899|NCT04040504|Experimental|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
9671063|NCT05053503|Active Comparator|Active tAN + lofexidine|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 168 hours (7 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
10155900|NCT04040504|Active Comparator|Pentax ED-34i10T Duodenoscope|Pentax ED-34i10T Duodenoscope
10155901|NCT04040374|Experimental|AI-based diagnosis|• AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
10155902|NCT04040374|Active Comparator|Expert endoscopist diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
10155903|NCT04040452|Experimental|Treatment|"Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte). To eliminate excess exposure and the associated side effects, all patients enrolled in the study will not be given any additional NSAIDs (except aspirin, which is standard of care in many post-operative cardiac surgery patients) during the study period.~Dosage and Route of Administration:~Continuous ketorolac 0.08mg/kg/hr, with a maximum of 5mg/hr for patients weighing greater than or equal to 60kg, administered intravenously by nursing staff. Study drug will infuse continuously for 48 hours.~Intermittent Plasmalyte 0.033mL/kg (max 2mL) infusion every 6 hours for 48 hours."
10155904|NCT04040452|Placebo Comparator|Standard of care|"Description: Patients randomized to the standard of care arm of the study will receive a generically marked syringe of Plasmalyte to be infused at the same rate as the treatment medication, and will only receive intermittent dosing of ketorolac (current standard of care). As in the treatment group, no additional NSAIDs (except aspirin) are to be given during the 48 hour study period.~Dosage and Route of Administration~Continuous Plasmalyte infusion to match the aforementioned ketorolac dosing~Intermittent ketorolac 0.5mg/kg IV infusion every 6 hours (max 30mg per dose)"
10155905|NCT04040257|No Intervention|Individual Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
10155906|NCT04040257|Experimental|Group Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
10155907|NCT04040166|Other|PET/MRI scan with 68Ga DOTATATE|PET/MRI scan with 68Ga DOTATATE of carotid arteries in in patients following head and neck radiation therapy
10155908|NCT04040309|Experimental|Plasma rich in growth factors group|Group of patients who will receive 1 ml of PRGF 2nd fractions injections into their trigger points in the masseter muscle.
9694810|NCT04784832|Active Comparator|Sequence 3 - Control 2|Paired Associative Stimulation Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
10155909|NCT04040309|Active Comparator|Lidocaine group|Group of patients who will receive 1 ml 2% Lidocaine injections into the myofascial trigger point in the masseter muscle.
10155910|NCT04040088|Experimental|Cohort A (68Ga-DOTATATE, PET/CT)|Patients with newly diagnosed neuroendocrine cancer receive 68Ga-DOTATATE intravenously (IV) and undergo PET/CT over 20-30 minutes at diagnosis (before any treatment) and at the time of radiation treatment planning.
10155911|NCT04040088|Experimental|Cohort B (68Ga-DOTATATE, PET/CT)|Patients with previously diagnosed with neuroendocrine cancer receive 68Ga-DOTATATE IV and undergo PET/CT over 20-30 minutes at the time of radiation treatment planning.
10155912|NCT04039906|No Intervention|Removal of needle with existing method|Participants will remove needles from syringes with the existing method like they are already doing. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
10155913|NCT04039906|Experimental|Removal of needle with using ANDYs|Participants will remove needles from syringes with Andy. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
10155914|NCT04039854|Active Comparator|Volatile anaesthetics arm|Patients randomised to receive volatile anaesthetics will receive either isoflurane, sevoflurane or desflurane during the surgical procedure.
10155915|NCT04039854|Active Comparator|Propofol anaesthetics arm|Patients randomised to receive propofol will not receive any volatile anaesthetics during the surgical procedure.
10155916|NCT04039997|Experimental|Chest compression without cpr feedback device|teaching resuscitation without application of cpr feedback device
10155917|NCT04039997|Experimental|Chest compression with cpr feedback device|teaching resuscitation with application of CPRMeter - cpr feedback device
10155918|NCT04039828|Experimental|Stratum|"Stratum 1: From 3 months to <18 months= 175 Stratum 2: From 18 months to 59 months= 175~In total, 350 participants will be enrolled"
10155919|NCT04039880|Experimental|Cohort A (mass balance)|evaluation of mass balance and metabolite profiling
10155920|NCT04039880|Experimental|Cohort B (biliary evaluation)|evaluation of biliary elimination
10155921|NCT04040023|Other|I Group: PBMi|Non-drug intervention First part of PBM program (PBMi) Training part for medical care staff to improve transfusion practices
10155922|NCT04040023|Experimental|C Group: PBMc|"Patient Blood Management: full program~PBMi intervention and Drug intervention (systematic correction of pre- and postoperative iron and vitamin deficiencies, and erythropoietin preoperative treatment for anemic patient)"
10155923|NCT04040075|Other|Open label|Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation
10155924|NCT04040010|Experimental|Postmenopausal women colostrum supplement|
10155925|NCT04040010|Experimental|Osteoporosis patients colostrum supplement|
10155926|NCT04040010|Experimental|Osteopenia patients colostrum supplement|
10155927|NCT04040010|Placebo Comparator|Postmenopausal women placebo|
10155928|NCT04040010|Placebo Comparator|Osteoporosis patients placebo|
10155929|NCT04040010|Placebo Comparator|Osteopenia patients placebo|
10155930|NCT04040036|Experimental|VR-Rollercoaster|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, individuals feel as if they are getting on and riding a rollercoaster. The rollercoaster speeds up and slows down.
10155931|NCT04040036|Experimental|VR-Ocean Rift|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Ocean Rift Group, individuals can take an underwater tour with 12 different marine animals with slow music.
10155932|NCT04040036|No Intervention|Control|They would be monitored during the procedure if their informed consent was received. Control group children did not receive any distraction techniques.
10155933|NCT04040101|No Intervention|Healthy Adult|balance assessment
10155934|NCT04040101|No Intervention|Stroke|balance assessment
10155935|NCT04040101|Experimental|Stroke smartphone training|smartphone balance training
10155936|NCT04040101|Active Comparator|Stroke traditional training|traditional physical therapy training
10155937|NCT04040140|Experimental|APA Treatment|Oncology patients with a pain rating of four or greater will receive APA treatment for patients' cancer-related pain. The ear points will be determined by the corresponding body points related to the patient's specific pain. Pain data will be tracked by electronic surveys and Electronic Health Records.
10155938|NCT04039984|Experimental|Prime Cup|The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm CoCr femoral head, articulating on a highly crosslinked acetabular liner.
10155939|NCT04040127|Experimental|Cord blood stem cells|cord blood stem cells from Invitrx
10155940|NCT04040127|Placebo Comparator|0.9% sodium chloride (saline)|canal will be rinsed by saline solution.
10155941|NCT04040049|Experimental|FLT190|FLT190 is a replication-incompetent adeno- associated viral (AAV) vector. Administered by a single intravenous infusion.
10155942|NCT04040153|Experimental|Guiding Good Choices|Enrollment in the intervention, Guiding Good Choices, a substance use initiation prevention program, will be recommended by the pediatrician to parents of those adolescents empaneled with an intervention arm pediatrician
10155943|NCT04040153|No Intervention|Control|Parents of adolescents empaneled with a control arm pediatrician will not be offered Guiding Good Choices
10155944|NCT04039971|Active Comparator|Tendon-Bone Graft|Participants receive the Quadriceps Tendon Tendon-Bone Graft technique during ACL reconstruction.
10155945|NCT04039971|Active Comparator|All-Soft-Tissue Graft|Participants receive the Quadriceps Tendon All-Soft-Tissue Graft technique during ACL reconstruction.
10155946|NCT04040114|No Intervention|Lead-in phase|During the lead-in phase treating clinicians will not be given the Molemap artificial intelligence diagnosis in real-time (i.e. in clinic with the patient).
10155947|NCT04040114|Active Comparator|Active phase|During the active phase treating clinicians will be given the Molemap artificial intelligence diagnosis in real-time.
10155948|NCT04039802||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery
10155949|NCT04039802||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures
9671064|NCT05053503|No Intervention|Sham tAN + placebo|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 placebo pills four times per day for 7 days. The placebo will appear similar to lofexidine in size, shape, color, and smell to lofexidine.
9694811|NCT04784832|Experimental|Sequence 3 - Training (same task)|Paired Associative Stimulation Mental training (one task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
10155950|NCT04039815|Experimental|ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group|"patients in study group, so called ABC (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days"
10155951|NCT04039815|Placebo Comparator|normal saline group|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
10155952|NCT04039776|Experimental|Bone patellofemoral joint indices|Evaluation of the bone index values in patients affected by patellofemoral joint disorders, obtained from CT scans performed in both orthostatism and clinostatism
10155953|NCT04039789|Active Comparator|Control|Usual Care: that consists of healing the wound (assessment, cleaning, disinfection, debridement and topical treatment) and compression therapy multilayer usual practice, according to the recommendations for the treatment of cutaneous ulcers of the Region of Madrid.
10155954|NCT04039789|Experimental|Intervention|"ACTIVE LEGS: The usual care plus experimental intervention. It is a structured educational intervention, directed by nurses and carried out in the health center consultations. The intervention Active Legs has been designed based on the available evidence. It incorporates a program of lower limb exercise at home and daily walking patterns.~Home program of lower limb exercises. The nurse will instruct the patients in the performance of 4 exercises of lower limbs of progressive difficulty that must be performed at home 5 days a week, twice a day Daily walking program. In addition, patients must ambulate progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)) .~At the start of the study, the Active Legs diary will be provided, showing the patterns of the exercise and walking program graphically and a pedometer."
10155955|NCT04039672|Experimental|Biopsy|Skin biopsy before BRAFi/MEKi treatment
10155956|NCT04039685|Experimental|Aerobic exercise group|
10155957|NCT04039685|Experimental|Resistance exercise group|
10155958|NCT04039685|Experimental|Combined (aerobic+resistance) exercise group|
10155959|NCT04039685|No Intervention|Non-exercise group|
10155960|NCT04039646|Active Comparator|Standard postoperative care group|Patients received standard postoperative care as ususal.
10155961|NCT04039646|Experimental|ERAS group|Patients received postoperative ERAS treatment.
10155962|NCT04039659|No Intervention|Control Group|Patients will be cured with dressings wound everyday or before if there are complications in surgical incisions.
10155963|NCT04039659|Active Comparator|PICO group|Patients will carry the device for 7 days uninterrupted until its withdrawal.
10155964|NCT04039698|Experimental|Telemedicine|Sofosbuvir 400mg and velpatasvir 100mg qd for 12 weeks Telemedicine support
10155965|NCT04039711|Other|Genital infections|Women with vaginal/cervical sampling indications
10155966|NCT04040062|Experimental|SCC|Subjects will be treated according to their frequency response pattern which may show one or more distinct frequencies of stimulation that generated increased SCC
10155967|NCT04039958|Experimental|T test|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
10155968|NCT04039958|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
10155969|NCT04039958|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
10155970|NCT04039763|Experimental|Real Time Continuous Glucose Monitoring|"Participants wear Real time continous glucose monitoring (Dexcom G6), with alarms for when their glucose is too low or too high. They will be able to view their data on the Dexcom app on their smartphones or a Dexcom receiver and share this with a nominated caregiver. Participants can chose to share data between study visits via Dexcom clarity with the research/clinical team, who will support them making changes to their insulin regime in light of the data."
10155971|NCT04039763|Placebo Comparator|Standard care|Standard care - finger prick self monitoring of blood glucose.
10155972|NCT04039737|Experimental|Treatment Group|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
10155973|NCT04039737|No Intervention|Control Group|
10155974|NCT04039477|Experimental|Arm A - KZR-616 30mg|KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks
10155975|NCT04039477|Experimental|Arm B - KZR-616 45mg|KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.
10155976|NCT04039373|Experimental|Treatment Arm|
10155977|NCT04039516|Experimental|Lutathera Treatment Arm|• 4x cycles of 7.4 GBq (200mCi) of Lutathera therapy (177Lu-DOTA0-Tyr3-Octreotate) with concomitant amino acids for participants randomised onto the Lutathera therapy arm, every 8 weeks, plus long term somatostatin analogues (SSTA).
10155978|NCT04039516|No Intervention|Best Supportive Care|Somatostatin analogue treatment according to current standard, routine care
10185888|NCT03741296|Active Comparator|single stage revision|One surgery where the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided and washed out before a new artificial hip joint (prosthesis) is implanted. All the procedures will be done in a single surgery.
10155979|NCT04039581|Experimental|Group Kinesio Taping and TENS|"The number of participants in this group is anticipated to be 30. The treatment method for this group is the conventional treatment + KT (Kinesio Taping) relaxation technique (muscle inhibition technique). In KT technique, while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.~In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises."
10155980|NCT04039581|Active Comparator|Group TENS|The number of participants in this group are anticipated to be 30. This group will be receiving only conventional treatment. In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist. Therapeutic exercises will consist of active shoulder evolution, active cervical rotations, active cervical lateral flexion movement and active shoulder flexion and abduction exercises.
10155981|NCT04039581|Active Comparator|Group Kinesio Taping|The number of participants in this group are anticipated to be 30. This group will be receiving only Kinesio Taping relaxation technique (muscle inhibition technique). In kinesio taping technique while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.
10155982|NCT04039334|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 week. All exercise sessions will be performed at home.
9671065|NCT05053503|Sham Comparator|Sham tAN + lofexidine|Participants will have the earpiece applied and the cable connected to the Patient Controller, but tAN stimulation will not be turned on. Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
10155983|NCT04039334|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive creative dance based exercise training for 60 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised in a clinic per week.
10155984|NCT04039594||ECMO|
10155985|NCT04039555|Active Comparator|Active Arm - CO2 intimate|Patients will receive 2 sessions of CO2 laser treatment, spaced 4 to 6 weeks apart
10155986|NCT04039555|Active Comparator|Active Arm - Erbium-yag|Patients will receive 2 sessions of Erbium-Yag laser treatment, spaced 4 to 6 weeks apart
10155987|NCT04039555|Sham Comparator|Sham Arm|Patients will receive 2 sessions of Erbium-Yag laser or CO2 laser treatment with non-therapeutic energy, spaced between 4 and 6 weeks apart
10155988|NCT04039633|Experimental|Burst spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
10155989|NCT04039633|Sham Comparator|sham spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
10155990|NCT04039282|Other|Patient Participant|Patients will be asked to complete an 3 days worth of an online dietary recall prior to their out patient appointment with the dietitian
10155991|NCT04039282|Other|Dietitian Participant|The Dietitian will be asked to review the patients completed dietary recalls prior to the patient attending their out patient appointment.
10155992|NCT04039490|No Intervention|Ultrasound-only Pediatric Vessel Cannulation|The standard of care for vessel cannulation currently employed at CNMC
10155993|NCT04039490|Experimental|SCENERGY-guided Pediatric Vessel Cannulation|The addition of the SCENERGY guidance combined with the ultrasound for pediatric vessel cannulations.
10155994|NCT04039568|Active Comparator|Active Control Group|"Ten to fifteen participants in the HEP arm will participate in the program for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.~The Health-Enhancement Program (HEP) was designed and used as a manualized active control in meditation-based intervention trials. HEP controls for several non-specific factors found in a meditation groups, including: group support and morale, behavioural activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP is tailored to be structurally equivalent to SSM with similar-sized groups, meeting schedule, total contact hours, amount of home practice and encouragement to keep practice logs."
9671066|NCT05053503|Active Comparator|extended-release injectable naltrexone|Extended-release injectable naltrexone will be administered according to the clinical site's standard of care.
9671067|NCT05053503|Experimental|Active tAN + extended-release injectable naltrexone|"Extended-release injectable naltrexone will be administered according to the clinical site's standard of care. Participants will be provided with a Spark Sparrow Ascent Therapy System and instructed to administer therapy according to the specified frequencies:~Month 1 (Days 1 - 28): a minimum of 2 hours per day at least 5 days a week~Month 2 (Days 29 - 56): a minimum of 2 hours per day at least 3 days a week~Month 3 (Days 57 - 90: a minimum of 2 hours per day at least 1 day per week"
9671068|NCT05053438|Active Comparator|Intensive Multidisciplinary Intervention (Standard Care)|Children with a history of chronic food refusal will be randomized to receive the standard of care. The standard of care for tube wean is to accomplish the balance between enteral supplementation and oral intake, the tube feeding regimen will follow the schedule of therapeutic meals (e.g., mid-day supplementation occurs after morning therapeutic meals).
9694812|NCT04784832|Experimental|Sequence 3 - Training (different task)|Paired Associative Stimulation Mental training (two tasks) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
10155995|NCT04039568|Experimental|Intervention Group|"Ten to fifteen participants in the SSM arm will be trained for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.~This standardized, manualized therapy will be delivered by certified meditation instructors. On day 1, participants will learn the nature of meditation, and then undergo personal guided meditation. Training on days 2-4 includes understanding the nature of the mind and the thoughts arising from it, guided meditations by the instructor, and a discussion of meditation processes. Weekly 75 min reinforcement sessions will include 20 minutes of guided meditation practice, and then focus on participants' experiences with meditation during the week, additional observations, and a review of relevant knowledge to support their home practice. Participants will also be encouraged to practice twice daily at home for 20 minutes per session."
10155996|NCT04039321|Active Comparator|ESPB group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
10155997|NCT04039321|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
10155998|NCT04039724|Experimental|Sequence A|"Period 1 : HCP0605+HGP0816~Period 2 : HCP1305"
10155999|NCT04039724|Experimental|Sequence B|"Period 1 : HCP1305~Period 2 : HCP0605+HGP0816"
9671069|NCT05053438|Experimental|Intensive Multidisciplinary Intervention (Standard Care) + Hunger provocation (Rapid Tube Wean)|"Children with a history of chronic food refusal will be randomized to receive the experimental arm that combines standard care with rapid tube wean.~All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use regular tube wean sheet to provide credit for oral intake for remainder of admission."
9671070|NCT05053477|Active Comparator|Control Group|Patients will receive median nerve perineural injection of bupivacaine with mehylprednisolone under ultrasound guidance
10156000|NCT04039529|No Intervention|CT-only guided biopsy|The current standard of care for biopsy at Temple University Hospital.
10156001|NCT04039529|Experimental|SCENERGY-guided Biopsy|The use of the SCENERGY to fuse CT and Ultrasound for biopsy
10156002|NCT04039386|Experimental|Cell Phone Based Cognitive Based Therapy|Young adults with hip pain
10156003|NCT04039386|Placebo Comparator|Placebo|Young adults with hip pain
10156004|NCT04039269|Active Comparator|Multiple (watch > 3 times)|Preoperative video information
10156005|NCT04039269|Active Comparator|single (watch 1 time)|Preoperative video information
10156006|NCT04039269|No Intervention|conventional (do not watch)|Do not watch video
10156007|NCT04039425||cancer patient|"Recently diagnosed cancer stage 1, 2, or 3~Assigned to receive immunosuppressive chemotherapy treatment~Natural hair that has not been dyed or permed in the past 3 months"
10156008|NCT04039256|Experimental|PVR implantation group|Patients enrolled receive PVR intervention
10156009|NCT04039243|Experimental|Active Treatment|Up to 12 sessions of Parent-Child CBT using an adaptation of the Being Brave protocol
10156010|NCT04039243|Active Comparator|Parent Education|Parents receive educational materials about how to help young children overcome shyness and anxiety
10156011|NCT04039243|No Intervention|Monitoring|
10156012|NCT04039048|Experimental|ctDCS during Balance training|
10156013|NCT04039048|Sham Comparator|ctDCS sham during Balance training|
10156014|NCT04039074|Experimental|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
10156015|NCT04039074|Active Comparator|Iyengar yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
10156016|NCT04039074|Active Comparator|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
10156017|NCT04039126|Experimental|PATIENTS WITH MALIGNANT PLEURAL EFFUSION|PARTICIPANTS WITH MALIGNANT PLEURAL EFFUSIONS REQUIRING PLEURODESIS, COMBINATION OD POVIDONE IODOONE-TETRCYCLINE TO BE USED.
10156018|NCT04039126|Active Comparator|PATEINT WITH MALIGANT PLEURAL EFFUSION REQUIRNG PLEURODESIS|TO USE POVIDONE IODINE ALONE IN THIS GROUP
10156019|NCT04039087|Active Comparator|Sildenafil|active sildenafil 40 mg p.o. three times per day
10156020|NCT04039087|Placebo Comparator|Placebo Arm|placebo three times per day
10156021|NCT04039152||Pre- interventions group|Without clinical pharmacists recommendations to optimize antibiotics use
10156022|NCT04039152||Post - interventions group|interventions include clinical pharmacists recommendations to optimize antibiotics use
10156023|NCT04039009||Infertility patients|Infertility patients will be examined according to the pelvic organ prolapse quantification classification system during hysteroscopy.
10156024|NCT04038944||Subjects with new onset atrial fibrillation|Subjects with new onset atrial fibrillation who may or may not require electrical cardioversion
10156025|NCT04038970|Experimental|KN019 5mg/kg|Intravenous (IV) solution, 5 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
10156026|NCT04038970|Experimental|KN019 10mg/kg|Intravenous (IV) solution, 10 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
10156027|NCT04038970|Placebo Comparator|Placebo|Intravenous (IV) solution, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
10156028|NCT04038840|Experimental|Healthy Control (HC) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
10156029|NCT04038840|Experimental|Schizophrenia (SZ) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
10156030|NCT04038853|Experimental|Vitamin D|Intervention drug, containing 1,25-dihydroxy-vitamin D, comes in original packages as vials containing a total amount of 10 ml of clear solution. 5 drops accounting for 1000 IU of 1,25-dihydroxy-vitamin D will be administered orally on a daily basis.
10156031|NCT04038853|Placebo Comparator|Placebo|A placebo identical to the study intervention drug in all its characteristics (package, visual characteristics of the fluid, smell, and taste) will be administered in the same manner.
10156032|NCT04038866|Experimental|DUAL-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait with a dual-task program with secondary cognitive and upper limb motor tasks.~In this group, the training of the tasks (walking and cognitive or motor) was performed separately and then they were trained at the same time under a progression system. Cognitive/motor secondary tasks were different from those used in the assessment of gait.~Each training session consisted of three parts: the initial warm-up, dual-training, and back-to-calm."
10156033|NCT04038866|Active Comparator|SINGLE-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait without a dual-task program (physical and walking exercises without additional load of cognitive or upper limb motor tasks).~Each training session consisted of three parts: initial warm-up, physical exercise in single-task condition, and back-to-calm.~The objectives and walking exercises were the same as those performed in the experimental group."
10156034|NCT04038775|Experimental|Volunteering|"The experimental arm will receive a volunteer prescription from their provider and assistance from a study team member to find a volunteer job."
10156035|NCT04038775|No Intervention|Control|The control arm will not be recommended to volunteer or assisted in finding a volunteer activity. They will answer the same survey questions as the intervention subjects.
10156036|NCT04038879||Mitral/Aortic Regurgitation|Subjects identified with mitral or aortic regurgitation will be asked to undergo testing with trans thoracic echocardiogram, stress echocardiography, and cardiac MRI with and without contrast. In addition, patients will be asked to answer the KCC and EQ5DL questionnaires.
10156037|NCT04039139|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
10156038|NCT04039139|Active Comparator|Mind Body Intervention 1|Participants will receive a mind body educational-based intervention to learn the techniques comprising intervention 1.
10156039|NCT04039139|Experimental|Mind Body Intervention 2|Participants will receive a mind-body educational-based intervention to learn the techniques comprising intervention 2.
10156040|NCT04038788|Active Comparator|Active tRNS|In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active stimulation group were maintained on their antipsychotic medications throughout the study period.
10156041|NCT04038788|Sham Comparator|Sham treatment|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham group were maintained on their antipsychotic medications throughout the study period.
10156042|NCT04038892|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. After the training given by the physiotherapist, all exercise sessions will be performed at home.
10156043|NCT04038892|Experimental|Nintendo Wii Fit Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive Nintendo Wii Fit based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
10156044|NCT04038892|Experimental|BreathingLabs Breathing Games Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive BreathingLabs Breathing Games based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
9520073|NCT03280719|Experimental|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
9520074|NCT03280706|Experimental|Maltodextrin|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of maltodextrin 200kcal, no protein or fat, 49,5g of carbohydrate.
9694813|NCT04784832|Sham Comparator|Sequence 4 - Control|Transcranial magnetic stimulation Motor task Mental training
10156045|NCT04038749|Experimental|Pharmaceutical method- Bromocriptine|
10156046|NCT04038749|Experimental|Pharmaceutical method- Cabergoline|
10156047|NCT04038749|Other|Without medications that inhibit lactation|
10185889|NCT03741296|Active Comparator|two-stage revision|"Patients will undergo 2 separated surgeries. In the first operation, the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided, washed out and a spacer will be placed in the hip (temporarily replace prosthesis).~A secondary surgery to re-implant the hip will be performed with an interval period of 4-10 weeks when the infection is cleared.~The site will be debrided and irrigated, and any component/spacer will be removed. A new artificial joint will then be implanted."
10185890|NCT03741283|Experimental|Optimisation of nutrition and medication|"N=approx.~65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition."
10185891|NCT03741283|No Intervention|Standard care|N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.
10185892|NCT03741270|Experimental|Vaccine|
10185893|NCT03741257|Active Comparator|Group A|Received Hypertonic saline 3% as resuscitation fluid.
10185894|NCT03741257|Active Comparator|Group B|Received Hypertonic saline 1.8% as resuscitation
10185895|NCT03741244|Experimental|Temozolomide and apatinib|"Patients have treated with postoperative concurrent chemoradiation. Then Temozolomide (150mg/m2/d d1-5 in the first cycle, followed by 200mg/m2/d d1-5 q28d) + apatinib (500mg/d QD).~After 6 cycles,apatinib single drug maintained until progress."
9520075|NCT03280706|Active Comparator|Orange Juice|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of orange juice, 200kcal, 2,82g of protein, 0,67g of fat, 47,08g of carbohydrate.
9671071|NCT05053477|Active Comparator|PRF Group|Patients will receive median nerve pulsed radiofrequency (PRF) and median nerve perineural injection of bupivacaine under ultrasound guidance
9671072|NCT05053477|Active Comparator|PRP Group|Patients will receive median nerve perineural injection of platelet-rich plasma (PRP) under ultrasound guidance
9694814|NCT04784832|Experimental|Sequence 4 - Cathodal|Transcranial magnetic stimulation Cathodal transcranial direct current stimulation Motor task Mental training
9973183|NCT01328470|Active Comparator|adjunctive cilostazol|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; [group 3, 20 patients]) for 14 days.
9973184|NCT01328470|Active Comparator|75mg clopidogrel|control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).
9973185|NCT01328483|No Intervention|No Intrapartum Oropharyngeal (IP-OP) Suction|Neonates randomized to No IP-OP group received supportive treatment as per standard unit protocols. They were also assessed as vigorous or non-vigorous and received care according to NRP 2005.
9973186|NCT01328483|Experimental|Intrapartum Oropharyngeal (IP-OP) suction|The neonates randomized to IP-OP group were provided oropharyngeal suctioning at the delivery of head before the delivery of shoulder, using suction machine at a negative pressure of 100mm of Hg or Dee Lee's suction trap in the event of electricity failure or non availability of suction machine.Subsequently, all the neonates born through MSAF were assessed by pediatrician as vigorous or non vigorous and provided care as per NRP guidelines 2005.
9973187|NCT01328509||Sepsis|Patients with sepsis
9973188|NCT01328509||Control|Patients with no clinical evidence of sepsis, but who are critically ill
9973189|NCT01328522|Experimental|SAR153191 drug product 1|"SAR153191 drug product 1 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
9973190|NCT01328522|Experimental|SAR153191 drug product 2|"SAR153191 drug product 2 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
9973191|NCT01328639|Active Comparator|Usual Care|Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.
9973192|NCT01328639|Experimental|TeamCare Depression Intervention|Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.
9973193|NCT01328652|Experimental|Proton Pump Inhibitor|Treatment with dexlansoprazole 60 mg once daily for 3 months
9973194|NCT01328665|Experimental|Expressive Writing|Affectionate Writing Intervention for 20 minutes per day, 2 times per week, 6 weeks.
9973195|NCT01328665|No Intervention|No writing|Control Group -- No writing
9973196|NCT01328678||Alopecia Areata|Individuals with Alopecia Areata (AA)
9973197|NCT01328704||Triathletes|Group of individuals who are participating in a triathlon training program at the Avera Sports Institute
9973198|NCT01328730|Experimental|Firebird 2 stent group|patients who were implated with Firebird 2 SES
9973199|NCT01328730|Active Comparator|Cypher Stent Group|patients who were implanted with Cypher SES
9973200|NCT01328821|Placebo Comparator|Part A|"Single ascending dose administration of four doses of CTP-499 as tablets under fasting condition.~8 subjects per dose group will be enrolled with a 3:1 randomization of active drug to placebo.~Dose levels: 600mg -> 1200mg -> 1800mg -> 2400mg"
9973201|NCT01328821|Active Comparator|Part B|Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.
9973202|NCT01328834|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase
10156048|NCT04038762|Active Comparator|Conventional nasal intubation|Passage of an endotracheal tube via the nare followed by video laryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
10156049|NCT04038762|Experimental|Nasotracheal Intubation with cuff inflation-deflation method|Nasotracheal intubation placed with video laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
9973203|NCT01328860|Experimental|Biologic; Stem Cells|
9973204|NCT01328886|Experimental|Omalizumab|
9694815|NCT04784832|Experimental|Sequence 4 - Anodal|Transcranial magnetic stimulation Anodal transcranial direct current stimulation Motor task Mental training
9973205|NCT01328899|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
9973206|NCT01328912|Experimental|Remote ischemic preconditioning stimulus|
9973207|NCT01328912|Placebo Comparator|Control|
9973208|NCT01328925|Experimental|Nitazoxanide Oral Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml
9973209|NCT01328925|Placebo Comparator|Placebo Oral Suspension|Placebo Oral Suspension
9973210|NCT01328938|Experimental|Stage I - Arm I: GCPGC I (3.6mg)|GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
9973211|NCT01328938|Experimental|Stage I - Arm II: GCPGC II (6mg)|GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
9973212|NCT01328938|Experimental|Stage II - Arm I: GCPGC|"GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).~The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I."
9973213|NCT01328938|Active Comparator|Stage II - Arm II: Neulasta|Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)
9973214|NCT01328977|Active Comparator|emails, book|
9973215|NCT01328977|Active Comparator|didactic teaching from experts|
9973216|NCT01328977|Experimental|personal coaching by development profs|
9973217|NCT01329003||exposed workers|At least six months of occupational exposure to Caesar stone
9973218|NCT01329016|Active Comparator|GDM Subjects|Women with GDM requiring treatment
9973219|NCT01329016|No Intervention|Non-pregnant Type 2 Diabetes Milletus Subjects|Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment
9973220|NCT01329016|No Intervention|Healthy Pregnant Women|Healthy pregnant women with normal 1-hour glucose tolerance test
10156050|NCT04039165|Experimental|Intervention Group|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, and complete a group walk or indoor exercise during the group sessions. The investigators will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program. During times when in-person visits cannot happen (e.g., COVID-19), we will do virtual group sessions instead of meeting at the clinics, conducted via videoconference platform (i.e., Zoom), the group walks will not happen, and all exercise will be done individually to comply with social distancing measures.
10156051|NCT04039165|No Intervention|Wait-list Control Comparison Group|Participants in the waitlist control group will not receive any active intervention during the initial study period (weeks 1-9). At Week 10, this group will receive the same intervention and assessments as described in the active treatment group above.
10156052|NCT04038814||VAP1 - historical group|Routine prevention of VAP
10156053|NCT04038814||VAP2 - study group|Modified prevention of VAP
10156054|NCT04038723|Experimental|Pre- and Post-HIIT|Participants will be evaluated before and after exercise training.
10156055|NCT04038918|Experimental|Progressive Muscle Relaxation Exercise Group|Standard postoperative physiotherapy program plus progressive muscle relaxation (PMR) exercise will be applied.
10156056|NCT04038918|Other|Control Group|Standard postoperative physiotherapy program will be applied.
10156057|NCT04039178|Active Comparator|Treatment group|Real BQ treatment, 40 treatments including 20 minutes of device guided functional motor tasks.
10156058|NCT04039178|Sham Comparator|Control group|Sham BQ treatment, (zero intensity) 40 treatments including 20 minutes of device guided functional motor tasks.
10156059|NCT04038801|Active Comparator|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed over four visits at 1-weekly intervals using an assortment of manual periodontal curettes.
10156060|NCT04038801|Experimental|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
10156061|NCT04038801|Experimental|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
10156062|NCT04038398|Other|FiO2 : 100% - 50% - 21%|see above
10156063|NCT04038398|Other|FiO2: 21% - 50% - 100%|see above
10156064|NCT04038684|Experimental|Mindfulness-Based Weight Control|All participants will be randomly assigned to a 12-session group-based Mindfulness-Based Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the MBWC intervention will receive mindfulness curriculum informed by Mindfulness-Based Stress Reduction plus the standard behavioral weight control components. Group sessions will be approximately 60 minutes each week. Outside of group sessions, participants will be asked to engage in dietary self-monitoring (MBWC and SBWC groups) and practice mindfulness skills (MBWC only).
10156065|NCT04038684|Active Comparator|Standard Behavioral Weight Control|All participants will be randomly assigned to a 12-week group-based Mindfulness-Based Behavioral Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the SBWC intervention will receive the SBWC without mindfulness components. Each of the 12 group sessions will be approximately 60 minutes. Outside of group sessions, participants will be asked to practice dietary self-monitoring at home during the week.
10156066|NCT04038411|Experimental|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 Antibody: 240mg, d1, Chidamide: 20mg, twice a week, Lenalidomide: 25mg, d1-14 Etoposide:100mg/m2, d1-3 and 21 days made one treatment cycle.
10156067|NCT04038437|Experimental|CPX-351 and Venetoclax|CPX-351 and Venetoclax will be administered over 28 day cycles
10156068|NCT04038424|Experimental|Study group|The intervention group (n = 30) will receive Routine Hospital Management (RHM), conventional rehabilitation activity and AT (painting, coloring, listening to music and Hand Therapy Ball Exercises). Overall 9 sessions over a period of three weeks will be performed and each session will take around 30 min.
10156069|NCT04038424|No Intervention|Control group|The control group (n = 30) will receive only the Routine Hospital Management (RHM) and the department conventional rehabilitation activity.
10156070|NCT04038606|Active Comparator|acceptance of mastectomy|Assess the determinants of acceptance of mastectomy based on personal background,Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
10156071|NCT04038606|Experimental|rejection of mastectomy|Assess the determinants of rejection of mastectomy based on personal background, Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
10156072|NCT04038710||Patients with severe disease|Patients that are eligible to enroll in Vertex's triple combination therapy through the expanded access program.
10156073|NCT04038450||Practicing Physical Therapists|licensed physical therapists currently practicing
10156074|NCT04038450||Student Physical Therapists|students currently enrolled in DPT program
10156075|NCT04038476|Other|Standard monitoring|"When assigned to the group Standard monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. The examiner (doctor or physicians involved in the study) are blinded to the transcutaneous CO2 measurement. An adjustment of the sedation management therefore takes place on the basis of the monitoring measures mentioned above. Transcutaneous CO2 monitoring is recorded in the background (Excel table of all registered values) and also monitored by the sedation assisting nurse and integrated into the standard sedation protocol."
10185896|NCT03741244|Active Comparator|Temozolomide|Patients were treated with postoperative concurrent chemoradiation.Then Temozolomide alone chemotherapy 6 cycles(first cycle 150mg/m2/d d1-5, later 200mg/m2/d d1-5 q28d).
9520076|NCT03280706|Active Comparator|Coffee with milk|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of coffee with milk, 200kcal, 10,6g of protein, 10,73g of fat, 14,9g of carbohydrate.
9694816|NCT04784832|Experimental|Sequence 4 - Immobilization|Transcranial magnetic stimulation Arm immobilization Motor task Mental training
9973221|NCT01329055||Hemodialysis patients|
9973222|NCT01329068|Active Comparator|Individual consult|regular individual consult
9973223|NCT01329068|Active Comparator|group medical consult|regular group medical consult
9973224|NCT01329081|Experimental|Six weeks strength training in teams and patient education|
9973225|NCT01329081|Experimental|Supervised home training with focus on activities|
9973226|NCT01329094||Patients with severe mental illness|In-patients and out-patients with severe mental illness attending treatment at Aarhus University Hospital, Risskov.
9973227|NCT01329094||Healthy controls|Healthy controls recruited from staff members at Aarhus University Hospital, Risskov
9973228|NCT01329107|No Intervention|No intervention|Standard Care
9973229|NCT01329107|Experimental|Multimodal intervention|Intervention group will be assigned to specific decribed multimodal intervention
9973230|NCT01329120||Pectus excavatum|Patients who has undergone minimally invasive repair of pectus excavatum
9973231|NCT01329120||Pectus carinatum|Patients who has undergone open surgical repair of pectus carinatum
9973232|NCT01329133|Active Comparator|DBS of subthalamic nucleus|
9973233|NCT01329133|Active Comparator|DBS of ventral striatum|
9973234|NCT01329172|Experimental|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 (PUFA n-3)
9973235|NCT01329172|Placebo Comparator|placebo|sun flower oil
9973236|NCT01329211||Gastroparesis Patients|
9520077|NCT03280680|Experimental|Female+male group sessions|
9520078|NCT03280680|Experimental|Female group sessions|
9520079|NCT03280680|Other|No group sessions|
9694817|NCT04784988|Experimental|PROPEL-like arm|Adynovate prophylaxis targeting a 12% FVIII through level based on PK assessment with my-PK-fit
9694818|NCT04784988|Active Comparator|Control arm|standard treatment with plasma derived or recombinant products containing FVIII according to current guidelines
9973237|NCT01329211||Gastroparesis Patients' Caregivers|
9973238|NCT01329224||TAM patients|All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
9973239|NCT01329237|Other|dynamic physical exercise OCT|dynamic physical exercise and optical coherence tomography imaging
9973240|NCT01329250|Experimental|Moxifloxacin|Moxifloxacinin escalating dose
9973241|NCT01329276|Other|Symbicort® forte Turbohaler®|
9973242|NCT01329276|Placebo Comparator|Placebo (lactose)|
9973243|NCT01329289|Experimental|SOM230 with Bortezomib and Dexamethasone|
9973244|NCT01329302|Active Comparator|Group A: Direct aspiration|
9973245|NCT01329302|Active Comparator|Follicular Flushing|
9973246|NCT01329315|Active Comparator|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
9973247|NCT01329315|Active Comparator|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
9973248|NCT01329315|No Intervention|DPB|Drug Prevention Booklet (DPB)- National Institute on Drug Abuse (NIDA)-developed drug prevention booklet to address preventing marijuana initiation, and marijuana use.
9973249|NCT01329354|Experimental|Autologous effector lymphocytes|
9973250|NCT01329367|Active Comparator|Control group|"Control group: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
9973251|NCT01329367|Experimental|Protein group|"Protein group: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
9973252|NCT01329367|Experimental|Antioxidant group|"Antioxidant group: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
9973253|NCT01329393|Experimental|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
9973254|NCT01329393|Active Comparator|Illness Management and Recovery|
9973255|NCT01329406|Experimental|Milnacipran|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
9973256|NCT01329406|Placebo Comparator|Placebo|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
9973257|NCT01329432|Sham Comparator|take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
9973258|NCT01329432|Experimental|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
9973259|NCT01329445||DeNovo NT patient|Patients who have received or who are scheduled to receive a DeNovo NT graft for repair of 1-2 knee cartilage lesions.
9973260|NCT01329458||Focal liver lesions|Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound
9973261|NCT01329471||Umbilical cord blood|
9973262|NCT01329484|Experimental|Cognitive training|
9973263|NCT01329484|Experimental|Reminiscence therapy|
9973264|NCT01329484|Other|Control|This group will receive neither of the above interventions or any other similar interventions
10156076|NCT04038476|Other|Standard monitoring + transcutaneous CO2 monitoring|"When assigned to the group Standard monitoring + transcutaneous CO2 monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. In this group, the values of transcutaneous, continuous CO2 monitoring, including an alarm sound, are accessible to the treating physicians. Moreover, sedation management is adjusted on the basis of transcutaneous CO2 measurement. The above-mentioned measurements of the standard monitoring are carried out as described, in addition there is the the transcutaneous CO2 monitoring."
10156077|NCT04038528||Telemedicine Group|Patients in this group monitor blood sugar levels at home and upload their data through a telemedicine systems.
10156078|NCT04038528||Control Group|The control group will attend their routine appointments scheduled by their GPs and specialists in outpatient clinics and will record blood sugar levels according to the traditional method as per GP or specialist physician's indications.
10156079|NCT04038658|Experimental|Intervention Group (MoveIt)|10-minute Qigong exercise session (video demonstration via website) delivered twice a day at set break times during the working day for 12 consecutive weeks
10156080|NCT04038658|No Intervention|Wait-list control group|No intervention for 12 weeks. Then received the MoveIt Intervention for 12 weeks.
10156081|NCT04038554||Acute Pancreatitis|Patients older than 18 years old diagnosed of acute pancreatitis according to Atlanta 2012.
10156082|NCT04038554||Healthy Control|Healthy people with a proximity relationship with case patients and similar age (+/- 5 years).
10156083|NCT04038645|Active Comparator|Experimental Group (laser)|"The patients (n=18) will receive infrared LEDs in 6 points (3 on the right side and 3 on the left side) using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt (mW) . The LED light outputs will be positioned in direct contact with the skin. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
10156084|NCT04038645|Placebo Comparator|Control group (Placebo)|The patients (n=18) will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days (by the same evaluator), as well as the evaluation of serum CRP.
10156085|NCT04038619|Experimental|Treatment (loperamide, colonoscopy, FMT)|Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
10156086|NCT04038463|Experimental|Early Follicular Phase (EFP)|The group will engage in the Resistance Training intervention on the fourth day of their menstrual cycle, which will correlate with the middle of the early follicular phase (EFP).
10156087|NCT04038463|Experimental|Late Follicular Phase (LFP)|The group will engage in the Resistance Training intervention on the eleventh day of their menstrual cycle, which will correlate with the middle of the late follicular phase (LFP).
10156088|NCT04038463|Experimental|Early Luteal Phase (ELP)|The group will engage in the Resistance Training intervention on the eighteenth of their menstrual cycle, which will correlate with the middle of the early luteal phase (ELP).
10156089|NCT04038463|Experimental|Late Luteal Phase (LLP)|The group will engage in the Resistance Training intervention on the twenty-fifth day of their menstrual cycle, which will correlate with the middle of the late luteal phase (LLP).
10156090|NCT04038320||HCV infected patients|All HCV infected confirmed by HCV RNA,
10156091|NCT04038632|Experimental|District Hospital focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be implemented at the DH level. PHCs in this district, will only conduct systematic TB screening.
10156092|NCT04038632|Experimental|Primary Health Center focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be done at the PHC.
10156093|NCT04038671|Experimental|Activated Carbon Dressing|A low-adherent, comprised of 100% pure activated carbon and also conforms to body contours to maintain contact with the incision surface. The dressing may be used either dry or moistened with sterilized water over dry or discharging, partial and full thickness wounds.
10156094|NCT04038671|Active Comparator|Knitted Cellulose Acetate Mesh|a non-adhering dressing, comprised of a knitted cellulose acetate mesh impregnated with a specially-formulated petrolatum emulsion.
10156095|NCT04038671|Active Comparator|Antimicrobial Alginate Dressing with Silver|a non-adherent antimicrobial alginate dressing with silver
10156096|NCT04038307|Placebo Comparator|control|will receive 100 ml of saline
10156097|NCT04038307|Experimental|paracetamol group|will receive 1gm paracetamol (100ml)
10156098|NCT04038359|Experimental|Duvelisib, Continuous and Intermittent Dosing|Duvelisib 25 mg BID continuously for 10 weeks, followed by 25 mg BID dosed two weeks on and two weeks off of each subsequent 4-week cycles.
10156099|NCT04038359|Experimental|Duvelisib, Intermittent Dosing|Duvelisib 25 mg BID dosed two weeks on and two weeks off.
10156100|NCT04038294|Experimental|Protein Supplementation|The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).
9694819|NCT04784676|Experimental|nanohybrid composite blocks|nanohybrid composite CAD/CAM blocks
9694820|NCT04784676|Active Comparator|ceramic blocks|ceramic CAD/CAM blocks emax
9520080|NCT03280667|Experimental|Pembrolizumab plus Denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D, continued until disease progression or prohibitive toxicity
10156101|NCT04038294|Placebo Comparator|Placebo Supplementation|Enrolled patients allocated to the control group will receive the same supplementation schedule as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no nutritional benefit).
10156102|NCT04038216||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
9520081|NCT03280654||Group 1:VAI levels <7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 Group 1 was defined as VAI levels <7,55
9520082|NCT03280654||group 2:VAI levels >=7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 group 2 was defined as VAI levels >=7,55
9671073|NCT05053724|Experimental|Start to move group|In the Start to move group, physical therapy was included according to the Gosselink protocol, which establishes 6 levels of care divided according to system stability and state of consciousness. At level 0, no physical mobilization therapy was applied due to systemic lability. From level 1 to 5, passive mobilizations, use of muscle electrostimulation, active mobilizations and exercises against resistance, application of conventional cycloergometer, up to walking with assistance if the subject is able to perform it.
9671074|NCT05053724|Active Comparator|Conventional treatment group|In the conventional treatment group, passive mobilization, active-assisted mobilization and exercises against resistance, facilitation of high functional positions such as sedentary, bipedal and walking were applied, according to conventional treatment protocol.
9671075|NCT05053178|Experimental|Intervention group|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented.
10156103|NCT04038216||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures.
9671076|NCT05053178|No Intervention|Control group|For the students in the control group, the standard support program given by the school administration and course instructors will be applied for clinical problems. At the end of the study, it is planned to apply mandala activities among the students in the control group
9694821|NCT04784897|Experimental|Brilacidin + SoC|Brilacidin IV infusion, 3 days and up to 5 days, in addition to Standard of Care
10156104|NCT04038229|No Intervention|Standard of care|Prospective derived data from children and adolescents undergoing spinal fusion due to idiopathic scoliosis
10156105|NCT04038229|Experimental|Enhanced recovery pathway|Children and adolescents undergoing spinal fusion due to idiopathic scoliosis using the pre -per and postoperative enhanced recovery protocol
10156106|NCT04037891|Experimental|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in an open-label manner at intervals of 1 week and will have weekly clinic visits until Day 14, after which the visit will be every two weeks. When the first 3 patients have completed two weeks of treatment and the safety and tolerability data has been reviewed by the PI and an independent clinician, provided the data is favourable the randomisation process will begin (Part 2). The first 3 patients will continue treatment for a total of 8 weeks and will be assessed throughout the trial by the Principal Investigator according to the Schedule of Events Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
10156107|NCT04037891|Placebo Comparator|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
10156108|NCT04037982|Experimental|LPD|In this group, patients will undergo laparoscopic pancreaticoduodenectomy.
10156109|NCT04037982|Active Comparator|OPD|In this group, patients will undergo open pancreaticoduodenectomy.
10156110|NCT04038008|Other|Sequence AB|13 subjects assigned to the sequence AB will receive a single 200 mg dose of test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 1 and a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
10156111|NCT04038008|Other|Sequence BA|13 subjects assigned to the sequence BA will receive a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in Period 1 and test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
10156112|NCT04038034|Placebo Comparator|group A|35 patients treated with pressure lowering drugs and placebo
10156113|NCT04038034|Experimental|group B|35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
10156114|NCT04037878|Experimental|TAP block group|Patients in this arm will be given Transversus Abdominal Plane(TAP) block after the induction of anesthesia. They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
10156115|NCT04037878|Experimental|Local infiltration|Patients in this arm will be given local and intraperitoneal infiltration of local anesthetic before closure.They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
9520083|NCT03280641||Dabigatran Group|Patiets with atrial fibrillation received dabigatran (110mg, bid).
9520084|NCT03280641||Warfarin Group|Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
9694822|NCT04784897|Placebo Comparator|Placebo + SoC|Placebo IV infusion, 3 days and up to 5 days, in addition to Standard of Care
10156116|NCT04037878|Other|Control group|These patients will be given post operative analgesia in the form of patient controlled intravenous analgesia(PCIA) using tramadol. Neither local infiltration nor TAP block will be administered
9694823|NCT04785014|Experimental|aspiration group|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
9973265|NCT01329497|Experimental|interventional group|
9973266|NCT01329510|Experimental|methylphenidate|
10156117|NCT04038060|Experimental|WhatsApp Group|Participants will be assigned to participate in a WhatsApp Group
10156118|NCT04038060|Experimental|2-way SMS|Participants will be assigned to receive weekly 2-way SMS initiated by the study team
10156119|NCT04038060|Experimental|2-way SMS and monthly counseling sessions|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and monthly counseling sessions
10156120|NCT04038060|Experimental|2-way SMS and drug level feedback|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and drug level feedback
10156121|NCT04038060|Experimental|WhatsApp Group and monthly counseling sessions|Participants will be assigned to participate in a WhatsApp Group and monthly counseling sessions
10156122|NCT04038060|Experimental|WhatsApp Group and drug level feedback|Participants will be assigned to participate in a WhatsApp Group and drug level feedback
10156123|NCT04038151|Experimental|Condition A: Hybrid Leg|Subject will be trained on use of the experimental device, the Hybrid Leg.
10156124|NCT04038151|Other|Condition B: Passive Leg|Subject will use their currently prescribed home passive prosthesis
10156125|NCT04038177|Experimental|Superset strength training|This is the experimental group that performs strength training with sets and rest intervals programmed in a superset manner
10156126|NCT04038177|Active Comparator|Traditional strength training|This is the comparator group that engages in strength training with sets and rest intervals programmed in accordance with the recommendations from The American College of Sports Medicine
10156127|NCT04038125|Other|Ozurdex Implant|Intravitreal injection of Ozurdex implant
10156128|NCT04038242|Experimental|Resilience promotion program|Subjects in the intervention group will participate in an eight-session resilience promotion program.
10156129|NCT04038242|No Intervention|Treatment as usual|Treatment as usual for subjects in the control group.
10156130|NCT04037787|No Intervention|Usual care|Perioperative care for colorectal cancer cancer is managed according to current hospital clinical practice.
10156131|NCT04037787|Experimental|ERAS protocol|Perioperative care for colorectal cancer surgery is managed according to ERAS protocol.
10156132|NCT04038164|Experimental|Dog-Assisted Therapy (DAT) and pharmacological treatment|The DAT program comprised 12 manualized sessions and included two phases: 1) individual intervention (6 sessions) and 2) group activity (6 sessions). Patients participated in weekly sessions for about 3 months. Each session lasted 45 minutes. The groups were formed by 3-4 patients. Sessions included the participation of two certified therapy dogs, two technicians specialized in DAT and a psychologist. Participants in this group were visited by their psychiatrist in order to monitor their adherence to medications.
10156133|NCT04038164|Active Comparator|Treatment as usual (TAU, pharmacological treatment)|Participants received their usual treatment. They were visited by their psychiatrist in order to monitor their adherence and continuation on medications as prescribed. Inclusion and exclusion criteria were the same as for the experimental group. Participants in the TAU group did not receive DAT sessions.
10156134|NCT04038021|Experimental|PEth-based CM|PEth-based CM participants will receive gift cards (starting at $30) each time they submit a blood spot sample (via finger prick ) with a negative alcohol result. They will receive an additional $5 (building on the previous amount) for each additional negative alcohol result in a row. There is a cap at $100 for each negative result.
10156135|NCT04038021|Active Comparator|Non-contingent Control|Non-contingent control participants will receive gift cards each visit if they provide a pinprick blood sample regardless of whether the results are positive or negative for alcohol. Their level of reinforcement (amount in gift cards) will be equal to the average weekly CM earnings from the previous month.
10156136|NCT04038073||ADHD|Attention Deficit/Hyperactivity Disorder
10156137|NCT04038203||Neonates with UAC placement|Neonates with birth weight less than 1500 grams with UAC placed on admission. Raman measurements will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
9973267|NCT01329523||Subjects with AD|Subjects with a diagnosis of dementia
10156138|NCT04038112|Other|Method of Levels (MOL)|all participants will be offered intervention
10156139|NCT04037904||H. pylori negative group|Subjects who have not have H. pylori infection, and had not receive H. pylori eradication
10156140|NCT04037904||H. pylorieradicated group|Subjects who have had H. pylori infection currently and received successful H. pylori eradication according to appropriated indication
10156141|NCT04037826|Experimental|L. reuteri Gastrus|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475)
10156142|NCT04037826|Placebo Comparator|Placebo|Placebo chewable tablets
10156143|NCT04037774|Active Comparator|dex 5microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 5micrograms of dexmedetomidine.
10156144|NCT04037774|Active Comparator|dex 10microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 10micrograms of dexmedetomidine.
10156145|NCT04037774|Placebo Comparator|placebo|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of placebo.
10156146|NCT04037644|Experimental|Albumin|fluid loading with 200 mL of 4% albumin over a 10' interval
10156147|NCT04037644|Active Comparator|Ringer Lactate|fluid loading with 5 mL/kg actual body weight of Ringer Lactate over a 10' interval
10156148|NCT04037540|Experimental|Operational approach|The patients enrolled in this arm underwent surgical treatment of the Jones fracture.
10156149|NCT04037540|Experimental|Conservative approach|The patients enrolled in this arm were treated conservatively, using fixation of the injured extremity.
10156150|NCT04037943|Experimental|Low-dose group|Low-dose group will received 30 grams of walnuts everyday during the study period of 6 months.
10156151|NCT04037943|Experimental|High-dose group|High-dose group will received 60 grams of walnuts everyday during the study period of 6 months.
10156152|NCT04037943|No Intervention|Control group|Control group will received non-edible gifts during the study period of 6 months.
10156153|NCT04038190|Experimental|Behavioral Activation Course|Behavioral activation course condition administered in a college freshman orientation seminar
10156154|NCT04038190|No Intervention|Standard Orientation Course|Standard freshman orientation seminar course condition
10156155|NCT04037852|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
10156156|NCT04037852|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
10156157|NCT04037852|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
10156158|NCT04037709|Placebo Comparator|scaling and root planing (SRP) + PDT placebo|"17 patients will receive periodontal treatment (scaling and root planing - SRP) with universal curettes and ultrasound depending on their needs. The SRP will be done in one session. Periodontal treatment will be performed by only one experienced researcher, who will not do the periodontal exams. Periodontal reassessment will be performed after 7 and 21 days.~The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application."
10156159|NCT04037709|Experimental|scaling and root planing (SRP) + PDT|"17 patients will receive the same scaling and root planing treatment that placebo group.~However the PDT will be done using methylene blue 0.005% - Chimiolux 5, DMC - purified water and methylene blue.The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pocket."
10156160|NCT04037618|Experimental|[14C]-EYP001a|[14C]-EYP001a dose A containing 100 μCi radioactivity
10156161|NCT04037722|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
9694824|NCT04785014|Active Comparator|control group|no aspiration was performed in the control group. Additionally, the participants in both groups were trained on how to perform exercises and were also recommended to practice cold treatment for 15 min both in the morning and evening for 2 weeks.
9973268|NCT01329523||Family Members|Younger biological family members of the patients with dementia
10156162|NCT04037722|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
10156163|NCT04037722|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
10156164|NCT04037670|Experimental|SASI bypass|Patients with super obesity underwent SASI bypass
10156165|NCT04037553||Group 1|Patients underwent right ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the left) was applied to the patients and ICP values were documented following 3 respiration cycles.
10156166|NCT04037553||Group 2|Patients underwent left ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the right) was applied to the patients and ICP values were documented following 3 respiration cycles.
10156167|NCT04037553||Group 3|Patients underwent left head and neck surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, gel pillow with the height of 4,5 cm was placed under the shoulders of patients to extend the neck. Following 3 respiration cycles, the ICPs were noted. Then, right or left lateral neck rotation was applied depending on the operation side (approximately 60-70 degree to the opposite site). After 3 respiration cycles, ICPs were documented again.
10156168|NCT04037592|Experimental|Active standardized iTBS-DMPFC|This active group will receive standardized dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
10156169|NCT04037592|Experimental|Active high-dosage iTBS-DMPFC|This active group will receive high dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
10156170|NCT04037592|Sham Comparator|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Patients in the sham group will receive the same standardized or high-dosage iTBS performing by a sham coil
10156171|NCT04037579||Down Syndrome Cordoba Association|The participant will answer a questionnaire related to social skills and physical activity
10156172|NCT04037579||Down Syndrome Granada Association|The participant will answer a questionnaire related to social skills and physical activity
10156173|NCT04037579||Down Syndrome Malaga Association|The participant will answer a questionnaire related to social skills and physical activity
10156174|NCT04037579||Observers in Cordoba|Observers from Cordoba, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
10156175|NCT04037579||Observers in Granada|Observers from Granada, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
10156176|NCT04037579||Observers in Malaga|Observers from Malaga, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
10185897|NCT03741218|Experimental|1|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast the placebo (PLA) the first time and grape (GRAP) the second time.
10185898|NCT03741218|Experimental|2|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast grape (GRAP) the first time and the placebo (PLA) the second time.
10185899|NCT03741205|Experimental|Treatment Group|SPEAC System
10185900|NCT03741205|No Intervention|Standard of Care|Standard of Care
10156177|NCT04037696|Experimental|Experimental group|The experimental group will receive individual face-to-face brief MI (about 5 minutes) on a health-related lifestyle practice. The experimental group will then receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up.
10156178|NCT04037696|Other|Control group|The control group will be given general brief advice and receive a self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
10156179|NCT04037449|Experimental|TAP block|Transversus Abdominis Plane (TAP) block technique will be carried out by a restricted group of anaesthesiologists. Standard monitoring will be applied to all patients, which will include pulse oximetry, electrocardiogram and non-invasive monitoring of blood pressure.
10156180|NCT04037449|Active Comparator|Conventional analgesia|Patients be given conventional endovenous analgesia, and morphine 2 mg / ev every 15 minutes until the level of pain measured by a Visual Analogue Scale (VAS) ≤ 3
10156181|NCT04037566|Experimental|XYF19 CAR-T cell|"One arm study consisting of 3 + 3 dose escalation study design followed by dose expansion phase at determined MTD."
10156182|NCT04037735|Experimental|ATTUNE|Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
10156183|NCT04037735|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
9671077|NCT05053113|Experimental|Group 1 (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls over 30-45 minutes each from a health coach weekly during month 1, twice monthly during months 2-4, and monthly during months 5-6 for a total of 12 phone calls that focus on identifying needs, practicing autonomy supportive behaviors, and the development of a mutual support plan. Participants also engage in at least one physical activity per week with their partner and monitor their own and each other's activity using a FitBit. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days. Participants also receive an electronic newsletter twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity.
9694825|NCT04785053|Active Comparator|Healthy young participants|a group of 20 cognitively intact younger participants (age 21-35)
10156184|NCT04037800|Experimental|SFUR-RARP|Patients in which RARP with sustainable functional urethral reconstruction (SFUR) is performed.
10156185|NCT04037800|Active Comparator|Standard RARP|Patients in which standard RARP is performed.
10156186|NCT04037488||Cohort: ADT patients|"All enrolled patient data entered in single group cohort. All patient who started androgen deprivation therapy for prostate cancer can included this cohort by following inclusion and exclusion criteria. We do not planned any intervention on this cohort. We measuring changes of body composition by Inbody 320 in the planned follow-up period.~We planned sub-group analysis for timing of intervention (Intervention 1) , ADT type(Intervention 2), LHRH agonist type(Intervention 3), patients age(Intervention 4), initial PSA level (Intervention 5) and Gleason Grade Group (Intervention 6)."
10156187|NCT04037657|Experimental|HSK3486|0.288 mg/kg ，0.432 mg/kg ，0.540 mg/kg ，0.648 mg/kg，0.810 mg/kg There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
10156188|NCT04037657|Active Comparator|Propofol|2.5 mg propofol
10156189|NCT04037501|Experimental|Intervention|
10156190|NCT04037501|No Intervention|care as usual|
10156191|NCT04037631||Patients without clinically significant age-related cataract|
10156192|NCT04037475|Placebo Comparator|Control (placebo)|The patients will receive an agent with the same vehicle as methylene blue to mimic irrigation with the photosensitizer and the laser will be switched off at the time of application. The placebo PDT procedures will be performed on the lesion: Application of methylene blue placebo with a carpule syringe and needle (with stop and without bevel) inside the lesions; 1 minute of pre-irradiation will be expected. The irradiations will be performed with the same device positioned in the same way and at the same time of application, however, the laser will be turned off. The beep sound will be recorded and turned on during application to blind treatment to the patient. The patient will receive a catheter with acyclovir cream and will be advised to spread on the lesions four times a day for 7 days, which will be their return for reevaluation. It will be washed in abundance with saline (saline solution) until the total removal of the placebo from the photosensitizer.
10156193|NCT04037475|Experimental|experimental group|Patients will be treated with photodynamic therapy and will receive a placebo ointment simulating acyclovir cream. If the lesions are in the vesicle phase, they will be ruptured with a sterile needle. The methylene blue solution at 0.005% concentration will be gently placed on the lesions. Application of methylene blue on the lesions.1 minute of pre-irradiation will be expected. The irradiations will be performed with the Laser Duo® with a wavelength of 660 nm, with a power of 100 mW(milliwatts), the energy density of 300 J / cm², with the energy of 3 J (joules) in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each lesion with energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. Patients will receive a tube with a placebo cream simulating aciclovir and the same will be advised to spread the cream 4 times per day for 7 days.
10185901|NCT03741192|Experimental|Treatment Group|SPEAC System
10185902|NCT03741192|No Intervention|Standard of Care|
9694826|NCT04785053|Active Comparator|Healthy older participants|A group of 20 cognitively intact older participants (age 55+)
9694827|NCT04785053|Active Comparator|Older MCI/mild AD participants|A group of 20 cognitively impaired older participants (age 55+)
9694828|NCT04784689||Prospective - Cancer Patients that have received COVID-19 Vaccination|
9520085|NCT03280602|Active Comparator|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
10156194|NCT04037124||Cervical procedure abandoned|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is abandoned due to intraoperatively reported lymph node matestasis. Patient is referred for primary (chemo)radiation.
10156195|NCT04037124||Cervical procedure completed|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is completed. Patient is referred for adjuvant chemoradiation.
10156196|NCT04037436|Experimental|Intervention|"At regular intervals (the steps) one cluster (i.e., one site) is randomised to cross from the control to the intervention under evaluation. This process continues until all clusters have crossed over to be exposed to the intervention. At the end of the study there will be a period when all clusters are exposed. Four sites are cluster-randomized to implement MoveSTroNg at one of four start times, each three weeks apart."
10156197|NCT04037436|Other|Control|Each cluster contributes observations under both control and intervention observation periods.
10156198|NCT04037111|Experimental|drug treatment and active VNS|At the same time, actice VNS, escitalopram oxalate tablets were treated for 2 months.
10156199|NCT04037111|Sham Comparator|drug treatment and sham VNS|It received oxacillin oxalate tablets and sham VNS for 2 months.
10156200|NCT04037111|Other|drug treatment|The dose of escitalopram oxalate tablets was maintained at 10-20mg/ day without VNS stimulation.
10156201|NCT04037202|Experimental|Study Group|"The first session of the foot massage was performed after mothers were taken to the postpartum service and after the effect of the first analgesia had elapsed (4-6 hours after birth).~The researcher prepared the mother for foot massage (foot care, proper position, etc.) and gave a total of 20-minute massage of foot massage, 10 minutes for each foot. VAS was repeated immediately after the first session (in the 20th minute) and after 30 minutes (in the 50th minute). The second session was performed on the second day, 20-24 hours after the first session (before the discharge). The VAS was analyzed before the second (last) session (0th minute), and the VAS was repeated immediately after the application (20th minute) and 30 minutes (50th minute), and the PCS was administered for the last time. Administered analgesics were recorded in the DFC and the administration made with package leaflet was supported."
10156202|NCT04037202|No Intervention|Control Group|Routine procedures were applied and VAS was repeated at the same time periodical as the study group mothers (0th, 20th and 50th minute) and after 20-24 hours (before discharge), at the same time intervals (0th, 20th and 50th minute) pain status was measured by using VAS and PCS was administered for the last time and analgesics administered were recorded on the DFC.
10156203|NCT04037176|Active Comparator|Omalizumab|"Omalizumab is a sterile solution in a prefilled syring for subcutaneous injection. The syrings contains 75 mg or 150 mg omalizumab.~75 patients will have Omalizumab in doses depending of body weight and IgE every 2. or 4. week for 6 month Omalizumab is administered subcutaneously"
10156204|NCT04037176|Placebo Comparator|Placebo|"Placebo contains sodium chloride 0,9 % in a prefilled syring for subcutaneous injection.~25 patients will have placebo depending of the body weight and IgE every 2. or 4. week in 3 month. They will subsequently get Omalizumab for 3 month if nonresponders.~Placebo is administered subcutaneously"
10156205|NCT04037319||Main cohort|Will undergo surgery for colorectal cancer with curative intent as planned by local cancer multidisciplinary team.
10156206|NCT04037332||Pre-RAS roll-out . Group I|I. Children presenting directly to a referral health facility without prior administration of RAS (pre-RAS): provides a baseline assessment of artemisinin resistance marker prevalence before the introduction of RAS
10156207|NCT04037332||Post-RAS roll-out - Group II|II. Children presenting directly to a referral health facility without prior administration of RAS (post-RAS): group not receiving pre-referral RAS and hence having baseline pressure for K13 resistance markers.
10156208|NCT04037332||Post-RAS roll-out - Group III|III. Children receiving pre-referral RAS from community-based provider and successfully referred to a referral health facility: group receiving pre-referral RAS (monotherapy).
10156209|NCT04037332||Post-RAS roll-out - Group IV|IV. Children receiving pre-referral RAS from community-based provider but not completing referral to a referral health facility, followed-up at their home on day 28: children malaria-positive on Day 28 may have an increased chance of harboring a resistant infection.
10156210|NCT04037280|Experimental|Isometric strenghtening 1|once a day (1RI): patients in this group will have to play 20 tonic contractions of Pelvic Floor Muscle with a duration of 5 seconds each, performed in supine position), in sitting position and in standing position.
9694829|NCT04784741|Other|Control group|The control group was given the static hamstring muscle stretches, five sessions on alternative days according to the set protocols.
10156211|NCT04037280|Experimental|Isometric strenghtening 2|twice a day (2RI): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
10156212|NCT04037280|Experimental|Functional strenghtening 1|once a day (1RF): patients in this group will have to play 10 times the postural passage from supine position to sitting position on a bed and 10 times the postural passage from sitting position to erect position (STS), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional act. In sequence, starting from erect position, they will have to play 10 trunk flexion bending their knees (as to pick up an object on the ground), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional movement.
10156213|NCT04037280|Experimental|Functional strenghtening 2|twice a day (2RF): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
10156214|NCT04037098|Experimental|Magnesium|Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
10156215|NCT04037098|Placebo Comparator|Control|2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.
10156216|NCT04037358|Experimental|Radium-223 and SABR|First radium-223 infusion will be within two weeks of SABR
10156217|NCT04037358|Active Comparator|SABR|SABR(1-5 fractions) will be administered for all men
9694830|NCT04784741|Experimental|Experimental Group|Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.
10156218|NCT04037423||PE patients treated with CDT|Acute pulmonary embolism patients undergoing catheter-directed embolectomy.
10156219|NCT04037514|Experimental|Paracetamol|Intravenous paracetamol 15 mg/kg/6h for 3 or 6 days
10156220|NCT04037514|Active Comparator|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24 h (day 1) and 5 mg/kg/24h (day 2 and 3) for 3 or 6 days
10156221|NCT04037306|Active Comparator|Rapid Feedback|Participants received daily feedback on both fiber intake and stool butyrate measurements.
10156222|NCT04037306|Active Comparator|Delayed Feedback|Participants received daily feedback on fiber intake and one-time feedback on stool butyrate measurements at the end of the study period.
10156223|NCT04037384|Active Comparator|Eye Yoga group|Eye yoga exercises
9671078|NCT05053113|Active Comparator|Group 2A (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls from a health coach as in Intervention I that focus on providing support for behavioral skills, including monitoring physical activity, goal-setting, and problem-solving to overcome barriers to physical activity. Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
9671079|NCT05053113|Active Comparator|Group 2B (FitBit, newsletter, accelerometer)|Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 to share basic health education related to physical activity and provide support for engagement. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
10156224|NCT04037384|Placebo Comparator|Reading Group|Passive reading
10156225|NCT04037267|Experimental|Endoscopic Treatment|Endoscopy was performed using a rigid endoscope. The hematoma was removed by a technique using irrigation and aspiration. The ventricular drainage catheter was placed on the surgical side. Six hours after surgery, we administered 20,000 U urokinase with 5 ml saline every 8 hours through the catheter and the catheter was closed for 1 hour to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
10156226|NCT04037267|Active Comparator|EVD Treatment|The surgeons used a soft catheter to puncture in depth of about 5 cm. The next step was to fix the drainage catheter. Postoperative CT was done immediately to confirm positioning of the soft catheter and stability of the hematoma. Six hours or more after catheter placement, we administered 20,000 U urokinase with 5 ml saline every 8 hours and the catheter was closed for 1 h to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
10156227|NCT04037163||CCTA-FFR|Patients who underwent CCTA within 90 days before FFR measurement will be included in the present study.
10156228|NCT04037345|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
10156229|NCT04037345|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
10156230|NCT04037345|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
10156231|NCT04037085|Experimental|Ketamine|Ketamine - IV after cord clamping; IV infusion for 12 hours OR in the weaning population IV Ketamine infusion for 12 hours in the Montefiore CTRC
10156232|NCT04037397|Active Comparator|Antiarrhythmic Medications|Patients randomized to the antiarrhythmic drug group are administered medications approved for treatment of AF by the regulatory bodies of each participating country. The selection of antiarrhythmic drugs and dosages is left to the discretion of the investigator, and will follow the AHA/ACC/HRS general guidelines
10156233|NCT04037397|Active Comparator|Radio Frequency Catheter Ablation|Patients randomized to radiofrequency catheter ablation will undergo isolation of the pulmonary veins with confirmation of entrance block into each vein. The CARTO TM(Biosense Webster, CA) system will be used to reconstruct the atrial geometry and assist for mapping and ablation. Ablation will be performed using approved ablation devices (Biosense Webster, CA).
10156234|NCT04037046|Experimental|Screening HCV with DBS at primary care centers|Patients assigned to the strategy 1 will receive an invitation letter for HCV screening with DBS at the primary care center to be performed by the general practitioner
10156235|NCT04037046|Active Comparator|Screening HCV and CCR with FOT at primary care centers|Patients assigned to the strategy 2 will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
10156236|NCT04037046|Active Comparator|Self-testing at home for screening HCV and CCR|Patients assigned to the strategy 3 will receive an invitation letter for self-testing at home for HCV screening with DBS, and CCR screening with FOT
10156237|NCT04036812|Experimental|Superficial cervical plexus block group|
10156238|NCT04036812|Sham Comparator|Control group|
10156239|NCT04036825|Experimental|Liquid Nutritional Supplement from Hospital Product|This group received liquid nutritional supplement from hospital product. The product is in a form of low lactose milk ready to drink with volume 200 ml and will be given 2 times daily for 14 days. This product is consist of 1.017 kcal/ml, 10 vitamin and 9 mineral
10156240|NCT04036825|Placebo Comparator|Placebo|This group received standard liquid nutritional supplement as a placebo. Placebo will be given 2 times daily for 14 days
10185903|NCT03741166||Subject aged 45-49 with Average CRC Risk|Subjects will be men and women, 45-49 years of age, who enroll in Exact Sciences Protocol 2018-10. Subjects will provide a blood sample at time of enrollment.
10156241|NCT04036955|Experimental|intervention group|"The INFOSA-DEM programme consists of five, 90-minute informational/training sessions delivered consecutively over one week. Morning or afternoon groups are offered depending on the caregiver's availability. Programme content was developed for use in small groups of 6-8 caregivers. Topics covered in the sessions include basic concepts in dementia and specific issues such as nutrition, rest, medication, physical and cognitive changes, management of behavioural symptoms, affective problems in the patient and informal caregiver, verbal and non-verbal communication techniques, caregiver self-care and information on available resources and community services.~The sessions are conducted using audio-visual material to facilitate understanding of the content and to encourage active participation among caregivers when talking about their experiences."
10156242|NCT04036955|No Intervention|usual care|Caregivers in the Group control received usual care in the centres where the follow-up was carried out. This consisted of annual or quarterly consultations with a health professional (GP, geriatrician or neurologist) and, depending on the health centre, a nurse and social worker.Currently, there is no homogenous protocol for all care centres for the patient with high levels of cognitive impairment and dependency.
10185904|NCT03741153||study group|includes patients who will be diagnosed with Pseudoexfoliation syndrome
9671080|NCT05053061|Experimental|Telerehabilitation Arm|
10185905|NCT03741153||control group|age matched controls who do not have Pseudoexfoliation syndrome
10185906|NCT03741140|Other|medial frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the medial frontal lobe will be included in this arm, and will undergo motivation phenotyping.
10185907|NCT03741140|Other|lateral frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the lateral frontal lobe will be included in this arm, and will undergo motivation phenotyping.
10185908|NCT03741140|Other|Healthy participants|20 healthy participants (up to 10 healthy participants can be replaced) will be included in this arm, and will undergo motivation phenotyping.
10185909|NCT03741114|Active Comparator|Foley's Catheter plus TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
10185910|NCT03741114|Active Comparator|Foley's Catheter plus placebo to TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
10185911|NCT03741075|Active Comparator|BUAL plus placebo|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus 200 ml saline topical application to placental bed
10185912|NCT03741075|Experimental|BUAL plus topical tranexamic acid|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus topical application of 20ml saline contains 2 gm tranexamic acid
10185913|NCT03741049||Consultants|
10185914|NCT03741049||Trainee anaesthetists|
10185915|NCT03741049||Paramedics|
10185916|NCT03741049||Students|
10185917|NCT03741036|Active Comparator|autogenous bone graft as a space filling material|Autogenous bone from sub mental bone had been grafted in jumping gap between implant and freshely extracted socket
10185918|NCT03741036|Active Comparator|deproteinized bovine as a space filling material|Granules of deproteinized bovine bone of 0.25-1.0 mm diameter were used to fill the remaining defect when the distance of the defect wall to the implant surface was > 3 mm.
10185919|NCT03741036|Active Comparator|nano-hydroxyapatite alloplast as a space filling material|The patient was treated using alloplast material mixed with a nano-bone graft to fill gap between implant and freshely extracted socket
10185920|NCT03740971|Experimental|Guideline-based therapy+RIC|RIC is given twice a day with 200mmHg pressure.
10185921|NCT03740971|Active Comparator|Guideline-based therapy|
10185922|NCT03740945|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
10185923|NCT03740945|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
10185924|NCT03740932||Study group (group A):|It will consist of 30 subjects who will have cyclic pelvic pain
10185925|NCT03740932||Study group (group B):|It will consist of 30 subjects who will have non cyclic pelvic pain.
10185926|NCT03740932||Control group (group C):|It will consist of 30 subjects normal women who will not having pelvic pain.
10185927|NCT03740893|No Intervention|Cohort A (standard care reference cohort)|
10185928|NCT03740893|Experimental|Cohort B (AZD6738 monotherapy)|
10185929|NCT03740893|Experimental|Cohort C (olaparib monotherapy)|
10185930|NCT03740893|Experimental|Cohort D (durvalumab monotherapy)|
10185931|NCT03740867|Experimental|Group1|"Those with poor cognition (MOCA score<23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
10185932|NCT03740867|Experimental|Group2|"Those with good cognition (MOCA score≥23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
10185933|NCT03740854|Active Comparator|Pressure Controlled Ventilation|Patients undergoing pressure controlled ventilation
10185934|NCT03740854|Active Comparator|Volume Controlled Ventilation|Patients undergoing volume controlled ventilation
10185935|NCT03740828||Women undergoing IVF treatment|Device: KIDScore D3 study
10185936|NCT03740763|Active Comparator|Spinal Cord Stimulation (SCS)|"Spinal Cord Stimulation (SCS)~Pharmacological analgetic treatment and treatment with SCS for 3 months~Add-on physiotherapy for 6 months to SCS and pharmacological analgetic treatment~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
9520086|NCT03280602|Active Comparator|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
9694831|NCT04784520|Experimental|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
10156243|NCT04036760||Standard of Care transitional care coordination|
10156244|NCT04036760||Research transitional care coordination|
10156245|NCT04036721|Experimental|ARM A - PROLONGED|induction dose 1-4mg/kg of prednisone, prednisone 60mg q24h for 2-4wks, tapering not faster than 10mg each 14d, maintenance dose 10mg q24h for 8wks, withdraw of treatment during 4wks, summary of treatment time not shorter than 12-24wks.
10156246|NCT04036721|Active Comparator|ARM B - FAST REDUCTION|induction dose 1-4mg/kg of prednisone, prednisone 30-60 mg q24h, tapering not faster than 10mg each 7d, summary of treatment time 6-12wks.
10156247|NCT04036695|Experimental|Reveal LINQ insertable cardiac monitoring system|In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
10156248|NCT04036916|Experimental|Virtual Reality Training (Experimental)|Participants will receive multi-modal sensorimotor training interventions, including activities training the vestibular system, oculomotor control and visual perception, neuromotor control and strengthening of the cervical spine, postural control/ balance exercises, and exercises integrating the use of multiple types of sensory information for controlled motor output, including speed and accuracy. Novel headset virtual reality (VR) games/activities; compliant balance surfaces; resistance bands/weight; and biofeedback devices will be utilized to deliver the training intervention. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 12 sessions over 6 weeks.
10156249|NCT04036916|No Intervention|No Virtual Reality Training (Control)|True control.
10156250|NCT04036890|Experimental|2% minocycline hydrochloride controlled-delivery system (MHS)|Mechanical ultrasonic/ hand instrumentation and subsequent administration of MHS on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
10156251|NCT04036890|Placebo Comparator|Placebo|Mechanical ultrasonic/ hand instrumentation and subsequent administration of a placebo gel on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
10156252|NCT04036981||Brachialis|Targeted muscle for BoNT A injection
10156253|NCT04036981||Biceps|Targeted muscle for BoNT A injection
10156254|NCT04036981||Brachialis plus Brachioradialis|Targeted muscles for BoNT A injection
10156255|NCT04036734|Active Comparator|Transverse Ultrasound Orientation|Transverse placement of ultrasound to long axis of target lower limb vein
10156256|NCT04036734|Experimental|Longitudinal Ultrasound Orientation|Longitudinal placement of ultrasound to long axis of target lower limb vein
10156257|NCT04036851|No Intervention|Local standard of care|Women receive integrated antenatal and HIV services during pregnancy and are referred to general adult HIV services after delivery; no standardized peer support groups exist for this patient population.
10156258|NCT04036851|Experimental|Peer support intervention|Women will be invited to attend monthly peer support groups during pregnancy and postpartum, separate from any routine health services.
10156259|NCT04036786|Experimental|study gorup|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
10156260|NCT04036786|Other|control group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
10156261|NCT04036708|Experimental|MISC and WTM|Wetting method (WTM)+ Mediational Intervention for Sensitizing Caregivers (MISC) bi-weekly for 12 months.
9671081|NCT05053048|Experimental|STD-SL-PLUS stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The control stem (STD-SL-PLUS stem) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron.
9973269|NCT01329523||Control Group|Individuals without dementia matched in age to the patients with a dementia diagnosis
10156262|NCT04036708|Active Comparator|WTM only|WTM trainings only (recommended standard of care) bi-weekly for 12 months.
10156263|NCT04036656|Experimental|Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg|Participants will receive a single oral dose of SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg under fasted conditions.
10156264|NCT04036656|Experimental|Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg|Participants will receive a single oral dose of SYHA136 1 mg or Placebo matching SYHA136 1 mg under fasted conditions.
10156265|NCT04036656|Experimental|Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg|Participants will receive a single oral dose of SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg under fasted conditions.
10156266|NCT04036656|Experimental|Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg|Participants will receive a single oral dose of SYHA136 5 mg or Placebo matching SYHA136 5 mg under fasted conditions.
10156267|NCT04036656|Experimental|Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg|Participants will receive a single oral dose of SYHA136 10 mg or Placebo matching SYHA136 10 mg under fasted conditions.
10156268|NCT04036656|Experimental|Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg|Participants will receive a single oral dose of SYHA136 20 mg or Placebo matching SYHA136 20 mg under fasted conditions.
10156269|NCT04036656|Experimental|Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg|Participants will receive a single oral dose of SYHA136 35 mg or Placebo matching SYHA136 35 mg under fasted conditions.
10156270|NCT04036656|Experimental|Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg|Participants will receive a single oral dose of SYHA136 50 mg or Placebo matching SYHA136 50 mg under fasted conditions.
10156271|NCT04036422|Experimental|Computer based exercise group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week to a total of twenty hours over a four week period. In addition to this, these patients will receive half an hour of conventional occupational therapy and half an hour of Rejoyce computerized exercise seven days a week to a total of twenty eight hours over a four weeks period.
10156272|NCT04036422|Active Comparator|Conventional treatment group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week, to a total of twenty hours over a four week period. In addition to this, patients in this group will receive one hourly sessions of conventional occupational therapy seven days a week to a total of twenty eight hours over a four week period.
10156273|NCT04036461|Experimental|Arm 1 (CC-99712 monotherapy)|CC-99712 will be administered via intravenous (IV) infusion once per 21-days on a Once every three weeks (Q3W) schedule, and once per 28-days on a Once every four weeks (Q4W) schedule
10156274|NCT04036461|Experimental|Arm 2 (CC-99712 and BMS-986405 combination)|CC-99712 will be administered as indicated above. BMS-986405 will be administered orally TIW every week during a 21-day cycle (eg, Day 1, Day 3, Day 5, Day 8, Day 10, Day 12, Day 15, Day 17, and Day 19), with 48 hours between each dose with a week
9671082|NCT05053048|Active Comparator|NT-SL-PLUS Stem|Rectangular SL straight stems made of titanium alloy (Ti-6Al-7Nb). The experimental stem (NT SL-PLUS) underwent alumina grit blasting to reach the adequate roughness of 4-6 micron. The surface of the NT SL-PLUS stem was thereafter additionally treated chemically by short-acid etching with HF and mechanically by dry ice blasting in order to loosen and remove the residual alumina particles up to 96% without changing the existing surface microtopography.
9671083|NCT05053256||HFpEF|Heart failure with preserved ejection fraction
10156275|NCT04036578|Other|Pelvic Floor Dysfunction With and Without POP|group 1(Pelvic Floor Dysfunction Without POP Stage I~II) and group 2(Pelvic Floor Dysfunction With POP Stage I~II)
10156276|NCT04036474|Experimental|Smoking Prevention Education Program|In addition to the lecture on the hazards of smoking, students received the SPEP intervention. The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. The SPEP intervention was delivered to participants in their usual classroom setting, during school hours combined with relevant school subjects such as physical education class. The duration of SPEP intervention took approximately one month.
10156277|NCT04036474|No Intervention|Control|Immediately after the collection of baseline data, students received a one-time lecture on the hazards of smoking by the research assistant.
10156278|NCT04036513|Experimental|MINST|"Usage of magnification loupes, specific thin and delicate tips together with piezoelectric device and specifically designed Hu-Friedy mini five, micro mini five, and after five Gracey curettes under local anaesthesia."
10156279|NCT04036513|Active Comparator|Conventional SRP|Conventional non-surgical mechanical treatment using piezoelectric device (PiezoLED, Kavo) and standard Gracey curettes under local anaesthesia.
10156280|NCT04036539|Placebo Comparator|Control (placebo)|Patients in Control will receive the photobiomodulation placebo,application, but with the laser off. Procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described: Simulations will be performed with the same laser.This will require 10 seconds of application simulation per point. As 10 points will be simulated, it will take 100 seconds for this simulation.5 points lingual and 5 points at vestibular
10156281|NCT04036539|Experimental|Experimental:|Experimental: Molar verticalization + PBM (n = 17 + 3) - patients will receive laser treatment (photobiomodulation) in order to modulate orthodontic movement and act on inflammation and pain. The procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described:The irradiations will be performed with the red diode laser ( = 660 nm) with 100 milliwatts output power The power of the device will be 100miliWatts and the wavelength used will be 808 nanometers (± 10nm). The optical fiber diameter of the device is 600 micrometer, therefore a spot (area) of 0.002826 centimeter2. The energy delivered per point will be 1Joule. This will require 10 seconds of application per point. As 10 points will be irradiated, the total application time will be 100 seconds and the total energy delivered will be 10Joule. The energy density will be 25 Joule / cm2 and the power density will be 35.38 Watt / cm2
10156282|NCT04036383|Active Comparator|vestibüler|vestibular exercise training
10156283|NCT04036383|Experimental|balance training|vestibular exercise training+ balance training with computerized balance system
10156284|NCT04036383|Experimental|square-step|vestibular exercise training+ square step exercise
10156285|NCT04036643|Experimental|patient with rectal cancer|Patient with rectal cancer treated by neoadjuvant chemo-radiation therapy with clinical complete response
10156286|NCT04036487|Experimental|IH group|Inhalation anesthesia will be given during transaxillary endoscopic breast augmentation.
10156287|NCT04036487|Active Comparator|TIVA group|Total intravenous anesthesia will be given during transaxillary endoscopic breast augmentation.
10156288|NCT04036565||The experimental group|The first post-test measurements were taken right after the participants completed the sunlight therapy (two to four weeks after the start of the intervention), and the second post-test measurements were taken one month after the intervention was completed (six to eight weeks after the start of the intervention).
10156289|NCT04036565||The control group|Standard care.The first and second post-test measurements were taken two and six weeks, respectively, after they started receiving standard care.
10156290|NCT04036500|Experimental|Estradiol|Subjects will take estradiol 1 mg orally after time 0 blood draw. They will get 7 blood draws at hours 0,1,2,3,4,6,8. A wash-out period of at least one week will allow for complete clearance of the exogenous oral estradiol before testing the pharmacokinetics of sublingual estradiol on the same ten patients in the same manner. On day 2 of study, subject will take estradiol 1 mg sublingually after time 0 blood draw, supervised by a research team member to ensure proper dissolution. Blood will be drawn at hours 0,1,2,3,4,6,8 as on day 1 of study.
10156291|NCT04036448||Lenalidomide in IPSS Low-or intermediate-1-risk del population|For the IPSS Low- or intermediate-1-risk del (5q) (MDS), Lenalidomide treatment must not be started if the ANC < 0.5 x 109/L and/or platelet counts < 25 x 109/L. The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
10156292|NCT04036448||Lenalidomide in Refractory/relapsed rrMC/ Follicular lymphoma population|For the Refractory/relapsed Mantle cell lymphoma (rrMCL), the recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles. For the Follicular lymphoma (FL), the recommended starting dose of rituximab is 375 mg/m2 intravenously (IV) every week in Cycle 1 (days 1, 8, 15, and 22) and day 1 of every 28-day cycle for Cycles 2 through 5.
9671084|NCT05053256||HFrEF|Heart failure with reduced ejection fraction
9671085|NCT05053100||Observational (record review, blood collection)|Patients' electronic health record are reviewed for 12 months and/or undergo collection of blood at pretreatment and on days 7, 28, 90, and 180.
9973270|NCT01329536||AD Patients with Agitation|Patients with a diagnosis of probable Alzheimer's Disease who show signs of agitation based on the Cohen-Mansfield Agitation Inventory
9973271|NCT01329536||AD Patients without Agitation|Patients with a diagnosis of probable Alzheimer's Disease who do not show signs of agitation based on the Cohen-Mansfield Agitation Inventory and are matched in both age and gender to the AD Patients with Agitation
9973272|NCT01329588|Placebo Comparator|Sugar pill|
9973273|NCT01329588|Experimental|Treatment arm|
9973274|NCT01329601|Experimental|Cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
9973275|NCT01329601|Active Comparator|Booklet-based training|Home based training of episodic memory using paper-pencil exercizes
9973276|NCT01329614|Experimental|Nicotine Replacement Therapy, 7mg dose|
9973277|NCT01329614|Experimental|Nicotine Replacement Therapy, 21mg dose|
9973278|NCT01329614|Placebo Comparator|Nicotine Replacement Therapy, Placebo|
9973279|NCT01329614|Experimental|Nicotine Replacement Therapy, 42mg dose|
9973280|NCT01329627|Experimental|Paclitaxel/doxorubicin/cyclophosphamide|
9973281|NCT01329640|Experimental|Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide|
9973282|NCT01329653|Experimental|aerobic training|12 weeks of aerobic training, 4X/week
9973283|NCT01329653|Placebo Comparator|wait list control|wait list control condition, 12 weeks to parallel the active intervention group
9973284|NCT01329666|Experimental|50,000 IU Vitamin D3|
9973285|NCT01329666|Placebo Comparator|Placebo (inactive Vitamin D3)|
9973286|NCT01329692|Experimental|Lifestyle counseling|"This is a seven-week group education, counseling, nutrition, exercise, and journaling program of the Duke Metabolic and Weight Loss Surgery Center designed to help postoperative bariatric surgery patients who are failing to progressively lose weight resume an expected pattern of weight loss and improved overall outcome.~Weeks 1 and 2 consist primarily of a review of current dietary habits. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed."
9973287|NCT01329692|No Intervention|RYGB regular post-op care|Regular care and follow-up after RYGB surgery
9973288|NCT01329705|Active Comparator|Control|All patients will be treated with the current standard of care including onabotulinum toxin
9973289|NCT01329705|Experimental|Dynasplint|Patients in the experimental Dynasplint group will be treated with the current standard of care, including onabotulinum toxin, and use the Ankle Dorsiflexion Dynasplint
9973290|NCT01329718|Experimental|CRC Group|
9973291|NCT01329731|Active Comparator|Test|1.25% fluoride (elmex® gelée)
9973292|NCT01329731|Placebo Comparator|Control|0% fluoride (negative control)
9973293|NCT01329744|Experimental|Treatment|Recombinant IGF-I
9973294|NCT01329744|Placebo Comparator|Placebo|
9973295|NCT01329757|Active Comparator|GH|Administration of a daily dose of GH (0.4mg)for 1 year
9973296|NCT01329757|Placebo Comparator|Placebo|Administration of a daily dose of placebo for 1 year
9973297|NCT01329770|Experimental|Ascorbic Acid and alpha-tocopherol|Two daily doses of the combination of antioxidants, administered at breakfast and dinner
9973298|NCT01329770|Placebo Comparator|Placebo|Two daily doses of placebo, administered at breakfast and dinner
9973299|NCT01329783||EuroSIDA sub-cohort|HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)
9973300|NCT01329796|Experimental|Pertubation with Endole® (lignocaine)|Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
9973301|NCT01329796|Placebo Comparator|Placebo|Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
9973302|NCT01329809|Experimental|JX-594 Intravenous infusion|JX-594 will be administered intravenously to patients with measurable intra-hepatic disease who are not eligible for intratumoral injection of JX-594.
9973303|NCT01329809|Experimental|JX-594 Intratumoral Injection|JX-594 will be injected directly into the liver tumor of patients who have at least two measurable intra-hepatic tumors, one of which must be at least 1.5cm in diameter and safety injectable.
9973304|NCT01329822|Experimental|Caloric restriction group|CR group were educated by a dietitian to reduce their usual energy intake to 1400 kcal/day (-500 kcal/day, -26% from baseline) for weight reduction and the recommended macronutrient composition was the 50-55% of energy intake as carbohydrate, 15-20% as protein and 20-25% as fat. Daily energy intake and nutrient composition were determined using a computer-aided nutritional analysis program (CAN-Pro 3.0; Korean Nutrition Society, Seoul, South Korea).
9973305|NCT01329822|No Intervention|Control group|Control group - ad libitum diet
9973306|NCT01329835|Experimental|Written information via brochure|Written information by a brochure
9973307|NCT01329835|No Intervention|standard care|standard prenatal care
9973308|NCT01329835|Experimental|Lifestyle counseling|Psycho-education based on principles of motivational interviewing and positive reinforcement
9973309|NCT01329861|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
9973310|NCT01329861|No Intervention|Control condition|Wait-list condition, received treatment after post-treatment assessment.
9973311|NCT01329874|No Intervention|Gow gates ,conventional block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
9973312|NCT01329874|No Intervention|Buccal infiltration, Lingual infiltration|
9973313|NCT01329887|Other|administration of ketanserin|
9973314|NCT01329913|Experimental|GT1-HCV 200 mg|
10156293|NCT04036591||Children under 24 months with ARIS|
10156294|NCT04036370|Active Comparator|PECS group|In addition to routine analgesic protocol; before anaesthesia induction; following the PECS I + II block, a continuous infusion catheter will be placed at the PECS II block level under the guidance of USG, and local anesthetic infusion will be started via the catheter at the end of the operation.
9671086|NCT05053282||master endurance athletes|men aged 65 to 75 with more than 150 minutes of running activity per week at least 15 years history of running
9671087|NCT05053282||elderly sedentary|men aged 65 to 75 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
9671088|NCT05053282||young endurance athletes|men aged 20 to 30 with more than 150 minutes of running activity per week at least 3 years history of running
9973315|NCT01329913|Experimental|GT1-HCV 400 mg|
10156295|NCT04036370|Sham Comparator|Control group|Peroperative and postoperative routine analgesic protocol will be performed with no additional intervention (block).
10156296|NCT04036526|Experimental|Group 1 Drop method|Group 1 will receive vaccine/placebo by drop method.
10156297|NCT04036526|Experimental|Group 2 Nasal actuator|Group 2 will receive vaccine/placebo with nasal actuator.
9973316|NCT01329913|Experimental|GTI-HCV 800 mg|
9973317|NCT01329913|Experimental|GT3-HCV 200 mg|
10156298|NCT04036630|Experimental|2kHz tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156299|NCT04036630|Sham Comparator|sham tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156300|NCT04036630|Experimental|2kHz tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156301|NCT04036630|Sham Comparator|sham tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156302|NCT04036630|Experimental|2kHz tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156303|NCT04036630|Sham Comparator|sham tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156304|NCT04036630|Experimental|env tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156305|NCT04036630|Active Comparator|time-reversed env-tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156306|NCT04036630|Sham Comparator|sham tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
10156307|NCT04036617|Experimental|NaQuinate|Initial SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150 mg
10156308|NCT04036617|Experimental|Placebo|Initial SAD cohorts will receive 1 placebo dose between 10-150 mg . MAD cohorts will receive 7 days placebo dosing between 70-150 mg
10156309|NCT04036604|Experimental|Group of pelvic floor exercise|Group of pelvic floor exercise include 47 elderly people which contains contraction and repetition of pelvic floor muscle exercises during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.
10156310|NCT04036604|No Intervention|Group of pelvic floor education|Group of pelvic floor education include 47 elderly people which contains anatomy of pelvic floor and dysfunction during once a week for 8 weeks performed by an expert pelvic health physiotherapist.
10156311|NCT04036305||EDS Patients|Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome
10156312|NCT04036305||Healthy Volunteers|Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome
10156313|NCT04036344|No Intervention|Control|Control participants receive treatment for a facial skin cancer with Mohs micrographic surgery (MMS), however, do not receive a peer mentor. Participants complete 3 online Skin Cancer Index (SCI) surveys at enrollment, 1 week follow-up, and 3 month follow-up.
9671089|NCT05053282||young sedentary|men aged 20 to 30 with no history of regular physical activity training and no more practice than 150 minutes of moderate or 75 minutes of vigorous intensity per week according the ACSM recommendations
9671090|NCT05053295|Experimental|Immuncell-LC/Nivolumab group|Patients will receive nivolumab once a day at 4-week intervals and Immuncell-LC 12 times (3 treatments once a week, followed by 5 treatments every other week, and finally 4 treatments every 4 weeks).
9671091|NCT05053269||good body weight growth|body weight growth after birth is consistent with the growth curve
9671092|NCT05053269||poor body weight growth|body weight growth after birth is inconsistent with the growth curve
9973318|NCT01329913|Experimental|GT3-HCV 400 mg|
9973319|NCT01329913|Experimental|GT3-HCV 800 mg|
10156314|NCT04036344|Experimental|Mentee - Preoperative Consult|Mentees are enrolled at preoperative consultation visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
10156315|NCT04036344|Experimental|Mentee - Same Day Surgery|Mentees are enrolled at same day surgery visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
10156316|NCT04036201|Experimental|Group 1(22-24 mm)|Group 1 (patients with axial length between 22 and 24 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyalurindase 150 IU (1 ml) to a total volume of 7 ml.
10156317|NCT04036201|Experimental|Group 2(24.1-26 mm)|Group 2 (patients with axial length between 24.1 and 26 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyaluronidase 150 IU (1 ml) to a total volume of 7 m
10156318|NCT04036253|Active Comparator|Eprex/Erypo|"Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
10156319|NCT04036253|Experimental|Hemax PFS|"receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
10156320|NCT04036240|Experimental|Finger feeder|HMF supplementation will be given by finger feeder
10156321|NCT04036240|No Intervention|Control|HMF supplementation will be given by mother preference such as cup, bottle.
10156322|NCT04036162|Experimental|Young group|Young Right-handed healthy volunteers
10156323|NCT04036162|Experimental|Aged group|Aged Right-handed healthy volunteers
10156324|NCT04036149|Experimental|LUCIA|CT LUCIA 611P - Intraocular lens
9973320|NCT01329952||Current intravenous drug users|Those who were actively injecting drugs at the time of their hepatitis C treatment.
10156325|NCT04036149|Active Comparator|ASPHINA|CT ASPHINA 409MP - Intraocular lens
10156326|NCT04035824|Active Comparator|Gastrodia and Uncaria granule|Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
10156327|NCT04035824|Placebo Comparator|Placebo|Placebo of Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
10156328|NCT04035850|Experimental|Participants|Vortioxetine PO tablets, 5-20mg Daily
10156329|NCT04036175|Other|Group 1|Standard oxygen - High-Flow Nasal Oxygen - Non-invasive ventilation - Standard Oxygen (20 minutes for each condition)
10156330|NCT04036175|Other|Group 2|Standard oxygen - Non-invasive ventilation - High-Flow Nasal Oxygen - Standard Oxygen (20 minutes for each condition)
10156331|NCT04035876|Experimental|Camrelizumab plus apatinib|
10156332|NCT04035863|Experimental|PBM + physiotherapy exercises|"will be submitted to active PBM and physiotherapeutic exercises.~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated at the lesion level with a wavelength of 808 nm, 25 J per point for 12 sessions. The same laser device (Laser DMC Therapy EC).~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
10156333|NCT04035863|Sham Comparator|SHAM PBM + physiotherapy exercises|"will be submitted to sham PBM and physiotherapeutic exercises.~For irradiation sham, the individuals will be positioned comfortably in lateral decubitus on the examining table. The same laser device (Laser DMC Therapy EC) will be used but the device will emit sound but not light.~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
10156334|NCT04035889|Experimental|Group 1|Participants assigned to Group 1 will take 2 weeks of melatonin followed by 2 weeks of placebo
10156335|NCT04035889|Experimental|Group 2|Participants assigned to Group 2 will take 2 weeks of placebo followed by 2 weeks of melatonin.
10156336|NCT04036019|Experimental|C-CAR066|Autologous C-CAR066 administered by intravenous (IV) infusion
10156337|NCT04035772|Experimental|Wiki101 and WikiTrauma|"Wiki101, a theory-based continuing professional development (CPD) program, will train participants at the selected trauma centers to use WikiTrauma effectively and safely to create and share different types of Knowledge Transfer (KT) tools (e.g., care protocols, order sets, patient decision aids). Participants will receive Wiki101 training and then gain access to WikiTrauma with editing rights to the knowledge implementation tools (e.g. care protocols, order sets, care pathways) found in the wiki.~WikiTrauma is the wiki we created to promote best practices in trauma care and will be implemented in four trauma centers in Quebec during 12 months. During this period, we will continue to measure the impact on the quality of care."
10156338|NCT04035954|Active Comparator|Interventional|The control group will continue the routine physiotherapy program based on NDT: Neurodevelopmental Therapy twice a week, 2 days / 1 hour / day during 8 weeks.
10156339|NCT04035954|Experimental|Experimental|The treatment group will participate in clinical pilates exercises 2 days / 1 hour / day during 8 weeks.They will also continue their weekly routine physiotherapy programs.
10156340|NCT04036123|Experimental|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
10156341|NCT04036227|Experimental|GS-248|"Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses)~Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I."
10156342|NCT04036227|Placebo Comparator|Placebo|Matching placebo oral solution
10156343|NCT04035980|No Intervention|Conventional care|Screening HCV with dried blod spot (DBS) testing and referral to tertiary care hospital to evaluate disease stage and treatment of HCV RNA positive patients
10156344|NCT04035980|Active Comparator|Telemedicine care|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
10156345|NCT04036136|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
9973321|NCT01329952||Past drug users|Those who stopped injecting drugs intravenously at least 6 months prior to the start of treatment for hepatitis C
10156346|NCT04036136|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
10156347|NCT04035720|Experimental|Quantitative risk estimation|Participants will be exposed to case-scenarios. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating the probability of risk progression (20%, 25%, 85%, 90%). This information may or may not be accurate to reflect potential errors of risk prediction tools.
10156348|NCT04035720|Active Comparator|Qualitative risk estimation|Participants will be exposed to the same case-scenarios as the intervention arm. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating a qualitative probability of risk progression (low, high). This information may or may not be accurate to reflect potential errors of risk prediction tools.
10156349|NCT04035902|Experimental|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered during surgery
10156350|NCT04035902|Active Comparator|control|Ferric carboxymaltose is not administered
10156351|NCT04035993|Experimental|Intervention group|
10156352|NCT04035915|Experimental|Limited driving pressure ventilation|
10156353|NCT04035915|Experimental|Conventional mechanical ventilation strategies|
10156354|NCT04035785|Experimental|Kangfu anti-inflammatory suppository|"Kangfu Xiaoyan Suppository was used for 21 days, while levofloxacin + metronidazole for 10 days, levofloxacin + metronidazole for 4 days.~One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
10156355|NCT04035785|Placebo Comparator|antibiotics alone group|"One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gram-negative bacteria. Bacterial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
10156356|NCT04035928|Experimental|3D digital scanning for maxillofacial prosthetics|
9973322|NCT01329965|Experimental|LPS|LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.
9973323|NCT01329965|Placebo Comparator|Saline|A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.
10156357|NCT04035798|Experimental|memantine (MM)|The participants will receive memantine 5mg (1 capsule) per day for 12 weeks.
10156358|NCT04035798|Placebo Comparator|Placebo|The participants will receive one capsule of placebo per day for 12 weeks.
10156359|NCT04035655|Experimental|Clinical and electrophysiological evaluation of tDCS session|"In this prospective case-control study, the investigator's main goal was to evaluate the impact of a single standard-care tDCS session on brain activity (EEG).~The effect of a single 20 minutes 2 mA tDCS session with the anode placed over the left dorsolateral prefrontal cortex and the cathode over the right supraorbital cortex administered as routine care were evaluated by combined behavioral and electrophysiological assessments immediately before and after the stimulation.~The study consisted of the following interventions, administered immediately before and after the stimulation session:~detailed behavioral assessment by the Coma Recovery Scale-Revised (CRS-R)~5 minutes resting state high-density EEG recordings and 6 minutes auditory oddball paradigm immediately.~Additionally, clinical anatomical MRI (T1) acquired as routine care were used to model the estimated tDCS-induced electric fields in the entire head of patients, based on available T1-weighted MRI."
10156360|NCT04035733|Experimental|Open-label single arm study|
10156361|NCT04035707|Experimental|anaesthesia with rocuronium|rocuronium is used during anaesthesia
10156362|NCT04035707|Experimental|anaesthesia without rocuronium|during anaesthesia rocuronium is not used
10156363|NCT04035629|Experimental|Hyperpolarized 129Xe MRI for lung diagnosis|All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung.
10156364|NCT04035603|Experimental|D-Cycloserine Augmentation|D-cycloserine (DCS) augmentation of CET sessions
10156365|NCT04035603|Placebo Comparator|Placebo Augmentation|Placebo (PBO) augmentation of CET sessions
10156366|NCT04035616|Placebo Comparator|Placebo|placebo were manufactured and supplied by B-Crobes Laboratory Sdn. Bhd. as powder in identical sachets with active comparator and labelled as A
10156367|NCT04035616|Active Comparator|Hexbio® MCP|The treatment sample is labelled as B.This is an orange-flavoured, granulated microbial cell preparation containing 30 billion colony forming units (cfu) of Lactobacilli and Bifidobacteria strains: Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC® 02120. The placebo sample was similar in appearance and taste, but contained no microbial cells.
10156368|NCT04035642|Experimental|IGRT 24 Gy Single dose|Patients will be treated using image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with a single fraction at a prescription dose of 24 Gy.
9671093|NCT05053009|Experimental|Ibuprofen sustained release|Single dose of 800 mg Brufen Retard oral premedication will be administered 1 hour before local anesthesia
10156369|NCT04035681|Experimental|Problem-Solving Therapy|Participants who are assigned to receive problem-solving therapy will work with a research team member for six, one-hour sessions. During each session, participants will identify a problem (big or small) and create a plan to work on that problem.
10156370|NCT04035681|Active Comparator|Stroke-Related Health Education|Participants who are assigned to receive stroke-related health education will work with a research team member who will teach them about various topics related to stroke over six, one-hour sessions. Each session will cover information about a different topic related to stroke.
10156371|NCT04035460|Active Comparator|Helmet oxygenation group|Patients randomized to helmet NIPPV will receive noninvasive oxygenation and ventilation via a latex free helmet
10156372|NCT04035460|Active Comparator|High Flow Nasal Oxygen|Oxygen will be passed through a heated humidifier and applied continuously through large-bore nasal prongs
10156373|NCT04035512|Experimental|Expressive writing|The expressive writing group will perform the writing task, for 3 consecutive days, 20 minutes each day
10156374|NCT04035512|No Intervention|Control group|Any intervention
10156375|NCT04035746||Single-group study|Assessment of microcirculation, brain plasticity and clinical function
10156376|NCT04036084||Patients|Patients with CADASIL disease : Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL
10156377|NCT04036084||Control|
10156378|NCT04035395|Experimental|Intervention|Participants randomized to the intervention group will receive the SyV 2.0 program, which in addition to standard diabetes management services of SyV 1.0 services, could include MTM services, care coordination by a team of behavioral health care providers, and/or referrals to community-based lifestyle programs, as determined by their tailored care plan. The participant will be seen by evaluation staff to complete baseline assessment for the study. Then, an individualized care plan will be developed by SyV 1.0 interdisciplinary staff and reviewed by the chronic care case management team. The care plan will include information on additional services provided by UTHealth such as, but not limited to, behavioral health services, or pharmacy services. Each participant will receive an individualized care plan and when applicable, referrals to community-based programs. Evaluation staff and CHWs will make follow-up appointments for the participant depending on their care plan.
10156379|NCT04035395|No Intervention|Control|Participants randomized to the usual care group will receive the SyV 1.0 program which includes community based program referrals (excluding intervention programs) and home-based visits from CHWs. These participants will also receive the standard follow-up from UTHealth staff such as a phone call, an information session as per their treatment plan, and /or a onetime mailing of information about the importance of following their treatment plan. Before implementation begins, additional details about standard care will be ascertained from partner organizations to better understand how these differ from the treatment conditions of the intervention group. Once the participant completes 12 months in the study, 2.0 services will be initiated.
10156380|NCT04035356||HAART 300|HAART 300 Aortic Annuloplasty Device
10156381|NCT04035356||HAART 200|HAART 200 Aortic Annuloplasty Device
10156382|NCT04035941|Experimental|Feasibility|The cycle training intervention group
10156383|NCT04035538|Experimental|A group|
10156384|NCT04035538|Experimental|B group|
10156385|NCT04035525|Experimental|MaxSimil® fish oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g MaxSimil® fish oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
10156386|NCT04035525|Active Comparator|Rice bran oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
10156387|NCT04035525|Active Comparator|CoQ10 as powder form|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
10156388|NCT04035447|Experimental|Behavioral Symptom Management for Young Adult Cancer Survivors|The proposed intervention will provide systematic training in cognitive and behavioral coping skills (e.g., activity-rest cycling, cognitive restructuring, relaxation training) delivered over the course of 8 sessions (10 therapy hours). By employing these strategies, participants learn to adjust their thoughts, behaviors, and emotions in the service of better managing symptoms.
10156389|NCT04035447|Active Comparator|Waitlist Control|Waitlist control participants will receive the intervention and receive systematic training in cognitive and behavioral coping skills approximately 6 months into their participation in the study.
10156390|NCT04035343|Active Comparator|Conventional face down positioning|Patients in third arm will be treated with the current standard of care, that is, they will be kept supine in the ophthalmic surgery chair after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will transition to face down positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
10156391|NCT04035343|Experimental|Supine positioning|Patients in the second arm will be kept supine after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will maintain supine positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
10156392|NCT04035291|Active Comparator|Interventional|The first group (n = 25) will be asked to apply the physiotherapy program by the family at home that includes the principles of therapeutic handling-holding-positioning of NDT principles, starting at the third month for 8 weeks. And It will last for at least 45 minutes, 3 days a week. Family education will be evaluated after 4 weeks and improvements will be made in accordance with the motor development of the infant. The program will be implemented by families for 8 weeks.
10156393|NCT04035291|Experimental|Experimental|In the second study group (n = 25), family collaborative physiotherapy program will be applied by the family. This program will start from the postterm third month, and will include family trainings based on the goal-oriented active motor learning model of the baby in an 8-week in enriched environment and to include holding-carrying-positioning trainings in daily routines. Also it will last for at least 45 minutes, 7 days a week. All members of the family will be included in the family trainings and home visits will be made at 2-week intervals. Families will be encouraged to apply the physiotherapy processes of their babies in their natural environment at every moment of their daily routines (feeding, carrying on lap, gas extraction, changing the bed, sleeping, waking time, shopping moment, playing games etc.).
10156394|NCT04035291|No Intervention|control|In the third study group, families who are out of town or who cannot participate in the treatment program for other reasons will be included in the evaluations.
10156395|NCT04035304|Experimental|Mindfulness Coach Mobile App|Participants in this condition will complete 3 assessments: initial, end of month two and end of month four. Each participant, following initial assessment will be provided with a link to download the Mindfulness Coach mobile app as well as with brief recommendations for how to use the app over the subsequent 16 weeks of the study. Mindfulness Coach is a mobile app for iPhone and Android, developed by the VA National Center for PTSD in collaboration with National Center for Telehealth and Technology (T2).
10156396|NCT04035304|No Intervention|No Treatment Control Group|Participants in this condition will initially be provided with links to resources for Veterans with PTSD (http://ptsd.va.gov) and will be told that they will be contacted again in 8 weeks (60 days) to complete a second assessment. Each participant will then be provided with a link to download the Mindfulness Coach mobile app and with brief recommendations for how to use the app over the subsequent 8 weeks of the study (see description above). Participants will participate in a final follow up survey 8 weeks after receiving the app.
10156397|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - TAI|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to TAI
10156398|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - PPV|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to PPV
10156399|NCT04035239|Experimental|BGS use|Use of BGS goggles for a 3-6 weeks period.
10156400|NCT04035135|Experimental|Open Label Treatment Arm|One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.
10156401|NCT04035187|Experimental|Sequence A (fast, medium, oral solution, then slow)|Participants first receive fast tablet, then medium tablet, then oral solution, and then slow tablet. Washout period is (at least) one week.
10156402|NCT04035187|Experimental|Sequence B (medium, slow, fast, then oral solution)|Participants first receive medium tablet, then slow tablet, then fast tablet, and then oral solution. Washout period is (at least) one week.
10156403|NCT04035187|Experimental|Sequence C (slow, oral solution, medium, then fast)|3, 4, 2, 1 Participants first receive slow tablet, then oral solution, then medium tablet, then fast tablet. Washout period is (at least) one week.
10156404|NCT04035187|Experimental|Sequence D (oral solution, fast, slow, then medium)|Participants first receive oral solution, fast tablet, then slow tablet, and then medium tablet. Washout period is (at least) one week.
10156405|NCT04035213|Experimental|Behavior of Sleep Course|A semester-long course focused on sleep improves college students' sleep patterns over one semester. The listed aims of this course are to: 1) provide students with a comprehensive understanding of sleep; 2) afford an overview of the multiple ways sleep impact health, performance and well-being; and 3) to assist students in discovering how their own sleep-wake patterns impact their day to day functioning.
10156406|NCT04035213|No Intervention|Control|Students from other upper level departmental courses with content that does not include a focus on or discussion of sleep
10156407|NCT04035122|Experimental|Robotic Treatment|The Lokomat is a robotic device. For treatment with the robotic system, the amount of body weight supported will initially set at 70% of every patient's weight, then decreasing in accordance with load tolerance, although not providing less than 20% support. The selected speed will be adapted to the patient's working comfort under the supervision of a trained physiotherapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
10156408|NCT04035122|Active Comparator|Conventional Treatment|The CG will perform traditional overgroung gait rehabilitation. Exercises in this program are designed with gradual increments to meet each patient's abilities and were supervised by a physical therapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
10156409|NCT04035317|Experimental|Aesculus hippocastanum|Patients will receive extract of Aesculus hippocastanum
9973324|NCT01329991|Active Comparator|oral dose of 200 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
10156410|NCT04035317|Placebo Comparator|Placebo|Patients will receive placebo
10156411|NCT04035252||1. Young healthy group|Male or female between the age of 18 and 40 years old. No presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
10156412|NCT04035252||2. Patients with an AAA|Individuals (>60 years) with a small, stable, abdominal aortic aneurysm (i.e. AAA diameter of 30-50 mm)
10156413|NCT04035252||3. Healthy older group|Healthy age- and sex- matched with group 2 with no presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
10156414|NCT04035265|Active Comparator|pain+ / synovitis +|SLE patients with inflammatory pain and synovitis determined by the practitioner during physical examination of radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP. Defining synovitis as pain and inflammation and/or deformity (present or existing over the past year) included in the clinical history
9671094|NCT05053009|Placebo Comparator|Placebo|1 capsule of 500 mg of glucose oral premedication will be adminstered 1 hour before local anesthesia
9973325|NCT01329991|Active Comparator|oral dose of 400 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
9973326|NCT01329991|Active Comparator|oral dose of 800 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
10156415|NCT04035265|Active Comparator|pain + / synovitis -|SLE patients with inflammatory pain without determined synovitis. Current (or over the past year) pain in radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP, with no synovitis
10156416|NCT04035265|Active Comparator|pain - / synovitis -|SLE patients without inflammatory pain with normal physical examination currently or over the past year
10156417|NCT04035265|Placebo Comparator|healthy|control patients (healthy participants: no pain, no SLE, no family affected by systemic inflammatory disease, a blood test with no elevation APR or autoimmunity +)
10156418|NCT04035330|Experimental|etidronate in sodium hypochlorite|It comes in a capsule containing 0.9 g of etidronate powder, which should be mixed immediately with 10 mL of a NaOCl solution of choice directly before treatment, resulting in a combined irrigant containing both active chlorine and approximately 9% etidronate. Irrigation with a total volume of 25 ml for each case
10156419|NCT04035330|Active Comparator|sodium hypochlorite|irrigation with 2.5% NaOCl with a total volume of 25 ml for each case
10156420|NCT04035096|Experimental|The high-dose vitamin C with very low carbohydrate diet group|"Initiation of High dose IVC therapy: start with 25g IVC biweekly for one week; 50g IVC biweekly for one week; 75g biweekly for one week.~Blood vitamin C level measurement: Confirm the plasma vitamin C level above 350 mg/dl by Arkray company PocketChem VC ( Kyoto, Japan) from the 75g/dose~Once the target blood level is confirmed, the dose remains g biweekly for 12 weeks. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level. The blood vitamin C level will be checked again and record. The final dose will be kept for 12 weeks.~The Riordan IVC protocol (Taiwan)~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks~The infusion schedule change within 2 weeks is accepted with the fixed frequency per week or month~VLCD intervention in the first 12 weeks"
10156421|NCT04035096|Active Comparator|The control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~Usual care"
10156422|NCT04035109|Other|Anakinra (Period 1) then Placebo (Period 2)|Subjects randomized to this arm will receive a single injection of anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their first allergen challenge (Period 1), followed by the matching saline placebo after their second allergen challenge (Period 2).
10156423|NCT04035109|Other|Placebo (Period 1) then Anakinra (Period 2)|Subjects randomized to this arm will receive a single injection of saline placebo administered subcutaneously after their first allergen challenge (Period 1), followed by anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their second allergen challenge (Period 2).
10156424|NCT04035018|Experimental|pharmacopuncture therapy|The physicians will select one or more pharmacopuncture therapy for each participants. The physicians will also decide dosage and frequency of treatment according to the participant's status.
10156425|NCT04035018|Active Comparator|physical therapy|The physicians will select one or more physical therapy for each participants. The physicians will also decide intensity and frequency of treatment according to the participant's status.
10156426|NCT04035005|Experimental|Ocrelizumab|Participants will receive ocrelizumab by IV infusion every 24 weeks.
10156427|NCT04035005|Placebo Comparator|Placebo|Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.
10156428|NCT04034940|Other|primary PCI STEMI patients|All Patients with AMI refered for primary PCI in single center
10156429|NCT04035083|Experimental|Laser activated irrigation|Laser activated irrigation of sodium hypochlorite using a 980 nm diode laser device
10156430|NCT04035083|Active Comparator|Passive ultrasonic irrigation|passive ultrasonic irrigation of sodium hypochlorite using an ultrasonic laser device
10185937|NCT03740763|Active Comparator|Physiotherapy|"Physiotherapy~Pharmacological analgetic treatment for 3 months~Physiotherapy for 3 months and pharmacological analgetic treatment~Add-on SCS in combination with physiotherapy and pharmacological analgetic treatment for 3 months~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
10185938|NCT03740750|Placebo Comparator|control|sham heat and sham TENS
10185939|NCT03740750|Experimental|heat only|heat applied to the back for 4 hours with sham TENS
10185940|NCT03740750|Experimental|Tens only|Tens applied for 4 hours with sham heat
10185941|NCT03740750|Experimental|Heat and Tens continuous|Heat and Tens applied together for 4 hours
10185942|NCT03740750|Experimental|Tens 15|Tens applied only 15 minutes each hour for 4 hours, sham heat
10185943|NCT03740750|Experimental|Heat and Tens 15|Heat applied for 4 hours with tens only applied the last 15 minutes of each hour
10185944|NCT03740711|Experimental|Early LA venting|When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
9671095|NCT05053217|Active Comparator|Patients diagnosed with fibromyalgia|
9671096|NCT05053217|Active Comparator|Patients without a diagnosis of fibromyalgia|
9671097|NCT05052840|Experimental|Muscle endurance training (MET)|
9671098|NCT05052840|Active Comparator|Conventional Treatment|
9671099|NCT05053074|Experimental|NHF - NHF/CO2|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) alone, then NHF (30l/min) plus 1% CO2.
9671100|NCT05053074|Experimental|NHF/CO2 - NHF|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) plus 1% CO2 , then NHF (30l/min) alone.
9671101|NCT05053386|Experimental|Idarubicin|10mg idarubicin is dissolved in 5ml water for injection, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
10156431|NCT04034823|Experimental|KN035 in combination with trastuzumab and docetaxel|
10156432|NCT04035070|Experimental|Root canal irrigation with co-amoxiclav-clindamycin solution|Alternate irrigation with 1 mL antibiotic-containing solution followed by 4 mL 2.5% sodium hypochlorite solution between each size instrument and the consequent one. The antibiotic-containing solution will be prepared by mixing equal quantities of 1.2 gm Co-amoxiclav solution and 600 mg Clindamycin solution at a ratio of 1:1 by volume.
10156433|NCT04035070|Experimental|Root canal irrigation with MTAD|Irrigation with 5 mL MTAD irrigating solution for 5 minutes between each size instrument and the consequent one.
10156434|NCT04035070|Active Comparator|Root canal irrigation with 2.5% sodium hypochlorite|Irrigation with 5 mL 2.5% sodium hypochlorite irrigating solution between each size instrument and the consequent one.
10156435|NCT04035057|Experimental|Behaviorally Enhanced Training Strategies|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions. The two conditions will differ in their training focus during the subsequent half-day training. The Behaviorally Enhanced condition will involve therapist engagement in repeated self-exposure and partner-exposure exercises with the goal of targeting and reducing therapists' reservations about using exposure with their patients. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Behaviorally Enhanced condition will include regular sampling and feedback on therapists' remaining reservations about exposure in additional to counseling the implementation of exposure with therapists' patients.
10156436|NCT04035057|Active Comparator|Standard Didactic Training|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions.The two conditions will differ in their training focus during the subsequent half-day training. The Standard Didactic condition will involve additional didactic instruction related to common barriers and more advanced delivery concepts than will be presented in the half-day training for the Behaviorally Enhanced condition. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Standard Didactic condition will involve counseling on the implementation of exposure with therapists' patients without explicit focus on therapists' remaining reservations about exposure.
10156437|NCT04034758|Placebo Comparator|Placebo capsule arm|Oral administration of 30 placebo capsule containing edible pigmented starch together with full dose of oral 5-Aminosalicylic acid(5-ASA).
10156438|NCT04034758|Active Comparator|SQIMC-md FMT arm|Oral administration of 30 SQIMC-md capsules containing 2*10^13 copies of prepared fecal microbiota lyophilized powder from multiple healthy donors' fresh feces together with full dose of oral 5-Aminosalicylic acid(5-ASA).
10156439|NCT04034966|Active Comparator|Claria|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) with the telemedicine module. The telemedicine module is the platform for storing patient information directly from the PD machine. Handling will be done according to the basic operating instructions established by the manufacturer.
10156440|NCT04034966|No Intervention|Control|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) without the telemedicine device. the device is used for automated peritoneal dialysis. Handling will be done according to the basic operating instructions established by the manufacturer.
9671102|NCT05053386|Active Comparator|Epirubicin|50mg epirubicin is dissolved in 5ml 5% glucose solution, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
9671103|NCT05052788||Case group|40 patients according to inclusion criteria .
9671104|NCT05052788||Control group|20 normal people with no history of previous brain insult and with free neurological examination .
9671105|NCT05052593|Experimental|Compressive myofascial release|". patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. with pressure directed from distal to proximal.~Conventional treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)"
10156441|NCT04034901|Experimental|Monitoring of cardiorespiratory parameters|Monitoring of cardiorespiratory parameters with BORA Band
10156442|NCT04034979|No Intervention|Phase I-Baseline evaluation|The first two months of the investigator's project will be a baseline evaluation of the current decision making process about goals-of-care in a local ICU setting (Levis, Quebec). A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) dyads of physicians and newly admitted elderly patients discussing goals-of-care.
9671106|NCT05052593|Active Comparator|Conventional treatment|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
9671107|NCT05052879|Experimental|TORONTO 20 + 30/60|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of Toronto association, oral;~1 tablet of tadalafil placebo, oral."
9671108|NCT05052879|Active Comparator|TADALAFIL|"The study is double-dummy. The patient must take 2 tablets before the sexual intercourse, as follows:~1 tablet of tadalafil , oral;~1 tablet of Toronto association placebo, oral."
9671109|NCT05052892||Training cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
9671110|NCT05052892||Validation cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
9826373|NCT02416180|Experimental|SERETIDE EVOHALER|Subjects will switch from their current usual maintenance treatment of SERETIDE via DISKUS Inhaler to an equivalent dose of SERETIDE via the MDI (EVOHALER) at Visit 1. Subjects will use the MDI as 2 inhalations twice daily for approximately 14 days. Subjects will revert back to using SERETIDE DISKUS Inhaler again from Visit 2 (after 14 days) starting with the next scheduled dose.
10156443|NCT04034979|Experimental|Phase II-Impact of the decision aid|The two following months will be an evaluation of the decision making process about goals-of-care in the same local ICU setting using only the decision aid without any training. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care, whether the physician chooses to use the context-adapted decision-aid or not.
10156444|NCT04034979|Experimental|Phase III- Impact of the decision aid and the|This phase will be an evaluation of the decision making process about goals-of-care in the same local ICU setting after intensivists complete the training program and using the DA. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care using the context-adapted decision aid and the new skills learned in the training program.
10156445|NCT04034771|Experimental|propofol and melatonin|propofol iv infusion and melatonin 10 mg tablet through a nasogastric tube, once at admission.
10156446|NCT04034771|Active Comparator|propofol and placebo|propofol iv infusion and a placebo tablets through a nasogastric tube once at admission
10156447|NCT04034706||PCOS females|Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.
10156448|NCT04034706||Non-PCOS control females|Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.
10156449|NCT04034953|Other|Colorectal Cancer Screening|"Potential screening participants will firstly be briefed about the CRC screening pilot program launched by the Department of Health (DH).~This project will offer screening referrals to the government pilot program or FIT screening tests for a total of 10,000 consecutive visitors."
10156450|NCT04034953|Other|Prostate Cancer Screening|A blood test for Prostate Specific Antigen (PSA) will then be performed. Subsequently, for subjects with serum PSA 4-10 ng/ml, additional blood tests for Prostate Health Index (PHI) will be performed for the further assessment of risk of prostate cancer. Subjects with serum PSA > 10 ng/ml; or PHI ≥ 35 will be referred for Trans-rectal Ultrasound-guided Prostatic Biopsy (TRUS+PB). Subjects with serum PSA < 4 ng/ml or with PHI level < 35 will be invited to repeat the prostate screening tests every 2-years. We aim to screen not more than 5,000 subjects. For all patients recruited for prostate cancer screening, the study team will continue follow the subjects, by phone or mail or other means, for the long term clinical outcome for up to 10 years.
10156451|NCT04034953|Other|Breast Cancer Screening|Up to 5,000 eligible female subjects will receive a mammography on a 2-yearly basis. Individuals with abnormal findings on mammography will be referred for subsequent follow-up by the Jockey Club Breast Health Centre (BHC) run by the Hong Kong Breast Cancer Foundation (HKBCF).
10156452|NCT04034875|Experimental|Patients with acquired brain injury|
10156453|NCT04034862|Experimental|2DR|Switch from 3 drug regimen (DTG+ABC+3TC) to 2 drug regimen (DTG+3TC)
10156454|NCT04034862|No Intervention|3DR|Continued 3 drug regimen treatment (DTG+ABC+3TC)
10156455|NCT04034784|Experimental|Discrete(TM)|Intraperitoneal injection
10156456|NCT04034784|Sham Comparator|Control Lactated Ringer's Solution (Control LRS)|Intraperitoneal injection
10156457|NCT04034836|Experimental|The scalp blocks group|The scalp blocks group will receive scalp blocks with ropivacaine, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine (5 ug/mL) and i.v. saline 2ml;
10156458|NCT04034836|Active Comparator|The i.v. group|The i.v. group will receive scalp blocks with ropivacaine 20ml, plus saline 2ml with epinephrine (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously.
10156459|NCT04034836|Active Comparator|The control group|The control group will receive scalp blocks with ropivacaine, 20ml, plus saline 2ml with epinephrine (5 ug/mL) and i.v. saline 2ml;
10156460|NCT04034849|Experimental|Test group|Low-Level Laser Therapy was applied in the test group with a Diode Laser Fox (A.R.C. Laser, Italy) using these parameters: a wavelength of 810 nm, a power of 0.6 W, a power density of 1.2 W/cm2, a beam area of 0.08 cm2 and an energy of 6 J with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
10156461|NCT04034849|Placebo Comparator|Placebo group|Low-Level Laser Therapy was applied in the placebo group with a Diode Laser Fox (A.R.C. Laser, Italy) turned off with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
10156462|NCT04034888|Experimental|Home Exercise Program (HEX)|Customized home exercise program
10156463|NCT04034745||Standard of Care telotristat ethyl (Xermelo) Treatment|Treatment of telotristat ethyl (Xermelo) with DXA scans and bionutritional assessments (24-hour food recall and taste/smell alteration) conducted 3x during telotristat ethyl treatment.
10156464|NCT04035031|Experimental|Forxiga first, placebo second|Forxiga followed by placebo
10156465|NCT04035031|Experimental|Placebo first, Forxiga second|Placebo followed by forxiga
10156466|NCT04034732|Experimental|Mindfulness-based Relapses Prevention (MBRP)|The MBRP program will be delivered by an instructor with training in MBSR/MBCT who has more than two years of teaching experience in MBSR/MBCT. The MBRP programme will consist of 2.5 hour weekly sessions for 8 weeks. The mindfulness curriculum will include training in mindfulness through (1) a body scan, (2) sitting meditation and (3) mindful stretching exercises.
9826374|NCT02416193|Experimental|High Dose|50,000 IU cholecalciferol once weekly for three months
10156467|NCT04034732|Active Comparator|Usual Care Control Group (UCCG)|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
10156468|NCT04034693|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
10156469|NCT04034693|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
9671111|NCT05052515|Placebo Comparator|Placebo|Oral treatment Two tablets twice a day for one year
9671112|NCT05052515|Experimental|Nutritional Supplementation|Oral treatment Two tablets twice a day for one year
10156470|NCT04034407|Experimental|Damage control surgery|In the damage control surgery (DCS) group the surgeon was asked to perform rapid source control by stapling the perforated segment leaving blind ends or suturing the perforation site if possible, doing a thorough lavage of the abdominal cavity and placing an intra-abdominal negative pressure system avoiding the retraction of the abdominal wall with dynamic sutures as published. The second-look operation was scheduled for a time 24-48 hours after primary surgery that would be during regular working hours with a colorectal surgeon on hand to make the decision for either anastomosis or ostomy.
10156471|NCT04034407|Active Comparator|Control group|In the conventional treatment group (Group C), the decision to reconstruct the colon or perform a Hartmann procedure was made by the surgeon during the emergency operation. After performing the anastomosis or the Hartmann procedure, patients with advanced peritonitis received an intraabdominal negative pressure system at the discretion of the operating surgeon.
10156472|NCT04034446|Experimental|A|Single dose of CD19-CD22 CAR-T cells
10156473|NCT04034524||New users of GLP1 receptor agonists (exposure)|
10156474|NCT04034524||New users of basal insulin (reference)|
10156475|NCT04034680|Experimental|Home care services - Intervention group|Totally 5 municipalities (25 persons with dementia) will be included in the intervention group, and will receive training in the TIME model. This includes two hours of lectures about dementia and neuropsychiatric symptoms (NPS) and three hours of training and roleplay in using the TIME model. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational and information files. From each municipality, three staff members, called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
10156476|NCT04034680|Active Comparator|Home care services - Control group|Totally 5 municipalities (25 persons with dementia) will be included in the Control group. The municipalities in the control group will receive the same two hours lectures about dementia and NPS as the intervention group. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
10156477|NCT04034563|Other|Risk of advanced neoplasia at 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy at 3-years
10156478|NCT04034563|Other|Risk of advanced neoplasia beyond 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy beyond 3-years
10156479|NCT04034914|Experimental|Yoga Therapy|
10156480|NCT04034602|Experimental|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
10156481|NCT04034602|Active Comparator|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
9671113|NCT05052866|Experimental|Robot Intervetnion|Participants in this Arm will interact with Ryan Companionbot.
10156482|NCT04034615|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
10156483|NCT04034615|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
9671114|NCT05052567|Experimental|CEND-1|CEND-1+paclitaxel (albumin-bound type)+gemcitabine
9671115|NCT05052424||Children with MIS-C|"Children (age <18 years) hospitalized in the Children´s University Hospital of Cologne diagnosed with MIS-C (WHO criteria)~Assessment of clinical data~Blood samples are taken before therapy and on days 1,2,5,7 und 9.~RNA and protein expression of cytokines and immune cell-related markers will be determined via multiplex ELISA, FACS, quantitative PCR, RNAseq, and Western blot."
9671116|NCT05052619|Experimental|Preventive use of advanced antibiotics group|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
10156484|NCT04034615|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
10185945|NCT03740711|Active Comparator|Conventional LA venting|When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
9671117|NCT05052619|Other|Routine group|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
9671118|NCT05052931|Experimental|treatment group|Nab-paclitaxel combined with oxaliplatin and S-1
9671119|NCT05052437|Experimental|Utidelone|
9671120|NCT05052437|Experimental|Utidelone plus capecitabine|
9671121|NCT05052775|Active Comparator|Chlorhexidine Group|These patients were control group given chlorhexidine mouthwash 2 times per day for 15 days
9671122|NCT05052775|Experimental|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
9671123|NCT05052775|Experimental|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
9671124|NCT05052814|Experimental|Calcium hydroxide ( Ca(OH)2 )|Root canal medicament which was placed into root canals with a lentulo spiral.
9671125|NCT05052814|Experimental|Chlorhexidine gel (CHX gel)|Root canal medicament which was placed into root canals with a lentulo spiral.
10156485|NCT04034472|Other|Cardiometabolic risk in women with obesity|The use of interactive digital technology as adjuvant tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However. it was note fully investigated if this can contribute to decrease inflammatory markers in obese women. In the present investigate it was amied to evaluate the effects of clinical approach associated to use of electronic means on inflammatory markers in women with obesity.
10156486|NCT04034628||Laparoscopic insertion|Individuals who undergo laparoscopic PD catheter insertion
10156487|NCT04034628||Percutaneous insertion|Individuals who undergo percutaneous PD catheter insertion by either a nephrologist or radiologist.
10156488|NCT04034589|Experimental|Pyrotinib plus fulvestrant|Pyrotinib(400 mg once daily) + fulvestrant (500 mg, administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days)
10156489|NCT04034641|Experimental|probiotics plus standard therapy|
10156490|NCT04034641|Placebo Comparator|placebo plus standard therapy|
10156491|NCT04034394|Experimental|Electromoxibustion|Participants in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside (Fort Mayer, Guangzhou, China).
10156492|NCT04034394|Active Comparator|Knee health education|Participants in this group will attend 2 sessions (120 minutes each, 1-week apart) of health education related to knee OA symptom management.
10156493|NCT04034537|Experimental|cPSTA GROUP|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo cardiac Phase Space Tomography Analysis (cPSTA) signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
10156494|NCT04034433|Experimental|Exercise|
10156495|NCT04034433|No Intervention|Control|
10156496|NCT04034485|Experimental|LIB003 (lerodalcibep)|300 mg SC Q4W
10156497|NCT04034485|Active Comparator|evolocumab|420 mg SC Q4W
10156498|NCT04034329||ASVAL - group|GSV diameter ≤ 6 mm
10156499|NCT04034329||EVLA-group|GSV diameter > 6 mm
10156500|NCT04034550|Experimental|hospitalized patients diagnosed with leptospirosis|hospitalized patients diagnosed with leptospirosis: 12 months of follow up with biological samples and data collection
10156501|NCT04034277|Experimental|Lee Silverman Voice Therapy|LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.
10156502|NCT04034277|Active Comparator|Conventional Treatment|The content and dose of standard SLT is poorly defined within the published literature. For this reason, the standard therapy intervention will encompass all SLT techniques that are not LSVT®. Treatment will be individualized and may include any of the following: exercises targeting respiration, phonation, articulation, behavioral strategies to reduce prosodic abnormality
10156503|NCT04034511|Experimental|Medically-tailored meal delivery and medical nutrition therapy|Participants assigned to this arm will receive home-delivered, medically-tailored meals for 3 months combined with monthly individual Medical Nutrition Therapy sessions for 6 months. Participants will also receive participants' usual case management services from participants' Medicaid insurance program.
10156504|NCT04034511|No Intervention|Usual care|Participants assigned to this arm of the study will receive usual care and case management services from participants' Medicaid insurance program.
10156505|NCT04034316|Experimental|MSC|"During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:~25% reduction of the ongoing immunosuppressive treatment following the first administration;~50% reduction of the ongoing immunosuppressive treatment following the second administration;~interruption of the ongoing immunosuppressive treatment following the third administration.~In the case that the hypothesis that P ≥ 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
10156506|NCT04034368|Experimental|Experimental Arm|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
10156507|NCT04034173|Other|RAS mutations frequency <= 7%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~5-FU 400 mg/m² BSA, bolus, D1~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
10156508|NCT04034173|Other|RAS mutation frequency >7% to <=14%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~5-FU 400 mg/m² BSA, bolus, D1~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
10185946|NCT03740685||Patients with acute pancreatitis|All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
9671126|NCT05052814|Experimental|Calcium hydroxide+ CHX gel|Root canal medicament which was placed into root canals with a lentulo spiral.
9671127|NCT05052463||sodium (hypo-hyper-normonatremia)|
9671128|NCT05052463||potassium (hypo-hyper-normokalemia)|
9671129|NCT05052463||calcium (hyper-hypo-normocalcemia)|
9671130|NCT05052463||magnesium (hyper-hypo-normocalcemia)|
9671131|NCT05052463||phosphor (hypo-hyper-normophosphatemia)|
9671132|NCT05052944||Cochlear implant recipients|Patients with single-sided deafness undergoing cochlear implantation
9671133|NCT05052450||Dementia with Alzheimer|Patients previously diagnosed with Alzheimer disease would be included
9671134|NCT05052450||Dementia with Lewy Body Dementia|Patients previously diagnosed with Lewy Body Dementia would be included
9671135|NCT05052450||Dementia with Fronto-Temporal Dementia|Patients previously diagnosed with Fronto-Temporal Dementia would be included
9671136|NCT05052450||Dementia with Vascular Disease|Patients previously diagnosed with Dementia with Vascular Disease would be included
9671137|NCT05052450||Dementia with Parkinson Disease|Patients previously diagnosed with Dementia with Parkinson Disease would be included
9973327|NCT01329991|Active Comparator|oral dose of PLX5622-dose to be determined|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
10156509|NCT04034173|Other|RAS mutation frequency >14% to <=20%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~5-FU 400 mg/m² BSA, bolus, D1~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
10156510|NCT04034225|Experimental|SNS-301 added to pembrolizumab|"SNS-301~Pembrolizumab"
10156511|NCT04034069|Experimental|cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of priming iTBS protocol (cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
10156512|NCT04034069|Active Comparator|Sham cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of non-primed, standard iTBS (sham cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
10156513|NCT04034069|Sham Comparator|Sham cTBS + sham iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
10156514|NCT04034199|Experimental|Denosumab group|Patients randomized into the denosumab group will receive denosumab 60mg subcutaneously every 6 months, for a total duration of 1 year. DEXA scan would be repeated at 1 year.
10156515|NCT04034199|Active Comparator|Zoledronic acid|Patients randomized into the denosumab group will receive one dose of zoledronic acid at 5mg intravenously. DEXA scan would be repeated at 1 year.
10156516|NCT04034030|Experimental|Treatment Group|This study will be conducted over one year in 10 focal CSWS patients ranging in age from 3 to 21 years. The patients will be recruited from the large patient population that is served by the Children's Mercy Comprehensive Epilepsy Monitoring Unit (EMU) in Overland Park, Kansas. Subjects will be identified from these EMU patient population. Those meeting inclusion criteria will be approached for possible enrollment. Inclusion criteria will be defined by patients that were diagnosed with focal CSWS in accordance with the ILAE classification with SWI >85% during NREM sleep on their previous or most recent EEG. Patients and their parents/guardians will provide assent/consent for participation in the study after being briefed on the nature of the study, by reading and signing assent and assent/consent forms, respectively
9826375|NCT02416193|Active Comparator|Low Dose|5,000 IU cholecalciferol once weekly for three months
10156517|NCT04034108|Experimental|Experiment group|All the patients were classified as AIS-A at the time of admission to the clinical center. The MRI was performed in all cases prior to and after the surgery. Surgeries were performed between 12 hours to 30 days after trauma. At 15 days after surgery, with protection of a tailored chest-waist cast made of polyurethane 8 foam for thoracic/lumbar injuries or a neck support for cervical injuries, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers.
10156518|NCT04034160|Experimental|burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The beef patty (Beef Patty Chuck) will be 80% lean and 20% fat.
10156519|NCT04034160|Active Comparator|vegetarian burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The vegetarian patty (Impossible Burger) will be 18% fat.
10156520|NCT04033913||Adult patient learning self-catheterization|Patients who have successfully perform self-catheterization during a day hospital in a neuro-urology department complete a questionnaire validated by experts on the different criteria that guided the final choice of the catheter
10156521|NCT04034290|Experimental|Stage 1 (GamFluVac intranasal drip)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated by intranasal drip
10156522|NCT04034290|Experimental|Stage 1 (GamFluVac with the help of a spray dispenser)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated intranasally with the help of a spray dispenser
10156523|NCT04034290|Experimental|Stage 2 Vaccine|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
10156524|NCT04034290|Placebo Comparator|Stage 2 (Controll Group)|Placebo
10156525|NCT04033861|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
10156526|NCT04033861|Placebo Comparator|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
10156527|NCT04033731||Controls|Participants will include 15 healthy men and women aged 18-40 years, right-hand dominant, Native English speakers, with normal or corrected-to-normal vision.
10156528|NCT04033900|Experimental|Prewarming|Active warming is allowed prior to surgery with forced-air warming devices
10156529|NCT04033900|No Intervention|No prewarming|Non active warming is allowed before surgery
10156530|NCT04033978|Experimental|Cognitive remediation arm|Participants will be enrolled in a cognitive remediation group. The program will last 10 weeks and be composed of 10 participants. This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
10156531|NCT04033978|Active Comparator|Control group|Participants will be enrolled in an information control group. They will receive information about psychosocial rehabilitation and recovery process. The program lasts 10 weeks.
10156532|NCT04033627|Experimental|In Vitro T cell depletion|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
10156533|NCT04033939|Experimental|HSK3486-01|Randomized to receive HSK3486 (0.016mg/kg,0.064mg/kg )as a single IV injection. HSK3486-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
9671138|NCT05052541|Experimental|Analgesia Arm: THC (tetrahydrocannabinol), then THC/CBD (cannabidiol), then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
9671139|NCT05052541|Experimental|Analgesia Arm: THC, then Placebo, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
9826376|NCT02416453|Experimental|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
10156534|NCT04033939|Placebo Comparator|Placebo-01|Randomized to receive placebo (0.016mg/kg,0.064mg/kg )as a single IV injection. placebo-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
10156535|NCT04033939|Experimental|HSK3486-02|Randomized to receive either HSK3486（0.128mg/kg,0.192mg/kg,0.288mg/kg,0.432mg/kg,0.540mg/kg,0.648mg/kg,0.810mg/kg) as a single IV injection. HSK3486-02 was open-label.(5 HSK3486-02: 1 propofol-02)
10156536|NCT04033939|Active Comparator|Propofol-02|Randomized to receive propofol (2.5mg/kg) as a single IV injection. Propofol-02 was open-label.(5 HSK3486-02: 1 propofol-02)
10156537|NCT04033965||women <35 with early breast cancer|
10156538|NCT04033965||women>65 years old with early breast cancer|
10156539|NCT04033588|Other|Freedom® Total Knee System|A prospective, multi-centre, non-comparative, post-market clinical follow-up study to evaluate the survivorship, safety and performance of the Freedom® Total Knee System in United Kingdom
10156540|NCT04033796|Active Comparator|25,000 IU|
10156541|NCT04033796|Active Comparator|50,000 IU|
10156542|NCT04033796|Placebo Comparator|Placebo|
10156543|NCT04033575|Sham Comparator|Fluoride Control|Colgate Cavity Protection 0.76% as Na MFP Toothpaste
10156544|NCT04033575|Active Comparator|Colgate Total SF|Colgate Total Clean Mint White Paste 1100 ppm F Toothpaste
10156545|NCT04033679|Experimental|Active TDCS|In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.
10156546|NCT04033679|Sham Comparator|Sham TDCS|In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.
10156547|NCT04033835|Experimental|MBT-I|12 sessions of MBT
10156548|NCT04033835|Active Comparator|Waiting list control|Treatment as usual
10156549|NCT04033809|Active Comparator|Multigrain powder (S)|Oral high fiber multigrain supplements
10156550|NCT04033809|No Intervention|Standard care (C)|Standard care without oral high fiber multigrain supplements
10156551|NCT04033666|Active Comparator|High Flow nasal cannula|It will be administered as part of the high-flow nasal cannula treatment to reduce the symptoms of acute asthma
9671140|NCT05052541|Experimental|Analgesia Arm: THC/CBD, then THC, then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
9826377|NCT02416453|Experimental|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
10156552|NCT04033666|Active Comparator|NIV noninvasive ventilation|It will be administered as part of the Noninvasive ventilation treatment to reduce the symptoms of acute asthma
10156553|NCT04033874|Experimental|Kangaroo care|"Heel stick procedure will be performed during kangaroo care.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
10156554|NCT04033874|Experimental|Mother's lap|"Heel stick procedure will be performed during newborns who are holding on their mother's lap.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
10156555|NCT04033874|Experimental|White noise|"Heel stick procedure will be performed during newborns listened to white noise.~For the white noise; the track named do not cry your baby, pt. 2 will be played in Orhan Osman's Colic album. The white noise level will be adjusted to an average of 55 decibels. During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
10156556|NCT04033874|Experimental|Ambient sound|"Heel stick procedure will be performed during newborns listened to ambient sound.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
10156557|NCT04033887||HCV-only infected|"Archived frozen plasma samples from individuals that were characterised to be HCV-antibody positive or HCV-antibody negative (HCV-only infected). These samples are characterised for their HIV status (negative)."
10156558|NCT04033887||HCV/HIV co-infected|"Archived frozen plasma samples from HCV-positive or HCV-negative individuals who are HIV infected (HCV/HIV co-infected)."
10156559|NCT04033783|Experimental|6MWT - assessor walks behind the patient|In this experimental condition, the assessor walks behind the patient to continuously measure oxygen saturation during the test (recommended procedure)
10156560|NCT04033783|Active Comparator|6MWT - assessor does not walk behind the patient|In this experimental condition, the assessor does not walk behind the patient. The patient carries the pulse oximeter to continuously measure oxygen saturation during the test.
10156561|NCT04033744|Experimental|PRF (platelet-rich fibrin)|PRF will be used after the extraction of the third molar to prevent periodontal defects to second molar
10156562|NCT04033744|Active Comparator|spontaneous healing|after the extraction of the third molar the socket will be left to heal spontaneously
10156563|NCT04033523|Experimental|High intensity-interval training (HIIT)|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
10156564|NCT04033523|No Intervention|normal counterparts|gender-matched normal counterparts (NC) did not receive any form of intervention
10156565|NCT04033497|Experimental|TRAMs I|"Magnetic resonance imaging (MRI)-based treatment response assessment maps (TRAMs)~Patients with an enlarging lesion in the site of a brain metastasis treated with stereotactic radiation for which neurosurgical resection is planned will undergo preoperative TRAMs"
9826378|NCT02416453|Experimental|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
10156566|NCT04033562|Active Comparator|Lidoderm patch|Participants will receive a topical 3.6% Lidocaine/1.25% Menthol patch at the time of their Cesarean section. Patches will be replaced every 12 hours for a total of 60 hours.
10156567|NCT04033562|Active Comparator|Infusion pump|Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.
10156568|NCT04033601|Experimental|non-pharmacological intervention group|
10156569|NCT04033601|Experimental|control group|
10156570|NCT04033536|Active Comparator|Involved target SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined Involved Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
10156571|NCT04033536|Active Comparator|Elective target SSRS|SSRS with 16 Gy in single fraction to the defined Elective Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
10156572|NCT04033484|Active Comparator|Biological Mesh|Using biological mesh to recnostruct the pelvic floor following ELAPE
10156573|NCT04033484|Experimental|Biological Mesh With Negative Pressure Wound Therapy|Using biological mesh compined with negative pressure wound therapy to recnostruct the pelvic floor following ELAPE
10156574|NCT04033510||AF/NR|Single cohort with a known or new diagnosis of atrial fibrillation, and intention attain/maintain normal rhythm. Subjects with be their own controls: Tablet-based cognitive testing to be performed while in atrial fibrillation (AF), and while they are in normal rhythm (NR). Results of both sets of cognitive testing will be compared.
10156575|NCT04033471|Active Comparator|MI|Bupivacaine 0.25% + midazolam 5mg in total volume 10m1
10156576|NCT04033471|Active Comparator|MM|Bupivacaine 0.25% + midazolam 5mg and morphine 5mg in total volume 10ml
10156577|NCT04033471|Active Comparator|MO|bupivacaine 0.25% + morphine 5 mg in total volume 10 ml
10156578|NCT04033458|Experimental|Treatment Sequence ABECD|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B), then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and, then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156579|NCT04033458|Experimental|Treatment Sequence BCADE|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and, then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156580|NCT04033458|Experimental|Treatment Sequence CDBEA|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then, JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then, JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156581|NCT04033458|Experimental|Treatment Sequence DECAB|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regiment 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10185947|NCT03740633|Experimental|Study group|Patients in the study group accept functional training and regular care.
10185948|NCT03740633|Active Comparator|Control group|Patients in the control group only accept regular care.
10185949|NCT03740620|Active Comparator|intervention group|In the intervention group, a nasotracheal tube is inserted into the nostril with the bevel of the tube facing the cephalad direction of the patient.
9826379|NCT02416622|Experimental|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
9826380|NCT02416622|Experimental|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
10156582|NCT04033458|Experimental|Treatment Sequence EADBC|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then, JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156583|NCT04033458|Experimental|Treatment Sequence DCEBA|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156584|NCT04033458|Experimental|Treatment Sequence EDACB|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156585|NCT04033458|Experimental|Treatment Sequence AEBDC|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and then JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156586|NCT04033458|Experimental|Treatment Sequence BACED|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156587|NCT04033458|Experimental|Treatment Sequence CBDAE|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
10156588|NCT04033133|Experimental|Multiple Sclerosis|People with MS get tDCS with different intensities.
10156589|NCT04033133|Active Comparator|Healthy Subjects|Healthy subjects get tDCS with different intensities.
10156590|NCT04033159|Experimental|cohort 1|DYN101 in a low dose (1.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
10156591|NCT04033159|Experimental|cohort 2|DYN101 in a middle dose (4.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
9826381|NCT02416622|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
9973328|NCT01329991|Placebo Comparator|Placebo Comparator|2 patients per cohort will be randomly assigned to take placebo. 8 patients total will be randomized to take placebo in this study.
10156592|NCT04033159|Experimental|cohort 3|DYN101 in a high dose (9 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3-4 subjects with a mutation in DNM2 (subcohort a) and 2-3 subjects with a mutation in MTM1 (subcohort b).
10156593|NCT04033250|Experimental|Interventional arm (group A)|"Patients with risk factors for IBP who will receive intensified bowel preparation"
10156594|NCT04033250|Active Comparator|Control arm (group B)|Patients with risk factors for IBP who will receive standard bowel preparation
10156595|NCT04033250|Active Comparator|Control arm (group c)|Patients without risk factors for IPB who will receive standard bowel preparation
10156596|NCT04033172|Experimental|Pyrotinib plus Fulvestrant|
10156597|NCT04033302|Experimental|Single arm|Multiple CAR T cells to treat CD7-positive hematological malignancies
10156598|NCT04033198||fourth decade|appendectomy done , appendix send for histopathological examination
10156599|NCT04033198||fifth decade|appendectomy done , appendix send for histopathological examination
10156600|NCT04033198||sixth decade|appendectomy done , appendix send for histopathological examination
10156601|NCT04033198||older than 60 years|appendectomy done , appendix send for histopathological examination
10156602|NCT04033185|Active Comparator|study group|virtual reality, robot-assisted gait training, conventional treatment
10156603|NCT04033185|Other|control group|conventional treatment
9973329|NCT01330004||Hemodialysis patients|
10156604|NCT04033016|Experimental|Facebook and motivational interviewing group|Women from this group were included in social media intervention and in two sessions of motivational interviewing.
10156605|NCT04033016|Experimental|Facebook only group|Women from this group were included in the social media intervention only.
10156606|NCT04033016|No Intervention|control group|women from this group only received the information on the benefits of physical activity during pregnancy.
9671141|NCT05052541|Experimental|Analgesia Arm: THC/CBD, then Placebo, then THC|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
9826382|NCT02416622|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
9973330|NCT01330056|Active Comparator|FOPS|"Functional organ preservation surgery (FOPS) group as a first-line treatment modality~Postoperative RT or CRT may be included for the patients of this group"
10156607|NCT04033393|Experimental|Game based dual-task training group|Participants in dual-task training group will execute game based dual-task training with treadmill, 3 times per week for 8 weeks
10156608|NCT04033393|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training, 3 times per week for 8 weeks
10156609|NCT04033146|Experimental|Economical muscle dynamics|The investigators are trying to figure out how to optimize muscle contractile conditions for mobility. To do this, the investigators are systematically altering muscle contraction conditions for all participants.
10156610|NCT04033029||Patients under CVVHDF with high adsorption membrane|Continuous venovenous hemodiafiltration mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
9973331|NCT01330056|Active Comparator|CRT|"Concurrent chemoradiotherapy or radiotherapy group as a first-line treatment modality~Salvage surgery may be applied for the patients for persistent or recurrent cancers after CRT or RT"
9826383|NCT02416713|Placebo Comparator|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
9973332|NCT01330082|Experimental|Photodynamic therapy|will be treated by PDT using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
9973333|NCT01330082|Experimental|Light-emitting diode Irradiation|will be treated only by using Light-emitting diode(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark)
9973334|NCT01330082|Experimental|applying photosensitizer|will be treated only by toluidine blue O
10156611|NCT04033055|Experimental|CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
10156612|NCT04033055|Active Comparator|CycloMesh™ soaked in saline solution 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
10156613|NCT04033094||MorphaBond ER|
10156614|NCT04033094||Comparator Group|
10156615|NCT04033341|Experimental|LY3214996 + [14C]-LY3214996|A single dose of LY3214996 and [14C]-LY3214996 administered orally.
10156616|NCT04033406|Experimental|VIR-2482|VIR-2482
10156617|NCT04033406|Placebo Comparator|Placebo|Placebo
10185950|NCT03740620|Active Comparator|conventional group|In the conventional group, a nasotracheal tube is inserted in a usual way, i.e., with the bevel of the tube facing the left side of the patient.
10185951|NCT03740607|Experimental|Virtual reality during PIV placement|Randomized consented adult subjects will participate in a six-minute healthcare virtual reality software program via Samsung Gear virtual reality headsets while receiving 18 or 20-gauge peripheral intravenous catheter placement in peri-operative suite in preparation for surgery. They will be asked to rate their pain and discomfort afterwards using a graphic rating scale. They will be asked several questions about satisfaction, in order to elicit clinical significance of this intervention. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
10185952|NCT03740607|Placebo Comparator|Standard PIV placement|Adult control arm subjects will receive 18 or 20-gauge peripheral intravenous catheter placement according to current standard protocol, without virtual reality distraction .They will be asked to rate pain and discomfort afterwards using a graphic rating scale. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
10185953|NCT03740594|Active Comparator|KMC 60 min group|
10185954|NCT03740594|Active Comparator|KMC 120 min group|
10185955|NCT03740594|Active Comparator|control group|
10185956|NCT03740581|Active Comparator|Intensive|New anti-diabetic drug regimen with (mandatory) Insulin >= 3 times per day
10185957|NCT03740581|No Intervention|Conventional|Old anti-diabetic drug regimen with or without Insulin (<3 times per day) to be continued as before
10185958|NCT03740568|Other|Normal Progesterone group|Progesterone level >10.64 ng/mL on day 4 of progesterone supplementation
10185959|NCT03740568|Experimental|Low Progesterone group|Progesterone level <10.64 ng/mL on day 4 of progesterone supplementation
10185960|NCT03740555|Experimental|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose,
10185961|NCT03740555|Placebo Comparator|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose
10185962|NCT03740555|Experimental|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route
10185963|NCT03740555|Placebo Comparator|Placebo, multiple ascending doses|Placebo, multiple ascending doses, Intravenous route,
10185964|NCT03740477|Experimental|Intrevention|Eligible participants will receive a 30-second smartphone-based ECG
10185965|NCT03740464|Experimental|Study group|Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
10185966|NCT03740464|Active Comparator|Control group|Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
10185967|NCT03740451|Experimental|Experimental group 1|Active mobilization of soft tissues
10185968|NCT03740451|Experimental|Experimental group 2|Passive mobilization
9973335|NCT01330095|Active Comparator|Eearly administration|Administration of Bifidobacterium within 48h after birth
9973336|NCT01330095|Active Comparator|Late administration|Administration of Bifidobacterium more than 48h after birth
9977830|NCT01365637|Experimental|Cohort 4 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
10185969|NCT03740451|No Intervention|Control group|No intervention
9826384|NCT02416713|Experimental|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
10156618|NCT04033042|Experimental|Protocol 1|RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.
10156619|NCT04033042|Experimental|Protocol 2|"RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.~One group of subjects will receive training in the use of the device the other will not. Both groups will receive the instructions for use."
10156620|NCT04033380|Active Comparator|Resin bloc endocrown|composite-based blocs (Grandio Blocs, VOCO)
10156621|NCT04033380|Active Comparator|Ceramic endocrown|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
10156622|NCT04033276|Active Comparator|Rituximab|Inj Rituximab 375mg/m2 IV given on day 0
10156623|NCT04033276|Active Comparator|Combination of high-dose IVIG and Rituximab|IV Rituximab 375mg/m2 on day 0 and IV high-dose IVIG 2g/kg on day 0
10156624|NCT04032691|Experimental|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
10156625|NCT04032886|Experimental|classic kinesio tape|this group will receive mechanical correction tape with classic tape plus exercise.
10156626|NCT04032886|Experimental|performance kinesio tape|this group will receive mechanical correction tape with performance tape plus exercise.
10156627|NCT04032886|Other|control|this group will receive only exercise.
10156628|NCT04032639||Prader-Willi Syndrome|24 children and adolescents (7-16 years) with diagnosed Prader-Willi Syndrome will be recruited
9826385|NCT02416713|Experimental|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
9826386|NCT02416713|Experimental|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
10156629|NCT04032639||Controls|24 children and adolescents (7-16 years) without diagnosed Prader-Willi Syndrome will be matched for age, sex, and BMI-percentile to the Prader-Willi group
10156630|NCT04032925|Experimental|PICSO therapy Group|"This will be the only treatment of the PICSO VIPER study. Within this group patients will be randomised to have cycles of 2 minutes of balloon-induced myocardial schema with PICSO device in ON vs OFF modality."
10156631|NCT04032860|Experimental|ETV group|group in which patients take ETV as antiviral therapy after curative treatment
10156632|NCT04032860|Experimental|TDF group|group in which patients take TDF as antiviral therapy after curative treatment
10156633|NCT04032873|Other|Provider Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by the orthopaedic surgeon before the decision for immobilization has been made.
10156634|NCT04032873|Other|Research Team Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by a member of the study team after the decision for immobilization has been made.
10156635|NCT04032678|Experimental|1 (DGT7)|"Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard Touch 7 - DGT7, Schiller Medical, France) with recommended by the manufacturer adult pads (FRED-PA1, Schiller) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.~Other Name: DGT7"
10156636|NCT04032678|Active Comparator|2 (LP15)|"Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.~Other Name: LP15"
10156637|NCT04032730|No Intervention|Control|Participants assigned to the control arm will undergo treatment and care for MDR/XDR-TB as per the South African Department of Health guidelines.
10156638|NCT04032730|Experimental|Intervention|Participants assigned to the intervention arm will undergo extensive counselling, participants will be provided with an electronic pillbox that monitors their adherence to one of their TB and one of their ART medication. Based on the recordings provided by the wisepill device we will determine if a participant is adherent to their medication and intervene with counselling, phone calls, home visits and relevant referrals.
10156639|NCT04032821|Experimental|Alkotinib（300mg）First empty stomach, after the meal|Alkotinib（300mg），Subjects need to be fasting overnight for at least 10 hours before being warmed to 240 mL on an empty stomach Water service, lunch 4 hours later, dinner 10 hours later.
9977831|NCT01365663|Experimental|Cohort 1|0.25 mg/kg in Healthy Subjects
10156640|NCT04032821|Experimental|Alkotinib（300mg）After eating first, after fasting|Alkotinib（300mg），Subjects need to be fasting for at least 10 hours overnight, starting 30 min before taking the medication A standard meal (800-1000 CAL) can be taken before taking the medicine, and 240 mL warm water can be taken after the meal Lunch hours later, dinner 10 hours later.
10156641|NCT04032665||Stable coronary and peripheral artery disease (CAD/PAD)|Stable CAD/PAD patients with previous percutaneous coronary intervention and drug eluting stent-implantation treated with dual antiplatelet therapy (ASA+clopidogrel)
10156642|NCT04032665||Acute coronary artery disease (ACS)|Patients with troponin-positive ACS (NSTEMI/STEMI) with planned percutaneous coronary intervention and drug eluting stent-implantation treated with P2Y12 inhibitor (ticagrelor) and ASA
10185970|NCT03740425||Transfusion|Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
10185971|NCT03740425||No Transfusion|Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
10156643|NCT04032769|Experimental|Modified strategy MODS|"the threshold of D-dimer will depend on the YEARS rule (MODS strategy):~If all the three items of YEARS are negative (i.e. No hemoptysis, No clinical sign of deep venous thrombosis and PE is not the most likely diagnosis), then the threshold of D-dimer will be raised at 1000 ng/ml.~If at least one item of YEARS is positive, then the threshold will remain unchanged (>500 ng/ml for patients aged < 50 and > agex10 for patients aged 50 and over).~A positive result of D-dimer and the absence of other obvious cause for PE will mandate a CTPA, or V/Q scan if CTPA is contra-indicated.~A negative result of D-dimer will rule out PE."
10156644|NCT04032769|No Intervention|Control group|All included patients will be tested with D-Dimer, threshold for ordering a CTPA as usual
10156645|NCT04032847|Experimental|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001.
10156646|NCT04032847|Experimental|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor.
10156647|NCT04032899|Experimental|L. fermentum CECT5716 3x109 ufc|Volunteers will take 1 capsule per day with L. fermentum CECT5716 3x109 cfu mixed with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
9973337|NCT01330121|Active Comparator|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
10156648|NCT04032899|Placebo Comparator|Maltodextrin|Volunteers will take 1 capsule per day with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
10156649|NCT04032951|Experimental|Adominal neoplasms patients|Patients in whom EUS-FNTA is performed with a novel type of biopsy neede.
10156650|NCT04032938||the control group|30 healthy people as the control group.
10156651|NCT04032938||the case group|60 patients were admitted to intensive care unit (ICU) as the case group after cardiac surgery and extracorporeal circulation. This group should contain 30 patients with fever and/or hemodynamic instability and 30 patients with normothermia and normal hemodynamic.
10156652|NCT04032834|Other|Part 1, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
10156653|NCT04032834|Other|Part 1, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
9973338|NCT01330121|No Intervention|Standard therapy|Standard therapy: Nurses distribute a education pamphlet on diabetes
9973339|NCT01330147||Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
9973340|NCT01330160||cohort of stroke patients|patients, over 40 years old and without dementia, displaying an hemorrhagic or an ischemic stroke, with a sus-tentorial localization, and included 72h before the onset of symptoms
10156654|NCT04032834|Other|Part 1, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
10156655|NCT04032834|Other|Part 1, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
10156656|NCT04032834|Other|Part 1, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
10156657|NCT04032834|Other|Part 1, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
10156658|NCT04032834|Other|Part 2, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
10156659|NCT04032834|Other|Part 2, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
10156660|NCT04032834|Other|Part 2, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
10156661|NCT04032834|Other|Part 2, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
9973341|NCT01330173|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
9973342|NCT01330186||Anal cancer|
9973343|NCT01330199|Experimental|TDF 150mg + MVC 150mg|Subjects will receive a single dose of tenofovir 150 mg and maraviroc 150 mg.
9973344|NCT01330199|Experimental|TDF 300mg + MVC 300mg|Subjects will receive a single dose of tenofovir 300 mg and maraviroc 300 mg.
9973345|NCT01330199|Experimental|TDF 600mg +MVC 600mg|Subjects will receive a single dose of tenofovir 600 mg and maraviroc 600 mg.
9973346|NCT01330199|Experimental|FTC 100mg + RAL 200mg|Subjects will receive a single dose of emtricitabine 100 mg and raltegravir 200 mg.
9977832|NCT01365663|Experimental|Cohort 2|0.5 mg/kg in Healthy Subjects
10156662|NCT04032834|Other|Part 2, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
9826387|NCT02416791|Active Comparator|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
9826388|NCT02416791|Active Comparator|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
9973347|NCT01330199|Experimental|FTC 200mg + RAL 400mg|Subjects will receive a single dose of emtricitabine 200 mg and raltegravir 400 mg.
10156663|NCT04032834|Other|Part 2, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
10156664|NCT04032834|Other|Part 3, Arm A of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask.
10156665|NCT04032834|Other|Part 3, Arm B of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece.
10156666|NCT04032834|Other|Part 3, Arm C of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask.
10156667|NCT04032834|Other|Part 3, Arm D of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece.
10156668|NCT04032574|Experimental|Herbal medicinal product|three times daily two film coated tablets containing: extracts of restharrow root (Ononidis radix) 80mg,Java tea (Orthosiphonis folium) 90mg, goldenrod herb (Solidaginis herba) 180mg
10156669|NCT04032574|Placebo Comparator|Placebo|three times daily two film coated tablets
10156670|NCT04032600|Other|Full paracentesis|All ascites is drained
10156671|NCT04032600|Other|Fractioned paracentesis|3 Liters are drained, then the drain is clamped and the rest of the ascites is drained on the next day
10156672|NCT04032587|Experimental|Non-treatment seeking subjects with Alcohol Use Disorder|AUD; mild vs. moderate to heavy
10156673|NCT04032587|Active Comparator|Healthy Controls|
10156674|NCT04032405|Active Comparator|CAF+CTG|the combined connective tissue graft (CTG) with coronally advanced flap (CAF)
10156675|NCT04032405|Experimental|CAF+CTG+i-prf|the combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
10156676|NCT04032457|Active Comparator|A1 - SiHyDD to Moist|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
10156677|NCT04032457|Active Comparator|A2 - Moist to SiHyDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
10156678|NCT04032457|Active Comparator|A3 - SiHyDD to OASDD|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of ACUVUE® OASYS 1-Day contact lenses.
10156679|NCT04032457|Active Comparator|A4 - OASDD to SiHyDD|1 week of ACUVUE® OASYS 1-Day contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
10156680|NCT04032457|Active Comparator|A5 - SiHyDD to DT1|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of Alcon DAILIES TOTAL 1® contact lenses.
10156681|NCT04032457|Active Comparator|A6 - DT1 to SiHyDD|1 week of Alcon DAILIES TOTAL 1® contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
10156682|NCT04032457|Active Comparator|B1 - HydDD to Moist|1 week of Test HydDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
10156683|NCT04032457|Active Comparator|B2 - Moist to HydDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
10156684|NCT04032457|Active Comparator|B3 - HydDD to BioTrue|1 week of Test HydDD contact lenses followed by cross over to 1 week of BIOTRUE ONEday® contact lenses.
10156685|NCT04032457|Active Comparator|B4 - BioTrue to HydDD|1 week of BIOTRUE ONEday® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
10156686|NCT04032457|Active Comparator|B5 - HydDD to AqCom+|1 week of Test HydDD contact lenses followed by cross over to 1 week of DAILIES® AquaComfort PLUS® contact lenses.
10156687|NCT04032457|Active Comparator|B6 - AqCom+ to HydDD|1 week of DAILIES® AquaComfort PLUS® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
10156688|NCT04032548|Placebo Comparator|Placebo|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
10156689|NCT04032548|Experimental|Propolis|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
10156690|NCT04032548|Active Comparator|Chlorhexidine|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
10185972|NCT03740412|Experimental|Sedentary behaviour reduction (behaviour change techniques)|Intervention group attending visits 1, 2, 3, 4, 5
10185973|NCT03740412|No Intervention|Usual care|Will receive usual orthopaedic care, attending visits 1, 4, 5
9826389|NCT02416791|Experimental|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
9973348|NCT01330199|Experimental|FTC 400mg + RAL 800mg|Subjects will receive a single dose of emtricitabine 400 mg and raltegravir 800 mg.
9973349|NCT01330238|Active Comparator|Zoledronic acid|Single infusion of 5 mg zoledronic acid I.V.
9671142|NCT05052541|Experimental|Analgesia Arm: Placebo, then THC, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
9973350|NCT01330238|Placebo Comparator|Placebo|Single infusion of 100 ml isotonic NaCl-solution I.V.
10156691|NCT04032522||Intervention Arm (A)|Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA >1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.
10156692|NCT04032522||Control Arm (B)|The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.
10156693|NCT04032496|Experimental|Mindfulness Intervention|Participants in this arm will participate in the Contemplative-Based Intervention for People Living with SLE intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
10156694|NCT04032496|Active Comparator|HEP Intervention|Participants in this arm will participate in the Health Enhancement Program (HEP) intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
10156695|NCT04032314||Healthy controls - cross-sectional project design|
10156696|NCT04032314||Patients - cross-sectional project design|
10156697|NCT04032314||Patients - longitudinal project design|
9973351|NCT01330251||Patients with diabetes having Roux-en-Y gastric bypass|
10156698|NCT04032262|Other|Parkinson's Disease Relationship to the GI track|Patients with Parkinson's.
10156699|NCT04032236|Other|smoking group|35 smoking case
10156700|NCT04032236|Other|nonsmoking group|35 nonsmoking case
10156701|NCT04032431|Experimental|Telerehab VR intervention|The telerehab VR intervention consists of a custom-made software running on a computer connected with a commercial VR device (i.e. Oculus Rift). PwMS will be requested to reproduce several ADLs from the three main areas of self-care, dressing and meal preparation. The user can physically see his/her hands within the virtual scenario and, during the exercise, the hand coordinates are continuously recorded. Thus, data on 3D trajectory, speed, accuracy on target placement and movement smoothness, will be accessible. They will be stored in the PC and also be remotely sent to the clinical center for further analysis/processing. Both target position and task complexity will define the exercise difficulty, which can be modified automatically, on the basis of the previous performance or manually modified by the user
10156702|NCT04032431|Active Comparator|Conventional therapy|Conventional therapy will focus on task-related upper-limb treatments while in a sitting or prone position, representing the standard care in MS. Several manual techniques, therapy tools and objects of ADL will be allowed during treatment. No restrictions will be placed on the material used (ie, ADL, reaching and grasping material). Use of additional electrical or mechanical therapy devices (ie, support arm systems, splints) will be avoided. The interventions will be conducted on a one-on-one basis in the physiotherapy or occupational therapy department of each participating center. Training and therapy content will be tailored to each participant's preferences, the agreed movement aims and the motor function level of each MS patient.
10156703|NCT04032366||PEEP 5|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, without inhaled nitric oxide
10156704|NCT04032366||PEEP 10|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, without inhaled nitric oxide
10156705|NCT04032366||PEEP 10 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, with inhaled nitric oxide
10156706|NCT04032366||PEEP 5 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, with inhaled nitric oxide
10156707|NCT04032340||Elderly with a companion dog|elderly living at home with a dog consulting his family doctor
10156708|NCT04032340||Elderly without a companion dog|elderly living at home without a dog consulting his family doctor
10156709|NCT04032392|Experimental|Autologous γδT cells|"Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions.~Dose escalation subjects will receive 6 infusions with dose of γδT cells escalation from 1×10e9 to 6×10e9.~Constant dose subjects will have single infusion intravenously at a target dose of 1~2×10e9 γδT cells."
10156710|NCT04032379||Certain IIH or IIH-WOP|According to revised diagnostic criteria, Friedmann, 2013.
10156711|NCT04032379||Suspected IIH|IIH is suspected, does not fulfill diagnostic criteria.
10156712|NCT04032379||IIH ruled out|Patients in whom another diagnosis is made.
10156713|NCT04032353|Other|Medical Consortium|subjects involved in medical consortium for screening upper gastrointestinal canccers(MCSC)
9671143|NCT05052541|Experimental|Analgesia Arm: Placebo, then THC/CBD, then THC|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
9671144|NCT05052541|Experimental|Reduction Arm: THC/CBD|Subjects in this parallel arm will be assigned to 13 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
9973352|NCT01330251||Patients without diabetes having Roux-en-Y gastric bypass|
9973353|NCT01330251||Control subjects (patients having gastroscopy, no surgery)|
9973354|NCT01330264||Dyad|
9977833|NCT01365663|Experimental|Cohort 3|1.0 mg/kg in Healthy Subjects
10156714|NCT04032002|Other|Patients hereditary bradykinetic angioedema|
9520087|NCT03280589|Active Comparator|Sitting Quietly|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. Instructions will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. The total duration of this session will be approximately 40 minutes.
9671145|NCT05052541|Placebo Comparator|Reduction Arm: Placebo|Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
9671146|NCT05052177||Patient with systemic right ventricles with severe tricuspid regurgitation and high surgical risk|"inclusion criteria:~> 18-years-old~Right systemic ventricle~Severe tricuspid regurgitation~Symptomatic patient (NYHA 2 - 4) despite optimal medical therapy~High-risk surgical patient deemed not eligible for surgery by a multi-disciplinary and thus having underwent a percutaneous treatment of tricuspid regurgitation~exclusion criteria - pregnant ou breastfeeding women"
9671147|NCT05052164|Experimental|Gluten-free nutrition plan + exercise group|Celiac women who perform a physical exercise program 3/4 times per week and a gluten-free isocaloric dietary plan.
9671148|NCT05052164|Experimental|Gluten-free nutrition plan group|Women with celiac disease following a gluten-free isocaloric dietary plan.
9671149|NCT05052164|Active Comparator|Celiac controls group|Women with celiac disease in whom all variables are measured but no intervention is performed.
9826390|NCT02416908|Experimental|Phase I Schedule A (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
10156715|NCT04032002|Other|healthy volunteers|
10156716|NCT04032080|Experimental|LY3023414 + prexasertib|Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression. Patients whose disease does not respond to the combination of LY3023414 and prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician.
10156717|NCT04032015|Active Comparator|rTMS treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own MRI images. Daily treatment regiments will last 30 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
10156718|NCT04032015|Sham Comparator|Sham treatment|"Sham rTMS will be delivered for 20 sessions over 4 weeks. To maximize sham validity, both 1) a direction-sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity 10Hz electrical stimulation will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS treatment. Daily treatment regiments will last 30 minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS sessions for adverse events and/or side effects.~Upon completing the 20 sham sessions, participants are unblinded and offered 20 treatments of active rTMS. The open-label treatment would follow the active rTMS treatment protocol."
10156719|NCT04032054||A|mono-axial
10156720|NCT04032054||B|poly-axial
9973355|NCT01330277||Participants with Hunter syndrome|Participants diagnosed with Hunter syndrome (Mucopolisaccharidosis type 2) aged between 2 months to 50 years
9973356|NCT01330329|Experimental|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention.
9973357|NCT01330329|Experimental|Standard behavioral treatment (SBT)|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program.
10156721|NCT04032223|Experimental|3D printed metal copings|3D printed primary and secondary metal copings inderctly from 3D printed resin in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
10156722|NCT04032223|Active Comparator|Cast metal copings|Cast metal primary and secondary metal copings in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
10156723|NCT04032132|Experimental|curcumin paste in conjunction with open flap debridement surge|curcumin paste (2% circumin) in conjunction with open flap debridement surgery
9671150|NCT05052164|No Intervention|Non-celiac controls group|Non celiac menopausal or post-menopausal in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
9671151|NCT05052086|Experimental|Magnetomotoric ultrasound|Magnetomotoric ultrasound in addition to MRI.
9973358|NCT01330342||HIV patients without lymphoma|HIV-infected subjects on cART without a diagnosis of lymphoma
10156724|NCT04032132|Placebo Comparator|open flap debridement surgery only|surgical treatment for periodontal pocket
10156725|NCT04032184|Active Comparator|Fluoride toothpaste|
10156726|NCT04032184|Experimental|fluoride toothpaste and chlorhexidine mouthwash|
10156727|NCT04032184|Experimental|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|
10156728|NCT04031937|Active Comparator|major depressive disorder|psychometric scales psychomotor assessment
10156729|NCT04031937|Active Comparator|Control|psychometric scales psychomotor assessment
10156730|NCT04032197|Experimental|Semaglutide|Semaglutide injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg semaglutide is reached.
10185974|NCT03740399|Active Comparator|Group sitting|we are performing spinal anesthesia in sitting position pregnant patients
9973359|NCT01330342||HIV patients with lymphoma|HIV seropositive individuals with lymphoma
10156731|NCT04032197|Placebo Comparator|Placebo|Placebo injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg placebo is reached.
10156732|NCT04032119|Experimental|Epinephrine|0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection
10156733|NCT04032119|Active Comparator|Non-epinephrine|No epinephrine would be added into the solution
9973360|NCT01330407|Experimental|gp2|Cultured Epidermal Autografts
9662043|NCT05131984||Multiple Sclerosis patients on Ocrelizumab at Boston Medical Center|All MS patients at the Boston Medical Center MS Clinic who have been diagnosed with RRMS or PPMS, ages 18 or older, on Ocrelizumab for at least one year and have received at least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg), who have been followed at these institutions for clinical care and brain and/or spinal cord MRI, and who have received Ocrelizumab infusions at these institutions for the duration of the study period.
9662044|NCT05131971|Experimental|Cohort 1: Participants receiving GSK3888130B at dose level 1|
9973361|NCT01330407|Active Comparator|gp1|cryopreserved skin allografts.
9973362|NCT01330472|Active Comparator|Xanax XR tablets 3 mg (sourced from Caugus)|Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE)
10156734|NCT04032210|Experimental|Regimen using dual Zinc plus Arginine based toothpaste|
10156735|NCT04032210|Experimental|Regimen using Zinc based toothpaste (Crest complete)|
10156736|NCT04032210|Active Comparator|Fluoride based toothpaste (Signal)|
9973363|NCT01330472|Experimental|Xanax XR tablets 3 mg (sourced from Barceloneta),|Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST)
10156737|NCT04032275||Untreated chronic HBV infected person group|Enrolled in the Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Department of Liver Histology, Department of Hepatology, Chronic HBV HBV infection.
10156738|NCT04031859|Experimental|Group A|In this group a VTE risk stratification procedure will be used
10156739|NCT04031859|No Intervention|Group B|In this group a standard VTE risk stratification procedure will be used (Caprini VTE risk assessment tool)
10156740|NCT04031924||Liver Transplantation|Sixteen individuals with liver transplantation were included in the study, and their physical and demographic characteristics of the individuals recorded. The Senior Fitness Test (SFT) was used to evaluate to physical fitness. The Tampa Scale for Kinesiophobia (TSK) was used to assess kinesiophobia; the Fatigue Impact Scale (FIS) and Fatigue Severity Scale (FSS) to evaluate fatigue; the Berg Balance Scale (BBS) and the Timed Up and Go test (TUG) to evaluate the balance; the International Physical Activity Questionnaire (IPAQ) to determine the level of physical activity;and the Hospital Anxiety and Depression Scale (HADS) to evaluate psychological status.
10156741|NCT04031924||Healthy Subjects|Sixteen age- and sex-matched healthy subjects were included in the study.
10156742|NCT04032249|Active Comparator|Control Group (CG)|Education and modifying diet
10156743|NCT04032249|Experimental|Intervention Group (IG)|Education, modifying diet and Indications to record self-weighing with a frequency of 2 times per week
10156744|NCT04031911|Other|Control group|Control group benefiting from standard support (AFU (Association Française d'Urologie) information sheet), but applied in a more supervised way (communication document, process studies, etc.).
9973364|NCT01330485|Experimental|Affect Regulation Training|Affect Regulation Training as described in Berking & Whitley, 2014.
10156745|NCT04031911|Experimental|Study group|"Study group benefiting from a short spa treatment (5 days) with hydroposturotherapy (HPT arm) in Vittel or Capvern: posturotherapy, lumbar percussion and controlled hyperdiuresis."
10156746|NCT04031872|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer with LY3200882 and capecitabine
10156747|NCT04031781|Active Comparator|Receiving repetitive transcranial magnetic stimulation (rTMS)|This group received 5 rTMS sessions, delivered over one week over the left dorsolateral prefrontal cortex (LDLPFC ) at 5-Hz frequency and 100% motor threshold intensity.
10156748|NCT04031781|Placebo Comparator|Group receiving placebo rTMS|This group received Placebo rTMS was given with the same stimulation frequency at a fixed intensity of 50% of the machine output
10156749|NCT04031794||Conventional ARDS treatment group|Patients who they or their 1st degree relative refuse to initiate ECMO. They will receive conventional ARDS treatment.
10156750|NCT04031794||ECMO group|Patients who ECMO is initiated for treat refractory hypoxemia. They will receive conventional ARDS treatment and ECMO support
10156751|NCT04031755|Experimental|Minocycline versus Placebo|"Phase 1: 4 weeks of daily minocycline 100mg BID dosing~2-week washout period~Phase 2: 4 weeks of daily placebo dosing"
10156752|NCT04031755|Experimental|Placebo versus Minocycline|"Phase 1: 4 weeks of daily placebo dosing~2-week washout period~Phase 2: 4 weeks of daily minocycline 100mg BID dosing"
10156753|NCT04031742|Experimental|Part 1: IBI306|Participants received open-label IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
10156754|NCT04031742|Experimental|Part 2: IBI306|Participants received open-label 450mg Q4W subcutaneously for 12 weeks.
10156755|NCT04031898||full analysis set|All eligible patients who meet all inclusion criteria and none of the exclusion criteria
10156756|NCT04031677|Other|Standard arm|Surgery alone
10156757|NCT04031677|Experimental|Experimental arm|Preoperative chemotherapy and surgery
10156758|NCT04031703|Experimental|6 cycles of PC adjuvant chemotherapy|6 cycles of PC (Paclitaxel 80 mg/m2 ivgtt d1,8,15+ Carboplatin Auc = 2 ivgtt d1,8,15, 28 days per cycle).
10156759|NCT04031703|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|3 cycles of FEC (epirubicin100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
10156760|NCT04031664|Experimental|Qianjin Capsule of Gynaecology|"On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days.~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
9671152|NCT05052281|Experimental|Intervention group|"The first MB course session and technology training will take place in-person, prior to 23 weeks gestation. The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress. Sessions are delivered 1-on-1 with a trained facilitator and are based on principles of cognitive-behavioral therapy (CBT) and attachment theory. The MB course is divided into 3 sections: 1) Pleasant Activities; 2) Thoughts; 3) Contact with Others. Throughout each module, mindfulness skills training will be integrated as a strategy to help center participants. All participants will receive a Participant Manual for Families, containing worksheets that correspond to the 12 sessions."
10156761|NCT04031664|Placebo Comparator|Antibiotics alone group|"Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days.~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
10156762|NCT04031534|Experimental|Measure of hypoxia by F-Miso PET scan and RMI|Patient will undergo F-Miso PET scan and MRI to detect hypoxia. Imaging will be correlated with immunohistochemistry on tumour biopsy
10156763|NCT04031482||Ongoing or incipient targeted therapies|Ongoing or incipient targeted therapies with biologics and/or other targeted therapies (e.g. Janus kinase inhibitors)
10156764|NCT04031469||General Population|The general population will have their microbiome sequenced from stool samples provided.
10156765|NCT04031612||Neoadjuvant Breast Cancer|Patients undergoing neoadjuvant therapy for breast cancer
10156766|NCT04031638||Radioactive Iodine treatment for thyroid cancer|
10156767|NCT04031547|Active Comparator|Active tES-fMRI|
10156768|NCT04031547|Sham Comparator|Inactive/Sham tES-fMRI|
10156769|NCT04031573|Experimental|Ivabradine (Low)|
10156770|NCT04031573|Experimental|Ivabradine (High)|
10156771|NCT04031573|Placebo Comparator|Control|
10156772|NCT04031586||Children diagnosed with Solid Tumors|Children diagnosed with solid tumors in Managua, Nicaragua in Central America
10156773|NCT04031625||Metastatic Colorectal Cancer|
10156774|NCT04031430|Experimental|telemonitoring group (TM)|
10156775|NCT04031430|Active Comparator|Patient self-monitoring group (PSM)|
10156776|NCT04031430|No Intervention|control group (CC)|
10156777|NCT04031365|Experimental|Acupuncture and Cognitive Behavioral Therapy|Participants will receive four sessions of a brief acupuncture therapy in addition to a brief cognitive behavioral therapy.
10156778|NCT04031365|Active Comparator|Cognitive Behavioral Therapy|Participants in this group will receive a brief cognitive behavioral therapy in addition to four telephone follow-ups.
10156779|NCT04031391|Experimental|physical activity group|
10156780|NCT04031391|No Intervention|Control group|
10156781|NCT04031417|Other|Placebo|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
10156782|NCT04031417|Other|soy isoflavones|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
10156783|NCT04031417|Other|soy isoflavones & cocoa polyphenols|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
10156784|NCT04031235|Experimental|Safe Sleep Education|Mothers in the intervention group will receive education on American Academy of Pediatrics safe sleep recommendations using a specially-designed children's book (Sleep Baby, Safe and Snug). In addition, they will receive information on the importance of reading with their infant using a brochure created by the AAP.
10156785|NCT04031235|Active Comparator|Infant Reading Education|Mothers in the control group will receive education on American Academy of Pediatrics recommendations on reading and talking to infants using a specially-designed children's book (Read Baby, Every Day). In addition, they will receive information on safe sleep using a brochure created by the AAP.
10156786|NCT04031378|Active Comparator|A|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation using PET/CT imaging studies every 6 months
10156787|NCT04031378|Experimental|B|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months stratified by whether disease is castrate-sensitive (mCS-PCa) or castrate-resistant (mCR-PCa)
10156788|NCT04031326|Experimental|LENA Home|Home visitors assigned to the intervention group will be trained to use and administer LENA Home in addition to the standard ECS curriculum during designated home visits beginning when the child is between 6- and 9-months old.
10156789|NCT04031326|No Intervention|Standard Practice|Home visitors assigned to the control group will administer the standard ECS curriculum only
10156790|NCT04031170|Experimental|Intervention|Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic & Advanced Parent Training Program. It consists of twelve (12) 2-hour classes led by Dean Coffey, a senior psychologist and certified peer coach in the Incredible Years Parent Training Series.
10156791|NCT04031170|Other|Control|Parents assigned to the control arm will be emailed and mailed written parent education materials from the American Academy of Pediatrics called the Bright Futures handouts. The control group is offered the Incredible Years® School Age Basic & Advanced Parent Training Program after a 3-month wait list period.
10156792|NCT04031131|Active Comparator|Intervention Arm|topical anaesthetic gel and lubricating gel
10156793|NCT04031131|Placebo Comparator|Control Arm|lubricating gel alone
10156794|NCT04031157|Experimental|PGT arm|Predictix Antidepressant-guided treatment condition
10156795|NCT04031157|No Intervention|soc arm|Standard of Care condition
9671153|NCT05052281|Active Comparator|Stress monitoring (control) group|This group will not receive any additional intervention but will engage in stress monitoring via biosensors and EMA text messages through the 14 week period
10156796|NCT04031274||TAVI no MR|Patients undergoing TAVI with MR up to moderate following the procedure
10156797|NCT04031274||TAVI + MR no further intervention|Patients undergoing TAVI with MR more than moderate following the procedure, no further mitral valve intervention
10156798|NCT04031274||TAVI + MR undergoing TMVR/r|Patients undergoing TAVI with MR more than moderate following the procedure, underwent transcatheter mitral valve intervention
10156799|NCT04031066|Experimental|Velmanase alfa|
10156800|NCT04031066|Placebo Comparator|placebo|
10156801|NCT04031300|Experimental|RSP-20|Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 48 days.
10156802|NCT04031248|Experimental|WBV group (experimental)|"Participants in the experimental group will follow a program that will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work.~The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience."
10156803|NCT04031248|Active Comparator|Exercise group (control)|Control subjects will perform the same exercise program without whole-body vibration.
10156804|NCT04031209||G7 G7 Acetabular System|All patients will receive G7 G7 Acetabular System
10156805|NCT04031092|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for patients with chronic pain.
10156806|NCT04031092|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
10156807|NCT04031196|Active Comparator|QLB group, Quadratus Lumborum Block group|the patient placed in the lateral decubitus position, the low-frequency convex probe of Sonosite M Turbo ultrasonography was placed in the anterior axillary line midway between subcostal margin and iliac crest to identify the abdominal muscle layers, then the probe was moved to the posterior axillary line to visualize the quadratus lumborum muscle attached to the transverse process of the L4, With the psoas major muscle placed anteriorly, the erector spinae muscle posteriorly, a 22-gauge, 80 mm needle was inserted in-plane into the posterior aspect of QL muscle (between quadratus lumborum and erector spinae muscle), and then 0.5ml/kg of 0.25% levobupivacaine local anesthetic was injected behind the muscle as a bolus dose. The block was performed bilaterally.
10156808|NCT04031196|Active Comparator|TAP block group,Transversus Abdominis Plane Block group|patient placed in the supine position, a linear multifrequency 6-13 MHz probe of Sonosite M Turbo ultrasonography was placed posterior to the midaxillary line at the midpoint between the inferior costal margin and the iliac crest, a 22-gauge, 50 mm needle was placed using an in-plane technique between the internal oblique and transversus abdominis muscle then local anesthetic was injected in a bolus dose 0.5ml/kg of 0.25% levobupivacaine, the block was done bilaterally.. after ultrasound Identification of the plane between the internal oblique and transversus abdominis muscle,
10156809|NCT04030910|Experimental|'LIFEView' intervention|"The 'LIFEView' session(s) involves the use of audiovisual software by Motitech AS (technology provided by and used with permission from Motitech AS). For its primary uses as Motiview, the audiovisual software was coupled to a mobile user-adapted cycle-trainer. Since a secondary benefit of the virtual cycle trip may include reminiscence which may in-turn facilitate conversation of past experiences, the audiovisual software is being adapted for use in reminiscence therapy for a palliative care population.~As there is an extensive library available to participants and 'LIFEView' sessions could potentially be longer than feasible for research personnel to conduct, each 'LIFEView' session will be limited to up to 3 videos per session or up to 1 hour of videos per session, whichever is a shorter duration. Additional post-study 'LIFEView' sessions can be provided upon request from participants."
10156810|NCT04031079|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program).
10156811|NCT04031079|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
9671154|NCT05052385||ECP only (aGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
9662045|NCT05131971|Placebo Comparator|Cohort 1: Participants receiving placebo|
9671155|NCT05052385||ECP and Ruxolitinib (aGVHD patients)|Patients treated with ECP and Ruxolitinib
9671156|NCT05052385||Ruxolitinib only (aGVHD patients)|Patients treated with Ruxolitinib and other Standard Of Care treatments (SOC)
9671157|NCT05052385||ECP only (cGVHD patients)|Patients treated with ECP and other Standard Of Care treatments (SOC)
9977834|NCT01365663|Experimental|Cohort 4|1.5 mg/kg in Healthy Subjects
9662046|NCT05131971|Experimental|Cohort 2: Participants receiving GSK3888130B at dose level 2|
9662047|NCT05131971|Placebo Comparator|Cohort 2: Participants receiving placebo|
9662048|NCT05131971|Experimental|Cohort 3: Participants receiving GSK3888130B at dose level 3|
9662049|NCT05131971|Placebo Comparator|Cohort 3: Participants receiving placebo|
9662050|NCT05131971|Experimental|Cohort 4: Participants receiving GSK3888130B at dose level 4|
9662051|NCT05131971|Placebo Comparator|Cohort 4: Participants receiving placebo|
9662052|NCT05131971|Experimental|Cohort 5: Participants receiving GSK3888130B at dose level 5|
10156812|NCT04030949||Ateendes STD clinics Östergötland physician appointment|"Attendees with an appointment to a physician (if she has symptoms or if she wishes a gynecological exam).~The exam starts with an Abbot multi-collect swab taken from the anal verge, at the opening of the anal canal.~A pediatric proctoscope (a proctoscope designed and manufactured to examine children) is used for sampling the rectal specimens using an Abbot multi-collect swab and a standard Sigma swab of Sigma virocult, followed by vaginal speculum exam. Firstly samples from the lateral fornix for wet smear are collected, secondly a swab for methylene-blue staining from the endocervical orifice followed by two Abbot multi-collect swabs for chlamydia/gonorrhoea and M.genitalium respectively from the orifice, the portio and the vaginal wall and one standard Sigma swab of Sigma virocult from the same areas. Lastly a sample is collected from the distal urethra and stained with methylene blue."
10156813|NCT04030949||Ateendes STD clinics Östergötland, nurse appointment|"The participant collects the rectal sample for chlamydia and gonorrhea (Abbot multi-collect swab) first and is instructed to try not to touch the perianal/perineal areas. Then the vaginal samples for chlamydia/gonorrhoea and M.genitalium are collected.~There is a group of women who have been tested positive for chlamydia by self-collected vaginal swab which is sent to the patient by mail. Those are requested to attend the STD-clinic for partner tracing and are offered antibiotic treatment with doxycycline. Those accepting to participate in the study will answer the study questions and will be tested again and a nurse will collect firstly an Abbot multi-collect swab from the anal verge, at the opening of the anal canal and then two rectal swabs using a pediatric proctoscope (one Abbot multi-collect and one standard Sigma swab of Sigma virocult) and the participant will self-collect a new vaginal sample for chlamydia/gonorrhea and one for M.genitalium (two Abbot multi-collect swabs)"
10156814|NCT04030949||Ateendes STD clinics Östergötland+Jönköping partner chlamydia|"Women attending the STD clinics because of a verified chlamydia infection of their current partner. This group of patients is examined and tested by a nurse or doctor before doxycycline treatment is offered.~Those accepting to participate in the study answer the questions about the experience of receptive anal sex and fellatio (and condom use) during the last 12 months and even additional questions regarding fellatio and whether it happened that a male partner ejaculated in oral cavity of the participant.~The first sample is an Abbot multi-collect swab taken from the anal verge and the anal canal and two more swabs are taken under the use of a pediatric proctoscope: one Abbot multi-collect and one standard Sigma swab of Sigma virocult and finally vaginal samples are collected (one Abbot multi-collect and one standard Sigma swab of Sigma virocult)"
10156815|NCT04030923|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses on the left DLPFC for 10 consecutive sessions totally over period of 10 days.
10156816|NCT04030923|Sham Comparator|sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses with coil perpendicular on scalp over the occipital cortex for 10 consecutive sessions totally over period of 10 days.
10156817|NCT04030689||Axis 2|Each patient diagnosed HIV positive following VihTest test will be invited to participate to ALSO-Parcours; This program aimed to decribe the link to care for this population and to make a descriptive analysis of this HIV+ patients.
10185975|NCT03740399|Active Comparator|Group lateral decubitus position|we are performing spinal anesthesia in lateral decubitus position pregnant patients
10185976|NCT03740399|Active Comparator|Group Modified 45-degree head-up tilt|we are performing spinal anesthesia in Modified 45-degree head-up tilt position pregnant patients
10185977|NCT03740386|Experimental|lidocaine|lidocaine 2% 1:80000
10185978|NCT03740386|Experimental|articaine|articaine 4% 1:200000
9977835|NCT01365663|Experimental|Cohort 5|2.0 mg/kg in Healthy Subjects
10185979|NCT03740386|Experimental|bupivacaine|bupivacaine 0,5% 1:200000
10185980|NCT03740373|Experimental|Treatment Sequence 1|Subjects will receive BGF MDI with 10 s breath hold during Treatment Period 1 and BGF MDI with 3 s breath hold during Treatment Period 2
10185981|NCT03740373|Experimental|Treatment Sequence 2|Subjects will receive BGF MDI with 3 s breath hold during Treatment Period 1 and BGF MDI with 10 s breath hold during Treatment Period 2
10185982|NCT03740347||Juvenile idiopathic arthritis and chronic pain|Patients followed for juvenile idiopathic arthritis and chronic pain in Necker Hospital
10185983|NCT03740321|Experimental|Embospheres 500-700 microns|Intervention.Embolization with 500-700 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
10185984|NCT03740321|Experimental|Embospheres 700-900 microns|Intervention.Embolization with 700-900 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
10185985|NCT03740308|Active Comparator|Locally Made Zirconia Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
10185986|NCT03740308|Experimental|ZR Zirconia Crwons NuSmile ® Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions. (Same as Arm 1 Description)
10185987|NCT03740295|Placebo Comparator|Control Multiple Sclerosis|
10185988|NCT03740295|Experimental|Intervention Multiple Sclerosis|
10185989|NCT03740269||oral health educational program|poster for oral health education program for a group of egyptian school girls
9662053|NCT05131971|Placebo Comparator|Cohort 5: Participants receiving placebo|
9662054|NCT05131971|Experimental|Cohort 6: Participants receiving GSK3888130B at dose level 6|
9662055|NCT05131971|Placebo Comparator|Cohort 6: Participants receiving placebo|
9662056|NCT05131971|Experimental|Cohort 7: Participants receiving GSK3888130B at dose level 7|
9662057|NCT05131971|Placebo Comparator|Cohort 7: Participants receiving placebo|
9662058|NCT05131945|Experimental|Group 1: Standard Suction Thoracentesis|treatment techniques suction is a standard of care and used for draining fluid around the lung.
10156818|NCT04030819|No Intervention|control group|no intervention
10156819|NCT04030819|Experimental|experimental group|schema therapy
10156820|NCT04030845||breast reconstruction|
10156821|NCT04030845||oncoplastic breast-conserving surgery|
10156822|NCT04030663|Active Comparator|papaverine|
10156823|NCT04030663|Active Comparator|nitroglycerine|
10156824|NCT04030663|Placebo Comparator|xlyocaine|
10156825|NCT04030858|Experimental|Treatment group|The treatment group will eat a nutrient-dense plant-based diet and attend weekly nutrition education sessions.
10156826|NCT04030858|No Intervention|Control group|
10156827|NCT04030780|Active Comparator|Cohort 1FD (on-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks on-PPI+ sporebiotics (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
10156828|NCT04030780|Placebo Comparator|Cohort 1FD (on-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks on-PPI+ placebo (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
10156829|NCT04030780|Active Comparator|Cohort 2FD (off-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks of sporebiotics (2) followed by 8 weeks of sporebiotics (open label)
10156830|NCT04030780|Placebo Comparator|Cohort 2FD (off-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks of placebo (2) followed by 8 weeks of sporebiotics (open label)
10156831|NCT04030988|Active Comparator|Active|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
10156832|NCT04030988|Placebo Comparator|Placebo|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
10156833|NCT04030806|Experimental|Intervention group|"All patients will perform 60 minutes of intervention, twice a week, for six weeks. During the intervention, the patient will be positioned seated in a chair with a table in front of him and a mirror (50cm x 50cm) will be placed vertically between his upper extremity.~The patient's paretic upper extremity will be positioned behind the mirror, allowing only the movements of his healthy upper extremity to be visualized. The reflective side of the mirror will be facing the healthy upper extremity , the patient will perform the exercises observing the movements of his healthy upper extremity through the reflection produced by the mirror, interpreting as the movement of his paretic member."
10156834|NCT04030806|Sham Comparator|Control group|All patients will perform 60 minutes of intervention, twice a week, for six weeks. The mirror will be placed in the same position as the intervention group. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm. In the control group, the patients will be submitted to the same bimanual activities of the intervention group, but without the reflecting side of the mirror. Thus, the nonreflective side of the mirror will be facing the healthy arm, the patient will perform the same exercises visualizing only the movement of the healthy member.
10156835|NCT04030650||healthy volunteers|
10156836|NCT04030650||patients|patients with lower limb amputations
10156837|NCT04030884|Experimental|Intervention Lap.Chol.|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a laparoscopic cholecystectomy.
10156838|NCT04030884|No Intervention|Control Lap.Chol.|The participants received standard care for their laparoscopic cholecystectomy.
10156839|NCT04030884|Experimental|Intervention Thyroidectomy|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a thyroidectomy.
10156840|NCT04030884|No Intervention|Control Thyroidectomy|The participants received standard care for their thyroidectomy.
10156841|NCT04030897|Active Comparator|Online Programs + Information/Psychoeducation/Referral (IPR)|"Includes 2 online, one-session programs (one for youths; one for parents) and Primary Care-based IPR. The 30-min, self-administered YOUTH PROGRAM includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change. In the 15-min Qualtrics-based PARENT PROGRAM, parents read 2 scientific passages on (1) the notion that emotions are flexible in youth and adults, and (2) that failure promotes personal growth. After each passage, parents write a persuasive summary of its main arguments, directed to fellow parents who may benefit from the information."
10156842|NCT04030897|Placebo Comparator|Information/Psychoeducation/Referral (IPR; usual care control)|Information, Psychoeducation and Referral (IPR) represents usual care in the Stony Brook University Hospital's Pediatric Primary Care Division. Families of a youth with elevated MD symptoms during a PC visit receive a folder containing informational materials about the nature of depression and referrals to providers in their area. All families in this study will receive PC-based IPR.
10156843|NCT04030793|Experimental|Individualized stimulation group|Based on transcranial direct current stimulation (tDCS) simulation, individualized stimulation on leg motor areas during 30 minutes.
10156844|NCT04030793|Active Comparator|Conventional stimulation group|Conventional stimulation on leg motor areas during 30 minutes.
10156845|NCT04031053||Intensive Pharmacokinetic Group|After receiving the first dose of ITZ, a single blood sample will be collected 12-hours post-dose. On Day 7, the blood will be collected for intensive PK study. After 7 days of combined ITZ + EFV, a blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. An identical set of intensive PK blood samples will be drawn 2 weeks after initiating the EFV based regimen.
10156846|NCT04031053||Trough Level Group|On Days 7 and 14, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. After initiating an EFV based regimen, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose on Days 7 and 14.
10156847|NCT04030767|Experimental|lip repositioning technique with Botox injection.|"Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity (Binder et al., 1998).~Therefore, the technique is a useful adjunct in the esthetic improvement of the smile and provides better results when combined with resective gingival surgery(Pedron & Mangano, 2018)."
10156848|NCT04030767|Active Comparator|lip repositioning technique.|Lip repositioning aims to limit the retraction of elevator smile muscles. Lip repositioning results in a shallow vestibuler restricting of the muscle pull; Thereby limiting the gingival display during smiling.(Makkiah, 2017) It is a less invasive, viable substitute for patients, has fewer post-operative complications and provides a faster recovery compared to orthognathic surgery(Grover, Gupta, & Luthra, 2014).
9520088|NCT03280589|Experimental|Deep Breathing Self Paced|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
9520089|NCT03280589|Experimental|Deep Breathing Externally paced|Participants will have an instructional video with auditory queues prompting them to inhale and exhale at 6 bpm (approximately 4 seconds between inhale and exhale). Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
9662059|NCT05131945|Experimental|Group 2: Gravity Thoracentesis.|treatment techniques (gravity ) is a standard of care and used for draining fluid around the lung.
9662060|NCT05131932|Experimental|Inlet patch|Patients found to have an inlet patch on upper endoscopy
9662061|NCT05131932|No Intervention|Controls|Patients without an inlet patch on upper endoscopy
10156849|NCT04030715|Other|the successful group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
10156850|NCT04030715|Other|the failure group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
10156851|NCT04030741|Active Comparator|Meronem and flagyl|Children in Non-operative treatment (group A) Children in non-operative treatment group will be given intravenous meropenem (10 mg/kg/dose x IV x TDS) and metronidazole (20 mg/kg/day divided into 3 doses) for at least 48 hours. Once the child starts tolerating oral intake and becomes clinically improved, the treatment will be changed to oral ciprofloxacin (20 mg/kg/day) divided into 2 divided doses) and metronidazole (20 mg/kg/day divided into 3 doses for another 8 days.
10156852|NCT04030741|Active Comparator|Surgery (appendectomy)|"Children in group B: appendectomy will b done and post operative single dose of antibiotics.~discharge after 24hour and Follow up after 1 week."
10156853|NCT04030598|Experimental|IONIS-PKK-LRx (Part A)|IONIS-PKK-LRx administered subcutaneously (SC) to participants with HAE-1/HAE-2 every 4 weeks for up to 12 weeks.
10156854|NCT04030598|Experimental|IONIS-PKK-LRx (Part B)|IONIS-PKK-LRx administered SC to participants with HAE-nC1-INH every 4 weeks for up to 12 weeks.
10156855|NCT04030598|Placebo Comparator|Placebo|Placebo will be administered SC to HAE-1/HAE-2 participants every 4 weeks for up to 12 weeks during Part A.
10156856|NCT04030624|Experimental|Remote Electronic Patient Monitoring|"The Remote Electronic Patient Monitoring intervention will entail monitoring of vital sign data and patient reported assessments to address and manage any concerning issues identified.~The Remote Patient Monitoring system uses algorithms that can indicate when patient vitals and patient-reported outcomes have changed.~Automatic patient surveys are sent to the patient with results displayed on the clinician user interface (i.e., dashboard) on a computer located in the clinical area.~Qualitative interviews with patient participants and their oncology clinicians using a semi-structured interview guide will be conducted."
10156857|NCT04030637||CRC cases|samples will be collected from subjects with known diagnosis of colorectal cancer
9662062|NCT05131906|Experimental|People with Parkinson's disease on medication who freeze|We will be testing each of the 15 participants both with and without the removeable lasers on their shoes.
10156858|NCT04030637||Healthy cases|samples will be collected from healthy subjects with normal colonoscopy findings
10156859|NCT04030637||Cases with pathologies|samples will be collected from subjects whose colonoscopies showed other pathologies (e.g. inflammatory polyps, adenomas, diverticular diseases)
10156860|NCT04030754|Experimental|amniotic membrane group|amniotic dressing will be applied to these patients
9662063|NCT05131893||LuminalA|"tamoxifen (+ LHRH analogue for premenopausal participant)~non-steroidal aromatase inhibitor (+ LHRH analogue for premenopausal participant)~Non-steroidal aromatase inhibitor in non-resectable tumor (+ LHRH analogue in premenopausal participant) + CDK4 / 6 inhibitor"
9664658|NCT05302518|Active Comparator|Cognitive behavioral therapy with exposure in vivo|This arm of the study will receive cognitive behavioral therapy with exposure in vivo. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
10156861|NCT04030754|Experimental|duoderm group|duoderm dressing will be applied to these patients as intervention
10156862|NCT04030442|Placebo Comparator|Smoked cannabidiol 0%|
10156863|NCT04030442|Active Comparator|Smoked cannabidiol 3.4%|
10156864|NCT04030442|Active Comparator|Smoked cannabidiol 12.7%|
10156865|NCT04030468|Experimental|General practitioners|Educational intervention
10156866|NCT04030468|Experimental|Patients|Informative intervention
9671158|NCT05052385||ECP and treatment combination (cGVHD patients)|Patients treated with ECP and Ruxolitinib or Ibrutinib
9671159|NCT05052385||Treatment combination only (cGVHD patients)|Patients treated with Ibrutinib and/or Ruxolitinib and other Standard Of Care treatments (SOC)
10156867|NCT04030468|Experimental|General practitioners and patients|Combined strategy
10156868|NCT04030468|No Intervention|Control|No intervention
10156869|NCT04030494|Other|Blood pressure (BP)|Group for the validation of blood pressure measurement by the device
10156870|NCT04030494|Other|Atrial fibrillation (AF)|Group for the validation of detection of AF by the device
10156871|NCT04030494|Other|Valvular heart disease (VHD)|Group for the validation of detection of VHD by the device
10156872|NCT04030533|Experimental|Cohort 1: Guselkumab (SC): Dose 1|Participants will receive a single subcutaneous (SC) injection of guselkumab (dose 1), administered on Day 1.
10156873|NCT04030533|Experimental|Cohort 2: Guselkumab (SC): Dose 2|Participants will receive a single SC injection of guselkumab (dose 2), administered on Day 1.
10156874|NCT04030533|Experimental|Cohort 3: Guselkumab (IV): Dose 1|Participants will receive a single intravenous (IV) infusion of guselkumab (dose 1), administered on Day 1.
10156875|NCT04030533|Experimental|Cohort 4: Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2), administered on Day 1.
9973365|NCT01330485|Active Comparator|Common Factor Control Condition (CFC)|Common factor based therapy control condition
10156876|NCT04030533|Experimental|Cohort 5: Ustekinumab (IV): 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 milligrams per milliliter (mg/mL) solution on Day 1.
10156877|NCT04030572|Experimental|Clonidine Pill|One week period of clonidine, 0.1 mg tabs, one by mouth daily at bedtime
10156878|NCT04030546|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until the last chemotherapy session
10156879|NCT04030546|No Intervention|Usual care|Patient will receive usual care
10156880|NCT04030507|Experimental|Inflammatory Breast Cancer Managed with Curative Intent|"Patients will receive an initial screening magnetic resonance imaging (MRI) of the brain~If no evidence of intracranial involvement is identified, additional screening MRIs of the brain every six months for two years and at initial systemic progression."
10156881|NCT04030507|Experimental|HR+ or HER2+ Metastatic Breast Cancer - Screening Arm|"An initial MRI screening will be conducted~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
10156882|NCT04030507|No Intervention|HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm|No initial MRI screening will be conducted
10156883|NCT04030507|Experimental|Triple Negative Breast Cancer|"An initial MRI screening will be conducted~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
10156884|NCT04030390|Experimental|Physical Fatigue Condition|
10156885|NCT04030390|Placebo Comparator|Control Condition|
10156886|NCT04030611||control group|Participants in the type 2 DM group were diagnosed with DM based on criteria recommended by the American Diabetes Association and required to have a fasting plasma glucose of ≥7mmol/L or an HbA1c of ≥6.5%, as measured on 2 separate occasions.
10156887|NCT04030611||diabetic retinopahty group|Participants in th ediabetic retinopahty group group were diagnosed according to the International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales.
10156888|NCT04030273||Open (laparotomic) myomectomy|Women undergoing uterine myomectomy by open surgery (laparotomy).
10156889|NCT04030273||Laparoscopic myomectomy|Women undergoing uterine myomectomy by laparoscopy.
10156890|NCT04030273||Robotic myomectomy|Women undergoing uterine myomectomy by robotic surgery.
10156891|NCT04030156||ultrasonographic tonsil volume|All measurements were done by the same radiologist with over 20 years of experience. GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) was used in USG examination. The patients were viewed using a 2-9 MHz linear probe from the submental region. The examination was done while the patient was in a supine position, with a neck support. Right tonsil measurement was done by turning the neck slightly to the upper left whereas left tonsil measurement was done by turning the neck slightly to the upper right. Tonsil volume was calculated with standard ultrasonography formula (height x length x thickness x 0.52) due to its ellipsoid shape.
10156892|NCT04030156||Actual tonsil volume|Excised tonsil volumes were calculated by water replacement method.
10156893|NCT04030481||Group A: Sevoflurane, sufentanil and rocuronium|sevoflurane (1-3%)and sufentanil (0.5-2 mcg/kg/h) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
10156894|NCT04030481||Group B: Propofol, sufentanil and rocuronium|propofol (4-12 mg/kg/h) and sufentanil (0.5-2 mcg/kg/h/) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
10156895|NCT04030312|Active Comparator|Standard Infant Formula|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of standard 20 calorie-per-ounce infant formula up to two times during the duration of the study to treat hypoglycemia.
9516842|NCT03311698|Experimental|Intervention|Households receiving the intervention will receive (1) Interventions to promote homestead food production, increase agricultural production and food diversity, (2) nutritional counselling, including locally adapted instructions on the mix and quantity of food suitable for children of ages 6-24 months, and (3) a health-focused intervention, including information on micronutrient supplementation, integrated management of child illnesses, and prevention and management of child malnutrition with a focus on the first 1,000 days.
9671160|NCT05052125|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94% Intervention: Drug: Oxygen gas
9671161|NCT05052125|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92% Intervention: Drug: Oxygen gas
9671162|NCT05052073||MD patients|"patients with different forms of muscle dystrophy, for example~facioscapulohumeral dystrophy~dysferlinopathy~caveolinopathy"
9671163|NCT05052073||Controls|- healthy age- and sex-matched controls (10 men, 10 women)
9973366|NCT01330485|No Intervention|Waitlist Control Condition|Wait List Control
9973367|NCT01330498||Tysabri (natalizumab) infusing|Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).
9671164|NCT05052242||one group compared two measurement methods|one group compared two measurement methods
10156896|NCT04030312|Experimental|Commercially-Sterilized Donor Human Milk|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of 20 calorie-per-ounce commercially-sterilized donor human milk up to two times during the duration of the study to treat hypoglycemia.
10156897|NCT04030351|Experimental|dried fruit|100 g per day of dried fruit
9671165|NCT05052138|Experimental|Tactile massage 1|Tactile massage 1 will receive one 15-min tactile massages (hand massage) per week for 6 weeks
9671166|NCT05052138|Experimental|Tactile massage 2|Tactile massage 2 will receive five 15-min tactile massages(hand massage) per week for 6 weeks
10156898|NCT04030351|No Intervention|no dried fruit|no intervention to be given
10156899|NCT04030208|Other|Sequence A|If patient is randomly assigned to Sequence A, they will be placed on a traditional ventilator for the first period. This period will be 1 hour in duration. Delivered tidal volume, respiratory rate (RR), and peak pressure will be recorded throughout the period using the ventilator. Heart rate (HR), Blood Pressure (BP), and oxygen (O2) saturation measurements will be recorded every 5 minutes. Arterial blood gas (ABG) data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing. Next, the study participant will be transitioned to the Umbulizer to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be taken every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour.
9671167|NCT05052138|No Intervention|comparison group|The comparison group will receive regular care and activities.
9671168|NCT05052255|Experimental|Part 1: Dose Escalation / Part 2: Cohort Expansion|"Part 1-Dose Escalation: Escalating doses of RVU120, in patients who have progressed from previous therapy.~Part 2-Cohort Expansion: Recommended dose in patients with tumor types selected from part 1."
9671169|NCT05052151|Active Comparator|Low temperature|Dialysate temperature
10156900|NCT04030208|Other|Sequence B|If patient is randomly assigned to Sequence B, they will be shifted to the Umbulizer for the first period. This period will be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour. Next, the study participant will be transitioned to a traditional ventilator to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using the ventilator. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing.
10156901|NCT04030260|Experimental|Regorafenib and Nivolumab in Combination with Radiotherapy|
10156902|NCT04030364|Other|Self-referral to group exercise classes|"Structured, multi-component, supervised group exercise classes are the health related intervention proposed for this study. The group classes will occur at a local CrossFit gym facility.~For the purposes of this project, all eligible Rosemount Clinic patients with type 2 diabetes mellitus will receive an email or letter mail invitation to self-refer to a structured, facility-based, supervised aerobic and resistance exercise program. Interested patients will be invited to attend a 1-hour information session at the exercise facility at the time of implementation start up where they will complete an initial baseline survey. This session will also serve as an initial meet and greet for participants to meet exercise trainers prior to starting exercise classes and to receive a tour of the facility."
10156903|NCT04030130|Experimental|NDURE|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system-(care coordination), interpersonal-(social support), and individual- (health belief model [HBM]; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, enhance HNSCC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE navigation sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit, time points chosen to facilitate case identification and coordination across key care transitions.
10156904|NCT04030130|No Intervention|Usual Care|UC consists of discussions about the indications, risks/benefits/alternative, Guidelines, timing, and logistical details of adjuvant therapy. These discussions will be administered according to practice patterns of the involved providers.
10156905|NCT04030286||Control|Healthy patients
10156906|NCT04030286||Periodontitis|Patients with periodontal disease
10156907|NCT04030286||Cardiovascular|Patients with cardiovascular disease
9973368|NCT01330511||Bilateral Hydronephrosis Grade I-II|Patients with Bilateral Hydronephrosis Grade I-II
10156908|NCT04030286||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
10156909|NCT04030195|Experimental|Dose Level 1 of PBCAR20A CAR T cells|"1 x 10^6 CAR T cells per kg body weight.~In this study, PBCAR20A, allogeneic anti-CD20 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).~Route of Administration: Intravenous infusion.~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR20A infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
9671170|NCT05052151|Active Comparator|High temperature|Dialysate temperature
9671171|NCT05052151|Active Comparator|Low bicarbonate|Dialysate bicarbonate concentration
9671172|NCT05052151|Active Comparator|High bicarbonate|Dialysate bicarbonate concentration
9671173|NCT05052034||BAROQUE MUSIC|This group would listen to baroque music to control their anxiety level during their oral surgeries.
9671174|NCT05052034||CLASSICISM MUSIC|this group would listen to classical music to control their anxiety level during their oral surgeries.
9671175|NCT05052034||CONTROL GROUP|This group would not listen to music during their oral intervention, acting as a control group.
9973369|NCT01330511||Bil. Hydronephrosis Grade III-IV, Other|Patient with Bilateral Hydronephrosis Grade III-IV and others with any hydronephrosis and distended bladder or MCKD
9977836|NCT01365663|Placebo Comparator|Saline 0.9%|
10156910|NCT04030195|Experimental|Dose Level 2 of PBCAR20A CAR T cells|3 x 10^6 CAR T cells per kg body weight.
10156911|NCT04030195|Experimental|Dose Level 3 of PBCAR20A CAR T cells|6 x 10^6 CAR T cells per kg body weight.
9973370|NCT01330511||Unilateral Hydronephrosis Grade I-II|Patients with Unilateral Hydronephrosis Grades I-II
10156912|NCT04030039||chronic hepatitis B patients during the immune control period|Patients with chronic HBV infection during the immune control period do not have any clinical treatment intervention cohort
10156913|NCT04030039||Therapy group A|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with interferon
10156914|NCT04030039||Therapy group B|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they stopped to be treated with interferon
10156915|NCT04030039||Therapy group C|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential nucleoside analogues
10156916|NCT04030039||Therapy group D|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential interferon
10156917|NCT04030039||Therapy group E|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with the nucleoside analogues
10156918|NCT04030429|Experimental|Crizotinib arm|Crizotinib 250 mg bid orally
10156919|NCT04030065|Experimental|Experimental Arm - omega 3 fatty acid|
10156920|NCT04030065|No Intervention|Control Arm - No intervention|
10156921|NCT04030455|Experimental|Treatment (cisplatin, docetaxel, pembrolizumab)|Patients receive cisplatin IV over 1 hour, docetaxel IV over 1 hour (patients who develop significant adverse events to cisplatin treatment may receive carboplatin IV over 1 hour instead), and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who completely respond to the study drugs (the disease appears to go away) then receive pembrolizumab IV over 30 minutes on day 1 for 4 additional cycles in the absence of disease progression or unacceptable toxicity.
10156922|NCT04030091|Experimental|3 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 3 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
10156923|NCT04030091|Experimental|2 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 2 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
10156924|NCT04030013|Active Comparator|Group education for 2 years|Patients who will receive structured diabetes education in groups , Group 1
10156925|NCT04030013|Active Comparator|One to one education for 2 years|Patients who will receive one to one structured diabetes education, Group 2
10156926|NCT04030013|No Intervention|Control group without structured education|Patients who will not receive structured diabetes education, Group 3
10156927|NCT04030117|Experimental|ACTIVA Test arm|Treatment of decay in Class II second primary molars using ACTIVA restorative material.
10156928|NCT04030117|Active Comparator|Compomer Comparator arm|Treatment of decay in Class II second primary molars using compomer restorative material.
10156929|NCT04029987|Active Comparator|Trans Muscular Quadratus Lumborum fascial plane Block|"In group (Trans Muscular Quadratus Lumborum Block),will undergo ultrasound guided trans-muscular quadratus lamborum block as follows:~A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoas Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
10156930|NCT04029987|Active Comparator|Intra Muscular Quadratus Lumborum fascial plane Block|"In group Intra Muscular Quadratus Lumborum Block ,will undergo ultrasound guided intra-muscular quadratus lamborum (QL) block as follows:~A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
10156931|NCT04029987|Placebo Comparator|group c → control|group c → control ,will receive conventional analgesia in the form of paracetamol with 15 mg\ k.g every 6 hours, and naluphin 0.1 mg \kg on demands
10156932|NCT04029701|Experimental|Research group|"Subjects who are recruited into this group are asked to take the Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
10156933|NCT04029701|Placebo Comparator|Control group|"Subjects who are recruited into this group are asked to take the placebo of Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
10156934|NCT04029714|Active Comparator|Arm 1: Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and initiation of curative treatment are performed according to the urologist's judgement.
10156935|NCT04029714|Experimental|Arm 2: Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
10156936|NCT04029766|Experimental|HSK3486|0.288 mg/kg bolus (1 min)+ 1 mg/kg/h constant infusion (30 min) or 0.540 mg/kg bolus (1 min)+ 2 mg/kg/h constant infusion (30 min)
9973371|NCT01330511||Unilateral Hydronephrosis Grade III-IV|Patients with Unilateral Hydronephrosis Grade III-IV
10156937|NCT04029831|Experimental|K61|Patients in K61 group received propofol and ketamine in a ratio of 6:1. The 6:1 ketofol mixture was made by mixing 30 mL of 1% propofol (10 mg/mL) and 1 mL of ketamine (50 mg/ml), then 19 mL of 0.9% NaCl was added until the volume of the mixture was 50 mL. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
9973372|NCT01330524|Active Comparator|Avastin and Triamcinolone|
9973373|NCT01330524|Placebo Comparator|Placebo|
9973374|NCT01330550|Experimental|high fiber sugar free biscuit.|High fiber sugar free biscuit will regulate Blood sugars.
9973375|NCT01330563|Experimental|CKD-501|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
9973376|NCT01330563|Experimental|ketoconazole|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
9973377|NCT01330589|Experimental|AB: Placebo (A); St. Johns Wort (B)|Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort
9973378|NCT01330589|Experimental|BA: St. Johns Wort (B); Placebo (A)|Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo
9973379|NCT01330602|Experimental|Lifestyle counseling|"All participants randomised into the IMPRESS Intervention group will undergo tailored health profiling.This individual assessment will be carried out within the clinic setting.~The key elements of the IMPRESS intervention include:~Promoting a healthy lifestyle~Supporting lifestyle and risk modification~Encouraging active self-management of risk and chronic disease~Improving coordination of care~Pharmacological therapy All the individuals in the intervention group will receive a comprehensive report on their risk status and ideal goals."
9973380|NCT01330602|No Intervention|Usual care arm|"Usual Care Following the assessment of absolute cardiovascular risk, usual care participants will be provided a report outlining areas in which improvements could be made for the prevention of atherosclerotic burden.~No restrictions will be made in respect to usual care management. As such, the prescription of standard medications for primary prevention of atherosclerotic burden based on individual risk factors is anticipated in 20-30% of usual care participants.~At 18 months and three years those in the usual care arm will be invited to undergo repeat CIMT measurements, pathology, absolute risk score calculation and health-related questionnaires as part of the structured study follow-up"
9973381|NCT01330615|Active Comparator|Cryotherapy with EMLA|EMLA applied before cryotherapy
9973382|NCT01330615|Placebo Comparator|Cryotherapy with placebo analgesia|Placebo cream applied instead of EMLA
9973383|NCT01330641|Active Comparator|Anterior injection Route|Group of patients injected with medication using the anterior route
9973384|NCT01330641|Active Comparator|Posterior Injection|Group of patients receiving injection through a posterior route
9973385|NCT01330641|Active Comparator|Lateral Injection|Group of patients receiving subacromial injection through a lateral route
9973386|NCT01330654|Active Comparator|Beta blocker|These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
9973387|NCT01330654|No Intervention|Control|This arm will receive no additional treatment prior to surgery
9973388|NCT01330667|Experimental|Formula Supplementation|Participants will supplement feedings with early limited formula following nursing.
9973389|NCT01330667|No Intervention|Control|Participants will be instructed to continue exclusively breastfeeding with no formula supplementation.
9973390|NCT01330680|Experimental|Coffee|
10156938|NCT04029831|Experimental|K41|Patients in K41 group received propofol and ketamine in a ratio of 4:1. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
10156939|NCT04029753|Experimental|Walk out from operating room|Patients will return to the ward after surgery by walking.
10156940|NCT04029753|No Intervention|Leave operating room by transporting bed|Patients will return to the ward after surgery by lying on the transporting bed.
10156941|NCT04029792|Experimental|Combination of Plant Extracts (BSL_EP028)|Volunteers will take twice at day for 8 weeks a capsule containing the combination of a plant extracts (BSL_EP028)
10156942|NCT04029792|Placebo Comparator|Placebo|Volunteers will take twice at day for 8 weeks a capsule containing maltodextrin.
10156943|NCT04029818|Experimental|Probiotic|Volunteers will take a capsule with Bifidobacterium BSL_PS404 (3x109 cfu) daily.
10156944|NCT04029818|Placebo Comparator|Placebo|Volunteers will take a capsule with maltodextrin daily.
10156945|NCT04029974|Experimental|Treatment|Progressive elevation (0 degrees, 25 degrees, 50 degrees, 75 degrees; x2 minutes in each position) while on robotic tilt-stepper at the cadence of 0, 40, and 80 steps/minute.
10156946|NCT04029935|Experimental|Physical Fatigue Condition|
10156947|NCT04029935|Placebo Comparator|Control Condition|
10156948|NCT04029805|Experimental|Combination of a Plant Extract and a Probiotic|Volunteers will take twice at day for 12 weeks a capsule containing the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
9973391|NCT01330680|Active Comparator|Decaffeinated coffee|
9973392|NCT01330693|Active Comparator|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
9973393|NCT01330693|Placebo Comparator|Placebo|Sugar pill
9973394|NCT01330706|Experimental|Sterile Saline solution|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
9973395|NCT01330732||1|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
9973396|NCT01330745|Other|aortic valve replacement|
9973397|NCT01330758|Active Comparator|40 mg AZD8931 wet granulation tablet formulation|
9973398|NCT01330758|Experimental|40 mg AZD8931 roller compacted tablet formulation|
9973399|NCT01330771||hMG-HP/r-FSH|Patients with a condition
9973400|NCT01330784||hMG-HP|Patients with a condition
9973401|NCT01330797||LOCS III|Cohort is composed of cases with a diagnosis of wet age-related macular degeneration and those that received intravitreal ranibizumab
10156949|NCT04029805|Placebo Comparator|Placebo|Volunteers will take twice at day for 12 weeks a capsule containing maltodextrin.
10156950|NCT04029779|Experimental|Immediate implant placement coated with I-PRF|The test group received implants coated with injectable platelet-rich fibrin and also the sockets were injected with injectable- platelet rich fibrin
10156951|NCT04029779|No Intervention|immediate implant only|The control group received immediate dental implants only after extraction of the teeth without any local coating.
10156952|NCT04029948|Active Comparator|laser ERBT|Laser En Bloc Resection Of bladder Tumor
10156953|NCT04029948|Active Comparator|electro-surgical ERBT|electro-surgical En Bloc Resection Of bladder Tumor
10156954|NCT04029857|Active Comparator|Group I (standard of care)|Patients receive standard of care nutritional supplementation.
10156955|NCT04029857|Experimental|Group II (Impact Advanced Recovery)|Patients receive Impact Advanced Recovery PO or via feeding tube BID on days 1-7 for weeks 1, 3, and 5 during chemotherapy and radiation therapy before surgery. Starting 5-7 days before surgery, patients receive Impact Advanced Recovery PO TID until surgery. Within 2 days following surgery, patients may continue to receive Impact Advanced Recovery via feeding tube at the discretion of the treating physician.
10156956|NCT04029909|Experimental|Gimatecan 0.6mg/m2/d|Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
10156957|NCT04029909|Experimental|Gimatecan 0.8mg/m2/d|Three or six patients will be treated with the dose of 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
10156958|NCT04029909|Experimental|Gimatecan 0.4mg/m2/d|Three or six patients will be treated with the dose of 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
10156959|NCT04029675|Experimental|Study Group ( High dose vitamin C group )|They will receive 1.5 gm intravenous (IV) Vitamin C in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes every 6 hours daily for 4 days or until ICU discharge.
10156960|NCT04029675|Active Comparator|Control Group (Daily requirements vitamin C Group )|They will receive standard daily requirements of Vitamin C intravenously which is 75-90 mg in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes daily for 4 days or until ICU discharge
10156961|NCT04029727|Experimental|Combination of Plant Extracts (BSL_EP025)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP025)
9973402|NCT01330810|Active Comparator|C3 tablet|4g C3 tablet
9973403|NCT01330810|Active Comparator|Meriva|2g Meriva powder
10156962|NCT04029727|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
10156963|NCT04029636||Established LONIPC|The first cohort will comprise of patients with established LONIPCs and the investigative procedures in this study will provide data on the scope of abnormalities and pathology across the spectrum of these conditions.
10156964|NCT04029636||Trajectory of LONIPC|The second, prospectively followed, cohort will provide data on the sequence and temporal development of these abnormalities, and therefore provide information on the trajectory of LONIPCs
10156965|NCT04029402||Diabetic kidney disease|Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.
10156966|NCT04029402||Healthy controls|Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities
10156967|NCT04029649|Experimental|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|This group received capsule contains 180 mg Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum with dose 3x1 capsule a day for 90 days
10156968|NCT04029649|Placebo Comparator|Placebo|This group received empty capsule with dose 3x1 capsule a day for 90 days
10156969|NCT04029558|Experimental|Combination of plant extracts (BSL_EP024)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP024)
10156970|NCT04029558|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
10156971|NCT04029662|Experimental|Group Valsalva Maneuver|Patients who undergo spinal anesthesia and perform Valsalva maneuver to reduce the pain intensity
10156972|NCT04029662|No Intervention|Group Control|Patients who undergo spinal anesthesia and perform nothing to reduce the pain intensity
10156973|NCT04029571|Experimental|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
10156974|NCT04029571|Active Comparator|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
10156975|NCT04029571|No Intervention|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
10156976|NCT04029532||Non-overweight/obese & normal weight|Body mass index (BMI) < 24.0 kg/m^2
10156977|NCT04029532||Overweight and obese|Body mass index (BMI) >= 24.0 kg/m^2
9973404|NCT01330823|Active Comparator|L-Carnitine|L-Carnitine 4 g daily for Intervention
9973405|NCT01330823|Placebo Comparator|Placebo|Placebo (tartaric acid)
9973406|NCT01330849|Experimental|Toolkit intervention|
9973407|NCT01330849|No Intervention|Waiting List Control Group|Children eligible for the study according to the inclusion criteria, but randomly allocated to the waiting list control group are promised to receive the intervention AFTER the study is finished.
9973408|NCT01330888||Group 1|ARNG Chaplains
9973409|NCT01330901|Experimental|Ustekinumab|Ustekinumab 90 mg subcutaneously at week 0, 4 and 16
9973410|NCT01330927|Experimental|VA106483 0.5 mg|
9973411|NCT01330927|Experimental|VA106483 1 mg|
9973412|NCT01330927|Experimental|VA106483 2 mg|
10156978|NCT04029428|Active Comparator|90Y DOTATATE|Therapy 90Y DOTATATE, total activity 4x3.7GBq (14.8 GBq), i.v. infusion of 90Y DOTATATE administered for 20 min. via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
10156979|NCT04029428|Experimental|177Lu DOTATATE or mix 90Y and 177Lu DOTATATE (50% each)|Therapy 177Lu DOTATATE, total activity 4x5.55GBq (22.2 GBq), i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution (AA) 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other or therapy 90Y and 177Lu DOTATATE, 4x3.7GBq total activity 14.8 GBq, (mix 50% each 90Y and 177Lu), i.v. infusion of mix 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y and 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
10156980|NCT04029350|Experimental|Anlotinib Combined With Osimertinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Osimertinib 80mg p.o, qd. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
10156981|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Conservational|After ESWT therapy patients suffer from extreme pain will recieve only conservational therapy (26 patients)
10156982|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Local|After ESWT therapy patients suffer from extreme pain will receive local steroid injections
10156983|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Tibial nerve|After ESWT therapy patients suffer from extreme pain will receive tibial nerve block
10156984|NCT04029506||medical staff group|medical staff in Qilu Hospital who recieveing endoscopy for physical examination
10156985|NCT04029506||general population group|general population who recieveing endoscopy for physical examination in Qilu Hospital
9671176|NCT05052021||Perioperative or Recent Covid19 Infection|"Patients will be classified as having Perioperative Covid19 Infection if they test positive for SARS-CoV-2 within 7 days before and 30 days after surgery.~Patients will be classified as having Recent Covid19 infection if they tested positive for Covid19 within 1-6 weeks before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
9671177|NCT05052021||No or Previous Covid19 Infection|"Patients will be classified as having No Covid19 Infection if they have never tested positive for Covid19.~Patients will be classified as having Previous Covid19 Infection when they tested positive for Covid19 infection 7 weeks or more before surgery.~These patients will be analysed together as a group, as it is likely that their risk for complications will be similar."
10156986|NCT04029441||the successful eradication cohort|the subjects who eradicate the Hp successfully after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
10156987|NCT04029441||the failure eradication cohort|the subjects who fail to eradicate the Hp after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
10156988|NCT04029467|Active Comparator|Precedex|participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation
10156989|NCT04029467|Experimental|Dexmedetomidine|participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation
10156990|NCT04029168||Pelvic floor surgery|The group will consist of females with pelvic floor disorders (pelvic organ prolapse, stress urinary incontinence) qualified for pelvic floor surgery
10156991|NCT04029324|Active Comparator|Immediate implant placement|Implants are placed immediately after extraction
10156992|NCT04029324|Placebo Comparator|Early implant placement|Implants are placed 4-8 weeks after extraction
10156993|NCT04029246|No Intervention|Letter only|
10156994|NCT04029246|Active Comparator|Letter plus phone call|
10156995|NCT04029246|Active Comparator|Letter plus incentive|
10156996|NCT04028999|Experimental|the EO31 shoulder sling|To develop and evaluate the effects of the EO31 shoulder sling for the prevention of pain, subluxation, spasticity, as well as effect on increasing functional use of the UL in activities of daily living.
10156997|NCT04029090|Experimental|Sequence 1|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
10156998|NCT04029090|Experimental|Sequence 2|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
10156999|NCT04029090|Experimental|Sequence 3|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
10157000|NCT04029194|Experimental|Treatment|
10157001|NCT04029194|No Intervention|Control|
10157002|NCT04029207||African Surgical OutcomeS-2 Trial|The ASOS-2 Trial is a cluster randomised trial purposively recruiting hospitals across Africa. To be eligible for inclusion a hospital must perform at least 20 cases of adult in-patient surgery with anaesthesia per week, have local ethics approval for the trial, have local hospital management approval and have established a local hospital study team. The trial excludes hospitals with lower surgical volume. The trial aims to include all consecutive adult in-patient surgical cases at participating hospitals (both elective and emergency surgery). Patients under the age of 18 and patients who have already been recruited into the trial are excluded from recruitment. Follow-up is in-hospital, censored at 30 days.
10157003|NCT04029272|Active Comparator|Metformin|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d."
10157004|NCT04029272|Experimental|Metformin+EQW|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d.~EQW: Participants will receive long-acting Exenatide once a week for 12 weeks"
9973413|NCT01330927|Experimental|VA106483 4 mg|
9973414|NCT01330927|Placebo Comparator|Sugar pill|
10157005|NCT04029155|Active Comparator|TBNA with Conventional bronchoscope|patients in this arm will undergo bronchoscopy by a conventional probe
10157006|NCT04029155|Experimental|TBNA with a Ultrathin bronchoscope|Patients in this arm will undergo bronchoscopy by a ultra thin probe
10157007|NCT04029220|Experimental|Parent Peer Navigation (PPN) by Family Run Organization|In this arm, families receive PPN services from a trained provider with lived experience whose role is to effectively engage parents/caregivers in necessary treatment for their children by helping them connect with assessment, treatment and community-based resources and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support once the PPN is no longer involved. PPN providers use the foundational competencies and skills to educate, inform and support families who are just entering the child-serving systems due to emerging behavioral health issues of their child.
10157008|NCT04029220|Active Comparator|Resources provided by Family Support Organization|"The active comparator is service provided by Family Support Organizations (FSOs), which provide information and resources for families about disabilities, special education and other services as well as workshops and parent support groups. Unlike PPN services, FSO staff members are not veteran caregivers of a child with mental health challenges, do not provide personalized service delivery, do not provide a comprehensive assessment of family needs, and do not prepare families to make use of services through support for their initial and continued involvement in them. Finally, whereas PPNs participate in comprehensive training and coaching, training for FSO staff tends to be more general and consists primarily of being aware of local resources to which families may be referred."
10157009|NCT04028986||Surgery group|patients treated by surgery before starting the IVF/ICSI treatment
10157010|NCT04028986||Ulipristalacetate group|patients treated by ulipristalacetate before starting IVF/ICSI treatment
10157011|NCT04029129|No Intervention|High exposure|Ambient air was allowed freely into the room.
10157012|NCT04029129|Experimental|Medium exposure|Limited air filtration was used to partially reduce levels of pollution in the room relative to outside.
10157013|NCT04029129|Experimental|Low exposure|Doors and windows were closed and sealed and full filtration was used to maximally reduce pollution in the room.
10157014|NCT04028778|Experimental|Gefitinib + Anlotinib|Patients will be treated with Gefitinib 250mg, p.o., qd and anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle.
10157015|NCT04028778|Placebo Comparator|Gefitinib + Placebo|Patients will be treated with Gefitinib 250mg, p.o., qd and placebo to simulate anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle
10157016|NCT04028856||Continuous interferon treatment group|Patients with chronic hepatitis B treated with continuous interferon for 48 weeks
10157017|NCT04028856||Intermittent interferon treatment group|patients with chronic hepatitis B treated with intermittent interferon for 48 weeks, in which interferon therapy was intermittent for 3 months
10157018|NCT04028752||Males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
10157019|NCT04028830|Experimental|Arm 1|Medical representative presentation with the help internet tool for decision ANTIBIOCLIC
10157020|NCT04028830|Experimental|Arm 2|Medical representative presentation without presentation of the internet tool for decision support
10157021|NCT04028830|No Intervention|Arm 3|Usual practice without intervention regarding the prescription of antibiotics
10157022|NCT04028765|Active Comparator|Oral Misoprostol|Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated
10157023|NCT04028765|Active Comparator|Oxytocin|IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol
10157024|NCT04028895|Other|Experimental|
10157025|NCT04028791|Experimental|AS and AA|Participants will be submitted to 45 minutes of exercise on ergocycle.
10157026|NCT04028882||Non viremic HIV patients under treatment|Patients with various immune activation profiles
10157027|NCT04028726|Active Comparator|Cluster set Resistance Training Protocol|Cluster set configuration is the new training approach that it is being tested.
10157028|NCT04028726|Sham Comparator|Traditional Resistance Training Protocol|Traditional is commonly used in training sessions.
10185990|NCT03740243|Active Comparator|buprenorphine|"Buprenorphine 2 mg to 8 mg daily: Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine 8 mg to 16 mg daily: Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
10185991|NCT03740243|Experimental|buprenorphine/naloxone|"Buprenorphine/naloxone 4 mg/1 mg daily once daily or twice daily (BID): Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine/naloxone 8 mg/2 mg daily once daily or twice daily (BID): Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
10185992|NCT03740217|Other|Treatment A|Single oral dose of 400 mg GKT137831 administered as 4 x 100 mg capsules in fasting conditions.
10185993|NCT03740217|Other|Treatment B:|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fasting conditions.
10185994|NCT03740217|Other|Treatment C|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fed conditions.
10185995|NCT03740191|Other|Proton Therapy of Prostate Cancer|"Patients with low and intermediate risk are included. The following interventions are performed:~'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire~kV x-ray images~Conebeam CT"
10185996|NCT03740178|Experimental|Donepezil + MK-4334|Oral MK-4334 60/120 mg QD and open-label, oral donepezil 10 mg QD.
10185997|NCT03740178|Placebo Comparator|Donepezil + Placebo|Placebo to MK-4334 QD and open-label, oral donepezil 10 mg QD.
10185998|NCT03740165|Experimental|Pembrolizumab + Olaparib|Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
9973415|NCT01330940|Placebo Comparator|Water drinking|32 ounces of water/24 hours
10157029|NCT04028804||FDG PET|FDG PET imagaing
10157030|NCT04028804||FLT PET|FLT PET imaging
10157031|NCT04029103|Active Comparator|used m-DAKBAS|"m-DAKBAS application was downloaded to the mobile phones of the participants who met the research criteria and accepted to participate in the study; the participants were given a username and a password for the confidentiality. They were instructed how to use the application after a number of trials.~The participants were asked to send their blood sugar levels each time they measured it and foot observations daily through the application. Using the admin panel, the researcher followed the participants' frequency of using the application and the data they sent throughout 24 weeks and tried to find solutions to the problems experienced (for example: hyperglycaemia, insulin dosage adjustments). The participants were provided with feedback in line with these data; SMS reminders were sent if the tasks were not completed."
9973416|NCT01330940|Active Comparator|orange soda drinking|32 ounces orange soda
10157032|NCT04029103|Experimental|not used m-DAKBAS|The participants who met the research criteria and accepted to participate in the study were given training via verbal instruction about the information in the content of m-DAKBAS (definition of Diabetic Foot, risk factors, protective precautions, daily foot care)
10157033|NCT04028713|Active Comparator|Standard dosing group|Patients will continue to receive adalimumab according to the standard dosing schedule.
10157034|NCT04028713|Experimental|Dose tapering group|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
10157035|NCT04028817|Experimental|group treatment|This group will receive laser treatment combined with low intensity exercises
10157036|NCT04028817|Placebo Comparator|group control|This group will receive placebo laser treatment combined with low intensity exercises
10157037|NCT04028739|Experimental|Theracurmin CR-033P|1 Capsule with 150mL water, Single, curcumin 90mg/day
10157038|NCT04028739|Experimental|Theracurmin CR-031P|3 Capsule with 150mL water, Single, curcumin 90mg/day
10157039|NCT04028739|Experimental|Curcumin|1 Capsule with 150mL water, Single, curcumin 90mg/day
10157040|NCT04028869||Glycyrrhizin preparation treatment group|Clinical effect of glycyrrhizic acid preparation for 144 weeks of autoimmune liver disease and safety during treatment
10157041|NCT04028661|Experimental|Intervention group|use of 3D printed Modified Twin Block Appliance.
10157042|NCT04028661|No Intervention|Untreated control group|No treatment phase of 8 months.
10157043|NCT04029740|Other|Healthy controls|40 Healthy controls matched on gender and age with no current psychopathology will have exosomal microRNAs measured twice over a 3 month period.
10157044|NCT04029740|Experimental|panic disorder receiving CBT|40 adult patients diagnosed with primary panic disorder will have their exosomal microRNAs measured 2x over 3 months.
10157045|NCT04029285|Other|Traditional Gym Based exercise - Control|Twice weekly sessions of TGB exercise for six weeks.
10157046|NCT04029285|Experimental|Exergaming|Twice weekly sessions of exergames for six weeks.
10157047|NCT04029038|Experimental|Treatment (CD19-CD22 CAR T cells)|Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
10157048|NCT04028609|Experimental|Intervention|Subjects receive an intervention with 4 components: development of a personal health plan; review and support for medication adherence; connection with primary care provider within 30 days; and education about clinical indicators that call for immediate intervention.
10157049|NCT04028609|Active Comparator|Services as Usual|Subjects receive medical services as usual.
10157050|NCT04028583|Experimental|PIM-Check group|
10157051|NCT04028583|Active Comparator|STOPP/START group|
10157052|NCT04028635|Experimental|Cognitive-behavioral therapy plus VR-based body exposure|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, six sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which the they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions, until a healthy BMI value is reached.
10157053|NCT04028635|Active Comparator|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the centre in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
10157054|NCT04028622|Experimental|TCAD (telemedicine anesthesia consultation)|Patients having a telemedicine anesthesia consultation
10157055|NCT04028596|Active Comparator|Acetaminophen|Trade name: Paracetamol Pharmaceutical form: Tablet (oral use) Once 1000 mg 2h before the ECT-session. Total maximum of five times over the course of weeks
10157056|NCT04028596|Active Comparator|Nimodipine|Trade name: Nimotop Pharmaceutical form: Film-coated tablet (oral use) Once 60mg 2h before the ECT-session. Total maximum of five times over the course of weeks.
10157057|NCT04028596|No Intervention|Control|Glass of water (50cc) only. Once 2h before the ECT-session. Total maximum of five times over the course of weeks.
10157058|NCT04028570|Experimental|Radiation|This study involves a 3+3 design. The starting cohort (n=3) will receive a neoadjuvant Background dose to the affected hemithorax (starting at 0 cGy) as well as concomitant Boost dose (of at least 2100 cGy) to a part of the gross tumour volume (GTV). The radiation will be delivered over 3 alternate days over 5-7 calendar days followed by macroscopically complete extensive pleural resection (either extra-pleural pneumonectomy or extended pleurectomy decortication, at the surgeon's discretion) after 7 to 14 days. If no dose limiting toxicities (DLTs) seen, then the Background RT dose will be increased by 600 cGy (up to 1800 cGy) and the cohort (n=3) for the next dose level will be accrued. If only 1 DLT seen, then an additional 3 patients will be treated on this dose level. If 2 or more DLTs seen at any given dose level, then the previous dose level will be defined as the maximum tolerated dose (MTD). Patients will be stratified by type of resection.
10157059|NCT04028505|Experimental|Terlipressin Continuous Infusion|Standard of care being given at AKUH + Continuous infusion of Terlipressin (Terlipressin Injectable Product) at a rate of 0.5mg/hour for the first 24 hours
9973417|NCT01330992|Experimental|Ocular Light or Dark Exposure|Ocular Light or Dark Exposure
10157060|NCT04028505|Active Comparator|Terlipressin Bolus Infusion|Standard of care being given at AKUH + Bolus infusion of Terlipressin (Terlipressin Injectable Product) at a frequency of 2mg every six hourly for first 24 hours
10157061|NCT04028479||Validation Cohort|Patients enrolled into the study to allow validation of a specific element, process, or endpoint. Validation will be done showing concordance with traditional interventional trial standards.
10157062|NCT04028479||Analysis Cohorts|Patient who are enrolled into the study to allow analysis to determine any association, effect, or benefit. Cohorts can be determined prospectively and/or retrospectively for data already collected, Cohorts are identified to highlight collection of information on patients who are already receiving any treatment or testing as determined by the physician and patient independent of this study. Because many analysis cohorts will be determined in patients already enrolled in the study, this group is inclusive of many different sub-groupings or specific analysis cohorts of patients.
9973418|NCT01331031||Adolescents|Adolescents between 10 and 20 years of age and enrolled in a municipal school system.
10157063|NCT04028479||Retrospective Chart Review Cohorts|"This arm will use retrospective data obtained through systematic chart review on previously seen patients to compare, contrast, or enhance the efforts of the prospective arms. Because most RWD has been traditionally obtained through retrospective methods, this is also considered the control arm. Data in this arm will be collected without any patient identifiers. This arm is optional."
10157064|NCT04028544|Experimental|The Treatment Group|standard treatment + Qishenyiqi dropping pills (QSYQ) (oral use, 1 bag each time, three times a day)
10157065|NCT04028544|Placebo Comparator|The Control Group|standard treatment + placebo (oral use, 1 bag each time, three times a day).
10157066|NCT04028518|Experimental|The high-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
10157067|NCT04028518|Experimental|The low-dose group|"Experimental: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
10157068|NCT04028518|Experimental|Active Comparator: Alteplase|"Active Comparator: Alteplase Drug: Alteplase for Injection Dose:50mg;20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours of medication.Subjects were monitored according to the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018."
10157069|NCT04028453||Mother|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation questionnaire.
10157070|NCT04028258|Other|Group A: study+wash out+control|Study product (3 weeks) + wash out (2 weeks) + control product (3 weeks)
10157071|NCT04028258|Other|Group B: control+wash out+study|Control product (3 weeks) + wash out (2 weeks) + study product (3 weeks)
10157072|NCT04028219||Transgender patients|Gender dysphoric patients undergoing hormone treatment
10157073|NCT04028531||Sample Collection|"Blood tests required for assessment~Specimens and data will also be collected from outside sites~Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute"
10157074|NCT04028245|Experimental|Spartalizumab and Canakinumab|Subjects with renal cell carcinoma will receive study treatment Q4 weeks x 2 doses prior to radical nephrectomy.
10157075|NCT04028557|Experimental|Customized CDS|The customized CDS will be designed and implemented with comprehensive application of known best practice principles in CDS design. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
10157076|NCT04028557|Active Comparator|Commercial CDS|The commercial CDS is available to all institutions using the Epic electronic health record vendor, but violates some CDS design best practices, notably not being tailored to the end users of a given health system. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
10157077|NCT04028310|Experimental|Phonological group|
10157078|NCT04028310|Experimental|visual-attention group|
10157079|NCT04028440|Experimental|Autologous γδT cells|Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions, single infusion intravenously at a target dose of 1~2×10e9 γδT cells (constant dose).
10157080|NCT04028323|Experimental|Experimental group|Drug: Terlipressin. Terlipressin should be administrated with an initial dose of 1-2 mg intravenously and slowly injected (over 1 minute) while monitoring the heart rate and blood pressure. The maintenance dose should be administrated every 4-6 hours. Each dose of terlipressin is 1mg. The usual duration of therapy is 3-5 days.
10157081|NCT04028323|Active Comparator|Control group|Drug: Octreotide. Octreotide should be continuously and intravenously dripped at the speed of 0.025-0.05 mg/h and could be diluted with saline with the maximum duration of 5 days. The usual duration of therapy is 3-5 days.
10157082|NCT04028492|Experimental|Tradipitant|Oral Capsule
9671178|NCT05051826|Experimental|1.Drag Umbrella 2. Hand Resistance 3.Resistance Suit|"In the water, a small umbrella is attached to the athlete to increase resistance.~In the water, increase resistance by increasing the area of the hand.~In the water, use swim shorts that increase resistance"
9671179|NCT05051826|Experimental|1 Resistance 2 Bands Swiss Ball 3 Medicine Ball 4 Pulley Pull|"On land, use a stretch rope to increase resistance.~On land, inflatable bouncy balls are used to increase strength.~On land, solid balls are used to increase strength.~On land, pulleys are used to increase resistance."
9671180|NCT05051748|Active Comparator|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
9671181|NCT05051748|Active Comparator|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA).
9973419|NCT01331044|Experimental|RUTF|Ready to use Therapeutic Food (RUTF) Plumpy nut.
10157083|NCT04028492|Placebo Comparator|Placebo|Oral Capsule
10157084|NCT04028336|Experimental|TITRATION|"All patients hospitalized in intensive care and meeting inclusion criteria and without criteria for non-inclusion will be included in this study. All patients will benefit from Lung ultrasound (LUS) and esophageal pressure measurement (Peso) according to the habits of the service. A PEP titration pulmonary opening (PEP-OP) test using a recruitment maneuver was then performed in all patients followed by a new LUS and Peso measurement."
10157085|NCT04028427|Experimental|Participants randomly assigned to VGI|
9973420|NCT01331044|Active Comparator|Khichuri - Halwa|Cereal Legume
9973421|NCT01331057||1:Sri Lankais|Children aged of four to six years old, in the nursery school and if their first language is unique : tamil.
10157086|NCT04028427|Experimental|Participants randomly assigned to MBI|
10157087|NCT04028349|Experimental|Single Arm|Ad26.ZEBOV/ MVA-BN-Filo Vaccines
10157088|NCT04028466|Experimental|Vonoprazan|Patients will be randomized to receiving vonoprazan, which will be taken 30 minutes before the first meal of the day for 14 days
10157089|NCT04028466|Active Comparator|Omeprazole|Patients will be randomized to receiving omeprazole, which will be taken 30 minutes before the first meal of the day for 14 days
10157090|NCT04028193|Other|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
10157091|NCT04028193|Other|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
9973422|NCT01331057||2: Algerian|Children aged of four to six years old, in the nursery school and if their first language is unique : arabic.
9973423|NCT01331057||3: Mali|Children aged of four to six years old, in the nursery school and if their first language is unique : SONINKE.
10157092|NCT04028154|Experimental|ESP Block|
10157093|NCT04028154|Active Comparator|TLIP Block|
10157094|NCT04028141||participants undergoing procedural sedation|"The study gathered observational data about participants who underwent procedural sedation according to the new standard protocol with ketofol in a 1 on 4 concentration.~The participant was observed for complications or cardiorespiratory interventions by the sedating physician until he was fully awake. Thirty minutes after the awakening, the participant was questioned for his remembrance and perception of the sedation and procedure. He was observed for complications until discharge"
10157095|NCT04028271|Experimental|experimental|local anesthesia applyed with Comfort in system
10157096|NCT04028271|Active Comparator|conventional injection|local anesthesia applyed with conventional syringe
10157097|NCT04028180|Experimental|Midge Repellency|Treatment of forearm with insect repellent and exposure to midges every 1 hour for 12 hours
10157098|NCT04027972|Experimental|Primary|6 Subjects will receive all 4 types of medication administration in random sequence
10157099|NCT04028076|Experimental|Peers LEAD|8-week educational behavioral intervention
10157100|NCT04027985|Experimental|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
10157101|NCT04027985|Sham Comparator|Control group|the patients will receive sham KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
10157102|NCT04028128|Experimental|Cocoa group|The cocoa was provided in 5 g sachets. The intervention last 10 weeks. Cocoa was provided in a single daily dose of 5 g, which provided 425 mg of flavonoids
10157103|NCT04028128|Placebo Comparator|Placebo group|Maltodextrin (5 g) was supplied as placebo in sachets identical to those provided for cocoa.
9973424|NCT01331070|Experimental|PATIENT|Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD
9973425|NCT01331070|Other|Accepts Healthy Volunteers|Control arm with the same intervention
10157104|NCT04027829|Experimental|Dexmedetomidine|Intravenous infusion of dexmedetomidine for 50 min after surgery at intensive care unit
10157105|NCT04027764|Experimental|Toripalimab Combined With S1 and Albumin Paclitaxel|
10157106|NCT04027790||Group 1 - Cancer Patients|Subjects with known colorectal cancer (i.e. AJCC/UICC stages 0, I, II, and III) who provide plasma at least 7 days after diagnosis by colonoscopy, but prior to surgery or treatment
10157107|NCT04027790||Group 2 - Screening Subjects|Prospectively enrolled subjects reporting for screening colonoscopy who provide a blood sample up to 2 weeks prior to bowel prep and prior to colonoscopy. We accept all subjects who meet the institutional criteria as average risk subjects referred for a screening colonoscopy for colorectal cancer, including subjects undergoing a colonoscopy as a follow-up to a positive (non-colonoscopic) test
10157108|NCT04027660||Exposed Immediate Zirconia Implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications to be enrolled in an immediate implant.~No Active Infection~No loss of buccal plate~ASA 1 or ASA 2 Patient~Extraction of the tooth will be performed and in the same clinical act, a zirconia dental implant will be placed toghether with a provisional or an individualized customs healing abutment. The jumping gap will be filled with a xenograft biomaterial.~Final Zirconia Crown delivered 3 month after healing.~3 STL files will be generated - Before extraction, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 will be at the gingival margin(measure 1), at 2mm (measure 2) and 4 mm (measure 3) apical to gingival margin. Both palatal and buccal references are joined by a line that gives a distance.Difference on the dimensions of each line with different time of evaluation represent ridge loss."
9671182|NCT05051748|Active Comparator|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
9973426|NCT01331096||Anesthetic drugs manually administrated|
9973427|NCT01331096||Automated anesthesia delivery system|
9973428|NCT01331122|Experimental|droxidopa|Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
9973429|NCT01331122|Placebo Comparator|placebo|placebo
9977837|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
9671183|NCT05051748|Active Comparator|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
9671184|NCT05051748|Active Comparator|In-office bleaching + Remineralization|n-office bleaching was applied followed by MI-Paste Plus®
9671185|NCT05051748|Active Comparator|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
9671186|NCT05051748|Active Comparator|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by in-office bleaching and lastly MI-Paste Plus®
9671187|NCT05051748|No Intervention|Control|no treatment (control).
9671188|NCT05051956||CDK4/6 inhibitors|The patient who is started on one of the CDK 4/6 inhibitors (palbociclib 125 mg 3 weeks on 1 week off) or ribociclib 600 mg 3 weeks on 1 week off) will be followed up for adverse events.
9671189|NCT05051761|Experimental|Jaktinib 50mg BID|Jaktinib administered orally. Placebo administered orally to maintain the blind.
9671190|NCT05051761|Experimental|Jaktinib 75mg BID|Jaktinib administered orally. Placebo administered orally to maintain the blind.
9671191|NCT05051761|Placebo Comparator|placebo|Placebo administered orally.
10157109|NCT04027660||Non-exposed delayed Zirconia implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications not to be enrolled in an immediate implant.~Active Infection~Loss of the buccal plate.~Extraction will be performed but a classical implant approach will be made, that include a waiting period of 3 month before implant placement and 3 month after osseointegration period before place final crown.~Implant placement with Guided bone regeneration (xenograft), if needed. Final Zirconia Crown 3 month after implant placement.~4 STL files will be generated - Before extraction, before implant placement, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion~Measure 1,2 and 3 the same has the other group"
10157110|NCT04027751|Experimental|Tropisetron|Patients allocated to this arm will receive single dose of intravenous Tropisetron (5mg) before anesthesia induction.
10157111|NCT04027751|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of saline solution before anesthesia induction.
10157112|NCT04027933|Active Comparator|Experimental|Education Based on Standard Patient Simulation was given to this group
10157113|NCT04027933|No Intervention|Control|Control group
10157114|NCT04028024|Other|inhibiting systemic inflammatory response|Ulinastatin 5000U/kg in 20ml NS i.v. before occlusion of aorta
10157115|NCT04028037|Experimental|FTPG treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. In Test group, the harvest of palatal graft was performed using FTPG technique. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
9671192|NCT05051657|Experimental|PKU express pus|PKU express plus to be transitioned onto over a maximum of 6 weeks and then incorporated into each participants usual diet for 28 days. Amount taken and frequency to be determined by dietitian.
9671193|NCT05051670|Experimental|SP group|patients group underwent gastrectomy using da vinci SP
10157116|NCT04028037|Active Comparator|Sub-epithelial connective tissue graft (SCTG) treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. To ensure an effective randomization only at this stage the patients were assigned to the test and to the control group.In control group trap door technique was used to obtain connective palatal graft. SCTG was adapted to recipient site in way that the first mm upon cementoenamel junction (CEJ) was covered , the flap is stabilized with interrupted sutures. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
10157117|NCT04027959|Experimental|Epilation|Hair epilated prior to application of Vitamin B12 solution to skin
10157118|NCT04027959|Experimental|Oleic Acid|Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin
9671194|NCT05051709|Active Comparator|Foot with no fusion|
9671195|NCT05051709|Active Comparator|Foot with fusion|
9671196|NCT05051865|Experimental|Camrelizumab Combined With SHR1020|Camrelizumab combined with SHR1020 for advanced melanoma.
9671197|NCT05051878|Experimental|articulating paper occlusal adjustment|occlusal adjustments of implant supported prosthesis according to articulating paper occlusal analysis
9671198|NCT05051878|Experimental|T-scan occlusal analysis|occlusal adjustments of implant supported prosthesis according to T-scan occlusal analysis
9694832|NCT04784793|No Intervention|Phase1: Design and development|"We conducted focus group meetings to discuss the content, features and design of the app.~The focus group consisted of physiotherapists and young adults. The focus group members discussed the variety of topics in subgroups (login parameters, self-monitoring, exercises content, video or animation types, exercise diary, reminders, encouragement, method, etc)."
9694833|NCT04784793|No Intervention|Phase 2: Testing the app|We tested the prototype version app interface in the 2nd phase. All participants downloaded the prototype app and used the app for one week.
9694834|NCT04784793|No Intervention|Phase 3: Usability evaluation|"We conduct a think-aloud interview and evaluate the quantitative usability in the third phase.~The quantitative usability was assessed by the System Usability Scale (SUS), and the adapted Usability, Satisfaction and Ease to Use (USE) Questionnaire."
9694835|NCT04784793|Active Comparator|Phase 4: Pilot randomized controlled trial/ The app-based group|"The app-based group:~Participants in the intervention group received their smartphone-based- home exercise program."
9694836|NCT04784793|Experimental|Phase 4: Pilot randomized controlled trial/ The control group|"The control group:~Participants in the control group received their home exercise programs as a paper handout."
9694837|NCT04784728|Experimental|Lidocaine topical system with swimming (Treatment A)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects swim for 15 minutes in a heated pool 4 hours after topical system application.
10157119|NCT04027959|Experimental|No Prep|Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin
10157120|NCT04027699|Experimental|Mini-bolus|"First injection of 2ml/kg (saline solution)~Second injection of 18ml/kg (saline solution)"
10157121|NCT04027907||T2DM|
10157122|NCT04027907||healthy controls|
10157123|NCT04027842|Experimental|Prewarming group|Participants in Prewarming group was warmed with forced air warming device (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) over the entire body for 10 minutes before anesthesia was induced in the operating theater. All participants received active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
10157124|NCT04027842|No Intervention|Non-prewarming group|In Non-prewarming group, no active warming was conducted before induction of anesthesia. Only standard care was provided with introperative active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
10157125|NCT04027582|Active Comparator|Low Fidelity Simulator - Wooden block|This simulator consists of a simple series of wooden panels with holes. The resident learns how to manipulate the fiberoptic bronchoscope through the holes.
10157126|NCT04027582|Active Comparator|High fidelity Simulator - ORSIM|The ORSIM® bronchoscopy is a virtual reality simulator (Airway Simulation Limited, Auckland, New Zealand). It consists of hardware and software components that interact to create a high-fidelity virtual reality simulation. A replica fiberoptic scope is advanced by the resident through a desktop sensor, which is connected to a laptop computer. The laptop software program provides a virtual airway in which the user must navigate the probe.
10157127|NCT04027621|Active Comparator|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
10157128|NCT04027621|Placebo Comparator|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
10157129|NCT04027517|Experimental|JTZ-951|Oral doses once daily
10157130|NCT04027517|Active Comparator|Darbepoetin Alfa|Intravenous doses of Darbepoetin Alfa administered once weekly
10157131|NCT04027634|No Intervention|Control group|The control group (CG) received routine care and was required to walk during 6-7 pm.
10157132|NCT04027634|Experimental|Baduanjin program|The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
10157133|NCT04027465|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
10157134|NCT04027465|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses of egg protein, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
10157135|NCT04027387|Experimental|TMB-365 400 mg- Group 1|Single dose of TMB-365 400 mg or matching placebo by intravenous infusion
9671199|NCT05051800|Experimental|Early Intervention|Families will receive the online program to support coping and communication near the time of a child's cancer diagnosis
9826391|NCT02416908|Experimental|Phase I Schedule B (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
9973430|NCT01331135|Experimental|sirolimus treatment|Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
10157136|NCT04027387|Experimental|TMB-365 800 mg- Group 2|Single dose of TMB-365 800 mg or matching placebo by intravenous infusion
10157137|NCT04027387|Experimental|TMB-365 1600 mg- Group 3|Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion
10157138|NCT04027673|Experimental|Treatment|Participants in the treatment group complete interactive modules. They will be asked to complete one module per week, for a total of eight weeks.
10157139|NCT04027673|No Intervention|Control|Participants in the control group will have no active study requirements for the eight weeks following Survey Session 1.
10157140|NCT04027543||Neoadjuvant chemoradiotherapy|Patients who had chemoradiotherapy before surgery.
10157141|NCT04027543||Neoadjuvant chemotherapy|Patients who had chemotherapy before surgery.
10157142|NCT04027543||Surgery alone|Patients who only had oesophagectomy. Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic. The appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
9973431|NCT01331148|Active Comparator|Vitamin D|10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
10157143|NCT04027478|Active Comparator|FMD (fasting-mimicking diet)|Over the course of three rounds of chemotherapy, patients in the FMD will consume a diet that consists of 10 cal/kg/day and includes 50% fat, 40% carbohydrates, and no more than 10% protein. The diet includes nuts, olives, vegetable broth, broccoli/cauliflower, white rice/puffed rice cake, onion, tea/coffee, almond milk. The diet prohibits meat products, dairy, alcohol, sugar, and artificial sweeteners. Patients will be instructed to drink 2 cups of water each morning, take their usual medications and limit exercise to walking.
10157144|NCT04027478|No Intervention|regular diet|Diet not influenced by a fast-mimicking diet.
9671200|NCT05051800|Active Comparator|Delayed Intervention|Families will receive the online program to support coping and communication approximately 6 months after a child's cancer diagnosis
9671201|NCT05051514||Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
10157145|NCT04027530|Experimental|Ertugliflozin 15mg once daily|Once daily treatment with oral ertugliflozin (steglatro) 15mg for 4 consecutive weeks.
10157146|NCT04027530|Placebo Comparator|Placebo|Once daily treatment with a placebo pill for 4 consecutive weeks.
10157147|NCT04027400|Active Comparator|Primarily visual computer exercises|Participant performs visual computer exercises 30 minutes a day, five days a week for one month.
10157148|NCT04027400|Experimental|Visual+Audio|Participant performs audio computer exercises and some visual computer exercises 30 minutes a day, five days a week for one month
10157149|NCT04027452|Experimental|Traumatic memory reactivation|Audio recording of traumatic memory that triggers symptoms of PTSD, anxiety, depression, played before each ECT treatment.
10157150|NCT04027452|Placebo Comparator|Neutral memory reactivation|Audio recording of neutral (non-traumatic) memory played before each ECT treatment.
10157151|NCT04027647|Experimental|Treatment|Daily administration of oral Dacomitinib
10157152|NCT04027504|Experimental|Fitabisc|Participants receiving fitabisc preoperatively
10157153|NCT04027556|Experimental|Low dose - lean body weight|Low CT contrast media dose calculated based on lean body weight
10157154|NCT04027556|Active Comparator|Standard dose|Standard CT contrast media dose calculated based on total body weight
10157155|NCT04027569|Active Comparator|PSFS group|Patients in this arm will complete the patient specific functional scale (PSFS) during their visits
10157156|NCT04027569|Experimental|PROMIS PF group|Patients in this arm will complete the PROMIS Physical Function during their visits
10157157|NCT04027374||Fetal surgery group|Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0.
10157158|NCT04027374||Glucocorticoid control group|Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
10157159|NCT04027374||Healthy controls|Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1.
10157160|NCT04027413|Placebo Comparator|Placebo/ Control|participants in this group will receive carbohydrate product which does not include protein at all
10157161|NCT04027413|Experimental|Intervention group|Participants in this group will receive high protein product
10157162|NCT04027738|Experimental|PRP injection|The patients received a single 3-ml injection of PRP.
10157163|NCT04027491|Experimental|Virtual reality intervention|"Participant undergo 12 treatment sessions, during a 4-week period (3 sessions per week).~Each intervention session lasts 45 minutes."
10157164|NCT04027491|No Intervention|Observational|Participant undergo a 4 weeks observational period. No intervention are performed.
10157165|NCT04027881|Experimental|STAR - immediate|Receive 15-week STAR intervention immediately after pretest.
10157166|NCT04027881|No Intervention|STAR - waitlist control|No intervention for the 15 weeks after pretest.
10157167|NCT04027335|Experimental|Leva Arm|Subjects will undergo training in the use of a vaginal device and its associated app, to be used twice daily to perform pelvic floor muscle exercises guided by the device/app for 10 weeks.
10157168|NCT04027725|Experimental|Sensorimotor neurofeedback training group|"Three interventions will be administered :~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours.~The third intervention is the neurofeedback training sensorimotor that will be recorded at channel Cz according to the international 10-20 system."
10157169|NCT04027725|No Intervention|Control Group|"Three interventions will be administered :~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours~The psychopedagogical care: each session will be organized using the same video material"
10157170|NCT04027257|Experimental|STAR|Receive 15-week STAR intervention immediately after pretest.
10157171|NCT04027257|No Intervention|Waitlist Control|No intervention for the 15 weeks after pretest.
10157172|NCT04027270|No Intervention|Standard of Care|These individuals will receive standard of care for post operative recovery following a prostatectomy.
9671202|NCT05051514||Moderate Severity OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.
9671203|NCT05051514||High Severity OSAS|Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour.
9694838|NCT04784728|Experimental|Lidocaine topical system with showering (Treatment B)|One topical system is applied to the mid- to upper-back for 12 hours. Subjects take a 10-minute shower 8 hours after topical system application.
9694839|NCT04784728|Experimental|Lidocaine topical system under normal conditions (Treatment C)|One topical system is applied to the mid- to upper-back for 12 hours. Topical systems are not exposed to water during this period.
9973432|NCT01331148|Placebo Comparator|Placebo|placebo only, all patients will receive calcium/vitamin D chew
9977838|NCT01365676|Active Comparator|GAMALINE® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
9977839|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 45-55 years old|Climacteric women with PMS symptoms
10157173|NCT04027270|Experimental|Physical Therapy|These individuals will receive post operative physical therapy in addition to standard of care for post operative recovery following a prostatectomy.
10157174|NCT04027322|Active Comparator|Budesonide|"Drug Name: budesonide Dose: 2000mcg (2mg) of budesonide nebulizer solution is mixed with normal saline solution to make a total volume of 8mL.~Frequency: Stat Dose Route: Nebulization"
10157175|NCT04027322|Active Comparator|Dexamethasone|"Drug Name: Dexamethasone Sodium phosphate Dose: 8mg of IV formula of dexamethasone is mixed with normal saline to make a total volume of 8ml.~Frequency: Stat Dose Route: Nebulization"
10157176|NCT04027322|Placebo Comparator|Control|Drug Name: Normal Saline Dose: 8ml. Frequency: Stat Dose Route: Nebulization
10157177|NCT04027244||Primary cohort|Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).
10157178|NCT04027244||Frailty & cognitive additional assessments|Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).
10157179|NCT04027244||Cardiac MRI additional assessments|Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).
10157180|NCT04027244||Biomarkers additional assessments|Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).
10157181|NCT04027244||Historical cohort|Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).
10157182|NCT04027192|Experimental|Bridging part: intervention sequence ABC or BAC|10 healthy male participants will be randomly allocated to this arm. The study interventions will follow the sequence ABC or BAC: A: single dose of 50 mg BAY2328065 given as LSF in fasted state B: single dose of 50 mg BAY2328065 given as tablet in fasted state C: single dose of 50 mg BAY2328065 given as tablet in fed state (i.e. after a high caloric and high fat meal)
10157183|NCT04027192|Experimental|Multiple dose escalation part: dose 1|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day"
10157184|NCT04027192|Experimental|Multiple dose escalation part: dose 2|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
10157185|NCT04027192|Experimental|Multiple dose escalation part: dose 3|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
10157186|NCT04027192|Experimental|Multiple dose escalation part: dose 4|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
10157187|NCT04027192|Experimental|Multiple dose escalation part: dose 5|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).~The study intervention will be administered with a single dose on the first dosing day followed by a treatment pause of 2 days followed by twice daily doses for 1 day followed by three times daily doses for 9 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
10157188|NCT04027062|Other|Diabetes Continuing Education Program|"the physicians will be assessed before and after intervention~the intervention group will be enrolled to the intervention program proposed to be (lecture + interactive workshop + group discussion + role play)"
10157189|NCT04027179|Experimental|FMS chlorhexidine mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of 0.12% chlorhexidine gluconate mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with 0.12% chlorhexidine gluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
10157190|NCT04027179|Placebo Comparator|FMS placebo mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of placebo mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
10157191|NCT04027179|Active Comparator|FMS no mouthwash|Full-mouth scaling and root planning with manual curettes.
10157192|NCT04027205|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
10157193|NCT04027205|Active Comparator|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation.
9671204|NCT05051423||Patients diagnosed with primary gastric tumors referred to our department for EUS local staging.|"Patients will be included or excluded according to the following criteria used throughout the study:~Inclusion criteria: Patients diagnosed with primary gastric tumors referred for local staging by EUS (n=40); Age 18 to 90 years old, men or women; Signed informed consent for EUS with contrast-enhancement and tissue sampling~Exclusion criteria: Prior treatment with chemo-radiotherapy; Failure to provide informed consent; severe coagulopathy.~Data collected for each participant will include: Personal data (name, surname, age, sex); results from previous investigations (blood count, liver and renal function tests, tumoral markers, gastroscopy, computed tomography), EUS variables (including CEH-EUS), histological and immunohistochemical findings, TNM and pTNM status (if possible), molecular analysis findings."
9671205|NCT05051410|No Intervention|control|single visit root canal treatment will be performed with no additional irrigation.
9671206|NCT05051410|Experimental|intracanal cryotherapy with needle irrigation|single visit root canal treatment will be performed with additional irrigation with cold saline using needle irrigation.
9671207|NCT05051410|Experimental|intracanal cryotherapy using Endovac system|single visit root canal treatment will be performed with additional irrigation with cold saline using EndoVac system.
9671208|NCT05051774|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the 12 weeks intervention consists of three monthly group education and center-based group exercise followed by 20 minutes of individualized telephone follow-up at weeks 3, 7, and 11.
10157194|NCT04027010|Experimental|"Healthy U tablet application"|Healthy U is a self-administered intervention implemented through a tablet app with interactive learning experiences, including videos, digital games, quizzes, and role-plays. Healthy U takes youth 3-4 hours to complete. The goals of Healthy U are to: 1) Increase male youth's perception of vulnerability to unplanned fatherhood, STDs and HIV; 2) Increase male youth's self-efficacy for negotiating condom use with their partners; 3) Increase male youth's self-efficacy for using condoms correctly and consistently every time they have sex; and 4) Increase male youth's engagement with goals and dreams for their future.
10157195|NCT04027010|No Intervention|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition. OYA does not provide much programming to youth in its facilities related to sexual health and pregnancy prevention.
10157196|NCT04026971|Experimental|Phone Application Supported Nutrition Education|Classic nutrition training and diet list is provided. Then notification was sent to obese patients for 3 months by phone application named 'MotiVe'
10157197|NCT04026971|Other|Classical Nutrition Education|Classic nutrition training and diet list is provided.
10157198|NCT04027127|Active Comparator|ACS GRUP|"Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared.~GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared."
10157199|NCT04027127|Active Comparator|plasebo grup|It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.
10157200|NCT04026958|Experimental|Clarithromycin|Participants in this study arm will receive clarithromycin for 14 days.
10157201|NCT04026958|Placebo Comparator|Placebo|Participants in this study arm will receive a placebo to match clarithromycin for 14 days.
10157202|NCT04027166|Experimental|administration immediate|Methadone will be administered prior to study procedures
10157203|NCT04027166|Experimental|administration delayed|Methadone will be held for four hours until the end of all study procedures.
10157204|NCT04027036|Active Comparator|fIPV Intramuscular|180 children will receive 0,1 ml of inactivated poliovirus vaccine intramuscularly
9671209|NCT05051774|No Intervention|Control Group|The control group will receive the usual care provided in the study hospital included an unstructured health education conducted by a nurse on healthy lifestyle and health assessment and brief unstructured health education on their conditions, focusing on the risk factors management and stress management by the cardiologist.
10157205|NCT04027036|Active Comparator|fIPV Intradermal|180 children will receive 0,1ml of inactivated poliovirus vaccine intradermally
10157206|NCT04026932|Placebo Comparator|Unmodified music group|34 participants in Group 1 will listen to the music without any modification for at least two hours a day in total.
10157207|NCT04026932|Experimental|Modified tinnitus relieving sound group|34 participants in Group 2 will listen to the music modified according to the matched dominant tinnitus pitch for at least two hours a day in total.
10157208|NCT04026919|Experimental|to analyze the effectiveness of Ok en Casa Zaindoo|The multicomponent online programme is composed of the components explained in the detailed study description:
10185999|NCT03740165|Experimental|Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
10186000|NCT03740165|Active Comparator|Placebo for Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
9973433|NCT01331174|Experimental|High dose PSW groups|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W. These settings were based on the fact that applications with mean power below 20W minimize the thermal effects
9973434|NCT01331174|Placebo Comparator|Placebo|A placebo group was also established, in which the PSW device was turned on but kept in stand-by mode during 19 minutes without any electrical current being applied in the patients
9973435|NCT01331174|No Intervention|Control|The control group was composed of patients that were not submitted to any form of treatment and all patients were instructed to maintain their daily activities
9671210|NCT05051553|Experimental|Treatment 1A|
9671211|NCT05051553|Experimental|Treatment 1B|
9671212|NCT05051553|Experimental|Treatment 2A|
9671213|NCT05051553|Experimental|Treatment 2B|
9671214|NCT05051553|Experimental|Treatment 2C|
9973436|NCT01331226|Experimental|3 session telephone counseling|
9973437|NCT01331226|Experimental|1 session telephone counseling|
10157209|NCT04026880|Active Comparator|Treatment Arm|weekly IM administration of 25 mg Testosterone Enanthate for 12 weeks
10157210|NCT04026880|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks
10157211|NCT04027283|Active Comparator|Erythritol|18 volunteers receive 50g erythritol dissolved in 300mL tap water via a nasogastric tube
9671215|NCT05051462|Experimental|Intervention group|Study participants participating in family constellation therapy between assessment 1 and 2.
10157212|NCT04027283|Active Comparator|Erythritol + lactisole|18 volunteers receive 50g erythritol with lactisol (450ppm) dissolved in 300mL tap water via a nasogastric tube
10157213|NCT04027283|Active Comparator|D-allulose|18 volunteers receive 25g D-allulose dissolved in 300mL tap water via a nasogastric tube
9671216|NCT05051462|No Intervention|Wait-list control group|Study participants participating in family constellation therapy only after all 3 assessment points.
10157214|NCT04027283|Active Comparator|D-allulose + lactisole|18 volunteers receive 25g D-allulose with lactisole (450ppm) dissolved in 300mL tap water via a nasogastric tube
10157215|NCT04027283|Placebo Comparator|Tap water|18 volunteers receive 300mL tap water via a nasogastric tube
10157216|NCT04027283|Placebo Comparator|Tap water + lactisole|18 volunteers receive 300mL tap water + lactisole (450ppm) via a nasogastric tube
10157217|NCT04027231||Ahlback I|
10157218|NCT04027231||Ahlback II|
10157219|NCT04027231||Ahlback III|
10157220|NCT04027231||1 year following TKA|
10157221|NCT04027231||TKA revision|
10157222|NCT04027088|Experimental|Immunonutrition|Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
10157223|NCT04027088|Placebo Comparator|Standard|Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients
10157224|NCT04026906|Experimental|Skin Glue|Patients in the intervention group will receive standard peripheral intravenous catheter (PIVC) securement (with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape). In addition they will receive a drop of cyanoacrylate glue (Dermabond® topical skin adhesive) at both the PIVC insertion site and under the hub of the catheter.
10157225|NCT04026906|Placebo Comparator|Standard Care|Patients in the control group will receive standard PIVC placement with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape.
10157226|NCT04026854||Psychiatric nurses|Nurse with a degree in the state or psychiatric sector. Work in a psychiatric ward that offers full hospitalization, a day hospital (HdJ) or a medico-psychological center (CMP).
9671217|NCT05051839|Experimental|Radiographic bone level|
9973438|NCT01331226|Active Comparator|written materials|
10157227|NCT04026841|Experimental|PD-1 Antibody Sintilimab|Patients receive the treatment of PD-1 antibody Sintilimab
10157228|NCT04026789|Active Comparator|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
10157229|NCT04026789|Active Comparator|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
10157230|NCT04026568|Experimental|Single dose 4AP|15mm opaque capsule containing 10mg of 4-AP
10157231|NCT04026568|Placebo Comparator|Placebo|Opaque capsule identical looking to the 4AP placebo pill
9671218|NCT05051839|Experimental|Peri implant soft tissue volume|
9671219|NCT05051280|Experimental|CBCT guidance group|Left atrial appendage occlusion under cone-beam computed tomography fusion image guidance
9671220|NCT05051384|Experimental|Intraocular tumor|New sonographic software technique on ultrasonography to detect low-vascular flow inside intraocular tumors
9671221|NCT05051397|Experimental|HYPERCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=50mmHg will be targeted
9671222|NCT05051397|Active Comparator|NORMOCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=40mmHg will be targeted
9671223|NCT05051332|Experimental|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm^3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
9694840|NCT04784949|Experimental|Portland cement|pulpotomy with PRF and white Portland cement
9694841|NCT04784949|Experimental|Mineral trioxide aggregate|pulpotomy with PRF and Mineral trioxide aggregate
9977840|NCT01365676|Active Comparator|GAMALINE® 45-55 years old|Climacteric women with PMS symptoms
9977841|NCT01365702||Tiotropium in TB destroyed lung|
10157232|NCT04026581||Assessment|A comprehensive AAC assessment collecting clinical and personal data required to select a speech-generating device (SGD) is conducted along with a trial of three AAC technology solutions, followed by a trial for BCI access to an AAC system.
10157233|NCT04026581||Training and Treatment|AAC training and treatment services will be provided and communication performance outcomes monitored over the course of studying clinical treatment services. At monthly home visits the SLP gathers clinical and personal data on communication performance outcomes and user satisfaction of their AAC system and any alternative access methods.
10157234|NCT04026763|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as a US guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy guided prostate biopsy.
10157235|NCT04026607|Experimental|Whey Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
10157236|NCT04026607|Experimental|Pea Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
10157237|NCT04026607|Experimental|Collagen Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
10157238|NCT04026776|Experimental|Preterm Group|Subjects with very low birth weight (<37 completed weeks' gestation and birth weight <1500 g) will receive a dietary intervention (high/low salt diet) and FDA approved drug, Allopurinol
9671224|NCT05051332|Active Comparator|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.
10157239|NCT04026776|Active Comparator|Term-born control group|Subjects with birth weight ≥2500 g will receive a dietary intervention (high/low salt diet)
10157240|NCT04026659|Experimental|Multi-modal exercise programme|The 10-week multi-modal exercise programme will comprise of twice weekly supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
10157241|NCT04026555|Active Comparator|MEWS++ Monitoring|This consists of all the patients that will be receiving MEWS++ escalation monitoring and provider alerting.
10157242|NCT04026555|Placebo Comparator|Standard of Care Monitoring|Patients in the control arm will have a score calculated but no alert will be sent.
10157243|NCT04026698|Experimental|Resident and Family Engagement Intervention.|The intervention has three components: leadership coaching for managers, administrators/ directors of care in long-term care settings; a one-day in-person training session for staff and managers; and resident and family led huddles (brief, 15 minute meetings) with staff.
10157244|NCT04026633|Experimental|Experimental: Enhanced Intervention|Participants assigned to this arm will complete a personal writing task about alcohol use.
10157245|NCT04026633|Placebo Comparator|Placebo Comparator|Participants assigned to this arm will complete a personal writing task about eating behaviors.
10157246|NCT04026685|Active Comparator|Phenylephrine infusion only|Phenylephrine infusion only
10157247|NCT04026685|Active Comparator|Phenylephrine infusion and Ringer-Acetate bolus|Phenylephrine infusion and Ringer-Acetate bolus
10157248|NCT04026828||Periodontitis Group|Chronic periodontitis and aggressive periodontitis patients
10157249|NCT04026828||Control Group|Both periodontal and medically healthy volunteers.
10157250|NCT04026724||Exposed group|Chinese patent medicine combined with western medicine routine treatment
10157251|NCT04026724||Non-exposed group|Western medicine routine treatment
10157252|NCT04026815||60 - 65 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
10157253|NCT04026815||65 - 69 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
10157254|NCT04026815||70 - 74 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
10157255|NCT04026815||75 - 79 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
10157256|NCT04026815||80 - 84 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
10157257|NCT04026815||85 - 89 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
10157258|NCT04026815||≥90 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
10157259|NCT04026516|Experimental|CAVA Dizziness Trial Arm|All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
10157260|NCT04026802|Experimental|In--Bed Resistance Training Device|The present invention provides full body resistance training devices that attach to a planar edge, such as a footboard, headboard, or sideboard of a bed. The devices employ resistance bands for resistance training in both the incursion (force applying) and excursion (force releasing) phase of exercise.
10157261|NCT04026802|Active Comparator|Standard of Care|No resistance training device
10157262|NCT04026503|Experimental|Live Long Walk Strong|8 week rehabilitation program
10157263|NCT04026503|Active Comparator|8 week wait list control|8 week wait list then followed by 8 weeks of the Live Long Walk Strong rehabilitation program
10157264|NCT04026451|Experimental|Intervention|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SEF95 obtained by SedLine® monitor to keep a SAS 1-2. The target of SEF95 will be 10-13 Hz to keep SAS 1-2.
10157265|NCT04026451|Active Comparator|Control|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SAS (1-2). SedLine® monitor will be also used in these patients but the screen will be covered.
10157266|NCT04026464|Active Comparator|Ibuprofen+Acetaminophen Group|Infants with PDA randomized to the combined treatment group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) and oral acetaminophen (15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses).
10157267|NCT04026464|Placebo Comparator|Ibuprofen Group|Infants with PDA randomized to the control mono therapy group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) alone.
10157268|NCT04026061|Experimental|FMA group|Receiving the FMA training and tool
10157269|NCT04026061|Placebo Comparator|control group|Receiving a simple tablet training and some websites
10157270|NCT04026074|Experimental|Fentanyl i.v. (intravenously)|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
10157271|NCT04026074|Experimental|Remifentanil i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
10157272|NCT04026074|Experimental|Clonidine i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
10157273|NCT04026074|Experimental|EMLA salve|Patients will be administered the medication (salve) and additionally will be administered i.v. saline as placebo
10157274|NCT04026074|Placebo Comparator|Placebo|Patients will be administered i.v. placebo (0,9% NaCl) and placebo salve (skin protection salve)
10157275|NCT04026152|Experimental|Resistance training + Unified Protocol|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will also receive four weekly hour-long sessions with a therapist to learn cognitive-behavioural strategies to assist them with managing their anxiety when exercising. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
10157276|NCT04026152|Active Comparator|Resistance training|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
10157277|NCT04026152|No Intervention|Waitlist|Participants randomly assigned to this condition will maintain their usual physical activity and exercise routine and not engage in any additional exercise than they were prior to the study. These participants will fill out questionnaires (~20 minutes each time) following randomization into this condition, once per week for four weeks, and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up. After completing the last follow-up, participants in the waitlist condition will be re-randomized into either the resistance training only or resistance training + Unified Protocol conditions.
10157278|NCT04026100|Experimental|CTA101|
10157279|NCT04026087||patient with kidney transplant|Blood sample will be took from subjects during this research
10157280|NCT04026139|Experimental|experimental group|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
10157281|NCT04026139|Active Comparator|control group|The control group underwent active joint range-of-motion exercises and isometric contraction exercises.
10157282|NCT04026321|Experimental|SQ-001 125mL/day|
10157283|NCT04026321|Experimental|SQ-001 250mL/day|
10157284|NCT04026321|Experimental|SQ-001 500mL/day|
10157285|NCT04026321|Experimental|SQ-001 625mL/day|
10157286|NCT04026321|Placebo Comparator|saline(0.9% NaCl injection)|
10157287|NCT04026334|Experimental|V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline|
10157288|NCT04026373|Experimental|modified Prolonged Exposure|
10157289|NCT04026373|Active Comparator|Treatment as usual|
10157290|NCT04026295|Experimental|Short burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of SBLTT
10157291|NCT04026295|Active Comparator|Traditional Locomotor Treadmill Training (TLTT)|TLTT will consist of walking at steady-state speeds. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of TLTT
10157292|NCT04026022|Placebo Comparator|Standard pain management|Besides the standard pain management a placebo TTS (normal wound plaster) will be administered in the Emergency Room (ER) or Post Anaesthesia Care Unit (PACU)
10157293|NCT04026022|Experimental|Modified pain management|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial i.v. treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day
10157294|NCT04026282|Experimental|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
10157295|NCT04026282|Active Comparator|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about 14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
10157296|NCT04026256|Active Comparator|Teriparatide only|daily subcutaneous injection teriparatide for 3 months
10157297|NCT04026256|Active Comparator|Denosumab only|one dose of subcutaneous injection denosumab
10157298|NCT04026256|Active Comparator|Denosumab and teriparatide|daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab
10157299|NCT04026230|Experimental|Atorvastatin|Capsules of atorvastatin. Daily dose of 80 mg for max. 5 years or until development of castration resistance.
10157300|NCT04026230|Placebo Comparator|Placebo|Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 5 years or until development of castration resistance
10186001|NCT03740139|Experimental|Intervention|"The Police-Mental Health Linkage System~In the case of an encounter between law enforcement and subjects randomized to this group, the officer will receive a notice disclosing that the participant receives services in a mental health clinic and that he/she has the opportunity to call to speak with a mental health professional."
9973439|NCT01331252|Experimental|supine body position|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
9671225|NCT05051319||Elderly participants living at home|Participants over the age of 65, living at home, not having mental and communication problems that would prevent the evaluations, and volunteering to participate in the study. The sociodemographic information of the participants such as gender, duration of education, living environment and people with whom they live were recorded. In addition, information about the medical condition of geriatric individuals, such as body mass indexes and the number of drugs used, was also recorded in the form. In order to evaluate the cognitive status of the participants, the Standardized or Standardized Mini-Mental Test for the Uneducated was used according to their educational status. The Center for Disease Control Health-Related Quality of Life-4 Scale (CDC HRQoL-4) was used to assess quality of life, and the Geriatric Depression Scale was used to assess emotional status. In addition, the presence of pain and pain levels according to body regions were determined with a 6-point Likert-type scale.
9694842|NCT04784949|Experimental|Biodentine|pulpotomy with PRF and Biodentine
9694843|NCT04784468||Covid-19|Covid-19 patients
9973440|NCT01331252|Experimental|semi-recumbent|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
10157301|NCT04026243|Active Comparator|QL group (n = 25)|After general anesthesia (GA), patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then moved dorsally until the QL muscle is identified with its attachment to lateral edge of the transverse process of the L4 vertebral body with identification of shamrock sign. The needle is inserted in-plane to transducer (lateral edge) and tip of needle is advanced through the QL muscle. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the QL and psoas major.
10157302|NCT04026243|Active Comparator|TF group (n = 25)|After GA, patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in midaxillary line just cephalad to the iliac crest. Scanning anteriorly will identify the three muscles of the anterior abdominal wall. The transversus abdominis typically tapers to form a hyper echoic aponeurosis that passes posterior to quadratus lumborum. Scan will be continued posteriorly to visualize solid organs or viscera deep to the transversus abdominis. The needle will be positioned such that it enters the skin anterior to the ultrasound probe and passes in-plane posterolateral through the three lateral abdominal muscles. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the transversus abdominis muscle and the transversalis fascia anterolateral to quadratus lumborum.
10157303|NCT04026269|Experimental|MOAP treatment|Chlormethine Hydrochloride Injection 10mg d1,8 iv Vindesine Sulfate for Injection 4mg d1,8 iv Doxorubicin Hydrochloride Injection 25mg/m2 d1,8 iv Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po 28 days/Cycle
10157304|NCT04026178|Experimental|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI Patients (males and females) ≤ 40 kg: 0.06mg/kg Male patients > 40 kg: 2.5mg Female patients > 40 kg: 5mg
10157305|NCT04026165|Experimental|Selonsertib|"Run-in Period (5 Weeks): Participants will receive placebo for at least one week and then SEL 18 mg for at least 4 weeks.~Double-Blind Treatment: Participants will be randomized to receive SEL 18 mg until death, study drug discontinuation, kidney failure, or the global study end date."
10157306|NCT04026165|Placebo Comparator|Placebo|"Run-in Period (5 Weeks): Participants will receive placebo for at least one week and then SEL 18 mg for at least 4 weeks.~Double-Blind Treatment: Participants will be randomized to receive placebo until death, study drug discontinuation, kidney failure, or the global study end date."
10157307|NCT04025970||Cancer of Unknown Primary (CUP)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for possible cancer of unknown primary (CUP).~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
10157308|NCT04025970||Suspected CANcer (SCAN)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for suspected cancer (SCAN) based on serious non-specific symptoms and signs of cancer.~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
10157309|NCT04025762|Experimental|Day and night hybrid closed loop control|"The day and night hybrid closed-loop system (CamAPS FX) will consist of:~Dana RS insulin pump (Sooil)~G6 real-time CGM sensor (Dexcom)~An unlocked android smartphone hosting the CamAPS FX app with Cambridge control algorithm"
10157310|NCT04025762|Active Comparator|Sensor augmented pump therapy|The comparator will consist of Dana RS insulin pump (Sooil) and G6 real-time CGM sensor (Dexcom)
10157311|NCT04025749|Experimental|Immediate intervention group|Thirty children with CP aged 8 to 12 years (or fifteen with neuroimage data) will participate in a computerized executive training program from home (12 weeks, 5 days a week, 30 min a day).
10157312|NCT04025749|Other|Wait-list delayed intervention|Thirty children with CP (or fifteen with neuroimage data) matched by age, sex, motor and cognitive impairment severity.
9973441|NCT01331265||no treatment|
10157313|NCT04025736|Experimental|Patients received Tranexamic acid|The patient was assigned as intervention group, TXA will be aspirated into a syringe. In TXA group, TXA 1000 mg (20 mL) was given intravenously 10 minutes before surgery.
10157314|NCT04025736|Placebo Comparator|Patients received same volume of saline|In the control group, the patient received 20ml saline intravenous also 10 min before surgery.
10157315|NCT04025697|Placebo Comparator|Conventional CD|A conventional Complete denture will be constructed and the amount of denture tooth movement will be measured
9694844|NCT04784468||Influenza|Influenza patients
9973442|NCT01331278|Active Comparator|Custom Cutting Blocks|
9973443|NCT01331278|Active Comparator|Computer Assisted Surgery|
9973444|NCT01331317|Other|Paricalcitol|Crossover study between paricalcitol and placebo
9973445|NCT01331330|Active Comparator|Group B|Low Programming
9973446|NCT01331330|Experimental|Group A|Normal Programming
9973447|NCT01331356|Experimental|Injection of botulinum toxin type A|
10157316|NCT04025697|Active Comparator|Rapid Prototyped Denture|A digital light processed denture will be constructed and the amount of tooth movement will be measured
10157317|NCT04025671|Experimental|Nasal Spray Naloxone|This arm will be randomized to administer a nasal spray naloxone device in a simulated overdose setting.
10157318|NCT04025671|Active Comparator|Intramuscular|This arm will be randomized to administer a intramuscular naloxone device in a simulated overdose setting.
10157319|NCT04025671|Active Comparator|Improvised Nasal Atomizer|This arm will be randomized to administer an improvised nasal atomizer naloxone device in a simulated overdose setting.
10157320|NCT04025957|Experimental|SHR-1501 dose escalation|SHR-1501 given subcutaneously
10157321|NCT04025957|Experimental|SHR-1501 dose expansion|SHR-1501 given subcutaneously
10157322|NCT04025892|Experimental|Tracking group|Participants will be asked to track weight daily for six weeks
10157323|NCT04025931|Experimental|chidamide combined with Toripalimab|"chidamide 30mg orally twice a week;~240 mg of toripalimab (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
10157324|NCT04025996||Diseased Group|Patients with type 2 diabetic retinopathy and known cardiac dysfunction.
10157325|NCT04025944||chronic hepatitis B|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
10157326|NCT04025944||chronic hepatitis C|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
9694845|NCT04784468||Cotrol|Control group
10157327|NCT04025814|Experimental|CaregiverAssist|Parents and School Mental Health Providers (SMHPs) will participate in focus groups and discussions to facilitate the build, design, and use of a digital Health (dHealth) tool to improve parent adherence sustained use of evidence-based parenting strategies. Parents will participate in a 2-month trial during which time they will use the dHealth tool in daily life contexts.
10157328|NCT04025775|Experimental|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 20 days~The CamAPS HX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
10157329|NCT04025775|Active Comparator|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 20 day study period.Participants will be wear a masked continuous glucose monitoring (CGM) system during the 20 day study period.
10157330|NCT04025840|No Intervention|Control|Patients in this group receive general anesthesia, without epidural block and perioperative dexamethasone. Patient-controlled intravenous analgesia is provided after surgery.
10157331|NCT04025840|Experimental|Epidural block|Patients in this group receive combined epidural-general anesthesia (0.375% ropivacaine for epidural block), without perioperative dexamethasone. Patient-controlled epidural analgesia is provided after surgery.
10157332|NCT04025840|Experimental|Dexamethasone|Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.
10157333|NCT04025840|Experimental|Epidural block+Dexamethasone|Patients this group receive dexamethasone (10 mg) before anesthesia induction and combined epidural-general anesthesia (0.375% ropivacaine for epidural block). Patient-controlled epidural analgesia is provided after surgery.
10157334|NCT04025918|Experimental|vasopressor delivery automated system|vasopressor delivery automated system that administered phenylephrine and ephedrine based on data from continuous non-invasive hemodynamic monitor
10157335|NCT04025918|Active Comparator|manual vasopressor delivery|manual bolus that delivered phenylephrine and ephedrine based on data from non-invasive intermitted blood pressure monitor
10157336|NCT04025723|Active Comparator|Young|men aged between 18 to 30 years old
10157337|NCT04025723|Active Comparator|Middle-aged|men aged between 35 to 50 years old
10157338|NCT04025645||PATIENTS WITH CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITH CHOLELITHIASIS
10157339|NCT04025645||PATIENTS WITHOUT CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITHOUT CHOLELITHIASIS
10157340|NCT04025866|Active Comparator|Conventional rehabilitation|Conventional rehabilitation treatment for inpatients with femur fracture
10157341|NCT04025866|Active Comparator|Aerobic exercise|Addition of cycle ergometer for upper limb to conventional rehabilitation treatment for femur fracture
10157342|NCT04025632|Experimental|0.3 mg/kg zilucoplan|Daily subcutaneous (SC) injection
10157343|NCT04025632|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection
10157344|NCT04025567|Experimental|1/Arm 1|Oral vancomycin
10157345|NCT04025385|No Intervention|Control Group|Patients will participate in regular training units
10157346|NCT04025385|Active Comparator|HIIT Group|Patients will participate in high intensity interval training
10157347|NCT04025229|Experimental|HIIT exercise|Participants will perform HIIT exercises as instructed by the study team in the weeks prior to standard of care surgery
10157348|NCT04025437|Experimental|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
9973448|NCT01331369|Active Comparator|Control|Usual care. It means routine medical care that include free demand consultation and free medicines.
9977842|NCT01365715|Experimental|Preoperative embolization|32 patients with spinal metastasis/metastases will undergo arteriography and receive transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
9516843|NCT03311698|No Intervention|Control|Households receive the standard of care in the area for agricultural and health services.
9694846|NCT04784910|Experimental|DWP14012 20mg|orally, once daily
9694847|NCT04784910|Active Comparator|Lansoprazole 15mg|orally, once daily
9694848|NCT04784923||Instrumentation patients|Instrumentation patients
10157349|NCT04025437|Active Comparator|Neoadjuvant radiotherapy plus hepatectomy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
10157350|NCT04025593|Active Comparator|RCHOP|
10157351|NCT04025593|Experimental|RCHOPX|
10157352|NCT04025606|Active Comparator|Thoracic epidural analgesia|Standard thoracic epidurals preoperatively at the dag of surgery.
10157353|NCT04025606|Experimental|Paravertebral block|Paravertebral block inserted at the end of the operation by the surgeons
10157354|NCT04025476||VKH patients|acute VKH patients
10157355|NCT04025476||control|health people age/sex match to the VKH patients
10157356|NCT04025268|Active Comparator|pregnant women receiving group prenatal care (GPNC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to receive the 10-session GPNC intervention.
10157357|NCT04025268|Active Comparator|pregnant women receiving standard of care (SOC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to continue with standard of care (SOC) prenatal care visits.
10157358|NCT04025320|Experimental|Group 1|"Intraneural facilitation treatment for 50-60 minutes. 50 minutes if ultrasound received.~9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
10157359|NCT04025320|Sham Comparator|Group 2|"SHAM treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
10157360|NCT04025502||Healthy Volunteer Subjects (HV)|"Male and female subjects 21-50 years of age, who are in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.~Healthy Volunteer Subjects will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
10157361|NCT04025502||Subjects with Schizophrenia (SZ)|"Otherwise healthy male and female subjects 21-50 years of age, who have a current diagnosis of Schizophrenia with a duration of illness greater than or equal to one year.~Subjects with Schizophrenia (SZ) will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
10157362|NCT04025294|Experimental|Students playing videogame|The experimental group will consist of our videogame intervention including the five mini-games.
10157363|NCT04025294|Active Comparator|Students receiving school climate assessment|The control group differs from the experimental group as it includes the school climate assessment tool but excludes the mini-games
10157364|NCT04025307|Experimental|bacTRL-IL-12|single-dose, 1 mL IV infusion of bacTRL-IL-12
10157365|NCT04025203|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
10157366|NCT04025203|Active Comparator|Ibuprofen arginine|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
9671226|NCT05051358||Subjects undergoing Therapeutic Endoscopic Ultrasound|"Procedures that will be captured include:~EUS- ERCP, Endoscopic Hepatology - EUS, EUS-Coils placement, EUS Glue injection, EUS-Fiducial placement, EUS-Neurolysis, EUS-Stent placement, EUS-alcohol injection, EUS-guided Ablation, EUS-guided anastomosis, EUS Guided ERCP for gallbladder, pancreatic duct or biliary duct drainage, EUS guided - Hemostasis, EUS guided- Therapy for cancer or premalignant lesion (Injection, neurolysis, fiducial, aspiration, RFA ), EUS - Fluid Collection, abscess or cavity drainage, EUS - Guided Ductal Drainage, EUS - Guided Anastomosis"
10157367|NCT04025203|Active Comparator|Gabapentin|Oral capsule pharmaceutical treatment. Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
10157368|NCT04025203|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
10157369|NCT04025177|Experimental|Neonates with an open PDA|Neonates born between 23 (0/7) and 26 (6/7) weeks gestational age with an open PDA, according to clinical protocol criteria, and no contraindication to the use of indomethacin.
9671227|NCT05051345|Experimental|Goal 1 (Wellness app)|Participants download and use the Wellness app onto their smartphones. Participants also receive information on the services provided for pregnant women and smoking cessation.
9694849|NCT04784767|Experimental|1A: 25 µg of SpFN + ALFQ on Days 1, 29 and 181.|Up to 20 participants will receive 25 µg of SpFN_1B-06-PL vaccine with 0.5 mL ALFQ adjuvant in a total 1.0 mL injection volume.
10157370|NCT04025528||Hypercapnic|Obese patients with daytime hypercapnia
10157371|NCT04025528||Eucapnic|Obese patients with normal daytime carbon dioxide levels
10157372|NCT04025281|Active Comparator|Extra virgin olive oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
10157373|NCT04025281|Active Comparator|Refined olive oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
10157374|NCT04025450|Experimental|Chidamide plus VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
10157375|NCT04025450|Active Comparator|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
10157376|NCT04025255|Experimental|Braini|28-day oral capsules of Braini
9694850|NCT04784767|Placebo Comparator|1B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
10157377|NCT04025255|Placebo Comparator|Placebo|28-day oral capsule of placebo comparator
10157378|NCT04025346|Active Comparator|Capsimax|
10157379|NCT04025346|Placebo Comparator|Placebo|
10157380|NCT04025619|Experimental|treatment group|the data is collected from the same participant after the intervention.
10157381|NCT04025619|No Intervention|Control group|The Collect the data from the same participant before the intervention as control
10157382|NCT04025489|Experimental|Vitamin D and Placebo|Doses of cholecalciferol (commercial name, Calcirol) 60,000IU (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose Granules) to the placebo group according to the random numbers generated by the computer.
10157383|NCT04025164|Experimental|Hypofractionated Radiotherapy|"40 Gy/15 fractions irradiation is delivered to the whole breast, 2.67 Gy per fraction, 5 fractions weekly.~Tumor bed is boosted to 48 Gy simultaneously, 3.2 Gy per fraction, 5 fractions weekly."
10157384|NCT04025164|Active Comparator|Conventional Irradiation|"50 Gy/25 fractions irradiation is delivered to the whole breast, 2 Gy per fraction, 5 fractions weekly.~Additional 10 Gy/5 fractions is boosted to tumor bed sequentially, 2 Gy per fraction, 5 fractions weekly."
10157385|NCT04025151|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
10157386|NCT04025151|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through SMS
10157387|NCT04025060|Experimental|Caffeine-free Soda|Consumption of caffeine-free soda daily for two weeks
9826392|NCT02416908|Experimental|Phase II (selinexor)|"Selinexor will be given at the schedule as determined in Phase 1.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
10157388|NCT04025060|Experimental|Carbonated Water|Consumption of unsweetened, carbonated water daily for two weeks
10157389|NCT04025060|Active Comparator|Regular Soda|Consumption of regular soda daily for two weeks
10157390|NCT04024982|Other|Lecture followed by Simulation|Subjects will undergo the lecture on TEE first followed by the simulation session.
10157391|NCT04024982|Other|Simulation followed by Lecture|Subjects will undergo the TEE simulation first followed by the lecture.
10157392|NCT04024969||Clinically isolated syndrome|Those presenting for diagnositic evaluation of multiple sclerosis, not currently meeting the 2017 McDonald criteria.
9977843|NCT01365715|Active Comparator|Control group|32 patients with spinal metastasis/metastases will undergo arteriography of spinal metastasis/metastases without receiving transcatheter arterial embolization prior to surgery.
10157393|NCT04025138|Experimental|female subjects involved in races over 100 km (F>100)|Female subjects involved in races over 100 km (F>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
10157394|NCT04025138|Experimental|female subjects involved in races less than 60 km (F<60)|Female subjects involved in races less than 60 km (F<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
10157395|NCT04025138|Experimental|male subjects involved in races over 100 km (H>100)|Male subjects involved in races over 100 km (H>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
10157396|NCT04025138|Experimental|male subjects involved in races less than 60 km (H<60)|Male subjects involved in races less than 60 km (H<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
10157397|NCT04025021|No Intervention|Control group (standard fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. As feedings are advanced to goal of 150 ml/kg/day, the TPN and SMOF lipids (Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil) will be decreased per standard management and NICU guidelines."
10157398|NCT04025021|Experimental|Intervention group (targeted fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. During this time, as the volume decreases, the TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day. Breast milk analysis will occur on a weekly basis immediately after birth for all infants enrolled in the study."
10157399|NCT04025034|Experimental|Study Group|Use of SONOPET(R) to orbital surgery.
10157400|NCT04025099|Experimental|Internal Cues|"Over 10 weeks, participants will be asked to participate in the following:~Classes (held in STAR Tower 419/420 IPE Space and Conference Room 413)~One ~60-minute Intuitive Eating class per week (total = 10 classes);~Two ~60-minute yoga classes per week (total = 20 classes);~Repeat one of the ~60-minute yoga classes each week on the participants' own, in a space participants feel comfortable, using a video recording (total = 10 classes).~Assessments (held in STAR tower)~Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
10186002|NCT03740139|No Intervention|No Intervention|In the case of an encounter between law enforcement and subjects randomized to this arm of the study, the officer will not receive any notice.
10157401|NCT04025099|Active Comparator|External Cues|"Over the next 10 weeks, participants will be asked to participate in the following:~Classes (held in STAR Tower 419/420 IPE Space)~One ~60-minute Healthy Eating class per week (total = 10 classes);~Participants will be provided with a UD group fitness membership. Using this membership, participants will be asked to attend at least 2 cardio fitness classes per week and do an additional 30 minutes of heart-raising activity on participants' own (total = 3 exercise sessions/week).~Assessments (held in STAR tower)~Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
10157402|NCT04025099|No Intervention|Assessment Only|"Over the next 10 weeks, participants will be asked to participate in the following:~a. Assessments (held in STAR tower)~•Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
10157403|NCT04025073|Experimental|Intervention Group|The intervention group will be assigned to the DASH diet with moderately reduced caloric intake and will participate in a nutrition education program.
10157404|NCT04025073|Experimental|Control Group|The control group will continue to follow the standard hospital diet and will participate in the same nutrition education program as the intervention group.
10186003|NCT03740113|Experimental|Kids SipSmartER|Kids SIPsmartER is a 12 session, 6-month program with an integrated two-way short service message (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes
10186004|NCT03740113|No Intervention|Control|Control arm receives no intervention
10186005|NCT03740087|Experimental|Omnivorous diet|This group was assigned a meal containing beef (test meal) that consisted of 200 g roast beef with salad (lettuce, tomato, lentils) and a cup of rice.
10186006|NCT03740087|Active Comparator|Vegan diet|This group was assigned a control meal consisted of salad (lettuce, tomato, lentils) and a cup of rice.
10186007|NCT03740074|Experimental|PAI|Participants will utilize a MIO Slice wearable device to generate a PAI score, which will be utilized to provide feedback and incentive for physical activity.
10186008|NCT03740061||Antwerp|
10186009|NCT03740061||Barcelona|
10186010|NCT03740061||Istanbul|
10186011|NCT03740061||Oldenburg|
10186012|NCT03740061||Krakow|
10186013|NCT03740061||Bialystok|
10186014|NCT03740061||Rome|
10186015|NCT03740061||Madrid|
10186016|NCT03740061||Leuven|
10186017|NCT03740022|Active Comparator|ACL plasty|The surgical procedure consists of a ligamentoplasty of the antero crusader ligament (ACL) with the patellar tendon according to a conventional arthroscopic procedure.
10186018|NCT03740022|Experimental|ACL + ALL plasty|The surgical procedure consists of a hamstring ligamentoplasty (DIDT) of the antero crusader ligament (ACL) and anterolateral ligament (ALL) according to a published arthroscopic procedure.
10186019|NCT03739970|Experimental|Investigational Group- Silk Peptide|"Ingredient: Silk Peptide~Type: Yellow granule stick~Weight: Silk Peptide 9g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
10186020|NCT03739970|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose~Type: Yellow granule stick~Weight: Silk Peptide 0g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
10186021|NCT03739957|Experimental|BPCO Media Kit|The kit is composed of a Bluetooth pulse oximeter and an APP for Android system downloadable from Google Play and installed on the Android smartphone of the patient from version 4.1 on.
10186022|NCT03739944|Active Comparator|Laparotomic radical hysterectomy|
10186023|NCT03739944|Active Comparator|Laparotomic radical trachelectomy|
9977844|NCT01365741|No Intervention|Standard administration of Efient|The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
10186024|NCT03739944|Active Comparator|Laparoscopic radical hysterectomy|
10186025|NCT03739944|Active Comparator|Laparoscopic radical trachelectomy|
10186026|NCT03739892|Other|stroke patients|stroke patients with upper limb motor deficit receiving standard care of rehab
10186027|NCT03739879|Experimental|Inspiratory muscle training (IMT)|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
10186028|NCT03739853|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice following international recommendations and National requirements for the prescription of biologic therapy[19-22]. Commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
10186029|NCT03739853|Experimental|Combination csDMARD|Arm 2 - Combination DMARD arm. All participants will be prescribed methotrexate with an additional DMARD (either sulfasalazine or leflunomide) at baseline. Response will be assessed after 12 weeks of therapy using the Minimal Disease Activity (MDA) criteria. Participants who achieve the MDA criteria by week 12 on this combination therapy will continue . Participants who show a significant response by in week 12 (a reduction in tender and swollen joint counts of at least 20%) but do not yet meet the MDA criteria should continue on this therapy for an additional 12 weeks before review. Participants failing to show significant response (reduction in joint counts by less than 20%) by week 12 on this combination therapy or those failing to meet MDA criteria by week 24 will be eligible for rescue therapy
10157405|NCT04025047||Transvaginal mesh|Patients who undergo pelvic reconstruction surgery using trans-vaginal mesh (commercial mesh kits or self-cut synthesized mesh).
10157406|NCT04025112|Experimental|Armeo|Patients group (54 patients) for robotic therapy.
9973449|NCT01331369|Experimental|Intervention|Intensification of care. Besides routine medical care that include free demand consultation and free medicines, subjects were invited to have 6 structured medical encounters based on a social-psychological approach. Doctors must follow a protocol to conduct the encounter that have around 30 minutes each.
9973450|NCT01331382|Experimental|250mg trans- resveratrol|
10157407|NCT04025112|Active Comparator|Conventional|Patients group (54 patients) for conventional rehabilitation protocol.
10157408|NCT04024618|Active Comparator|Parenteral Nutrition|Patients who have been randomized to receive PN will be started on day 5 post AHSCT. This will be if patient intake is < 80% of usual oral intake at that time. The central venous catheter required for PN administration will be already in place for AHSCT treatment, prior to admission and pre-transplant evaluation. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
10157409|NCT04024618|Experimental|Enteral Nutrition|Patients who have been randomized to receive EN will have a Nasogastric tube (NGT) inserted on day 5 post AHSCT, prior to start of Enteral feeds. This would be a polyurethane tube, 8-10 French, which will be inserted by physician or Nurse Practitioner with position confirmed by radiological examination. This will be if patient intake is < 80% of usual oral intake at that time. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
10157410|NCT04024722|Experimental|Single ovary treatment|
10157411|NCT04024722|Experimental|Dual ovary treatment|
10157412|NCT04024605|Experimental|Sunflower|Biscuits containing sunflower isolate intrinsically labelled with 15N and 2H
10157413|NCT04024605|Experimental|Rapeseed|Biscuits containing rapeseed isolate intrinsically labelled with 15N and 2H
10157414|NCT04024605|Experimental|Flaxseed|Biscuits containing flaxseed isolate intrinsically labelled with 15N and 2H
9973451|NCT01331382|Experimental|250mg trans-resveratrol with 20mg piperine|
9973452|NCT01331382|Placebo Comparator|Placebo|
10157415|NCT04024605|Experimental|Lupin|Biscuits containing lupin flour intrinsically labelled with 15N and 2H
10157416|NCT04024540|Experimental|isocaloric dietary restriction|Very low caloric diet 400 kcal/d for a week, 600 kcal/d for another week and 800 kcal/d for 2 weeks and 1000 kcal/d for 2 months.
10157417|NCT04024540|Active Comparator|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
10157418|NCT04024683||Serratus block group|Realization of a serratus block and para-vertebral catheter
10157419|NCT04024683||Control group|Realization of a para-vertebral catheter
10157420|NCT04024592|Experimental|children|
10157421|NCT04024839|Active Comparator|Post Isometric Relaxation|Post Isometric Relaxation was applied three times a week for the duration of three weeks.
10157422|NCT04024839|Experimental|Active Isolated stretch|Active Isolated stretch was was applied three times a week for the duration of three weeks.
10157423|NCT04024800|Experimental|Arm 1|AE37 peptide vaccine every 21 days for 5 doses + Pembrolizumab every 21 days for 2 years (Maximum 35 cycles)
10157424|NCT04024748||Patients already scheduled for a FDG test|Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited.
10157425|NCT04024826|Experimental|Early Follicular Phase (EFP)|This group is comprised of participants at the Early Follicular Phase (EFP) of the menstrual cycle.
10157426|NCT04024826|Experimental|Late Follicular Phase|This group is comprised of participants at the Late Follicular Phase (LFP) of the menstrual cycle.
10157427|NCT04024826|Experimental|Early Luteal Phase|This group is comprised of participants at the Early Luteal Phase (ELP) of the menstrual cycle.
10157428|NCT04024826|Experimental|Late Luteal Phase|This group is comprised of participants at the Late Luteal Phase(LLP) of the menstrual cycle.
10157429|NCT04024696|Experimental|Dosing Cohorts|Three (3) dose cohorts are pre-set to include 40 mg BID, 60 mg BID and 80 mg BID,respectively.The pre-set dose group is subject to change during the study and the actual dosage increment is determined by the Data safety Monitoring Committee (DSMC).
10157430|NCT04024774||index cases and their parents|
9973453|NCT01331395|No Intervention|IVF-No Acupuncture|IVF with no Traditional Chinese Medicine: Acupuncture
9973454|NCT01331395|Active Comparator|IVF-Acupuncture|IVF with Traditional Chinese Medicine: Acupuncture
9973455|NCT01331460|Experimental|RBT Experimental|
9973456|NCT01331460|Active Comparator|Case-Management: Treatment as Usual|
9973457|NCT01331473|Active Comparator|Carotid Artery Stenting without Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
9973458|NCT01331473|Active Comparator|Carotid Artery Stenting with Proximal Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
9973459|NCT01331486|Placebo Comparator|Placebo|Placebo capsule
10157431|NCT04024852|No Intervention|Control group|The control group did daily mild exercise (walking) outdoors for 30 minutes, for maximum 70 days.
10157432|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes. Total study period lasted for maximum 70 days.
10157433|NCT04024865||Treated with domperidone|Women who received a prescription for domperidone during the six months following delivery.
10157434|NCT04024865||Unexposed group (reference)|Women with no prescription for domperidone during the six months following delivery.
10157435|NCT04024813|Placebo Comparator|Placebo (N=25)|Placebo for the remainder of the study
10157436|NCT04024813|Experimental|Seladelpar 5 mg (N=25)|5 mg seladelpar daily for the remainder of the study
10157437|NCT04024813|Experimental|Seladelpar 10 mg (N=25)|10 mg seladelpar for the remainder of the study
10157438|NCT04024813|Experimental|Seladepar 25 mg (N=25)|25 mg seladelpar for the remainder of the study
10157439|NCT04024527|Active Comparator|Dual therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
10157440|NCT04024527|Experimental|Metronidazole plus dual therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
10157441|NCT04024878|Experimental|Stanfard Platinum|"A total of 5 NeoVax immunizations will be administered over a 3-week period~Two booster vaccinations will be given at Week 12~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks."
10157442|NCT04024878|Experimental|Stanfard Platinum with Surgical or Core Needle Biopsy|"A total of 5 NeoVax immunizations will be administered over a 3-week period~Two booster vaccinations will be given at Week 12~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.~Will undergo required surgical or core needle biopsy at first recurrence with progression free interval"
10157443|NCT04024891|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye, 1 hour post medically-induced mydriasis
10157444|NCT04024891|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye, 1 hour post medically-induced mydriasis
10157445|NCT04024306||ULTRAFILTRATION|
10157446|NCT04024306||DIURETICS|
10157447|NCT04024319||Genicular Nerve Block|GNB will be performed on this group of patients undergoing TKR. The patient will be positioned in the supine position, with the extremity to operate slightly in external rotation. The anesthesiologist will be located ipsilateral to the knee to intervene; asepsis will be performed with 70% chlorhexidine, sterile gloves will be used and the ultrasound probe will be protected with a sterile cover. The ultrasound transducer will be placed in a long axis of the knee in the corresponding area to block according to anatomical repairs. 4 ml of 0,2% ropivacaine was administered in each GN.
10157448|NCT04024319||Local Infiltration Analgesia|Retrospectively, the data of the patients belonging to the control group (LIA) were collected through the electronic file in the SAPP program of the internal network of the Barcelona Clinic Hospital in chronological order until completing 35 cases. To include them in the control group, the patients had to meet the same criteria as those belonging to the intervention group (GNB), therefore, the surgery should have been performed under spinal anesthesia and subsequently followed with an oral analgesia schedule meeting criteria of fast track hospitalization. The same data were obtained as in the GNBG, demographic data (age, sex, weight, height, hematocrit, hemoglobin, ASA), duration of the surgery and ischemia time, PACU VAS, AM VAS, PM VAS and finally some data of the post-operative period (hematocrit, hemoglobin, transfusion, hospital stay)
10157449|NCT04024254|Experimental|Folic Acid|Folic Acid supplement 1 mg by mouth daily
10157450|NCT04024254|No Intervention|No Supplementation|
10157451|NCT04024384|Experimental|Daratumumab|Daratumumab as maintenance after peripheral blood stem cell transplantation from HLA-identical or haploidentical family donor in the treatment of refractory or relapsed multiple myeloma
10157452|NCT04024449||Celiac Disease|"Celiac disease with the following criteria;~13 ≤ Age ≤20~At least one year after menarche~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia."
10157453|NCT04024449||Control|"The adolescent with the following criteria;~13 ≤ Age ≤20~At least one year after menarche~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia.~Control group; with normal menstrual period, Non-chronic diseases"
10157454|NCT04024137|Experimental|ZSP1273-200 mg BID|Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
9973460|NCT01331486|Active Comparator|Low dose|
10157455|NCT04024137|Experimental|ZSP1273-400 mg BID|Subjects will receive 10 doses of ZSP1273 400mg（200mg*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
10157456|NCT04024137|Experimental|ZSP1273-600 mg QD|Subjects will receive 5 doses of ZSP1273 600mg （200mg *3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .
10157457|NCT04024137|Placebo Comparator|Placebo|Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
10157458|NCT04024241||high dose of cytarabine|high dose of cytarabine
10157459|NCT04024241||HAM|medium dose of cytarabine and mitoxantrone
10157460|NCT04024150||Newborns exposed|Newborns exposed in-utero to raltegravir
10157461|NCT04024150||Newborns controls|Newborns exposed to antiretroviral therapy without anti-integrase
10157462|NCT04024163|Experimental|Benznidazole|Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days
10157463|NCT04024111|Experimental|KONTAKT(c)|A social skills group training
10157464|NCT04024111|Active Comparator|Art group|A social Art group
10157465|NCT04024176|Experimental|Moderate hemophiliac patients|Each participant will perform a gait analysis and clinical examination
10157466|NCT04024371||HV|Humans aged 20-55 without a diagnosis of a psychiatric and neurological disorder.
10157467|NCT04024371||SZ|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Schizophrenia.
10157468|NCT04024371||MDD|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD.
10157469|NCT04024345|Experimental|Psychometric assessment group|Arms to whom the psychometric assessment will be administered
10157470|NCT04024332|Experimental|Group A (healthy)|On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
10157471|NCT04024332|Experimental|Group B (severe renal function impairment)|On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
10157472|NCT04024072|Experimental|Perrigo active|Test product
10157473|NCT04024072|Active Comparator|Reference active|Azopt ophthalmic suspension
9694851|NCT04784767|Experimental|2A: 50 µg of SpFN + ALFQ on Days 1, 29, and 181.|Up to 20 participants will receive 3 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
9973461|NCT01331486|Active Comparator|Mid dose|
9973462|NCT01331486|Active Comparator|High dose|
9973463|NCT01331499|Experimental|Bipolar Sealer|Standard of care blood sparing techniques with bipolar sealer
10157474|NCT04023968|Experimental|YESplus workshop|Your Enlightened Side, plus more (YESplus) is an four-day, 15-hour integrative life skills workshop with a strong emphasis on breathing techniques and social connectedness. In addition to specific contemplative techniques such as yoga, mindfulness meditation, and compassion meditation that help cultivate inner peace, YESplus incorporates discussions and other activities to facilitate social connectedness, leadership, and community service. During the workshop, participants have ample time to learn and practice the Sudarshan Kriya Yoga (SKY) technique, as well as to ask questions. SKY has four sequential, form- and rhythm-specific breathing components interspersed with normal breathing while sitting in a relaxed position with eyes closed, followed by Yoga Nidra. A certified instructor with a minimum of 1,000 hours of SKY instruction training will lead each workshop.
10157475|NCT04023968|Active Comparator|WOW! workshop|"A comparison workshop titled Wisdom On Wellness (WOW!) will be implemented to control for potential expectancy effects, time commitment, group-based interactions, and wisdom/knowledge of YESplus that is anticipated to have beneficial effects on stress management and well-being, allowing for more rigorous evaluation of the contemplative practices and other activities unique to the YESplus workshop. This workshop differs from YESplus due to the increased focus on cognitive approaches to conceptualizing and managing stress (e.g. thoughts about the past and future versus present moment), and absence of physical or somatic activities."
9827498|NCT02458235|Experimental|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
10157476|NCT04023929||Term babies|Babies who are born at or after 37 gestational weeks.
10157477|NCT04023929||Preterm babies|Babies who are born between 32 and 36+6 gestational weeks.
10157478|NCT04023929||Very preterm babies|Babies who are born before 32 gestational weeks.
10157479|NCT04023916|Experimental|Sintilimab-R-CHOP|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and Sintilimab, rituximab, and CHOP during Cycles 2-6 (21-day cycle) ,Sintilimab and rituximab during Cycles 6-8 (21-day cycle) , followed by Sintilimab from Cycles 9-14 (8-week cycle) during consolidation treatment.
10157480|NCT04024046||Control - Placebo|"Placebo Drink-Mix Daily for 180 days~Placebo Capsules Daily for 180 days"
10157481|NCT04024046||Group 1|"Uqora Drink-Mix Daily for 180 days~Placebo Capsules Daily for 180 days"
10157482|NCT04024046||Group 2|"Uqora Drink-Mix Daily for 180 days~Uqora Capsules Daily for 180 days"
10157483|NCT04024033|Active Comparator|capsule|patinets receiveing pine cone extract tablets
10157484|NCT04024033|Placebo Comparator|placebo capsule|patinets receiving placebo
10157485|NCT04023851||Adolescent patient|"Participant between the ages of 15-18~Participants who are taking antiepileptic drug for seizure control"
10157486|NCT04023851||Parents with epilepsy children|"Participants who have child with epilepsy (ages of 1-15)~Participants' child who are taking antiepileptic drug for seizure control"
10157487|NCT04023838|Placebo Comparator|Right conventional radial approach|After local anesthesia on right wrist area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
10157488|NCT04023838|Active Comparator|Left distal radial approach|After local anesthesia on left anatomical snuffbox area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
10157489|NCT04023760|Experimental|Treatment group A: Cyclosporine in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on cyclosporine as part of their immunosuppressive regimen
10157490|NCT04023760|Active Comparator|Cyclosporine in healthy subjects|"Results from Treatment group A will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of cyclosporine at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
10157491|NCT04023760|Experimental|Treatment group B: Tacrolimus in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on tacrolimus as part of their immunosuppressive regimen
10157492|NCT04023760|Active Comparator|Tacrolimus in healthy subjects|"Results from Treatment group B will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of tacrolimus at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
10157493|NCT04023864|Experimental|Platycodon Grandiflorus Extract(GCWB107) group|Once-daily, once a tablet, after meals (900 mg/day, 571 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
10157494|NCT04023864|Placebo Comparator|Placebo group|Once-daily, once a tablet, after meals (900 mg/day, 0 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
10157495|NCT04023721|Experimental|Cohort 1 - Inarigivir Soproxil Alone|Cohort 1, 400 mg Inarigivir daily for 24 weeks and after treatment discontinuation will be followed for a further 18 months.
10157496|NCT04023721|Experimental|Cohort 2 Arm A - Inarigivir Soproxil and NUC|Cohort 2, Arm A, 400 Inarigivir daily in addition to their prestudy nucleoside/nucleotide (NUC) analogue inhibitors for 48 weeks. At Week 48 subjects will stop both inarigivir and the NUC and be followed for a further 48 weeks off treatment.
10157497|NCT04023721|Experimental|Cohort 2 Arm B - Inarigivir Soproxil and NUC|Cohort 2, Arm B, 400 mg Inarigivir daily plus prestudy nucleoside/nucleotide (NUC) analogue inhibitors for at least 24 weeks and up to 48 weeks. After treatment discontinuation of both inarigivir and the NUC, subjects will be followed off treatment up to Week 96.
10157498|NCT04023903|Experimental|RTA 402 5mg 3cap at fasting|
10157499|NCT04023903|Experimental|RTA 402 5mg 3cap after meal|
10157500|NCT04023877|Experimental|E2027|Participants will receive approximately 130 microcurie (μCi) of [14C]E2027 as a single 50 milligram (mg) (free base), capsule, orally on Day 1.
10157501|NCT04023643|Experimental|CPAP + PS|Weaning from mechanical ventilation using CPAP + PS
10157502|NCT04023643|Active Comparator|SIMV + PS|Weaning from mechanical ventilation using SIMV+PS
10157503|NCT04023825|Experimental|experimental group|Patients will receive loco regional anesthesia
10157504|NCT04023825|No Intervention|control group|Patients will not receive loco regional anesthesia
10157505|NCT04023734|Experimental|Intervention|A targeted and tailored pharmacist intervention at baseline and at 1-month follow-up.
10157506|NCT04023734|Active Comparator|Control group|Usual care based on the Indonesian guideline at baseline and 1-month follow-up.
10157507|NCT04023981|No Intervention|Standard care alone|Patients randomly allocated to standard care will be cared for on the appropriate mattress indicated for use in that participating centre according to local policy e.g. foam mattress or dynamic air mattress. Standard care may also include a mattress overlay or the use of a wedge or pillows to maintain the position of the participant, or pressure offloading boots on the foot if the need arises during the study period.
10157508|NCT04023981|Experimental|Parafricta bootees plus standard care|Patients randomly allocated to Parafricta plus standard care will be cared for on the appropriate mattress as above and care may possibly include a mattress overlay or the use of a wedge or pillows. Participants will in addition be issued with Parafricta bootees (one pair and up to two spare pairs). The patient and clinical staff and the patient's carers will be instructed in the use of Parafricta bootees, which are intended to be worn throughout the day and night and removed only for normal daily washing or examination of the patient's feet. Either the slip-on bootees or the Velco-closure bootees will be selected for the participant at the judgment of the clinical ward nurses.
10157509|NCT04023773|Experimental|Liver perfusion|"Device: Liver Machine Perfusion (MP) Device~The liver grafts will be preserved at hypothermic and normothermic temperature on the institutional-developed Liver MP Device, and have continuous perfusion with oxygen supply in the ex vivo organ preservation phase."
10157510|NCT04023955||Intervention|Twitter messages delivered over 1 month period
10157511|NCT04023591||Surgery|Surgery/ Occupational Therapy
10157512|NCT04023786|Experimental|56 patients, one arm|All patients benefits of a passive leg raising test and a PEEP test to compare these two tests.
9827499|NCT02458287|Experimental|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
10157513|NCT04023565|Experimental|perindopril + moxonidine|perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
10157514|NCT04023617|Experimental|Nivolumab + Docetaxel|"Nivolumab was administered at a dose of 300 mg on the first day of the 21-day cycle (every 3 weeks; q3w) when combined with docetaxel, and administered at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w) after stopping docetaxel treatment.~On the first day of each cycle (21 days), docetaxel 75 mg/m2 was infused by IV on Day 1 of each 21-day cycle for 4-6 cycles (judged by investigator)."
10157515|NCT04023617|Active Comparator|Nivolumab|Nivolumab was administered in the monotherapy group at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w).
10157516|NCT04023539|Active Comparator|Intervention group|Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
10157517|NCT04023539|Placebo Comparator|Control group|Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
10157518|NCT04023747||Cohort 1|Participants with Monoclonal B-Cell Lymphocytosis or Asymptomatic Chronic Lymphocytic Leukaemia
10157519|NCT04023747||Cohort 2|Participants with IgM Monoclonal Gammopathy or Asymptomatic Waldenstrom's Macroglobulinaemia
10157520|NCT04023747||Cohort 3|Participants with IgA or IgG Monoclonal Gammopathy or Smouldering Myeloma
10157521|NCT04023630|Experimental|rivaroxaban plus ticagrelor|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus ticagrelor 90 mg tablet twice daily for 12 months
10157522|NCT04023630|Active Comparator|rivaroxaban plus clopidogrel|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily for 12 months
10157523|NCT04023500|Active Comparator|Motivational interview|The MI-intervention is used as a part of normal dental hygienist appointment. Dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients. Dental hygienist support patients in decision making although patients were addressed as an active agent.
10157524|NCT04023500|Active Comparator|Prevailing education|In control group prevailing, more professional-centered education is used. Dental hygienist define patients educational needs and give direct instructions how to change behaviour and self-care.
9516844|NCT03311685|Experimental|Laparoscopic POP repair|"Patients undergoing laparoscopic surgery for the repair of pelvic organ prolapse.~vaginal tactile imager"
9827500|NCT02458287|Experimental|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
9827501|NCT02458287|Placebo Comparator|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
9827502|NCT02458287|Placebo Comparator|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
9827503|NCT02458352|Other|Standard dose CT, Ultra-low dose CT|Standard dose non-contrast enhanced CT (clinically indicated) and Ultra low dose non-contrast enhanced CT (as part of the trial)
10157525|NCT04023513|Experimental|Strength Training and Protein high|6 weeks of high protein intake (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
10157526|NCT04023513|Experimental|Strength Training and Protein low|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
10157527|NCT04023513|Other|Control|No Intervention.
10157528|NCT04023422|Active Comparator|Clinical intervention|Clinical health navigator, a community health worker, facilitates preparation for, attends, and confirms patients's understanding of an office visit.
10157529|NCT04023422|Experimental|Clinical intervention AND Home Visit|Patient receives Clinical intervention and Home visits. Care coordination activities occur taking into account the home environment, its social and physical characteristics.
9973464|NCT01331499|Active Comparator|Control|Standard of care blood sparing techniques without the use of bipolar sealer
10157530|NCT04023422|Experimental|Clinical intervention AND Feedback|
10157531|NCT04023422|Experimental|Clinical intervention AND Home Visit AND Feedback|
10157532|NCT04023175|Active Comparator|In office|Patients will undergo our standard in office preoperative counseling.
9977845|NCT01365741|Active Comparator|Upright administration of Efient|The test person will ingest Efient in an upright position, and remain supine during 2 hours.
9977846|NCT01365754|Active Comparator|A|A - Fusion
9977847|NCT01365754|Active Comparator|B|B - Dynamic (new)
10157533|NCT04023175|Experimental|Virtual visit|Patients will undergo preoperative counseling using telemedicine virtual visits.
10157534|NCT04023474|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft in clinic at the time any pertinent post-operative complication is identified.
10157535|NCT04023474|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
10157536|NCT04023084|Experimental|Atopic Dermatitis Group|Receive crisaborole intervention
10157537|NCT04023149|Experimental|experimental group|Patients will receive rhIL-2 solution oral gargle twice per day (2 million units of rhIL-2 dissolved in 5ml normal saline for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
10157538|NCT04023149|Placebo Comparator|control group|Patients will receive placebo solution oral gargle twice per day (5ml for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
10157539|NCT04023136|Other|only one arm (resected patients)|liver resection group
10157540|NCT04023058|No Intervention|CABG/increasing MR|non-massive IMR with increasing IMR during exercise - CABG only
10157541|NCT04023058|Experimental|CABG+mitral surgery (MS)/increasing MR|non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
10157542|NCT04023058|No Intervention|CABG/non-increasing MR|non-massive IMR non-increasing IMR during exercise - CABG only
10157543|NCT04023058|Experimental|CABG+MS/non-increasing MR|non-massive IMR non-increasing IMR - CABG+ mitral surgery
10157544|NCT04023058|Other|Control 1|massive IMR at rest without increasing during exercise - CABG+ mitral surgery
10157545|NCT04023058|Other|Control 2|massive IMR at rest with increasing during exercise - CABG+ mitral surgery
10157546|NCT04023097|Experimental|Toothwave contraindicated subject|"the Toothwave toothbrush is contraindicated for people in certain conditions, e.g. pregnant or nursing women, people with pacemaker and more.~This arm is assembled from contraindicated subject, who should exclude themselves from use of the device, based on the user manual and box sleeve."
10157547|NCT04023097|Active Comparator|potential users of the Toothwave device|The control arm is assembled from people who can use the toothbrush and should recognize themselves as potential users.
10157548|NCT04023331|Experimental|67Cu-SARTATE|"64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg.~67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as a slow IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion."
10157549|NCT04023214||ADPKD|ADPKD patients
10157550|NCT04023214||Controls|Healthy volunteers
10157551|NCT04023357|Experimental|PEEK|"PEEKs (polyetheretherketones) are presented as alternative materials to metal and glass ceramics,1 Their elastic modulus comparable to those of cortical bone and dentin so the polymer could exhibit good stress distribution. Also they have high fracture resistance, and low abrasion to the antagonist enamel.~Yet clinical studies are needed to evaluate their clinical performance."
10157552|NCT04023357|Active Comparator|Emax|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for Endocrowns
10157553|NCT04023344|Active Comparator|Humalog® Mix 25|Insulin Humalog® Mix 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
10157554|NCT04023344|Experimental|Insulin Lispro Biphasic 25|Insulin Lispro Biphasic 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
10157555|NCT04023370|Experimental|BeGraft Peripheral Stent Graft System|Covered stent
10157556|NCT04023370|Active Comparator|Bare metal stent system|bare metal stent
10157557|NCT04023461|No Intervention|Clinical Treatment Group|
10157558|NCT04023461|Experimental|Interventional Ablation Group|
10157559|NCT04023383|Placebo Comparator|Control|The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
10157560|NCT04023383|Experimental|HyaRegen NCH gel group|In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
10157561|NCT04023201||Parkinson's disease patients|Parkinson's disease patients with or without nocturnal symptoms
9973465|NCT01331525|Experimental|Single stage non-randomised|"Patients will receive Carboplatin and Etoposide. Both Chemotherapy drugs will be delivered as a 21 day cycle (q21) with up to a maximum of 6 cycles delivered according to response unless progressive disease (RECIST Version 1.0) and or excessive toxicity.~Ipilimumab will be administered at a dose of 10mg/kg IV on day 1 of cycles 3-6 of Chemotherapy.~In the absence of immune related progression of disease or unacceptable toxicity, subsequent maintenance doses of Ipilimumab will be delivered every 12 weeks starting at week 30 at a dose of 10 mg/kg until unacceptable toxicity or immune related disease progression"
9973466|NCT01331538||adolescents with TMD|adolescents with temporomandibular dysfunction
9973467|NCT01331538||No TMD|adolescents without temporomandibular dysfunction
9973468|NCT01331551||men with inflammatory bowel disease|Men between the ages of 18-55 with inflammatory bowel disease who are taking mesalamine medication.
9973469|NCT01331564|Experimental|electronic intervention group 2|(e-intervention 2) receives a behavioral intervention through a website during pregnancy and until 18 months postpartum
9973470|NCT01331564|Experimental|electronic intervention group 1|(e-intervention 1) receives a behavioral intervention through a website during pregnancy. During the postpartum period this arm receives the same non-weight-related information as the control arm
9973471|NCT01331564|Placebo Comparator|Control|
9973472|NCT01331577|Experimental|Cognitive behavioural Intervention|
9973473|NCT01331577|Experimental|Integrative Kinesiology Intervention|
9973474|NCT01331577|No Intervention|Waiting-List control group|
9973475|NCT01331590|Experimental|G-CSF + Ifosfamide + Etoposide + Dexamethasone + Mesna|"G-CSF = 10 mcg/kg/d SQ starting on day 1 and continuing until ANC >=1000/mcL x 2 days~Ifosfamide = 3330 mg/m2/d CIVI over 24 hours on Days 4-6~Etoposide = 150 mg/m2 IV over 2 hours BID on Days 4-6~Dexamethasone = 5 mg/m2 PO or IV BID on Days 4-10~Mesna = 2660 mg/m2/d continuous IV infusion over 24 hours on Days 4-6. 2000 mg/m2 continuous IV infusion over 12 hours on Day 7 to be started immediately after completion of ifosfamide."
9973476|NCT01331603||MDS and primary myelofibrosis patients|patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
9973477|NCT01331629|Experimental|ART-THERAPIE|supported in art therapy with other supportive care available in the facility
9973478|NCT01331629|No Intervention|standard group|standard care (supportive care available in each facility)
9973479|NCT01331642||Observation|Patients with Gaucher disease or high-grade suspicion for Gaucher disease
9973480|NCT01331655|Experimental|Arm 1|
9973481|NCT01331655|Experimental|Arm 2|
9973482|NCT01331655|Active Comparator|Arm 3|
9973483|NCT01331668||renal allograft donors and recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven
9973484|NCT01331707|Active Comparator|Promus Element|
9973485|NCT01331707|Active Comparator|Resolute Integrity|
9973486|NCT01331720||FSH:LH 1:1 - Treatment Group A|"Patients with a condition~LH (luteinizing hormone)"
9973487|NCT01331720||FSH:LH 3:2 - Treatment Group B|Patients with a condition
9973488|NCT01331720||FSH:LH 3:1 - Treatment Group C|Patients with a condition
9973489|NCT01331720||FSH:LH 3:0 - Treatment Group D|Patients with a condition
9973490|NCT01331720||Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E|Patients with a condition
9973491|NCT01331733||hMG-HP|Patients with a condition
10157562|NCT04023266|Experimental|Intravenous N-Acetylcysteine arm|On arrival at the recruiting hospital, eligible and consenting STEMI patients randomly allocated to the experimental arm would be administered an intravenous N-Acetylcysteine bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours.
10157563|NCT04023266|No Intervention|Control arm|Patients randomized to this arm would receive no experimental therapies and would continue to receive all standard guideline recommended medical therapies and interventions.
9827504|NCT02458365|Experimental|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
9973492|NCT01331733||hMG-HP + GnRH antagonist|Patients with a condition
9973493|NCT01331746|Experimental|APD515|Active APD515 treatment 20 mg qds for 7 days
9973494|NCT01331746|Placebo Comparator|Placebo|
9973495|NCT01331759|Experimental|Immediate Neuropattern™|The experimental group will undergo Neuropattern™ stress diagnostics immediately after inclusion in the study.
9973496|NCT01331759|Placebo Comparator|Later Neuropattern™|The control group will undergo Neuropattern™ stress diagnostics three months after inclusion in the study.
9973497|NCT01331772|Other|Control arm|Dietetic follow-up only
9973498|NCT01331772|Experimental|Intervention arm|Dietetic + adapted physical activity
9973499|NCT01331785|Experimental|Midodrine|
9973500|NCT01331798|Experimental|Test: TissuGlu Adhesive|Patients received the TissuGlu Adhesive Treatment
9973501|NCT01331798|Active Comparator|Control|Control Arm received no TissuGlu- Standard of Care received.
9973502|NCT01331863|Experimental|single arm surgery|Airway and/or pulmonary Vessels Transplantation
9973503|NCT01331876|Experimental|reference therapy|20 OCD patients following 15 sessions of the reference CBT (Bouvard,2006)
9973504|NCT01331876|Experimental|experimental therapy|20 OCD patients following 15 sessions of reference CBT associated with a new psychopedagogic task developed by our team.
9973505|NCT01331889||Potassium concentration|plasma potassium concentrations in the Fluid Management System (FMS) reservoir, arterial blood, and central venous blood
9973506|NCT01331902|Experimental|Adenosine Followed by Nicorandil|
9973507|NCT01331902|Experimental|Nicorandil Followed by Adenosine|
9973508|NCT01331915|Experimental|Theravac|Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
9973509|NCT01331928|Experimental|Capecitabine, Oxaliplatin, Docetaxel , Gastric cancer|
9973510|NCT01331941|Experimental|Group 1|Cancer subjects with normal renal function.
10157564|NCT04023435|Experimental|PNE education|All subjects will be tested before and after receiving PNE education
10157565|NCT04023279|Experimental|TENS|Conventional TENS of 100 Hz and 100 usec for 20 minutes
9520090|NCT03280589|Experimental|Sheetali/Sheetkali, self-paced:|Participant will follow on-screen instructions for Sheetali/Sheetkari with shaped lips/mouth as indicated (i.e., inhaling through the mouth held specific to each practice and exhaling through nostrils), fully filling and emptying the lungs with each breath. In Sheetali, the tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one minute rest followed by Sheetkari. In Sheetkari, the tongue is not rolled into a tube; instead, it is rolled up to touch the upper palate. The teeth are then exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary. The total duration of this session will be approximately 40 minutes.
10157566|NCT04023279|Experimental|Myofascial Therapy|Conventional TENS of 100 Hz and 100 usec for 20 minutes plus myofascial release therapy in the brachial biceps; Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding
10157567|NCT04023292|Experimental|Arm I (2 weeks preoperative endocrine therapy))|Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
10157568|NCT04023292|Active Comparator|Arm II (4 weeks preoperative endocrine therapy)|Patients receive endocrine therapy before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
10157569|NCT04023318|Experimental|Integrated Lifestyle Intervention|
10157570|NCT04023305|Experimental|Nonfocal ARDS|ARDS patient with nonfocal lung imaging phenotype
10157571|NCT04023305|Experimental|Focal ARDS|ARDS patient with focal lung imaging phenotype
9671228|NCT05051345|Experimental|Goal 2 (counseling, Wellness app, self-help)|Participants receive telephone counseling sessions over 30-45 minutes for a minimum of 6 sessions in the prenatal period and about 4-6 postpartum period. Participants who start counseling after birth, may receive 6-8 sessions up to 4 months postpartum. Participants may also use the Pregnancy and Wellness smartphone app that provides wellness messages, smoking cessation information, relapse prevention tips, and tips to create a smoke-free home. Participants also receive tobacco cessation self-help materials including National Partnership for Smoke Free Families and Forever Free Baby and Me.
9694852|NCT04784767|Placebo Comparator|2B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1, 29, and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1, 29, and 181.
10157572|NCT04023123||Anterior Cornea Striae|Eyes with anterior cornea striae present
10157573|NCT04023123||Hypotony Maculopathy|Eyes with hypotony maculopathy present
10157574|NCT04023123||Hypotony only|Eyes with intraocular pressure less than 10 without cornea striae and/or maculopathy
10157575|NCT04023110|Experimental|Carvedilol|"Carvedilol will be initiated at 3.125mg twice daily and uptitrated as tolerated in a stepwise fashion to a maximum dose of 25mg twice daily or to a systolic blood pressure (SBP) of 110-120mmHg or heart rate (HR) of 50-55 beats per minute (bpm). Patients will start carvedilol in the evening after first dose of chemotherapy and will continue on medication for 12 months.~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months."
10157576|NCT04023110|No Intervention|Usual Care|Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months.
10157577|NCT04023448|Experimental|coloplasty(CP)|After purse-string suture and ligation of the head of the stapler at the colonic end, 5cm away from the colonic end, 5cm longitudinal incision was made to the proximal end of the teniae coli in the anterior wall of the colon, transverse suture was performed, and the plasmomuscular layer was embedded, then end to end colon-rectum (or anal canal) anastomosis was performed
10157578|NCT04023448|No Intervention|straight colorectal anastomosis (SCA)|End to end colon-rectum (or anal canal) anastomosis was performed routinely
10157579|NCT04023045|Active Comparator|Habitual Prosthesis|Participant's prescribed prosthesis
10157580|NCT04023045|Experimental|Assist-Knee|Experimental knee prosthesis
10157581|NCT04023006||Edentulous Patients|The investigational device is part of a treatment concept for edentulous patients of all ages, gender and races. The incidence for tooth loss has not declined over years, and the prevalence for edentulism is significantly higher for adults 50 years and older. For this descriptive two-part survey, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) patients will be enrolled, i.e. 10 dentures will be fabricated within this study.
10157582|NCT04023032|Experimental|multicomponent cognitive intervention|
9827505|NCT02458365|Other|Comparison|Health In Motion
10157583|NCT04022850|Active Comparator|Passive dissemination|Passive dissemination strategies focused on the distribution of materials, support tools and training
10157584|NCT04022850|Experimental|Intuitive de-implementation|Mindless externally imposed de-implementation strategies to discourage the non-desired behavior and to encourage the preferred/desired behavior
10157585|NCT04022850|Experimental|Reflexive de-implementation|Active de-implementation strategies targeting conscious cognition processes to discourage the non-desired behavior and to encourage the preferred/desired behavior
10157586|NCT04022746|Experimental|Diagnostic (MRI/MRE)|Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
10186030|NCT03739853|Experimental|Early TNF inhibition|Early biologic arm. All participants will be prescribed methotrexate (given weekly) with a TNF inhibitor (adalimumab given every two weeks) at baseline. Treatment with TNF inhibitor will be continued until week 24 at which time the TNF inhibitor will be tapered to week 32. The TNF inhibitor will be stopped completely after week 32 and participants will continue on methotrexate. In case of flare of disease, participants will be eligible for rescue therapy
9973511|NCT01331941|Experimental|Group 3|Cancer subjects with moderate renal impairment.
9973512|NCT01331941|Experimental|Group 4|Cancer subjects with severe renal impairment.
9973513|NCT01331941|Experimental|Group 2|Cancer subjects with mild renal impairment.
9973514|NCT01331954|Experimental|HIFU|
9973515|NCT01331967|Experimental|Pioglitazone, Placebo|
9973516|NCT01331980||cystic fibrosis|children aged 6-12 years of age and Tanner stage 1 with a diagnosis of cystic fibrosis
9973517|NCT01331980||healthy controls|children ages 6-12 years and Tanner stage 1 without cystic fibrosis or other chronic disease that affects bone health
9973518|NCT01331993|Experimental|1|Treatment order : A, B, C
9973519|NCT01331993|Experimental|2|Treatment order : B, C, A
9973520|NCT01331993|Experimental|3|Treatment order : C, A, B
9973521|NCT01331993|Experimental|4|Treatment order : A, C, B
9973522|NCT01331993|Experimental|5|Treatment order : B, A, C
9973523|NCT01331993|Experimental|6|Treatment order : C, B, A
9973524|NCT01332006|Experimental|Intra-bone injection|Intra-bone transplantation of hematopoietic stem cells from cord blood
9973525|NCT01332032||Reminder Letter|"A letter sent to women reminding them that are coming due or overdue for a mammogram. It contains a reminder that their primary care provider (PCP) recommends mammography screening every 1-2 years. It urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. Repeat Booster letters will be sent in subsequent years to those failing to get a mammogram."
9973526|NCT01332032||Reminder Call|"A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a mammogram within 2 weeks, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offer to schedule a mammogram for her. Repeat Booster letters will be sent and repeat scheduler calls made in subsequent years to those failing to get a mammogram."
9973527|NCT01332032||Counselor Call|"A reminder letter as above is sent first. If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet. The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule. If a woman does not schedule within 8-10 days, a counselor will call. The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing. Repeat booster letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram. techniques. Average calls last 20-30 minutes."
9973528|NCT01332045|Sham Comparator|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
9973529|NCT01332045|Active Comparator|Continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
9973530|NCT01332058|Experimental|Motivational Interviewing (MI)|
9973531|NCT01332084|Experimental|hypoallergenic wheat cereals|HA wheat cereal used in a SOTI test
9973532|NCT01332097|Experimental|Treatment A|single 75mg oral dose of BCT197 capsules + single oral dose of prednisone placebo capsules
9973533|NCT01332097|Placebo Comparator|Treatment B|single oral dose of BCT197 placebo capsules + single oral dose of prednisone placebo capsules
9973534|NCT01332097|Active Comparator|Treatment C|single oral dose of BCT 197 placebo capsules + single oral dose of 40mg prednisone capsules
9973535|NCT01332097|Experimental|Treatment D|single oral dose of 20mg dose of BCT197 capsules
9973536|NCT01332097|Placebo Comparator|Treatment E|single oral dose of BCT 197 placebo capsules
9973537|NCT01332097|Experimental|Treatment F|single oral dose of 20 mg dose of BCT197 capsules on Day 1 and Day 6
9973538|NCT01332097|Placebo Comparator|Treatment G|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
9973539|NCT01332097|Experimental|Treatment H|single oral dose of 75mg dose of BCT197 capsules on Day 1 and Day 6
9973540|NCT01332097|Placebo Comparator|Treatment I|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
9973541|NCT01332110|Experimental|Knee abduction moment-reducing footwear|Footwear that is known to decrease knee abduction moments of force in healthy subjects. May include orthotics, or footwear that allows relative movement between the heel section of the outsole and rest of the shoe.
9973542|NCT01332110|Placebo Comparator|Control footwear|Standard, off-the-shelf running shoes with no mechanical modifications.
9973543|NCT01332136||Endoscopic sinus surgery|Patients electing endoscopic sinus surgery for chronic rhinosinusitis
9973544|NCT01332136||Medical management|Continued medical management for symptoms of chronic rhinosinusitis
9973545|NCT01332162|Experimental|Biventricular pacing|All patients will be pacing during two years
9973546|NCT01332162|Active Comparator|No Pacing during the first year|No Pacing during the first year. In the second year all patients will be pacing
9973547|NCT01332175|Active Comparator|Provent|
9973548|NCT01332175|Placebo Comparator|Placebo-Provent|
9973549|NCT01332175|Active Comparator|CPAP|
9973550|NCT01332201|Experimental|Advagraf|
9973551|NCT01332201|Active Comparator|Prograf|
9973552|NCT01332214|Experimental|AZD2820|
9973553|NCT01332214|Placebo Comparator|Placebo|
9973554|NCT01332240|Experimental|Endosonography|Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
9973555|NCT01332279|Experimental|Treatment (enzyme inhibitor and radiation therapy)|Patients receive RAD001 PO and erlotinib hydrochloride PO QD. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT BID 5 days a week for 5 weeks.
9973556|NCT01332344||Asthma patients treated with inhaled corticosteroids|Asthma subjects newly prescribed inhaled corticosteriods
9973557|NCT01332370||Adults with Type 2 Diabetes|Subjects with a diagnosis (ICD-9 code) of diabetes
9973558|NCT01332383||Patients prescribed AMERGE|Patients with migraine disorders prescribed AMERGE during study period
9973559|NCT01332396||Patients prescribed TYKERB|Patients with HER2 overexpressing inoperable or recurrent breast cancer
9973560|NCT01332409||Patients prescribed salmeterol and fluticasone|Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
10157587|NCT04022837|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
10157588|NCT04022837|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
10157589|NCT04023019||Group 1: ITI with Nuwiq, octanate, or wilate|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery and for prophylaxis.
10157590|NCT04023019||Group 2: ITI with Nuwiq, octanate, or wilate with emicizumab|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate, in combination with emicizumab prophylaxis. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery.
9516845|NCT03311685|Experimental|Vaginal POP repair|Patients undergoing vaginal surgery for the repair of pelvic organ prolapse. vaginal tactile imager
9662064|NCT05131893||LuminalB (Her2 negative)|"12 times weekly paclitaxel (80 mg / m˄2) followed by 4 times every 3 weeks epirubicin (E) (90-100 mg / m˄2) + cyclophosphamide (C) (600) (preferred)~4x 3 weekly E (90-100mg / m˄2) + C (600mg / m˄2), then~docetaxel (90-100 mg / m˄2) 4 times in every 3 weeks or~12x weekly paclitaxel (80mg / m˄2)~4x every 2 weeks Epirubicin (E) (90-100mg / m˄2) + Cyclophosphamid (C) (600mg / m˄2), then~4 times every 2 weeks with paclitaxel (175 mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2)~TC: docetaxel (75 mg / m˄2) + cyclophosphamide (600 mg / m˄2) every 21 days with GCSF prevention (6 cycles)"
9694853|NCT04784767|Experimental|3A: 50 µg of SpFN + ALFQ on Days 1 and 181.|Up to 20 participants will receive 2 intramuscular injections of: 50 ug of SpFN_1B-06-PL with 0.5 mL ALFQ adjuvant.
9827506|NCT02458469|Active Comparator|Buspirone|This drug will be taken for two week period
10157591|NCT04023019||Group 3: Prophylaxis with emicizumab, aPCC, or rFVIIa|Participants receiving routine prophylaxis with emicizumab, aPCC, or rFVIIa without immune tolerance induction. On-demand aPCC/rFVIIa can be used as needed to treat bleeding episodes or during surgery.
10157592|NCT04022772|Experimental|GROUP I (PACK Health program)|Patients participate in PACK Health program consisting of weekly contact with an assigned health coach via text message, phone call, and email for 3 months. After 3 months, patients continue to be contacted by the health coach at least once monthly for an additional 3 months.
10157593|NCT04022772|Active Comparator|GROUP II (standard of care)|Patients receive standard of care support services over 6 months.
10157594|NCT04022811|Experimental|Artificial tears|0.1% bromfenac VS Artificial tears
10157595|NCT04022681||Non-specific liver disease|Patients who were categorised as having a non-specific liver disease in the original BALLETS study.
10157596|NCT04022928|Experimental|PRP injection|Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
10157597|NCT04022889|Experimental|Stage 1|Stage 1 is a randomized, 2-period crossover design. Test platelets stored for 7 days will be radiolabeled using either the BEST or Variant 1 methods (depending on the period and randomization scheme for the Test platelets) for 12 healthy subjects. The recovery and survival for Test platelets prepared with the BEST and Variant 1 methods will be compared with each other and against the fresh platelet Control.
10157598|NCT04022889|Experimental|Stage 2|Stage 2 is a single arm study in which all Test platelets will be prepared for radiolabeling using the Variant 1 methodology. The recovery and survival for Test platelets will be compared against the fresh platelet Control. Recovery and survival of INTERCEPT platelets will be assessed after Day 7, 6 or 5 days of storage for up to 24 evaluable subjects. The storage duration of the Test platelet components will be determined by Cerus based on the outcome of Stage 1.
10157599|NCT04022642|Experimental|HIIT Group|Two HIIT sessions delivered at the beginning of Physical education classes
10157600|NCT04022642|No Intervention|Control Group|Usual programmed Physical education classes
10157601|NCT04022720|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft.
10157602|NCT04022720|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
10157603|NCT04022759|Active Comparator|Treatment as Usual|Participants randomised to the 'treatment as usual' group will receive behavioural activation guided-self help intervention as routinely delivered in the service.
10157604|NCT04022759|Experimental|Treatment with Security Prime|Participants randomised to the experimental group will receive behavioural activation guided self-help intervention as is routinely delivered in the service with additional attachment security priming intervention.
10157605|NCT04022941|Experimental|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.
10157606|NCT04022941|Placebo Comparator|Placebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
10157607|NCT04022915|Experimental|Acute pulmonary embolism|Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
10157608|NCT04022876|Experimental|Part 2 NSCLC: ALRN-6924+Carboplatin+Pemetrexed|
10157609|NCT04022876|Experimental|Part 2 NSCLC: Placebo+Carboplatin+Pemetrexed|
10157610|NCT04022876|Experimental|Part 1 SCLC: ALRN-6924+Topotecan|
10157611|NCT04022798|Experimental|Experimental group|Neural mobilization (NM), lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
10157612|NCT04022798|Active Comparator|Control group|lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
10157613|NCT04022824||OSA|
10157614|NCT04022824||Non-OSA|
10157615|NCT04022785|Experimental|Treatment (BRD4 Inhibitor PLX51107, azacitidine)|Patients receive PLX51107 PO QD on days 1-21 and azacitidine SC or IV over 15 minutes on days 8-14 and 22-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
10157616|NCT04022863||ovarian tumor benign|all pathological proven benign ovarian tumors
10157617|NCT04022863||ovarian tumor borderline|all pathological proven borderline ovarian tumors
10157618|NCT04022863||ovarian tumor malignant|all pathological proven malignant ovarian tumors
10157619|NCT04022707|Experimental|High-Velocity Resistance Circuttraining (HVRCT)|The participants will perform three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three weeks from 1 to 3 circuits.
10157620|NCT04022707|Experimental|Educational Control (CON)|A supervised program will be provided to the participants that includes lectures on health and fitness.
10157621|NCT04022629|Active Comparator|Treatment Group 1|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
10157622|NCT04022629|Active Comparator|Treatment Group 2|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
10157623|NCT04022590|Experimental|E-clothes|The participants with E-clothes do aerobic training at home
10157624|NCT04022590|Active Comparator|Home exercise|The participants with healthy consultation do aerobic training at home.
10157625|NCT04022655||ANCA-associated Vasculitis|Patients with ANCA-associated vasculitis admitted to the ICU
10157626|NCT04022993|Active Comparator|Lantus® SoloStar®|Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement
10157627|NCT04022993|Experimental|Insulin RinGlar®|Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement
10157628|NCT04022330|Other|Blood sampling|
10157629|NCT04022304|Experimental|Sequence: Humulin® N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
10157630|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
9827507|NCT02458469|Active Comparator|Trazodone|This drug will be taken for two week period
9827508|NCT02458469|Placebo Comparator|Placebo|A placebo pill will be taken at bed time for two week period
10157631|NCT04022304|Experimental|Sequence: Humulin® N- Humulin® N-Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
10157632|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
10157633|NCT04022304|Experimental|Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
10157634|NCT04022304|Experimental|Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.~The treatment periods will be separated by 5-7 days"
10157635|NCT04022577|Experimental|experimental group|The experimental group will participate in a eight session course of Adherence Therapy
10157636|NCT04022577|Placebo Comparator|control group|The control group received routine care
10157637|NCT04022395|Experimental|stress cardiac MRI|"To optimize the scan protocol and the sequence parameters~To investigate the clinical compliance of stress induced cardiac MRI in pediatric patients~To test the ability of stress cMRI to visualize coronary arteries morphological irregularities, the corresponding wall motion abnormalities and perfusion - viability features"
10157638|NCT04022382|Experimental|Restylane Defyne recipient|
9662065|NCT05131893||Her2 positive|"4x 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly) or~4x 3 weekly docetaxel (100mg / m˄2) + trastuzumab +/- pertuzumab~Docetaxel (75 mg / m˄2) + carboplatin (AUC6) + trastuzumab +/- pertuzumab 6 times every 3 weeks c) E (90-100mg / m˄2) + C (600mg / m˄2) 4x every 2 weeks, then 12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly)"
9662066|NCT05131893||Triple-negative breast cancer|"Paclitaxel (80 mg / m˄2) +/- carboplatin (AUC2) 12 times weekly, then E (90-100 mg / m˄2) + C (600 mg / m˄2) 4 times three weekly (preferred)~4x every 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~4x docetaxel (90-100mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2 )~4x every 2 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~4 times every 2 weeks paclitaxel (175 mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2)"
9662067|NCT05131880|Experimental|Experimental|"The experimental group will participate in a physiotherapy program with the addition of the Fisior Tapestry Method physiotherapy program, three sessions per week, for 12 weeks.~An initial assessment will be made at the beginning of the study, another one at the end of the intervention, and another one at follow-up."
9662068|NCT05131880|Active Comparator|Control|The control group will participate in a physiotherapy program three sessions per week for 12 weeks.
9662069|NCT05131867|Active Comparator|triple H group|The patients will receive nimodipine (60 mg/4 hours) orally or via nasogastric tube from the first day of admission, then after the diagnosis of vasospasm is confirmed, Triple H therapy (hypertension, hypervolemia and hemodilution) will be started. norepnnephrine (0.01-0.2ug/kg/min) to mentain main arterial blood pressure >100mmhg and hypervolemia to maintain the CVP around 12---14 mmHg and hemodilution to maintain the haematocrit between 30% and 33%.
9664659|NCT05302505|Experimental|Simulation|"Theoretical training in e-learning for nurses on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication~And simulation-based training (procedural) on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication"
10157639|NCT04022538|Experimental|Sandwich osteotomy with simultaneous implant placement|This group will undergo Sandwich osteotomy procedure and segment will be fixed using the dental implants placed simultaneously during the same surgical procedure. The remaining gap will be filled using xenograft.
10157640|NCT04022538|Active Comparator|Sandwich osteotomy using micro-plates fixation|This group will undergo Sandwich osteotomy procedure and segment will be fixed using micro-plates and screws, and the gap will be filled using xenograft.
10157641|NCT04022486||Children admitted in the PICU for severe bronchiolitis|Children admitted in the Pediatric Intensive Care Unit (PICU) for severe bronchiolitis between January 1st, 2010 and April 30th, 2018
10157642|NCT04022473|Experimental|Bafiertam|oral capsules administered twice daily
10157643|NCT04022473|Active Comparator|Tecfidera|oral capsules administered twice daily
10157644|NCT04022408|Experimental|Liquid based cytology|.Liquid-based cytology (LBC), enables cells to be suspended in a monolayer. LBC makes better cytological assessment possible with improved sensitivity and specificity, since fixation is better and nuclear details are well preserved in the technique. Preneoplasticand neoplastic cells are not obscured by other cells, such as normal epithelial and inflammatory cells. LBC techniques are currently applied to cytological samples from several tissues or fluids. They include uterine cervix , endometrium, aspirates from breast , thyroid tumors, ascites and pleural effusion, and urine , LBC technology is suggested as an appropriate diagnostic method for metastatic tumors in cerebrospinal fluid .
10157645|NCT04022408|Active Comparator|Conventional cytology|It is a gold standard for histopathological diagnosis of pancreatobiliary malignancies till date
10157646|NCT04022434|Placebo Comparator|Placebo|"Psyllium powder is used as the placebo. A member of the research staff will package and dispense L-alanine and placebo in similar containers. A standard measuring spoon will be provided to the subject for preparing the placebo solution. Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.~Meal Placebo Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
10157647|NCT04022434|Experimental|Experimental Alanine|"L-alanine, USP (Spectrum® Chemicals and Laboratory Products, Gardena, CA) will be packaged and dispensed by one member of the research staff who will have no other role in the study. A one-month supply will be dispensed to the subjects.~Meal L-Alanine Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
10157648|NCT04022499|Experimental|Pre-NDPP|Presessions + usual care NDPP
10157649|NCT04022499|Active Comparator|Usual care NDPP|Usual care NDPP only
10157650|NCT04022525||leflunomide responsive vs non-responsive|
10157651|NCT04022161|Placebo Comparator|Nitrogen|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
10157652|NCT04022161|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled nitric oxide (iNO) will be weaned and discontinued.
10157653|NCT04022421|Experimental|hydroxychloroquine arm|
10157654|NCT04022096|Experimental|Tegoprazan 25mg QD|Tegoprazan 25mg tablet, once daily, oral administration
10157655|NCT04022096|Active Comparator|Lansoprazole 15mg QD|Lansoprazole 15mg capsule, once daily, oral administration
10157656|NCT04022174|Experimental|Moderate dosage training|
10157657|NCT04022174|Experimental|Intensive dosage training|
10157658|NCT04022252|Experimental|Tooth Movement|Canine distalization on premolar extracted patients
10157659|NCT04022252|Experimental|Biochemistry measurements|biochemistry analysis of IL-8, OPG, RANKL
10157660|NCT04022252|Experimental|periodontal measurements|gingival and plaque index, blooding on probing, pocket depth
10157661|NCT04022291|Experimental|Biocon Insulin 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
10157662|NCT04022291|Active Comparator|Humulin® 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
10157663|NCT04022317|Experimental|Biocon Insulin R|0.3 IU/kg Dose per administration, subcutaneous Route of administration
10157664|NCT04022317|Active Comparator|Humulin® R (regular insulin human)|0.3 IU/kg Dose per administration, subcutaneous Route of administration
9973561|NCT01332422||Pediatric patients prescribed ADOAIR|Pediatric patients with asthma prescribed ADOAIR during study period
10157665|NCT04022031||Exposed group|Chinese patent medicine combined with western medicine routine
10157666|NCT04022031||Non-exposed group|Western medicine routine treatment
10157667|NCT04022369|Experimental|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. Education program based on Empowerment model. Weekly motivational telephone interviews were conducted with the patients, and the home visits and telephone interviews were repeated when belived necessary. The purpose of the study were explained to all individuals involved in the study. Body movements, balance levels, exercise durations, and strengths of individuals before exercise program and after exercise program were evaluated. A booklet demonstrating the exercises was given to the patients to enhance their understanding, and they were allowed to ask questions about the exercise program during the training.
10157668|NCT04022369|No Intervention|Control Group|The patients in the control group continued their standard treatment and care. Data collection forms were applied to the patients in the control group at the first month and 12 weeks after discharge. After the study was completed, all patients in the control group were provided with home-based exercise training booklets.
10186031|NCT03739801|Experimental|Treatment (ramucirumab, liposomal irinotecan[MM-398])|Patients receive ramucirumab IV over 30 minutes and MM-398 IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10157669|NCT04022018|Experimental|Adaptive radiotherapy group|Concurrent adaptive external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of adaptive radiotherapy group patients. CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
10157670|NCT04022018|Active Comparator|Control group|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients.
10157671|NCT04022265|Active Comparator|Control Site -Drill site|The control sites (Drills) will be prepared with a lanceolate drill (FS 230, Sweden / Martina), with a maximum diameter of 2.3 mm,
10157672|NCT04022265|Experimental|Test site -sonic site|test sites will be prepared with conical diamond inserts of increasing diameter (SFS99.000.014 to SFS99.000.024, Komet-Brasseler-GmbH, Germany) mounted on a sonic-air surgical instrument
10157673|NCT04022226|Active Comparator|Methohexital|Standard of care anesthesia that does not affect slow wave characteristics
10157674|NCT04022226|Experimental|Ketamine|Standard of care anesthesia that suppresses slow wave characteristics
10157675|NCT04022109||Gastric cancer patients undergoing surgery|Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
9527681|NCT03217838|Experimental|Group 2 Arm A (AZD2811 Dose 4 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 4 on Days 1 and 4 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
9664660|NCT05302505|No Intervention|Control|"Theoretical training for nurses in e-learning on :~arteriovenous fistula puncture~use of ultrasound with echoreferencing and ultrasound guidance~therapeutic communication"
10157676|NCT04022109||Gastric cancer patients|Patients with histologically confirmed gastric cancer (adenocarcinoma)
10157677|NCT04022109||Control group patients without gastric cancer|Patients without gastric malignant disease according to data obtained in upper endoscopy
10157678|NCT04022109||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
10157679|NCT04022109||Patients with dyspeptic symptoms|Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
10157680|NCT04022135|Active Comparator|Folic acid|0.6 mg/day
10157681|NCT04022135|Experimental|(6S)-5-methyltetrahydrofolic acid (Metafolin)|0.625 mg/d (an equimolar dose to folic acid)
10157682|NCT04021992|Experimental|GVD with or without R|Gemcitabine 1000mg/m2, d1,d8, intravenous drip; Vinorelbine 50mg/m2, d1,d8, oral; Doxorubicin liposomes 30mg/m2, d1,intravenous drip; With or without rituximab 375 mg/m2, d0,intravenous drip; All patients received up to 6 treatment cycles of 21 days.
10157683|NCT04022122||Heart Failure patients|The study does not imply any specific therapeutic intervention, and will not imply any change in the management of the participating patients, who will follow the usual clinical controls and will receive the medical and invasive treatments usually provided to patients with HF in our health area; as well as the different modalities of specific health education for this disease. At the time of hospital discharge, patients will be handled according to the usual protocols of the center established for outpatient follow-up of HF patients.
10157684|NCT04022070|Other|Dynamic Tape|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage in a sample of subjects affected by plantar fasciitis.
10157685|NCT04022005|Experimental|Chidamide combined with R-GemOx|Chidamide, 20 mg,twice per week; Rituximab 375mg/m2, d1, intravenous drip; Gemcitabine 1000mg/m2, d2, intravenous drip; Oxaliplatin 100mg/m2, d2,intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive chidamide maintenance therapy.
10157686|NCT04022057|Active Comparator|Pre-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through both the popliteal and the saphenous catheter
10157687|NCT04022057|Sham Comparator|Post-GA|10 mL of 5% dextrose injection before the start of surgery and 10 ml of 1% ropivacaine injection at the end of surgery through both the popliteal and the saphenous catheter
10157688|NCT04021940|Experimental|Dose adjusted ULOD|dose adjusted ULOD using 60J/cm3 applied to the larger ovary. The number of punctures (Np) per ovary will be calculated according to the following formula: Np = 60 J/cm3 divided by 30 W x 4 s.
10157689|NCT04021940|Active Comparator|Fixed dose ULOD|600 J for the larger ovary will be delivered through four punctures, each for 4 s and 40 W
10157690|NCT04021667|Experimental|INDIVIDUAL BREASTFEEDING TRAINING|"Individual Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates."
10157691|NCT04021667|Experimental|GROUP BREASTFEEDING TRAINING|"Group Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates.The groups were composed of five pairs of parents."
10157692|NCT04021667|No Intervention|Control Group|Control Group: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates. Routine procedures were applied to the mother and father candidates.
10157693|NCT04021953|Experimental|Intervention Group|"The online intervention comprises a series of six videos, each about 10-minutes in length, entitled the People Like Us series. The intervention was developed by gayhealth.sg and Action for AIDS Singapore in 2018. The series follow the love and sex lives of four ethnically-diverse GBQ men of varying socioeconomic backgrounds, as they negotiate issues of sexual health, mental health, and relationships throughout the six-part miniseries.~The intervention group will also be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention."
10157694|NCT04021953|Active Comparator|Control Group|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
10157695|NCT04021758|Experimental|Peer to peer program intervention|The experimental condition for the proposed project is the Airman's Edge program, a peer to peer program in which peer mentors will be trained to provide a series of interventions aimed at reducing risk for suicidal behaviors both directly and indirectly through the targeting of emotion dysregulation, cognitive rigidity, and contextual risk factors (e.g., insomnia, meaning in life, social support, firearm availability).
10157696|NCT04021758|No Intervention|Wait list|
10157697|NCT04021849|Experimental|Intervention|Participants will be gathered in a classroom with computers to receive an asynchronous virtual class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
10157698|NCT04021849|Sham Comparator|Control|Participants will be gathered in a classroom with computers to receive a face-to-face class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
10157699|NCT04021914|Experimental|EnChroma glasses|EnChroma products improve brightness and color purity of primary colors for CVD people. Each participant with CVD will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life.
10157700|NCT04021927|Experimental|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
10157701|NCT04021901||F21|balloon diameter F21
10157702|NCT04021901||F24|balloon diameter F24
10157703|NCT04021602|Active Comparator|Intervention 1 (Tx1) - DPP + Breastfeeding + Usual Care|Patients randomized to Tx1 will receive education in both the Diabetes Prevention Program (DPP) and in Breastfeeding. At baseline, this includes 16 DPP sessions (core curriculum), one 2-hour breastfeeding session, and participation in a professional peer support group. The 2-hour breastfeeding session is pre-recorded into four (4) 30-minute sessions and archived on a secure, private Facebook group. Participants will have access to all four breastfeeding sessions by week 24 of pregnancy and they need to complete all sessions by week 30 of pregnancy. At delivery, the patient will receive usual lactation support in the hospital, additional breastfeeding assessment and support (at day 3, day 10, week 3 and week 6), followed by 6 DPP sessions (post-core curriculum).
9671229|NCT05051345|Experimental|Goal 3 (Smoke-free Homes)|Participants receive the Smoke-Free Homes kit providing guidance for how to talk with household members and visitors about not smoking inside the home. Participants may also receive 3 separate Smoke-Free Homes mailings over 6 weeks, and a coaching call from a Baby Steps for Health counselor to help follow the steps described in the mailed materials in order to set up a smoke-free home.
10157704|NCT04021602|Active Comparator|Intervention 2 (Tx2) - DPP Only + Usual Care|Patients randomized to Tx2 will receive education in only the Diabetes Prevention Program. At baseline, this includes 16 DPP sessions (core curriculum). At delivery, the patient will receive usual lactation support in the hospital, followed by 6 DPP sessions (post-core curriculum).
10157705|NCT04021602|Placebo Comparator|Intervention 3 (Tx3) - Usual Care Only|Patients randomized to Tx3 will receive only usual standard of care. At baseline, the patient will receive only regular prenatal care provided by their physician. At delivery, the patient will receive standard of care breastfeeding support provided by the hospital.
10157706|NCT04021810|Active Comparator|CPAP only|Obstructive sleep apnea patients with CPAP treatment only
10157707|NCT04021810|Active Comparator|Mandibular Advancement Device only|Obstructive sleep apnea patients with Mandibular Advancement Device only
10157708|NCT04021810|Experimental|CPAP + Mandibular Advancement Device|Obstructive sleep apnea patients with combined CPAP and Mandibular Advancement Device
10157709|NCT04021836|Other|3d evaluation of naso labial changes using alar cinch suture|
10157710|NCT04021836|Other|3d evaluation of nasolabial change without Alar cinch|
10157711|NCT04021823||DBS patients|Patients with treatment resistant major depression participating in the FORESEE III study.
10157712|NCT04021823||Healthy controls|Age- and sex-matched healthy controls undergoing analyses of neurodegenerative markers (neurofilament light protein) in blood and metabolomic analyses in blood and urine.
10157713|NCT04021498|Placebo Comparator|Placebo|"placebo~1 year"
10157714|NCT04021498|Experimental|Simvastatin|"40 mg~1 year"
10157715|NCT04021576|Experimental|intervention|preventative training program
10157716|NCT04021576|No Intervention|control|no such training
10157717|NCT04021979|Experimental|Enteral Nutritional+PEG|Enteral Nutritional Powder with low volume 1.5L PEG
10157718|NCT04021979|Placebo Comparator|Self-controlled diet+PEG|Self-controlled diet with normal amount of 2L PEG
10157719|NCT04021615|Experimental|Group A (study group)|Twenty five patients will receive comprehensive rehabilitation program combined with inspiratory muscle training.
10157720|NCT04021615|Active Comparator|Group B (Control group)|Twenty five patients will receive traditional chest physical therapy combined with inspiratory muscle training.
10157721|NCT04021511|No Intervention|Phase A|The first one (Phase A) will occur in the emergency department with the application of OAR only by the physicians (without changing the standard of care) during 4 weeks
10157722|NCT04021511|Experimental|Phase B|The second one (Phase B) will occur after the Phase A. Nurses will apply OAR according to the protocol. This phase will also lasts 4 weeks.
10157723|NCT04021550|Experimental|Combined Treatment|Subjects will be given 80 mg/day Telmisartan + 600 mg/day Alpha-Lipoic Acid. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
10157724|NCT04021550|Placebo Comparator|Placebo Control|Subjects will be given placebo capsules. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
9662103|NCT05131360|Experimental|Awareness and Connection|Participants partake in the introduction or foundational mindfulness for one day and then perform awareness and connection-based mindfulness techniques for 5 days on the HMI app.
9973562|NCT01332448||Orlistat 120|Orlistat 120mg tid
10157725|NCT04021433|Experimental|MDD|Treatment resistant patients will be treated with multiple doses of IM/SC ketamine [dose range 0.3-1.5mg/kg]
10157726|NCT04021745|Experimental|App-based mindful eating|The intervention will be delivered through a mindful eating smartphone application using the latest evidence-based mindful eating methods and behavior change theory.
10157727|NCT04021693|Experimental|Handheld Ultrasound Devices|
10157728|NCT04021693|No Intervention|No Handheld Ultrasound Devices|
10157729|NCT04021589|Experimental|WLS-intervention group|chemotherapy + WLS
10157730|NCT04021589|Active Comparator|the control group|chemotherapy
10157731|NCT04021563|Experimental|SR419|Ascending single and multiple doses of SR419 orally
10157732|NCT04021563|Placebo Comparator|Placebo|Ascending single and multiple doses of placebo orally
10157733|NCT04021342|Active Comparator|Montmorency tart cherry concentrate|Participants will consume 30 ml of Montmorency tart cherry concentrate (MC) concentrate (King Orchard farms, USA) twice daily, once in the morning and again in the evening. According to the manufacturer each 30 ml dose of MC is estimated to be equivalent to approximately 90 whole cherries (equating to ~180 cherries per day).
9973563|NCT01332448||Orlistat 60|Orlistat 60 mg tid
10157734|NCT04021342|Placebo Comparator|Isocaloric cherry flavoured placebo|The PLA is prepared by mixing by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United States), dextrose, fructose with water to best match the calorie content of the MC concentrate. Additional lemon juice, for tartness, and artificial food colouring is added so the final product had a similar visual properties to the active comparator.
10157735|NCT04021888|Experimental|Exercise Group|
10157736|NCT04021888|Active Comparator|Control|
10157737|NCT04021459|Other|women with endometrial cancer|
10157738|NCT04021420|Experimental|low intensity pulsed UltraSound|SonoCloud® is an active implantable device (implantation duration until 16 weeks at maximum after inclusion). SonoCloud® delivers low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB.
10157739|NCT04021303|Experimental|Experimental Cereal|Experimental cereal with probiotics, prebiotic fiber and low carbohydrates through all the duration of the study.
10157740|NCT04021303|Active Comparator|Conventional cereal|Conventional gluten free cereal between 4 and 6 months old, and conventional gluten cereal between 7 and 12 months old.
10157741|NCT04021225|Active Comparator|Ectoin® Allergy Eye Drops 2%|"20 Patients:~- Ectoin® Allergy Eye Drops 2% (bitop AG)"
10157742|NCT04021225|Active Comparator|Ectoin® Eye Spray Colloidal|"20 Patients:~-Ectoin® Eye Spray Colloidal (bitop AG)"
10157743|NCT04021225|Active Comparator|Tears Again® Eye Spray|"20 Patients:~- Tears Again® Eye Spray (Optima Pharmazeutische GmbH)"
10157744|NCT04021212||Patients with pituitary adenomas resection|Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once
10157745|NCT04021251|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on P0.2 for minimum 10 hours per day with a maximum of 15 minutes between each measurement for 5 days distributed over a time period of 10 days. Spectral data will be compared to standard BG and/or FGM measurements.
10157746|NCT04021251|Experimental|Medium term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements.
10157747|NCT04021251|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 90 days distributed over a time period of 6 months. Spectral data will be compared to standard BG measurements.
10157748|NCT04021251|Experimental|Medium term collection of IMD data, increased # of sessions|Subjects will collect spectral raman data on P0.2 four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements. The number of optical sessions performed each time measurements are done are increased compared to the investigation's second arm.
10157749|NCT04021264|Active Comparator|PRE-GA|14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
10157750|NCT04021264|Sham Comparator|POST-GA|14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
9662104|NCT05131334|Other|intervention group|The pilot study applied an open-label, unblinded, repeated measures design with three time points of pupillometry measurements at two testing days. Patient serving as their own controls
10157751|NCT04021186|Experimental|Intervention|Insulin treatment using standard measurements.
10157752|NCT04021186|No Intervention|Control|Standard care.
10157753|NCT04021082|Experimental|Cohort A|Cerdulatinib dosing of patients with Peripherial T-Cell Lymphoma (PTCL) not otherwise specified (NOS); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
10157754|NCT04021082|Experimental|Cohort B|Cerdulatinb dosing of patients with nodal lymphomas of T follicular helper (TFH) phenotype origin, including angioimmunoblastic T cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), and nodal PTCL with TFH phenotype; Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
10157755|NCT04021082|Experimental|Cohort C|Cerdulatinb dosing of patients with Anaplastic large cell lymphoma (ALCL) (anaplastic lymphoma kinase positive [ALK+] and negative [ALK-]); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
10157756|NCT04021082|Experimental|Cohort D|Other rare types of extranodal non-cutaneous aggressive PTCL, including hepatosplenic T-cell lymphoma (HSTCL), enteropathy-associated T-cell lymphoma (EATL type I), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, EATL type II), and extranodal NK/T-cell lymphoma (nasal type); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
10157757|NCT04021199|Active Comparator|T1D Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
9671230|NCT05051345|Experimental|Goal 4 (counseling)|Non-pregnant participants receive telephone counseling sessions over 30 minutes for 6-8 sessions over a 3 month period.
10157758|NCT04021199|Experimental|MODY Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
10157759|NCT04021108|Other|Cohort 1|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 1 will receive Nivolumab alone (every 2 weeks for two doses, and then every 4 weeks)"
10157760|NCT04021108|Experimental|Cohort 2|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.~Subjects in Cohort 2 will receive Nivolumab (every 2 weeks for two doses, and then every 4 weeks) plus radiation therapy (total 5 sessions)"
10157761|NCT04021160|Active Comparator|Active Group|A total of 16, every other day sessions of rTMS at 10 Hz frequency will be applied to 4 locations along the perilesional area (see target selection). Intensity will be 100% of motor threshold, 25 trains - 40 pulses per train with 20 seconds intertrain interval and a total of 1000 pulses per session. The coil handle will be directed downwards at 45º of the sagittal plain to ensure that the induced electric field be perpendicular to the underlying gyrus.
10157762|NCT04021160|Sham Comparator|Sham Group|Sham group will receive the same sessions as above with the exact same parameters yet a sham coil identical in shape and size to the active coil will be used instead. The sham coil produces sounds and sensations very similar to the active one.
10157763|NCT04021147|Experimental|Action Observation|
10157764|NCT04021147|Experimental|Motor Imagery|
10157765|NCT04021147|Experimental|Visual mirror feedback|
10157766|NCT04021147|Active Comparator|Orofacial exercise|
10157767|NCT04021407|Active Comparator|LMA|36 patients were ventilated with LMA during dacryocystorhinostomy surgery
10157768|NCT04021407|Active Comparator|AirQ|36 patients each were ventilated with air Q airway during dacryocystorhinostomy surgery
10157769|NCT04021121|Experimental|High Dose RIF with LZD|Arm 1 participants will receive high dose oral RIF (35mg/kg/day) and LZD 1200 mg daily for the first 4 weeks of therapy, along with standard doses of Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). After 4 weeks, LZD will be discontinued and high dose RIF will return to standard dose for the remainder of treatment.
10157770|NCT04021121|Experimental|Standard dose RIF with LZD|Arm 2 participants will receive standard dose RIF, INH, PZA, and EMB along with LZD 1200 mg daily. After 4 weeks, LZD will be discontinued.
10186032|NCT03739788|Experimental|BMS-986165|Oral and intravenous administration
9671231|NCT05051085|Experimental|"Internet-delivered treatment: SpilleFri."|"All participants receive the internet-delivered therapist-assisted 8-modules treatment program SpilleFri."
9671232|NCT05051683|Active Comparator|group (1)|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer
9671233|NCT05051683|No Intervention|group (2)|surgical management of acute perforated peptic ulcer
9671234|NCT05050968|Experimental|Adapted Physical Activity Group|Patients will follow a 3-month physical activity program 3 times a week between V1 and V2. Then, between V2 and V3, no APA program will be offered to both groups.
9671235|NCT05050968|No Intervention|Control group|Patients will receive standard hospital management
9671236|NCT05051241|Experimental|GFH018|"The duration of the first cycle is 31 days and the subsequent periods are 28 days.~Subjects will receive treatment with GFH018 until disease progression (clinically- or radiologically-confirmed), occurrence of intolerable toxicity, or subjects discontinue from the study treatment for other reasons."
9671237|NCT05051007|Active Comparator|fentanyl group|
9671238|NCT05051007|Active Comparator|lidocaine group|
9973564|NCT01332448||Placebo|No active drug
10157771|NCT04021121|Experimental|High Dose RIF|Arm 3 participants will receive high dose oral RIF (35mg/kg/day) for the first 4 weeks of therapy, along with standard doses of INH, PZA, and EMB. After 4 weeks, high dose RIF will return to standard dose for the remainder of treatment.
10157772|NCT04021121|Active Comparator|Standard Dose RIF|Arm 4 participants will receive standard doses of RIF, INH, PZA, and EMB.
10186033|NCT03739762|Experimental|i-STAND|i-STAND participants have a Baseline visit followed by their first Coaching visit. They are offered wristbands that vibrate every 15 minutes to prompt a standing break, standing desks, a workbook and 10 phone-based coaching sessions focused on sitting less and standing more. At 3 months they will participate in a measurement visit. The program ends at 6 months where they wear an activPAL and participate in a measurement. Their coach will provide feedback on their sitting time from the activPAL after all activPAL wears (Baseline, 3, 6 and 12 month). They may also opt in to wear an activPAL at 6 weeks and receive feedback. They will be re-randomized at 6 months, where half will be assigned to intervention boosters (5 more phone coaching sessions / one 9-month optional activPAL wear) before the 12 month time point for a final activPAL wear and final measurement visit. Those not randomized to receive boosters will have no further contact with the study team until the 12 month time point.
9973565|NCT01332474||JCP|treatment of Equinus Foot due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older
10186034|NCT03739762|Active Comparator|Healthy Living control|In this arm, participants have a phone-based Baseline visit followed by their first phone-based Coaching visit. They are not offered any prompting devices or desks, and their coaching sessions focus on a variety of topics related to healthy living, but without a focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants are given a workbook. All content is from Kaiser Permanente Washington and is available to all members. Participants will select topics of interest and review them with their health coach. At 3 months, participants will participate in a measurement visit. The program ends at 6 months where participants will wear an activPAL and participate in a measurement visit. After that, they will not have contact with the study team until 12 months when they will again wear an activPAL and participate in their final measurement visit.
10186035|NCT03739749|Active Comparator|Fascia lata autograft|Arthroscopic superior capsular reconstruction using a fascia lata autograft
10186036|NCT03739749|Active Comparator|Fascia lata allograft|Arthroscopic superior capsular reconstruction using a fascia lata allograft
10186037|NCT03739749|Active Comparator|Achilles tendon allograft|Arthroscopic superior capsular reconstruction using an achilles tendon allograft
10186038|NCT03739749|Active Comparator|Bovine pericardium allograft|Arthroscopic superior capsular reconstruction using a bovine pericardium allograft
10186039|NCT03739749|Active Comparator|Swine dermal xenograft|Arthroscopic superior capsular reconstruction using a swine dermal xenograft
10186040|NCT03739749|Active Comparator|Collagen allograft|Arthroscopic superior capsular reconstruction using a collagen allograft
10186041|NCT03739736||Combination of TB/HIV prevention activities (A)|Communities in the intervention group (A) were exposed to a combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. In this arm, ART was initiated regardless of CD4 count
9662105|NCT05131295|Experimental|Dapsone|Besides the standard of care, those assigned to the dapsone group received orally 100mg (2.5 ml) of dapsone suspension daily, from the admission day until the 15th-day post-ictus.
9662106|NCT05131295|Placebo Comparator|Placebo|Besides the standard of care, those assigned to the placebo group received orally 2.5 ml of aluminum hydroxide gel daily, from the admission day until the 15th-day post-ictus.
9662107|NCT05131256|Experimental|patients suffering from obesity with BED|
9662108|NCT05131256|Active Comparator|patients suffering from obesity without BED|
9662109|NCT05131256|Active Comparator|healthy participants|
9662110|NCT05131243|Experimental|ctDNA positive patients|Postoperative ctDNA-positive patients will receive chemotherapy for 6 months.The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
9662111|NCT05131243|Active Comparator|ctDNA negative patients|Postoperative ctDNA-negative patients will receive chemotherapy for 3 months. The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
9662112|NCT05131178|Placebo Comparator|Saline|ON-Q Pump® with continuous infusion of saline (270 mL of normal saline)
9662113|NCT05131178|Experimental|Bupivacaine|ON-Q Pump® with continuous infusion of bupivacaine (270 ml of 0.5 % bupivacaine)
9662114|NCT05131126|Experimental|Patient requiring anterior abutment surgery by Latarjet method|
9662115|NCT05131126|Active Comparator|Healthy volunteers|
9662116|NCT05131087|Experimental|Cadence|Cadence procedure
9662117|NCT05131048|Active Comparator|Conventional group|"Patients will be given thermal therapy with the hot pack for 20 minutes followed by Conventional physiotherapy will consist of a set of exercises. The exercise components willl be chosen based on previous studies (Deyle 2000) and will comprises of~stretches of lower limb muscles (gastrocnemius, soleus and hamstring)~isometric quadriceps work~straight leg raising~Joint mobilization includes anteroposterior (AP) glide of the tibia on the femur~the patella glides in all directions Subjects will participate in a 45-minute physical therapy session, on alternate days weekly for 6 weeks, in our centre under the close surveillance of a physical therapist. A total of 24 sessions will be given to this group."
9662118|NCT05131048|Experimental|interventional group|"Patients in this group will perform home-based hip Strengthening exercises to strengthen hip abductor and adductor muscles. Six different home-based exercises will be taught. This group will have 3 sessions in 1st week in the hospital under the supervision of a trained physiotherapist just to teach them and ensure that patients are doing exercises correctly on their own. After that, patients will perform exercises 5 days at home and 1 session at the hospital per week. The therapist will be trained to deliver different exercises and adjust the intensity of exercise accordingly advise the participants to complete 10 repetitions of every exercise at home96.~Abduction in side-lying~Abduction in standing~Standing wall isometric hip abduction~Hip Adduction in side-lying~Hip abduction in a standing position~Towel press"
10157773|NCT04021017|Experimental|Treatment|"Participants randomized to the treatment arm will be divided by maturational status:~Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months.~o These participants will also receive progesterone (Provera 10 mg tablet) orally every 4 weeks, for 7 days during the second half of the planned menstrual cycle, in order to induce a menstrual period.~Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches:~3.1 mcg/day (1/8 patch) for first six-months,~6.2 mcg/day (1/4 patch) for second six-months,~12.5 mcg/day (1/2 patch) for third six-months, and~25 mcg/day (full patch) for final six-months."
10157774|NCT04021017|No Intervention|No Treatment|The participants in this group will not receive the estrogen patch nor the oral progesterone.
10157775|NCT04021173|Experimental|Anfibatide|
10157776|NCT04021173|Placebo Comparator|Placebo|
10157777|NCT04021446|Active Comparator|Exercise|Will receive the exercise intervention
10157778|NCT04021446|No Intervention|Attention Control|Will not receive the exercise intervention
10157779|NCT04020978|Other|Patients with GUC|Each patient with GUC will first undergo an X-ray CT scan for attenuation correction purpose. After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds. The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes. After the PET scan, the patient gets off the scanner. One blood sample (10cc) will be drawn using a butterfly method with the time recorded.
10157780|NCT04021329|Other|EMDR Therapy|One arm will be a group subjected to EMDR Therapy
10157781|NCT04021329|Other|CBT Therapy|other arm will be a group subjected to CBT Therapy
10157782|NCT04021355|Experimental|Early Sodium|Early sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for 9 days and in addition will take 2 g of sodium in the form of salt tablets with breakfast each day.
10157783|NCT04021355|Experimental|Late Sodium|Late sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for the next 9 days and in addition will take 2 g of sodium with dinner each day.
10157784|NCT04020939|Experimental|Patients undergoing intestinal resections|"Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence~Drug:~Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only"
10157785|NCT04021095|Experimental|Decompressive craniectomy|3D printed skull replacement piece will be fitted to subject.
10157786|NCT04020874|No Intervention|Baseline|Year 1, no intervention to generate baseline, comparative data for subsequent years
10157787|NCT04020874|Experimental|HuTT-2x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 2 times each week throughout the regular season.
10157788|NCT04020874|Experimental|HuTT-4x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 4 times each week throughout the regular season.
10157789|NCT04020900||Children <18 years, admitted for a general anesthesia.|Children <18 years, admitted for a general anesthesia.
10157790|NCT04021277|Experimental|ACT with chemotherapy in metastatic solid tumours|Part 1: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with solid tumours
10157791|NCT04021277|Experimental|ACT with chemotherapy in metastatic CRC|Part 2: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with metastatic colorectal cancer
10157792|NCT04021277|Experimental|ACT with chemotherapy in metastatic PDAC|Part 2: PS101 administered together with standard of care chemotherapy (Gemcitabine and nab-paclitaxel) and US insonation over the targeted liver metastasis in patients with metastatic Pancreatic Duct Adenocarcinoma (PDAC)
10157793|NCT04020796|Active Comparator|Beetroot juice|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of beetroot juice in a single moment.
10157794|NCT04020796|Placebo Comparator|Mineral water|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of mineral water in a single moment.
10157795|NCT04020952|Active Comparator|"st.st 0.019×0.025 wire"|
10157796|NCT04020952|Experimental|"st.st 0.016×0.022 wire"|
10157797|NCT04020952|Experimental|"st.st 0.017×0.025 wire"|
10157798|NCT04020757|Other|Bicarb Variation|Variation in dialysis bicarbonate, lowered to 30 mEq/L for week 2 of 3
10157799|NCT04020731|Experimental|Right-handed healthy volunteers|Magnetoencephalography (MEG) records
10157800|NCT04020666||HUK group|On the basis of routine treatment for cerebral infarction, patients in the HUK group were also given Urinary Kallidinogenase at 0.15 PNA unit/day, for a 10-day course.
9662119|NCT05131009||Patients with pulmonary complications following abdominal surgery|
10157801|NCT04020666||control group|The control group were given routine treatment for cerebral infarction, including anti-platelet aggregation, anticoagulation, lipid-lowering and plaque stabilizing, free radical scavenging, nerve nutrition and brain protection.
10157802|NCT04020640||Exclusive breastfeeding (EBF)|provision of breast milk only, allowing only receiving oral rehydration salts (ORS), drops and syrups (vitamins, minerals, medicines) as necessary
10157803|NCT04020640||Predominant breastfeeding (PBF)|providing breast milk plus other liquids (water and water-based drinks, fruit juice) and ORS, drops and syrups (vitamins, minerals, medicines)
10157804|NCT04020640||Partial breastfeeding (PartBF)|provision of breast milk plus infant formula or cow milk or other solid/semi-solid complementary foods
10157805|NCT04020653|Placebo Comparator|Placebo + ACT|Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
10157806|NCT04020653|Experimental|5 ALA/SFC+placebo+ACT BID|"5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.~Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14)."
10157807|NCT04020653|Experimental|5-ALA/SFC+placebo+ACT QD|5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).
10157808|NCT04020744|Active Comparator|healthy elderly participants receiving feedback from the hippocampus|This group will consist of healthy elderly volunteers, who will receive feedback from their hippocampal activity.
10157809|NCT04020744|Sham Comparator|healthy elderly participants receiving feedback from another area|This group will consist of healthy elderly volunteers, who will receive feedback from another brain area.
10157810|NCT04020744|Experimental|patients with MCI receiving feedback from the hippocampus|This group will consist of patients with mild cognitive impairment, who will receive feedback from their hippocampal activity.
10157811|NCT04020744|Sham Comparator|patients with MCI receiving feedback from another brain area|This group will consist of patients with mild cognitive impairment, who will receive feedback from another brain area.
9662120|NCT05131009||Patients without pulmonary complications following abdominal surgery|
10157812|NCT04020965|No Intervention|Control arm|This arm includes all households in villages randomized to the active control arm (double-sized) or passive control arm of the original trial. Village-level promoter visited households enrolled in the WASH Benefits Kenya study active control arm and strictly engaged in recording the child's MUAC and referring children identified as malnourished (MUAC<11.5 cm) to health clinics, for two years. These visits were also conducted in all active comparator arms. Households in active control and active comparator villages which were not enrolled in the original study did not receive such visits.
10157813|NCT04020965|Experimental|Water Treatment|This arm includes all households in villages randomized in the original WASH Benefits trial to the water treatment arm, combined water treatment with handwashing and sanitation (WASH) arm, and combined WASH + nutrition arm. Village-level promoter visited households enrolled in the original trial to promote the interventions for approximately two years.
10157814|NCT04020783||Observation group|sequential
10157815|NCT04021043|Experimental|Group I (ipilimumab, BMS-986156, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
10157816|NCT04021043|Experimental|Group II (ipilimumab, BMS-986156, SBRT, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
10157817|NCT04021043|Experimental|Group III (nivolumab, BMS-986156, SBRT)|Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
10157818|NCT04020679|No Intervention|Control arm|Participants will not receive GOCI materials
10157819|NCT04020679|Experimental|Intervention|Participants will receive GOCI materials and clinicians will receive training.
10157820|NCT04020614||Survey|All of the patients that enrolled in this study will be in this group.
10157821|NCT04020510|Active Comparator|Standard Injections|For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 30mL of injectable saline injected in 30 sites with 1mL per injection along the posterior wall of the bladder above the trigone.
10157822|NCT04020510|Experimental|Reduced Injections|"For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone."
9662121|NCT05130944|Experimental|Entre Nosotras (group psychosocial intervention) + stress management intervention|Experimental condition: Women residing in the study community (displaced and host population) will receive both group psychosocial intervention and stress management intervention. Participants will be given the Spanish version of the Doing What Matters in Times of Stress illustrated guide, that is published and made publicly available by the World Health Organization.
9662122|NCT05130944|Active Comparator|Entre Nosostras (group psychosocial intervention)|Comparison condition: Women residing in the study community (displaced and host population) will receive group psychosocial intervention only.
10157823|NCT04020991||Doctors working in a tertiary hospital|Doctors working in a tertiary hospital
10157824|NCT04020393||Block group|The patients that had received Sphenopalatine ganglion block(SPGB) before the surgery
10157825|NCT04020393||Control Group|The patients that had not received SPBG before the surgery
10157826|NCT04020692|Experimental|"intervention  group"|"Patient At D0, the patient receives his discharge drugs prescription and benefits from a pharmaceutical counselling.~At D+3, he benefits from a telephone follow-up (good understanding of the methods of taking drugs, collection of difficulties).~Community pharmacist At D0, he receives the discharge drugs prescription. At D+3, he is contacted to collect information relating to drugs 'dispensation.~The attending physician At D0, he is informed of the patient's discharge and his drugs treatment~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
10157827|NCT04020692|No Intervention|Control group|"At D0, the patient receives his discharge drugs prescription.~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
10157828|NCT04020458|Active Comparator|Periodontitis, no kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
10157829|NCT04020458|Active Comparator|Experimental- chronic kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
10157830|NCT04020458|No Intervention|Control- no Periodontitis or kidney disease.|Only regular dental cleaning
10157831|NCT04020601|Active Comparator|PRE-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through the interscalene catheter
10157832|NCT04020601|Sham Comparator|POST-GA|10 ml of 5% dextrose injection before the start of surgery and 1% ropivacaine injection at the end of surgery through the interscalene catheter
10157833|NCT04020497|Experimental|Ensemble + SAU (Support as usual)|The five-session Ensemble program provided to informal caregivers targeted support + SAU
10157834|NCT04020497|Active Comparator|SAU (Support as usual)|SAU alone which was chosen as a control condition.
10157835|NCT04020861|Active Comparator|PBM + TENS|The patients will be submitted to the active PBM and active TENS
10157836|NCT04020861|Active Comparator|PBM|The patients will be submitted to the active PBMT and placebo TENS
10157837|NCT04020861|Active Comparator|TENS|The patients will be submitted to the placebo PBMT and active TENS
10157838|NCT04020861|Placebo Comparator|Placebo|The patients will be submitted to the placebo PBMT and placebo TENS.
10157839|NCT04020588|Active Comparator|Celecoxib|Celecoxib 200 mg twice a day
10157840|NCT04020588|Active Comparator|Minocycline|Minocycline 100 mg twice a day
10157841|NCT04020588|Placebo Comparator|Placebo|Placebo capsules twice a day
10157842|NCT04020705|Experimental|Citicoline eye drops (OMK1)|45 patients will be treated with active treatment (OMK1)
10157843|NCT04020705|Placebo Comparator|hypromellose based ocular lubricant|45 patients will be treated with placebo (lubricant eye drops)
10157844|NCT04020536||kala-azar group|
10157845|NCT04020536||epidemic hemorrhagic fever group|
10157846|NCT04020536||brucellosis group|
10157847|NCT04020627|Experimental|BiPAP Group|Bilevel Positive Airway Pressure
10157848|NCT04020627|Experimental|CPAP Group|Continuous Positive Airway Pressure
10157849|NCT04020380|Experimental|Azithromycin 250 mg|Azithromycin, 250 mg capsules once a day for a total of 3 months
10157850|NCT04020406||Antibacterial Activity of Urea|Activity of Urea Solution against Ocular Bacterial Isolates
10157851|NCT04020562|Experimental|Mild Resistive Expiratory Technique|Mild resistive Expiratory Technique from EMST150- five-week training protocol.
10157852|NCT04020562|Active Comparator|Conventional Training|Breathing exercise, Assistive Coughing, ROM Exercises, Sustained stretching, Splinting, Bracing, Functional Mobility, Tilt table standing
10157853|NCT04020419|Experimental|Pediaberry group|PediaBerry™ is a proprietary blend powdered berry extracts
9662123|NCT05130931|Experimental|Manual therapy and Diacutaneous Fibrolysis.|
9662124|NCT05130931|No Intervention|Standard healthcare.|
9662125|NCT05130918|Experimental|Phenolmicin P3 and Bosexil|Group in which patients were administered Phenolmicin P3 and Bosexil suppositories twice a day for 5 days, then once a day for other 10 days after thulium laser enucleation of prostate was performed.
10157854|NCT04020419|Placebo Comparator|Placebo|Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).
10157855|NCT04020770|Experimental|Vibrating Ball|Vibrating ball is held in both hands. Participants complete 5 30-second bouts of 68 Hz vibration with a 1 minute rest in between each bout.
10157856|NCT04020354|Experimental|HABIT-ILE|Early HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
9671239|NCT05051202|Experimental|25g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 25 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
10157857|NCT04020354|Active Comparator|Usual Care|A two weeks period of usual customary care
10157858|NCT04020211||HF10|SCS stimulation with HF10 therapy
10157859|NCT04020432||pregnant women|"Pregnant women are coming to their monthly consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Pregnant women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
10157860|NCT04020432||childbearing age women|"Women of childbearing age, who are coming for a gynecological consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Childbearing age women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
10157861|NCT04020484|Experimental|Intervention Group|Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.
9671240|NCT05051202|Active Comparator|25g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 25 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
10157862|NCT04020484|Other|Waitlist Control|Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete the Baseline and Immediate Follow-up questionnaire at comparable times to families in the intervention arm; they will not complete the Extended Follow-up questionnaire. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session.
10157863|NCT04020367|Other|patients with biopsy|
10157864|NCT04020289|Experimental|"BalancingMySwing"|"Psychoeducational Program BalancingMySwing for bipolar disorder"
10157865|NCT04020289|Other|treatment as usual (TAU)|Patients received treatment as usual
10157866|NCT04020159||Participants with COL6-related dystrophy|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
10157867|NCT04020328|Experimental|leflunomide + low dose glucocorticoids therapy group|the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment
10157868|NCT04020328|No Intervention|Basic conservative treatment group|the basic conservative treatment group is the delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, RAS inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy
10157869|NCT04020302|Experimental|Shopping group|Participants will receive an 8-week intervention which will include weekly sessions that are delivered in an alternating group-individual format. Sessions will provide participants the opportunity to practice and apply self-monitoring techniques across a variety of shopping tasks and settings to promote generalization and transfer of learning (Phase B).
10157870|NCT04020315|Experimental|Generalized aggressive periodontitis|Non-surgically performed scaling and root planing.
10157871|NCT04020549|Experimental|Intervention|
10157872|NCT04020549|Sham Comparator|Study Skills Control|
10157873|NCT04020237|No Intervention|Observational arm|General counselling to particulate matter practice score.
10157874|NCT04020237|Other|Interventional arm|Active education and feedback on the particulate matter practice score that affects real life.
10157875|NCT04019925|Other|ADM/MDM hip prosthesis|Type of prosthesis participant received.
10157876|NCT04020263|Experimental|Levosimendan|Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.
10157877|NCT04020263|Placebo Comparator|Placebo|Control group: Patients with cardiogenic shock treated with placebo for levosimendan in addition to the conventional strategy.
10157878|NCT04020029|Experimental|Mindset Intervention|Mindset Intervention will include watching three brief ~10-25 minute films and respond to a number of short reflection activities after viewing the films.
10157879|NCT04020029|Active Comparator|Treatment As Usual (TAU)|TAU Control Arm will complete the same assessments as those participants in the Mindset Intervention Arm, but will not view the short films or complete the corresponding response activities.
10157880|NCT04020224|Experimental|Treatment with pathogen reduced whole blood|Subjects will receive one amustaline/GSH treated whole blood product.
10157881|NCT04020224|Active Comparator|Treatment with Standard of Care|Subjects will receive the Standard of Care (SOC), either one red blood cell (RBC) component or one whole blood product
10157882|NCT04020094|Experimental|Treatment: all patients|
10157883|NCT04020107|Active Comparator|Compressive garment associated with physical therapy|
10157884|NCT04020107|Placebo Comparator|Low compressive garment associated with physical therapy|
10157885|NCT04020016|Experimental|Part 1 Single Ascending Dose|Impaired liver function subjects and healthy liver subjects single ascending dosing up to 162 mg BID of Nalbuphine ER
10157886|NCT04020016|Experimental|Part 2 Multiple Ascending Dose|Impaired liver function subjects will receive multiple ascending dosing up to 162 mg BID of Nalbuphine ER
9671241|NCT05051202|Experimental|35g Sugars From Fiber per day|Administered in 50 g Flapjack containing 35 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
10157887|NCT04020081|Experimental|Effect of yoga exercises in COPD patients after 12 weeks.|Yoga group
10157888|NCT04020081|No Intervention|COPD patients lung functions without yoga excercises.|Control group
9662126|NCT05130918|No Intervention|Controls|Group in which patients were not administered Phenolmicin P3 and Bosexil suppositories after thulium laser enucleation of prostate was performed.
10157889|NCT04019977|Experimental|Nurse Home Visiting Group|This group will be offered services from the nurse home visiting program.
10157890|NCT04019977|No Intervention|Non-intervention Group|This group will not be offered services from the nurse home visiting program.
10157891|NCT04020146||group 1;|healthy controls (C, n=15),
10157892|NCT04020146||group 2|periodontitis patients with stage 3 grade B; (P, n=15)
10157893|NCT04020146||group 3|peri-implantitis patients (PI, n=15).
10157894|NCT04020055|Experimental|migalastat HCl 150 mg|All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.
10157895|NCT04020003|Other|Routine treatment|Routine treatment group: control infection, remove or control the primary disease; mechanical ventilation with low tidal volume and high PEEP mechanical ventilation strategy; strictly control volume, strengthen airway management, timely nutritional support and severe rehabilitation treatment.
10157896|NCT04020133|Active Comparator|the control group|this group will receive post-operative saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
10157897|NCT04020133|Active Comparator|the intervention group|this group will receive popliteal plexus block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg in addition to standard saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
10157898|NCT04019899|Active Comparator|Control group|
10157899|NCT04019899|Experimental|Study group|
10157900|NCT04020042|Experimental|Ultrasound imaging guidance|Determination of epidural needle site by using ultrasound guidance
10157901|NCT04020042|Active Comparator|Traditional landmark palpation|Depermination of epidural needle site by using traditional landmark method
10157902|NCT04019938||Diabetic adults|
10157903|NCT04019886|Experimental|Experimental Group|"It consists following techniques-~Peri-oral stimulation~Vertebral pressure~Anterior stretch -lifting posterior basal area~Co-contraction -abdomen~Intercoastal stretch~Moderate manual pressure"
10157904|NCT04019886|No Intervention|Control Group|Outcome measure will be measured at baseline on first day prior to the intervention and on 5th day after the treatment.
10157905|NCT04020120||ADHD in professional activity|Adult ADHD patients in active employment at the time of inclusion or who were in employment within 3 months prior to inclusion
10157906|NCT04019912|Experimental|Gait Training plus music|Patients will be randomly assigned to the rehabilitation group through gait trainer3 with Rhythmic Auditory Stimulation (RAS). All patients will undergo a complete clinical and neurophysiological evaluation at baseline. The training program consist of 45 minutes of treadmill training with RAS. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists with 2 years of RAS training.
10157907|NCT04019912|Active Comparator|Traditional Gait Training|Patients will be randomly assigned to the non-Rhythmic Auditory Stimulation (RAS) treadmill walking group. All patients will undergo a complete clinical and neurophysiological evaluation at baseline.The daily training program consist of 45 minutes of conventional gait training using a non-RAS treadmill. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. Non-RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists.
10157908|NCT04019951|Experimental|Propionate (1 g)|Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
10157909|NCT04019951|Experimental|Propionate (3 g)|Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
10157910|NCT04019951|Placebo Comparator|Placebo|Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
10157911|NCT04019860|Experimental|High Intensity Interval Training|High intensity interval training for seven weeks. Three weekly, supervised training sessions.
10157912|NCT04019860|Experimental|Time-Restricted Eating|Time-restricted eating for seven weeks. Maximal daily eating window of 10 hours.
10157913|NCT04019860|Experimental|High Intensity Interval Training & Time-Restricted Eating|
10157914|NCT04019860|No Intervention|Control|Will be given information about the recommended level of physical activity for health benefits and a healthy diet.
10157915|NCT04019782|Experimental|Collagen-PVP|Collagen-polyvinyl pyrrolidone (collagen-PVP).
10157916|NCT04019782|Active Comparator|Hylan G-F 20|Hylan G-F 20.
10157917|NCT04019795|Sham Comparator|Non-Active REVIAN (Sham) Cap 100|Sham (Control) Group
10157918|NCT04019795|Experimental|Active REVIAN Cap 101|(625 nm and 660 nm)
10157919|NCT04019795|Experimental|Active REVIAN Cap 102|(425 nm)
10157920|NCT04019795|Experimental|Active REVIAN Cap 103|(425 nm, 625 nm and 660 nm)
10157921|NCT04019847|Experimental|STAK Tool|The STAK Tool enables patients to apply a high intensity stretch to their knee independently. Patients are asked to do this for a maximum of 60 mins per day.
9662127|NCT05130905|Experimental|Supplementation with RiteStart|Once enrolled into the study, participants were instructed to take RiteStart Supplement daily for 12 weeks.
9662128|NCT05130892|Experimental|Colchicine group|1 tablet (0.5mg) / time, once a day
9662129|NCT05130892|Experimental|Tranilast group|1 capsule (0.1g) / time, 3 times a day;
9662130|NCT05130892|Experimental|Oridonin group|2 tablets (0.5g) / time, 3 times a day
10157922|NCT04019847|Active Comparator|Standard treatment|Patients are treated as per their Clinician's prescription. Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain ROM and function.
9671242|NCT05051202|Active Comparator|35g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 35 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
10157923|NCT04019769|Experimental|1|All patients will receive L-glutamine 10-30mg daily based on weight for 3 months
10157924|NCT04019496||Episodic Migraine|
10157925|NCT04019496||Healthy controls|equal to or less than 1 headache day/month
10157926|NCT04019639|Experimental|CG Paste+EasyFoam|"The subjects assigned to the test group through random assignment will receive the wound treatment by applying CG Paste and EasyFoam. CG Paste is a medical device currently marketed in CGBio.It is a free-flowing, acellular allogeneic dermis processed from human tissue skin, and then granulated and homogenized. This increases the water content and viscosity of the micronized ADM particles mixed with the gelatin sol carrier to protect the wound area and maintain the wet environment by applying to the desired wound area.It contains collagen, elastin and various growth factors in the dermis and has excellent tissue compatibility compared to the heterogeneous or synthetic material, so that the immune rejection is hardly observed in the graft site.~It also contains collagen, elastin, fibronectin, laminin, and proteoglycans, which are components of the human skin, to help the interaction between normal cells and extracellular matrix."
10157927|NCT04019639|Active Comparator|EasyFoam|"Subjects randomly assigned to the control group receive EasyFoam treatment for wound healing.~The foam has excellent moisture permeability, absorbs a large amount of exudates, and prevents scar formation to minimize scar formation."
9827509|NCT02458638|Experimental|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
10157928|NCT04019548|Experimental|Prophylactic PEG|Prophylactic PEG tube will be placed before the start of the study treatment (CRT). The enteral nutrition will start following the assessment by the clinical dietitian in order to complete the current oral consumption according to the estimated energy needs (on the basis of 30 to 35 kcal / kg adapted and 1.2 to 1.5 g / prot./ kg.BW) with an increase as needed during the treatment.
10157929|NCT04019548|Experimental|Reactive PEG|Reactive PEG tube will be placed and enteral nutrition initiated, during the study treatment period in case of decrease of oral intake less than 2/3 of estimated energy requirements (based on 30-35 kcal / adapted kg .BW and 1.2 - 1.5 g/prot./adapted kg. BW) for a period of or anticipated to be, greater than 7 days or weight loss ≥ 5% from pre-treatment baseline).
10157930|NCT04019561|Experimental|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
10157931|NCT04019561|Placebo Comparator|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
10157932|NCT04019561|Experimental|MEDI0382 low dose|MEDI0382 low dose administered subcutaneoously
10157933|NCT04019561|Placebo Comparator|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
10157934|NCT04019457|Experimental|Dietary fiber 1|Participants receive cereal flakes 1 to include it in their normal diet.
10157935|NCT04019457|Experimental|Dietary fiber 2|Participants receive cereal flakes 2 to include it in their normal diet.
10157936|NCT04019665|Other|SAGE and MMSE score|
10157937|NCT04019392|Active Comparator|Wetted ice with elastic wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied to each participants' lower leg for 30 minutes using an elastic wrap. The elastic wrap will be applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half. The elastic wrap application will consist of pulling the wrap to its full tension, measuring the length of the wrap, and calculating 75% of the total length to apply to the body part.
10157938|NCT04019392|Active Comparator|Game Ready|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
10157939|NCT04019431|Experimental|Whey protein|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
9977848|NCT01365767||Crohn Disease|Patients with Crohns Disease referred to referred to a Magnetic Resonance Imaging Scan.
10157940|NCT04019431|Active Comparator|Vegetable proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
10157941|NCT04019431|Active Comparator|Animal proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days.Patients will be given four meals per day containing natural animal protein (meat, fish, eggs, dairy products without whey protein).
10157942|NCT04019743|Experimental|Group 1|"Period 1: Treatment A~Period 2: Treatment B~Period 3: Treatment C"
10157943|NCT04019743|Experimental|Group 2|"Period 1: Treatment C~Period 2: Treatment A~Period 3: Treatment B"
10157944|NCT04019743|Experimental|Group 3|"Period 1: Treatment B~Period 2: Treatment C~Period 3: Treatment A"
10157945|NCT04019743|Experimental|Group 4|"Period 1: Treatment C~Period 2: Treatment B~Period 3: Treatment A"
10157946|NCT04019743|Experimental|Group 5|"Period 1: Treatment B~Period 2: Treatment A~Period 3: Treatment C"
10157947|NCT04019743|Experimental|Group 6|"Period 1: Treatment A~Period 2: Treatment C~Period 3: Treatment B"
10157948|NCT04019509|Active Comparator|Tg AB positive, TPO AB negative|Includes patients with only anti-thyroglobuline autoantibodies present and no anti-thyreoperoxydase antibodies at start of fertility treatment.
10157949|NCT04019509|Active Comparator|Tg AB negative, TPO AB negative|Includes patients without thyroid autoantibodies at start of fertility treatment
9977849|NCT01365780|Active Comparator|With HBOT|Patients, who receive hyperbaric Oxygen Therapy after their surgical treatment
10157950|NCT04019509|Active Comparator|Tg AB positive, TPO AB positive|Includes patients with anti-thyroglobuline autoantibodies and anti-thyreoperoxydase antibodies at start of fertility treatment.
10157951|NCT04019730|Experimental|low carbohydrate diet|less than 10 En% carbohydrates
10157952|NCT04019730|Experimental|high carbohydrate diet|more than 50 En%carbohydrates
10157953|NCT04019717|Experimental|8 weeks|
10157954|NCT04019717|Experimental|12 weeks|
10157955|NCT04019574|Experimental|CR845 0.5 mcg/kg IV (Therapeutic Dose)|
10157956|NCT04019574|Experimental|CR845 3 mcg/kg IV (Supratherapeutic Dose)|
10157957|NCT04019574|Placebo Comparator|Placebo IV|
10157958|NCT04019574|Active Comparator|Moxifloxacin 400 mg|
10157959|NCT04019652|Experimental|10 mg CS-3150 (Treatment Sequence 1)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 10-mg dose of CS-3150, a 40-mg dose of CS-3150, a 400-mg dose of moxifloxacin, followed by placebo.
10157960|NCT04019652|Experimental|40 mg CS-3150 (Treatment Sequence 2)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 40-mg dose of CS-3150, placebo, a 10-mg dose of CS-3150, followed by a 400-mg dose of moxifloxacin.
10157961|NCT04019652|Experimental|Moxifloxacin (Treatment Sequence 3)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 400-mg dose of moxifloxacin, 10-mg dose of CS-3150, placebo, 40-mg dose of CS-3150.
10157962|NCT04019652|Experimental|Placebo (Treatment Sequence 4)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral dose of placebo, 400-mg dose of moxifloxacin, 40-mg dose CS-3150, 10-mg dose of CS-3150.
10157963|NCT04019587||Test of reliability and validity|
10186042|NCT03739736||Standard of care (C)|"The standard of care arm (C) communities have access to TB/HIV testing, care and treatment services (usually at the health facility) and according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility."
10186043|NCT03739736||Combination of TB/HIV prevention activities (B)|The intervention in arm B was the same as in arm A, consisting in a package of combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. Differently to arm A, in arm B national guidelines on CD4 count were used for ART initiation. During the trial the thresholds for commencement of ART changed from 500 CD count to 350 CD count and then, in 2016, to universal ART regardless of CD4 count.
10186044|NCT03739697|Active Comparator|spontaneous breathing|spontaneous breathing after adminitration of anesthetics
10186045|NCT03739697|No Intervention|mechanical ventilation|mechanical ventilation after adminitration of anesthetics and neuromuscula blockade
10186046|NCT03739671|Placebo Comparator|Non-vitamin D supplementation|Group not receiving vitamin D supplementation
10186047|NCT03739671|Experimental|Vitamin D supplementation|Group receiving vitamin D supplementation
10186048|NCT03739658|Experimental|Cognitive Based Neuromuscular Education|It will be applied for one hour. There are individual and partner parts. For example, in this training, the athlete will throw the tennis ball up and down on one foot.
10186049|NCT03739658|Experimental|Game Based Education|It will be applied for one hour. There are individual and partner parts. The active game will be played using the Xbox game console and the kinect sensor.
10186050|NCT03739658|No Intervention|Control Group|You will not receive any training. Athletes who continue their training as athletes in the other group.
10186051|NCT03739632|Experimental|10 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks
10186052|NCT03739632|Experimental|20 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks
10186053|NCT03739632|Experimental|40 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks
10186054|NCT03739632|Placebo Comparator|comparator|Placebo tablets is to be given orally, twice daily, for 6 weeks
10186055|NCT03739619|Experimental|Gemcitabine, bendamustine, nivolumab|Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
10186056|NCT03739606|Experimental|Treatment (flotetuzumab)|Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10186057|NCT03739580|Experimental|drug-coating balloon|drug-coating balloon (Orchid) intervention
10186058|NCT03739580|Active Comparator|stent deployment|metal bare stent intervention
10186059|NCT03739541|Experimental|[14C]-Benznidazole|A single dose of 100 mg [14C]-BNZ, orally administered on Day 1 following an overnight fast.
10187851|NCT03722082|Experimental|Enhancing cognitive reserve intervention|This intervention focuses in the improvement of academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the hospital and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. The groups will be made with parents and children, adolescents and young adults separately being the content of the sessions the same but adapted to the age of the attendees.
10187852|NCT03722082|Placebo Comparator|Supportive Intervention|The participants will not receive any structured intervention focused to enhance cognitive reserve. The therapists will adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise.
9977850|NCT01365780|No Intervention|Without HBOT|"Patients who receive the same surgical treatment of their radius fracture than the patients of the group with HBOT, but no hyperbaric oxygen therapy (comparison group)"
10157964|NCT04019691|Active Comparator|Mix-and-Match group|Cataract surgery and implantation of a Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
10157965|NCT04019691|Active Comparator|EDOF group|Cataract surgery and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
10157966|NCT04019691|Active Comparator|Trifocal group|Cataract surgery and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
10157967|NCT04019522|Experimental|Hypoxia|During each session, study participants will receive a single sequence of AIH, consisting of 15 x 60-seconds periods of hypoxia alternating with 90-seconds of normoxia (21% O2), for a total of 30 minutes, whilst in a seated upright position. AIH will be applied by directing gas flow to a reservoir bag connected via plastic tubing to a non re-breathing facemask/respiratory valve system while the participants are in a seated position. Defined gas mixtures will be delivered by manual adjustment of one-way valves attached to a hypoxia generator.
10157968|NCT04019678|Experimental|Group 1: experimental|patients with micro metastatic sentinel lymph node and/or parasentinella lymph node (ypN1mi). Axillary dissection is not performed.
10157969|NCT04019678|Active Comparator|Group 2: standard|patients with negative sentinel lymph node (ypN0) or with ITC finding (ypN0 / YpN0 (i +)). Axillary dissection is not performed as standard treatment.
10157970|NCT04019366|Experimental|Group I|The experimental group was treated with Balance Training on Biodex Stability System along with traditional exercises.
10157971|NCT04019366|Active Comparator|Group II|The Control group was treated with Traditional exercises only for Symptomatic knee osteoarthritis.
10157972|NCT04019340|No Intervention|Control|Usual care for patients in the CG is defined as visiting the outpatient wound clinic as prescribed by the physician. Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses.
10157973|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient wound clinic as prescribed by the physician). Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a pluridisciplinary educational program
10157974|NCT04019171|Experimental|interval exercise training|
10157975|NCT04019171|No Intervention|waiting list|
10157976|NCT04019184|Experimental|Glutamine group|Intravenous infusion of 0.5 g/kg body weight (2.5 ml/kg body weight) L-alanyl-Lglutamine over 12 h after randomization
10157977|NCT04019184|Placebo Comparator|Control group|Intravenous infusion of 2.5 ml/kg body weight sodium chloride 0.9 % over 12 h after randomization
10157978|NCT04019067|Experimental|MCE first group|"Patients randomized to the MCE first group will have a MCE deployed as the first detection method."
10157979|NCT04019067|No Intervention|standard of care group|For patients randomized to the Standard Care Group, gastroenterologists choose which procedures to perform and when to perform them based on their interpretation of the patient's presentation.
10157980|NCT04019210|Experimental|MODIFIED TRABECULECTOMY|"Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane.~Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm."
10157981|NCT04018950|Experimental|ETX2514 and 14C-ETX2514|Participants will receive a single intravenous infusion of 1 gram non-labeled ETX2514 and 1 microCurie (µCi) of 14C-ETX2514 in normal saline, administered as a 3-hour infusion.
10157982|NCT04018885|Experimental|ALA 2.5% 0.5h|Topical application of 2.5% ALA for 0.5 hour
10157983|NCT04018885|Experimental|ALA 2.5% 1.5h|Topical application of 2.5% ALA for 1.5 hours
10157984|NCT04018885|Experimental|ALA 2.5% 3h|Topical application of 2.5% ALA for 3 hours
10157985|NCT04018885|Experimental|ALA 5% 0.5h|Topical application of 5% ALA for 0.5 hour
10157986|NCT04018885|Experimental|ALA 5% 1.5h|Topical application of 5% ALA for 1.5 hours
10157987|NCT04018885|Experimental|ALA 5% 3h|Topical application of 5% ALA for 3 hours
10157988|NCT04018885|Experimental|ALA 10% 0.5h|Topical application of 10% ALA for 0.5 hour
10157989|NCT04018885|Experimental|ALA 10% 1.5h|Topical application of 10% ALA for 1.5 hours
10157990|NCT04018885|Experimental|ALA 10% 3h|Topical application of 10% ALA for 3 hours
10157991|NCT04018937|Experimental|Reduced Intensity Conditioning with FAM|Children with SCD will received reduced intensity conditioning with fludarabine, alemtuzumab and melphalan (FAM) during HSCT with a HLA matched sibling donor
10157992|NCT04019028|Experimental|Navigated low frequency rTMS|"Application of 1Hz low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image."
10157993|NCT04019028|Experimental|only low frequency rTMS(not using Navigation System)|"Application of low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere not using a navigation system.~TMS coil is fixed on the target area based on MEP hotspot."
10157994|NCT04019028|Sham Comparator|Navigated Sham rTMS|"Application of repetitive transcranial magnetic stimulation with sham mode(no stimulation) to the primary motor area of the dominant hemisphere using a navigation system.~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image.~Sham stimulation is stimulated by the same frequency, intensity and time as the actual stimulus in such a way that the 8-shaped coil is placed at a 90 degree angle to the scalp in the same manner as rTMS and sounds are heard but the magnetic stimulus is not transmitted to the cerebrum"
10157995|NCT04018963||Uninostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the single nostril approach.
10157996|NCT04018963||Binostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the bilateral nostril approach.
10157997|NCT04019119|Experimental|Intervention: digital intervention Behaviour Change Technique|The assigned participants will receive an intervention based on gamification and the use of behavior change techniques to reduce sedentary lifestyle. Thus, a new mobile application will be used for 12 weeks that proposes to the user the realization of activities with the aim of reducing their sedentary behavior. The development of the application is based on previous analyzes that propose 6 clusters that encompass 33 factors that influence sedentary behavior. In this way, the application is designed to act on the two accessible: social support and behavior. On the social support, he proposes to the user to share his achievements in social networks or in an internal network of game users. In terms of habit modification, behavior modification strategies proposed in the Michie et al. (2013) taxonomy are applied, such as the following: establishment of personalized goals, rewards and reminders, awareness of achievements achieved, among others
10157998|NCT04019119|No Intervention|Control Group|The control group will receive the usual indications about the harms of sedentary lifestyle and the benefits of physical activity, not receiving specific intervention. In case the use of the intervention applied in the experimental group is beneficial, the participants assigned to the control group will be offered the opportunity to receive the intervention outside the study to allow the benefit to be used.
9527682|NCT03217838|Experimental|Group 2 Arm B (AZD2811 Dose 2 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
9662131|NCT05130892|No Intervention|Non-intervention group|
10157999|NCT04019158|Experimental|Parkinson's Disease patients|Parkinson's Disease patients will walk in three conditions for +- 15 minutes per condition: walking over ground, walking on a treadmill, walking on a treadmill in virtual reality
10158000|NCT04019236|Other|" interventional "|New other than Routine nursing care will be used.
10158001|NCT04019236|No Intervention|" Control group "|Routine care only will be done for this group
10158002|NCT04019093|Experimental|Jaw pain patients|Individuals seeking care for jaw pain, including temporomandibular joint and muscle disorder (TMD).
10158003|NCT04019093|Experimental|Healthy controls|Healthy social drinkers without jaw pain recruited as a comparison group.
10158004|NCT04019197|Experimental|Participants with HIV and lipohypertrophy: semaglutide arm|Participants with HIV/lipohypertrophy will receive semaglutide 0.25 mg x4 weeks, then semaglutide 0.5 mg x4 weeks, then semaglutide 1.0 mg x24 weeks, then no drug x24 weeks.
10158005|NCT04019197|Placebo Comparator|Participants with HIV and lipohypertrophy: placebo arm|Participants with HIV/Lipohypertrophy will receive placebo x32 weeks, then no placebo for 24 weeks.
10158006|NCT04019106|Experimental|Dosing Level 1|0.0625 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
10158007|NCT04019106|Experimental|Dosing Level 2|0.125 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
10158008|NCT04019106|Experimental|Dosing Level 3|0.25 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
10158009|NCT04019132||Older adults|Older adults aged >65 years
10158010|NCT04019132||Young group|Younger adults between the age of 20 and 35 years
10158011|NCT04018976|Experimental|Heat and Vacuum|AVACEN 100 applies heat and vacuum to hand
10158012|NCT04018976|Active Comparator|Heat Only|AVACEN 100 applies heat only
10158013|NCT04018976|Sham Comparator|Sham|AVACEN 100 applies neither heat nor vacuum
10158014|NCT04018911|Active Comparator|Hearing Aid standard NR_1|Hearing Aid with standard Noise Reduction (NR) serves as reference condition.
10158015|NCT04018911|Experimental|Hearing Aid with NR_2|NR_2: Noise Reduction principle 2
10158016|NCT04018911|Experimental|Hearing Aid with NR_3|NR_3: Noise Reduction principle 3
10158017|NCT04018911|Experimental|Hearing Aid with NR_4|NR_4: Noise Reduction principle 4
10158018|NCT04018807|Other|Resource Pamphlet|Participants will receive a pamphlet detailing mental health and social service providers at the local, state, and national level.
10158019|NCT04018807|Experimental|Remote Therapy|Participants will receive eight 30-minute remote therapy sessions over the course of twelve weeks.
10158020|NCT04019223||anti-tissue transglutaminase group|serum IgA-tissue transglutaminase antibody (tTG) was analyzed in serum using a quantitative automated ELISA method by means of a commercially available detection kit using recombinant human tTG as antigen recommended cut-off by the manufacturer > 8 U/mL).
10158021|NCT04019223||biopsy group|upper gastrointestinal endoscopic examination will be done and the jejunal histopathological examinations will be done at the Histopathology Laboratory. The features consistent with CD included: hyperplasia of crypts, atrophy of villous, and increase of intraepithelial lymphocytes.Duodenal samples will be processed using haematoxylin/eosin staining and CD3 immunophenotyping. The number of intra-epithelial lymphocytes (IEL), the architecture of villi, and the inflammatory cell infiltration of the lamina propria will be assessed. Histopathological changes will be classified according to the Marsh-Oberhuber criteria.Lymphocytic enteropathy (Marsh 1 lesion) was defined as 25 or more IEL per 100 epithelial nuclei, and normal villous architecture.
10158022|NCT04018833||ranibizumab|Patients nonresponsive to bevacizumab that were switched to ranibizumab
10158023|NCT04018833||aflibercept|Patients nonresponsive to bevacizumab that were switched to aflibercept
10158024|NCT04018781||MR group|Patients who benefit from a full process of medication reconciliation (entrance and discharge) before being discharged to home.
10158025|NCT04018781||Control group|Patients who benefitted from a medication reconciliation at entrance only before being discharged to home.
10186060|NCT03739515|Experimental|HSCP team|Patients in this arm will receive comprehensive assessment and/or pre-discharge services by an ED-based HSCP team
10186061|NCT03739515|Active Comparator|Routine care|Patients in this arm will receive routine ED care
10158026|NCT04018482|Experimental|Open label test arm|Subjects will have their right eye treated with 5% Povidone Iodine per standard institutional protocol prior to receiving their intravitreal injection (2 drops of PI followed by application of 3.5% non-preserved lidocaine gel for 10 minutes, followed by 1 drop of PI for 30 seconds prior to injection). Subjects will have their left eye treated with Avenova per the same application protocol as PI prior to receiving their intravitreal injection. Prior to and following disinfecting both eyes but before the injection, a physician will gently swab the inferior conjunctival fornix (white part of each eye below the lower eye lid) with an ocular brush. Swabs will be cultured to compare bacterial counts. Subjects will be asked to complete a questionnaire regarding comfort of the disinfectant and injection procedure in general immediately following the injection and 1-2 hours post-injection.
10158027|NCT04018742||Patients with an abscess|Patient diagnosed with a cerebral abscess at admission; and to benefit from an abscess puncture as part of routine care.
10158028|NCT04018443||patients admitted ti surgical ICU after major surgery|patient admitted to surgical ICU after major surgery for post-operative close monitoring, assessment and resuscitation of the intravascular volume status
9662132|NCT05130879|Experimental|BRAW intervention group|BRAW is designed as an online intervention comprising of six sessions over six weeks. The six sessions are: (1) happiness and positivity, (2) cognitive restructuring, (3) behavioural activation, (4) emotion regulation, (5) positive work climate and (6) problem solving.
9662133|NCT05130879|No Intervention|Waitlist control group|Participants will receive the intervention after the follow-up assessment.
10158029|NCT04018534|Experimental|Control group|The patients in control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society(BOS) educational goals.
10158030|NCT04018534|Experimental|Video assisted education group|The patients in one of the study groups received a video assisted education
10158031|NCT04018534|Experimental|Hands-on training group|The patients in other study group received a hands-on training.
10158032|NCT04018703|Experimental|Dexmedetomidine|Dexmedetomidine will be used for perioperative sedation.
10158033|NCT04018703|Experimental|Midazolam|Midazolam will be used for perioperative sedation.
10158034|NCT04018586|Experimental|Heat and Vacuum|AVACEN 100 device applies heat and vacuum to hand
10158035|NCT04018586|Active Comparator|Heat Only|AVACEN 100 device with heat only
10158036|NCT04018586|Sham Comparator|Sham|AVACEN 100 device with neither heat nor vacuum
10158037|NCT04018690|Experimental|Experimental|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.
10158038|NCT04018690|Active Comparator|Control Group|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine
10158039|NCT04018625|Experimental|Intervention|Participants (n = 30) will be randomized to receive the SMART Pregnancy stress management program via an online portal.
10158040|NCT04018625|Active Comparator|Treatment as usual|Participants (n = 30) will be randomized to receive treatment as usual, including referrals to community based support groups and individual mental health providers.
10158041|NCT04018417|Experimental|Amphotericin B|The eye bank will add amphotericin B 0.255 μg/mL to the Optisol-GS donor cornea storage solution.
10158042|NCT04018417|No Intervention|Control|The donor cornea will be stored in Optisol-GS per the eye bank's standard procedure.
10158043|NCT04018560|Experimental|Intervention|
10158044|NCT04018560|No Intervention|Usual care|
10158045|NCT04018391|Experimental|Stepped care for non-adherence and depression|Participants will be randomized approximately two weeks post-baseline. Those randomized to the experimental condition will receive the Intervention and Stepped Care Treatment Protocol
10158046|NCT04018391|Active Comparator|Enhanced Usual Care|Participants will be randomized two weeks post-baseline. Those randomized to the control condition will receive Enhanced Usual Care.
10158047|NCT04018599|Experimental|40 mg MSB11022 via Auto-injector|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.
10158048|NCT04018599|Experimental|40 mg MSB11022 via Pre-filled Syringe|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.
10158049|NCT04018508|Experimental|Massages|During routine clinic visits, subjects will receive a total of six 30-minute massages (one massage per week for 4 weeks, then one massage every two weeks for 4 weeks).
10158050|NCT04018508|No Intervention|Control|Subjects randomized to the control arm will also attend routine clinic visits at the same pre-prescribed intervals (one clinic visit per for 4 weeks, then one visit every two weeks for 4 weeks).
10186062|NCT03739489|Active Comparator|rTMS-PSI|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the posterior superior insula right.
9662134|NCT05130749||Primary Healthcare Nurses|Nurses allocated in primary Healthcare settings
9662135|NCT05130749||Non Nurses Primary Healthcare|Other Healthcare providers allocated in primary health care settings
9662136|NCT05130736|Experimental|Robot|Patients treated using a rehabilitation robot
9662137|NCT05130736|Active Comparator|Control|Patients receiving traditional rehabilitation treatment (robot used only as assessment tool)
9662138|NCT05130684|Experimental|Neo-CRT|"Nivolumab 240 mg, 30-min IVF, Q2W on days -14, 1, 15, and 29;~Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8, 15, 22, and 29;~Cisplatin 30 mg/m2,1h-IVF,on days 1, 8,15, 22, and 29;~RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."
9662139|NCT05130658|Experimental|C-MILL training group|The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions, one before the training and one after the training. The participants will undergo 10 training sessions. Individuals in the CTG will receive gait and balance training sessions with the virtual reality and auditory cues using C-MILL (such as walking on a pathway, obstacle avoidance, lateral balance etc.) to provide task specific training. C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
10158051|NCT04018365|Experimental|Treatment of empagliflozin|Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of <7.0%, 10 mg will be continued: in case of >=7.0%, it will be increased to 25 mg.
10158052|NCT04018716|Experimental|MTA|mineral trioxide aggregate
10158053|NCT04018716|Active Comparator|Dycal|calcium hydroxide cement
10158054|NCT04018521|Active Comparator|Parent Connectors|trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or caregivers of all newlyenrolled youth or young adults (Y/YA) in FEP services
10158055|NCT04018521|Active Comparator|Usual Care|Coordinated Specialty Care (CSC)
10158056|NCT04018456|Experimental|Biodentine|Intervention group: application of biodentine as pulp space barrier during regenerative endodontic treatment.
10158057|NCT04018456|Active Comparator|White MTA|Control group: application of White MTA as pulp space barrier during regenerative endodontic treatment.
10158058|NCT04018729|Experimental|Endobronchial valve + marrow-derived mesenchymal stromal cell|
10158059|NCT04018729|Active Comparator|Endobronchial valve|
10158060|NCT04018638|Experimental|Adults with TKR Perform Home Exercise Program|Participants that have a total knee replacement will complete a home-based exercise program
10158061|NCT04018638|No Intervention|Healthy Controls Only|Participants that have no history of knee joint dysfunction will serve as age-matched uninjured controls
10158062|NCT04018573|Active Comparator|Parent Support Film|Parents will watch Lead with Love, a 35-minute documentary style film designed to provide support, information, and behavioral guidance to parents with a lesbian, gay, or bisexual child. One month later, parents will look over material that reviews the major points of the film. All of this material is presented online via our webapp.
10158063|NCT04018573|Experimental|Parent Support Film + PATHS Sexual Communication Toolkit|Parents in this arm will have the option of watching Lead with Love, and then will engage with our parent toolkit, designed to increase the frequency and quality of parent-child communication about HIV and condoms. One month later, parents will engage with booster content, customized to address their self-reported barriers to communicating with their sons. All of this material is presented online via our webapp.
10158064|NCT04018768||Ibuprofen + Percocet|
10158065|NCT04018768||Percocet|
10158066|NCT04018170|Experimental|JW1601|tablet formulation
10158067|NCT04018170|Placebo Comparator|Placebo|tablet formulation identified with JW1601
10158068|NCT04018378|Experimental|RT|"period 1: HGP1604 1mg (reference drug, R) will be administered once orally.~period 2: HIP1502 1mg (test drug, T) will be administered once orally after 14 days of the washout period."
10158069|NCT04018378|Experimental|TR|"period 1: HIP1502 1mg (test drug, T) will be administered once orally.~period 2: HGP1604 1mg (reference drug, R) will be administered once orally after 14 days of the washout period."
10158070|NCT04018157|Active Comparator|ketodex|ketamine dexmedetomidine mixture
10158071|NCT04018157|Active Comparator|ketofol|ketamine propofol mixture
10158072|NCT04018157|Placebo Comparator|placebo|normal saline
10158073|NCT04018651|Experimental|PrEP Master Adherence Intervention|The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.
10158074|NCT04018144||Group-1|Healthy individuals
10158075|NCT04018144||Group-2|Periodontitis patients-stage 3-grade B
10158076|NCT04018144||Group-3|Periodontitis patients-stage 3-grade C
10158077|NCT04018339|Experimental|RTA 402 5mg or 10mg oral administration|
10158078|NCT04018339|Placebo Comparator|Placebo|
10158079|NCT04018287||HPP-Group|"genetical verified hypophosphatasia~age >18 years~written informed consent~complete serological and radiological examinations"
10158080|NCT04018287||Control-Group|"healthy men and women without any history of musculoskeletal diseases~Alkaline phosphatase (AP) in reference range~written informed consent~complete serological and radiological examinations"
9664661|NCT05302492|Experimental|Sleep apnea group with CPAP|"Intervention group: CPAP for 3 months in elderly diagnosis with sleep apnea and AHI > 15/h.~Control group: sleep apnea and patient refuse treatment or poor compliance."
10158081|NCT04018404|No Intervention|Control|Subjects will be approached for enrollment prior to or following clinic visit with physician. Only children present with a biological mother will be considered for enrollment. Charts of controls will be flagged so that they will not be able to be enrolled in the FRI clinical program if they present to a morning clinic where the program is offered.
10158082|NCT04018404|Experimental|Subject|Mothers and children will be approached by study personnel (separate from Outreach Coordinators who will obtain consent for use of information to evaluate the FRI Clinical Program) for enrollment in the FRI Research Program following completion of all FRI Clinical Program activities for that day. Both mother and child will be enrolled and contribute data and samples to the FRI Research Program.
10158083|NCT04018313|Experimental|CT-P39 (Part 1)|150 mg/mL, Solution for injection in PFS
10158084|NCT04018313|Active Comparator|EU-approved Xolair (Part 1)|150 mg/mL, Solution for injection in PFS
10158085|NCT04018313|Experimental|CT-P39 (Part 2)|150 mg/mL, Solution for injection in PFS
10158086|NCT04018313|Active Comparator|EU-approved Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
10158087|NCT04018313|Active Comparator|US-licensed Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
10158088|NCT04018274|Experimental|Sequence 1|In Treatment Sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into Period 2 where they will receive PF-06651600 PO for 9 days followed by administration of a single dose of OC on the morning of Day 10.
10158089|NCT04018274|Experimental|Sequence 2|In Treatment Sequence 2, Period 1, participants will be dosed with PF-06651600 PO QD for 9 days and administered a single dose of OC on the morning of Day 10. After a washout period of at least 10 days, participants will continue into Period 2 and will receive an additional single dose of OC.
10158090|NCT04018040|No Intervention|Control Group|Patients will be asked to continue their usual diet patterns over an 8 week period
10158091|NCT04018040|Experimental|Intervention Group|Patients will follow a lacto-ovo vegetarian diet for an 8 week period. patients will be provided with a lacto-ovo vegetarian food box delivery service with fresh ingredients and recipes to cover four dinners per week.
10158092|NCT04018118||Eosinophilia/Hypereosinophilic syndrome|patient with eosinophilia and/or hypereosinophilic syndrome
10158093|NCT04017884|Experimental|Remin Pro Forte.|intervention
10158094|NCT04017884|Active Comparator|Remin pro.|comparator
10158095|NCT04017897|Experimental|Experimental|
10158096|NCT04018300|Experimental|Ferrous sulfate|Subjects will take a 65 mg Fe capsule of ferrous sulfate, once daily for 21 consecutive days. The first treatment capsule will be consumed with a semi-purified meal (egg albumin, sugar, vanilla, maltodextrose and corn oil) and will have blood drawn hours 0, 1, 2, 3, 4, 6 and 8 post consumption. Serum will be used to determine non-transerrin bound iron, serum iron and percent saturation. Throughout the treatment period, subjects are informed to consume the capsule with food and report symptoms in an online questionnaire. Following three weeks treatment, participants return for a blood draw and oxidative stress indicators are measured. A three week washout period with placebo treatment takes place between treatment crossover.
10158097|NCT04018300|Experimental|Aspiron|AspironTM which is an iron-enriched supplement will follow the same guidelines and protocol as ferrous sulfate arm. Equivalent 65 mg Fe per capsule will be administered to participants.
10158098|NCT04018300|Placebo Comparator|Placebo|Participants will follow the same description for the other two experimental treatment groups. Capsules will be given to subjects in opaque formation, therefore will be unable to differentiate the iron supplements.
10158099|NCT04017923||20-29 age group|
10158100|NCT04017923||30-39 age group|
10158101|NCT04017923||40-64 age group|
9671243|NCT05051202|Experimental|45g Sugars From Fiber per day|Administered in 50 g Flapjacks containing 45 g Fiber (from Sugars from Fiber), taken 3 times per day, after meals, for a 14 day period
9671244|NCT05051202|Active Comparator|45g Resistant Maltodextrin per day|Administered in 50 g Flapjacks containing 45 g Resistant Maltodextrin, taken 3 times per day, after meals, for a 14 day period
9671245|NCT05051124|Experimental|Sub-Aim 2.2 Participants|
9671246|NCT05051137||Infliximab initiators|Rheumatoid arthritis patients initiating infliximab after treatment with methotrexate for a minimum of 30 days.
10158102|NCT04017923||65 and older age group|
10158103|NCT04018105|Experimental|taking metformin 30 or 60 minutes before the OGTT|
10158104|NCT04018105|Placebo Comparator|No metformin before OGTT|
10158105|NCT04018092|Experimental|Active NIR-PBM|"For transcranial stimulation, the study team will use two MedX units (1116 Rehab Console, MedX Health), whereas intranasal stimulation is delivered using the 810 Intranasal device (Vielight Inc). During each lab session, six transcranial LED clusters will be placed on the scalp in two distinct configurations guided by 10-20 EEG system. Total transcranial stimulation time is 40 minutes, 20 min per cluster. Concurrently, two 810 intranasal devices will be placed in each nostril for 25 min of total dose per nostril. For at home sessions, participants will use the standalone 810 Intranasal device only.~Total amount of sessions:~16 sessions of stimulation will occur in the laboratory. Each session will last approximately 90 minutes and will include two 20-minute segments of NIR stimulation.~AND~44 sessions of intranasal stimulation in the home. Each session will last 25 minutes and will occur on weekdays when there is no in-lab session."
10158106|NCT04018092|Sham Comparator|Sham NIR-PBM|"Participants randomized to the Sham control group will undergo identical procedures as the Active group. The only difference is that the sham NIR devices are modified not to deliver stimulation. Because NIR is invisible, participants are unable to detect whether NIR is being delivered."
10158107|NCT04017741|Active Comparator|Active group|The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.
10158108|NCT04017741|Placebo Comparator|Placebo group|The placebo group will be administered 4mls of 0.9% saline.
10158109|NCT04018131|Active Comparator|Cimetidine|
10158110|NCT04018131|Placebo Comparator|Placebo|
10158111|NCT04017845|Active Comparator|Household-Open Invitation (HOI)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
10158112|NCT04017845|Active Comparator|Recommendation By Physician (RBP)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
10158113|NCT04017767|Experimental|Moderate to Severe Obstructive Sleep Apnea (OSA)|Individuals with moderate to severe OSA defined as having an Apnea-hypopnea Index (AHI) that is greater than or equal to 15.
10158114|NCT04017767|Active Comparator|Without OSA|Individuals without OSA defined as having AHI less than 5.
10158115|NCT04018014||< 30 kg/m2|patients with BMI < 30/kg/m2
10158116|NCT04018014||>30 kg/m2|patients with BMI > 30 kg/m2
10158117|NCT04017793|Active Comparator|Mindfulness Based Stress Reduction Program|
10158118|NCT04017793|Active Comparator|Relaxation Group|
10158119|NCT04017715|Experimental|warm up|warm up exercises
10158120|NCT04017715|Experimental|cool down|cool down exercises
10158121|NCT04017715|Active Comparator|control|Following conventional protocol
10158122|NCT04017858|Experimental|Experimental|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
10158123|NCT04017858|Active Comparator|Control|Patients will be submitted to total knee replacement.
9527683|NCT03217838|Experimental|Group 2 Arm B (AZD2811 Dose 6 + Azacitidine 75 mg/m^2)|Participants with AML will receive Azacitidine 75 mg/m^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 6 on Days 1, 4, 15, and 18 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
10158124|NCT04017988|Experimental|Ethanol Extracts of Porphyra Tenera(PTE10) group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 2.5 g/day)
10158125|NCT04017988|Placebo Comparator|Placebo group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 0 g/day)
10158126|NCT04018027|Active Comparator|Difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablet administered twice daily
10158127|NCT04018027|Active Comparator|Difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablet administered twice daily
10158128|NCT04018027|Active Comparator|Difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg tablet administered twice daily
10158129|NCT04018027|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
10158130|NCT04017728|Active Comparator|Conventional Percutaneous Vertebroplasty|The cement is injected after the successful puncture.
10158131|NCT04017728|Experimental|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied to destroy the metastatic lesion before coment injection.
10158132|NCT04017663||Public group|patients who performed cardiovascular rehabilitation in a public center
10158133|NCT04017663||Private group|patients who performed cardiovascular rehabilitation in a private center
10158134|NCT04017637|No Intervention|Usual Care (UC)|Those randomized to the UC group will complete baseline and post-intervention assessments only. No intervention will be administered.
10158135|NCT04017637|Experimental|Resistance Training Intervention (RT)|Those randomized to the RT group will complete baseline and post-intervention assessments at weeks 0 and 12. For the intervention, they will complete resistance training for approximately 12 minutes 2x per week for 12 weeks.
10158136|NCT04017650|Experimental|Treatment (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV over 1 hour on days 1 and 15, and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10158137|NCT04017572|Active Comparator|Standard treatment|APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.
10158138|NCT04017572|Active Comparator|Optimized treatment|APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.
10158139|NCT04017689||Verbal Information Group|Verbal Information
10158140|NCT04017689||Photo Group|Information by photos
10158141|NCT04017689||Video Group|Information by video
10158142|NCT04017585|Active Comparator|patients with IBS treated with gluten|patients receiving gluten
10158143|NCT04017585|Placebo Comparator|patients with IBS treated with placebo|patients receiving placebo
10158144|NCT04017780|Experimental|Single-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator, single limb with intentional leaks.
10158145|NCT04017780|Experimental|Double-limb circuit with Intensive Care Unit ventilator|Non invasive ventilation delivered with an intensive care unit ventilator with a double limb circuit.
10158146|NCT04017780|Experimental|Double-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator with a double limb circuit.
10158147|NCT04017624|Experimental|Fresh Truck with stipend|Referral to Fresh Truck mobile market
10158148|NCT04017624|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
10158149|NCT04017676|No Intervention|Control group|The first group will be under the usual treatment conditions (TAU)
10158150|NCT04017676|Experimental|Experimental group|The second group will be exposed to a multidisciplinary therapeutic program that has a monitoring component and after two months an intervening component will be.
10158151|NCT04017377|Experimental|Chemotherapy+ Radiation therapy|"Chemotherapy: Patients firstly receive an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m^2 up to 70 mg/m^2, Patients secondly receive weekly cisplatin (40 mg/m^2). Treatment repeats every week until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic. Concurrent chemotherapy is a weekly regimen during radiotherapy. Patients will complete at least 4 cycles of concurrent chemoradiotherapy, until the maximal tolerated dose (MTD) appeared.~Radiation therapy: Patients also receive pelvic radiation therapy once daily (Monday-Friday) for a total of 28 fractions and intracavitary brachytherapy twice a week for a total 5 fractions. Complete radiotherapy within 55 days."
10158152|NCT04017598|Active Comparator|Ferrous Sulfate|Iron will be given orally in the form of tablets. A supplement of 60 mg will be taken daily for 12 weeks. World Health Organization standard dose and commonly used form of iron.
10158153|NCT04017598|Experimental|Ferrous Bisglycinate|Iron will be given orally in the form of tablets. A supplement of 18 mg will be taken daily for 12 weeks. Ferrous bisglycinate has a bioavailability 2-4x greater than ferrous sulfate.
10158154|NCT04017598|Placebo Comparator|Placebo|Placebo will be given orally in the form of tablets as a control made of microcrystalline cellulose.
10158155|NCT04017299|Active Comparator|Virtual reality with computer graphics|Use of Virtual reality with computer graphics
10158156|NCT04017299|Active Comparator|Virtual reality with real movies|Use of Virtual reality with real movies
10158157|NCT04017299|Active Comparator|Music therapy (dedicated device and music scores)|Use of music therapy (dedicated device and music scores)
10158158|NCT04017299|Other|Usual device (TV radio)|usual distraction : watching TV
10158159|NCT04017429|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
10158160|NCT04017429|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
10158161|NCT04017455|Experimental|bevacizumab and atezolizumab|1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy
9671247|NCT05051137||Sulfasalazine + Hydroxychloroquine initiators|Rheumatoid arthritis patients initiating sulfasalazine and hydroxychloroquine after treatment with methotrexate for a minimum of 30 days.
9671248|NCT05051228||GEAR cohort|This is a noninvasive study that screens healthy and non-healthy volunteers for cardiovascular disease.
9671249|NCT05051163|Experimental|Ceftriaxone|Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily
9671250|NCT05051163|Active Comparator|Ampicillin and Gentamicin|"Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly~Gentamicin will be administered intravenously at a dose 5mg/kg once daily"
9671251|NCT05051098||TherVacB Subgroup|"No interventions. The participating study centers of the EU funded project TherVacB recruit patients with stricter inclusion- and exclusion criteria, hence forming a sub-cohort."
10158162|NCT04017481|Experimental|Repetitive stimulating transcranial stimulation (rTMS)|Subjects receive 8 sessions M1 Neuromodulation using rTMS according to the protocol ( 80% resting motor threshold, 10 Hertz; 1000 pulses; 25 trains de 4 seconds con 25 seconds intertrain.
10158163|NCT04017481|Experimental|EEG guided Neurofeedback (NFB)|Subjects receive 8 sessions M1 EEG guided NFB with virtual reality goggles in order to modify the beta rhythm. The sessions have a duration of 20min
10158164|NCT04017481|Experimental|rTMS + NFB|Subjects receive both interventions sequentially
10158165|NCT04017481|No Intervention|No intervention|No interventions, the patient just comes to be evaluated sequentially according to the timing of experimental groups.
10158166|NCT04017559|Experimental|Intervention cohort|All participants were entered into the intervention cohort to receive the Motivational Interviewing intervention
10158167|NCT04017312|Active Comparator|HFCWO group|Subjects in this arm of treatment will use The Vest® as their primary airway clearance modality for the duration of the study.
10158168|NCT04017312|Active Comparator|OPEP group|Subjects in this arm of treatment will use the Acapella® as their primary airway clearance modality for the duration of the study.
10158169|NCT04017364|Active Comparator|PTCA of coronary de novo lesion PCB|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
10158170|NCT04017364|Experimental|PTCA of coronary de novo lesion SCB|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
10158171|NCT04017507||Oscillating-rotating electric toothbrush|Twice daily brushing
10158172|NCT04017507||Side-to-side electric toothbrush|Twice daily brushing
10158173|NCT04017507||Manual toothbrush|Twice daily brushing
10186063|NCT03739489|Active Comparator|rTMS-M1|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the right primary motor cortex.
10186064|NCT03739489|Active Comparator|rTMS-F3|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the left pre frontal dorsolateral cortex.
10186065|NCT03739476|Experimental|Interventional|Quetiapine 25 miligrames 1 hour after surgery and each 12 hours for 3 days
10186066|NCT03739476|Placebo Comparator|control|Placebo 1 hour after surgery and each 12 hours for 3 days
10186067|NCT03739463|Experimental|MAG-DHA|1500 MG of MAG-DHA per day until childbirth or for up to 2 weeks
10186068|NCT03739463|Placebo Comparator|Placebo|1500 MG of oleic acid per day until childbirth or for up to 2 weeks
10186069|NCT03739450|Experimental|Problem Solving Training + Education|Participants in this arm will receive the TBI-specific education intervention and the Problem Solving Training (PST) intervention.
10186070|NCT03739450|Active Comparator|Education|Participants in this arm will only receive the TBI-specific education intervention.
10186071|NCT03739424|Experimental|Whole egg powder arm|The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
10186072|NCT03739424|Active Comparator|Whole milk powder arm|The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.
10186073|NCT03739424|Placebo Comparator|Gelatin arm|The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.
10186074|NCT03739411|Experimental|Cohort I (hyperpolarized C13, MRI)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously IV and undergo MRI. The second hyperpolarized 13 C injection/imaging will be started approximately 15 to 60 minutes after the first injection for those who are willing to receive two 13 C injections
10186075|NCT03739411|Experimental|Cohort II (hyperpolarized C13, MRI, radiation, temozolomide)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRI before standard treatment with radiation therapy and temozolomide and 4 weeks after completion of radiation therapy.
10186076|NCT03739398|Experimental|LUTRONIC GENUS laser with LASEMD laser|
10186077|NCT03739398|Active Comparator|LUTRONIC GENUS laser without LASEMD laser|
10186078|NCT03739385|Experimental|Intergenerational Group|Pre-school children and residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
10187853|NCT03722069|Other|Low sodium diet|22 patients were randomized to receive 3 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
9671252|NCT05051046|Experimental|Hypnosis|
10158174|NCT04017286||depressive disorder group|At 21 weeks of pregnancy, women diagnosed with depressive disorder by the Hamilton depression scale and Beck depression rating scale and their offspring were enrolled.
10158175|NCT04017286||Nutrient-deficient group|Nutrients (Vitamin A,D,E) were tested at 21 weeks of pregnancy, and pregnant women with one or more nutrient deficiencies or insufficiency and their offspring were enrolled.
10158176|NCT04017286||depressive disorder and nutrient deficiency group|At 21 weeks of pregnancy, pregnant women with depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
10158177|NCT04017286||Neither group|At 21 weeks of pregnancy, pregnant women without depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
10158178|NCT04017533|Experimental|GMK Sphere|Patients receive a cementless GMK Sphere Total Knee Replacement
10158179|NCT04017260|Experimental|open and closed technique|treatment of pilonidal sinus by open and closed approach
10158180|NCT04017260|Experimental|Rhomboid flap technique|treatment of pilonidal sinus by Rhomboid flap
10158181|NCT04017260|Experimental|karydakis technique|treatment of pilonidal sinus by Karydakis
10158182|NCT04017260|Experimental|open technique|treatment of pilonidal sinus by open approach
10158183|NCT04017351|Experimental|Subjects with virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery will have access to artificial intelligence virtual assistance (AIVA)
10158184|NCT04017351|No Intervention|Subjects without virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery
10158185|NCT04017338|Experimental|Non Randomized Intervention|"Intervention description: recipients on the wait-list for lung, heart, kidney, and/or pancreas transplants will all receive antiviral treatment in the form of 8 total doses of oral tablets. Lung recipients will also receive donor lungs that are treated with normothermic EVLP (details of both described below).~Drug: All recipients will receive glecaprevir (300mg)/pibrentasvir (120mg) supplied as three tablets per dose 6-12 hours prior to transplant, and for 7 days post-transplant. Other Names: Maviret. Patients will also receive ezetimibe (10mg), supplied as one tablet per dose to be taken at the same time as Maviret tablets (6-12 hours prior to transplant in addition to 7 daily doses post-transplant).~Ex Vivo Lung Perfusion (EVLP): Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions. Other names: Normothermic EVLP."
10158186|NCT04017494||Single ventricle|Patients with single ventricle lesions
10158187|NCT04017234|Experimental|PMP group|children received health education for eye and the intervention(which included frequency following response, eye exercise, and transcutaneous electrical nerve stimulation) a 30 minute three times per week for four weeks.
10158188|NCT04017234|No Intervention|control group|children just received health education for eye
10158189|NCT04017403|Experimental|Probiotic group|The probiotic group was treated with Bifidobacterium tripleis,one day before surgery to the sixth day after surgerythe drug is taken orally, 4 capsules at a time, 2 times a day.
10158190|NCT04017403|Placebo Comparator|Placebo group|The control group was given the same package of placebo,one day before surgery to the sixth day after surgery. The drug is taken orally, 4 capsules at a time, 2 times a day.
10158191|NCT04017325||TOOKAD VTP TREATMENT|Subjects randomized in the treatment arm (TOOKAD VTP treatment) in the initial period of the study.
10158192|NCT04017325||Active surveillance|Subjects randomized in the control group (active surveillance) in the initial period of the study.
10158193|NCT04017195|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.
10158194|NCT04017195|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1, followed by Treatment A to the left buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
10158195|NCT04017195|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment B to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
10158196|NCT04017195|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment A to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
10158197|NCT04017208|Experimental|ASP2713|Participants will receive a single dose of ASP2713. Up to 8 dose levels will be administered in the study.
10158198|NCT04017208|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
10158199|NCT04017221||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current use of a SGLT2 inhibitor alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
10158200|NCT04017221||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current use of a DPP-4 inhibitor alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
10158201|NCT04017221||Other treatment combinations|Current use of other antidiabetic drugs, current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
10158202|NCT04017416||Standard Care|Audiologists in the standard care group were instructed to manage the patients in the same way as they would do in their routine clinics which were in accordance with national practice guidelines and were typical of National Healthcare Services (NHS) audiology departments across the UK.
10158203|NCT04017416||I-PLAN|Audiologists were instructed to deliver the I-PLAN in addition to standard care at the hearing aid fitting consultation.
10158204|NCT04016948|Experimental|Probe-based confocal laser endomicroscopy(pCLE)|Confocal laser endomicroscopy optical biopsy will be performed in surgery for patients assigned to this group
10158205|NCT04016948|Active Comparator|Intra-operative frozen section(IFS)|Intra-operative frozen section will be performed for patients assigned to this group
10158206|NCT04016870|Active Comparator|New Device|New pacemakers will be sourced from pacemaker manufacturers.
10158207|NCT04016870|Experimental|Reconditioned Device|Donated devices are inspected according to specific protocols that evaluate physical and electrical (battery longevity) suitability for future use. Devices deemed to be acceptable are shipped to a third-party vendor (NEScientific) for disassembly, cleaning and re-sterilization.
10158208|NCT04017065||Patients treated with the MAXFRAMETM system|Any patient undergoing surgical treatment (primary or revision) for deformity correction using the MAXFRAME™ system
10158209|NCT04016961|Experimental|Animal Assisted Therapy - Dog Session|Therapy dog added to PT and OT session
10158210|NCT04016961|Active Comparator|Treatment as usual - No Dog session|No dog added to PT and OT session - PT and OT session as usual standard of care
10158211|NCT04017052|Other|Booster vaccination|Intervention = one i. m. TBE booster vaccination (FSME-Immun) at visit 1.
10158212|NCT04016857|Experimental|RIPC Group|Remote ischemic preconditioning
10158213|NCT04016857|Sham Comparator|Control Group|Sham remote ischemic preconditioning
10158214|NCT04016831|Other|Mapping Enhanced Counseling (MEC) only|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
10158215|NCT04016831|Experimental|Mapping Approaches to Prepare for Implementation Transfer|an implementation intervention to explore and address agency preparation needs in order to promote implementation success (includes MEC training)
10158216|NCT04017013|Active Comparator|Epidural Analgesia|"The placement of the thoracic epidural catheter will be located depending on surgical incision as follows:~Surgery of the upper abdomen: T7-T8.~Surgery of lower abdomen: T8-T9. The epidural catheter placement technique will be determined by the treating anesthesiologist. However, once the epidural space is located and the respective catheter is inserted, the correct location of the catheter should be tested with lidocaine at 2% CE 5 cc and a sensitivity test with temperature should be performed on the target dermatomes. A negative test for an adequate location of the catheter indicates that the procedure should be repeated until the epidural space is correctly located. Once this is achieved, the catheter will be left 4 cm away from the skin. The catheter will be fixed according to the institutional protocol."
10158217|NCT04017013|Experimental|Lidocaine Infussion|Intravenous lidocaine
10158218|NCT04017000|Active Comparator|BlaST study|"Patients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding.~The participants Urodynamic clinic will run according to routine care."
10158219|NCT04017000|Other|Calibration Sub Study|"Any patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study.~Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound.~Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change."
10158220|NCT04016779|Placebo Comparator|Placebo|Placebo qd
10158221|NCT04016779|Experimental|SPN-812|SPN-812 qd
10158222|NCT04017078||Patients who referred for periodontal therapy|Patients who referred to Baskent University, Faculty of Dentistry, Department of Periodontology, during 2016-2018
10158223|NCT04017091|Experimental|VR Group|ABI Patients Twenty-one patients with ABI participated in this pilot study (Figure 1): 9 diagnosed with stroke (43%), 6 with TBI (29%), 2 with anoxic injury (10%), 3 with brain tumor (14%), and 1 with amyloid angiopathy (5%).
10158224|NCT04017091|No Intervention|Control Group (Standard Care)|The 12 Controls were age- and gender-matched (and etiology when possible) patients who had previously received traditional neurorehabilitation and completed the same measures as the VR group prior to onset of the study, but they did not receive VR treatment.
10158225|NCT04016883|Sham Comparator|Conventional web platform|Participants asked to review the web platform for 4 weeks.
10158226|NCT04016883|Experimental|Problem Solving Therapy offered through a web platform|4 sessions with cognitive behavioral therapy, offered through a web platform. Each session will be offered per week.
10158227|NCT04016844|Active Comparator|tDCS effects on glucose uptake in leg muscles|tDCS Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time tDCS will be applied to the motor cortex (M1) corresponding to the more-affected leg.
10158228|NCT04016844|Placebo Comparator|Sham effects on glucose uptake in leg muscles|Sham Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time SHAM will be applied to the motor cortex (M1) corresponding to the more-affected leg.
9671253|NCT05051046|No Intervention|General anesthesia|Common practice
10158229|NCT04016935||Patients with primary invasive ER+ HER2- breast cancer|Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy
10158230|NCT04016909|Experimental|aerobic exercise plus calorie restriction|"The experimental intervention: both exercise and calorie restriction, as described below:~Exercise intervention. 6 months, 72 supervised aerobic exercise training sessions on cycle ergometers, including 3 sessions of training per week. A warm-up procedure consisting of 5 min of low-intensity stretching was completed by all women before the aerobic training. Subsequently, a 50 min aerobic training at an intensity between 60% and 70% of the maximum heart rate (HR) was performed. Thereafter, a cool-down consisting of 5 min of low-intensity stretching and breathing exercises was completed. HR was recorded continuously throughout the training sessions using an HR monitor (S625X, Polar Electro, Kempele, Finland).~Calorie restriction intervention. The CR intervention was designed to create a 12.5% energy deficit, with the goal of reducing body weight by 5%-10% over 6 months."
10158231|NCT04016909|No Intervention|Control|No intervention and participants were instructed to maintain their regular physical activity and diet regime for 6 months; they were also prohibited from participating in any weight-loss or exercise program.
10158232|NCT04016922||Group A|Patients with mild anemia (Hb concentration: 9.0-10.9 g\dl).
10158233|NCT04016922||Group B|Patients with moderate anemia (Hb concentration: 7.0-8.9 g\dl).
10158234|NCT04016922||Group C|Patients with severe anemia (Hb concentration: >7.0 g\dl).
10158235|NCT04017026||6 mm implants|Patients were treated with 6mm short implants (Straumann, SLA, SLActive, 4.1 or 4.8 mm in diameter).
10158236|NCT04017117|Experimental|Custom Made Poly Ether Ether Ketone Mesh|Applying Poly Ether Ether Ketone mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
10158237|NCT04017117|Active Comparator|Conventional Titanium mesh|Applying Titanium mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
10158238|NCT04017104||18F-FDG PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-FDG PET/CT procedure.~18FFDG is considered standard care and has been approved by Health Canada."
10158239|NCT04017104||68Ga-DOTATOC PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 68Ga-DOTATOC PET/CT procedure.~The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
10158240|NCT04017104||18F-DCFPyL PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-DCFPyL PET/CT procedure.~The 18F-DCFPyL radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
10158241|NCT04017169||No reflow phenomenon|"Those that during procedure experience no reflow phenomenon~To define no reflow requires:~• Angiographic evidence of reopening of occluded coronary artery and successful stent placement with no evidence of flow-limiting residual stenosis (<50%), dissection, vessel spasm, or thrombus burden~and~Angiographic documentation of a TIMI flow grade ≤II, or~A TIMI flow grade III with a myocardial perfusion grade 0 or I, at least 10 min after the end of PCI procedure."
10158242|NCT04017169||No NRP|Normal angiographic coronary flow/blush post patent culprit vessel.
10158243|NCT04017156|Experimental|Test site (torque of <10 Ncm)|The test sites (<10 Ncm) will be over-prepared with drills of larger diameter
10158244|NCT04017156|Other|Control site (torque of ~30 Ncm)|the standard sites (~30 Ncm)will be prepared with the corresponding drills suggested by the manufacturer
10158245|NCT04016792|Placebo Comparator|Placebo|Placebo qd
10158246|NCT04016792|Experimental|SPN-812|200 mg SPN-812
10158247|NCT04016987|Experimental|Automated, Individualized Education|Subjects will be given instructions to install the patient-end App, which includes the following functions: diabetes education, patient-doctor communication, diabetes diary, peer support, reminder for blood sugar test and related abnormal results. They receive push notifications that provides recommended education materials which meet the needs of the patient by considering his/her baseline diabetes-related knowledge.
10158248|NCT04016987|No Intervention|Routine care|Subjects only receive the education provided by health-care professionals in the outpatient department
10158249|NCT04016753|Experimental|Monotherapy|
10158250|NCT04016701|Experimental|VR Intervention|Eight weeks of training with Floreo's VR Joint Attention Module with two sessions per week
10158251|NCT04016701|Active Comparator|Treatment as Usual|Regularly scheduled therapy
10158252|NCT04016688|Active Comparator|ES Erector Spinae Plane Block|"bilateral ESP block at the level of T9 by a linear ultrasound (US) transducer (Phillips Saronno Italy) placed vertically 3cm lateral to the midline to visualize the back muscles superior to the transverse process.~A 22-G short bevel needle (spinocan, B.Braun, melsungen AG, Germany) will be inserted in cranial-caudal direction until it make contact with the transverse process. Confirmation of the correct position of the tip of the needle is by injection of 1 ml saline causing hydrodisscetion between the erector spinae muscle and the transverse process. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected.The same procedure is done on the other side of the back."
10158253|NCT04016688|Active Comparator|TAP Transversus Abdominis Plane Block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
10158254|NCT04016610|Experimental|ASR Treatment|Single and/or multi-treatment ASR device applied to the keloid scar for a period of 2 minutes for each 3 cm.
10158255|NCT04016766|Experimental|Prepartying mobile app intervention|Mobile app intervention
10158256|NCT04016766|No Intervention|Control|Control participants receive a personalized attention control task (i.e., listing and ranking favorite movies, music, and books), which controls for the time needed by the intervention group to view the intervention material.
10158257|NCT04016727|Experimental|PRP group|patients in which 60 units of prp was injected
10158258|NCT04016727|No Intervention|Control group|patients not given any intervention
10158259|NCT04016597||Lung diffusing capacity measurements|Participants perform single-breath lung diffusing capacity measurements in random order during one study visit.
10158260|NCT04016467|Experimental|Thoracic Manipulation (ThM)|Will undergo spinal manipulation between pain assessment pre and post.
10158261|NCT04016467|Sham Comparator|Sham thoracic treatment (ThS)|Sham manipulation between pain assessment pre and post
10186079|NCT03739385|Active Comparator|Peer Group Children|Pre-school children will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
10158262|NCT04016389|Experimental|Neo-Adjuvant Chemotherapy, Surgery, and Adjuvant Chemotherapy|"Participants will receive neo-adjuvant treatment cisplatin or carboplatin with paclitaxel, intravenously, either once every cycle or once a week, for three (21-day) cycles.~After neo-adjuvant treatment, depending on their status, participants may have the trachelectomy done.~Adjuvant treatment may include standard chemotherapy and radiotherapy, or a hysterectomy may need to be done."
10158263|NCT04016350|Experimental|Exercise Training with Inulin Propionate Ester|Study participants underwent 4 week supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation at doses of 10g / day.
10158264|NCT04016350|Experimental|Exercise Training with Placebo|Study participants underwent 4 week supervised moderate intensity exercise training combined with cellulose as placebo at doses of 10g / day.
10158265|NCT04016584|Experimental|Latino adults with type 2 diabetes|"Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -~hemoglobin A1c > 8% at or prior to enrollment, or~hemoglobin A1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):~Fasting plasma glucose > 130 mg/dL~2-hour post-prandial or random blood glucose > 180 mg/dL~> 1 hypoglycemic event (blood glucose < 70 mg/dL) , or~adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider."
10158266|NCT04016740|Experimental|Multimodal General Anesthesia|"Intraoperative~The anesthesiologists involved in this study will be trained to infer differences in anti-nociception, unconsciousness movement and changes during other perioperative events by monitoring EEG. They will also be trained in titrating hypnotic and nociceptic medications based on changes in EEG.~Routine anesthetic induction~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.25% ropivacaine on either side of the sternum after anesthetic induction but before surgical incision~Ketamine (0.06 to 0.12 mg.kg/hr)~Remifentanil (0.05-0.2 mcg/kg/min)~Dexmedetomidine (0.2-1.0 mcg/kg/hr)~Rocuronium intermittent bolus (TOF)~Propofol infusion ± Sevoflurane titrated based on EEG monitoring~Postoperative~Standard pain management protocol~Dexmedetomidine infusion 0.2-1.4 mcg/kg/hr (EEG guided)~Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion"
10158267|NCT04016740|Other|Standard Practice with EEG monitoring|The initial 2 patients will receive standard anesthesia practice and perioperative EEG monitoring will be recorded to learn the patterns associated with our standard practice.
10158268|NCT04016480|Active Comparator|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
10158269|NCT04016480|Active Comparator|Conventional Oxygen Therapy|Conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
10158270|NCT04016428|Experimental|OPTIMISM Intervention|Participants will receive online delivery of a mindfulness-based program for improving sleep in pregnancy, along with the usual care they would receive from their provider.
10158271|NCT04016428|Active Comparator|Sleep Education|Participants will receive online delivery of an education program on sleep in pregnancy, along with the usual care they would receive from their provider.
10158272|NCT04016493||Control group (CAF+CTG; N=20)|
10158273|NCT04016493||Test group (TUN+CTG; N=20)|
10158274|NCT04016441||Subjects|Subjects who are capable of completing an online, English survey.
10158275|NCT04016545||Treated patients|
10158276|NCT04016675|Experimental|Study Group|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
10158277|NCT04016675|Active Comparator|Control Group|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
10158278|NCT04016506||Pancreas injury|children with Pancreas trauma
10158279|NCT04016337|Experimental|Intervention with beverage added with sucralose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with sucralose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener sucralose was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
10158280|NCT04016337|Experimental|Intervention with beverage added with saccharose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with saccharose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener saccharose was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
10186080|NCT03739385|Active Comparator|Peer Group Seniors|Residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
10186081|NCT03739385|No Intervention|Control Group Children|Pre-School children will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
10186082|NCT03739385|No Intervention|Control Group Seniors|Residential seniors will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
9671254|NCT05050929|Active Comparator|20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain Metastases|Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
10158281|NCT04016337|Experimental|Intervention with beverage added with stevia|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with stevia extract was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener stevia was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
10158282|NCT04016519||Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
10158283|NCT04016272|Experimental|Active tDCS|
10158284|NCT04016272|Placebo Comparator|Sham tDCS|
10158285|NCT04016246|Experimental|Propofol|"Propofol (Propofol LIPURO 1% 100mL), Pharmacologic form: 10mg/ml. Considering the birthweight of most preterm babies, Propofol will be diluted to a final concentration of 1mg/ml by the nurse.~Treatment initiation: the 1st dose will be injected following usual management of LISA procedure included the installation of the newborn and the atropine and caffeine injections and sugar solution administration Dose per administration: 0.5mg/kg per dose of Propofol. Number of administrations: Several administrations of 0.5 mg/kg are possible, according the level of sedation achieved, as evaluated by the FANS score. If the FANS score is ≥6, a new dose will be injected up to a total of two (before 28 wGA) or 3 (between 28 - 31 wGA) administrations of the drug. (See paragraph 5.3)"
10158286|NCT04016246|Placebo Comparator|medialipide|"Name of treatment for placebo: Medialipide® (B. BRAUN) Pharmacological form: 20g/100ml Medialipide 20% will be used as the placebo. This is an emulsion of medium and long triglycerides based on soya oil and having same appearance organoleptic characteristics as Propofol.~Dose per administration: Same volume as for the Propofol administration~Number of administrations: according the same protocol that for the Propofol administration.~Modalities of preparation : The same dilution procedure as Propofol lipuro 1% SPC (Summary of Product Characteristics):1 part of Medialipide 20% with 9 parts of 5% w/v glucose solution or 0.9% w/v sodium chloride solution as shown in parenteral nutrition which is in accordance with medialipide 20% SPC"
10158287|NCT04016233|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, each with 3 douches. Sequence A will be 3 sequential doses of TFV douche; Sequence B will be one dose of TFV douche followed by 2 sequential non-medicated douches; Sequence C will be 2 sequential non-medicated douches followed by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by various specimen collections over 8 days according to individual sampling schedule assigned to each participant. Specimens will be collected on Days 1, 2, 4, and 8 post sequence administration.
10158288|NCT04015999|Experimental|Intervention arm|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
10158289|NCT04015999|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
10158290|NCT04016064|Other|group 1;|Er:YAG laser
10158291|NCT04016064|Other|group 2|Nd:YAG laser
10158292|NCT04016064|Other|group 3|Electrosurgery
10158293|NCT04016129|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
10158294|NCT04016038||QualiPas Observational|Prospective qualitative study through a participant observation procedure with 8 care teams practicing within Palliative Care Units, Palliative Care Mobile Team or Territorial Palliative Care Team.
10158295|NCT04016038||QualiPas clinical interview|Qualitative study retrospective research interviews with the doctor and another carer involved in the care of the patient, and close relatives of patients who had sedated before their death. The interviews will be based on 50 cases of patients who have been sedated.
10158296|NCT04016038||QualiPas Focus|Qualitative study by group focus group interviews with clinical teams participating in the project.
10158297|NCT04016012|Experimental|Intervention arm|Participants in the intervention group will receive local zambian foods and standard health care for eight (8) weeks.
10158298|NCT04016012|No Intervention|Control arm|The control group will have their usual (standard) diet in their home and receive standard health care for eight (8) weeks.
10158299|NCT04016051|Experimental|Clarithromycin DST|"Participants received oral administration of Clarithromycin DST twice a day:~125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years).~187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years).~250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years).~For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw."
10158300|NCT04016051|Active Comparator|Clarithromycin Syrup|"Participants received oral administration of Clarithromycin Syrup twice a day:~2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years).~3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years).~5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years)."
10158301|NCT04016155|Active Comparator|SMBG|Patients use their own glucometers as control
10158302|NCT04016155|Experimental|Flash CGMS|
10158303|NCT04015973|No Intervention|Group A: Control|Standard Care
10158304|NCT04015973|Experimental|Group B: High energy diet|High energy diet for 8-12 weeks pre-surgery
10158305|NCT04016116|Experimental|Pembrolizumab (Cohort 1)|Pembrolizumab IV every 3 weeks (Cohort 1: Advanced progressive MPNs)
10158306|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 1: Advanced progressive MPNs)
10158307|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib (Cohort 2)|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 2, unresponsive to PD-1)
10158308|NCT04016090|Placebo Comparator|Placebo treatment|Participant will be asked to ingest a placebo capsule.
10158309|NCT04016090|Experimental|Folic Acid|Participant will be asked to ingest a capsule containing 5 mg of folic acid.
10158310|NCT04016220|Experimental|Budesonide group|The experimental group received a first nebulization of 5 mg of terbutaline(solution of 5mg/ 2 ml ) in association with 0.5 mg of ipratropium bromide (solution of 0.5 mg/ 2 ml) and 0.5 mg of budesonide (solution of 0.5 mg/2 ml) followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min. All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
10158311|NCT04016220|Placebo Comparator|normal saline|The control group received a nebulization of 2 ml normal saline at baseline, 20, 40, 60 and 120 min as placebo comparator in association with nebulized terbutaline . All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
10158312|NCT04015908|Experimental|multi-modal|"3 Different Non-opioid pain medication taken every 6 hours~Celecoxib 100mg~Acetaminophen 325mg~Pregabalin 50 mg~Plus, for breakthrough pain~oxycodone 5-10 mg will be taken every 4 hours as needed for pain."
10158313|NCT04015908|Active Comparator|Control|7 day supply of Percocet (oxycodone 5mg/acetaminophen 325 mg) to be taken 1-2 by mouth every 4 hours as needed for pain.
10158314|NCT04016025|Active Comparator|cream|Treatment with topical Methylprednisolone aceponate 0,1% cream (Advantan®) plus Basic care (Bepanthen® Sensiderm)
10158315|NCT04016025|Active Comparator|fatty ointment|Treatment with topical Methylprednisolone aceponate 0,1% fatty ointment (Advantan®) plus Basic care (Bepanthen® Sensiderm)
10158316|NCT04016207||Guanfacin regular treatment|
10158317|NCT04016103|Experimental|MY01 Device|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
10158318|NCT04015947|Experimental|Active treatment|This is an open label, single-institution pilot study to evaluate local response to split-thickness skin grafts from a matched bone marrow donor to chronic GVHD-affected skin in a hematopoietic stem cell transplant patient.
10158319|NCT04015986|Experimental|Intervention arm|MDCF-2 prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth).
10158320|NCT04015986|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
10158321|NCT04015882|Active Comparator|exercise|the exercise group will applied virtual reality exercises by Nintendo Wii Fit Plus System Game Console.
10158322|NCT04015882|No Intervention|control|No exercise applied the control group.
10158323|NCT04015869|Active Comparator|allopregnanolone|allopregnanolone
10158324|NCT04015869|Placebo Comparator|placebo|placebo
10158325|NCT04015895||Patient with cancer|Patient with cancer will be included. They will have to answer at DEFCO tool.
10158326|NCT04016168||Patients with DILD|Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
10158327|NCT04015830|Experimental|Older Adults with HIV (N = 60)|African Americans and Whites age 50 and older
10158328|NCT04015817|Experimental|Etude longitudinale|Work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, support from the mobile palliative care team
10158329|NCT04015596|Experimental|Intervention|Participants receive Naproxen Sodium.
10158330|NCT04015596|Placebo Comparator|Placebo|Participants receive placebo.
10158331|NCT04015414|Active Comparator|Varenicline (Champix)|Varenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues.
10158332|NCT04015414|Active Comparator|Cytisine (Tabex)|Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
10158333|NCT04015700|Experimental|Vaccine (GNOS-PV01 + INO-9012)|"Standard radiation therapy will be administered per standard of care and is outside the scope of this study.~GNOS-PV01 + INO-9012 will be given on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle beginning with Cycle 2 for a total of 8 cycles or until intolerance or progression"
10158334|NCT04015557|Experimental|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
10158335|NCT04015557|Experimental|Acetaminophen + N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
10186083|NCT03739359|Active Comparator|Gas flow 50 L/min|In this group, nasal cannula gas flow will be set at 50 L/min.
10186084|NCT03739359|Experimental|GF:IF=1|In this group, nasal cannula gas flow will be set at each individual patient's own inspiratory flow (GF:IF=1)
10158336|NCT04015765|Experimental|Group treatment h-APC and EMR|Standard endoscopic mucosal resection (EMR) technique will be used for primary removal of all polyps. Submucosal injection will be used to lift the polyp from the muscularis propria. Injection is used as per the current standard of care using a contrast agent and a lifting agent (e.g. NaCl 0.9% or Voluven). Snare electrocautery resection will be facilitated until complete visible removal of the complete polyp. Electrocautery snare technique is facilitated using standard microprocessor controlled electrocautery (e.g. ERBE VIO Endocut 3-1-6). Ablation of the margin after visibly complete removal of the polyp is routinely applied. For thermal ablation hybrid APC (Erbe Hybrid APC) will be applied using standard settings on the margin and resection base. Once resection and thermal ablation is considered complete the mucosal defect can be closed with clips or another preventative measure applied to reduce the risk for post-polypectomy bleeding.
10158337|NCT04015544|Experimental|Watermelon|Watermelon puree 710 mL per day for six weeks
10158338|NCT04015544|No Intervention|Control|No intervention
10158339|NCT04015479|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
10158340|NCT04015479|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
10158341|NCT04015713||TB HIV-negative|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
10158342|NCT04015713||TB HIV-positive|"Patients will receive standard TB treatment and will be followed according to the national procedures.~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.~All participants will be followed 24 weeks."
10158343|NCT04015492|Experimental|BAY94-9027 / Adynovi|Treatment sequence A-B with washout before each treatment
10158344|NCT04015492|Experimental|Adynovi / BAY94-9027|Treatment sequence B-A with washout before each treatment
10158345|NCT04015570|Experimental|High Volume Plasma Exchange with SMT|"PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity.~Standard Medical Treatment (Albumin + High Caloric Diet)"
10158346|NCT04015570|Active Comparator|Standard Medical Treatment|Standard Medical Treatment (Albumin + High Caloric Diet)
10158347|NCT04015687|Experimental|AG-881 (Group 1)|On Day 1 of Period 1, Group 1 participants will receive a single 50-milligram (mg) oral dose of lamotrigine at Hour 0. In Period 2, they will receive 50-mg oral doses of AG-881 once daily (QD) for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14.
10158348|NCT04015687|Experimental|AG-881 (Group 2)|Following a safety and tolerability review of the data from at least 7 days of AG-881 dosing of Group 1 participants in Period 2, Group 2 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1, and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
10158349|NCT04015687|Experimental|AG-881 (Group 3)|Following a safety and tolerability review of the data from Group 1 participants, and from at least 7 days of AG-881 dosing of Group 2 participants in Period 2, Group 3 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1; and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15) with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
10158350|NCT04015752||diabetics|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present, medication used, controlled or not.~Complete physical examination with special attention to :~Vital signs ( MAP, pulse, temp, RR). Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~Laboratory investigations includes :~CBC , Liver and kidney functions → baseline and follow up. Arterial Blood Gases (ABG). Lactic acid level. HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
10158351|NCT04015752||non diabetics|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present medication used, controlled or not.~Complete physical examination with special attention to :~Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
9671255|NCT05050929|Experimental|8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain Metastases|A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
9671256|NCT05051267|No Intervention|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, when the baby starts to cry, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
9973566|NCT01332513|Experimental|ABFCED sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 milligram (mg) twice daily (BID) dosing of ezogabine modified release (MR) tablet in periods A, B, C, D and E and will receive 200 mg three times daily (TID) dosing of ezogabine immediate release (IR) tablet in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
10158352|NCT04015752||patients devoloped hyperglycemia in ICU only|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present medication used, controlled or not. 2. Complete physical examination with special attention to : Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, CVP,..). 3. Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
10158353|NCT04015505|Experimental|Intervention|Participants will receive 5 sessions of a psychological (talking therapy) intervention based on the wisdom enhancement 'timeline technique' within cognitive behavioural therapy for older adults.
10186085|NCT03739359|Experimental|GF:IF=0.5|In this group, nasal cannula gas flow will be set at 50% of each individual patient's own inspiratory flow (GF:IF=0.5)
10186086|NCT03739346|Experimental|Control|Tell, show, do technique
10186087|NCT03739346|Experimental|Intervention|Hypnosis.
10186088|NCT03739333|Experimental|patients with glioblastoma|implementation of 11C-Methionine PET-MRI
10186089|NCT03739294|Experimental|PILOT: 4 puffs once|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms
10186090|NCT03739294|Experimental|PILOT: 4 puffs once a day for 7 days|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms for 7 days
10186091|NCT03739294|Experimental|LARGE: 4 puffs once|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) once
10186092|NCT03739294|Experimental|LARGE: 4 puffs once a day for 7 days|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) daily for 7 days
10186093|NCT03739294|Experimental|LARGE: 1 puff once|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (1 puff) once
10186094|NCT03739294|Experimental|LARGE: 1 puff once a day for 7 days|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 (1 puff) daily for 7 days
10186095|NCT03739281|Other|Nuclear medicine imaging|Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
10186096|NCT03739255|Experimental|Cacicol20|One drop of Cacicol20 will be applied 4-6 hours after the surgery, in one of the randomly chosen eye, and thereafter one drop daily until the reepithelialization is completed.
10186097|NCT03739255|Placebo Comparator|Placebo|One drop of conservative free artificial tear (Oculac, Thea Laboratories) will be applied to one eye at the same time when Cacicol20 is instilled to the other eye.
10186098|NCT03739229|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of study vaccine (total dose 0.50 ml at each study vaccine administration).
10186099|NCT03739229|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of placebo (total dose 0.50 ml at each placebo administration).
10186100|NCT03739216||Open label|Open label registry study of patients treated with the ClariFix device for chronic rhinitis.
10186101|NCT03739190|Experimental|Test Condom: Thin NRL Condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
10186102|NCT03739190|Active Comparator|Reference condom A: Medium Thickness NRL Condom|
10186103|NCT03739190|Active Comparator|Reference condom B: Thick NRL Condom|
10186104|NCT03739151|Other|Behavioral Obesity Treatment|All participants will receive gold-standard behavioral obesity treatment
10186105|NCT03739125|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
10186106|NCT03739125|Placebo Comparator|Placebo|Placebo
10186107|NCT03739112|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
10186108|NCT03739112|Active Comparator|Quadrivalent Comparator Vaccine|Single dose - 15 ug/strain of Quadrivalent Comparator Vaccine
10186109|NCT03739060|Active Comparator|Active TENS group|Conventional transcutaneous electric nerve stimulation
10186110|NCT03739060|Placebo Comparator|Placebo TENS group|0 amperes transcutaneous electric nerve stimulation
10186111|NCT03739047|Experimental|Desensitization with flipped spoon|Children in this study will receive behavioral feeding treatment. This arm will include desensitization.
10186112|NCT03739047|Placebo Comparator|flipped spoon|Children in this study will receive behavioral feeding treatment.
10186113|NCT03739021|Experimental|Group 1 (30 participants)|
10186114|NCT03739021|Experimental|Group 2 (30 participants)|
10186115|NCT03738982|Experimental|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
10186116|NCT03738969||Laparotomy group|Patients in this group accepted laparotomic radical hysterectomy for cervical cancer.
10186117|NCT03738969||Laparoscopy group|Patients in this group accepted laparoscopic or robotic radical hysterectomy for cervical cancer.
10186118|NCT03738956|Experimental|Open label clinical trial|NSAID refractory axial spondyloarthritis patients who are eligible after considering inclusion and exclusion crietria will be put on 5 mg tofacitinib BD ,at the end of 1st and 3rd month they will be assessed for safety and efficacy.Those who will not respond will be put on 10 mg tofacitinib BD.All patients will be assessed at the end of 6th month.If any adverse event occur they will be treated accordingly.
10187854|NCT03722069|Other|Normal sodium diet|22 patients were randomized to receive 7 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
10187855|NCT03722056||gastric GIST|patients with suspected gastric GIST with size > 2cm are subjected for laparoscopic resection.
10158354|NCT04015635||Study group|"80 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
10158355|NCT04015635||Control|"80 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.~Clinical and laboratory assessment. NO intervention."
10158356|NCT04015674|Experimental|Exercise group|Patients will remain in supine position for 5 minutes to measure their vascular caliber of the AVF by echography. After, will be instructed to perform 30 minutes on stationary bicycle (Model Monark). The AVF vascular caliber will be measured during aerobic exercise. Because it is a cross-over trial, participants will perform the other arm after 7 days.
10158357|NCT04015674|Active Comparator|Control group|The patients will perform 30 minutes of rest in a chair and the measurements will be performed in the same moments established by the exercise group. Because it is a cross-over trial, participants will perform the other arm after 7 days.
10158358|NCT04015778|Experimental|Nivolumab Mono|In arm A, 24 participants will be enrolled into this arm according to PD-L1 expressing level (≥50%).Arm A consists of 3 cycles of neoadjuvant nivolumab (240mg every 2 weeks), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
10158359|NCT04015778|Experimental|Nivolumab Plus Chemo|In arm B, up to 12 participants will be enrolled into each subgroup according to PD-L1 expressing level (<1% and 1%-49%).arm B consists of 3 cycles of neoadjuvant nivolumab (360mg every 3 weeks) with nab-paclitaxel and carboplatin(nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every three weeks ), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
10158360|NCT04015531|Active Comparator|Conventional radiotherapy|"50 Gy in 25 fractions to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla), followed by tumor bed boost of 10 Gy in 5 fractions in case of breast conserving surgery.~Total time: 5-6 weeks."
10158361|NCT04015531|Experimental|Hypofractionated radiotherapy|"40 Gy in 15 fractions (2.67 Gy each) to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla).~Patients undergoing breast conserving surgery will receive concomitant boost with total dose of 48 Gy in 15 fractions (3.20 Gy each) to tumor bed.~Total time: 3 weeks."
10158362|NCT04015661|Experimental|Nab-paclitaxel+Nedaplatin|induction chemotherapy by nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
10158363|NCT04015661|Active Comparator|Paclitaxel+Nedaplatin|induction chemotherapy by paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
10158364|NCT04015427|Active Comparator|screw-retained|Patients in group A will receive a screw-retained implant crown. Following this first period of 16 weeks, the screw-retained implant crown will be replaced by a new intraorally cemented implant crown. Cement removal will be preformed according to best clinical procedure. These implant crowns will again be left for another period of 16 weeks and followed up for the harvesting of microbiological samples every 8 weeks. After the second 16-week the implant crowns will be removed to evaluate any excess cement. All patients will be fitted with the original screw-retained implant crown. Clinical parameters for inflammation and probing depths will be obtained after each 16 week-period.
10158365|NCT04015427|Active Comparator|cement-retained|In group B the implant crowns will be incorporated in a reverse pattern. During the first 16 weeks a cemented implant crown will be inserted and any possible cement residues will be removed according to best clinical procedure, while for the second period of 16 weeks patients will be fitted with a screw-retained single implant crown. Again, microbiological and clinical parameters will be obtained at the same intervals as in Group A.
10158366|NCT04015583|Experimental|exergaming group|"The exergaming group (EXG) performed exercise using Exerheart® devices (D&J Humancare, Busan, South Korea) composed of a running/jumping mat [730(W) × 730(D) × 130(H)] and a tablet PC on a stand (can be adjusted to any height between 70 and 155 cm) (Supplemental Figure 1A). Exerheart® is an exergaming developed for in-situ running along with the video game called Alchemist's Treasure (D&J Humancare, Busan, South Korea). To play this game, the subject has to run or jump on a spot on the mat to move a virtual avatar on the screen of the tablet PC to the front, back, left, and right along with music. The subject can control the speed of avatar movement by running or jumping speed on the mat."
10158367|NCT04015583|Active Comparator|treadmill exercise group|The treadmill exercise group (TEG) performed exercise using commercial treadmills (MOTUS, Gyeonggi-do, South Korea). Each subject walked or ran on the treadmill at a comfortable speed.
10158368|NCT04015388||Diabetes Mellitus / Hyperglycemia|iPro Continuous Glucose Monitoring on subjects with blood sugar value >140 mg/dL upon admission to the intensive care unit or who have been diagnosed with type 1 or type 2 diabetes or have glycosylated hemoglobin A1C (HbA1C) values > 6.5% prior to admission.
10158369|NCT04015466||Cases|Patients with high diagnostic suspicion of advanced GC diagnosis
10158370|NCT04015466||Control|Patients with confirmed absent of GC
10158371|NCT04015375|Experimental|Dapsone gel, 7.5% (Torrent Pharmaceuticals Ltd.)|Topical, once daily for 84 days
10158372|NCT04015375|Active Comparator|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical, once daily for 84 days
10158373|NCT04015375|Placebo Comparator|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical, once daily for 84 days
10158374|NCT04015193||Full responders|Full responders: no signs or symptoms of Raynaud's phenomenon (RP) in Raynaud condition score, no RP during cooling-recovery experiment.
10158375|NCT04015193||Partial responders|Partial responders: at least 25% reduction in Raynaud condition score and finger ischemia time during cooling and recovery.
10158376|NCT04015193||Non-responders|Non-responders: no or less than 25% reduction in Raynaud condition score and/or finger ischemia time during cooling and recovery.
10158377|NCT04015063|Other|Primary Subjects|Women subjects 40-65 years of age that meet the specified inclusion/exclusion criteria taking P29429-01 as a skin care product per the protocol.
10158378|NCT04014985|Other|Girls with RETT syndrome|100 girls over 18 years old with RETT syndrome
10158379|NCT04015310||PSC patients attending outpatient|Primary sclerosing cholangitis, as defined by EASL and AASLD guidelines.
10158380|NCT04015297|Experimental|control|healthy controls
10158381|NCT04015297|Experimental|patient|patients diagnosed with endometriosis
10158382|NCT04015076|Experimental|Single Ascending Dose|Inzomelid or Placebo
10158383|NCT04015076|Experimental|Multiple Ascending Dose|Inzomelid or Placebo
10158384|NCT04015076|Experimental|Patients with CAPS|Inzomelid Open Label
10158385|NCT04015245|Experimental|SNMC|
10158386|NCT04015245|No Intervention|non-SNMC|
10158387|NCT04014959|Experimental|All Participants|All participants follow the same procedures.
10158388|NCT04015271|Experimental|Action Observation + Repetitive Task Practice|Action Observation (AO) therapy regimen will include watching a 6 minute video of another person completing a specified functional task (Putting on a shirt, pick up a sandwich and bring to mouth, eat food with a spoon, or cut meat with knife and fork). Subjects will be instructed to carefully watch the AO video and prepare to physically perform the task immediately after observing the video. The Repetitive Task Practice (RTP) therapy regimen emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task that is matched to the AO recording. The AO + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
10158389|NCT04015271|Placebo Comparator|Placebo Video + Repetitive Task Practice|The control placebo videos (PV) will be 6 minutes, and will include a series of changing static images without animals, human beings, or sound (i.e. pictures of buildings, trees, cruise ships, mountains, beach umbrellas, beds, and tables). A Repetitive Task Practice (RTP) therapy regimen will be completed immediately after observing the PV, which emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task. These tasks include putting on a shirt, picking up a sandwich and bringing it to mouth, eating food with a spoon, or cutting meat with knife and fork. The PV + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
10158390|NCT04015219|Experimental|Treatment Arm|PROKERA SLIM + Standard of Care
10158391|NCT04015219|Active Comparator|Control Arm|Standard of Care
10158392|NCT04015089|Experimental|Partially hydrolyzed formula (pHF)|Infants fed exclusively with a infant formula based on partially hydrolyzed serum cow's milk proteins.
10158393|NCT04015089|Active Comparator|Standard formula (SF)|Infants fed exclusively with a standard formula based on intact cow's milk proteins
10158394|NCT04015206|Experimental|IPT-G+UCT|10 sessions of Group Interpersonal therapy added to pharmacotherapy + clinical management plus one individual session pre-group and one session pos-group
10158395|NCT04015206|Active Comparator|Usual treatment (UCT)|Pharmacotherapy + Clinical management once a month
10158396|NCT04015258|Experimental|Blueberries|Fresh blueberries purchased from local supermarket will be distributed to each participant for 1 week's consumption, 160 grams per day
10158397|NCT04015258|Experimental|Blueberry powder|Freeze-dried blueberry powder will be distributed to each participant for 1 week's consumption, 20 grams per day, equivalent to 160 grams of fresh blueberries
10158398|NCT04015258|Placebo Comparator|Blueberry components capsules|Encapsulated microcrystalline cellulose powder will be blinded as blueberry components capsules to be distributed to each participant for 1 week's consumption
10158399|NCT04015284|Experimental|SSNB + PCB|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL ropivacaine 0.5%, then single shot US-guided posterior cord block (PCB) with 10 ml ropivacaine 0.5%.
10158400|NCT04015284|Active Comparator|ISBPB|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL ropivacaine 0.5%.
10158401|NCT04015024|Experimental|SKLB1028 150mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs.
10158402|NCT04015024|Experimental|SKLB1028 200mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
9973567|NCT01332513|Experimental|BCADFE sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
10158403|NCT04015024|Experimental|SKLB1028 300mg qd|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
10158404|NCT04015323|Experimental|IFC Therapy 2 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 2 kHz
10158405|NCT04015323|Experimental|IFC Therapy 4 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 4 kHz
10158406|NCT04015323|Experimental|IFC Therapy 8 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 8 kHz
10158407|NCT04015037|Experimental|Group A|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
10158408|NCT04015037|Experimental|Group B|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
10158409|NCT04014933||open-angle glaucoma|patients with a diagnosis of open-angle glaucoma, i.e. untreated IOP >21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
10158410|NCT04014933||normal tension glaucoma|patients with a diagnosis of normal tension glaucoma, i.e. untreated IOP </=21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
10158411|NCT04014933||healthy controls|individuals with normal optic disc and IOP </21mmHg and normal visual fields
10158412|NCT04014777|Experimental|NGM621 Cohort 1 Single Ascending Dose|NGM621 single IVT injection Cohort-Dose 1
10158413|NCT04014777|Experimental|NGM621 Cohort 2 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 2
10158414|NCT04014777|Experimental|NGM621 Cohort 3 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 3
9527684|NCT03217838|Experimental|Group 3 Arm A (AZD2811 Dose 2 + Venetoclax 200 mg)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle and venetoclax 100 mg orally (PO) on Day 1 and 200 mg PO from Days 2 to 28 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
10158415|NCT04014777|Experimental|NGM621 Cohort 4 Multiple Dose|NGM621 multiple IVT injection Cohort--Dose 4
9671257|NCT05051267|Experimental|Mothers Embrace|A mothers embrace is one of the earliest and most common care events that mothers offer to their babies. Close physical contact between mother and baby during hugs can reduce stress by facilitating co-regulation of mother and baby. In a study conducted in Turkey, it was stated that holding the baby on the lap for pain relief in painful interventions is a practical and easy method.
10158416|NCT04014816||Group I|Patients who had GI dysfunction (Group I) for one or more occasions.
10158417|NCT04014816||Group II|Patients who had normal GI function (Group II) for one or more occasions.
10158418|NCT04014673|Other|Patients with a PGRN gene mutation|Symptomatic patients with a PGRN gene mutation
10158419|NCT04014673|Other|Presymptomatic individuals|Asymptomatic 'At-risk' individuals with a PGRN gene mutation
10158420|NCT04014673|Other|healthy volunteers|'At-risk' individuals without a PGRN gene mutation
10158421|NCT04014621|Active Comparator|Treated|Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
10158422|NCT04014621|Sham Comparator|Control|Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
10158423|NCT04014946|Other|ICD implantation|Implantation of a Lumax 540 single/dual chamber ICD or successor according to local practice within 3 months after enrolment. The patient will be implanted with a single or dual chamber device according to ESC guidelines.
10158424|NCT04014517|Active Comparator|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
10158425|NCT04014517|Experimental|Immunonutrition|Impact
10158426|NCT04014829||Control|Preoperative assessment with questionnaires, Mechanical Temporal Summation, and Pain-Pressure Threshold. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 4 and 6 months.
10158427|NCT04014829||Chronic Post-Hysterectomy Pain (CPHP)|Preoperative assessment with questionnaires, Mechanical Temporal Summation, and Pain-Pressure Threshold. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 4 and 6 months.
10158428|NCT04014712|Experimental|acute BH4/Tetrahydrobiopterin treatment|Oral supplement, Pill, 10 mg/kg of body weight
10158429|NCT04014712|Placebo Comparator|Placebo|Oral supplement, Pill, Placebo pill with inert excipient
10158430|NCT04014504||study group|The results of the hearing screening test of the beats of the patients who have undergone pethidine in the active phase of labor will be examined. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at.
10158431|NCT04014504||control group|In the active phase of labor, hearing screening test results of beats of pediatric patients will be evaluated. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at. control group.
10158432|NCT04014699|Experimental|modified 2.2mm micoincision|
10158433|NCT04014699|Active Comparator|conventional 2.2mm microincision|
10158434|NCT04014686|Sham Comparator|Control group|No exercise intervention
10158435|NCT04014686|Experimental|Exercise intervention group|Exercise intervention group (resistance band exercise training for 12 weeks, 3x per week, for 60 minutes per day).
10158436|NCT04014634|Placebo Comparator|Placebo|Injection of NaCl
10158437|NCT04014634|Experimental|Verum|
10158438|NCT04014790|Experimental|RGI-2001|Subjects will be administered RGI 2001 in combination with standard of care treatment
10158439|NCT04014543|Experimental|Gastrostomy|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
10158440|NCT04014855|Active Comparator|obese children 1|iron supplementation
10158441|NCT04014855|Active Comparator|obese children 2|lactoferrin supplementation
10158442|NCT04014556|Active Comparator|Aflibercept plus micropulse laser (group A)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
10158443|NCT04014556|Active Comparator|Aflibercept monotherapy (group B)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
10158444|NCT04014582|Experimental|Communal Coping Intervention|This group will participate in diabetes education + a communal coping based intervention.
10158445|NCT04014582|Active Comparator|Control|This group will participate in diabetes education and an individual intervention.
10158446|NCT04014725|Experimental|Eligible patients for AI test|
10158447|NCT04014881|Experimental|CD123+ Acute Myeloid Leukemia|Patients will receive CD123-targeted CAR-T cells in the dose-climbing trial. Each dose group has 3 patients and the the maximum dose can be extended.
10158448|NCT04014569|Experimental|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA algorithm
10158449|NCT04014647||Event-free|Patients who have had no negative events (as described in group 2)
10158450|NCT04014647||Negative event|"Group 2 - patients with one or more of the following negative events post-operatively:~Whether the patient has been prescribed inotropic support~Wound infection by assessing use of antibiotics.~Length of stay in hospital >1 week~Reduced renal function assessed by having any AKI alert during hospital stay~Cardiac event within 31 days following surgery~Death within 31 days following surgery"
10158451|NCT04014608||Baseline Control|Standard Practice before the intervention was introduced
10158452|NCT04014608||Intervention initiative|Standard Practice plus Admission Surveillance for toxigenic C. difficile.
10158453|NCT04014595||Rotational atherectomy + Cutting Balloon|Rotational atherectomy in combination with cutting balloon in severely calcified coronary lesions
10158454|NCT04014491|Experimental|Scapula control exercise|Subjects will perform three exercises with EMG biofeedback and verbal cues. Three exercises are elevation in scapular plane, sidelying external rotation and dynamic hug plus
10158455|NCT04014491|Experimental|Scapula strengthening exercise|The subjects in the scapular strengthening group will be asked to perform the three exercises the same as scapula control exercise group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
10158456|NCT04014491|Other|Healthy subject group|Healthy subjects will be included to compare the differences in corticospinal system between healthy subjects and subjects with shoulder impingement syndrome, so this group will not receive any treatment.
10158457|NCT04014478|Experimental|Endovascular Denervation|
10158458|NCT04014452|Experimental|Microwave ablation group|Microwave ablation is used for the treatment of Complicated Monochorionic Pregnancies
10158459|NCT04014452|Active Comparator|Radiofrequency ablation group|Radiofrequency ablation is used for the treatment of Complicated Monochorionic Pregnancies
10158460|NCT04014465||patients with radiotherapy|The patients of lung cancer or esophagueal cancer, who received definitvie RT, should included in this Cohort.
10158461|NCT04014439||Normal Diaphragm|Diaphragm thickness is 2 mm or more
10158462|NCT04014439||Thinning Diaphragm|Diaphragm thickness is less than 2 mm
10158463|NCT04014153||Group 1 (5-year prognosis)|
10158464|NCT04014153||Group 2 (1-year prognosis)|
10158465|NCT04014426|Other|Exposed|Healthcare workers participating at two PIPAC
10158466|NCT04014426|Other|Non-exposed|Healthy volunteers unexposed to chemotherapy
10158467|NCT04014127||Controls|25 controls with preserved renal function
10158468|NCT04014127||Kidney Donors|25 living kidney donors who have donated a kidney at least 12 months prior to enrollment in the study.
10158469|NCT04014127||Pre-dialysis|25 patients with pre-dialysis chronic kidney disease stage 5
10158470|NCT04014127||Peritoneal dialysis|25 patients with chronic kidney disease stage 5 undergoing peritoneal dialysis
10158471|NCT04014010||Cohort|Patients ages ≥ 45 receiving their index (i.e. first) non-cardiac surgery with an overnight stay at the Nova Scotia Health Authority Queen Elizabeth II (QEII) hospitals (Victoria General and Halifax Infirmary) Halifax, Canada, from January 1, 2013 to December 1, 2017 will be included. Patients under going cardiac surgery or deceased organ donation will be excluded. Patients without an electronic anesthetic record during surgery will also be excluded. Preliminary analysis of the intraoperative database estimates approximately 35,000 patients in this cohort.
10158472|NCT04014309|Experimental|Supportive and survivorship care program|Routine distress screening will be conducted using the Distress Thermometer (DT) and an accompanying problem list. Participants will complete the screening tool before their consults with oncologists and the results will be stored in their medical records. During the consult, oncologists will review the DT scores and problem list with each participant to provide the corresponding educational materials, advice or referrals. Highly distressed participants may be referred by oncologists to the supportive care nurses (SCN) for further triage and review.
10158473|NCT04014309|Placebo Comparator|Usual care|No routine distress screening will be performed.
10158474|NCT04014088|Active Comparator|helmet CPAP|helmet CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
10158475|NCT04014088|Active Comparator|facemask CPAP|facemask CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
10158476|NCT04014192|Experimental|Dapagliflozin Group|10mg/d for one week
10158477|NCT04014192|Experimental|Empagliflozin Group|10mg/d for one week
10158478|NCT04014192|Experimental|Canagliflozin Group|100mg/d for one week
10158479|NCT04014192|No Intervention|Normal Glucose Tolerance Group|
10158480|NCT04014218|Experimental|Inhalation sedation|
10158481|NCT04014218|Active Comparator|Propofol|
10158482|NCT04014140||Patients with multi-vessel coronary artery disease (MVCAD)|iFR measurements will be taken pre-operatively during the invasive coronary angiography.
10158483|NCT04014023|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
10158484|NCT04014023|Experimental|DWP16001 Bmg|DWP16001 Bmg, Tablets, Orally, Once daily
10158485|NCT04014023|Experimental|DWP16001 Cmg|DWP16001 Cmg, Tablets, Orally, Once daily
10158486|NCT04014023|Placebo Comparator|Placebo|Placebo, Tablets, Orally, Once daily
10158487|NCT04014166|Experimental|15 refractory ITP patients|15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose.
10158488|NCT04014101|Experimental|SHR-1210+ apatinib|SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.
10158489|NCT04014244|Experimental|Corticosteroids vs. Dextrose|In the first part of the study examiner will randomize substance for left hand infiltration using a dice (odd number - corticosteroids; even number - 5% glucose). Right hand will be infiltrated with the remaining substance.
10158490|NCT04014244|Experimental|Corticosteroids or Dextrose vs. Surgery|In the second part of the study examiner will randomize treatment procedure for left hand using a dice (odd number - corticosteroids or 5% glucose; even number - surgery). Substance for injection will be determined according to the results of the first part of the study - more effective one, or in case of non-inferiority 5% glucose will be used. Surgical release will be performed by the same plastic surgeon. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
10158491|NCT04014361|Experimental|LY3154885 - Part A|LY3154885 administered orally in two of three study periods.
10158492|NCT04014361|Placebo Comparator|Placebo - Part A|Placebo administered orally in one of three study periods.
10158493|NCT04014361|Experimental|LY3154885 - Part B|LY3154885 administered orally alone.
10158494|NCT04014361|Placebo Comparator|Placebo - Part B|Placebo administered orally alone.
10158495|NCT04014361|Experimental|LY3154885 + Itraconazole - Part B|LY3154885 administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. LY3154885 co-administered with itraconazole, orally, once.
10158496|NCT04014361|Placebo Comparator|Placebo + Itraconazole - Part B|Placebo administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. Placebo co-administered with itraconazole, orally, once.
10158497|NCT04014361|Experimental|LY3154885 - Part C|LY3154885 administered orally on consecutive days.
10158498|NCT04014361|Placebo Comparator|Placebo - Part C|Placebo administered orally on consecutive days.
10158499|NCT04014361|Experimental|LY3154885 - Part D|LY3154885 administered orally once in each of three study periods.
10158500|NCT04014283|Active Comparator|BRCA(+) Selenium deficiency|Placebo: 100 Supplement: 100
10158501|NCT04014283|Active Comparator|BRCA(+) Selenium excess|Diet modification: 500 Observation: 500
10158502|NCT04014283|Active Comparator|BRCA(-) Selenium deficiency|Placebo: 900 Supplement: 900 Diet modification: 900 Observation: 900
10158503|NCT04014283|Active Comparator|BRCA(-) Selenium excess|Diet modification: 1100 Observation: 1100
10158504|NCT04014283|Active Comparator|BRCA(+) Selenium excess, age > 50|Diet modification: 200 Observation: 200
10158505|NCT04014257|Experimental|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
10158506|NCT04013997|Experimental|Exoskeletal-assisted walking training group|Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians identified patients admitted to the unit who may be eligible for the study.
10158507|NCT04013997|No Intervention|Matched control group|"Twenty inpatients with SCI were identified as the matched control group through reviewing an acute inpatient rehabilitation database of Uniform Data System for Medical Rehabilitation by a person blinded to the study.~The control group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. The control groups received the same amount of acute rehabilitation time per week as the intervention group."
10158508|NCT04014036|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
10158509|NCT04014036|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
10158510|NCT04014400|Experimental|Suprathel|Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
10158511|NCT04014400|Active Comparator|Xeroform|After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.
10158512|NCT04013984|Experimental|Accupuncture|"Acupuncture twice a week during the preceding cycle and the ovarian stimulation by GnRH agonist stopped protocol."
10158513|NCT04013984|No Intervention|Non-accupuncture|"Ovarian stimulation by GnRH agonist stopped protocol without intervention."
10158514|NCT04013815|Experimental|group E|patients receiving the ESP block
10158515|NCT04013815|Active Comparator|group I|patients receiving the intercostal nerve block
10158516|NCT04013776|Active Comparator|Phosphate supplemented diet|All participants will undergo phosphate testing after following a phosphate supplemented diet for 5 days
10158517|NCT04013776|No Intervention|Low phosphate diet|All participants will undergo phosphate testing after following a low phosphate diet for 5 days
10158518|NCT04013698|Experimental|PEEP level 5 cmH2O to 15 cmH2O|
10158519|NCT04013698|Experimental|PEEP level 15 cmH2O to 5 cmH2O|
9694854|NCT04784767|Placebo Comparator|3B: Placebo (Sodium chloride, USP, for injection (0.9% NaCl) on Days 1 and 181.|4 participants will receive 1.0mL of normal saline as Placebo on Study Days 1 and 181.
10158520|NCT04013568|Active Comparator|Group 1 - Agree to Exercise Program|12-week exercise program
10158521|NCT04013568|No Intervention|Group 2 - Declines Exercise Program|Same biometric and biomarker assessment at as Group 1 (at baseline, after 12 weeks and annually) however they will not participate in the exercise sessions
10158522|NCT04013581|Experimental|TZD group|Pioglitazone added to Metformin, DPP-4 inhibitors, Sulfonylurea
10158523|NCT04013581|Active Comparator|SGLT-2 inhibitor group|Empagliflozin added to Metformin, DPP-4 inhibitors, Sulfonylurea
10158524|NCT04013919||Type 1 Diabetes|
10158525|NCT04013919||Type 2 Diabetes|
10158526|NCT04013945|Active Comparator|Superba Boost capsules|1000 mg krill oil concentrate per capsule
10158527|NCT04013945|Placebo Comparator|Placebo capsules|1000 mg capsule composed of mixed vegetable oil.
10158528|NCT04013646|Experimental|UCB infusion and EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
10158529|NCT04013646|Experimental|UCB infusion and placebo EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
10158530|NCT04013646|Placebo Comparator|Placebo UCB infusion and placebo EPO injection group|Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
10158531|NCT04013659|Experimental|G1 - Permanence of the Whitening Gel|Permanence of the Whitening Gel (Biological Product: 35% Hydrogen Peroxide) on the tooth enamel during the 15 minutes of dental-bleaching
10158532|NCT04013659|Experimental|G2 - Renewal of the Whitening Gel|3 Whitening Gel (Biological Product: 35% Hydrogen Peroxide) renewal every 5 minutes during the 15 minutes of dental-bleaching
10158533|NCT04013620|Experimental|transient belatacept|
10158534|NCT04013750|Experimental|left hemiplegia|Patients in the left hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
10158535|NCT04013750|Experimental|right hemiplegia|Patients in the right hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
10158536|NCT04013750|No Intervention|control|10 patients with right hemiplegia and 10 patients with left hemiplegia formed the control group and these patients were in line for inpatient rehabilitation programme.
10158537|NCT04013958|Active Comparator|IV Ketamine|IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.
10158538|NCT04013958|Experimental|IM Ketamine|IM Ketamine group will receive IM Ketamine with IV morphine.
10158539|NCT04013633|Experimental|Lifesaver virtual reality (VR) training|Training using the Lifesaver VR application. Lifesaver VR is an interactive game that can be played on smartphones allowing users to 'resuscitate' a victim of cardiac arrest, while wearing VR-goggles showing a filmed CPR-scenario
10158540|NCT04013633|Active Comparator|Face-to-face training|A short face-to-face CPR training based on international guidelines provided by certified instructors
10158541|NCT04013594|Experimental|carbohydrate group(CHO group)|
10158542|NCT04013594|No Intervention|control group|
10158543|NCT04013672|Experimental|Arm A - Have not received immunotherapy|Arm A is patients with first recurrence of glioblastoma who have failed prior chemotherapy and radiation but have not received any immunotherapy.
10158544|NCT04013672|Experimental|Arm B - Have failed prior anti-PD1 therapy|Arm B is an exploratory arm of 10 patients who have failed prior anti-PD1 therapy.
10158545|NCT04013880|Experimental|Treatment (ASTX727, FT-2102)|Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10158546|NCT04013906|Experimental|Rotational atherectomy|Patients will undergo rotational atherectomy
10158547|NCT04013906|Experimental|Intravascular lithotripsy|Patients will undergo intravascular lithotripsy
10158548|NCT04013711|Experimental|Thermal Imaging|Patients will undergo non-invasive, thermal imaging of their whole breast or head and neck cancer site, during the course of the radiotherapy treatment, at weekly time intervals.
10158549|NCT04013724|Experimental|Intervention group|"The behavioral group intervention consisted of 6 sessions over 12 weeks and were led by 2 trained facilitators, followed by monthly group meetings from weeks 14 to 26. This program was adapted from the Royal Australian College of General Practitioners' Supporting Smoking Cessation Guide for Health Professionals17 and the World Health Organization's Strengthening Health Systems for Treating Tobacco Dependence in Primary Care training package.18~The topics that were explored during the group sessions include:~Introduction to the Program and Reasons to Quit~Benefits of Quitting and Understanding Why We Smoke and Ways of Quitting~Withdrawal Symptoms and Social Support~Dealing with Stress and Anxiety and Coping with Depression~Assertiveness Training and Anger Management~Tobacco-Free Lifestyle and Dealing with High Risk Situations"
10158550|NCT04013724|No Intervention|Control|The control group was provided questionnaires to fill at the end of Weeks 4, 12, and 26. During the rest of the study, they continued receiving usual care, including clinical care at CSAT.
10186119|NCT03738943|Experimental|ATP, Ach, SNP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Acetylcholine: 1, 4, 8, and 16 μg/dl forearm volume/min for 3 minutes each.~Sodium Nitroprusside: 0.25, 0.5, 1, and 2 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
10158551|NCT04013542|Experimental|Treatment (nivolumab, ipilimumab, radiation therapy)|"CONCURRENT THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 8 cycles, and treatment with ipilimumab repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 1 day of starting nivolumab and ipilimumab, patients also undergo radiation therapy 5 days a week (Monday-Friday) over 6-7 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
10158552|NCT04013607|Experimental|Fiber drink|A drink high in fructo- and galacto-oligosaccharides.
10158553|NCT04013516|No Intervention|Pure Control|Respondents received New Incentives' normal program.
10158554|NCT04013516|Placebo Comparator|Reminder Call|Respondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives.
10158555|NCT04013516|Experimental|Small Additional Incentive|Respondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
10158556|NCT04013516|Experimental|Large Additional Incentive|Respondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
10158557|NCT04013412|Experimental|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
10158558|NCT04013412|No Intervention|Control|Ad libitum diet for four days immediately before surgery
10158559|NCT04013386|Active Comparator|Aprepitant/Dexamethasone Group|
10158560|NCT04013386|Active Comparator|Mertazepine /Dexamethasone Group|
10158561|NCT04013386|Active Comparator|Dexamethasone Group|
9527685|NCT03217838|Experimental|Group 3 Arm A (AZD2811 Dose 2 + Venetoclax 400 mg)|Participants with AML will receive IV infusion of AZD2811 Dose 2 on Days 1 and 4 of each 28-day cycle and venetoclax 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
10158562|NCT04013334|Experimental|MTG201 plus Nivolumab|Single arm, open-label, patients receive both MTG201 and nivolumab
10158563|NCT04013438|Experimental|FET cycle, discontinue estradiol after 6 gestational weeks|In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
10158564|NCT04013438|Active Comparator|FET cycle, continue estradiol till 12 gestational weeks|Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.
10158565|NCT04013074|Experimental|TIPS+Standard Medical Treatment|TIPS along with standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
10158566|NCT04013074|Active Comparator|Standard Medical Treatment|standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
10158567|NCT04013490|Placebo Comparator|Placebo capsule|Subject receive the Placebo product for 4 weeks.
10158568|NCT04013490|Active Comparator|Cassava dietary fiber capsule 1.5 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 1.5 g/day for 4 weeks.
10158569|NCT04013490|Active Comparator|Cassava dietary fiber capsule 3 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 3 g/day for 4 weeks.
10158570|NCT04013477|Experimental|Cohort1|"drug : DA-5207 80mg/40cm²~placebo : 40cm²"
10158571|NCT04013477|Experimental|Cohort2|"drug : DA-5207 120mg/60cm²~placebo : 60cm²"
10158572|NCT04013477|Experimental|Cohort3|"drug : DA-5207 160mg/80cm²~placebo : 80cm²"
10158573|NCT04013477|Active Comparator|Cohort4|drug : Aricept
10158574|NCT04013204|Experimental|Intervention group|Intervention group: Before the patient returns to the doctor and the prescription is issued, the EDCM system will feed back the EndoPAT test results to the responsible doctor through the automatically generated information on the doctor's mobile phone, but will not let the patient know the endothelium test results (blinded to the patient).
10158575|NCT04013204|No Intervention|Control group|Control group: The EDCM system will not report the EndoPAT test results to the responsible doctor (the doctor cannot see the final EFT results), nor can the patients know the EFT results.
10158576|NCT04013451|Experimental|Intervention Group|Participants allocated to the intervention group will participate in the intervention (acts of kindness).
10158577|NCT04013451|No Intervention|Control Group|Participants allocated to the control group will not participate in the intervention and will act as the comparison condition.
10158578|NCT04013113|Active Comparator|Standard Medical Treatment|Group A will be given standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
10158579|NCT04013113|Experimental|Hemoadsorption plus standard medical therapy|
10158580|NCT04013113|Experimental|Plasma Exchange plus standard medical therapy|
10158581|NCT04013295|Experimental|Prize-linked savings intervention|Participants in the intervention group will be assisted with opening bank accounts at the partner bank and will be eligible for monetary rewards linked to the amount they save in these project accounts. During the intervention period, information about participants' savings activities will be shared with the study team at regular intervals by the bank. Winners will learn of their prize via text message and will have their prize money deposited into their accounts. Respondents who did not win the lottery will also receive a text message, which will remind them to save.
10158582|NCT04013295|No Intervention|Control|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
10158583|NCT04013230|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic.
10158584|NCT04013230|Active Comparator|Web-COP|Usual care plus group sessions and a web-based treatment program
10158585|NCT04013425|Experimental|Ice Cream Cone Technique|Atraumatic extraction followed by addition of barrier membrane and xenograft in the socket.
10158586|NCT04013425|No Intervention|Spontaneous Healing|Spontaneous Healing after Atraumatic Extraction
10158587|NCT04013243|Active Comparator|Magnesium Sulfate group|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
10158588|NCT04013243|Placebo Comparator|Placebo group|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
10158589|NCT04013347||Early Surgery|Surgery after ≤ 42 days from the end of neoadjuvant radio-chemotherapy
10158590|NCT04013347||Late Surgery|Surgery after 43-56 days from the end of neoadjuvant radio-chemotherapy
10158591|NCT04013347||Very Late Surgery|Surgery after 57 or more days from the end of neoadjuvant radio-chemotherapy
10158592|NCT04013373||BIS home-based monitoring|
10158593|NCT04013178|Experimental|Accentuated eccentric loading + electromyostimulation|This group will undertake a supervised 12-week intervention involving accentuated eccentric loading and electromyostimulation of the knee extensors, dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
10158594|NCT04013178|Active Comparator|Traditional resistance training|This group with undertake a supervised 12-week intervention involving volume matched dynamic resistance training of the knee extensors, and dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
10158595|NCT04013308|Experimental|10 iontophoresis treatments with potassium iodide|
10158596|NCT04013308|No Intervention|10 iontophoresis treatments with placebo|
10158597|NCT04013022||Young|Healthy young subjects (age 18 - 30 )
10158598|NCT04013022||Old Sedentary|Healthy and sedentary old subjects (age 65 - 75)
10158599|NCT04013022||Old Endurance Trained|Healthy old subjects ( age 65 - 75) who participated in endurance sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
10158600|NCT04013022||Old Strength Trained|Healthy old subjects ( age 65 - 75) who participated in resistance training/sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
10158601|NCT04013256|Experimental|Dermal Exposure to Thirdhand Cigarette Smoke|Participants will wear clothing that has been exposed to cigarette smoke, for 3 hours while breathing filtered, temperature and humidity controlled air.
10158602|NCT04013256|Active Comparator|Inhalational Exposure to Thirdhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 22 hours, for 3 hours while wearing clean clothing.
10158603|NCT04013256|Active Comparator|Inhalational Exposure to Secondhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 30 minutes, for 3 hours while wearing clean clothing.
10158604|NCT04013256|Sham Comparator|Clean Air Exposure|Participants will breathe filtered, temperature and humidity controlled air while wearing clean clothing for 3 hours.
10158605|NCT04013360|Active Comparator|Breath Stacking|Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes.
10158606|NCT04013360|Active Comparator|Expiratory Positive Airway Pressure|Therapeutic technique consisting of a face mask, a one-way valve and an expiratory resistor, responsible for resistance to expiratory flow, which will determine the level of pressure in the airway.
9973568|NCT01332513|Experimental|CDBEAF sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
10158607|NCT04012983||diabetic patients with periodontitis|
10158608|NCT04012983||periodontitis patients|
10158609|NCT04012983||healthy control|
10158610|NCT04013048|Experimental|[14C]-Fluzoparib|Patients will receive single dose of [14C]- Fluzoparib.
10158611|NCT04013165|Active Comparator|Active control|Usual care of the Community Mental Health Service
10158612|NCT04013165|Experimental|Village-based intervention|Individual-based case management + group-based program
10158613|NCT04013087|Experimental|Test Formula|Feihe Stage 1 infant formula
10158614|NCT04013087|Active Comparator|Control formula|A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used)
10158615|NCT04013087|Other|Breast feeding|Breast fed of human milk
10158616|NCT04013321|Experimental|Test intervention group|Chronic insomniacs will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device.
10158617|NCT04013321|Active Comparator|Active control|Chronic insomniacs in the active control group will be tracking their sleep with the device, without feedback or coaching. But they will also undergo online cognitive behavioral therapy for insomnia (CBTi).
10158618|NCT04013321|No Intervention|Passive control|Chronic insomniacs in the passive control group will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
10158619|NCT04013321|No Intervention|Healthy control|Healthy sleepers will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
10158620|NCT04013464|Experimental|MDD and Health Control|MDD in open label
10158621|NCT04012905|Experimental|Short tapering corticosteroids|Corticosteroid taper over 28 weeks
10158622|NCT04012905|Active Comparator|Long tapering corticosteroids|Corticosteroid taper over 52 weeks
10158623|NCT04012918|Experimental|A.I. + Capeciabine|Patients will receive Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
10158624|NCT04012918|Active Comparator|A.I|Patients will receive aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor.
10158625|NCT04012879|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
10158626|NCT04012515|Experimental|CAVA Electrode Pad Appraisal Trial Arm|All trial participants are within this arm. All participants will wear the same selection of electrode pads and follow the same replacement schedules.
10158627|NCT04012645|Experimental|experimental group|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used during the surgeries.
10158628|NCT04012645|Active Comparator|control group|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
10158629|NCT04012541|Experimental|treatment group|"post-myocardial infarction management~basic periodontal examinations~active dental procedure"
10158630|NCT04012541|Active Comparator|control group|"post-myocardial infarction management~basic periodontal examinations"
10158631|NCT04012892|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
10158632|NCT04012632||cases|Early puberty cases of Han Chinese
10158633|NCT04012632||controls|Controls were matched to cases at 1:1 by age (± 3 months)
10158634|NCT04012866|Experimental|SEQ (sequential training group)|The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
10158635|NCT04012866|Experimental|DUAL (dual training group)|The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
10158636|NCT04012866|Active Comparator|CI (control intervention group)|The control intervention group (CI) will receive a control training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
10158637|NCT04012593||premenopausal women|diary
10158638|NCT04012619|Experimental|Anlotinib Hydrochloride Combined With AP|Patients receive pemetrexed (500mg/m2) with cisplatin (75mg/m2)/carboplatin (area under the curve 5) once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14 of a 21-day cycle. Anlotinib with AP will be administrated up to 4 cycles followed by maintenance treatment with anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle until disease progression or treatment intolerance.
10158639|NCT04012710|Active Comparator|Laparoscopy|Abdominal conventional laparoscopy for salpingo-oophorectomy
10158640|NCT04012710|Active Comparator|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
10158641|NCT04012554|Experimental|avoiding chest drainage tube placement after resection of lung|This group of patients underwent avoiding chest drainage tube placement after VATS of the lung.
10158642|NCT04012554|Other|indewlling chest drainage tube after resection of lung|This group of patients underwent indewlling chest drainage tube after VATS of the lung.
10158643|NCT04012489|Active Comparator|Breath Stacking|Breath stacking: patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
10158644|NCT04012489|Experimental|Air Stacking|Air stacking: the same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
10158645|NCT04012762|Active Comparator|Moderate-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 25 Hz for training frequency in moderate-intensity group.
10158646|NCT04012762|Active Comparator|Vigorous-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 40 Hz for training frequency in vigorous-intensity group.
10158647|NCT04012476|Experimental|ICG|Patients undergoing total thyroidectomy with visualization of the parathyroid glands under infrared light after intraoperative intravenous injection of 5 mg of indocyanine green
10158648|NCT04012723|Experimental|MY01 Device|"Device: MY01 Device~Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure"
10158649|NCT04012658||Patients with the genetic diagnosis of Wilson's Disease|
10158650|NCT04012658||Asymptomatic Wilson's Disease carriers|
10158651|NCT04012658||Relatives of Wilson's Disease patients or carriers|
10158652|NCT04012658||Unrelated healthy controls|
10158653|NCT04012788|Active Comparator|probiotic arm|inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L. casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day
10158654|NCT04012788|Placebo Comparator|placebo arm|placebo powder, 15 g
10158655|NCT04012684|Experimental|rTMS: left first|One-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
10158656|NCT04012684|Experimental|rTMS: right first|"One-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.~After at least two weeks, stimulations of the same parameters are given over left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well."
10158657|NCT04012684|Sham Comparator|Sham: left first|One-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
10158658|NCT04012684|Sham Comparator|Sham: right first|One-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
10158659|NCT04012775|Active Comparator|Insulin Humulin® NPH|Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
10158660|NCT04012775|Experimental|Insulin Rinsulin® NPH|Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
10158661|NCT04012749|Active Comparator|Advance directive|Messaging and advance directive distribution. All arms receive physician advance care planning education at the clinic level.
10158662|NCT04012749|Active Comparator|Advance directive and Prepare|Messaging and advance directive distribution plus introduction to the Prepare For Your Care website. All arms receive physician advance care planning education at the clinic level.
9671258|NCT05051267|Experimental|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb (Balci, 2006). It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvery Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies (Karp, 2015). In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position (Karakoç, & Türker, 2014).
9973569|NCT01332513|Experimental|DECFBA sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
10158663|NCT04012749|Active Comparator|Advance directive, Prepare and Facilitator|Messaging and advance directive distribution, introduction to the Prepare For Your Care website, plus patient engagement from a trained facilitator who also can interact with the primary care physician. All arms receive physician advance care planning education at the clinic level.
10158664|NCT04012736||Celiac disease|Celiac disease subjects enrolled after diagnosis and before gluten free diet initiation
10158665|NCT04012736||Control|Healthy controls with no chronic condition
10158666|NCT04012697|Experimental|Peer Support|Peer support services from a peer support worker in the emergency department.
10158667|NCT04012697|No Intervention|Usual care|Usual care in the emergency department.
10158668|NCT04012567|Experimental|The Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
10158669|NCT04012567|Active Comparator|The BIOSURE HA Interference Screw|The Biosure HA Interference Screw, an absorbable screw made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
10158670|NCT04012606|Experimental|TORIPALIMAB|
10158671|NCT04012606|Active Comparator|Chemotherapy|
10158672|NCT04012580|Experimental|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the program, participants will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact provided on a weekly basis.
10158673|NCT04012580|No Intervention|Treatment as usual control|Participants will not receive access to the transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) program for 12-weeks. Participants will be permitted to access community resources (e.g., support groups). After 12-weeks, participants will be offered the program although their treatment data will not be included in the current study.
10158674|NCT04012528||"the before group"|75 teenagers after scoliosis surgery before ERAS program implementation
9973570|NCT01332513|Experimental|EFDACB sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
10158675|NCT04012528||"the after group"|75 teenagers after scoliosis surgery after ERAS program implementation
10158676|NCT04012502|Active Comparator|conventional treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
9527686|NCT03217955|Experimental|CBT-SA|"Group sessions for 4 weeks, two sessions per week, 60 minutes per session, two trainers (a CBT therapist and a CBT assistant); eight participants, and;~Individual sessions (crystallizing learned skills, focus on individual needs) during 6-8 weeks, one session per week, 45 minutes per session"
10158677|NCT04012502|Experimental|Toxicities reduced treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
10158678|NCT04012450|Active Comparator|Epidural Anesthesia|Women in labor receiving epidural anesthesia
10158679|NCT04012450|Active Comparator|Spinal-epidural|Women in labor receiving spinal-epidural anesthesia
10158680|NCT04012424|Experimental|Drug (400mg Curcumin) Curcumin is apice|"Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~patients will take 400mg capsule curcumin one hour before endodontic treatment and study its effect on post endodontic pain immediately and after 8,12,24,48 hours after completion of endodontic treatment"
10158681|NCT04012424|Placebo Comparator|Starch(400mg starch) starch is sometype of carbohydrates|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
10158682|NCT04012437|Experimental|Experimental|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a mobile app and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter. The groups use of a masturbation aid device called Myhixel I from the spanish company New Wellness Concept SL.
10158683|NCT04012437|Active Comparator|Control|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a video tutorial and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter.
10158684|NCT04012333|Experimental|Intervention|Patients will receive standard care plus OLIMEL 7,6%E or if no central venous access available PeriOLIMEL 2,5%E to reach protein targets: >2.2g/kg/day
9671259|NCT05051267|Experimental|Mother's Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks (Eskandari, Keshavarz, & Jahdi, 2010). Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks (Djordjevic, 2010 ). The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it (Arabin, 2002). It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements (Campbell-Yeo, Fernandes, & Johnston, 2011).
10158685|NCT04012333|No Intervention|Standard Care|Patients will receive standard care (enteral nutrition only) to stay below the protein level: <1.2g/kg/day
10158686|NCT04012320||Pamidronate therapy|
10158687|NCT04012320||Zoledronate therapy|
10158688|NCT04012307|Other|Sequence AB|20 subjects assigned to the sequence AB will receive a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in Period 1 and a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10158689|NCT04012307|Other|Sequence BA|20 subjects assigned to the sequence BA will receive a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in Period 1 and a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10158690|NCT04011956||Retrospective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures from 2002 to Feb 28th 2019 were recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
10158691|NCT04011956||Perspective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures after Mar. 1st 2019 will be recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
10158692|NCT04012359||Bullous emphysema|Participants with known bullous emphysema will undergo lung ultrasound according to standard of care clinical practice during a regular follow-up consultation or scheduled hospitalization.
10158693|NCT04012359||Pneumothorax|Participants hospitalized in pulmonary medicine units for the treatment of a pneumothorax will undergo lung ultrasound according to standard of care clinical practice.
10158694|NCT04012112|Experimental|single-arm trials|longitudial study of the thoracolumbar brace in the neuromuscular scoliosis for 6 months
10158695|NCT04012372|Experimental|ROSA water|Ad libitum hydration with ROSA oligomineral water
10158696|NCT04012372|Active Comparator|Control water|Ad libitum hydration with other waters
10158697|NCT04011969||Colorectal cancer suspects|Patients suspected with colorectal cancer who come to our hospital to conduct colonoscopy procedure will be recruited for this study and will undergo a series of examinations.
10158698|NCT04012034|Experimental|Radiofrequency A|Treatment with radiofrequency
10158699|NCT04012034|Placebo Comparator|Placebo|Treatment with radiofrequency without energy
10158700|NCT04012073|Experimental|IPERPEEP|"End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial.~Set PEEP will be ≥5 cmH2O and chosen to ensure the maximum recruitment, with a maximum plateau pressure of 30 cmH2O. Recruitment across two adjacent PEEP levels will be normalized to the changes in applied PEEP: Recruitment/cmH2O (Rec) will be computed as the ratio of recruitment and PEEP difference.~Rec ≥ 19 ml/cmH2O will lead to the higher PEEP value.~Rec< 7 ml/cmH2O will lead to lower PEEP value.~19 ml/cmH2O >Rec≥7ml/cmH2O: the choice among two adjacent PEEP levels will be left to the attending physician.~In patients with airway closure, no PEEP lower than airway opening pressure will be tested or used (due to interferences with EELV measurement) for the whole duration of treatment. A 5-step PEEP trial will re-assess EELV at different PEEP levels every 12-24 hours,after body position or ventilator settings changes."
10158701|NCT04012073|Active Comparator|EXPRESS|PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O
10158702|NCT04012060|Active Comparator|Conventional group|All patients undergoing aortic valve replacement through full sternotomy.
10158703|NCT04012060|Experimental|Limited access group|All patients undergoing aortic valve replacement through partial upper hemisternotomy.
10158704|NCT04012060|Other|Registry group|"All patients unwilling or unable to participate in the randomized part of the trial.~All patients will undergo aortic valve replacement through median full sternotomy."
10158705|NCT04012021|Experimental|EX-VIVO SPECIMENS|"Three groups of ex-vivo surgical specimen:~Group A: native livers in transplant recipients Group B: liver grafts excluded for donation Group C: primary pancreatic cancer"
10158706|NCT04012086|Experimental|physical therapy (PT)|The physical therapy program consisted of 6 individual sessions/week, each lasting 60 minutes for 4 weeks in addition to their usual pharmacological therapy
10158707|NCT04012086|No Intervention|No physical therapy (CT)|Subjects in CT group received only standard medication.
10158708|NCT04012125|Experimental|Prospective, single-arm trial|
10158709|NCT04012385|No Intervention|Control|Subjects assigned to control group receives only a booklet including the recommendations for a correct diet by the Italian National Institute for Research on Food and Nutrition (INRAN), presently called (CRA-NUT) .
10158710|NCT04012385|Experimental|Intervention|"Subjects assigned to the intervention group will follow a nutritional pathway based on a Mediterranean diet pattern for 4 months and receive suggestions on the regular practice of physical activity, under the guide of some nutritionists, who will propose individualized diets for each subject.~All subjects of both groups will undergo urologic examination, measurement of weight, height and abdominal circumference, an interview on demographic data and lifestyle variables, and will provide blood and semen samples in fasting conditions, at the enrollment (baseline), at the end of the intervention phase (after 4 months) and at the end of follow-up (after 8 months)."
10158711|NCT04012255|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
10158712|NCT04012255|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
10158713|NCT04012268|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs. They will also accept medication treatment by professional neurologists.
10158714|NCT04012268|Other|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists.
10158715|NCT04012281||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured fractional flow reserve after PCI
10158716|NCT04012047|Active Comparator|Levcromakalim|
10158717|NCT04012047|Placebo Comparator|Saline|
10158718|NCT04012008|Active Comparator|Standard care|"Regular follow-up by internists every 3 month~May consult nephrologists case-by-case"
10158719|NCT04012008|Experimental|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
10158720|NCT04012229||Patients treated by chemotherapy for an early breast cancer|Patients (Women or Men) older than 18 years old, histologically confirmed invasive early breast cancer, treated by neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 were included.
10158721|NCT04012294|Experimental|allopurinol|150 mg daily for a month then 300 mg daily for the rest of the study (5 months)
10158722|NCT04011943|Experimental|Participants with bowel diseases|Treatment by transplantation of fecal microbiota
10158723|NCT04011943|Experimental|autologous transplantation of fecal microbiota - healthy|Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)
10158724|NCT04011943|Experimental|Both autologous and heterologous transplantation - healthy|Healthy volunteers will receive both autologous and heterologous transplantation (capsules)
10158725|NCT04011943|Placebo Comparator|placebo capsules - healthy|Healthy volunteers will receive placebo capsules
10158726|NCT04012346|Active Comparator|Active Comparator: MCI patients with real iTBS|Patients will receive real iTBS in a week-long sessions.
10158727|NCT04012346|Sham Comparator|Sham Comparator: MCI patients with sham iTBS|Patients will receive sham iTBS in a week-long sessions.
10158728|NCT04011930|Active Comparator|Experimental study|"vitamin D Generic name -cholecalciferol (40,000IU)Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks.~Drug cholecalciferol- ingredients -cholecalciferol (40,000 IU) Microcrystalline cellulose(58.1 gm),hydroxy toluene (.2mg),magnesium stearate(3mg0,gelatin capsule shell(1mg)~other name D-rise"
10158729|NCT04011930|Placebo Comparator|Experimental control|"Placebo oral capsule Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks~placebo oral capsule-ingredients-microcrystalline cellulose,butylated hydroxy toluene~,magnesium stearate~other name D-rise"
9977851|NCT01365832|Experimental|Sleep apnea|"Participants with Obstructive Sleep Apnea (OSA).This arm will undergo a pre-treatment blood draw, six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw 3 and 6 months later.~Intervention: Procedure: Continuous Positive Airway Pressure (CPAP)"
10158730|NCT04011865|Active Comparator|Robotic-assisted surgery|
10158731|NCT04011865|Sham Comparator|Laparoscopic surgery|
10158732|NCT04011917||Caseload group|
10158733|NCT04011917||Prediction group|
10158734|NCT04011813||"Control arm, H-"|semen treated without hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
10158735|NCT04011813||"Experimental arm, H+"|semen treated with a 50mM hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
10158736|NCT04011553|Experimental|Virtual group|This virtual realtiy was implemented with MarVAJED® (Marmara Visual Auditory Joint Education Device) system which was developed by Marmara University, Department of Physiotherapy and Rehabilitation, Istanbul,Turkey. MarVAJED® is a system that evaulates the range of motion of the joints, analyzes the sensation of joint position, provides biofeedback support to increase joint control and the same time allows exercises to be controlled. This device analyzes the joint motion with the help of small sensors (Figure 2). The obtained data transfers to your mobile phone, to the tablet or to your personal computer. It stores the data by downloading it to the central server via internet for storage.
10158737|NCT04011553|Active Comparator|Control group|Conventional physiotherapy consists of electrotherapy and exercise programs. Hotpack or coldpack, therapeutic ultrasound (US) and conventional TENS were applied as electrotherapy program.
10158738|NCT04011657|Experimental|Voluntary CDSS|Voluntary use of computerized decision support with prospective review and feedback
10158739|NCT04011657|No Intervention|Compulsory CDSS|Compulsory use of computerized decision support with prospective review and feedback
10158740|NCT04011566||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
10158741|NCT04011904|Experimental|Traditional Inuit Diet|This will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%).
10158742|NCT04011904|Placebo Comparator|Westernized Diet|This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%).
10158743|NCT04011514||Baseline period|Usual care. Stroke patients admitted to the ED during the 3-month baseline inclusion period.
10158744|NCT04011514||Intervention period|Intervention: 2 month implementation period of specialized stroke nurses allocated to ED for nurse specific treatment of stroke patients specific observations and care
10158745|NCT04011579|Experimental|MSFIT|The MSFIT group will self-manage Pilates exercises at-home through a tool based on XBox Kinect for 12 weeks, performing at least 3 sessions/week for a total of 30 minutes of exercises for each session(also distributed during the day with a minimum slot of 10 minutes). No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
10158746|NCT04011579|No Intervention|CTRL|No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
10186120|NCT03738943|Experimental|ATP, ADP, AMP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine Diphosphate: 20, 40, 80, and 160 μg/dl forearm volume/min for 3 minutes each.~Adenosine Monophosphate: 25, 50, 100, and 200 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
10186121|NCT03738943|Experimental|ATP, UTP, Adenosine|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Uridine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine: 3.125, 6.25, 12.5, and 25 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
10186122|NCT03738930|No Intervention|normal follow-up group|normal follow-up in ACS patients after PCI
10186123|NCT03738930|Experimental|AI based mHealth system follow-up group|AI based mHealth system follow-up in ACS patients after PCI. ACS patients in this group will receive message to take more notice to bleeding events.
10186124|NCT03738917|Active Comparator|Dextromethorphan|Usual clinical practice + dextromethorphan (15 milligrams unit), one 15 mg-tablet t.i.d. up to a maximum of 14 days.
10186125|NCT03738917|Active Comparator|Ipratropium|Usual clinical practice + ipratropium bromide 20Micrograms Inhaler each puff), 2 puffs t.i.d. up to a maximum of 14 days.
10186126|NCT03738917|Active Comparator|Honey|Usual clinical practice + Honey 30 g (full tablespoon) t.i.d. up to a maximum of 14 days. Patients will be given two 750 milligram bottles of wildflower honey (the most frequent type of honey used in our country) and patients will be recommended to add the honey to a cup of lemon or thyme juice, milk herbal tea, yogurt, as a hot toddy, etc.
10186127|NCT03738917|Placebo Comparator|Usual clinical practice|Usual care.
10186128|NCT03738891|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen.
9973571|NCT01332513|Experimental|FAEBDC sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
9973572|NCT01332526||Patients with BMI> 30 and metabolic syndrome ( ATP III).|Patients with BMI> 30 and metabolic syndrome ( ATP III).
9977852|NCT01365858|Experimental|Virtual reality-based cognitive training|
10158747|NCT04011644|Active Comparator|Self monitored|"Patients of this group will continue receiving regular care from their physician with no interference from the two experimental groups. Patient subjects will download the app on their Android or Apple smart phone that will direct them to external information hosted on the internet that may help reduce their drinking (e.g., NIAAA resources). For the first 12 weeks, once a week patients can set a weekly goal related to their alcohol use or other health related behaviors (e.g., I will only drink on Friday this week.). At the end of the week subjects will be prompted to take a weekly survey, which will include questions such as a variation of the brief alcohol monitor (BAM) and timeline followback. Patients will then receive feedback on the amount of drinks they had compared to their goal. Then the patient will set a new goal for the following week. Patients will complete quarterly surveys on the A-CHESS app to assess study outcomes."
10158748|NCT04011644|Experimental|Peer supported|Patients will be asked to take the same surveys and have the access to the same information as the self-monitoring group. Patient subjects in this group will have access to discussion boards where they can talk to one another and have the ability to share and see stories of other patients. The only involvement of someone other than patients themselves in the peer-supported group will be by a sponsor (i.e., a dedicated user from the area with a sustained history of successful alcohol reduction). The sponsor will participate in discussion groups and encourage use of the system. Patient-reported feedback will be presented directly to the patient.
10158749|NCT04011644|Experimental|Clinically integrated|Patients in the clinically integrated group will receive the same intervention as the peer-supported group aside from three differences: 1) patients have the option to share selected elements of their app data with the University of Wisconsin (UW) Health health coach, 2) the health coach will replace the role of the sponsor in the peer-support group, and 3) patients will have the option to attend an initial 60- to 90-minute and two 30-minute follow-up consultations with the health coach in-person, via phone, or via video chat.
10158750|NCT04011670|Active Comparator|Caffeine group|Participants will receive a caffeine tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
10158751|NCT04011670|Placebo Comparator|Placebo group|Participants will receive a placebo tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
10158752|NCT04011774|Experimental|PLANI-REV|Persons with schizophrenia who will benefit from the fifteen weekly sessions of PLANI-REV group program
10158753|NCT04011774|Active Comparator|RELAXATION|Persons with schizophrenia who will benefit from a non cognitive stimulation, namely RELAXATION, in a day-care clinic or day-care therapeutic activities center during fifteen weekly sessions. This activity will be 15 groups sessions of relaxation.
10158754|NCT04011761|Active Comparator|Experimental Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
10158755|NCT04011761|No Intervention|Control Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the control arm will receive treatment prescribed by pediatricians.
10158756|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2A|Subjects who carried out 3 attempts at Visit 1, failed to achieve nebulization success and subsequently were included in Test Arm 2A for Visit 2
10158757|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2B|Subjects who carried out 3 attempts at Visit 1, achieved nebulization success and were subsequently included in Test Arm 2B for Visit 2
10158758|NCT04011748|Experimental|Haire regrowth by SCE|AA subjects will receive Stem Cell Educator therapy combined with oral minoxidil. Hair regrowth will be evaluated during one-year follow-up studies.
10158759|NCT04011748|Experimental|Minoxidil therapy|Control subjects will receive treatment with topical 5% minoxidil
10158760|NCT04011800|Active Comparator|Catheter ablation|Patients will undergo catheter ablation of atrial fibrillation.
10158761|NCT04011800|Experimental|Risk factor modification|Patiemt will undergo risk factor intervention and antiarrhythmic drugs
10158762|NCT04011501|Experimental|Continuous unilateral ESP block|Erector spine block and catheter placement will be performed for continuous analgesia on this group of patients undergoing minimally invasive cardiac surgery. Initially a volume of 20 ml of Levobupivacaine 0.25% will be administered and subsequently a 22G catheter will be introduced and fixed 10-12 cm from the skin. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
10158763|NCT04011488|No Intervention|Standard patient information data sheet|
10158764|NCT04011488|Experimental|SDM Tool|A simple, one-page tool that provides a framework for the patient discussion, which improves the consistency of the patient-provider communication. This SDM can also be customized to a specific patient based on gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).
10158765|NCT04011527||Patients with Coronary Artery Disease|Patients with Coronary Artery Disease undergoing a Rotational Atherectomy in Coronary Lesion/s
10158766|NCT04011462|Experimental|Prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
10158767|NCT04011462|Experimental|Prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
10158768|NCT04011462|No Intervention|Standard care|warming with cotton sheet and blanket for 20 minutes.
10158769|NCT04011878|Experimental|isolated trabeculodysgensis|etiology of primary congenital glaucoma
10158770|NCT04011475||Subjects with Tiotropium and Olodaterol|
10158771|NCT04011475||Subjects treated with other LABA/LAMA therapy|
10158772|NCT04011475||Subjects treated with LAMA therapy|
10158773|NCT04011449|Experimental|Device Implantation|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
9977853|NCT01365858|Active Comparator|Cognitive rehabilitation (without extra computer training)|
10158774|NCT04011345|Other|Folic Acid Supplement [Phase 1]|Phase 1: Folic acid supplement (1 mg per day) for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Placebo for 12 weeks
10158775|NCT04011345|Other|Placebo [Phase 1]|Phase 1: Placebo for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Folic acid supplement (1 mg per day) for 12 weeks
10158776|NCT04011371|Experimental|Cyanoacrylate closure|Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.
10158777|NCT04011319|No Intervention|convention culture|Each droplet separate culturing an individual embryo.
10158778|NCT04011319|Experimental|group culture|Embryos were cultured in the same droplet.
10158779|NCT04011280|Experimental|Low Dose Varenicline|0.5 mg twice daily with 0.5 mg daily titration over one full week
10158780|NCT04011280|Active Comparator|Standard Dose Varenicline|1.0 mg twice daily with standard titration
10158781|NCT04011332|Experimental|Intervention Group|
10158782|NCT04011332|No Intervention|Control Group|
10158783|NCT04011423|Experimental|Unstable shoes|Wearing unstable shoes during the whole-body vibration training
10158784|NCT04011423|Active Comparator|Stable shoes|Wearing stable shoes during the whole-body vibration training
10158785|NCT04011124|Experimental|Rifampicin + Fluzoparib|
10158786|NCT04010955||Edoxaban Monotherapy|"edoxaban monotherapy without additional antiplatelet therapy in long term stroke prevention.~However, transient additional antiplatelet therapy will be allowed at the discretion of duty physicians."
10158787|NCT04010955||Edoxaban and antiplatelet combination|edoxaban plus additional antiplatelet therapy in long term stroke prevention. However, transient cessation of antiplatelet therapy will be allowed at the discretion of duty physicians.
10158788|NCT04011020|Experimental|Treatment of T1D with Stem Cell Educator therapy|Recruited T1D subjects will receive one treatment with SCE therapy.
10158789|NCT04011020|Experimental|Conventional insulin therapy|Control group will receive conventional insulin therapy.
10158790|NCT04011085||Group1|Patients currently undergoing treatment for early breast cancer (either targeted HER2 therapy and chemotherapy OR targeted HER therapy alone)
10158791|NCT04011085||Group2|Patients with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving locoregional treatment, chemotherapy or targeted HER2 therapy; patients may still be receiving hormone therapy)
10158792|NCT04011085||Group3|Patients receiving treatment for metastatic breast cancer
10158793|NCT04011202|Experimental|VR Group|Receives the VR protocol
10158794|NCT04011202|No Intervention|Control Group|Receives regular care
10158795|NCT04011059|Placebo Comparator|Comparison/control group|Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.
10158796|NCT04011059|Active Comparator|Experimental group|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed.
10158797|NCT04011410|Experimental|Hydroxychloroquine|"Hydroxychloroquine (HCQ)~DOSAGE FORM: 200 mg tablet, oral route~DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg~FREQUENCY: HCQ is taken twice daily (morning and night) with food.~DURACTION OF HCQ: 90-days"
10158798|NCT04011397|Experimental|Intervention group|Exercise intervention (reduced-exertion, high-intensity interval training) alongside normal treatment. [low recruitment prohibited control arm]
10158799|NCT04011293|Experimental|A|Single dose of CNCT19
10158800|NCT04011215|Experimental|wool-first (wool X standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing
10158801|NCT04011215|Active Comparator|standard-first (standard X wool)|standard clothing to be worn for 6 weeks followed by 6 weeks of superfine merino wool clothing
10158802|NCT04010994|Other|rtACS|repetitive transorbital ACS
10158803|NCT04011241|Experimental|Reference - BI 1323495 alone|Reference followed by Test
10158804|NCT04011241|Experimental|Test - BI 1323495 + Itraconazole|
10158805|NCT04011098|Active Comparator|Control Group (No Additional Epidural Fentanyl Bolus)|The Control group will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
10158806|NCT04011098|Experimental|Fentanyl bolus group|The Fentanyl bolus group will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
10158807|NCT04010968|Active Comparator|FCR|"FCR :~rituximab (R): 375 mg/m² IV D1 cycle 1 and 500 mg/m² IV D1 cycles 2 to 6.~fludarabine (F): 40 mg/m² orally, D2 to D4 - cycles 1 to 6.~cyclophosphamide (C): 250 mg/m² orally, D2 to D4 - cycles 1 to 6."
10158808|NCT04010968|Experimental|venetoclax and ibrutinib (I+VEN)|"ibrutinib: 420 mg/d orally, continuously from Month 1 to the end of treatment, either Month 15 or Month 27~venetoclax: stepwise weekly dose ramp-up beginning at Month 4 from a starting dose of 20 mg/d to the final dose of 400 mg/d (20, 50, 100, 200 and then 400 mg) over a 5 weeks, and then 400 mg/d continuously from Month 5 to the end of treatment, either Month 15 or Month 27."
10158809|NCT04011267|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in the SOPeD software three times/week at home via web-software. In the follow-up period, patients will follow the same schedule set by the project till the end of the study.
10158810|NCT04011267|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
10158811|NCT04011254||Healthy Control|Healthy control
10158812|NCT04011254||Haemodialysis %IDWG >4%|Patient on regular haemodialysis with average IDWG >4%
10158813|NCT04011254||Haemodialysis %IDWG <4%|Patient on regular haemodialysis with average IDWG <4%
10158814|NCT04011228||Type 2 diabetic patients|
10158815|NCT04011228||Prediabetic patients|
10158816|NCT04011228||Women with gestational diabetes|
10158817|NCT04011228||Healthy control subjects|
10158818|NCT04011228||Pregnant women without gestational diabetes|
10158819|NCT04011384|No Intervention|Control Group|Participants in this arm will view the typical web-based ordering system platform (usual care group).
10158820|NCT04011384|Experimental|Behavioral Economic Intervention Group|Participants in this arm will be exposed to the web-based ordering system with multiple behavioral economic interventions applied, including healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
10158821|NCT04011163|Experimental|VPIA analgesia|VPIA pump will be connected to patients after surgery for up to three days. The vital signs (oxygen saturation, respiratory rate, heart rate) will be closely monitored when patients are using VPIA pump. Intravenous medication (morphine) will be given intravenously.
10158822|NCT04011306|Experimental|Lumina24 BLU|Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site.
10158823|NCT04011033|Experimental|TACE+iNKT for unresectable HCC|TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TACE will be performed at 0th and 4th week. 5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
10158824|NCT04011033|Other|TACE for unresectable HCC|TACE will be conducted at 0th week and 4th week.
10158825|NCT04011137|No Intervention|Control|No exercise - 30-min of rest
10158826|NCT04011137|Experimental|High-intensity interval training|8 x 60 s intervals at 70% peak power output (intersperesed with 60 s recovery intervals at 10% peak power output)
10158827|NCT04011137|Experimental|Moderate-intensity continous training|25 min at 45% peak power output
10158828|NCT04010929|Experimental|Laser+MTA group|before the MTA condensation, Er, Cr: YSGG laser was applied to the exposure area
10158829|NCT04010929|Active Comparator|MTA group|MTA was applied to the exposed area
10158830|NCT04011007|Active Comparator|vitrectomy without ILM peeling|vitrectomy without ILM peeling
10158831|NCT04011007|Active Comparator|vitrectomy with inverted ILM flap technique|vitrectomy with inverted ILM flap technique
10158832|NCT04010942|Active Comparator|Vitamin D|"Group V : number of 60 women will receive 100000 IU Cholecalciferol Intramuscular every month + 2000 mg Metformin (oral: 2 tablets 1000 per day) for 5 months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day,from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
10158833|NCT04010942|Placebo Comparator|Control|"Group C: number of 60 patients will receive Metformin 2000mg (oral: 2 tablets1000 mg per day) for months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day, from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
10158834|NCT04010916|Active Comparator|Group Pre = preoperatively before inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
10158835|NCT04010916|Active Comparator|Group Pre-T = preoperatively after inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
10158836|NCT04010916|Active Comparator|Group Post = Postoperatively group|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
10158837|NCT04010903|Experimental|HEALTHY SUBJECTS|SUBJECTS WITH BMI<27 and HOMA<4
10158838|NCT04010903|Experimental|OVERWEIGHT NON INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA<4
10158839|NCT04010903|Experimental|OVERWEIGHT INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA>4
10158840|NCT04010513|Experimental|Hypnosis|
10158841|NCT04010513|Active Comparator|Standard of Care|
10158842|NCT04010799|Experimental|CHF6333|"CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).~CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days."
10158843|NCT04010799|Placebo Comparator|CHF6333 Placebo|"Part I (SAD): Single dose of placebo matching CHF6333 at each period~Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days"
10158844|NCT04010617|Experimental|Pharyngeal Electrical Stimulation|Orotracheal intubated patients at high risk of extubation failure will receive open-label PES
10158845|NCT04010487||Endometrial carcinoma arising in adenomyosis|Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
10158846|NCT04010487||Adenomyosis without malignancy|Patients pathologically diagnosed with adenomyosis
10158847|NCT04010864||SHARP-2|ShangHai At Risk for Psychosis-Phase 2
10158848|NCT04010656|Experimental|PVR-based home self-catheterization|Patients will learn to self-catheterize preoperatively prior to urogynecology surgery requiring trial of void. First post-operative void will be used to collect basic information about voiding function. All participants will leave the hospital and self-catheterize until they achieve two sequential voids with post-void residual (PVR) less than half the volume voided. The cases of urinary retention captured with abnormal PVR will be used to compare the diagnostic accuracy of several commonly-used, pre-defined parameters for trial of void.
10158849|NCT04010526|Experimental|treatment|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of autologous ADIpose will be performed
9973573|NCT01332526||Patient with BMI> 30 without metabolic syndrome.|Patient with BMI> 30 without metabolic syndrome.
10158850|NCT04010526|Placebo Comparator|placebo|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of placebo will be performed
10158851|NCT04010604||SMA type I|
10158852|NCT04010604||SMA type II|
10158853|NCT04010604||SMA type III|
10158854|NCT04010604||Asymptomatic carriers of SMA|
10158855|NCT04010604||Relatives of SMA patients and carriers|
10158856|NCT04010604||Unrelated healthy controls|
10158857|NCT04010643|Active Comparator|online cognitive behavioural therapy (oCBT)|"20 hours of online engagement with the oCBT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of of the MoodGym program, followed by 2 hours of practical online CBT homework. To equate time and type of engagement spent in doing oCBT and oCBT+NCRT, 1 final hour per week is dedicated to completing online puzzles."
10158858|NCT04010643|Experimental|online neurocognitively-enhanced CBT (oCBT+oNCRT)|"20 hours of online engagement with the oCBT+oNCRT programme over 5 weeks, distributed as follows.~Each week, the participants complete 1 hour of the MoodGym program, followed by 1 hour of practical online CBT homework & 3 hours of the online NCRT programme Cognifit targeting attention, memory, and planning ability."
10158859|NCT04010708||IOMUM|Pregnant women
10158860|NCT04010760||PE confirmed|Patients admitted with confirmed pulmonary embolism.
10158861|NCT04010760||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
10158862|NCT04010760||Controls|Healthy controls same gender and age (within af range of 10 years) as PE patients
10158863|NCT04010838|No Intervention|Conventional treatment|
10158864|NCT04010838|Experimental|Spinal cord stimulation and conventional treatment|
10158865|NCT04010890|Experimental|Culturally adapted CBT|Ca_CBT will be delivered to the experimental group using the newly developed manual . The intervention will be delivered over 8-12 sessions. The Control group will receive standard CBT
10158866|NCT04010890|Active Comparator|Standard CBT|Participants in this group will receive standard CBT
10158867|NCT04010552|Experimental|NALIRINOX treatment|Patients will be treated with NALIRINOX, a combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin. Treatment regimen will consist of 8 cycles of neoadjuvant NALIRINOX prior to surgery and trial duration is expected to be 24 months.
10158868|NCT04010500|Experimental|Rugby Players|
10158869|NCT04010669|Active Comparator|Study group|The study group includes participants who will receive somatostatin postoperatively (after liver resection).
10158870|NCT04010669|Placebo Comparator|Control group|The control group includes participants who will receive placebo (a 24 hours infusion of 1000ml Normal Saline solution 0.9%) postoperatively (after liver resection).
10158871|NCT04010591||UDS group|All enrolled patients with urodynamic study
10158872|NCT04010877|Experimental|Multiple CAR T cells to treat AML|Multiple CAR T cells to treat AML
10158873|NCT04010734|Active Comparator|peroral Cholangioscopy examination|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to the peroral Cholangioscopy examination with both visual and tissue diagnosis. The visual diagnosis is based on morphological and vascular patterns (presence or not of nodular or papilary masses, irregularity of the surface, morphology of the vessels and the fragility of mucosa). The tissue diagnosis consists on cytopathological evaluation after tissue sampling using minuature biopsy forceps (SpyBite). During this, 5-8 samples are taken under visual control, from different parts of the lesion."
10158874|NCT04010734|Active Comparator|ERCP examination with sampling|"Patient with suspected malignant biliary stricture (SMBS) is allowed:~to ERCP examination with both sampling by brushing and forceps biopsy, with subsequent pathological evaluation and an additional fluorescence in situ hybridization(FISH) examination of the specimens.~ERCP (Endoscopic retrograde cholangiopancreatography) is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Brushing and endocanal forceps biopsies were the most used techniques, both with different specificity and sensitivity. It was demonstrated that Fluorescence in Situ Hybridization (FISH) improved the diagnostic yield of routine cytology. That is the reason why the investigators will combine FISH with the sampling methods to maximize the chance to make early diagnosis of the biliary stenosis."
10158875|NCT04010578|Experimental|MK-7 and vitamin D3 supplementation|Patients will receive a daily MK-7 and vitamin D3 supplementation for 3 months.
10158876|NCT04010578|Placebo Comparator|Placebo|Patients will receive a daily placebo for 3 months.
10158877|NCT04010786|Experimental|Active treatment NNC0247-0829|Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment
9694855|NCT04784572|Other|First injection delay and second injection delay|"During the first injection, the patient will make 3 scales: END, EVAF and insight and there will be an assessment of induration, redness and swelling done with nurses.~During the second injection, the patient will perform the END and EVAF scale and then follow up with a maintenance"
10158878|NCT04010786|Placebo Comparator|Placebo|In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo
10158879|NCT04010383||normal visual field subjects|"Cataract yes or no~Age range 40 - 80 years~normal visual field (MD: < +2 dB)~Refractive error within ±5 dpt. spherical equivalent~Astigmatism of < -3 dpt.~Visual acuity of ≥0.3 logMar (decimal ≥0.5)~Experience in perimetry (history of at least one perimetry examination)~False positive or negative errors each less than 20% in each examination"
10158880|NCT04010383||Glaucomatous subjects|"Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma~Early to moderate visual field loss (MD: +2 to +12 dB)~Refractive error within ±5 dpt. spherical equivalent~Astigmatism of < -3 dpt.~Visual acuity of ≥0.3 logMar (decimal ≥0.5)~Experience in perimetry (history of at least one perimetry examination)~False positive or negative errors each less than 20% in each examination~Cataract yes or no~Age range 40 - 80 years"
10158881|NCT04010409||ASD Group|Autism spectrum disorder participants, no intervention
10158882|NCT04010409||TD Group|Typically developmental controls,no intervention
10158883|NCT04010422||ASD group|"Inclusion Criteria:~Having a clinical diagnosis of autism spectrum disorder~Aged over 20 years; able to read and sign an informed consent form.~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~Unable to cooperate with the examinations.~Younger than 20 years old"
9671260|NCT05051267|Experimental|Mothers Embrace and White Noise Applied Group|One minute after the procedure, the baby's pain score will be evaluated. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the white noise will continue to be listened to. The crying time of the baby after the procedure will be noted. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to pre-procedural basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
10158884|NCT04010422||TD Group|"Inclusion Criteria:~Aged over 20 years; able to read and sign an informed consent form.~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.~Exclusion Criteria:~Unable to cooperate with the examinations.~Younger than 20 years old.~Having a clinical diagnosis of autism spectrum disorder"
10158885|NCT04010227|Experimental|Acceptance and Commitment Therapy|Patients and caregivers in the ACT arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
10158886|NCT04010227|Active Comparator|Education/Support|Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
10158887|NCT04010110||Patients on hydroxychloroquine|A data collection sheet was used to collect patient's information. All patients underwent a complete ophthalmic examination including assessment of visual acuity, anterior segment examination looking for corneal verticillata and a dilated fundus examination looking for retinal pigment epithelium (RPE) depigmentation either in a para-foveal or extra-macular distribution within the retina. Ancillary tests were done which included: visual field testing (10-2), spectral domain ocular coherence tomography (SDOCT). Fundus auto-fluorescence and mf-ERG were done if further ancillary testing was needed in doubtful cases or to confirm findings.
10158888|NCT04010084|Placebo Comparator|Control group|
10158889|NCT04010084|Active Comparator|Laser group|
10158890|NCT04010448|Experimental|TV P2-VP8|
10158891|NCT04010448|Active Comparator|Rotarix®|
10158892|NCT04010006|Experimental|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
10158893|NCT04010006|Active Comparator|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
10158894|NCT04010162||Group-1: King's College Hospital|Doctors in King's College Hospital, London, The United Kingdom (Excluding Urology and Gynecology)
10158895|NCT04010162||Group-2: Uludag University Hospital|Doctors in Uludag University Hospital, Bursa, Turkey (Excluding Urology and Gynecology)
10158896|NCT04010162||Group-3: The United States|Doctors from The United States (Excluding Urology and Gynecology)
10158897|NCT04010162||Group-4: The World|Doctors from all over the world (Excluding Urology and Gynecology)
10158898|NCT04010253|Experimental|SIMEOX|
10158899|NCT04010253|Active Comparator|Autogenic Drainage|
10158900|NCT04010240||Retrospective cohort|For eligible subject, tumor material will be tested by immunohistochemistry (Pan-Trk ICH testing with mAb EPR17341).
10158901|NCT04010149|Experimental|Active tDCS|During cognitive training in the first 2 weeks, participants will also received brain stimulation. The investigators will use a total current intensity of 2mA for 20 minutes, preceded by 30 seconds ramping up and followed by 30 seconds ramping down (total stimulation time = 21s).
10158902|NCT04010149|Sham Comparator|SHAM tDCS|During sham stimulation, concurrent with the cognitive training, The investigators will use the same setup as in the active condition but after ramping up, the current will be brought back to zero and the process repeated 30 seconds before the end of the 21 minutes time interval (total sham stimulation time = 21s).
10158903|NCT04010019|Experimental|Enhanced Facebook Condition|The enhanced Facebook group will be moderated by clinicians and offer psychosocial pain management techniques.
10158904|NCT04010019|Active Comparator|Control Facebook Condition|In the control condition, there will be no outside intervention; rather, the investigators will instruct participants to offer mutual support for the duration of the group and will not comment further.
10158905|NCT04010331|Experimental|Nokyong Mixture Extract(CME-PI) group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 1 g/day)
10158906|NCT04010331|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 0 g/day)
10158907|NCT04010136|No Intervention|Control group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will be given no intervention
10158908|NCT04010136|Experimental|Identification tool group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive access to the Identification tool Supportive and Palliative Care Indicators Tool (SPICT-PT) with a brief training on how to use it.
10158909|NCT04010136|Experimental|Standard Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training according to the Center Healthcare Administrative Region standard model of training.
10158910|NCT04010136|Experimental|Clinical cases based Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training using a clinical cases based model.
10158911|NCT04010318||Corrected group|The patients in which the PVI will corrected by fluid to level below 15
9694856|NCT04785040||1|
10158912|NCT04010318||Uncorrected group|Patients in which intravenous fluid administration didn't result any change in PVI or changed but still higher than 15
10158913|NCT04010279|Active Comparator|spontaneous breathing|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the spontaneous position.
10158914|NCT04010279|Active Comparator|spontaneous breathing with APL 5 cmH2O|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the 5 cmH2O position.
10158915|NCT04010279|Active Comparator|CPAP 5cmH2O PEEP|volunteers will breath via an anesthesia face mask spontaneously on the CPAP mode of the anesthesia workstation with 5 cmH2O PEEP.
10158916|NCT04010292|Experimental|Patient education card|
10158917|NCT04010292|No Intervention|Control|
10158918|NCT04009980|Experimental|OMK2 group|Patients receiving topical administration of OMk2 ophthalmic solution for 36 months three times/day
10158919|NCT04009980|Placebo Comparator|Placebo group|Patients receiving receiving only the excipients of OMk2 (placebo) for 36 months three times/day
10158920|NCT04010305|Placebo Comparator|Placebo|Sublingual Film with no active drug; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
10158921|NCT04010305|Experimental|20 micrograms|Sublingual Film containing 20 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
10158922|NCT04010305|Experimental|60 micrograms|Sublingual Film containing 60 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
10158923|NCT04010305|Experimental|120 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501; single administration of 2 films with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
10158924|NCT04010305|Experimental|180 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501.
10158925|NCT04010032|Experimental|PIEB (Programmed intermittent epidural bolus)|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection)
10158926|NCT04010032|Active Comparator|CEI (Continuous epidural infusion)|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device
10158927|NCT04010071|Experimental|axitinib plus toripalimab|"Axitinib (Inlyta, Pfizer Inc.) is a novel oral angiogenesis inhibitor that selectively targets vascular endothelial growth factor (VEGFR) 1, 2 and 3.~Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody."
10158928|NCT04009993|Experimental|A-BIRTHPERFORM digital tool|interactive partogram that maternity care professionals of the experimental group use, in interactive and device will guide the professional thought the NICE guidelines on labour care
10158929|NCT04009993|No Intervention|control group with conventional partogram use|Conventional care in each participant hospital, with conventional partogram in each centre
10158930|NCT04009954||Delayed transit|CRC patients with delayed gut transit recovery( first time defecation >3 day )
9827683|NCT02465034|Active Comparator|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
10158931|NCT04009954||Normal transit|CRC patients with normal gut transit recovery( first time defecation <=3 day )
10158932|NCT04009759|Active Comparator|Morphine|"Morphine group (M) (n=80), where patients will be treated with i.v. injection of Morphine 2 mg/ml - 5 ml - 10 mg Epidural. The treatment will be given during CPR as soon as possible."
10158933|NCT04009759|Active Comparator|Ketamine|"Ketamine (K) group (n=80), where patients will be treated with i.v. injection of S-Ketamine 10 mg/ml - 5 ml - 50 mg Ketamin Abcur. The treatment will be given during CPR as soon as possible."
10158934|NCT04009759|Placebo Comparator|Saline|"Control group (n=80), where patients will be treated with i.v. 5 ml of NaCl 0,9% B. Braun. The treatment will be given during CPR as soon as possible."
10158935|NCT04009915|Experimental|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer
10158936|NCT04009915|Active Comparator|open surgery|Patients undergo a standard open operation for stage II-III lung cancer
10158937|NCT04009655|Experimental|music therapy|The infant will receive music therapy over 3 consecutive days and will obtain standard care as usual
10158938|NCT04009655|No Intervention|control|The infant does not receive any sound emission because the headphone will be turned off and will obtain standard care as experimental
10158939|NCT04009538|Experimental|COPD patients participated PR program|COPD patients participated first and second PR program
10158940|NCT04009590|Experimental|GROUP I (Quit4Health)|Participants utilize Quit4Health intervention that includes interactive features, coping strategies and games related to cigarettes and other tobacco products for 1 month.
10158941|NCT04009590|Active Comparator|Group II (educational booklet)|Participants read an educational booklet about cigarettes and other tobacco products for 1 month.
10158942|NCT04009772|Active Comparator|"Cefepime , Maxipime® 1 gm"|"Patient will receive Cefepime ,Maxipime® 1 gm IV during cesarean section just before skin incision"
10158943|NCT04009772|Active Comparator|"Cefuroxime, Zinnat® 1gm plus metronidazoleFlagyl® 500"|"Patient will receive Cefuroxime, Zinnat® 1gm ,and metronidazoleFlagyl® 500 IV; just before skin incision for emergency cesarean section"
10186129|NCT03738878|Active Comparator|valsartan then LCZ696|"After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
10186130|NCT03738878|Active Comparator|LCZ696 then valsartan|"After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
10186131|NCT03738839|Experimental|Direct Bonding|On the individual teeth Conventional bracket placement Use conventional composite
10186132|NCT03738839|Experimental|Indirect bonding|On the dental stone models Indirect bracket placement Use flowable composite Use transfer trays
10186133|NCT03738839|Active Comparator|Quantitative Light-Induced Fluorescence|Use special device and software Determination of the number and effect of caries
10158944|NCT04009863|Active Comparator|HIFU on NMNG|The patients with non-toxic multinodular goiter are assigned to have high intensity focused ultrasound treatment.
10158945|NCT04009863|Active Comparator|RAI on NMNG|The patients with non-toxic multinodular goiter are assigned to have radioactive iodine (i131) treatment.
10158946|NCT04009941|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
10158947|NCT04009889|Active Comparator|verum|probiotic bland with 5 different lactobacilli
10158948|NCT04009889|Placebo Comparator|placebo|Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
10158949|NCT04009811|Experimental|Suersen obturator then membraneous obturator|
10158950|NCT04009811|Experimental|Membraneous obturator then Suersen obturator|
10158951|NCT04009616|Experimental|Aloe Vera mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving aloe vera mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying aloe vera mouthwash for 5 days rinsing phase."
10158952|NCT04009616|Experimental|Chlorhexidine mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving chlorhexidine mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying chlorhexidine mouthwash for 5 days rinsing phase."
10158953|NCT04009616|Placebo Comparator|Placebo mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving placebo mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying placebo mouthwash for 5 days rinsing phase."
10158954|NCT04009876|Experimental|Chemotherapy + Surgery|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection
10158955|NCT04009876|Experimental|Chemotherapy + Watch-and-wait|"Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and watch-and-wait surveillance protocol."
10158956|NCT04009694|Experimental|Pelvic Floor Muscle Training|"Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist.~Participants will be assessed at weeks 0 / 4 / 10 & 16 and the outcome measures will be recorded at week 0 & week 16.~During each assessment, participants will be educated regarding the anatomy of pelvic organ prolapses and the pelvic floor muscles. They will be taught how to contract their pelvic floor, offered a vaginal examination, given a personalised pelvic floor muscle training programme (including the Knack) - up to a ten second hold long contractions (x 10 repitations) and up to 10 quick contractions. They will also be taught a sub max contraction for up to 30 seconds, offered lifestyle management advice including avoiding heavy lifting or straining. A leaflet explaining the aforementioned information will also be provided at the initial assessment."
10158957|NCT04009564|Experimental|Date seeds filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 45 g of date seeds coffee in 280 ml of boiled water, coffee flavour and brown food colouring ( made using a filter coffee machine). it will be served in a paper cup with lid
10158958|NCT04009564|Experimental|Normal filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 6 g of coffee in 280 ml of boiled water (made using a filter coffee machine) it will be served in a paper cup with lid
10158959|NCT04009564|Placebo Comparator|Placebo|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 280 of boiled water, coffee flavour and brown food colouring it will be served in a paper cup with lid
10158960|NCT04009850|Experimental|Menthol e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a menthol flavored e-cigarette
10158961|NCT04009850|Experimental|Tobacco e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a tobacco flavored e-cigarette
10158962|NCT04009642||Type 2 Diabetes|
10158963|NCT04009642||Non Diabetic|
10158964|NCT04009928|Experimental|Active followed by sham stimulation|2 weeks of active stimulation of the medial forebrain bundle or subcallosal cingulate at the optimized stimulation settings derived during the open-label phase. After 1 week of washout period (with no stimulation), subjects undergo 2 weeks of sham stimulation
10158965|NCT04009928|Sham Comparator|Sham followed by active stimulation|"2 weeks of sham-stimulation, followed by 2 weeks of active stimulation, separated with 1 week washout period.~This is a crossover study, patients will undergo both arms, the order of which they do is randomized."
10158966|NCT04009707||patients with alcool use desorders|Patient cared for in the addictology department of the University Hospital of Nîmes
10158967|NCT04009603|Active Comparator|Metformin|Group no 1(26 patients) Metformin tablets at a dose of 500mg BD for 12 weeks
10158968|NCT04009603|Experimental|Probiotic|Group no 2(26 patients): will be given probiotics alone at a dose of 180mg B.D for 12 weeks
10158969|NCT04009603|Experimental|Metformin and Probiotic|Group no 3(26 patients): will be given metformin 500mg B.D and probiotics 180mgram O.D. for 12 week
10158970|NCT04009525|Experimental|MSD-HSCT|matched sibling donors hematopoietic stem cell transplantation
10158971|NCT04009525|Experimental|URD-HSCT|unrelated donor hematopoietic stem cell transplantation
10158972|NCT04009525|Experimental|haplo-HSCT|haplo-identical hematopoietic stem cell transplantation
10158973|NCT04009317|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally , twice daily in 28-day cycle.
10158974|NCT04009317|Active Comparator|Crizotinib|Crizotinib tablet 250mg administered orally, twice daily in 28-day cycle.
10158975|NCT04009382|Experimental|Baduanjin|This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
10158976|NCT04009382|Active Comparator|Cognitive Fitness Program|This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
10158977|NCT04009226||Participants with GNE|
10158978|NCT04009304|Experimental|In-person|OSNAP intervention delivered to afterschool sites using an in-person train-the-trainer model implementation strategy
10158979|NCT04009304|Experimental|Online|OSNAP intervention delivered to afterschool sites using an online training model implementation strategy
10158980|NCT04009304|No Intervention|Control|
10158981|NCT04009122|Experimental|IGEN-0206|a sachet after each meal, preferably (3 sachets per day)
10158982|NCT04009122|Placebo Comparator|Placebo|a sachet after each meal, preferably (3 sachets per day)
10158983|NCT04009122|No Intervention|group C|standard treatment
10158984|NCT04009369|No Intervention|Emergency Physician Group|Usual care by the EP without the intervention of the ED PT.
10158985|NCT04009369|Experimental|Physical Therapist Group|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
10158986|NCT04009473|Experimental|SEGOVA Intervention Group|Intervention group of 50-100 patients with ovarian failure would be subjected to a three-day procedure named SEGOVA: bone marrow derived StEm cell treatment, Growth factor incubation and Ovarian In Vitro Activation. After the procedure, one year follow up of hormones measurements (follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH)) and follicle counts would be established. In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed. The fertilization, cleavage and clinical pregnancy rate will be monitored.
10158987|NCT04009135|Experimental|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
10158988|NCT04009135|Experimental|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind & acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
10158989|NCT04009135|Placebo Comparator|Attention Control (AC)|Patients in the control condition will be given access online psychoeducation about depression and chronic pain. They will be provided weekly phone calls to query symptoms and well-being.
10158990|NCT04009252|Experimental|Intervention Group|3D model to be printed and used as teaching tool to discuss injury with patient as well as its associated long-term outcomes and potential complications. The operative plan will also be reviewed with the patient using the model as well as post-operative course (ie rehabilitation)
10158991|NCT04009252|No Intervention|Control Group|The CT image will be shown to the patients along with teaching
10158992|NCT04009278|Experimental|1. Self-compression arm|Intervention consist in a explanation by the radiographer to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain.
10158993|NCT04009278|No Intervention|2. Control arm|The mammography will be performed as normal clinical practice, with compression controlled by the radiographer.
10158994|NCT04009434|Other|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy
10158995|NCT04009434|Experimental|TAVI/MitraClip|Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.
10158996|NCT04009421||High and low coronary artery plaque burden|Patients with high plaque burden defined as plaque in >=4 segments of the coronary tree and low plaque burden as plaque in <4 segments of the coronary tree assessed by postprocessing of CT coronary angiography images and cardiovascular events and mortality.
10158997|NCT04009187|Active Comparator|Training group|Training group will first receive 30 minutes of education about biomechanically efficient propulsion techniques. They will be tested on this knowledge to make sure participants understand the material. The participant then will be asked to come into the lab for 6 sessions of training, two times per week for three weeks. The training is an hour of the proper wheelchair propulsion techniques broken into 5 parts, 7 minutes each with breaks. Based on the motor learning principles, we gradually increase the components of the training by focusing either hand reaching toward the back of the wheel or hands reaching down toward the axle.
10158998|NCT04009187|Active Comparator|Control group|Control group will first receive 30 minutes of education about the biomechanically efficient propulsion. They will be tested on this knowledge to make sure participants understand the material. No further training will be implemented with this group.
10158999|NCT04009486|Experimental|Obstructive Sleep Apnea|Subjects will undergo 6 weeks of whole body vibration.
10159000|NCT04009343|Active Comparator|Artemether-lumefantrine|Standard 6-dose regimen
10159001|NCT04009343|Experimental|Dihydroartemisinin-piperaquine|Standard 3-dose regimen
10159002|NCT04009031|Experimental|Bootle Blast|"Bootle Blast is a series of 13 mini-games targeting different upper limb motor therapy goals. Bootle Blast is designed with many of the features of mainstream video games known to be appealing to young people. Game rewards are linked to meeting therapeutic objectives, such as daily play targets that are customizable to each child. Bootle Blast is played through movements of the upper limbs tracked via a low-cost camera/sensor (Microsoft Kinect, no hand-held controls needed). The movements required to play are customizable to each child's range of motion. Some of the mini-games are mixed reality, where children interact and manipulate real-life objects (e.g. musical instruments, coloured building blocks) to play the game. The use of skeletal tracking and mixed reality enables both gross and fine motor skills to be practiced in line with each child's therapy goals and motor abilities."
10159003|NCT04008979|Experimental|PL-ASA 325 mg|Novel aspirin formulation being tested
10159004|NCT04008979|Active Comparator|IR 325 mg|Immediate release aspirin
10159005|NCT04008979|Experimental|PL-ASA-650|Novel aspirin formulation being tested
10159006|NCT04008979|Active Comparator|IR 650|Immediate release aspirin
10159007|NCT04009083|Other|Standard of Care|
10159008|NCT04009083|Experimental|18F-Fluciclovine PET Scan|
9973574|NCT01332526||Normal healthy control|healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).
10159009|NCT04009018|Other|Psycometric analyses|It will be a validation study of the Perioperative Satisfaction Scale in Regional Anesthesia. This study is not experimental research. This is a psychometric assessment study of a questionnaire and data will collect pencil-paper survey and face to face from the patients who will get regional anesthesia in the postoperative second day.
10159010|NCT04008732|Experimental|MED2005 (0.6 mg)|MED2005 (0.2% GTN) gel to be used topically in Part 1 of the study
10159011|NCT04008732|Experimental|MED2005 (1.2 mg)|MED2005 (0.4% GTN) gel to be used topically in Part 1 of the study
10159012|NCT04008732|Experimental|MED2005 (1.8 mg)|MED2005 (0.6% GTN) gel to be used topically in Part 1 of the study
10159013|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 1|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
9527687|NCT03217955|Active Comparator|Standard Treatment|Participants in both study conditions will receive ST. Participants are hospitalized or attending day-treatment at the Department of Early Psychosis, Amsterdam, the psychosis department of the ABC team, Utrecht, Parnassia Den Haag and collaborating (local community) mental health centers.
10159014|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 2|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
10159015|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 1|MED2005 (0.8% GTN) gel to be used topically in Part 1 of the study
10159016|NCT04008732|Active Comparator|Intravenous (I.V.) dose of GTN (0.3 mg)|GTN solution for infusion (1 mg/ml) to be used intravenously in Part 2 of the study
10159017|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 2|MED2005 (0.8% GTN) gel to be used topically in Part 2 of the study
10159018|NCT04009044|Experimental|Treatment (afimoxifene)|Patients apply afimoxifene gel topically QD to both breasts for 4 weeks and then undergo core needle biopsies of both breasts.
10159019|NCT04008771|Experimental|Severe Disease|Subjects with baseline BCVA between 20/16000 and hand motion (HM). Subjects received 2.0 μM concentration intravitreal injections on each Day 0 and Day 21.
10159020|NCT04008771|Experimental|Moderate to Severe Disease|Subjects with baseline BCVA from 20/60 to 20/16000. The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten [10]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
10159021|NCT04008784||Crisaborole 2% Topical Application Ointment [EUCRISA]|Crisaborole 2% Topical Application Ointment [EUCRISA] applied twice a day for 8 weeks
10159022|NCT04008784||Crisaborole 2% plus Triamcinolone Acetonide 0.1%Ointment|Crisaborole 2% plus Triamcinolone Acetonide 0.1% Ointment applied twice a day for the first 2 weeks, followed by Crisaborole 2% alone applied twice a day for the following 6 weeks
10159023|NCT04008654|Active Comparator|ERAS group|This groups will receive ERAS protocol
10159024|NCT04008654|Placebo Comparator|Conventional care|This group will not receive the ERAS protocol.
10159025|NCT04008641||Parents after pediatric antenatal consultation|Survey after pediatric antenatal consultation, for both members of couple if possible
10159026|NCT04008849||Subjects treated with MGTA-456|MGTA-456 is an investigational expanded CD34+ cell therapy
10159027|NCT04008719|Other|Patients|Assessments are made by a psychiatrist
10159028|NCT04008693|Active Comparator|Kyolic® Hi-Po Formula - Kyolic|Aged garlic extract
10159029|NCT04008693|Placebo Comparator|Placebo|Maltodextrin
10159030|NCT04008745|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in an educational booklet three times/week at home. In the follow-up period, patients will follow the same schedule set by the project till the end of the study (16-weeks).
10159031|NCT04008745|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
10159032|NCT04008992|Experimental|Part A SAD - A1 Cohort|Single Ascending Dose
10159033|NCT04008992|Experimental|Part A SAD - A2 Cohort|Single Ascending dose
10159034|NCT04008992|Experimental|Part A SAD- A3 Cohort|Single Ascending dose
10159035|NCT04008992|Experimental|Part A SAD- A4 Cohort|Single Ascending dose
10159036|NCT04008992|Experimental|Part A SAD - A5 Cohort|Single Ascending dose
10159037|NCT04008992|Experimental|Part A SAD- A6 Cohort|Single Ascending dose
9977854|NCT01365871|Active Comparator|basal injection|basal injection of anesthetics
9977855|NCT01365871|Active Comparator|basal + apical injection|basal + apical injection of anesthetics
9977856|NCT01365897|Placebo Comparator|Placebo|Control Group
10159038|NCT04008992|Experimental|Part B MAD- B1 Cohort|Multiple Ascending Dose
10159039|NCT04008992|Experimental|Part B MAD - B2 Cohort|Multiple Ascending Dose
10159040|NCT04008992|Experimental|Part B MAD - B3 Cohort|Multiple Ascending Dose
10159041|NCT04008992|Experimental|Part B MAD - B4 Cohort|Multiple Ascending Dose
10159042|NCT04008992|Experimental|Part C JMAD - C1 Cohort|Japanese Multiple Ascending Dose
10159043|NCT04008992|Experimental|Part C JMAD - C2 Cohort|Japanese Multiple Ascending Dose
10159044|NCT04008992|Experimental|Part C JMAD - C3 Cohort|Japanese Multiple Ascending Dose
10159045|NCT04008862|Experimental|Partnership-based care|Each patient will serve as his/her own control
10159046|NCT04008966|Active Comparator|single trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection
10159047|NCT04008966|Active Comparator|Dual trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously
10159048|NCT04008901|Active Comparator|Treatment group|The randomly assigned target was given a Lonicera Flos extract (BST104) 175 mg/day for eight weeks.
10159049|NCT04008901|Placebo Comparator|Placebo group|The randomly assigned target was given a placebo for eight weeks.
10159050|NCT04008953||Sixteen patients having end stage renal disease|Intravascular volume assessment in 16 pediatric patients under going renal transplant surgery using ultrasonography, CVP and echocardiography
10159051|NCT04008914||readmission at 30 days|
10159052|NCT04008914||readmission at 90 days|
10159053|NCT04008888|Experimental|A:Allogeneic Stem Cell Transplant Group|Fludarabine+Melphalan followed by Allogeneic SCT.
10159054|NCT04008888|Experimental|B:Autologous Stem Cell Transplant|Melphalan followed by Autologous SCT.
10159055|NCT04008888|Experimental|C:Non-Transplant|Consolidated Chemotherapy for Patients Unable to Receive Transplantation
10159056|NCT04008680|Other|Low response burden|Participants will be assigned to complete only the EQ-5D-5L questionnaire.
10159057|NCT04008680|Other|Low to medium response burden|Participants will be assigned to complete the General Anxiety Disorder-7 (GAD-7) questionnaire first, followed by the EQ-5D-5L questionnaire.
10159058|NCT04008680|Other|Medium to high response burden|Participants will be assigned to complete the Pain Catastrophizing Scale (PCS) questionnaire first, followed by the GAD-7, and lastly the EQ-5D-5L questionnaire.
10159059|NCT04008680|Other|High response burden|Participants will be assigned to complete the Brief Pain Inventory (BPI) questionnaire first, followed by the PCS secondly, the GAD-7 third, and lastly the EQ-5D-5L questionnaire.
10159060|NCT04008927|Other|All patients|All participants recruited during the RDS survey.
10159061|NCT04008927|Other|HCV infected patients|HCV-RNA assay (GeneXpert, Cepheid) will be performed to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL)
10159062|NCT04008927|Other|Patients with hepatitis C|Patients diagnosed with chronic hepatitis C will be prescribed with DAA treatment on research site. After one month they will be referred to conventional health structure for treatment follow-up.
10159063|NCT04008667|Experimental|Intervention arm|"Receiving the acupoint application and optimal supports.~The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
10159064|NCT04008667|Placebo Comparator|Placebo arm|"Receiving the fake acupoint application and optimal supports.~The fake acupoint is~The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
10159065|NCT04008667|No Intervention|Control arm|"Receiving the optimal supports.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
10159066|NCT04008498|Experimental|AEEG monitoring|"Babies whose families consent to involvement will have their head cleaned, EEG leads attached, the monitor set up, and observations.~Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.~Before being discharged home, the babies will have additional follow-up. They will receive magnetic resonance imaging (MRI) of the brain on a 1.5T scanner at the University of Sheffield. They will also have a standardised examination of their neurological system performed by a physiotherapist (The Hammersmith Neonatal Neurological Examination)."
10159067|NCT04008511|Experimental|Phase Ib: Regorafenib plus XELOX|"Phase Ib followed a Modified toxicity probability interval (mTPI) design to determine the maximum administered dose (MAD), there are 3 dose levels, and the dose level started from Group A:~Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX. (Regorafenib qd po for 14 days, every 3 weeks; XELOX: Oxaliplatin 130 mg/m2 IV, day 1, Capecitabine 1000 mg/m2 bid po for 14 days)"
10159068|NCT04008511|Experimental|Phase II: Regorafenib plus XELOX|Regorafenib MAD qd po for 14 days, every 3 weeks, Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
9973575|NCT01332526||Patients with CKD stage III and uric acid < 7 mg/dl|"Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
10159069|NCT04008511|Active Comparator|Phase II: XELOX|Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
10159070|NCT04008550|No Intervention|No Pulmonary Arterial Hypertension before TAVI|No intervention has been done in this group of patients.
10159071|NCT04008550|Other|Pulmonary Arterial Hypertension before TAVI|In this group, a right heart catheterization is done 3 months after TAVI in order to evaluate PAH (persistence or regression).
10159072|NCT04008459||Degenerative musculoskeletal spinal conditions|Participants are included who are enrolled in a 6-week physiotherapy exercise class aimed at improving function in people with degenerative spinal conditions.
10159073|NCT04008290|Experimental|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl containing 0.6 mg liraglutide.
10159074|NCT04008290|Placebo Comparator|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl saline (0.9%) solution.
10159075|NCT04008264||Standard post operative pain regimen|There will be a 3 month pre-intervention phase where participants will be placed on a standard post-operative analgesic regimen consisting of an opioid, a NSAID, and acetaminophen. Patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery.
10159076|NCT04008264||Scopolomine group|During the observational phase, patients will be on scopolamine for a total 6 day course (one patch applied at time of surgery, prescription for one patch), and patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery. The patients who incorporate scopolamine into their post operative analgesia regimen will be eligible for inclusion in the study.
10159077|NCT04008485|Experimental|Asymptomatic high-risk women|Women will be scheduled to attend for MIS measurement at 20-22 weeks, to be repeated at 26-28 weeks. This measurement will be taken at the same time as the routine examination which they receive when they attend the prematurity clinic. At each study visit the patient will undergo a vaginal examination. Triple high vaginal swabs will then be taken for bacteriology and fetal fibronectin. The sterile magnetic impedance probe will then be introduced, data being captured automatically by pressing the data capture button on the handle of the device. A transvaginal scan will also be performed to measure CL.
10159078|NCT04008485|Experimental|Symptomatic pregnant women|These women (≥ 16 years of age) will be approached when they attend the labour delivery room or triage with symptoms of preterm labour as detailed above. As a matter of clinical routine these women receive a speculum examination, triple vaginal swabs taken, and fetal fibronectin and cervical length scans as indicated. The study will be explained to them and study materials provided. They will be asked to contact research staff by telephone or through their clinical midwife if they wish to participate. They will be given time to decide. If they agree to take part, written informed consent will then be obtained by research staff who will also conduct the MIS study. If clinical assessments have not already been performed by the time of obtaining consent they will be carried out at the same time
10159079|NCT04008199|No Intervention|Control|Control group will not receive any intervention. Households in this group will only be surveyed.
10159080|NCT04008199|Experimental|Treatment|Treatment group will receive an invitation to join Super Abbu in addition to identical surveys to those in the control group.
10159081|NCT04008589|Experimental|rtACS|repetitive transorbital ACS
10159082|NCT04008589|Experimental|tDCS/rtACS|Sequential tDCS - tACS
10159083|NCT04008589|Sham Comparator|Sham stimulation|
10159084|NCT04008160||healthy persons|
10159085|NCT04008160||individuals with paraplegia|
10159086|NCT04008225||ARDS group|Inpatients hospitalized in medical intensive care with a table of ARDS defined according to the Berlin criteria and requiring an BAL for a diagnostic purpose under a suspicion of pneumopathy acquired under mechanical ventilation.
10159087|NCT04008225||Control group|The control group will be made up of patients with an BAL considered normal (endoscopy patients from the pneumology department). The normality of the BAL is defined by a normocellular wash with cellularity: < 150,000 to 200,000 cells/mL Cell composition (formula): macrophages: 80-90%, lymphocytes 5 to 10% (< 20%), neutrophils: < 5%, eosinophils: < 2%.
10159088|NCT04008563|Experimental|Bariatric Surgery and Progestin Intrauterine Device|This group will receive a progestin intrauterine device and be offered to undergo bariatric surgery.
10159089|NCT04008563|No Intervention|Progestin Intrauterine Device Alone|This group will receive a progestin intrauterine device alone.
10159090|NCT04008381|Experimental|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
10159091|NCT04008147|Active Comparator|No GDM, non-anemic|12 women with no gestational diabetes who are not anemic
10159092|NCT04008147|Active Comparator|No GDM, anemic|12 women with no gestational diabetes who are anemic
10159093|NCT04008147|Experimental|GDM, non anemic|12 women with gestational diabetes who are not anemic
10159094|NCT04008147|Experimental|GDM, anemic|12 women with gestational diabetes who are anemic
10159095|NCT04008173||Male|Non-interventional patient registry
10159096|NCT04008173||Female|Non-interventional patient registry
10159097|NCT04008173||Kidney Disease|Non-interventional patient registry
10159098|NCT04008173||Diabetes|Non-interventional patient registry
9527688|NCT03217773|Experimental|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
10159099|NCT04008173||Elderly|Non-interventional patient registry
10159100|NCT04008251|Experimental|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
10159101|NCT04008407|Active Comparator|ESD|Lesion with overt stigmata of SMIC or those with high risk (=> 10%) for covert SMIC.
10159102|NCT04008407|Active Comparator|EMR|Lesion with no overt or a low risk for (<10%) for covert SMIC
10159103|NCT04008420||Adults who are scheduled to undergo robotic esophagectomy|Adults who are scheduled to undergo robotic esophagectomy
10159104|NCT04008186|Experimental|Omaveloxolone and Multiple Drugs (Part 1)|Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27
10159105|NCT04008186|Experimental|Omaveloxolone & Gemfibrozil (Part 2)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18
10159106|NCT04008186|Experimental|Omaveloxolone and Itraconazole (Part 3)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.
10159107|NCT04008186|Experimental|Omaveloxolone and Verapamil (Part 4)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.
10159108|NCT04008342|Experimental|Intervention group|The intervention group (IG) was submitted to 16 multisensory sessions that followed the protocol.
10159109|NCT04008342|No Intervention|Control group|The control group (CG) received usual care with routine interventions and services in the LTC, such as bath, hygiene care, watching TV and so on.
10159110|NCT04008433|Experimental|Lidocaine pre-intravenous injection|The initial dose of lidocaine for pre-injection was set at 0.5mg /kg according to previous literature and preliminary test results. The dose of lidocaine was according to the patients' pain level. If there is no pain (negative reaction), the dose of lidocaine in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of lidocaine will be increased in the next patient until the patient is painless.
10159111|NCT04008394|Experimental|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
10159112|NCT04008303||Patients with migraines|"Patients seen in clinic and assessed with Migraine Headache Diagnostic Criteria to ensure diagnosis.~Patients track the characteristics of migraine headaches for one month before surgery.~After this month, patients receive surgery in the operating room for migraine.~After surgery, patients track the characteristics of migraine headaches for 3 months.~Patients will then be asked to track the characteristics migraine headaches again at 1 year and 2 years and 5 years after surgery. For these time periods, patients only have to keep track of the characteristics for 1 month intervals."
10159113|NCT04008316|Experimental|colchicine 1mg/day|Colchicine per os: 1 tablet (1mg) / day during 6 months
10159114|NCT04008316|Placebo Comparator|placebo|placebo 1 tablet / day during 6 months
10159115|NCT04008212||EVAR aneurysm|
10159116|NCT04008212||Stenosis|
10159117|NCT04008121|Experimental|Adult participants with normal or diseased eyes|500 mg dose of intravenous fluorescein sodium followed by ocular angiography; after a minimum of 3 days, participants will receive a single intravenous dose of MB-102 at 4 μmol/kg followed by ocular angiography
10159118|NCT04008043|Experimental|Dexamethasone|Participants in this arm will take a 6mg dexamethasone tablet the day before surgery, a 6 mg tablet the day of surgery, a 4mg tablet the day after surgery and a 2mg tablet the second day after surgery. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
10159119|NCT04008043|Active Comparator|Vicodin|Participants in this arm will take a vicodin tablet every 4-6 hrs as needed to a maximum of 8 tablets after surgery. Each tablet has 300 mg acetaminophen and 5 mg hydrocodone. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
10159120|NCT04008472|Experimental|Telemedecine|Patients benefiting from telemedicine
10159121|NCT04008472|No Intervention|Control|routine care without telemedecine
10159122|NCT04008108|Experimental|Patient with urinary incontinence|Patient with urinary incontinence
10159123|NCT04007809|Experimental|New-onset Type 1 diabetes|
10159124|NCT04007731|Experimental|High protein, high fibre and creatine load bar (DrRip)|1 new protein bar (260 kcal) after training every day
10159125|NCT04007731|Active Comparator|Voltage energy bar|1 control commercially available protein bar (260 kcal) after training every day
10159126|NCT04007744|Experimental|Treatment (sonidegib, pembrolizumab)|Patients receive sonidegib PO QD on days 1-8, and pembrolizumab IV over 30 minutes on day 8. Treatment repeats every 21 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
10159127|NCT04007926|No Intervention|Control Group|Participants assigned to the control arm of the study will be asked to maintain their normal dietary and exercise habits.
10159128|NCT04007926|Experimental|Aerobic exercise group|Participants randomised to the aerobic exercise intervention will undertake a 12-week aerobic exercise training programme.
10159129|NCT04007926|Experimental|Resistance exercise group|Participants randomised to the resistance exercise intervention will undertake a 12-week aerobic exercise training programme.
10159130|NCT04007965|Experimental|Opacified posterior capsule|PCO
10159131|NCT04007965|Active Comparator|Clear posterior capsule|CPC
10159132|NCT04007822||Physiotherapists|Physiotherapists will be recruited using the following inclusion criteria: (1) two years of experience in treating patients with chronic pain, (2) currently working in an MSK outpatient clinic and (3) able to read and speak English to a level allowing satisfactory completion of the study procedures. There are no exclusion criterium. Potential participants will be recruited through the relevant gatekeeper. The gatekeeper will be responsible of forwarding the participant information sheet and consent form to the physiotherapists. Physiotherapists will be asked to demonstrate their interest by replying to the email. Any questions will be answered by the research team via email or phone.
10159133|NCT04007978|Experimental|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
10159134|NCT04007835|Experimental|Anlotinib Hydrochloride combined with EGFR-TKI|Patients receive anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of following EGFR-TKIs: Gefitinib is administered 250 mg once per day. Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
10159135|NCT04007770|Experimental|Acupuncture|
10159136|NCT04007770|Sham Comparator|Sham Acupuncture (SA)|
10159137|NCT04007770|Other|Wait-List Control|This arm is Closed to accrual.
10159138|NCT04007653||Patients treated with heparin+edoxaban for VTE|Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
10159139|NCT04007653||Patients treated with heparin+VKA for VTE|Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
10159140|NCT04008030|Experimental|Arm A: Nivolumab Monotherapy|Specified dose on specified days
10159141|NCT04008030|Experimental|Arm B: Nivolumab + Ipilimumab Combination|Specified dose on specified days
10159142|NCT04008030|Active Comparator|Arm C: Investigator's Choice Chemotherapy|Specified dose on specified days. Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress
10159143|NCT04007913|Experimental|teleCBIT|Patient receive eight sessions of individual teleCBIT, in accordance with Woods et al's (2008) protocol, from a licensed psychologist.
10159144|NCT04007679|Experimental|Pain education group|Pain education was conducted in physical conditions similar to the university classrooms where the study was performed for all participants.
10159145|NCT04008017||stable Chronic obstructive pulmonary disease|clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
10159146|NCT04008017||acute exacerbation of Chronic obstructive pulmonary disease|patients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
9977857|NCT01365897|Experimental|Modafinil 200mg|Modafinil 200mg taken orally.
10159147|NCT04007887|Experimental|Intervention|Post-MI patients attending an adult education program designed to inform and motivate them on how to best control cardiovascular risk factors as a means to offer optimized secondary prevention of cardiovascular events
10159148|NCT04007887|No Intervention|Controls|Usual care for post-MI patients
10159149|NCT04007900|Experimental|Positive Affect Treatment|Individuals randomized to the intervention will participate in 20 therapy visits. Before each therapy visit, the participant will meet briefly with a member of the research staff, who will measure weight (blind to the participant) and administer the CHEDS, PANAS, and a pre-session feedback form that will assess how helpful the skills learned in the prior session had been over the past week. After the session, the participant will complete the post-session feedback form, which will assess how helpful the skills he or she perceived the skills from this session to be. These procedures will take approximately 10 minutes. Each intervention session will take approximately 50 minutes to complete. Therefore, each intervention visit will be approximately 1 hour long. Therapy sessions will take place either in the private office of a study therapist or in a consultation room of the Ambulatory Research Center.
10159150|NCT04007900|No Intervention|Waitlist|For participants randomized to the waitlist control, the opportunity will be offered to participate in the intervention following the second assessment (20 weeks following their Baseline assessment).
10159151|NCT04007757||1|Participants who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study who live in the area of University of Cincinnati, Massachusetts General Hospital, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of participant or legal representative to provide informed consent. Racial/ethnic category of Caucasian, African American or Hispanic.
10159152|NCT04007718|Experimental|Active|
10159153|NCT04007718|Sham Comparator|Control|
10159154|NCT04007640|Other|Volunteer patient|1st stage: To adjust the transducer, test and validate pancreatic MRI sequences on volunteers without history of known pancreatic disorders. Adjustment of MRI parameters is needed to optimize data acquisition, especially in obese patients. Moreover, an external material (transducer) has to be applied on the abdomen. The right position has to be tested and specified before stages 2 and 3 of the study. We aim to include volunteers without history of known pancreatic disorders for the Stage 1, meaning volunteers without personal history or symptoms suggesting pancreatic disorders.
10159155|NCT04007640|Other|Obese volunteers with indication for hepatic MRI|2nd stage: To validate and assess pancreatic MRI sequences on obese volunteers with indication for hepatic MRI , in relation with acceptable resolution and field of view criteria applicable to the typical anteroposterior diameters found in obese persons. For Magnetic Resonance Elastography (MRE), the amplitude setting of the MRE transducer will be adapted to the size of obese patients, in addition to the aforementioned adjustments to spatial resolution and field of view sizes. The effect of frequency on MRE data quality will be investigated. The effects of respiratory motion will be investigated; indeed in obese patients respiration amplitude is typically low and this enables to acquire data in free breathing mode over long periods of time, which offers more possibilities (notably in terms of averaging, spatial resolution, mechanical wave sampling rate) than when constraining acquisition parameters with a maximum breath hold time of less than 20s.
10159156|NCT04007640|Other|Obese patient|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
10159157|NCT04007640|Other|Non obese patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
10159158|NCT04007640|Other|Overweight patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
10159159|NCT04007549|Experimental|Individual brief motivational intervention|Individual brief motivational intervention (IBMI) on tobacco/alcohol risk reduction for the breast cancer patient; the partner receive e-mail or postal brief advices.
10159160|NCT04007549|Active Comparator|Couple-based brief motivational intervention|Couple-based brief motivational intervention (CBMI) on tobacco/alcohol risk reduction.
10159161|NCT04007562||Lipin-1 deficiency|Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months.
10159162|NCT04007588|Experimental|Nivolumab+BMS-986205|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~BMS-986205 will be administered orally on a daily basis"
10159163|NCT04007588|Experimental|Nivolumab|-Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
10159164|NCT04007588|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~Ipilimumab will be administered intravenously every 6 weeks"
10159165|NCT04007614||Patients|Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.
10159166|NCT04007484|Experimental|HP+CPB/DHCA group|For patients randomized into the intervention group, a hemoperfusion device will be connected in series to the extracorporeal circulation machine in advance to ensure that every single patient will undergo continuous hemoperfusion from the beginning to the end of CPB.
10159167|NCT04007484|No Intervention|CPB/DHCA group|For patients randomized into the CPB/DHCA group, no hemoperfusion device will be connect to the extracorporeal circulation machine. Patients will undergo CPB and DHCA without continuous hemoperfusion.
10159168|NCT04007315|Experimental|SaeboGlove Therapy + usual care|Use for 6 weeks - given an individualised self-management training programme involving repetitive grasping and releasing movements.
10159169|NCT04007315|Active Comparator|Usual care|Usual NHS rehabilitation care based on National Clinical Guidelines for 6 weeks + 2 study visits and one study phone call
10159170|NCT04007211|Experimental|ABT13107|
10159171|NCT04007211|Active Comparator|Hyalobarrier|
10159172|NCT04007354|No Intervention|Intubated|The patient was intubated with a left-sided double-lumen endobronchial tube. The protective ventilation was performed as follows: a tidal volume of 6 mL/kg predicted body weight, I:E ratio of 1:2, a respiratory rate to maintain PaCO2 within 35 to 45 mmHg, and positive end-expiratory pressure at 5 cmH2O. If the airway pressure exceeded 25 cmH2O, tidal volume was adjusted.
10159173|NCT04007354|Experimental|Non-intubated|The patients were oxygenated via facial mask with O2 5~10 L/min during the whole procedure. The end-tidal carbon dioxide (EtCO2) was measured by insertion of a detector inside one of the nostrils. Respiration rate was maintained between 12 and 20 breaths/min with adjustment of anesthetics.
10159174|NCT04007302|Experimental|walking with distraction|the patient walks in front of a screen with virtual reality simulation
10159175|NCT04007302|Active Comparator|Walking without distraction|the patient walks on a treadmill without virtual reality simulation
10159176|NCT04007406|Experimental|DP13 low|DP13 for 8 weeks
10159177|NCT04007406|Experimental|DP13 middle|DP13 for 8 weeks
10159178|NCT04007406|Experimental|DP13 high|DP13 for 8 weeks
10159179|NCT04007432|Experimental|Older patients with hip fracture|Older patients admitted for hip fracture surgery
10159180|NCT04007458|Active Comparator|Letter|Patients will receive a letter reminding them that they are overdue for repeat annual screening.
10159181|NCT04007458|Experimental|Community Health Worker phone call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
10159182|NCT04007445|Active Comparator|Formally Directed Group (Exercise Group)|A group performing a 12 - week guided exercise program at an accessible Community Health and Wellness Center
10159183|NCT04007445|Placebo Comparator|Self-Directed Group (Control Group)|A group receiving educational information about physical activity and exercise at home and then self-directing a 12 - week exercise program on their own.
10159184|NCT04007263|Placebo Comparator|Placebo|Placebo intravenous infusion over 30 minutes, five days of once daily dosing
10159185|NCT04007263|Experimental|NP10679 25 mg|NP10679 25 mg intravenous infusion over 30 minutes, five days of once daily dosing
10159186|NCT04007263|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion over 30 minutes, five days of once daily dosing
10159187|NCT04007263|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion over 30 minutes, five days of once daily dosing
10159188|NCT04007510|Experimental|EPI-CAL mHealth data network|"This arm of the study involves the use of the mobile health technology (app) to measure outcomes within an early psychosis (EP) program."
10159189|NCT04007510|Experimental|DUP Evaluation|A subset of individuals will participate in interviews to validate a tool to determine the duration of untreated psychosis in community settings
10159190|NCT04007237|Experimental|Selsun Shampoo (SeS2 shampoo)|Subject were given the SeS2 1.8% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
10159191|NCT04007237|Active Comparator|Ketoconazole shampoo|Subject were given the Ketoconazole 2% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
10159192|NCT04007328|Experimental|methylprednisolone|20 mg of methylprednisolone IV Q12H for 5 days
10159193|NCT04007328|Placebo Comparator|Placebo|normal saline IV Q12H for 5 days
10159194|NCT04007341|No Intervention|Saline group|Patients in the saline group were infused with an identical volume of normal saline.
10159195|NCT04007341|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group were infused with a loading dose of dexmedetomidine (1.0 mcg/kg over 10 min) and were thereafter infused at a rate of 0.5 mg/kg/h.
10159196|NCT04007185||Control group|30 patients undergoing biopsy for brain tumour. They have the effect of the tumour but not the impact of surgery. Changes in QoL will inform the RCI measures planned
10159197|NCT04007185||Surgery Group|The main test group. This group have been determined by their treating surgeon to undergo a resection of the tumour so will be different from the control arm by undergoing a safe, maximal resection of their tumour
10159198|NCT04007250||FENIX participants|Individuals being treated with the FENIX™ Continence Restoration System.
10159199|NCT04007172|Experimental|Neural Therapy & home exercise program|"Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
10159200|NCT04007172|Experimental|Physical Therapy & home exercise program|"Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
10159201|NCT04007419|Experimental|Single Arm|The Promotoras de Donación eLearning module will be launched and 40 participating lay health educators trained. Access to the module will be provided via a link to the website embedded in an announcement email. To assess the impact of the Promotoras de Donación eLearning module on lay health educators' knowledge of organ donation and the need for Hispanic donors, and confidence communicating about donation and promoting the act of donor registration, participating lay health educators will complete a brief online survey upon enrollment (pre) and after completing the module (post). Then, trained lay health educators will hold at least 2 small group sessions with mature Latina (6-8 per session); in all, 80 sessions are anticipated with 480 to 640 mature Latina. Participating mature Latina will complete anonymous paper-pencil surveys before and after each session to assess changes in attitudes toward organ donation and donor registration and intent to register as posthumous organ donors.
10159202|NCT04007393|Other|LSMT x 12 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=12 weeks: if body mass index (BMI) is down 5% at T=12 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 36 weeks); if BMI is not down 5% at T=12 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=24 weeks. At T=24 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 24 weeks); if BMI is not down by 5% at T=24 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 24 weeks).
10159203|NCT04007393|Other|LSMT x 24 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks. At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
10159204|NCT04007003|Experimental|optimal injection technique|Subjects will be trained on site regarding optimal insulin injection technique, including avoiding injections in lipohypertrophy areas and proper rotation. Furthermore subjects are provided with access codes to watch online training modules on the Becton Dickinson (BD) and Me(TM) platform
10159205|NCT04006938|Experimental|Single Bout ('S') - 30 minutes of moderate intensity cycling|Subjects will perform a single 30-minute bout of moderate intensity cycling before breakfast
10159206|NCT04006938|Experimental|Multiple Bout ('M')|Subjects will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
10159207|NCT04006990|Experimental|Intervention|Subjects are given recliner chairs and education on the dangers of bedrest
10159208|NCT04006990|No Intervention|Control|Subjects are treated with standard care
10159209|NCT04007055|Experimental|Experimental: screening/treating for HPR|Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
10159210|NCT04007055|No Intervention|Control: guideline based therapy|Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
10159211|NCT04006873|Active Comparator|Tezacaftor/Ivacaftor in combination with Ivacaftor|"A film-coated tablet containing 100mg tezacaftor and 150mg ivacaftor will be taken in the morning.~A film-coated tablet containing 150mg ivacaftor will be taken in the evening.~Participants will take these tablets for 28 days.~All tablets are licensed for use in the EU."
10159212|NCT04006873|Placebo Comparator|Placebo|A visually matched placebo to the active drugs will be taken in the morning and in the evening for 28 days.
10159213|NCT04006977|Placebo Comparator|Arm 1: placebo plus standard therapy|placebo plus standard therapy
10159214|NCT04006977|Experimental|Arm 2: DSF plus standard therapy|DSF (4 sachets/day) plus standard therapy
10159215|NCT04006834||MDD with hypersomnia|Patient with a history of MDD and ESS >10
10159216|NCT04006834||MDD without hypersomnia|Patient with a history of MDD and ESS <=10
10159217|NCT04006912|Experimental|Minimal residual theoretical astigmatism group|
10159218|NCT04006912|Active Comparator|Steep meridian incision design group|
10159219|NCT04007016||Pemberton osteotomy （PO）|PO group received Pemberton osteotomy
10159220|NCT04007016||"inner L shaped iliac osteotomy (ILSO)"|"ILSO group received inner L shaped iliac osteotomy"
10159221|NCT04007081|Experimental|Participants with Xerostomia|Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration
10159222|NCT04006847|Experimental|Eicosapentaenoic Acid (EPA)|"Phase I: TKI with escalating/de-escalating doses of EPA to determine MTD.~Phase I dose levels: Dose Level 1 = EPA 1500 mg orally once per day; Dose Level 2 = EPA 2000 mg orally once per day; Dose Level 3 = EPA 3000 mg orally once per day; Dose Level -1 = EPA 1000 mg orally once per day; Dose Level -2 = EPA 500 mg orally once per day.~Phase II: TKI administered in combination with the recommended Phase II dose of EPA"
10159223|NCT04007133||Diabetic patients|Patients with non-insulin-dependent diabetes, taking statins for at least 1 month
10159224|NCT04006821|Experimental|PD-1 antibody + Apatinib mesylate|Every patient will receive PD-1 antibody 200mg iv every 2 weeks and apatinib 250mg or 500mg (according to the patient's tolerance) orally every day. PD-1 antibody will be administered until disease progression or lasts for two years. Apatinib mesylate will be administered until disease progression.
10159225|NCT04006899||subj 1|Three commercially available BIA devices vs SBIS device
10159226|NCT04007120|Experimental|RVT-1601 Low Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
10159227|NCT04007120|Experimental|RVT-1601 Mid Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
10159228|NCT04006808|Experimental|PED-HZ/su 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, receiving 2 doses of the investigational vaccine (PED HZ/su)
10159229|NCT04006808|No Intervention|Control 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, not receiving the investigational vaccine but being treated according to the local standard of care
9527689|NCT03217773|Active Comparator|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
9527690|NCT03218007|Experimental|acute coronary syndrome|
9527691|NCT03217903|Experimental|Patients with High-risk MDS With Excess Blasts|
10159230|NCT04006808|Experimental|PED-HZ/su 1-11 Group|"Paediatric renal transplant recipients aged 1 to 11 years old, receiving 2 doses of the investigational vaccine (PED HZ/su).~Enrolment into this group will be in a staggered manner. Following enrolment into the PED-HZ/su 12-17 group, a safety evaluation of data collected up to visit month 2 will be performed. Upon favourable outcome of the evaluation, enrolment into this group will begin."
10159231|NCT04006808|No Intervention|Control 1-11 Group|Paediatric renal transplant recipients aged 1 to 11 years old, not receiving the investigational vaccine but being treated according to the local standard of care
10159232|NCT04006860|Experimental|SHC014748M: Fast + Fed|Participants will receive a single oral dose of SHC014748M capsules in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fed condition on Day 8 of treatment period 2.
10159233|NCT04006860|Experimental|SHC014748M: Fed + Fast|Participants will receive a single oral dose of SHC014748M capsules in fed condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fasted condition on Day 8 of treatment period 2.
10159234|NCT04006782|Other|Narrow dental implants in multiple fixed prosthesis|
10159235|NCT04006470||Stannous Fluoride Dentifrice|Twice daily use
10159236|NCT04006470||Positive control dentifrice|Twice daily use
10159237|NCT04006470||Negative control dentifrice|Twice daily use
10159238|NCT04006496|Experimental|Experimental: Intervention|In-patient, Chemotherapy patients in this arm will receive the expressive writing intervention twice each week for two weeks. These writing samples will be reviewed and analyzed. These patients will receive coaching from an expert expressive writing coach and will be allowed to ask questions and receive guidance. All patients will receive standard of care treatment in addition to the intervention.
10159239|NCT04006496|No Intervention|Control|Patients in the control group will not interface with the expressive writing coach for guidance nor have their writing samples reviewed and analyzed. All patients in the control arm will still receive standard care
10159240|NCT04006613|Experimental|Circuit Training|Structured intervention to improve aerobic capacity, balance and strength
10159241|NCT04006613|Active Comparator|Usual Care|Unstructured intervention to improve mobility and balance
10159242|NCT04006587|Experimental|IS intervention|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
10159243|NCT04006587|No Intervention|control|standard care without IS intervention
10159244|NCT04006639|Active Comparator|Bilateral superficial cervical plexus block with Bupiv|Patients, who will have tracheostomy procedure, might receive bilateral superficial cervical plexus block with 10 mL of Bupivacaine 0.5% (20 mL spuit with 25 G 1.5 inch needle) on each side before tracheostomy procedure.
10159245|NCT04006639|Active Comparator|Local infiltration of Lidocaine 2%|Patients, who will have tracheostomy procedure, might receive local infiltration of Lidocaine 2% (5 mL spuit with 25 G 1.5 inch needle) before tracheostomy procedure.
10159246|NCT04006704|Experimental|D/C/F/TAF (Whole Placebo Tablet then Split Placebo Tablet)|Participants will receive scored film-coated 10 milligram (mg) FDC matching placebo tablets (Intake period 1) swallowed whole followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed as a split tablet on Day 1. Both the intakes will be separated by at least 15 minutes.
10159247|NCT04006704|Experimental|D/C/F/TAF (Split Placebo Tablet then Whole Placebo Tablet)|Participants will receive scored film-coated 10 mg FDC matching placebo tablets (Intake period 1) swallowed as a split tablet followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed whole on Day 1. Both the intakes will be separated by at least 15 minutes.
10159248|NCT04006743|No Intervention|The routine care group|In the routine care group, while a neonatal nurse performed the OGT insertion procedure, physiological measurements of the highest value of heart rate and the lowest value of oxygen saturation were recorded by one researcher (the first author) 1 min before the procedure, during the process and after the process in 1st and 2nd minutes acquired for each infant in the unit with an individual monitor.
10159249|NCT04006743|Experimental|The swaddling group|In this group, preterm infants were given swaddling method.
10159250|NCT04006743|Experimental|The expressed breast milk group|In this group, preterm infants were given expressed breast milk method.
10159251|NCT04006743|Experimental|The facilitated tucking group|In this group, preterm infants were given facilitated tucking method.
10159252|NCT04006743|Experimental|The swaddling and expressed breast milk group|In this group, preterm infants were given combined swaddling and expressed breast milk method.
10159253|NCT04006743|Experimental|The facilitated tucking and expressed breast milk group|In this group, preterm infants were given combined facilitated tucking and expressed breast milk method.
10159254|NCT04006678|Experimental|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
10159255|NCT04006678|Active Comparator|conventional sandwich osteotomy|:conventional segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla.
10159256|NCT04006561||newly-diagnosed patients with primary CNS lymphoma|
10159257|NCT04006483||Stannous Fluoride Dentifrice|Twice daily brushing
10159258|NCT04006483||Positive control dentifrice|Twice daily brushing
10159259|NCT04006483||Negative control dentifrice|Twice daily brushing
10159260|NCT04006574|Experimental|core stabilization training|Patient with hip dysplasia aged between 20-60, non-operated
10159261|NCT04006574|Active Comparator|traditional physiotherapy and core stabilization|Patient with hip dysplasia aged between 20-60, non-operated
10159262|NCT04006184||Endovenous Thermal Ablation|Limbs treated with either radiofrequency ablation or endovenous laser ablation
10159263|NCT04006184||Cyanoacrylate Closure|Limbs treated with cyanoacrylate closure system
10159264|NCT04006262|Experimental|Experimental arm|"Neo-adjuvant treatment (6 cycles - 12 weeks)~Surgery~Adjuvant treatment (9 cycles - 9 months)"
10159265|NCT04006691|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml. 3-6 once weekly intravesical instillations for the ablation treatment.
9671261|NCT05051267|Experimental|Mothers Embrace and Mother's Voice Group|After the procedure, the baby will continue to listen to the baby who is in the mother's arms. One minute after the procedure, the baby's pain score will be evaluated and the HR and O2 values will be noted. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the mother's voice will continue to be listened to. The crying time of the baby after the procedure will be noted. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
10159266|NCT04006275|Experimental|Sonovue and Sonazoid Group|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~Contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
10159267|NCT04006275|Experimental|Sonazoid and Sonovue Group|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
10159268|NCT04006080|Experimental|Vedolizumab|
10159269|NCT04006093|Experimental|participants with normal renal function|
10159270|NCT04006093|Experimental|participants with end-stage renal disease|
10159271|NCT04006067|Experimental|Group A|
10159272|NCT04006067|No Intervention|Group B|
10159273|NCT04006340|Placebo Comparator|Empirical group|Patients receive conventional triple therapy containing esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days
10159274|NCT04006340|Active Comparator|Genotypic resistance-guided tailored group|"Patients receive triple or quadruple therapy by resistance-associated mutations in 23S ribosomal RNA which are identified by polymerase chain reaction (PCR).~Triple therapy contains esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days and quadruple therapy contains esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days."
10159275|NCT04006236|Experimental|Experimental Infant Formula|extensively hydrolyzed casein protein
10159276|NCT04006236|Active Comparator|Control Infant Formula|extensively hydrolyzed casein protein
10159277|NCT04006301|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
10159278|NCT04006301|Experimental|Part 2: Dose Expansion|Two groups of participants with either non-small cell lung cancer or other solid tumors harboring KRAS G12C mutation will receive JNJ-74699157 at RP2D determined in Part 1.
10159279|NCT04006158|Experimental|LightStim LED Bed|Full body LED bed device.
10159280|NCT04006314|Other|Receiving PRP injections or PRP plus neural prolotherapy|PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
10159281|NCT04006041|Experimental|Toripalimab group|All patients will receive standard fractionation radiation therapy (RT) scheme: 44Gy in 20 fractions over 4 weeks, concurrently with 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 and 2 cycles of toripalimab 240 mg on days 1, 22. Esophagectomy is performed 6-8 weeks after CRT completion.
10159282|NCT04006353|Experimental|Group 1: ABT|Intravenous infusion of 320 mg ABT on Day 1, 2, 3, and 8.
10159283|NCT04006353|Experimental|Group 2: ABT+RIF|600mg Rifampicin once daily from Day 1 to 16. Intravenous infusion of 320 mg ABT on Day 7, 8, 9 and 14.
10159284|NCT04006249|Other|diagnostic test|
10159285|NCT04006132|Experimental|Ponto 3 SuperPower sound processor|All patients will be fitted with two bone-anchored sound processors (Ponto 3 SuperPower), unilaterally and bilaterally.
10159286|NCT04006054|Experimental|Dexmedetomidine treatment group|Dexmedetomidine will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
10159287|NCT04006054|Active Comparator|Midazolam treatment group|Midazolam will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
10159288|NCT04006327||Palliative care patients and their family caregivers|The present study is a cross-sectional study with single group study design. Only palliative care patients and their family caregivers will be recruited.
10159289|NCT04005872|Experimental|Nano Silver Fluoride|2 drops of nano silver fluoride (NSF) applied on the last soft carious layer using micro brush
10159290|NCT04005872|Active Comparator|Calcium Hydroxide|Calcium hydroxide placed on the last soft carious layer approaching the pulp
10159291|NCT04005833||COPD exacerbation|COPD exacerbation, compared according to blood fibrocytes level measured during the suspected exacerbation (Day 1)
10159292|NCT04005781|Experimental|Hydroxychloroquine sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
10159293|NCT04005781|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
10159294|NCT04005807|Experimental|Cohort 1 (fasted condition)|10 mg BPN-14967 or placebo
10159295|NCT04005807|Experimental|Cohort 2 (fasted condition)|25 mg BPN-14967 or placebo
10159296|NCT04005807|Experimental|Cohort 3 (fasted condition)|50 mg BPN-14967 or placebo
10159297|NCT04005807|Experimental|Cohort 4 (fed condition)|10 mg BPN-14967 or placebo
10159298|NCT04005807|Experimental|Cohort 5 (high-fat fed condition)|10 mg BPN-14967 or placebo
9671262|NCT05050760|Experimental|The experimental group|Drug：DCF+Camrelizumab Camrelizumab:200mg/time,IV,Q3W
9671263|NCT05050877||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
9671264|NCT05051215||Control group|40 healthy volunteers were included in the healthy control group
10159299|NCT04005768|Experimental|Hydroxychloroquine Sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
10159300|NCT04005768|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
10159301|NCT04005950||medical doctors|
10159302|NCT04005950||paramedics|
10159303|NCT04005846|Other|Active tDCS first / Sham tDCS second|Receiving active tDCS during the first visit followed by sham tDCS on the next visit
10159304|NCT04005846|Other|Sham tDCS first / Active tDCS second|Receiving sham tDCS during the first visit followed by active tDCS on the next visit
10159305|NCT04005820|Experimental|children and young adults supported in one of SFCE's centers|
10159306|NCT04005898|Experimental|Experimental: near-infrared cholangiography|Each subject included in the study will be subjected to a fluorescence cholangiography. The control group will be the same patient. The study consists of knowing if fluorescence is able to visualize structures that are not seen with the naked eye. For this purpose the structures are visualized with normal light and then with infrared light of the same patient. During laparoscopic cholecystectomy it will change between normal and infrared light.
10159307|NCT04005911||Post-Surgical|Patients who underwent surgery and were admitted to the PACU
10159308|NCT04005989|Placebo Comparator|PLACEBO GROUP|injection of saline solution
10159309|NCT04005989|Active Comparator|Low dose group|hASC injection (1x10e6 / kg body weight)
10159310|NCT04005989|Active Comparator|Intermediate Dose|injection of hASC (2x10e6 / kg of body weight)
10159311|NCT04005989|Active Comparator|High dose group|injection of hASC (4x10e6 / kg body weight)
10159312|NCT04005937|Experimental|H-reflex|H-reflex with different interstimulus interval of the plegic side soleus muscle were tested
10159313|NCT04005924|No Intervention|Control|Bread and sugar-free blackberry jam breakfast
10159314|NCT04005924|Experimental|Low dose|Bread and sugar-free blackberry jam breakfast with 6 g arabinogalactan
10159315|NCT04005924|Experimental|High dose|Bread and sugar-free blackberry jam breakfast with 21 g arabinogalactan
10159316|NCT04005976||Patients with heritable thoracic aortic disease (H-TAD)|Patients with heritable thoracic aortic disease (H-TAD) with causal mutations in the known H-TAD genes.
9527692|NCT03217825|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
10159317|NCT04005612|Experimental|vitamin d3 group|weekly Dietary Supplement: Vitamin D3 50,000 IU Vitamin D3 / week for 8 weeks
10159318|NCT04005612|Experimental|omega3-Fatty Acid group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
10159319|NCT04005612|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3 FA) once daily
10159320|NCT04005612|No Intervention|Control group|NO INTERVENTION
10159321|NCT04005547|Experimental|Program+survey|
10159322|NCT04005547|No Intervention|Survey-only|
10159323|NCT04005508||OSA (Watch PAT AHI >/= 15 events per hour)|Patients found to have OSA by an overnight sleep study
10159324|NCT04005508||Non-OSA (Watch PAT AHI < 15 events per hour)|Patients found NOT to have OSA by an overnight sleep study
10159325|NCT04005716|Experimental|tislelizumab plus etoposide and platinum|
10159326|NCT04005716|Active Comparator|Placebo plus etoposide and platinum|
10159327|NCT04005560|Other|patient|Score of PedSQL who is the Pediatric Quality of Life Questionnaire
10159328|NCT04005443|Other|PET at 68Ga-NODAGA-RGD|The first PET scan will be performed within a maximum of one month following the initial ophthalmologic assessment including OCT and measurement of visual acuity (M0);
10159329|NCT04005664|No Intervention|Bolus group|Hypotension occurring under spinal anaesthesia (SBP < 90mmHg) requires pharmacological treatment. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. The dose within this range will be decided by the attending anaesthetist. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
10159330|NCT04005664|Active Comparator|Phenylephrine coload group|Phenylephrine 500ug will be added to the first litre of ringer's lactate infused on initiation of spinal anaesthesia. If the phenylephrine infusion protocol is being used, and the mean arterial pressure (MAP) rises to greater than 20% of the initial MAP, and where this rise in MAP is not due to a recent bolus of either phenylephrine or ephedrine (within 2 minutes), the Ringers Lactate infusion will be switched off. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
10159331|NCT04005469|Experimental|Trepostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
10159332|NCT04005430|Experimental|Phase 1|Phase I open label study
10186134|NCT03738813|Experimental|Treatment Group|"The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.~In Treatment Group, the movements will be performed using Gloreha ARIA. Gloreha Aria is a sensor-based therapy device designed for motor recovery of impaired upper limb. Gloreha Aria is equipped with sensors that can detect any movements in space: the software processes and displays them on the screen."
9527693|NCT03217825|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
9527694|NCT03217825|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
10159333|NCT04005365|Experimental|Prop+neochemo|
10159334|NCT04005313|Experimental|Comparison between unisensory and multisensory stimulation|The same person receive unisensory and multisensory stimulation on separate day.
10159335|NCT04005313|Experimental|The treatment effect of multisensory stimulation|The persons living in long-term care facility would receive multisensory stimulation for one month.
10159336|NCT04005313|Experimental|Multisensory stimulation and virtual reality.|The subjects would receive vibroacoustic therapy or virtual reality.
10159337|NCT04005313|Experimental|Vibroacustic therapy on neck pain.|The subjects would receive either vibroacustic therapy or music therapy.
10159338|NCT04005326|Experimental|QLB Group|this group will receive ultrasound-guided transmuscular quadratus lumborum block; (Anterior QLB or QLB III)
10159339|NCT04005326|Experimental|FIB Group|this group will receive suprainguinal fascia iliaca block
10159340|NCT04005222|Other|SELENIUM|The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
10159341|NCT04005222|Other|MELATONIN|The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.
10159342|NCT04005573|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
10159343|NCT04005573|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
10159344|NCT04005573|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
10159345|NCT04005573|Other|control group|no intervention was given
10159346|NCT04005417||Stannous fluoride dentifrice|Twice daily brushing
10159347|NCT04005417||Positive control dentifrice|Twice daily brushing
10159348|NCT04005417||Negative control dentifrice|Twice daily brushing
10159349|NCT04005157|Experimental|Patients undergoing bronchoscopic MWA|Patients meeting the inclusion criteria will be enrolled in the study and undergo ENB guided MWA. Chest CT will be performed at 1 day after the procedure to confirm the complications and then at 1 month, every 3 months for 2 years, and every 6 months for 3 years thereafter after the procedure. PET/CT will be performed 3 months after MWA to assess the treatment response.
10159350|NCT04005261||patients with type 2 diabetes treated with insulin|"Patients with type 2 diabetes who have been using insulin for at least six months.~They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital"
10159351|NCT04005248|Other|Testing for HCV|HCV IgG test and questionnaire; both at visit to the sexual health clinic
10159352|NCT04005300|Experimental|low calorie feeding group|Enteral nutrition was fed at 10-20kcal/kg/d for the first three days before identifying the refeeding syndrome
10159353|NCT04005300|Active Comparator|standard calorie feeding group|Enteral nutrition was fed at 500-750kcal/d for the first three days before identifying the refeeding syndrome
10159354|NCT04005300|No Intervention|RFS group|The definition of RFS is that serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded. And it is divided into three sub-group that is Group 1 that a drop of >0.16 mmol/L from any previous measurement, to below 0.65 mmol/L within 72 h after starting nutritional support, Group 2 that their serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded, and Group 3 that their serum phosphate concentration decreased to below 0•32 mmol/L within 72 h after starting nutritional support.
10159355|NCT04005300|No Intervention|nRFS group|It is not up to the RFS definition
10159356|NCT04005066|Other|Cohort 1|metastatic colorectal cancer patients who are accordance with Elunate® package insert
10159357|NCT04005066|Other|Cohort 2|other patients suitable for according to investigator's judgement
10159358|NCT04005118||preoperative preparation on microbiome composition|Mechanical Bowel Preparation + oral antibiotics group: receiving mechanical bowel preparation only MBP will be prepared with 4 liters of Polyethylene glycol (PEG) solution to be started 24 hours before the planned surgery. 500mg of Metronidazole will be administrated 3 times one day before the surgery at 2 pm, 3 pm and 10 pm.
10159359|NCT04005040|Active Comparator|Mobile X-ray|Intervention: X-ray examination in the patients own home
10159360|NCT04005040|Placebo Comparator|X-ray at the Hospital|Control: X-ray at the hospital
10159361|NCT04005001|Experimental|Experimental|The experimental arm will involve patients monitored by HindSight.
10159362|NCT04005001|Active Comparator|Control|The control arm will involve patients monitored by InSight.
10159363|NCT04004858|Active Comparator|Standard margin|Patient cohort planned with the current standard PTV margin
10159364|NCT04004858|Experimental|Reduced margin|Patient cohort planned with the reduced margin validated from the retrospective study
10159365|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
10159366|NCT04005378|Other|Usual Care|Usual care provided by CSC center
10159367|NCT04004754||Complicated CL in Gondar|Patients treated with miltefosine in Gondar will be followed up to see outcomes of treatment
10159368|NCT04004754||Complicated CL in Boru Meda|Patients treated with miltefosine in Boru Meda hospital will be followed up to see outcomes of treatment
9527695|NCT03217825|Active Comparator|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
9527696|NCT03217929|Active Comparator|Active-taVNS|
9527697|NCT03217929|Sham Comparator|Sham-taVNS|
10159369|NCT04005014|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SE and presence of high myopia in the subsequent 10 years.
10159370|NCT04005014|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
10159371|NCT04004949||study group (high scapular dyskinesia )|group A (30 patients): with high scapular dyskinesia scores
10159372|NCT04004949||control group (low or no scapular dyskinesia )|group B (30 patients): with low or no scapular dyskinesia scores. (30 patients): with low or no scapular dyskinesia scores.
10159373|NCT04005170|Experimental|PD-1 group|All patients will receive standard fractionation radiation therapy (RT) scheme: 50.4 Gy in 28 fractions over 5-6 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 and 2 cycles of toripalimab 240 mg on days 1, 22 followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
10159374|NCT04004923|Active Comparator|Monopolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
10159375|NCT04004923|Active Comparator|Bipolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
10159376|NCT04004975|Experimental|anlotinib|12 mg daily from day 1 to 14 of a 21-day cycle
10159377|NCT04004806|No Intervention|Pre-Intervention|Phase 1 (Observational phase): All residents and staff physicians rotating through the inpatient medicine services during the first three (3) months, who agreed to be a part of the study, will be provided with Hill Rom tracking devices to quantify the time spent at the patient's bedside by each member as part of the daily practice.
10159378|NCT04004806|Experimental|Intervention|Phase 2 (Intervention phase): The interventional phase will be six (6) months duration. During this period, the recorded time spent by the individual study participants at the patient's bedside will be compared to their respective peers, and percentile scores will be generated. Based on these percentile scores, the study participants will receive emails notifying them of the results. Participants whose scores fall in the lower 50th percentile will be encouraged to increase patient interaction times. Participants with scores in the top 50th percentile will receive congratulatory emails to encourage them to keep up the performance.
10159379|NCT04004806|No Intervention|Post-Intervention|Phase 3: (Post Intervention observation phase): The final phase of the study will be again three (3) months. The intervention of feedback emails and text pages will be discontinued and the study participants will only be monitored to see if the past intervention made an impact on their daily clinical practice in terms of time spent with the patients.
9520091|NCT03280589|Experimental|Sheetali/Sheetkari, externally-paced|The participant will follow on screen instruction for Sheetali/Sheetkari with shaped lips/mouth as indicated, fully filling and emptying the lungs with each breath. The tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one-minute rest before continuing. In Sheetkari the teeth are exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be an auditory queue to prompt the participant to breathe in and out. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary.The total duration of this session will be approximately 40 minutes.
9520092|NCT03280576||Sepsis|Patients with sepsis
9520093|NCT03280576||Cardiac Surgery|Patients undergoing cardiac surgery
9520094|NCT03280576||Healthy controls|Normal individuals
10159380|NCT04004676|Active Comparator|Placebo|isocaloric carbohydrate - only containing drink will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
10159381|NCT04004676|Experimental|Ketone_CHO|Ketone - Carbohydrate supplementation will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
10159382|NCT04004871|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive induction chemotherapy with Nab-paclitaxel, cisplatin and fluorouracil every three weeks for three cycles before radiotherapy, and then receive concurrent chemoradiotherapy.
10159383|NCT04004897|Other|Preeclampsia group|Patients with preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
10159384|NCT04004897|Other|Pregnants without preeclampsia|Pregnant women without preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
10159385|NCT04004728|Other|laser, leg veins, sclerotherapy|to compare laser and sclerotherapy on treating leg veins
10159386|NCT04005092|Active Comparator|Helmet Continuous Positive Airway Pressure(hCPAP)|Helmet CPAP produce a better physiological outcomes after 1-hour intervention
10159387|NCT04005092|Active Comparator|High Flow Nasal Cannula(HFNC)|HFNC produce a better physiological outcomes after 1-hour intervention
10159388|NCT04004624|Active Comparator|Study Arm|The left ventricle is mapped during atrial and right or left ventricular pacing (site close to the infarct) at a similar cycle length of 600ms. Radio-frequency ablation is performed selectively in areas of activation slowing (defined as ≤40ms per 5mm while voltage abnormalities and late potentials were not specifically targeted.
10159389|NCT04004624|No Intervention|Control|Patient who underwent ablation using similar technology and irrigated catheters guided by standard substrate mapping techniques.
10159390|NCT04004884||UPA Treatment|Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018
10159391|NCT04005131|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 10 weeks
9520095|NCT03280524|Placebo Comparator|Control Group|Control Group will receive self-care guidelines with feet
9520096|NCT03280524|Experimental|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
9520097|NCT03280511|Experimental|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
9520098|NCT03280498|Other|Intubation with Cole formula|ASA I-II pediatric patients in the age range of 2-10 years, planned to undergo elective surgeries under general anesthesia with endotracheal entubation,
10159392|NCT04005131|Active Comparator|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 weeks
10159393|NCT04004598|Experimental|golf training|12-week golf training program
10159394|NCT04004988|Experimental|Tirzepatide Test|Tirzepatide administered subcutaneously (SC) to healthy participants via an autoinjector (AI) in one of two study periods.
10159395|NCT04004988|Experimental|Tirzepatide Reference|Tirzepatide administered SC to healthy participants via a prefilled syringe (PFS) in one of two study periods.
10159396|NCT04004702|Experimental|Levetiracetam|All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year
9671265|NCT05051215||NPM group|60 patients of NPM (30 PCM and 30 GM)were included
10159397|NCT04004455||Childhood cancer|Children with an established cancer diagnosis (any type) between 8-18 years old that are currently being treated for cancer (not necessarily hospitalized) in the University Hospital Brussels or Ghent.
10159398|NCT04004455||Healthy controls|Healthy children between 8-12 years old, selected based on age and sex.
10159399|NCT04004507|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye (QD) for one day.
10159400|NCT04004507|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye (QD) for one day.
10159401|NCT04004663|Experimental|Treatment Sequence 1|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D).
10159402|NCT04004663|Experimental|Treatment Sequence 2|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment D); Period 3 (Treatment A); Period 4 (Treatment C).
10159403|NCT04004663|Experimental|Treatment Sequence 3|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment C); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment B).
10159404|NCT04004663|Experimental|Treatment Sequence 4|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment D); Period 2 (Treatment C); Period 3 (Treatment B); Period 4 (Treatment A).
10159405|NCT04004312|Experimental|Single Fraction SBRT in the treatment of prostate cancer|Prior to treatment, a hydrogel spacer will be inserted between the recutm and prostate. A urinary catheter will also be inserted in the bladder. A single dose of 19Gy will be delivered with an IMRT technique. The treatment should last approximately 30 minutes. After the treatment, the urinary catheter will be removed.
10159406|NCT04004689||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join the rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
10159407|NCT04004494|Experimental|3D Reconstruction|Chest contrast-enhanced computed tomography will be performed preoperatively, and 3-dimensional reconstruction will be formed based on the data of chest CT. Video-assisted segmentectomy will be performed guided by the image of 3-dimensional CT. IPS-lung software (Shenzhen Yorktal Digital Medical Imaging Technology Company, Shenzhen, China) will be used preoperatively to construct a 3D-image to ascertain the position and structure of targeted segmental blood vessels and bronchi.
9671266|NCT05050617||Acute Pulmonary Embolism|Subjects in this single cohort will undergo point-of-care echocardiography at the time of presentation and subsequent follow up to assess for short term adverse events or complications.
9973576|NCT01332526||Patients with CKD stage III and uric acid > 7 mg/dl|"Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
10159408|NCT04004494|No Intervention|Chest computed tomography|Chest contrast-enhanced computed tomography will be performed preoperatively. Video-assisted segmentectomy will be performed based on the image of preoperative chest CT
10159409|NCT04004559||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|Cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the training cohort.
10159410|NCT04004559||Sun Yat-sen University Cancer Center|Cohort of Sun Yat-sen University Cancer Center is validation cohort 1.
10159411|NCT04004559||Tungwah Hospital of Sun Yat-Sen University|Cohort of Tungwah Hospital of Sun Yat-Sen University is validation cohort 2.
10159412|NCT04004650|No Intervention|Primary closure|Primary perineal closure after extralevator abdomino perineal resection
10159413|NCT04004650|Experimental|Gluteal turnover flap|Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection
10159414|NCT04004715|Experimental|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
10159415|NCT04004715|Active Comparator|Whey Protein|commercially available whey protein isolate
10159416|NCT04004715|Active Comparator|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
10159417|NCT04004585|Experimental|Intervention|This was a single arm study with all participants receiving the same intervention. Participants will receive a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour.
10159418|NCT04004546|Experimental|Intervention group|At baseline: video and education booklet. 2-weeks after enrollment: telephone call by nurse.
10159419|NCT04004546|No Intervention|Control group|Usual care
10159420|NCT04004637|Experimental|CD7 CAR-T cells Infusion|
10159421|NCT04004377||acoustic neuroma monitored radiologically|patient with an acoustic neuroma (vestibular schwannoma) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, monitoring by radiology
10159422|NCT04004377||acoustic neuroma whose treatment is surgical|patient with an acoustic neuroma (vestibular schwannoma or) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, resection surgery planified
9527698|NCT03217630||Diabetic patients|
9973577|NCT01332526||Patient with asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
10159423|NCT04004468|Active Comparator|Standard Periodization Training|Utilization of traditional periodization strength training model
10159424|NCT04004468|Active Comparator|Conjugate Training|Utilization of conjugate strength model
10159425|NCT04004520|Experimental|Virtual Reality with Meditation|Participants will receive a virtual reality and audio guided mindfulness meditation program available at (https://guidedmeditationvr.com/)
10159426|NCT04004520|Other|Virtual Reality Control|Participants will receive a virtual reality of historic photographs and written narratives program (https://lookingglassvr.com/)
10159427|NCT04004520|Other|Audio Control|Participants will receive an online audio-only guided mindfulness meditation available at (https://www.uclahealth.org/marc/mindful-meditations).
10159428|NCT04004299|Other|HCV self-test intervention|Diagnostic intervention: participant performs capillary blood sampling at home in between outpatient clinic visits (3 months after) and sends the sample to the investigator's laboratory by regular post mail for HCV RNA analysis. This is on top of standard of care ALT measurement at every 6-monthly outpatient clinic visit, followed by HCV RNA testing if ALT is elevated. Follow-up period is 2 years, in which participants will perform and send in 4 self-tests, in combination with filling out 4 questionnaires into sexual risk behavior.
10159429|NCT04004221|Experimental|Tislelizumab|200mg intravenously (IV) every 3 weeks(Q3W)
10159430|NCT04004572|Experimental|LEAP Regimen|Pegaspargase, 2500IU/m2, im, day 1 Sintilimab, 200mg, iv day1 Anlotinib, 8mg, oral, day 1-14 The LEAP regimen will be repeated every 3 weeks.
10159431|NCT04004091|Experimental|24-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 24 days of pregnancy. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
10159432|NCT04004091|Experimental|26-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
10159433|NCT04004091|Experimental|28-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 28 days of pregnancy. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
10159434|NCT04004091|No Intervention|24-Day Non Spermine Group|Subjects are not given any intervention. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
10159435|NCT04004091|No Intervention|26-Day Non Spermine Group|Subjects are not given any intervention. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
10159436|NCT04004091|No Intervention|28-Day Non Spermine Group|Subjects are not given any intervention. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
10159437|NCT04004143||Cross-sectional|a cross-sectional study.
10159438|NCT04004156|Experimental|Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
10159439|NCT04004234|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
10159440|NCT04004247|Experimental|Experimental group|"10-12 young healthy volunteers. Placed on semi-sitting position on the bed (40 deg.elevation). Calibration of electrical impedance tomography (EIT) on defined tidal volume 500ml, done with 500ml syringe connected to closed breathing circuit using full face mask as an interface.~Insertion an esophageal and nasopharyngeal catheter for pressures measurement. In the first phase - spontaneous breathing with full face mask at 0, 5 and 10 cm H20 levels of PEEP.~In the second phase - high flow oxygenation through nasal cannula, start with flow rate 10 L/min with gradual increase up to 60 L/min.~Spirometry to determine functional residual capacity (FRC) before and after procedure is planed."
10159441|NCT04004182|Active Comparator|OGTT session|Oral Glucose Tolerance test (OGTT)
10159442|NCT04004182|Active Comparator|Fruit bar|Fruit bar Plus Oral Glucose Tolerance test (OGTT)
10159443|NCT04004182|Experimental|Fruit bar with bilberry|Fruit bar with addition of 600 mg bilberry anthocyanins Plus Oral Glucose Tolerance test (OGTT)
10159444|NCT04004182|Experimental|Fruit bar with bilberry and apple|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols Plus Oral Glucose Tolerance test (OGTT)
10159445|NCT04004208|Experimental|Aflibercept arm|Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.
10159446|NCT04004208|Active Comparator|Laser photocoagulation arm|Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.
10159447|NCT04004169|Experimental|Arm 1: Intervention (stimulation ON)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
10159448|NCT04004169|Sham Comparator|Arm 2: Control (stimulation OFF)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
10159449|NCT04004195|Experimental|Healthy participants|
10159450|NCT04004195|Experimental|Participants with mild renal impairment|
10159451|NCT04004195|Experimental|Participants with moderate renal impairment|
10159452|NCT04004195|Experimental|Participants with severe renal impairment|
10159453|NCT04003987|Active Comparator|ESP Block|For the ESP block the ultrasound is positioned in a parasagittal fashion, 2-3 inches lateral to the spinous process. This approach visualizes the transverse process. The needle is inserted cranial-to-caudal to make contact with the shadow of the transverse process, with the needle tip deep to the fascial plane of the erector spinae muscle. Injection of saline confirms the location of the needle, and the anesthetic is injected (40 ml into each side; 20 ml injected at T8 and 20 ml injected at T12)
10186135|NCT03738813|Active Comparator|Participants Usual Care (PUC)|The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.In Control Group, these activates will be performed without any device.
10159454|NCT04003987|Active Comparator|TAP Block|For the TAP block, the ultrasound probe is placed transverse to the abdominal wall, between the iliac crest and the costal margin. The needle is placed in the plane of the probe and advanced until it is between the internal oblique and the transversus abdominis muscles. Once in the plane, 2 mL of saline is injected to confirm needle position, then the local anesthetic solution is injected (40 ml into each side; 20 ml injected for subcostal TAP and 20 ml injected for posterior TAP).
10159455|NCT04004052|Active Comparator|Group 1|Blockade of the LFCN is performed for therapeutic management of MP in group 1.
10159456|NCT04004052|Active Comparator|Group 2|Ten sessions of conventional TENS were applied to the group 2 daily 20 minutes per session, 5 days per week, for 2 weeks.
10159457|NCT04004052|Sham Comparator|Group 3|Sham TENS was applied to the group 3 with the same protocol.
10159458|NCT04004117|Experimental|Fentanyl s/l|Sublingual fentanyl will consist in liquid fentanyl at a concentration of 25 mcg/mL, with preparation by the pharmacist of pre-dosed syringes of 12,5 mcg (0,5 mL).
10159459|NCT04004117|Placebo Comparator|Placebo|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
10159460|NCT04003948|Experimental|Fixed dose|Ibogaine Hydrochloride 100 mg on each administration.
10159461|NCT04003948|Experimental|Ascending dose|Ibogaine Hydrochloride on ascending doses (100-200-300-400-500-600).
10159462|NCT04004026||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform 3 m backwards walk test.
9973578|NCT01332526||Hemodialysis patients|"Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.~CKD: nondiabetic nephropathy~duration hemodialysis 3-48 months~Hb-11-13 g/dl~well controlled hypertension ( < 140/90 mmHg)~without ACEi, ARB, allopurinol treatment~residual diuresis will be estimated for last 48 hours-between mid and next dialysis"
9973579|NCT01332539||drug-resistant partial epilepsy|
10159463|NCT04004104|Active Comparator|Control - Upright Exercise|Participants will perform upright exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
10159464|NCT04004104|Experimental|Intervention - Supine Exercise|Participants will perform supine exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
10159465|NCT04003844|Experimental|Experimental|Investigational product (IP)
10159466|NCT04003831|Other|Optical Coherence Tomographer|
10159467|NCT04003714|Experimental|Repetitive Transcranial Magnetic Stimulation Group|Patients in r-TMS group received r-TMS 20-min (1000 pulses) daily session, 5 days per weeks, for a total of 10 sessions.
10159468|NCT04003714|Sham Comparator|Sham Group|Control group received sham r-TMS with the same protocol.
10159469|NCT04003935||Control|Continuing habitual diet and lifestyle.
10159470|NCT04003935||Active 1|Ingestion of a macro- and micro-nutrient rich shake, otherwise continuing habitual diet and lifestyle.
10159471|NCT04003935||Active 2|Ingestion of an encapsulated vitamin and phytonutrient supplement, otherwise continuing habitual diet and lifestyle.
10159472|NCT04004013|Active Comparator|Lifenol|50 participants who meet the eligibility criteria will be randomised under active arm and will receive Lifenol product during 12 months
10159473|NCT04004013|Placebo Comparator|Placebo|50 participants who meet the eligibility criteria will be randomised under Placebo arm and will receive placebo product during 12 months
10159474|NCT04003727|Active Comparator|Neutral Position|Head and neck will be on neutral position.
10159475|NCT04003727|Active Comparator|Sniffing Position|Head and neck will be on sniffing position
10159476|NCT04003727|Active Comparator|Head Extension position|Head will be on simple extension position
10159477|NCT04004000|Experimental|Treatment|FSHD1 subjects with genetic confirmation with receive 15 mg of losmapimod twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for for up to approximately 1 year.
9973580|NCT01332539||controlled partial epilepsy|
10159478|NCT04003883||Emergency physicians|Emergency physicians doing shifts at the Medical University of Vienna's emergency response car will recieve a thorough cardiac pretesting. During shifts they will be attached to a Holter-ECG to detect changes in ST-T Segment and other ECG changes. Furthermore surrogate parameters of stress will be measured
10159479|NCT04003870|Experimental|Runner|Subject will undergo an assessment wearingeither the CASO or the HL. Sequence of CASO of HL will be randomly allocated.
10159480|NCT04003909|Experimental|ESP group|patients will have ultrasound guided ESP block before spinal anesthesia.
10159481|NCT04003909|Experimental|Control group|patients will have spinal Anesthesia without ESP block
10159482|NCT04003857|Experimental|PNEUMOSTEM®|A single intratracheal administration of Pneumostem® (10.0 x 10^6 cells/kg)
10159483|NCT04003857|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
9973581|NCT01332552|Experimental|Part 1: Single dose escalation|GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food
9973582|NCT01332552|Experimental|Part 2: Repeat dose escalation|GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID
9973583|NCT01332552|Experimental|Part 3: GSK2485852 + Ritonavir|GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;
9973584|NCT01332565|Experimental|Single Arm|All subjects will receive a 50 mg single dose of GSK1349572
9973585|NCT01332591|Active Comparator|Complete revascularization|"Percutaneous coronary intervention of non-infarct coronary arteries"
9973586|NCT01332591|No Intervention|Conservative management|standard guideline-based medical therapy
10159484|NCT04003792|Experimental|single arm prospective trial|
10159485|NCT04003662||inpatients|Vital signs measurement - standard of care and prototype
9973587|NCT01332604|Experimental|A|
9973588|NCT01332604|Experimental|B|
10159486|NCT04003662||outpatients|Vital signs measurement - standard of care and prototype
10159487|NCT04003662||Healthy controls|Vital signs measurement - standard of care and prototype
10186136|NCT03738800|Experimental|CD5789 Cream 200 µg/g|CD5789 200 µg/g, topical, 50g
10186137|NCT03738800|Experimental|CD5789 Cream 100 µg/g|CD5789 100 µg/g, topical, 50g
10186138|NCT03738800|Placebo Comparator|CD5789 Cream Vehicle|CD5789 Cream Vehicle, topical, 50g
10159488|NCT04003701|Active Comparator|Usual care group (control group)|Within the usual care, no one of the attendees in the room will have specific interaction with the child during this procedure, with the exception of normal/necessary interaction by the nurse and/or parent. Only minimal distraction is allowed. The child will sit down on the treatment table with the legs stretched out in front of him and the puncture-side arm in a 90-90 position next to the head or stretched out and lying down along the body, with the nurse at the puncture side and the parent at the other side standing next to him. The researcher is also present in the room, within the child's field of vision. At the end of the procedure, the nurse tells the child that he/she did very well.
10159489|NCT04003701|Experimental|Robot-assisted puncture procedure (experimental group)|During the experimental intervention, the child, a nurse, one of the parents/guardians, a researcher and the humanoid robot NAO (H25 Academic Edition, Aldebaran Robotics, Paris, France) will be present in the same room. The child will sit down in the same position as with the usual care. Next to the patient a humanoid robot of three-foot tall will sit on eye level on a slanted reading table, at the non-puncture side. The nurse will carry out the puncture procedure as performed as usual. The robot is programmed to distract the child during the entire procedure (before, during and after the puncture) by playing a game with the child based on his/her interests. The child can therefore choose between a number of games in different themes. In the end the robot tells the child that he/she did very well. During the whole intervention, the robot will be re-activated for each phase only when the child and the nurse are ready.
10159490|NCT04003688|Placebo Comparator|Placebo group|Patient will be administered saline solution followed by venous general anesthesia.
10159491|NCT04003688|Experimental|Magnesium sulfate through real weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's actual weight followed by venous general anesthesia.
10159492|NCT04003688|Experimental|Magnesium sulfate through ideal corrected weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's ideal corrected weight followed by venous general anesthesia.
10159493|NCT04003753|Experimental|Exposure|"Study phase 1: The experimental intervention in the experimental group consists of three 20-minutes VR exposures (total duration in VR: 60 minutes).~Study phase 2: The experimental intervention in the experimental group consists of six 30-minutes VR exposures as home training (total duration in VR: 3 hours) within two weeks."
10159494|NCT04003753|No Intervention|Control|"Study phase 1: The control group will not receive any active treatment. Instead they will use an App to make virtual tours (three times 20 minutes, total duration in VR: 60 minutes).~Study phase 2: The control group will not receive any active treatment (untreated comparison group)."
10159495|NCT04003363||Participants with Myotonic Dystrophy|
10159496|NCT04003415|Experimental|Investigational Device Arm|Once consented for the study, participants will undergo testing with the investigational device for a one hour period. Testing will entail the participant wearing an EKG monitor, a respiratory rate monitor, a pulse oximeter, and being positioned next to the investigational device. The investigational device is contactless and captures chest movement of participants which allows it to estimate real time heart rate and respiratory rate. Additional data collected with the EKG monitor, respiratory rate monitor, and the pulse oximeter will be used to validate the vital sign data collected by the investigational device. After data collection is complete, participant involvement will then be over. Participants will have the option to return on a later date for additional testing (up to a maximum of three sessions total), within the six month window of the study. Participants will continue their standard of care therapies for their respiratory condition.
10159497|NCT04003428|Experimental|Per-caesarean HIFU shots|Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
10159498|NCT04003259|Experimental|Overweight and obese subjects|1-year lifestyle programme
10159499|NCT04003597|Placebo Comparator|Usual-salt diet|Usual-salt diet followed for 5 weeks
10159500|NCT04003597|Active Comparator|Reduced-salt diet|Reduced-salt diet followed for 5 weeks
10159501|NCT04003298|Experimental|Electric toothbrush and power interdental device|Electric toothbrush and power interdental device
10159502|NCT04003298|Active Comparator|Electric toothbrush|Electric toothbrush
10159503|NCT04003480|Experimental|FRAME|Vein graft to be treated with FRAME
10159504|NCT04003441|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
10159505|NCT04003441|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
10159506|NCT04003376|Active Comparator|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata
10159507|NCT04003376|Experimental|fractional carbon dioxide laser and triamcinolone acetonide|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide (10mg/ml)
10159508|NCT04003376|Experimental|fractional carbon dioxide laser and platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
10159509|NCT04003376|Experimental|fractional carbon dioxide laser and vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
10159510|NCT04003571|Experimental|Augmented reality with functional electrical stimulation group|Ten participants in group A will undergo 30 minutes interactive augmented reality with functional electrical stimulation intervention and 30 minutes traditional physiotherapy per day, 3 days a week for 8 weeks.
10159511|NCT04003571|Active Comparator|Traditional physiotherapy group|Ten participants in group B will undergo 30 minutes treadmill and balance training as well as 30 minutes traditional conventional physiotherapy a day, 3 days a week, for 8 weeks.
9520099|NCT03280472|Experimental|Cognitive Bias Modification|Participants will complete three session of cognitive bias modification.
9520100|NCT03280472|Other|Symptom Tracking|Participants will track their symptoms.
9520101|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
10159512|NCT04003467|Experimental|EBP05 1.5mg|subjects will be randomly assigned to receive 3 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
10159513|NCT04003467|Experimental|Placebo for EBP05 0.5mg (1, 2, 3 or 5)|subjects will be randomly assigned to receive 3 or 5 tablets of matching EBP05 placebo orally each day for 6 months
10159514|NCT04003467|Experimental|EBP05 2.5mg|subjects will be randomly assigned to receive 5 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
10159515|NCT04003467|Experimental|EBP05 0.5mg|subjects will be randomly assigned to receive 1 tablet of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
10159516|NCT04003467|Experimental|EBP05 1.0mg|subjects will be randomly assigned to receive 2 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
10159517|NCT04003402|Experimental|Sequence 1: Participants receiving treatment sequence A,B,C,D|"Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol"
10159518|NCT04003402|Experimental|Sequence 2: Participants receiving treatment sequence B,D,A,C|"Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol"
10159519|NCT04003402|Experimental|Sequence 3: Participants receiving treatment sequence C,A,D,B|"Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol"
10159520|NCT04003402|Experimental|Sequence 4: Participants receiving treatment sequence D,C,B,A|"Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.~D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol"
10159521|NCT04003324|Experimental|Intervention group|Self-monitoring tool (Activator) and general information
10159522|NCT04003610|Experimental|Pemigatinib + Pembrolizumab|Combination of pemigatinib plus pembrolizumab.
10159523|NCT04003610|Experimental|Pemigatinib|Pemigatinib alone.
10159524|NCT04003610|Active Comparator|Standard of Care|Chemotherapy or pembrolizumab.
10159525|NCT04003558||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is a training cohort.
9671267|NCT05050656|Active Comparator|Group D (duloxetine group)|Two hours before surgery, participants received oral duloxetine 60 mg tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
9671268|NCT05050656|Placebo Comparator|Group C (control group)|Two hours before surgery, participants received oral placebo tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
10159526|NCT04003558||Sun Yat-sen University Cancer Center|The cohort of Sun Yat-sen University Cancer Center is a validation cohort.
10159527|NCT04003558||Tungwah Hospital of Sun Yat-Sen University|The cohort of Tungwah Hospital of Sun Yat-Sen University is a validation cohort.
10159528|NCT04003558||Shunde hospital of southern medical university|The cohort of Shunde hospital of southern medical university is a validation cohort.
10159529|NCT04003545|Active Comparator|Active group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
10159530|NCT04003545|Placebo Comparator|Placebo group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
10159531|NCT04003337|No Intervention|GROUP A: Morphological embryo selection|Patients enrolled in group A will receive an embryo transfer according to classical morphological criteria.
10159532|NCT04003337|Active Comparator|GROUP B: Morpho-kinetics embryo selection|Patients enrolled in group B will receive an embryo transfer according to new morphokinetics criteria.
10159533|NCT04003350|Active Comparator|Opioid Regimen|"Weeks 1-4~Oxycodone 5 mg PRN q4h (30 tablets)~Tramadol 50 mg PRN q6h (30 tablets)"
10159534|NCT04003350|Experimental|Multimodal pain regimen with PRN opioids|"Weeks 1-4~Tylenol 1000 mg q8h (standing)~Meloxicam 15 mg qD (standing).~Gabapentin 200 mg BID (with morning and evening Tylenol dose)~Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)~Esomeprazole 20mg daily if not already on another H2 blocker or PPI~Oxycodone 5 mg PRN q4h (30 tablets)~Tramadol 50 mg PRN q6h (30 tablets)"
10159535|NCT04003246|Experimental|Single Arm: Therapeutic Intervention|
10159536|NCT04003207|Experimental|Phelan-McDermid syndrome|Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy
10159537|NCT04003220||MyeloDysplastic Syndrome|platelets <150 G/l and diagnosis of myelodysplasia according to the WHO classification (abnormal bone marrow features).
10159538|NCT04003220||Idiopathic Chronic Thrombocytopenia of Unknown Significance|Acquired thrombocytopenia lasting>6 months, without feature of dysimmunity (antiplatelet Ab, or anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab, cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia in the family. All ICTUS patients included in the study will thus have a bone marrow aspiration.
10159539|NCT04003220||Immune Thrombocytopenic Purpura|Diagnosis of Immune Thrombocytopenic Purpura (ITP) is made according to the international ITP consensus (diagnostic criteria of Rodeghiero){Provan, 2010 #18}, knowing that a presumptive diagnosis of ITP is made when the history, physical examination, complete blood count, and examination of the peripheral blood smears do not suggest other etiologies for the thrombocytopenia
10159540|NCT04003220||healthy volunteers undergoing cardiac surgery|patients with normal blood counts undergoing cardiovascular surgery for valve replacement, or healthy bone-marrow donors
10159541|NCT04003233|Experimental|Spring Distraction System|The SDS device will be implanted during a scoliosis correction operation.
9527699|NCT03217630||Non-diabetic patients|
10159542|NCT04003233|Experimental|Minimal Invasive Deformity Correction system|The MID-C device will be implanted during a scoliosis correction operation.
10159543|NCT04003181|Active Comparator|Positive breath test|Patients with a positive breath test are treated with antibiotics.
10159544|NCT04003181|Active Comparator|Positive SeHCAT scan|Patients with a positive SeHCAT scan are treated with a bile acid binder.
10159545|NCT04003181|No Intervention|No intervention|Patients with a normal breath test and a normal SeHCAT scan receive no intervention.
10159546|NCT04003194|Experimental|Pinto beans|1/2 cup pinto beans eaten daily by free-living individuals for 12 consecutive weeks.
10159547|NCT04003194|Active Comparator|Green beans|1/2 cup green beans eaten daily by free-living individuals for 12 consecutive weeks.
10159548|NCT04003051|Experimental|Supportive Care (Project Prepare website)|Patients use the password-protected Project Prepare website on a computer, tablet, or phone over 10 weeks to view: videos of the swallowing and trismus exercises, tips and stories from former patients, what to expect each week of treatment, recipes and cooking demonstrations, how to take care of their teeth during treatment, strategies for stress relief, and strategies for dry mouth and nausea. This website is designed to reach underserved populations who do not have ready access to specialized preventive care.
10159549|NCT04002986|Experimental|Women at intermediate/high risk of breast cancer|Women age 35 years old identified at intermediate/high risk of breast cancer will receive genetic testing
10159550|NCT04003012|Active Comparator|EMLA|The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.
10159551|NCT04003012|Active Comparator|Lidocaine|The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.
10159552|NCT04003168|Experimental|Human BCMA targeted T Cells Injection|"A single infusion of anti-BCMA CAR transduced T cells administered intravenously at a target dose of 3 to 9 x 10^6 CAR T +cells/kg. The classic 3+3 dose escalation will be applied."
10159553|NCT04003038|Active Comparator|Group I (wound care with a standard dressing)|Patients receive wound care with a standard dressing (bandage) after surgery for 7 days.
10159554|NCT04003038|Experimental|Group II (NPWT)|Patients receive NPWT after surgery for 7 days.
10159555|NCT04002921||Right colectomy|Patient with scheduled right colectomy and with a documented preoperative scan.
10159556|NCT04002765|Other|New RA patients|"Adults aged 18 to 90 years-old~Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria~Onset of disease duration at least 1 year and at most 10 years prior to inclusion"
10159557|NCT04003077|Experimental|Laser meridian massage|They are treated with laser meridian massage on the back including Bladder meridian and Governor vessel three times a week for 4 weeks.
10159558|NCT04003077|No Intervention|Control|A control group of participants without laser meridian massage treatment are matched by age.
9671269|NCT05050890||Breast cancer|Breast cancer patients who are currently receiving neoadjuvant therapy
9973589|NCT01332617|Experimental|Treatment with combination therapy|Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
10159559|NCT04003090|Experimental|Citicoline eyes|Patients had to administer 3 drops/day of an ophthalmic solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride for 14 days before surgery and 2 hours prior to surgery.
10159560|NCT04002856|Experimental|Profhilo®|"The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated after 1 month (T1).~2 mL of Profhilo® was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 vertical-lines (3-4-3 ). The amount of product injected was 0.2 ml for each injection point."
10159561|NCT04002999|Active Comparator|Ceramic braces, directly placed|Patients in this group will be treated with directly-bonded traditional tooth-colored ceramic brackets
10159562|NCT04002999|Experimental|Ceramic braces, indirectly placed|Patients will be treated with the same brackets from treatment group 1 but using the indirect bonding technique
10159563|NCT04002999|Experimental|3D printed customized ceramic braces|Patients will be treated using indirectly bonded 3D-printed ceramic (tooth-closed) brackets
9671270|NCT05050786|Active Comparator|Standard wound dressing|
9973590|NCT01332643|Active Comparator|Test|The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
9973591|NCT01332643|No Intervention|control|The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.
9973592|NCT01332669|Active Comparator|chemoembolization|HCC patients received chemoembolization
9973593|NCT01332669|Other|Historical use of c-TACE using Lipiodiol and doxorubicin|The control arm will be of the patients that have been treated historically in the centers with conventional TACE (that is Lipiodiol plus doxorubicin).
10186139|NCT03738787|Experimental|Pancreatic duct occlusion|Patients considered at high risk for pancreatic fistula or oncological relapse due to introperative evaluation submitted to pancreatic duct occlusion with Neoprene-based glue.
10186140|NCT03738787|Active Comparator|Pancreato-Jejunal anastomosi|Patients considered at low risk for pancreatic fistula submitted to pancreato-jejunal anastomosis.
9671271|NCT05050786|Experimental|Negative Pressure Wound Therapy (NPWT)|
9671272|NCT05050604|Experimental|Choline Alfoscerate|
9973594|NCT01332682|Experimental|Resistance Training and Nutrition Counseling|
9973595|NCT01332682|Other|Nutrition Counseling|
9973596|NCT01332695|Experimental|ST101|ST101 oval tablets
10159564|NCT04002739|Experimental|Patients with Acute Coronary Syndrome (ACS)|Patients admitted to a Coronary Care Unit (CCU) with a new diagnosis of ST Elevation Myocardial Infarction (STEMI) or Non ST Elevation Myocardial Infarction (NSTEMI). Patients are eligible within 72 hours from the admission in CCU. All patients admitted to CCU are going to perform the following procedures/exams as standard clinical practice: coronary angiogram, blood samples, echocardiogram, 24-hour Holter EKG Monitoring. The experimental arm will also perform a polygraphy during CCU stay, a bioelectrical impedance and will complete baseline questionnaires assessing daytime sleepiness such as Epworth Sleepiness Scale (ESS), STOP-BANG and Mallampati score. After the discharge from CCU, patients that had a diagnosis of Obstructive Sleep Apnea Syndrome are going to complete a follow up visit in 90 days undergoing a new polygraphy, bioelectrical impedance, questionnaires (ESS, STOP-BANG and Mallampati Score), echocardiogram.
10159565|NCT04002778|Active Comparator|ROSE by endosonographer|Submitted to fine-needle aspiration. Endosonographer's on-site evaluation of sample adequacy and categorization
10159566|NCT04002778|Other|non-ROSE|Submitted to fine-needle aspiration.
10159567|NCT04002804|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
10159568|NCT04002752|Experimental|Panel A: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 1) or matching placebo as single subcutaneous injection.
10159569|NCT04002752|Experimental|Panel B: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 2) or matching placebo as single subcutaneous injection.
10159570|NCT04002752|Experimental|Panel C: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 3) or matching placebo as single subcutaneous injection.
10159571|NCT04002895|Experimental|Foliglurax|
10159572|NCT04002869||Active TB suspicion|This study will include both adults and children with suspicion of different degrees of severity of active TB (pulmonary and extrapulmonary) to bring the investigator's study population into line with the routine clinical practice and to avoid the spectrum bias
10159573|NCT04002869||Latent TB infection|Individuals with latent TB infection (adults and children), with positive TST and/or IGRAs; without any sign or radiological evidence of TB disease or any clinical picture compatible with the criteria defined in the section TB cases.
10159574|NCT04002869||NTM infection|Adult and pediatric patients with lymphadenopathies caused by NTMs or individuals with chronic respiratory diseases with a NTM microbiologically confirmed by culture isolation.
10159575|NCT04002869||Uninfected control|Both adult and children without active TB and no immunologic evidence of M. tuberculosis infection, with negative TST and/or IGRAs
10159576|NCT04002869||Other respiratory diseases|Subjects with ARIs, and subjects with lung cancer; without any clinical picture compatible with the criteria defined in TB cases section. Patients with ARIs will be identified as individuals with clinical signs, symptoms and radiology of respiratory infections, and microbiological confirmation of non-TB origin. Patients with lung cancer will be identified as those with a high clinical suspicion, a suggestive chest X-ray/computed tomography scan, and a confirmed histopathological/cytological diagnosis
10159577|NCT04002544|Active Comparator|NTG group|In this group, nitroglycerin patch will be applied near the radial artery pulsation covered with a gauze.
10159578|NCT04002544|Placebo Comparator|Control group|In this group, no patch as applied to the patient. However, a gauze will be applied to confirm blinding
10159579|NCT04002687|Experimental|ATV-PG 1000-400 mg + AQ 612 mg|T1 (n=16) - Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.
10159580|NCT04002687|Active Comparator|ATV-PG 1000-400 mg + AQ unmatched placebo|T 2 (n=12) - Atovaquone (ATV)-Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) unmatched placebo on days 1,2, 3.
10159581|NCT04002687|Active Comparator|ATV-PG unmatched placebo + AQ 612 mg|T 3 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + Amodiaquine (AQ) 612 mg on days 1,2, 3.
10159582|NCT04002687|Placebo Comparator|ATV-PG unmatched placebo + AQ unmatched placebo|T 4 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + AQ unmatched placebo on days 1,2, 3.
10159583|NCT04002830|Experimental|Taliglucerase Alpha|Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease
10159584|NCT04002661|Active Comparator|Arm 1 - Active|Participants will take flibanserin 100mg orally every night for approximately 3 months.
10159585|NCT04002661|Placebo Comparator|Arm 2 - Placebo|Participants will take a placebo orally every night for approximately 3 months.
10159586|NCT04002557||Focus group|"This is a qualitative study using focus group discussions with young people aged 12-18 who are receiving consultation summaries.~Patients attending a single diabetes service will be invited to enrol. This service serves a population from a wide geographic area and socio-economic backgrounds.~Interviews will be conducted by a qualitative researcher with relevant experience. They will be held on the day of a participant's clinic appointment within the same hospital or on the day agreed with the participant."
9973597|NCT01332695|Placebo Comparator|Placebo|oval tablets to match ST101 tablet
9671273|NCT05050604|Placebo Comparator|Placebo of Choline Alfoscerate|
10159587|NCT04002882||Subjects with Cystic Fibrosis|n=60 patients with CF ages 16-30
10159588|NCT04002882||Healthy Controls|n=30 healthy controls matched to participants with CF for age, sex, BMI, and race.
10159589|NCT04002596|Experimental|ExAblate MRgFUS treatment|Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD
10159590|NCT04002622|Experimental|TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
9671274|NCT05050812|Experimental|Grounded|All participants will sleep on a grounding mat for at least six hours per 24-hour period.
9827684|NCT02465034|Active Comparator|Healthy Control|Healthy individuals will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
9973598|NCT01332708|Experimental|Obese and overweight subjects|The participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.
9973599|NCT01332734||severe sepsis and septic shock|
9973600|NCT01332747|Experimental|Safoof e Muhazzil in its conventional powder form|safoof e muhazzil in its conventional powder form 5 gms twice daily given orally
10159591|NCT04002492|Experimental|Addition of bodyweight training|All participants in this study fall into this non randomized single group. These participants will complete a total of 12 bodyweight training sessions over a six to eight week time period. Participants will attend one session per week at Holy Name Medical Center's Physical Therapy Center and will train for one session at their home or chosen location with the aid of a video guide.
10159592|NCT04002726|Active Comparator|Group Aa|Allocated to do the app-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
10159593|NCT04002726|Active Comparator|Group As|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
10159594|NCT04002726|Active Comparator|Group Sa|Allocated to do the slide-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
10159595|NCT04002726|Active Comparator|Group Ss|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
10159596|NCT04002531|Other|Single Visit|"General and neurological examination~Vital signs including height, weight, blood pressure, pulse, temperature~12 lead ECG~2 hour Holter monitor for heart rate variability~Echocardiogram~Renal function will be assessed by the eGFR. The eGFR will be calculated from serum creatinine using CKD-EPI equation.~CBC with differential~Complete metabolic panel~Urinalysis~Urine Albumin/creatinine ratio.~Urine and plasma samples for biomarkers (Gb3, lyso-Gb3) that will be stored in -80 freezer and assayed in our lab.~Brief Pain Inventory questionnaire.~Quality of Life Questionnaires (SF36)"
10159597|NCT04002635|Active Comparator|Hormonal Replacement Therapy|Artificial preparation of the endometrium using estradiol valerate 2mg 3x/day, and vaginal micronized progesterone 2x 400mg/day.
10159598|NCT04002635|Experimental|Letrozole|Using letrozole for ovulation induction before planning the frozen embryo transfer
10159599|NCT04002427|Experimental|Only one study arm|"[14C]AZD7594 Solution for Infusion 5 µg/mL (1.1 kBq/mL)~AZD7594 Inhalation Powder, SD3FL Inhaler"
10159600|NCT04002570||GROUP I/GROUP I bis|20 breast cancer patients who performed radiotherapy treatment
10159601|NCT04002570||GROUP II|maximum 10 patients who performed radiotherapy and chemotherapy and/or immunotherapy and/or neo-adjuvant hormone therapy or/and adjuvant immunotherapy/hormone therapy.
10159602|NCT04002570||CONTROLS GROUP|healthy women with +/- 5 years compared to breast cancer patients age
10159603|NCT04002609||Group A, Active comparator|Patients in this group did not receive any rountine oxygen supplementation during the procedure. Rescue supplemental oxygen through nasal cannual was provided if clinically significant desaturation could be observed during bronchoscopy. This significant desaturation was defined as systemic oxygen saturation ≤90% on pulsoxymetry or a relative change of ≥ 4% lasting for 1 minute. N=31 patients
10159604|NCT04002609||Group B, Active comparator|Supplemental oxygen was provided for the patients through nasal cannula by a flow rate of 2 l/minutes throughout the procedure. N= 31 patients
10159605|NCT04002609||Group C, Active comparator|Supplemental oxygen administration through nasal cannula by a flow rate of 4 l/minutes throughout the procedure. N= 30 patients
10159606|NCT04002414|Active Comparator|Usually Active- Decrease|Participants who usually meet or exceed recommended levels of physical activity who will be asked to minimize activity during stimulation.
10159607|NCT04002414|Experimental|Usually Active- Maintenance|Participants who usually meet or exceed recommended levels of physical activity who will be asked to maintain usual level of activity during stimulation.
10159608|NCT04002414|Experimental|Usually Insufficiently Inactive- Increase|Participants who are usually inactive who will be asked to try to increase activity to the recommended level during stimulation.
10159609|NCT04002414|Active Comparator|Usually Insufficiently Inactive- Maintenance|Participants who are usually inactive who will be asked to maintain inactivity during stimulation.
10159610|NCT04002466||Children (6-59 months)|
10159611|NCT04002466||Women of Reproductive Age (15-49 years)|
10159612|NCT04002466||Adult Men (15-49 years)|
9520102|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
10159613|NCT04002323||HIV-1 ART-Naive|Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)
9671275|NCT05050734|Experimental|CBIT-E|For those randomized to CBIT-E, treatment will be administered according to the standard CBIT manual, which includes psychoeducation, functional assessment/interventions, habit reversal training, relaxation techniques, and a motivational reward program. However, there will be two modifications. CBIT-E will include additional in-session and out of session practice of exercises, called competing response. Treatment will include a screening visit, baseline assessment, 11 weeks (9 sessions) of CBIT-E, a post treatment assessment, and a three-month follow up assessment. Further, starting after session 3, there will be four 15-minute practice periods scheduled each week between sessions. During these practice periods, the child and therapist will meet over Microsoft Teams and the therapist will administer an enhanced reward task.
10159614|NCT04002713||ALT&AMT free flap reconstruction|Patients who underwent ALT or AMT free flap reconstruction after head and neck cancer surgery between March 1, 2008 and February 28, 2017
10159615|NCT04002271|Active Comparator|Group SA|Patients in Group SA will undergo spinal anaesthesia.
10159616|NCT04002271|Active Comparator|Group GAS|Patients in Group GAS will undergo general inhalational anaesthesia using sevoflurane.
10159617|NCT04002271|Experimental|Group TIVA|Patients in Group TIVA will undergo general anaesthesia using propofol total intravenous anaesthesia.
10159618|NCT04002700||Target Cohort 1|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years without a recent dementia diagnosis.
10159619|NCT04002700||Target Cohort 2|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years without a recent dementia diagnosis.
9520103|NCT03280446|Experimental|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
9520104|NCT03280420|Active Comparator|early catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 3 days.
10159620|NCT04002700||Target Cohort 3|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged greater than or equal to (>=) 65 years.
10159621|NCT04002700||Target Cohort 4|Participants will be analyzed for stroke-risk who are new users of haloperidol aged >= 65 year.
10159622|NCT04002700||Target Cohort 5|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years.
10159623|NCT04002700||Target Cohort 6|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years.
10159624|NCT04002700||Comparator Cohort 7|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years without a recent dementia diagnosis.
10159625|NCT04002700||Comparator Cohort 8|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged >= 65 years.
10159626|NCT04002700||Comparator Cohort 9|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years.
10159627|NCT04002453||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
10159628|NCT04002440|Active Comparator|AMIA with SHARESOURCE|For this arm, dialysis nurses will review those patients using the AMIA with SHARESOURCE connectivity platform twice a week and will contact patients who meet certain triggers. They will then offer patients interventions, ie. a change in the preset AMIA ultrafiltration program, in order to achieve prescribed dry weight.
10159629|NCT04002440|Placebo Comparator|HomeChoice PRO|For this arm, routine standard of care for peritoneal dialysis patients will continue using the HomeChoice PRO device. Data regarding treatments will be captured on a chip to be analyzed at the end of 6 months to evaluate compliance with treatments.
10159630|NCT04002349|Placebo Comparator|A: Placebo group|Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning
10159631|NCT04002349|Experimental|B: Budesonide Nasal Spray (Rhinocort)|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning
10159632|NCT04002349|Experimental|C: Levocabastine Nasal Spray (Livostine)|Treated by Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
10159633|NCT04002349|Experimental|D: Combined Treatment|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
10159634|NCT04002206|Experimental|Muscle Energy Technique|Post isometric relaxation technique was used in experimental group
10159635|NCT04002206|Active Comparator|Static Stretch|Static stretching was given in control group
10159636|NCT04002284|Experimental|anlotinib|anlotinib 12mg qd p.o. d1-14/21day/cycle
10159637|NCT04002336|Active Comparator|Traditional Voice Therapy|Standard of care (traditional) voice therapy.
10159638|NCT04002336|Experimental|App Group|Voice therapy using a smartphone app.
10159639|NCT04002076|Experimental|Robot-assisted hand combined with occupational therapy|Ten participants in group A will undergo robot-assisted hand (with visual feedback) combined with occupational therapy. They will receive 60 minutes a day and 3 days a week robot-assisted hand and occupational therapy for six weeks.
9520105|NCT03280420|Active Comparator|late catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 7 days.
9671276|NCT05050734|No Intervention|Waitlist Control (WLC)|These participants will not receive treatment during the 11-week period. Instead, they will be placed on a waitlist to receive standard CBIT following the end of the study period. The final assessment will be approximately 11 weeks after baseline.
10159640|NCT04002076|Active Comparator|Traditional occupational therapy|Another 10 participants allocated to the group B will receive 60 minutes a day and 3 days a week traditional occupational therapy for six weeks.
10159641|NCT04002115|Experimental|Clofarabine 30 mg/m^2|Day -14 through Day -10 Clofarabine 30 mg/m^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.
10159642|NCT04002128|Placebo Comparator|Group air|"Group air was mechanically ventilated using 35% oxygen in 65% air during the whole surgical procedure.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
10159643|NCT04002128|Active Comparator|Group nitrous oxyde (N2O)|"Group N2O was mechanically ventilated using 35 % oxygen and 65 % of nitrous oxyde during the surgical procedure.~Nitrous oxyde may increase cuff pressure during the general endotracheal anesthesia and result in the respiratory symptoms like sore throat, hoarseness and postoperative cough.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
10159644|NCT04002141|Experimental|Endometriosis Letrozole|Participants will be asked to take 5mg letrozole daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to letrozole. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
9520106|NCT03280407|Active Comparator|A, capecitabine|Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy
9671277|NCT05050643|Active Comparator|CACP-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
9973601|NCT01332747|Experimental|compressed tablet of safoof e muhazzil|compressed tablet of safoof e muhazzil is given in equivalent dose orally
9973602|NCT01332747|Active Comparator|atorvastatin|atorvastatin 10mg daily as a standard control
9973603|NCT01332760|Active Comparator|narrow diameter heavy dental tool|periodontal tools for dental scaling and cleaning provided that have a narrow diameter (8mm) made of heavy material (steel).
9973604|NCT01332760|Experimental|light large diameter dental tool|periodontal tools for scaling and tooth cleaning provided with large diameter (11mm) handle made of light weight material
9973605|NCT01332773|Experimental|Artery first group|"The basic principle of the artery first approach is the early identification of the SMA at its origin at the aorta with the further resection then being guided by its anatomic course.~The dissection is carried cephalad along the aorta until the origin of the SMA is reached. The posterior and right aspect of the SMA is then dissected over a few centimeters. On the right side of the SMA a replaced or accessory right hepatic artery, if present, will be identified and preserved. This maneuver should be done, if infiltration of the SMA is suspected as the procedure can be terminated at this point. Once the situation at the SMA is assessed and resectability is confirmed resection will be done."
9973606|NCT01332773|Active Comparator|Conventional Group|A wide Kocher manoeuver is performed to fully mobilize the duodenum and the head of the pancreas. The colonic mesentery on the right side is separated from the anterior surface of the duodenum and the head of the pancreas. The size of the tumor and its relation to the superior mesenteric artery, the celiac trunk, the mesentery, the portal vein, and the superior mesenteric vein is assessed. If resectability is given a Kausch-Whipple's resection is performed.
9973607|NCT01332786|Experimental|Tigecycline|
9973608|NCT01332825|No Intervention|olfactory dysfunction|subjects diagnosed with olfactory dysfunction
9973609|NCT01332825|No Intervention|normal olfaction, no saline|no smell dysfunction, not randomized to saline nasal irrigation for 7 days
9973610|NCT01332825|Other|normal olfaction|normal olfaction, randomized to saline nasal irrigation for 7 days
9973611|NCT01332838|Experimental|Sigvaris special compression stocking|
9973612|NCT01332838|Active Comparator|Standard Compression|
9973613|NCT01332864|Active Comparator|OMT to the head and rest of body|OMT is the intervention that will be applied to areas of somatic dysfunction as well as to the head using a compression of the fourth ventricle (CV4) technique.
9973614|NCT01332864|Placebo Comparator|Light touch|Light touch will be applied to the head region for 10 minutes with the patient at rest in the supine position.
9973615|NCT01332864|Experimental|OMT with CV4 to head|OMT is the intervention using the CV4 technique to the head region for 10 minutes with patient at rest.
9973616|NCT01332864|Active Comparator|OMT to the body except the head region|OMT is the intervention that will be applied to areas of somatic dysfunction in any region except the head.
9973617|NCT01332877|Experimental|enriched breakfast|high carbohydrate, high protein breakfast providing 600 kcal, 50% carbohydrate, 20% protein, 30% fat
9973618|NCT01332890|Experimental|Sequence 1|
9973619|NCT01332890|Experimental|Sequence 2|
9973620|NCT01332890|Experimental|Sequence 3|
9973621|NCT01332890|Experimental|Sequence 4|
9973622|NCT01332890|Experimental|Sequence 5|
9973623|NCT01332890|Experimental|Sequence 6|
9973624|NCT01332903|Experimental|1|[14C] AZD5069
9973625|NCT01332916|Experimental|patients aged 45 and over group|patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
9973626|NCT01332916|Active Comparator|healthy volunteers (controls) aged 45 and over|healthy volunteers (controls) aged 45 and over
9973627|NCT01332929|Experimental|Bevacizumab|first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
9973628|NCT01332942|Placebo Comparator|Placebo|
9973629|NCT01332942|Experimental|Molidustat (BAY85-3934) 5 mg|
9973630|NCT01332942|Experimental|Molidustat (BAY85-3934) 10 mg|
9973631|NCT01332942|Experimental|Molidustat (BAY85-3934) 25 mg|
9973632|NCT01332942|Experimental|Molidustat (BAY85-3934) 50 mg|
9973633|NCT01332942|Experimental|Molidustat (BAY85-3934) 75 mg|
9973634|NCT01332955|Experimental|Telaprevir-pegIFN alfa-2a-ribavirine|Single Group Assignment
9973635|NCT01333007||Cohort|
9973636|NCT01333020|Experimental|transglutaminase cross-linking of emulsion|The impact of enzyme cross linking of the protein stabilising the test emulsion on gastric emptying rate will be assessed. In this crossover study the subjects will also consume ( on a separate day)an emulsion of the same formulation but not cross-linked.
9973637|NCT01333085|Experimental|RAD001-paclitaxel-carboplatin|RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles
9973638|NCT01333124|Experimental|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
9973639|NCT01333137|Active Comparator|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
9973640|NCT01333137|Experimental|P276-00 along with Gemcitabine and carboplatin|P276-00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days.In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
9973641|NCT01333150|Experimental|Propranolol|
10159645|NCT04002141|Placebo Comparator|Endometriosis Placebo|Participants will be asked to take one tablet placebo daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to placebo. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
10159646|NCT04002141|No Intervention|No Endometriosis Control|Participants will be asked to complete surveys during their ovarian stimulation and up to 12 weeks following retrieval to evaluate symptoms of pelvic pain. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
10159647|NCT04002232|Experimental|CPP-ACP-NaF|Dental varnish that contains calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
10159648|NCT04002232|Placebo Comparator|Placebo|Dental varnish base that does not contain calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
10159649|NCT04002219|Experimental|Active arm|Subjects will receive treatment with active beverage containing the active ingredient
10159650|NCT04002219|Placebo Comparator|Placebo arm|Subjects will receive treatment with placebo beverage not containing the active ingredient
10159651|NCT04001920|Experimental|Training program|12-week strength and endurance training program
9671278|NCT05050643|Active Comparator|CACP-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
9671279|NCT05050643|Active Comparator|HCMA-EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
9671280|NCT05050643|Active Comparator|HCMA-EBQI-LC|Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
9671281|NCT05050539|Active Comparator|Early Responders to Low Intensity|Early responders will include those with targeted levels of fidelity by the October assessment. They will continue to receive low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
9973642|NCT01333150|Experimental|Placebo|
9973643|NCT01333163|Active Comparator|GLP-1|
10159652|NCT04001972|Experimental|Intervention group|Brief advice (AWARD model) + NRT-S + IM Apps and Chatbot
10159653|NCT04001972|Active Comparator|Control group|Brief advice (AWARD model) + regular SMS
10159654|NCT04001959|Active Comparator|Silver Diamine Fluoride|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Next, dry the tooth for 30 seconds with air jet followed by a drop of 30% Diamino Fluoride Silver with a disposable applicator brush for 3 minutes and after that time washing for 1 minute.
10159655|NCT04001959|Experimental|Silver Diamine Fluoride with Potassium Iodide|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Then the tooth is dried for 30 seconds with an air jet and applied one drop of the Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the surface treated with Diamino , until the formed creamy white color becomes transparent. After these steps have been completed, rinse with water for 1 minute.
9671282|NCT05050539|Active Comparator|Non-Responders Continue Low Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to continue receiving low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
9671283|NCT05050539|Experimental|Non-Responders Increasing to High Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to have high intensity support added (low intensity + holistic individualized facilitation, tailored educational materials).
9671284|NCT05050630|Experimental|TR2-ICE|All patients eligible for inclusion were treated with TR2-ICE, and the first efficacy evaluation was conducted after the second course of treatment. If the patient can achieve complete response (CR), partial response (PR), and disease stability (SD), the clinical benefit is considered, and the TR2-ICE treatment regimen is continued. The second efficacy assessment was performed after the 4th course of treatment. If patients achieved complete response (CR) or partial response (PR) compared to baseline, the clinical treatment was considered effective and the TR2-ICE treatment regimen was continued. After the completion of six courses of induction chemotherapy, an end-of-course assessment was performed. Patients with CR and PR can choose to undergo autologous hematopoietic stem cell transplantation consolidation therapy, or lenalidomide or Tirelarizin monotherapy or both combination maintenance therapy.
9671285|NCT05050513||interventional group|kidney graft preserved with M101
9671286|NCT05050513||control group|kident graft preserved in standard condition (without M101)
9973644|NCT01333163|Placebo Comparator|Placebo|
9973645|NCT01333176|Experimental|All volunteers have HbA1c test|All candidates receive same procedure
9977858|NCT01365923|Active Comparator|Remifentanil group|Remifentanil group : remifentanil effect site-TCI 2-4ng/ml
9671287|NCT05050526|Experimental|Exercise program|Participants in the experimental group will take part in a 12-week exercise program.
9671288|NCT05050526|No Intervention|Control|Participants in the control group will not receive any intervention.
9671289|NCT05050422|Placebo Comparator|Control|
9671290|NCT05050422|Active Comparator|Study|
9671291|NCT05050370|Experimental|Lifestyle-integrated exercise and care support|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and cancer-related information with personalized support.
9973646|NCT01333202|Experimental|Fresh lime|Those who were randomly assigned to receive fresh lime were instructed to use it every time they began to crave cigarettes and as often as they needed. Fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible. All participants in this group had to report the number of fresh lime slices used per day in the self-report card.
9973647|NCT01333202|Active Comparator|Nicotine gum|"The dosage of nicotine gum used in this group was primarily based on the participants' FTND scores. Those with FTND score of 4 or above were given 4-mg nicotine gum. The 2-mg gum was assigned only to light smokers. Appropriate gum use by chew and park technique was instructed to all subjects in this group. They were advised to use the gum whenever they began to crave a cigarette but not to exceed more than 20 pieces per day. All participants in this group also had to report the total number pieces of gum used per day in the self-report card. Like the lime use group, phone calls were also made every 2-3 days during the initial month of study to remind them of technique and record keeping."
9973648|NCT01333215||Group 1|Depressed older suicide non-attempters
9973649|NCT01333215||Group 2|Depressed older suicide attempters
9973650|NCT01333228|Experimental|Endothelial Progenitors Cells|Autologous bone marrow-derived endothelial progenitor cells
9973651|NCT01333241|Experimental|Lifestyle behavior intervention group|The 6-month lifestyle behavior intervention includes group education and individual teaching and coaching.
9973652|NCT01333241|Sham Comparator|Control group|Disaster Preparedness/Home Safety group education and teaching
9973653|NCT01333254|No Intervention|Indwelling urinary catheter|Patients in this group with hip fracture will get an indwelling catheter at arrival to the orthopaedic ward. The patients with arthrosis get the indwelling catheter in the morning at the day of surgery. In both cases the indwelling catheter is inserted after shower with skin disinfectant. The catheter system is kept close. The catheter will be removed in the morning on day 2 after surgery. The patients are bladder-scanned every four-hour until normal bladder function is recaptured. If the bladder volume exceeds 400ml and the patient is unable to urinate, the patient will be re-catheterised. The procedure of the patients in this arm is in accordance with common practice in the Orthopaedic clinic.
9973654|NCT01333254|Experimental|Intermittent urinary catheterisation|Patients randomised to this arm will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 400 ml urine in the bladder, the patient will be intermittent catheterised.
9973655|NCT01333267|Experimental|PTHrP group|Subjects receive PTHrP(1-36) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTHrP doses.
9973656|NCT01333267|Experimental|PTH dosing group|Subjects receive PTH(1-34) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTH doses.
9973657|NCT01333280|Experimental|Double Trouble (DTR) group|Double Trouble in Recovery groups
9973658|NCT01333280|Active Comparator|Treatment as usual|Treatment as usual while on a waiting list for DTR groups
9973659|NCT01333293|Experimental|Omalizumab|
9973660|NCT01333293|Placebo Comparator|Placebo|
9973661|NCT01333306|Experimental|tDCS and cognitive training|
9973662|NCT01333332|Experimental|Capecitabine, Radiation|
9973663|NCT01333371|Active Comparator|closed reduction with percutaneous k-wire fixation and casted|
9973664|NCT01333371|Active Comparator|open reduction internal fixation with a volar locked plate|
9973665|NCT01333410|Active Comparator|0.1% tacrolimus ointment|
9973666|NCT01333410|Active Comparator|0.1% mometasone furoate cream|
9973667|NCT01333423|Experimental|Doxil + Seliciclib|Doxil (Liposomal doxorubicin) 40 mg/m2 intravenous (IV) over 2 -3 hours on Day 4 and Seliciclib starting dose 200 mg orally twice a day on Days 1 - 3 of 28 day cycle
9973668|NCT01333449|Experimental|Single Arm|Decitabine 20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
9973669|NCT01333462|Placebo Comparator|Phosphate Buffered Saline (PBS) IN|
9973670|NCT01333462|Active Comparator|Fluzone 4 mcg HA IN|
9973671|NCT01333462|Active Comparator|Fluzone 15 mcg HA IM|
9973672|NCT01333462|Experimental|NB-1008 4 mcg HA 5% W805EC|
9973673|NCT01333462|Experimental|NB-1008 4 mcg HA 10% W805EC|
9973674|NCT01333462|Experimental|NB-1008 4 mcg HA 15% W805EC|
9973675|NCT01333462|Experimental|NB-1008 4 mcg HA 20% W805EC|
9973676|NCT01333462|Active Comparator|Fluzone 10 mcg HA IN|
9973677|NCT01333462|Experimental|NB-1008 10 mcg HA 5% W805EC|
9973678|NCT01333462|Experimental|NB-1008 10 mcg HA 10% W805EC|
9973679|NCT01333462|Experimental|NB-1008 10 mcg HA 15% W805EC|
9973680|NCT01333462|Experimental|NB-1008 10 mcg HA 20% W805EC|
9973681|NCT01333514|Experimental|Carbohydrate based prandial insulin dosing|Subjects will received prandial insulin based on the amount of carbohydrates consumed.
9973682|NCT01333514|Active Comparator|Usual Care Prandial insulin dosing|Subjects will received prandial insulin if they consume 50% or more of their meal-tray as is the usual care.
9973683|NCT01333553||Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
9973684|NCT01333566|Experimental|Intervention Group|
9973685|NCT01333566|Placebo Comparator|Control Group|
9973686|NCT01333579|Active Comparator|Active rTMS|1Hz active rTMS delivered to the unaffected hemisphere
9520107|NCT03280407|Experimental|B, FOLFOX or CAPOX|Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice
9520108|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
10159656|NCT04001998|Experimental|Tablet vs Capsule Formulation|Single oral dose of BLD-2660 capsule or tablet formulation
10159657|NCT04001998|Experimental|Dose Proportionality|Single oral dose of BLD-2660 tablet formulation
10159658|NCT04001985|Active Comparator|Immediate NG tube removal|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
10159659|NCT04001985|Active Comparator|NG tube clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
10159660|NCT04002089|Experimental|Cohort 1 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.
10159661|NCT04002089|Experimental|Cohort 2 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.
10159662|NCT04002089|Experimental|Cohort 3 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only
10159663|NCT04002089|Active Comparator|Cohort 4 - bupivacaine|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.
10159664|NCT04002245|Experimental|Go back|Application of a compress impregnated with alcoholic Betadine® by movement of return
10159665|NCT04002245|Experimental|Technique of snail|Application of a compress impregnated with alcoholic Betadine into a single movement from the center towards the periphery and covering the end surface of followed by spontaneous drying time 30 seconds.
10159666|NCT04002011|Active Comparator|Group VKA|"103 patients. First intake at postoperative day 1 or later when anticoagulation is secondary indicated.~Dosage adapted to INR = [2.0-3.0], parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) until INR > or = 2.0.~Daily INR during hospital stay, then management by familial doctor. Duration: 3 months"
10159667|NCT04002011|Active Comparator|Group DOAC|"103 patients - One drug among the 4 DOAC according the morbidity of each patient (preoperative DOAC, oral nutrition recovery).~First intake at hospital discharge - parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) during hospital stay.~Regular daily dosages according the drug, its indication (atrial fibrillation/flutter or biological mitral replacement/repair or biological tricuspid replacement versus venous thromboembolism) and the morbidity of each patient (age, weight, creatinine ou its clearance).~Validation by one referent pharmacist. No biological monitoring. Duration: 3 months"
10159668|NCT04001907|Experimental|exercise combined with β-hydroxy-β-methylbutyrate (HMB)|Resistance Exercise ( 3d/week) and HMB: 3g/d as three 1g capsules orally, for 9 weeks
10159669|NCT04001907|Placebo Comparator|exercise combined with placebo|Resistance exercise ( 3d/week) and placebo as 3g/d maltodextrin as three 1g capsules orally, for 9 weeks
10159670|NCT04002024|Active Comparator|Placebo and Treatment Arm A|The patients in treatment arm A group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the right side of their face and placebo which is moisturizer without those active ingredients on the left side of their face.
10159671|NCT04002024|Active Comparator|Treatment and Placebo Arm B|The patients in treatment arm B group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the left side of their face and placebo which is moisturizer without those active ingredients on the right side of their face.
10159672|NCT04001842|Experimental|Axially vascularized constructs|Reconstructing a mandibular defect using an axially vascularized bone substitute using the arteriovenous loop (AVL)
10159673|NCT04001712|Experimental|early caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate upon start of the respiratory support Caffeine citrate was given at a loading dose of 10 mg/kg and with a daily maintenance dose of 5 mg/kg until the patient was off respiratory support
10159674|NCT04001712|Active Comparator|late caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate 6 hours before weaning of respiratory support
10159675|NCT04002154|Experimental|A - papilocare alternative days|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
10159676|NCT04002154|Experimental|B - papilocare semiintensive|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
10159677|NCT04002154|No Intervention|C - standard of care|Arm C: usual clinical practice: no treatment
9520109|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
9520110|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.~Inclusion before initiation of anticoagulation."
9520111|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
9520112|NCT03280355|Experimental|Singing Training|Singing Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
9520113|NCT03280355|Active Comparator|Physical Training|Physical Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
9973687|NCT01333579|Placebo Comparator|Placebo rTMS|1Hz placebo rTMS delivered to the vertex
9973688|NCT01333605|Experimental|IGEV regimen|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles
9973689|NCT01333618|Experimental|curving introducer|
9973690|NCT01333618|Placebo Comparator|straight introducer|
9973691|NCT01333631|Experimental|Valporoic acid + chemoradiotherapy|
9973692|NCT01333644||HIV-Infection|Treated HIV-infected individuals with an undetectable HIV RNA level (< 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals.
9973693|NCT01333657||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
9973694|NCT01333657||Sepsis|"sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
9973695|NCT01333670|Experimental|Prontosan wound irrigation solution|
9973696|NCT01333670|Active Comparator|Standard care|
9973697|NCT01333683||Control|Normal subjects
9973698|NCT01333683||AH|Arterial hypertension patients
9973699|NCT01333696|Experimental|Pemetrexed|500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
9973700|NCT01333709|Experimental|Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy within 2-4 weeks after the end of the induction chemotherapy."
9973701|NCT01333709|Other|Arm B: RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
9973702|NCT01333709|Other|Arm C: RCT Cap 50 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
9973703|NCT01333709|Experimental|Bras D: RCT Cap 60 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 60 grays (2Gy/day, 5 days a week, 6 weeks, boost 14 Gy)."
9973704|NCT01333735||Patients with chemotherapy group|Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
9973705|NCT01333735||Patients without chemotherapy group|patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
9973706|NCT01333748|Experimental|patients group|Patients with ovarian and/or breast cancer
9973707|NCT01333748|Other|control population|control population without history of breast and/or ovarian cancer
9973708|NCT01333761|Experimental|TCD/Cardiox FDS/TEE testing|All patients enrolled will be evaluated with TCD and Cardiox FDS and TEE for the presence of RTLS.
9973709|NCT01333774||Group 1|
9973710|NCT01333787|Active Comparator|Dietary Fiber Mixture|The dietary fiber mixture was composed of six different types of fibers. It was used for treatment of chronic constipation in children.
9973711|NCT01333787|Placebo Comparator|Maltodextrine|Blinded control group
9520114|NCT03280342|Active Comparator|IR-TPM (Topamax)|IR-TPM (Topamax)
9973712|NCT01333800|Active Comparator|Ciclesonide|
9973713|NCT01333800|Placebo Comparator|Beclomethasone|
9973714|NCT01333826|Experimental|Unconditional cash transfers|Monthly cash transfers given to households with school aged girls with no strings attached. Transfer amounts randomized within this arm.
9973715|NCT01333826|Experimental|Conditional Cash Transfer|Monthly cash transfers given to households with school aged girls conditional on regular school attendance (80%). Transfer amounts randomized within this arm.
9973716|NCT01333826|No Intervention|Control Group|No cash transfer program implemented in this group.
9973717|NCT01333839|Active Comparator|standard exercise intervention|12 weeks of endurance exercise training
9973718|NCT01333839|Active Comparator|modified exercise intervention|combined endurance + strength exercise training
9973719|NCT01333839|Active Comparator|modified 2 exercise intervention|combined endurance + strength exercise training + oral protein supplements
9973720|NCT01333852|Active Comparator|Paclitaxel, placebo|Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
9973721|NCT01333852|Experimental|Paclitaxel plus metformin|Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
9973722|NCT01333878|Experimental|Open-Label Subcutaneous Abatacept|Open-Label Subcutaneous Abatacept
9973723|NCT01333891|Active Comparator|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
9973724|NCT01333891|Active Comparator|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
9973725|NCT01333891|Active Comparator|Suction Cup|suction force of 25, 50, 75, and 100 mmHg
9973726|NCT01333904|Experimental|PUR118|
9973727|NCT01333917|Experimental|Curcumin|4g Curcumin C3 tablet daily
9973728|NCT01333930|Experimental|Test product (Active O2)|
9973729|NCT01333930|Placebo Comparator|Placebo (Adelholzener Mineralwasser)|
9973730|NCT01333969|Active Comparator|Ishcemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components).
9973731|NCT01333969|No Intervention|Control|In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
9977859|NCT01365923|Active Comparator|Dexmedetimidine group|Dexmedetomidine group: remifentanil effect site-TCI 2-4ng/ml + dexmedetomidine 0.5mcg/kg
10159678|NCT04001764|Active Comparator|The first group|The radial artery catheterization with ultrasound-guided short axis out of plane intervention will be performed over 2 cm of the wrist for this group.
10159679|NCT04001764|Experimental|The second group|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
10159680|NCT04001764|Experimental|The third group|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
10159681|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach bath|Subjects will complete a total of 5 study visits over 11 days. At visits 1-4, subjects will soak their forearms in either dilute bleach or dilute vinegar for 10 minutes. At all visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected.
10159682|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach gauze soaks|Subjects will complete a total of two study visits over 21 days, and will be instructed to apply gauze soaks daily at home over the 21-day study period. At baseline and 21-day follow-up visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected. Subjects will also be provided with a non-invasive skin barrier measurement device to take daily recordings at home.
10159683|NCT04001751|Experimental|Therapeutic educational postural yoga program|Daily 15-min yoga sessions at home during 12 weeks. One 90-min yoga-therapeutic education session/week (during 6 weeks).
10159684|NCT04001725|Active Comparator|A (Dexamethasone)|Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route (control arm). The total dose can either administered once a day or through a refracted schedule
10159685|NCT04001725|Experimental|B (Dexamethasone and Metformin)|"Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route.The total dose can either administered once a day or through a refracted schedule.~The same patients subjected at a metformin. Metformin initial dosage will be 850 mg per day, and will be escalated based on patient tolerability up to a maximum of 2550 mg daily (experimental arm)."
10159686|NCT04001868|Experimental|Experimental Group|Application of the sub occipital inhibition technique.
10159687|NCT04001868|Placebo Comparator|Placebo Group|Hand contact in the sub occipital region without executing any technique.
10159688|NCT04001790|Experimental|Project Search + ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center where they rotate through three 10-12 week internships within the business learning marketable skills, social communication, and adaptive behavior in the business setting. In order to meet the unique needs of youth with ASD, Wehman, et al. (2014) enhanced the Project SEARCH model by adding autism supports to the original model. Those added supports were: 1) on-site, intensive, systematic instruction using the principles of applied behavior analysis, 2) on-site support and consultation from a behavior/autism specialist, and 3) intensive staff training in ASD and the Project SEARCH Model.
10159689|NCT04001790|No Intervention|Business as Usual|Business as Usual means these youth remain in their high school programs as determined on their individualized education plans
10159690|NCT04001699|Experimental|Intervention|Preoperative assessment conducted by an interprofessional team
10159691|NCT04001699|Active Comparator|Usual care|Usual care
10159692|NCT04001673|Active Comparator|Pharmacist's intervention|Evaluation of knowledge and adherence of patients treated by bDMARDs before and after the intervention of a pharmacist that will give information concerning bDMARDs management.
10159693|NCT04001673|No Intervention|Control|Evaluation of knowledge and adherence of patients treated by bDMARDs who did not receive pharmacist's intervention.
10159694|NCT04001647|Experimental|TUDCA|Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
9671292|NCT05050396|Experimental|Cooled radio frequency|In CRF, water circulates inside the probe to remove heat, modulating the thermal heat in the tissue to around 60°C, and alters the overall size, shape, and projections of lesions compared to conventional RFA. It is postulated that the greater sized CRF lesions may reduce the number of technical failures in the setting of a complex and variable neuronal innervation to the knee. The ability to target a greater amount of neuronal tissue is believed to produce long-term pain relief at least to the duration of relief produced by conventional RFA [27]
9827685|NCT02465073|Active Comparator|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. ( NXTSC).
10186141|NCT03738761|Experimental|Amlessa® Arm|Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.
10186142|NCT03738761|Experimental|Co-Amlessa® Arm|Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
9520115|NCT03280342|Active Comparator|XR-TPM (Trokendi XR)|
10159695|NCT04001647|Placebo Comparator|Placebo|Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
10159696|NCT04001660|Experimental|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
10159697|NCT04001738|Active Comparator|Direct Transfer to Angio Suite|After a fast neurological evaluation, patient will be direct transferred to angiography suite where endovascular treatment (EVT) team will be waiting for it. It will be done a cone beam-CT and if the image don't contraindicate endovascular treatment it will be performed and the large vessel occlusion will be confirmed by arteriography. If intravenous treatment have not been previously administered, it will be able to start in parallel.
10159698|NCT04001738|No Intervention|Direct Transfer to CT Scan|After a fast neurological evaluation, patient will be transferred to CT suite where usual image protocol will be performed (CT and CT-angio). Within 6 hours from onset CT perfusion could be required to take detections. Once interpreted image results, it will be decided intravenous and/or endovascular treatment.
10159699|NCT04001595||Participants with FKRP genetic mutation|
10159700|NCT04001608|Experimental|Seraprevir and sofosbuvir|Subjects will receive oral tablets of Seraprevir 100mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12.
10159701|NCT04001582||Participants with FSHD|
10159702|NCT04001465|Active Comparator|Volumetric methacholine challenge|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer
10159703|NCT04001465|Active Comparator|Methacholine challenge with spirometer|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer fitted with an ultrasonic spirometer
10159704|NCT04001478||Control group|Patients who are attending hospital for a gastroscopy as part of their routine clinical care as a 2 week wait rule referral and those on Barrett's surveillance , will be asked to give a sample of their breath prior to the procedure.
10159705|NCT04001478||Early oesophageal cancer (T1)/ Barrett's high grade dysplasia|Patients who have known pre-diagnosed T1 oesophageal adenocarcinoma or HGD attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation. Patients will be sampled upon return for follow up endoscopy to assess breath profile changes and correlation with endoscopy findings.
10159706|NCT04001478||Advanced Oesophageal cancer (T2/3/4)|Patients who have been diagnosed with oesophageal adenocarcinoma attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation.
10159707|NCT04001439|Other|Clinical trial|the study design is an open-label, single-arm propective clinical trial. In this proof-of-concept study we will assess feasibility safety and potential efficacy of an intervention of FMT in SZ subjects with MD.
10159708|NCT04001231|Experimental|Single arm of exenatide once-weekly suspension|Exenatide once-weekly suspension via subcutaneous (SC) injection
10159709|NCT04001543|Experimental|Immunomodulating oral supplementation|"The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
10159710|NCT04001543|Active Comparator|Sip feed control|"The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
10159711|NCT04001218|Experimental|Painful condition|Participants will be injected with 0.5ml hypertonic saline (5.8%) into a neck muscle
10159712|NCT04001218|Experimental|Control condition|Participants will be injected with 0.5ml Isotonic saline (0.9%) into a neck muscle
10186143|NCT03738748|Experimental|Ultrasound-guided Percutaneous Neuromodulation|This group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L3 (1 times/ 4 weeks).
10186144|NCT03738748|Active Comparator|TENS therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region (1 times/ 4 weeks).
10186145|NCT03738735|No Intervention|Control|Patients will receive standard of care lactated ringer's solution for the arthroscopic irrigation during surgery.
9826393|NCT02416934|Experimental|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
10159713|NCT04001400|Experimental|High-dose rabeprazole|Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
10159714|NCT04001400|Active Comparator|Standard-dose rabeprazole|Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks
10159715|NCT04001387||Spinal anesthesia|
10159716|NCT04001413|No Intervention|Arm A: Observational|No intervention, observational arm.
10159717|NCT04001413|Experimental|Arm B: Durvalumab Alone|Durvalumab will be administered as an IV Infusion.
10159718|NCT04001413|Experimental|Arm C: MEDI0457 and Durvalumab|MEDI0457 is an injection. Durvalumab will be administered as an IV Infusion.
10159719|NCT04001335||CL suspicion|Patients with skin lesions suspected to be cutaneous leishmaniasis
10159720|NCT04001530|Experimental|Half-normal saline|Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters
10159721|NCT04001530|Active Comparator|Normal saline|Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters
10159722|NCT04001283|Experimental|sodium nitrite 24hours before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 24 hours prior to CABG surgery
10159723|NCT04001283|Experimental|sodium nitrite 30minutes before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 30 minutes prior to CABG surgery
10159724|NCT04001283|Placebo Comparator|0.9% sodium chloride|Intravenous normal (0.9%) sodium chloride infused at 1ml/min
10159725|NCT04001153||Upper primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
9973732|NCT01333982|Experimental|Referral compliance|Health workers will receive a basic maternal, newborn and child health training under the MNCS programme. Newborn sepsis management training will be organised for the study. The Bangladesh Perinatal Society (BPS) will take the lead in developing and implementing the training programme with support from Saving Newborn Lives (SNL) and other partners.Referral slips will be used in the intervention unions for all the sick newborns identified so that they seek care on a timely fashion.
9973733|NCT01333982|Experimental|Neonatal sepsis|Existing health delivery systems in the community level in managing neonatal sepsis.
9973734|NCT01333995|No Intervention|Usual Health Message|No intervention mothers will recieve standard maternal and child care education
9973735|NCT01333995|Sham Comparator|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
10159726|NCT04001153||Lower primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
10159727|NCT04001153||Upper primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
10159728|NCT04001153||Lower primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
10159729|NCT04001309|Experimental|Infectious diseases physician led|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly~Also including standard of care~infectious disease consultant on demand~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
10159730|NCT04001309|Experimental|Multiprofessional team|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention~Also including standard of care~infectious disease consultant on demand~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
10159731|NCT04001374||Ticagrelor|Ticagrelor 90mg tablet bid for 12 months
10159732|NCT04001374||Ticagrelor + ASA|Ticagrelor 90mg tablet bid for 12 months and enteric coated aspirin 81mg-100mg daily p.o. for 12 months
10159733|NCT04001140|Active Comparator|Intervention group|The intervention group will take part in the sessions of the intervention, in which they learn different skills for the purpose of emotion regulation. All participants will complete the questionnaires and take part in the experiment again. This group prevention program, which is short-term, entailing 7 sessions, synthesizes techniques from three therapeutic models: Cognitive-Behavioral Therapy, Dialectical-Behavioral Therapy and Acceptance and Commitment Therapy.
10159734|NCT04001140|No Intervention|Waiting-list group|The waiting-list group will receive the intervention 7 weeks after the intervention group finishes. The intervention group will finish the research in week 7, while the waiting-list group will start to attend the intervention. They will complete the questionnaires and the experiment.
10159735|NCT04001114|Other|Smokers with schizophrenia|This is a diagnostic group, defined independently from this study.
10159736|NCT04001114|Other|Smokers without schizophrenia|This is a diagnostic group (i.e., no diagnosis of schizophrenia), defined independently from this study.
10159737|NCT04001296|Experimental|21 day Brush Day and Night intervention|The 21 day Brush Day and Night programme aims to instruct on and encourage twice a day brushing with a fluoridated toothpaste.
10159738|NCT04001296|No Intervention|Control schools|Schools / children who receive only toothpaste / toothbrushes, no 21 day Brush Day and Night intervention
10159739|NCT04001322|Experimental|14 Intervention LGAs|Various target beneficiaries will receive broadcast, targeted and individualized SMS messages on immunization.
10159740|NCT04001322|Other|7 Control LGAs|This arm will not receive any SMS messages on immunization
10159741|NCT04001569|Experimental|AZD8186 in combination with paclitaxel|
9973736|NCT01334008|Other|Blood sampling|
9973737|NCT01334034|Experimental|Dose levels 1-7|
9973738|NCT01334047|Experimental|DC vaccine|Dendritic cells loaded with amplified ovarian cancer stem cell mRNA, hTERT and Survivin.
10159742|NCT04001361|Sham Comparator|Sham|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser inserted into knee joint but not turned on.
10159743|NCT04001361|Experimental|Laser Only|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser fiber is inserted into knee over an 18 gauge needle and micro-channels are made into the damaged cartilage.
10159744|NCT04001361|Experimental|Laser plus Marrow|Under conscience sedation, a 10mL marrow aspiration is performed. Laser fiber is inserted into the knee over an 18 gauge needle and micro-channels are made into the damaged cartilage. After the channels are made, marrow aspirate is injected over the same 18 gauge needle.
9973739|NCT01334060|No Intervention|CML HLA A2-|
10159745|NCT04001205||No oral anticoagulation|Patients without oral anticoagulation for AF
10159746|NCT04001205||Oral anticoagulation|Patients with long term oral anticoagulation
10159747|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 610|
10159748|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
10159749|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 430|
10159750|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 520|
10159751|NCT04001179||Presence of pulmonary embolism|≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
10159752|NCT04001179||No pulmonary embolism|Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
10159753|NCT04001088|Experimental|Probiotic|Probiotics in a capsule.
10159754|NCT04001088|Placebo Comparator|Placebo|Non active ingredients in a capsule.
10159755|NCT04001127|Experimental|High Intensity Functional Training|Intervention group assigned to 16 weeks of group-based high intensity functional training supervised by physiotherapists.
10159756|NCT04000828|Other|single Arm|all patients receive the measurement with Sensimed Triggerfish
10159757|NCT04000919|Sham Comparator|Effects of single-dose of carbidopa (50mg) on CNS excitability|Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
10159758|NCT04000919|Placebo Comparator|Effects of single-dose placebo on CNS Excitability|Participants will visit the lab and on one of four different occasions and will receive a placebo. Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
10159759|NCT04000919|Active Comparator|Effects of single-dose 5HTP/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive 5HTP combined with carbidopa (50-200mg HTP/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
10159760|NCT04000919|Active Comparator|Effects of single-dose L-DOPA/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive L-DOPA combined with carbidopa (50-200mg L-DOPA/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
10159761|NCT04000945|Experimental|BTL-899 Therapy Arm|
10159762|NCT04000945|Sham Comparator|Sham Arm|
10159763|NCT04000958|Experimental|PIFR group|
10159764|NCT04000958|Active Comparator|control group|
10159765|NCT04000724|Experimental|Text+Step|The TechStep Text+Step messaging intervention is a six-month technology-based culturally competent theory-based text messaging intervention that sends three automated text messages to participants daily to reduce HIV risk and increase PrEP uptake and adherence.
10159766|NCT04000724|Experimental|WebApp+Step|The TechStep WebApp+Step website intervention is a six-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV sexual risk reduction and PrEP uptake and adherence.
10159767|NCT04000724|Experimental|Information|The Information/No Step intervention includes nothing more than access to a website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
10159768|NCT04000893|Experimental|Resistance exercise session|Acute isometric session, about 20 minutes.
10159769|NCT04000893|Active Comparator|Aerobic exercise session|Acute aerobic session, about 20 minutes.
10159770|NCT04000789|Experimental|NPDR|
10159771|NCT04000789|Active Comparator|NPDR Comparator|
10159772|NCT04000789|Experimental|PDR|
10159773|NCT04000789|Active Comparator|PDR Comparator|
10159774|NCT04000711|Experimental|Outpatient oral antibiotic treatment group.|After randomization, participants assigned to receive outpatient treatment with oral cefixime at a dose of 8 mg/kg/day were discharged. Treatment was provided by the researchers. Subjects were evaluated daily at the outpatient clinic of the hospital. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed in the outpatient group, they were re-admitted to the hospital to receive intravenous antibiotics. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
10159775|NCT04000711|Active Comparator|Inpatient intravenous antibiotic treatment group.|After randomization, participants continued intravenous inpatient antibiotic with cefepime 150 mg/kg/day according to local standard of care guidelines. Subjects were evaluated daily. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed, treatment was changed according to clinical guidelines. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
9973740|NCT01334060|No Intervention|AML HLA A2-|
9973741|NCT01334060|Experimental|AML HLA A2+|
9973742|NCT01334060|Experimental|CML HLA A2+|
9973743|NCT01334073|Experimental|Axitinib plus everolimus|
9973744|NCT01334099|Experimental|Radiation combined with CP-675,206|
9973745|NCT01334112|Experimental|Axitinib|Oral Axitinib (5mg, twice daily) will be administered to all patients
9973746|NCT01334138|Experimental|4-week diet, low in sodium|The study subjects go on a 4-week diet, low in sodium.
9973747|NCT01334151|Active Comparator|Humalog®|Humalog®, administered subcutaneously on 1 occasion
9973748|NCT01334151|Experimental|BIOD- 105|BIOD- 105 administered subcutaneously on 1 occasion
10159776|NCT04001023|Experimental|PDS|18F-EF5 PET/CT and 18F-FDG PET/CT scan prior to primary cytoreductive surgery and targeted sample collection during primary cytoreductive surgery
10159777|NCT04001023|Experimental|IDS|"18F-EF5 PET/CT and 18F-FDG PET/CT scans prior to diagnostic laparoscopy and after neoadjuvant chemotherapy before interval cytoreductive surgery .~Targeted sample collection during diagnostic laparoscopy and interval cytoreductive surgery"
10159778|NCT04000906|Experimental|Experimental Arm|Pressurized intraperitoneal aerosol chemotherapy (PIPAC) administration of Nab paclitaxel and cisplatin
10159779|NCT04000984|Experimental|Mindfulness-Based Intervention|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the in the Mindfulness-Based Training program that will meet weekly for 8 weeks. Each session will last approximately one-and-a-half hours.
10159780|NCT04000984|Active Comparator|Cognitive Rehabilitation Training|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the Cognitive Rehabilitation program that will meet weekly for 8 weeks. Each session will last one-and-a-half hours.
10159781|NCT04000984|No Intervention|Treatment As Usual|Participants in the Treatment As Usual group were only required to attend baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. Participants in this group will not receive an intervention for the duration of the study. They received treatment as usual which is 6 months to 1-year follow up visits with their attending neurologist of psychologist.
10159782|NCT04000971|Active Comparator|Integrated Stroke Practice Unit (ISPU)|ISPU personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge. This will be supplemented by a more integrated model designed to increase coordination through team-based initiatives across the continuum of care for stroke - from acute and in-hospital care through 12 months post-discharge. Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, increase understanding, and build positive behavior change for patients and caregivers. Primary outcomes will be assessed by phone at 3, 6, 12, and 24 months; secondary outcomes will be assessed at 3, 6, and 12 months.
10159783|NCT04000971|Active Comparator|Comprehensive or Primary Stroke Center (CSC/PSC)|CSC/PSC personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge, follow-up clinic visits as recommended by their outpatient provider, and other clinic visits initiated by the patient when issues arise. Primary outcomes will be assessed by phone at 3, 6, 12, and 24 months; secondary outcomes will be assessed at 3, 6, and 12 months.
10159784|NCT04000750|Experimental|Time Restricted Eating (16:8)|Participants will consume all calories within an 8 hour window each day.
10159785|NCT04000750|Active Comparator|Control|Participants will consume all calories within a ~12 hour window each day (4 separate meals + needed snacks).
10159786|NCT04000841|Experimental|Intervention|Intervention participants receive access to the Mindful You app for 12 weeks. They will use the app to listen to guided meditations and to receive notifications, messages, and reminders that they select and ones sent to all participants by the app.
9973749|NCT01334151|Experimental|BIOD-107|BIOD-107 administered subcutaneously on 1 occasion
10159787|NCT04000841|No Intervention|Waitlist Control|Waitlist control participants will continue business as usual with regards to stress-management and reduction.
9671293|NCT05050396|Experimental|Thermocoagulant radio frequency|Conventional radiofrequency Ablation RFA of the knee can be performed under fluoroscopic, or other imaging, guidance, with a cannula advanced into the joint towards the area connecting the shaft to the epicondyle. The area is stimulated to identify the nerve position and to ensure that no motor nerves are activated, as evidenced by absence of fasciculations. The RF electrode is then advanced through the cannula to the target area [18] The electrode tip heats up targeted local tissue within a few millimeters to a temperature typically greater than 47°C (ranging from 70°C to 90°C) for 120 130 seconds, generated through an electromagnetic field with a frequency of 250 kHz . [15,18] The ablative heat is provided via flow of electrical current, generating a well-delineated lesion [24]
9977309|NCT01360086|Experimental|Perioperative CT with 5FU-Cisplatine-Cetuximab|6 cycles of intravenous Cetuximab (500mg/m²), Cisplatine (50mg/m²) and LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks. Surgery was planned 3-4 weeks after the end of neaodjuvant CT and postoperative CT, with the same regimen, planned for 6-8 weeks after surgery.
9520116|NCT03280329|No Intervention|Control|the patients who belong to this group will not be assigned to a regulated music therapy treatment, thus they will listen to the background sounds (alerts, voices) right in the Intensive Care environment; radio use will be allowed according to medical/ nursing judgements
10159788|NCT04001010|Experimental|inhaled THC/CBD (PPP011)|PPP011 (synthetic THC/CBD) inhalation with mighty medic device
10159789|NCT04001010|Placebo Comparator|Placebo|Placebo inhalation with mighty medic device
10159790|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX15|Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.
10159791|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX07|Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.
9977310|NCT01360138|Active Comparator|midline approach|cervical epidural steroid injection with 18G Touhy epidural needle by midline approach
9977311|NCT01360138|Active Comparator|paramedian approach|cervical epidural steroid injection with 18G Touhy epidural needle by paramedian approach
9977312|NCT01360151|Experimental|experimental|Arm 1 : combination treatment of ranibizumab(Lucentis) and verteporfin(Visudyne) injection
10159792|NCT04000698|Experimental|intervention/treatment|"Preparative chemotherapy before allogeneic HSCT~Fludarabin~Cytarabine~Venetoclax~Daratumomab~Vecanoid~treosulfan~fludarabine~thiophosphomide~Venetoclax~Plerixafor~abatacept~tocilizumab~rituximab~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
10159793|NCT04000867|Active Comparator|real TCMS treatment|Subjects with DN located in their bilateral feet that have been previously identified and have a graded average baseline score of at least 5 in each foot will receive either TCMS treatment or Sham treatment on clinic day-1 according to the contents of a sealed opaque envelope corresponding to the subject's number in the series and opened immediately before treatment on day 1. (Our statistician will have generated these envelopes and their contents in advance.) Subjects and staff evaluating the subject's response will remain blinded to treatment assignment; only the staff member setting the treatment mode will know whether it is active or sham.
10159794|NCT04000867|Sham Comparator|Sham TCMS treatment|Patients in the sham treatment group, will use the same device. The device will be switched into sham mode by the clinician by pressing a small, non-descript button on the backside of the pulse generator. The treatment device in sham mode will produce a clicking sound once every 6 seconds like the TCMS treatment mode, but no magnetic pulses will be output.
10159795|NCT04000646|Other|standard care|Standard care non-pharmacologic interventions during anesthesia induction
10159796|NCT04000646|Experimental|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
10159797|NCT04000932|Experimental|Platelet rich plasma (PRP) -T lab PRP kit|A single 1ml PRP extract injection will be will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel. performed once into the carpal tunnel in the wrist . PRP will be obtained by centrifugation of autologous anticoagulated whole blood.
10159798|NCT04000932|Active Comparator|Diprospan ®, Schering Plough|A single steroid injection (1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel.
10159799|NCT04000633|Active Comparator|lidocaine group|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
10159800|NCT04000633|Placebo Comparator|Placebo group|the patients of this group will recieve nebulization of 5 ml of normal saline prior to induction of general anesthesia
10159801|NCT04000607|Experimental|Edwards Transcatheter Atrial Shunt System|
10159802|NCT04000464|Experimental|Single Arm|24 Week Lifestyle Modification intervention
10159803|NCT04000308|Experimental|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
10159804|NCT04000308|Active Comparator|Wound Infiltration|Patricipants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
10159805|NCT04000386|Experimental|zinc oxide nanoparticles coated socks|62 patients with zinc oxide nanoparticles coated socks
10159806|NCT04000386|Placebo Comparator|placebo|62 patients with placebo socks
10159807|NCT04000347|Active Comparator|2.5% benzoyl peroxide|43 patients with 2.5% benzoyl peroxide gel
10159808|NCT04000347|Active Comparator|5% benzoyl peroxide|43 patients with 5% benzoyl peroxide gel
10159809|NCT04000412||CASE GROUP|patients with chronic infarction undergoing catheter ablation of ventricular arrhythmias
10159810|NCT04000425||ctDNA detection|The blood samples for ctDNA and other tumor markers (such as CEA, et al.) will be first collected within 7 days before surgery, and then be tested after radical gastrectomy in scheduled interval.
9520117|NCT03280329|Active Comparator|Personalised treatment|A music therapy advice will be performed with each patient (if possible from the neurological point of view) or their caregivers to assess their musical preferences and a list of songs will be generated which will be reproduced for 2 hours per day from admission to discharge with the use of earphones.
9520118|NCT03280329|Active Comparator|Generalized treatment|"Music will be broadcasted in each patient room after the creation of a 'weekly playlist' with the following considerations:~Daily sound reproduction from 7 am to 11 pm, with 10 minutes break about every 50 minutes of music;~Spread through the environment with specifically designated speakers, at a controlled volume (30-50 dB);~Choice of playlist of music both classic and modern, with very easy listening, selected according to the daily hours to restore circadian rhythm and following predictable activities of care provided to patients (hygienic care, retail food, administration other therapies, physiotherapy, visit by relatives, …);~Mixing tracks so that there is continuity and fluidity of listening"
9520119|NCT03280316|Experimental|patients with SVMs undergoing SNM|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
9520120|NCT03280316|Experimental|patients with SVMs receiving BTXA|patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
9520121|NCT03280316|Experimental|patients with SVMs receiving drug|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
9977313|NCT01360151|Active Comparator|active comparator|Arm 2 : Treatment of verteporfin(Visudyne)
9977314|NCT01360151|No Intervention|normal control group|Arm 3 : normal control group
10159811|NCT04000477|Experimental|Kevorkian curette|
10159812|NCT04000477|Experimental|Cytobrush|
10159813|NCT04000516|No Intervention|Control|The control group was asked to continue their usual eating schedule and pattern.
10159814|NCT04000516|Experimental|Evening Fasters (EF)|Evening fasters were asked to not consume food after 3 pm until the next morning.
10159815|NCT04000516|Experimental|Morning Fasters (MF)|Morning fasters were asked to not consume food from the time they woke until 11 am.
10159816|NCT04000503|Experimental|Community Health Worker Self-Collection|Door-to-door recruitment of women for self-collected HPV testing
10159817|NCT04000503|Experimental|Community Health Meeting Self-Collection|Community health meeting recruitment of women for self-collected HPV testing
10159818|NCT04000451|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
9520122|NCT03280290|Experimental|receivers|"Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)~In a complete remission rate of leucocytes with ≥ 2G / L~Affiliated to social security person or beneficiary of such a scheme."
9664662|NCT05302492|Experimental|sleep disturbance without sleep apnea nor PLMS|Intervention group: light box on elderly with sleep disturbance with PSQI > 5 and no OSA and no PLMS control group: elderly with sleep disturbance with PSQI > 5 and no OSA and no PLMS refuse light box or poor compliance
10159819|NCT04000451|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
10159820|NCT04000256||Spinal Cord Injury|The data during the first visit involves questionnaires, performance and observational measures for baseline evaluation. The 2nd to 8th visit involves feedback survey and interview data collection based on experiences of participants undergoing activity-based training using upper extremity rehabilitation equipment.
10159821|NCT04000542|Experimental|Eligible Participants|Eligible Participants that consent will receive the pharmacist intervention.
10159822|NCT04000438|Experimental|Experimental DF01 high dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
10159823|NCT04000438|Experimental|Experimental: DF01 medium dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
10159824|NCT04000438|Experimental|Experimental: DF01 low dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
10159825|NCT04000438|Placebo Comparator|Placebo comparator: PL1|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
10159826|NCT04000295|Experimental|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
10159827|NCT04000295|Active Comparator|Weekly Paclitaxel|Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity
10159828|NCT04000568||Study Population|All the infants enrolled in the study will receive 1 h of NAVA-NIV and 1h PC-NIV in a cross-over study design
10159829|NCT04000204|Experimental|HYAJOINT Plus|
10159830|NCT04000204|Active Comparator|Durolane|
10159831|NCT04000230|Experimental|TCIT|Teachers in the intervention group receive TCIT in the first half of the school year and booster coaching is provided throughout the second half of the school year as the Waitlist Control group is trained.
10159832|NCT04000230|Active Comparator|Waitlist Control|Waitlist Control teachers do not receive any intervention for the first half of the school year. They then receive the same TCIT training as the intervention group in the second half of the school year.
10159833|NCT04000490||patient with a chest pain|adult patient with a chest pain calling for urgency center
10159834|NCT04000191|Active Comparator|Usual monitored anesthesia care (MAC)|Monitored anesthesia care (MAC) administered by anesthesiology and injection of local anesthesia by the operating surgeon.
10159835|NCT04000191|Experimental|MAC and perianal ice|Monitored anesthesia care (MAC) administered by anesthesiology, application of ice to the perianal area after it is prepared with betadine, and injection of local anesthesia by the operating surgeon.
9664663|NCT05302466|Active Comparator|gymnastic (control group)|"usual care home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily."
10159836|NCT03999970|Active Comparator|Phlebotomus papatasi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus papatasi fed on blood twice in the laboratory prior to human exposure.
10159837|NCT03999970|Active Comparator|Phlebotomus duboscqi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus duboscqi fed on blood twice in the laboratory prior to human exposure.
10159838|NCT04000100|Placebo Comparator|Control group|This group received supraclavicular block using 25mL of 0. 5% bupivacaine and 1 mL normal saline
10159839|NCT04000100|Active Comparator|Neostigmine group|This group received 25 mL 0. 5% bupivacaine and 1 mL neostigmine (0.5 mg)
10159840|NCT03999892|Experimental|Consumers with SMI|Consumers with serious mental illness who attend a psychiatric rehabilitation program (PRP) will participate in a group-based diet and physical activity program.
10159841|NCT03999892|Other|Staff at PRP|Staff and peer leaders who work at a psychiatric rehabilitation program (PRP) will observe sessions of a group-based diet and physical activity program for consumers with SMI.
10159842|NCT04000178|Other|group A|patients who received polyurethane stents
10159843|NCT04000178|Experimental|group B|patients who received silicone stents
10159844|NCT04000074|Experimental|Telephonic Services - Intervention|Persons in this group are linked with a telephonic case manager to help address their social needs.
10159845|NCT04000074|No Intervention|Telephonic Services - Control|Persons in this group are similar in risk to those in the 'Telephonic Services - Intervention' arm, but are not linked with a case manager.
9664664|NCT05302466|Experimental|gymnastic plus dental bite pads (intervention group)|Identical home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily plus dental bite pads during exercise. The dental bite pads are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise.
9664665|NCT05302453|Experimental|Study Group|BBAT exercises to the participants in the study group, were performed under the leadership of two physiotherapists with internationally valid training certificates. In the face-to-face training, BBAT exercises were taught to the participants. Then the training went on via Google Meet. The lying exercises were shown on one participant before each group study and participants were asked to do lying exercises at home. Sitting and lying exercises were performed as a hybrid at one hour/in a week for 12 weeks. At the beginning and end of each group training, feedback was received from the participants' own experiences of the effects of the exercises on the body, emotions, and thoughts.
10159846|NCT04000074|Experimental|In-Person Services - Intervention|Persons in this group are linked with an in-person case manager who makes home visits to help address their social needs.
10159847|NCT04000074|No Intervention|In-Person Services - Control|Persons in this group are similar in risk to those in the In-Person Services - Intervention' arm, but are not linked with a case manager.
10159848|NCT04000321|Experimental|Windmill group 30 Mins|In the Windmill Group, the Windmill technique is carried out after 30 minutes. The windmill technique of the umbilical cord for placental development is performed by a trained obstetrician or midwife with a doctor presence. In a frustrated attempt to develop placenta using the Windmill technique, a manual removal is performed according to the clinic standard.
10159849|NCT04000321|Active Comparator|Control Group|In the control group, after a total of 45 minutes of unsuccessful application of the traditional and customary measures, the Windmill technique is used. If unsuccessful, a manual placenta removal is performed according to hospital Standards.
10159850|NCT04000113|Experimental|laser acupuncture treatment|Subjects accept low-dose near-infrared laser acupuncture (10mWx10) treatment for 5 minutes in each trial.
10159851|NCT04000113|Sham Comparator|Sham laser acupuncture treatment|Subjects accept the sham (blank) laser acupuncture treatment for 5 minutes in each trial.
10159852|NCT03999905|Experimental|Intervention Arm|Online training on Oral anticoagulant counseling.
10159853|NCT03999905|No Intervention|Control Arm|No counseling training
10159854|NCT04000087|Experimental|Intervention|Care teams randomized to intervention will have access to the screening tool.
10159855|NCT04000087|No Intervention|Control|Care teams randomized to control will continue routine practice.
10159856|NCT04000126|Active Comparator|Control C|This group will be given induction anesthesia agents in standard doses (fentanyl 3mcg/kg, propofol 2mg/ kg, rocuronium 0,6mg/kg)
10159857|NCT04000126|Experimental|Lignocaine group L|This group will be given additionally 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
10159858|NCT04000126|Placebo Comparator|Placebo P|This group will be given additionally 100 ml 0,9% NaCl iv 10 min before intubation
10159859|NCT04000022||Non-Treatment Resistant Patients|
10159860|NCT04000022||Treatment-Resistant Patients|The group of patients from NCT03944213
10159861|NCT04000165|Experimental|SC|subjects with SCD
10159862|NCT04000152|Active Comparator|Control group (group 1)|Deferred single blastocyst transfer with blastocyst selection according to morphology.
10159863|NCT04000152|Experimental|Intervention group (group 2)|Deferred single blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).
10159864|NCT03999736|Experimental|Treatment|"14 sessions x 30 minutes of 2mA transcranial direct current stimulation to the dorsolateral prefrontal cortex.~10 x sessions over the course of the initial two weeks (e.g. 5 x per week with flexibility).~4 x sessions over the course of a two week maintenance treatment."
10159865|NCT03999645|Active Comparator|Group E: Early LC (n=60)|Early laparoscopic cholecystectomy (within 72h from symptom onset)
9520123|NCT03280290|Experimental|Donors|"Member of the siblings and HLA-matched A, B, Cw, DR, DQ~Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)~Having a rate of circulating lymphocytes ≥ 1 G / L~Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population~The statutes CMV and EBV are known (positive or negative).~Affiliated to social security person or beneficiary"
10159866|NCT03999645|Active Comparator|Group L: Late LC (n=60)|Late laparoscopic cholecystectomy (after 72h up to seven days from symptom onset)
10159867|NCT03999619|Experimental|Experimental|Children will enter into the Move 2 Learn program immediately following their first assessment (between week 0 to 10)
10159868|NCT03999619|Other|Wait-list Control|Children will not participate in the program until after their second assessment (between week 11 to 21). Their control period will take place between week 0 and 10.
10159869|NCT03999671|Experimental|INSTRUMENT SF 36|Instrument SF36 Spanish version, validated in Spain, translated in several languages and applied to multiple studios in Mexico. The 36 items explore 8 dimensions: the state of physical health, physical function, physical role, body pain, general health, vitality, social function, emotional role and mental health: considering depression, anxiety, self-control, and general well-being.
10159870|NCT03999671|Active Comparator|Checklist|Verify that the interventions of both groups were carried out
9520124|NCT03280277|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
9977315|NCT01360164|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.
10159871|NCT03999632|Experimental|Mankai Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group A (Wolffia Globosa) will be allowed to have two meals a day and one protein shake (Wolffia Globosa) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Wolffia Globosa) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
10159872|NCT03999632|No Intervention|Control Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group B (Control) will be allowed to have two meals a day and one protein shake (Control) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Control) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
10159873|NCT03999580|Experimental|Experimental Arm:|"Experimental: Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day~3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)."
9520125|NCT03280251|Experimental|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
9520126|NCT03280251|Experimental|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
9520127|NCT03280251|Experimental|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
9973750|NCT01334164|Experimental|Recovery Management Checkup (RMC)|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
9973751|NCT01334164|Active Comparator|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own.
9973752|NCT01334177|Experimental|Treatment (immunotherapy and monoclonal antibody therapy)|Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9973753|NCT01334203|Experimental|Ranolazine|
9973754|NCT01334203|Placebo Comparator|Placebo|
9973755|NCT01334242|Experimental|LX4211|400 mg of LX4211 administered orally
9973756|NCT01334242|Placebo Comparator|Placebo|Nonidentical placebo administered orally
9973757|NCT01334255|Experimental|0.5 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
9973758|NCT01334255|Experimental|2.0 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
9973759|NCT01334268|Active Comparator|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Subjects will be randomized to be treated with Taxus Liberte Paclitaxel-Eluting Coronary Stent System by an interactive voice response system (IVRS).
9973760|NCT01334268|Experimental|Medtronic Resolute (Zotarolimus-eluting stent)|Subjects will be randomized to be treated with Medtronic Resolute (Zotarolimus-eluting stent) by an interactive voice response system (IVRS).
9973761|NCT01334281||Blood: Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
9973762|NCT01334281||Blood: NOT Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
9973763|NCT01334294||1. Received therapy for CNV|
9973764|NCT01334307|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
9973765|NCT01334307|Placebo Comparator|Control|Standard of Care
9973766|NCT01334320|Experimental|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
9973767|NCT01334320|No Intervention|wait and see|patient underwent primary tumor excision transorally as initial treatment, and without a cervical intervention
9973768|NCT01334333|Active Comparator|Prograf®|Prograf® is a twice daily formulation of tacrolimus
9973769|NCT01334333|Experimental|Advagraf®|Advagraf® is a once daily formulation of tacrolimus
9973770|NCT01334346|Active Comparator|Neutral Shoe|Conventional, non-minimalist, footwear.
9973771|NCT01334346|Experimental|Partial minimalist shoe|
9973772|NCT01334346|Experimental|Full minimalist|
9973773|NCT01334359|Experimental|Treatment Group|Participants randomized to the afterschool intervention
9973774|NCT01334359|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
9973775|NCT01334372|No Intervention|Treatment as Usual|Treatment as usual (TAU) outpatient care will consist of existing outpatient clinical practices utilized in the Mental Health Clinic.
9973776|NCT01334372|Experimental|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
9973777|NCT01334385||OEF/OIF Veterans through VA ECHCS|
9973778|NCT01334398||Initial Treatment Group|
9973779|NCT01334398||Deferred Treatment Group|
9973780|NCT01334424|Placebo Comparator|no propofol|induction anesthesia with midazolam 0.2 - 0.3 mg/kg
9973781|NCT01334424|Experimental|propofol induction|induction anesthesia with propofol 2 - 2.5 mg/kg
9977316|NCT01360177|Experimental|Radioactive Iodide and PET/CT|
9977317|NCT01360190|Active Comparator|fluoxetine|
9520128|NCT03280251|Experimental|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
9520129|NCT03280238|Experimental|Experiment|"Individualized painful electrical stimuli, Surpass LT stimulator (EMS Biomedical, Korneuburg, Austria) with a bipolar felt pad electrode~Measurement of pupil diameter, Algiscan® (iDMed, Marseille, France)~Measurement of Analgesia Nociception Index, PhysioDoloris® (MetroDoloris, Lille, France)"
9520130|NCT03280225||VISNs requesting implementation support|VA has divided the country into regions of care and these are called Veteran Integrated Service Networks (VISNs). This group consists of VISNs with facilities that need additional implementation support to fully implement REACH VET and that agree to participate.
9520131|NCT03280212|Experimental|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants <60kg will receive 500mg two times daily (BID), and participants >100kg will receive 1000mg BID."
9973782|NCT01334424|Experimental|propofol maintenance|induction anesthesia with midazolam 0.2 - 0.3 mg/kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
9973783|NCT01334424|Experimental|propofol induction and maintenance|induction anesthesia with propofol 2 - 2.5 mg/ kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
9973784|NCT01334450|Active Comparator|High Frequency TMS to prefrontal cortex|
9973785|NCT01334450|Active Comparator|Low Frequency TMS to Prefrontal cortex|
9973786|NCT01334450|Sham Comparator|Sham TMS on Prefrontal Cortex|
9973787|NCT01334463||mTBI+PTSD|History of active duty-related mild TBI and history of active duty-related PTSD
9973788|NCT01334463||mTBI Only|History of active duty-related mild TBI and no history of active duty-related PTSD
9973789|NCT01334463||PTSD Only|No history of active duty-related mild TBI and history of active duty-related PTSD
9973790|NCT01334463||No mTBI, No PTSD|No history of active duty-related mild TBI and no history of active duty-related PTSD
9973791|NCT01334489|No Intervention|Usual management|Usual management of monochorionic pregnancy without the pessary placement
9973792|NCT01334489|Other|Arabin Cervical Pessary|"The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.~The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs."
9973793|NCT01334502|Experimental|everolimus and RCHOP|Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.
9973794|NCT01334528||OEF/OIF Veterans mTBI|Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans with a history of mild traumatic brain injury (mTBI) with persistent self-reported symptoms.
9973795|NCT01334541||SAFE VET|
9973796|NCT01334541||E-CARE|
9973797|NCT01334567|Experimental|Tenofovir DF|
9973798|NCT01334580|Active Comparator|Methadone Drug Counseling|Methadone Drug Counseling is provided by skilled drug counselors over a 12 week period and focuses on cessation of illicit drugs
9973799|NCT01334580|Experimental|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
9973800|NCT01334593||Rectal Cancer|
9973801|NCT01334619|Other|ropivacaine volume titration|
9973802|NCT01334632|Active Comparator|Continuous interscalene block|Continuous interscalene block with bolus ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2% 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
9973803|NCT01334632|Placebo Comparator|PCA morphine|Patients with iv self-administration of morphine, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
9973804|NCT01334658|Active Comparator|Balanced Salt Solution (BSS®)|Subjects who received Balanced Salt Solution.
9973805|NCT01334658|Active Comparator|Glucose-bicarbonate-Ringer Lactate (GBRL)|Subjects who received glucose-bicarbonate-Ringer Lactate.
9973806|NCT01334671|Experimental|group 1, Atorvastatin|STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
9973807|NCT01334671|Experimental|group 2 , Atorvastatin|Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
9973808|NCT01334671|Experimental|group 3 , Atorvastatin|Group 3 will be administered with atorvastatin 20mg per day until the end of the trial
9973809|NCT01334684|Other|Metformin|"At study entry, all oral hypoglycemic agents will be discontinued for 5 days and then metformin (2,550 mg/daily) will be given for 3 months. Fasting plasma glucose will be measured at baseline and 3 months after metformin treatment. Patients will be stratified according to the median value of metformin efficacy as indicated by fasting glucose change after metformin treatment (i.e. baseline fasting glucose minus 3-month fasting glucose).~So, two subgroups of patients will be obtained, defined as relatively high responders (individual fasting glucose change > median value) or relatively low responders (individual fasting glucose change < median value) to metformin monotherapy."
9973810|NCT01334697|Experimental|Cardiotrophin-1|
9973811|NCT01334697|Placebo Comparator|Placebo|
9973812|NCT01334736|Placebo Comparator|Usual care|
9973813|NCT01334736|Active Comparator|Lung Age|
9973814|NCT01334736|Active Comparator|Contingency Management|
9973815|NCT01334736|Active Comparator|Lung age + Contingency Management|
9977318|NCT01360190|Placebo Comparator|placebo|
10159874|NCT03999580|Active Comparator|Control Arm:|"Active Comparator: Vitamin D3 600 UI/day then 600 UI/day~600 UI/day as induction therapy for 4 weeks, then 600 UI/day as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
9671294|NCT05050331|Experimental|Muscle Energy Technique (MET) Group|Post-isometric relaxation was given as the form of MET. It was applied to gastrocnemius and soleus with patient supine and foot extended, knee was flexed for soleus and extended for gastrocnemius muscle. The patient ankle was dorsiflexed by the therapist until the point of discomfort or resistance, and the patient was instructed to exert pressure using 20% force for 5-7 seconds toward plantar flexion. Relaxation was given for 5 seconds and the therapist passively dorsiflex the ankle to a new barrier. Gastrocnemius and soleus both received a single set of 5 repetitions separately. Treatment was given for 4 weeks, 3 sessions per week.
10159875|NCT03999606|Active Comparator|Mindfulness Training|Participants in the control group will be assigned to a online based mindfulness training.
10159876|NCT03999606|Experimental|Music Training|Participants in the experimental group will be assigned to a online based choir program.
10159877|NCT03999866|Active Comparator|satisfaction of instructor|visual analogy scale of the satisfaction of the instructor was recorded
10159878|NCT03999866|Active Comparator|satisfaction of the patient|visual analogy scale of the satisfaction of the patient was recorded
10159879|NCT03999866|Active Comparator|duration of view|duration of the visualization the vocal cords was recorded
10159880|NCT03999801||All|All subjects that previously received RGX-314 in a parent study are enrolled into this arm.
10159881|NCT03999957|Other|Interventional Arm|Telehealth conferencing
10159882|NCT03999840|Experimental|IMP|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
9520132|NCT03280212|No Intervention|Control Arm|"No intervention~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
9671295|NCT05050331|Experimental|Trigger Point Release Group|Trigger points of gastrocnemius muscle was released. The patient in prone lying with legs extended and the therapist in walk standing position, applied vertical downward pressure toward the trigger points for 90 seconds with the therapist's thumb. Three repetitions was given with 30 seconds relaxation time. After that, 3 longitudinal strokes in caudal to cranial direction was given by the therapist's thumb over the taut band. Treatment was provided for 4 weeks, 3 sessions per week.
10159883|NCT03999840|Placebo Comparator|Placebo|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
10159884|NCT04000139|Active Comparator|Standardized anthocyanin rich extract|3 doses of 2x 500mg in capsules daily
9973816|NCT01334749||Acute Stroke|Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German
10159885|NCT04000139|Placebo Comparator|Placebo|3 doses of 2x 500mg in capsules daily
10159886|NCT03999827|Experimental|Immediate Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning immediately after randomisation.
10159887|NCT03999827|Active Comparator|Delayed Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning 12 weeks after randomisation.
10159888|NCT03999697|Experimental|CAR-CD22 Cell immunotherapy|Enrolled patients will receive CAR-CD22 cell immunotherapy with a novel specific chimeric antigen receptor targeting CD22 antigen by infusion.
10159889|NCT03999775|Active Comparator|Calcium, vitamin D and bioactive collagen peptides supplement|In this arm, all patients received a sachet containing 5mg bioactive collagen peptides, 500 mg calcium lactate and 400 IU vitamin D3 per day.
10159890|NCT03999775|Active Comparator|Calcium and vitamin D supplement|In this arm, all patients received a chewable tablet containing 500 mg calcium carbonate and 400 IU vitamin D3 per day.
10159891|NCT03999723|Experimental|Vitamin C|Oral vitamin C (ascorbic acid) will be given in a dose of 1000 mg daily (two capsules of 500 mg once daily) starting day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier.
10159892|NCT03999723|Placebo Comparator|Placebo|Placebo will be administered orally as two capsules once daily that look and taste identical to the capsules containing vitamin C. Treatment will start day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier. The content of the placebo capsules is glucose monohydrate, potato starch, gelatin, magnesium stearate and talc.
10159893|NCT03999788|Experimental|multiple sclerosis patients|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
10159894|NCT03999788|Experimental|control subjects|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
10159895|NCT03999788|Experimental|multiple sclerosis patients with spasticity and selected SNPs|iTBS therapeutic protocol
10159896|NCT03999762|Active Comparator|Density gradient sample prep|Standard density gradient sample preparation
10159897|NCT03999762|Experimental|Automated sample prep|Automated experimental sample preparation
10159898|NCT03999567|Experimental|Pen and Paper vs. Mobile Digit Symbol Substitution Test|This validation study will assess the convergent validity of the mobile DSST application with the pencil version of the DSST. Correlations between performance on app-based version of the DSST and paper-based version of DSST will be measured.
10159899|NCT03999502|Experimental|Intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
9520133|NCT03280199|Other|Type of simulator - 1|"VR simulator with physical mannequin and probe.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
9520134|NCT03280199|Other|Type of simulator - 2|"VR simulator with virtual mannequin / abdomen~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
9520135|NCT03280199|Other|Type of image acquisition - 3|"US images are acquired through real US volumes from patients~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
10159900|NCT03999372|Experimental|PICSI procedure|PICSI procedure: PICSI dishes are conventional plastic culture dishes pre-prepared with 3 microdots of powdered. The powdered HA is re-hydrated by adding 5 μL droplets of fresh culture medium to each of the three microdots. A 2 μL droplet with suspension of treated spermatozoa is then connected with a pipette tip to these culture medium droplets. The PICSI dish is incubated under oil; within 5 minutes the bound spermatozoa are attached by their head to the surface of the HA-microdots and are spinning around their head. An ICSI injecting pipette is used to pick the best motile HA-bound sperm up and inject them one by one into an oocyte. The ICSI injecting pipette can be previously loaded with viscous medium (PVP or Sperm Slow) to facilitate sperm micromanipulation.
10159901|NCT03999372|Active Comparator|ICSI procedure|ICSI procedure: following sperm preparation as described before, samples were incubated until time of injection. Each oocyte was injected with a single morphologically abnormal and immobilized in polyvinyl Pyrolidone (PVP) spermatozoon. Individual sperm subjected to ICSI was examined and evaluated. The injection procedure was carried out in a sterilized dish using holding pipette and injection needle. Intra cytoplasmic sperm injection was performed according to the protocol of Van Steirteghem.
10159902|NCT03999385|Experimental|Immediate Training Group|8 weeks of training in Mindful Self-Compassion.
10159903|NCT03999385|Other|Waitlist Control Group|No intervention for approximately 12 weeks. After this waiting period, participants will complete 8 weeks of training in Mindful Self-Compassion.
10159904|NCT03999450|Experimental|Behavioral intervention|Patients admitted to Strong Hospital with opioid use will be given 1 to 3 brief motivational interventions and computer based cognitive behavioral therapy
10159905|NCT03999398||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
10159906|NCT03999398||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
10159907|NCT03999476|Experimental|ambu scope2|intubation of cancer tongue patients with ambu scope2 device
10159908|NCT03999476|Active Comparator|fiberoptic|intubation of cancer tongue patients with fiberoptic device
10159909|NCT03999437|Experimental|Treatment # 1|
10159910|NCT03999437|Experimental|Treatment # 2|
10159911|NCT03999437|Placebo Comparator|Placebo Control|
10159912|NCT03999541|Experimental|Freeze-all|Good quality embryos (either day 3 or 5) will be frozen and subsequent frozen embryo transfer will be arranged within three months of the egg retrival.
10159913|NCT03999541|No Intervention|Fresh embryo transfer|Women will undergo fresh embryo transfer at the cleavage (day 3) or blastocyst stage (day 5).
10159914|NCT03999099|Placebo Comparator|Placebo|
10159915|NCT03999099|Experimental|Suvorexant 10mg|Suvorexant 10mg oral dose
10159916|NCT03999099|Experimental|Suvorexant 20mg|Suvorexant 20mg oral dose
10159917|NCT03999216|Active Comparator|Loop only|Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.
10159918|NCT03999216|Active Comparator|Loop + Thiazide|Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.
10159919|NCT03999294|No Intervention|Control Group|
10159920|NCT03999294|Experimental|Experimental Group|
10159921|NCT03999203||A - T2 High Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL and consistently high FeNO levels ≥30 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
10159922|NCT03999203||B - T2 Low Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≤ 0.2x10^9/mL and consistently low FeNO levels <30 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
10159923|NCT03999203||C - Mild/Moderate Asthmatics|mild/moderate severe asthmatics (defined as step 2/3 using the GINA classification of severity) recruited from general respiratory clinics in the Belfast HSC Trust Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
10159924|NCT03999203||D - T2 Intermediate|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL OR consistently high FeNO levels ≥30 ppb.~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
10159925|NCT03999528||study group|RA Patients
10159926|NCT03999528||control group|normal control
9671298|NCT05050461|Active Comparator|Cases|Patients with a history of B-NHL
10159927|NCT03999281||Diabetic Foot Ulcers (DFU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 54 with diabetic foot ulcers
9977319|NCT01360203|No Intervention|Current Care|Patients will receive the current care provided to heart failure patients at each of the study sites
10159928|NCT03999281||Venous Leg Ulcer (VLU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 venous leg ulcers.
10159929|NCT03999190||30 subjects with schizophrenia|
10159930|NCT03999190||30 healthy controls|
10159931|NCT03999307|Experimental|Low-Level Laser Therapy (LLLT)|In the LLLT group, a low-level laser with wavelength of 808 nm, output of 250 mW, energy of 4 Joules per point and application time of 16 seconds per point will be applied on each tooth of the six maxillary anterior teeth according to this protocol: the root will be divided theoretically into 2 halves; gingival and cervical, and laser will be applied in the center of each half from both buccal and palatal sides which means 4 application points and a total energy of 16 Joules per tooth.
10186146|NCT03738735|Experimental|Intervention|Patients will receive hyperosmolar saline for the arthroscopic irrigation during surgery.
9671299|NCT05050461|Other|Controls|Spouses of cases
9520136|NCT03280199|Other|Type of image acquisition - 4|"US images are acquired through computer-generated images.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
10159932|NCT03999307|Experimental|Flapless Corticopuncture|In the flapless corticopuncture group, 3 interdental punctures located between the roots of the six maxillary anterior teeth from both the buccal and palatal sides, will be done using a 1-mm diameter round surgical Tungsten bur with 1 mm depth and 1.5 mm space between each puncture. These punctures start 2 mm from the free gingiva. Besides, an additional 2 parallel set of punctures with the same dimensions of the interdental ones will be done in the extraction sockets from both the buccal and palatal sides.
10159933|NCT03999307|Experimental|Control|Patients in control group will undergo typical orthodontic treatment only with no LLLT or flapless corticopuncture application.
10159934|NCT03999255|Experimental|Patients undergoing intrarenal surgery|
10159935|NCT03998995|Experimental|IVR rehabilitation game intervention|Clinical trial patients' use the IVR rehabilitation game for two 15 minute sessions during one physical therapy session with their usual practitioner, with support from the physiotherapist and the game expert on the team.
10159936|NCT03999008|Active Comparator|Budesonide|"Oral viscous budesonide will be given in apple sauce according to body weight at inclusion:~< 10 kg: 250 mcg BID in 5 ml apple sauce 10 kg to <15 kg: 500 mcg BID in 5 ml apple sauce >15 kg: 1000 mcg BID in 5 ml apple sauce"
10159937|NCT03999008|Placebo Comparator|Placebo|Placebo: 5 ml apple sauce BID plus 1 mL saline
10159938|NCT03999060|Experimental|Electric Stimulation|
10159939|NCT03999151|Active Comparator|Arm A: Reference Group|Arm A will receive print educational materials about the benefits of exercise and diet for men with prostate cancer, with recommendations geared at men living with prostate cancer, mailed around the date of surgery. They also receive a 9-week text messaging program focused on recovery after radical prostatectomy surgery.
10159940|NCT03999151|Experimental|Arm B (Arm A + Exercise)|Arm B receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise habits and various tools, such as the ability to track exercise; additional educational print materials on exercise; additional text messages over 2 years that supports healthy exercise habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years.
10159941|NCT03999151|Experimental|Arm C (Arm A + Diet)|Arm C receives the following: Arm A material plus access to an online portal with additional educational materials to help improve diet habits and various tools, such as the ability to track diet; additional educational print materials on diet; additional text messages over 2 years that supports healthy diet habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
9973817|NCT01334762|Experimental|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
9973818|NCT01334762|Active Comparator|CC/IUI|Patients received 100 mg CC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
10159942|NCT03999151|Experimental|Arm D (Arm A + Exercise + Diet)|Arm D receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise and diet habits and various tools, such as the ability to track exercise and diet; additional educational print materials on exercise and diet; additional text messages over 2 years that supports healthy exercise and diet habits; a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
10159943|NCT03999359|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
10159944|NCT03999359|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
10159945|NCT03999138||Single Arm|
10159946|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 4 week|Standard MERIT + 4 week baseline period
10159947|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 6 week|Standard MERIT + 6 week baseline period
10159948|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 8 week|Standard MERIT + 8 week baseline period
10159949|NCT03999164|Experimental|Moderate to Severe Traumatic Brain Injury|All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
10159950|NCT03999073||Subjects with coarctation|
10159951|NCT03999073||Controls|
10159952|NCT03999177|Experimental|Kinect-TOLF prototype|
10159953|NCT03999086||Control Group|Traditional evaluation/standard-of-care evaluation of patients undergoing multi-level spinal fusion surgery. These patients will receive point-of-care laboratory testing.
10159954|NCT03999086||Intervention arm|Utilization of TEG for decision-making regarding intra-operative transfusion in major spinal reconstruction surgery.
10159955|NCT03999125|Active Comparator|Group 1|Aflibercept intravitreal injection for CSME
9520137|NCT03280186|Experimental|Patients With SVMs|Patients with SVMs will be included in the group and undergo surgery.
9520138|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fed|fasted
9520139|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fasted|fed
9520140|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fed|fed
10159956|NCT03999125|Other|Group 2|Ranibizumab Intravitreal Injection for CSME
10159957|NCT03999125|Experimental|Group 3|Dexamethasone Implant for CSME
10159958|NCT03998982|Active Comparator|glycyrrhetinic acid Combining HD-DXM|Compound glycyrrhizin tablets 75mg three times per day, 1 month, and HD-DXM (orally at 40 mg daily for 4d )
10159959|NCT03998982|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
10159960|NCT03998956|Active Comparator|Circumferential PV isolation|Circumferential PV isolation only
10159961|NCT03998956|Experimental|Circumferential PV and BOX isolation|Circumferential PV and BOX isolation
10159962|NCT03998956|Experimental|circumferential PV and BOX isolation with substrate ablation|Atrial substrate ablation apart from circumferential PV and BOX isolation
9520141|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fasted|fasted
9520142|NCT03280147|Experimental|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
10159963|NCT03998969|Experimental|Pantoprazole and DA-5204|Pantoprazole 40mg once daily and 'DA-5204' twice daily by mouth, administered for 4 weeks
10159964|NCT03998969|Active Comparator|Pantoprazole and placebo|Pantoprazole 40mg once daily and 'placebo' twice daily by mouth, administered for 4 weeks
10159965|NCT03999034|Experimental|Patients|experimental, cognitive test, no treatment investigated. 140 patients (90 relasping remitting and 50 progressive multiple sclerosis)
10159966|NCT03999034|Experimental|Healthy controls|experimental, cognitive test, no treatment investigated. 400 healthy controls divided into 20 groups, due to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not).
10159967|NCT03999021|Experimental|Experimental Arm|All participants to receive study intervention.
10159968|NCT03998657|Experimental|Exablate Treated Arm|Treatment with Exablate Prostate 2100 Type-3 System
10159969|NCT03998696|Active Comparator|Weekly Cisplatin|Inj. Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.
10159970|NCT03998696|Experimental|Three weekly Cisplatin|Inj. Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.
10159971|NCT03998709|Other|Elevation of fasting FFA and Glucose|People with normal fasting glucose and normal fasting FFA (normal fasting glucose / normal glucose tolerance - NFG / NGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive intralipid and dextrose to raise fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
10159972|NCT03998709|Other|Lowering of fasting FFA and glucose|People with elevated fasting glucose and elevated fasting FFA (Impaired fasting glucose / impaired glucose tolerance - IFG / IGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive insulin to lower fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
10159973|NCT03998722|Experimental|Vagivital|Vagivital once Daily for 12 weeks
10159974|NCT03998670|Experimental|Prism Group|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by prism and alternate cover test (PACT) at distance or near) equally divided between the 2 lenses will be prescribed to the participant
10159975|NCT03998670|Placebo Comparator|Non-Prism Group|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism will be prescribed to the participant
10159976|NCT03998644||healthy|Subjects without colorectal disorders.
10159977|NCT03998644||precancerous|Subjects with risk factors that may contribute to the carcinogenesis.
10159978|NCT03998644||colorectal cancer|Patients who were identified by standard procedures to suffer with colorectal cancer.
10159979|NCT03998761|Active Comparator|Micronized progesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening).
10159980|NCT03998761|Active Comparator|Micronized progesterone plus dydrogesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening).
10159981|NCT03998917||Chronic Kidney Disease (CKD) Patients|Patients with chronic kidney disease and a glomerular filtration rate less than 60 ml/min of creatinine. Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
10159982|NCT03998917||Control cohort|The control cohort will consist of a group of people from the same age group as the CKD group but without chronic kidney disease. The exclusion criteria apply to this group. They will be selected from the spouses and other volunteers. This group will also perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
10159983|NCT03998605|Experimental|Abuse Prevention Program Condition|"The abuse prevention program will address: (1) BEFORE -- (a) Learning about problem of abuse and what abuse is; (b) Knowing about types of abuse, who the abusers are and where abuse happens; (c) Planning ahead and identifying safe people; (2) DURING -- (a) Rejecting abuse by saying no; (b) Getting away if possible/staying safe and paying attention, (c) Staying calm and getting home; and (3) AFTER -- (a) Telling your safe person, (b) Knowing what to do and what not to do, and (c) Reporting the abuse and getting help to cope with the event."
10159984|NCT03998605|Active Comparator|Control condition|During the study the control group will receive 12 activity sheets from the ESCAPE-NOW curriculum. Six activity sheets will be given at the initial meeting and half way through the study the remaining activity sheets will be mailed to the dyads. We chose these activity sheets because they provide abuse information that was designed for individuals with ID.
10159985|NCT03998631|Placebo Comparator|Saline Flush|This is the control arm. The TEVAR or TAVI device will be flushed with at least 60mL of standard saline to reduce bubbles in the reservoir prior to deployment. This is the standard of care.
9520143|NCT03280147|Active Comparator|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
9973819|NCT01334775|Experimental|Experimental - Cousin Biotech Adhesix|Placement of a self-adhering (sutureless) surgical mesh in open anterior inguinal hernia repair
10159986|NCT03998631|Experimental|Carbon Dioxide and Saline Flush|Carbon dioxide flush of the TEVAR or TAVI device followed by saline flush.
10159987|NCT03998930|Experimental|brain injuried patients|"Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R),~15-minute break between the two evaluations.~Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task (imagine moving the right or left wrist)."
10159988|NCT03998748|Experimental|Experimental|This group of participants will receive the feedback that they have a genetic vulnerability to depression.
9520144|NCT03280134|No Intervention|predictive nSLN-|No further axillary lymph node dissection (ALND)
10159989|NCT03998748|Active Comparator|Control|This group of participants will receive the feedback that they do not have a genetic vulnerability to depression.
10159990|NCT03998904|Experimental|Muscle preservation|Muscle preservation for hamsting graft
10159991|NCT03998904|Active Comparator|None preservation|No muscle preservation for hamstring graft
10159992|NCT03998787||Patients with Parkinson's disease|Patients with Parkinson's disease
10159993|NCT03998787||Healthy Subjects|Healthy subjects
10159994|NCT03998800|Experimental|L-arginine and L-citrulline|10 days of supplementation with 1.5 g of L-arginine and 1.5 g of L-citrulline per day
10159995|NCT03998800|Experimental|L-arginine|10 days of supplementation with 3 g of L-arginine per day
10159996|NCT03998800|Placebo Comparator|Placebo (corn-starch)|10 days of supplementation with corn-starch
10159997|NCT03998852|Experimental|Molecular imaging|Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
10159998|NCT03998826|Experimental|Piroxicam drug|20 mg piroxicam
10159999|NCT03998826|Placebo Comparator|Placebo|placebo
10160000|NCT03998865|Experimental|PEEK Provisional Abutment|The provisional crown will be fixed onto a PEEK abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
10160001|NCT03998865|Active Comparator|Titanium Provisional Abutment|The provisional crown will be fixed onto a titanium abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
10160002|NCT03998891||salt restricted diet|In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.
10160003|NCT03998891||normal salt diet|In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.
10160004|NCT03998592|Experimental|Low-dose vaccine|
10160005|NCT03998592|Experimental|Mid-dose vaccine|
10160006|NCT03998592|Experimental|High-dose vaccine|
10160007|NCT03998592|Placebo Comparator|Placebo|
10160008|NCT03998514|Experimental|Group A1 single ascending dose (SAD)|CB4211 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
10160009|NCT03998514|Experimental|Group A2 SAD|CB4211 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
10160010|NCT03998514|Experimental|Group A3 SAD|CB4211 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
10160011|NCT03998514|Experimental|Group A4 SAD|CB4211 Dose 4 (N=1) Placebo (N=1) Subcutaneous injection
10160012|NCT03998514|Experimental|Group A5 SAD|CB4211 Dose 5 (N=6) Placebo (N=2) Subcutaneous injection
10160013|NCT03998514|Experimental|Group A6 SAD|CB4211 Dose 6 (N=6) Placebo (N=2) Subcutaneous injection
10160014|NCT03998514|Experimental|Group B1 multiple ascending dose (MAD)|CB4211 Dose to be determined (TBD) (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
10160015|NCT03998514|Experimental|Group B2 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
10160016|NCT03998514|Experimental|Group B3 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
10160017|NCT03998514|Experimental|Part C|CB4211 Dose TBD (N=10) Placebo (N=10) Subcutaneous injection once daily for 28 days
9520145|NCT03280134|Active Comparator|predictive nSLN+|axillary lymph node dissection (ALND)
9671300|NCT05050409|Experimental|Brief mindfulness followed by brief mindfulness for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive another single session of brief mindfulness. Responders will continue to receive standard of care.
10160018|NCT03998137||Autograft|Standard Rigid Fixation plus autograft
10160019|NCT03998137||AUGMENT® Injectable|Standard rigid fixation plus AUGMENT® Injectable Bone Graft
10160020|NCT03998150|Active Comparator|HoLEP holmium laser enucleation of the prostate|holmium laser enucleation of the prostate
10160021|NCT03998150|Active Comparator|BPEP bipolar plasmakinetic enucleation of the prostate|bipolar plasmakinetic enucleation of the prostate
10160022|NCT03998371||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology and FISH.
10160023|NCT03998371||Non-cancer participants group|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
10160024|NCT03998254|Experimental|V503|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
10160025|NCT03998254|Active Comparator|Gardasil|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
10160026|NCT03998397|Experimental|patients with alcohol use disorders|
10160027|NCT03998397|Experimental|patients without alcohol use disorders|
10160028|NCT03998384|Active Comparator|group of autoserum|One of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.
10160029|NCT03998384|Placebo Comparator|group of placebo|The other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.
10160030|NCT03998176|Experimental|B/F/TAF|Participants will receive B/F/TAF for 48 weeks
10160031|NCT03998215|Experimental|Diphtheria booster vaccination|One booster dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
10160032|NCT03998449|Experimental|Cholera vaccination|Two doses of the vaccine against cholera
10160033|NCT03998306|Experimental|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive probiotic lozenge before falling asleep for12 weeks. They will receive hygienic and dietetic instructions. examination will be conducted before study and after 12 weeks.
9520146|NCT03280095|Experimental|Treatment 1|One capsule of test product (co-codamol 15mg/500mg capsule) containing 15mg codeine phosphate hemihydrate and 500mg paracetamol.
9520147|NCT03280095|Experimental|Treatment 2|Two capsules of test product (co-codamol 15mg/500mg capsule), each containing 15mg codeine phosphate hemihydrate and 500mg paracetamol (i.e. a total dose of 30mg codeine phosphate hemihydrate and 1000mg paracetamol).
9520148|NCT03280095|Active Comparator|Treatment 3|One tablet of reference product (co-codamol 30mg/500mg tablet) containing 30mg codeine phosphate hemihydrate and 500mg paracetamol.
9671301|NCT05050409|Experimental|Standard care followed by brief mindfulness for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive one session of brief mindfulness. Responders will continue to receive standard of care.
10160034|NCT03998306|Sham Comparator|CONTROL|no intervention
10160035|NCT03998423|Experimental|1 dose fecal microbiota transplant|This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.
10160036|NCT03998423|Experimental|2 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.
10160037|NCT03998423|Experimental|3 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.
9520149|NCT03280082|Other|MUAC Program|"At the CRENAS, MUAC as unique anthropometric criteria for admission, monitoring, and care for the SAM output will be used.~The criteria for admission include:~MUAC <120 mm~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
10160038|NCT03998124|Experimental|Peer-led intervention|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
10160039|NCT03998124|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
10160040|NCT03998436|Active Comparator|Galnobax® 14% gel plus SoC|Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)
10160041|NCT03998436|Sham Comparator|SoC Only|Only Standard of Care will be administered twice daily (150 subjects)
10160042|NCT03998436|Placebo Comparator|Vehicle plus SoC|Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)
10160043|NCT03998098||Oxygen Saturation (Oximetry)|Arm to determine the performance of the Oxygen Saturation measurement in LifeLight First
10160044|NCT03998098||Heart Rate (Pulse)|Arm to determine the performance of the Heart Rate measurement in LifeLight First
10160045|NCT03998098||Respiratory Rate|Arm to determine the performance of the Respiratory Rate measurement in LifeLight First
10160046|NCT03998098||Blood Pressure|Arm to determine the performance of the Blood Pressure measurement in LifeLight First
10160047|NCT03998475|Experimental|Transition preparation program|Transition preparation intervention for young adults with type 1 diabetes (T1D)
10160048|NCT03998345|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6. If 10mg/kg cannot be tolerated, add a dose level of 400mg to assess the tolerance
10160049|NCT03998111|Experimental|Trial|Participants will undergo one trial visit where they will ingest an oral glucose load diluted in solution (oral glucose tolerance test) and blood samples will be measured over the following 2-hours. The buffy coat layer from the baseline sample will be obtained to extract DNA.
10160050|NCT03998085|Experimental|anlotinib|
10160051|NCT03998072|Experimental|Intervention|
9520150|NCT03280082|Other|Standard Program|"Regular screenings in the communities on children between 6 and 59 months of age. Children with MUAC<125 mm will be referred to Nutrition Centers for admission.~The criteria for admission include:~MUAC<115 mm and/or~Z score <-3 and /or~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
9520151|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity & evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
9520152|NCT03280043||Cases|Women who underwent reduction mammoplasty and then developed a hematoma which required return to the operating room for evacuation.
9520153|NCT03280043||Controls|Women who had uncomplicated reduction mammoplasty.
9973820|NCT01334775|Active Comparator|Conventional - Cousin Biotech Biomesh P8|Placement of the conventional (sutured) surgical mesh in open anterior inguinal hernia repair
9671302|NCT05050409|Experimental|Brief mindfulness followed by MORE for non-responders|1 session of brief mindfulness, plus standard of care. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
9973821|NCT01334788|Experimental|sleep deprivation|These are subjects who are randomized to undergo sleep deprivation.
10160052|NCT03998072|No Intervention|Treatment as usual (waiting list control)|
10160053|NCT03998059||30 immune thrombocytopenia(ITP) patients|A total of 30 cases. The investigators plan to take 20ml of peripheral blood (PB) of these 30 ITP patients at 6 time points, including 1 day before surgery, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery
10160054|NCT03998059||20 normal controls|A total of 20 cases.18 age- and gender- matched healthy donor will also be enrolled as controls and taken 20ml of peripheral blood.
10160055|NCT03998059||Spleens of the 30 cases patients(ITP)|These 30 ITP patients agree to have splenectomy.The investigators will take a small amount of spleen tissue during surgery.
9973822|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
9520156|NCT03280017|Experimental|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
10160056|NCT03998059||Spleens of the 10 cases patients(normal controls)|The investigators also plan to take splenic tissue from 10 patients who have splenectomy due to hereditary spherocytosis or trauma.
10160057|NCT03997877|Active Comparator|Control|"The usual physical activity valued by the YPAS questionnaire (Yale Physical Activity Survey) will be maintained. The questionnaire allows to calculate the time in physical activity expressed in hours / week, the energy expenditure expressed in MET-h / week and the summary index of physical activity that takes into account the frequency and duration of physical activity and oscillates from 0 to 137. A value below 51 identifies sedentary patients. Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
10160058|NCT03997877|Experimental|Intervention|"It is intended that the exercise program have a duration of 6 months and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule and without the need for instruments or special facilities. In this sense the walk is adjusted to these assumptions and the goal of 10.000 steps / day can encourage compliance.~The subjects assigned to the intervention group will be supervised and trained by a physiotherapist who will explain the training program and resolve the doubts raised by the patient.~Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
10160059|NCT03997916|Other|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG), also known as sleep study, in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient. There will be no separate arm to test a different device.
10160060|NCT03997903|Experimental|Imatinib Intervention|
10160061|NCT03997864|Active Comparator|Treatment - prazosin|Participants randomized to this group will receive the medication prazosin.
10160062|NCT03997864|Placebo Comparator|Control - placebo|Participants randomized to this group will receive placebo .
10160063|NCT03997773|Experimental|Intervention|Will receive the intervention
10160064|NCT03997773|No Intervention|Usual care|Will receive usual care - will be the control group
10160065|NCT03997929||CASE (intra abdominal candidiasis)|Critically ill patients with a confirmed diagnosis of intra abdominal candidiasis (IAC) Definition of IAC : sterilely collected peritoneal fluid cultures that are positive for Candida spp. as determined by the signs and symptoms consistent with an active infection
10160066|NCT03997929||CONTROL (bacterial intra abdominal infection)|Critically ill patients with a non candida intra abdominal infection (bacterial peritonitis)
10160067|NCT03998033|Experimental|ET140202 T cells|ET140202 Receptor (+) T Cells
10160068|NCT03997734|Experimental|Treatment A-AB001|Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.
10160069|NCT03997734|Experimental|Treatment B-AB001|Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
10160070|NCT03997734|Active Comparator|Treatment C|Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.
10160071|NCT03997734|Placebo Comparator|Treatment A-Placebo|Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.
10160072|NCT03997734|Placebo Comparator|Treatment B-Placebo|Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
10160073|NCT03998020|Other|chronic sleep disorders|Subjects with chronic sleep disorders responsible of hypersomnolence measured by a scale of severity of sleep disorder, and blood parameters (blood sample)
10160074|NCT03997942||proprioceptive neuromuscular facilitation|PNF will be applied to randomly selected patients.
10160075|NCT03997942||Mirror therapy|Mirror therapy will be applied to randomly selected patients.
10160076|NCT03997942||Standart therapy|Standard treatment will be applied to randomly selected patients.
10160077|NCT03997890|Experimental|Symfony group|The subjects who underwent cataract surgery with binocular implantation of either Symfony or Symfony toric IOLs
10160078|NCT03997760|Experimental|SHP655|Participants with baseline SCD will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner for 14 days.
10160079|NCT03997760|Placebo Comparator|Placebo|Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion for 14 days.
10160080|NCT03997955|Experimental|Experimental group|Myofascial induction
10160081|NCT03997955|Sham Comparator|Control group|Sham myofascial induction
10160082|NCT03997994|Experimental|Experimental: DCB Treatment|Stricture patients treated by DCB
9520157|NCT03280017|Placebo Comparator|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
9520158|NCT03280004||Moxifloxacin group|
9520159|NCT03280004||β-lactams group|
10160083|NCT03997747||comprehensive genomic analysis group|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. The therapy patients received would not be based on the results of the genomic analysis.
10160084|NCT03997695|Active Comparator|Core stabilization exercise group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional."
10160085|NCT03997695|Experimental|Core stabilization exercise plus kinesio taping group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.~Kinesio Taping:~The Kinesio Taping was carried out 2 days a week for 6 weeks (12 sessions) by experienced and certificated physiotherapist. Kinesio taping was applied to spinal region."
10160086|NCT03997656|Experimental|MyDipp|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program. Each lesson will take 30 to 60 minutes to complete. The lesson will be considered complete if the participants clicked through all of the pages and answered multiple choice questions to indicate engagement and understanding.
10160087|NCT03997656|Other|Control|Participants in the control group (usual care) will receive standard health education from primary care providers in the clinic. In addition, they also will be provided with pamphlets and booklets about various health topics. They will be given a diary to record their weights, diet, physical activities and blood test result.
10160088|NCT03997682|Experimental|Hands-Up Program|Participants will be guided through a 45 minutes exercise program, set up as a group exercise class, with program modifications being made for each individual participant. In order to meet the requisite number of participants there will be approximately 4 cohorts of 10 participants. Immediately after the exercise class participants will attend a 30-minute educational session. The educational sessions will cover bone health principles, nutrition for bone health, osteoporosis practice guidelines, ways to self-monitor balance and lower extremity strength, impacts of physical activity, home hazard detection, hazards at work and in the community, postural effects on bone loading and fracture risk, and integrating physical activity in daily life. Nutritional education will emphasize the importance of calcium and vitamin D, sources of both diary and dairy free calcium, vitamin D supplements, the importance of protein, and meat and meat-free sources of protein.
10160089|NCT03997682|No Intervention|Standard Care|The control group will receive usual care after a distal radius fracture. The standard care for a distal radius fracture will receive an assessment related to whether casting or surgery is necessary. The participant may be in a cast for 6 weeks with routine check up and x-rays to monitor the healing, at 3 months, 6 months and 12 months. The participant should receive some physical therapy related to restoring function of the hand and wrist.
10160090|NCT03997630|Experimental|Interventional group|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
10160091|NCT03997630|Active Comparator|Control group|Control group: All patients included in this group will receive a low flow oxygenation (flow rate < 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
10186147|NCT03738722|Experimental|High-flow-nasal-cannula-therapy (HFNCT)|100% Oxygen at 80 l/min with flow reductions of 20 l/min, jaw thrust, with opened and closed mouth, using different flow rates (80l/min, 60l/min, 40l/min, 20l/min, 1l/min) within each subject.
10186148|NCT03738709|Experimental|Occupational therapy group sessions|In the collective experimental group, the care includes 6 group sessions of one hour each, programmed over 2 weeks and progressive courses.
9671303|NCT05050409|Experimental|Standard care followed by MORE for non-responders|Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. At the one-month post-surgical follow-up, non-responders will receive the 8 session MORE intervention. Responders will continue to receive standard of care.
9671304|NCT05050253|Experimental|SOS group|Peritoneal lavage with super-oxidized solution (SOS)
9826394|NCT02416934|Placebo Comparator|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
9826395|NCT02416973|Other|Sham of Provant|Sham of Provant
9671305|NCT05050253|Active Comparator|Control group|Peritoneal lavage with Ringer's lactate
9671306|NCT05050357|Active Comparator|hormonal intrauterine device arm|
9671307|NCT05050357|Active Comparator|progestin arm|
9671308|NCT05050188|Experimental|cohort 1: H008 20mg|H008 20mg tablets, orally, once, daily, for 7 days
9671309|NCT05050188|Experimental|cohort 1: H008 placebo 20mg|H008 placebo 20mg tablets, orally, once, daily, for 7 days
9671310|NCT05050188|Experimental|cohort 1: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
10160092|NCT03997331|Experimental|Intervention|"Subjects in the Intervention arm will receive the following:~Automated in-app messages containing behavioral and educational content that is tailored to each subject based on an assessment of their entry survey results and on their adherence and glucose data. (Behavioral Support Engine).~Targeted in-app messages and phone calls from clinicians or as designated by the Investigator (through the CRx Care app) based on the subject's adherence and glucose data.~Push notifications that alert the subject that it is time to complete a regimen event (ie take medication or take a fasting blood glucose reading).~Push notifications that alert the subject that they have missed a scheduled regimen event.~In-app messages containing adjustments to the subject's insulin glargine dose when the Investigator(s) approves an adjustment in the CRx Care App. (Treatment Support Engine)."
10160093|NCT03997331|Active Comparator|Control|Subjects in the Control arm will receive the CRx Health solution for self-management of chronic conditions.
10160094|NCT03997591||Conventional therapy|Group doing conventional rehabilitation was assessed at T0 and then after 6 weeks of conventional therapy (occupational therapy, physical therapy, aquatic therapy, musicotherapy, others)
10160095|NCT03997591||Ready2E.A.T. therapy|Group doing Ready2E.A.T. program received a mean of 1 hour per week and was assessed at T0 and then after 6 weeks of this program implementation.
9671311|NCT05050188|Experimental|cohort 2: H008 40mg|H008 40mg tablets, orally, once, daily, for 7 days
10160096|NCT03998267|Active Comparator|Intervention arm|"For the subjects using the app (intervention group): The mobile app team shall do the following:~Educate/train patients on app usage~Patients will be subscribed to the app and their profile on the app will be created~Subjects will log in their blood sugar readings and communicate with the mobile app team (educators and physician) via the app~Additionally patients will be placed on a diet and lifestyle plan as agreed upon by the patient and health care provider team, best suited towards the patient's needs~Throughout the study, patient will receive notifications and advice on how to follow diet and lifestyle changes~Throughout the study; patient interaction and app usage will be tracked~Patients will additionally be interviewed by the research team together with Droobi to capture app experience at 3 months and 6 months"
10160097|NCT03998267|Placebo Comparator|Standard of care arm|"For the subjects not using the app (the standard of care group):~At time 0, will be seen by the dietician and diabetes educators at HGH endocrine clinics as part of standards of care~The educators contact number and diabetes hotline number will be provided to the patients~o The diabetes hotline number #16099 is a new service provided to diabetes patients at the national diabetes center to help communicate with the diabetes educators with questions relating to their diabetes management, medication adjustment such as dose titrations etc.~Appointments thereafter with the educator and/or dietician will be decided and scheduled according to the individual patient needs, with a minimum visit every 3 months during the study period"
10186149|NCT03738709|Active Comparator|Individual Occupational therapy sessions|In the individual control group, care consists of 6 individual sessions of 45 minutes each, not programmed over 2 weeks and progressive courses.
10186150|NCT03738670|Experimental|RFA|Single-arm prospective observational study
10186151|NCT03738657||Screening|Olfactory screening
10186152|NCT03738657||On Study|Taste testing
10186153|NCT03738605|Experimental|Laser Group|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
10186154|NCT03738605|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
10186155|NCT03738592|Experimental|cochlear implant children|18 cochlear implant children wil include in this study
10186156|NCT03738592|Other|normal hearing children|18 normal hearing children wil include in this study
10186157|NCT03738579|Active Comparator|Control Group|After standard of care debridement and irrigation (using normal saline), Mepilex foam dressing will be used. Foam dressing will be used throughout the study, including for mid-week dressing changes.
10186158|NCT03738579|Active Comparator|Antibacterial Control|After standard of care debridement and irrigation (using normal saline), Mepilex AG foam dressing will be used. This dressing will be used throughout the study, including for mid-week dressing changes.
10186159|NCT03738579|Experimental|Next Science Group|Standard of care debridement will be performed as well as irrigation using TorrentX Wound Wash,then BlastX Wound gel will be applied to the wound before covering treatment site with Mepilex foam dressing (no AG component). BlastX will re-applied again mid-week during mid-week dressing change.
10186160|NCT03738540|Experimental|Experimental|This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
10186161|NCT03738540|Active Comparator|Control|This is the control arm of the study. This includes This includes 25 weekly then biweekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
10186162|NCT03738527|Experimental|TXA arm|
10186163|NCT03738527|Placebo Comparator|Placebo arm|
10186164|NCT03738514|Active Comparator|Group 1|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
10186165|NCT03738514|Sham Comparator|Group 2|dentifrice containing 5% potassium nitrate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
10186166|NCT03738514|Placebo Comparator|Group 3|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
9671312|NCT05050188|Experimental|cohort 2: H008 placebo 40mg|H008 placebo 40mg tablets, orally, once, daily, for 7 days
9671313|NCT05050188|Experimental|cohort 2: Lansoprazole 30mg|Lansoprazole 30mg capsule, orally, once, daily, for 7 days
9826396|NCT02416973|Other|Active Treatment|Active Provant Treatment
9826397|NCT02416973|Other|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
9973823|NCT01334801||Aortic Stenosis|Restricted aortic valve motion and a peak Doppler aortic velocity > 2.5 m/sec blood draw
10160098|NCT03997396||the DGM group|The subject recruitment was implemented in the obstetrics department of the First People's Hospital of Chongqing Liangjiang New Area, China. 255 pregnant women diagnosed with GDM by IADPSG2010 standard and their children will be enrolled into the GDM group.
10160099|NCT03997396||the Non-GDM group|In the obstetrics department of Chongqing First People's Hospital of Liangjiang New Area,China,the healthy pregnant women and delivery children in the same period were enrolled into the non-GDM group in a 1:1 ratio.
10160100|NCT03997461|Experimental|BPro vs Oscar 2|Blood pressure measurement with BPro and Oscar 2 simultaneously during 24 hours under ambulatory conditions
10160101|NCT03997474|Experimental|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
10160102|NCT03997474|Experimental|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL-2.
9520160|NCT03279978|Experimental|BI 730357|
9671314|NCT05050305|Experimental|Marizomib plus pomalidomide and dexamethasone|"A safety run-in using a modified 3+3 dose de-escalation design with relapsed/refractory multiple myeloma (RRMM) cohort, expanded to a total of 16 participants once recommended phase 2 does (RP2D) has been identified.~Marizomib (MRZ) at a pre-determined dose on Days 1, 8, 15, 22 of a 28 day study cycle~Pomalidomide (POM) at a daily predetermined dose on Days 1-21 of a 28 day study cycle~Dexamethasone (DEX) at a daily predetermined dose on Days 1, 2, 8, 9, 15, 16, 22, 23 of a 28 day study cycle~Simultaneously, relapsed/refractory multiple myeloma (RRMM) with central nervous system (CNS) involvement cohort will receive an identical modified 3+3 dose de-escalation design and expanded to an efficacy-evaluable total of 30 patients once recommended phase 2 does (RP2D has been identified"
10160103|NCT03997474|Experimental|Cohort C|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
10160104|NCT03997344|Experimental|Nature hiking|Group hikes in a natural setting (e.g., park, wilderness area)
10160105|NCT03997344|Active Comparator|Urban hikes|Group hikes in a urban setting (e.g., downtown area)
10160106|NCT03997487|Experimental|Children examined|All children examined for clinical signs of trachoma will be invited to participate to have photos of conjunctivae taken with the TOFTEE smartphone app and a DSLR camera.
10160107|NCT03997578|Active Comparator|NIPSA|Patients will be treated with only NIPSA technique.
10160108|NCT03997578|Experimental|NIPSA plus Connective tissue graft|Patients will be treated with NIPSA technique associated to a connective tissue graft.
10160109|NCT03997539|Experimental|pyrotinib 320mg + vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
10160110|NCT03997539|Experimental|pyrotinib 400mg + vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
10160111|NCT03997539|Experimental|Pyrotinib + vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
10160112|NCT03997539|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
10160113|NCT03997513|Experimental|Pulmonary Telerehabilitation Intervention Group|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
10160114|NCT03997513|No Intervention|Usual Care Group|Participants randomized to the usual care arm will also be enrolled in our institution's telehealth program, will receive an automatic blood pressure monitor, portable pulse oximeter, and scale and will be in regular contact with a telehealth provider. A study team member will meet with participants randomized to the usual care arm to discuss the importance of exercise and will encourage exercise (strength training, light aerobic activity such as walking or cycling) a minimum of 20-40 minutes three times per week at discharge.
10160115|NCT03997552|Experimental|Non-incised papillae surgical approach (NIPSA)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
10160116|NCT03997552|Active Comparator|marginal approach by palatal incision|A small incision in the palatal aspect and a limited papila elevation to the buccal aspect will be made for treating isolated periodontal defect. Enamel matrix derivates will be applied on the debrided root surfaces.
9671315|NCT05050201|Experimental|Sleepio Intervention|Participants using the Sleepio application - access for 6 sessions, over 10 weeks
9520161|NCT03279978|Placebo Comparator|Placebo|
9520162|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
9520163|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
10160117|NCT03997552|Active Comparator|Minimally invasive surgical technique (MIST)|The incision of the defect-associated papilla will be performed according to the principles of the papilla preservation techniques. Enamel matrix derivates will be applied on the debrided root surfaces. Stable primary closure of the flaps will be obtained with internal modified mattress sutures.
10160118|NCT03997500|Placebo Comparator|Normal saline|Simultaneous with subarachnoid block, a bolus of normal saline was given followed by normal saline infusion
10160119|NCT03997500|Experimental|Norepinephrine|Simultaneous with subarachnoid block, a bolus of norepinephrine was given followed by norepinephrine infusion
10160120|NCT03997565||Patients TKR|
10160121|NCT03997565||Healthy subjects|
10160122|NCT03997292||Alteplase group|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion
10160123|NCT03997292||Urokinase group|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End
10160124|NCT03997279|Experimental|S.boulardi|Quadruple eradication therapy with S. boulardi
10160125|NCT03997279|Placebo Comparator|Placebo|Quadruple eradication therapy without S. boulardi
10160126|NCT03997253|Experimental|blood and urine samples|blood and urine samples at D0, D7, D14, M1, M3, M6 and M12
10160127|NCT03997227|Active Comparator|Block group|
10160128|NCT03997227|No Intervention|control group|
10160129|NCT03997214|No Intervention|Control group|as usual care
10160130|NCT03997214|Experimental|experimental group|The intervention of inspiratory muscle strength training
10160131|NCT03997201|Other|Ripple Mapping guided ischaemic VT ablation|Patients referred for ablation of ischaemic VT undergo Ripple Mapping guided procedure.
10160132|NCT03996863|Experimental|Otoband efficacy on CINV|"Participants will wear the Otoband during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The Otoband will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the OtoBand is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the OtoBand 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
10160133|NCT03996863|Placebo Comparator|Placebo device efficacy on CINV|"Participants will wear the placebo device during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The placebo device will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the device is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the device 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
10160134|NCT03996954|Active Comparator|Normal ECGs|Patients with normal ECGs
10160135|NCT03996954|Active Comparator|Abnormal ECGs|Patients with different kinds of abnormal heart rhythms will be enrolled in order to compare whether Alivecor can accurately differentiate between these abnormal heart rhythms and normal sinus rhythm/sinus tachycardia. Also, Alivecor diagnostic accuracy in differentiating between different kinds of arrhythmias will be assessed.
10160136|NCT03996967||BA Group|The bacterial group: Patients will be assorted to this group if he/she has a bacterial pathogen culture of fluid from a normally sterile site (e.g. blood, pleural fluid)
10160137|NCT03996967||VI Group|"The viral group: Patients will be assigned to this group if they have negative bacteria microbiological tests, negative malaria blood slides, X-rays without endpoint pneumonia, no evidence of fungal infection, and positive PCR for a viral pathogen from nasopharyngeal swabs."
10160138|NCT03996967||MA Group|The malarial group: Patients will be assigned to this group if they have normal X-rays, no bacterial infection and >0 asexual P. falciparum parasites if they are aged < 1 year, or > 2,500 asexual parasites/µl of blood if they are aged > 1 year
10160139|NCT03997149|Experimental|Stress Condition|The stress condition involved the Trier Social Stress Test (TSST), a standardized laboratory stressor designed to elicit psychological stress and cortisol responses. Following the TSST, participants were brought to a separate room, instructed to rest and given the option to eat at their leisure. Books and magazines were included in the room for the participant to utilize.
10160140|NCT03997149|Placebo Comparator|Rest Condition|Participants completed a control condition on a separate day. This condition followed the same sequence of events as the stress condition with the exception that the 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
10160141|NCT03997019|Active Comparator|group A|opioid analgesia
10160142|NCT03997019|Active Comparator|group B|ESP block
10160143|NCT03996837|Experimental|Fresh embryo transfer with intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
10186167|NCT03738501|Experimental|Chest physiotherapy with SET|Chest physiotherapy will be provided by a single physiotherapist not involved in outcomes assessment. Airway clearance technique will be Slow Expiratory Technique (SET). SET is a slow modulation of airflow in order to remove bronchial secretions within infants lungs. Experimental group will also benefit for standard medical and non-pharmacological care (e.g Standard Treatment)
10160144|NCT03996837|No Intervention|Fresh embryo transfer without intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
10160145|NCT03996837|Experimental|Freeze embryo transfer with intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
10160146|NCT03996837|No Intervention|Freeze embryo transfer without intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
10160147|NCT03997175|Experimental|Intervention|The children were in daily contact with biodiversity sand 5 days a week for two weeks.
10160148|NCT03997175|Placebo Comparator|Placebo|Children were in contact with normal but colored sand that looked as it were the biodiversity sand. All the other details were as above.
10160149|NCT03996902|Experimental|Tailored intervention|Brief Motivational Smoking Intervention
9826398|NCT02417064|Experimental|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
9826399|NCT02417064|Experimental|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
10160150|NCT03996902|Experimental|Control|Intervention consistent with standard clinical practice (Control)
10160151|NCT03997006|Active Comparator|Group A (n=30)|Aminophylline group
10160152|NCT03997006|Active Comparator|Group NA (n=30)|Neostigmine/Atropine group
10160153|NCT03996915|Experimental|experimental PDT group|G1-20 patients Photodynamic therapy with methylene blue as photosensitizer device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point (6 points) and radiant 90 seconds. Photosensitiser (PS) will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.Six points with the distances of 1 cm between them will be irradiated.
10160154|NCT03996915|Active Comparator|control tongue scrapper group|G2-20 patients Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum in order to promote the mechanical removal of tongue coating
10160155|NCT03997058|No Intervention|Control group|
10160156|NCT03997058|Experimental|Auricular acupoint pressing group|
10160157|NCT03997058|Active Comparator|Oral estazolam group|
10160158|NCT03997058|Active Comparator|Combined treatment group|
10160159|NCT03996733|Active Comparator|GControl|Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.
10160160|NCT03996733|Experimental|GModel|"Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.~Participants in this group will also practice jugular vein puncture on our homemade jugular central venous catheterization training model."
10160161|NCT03996928|Experimental|Eccentric exercise by physiotherapist|"A physiotherapist will apply (in this order) a plan of stretching exercises, warm-up exercises and eccentric exercises of epicondylar muscle,according to a program of 10 sessions of 20 minutes each, during two weeks.~Before exercise, ultrasounds will be applied at intensity of 0.1 wat/cm2, which is considered as a placebo, in order to achieve greater adherence and monitor the treatment."
10160162|NCT03996928|Active Comparator|Illustrated booklet|A physiotherapist will train the patient an exercise plan equivalent to the one above explained with the help of illustrations. Now, in order to achieve palmar flexion at the same time the patients will contract their epicondylar muscles (the eccentric effect), and elastic band is used.
10160163|NCT03997032|Experimental|Patients with Diabetes|Patients with Type 1 or Type 2 Diabetes
10186168|NCT03738501|Active Comparator|Standard treatment|Medical treatment, health education for parents, rhinopharyngeal clearance using isotonic saline solution, advices.
10186169|NCT03738488|Experimental|3D printing + images|Surgery planification with the combination of all the images available and a 3D biomodel printed from that images.
10186170|NCT03738488|Active Comparator|Images|Surgery planification with all the images available
10186171|NCT03738449|Experimental|Group 1|"Period 1: D484~Period 2: CKD-387"
10186172|NCT03738449|Experimental|Group 2|"Period 1: CKD-387~Period 2: D484"
10160164|NCT03997110|Active Comparator|Arm A Or Control Arm- Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
10160165|NCT03997110|Experimental|Arm B or Experimental Arm-Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
10160166|NCT03996941||seguiPrEP|MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.
10160167|NCT03997188|Experimental|Hepilor arm|patients received ZLC solution. The prescribed dose was 10 ml, in the morning and evening, between meals.
10160168|NCT03997188|Placebo Comparator|Placebo arm|Patients received a placebo solution. The prescribed dose was 10 ml, in the morning and evening, between meals
9973824|NCT01334801||Aortic regurgitation|Echocardiographic and Doppler evaluation revealing aortic regurgitation with data adequate to calculate regurgitant volume
9973825|NCT01334801||Aortic valve replacement|Mechanical or biological aortic valve replacement
9973826|NCT01334801||Mitral regurgitation|Echocardiographic and Doppler evaluation revealing mitral regurgitation with data adequate to calculate regurgitant volume
10160169|NCT03997045|Experimental|Intervention group|Pregnant women receiving usual care and participating in supervised physical exercise program.
10160170|NCT03997045|No Intervention|Control group|Pregnant women that are receiving usual care but are not participating in supervised physical exercise program.
10160171|NCT03996889||Popliteal aneurysm patients with GORE VIABAHN®|The study population will include all popliteal aneurysm patients treated with GORE VIABAHN® stent graft in scheduled elective surgery, whether symptomatic or asymptomatic.
10160172|NCT03996746||Non-dialysis Group|non-dialysis patients with CKD 2-5
10160173|NCT03996746||Hemodialysis Group|patients with CKD 5 under hemodialysis for more than 3 months
10160174|NCT03996759||Critically ill patients|Patients admitted in ICU
10160175|NCT03996772|Experimental|Direct Oral Anticoagulant|"If the patient is randomized in this arm, a direct oral anticoagulant (DOAC) included:~Direct thrombin inhibitor: Dabigatran~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban will be prescribed to the patient. Choice and dose of DOAC treatment as well as the use of concomitant medication during the study treatment will be at the Principal Investigator´s discretion within the spectrum of licensed doses labelled for stroke prevention in atrial fibrillation patients in Europe following the Summary of Product Characteristics."
10160176|NCT03996772|No Intervention|No Anticoagulant|If the patient is randomized in this arm investigators will use their best judgment to decide upon the prescription of an antiplatelet drug of their choice or no such therapy
10160177|NCT03996980|Experimental|Custom-made foot orthoses|treatment intervention custom-made polypropylene foot orthoses for a period of 4 weeks
10160178|NCT03996980|Placebo Comparator|Placebo|a flat insole for a period of 4 weeks
10160179|NCT03996993||Hormone Therapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.
10160180|NCT03996993||Salvage Radiotherapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.
10160181|NCT03996707|Other|Immediate protected weight-bearing|Immediate protected weight-bearing
10160182|NCT03996707|Other|Traditional non weight bearing|Strict non-weight-bearing
10160183|NCT03996798|Experimental|Jessa Hospital, Herk-de-Stad|"Back to Work methodology: a revalidation trajectory with standard revalidation therapy in combination with an early focus on back to work, using a Disability Case Manager"
10160184|NCT03996798|No Intervention|Revalidation and MS Clinic Overpelt|"Standard revalidation therapy without explicit focus on back to work"
9520164|NCT03279952|Other|medication arm|CNS Stimulant
9973827|NCT01334801||Mitral valve replacement|Mechanical or biological mitral valve replacement
10160185|NCT03996811|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity for 40 min, three times a week on non-dialysis days. We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the target heart rate, as determined by the Karvonen method, and 12-13 on the RPE.
10160186|NCT03996811|No Intervention|usual-care group|Hospital routine care
10160187|NCT03996408|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
10160188|NCT03996512|Experimental|Post scaphoid fracture with screw fixation|Post surgical rehabilitation using an early active controlled wrist motion rehab protocol that limits the amount of proximal carpal row loading forces
10160189|NCT03996499|Experimental|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
10160190|NCT03996460|Placebo Comparator|Placebo powder|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1). Fifteen (15) patients in arm 1 (group 1) will receive the matching placebo powder orally once daily for 12 weeks (90 days).
10160191|NCT03996460|Active Comparator|192 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 2 (group 2) will receive the 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally once daily for 12 weeks (90 days).
10160192|NCT03996460|Active Comparator|384 mg powder of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 3 (group 3) will receive the 384 mg powder of K0706 (equivalent to 192 mg capsule of K0706) orally once daily for 12 weeks(90 days).
10160193|NCT03996343|Experimental|Endotracheal intubation|
10160194|NCT03996343|Experimental|Laryngeal mask airway|
10160195|NCT03996525|Experimental|Electrical Stimulation|"Electrical Stimulation~The patient will receive active electrical stimulation."
10160196|NCT03996525|Placebo Comparator|Sham Treatment|"No Electrical Stimulation~The patient will receive sham electrical stimulation."
10160197|NCT03996382|Other|Suspicion of cardiac amyloidosis|Patients who display signs of cardiac amyloidosis will be referred for further diagnosis.
10160198|NCT03996538|Experimental|Metformin Hydrochloride Extended Release Tablets|Patients will consume 3 tablets of 500mg metformin hydrochloride extended-release tablets daily (1500mg/day (after 3 week dose gradation)).
10160199|NCT03996538|Placebo Comparator|Placebo|Patients will consume 3 identical placebo tablets (after similar 3 week dose gradation).
10160200|NCT03996421|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
10160201|NCT03996421|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
10160202|NCT03996577|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
10160203|NCT03996577|Experimental|Experimental: lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
10160204|NCT03996603|Experimental|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
10160205|NCT03996603|No Intervention|Control Cohort|No intervention will be given.
10160206|NCT03996616|No Intervention|Control Group|"During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.~The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor."
10160207|NCT03996616|Active Comparator|Assigned Intervention|During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
9520165|NCT03279939|Experimental|Subjects with Normal Eyes|OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
10160208|NCT03996629|Experimental|Pharmacist-managed anticoagulation service|
10160209|NCT03996629|No Intervention|Usual medical care|
10160210|NCT03996551|Experimental|Intervention Group|This group will receive access to the 12-week kidney transplant specific weight gain prevention online resource (ExeRTiOn online resource). After the 12 weeks, they will be offered the option to continue using the website up until the completion of the study (12 months)
10160211|NCT03996551|No Intervention|Control group|This group will not receive the online resource. They will receive the standard encouragement to follow a healthy diet and perform physical activity during routine transplant follow up appointments.
9520166|NCT03279939|Experimental|Subjects with Pathology|OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
9520167|NCT03279926|Experimental|PLAY|Preschoolers & their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
9973828|NCT01334801||Hypertrophic cardiomyopathy|Patients with known hypertrophic cardiomyopathy who are referred for clinically indicated echocardiography
9973829|NCT01334801||Severe TR with pacemaker / ICD lead|Patients referred for clinically indicated echocardiography who have severe tricuspid regurgitation associated with a pacemaker or defibrillator lead documented by echocardiography
9973830|NCT01334801||Prosthetic valve dysfunction|Patients with prior heart valve replacement or repair referred for clinically indicated echocardiography who demonstrate stenosis, regurgitation, dehiscence.
9973831|NCT01334801||Normal controls|Patients with no heart murmur or history of valve replacement, stenosis, regurgitation, or hypertrophic cardiomyopathy
9973832|NCT01334801||Left ventricular assist device patients|Patients with previously implanted LVAD
9973833|NCT01334801||Renal dialysis patients|Patients on hemodialysis, peritoneal dialysis, or chronic kidney disease with dialysis fistula to be created.
9973834|NCT01334840|Experimental|BW|Bicarbonated mineral water without meal
9973835|NCT01334840|Experimental|BW with meal|Bicarbonated mineral water with meal
9973836|NCT01334840|Active Comparator|CW|Mineral water low in mineral content (control) without meal
9973837|NCT01334840|Active Comparator|CW with meal|Mineral water low in mineral content (control) with a meal
9973838|NCT01334853||Cohort 1|50 eosinophilic subjects to be evaluated
9973839|NCT01334853||Cohort 2|50 non-eosinophilic subjects to be evaluated
9973840|NCT01334879|Active Comparator|With Loading Doses|5 patients will receive intravitreal injections every 30 days (+/- 7 days) for the first 4 months and every month thereafter until month 12 (maximum of 12 injections)
9973841|NCT01334879|Active Comparator|Physician Discretion|5 patients will receive intravitreal ranibizumab every 30 days (+/- 7 days) on as needed basis based on the criteria defined in the study.
9973842|NCT01334892|Active Comparator|L-CsA|Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
9973843|NCT01334892|Placebo Comparator|L-CsA placebo|Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)
9973844|NCT01334905|Experimental|Part A group|fasted condition then fed condition
9973845|NCT01334905|Experimental|Part B group|fed condition then fasted condition
9973846|NCT01334931|Experimental|Large field of view|Patients will have coronary angiography performed with large field of view lens
9973847|NCT01334931|Active Comparator|Medium field of view|Patients will have coronary angiography performed with medium field of view lens
9973848|NCT01334983|Experimental|REST|Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
9973849|NCT01334983|No Intervention|Wait list control|Participants instructed in REST after completing week 8 outcome measures
9973850|NCT01335022|Experimental|Cardiovascular Disease Education|6 lectures on cardiovascular disease were given over a 2 month time period
9973851|NCT01335035|Experimental|ICL670|
9973852|NCT01335048|Experimental|Atorvastatin-Clopidogrel group|Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
10160212|NCT03996681|Experimental|TACE plus methylcantharidimide tablets|Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment. Every 6 weeks is a cycle.
9973853|NCT01335048|Active Comparator|Clopidogrel group|Patients who receive clopidogrel 150 mg daily
9973854|NCT01335074|Experimental|Temsirolimus + Sorafenib|
9973855|NCT01335087|Active Comparator|Lifestyle|Standard care for OSA: lifestyle, and sleep hygiene counselling
9973856|NCT01335087|Experimental|Continuous positive airway pressure CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
9973857|NCT01335087|No Intervention|Reference|This group will be followed according to cardiovascular protocols and will be evaluated as a reference group.
9973858|NCT01335100||ambulatory CP|ambulatory children with cerebral palsy undergoing Botulinum toxin injections to lower limbs
9973859|NCT01335100||controls|age and gender matched sibilings
9973860|NCT01335126|Experimental|Test|
9973861|NCT01335139|Experimental|SCIT + Placebo|Subcutaneous immunotherapy (SCIT) + sublingual immunotherapy (SLIT) placebo
9973862|NCT01335139|Experimental|SLIT + Placebo|Sublingual immunotherapy (SLIT) + subcutaneous immunotherapy (SCIT) placebo
9973863|NCT01335139|Placebo Comparator|Placebo + Placebo|Sublingual immunotherapy (SLIT) placebo + subcutaneous immunotherapy (SCIT) placebo
9973864|NCT01335152|Experimental|Web-based workbook|Participants will use one chapter of the web-based workbook each week for 10 weeks. The workbook consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
9973865|NCT01335152|No Intervention|Waitlist control group|Participants will no intervention for the first 10 weeks of the study and then will receive the web-based intervention.
9973866|NCT01335165|Experimental|TT30 (ALXN1102 Formulation)|IV: 0.1, 0.3, and 1.0 mg/kg
9973867|NCT01335165|Experimental|TT30 (ALXN1103 Formulation)|"IV: 3.0, 6.0, and 10.0 mg/kg~SC: 1.0 and 3.0 mg/kg"
9973868|NCT01335178|Experimental|Intervention|Participants received the behavioral intervention, which was designed to motivate parents to protect their children from tobacco smoke exposure
9973869|NCT01335217|Other|Open-label TNS treatment|There is only one arm in this open label treatment of MDD co-occuring with PTSD.
9973870|NCT01335243|Experimental|TLIF surgery|
9973871|NCT01335256|Experimental|Arm 1|
9973872|NCT01335269|Experimental|Treatment arm|BI 853520 once daily in a dose escalation schedule
9973873|NCT01335321|Active Comparator|Hylan GF-20 alone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 only
9973874|NCT01335321|Experimental|Triamcinolone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 associated with 1ml of triamcinolone
9973875|NCT01335347|Experimental|Experimental Low Dose|Biological: One dose of a live replication incompetent adenovirus given in a capsule
9973876|NCT01335347|Experimental|Experimental Medium Dose|"Biological: One or two doses of replication incompetent adenovirus given in a capsule~Other: Placebo capsules of the same size and shape"
9973877|NCT01335347|Experimental|Experimental High Dose|Biological: One dose of replication incompetent adenovirus in a capsule
9973878|NCT01335347|Placebo Comparator|Placebo Control|Capsules of the same size and shape as the experimental
9973879|NCT01335360||Subjects >80kg|As above
9973880|NCT01335360||Subjects <70kg|As above
9973881|NCT01335360||Subjects 70-80kg|As above
9973882|NCT01335373||Group 1|
9973883|NCT01335386|Experimental|KLYX|
9973884|NCT01335386|Active Comparator|Glycerine|
9973885|NCT01335412||IXIARO exposed group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of IXIARO
9973886|NCT01335412||Comparison group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of JE-VAX
9973887|NCT01335438|Experimental|Cementless Nexgen CR|Cementless fixation of Nexgen CR TKR
9973888|NCT01335438|Active Comparator|Cemented Nexgen CR|Cemented fixation of Nexgen CR TKR
9973889|NCT01335451|Experimental|Active|Each cohort will have 6 subjects that will receive AZD5213
9973890|NCT01335451|Placebo Comparator|Placebo|Each cohort will have 2 subjects that will receive placebo
9973891|NCT01335490|Experimental|Biolite Cook Stove|Provision of two cook stoves to each subject. Each stove burns wood fuel, but more efficiently than a traditional three stone fire.
9973892|NCT01335490|Experimental|LPG Cook Stove|Provision of a two-burner liquified petroleum gas stove to each subject, along with fuel needed for the family during the follow up period.
9973893|NCT01335490|No Intervention|Control|
9973894|NCT01335503|Active Comparator|AN-PEP with low caloric meal|
9973895|NCT01335503|Active Comparator|AN-PEP with high caloric meal|
9973896|NCT01335503|Placebo Comparator|Placebo with low caloric meal|
10160213|NCT03996486|Experimental|Hemophilia|Dose escalation starting with 200 mg of BAY1093884
10186173|NCT03738436|Active Comparator|traditional neuromuscular training, NMT|Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
9973897|NCT01335503|Placebo Comparator|Placebo with high caloric meal|
9973898|NCT01335529|Experimental|Boceprevir, PegIFN alfa 2b, Ribavirin|"Standard Treatment :~Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories (< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; > 105 kg: 1400mg)~Three-drug-regimen:~Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment~Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food"
9973899|NCT01335555||Patients Pre and Post-chemotherapy|
9973900|NCT01335568|Experimental|surgery|chronic liver insufficiency, cirrhosis
9973901|NCT01335607|Active Comparator|Part A: Samatasvir cap→tab→tab; Part B: cap|Part A: Samatasvir capsule as a single dose on Day 1 (fasting state) followed by samatasvir tablet as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
9973902|NCT01335607|Active Comparator|Part A: Samatasvir tab→cap→tab; Part B: cap|Part A: Samatasvir tablet as a single dose on Day 1 (fasting state) followed by samatasvir capsule as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
9973903|NCT01335646|Active Comparator|Surgery|
9973904|NCT01335646|Active Comparator|Non-operative|
9973905|NCT01335659||ostial lesion|ostial lesion will be evaluated by IVUS and FFR
9973906|NCT01335672||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
9973907|NCT01335685|Experimental|Arm A: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle for up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles [34 months]).
9973908|NCT01335685|Experimental|Arm A: Ixazomib 3.7 mg|Ixazomib 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 10 maintenance cycles; overall up to 19 cycles [21 months]).
9973909|NCT01335685|Experimental|Arm B: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 15 maintenance cycles; overall up to 27 cycles [25 months]).
9973910|NCT01335685|Experimental|Arm B: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 cycle plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles [58 months]).
9973911|NCT01335685|Experimental|Arm B: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 24 cycles [24 months]).
9977320|NCT01360203|Experimental|Care Transition Intervention|Care transition intervention beginning prior to discharge and through six months post-discharge.
10160214|NCT03996564|Active Comparator|Acupuncture Group|"Battlefield Acupuncture (BFA) has a structured administration sequence that was utilized to limit any variability between investigators administering the treatment. The BFA technique has been suggested that the needles are placed not just in an acupoint but actually acupoint zones. BFA utilizes one to ten (maximum five points per ear) ASP semi-permanent gold needles® placed in one or both ears. The ASP Gold needle® is a sterile device which inserts a small 2 mm needle into the auricle. It is comprised in single-needle applicator ensuring ease of insertion combined with excellent precision. The needles remain in the ear and fall out spontaneously as early as two hours and up to seven days. After administration of the BFA, if subjects felt that their pain was not controlled based on verbal response, rescue medication could be administered to control pain to a tolerable level for discharge."
10160215|NCT03996564|Active Comparator|Standard Care Group|Participants randomized to the standard care group were treated with one, or a combination of selected medications to include oral Acetaminophen 500mg-1000mg, Diclofenac 50mg-75 mg orally, Diazepam 5mg-10 mg intravenous or oral, Hydrocodone 5mg/325mg-10mg/650mg mg oral, or intramuscular Ketorolac 30mg-60 mg, as deemed appropriate by the treating investigator (medical provider). Standard treatment was administered by the investigators based on the patient's presentation and driving status as many of the medications cannot be administered if the subject would operate a vehicle. No standardized algorithm was specified and the route and dose of medications was administered at the provider's discretion. After administration of the traditional standard care medications, if subjects felt their pain was not controlled based on verbal responses, rescue medication would be given to control pain to a more tolerable level for discharge.
10160216|NCT03996434|Experimental|Coasting group|Including 150 patients who will undergo withholding gonadotropin administration for at least 24 hours before triggering ovulation with hCG. GnRH agonist will be continued daily till the day of triggering. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml, then 5000 IU of hCG will be given.
10160217|NCT03996434|Active Comparator|Antagonist group|"Including 150 patients who will receive GnRH antagonist (subcutaneous injection Cetrorelix acetate 0.25 mg (Cetrotide, Serono, UK)) daily until the day of hCG administration.~GnRH agonist will be discontinued at the start of antagonist administration.~E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml and TVS revealed that follicles diameter is ≥ 18 mm, then 5000 IU of hCG will be given."
10160218|NCT03996668|No Intervention|Control|Subjects received standard operating room dress including sequential compression devices.
10160219|NCT03996668|Experimental|Experimental|Subjects wore thigh high compression stockings in addition to standard operating room dress including sequential compression devices.
10160220|NCT03996642|Other|Patients with Active Cancer|Eligible participants will undergo an unknown number of Avatar-life review sessions depending on acceptability of the intervention to subjects and the capacity of the team to provide the intervention.
10160221|NCT03996655|Experimental|Group S|Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
10160222|NCT03996655|Active Comparator|Group N|Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
10160223|NCT03996317|No Intervention|Standard care|Standard practice where 10L/min O2 is delivered to patient by mask when any fetal tracing abnormalities are identified.
10160224|NCT03996317|Experimental|Room air|O2 will be withheld at times when fetal tracing abnormalities are identified. Patient will continue to breath room air.
10160225|NCT03996135|Experimental|Experimental : Cannulation with AccuVein AV400|Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation
10160226|NCT03996135|No Intervention|Control|Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.
10160227|NCT03995979|Experimental|Protein Restriction Group|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided.
10160228|NCT03996109|Experimental|Aim2Be|Youth-parent dyads randomized to Aim2Be
10160229|NCT03996109|Active Comparator|BnLt|Youth-parent dyads randomized to BnLt
10160230|NCT03996057|Experimental|Methenamine augmentation|2g methenamine hippurate twice daily for 90 days added to a baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
10160231|NCT03996057|Active Comparator|No methenamine augmentation|Baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
10160232|NCT03996096||Group with the TKI withdrawal syndrome|There is no intervention. Patients will stop their tyrosine kinase inhibitor yielding to 2 subsets: patients with or without the TKI withdrawal syndrome.
10160233|NCT03996096||Group without the TKI withdrawal syndrome|As abovementioned.
10160234|NCT03996070|Active Comparator|Treatment arm|Therapeutic dose regime
10160235|NCT03996070|Placebo Comparator|Sham arm|Sub-therapeutic dose regime
10160236|NCT03996031||Study Sample|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests. Following the baseline assessment, participants will engage with the Plan to Thrive app for a 90-day period.
10160237|NCT03996226|Experimental|E7386: Fed + Fast|Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
9973912|NCT01335685|Experimental|Arm C: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles [40 months]).
10160238|NCT03996226|Experimental|E7386: Fast + Fed|Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
10160239|NCT03996044|Experimental|Group 1|Thirteen patients who will receive treatment with teeth brushing, dental floss and tongue scraper.
10160240|NCT03996044|Experimental|Group 2|Thirteen patients who will receive treatment with teeth brushing, dental floss and antimicrobial photodynamic therapy applied to the back and middle third of the tongue.
10160241|NCT03996044|Experimental|Group 3|Thirteen patients who will receive treatment with teeth brushing, dental floss and probiotics.
10160242|NCT03996044|Experimental|Group 4|Thirteen patients who will receive treatment with teeth brushing, dental floss, antimicrobial photodynamic therapy applied to the back and middle third of the tongue and probiotics..
10160243|NCT03996083|Experimental|Multicomponent exercise intervention|The multicomponent exercise program consisted of strength and balance exercises performed on two non-consecutive days per week and lasting approximately an hour per session. Strength exercises were mainly focused on lower limb strengthening. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. As for balance exercises, the first weeks consisted of mainly less complex static balance exercises and progressed to more complex and dynamic balance exercises. These exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.
10160244|NCT03996083|Experimental|Walking intervention|Participants assigned to the walking group walked with the research staff two days per week; additionally, they walked partially supervised by LTNH staff, family members or caregivers the rest of the week. Daily walking goals were set follows: walking between 5 to 10 minutes on the first month, up to 15 minutes on the second, and finally 20 minutes per day on the third month. The final goal was to get as close as possible to the recommendations of engaging in 150 minutes of aerobic exercise per week from the World Health Organization (WHO). Participants were asked to walk as fast as they could and rest was allowed whenever needed. Walking goals were achieved in one or multiple sessions, depending on each participant´s capacities. Those participants that met the walking goals without any rest were encouraged to walk at a faster pace.
10160245|NCT03996005|Experimental|MRI Guided Transurethral Ultrasound|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
10160246|NCT03996252|Experimental|Combination treatment arm|Combination of calcipotriene 0.005% foam (Sorilux) and Fluorouracil Cream, 5% USP (generic) applied for four consecutive nights for the treatment of scalp actinic keratoses.
10160247|NCT03996161|Active Comparator|Supine position|After the induction of anesthesia, mask ventilation is performed in the supine position.
10160248|NCT03996161|Experimental|Semi-sitting position|After the induction of anesthesia, mask ventilation is performed in the semi-sitting position.
10160249|NCT03996213|No Intervention|supine group|induction of anesthesia will be initiated while patient in supine position
10160250|NCT03996213|Active Comparator|head down|induction of anesthesia will be initiated while patient in head down position
10160251|NCT03996213|Active Comparator|leg elevation|induction of anesthesia will be initiated while patient in leg elevation position
10160252|NCT03996122||resistant patients with schizophrenia|Age 18 - 60 years No MRI contraindication
10160253|NCT03995992|Active Comparator|multi sport|During 10 days, each morning, from 9 am to 12 pm, participants had sporting activities: mountain walking, mountain biking, climbing, canyoning and collective orienteering running. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
10160254|NCT03995992|Experimental|diving|During 10 days, each morning, from 9 am to 12 pm, participants had diving activities. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
10160255|NCT03996278||Patients in the Grafalon group|Patients in the Grafalon group (n=150) will be followed prospectively and data prospectively collected thanks to the Astre database
10160256|NCT03996278||Patients in the Thymoglobulin group|Patients in the thymoglobulin group (n=150) will be selected and analyzed retrospectively from the Astre database
10160257|NCT03995927||Data collection/questionnaire|Data collection for patient medical charts and patient fill out questionnaires first visit and post-treatment visits
10160258|NCT03996018||group 1(HIV Uninfected)|Participant is HIV negative per antibody screen conducted on premises and participant is enrolled on HPTN 083 study
10160259|NCT03996018||group 2 (HIV Infected)|Participant has initiated ART therapy as a patient at St Jude Children's Research Hospital, newly diagnosed HIV and prolonged HIV
10160260|NCT03995953|No Intervention|Control|2 control zones with no intervention at the clinic or community level
10160261|NCT03995953|Experimental|SHIELD: Community-based behavioral intervention|2 clinic zones where participants attend modules designed to educate and empower adolescent girls and young women (AGYWs) and their families, along with attendance at community-based youth clubs to foster peer support.
10160262|NCT03995953|Experimental|SHIELD: Community- based behavioral intervention & IWC Clinic|2 clinic zones where participants receive the Support for HIV Integrated Education, Linkages to care, and Destigmatization (SHIELD) intervention along with the coupled benefits of having an integrated wellness care (IWC) clinic within health facilities where adolescent girls and young women (AGYWs) can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and human papilloma virus (HPV) vaccination.
10160263|NCT03995732|Experimental|40 mg treatment group|PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
10160264|NCT03995732|Experimental|80 mg treatment group|PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
10160265|NCT03995732|Experimental|160 mg treatment group|PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
10160266|NCT03995732|Placebo Comparator|placebo control group|placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
10160267|NCT03995836||Obstructive Sleep Apnea|
10160268|NCT03995836||Non Obstructive Sleep Apnea|
10160269|NCT03995810|Experimental|Carnosine|Carnosine, capsulle, 2 g/day, 8 weeks
10160270|NCT03995758|Active Comparator|Standard laser lithotripsy|standard of care for stone fragmentation in ureteroscopy
10160271|NCT03995758|Active Comparator|MOSES laser lithotripsy|MOSES technology used for stone fragmentation in ureteroscopy
10160272|NCT03995745|Experimental|adherence based financial incentives|Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
10160273|NCT03995745|No Intervention|control|Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
10160274|NCT03995706|Experimental|Breast Brain Metastasis and Glioblastoma|Sacituzumab Govitecan treatment will be initiated with a 10mg/kg standard dose without any dose escalation on day-1, prior to surgery. Sacituzumab govitecan and will continue to be administered by IV infusion over 3 hours on Days 1 and 8 of a 21 day cycle post-operatively until progression.
10160275|NCT03995888|Experimental|Healthy Volunteers|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
10160276|NCT03995888|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
10160277|NCT03995797|Active Comparator|Treatment arm|Treatment with erbium YAG laser
10160278|NCT03995797|Placebo Comparator|Sham arm|Sub therapeutic procedure with erbium YAG laser
10160279|NCT03995719|Other|Preoperative education|Each patient had individual consultation several days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
10160280|NCT03995719|Other|Postoperative education|Each patient had individual consultationseveral days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
10186174|NCT03738436|Experimental|modified visual feedback, MVF|Starting from 4 weeks post-surgery, eight-week physical therapy program consisted of traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles.
10186175|NCT03738384|Experimental|TKR Patients|Any patient 3-6 weeks post-op from a TKR
10186176|NCT03738371||Team of health professionals|Team of health professionals involved in thrombectomy (including specialized nurses in anesthesiology, anesthesiologists, neuroradiologist and technicians specialized in electro-radiology) will participate to in situ simulation.
10186177|NCT03738358|Experimental|Trehalose|
10186178|NCT03738358|Placebo Comparator|Placebo|
10186179|NCT03738345|Experimental|Oxygenation on hypoxemia patients|Adult patients with hypoxemia will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then patients will be placed on high flow nasal cannula (HFNC), HFNC flow will be titrated based on the hospital's policy or protocol and patient's comfort, patient's clinical effects on oxygenation will be monitored and recorded during the titration process.
10186180|NCT03738345|Experimental|Lung expansion on healthy volunteer|Adult healthy volunteers will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then they will be placed on HFNC, HFNC flow will be increased sequentially by research protocol and their comfort, subjects' lung expansion effects in different flow will be quantified by Electrical impedance tomography (EIT), a noninvasive assessment tool. Their comfort will also be assessed using a visual scale.
10186181|NCT03738319||HGSOC group|This group includes patients of high grade serous ovarian cancer (HGSOC).
10186182|NCT03738319||Control group|This group includes patients of benign gynecologic diseases as control.
10186183|NCT03738306|Experimental|Mezieres Method|The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
10186184|NCT03738306|Active Comparator|Conventional Physiotherapy|The treatment with conventional physiotherapy will include stretching of hamstrings, gluteus, (and others) hot pack, transcutaneous electrical nerve stimulation, ultrasound and some exercises of core performance.The time of treatment will be of 1 hour, two times a week, during 5 weeks.
10186185|NCT03738254|Active Comparator|Paper PRO|Participants in the Paper PRO arm completed daily patient reported outcome diaries on paper
9520168|NCT03279926|Experimental|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
10186186|NCT03738254|Active Comparator|ePRO|Participants in the ePRO arm completed daily patient reported outcome diaries online via a smartphone app.
10186187|NCT03738254|Experimental|Game-Motivated ePRO|Participants in the Game-Motivated ePRO arm completed daily patient reported outcome diaries online via a smartphone app. These participants were also given access to a game that rewarded the participant with an in-game reward that helped the participant complete various in-game quests.
10160281|NCT03995862||Patients in care, at high risk of HIV infection|Patients in care, at high risk of HIV infection, according to the criteria defined by the French Ministry Of Health for the use of FTC / TDF in PreP (men who have sex with men, transgender, heterosexual women migrants or not, sex workers (sexual intercourse in exchange for money, drugs, housing, food), intravenous drug users) HIV-negative, exposed by their sexual practices to a high risk of HIV infection.
10160282|NCT03995628|Experimental|Steroid Group|Participants will receive a one-time dose of oral dexamethasone at 0.5 mg/kg on the third post-operative day
10160283|NCT03995628|No Intervention|No Steroid Group|Participants will not receive dexamethasone
10160284|NCT03995602|Experimental|Dragon fruit first then placebo|2 weeks of dragon fruit juice intake or placebo with crossover to the other
10160285|NCT03995602|Experimental|Placebo first then dragon fruit|2 weeks of dragon fruit juice intake or placebo with crossover to the other
10160286|NCT03995693|Experimental|Concentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of CONCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
10160287|NCT03995693|Experimental|Concentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of concentric cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
10160288|NCT03995693|Experimental|Eccentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
10160289|NCT03995693|Experimental|Eccentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
10160290|NCT03995615|No Intervention|Group I (Control)|• Group I (Control) - 15 periodontally healthy patient with probing depth< 3mm and ≤ 10% sites with bleeding on probing.
10160291|NCT03995615|No Intervention|• Group II|• Group II - 15 systemically healthy chronic periodontitis patient who had presented >25% of sites with gingival bleeding ,surface demonstrating supra-gingival plaque accumulation and an absence of probing depth ≥ 4mm and clinical attachment level ≥3mm
10160292|NCT03995615|No Intervention|• Group III|• Group III - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1with out scaling and root planing
10160293|NCT03995615|Active Comparator|• Group IV|• Group IV - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1 with scaling and root planing. Periodontal clinical parameters will be assessed
10160294|NCT03995485|Experimental|KW-136+SOF|Treatment-naive and experienced subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
10160295|NCT03995394|Experimental|Positive Reinforcement Group|"In the intervention group, participants will receive two text messages weekly. The first text message will ask if participants completed the recommended activity. If the participants respond yes, the participant will receive a positive reinforcement response. If the participants respond no, the participant will receive a text message stating, Thank you for your response."
10160296|NCT03995394|No Intervention|Control Group|"For the control group, participants will receive two text messages weekly. The first text message will ask if the participants completed the recommended activity. When the participant responds, the participant will receive a second text message stating, Thanks for your response."
10160297|NCT03995420|Experimental|Virtual Reality Therapy (V-NeST)|Participants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
10160298|NCT03995420|Other|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) only.
10160299|NCT03995550|Experimental|Single ascending dose Cohort A|Single dose of LEO 142397 or placebo.
10160300|NCT03995550|Experimental|Single ascending dose Cohort B|Single dose of LEO 142397 or placebo.
10160301|NCT03995550|Experimental|Single ascending dose Cohort C|2 single doses, separated by a washout of ≥7 days.
10160302|NCT03995550|Experimental|Single ascending dose Cohort D|2 single doses, separated by a washout of ≥7 days.
10160303|NCT03995550|Experimental|Single ascending dose Cohort E|Single dose of LEO 142397 or placebo.
10160304|NCT03995550|Experimental|Single ascending dose Cohort F|Single dose of LEO 142397 or placebo.
10160305|NCT03995550|Experimental|Single ascending dose Cohort G|Single dose of LEO 142397 or placebo.
10160306|NCT03995550|Experimental|Single ascending dose Cohort H|Single dose of LEO 142397 or placebo - tentative, female-only cohort (to be included only if the number of women recruited in the remaining cohorts is insufficient to assess the pharmacokinetics of LEO 142397 in women). Dose level ≥ that in Cohort C and ≤ that in Cohort D.
10160307|NCT03995550|Experimental|Multiple ascending dose Cohort K|Multiple doses of LEO 142397 or placebo.
10160308|NCT03995550|Experimental|Multiple ascending dose Cohort L|Multiple doses of LEO 142397 or placebo.
10160309|NCT03995550|Experimental|Multiple ascending dose Cohort M|Multiple doses of LEO 142397 or placebo.
10160310|NCT03995550|Experimental|Multiple ascending dose Cohort N|Multiple doses of LEO 142397 or placebo.
10160311|NCT03995550|Experimental|Multiple ascending dose Cohort O|Multiple doses of LEO 142397 or placebo.
10160312|NCT03995550|Experimental|Multiple ascending dose Cohort P|Multiple doses of LEO 142397 or placebo in Japanese-only subjects. Same dose level as for Cohort M.
10160313|NCT03995407|Active Comparator|Control|"Participants in the control arm will receive usual care."
10160314|NCT03995407|Experimental|100% Whey Protein|Participants will receive 100% Whey Protein oral nutritional supplements.
10160315|NCT03995498|Active Comparator|Individualized carbohydrate intake|"Based on glucose sensor level, carbohydrate (orange juice, Oasis classic) will then be given as follow:~If sensor glucose level is under < 4.5 mmol/L, the camp staff will treat hypoglycemia according to the camp procedure, If sensor glucose level is between 4.5 and 7.0 mol/L, 0.5g of CHO/kg body weight will be given, If sensor glucose level is between 7.1 and 10.0 mmol/L, 0.25g of CHO/kg body weight will be given, If sensor glucose level is between 10.1 and 15.0 mmol/L, no CHO will be given, If sensor glucose level is > 15.1 mmol/L, the camp staff will treat hyperglycemia according to the camp procedure."
10160316|NCT03995498|Active Comparator|Usual camp protocol|As per camp routine care, there will be no mandatory glucose level measurement before the start of physical activity if no symptoms of hypoglycemia or hyperglycemia appear.
10160317|NCT03995563|Active Comparator|D group|0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
10160318|NCT03995563|Placebo Comparator|N group|0.19% Ropivacaine 8mL only every other day injection during 10 days
10160319|NCT03995446|Experimental|low-level laser therapy|808nM wavelength, power density of 300mW
10160320|NCT03995446|Sham Comparator|Sham laser acupuncture treatment|received the same manner except for joule.
10160321|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose escalation|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
10160322|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose expansion|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
10160323|NCT03995472|Experimental|SHR-1501 and SHR-1316 Indication expansion|SHR-1501 given subcutaneously with a recommended dose. SHR-1316 given intravenously.
10160324|NCT03995186|Experimental|Behavioural activation group|
10160325|NCT03995186|Active Comparator|Activity monitoring group|
10160326|NCT03995186|No Intervention|Waiting list control group|
10160327|NCT03995368|Experimental|People with Schizophrenia|People who have been diagnosed with schizophrenia and meet the investigators' research criteria for symptoms indicative of schizophrenia within their lifetime.
10160328|NCT03995368|Experimental|People with TBI|People who have been diagnosed with a mild or moderate traumatic brain injury (TBI) and meet research criteria indicative of TBI within their lifetime.
10160329|NCT03995368|Experimental|Healthy Controls|People without a history of psychiatric illness or TBI and who do not meet research criteria for a psychiatric illness or TBI.
10160330|NCT03995251|Experimental|Standard Medical Treatment +Intramuscular Testosterone + Exerc|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
10160331|NCT03995251|Active Comparator|Standard Medical Treatment+Exercise|Standard Medical Treatment +Exercise
10160332|NCT03995160|Active Comparator|Total knee replacement with use of closed suction drainage|Use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
10160333|NCT03995160|Active Comparator|Total knee replacement without use of closed suction drainage|Without the use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
10160334|NCT03995095|No Intervention|Control group|Group of participants that received usual psychological attention.
9671316|NCT05050071|Active Comparator|Calcium hydroxide (7 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
9671317|NCT05050071|Experimental|Allium sativum (7 days)|is a species of bulbous flowering plant in the onion genus Allium
10160335|NCT03995095|Experimental|Experimental group|Group of participants that received usual psychological attention plus attention of spiritual needs following the Kibo protocol (intervention).
10160336|NCT03995082|Experimental|Experimental Group|Patients will receive the results from the PROM survey in graphical form each time they complete a survey.
10160337|NCT03995082|No Intervention|Normative Control|These patients will complete the PROM surveys, but will not be presented with the results of the survey.
10160338|NCT03995329|Other|healthy non smokers|"Healthy non smokers males, aged 18-55years,receiving no medications~Intervention: the use of an IQOS Examination of pulmonary function, exhaled CO, blood pressure, heart rate and O2 saturation immediatly after IQOS"
10160339|NCT03995147|Experimental|Treatment Arm|
10160340|NCT03995342|Experimental|exprimental: Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
10160341|NCT03995342|Placebo Comparator|Active comparator: maltodextrin|Placebo (maltodextrin) 15grams after dissolution by mouth， every morning for three months.
10160342|NCT03995511|Experimental|Bilateral sagittal split|
10160343|NCT03995316|Other|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
10160344|NCT03995316|Other|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
10160345|NCT03995056|No Intervention|Control-group|Subjects diagnosed with NAFLD and a sedentary lifestyle will have no changes in their habits and diets.
10160346|NCT03995056|Experimental|Exercise-group|This group with diagnosed NAFLD patients will perform a high-intensity aerobic interval exercise training without changing their diets.
10160347|NCT03995277|Other|Healthy cohort - high dose|Apparently healthy subjects, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
10160348|NCT03995277|Other|Hypothyroid cohort|Subjects under thyroid medication, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
10160349|NCT03995277|Other|Healthy cohort - low dose|Apparently healthy subjects, who take 50 µg/d of biotin at the same time each morning for 20 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), after 20 days of biotin supplementation (day 20), and 10 days after participants stopped taking biotin (day 30).
10160350|NCT03995381|Experimental|DAs group|Shared decision making using decision aids
10160351|NCT03995381|No Intervention|Control group|Standard oral explanation guided with booklets
10160352|NCT03995134||Propofol and Remifentanil|Procedural sedation in Dentistry provided by a Target Controlled Infusion pump using propofol as the sedative/hypnotic agent and Remifentanil as the opioid analgesic agent.
10160353|NCT03994952||Uninjured Physically Active Young Adults|"This is a group of physically active, and currently uninjured young adults. They will complete a single balance assessment, the modified balance error scoring system protocol, as outlined by the Sway Balance application.~There is no comparison group for this investigation."
10160354|NCT03995043|Experimental|Control Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~Personal Support from community peer mentor to access counselling services through SRH"
10160355|NCT03995043|Experimental|Case Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~Personal Support from community peer mentor to access counselling services through SRH~Access to Contraception and counselling and service provision will be provided by the mobile reproductive health team at contraceptive access points."
10160356|NCT03994965|Experimental|Patients|"40 antipsychotic-free, first-episode schizophrenia spectrum patients will receive 6 weeks of treatment with a selective serotonin 2A Receptor (2AR) blockade.~Before initiation of treatment patients will undergo: positron emission tomography (PET) imaging of the serotonin 2AR binding potential using the radioligand [¹¹C]Cimbi-36; magnetic resonance spectroscopy (MRS) of cerebral glutamate levels; structural Magnetic Resonance Imaging (MRI), including diffusion tensor imaging (DTI); cognitive and psychopathological examinations; Electrocardiography (ECG), and blood sampling for genetic- and metabolic analyses.~(Full description will be updated on approval)."
10160357|NCT03995108|Experimental|Mavorixafor|Participants (adults and adolescents [12 to 17 years of age weighing >50 kilograms [kg]) will receive mavorixafor 400 milligrams (mg) once daily (QD) orally for 52 weeks in the Randomized Period. Adolescents weighing ≤50 kg will receive mavorixafor 200 mg QD. Participants who complete the Randomized Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent adjudication committee (AC), will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
10160358|NCT03995108|Placebo Comparator|Placebo|Participants will receive placebo matching to mavorixafor QD orally for 52 weeks in the Randomized Period. Participants who complete the Randomized Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent AC, will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
10160359|NCT03994991|Experimental|Active TMS|Patients in the active TMS group will receive active TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
10160360|NCT03994991|Sham Comparator|Sham TMS|Patients in the shamTMS group will receive sham TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
10160361|NCT03994731|Experimental|Pegloticase with methotrexate (MTX)|Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period and Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 52 weeks
10160362|NCT03994731|Placebo Comparator|Pegloticase with placebo for methotrexate (MTX)|Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period, placebo for MTX (weekly) in the Run-in Period, then pegloticase (every 2 weeks) with placebo for MTX (weekly) for 52 weeks
10160363|NCT03994757|Experimental|MRBI group|
10160364|NCT03994757|Sham Comparator|Control group|
9973913|NCT01335685|Experimental|Arm C: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 21 cycles [24 months]).
9977321|NCT01360216|Experimental|LARC education and training|Clinicians and contraceptive educators practicing in clinics assigned to this arm receive a special half-day Continuing Medical Education (CME/CEU) accredited LARC education and training session.
9520169|NCT03279926|Experimental|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
9520170|NCT03279913|Experimental|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
10160365|NCT03994926|Experimental|Experimental|Directed smoking of about 3.6% THC cannabis cigarette
10160366|NCT03994666|Experimental|simple dose|
10160367|NCT03994666|Experimental|double dose|
10160368|NCT03994666|Placebo Comparator|placebo|
10160369|NCT03994900|Experimental|Blood sampling for HbNO assessment|
10160370|NCT03994861|Active Comparator|Patients with musculoskeletal disorders|Patients with either shoulder pain, knee pain, hip pain, low back pain, pelvic pain or neck pain as their primary pain complaint, lasting for 6 weeks or longer
10160371|NCT03994861|Sham Comparator|Healthy controls|Age- and gender-matched healthy controls (without musculoskeletal pain)
10160372|NCT03994783|Active Comparator|Standard of Care (SOC)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants)
10160373|NCT03994783|Experimental|Standard of Care plus Rituximab (SOCR)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants) Rituximab (375 mg/m2 max 1 g (no dose adjustment for paediatric participants), n=2 14 days +/- 2 days apart)
9671318|NCT05050071|Experimental|Combination (7 days)|combination between Calcium hydroxide and Allium sativum
9671319|NCT05050071|Active Comparator|Calcium hydroxide (14 days)|is also known as slaked lime or calcium hydrate. It is produced by the hydration of lime
10160374|NCT03994705|Experimental|Dose-Escalation|
10160375|NCT03994939|Experimental|Intervention|Received Families Talking Together (FTT) intervention, an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative sexual and reproductive health outcomes in adolescents age 10-14. The FTT intervention consisted of two components. Component 1 was comprised of 2 FTT intervention sessions between a parent and bilingual/bicultural promotor trained to deliver FTT in English or Spanish. These sessions highlighted adverse health consequences of sex to motivate parents to communicate with their adolescent and provided guidance to parents on communication strategies. Component 2 was comprised of written supplemental materials that promotores used to guide each intervention session. Experimental condition families will complete all measurement assessments.
10160376|NCT03994939|No Intervention|Control|Parents randomized to the control group did not receive any intervention sessions and only completed assessment questionnaires.
10160377|NCT03994718|Experimental|Music|The musician will either offer music that can either be played for the participant or an instrument so they can experience playing themselves. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. The outpatient music intervention will consist of providing a recording of similar music for the participant to listen to for at least 30 minutes per week, along a with telephone call session with the music therapist.
10160378|NCT03994718|Experimental|Visual art|The creative visual artist will assess interest in spending time using the materials provided. Participants will be offered watercolor painting, drawing, or adult coloring. There will be a guided activity based on their art making preference. A standardized prompt will be utilized for both writing and visual art sessions. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For remote follow-up sessions, participants will be supplied with a small art kit to use at home.
10160379|NCT03994718|Experimental|Creative writing|The writer will ask the participant about their interests and experiences in writing or storytelling. The following options are offered; introduction to journaling, storytelling or writing exercises with prompts to get started, interactive writing or storytelling activities. For participants who are unable to write or prefer not to, the writer can scribe their words on a laptop and print them out. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For follow-up sessions, participants will be supplied with a journal.
10160380|NCT03994692|Experimental|PEEK eminoplasty|"CT scan with bony window for facial bones and DICOM files on CD .then, Using cad cam software (mimics 15) , the virtual design and surgery will be done.~under general anathesia The TMJ will be exposed using the endural incision line and the articular eminence will be identified then blunt dissection so that the front wall of the articular capsule can be exposed completely.~The patient specific PEEK eminence will be inserted and secured with two to three pre-planed screws .~Functional mandibular movements were reproduced to confirm absence of subluxation and then closure"
9520171|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass~ARF was defined as one of the following conditions:~If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) < 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,~If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) < 90% or PaO2 <60 mmHg despite oxygen therapy ≥ 3 L/min."
9520172|NCT03279861|Active Comparator|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
9520173|NCT03279861|Active Comparator|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
9671320|NCT05050071|Experimental|Allium sativum (14 days)|is a species of bulbous flowering plant in the onion genus Allium
9671321|NCT05050071|Experimental|Combination (14 days)|combination between Calcium hydroxide and Allium sativum
9520174|NCT03279835||Absence of cognitive disorder|
9520175|NCT03279835||Asymptomatic cognitive disorder|
9520176|NCT03279835||Symptomatic cognitive impairment|
9520177|NCT03279835||HIV associated dementia|
9520178|NCT03279822||Group|
9520179|NCT03279809|Experimental|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
10160381|NCT03994692|Active Comparator|autogenous onlay grafting eminoplasty|"under general anesthesia , chin graft was taken Layered Endural approach to TMJ making wedge in eminence by mallet & chisel (green stick fracture), then wedging piece of chin graft to increase the height of the eminence creating an obstacle to treat dislocation by manipulation of patient mandible intra operative.~- Functional mandibular movements were reproduced to confirm absence of subluxation then closure"
10160382|NCT03994744|Experimental|Sintilimab and Metformin|"Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).~The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up."
10160383|NCT03994640|Experimental|Cannabis cream|Cannabis cream topical skin application in experimental group
10160384|NCT03994640|Placebo Comparator|Placebo cream|Placebo cream topical skin application in control group
10160385|NCT03994913|Experimental|CAR-CD19-T Cells|The subjects are enrolled into 3 dose levels cohorts in sequence.
10160386|NCT03994978||Surgical group|Patients with uncomplicated recurrent diverticulitis undergoing elective sigmoid resection
10160387|NCT03994978||Conservative group|Patients with uncomplicated recurrent diverticulitis with conservative treatment
10160388|NCT03994588|Active Comparator|study arm|In this arm a light weight, wide pore, soft polypropylene mesh will be used for intraperitoneal hernia repair
10160389|NCT03994588|Active Comparator|control|in this arm a double mesh (vicryl + polypropylene mesh) will be used for intraperitoneal hernia repair.
10160390|NCT03994315|Experimental|B. infantis EVC001 + LNT (3 g/L then 8 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 1 [B. infantis + LNT (3 g/L then 8 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 3 g/L for 2 weeks followed by 8 g/L for the next 2 weeks, without a washout period in between.
10160391|NCT03994315|Experimental|B. infantis EVC001 + LNT (6 g/L then 12 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 2 [B. infantis + LNT (6 g/L then 12 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 6 g/L for 2 weeks followed by 12 g/L for the next 2 weeks, without a washout period in between.
10160392|NCT03994315|Active Comparator|B. infantis EVC001 alone|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days.
10160393|NCT03994341||NEC Group|Infrared images of the abdomen, timed at handling. A FLIR Thermovision a320M thermal IR camera bound with an Microsoft Kinect RGB-D sensor system connected to a laptop will be used. Both imaging technologies are non-invasive and represent no risk to the subject. The thermal images record the temperature distribution, the Kinect sensor will acquire color image and depth image that will be used to segment the subject from the background bedding surface. All three sets of images will be collected in synchronization. Thermography requires period of slight cooling of the skin surface to stabilize the body surface temperature. The room temperature will be maintained slightly below thermoneutrality. Thermographic camera will be positioned about 60-70 cm above the baby.
10160394|NCT03994341||Normal Group|Same procedure for both experimental and active comparator.
10160395|NCT03994536|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses (transition coordinators) who meet the participants at three occasions during the study period and participants will be offered to meet peers with type 1 diabetes during an adolescent day.
10160396|NCT03994536|Experimental|Comparison group: Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
10160397|NCT03994406|Experimental|CLM2 Topical Gel|CLM2 topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
10160398|NCT03994406|Placebo Comparator|Placebo Topical Gel|Placebo topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
10160399|NCT03994445|Experimental|Intervention group|Intervention group will be enrolled to the intervention program proposed to be (pharmacotherapy + counseling+ motivator phone messages).
10160400|NCT03994445|No Intervention|Control group|Control group will receive the standard treatment of the Ministry of the Health program (pharmacotherapy + counseling) only.
10160401|NCT03994497|Other|Patient in need of a kidney transplant|
10160402|NCT03994354||1,2|"J-P drain group~Penrose drain group"
10160403|NCT03994250|Active Comparator|Kinematic Arm|Kinematic Alignment for TKR surgery
10160404|NCT03994250|Placebo Comparator|Control Arm|Mechanical alignment for TKR surgery
10160405|NCT03994120|Active Comparator|Motor Cortex rTMS|Motor Cortex rTMS
10160406|NCT03994120|Active Comparator|PPC rTMS|PPC rTMS
10160407|NCT03994120|Placebo Comparator|vertex rTMS|vertex rTMS
10160408|NCT03994211|Experimental|Arm A (core phase)|
10160409|NCT03994211|Experimental|Arm B (core phase)|
10160410|NCT03994211|Experimental|Extension phase|
10186188|NCT03738176|Experimental|sesame oil in orabase|20 gm sesame oil-80 gm CMC 3 times per day for one month
9520180|NCT03279809|Placebo Comparator|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
9520181|NCT03279796|Experimental|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
9520182|NCT03279796|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
9671322|NCT05050448|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
10160411|NCT03994107|Experimental|PLD/albumin-bound paclitaxel/Trastuzumab|"First phase~PLD: Level 1：30mg/m2； Level 2：35mg/m2； Level 3：40mg/m2； IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion , Subsequent infusions 6mg/kg. d1, q21d×6.~Second phase~PLD: maximum tolerated dose (MTD). IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion ,Subsequent infusions 6mg/kg. d1, q21d×6."
10160412|NCT03994198|Experimental|Alpha-lactalbumin|Participants will consume 60 g of alphalactalbumin (fraction of whey protein) for 3 training days.
10160413|NCT03994198|Active Comparator|Collagen peptides|Participants will consume 60 g of collagen peptides for 3 training days.
10160414|NCT03994185|Experimental|Group Treated with stent graft|This is a single arm study. All subjects will be treated with the WRAPSODY stent graft.
10160415|NCT03994263|Experimental|iTind arm|ITind device implant
10160416|NCT03994302||Immune toxicity induced by drugs and chemotherapies|Immune toxicity induced by drugs and chemotherapies Case reported in the World Health Organization (WHO) of immune toxicities(such as Antiphospholipid syndrome) of patient treated by a drug, with a chronology compatible with the drug toxicity
10160417|NCT03994237||ALZHEIMER CAREGIVER|Caregiver available to accompany the patient to the consultation, helping calling for the first time the memory center, aidant who noticed a cognitive disorder help, having a family link identified with the patient
10160418|NCT03994081|Experimental|transcranial alternating current stimulation (tACS) at alpha|10 Hz tACS with an amplitude of 1 mA for 40 minutes. Uses tACS device.
10160419|NCT03994081|Sham Comparator|sham stimulation|Will include 20 seconds of ramp-up, 40 seconds of 10 Hz tACS at 1 mA, and 20 seconds of ramp-down for a total of 80 seconds of stimulation. Uses sham tACS device.
10160420|NCT03994055|Experimental|Anti-inflammatory Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20-30%. Fat: 30-40%. Carbohydrates: 40-50%. The diet will be individualized according to the patients' comorbidities (obesity, type 2 diabetes, hypertension, renal insufficiency).~This group will include the consumption of foods that contain immune modulating nutrients:~Omega-3 fatty acids, antioxidants, soluble fiber, probiotics. The recommendation to include these foods will be made according to the patients' access to food in their home area."
10160421|NCT03994055|Active Comparator|Low residue Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20%. Fat: 20%. Carbohydrates: 60%. Diet will have lactose restriction, fiber restriction and fat restriction."
10160422|NCT03994016|Experimental|WiseGuyz Participant|Individuals in this arm will receive the WiseGuyz program in their grade 9 year.
10160423|NCT03994016|No Intervention|Comparison Participant|Individuals in this arm will not receive any intervention in their grade 9 year, and will be used to create a matched comparison group for individuals in Arm 1 (WiseGuyz Participants).
10160424|NCT03993964|Experimental|Experimental: Pyrotinib + SHR6390|Pyrotinib combine with SHR6390 should be administrate to all subjects. pyrotinib 400mg qd combined with SHR 6390 125mg qd
10160425|NCT03994068|Experimental|VIVO mapping pre-procedure|15 patients with structurally normal heart and indication for PVC/VT catheter ablation, who will undergo pre-procedural non invasive mapping with VIVO mapping system.
10160426|NCT03994549|Active Comparator|ZP7570|Single subcutaneous injection
10160427|NCT03994549|Placebo Comparator|Placebo|Single subcutaneous injection
10160428|NCT03994289|No Intervention|Control|Participants remain seated for 2 hours after the intake of a standardized breakfast.
10160429|NCT03994289|Experimental|Motor-assisted cycling|Participants will perform 3 bouts of motor-assisted cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
10160430|NCT03994289|Experimental|FES cycling|Participants will perform 3 bouts of FES cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
10160431|NCT03994133||Daily Home Dialysis patients|Daily Home Dialysis patients with low-flow dialisate for more than 3 months in France
10160432|NCT03993938|Experimental|Patients for TMVR|Patients with severe mitral regurgitation scheduled for TMVR procedure at Henry Ford Hospital - main campus.
10160433|NCT03994042|Experimental|Mental imagery neurofeedback training|Complete intervention with mental imagery neurofeedback training. Patients recruited by physioterapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
10160434|NCT03993990|Experimental|Experimental group|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation).
10160435|NCT03993990|No Intervention|Control group|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
10160436|NCT03994432|Experimental|Intervention group|"patients with symptomatic endometriosis in therapy with estro-progestins or progestins, who will be asked to follow a mediterranean diet and to practice an aerobic physical exercise according to the 7-minutes workout model"
10160437|NCT03994432|No Intervention|Control group|patients with symptomatic endometriosis in therapy with estro-progestins or progestins.
10160438|NCT03994029|Experimental|Polyphenol supplementation|120mg per day of powder polyphenol for 60 days
10160439|NCT03994029|Placebo Comparator|Placebo|1 tab PO QD per day of placebo for 60 days
10160440|NCT03994393|Active Comparator|Cohort 1|Participants with no evidence of T790M
10160441|NCT03994393|Active Comparator|Cohort 2|Participants with evidence of T790M
10160442|NCT03993977|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
10160443|NCT03993977|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
10160444|NCT03994328||Group 1|500 patients already receiving safinamide (50 or 100 mg/day) as add-on to L-dopa for no more than 2 months.
10160445|NCT03994328||Group 2|500 patients receiving rasagiline 1 mg/day as add-on to L-dopa for no more than 2 months.
10160446|NCT03994328||Group 3|235 patients receiving other SoC drugs as add-on to L-dopa for no more than 2 months.
10160447|NCT03994458|Experimental|Experimental|Participants get the full program for 6 weeks.
10160448|NCT03994458|Placebo Comparator|Placebo|Participants get the placebo program for 6 weeks.
10160449|NCT03994276|Placebo Comparator|Phase 1: Control|oral glucose tolerance test (OGTT): 58g Dextrose in 330ml water
10160450|NCT03994276|Active Comparator|Phase1: Chickpea Control|"sub-cellular Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring"
10160451|NCT03994276|Experimental|Phase1: Chickpea Powder|Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring
10160452|NCT03994276|Active Comparator|Phase 2: Control|Wheat bread: breakfast consisting of a 100% wheat bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
10160453|NCT03994276|Experimental|Phase 2: 30%Chickpea Powder|Wheat bread: breakfast consisting of a 70% wheat / 30% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
10160454|NCT03994276|Experimental|Phase 2: 60%Chickpea Powder|Wheat bread: breakfast consisting of a 40% wheat / 60% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
10160455|NCT03994380|Experimental|Intervention|rhDNAse 2.5 mg nebulizer daily for 4 weeks
10160456|NCT03993769|Experimental|A19010-F, B19010-F Use Group|Use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
10160457|NCT03993769|Experimental|B19010-F, A19010-F Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
10160458|NCT03993886|Other|Arm 1|Adult (≥ 18 years of age) ambulatory patients diagnosed with heart failure and/or undergoing cardiac management.
10160459|NCT03993886|Other|Arm 2|Adult (≥ 18 years of age) patients undergoing chronic hemodialysis.
10160460|NCT03993886|Other|Arm 3|Adult (≥ 18 years of age) patients (i) implanted with the CardioMEMS HF device and (ii) diagnosed with heart failure and/or undergoing cardiac management.
10160461|NCT03993886|Other|Arm 4|Adult (≥ 18 years of age) patients diagnosed with heart failure and/or undergoing cardiac management.
10160462|NCT03993704|Experimental|Active|450 mg, 1125 mg, or 2250 mg of LHF-535 given once daily for 14 days
10160463|NCT03993704|Placebo Comparator|Placebo|Placebo to match LHF-535 given once daily for 14 days
10160464|NCT03993743|Experimental|CD147-CART|Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery
10160465|NCT03993899|Active Comparator|Cochlear implant (CI) with FineHearing Strategy then HDCIS|cochlear implant with FineHearing strategy first during 15 days then with HDCIS strategy during 15 days
10160466|NCT03993899|Active Comparator|CI with HDCIS Strategy then FS4|cochlear implant with HDCIS strategy first during 15 days then with FS4 strategy during 15 days
10160467|NCT03993782|Experimental|A19010-R, B19010-O Use Group|Use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
10160468|NCT03993782|Experimental|B19010-O, A19010-R Use Group|Use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
10160469|NCT03993483|Experimental|Higher Load|One arm and one leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
10160470|NCT03993483|Experimental|Lower Load|The other arm and leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
10160471|NCT03993795|Experimental|A19010-W, B19010-F Use Group|Use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
10160472|NCT03993795|Experimental|B19010-F, A19010-W Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
10160473|NCT03993808|Experimental|Educational/behavioral support for hypertension self efficacy|On-site monitoring of pulse, blood pressure, weight, and surveys, at Months 0,1,3,6; Four educational sessions to address: 1) basics about blood pressure (BP); 2) training in home BP monitoring with personal Omron 10 device; 3) information about Dietary Intervention to lower Systemic Blood Pressure (DASH) eating plan, recipes and cooking demonstrations; 4) education about BP medication adherence. Interventions occur on the background of Carter Burden Network's implementation of a DASH-congruent menus for congregant meals for all seniors attending the sites, including those not enrolled in the protocol.
10160474|NCT03993860|Experimental|Intervention arm|Infants will be given fish powder called Chisense (Potamothrissa acutirostris) for a period of 6 months from the time they are 6 months up to the time they are 12 months.
10160475|NCT03993860|Placebo Comparator|Control arm|Infants will be given fish powder called sorghum powder for a period of 6 months from the time they are 6 months up to the time they are 12 months.
10160476|NCT03993548|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
10160477|NCT03993639|Experimental|KRN125|Single SC administration
10160478|NCT03993509|Experimental|1 Hz Arm|Subjects will receive a continuous train of 1 Hz stimulation until all 3000 pulses are delivered. Consistent with the 10 Hz condition, TMS will occur during the Sternberg WM paradigm.
10160479|NCT03993509|Experimental|10 Hz Arm|Subjects will receive 75, 4 second trains at 10 Hz, separated by a 36 second ITI. Stimulation will occur while subjects are doing the Sternberg WM paradigm. The timing of the Sternberg task will be jittered so that each rTMS train will be administered during the maintenance interval of a WM trial.
10160480|NCT03993652|Experimental|Screen-time and Snacking|Aim: to reduce both screen-time and unhealthy snacking
10160481|NCT03993652|Experimental|Screen-time only|Aim: to reduce screen-time only
10160482|NCT03993652|Experimental|Snacking only|Aim: to reduce unhealthy snacking only
10160483|NCT03993652|No Intervention|Control|Control
10160484|NCT03993600|Sham Comparator|Healthy volunteers|sweat test and skin biopsy
10160485|NCT03993600|Experimental|Patients with Cystic fibrosis|sweat test and skin biopsy
10160486|NCT03993600|Experimental|Heterozygotes subjects|sweat test and skin biopsy
10160487|NCT03993561|Experimental|TSSP Group|A one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists will be provided
10160488|NCT03993730|Other|Device Implantation|A prospective, blocked, randomised, controlled trial of primary prophylaxis ICD therapy or ILR insertion in patients with LVEF <45% and LGE on CMR.
10160489|NCT03993730|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF <45% and no LGE on CMR.
10160490|NCT03993431|Experimental|Bio-active cement|Bio-active cement dispensed into the crown, and the crown was properly positioned over the tooth, cement was allowed to self-set for 20 seconds while maintaining gentle pressure on the crown, then flash cured using a light curing unit to remove excess cement, buccal and lingual surfaces were light cured for extra 10 seconds each.
10160491|NCT03993431|Active Comparator|Packable glass ionomer|Dentin conditioner was applied to the prepared crown surfaces for 20 sec, then rinsed, and dried. Capsule was activated, mixed for 10 seconds in an amalgamator, then loaded into the capsule applier to extrude cement directly into the crown, the crown was properly positioned over the tooth, cement was allowed to self-set for 2 minutes while maintaining gentle pressure on the crown, excess cement was removed before complete setting of cement.
10160492|NCT03993626|Experimental|CXD101 and Nivolumab combination|"CXD101 will be presented as 10mg HPMC capsules and will be taken orally for 5 consecutive days repeated every three weeks on an outpatient basis.~Nivolumab will be presented as a 10 mg/mL solution in a single-dose vial, administered as iv infusion over 60 mins, repeated every two weeks.~CXD101 in combination with nivolumab will be administered in the Phase II component of the trial at doses determined in the Phase Ib component."
10160493|NCT03993522|Experimental|CTO Exerciser|"2x Symptom limited cardiopulmonary exercise tests~1x Sub-maximal cardiopulmonary exercise test (20 minutes)"
10160494|NCT03993418|Experimental|Stevia arm|stevia drops
10160495|NCT03993418|No Intervention|Control arm|No change in diet
10160496|NCT03993444|Experimental|communication and problem solving|Three smal group sessions (separate for employees (length 2 hours each) and for supervisors (length 2,5 hours each)) focused on training communication and problem solving skills.
10160497|NCT03993444|Active Comparator|psychoeducation|Two, 1 hour, lectures, one on the topic of pain and one on the topic of stress (for employees and supervisors combined).
10160498|NCT03993496||EVAR Patients|Patients with infrarenal abdominal aortic aneurysm scheduled for elective endovascular aneurysm repair (EVAR) surgery will undergo intraoperative assessments of aneurysm wall pulsatility using ultrasound M-Mode.
10160499|NCT03993470|Experimental|experimental|The short foot exercise daily for 4 weeks
10160500|NCT03993470|Placebo Comparator|Control|A placebo excercise daily for 4 weeks
10160501|NCT03993535|Other|SSRI or cognitive behavioral therapy|selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine) or cognitive-behavioral therapy, depending on availability and patient preference
10160502|NCT03993327|Experimental|Diagnostic (iodine I 124 monoclonal antibody M5A, PET scan)|Patients receive iodine I 124 monoclonal antibody M5A IV on day 0 and undergo PET scan on days 2 and 6.
10160503|NCT03993340||1|Rescue stenting group
10160504|NCT03993405|Active Comparator|Control group:young|Sixty older subjects will be evaluated in this study.
10160505|NCT03993405|Active Comparator|Control Group:Middle-aged|Sixty middle-aged subjects will be evaluated in this study.
10160506|NCT03993405|Experimental|Experimental group:older|Sixty older subjects will be evaluated in this study.
10160507|NCT03993366|Experimental|Simple Meal Announcement|Before every meal, the meal will be simply announced to the algorithm by a member of the study team. Meal bolus computation will be independent of the carbohydrate content of the meal.
10160508|NCT03993366|Active Comparator|Full Carbohydrate counting|The carbohydrate content of the meal selected by the participant will be entered into the dosing algorithm by a member of the study team at the onset of the meal to compute the insulin prandial bolus.
10160509|NCT03993041|Experimental|Cognitive-behavioral therapy (CBT)|Individuals in the CBT arm are expected to participate in a phone screen + baseline phase (one assessment) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
10160510|NCT03993041|Active Comparator|Waitlist Control|Individuals in the Waitlist Control arm are expected to participate in a phone screen + baseline phase (two assessments, 12 weeks apart) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
10160511|NCT03993093||HIV with OIs|Treatment naive HIV patients with OIs
10160512|NCT03993353|Experimental|Tadalafil and Pembrolizumab|Tadalafil for up to 12 months and pembrolizumab for up to 24 months.
10186189|NCT03738176|Active Comparator|triamcinolone in orabase|140 gm triamcinolone-50 gm Na CMC 3 times per day for one month
9671323|NCT05050448|Experimental|SAM2 Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wireless SAM Ultrasonic Diathermy Device for 1 hour at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
9671324|NCT05050448|Placebo Comparator|Topical Pain-Relief Gel|Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
9671325|NCT05050110|Other|chronic kidney disease patients|Evaluation of Increased fruits and vegetables consumption in chronic kidney disease patients maintaining normokalemia with patiromer
9671326|NCT05050058||Neonates born to diabetic mothers|
10160513|NCT03993106|Experimental|Study Drug|All study participants will receive sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. All study participants will receive two doses of study drug on Days 1 and 15 of each 4 week cycle.
10160514|NCT03993184|Experimental|90-minute Hot Yoga Classes|This group will complete 3, 90-minute hot yoga classes weekly for 12 weeks.
10160515|NCT03993184|Experimental|60-minute Hot Yoga Classes|This group will complete 3, 60-minute hot yoga classes weekly for 12 weeks.
10160516|NCT03993184|No Intervention|Control|This group will maintain their current physical activity for 12 weeks.
10160517|NCT03993067|Active Comparator|Standard Treatment|Fibrin glue and Tabotamp on cut surface
10160518|NCT03993067|Experimental|Hemopatch|Hemopatch on cut surface
10160519|NCT03993015||Patients attending the Obstetrical Emergency Unit|Patients attending the Obstetrical Emergency Unit of CHU Montpellier during 2018
10160520|NCT03993080|Experimental|Virtual reality relaxation|Virtual reality relaxation using virtual landscape and audio features and sound
10160521|NCT03993080|No Intervention|Treatment as usual|Seated in similar environment as experimental group for same time
10160522|NCT03993275||Patients with Stroke|30 Patients suffering a stroke will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 4 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
10160523|NCT03993275||Patients with Multiple Sclerosis|50 Patients suffering multiple sclerosis will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 3 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
10160524|NCT03993236|Experimental|Rosuvastatin/Ezetimibe 10/10mg|The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.
10160525|NCT03993236|Active Comparator|Rosuvastatin 20mg|The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days
10160526|NCT03992937|Experimental|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
10160527|NCT03992937|Active Comparator|LNG-IUS|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.
10160528|NCT03993145|Experimental|Web-based lifestyle intervention|participants will be provided access to web-based lifestyle intervention program with personalized coaching from a clinical dietician
10160529|NCT03992885|Experimental|combination therapy with ectiecinib, pemetrexed and platinum|ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally;Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle, a total of 6 cycles.Maintenance therapy: ectinib: ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally, pemetrexed 500mg/m2,d intravenous infusion, day 1,21 days for a cycle
10160530|NCT03992924|Active Comparator|angiography-guided PCI|
10160531|NCT03992924|Experimental|FFR-guided PCI|
10160532|NCT03992924|Experimental|OCT-guided PCI|
10160533|NCT03992989|Experimental|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
10160534|NCT03992989|Active Comparator|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
10160535|NCT03992898||Chronic hepatitis cohort|In this cohort, patients were defined as type A acute-on-chronic liver failure (ACLF) patients who have chronic liver disease but without cirrhosis.
10160536|NCT03992898||Cirrhosis cohort|In this cohort, patients were defined as type B and type C ACLF patients with cirrhosis.
10160537|NCT03992911|Experimental|FOLFSIM Plus Teripalimab|Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab
10160538|NCT03992911|Active Comparator|EP/EC|Etoposide plus Cisplatin or Carboplatin
10160539|NCT03992963|Active Comparator|Hearing Aid without frequency lowering enabled|
10160540|NCT03992963|Experimental|Hearing Aid with frequency lowering enabled|
10160541|NCT03992976||Teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
9671327|NCT05050058||Neonates born to non-diabetic mothers (control)|
9671328|NCT05049837||Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
10186190|NCT03738137|Experimental|Narcotrend|After 0.1µg/kg sufentanil is applied, miidazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the Narcotrend index stage C.
10186191|NCT03738137|Experimental|BIS|After 0.1µg/kg sufentanil is applied, midazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by bispectral index (BIS; between 70 and 85).
10186192|NCT03738137|Experimental|No monitoring|After 0.1µg/kg sufentanil is applied, midazolam iss given by non-anaesthetist physicians according to patient's tolerance .
10160542|NCT03992976||Parents of teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
10160543|NCT03992820|Experimental|TENS arm (trial arm)|The trial group will have the TENS (transcutaneous electrical nerve stimulator) to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.
10160544|NCT03992820|Other|EMLA arm (Control arm)|The control group will have EMLA (Eutatic mixture of local anaesthetic) applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution.
10160545|NCT03992859|Experimental|serratus catheter|Continuous serratus plane block: Ropivacaine 0.2% infusion through a multiple hole catheter (C-Cat Cimpax Denmark)at a fixed dose of 12 ml/h and a multimodal analgesia with acetaminophen and a PCA of morphine
10160546|NCT03992859|No Intervention|standard treatment|Post-operative multimodal analgesia with Acetaminophen and PCA of Morphine
10160547|NCT03992833|Experimental|lung cancer screening|"Participants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules.~At baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected."
10160548|NCT03992807|Experimental|A patient decision aid|A patient decision aid that includes not only the standard general information, but also the quantitative risk information on the possible outcomes of cataract surgery as well as value clarification exercise.
10160549|NCT03992807|Active Comparator|A usual education booklet|A traditional booklet with standard general information developed by the National Eye Institute (NEI) to help patients understand cataract.
10160550|NCT03992794||Total patients|Consecutive patients presenting to the ED with either a suspected or documented infection in which blood samples were taken during routine. An extra blood sample was taken to measure PCT & MR-proADM using the Samsung IB10 point of care assay.
10160551|NCT03992560|No Intervention|Standard CRT implantation|
10160552|NCT03992560|Experimental|MRI guided CRT implantation|
10160553|NCT03992573|Experimental|Study group|
10160554|NCT03992573|No Intervention|Control group|
10160555|NCT03992495||Neck pain|People suffering from neck pain at the time of recruitment
10160556|NCT03992495||Healthy|Participants with no significant past neck pain, chronic pain or other relevant medical disorders.
10160557|NCT03992690|Experimental|WANR protocol|Including training with Brain-machine interfaces, visuo-tactile feedback and assisted locomotion
10160558|NCT03992690|Active Comparator|Classical physiotherapy protocol|Training with classical physiotherapy protocol
10160559|NCT03992651|Experimental|Experimental group|One single group of healthy subjects
10160560|NCT03992599||Laparoscopic modified central mesocolic excision|Patients receiving laparoscopic colectomy with the concept of modified complete mesocolic excision for right-sided colon cancer
10160561|NCT03992664|Experimental|EDUCATION|If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
10160562|NCT03992664|No Intervention|NON-INTERVENTION|The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
10160563|NCT03992534|Experimental|LACTIN-V|"Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)~Dosage: LACTINV is a powder formulation of Lactobacillus crispatus CTV-05 provided in a prefilled vaginal applicator at a dose of 2 x 10^9 CFU of L. crispatus CTV-05. Route of Administration: LACTIN-V powder is administered vaginally using a specially designed applicator.~Formulation: LACTIN-V is supplied as a pre-filled, single-use applicator. Each applicator contains LACTIN-V powder at a dose of 2 x 10^9 CFU. The LACTIN-V powder formulation contains L. crispatus CTV-05 and a preservation matrix containing inactive excipients of non-animal origin."
10160564|NCT03992638|Experimental|L-PRF membrane|Periodontal plastic surgical procedures (coronally advanced flap, CAF) in combination with a double layer autologous leucocyte and platelet-rich fibrin (L-PRF) membrane.
10160565|NCT03992638|Active Comparator|Control|CAF
10160566|NCT03992586|Experimental|Pink lenses|Pink-colored lenses
10160567|NCT03992586|Placebo Comparator|Clear lenses|Clear lenses
10160568|NCT03992716|Experimental|SmofKabiven® extra Nitrogen|Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
10160569|NCT03992716|Active Comparator|Olimel N9E|Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
9671329|NCT05049837||Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
10160570|NCT03992742|Experimental|Intervention Group (subgroup A+B+C)|Personalized instant messaging (PIM) + optional cocktail interventions (OCI) + AWARD advice + referral card + warning leaflet+ COSH booklet
10160571|NCT03992742|Experimental|Control Group (subgroup D+E+F)|Regular instant messaging (RIM) + personalized instant messaging (PIM) + AWARD advice + referral card + warning leaflet+ COSH booklet
10186193|NCT03738137|Experimental|Lidocaine|Only topical anesthesia was applied.
9671330|NCT05049837||Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples.
10160572|NCT03992755|Experimental|LIQ861 Inhaled Treprostinil|LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg. LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg capsule strength to 200 μg capsule strength treprostinil four times a day (QID) in individual patients. Titrating to dose levels beyond 200 μg capsule strength QID, under clinical investigator supervision, requires review and approval from the Medical Monitor.
10160573|NCT03992547|Experimental|robot assisted gait traing|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks.
10160574|NCT03992508|Other|complex decongestive treatment|In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
10160575|NCT03992508|Experimental|intermittent pneumatic compression|In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
10160576|NCT03992677||Brugada VF|Confirmed Brugada Syndrome by either Spontaneous or drug induced Type 1 ECG, confirmed cardiac arrest or appropriate ICD therapy for potentially lethal arrhythmia.
10160577|NCT03992677||Brugada relative|Relatives of Brugada syndrome patients with proven no pathology by Ajmaline challenge
10160578|NCT03992677||Ventricular ectopy|Patients undergoing ablation with ECGi system for other arrhythmias -these patients will be similar to our original controls and provide a repeat set of controls.
10160579|NCT03992677||AF|Patients with AF undergoing ablation with ECGi system (n=10). These patients will be older and have varying RR intervals which may cause a falsely low V-CoS.
10160580|NCT03992677||Ischaemic VF|Out-of-hospital cardiac arrest primary PCI with full recovery of left ventricular function and full revascularisation (n=10) - the purpose of this group is to confirm that the changes detected in our SCD group are not secondary to the SCD event. These are patients who have had a cardiac arrest secondary to coronary occlusion, but have made a full recovery with normal LGE-MRI and no indication for ICD.
10160581|NCT03992677||Athletes|Athletic Hypertrophy (n=10) - Elite athletes often have physiological LVH and abnormal ECGs at rest. It is unclear if these variations in activation will lead to a decrease in V-CoS.
10160582|NCT03992170|Experimental|Single Arm|"Patients will receive Daratumumab (16 mg/Kg day) every week for 8 weeks intravenous (8 infusions) and then every 2 weeks for 16 weeks intravenous (8 more infusions).~If MRD positive by NGF, the patients will receive Daratumumab every 4 weeks for 80 weeks intravenous; if MRD negative by NGF, the patients can stop the treatment."
10160583|NCT03992157|Experimental|holter-ECG|Implementation of an ECG Holter during hospitalisation patient.
10160584|NCT03992157|No Intervention|Crontrole|No implementation of an ECG Holter
10160585|NCT03992079|No Intervention|Control|The control group will receive standard preoperative and postoperative directions, with the anesthesiologist and surgeon's preferences for analgesia during and after surgery.
10160586|NCT03992079|Experimental|Experimental|The experimental group will receive routine directions for surgery and a ReCOVER patient education document on the Enhanced Recovery protocol, with instructions on preoperative preparation, postoperative wound care, pain management, preventing and managing constipation, activity limitations, and return precautions. The information sheet will be provided to patients in clinic and reviewed with a member of the healthcare team to ensure an understanding of the plan.
10160587|NCT03992105|Other|historical cohort|150 homeless patients in crisis, identified from an extraction of the database of psychiatric emergencies of the same territory, and matched for age, sex, and main diagnosis.
10160588|NCT03992131|Experimental|Arm A: Oral rucaparib and oral lucitanib|"Phase 1b (Dose escalation): Up to 55 patients with advanced or metastatic solid tumors.~Phase 2 (Dose expansion): Up to 80 patients with High Grade Ovarian Cancer."
10160589|NCT03992131|Experimental|Arm B: Oral rucaparib and IV sacituzumab govitecan|"Phase 1b (Dose escalation): Up to 55 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, platinum resistant Ovarian Cancer, or a tumor with a BRCA1, BRCA2, PALB2, RAD51C, or RAD5/1D mutation~Phase 2 (Dose expansion): Up to 139 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, or platinum resistant Ovarian Cancer"
10160590|NCT03992144|Experimental|amoxicillin|single preoperative oral 500 mg dose of Amoxicillin before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
10160591|NCT03992144|Experimental|metronidazole|single preoperative oral 400 mg dose of metronidazol before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
10160592|NCT03992144|Active Comparator|conventional group|conventional therapy for prevention of dry socket post operative; 400mg metrinidazol 3 times a day for 5 days 500mg of amooxicillin 2 times a day for 5 days painkiller 48 hours after extraction then sos
9671331|NCT05049837||Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
10186194|NCT03738124|Experimental|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA Thoracic Stent Graft System is administered.
9671332|NCT05049837||Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
10160593|NCT03992066|Experimental|Vadadustat 600 mg|Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.
10160594|NCT03992066|Experimental|Vadadustat 750 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.
10160595|NCT03992066|Experimental|Vadadustat 900 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.
10160596|NCT03992066|Other|Erythropoiesis-stimulating agent|Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.
10160597|NCT03992196|Experimental|Rotigotine|Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.
10160598|NCT03992222|Experimental|administration of a physical exercise programme|administration of a Physical exercise program for 24 weeks.
10160599|NCT03992222|No Intervention|control|
10160600|NCT03992248|Experimental|Time Restricted Feeding|Participants are instructed to eat within a limited time frame during the day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
10160601|NCT03992248|Other|Control|Participants are instructed to spread their habitual food intake over at least 14hrs per day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
10160602|NCT03992261|Experimental|Halobetasol Propionate Foam|2 weeks of application, 2 times daily
10160603|NCT03992378|Experimental|Active Treatment|Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
10160604|NCT03992378|Sham Comparator|Sham Control|Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
10160605|NCT03992313|Experimental|Facility-based testing intervention|Community Health Workers (CHWs) will provide information inside their groups on the possibility to be tested in health centers for HCV infection. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center that will be in charge to give result to the participant and to refer to care in case of active infection.
10160606|NCT03992313|Experimental|Community-based testing intervention|After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the village of participants. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS and sent to Phnom Penh for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center of each cluster and CHWs will be in charge to give result to the participant and to refer to care in case of active infection.
10160607|NCT03992300|Experimental|Intraoral scanning|An intraoral scanning is taken. An auxiliary device is used to achieve better accuracy. A zirconia framework is produced
10160608|NCT03992300|Active Comparator|Conventional scanning|A conventional elastomeric impression is taken and a zirconia framework is produced
10160609|NCT03992287|Experimental|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
10160610|NCT03992287|Placebo Comparator|Placebo|Placebo for 12 weeks
10160611|NCT03992326|Experimental|TIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Low Dose Irradiation (LDI), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
10160612|NCT03992118|Experimental|Feeding Challenges|Parents will be coached to implement strategies to address factors contributing to feeding challenges based on a multidisciplinary assessment using the medico-oral-behaviour-sensory-environment (MOBSE) approach.
10160613|NCT03991767|Experimental|period 1|"Period 1: Retrospective period:~Collection of data from the 12 months preceding the start of the research of hospitalized patients:~number of hospitalizations,~number of HIV serologies performed,~number of patients with socio-demographic criteria justifying HIV screening.~Start of research: Implementation of the POP-UP electronic alert~Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.~Six possibility to answer:~Patient accept to participate: patient is include and receive HIV serology during their hospitalization.~Not time to answer to the alert~Patient already has a serology less than 3 months old~Patient followed for a known HIV infection.~Patient who refused the test~Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization."
10160614|NCT03992027|Experimental|Immediate CF-CBT Intervention|This group will enter immediately into the 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT).
9520183|NCT03279783|No Intervention|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
10160615|NCT03992027|Other|Waitlist control|This group will enter into the same 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT) 3 months after enrollment.
10160616|NCT03991871|Placebo Comparator|Control Group|35 hours ECP treatment, initial treatment pressure is 75 mmHg
10160617|NCT03991871|Experimental|Intervention Group|35 hours ECP treatment, initial treatment pressure is 300 mmHg
10160618|NCT03992339|Experimental|ATG-010|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.
10160619|NCT03992391|No Intervention|Qualitative Interviews|Qualitative Interviews with adolescents, their parents and clinicians.
10160620|NCT03992391|Experimental|Open Pilot|Open-label pilot group of adolescents (n=10) in a suicide prevention intensive outpatient program
10160621|NCT03992391|Experimental|Open-label trial|Open-label trial of adolescents (n=40) in a suicide prevention intensive outpatient program
10160622|NCT03992365|Experimental|Quiklean®|Quiklean® (32 tablets)
10160623|NCT03992365|Active Comparator|GroKlean-Prep with Dulcolax®|2 sachets of Klean-Prep with 1 tablet of Dulcolax®
10160624|NCT03992053|Active Comparator|Group 1|conventional 2-D fluoroscopy guidance as the first choice of guidance
10160625|NCT03992053|Active Comparator|Group 2|3-D CT guidance as the first choice of guidance
10160626|NCT03991936|Placebo Comparator|Placebo|Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.
10160627|NCT03991936|Experimental|Triamcinolone Acetonide 2.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
10160628|NCT03991936|Experimental|Triamcinolone Acetonide 5.0 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
10160629|NCT03991936|Experimental|Triamcinolone Acetonide 7.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
10160630|NCT03991936|Experimental|Triamcinolone Acetonide 10 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
10160631|NCT03991897|Experimental|Ketogenic diet|"the intervention will consist of 3 phases: a one week run-in period, 24 weeks strict KD and 24 weeks Modified Atkins Diet.~Every day, 40 g of KetoCal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals and to ensure ketosis during the night (some patients drink some sips of the shake during the night). During this run-in period, patients will become familiar with their diet and, in particular, they will learn which foods are allowed and which are not."
10160632|NCT03991897|Active Comparator|Isocaloric diet|During the run-in period, the dietician will discuss the diet and maintenance of an isocaloric diet with the patients. As such, the diet of the control group will not change from their normal dietary pattern, unless a patient is following an Atkins-like diet. In the latter case, the patient will be asked to change the diet to a normal Belgian diet.
10160633|NCT03991845|Experimental|Low dose Vit D|All Patients belonging to arm 1 will be treated with low dose oral Vit D (2000 IU/day) for 12 weeks
10160634|NCT03991845|Active Comparator|High dose Vit D|All patients in this group will be treated with high dose oral Vit D (60,000 IU/week) for 12 weeks
10160635|NCT03991845|No Intervention|Placebo|No Vit D supplementation will be given to patients in this group
10160636|NCT03991975|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10160637|NCT03991754|Experimental|Amiodarone|Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.
10160638|NCT03991754|Placebo Comparator|Control|Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI
10160639|NCT03991962|Experimental|mFOLFIRINOX followed by SBRT|Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).
10160640|NCT03991910|Placebo Comparator|control|control patients will be given a placebo
10160641|NCT03991910|Experimental|treatment|Ramipril 5 mg treatment group
10160642|NCT03991858|Other|Phone follow-up|Phone follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
10160643|NCT03991858|Experimental|Telerehabilitation follow-up|Telerehabilitation follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
10160644|NCT03991780|Experimental|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib (tablet taken orally) twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
10160645|NCT03991819|Experimental|Phase 1|"Cycle 1 = 28 days and Cycle 2 and Future Cycles = 21 days~Binimetinib, by mouth (orally): Level 1: 45 mg, twice a day, continuously; Level -1: 30 mg, twice a day, continuously; Level -2: 30 mg, twice a day, for Days 1-14 of each cycle only~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 8 of Cycle 1, then Day 1 of Cycle 2 and future cycles."
10160646|NCT03991819|Experimental|Phase 1b|"All Cycles = 21 days~Binimetinib, by mouth (orally), at the best dose found in Phase 1 of the study, twice a day, continuously.~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 1 of every cycle."
10160647|NCT03991637|Experimental|NICMP Spectral Reading|Non-invasive spectral data is collected from this arm to function as the intervention of interest.
10160648|NCT03991637|Active Comparator|Venipuncture CMP|"A standard CMP blood draw is performed to function as the gold standard reference value.~Specifically, the outcome of the experimental arm is cross-validated against the active comparator arm to determine the NICMP accuracy, relative to the venipuncture method."
10160649|NCT03991442|Experimental|BR1010 and Fimasartan/Amlodipine placebo|BR1010 or Fimasartan/Amlodipine
10160650|NCT03991442|Active Comparator|BR1010 placebo and Fimasartan/Amlodipine|BR1010 or Fimasartan/Amlodipine
10160651|NCT03991455|Other|Apyx device treatment|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system. Using the device, SSLF can be performed transvaginally without the need for any incisions or blind dissections and without the requirement of heavy anesthesia.
9671333|NCT05049837||Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
10186195|NCT03738111|Experimental|TG02 Citrate|TG02 citrate capsules given orally.
10186196|NCT03738072|Experimental|StiMic stimulation condition|StiMic stimulation condition will be evaluate during stereo-electro-encephalography and this condition will be compare to standard stimulation condition
10160652|NCT03991390|Experimental|Core stability and feedback visual laser exercises|"Two complementary protocols for the treatment of balance after stroke in patients with pusher syndrome were designed, including multidimensional physiotherapy exercises. Both protocols differentiate 3 levels of difficulty: Second level requires maintenance of balance sitting 5, if the patient does not succeed, stays in level 1. To move to L3 patients must stay seated 10''. Each exercise is repeated 5 times, always considering patients' levels of fatigue and safety.~Visual feedback with laser (Motion Guidance Clinical Kit, approved for therapeutic use): Through visual aid, patients' verticality is achieved by encouraging their active participation in correcting the imbalance while performing the exercises.~Core stability: The exercises have to be adapted for the pusher patient avoiding overuse of the less affected side of the body, and strengthening the muscles that stabilize the trunk."
10160653|NCT03991390|Active Comparator|Control stroke|Rehabilitation program is based on a comprehensive approach, where the patient follows a personalized plan of exercises according to the deficits, the previous situation and personal concerns.
10160654|NCT03991429||Group 1|Patients with BPH and significant improvement in storage symptoms after BOO procedures
10160655|NCT03991429||Group 2|Patients with BPH who have persistent storage symptoms after BOO procedures
10160656|NCT03991429||Group 3 (Control group)|Men without LUTS who are planning to undergo radical prostatectomy
10160657|NCT03991351||Men aged 18-34|Participants will be males aged 18-34. Each individual will be exposed to images of men with either a muscular, skinny or overweight physique or the control images of landscapes.
10160658|NCT03991689|Experimental|the six weeks solution-focused pain management groups|
10160659|NCT03991676|Experimental|Values-Based Behavioral Treatment|
10160660|NCT03991416|Experimental|Understanding Your Baby|Understanding Your Baby plus postnatal care as usual
10160661|NCT03991416|Active Comparator|Care As Usual|Postnatal care as usual
10160662|NCT03991364|Experimental|Constant gait speed group|experimental group that applied the speed of the robot-assisted gait training constantly
10160663|NCT03991364|Other|Increasing gait speed group|control group that applied the gradual increase of the speed of the robot-assisted gait training
10160664|NCT03991325||difficult laryngoscopy|group of patients with Cormack and Lehane grade III or IV
10160665|NCT03991325||easy laryngoscopy|group of patients with Cormack and Lehane grade I or II
10160666|NCT03991585|Experimental|Three times a week MCRF|Participants in this arm will participate in the MCRF intervention sessions three times a week for 12 consecutive weeks.
10160667|NCT03991585|Experimental|One time a week MCRF|Participants in this arm will participate in the MCRF intervention sessions one time a week for 12 consecutive weeks.
10160668|NCT03991559|Active Comparator|Dose-Escalation, intranasally|With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.
10160669|NCT03991559|Active Comparator|Dose-Escalation, inhalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
10160670|NCT03991598|Experimental|intervention|EDs 1 to 7 will then be randomly phased-in INT every 3 months.
10160671|NCT03991598|No Intervention|control|During the first 6 months and throughout CTRL time
10160672|NCT03991572|Active Comparator|Real Stimulation|The Real Stimulation of rTMS lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . Behavior and MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
10160673|NCT03991572|Sham Comparator|Sham Stimulation|The procedure of Sham Stimulation protocol was performed by a placebo coil,lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
10160674|NCT03991520|Experimental|Active Treatment with Anakinra|10 subjects will be enrolled in this group. Initial treatment will consist of 100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
9977322|NCT01360216|No Intervention|Standard practice- control|Clinicians and contraceptive educators practicing in clinics assigned to this arm do not receive special LARC training and education session. Standard practice will be followed at clinics assigned to the control arm.
10160675|NCT03991520|Placebo Comparator|Standard Comparison|10 subjects will be enrolled in this group. This group will be given placebo injections as their initial treatment. The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection. These individuals will self-administer the placebo each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
10160676|NCT03991546|Experimental|Acceptance and Commitment Therapy|Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy.
10160677|NCT03991546|No Intervention|Control group|Subjects randomizing into this arm did not receive the text message study intervention.
10160678|NCT03991312|Experimental|Part 1|"Period 1: Day 1, participants will receive 20 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 9, participants will receive 200 mg of itraconazole, once daily and 20 mg of mitapivat sulfate on Day 5."
10160679|NCT03991312|Experimental|Part 2|"Period 1: Day 1, participants will receive 50 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 12, participants will receive 600 mg of rifampin, once daily and 50 mg of mitapivat sulfate on Day 8."
10160680|NCT03991273|Experimental|Y-M2M©|a group-based M2M© program conducted onsite at a local YMCA
10160681|NCT03991273|Experimental|B-M2M©|a blended program that provides Y-M2M© and a home-based M2M© via videoconferencing
10186197|NCT03738059|Placebo Comparator|group I (placebo)|will receive intravenous normal saline (NS)
10186198|NCT03738059|Experimental|group II (Dex 0.5)|will receive intravenous Dex 0.5 mcg/kg
10160682|NCT03991650||Control|"n=30 healthy participants will be recruited using social networks and leaflets of information distributed by the research team at the Hospital Cliníc de Barcelona.~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants' data will also be monitored with a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
10160683|NCT03991650||Experimental|"The recruitment process will be carried out in patients of external consultations and the day hospital of the Addictions Unit at the Hospital Clinic of Barcelona.~n=30 patients with Anxiety and Alcohol Use Disorder.~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants will also be monitored using a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
10160684|NCT03991260||The tested injected doses of 99mTc- ADAPT6 500 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 500 µg. Subjects withdrawn from the study for any reason will be replaced.
10160685|NCT03991260||The tested injected doses of 99mTc- ADAPT6 1000 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 1000 µg. Subjects withdrawn from the study for any reason will be replaced.
10160686|NCT03991247|Experimental|Internet Behavioral therapy program + spa therapy|Patient following a program of computerized behavioral therapy for insomnia management during a 3 weeks spa treatment.
10160687|NCT03991247|Active Comparator|Internet Behavioral therapy program at home|Patient following a program of computerized behavioral therapy for insomnia management during 3 weeks at home.
10160688|NCT03990974|Experimental|Postoperative antimicrobial prophylaxis|Patients will receive postoperative antimicrobial prophylaxis for 3 days in 24 hours after hepatectomy.
10160689|NCT03990974|Sham Comparator|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy, unless the clinicians suggest he/she need antibiotics to treat or prevent infection.
10160690|NCT03991208|Experimental|Rest|Pharmacokinetics of Single Dose Malarone at Rest
10160691|NCT03991208|Experimental|Exercise|Pharmacokinetics of Single Dose Malarone under exercise in a heat chamber
10160692|NCT03991026|Experimental|Healthy food and Education/Cooking Classes|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, healthy eating attitudes, and demographics. Every week for 6 weeks, participants will pick-up a healthy food bag (e.g. fresh vegetables) for a $3 co-pay and attend an hour-long education classes at East Baltimore Medical Center. All participants will complete a survey at healthy food bag pick-up or an education class. Surveys at bag pick-up will ascertain outcomes like vegetable consumption. Surveys at education classes will ascertain outcomes like healthy eating attitudes. At 6 weeks, all participants will complete a follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again at 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
10160693|NCT03991026|No Intervention|Control Group|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, cooking habits, food security, healthy eating attitudes, and demographics. As a control group, participants will not partake in the healthy food bag pick-ups or cooking classes therefore they will not fill out those associated surveys. After the 6 weeks of the intervention, control participants will be given the follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again after 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
10160694|NCT03990935|Active Comparator|sodium fluoride varnish|"The fluoride varnish will be bifluorid 10 single use by voco (Germany). It Contains 5 % sodium fluoride (equal to 22,600 ppm fluoride).~A thin coat will be applied on the tooth surface by using a brush. 10-20 s are sufficient for the varnish to be absorbed and then dry with air. Participants will be informed that they should not brush their teeth for 12-24 hours after the application and not to eat, or drink for at least 30 minutes after use to get the best results."
10160695|NCT03990935|Experimental|Ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
10160696|NCT03991195|Experimental|Probiotic supplemented group with aMCI|Thirty participants in this group will take Bifidobacterium for three months.
10160697|NCT03991195|Placebo Comparator|Placebo group with aMCI|Thirty participants in this group will take placebo for three months.
10160698|NCT03991039|Active Comparator|Gamma knife group|Patients selected to be treated with gamma knife radiosurgery
10160699|NCT03991039|Active Comparator|MVD Group|Patients treated with microvascular decompression
10160700|NCT03990948||Patients with obesity|In 100 patients with obesity, blood samples will be collected.
10160701|NCT03990948||Patients with a Sleeve Gastrectomy|In 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
10160702|NCT03990948||Patients with a Roux-en-Y Gastric Bypass|In 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
10160703|NCT03991117|Experimental|80 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
10186199|NCT03738059|Experimental|group III (Dex 0.25)|will receive intravenous Dex 0.25 mcg/kg
10186200|NCT03738059|Experimental|group IV (Dex 0.2)|will receive intravenous Dex 0.2 mcg/kg.
10160704|NCT03991117|Experimental|80 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
10160705|NCT03991117|Experimental|30 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
10160706|NCT03991117|Experimental|30 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
10160707|NCT03991065|Experimental|with endoscopy|high digestive endoscopy
10160708|NCT03991065|No Intervention|without endoscopy|no endoscopy
10160709|NCT03991130|Experimental|High Dose IL-2 and Nivolumab|
10160710|NCT03991143|Experimental|ATH3G10|Phosphorylcholine human monoclonal antibody (ATH3G10)
10160711|NCT03991143|Placebo Comparator|Placebo|Placebo to ATH3G10, 0.9% sodium chloride
10160712|NCT03991104|Experimental|SOX-based Chemoradiotherapy|IMRT is delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy over 5 weeks. Concurrent Oxaliplatin (3 levels for phase I: 110mg/m², 120 mg/m² and 130 mg/m², d1) and fixed dose of S-1 (80mg/ m², d1-14) are administered concurrently with IMRT, every 4 weeks. The recommended dose of Oxaliplatin are then further evaluated in the Phase II setting.
10160713|NCT03990961|Experimental|Pembrolizumab Treatment|
10160714|NCT03990857|Experimental|Intervention|Group of participants with a recent DM2 debut (less than 5 months) treated according to the comprehensive care protocol in DM2 with comorbidities attended in Primary care nurse office
10160715|NCT03990857|No Intervention|comparison group|Participants in the study that do not receive the intervention. usual care.
10160716|NCT03990987||Day group|patients in Day group accept operation from 8：00～12：00
10160717|NCT03990987||Night group|patients in Night group accept operation from 18：00～22：00
10160718|NCT03991052|Active Comparator|EV1000 monitor|MAP management will be done as usual (adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
10160719|NCT03991052|Experimental|EV1000 monitor + closed-loop system|Fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
10160720|NCT03990753||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and microbiome/peptidome examination.
10160721|NCT03990675|Experimental|FNA, FNB|
10160722|NCT03990779||Children with congenital cardiac disease|Children with congenital cardiac disease who undergoing surgery
10160723|NCT03991013|Active Comparator|Supplementary dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later for the first 14 days.
10160724|NCT03991013|Placebo Comparator|Placebo dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with a matching placebo taken 12 hours later for the first 14 days.
10160725|NCT03990844|Placebo Comparator|0% Okra seed noodle|In this arm, subjects will consume noodles made with 0% okra seed. This serves as a control arm for the study.
10160726|NCT03990844|Experimental|10% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
10160727|NCT03990844|Experimental|20% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
10160728|NCT03990805|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
10160729|NCT03990805|Placebo Comparator|saline|saline
10160730|NCT03990701|Experimental|Single Arm|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 150 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease.
10160731|NCT03990922|Experimental|CTPVB with ropivocaine|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
10160732|NCT03990922|Placebo Comparator|CTPVB with saline|Continuous Paravertebral block with saline and Patient-controlled analgesia with morphine
10160733|NCT03990532|Experimental|treatment group|
10160734|NCT03990558||Primary ICH|Subject with acute brain injury will have data collected, including EEG, behavioral, clinical, and outcome measures.
10160735|NCT03990584|Experimental|three irrigation activation methods|"Manual dynamic irrigation was performed using a well-fitting gutta-percha cone inserted to WL with in-and-out vertical strokes of 5 mm at a rate of approximately 100 strokes per minute in order to hydrodynamically displace the irrigant.~Passive ultrasonic irrigation was performed using a non-cutting size 25 file attached to a piezoelectric ultrasonic unit.~Sonic irrigation was performed using an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA). A suitable-size activator tip was selected and loosely placed at 2 mm from working length, and the device was operated at 10,000 cycles/min using a pumping action to move the tip to produce vertical strokes of 2-3 mm."
10160736|NCT03990584|Active Comparator|Conventional needle irrigation (control)|Conventional needle irrigation was performed with short, in-and-out vertical strokes of 2-3 mm at a rate of approximately 100 strokes per minute.
10160737|NCT03990480|Active Comparator|valsartan|Group I treated with valsartan (160 mg/d, n = 100)
10160738|NCT03990480|Active Comparator|amlodipine|Group II amlodipine (10 mg/d, n = 100).
10160739|NCT03990480|No Intervention|Control|30 healthy subjects are enrolled as control group (Group III).
10160740|NCT03990350||Hispanic children with obesity|
10160741|NCT03990350||Hispanic children without obesity|
10160742|NCT03990350||Caucasian non-Hispanic children with obesity|
10160743|NCT03990350||Caucasian non-Hispanic children without obesity|
10160744|NCT03990727||Retinitis pigmentosa|Any type of retina dystrophy with pigment / retinitis pigmentosa
10160745|NCT03990727||Usher Syndrome|Retina dystrophy or retinitis pigmentosa associated with audition problems
10160746|NCT03990727||Cone>rod syndromes|Retina dystrophy diagnosed or started in central vision.
10160747|NCT03990727||Retinitis pigmentosa sx|Retinitis pigmentosa with any type of other features
10160748|NCT03990441|Experimental|Intervention|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
10160749|NCT03990441|Placebo Comparator|Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
10160750|NCT03990623|Experimental|Diagnostic (CT perfusion scans, liver biopsy)|Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.
10160751|NCT03990597|Experimental|Supportive care (StrataXRT, placebo)|Beginning first day of CSI proton radiation therapy, caregivers apply StrataXRT gel to half of the patient's forehead and one ear and placebo to the other half of the forehead and the other ear BID until the last day of radiation therapy.
10160752|NCT03990714|Experimental|Intracorporeal anastomosis|The specimen was preferentially extracted via a small Pfannenstiel-type incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). The incision for the extraction of the right colon is sutured in two layers by absorbable suture. The ileum was held by the assistant to prevent rotation of its mesentery. A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon, respectively, and then held by the assistant. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed. Drains were not used routinely.
10160753|NCT03990714|Experimental|Extracorporeal anastomosis|The mobilized colon was externalized preferentially via a transverse or midline incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed.The incision for the extraction of the right colon and the realization of the anastomosis is sutured in two layers by absorbable suture. Drains were not used routinely.
10160754|NCT03990636|Experimental|Metil 5-aminolevulinate arm|Metil 5-aminolevulinate arm with photo activation.
10160755|NCT03990636|Placebo Comparator|Placebo arm|Placebo (without metil 5-aminolevulinate) arm with photo activation.
10160756|NCT03990610|Experimental|Treatment (vascularized lymph node transfer)|Patients undergo vascularized lymph node transfer during standard of care breast reconstructive surgery.
10160757|NCT03990519|Experimental|Cohort1: JNJ-2636682/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
10160758|NCT03990519|Experimental|Cohort 2: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
10160759|NCT03990519|Experimental|Cohort 3: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2.
10160760|NCT03990324|No Intervention|Control group|The control group did not received intervention and sat on a table for approximately 5 minutes
10160761|NCT03990324|Experimental|Stretching group|The stretching group received a standardized manual stretching protocol
10160762|NCT03990454|Experimental|Dose escalation|"The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented.~A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met."
10160763|NCT03990337|No Intervention|Control group (CPG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage using finger palpation without ultrasonography
10160764|NCT03990337|Active Comparator|Ultrasound group (USG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage after localization with ultrasonography
10160765|NCT03990207|Experimental|PowerSpiral Enteroscopy System|Subjects who have a medical indication for antegrade enteroscopy
10160766|NCT03990272|Experimental|artemisia annua allergen extract drops|
10160767|NCT03990272|Placebo Comparator|Placebo drops|
10160768|NCT03990389|No Intervention|Usual Care Group|"Subjects will undergo screening including Rapid Estimate of Adult Literacy in Medicine (REALM-R) and Edinburgh Postnatal Depression Scale (EPDS) and a few additional questions.~Eligible subjects randomized to usual care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
10186201|NCT03738046|Experimental|Pilot Treatment Arm|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
10160769|NCT03990389|Experimental|Chabot Care Group|"Subjects will undergo screening including REALM-R and EPDS and a few additional questions.~Eligible subjects randomized to chatbot care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.~In addition to the above procedures, eligible subjects randomized to chatbot care will receive weekly messages from the chatbot asking them to complete a depression severity measure and side-effect burden assessments. Within week 1 subjects will receive a check-in call from a study coordinator to answer any questions regarding use of the chatbot.~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
10160770|NCT03990389|No Intervention|Provider Subject Cohort|20 provider subjects from each study site will be enrolled to ensure they understand the study and consent to have their patients enrolled in the study
10160771|NCT03990259||Male|The male individuals of the study population
10160772|NCT03990259||Female|The female individuals of the study population
10160773|NCT03990246|Experimental|Acid stable emulsion with solid droplets|Acid stable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
10160774|NCT03990246|Experimental|Acid stable emulsion with liquid droplets|Acid stable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
10160775|NCT03990246|Experimental|Acid unstable emulsion with solid droplets|Acid unstable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
10160776|NCT03990246|Experimental|Acid unstable emulsion with liquid droplets|Acid unstable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
10160777|NCT03989973||Cirrhosis patients|Patients were diagnosed by liver biopsy, CT or ultrasound
10160778|NCT03990220||Treatment|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of yoghurt containing Lactobacillus rhamnosus, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
10160779|NCT03990220||Control|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of milk, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
10160780|NCT03989934|Experimental|The Mind in Action|The Mind in Action is a mindfulness intervention developed by the Holistic Life Foundation (HLF), a Baltimore-based non-profit organization. The curriculum will be delivered over approximately 40 sessions and will follow HLF's typical program modifications for high school students (i.e., sustained focus on breath work and meditation). Each program session will include an initial exercise of focusing on the breath to center oneself, followed by the introduction and practice of different breathing techniques (e.g., rhythmic breathing) that enhance calmness and reduce physiological arousal, and concluding with a brief guided meditation. Instructors will describe benefits of the practices for health and stress management. Participants are given assignments between sessions to reinforce lessons (e.g., breathing exercises or periods of meditation).
10160781|NCT03989934|Active Comparator|Healthy Topics|Adapted from the Glencoe Health Curriculum (McGraw Hill), Healthy Topics is designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
10160782|NCT03990155|Experimental|HFNCOT+ECCO2R|Patients on NIV+ECCO2R who have reached at least for 4 consecutive hours, a RR <25 bpm + pH >7.35 + absence of clinical signs of respiratory distress after treatment with NIV+ECCO2R
10160783|NCT03990376|Other|Blood volume assessment with Blood Volume Analyzer|Injections of 1 mL of I-131-labeled serum albumin based on each patient's height and weight - 1 pre-surgical and 1 post-surgical
10160784|NCT03989999|Experimental|TCD Group|Transcranial Doppler within 8 hours of traumatic injury
10160785|NCT03989999|No Intervention|CONTROL Group|Mild TBI management with SFMU recommandations
10160786|NCT03990064|Experimental|musicotherapy|daily sessions of music listening during 2 months, associated with their standard treatment,
10160787|NCT03990064|No Intervention|waiting list|waiting list
10160788|NCT03990129|Other|Study population|All participants
10160789|NCT03990090|Experimental|TG103|Escalating doses of TG103 administered subcutaneously (SC) once in healthy participants.
10160790|NCT03990090|Placebo Comparator|Placebo|Placebo administered SC once in healthy participants.
10160791|NCT03990051|Experimental|Pro-ocular™|Pro-ocular™ 1% topical gel applied dermally to forehead twice daily, morning and before bedtime.
10160792|NCT03990051|Placebo Comparator|Placebo|Vehicle topical gel without active ingredient applied dermally to forehead twice daily, morning and before bedtime.
10160793|NCT03990142|Experimental|Group 1: patients without intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients without intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
10160794|NCT03990142|Experimental|Group 2: patients with intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients with intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
10160795|NCT03990181|Experimental|Meal & natural polyphenol supplement (NPPS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
10160796|NCT03990181|Experimental|Drink & natural polyphenol supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
10160797|NCT03990181|Placebo Comparator|Meal & control supplement (CS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
10160798|NCT03990181|Placebo Comparator|Drink & control supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
10160799|NCT03990116|Experimental|Lateral kangaroo|Placing the infant in lateral on the parents chest, keeping the head neutral and limbs flexed towards body midline
9671334|NCT05049603|Experimental|Atorvastatin|Atorvastatin 20 mg/day (the experimental treatment), one tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks, associated with intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks
9671335|NCT05049603|Placebo Comparator|Placebo|Intravenous methylprednisolone pulse therapy (the standard treatment), given over a period of 12 weeks, and placebo (one tablet/day, given approximately at 10 pm, after dinner and before going to bed) for 24 weeks
9671336|NCT05049941||group1|Group (1): veno-arterial carbon dioxide tension / arteriovenous oxygen content P(v-a)CO2/C(a-v)O2 ratio group.
9671337|NCT05049941||group 2|Group (2): Lactate clearance (LC) group; Lactate level was measured then LC rate was calculated by the equation [(lactate(T0)- lactate(T8))/lactate(T0)] × 100%.
9671338|NCT05049941||group 3|"Group (3):~veno-arterial carbon dioxide tension group; P(v-a)co2 difference"
9671339|NCT05049746||Ancillary-Correlative (interview, questionnaire, discussion)|Patients undergo interviews and complete questionnaires over 1-2 hours. Patients and physicians also participate in a discussion and complete shared decision-making questionnaire over 15-30 minutes. Subsequently, a decision support tool will be developed consistent with standards for content development and evaluation from the IPDAS Collaboration and implemented through an iterative process of design, development and evaluation to engage end users in its development. Once developed, field testing of the decision tool will be conducted to demonstrate feasibility and acceptability in real-world clinical setting, followed by pilot testing to evaluate the efficacy of the decision support tool.
10160800|NCT03990116|Active Comparator|Prone Kangaroo|placing the baby in upright and ventral position between mother's breasts or over the father chest, in skin-to skin contact with no clothes in between and with lower limbs flexed
10160801|NCT03990103|Experimental|Experimental arm|S1+Paclitaxel (IV&IP)+Bevacizumab (IP)
10160802|NCT03990103|Active Comparator|Control arm|S1+Oxaliplatin (IV)
10160803|NCT03989986|Experimental|iPeer2Peer Mentorship|In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
10160804|NCT03989986|No Intervention|Waitlist Control Group|The control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.
10160805|NCT03990038|Active Comparator|Group C|"Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter.~They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery"
10160806|NCT03990038|Active Comparator|Group U|"Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down.~They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total"
10160807|NCT03989908|Experimental|Co-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the same direction in the production of the microfluidic noodle.
10160808|NCT03989908|Experimental|Counter-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the opposite direction in the production of the microfluidic noodle.
10160809|NCT03989908|Placebo Comparator|Mee Sua|Mee Sua is used as a control to compare the outcome due to its similarity in textural properties
10160810|NCT03990831|Other|burn injury and normal patient|HbO2 PFC perfusion using fNIRS
10160811|NCT03989921||normo responders|that have an AMH dosage greater than or equal to 1.2 ng/mL
10160812|NCT03989921||poor responders|with a dosage of less than 1.2 ng/mL
10160813|NCT03990688|Experimental|AK3280 (Cohort 1)|Subjects in Cohort 1 are administered with an oral dose of 100 mg AK3280 b.i.d from Day 1 to Day 14.
9671340|NCT05049915|Experimental|Masquelet technique: bioactive glass|
9671341|NCT05049915|Active Comparator|Masquelet technique: RIA + TCP|
9671342|NCT05049694|Experimental|zirconia crowns|esthetic crowns for capping permanent molars with caries
9671343|NCT05049694|Experimental|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
9977860|NCT01365936|Active Comparator|menotrophin|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
10160814|NCT03990688|Experimental|AK3280 (Cohort 2)|Subjects in Cohort 2 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 2 will be based on the emerging data from previous cohort.
10160815|NCT03990688|Experimental|AK3280 (Cohort 3)|Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.
10160816|NCT03990688|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose cohort.
10160817|NCT03990168|Experimental|Experimental|Participants will receive one anodal tDCS at 1 mA intensity over the left superior temporal gyrus (T3 in 10-20 international system) and the cathode tDCS over the right orbitofrontal area (Fp2 in 10-20 international system). tDCS will be delivered for 20 minutes during fluency intervention for six consecutive days.
10160818|NCT03990168|Sham Comparator|Sham Comparator|Participants will receive sham tDCS while the one anode electrode will be positioned over the left superior temporal gyrus and the cathode will be placed over the right orbitofrontal similar to the active mode. The sham stimulation will break down after 30 seconds at the beginning of 20 minutes of fluency intervention for six consecutive days.
10160819|NCT03989739||robotic distal pancreatectomy|
9671344|NCT05049642|Experimental|Group 1|Patients will either be randomized to group 1 (instillation of 1 drop of C-NAC) or group 2 (no instillation of C-NAC) in a 1:1 fashion. Afterwards one drop of C-NAC will be instilled into the study eye of group 1. 1 hour after treatment VAS and the symptom questionnaire will be performed repeatedly in both groups. Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days. Patients assigned to group 1 will receive Lacrimera® for home treatment over the following 5 days. 1 drop of Lacrimera® is supposed to be installed into the eye 20 minutes prior to installation of the respective antibiotic eye drops or ointments.
9973914|NCT01335685|Experimental|Arm D: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles [38 months]).
9973915|NCT01335711|Experimental|IMP_C/C IL28B|C/C IL28B subjects to whom IMP will be administrated prior to SOC
9973916|NCT01335711|Active Comparator|SOC_C/C IL28B|C/C IL28B subjects to whom only SOC will be administrated
9973917|NCT01335711|Experimental|IMP_non-C/C IL28B|non-C/C IL28B subjects to whom IMP will be administrated prior to SOC
9973918|NCT01335711|Active Comparator|SOC_non-C/C IL28B|non-C/C IL28B subjects to whom only SOC will be administrated
9973919|NCT01335737|Experimental|aerobic training|12 weeks of aerobic training, 4 times/week
9973920|NCT01335737|Placebo Comparator|wait list control|wait list control condition, 12 weeks + 4 to parallel the deconditioning protocol in active intervention group
9973921|NCT01335763|Other|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
9973922|NCT01335776|Experimental|Cognitive Behavior Therapy|Cognitive Behavior Therapy for insomnia consists of stimulus control therapy, sleep restriction therapy, cognitive therapy and relaxation.
9973923|NCT01335776|Experimental|Mindfulness-Based Stress Reduction|The program consists of three primary components: theoretical material related to relaxation, meditation, and the mind-body connection; experiential practice of meditation and yoga and home based practice; group process focused on problem solving and support.
9973924|NCT01335802||Subclinical hypothyroidim|Women having subclinical hypothyroidism and/or TPOab-positive.
9973925|NCT01335802||Controls|Women having normal levels of TSH and TPOab-negative.
9973926|NCT01335815||elective knee and limb endoprothesis|
9973927|NCT01335828|Other|echography/elastography|
9973928|NCT01335841|Experimental|3D fluoroscopy and navigation station|
9973929|NCT01335841|Active Comparator|2D and anatomical landmarks|
9973930|NCT01335854|No Intervention|Usual Care|Usual care for 3 months. This consists of a phone call after one week of treatment, and clinic appointments at the sleep center following one month and three months of CPAP treatment.
9973931|NCT01335854|Experimental|Web-Access to CPAP Data|Usual care and web-based access to CPAP adherence data for 3 months. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website.
9973932|NCT01335854|Experimental|Web-Access to CPAP Data & Incentive|Usual care and web-based access to CPAP data for 3 months with financial incentives. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website. Financial incentive terminated after 1 week.
9973933|NCT01335880|Active Comparator|Promotion I|Three month time horizon
9973934|NCT01335880|Experimental|Promotion II|One week time horizon
9973935|NCT01335893|Experimental|ICG injection group|This group will receive a single dose of ICG, diluted in saline solution, prior to surgery. Then, during their surgery, they will be imaged with the camera and imaging probe we have developed.
9973936|NCT01335906|Experimental|Evidence-based informed consent|
9973937|NCT01335906|No Intervention|Usual information|
9973938|NCT01335919||Neonate|Subjects admitted for surgery or to the pediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) who require daily and/or multiple blood samples for hemoglobin measurement.
9973939|NCT01335945|Other|Cryoablation|Freezing of the celiac plexus
9973940|NCT01335958|Experimental|A|
9973941|NCT01335984|Experimental|Telemonitoring group|The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
9973942|NCT01335984|Experimental|Telemonitoring & Telemedicine group|The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
9973943|NCT01335984|Other|Control group|The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)
9973944|NCT01336010|Experimental|Group A - 8 weeks therapy|8 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 2 weeks of therapy.
9973945|NCT01336010|Experimental|Group B - 16 weeks therapy|16 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 4 weeks of therapy.
9973946|NCT01336010|Experimental|Group C - 24 weeks therapy|24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 6 weeks of therapy.
9973947|NCT01336010|Experimental|Group D - 32 weeks (gt1) or 24 weeks (gt 2/3)|32 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy.
9973948|NCT01336010|Experimental|Group E - 48 weeks (gt 1) or 24 weeks (gt 2/3)|48 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 2/3).
9973949|NCT01336010|No Intervention|Untreated Group|Observation only. No treatment for hepatitis C administered. Subjects who have undetectable HCV RNA at baseline, do not wish to commence treatment or are ineligible for treatment.
9973950|NCT01336049|Experimental|Nimotuzumab|
9973951|NCT01336062|Experimental|Nanoparticle Albumin-Bound Paclitaxel|The study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
9973952|NCT01336075|Active Comparator|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic radiofrequency ablation
9973953|NCT01336075|Active Comparator|Percutaneous ablation|Percutaneous radiofrequency catheter ablation
9973954|NCT01336088|Experimental|ADX48621|
9973955|NCT01336088|Placebo Comparator|ADX48621 Matching Placebo|
9973956|NCT01336101|Other|SFA stenting|
9973957|NCT01336127|Experimental|occupational therapy|10 weeks occupational therapy according to a protocol (OTiP protocol) based on the Dutch guidelines of occupational therapy in Parkinson's disease
9973958|NCT01336127|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (6 months).
9973959|NCT01336153|Experimental|MLC601|MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
9973960|NCT01336153|Placebo Comparator|Placebo|
9973961|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
9973962|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 30 μg|split-virion, non-adjuvanted H1N1 vaccine of 30 μg.
9973963|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 45 μg|split-virion, non-adjuvanted H1N1 vaccine of 45 μg.
9973964|NCT01336166|Placebo Comparator|Placebo control|Placebo control
9973965|NCT01336179|Experimental|Miswak, dental plaque and gingivitis|
9973966|NCT01336179|Active Comparator|Toothbrush, dental plaque and gingivitis|
9973967|NCT01336192|No Intervention|Best supportive care|Best supportive care
9973968|NCT01336192|Experimental|Maintenance gemcitabine|Maintenance therapy of gemcitabine alone
9973969|NCT01336218|Experimental|1|Fostamatinib
9973970|NCT01336218|Experimental|2|Rifampicin
9973971|NCT01336231||patients group|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
9973972|NCT01336244|Experimental|GLPG0778 ascending doses|Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.
9973973|NCT01336244|Placebo Comparator|Placebo|Twice daily for 13 days, matching the scheme of the multiple ascending dose.
9973974|NCT01336257|Experimental|Electronic Reminder|alert from SEBASTIAN decision support system
10160820|NCT03989739||laparoscopic distal pancreatectomy|
9973975|NCT01336257|No Intervention|control|
9973976|NCT01336270||MELANOMA 10mm|patients with a melanoma larger than 10mm or with cutaneous metastasis
9973977|NCT01336270||STAGE III MELANOMA|stage III melanoma patients who shall undergo a regional lymph node dissection
9973978|NCT01336270||SENTINEL NODE PROCEDURE|retrospective study of patients who underwent a sentinel node procedure
9973979|NCT01336270||STAGE IV MELANOMA|stage IV patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
9973980|NCT01336283|Active Comparator|COPD with emphysema|Analyze what type of training is more appropriate and beneficial as the patient characteristics that apply to you.
9973981|NCT01336283|Active Comparator|COPD non-emphysema|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
9973982|NCT01336309||Focus Group|We conducted three focus groups per site, at three sites, with around eight people each. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We will administer the Yoga Research Tool.
9973983|NCT01336309||Cognitive Interviews|We conducted cognitive interviews at three different sites, with about ten in each group. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We collected this data via a large, online survey and administered the Yoga Research Tool.
9973984|NCT01336309||Survey Prototype Administration|We administered a prototype of the study measure to a large group of yoga students, with about 450 total participants. These data were used to further inform the refinement and selection of items to be used in the final measure.
9973985|NCT01336309||Reliability and Validity Testing|We are conducting yoga classes at community partner facilities near each site, with about ten participants in each class. Participants at each class will complete the study measure and related questionnaires, in order to test the reliability and validity of the study measure.
9973986|NCT01336322|Active Comparator|Metformin|Metformin 850 mg bid
9973987|NCT01336322|Active Comparator|Sitagliptin|Sitagliptin 100 mg qd
9973988|NCT01336322|Active Comparator|Sitagliptin+Metformin|Sitagliptin 100 mg qd plus Metformin 850 mg bid
9973989|NCT01336335|Experimental|CPAP|OSA treatment with CPAP
9973990|NCT01336335|No Intervention|control|no intervention
9973991|NCT01336348|Experimental|prasugrel|Prasugrel 60 mg loading dose
9973992|NCT01336348|Active Comparator|Tirofiban|Tirofiban will be at a bolus only of 25uM or followed by 2 hour infusion
9973993|NCT01336361||Physical Therapists|Physical Therapists who are members of the American Physical Therapy Association (APTA) and live in the United States .
9973994|NCT01336374||Greened Vacant Lot|A cluster of vacant lots is greened. People living around this area make up this cohort.
9973995|NCT01336374||Control Site|The control site is a cluster of vacant lots that will not be greened. The people living around these lots make up the control group.
9973996|NCT01336387|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30* PO on days 1-28.
9973997|NCT01336387|Placebo Comparator|Arm II (placebo)|Participants receive placebo* PO on days 1-28.
10160821|NCT03990740||Cases|Patients suffering from keratoconus and requiring a first optical corneal transplant
9671345|NCT05049642|No Intervention|Group 2|Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days.
9973998|NCT01336400||PGD-FISH|"Following couples opting for preimplantation genetic diagnosis on the basis of FISH:~couples suffering a complex chromosomal rearrangement (CCR)~couples with X-linked recessive disorders~couples that carry a balanced chromosomal rearrangement"
9973999|NCT01336400||PGD-PCR|"Following couples opting for preimplantation genetic diagnosis on the basis of PCR:~-couples at risk for the transmission of monogenic diseases"
9974000|NCT01336439|Active Comparator|M group|A total of 25U of botulinum toxin type A was injected into each side masseter muscle in this arm.
9974001|NCT01336439|Active Comparator|MT group|A total of 25U of botulinum toxin type A was injected into each side masseter and temporal muscle in this arm.
9974002|NCT01336452|Other|CCRTx|consecutive patients who plan to undertake CCRTx due to advanced hepatocellular carcinoma
9974003|NCT01336543|Experimental|Active Treatment|"ACTIVE TREATMENT intervention below:~NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 60 mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
9977323|NCT01360242|Active Comparator|MIMI procedure (two-step strategy)|Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for > 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
9977324|NCT01360242|Sham Comparator|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
9977325|NCT01360255||Patients treated with TACE|Patients treated with transarterial chemoembolisation (TACE) are included in this clinical trial
9977326|NCT01360281|Experimental|ECR|
9977327|NCT01360281|No Intervention|Control|
9977328|NCT01360281|Experimental|NMES|
9977329|NCT01360294||Asthma with small airway disease|
9977330|NCT01360294||Asthma without small airway disease|
9977331|NCT01360307||Major Depressive Disorder Patients|
9977861|NCT01365936|Active Comparator|recombinant FSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
9977862|NCT01365975||Community Intervention Program Population: The Chinese Childre|Community sample of mothers, fathers and offspring from 2 provinces in China who participated in a community public health study in 1994-1996.
10160822|NCT03990740||Controls|Patients with an indication of orbital exenteration operation due to an orbital tumor
10160823|NCT03990571|Experimental|Treatment (axitinib, avelumab)|Patients receive axitinib PO BID on days 1-28 and avelumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9977863|NCT01366001|Experimental|ALKS 33-BUP|
9977864|NCT01366001|Experimental|ALKS 33|
9977865|NCT01366001|Placebo Comparator|Placebo|
9977866|NCT01366053||Prostate Cancer|Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.
9977867|NCT01366066|Active Comparator|TMNS treatment - Stress incontinence|Women with stress incontinence treated with active TMNS (vibration)
9977868|NCT01366066|No Intervention|No treatment - stress incontinence|Women with stress incontinence NOT treated with TMNS (vibration)
9977869|NCT01366066|Active Comparator|TMNS treatment - Urge incontinence|Women with stress incontinence treated with TMNS (vibration)
9977870|NCT01366066|No Intervention|No treatment - urge incontinence|Women with urge incontinence NOT treated with TMNS (vibration)
9977871|NCT01366079|Experimental|Position change|Position change group
9977872|NCT01366079|Active Comparator|Left lateral|Left lateral position
9977873|NCT01366105|No Intervention|Dry Dressing|Incisions that were dressed with a sterile dry dressing at end of operation.
9977874|NCT01366105|Experimental|Negative Pressure Wound Therapy|Incisions dressed with a V.A.C. (NPWT) postoperatively.
9977875|NCT01366118|Experimental|TT tailored Ch plus IMRT|
9977876|NCT01366183||Observational (quality of life questionnaire)|"Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.~Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed."
9977877|NCT01366222|Placebo Comparator|Placebo|
9977878|NCT01366222|Active Comparator|Food concentrates (FC)|Food concentrates (FC) was including fruit and vegetable, fish and probiotics.
9977879|NCT01366235|Experimental|Southeast Asians|
9977880|NCT01366235|Experimental|Korean|
9977881|NCT01366235|Experimental|Caucasians|
9977882|NCT01366235|Experimental|Africans|
9977883|NCT01366248||IO Clinic Breast Cancer Patients|Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
10160824|NCT03989765|Experimental|Intervention arm|Municipalities in the intervention arm will, in Stage 1, be part of developing the intervention to reduce the rate of compulsion. In Stage 2 they will implement the intervention through their services.
10160825|NCT03989765|No Intervention|Control municipality|As all outcome measures will be collected from the National Patient Register, there will be treatment as usual.
10160826|NCT03989687|Experimental|glass ionomer sealant|glass ionomer sealant
10160827|NCT03989687|Experimental|isolation|isolation type either rubber dam or cotton roll isolation
10160828|NCT03989752|Experimental|Wearable robotic exoskeleton-assisted walking program|Total of 34 training sessions (60 min/session) during 16 weeks (1-3 session/week). Session intensity will be individualized and safely progressed thereafter (standing time, number of steps) to maintain a moderate-to-vigorous intensity (Borg rate of perceived exertion ≥12/20).
10160829|NCT03989726|Experimental|High density voltage and fractionation map guided group|"Complex fractionated atrial electrogram (CFAE), voltage and fractionation map will be performed with a multielectrode mapping catheter.~The mapping should be performed in AF.~First, low-voltage zone is defined as an area with bipolar peak-to-peak voltage amplitudes < 0.5mV.~A voltage-map guided segmental PV isolation is performed. Radiofrequency energy is applied in the antral regions of the PVs. High voltage zone over 0.5mV in the antral region is targeted. IF PV isolation in not achieved by voltage-guided segmental ablation, additional Lasso catheter guided segmental antral ablation is performed.~Radiofrequency energy is delivered at target sites for 15-30 sec guided by contact force, lesion size index (LSI) and local electrogram elimination.~If the patient is still in AF after PV isolation, additional fractionation map guided ablation is performed. The fractionation area within low voltage area (<0.5mV) should be targeted."
10160830|NCT03989726|Active Comparator|Circumferential PV isolation|A control group will be chosen from database of patients who underwent AF ablation between 2018-2019. A control group includes the same number of consecutive patients who underwent anatomy-based circumferential PV isolation.
10160831|NCT03989622|Experimental|evaluation of the visual field on the ground|evaluation of the visual field on the ground followed by 10 reeducation sessions
10160832|NCT03989622|No Intervention|usual care|control session followed by 10 re-education sessions
10160833|NCT03989609|Experimental|Dexmedetomidine Group|patients will receive dexmedetomidine as sedative
10160834|NCT03989609|Active Comparator|Midazolam|patients will receive midazolam as sedative
10160835|NCT03989635|Experimental|QAW039|QAW039 450mg
10160836|NCT03989635|Placebo Comparator|Placebo|Placebo to QAW039
10160837|NCT03989804|Experimental|Targeted follow-up|
10160838|NCT03989804|No Intervention|Usual practice|Usual practice at the fitness center is self-directed use
10186202|NCT03738033||use of the educational platform|Before the hand-on practice and assessements, the participants use the platform for learning.
10186203|NCT03738033||without use of the educational platform|Before the hand-on practice and assessements, the participants did not use the platform for learning.
10186204|NCT03738007|Experimental|HA IDF II|
10186205|NCT03738007|Active Comparator|Perlane|
10186206|NCT03737968|Experimental|Durvalumab monotherapy Arm|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
10186207|NCT03737968|Active Comparator|Durvalumab + tremelimumab combination therapy Arm|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
10186208|NCT03737942||control group|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
10186209|NCT03737942||T2DM without neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
10186210|NCT03737942||T2DM with neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
10186211|NCT03737929|Experimental|Hybrid ablation procedure|In the hybrid ablation procedure, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure.
10186212|NCT03737929|Active Comparator|Percutaneous endocardial catheter ablation procedure|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint).
10186213|NCT03737916|Experimental|dextrose group|"Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation"
10186214|NCT03737916|Placebo Comparator|control group|"Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: Normal Saline Normal saline is safe for perineural injection."
10186215|NCT03737890|Experimental|Inspiratory muscle Training|4 weeks of inspiratory muscle training
9520184|NCT03279783|Active Comparator|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
9974004|NCT01336582|Experimental|docetaxel|
10160839|NCT03989817|Active Comparator|VIP|To investigate the role of VIP on cranial hemodynamic and headache in healthy volunteers.
10160840|NCT03989817|Placebo Comparator|Saline|To investigate the role of saline on cranial hemodynamic and headache in healthy volunteers.
10160841|NCT03989596|Experimental|Radiotherapy with hyperthermia|10x 3.25 Gy + hyperthermia + surgery or radiotherapy boost (4x 4 Gy + hyperthermia)
10160842|NCT03989778|Experimental|Vitamin D supplement|he intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas
10160843|NCT03989778|No Intervention|Control|control group will receive Metformin treatment during the study period.
10160844|NCT03989674|No Intervention|White bread|
10160845|NCT03989674|Experimental|Anthocyanin-fortified bread (2% w/w)|
10160846|NCT03989674|Experimental|Anthocyanin-fortified bread (4% w/w)|
10160847|NCT03989648|Active Comparator|Esmarch bandages|
10160848|NCT03989648|Active Comparator|simple leg elevation|
10160849|NCT03989791|Active Comparator|Absolute diet|
10160850|NCT03989791|Experimental|Normal diet|
10160851|NCT03989830|Experimental|Second-line chemotherapy combined with Endostar|Second-line chemotherapy+Endostar
9826400|NCT02417064|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
9974005|NCT01336582|Active Comparator|Taxotere|Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)
10160852|NCT03989856|Experimental|Suturing group|"The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.~The running suture starting from central area, around the ovarian hilus to peripheral tissue, will be performed with intraovarian knots to re-approximate the edges to achieve satisfying hemostasis. Knots will not be detectable on the ovarian surface for prevention of adhesion. Mean time for hemostasis of ovary was recorded in a form. The cyst wall will be removed from the abdomen by means of an endobag. All resected cyst walls will be sent to the pathology laboratory, to confirm the histopathology of endometriosis."
10160853|NCT03989856|Active Comparator|Bipolar group|In bipolar coagulation group, after stripping the ovarian cyst wall, bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). In laparoscopic suturing group, no bipolar coagulation will be performed during or after stripping the ovarian cyst wall.
10160854|NCT03989518|Experimental|Simple stimuli|Two perceptually simple stimuli are used during all experimental phases (geometrical figures).
10160855|NCT03989518|Experimental|Complex stimuli|Two complex stimuli are used in all experimental phases. Stimuli consist of photographs of real objects of the same size and shape as the simple stimuli, but include perceptually more complex patterns, details and colors.
10160856|NCT03989284|Experimental|Peer counseling group|Peer counselors performed 1-hour home visits weekly to their assigned clients for three months.
10160857|NCT03989284|Experimental|Social engagement group|Senior citizens joined 3-hour weekly social events held at the OSCA Center for three months.
10160858|NCT03989284|Experimental|Combination group|Senior citizens in this group underwent both peer counseling and social engagement interventions mentioned above.
10160859|NCT03989284|No Intervention|Control group|Senior citizens in this group had access to usual or standard care from health and aged care services that were usually available.
10160860|NCT03989336|Experimental|Manganese primed Sintilimab plus nPP chemotherapy|Subject received Manganese primed Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
10160861|NCT03989336|Active Comparator|Sintilimab plus nPP chemotherapy|Subject received Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
10160862|NCT03989323||Patients treated with immunotherapy|Patients receiving for the first time an immunotherapy treatment for their cancer (Checkpoints inhibitors, such as PD-1 or PD-L1 or CTLA4…). Patients will be enrolled before starting the immunotherapy treatment and will be followed up for 5 years or until the permanent discontinuation of the immunotherapy treatment to describe the arm.
10160863|NCT03989505||Cohort|214 consecutive patients undergoing contrast-enhanced diagnostic and/ or therapeutical intervention in the cath lab of the University Heart Center Hamburg
9662140|NCT05130658|Active Comparator|Treadmill training group (TTG)|The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions, one before the training and one after the training. The participants will undergo 10 training sessions. Individuals in TTG group will walk on the treadmill (C-MILL) or stand on the treadmill (C-MILL) with no visual or auditory cues.
10160864|NCT03989310|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
10160865|NCT03989310|Experimental|anti-PD-1 antibody plus nPG chemotherapy|Subject received anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
10160866|NCT03989479|Active Comparator|Conventional Toothbrush|Brushing with conventional Kid's Soft Toothbrush, Colgate (5-9-year-old)
9826401|NCT02417129|Experimental|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
9826402|NCT02417129|Active Comparator|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
9671346|NCT05049629|Experimental|Eye 1|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
10160867|NCT03989479|Experimental|T-shaped Toothbrush|Brushing with T-shaped toothbrush (Denson™, Malaysia)
10160868|NCT03989531|Experimental|Adrecizumab on top of standard of care|8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion
10160869|NCT03989531|Placebo Comparator|Placebo on top of standard of care|100 mL saline as single dose infusion
10160870|NCT03989544|Experimental|Tezepelumab via Vial-and-syringe|Participants will be randomized to a single dose of tezepelumab via SC administration with Vial-and-syringe
10160871|NCT03989544|Experimental|Tezepelumab via APFS|Participants will be randomized to a single dose of tezepelumab via SC administration with APFS
10160872|NCT03989544|Experimental|Tezepelumab via AI|Participants will be randomized to a single dose of tezepelumab via SC administration with AI
10160873|NCT03989700|Experimental|Low dose|Low dose of thiamin supplementation
10160874|NCT03989700|Experimental|High dose|High dose of thiamin supplementation
10160875|NCT03989700|Placebo Comparator|Placebo|placebo supplementation
10160876|NCT03989557|Experimental|Monitoring Arm|Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
10160877|NCT03989557|Experimental|Conventional Arm|Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.
10160878|NCT03989492|Experimental|Autonomic responses to stressors|Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.
10160879|NCT03989297||NPC patients|Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.
10160880|NCT03989388|Experimental|Intervention Group|Occupational Self-Analysis Programme
10160881|NCT03989388|Active Comparator|Control group|Vocational guidance or usual rehabilitation (in the case of ABI participants)
10160882|NCT03989713|Experimental|MRD-triggered arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~Consolidation therapy: Patients receive one cycle of HAM and are further allocated based on the MRD-results assessed by flow cytometry with a cut of level of 0.1%: if the MRD is negative they remain in the MRD-triggered arm, whereas MRD positive patients cross over to the prophylactic arm.~(Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~Observation: No treatment will be given in the MRD-triggered arm. (Duration: 48 weeks in total.)~Safety follow-up and observational follow-up"
10160883|NCT03989713|Experimental|Prophylactic Arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~Consolidation therapy: Patients may receive up to two cycle of Q-HAM. (Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~Maintenance therapy: Quizartinib will be given as single-agent therapy. The dose of quizartinib is aimed to be increased during maintenance therapy. (Up to 12 cycles. Duration: four times three cycles á 28 days, 48 weeks in total.)~Safety follow-up and observational follow-up"
10160884|NCT03989193|Experimental|Computer guided alveolar ridge splitting technique|Computer guided alveolar ridge splitting using piezo electric device and a 3D printed surgical guide. An L shaped splitting pattern with one crestal and one distal cut will be performed.
9826403|NCT02417233|No Intervention|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
10160885|NCT03989375|Experimental|experiment group|
10160886|NCT03989375|No Intervention|control group|
10160887|NCT03989453|Experimental|Chi Kung group|This group receives physical training based on Chi Kung.
10160888|NCT03989453|No Intervention|Control Group|This group does not receive any treatment.
10160889|NCT03989271|Active Comparator|Quercetin|Quercetin 2000 mg/day Quercetin is provided as orange flavored soft chews and each chew will have 250 mg of quercetin Quercetin will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.
10160890|NCT03989271|Placebo Comparator|Placebo|"Placebo is also provided as soft chews that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.~Placebo will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months."
10160891|NCT03989258|Active Comparator|Cohort 1|High monogenic breast cancer risk
9974006|NCT01336595|Experimental|Zirconium Femoral Component|Oxidized zirconium femoral component of Genesis II TKR system is used.
10160892|NCT03989258|Active Comparator|Cohort 2|High polygenic breast cancer risk
10160893|NCT03989258|No Intervention|Cohort StMG|Standard mammography screening in age 50-69
10160894|NCT03989583||Children's feet temperature|The thermal images were taken from 162 children who were 9- 10 years old in two schools in Mérida (Badajoz), Spain. Their parents or legal guardians were informed and signed an informed consent. All children were taken infrared images, so that skin temperature was evaluated, by dividing the thermograms in regions of interest in dorsal and plantar images of each foot. Shoes were divided into two regions of interest. The measures were taken in two different days: the first day, children wore school footwear and the second sports shoes.
10160895|NCT03990025|Other|Linked Color Imaging - White Light Imaging|Participant undergoes gastroscopy via Linked Color Imaging first, then followed by White Light Imaging
10160896|NCT03990025|Other|White Light Imaging - Linked Color Imaging|Participant undergoes gastroscopy via White Light Imaging first, then followed by Linked Color Imaging
9974007|NCT01336595|Active Comparator|Cobalt Chrome|Cobalt-Chromium Femoral component of Genesis II system is used.
10160897|NCT03989960|Experimental|LISA+SNIPPV group|receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation
10160898|NCT03989960|Active Comparator|InSurE group|receives intubation-surfactant- extubation technique and selects CPAP ventilation
10160899|NCT03989466|Experimental|Treatment (itacitinib, alemtuzumab)|"CYCLE 1: Patients receive itacitinib PO QD on days 1-28 and alemtuzumab IV over 2 hours on days 15, 17, 19, 21, 23, 25, and 27 in the absence of disease progression of unacceptable toxicity.~CYCLE 2 AND BEYOND: Patients receive itacitinib PO QD on day 1-28 and alemtuzumab IV over 2 hours on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a response (CR/CRi or PR) may receive itacitinib for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity."
10160900|NCT03989115|Experimental|RMC-4630 and Cobimetinib|RMC-4630 and Cobimetinib for oral administration
10160901|NCT03989115|Experimental|RMC-4630 and Osimertinib|RMC-4630 and Osimertinib for oral administration
10160902|NCT03989141|Experimental|Repeated cannulation Buttonhole|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
10160903|NCT03989141|Active Comparator|Single cannulation Buttonhole|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
10160904|NCT03989128||Observational (survey)|Participants complete a survey over 5-10 minutes
10160905|NCT03989063|Experimental|Amputees (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
10160906|NCT03989063|Active Comparator|Amputees (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
10160907|NCT03989063|Experimental|Diabetes (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
10160908|NCT03989063|Active Comparator|Diabetes (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
9662141|NCT05130658|No Intervention|Healthy Control|HCG will participate in up to four sessions. The participants will be screened for the inclusion/exclusion criteria and consented during the first session. They will participate in two data collection sessions and one C-MILL session.
10160909|NCT03988959|Other|Control|Standard resection
10160910|NCT03989167|Experimental|Intervention group|Group receiving the Clinical decision support
10160911|NCT03989167|No Intervention|Control group|
10160912|NCT03989050||Melanoma patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for melanoma
10160913|NCT03989050||Non-small cell lung cancer (NSCLC) patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for NSCLC
10160914|NCT03989050||other malignancy patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for other malignancy
10160915|NCT03988972|Experimental|diathermy group|"Diathermy incisions will be carried out using monopolar blade pen electrode, set on cutting mode and delivering a 35 continuous current. Electrosurgical cutting was performed without pressure or mechanical displacement.~'Bleeders' will be controlled by using diathermy, on coagulating mode, and will be applied to a hemostat on the vessels"
9974008|NCT01336621|Experimental|Retigabine IR|Open label flexible dose between 300 mg/day (Minimum) and 1200 mg/day (maximum).
9974009|NCT01336660|Experimental|Equine F(ab')2 antivenom|Intensive care support and Equine F(ab')2 antivenom
10160916|NCT03988972|Active Comparator|scalpel group|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
10160917|NCT03988985|Experimental|PATIENT-GP-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
10160918|NCT03988985|Active Comparator|GP-FEEDBACK|Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
10160919|NCT03988985|No Intervention|NO-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.
10160920|NCT03989089|Experimental|Pembrolizumab single agent|Pembrolizumab 200 mg will be given intravenously every 3 weeks , on Day 1 on each 3 week cycle. Pembrolizumab can be given up to 35 adminstration (2 years).
10160921|NCT03989037|Experimental|SIBP-01 & Docetaxel & Carboplatin|SIBP-01→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; SIBP-01: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
10160922|NCT03989037|Active Comparator|Herceptin & Docetaxel & Carboplatin|Herceptin→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; Herceptin: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
10160923|NCT03988946|Experimental|Transcatheter Mitral Valve Replacement|Replacement valve delivered through a transfemoral access and transseptal approach
9520185|NCT03279757|Experimental|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
10160924|NCT03989219|Experimental|lung nodules were found by CT scanning|Plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
10160925|NCT03988712||Iron deficiency anaemia with bowel symptoms|Patients with IDA presenting with bowel symptoms like change in bowel habits, weight loss and abdominal mass other than rectal bleed
10160926|NCT03988712||Iron deficiency anaemia with no bowel symptoms|Patients with IDA with no bowel symptoms
10160927|NCT03988712||Iron deficiency anaemia with rectal bleeding|Patients with IDA and rectal bleeding
10160928|NCT03989024|Experimental|Pulsatile Gonadotropin-releasing Hormone|Drug: Gonadorelin. Use Gonadorelin for 3 months to treat PCOS. The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.
10160929|NCT03989024|Experimental|Clomiphene|Use Clomiphene for 3 months to treat PCOS
10160930|NCT03988790|Experimental|VOC analysis|VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
10160931|NCT03988816|Experimental|Roflumilast|Roflumilast tablets will be supplied at a concentration of 500 mcg. Each tablet contains 500mcg of the active ingredient in addition to the excipients: lactose monohydrate, corn starch, povidone and magnesium stearate. The coating contains hypromellose, macrogol, titanium dioxide, yellow iron oxide. Patients should take 1 tablet once daily, before, during or after meals, at the same time each day.
10160932|NCT03988816|Placebo Comparator|Placebo (control)|Roflumilast placebo-containing tablets will look similar to active roflumilast tablets and will be supplied to patients in packs identical to those of the active drug.
10160933|NCT03988881||1 PCI Group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with positive dobutamine stress echocardiography and positive Fractional Flow Reserve recieving revascularization (PCI or CABG) Drug: Standard of care after acute myocardial infarction
10160934|NCT03988881||Group 2 OMT group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with negative dobutamine stress echocardiography and negative Fractional Flow Reserve or the mismatching cases Standard of care after acute myocardial infarction
10160935|NCT03988894|No Intervention|Control: Usual Care|All participants will (a) receive a general hypertension health education booklet from the Heart and Stroke Foundation of Ontario;(b) be encouraged to see their family physicians or primary health care providers regarding their blood pressure status; those who do not have a primary health care provider will be referred to a walk-in clinic or a community health centre; and (c) have access to family physicians, tele-health, emergency care, hospital and other health care facilities in the Greater Toronto Area as required.
10160936|NCT03988894|Active Comparator|Intervention: mDASHNa-CC app use|In addition to usual care, those participants randomized to the intervention group will be offered use of the app.Then, they will load the app in their smartphones and be requested to review educational contents, conduct dietary self-assessment, and monitor blood pressure for 8 weeks.By the end of eight weeks post randomization, seniors will be prompted by phone using an audible alert to complete the app Evaluation Questionnaire on the smartphone, which ascertains likes and dislikes with the app.
10160937|NCT03988725|Experimental|Vitamin E intervention|All study participants receive Vitamin E 800 IU once daily for 6 months
10160938|NCT03988751|Active Comparator|Continuous Ambulation|The total distance will be 40 meters. Study team members will walk, support, and coach the subject to walk as slow as he/she wants
10160939|NCT03988751|Active Comparator|Interval Ambulation|The subject will walk a total distance of 40 meters. This distance will be divided into four intervals of 10 meters to equal the same measured distance as the continuous group. The subject will receive two minutes of rest between each interval and will be supported and coached to walk as fast as they can.
10160940|NCT03988764||Antibody-negative|"Patient has been found negative for at least three T1D antibodies.~The investigators will proceed with whole exome sequencing"
10160941|NCT03988764||Antibody-positive|"Patient has been found to be positive for at least one T1D autoantibody.~No further studies will be performed as part of the main study."
10160942|NCT03988777||Prospective Magseed|This cohort includes patients with an impalpable breast lesion that are scheduled for breast conserving surgery with Magseed localisation after September 2018. Their data will be prospectively collected and analysed.
10160943|NCT03988777||Retrospective hooked-wire|This cohort includes patients with an impalpable breast lesion that were scheduled for breast conserving surgery with hooked-wire before September 2018. Their data will be retrospectively collected and analysed.
10160944|NCT03988673|No Intervention|decision aid with information only (control)|decision aid with information only, without values clarification method (VCM)
10160945|NCT03988673|Active Comparator|decision aid with implicit VCM|decision aid with information plus an implicit VCM
9662142|NCT05130619|Experimental|Treatment order A-.B-C-D|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
10160946|NCT03988673|Active Comparator|decision aid with explicit VCM|decision aid with information plus an explicit VCM
10160947|NCT03988517|Active Comparator|levothyroxine at Iftar|Patients took levothyroxine 30 minutes before breaking the fast at sunset (iftar)
10160948|NCT03988517|Active Comparator|Levothyroxine at Suhour|Patients took levothyroxine 30 minutes before an early morning meal before sunrise (suhour)
10160949|NCT03988608|Experimental|Eltrombopag|Subjects will start eltrombopag treatment at 25 mg/day since Day 1.
10160950|NCT03988478|Experimental|Behavioral, detoxificaiton & psychotherapy|Providing treatment as usual (detoxificaion) & psychotherapy
10160951|NCT03988530|Active Comparator|DPI-386 Nasal Gel|DPI-386 Nasal Gel (0.2 mg / 0.12 g)
10160952|NCT03988530|Placebo Comparator|Placebo Nasal Gel|placebo nasal gel (0.12 g)
10160953|NCT03988738|Experimental|Intervention|Participants will receive messages regarding blood donation promotion and campaigns through social media once or twice a week for six months.
10160954|NCT03988738|Sham Comparator|Control|Participants will receive a message regarding blood donation at the beginning of the study through social media. After four months they will receive another message including information about upcoming blood donation campaigns.
10160955|NCT03988660||Healthy controls|Healthy individuals
10160956|NCT03988660||Histologically confirmed appendicitis|Patients who have diagnosis of appendicitis on histology
10160957|NCT03988660||Histologically normal appendix|Patients who have diagnosis of a normal appendix on histology
10160958|NCT03988660||Alternative diagnosis group|Patients who diagnosed with a condition other than appendicitis
10160959|NCT03988686|Experimental|Intervention Group|Radical prostatectomy plus standard care
10160960|NCT03988686|Active Comparator|Comparator Group|Standard care, currently ADT +/- other systemic therapies.
10160961|NCT03988387|Experimental|Peer Support PS)|Participants randomized to the PS arm will be assigned a trained peer supporter (PSr) to enhance adherence to PrEP.
10160962|NCT03988387|Experimental|Reminders and Resource Transfer (RRT)|Participants randomized to the RRT arm will receive weekly SMS text messages and resource transfers to enhance adherence to PrEP.
10160963|NCT03988218|Experimental|Anorexia|Subjects with anorexia nervosa
10160964|NCT03988218|Active Comparator|Control|Subjects without eating disorders
10160965|NCT03988231|Active Comparator|Enoxaparin 40mg once daily|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
10160966|NCT03988231|Placebo Comparator|Placebo|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
10160967|NCT03988465||Cardiac Surgery Patients|Patients undergoing cardiopulmonary bypass surgery, including placement of a ventricular access device.
10160968|NCT03988413|Experimental|25mg|Tablets, Oral, 25mg, single dose
10160969|NCT03988413|Experimental|50mg|Tablets, Oral, 50mg, single dose
10160970|NCT03988413|Experimental|100mg|Tablets, Oral, 100mg, single dose
10160971|NCT03988413|Experimental|200mg|Tablets, Oral, 200mg, single dose
10160972|NCT03988413|Experimental|400mg|Tablets, Oral, 400mg, single dose
10160973|NCT03988413|Experimental|800mg|Tablets, Oral, 800mg, single dose
10160974|NCT03988205|Experimental|Intervention|The study intervention is the application of a prescribed outpatient care model including a nurse teacher educational program and quality of life surveys for both subjects and caregivers. Induction therapy and medical follow up are performed without prophylactic admission to an inpatient facility. Subjects will also receive CPX-351 according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
10160975|NCT03988491||End stage renal disease on maintanance hemodialysis|End-stage renal disease due to any etiology on maintenance hemodialysis and consented to participate in the study.
9974010|NCT01336660|Placebo Comparator|Placebo|Intensive care support plus placebo
10160976|NCT03988556|Experimental|Cohort A1 - Head & neck cancer - Prophylactic intent|"Patients with head & neck cancer starting radiotherapy +/- chemotherapy +/- targeted therapy (no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing both oral mucositis and radiodermatitis.~."
10160977|NCT03988556|Experimental|Cohort A2 - Head & neck cancer - Curative intent|"Patients with head & neck cancer having started radiation therapy and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated whether they are oral mucositis or radiodermatitis lesions."
10160978|NCT03988556|Experimental|Cohort B1 - Breast cancer - Prophylactic intent|"Patients with breast cancer starting radiation therapy (i.e. no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing radiodermatitis."
10160979|NCT03988556|Experimental|Cohort B2 - Breast cancer - Curative intent|"Patients with breast cancer having started radiation therapy and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated."
10160980|NCT03988166|Other|Chronic Total Occlusion Percutaneous Coronary Intervention|CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.
10160981|NCT03988348|Experimental|study group|infraumbilical transverse incision will be done
9974011|NCT01336699|Experimental|Cohort A|WRSs2 vaccine 1x10^3 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^3 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
9974012|NCT01336699|Experimental|Cohort B|WRSs2 vaccine 1x10^4 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^4 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
9974013|NCT01336699|Experimental|Cohort C|WRSs2 vaccine 1x10^5 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^5 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
9974014|NCT01336699|Experimental|Cohort D|WRSs2 vaccine 1x10^6 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^6 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
9974015|NCT01336699|Experimental|Cohort E|WRSs2 vaccine 1x10^7 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^7 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
9974016|NCT01336725||Morbid obesity|All attending learning and mastery courses for persons with morbid obesity
9974017|NCT01336751|Experimental|Insulin glargine|"Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
9974018|NCT01336751|Active Comparator|Lispro mix|"Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
9974019|NCT01336777||Insulin resistant group|there is no intervention
9974020|NCT01336777||Insulin sensitive group|There is no intervention
9974021|NCT01336816|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
9974022|NCT01336816|Placebo Comparator|Placebo Wintergreen|Subjects allow study placebo lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
9974023|NCT01336829|Experimental|001|ETR/telaprevir Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
9974024|NCT01336829|Experimental|002|telaprevir/ETR Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
9974025|NCT01336829|Experimental|003|TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
9974026|NCT01336829|Experimental|004|telaprevir/TMC278 Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
9974027|NCT01336842|Experimental|Phase I dose-escalation|Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
9974028|NCT01336855||HIV Positive|HIV-1 positive subjects
9974029|NCT01336855||HIV negative subjects|HIV-1 seronegative control group
9974030|NCT01336881||Correlative (tissue analysis)|Archived tumor tissue samples are analyzed for hepatoblastoma and other liver tumor biomarkers by microRNA array profiling and exome sequencing. Results are then compared with patients' clinical data.
9974031|NCT01336907||naive CNV subjects|Newly diagnosed CNV, before any treatment (naïve)
9974032|NCT01336907||previously diagnosed CNV subjects|Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
9974033|NCT01336920|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9974034|NCT01336946|Experimental|health promotion program|Psycho education and behavioural group sessions and supervised walking sessions will be performed.
9974035|NCT01336946|No Intervention|Control group|No intervention will be performed in this control group.
9664666|NCT05302453|No Intervention|Control Group|The Control group was warned to continue with daily routines and not to take any training that includes body-mind approaches such as yoga or Tai chi for 12 weeks.
9974036|NCT01337011|Experimental|intra-coronary administration|Application of stem cells using the intra-coronary route.
9974037|NCT01337011|Experimental|intra-myocardial administration|Application of stem cells using the intra-myocardial route.
9974038|NCT01337024||Control group|Healthy volunteers, examined with ECG without any treatment (controls)
9974039|NCT01337024||100 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 100 units BoNT/A
9974040|NCT01337024||300 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 300 units BoNT/A
9974041|NCT01337037||standard VATS group|patients undergo standard VATS lobectomy using non-modified equipments,without limits of staples
9974042|NCT01337037||modified equipments group|patients undergo VATS lobectomy with modified VATS lobectomy equipments designed designed according to the experience of chinese lobectomy surgery: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.).
9974043|NCT01337037||less staples group|patients undergo VATS lobectomy with at most 4 staples used.
9974044|NCT01337037||open group|patients undergo lobectomy by thoracotomy approach
10160982|NCT03988348|Active Comparator|control group|Direct intraumbilical transverse incision will be done
9974045|NCT01337063|No Intervention|Pre-intervention|Usual care regarding medication reconciliation as currently practiced at each participating site.
9974046|NCT01337063|Experimental|Intervention|Improved medication reconciliation process using continuous quality improvement methods, mentored implementation, and an implementation guide.
9974047|NCT01337102|Other|Physician to receive results|Arm 1 Physician to receive the results of the Lung QoL scale
9974048|NCT01337102|Other|Physician Does Not Receive Results|Arm 2 Physician does not receive the results of the Lung QoL scale
9974049|NCT01337141|Experimental|Interventional telematic|80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
9974050|NCT01337141|Other|Control|80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
9974051|NCT01337154|Experimental|Tamibarotene|Subjects will receive tamibarotene, 6 mg/m2, divided as twice daily orally starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Chemotherapy will include paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6)administered once every 3 weeks for up to 6 cycles.
9974052|NCT01337154|Placebo Comparator|Placebo|Subjects will take an equal number of placebo tablets as the group receiving tamibarotene divided as twice daily orally, starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6) will be administered once every 3 weeks for up to 6 cycles.
9974053|NCT01337180||Main study group|"Inclusion criteria: Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers and workers in the production and maintenance departments will be invited to participate. Non-smokers and smokers and male and female workers will be included in the main study group (study A).~Sputum part of study: nonsmokers."
9974054|NCT01337193|Active Comparator|Pelvic floor muscle exercises|Three pelvic floor muscle exercises will be performed with verbal cueing from the instructor.
9974055|NCT01337193|Experimental|Pelvic floor exercises with biofeedback|Pelvic floor exercises will be performed with biobeedback cueing.
9974056|NCT01337206|Experimental|Stenting Arm|Stenting Arm
9974057|NCT01337206|Active Comparator|Dilation Arm|Dilation Arm
9974058|NCT01337219|Other|Arm A|experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)
9974059|NCT01337219|Other|Arm B|standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)
9974060|NCT01337232|Active Comparator|1 session per week|
9974061|NCT01337232|Experimental|2 sessions per week|
9974062|NCT01337258||Men at increased risk for Prostate Cancer (PCA)|
9974063|NCT01337271|Active Comparator|PSV|
9974064|NCT01337271|Experimental|NAVA|
9974065|NCT01337310|Experimental|Tesetaxel|Tesetaxel administered orally once every 21 days for at least 2 cycles
9974066|NCT01337323||New prescription for fluticasone furoate nasal spray|patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.
9974067|NCT01337362|Active Comparator|Patients with hypoglycemia awareness|Patients who have symptoms when the blood sugar level is low
9974068|NCT01337362|Experimental|patients with hypoglycaemic unawareness.|Patients who do not feel any symptoms when the blood sugar levels are low
9974069|NCT01337375|Experimental|A/B|
9974070|NCT01337375|Experimental|C/D|
9974071|NCT01337388||Cohort|
9974072|NCT01337401|Experimental|Blinded Cediranib|
9974073|NCT01337401|Placebo Comparator|Blinded Placebo|
9974074|NCT01337414|Experimental|VMS diary booklet|
9974075|NCT01337414|Active Comparator|Usual Care (e.g. Amsler grid monitoring)|
9974076|NCT01337427|Placebo Comparator|Placebo for 48 weeks, BIIB017 for 48 weeks|Placebo every 2 weeks for 48 weeks followed by 125 mcg BIIB017 SC every 2 or 4 weeks for 48 weeks.
9974077|NCT01337427|Experimental|BIIB017 every 2 weeks for 96 weeks|125 mcg BIIB017 SC every 2 weeks for 96 weeks.
9974078|NCT01337427|Experimental|BIIB017 every 4 weeks for 96 weeks|125 mcg BIIB017 SC every 4 weeks for 96 weeks.
9974079|NCT01337440|Active Comparator|UDCA pretreatment|"Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
9974080|NCT01337440|Active Comparator|Sitagliptin pretreatment|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
9974081|NCT01337453||Flu-like symtoms, incidence|The frequency of FLS will be estimated by number of patients and number of Botox treatments.
9974082|NCT01337466|Experimental|[124I]FIAU|single dose study of [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection who will undergo PET-CT scanning
9974083|NCT01337479||Participants of specific phase III entecavir studies|Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections
9974084|NCT01337492|Experimental|Sorafenib|
9974085|NCT01337518|Experimental|EZN-4176|
9974086|NCT01337531|Experimental|gonadotropin|recombinant or highly purified gonadotropin
9974087|NCT01337531|Active Comparator|Gonadotropins|recombinant versus highly purified gonadotropin
9974088|NCT01337544|Experimental|IL-15 STIMULATED NK CELLS|
9974089|NCT01337557|Experimental|Bepotastine|
9974090|NCT01337570|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
9974091|NCT01337570|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
9974092|NCT01337583|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
9974093|NCT01337583|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
9974094|NCT01337622|Experimental|No routine check for gastric residuals|
9974095|NCT01337622|Active Comparator|Routine check for gastric residuals|
9974096|NCT01337648||TBI prior to stem cell transplantation|
9974097|NCT01337661||COPD subjects|Adult male and female subjects with COPD
10160983|NCT03988244|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
10160984|NCT03988582|Experimental|HCT (hematopoietic cell transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
10160985|NCT03988582|Experimental|SOT (solid organ transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
10160986|NCT03988582|Experimental|Other immune competent or immune compromised patients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
10160987|NCT03988361||Control group|Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
10160988|NCT03988361||Study group|"Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS.~The sperm used in this group is considered to be enriched in non apoptotic cells."
10160989|NCT03988322|Experimental|Quantitative assessment of imaging biomarkers|This is the intervention arm. In this arm, the participants will be scanned with low-dose CT with pre-defined scanning parameters for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the volume of the nodule. The quantitative assessment of imaging biomarkers of lung cancer, COPD and cardiovascular disease will be recorded.
10160990|NCT03988322|Active Comparator|Visual assessment of imaging biomarkers|This is the control arm. In this arm, the participants will be scanned with low-dose CT with routine scanning parameters used for lung cancer screening in the hospital for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the diameter of the nodule. The imaging biomarkers related to lung cancer, COPD and cardiovascular disease will be visually assessed.
10160991|NCT03988452|Active Comparator|Darunavir/r Zidovudine Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
10160992|NCT03988452|Experimental|Darunavir/r Tenofovir Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
10160993|NCT03988452|Experimental|Dolutegravir Zidovudine Lamivudine|Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
10160994|NCT03988452|Experimental|Dolutegravir Tenofovir Lamivudine|Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
10160995|NCT03988153|Experimental|Probiotic Milk Formula (PMF)|Twenty subjects should drink 200 mL of PMF (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
10160996|NCT03988153|Placebo Comparator|Skimmed Milk Formula|Twenty subjects should drink 200 mL of skimmed milk drink (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
10160997|NCT03988101|Experimental|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
10160998|NCT03988101|Placebo Comparator|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
10160999|NCT03988140|Experimental|Implant placed at supra crestal level (SL)|Implants were placed at supra crestal level (SL)
10161000|NCT03988140|Other|Implant placed at crestal level (CL).|Implants were placed at crestal level (CL)
10161001|NCT03987945||Left atrial appendage occlusion|Patients with non-valvular atrial fibrillation who have received left atrial appendage occlusion procedure.
10161002|NCT03988010|Experimental|Amantadine Sulphate|200 mg ıv Amantadine Sulphate in 500 cc solution
9974098|NCT01337713|Experimental|Swedish Massage|
10161003|NCT03988010|Placebo Comparator|Placebo group|iv 500 cc %0.9 sodium chloride
10161004|NCT03987971|Experimental|Deep acupuncture on GB26|
10161005|NCT03987971|Sham Comparator|Superficial acupuncture on GB26|
10161006|NCT03987971|No Intervention|waiting list|
10161007|NCT03987867|Experimental|Arm: CIK+PD-1 inhibitor+chemotherapy|"CIK cell, IBI308, Pemetrexed, Liposome paclitaxel, Carboplatin~IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Liposome paclitaxel intravenous infusion 135mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
10161008|NCT03988075|Active Comparator|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
10161009|NCT03988075|Experimental|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
10161010|NCT03987776|Experimental|Anti-inflammatory diet|energy-reduced diet with the use of low glycemic foods, wholegrain products, legumes, colorful vegetables and fruit, nuts, seeds, marine fish, olive oil, green/black tea, and multiple spices and herbs
9974099|NCT01337713|Sham Comparator|Light Touch|
9974100|NCT01337726|Active Comparator|Illness Management Only|
9974101|NCT01337726|Experimental|Combined Psychotherapy & Illness Management|
9974102|NCT01337765|Experimental|BEZ235 + MEK162|
10161011|NCT03987776|Experimental|Control energy-resticted diet|isocaloric to anti-inflammatory diet, energy restricted diet (55-60% carbohydrates, 25% fat, 15-20% protein) used in a standard obesity management
10161012|NCT03988036|Experimental|HER2-enriched|"Trial treatment is defined as neoadjuvant therapy only. The Investigational Medicinal Products (IMPs) are pembrolizumab, trastuzumab biosimilar and pertuzumab.~Trastuzumab Biosimilar (Trazimera®) - Investigational Medicinal Product~Loading dose: 8 mg/kg bodyweight at initial administration infusion over 90 min; monitor patient for at least 6 h afterwards.~Maintenance dose: 6 mg/kg bodyweight, over 30-90 min; monitor patient for 2 h afterwards.~Route: Intravenous infusion.~Schedule: Every 3 weeks during the neoadjuvant phase.~Pertuzumab (Perjeta®) - Investigational Medicinal Product~Loading dose: 840 mg, initial administration.~Maintenance dose: 420 mg.~Route: Intravenous infusion.~Schedule: Every 3 weeks during the neoadjuvant phase.~Pembrolizumab (Keytruda®) - Investigational Medicinal Product~Dose: 200 mg.~Route: Intravenous infusion.~Schedule: Every 3 weeks during the neoadjuvant phase."
10161013|NCT03988114|Experimental|Abemaciclib + NSAI|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally.
10161014|NCT03987906|Experimental|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
10161015|NCT03987906|No Intervention|Standard Oncology Care|The control arm receives standard oncology care, which includes routine symptom screening at every outpatient visit.
10161016|NCT03987659|Active Comparator|Root Canal Treatment without dECMs release|Two visit non-surgical root canal therapy with conventional irrigation protocols
10161017|NCT03987659|Experimental|Root Canal Treatment with dECMs release|Two visit non-surgical root canal treatment with irrigation protocols that optimise release of soluble dentine extracellular matrix components (dEMCs)
10161018|NCT03987997|Active Comparator|Association electrical muscle stimulation with cyclo-ergometer|Randomized leg with receive electrical muscle stimulation of the quadriceps in addition to early mobilization of lower limbs with cyclo-ergometer.
10161019|NCT03987997|Other|Cyclo-ergometer only|This control group correspond to the leg which don't receive electrical muscle stimulation (as usually supported)
10161020|NCT03987672|Other|Assess Nutritional Effects of Nutritional Formula|Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.
10161021|NCT03987646|Experimental|xenograft cortical flexible sheet|a-traumatic tooth removal , socket lavage and curettage, performing a vestibular access horizontal incision corresponding to the socket 3-4 mm apically from the muccogingival junction , a tunnel is then created from the socket office and extended apically till it connects with the vestibular access incision, a computer guided surgical template is then used to deliver the implant in its optimal position, a slowly resorbable membrane shield is then introduced through the tunnel and stabilized with a membrane tac , it is a sturdy fixable membrane barrier placed above the labial plate
10161022|NCT03987854|Experimental|complete diet and lifestyle program|
10161023|NCT03987880|Active Comparator|4.0 mm zone|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
10161024|NCT03987880|Experimental|3.5 mm zone|PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
10161025|NCT03987893|Experimental|PEG+Lactulose|this arm will recieve PEG3350 in addition to standard of care
10161026|NCT03987893|Active Comparator|Lactulose alone|this arm will recieve only standard of care for management of hepatic encephlaopathy with ACLF
10161027|NCT03987763|Experimental|IDP-122 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 6 to 11 years 11 months) will apply IDP-122 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
10186216|NCT03737890|Active Comparator|Hold Relax Pectoral Stretch|4 weeks of hold relax pectoral stretch
10186217|NCT03737877|Experimental|Diet modification|
10186218|NCT03737864|Active Comparator|Motivational Interview|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
10186219|NCT03737864|Experimental|Patient navigation and MI|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification plus patient navigation for 30 days, or until the patient is successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
10186220|NCT03737825|Active Comparator|Program 1|Computerized gaming rehabilitation Program 1.
10186221|NCT03737825|Placebo Comparator|Program 2|Computerized gaming rehabilitation Program 2.
10186222|NCT03737786|Active Comparator|GA with mild hypercarbia (GAH)|Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
10186223|NCT03737786|Active Comparator|GA with normocarbia (GAN)|Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
10186224|NCT03737773|Active Comparator|group prisms|Patients that receive active prismatic lenses
10186225|NCT03737773|Placebo Comparator|group placebo lenses|Patients that receive non-active prismatic lenses
10186226|NCT03737721|Experimental|Avelumab and Radical radiotherapy|Single-arm combining Avelumab with radical radiotherapy.
10186227|NCT03737708|Experimental|tacrolimus + biologics|Participants will receive tacrolimus daily for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
10161028|NCT03987815|Experimental|Study Arm|Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles
10161029|NCT03987698|Experimental|Arm 1: CIK+PD-1i|"SHR-1210 & CIK cells~SHR-1210,200mg/d,intravenous infusion,d1; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
10161030|NCT03987698|Active Comparator|Arm 2: Control|SHR-1210,200mg/d,intravenous infusion,d1; Q3W.
10161031|NCT03987737|Experimental|small catheter|In the study arm, a small catheter will be placed in the rectum by the MRI technician and the examination will be executed with the small catheter in situ.
10161032|NCT03987737|No Intervention|control group|In the control arm, subjects will be scanned immediately after rectal evacuation on the toilet without small catheter in situ.
10161033|NCT03987542||Exposed|Patients who had their asparaginase treatment truncated or had no asparaginase enzyme activity.
10161034|NCT03987542||Unexposed|Patients who did not have their asparaginase treatment truncated and had measurable asparaginase enzyme activity
10161035|NCT03987724|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
10161036|NCT03987594|Placebo Comparator|TUF|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
10161037|NCT03987594|Experimental|TUF+HD|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
10161038|NCT03987750|Experimental|Safinamide 100mg|Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide
10161039|NCT03987750|Experimental|Safinamide 150mg|Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study
10161040|NCT03987750|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)
10161041|NCT03987633||Displaying trait of interest|There are 19 disease areas under investigation. Enrolled patients are segmented into cohorts based on data collected through questionnaires and medical histories. This data-driven approach does not allow for precisely predefined cohorts for the diseases under investigation. Therefore, as a default, the two general predefined cohorts are set as either displaying or not displaying a trait that would form the basis of an investigation.
10161042|NCT03987633||Not displaying trait of interest|Please see above.
10161043|NCT03988062|Experimental|TrelliX Embolic Coil System|
10161044|NCT03987607||Patients scheduled for elective surgery|Patients scheduled for elective surgery requiring neuromuscular blockade
10161045|NCT03987399|Experimental|Tailored educational intervention|The intervention will be based on previous research and results from baseline (T1). The intervention will be a one-day educational day and includes lectures and workshops with main focus on the lowest competence in pediatric postoperative pain management. Healthcare providers at the included surgical wards will be invited to participate on this educational day. As a supplement, there will be provided clinical supervision in pediatric postoperative pain management and reminders (such as lectures and posters) over a period of six months after educational day.
10161046|NCT03987308|Experimental|Beinaglutide|Five-week Beinaglutide pump treatment group
10161047|NCT03987308|Experimental|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
10161048|NCT03987516|Experimental|Active intervention|Patients will be included in an active intervention.
10161049|NCT03987516|No Intervention|Control group|Patients in the control group will not receive any intervention
10161050|NCT03987295|Experimental|AL001|AL001 every 4 weeks for up to 96-weeks
10161051|NCT03987334|Experimental|Experimental Group (VRT)|Subjects in the experimental group (VRT) will undergo 30 minutes of motor control exercises using a virtual reality-based sensorimotor rehabilitation provided using the Virtual Reality Rehabilitation System (VRRS) of Khymeia Group. The equipment includes a computer workstation connected to a 6 degrees of freedom (DOF) motion-tracking system (Polhemus G4, Vermont, US), a high-resolution LCD displaying the virtual scenarios on a large screen and a software processing the motion data coming: from the receiver of the sensors end-effectors placed on the sternum and on the head through a helmet. The system has been found to reliably record head position and cervical range of motion among asymptomatic people as well as persistent neck pain patients. The VRRS allows the participant to perform the requested motor tasks, while the movement of the system's end-effector is simultaneously represented in a virtual scenario.
10161052|NCT03987334|Active Comparator|Control Group (CT)|Control group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
10161053|NCT03987477|Experimental|Experimental group|The experimental group will be exposed to a brief online program aimed at the modification of negative emotional cognitive biases. The program consists of an introduction and four 1-hour sessions, in video format. In each session, participants are required to complete some open questions and scales about the type of cognitive bias addressed in each session. All sessions are structured in four parts: 1) description and examples of some specific cognitive biases; 2) information about negative consequences of each bias; 3) explanation of adaptive strategies to modify cognitive biases (i.e., the four-questions approach used in standard Cognitive behavioral therapy); and 4) use of some practices to familiarize participants with the use of those strategies.
10161054|NCT03987477|Other|Waiting list group|The control group will be composed of individuals waiting for the treatment. Participants will not be exposed to the experimental program or any other between the pre-evaluation and the post-evaluation sessions. Participants in this group will have access to the potential benefits of the intervention after the post-evaluation of both groups.
10161055|NCT03987269|Active Comparator|Intervention, Virtual Reality Group|The intervention group to experience the virtual reality embodied narrative experience.
9977332|NCT01360320|Experimental|Green tea extract|Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG, bid for 3 years
10161056|NCT03987269|Placebo Comparator|Control, Narrative Video Group|The control group to watch the same narrative video content that has been formatted for standard television
10161057|NCT03987256|Experimental|ECRB needling with adjuvant PRP infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with PRP"
10161058|NCT03987256|Active Comparator|ECRB needling with adjuvant NaCl 0.9% infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with Saline solution"
10161059|NCT03987438|Experimental|Behavioral intervention|Participants randomized to the behavioral intervention group will be provided with a mobile APP which incorporates behavioral support including health knowledge education, mental health counseling, diet advice, exercise guidance and weight management. Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their performance recorded in the APP. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Investigators conduct face-to-face health education, lifestyle guidance, mobile APP software inspection. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
10161060|NCT03987438|No Intervention|Control group|Participants randomized to the control group have regular care in their local hospitals. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
9977333|NCT01360320|Placebo Comparator|Placebo|Placebo, packed in hard gelatine capsules, bid for 3 years
10161061|NCT03987386|Active Comparator|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy daily over 6.5 weeks after standard of care surgery.
10161062|NCT03987386|Experimental|Arm II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy over 4.5 weeks after standard of care surgery.
10161063|NCT03987503|Experimental|at Point-of-Diagnosis HCV treatment|At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
10161064|NCT03987503|Active Comparator|Passive observation|Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).
10161065|NCT03987529||Sevoflurane+Remifentanil|Using inhalent agent(Sevoflurane), continuous infusion of Remifentanil
10161066|NCT03987529||Propofol+Remifentanil|Using continuous infusion of Propofol and Remifentanil
10161067|NCT03987204|Experimental|Ivabradine|Patients with permanent atrial fibrillation and previously implanted pacemakers who will be started on ivabradine.
10161068|NCT03987321|Experimental|Denali Group|Those who received Denali filter placement
10161069|NCT03987321|Experimental|Celect Group|Those who received Celect filter placement
10161070|NCT03987152|Other|Sirolimus|Sirolimus administration: during Challenge and Rechallenge phase. Compared with the period 2 months before start of Sirolimus.
10161071|NCT03987425|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
10161072|NCT03987425|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
10161073|NCT03987490|Experimental|Parents of Girls|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
10161074|NCT03987490|Experimental|Parents of Boys|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
10161075|NCT03987087|Experimental|Radiotherapy group|Thoracic intensity modulated radiation therapy (IMRT) concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.Cisplatin Thoracenteral infusion chemotherapy。 Thoracic intensity modulated radiation therapy (IMRT) concomitant with Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations.
10161076|NCT03987087|Active Comparator|Chemotherapy group|"EGFR-TKI on paticipants with known sensitive EGFR mutations,Cisplatin Thoracenteral infusion chemotherapy.~Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations."
10161077|NCT03987243|Other|Intervention|Two interventions will be provided. The first intervention is a structured education regarding pressure ulcer prevention through weight shifts at start of study. The second intervention is the use of a mobile seat interface pressure map (IPM), which will occur during two intervention phases.
10161078|NCT03987178|Experimental|Head Dunk|Subjects who are assigned to be in this arm are asked to sit in a hot tub for 15 minutes and instructed to submerge his or her head in the hot tub at least once and at least up to the eyebrows during his or her time in the hot tub.
10161079|NCT03987178|Placebo Comparator|No Head Dunk|Subjects assigned to this arm are asked to sit in a hot tub for 15 minutes but to keep his or her chin above water during the entire time.
10161080|NCT03987230|Active Comparator|Oust™ Demodex® Wipes™|Participant cleans eyelids with Oust™ Demodex® Wipes™
10161081|NCT03987230|Active Comparator|I-LID N LASH PLUS® Eyelid Cleanser|Participant cleans eyelids with I-LID N LASH PLUS® Eyelid Cleanser
10161082|NCT03987230|Active Comparator|Blephadex Lid Wipes|Participant cleans eyelids with Blephadex Lid Wipes
10161083|NCT03987230|Active Comparator|Eye Cleanse Lid Wipes|Participant cleans eyelids with Eye Cleanse Lid Wipes
10161084|NCT03987230|Active Comparator|Blephademodex|Participant cleans eyelids with Blephademodex
9977334|NCT01360333|Other|Tap water, sodium chloride, carbohydrate rich fluid|
10161085|NCT03987230|Placebo Comparator|Sensitive Eyes® Plus Saline Solution|Participant cleans eyelids with Sensitive Eyes® Plus Saline Solution
10161086|NCT03987061|Experimental|MOTIV bioresorbable vascular scaffold|MOTIV bioresorbable vascular scaffold for below-the-knee artery disease
9662143|NCT05130619|Experimental|Treatment order B-D-A-C|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
10161087|NCT03986931|Experimental|Pharmacist-Bidirectional Texting Group|Patients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.
10161088|NCT03986931|Active Comparator|Control Group|Patients randomized to the control group will also return 7 morning and 7 evening blood pressure measurements. The report will be shared with a pharmacist who will call the patient to discuss the measurements and possibly recommend follow up with a physician, but no other pharmacist intervention or monitoring will occur during the 12 months.
10161089|NCT03986970|No Intervention|Arm 1: Control|No PrEP.
10161090|NCT03986970|Experimental|Arm 2: FTC-TDF|FTC-TDF one day, 5 hours before circumcision.
9826404|NCT02417233|Active Comparator|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
10161091|NCT03986970|Experimental|Arm 3: FTC-TDF|FTC-TDF one day, 21 hours before circumcision.
10161092|NCT03986970|Experimental|Arm 4: FTC-TDF|FTC-TDF two days, 5 hours before circumcision.
10161093|NCT03986970|Experimental|Arm 5: FTC-TDF|FTC-TDF two days, 21 hours before circumcision.
10161094|NCT03986970|Experimental|Arm 6: FTC-TAF|FTC-TAF one day, 5 hours before circumcision.
10161095|NCT03986970|Experimental|Arm 7: FTC-TAF|FTC-TAF one day, 21 hours before circumcision.
10161096|NCT03986970|Experimental|Arm 8: FTC-TAF|FTC-TAF two days, 5 hours before circumcision.
10161097|NCT03986970|Experimental|Arm 9: FTC-TAF|FTC-TAF two days, 21 hours before circumcision.
10161098|NCT03987165|Experimental|Music Therapy|Music therapy by a certified music therapist will be delivered to infants over a period of 5 days. There will be two periods of data collection each day, one in the morning and one in the afternoon. Each baby will receive music therapy during one of these time points, with each baby serving as their own control during the second timepoint.
10161099|NCT03987165|No Intervention|Control|
10161100|NCT03987412|Experimental|Behavioral intervention|Pregnant women randomized to the behavioral intervention group will recieve a face-to-face education about the risks of GDM at their local rearch centers. Then they will be provided with a mobile APP incorporating nutrition, exercise and phycological support. They will also have regular prenatal care in their local hospitals.
10161101|NCT03987412|No Intervention|Control group|Pregnant women randomized to the control group only have regular prenatal care in their local hospitals.
10161102|NCT03987022|Experimental|"ICE-T"|"Regimen #1 ICE-T Opioid Sparing Regimen At the end of surgery patients will receive 30mg of intravenous (IV) toradol. Once out of the post anesthesia care unit (PACU) patients will receive~ICE PACKS applied to the surgical sites every hour for 20 minutes Around the clock (ATC) until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol per os (PO) every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV every 3 hours as needed (PRN) for breakthrough pain.~Patients will be discharged home with (PO) Tylenol and PO toradol as needed (PRN)."
10161103|NCT03987022|Active Comparator|Standard of care|"Regimen #2 STANDARD Postoperative Regimen~Once out of the PACU patients will receive Standard postoperative regimen~Motrin 600mg PO every 4 hours PRN pain scale 1-3 pain~Percocet 1 tab PO every 4-6 hours PRN pain scale 4-6 pain~Percocet 2 tabs PO every 7-10 hours PRN pain scale 7-10 pain~Patients will receive dilaudid 0.2mg IV every 3 hours PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
10161104|NCT03986853|Experimental|Blood sample|Blood sampling Under general anesthesia
10161105|NCT03986892||COmPLETE-Health|No intervention
10161106|NCT03986892||COmPLETE-Heart|No intervention
10161107|NCT03987035|Experimental|BGP Stent Graft System|BGP Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms
10161108|NCT03987048||Cirrhotic patients with septic shock|All consecutive adult cirrhotic patients admitted to the ICU with septic shock from 2002 to 2013.
10161109|NCT03986749|Experimental|ARCR-BursaSeries|Tendon healing in the reconstruction of the rotator cuff, taking advantage of augmentation potential of the subacromial bursa.
10161110|NCT03986801|Experimental|PASS pharmaceutical interview|
10161111|NCT03986801|No Intervention|Usual management out of hospital|
10161112|NCT03986671|Experimental|EMG Testing|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmenbrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
10161113|NCT03986736||Patients with major trauma|Patients with major trauma will be included in the study.
10161114|NCT03986918||Ovation and Ovation Tribute|All patients having undergone a total hip arthroplasty that received the Ovation® or Ovation Tribute® (Ortho Development, Draper, Utah) Hip system will be sent the survey.
10161115|NCT03986645|Experimental|4DFLOW|Acquire MR 4DFLow data.
10161116|NCT03986983|Experimental|Experimental group of Aerobic exercise|The participants perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
10161117|NCT03986983|Experimental|Experimental group of Shockwave therapy and Aerobic Exercise|"The participants do the Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position.~In addition, the participants also perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch."
10161118|NCT03986983|No Intervention|Control group|The participants do not perform any type of intervention.
10161119|NCT03986840|Experimental|Exercise program|The exercise program was applied for 6 weeks. A total of 18 sessions were distributed in 3 weekly sessions. The participants performed a resistance exercises: leg press at an intensity of 40%-60% with 10 repetitions, 12 repetitions of steps with their bodyweight and a plantar flexion followed by a cardiovascular HIIT exercise walking on a treadmill.
10161120|NCT03986840|Active Comparator|Daily activities|The patients who belongs to this group will continue to perform their daily routines.
10161121|NCT03986996|Active Comparator|Group 1 -Amoxycillin Doxycyclin and metronidazole|triple therapy with amoxicillin, metronidazole and tetracycline twice daily, for 2 weeks.
10161122|NCT03986996|Experimental|Group 2 -Amoxycillin and Doxycyclin|double therapy with Amoxycillin and Doxycyclin twice daily, for 2 weeks.
10161123|NCT03986762|Experimental|Open Label Clav|
10161124|NCT03986658|Experimental|Adolescents|Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
10161125|NCT03986775|Active Comparator|citrus drink with isomaltulose|
10161126|NCT03986775|Placebo Comparator|citrus drink with sucrose|
10161127|NCT03986905|Experimental|Scopolamine Nasal Gel|DPI-386 Nasal Gel + placebo patch
10161128|NCT03986905|Placebo Comparator|Placebo|placebo nasal gel + placebo patch
10161129|NCT03986905|Active Comparator|TDS Patch|placebo nasal gel + TDS patch
10161130|NCT03986827|Experimental|Cool Kids Anxiety Program - Social Enhanced (CK-E)|CK-E is a G-CBT treatment developed specifically for treatment of youth SAD. The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session.
10161131|NCT03986827|Active Comparator|Cool Kids Anxiety Program (CK)|"The standard Cool Kids Anxiety Program is a treatment program based on generic CBT techniques such as cognitive restructuring and gradual exposure.~The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session."
10161132|NCT03986788|Other|Weightlessness|Weightlessness measurements during flight
10161133|NCT03986567|Active Comparator|control|Providing with a paper notification card to the STI diagnosed young person
10161134|NCT03986567|Experimental|intervention web app|providing to the STI diagnosed young person, with a code number to enter into the app to notify sexual partners
10161135|NCT03986567|Experimental|intervention game|providing to the STI diagnosed young person, with a code number to enter into the app and play a game to get motivated to notify sexual partners
10161136|NCT03986697|Active Comparator|Bictarvy|Intervention group: those randomised to switch antiretroviral therapy to Bictegravir, Emtricitabine and Tenofovir Alafenamide fixed dose combination.
10161137|NCT03986697|No Intervention|Usual therapy|Control group: those randomised to continue their usual antiretroviral regime
10161138|NCT03986515|Experimental|treatment group|"apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events.~SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events.~(the first dose of SHR-1210 is set on the 3-5 days after apatinib"
10161139|NCT03986528|Experimental|Kanglaite Injection + Chemotherapy|Participants receive Kanglaite Injection PLUS first-line chemotherapy.
10161140|NCT03986528|Active Comparator|Chemotherapy|first-line chemotherapy.
10161141|NCT03986632|Experimental|Tundra gifts program|
10161142|NCT03986632|No Intervention|Comparison|
10161143|NCT03986476|Experimental|Lactobacillus reuteri strain 1|Probiotic compound
10161144|NCT03986476|Experimental|Lactobacillus reuteri strain 2|Probiotic compound
9671347|NCT05049629|Active Comparator|Eye 2|The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
10161145|NCT03986476|Placebo Comparator|Placebo|Placebo
10161146|NCT03986606|Experimental|Open-label Dose Escalation and Expansion Study of PSB205|"Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts."
10161147|NCT03986463||Cohort 1|"Stage III NSCLC as per the American Joint Committee on Cancer 8th edition (AJCC 8th ed.)~Appropriate to undergo concurrent chemotherapy and radiation~Planned radiation dose must be between 54 and 66 Gy~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~No prior system chemotherapy (induction) for their stage III NSCLC, any adjuvant chemotherapy given for resected disease must have been at least 100 days prior to enrollment"
10186228|NCT03737708|Active Comparator|methotrexate + biologics|Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
9671348|NCT05049850|Experimental|Imlifidase|Imlifidase is administered intravenously as one dose of 0.25 mg/kg over 15 minutes within the 24-hour period prior to transplantation. (A second dose may be given if the crossmatch test at 4 hours after the first dose remains positive.)
9826405|NCT02417233|Active Comparator|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
9826406|NCT02417246|Active Comparator|Study Sequence A|Start with brand name metoprolol ER, switch to Generic B metoprolol, switch back to brand name metoprolol ER, then switch to Generic A metoprolol
9974103|NCT01337778|Active Comparator|Primary Care for DILs|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced gender-based violence. A comprehensive health examination for mothers-in-law will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
9974104|NCT01337778|Experimental|Standard Care plus Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the daughter-in-law's (DILs) pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with mothers-in-law (MILs), and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce gender-based violence (GBV) and protect and promote their family's health.
9974105|NCT01337791|No Intervention|control|
9974106|NCT01337791|No Intervention|telbivudine|
9974107|NCT01337804|Experimental|Zegerid-Prilosec|Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.
9974108|NCT01337804|Experimental|Prilosec-Zegerid|Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.
9974109|NCT01337817|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
9974110|NCT01337817|Active Comparator|Ariva Wintergreen|Subjects allow study comparator lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
9974111|NCT01337830|Experimental|Ariva® Silver Wintergreen|Subjects allow study product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
9974112|NCT01337830|Active Comparator|Silver Wintergreen|Subjects allow comparator product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
9974113|NCT01337843|Active Comparator|Control Group|Control Group participants will receive a well-regarded book for back pain patients.
9974114|NCT01337843|Experimental|Wellnes Workbook|Participants will receive the Wellness Workbook, a web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase their physical activity and manage stress with relaxation and mindfulness training
9974115|NCT01337856|Other|WHO alcohol handrub protocol|handrubbing with alcohol using the standard 7-step technique (WHO alcohol handrub protocol)
9974116|NCT01337856|Other|CDC alcohol handrub protocol|Handrubbing with alcohol covering all hand surfaces in no particular order (CDC alcohol handrub protocol)
9974117|NCT01337856|Other|Chlorhexidine handwashing|chlorhexidine handwashing using the standard 7-step technique (WHO handwashing protocol)
9974118|NCT01337869|Active Comparator|Bascom Cleft Lift Technique|
9974119|NCT01337869|Active Comparator|Limberg Flap Technique|
10186229|NCT03737695||Ancillary-Correlative (biospecimen, clinical info collection)|Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
10186230|NCT03737682||hemostasis achievement|in which hemostasis at the exposure site was achieved in five minutes were included in group A
10186231|NCT03737682||No hemostasis achievement|in which hemostasis at the exposure site couldn't be achieved in five minutes where included in group B
9974120|NCT01337882|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
9974121|NCT01337882|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
9974122|NCT01337895|Active Comparator|Lifestyle counselling|These participants will be assigned to a 500 kcal/day energy-restricted diet that is low in dairy products (no more than 1 serving per day).
9974123|NCT01337895|Experimental|High dairy|These participants will be assigned a 500 kcal/day energy-restricted diet that is high in dairy (4 or more servings per day).
9974124|NCT01337921|Experimental|Multi-strain Synbiotic|Multi-strain probiotic with prebiotics
9974125|NCT01337921|Active Comparator|Multi-strain Probiotic|Multi-strain Probiotic without prebiotics.
9974126|NCT01337934|Placebo Comparator|Lactated Ringer|Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
10161148|NCT03986463||Cohort 2|"Stage IV NSCLC or stage III NSCLC, as per the AJCC 8th ed.~Planning to start systemic cytotoxic chemotherapy, without concurrent radiation~Previous treatment with tyrosine kinase inhibitors or immunotherapy (PD-1, PD-L1, CTLA4 directed antibodies) is allowed as long as no cytotoxic chemotherapy was given concurrently~Previous palliative radiation is permitted, but must have been completed at least at least 21 days prior to the initiation of treatment~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~If cytotoxic chemotherapy was previously given for adjuvant or stage III NSCLC it must have been at least 100 days prior to enrollment"
9826407|NCT02417246|Active Comparator|Study Sequence B|Start with brand name metoprolol ER, switch to Generic A metoprolol, switch back to brand name metoprolol ER, then switch to Generic B metoprolol.
9826408|NCT02417376|Active Comparator|Experimental|"Periodontal intervention in the form of scaling and root planing by:~ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and~gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
9520186|NCT03279757|Experimental|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
10161149|NCT03986463||Cohort 3|"Patients with advanced NSCLC set to undergo palliative radiation to the primary or regional or distant metastatic lesion(s), including intracranial lesions~Radiation dose scheduling must be 2.5 to 4.0 Gy on days 1 through 3 for extracranial treatment, ideally 40 Gy in 15 fractions, 20 Gy in 5 fractions, or 30 Gy in 10 fractions.~Radiation dose for brain lesions must be 6 to 9 Gy per dose, ideally 30 to 35 Gy in 5 daily fractions or 27 Gy in 3 fractions on alternating days~No plans for concurrent chemotherapy to be given~Five patients in cohort 3 will receive radiation to the primary tumor and five patients will receive radiation to brain lesions"
10161150|NCT03986281|Active Comparator|Omron HeartGuide Smartwatch|Readings from the Omron HeartGuide Smartwatch
9520187|NCT03279757|Experimental|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
9826409|NCT02417376|No Intervention|Control|No periodontal intervention in any form.
9826410|NCT02417441|Experimental|Early Embryo Viability Assessment + Morphological Grading|Embryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
9826411|NCT02417441|No Intervention|Morphological Grading|Embryos of subjects randomized in this group were assessed only using morphological grading to identify optimal embryos for transfer.
10161151|NCT03986281|Active Comparator|Arterial Line|Readings from the arterial line
10161152|NCT03986177|Experimental|Intervention|The intervention arm will receive a multi-faceted self-management intervention package.
10161153|NCT03986177|No Intervention|Enhanced care|The control arm will receive usual care plus basic asthma education from a trained nurse educator.
10161154|NCT03986255|Experimental|Lumbar Puncture|Participants will undergo Lumbar puncture procedure
10161155|NCT03986307|Experimental|Omega-3|Elderly supplemented with omega-3.
10161156|NCT03986307|Placebo Comparator|Placebo|Elderly supplemented with corn oil.
10161157|NCT03986242|Experimental|static stretchin|Static extremity muscles of the lower extremities, including: gluteal muscles (major muscle group: gluteus maximus), anterior thigh muscles (strand rectus, medial femoral muscle, lateral femoral muscle, medial femoral muscle), posterior thigh muscles (main muscle) Group: semimembranosus, semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). 4 groups per muscle group, 30 seconds/group
10161158|NCT03986242|Experimental|non- vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each leg of each pair performs 30 seconds/group for a total of 4 groups for a total time of 20 minutes.
10161159|NCT03986242|Experimental|Vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each muscle group of each foot performs 30 seconds/group, a total of 4 groups, the vibration frequency is 28 Hz, and the total time is 20 minutes.
9826412|NCT02417532|Experimental|Rehabilitation using REX|Exercises using Rex mobility assist device
10161160|NCT03986268|Active Comparator|study group|The patients measured a total of 25 OH vitamin D3 levels, initial, 3'th month and 6'th month of neoadjuvant therapy with replacement treatment with vitamin D3 at least weekly 50000 IU for eight weeks.
10161161|NCT03986268|Other|control group|The patients had measured a total of 25 OH vitamin D3 levels, previously treated with neoadjuvant therapy without replacement treatment with vitamin D3.
10161162|NCT03986346|Experimental|Laser group|Participants in this group receive pulsed dye laser to treat the scar.
10161163|NCT03986346|Active Comparator|Control group|Participants in this group receive standardized care.
10161164|NCT03986450|Active Comparator|ERAS group|Patients in this group will receive ERAS protocol preoperatively, perioperatively and postoperatively.
10161165|NCT03986450|No Intervention|Control|This group of patients will not receive ERAS care and will undergo a standard laparoscopic hysterectomy.
9671349|NCT05049759|Experimental|Feasibility testing|The feasibility trial, aims to assess the feasibility of the intervention, including assessment of acceptability and outcome measures. Twenty youths with anxiety and/or depressive symptoms will be recruited to the intervention. Physical activity will be measured using the Actigraph GT3X+ monitor at baseline and post-intervention. Outcome measures concerning symptom change will be assessed (anxiety and depression). Semi-structured qualitative interview with participants, caregivers and referring specialists will help identify possible contextual and practical factors associated with delivery of the intervention and explore acceptability of assessment procedures, the intervention, and perceived benefits and barriers to participation.
9671350|NCT05049863|Experimental|Phase I Dose Level 0: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
9826413|NCT02417753|Experimental|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
9826414|NCT02417831|Active Comparator|tamsulosin capsules|
9826415|NCT02417831|Active Comparator|tamsulosin HCl capsules|
10161166|NCT03986385|Experimental|A(apatinib Xelox)|Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles
10161167|NCT03986385|Active Comparator|B(Xelox)|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles
10161168|NCT03986359|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
10161169|NCT03986359|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
10161170|NCT03986320|Experimental|Keeogo™ Dermoskeleton|Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
10161171|NCT03986398|Experimental|Prophylactic efficacy of Urell®|Prophylactic efficacy of Urell® on urinary tract infections in patients with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty
10161172|NCT03986190|Experimental|Healthy Juntos Intervention Condition|Parent-adolescent dyads randomized to the Healthy Juntos intervention condition will access a program that includes didactic, behavioral, and positive parenting content from their smartphones for 8 weeks.
10161173|NCT03986190|No Intervention|Control Group|This group will receive a digital standard of care - a list of publicly available lifestyle apps and websites which they may access at their discretion.
10161174|NCT03986411|Other|Feasibility study of physiotherapy for UI in athletic women|A mixed methods study with 3 distinct but related phases to explore the feasibility of conducting an RCT of physiotherapy as management of urinary incontinence in athletic women
10161175|NCT03986489|Experimental|Mindfulness-based dance/movement therapy|Participants assigned to the M-DMT group condition will receive care as usual plus 12 weekly 90-minute group M-DMT sessions delivered online by a board-certified dance/movement therapist. The therapist is instructed to follow the M-DMT manualized protocol.
10161176|NCT03986489|Active Comparator|Chronic pain social support group|Participants assigned to the control condition will participate in a 12-session (90-minute session/week) online social support group.
10161177|NCT03986164|Active Comparator|Guided surgery (GS)|Installation of dental implant with the aid of the virtually planned guide by means of specific software
10161178|NCT03986164|Active Comparator|Conventional surgery (CS)|Installation of dental implant performed freehand using a conventional surgical guide made by study models
10161179|NCT03986151|Active Comparator|Conventional radial access|
10161180|NCT03986151|Experimental|Distal radial access|
10161181|NCT03986294|Experimental|S1 and liposomal irinotecan|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.
10161182|NCT03986294|Experimental|Liposomal irinotecan, Leucovorin and 5-fluoracil|Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
10161183|NCT03986554|Other|Randomization Visit A|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Each sequence will be use VFSS to visualize swallows.
10161184|NCT03986554|Other|Randomization Visit B|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Sequences 1 and 3 will use videofluoroscopy only, while sequence 2 will use VFSS with simultaneous pharyngeal high resolution manometry in order to visualize swallows.
10161185|NCT03986073|Experimental|Low dose group|Subjects in the low dose group administrated one TQ-F3083 capsule 10mg, one TQ-F3083 blank analog capsule and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
10161186|NCT03986073|Experimental|High dose group|Subjects in the high dose group administrated twoTQ-F3083 capsules 20mg and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
10161187|NCT03986073|Active Comparator|Positive drug control group|Subjects in the positive drug control group administrated two TQ-F3083 blank analog capsules and one Linagliptin tablet orally, once daily for 12 weeks.
10161188|NCT03986073|Placebo Comparator|Placebo group|Subjects in the placebo group administrated two TQ-F3083 blank analog capsules and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
10161189|NCT03986125|Experimental|Emotional Awareness & Expression Therapy|Participants will attend three individual sessions focused on becoming aware of and expressing avoided or conflicted emotions.
10161190|NCT03986125|Experimental|Mindfulness Meditation Training|Participants will attend three individual sessions focused on increasing equanimity and compassion and reducing self-judgement.
10161191|NCT03986125|No Intervention|Wait-List Control|Participants will receive the intervention of their choice following assessment at four and eight weeks after randomization.
10161192|NCT03986112||hypertensive group|Evaluation of the ability of carotid sonography and inferior vena cava sonography for the post-induction hypotension in hypertensive patients undergoing general anesthesia
10161193|NCT03985891|Experimental|JS001 in combination with Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks) in combination with JS001 (3mg/kg, Q2W). Patients will receive 6 cycles treatment in pre-operation and same cycles after operation.
10161194|NCT03985891|Active Comparator|Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks). Patients need to receive 6 cycles treatment in pre-operation and same cycles after operation.
10161195|NCT03985852|Active Comparator|Patient Directed Standard of Care|Patients receive pre-test genetic counseling and, if relevant, post-test counseling for a negative result from an automated genetics education assistant.
10161196|NCT03985852|No Intervention|Enhanced Standard of Care|Patients receive standard counseling from a genetic counselor.
9520188|NCT03279757|Experimental|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
9520189|NCT03279757|Experimental|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
9826416|NCT02417844|Active Comparator|Tamsulosin HCl|
10161197|NCT03986099|No Intervention|Standard of care|SOC viral load
10161198|NCT03986099|Active Comparator|Near point of care|POC viral load
10161199|NCT03985904|Experimental|Art Therapy|Participants will attend art therapy group sessions for three months in a designated museum.
10161200|NCT03985904|No Intervention|Control|Participants will NOT attend art therapy group sessions but will continue with usual care during the three months
10161201|NCT03986008|Experimental|Benaglutide|Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
10161202|NCT03986008|Active Comparator|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.
10161203|NCT03985774||Patients requiring carotid revascularization|Symptomatic patients, male or female, with atherosclerotic extracranial internal carotid stenosis (ICA) with or without involvement of the contiguous common artery (CCA), that require carotid revascularization.
10161204|NCT03986086|Experimental|MPH966|Participants receive MPH966 at RP2D tablet orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
10161205|NCT03986086|Placebo Comparator|Placebo|Participants receive MPH placebo tablet matching MPH966 orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
10161206|NCT03985917|Experimental|Intervention Singing Group Program|Singing group intervention program that includes six components: (1) vocal warm-up exercises; (2) vocal technique; (3) rehearsal of repertoire; (4) break for socialization; (5) creation and presentation of a show; (6) assessment of participants performance (vocal tuning).
10161207|NCT03985917|Active Comparator|Alternative Social and Leisure Activities|While the experimental group is participating in the intervention program, the control group will participate in the other activities proposed by the day care centers, which will be registered.
10161208|NCT03985969|Experimental|DDI|Period 1: study of elafibranor's pharmacokinetics Period 2: study of elafibranor's pharmacokinetics under CHRONO-INDOCID® (indomethacin) at steady state
10161209|NCT03985982|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.
10161210|NCT03985982|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
10161211|NCT03985826||Childhood ALL survivors|The cohort of childhood ALL survivors will be identified in the Danish part of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-Register .
10161212|NCT03985826||Comparison cohort|A reference cohort (comparison cohort) of individuals will be sampled randomly from the source population matched by age and sex and without a history of childhood cancer in the calendar year where the case was diagnosed (density sampling). For each childhood ALL-patient we will choose ten comparison subjects.
10186232|NCT03737669|Experimental|Mirasol-treated Fresh Whole Blood|Standard Fresh Whole Blood, treated with Mirasol Pathogen Reduction Technology
10186233|NCT03737669|Placebo Comparator|Standard Fresh Whole Blood|Standard-issue fresh whole blood
9826417|NCT02417844|Active Comparator|Tamsulosin|
10186234|NCT03737656|Experimental|Progesterone Vaginal Ring (Group A)|Insertion of the vaginal ring on Day 1 and continuous use until 91 days of treatment are completed. In this group, 28 participants will be included.
10186235|NCT03737656|Experimental|Progesterone Vaginal Ring (Group B)|Insertion of the vaginal ring on Day 1, removal for 2 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
9974127|NCT01337934|Active Comparator|Albumin|Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
9974128|NCT01337947||exercise training|12 weeks of exercise treatment/program for DM1 subjects
9974129|NCT01337999||HE-4 levels, healthy premenopausal women|
9974130|NCT01338064||exposed workers|At least six months of occupational exposure to Caesar stone
9974131|NCT01338077|Experimental|Sodium alginate|Oral suspension, 50 mg/ml
9974132|NCT01338077|Active Comparator|Omeprazole|20 mg/cap
9974133|NCT01338090||89Zr-bevacizumab|
9974134|NCT01338103|Experimental|Rituximab|
9974135|NCT01338116|Experimental|Management by TREAT/PCR|The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly.
9974136|NCT01338116|No Intervention|Usual management|Patients will be managed by physicians as in regular clinical practice.
9974137|NCT01338129|Experimental|vitamin c|administration of vitamin c for 45 days following ankle fracture operation
9974138|NCT01338129|Placebo Comparator|placebo|placebo pills
9974139|NCT01338142|Placebo Comparator|CCC|Crystalline calcium carbonate (CCC)
9974140|NCT01338142|Experimental|ACC|Amorphous calcium carbonate (ACC)
9974141|NCT01338285||1|Workers exposed to high levels of formaldehyde and unexposed workers in Guangdong Province, China.
9974142|NCT01338311|Active Comparator|salbutamol|
9974143|NCT01338311|Placebo Comparator|placebo|200mcg twice daily for a total of 7 doses
9974144|NCT01338337|No Intervention|Support treatment|Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed.
9974145|NCT01338337|Experimental|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
9974146|NCT01338350|Experimental|1|
9974147|NCT01338350|Placebo Comparator|2|
9974148|NCT01338363||All first time users of esomeprazole|
9974149|NCT01338363||All first time users of other PPIs|
9974150|NCT01338363||All first time users of H2-receptor antagonists|
9974151|NCT01338376|Experimental|Structured Education Group|Subjects received structured diabetes education
9974152|NCT01338376|Active Comparator|Conventional Care Group:|Subjects received conventional diabetes education
9974153|NCT01338389|Experimental|CITICOLINE|Daily oral administration of 800 mg citicoline
9974154|NCT01338389|Placebo Comparator|Placebo|Daily oral administration of placebo
9974155|NCT01338402|Other|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear basis for one week in Phase 1.
9974156|NCT01338402|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
9974157|NCT01338402|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
9974158|NCT01338428|Active Comparator|Brochure|
9974159|NCT01338428|Experimental|Enhanced AAA Sexual Assault Education|
9974160|NCT01338441|Experimental|Erythromycin|
9974161|NCT01338441|Placebo Comparator|Placebo|
9974162|NCT01338454|Active Comparator|tranexamic acid|TA administered intravenously over a 5 min period at delivery of the anterior shoulder
9974163|NCT01338454|No Intervention|saline|10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder
9974164|NCT01338467|Experimental|EYEOP Treatment|Open label, all subject treated by the EYEOP device
9974165|NCT01338480|Experimental|video|Participants in the intervention group watched an educational video illustrating informed consent information
9974166|NCT01338480|No Intervention|control|Participants in the control group read an informed consent document.
9974167|NCT01338519||PCOS and hirsutism|
9974168|NCT01338532|Active Comparator|Supervised exercise + patient education|
9974169|NCT01338532|Active Comparator|Patient education|
9977335|NCT01360346|Experimental|Enteral Sedation (EN)|Melatonin, Hydroxyzine, and Lorazepam. At every work shift, it will be checked the possibility to decrease the Lorazepam and then the Hydroxyzine dosage to quickly obtain and continuously maintain a RASS level = 0
9977336|NCT01360346|Active Comparator|Intravenous Sedation (IV)|Intravenous propofol or midazolam administration at the ICU admission to discharge at the compatible lowest level with harsh ICU environment. At every shift nurses are requested to give intravenous lowest dosage to obtain RASS=0
9977337|NCT01360359|Experimental|Core Stabilization|"8-week core stabilization program in 3 stage that emphasizes use of specific local trunk stabilizing muscles to restore active control and stability to the trunk.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
9977338|NCT01360359|Active Comparator|Trunk Motion and Fitness|"8-week exercise program in 3 stages emphasizing spine motion, general trunk flexibility and strengthening and cardiovascular fitness.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
9977339|NCT01360372|Active Comparator|Methylnaltrexone|
9974170|NCT01338545||Cohort|
9974171|NCT01338558|Experimental|K-RAS mutated|
10161213|NCT03985748|Experimental|Breath Actuated Nebulizers (BAN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
10161214|NCT03985748|Active Comparator|Standard Nebulizer (SN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
10161215|NCT03985865|Experimental|Intragastric quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
10161216|NCT03985865|Experimental|intragastric denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
10161217|NCT03985865|Placebo Comparator|Intragastric placebo|0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
10161218|NCT03985865|Experimental|Intraduodenal quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
10161219|NCT03985865|Experimental|Intraduodenal denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
10161220|NCT03985865|Placebo Comparator|Intraduodenal placebo|0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
10161221|NCT03985696|Experimental|patients with DLBCL|
10161222|NCT03985696|Active Comparator|Healthy volunteers|
10161223|NCT03985800|Active Comparator|TEAM-care as usual approach|Patients will be triaged based on their physical health (PH) and behavioral health (BH) complexity to determine the frequency of in-person visits and how much of these visits will be devoted to medical versus BH issues
10161224|NCT03985800|Active Comparator|TECH-telehealth approach|Each patient will have an initial face-to-face visit with the core treatment team described above and undergo the same triage process to determine their PH/BH care needs. Each TECH patient will participate in one face-to-face treatment team visit per year unless more frequent visits are deemed to be medically necessary; however, all other interactions will be conducted via technology-supported modalities
10161225|NCT03985735||Group good sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are more than six hours."
10161226|NCT03985735||Group poor sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).~Sleeping time are less than two hours."
10161227|NCT03985618|Active Comparator|Randomized Caesarean section|Randomized to planned pre-labour Caesarean section
10161228|NCT03985618|Active Comparator|Randomized Induction of Labour|Randomized to planned induction of labour
10161229|NCT03985618|Active Comparator|Preference Caesarean section|Preference for planned pre-labour Caesarean section
10161230|NCT03985618|Active Comparator|Preference Induction of Labour|Preference for planned Induction of Labour
10161231|NCT03985566|Experimental|Fibre Grains|Fibre grains were used to partially replaced Jasmine white rice in this arm.
10161232|NCT03985566|Placebo Comparator|Jasmine white rice|Jasmine white rice is used as a control to compare the outcome.
10161233|NCT03985488||Eview Fluoroscopy Machine|The Eview Fluoroscopy Machine is the standard of care fluoro machine used in endoscopy.
10161234|NCT03985488||Fluoroshield Device|The FluoroShield technology (Omega Medical Imaging) has been developed in an effort to further reduce the degree of radiation exposure to patients and provides. This technology is an additional component that can be fitted to the preexisting Eview fluoroscopy machines, in order to further filter radiation that has passed through the pre-existing machine.
10161235|NCT03985592|Other|Educational Intervention for ICU-Based Clinicians|ICU-based clinicians (e.g. physicians, RNs, and social workers) will be provided with educational modules related to bereavement support for family members. Following the modules a survey will be provided to participants to assess their perceived usefulness of the modules.
10161236|NCT03985592|Experimental|Educational material and personalized card of condolence|Members of the ICU team who cared for deceased ICU patients will be asked to send a letter of condolence to family members listed as the patient's primary contact and provide them with educational modules related to bereavement support for family members.
10161237|NCT03985592|Experimental|Virtual meeting with the care team to address unmet needs|At 8-12 weeks post-death, we will contact FMs and invite them to meet virtually with the care team. Our observational studies indicated that the most common need reported by bereaved FMs was the desire to meet with the care team to review events during the ICU stay and particularly the events that led to death, and that this was the type of support that ICU clinicians were most comfortable providing.
10161238|NCT03985592|Experimental|Offering a facilitated storytelling intervention session|At six months post-death, we will contact FMs and administer the Inventory of Complicated Grief-Revised (ICG-r), Brief Grief Questionnaire (BGQ), Impact of Events Scale - Revised (IES-r), Patient Health Questionnaire-9 (PHQ-9), and the Bereavement Dependency Scale (BDS). FMs who complete all questionnaires will be invited to participate in a 1-2-hour narrative exploration of their grief and bereavement experience, regardless of the severity of their symptoms. Those with severe symptoms will be notified of symptom severity, with a suggestion to participate in the narrative exploration of their grief and bereavement experience. Storytelling interventions require specialized resources but the results of Barnato et al., as well as the response to our qualitative interviews, suggest that this intervention may only be helpful for selected FMs. Storytelling interventions have been shown to reduce healthcare utilization and improve subjective health following a traumatic experience.
10161239|NCT03985683|Active Comparator|Control group|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
9974172|NCT01338558|Experimental|K-RAS native A|
9974173|NCT01338558|Active Comparator|K-RAS native B|
9977340|NCT01360372|Placebo Comparator|saline placebo injection|
10161240|NCT03985683|Experimental|Experimental (Nutritional Interventional)|In experimental group athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively. Average carbohydrates required for athletes are 6 to 10 gram per kilogram per day. T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test will use as baseline assessment and after 6 days of intervention.
9671351|NCT05049863|Experimental|Phase I Dose Level 1: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
9671352|NCT05049863|Experimental|Phase II: MMF + Irinotecan + Allopurinol|-Mycophenolate mofetil (MMF) will be administered at a dose of 1 g TID (3 g/day) on a daily basis (Days 1 through 21). Allopurinol will be administered at dose of 300 mg/day on a daily basis (Days 1 through 21). Irinotecan will be given at the assigned dose level on Days 1 and 8. Cycles are 21 days.
9671353|NCT05049707|Placebo Comparator|Control|The control arm will receive an equivalent volume of normal saline as the treatment group
9671354|NCT05049707|Experimental|IV magnesium|We will randomize patients in the treatment group to receive either a 50 mg/kg bolus of intravenous magnesium preoperatively followed by a magnesium infusion of 15mg/kg/hr, to be given after intraoperative neuromonitoring staff have been able to record baseline neurological data.
10161241|NCT03985995|Active Comparator|CBD 800 mg p.o.|The study Investigational Medical Product (IMP) is a cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration.
10161242|NCT03985995|Placebo Comparator|Placebo p.o.|Participants in the control arm will be receiving a single dose of oral placebo solution 8 ml matched to the active comparator.
10161243|NCT03985670|Experimental|treatment group|teripalimab 240mg d1 paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1
10161244|NCT03985670|Active Comparator|chemotherapy followed by immunotherapy|paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1 teripalimab 240mg d3
10161245|NCT03985722|Experimental|Unlimited cycles of Olaratumab and Trabectedin|"The study is a phase I, non-randomised, one-armed, multicenter trial, open-label,.~The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin."
10161246|NCT03985787|Experimental|All Participants|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
10161247|NCT03985709|Experimental|Probiotcal group|Probiotic (Lactobacillus casei) once daily taken by 3 months
10161248|NCT03985579|Experimental|Standard care and Kinesiology taping Group|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders.
10161249|NCT03985579|No Intervention|Standard care Group|Assistance in baby feeding, manual of device-assisted (lactator) milk expression, cold compress, ibuprofen, gentle breast massage, breathing and shoulder girdle exercise.
9520190|NCT03279757|Experimental|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
9671355|NCT05049668||RACE 1 patients|After exiting the RACE trial (NCT02099747) patient will be invited to participate in this study
9671356|NCT05049811|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
9671357|NCT05049811|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
10161250|NCT03985631|Experimental|Telerehabilitation|Tai Chi intervention by telerehabilitation (3-month intervention, three sessions per week: two supervised session and one unsupervised session).
10161251|NCT03985319|Experimental|YYD601 20mg|Esomeprazole IR 10mg + esomeprazole SR 10mg
10161252|NCT03985319|Active Comparator|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg. Astrazeneca
9671358|NCT05049447|Active Comparator|Verum arm|Intervention: Drug: Verum (Pascoflair)
10161253|NCT03985410|Experimental|Treatment Sequence ABC|Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
10161254|NCT03985410|Experimental|Treatment Sequence ACB|Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
9671359|NCT05049447|Placebo Comparator|Placebo arm|Intervention: Drug: Placebo
9671360|NCT05049889|Active Comparator|History of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
9520191|NCT03279757|Other|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
10161255|NCT03985410|Experimental|Treatment Sequence BAC|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
10161256|NCT03985410|Experimental|Treatment Sequence BCA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
10161257|NCT03985410|Experimental|Treatment Sequence CAB|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
10161258|NCT03985410|Experimental|Treatment Sequence CBA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
10161259|NCT03985202|Experimental|Structured Exercise Programme|"An initial 45 min exercise counselling incorporating behaviour modification techniques.~Participants will be offered three sessions per week of aerobic interval exercise on a cycle ergometer over nine weeks. Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.~Following this:~Participants will be encouraged to comply with current physical activity recommendations: 150 min of moderate intensity aerobic exercise per week (brisk walking / cycling). They will also be sign posted to local exercise facilities."
10161260|NCT03985280|Experimental|Cooled radiofrequency|The procedure will be performed under regimen of major ambulatory surgery, it will be done under guidance of combined X-ray and ultrasound. . The nerves will be located b, after applying AL (Lidocaine 1%), a RF needle will be placed in the objective position.After verifying the positive sensitive and negative motor responses the cooled radiofrequency will proceed (previous application of local anesthesia (lidocaine 2%)). Cooled RF will be performed for 2:30 minutes at 60 degrees.
10161261|NCT03985280|Active Comparator|Intraarticular local anesthetic and steroids injections|An intraarticular injection will be done in ambulatory surgery regimen with a 22 Gauge needle. Intraarticular injection will be done under Fluoroscopic guidance (X-rays) with intra articular position confirmation by infusion of iodine contrast (Omnipaque 240). Once the needle position has been verified we will administer 10 mg of bipuvacaine, and 40 mg triamcinolone hexacetonide.
10161262|NCT03985176||Aneurysmal SAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
10161263|NCT03985475||Person with a skin infection|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
10161264|NCT03985228|Experimental|Fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks.
9671361|NCT05049889|Active Comparator|No history of Immersion Pulmonary Edema|"The participants will have 2 visits:~At visit 1 (Day 0), the participants will perform a terrestrial exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected.~At visit 2 (Day 7), the participants will perform a swimming exercise, have a transthoracic cardiac ultrasound, a transthoracic pulmonary ultrasound and several blood samples will be collected."
10161265|NCT03985228|Placebo Comparator|Placebo milk|The subjects assumed daily 250 ml of placebo milk for 12 weeks.
10161266|NCT03985553|Other|Parenting Self-Management Program|Participants were provided a Parenting Self -Management Program booklet with the twenty-four fact sheets at the beginning of the four-week program on topics such as adaptive babycare techniques, advocacy in the courts, emergency planning, safety in the community, talking to children about disability, managing pain/fatigue, connecting to other parents with SCI/D, and wheelchair adjustment/management during and after pregnancy. Sessions included topic introduction, participant interaction, goal setting, resource utilization, and program evaluation. Participants were allowed to choose which resources they wanted and what tips to incorporate into their parenting roles. Participants were asked to develop a weekly goal to encourage achievement, allowing individuals to identify what they wanted or decided to do that could be related to parenting directly or indirectly, such as health and wellness goals that gave them more energy or strength to complete parenting tasks.
10161267|NCT03985423|Experimental|Emapalumab|
10161268|NCT03985254|Active Comparator|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
9671362|NCT05049486|No Intervention|MRI sequences and (DTI)|The aim of this study is to obtain finer details of tissues surrounding a lead in the pelvis using a combination of high resolution anatomical MRI sequences and diffusion tensor imaging (DTI). To do so, the patient will undergo a MRI scan (3 Tesla) of the pelvis using sequences including anatomical sequences and diffusion tensor imaging technique for construction of sacral nerve tractography prior to permanent SNS. This will be performed over an hour: first 30 minutes for anatomical sequences and the second 30 minutes for DTI sequencing.
9520192|NCT03279744|Experimental|Single-Arm|Radion™-pdt
9671363|NCT05049486|Active Comparator|CT scan|Three to 4 weeks after the procedure the patient will undergo a limited CT scan of the pelvis to visualise the position of the SNS lead. The scan will focus only on the sacrum, implanted lead, and rectum and will not be extended beyond this area. Imaging from this CT will be superimposed to the MRI imaging the patient had pre-operatively, and a computational simulation will be performed.
9671364|NCT05049785|Active Comparator|Arm I (counseling)|Patients attend 13 nutrition counseling sessions over 45 minutes each for 1 year. Patients may receive nutrition handouts.
9974174|NCT01338571||Healthly children|Children will be given yogurt twice a day for four weeks. The dose for an adult is 8 ounces of yogurt twice a day. The dose will be scaled to the children based upon surface area dosing charts, but will not exceed a resistant starch load of 1 gram per year of age plus 10 grams10.
9974175|NCT01338584|Experimental|Pelvic floor muscle training, post prostatectomy|Pelvic floor muscle training will be taught on the day of admission
9974176|NCT01338597|Experimental|standard|3 trocars are needed. two in the circumareolar region and one in the parasternal region. the dissection area begins from the trocar site and extends to the neck.
9974177|NCT01338597|Experimental|limited dissection|the dissection is reduced by creating a long tunnel from the trocar site and the dissection area confined in the upper chest wall and in the neck.
9974178|NCT01338623|Experimental|Tansulosine|
9974179|NCT01338662||Group A-1|"study enroll number 3n+1 (N=0,1,2...)~initial treatment- amantadine~add levodopa when the patient become to need further treatment."
9974180|NCT01338662||Group A-2|"study enroll number 3n+2 (N=0,1,2...)~initial treatment: amantadine~add dopamine agonist when the patient become to need further treatment."
9974181|NCT01338662||Group B|"study enroll number 3n+3 (N=0,1,2...)~initial treatment: dopamine agonist~add levodopa when the patient become to need further treatment. but cannot use amantadine"
9974182|NCT01338675|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
9974183|NCT01338688||Td ,Td and TIG|
9974184|NCT01338701|Experimental|Auricular (Ear) Acupuncture|Auricular (Ear) Acupuncture is administered in a step-wise, algorithmic acupuncture approach in which needles are inserted at specific auricular landmarks. The sequence and location of needled points is determined by the participant's severity of headache pain at presentation and response to needling. Between six and nine points are needled in each treatment session depending on the individual's response (i.e., a decrease or persistence of headache pain). In-dwelling ASP needles are inserted at the end of each session. Participants are instructed to remove the needles after 3 days, or sooner if pain or redness developed at a needle site. Ten 45-minute acupuncture treatment sessions are administered over 6 weeks.
9974185|NCT01338701|Experimental|Traditional Chinese Acupuncture (TCA)|A semi-standardized form of Traditional Chinese Acupuncture (TCA) is administered, incorporating the insertion of up to 22 acupuncture needles associated with each individual participant's: (1) primary headache pattern (up to three pairs of points); (2) secondary headache pattern (up to 2 pairs of points); (3) Ah-Shi or tender points (up to 4 points); (4) constitutional points (source points on two meridians); and, (5) up to 2 pairs of additional points from a selected list. Point selection was reassessed every two weeks per TCM diagnostic and treatment principles. While the majority of points were located on the limbs, points also included local points of tenderness to the head, as well as the front and back of the torso. Ten 60-minute TCA sessions are administered over 6 weeks.
9974186|NCT01338701|Other|Usual Care|All study participants continue to receive routine usual care for their TBI, headaches and associated symptoms as determined by their clinical team.
9974187|NCT01338714|Experimental|A foumula|Compound Herbal Formula (RHD-1)
9974188|NCT01338714|Placebo Comparator|B formula|dilute Compound Herbal Formula
9974189|NCT01338727|Experimental|Breastfeeding Peer Counseling|
9974190|NCT01338727|No Intervention|Standard Care|
9974191|NCT01338740||Switch from Adalimumab to Infliximab|Moderately to severely active Crohn's disease patients with primary non-response or loss of response to Adalimumab, will switch to Infliximab.
9974192|NCT01338766|Experimental|Surgery|Decompression using the iO-Flex® system
9974193|NCT01338779||Group 1 - kidney tolerant|Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).
9974194|NCT01338779||Group 2 - acceptor|Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) < 40 mL/min and/or creatinine > 50% above baseline value, and thus did not qualify for group 1.
9974195|NCT01338779||Group 3 - kidney graft loss|Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.
9974196|NCT01338779||Group 4 - kidney monotherapy|Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).
9974197|NCT01338779||Group 5 - kidney standard immunotherapy|Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.
9974198|NCT01338779||Group 6 - kidney chronic rejector|Enrollment for group 6 is closed. Chronic allograft nephropathy group.
9974199|NCT01338779||Group 7 - kidney identical twin|Enrollment for group 7 is closed.
9974200|NCT01338779||Group 8 - living kidney donors|Corresponding to recipients in group 1 or 4.
9974201|NCT01338779||Group 9 - healthy controls|Enrollment for group 9 is closed.
10186236|NCT03737656|Experimental|Progesterone Vaginal Ring (Group C)|Insertion of the vaginal ring on Day 1, removal for 4 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
10186237|NCT03737630|Experimental|GExp|This group will perform the inspiratory muscle training with moderate load
9974202|NCT01338779||Group 10 - liver tolerant|Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).
10161269|NCT03985254|Experimental|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
10161270|NCT03985449|Other|Active Implementation phase|See the 'detailed description' section to read about the intervention(s) clinicians will use during the active implementation phase of the randomized stepped-wedge design.
10161271|NCT03985397|Experimental|Experimental group (EG)|At the first interview, after the application of the scales to the intervention group patients, planned discharge training and the manual prepared by the researcher were given. The second interview was performed 4 weeks later and the same scales were reapplied.
10161272|NCT03985397|No Intervention|Control group|In the first interview, scales were applied to the control group patients but planned discharge training was not given. The second interview was carried out 4 weeks later, and after the same scales were reapplied to the control group patients, planned discharge training was given. Therefore, the right of individuals to get education was not prevented.
10161273|NCT03985436|Experimental|Trek for Surgical Success|Cognitive behavioral therapy for pain
10161274|NCT03985124|Experimental|Intervention TIK-T|24 kindergartens will receive the full intervention. Dosage: 1 3 hour implementation session for kindergarten leaders; 1 x 2-day training workshop for kindergarten leaders and a lead resource person in each kindergarten who will support teachers in learning and implementing Emotion Coaching with children; 2 full training days for all teachers/childcare workers in Emotion Coaching; 2 x booster sessions for all teachers with the resource person in their kindergarten to assist them in using Emotion Coaching with children in their kindergartens.
10161275|NCT03985124|No Intervention|wait list control|24 kindergartens will be in the 12-month wait list condition
10161276|NCT03985241|Experimental|Functional Assessment of Myocardial Ischemia by icECG|Evaluation of ST-Shifts in the icECG acquired downstream of a coronary lesion during pharmacologic inotropic stress using dobutamine (40mcg/kg/min).
10161277|NCT03985345|Experimental|EMY Probe|
10161278|NCT03985137||HIV-infected patients|Male patient presenting at a follow-up consultation for HIV infection or following a Sexual Viral Exposure (EVA) accident, pre-exposure prophylaxis (PrEP) or screening for a Sexually Transmitted Infection (IST).
10161279|NCT03985059||Cases|Patients with ischemic stroke or transient ischemic attack who have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
10161280|NCT03985059||Controls|Patients with ischemic stroke or transient ischemic attack who do not have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
10161281|NCT03985514|Active Comparator|Antibiotic treatment|Patients will receive in-hospital intravenous antibiotics (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3). Surgery if no symptom relif occur.
10161282|NCT03985514|Other|Clinical observation|"Patients are followed by in-hospital Active observation (watchful waiting) according to clinical routine. Patients are observed until either, recovery and dismissal from hospital, or decision for intervention (surgery) is taken."
10161283|NCT03985306|Experimental|Feasibility trial group|Every trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
10161284|NCT03985462|Experimental|VSEL Max|A total of 300,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a high dose group
10161285|NCT03985462|Experimental|VSEL Medium|A total of 200,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a middle dose group
10161286|NCT03985462|Experimental|VSEL Mini|A total of 100,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a low dose group
10161287|NCT03985462|No Intervention|Control|5 mL plate-rich plasma with no cells inside were injected into the bilateral fallopian tubes as a control group
10161288|NCT03985111||No CVC inserted|Patients undergoing major elective colorectal resection without central venous catheter inserted pre-operatively
10161289|NCT03985111||CVC inserted|Patients undergoing major elective colorectal resection with a central venous catheter inserted pre-operatively
10161290|NCT03985046|Experimental|Sintilimab plus chemotherapy|
10161291|NCT03985020|No Intervention|Standard of Care|The control group will receive standard of care dietary advice for their solid food and beverage intake.
10161292|NCT03985020|Active Comparator|Water Intervention|We will order and deliver bottled water to the homes of subjects in the treatment group. We will provide each participant with a weekly supply of about 36 16.9 fl oz single-serving containers. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously.
10161293|NCT03985020|Experimental|Stevia Intervention|We will order and deliver a commercially-available stevia-sweetened soft drink Zevia (Los Angeles, CA) to each participant in the treatment group. We will provide each participant with a weekly supply of 24 12 fl oz single-serving containers. Zevia will be provided in an assortment of flavors for the first week, then catered to the preference of the participant for the remainder of the study. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously. Participants will also be asked to keep track of how many containers they consume using a sticker chart, and we will also phone parents weekly to verify the sticker charts
10161294|NCT03985098|Experimental|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
10161295|NCT03985098|No Intervention|Control|usual care
10161296|NCT03984903|Active Comparator|Face-to-face Learning Group|
10161297|NCT03984903|Experimental|Multimedia Learning Group|
9977341|NCT01360385||Central Retinal Vein Occlusion|CRVO-patients with planned treatment with intravitreal injections of ranibizumab, who receive three monthly injections of ranibizumab and a 3 month follow-up period, during which ranibizumab injections are provided as needed.
10161298|NCT03985358|No Intervention|Control Group|Patients randomized to the Control Group will not receive opioid counseling and will only receive their standard of care instructions for preoperative and postoperative care.
10161299|NCT03985358|Experimental|Treatment Group|Patients randomized to the Treatment Group will have opioid counseling plus standard of care instructions given by the same counselor (investigator on the study) using the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher).
10161300|NCT03984773|No Intervention|Control|Clinicians will receive current standard communications regarding serious illness performance.
10161301|NCT03984773|Experimental|Mortality Estimates and Nudges|Clinicians will receive a weekly email with upcoming patients that have high mortality estimates to consider for a serious illness conversation. Clinicians will have the opportunity to review the list and pre-commit (using an opt-out design) to patients appropriate for a conversation. They will receive a nudge on the day of the patient visit through a text message reminding them of their pre-commitment to conduct a serious illness conversation
10161302|NCT03984929|Experimental|Localized Information Resource Intervention|
10161303|NCT03984929|Active Comparator|Generic Information Resource Intervention|
10161304|NCT03984955|Active Comparator|Group A PRP injection|"Platelet-Rich Plasma injection Single therapeutic injection of Platelet-Rich Plasma performed under ultrasound guidance.~This group will also undergo a class-based physiotherapy intervention. This outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and those receiving the sham injection."
10161305|NCT03984955|Active Comparator|Group B Ostenil Tendon|Sodium hyaluronate with mannitol (Ostenil Tendon) Single therapeutic injection of sodium hyaluronate with mannitol (marketed under the device name Ostenil Tendon) under ultrasound guidance. This group will also undergo a class-based physiotherapy intervention.
10161306|NCT03984955|Sham Comparator|Group C control group|Subcutaneous sham injection. This group will also undergo a class-based physiotherapy intervention. The outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and to those receiving PRP injection.
10161307|NCT03984695|No Intervention|Control|"15 minute discharge planning session with health educator~Health education booklet containing SHE-Women intervention content in print form(N~100)~access to health educator via text message"
10161308|NCT03984695|Experimental|Intervention|"Deliver text-Web intervention to (N ~100) women~Researchers will deliver the integrated, multimedia electronic women's health literacy intervention arm of SHEWomen in text-Web format for individuals recently released from jail. Two health educators will be responsible for delivering content to participants, with an estimated contact time of ~10 hours pushed to participants over approximately a 5-day period."
10161309|NCT03984643|Experimental|Deep Brain Stimulation|Subjects in this study will have been implanted with a DBS lead in the VIM as part of their routine clinical care and have an existing set of brain MRI's.
10161310|NCT03984656|Active Comparator|AL group|patients will receive a local infiltration of 10 mL Lidocaine without epinephrine 20 mg/mL
10161311|NCT03984656|Experimental|Serratus group|patients will receive ultrasound guided serratus plane block injection of 30 mL Ropivacaine 4.75 mg/mL
10161312|NCT03984747||Adult Transplant Patients|Adult subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
10161313|NCT03984747||Pediatric Transplant Patients|Pediatric subjects between ages 2-17 who have undergone at least one organ transplant prior to enrollment and are willing to provide assent/LAR is willing to provide consent.
10161314|NCT03984747||Pregnant Transplant Patients|Pregnant subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
10161315|NCT03984877||Amyloidosis|TAVI patients with diagnosis of amyloidosis
9520193|NCT03279705|Experimental|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
9520194|NCT03279705|Active Comparator|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
10161316|NCT03984877||Non-Amyloidosis|TAVI patients without diagnosis of amyloidosis
10161317|NCT03984799|Experimental|Bronchoscopy|Research bronchoscopy
10161318|NCT03984864|Experimental|Exercise therapy Chosen|
10161319|NCT03984864|Active Comparator|Exercise therapy no Chosen|
10161320|NCT03984630|No Intervention|Control Arm|Participants were informed to continue to receive usual care by their Obstetrician and were asked to send in body weights weekly.
10161321|NCT03984630|Experimental|Intervention Arm|Received snacks high in fiber, attended weekly phone calls, recorded daily food intake and reported weekly body weight for 12 weeks.
10161322|NCT03984760|Experimental|Ferric Citrate Capsule|Ferric Citrate Capsule, product specification: 500 mg/cap, manufactured by Panion & BF Biotech Inc.
10161323|NCT03984760|Active Comparator|Sevelamer Carbonate Tablet|Sevelamer carbonate tablet group, product specification: 800 mg/tablet, manufactured by Genzyme Ireland Limited
10161324|NCT03984734|Active Comparator|Control group|Patients undergoing pancreatoduodenectomy with antrectomy
10161325|NCT03984734|Experimental|Study group|Patients undergoing pancreatoduodenectomy with pylorus-preserving pancreatoduodenectomy
10161326|NCT03984721|Experimental|Amylose typing|Amyloidosis typing by nanoLC-MS/MS in patients diagnosed with Amyloidosis but unable to be typed
10161327|NCT03984591|Active Comparator|Spironolactone|Spironolactone used according to heart failure guidelines
10161328|NCT03984591|Active Comparator|Eplerenone|Eplerenone used according to heart failure guidelines
10161329|NCT03984708|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
10161330|NCT03984708|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
9520195|NCT03279692|Experimental|Pembrolizumab|"Pembrolizumab will be administered every 3 weeks~Pembrolizumab will be administered through IV infusion"
9520196|NCT03279679|Experimental|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
10161331|NCT03984578|Experimental|Colon cancers|Pre-operative CAPEOX 1 cycle Pre-operative Pembrolizumab 2 cycles with cycle 1 on Day 1 (concurrent with start of CAPEOX) and cycle 2 on Day 22
10161332|NCT03984578|Experimental|Rectal Cancers|Following completion of neo-adjuvant chemo-radiotherapy, 2 cycles of pre-operative Pembrolizumab administered 3 weeks apart.
10161333|NCT03984604|Active Comparator|CHI-921|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (CHI-921) for 3 weeks, followed by another 3 weeks of treatment at 1.0 mL for and another 3 weeks of treatment at 2.0 mL.
10161334|NCT03984604|Placebo Comparator|Placebo|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (placebo) for 3 weeks, followed by another 3 weeks of placebo treatment at 1.0 mL for and another 3 weeks of placebo treatment at 2.0 mL.
10161335|NCT03984539|Active Comparator|CBT-E|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). CBT-E will occur over the course of 25 weeks and be delivered as it typically is in the clinic setting of the investigators.
10161336|NCT03984539|Experimental|CBT-T|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). Participants who agree to participate will receive 10 weeks of CBT-T.
10161337|NCT03984682|Experimental|Experimental group|Patients will benefit from regular care + Joint Crisis Plan
10161338|NCT03984682|No Intervention|Control group|Patients will benefit from regular care
10161339|NCT03984526|Placebo Comparator|Control group|intravenous normal saline pretreatment
10161340|NCT03984526|Experimental|Atropine group|intravenous atropine 0.5mg pretreatment
10161341|NCT03984526|Experimental|Ephedrine group|intravenous ephedrine 8mg pretreatment
10161342|NCT03984500|Other|Education|"During phase 1 of this study parents who attend in person education sessions will be recruited to have their standard sessions video-taped, timed, and reviewed by the SCTaware Team. Subjects will complete before and after education questionnaires that will then be reviewed to see how much participants learned about SCT, how education was not clear and/or appropriate (too much medical jargon). The SCTaware education will then be created based on review of these videos and participants' survey responses.~For phase 2 of the study, the same recruitment strategy will be utilized. Participants will receive SCTaware and complete before and after questionnaires for evaluation. Participants in this phase will also complete follow-up questionnaires at 1 and 6 months."
10161343|NCT03984461|Active Comparator|Group A - PRP plus Lipoaspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate). Total Volume varies by joint.
10161344|NCT03984461|Active Comparator|Group B - PRP plus Bone Marrow Aspirate|Equal proportions of PRP plus bone marrow aspirate. Total Volume varies by joint.
10161345|NCT03984461|Active Comparator|Group C - PRP plus Lipoaspirate plus Bone Marrow Aspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate) plus bone marrow aspirate. Total Volume varies by joint.
10161346|NCT03984188|Experimental|Low-dose Theophylline Group|Participant in this group will receive low-dose theophylline in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment, over a one year period.
10161347|NCT03984188|Placebo Comparator|Placebo Group|Participant in this group will receive a placebo in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment.
10161348|NCT03984318|Experimental|patient treated with immune checkpoint targeted monoclonal AB|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
10161349|NCT03984370|Experimental|80 ug of sc dasiglucagon|80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
10161350|NCT03984370|Experimental|200 ug of sc dasiglucagon|200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
10161351|NCT03984370|Placebo Comparator|0.4 mL of sc saline (placebo)|0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
10161352|NCT03984331|Experimental|Fish skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.
10161353|NCT03984331|Active Comparator|Cadaver skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.
10161354|NCT03984292|Experimental|Mass Learning|Single teaching session of 3 hours shall be provided
10161355|NCT03984292|Experimental|Distributed Learning|Three teaching sessions of 1 hour each shall be provided.
10161356|NCT03984201|Active Comparator|iTBS over L-DLPFC to dACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the dorsal anterior cingulate cortex (dACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
10161357|NCT03984201|Active Comparator|iTBS over L-DLPFC to sgACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the subgenual cingulate cortex (sgACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
10161358|NCT03984201|Sham Comparator|Sham iTBS over L-DLPFC|"Participants will receive sham iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system.~Sham stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
10161359|NCT03984227||SLE patient group|SLE diagnosed patients between (18- 60) years old will be enrolled. All participants should met at least four of the American College of Rheumatology criteria (Hochberg, 1997). Disease activity will be assessed in accordance with the SLE Disease Activity Score (SLEDAI 2000 (SLEDAI-2K) (Ward et al., 2000).
10161360|NCT03984227||control group|The control group will include age and sex matched healthy volunteers
10161361|NCT03984253||Severe Asthma|All patients with severe asthma who will be treated in the participating centers should be continuously enrolled in the register.
10161362|NCT03984175|Experimental|Patients with ARDS at three Intermountain tertiary hospitals|
10161363|NCT03984435||Patients|Patients with a diagnosed malignancy who have been referred for radiotherapy with extended treatment time (>10 minutes)
10161364|NCT03984435||Radiographers|Radiographers from radiotherapy departments in the UK who deliver radiotherapy
9974203|NCT01338779||Group 11 - liver standard immunotherapy|Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.
10161365|NCT03984409|Active Comparator|Group 1|Potassium citrate x 7days Off therapy x 7 days 500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Return to potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
10161366|NCT03984409|Active Comparator|Group 2|500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Off therapy x 7 days Potassium citrate x 7days Continue on potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
10161367|NCT03984422||Raynaud phenomenon|Use of smartphone application
10161368|NCT03984344|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
10161369|NCT03984344|Experimental|Active cTBS|Continuous TBS will be delivered at 80% of RMT and will be applied as 600 pulses in a 40-second train of uninterrupted 50Hz bursts to the right dorsolateral prefrontal cortex.
10161370|NCT03984344|Sham Comparator|Sham TBS|Sham stimulation will be given at the right or left dorsolateral prefrontal cortex (counterbalanced) for 40 seconds or 3 minutes and 9 seconds (counterbalanced), at the same frequency as active TBS (50Hz), however a sham coil will be used.
10161371|NCT03984279||Sequentiel group (SEQ)|
10161372|NCT03984279||Siral group (SPI)|
10161373|NCT03984383||Lung-derived endothelial cells|Every patient of more than 18 years undergoing lung cancer surgery in the department of thoracic surgery of the University Hospital of Lille.
10161374|NCT03984383||Umbilical cord-derived endothelial cells|Every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.
10161375|NCT03984123|Other|Double cuff inflation|The first arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end-diastolic volume of left ventricle
10161376|NCT03984123|Other|Single cuff inflation|The second arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
10161377|NCT03984123|No Intervention|Standard treatment|The third arm utilizes no cuff inflation to cause remote conditioning and serves as control group. Follow up echocardiography is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
10161378|NCT03984474||Single bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
10161379|NCT03984474||Double bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
10161380|NCT03984110|Experimental|Combination of Ozurdex and Eylea|Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
10161381|NCT03984110|Active Comparator|Eylea Monotherapy|Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
10161382|NCT03984149||FH pediatric patients|1000 clinically diagnosed FH pediatric patients (age <18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database
10161383|NCT03984136|Experimental|Intervention group|Men will be required to exchange the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends conditionally.
10161384|NCT03984136|Active Comparator|Control group|Men will share the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends freely without conditional exchange requirement.
10161385|NCT03984357|Experimental|PD-1 blocking antibody combined with IC+IMRT|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blocking antibody (360 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of PD-1 blocking antibody are administrated concurrently with IC and IMRT, respectively. After 4 weeks of the completion of IMRT, adjuvant PD-1 blocking antibody (480 mg per cycle) will begin every 4 weeks for 6 cycles.
9974204|NCT01338831|Experimental|Breast & Prostate Cancer Group|Dose Escalation
10161386|NCT03984097|Experimental|Treatment Phase: TAK-079 and LenDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with lenalidomide, orally, once daily for 21 days and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until progressive disease (PD) or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are greater than (>) 75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
10161387|NCT03984097|Experimental|Treatment Phase: TAK-079 and VRd|TAK-079 subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with bortezomib, subcutaneously, once on Days 1, 8, and 15, for a maximum of 8 cycles, lenalidomide, orally, once daily for 21 days, and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until PD or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to 2 years. The dosage of dexamethasone can be reduced for participants who are >75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
10161388|NCT03984097|Experimental|Safety Extension Phase: TAK-079 and, if applicable, backbone therapy (LenDex, VRd, or PomDex)|TAK-079 dosing and, if applicable, backbone therapy will be administered as per the schedule outlined in the parent study.
10161389|NCT03983954|Experimental|Naptumomab estafenatox 2 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 2 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161390|NCT03983954|Experimental|Naptumomab estafenatox 5 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 5 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161391|NCT03983954|Experimental|Naptumomab estafenatox 10 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161392|NCT03983954|Experimental|Naptumomab estafenatox 15 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161393|NCT03983954|Experimental|Naptumomab estafenatox 20 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161394|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 10 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161395|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 15 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161396|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at MTD and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161397|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP, at the previous dose level, and durvalumab|NAP, at the previous dose level, and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
10161398|NCT03983967|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Cytokine-Induced Killer cells; Immuncell-LC) 3 times(3 treatments at a frequency of once per week) or 6 times(3 treatments at a frequency of once per week followed by 3 treatments every 2 weeks)
10161399|NCT03984019|Other|A|Radiotherapy; SBRT Additional cardiac diagnostics
10161400|NCT03983889|Experimental|F|Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance
9974205|NCT01338831|Experimental|Breast Cancer Group|Dose Expansion
9671365|NCT05049785|Experimental|Arm II (nutrition and PA intervention)|Patients attend 2 tasting sessions for low-fat and low-sugar recipes and complete 2 PA sessions over 1 hour for each session.
9671366|NCT05049577|Placebo Comparator|Control group|To maintain blinding, in the control group, the remifentanil infusion was replaced with 50 ml of normal saline in 50 ml syringe. The remifentanil (or saline) infusion was run until the pump indicated the target Ce had been achieved. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia in all patients was induced using 2 mg/kg of 2% propofol. The attending anesthesiologist asked the patients how they felt pain to evaluate pain severity of PIP while half -dose of propofol was administered. After the rest of the propofol was administered, the attending anesthesiologists asked the same question.
9671367|NCT05049577|Experimental|Remifentanil group|Remifentanil 1 mg was diluted into 50 ml of normal saline. A commercial TCI pump (Orchestra Base Primea, Fresenius Vial, France) was used for the effect-site TCI of remifentanil. The study groups received remifentanil to a target Ce of 4 ng/ ml. Pharmacokinetic model for remifentanil was the Minto model (Height, Weight, and Age) Anesthesia induction and the evaluation of pain were same as control group
9671368|NCT05049408||Group OSCC|Patients with Oral Squamous Cell Carcinoma (OSCC)
9974206|NCT01338831|Experimental|Prostate Cancer Group|Dose Expansion
9974207|NCT01338831|Experimental|Uterine Leiomyoma Group|Dose Expansion
9974208|NCT01338844|Experimental|D-Chiro-inositol|Patients will receive 1.2g/day of D-chiro-inositol
9974209|NCT01338844|Active Comparator|Myo-inositol|Patients will receive 4g/day of myo-inositol
9974210|NCT01338896|Experimental|Sequence A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)
9974211|NCT01338896|Experimental|Sequence B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)
9974212|NCT01338909|Experimental|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
9974213|NCT01338909|Active Comparator|Clopidogrel|Clopidogrel 150mg/day starting from Day 1 until Day 5
9974214|NCT01338922|Experimental|Insulin pump therapy (CSII)|Continuous subcutaneous insulin infusion therapy using different devices with marketing approval and different insulins
9974215|NCT01338922|Active Comparator|Multiple daily injection therapy (MDI)|Multiple daily injection therapy using different devices with marketing approval and different insulin types
9974216|NCT01338935|Experimental|Part I|Ascending dose tolerance, PK, and estimation of ED95 for CW 002
9974217|NCT01338935|Experimental|Part II|Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal
9974218|NCT01338935|Experimental|Part III|Intubation with CW 002 and Neostigmine reversal
9974219|NCT01338961|No Intervention|Normothermic CPB|Standard management. Patients will be kept at normothermia throughout the procedure (>36oC).
9974220|NCT01338961|Active Comparator|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
9974221|NCT01339026|Active Comparator|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
9974222|NCT01339026|Active Comparator|Clopidogrel|Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
9974223|NCT01339039|Experimental|Part 1|Maximum Tolerated Dose Determination of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
9974224|NCT01339039|Experimental|Part 2|Surgical Arm: Safety evaluation of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
9974225|NCT01339039|Experimental|Part 3|Safety and tolerability of Plerixafor (daily) at MTD dose from Part 1 and Bevacizumab (every 2 weeks)
9974226|NCT01339065|Active Comparator|Ketamine|will be given low sub-anesthetic doses of Ketamine 0.5mg/kg.
9974227|NCT01339065|Placebo Comparator|Placebo|will get placebo treatment
9974228|NCT01339078|Active Comparator|Plastic stenting|Patients will be randomized towards plastic stenting.
9974229|NCT01339078|Experimental|Kaffes stenting|Patients will be randomized towards Kaffes stenting.
9974230|NCT01339104|Experimental|Regorafenib|
9974231|NCT01339117|Experimental|High fermentable substrate diet|High fermentable substrate diet provided for two days
9974232|NCT01339117|Experimental|Low fermentable substrate diet|Low fermentable substrate diet provided for two days
9974233|NCT01339130|Other|behavioral and physiological tests|Computerized tests and Electrophysiological measurements
9974234|NCT01339143|Active Comparator|Pioglitazone|pioglitazone: 15mg, QD, PO, 16 weeks
9974235|NCT01339143|Experimental|vildagliptin|vildagliptin 50mg,BID,PO,16 weeks
9974236|NCT01339156|Experimental|P3914|
9974237|NCT01339156|Placebo Comparator|Placebo|
9974238|NCT01339169|Experimental|YF476 treatment|
9974239|NCT01339182|Experimental|Pegylated-Somatropin, 10mcg/kg|
9974240|NCT01339182|Experimental|Pegylated-Somatropin, 30mcg/kg|
9974241|NCT01339182|Experimental|Pegylated-Somatropin, 60mcg/kg|
9974242|NCT01339182|Experimental|Pegylated-Somatropin, 120mcg/kg|
9974243|NCT01339182|Experimental|Pegylated-Somatropin, 200mcg/kg|
9974244|NCT01339195|Experimental|Behavioral|Behavioral: French adaptation of NINDS-Canadian Stroke Network battery
9974245|NCT01339208|Experimental|Telemedicine Diabetes Intervention|
9974246|NCT01339221||Cohort A|Children confirmed with G1 and/or P[8] cases from the RotaBel study
9974247|NCT01339221||Cohort B|Children hospitalized for severe gastroenteritis in the study hospitals and tested positive for rotavirus
9974248|NCT01339234|Experimental|Body-weight supported treadmill training|
9974249|NCT01339286|Experimental|atomoxetine|
9974250|NCT01339312|Experimental|VRVg Vaccine Group 1|Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
9974251|NCT01339312|Experimental|VRVg Vaccine Group 2|Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
9974252|NCT01339312|Active Comparator|Verorab Vaccine Group 1|Participants aged 18 years or older will receive Verorab Vaccine
9974253|NCT01339312|Active Comparator|Verorab Vaccine Group 2|Participants aged 10 to 17 years will receive Verorab Vaccine
9671369|NCT05049408||Group OPMD|Patients with oral potentially malignant disorders (OPMD)
10161401|NCT03983889|Experimental|DR|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
10161402|NCT03983889|Experimental|DF|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance
10161403|NCT03983889|Experimental|PR|Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
10161404|NCT03983811|Experimental|Chemotherapy+Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
10161405|NCT03983811|Placebo Comparator|Chemotherapy+Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
10161406|NCT03983746|Experimental|traditional physical therapy program (control group)|fifteen children with DS received a traditional exercises program with instructions to the children for 60 minutes aiming to improve posture control and balance
10161407|NCT03983928|Experimental|TQB2450 Combined with Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10161408|NCT03983902|Active Comparator|Delayed cord clamping|Delayed cord clamping
10161409|NCT03983902|Active Comparator|Umbilical cord milking|Umbilical cord clamping
10161410|NCT03983902|Active Comparator|Immediate cord clamping|Immediate cord clamping
9520197|NCT03279679|Other|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
10186238|NCT03737630|Active Comparator|GCon|This group will initiate inspiratory muscle training with low load
10186239|NCT03737617|Experimental|Active arm|Weekly subcutaneous immunoglobulin therapy (0.1g/Kg) Cuvitru 20% Injectable Solution for 1 Year
10186240|NCT03737617|No Intervention|Control|Standard Care arm without immunoglobulin replacement therapy
10186241|NCT03737578|Experimental|Daily hemodialysis patients|"Description: End stage renal disease patients starting daily hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
10186242|NCT03737578|Active Comparator|Conventional hemodialysis patients|"Description: End stage renal disease patients currently treated by conventional hemodialysis or starting conventional hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
9974254|NCT01339325|Active Comparator|LESS cholecystectomy|Laparo-endoscopic single site cholecystectomy, the entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
10186243|NCT03737552||Children and adolescents with ADHD|Children and Adolescents with ADHD children or Adolescents, male or female, ages 6-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
10186244|NCT03737552||Healthy control children and adolescent|children or Adolescents, male or female, ages 6-17,medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
10186245|NCT03737539||Stage II colorectal cancer|Patients diagnosed with stage II colorectal cancer
10186246|NCT03737539||Stage III colorectal cancer|Patients diagnosed with stage III colorectal cancer
10186247|NCT03737474|Experimental|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
10186248|NCT03737448|Experimental|Group 1|"AD with serum creatinine ≥ 1 and < 2 mg/dL, OR~ACLF 1 with~liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~liver failure and West Haven grade 1-2 hepatic encephalopathy, or~coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR~ACLF 2 with~liver failure and coagulation failure, or~liver failure and West Haven grade 3-4 hepatic encephalopathy."
10186249|NCT03737448|Experimental|Group 2|"ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR~ACLF 2 with~liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or~coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL)."
10186250|NCT03737422|Active Comparator|hesperidin and flaxseed|
9974255|NCT01339325|Active Comparator|Standard LAP-CHOLE|Standard laparoscopic cholecystectomy. The entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
10186251|NCT03737422|Placebo Comparator|control|
9671370|NCT05049408||Group HC|Healthy Control
9671371|NCT05049239|Experimental|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.
9671372|NCT05049239|Active Comparator|Physical training combined with cognitive support|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks.~The cognitive support consists of person centred individual occupational therapy."
9671373|NCT05049239|No Intervention|Control group|The control group receive no intervention.
9520198|NCT03279666|Active Comparator|tenaculum with intracervical blockage|
9520199|NCT03279666|No Intervention|No tenaculum with intracercical blockage|
10161411|NCT03983785|Experimental|Pilates|
10161412|NCT03983785|Experimental|Elastic Taping|
10161413|NCT03983785|No Intervention|Wait List Control|
10161414|NCT03983694||BabyLux device|Cerebral haemodynamics of neonates undergoing erythrocyte transfusion according to the local clinical guidelines are monitored with BabyLux device before and after transfusion and with traditional NIRS during itself.
10161415|NCT03983798||Simulation training in psychiatry|Convenient sample of 72 voluntary medical students, allocated among 6 groups of around 12 students, will be recruited at Paris Descartes, Paris Diderot and Brest Universities between september of 2018 and June of 2019.
9671374|NCT05049161|Experimental|Temelimab 18 mg/kg|Monthly IV repeated dose
10161416|NCT03984032|Experimental|LMA Protector Cuff Pilot|
10161417|NCT03984032|Active Comparator|LMA Supreme|
10161418|NCT03983915|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
10161419|NCT03983915|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
10161420|NCT03983629||CDA patients|
10161421|NCT03983642|Experimental|Intervention group|The intervention group received a session of 40min for an 8 weeks' period. Both games requested the participants to stand on a balance board in front of the television, without shoes, while trying to control their avatars by shifting their body weights.
10161422|NCT03983642|No Intervention|Control group|Participants in the control group were followed-up by an assessor, who made sure that they will not get involved in any type of training program during the eight weeks' period of the trial.
10161423|NCT03983551|Experimental|Dipeptidyl peptidase 4 inhibitors|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
10161424|NCT03983551|Active Comparator|Sulfonylureas|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
10161425|NCT03983759|Experimental|treatment group|"phlebotomation 50ml 1-7 days before chemotherapy for culture of R-CIK cells chemotherapeutic regimen EP or EC as follows: VP-16 100mg/m2 D1-3 plus cisplatin 75mg/m2 D1 or VP-16 100mg/m2 D1-3 plus carboplatin AUC=5 D1 R-CIK cells were transfused back to the patients 2-7 days after the end of chemotherapy, and the amount of R-CIK cells returned each time was about 5×109 three weeks each cycle efficacy evaluated every two cycles patients with the efficay is CR, PR or SD after 4-6 cycles enter the sintilimab maintenance therapy for one year or until the progression of disease, or occurrence of intolerable adverse events.~the dose of sintilimab is fixed dose of 200mg every three weeks"
10161426|NCT03983681|Experimental|Experimental|The experimental group will receive memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
10161427|NCT03983681|Placebo Comparator|Control group|The control group will receive placebo memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
10161428|NCT03983408|Active Comparator|KRG group|"Enrollment: 60 patients~Drug: Korean Red Ginseng (KRG) 2,000 mg/day for total 24 weeks (2 Korean Red Ginseng extract tablet twice a day, ginsenoside Rg1+Rb1+Rg3 7.0 mg/g per each tablet)"
9671375|NCT05049161|Experimental|Temelimab 36 mg/kg|Monthly IV repeated dose
9671376|NCT05049161|Experimental|Temelimab 54 mg/kg|Monthly IV repeated dose
9671377|NCT05049538||Observational (biospecimen collection, Pap smear)|Patients undergo collection of blood samples for liquid biopsy during pre-treatment consultation before hysterectomy, after hysterectomy but before starting any chemotherapy, and at the end of last chemotherapy cycle. Patients also undergo collection of tissue samples during hysterectomy. Patients may also undergo Pap smears before and after hysterectomy.
9671378|NCT05049304|Experimental|OA-enriched functional olive oil|
9671379|NCT05049304|Active Comparator|Olive oil not enriched in OA|
10161429|NCT03983408|Placebo Comparator|Placebo group|"Enrollment: 60 patients~Drug: Placebo for 12 weeks, following Korean Red Ginseng 2,000mg/day for another 12 weeks"
10161430|NCT03983421|No Intervention|Treatment as Usual|Treatment as usual enhanced with a brief psychosis literacy training (45-60 minutes) for the counselors at the university's student health and counseling center
10161431|NCT03983421|Other|Screening|Implementation of the Prodromal Questionnaire - Brief, which is a screening tool to detect risk of psychosis.
10161432|NCT03983421|Other|Screening Plus Warm Hand-Off|Addition of a warm hand-off to coordinated specialty care (CSC) for those determined eligible on the screening tool.
10161433|NCT03983655|Experimental|Real High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.
10161434|NCT03983655|Sham Comparator|Sham High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.
10161435|NCT03983434|Experimental|Healthy volunteers|Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
10161436|NCT03983434|Experimental|Irritable Bowel Syndrome Patients with Diarrhea|Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
10161437|NCT03983434|Experimental|Irritable Bowel Syndrome Patients with Constipation|Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
10161438|NCT03983473|Other|Crohn's disease|Patients suffering from established Crohn 's disease without spondyloarthritis
10161439|NCT03983473|Other|Spondyloarthritis|Patients with established spondyloarthritis without Crohn 's disease
10161440|NCT03983473|Other|Crohn + spondyloarthritis|Patients suffering from both spondyloarthritis and Crohn 's disease
10161441|NCT03983473|Other|healthy controls|Patients without spondyloarthritis and Crohn 's disease
10161442|NCT03983304|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
10186252|NCT03737409|Experimental|Oxygen therapy with POC (AOT group)|Patients will receive ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
10186253|NCT03737409|Sham Comparator|Sham oxygen therapy with POC (air group)|Patients will receive sham ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
10161443|NCT03983460|Experimental|Dupimulab arm|"At Day 0, patients will receive Dupilumab treatment. The recommended dose of Dupilumab for adult patients is an initial dose of 600mg followed by 300mg given every two weeks administered as subcutaneous injection. Dupilumab could be self-administered by subcutaneous injection into thigh or abdomen or injected in the upper arm in case of administration by the patient's caregiver. It is recommended to rotate the injection site with each injection.~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
10161444|NCT03983460|Active Comparator|Optimized TCS treatment arm|"At Day 0, patients will receive topical corticosteroid treatment (TCS) adapted to the AD severity (potent and very potent TCS) with a personal therapeutic education for treatment optimization. It will be asked to perform, every day, an application of topical corticosteroid (TCS) (betamethasone valerate cream 0.1%, and if not active, clobetasol propionate cream 0.05%) on active lesions. Once the AD lesion is cleared, the patients will continue to apply TCS on healed lesions, twice a week until the end of the treatment period to prevent relapse.~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
10161445|NCT03983499|Experimental|Special Intervention|The special intervention (SI) arm addresses glycemic control, medication adherence, control of modifiable CVD risk factors, health behavior change, and psychosocial and cultural barriers to self-management. The SI arm consists of a collaborative care team approach with four main elements including: 1) Specialized clinical care by a medical provider; 2) Specialized behavioral health care by a behavioral health provider; 3) Group-based chronic disease self-management education by peer-leaders; 4) Intensive, proactive care coordination facilitated by a patient registry and electronic health records.
10161446|NCT03983499|No Intervention|Usual Care|Participants randomized to the Usual Care (UC) arm continue to see their primary care provider and receive referrals to health education. At the discretion of the provider, UC patients are screened and referred to behavioral health (BH) care.
10161447|NCT03983330|Experimental|Intervention group|"The trained RA will deliver brief MI to each subject individually via WeChat or WhatsApp in the smart phones throughout the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once per 2-3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering message through WeChat or WhatsApp will be interactive, depended on subjects' actions and responses.~Start from 6 months, minimal messages by merely following the subjects' progress and responding to their questions to maintain contact will be provided to subjects till one-year follow-up.~The readiness of quitting smoking will be assessed at 3-month follow-up. For those who are willing to take further actions to promote their health, i.e. with an intention to quit smoking, health advice on smoking will be given with more emphasis on the health benefits of quitting. The whole intervention will be given through WeChat/WhatsApp."
10161448|NCT03983330|Other|Control group|Subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months
9974256|NCT01339325|Active Comparator|LESS Cholecystectomy not blind|Laparo-endoscopic single site cholecystectomy. The patient is aware of the procedure he underwent.
10161449|NCT03983603|Experimental|Plant stanol group|This arm receives soft chews containing 0.5g of plant stanols (delivered as plant stanol esters).
10161450|NCT03983603|Placebo Comparator|Placebo group|This arm receives soft chews that do not contain 0.5g of plant stanols (delivered as plant stanol esters).
10161451|NCT03983525|Experimental|Goji berry|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
10161452|NCT03983525|Active Comparator|Lutein + zeaxanthin supplementation|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
10161453|NCT03983265|Other|computer guided condylar reposition device|surgical procedure : under general anesthesia after BSSO condyle will be repositioned by computer guided repostioning device
10161454|NCT03983538||Patients receiving chemotherapy|Patients receive a protocol-approved chemotherapy regimen containing Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel) based on the patient and/or physician preference.
10161455|NCT03983447|Experimental|School-based intervention to promote Physical Activity (PA)|"This intervention included :~Physical (Environmental) adaptation of playground~Time adaptation of lunch breaks~Curriculum-based program of children~Workshops and newsletters for parents~Meetings for teachers"
10161456|NCT03983447|No Intervention|Control|Nothing has changed in the school.
10161457|NCT03983395|Experimental|Part 1: Cohort 101 - ISB 1302 250 ng/kg|Cohort 101, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
10161458|NCT03983395|Experimental|Part 1: Cohort 201 - ISB 1302 325 ng/kg|Cohort 201, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
10161459|NCT03983395|Experimental|Part 1:Cohort 301- ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Cohort 301, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
9974257|NCT01339338|Experimental|warm media|Subjects undergo HSG using a warm media heated with a 37℃ water-bathing
9974258|NCT01339338|No Intervention|cold media|the contrast media under room temperature without heat
9974259|NCT01339351|No Intervention|Usual Psychosocial Care|Participants are free to use any psychosocial care available to cancer patients. No restrictions to participation in other groups or services.
9974260|NCT01339351|Experimental|Therapeutic Group by teleconference|ten 90 minute group sessions by teleconference. Lead by social workers. Sessions focus on information, story sharing and coping.
9974261|NCT01339364|Active Comparator|Didactic Lecture|
9974262|NCT01339364|Experimental|Lecture plus Case Disscussion|
9974263|NCT01339364|Experimental|Lecture plus Small Group Education|
9974264|NCT01339377|Experimental|AO-1000 Treatment|Oxygen-ozone treatment with the AO-1000 device
9974265|NCT01339442|Experimental|Dose Level 1 - Phase 1A|"BKM120 80 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
9974266|NCT01339442|Experimental|Dose Level 2 - Phase IA|"BKM120 100 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
9974267|NCT01339442|Experimental|Phase IB|"BKM120 (dose to be determined in Phase IA)PO 5 days on/ 2 days off per week.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
9974268|NCT01339442|Experimental|Cohort C|"BKM120 (dose determined in Phase IA) PO daily.~Fulvestrant 500 mg IM on Day 1 and Day 15 during Cycle 1 then monthly on Day 1 of subsequent cycles."
9974269|NCT01339455|Experimental|AHSCT|All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.
9974270|NCT01339468|Experimental|Arm 1|Intravenous Prograf therapy followed by oral Advagraf therapy
9974271|NCT01339468|Active Comparator|Arm 2|Intravenous Prograf therapy followed by oral Prograf therapy
9974272|NCT01339481||Subjects with RA initiating abatacept treatment regimen|Subjects naïve to both abatacept and belatacept
9974273|NCT01339494|Active Comparator|arginine supplementation|Oral L-arginine supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Arginine will be given every 4 hours.
9974274|NCT01339494|Active Comparator|citrulline supplementation|Oral L-citrulline supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Citrulline will be given every 4 hours
10161460|NCT03983395|Experimental|Part 1:Cohort 401- ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Cohort 401, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
10161461|NCT03983395|Experimental|Part1Cohort501-ISB1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Cohort 501, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
10161462|NCT03983395|Experimental|Part1Cohort601-ISB1302 325ng/kgD1;550 ng/kg D8;900 ng/kgD15,22|Cohort 601, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
10161463|NCT03983395|Experimental|Part 1 Cohort 701- ISB 1302 escalating doses,1200 ng/kg D15,22|Cohort 701, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
10161464|NCT03983395|Experimental|Part 2 (Dose Expansion) -ISB 1302 at the MTD and/or RP2D dose|Subjects treated with ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
10161465|NCT03983356|Experimental|Group of GPs receiving training|GPs, psychologists and social workers in the intervention regions will receive a training program.
10161466|NCT03983356|No Intervention|Group of GPs receiving no attention|GPs, psychologists and social workers in the control regions will not receive information about the intervention.
10161467|NCT03983720|Experimental|Patient with multiple sclerosis and lowly fatigued|"Patient with multiple sclerosis and lowly fatigued will be included.~They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
10161468|NCT03983720|Experimental|Patient with multiple sclerosis and highly fatigued|"Patient with multiple sclerosis and highly fatigued will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
10161469|NCT03983720|Active Comparator|Healthy subjects|"Healthy subjects will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
10186254|NCT03737396|Active Comparator|Electronic health screening|Self-administered electronic health screening on tablet
9974275|NCT01339507||Bepreve|Subjects with a history of allergic conjunctivitis.
9974276|NCT01339507||Lastacaft|Subjects with a history of allergic conjunctivitis.
9974277|NCT01339520|Experimental|Scorecard|Score of points for variables.
9974278|NCT01339520|No Intervention|Control|Standard of care for diabetes subjects
9974279|NCT01339533|Experimental|APRV ls|APRV low stretch will titrate Plow to maintain release volumes between 4 and 8 cc/kg.
9974280|NCT01339533|Active Comparator|AC/VC Conventional Ventilation|Standard volume control ventilation with the ARDS Net protocol.
9974281|NCT01339533|Experimental|APRV h|APRV Habashi protocol which sets Plow equal to 0.
9974282|NCT01339546||Study population|All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study
9974283|NCT01339572|Experimental|Plerixafor|All subjects will receive filgrastim as part of their primary mobilization regimen. If a subject does not meet minimum peripheral blood CD34+ cell count levels or fails to adequately collect a threshold number of CD34+ cells, plerixafor will be added to the mobilization regimen.
9974284|NCT01339572|Active Comparator|Observation|All subjects will receive filgrastim as part of their primary mobilization regimen. If the subject meets minimum peripheral blood CD34+ cell count levels or adequately collects a threshold number of CD34+ cells, plerixafor will not be added to the mobilization regimen.
9974285|NCT01339585|Experimental|Timing of tDCS|
9974286|NCT01339585|Experimental|Alternative timing of tDCS|
9974287|NCT01339598|Sham Comparator|Sham transcranial direct current stimulation|
9974288|NCT01339598|Active Comparator|Transcranial direct current stimulation|
9974289|NCT01339598|Active Comparator|Different transcranial direct current stimulation montage|
9974290|NCT01339611|Experimental|Educational Program|Patients who are going to use of oral anticoagulant will participate in an individual orientation, using instructional material (slides and illustrative booklet) during hospitalization period and the telephone follow-up at a week and four weeks after discharge
9974291|NCT01339611|Other|usual care|Patients who are going to use of oral anticoagulant will have usual orientation from the health service (illustrative booklet) during hospitalization time. No telephone follow-up after discharge.
9974292|NCT01339624|Active Comparator|NASAL FENTANYL,|
9974293|NCT01339624|Active Comparator|KETOROLAC + MORPHINE|
9974294|NCT01339637||Diabetes risk factors|Very dark skin subjects with with diabetes risk factors
9974295|NCT01339650|Experimental|ABT-767|ABT-767 monotherapy
9974296|NCT01339663|Experimental|Treatment (dose-escalation, T-APC boost, CTL)|"INFUSION I: Patients receive high-dose cyclophosphamide IV on day days -4 and -3 and low-dose IL-2 SC BID on days 0-14. Patients also receive CTL IV on day 0.~INFUSION II: Beginning 6-48 hours later, patients receive high-dose cyclophosphamide, low-dose IL-2, and CTL as in Infusion I. Patients also receive T-APC vaccine IV within 18-36 hours following CTL infusion and in week 4, and IL-2 SC BID on days 0-14 following second T-APC vaccination."
9974297|NCT01339676|Experimental|1|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
9974298|NCT01339676|Placebo Comparator|2|Identically appearing once weekly peroral capsules
9974299|NCT01339702||"Pre-implementation cohort (before)"|This cohort is a combination of retrospective and some prospective severe TBI patients cared for in the EMS systems of Arizona BEFORE implementation of the national prehospital TBI management guidelines
9974300|NCT01339702||"Post-implementation cohort (after)"|"This cohort is a comprised of prospective severe TBI patients cared for in the EMS systems of Arizona AFTER training EMS providers in the implementation of the national prehospital TBI management guidelines. It is intended that these patients will receive the bundle of care specified in the TBI Guidelines."
9974301|NCT01339741|Active Comparator|Vitamin D|
9974302|NCT01339741|Placebo Comparator|Placebo|
9974303|NCT01339754|Experimental|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
9974304|NCT01339780|Experimental|Breast Cancer|
9974305|NCT01339780|Experimental|Prostate Cancer|
9974306|NCT01339806|Other|Standard of Care for mTBI Provider Arm|Arm 1: Psychoeducational Control Group. Individuals assigned to arm 1 will receive psychoeducational materials specifically adapted for persistent management of symptoms and routine follow-up with medical providers (every three weeks). Additionally, subjects assigned to this group will receive medical care (e.g., psychopharmacological management of depression) and/or referral for symptom management (e.g., vestibular rehabilitation) of non-cognitive complaints, consistent with the current standard of care treatment model for managing post-concussive symptoms (see Figure below adapted with permission from authors; Brenner et al., 2009).
9974307|NCT01339806|Experimental|Computer Based Therapy Group|"Arm 2: Non-therapist directed computerized cognitive rehabilitation. Individuals assigned to treatment arm 2 will receive ten hours of in-clinic, computerized treatment per week throughout the 6-week treatment trial. Participants will be scheduled for 2 hours per day, proctored by clinic staff (certified recreation therapist or neuropsychology technician) who will be responsible for recording daily performance, providing positive reinforcement of participation, and effort. Computer programs selected for this treatment trial include both skill-specific training (e.g., attention processes) and general cognitive activation. These computer programs are commercially available and advertised as brain fitness or brain training."
9974308|NCT01339806|Experimental|Cognitive Rehab Group|"Arm 3: Therapist-directed individualized cognitive rehabilitation. Individuals assigned to treatment arm 3 will receive 10 hours of individual and group cognitive rehabilitation treatment (including homework assignments) per week conducted by credentialed speech therapists and occupational therapists. The treatment components will include five hours of weekly individual therapy (one-hour sessions; two hours focused on compensatory strategies and three hours focused on restorative strategies), two hours of weekly group therapy (one hour sessions focused on compensatory strategies), and three hours of weekly computer-based homework proctored by clinic staff who will be responsible for recording performance, and providing positive reinforcement of participation and effort."
9974309|NCT01339806|Experimental|Cognitive and Psychological Based Rehab|"Arm 4: Integrated interdisciplinary cognitive rehabilitation combined with cognitive-behavioral psychotherapy. Individuals assigned to treatment arm 4 will receive 10 hours of individual and group treatment per week conducted by credentialed therapists and doctoral-level psychologists. The treatment components will include four hours of weekly 1 hr individual therapy sessions; 2 hrs of cognitive rehabilitation, 1 hr of cognitive rehab & 1 hr of individual psychotherapy targeting anxiety/combat stress symptoms including relaxation training & exposure therapy and cognitive-behavioral principles, 3 hrs of weekly group therapy & three hours of weekly homework including 30-mins relaxation training, 30-mins cognitive-behavioral psychotherapy homework, and 2 hrs of computerized cognitive rehabilitation exercises proctored by clinic staff."
9974310|NCT01339819|Experimental|Arm 1|Dabigatran Therapy
9974311|NCT01339819|Active Comparator|Arm 2|Phenprocoumon Therapy
9974312|NCT01339845|Active Comparator|Vaccine arm|Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone
9974313|NCT01339845|Active Comparator|Vaccine plus hygiene and safe water arm|Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change
10161470|NCT03983252|Experimental|Relapsing Remitting Multiple Sclerosis starting Alemtuzumab|"Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (defined by International Panel Criteria), age 18-60 years, enrolled to start treatment with alemtuzumab.~Subjects will undergo [F-18]PBR06 PET scans at baseline, 6 months and 18 months."
10161471|NCT03983239|Experimental|Fedratinib plus Rifampin|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of rifampin. On Day 17, a single dose of fedratinib will be concomitantly administered with rifampin.
10161472|NCT03983239|Experimental|Fedratinib plus Efavirenz|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of efavirenz. On Day 17, a single dose of fedratinib will be concomitantly administered with efavirenz.
10161473|NCT03983278|Experimental|School Model|School Model (n=47 schools): Vision screening will be carried out by the vision screeners; refraction will be done at the schools by refractionists, and children who need them will be given free spectacles at the school within two weeks.
10161474|NCT03983278|Experimental|Referral Model|Referral Model (47 schools): Vision screening carried out by the vision screeners, and children are referred to nearby Vision Center/ secondary center for refraction and delivery of free spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary.
10161475|NCT03983278|Experimental|Referral Model + Cost Recovery|"Referral Model + Cost Recovery (47 schools): Vision screening carried out by the vision screeners; children referred to Vision Center for refraction and delivery of spectacles with an option to purchase upgrade spectacles (which was shown to be appealing to families in the recent PRICE study. These spectacles have scratch-proof coatings and designs selected to appeal to local children. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary."
10161476|NCT03983369|Experimental|"preventive treatment with LLLT (Laser group)"|
10161477|NCT03983369|Placebo Comparator|control group with a placebo intervention|
10161478|NCT03983187|No Intervention|Control|
10161479|NCT03983187|Experimental|Rotating Magnetic Therapy group|
10161480|NCT03983109|Experimental|Detection by EpiFaith syringe with air|
10161481|NCT03983109|Experimental|Detection by EpiFaith syringe with saline|
10161482|NCT03983174|Experimental|Drainage seton with flap|Drainage seton will be put around the external anal sphincter with mucosal advancement flap
10161483|NCT03983174|Experimental|EAS sparing seton|Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done
10161484|NCT03983161|Experimental|Fedratinib in moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to subjects with moderate hepatic impairment
10161485|NCT03983161|Experimental|Fedratinib in severe hepatic impairment subjects|A single dose of 200 mg of fedratinib will be given to subjects with severe hepatic impairment
10161486|NCT03983161|Experimental|Fedratinib in healthy vs moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to healthy subjects with normal hepatic function.
10161487|NCT03983161|Experimental|Fedratinib in healthy vs severe hepatic impairment subjects|A single oral dose of 200 mg of fedratinib will be given to healthy subjects with normal hepatic function.
10161488|NCT03983148|Experimental|Motivational interviewing|Other than usual medical care received by children, their parents in this group will receive three individual, face-to-face interventions on motivational interviewing by a trained registered nurse at baseline, 3-month and 6-month, with each session is about 60 minutes. All sessions of motivational interviewing will be scheduled based on the treatment schedule of the children and conducted in an interview room inside the pediatric oncology unit. A 25-30 minutes semi -structured interview will be conducted for process evaluation at 6-month.
10161489|NCT03983148|Placebo Comparator|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
10161490|NCT03982992|Experimental|DLI-TARGET|"14d screening period: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 1 (all patients): d1-28: blinatumomab continuous infusion i.v., d4: allogeneic donor lymphocyte single infusion i.v., d29: methotrexate, cytarabine, dexamethasone infusion i.th.~Cycle 2 (only patients with toxicity ≤ grade 2 CTCAE in cycle 1): d43-d70: blinatumomab continuous infusion i.v., d46: allogeneic donor lymphocyte single infusion i.v., d71: methotrexate, cytarabine, dexamethasone infusion i.th."
10161491|NCT03982940|Experimental|BGP+ Stent Graft System|Application of BeGraft Peripheral Plus (BGP+) Stent Graft System as bridging stent in Branched Endovascular Repair (BEVAR) for complex aortic aneurysms
10161492|NCT03983200|Sham Comparator|Control group|Mecobalamine 0.5mg, tid
10161493|NCT03983200|Experimental|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min,bid + Mecobalamine 0.5mg, tid
10161494|NCT03983057|No Intervention|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
10161495|NCT03983057|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 3mg/kg
10161496|NCT03983122|Experimental|Study group|Patients who undergo laparoscopic sleeve gastrectomy
10161497|NCT03983213||Pat. after mpfl reconstruction|All 45 subjects operated with mpfl reconstruction included to chek-up after follow-up.
10161498|NCT03982888|Experimental|DBS Treatment|Deep brain stimulation of both limbic and dysfunctional reward processing circuits for treatment of repetitive self injurious behaviours in children with ASD
10161499|NCT03982966|Experimental|Omega 3|Group 1 will be 40 patients that will take Omega 3 fatty acids (fish oil)
10161500|NCT03982966|No Intervention|Control|20 patients will not take omega 3 fatty acids.
9520200|NCT03279666|Active Comparator|Tenaculum without intracervical blockage|
9520201|NCT03279666|No Intervention|No Tenaculum without intracervical blockage|
9671380|NCT05049187||Group 1 COVISHIELD|Participants will receive one dose of COVID-19 vaccine (Covishield) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
9974314|NCT01339845|No Intervention|Non-intervention arm|30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices
9974315|NCT01339871|Experimental|Pazopanib + Vorinostat|Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
9974316|NCT01339884|Active Comparator|Resveratrol, 1g daily|15 participants will receive resveratrol 1g daily
9974317|NCT01339884|Active Comparator|Resveratrol, 5g daily|15 participants will receive resveratrol, 5g daily
9974318|NCT01339949|Experimental|24 Gy radiation|
9974319|NCT01339949|Sham Comparator|Sham 24 Gy radiation|
9974320|NCT01339962||Non-Interventional Study|Outcomes Research Study
9974321|NCT01339975||Group A. Surgically treated patients|Patients having a radical or partial nephrectomy.
9974322|NCT01339975||Group B. Patients treated with targeted therapies|Patients treated by RCC-directed targeted therapy
9974323|NCT01339988|Experimental|Busulfan/Cyclophosphamide|
9974324|NCT01340001|Sham Comparator|Sham Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
9974325|NCT01340001|Experimental|Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
9974326|NCT01340040|Experimental|MEDI-573|MEDI-573
9974327|NCT01340079|Experimental|Virtual world|Virtual world delivery method
9974328|NCT01340079|Active Comparator|face to face|face to face method of health education
9974329|NCT01340092|Active Comparator|Family Navigator|Family navigation
9974330|NCT01340092|No Intervention|Standard Care|standard care
9974331|NCT01340118|Experimental|Budesonide|Patients with FeNO level greater than 25 ppb were randomly allocated to one of two groups. Randomisation was stratified by baseline FeNO. In one group (treatment group), participants were assigned to once daily treatment with 400 µg budesonide. In the other group (non-treatment group), participants did not receive any medication.
9974332|NCT01340118|No Intervention|remain untreated|
9974333|NCT01340131|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 40mg/S-Amlodipine 5mg Intervention
9974334|NCT01340131|Active Comparator|Free combination Therapy|Co-administration of single oral doses of a 40mg tablet of Telmisatan and a 5 mg tablet of S-Amlodipine
9974335|NCT01340157|Experimental|Fasting|Treatment A: 1200mg fexinidazole administered in fasting conditions by oral route
9974336|NCT01340157|Experimental|Meal 1: Plumpy Nuts|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 1) by oral route
9974337|NCT01340157|Experimental|Meal 2: Rice + beans|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 2) by oral route
9974338|NCT01340170|Experimental|Soft bone drilling protocol|A soft bone drilling protocol will be used in bone quality 3 and 4
9974339|NCT01340170|Active Comparator|Standard drilling protocol|A standard drilling protocol will be used in bone quality 1 and 2
9974340|NCT01340183|Experimental|AZD5099|IV Dose
9520202|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
9671381|NCT05049187||Group 2 COVAXIN|Participants will receive one dose of COVID-19 vaccine (Covaxin) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly.
9974341|NCT01340183|Placebo Comparator|Placebo|IV Dose
9974342|NCT01340235|Experimental|Oral erythromycin|Oral erythromycin
9974343|NCT01340248|Experimental|Dilatrend 64mg capsule|"* Randomized, open-label, single dose, two-period, two-way, crossover study~group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
9974344|NCT01340261||Pediatric Pain Rehab Patients|
9974345|NCT01340274|Active Comparator|Treatment as Usual|"Clients will receive 12 sessions of Treatment as usual , delivered 1 session per week for 12 consecutive weeks."
9974346|NCT01340274|Experimental|CRAFT Treatment|"Clients will receive 12 sessions of CRAFT, delivered 1 session per week for 12 consecutive weeks."
9974347|NCT01340287|Active Comparator|1 = Tested product|
9974348|NCT01340287|Sham Comparator|2 = Control product|
9974349|NCT01340313||Group 1|4 times evaluation according to doses in 1 group
9974350|NCT01340326|Active Comparator|Valsartan,high dose|high dose group (valsartan up to 320 mg/day)
9974351|NCT01340326|Other|Valsartan, usual dose|usual dose group (valsartan 80 mg/day)
9974352|NCT01340339|Experimental|BILITRON BED®|Super-LED reverse phototherapy
9974353|NCT01340339|Active Comparator|BILIBERÇO®|Fluorescent Reverse Phototherapy
9977342|NCT01360411||Pancreatic lesions|"Any patient with a solid pancreatic lesion of unknown histology may be recruited. Cystic lesions are not included.~Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively."
9977343|NCT01360411||Intramural upper GI-lesions|Patients with intramural lesions discovered by endoscopy or other imaging modalities are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
9977344|NCT01360411||Lymph nodes|Patients with visible mediastinal lymph nodes or retroperitoneal lymph nodes in patients with inflammatory or malignant diseases are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
9977345|NCT01360424|Experimental|teriparatide|
9977346|NCT01360437|Active Comparator|Prasugrel|
9977347|NCT01360437|Experimental|Ticagrelor|
9977348|NCT01360463|Experimental|Behavioral and Drug Risk Counseling|Participants assigned to this arm will receive bi weekly Behavioral and Drug Risk Counseling (BDRC) counseling for six months.
9977349|NCT01360463|Active Comparator|Treatment as Usual|Participants assigned to this arm will receive methadone treatment without and alterations.
9977350|NCT01360476|Active Comparator|Vitamin D|
9977351|NCT01360476|Placebo Comparator|placebo|
10161501|NCT03982953||PD patients with STN-DBS|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that are planned to undergo craniectomy with implantation of bilateral DBS electrodes in the subthalamic nucleus
10161502|NCT03982953||Controls - PD patients with medical treatment|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that do not undergo DBS for personal reasons or contraindications for this treatment. Age, sex and disease-severity matched with PD patients with STN-DBS.
10161503|NCT03982758|Experimental|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
10161504|NCT03982758|Experimental|isometric of lower limbs|Isometric session for lower limbs: 4 series with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute.
10161505|NCT03982823|Experimental|Hand-Sewn Sleeve Gastrectomy|
10161506|NCT03982823|Active Comparator|Stapled Sleeve Gastrectomy|
10161507|NCT03982862|Active Comparator|control group|0.9% Normal saline 0.1 ml +Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1cm2 scar volume
10161508|NCT03982862|Experimental|botox group|4U Botox® diluted to 0.1 ml + Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1 cm2 scar volume
10161509|NCT03982771|Experimental|BCD regimen|Bortezomib, cyclophosphamide and dexamethasone (the BCD regimen) would be utilized in newly diagnosed iMCD (idiopathic Multicentric Castleman's disease) patients
10161510|NCT03982849|Active Comparator|Hydroquinone group|Hydroquinone 4% cream Cream applied once daily at night on affected areas for 3 months.
10161511|NCT03982849|Experimental|Silymarin group|Silymarin 0.7% cream Cream applied twice daily on affecectec areas for 3 months.
10161512|NCT03983005||Patients with suspected lung cancer|Patients with pulmonary parenchymal lesions suspected for malignancy in contact or adjacent to the esophagus which can be sampled by EUS-B-FNA
10161513|NCT03982836|Experimental|Fructooligosaccharide|All the 25 volunteers received the sandwich containing 20 grams of fructooligosaccharide
10161514|NCT03982836|Experimental|Partially hydrolyzed guar gum|All the 25 volunteers received the sandwich containing 20 grams of partially hydrolyzed guar gum
10161515|NCT03982836|Placebo Comparator|Maltodextrin|All the 25 volunteers received the sandwich containing 20 grams of Maltodextrin
10161516|NCT03982875|Experimental|SmartBag arm|"The Alfred SmartBag System will be placed on the ostomy site during surgery. The system will be used to wirelessly monitor ostomy function in the hospital setting and the patient will otherwise receive the standard of care. At discharge the patient will continue to use the Alfred SmartBag System and ostomy function will be monitored by the research and clinical teams remotely.~If participant's output is (i) less than 50mL or greater than 1500mL per day or (ii) greater than 1200mL in two days; the mobile app will alert not only the participant but also the clinical staff (nurse).~Participants will also receive support from a 'Patient Coach', a trained health coach who is also an ostomy patient to provide quality of life support."
10161517|NCT03982810||Surgical Site Infections|Patients equal or greater than 18 years of age undergoing non-emergent non-cardiac surgical procedures involving a skin incision will be included in the study.
10161518|NCT03982615|Experimental|Laser-Lok abutment|Laser-etched abutment
10161519|NCT03982615|Active Comparator|Standard Healing abutment|Standard abutment which is not laser-etched
10161520|NCT03982537|Experimental|Nature's Blend N-Acetyl-L-Cysteine 600 mg with Chemotherapy|The treatment with NAC will be given twice daily for at least 10 days with the goal to cover the window of opportunity time between the treatment decision for CRT and the beginning of treatment (usually 14-21 days).
10161521|NCT03982537|Other|Standard of Care Chemotherapy (CONTROL)|Patients will receive definitive or adjuvant concurrent chemotherapy and radiotherapy as per standard of care
10161522|NCT03982719|Experimental|Brief protocol|4 intervention sessions with the occupational therapist of 30 minutes duration.
10161523|NCT03982719|Active Comparator|Intense Protocol|6 intervention sessions with the occupational therapist of 60 minutes duration.
10161524|NCT03983135|Experimental|Study group|Patients who undergo revisional bariatric surgery
10161525|NCT03982641||Colon surgery|patients diagnosed with colon cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
10161526|NCT03982641||Rectal surgery|patients diagnosed with rectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
10161527|NCT03982472|Experimental|TENS right side|TENS stimulation at the right side
10161528|NCT03982472|Experimental|TENS left side|TENS stimulation at the left side
10161529|NCT03982472|No Intervention|sham stimulation|Sham stimulation
10161530|NCT03982732||Women vaccinated at less than 24 weeks|Women receiving a pertussis containing vaccine at less than 24 weeks
10161531|NCT03982732||Women vaccinated at 24-27+6 weeks|Women receiving a pertussis containing vaccine at 24-27+6 weeks
10161532|NCT03982732||Women vaccinated at 28-31+6 weeks|Women receiving a pertussis containing vaccine at 28-31+6 weeks
10161533|NCT03982667|Experimental|PCT group|For patients randomly assigned to the PCT-guided group, measurements of serum PCT concentrations (Day 1, 3, 7, and 9) will be taken and made available to the attending physicians. This means 3 ml of whole blood will be sampled from the arterial line of the patients for each measurement the serum PCT in plain tubes. The samples will be immediately assayed for the PCT measurement using the available device and the results will be ready in next 30 minutes after running the system.
10161534|NCT03982667|No Intervention|Standard-of-care group|
10161535|NCT03982654|Experimental|Bloomlife|
10161536|NCT03982563|Experimental|Growth Mindset|
10161537|NCT03982563|Experimental|Gratitude|
10161538|NCT03982563|Experimental|Behavioral Activation|
10161539|NCT03982563|Sham Comparator|Study Skills|
10186255|NCT03737396|No Intervention|Paper-based health screening|Routine-care nurse-administered, paper-based health screening
10186256|NCT03737357|Experimental|SLActive® implant|
10186257|NCT03737357|Active Comparator|SLA® implant|
9974354|NCT01340352||study group: previous preterm labor|
9974355|NCT01340352||control group:previous term delivery|
9974356|NCT01340365|Other|Usual Care|
10161540|NCT03982550|No Intervention|Control Period|Participants will serve as their own controls. All 12-week control periods will take place before the RT intervention to ensure that results are not confounded by detraining effects or long-term cognitive benefits of RT. In addition, a control period equal in duration to the intervention allows direct within-subjects statistical comparisons, accounting for each participants' baseline and rate of aging - i.e. age-associated cognitive decline and arterial stiffening. Participants will not be monitored, but may be contacted for scheduling.
10161541|NCT03982550|Experimental|Intervention Period|Participants will perform a periodized and progressive total-body RT program emphasizing development of lower and upper body strength. All 36 training sessions (3 days per week for 12 weeks) will be performed at the CERC, supervised by an exercise specialist. Participants will be encouraged to continue normal activities of daily living and eating routines outside the RT program of the present study. Because this is a proof-of concept study on normal aging, participants may be contacted for scheduling, but will not be monitored outside of training.
10161542|NCT03982797|Experimental|treated with IMUNO BCG Moreau RJ adjuvant.|
10161543|NCT03982784|Experimental|single-injection TQLB(transmuscular quadratus lumborum block)|Single-injection of TQLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
10161544|NCT03982784|Active Comparator|Control|postoperative IPCA is given alone
10161545|NCT03982524|Experimental|CBT complemented with emotion regulation training|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning nonjudgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
10161546|NCT03982524|Active Comparator|Cognitive behavior therapy (CBT)|"This arm is based on conventional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
9671382|NCT05049356||Children referred to outpatient clinic|Diagnostic interview (Schedule for Affective Disorders and Schizophrenia (K-SADS) cf. Diagnostic and Statistical Manual of Mental Disorders (DSM-5)) with parents. Diagnostic groups/cohorts (e.g., DMDD, ADHD, Oppositional Defiant Disorder) will be based on the diagnoses given cf. K-SADS.
10161547|NCT03982381|Active Comparator|Metformin|Metformin 1000-3000 mg per day according to clinical guidelines. Split into 2-3 doses per day.
10161548|NCT03982381|Experimental|Dapagliflozin|Dapagliflozin 10 mg once daily
10161549|NCT03982446||Patients with germline mutations|This group will comprise of patients with pancreatic cancer who carry pathogenic mutations in genes associated with a predisposition to cancer.
10161550|NCT03982446||Patients without germline mutations|This group will comprise of patients with pancreatic cancer who did not carry pathogenic mutations in any of the genes tested, that have been previously shown to be associated with a predisposition to cancer.
10161551|NCT03982680|Experimental|Toripalimab combined with Gem/5-FU|All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles.After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.
10161552|NCT03983083|Experimental|Intervention|Aspects of the HEALED intervention are based on various components of successful interventions for breast cancer survivors and older adults, NCI funding priorities, CPS-3 survivor preferences discussed in prior focus groups and survivorship research from other cohorts. As such, HEALED participants will receive monthly motivational e-mails, based on prior studies of the most effective delivery time intervals for interventions involving cancer survivors, with links to a web-based platform which will provide: physical activity information (largely consisting of publicly available evidence-based resources), at-home exercise demonstrations/videos for survivors of all fitness levels, personal survivor stories, physical activity/sitting recommendations (based on National Guidelines and ACS guidelines for survivors), positive messaging, a space for SMART goal setting, a platform for physical activity tracking, a discussion board, etc.
10161553|NCT03983083|No Intervention|Wait-list control|"Wait-listed control group will be instructed to continue behavior as-usual. They will receive access to the HEALED website at the end of the 12-week intervention period."
10161554|NCT03982290|Active Comparator|Lactobacillus plantarum PS128 (PS128)|Subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 16 weeks.
10161555|NCT03982290|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules, 2 capsules per day, for the first 8 weeks. The following 8 weeks, subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 8 weeks.
10161556|NCT03982290|No Intervention|Normal Control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
10161557|NCT03982251|Experimental|High frequency whole body vibration|This group will receive a single 8-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
10161558|NCT03982251|Active Comparator|low frequency whole body vibration|This group will receive a single 12-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
10161559|NCT03982342|Active Comparator|Catheter-closure of PDA|Infants randomized to this group will undergo a catheter procedure to close hemodynamically-significant patent ductus arteriosus (HSPDA).
9671383|NCT05049356||Typical developing children and their parent(s)|Norm values on hair cortisol data will be obtained from typical developing children and their parent(s) by the same procedure as described under Outcome measure(s), 21. Stress Response by Cortisol levels.
9977352|NCT01360528||Extremely low birth weight|Extremely low birth weight under 1000 gram
10161560|NCT03982342|Active Comparator|Conservative management of PDA|"Infants randomized to this group will be treated to reduce the symptoms of a hemodynamically-significant patent ductus arteriosus (HSPDA), in the hopes that over time the HSPDA will become reduced in size (to the point of no longer meeting criteria for being hemodynamically significant) or close naturally. Infants in this group with declining health status attributable to a PDA which meet qualifying criteria may receive catheter closure (intervention) if deemed medically necessary."
10161561|NCT03982134|Experimental|PDR001 with Panobinostat|All enrolled patients will be treated with a combination of PDR001 at 400mg every 4 weeks and panobinostat. Dose and frequency of Panobinostat will vary depending upon the dose-level cohort of the study participants. Each participant will be assigned to a particular dose-level cohort.
10161562|NCT03982264|Active Comparator|ESD group|In ESD group, enrolled patients will receive the treatment modality of ESD to remove the rectal NET
9974357|NCT01340365|Experimental|Tai Chi|Individuals will take part in community-based Tai Chi classes twice a week for 6 months as well as practice Tai Chi outside of class twice a week for the same 6 month period.
10161563|NCT03982264|Experimental|EMR-C group|In EMR-C group, enrolled patients will receive the treatment modality of EMR-C to remove the rectal NET
10161564|NCT03982329|Active Comparator|nrTMS group|15 minutes low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days
10161565|NCT03982329|Sham Comparator|sham group|15 minutes sham stimulation of the uneffected hemisphere at 7 consecutive days
10161566|NCT03982277|Experimental|High dose Rifampin + DTG|High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
10161567|NCT03982277|No Intervention|Standard dose Rifampin + DTG|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
10161568|NCT03982277|Experimental|High dose Rifampin + EFV|High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
10161569|NCT03982277|No Intervention|Standard dose Rifampin + EFV|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
10161570|NCT03982303|Experimental|Hemay102 at the dosage of 5mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 5mg/m2.
10161571|NCT03982303|Experimental|Hemay102 at the dosage of 10mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 10mg/m2.
10161572|NCT03982303|Experimental|Hemay102 at the dosage of 20mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 20mg/m2.
10161573|NCT03982303|Experimental|Hemay102 at the dosage of 40mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 40mg/m2.
10161574|NCT03982303|Experimental|Hemay102 at the dosage of 60mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 60mg/m2.
10161575|NCT03982303|Experimental|Hemay102 at the dosage of 90mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 90mg/m2.
10161576|NCT03982303|Experimental|Hemay102 at the dosage of 120mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 120mg/m2.
10161577|NCT03982082|Experimental|Device feasibility (MuscleSound technology)|Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.
10161578|NCT03981965|Experimental|Focus guidelines|"Participants enrolled in a 2-phase physical activity program divided in 2 phases as described above. Briefly, The activity consisted in a 1-h set of exercises twice per week. The first 12-week phase was performed in group under the direct supervision of a health monitor. The second 12-week phase was autonomous, and consisted of the same physical performance while maintaining virtual link through a social network based on the mobile phone.~The FOCUS guidelines provided 2 features, the participation in monthly health talks provided by the principal investigator and the availability of a virtual mailbox to transmit any comment or suggestion."
10161579|NCT03981965|Active Comparator|Active group|Participants enrolled in a 2-phase physical activity program divided into 2 phases as described above. This group lacked the monthly talks and did not have access to the virtual mailbox.
9974358|NCT01340391|Experimental|splinting method|A new splinting method has been invented. This is a study using the splint / cast in treatment of distal radius fractures.
9974359|NCT01340404|Experimental|Stem Cell Transplantation|
9974360|NCT01340404|Active Comparator|Transfusion program|
9974361|NCT01340417|Experimental|one label|Measurements of melatonin levels in urine, blood, milk.
9974362|NCT01340430|Experimental|FEC-paclitaxel-trastuzumab|fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks
10161580|NCT03981965|No Intervention|Inactive|Women of similar clinical characteristic who did not participate in the PA program.
10161581|NCT03982056||Main study group|"Assessments performed:~Height~Mass~Body fat density~Bone density~Lean muscle density~Lung volume measurements~Floating technique~Buoyancy"
10161582|NCT03982056||Validation group|"Assessments performed:~Height~Mass~Body fat density~Bone density~Lean muscle density~Lung volume measurements~Floating technique~Buoyancy"
10161583|NCT03982212|Experimental|Intratumoral Copaxone|Eligible subjects receive at least 1 and up to 3 doses of Copaxone® 40 milligrams (mg) intratumorally prior to standard of care surgery. The doses will be administered at least 48 hours apart. The last dose will be given within 96 hours of standard of care surgery.
10161584|NCT03982628||Sepsis|Adults admitted to a mixed medical/surgical ICU for sepsis with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
10161585|NCT03982628||Trauma|Adults admitted to a mixed medical/surgical ICU for trauma (without sepsis) with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
10161586|NCT03982225|Experimental|2.5% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 2.5% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
10161587|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
10161588|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.4 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.4 mL injections, 1.0 cm apart, up to 20.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
10161589|NCT03982225|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants receive placebo administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
10161590|NCT03982355||Breast Cancer|Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
10161591|NCT03982355||Rectal Cancer|Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
10161592|NCT03982017|Active Comparator|Usual care|Consists of routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
10161593|NCT03982017|Experimental|Application|Participants will be provided a special link to navigate to the online content and resources.
10161594|NCT03982173|Experimental|previously treated patients with solid tumors|previously treated patients with solid tumors harboring a high mutational load.
10161595|NCT03982238|Active Comparator|Control group|continuous subcutaneous insulin infusion therapy
10161596|NCT03982238|Experimental|Metformin|metformin therapy
10161597|NCT03982238|Experimental|Dapagliflozin|Dapagliflozin
10161598|NCT03982121|Experimental|A|FOLFOX IV + NIVOLUMAB IV
10161599|NCT03982121|Experimental|B|FOLFOX IV + GLA IT
10161600|NCT03982121|Experimental|C|FOLFOX IV + IPILIMUMAB IT
9520203|NCT03279640|Experimental|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
10161601|NCT03982121|Experimental|D|FOLFOX IV + NIVOLUMAB IV + GLA IT
10161602|NCT03982121|Experimental|E|FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT
10161603|NCT03982121|Experimental|F|LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT
10161604|NCT03982108|Experimental|Knotless suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knotless suture-bridge technique.
10161605|NCT03982108|Active Comparator|Knot-tying suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knot-tying suture-bridge technique.
10186258|NCT03737344|Active Comparator|IL-1Ra Kineret®|100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
10186259|NCT03737344|Placebo Comparator|IL-1Ra Placebo|100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
10186260|NCT03737331|Experimental|Fractal visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be fractal (i.e., pink noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
9974363|NCT01340443||Cohort|
9974364|NCT01340456|Experimental|Rifampicin 10 mg QD|
10186261|NCT03737331|Active Comparator|Periodic visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be periodic (i.e., invariant). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
10186262|NCT03737331|Sham Comparator|Random visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be random (i.e., white noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
10186263|NCT03737331|No Intervention|Control|Natural walking.
10186264|NCT03737318|Experimental|Group 1|Traditional articulation treatment
10186265|NCT03737318|Experimental|Group 2|Biofeedback--visual-acoustic
10186266|NCT03737318|Experimental|Group 3|Biofeedback-ultrasound
10186267|NCT03737305|Active Comparator|Control Group|Control group of conventional therapy with manual distraction performed by the physiotherapist in the office (active comparator)
9974365|NCT01340456|Experimental|Rifampicin 20 mg QD|
9974366|NCT01340456|Experimental|Rifampicin 100 mg QD|
10186268|NCT03737305|Experimental|Distractor Test Group|Test group with manual distraction performed by the physiotherapist in the office and the condylar distraction performed by the patient with the condylar distraction device in an ambulatory basis.
10186269|NCT03737292|Experimental|Exparel|Intercostal injection of 266mg of Exparel diluted to 30 ml.
10186270|NCT03737292|Active Comparator|Bupivacaine|Intercostal injection of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml.
10186271|NCT03737279|Experimental|Meditation|"Intervention Group:~Routine care plus twice daily mindful meditation"
10186272|NCT03737279|Active Comparator|Routine care|"Control Group:~Routine care which includes ACOG educational pamphlets on day 1, 2 and 3 after randomization"
10186273|NCT03737266|Experimental|Sonographically assisted breast surgery|Sonography assisted breast surgery
10186274|NCT03737266|Active Comparator|Conventional breast surgery|Conventional breast surgery
10186275|NCT03737227|Other|Cinematographic recording|Cinematographic recordings of the asymptomatic participants during flexion and extension of the lumbar spine.Cinematographic recordings will be performed twice with an interval of two weeks.
10186276|NCT03737214|Experimental|Lucerastat|Dose will be based on subject's eGFR.
10161606|NCT03981913||Healthy control (HC)|Participants without neurological or psychiatric disturbance (n= 30)
10161607|NCT03981913||Parkinson's disease (PD)|Participants with idiopathic Parkinson's disease but without other neurological or psychiatric disturbance (n= 30)
10161608|NCT03982004|Experimental|Epicutaneous cryoimmunotherapy+imiquimod+pembrolizumab+GM-CSF|"Epicutaneous cryoimmunotherapy treatments (6 total) during weeks 1-15 (every 2 weeks for the first 2 treatments, then every 3 weeks until week 15)~Topical imiquimod will be applied 5 days per week (5 days on, 2 days off from weeks 1-15)~Pembrolizumab will be given every 3 weeks for a minimum of 4 cycles starting at Week 3 until disease progression or unacceptable toxicity.~Intra-lesional GM-CSF 250 mcg every 2 weeks x 2 doses then every 3 weeks for 3 doses"
10161609|NCT03981926|No Intervention|In-Person|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek atopic dermatitis care from primary care practitioners or dermatologists, just as they would in the real world.
10161610|NCT03981926|Experimental|Team-Based Connected Health (TCH)|The intervention arm is the team-based connected health (TCH) model, which purports to increase access to specialists and improve outcomes. Specifically, TCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. TCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
10161611|NCT03981887|Experimental|Nafithromycin 200 mg as IV infusion|Nafithromycin 200 mg administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
10161612|NCT03981887|Placebo Comparator|placebo administered as IV infusion|Placebo administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
10161613|NCT03981900||Rheumatoid arthritis|All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib
10161614|NCT03981874|Experimental|Telephonic interview|Parents or patients will be contacted by phone in order to precise whether there are persistent sequelae or not
10161615|NCT03981848||Relapse|Relapse of tumor within two years after liver transplantation
10161616|NCT03981848||Non-relapse|Non-relapse of tumor within two years after liver transplantation
10161617|NCT03981679|Experimental|Biological collection|"For all the patients include in the study :~- Blood samples collected before the colonoscopy In parallel to this biological collection, standardized clinical data will be entered into a database"
10161618|NCT03981510|Experimental|Children being investigated with 3D-transit|"4 groups of each 20 children will be investigated with respectively one or two capsules:~Healthy children (1)~Children with chronic constipation (2)~Children with neurofibromatosis type 1 (2)~Children with cancer receiving treatment with Vincristine (1)"
10161619|NCT03981757|Experimental|NeurOS Group|Apply the single use NeurOS cerebral oximetry sensor adhesive onto patients' head who are going to have CEA surgery in the operating room before anesthesia induction.
10161620|NCT03981601|Active Comparator|lovastatin 40 mg with bone graft|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
10161621|NCT03981601|Active Comparator|without drug with bone graft|after tooth extraction, put the bone graft wifin tooth socket
10161622|NCT03981536|Experimental|AP-101: Dose Level 1|Single dose of AP-101
10161623|NCT03981536|Experimental|AP-101: Dose Level 2|Single dose of AP-101
10161624|NCT03981536|Experimental|AP-101: Dose Level 3|Single dose of AP-101
10161625|NCT03981627|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation
10161626|NCT03981627|Active Comparator|NovoRapid®|Subcutaneous injection of insulin aspart
9974367|NCT01340469|Active Comparator|study|Probiotics supplementation .
9977353|NCT01360528||Very low birth weight|Between 1000-1500 gram babies
10161627|NCT03981718|Active Comparator|Group: Standard|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive fat grafting procedure per standard of care during their 2nd stage breast reconstruction.
10161628|NCT03981718|Experimental|Group: Experimental|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive their fat grafting procedure until 6 months after their 2nd stage breast reconstruction.
10161629|NCT03981549|Active Comparator|Immediate Cellular Therapy / Deferred Sham Therapy|"At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.~At 6 months: Sham bone marrow aspiration and sham intravitreal injection."
10161630|NCT03981549|Sham Comparator|Immediate Sham Therapy / Deferred Cellular Therapy|"At baseline: Sham bone marrow aspiration followed by sham intravitreal injection.~At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells."
10161631|NCT03981783|Active Comparator|Best available care (BAC)|
10161632|NCT03981783|Experimental|Telerehabilitation (TH)|
10161633|NCT03981666|Experimental|Patients with insomnia|adult outpatients with a localized or metastatic breast, colorectal, pulmonary or urological cancer
10161634|NCT03981770||Group good sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are more than four hours.
10161635|NCT03981770||Group poor sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are less than four hours.
10161636|NCT03981692|Active Comparator|Consecutive Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. Immediately after these trainings, they should expected to find the letters Z in the mixed letters, search for the five words you read on the previous page, find the similarities between the concepts, find the letter in the given tables, derive the fruit names starting with the letter, count the days of the week etc. Attention, memory and arithmetic training will be given the ability to run.
10161637|NCT03981692|Active Comparator|Integrated Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. They will be done similar cognitive activities during with this simple balance trainings.
10161638|NCT03981835||Post -PCI Patients scheduled for Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Cardiac Surgery. No intervention will be administered.
10161639|NCT03981835||Post -PCI Patients scheduled for Non- Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Non-Cardiac Surgery. No intervention will be administered.
10161640|NCT03981562|Experimental|1000 IU Vitamin D|
10161641|NCT03981562|Experimental|4000 IU Vitamin D|
10161642|NCT03981562|Placebo Comparator|Placebo|
10161643|NCT03981640|Experimental|Black Adults|Black adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
10161644|NCT03981640|Experimental|White Adults|White adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
10161645|NCT03981484|Experimental|PCC|single dose of 4-Factor PCC in addition to standard resuscitation methods
9520204|NCT03279640|Experimental|Single stimulation|"rTMS on ipsilesional M1~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
9974368|NCT01340469|Placebo Comparator|control|The control group received daily placebo liquid .
10161646|NCT03981484|Active Comparator|Standard of Care|standard resuscitation methods only
10161647|NCT03981523|Experimental|BZN-60|150 mg twice a day for 60 days.
10161648|NCT03981523|Experimental|BZN-30|150 mg once a day for 30 days.
10161649|NCT03981523|Experimental|BZN-90|150 mg once a day for 90 days.
10161650|NCT03981523|Experimental|NFX-60|240 mg twice a day for 60 days.
10161651|NCT03981523|Experimental|NFX-30|240 mg twice a day for 30 days.
10161652|NCT03981523|Experimental|NFX-90|240 mg once a day for 90 days.
10161653|NCT03981445|Experimental|On-site Integrated Care with Adherence Counseling|Participants randomized to the on-site integrated care with adherence counselling arm will be prescribed pre-exposure prophylaxis (PrEP) (Truvada®) and, if indicated, Hepatitic C (HCV) treatment (Epclusa®) at the OAT clinic or SAP from which they were recruited. In addition to PrEP and, if indicated, HCV care, participants in the on-site integrated care arm will receive any required health care services as per local standard of care. Addiction treatment, OAT, and mental health services will be provided, if necessary and available. Participants recruited at syringe access programs (SAP) will be offered addiction counseling and treatment, including OAT when in the integrated care arm in addition to site standard of care.
10161654|NCT03981445|Experimental|Off-site Referral to Specialized Care with Patient Navigation|Participants randomized to the off-site referral to specialized care and patient navigation group will be linked to primary care for PrEP and, if necessary, HCV treatment by a patient navigator. Given the replicated success of the AntiRetroviral Treatment Access Study (ARTAS) intervention regarding linking HIV-infected individuals to HIV primary care, we adapted ARTAS to facilitate people who inject drugs linkage with PrEP and, if necessary, HCV treatment services. Participants in the off-site care arm will be prescribed PrEP and, if necessary, HCV treatment by their off-site physician. All necessary care will also be provided to participants by their off-site physician. Off-site physicians will be notified that if their patients are placed on a waiting list, unable to afford, or are otherwise unable to immediately access PrEP or HCV treatment, Truvada® and Epclusa® are available to participants of the M2HepPrEP study immediately and free of charge.
10161655|NCT03981458|Active Comparator|Hyalofemme|Hyalofemme is a cream/gel containing hyaluronic acid, designed to be applied vaginally. This is primarily used in treatment of atrophic vaginitis and is applied by the patient once every three days. We intend treatment to continue for 6 months.
10161656|NCT03981458|Active Comparator|Ialuril|Ialuril is a bladder instillation designed to be delivered to the bladder via catheter. This is primarily used in patients suffering from recurrent UTI and acts to help rebuild the lining of the bladder, reducing irritation. Ialuril is applied weekly for 6 weeks, followed by every 2 weeks for 6 weeks, then once monthly for maintenance. Treatment will be continued for 6 months.
10161657|NCT03981419|Experimental|GRF6021|"Subjects will receive GRF6021 per the following schedule:~On the day before surgery~On the day of surgery within 4 hours before surgery start (first incision)~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)~On the day after surgery"
10161658|NCT03981419|Placebo Comparator|Placebo|"Subjects will receive Placebo per the following schedule:~On the day before surgery~On the day of surgery within 4 hours before surgery start (first incision)~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)~On the day after surgery"
10161659|NCT03981432|Experimental|Constitutional leanness|Constitutional leanness
10161660|NCT03981432|Experimental|Normal weight|Normal weight women
10161661|NCT03981432|Experimental|Anorexia nevrosa|women presenting Anorexia nevrosa
10161662|NCT03981250|No Intervention|Control Group|The control group will be asked to keep their lifestyle behaviour and not increase their physical activity levels during the study period.
10161663|NCT03981250|Experimental|Exercise Group|The exercise group will engage in a home-based resistance exercise intervention for 12 weeks. They will perform 6 exercises, one each day for one minute, for 6 days a week.
10161664|NCT03981263|Other|MEAVANTI + Standard protheses|The patients will benefit from the experimental prothesis (MEAVANTI), after a wash-out period of 15 days, they will benefit from the standard non-adherent prothesis.
9977354|NCT01360528||Low birth weight|Between 1500-2500 gram
10161665|NCT03981263|Other|Standard + MEAVANTI protheses|The patients will benefit from the standard non-adherent prothesis, after a wash-out period of 15 days, they will benefit from the experimental prothesis (MEAVANTI).
10161666|NCT03981172||Non-obese/HED|Non-obese women given 60 gram portions of high energy density snack foods to consume daily for two weeks.
10161667|NCT03981172||Non-Obese/LED|Non-obese participants that were given 60 gram portions of low energy density foods to consume daily for two weeks.
10161668|NCT03981172||Obese/LED|Obese participants that were given 60 gram portions of low energy density snack foods to consume daily for two weeks.
10161669|NCT03981172||Obese/HED|Obese participants that were given 60 gram portions of high energy density snack foods to consume daily for two weeks.
10161670|NCT03981328|Active Comparator|self-monitored blood glucose|The control group participants will perform self-monitored blood glucose testing with a study-provided blood glucose meter, including testing supplies. They will perform capillary blood glucose monitoring as routinely used for patients with GDM i.e. at least four capillary blood glucose values daily including measurements at fasting as well as 1h after starting each meal by using a routinely available blood glucose measurement device.
10161671|NCT03981328|Experimental|Continuous glucose monitoring|Patients randomized to the intervention group will be equipped with a real-time CGM sensor (Dexcom G6 sensor, a small flexible device that records interstitial glucose levels every five minutes). The sensor will be inserted into the subcutaneous tissue of the anterior abdomen wall. Additionally, patients will be advised to record capillary blood glucose values if glucose alerts or readings do not match with symptoms or expectations. Participants will be educated how to exchange the sensor (has to be exchanged every ten days) and will be equipped with a real-time CGM monitor and instructed in its use. The monitor provides the user with information about current glucose levels and notifies the patient before she reaches her upper or lower glucose threshold and when glucose levels change rapidly. All patients in the intervention group will specifically trained how to use the system.
10161672|NCT03981289||CAPN3 (LGMD2A)|Clinical Assessments, Biomarkers
10161673|NCT03981289||DYSF (LGMD2B)|Clinical Assessments, Biomarkers
10161674|NCT03981289||ANO5 (LGMD2L)|Clinical Assessments, Biomarkers
10161675|NCT03981289||DNAJB6 (LGMD1D)|Clinical Assessments, Biomarkers
10161676|NCT03981289||Sarcoglycan (LGMD2D) (LGMD2E) (LGMD2C) (LGMD2F)|Clinical assessments
10161677|NCT03981159|Experimental|Active group (under physical training)|Subjects belonging to this arm underwent physical training for three months, twice per week (60 minutes per session).
10161678|NCT03981159|No Intervention|Passive group (no physical training)|Subjects served as controls.
10161679|NCT03981042|No Intervention|Control group|waiting for a 3-minute delay after injection of the atracurium before laryngoscopy
10161680|NCT03981042|Experimental|Monitoring group|waiting for the TOF ratio at 0 at the corrugator supercilli before laryngoscopy
10161681|NCT03981406|Experimental|Palliative Care|Palliative care is comprehensive, coordinated interdisciplinary care for patients and families facing a potentially life-threatening illness. This consists of specially trained teams of professionals including physicians, nurses, social workers, and chaplains that provide care and support in inpatient and outpatient settings.
10161682|NCT03981406|Placebo Comparator|Standard of Care|Standard of care for idiopathic pulmonary fibrosis
10161683|NCT03981146|Experimental|Nivolumab|Patients will receive 480mg of Nivolumab on a four weekly cycle for a maximum of two years.
10161684|NCT03981237|Experimental|Root canal treatment with laser-activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of a pulsed erbium laser. The canals are then dried and obturated.
10161685|NCT03981237|Active Comparator|Root canal treatment with ultrasonically activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of an ultrasonically driven instrument. The canals are then dried and obturated.
10161686|NCT03981185|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
10161687|NCT03981068|Experimental|Re-Irradiation with protons|60 Gy in 50 fraktions, 10 weekly with protons
10161688|NCT03981081|Experimental|eosinophil-guided group|patients will receive prednisone at a dose of 1mg/kg/day for up to 5 days or during the hospital stay if less than 5 days, only if the eosinophil count is> 2%
10161689|NCT03981081|Active Comparator|control group|a treatment based on prednisone at a daily dose of 1 mg/kg will be routinely administered for a maximum of 5 days, or during the hospital stay, if it is less than 5 days
10161690|NCT03980873|Experimental|Experimental|An experimental group. The psychological treatment includes 10 sessions of cognitive-behavioural treatment ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders
10161691|NCT03980873|No Intervention|Control|Three-month waitlist
10161692|NCT03980977|Other|skin and/or tumor Biopsy and blood sample|
10161693|NCT03981120|No Intervention|Standard Care Group|Patients in the control arm will not undergo laser and acupuncture treatment. The treatment and control group will be compared to the baseline pregnancy rate of women meeting the same inclusion and exclusion criteria from the clinic through a chart review over the two years prior to initiation of the study.
10161694|NCT03981120|Experimental|Laser and Acupuncture Group|"The patients in the treatment arm will have 7 treatments before transfer (2-4 sessions a week), for the 3 weeks from starting estrace leading to the day before embryo transfer, then one (before and after transfer) on the day of transfer (total 8 sessions). Each treatment leading up to transfer day treatment consists of:~Traditional Acupuncture at points Sp9 to SP6 EA2Hz Milliamp (Pantheon device), ST-36 B, LI4 unilateral, LV3 unilateral and/or LU7 unilateral, K6 unilateral.~Bioflex Array (Photobiomodulation) - simultaneously array placements with each treatment over the sacrum (points BL-31, BL 32, BL 33 BL 34, DU2, DU3) and lower Abdomen above uterus (Ren 2 to Ren 6)~Laser acupuncture over ST-9, ST10, SJ 17, ST-11. Ren 3 and Ren 4. 6.75 J per point at ST 9, ST10 (over carotid) and SJ17 (vertebral artery).~On the day of FET on site at IVF clinic there will be a before and after traditional and laser acupuncture treatment."
10161695|NCT03981094|Experimental|BMS-986278|
10161696|NCT03981094|Experimental|Pirfenidone|
10161697|NCT03981094|Experimental|BMS-986278 + Pirfenidone|
10161698|NCT03981029||FACT High-dose folic acid treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily high-dose folic acid supplementation during pregnancy.
10161699|NCT03981029||FACT Placebo treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily placebo supplementation during pregnancy.
10161700|NCT03981055|Experimental|Active tDCS and Active TUS|Active tDCS and Active TUS for 20 min
10161701|NCT03981055|Sham Comparator|Sham TDCS and Sham TUS|Sham TDCS and Sham TUS for 20 min
10161702|NCT03981276||Primary participant:|"Participants affected by hereditary spastic paraplegia (HSP) or a phenotypically related disorder Primary participants will be followed at annual intervals. The workup includes clinical, imaging, sensor-based, patient/observer reported and molecular outcome parameters and biosampling.~Participants with unknown genetic diagnosis may receive genetic testing including whole exome or whole genome sequencing and other OMICS techniques."
10161703|NCT03981276||Secondary participant/ First or second-degree|First or second degree unaffected family members of primary participants. Secondary participants may undergo the same study procedures as primary participants.
10161704|NCT03981276||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as primary participants.
10161705|NCT03980847|Active Comparator|Alendronate 20 mg with bone graft|after tooth extraction, put teh Alendronate 20mg with bone graft within teh tooth socket
10161706|NCT03980847|Active Comparator|bone graft alone|after tooth extraction, put the bone graft within the tooth socket
10161707|NCT03980951|Active Comparator|combined spinal epidural group|Bupivacaine 2.5 mg
10161708|NCT03980951|Active Comparator|dura puncture epidural group|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
10161709|NCT03980951|Active Comparator|epidural|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
10161710|NCT03980964|Experimental|Active NMES|Treatment arm receives an active NMES therapy including a conductive garment with NMES therapy, electrodes, and mobile app.
10161711|NCT03980964|Sham Comparator|Inactive NMES|Control arm receives inactive NMES therapy including a conductive garment (no NMES and no electrodes), and mobile app.
10161712|NCT03981315||Lithogenic bile in symptomatic patient|Patients who are performed a cholecystectomy as a treatment of their gallbladder disease
10161713|NCT03981315||Lithogenic bile in asymptomatic patient|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) and gall stones are found
10161714|NCT03981315||Non-lithogenic bile|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) without gall stones
10161715|NCT03981302|Experimental|Family nursing conversations|The intervention will consist of structured family nursing conversations between a nurse, the patient and their selected family members. The patients will receive the intervention and usual treatment.
10161716|NCT03981302|No Intervention|Usual treatment|The patients will receive usual treatment.
10161717|NCT03980795|Experimental|Intervention|The intervention (I) group received monthly exercise physiologist consultations, exercise prescription (resistance and aerobic exercise program using exercise bands) and weekly phone calls over 12 weeks.
10161718|NCT03980795|No Intervention|Control|Usual care
10161719|NCT03981133|Experimental|A: unrestricted pacifier|recommendation to offer a pacifier at the facility providing maternity and newborn services the first days of life
10161720|NCT03981133|Active Comparator|restricted pacifierr|recommendation not to offer a pacifier to normal new born infant at the maternity thre first days of live
10161721|NCT03981003||MS Patients|
10161722|NCT03980782|Experimental|Music Intervention|Each participant will receive a 30 minute individual music intervention twice daily.
10161723|NCT03980782|No Intervention|Care as usual|Each participant will receive care as usual.
10161724|NCT03981016|Experimental|Biological collection|"For the patients include in the study :~blood samples collected at different times : Before surgery and during the post-operative visit and~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
10161725|NCT03980821|Experimental|AZD4635 monotherapy|Dose escalation of AZD4635 monotherapy for patients with advanced solid malignancies
9520205|NCT03279627||Hypoglycemia|This group will be those who experience a BG < 70 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
9974369|NCT01340508|Experimental|Intensity modulated Radiotherapy|Intensity modulated radiotherapy, dose escalation, rectal cancer, volumetric modulated arc therapy
10161726|NCT03980860|Active Comparator|HIIT (High Intensity Interval Training)|Subjects are undergoing high intensity interval training
10161727|NCT03980860|Active Comparator|Low intensity training long duration|Subjects are undergoing a lower intensity training program for a long duration
10161728|NCT03980860|No Intervention|Control|No exercise program intervention (usual care)
10161729|NCT03980990|Experimental|Metformin Continuation|Patients undergoing angiography will continue their metformin without interruption at their next scheduled dose following angiography.
10161730|NCT03980990|No Intervention|Metformin Interruption|Patients undergoing angiography will interrupt their metformin for 48 hours post angiography.
10161731|NCT03981198|Other|RAP treatment|Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.
10161732|NCT03980756|Experimental|Group A1|Period 1: Test Drug(AD-206 20mg) Period 2: Reference Drug(Esomeprazole 20mg)
9977355|NCT01360541|Experimental|Radiofrequency ablation|Endoscopic radiofrequency ablation of BE
10161733|NCT03980756|Experimental|Group A2|Period 1: Reference Drug(Esomeprazole 20mg) Period 2: Test Drug(AD-206 20mg)
10161734|NCT03980756|Experimental|Group B1|Period 1: Test Drug(AD-206 40mg) Period 2: Reference Drug(Esomeprazole 40mg)
10161735|NCT03980756|Experimental|Group B2|Period 1: Reference Drug(Esomeprazole 40mg) Period 2: Test Drug(AD-206 40mg)
10161736|NCT03980808|Experimental|ASL-ADE Intervention Arm|One-half of enrolled participants will view the ASL-ADE video intervention.
10161737|NCT03980808|Sham Comparator|Control Arm|One-half of enrolled participants will view a non-health related video approximately the same length as the video intervention.
10161738|NCT03980665|Experimental|Arsenic trioxide combined with cART|Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
10161739|NCT03980665|No Intervention|Without arsenic trioxide therapy|Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
10161740|NCT03980652|Other|Intervention|Change of gloves and use of separate, sterile instruments before closing the abdominal wall
10161741|NCT03980652|No Intervention|Current routine hospital practice|No change of gloves or use of separate, sterile instruments before closing the abdominal wall
10161742|NCT03980704|Active Comparator|High Protein|Provision of 400 ml per day of high protein oral nutritional supplements
10161743|NCT03980704|Experimental|Immuno ONS|Provision of 400 ml per day of immunostimulating oral nutritional supplements
10161744|NCT03980548||CABG patients|
10161745|NCT03980548||PAD patients|
10161746|NCT03980548||Healthy volunteers|
10161747|NCT03980548||Patients with CAD|
9826418|NCT02417935|Experimental|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
10161748|NCT03980691|Experimental|Chidamide combined with CAR-T or TCR-T cell therapy|Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.
10161749|NCT03980691|No Intervention|without intervention|Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
10161750|NCT03980613||Spontaneous subarachnoid haemorrhage|Patients with verified spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
10161751|NCT03980613||Controls|Patients without spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
10161752|NCT03980405|Experimental|Group 1|Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
10161753|NCT03980405|Experimental|Group 2|6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2
10161754|NCT03980353||Children before entrance in primary school|Children with type 1 diabetes, who are too young to go to primary school at the start of the school year 2018-2019, followed in the Diabetology Department of Lyon Pediatric Hospital.
10161755|NCT03980379|Experimental|experimental group|304 injection.WILL be administered single dose IV in the patients with CD20 positive B cell NHL
10161756|NCT03980379|Active Comparator|control group|Rituximab will be administered single dose IV in the patients with CD20 positive B cell NHL.
10161757|NCT03980639||abatacept|patients with abatacept prescription
10161758|NCT03980639||others bDMARDs|patients with at least one bDMARD prescriptions
10161759|NCT03980444|Experimental|control group, no basket of wire|"The dividing person and the patients themselves were not aware of which group they were in. They were double-blind Was.~In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
10161760|NCT03980444|Sham Comparator|using a basket of wires|In group B (using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
10161761|NCT03980457|Experimental|Exo-group|Standard rehabilitation plus use of Exoskeleton
10161762|NCT03980457|Placebo Comparator|Control-Group|Standard rehabilitation
10161763|NCT03980431|Experimental|FBY in suspected malignant brain tumor|This arm investigates the metabolic characteristics of FBY in suspected malignant brain tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after FBY PET scan.
9826419|NCT02417935|Active Comparator|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
9826420|NCT02417961|Experimental|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
10161764|NCT03980431|Experimental|FBY in suspected recurrent glioma|This arm investigates the value of FBY to differentiate tumor progression from pseudoprogression. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operation, MRI follow up or change of treatment strategy, according to specific conditions, will be recommended for the definitive diagnosis as well as the management of patients.
10161765|NCT03980600|Experimental|Donor site treatment with NFC dressing/FibDex®|"Patients requiring skin graft donor site treatment were enrolled in the investigation. Patients were selected based on clinical evaluation by a plastic surgeon.~Of the total 33 patients enrolled in the study, nine patients were treated during the optimization phase with experimental NFC dressing Types 1-3. The remaining 24 patients were treated with the final product Type 4 (FibDex®). The mean age of patients treated with NFC dressing/FibDex® was 50 ± 18 years, in the range of 21-74 years.~Suprathel® was used to treat donor sites in the same patients as a reference material. During the optimization phase, Suprathel was intra-individually compared with NFC dressing types 1-3 in five patients out of nine. From the remaining 24 patients, Suprathel was intra-individually compared with FibDex® in 17 patients."
10161766|NCT03980496|Active Comparator|omeprazole infusion (OI) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.
10161767|NCT03980496|Active Comparator|omeprazole bolus (OB) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.
10161768|NCT03980288|Experimental|CAR-GPC3 T Cells|The subjects enrolled will be sequentially assigned to Part 1 at 3 dose levels via typical 3+3 dose escalation method and then Part 2, cohort expansion stage, 3 cohorts of CAR T therapy combination with currently available treatment for HCC. stage Part 1: Dose escalating: 3 dose level Part 2: 3 cohorts Cohort 1. Combination with tyrosine kinase inhibitors Cohort 2. Combination with PD-1 / PD-L1 monoclonal antibody Cohort 3. Combination with the drugs may benefit for patient at investigator's discretion
10161769|NCT03980535|Experimental|Device Feasibility (MRI, MRSI)|Patients undergo an additional investigational MRI or MRSI sequence along with the standard MRI or MRSI. Healthy volunteers undergo an investigational MRI or MRSI sequence. Healthy volunteers may also undergo an additional standard sequence if there is one that can be compared to the investigational sequence. All MRI or MRSI procedures, including the standard MRI or MRSI, are no longer than 60 minutes.
10161770|NCT03980418|Experimental|all included patients will have the same procedure|After the conventional DaTSCAN SPECT/CT exam in conventional camera, all patients included will have two recordings of DaTSCAN SPECT/CT in semiconductor CZT (cadmium zinc telluride) camera; one focused on the striatum and the other focused on the total brain
10161771|NCT03980678|Active Comparator|Mineral Rich Algae with orange flavoring|Participants will consume the Aquamin Soluble (Mineral Rich Algae) equivalent of 1000mg Calcium in 250 ml of orange flavoured water.
10161772|NCT03980678|Placebo Comparator|Water with orange flavoring|Participants will consume a placebo of maltodextrin in 250 ml of orange flavoured water (40mg Calcium).
10161773|NCT03980262|Experimental|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
10161774|NCT03980262|Active Comparator|MoneySmart|A financial education program available through the Federal Deposit Insurance Corporation. Money Smart includes programs for adults and school-aged children, a parent/caregiver guide and a train-the-trainer program. MoneySmart is an Extension-approved program designed to improve money-management practices and financial confidence for parents MoneySmart involves eight weekly sessions that includes one-to-two hour modules with take-home guides for adults. For children, there are eight sessions that include take-home worksheets and a parent/caregiver guide.
10161775|NCT03980392|Experimental|Facility-based Intervention|A group will consist of 5 or 10 persons depending on the size of the study center. Exercise training will be guided by study exercise therapists at a gym and consist of programs for progressive muscle strength training, aerobic exercise, and exercises to improve postural balance and flexibility using elastic bands, floor plate and chairs (three times per week, 60 min per session).The cognitive training program is a program including tasks to be effective in episodic memory, executive function, attention, working memory, calculation, and visuospatial function (twice per week, 60 min per session). The nutritional intervention is conducted by study nutritionists (three individual sessions and seven group sessions). Management of metabolic and vascular risk factors will include additional meetings with the study nurse (at 0, 4, 8, 16, and 20 weeks), and the study physician (at 0 and 12 weeks). Motivational training is conducted by psychologist (four group session).
10161776|NCT03980392|Experimental|Home-based Intervention|The nutritional intervention, management of metabolic and vascular risk factors, social activity, and motivational training in the home-based intervention are similar to the facility-based intervention. The physical exercise programs consist of one group session (60 min) and two home-based sessions (60 min per session) per week in the first 2 months of the trial. During the remaining months of the 6-month study, participants in the home-based intervention attend a 1-h physical exercise group session per two weeks and two or three exercise sessions (60 min per session) alone at home per week. The cognitive training programs consist of one group session (60 min) and one home-based sessions (60 min per session) per week in the first 2 months of the trial. For the remainder of the 6-month study, participants in the home-based intervention attend a 1-h group cognitive training session per two weeks and one or two cognitive training sessions (60 min per session) alone at home per week.
10161777|NCT03980392|No Intervention|Controls|They are waiting list controls. They will receive the multi-domain intervention after this study.
10161778|NCT03980236|Experimental|Livongo-Insulia Study App Arm|Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration
10161779|NCT03980366|Experimental|ECT to treat self-injurious behaviors in adults with ASD|After initial exams and pre-screening, participants will receive bilateral Electroconvulsive Therapy (ECT) for 12 treatments sessions over the course of 4 weeks, plus non-ECT follow-up sessions at 1, 2, 6, and 12 months post-ECT treatment.
9520206|NCT03279627||Hyperglycemia|This group will be those who experience a BG > 250 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
10161780|NCT03980210|Experimental|Hyperbaric oxygen therapy|"Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)~Five successive steps:~FiO2 0.21 - 1 ATA~FiO2 1 - 1 ATA~FiO2 1 - 2.5 ATA~FiO2 0.21 - 2.5 ATA~FiO2 0.21 - 1 ATA"
10161781|NCT03980197|Experimental|Intervention|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
10161782|NCT03980197|Active Comparator|Control|No active surveillance test and preemptive isolation performed. Only standard precaution is needed, and if clinical isolates reveals MDRO, start contact precaution.
10161783|NCT03980327|Experimental|probiotic|Lactobacillus rhamnosus (5 billion colony forming units per day) and Lactobacillus johnsonii (200 million colony forming units per day) given orally or through a gastrostomy tube daily for 3 months
10161784|NCT03980327|Placebo Comparator|control|1 mL of pure medium chain triglyceride oil given orally or through a gastrostomy tube daily for 3 months
10161785|NCT03980223|Experimental|Doxy PEP|Doxycycline 200mg in addition to standard of care STI testing and treatment
10161786|NCT03980223|No Intervention|Control|The control arm will consist of standard of care STI testing and treatment
10161787|NCT03980249|Experimental|Carvedilol + Standard Treatment|Subjects will receive carvedilol starting at 6.25 mg orally (PO) twice daily for 1-2 weeks and if tolerated will then be increased to 12.5 mg PO twice daily starting on day 1 of concurrent chemoradiotherapy and continue daily until the end of adjuvant cycle 6 of temozolomide and Tumor Treated Fields.
10161788|NCT03980041|Experimental|IPI-549 + Nivolumab|Participants receive IPI-549 orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
10161789|NCT03980041|Active Comparator|Placebo + Nivolumab|Participants receive placebo orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
10161790|NCT03980184|Experimental|Study Medication|guanfacine 3mg/day (GUA)
10161791|NCT03980184|Placebo Comparator|placebo|placebo (PBO)
10161792|NCT03979976|Active Comparator|ramipril group|Use of ramipril 10mg/day per 12 weeks
10161793|NCT03979976|No Intervention|Control Group|Without ramipril
10186277|NCT03737201|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
10186278|NCT03737201|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
10186279|NCT03737201|Active Comparator|control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
10186280|NCT03737175|Experimental|Carotid Artery Stenting group|Carotid Artery Stenting
10186281|NCT03737175|Active Comparator|Carotid Endarterectomy group|Carotid Endarterectomy
10186282|NCT03737162|Experimental|Covered stent group|Covered stent
10186283|NCT03737162|Active Comparator|Bare-metal stent group|Bare-metal stent
9826421|NCT02418000|Experimental|E6201 240 mg/m^2 IV weekly|E6201 240 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
10186284|NCT03737097|Experimental|Online Spaced Education|The intervention cohort will participate in an online spaced education on fall prevention education developed for patients with multiple sclerosis.
10186285|NCT03737097|Active Comparator|Brochure Education|The control cohort will receive the fall prevention education in bolus through a Brochure developed by the National Multiple Sclerosis Society. The brochure was translated to portuguese and will be used in the study with authorization of the Society.
10186286|NCT03737084|Experimental|CBCT Intervention|The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver. The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
10186287|NCT03737084|No Intervention|Control group|Control group participants will receive standard hospital care. Patients and caregivers of the control group will receive the same CBCT intervention at the end of the study.
10186288|NCT03737071|Experimental|Low Carbohydrate Diet|Low Carbohydrate Diet
10186289|NCT03737032|Experimental|Intermittent, Continuous, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Continuous theta burst stimulation, 3) Sham theta burst stimulation.
10186290|NCT03737032|Experimental|Intermittent, Sham, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Sham theta burst stimulation, 3) Continuous theta burst stimulation.
10186291|NCT03737032|Experimental|Continuous, Intermittent, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Sham theta burst stimulation.
10186292|NCT03737032|Experimental|Continuous, Sham, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Sham theta burst stimulation, 3) Intermittent theta burst stimulation.
10186293|NCT03737032|Experimental|Sham, Intermittent, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Continuous theta burst stimulation.
10161794|NCT03980106|Experimental|Experimental RI-PI|They receive the Reciprocal Inhibition (RI) technique in the first stage and then the Post-isometric Inhibition (PI) technique in the second stage.
10161795|NCT03980106|Experimental|Experimental PI-RI|They receive the Post-isometric Inhibition (PI) technique in the first stage and then the Reciprocal Inhibition (RI) technique in the second stage.
10161796|NCT03980093|Experimental|Education plus Values|
10161797|NCT03980093|Active Comparator|Education|
10161798|NCT03979833||1|Individuals currently living, over the age of 18 years and known carriers of a pathogenic variant in the VHL gene.
10161799|NCT03980171|Experimental|Obinutuzumab+venetoclax+lenalidomide|Patients in both dose escalation and dose expansion will receive 6 cycles of induction treatment consisting of obinutuzumab (flat dose of 1000mg) and protocol defined dose levels of venetoclax and lenalidomide.
10161800|NCT03979846|Experimental|Arm I (usual care, computer-based symptom reporting)|Participants receive usual care for 3 weeks, then use a computer based symptom reporting system for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
10161801|NCT03979846|Experimental|Arm II (computer-based symptom reporting, usual care)|Participants use a computer based symptom reporting system for 3 weeks, then receive usual care for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
10161802|NCT03980002|Experimental|FCR/BR alternating with ibrutinib|FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
10161803|NCT03980132|Experimental|Preoperative Lugol Solution preparation|Patients will receive Lugol Solution preparation for 10 days before thyroidectomy
10161804|NCT03980132|No Intervention|No preparation|Patients will not receive preparation before thyroidectomy
10161805|NCT03980067|Experimental|Virtual Reality Group|The children in the experimental group will receive the standard of care (access to in room activity including television (TV) distraction if desired, parent support and distraction at bedside, and quiet time) in addition to our intervention, an interactive virtual reality game, played for a minimum of 5 minutes prior to procedural sedation.
10161806|NCT03980067|No Intervention|Standard of Care|The children in the control group receiving standard of care will have access to in room activity including TV distraction if desired, parent support and distraction at bedside, and quiet time.
10161807|NCT03980080|Experimental|OSE-127: Part 1 (SAD), Cohort A & Cohort B|
10161808|NCT03980080|Placebo Comparator|Placebo: Part 1 (SAD), Cohort A & Cohort B|
10161809|NCT03980080|Experimental|OSE-127: Part 2 (MAD)|
10161810|NCT03980080|Placebo Comparator|Placebo: Part 2 (MAD)|
10161811|NCT03980054|Experimental|Arm Pyrotinib|Intervention: Drug: Pyrotinib
10161812|NCT03980054|Placebo Comparator|Arm Placebo|Intervention: Drug: Placebo
10161813|NCT03979781|Experimental|Treatment Group|Intervention group
10161814|NCT03979781|Active Comparator|Control Group|Standard of Care group
10161815|NCT03980119|Experimental|HITSystem 3.0 Intervention|All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.
10161816|NCT03980119|No Intervention|Control|All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.
10161817|NCT03979859|Experimental|WCK 4873|200 and 400 mg tablets Dosage form : Oral tablets Doses : To be determined based on the safety, tolerability and PK results of the single dose and food effect study
10161818|NCT03979859|Placebo Comparator|Placebo|Visually matching placebo
10161819|NCT03979768|Experimental|Risk Assessment Only pharmacies (RTO-group)|Offered a diabetes risk assessment service without any blood sample testing.
10161820|NCT03979768|Experimental|HbA1c-group /pharmacies|Offered a diabetes risk assessment service including a measurement of Haemoglobin A1c (HbA1c) to the people with a high risk of developing type 2 diabetes on the risk assessment form (The Finnish Diabetes Risc Score (FINDRISC) to those with a western background, and Leicester Risk Assessment (LRA) form for those with a non-western background.
10161821|NCT03980015||erythema migrans|patients with erythema migrans
10161822|NCT03979989|Experimental|Tapentadol IR|A single oral dose of tapentadol IR was administered in a fasted state (Treatment A).
10161823|NCT03979989|Experimental|Omeprazole, Tapentadol IR|Oral doses of omeprazole were administered once daily in a fasted state on 4 consecutive days (Days -3 to 1), plus 1 capsule of CG5503 IR administered 2 hours after the administration of omeprazole on Day 1 (Treatment B).
10161824|NCT03979755||Study Group|Women cancer survivors living in Campo Belo, Minas Gerais.
10161825|NCT03979755||Control Group|Women in routine follow-up in the public health system in Campo Belo, Minas Gerais.
10161826|NCT03979898|Experimental|Astrostem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells
10161827|NCT03979924|Other|Interventional Step|The interventional step will comprise the same follow-up as the observational step, except for the addition of an early and preventive care, conducted by a specialized physiotherapist using an active exercise handbook elaborated with the patient's therapeutic education transversal Unit (Utep). This aims at increasing the patient's adhesion to the program and to limit the reduction of mouth opening and its consequences ( Trismus rehabilitation)
10161828|NCT03979716|Experimental|Anosmic patients|
10161829|NCT03979716|Experimental|Hyposmic patients|
10161830|NCT03979716|Experimental|Normosmic patients|
10161831|NCT03979729||3D + 2D-Mammogram Recipients (Patient Group A)|Women presenting for mammographic screening who selected 3D + 2D- mammogram. These women will undergo in-person or telephone interviews.
10161832|NCT03979729||2D-Mammogram Recipients (Patient Group B)|Women presenting for mammographic screening who selected 2D- mammogram alone (declined 3D + 2D- mammogram). These women will undergo in-person or telephone interviews.
10161833|NCT03979729||Women Who Have Never Received a Mammogram (Patient Group C)|Women who have never undergone recommended mammographic screening. These women will participate in a onetime facilitated focus group.
10161834|NCT03979729||Providers|Primary care providers (physicians, physicians assistants, and advanced nurse practitioners) working in clinics providing primary care for underserved patient populations in New Mexico, including primary care providers at a RIOSNET-affiliated and UNM-affiliated clinics
10161835|NCT03979703|Experimental|Intervention group|Intervention will be a 12 week yoga class
10161836|NCT03979703|No Intervention|Control group|Control group will not participate in the 12 week yoga class but will participate in Surveys, 6 minute walking test, lung function test, and biomarker analysis. Furthermore, they will be offered a yoga class after the study.
10161837|NCT03979690|Experimental|Subjects Receiving Colonoscopy|Subjects receiving tandem colonoscopies using the NISInspire-C System followed by a Conventional Colonoscopy
10161838|NCT03979664|Active Comparator|Active Iontophoresis|One active iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
10161839|NCT03979664|Sham Comparator|Inactive Iontophoresis|One inactive iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
10161840|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 1)|Patients with NRAS Melanoma receiving the 1st dose of the treatment (400 milligrams)
10161841|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 2)|Patients with NRAS Melanoma receiving the 2nd dose of the treatment (800 milligrams)
10161842|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 3)|Patients with NRAS Melanoma receiving the 3rd dose of the treatment (600 milligrams twice a day)
10161843|NCT03979456|Active Comparator|6-month dosing interval|This arm is receiving standard dose rituximab 500 mg every 6 months
10161844|NCT03979456|Experimental|12-month dosing interval|This arm is receiving the comparator dose rituximab 500 mg every 12 months
10161845|NCT03979573|Other|Intervention Arm|"PSA testing~Multiparametric MRI (mp-MRI)~Radiomics~MR-guided biopsy (MR-guided and systematic US-guided)~Molecular Markers (Histological analysis of biopsy cores)"
10161846|NCT03979469|Experimental|opiod free general anesthesia|In group A opioid free anesthesia is administered. Anesthesia and analgesia were achieved with ketamine(1mg/kg, bolus), dexmedetomidine(1mcg/kg, over 10 minutes), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg). Anesthesia induction with ketamine(1mg/kg), propofol 1% 2-3mg/kg, rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
10161847|NCT03979469|Active Comparator|opioid based general anesthesia|In group B opioid based anesthesia is administered.Anesthesia and analgesia were achieved with remifentanil(0.3mcg/kg/minute), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg).Anesthesia induction with propofol 1% 2-3mg/kg,fentanyl(2mcg/kg), rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
10161848|NCT03979404|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
10161849|NCT03979326|Experimental|Young women during various of phases of menstrual cycle.|The group of 40 young women will have their hamstring muscle stretched in different phases of the menstrual cycle: follicular, ovulatory and luteal. Static stretching will last 3x 45 seconds with a 15 second break between repetitions. Before and after the intervention a series of tests will be performed.
10161850|NCT03979508|Experimental|Group 1 (surgery)|Patients undergo standard of care surgical resection.
10161851|NCT03979508|Experimental|Group 2 (abemaciclib, surgery)|Patients receive abemaciclib PO BID on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.
10161852|NCT03979248|Experimental|BMS-986165 + Rabeprazole|
10161853|NCT03979586|Experimental|Patient phototype I to IV|The study will be conducted in the Laser Dermatological and Plastic Center of the Conception Hospital in Marseille. It will be a prospective, controlled, hemiface, single-blind, independent-evaluator pilot study of 20 patients, 30 to 70 years old, with phototype I to IV (Fitzpatrick scale). By this study in hemiface, each patient will be his own witness. Neither the patient nor the examining doctor will know the choice of the hemiface of application of hyaluronic acid. This will be a single-blind study with independent evaluator. Patients will be included for 3 months, and followed for a period of 3 months.
10161854|NCT03979287|Experimental|IFC and Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour. Participants will receive treatment with Interferential current therapy plus a program of therapeutic exercise focused on the neck region
10161855|NCT03979287|Active Comparator|Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour.This group will only receive the same therapeutic exercise program.
10161856|NCT03979352|Active Comparator|Empagliflozin arm|"Participant will be treated by empagliflozin for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the placebo arm.~Participant and research staff is blinded to arm assignment."
10161857|NCT03979352|Placebo Comparator|Placebo arm|"Participant will take placebo for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the empagliflozin arm.~Participant and research staff is blinded to arm assignment."
10161858|NCT03979560|No Intervention|Control|"The control group will benefit from the usual support (depending on the practices of the department, prescription or not of oral nutritional supplements and physiotherapy at home, but without home intervention of adapted physical activity professionals or dieticians).~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
10161859|NCT03979560|Experimental|Nutrition intervention with appropriate physical activity|"Intervention at home of professionals:~Patients in this arm will benefit from 14 home interventions~7 home nutrition support (NS) sessions in 3 months or 1 session every 10 days (+/-4 days). These sessions will be conducted by a dietician from the company Saveurs et Vie.~7 home sessions of adaptive physical activity (APA) in 3 months, one session every 10 days (+/-4 days). These sessions will be conducted by professionals from association group Siel Bleu.~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
10161860|NCT03979261||sex ratio evaluation|Valvular surgery is performed in 30-40% of cases. The Cardiology and Cardiac Surgery De la Timone services 1000 patients as part of their valvulopathy and 450 benefit from cardiac surgery. On the other hand, transcriptomic analysis by microarray will only be done on 40 patients because the analysis costs 150 € / patients.
10161861|NCT03979599|Active Comparator|magnesium sulphate& levobupivacaine|Levobupivacaine add to magnisum sulphate
10161862|NCT03979599|Placebo Comparator|levobupivacaine|levobupivacaine
10161863|NCT03979235||Heahlthy people|perform motor function assessment by using scales, sEMG, and inertia sensors
10161864|NCT03979235||People with motor deficits|perform motor function assessment by using scales, sEMG, and inertia sensors
10161865|NCT03979235||Patients with dysphagia|perform motor function assessment by using scales, sEMG, and inertia sensors
10161866|NCT03979209|Experimental|Mometasone 1mg|1mg capsule dissolved in 240mg saline solution nasal irrigation
10161867|NCT03979209|Experimental|Mometasone 2mg|2mg capsule dissolved in 240mg saline solution nasal irrigation
10161868|NCT03979209|Experimental|Mometasone 4mg|4mg capsule dissolved in 240mg saline solution nasal irrigation
9977356|NCT01360541|Active Comparator|Surveillance|Endoscopic surveillance and PPI treatment
10161869|NCT03979053||Patients with AIH|60 adult participants will be recruited who are over the age of 18 and are attending a hepatology appointment at KCH NHS FT and are either being investigated for AIH or have confirmed AIH
10161870|NCT03978910|Experimental|Weigthlessness|during a flight
10161871|NCT03978988|Experimental|Thrombectomy + Carotid Stenting|"Intravenous thrombolysis will be administered if possible. Standard mechanical thrombectomy(MT) will be performed with a balloon Guide Catheter. MT technique will be left at the discretion of the operators.~Concerning the cervical disease, emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion. An intravenous bolus of 250mg of Aspirin (up to Imaging 24H) will be given at the end of the procedure in case of absence of complication.~Intravenous sedation or general anesthesia will be permitted.A second antiplatelet agent is used if a thrombus is formed : IV or nasogastric tube (choice by operator) A dual antiplatelet therapy is administered after 24H imaging follow-up excluding intracranial hemorrhagic complications (discretion of the local practice)"
10161872|NCT03978988|No Intervention|Thrombectomy alone|"Endovascular procedure:~Intracranial thrombectomy alone (carotid angioplasty may be performed)"
10161873|NCT03978949|Experimental|Probiotics|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
10161874|NCT03978949|Placebo Comparator|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
10161875|NCT03979014|Experimental|Vaccinated Arm|Add vaccine
10161876|NCT03979014|No Intervention|Control|No intervention
10161877|NCT03979092|Experimental|IP-ACLS|
10161878|NCT03979092|Other|Waitlist|
10161879|NCT03979196|Active Comparator|Inpatient Management|Women in this arm will follow the standard of care for admission to high-risk units at Sunnybrook Health Sciences Centre or North York General Hospital.
10161880|NCT03979196|Active Comparator|Outpatient Management|Women in this arm will be encouraged to follow the standard of care established in the high-risk clinics at Sunnybrook Health Sciences Centre or North York General Hospital.
10161881|NCT03978962||Study population|Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure
10161882|NCT03978871|Experimental|Growth Mindset|Persuasive education about emotions, brain development, and teenagers' ability to learn how to manage emotions
10161883|NCT03978871|Active Comparator|Brain Education|Neutral education about functions of different parts of the brain
10161884|NCT03978975|Active Comparator|normal weight women|20 women with a body mass index ranging between 18,5 and 24,9 kg.m2
10161885|NCT03978975|Experimental|overweight women|20 women with a body mass index ranging between 25 and 29,9 kg.m2
10161886|NCT03979001||Patients|Patients referred for polysomnography diagnosis of obstructive sleep apnea syndrome
10161887|NCT03979001||Controls|Person without obstructive sleep apnea syndrome
10161888|NCT03979105||Ketamine infusion|Ketamine infusion treatment for acute pain in adult population in all type of surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 48 hours.
10161889|NCT03978884|Experimental|Mild Hypertensive|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg
10161890|NCT03978884|Experimental|Mild Hypertensive with Diabetes|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg and diabetes.
10161891|NCT03978884|Experimental|Severe Hypertension|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg
10161892|NCT03978884|Experimental|Severe Hypertension with Diabetes|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg with diabetes
10186294|NCT03737032|Experimental|Sham, Continuous, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Continuous theta burst stimulation, 3) Intermittent theta burst stimulation.
10161893|NCT03979131|Experimental|Resectable GC and GEJC+avelumab+FLOT preoperative treatment|Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year.
9826422|NCT02418000|Experimental|E6201 320 mg/m^2 IV weekly|E6201 320 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
10161894|NCT03979027|No Intervention|No Breakfast|Fasting. Ad libitum water intake permitted.
10161895|NCT03979027|Experimental|Breakfast|Ad libitum intake of ready-to-eat-cereal with milk. Participants were given a choice of four commercially available RTECs with 1.8% fat cow's milk. Ad libitum water intake was also permitted. The four ready-to-eat-cereals were corn flakes, toasted rice, shredded whole wheat pieces with a sugar topping, and wheat, corn and oat shapes.
10161896|NCT03979157|Experimental|Healthy Volunteers|Multispectral Optoacoustic Tomography (MSOT) of proximal and distal leg muscles (total of 12 sites: left and right, 3 measurement points of Musculus quadriceps, and 3 measurement points of Musculus triceps surae) before and after the 6-Minute-Walk-Test by to independent investigators. Repetition of the same protocol after 14 days.
10161897|NCT03978923||the drill-inserted implants (G1)|
10161898|NCT03978923||the ultrasonic device- inserted implants (G2)|
10161899|NCT03978819||Patients with large CPA tumors|Patients with large cerebellopontine angle tumors (>2 x 2cm) undergoing elective surgery
10161900|NCT03978845|Experimental|Phrenic Nerve Blockade|All patients will be submitted to bilateral phrenic nerve block on its cervical portion.
10161901|NCT03978689|Experimental|CUE-101 dose escalation and expansion|Part A&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)
10161902|NCT03978689|Other|Pembrolizumab and CUE-101|Part C&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)
10161903|NCT03978572|Active Comparator|Resistance Training|12 weeks of whole-body progressive resistance training, three days per week, lower-extremity focused (60% of exercises targeting lower extremities)
10161904|NCT03978572|Active Comparator|Moderate-intensity continuous cycling|12 weeks of progressive endurance cycling on a stationary bicycle at a target heart rate, three days per week.
10161905|NCT03978572|Experimental|High-intensity interval cycling|12 weeks of progressive high-intensity interval cycling on a stationary bicycle, three days per week.
10161906|NCT03978585|Experimental|HTEMS Arm|High tone therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
10161907|NCT03978585|Active Comparator|TENS Arm|TENS therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
10161908|NCT03978663|Experimental|Neoadjuvant radiotherapy|3 doses of stereotactic radiotherapy administered prior to neoadjuvant chemotherapy in high-risk breast cancers.
10161909|NCT03978442|Experimental|CPT-SMART|COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) - an intervention that combines evidence-based PTSD treatment with guideline-concordant cognitive-behavioral smoking cessation counseling, bupropion, and intensive behavioral therapy through CM.
10161910|NCT03978442|Active Comparator|Combined Contact Yoked Control|COMBINED CONTACT YOKED CONTROL (CCYC) - an intervention that is identical to CPT-SMART for PTSD and smoking treatment, except for using non-contingent payment (i.e., yoked CM) to control for compensation and monitoring.
10161911|NCT03978494|Experimental|Period 1: Advagraf®; Period 2: Generic tacrolimus|In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.
10161912|NCT03978494|Experimental|Period 1: Generic tacrolimus; Period 2: Advagraf®|In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.
10161913|NCT03978559|Experimental|CAS with TMP/SMZ|
10161914|NCT03978559|Active Comparator|TMP/SMZ|
10161915|NCT03978416|No Intervention|Focus groups|"Information on practical and cultural barriers and promoters of successful weight management will be collected through focus groups. This will include include food access, dietary patterns, physical activity, time and financial constraints, and additional psychosocial and cultural factors.~A total of 30 participants will be recruited for the focus groups."
10161916|NCT03978416|Experimental|Pilot behavioral intervention|A prototype bilingual English-Spanish lifestyle intervention for weight reduction will be created. The prototype will then be iteratively refined during a series of short-term tests with 5 participants per test (two tests lasting 4 weeks, followed by a final test lasting 12 weeks) of intervention delivery.
10161917|NCT03978429|Experimental|Intervention Arm|"Community-based Pre-eclampsia/Eclampsia Detection and Management~Strengthened Referral Network from Community to Referral hospital levels~Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~Antenatal Care Nurses will receive bluetooth blood pressure monitors.~Community Health Workers within the intervention arm facilities will receive training in pre-eclampsia features and will be provided with smart phones and access to a smart phone application that will prompt them to initiate follow ups with pregnant women within the community and they will receive SMS/text messages reminders about pregnant women within the community who require follow up."
10161918|NCT03978429|No Intervention|Enhanced Usual Care|"Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~Antenatal Care Nurses will receive bluetooth blood pressure monitors."
10161919|NCT03978390|Experimental|Superhero images, Reward at the beginning,|Also, Showing superhero images for 5 minutes before starting the dental procedure. Also, providing the children with reward before begging the dental procedure and telling them that they can only keep it if they cooperate during the treatment procedure.
10161920|NCT03978390|Experimental|Superhero images, Reward at the end|Universally-accepted positive reinforcement to increase children cooperation in dental settings
10161921|NCT03978390|Experimental|No Superhero Images, Reward at the beginning|Showing superhero images for 5 minutes before starting the dental procedure
9826423|NCT02418000|Experimental|E6201 160 mg/m^2 IV twice weekly|E6201 160 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
10161922|NCT03978390|Active Comparator|No Superhero Images, Reward at the end|Showing no picture before starting the dental procedure
10161923|NCT03978364|Experimental|azacitidine|"azacitidine~azacitidine 75mg/m2，iH，qd， d1-7"
10161924|NCT03978364|Active Comparator|azacitidine combined HHT|azacitidine+HHT azacitidine 75mg/m2，iH，qd， d1-7 HHT 3mg/m2,ivdrip qd,d1-3
10161925|NCT03978468|Active Comparator|Usual Care Group|Children will receive usual care.
10161926|NCT03978468|Experimental|Interagency Collaboration (ICollab Group)|Subjects of this arm will receive ICollab intervention in addition to usual care which consists of communication with Home Health Nurse (HHN) , Collaborative meetings, and communication with Primary Care Physician (PCP)
10161927|NCT03978455||Patients Who Smoke|"This group will consist of up to 100 English-speaking adult smokers recruited from their primary care clinic who are willing to complete a brief phone-based interview about their experience in using the Learn, Connect, and Quit (LCQ) tablet-based mobile application. The LCQ app presents smoking and cessation-related educational and motivational content in an easily accessible manner (i.e., via videos) and provides avenues for smokers to connect to evidence-based treatment."
10161928|NCT03978455||Clinic Staff|"Rooming staff and physicians from the primary care clinic (where Patients Who Smoke group participants are recruited) will be asked to participate in interviews about the feasibility of implementing the LCQ app including implementation burden, impact on clinical workload, and clinical utility of the app (i.e., Did patients ask more questions about smoking treatment? How challenging was it to try to give all smokers the app to explore?)."
10161929|NCT03978481||Eradicated group|Gastric cancer patients received subtotal gastrectomy, with Helicobacter pylori eradication
10161930|NCT03978481||Negative group|Gastric cancer patients received subtotal gastrectomy, without Helicobacter pylori eradication or Helicobacter pylori negative
10161931|NCT03978338|Experimental|Intervention group|The experimental group will take the brain polypeptide solution .
10161932|NCT03978338|Placebo Comparator|Control group|The control group was treated with the same package of placebo .
10161933|NCT03978286|Experimental|Vortioxetine therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
10161934|NCT03978286|Experimental|Sertraline therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
10161935|NCT03978299||Positive PSA result|"Men with a positive PSA test defined as:~Serum total PSA concentration is over 10 ng/ml.~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is under 25%, in at least in two determinations."
10161936|NCT03978299||Negative PSA result|"Men with a negative PSA test defined as:~Serum total PSA concentration is under 10 ng/ml.~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is over 25%."
10161937|NCT03978507|Experimental|DeFOG group|feedback number of steps + cueing
10161938|NCT03978507|Active Comparator|Control group|feedback number of steps
10161939|NCT03978195|Experimental|Treatment|
10161940|NCT03978195|No Intervention|Control|
10161941|NCT03978221|Experimental|diaphragmatic tissue doppler evaluation|A tissue Doppler evaluation, using a sectorial probe, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration randomly assessed in spontaneous breathing with Venturi Mask and in Non-invasive ventilation with a helmet or facial mask
10161942|NCT03978143|Other|Sequence 1|Receive treatments in the following order from Periods 1-6: A, B, C, D, E, G
10161943|NCT03978143|Other|Sequence 2|Receive treatments in the following order from Periods 1-6: A, C, B, D, E, G
10161944|NCT03978143|Other|Sequence 3|Receive treatments in the following order from Periods 1-6: B, A, C, D, E, G
10161945|NCT03978143|Other|Sequence 4|Receive treatments in the following order from Periods 1-6: B, C, A, D, F, H
10161946|NCT03978143|Other|Sequence 5|Receive treatments in the following order from Periods 1-6: C, A, B, D, F, H
10161947|NCT03978143|Other|Sequence 6|Receive treatments in the following order from Periods 1-6: C, B, A, D, F, H
10161948|NCT03978026|Experimental|nap in a bed|the participants take a nap of 30 min in a bed in a bedroom
10161949|NCT03978026|Experimental|nap in an armchair|the participants take a nap of 30 min in a car sit in a bedroom
10161950|NCT03978026|Experimental|nap in teh Sombox|the participants take a nap of 30 min in the micro-hotel Sombox
10161951|NCT03978026|Sham Comparator|no nap in a bed|the participant stay awaked for 30 min in a bed in a bedroom
9826424|NCT02418000|Experimental|E6201 240 mg/m^2 IV twice weekly|E6201 240 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
9826425|NCT02418000|Experimental|E6201 320 mg/m^2 IV twice weekly|E6201 320 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle)
9826426|NCT02418026|No Intervention|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
10161952|NCT03978013|Experimental|Pomegranate|
10161953|NCT03978013|Active Comparator|Apple|
10161954|NCT03978208|Active Comparator|Placebo Comparator|ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days
10161955|NCT03978208|Active Comparator|ATB-346 mid-dose|ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days
10161956|NCT03978208|Active Comparator|ATB-346 standard dose|ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days
10161957|NCT03978208|Placebo Comparator|Active Comparator|Overencapsulated placebo tablet taken by mouth once daily for 14 days
9826427|NCT02418026|Experimental|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
9826428|NCT02418156||Single Arm|Subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
9826429|NCT02418182|Placebo Comparator|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
9826430|NCT02418182|Experimental|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
9826431|NCT02418312|Active Comparator|histamine-2 receptor antagonist group|famotidine 40mg qd for 6 months.
9974370|NCT01340534|Experimental|Oxygen 80% FIO2|Group of 181 patients that will receive supplemental oxygen 80% FIO2 during surgery (cesarean) and two hours after the procedure.
9974371|NCT01340534|Placebo Comparator|Use of air (no oxygen during surgery)|Group of 181 patients that will not receive supplemental oxygen during surgery (cesarean).
9826432|NCT02418312|Placebo Comparator|placebo group|placebo for 6 months.
9826433|NCT02418455|Experimental|UX003|UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.
9974372|NCT01340547|Other|Single Arm|Single Arm, non-blinded, non-randomized
9974373|NCT01340599|Experimental|Arm I (Polyphenon E)|Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
9974374|NCT01340599|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
9974375|NCT01340612|Active Comparator|coiling|
9974376|NCT01340612|Active Comparator|coiling plus stenting|
9974377|NCT01340638|Active Comparator|Cookgas|This group will be assigned to use cookgas mask
9974378|NCT01340638|Active Comparator|LMA mask|This group will be assigned to use LMA mask
9974379|NCT01340677|Experimental|001|Canagliflozin 100 mg Type=1 unit=mg number=100 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 300 mg Type=1 unit=mg number=300 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 50 mg Type=1 unit=mg number=50 form=tablet route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
9974380|NCT01340690|Active Comparator|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
9974381|NCT01340690|Placebo Comparator|placebo suspension|2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.
9974382|NCT01340703|Other|optic disc pit maculopathy|
9974383|NCT01340716|Active Comparator|stretching exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style.
9974384|NCT01340716|Experimental|Tai Chi Chuan exercise|patients in this group held weekly classes of two stretching for 12 weeks.
9974385|NCT01340729|Experimental|TPI 287|Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule.
9974386|NCT01340742|Active Comparator|1|Arm remote preconditioning
9974387|NCT01340742|Placebo Comparator|2|Control group.
9974388|NCT01340755|Experimental|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
9974389|NCT01340781||Hospitalized medical patients|"Adult age 18-65 years old admitted to the general medical floors at MetroHealth Medical Center who are expected to stay a minimum of 48 hours.~Potential subjects cannot have a known diagnosis of OSA, a tracheostomy, respiratory failure requiring noninvasive ventilation, currently pre or post surgical intervention, or clinically unstable patients with plans for transfer to a higher acuity of care or transferred from intensive care."
9974390|NCT01340807|Experimental|Prosthetic Feet|Randomized to 4 different prosthetic feet (SACH, SAFE, TALUX, and Proprio Foot)
9974391|NCT01340820|Experimental|AERAS-422 Low dose|>=10^5 to < 10^6 CFU
9974392|NCT01340820|Experimental|AERAS-422 High Dose|>=10^6 CFU
9974393|NCT01340820|Active Comparator|BCG Tice|BCG Tice 1-8 x 10^5 CFU
9974394|NCT01340833|Experimental|Study Medication|GSK2118436
9974395|NCT01340846|Experimental|Part A|Warfarin dosed at 15mg
9974396|NCT01340846|Experimental|Part B|Ketoconazole dosed at 400mg
9974397|NCT01340846|Experimental|Part C|Gemfibrozil dosed at 600mg
9826434|NCT02418468|Experimental|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
9974398|NCT01340846|Experimental|Part D|GSK2118436 dosed alone
9974399|NCT01340859|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
9974400|NCT01340859|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
9977357|NCT01360567|Placebo Comparator|B formula|placebo
9977358|NCT01360567|Experimental|A formula|Green tea extract
9977359|NCT01360606|Other|SBRT|
9977360|NCT01360658|Experimental|Intravenous immunoglobulins|Intravenous immunoglobulins
9977361|NCT01360671|Experimental|Sildenafil|iv sildenafil
9977362|NCT01360697|Experimental|JADE- JA|Use the JADE portal to monitor the delivery of structured care.
9977363|NCT01360697|Active Comparator|Usual care|Patients will receive usual care in between two annual comprehensive assessments.
9977364|NCT01360710|Experimental|Moxonidine|
10186295|NCT03737019|Experimental|ACT in County Council of Kalmar|Group education with ACT in six primary health care centers in County Council of Kalmar
10161958|NCT03978052|Experimental|1|"EGCG + multimodal intervention (n=50) Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~+ personalized intervention"
10161959|NCT03978052|Active Comparator|2|"Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~non personalized intervention"
10161960|NCT03978052|Placebo Comparator|3|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~+ personalized intervention"
10161961|NCT03978052|Sham Comparator|4|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)~non personalized intervention"
10161962|NCT03978182|Active Comparator|active accelerated deep rTMS|Stimulation: We will use a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil, which includes a sham option. In analogy to our former accelerated rTMS studies (2, 3), all patients will receive 20 dTMS sessions (5 sessions per day; 4 consecutive days) with a stimulation intensity of 120% of the subject's resting MT, as reported by Levkovitz et al.(4). Furthermore, we selected these FDA approved dTMS parameters, so that for one session each dTMS repetition includes 2-sec pulse trains separated by 20-sec inter-train intervals. Patients will receive 55 trains in each treatment session, for a total of 1980 pulses per session. This makes 9900 pulses/day, and in total 39600 pulses per treatment.
10161963|NCT03978182|Sham Comparator|sham|Built-in sham in the H1 Helmet (same device as active treatment)
10161964|NCT03978169||General anaesthesia with orotracheal intubation|surgery patients under general anaesthesia with orotracheal intubation
10161965|NCT03978169||General anaesthesia with laryngeal mask|surgery patient under general anaesthesia with laryngeal mask
10161966|NCT03978169||Spinal anaesthesia|surgery's patients under Spinal anaesthesia
10161967|NCT03978156|Experimental|Dronabinol, Then Placebo|Participants will take 2.5 mg of Dronabinol for 2 weeks, 1 week washout and then take 2 weeks of placebo (microcrystalline cellulos). Subjects will take up to 8 capsules daily of the treatment daily during each phase.
9520207|NCT03279627||Glycemic control|This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
10161968|NCT03978156|Experimental|Placebo, Then Dronabinol|Participants will take placebo (microcrystalline cellulos) for 2 weeks, 1 week washout and then take 2.5 mg of Dronabinol for 2 weeks. Subjects will take up to 8 capsules daily of the treatment daily during each phase.
10161969|NCT03978273|Experimental|Night-time brace + virtual-brace|Patients are conventionally treated with night-time brace. Additionally, they use the new developped virtual-brace (MD).
10161970|NCT03978273|Active Comparator|Night-time brace only|Patients are conventionally treated with night-time brace only.
10161971|NCT03978234|Experimental|Single group|Single group
10161972|NCT03978247|Experimental|NASHMIR group|Validation of the NASHMIR Test
10161973|NCT03977987||The treatment group|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who agree to receive the antiviral treatment during the late pregnancy.
10161974|NCT03977987||The control group with high HBV DNA level|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who decline to receive the antiviral treatment during the late pregnancy.
10161975|NCT03977987||The control group with low HBV DNA level|Pregnant women with high HBV DNA level < 2*10^6 IU/ml
10161976|NCT03977961||DDD Patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) with a diagnosed DDD fulfilling the inclusion criteria and scheduled for surgery will be considered for this study.
10186296|NCT03737019|Placebo Comparator|Control health care centers of County Council of Jönköping|Five primary health care centers of County Council of Jönköping that do not get education.
10186297|NCT03736993|Other|Additional blood sampling|non-small cell lung cancer (NSCLC)
10186298|NCT03736980|Experimental|Psilocybin Group 1|Group 1: randomized, placebo-controlled, double-blind, cross-over design
10186299|NCT03736980|Experimental|Psilocybin Group 2|Group 2: randomized, placebo-controlled, double-blind, cross-over design
10186300|NCT03736980|Experimental|Psilocybin Group 3|Group 3: randomized, placebo-controlled, double-blind, cross-over design
10186301|NCT03736980|Experimental|Psilocybin Group 4|Group 4: randomized, placebo-controlled, double-blind, matched group design
10186302|NCT03736941|Experimental|Patients with venous leg|"After inclusion, the medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. Follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.~During the various visits, clinical data will be collected in the patient's medical file as well as the answers to the questionnaires."
10186303|NCT03736915|Active Comparator|1 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
10186304|NCT03736915|Active Comparator|3 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
10186305|NCT03736915|Active Comparator|5 cc needle with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
10161977|NCT03977766|Experimental|nurse then patient digital prevalidation of chemotherapy|"Outpatient Chemotherapy prevalidation will done~with the help of a nurse, using the digital application, for cycle 2 and 3.~by the patient alone, using the digital application, for cycle 4 and 5."
10161978|NCT03977740|Experimental|chest PNF|"participants received conventional chest physiotherapy along with chest PNF technique 5 days for 1 week.~Chest PNF technique includes oblique downward pressure at the sternum, diagonal pressure at lower rib cage at the supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on the elbow."
10161979|NCT03977740|Active Comparator|Conventional|participants received conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
10161980|NCT03977688||none Cyto|septic shock, refractory, without Cytokin-adsorption therapy
10161981|NCT03977688||cyto|septic shock, refractory, treated with Cytokin-adsorption therapy
10161982|NCT03977675|Experimental|Ketamine 0.3 mg/kg|Subjects are assigned to receive a dose of 0.3 mg/kg of Ketamine.
10161983|NCT03977675|Experimental|Ketamine 0.5 mg/kg|Subjects are assigned to receive a dose of 0.5 mg/kg of Ketamine.
10161984|NCT03977675|Experimental|Ketamine 0.7 mg/kg|Subjects are assigned to receive a dose of 0.7 mg/kg of Ketamine.
10161985|NCT03977974|Experimental|LY3526318 - Part A|LY3526318 administered orally once.
10161986|NCT03977974|Placebo Comparator|Placebo - Part A|Placebo administered orally once.
10161987|NCT03977974|Experimental|LY3526318 - Part B|LY3526318 administered once orally on consecutive days.
10161988|NCT03977974|Placebo Comparator|Placebo - Part B|Placebo administered once orally on consecutive days.
10161989|NCT03977831|Active Comparator|Open Radical Cystectomy (ORC)|Open radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an iliac conduit urinary diversion is performed.
10161990|NCT03977831|Active Comparator|Robot-assisted Radical Cystectomy (iRARC)|Robot-assisted radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an intracorporeal iliac conduit urinary diversion is performed.
10161991|NCT03977805|Experimental|Hetrombopag Olamine|Hetrombopag Olamine (5 mg, 100 uCi)
10161992|NCT03977922|Experimental|Diet group|"The diet group will be involved in a 12-week pilot nutrition program based on the anti-inflammatory diet studied by Allison and Ditor (2015). The nutrition program will entail:~Once per week (Monday mornings), nutrition program members will come to Power Cord to pick up their box of ingredients for their meals that week (Monday to Friday). Recipe cards will accompany the ingredients, and enough food will be provided for 3 meals and 2 snacks per day. The meals will be based on the anti-inflammatory diet previously studied in Allison and Ditor (2015).~10-12 online videos that cover basic kitchen/cooking skills, how to prepare the meals in the program, how to shop for healthy foods at the grocery store, etc.~At the beginning of the program each member will be provided with a few pieces of accessible kitchen equipment that will made food preparation and cooking much easier.~Once per month, we will be offering a live cooking class."
10161993|NCT03977922|No Intervention|Control group|The control group will eat their usual diet for the 12-week period.
10161994|NCT03977662|Experimental|PTG with adult pancreatic islet co-transplantation|People with Type 1 (c-peptide negative) diabetes with stable kidney or liver allografts on chronic immunosuppression who receive study intervention, which is co-transplantation of allogeneic parathyroid (PTG) with adult pancreatic islets in people with Type 1 diabetes in the intramuscular (IM) site
10161995|NCT03977792|Experimental|Experimental treatment|"Subjects treated with BOR15001L7.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
10161996|NCT03977792|Active Comparator|Comparator treatment|"Subjects treated with Docosanol 10%.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
10161997|NCT03977519|Experimental|MA group|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used at EX-B8,BL32,SP8,and SP6.
10161998|NCT03977519|Active Comparator|TENS group|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used to stimulate the area along the lower borders of the ribs and the upper borders of the hip crests on both sides.The parameters of the electric acupuncture apparatus：Continuous wave,the frequency is 100Hz, the current intensity is 2.5mA-5mA.
9826435|NCT02418468|Experimental|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
10161999|NCT03977649|Experimental|erenumab|monthly subcutaneous erenumab 140 mg for 12 weeks
10162000|NCT03977649|Placebo Comparator|placebo|monthly subcutaneous masked placebo for 12 weeks.
10162001|NCT03977545|Other|Newborn with risk of neonatal opioid abstinence syndrome|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 7 days
10162002|NCT03977545|Other|Eutrophic term newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
10162003|NCT03977545|Other|Term newborn with low birth weight|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
10162004|NCT03977545|Other|Eutrophic premature newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
10162005|NCT03977701|Experimental|Mono-morphemic Singleton PD|Speech sound treatment on mono-morphemic singleton consonants for children with PD.
9977365|NCT01360710|Active Comparator|Irbesartan|
10162006|NCT03977701|Experimental|Mono-morphemic Singleton PD-SLI|Speech sound treatment on mono-morphemic singleton consonants for children with PD-SLI.
10162007|NCT03977701|Experimental|Mono-morphemic Cluster PD|Speech sound treatment on mono-morphemic consonant clusters for children with PD.
10162008|NCT03977701|Experimental|Mono-morphemic Cluster PD-SLI|Speech sound treatment on mono-morphemic consonant clusters for children with PD-SLI.
10186306|NCT03736850|Experimental|CS3006|
10162009|NCT03977701|Experimental|Bi-morphemic Singleton PD|Treatment on singletons in bi-morphemic contexts for children with PD.
10162010|NCT03977701|Experimental|Bi-morphemic Singleton PD-SLI|Treatment on singletons in bi-morphemic contexts for children with PD-SLI.
10162011|NCT03977701|Experimental|Bi-morphemic Cluster PD|Treatment on bi-morphemic consonant clusters for children with PD.
10162012|NCT03977701|Experimental|Bi-morphemic Cluster PD-SLI|Treatment on bi-morphemic consonant clusters for children with PD-SLI.
10162013|NCT03977701|Experimental|Bi-morphemic Singleton SLI|Treatment on singletons in bi-morphemic contexts for children with SLI.
10162014|NCT03977701|Experimental|Bi-morphemic Cluster SLI|Treatment on bi-morphemic consonant clusters for children with SLI.
10162015|NCT03977844|Active Comparator|Technical Assistance|Technical Assistance. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security.
10162016|NCT03977844|Experimental|Community Engagement and Planning|Community Engagement and Planning. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security. In addition, community agencies will be invited to meet with one another to develop novel and investigator supported coalitions using principles of community partnered participatory research that will adapt toolkits and other local assets to seek to enhance community resilience related to threats of disaster risk, financial insecurity, housing insecurity, mental health, or other coalition-determined domains.
10162017|NCT03977844|Active Comparator|Community Resources (CR)|Community Resources (CR). At the Individual level of randomization, individuals in the Community Resources (CR) arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security.
10162018|NCT03977844|Experimental|Community Resources (CR) + eBT|Community Resources + eBT. At the Individual level of randomization, individuals in the CR+eBT arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security, along with an interactive component to support CBT-informed coping with mood and stressors at the individual level.
10162019|NCT03977610|Experimental|Ga68-PSMA ligand|Glass vial with 4~20 mCi(148-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), more than 0.33 mCi/mL @ EOS; One time dose of 2-5 mCi (74-185 MBq) for PET Imaging ; i.v. injection
10162020|NCT03977870||patients with Venous thromboembolism (VTE)|
10162021|NCT03977493|Active Comparator|Xeomin®|Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).
10162022|NCT03977493|Placebo Comparator|Placebo concentrate|Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).
10162023|NCT03977558|Experimental|Intervention group|Isocaloric diet, based on individual energy requirements calculated from indirect calorimetry and physical activity adjustment Participants will be asked to eat daily ~50g canola oil
10162024|NCT03977558|Active Comparator|Control group|Standard dietary advice that is used as current best practice in the treatment of lipid disturbances of European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidemias)
10162025|NCT03977441|Placebo Comparator|control group|treated with Pramipexole 0.75mg/d（0.25mg tid)+placebo 25mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+placebo 50mg qn * 10 weeks
10162026|NCT03977441|Experimental|experimental group|treated with Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine25 mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine 50mg qn * 10weeks
10162027|NCT03977571|Experimental|Deferred nephrectomy|Surgery after induction therapy (Nivo + Ipi), followed by maintenance therapy (Nivo)
10162028|NCT03977571|Active Comparator|No surgery|Induction therapy (Nivo + Ipi), followed by maintenance therapy alone (Nivo).
10162029|NCT03977532|Experimental|patients with sickle cell disease|
10162030|NCT03977506|Experimental|Behavoiral|The evaluation will be realized on two different assessment grids during the test on the road
10162031|NCT03977298|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine
10162032|NCT03977298|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
10162033|NCT03977220|Experimental|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
10162034|NCT03977324|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
10162035|NCT03977324|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
10162036|NCT03977272|Active Comparator|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
10162037|NCT03977272|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 200mg.
10162038|NCT03977350||Patients over 65 years undergoing heart surgery|Patients over 65 years undergoing heart surgery under anesthesia, EEG monitored
10162039|NCT03977454|Experimental|Group 1 patients will receive nerve block per standard of care|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service.~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI."
10162040|NCT03977454|Active Comparator|Group 2 will NOT receive any nerve blocks.|Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.
10162041|NCT03977259|No Intervention|Standard fortification|Standard of care fortification with multicomponent human milk fortifier (24 kcal/oz) and liquid protein (0.27 g/dL); additional protein and/or calories added only for growth faltering.
10162042|NCT03977259|Experimental|Individually targeted fortification|"Standard of care fortification plus extra protein and/or calories to ensure that base milk has protein 1 g/dL and calories 67/dL."
10162043|NCT03977103|Experimental|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
10162044|NCT03977285|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
10162045|NCT03977285|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
10162046|NCT03977285|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
10162047|NCT03977389||Population of the study|"Patient undergoing total wrist denervation between January 1995 and December 2013 at Brest CHRU, performed by the same senior surgeon.~Total wrist denervation is a routine procedure in orthopedic surgery for wrist arthritis."
10162048|NCT03977207|Experimental|Levothyroxine|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.~The intervention period is 24 weeks. Patients will undergo up to two subsequent dose titrations after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points. Patients whose TSH levels are higher or lower than the therapeutic TSH target of 0.5-3.0mIU/L will undergo a dose adjustment (+/- 25mcg), while those whose TSH levels are in target range will continue the prior dose."
10162049|NCT03977207|Placebo Comparator|Placebo|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.~The intervention period is 24 weeks. Patients in the placebo arm will undergo an equivalent titration in placebo pills (as that of the experimental arm) after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points."
10162050|NCT03977376|Experimental|Intervention|Valuation instruments were two validated scales: ESAS y HADS. Experimental nursing instrument: Guide of hosting.
10162051|NCT03977376|No Intervention|Control|Valuation instruments were two validated scales: ESAS y HADS. Without Guide of hosting.
10162052|NCT03977415||RA with no ILD|"Subjects diagnosed with RA less then 2 years and without a diagnosis of ILD, will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~Medical history and Physical exams~Quality of Life Questionnaires~Collection of Sputum and Blood~Radiology (HRCT)~Lung Function Test"
10162053|NCT03977415||RA with ILD|"Patients diagnosed with RA less than 2 years, and clinically diagnosed with interstitial lung disease (ILD), will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~Medical history and Physical exams~Quality of Life Questionnaires~Collection of Sputum and Blood~Radiology (HRCT)~Lung Function Test~Spirometry"
10162054|NCT03977246|Experimental|Open-placebo|The open-placebo intervention session
10162055|NCT03977246|Placebo Comparator|Control|The control session
10162056|NCT03977480|Active Comparator|Hemay007 400 mg BID group|Patients will orally take Hemay007 tablets 400 mg BID for 12 weeks.
10162057|NCT03977480|Active Comparator|Hemay007 800 mg QD group|Patients will orally take Hemay007 tablets 800 mg QD for 12 weeks.
10162058|NCT03977480|Active Comparator|Hemay007 600 mg BID group|Patients will orally take Hemay007 tablets 600 mg BID for 12 weeks.
10162059|NCT03977480|Placebo Comparator|placebo group|Patients will orally take placebo tablets for 12 weeks.
10162060|NCT03977181|Experimental|Health Club|A group-based community health club akin to an ART adherence club
9977366|NCT01360723||urothelial carcinoma|Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
10162061|NCT03977181|Experimental|One-on-one|One-on-one adherence counselling and support
10162062|NCT03977181|No Intervention|Medication pick-up|Community-based medication dispensary
10162063|NCT03977116|Experimental|heart failure patients with diabetes treated by SGLT2 drugs|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
10162064|NCT03977116|Placebo Comparator|heart failure patients with diabetes treated by placebo|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received placebo therapy.
10162065|NCT03977090|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
10162066|NCT03977012||Patients with CRPS Type I|"Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care.~-drug name: norspan patch 5~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks"
10162067|NCT03977129|Experimental|QFR group|
10162068|NCT03977129|Active Comparator|CAG group|
10162069|NCT03977233|Experimental|SingleArm: FOLFIRINOX|Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.
10162070|NCT03976869|Experimental|Cohort 1|The study will include adolescent patients of 12 to 17 years of age, with subgroups of 12-14 years age and 15-17 years age.
10162071|NCT03976921|Experimental|CCTA Strategy|CCTA will be performed with one of the latest generation scanners. A stenosis > 50% will be considered as significant from an anatomical point of view. For coronary stents, degree of intrastent restenosis will be evaluated by visual assessment of intraluminal contrast density. ISR > 50% will be considered as significant from an anatomical point of view. For CABG, each graft will be visually evaluated and scored as patent, non-significant stenosis ≤ 50%, significant stenosis > 50%, or occluded. For patients with positive CCTA results, additional stress CTP will be performed subsequently. If indicated, vasodilatation will be induced with i.v. adenosine injection or regadenoson. Static or dynamic CTP will be performed according to local practice and scanner technology available. For all patients with previous history of MI the presence of reversible ischemia will be obtained by the comparison between rest and stress perfusion.
10162072|NCT03976921|Active Comparator|Standard of care Strategy|Patients randomized to this group will be evaluated according to current clinical guidelines with the following approaches: (a) stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET; (b) direct referral to ICA.
10162073|NCT03977051||Focus group|Focus group to explore immunosuppressant medication adherence in kidney transplant patients
10162074|NCT03976726||i-gel size #3|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
10162075|NCT03976726||i-gel size #4|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
10162076|NCT03976726||i-gel size #5|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
10162077|NCT03976713|Experimental|Bufei Yishen granule plus Western medicine|Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
10162078|NCT03976713|Placebo Comparator|Placebo Bufei Yishen granule plus Western medicine|Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
10162079|NCT03977077|Experimental|Albumin binding taxol|
10162080|NCT03976817||SA-AVR group|Patients who underwent the supra-annular aortic valve replacement (SA-AVR) technique in our institution between December 2010 and December 2017 were retrospectively reviewed.
10162081|NCT03977038||TRD sample|Individuals in the treatment resistant depression (TRD) sample suffer from the condition called TRD. The intervention that will be administered to this group is the standardized rTMS treatment using High Frequency dTMS (HF-dTMS) stimulation over L-DLPFC, at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks.
10162082|NCT03977038||Healthy Controls (HC) sample|Individuals in the HC sample are age-, sex-, education-matched to the individuals in the TRD sample. HC sample does not receive any therapeutic treatment and are solely examined as a comparative measure of normal cognitive capabilities.
10162083|NCT03976661||DIAPASON 92 arm|Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
10162084|NCT03976661||Control arm|Arm will be constituted by people residing at the EHPAD (retirement home)
10162085|NCT03976765||Hospital discharge at day 7|
10162086|NCT03976804|Experimental|atherosclerotic cardiovascular event associated with tobacco|
10162087|NCT03976882|Experimental|Hetrombopag treatment|Study is 2:1 randomization ratio (hetrombopag to placebo).
10162088|NCT03976882|Placebo Comparator|Placebo treatment|Study is 2:1 randomization ratio (hetrombopag to placebo).
10162089|NCT03976830||Children diagnosed with cancer|Patients diagnosed with childhood cancer in participating sites in Central American countries
10162090|NCT03976570|Experimental|Occupational Therapy|Occupational Therapy
10162091|NCT03976856|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
10162092|NCT03976635|Active Comparator|Removable Mandibular Retractor|Patients in this group will be treated by the Removable Mandibular Retractor (RMR) in order to get rid of the anterior cross bite. This appliance is removable.
10162093|NCT03976635|Experimental|Bone-anchored intermaxillary Traction|Patients will be treated using bone-anchored intermaxillary traction. Class III elastics will be extended from the Adam's clasps placed in the upper removable appliance towards the heads of mini-implants placed between the permanent canine and lateral incisors on either side of the lower dental arch.
10162094|NCT03976908|Experimental|ON-OFF|Patients receive the same baseline, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
10162095|NCT03976908|Experimental|OFF-ON|Patients receive the same baseline, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
10162096|NCT03976700|Experimental|Bufei Jianpi granule|Patients in this arm will receive Bufei Jianpi granule.
10162097|NCT03976700|Placebo Comparator|Placebo Bufei Jianpi granule|Patients in this arm will receive placebo Bufei Jianpi granule.
10162098|NCT03976791|Experimental|Enlarged internal incision|enlarged the internal incision about 0.4mm
10162099|NCT03976791|Placebo Comparator|Regular 2.2mm incision|regular 2.2mm corneal incision for microincision coaxial phacoemulsification
10162100|NCT03976778|Other|a pre-post interventional study|intervention consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
10162101|NCT03976986|Experimental|cPOC - pPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by cPOC (continuous-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by pPOC (pulsed-flow).
10162102|NCT03976986|Experimental|pPOC - cPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by pPOC (pulsed-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by cPOC (continuous-flow).
10162103|NCT03976492||Normal group|normal population
10162104|NCT03976492||Brain injury group|patients with traumatic brain injury within 24 hours
10162105|NCT03976492||Non-brain injury group|Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
10162106|NCT03976622||vitiligo|Patients aged 18 to 75 years with non-segmental vitiligo;
10162107|NCT03976622||psoriasis|Patients aged 18 to 75 years with plaque psoriasis;
10162108|NCT03976622||atopic dermatitis|Patients aged 18 to 75 years with atopic dermatitis;
10162109|NCT03976622||alopecia areata|Patients aged 18 to 75 years with alopecia areata sclerosis;
10162110|NCT03976518|Experimental|ATEZOLIZUMAB|Atezolizumab will be administered at a flat dose of 1200 mg by intravenous route. Atezolizumab will be delivered in 250-mL 0.9% NaCl (sodium chloride) intravenous (IV) infusion bags. The administration will be repeated every 3 weeks (21 [± 3] days). The initial dose will be delivered over 60 (± 15) minutes. In case the first infusion is tolerated without any infusion-associated AEs the second infusion may be delivered over 30 (± 10) minutes. If the second 30 minutes infusion is well tolerated all the subsequent infusions may be administered over 30 (± 10) minutes. The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
10162111|NCT03976557|Experimental|BIP CVC|Polyurethane CVC with noble metal coating
10162112|NCT03976557|Active Comparator|Standard CVC|Standard CVC made of polyurethane
10162113|NCT03976544|No Intervention|Natural cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH), on the first or second day of the menstrual cycle. If these serum hormonal values are considered basal for the beginning of the follicular phase, patients are asked to come back on day 10 to 12 of the cycle for blood sample and transvaginal ultrasound scan in order to assess follicular growth.~The timing of ovulation is determined based on a combination of ultrasonography features (the presence of a dominant follicle and adequate endometrium) and endocrine hormonal values in serum blood samples. Ovulation is generally defined as an, at least, 180% increase of LH compared to the mean level in the previous 24h.~Frozen-warmed blastocyst transfer will take place six days following the spontaneous LH surge."
10162114|NCT03976544|Experimental|Hormone replacement therapy cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) on the first or second day of the menstrual cycle. If these values are considered basal for the beginning of the follicular phase, estrogen supplementation (Estradiol valerate, Progynova® 3x2mg/day) is started to induce proliferation of the endometrium. Blood sample and transvaginal ultrasound are thereafter performed ten to fourteen days later. If the endometrium is considered adequate (generally considered if triple line and above 6,5 mm thickness), embryo transfer is scheduled on the sixth day of progesterone (vaginal micronized progesterone, Utrogestan® 2x200mg twice a day) supplementation.~In case of escape spontaneous ovulation embryo transfer will be performed considering the presumable time of ovulation."
10162115|NCT03976336|Experimental|Berberine|
10162116|NCT03976336|Placebo Comparator|Identical Placebo|
10162117|NCT03976583|Active Comparator|Cpp-acp|MI paste Self-administration of the product by the patient once in the evening. A pea-size amount of the product should be applied per arch, using a dry finger or cotton pellet to distribute it evenly across all teeth and to work it into the interdental spaces. The product was then retained in the mouth for 1-3 min, and manipulated around the teeth using the tongue, before being expectorated and patient should not rinse it until 30 min.
10162118|NCT03976583|Experimental|Pearl powder|Pure pearl powder in the form of gel Self-administration of the product should be used once daily (in the evening), after a 2 min manual tooth brushing. .Participants were explicitly instructed to apply the gel by his finger allover the teeth and not to rinse their mouths after application and not to eat or drink for at least 30 min.
9520208|NCT03279614|Experimental|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
9520209|NCT03279601|Experimental|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
10162119|NCT03976427|Experimental|Guided Imagery|Participants will listen to a guided imagery recording
9520210|NCT03279601|Experimental|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
9520211|NCT03279575|Experimental|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
9977367|NCT01360723||Healthy controls group|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
10162120|NCT03976388|Experimental|Clinical virtual simulator|A clinical virtual simulator contains an interactive medical case depicting an acutely ill patient seeking care at the emergency department. The case will be delivered in small groups (up to 6 participants) in sessions lasting up to 20 minutes. After the simulation has been completed, a feedback session lasting up to 30 minutes will be delivered as well.
10162121|NCT03976388|Active Comparator|Standard educational session|A small-group discussion (up to 6 participants) using patients with the same condition as the one selected for the clinical simulator will be held for participants allocated to the control group. These sessions will be led by a physician and have a maximum duration of up to 60 minutes.
10162122|NCT03976674|Experimental|Patients in preparation for bariatric surgery|Patients in preparation for bariatric surgery in the endocrinology department will follow a cognitive behavioural therapy
10162123|NCT03976674|No Intervention|Control group|Standard practice
10162124|NCT03976687|Experimental|1: EYP001a Dose A|Dose A once daily morning dose
10162125|NCT03976687|Experimental|2: EYP001a Dose B|Dose B once daily morning dose
10162126|NCT03976687|Experimental|3: EYP001a Dose C|Dose C twice daily - first dose morning dose and second dose 3 hours post first dose
10162127|NCT03976505|Active Comparator|textual prescription healthy volunteers|
10162128|NCT03976505|Active Comparator|table prescription healthy volunteers|
10162129|NCT03976505|Experimental|textual prescription Parkinson's disease patients|
10162130|NCT03976505|Experimental|table prescription Parkinson's disease patient|
10162131|NCT03976297|Experimental|Control Tower Intervention|For participants in the intervention arm, the results of the prediction model will be presented through a GUI interface hereby known as the Control Tower. Participants receive scores from Control Tower (0-100; higher score indicating increased need) for palliative care and are subsequently ranked from highest to lowest. Red (7 or greater) is considered high risk. The intervention will include a Control Tower operator who will interact with the inpatient palliative care consult service. The operator will monitor the Control Tower during weekday normal business hours and select daily a cohort of participants in the intervention units with the highest need of palliative care review. The final list of participants will then be sent to palliative care. The palliative care team who is on service will also assess the need for each participants, and those participants which they agree could benefit they will approach the attending clinical team to suggest a palliative care referral.
10162132|NCT03976297|No Intervention|Standard of Care|For participants who are not in an intervention period they will receive the standard of care commensurate with their clinical unit. This is feasible given that this is a pragmatic clinical trial where the investigators can easily control the communication between the control tower operator and palliative care team to prevent any contamination between clusters. In addition to the usual source of care control the investigators intentionally have calibrated the prediction model and the Control Tower review to match the average capacity of the palliative care service, knowing that that the team will still receive palliative care consults through the traditional pathway i.e. the attending care team consulting palliative care directly.
10162133|NCT03976245|Active Comparator|etanercept|etanercept 50 mg subcutaneously injected per week
10162134|NCT03976245|Active Comparator|tofacitinib|tofacitinib 5 mg orally daily
10162135|NCT03976271|Active Comparator|T1DM poor glycaemic control|patients with type 1 diabetes and poor glycaemic control (HbA1c >8% / >64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
10162136|NCT03976271|Active Comparator|T1DM impaired awareness|patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
10162137|NCT03976271|Active Comparator|T1DM Normal awareness|patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
10162138|NCT03976271|Active Comparator|T2DM + Insulin|patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
10162139|NCT03976271|Active Comparator|Healthy control T2DM|healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
10162140|NCT03976271|Active Comparator|Healthy control T1DM|Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
10162141|NCT03976258||HIV-infected adults actively using heroin|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past.
10162142|NCT03976258||HIV-infected adults never having used heroin|HIV-infected adults on antiretroviral therapy matched to HIV-infected adults actively using heroin by age, sex and CD4+ count.
10162143|NCT03976258||HIV-infected adults initiating buprenorphine/naloxone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
10162144|NCT03976258||HIV-uninfected adults initiating buprenorphine/naloxone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
10162145|NCT03976258||HIV-infected adults initiating methadone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone
10162146|NCT03976258||HIV-infected adults initiating Vivitrol|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
9520212|NCT03279575|Experimental|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
9974401|NCT01340911|Active Comparator|Part 1A, Cohorts 1-6|"Approximately 48 healthy male subjects will be enrolled into 6 separate cohorts (8 subjects per cohort). Each Cohort of subjects will be dosed sequentially, approximately one week apart, at escalating doses. Within each cohort, 6 subjects will be randomized to receive a single dose of SRT3025, and 2 will be randomized to receive a single dose of placebo.~The following are the planned doses for Cohorts 1-6, with Cohort 1 being the lowest dose and Cohort 6 being the highest dose: 50, 150, 500, 1000, 2000, and 3000mg of SRT3025. Dose level may be altered as appropriate during the study based on real time analysis of the safety, tolerability, and /or PK data. Dose adjustment may involve an increase or decrease in dose or dividing the total daily dose allowing for twice-daily dosing. Total daily dosing will not exceed 3000mg."
10162147|NCT03976258||HIV-uninfected adults initiating methadone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone.
9974402|NCT01340911|Active Comparator|Part 1B, Cohorts 7-8|One to two of the doses administered in Part 1A may be selected for administration with food, based on expected changes in SRT3025 exposures with food, as well as safety, tolerability, and PK data from Part 1A. If initiated, the effect of a single dose of SRT3025 with a moderate fat/calorie meal may be initiated concurrently with a cohort in Part 2 of the study. Approximately 6 subjects would be enrolled into each cohort in Part 1B.
9974403|NCT01340911|Active Comparator|Part 2A, Cohorts 9-11|Approximately 16-24 healthy subjects will be enrolled into 2 to 3 cohorts (8 subjects per cohort) in Part 2A. Within each cohort, 6 subjects will be randomized to receive multiple doses of SRT3025, and 2 will be randomized to receive multiple doses of placebo. The repeat dosing component of the study will be initiated, and doses selected, based on the evaluation of safety, tolerability, and PK data from Part 1A. Subjects in Part 2A will be randomized to receive 14 consecutive days of dosing with SRT3025 or matched-placebo. Subjects in these Cohorts will be dosed sequentially (in the fasted state) approximately two weeks apart.
9974404|NCT01340911|Active Comparator|Part 2B, Cohorts 12-13|If initiated, the effect of repeat doses of SRT3025 with moderate fat/calorie meals would occur in Part 2B (Cohorts 12 and 13). Each of these cohorts would enroll approximately 6 subjects.
9974405|NCT01340950|Active Comparator|Better-Penetrating ART|zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours
9974406|NCT01340950|Active Comparator|Worse-Penetrating ART|tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily
9974407|NCT01340963||Class I|Structurally normal heart, no bundle branch block
9974408|NCT01340963||Class II|Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction
9974409|NCT01340963||Class III|Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)
9974410|NCT01340989|Experimental|4% oxygen|addition of 4% oxygen to the CO2 pneumoperitoneum
9974411|NCT01340989|Experimental|full conditioning|full conditioning of the peritoneal cavity by the laparoscopic gas: 4% oxygen, 10% nitrous oxide, humidification and set temperature of 32°C
9974412|NCT01340989|Active Comparator|CO2 pneumoperitoneum|standard laparoscopy with CO2 pneumoperitoneum
9974413|NCT01341002|Experimental|SCVO2 < 70%|guidelines transfusion + SCVO2 < 70%
9974414|NCT01341002|Active Comparator|currently intervention|guidelines transfusion
9974415|NCT01341015|Experimental|ultrasound for fracture|All patients receive ultrasound for potential ankle fracture.
9974416|NCT01341028|Active Comparator|Roux-en-Y gastric bypass (LRYGBP)|Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
9974417|NCT01341028|Experimental|LRYGBP plus gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
9974418|NCT01341041|Experimental|chlorine dioxide|2 arms
9974419|NCT01341041|Active Comparator|saline|one time wash with 50-100cc of normal saline
9974420|NCT01341054|Experimental|mouthwash with Chamomilla extract 1%|The Chamomile recutita mouthwash 1% was administered two times daily for 30 days.
9974421|NCT01341054|Experimental|mouthwash with Chamomilla extract 2%|The Chamomile recutita mouthwash 2% was administered two times daily for 30 days.
9974422|NCT01341054|Active Comparator|standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12%; oral hygiene teaching. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
9974423|NCT01341054|Experimental|mouthwash with Chamomilla extract 0.5%|The Chamomile recutita mouthwash 0.5% was administered two times daily for 30 days, starting on the first day of chemotherapy.
9974424|NCT01341080|Experimental|Varenicline|
9974425|NCT01341080|Placebo Comparator|Sugar pill|
9974426|NCT01341093|Active Comparator|usual care|
9974427|NCT01341093|Experimental|educational program+telephone follow up|
9974428|NCT01341106|Experimental|Treatment Arm|Patients will be treated with entecavir
9974429|NCT01341132||Suspected Liver Disease|"Alpha-feto protein > 400 ng / mL or~prior ultrasound with mass suspicious for hepatic malignancy or.~clinical risk of hepatocellular carcinoma or~prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma"
10162148|NCT03976258||HIV-uninfected adults initiating Vivitrol|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
9974430|NCT01341145|Experimental|Aerobic Exersice|12-week moderate aerobic exercise program
9974431|NCT01341145|Active Comparator|Relaxation|12-week at home progressive muscle relaxation program
9974432|NCT01341158|Experimental|Experimental arm|
9974433|NCT01341171||tamoxifen or aromatase inhibitors|
9974434|NCT01341184|Experimental|Group 1|16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
10162149|NCT03976219|Experimental|Evoked potentials of ECAPs and SSEPs|Patients implanted with a spinal cord stimulator. In this arm, we are measuring the evoked potentials of electric compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs).
10162150|NCT03976180|Active Comparator|standard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;
10162151|NCT03976180|Experimental|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
10162152|NCT03976180|Experimental|HFNO with intermediate FiO2 (50%)|HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
10162153|NCT03976180|Experimental|HFNO with high FiO2 (100%)|HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
10162154|NCT03976232|Experimental|tDCS-Group|Participants of this arm will receive tDCS and Conventional therapy for 2 weeks.
10162155|NCT03976232|Experimental|CST- Group|Participants of this arm will receive CST and Conventional therapy for 2 weeks.
10162156|NCT03976232|Active Comparator|combination of tDCS and CST|Participants of this arm will receive CST+ tDCS and Conventional therapy for 2 weeks.
10162157|NCT03976206|Experimental|VSEL Max|We carried out the subdermal application of VSELs with a 1-mL syringe (90,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
10162158|NCT03976206|Experimental|VSEL Medium|We carried out the subdermal application of VSELs with a 1-mL syringe (60,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
9974435|NCT01341184|Experimental|Group 2|16 subjects: TMC207 400mg orally on days 1 and 29, rifampin 600mg orally, every day on day 20-41
10162159|NCT03976206|Experimental|VSEL Mini|We carried out the subdermal application of VSELs with a 1-mL syringe (30,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
10162160|NCT03976206|No Intervention|Control|Subcutaneous injection of 0.4 mL platelet-rich plasma in the same part of the experimental group
10162161|NCT03976414||eMOM website users|"Any woman who visits the research tab on the eMOM website will see an invitation to participate in a research study about the impact of the website on her bladder and bowel symptoms. Women may use the intervention (the website) regardless of whether they opt to participate in the research study.~The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence."
10162162|NCT03976128|Experimental|Nordic Walking training|20 sessions of 45 minutes x 2 times/week x 10 weeks using NW
10162163|NCT03976128|Active Comparator|Conventional endurance training|20 sessions of 45 minutes x 2 times/week x 10 weeks using treadmill and cycloergometer training.
10162164|NCT03976024|Experimental|DHBN-FN arm|"Recruitment is planned in traditional hospitalization for DHBN-FN patients. Evaluation of streptococcal carriage by swab, pharyngeal, anal and perineal in patients hospitalized for a DHBN-FN at the end of hospitalization and 1 month after discharge from hospital during the reassessment consultation. Swabs made by the dermatologist.~The carriage of streptococcus in patients living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index"
10162165|NCT03976024|Active Comparator|Control arm (Erysipelas)|"Recruitment is planned in traditional hospitalization for patients with erysipelas.~The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission)."
10162166|NCT03976284|Experimental|Garden-fresh produce and exercise (GFPE)|Participants are encouraged to double their consumption of minimally processed fiber-rich plant foods, especially garden-fresh produce from the church community garden. Participants are also encouraged to limit pro-inflammatory foods rich in saturated fat, sodium and added sugar. Participants are also encouraged to engage in 150 minutes of moderate to vigorous physical activity per week, most likely in the form of brisk walking.
10162167|NCT03976193|Placebo Comparator|BfitBwell program|BfitBwell is a 3-month supervised exercise program for cancer survivors delivered at the Anschutz Health and Wellness Center. This program has demonstrated effectiveness for improving physical fitness, fatigue, and depression among participants
9974436|NCT01341197||Subjects undergoing bidirectional endoscopy and fecal tests|Subjects participating in the health check-up at National Taiwan University Hospital (Health Management Center)
9974437|NCT01341197||Patients with screening detected GI tract cancers|Patients with screening detected GI tract cancer, such as throat cancer, esophageal cancer, gastric cancer and colorectal cancers, from other screening sites in Taiwan and were referred to the National Taiwan University Hospital for confirmatory diagnosis and treatment.
9974438|NCT01341236|Active Comparator|continuous nutrition|
9974439|NCT01341236|Active Comparator|bolus nutrition|
9974440|NCT01341249|Experimental|DW224aa|DW224aa given by oral administration
9974441|NCT01341249|Active Comparator|DW224a|DW224aa given by oral administration
9974442|NCT01341275|Experimental|birth, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 10 ug dose of hepatitis B vaccine as a booster
9974443|NCT01341275|Experimental|birth, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 20 ug dose of hepatitis B vaccine as a booster
10162168|NCT03976193|Active Comparator|BfitBwell + 6, bi-weekly PA Behavior Change counseling session|Participants randomized to BfitBwell + PA behavior change counseling sessions will receive six, 1-1.5 hour sessions lead by a Certified Exercise Physiologist, trained on the study protocol. Sessions will be held once per week, every other week at the Anschutz Health and Wellness center. Participants will attend the sessions in groups, as schedules allow. Behavior change discussion topics will target self-efficacy for exercise, barriers to exercise, goal setting, behavior modification strategies, time management, cognitive reframing, and relapse prevention. Participants in this study arm will receive a group education workbook in congruence to discussion session topics to promote notetaking, and self-reflective journaling.
10162169|NCT03976115|Experimental|1. healthy volunteers|3x single dose of DDO-3055 and placebo
10162170|NCT03976115|Experimental|2. Patients with chronic kidney disease|3x single dose of DDO-3055 and placebo
10162171|NCT03976167|Active Comparator|Common nasal cannula|Oxygen administration up to 4 liters according defined protocol
10162172|NCT03976167|Experimental|High flow nasal cannula|Oxygen administered with high flow nasal cannula according child weight and protocol designed for this study
10162173|NCT03976076|Experimental|JBPOS0101 (investigational product)|
10162174|NCT03975946|Active Comparator|the rheopheresis group|
10162175|NCT03975946|Placebo Comparator|the shamapheresis group|
10186307|NCT03736837|Experimental|Anlotinib Plus Icotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Icotinib 125mg p.o, tid. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
10186308|NCT03736811|Active Comparator|Absorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyglactin 910 [Vicryl] or polydioxanone [PDS II] sutures.
10186309|NCT03736811|Experimental|Nonabsorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyester [Ethibond Excel] or polypropylene [Prolene] sutures.
10186310|NCT03736772|Experimental|LY3090106|LY3090106 administered subcutaneously (SC)
10186311|NCT03736772|Placebo Comparator|Placebo|Placebo administered SC
10186312|NCT03736759|Experimental|Exercise and vaccine in same arm|20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
10186313|NCT03736759|Active Comparator|Exercise and vaccine in different arms|20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
10186314|NCT03736759|No Intervention|vaccine only|20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
10186315|NCT03736733|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
10186316|NCT03736733|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
10186317|NCT03736707|Experimental|Selective HFOV|Selective HFOV will be provided
10186318|NCT03736707|Active Comparator|CMV|CMV will be provided
10186319|NCT03736694|Experimental|CBTI Workshop|The first intervention group (Group 1) will attend one half-day CBTI workshop in the community setting. The workshop is subdivided into 4 sessions, covering topics regarding regulation of stimuli, limit of sleeping duration, relaxation, sleep hygiene and alteration of cognitive beliefs (Arnedt, Cuddihy, & Swanson, et al, 2014; Morin, Savard, Ouellet, & Daley, 2003). One workshop has the capacity of 30 participants.
9662144|NCT05130619|Experimental|Treatment order C-A-D-B|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
10186320|NCT03736694|Experimental|Self-Help CBTI|The second intervention group (Group 2) will receive self-help CBTI. A CBTI webpage will be set up and the subjects are asked to review all the materials in it. The content is the same as that in Group 1.
10186321|NCT03736694|Active Comparator|SHE Workshop|The control group (Group 3) will receive SHE. To ensure uniformity of the therapy model, the participants will also need to attend one half-day face-to-face session, covering topics related to sleep hygiene only. The capacity is also 30 participants.
10186322|NCT03736642||restrictive anorexia nervosa with hunger|
10186323|NCT03736642||restrictive anorexia nervosa without hunger|
10186324|NCT03736642||constitutional thinness|
10186325|NCT03736642||control subjects without eating disorders|
10186326|NCT03736616|Experimental|Cohort A: Transplant eligible|"Patients receive RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin area under curve (AUC) 5 IV d2, Etoposide (VP16) 100mg/m2 IV d1-3 & Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~BEAM chemotherapy & autoHSCT: BEAM given as Carmustine (BCNU) 300mg/m2 IV day -6 respective to stem cell infusion, VP16 200mg/m2 IV BID day -5 to day-2, Cytarabine (Ara-C) 200mg/m2 IV BID day -5 to day -2, and Melphalan 140mg/m2 IV day -1. Autologous hematopoietic stem cell infusion on day 0. Only patients with CR/PR after RICE acalabrutinib will undergo BEAM and autoHSCT~Maintenance therapy: Post autoHSCT patients will receive Acalabrutinib 100mg oral BID starting on day +30 for 12 consecutive months or until progression or intolerance if occurs within those 12 months."
10186327|NCT03736616|Experimental|Cohort B: Transplant ineligible|"Patients receive RICE chemoimmunotherapy + Acalabrutinib Salvage therapy: RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin AUC 5 IV d2, Etoposide 100mg/m2 IV d1-3. Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~Maintenance therapy: Patients will receive Acalabrutinib 100mg oral BID for 12 consecutive months or until progression or intolerance if occurs within those 12 months. Maintenance therapy will only be given to patients with stable disease or better response after 3 cycles of RICE+ acalabrutinib"
10186328|NCT03736590|Experimental|Intervention - Financial Coaching Plus Social Needs Screening|Families in this intervention arm will receive financial coaching at each well child visit, in addition to clinic-based social needs screening and referral.
10162176|NCT03975933|Experimental|Free pregnancy tests at baseline but not for the future|We offer free pregnancy test service at baseline but the respondents do not have an opportunity to receive or buy a pregnancy test.
10162177|NCT03975933|Experimental|Free pregnancy tests at baseline and for the future|We offer free pregnancy test service at baseline and a free pregnancy test for future use.
10162178|NCT03975933|Experimental|Free pregnancy tests at baseline and future use (random price)|We offer free pregnancy test service at baseline and the respondents have an opportunity to buy a pregnancy test.
10162179|NCT03975933|No Intervention|Control Group|Control group. No intervention is implemented.
10162180|NCT03975933|Experimental|Pregnancy test for the future use|No free pregnancy tests at baseline, but receive a free pregnancy test for the future.
10162181|NCT03975933|Experimental|Pregnancy test for the future with random price|No free pregnancy tests at baseline, but receive an opportunity to buy a pregnancy test for the future (ranodmized price).
10162182|NCT03976154|Experimental|Dermabond|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Dermabond. The investigator performing the thoracic epidural will distribute the Dermabond at the catheter insertion site in a space no greater than a 2 cm circle around the site. Once the Dermabond is allowed to dry, mastisol will be applied to the surrounding skin and a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia with a goal rate of 6ml/hr.
10162183|NCT03976154|Active Comparator|Mastisol|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Mastisol spray. The investigator performing the epidural placement will distribute Mastisol spray both in close proximity to the catheter insertion site as well as around the insertion site. Once the Mastisol is allowed to dry, a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team with a goal rate of 6ml/hr.
10162184|NCT03976154|Active Comparator|Grip-lock|Catheter fixation will be performed after appropriate placement of a thoracic epidural with a Grip-Lok fixation bandage. The investigator performing the epidural placement will place the fixation bandage one centimeter caudal from the insertion site. Mastisol will be applied to the surrounding skin and a clear Tegaderm will then be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team in the operating room with a goal rate of 6ml/hr.
10162185|NCT03975985|Experimental|Core stability exercises|This group will be divided in two: core stability exercises (CSE) plus conventional therapy (CP) and CSE with transcutaneous electrical nerve stimulation (TENS) plus CP.
10162186|NCT03975985|Active Comparator|Conventional physiotherapy (CP)|CP consists in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
10162187|NCT03976050|Experimental|Dose escalation|Subjects in the dose escalation cohorts will receive ascending doses of HL-085 until the MTD is determined. The first three subjects will receive twice-daily doses (BID) of HL-085 6 mg. Additional cohorts may receive doses of HL-085 9, 12 or 18 mg BID respectively and sequentially. If DLTs are observed in <33.3% of subjects at the 18 mg dose.
10162188|NCT03976102|Experimental|Arm A: DRL_RI|DRL_RI (rituximab-Dr. Reddy's Lab) for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36
10162189|NCT03976102|Active Comparator|Arm B: MabThera®|MabThera® for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Week 12, 20, 28 and 36.
10162190|NCT03976063|Active Comparator|Nifedipine|
10162191|NCT03976063|Placebo Comparator|Placebo|
10162192|NCT03976141||a|
10162193|NCT03976011|Experimental|Transcutaneous Laryngeal Ultrasonography|All patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
10162194|NCT03976037|Active Comparator|Vaginal Misoprostol in combination with foley bulb|"Women in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
10186329|NCT03736590|Active Comparator|Control - Social Needs Screening and Referral|Families in this active control arm will receive social needs screening and referral to community resources to address identified social needs.
9520213|NCT03279575|Active Comparator|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
9520214|NCT03279575|Placebo Comparator|Control|Physicians in this arm will not be asked to complete any intervention.
9977368|NCT01360736|Experimental|Safety Planning - Military (SAFE-MIL)|Brief Safety Planning Using Stanley and Brown (2012) Model
10162195|NCT03976037|Active Comparator|Buccal Misoprostol in combination with foley bulb|"misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
10162196|NCT03975764||Preterm birth|Delivery between 24-32 weeks of gestation
10162197|NCT03975764||Term delivery|Delivery between 37-41 weeks of gastation
10162198|NCT03975972|Experimental|Occupational Therapy Based Literacy Intervention|For the intervention group, the results from the Inventory of Reading Occupations will be utilized to determine a prescriptive weekly intervention for each participant in the intervention group that will be provided to teachers based on student interest and literacy need. For the intervention group, each participant will be provided with a list of 12 questions that will be used to inform the intervention plan based on the interests of each participant within the intervention group. Collectively, the information from the 12 questions and the results of the Inventory of Reading Occupations will be used to determine a 9-week intervention plan for each participant within the intervention group. The researchers will work with the subjects twice per week, 30 minutes per session in the classroom using the prescriptive intervention that was determined from the assessments utilized.
10162199|NCT03975972|No Intervention|Standard Classroom Based Literacy Intervention|The control group will receive the standard reading instruction provided within the school. With the control group, the researchers will provide occupational therapy support to classroom teachers. But, will provide this support using the materials that are standardly provided within the classroom for literacy instruction. The researchers will provide support to the classroom teachers to students in the control group twice per week for 30 mintues per session in the classroom.
10162200|NCT03975920|No Intervention|Usual Care (UC)|The study control is UC, which involves the dental assistant supporting the jaw during the extractions with concurrent use of a bite block.
10162201|NCT03975920|Experimental|Experimental Care (EC)|The study intervention for EC is use of the Restful Jaw version 2 (RJ2) device, which supports the jaw during the extractions, with concurrent use of a bite block.
10162202|NCT03975998||Aymptomatic patients with severe mitral regurgitation|Watchful waiting Early Surgery
10162203|NCT03976089|Experimental|Recipe 4 Success intervention|10 lessons delivered across 10 successive weeks within Early Head Start infrastructure by families' regular Early Head Start home visitors. Lessons involved active coaching in which parents and children prepared healthy snacks or meals. Lessons also included information on children's self-regulation skills and healthy eating habits.
10162204|NCT03976089|Active Comparator|Treatment as usual Early Head Start|Regular Early Head Start home visitors continued to implement evidence-informed developmentally appropriate curriculum designed to promote children's physical health, cognitive skills, and social-emotional functioning as well as parents' capacities to support their children's development.
10162205|NCT03975725|Experimental|witcard|
10162206|NCT03975881|Experimental|Open Label|Patients aged 15 to 35 who made a suicide attempt and went through the emergency departments of the participating hospitals (Nantes, Angers, Rennes and Poitiers).
10162207|NCT03975894|Experimental|Intervention|Regular prophylactic blood transfusion given every 6-10 weeks during pregnancy to maintain a HbS% of <30%.
10162208|NCT03975894|No Intervention|Control|Symptom directed blood transfusion during pregnancy.
10162209|NCT03975777|Experimental|low-intensity exercise - high-intensity exercise|low-intensity exercise session followed by a high-intensity exercise session separated by a minimum of 14 days
10162210|NCT03975777|Experimental|high-intensity exercise - low-intensity exercise|high-intensity exercise session followed by a low-intensity exercise session separated by a minimum of 14 days
10162211|NCT03975738||A GP Surgery|A selection of healthcare workers from a GP Surgery to be recruited
10162212|NCT03975738||A Patient and Public Involvement and Engagement Group|A selection of healthcare workers from a Patient and Public Involvement and Engagement Group to be recruited
10162213|NCT03975738||Young Person's Steering Group|A selection of patients from a Young Person's Steering Group to be recruited
10162214|NCT03975738||An Acute Trust|A selection of healthcare workers from an Acute Trust to be recruited
9974444|NCT01341275|Experimental|4 weeks, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 10 ug dose of hepatitis B vaccine as a booster
9977369|NCT01360736|No Intervention|E-CARE|Treatment As Usual and Assessment Services of Study; Control Condition
10162215|NCT03975738||Hayward Hospital Social Care Team|A selection of healthcare workers from the Hayward Hospital Social Care Team to be recruited
10162216|NCT03975738||A Hospice|A selection of healthcare workers from a Hospice to be recruited
10162217|NCT03975738||West Midlands Cares|A selection of healthcare workers from a the West Midlands Cares Group to be recruited
10162218|NCT03975738||CRN Clinical Research Speciality Leads (CRSL)|A selection of healthcare workers from a group of CRN (Clinical Research Network) Clinical Research Speciality Leads (CRSL) to be recruited
10162219|NCT03975738||CRN Sub Speciality Leads (SSL)|A selection of healthcare workers from a CRN Sub Speciality Leads (SSL) to be recruited
10162220|NCT03975738||A District General Hospital|A selection of healthcare workers from a A District General Hospital to be recruited
10162221|NCT03975855||Suspicious axillary lymph nodes|All patients with histologically confirmed breast cancer or highly suspicious breast lesions presenting with suspicious axillary lymph nodes
10162222|NCT03975699||Patients in centre 1: Louis-Mourier Hospital|All SCD follow-up consultations were conducted jointly by a paediatrician and a clinical psychologist.
10162223|NCT03975699||Patients in centre 2: Evry hospital|All SCD follow-up consultations were conducted by a paediatrician alone. The unit had close links with the local psycho-medical paediatric care centre when specialized referrals were necessary.
10162224|NCT03975699||Patients in centre 3: Clamart hospital|All SCD follow-up consultations were conducted by a paediatrician alone.
9520215|NCT03279562|Experimental|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
9520216|NCT03279549|Active Comparator|dressing change group|Routine dressing change group
9520217|NCT03279549|Experimental|Dermal matrix dressing group|Limited debridement & Acellular dermal matrix dressing group.
9826436|NCT02418546|Active Comparator|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
9826437|NCT02418546|Experimental|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
9974445|NCT01341275|Experimental|4 weeks, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 20 ug dose of hepatitis B vaccine as a booster
9974446|NCT01341288|Experimental|Implant|Robotic implantation of brachytherapy seeds to treat prostate cancer
9974447|NCT01341327||Left Main disease|Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
9974448|NCT01341340|Experimental|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
9974449|NCT01341353|Active Comparator|Antiarrythmic Drugs|
9974450|NCT01341353|Experimental|ablation|
9974451|NCT01341366|Experimental|Fast-track perioperative program|
9974452|NCT01341366|Active Comparator|Traditional perioperative program|
9974453|NCT01341379|Experimental|N-carbamylglutamate (Carbaglu)|
9974454|NCT01341392|Experimental|CKD-501 0.5mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
9974455|NCT01341392|Experimental|CKD-501 Amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
9974456|NCT01341392|Experimental|Amlodipine 10mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
9974457|NCT01341405|Experimental|CG100649 2 mg|capsule, once daily
9974458|NCT01341405|Experimental|CG100649 4 mg|capsule, 4 mg, once daily for 28 days
9974459|NCT01341405|Active Comparator|celecoxib 200 mg|capsule, once daily
9974460|NCT01341418|Active Comparator|Suprapatellar approach|surgical approach for intramedullary nailing of the tibia
9974461|NCT01341418|Active Comparator|Infrapatellar approach|surgical approach for intramedullary nailing of the tibia
9974462|NCT01341431|Experimental|bee venom|
9974463|NCT01341431|Placebo Comparator|saline|
9974464|NCT01341496|Experimental|1|autologous tumor vaccine plus chemotherapy
9974465|NCT01341509|Active Comparator|FHL tendon transferred|Surgical group in which the FHL tendon was transferred
9974466|NCT01341509|Active Comparator|FHL tendon not transferred|
9974467|NCT01341522|Active Comparator|Control|Control
9974468|NCT01341522|Experimental|MRI|experimental
9974469|NCT01341535|Experimental|adaptive DPBN|"This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
9974470|NCT01341535|Active Comparator|standard IMRT|"This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
9520218|NCT03279549|Experimental|Epidermal cell spraying group|Limited debridement & Epidermal cell spraying group
9520219|NCT03279549|Experimental|BFGF group|Limited debridement & Basic fibroblast growth factor group
9520220|NCT03279536|Experimental|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
9520221|NCT03279536|Active Comparator|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
9974471|NCT01341548|Active Comparator|Civamide Nasal Solution 0.01%|
9974472|NCT01341548|Placebo Comparator|Vehicle Solution|
9974473|NCT01341561||weaning patients|
9974474|NCT01341613|Experimental|Cardioviva™ supplement capsule|
9974475|NCT01341613|Placebo Comparator|Placebo capsule|
9974476|NCT01341678|Other|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
9974477|NCT01341678|Other|Restricted Phosphorus Diet|Diet containing 750mg of phosphorus per day and administration of a phosphate binder (lanthanum carbonate)
9974478|NCT01341678|Other|High Phosphorus Diet|Diet containing 3000mg of phosphorus per day and phosphorus supplementation (NeutraPhos)
9974479|NCT01341691|Placebo Comparator|Placebo 20mg|
9974480|NCT01341691|Active Comparator|K2CG 60 mg extender|
9974481|NCT01341691|Active Comparator|K2CG 60 mg|
9974482|NCT01341691|Active Comparator|K2CG 20mg extender|
9974483|NCT01341691|Active Comparator|K2CG 20mg|
9974484|NCT01341691|Placebo Comparator|Placebo 60mg|
9977370|NCT01360749|Experimental|Lambdalina and placebo|Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.
10162225|NCT03975686|Experimental|intervention|
10162226|NCT03975686|No Intervention|control|
10162227|NCT03975673|Active Comparator|Conventional Total Hip Replacement (cTHR )|"Osteoarthritic patient undergoing the conventional technique~medializing the hip center of rotation~obtain a standing acetabular cup position fitting the Lewinneck recommendations (inclination 40°±10°, version 15°±10°)"
10162228|NCT03975673|Experimental|Kinematically Aligned Total Hip Replacement (KATHR )|"Osteoarthritic patient undergoing the kinematically aligned technique~restoring the acetabular center of rotation~restoring the constitutional acetabular anteversion by using the transverse acetabular ligament (TAL) as a reference landmark.~making personalized choice for the hip component design~considering additional spine surgery based on the assessment of the individual spine-hip relation."
10162229|NCT03975608|Experimental|"Adaptation of CALM"|"This is the patient group that receives the intervention (IG), i.e., the psychotherapeutic treatment, i.e., the adapted version of the psychotherapeutic program Managing Cancer and Living Meaningfully (CALM) which was originally designed for patients with cancer."
10162230|NCT03975335|Experimental|Intervention group|Health education on NCDs and behavioral risk factors was delivered through motivation and observational learning session.
10162231|NCT03975335|Placebo Comparator|Control group|Control group received session on carrier guidance.
10162232|NCT03975348|Other|Baseline conventional facemask|The patients will receive oxygen therapy through conventional facemask for 10 minutes
10162233|NCT03975348|Experimental|HFNC 40 L/min up|The patients will receive oxygen/air mixture through high flow nasal cannula at incremental, then decremental flows, starting at 40 L/min for 10 minutes
10162234|NCT03975348|Experimental|HFNC 60 L/min up|High flow nasal cannula at 60 L/min for 10 minutes
10162235|NCT03975348|Experimental|HFNC 80 L/min up|High flow nasal cannula at 80 L/min for 10 minutes
10162236|NCT03975348|Experimental|HFNC 100 L/min|High flow nasal cannula at 100 L/min for 10 minutes
10162237|NCT03975348|Experimental|HFNC 80 L/min down|High flow nasal cannula at 80 L/min for 10 minutes
10162238|NCT03975348|Experimental|HFNC 60 L/min down|High flow nasal cannula at 60 L/min for 10 minutes
10162239|NCT03975348|Experimental|HFNC 40 L/min down|High flow nasal cannula at 40 L/min for 10 minutes
10162240|NCT03975348|Other|Washout conventional facemask|Again, the patients will receive oxygen therapy through conventional facemask for 10 minutes, to reduce the influence of HFNC on CPAP therapy
10162241|NCT03975348|Active Comparator|CPAP|The patients will receive CPAP at 10 cmH2O for 10 minutes
10162242|NCT03975413||N=1 MS patient|"Single-Arm, Non-Randomized, Time Series, Single-Subject Study. Observational study of the FMT intervention.~Single subject studies are based on repeated observations within an individual over time and are acknowledged as an important research method for generating scientific evidence about the health or behavior of an individual. This design is desirable when the available patient pool is limited and thus it is not optimal to randomize participants to a control arm. The subject serves as his/her own control, rather than using another individual/group.These designs are used primarily to evaluate the effect of a variety of interventions in early stage clinical research development."
10162243|NCT03975452|Experimental|Primary resectable cT2-low lying-T3, N0-N1 rectal tumour|Primary resectable cT2-low lying-T3, N0-N1 adenocarcinoma of the rectum, without evidence of disease in lateral lymph nodes.
10162244|NCT03975426||conservative group|received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture.
10162245|NCT03975426||absorbable screws|received open reduction and internal fixation with fixation by absorbable screws.
10162246|NCT03975556|Experimental|Intervention|Intervention group consisting of culturally-appropriate foods and diet advice in an initial individual session followed by daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
10162247|NCT03975556|Active Comparator|Control|Control arm of standard portion-control general nutritional and cooking advice at the initial individual session, followed by text messages for 2 months. A reinforcement phase of 2-months will follow to repeat the education and text messages.
10162248|NCT03975374|Experimental|Tobramycin/Dexamethasone opthamic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days
10162249|NCT03975374|Active Comparator|Tobradex Opthalmic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days
10162250|NCT03975283|Experimental|Exparel (Liposomal Bupivicaine)|20 ml vial of liposomal bupivacaine containing 266 mg (maximum dose), will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
10162251|NCT03975283|Active Comparator|0.25% Bupivicaine HCL|Two 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes and levels via laparoscopy. Medication will be given just below the last rib and extend to below the lowest incision.
10162252|NCT03975400|No Intervention|Pre-Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States prior to campaign initiation.
10162253|NCT03975400|Active Comparator|Active Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States during the active campaign initiation.
10162254|NCT03975478|Active Comparator|Gastric bypass|Bariatric surgery by gastric bypass (GB)
10162255|NCT03975478|Experimental|Sleeve gastrectomy|Bariatric surgery by sleeve gastrectomy (SG)
10162256|NCT03975465|Experimental|Expiratory Muscle Strength Training|Patients randomized to the EMST arm will use the EMST150 device as packaged, i.e. following package instructions
10162257|NCT03975465|Active Comparator|Pharyngeal Muscle Strengthening Exercises|Patients randomized to Standard Care will receive swallowing exercises designed to strengthen muscles that contribute to pharyngeal phase motor events and increase structural range of motion
10162258|NCT03975361|Other|Bliss-Believe|Patients included in the BLISS-BELIEVE study (NCT03312907).
10162259|NCT03975296|Experimental|TMQLB group|
10162260|NCT03975296|Active Comparator|TPVB group|
10162261|NCT03975270|Experimental|Sintilimab in Combination With Nab-paclitaxe|Sintilimab 200 mg intravenous drip, first day Nab-paclitaxe120 mg/m2, intravenous drip, first day and eighth day
10162262|NCT03975569|Experimental|vulvovaginitis patients- lactobacillus gel|Daily use of vaginal gel containing lactobacilli by patients. Probiotic vaginal gel.
10162263|NCT03975114|Active Comparator|Chemo first|Standard chemotherapy followed at progression by durvalumab
10162264|NCT03975114|Experimental|Immuno Monotherapy first|Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
10162265|NCT03975114|Experimental|Immuno Combination Therapy first|experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
10162266|NCT03975088|Other|Persistent Diabetic macular edema|Authors defined refractory DME as eyes with persistent DME despite receiving at least 6 monthly Ranibizumab injections of anti VEGF, and then switched to Aflibercept, receiving at least three monthly injections.
10162267|NCT03975504|Other|LDCT Screening|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
10162268|NCT03975192|Experimental|Intervention Group|50% of subjects will be randomized to the Intervention group and will receive percutaneous electric nerve field stimulation (PENFS) through the BRIDGE Device for 120 hours to treat withdrawal symptoms in patients following opiate exposure in the PICU.
10162269|NCT03975192|No Intervention|Standard of Care Group|50% of subjects will be randomized to the Standard of Care group and will receive be started on the standardized PICU Methadone wean for patients following opiate exposure in the PICU.
10162270|NCT03975166|Experimental|Test Product|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
10162271|NCT03975166|Active Comparator|Reference Product|ADVAIR DISKUS® 100/50
10162272|NCT03974997|Other|serum concentration changes in cytokine TWEAK|We will perform a prospective study in which 50 patients with multiple sclerosis in the isolated clinical syndrome stage will be included over a 12-month period. Mental Cerebral MRIs will be performed for each patient at baseline (T0), month 6, and month 12. Serum dosages of TWEAK will be performed each month for each patient for one year. Patients will also be treated with soluble TNF, the leader in the TNF family of ligands, anti-TWEAK antibodies (which may interfere with the activity and dosage of TWEAK) as well as C-reactive Protein C ( search for intercurrent infectious episode). These dosages will be correlated with the clinical evolution (appearance or not of an inflammatory flare) as well as the data of the imagery (number of lesions raised or not by the gadolinium).
10162273|NCT03975244|Experimental|Exercise group|Three months of semi-supervised exercise program in patients awaiting bariatric surgery. Body composition, cardiovascular risk factors, physical fitness, physical activity levels and quality of life will be assessed before and at the end of the study. In addition, surgery time, hospital length of stay and operative complications also will be evaluated.
10162274|NCT03975244|No Intervention|Control group|The control group only will perform the evaluations of the study.
10162275|NCT03975205|Active Comparator|Doxil|This group of patients will receive Intravenous Doxil of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
10162276|NCT03975205|Experimental|doxorubicin|This group of patients will receive Intravenous Doxorubicin of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
10162277|NCT03975127|No Intervention|Routine|women will routinely be invited to attend for cervical screening via the SCCRS application.
10162278|NCT03975127|Experimental|SMS|Women aged under 30 years will be identified to receive an SMS following cervical screening invitation using information from the CHI Broadcast
10162279|NCT03975218||Patients with stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
10162280|NCT03975634|Experimental|Transcutaneous spinal stimulation|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while trunk control is assessed at 3 time points (acute) and/or while transcutaneous stimulation is applied in combination with activity-based locomotor training (40 sessions, 1.5 hours/day, 5 days/week; stimulation will be applied intermittently for no more than 10 minutes at a time during training)
10162281|NCT03974958|Experimental|AAA patients|Patients with abdominal aortic aneurysm (AAA)
10162282|NCT03974958|Experimental|PAOD patients|patients with peripheral arterial obstructive disease (PAOD)
10162283|NCT03975036|Experimental|Anlotinib&pd-1 antibody|Anlotinib 10mg/d,q.d.,p.o.&pd-1 antibody 200mg/d.q.3w.d.l.v
10162284|NCT03975023||hockey players|"During each study visit, the participants will undergo the following procedures:~NeuroCatch Platform (NCP) assessment (only if participant meets NCP-specific criteria)~RightEye's eye-tracking battery~Highmark Interactive's EQ application~Cambridge Brain Science's neuropsychological tests"
10162285|NCT03975010|Experimental|BUP TDS 20 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 20 mg for 3 days.
10162286|NCT03975010|Experimental|BUP TDS 40 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 40 mg for 3 days.
10162287|NCT03975010|Experimental|BUP TDS 40 mg for 4 day|Subjects will be randomized into the arms, use BUP TDS 40 mg for 4 days.
10162288|NCT03975049|Active Comparator|5-Fu + RT|5Fu + RT for five weeks --- 6-8 weeks of interval --- TME --- mFOLFOX * 6-8
10162289|NCT03975049|Experimental|mFOLFOXIRI|mFOLFOXIRI * 4 --- TME --- mFOLFOXIRI * 4
10162290|NCT03975049|Experimental|mFOLFOX|mFOLFOX * 9 --- TME --- mFOLFOX * 3
10162291|NCT03975062|Experimental|Abbreviated course group (ACG)|The patients receiving 3-days course of dabigatran etexilate during pre-cardioversion period. After cardioversion has been performed the patients continue with dabigatran etexilate until 30 days after cardioversion
10162292|NCT03975062|Active Comparator|Conventional course group (CCG)|The patients receiving 3-weeks course of dabigatran etexilate before cardioversion of AF. After cardioversion has been performed the patients will continue with dabigatran etexilate until 30 days after cardioversion
9974485|NCT01341704|Experimental|MSP3-LSP/AlOH|Synthetic polyprotein of 96 amino acids (186-276 in 3D7 strain) manufactured by solid-phase synthesis by SYNPROSIS, France; lyophilized product was formulated extemporaneously with aluminum hydroxide (Reheis). 30 microgram per dose; three dose schedule on study day 0, 28 and 56 for primary series
9974486|NCT01341704|Placebo Comparator|Control|Primary series: Verorab Rabies vaccine; Secondary/Booster series: 0.9% NaCL/Normal Saline
9974487|NCT01341717|Experimental|Sitagliptin along with metformin and insulin|
9974488|NCT01341717|Active Comparator|Glimepiride as an active comparator to Sitagliptin|
9974489|NCT01341743|Active Comparator|A|oral entecavir 1mg daily for 104 weeks
9974490|NCT01341743|Active Comparator|B|oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
9974491|NCT01341743|Active Comparator|C|oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
9974492|NCT01341756|Experimental|Radiotherapy for gastric cancer|Single arm study
9974493|NCT01341769|Placebo Comparator|Control Test Food|Snack base
9974494|NCT01341769|Experimental|Experimental Test Food 1|Snack Base containing ingredient 1
9974495|NCT01341769|Experimental|Experimental Test Food 2|Snack base containing ingredient 2
9974496|NCT01341769|Experimental|Experimental Test Food 3|Snack base containing ingredients 1 and 2
9974497|NCT01341808|Experimental|IBD patients|"Patients diagnosed with IBD~-> receive Epaxal Berna (virosomal hepatitis A vaccine)"
9974498|NCT01341834|Experimental|LBH589-RAD001|LBH589-RAD001, single arm dose finding study
9974499|NCT01341847|Active Comparator|Water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of the colonoscope during insertion since the scope is inserted into the anus until reach the cecum. Water will be infused as needed under endoscopist judgement through the adaptor on biopsy channel with endoscopic washer pump. The usual air insufflation will be used during colonoscope withdrawal to facilitate mucosal examination and perform any other intervention, such as biopsy
9974500|NCT01341847|Other|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
9974501|NCT01341860||controls|control group with a BMI of less thatn 25kg/m2
9974502|NCT01341860||obese group|Obese patients with BMI 25-30 kg/m2
9974503|NCT01341873|Experimental|Group I (FCI)|FCs receive 4 sessions of an APN FCI beginning during the admission for transplant and continuing for up to 100 days after transplant.
9974504|NCT01341873|Other|Group II (control)|FCs receive standard supportive care.
9974505|NCT01341886|Active Comparator|metformin|patients who receive metformin in addition to levothyroxine
9974506|NCT01341886|Placebo Comparator|levothyroxine|patients who receive only levothyroxine
9974507|NCT01341899|Experimental|stem cell transplantation|
9974508|NCT01341925|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
9974509|NCT01341925|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
9974510|NCT01341925|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
9974511|NCT01341925|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
9974512|NCT01341938|Active Comparator|Lozenge Self Help: self help materials & lozenge NRT.|Self-help materials + Commit® nicotine lozenges (4 mg)
9974513|NCT01341938|Experimental|Lozenge Assisted Self-help: lozenge NRT, phone counseling, & self help materials|Self-help materials + Commit® nicotine lozenges (4 mg) + Phone counseling
9974514|NCT01341938|Experimental|Assisted Self-Help: self-help materials & phone counseling without lozenges|Self-help materials + Phone counseling
9974515|NCT01341951|Experimental|G-CSF therapy in acute liver failure and alcoholic hepatitis|G-CSF therapy given in cases with acute liver failure and alcoholic hepatitis
9974516|NCT01341964|Experimental|Higher dose aspirin group|Clopidogrel 600 mg plus aspirin 325mg
9974517|NCT01341964|Active Comparator|Low dose aspirin group|Clopidogrel 600mg plus aspirin 81mg
9974518|NCT01342003||Subtype 1a|subtype 1a patients treated with peginterferon plus ribavirin
9974519|NCT01342003||subtype 1b|subtype 1b patients treated with peginterferon plus ribavirin
9974520|NCT01342016|Experimental|tacrolimus group|tacrolimus capsule + leflunomide placebo
9974521|NCT01342016|Active Comparator|leflunomide group|tacrolimus placebo + leflunomide tablet
9974522|NCT01342042|Active Comparator|Metformin|
9974523|NCT01342042|Active Comparator|exenatide-4|
9974524|NCT01342055|Experimental|Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg|
9974525|NCT01342055|Experimental|Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg|
9974526|NCT01342055|Experimental|Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg|
9974527|NCT01342055|Experimental|Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg|
9974528|NCT01342055|Experimental|Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg|
9974529|NCT01342055|Experimental|Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg|
9977371|NCT01360749|Experimental|Placebo and lambdalina|Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.
9977372|NCT01360775|Experimental|nutritional counseling|Supervision and monitoring of nutritional status of patients in the home care program, after making nutritional advice
9977373|NCT01360775|No Intervention|Not nutritional counseling|
9977374|NCT01360788||Healthy control subjects|Subjects with a significant smoking history (more than 10 pack-years) and a normal lung function.
10162293|NCT03975075|Experimental|Biofeedback|Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). The biofeedback training session will be conducted using the eSense Pulse smartphone application. Participants will receive further instruction explaining how physiological information will be displayed and used as a means of training to induce a relaxed state while receiving real time feedback. Participants will be instructed on using controlled breathing to assist with reaching this relaxed state. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone.
10162294|NCT03975075|Active Comparator|Control Group|"Participants (n=15) will undergo 30 minutes of self-administered 1-channel (ECG) physiological monitoring at home using the Mindfield eSense Pulse twice a week for four weeks (eight sessions in total). Participants will be provided with the following instructions: You will be monitored with this equipment for 30 minutes. During this time frame, please try to limit movement and conversation as much as possible. Prior to each training session, the Study Coordinator will meet with the participant via Zoom to virtually assist with setup. Following each training session, participants will respond to questionnaires over the phone."
10162295|NCT03974880||patency group|Freedom from restenosis or clinically driven re-intervention in the treated lesion at 1,3,6,12 months after procedures
10162296|NCT03974880||restenosis group|Restenosis was defined as a reduction in the luminal diameter of more than 50 percent according to any imaging examinations such as duplex ultrasound, CTA, MRI or DSA Re-intervention in the treated segment for the clinical progression at 1,3,6,12 months after procedures
10162297|NCT03974880||the second adverse events group|a composite of all-cause death, myocardial infarction, and stroke and any amputation at 1,3,6,12 months after procedures
10162298|NCT03975140|Experimental|Hypersensitive acupoint group|
10162299|NCT03975140|Active Comparator|Hyposensitive acupoint group|
10162300|NCT03975101|Experimental|VSEL Max|A mean volume of 5.5 mL platelet-rich plasma containing approximately 120,000 cells were prepared and injected into the selected knee of the patient
10162301|NCT03975101|Experimental|VSEL Medium|A mean volume of 5.5 mL platelet-rich plasma containing approximately 90,000 cells were prepared and injected into the selected knee of the patient
10162302|NCT03975101|Experimental|VSEL Mini|A mean volume of 5.5 mL platelet-rich plasma containing approximately 60,000 cells were prepared and injected into the selected knee of the patient
10162303|NCT03975101|No Intervention|Control|A mean volume of 5.5 mL platelet-rich plasma containing no VSELs injected into the selected knee of the patient
10162304|NCT03975257|Experimental|Preventive application of EHT02|application of one Ectoin Lozenge before SLIT-initiation
10162305|NCT03975257|Experimental|Therapeutic application of EHT02|application of one Ectoine Lozenge after SLIT-initiation
10162306|NCT03975257|No Intervention|No application of EHT02|SLIT-Initiation without Ectoin Lozenge
10162307|NCT03974984||"The Hvidovre population:"|We will include patients undergoing laparoscopic hemicolectomy for cancer scheduled for anesthesia with total intravenous anesthesia combined with epidural anesthesia and perioperative NSAID on Hvidovre Hospital.
10162308|NCT03974984||"The Zealand University Hospital population"|"The immunological and oxidative stress in relation to abdominal surgery (IMOX) study is ongoing at Zealand University Hospital, Roskilde. It is a prospective explorative study cohort that consists of 60 patients undergoing laparoscopic colorectal cancer surgery.~The population has been anesthetized according to the standard operating procedure with either total intravenous anesthesia with propofol and remifentanil or volatile anesthesia with sevoflurane combined with a fast acting opioid (remifentanil or sufentanil). Patients anaesthetized with other techniques including epidural or other regional blocks will be excluded from the analysis."
10162309|NCT03974789||Suspected Cushing Disease|
10162310|NCT03974854|Experimental|Arm A: XELOXIRI-3|capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days
10162311|NCT03974854|Active Comparator|Arm B: Gemcitabine|1000 mg / m2 on D1, D8 and D15, every 28 days
10162312|NCT03974932|Experimental|Cohort 1|HTX-011 + MMA
10162313|NCT03974932|Experimental|Cohort 2|HTX-011 + MMA
10162314|NCT03974932|Experimental|Cohort 3|HTX-011 + MMA
10162315|NCT03974932|Experimental|Cohort 4|HTX-011 + MMA
10162316|NCT03974607|Experimental|Physical Activity|Physical Activity Programme (PAP) was planned for the promotion of PA and other healthy habits in inactive adolescents as an agent of change intervention, in which a trained staff actively disseminates effective practices to improve the PA's habits of adolescents.
10162317|NCT03974607|No Intervention|No Physical Activity|The control group will be selected in a targeted manner according to the availability of the center. You will not be given any information about healthy habits nor will any physical training program be applied to you, so that you do not give indications that may produce a variation of your habitual behavior.
10162318|NCT03974581||Pharmacoinvasive strategy|Patients whom received pharmacoinvasive strategy (fibrinolysis and subsequently PCI) as reperfusion treatment.
10162319|NCT03974581||Primary PCI|Patients whom primary PCI as reperfusion treatment.
10162320|NCT03974893||Vegetarian Diet|Includes children following a vegetarian diet.
10162321|NCT03974893||Non-Vegetarian Diet|Includes children following a non-vegetarian diet.
10162322|NCT03974672||T drain|Patients treated with a T drain approach
10162323|NCT03974672||Stoma|Patients treated with a stoma
10162324|NCT03974815|Experimental|ACTIVE|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
10162325|NCT03974815|Sham Comparator|SHAM|Sham stimulation (tDCS) will be used in the dose of 0mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
10162326|NCT03974685|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single
10162327|NCT03974906|Experimental|GDT group|The fluid in GDT group (Goal-directed fluid therapy) will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the LiDCO monitoring system.
9520222|NCT03279523||F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
9520223|NCT03279510|Experimental|Hearing aids|All study participants will be fit with hearing aids.
9520224|NCT03279497|Experimental|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
9826438|NCT02418546|No Intervention|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
9974530|NCT01342120||Quetiapine|Quetipine users
9974531|NCT01342120||All other atypical antipsychotics|All other atypical antipsychotics users
9974532|NCT01342120||Risperidone|Risperidone users
9974533|NCT01342120||Olanzapine|Olanzapine users
9974534|NCT01342133||Newborns|
9974535|NCT01342133||Mothers|
9974536|NCT01342159|Active Comparator|Intravitreal bevacizumab injection|
9974537|NCT01342159|Active Comparator|Intravitreal Triamcinolone injection|
9974538|NCT01342159|Active Comparator|intravitreal bavacizumab with triamcinolone|
9974539|NCT01342185|Experimental|Medical ozone therapy with tianyi|
9974540|NCT01342185|Active Comparator|medical ozone therapy with humares|
9974541|NCT01342185|Placebo Comparator|Diammonium glycyrrhizinate Capsules|
9974542|NCT01342198|Experimental|1|Single Dose Pregabalin Controlled Release
9974543|NCT01342198|Experimental|2|Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin
9974544|NCT01342224|Experimental|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
9974545|NCT01342237|Experimental|topotecan|
9974546|NCT01342250|Experimental|Conventional plus hUC-MSCs treatment (low dose)|
9974547|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （medium dose）|
9974548|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （high dose）|
9974549|NCT01342263|No Intervention|Usual Care|Does not get to participate in the interactive chronic disease website.
9974550|NCT01342263|Experimental|iCDM|The iCDM will support patient self-management through collaborative planning and goal setting, education and skill development, support for behaviour change, and regular patient monitoring with follow-up. For each chronic condition, we have outlined sample patient signs and symptoms to be monitored, frequency of patient provider contact and frequency of patient prompt questions on their condition. The main premise of the iCDM is that only those patients who generate 'alerts' will be contacted by the iCDM nurse allowing for the potential to manage more patients than through traditional means of required patient follow-up regardless of patient condition . Across these five diseases are the following cross-cutting features: nutrition therapy, exercise therapy, psychological support, medication adherence and smoking cessation.
9974551|NCT01342276|Experimental|vHFC|Patients will get to participate in the interactive heart failure website (vHFC).
9974552|NCT01342276|No Intervention|Usual Care|Patients will not get to participate in the interactive heart failure website (vHFC).
9974553|NCT01342289|Experimental|Tacrolimus 60|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 60 days.
9974554|NCT01342289|Experimental|Tacrolimus 90|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 90 days.
9974555|NCT01342289|Experimental|Tacrolimus 120|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 120 days.
9974556|NCT01342302|Other|Couples Intervention|Single arm study design
9974557|NCT01342328|Placebo Comparator|Control|For this arm, the volunteer subject will receive a saline infusion during the sleep session.
9974558|NCT01342328|Experimental|Dexmedetomidine (DEX)|For this arm, the volunteer subject will receive a DEX infusion for sedation during the sleep session.
9974559|NCT01342328|Experimental|Propofol|For this arm, the volunteer subject will receive a propofol infusion for sedation during the sleep session.
9974560|NCT01342354|Experimental|Stereotactic Radiation|Escalating doses of SBRT in three doses over ten days.
9974561|NCT01342380||Seroquel|Participants who received Seroquel
9974562|NCT01342380||Pioglitazone|Participants who received pioglitazone
9974563|NCT01342432|Experimental|Balance reeducation plus exercise|exercises that challenge postural control are performed in addition to general exercises for stretch and strength of abdominal and paraspinal muscles
9974564|NCT01342432|Other|General exercise only|general exercise for stretch and strength of paraspinal and abdominal muscles
9974565|NCT01342497|Experimental|BBR-012|
9974566|NCT01342497|Placebo Comparator|Placebo|
9974567|NCT01342536|Experimental|lifestyle counseling (OHDC)|Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression
9974568|NCT01342536|Active Comparator|lifestyle counseling (CWD)|Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention
9974569|NCT01342562|Experimental|DXM-bupivacaine|
9974570|NCT01342562|Placebo Comparator|saline-bupivacaine|
9974571|NCT01342575|Experimental|Intra-operative maneuver group|
9974572|NCT01342588|Experimental|Electrical stimulation|Only arm of the study, the experimental
9974573|NCT01342601|Active Comparator|Ectoin products|
10162328|NCT03974906|No Intervention|Control group|Patients in the control group received conventional fluid therapy, decided by the attending anesthesiologists based on the patient's hemodynamic condition and responses, to maintain MAP >65 mm Hg, heart rate 50-100 bpm, and urine output >0.5 ml/kg/h.
10162329|NCT03974633|Placebo Comparator|Control|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, without administering any type of non-invasive analgesic
10162330|NCT03974633|Experimental|Vibration|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, while applicating a vibrating device on the skin below the injection site, before and during injection.
10162331|NCT03974633|Experimental|Cold|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a bag of 50mL of frozen physiologic saline covered with a plastic glove on the injection site for 50 seconds
10162332|NCT03974633|Experimental|Anesthetic cream|subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a uniform thickness of 2mm of the anesthetic cream EMLA covered with an adhesive transparent plastic dressing for 30 minutes
10162333|NCT03974776|Experimental|PF-06946860|Single subcutaneous administration of PF-06946860
10162334|NCT03974776|Placebo Comparator|Placebo|Single subcutaneous administration of placebo
10162335|NCT03974737||Adolescents with POTS|"Adolescents with Postural Orthostatic Tachycardia Syndrome (POTS) who meet diagnostic criteria for an orthostatic heart rate increase of >30, between ages 12-21 are eligible for this group. They will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
10162336|NCT03974737||Adolescents without POTS, Control Group|"Adolescents without Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21 are eligible for this group. This group of subjects will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and their urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
10162337|NCT03974737||Adolescents diagnosed with POTS who do not meet HR|"Adolescents diagnosed with Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21, who do not meet diagnostic heart rate criteria, are eligible for this group. This group of subjects will have a urine specific gravity conducted at beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.~Interventions performed:~Urine specific gravity measurement~CRI measurements, orthostatic vitals measurements~Survey administration"
10162338|NCT03974698|Active Comparator|Anterolateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
10162339|NCT03974698|Active Comparator|Lateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
10162340|NCT03974516|Experimental|Careseng 1370|"Four dose cohorts are employed for Careseng 1370 oral administration in healthy volunteers:~Level A (1 sachet): 1 sachet before breakfast;~Level B (2 sachets): 1 sachet before breakfast, 1 sachet before lunch;~Level C (3 sachets): 1 sachet before breakfast, 2 sachets before lunch;~Level D (4 sachets): 2 sachets before breakfast, 2 sachets before lunch"
10162341|NCT03974529|Experimental|Intensive running arm|20 patients will be assigned randomly to intensive running arm (intervention arm). They will be required to complete a designed training protocol.
10162342|NCT03974529|Active Comparator|Physiotherapy arm|10 patients will be assigned randomly to physiotherapy arm. They will be required to complete a designed training protocol.
10162343|NCT03974542|Experimental|telephone outreach|
10162344|NCT03974542|No Intervention|control|
10162345|NCT03974659|Active Comparator|Theta Burst Stimulation|"Intervention group: ten consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation.~Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).~The stimulation intensity was 80% Rest Motor Threshold.According to the patients' condition, age and tolerance,the intensity should be adjusted."
10162346|NCT03974659|Sham Comparator|sham Theta Burst Stimulation|sham group: we flip coil to make fake stimulation, the stimulation will also make sounds, but no magnetic field effect, the stimulation mode is the same as the intervention group.
10162347|NCT03974646|Experimental|intervention group|Participants assigned to the intervention group will receive both will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up , and a 12- weeks self-management intervention delivered by two dedicated and trained renal nurse educators. The intervention will involve three group-based sessions, CKD booklet and three follow-up phone calls.
9974574|NCT01342601|Placebo Comparator|Placebo products|
10162348|NCT03974646|No Intervention|control group|Participants randomized to the control group in this study will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up. Usual care consisted of brief verbal information (2-5 minutes) about taking medications, reducing salt, smoking cessation and reducing alcohol consumption. There will no structured program but only the provision of written material to patients.
10162349|NCT03974867|Experimental|Oral Prednisone Group|36 participants in Group 1 will receive oral prednisone 1mg/kg/d (maximum daily dosage is no more than 60mg) for 7 days, followed by a 7-day taper.
10162350|NCT03974867|Experimental|Intratympanic Methylprednisolone Group|36 participants in Group 2 will receive 7 intratympanic 40mg/ml methylprednisolone injections in 14 days, one injection every other day.
10162351|NCT03974412|Experimental|All eligible participants|All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.
10162352|NCT03974217|Experimental|Talazoparib|"Talazoparib is administered orally on a daily basis~Hydroxyurea is allowed for up to two cycles per institutional guidelines"
10162353|NCT03974178|Experimental|Fexinidazole|"Patients with a body weight ≥ 35 kg:~1800 mg (3 tablets) from day 1 to 4~1200 mg (2 tablets) from day 5 to 10~Patients with a body weight ≥ 20 and < 35 kg:~1200 mg (2 tablets) from day 1 to 4~600 mg (1 tablet) from day 5 to 10"
10162354|NCT03974295|Experimental|Intercourse Group|unlimited unprotected vaginal intercourse starting 24 hours after the frozen embryo transfer
10162355|NCT03974295|No Intervention|Pelvic Rest Group|pelvic rest after frozen embryo transfer until positive pregnancy test
10162356|NCT03974126|Experimental|40 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
10162357|NCT03974126|Experimental|80 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
10162358|NCT03974399|Other|study enrollment|all participants will take dietary supplement, Bacopa Monnieri, daily for 3 months
10162359|NCT03974282|Other|Virginia Commonwealth University|Enrolled at VCU
10162360|NCT03974165|Experimental|Cereal-legume product 1|Treatment with cereal-legume product-1
10162361|NCT03974165|Experimental|Cereal-legume product 2|Treatment with cereal-legume product-2
10162362|NCT03974165|Experimental|Cereal product|Treatment with cereal product
10162363|NCT03974165|Active Comparator|Reference food|Treatment with reference food
10162364|NCT03974360|Experimental|Erenumab|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
10162365|NCT03974191||131 participants with chronic low back pain|All the participants (n=131) with chronic low back pain (CLBP) from the cross-sectional study in 2006 are invited to participate in the present 13-year follow-up. The same examination battery used in the cross-sectional study plus a supplementary Chair Stand Test will be used.
10162366|NCT03974425|Other|Diabetic macular edema resistant to Bevacizumab|Patients resistant to 6 monthly Bevacizumab injection were switched to Aflibercept.
10186330|NCT03736577|Experimental|NorGeP-NH|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend.~Intervention: Drug reviews with NorGeP-NH Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH) and they will do a structured drug review on the participants' drug charts."
10186331|NCT03736577|No Intervention|Control nursing home|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend. Physicians will not attend any lecture about drug reviews and they will keep treating participants as usual."
10186332|NCT03736564|Experimental|68Ga-DOTATATE PET/CT|Subjects will undergo imaging by 68Ga-DOTATATE PET/CT
10186333|NCT03736551|Experimental|Intervention|The intervention arm will involve standard care plus an intermittent modified fasting regimen consisting of a very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet). All dietary intake on modified fasting days will be from LighterLife foodpacks, (4 x 150 kcal portions/day presented as milkshakes, cereal bars, soups and modified meals such as spaghetti bolognese, or macaroni cheese) providing ~600 kcal/day and 100% of the RNI for vitamins and minerals.
10186334|NCT03736551|Active Comparator|Standard Care|Renal Weight management Programme - Patients will attend individual appointments with the specialist dietitian and physiotherapist once a month, for 6 months. Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure (9). In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
10186335|NCT03736525|Experimental|Design For Wellness (DWELL)|Intervention participants will: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
10186336|NCT03736525|Other|Wait list control group|After the close of the study, we will open the Facebook group to all, and wait list control group participants can receive a delayed form of the intervention, which includes: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
10186337|NCT03736473|Other|MEDI9447 monotherapy|Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies
10186338|NCT03736460|Experimental|Mindfulness-based intervention|
10162367|NCT03974386|Experimental|Blood Purification|Patients will receive resuscitation and treatment according to current guidelines for septic shock. In addition to standard care, the patients will receive continuous venovenous hemofiltration and adsorption with oXiris blood purification set.
10162368|NCT03974386|No Intervention|Conventional Treatment|Patients will receive standard care, including resuscitation and treatment according to current guidelines for septic shock.
10162369|NCT03974451|Experimental|IOL implantation experimental|Implantation of the PhysIOL FineVision POD F® IOL
10162370|NCT03974451|Active Comparator|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL.
10162371|NCT03974308|Experimental|Study group 1|Patients with spine osteoarthritis who will be treated in polish spas in Subcarpathian Region. Comprehensive physiotherapy including balneotherapy will be applied.
10162372|NCT03974308|Active Comparator|Study group 2|Patients with spine osteoarthritis who will be treated in outpatient treatment. Comprehensive physiotherapy without balneotherapy will be applied.
10162373|NCT03974308|Other|Control group|Patients with spine osteoarthritis who will not have applied physiotherapy nor balneotherapy.
10162374|NCT03974490|Experimental|Intervention Group|"2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.~3 Times a week, intervention: Start with global body warming, 15 minutes, following the rhythm marked by the metronome. Central part of the session, 60 minutes, with rhythmic auditory stimulation exercises and music. Closure of the session, 15 minutes, round of impressions."
9520225|NCT03279497|Sham Comparator|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
10162375|NCT03974490|No Intervention|Historical control group|2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
10162376|NCT03974256|No Intervention|Group standard method|Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
10162377|NCT03974256|Experimental|Group automated method|Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
10162378|NCT03974477|Experimental|Intervention|"The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content (will be used an illustrative video and recipes with an adequate salt content); use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H. A leaflet will also be delivered about The new Food Wheel, a guide to the daily food choice!."
10162379|NCT03974477|No Intervention|Control|"No intervention will be carried out except the provision of a leaflet on The new Food Wheel, a guide to the daily food choice! to the participants."
10162380|NCT03974269|Active Comparator|Hypnosis arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
9974575|NCT01342614|Active Comparator|Fosinopril group|Fosinopril group received fosinopril, 10mg, once per day.
9974576|NCT01342614|Experimental|Metformin group|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
10162381|NCT03974269|Placebo Comparator|Sedation arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
10162382|NCT03974438|Experimental|Intervention - Acupunture (SDN)|Patients allocated to the intervention arm will receive SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain.
10162383|NCT03974438|Sham Comparator|Control - Sham acupunture|Patients allocated to the control arm will receive sham-SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain. The sham procedure consists of a blunted needle, that does not penetrate the skin.
10162384|NCT03974373|Experimental|BFP removal|this will be the group evaluated in this study, individuals who performed the BFP removal procedure.
10162385|NCT03974074|Experimental|Albumin infusion group|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
10162386|NCT03974074|No Intervention|Empty control|Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
10162387|NCT03973840|Experimental|healthy men treatment arm|Subjects were given 15 doses over 8 days, and then blood was drawn into several types of collection tubes at different storage conditions.
10162388|NCT03973775|Experimental|Test Drug Treatment Arm|Permethrin Cream 5%, Saptalis Pharmaceuticals, LLC
10186339|NCT03736460|Active Comparator|Physical training|
10162389|NCT03973775|Active Comparator|Reference Drug Treatment Arm|Elimite™ (Permethrin Cream 5%), Prestium Pharma, Inc.
10162390|NCT03973879|Experimental|PVSRIPO + Atezolizumab|Single PVSRIPO infusion at a dose of 5x10^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.
10162391|NCT03973710|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
10162392|NCT03973710|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
10162393|NCT03973749|Experimental|Group 1|Low salycilate diet on day one and High salycilate diet on day 7
10162394|NCT03973749|Experimental|Group 2|High salycilate diet on day one and Low salycilate diet on day 7
10162395|NCT03973944|Other|Cardiac resynchronization therapy|AV coupling by atrio-biventricular pacing
10162396|NCT03973788|Experimental|Intervention|repetitive transcranial magnetic stimulation
10162397|NCT03973606|No Intervention|Arab Women health literacy focus groups|Arab women in East Jerusalem will be part of focus groups. During the focus groups, a set of pre-prepared questions will be presented to the participants. The focus groups will be recorded and analyzed verbatim.
10162398|NCT03973606|Experimental|Health literacy workshop|Women from East-Jerusalem and other Arab communities in Israel will be invited to participate in a 4-sessions workshop designed to improve health literacy, self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
10162399|NCT03973684|Active Comparator|aPDT group|G1- 40 patient 40 patients will be included in this group. One section of Pdt will be performed with the photosensitizer (PS). PS will be applied in sufficience quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated. The apparatus shall be precalibrated at wavelength 660nm for 90 seconds per point.
10162400|NCT03973684|Experimental|experimental tongue scrapper group|40 patients will be included in this group. Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
10162401|NCT03973619|Active Comparator|Labial|Patients who received a labial graft as replacement of urethral tissue
10162402|NCT03973619|Active Comparator|Jugal|Patients who received a jugal (inner cheek) graft as replacement of urethral tissue
10162403|NCT03973983|Experimental|Ultrasound-guided pudendal nerve injection group|Patients who received Ultrasound-guided pudendal nerve injections
10162404|NCT03973983|Experimental|Finger-guided pudendal nerve injection group|Patients who received Finger-guided pudendal nerve injections
10162405|NCT03974009|Experimental|Calcaneal taping and Conventional therapy|Calcaneal Taping Technique along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
10162406|NCT03974009|Active Comparator|Sham taping and Conventional therapy|Sham taping along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
10162407|NCT03973957|Active Comparator|Control Arm|If undergoing talc slurry in the control arm, the patient will undergo IPC placement in the pulmonary procedure unit on day one of admission. The IPC will then be connected to a pleur-evac as standard of care protocol for chest tube drainage. At 1-2 hours post-IPC placement a chest x-ray will be obtained to assess for full lung re-expansion. If the lung does not fully expand the patient will be excluded from the study. Once full lung re-expansion has occurred, talc slurry will be ordered and the patient will be given 25 mcg of IV fentanyl. Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will be administered via the IPC. The patient will remain in the hospital, with continuous drainage measured daily for 2-5 days, depending on drainage of the effusion.
10162408|NCT03973957|Active Comparator|Intervention Arm|"An indwelling pleural catheter (IPC) will be placed during this visit. After complete drainage of the effusion, a chest x-ray will be done to determine if full lung reexpansion occurs. If there is lack of full lung re-expansion the patient will be excluded from the study at this time. If full lung re-expansion is present, the patient will receive an intravenous line (IV) by our nursing staff for analgesia prior to talc administration and will be pre-treated with 25 mcg of IV fentanyl.~Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will then be administered through the IPC. The IPC will then be connected to a circuit that will consist of the IPC connected to a 4-liter fluid drainage collection bag via a one-way Heimlich valve (picture of set up included in additional documents)."
10162409|NCT03973762|Experimental|DR Grading with CAD|DR Grading with CAD
10162410|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
10162411|NCT03973671||UC patients|"Patients diagnosed with primary or recurrent non-muscle-invasive bladder (NMIBC) cancer.~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.~The clinical (demographic, operative and follow-up) and pathological data of the patients will be collected in a complete anonymous way."
10162412|NCT03973801|Experimental|Auricular acupressure|
10162413|NCT03973658||First time users of hearing aids|Hearing aid fitting and usage
10162414|NCT03973736||PDAC patients diagnosed in 2008-2011|
10162415|NCT03973736||PDAC patients diagnosed in 2013-2016|
10162416|NCT03974035|No Intervention|Control Group|Patients undergoing elective bimaxillary osteotomy who receive a preincisional infiltration of lidocaine and adrenaline.
10162417|NCT03974035|Experimental|Study Group|Patients undergoing elective bimaxillary osteotomy who receive two infiltrations (firstly pre-incision with lidocaine and adrenaline, secondly pre-extubation with ropivacaine).
10162418|NCT03973476|Experimental|Intervention group|Mothers received a phone support service with their midwife during the 8 weeks after childbirth.
10162419|NCT03973476|No Intervention|Control group|Mothers received standard postpartum care
10162420|NCT03973489|Experimental|Wild Type (WT) MUD Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
10162421|NCT03973489|Experimental|Common Variant (CV) MUD Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
10162422|NCT03973489|Experimental|Wild Type (WT) Healthy Control Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
10162423|NCT03973489|Experimental|Common Variant (CV) Healthy Control Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
10162424|NCT03973515|Experimental|PB-201 50/50mg by mouth,every morning and noon for 7 days|
10162425|NCT03973515|Experimental|PB-201 100/50mg by mouth,every morning and noon for 7 days|
10162426|NCT03973515|Experimental|PB-201 100/100mg by mouth,every morning and noon for 7 days|
10162427|NCT03973515|Placebo Comparator|placebo|
10162428|NCT03973502|Experimental|18F-DOPA PET|PET/CT
9520226|NCT03279484|Experimental|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
9520227|NCT03279445||African American|Patient of African American race
9974577|NCT01342627|Experimental|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to protocol.~In case of disease progression Sorafenib administration will be discontinued."
9520228|NCT03279445||Caucasian|Patient of Caucasian race
9520229|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.~Patient may or may not be receiving terlipressin therapy."
9520230|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
9520231|NCT03279393|Active Comparator|PTSD Subjects|
9974578|NCT01342653|Experimental|NIPS plus HIPEC plus adjuvant chemotherapy|
9974579|NCT01342679|Experimental|dasatinib|
10162429|NCT03973580|Active Comparator|Attentional Bias Modification (ABM) group|Participants in this arm will participate in a six-session ABM task, one session per week.
10162430|NCT03973580|Placebo Comparator|Control group|Participants in this arm will participate in a six-session control task, one session per week.
10162431|NCT03973632|Experimental|Group A|Fasting at last 10h before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
10162432|NCT03973632|Experimental|Group B|Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Fasting at last 10h before taking 200mg（two pills） of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
10162433|NCT03973541|Experimental|Virtual Reality Exposure Therapy|VRET will include 360° videos with three scenarios a) riding a bus, b) going to a school cafeteria and c) a job interview. These scenarios were chosen based on clinical experience and frequently reported difficult situations in the literature . The order of the scenarios is jointly decided by the patient and therapist. In the videos the patients can make choices which determine the further course of the exposure scenario. For example, in the bus scenario the information system is out of order. Therefore, the patient has to ask the driver to announce, when they are at a particular stop. Depending on whether or not the patient decides to do so, the video will skip to one of two alternative continuations of the scenario. During the exposures the therapist will also motivate the patient towards acting in ways they consider unacceptable to provoke fear of ridicule, and make the patient act against him or her excessively rigid rules for social interaction to observe the consequences.
10162434|NCT03973541|Active Comparator|In Vivo Exposure Therapy|In vivo exposure consists of role-playing and guided exposure either inside or outside the therapist's office with active modelling from the therapist in early sessions. Staff members are called upon to conduct exposure. Similarly to the VRET during in vivo exposure the therapist will motivate the patient towards acting in ways they consider unacceptable.
10162435|NCT03973541|Placebo Comparator|Virtual Reality Relaxation Therapy|VR relaxation therapy will consist of a VR scenario of swimming with dolphins, created by the dolphin swim club (www.thedolphinswimclub.com). Swimming with real wild dolphins has been shown to have a positive effect on anxiety, although not specifically on SAD
10162436|NCT03973385|Experimental|cryotherapy group|cryotherapy by vapocoolant spray is applied on skin for 4 to 10 seconds ( or up to skin whitening) to 15 centimeters distance with sweeping action before ABG
10162437|NCT03973385|Placebo Comparator|control group|water spray is applied on skin for 4 to 10 seconds to centimeters distance with sweeping action before ABG
10186340|NCT03736460|No Intervention|Wait-list|
10186341|NCT03736447|Active Comparator|AR101 powder (Peanut allergen formulation)|Subjects will be randomized to active arm of ARC005 and will be administered IP (AR101) in escalating doses for approximately 6 months.
9520232|NCT03279393|Active Comparator|Trauma Control Subjects|
9520233|NCT03279393|Placebo Comparator|Healthy Control Subjects|
9520234|NCT03279380|Experimental|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
9520235|NCT03279380|Active Comparator|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
9520236|NCT03279380|Active Comparator|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
10162438|NCT03973255|Placebo Comparator|Home based vestibular rehabilitation program|Home-based vestibular rehabilitation program including vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises was given to each group in the form of a booklet. All exercises were demonstrated and performed first time at hospital under supervision. Booklet with descriptions and pictures of each exercise were given to patients in order to enable them to perform exercises at home. Vestibular rehabilitation exercises were prescribed as once daily with 10 repetitions at home for one month and wanted to mark a chart if the exercises were performed daily. A diary was used to monitor adherence with the program.
10162439|NCT03973255|Active Comparator|Biofeedback training|"Biofeedback training was performed five days a week during a month for 20 minutes for a total of 20 sessions with Tetrax ® (Sunlight Medical Ltd) static posture analysis device. Biofeedback training including catch, speedball, sky ball, gotcha exercises which requires following a visual target during weight transfer movements, capturing fast-moving objects by changing the center of gravity or quickly escaping from incoming objects, were applied to the patients in biofeedback training. There is a 30 seconds pause between each exercise."
10162440|NCT03973255|Active Comparator|Whole body vibration|Whole body vibration training was also performed five days a week during a month for 20 minutes for a total of 20 sessions with Power Plate Pro 5 (MDD CE 0086). In whole body vibration, single leg, squat and deep squat positions were applied respectively with 35 Hz frequency, including rest periods of 30 seconds between each application.
10162441|NCT03973463|Sham Comparator|Low fat diet,12 weeks low oil balance 1200 kcal / day|12 weeks low oil balance 1200 kcal / day
10162442|NCT03973463|Experimental|12-week resistance exercise 3 times a week|12-week stretch with resistance exercise, 3 times a week
10162443|NCT03973463|Experimental|12 weeks low oil balance and resistance exercise|12 weeks low oil balance 1200 kcal / day and 12-week stretch with resistance exercise, 3 times a week
10162444|NCT03973450||Pituitary tumours|Patients affected by pituitary tumours and followed-up at the Neuroendocrinology Unit over a 5 yrs period (2014-2018)
10162445|NCT03973190|Placebo Comparator|RET Group|Closure of the alveolus by first intention through palatal flap sliding according to the technique of Khoury et al. (2000).
10162446|NCT03973190|Active Comparator|SBC Group|Fill bone alveolus with Bone Ceramic® graft (Straumann AG, Basel, Switzerland) and cover it with palatal flap according to the technique of Khoury et al. (2000).
10162447|NCT03973190|Active Comparator|PRO Group|Alveolus sealing by a temporary ovoid pony of acrylic resin.
10162448|NCT03973346|Experimental|Intervention group|Encounters at primary care clinics with the risk screening tool
10162449|NCT03973346|No Intervention|Comparison group|Propensity score matched comparison encounters
10162450|NCT03973125|Experimental|Treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
10162451|NCT03973424|Experimental|Simple|This arm uses a simplified form of dietary tracking that involves tracking only high-calorie, high-fat foods, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
10162452|NCT03973424|Experimental|Standard|This arm uses standard calorie tracking, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
10162453|NCT03973307||Participants with bladder cancer|50 participants with histologically confirmed evidence of malignancy for bladder cancer following routine cystoscopy and biopsy.
10162454|NCT03973307||Participants without bladder cancer|50 participants with negative biopsy for bladder cancer following routine cystoscopy and biopsy.
10162455|NCT03973567|Experimental|refractory FD patients using antidepressants|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, proton pump inhibitors (PPI), motivation and anti-Helicobacter pylori（HP） treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
10162456|NCT03973567|Placebo Comparator|refractory FD patienTS using conventional treatment|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, PPI, motivation and anti-HP treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
10162457|NCT03973567|No Intervention|normal control|Age, sex and education matched, right-handed 30 normal people.
10162458|NCT03973294|Active Comparator|Supraglottic jet ventilation|Ventilation of the patient is performed over a steel laryngoscope or a thin catheter by means of jet ventilation (JV) using the TwinStream jet ventilator (C. Reiner Corp, Vienna, Austria). The driving pressure of the device is 1.5-3 bar and respiratory rates of 10-900 per min can be provided. In superimposed high frequency jet ventilation (SHFJV), jet ventilation of normal frequency and high frequency is conducted simultaneously and enables ventilation at two different pressure levels through the steel jet laryngoscope. It is equipped with two jet nozzles, which are placed at the distal end of the jet laryngoscope.
10162459|NCT03973294|Active Comparator|Subglottic jet ventilation|"Subglottic HFJV is performed through the LaserJet catheter. It is characterized by the delivery of small tidal volumes from a high pressure jet at very high frequencies (100-400) followed by passive expiration for a very short period before delivering the next jet, creating an auto-PEEP."
10162460|NCT03973138|Experimental|Treatment group|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab under the pro re nata (PRN) treatment regimen.
10162461|NCT03973411|Active Comparator|Ondansetron group|Patients will receive intravenous ondansetron before spinal anesthesia
10162462|NCT03973411|Placebo Comparator|Control group|Patients will receive intravenous saline before spinal anesthesia
9662145|NCT05130619|Experimental|Treatment order D-C-B-A|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
9974580|NCT01342692|Active Comparator|Azacitidine alone|
10162463|NCT03973398|Active Comparator|Quadratus Lumborum Block anterior subcostal (QLa)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
10162464|NCT03973398|Active Comparator|Quadratus Lumborum Block posterior (QLp)|Patients in this group will receive Posterior Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
10162465|NCT03973398|Placebo Comparator|Quadratus Lumborum Block anterior subcostal control (QLca)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
10162466|NCT03973398|Placebo Comparator|Quadratus Lumborum Block posterior control (QLcp)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
10162467|NCT03973437|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
10162468|NCT03973437|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
10162469|NCT03973554|Experimental|pearl powder|natural product, support bone and joint health
10162470|NCT03973554|Active Comparator|CPP-ACP|product for professional use containing the active ingredient (CPP-ACP), a special milk-derived protein that has a unique ability to release bio-available calcium and phosphate to tooth surfaces.
10162471|NCT03973320||Primary Total Hip Arthroplasty|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty
10162472|NCT03973359|No Intervention|Epidemiology|HCMV-seropositive pregnant women receiving standard care
10162473|NCT03973359|Experimental|Prevention|HCMV-seropositive pregnant women receiving hygienic information
10162474|NCT03973203|Experimental|Niacin in controls|The arm includes healthy controls supplemented with niacin.
10162475|NCT03973203|Experimental|Niacin in mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
10162476|NCT03973242|Active Comparator|DF-NBI|Initially, gastric mucosa is observed by conventional wight light endoscopy. Then, converting to dual-focus mode with narrow band imaging is done. Gastric mucosa is observed once again by DF-NBI mode.
10162477|NCT03973242|Placebo Comparator|WL|Conventional white light endoscopy use It is routine practice for the upper gastrointestinal endoscopy.
10162478|NCT03973086|Experimental|Citrus flavonone-O-glycosides (Low dose)|
10162479|NCT03973086|Experimental|Citrus flavonone-O-glycosides (High dose)|
10162480|NCT03973086|Placebo Comparator|Microcrystaline Cellulose- 400mg|
10162481|NCT03973216|Experimental|A primary care group-based therapeutic yoga program|A primary care care group-based therapeutic yoga program that consists of 9 sessions.
10162482|NCT03973099|Experimental|Placebo|Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
10162483|NCT03973099|Experimental|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner.
10162484|NCT03973073|Experimental|camouflage group|Topical applications and/or NB-UVB plus Capulin TM on-demand treatment period
10162485|NCT03973073|Other|blank group|Topical applications and/or NB-UVB on-demand treatment
10162486|NCT03973008|Experimental|Adujvant CT+CRT|Four to six weeks after D2 radical surgery, adjuvant chemotherapy was initiated with SOX regimen , repeated every three weeks, and adjuvant radiotherapy was started at the end of two cycles of adjuvant chemotherapy , with synchronous tegiol single drug chemotherapy. And the original SOX regimen was continued for 4 cycles after 3-4 weeks of radiotherapy.
10162487|NCT03973008|Active Comparator|Adujvant CT|The adjuvant chemotherapy was started 4-6 weeks after D2 radical operation. The SOX regimen was repeated every 3 weeks for 8 cycles.
10162488|NCT03972891|Experimental|12-weeks intervention break|The intervention break starts as soon as 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy. The intervention break will last for 12 weeks.
10162489|NCT03972891|No Intervention|traditional therapy|After 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy, the children will maintain their traditional therapy until more than 90% of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations (max. 12 weeks).
10162490|NCT03972878|Active Comparator|control snack|control snack
10162491|NCT03972878|Experimental|control cream|control spreadable cream
10162492|NCT03972878|Experimental|cream version 1|control spreadable cream, version 1
9974581|NCT01342692|Experimental|Azacitidine +Valproic acid|
9974582|NCT01342692|Experimental|Azacitidine +Lenalidomide|
10162493|NCT03972878|Experimental|cream version 2|control spreadable cream, version 2
10162494|NCT03972878|Experimental|cream version 3|control spreadable cream, version 3
10162495|NCT03972878|Experimental|control chocolate bar|control chocolate bar
10162496|NCT03972878|Experimental|chocolate bar version 1|control chocolate bar version 1
10162497|NCT03972748|Experimental|Itraconazole|Oral Itraconazole capsules, 200 mg
9974583|NCT01342692|Experimental|Azacitidine + Idarubicine|
9974584|NCT01342705|Experimental|phlebotomy|
9974585|NCT01342705|No Intervention|control|
9974586|NCT01342718|Experimental|GJS/Duolac7S|GJS: Real herbal extract granule/Duolac7S: Real probiotics
10162498|NCT03972761|Active Comparator|Group exposed to cognitive remediation|Computerized cognitive remediation program. Program performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
10162499|NCT03972761|Placebo Comparator|Group not exposed to cognitive remediation|Standard remediation performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
10186342|NCT03736447|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of ARC005 and will be administered escalating doses of IP (placebo) for approximately 6 months.
10162500|NCT03972982|Experimental|Simplified regimen group|Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.
10162501|NCT03972982|Active Comparator|Routine group|Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.
10162502|NCT03973047|Placebo Comparator|Group 1: BMT plus placebo|1 dose of BMT 1.75 mg via autoinjector plus placebo (dosed 30±5 minutes prior to BMT dosing) on Day 1.
10162503|NCT03973047|Active Comparator|Group 2: BMT plus Zofran|1 dose of BMT 1.75 mg via autoinjector plus Zofran 8 mg (dosed 30±5 minutes prior to BMT dosing) on Day 1.
10162504|NCT03972735|Experimental|NECT + follow up|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2 hours sessions are conducted by two trained facilitators.
10162505|NCT03972735|Placebo Comparator|TAU|"Drug treatment (antipsychotic, mood stabilizing) for people with schizophrenia or with bipolar disorder~Support in day-care hospital~No intervention specifically targeting self-stigma reduction or improvements in social functioning (social cognitive remediation or social skills training)"
10162506|NCT03972904|Experimental|Intervention group|The Light-Fat Rice® group
10162507|NCT03972904|Placebo Comparator|Control group|The comparable energy staple food group
10162508|NCT03972618|Experimental|School and village|Simultaneous installation of filters in schools and the village
10162509|NCT03972618|Experimental|School only|Initial installation in school only
10162510|NCT03972618|Experimental|Village only|Initial installation in village only
10162511|NCT03972618|No Intervention|Control|Control group. No filter installation initially.
9671384|NCT05049473|Experimental|Chemotherapy|"Pts with biological age up to 55 y with advanced stage will receive 6 cycles of intensive treatment: blocks (A1-B1-C1-A2-B2-C2). If after A1 and B1 cycles CR is observed, the rest of the cycles will be administered with reduced doses.~In pts with biological age >55 y with advanced stage block will receive A and B with attenuated doses (A1*-B1*-A2*-B2*-A3*-B3*).~Pts with biological age up to 55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 blocks. If CR is not reached, patients will complete the 6 treatment cycles.~Pts with a biological age >55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 attenuated blocks (A1*-B1*-A2*-B2*). If CR is not reached, patients will complete the 6 cycles of treatment."
9671385|NCT05049395|Active Comparator|Control group|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
10162512|NCT03972787|Experimental|Proactive Social Robot (Intervention)|Participants will have the opportunity to use ElliQ for a total of 8 weeks to determine the impacts of the system on participants' loneliness, mood, technology use, and quality of life.
10162513|NCT03972787|No Intervention|Waitlist Control|Participants will not receive any intervention for a total of 8 weeks to determine whether any impacts noted for participants' loneliness, mood, technology use, and quality of life are unique to ElliQ or are influenced by other factors.
10162514|NCT03972722|Experimental|GLS-010|Full-human anti-pd-1 monoclonal antibodies
10162515|NCT03972917||ulipristal acetate based therapy|Fertile women under ulipristal acetate treatment
10162516|NCT03973021|Experimental|VSEL Max|Each treatment: 120,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
10162517|NCT03973021|Experimental|VSEL Medium|Each treatment: 90,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
10162518|NCT03973021|Experimental|VSEL Mini|Each treatment: 60,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
10162519|NCT03973021|No Intervention|Control|In this group, the patients will receive 20 mL platelet-rich plasma(PRP) treatment and as a control group.
10162520|NCT03972774|Other|Cardiac PET stress testing and test-dependent management|Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not).
10162521|NCT03972774|Other|Management without stress-imaging|Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up.
10162522|NCT03972826|Other|1|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
10162523|NCT03972644|Active Comparator|Early intervention|Patients will undergo aortic valve replacement immediately
10162524|NCT03972644|No Intervention|Watchfull waiting|Patients will be followed and treated as recommended by guidelines.
10162525|NCT03972592|Experimental|Topical sirolimus|The experimental group will consist in one area of the CMLM (almost half of it) that will receive 0.1% sirolimus preparation. This product will be applied 1/day on the randomly allocated area, by a nurse at home, during 12 weeks.
10162526|NCT03972592|Placebo Comparator|Vehicle|The control group will consist in the other half area of the CMLM, that will receive the same vehicle than the one used in the topical 0.1% sirolimus preparation. It will be applied 1/day in the corresponding area by a nurse, at home, during 12 weeks.
10162527|NCT03973060|Experimental|Concentric muscular work|4 series of 12 repetitions of concentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
9671386|NCT05049395|Experimental|HFNO group|The patients are administered oxygen of 30L-60L/min until the end of the hysteroscopy operation.
9671387|NCT05049109|Experimental|Group X|Patients who have had stroke and high blood pressure will participate in 5 telehealth visits, which will take place over 3 months. In addition, remote BP monitoring will be given.
10162528|NCT03973060|Experimental|Eccentric muscular work|4 series of 12 repetitions of eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
10162529|NCT03973060|Experimental|Concentric-eccentric muscular work|4 series of 12 repetitions of concentric-eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
10162530|NCT03973060|Experimental|Isometric muscular work|6 seconds of contraction, with 20 seconds of rest with 24 repetitions, for a total working time of 12 minutes.
10162531|NCT03972566||CREST with Calcinosis cutis|
10162532|NCT03972566||CREST without Calcinosis cutis|
10162533|NCT03972683|Experimental|Handgrip Exercise Training Intervention|"Participants will visit the lab for baseline measurements designed to evaluate signaling mechanisms that regulate blood flow. A physician will place a catheter in the brachial artery for pharmacological infusions. The following drugs will be administered to each participant: acetylcholine, adenosine triphosphate, atropine, phenylephrine, and sodium nitroprusside (see Interventions for further details regarding each drug). The order of infusions will be randomized and blood flow will be allowed to return to baseline between each infusion (~15 min) with the exception of atropine, which will be administered last owing to its longer half-life.~Following baseline measurements, participants will complete a 7 week handgrip exercise training intervention, then they will return to the laboratory for post-training measurements. The post-training assessments will be performed in the same manner as the baseline visit; thus, the same drugs will be infused as described above."
9974587|NCT01342718|Placebo Comparator|GJS-P/Duolac7S|GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
10162534|NCT03972540|Experimental|Mindful eating intervention|The mindful eating intervention was taught by a mindfulness-based stress reduction instructor certified by the Center of Mindfulness at the University of Massachusetts Medical School.
10162535|NCT03973034||Normal people|
10162536|NCT03973034||Benign breast disease patients|
10162537|NCT03973034||Breast cancer patients in early stage|
10162538|NCT03972631|Placebo Comparator|Lifestyle education|The participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
10162539|NCT03972631|Experimental|Intensive Lifestyle Intervention|The participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
10162540|NCT03972501|Placebo Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
10162541|NCT03972501|Experimental|AZR-MD-001 Active Dose|AZR-MD-001 Active Dose will be dosed up to once daily.
10162542|NCT03972410|Experimental|Eye Movement Desensitization and Reprocessing (EMDR)|The EMDR treatment will follow the EMDR Recent Birth Trauma Protocol. This protocol was recently developed by some of the colleagues collaborating in this research project (Catteneo et al., 2018). This EMDR protocol can be used to intervene immediately after birth, or at later times. The main purposes of early intervention is to prevent the onset and development of PTSD and Post-partum Depression in the mother during the months following childbirth and to facilitate mother-newborn bonding.
10162543|NCT03972410|Active Comparator|Supportive Expressive Dynamic Psychotherapy (SEDP)|The SEDP treatment (Luborsky 1984; Book, 1998) is one of the most widespread treatments and can be considered the treatment as usual in Italian maternity wards. This intervention includes both supportive techniques (to create a positive, helpful and empathic relationship with the patient) and expressive techniques (aimed at helping the patient to express and to understand and change problems).
10162544|NCT03972423||IRCTC group|- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.
10162545|NCT03972423||CONTROL group|- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.
10162546|NCT03972371|Experimental|Treatment Group|The ProVee Urethral Expander is implanted into the prostatic urethra to treat BPH symptoms
10162547|NCT03972397|Experimental|Intercostal Nerve Cryoablation plus SOC Pain Control|Standard of Care (SOC)
10162548|NCT03972397|Active Comparator|Standard of Care (SOC) Pain Control|
10162549|NCT03972319|Experimental|Omega-3 Supplementation|Proof of Concept and Safety Study of 4 weeks of Omega-3 supplementation pre- Bariatric Surgery
9974588|NCT01342718|Placebo Comparator|GJS/Duolac7S-P|GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
9671388|NCT05049109|Active Comparator|Group Y|Patients who have had stroke and high blood pressure will participate in 3 visits with primary care and stroke practitioner.
9671389|NCT05049434|Experimental|Medicurtain®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
10162550|NCT03972215|Experimental|Berberine treatment|
10162551|NCT03972215|Placebo Comparator|Placebo control|
10186343|NCT03736434|Experimental|Mindfulness plus DASH group|Receives Mindfulness and DASH Diet education once a week for 8 weeks (2.5-hour sessions)
10186344|NCT03736434|Active Comparator|Education Group|The sham intervention includes general education on non-health related topics such as fire-safety and learning how to dispose of medication properly, once a week for 8 weeks (2.5-hour sessions)
10186345|NCT03736434|No Intervention|Control Group|Continue care as usual without intervention.
10186346|NCT03736421||Control Cohort|"This cohort is recruited to help to define what a normal PIVA value should be during a state of presumed euvolemia."
10186347|NCT03736421||Infection Cohort|This cohort are subjects with suspected infection, enriched to contain sepsis patients.
9671390|NCT05049434|Active Comparator|GUARDIX-SG®|Treat Medicurtain® 5ml prefilled syringe after surgery
9671391|NCT05049564|Experimental|keyhole group|patient harbored aneurysm who was treated by microsurgical clipping via keyhole approach.
9974589|NCT01342718|Placebo Comparator|GJS-P/Duolac7S-P|GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
10162552|NCT03972384|Experimental|Post-ICU Problem Solving|The PIC-UPS intervention focuses on self-regulation activities and environmental cues to overcome problems with memory, planning and decision-making. The interventionist uses guided discovery, reviews progress, and emphasizes generalization and transfer to other patient-identified problems. This approach may be more acceptable to participants because they can see the relevance of tasks to everyday life. Activities such as goal-setting, self-evaluation and reflective thinking behaviors enhance self-efficacy and increase the likelihood that the individual will engage in self-management behaviors. The first session of PIC-UPS will be delivered after enrollment to those participants randomized to the intervention group. Weekly intervention sessions will be conducted by a trained interventionist and supplemented by telephone reminders to complete daily homework. Follow-up data collection will be conducted in the home by a blinded data collector three months post-enrollment.
10162553|NCT03972384|No Intervention|Control Group|Participants in the control group will complete several surveys upon enrollment and randomization. Follow-up data collection will be conducted in the home for all participants control group by a blinded data collector three months post-enrollment.
10162554|NCT03972332||Sensitised|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
10162555|NCT03972332||Non-sensitised|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
10162556|NCT03972358|Experimental|Medical menstrual regulation|"Mifepristone 200 mg orally on day 1.~Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone)."
10162557|NCT03972345||Paediatric patients with iGHD or SGA|Children with one of the following confirmed diagnoses: isolated growth hormone deficiency (iGHD) or small for gestational age (SGA)
10162558|NCT03972293|Experimental|Within-participant Micro-randomization|"Each week in the study, with probability .25 for each, a participant is randomized to receive either a week of mood notifications, activity notifications, sleep notifications, or no notifications.~If the participant is assigned to receive mood, activity, or sleep notifications on a given week, then, for every day of that week the participant is randomized to: send notification on that day (with probability .5), or to not send a notification on that day (with probability .5)."
10162559|NCT03972293|Experimental|No intervention|Participants in this arm will not receive any notifications for the entire duration of the trial. Primary and secondary outcomes will still be collected on participants in arm 2 through the study app and Fitbit.
10162560|NCT03972462|Experimental|NPC-12G Gel 0.2% (Period 1)|A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.
10162561|NCT03972462|Active Comparator|Rapamune Tablet (Period 2)|Rapamune® (sirolimus) 2 mg tablet for oral dosing.
10186348|NCT03736421||Acute Heart Failure|This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
10186349|NCT03736382|Experimental|Experimental Group|The experimental group is comprised of participants with OSA and hypertension [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be treated with mild IH and CPAP. In the present proposal, the mild IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The mild IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2) = 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
10186350|NCT03736382|Sham Comparator|Control Group|The control group is comprised of hypertensive OSA participants [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be exposed to a sham protocol in addition to being treated with CPAP during sleep. The sham protocol will be administered during wakefulness for 15 days over a 3-week period. During the sham protocol the participants will be exposed to atmospheric levels of oxygen and carbon dioxide for the duration of the protocol.
10186351|NCT03736369|Experimental|DWP14012 40mg|Orally, once daily
10186352|NCT03736369|Active Comparator|Esomeprazole 40mg|Orally, once daily
10186353|NCT03736330|Experimental|Combinations treatment|Drug: Axitinib 5mg orally twice a day Combination Treatment：Anti-PD-1 Combinations of D-CIK Immunotherapy
10186354|NCT03736317|Sham Comparator|control group|Sham TBS delivered on left dlPFC or medial prefrontal cortex of amphetamine-dependent patients. Stimulation pulses are the same as the real group.
10186355|NCT03736317|Experimental|real mPFC cTBS group|The real cTBS stimulation pattern will be delivered on the medial prefrontal cortex.
10186356|NCT03736317|Experimental|real dlPFC iTBS group|The real iTBS stimulation pattern will be delivered on the left dorsal prefrontal cortex.
10186357|NCT03736317|Experimental|real dlPFC iTBS + real mPFC cTBS group|Combination therapy of real iTBS stimulation delivered on the left dorsal prefrontal cortex and real cTBS stimulation delivered on the medial prefrontal cortex.
10186358|NCT03736304|Placebo Comparator|Usual care|Patients will receive standard clinical care by the doctor in charge.
10186359|NCT03736304|Experimental|AKI alert|An AKI alert will send to the the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
10186360|NCT03736291|Active Comparator|active rTMS|"The Active rTMS: The magnetic head uses the Magro X100's 8-shaped coil, and the intervention site is the cerebellar vermis (1 cm below the occipital carina). The stimulation intensity is gradually increased by the 80%-100% exercise threshold according to the patient's tolerance. The total number of stimulation pulses per day is 600, the basic frequency is 5 Hz, and one short burst stimulus is given every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and every 10 short bursts are stimulated for 8 s. A total of 200 short bursts of stimulation. Intervention once a day, 5 times a week, intervention for 2 weeks, a total of 10 times."
10186361|NCT03736291|Sham Comparator|sham rTMS|"The sham rTMS: The sham stimulation method was to invert the 8 shaped coil, which was 180° to the scalp, and other intervention parameters were consistent with the study group."
10186362|NCT03736200|Active Comparator|Exergaming 1/day|Post stroke group that received 4 weeks of intensive therapy. (1/day)
10186363|NCT03736200|Active Comparator|physiotherapy|Post stroke group that received 4 weeks of traditional physiotherapy.
10162562|NCT03972267|Sham Comparator|Control Group - Free Gingival Graft|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the Control Group will not receive any kind of treatment in the palatal region.
10162563|NCT03972267|Experimental|Test Group - Free Gingival Graft + EMD|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. EMD will be applied immediately after the graft removal surgical procedure on the palatal donor area, leaving it in contact with the wound for 5 min. In sequence, it will be covered with an individualized acetate plate that will extend throughout the palatal area and be in position for 2 hours after the procedure
10162564|NCT03972046|Experimental|T-Vec + BRAF/MEK|"Participants will begin taking the following 3 medications:~BRAF Inhibitor dabrafenib 150 mg by mouth twice a day; MEK inhibitor trametinib 2 mg by mouth once a day; Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection (Dose #1: 10^6 PFU/mL; Dose #2: 10^8 PFU/mL 21 (+3) days after first dose; Subsequent doses: 10^8 PFU/mL every 14 (+/-3) days).~Dosing to continue for at least 3 months, or up to 6 months if no plateau in response.~May stop earlier than 3 months at physician discretion depending on side effects and response.~Ultrasound of tumor nodal basin(s) monthly.~Labs every 4 weeks: CBC with differential, CMP, LDH CT of chest/abdomen/pelvis every 3 months.~PET CT or brain MRI as needed at discretion of the investigator.~Manual tumor measurement in office prior to each injection."
10162565|NCT03972189|Experimental|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
10162566|NCT03972241|Experimental|Intervention|different interventions including foot insole or kinetic training
10162567|NCT03972241|No Intervention|control|No intervention
10162568|NCT03972228|Experimental|Microdevice Intervention|The intervention to be administered is the placement of the microdevice containing 19 FDA-approved drugs into the lung lesion and the device's subsequent surgical resection. All study subjects will receive this same intervention; there is only one arm.
10162569|NCT03971890|Experimental|DanceTherapy Group|The experimental group will receive a dance treatment.
10162570|NCT03971890|Experimental|Control Group|The control group will be subjected to a educational treatment.
10162571|NCT03972085|Experimental|Group 1|Patient received neural gliding exercises in addition electrotehrapy sessions.
10162572|NCT03972085|Active Comparator|Group 2|Patient received only electrotherapy sessions
10162573|NCT03972020|Experimental|Mindfulness Based Intervention|8 group sessions lasting 2.5 hours each, on a weekly basis.
10162574|NCT03972020|Active Comparator|Cognitive Behavioral Therapy|8 group sessions lasting 2.5 hours each, on a weekly basis.
10162575|NCT03972072|Experimental|Single Intervention Arm|daily imaging for MR-IGRT once weekly offline plan adaptation subjective/objective LENT-SOMA xerostomia-evaluation including flow measurements at baseline, 6 month-, 12 month- and 24 month-follow up EORTC-QoL questionnaires at baseline, 6 month-, 12 month- and 24 month-follow up
10162576|NCT03972449|Experimental|Beatboxing: BEAT-Speech|
10162577|NCT03972449|Experimental|Traditional Articulation Approach|
10162578|NCT03971968||Group 1 = Intervention group|Group 1 suffered from third degree full thickness burns in the face/neck and received a surgical procedure with Integra Artificial Skin in the past
10162579|NCT03971968||Group 2 = Control Group|Group 2 is the healthy skin of a comparable and/or contralateral skin-site of the face/neck
10162580|NCT03972059|Experimental|Experimental group|A 12-week high intensity interval circuit training program for weight management in overweight adults.
10162581|NCT03972059|No Intervention|Control group|No intervention for 12 weeks, participants perform all tests.
10162582|NCT03972007|Experimental|Immediate LEDT Group|The 940nm LED blanket will be positioned across the full length of the biceps brachii muscle in the dominant limb immediately before the muscle fatigue protocol.
10162583|NCT03972007|Experimental|LEDT Group 15Min|The 940nm LED blanket will be positioned across the length of the biceps brachii muscle in the dominant limb 15 minutes before the muscle fatigue protocol.
10162584|NCT03972007|Sham Comparator|Immediate Sham Group|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, immediately prior to the muscle fatigue protocol.
10162585|NCT03972007|Sham Comparator|Sham Group 15Min|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, 15 minutes before the protocol of muscle fatigue.
10162586|NCT03971981|Experimental|100% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
10162587|NCT03971981|Experimental|22% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
10162588|NCT03971916|Experimental|HBM9161 340mg|
10162589|NCT03971916|Experimental|HBM9161 510mg|
10162590|NCT03971916|Experimental|HBM9161 680mg|
10162591|NCT03971916|Placebo Comparator|Placebo|
10162592|NCT03971942|Experimental|Neutral ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
10162593|NCT03971942|Experimental|Positive ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
10162594|NCT03971695|Experimental|BI 706321|
10162595|NCT03971695|Placebo Comparator|Placebo|
10162596|NCT03971812||Patient with high grade astrocytoma|Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study
10162597|NCT03971903|Experimental|Attention bias modification treatment|12-session of ABMT
10162598|NCT03971903|Placebo Comparator|Placebo controls|12-session of placebo(i.e.,sham) training
10162599|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Healthy Subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.
10162600|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Psoriasis subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.
10162601|NCT03971851||Low frailty|Frailty risk score less than 5
10162602|NCT03971851||Intermediate Frailty|Frailty risk score 5-15
10162603|NCT03971851||High frailty|Frailty risk score 15 and above
10162604|NCT03971708|Other|Ropivacaine|This is the control where patients will receive ropivacaine via the TAP block infusion post-operatively.
10162605|NCT03971708|Active Comparator|Lidocaine|This is the study arm where patients will receive lidocaine via the TAP block infusion post-operatively.
10162606|NCT03971682|Experimental|Experimental - PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP is a structured individual program for detained youth. This program is based on Compassion Focused Therapy (CFT), which conceptualizes antisocial behavior and psychopathic traits as evolutionary rooted responses to deal with harsh rearing scenarios. The ultimate goal of the PSYCHOPATHY.COMP is to develop a compassionate motivation in these youth.~PSYCHOPATHY.COMP consists of 20 individual sessions, each lasting about 60 minutes, which run on a weekly basis. Sessions must be carried out by therapists skillful in CFT. Sessions are grouped into four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse prevention, and finalization.~The treatment group attended the PSYCHOPATHY.COMP program in addition to the Treatment As Usual (TAU) delivered at Portuguese juvenile detention facilities."
10162607|NCT03971682|Active Comparator|Treatment As Usual - TAU|"Treatment As Usual:~Subjects in this group received Treatment As Usual in Portuguese juvenile detention facilities (school frequency, token economy system for behavior control, frequency of a structured cognitive-behavioral group program, as well as individualized counseling sessions delivered by psychologists from the juvenile justice system) and did not attend the PSYCHOPATHY.COMP program."
10162608|NCT03971604|Experimental|group 1|treated with VA
10162609|NCT03971604|Experimental|group 2|treated with VE
10162610|NCT03971604|Experimental|group 3|treated with VA+VE
10162611|NCT03971604|No Intervention|group 4|No intervention
10162612|NCT03971773|Experimental|Patient ongoing hypnosis sessions|
10162613|NCT03971630|No Intervention|Standard care group|These patients will be followed by standard protocol in the Unit of HMV of the University Hospital of Santa María- University Hospital Arnau de Vilanova.
10162614|NCT03971630|Experimental|MyVENT group|These patients will be followed up using the telemedicine (MyVENT System and APP)
10162615|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm I (binimetinib, avelumab)|Patients will receive a 15-day lead-in of binimetinib, followed by binimetinib PO BID and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10162616|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm II (anti-OX40 antibody PF-04518600, avelumab)|Patients will receive a 15-day lead-in of anti-OX40 antibody PF-04518600, followed by anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10162617|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm III (utomilumab, avelumab)|Patients will receive a 15-day lead-in of utomilumab, followed by utomilumab IV over 60 minutes every 4 weeks and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10162618|NCT03971409|Experimental|Arm A (avelumab, binimetinib, liposomal doxorubicin)|Patients will receive a 15-day lead-in of binimetinib taken twice daily (PO BID), followed by binimetinib PO BID, and liposomal doxorubicin once every 28 days starting on Day 1 of Cycle 1, and 10mg/kg avelumab over 60 minutes every 2 weeks starting on Day 1 of Cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10162619|NCT03971409|Experimental|Arm B (avelumab, sacituzumab govitecan)|Patients will receive a 15-day lead-in of sacituzumab govitecan, followed by sacituzumab govitecan on Days 1 and 8 of every 21 day cycle and 10mg/kg avelumab over 60 minutes every 2 weeks. Cycles repeat in the absence of disease progression or unacceptable toxicity.
10162620|NCT03971409|Experimental|Arm C (avelumab, liposomal doxorubicin)|Patients will receive a 15-day lead-in of liposomal doxorubicin, followed by liposomal doxorubicin once every 28 days and 10mg/kg avelumab over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10162621|NCT03971747|Experimental|C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
10162622|NCT03971578||Autism Spectrum Disorders Group|Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old
10162623|NCT03971578||Normal Control Group|Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old
10162624|NCT03971357|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
10162625|NCT03971357|Placebo Comparator|Placebo|Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.
10162626|NCT03971240|Experimental|outcome of surgically evacuated traumatic ASDH|we will operate patients with traumatic acute subdural hematoma with some criteria and evaluate the outcome of surgery
10162627|NCT03971565||Patients with chronic lymphocytic leukemia|Patient with a minimum period of 90 days without treatment
10162628|NCT03971513|No Intervention|usual practice|Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine. if necessary. Antimicrobial prophylaxis is performed according to recommendations
10162629|NCT03971513|Experimental|TAP block|In addition of usual practice, patients receiving a TAP block at the beginning of the surgery
10162630|NCT03971617|Experimental|Hydrogen tablets|The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
10162631|NCT03971617|Placebo Comparator|Placebo tablets|effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water
10162632|NCT03971292||Validation phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
10162633|NCT03971292||Prospective phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
10162634|NCT03971331|No Intervention|control group|Patients in control group received usual care that was decided by attending.
10162635|NCT03971331|Experimental|study group|Patients in study group who had been placed the PAC were performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately.
10162636|NCT03971370|Experimental|Experimental 1|
10162637|NCT03971370|Experimental|Experimental 2|
10162638|NCT03971370|Active Comparator|Positive Control|
10162639|NCT03971487|Active Comparator|Ocrelizumab|Two doses of 300 mg of ocrelizumab will be administered as an intravenous infusion two weeks apart.
10162640|NCT03971487|Placebo Comparator|Placebo|Two placebo intravenous infusions will be administered two weeks apart.
10162641|NCT03971266|Experimental|Prevention (Fitbit, PRO diary)|Patients participant in movement assessment during 2 clinical trial visits. Patients also wear a Fitbit to track movements and complete a smartphone based PRO diary over 5-10 minutes to measure physical function, fatigue, sleep disturbance, social isolation, appetite, and body weight for up to 180 days.
10162642|NCT03971539|Experimental|Single Rising Dose|
10162643|NCT03971539|Experimental|Multiple Rising Dose|
10162644|NCT03971383|Experimental|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
10162645|NCT03971383|Placebo Comparator|Placebo|3 tablets one time, 3 times a day(tid)
10162646|NCT03971448|Active Comparator|Fiberglass above-knee walking cast (AKWC)|The standard treatment arm will be a posterior splint placed in the ED by the ED clinical team (nurse/physician) and then a fiberglass AKWC to be placed ideally within 72 hours in the fracture clinic. This AKWC will be in place for 3 weeks, which is currently the most common strategy to manage TF.
10162647|NCT03971448|Experimental|Landmark Pediatric Walker Boot (LPWB)|The Landmark Pediatric Walker Boot (LPWB) will be placed in the ED and will be kept on for a minimum of one week, and then for a duration dictated by the patient's comfort.
10162648|NCT03971201|Experimental|Surgery plus sorafenib|surgical resection followed by adjuvant sorafenib
10162649|NCT03971201|Active Comparator|sorafenib only|sorafenib only
10162650|NCT03971435||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360)
10162651|NCT03971149|Experimental|Behavorial intervention|
10162652|NCT03971214|Experimental|PD-1 inhibitor JS-001 consolidation for SCLC|The extensive-stage SCLC patients will receive PD-1 inhibitor JS-001 treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
10162653|NCT03971097|Active Comparator|Control Group (TAU)|Participants of the study who will receive the normal programming schedule or treatment as usual (TAU).
10162654|NCT03971097|Experimental|Experimental Group (TAU plus self-forgiveness model)|Participants of the study who will receive TAU plus six additional individual counseling sessions that include integration of a self-forgiveness model developed by Everett L. Worthington.
10162655|NCT03971175|Active Comparator|Forceps group|
10162656|NCT03971175|Experimental|Cryobiopsy group|
10162657|NCT03971227|Experimental|Acuity 200 contact lens|Rigid gas permeable contact lens for daily wear, fluoroxyfocon A
10162658|NCT03971227|Active Comparator|Acuity 100 contact lens|Rigid gas permeable contact lens for daily wear, hexafocon A
10162659|NCT03971188|Experimental|Internal Brace|Patients will undergo Internal Brace procedure for thumb CMC OA.
10162660|NCT03971188|Active Comparator|LRTI|Patients will undergo ligament reconstruction tendon interposition (most commonly performed surgery for thumb CMC OA) and serve as control group.
10162661|NCT03971136|Other|Children with sickle cell disease|Child from 12 months to 18 years old admitted for vaso-occlusive crisis
10162662|NCT03971123|Experimental|AC-SD-03 (for Part 1)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
10162663|NCT03971123|Experimental|AC-LMP-01 (for Part 1)|Tricaprilin LMP formulation, single dose (20g tricaprilin). Administered orally.
10162664|NCT03971123|Experimental|AC-SD-03P (for Part 1)|Placebo formulation, single dose. Administered orally
10162665|NCT03971123|Experimental|AC-1202 (for Part 2)|Tricaprilin SD formulation, single dose (20g caprylic triglyceride). Administered orally.
10162666|NCT03971123|Experimental|AC-SD-03 (for Part 2)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
10162667|NCT03970980|Experimental|FIO2 >90% group|This group receives FIO2 >90% during the surgery.
10162668|NCT03970980|Active Comparator|FIO2 <70% group|This group receives FIO2 <70% during the surgery.
10162669|NCT03970941||CERAMENT|Patients having a septic pseudarthrosis managed with two-stage treatment (Masquelet Technique) with CERAMENT®.
10162670|NCT03970941||NO CERAMENT COMPARATIVE COHORT|Patients having had a septic pseudarthrosis managed with two-stage treatment (only Masquelet Technique) without CERAMENT®.
10162671|NCT03970798|Experimental|KW-6356/Healthy Japanese adult male subjects|Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
10162672|NCT03971045|Experimental|Pembrolizumab and metronomic cyclophosphamide|.Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
10162673|NCT03970954|Experimental|1|Low-dose IL-2
10162674|NCT03970876|Experimental|ATGC-100 (Phase I/II)|ATGC-100 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
10162675|NCT03970876|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
10162676|NCT03970772|Experimental|Glucagon injection|Dilute Glucagon (1 mg/ml)
10162677|NCT03970772|Active Comparator|Glucose tablets|Dextrose glucose tablets
10162678|NCT03970902||Integrated Osteoporosis Care|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis in whom a complex patient-tailored intervention is provided.
10162679|NCT03970902||Care As Usual|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis receiving care as usual for the management of osteoporosis.
10162680|NCT03970889|No Intervention|Standard Care|Participants will be in their usual care, wearing a continuous glucose sensor and taking insulin by pump or by pens with memory
10162681|NCT03970889|Experimental|Klue|Subjects will wear an Apple watch on their dominant hand and receive alerts when eating behavior is detected by the Klue software.
10162682|NCT03970915|Experimental|ON (standard warming process + body warmer)|Patients included during the ON periods will constitute the experimental group. Warming will be provided by the body warmer in addition to the standard warming procedure (survival blanket and heating in the emergency vehicle).
10162683|NCT03970915|Sham Comparator|OFF / Control group (standard warming process )|Patients included during the OFF periods will constitute the control group. Warming will be provided by the standard warming procedure : survival blanket and heating in the emergency vehicle.
10162684|NCT03971058|Active Comparator|young individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
10162685|NCT03971058|Active Comparator|elderly individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
10162686|NCT03971760|Active Comparator|Group 1: 30cc/24h|This group represents the currently used value of drain output used to determine the timing of drain removal
10162687|NCT03971760|Experimental|Group 2: 50cc/24h|This group represents the experimental value of drain output used to determine the timing of drain removal
10162688|NCT03970928|Active Comparator|goal-directed fluid management (GDFM)|A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light. The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor. 0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
10162689|NCT03970928|No Intervention|Conventional fluid management group (CFMG)|This group will receive conventional fluid management described as follows: 0.9 % NaCl at a rate of 4- 8 mL/kg/h will be infused in CFGM group, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.
10162690|NCT03970616|Experimental|Tivozanib in Combination with Durvalumab|Tivozanib in Combination with Durvalumab
10162691|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Males|Arm 1 - Urine from males subjects
10162692|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Females|Arm 2 - Endocervical, self-collected (in the clinical setting) and physician-collected vaginal swabs and urine from female subjects
10162693|NCT03970850|Active Comparator|Multi-arm - FDA cleared NAATs (Comparator)|Arm 3 - Comparator (for females - vaginal and urine NAATs and for males - 3 urine NAATs)
10162694|NCT03970694|Experimental|Neoadjuvant chemoradiotherapy group|Neoadjuvant chemoradiotherapy（XELOX * 4 + radiotherapy）→ Surgery (if possible) → post-surgery chemotherapy.
10162695|NCT03970694|Other|Neoadjuvant chemotherapy group|Arm Type: control. Neoadjuvant chemotherapy（XELOX * 4）→ Surgery (if possible) → post-surgery chemotherapy.
10162696|NCT03971019|Experimental|Statin therapy (experimental group)|"On the basis of guiding patients to control their diet and improve their lifestyle, etc.~Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)"
10162697|NCT03971019|Other|Dietary intervention group (control group)|Guiding patients to control diet, improve lifestyle, etc.
10162698|NCT03970759||Stannous Fluoride Dentifrice|Twice daily brushing
10162699|NCT03970759||Positive Control Dentifrice|Twice daily brushing
10162700|NCT03970759||Negative Control Dentifrice|Twice daily brushing
9974590|NCT01342731|Experimental|Tigecycline|Tigecycline 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 d
10162701|NCT03970603|Active Comparator|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
10162702|NCT03970603|Active Comparator|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
10162703|NCT03970707|Experimental|Small Number of Players training protocol A|Small Sided Game: 4 vs 4
10162704|NCT03970707|Experimental|Large Number of Players training protocol B|Small Sided Game: 8 vs 8
10162705|NCT03970707|No Intervention|Control|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
10186364|NCT03736200|Active Comparator|Exergaming 2/day|Post stroke group that received 4 weeks of intensive therapy. (2/day)
10186365|NCT03736187|Experimental|Cephalexin|Group a will receive cephalexin 1gm before skin incision intravenous
10162706|NCT03970577|Experimental|Rituximab treatment|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
10162707|NCT03970577|Active Comparator|Oral steroid treatment|"The patients will continue exclusive oral steroid treatment, that will be progressively tapered, for a total of 24 weeks (by taking into account the initial oral steroid therapy administered during 8 weeks and the oral steroid treatment given after randomization).~Each patient will be followed up until 18 months after randomization. The patient will have study visits at inclusion, 4 weeks and 8 weeks after inclusion. At the time of randomization, patients who will have reached CR of MCNS will be allocated in test or control group and will be followed up similarly: visits at 1, 4, 16, 24 weeks, 12 and 18 months after randomization."
10162708|NCT03970668||Linagliptin plus insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment with linagliptin plus insulin
10162709|NCT03970668||Insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment only with insulin
10162710|NCT03971032|Other|Women undergoing hysteroscopy|Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy
10162711|NCT03970551|No Intervention|No Physical Intervention|The participant will actively stand up from a seated position without performing any physical counter-maneuvers either prior to or following the stand.
10162712|NCT03970551|Experimental|Supine Knee Raises|The participant will perform 30 seconds of raising their knees to their chest while sitting down before actively standing.
10162713|NCT03970551|Experimental|Leg Crossing|The participant will actively stand and then immediately cross their legs and tense their leg muscles for 60 seconds.
10162714|NCT03970551|Experimental|Cold Pressor Test|The participant will submerge their hands in ice water for approximately 45 seconds.
10162715|NCT03970551|Experimental|Serial 7's Stress Test|The participant will perform a mental arithmetic stress test for 30 seconds prior to standing.
10162716|NCT03970551|Experimental|Functional Electrical Stimulation|The participant will have their quadriceps passively contracted using mild electrical stimulation for approximately 30 seconds prior to standing.
10162717|NCT03970564||Suspected lung cancer|Suspected and later on confirmed lung cancer with evidence of mediastinal lymphadenopathy on computerised tomography
10162718|NCT03970473|Active Comparator|PRM 30 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 30 cm H2O in the semi-fowler position.
10162719|NCT03970473|Active Comparator|PRM 15 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 15 cm H2O in the semi-fowler position.
10162720|NCT03970486|Active Comparator|Needle Manipulation|Participant will receive dry needling intervention with manipulation.
10162721|NCT03970486|Active Comparator|In Situ|Participant will receive dry needling intervention without manipulation.
10162722|NCT03970356|Experimental|intervention|The antibiotic stewardship intervention will encourage to prescribe according to the latest relevant UTI guidelines which promote more restrictive use of antibiotics in case of non-specific symptoms.
10162723|NCT03970356|No Intervention|control|Usual care
10162724|NCT03970317|Experimental|Broad Band Light|Broad Band Light (BBL) motion treatment
10162725|NCT03970434|Experimental|Metformin|
10162726|NCT03970499|Experimental|glial cerebral tumor|patient with an indication of glial cerebral tumor surgery
10162727|NCT03970369|Experimental|Monitor|Activity monitoring with feedback. Participants in the Monitor group will wear a step counter to track if the activity prescription is being met.
10162728|NCT03970369|Active Comparator|Usual care|All children will receive the usual care, which includes personalized goals and an activity prescription. Participants in the usual care group will not receive a step counter.
10162729|NCT03970213|Placebo Comparator|Control Group|Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
10162730|NCT03970213|Experimental|TXA Group|One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
10162731|NCT03970421||patients without anticoagulant and / or antiplatelet treatment|Patients older than 16yo with no anticoagulant or antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
10162732|NCT03970421||patients on antiplatelet therapy (ASA and / or clopidogrel|Patients older than 16yo on antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
10162733|NCT03970421||patients on treatment with acenocoumarol and INR <2|Patients older than 16yo on acenocumarol and with INR <2 attended at ED because of Head Injury and with a Head CT performed.
10162734|NCT03970421||Others|patients on anticoagulant therapy with acenocoumarol and INR> = 2 or patients on treatment with direct thrombin inhibitors (dabigatran), or inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban) or patients on treatment with low molecular weight heparins (LMWH) attended at ED because of Head Injury and with a Head CT performed.
10162735|NCT03970629|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA via ROSA Robot
10162736|NCT03970629|Active Comparator|Conventional TKA|Conventional TKA
10162737|NCT03970460|Active Comparator|45-54 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
10162738|NCT03970460|Active Comparator|55-59 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
10162739|NCT03970460|Experimental|45-54 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
10162740|NCT03970460|Experimental|55-59 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
10162741|NCT03970226|Experimental|Tocilizumab Administration: Phase 0|In Phase 0, patients will receive one dose of tocilizumab prior to surgery.
10162742|NCT03970226|Experimental|Tocilizumab Administration: Feasibility Phase|During the Feasibility Phase, patients will receive tocilizumab every 2 weeks for up to 13 cycles (approximately 1 year). Patients will be followed for up to 5 years.
9671392|NCT05049564|Experimental|conventional group|patient harbored aneurysm who was treated by microsurgical clipping via conventional craniotomy.
9974591|NCT01342744|Experimental|Metformin|Metformin (850mg) 1 tab oral twice a day
9974592|NCT01342744|Placebo Comparator|Placebo|Placebo 1 tab oral twice a day
9974593|NCT01342809|Experimental|Follow up|Close follow up from written guidelines, supervision provided.
9974594|NCT01342809|No Intervention|Usual Treatment|
9974595|NCT01342822||PROMUS Element™|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987)
9974596|NCT01342822||Xience™ Prime stent|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987) versus the Xience™ Prime Stent (N=993).
9974597|NCT01342835|Active Comparator|drug: propofol|Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
9974598|NCT01342835|Active Comparator|Sevoflurane group:sevoflurane|Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.
9974599|NCT01342861|Sham Comparator|Observational period|A first period of follow-up on the 400 patients was designed to survey and evaluate current nutrition administration policy
9974600|NCT01342861|Experimental|Intervention period|The second period of follow-up on the 400 patients was designed to evaluate the impacts of adding milky food to the breakfast and of educating health care professionals on the early detection of undernutrition.
9974601|NCT01342874||Inositol group|Inositol dietary exposure 4000 mg/day
9974602|NCT01342874||Control group|folic acid 400 mcg/day
9974603|NCT01342900|No Intervention|standard care|The data from the InSPectra Monitor in the Control group will be inaccessible for the Investigator since this is not a part of their daily medical practice
9974604|NCT01342900|Active Comparator|Treatment group,|The data given by the monitor will be available for the Investigator and used to apply the optimization protocol
9974605|NCT01342939||MODY2|Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.
9974606|NCT01342939||MODY3|Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.
9974607|NCT01342939||Healthy control subjects|
9974608|NCT05251584|Experimental|Mupirocin and Gentamicin|2% mupirocin ointments apply at exit-site once daily after wound cleaning before recruit in the study then use 0.1% gentamicin cream apply at exit-site once daily after wound cleaning after entry to the study.
9974609|NCT05251571|Active Comparator|Conventional Exercise Group with Telerehabilitation|Exercises such as muscle strengthening exercises applied to antigravity muscles, agonist antagonist spastic muscles, stretching exercises for spastic muscles, weight transfer will be applied, and a telerehabilitation platform will be used in the home exercise program.
9974610|NCT05251571|Experimental|Balance Coordination Group with Telerehabilitation|Sit and stand exercise from chair, standing posture, weight transfer to right and left extremities, stepping over obstacles, standing on one leg with support from the table, standing on two legs with support from the table, hip abduction with support from the table, extension, flexion, supported tandem walking exercises such as stepping on the stairs, standing functional stretches will be applied. Whatsapp application-based Telerehabilitation platform will be used to deliver the home exercise program.
9974611|NCT05251558|Experimental|Telerehabilitation (TR)|Self PNF exercises determined for facial muscles (M. Frontalis, M. Orbicularis Oculi, M. Orbicularis Oris, M. Risorius etc.) will be applied.
9974612|NCT05251558|Active Comparator|Conventional Education Program (CEP)|Education will be given to cases with Bell's Palsy. Some exercises will be suggested in front of the mirror. Patients will be advised to gently massage upwards with their fingertips after applying a warm towel with a towel on the facial muscles.
9671393|NCT05049564|Experimental|endovascular group|patient harbored aneurysm who was treated by endovascular coiling via femoral approach.
9671394|NCT05049681|Experimental|SHR-1210（Camrelizumab）+Apatinib|Apatinib 250mg, q.d.po; SHR-1210（Camrelizumab） 200 mg，Intravenous injection,q2W ,A course of treatment need 28 days.
9974613|NCT05251545|Active Comparator|High power - short duration|Pulmonary vein isolation with high power settings of 45 Watts
9974614|NCT05251545|Active Comparator|Standard energy|Pulmonary vein isolation with standard power settings (30 Watts)
9974615|NCT05251532|Experimental|Kinesio Taping Group (KTG)|Distortion taping with Kinesio Tex will be applied to the patients in addition to conventional rehabilitation through a pediatric physiotherapist.
9974616|NCT05251532|Active Comparator|Conventional Rehabilitation Group (CRG)|Conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
9974617|NCT05251519|Experimental|Kinesio Taping Group (KTG)|Conventional rehabilitation application will be performed in addition to Kinesio Tex tape derotation taping.
9974618|NCT05251519|Active Comparator|Conventional Rehabilitation Group (CRG)|A conventional rehabilitation program will be applied to the patients through a pediatric physiotherapist.
9974619|NCT05251506|Experimental|laser lancing device (LMT-1000) first user|Subjects measure blood glucose using laser lancing device (LMT-1000) for first 2 months, then take a month for wash out period, after that do using lancet for following 2 months.
9974620|NCT05251506|Active Comparator|lancet first user|Subjects measure blood glucose using lancet for first 2 months, , then take a month for wash out period, after that do using laser lancing device (LMT-1000) for following 2 months.
9974621|NCT05251493|Active Comparator|Iron Isomaltoside/ferric derisomaltose|route: intravenous Dosage: 1000-1500 mg (100mg/mL), max dose 20mg/kg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)
9974622|NCT05251493|Active Comparator|Iron Sucrose|Route: Intravenous Dosage: 100 mg/mL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table
9974623|NCT05251467||People with CF age 12 years and over|Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.
9671395|NCT05049681|Active Comparator|SHR-1210（Camrelizumab）|SHR-1210（Camrelizumab） 200 mg，Intravenous injection. q2W ,A course of treatment need 28 days.
9671396|NCT05049096|Experimental|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
9974624|NCT05251454|Experimental|Electrical stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase). They will always be tested beforehand to ensure that they do not cause participants any discomfort or distress.
9974625|NCT05251441|Experimental|F50|Patients in the group in which fortification was started when enteral nutrition reached 50 cc/kg
9974626|NCT05251441|Active Comparator|F100|Patients in the group in which fortification was started when enteral nutrition reached 100 cc/kg
9974627|NCT05251428|Experimental|excision of the A1 pulley|
9974628|NCT05251428|Active Comparator|incision of the A1 pulley in the standard fashion|
9974629|NCT05251415||patients suffering from autoimmune disease|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity.
9974630|NCT05251389|Experimental|A: FMT from an ICI non-responding donor|Patients will receive FMT from an ICI non-responding donor (defined as ≥20% increase according to RECIST 1.1 criteria within the past 3 months). Patients will continue their anti-PD-1 treatment.
9974631|NCT05251389|Experimental|B: FMT from an ICI responding donor|Patients will receive FMT from an ICI responding donor (defined as ≥30% decrease or disappearance of all lesions according to RECIST 1.1 criteria within the past 24 months). Patients will continue their anti-PD-1 treatment.
9974632|NCT05251350||An incarcerated right inguinal hernia containing sigmoid colon|
9974633|NCT05251337|Experimental|Intervention - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - nausea/vomiting arm. This arm will receive peppermint inhaled aromatherapy patches (or mandarin as an alternative if they have a peppermint sensitivity).
9974634|NCT05251337|Experimental|Intervention - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive intervention will be allocated to the intervention - anxiety arm. This arm will receive lavender inhaled aromatherapy patches.
9974635|NCT05251337|Placebo Comparator|Control - nausea/vomiting|Patients indicating that nausea/vomiting is their primary symptom of concern and are randomized to receive control will be allocated to the control - nausea/vomiting arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
9974636|NCT05251337|Placebo Comparator|Control - anxiety|Patients indicating that anxiety is their primary symptom of concern and are randomized to receive control will be allocated to the control - anxiety arm. This arm will receive blank (no essential oil infusion) aromatherapy patches.
9974637|NCT05251311|Experimental|Social Risk Screening + Resource Map|Participants randomized to the experimental arm will receive a social risk assessment tool followed by an electronic resource map
9974638|NCT05251311|Active Comparator|Resource Map|Participants randomized to the active comparator group will receive only an electronic resource map
9974639|NCT05251298|Active Comparator|Intervention group|Patients in the intervention group come from the same region (Münsterland) and will undergo therapies coordinated through the online platform.
9974640|NCT05251298|No Intervention|Control group|Patients in the control group will undergo their usual therapies as prescribed by their neurologists.
9974641|NCT05251285||Prophylactic Nipple-Sparing Mastectomy|
9974642|NCT05251246|No Intervention|Without recovery management program|
9974643|NCT05251246|Experimental|Trained in the recovery management program|Half of the included volunteered participants are randomized in the intervention group
9974644|NCT05251220||10 women with objectively confirmed vulvovaginal atrophy|10 women with objectively confirmed vulvovaginal atrophy (genitourinary menopausal syndrome
9974645|NCT05251220||37 women with 1-2 degree prolapse of the vaginal walls combined with stress urinary incontinence|37 women with 1-2 degree prolapse of the vaginal walls combined with stress urinary incontinence
9974646|NCT05251220||7 with vaginal relaxation syndrome|7 with vaginal relaxation syndrome
9974647|NCT05251220||6 with vulvar lichen sclerosus|6 with vulvar lichen sclerosus
9974648|NCT05251194|Experimental|video laryngoscope at thyroid surgical position|"After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.~Next, the intubation practitioner will perform tracheal intubation with it."
9974649|NCT05251142|Experimental|Plyometric training|Jumps in place. Standing jumps. Multiple hops and jumps. Box drills. Depth jumps.
9974650|NCT05251142|Active Comparator|General exercises|Dumbbell Squat, Dumbbell Alternating Bench Press, Straight Arm Pulldowns, Dumbbell Front Raises, Reverse Flyes, Overhead Tricep Extensions, Dumbbell Bicep Curls, Jackknife Crunches, Oblique Crunches, External Rotation
9974651|NCT05251103|Experimental|time-restricted feeding trial|The participants were divided into the time-restricted feeding trial for 5 days
9974652|NCT05251103|Experimental|control trial|The participants in the control trial did not practice intermittent fasting methods
9974653|NCT05251064|Active Comparator|Suture|Standard suture wound closure
9974654|NCT05251064|Active Comparator|Adhesive wound closure device|Clozex wound closure device
9974655|NCT05251064|Active Comparator|Adhesive wound closure device with zip ties|Zipline wound closure device
10186366|NCT03736187|Experimental|Cephalexin &metronidazole|Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision
9671397|NCT05049096|Sham Comparator|sham-control group|In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
9671398|NCT05049070|Experimental|GoEyes|GoEyes Self administered refraction test + Standard of care refraction test
10162743|NCT03970239|Experimental|Parkinson's Disease patients|"All study participants undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). [11C] -DASB is a highly specific PET radiotracer which binds to the serotonin transporter (SERT).~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
10162744|NCT03970239|Experimental|Imaging of healthy volunteers|"All healthy volunteers undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [18F]-altanserin.~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
10162745|NCT03970408||Carpal tunnel syndrome|"Patients with CTS who fulfill the following eligibility criteria:~Inclusion criteria~Females and male patients referred with a CTS diagnosis confirmed by nerve conduction studies and positive Tinel and Phalen tests.~Age ranging from 30-50 years old.~The selected patient will be able to tolerate the entire standard neurodynamic technique.~Exclusion criteria~Symptoms referred to the neck.~Sever CTS~More than 10% limitation of neck flexion, rotation, and side bending ranges.~History of disease, trauma, or surgery to neck, thorax, or upper limbs.~Presence of peripheral neuropathy or cervical radiculopathy.~History of systemic disease associated with neuropathies such as diabetes mellitus, connective tissue diseases, thyroid disease, or obesity."
10162746|NCT03970408||Healthy control|Asymptomatic healthy age-matched control with no symptoms or history of upper quadrant disease, dysfunction, trauma or surgery.
10162747|NCT03970174|Experimental|Intervention|Two of the 4 Medicine wards will have implemented the care transition module of Care Connector
10162748|NCT03970174|No Intervention|Control|Remaining 2 of 4 Medicine wards will use all other aspects of Care Connector (except for care transition module)
10162749|NCT03970161|Experimental|T2DM Patients|Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
10162750|NCT03970161|Experimental|healthy control subjects|All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
10162751|NCT03970148|Experimental|Nd: YAG laser treatment|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
10162752|NCT03970187|Experimental|Exposure|Phase 1 (visit 1): 60 minutes exposure-based eye contact training in VR Phase 2 (home training): 9 blocks of 20 minutes exposure-based eye contact training in VR, distributed over a total duration of maximally 2 weeks
10162753|NCT03970187|No Intervention|Control|"Phase 1 (visit 1): waitlist. In order to prevent systematic preparation for the subsequent PST, a 60 minutes virtual reality games with fear-unrelated content will serve as the control intervention.~Phase 2 (home training): waitlist"
10186367|NCT03736161|Experimental|Group A- Tofacitinib|Tofacitinib 5mg twice daily orally. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD.
10186368|NCT03736161|Placebo Comparator|Group B- Methotrexate|Methotrexate in increasing dose starting from 15 mg weekly to a maximum dose of 25 mg weekly from the end of 1st month. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD.
10186369|NCT03736148|Experimental|Manual Manipulation|A single manual manipulation was applied to C3/C4 level, on the right side.
10186370|NCT03736148|Active Comparator|Instrument-assisted Manipulation|A single instrument-assisted manipulation was applied to C3/C4 level, on the right side.
10186371|NCT03736148|Placebo Comparator|Placebo|A placebo manipulation was applied on C3/C4 level, on the right side. The neck of th subject was placed in the pre manipulative position but no thrust was made. Then, the cervical was replaced in neutral position.
10186372|NCT03736148|No Intervention|Control|No contact was given to the subject.
10186373|NCT03736122|Experimental|BSG-001|Inhalation route, daily
10186374|NCT03736109||Group I:|Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
10186375|NCT03736109||Group II:|Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
10186376|NCT03736083|Active Comparator|Freestyle Libre Group|Freestyle Libre Group: Participants will use the Freestyle Libre flash glucose monitoring system throughout the study for 2-3 months.
10186377|NCT03736083|No Intervention|Control Group (standard diabetes care)|This group will receive standard care. At the around 1 week and 2 month visits, control group subjects will use a blinded Freestyle Libre Pro to provide data that can be used to compare glucose variability between groups. The Libre sensor will allow the study team to measure glucose values but the subjects will not have access to this information for management/treatment decisions and usual diabetes care will be unaffected. The Freestyle Libre Pro last 14 days, can be activated in clinic, and the sensor can be returned in person or via mail where the investigators will download the data.
10186378|NCT03736044|Experimental|TNF-blockers withdrawal|Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
10186379|NCT03736044|No Intervention|DMARDs control group|Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
10186380|NCT03736018|Active Comparator|CTCA + ICA|Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
10162754|NCT03970122|Experimental|GFB-887 SAD active|GFB-887 single dose active
10162755|NCT03970122|Placebo Comparator|GFB-887 SAD placebo|GFB-887 single dose placebo
10162756|NCT03970135|Experimental|Fasting|
10162757|NCT03970044|Experimental|Exenatide 2 mg plus Dapagaliflozin 10 mg|Exenatide extended release, 2 mg weekly, injected Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
10162758|NCT03970044|Active Comparator|Exenatide 2 mg|Exenatide extended release, 2 mg weekly, injected 14 weeks of treatment
10162759|NCT03970044|Active Comparator|Dapagaliflozin 10 mg|Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
10162760|NCT03970031|Active Comparator|MSDC-0602K|MSDC-0602K one tablet per day taken orally
10162761|NCT03970031|Placebo Comparator|Placebo|Placebo one tablet per day taken orally
10162762|NCT03970018||Autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease (ADPKD) patients starting peritoneal dialysis for end stage renal failure will be included in this study.
10162763|NCT03969849|Experimental|Part A: Cohort 1|Part A: Cohort 1 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
10162764|NCT03969849|Experimental|Part A: Cohort 2|Part A: Cohort 2 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
10162765|NCT03969849|Experimental|Part A: Cohort 3|Part A: Cohort 3 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
9662146|NCT05130606|Experimental|Video Arm|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles."
10162766|NCT03969849|Experimental|Part A: Cohort 4|Part A: Cohort 4 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
10162767|NCT03969849|Experimental|Part B|Part B: Randomized 1:1 will receive REGN5713-5714-5715 or matching placebo in Healthy Participants with birch pollen allergy
10162768|NCT03969979||testis with epididymo-orchitis|The patients' previously inflamed testis with epididymo-orchitis
10162769|NCT03969979||healthy testis|The patients' non inflamed testis
10162770|NCT03969927|Experimental|Low-Fidelity PDS Training|Individuals with stroke, PD, or MS
10162771|NCT03969927|Active Comparator|High Fidelity Fixed-Base Simulator Training|Individuals with stroke, PD, or MS
10162772|NCT03969836|Experimental|NeurOS Group|All patients will have both INVOS and NeurOS systems placed before and during cardiac surgery for monitoring cerebral oxygenation and brain blood volume.
10162773|NCT03969810|Experimental|Rounding Summary|"Surrogates who are assigned to the intervention group will receive a written rounding summary every day or every other day that the patient is in the ICU. The summary will be organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.~For patients assigned to the intervention group, the investigators will forward the previous day's summary to the ICU nurse at the beginning of each day shift. After participating in morning rounds, ICU nurses will be asked to modify the summary based on the plan for the day. Nurses will be asked to use the written summary to guide communication with surrogates that day."
10162774|NCT03969810|No Intervention|Usual Care|Usual ICU care
10162775|NCT03969862||Patient with an allergen-mediated IgE allergy|Patients with a clinical history consistent with an allergen-mediated IgE allergy & with a sensitization demonstrated by a positive Prick-Test for the allergen source tested
10162776|NCT03969862||Patient without an allergen-mediated IgE allergy|Patient without a clinical history compatible with an IgE allergy-mediated allergy and without PT sensitization to be allergen
10162777|NCT03969771|Experimental|Frequently Absent|8 weeks of training in Mindfulness-Based Stress Reduction
10162778|NCT03969771|Active Comparator|Normal Attendees (Controls)|8 weeks of training in Mindfulness-Based Stress Reduction
10162779|NCT03969732|Experimental|amyloid PET、T807 PET|PET/CT
10162780|NCT03969602|Experimental|Experimental Group|Participants randomized will receive six individual 1-hour sessions of CBT: two sessions before the operation and four after, delivered by a psychologist trained in CBT for chronic pain. The CBT intervention is tailored to reduce pain catastrophizing. Main techniques are: pain education and the influence of cognitions, emotions and behavior on pain and pain disability; identification of catastrophizing cognitions and replacing them with more adaptive cognitions; stress/anxiety reduction by diaphragmatic breathing and progressive muscle relaxation; emotion regulation skills training; cognitive restructuring; coping skills training to combat helplessness and foster a sense of control and self-efficacy for dealing with acute post-operative pain. The four postoperative sessions build on and further extend the skills learned preoperatively. Each session ends with specific homework assignments. All patients receive a homework book and an individually tailored instruction manual.
10162781|NCT03969602|Active Comparator|Control Group|Participants will have six meetings with members of the research team (in person or through telephone). In a first preoperative meeting a member of the team provides verbal information on the preparation for surgery, surgery itself and recovery from surgery, stressing the importance of postoperative exercise. Any questions raised by the patient are discussed. A booklet is provided with information about: structure of the spinal column and spinal diseases; examinations before surgery; the operative environment; surgical procedures; anesthetic procedures; postoperative care and postoperative pain reduction. A second preoperative (telephone) meeting is scheduled to answer any remaining questions. During the postoperative phase, instructions and an exercise manual are provided, Patients keep a diary to record their training activity. Three, six and eight months after discharge patients are contacted by telephone and their training progress is discussed.
10186381|NCT03736018|No Intervention|ICA only|Invasive coronary angiogram (ICA) performed only.
10186382|NCT03736005||General ICU admissions|Non- major trauma ICU admission Exposure to significant period of critical illness
10186383|NCT03736005||Major Trauma admissions|Exposure to Major Trauma Exposure to significant period of critical illness
10186384|NCT03735992|Experimental|Mind-body medicine group program|Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
10162782|NCT03969602|No Intervention|Observational Group (low catastrophizing)|Patients will be routinely prescribed medications for pain control and are referred for physical therapy on an out-patient basis in different sites or an in-patient basis in specialized rehabilitation centers following lumbar spinal fusion surgery, depending on the needs. Typically, a full rehabilitation regime starts 2-3 weeks after surgery. Usual programs involve active spinal mobilization aimed at gradually improving the range of motion, exercises to strengthen spinal deep muscles, and segmentary stretching involving the lower limb and back muscles, together with manual therapy. The patients are also given walking exercises and trained in how to change position.
10162783|NCT03969823|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
10162784|NCT03969745|Experimental|Time restricted feeding (TRF)|Participants restricted their daily energy intake window to between 8 am and 4 pm for two weeks. They were encouraged to not alter the quantity and composition of their diet or alter physical activity patterns.
10162785|NCT03969745|Active Comparator|Caloric deficit|The investigators observed significant weight loss in the TRF group with participants reporting to consume ~400 kilocalories less per day. Therefore the investigators added a caloric deficit group to control for the effects of weight loss on metabolism. Total energy expenditure was measured for one week and was used to prescribe a 400 kilocalories/day energy deficit diet to follow for two weeks.
10162786|NCT03969628|Experimental|Multivariate risk assessment group (ICCMS®)|Multivariate risk assessment group (ICCMS®): multivariate caries risk assessment based on International Caries Classification and Management System (ICCMS™) guide
10162787|NCT03969628|Experimental|Simplified risk assessment group (dental caries experience)|Simplified risk assessment group (dental caries experience): simplified caries risk assessment based on dental caries experience (WHO criteria)
10162788|NCT03969537||Telemedicine|The patients selected to participate in the study are cervical dystonia (CD) patients who receive treatment at Vanderbilt University Medical Center, where the study takes place.
10162789|NCT03969654|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA
10162790|NCT03969654|Active Comparator|Conventional TKA|Conventional TKA
10162791|NCT03969615|Active Comparator|Supplemental oxygen|5lpm of supplemental oxygen via a nasal cannula or face mask
10162792|NCT03969615|Experimental|SuperNO2VA nasal positive airway pressure device|Intervention arm will receive the SuperNO2VA nasal positive pressure device at 10lpm
10162793|NCT03969719|Placebo Comparator|Placebo|Palacebo
10162794|NCT03969719|Experimental|Low Dose|150 mg
10162795|NCT03969719|Experimental|High Dose|300 mg
10162796|NCT03969576|Experimental|DEB-TACE|172 subjects in this study group will be receive the treatment of drug-eluting bead TACE
10162797|NCT03969576|Active Comparator|cTACE|172 subjects in this study group will be receive the treatment of conventional TACE
10162798|NCT03969472|Experimental|probiotic group|apply probiotic after surgery
10162799|NCT03969472|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery without probiotic
10162800|NCT03969472|No Intervention|control|without electrophysiologic therapy and probiotic after surgery
10162801|NCT03969394|Experimental|Heart Failure Patients|Patients with Heart Failure
10162802|NCT03969784|Experimental|colorectal cancer patient with peritoneal carcinosis|
10162803|NCT03969784|Active Comparator|colorectal cancer patient without metastasis|
10162804|NCT03969758|Active Comparator|Ciprofloxacin plus Metronidazole therapy|Will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks. Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
10162805|NCT03969758|Active Comparator|Cefixime plus Metronidazole Therapy|Will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks.Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
10162806|NCT03969706|Experimental|Single Arm|Abemaciclib 200mg tablet PO twice daily administered on 28-day cycles Subjects remain on treatment until tumor progression or unacceptable toxicity.
10162807|NCT03969485|Experimental|Hybrid Fractional Laser|Hybrid Fractional Laser Treatment
10162808|NCT03969381||1 lymphoma patients|pre therapy and post therapy of lymphoma patients
10162809|NCT03969368|Experimental|Treatment Group|Treatment with the investigational device - rPMS
10162810|NCT03969368|Active Comparator|Control Group|Control group
10162811|NCT03969316|Active Comparator|Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
10162812|NCT03969316|Active Comparator|Transversus Abdominis Plane Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound between internal oblique and transversus abdominis muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
10162813|NCT03969251|Experimental|Transcranial Magnetic Stimulation (rTMS)|repetitive transcranial magnetic stimulation
10162814|NCT03969251|Sham Comparator|Sham (SS)|repetitive sham rTMS
10162815|NCT03969277|Experimental|Graded Motor Imagery|Each subject in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, and home exercises.
10162816|NCT03969277|Active Comparator|Standard Rehabilitation|Each subject in the Standard Rehabilitation group will receive a treatment protocol consisting of stretching and strengthening exercises, cold therapy, and home exercises.
10162817|NCT03969147|Active Comparator|MRI Comparison|MRI images will be obtained of the airways of healthy volunteers both with the ManMaxAirway oropharyngeal airway adjunct and with no airway adjunct in place in order to observe any changes to the airway anatomy caused by placement of the airway adjunct. The order of the scans (with and without airway adjunct) will be determined by randomization software in advance.
10162818|NCT03969147|Experimental|Tolerability Comparison|Healthy volunteers will self-place either the ManMaxAirway oropharyngeal airway adjunct or the Guedel Oropharyngeal airway adjunct, which will be left in place for an interval of one minute, while supervised by research staff. After completing a questionnaire and resting for a timed interval, they will then self-place the other airway adjunct, which will be left in place for the same length of time as the first, before completing another questionnaire. The order in which the devices are placed by each subject will be determined in advance via computer randomization.
10162819|NCT03969147|Active Comparator|Forced Oscillation|Volunteers from the tolerability comparison arm will also be invited as a subset of subjects to participate in a measurement of resistance to forced oscillation. The volunteers will be subject to forced oscillations in a pulmonary function lab with the ManMaxAirway oropharyngeal airway adjunct in place and with no airway adjunct in order to observe changes in resistance to oscillatory airflow
10162820|NCT03969030|Experimental|Intervention|"Participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD:~ART Refill~SMS notifications~Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery."
10162821|NCT03969030|No Intervention|Control|Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club).
10162822|NCT03969303||NOTAL OCT v.2.5 and Commercial OCT on AMD Patients|OCT Images will be obtained in the central 10 degrees of the macula in AMD patients using the NOTAL OCT v.2.5 device and a Commercial device (Zeiss Cirrus/Heidelberg SPECTRALIS).
10162823|NCT03969082|Experimental|Bibliotherapy|"Students will read to patients receiving active treatment using the read aloud method. This will be performed in a 1: 1 relationship for half an hour for 8-10 times during a period of six months."
10162824|NCT03969173|Active Comparator|PEEP3|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
10162825|NCT03969173|Active Comparator|PEEP6|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
10162826|NCT03969173|Active Comparator|PEEP9|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
10162827|NCT03969069||Fistula/chronic perianal conditions|Participants symptomatic of FI with chronic perianal disease
10162828|NCT03969069||Obstetric injury <12 months|Participants symptomatic of FI < 12 months following obstetric injury.
10162829|NCT03969069||Obstetric injury >12 months|Participants symptomatic of FI >12 months following obstetric injury.
10162830|NCT03969069||Neurogenic|Participants symptomatic of FI with evidence/history of neurological condition.
10162831|NCT03969238||Patients/Providers|Of the1,000 participants: (1) 900 will enroll as participants who use the helpline resources via verbal consent and (2) 100 will enroll as providers via online consent prior to survey data collection.
10162832|NCT03969290|Experimental|Sequence 1|Verofilcon A contact lens in the right eye (OD), with etafilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
10162833|NCT03969290|Active Comparator|Sequence 2|Etafilcon A contact lens in the right eye (OD), with verofilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
10162834|NCT03969342|Experimental|Trainees|Local mid-level providers who undergo five day training on point of care ultrasound for diagnosing pediatric pneumonia
10162835|NCT03969160|Experimental|Imaginal exposure|The experimental procedure consists of imaginal exposure to mental imagery of phobic and neutral stimuli, prompted through recorded verbal instructions. Participants' repeat the experimental procedure one week later in a follow-up session. Brain imaging data is only collected during day 1
10162836|NCT03969056|Experimental|Artificial Intelligence (AI) Activity group|Participants in this group receive an AI based intervention (automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning and message)
10162837|NCT03969056|Active Comparator|Control group|Participants in this group receive a standardized and fixed 10,000 daily steps goal intervention.
10162838|NCT03969043|Experimental|Young volunteers|"Volunteers between 18 ans 45 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
10162839|NCT03969043|Experimental|Older Volunteers|"Volunteers between 60 ans 85 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
10162840|NCT03968926||Vasoplegic ECMO|All patients during VA-ECMO support for cardiogenic shock who presented, within 48 hours after implantation, a vasoplegia defined by a norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2
10162841|NCT03968952|Active Comparator|SMARThealth Pregnancy|"The components of the SMARThealth Pregnancy intervention include:~Educational and Training component on high-risk pregnancy conditions, focusing on; Anaemia, Hypertensive Disorders of Pregnancy (HDPs) and Gestational diabetes mellitus (GDM).~An mHealth platform providing clinical decision support, lifestyle advice, recall and reminder system for Community Health Workers (CHWs) and Primary Care Physicians (PCPs).~Pregnant women in the intervention group will receive 3 visits at home by their CHW, in addition to their standard antenatal and postnatal care. One visit during the third trimester of pregnancy; one during Week 1 postpartum and; one visit during Week 6 postpartum."
10162842|NCT03968952|No Intervention|Enhanced Standard Care|"The control group will receive enhanced standard antenatal and postnatal care, involving:~An awareness programme for pregnant women, Community Health Workers (CHWs) and Primary Care Physicians (PCPs), held at the villages within the control group Primary Health Centre (PHC) cluster (Enhanced Standard Care). The community and health professionals will receive information on the high-risk conditions of anaemia in pregnancy, HDPs and GDM as part of the awareness programme.~Standard antenatal and postnatal care (consisting of free monthly antenatal care, and up to 7 postnatal visits), delivered by CHWs in partnership with their PHC doctor."
10162843|NCT03968913|Placebo Comparator|Control|Subjects will receive two injections of sterile saline after ACL injury, prior to surgery
10162844|NCT03968913|Active Comparator|One dose Anakinra, one dose placebo|Subjects will receive one injection of sterile saline and one injection of anakinra after ACL injury, prior to surgery
10162845|NCT03968913|Active Comparator|Two doses Anakinra|Subjects will receive two injections of anakinra after ACL injury, prior to surgery
10162846|NCT03969108|Experimental|Indocyanine Green|
10162847|NCT03969017|Experimental|NAs+Peg IFN Group|NAs+Peg IFN Group will receive the treatment of NAs (patients previously treated with telbivudine will be changed to entecavir) plus pegylated interferon (Peg IFN)α-2b.
10162848|NCT03969017|Other|NAs Group|NAs Group will be treated with NAs as before enrollment.
10162849|NCT03968900|Experimental|Sleep Restriction|4 hours time in bed (1 am to 5 am)
10162850|NCT03968900|Experimental|Sleep Extension|10 hours time in bed (10 pm to 8 am)
10162851|NCT03968601||cohorte 1|Severe primary chronic mitral regurgitation with preserved left ventricular ejection fraction.
10162852|NCT03968770|Experimental|Experimental group|Probiotic product plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
10162853|NCT03968770|Placebo Comparator|Control group|Sham probiotical plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
10162854|NCT03968783|Experimental|Monofilament suture|continuous double-layer unlocked suturing with 1.0 monofilament synthetic absorbable suture
10162855|NCT03968783|Active Comparator|Multifilament suture|continuous double-layer unlocked suturing with 1.0 multifilament synthetic absorbable suture
10162856|NCT03968614|Experimental|Electrical Dry Needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
10162857|NCT03968614|Active Comparator|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
10162858|NCT03968835||Biological Dressings|Bacitracin will be applied and covered with xeroform and gauze
10162859|NCT03968835||Artificial Dressings|the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft
10162860|NCT03968549|Placebo Comparator|Placebo|These patients will receive capsules containing vegetable oil and corn starch
10162861|NCT03968549|Active Comparator|Probiotic|These patients will receive capsules containing Lactobacillus acidophilus
10162862|NCT03968640|Active Comparator|CoQ10 group|The patients assigned to the CoQ10 group will receive the loading dose of CoQ10 (1,800 mg/day) for 4 weeks followed by the maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge, whichever comes first.
10162863|NCT03968640|Placebo Comparator|Placebo|Allocation-concealed placebo will be used as an appropriate control.
10162864|NCT03968588|Experimental|reduced-dose tacrolimus + standard-dose MMF|Tacrolimus dose was individually adjusted with a target trough blood level of between 3ng/mL and 8ng/mL throughout the study period (6 months after transplantation). MMF started within 72 hours after transplantation and the dose of MMF was 1.5~2.0g per day.
10162865|NCT03968588|Active Comparator|standard-dose tacrolimus + reduced-dose MMF|Control group, target trough blood level was between 5ng/mL and 15ng/mL throughout the study period. MMF dose was 0.5~1g per day and MMF started within 72 hours after transplantation.
10162866|NCT03968809||Standard Coronary Artery Disease Screening|All patients presenting for standard coronary artery disease screening will undergo additional imaging with CardioFlux MCG. These patients will be followed longitudinally for short and long term MACE.
10162867|NCT03968757||Obese patients eligible for laparoscopic RYGB surgery.|
10162868|NCT03968796|Active Comparator|Group 1|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
10162869|NCT03968796|Active Comparator|Group 2|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
10162870|NCT03968796|Active Comparator|Group 3|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
10162871|NCT03968796|Placebo Comparator|Group 4|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
10186385|NCT03735992|No Intervention|Wait list|Treatment as usual.
10186386|NCT03735979|Experimental|Argatroban|100µg/kg bolus followed by 3µg/kg per minute for 12 hours
10186387|NCT03735979|Experimental|Eptifibatide|135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours
10162872|NCT03968718|Experimental|Systematic ePROMs Assessment|"Intervention: The intervention is constituted by a Systematic ePROMs Assessment in routine cancer care in a comprehensive cancer centre.~This will involve preliminary sensitization and training of both clinicians and patients towards the use of ePROMs.~Data filled in by patients through electronic devices will be prompt made available to the clinician during the patient examination."
10162873|NCT03968744|Experimental|Safinamide|PO treatment: 2 weeks of treatment at dose 50 mg/day followed by 10 weeks at 100 mg/day
10162874|NCT03968887||Case group|Patients with postoperative delirium.
10162875|NCT03968887||Control group|Patients who have not had postoperative delirium.
10162876|NCT03968627||Protocol application|The study describes the method and the criteria used in the development of the protocol, the steps followed in its implementation in two Don Gnocchi Foundation Pilot Hospitals
10162877|NCT03968666||Gynecological surgery with ERAS protocol|Patients scheduled for benign gynecological surgery under ERAS protocol
10162878|NCT03968731|Experimental|ZEST treatment|The study subjects will receive the ZEST treatment protocol (Zocular Eyelid System treatment) to treat Meibomian Gland Dysfunction causing Contact Lens discomfort symptoms.
10162879|NCT03968575|Experimental|Laser|
10162880|NCT03968861||Standard care with moderate hypothermia|Surviving children allocated to standard care with moderate hypothermia in the TOBY-Xe trial
10162881|NCT03968861||30% Xenon for 24 hours combined with moderate hypothermia|Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial
10162882|NCT03968510||parathyroidectomy cases|patients who will be operated for primary hyperparathyroidism
10162883|NCT03968523|Active Comparator|TAP block|TAP block technique.
10162884|NCT03968523|Experimental|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
10162885|NCT03968497|Other|Postoperative pain assessment|Postoperative pain evaluation by a female and a male investigator, respectively at approximately 15-minute intervals.
10162886|NCT03968432|Sham Comparator|Standard Care|Be Sweet to Babies Videos and Pamphlet. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of the sweet solution during vaccination will be used.
10162887|NCT03968432|Active Comparator|Intervention|Be Sweet to Babies Videos, pamphlet, and MIAS&Q. MIAS&Q includes five questions and statements based on MI approach which was developed by the researcher and was reviewed further by a panel of parent representatives and HCPs representatives and the research team consisting of the supervisor and two Ph.D. committee members. This MIAS&Q intervention consists of four scaled questions and two open-ended questions and presents brief informative and affirmative questions and statements. This aims to help the parents reflect on their own thoughts, and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
10162888|NCT03968315|Experimental|Diagnostic (MRI, diaphragm fluoroscopy)|Patients undergo an MRI scan over 45-60 minutes and a diaphragm fluoroscopy 30 days before surgery.
10162889|NCT03968484|Experimental|<50.000/µl|Transfusion of platelets starting with a platelet count <50.000/µl
10162890|NCT03968484|Experimental|<20.000/µl|Transfusion of platelets starting with a platelet count <20.000/µl
10162891|NCT03968263|Active Comparator|Hycon device(Routine protocol)|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions.
10162892|NCT03968263|Active Comparator|Hycon device(Modified protocol)|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise.
10162893|NCT03968263|Active Comparator|Hycon device(Routine protocol) and Vibration|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
10162894|NCT03968263|Active Comparator|Hycon device(Modified protocol) and Vibration|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
10162895|NCT03968341|Experimental|intraocular antibiotic concentrations determination|"In the event that the patient develops unfavourably, the ophthalmologist include the patient in the trial.~The patient is reviewed at 48 hours after the introduction of probabilistic antibiotic therapy for clinical reassessment and the return of microbiological test results. Following this inclusion, the new samples will be taken when the patient passes through the operating room for the treatment of his pathology as part of the care. Ophthalmologists may have to adapt the patient's management (i.e. adjustment of antibiotic therapy) as part of their usual care routine. An anterior chamber puncture and a vitrectomy are performed. Eye fluids collected as part of the treatment are sent for analysis."
10162896|NCT03968380||Population in Quito|720 randomly chosen people living in District 17D06, Quito (Ecuador)
10162897|NCT03968380||Population in Esmeraldas|720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador)
10162898|NCT03968185||Interfascial infiltration|Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.
10162899|NCT03968185||Standard medical treatment|Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.
10186388|NCT03735979|Placebo Comparator|Placebo|
10186389|NCT03735966|Experimental|Pyrotinib plus trastuzumab and docetaxel and carboplatin|Pyrotinib + trastuzumab + docetaxel+carboplatin
10186390|NCT03735953|Experimental|Retroflexion arm|Retroflexion in the total colon and slow withdrawal to the rectum and record all visible colon polyps and other colon related diseases
10186391|NCT03735953|No Intervention|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the the rectum have a forward view and record all visible colon polyps and other colon related diseases
10186392|NCT03735940|No Intervention|Control phase|no intervention, i.e. care as usual
10162900|NCT03968276|Experimental|use of digital tablet|"if the patient is included in the study, an educational tablet (digital tablet) is given to the patient.~The first connection to the tablet and then to the My medication protects my vessels application is made by the investigator in the presence of the patient. The application is configured by the investigator with the choice of the vascular pathology(s) corresponding to the patient included and the prescribed anti-thrombotic treatments. Thus, for each patient, the content of the tablet is adapted and personalized according to his vascular profile.~After discharge from hospital, the patient has the educational tablet at his disposal for 1 month at home. The application offers patients various information supports (tools, questionnaires and pill box). Throughout its use, it may contact the investigating physician via a telephone number available within the application if it encounters a problem related to the study."
10162901|NCT03968146|Active Comparator|Group E|patients will receive Erector Spinae plane block in addition to intravenous fentanyl
10162902|NCT03968146|Other|Group C|Control group will receive only intravenous fentanyl.
10162903|NCT03968224|Experimental|Metformin/Dapagliflozin|Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.
10162904|NCT03968224|Active Comparator|Metformin|Metformin 1,700 mg/day
10162905|NCT03968198|Experimental|ASC (Adipose-derived Stem/Stroma Cells)|Patients administrated with autologous ASC in their ischemic inferiors limbs
10162906|NCT03968211|Experimental|Vaccine|Subjects who meet enrollment criteria will be administered a single intramuscular dose of the Salmonella typhi polysaccharide vaccine
10162907|NCT03968445|Experimental|Recent Myocardial Infarction|
10162908|NCT03968445|Experimental|undergoing elective percutaneous coronary intervention|
10162909|NCT03968367|Experimental|Magnetic activated sperm cell sorting for infertile man|A 0.5 mL aliquot of spermatozoa suspended in HTF-modified HEPES buffer, obtained either after sperm wash to remove the seminal plasma or after DGC, was centrifuged and the pellet (maximum of 107 cells) was resuspended in 80 uL of binding buffer with 20 uL of Annexin V-conjugated microspheres, both from the Annexin V microbead kit (Miltenyi Biotec, Huburn, CA, USA), for 15 min at room temperature. After addition of 400 lL of binding solution, the suspension was placed in the separation column (MiniMACS, Miltenyi Biotec). Labeled (apoptotic) cells were retained on the column and non-labeled (viable) cells passed through the column.
10162910|NCT03968133|Experimental|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5*10^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10^9 CFU/gram) per day.
10162911|NCT03968133|Placebo Comparator|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
10162912|NCT03968354||Steatosis group - Experimental1|Steatosis group
10162913|NCT03968354||NASH group without fibrosis - Experimental 2|NASH group without fibrosis
10162914|NCT03968354||Moderate fibrosis - Experimental 3|Moderate fibrosis
10162915|NCT03968354||Advanced fibrosis - Experimental 4|Advanced fibrosis
10162916|NCT03968354||Control group - Active Comparator|Control group
10162917|NCT03968458|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions.
10162918|NCT03968068|Experimental|Exercise|
10162919|NCT03968068|Experimental|Remote Ischaemic Conditioning|
10162920|NCT03968003|Experimental|Inulin|Group A (intervention group) will receive inulin 10 g.
10162921|NCT03968003|Placebo Comparator|Maltodextrin|Group B will receive placebo of isocaloric maltodextrin.
10162922|NCT03968003|Active Comparator|Dietary fiber|Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.
10162923|NCT03968120|No Intervention|Group Fix:One-lung ventilation with constant PEEP|Controll group: lung protective one-lung ventilation with fix positive end-expiratory pressure (PEEP)
10162924|NCT03968120|Active Comparator|Group Variable:One-lung ventilation with variable PEEP|Variable group: lung protective one-lung ventilation with variable positive end-expiratory pressure (PEEP)
10162925|NCT03967990|Experimental|refined-50/50-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) whole grain cornmeal flour
10162926|NCT03967990|Experimental|50/50-whole-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) whole grain cornmeal flour, followed by (3) refined cornmeal flour
10162927|NCT03967990|Experimental|whole-refined-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) refined cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
10162928|NCT03967990|Experimental|refined-whole-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) whole grain cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
10162929|NCT03967990|Experimental|50/50-refined-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) refined cornmeal flour, followed by (3) whole grain cornmeal flour
9977884|NCT01366248||CSS Match-Control Patients|For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
10162930|NCT03967990|Experimental|whole-50/50-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) refined cornmeal flour
10186393|NCT03735940|Experimental|Intervention phase|experimental intervention: spot monitoring device, i.e. use of DeltaScan
10186394|NCT03735927|No Intervention|Control phase|no intervention, i.e. care as usual
10162931|NCT03968302|Experimental|ARM A|The triple regimen, amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole 40 mg twice a day
10162932|NCT03968302|Experimental|ARM B|The quadruple regimen,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day, omeprazole 40 mg twice a day dose and colloidal bismuth subcitrate 240 mg twice daily
9671399|NCT05049018|Active Comparator|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was for one hour and 15 minutes rest in between. The first part included: muscle strengthening and facilitation exercises, stretching exercises, and postural reactions exercises. The second part included: functional exercise for facilitation of arm-reaching and arm-hand skills, manipulative tasks (grasping and release activities), and daily living activities for the affected upper limb.~The traditional treatment program was applied for both groups by therapists, experienced in stroke rehabilitation. It was carried out three sessions per week for twelve successive weeks."
9671400|NCT05049018|Experimental|Experimental Group|"Participants in the experimental group received two hours treatment program that included three parts, the first and the second parts (similar to that were applied for participants in the control group). These two parts were applied for one hour followed by 15 minutes rest, then the third part was applied for one hour. The third part of the program was a one-hour virtual reality intervention program by using (ArmeoSpring) virtual reality equipment to simulate a range of upper limb tasks that facilitate arm activities, manipulative skills, and daily living tasks through using different interactive games and soft-wares.~The traditional treatment part of the program was applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program was applied by other experienced physiotherapists, who were well trained in using the (ArmeoSpring) System. All three parts of the program were carried out three sessions per week for twelve successive weeks."
10162933|NCT03968250|Experimental|Cognitive Behavioral Therapy for Treating Fatigue|This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.
10162934|NCT03967964|Experimental|Group 1: AVD|Vaginal ring with 2.2 grams dehydroepiandrosterone (DHEA), wearing time 72 hours
10162935|NCT03967964|Experimental|Group 2: AVT|Vaginal ring with 35 mg testosterone, wearing time 72 hours.
10162936|NCT03967964|Experimental|Group 3: AVD+T|Vaginal ring with 1.5 grams DHEA and 25 mg testosterone, wearing time 72 hours.
10162937|NCT03967964|Active Comparator|Group 4: DHEA capsule|Capsules with 25 mg DHEA, oral administration every 8 hours for a 72-hour period.
10162938|NCT03967964|Active Comparator|Group 5: Testosterone transdermal gel|Testosterone transdermal gel with dosing valve (pump): administration of 3 pump actuations (equivalent to 5 mg of testosterone each) per day (total daily dose 15 mg), on 3 consecutive days (72 hours).
10162939|NCT03967977|Active Comparator|Tislelizumab in combination with chemotherapy|Tislelizumab: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
10162940|NCT03967977|Placebo Comparator|Placebo in combination with chemotherapy|Placebo: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
10162941|NCT03967756|Experimental|AI-assisted withdrawal group|A deep learning-based automatic polyp detection system was used to assist the endoscopist.
10162942|NCT03967756|No Intervention|Routine withdrawal group|Routine withdrawal without any assist.
10162943|NCT03967730|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
10162944|NCT03967821||Intervention|
10162945|NCT03967886|Experimental|YYD601 20mg|Esomeprazole magnesium Dihydrate.
10162946|NCT03967886|Active Comparator|Nexium 20mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
10162947|NCT03968042|Placebo Comparator|Regular treatment (RT)|Combination of vitamin B1, B6, C, E and mecobalamine
10162948|NCT03968042|Experimental|RT with NGF|Nerve growth factor adding to regular treatment
10162949|NCT03968042|Experimental|RT with EDV|Edaravone adding to regular treatment
10162950|NCT03968029|Experimental|Suturing meniscal augmented|Non-vascularised area meniscus tear was sutured and bone marrow was injected under a protective collagen membrane (ChondroGide)
10162951|NCT03968029|Active Comparator|Suturing meniscal|Non-vascularised area meniscus tear was only sutured
10162952|NCT03967743||Infants with rare genetic disorders|This is a prospective, registry study of infants with genetic disorders being seen clinically in the NICU GraDS program.
10162953|NCT03967847|No Intervention|Control|
10162954|NCT03967847|Experimental|Ketorolac|
10162955|NCT03967769|No Intervention|Standard Practice|Infants will have high Flow nasal cannulae placed into the nares before induction. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
10162956|NCT03967769|Experimental|Low Flow oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 0,2L/kg/min of oxygen flowing through the cannulae in this group during the study.
10162957|NCT03967769|Experimental|High Flow Oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 1L/kg/min of oxygen flowing through the cannulae in this group during the study.
10162958|NCT03967782|Experimental|cohorte 1|18 adolescents with obesity are involved and will perform the three conditions.
10162959|NCT03967678|Placebo Comparator|Beef from standard supply|
10162960|NCT03967678|Experimental|n-3 enriched beef from dietary supplement finished cattle|
10162961|NCT03967678|Active Comparator|n-3 enriched beef from grass finished cattle|
10186395|NCT03735927|Experimental|Intervention phase|experimental intervention: spot monitoring device (excl. sham), i.e. use of DeltaScan
9671401|NCT05048862||Neuromuscular disorder|Patients age at least 20 years, and have been diagnosed as neuromuscular disorders by the neurologist. Patients who are unable to read the questionnaire, fail to accept all the examinations, and refuse to provide inform consent are excluded from this study.
9671402|NCT05048862||Normal group|The normal group (age at least 20 years) who had no neurological symptoms or signs were also recruited. The neurological examination performed by the board neurologist must be normal in the normal group.
9671403|NCT05048810|Experimental|68Ga-DOTA-NT-20.3|Subjects will undergo PET imaging using 68Ga-DOTA-NT-20.3.
9671404|NCT05048836|Experimental|Food subsidy, no lifestyle support, 6 months|Participant will receive $40 healthy food subsidy for 6 months.
9974656|NCT05251038|Experimental|Experimental Group|"Patients will either receive a combination of:~Sotorasib + Liposomal Irinotecan (nal-IRI) + 5 Fluorouracil (5FU) + Leucovorin (LV)~OR~Sotorasib + Gemcitabine (GEM) + Nab-paclitaxel~*The combination of therapy received is based on the participants prior therapy and of the discretion of their treating physician"
9974657|NCT05251025|Experimental|Passive sustained stretching|Passive sustained stretching along with conventional treatments
9974658|NCT05251025|Experimental|Myofascial Release|Myofascial Release Technique along with conventional treatments
9974659|NCT05250999|Experimental|Skin stretch sensory stimuli|Skin stretch sensory stimuli along with conventional physiotherapy
9974660|NCT05250999|Experimental|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation along with conventional physiotherapy
9974661|NCT05250999|Active Comparator|Control Group|Conventional physiotherapy included balance exercises, static exercise and dynamic exercise.
9974662|NCT05250960|Experimental|Intervention - SCD arm|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
9974663|NCT05250960|No Intervention|Control - no SCD arm|Patient will receive 1L of LR during and after epidural placement with no use of SCDs
9974664|NCT05250934|Experimental|Robotic group|In the robotic group, each patient undergoes 20 upper limb robotic telerehabilitation sessions, each session lasting 1 hour. The frequency is 5 sessions/week. Each session is performed at the patient's home, with direct supervision of a caregiver and remote supervision of a physical therapist, using three webcams able to show (a) the frontal and (b) the sagittal plane of the patient, as well as (c) the monitor of the robot.
9974665|NCT05250921|Experimental|Corticision|Corticision will be performed on the lower anterior teeth using a surgical blade and a hammer.
9974666|NCT05250921|Active Comparator|Conventional method|A fixed appliance will be applied using conventional braces without any surgical procedure.
9974667|NCT05250882|Experimental|Double Check enhanced perioperative care protocol|Perioperative care according to a best practice protocol focussing on optimizing the intraoperative condition of the patient and thereby minimalize exposure to 6 known modifiable independent intraoperative risk factors: anemia, hypothermia, epidural anesthesia, vasopressor drug administration, incorrect antibiotic prophylaxis and hyperglycemia.
9974668|NCT05250882|No Intervention|Current practice|Perioperative care according to usual practice. Historical controls from the previously conducted LekCheck study will be used as replacement of a control arm.
9974669|NCT05250843|Experimental|TACE/HAIC and Lenvatinib and PD-1(Sintilimab) before liver resection|For patients staged BCLC B/C,TACE/HAIC combined with Lenvatinib and Sintilimab will be conducted as neoadiuvent therapy before liver resection
9974670|NCT05250843|Active Comparator|Direct surgery group|After being diagnosed with hepatocellular carcinoma, surgery will be immediately performed.
9974671|NCT05250817||Cohort 1|Participants with early stage and advanced/metastatic non-small cell lung cancer (NSCLC)
9974672|NCT05250817||Cohort 2|Participants from the general population
9974673|NCT05250804|Experimental|Experimental|All registered participants in the intervention group, will receive the intramuscular injection with Helfer Skin Tap Technique.
9974674|NCT05250804|No Intervention|No intervention|All registered participants in the intervention group, will receive the intramuscular injection with Routine Technique. Routine Technique involved inserting the injection intra muscularly at 90 degree angle into Dorso gluteal muscles without tapping after cleaning with alcohol swab.
9974675|NCT05250791|Active Comparator|lidocaine|
9974676|NCT05250791|Placebo Comparator|Placebo|
9974677|NCT05250765|Experimental|Bonding with rubberdam|The retainer is bonded under rubber dam isolation
9974678|NCT05250765|Active Comparator|Bonding under relative isolation|The retainer is bonded under relative isolation (hygrophormic suction, cotton pads)
9671405|NCT05048836|Experimental|Food delivery, no lifestyle support, 6 months|Participant will receive twice monthly healthy food delivery for 6 months.
9671406|NCT05048836|Experimental|Food subsidy, with lifestyle support, 6 months|Participants will receive food subsidy and healthy lifestyle support for 6 months.
9671407|NCT05048836|Experimental|Food delivery, with lifestyle support, 6 months|Participants will receive twice monthly food box deliveries and lifestyle support for 6 months.
9974679|NCT05250752|Other|On treatment|Assigned to oral treatment with dapagliflozin 10 mg for three consecutive days.
9974680|NCT05250726|Experimental|MENISC-T|Segmented, devitalized and sterile meniscus graft
9974681|NCT05250700||Adults (40-70yrs)|
9974682|NCT05250687|Experimental|MR guided high intensity focused ultrasound (MR-HIFU)|MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastases.
9974683|NCT05250687|Active Comparator|External beam radiation therapy (EBRT)|Patients will undergo radiotherapy for painful bone metastases.
9974684|NCT05250674||Adult women with indication for a breast biopsy procedure after an abnormal CEM or MRI examination.|Adult women presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination and no clear ultrasound or mammography correlation.
9977375|NCT01360788||Asymptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea). Concretely, this group did not present any respiratory symptoms, with a MRC dyspnea score of 1/5.
9671408|NCT05048836|Experimental|Food subsidy, no lifestyle support, 12 months|Participants will receive food subsidy for 12 months.
9671409|NCT05048836|Experimental|Food delivery, no lifestyle support, 12 months|Participants will receive twice monthly food box deliveries for 12 months.
10162962|NCT03967795|Other|All patients|"Citrulline genration test before starting enteral nutrition~At ICU admission, a blood sample is collected (i) before and (ii) 90 minutes after N2-L-Alanyl-L-Glutamine administration"
10162963|NCT03967938|Experimental|Olaparib|tablets of 300mg twice daily until disease progression
10162964|NCT03967574|Experimental|Real tDCS|Participants received the full tDCS intervention for a total of 20 minutes, one time, two weeks following the CSI
10162965|NCT03967574|Sham Comparator|Sham tDCS|The patients were set up in an identical way as with the real tDCS group, but only received active stimulation for 30 seconds, after which the current was gradually stopped. The participants continued wearing the electrodes until the end of the 20 minutes treatment.
10162966|NCT03967574|No Intervention|Control|Participants received no further intervention two weeks following their CSI
10162967|NCT03967665|Experimental|Treatment arm|NAC 400 mg three times per day from -14D pre-HSCT to +2 months
10162968|NCT03967665|No Intervention|Control arm|No-NAC concurrent control according to a 2:1 schedule.
10162969|NCT03967691|Placebo Comparator|Saline infusion|Subjects will be infused with saline (placebo) on study day 1
10162970|NCT03967691|Active Comparator|Tocilizumab infusion|Subjects will be infused with tocilizumab on study day 2
10162971|NCT03967691|Other|Saline infusion under tocilizumab influence|Subjects will be infused withsaline (but still under the influence of tocilizumab) on study day 3
10162972|NCT03967717||Patients with edematous states|Patients with edematous states receive standard of care diuretic.
10162973|NCT03968016|Placebo Comparator|Healthy|Control group
9662147|NCT05130606|Active Comparator|FORCE Fact Sheet|Participants in the FORCE Fact Sheet arm will receive a Fact sheet about HBOC and genetic services and will be asked to read it in their own time. The Fact Sheet is available in English and Spanish.
9662148|NCT05130580|Experimental|Arm I (educational materials, enhanced consult, decision aid)|Patients receive newly-developed educational materials about breast reconstruction and attend an enhanced consultation visit with their plastic surgeon to discuss options for breast reconstruction surgery, during which a decision aid application containing a customized presentation of possible breast reconstruction outcomes is presented. At the end of the consultation visit, patients complete questionnaires about decision-making and psychological well-being. Within 4-6 weeks and 3-6 months after beginning the reconstruction process, patients also complete questionnaires about satisfaction with their breasts, body image, and psychological well-being, and undergo two-dimensional (2D) and 3D imaging of the torso.
9671410|NCT05048836|Experimental|Food subsidy, with lifestyle support, 12 months|Participant will receive food subsidy and lifestyle support for 12 months.
10162974|NCT03968016|Active Comparator|Stable heart disease|Stable heart disease and non-hospitalized
10162975|NCT03967418|Other|Patients with behavioral addictions|Patients suffering from behavioural addiction (sexual addiction, excessive use of video games and eating disorders with bulimia episodes) will be recruited
10162976|NCT03967418|Other|Healthy volunteers|Healthy volunteers will be matched on gender, age and education level to patients
10162977|NCT03967652||cancer|Patients with definitively diagnosed of solid tumors
10162978|NCT03967652||Benign disease|Patients with definitively diagnosed of benign disease or precancerous lesion
10162979|NCT03967652||Normal|Healthy volunteers
10162980|NCT03967431|Experimental|Narrative Enhancement and Cognitive Therapy group|The patients in the experimental group received narrative enhancement and cognitive therapy which contains 20 times group meetings.
10162981|NCT03967431|No Intervention|Control group|The patients in the control group received routine care.
10162982|NCT03967535||Control|Individuals between 45-85 years old with no diagnosis of dementia. No intervention used
10162983|NCT03967535||Dementia|Individuals between 45-85 years old with a diagnosis of dementia. No intervention used
10162984|NCT03967301|Experimental|Probiotic isolated intestinal bacteria (active)|Patients randomized to active arm, will consume 5ml every 12 hours per day of a suspension of probiotics (Bioflora ® Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis y Bifidobacterium brevis) for 14 days.The content of each bottle is reconstituted up to 50 ml (10 doses) with drinking water The prescription of the intervention will be carried out and monitored through the electronic medical record. In the hospital setting, the probiotic is reconstituted by the nursing staff. If the patient is discharged before this period the patient and family will be instructed to perform the reconstitution at home.
10162985|NCT03967301|Placebo Comparator|Placebo|Patients randomized to the placebo arm, will consume 5ml every 12 hours per day of a suspension of placebo for 14 days. The prescription of the intervention will be carried out and monitored through the electronic medical record.
10162986|NCT03967639||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
10162987|NCT03967639||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
10162988|NCT03967314|Active Comparator|Group T = TLIP block group|After the induction of anesthesia and placement of the patient in a prone position, US-guided mTLIP block was performed via the lateral approach in group T. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
10162989|NCT03967314|Active Comparator|Group W = Wound infiltration group|After the induction of anesthesia and placement of the patient in a prone position wound infiltration was performed in group W. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
10162990|NCT03967613|Experimental|FES|Functional Eletrical Stimulation
10162991|NCT03967509|Experimental|Behavioral teacher training|Behavioral preschool teacher training (BPTT) delivered in an educational group format during nine 2,5-hour biweekly sessions with training at sessions and in between followed by supervisor's feedback on the practice and two optional coaching occasions on the spot.
9671411|NCT05048836|Experimental|Food delivery, with lifestyle support, 12 months|Participants will receive twice monthly food box deliveries and lifestyle support for 12 months.
10162992|NCT03967509|No Intervention|Waiting list control group|Preschool teachers worked with children as usual.
10162993|NCT03967561|Experimental|Progressive aerobic training|Water-based aerobic training performed with progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
9671412|NCT05048758||Individuals with AUD + moderate to severe ACE|Individuals with alcohol use disorder (AUD) and moderate to severe adverse childhood experiences (ACE)
9974685|NCT05250661|Experimental|Aqueous propolis extract|The individuals in the intervention group were asked to gargle with 5 ml aqueous propolis extract four times a day after meals (morning, noon, evening and night before bedtime) and wait average one minute in the mouth and then spit, in addition to the standard practice of the clinic. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. The patients were followed for 21 days. The 21-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
9974686|NCT05250661|No Intervention|Control|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, it was performed tanflex (3x1) and/or sodium bicarbonate (1x1) to the patients in the prevention of oral mucositis with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
9974687|NCT05250648|Active Comparator|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|
9974688|NCT05250648|Experimental|complete cytoreductive surgery without HIPEC|
9974689|NCT05250635||Patients underwent thoracic surgery|Patients underwent thoracic surgery and general anesthesia with usage of DLET are included. Those patients with abnormal breath sound, pulmonary disease or history of cardiothoracic surgery are excluded.
9974690|NCT05250557||Deferral of PCI group|Patients who undergo successful FFR pullback tracing and have a vessel determined to defer revascularization after FFR measurement will be included.
9974691|NCT05250557||PCI group|Patients who undergo successful FFR pullback tracing and have a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) will be included.
9974692|NCT05250544|Experimental|Stress ball group|For the adolescents in the stress ball group; Before the procedure, the adolescent's fear (with Childeren's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the stress ball will be introduced to the adolescents and they will be asked to hold it in their desired hands. After explaining how to squeeze the stress ball, the PCR Test will start a few seconds after the adolescent starts to squeeze. As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
9974693|NCT05250544|Experimental|Breathin exercise group|For the adolescents in the breathing exercise group; Before the procedure, the adolescent's fear (with Child's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the breathing exercise will be introduced and applied to the adolescents. After explaining how to do the breathing exercise, the adolescent will be expected to complete the exercises. The PCR Test process will begin immediately after the exercise is complete. As soon as the process starts, the stopwatch will be started and will be stopped when the process is finished. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
9974694|NCT05250531|Experimental|GROUP 1|33 patients in the multicomponent treatment group selected to group 1 (G1) will be treated with telerehabilitation for a total of 6 sessions of two hours once a week for 3 weeks. After 1 month, one more session will be applied for a two-hour follow-up and sustainability.
9974695|NCT05250531|Active Comparator|GROUP 2|As a control group, 33 patients selected to Group 2 (G2) will be given exercise and training with telerehabilitation.
9974696|NCT05250518|No Intervention|the control group|The control group will receive no prophylaxis of post-procedure bleeding.
9974697|NCT05250518|Experimental|APC group|The APC group will receive prophylaxis of post-procedure bleeding with argon plasma coagulation.
9974698|NCT05250518|Experimental|Clip group|The Clip group will receive prophylaxis of post-procedure bleeding with clip closure.
9974699|NCT05250492|Experimental|Patients with PENG block|
9974700|NCT05250492|Active Comparator|Patients with intra-articular infiltration|
9974701|NCT05250479|No Intervention|Control group|44 pregnant women won't receive mindfulness training
9974702|NCT05250479|Experimental|"experimental group mindfulness education"|mindfulness education 44 pregnant women will receive mindfulness training
9977376|NCT01360788||Symptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea) in this group.
9977377|NCT01360814||GROUP A (multidisciplinary intervention)|Patients receive six 90-minute sessions of a multidisciplinary structured intervention comprising physical therapy, education, a cognitive-behavioral intervention, discussion and support, spiritual reflection, and a relaxation exercise over 2-4 weeks. Caregivers are invited to sessions 1, 3, 4, and 6. Patients may also receive brief telephone contact during the 6 month follow-up period.
9977378|NCT01360814||GROUP B (standard medical care)|Patients receive standard medical care only. Patients may also receive brief telephone contact during the 6 month follow-up period.
9977379|NCT01360827|Experimental|Arm 1 (Part 1)|
9977380|NCT01360827|Experimental|Arm 2 (Expansion cohorts -Part 2 and Part 2a)|
9977381|NCT01360918|Active Comparator|Usual care|
9977382|NCT01360918|Active Comparator|Pulmonary vein isolation|
10162994|NCT03967561|Experimental|Non-progressive aerobic training|Water-based aerobic training performed without progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
10162995|NCT03967249|Experimental|IONIS GHR-LRx + SRL|IONIS GHR-LRx (as per dose in previous study) will be administered subcutaneously once every 28 days for 53 weeks.
10162996|NCT03967379|Experimental|Mobile app plus enhanced standard care|"Patients will received enhanced standard care in addition to access to the sexual health mobile app.~The app will also prompt patients to engage their partners with specific exercises."
10162997|NCT03967379|Other|Enhanced Standard Care|"Patients will receive Enhanced Standard Care~Patients will meet with a transplant clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or vulvovaginal GVHD~Patients will not have access to the sexual health mobile app"
10162998|NCT03967093|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with relapsed solid tumors, including malignant brain tumors, will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level (3.2 mg/kg) is reached.
10162999|NCT03967093|Experimental|Part 2: Ependymoma Patients|Cohort of patients with recurrent ependymoma will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
9671413|NCT05048758||Individuals with AUD + no or mild ACE|Individuals with alcohol use disorder (AUD) and no or mild adverse childhood experiences (ACE)
10163000|NCT03967093|Experimental|Part 2: Brain Tumor Patients|Cohort of patients with recurrent malignant brain tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
10163001|NCT03967093|Experimental|Part 2: DIPG Patients|Cohort of patients with recurrent diffuse intrinsic pontine glioma (DIPG) will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
10163002|NCT03967093|Experimental|Part 2: Other Solid Tumor Patients|Cohort of patients with relapsed non-central nervous system (CNS) solid tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
10163003|NCT03967119||Laparoscopic surgery|"The following parameters are assessed and recorded at the following time points in all participants.~The parameters assessed: mean arterial pressure, heart rate, pulse oxygen saturation, SVV, PPV, PWV, peak inspiratory pressure, plateau pressure, positive end-expiratory pressure, respiratory rate (all dynamic variables are assessed at two levels of tidal volume- 6 ml/kg and 12 ml/kg).~The time points: T0, before anesthetic induction; T1, immediately after anesthetic induction; T2, immediately after pneumoperitoneum; T3, 10 min before desufflation; T4, immediately after desufflation.~The desufflation-induced hypotension is defined as more than 20 % decrease in MAP at T4 from MAP at T3."
10163004|NCT03967015|Experimental|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will receive MUAC training and nutritional education at enrollment. A short message service (SMS) message will be sent at 7 days following enrollment asking them to measure and send their child's MUAC. Weekly SMS messages asking for the child's MUAC measurement will be sent every 7 days until the last study visit at 180 days following enrollment.
10163005|NCT03967015|No Intervention|Standard of care (SOC)|Participants randomized to the standard of care (SOC) arm will receive the same MUAC training and nutritional education as mothers in the MAMMS arm. To accurately simulate community malnutrition outreach programs, no SMS message will be sent to participants in this arm.
10163006|NCT03967028||Study group|primigravida scheduled for cesarean section
10163007|NCT03967262|Experimental|Intervention|
10163008|NCT03967262|No Intervention|Control|
10163009|NCT03967392|Active Comparator|GROUP X(xylocaine)|20 ml bupivacaine 0.5% + 20 ml normal saline.
10163010|NCT03967392|Active Comparator|GROUPX(Dxylocaine and dexamethasone)|20 ml bupivacaine 0.5% + 18 ml normal saline + 8 mg dexamethasone 2 ml
10163011|NCT03967041||Sarcopenic patients|
10163012|NCT03967041||Non-sarcopenic patients|
10163013|NCT03967353|No Intervention|Routine Treatment Group|Routine treatment group(6 months treatment regimen-2HRZE/4HR); Routine health education; Dose-taken supervised by family members
10163014|NCT03967353|Experimental|Intervention Group|Using mobile technology management means to manage newly treated smear-positive tuberculosis patients, to guide patients'treatment, infection control, doctor-patient communication, and to strengthen health education on infection control of patients.
10163015|NCT03967054|Experimental|Ivermectin mass drug administration|Ivermectin given monthly from July-October (4 times) as a 3-day course of 300 µg/kg/day to all eligible persons per exclusion/inclusion criteria. Per package insert, dosing of IVM will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
10163016|NCT03967054|Placebo Comparator|Placebo mass administration|Placebo given monthly from July-October (4 times) as a 3-day course to all eligible persons per exclusion/inclusion criteria. Dosing of placebo will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
10163017|NCT03967132|Active Comparator|Control Infant Formula|Milk-based infant formula
9974703|NCT05250466|Experimental|Group 1|
10163018|NCT03967132|Experimental|Experimental Infant Formula|Milk-based Infant Formula with oligosaccharides
10163019|NCT03967132|Other|Reference Group|Human-milk fed
10163020|NCT03967171|Experimental|before uterine incision oxytocin group|IV infusion of 20 IU of oxytocin started before uterine incision
10163021|NCT03967171|Active Comparator|after clamping the umbilical cord oxytocin group|IV infusion of 20 IU of oxytocin started immediately after clamping the umbilical cord
10163022|NCT03967496||No Delirium|No Delirium: CAM-ICU score of less than 3 throughout Post-Anesthesia Care Unit stay
10163023|NCT03967496||Initial Delirium|Initial Delirium: CAM-ICU score of 3 or more at 15 minutes following end of anesthesia and/or at 30 minutes following end of anesthesia
9974704|NCT05250466|Active Comparator|Group 2|
9974705|NCT05250453||Cardiac arrest|All patients having sudden cardiac arrest out-of-hospital in Pirkanmaa, Finland
10163024|NCT03967496||Delirium|Delirium: CAM-ICU score of 3 or more immediately prior to discharge from Post-Anesthesia Care Unit
10163025|NCT03967548|Experimental|0.004% single-dose|96 subjects will be treated with Germinal peptide eye drops 0.004% single dose (16 were pre-tested and 64 were formally tested).
10163026|NCT03967106|Experimental|Remote Ischaemic preconditioning|Remote IPC (RIPC) intervention daily for six weeks.
10163027|NCT03967106|Sham Comparator|Sham|Remote sham intervention daily for six weeks.
10163028|NCT03967158||Consecutive percutaneous coronary intervention|
10163029|NCT03966937|Experimental|Dry needling|The experimental group will receive dry needling over trigger points of Quadriceps muscles along with therapeutic exercises.
10163030|NCT03966937|Active Comparator|Control|The control group will only receive standardized therapeutic exercises for Patellofemoral pain syndrome.
10163031|NCT03967327|Active Comparator|MOR SR|"This arm includes MOR SR and placebo for BUP TDS, detailed information is as below:~Treatment dosage form dosage frequency duration MOR SR Tablet 10,30,60mg q12h 8 weeks~Placebo for Patch -- every 3-4 days 8 weeks BUP TDS"
10163032|NCT03967327|Experimental|BUP TDS|"This arm includes BUP TDS and placebo for MOR SR, detailed information is as below:~Treatment dosage form dosage frequency duration Placebo for Tablet -- q12h 8 weeks MOR SR~BUP TDS Patch 20/30/40mg every 3-4 days 8 weeks"
10163033|NCT03967288|Experimental|Chloroprocaine|50 mg of 1% spinal chloroprocaine (5 mL) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
10163034|NCT03967288|Active Comparator|Bupivacaine|10.5 mg of spinal hyperbaric bupivacaine (1.4 mL of 0.75% bupivacaine hydrochloride in 8.25% dextrose) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
10163035|NCT03966963|Experimental|Eye Movement Desensitization Reprocessing (EMDR)|Subjects with trauma-related symptomology resultant from CSA will undertake EMDR; they will be systematically observed through use of their quantitative treatment outcome measures at both pre- and post- treatment alongside one-month follow-up interview data to determine outcomes of interest (namely emotional, behavioural and neuropsychological functioning).
10163036|NCT03966885|Experimental|Brief Intervention (BI)|30 minute alcohol brief intervention delivered by lay provider during HIV clinic visit.
10163037|NCT03966885|Experimental|Brief Intervention + CETA|30 minute alcohol brief intervention delivered by lay provider during clinic visit followed by 6-12 weekly sessions of CETA.
10163038|NCT03967197|Experimental|Lidocaine|Patients randomized to the lidocaine intervention will receive 2 sprays of lidocaine hydrochloride 10% in each nostril 3-5 minutes before their test.
10163039|NCT03967197|Placebo Comparator|Placebo (Saline)|Patients randomized to placebo will receive 2 sprays of physiological saline in each nostril 3-5 minutes before their test.
10163040|NCT03966846|Experimental|Kefir Group|Kefir group received one bottle of kefir (180 ml) daily for 12 weeks. Microbial composition of the kefir included Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris, Lactococcus lactis ssp. diacetylactis, Leuconostoc mesenteroides ssp. cremoris, Lactobacillus kefyr, Kliyveromyces marxianus, and Saccharomyces unisporus.
10163041|NCT03966846|Placebo Comparator|Control Group|Control group received one bottle of milk (180 ml) daily for 12 weeks.
10163042|NCT03966768|Experimental|Duramesh suturable mesh for laparotomy closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be closed with Duramesh suturable mesh.
10163043|NCT03966768|Experimental|Conventional suture closure for laparotomy closure|Patients randomized to conventional laparotomy closure will be closed using size 1 slowly-absorbing polydiaxonone (PDS) single strand or looped suture, based on surgeon preference.
10163044|NCT03966768|Experimental|Open abdomen group closed in delayed fashion with Duramesh|Patients undergoing delayed primary closure of an open abdomen will also be studied. 20 study patients undergoing delayed primary closure of an open abdomen will be closed with Number 1 or Number 2 Duramesh
10163045|NCT03966976|Experimental|Vitaphone Arm|Follow-up via VITAPHONE in addition to conventional monitoring.
10163046|NCT03966976|Active Comparator|Conventional Arm|Conventional follow-up
10163047|NCT03966755|Experimental|UFA dietary recommendations|Dietary intervention aimed at increasing UFA consumption.
10163048|NCT03966755|No Intervention|Standard dietary recommendations|Standard of care dietary recommendations as currently performed in the clinic (2015-2020 United States Department of Agriculture (USDA) Dietary Guidelines for Americans)
10163049|NCT03966781|Active Comparator|ESWL followed by ERCP|Patients enrolled in the active treatment group will be subjected to ESWL followed by ERCP and pancreatic duct stenting.
10163050|NCT03966781|Sham Comparator|Sham ESWL followed by sham ERCP|Patients enrolled in the sham treatment group will be subjected to sham ESWL followed by sham ERCP with no pancreatic duct intervention.
10163051|NCT03966651|Experimental|PRRT with 177Lu-DOTATATE|
10163052|NCT03966560|Experimental|Primary open-angle glaucoma|"Participants over 40 years of age and diagnosed with primary open-angle glaucoma.~Medical treatment was initiated for the diagnosed participants."
10163053|NCT03966560|No Intervention|Healthy|Healthy volunteers who do not have systemic disease that may affect the choroidal thickness and have no ocular features that may affect test measurements.
10163054|NCT03966534|No Intervention|Control Group|Blood culture obtained as first test after venipuncture and prior to biochemistry test
10163055|NCT03966534|Experimental|Diversion Group|Biochemistry test obtained as first test after venepuncture and prior to blood culture
10163056|NCT03966859|Placebo Comparator|Placebo|Participants will receive lactose placebo tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
10163057|NCT03966859|Experimental|Atorvastatin|Participants will receive 20mg atorvastatin tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
10163058|NCT03966950|Experimental|melatonin group|for the melatonin group, 10 mg of melatonin will be taken per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
10163059|NCT03966950|Placebo Comparator|placebo group|For the placebo group, placebo will be administered per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
10186396|NCT03735914|Experimental|neuralgic patients|MRI experimentation
10163060|NCT03966833|Experimental|group-based interpersonal therapy (IPT-G)|14 weeks of group-based interpersonal therapy (IPT-G): StrongMinds is focused on treating depression in Uganda by training community members (in this case ELA club mentors) to act as mentors in IPT-G techniques. This intervention will be offered to 13-19 year old young women who score a 10 or higher on the PHQ-8. These adolescents who take up the offer will then be enrolled in the 14 weeks of therapy. Group therapy sessions build bonds between young women and encourage them to actively engage in the healing process and to support each other in the exploration of their depression triggers. With new healthier patterns and skills, women can learn to manage their current depression and ensure future depressive episodes can be quickly identified and resolved before the onset of any long-term consequences.
10163061|NCT03966833|Experimental|IPT-G + Unconditional Cash Transfer:|A one time lump sum of 200,000 UGX (~$54) be provided to all study participants in a random sub-set of intervention (IPT-G) clusters near or at the conclusion of the 14-week therapy. This treatment variation will allow for determination of whether complimentary income support enhances the effects of IPT-G on psychological wellbeing and other outcomes of interest.
10163062|NCT03966833|No Intervention|control|ELA clubs function as normal
10163063|NCT03966664||Septic patients|Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
10163064|NCT03966664||Healthy controls|Age and sex matched healthy volunteers.
10163065|NCT03966664||Non septic patients|Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
10163066|NCT03966729||HFrEF|"HFrEF (Heart failure with reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF < 40%.~LVEF = Left ventricular ejection fraction"
10163067|NCT03966729||HFmrEF|"HFmrEF (Heart failure with mid-range reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF 40-49%.~LVEF = Left ventricular ejection fraction"
10163068|NCT03966729||HFpEF|"HFmrEF (Heart failure with preserved ejection fraction): ESC Guideline heart failure 2016: patients with LVEF > 50%.~LVEF = Left ventricular ejection fraction"
10163069|NCT03966547|Experimental|Local anesthetic|
10163070|NCT03966547|Placebo Comparator|Isotonic NaCl|
10163071|NCT03966716|Experimental|Arthroplasty|Arthroplasty, hemi or total depending on patient characteristics and surgeon's choice
10163072|NCT03966716|Active Comparator|Internal Fixation|Internal fixation with 2-3 screws or pins, or sliding hip screw device, depending on each hospital's routine
10163073|NCT03966508|Experimental|hyperalgesia measurement|
10163074|NCT03966456||nivolumab|Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
10163075|NCT03966456||pembrolizumab|Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
10163076|NCT03966456||toripalimab|Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
10163077|NCT03966456||sintilimab|Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
10163078|NCT03966703|Experimental|conventional denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
10163079|NCT03966703|Experimental|implant fixed denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
10163080|NCT03966599|Active Comparator|Lateral position|The patient position was changed to lateral during surgery
10163081|NCT03966599|Active Comparator|prone position|The patient position was changed to prone during surgery
10163082|NCT03966794|Experimental|Epidural Electrical Stimulation|
10163083|NCT03966794|Experimental|Functional scaffold & Epidural Electrical Stimulation|
10163084|NCT03966690|Experimental|leg curl device starters|Group A randomly assigned to start with legcurl device
10163085|NCT03966690|Experimental|legpress device starters|Group A randomly assigned to start with legpress device
10163086|NCT03966378|Experimental|Grape seeds extract|Every week the grape seeds extract (gel) put into the tray and apply it to the upper teeth of the participant.
10163087|NCT03966378|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste apply to the teeth twice daily.
10163088|NCT03966430|Experimental|damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the damage control surgery group.
10163089|NCT03966430|Sham Comparator|non-damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the non-damage control surgery group.
10163090|NCT03966898|Experimental|SHR6390, Letrozole or Anastrozole|SHR6390, Letrozole or Anastrozole
10163091|NCT03966898|Placebo Comparator|Placebo, Letrozole or Anastrozole|Placebo, Letrozole or Anastrozole
10163092|NCT03966196|Other|Healthy Volunteers|oxymetry and finger pressure in Healthy subjects
10163093|NCT03966196|Experimental|COPD patients|oxymetry and finger pressure in COPD patients
10163094|NCT03966482|Experimental|Group before-after|Speech therapy with Semiocluded vocal tract exercise.
10163095|NCT03966300|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination)
10163096|NCT03966300|No Intervention|Control (standard/usual care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
10163097|NCT03966573|Other|Evaluating function, Radiographic imaging, Forms|"Tests for lower extremity function~Evaluating arthritis of hip and knee, leg length discrepancy and axis deviation radiographically~Evaluating quality of life, function and pain by forms"
10163098|NCT03966170|Experimental|Citicoline|Citicoline as neuroprotector
10163099|NCT03966170|Placebo Comparator|Placebo drug|Placebo
10163100|NCT03966326|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
10163101|NCT03966326|Active Comparator|PECS II group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
10163102|NCT03966391|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/ fear/fainting mitigation interventions from CARD during vaccination)
10163103|NCT03966391|No Intervention|Control (standard care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
10163104|NCT03966417|Active Comparator|Exercise training group|"Patient to be randomized to exercise training group will have exercise training sessions 2 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 75% of Vo2max."
10163105|NCT03966417|No Intervention|Usual care group|"Patient to be randomized to usual care group will undergo standard care fo 12 weeks."
10163106|NCT03966144|Experimental|RoboHear Device|Subjects will wear the Robo-Hear device and receive haptic stimuli. They will be tested on their ability to interpret these haptic sensations as sounds and words.
10163107|NCT03966222|Active Comparator|Open vein harvest|For the standard open conventional technique, the saphenous vein will be exposed by a longitudinal leg incision starting from the medial malleolus and ending at the upper medial thigh at the sapheno-femoral junction. The saphenous vein will be dissected free from its perivascular fat pedicle and visible side branches will be ligated and divided.
10163108|NCT03966222|Experimental|Endoscopic vein harvest|We will use the Terumo VirtuoSaph® Plus Endoscopic Vessel Harvesting System for all endoscopic vein extractions, which is an open carbon dioxide (CO2) system. Approximately 6 l/min of CO2 will be continuously insufflated in the subcutaneous tunnel.
10163109|NCT03966235|Experimental|Melatonin group|drug: melatonin tablets (Sigma-Aldrich Co. LLC, St. Louis, MO, USA); the frequency:3mg melatonin tablet was taken daily; duration: study treatment was maintained for 6 months.
10163110|NCT03966235|Placebo Comparator|Control group|drug: placebo tablet; the frequency: placebo tablet was taken daily; duration: study treatment was maintained for 6 months.
10163111|NCT03966469||Support Person Present|Participants who bring a support person with them to their preoperative appointment.
10163112|NCT03966469||Patient Present Only|Participants who present by themselves to their preoperative appointment.
10163113|NCT03966079|Experimental|Intervention arm|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
10163114|NCT03965936|Placebo Comparator|lipofilling|subcutaneous injection of lipoaspiate (microfat) in one temporal region
10163115|NCT03965936|Active Comparator|lipofilling enriched with adipose tissue derived stem cells|subcutaneous injection of lipoaspiate enriched with adipose tissue derived stem cells in one temporal region
10186397|NCT03735875|Experimental|Treatment (venetoclax, quizartinib)|Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
10186398|NCT03735836|Experimental|MaxSimil 2 capsules daily|Subjects will receive two (2) capsules per day of MAG-EPA/MAG-DHA omega-3 oils for a total of 600mg of MAG-EPA and 260mg of MAG-DHA daily during 20 consecutive weeks of treatment.
10186399|NCT03735836|Experimental|MaxSimil 3 capsules daily|Subjects will receive two (3) capsules per day of of MAG-EPA/MAG-DHA omega-3 oils for a total of 900mg of MAG-EPA and 390mg of MAG-DHA daily during 20 consecutive weeks of treatment.
10186400|NCT03735810|Experimental|SAD - Cohort 1|50 mg LBS-008 or placebo
10186401|NCT03735810|Experimental|SAD - Cohort 2|100 mg LBS-008 or placebo
10186402|NCT03735810|Experimental|SAD - Cohort 3|200 mg LBS-008 or placebo
10186403|NCT03735810|Experimental|SAD - Cohort 4|400 mg LBS-008 or placebo
10186404|NCT03735810|Experimental|SAD - Cohort 5|25 mg LBS-008 or placebo
10186405|NCT03735810|Experimental|MAD - Cohort 1|10 mg LBS-008 or placebo
10186406|NCT03735810|Experimental|MAD - Cohort 2|25 mg LBS-008 or placebo
10186407|NCT03735810|Experimental|MAD - Cohort 3|5 mg LBS-008 or placebo
10186408|NCT03735810|Experimental|MAD - Cohort 4|12 mg LBS-008 or placebo
10186409|NCT03735784|Experimental|AWARE condition|AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback.
10186410|NCT03735784|No Intervention|Standard Care condition|"Participants in the Standard Care condition have access to usual care at the drop-in center where the study is being conducted."
10186411|NCT03735771|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
10186412|NCT03735771|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
10186413|NCT03735771|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
10186414|NCT03735771|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
10186415|NCT03735758|Experimental|Pazopanib|Pazopanib; 800 mg; daily; oral
10186416|NCT03735758|Active Comparator|Chemotherapy|Guideline-conform chemotherapy
10186417|NCT03735732||weight status|
10186418|NCT03735732||mindset|
10163116|NCT03966027|Experimental|Hindfoot Offloading Braces / Immediate Weight-bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
10163117|NCT03966027|Placebo Comparator|No Hindfoot Offloading Braces / Delayed Weight-Bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
10163118|NCT03966183||UVFP patients post thyroplasty|Patients in this group are adults who have undergone type I medialization thyroplasty (with Montgomery implant, silicone implant, follow-up of more than 3 months) as a definitive procedure following unilateral vocal fold paralysis.
10163119|NCT03966183||Control participants|The people in this group are control subjects of the same age, sex and manual laterality as the patients.
10163120|NCT03966209|Experimental|treatment|JS001（PD-1 inhibitor）, 240mg I.V. Q3W,
10163121|NCT03965988|Experimental|Docosahexaenoic Acid|Docosahexaenoic acid
10163122|NCT03965988|Placebo Comparator|Placebo drug|Placebo
10163123|NCT03966040|Experimental|Immunization schedule of day 0-3-7|Three doses of schedule given at day 0, 3 and 7.
9827686|NCT02465073|Active Comparator|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site.( Next Science Wound Gel, plus standard of care).
10163124|NCT03966040|Experimental|Immunization schedule of day 0/0-3-7|Four doses of schedule given at day 0/0, 3 and 7.
10163125|NCT03966040|Experimental|Immunization schedule of day 0/0-7|Three doses of schedule given at day 0/0 and 7.
10163126|NCT03966040|Experimental|Immunization schedule of day 0/0-7-14|Four doses of schedule given at day 0/0, 7 and 14.
10163127|NCT03965910|Other|group 1|Group 1:Early rehabilitation
10163128|NCT03965910|Other|group 2|Group 2:Late rehabilitation
10163129|NCT03966092|No Intervention|Usual practice|Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations
10163130|NCT03966092|Experimental|QLB block|"Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations.~In addition, patients receiving a bilateral QLB at the end of the surgery"
10163131|NCT03965962|Experimental|Group 1: VRVg-2 + HRIG|Participants received 0.5 milliliters (mL) intramuscular (IM) injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28 along with HRIG single injection at Day 0.
10163132|NCT03965962|Active Comparator|Group 2: Verorab + HRIG|Participants received 0.5 mL IM injection of Verorab on Days 0, 3, 7, 14 and 28 along with HRIG single injection at Day 0.
10163133|NCT03965962|Active Comparator|Group 3: Imovax Rabies + HRIG|Participants received 0.5 mL IM injection of Imovax on Days 0, 3, 7, 14 and 28 along with HRIG single injection at Day 0.
10163134|NCT03965962|Experimental|Group 4: VRVg-2|Participants received 0.5 mL IM injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28.
10163135|NCT03965871|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163136|NCT03965871|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163137|NCT03965871|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163138|NCT03965871|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163139|NCT03966014|Active Comparator|EM-amoxicillin 3 x 10 days|
10163140|NCT03966014|Active Comparator|EM-amoxicillin 3 x 14 days|
10163141|NCT03966014|Active Comparator|EM-amoxicillin 2 x 14 days|
9974706|NCT05250453||ResusInj|OHCA survivors having CPR related injuries or carotid stenosis analyzed by CT
9974707|NCT05250453||ResusCPC|OHCA survivors neurological outcome
10163142|NCT03966014|Other|Controls|
10163143|NCT03966118|Experimental|Ramucirumab + Avelumab + Paclitaxel|Single-Arm
10163144|NCT03965949||Group 1|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support
10163145|NCT03965949||Group 2|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)
10163146|NCT03965949||Group 3|Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)
10163147|NCT03965949||Group 4|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
10163148|NCT03965767|Placebo Comparator|control|
10163149|NCT03965767|Active Comparator|local group|
10163150|NCT03965767|Active Comparator|systemic group|
10163151|NCT03965767|Active Comparator|combined local and systemic|
10163152|NCT03965858|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163153|NCT03965858|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163154|NCT03965858|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163155|NCT03965858|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
10163156|NCT03965819|Experimental|Randomized to consume Pain Bloc-R, Acetaminophen, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Investigational Natural Health Product in Study Period 1, Comparator in Study Period 2, and Placebo in Study Period 3.
10163157|NCT03965819|Experimental|Randomized to consume Acetaminophen, Placebo, then Pain Bloc-R|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Comparator in Study Period 1, Placebo in Study Period 2, and the Investigational Product in Study Period 3.
10163158|NCT03965819|Experimental|Randomized to consume Placebo, Pain Bloc-R, then Acetaminophen|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Investigational Product in Study Period 2, and Comparator in Study Period 3.
10163159|NCT03965975|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated urine cups. The urine sample was then sent the Lab and tested sequentially; first by the golden standard techniques used by the Lab (first intervention) and by the S-There device (comparative device - second intervention).
10163160|NCT03965780|Experimental|Training group|Participants in the training group will receive a 13-week training program delivered via videoconference. The program includes 13 modules delivered via videoconference over the course of the 3-month program in weekly 60- to 90-minute sessions. Participants will receive a training manual, be shown filmed vignettes, and will have access to a chatroom and an online resource centre.
10163161|NCT03965780|No Intervention|Wait-list control group|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above.
10163162|NCT03966001||Planned Cesarean Group|Pregnant women undergoing a planned cesarean section at 38-42 gestational week.
10163163|NCT03966001||Emergency Cesarean Group|Pregnant women who are planning to give normal birth between 38-42 weeks of gestation but have to been performed an urgent cesarean section due to an emergency such as acute fetal distress, cephalo-pelvic disproportion or another obstetrical condition.
10163164|NCT03966131|Experimental|patients with complete denture for the first time|Arm that allows to follow the adaptation of this population to the new complete denture during the tasks of speech production and swallowing.
9974708|NCT05250401||patients with liver cirrhosis|
10163165|NCT03966131|Experimental|patients with complete denture used to their complete denture.|Arm that allows a descriptive cross-sectional study of tongue pressure measurements during the tasks of speech production and swallowing
10163166|NCT03965884|Experimental|lumbal stabilization exercise group|
10163167|NCT03965884|Experimental|connective tissue massage group|
10163168|NCT03965884|No Intervention|control group|
10163169|NCT03965598||Ultra-high risk for psychosis (UHP)|"Ultra-high risk for psychosis (UHP) is defined as individuals at the prodromal stage of schizophrenia.~Inclusion Criteria: age of 13-30 years; meet the diagnostic criteria of COPS prodromal syndrome by SIPS clinical interviews; have not received any psychiatric medication; be in good health, without major mental illness or physical illness; normal intelligence, can be operated on a clinical scale; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: exclusion of current or previous psychiatric disorders by SCID interview; meet the diagnostic criteria for substance abuse and substance dependence in DSM-IV; contraindications for MRI; pregnant or lactating women."
10163170|NCT03965598||Healthy controls|"Inclusion Criteria: the gender, age, and education level of the group are matched with the Ultra-high risk group; 13 to 30 years old; right-handed; no history of mental illness; no mental disorder consistent with DSM-IV diagnostic criteria within two or three generations; No contraindications for MRI; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: history of disturbance of consciousness over 5 minutes; history of brain organic disease or head injury; history of alcohol and drug dependence; history of coma; history of endocrine disease; abnormity in examination of blood, heart, liver, or renal function; pregnant or lactating women."
10163171|NCT03965572||Postpartum women who requested cabergoline|A cohort of postpartum women, after a live birth, who request cabergoline for lactation suppression.
10163172|NCT03965572||Control group|An age-matched cohort of women after a live birth who have not requested cabergoline for lactation suppression.
10163173|NCT03966066|Experimental|low dose erythromycin group|Erythromycin 3-5mg/kg.d orally for 6 months
10163174|NCT03966066|No Intervention|Non-erythromycin treatment group|systemic treatment
9974709|NCT05250401||control group|
9974710|NCT05250375||Nucleotide-binding protein-like (NUBPL)-Primary Mitochondrial Disease adult and child subjects|Any patient with NUBPL-Primary Mitochondrial Disease is eligible to be enrolled
10163175|NCT03965585||Primary Infertility|Women with a diagnosed primary infertility undergoing hysteroscopy before IVF.
10163176|NCT03965585||Secondary Infertility|Women with a diagnosed secondary infertility undergoing hysteroscopy before IVF.
10163177|NCT03965585||Recurrent miscarriages|Women with recurrent miscarriages undergoing hysteroscopy before IVF.
9974711|NCT05250349||Isolated HF Group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) and clinical symptoms (NYHA I-III).
10163178|NCT03966105||Patients with CTS surgery indication|
10163179|NCT03966105||Patients with LSS surgery indication|
10163180|NCT03965416|Experimental|Doctor with white coat|Doctor during consultation is wearing a white coat
10163181|NCT03965416|Experimental|Doctor without white coat|Doctor during consultation is not wearing a white coat
10163182|NCT03965546|Experimental|ET140202-T cell combine with Sorafenib|Sorafenib treatment everyday and autologous ET140202-T cell administered by intravenous (IV) infusion
10163183|NCT03965546|Experimental|ET140202-T cell combine with TAE|TAE treatment ahead every two times of autologous ET140202-T cell administered by intravenous (IV) infusion
10163184|NCT03965546|Experimental|solo ET140202-T cell|autologous ET140202-T cell administered by intravenous (IV) infusion
10163185|NCT03965559||plasmapheresis group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the plasmapheresis during January 2006 to October 2015
10163186|NCT03965559||double filtration plasmapheresis (DFPP) group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the double filtration plasmapheresis (DFPP) during January 2006 to October 2015
10163187|NCT03965793|Active Comparator|Manual management of hypotension|Fluid and vasopressor will be managed as standard practice ( manually infusion of both fluid and vasopressors) following the investigators manual individualized hemodynamic protocol.(objective being to keep both stroke volume and MAP within 90 % of the target values)
10163188|NCT03965793|Experimental|Automated management of hypotension|Fluid and vasopressor will be managed with a novel active clinical decision support system to guide fluid administration and automated closed-loop system to maintain MAP within 90% of patient' baseline.
10163189|NCT03965663|Experimental|Trans-tibial Amputees|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living
10163190|NCT03965663|Experimental|Trans-tibial Amputees with TSR|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living. The subjects underwent a functional nerv-transfer surgery prior to participation, where the proximal part of the sural nerv was to the distal part of the saphenous nerv.
10163191|NCT03965624|Experimental|Ixazomib|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, in combination with dexamethasone 20 mg weekly. The investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see below) or de-escalation in case of response and severe adverse events.
10163192|NCT03965507||The group with sacroiliac joint dysfunction|The patient with sacroiliac joint dysfunction in lumbar disc hernia
10163193|NCT03965507||The group without sacroiliac joint dysfunction|The patient without sacroiliac joint dysfunction in lumbar disc hernia
10163194|NCT03965364||INCRAFT|Endovascular abdominal aortic aneurysm repair
10163195|NCT03965481|Experimental|Diagnostic (CECT, PET-MRI)|Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30 days before laparoscopy or cytoreduction. Patients who do not undergo cytoreduction based on diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after completion of chemotherapy and before cytoreduction.
10163196|NCT03965442||Control|"Patients who underwent mastectomy under standard general anesthesia~Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump."
10163197|NCT03965442||Esmolol|Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
10163198|NCT03965455||conventional group|
10163199|NCT03965455||diode laser group|
10163200|NCT03965715|No Intervention|Gait analysis with barefoot|Participants walk without assistance under gait detection.
10163201|NCT03965715|Experimental|Gait analysis with AFOs|Participants walk with AFOs under gait detection.
10163202|NCT03965715|Experimental|Satisfaction questionnaire|User feedback from the participants was obtained by questionnaire, the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) and SF-36, to compare the satisfaction of AFOs
9974712|NCT05250349||HF + CS group|Patients with echocardiography - confirmed Heart Failure (HFmrEF and HFrEF) with NYHA I-III symptoms, who were diagnosed with flow limiting Carotid Stenosis on carotid Doppler ultrasound.
9974713|NCT05250349||Control group|A cohort of patients without Heart Failure or other significant cardiac pathology and without Carotid Stenosis (a paired propensity match will be performed).
10163203|NCT03965637|Experimental|vitamin C|Intervention patients will be received double dose of Ascorbic acid via intravenous injection
10163204|NCT03965637|No Intervention|Control|Control patients will not be received any intervention
10163205|NCT03965338|Other|fMRI brain activity|screening
10163206|NCT03965312|Experimental|Temperature monitoring (1) and incubator test (2) groups|"In the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours.~In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator."
10163207|NCT03965429||Donor|In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor.
10163208|NCT03965429||Receiver|Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used
10163209|NCT03965520|Active Comparator|usual training|exercise intensity arranged by cardiopulmonary exercise test results
10163210|NCT03965520|Experimental|Novel exercise training|exercise intensity monitor by near-infrared spectrometer
10163211|NCT03965299|Experimental|VERUM transcutaneous tibial nerve stimulation (TTNS)|
10163212|NCT03965299|Sham Comparator|SHAM transcutaneous tibial nerve stimulation (TTNS)|
10163213|NCT03965286||Patients with chronic HCV will be on direct antiviral drugs|is defined as the presence of detectable viral replication for at least six months diagnosed by quantitative HCV RNA polymerase chain reaction (PCR)
10163214|NCT03965104|Experimental|Intervention pharmacists|Will receive the HC-PCP prior to starting enrollment, and then will provide care to their patients, which will include risk assessment, prescribing of antihypertensive medications, and follow-up monthly according to the Hypertension Canada Guidelines.
10163215|NCT03965104|No Intervention|Control pharmacists|Will provide usual pharmacist care. All patients with blood pressure above target will be entered into the study database and serve as the control group. No specific interventions or follow-up will be mandated other than usual pharmacist care, although all patients will be assessed at 3 months to determine change in BP since enrollment (the primary outcome).
10163216|NCT03965117|Experimental|norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect.
10163217|NCT03965078||CMO without epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery without evidence of epiretinal membrane at the time of diagnosis.
10163218|NCT03965078||CMO with epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery with evidence of epiretinal membrane at the time of diagnosis.
10163219|NCT03965156|Active Comparator|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
10163220|NCT03965156|Active Comparator|transversus abdominis plane block|Ultrasound guided transversus abdominis plane block
10163221|NCT03965000||Patients|Patients carrying one or both mutations.
10163222|NCT03965000||Controls|Patients not carrying a mutation Familial renal glucosuria causing mutation in the SLC5A2 gene and without impaired glucose tolerance and type 1 or 2 diabetes mellitus.
10163223|NCT03965169|Experimental|Patients undergoing prone spinal surgery|Patients undergoing elective spinal surgery in prone position under general anesthesia, which is performed by neurosurgeons in Seoul National University Hospital
10163224|NCT03964961|Experimental|Functional massage|
10163225|NCT03964961|Active Comparator|Conventional massage|
10163226|NCT03964922|Experimental|immune escape mecanims|Cohort study with a representative sample of patients
10163227|NCT03965182|Active Comparator|PEG group|Patients in the PEG group were instructed to take the first sachet of PEG at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
10163228|NCT03965182|Active Comparator|PEG plus SPMC group|Patients in the PEG plus SPMC group will be instructed to take the SPMC sachet at 19:00 hours the day before colonoscopy and the PEG sachet at 6:00 hours on the morning of the day of colonoscopy.
10163229|NCT03965182|Active Comparator|SPMC group|Patients in the SPMC group were instructed to take the first sachet of SPMC at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
10163230|NCT03965065|Experimental|Sutureless Aortic Valve Prosthesis|Patients receiving sutureless aortic valve prostheses
10163231|NCT03965065|Active Comparator|Conventional Aortic Valve Prosthesis|Patients receiving conventional biological aortic prostheses
10163232|NCT03965247|Experimental|Lithium|Increasing amounts of lithium for 11 plus or minus 1 day. Day 1: 400 mg at night Day 2: 600 mg at night Day 3-11: 800 mg at night. The lithium intervention was prepared from 200mg Priadel prolonged release tablets. The intervention was provided in blue and white gelatine capsules to be taken orally.
10163233|NCT03965247|Placebo Comparator|Rayotabs|The placebo intervention was 200mg Rayotabs. The intervention was provided in blue and white gelatine capsules to be taken orally - same as the lithium intervention to maintain blinding.
10163234|NCT03964909|Experimental|Diagnostic (fMRI, CVR MRI, rs-fMRI)|Patients undergo standard of care fMRI, CVR MRI over 3 minutes, and rs-fMRI over 6 minutes 1 month before and within 6 weeks after standard of care surgery.
10163235|NCT03965143||3D talar group|Patients that will undergo a 3D custom talar augment
10163236|NCT03965208|Active Comparator|Unfractionated heparin|Patients randomized to this group will receive anticoagulation with unfractionated heparin
10163237|NCT03965208|Experimental|Bivalirudin|Patients randomized to this group will receive anticoagulation with bivalirudin
10163238|NCT03964935|Experimental|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After scaling, root planing, and polishing (SRP), the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
9977383|NCT01360931||Lung Cancer group|Subject with histological confirmation of lung cancer
10163239|NCT03964935|Active Comparator|Minocycline HCL|Minocycline HCL Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
10163240|NCT03964935|Placebo Comparator|Distilled water|Used to irrigate periodontal pockets after SRP
10163241|NCT03965013|Experimental|Part 1 (healthy): NNC0268-0965|A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin)
10163242|NCT03965013|Placebo Comparator|Part 1 (healthy): placebo|A single dose of placebo (NNC0268-0965) given s.c.
10163243|NCT03965013|Experimental|Part 2 (type 1 diabetes): NNC0268-0965|A single dose of NNC0268-0965 given s.c.
10163244|NCT03965013|Active Comparator|Part 2 (type 1 diabetes): insulin glargine|A single dose of insulin glargine given s.c.
10163245|NCT03964948|Other|Healthy Volunteers|20 healthy volunteers will be recruited and will receive a kidney MRI and the same blood and urine labs that are collected for the other arms. Results will be compared to the disease groups.
10163246|NCT03964948|Other|Kidney Transplant|20 subjects that have received a kidney transplant that have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
10163247|NCT03964948|Other|Stage 2-5 CKD|20 subjects that have been diagnosed with stage 2-5 CKD and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
10163248|NCT03964948|Other|Lupus nephritis|"20 subjects that have that have active lupus nephritis and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.~Subjects that are post-lupus treatment will receive an additional MRI at the time of the next biopsy."
10163249|NCT03965195|Experimental|RIV4|Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff
9977384|NCT01360931||Control group|Subjects with no diagnosis of lung cancer
9977385|NCT01360944|Experimental|LAS 41004, variant 1, once daily|variant 1, once daily
9977386|NCT01360944|Experimental|LAS41004, variant 2, once daily|variant 2, once daily
10163250|NCT03965195|Active Comparator|IV4|Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff
10163251|NCT03964896|Experimental|Supportive Care (telephone intervention)|During standard of care chemotherapy, patients receive up to 18 telephone calls from a nurse using a standardized triage call script over 20 minutes.
10163252|NCT03964844||CASE|Patients who had an episode of diarrhoea caused by C. difficile in an hematological unit (2003-2018)
10163253|NCT03964844||CONTROL|Patients who have had an episode of diarrhoea not caused by C. difficile in an hematological unit (2003-2018)
10163254|NCT03964844||PROSPECTIVE COHORT|All patients diagnosed with an hematological/oncological disease or with any immunosuppressive condition, who have a positive detection of toxigenic Clostridium difficile in 2019.
10163255|NCT03964753|Experimental|Neo-adjuvant chemotherapy group|"cisplatin and nab-paclitaxel: Nab-paclitaxel, 125mg/m(2), d1,d8, Cisplatin, 75mg/m(2), d1, 3 week, 2 cycles.~Surgery:~4-6weeks after Neo-adjuvant chemotherapy"
10163256|NCT03964753|Active Comparator|Surgery alone|Surgery alone
10163257|NCT03964805|Active Comparator|group A|Embryo culture at 20% O2
10163258|NCT03964805|Active Comparator|group B|Embryo culture at 5% O2
10163259|NCT03964805|Active Comparator|group C|Embryo culture at 5% O2 and at 20% O2
10163260|NCT03964675|Experimental|Respiratory rate measurement|Simultaneous measurement of respiratory rate using SenseGuard and Capnography
10163261|NCT03964623||smokers|
10163262|NCT03964623||vapers|
10163263|NCT03964623||non smokers/non vapers|
10163264|NCT03964636||no contraceptive intake|
10163265|NCT03964636||combined 1st/2nd generation oral contraceptives intake|
10163266|NCT03964636||3rd/4th generation combined oral contraceptives intake|
10163267|NCT03964519|Experimental|20% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 20% less compared to the first repetition.
10163268|NCT03964519|Experimental|40% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 40% less compared to the first repetition.
10163269|NCT03964519|Placebo Comparator|Control group|This group will be just tested as a control group.
10163270|NCT03964740|Experimental|Intervention|Mobile App intervention group
10163271|NCT03964740|No Intervention|Control Group|No intervention group
10163272|NCT03964857|Other|Refined olive oil (ROO)|Control
10163273|NCT03964857|Experimental|Blended Oil 1|BO1, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 2
10163274|NCT03964857|Experimental|Blended Oil 2|BO2, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 1
10163275|NCT03964766|Experimental|rotary instrumentation|endodontic treatment will be performed with the use of pedo rotary files that will be activated by engine
10163276|NCT03964766|Active Comparator|hand istrumentation|endodontic treatment will be performed with the use of conventional hand files
10163277|NCT03964779||Anovulatory women|40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility
10163278|NCT03964779||Tubal factor women|40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility
10163279|NCT03964779||male factor couple|40 women with exclusive male factor of infertility and will be used as a control group
10163280|NCT03964571|Experimental|Diabetic foot patients|
10163281|NCT03964662|Experimental|Patients with stroke|Rehabilitation of patients with stroke using a new technological device: WeReha
10163282|NCT03964389|Experimental|Intervetion group|"A sessions of Therapeutic Neuroscience Education (TNE) joint a physical exercises programs"
10163283|NCT03964389|No Intervention|Control group|Only a therapeutic physical exercises programs
10163284|NCT03964493|Experimental|TNP-2092|TNP-2092 300 mg intravenous every 12 hours
10163285|NCT03964493|Active Comparator|Vancomycin|vancomycin 1 g intravenous every 12 hours
10163286|NCT03964558|Other|100 mg [14C]-acebilustat|a single oral dose of 100 mg [14C]-acebilustat
10163287|NCT03964467|Experimental|Experimental|Transcranial Direct Current Stimulation.1) Scalp measurements of the scalp will be taken using the 10-20 EEG measurement system to determine anode and cathode placement. 2) One 1x1 Bicarbon electrode with wires attached will be placed in the center of each 5 cm x 7 cm sponge electrode dampened with 8 ml of saline. 3) One sponge electrode will be placed over the ipsilesional PMd (F3) and the other sponge electrode over the contralesional supraorbital region(Fp2). 4) Each sponge electrode will be secured under the plastic EZ strap 5) The current from the Actividose II will be turned up to 2 MA. The current will ramp up/down in 15 seconds. We will observe for adverse effects and hit the pause button, then turn the machine off, if a participant does not tolerate the stimulation. Individuals in this arm will have the stimulation stay in current until the full dose is delivered. Each participant will then engage in the UE TRT as outlined below.
10163288|NCT03964467|Sham Comparator|Control|Individuals in this arm will have the stimulation cycled off after 2-3 minutes. All will be part of the Circuit-Based, UE Task Related Training. Each participant will engage in the training program for 1.5 hours; rotating through 5 stations at about 15 minute intervals, participating in standing as tolerated, but stations can be adapted to sitting. The goal is for each participant perform > 225 movements with the affected arm per session, at the highest functional level. Rest breaks given as needed. Examples of stations are: Reach-to-grasp tasks to objects of various weight, texture and dimension at different distances and table heights. Practice opening simulated locks and containers. Shoulder wheel involving grasping plastic plates with varied grip patterns and sliding them up and over the wheel from the unaffected to the affected side encouraging shoulder abduction, external rotation and supination. Bimanual/unimanual ball toss: catching, releasing.
10163289|NCT03964376|Experimental|Nasal High Flow Group|Nasal High-Flow oxygen delivery will be applied starting at airflow of minimum 20 Litre/minute. It will be titrated in 15Litre/minute increments to 35 Litre/minute and a maximum 50 Litre/minute as determined by patient comfort. O2 supplementation will be managed by the anesthesia and surgical health care team to maintain the oxygen saturation level in the blood between 92-95%. In the Nasal High-Flow group, when SPO2 is in the range of 92-95%, air will be given instead of oxygen for the 1st 3 nights and during the day, if required, till discharge, whichever is earlier.
10163290|NCT03964376|Other|Usual Care Group|In the usual care, patients will receive oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via facemask titrated to keep SpO2 level in the range of 92-95%. When SpO2 level reaches in the range of 92-95%, oxygen delivery will be discontinued.
10163291|NCT03964363|Experimental|Prehabilitation|Participants are scheduled for elective surgery and follow the home-based prehabilitation for 11-17 days
10163292|NCT03964363|Experimental|Prehabilitation + TAVI|Study participants who will undergo a TAVI form a subgroup with a modified enrolment procedure and longer duration of the intervention. The prehabilitation period is extended to 30 days.
10163293|NCT03964363|No Intervention|Control|Participants are initially evaluated for frailty prior to scheduled surgery but subsequently receive regular care without a prehabilitation program. All pre- and postsurgical evaluations will be identical to the prehabilitation group.
10163294|NCT03964363|No Intervention|Control+TAVI|The subgroup of participants who undergo a TAVI will be compared to a group of patients who will have had the same procedure. Hence the control group will also receive a screening via phone but then receive regular care. Follow-up after surgery will be identical in all groups.
10163295|NCT03964350|Experimental|Ethanol|Subjects will receive ethanol (0.4 or 0.8 g/kg) which will be administered in a gelatin vehicle.
9671414|NCT05048953||MRC GROUP|All newly admitted patients (shifted to ICU within 48 h of hospital admission), aged ≥ 16 years and expected to stay in ICU or critical care areas for 7 days will be included in the study after excluding those who fulfill excluding criterial. In all the participants, muscle strength will be assessed at day 1, day 4 and day 7, if the patients are awake as assessed by Richmond Agitation Sedation Scale (RASS) (19) between -1 and 1, and cooperative (20) assessed by being able to follow at least 3 out of 5 verbal commands with facial muscles (scored by the Score of 5 Questions). Assessment will be done by an ICU physician blinded to the result of ultrasound. The MRC score will be used for assessment of strength in the following six muscle groups bilaterally: wrist dorsiflexors, elbow flexors, shoulder abductors, hip flexors, knee extensors and ankle dorsiflexors. ICU-AW will be defined as MRC sum score < 48, in accordance with the international consensus statement.(1)
9671415|NCT05048953||Muscle ultrasound measurements (the index test)|"Muscle ultrasound will be performed by an ICU faculty or a DM resident of Critical care medicine (who has an experience of at least 25 muscle ultrasonography with at least 10 muscle ultrasonography performed under supervision) (21) and will be blinded to the result of MRC score of the patient. Muscle ultrasound images on day 1, day 4 and day 7 will be obtained in the participants.~The following parameters will be measured by muscle ultrasound~Muscle thickness~Muscle echogenicity~Muscle fasciculations Muscle thick"
9671416|NCT05048706|Experimental|Super Pulse Thulium fiber Laser|
9671417|NCT05048706|Active Comparator|Holmium: Yttrium-Aluminium-Garnet Laser|
9671418|NCT05048771||FERTITOP|300 patients (15-25 years) from 5 different hospitals (University Hospitals of Nancy, Strasbourg, Reims, Besançon, Dijon (France)) who have finished all cancer treatments for at least 2 years.
9671419|NCT05048940|Experimental|HETEROLOGOUS VACCINE|COVID-19 Vaccine Janssen, injectable suspension
9671420|NCT05048940|Active Comparator|HOMOLOGOUS VACCINE|Spikevax (Moderna), injectable dispersion
10163296|NCT03964350|Placebo Comparator|Placebo (gelatin vehicle)|Subjects will receive placebo of black cherry sugar-free jello.
10163297|NCT03964441||control|fetus with at least 2 ultrasound abnormalities and both parents
10163298|NCT03964441||comparison|fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling
10163299|NCT03964441||professional|obstetrician, midwife, geneticist, biologist
10163300|NCT03964285|Active Comparator|Rumination group|The patients will receive rumination induction. Rumination induction will follow a relevant activity for our patients: climbing steps. Rumination induction will be done right after climbing the steps.
10163301|NCT03964285|Experimental|distraction group|Distraction will follow a relevant activity for our patients: climbing steps. Distraction induction will be done right after climbing the steps.
10163302|NCT03964272|Experimental|ExAblate 4000 System|Exablate bilateral treatment for Parkinson's Disease Motor Features
10163303|NCT03964324|Experimental|Severe snorers|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are noninvasive.
10163304|NCT03964181||Students Grades 3-12|
10163305|NCT03964181||Parents of Students Grades K-12|
10163306|NCT03964181||School Based Teachers and Staff Grades K-12|
10163307|NCT03964103|Experimental|gQ-lab daily|
10163308|NCT03964103|Placebo Comparator|Placebo|
10163309|NCT03964259|Active Comparator|Standard Hydration Regimen|In the standard intravenous fluid (IVF) protocol, following completion of HDMTX infusion, post HDMTX IVF will be initiated at 125 mL/m2/hr (no maximum mL/hr total rate).
10163310|NCT03964259|Experimental|Reduced hydration regimen|The reduced intravenous fluid (IVF) protocol, post HDMTX IVF will be initiated at 62.5 mL/m2/hr following completion of HDMTX infusion.
10163311|NCT03964155|Experimental|Patients with SDRA|Patients within 24 hours from meeting the Berlin criteria for moderate or severe ARDS and receiving inhaled sedation with sevoflurane
10163312|NCT03963882|Experimental|Group A|Patients in group A don't receive neoadjuvant chemotherapy
10163313|NCT03963882|Experimental|Group B|Patients in group B receive neoadjuvant chemotherapy and achieve imaging response
10163314|NCT03963882|Experimental|Group C|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy
10163315|NCT03963882|Experimental|Group D|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy
10163316|NCT03964025|Experimental|Cardioskin™ and 3-lead Holter recorder|This is single-arm study. All subjects will receive the investigational device (Cardioskin™) and comparator device (3-lead Holter recorder).The subject will be wearing both the Cardioskin™ and 3-lead Holter recorder for a period of 24 hours, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
10163317|NCT03964168||Biologic Therapy|Patient's who received and discontinued a biologic therapy
10163318|NCT03964038|Active Comparator|gilteritinib|Participants will receive a single dose of gilteritinib under fasting conditions.
10163319|NCT03964038|Experimental|gilteritinib mini-tablet oral suspension|Participants will receive a single dose of gilteritinib oral suspension with water under fasting conditions.
10163320|NCT03964038|Experimental|gilteritinib mini-tablet|Participants will receive a single dose of gilteritinib mini-tablets under fasting conditions.
10163321|NCT03963934|Experimental|Women with uncontrolled hypertension|Women with uncontrolled hypertension and unsatisfactory medication adherence
10186419|NCT03735706|Active Comparator|Control group - 120 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.~The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV."
9671421|NCT05048966|Experimental|Group Wellness Class 1|
9671422|NCT05048966|Active Comparator|Group Wellness Class 2|
9977387|NCT01360944|Experimental|LAS41004, variant 3, once daily|variant 3, once daily
10163322|NCT03964129|Experimental|Avance Nerve Graft with autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested . Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained.
10163323|NCT03963986|Active Comparator|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
10163324|NCT03963986|No Intervention|STANDARD group|The STANDARD group participants dont receive an access to an online digital platform but they receive an adapted advice sheet.
10163325|NCT03964116|Other|AYA|Questionnaires set all 3 months and psychological interviews if needed
10163326|NCT03963726|Experimental|Stereotactic radiotherapy|In this study, the liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
10163327|NCT03963726|Experimental|Microwave ablation therapy|In this study, 3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
10163328|NCT03964012|Experimental|NmCV-5|"Subjects in this arm will receive polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~A single dose of 0.5 mL will be administered intramuscularly."
10163329|NCT03964012|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~A single dose of 0.5 mL will be administered intramuscularly."
10163330|NCT03963921|Experimental|F4 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
10163331|NCT03963921|Experimental|F3 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
10163332|NCT03963973|Experimental|RDN-929|low, medium and high dose of RDN-929 capsules
10163333|NCT03963973|Placebo Comparator|Placebo|Matching placebo capsules
10163334|NCT03964051|Experimental|Omalizumab 300 mg for s.c.injection|Omalizumab 300 mg steril solution in prefilled syringes are administrated every 2. week for 12 weeks
10163335|NCT03963713|Experimental|Stereotactic radiotherapy|"In this study, the metastases were treated with Stereotactic radiotherapy（SBRT）.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).~Stereotactic radiotherapy"
10163336|NCT03963713|Experimental|Conventionally-fractionated image- guided Intensity modulated|In this study, the metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
10163337|NCT03963999|Experimental|Patients Undergoing HCT|All patients enrolled will undergo grayscale US, Doppler US, US SWE and CEUS at specific time points as outlined in the protocol based on disease course.
10163338|NCT03963765|Active Comparator|Group I (Standard DL-PDT)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
10163339|NCT03963765|Experimental|Group II (DL-PDT with microneedles)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
10163340|NCT03963765|Experimental|Group III (DL-PDT with CO2 laser)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass~A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
9520237|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
10163341|NCT03963765|Experimental|Group IV (DL-PDT with microdermabrasion)|"Superficial skin curettage all face with a dermatological curette~Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
10163342|NCT03964064|Experimental|I125 Seed Implantation|3D-printing Template-assisted CT-guided I125 Seed Implantation Prescription dose: gtv140-160gy ctv100-140gy Particle activity: 0.4-0.5mCi
10163343|NCT03964064|Experimental|Stereotactic Radiotherapy|According to the tumor volume, location, organ function and other factors, the dosage of stereotactic directional radiotherapy was determined. The range of BED value of radiotherapy was 80-100 for tumors above 5 mm from gastrointestinal tract and 60-80 for tumors below 5 mm from gastrointestinal tract.
10163344|NCT03963752|Experimental|Ziyinxiehuo Granules and Megestrol Acetate|Experimental：Group Ziyinxiehuo Granules and Megestrol Acetate Tablet Intervention :Subjects in Group Ziyinxiehuo Granules and megestrol acetate tablet will be treated with Ziyinxiehuo Granules and megestrol acetate tablet for 6 months.1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Ziyinxiehuo Granules is administered after dissolved,1pack every time, 2 times per day after a meal; and the dosage of megestrol acetate is 6-8mg/d, which is taken in 3 times after a meal.
10163345|NCT03963752|Active Comparator|Gonadotrophin|Active Comparator: Group Gonadotrophin Intervention: Subjects in Group Gonadotrophin will be treated with gonadotrophin releasing hormone agonist for 6months. In our study Leuprorelin Acetate 3.75mg Injection will be applied, the dosage of which is 80μg/kg every time by subcutaneous injection, every 4 weeks for once.
10163346|NCT03963635||Lyme Infected|Subjects presenting with suspected Lyme Disease
10163347|NCT03963635||Controls|Subjects with no known Lyme Disease, past or present
10163348|NCT03963661|Experimental|c-SIGHT|SIGHT requires participants to grasp and lift rods with their less impaired arm.
10163349|NCT03963817||Normals|Imaging normal subjects for equipment refinement
10163350|NCT03963817||Subjects with AMD|Imaging subjects with AMD
10163351|NCT03963687|Active Comparator|Control Group|Participants will receive the Standard Nursing Education Intervention first
10163352|NCT03963687|Experimental|Intervention Group|Participants will receive the New Nursing Education Intervention first
10163353|NCT03963804||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
10163354|NCT03963804||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
10163355|NCT03963791|Experimental|Eggshell powder gel|prepared from eggshell powder. applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
10163356|NCT03963791|Active Comparator|CPP-ACP crème|CPP-ACP crème (GC Tooth Mousse). applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
10163357|NCT03963596|Active Comparator|Ranibizumab|Arm 1
10163358|NCT03963596|Active Comparator|Aflibercept|Arm 2
10163359|NCT03963648|Experimental|CRSwNP|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are non-invasive.
10163360|NCT03963375|Other|Group 1: LP at Baseline and Week 5|Group 1: LP at Baseline and end of Week 5. Week 5 is the optimal time point for assessing cladribine concentrations in CSF
10163361|NCT03963375|Other|Group 2: LP at Baseline and Week 10|"Group 2: LP at Baseline and end of Week 10. Week 10 is the expected nadir time for lymphocyte and monocyte levels in CSF"
10163362|NCT03963375|Other|Group 3: LP at Baseline and End of Year 1|Group 3: LP at Baseline and end of Year 1. To assess if cladribine effects on CSF markers are maintained at the end of the first treatment cycle
10163363|NCT03963375|Other|Group 4: LP at Baseline and End of Year 2|Group 4: LP at Baseline and end of Year 2. To assess if cladribine effects on CSF markers are maintained at the end of the last treatment cycle
10163364|NCT03963258|Active Comparator|control group|Over a 3-week period, the subjects in the control group received 1 hour daily of conventional upper limb training 5 times a week,including compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
10163365|NCT03963258|Experimental|whole-body vibration group|Subjects in the whole-body vibration group received half an hour of daily conventional upper limb training, followed by whole-body vibration training for an additional half hour per day,5 days per week during a 3-week period
10163366|NCT03963674|Experimental|Diacutaneous fibrolysis|
9520238|NCT03279354|Experimental|Intervention group|Family Move app intervention
9520239|NCT03279354|Placebo Comparator|Control group|"HK FitNuts app intervention"
9520240|NCT03279341|Active Comparator|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
10163367|NCT03963674|No Intervention|Control|
10163368|NCT03963466|Experimental|group 1|(left side of cheek) 1064-nm Q-Switched fractional laser+drug Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
10163369|NCT03963466|Experimental|group 2|(right side of cheek) 1064-nm Q-Switched laser+drug Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
10163370|NCT03963466|Experimental|group 3|(left side of cheek) 1064-nm Q-Switched fractional laser Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24
10163371|NCT03963466|Experimental|group 4|(right side of cheek) 1064-nm Q-Switched laser Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24
10163372|NCT03963323|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
10163373|NCT03963323|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
10163374|NCT03964142|Experimental|Cardiac Rehabilitation|Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
10163375|NCT03964142|No Intervention|Conventional management|Patients with conventional management and physical activity recommendation
10163376|NCT03963219|Experimental|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
9671423|NCT05048901|Experimental|Cabozantinib and Lanreotide|Oral cabozantinib 40-60 mg/day and lanreotide 120mg deep subcutaneous injection (SC) in day 1 every 4 weeks.
10163377|NCT03963219|Active Comparator|Standard Bolus Calculator|Standard bolus calculator
10163378|NCT03963440|Experimental|Cohorte 1|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
10163379|NCT03963479|Active Comparator|Magnesium-Vitamin B6|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
10163380|NCT03963479|Placebo Comparator|Placebo|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
10163381|NCT03963492|Active Comparator|Continuous Walking|Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks
10163382|NCT03963492|Experimental|Interval Walking|Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk
10163383|NCT03963336|Active Comparator|Group A|12 IIH patients for whom serum D-dimer was assessed by ELISA.They received acetazolamide and anticoagulant LMWH in the prophylactic dose for 2 weeks then continued on acetazolamide. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
10163384|NCT03963336|Active Comparator|Group B|12 IIH patients for whom serum D-dimer was assessed by ELISA. They received acetazolamide only. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
10163385|NCT03963336|No Intervention|Control group|24 healthy subjects for whom serum D-dimer was assessed by ELISA.
10163386|NCT03963089|Experimental|Study group|"Measure pulse pressure variation and systolic pressure variation after each set of tidal volume to 6mL/kg, 10mL/kg and 14mL/kg. Measure respiratory variation of aortic blood flow peak velocity via transesophageal echocardiography at tidal volume of 10mL/kg.~Measure stroke volume index via transesophageal echocardiography before and 5 min after fluid loading with 10mL/kg of crystalloid."
10163387|NCT03963271||Patients with unexplained polymorphic VT and/or VF|"Unexplained polymorphic VT and/or VF patients.~Patients with VF and the DPP6 risk haplotype, reported by the AUMC team.~The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+"
10163388|NCT03963271||Family members|Family members of index patients of group(s) mentioned above
10163389|NCT03963271||Control group|Control subjects with structurally normal hearts with an indication for a cardiac CT,
10163390|NCT03963570|Experimental|Safe Step - digital exercise program|Participants randomized to the experimental group will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
10163391|NCT03963570|Other|Control group|During 1 year, the participants randomized to the control group will receive an email every month with general falls prevention information in a short video.
9974714|NCT05250336||Patients with Primary Breast Cancer|"The pretherapeutic cores or specimen from patients who meet the following criteria were subjected for analysis~INCLUSION CRITERIA Primary Breast cancer Completed scheduled treatment at SGPGI Adequate quality histopathology material available in Department of Pathology archives With minimum 6 months follow up~EXCLUSION CRITERIA Insufficient data Incomplete treatment Insufficient follow up information Insufficient histological material for review"
9520241|NCT03279341|Active Comparator|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
10163392|NCT03963193|Experimental|Etoposide plus Cisplatin|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
10163393|NCT03963193|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
10163394|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 60~89 mL/min|Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)
10163395|NCT03963362|Experimental|Administration of GLA5PR 75 mg over 90 mL/min|Administration of GLA5PR 75 mg over 90 mL/min(CLcr)
10163396|NCT03963362|Experimental|Administration of GLA5PR 150 mg as 60~89 mL/min|Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)
10163397|NCT03963362|Experimental|Administration of GLA5PR 150 mg over 90 mL/min|Administration of GLA5PR 150 mg over 90 mL/min(CLcr)
9974715|NCT05250323||Case|Patients with genetic confirmation of Huntington's disease, symptomatic (motor manifestations with a score greater than 4 on the Unified HD scale), who can walk with minimal support, without sensory deficits or other systemic diseases an Investigator judgment that may interfere with the execution of the study, coming from the Enroll study.
10163398|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 30~59 mL/min|Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)
10163399|NCT03963245|Experimental|Intervention group|MA&R - an eight months rehabilitation intervention in addition to standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
10163400|NCT03963245|Active Comparator|Control group|Standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
10163401|NCT03963154|Experimental|Implantation of a therapeutical patch|All the patients will receive a single central subretinal implantation in one eye of a monolayer of Human Embryonic Stem Cells-derived Retinal Pigmented Epithelium (hESC-derived RPE). The implanted eye will be the one with the worst visual acuity.
10163402|NCT03963180|No Intervention|control group|the control group received 3 cups hot water on the 6th, 12th and 18th hours after the operation
10163403|NCT03963180|Experimental|study group|drank 3 cups of caffeinated coffee on the 6th, 12th and 18th hours after the operation.
10163404|NCT03962933|No Intervention|Flexcystoscopy|Control cystoscopy every 3 months as a standard procedure
10163405|NCT03962933|Active Comparator|Uine biomarker|Urine test every 3 months
10163406|NCT03962985|Other|Intervention|The 41 participants will attend the guided tours at the Montreal Museum of Fine Arts.
10163407|NCT03963557||Healthy participants|BMI 5th percentile to less than the 85th percentile
10163408|NCT03963557||Overweight/Obese participants|BMI 85th percentile or more
10163409|NCT03963115|Active Comparator|Coated syringe with epinephrine|Epinephrine was coated syinge before drawing the allergen to filled in.
10163410|NCT03963115|Placebo Comparator|placebo|Normal saline was coated syinge before drawing the allergen to filled in.
10163411|NCT03963024|Experimental|Single Arm Treatment|"Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;"
10163412|NCT03963076|Experimental|allergic rhinitis|administration of a nasal hypertonic spray twice a day for one month
10163413|NCT03963128|Active Comparator|Supplemented Vitamin D3|
10163414|NCT03963128|Placebo Comparator|Placebo|
10163415|NCT03963050|Experimental|CF|30 participants (randomized in 3 groups) with CF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
10163416|NCT03963050|Experimental|PF|30 participants (randomized in 3 groups) with PF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
10163417|NCT03963102|Active Comparator|Control Group 3 hours|Application of Ameluz for 3 hours.
10163418|NCT03963102|Experimental|Trial Group 4 hours|Application of Ameluz for 4 hours.
10163419|NCT03963167||Patient in treatment with BDP/FF/G fixed combination|
10163420|NCT03963037||Patients|The family members of our two kindreds who carry the truncating mutation in the Apolipoprotein B gene.
10163421|NCT03963037||Controls|The family members of our two kindreds who are no carriers of the truncating mutation in the Apolipoprotein B gene.
10163422|NCT03962881|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
10163423|NCT03962881|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
10163424|NCT03962881|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
10163425|NCT03962920|Active Comparator|Surgical treatment + antibiotics|Use antibiotic
10163426|NCT03962920|Placebo Comparator|surgical treatment + placebo|Use placebo
10163427|NCT03962907|Experimental|Carrier group - intervention|BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
10163428|NCT03962907|No Intervention|Carrier group - control|
10163429|NCT03962907|Experimental|Non - carrier group - intervention|Lifo-Scrub sol 4%®, 500ml, B. Braun
10163430|NCT03962907|No Intervention|Non - carrier group - control|
10163431|NCT03962842|Experimental|Pilates group|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
10163432|NCT03962842|No Intervention|Control group|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
10163433|NCT03962660|Experimental|HaRTS-TRENDS|See description below.
10163434|NCT03962660|Active Comparator|Standard Care (SC)|See description below.
10163435|NCT03962582|Experimental|Supportive Back Comparison|Motion Concepts matrx back to be attached to individual's wheelchair in place of the individual's back. It will be adjusted for size and to support the spinal curves as compared to a fabric back
10163436|NCT03962517|Experimental|Training with GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with the device."
10163437|NCT03962517|Active Comparator|Training without GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments without the device."
10163438|NCT03962478|Experimental|Stent with high-intensity focused ultrasound ablation|Patients undergo stent insertion with high-intensity focused ultrasound ablation on day 1.
10163439|NCT03962478|Active Comparator|Stent without high-intensity focused ultrasound ablation|Patients undergo stent insertion on day 1.
10163440|NCT03962829|Placebo Comparator|Placebo condition|Participants receive placebo capsule
10163441|NCT03962829|Active Comparator|mCPP condition|Participants receive active (mCPP) capsule
10163442|NCT03962699||Obese patients selected for bariatric surgery|Normospermic obese patients ((BMI>40), aged 20-50 years) who will undergo Bariatric surgery.
10163443|NCT03962699||Control Group: Non obese volunteers|Normospermic obese patients ((BMI>40), aged 20-50 years
10163444|NCT03962764||Incarcerated|Incarcerated fathers include fathers recruited in re-entry centers, detention facilitation and in county jails.
9671424|NCT05048615|Experimental|Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine|Patients will recieve Low-dose Venetoclax at a dose of 100mg/day por 21 days, oral itraconazol 100mg every 12 hours, and subcutaneous Azacitidine 75mg/m2 (maximun dose 100mg) daily for seven days. Each cycle duration is 21 days and patients will recieve a maximun of two cycles.
10163445|NCT03962764||Community|Community fathers include fathers who are recruited through community partners and self-referrals.
10163446|NCT03962751|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
10163447|NCT03962751|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
10163448|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
10163449|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
10163450|NCT03962751|No Intervention|Baseline Assessment Only|Participants complete baseline survey and conclude participation.
10163451|NCT03962452|Other|Mitochondrial disease|Unresolved index patients with suspected mitochondrial disease
10163452|NCT03962712||Low-Wage Workers from Minneapolis, MN|Low-wage workers from Minneapolis, MN, where the minimum wage will be increased to $15-an-hour over the study period.
10163453|NCT03962712||Low-Wage Workers from Raleigh, NC|Low-wage workers from Raleigh, NC, where the minimum wage will not be significantly changed over the study period.
10163454|NCT03962647|Experimental|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
10163455|NCT03962647|Active Comparator|Letrozole Control|
10163456|NCT03962725|Active Comparator|Control Group (C)|Endotracheal intubation would be facilitated by either Rocuronium (0.6-1mg kg-1) or Succinylcholine (1-1.5mg kg-1) and further dosing of Rocuronium would be left at the discretion of the anesthesia team members. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Neuromuscular blockade would be reversed with either Sugammadex or Neostigmine (based on institutional availability) and trachea would be extubated once patient meets criteria per attending anesthesiologist.
9671425|NCT05048823|Experimental|Intervention Protocol|Visceral techniques for the gastrointestinal system
10163457|NCT03962725|Experimental|No Relaxant Group (NR)|Endotracheal intubation would be facilitated by Succinylcholine (1-1.5mg/kg) or Remifentanil (1-2mcg kg-1) if Succinylcholine use is contraindicated. No non-depolarizing NMBA would be administered to the patients randomized to the NR group. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine) either as boluses or infusion would be recommended in case of sustained high peak airway pressures (>35mm Hg), high intra-abdominal pressure, involuntary patient/diaphragmatic movement hindering surgical exposure and dissection. Choice and dose of adjunct/s to optimize operating conditions would be left to the discretion of the anesthesia team.
10163458|NCT03962777|Experimental|oil pulling|patients used oil pulling therapy for 4 days
9671426|NCT05048823|Sham Comparator|Placebo Protocol|simulated visceral techniques in the region of the gastrointestinal system, without therapeutic intent
9671427|NCT05048537|Other|18F-FACBC PET/CT and the PSA kinetics for PCa patients with BCR.|
9974716|NCT05250323||Control|Age, gender-matched non-gene carriers family relatives
9974717|NCT05250310|Active Comparator|Yoga|Patients randomized to Yoga arm will practice chair yoga for 30 minutes at least three days a week for 16 weeks
9974718|NCT05250310|No Intervention|Standard of Care|Control group patients will follow standard of care (SOC) treatment.
10163459|NCT03962777|Active Comparator|chlorhexidine|patients used chlorhexidine digluconate for 4 days
10163460|NCT03962803|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
10163461|NCT03962803|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
10163462|NCT03962803|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
10163463|NCT03962816|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
10163464|NCT03962816|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
10163465|NCT03962816|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
10163466|NCT03962413|Active Comparator|The middle meatal antrostomy approach.|"The middle turbinate will be gently moved medially. Then uncinectomy is the next step which will be performed in numerous ways. Once the natural ostium will be identified, an ostium seeker will be placed through the ostium and then carefully will be pushed posteriorly to widen the ostium.~Using a through-cutting forceps, the ostium will be enlarged."
10163467|NCT03962413|Active Comparator|The endoscopic prelacrimal recess approach|A curved incision will be made between the anterior aspect of the IT and the posterior end of the nasal vestibule.the mucoperiosteum will be lifted posteriorly.Bone removal will be achieved. the anterior bony portion of the medial wall of the MS will be removed, .then the IT-NLD flap will be formed.The prelacrimal recess will be opened
10163468|NCT03962413|Active Comparator|The canine fossa approach.|"It will be done either transnasally or transorally:~** The transoral approach through a sublabial incision : CFA consist in a trocar placed in the canine fossa.After removal of the trocar a 4-mm microdebrider blade will be placed through the passage created by the trocar.~** The transnasal approach: A curved incision will be made between the anterior aspect of the Inferior Turbinate and the posterior end of the nasal vestibule,the mucoperiosteum will be lifted posteriorly Then the investigators will reach the anterior wall of the maxillary sinus through bone removal which will be achieved using a gauch and hammer and a high-speed electric drill."
10163469|NCT03962556||Non-Trigger Point|
10163470|NCT03962556||Trigger Point|
10163471|NCT03962673|Experimental|UVB- exposure|Each participant will receive a pre-determined dose of UVB light. Serum Vitamin D and microbiome samples of each participant will be compared before and after the UVB light exposures.
10163472|NCT03962491|Other|Daily Self-Monitoring Surveys|Asked to complete daily self-monitoring surveys.
10163473|NCT03962491|Experimental|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete daily self-monitoring surveys, with opportunity for monetary rewards.
10163474|NCT03962387||Atopic Dermatitis|
10163475|NCT03962374|Experimental|Frova|Frova will be used to facilitate the endotracheal intubation.
10163476|NCT03962374|Active Comparator|Stylet|Stylet will be used to facilitate the endotracheal intubation.
10163477|NCT03962439|Experimental|High-Demand Photography|A structured, high-demand photography course targeting 210 hours of engagement over 16 weeks.
10163478|NCT03962439|Active Comparator|Moderate-Demand Photography|A structured, moderate-demand photography course targeting 210 hours of engagement over 16 weeks.
10163479|NCT03962439|Placebo Comparator|At-Home Engagement Group|Participation, alone at home, in tasks that are relatively low in intellectual engagement.
10163480|NCT03962426|Active Comparator|Social Cognitive Training (SCT)|10 hours of computerized SCT using tablet with 30-minute sessions, 4-5 times per week
10163481|NCT03962426|No Intervention|Treatment as usual (TAU)|This arm is getting treatment as usual, meaning antipsychotic medication (any needed medication in general) and psychotherapy/occupational therapy
9671428|NCT05048550|No Intervention|A (control)|First visit assessments at 8 weeks corrected gestational age. No glasses prescribed.
9974719|NCT05250271|Other|Treatment sequence 1|Sequence of the treatments: Glucose (15g) - Glucose (5g) -Protein bar
10163482|NCT03962686||normoglycemics|In this cohort will be enrolled 30 normoglycemics patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
10163483|NCT03962686||patients with diabetes mellitus (DM) treated with metformin|In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
10163484|NCT03962686||patients with diabetes mellitus (DM) treated with metformin plus SLGT2i|In this cohort will be enrolled 20 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. These patients were treated before the surgical intervention by metformin 1000 mg daily (n 20) added to SLGT2i, 100 mg daily (n 30).
10163485|NCT03962361||Sudden cardiac death of ischemic cause|Patients admitted to the Coronary Care Unit for sudden cardiac death of ischemic cause and remain comatose (GCS < 8 points).
10163486|NCT03962621|Active Comparator|2940 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
10163487|NCT03962621|Active Comparator|1064 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 1064 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
10163488|NCT03962621|Experimental|Combined treatment group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm or 1064 nm laser (Fotona, Slovenia, EU) alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
10163489|NCT03962348|Experimental|Targeted Educational Campaign (TEC) for Correction Officers|The investigators will implement a Targeted Educational Campaign (TEC) within 3 jails at New York City's Rikers Island. The TEC is designed to lead to referrals of detainees (previously not detected as having potential mental health concerns) to Correctional Health Services (CHS) by Correction Officers.
10163490|NCT03962348|Experimental|Specialized Early Engagement Team|The investigators will implement a Specialized Early Engagement Team (SEET) in the same three jails. The SEET will increase the likelihood that referred individuals found to have first-episode psychosis enroll in Coordinated Specialty Care upon release.
10163491|NCT03962322|Experimental|Weaning TDI|A tissue doppler evaluation, using a sector transducer, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration in the modality of ventilation which precedes the trial, during the SBT and after extubation.
10163492|NCT03962075|Other|laparoscopic paravaginal repair|"patient enrolled in this arm were offered laparoscopic paravaginal repair by Using a 10mm laparoscope, video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique All cases received diclofenac potassium 100 mg and meperidine hydrochloride 50 mg intramuscular with anesthesia recovery and 12 hours later second dose of diclofenac potassium was given. Also 40-60 mg Enoxaparin was given 6-12 hours postoperatively as subcutaneous injection.~Foley's catheter was removed 6 hours postoperative"
10163493|NCT03962205|Experimental|Cognitive Behavioral life-style and well-being intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification and then 4 group-based 2-hour weekly sessions of the well-being intervention in addition to the treatment as usual.
10163494|NCT03962205|Placebo Comparator|Cognitive Behavioral life-style intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification in addition to the treatment as usual.
10163495|NCT03961984||Complex anal fistula|Patients with complex transsphincteric anal fistulas were treated with Biodesign® plug.
10163496|NCT03962114|Experimental|Intervention group|treatment with vitamin B3
10163497|NCT03962296|Experimental|Entelon|Three daily oral doses of 50mg tablets were administered to patients
10163498|NCT03962296|Active Comparator|Doxium|Three daily oral doses of 250mg tablets were administered to patients
10163499|NCT03962296|Placebo Comparator|Placebo|Three masking tablets were administered to patients
10163500|NCT03962283|Active Comparator|Rifaximin|ASA daily + misoprostol + Rifaximin (Rifaximin group)
10163501|NCT03962283|Placebo Comparator|Rifaximin Placebo|ASA daily + misoprostol + Placebo Rifaximin (Placebo group)
10163502|NCT03962010|Experimental|Dose level 1|
10163503|NCT03962010|Experimental|Dose level 2|
10163504|NCT03962010|Experimental|Dose level 3|
10163505|NCT03962010|Experimental|Dose level 4|
10163506|NCT03962010|Placebo Comparator|Placebo|
10163507|NCT03962010|Active Comparator|Dulaglutide|
10163508|NCT03962218|Experimental|Early Aquatic Therapy (EAT)|Aquatic physiotherapy treatment at time 1 (week 1)
10163509|NCT03962218|Other|Late Aquatic Therapy (LAT)|Control for Group 1 for the 5 first weeks of Group 1 treatment. Aquatic physiotherapy treatment at time 2 (week 6).
10163510|NCT03962192|Experimental|Survey tools|Survey instruments are shared with reviewers.
10163511|NCT03961867|Experimental|DS|D2 resection -- S1 * 1 cycle + DS * 6 cycles + S1 * 9 cycles
10163512|NCT03961867|Active Comparator|SOX|D2 resection -- SOX * 8 cycles + S1 * 8 cycles
10163513|NCT03962179|Experimental|VACStent Group|Patient s who received a VACStent
10163514|NCT03962244||SEMS Group|The outcome of using self-expanding metal stents (SEMS) in the treatment of postoperative leakage after esophagogastrostomy
10163515|NCT03962244||EVT Group|The outcome of using endoscopic vacuum therapy (EVT) in the treatment of postoperative leakage after esophagogastrostomy
10163516|NCT03962270|Experimental|Treatment group|
10163517|NCT03962270|Sham Comparator|Control group|
10163518|NCT03962049|Experimental|Normal Hepatic Function|Healthy participants with Normal Hepatic Function
10163519|NCT03962049|Experimental|Mild Hepatic Impairment|Presence of Mild Hepatic Impairment (score of 5 to 6, on the Child Pugh scale and with features of cirrhosis due to any etiology)
10163520|NCT03962049|Experimental|Moderate Hepatic Impairment|Presence of Moderate Hepatic Impairment (score of 7 to 9, on the Child Pugh scale and with features of cirrhosis due to any etiology)
10163521|NCT03962049|Experimental|Severe Hepatic Impairment|Presence of Severe Hepatic Impairment (score of 10 to 15 on the Child Pugh scale and with features of cirrhosis due to any etiology)
10186420|NCT03735706|Experimental|90 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.~A radiation dose reduction from 120 to 90 kV.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1."
10186421|NCT03735706|Experimental|100 kV - 0.417 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.~The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg."
9671429|NCT05048550|Experimental|B1 (intervention)|First visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed.
10163522|NCT03962127||First time ischemic stroke|Patients with a first event of ischemic stroke admitted to hospitals in Central Norway.
10163523|NCT03962257|No Intervention|Conventional|This group will have standard of care infertility counseling and consent processes.
10163524|NCT03962257|Experimental|Engaged MD|This group will have standard of care infertility counseling and access to online teaching modules and the ability to sign consents online.
10163525|NCT03962309||Patients in charge of the participating GPs|In the study will be included patients in charge of the participating GPs aged 40-70 years
10163526|NCT03961958|No Intervention|No protocolled propofol reduction|In phase 1, target-controlled infusion propofol anesthesia was adjusted to maintain BIS 40 to 60.
9520242|NCT03279341|Active Comparator|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
9520243|NCT03279328|Active Comparator|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
9671430|NCT05048550|Experimental|B2 (intervention)|First visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed.
9671431|NCT05048511||Normal|Women with sufficient vitamin D level, when 25(OH)D >20 ng/ml
9671432|NCT05048511||Deficient|women deficiency vitamin D level, when 25(OH)D <20 ng/ml
9974720|NCT05250271|Other|Treatment sequence 2|Sequence of the treatments: Glucose (15g) - Protein bar - Glucose (5g)
9974721|NCT05250271|Other|Treatment sequence 3|Sequence of the treatments: Glucose (5g) - Glucose (15g) - Protein bar
10163527|NCT03961958|Experimental|Two protocolled propofol reductions|In phase 2, there were 2 planned reductions in propofol target concentration: (1) immediately after loss of consciousness-reduction calculated using a predefined formula, and (2) before positioning-reduction equal to the average percentage decrease in CO after knee-chest position in phase
10163528|NCT03961945|Other|Screening Population|Those that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.
10163529|NCT03961945|Other|Upper endoscopy - Barrett's Esophagus|Those that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
10163530|NCT03961945|Other|Upper endoscopy - No Barrett's Esophagus|Those that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
10163531|NCT03961997|Other|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
10163532|NCT03961997|Other|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
10163533|NCT03961997|Other|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
10163534|NCT03961932|Experimental|Normal Renal Function|Healthy participants with Normal Renal Function (estimated Glomerular Filtration Rate (eGFR) ≥ 90 mL/min/1.73m^2)
10163535|NCT03961932|Experimental|Mild Renal Impairment|Presence of Mild Renal Impairment (eGFR 60-89 mL/min/1.73m^2)
10163536|NCT03961932|Experimental|Moderate Renal Impairment|Presence of Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m^2)
10163537|NCT03961932|Experimental|Severe Renal Impairment|Presence of Severe Renal Impairment (eGFR ≤ 29 mL/min/1.73m^2), not on hemodialysis
10163538|NCT03961932|Experimental|End-Stage Renal Disease|Presence of End-Stage Renal Disease (ESRD) requiring hemodialysis
10163539|NCT03961854|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
10163540|NCT03961854|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
10163541|NCT03961919|Experimental|FLAT-Auto|Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT
10163542|NCT03961841|Active Comparator|Chemoradiation|weekly 5-Fu and oxaliplatin
10163543|NCT03961841|Experimental|FLOT|Eight perioperative chemotherapy cycles
10163544|NCT03961841|Experimental|FOLFOX|Twelve perioperative chemotherapy cycles
10163545|NCT03961893|Experimental|Arm A: Standard colonoscopy then colonoscopy with G-EYE|Arm A: Standard colonoscopy then colonoscopy with G-EYE
10163546|NCT03961893|Experimental|Arm B: G-EYE colonoscopy then standard colonoscopy|Arm B: G-EYE colonoscopy then standard colonoscopy
9520244|NCT03279328|Active Comparator|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
9520245|NCT03279328|Active Comparator|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
9671433|NCT05049044||Cohort 1: cRT-CT+IO|Concomitant radio-chemotherapy and consolidation immunotherapy (cRT-CT+IO)
9671434|NCT05049044||Cohort 2: sRT-CT+IO|Sequential radio-chemotherapy and consolidation immunotherapy (sRT-CT+IO)
9671435|NCT05049044||Cohort 3: cRT-CT|Concomitant radio-chemotherapy (cRT-CT)
9671436|NCT05049044||Cohort 4: sRT-CT|Sequential radio-chemotherapy (sRT-CT)
9671437|NCT05049044||Cohort 5: CT|Chemotherapy only (CT)
9671438|NCT05049044||Cohort 6: CT+IO|Chemotherapy plus immunotherapy (CT+IO)
9671439|NCT05049044||Cohort 7: RT|Radiation therapy only (RT)
9671440|NCT05049044||Cohort 8: IO|Immunotherapy only (IO)
9671441|NCT05049044||Cohort 9: TT|Targeted therapy only (TT)
9974722|NCT05250271|Other|Treatment sequence 4|Sequence of the treatments: Glucose (5g) - Protein bar - Glucose (15g)
9977388|NCT01360944|Experimental|LAS41004, variant 4, once daily|variant 4, once daily
10163547|NCT03961828|Experimental|Thalassemia with HCV|The study was carried out upon 50 β-thalassaemic children infected with hepatitis C virus who attended for a medical check-up at the Hematology Unit, Pediatric Department, Tanta University Hospital. Hepatitis C virus infection was diagnosed by serological detection of HCV-Ab, and quantitative detection of serum HCV RNA by polymerase chain reaction (PCR).
10163548|NCT03961906|Active Comparator|Tübingen physiotherapy concept|Will receive our therapy concept and perform self-trainings on a regular basis.
10163549|NCT03961906|No Intervention|controls|Will receive standard-care which includes their regular physiotherapy as provided by the local therapist and can include self-trainings as well.
10163550|NCT03961659|Active Comparator|Liraglutid|Liraglutid will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutid could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
10163551|NCT03961659|Active Comparator|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but dapagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
10163552|NCT03961659|Active Comparator|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to100mg three times daily if appropriate. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but acarbose could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
10163553|NCT03961763|Active Comparator|omega-3 supplement|This group will receive a daily dose of 4g EPA+DHA (which is the recommended safe tolerable upper intake level of omega-3 supplements for healthy individuals) for eight weeks.
10163554|NCT03961763|Placebo Comparator|Placebo|This group will receive a daily dose of 4g olive oil placebo for eight weeks.
10163555|NCT03961750|Experimental|Intervention|A feasibility study examining a single patient group undertaking a 12 week, student-led, OTAGO exercise class for community dwelling older adults at Glasgow Caledonian University. OTAGO consists of progressive strength and balance exercises.
10163556|NCT03961802|Experimental|systematic early rehabilitation|systematic early rehabilitation
10163557|NCT03961802|No Intervention|without systematic rehabilitation|without systematic rehabilitation
10163558|NCT03961776||non-metastatic rectal adenocarcinoma nRCT indicated|Patients with histologically confirmed non-metastatic rectal adenocarcinoma and for whom treatment with nRCT has been indicated.
10163559|NCT03961672|Experimental|Treatment (duvelisib)|"INDUCTION: Patients receive duvelisib PO BID on days 1-28. Cycles repeat every 28 days for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive duvelisib PO BID on days 1-2, 8-9, 15-16, and 22-23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
10163560|NCT03961464|Experimental|d-cycloserine|oral, capsule, 250 mg
10163561|NCT03961464|Experimental|Placebo|oral, capsule, lactose
10163562|NCT03961412|Experimental|family-based intervention + education materials|The participants will identify their accompanying influential person (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. Their accompanying influential person is eligible if they are (a) aged 18 or older and (b) willing to participate in the study.
10163563|NCT03961412|Active Comparator|women only intervention + education materials|Only the participants will attend the 1.5-2 hour face-to-face intervention on cervical cancer and screening.
10163564|NCT03961477|Active Comparator|IF group|Interferential therpapy
10163565|NCT03961477|No Intervention|Placebo|No intervention
10163566|NCT03961607|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
10163567|NCT03961607|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 50 J/cm2) after applying 5% 5-aminolevulinic acid cream for 1.5h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
10163568|NCT03961503||Daptomycin (DAP)|DAP : Cohort of patients who received daptomycin as the first line treatment for at least 48 hours for the defined indication
10163569|NCT03961503||Vancomycin (VAN)|VAN : Cohort of patients who received vancomycin as the first line treatment for at least 48 hours for the defined indication
10163570|NCT03961555|Experimental|SYN023+Rabies vaccine|"SYN023:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form: 6mg/2mL, liquid,~Dosage: 0.3 mg/kg of SYN023~Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~Interventions: should be administered in deltoid muscle~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~Dosage: 1 mL after reconstitution~Frequency/duration: at Day 1, 4, 8, 15, 29"
10163571|NCT03961555|Active Comparator|HRIG+Rabies vaccine|"HRIG:~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible~Dosage form: 150 IU/mL or 300 IU/mL, liquid,~Dosage: 20 IU/kg of HyperRab (HRIG)~Frequency/duration: at Day 1~Rabies vaccine (RabAvert/Rabipur):~Interventions: should be administered in deltoid muscle~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use~Dosage: 1 mL after reconstitution~Frequency/duration: at Day 1, 4, 8, 15, 29"
10163572|NCT03961698|Experimental|Cohort A (TNBC)|"IPI-549 in combination with front-line treatment. Cohort A will include two sub-cohorts: Cohorts A1 and A2.~Cohort A1: Approximately 30 patients with locally advanced and/or metastatic TNBC with programmed death-ligand 1 (PDL1) positive disease based on immunohistochemistry (IHC) defined as IC1/2/3.~Cohort A2: Approximately 30 patients with locally advanced and/or metastatic TNBC with PDL1 negative disease based on IHC defined as IC0."
10163573|NCT03961698|Experimental|Cohort B (RCC)|"IPI-549 in combination with front-line treatment. Cohort B will include two sub-cohorts: Cohorts B1 and B2.~Cohort B1: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 positive disease based on IHC defined as IC1/2/3.~Cohort B2: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 negative disease based on IHC defined as IC0."
10163574|NCT03961594|Other|volume expansion in the ventilated patient|Including 51 patients, ventilated, under vasopressors suffering from septic shock. GLS, cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders. Patients with a 15% increase in cardiac output 20minutes after the end of volume expansion will be classified as persistent responders.
10163575|NCT03961633|Experimental|AWARE intervention|"This arm is the treatment group, which receives the intervention, and is the only arm in the study. See the intervention column for more descriptions."
10163576|NCT03961451||Group With Recommendations (GAR)|Patients in the GAR group will receive several recommendations and will have access to an online tool to increase motivation to engage in physical activity.
10163577|NCT03961451||Control Group (GC)|No recommendation given
10163578|NCT03961425|Active Comparator|NO CO2|Traditional De Airing maneuver
10163579|NCT03961425|Active Comparator|CO2 Cannula|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by non specific needle cannula
10163580|NCT03961425|Active Comparator|CO2 Cardia|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by commercial diffuser Cardia
10163581|NCT03961542|Experimental|Intervention Group|"This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.~Differences in fasting glucose and longitudinal changes over the study period should be additionally examined."
10163582|NCT03961542|No Intervention|Control Group|Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²).
10163583|NCT03961399|Active Comparator|biventricular stimulation (BiV) group|patients with Abbott Medical® CRT implanted with only biventricular stimulation (BiV).
10163584|NCT03961399|Experimental|SyncAVTM stimulation group|patients with Abbott Medical® CRT implanted and SyncAVTM stimulation activated
10163585|NCT03961373|Active Comparator|Standard Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy
10163586|NCT03961373|Experimental|Experimental Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy
10163587|NCT03961386|Experimental|FallsTalk-C|FallsTalk CG intervention
10163588|NCT03961386|Active Comparator|FallsTalk|FallsTalk intervention
10163589|NCT03961386|No Intervention|PostCardOnly|Postcard only- Control group
10163590|NCT03961711|Experimental|Telemedicine encounter|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
10163591|NCT03961711|Active Comparator|In-person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
10163592|NCT03961360|Experimental|162 mg/day Aspirin|
10163593|NCT03961360|Active Comparator|81 mg/day Aspirin|
10163594|NCT03961347|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
10163595|NCT03961347|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
10163596|NCT03961282|Experimental|Parkinson Disease Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
10163597|NCT03961282|Experimental|Healthy Participant Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
10163598|NCT03961074||Exposure group|Chinese women with iron deficiency anemia (IDA) during pregnancy.
9974723|NCT05250271|Other|Treatment sequence 5|Sequence of the treatments: Protein bar - Glucose (15g) - Glucose (5g)
10163599|NCT03961074||Control group|Chinese women without iron deficiency anemia (IDA) during pregnancy.
10163600|NCT03960944|Experimental|Yoga in School Group|30-mins yoga sessions were conducted in schools for 8-weeks
10163601|NCT03960944|No Intervention|Control Group|Usual Activities in school
10163602|NCT03961113||assessment by questionnaire|
10163603|NCT03960970|Active Comparator|One-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once
10163604|NCT03960970|Experimental|Two-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once and Azithromycin 500mg IV, Piggyback, once
9977389|NCT01360944|Experimental|LAS41004, variant 5, once daily|variant 5, once daily
10163605|NCT03960996|Experimental|Dacryocystorinostomy with bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy with bicanalicular intubation.
10163606|NCT03960996|Experimental|Dacryocystorinostomy without bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy without bicanalicular intubation.
10163607|NCT03961243|Experimental|YUVA-GT-F901|Gene transfer to treat Hemophilia B
10163608|NCT03960983|Experimental|Elderly pacients with complete dentures and Tongue Scraper|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of repeated before these steps
10163609|NCT03960983|Active Comparator|Elderly pacients with complete dentures and PDT|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
10163610|NCT03961139|Experimental|Continuous feeding (CF)|"Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~Feed volume increment per day is as per departmental protocol and same as comparator arm."
10163611|NCT03961139|Active Comparator|Bolus feeding (BF)|"Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes.~Feed volume increment per day is as per departmental protocol and same as experimental arm."
10163612|NCT03961022|Active Comparator|ReWin(d)|Subjects have to take ReWin(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
10163613|NCT03961022|Placebo Comparator|placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
10163614|NCT03961191||Benign group|Patients with benign cervical histology, including normal findings, inflammation and LSIL
10163615|NCT03961191||HSIL group|Patients with cervical histology of HSIL
10163616|NCT03961191||Cancer group|Patients with cervical histology of cancer
9974724|NCT05250271|Other|Treatment sequence 6|Sequence of the treatments: Protein bar - Glucose (5g) - Glucose (15g)
10163617|NCT03961334|Experimental|DOACs|Direct oral anticoagulants
10163618|NCT03961334|Active Comparator|Antiplatelets|Antiplatelets
10163619|NCT03961230|Experimental|Oral Chinese medicine|Participants in experimental group will receive Jueyin granule two times daily after meals three times per week for 8 weeks.
10163620|NCT03961230|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Jueyin granule placebo two times daily after meals three times per week for 8 weeks.
10163621|NCT03961126|Experimental|Group autologous platelet-rich plasma injection|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
10163622|NCT03961126|Active Comparator|Group Control|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
10163623|NCT03961217||Gynecological Cases|"Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy at~Radiumhemmat, Karolinska University Hospital and~Jubileumskliniken at Sahlgrenska University Hospital in Sweden."
10163624|NCT03961217||Prostate Cases|Prostate Cancer survivors treated with radiotherapy for localized prostate cancer at Sahlgrenska University Hospital, Gothenburg, Sweden
10163625|NCT03961217||Gynecological Rehab Cases|Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy
10163626|NCT03961048|Experimental|Bilateral catheters|patients receiving bilateral catheters (such as for patients undergoing sternotomies/midline incisions or with planned bilateral thoracotomy incisions)
10163627|NCT03961048|Experimental|Single catheter|patients who only have one catheter in place (such as in patients who have unilateral thoracotomies and not midline sternotomies)
10163628|NCT03960918|No Intervention|usual neuro-rehab training|stroke patient under usual neuro-rehab training
10163629|NCT03960918|Experimental|Novel exercise training|stroke patient under aerobic exercise training
10163630|NCT03960853|Experimental|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
10163631|NCT03960853|Placebo Comparator|volume controlled ventilation|patients will be allocated to volume controlled ventilation in operation
9977390|NCT01360944|Experimental|LAS41004, variant 6, once daily|variant 6, once daily
10163632|NCT03960749|Experimental|Sprotte 25G needle, stylet reinserted|
10163633|NCT03960749|Experimental|Sprotte 25G needle, stylet not reinserted|
10163634|NCT03960749|Experimental|Sprotte 22G needle, stylet reinserted|
10163635|NCT03960749|Experimental|Sprotte 22G needle, stylet not reinserted|
10163636|NCT03960749|Experimental|Spinocan 25G needle, stylet reinserted|
10163637|NCT03960749|Experimental|Spinocan 25G needle, stylet not reinserted|
10163638|NCT03960931|Experimental|Aquatic rehabilitation|
10163639|NCT03960931|Experimental|Land based physical activities|
10163640|NCT03960931|Other|Conventional rehabilitation|
10163641|NCT03960905||Children with the usage of anti-infective drugs|in conformity with the clinical practice
10163642|NCT03961152|Experimental|PainCoach-app group|In the PainCoach-app group, in addition to receiving the aforementioned usual care, the PainCoach app was downloaded on each patient's smartphone or tablet. Patients could use this app whenever they wanted until day 14 after surgery. They were not subjected to any different treatment compared to the control group, i.e. advice on pain management was delivered in an extra and different way, but the pain medication itself was exactly the same for both groups.
10163643|NCT03961152|No Intervention|Control group|The control group received usual care.
10163644|NCT03961087|Active Comparator|case group|patients with liver cirrhosis and frequent hepatic encephalopathy received coenzyme Q10 and Meclofenoxate in addition to usual hepatic support
10163645|NCT03961087|No Intervention|control group|patients with liver cirrhosis and frequent hepatic encephalopathy received usual hepatic support only
9974725|NCT05250245|Active Comparator|CPAP only group|Patients who are going to receive only CPAP treatment for their moderate-to-severe obstructive sleep apnea syndrome (OSAS)
10163646|NCT03960775|Experimental|Group A (dexmedetomidine)|dexmedetomidine infusion group
10163647|NCT03960775|Placebo Comparator|Group B (saline)|normal saline infusion group
10163648|NCT03960762|Active Comparator|Group A = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
10163649|NCT03960762|Active Comparator|Group B = SAP group|SAP block (Group SAP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
10163650|NCT03960788|Experimental|MRI with Gadoxetate Sodium|Subjects will receive Gadoxetate Sodium during MRI.
10163651|NCT03960866|Experimental|Nyxol Ophthalmic Solution 1%|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
10163652|NCT03960866|Placebo Comparator|Nyxol Ophthalmic Solution Vehicle|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
10163653|NCT03960736|Active Comparator|Group ESPB = Erector spinae plane block group|ESP block (Group ESP) will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
10163654|NCT03960736|Active Comparator|Group TEA = Thoracic epidural analgesia group|TEA will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
10163655|NCT03960801|Experimental|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
10163656|NCT03960801|Active Comparator|Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
10163657|NCT03960710||Neuronal network Training group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~Injection modalities (without injection, injected)~Major hepatectomy surgery~Importance of hepatic dysmorphia~Presence of intraperitoneal fluid effusion~Presence of renal polycystosis (especially on the right side)."
10163658|NCT03960710||Neuronal network Validation group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~Injection modalities (without injection, injected)~Major hepatectomy surgery~Importance of hepatic dysmorphia~Presence of intraperitoneal fluid effusion~Presence of renal polycystosis (especially on the right side)."
10163659|NCT03960697|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
10163660|NCT03960697|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
10163661|NCT03960814||Cohort 1|New users of basal insulins glargine and detemir
10163662|NCT03960684|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System
10163663|NCT03960671|Experimental|Anxiolytics|Pediatric patients treated with sedation using anxiolytics
10163664|NCT03960528|Active Comparator|Under direct vision erector spinae plane block|"20 ml bupivacaine 0,25%+ lidocaine 1% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
10163665|NCT03960528|Sham Comparator|Control group|"20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
9520246|NCT03279315|Experimental|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
9520247|NCT03279302|Experimental|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
9520248|NCT03279302|Experimental|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
9520249|NCT03279302|Experimental|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
9520250|NCT03279302|Experimental|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
9520251|NCT03279302|Experimental|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
9527700|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Escalation|"Traditional 3 + 3 dose escalation design.~Starting doses: sirolimus 3milligrams (mg) loading/1mg maintenance and epacadostat 300mg twice daily (BID). If 0 in 3 subjects develops dose limiting toxicity (DLT), next 3 subjects will be treated at dose level 2 (DL2): sirolimus 6mg loading/2mg maintenance and epacadostat 300mg BID. If 1 subject in dose level 1 (DL1) develops DLT, 3 additional subjects will be enrolled in DL1. If 2 or more subjects in a total of 6 subjects, or 2 or more subjects in the initial 3 subjects develop DLT, the next 3 subjects will be treated at dose level -1 (DL-1): 3mg loading/1mg sirolimus + epacadostat 100mg BID. If only 1 subject in a total of 6 develops DLT, dose escalation to DL2 will be made for the next 3 subjects. Same algorithm will apply to DL2 except no further dose escalation/de-escalation will be made.~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
9527701|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Expansion|"Once recommended phase 2 dose (RP2D) is defined, a total of 10 non-small cell lung cancer (NSCLC) patients who meet eligibility will be enrolled in the dose expansion cohort. Treatment will be sirolimus RP2D once daily and epacadostat RP2D twice daily (BID).~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
9974726|NCT05250245|Active Comparator|Combined use of CPAP and tolterodine|Patients who are going to receive combined use of CPAP and tolterodine 4mg a day treatment for their OSAS
9671442|NCT05049044||Cohort 10: BSC|Best supportive care only (BSC)
10163666|NCT03960541|Experimental|CD24Fc Treatment|Participants with HIV on antiretroviral therapy will be administered 3 doses of CD24Fc (240mg IV infusion) q2w during a 4-week window, followed by a 24-week follow-up window to assess safety and changes in LDL.
10163667|NCT03960541|Placebo Comparator|Placebo|Patients with HIV on antiretroviral therapy will be administered 3 doses of normal saline solution (100 ml, IV infusion) q2w during a 4-week window, followed by a 24-week follow-up window to assess safety and changes in LDL.
9826439|NCT02418585|Experimental|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
9826440|NCT02418585|Active Comparator|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
10163668|NCT03960619|Experimental|in-person & mHealth coping skills training|hybrid in-person and mHealth coping skills training and activity coaching intervention is to reduce physical disability and decrease pain, fatigue and stress while enhancing patients' abilities to cope with symptoms that interfere with activity.
10163669|NCT03960424|Experimental|Diabetes Telemonitoring (DTM)|"Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for Type 2 Diabetes (T2D), uses smart devices to share information between patients, caregivers, and clinicians. DTM includes:1) weekly real time virtual visit between patient and clinician 2) vital signs monitoring/interpretation 3) diabetes management 4) patient interactive educational videos and teach back quizzes, reinforcing self-management strategies 5) a caregiver app with supportive capability."
10163670|NCT03960424|Active Comparator|Comprehensive Outpatient Management (COM)|"Comprehensive Outpatient Management (COM) is the most realistic evidence-based comparator, in that it is the most frequently recommended and used option for US T2D patients. COM, like DTM, is consistent with the 2018 American Diabetes Association (ADA) Standards which include, but are not limited to, past medical and family history, social history, medications, screening, physical examination, laboratory evaluation, etc.Patients are instructed to monitor blood glucose (within physician recommendations), and have routine or well visits every 3 months. Patients can set appointments with a T2D educator. COM patients will receive monthly calls from the study Registered Nurse (RN) to collect data."
10163671|NCT03960346|Other|Esophageal Effects|To determine the correlation between rate of temperature decline and nadir cryoballoon temperatures rate of temperature decline and nadir esophageal temperatures during pulmonary vein isolation. Esophageal temperature probe is used during cryoablation to measure temperatures and then a 4-7 days post procedure esophagoscopy is performed to evaluate the physical effects on the esophagus.
10163672|NCT03960359||Episodic viral wheezers (EVW)|EVW: Wheezing during discrete time periods (exacerbations), absence of symptoms between exacerbations Among which SIW: EVW with ≥ 2 exacerbations over the last 6 months Clinical, microbiological and inflammatory phenotype
10163673|NCT03960359||Multiple trigger wheezers (MTW)|MTW : wheezing during exacerbations but also symptoms between episodes. Clinical, microbiological and inflammatory phenotype
10163674|NCT03960268|Experimental|Intervention|Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks
10163675|NCT03960593||Patients with cancer and / or hematological|The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.
10163676|NCT03960489|Experimental|Treatment Sequence 1 (ABCD)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 3 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
10163677|NCT03960489|Experimental|Treatment Sequence 2 (BDAC)|Participants will receive 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 1 followed by single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
9520252|NCT03279263|Experimental|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
9826441|NCT02418676|Experimental|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
9520253|NCT03279263|Experimental|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
9520254|NCT03279263|Experimental|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
9520255|NCT03279263|Placebo Comparator|Placebo|Placebo QDTablet
9671443|NCT05048589|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|QIV-SD single injection at Day 0
9671444|NCT05048589|Experimental|High-Dose Quadrivalent Influenza Vaccine|QIV-HD single injection at Day 0
10163678|NCT03960489|Experimental|Treatment Sequence 3 (CADB)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 2 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
10163679|NCT03960489|Experimental|Treatment Sequence 4 (DCBA)|Participants will receive single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 3 followed by 100 mg of roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
10163680|NCT03960502|Experimental|AG881|On Day 1, after fasting for 10 hours participants, will receive an oral capsule of [14C]AG-881 followed 2 hours later by a single intravenous (IV) infusion of [13C315N3]AG-881.
10163681|NCT03960229|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips (for ICSI) will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
10163682|NCT03960229|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
10163683|NCT03960411|Experimental|Doxycycline|Doxycycline 100 mg capsule by mouth every 12 hours for 7 days, administered early after primary PCI
10163684|NCT03960411|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 7 days, administered early after primary PCI
10163685|NCT03960450|Experimental|Part A: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
10163686|NCT03960450|Placebo Comparator|Part A: Vehicle cream|Daily application of vehicle cream
10163687|NCT03960450|Experimental|Part B: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
10163688|NCT03960450|Placebo Comparator|Part B: Vehicle cream|Daily application of vehicle cream
10163689|NCT03960294|Experimental|DOZE Users|Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
10163690|NCT03960385||Hospitalized and controls|Age-matched case of hospitalized dengue and non-dengue control
10163691|NCT03960385||Outpatient and controls|Age-matched dengue case and non-dengue control
10163692|NCT03960437|Other|Study Participant|Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.
10163693|NCT03960151|Experimental|Rolapitant|Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone
10163694|NCT03960281||Single implant crowns in the anterior maxilla|No drugs to be administered. Patients who have had a single implant crown placed since more than one year in the anterior maxilla (second premolar to second premolar) will be invited for a review session for dental examination and to fill the Oral Health Impact Profile (OHIP) questionnaire.
10163695|NCT03960398||Patients concerned by iatrogenic diseases|Patients living in the South-East of France and consulting in the emergency department of Toulon La Seyne sur Mer hospital for iatrogenic diseases
10163696|NCT03960203|Experimental|Comparator|The comparator arm will involve patients monitored by InSight.
10163697|NCT03960190|Experimental|1K expression kit|Subjects will be using the breastpump with the with 1K expression kit.
10163698|NCT03960190|Experimental|2K expression kit|Subjects will be using the breastpump with the with 2K expression kit.
10163699|NCT03960112|Experimental|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
10163700|NCT03960216|Sham Comparator|Minimal Periodontal Treatment (MPT)|Once the hopeless teeth have been extracted, randomized patients will receive a periodontal prophylaxis, in the form of supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and, after the last session, placebo capsules (one every 24 h for three days).
10163701|NCT03960216|Experimental|Intensive Periodontal Treatment (IPT)|Once the hopeless teeth have been extracted, randomized patients will receive non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and after the last session, systemic antibiotics (azithromycin 500 mgrs, every 24 h for three days).
10186422|NCT03735706|Experimental|90 kV - 0.365 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg."
10186423|NCT03735641||postoperative|Expanded Pedicled Deltopectoral Flap is a type of surgical flap that has been cut away from surrounding areas for transplantation.The postoperative patients are studied . Tested sensory recovery,skin color and Skin elasticity
10186424|NCT03735615|Experimental|chronic obstructive lung disease|
10186425|NCT03735615|Experimental|healthy control|
10186426|NCT03735602|Experimental|perceptual training|Orientation discrimination task, which is a cognitive task. Patients were trained for 1 hour per day, 15 days in total.
10186427|NCT03735576|Experimental|LLD-adapted cognitive behavioural therapy (CBT)|manualized 15-session individually-delivered cognitive behavioural therapy (CBT) specific for late life depression (LLD)
10186428|NCT03735576|Active Comparator|supportive unspecific intervention (SUI)|manualized 15-session individually-delivered supportive unspecific intervention (SUI)
10186429|NCT03735563|Experimental|Ketamine|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
10163702|NCT03959943||Innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction with additional sensory nerve coaptation.
10163703|NCT03959943||Non-innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction without sensory nerve coaptation.
10163704|NCT03960164|Experimental|Patient group|The group of patients included in the study following inclusion criteria with local (wound) and systemic test values prior and after to the application of the DRPM.
10163705|NCT03960086|Experimental|Custom-made foot orthoses|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
10163706|NCT03960086|Active Comparator|Heel Lifts|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.~Treatment period of 12 weeks"
10163707|NCT03959839|Experimental|Endoscopic Treatment|Rectal Endoscopic Submucosal Dissection
10163708|NCT03959839|Experimental|Minimally Invasive Laparoscopic Local Surgical Treatment|Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)
9826442|NCT02418676|Active Comparator|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
10163709|NCT03959904|Active Comparator|Small Stitch|Small stitch for wound closure
10163710|NCT03959904|Active Comparator|Large Stitch|Large Stitch for wound closure
10163711|NCT03960047|Experimental|Intervention: Virtual Reality Training|Uses virtual reality to train children to cross streets
10163712|NCT03960047|Experimental|Intervention: Streetside Training|Train children to cross streets using real traffic in curbside locations
10163713|NCT03960047|No Intervention|Control|Receives no intervention
10163714|NCT03960307||Septic patients|ICU patients with resuscitated sepsis, based on the sepsis-3 criteria. (n=30)
10163715|NCT03960307||Healthy controls|Apparently healthy controls (n=10)
10163716|NCT03960255||Normal adiposity group|Body fat < 25% and <32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
10163717|NCT03960255||High adiposity group|Body fat ≥ 25% and ≥32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
10163718|NCT03959826|Active Comparator|Job activity contracting|Standard services plus job activity contracting
10163719|NCT03959826|Experimental|Reinforcement for completing activities|Standard services plus job activity contracting plus reinforcement for completing job-related activities
10163720|NCT03959774|Experimental|breast or colorectal or lung cancer, age 70 or older|breast or colorectal or lung cancer, age 70 or older
10163721|NCT03959748||PAH adults|Patients with pulmonary arterial hypertension who are at least 18 years old at study entry
10163722|NCT03959748||PAH children|Patients with pulmonary arterial hypertension who are at least 3 months old and are less than 18 years old at study entry
10163723|NCT03959748||CTEPH|Patients with chronic thromboembolic pulmonary hypertension who are at least 18 years old at study entry
10163724|NCT03959995|Experimental|exercise|Exercise group
10163725|NCT03959995|Sham Comparator|control|active control group
10163726|NCT03959852|Active Comparator|Sub-Dissociative Ketamine alone|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
10163727|NCT03959852|Active Comparator|Fentanyl alone|1 mg/kg of Fentanyl IV administered over at least 1 minute
10163728|NCT03959852|Experimental|Sub-dissociative Ketamine and Fentanyl|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute
10163729|NCT03959982|Experimental|HHHFA Randomized Group|Subjects will be randomized to use the HHHFA device during bedtime for at least 4 hours. Subjects will complete MRC, SGRQ, CAT, CASA-Q and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
10163730|NCT03959982|Active Comparator|Control Group|Subjects will complete MRC, SGRQ, CAT, and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
10163731|NCT03960021|Experimental|Single arm|Each patient is treated with 2 RFA interventions.
10163732|NCT03959722|Experimental|Probiotics:Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a multispecies probiotics: Ecologic® PERFORMANCE ( 1*1010 CFU(Colony forming units)/daily dose, Winclove Probiotics B.V., Amsterdam).
10163733|NCT03959722|Placebo Comparator|Placebo: Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a placebo comparator (Winclove Probiotics B.V., Amsterdam)
10163734|NCT03959761|Experimental|Treatment Group|Intraperitoneal (IP) nivolumab treatment, after extensive debulking surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
10163735|NCT03959969|Experimental|Educational Video Recipients|Participants will be shown educational video on pain management after cesarean delivery on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
10163736|NCT03959969|Active Comparator|Standard of Care Recipients|Participants will be given standard of care discharge instructions for pain management on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
9826443|NCT02418676|Placebo Comparator|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
9974727|NCT05250232|Experimental|onlays conservative|conservative onlays preparation with partial cusp coverage only defective cusps
10163737|NCT03959865||Long-acting GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide once weekly or dulaglutide)
10163738|NCT03959865||Short-acting GLP-1RA|Patients who have been treated with daily GLP-1RA (exenatide bid or liraglutide or lixisenatide)
10163739|NCT03959865||Human GLP-1 based GLP-1RA|Patients who have been treated with GLP-1RA based on human GLP-1 (dulaglutide or liraglutide)
10163740|NCT03959865||Exendin-based GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide or lixisenatide)
10163741|NCT03959865||Fixed ratio combination of BI/GLP-1RA|Patients who have been treated with a fixed ratio combination of GLP-1RA and basal insulin (BI), such as IdegLira (insulin degludec / liraglutide) or IglarLixi (insulin glargine / lixisenatide)
10163742|NCT03959865||Flexible combination of BI/GLP-1RA|Patients who have been treated with any GLP-1RA in combination with any basal insulin (BI)
10163743|NCT03959527|Experimental|zoliflodacin|Participant in this arm will receive a single dose of zoliflodacin.
10163744|NCT03959527|Active Comparator|ceftriaxone and azithromycin combination|Participant in this arm will receive a single dose of comparators combination (ceftriaxone and azithromycin).
10163745|NCT03959579||"1st cohort = derivation cohort:"|"1st cohort = derivation cohort: 1990-1998: cardiac echo + simultaneous systematic endomyocardial biopsy"
10163746|NCT03959579||"2nd cohort = validation cohort"|"2nd cohort = validation cohort: 1999-2016: only cardiac echo with same protocol (endomyocardial biopsy only in case of doubt)"
10163747|NCT03959618||dietary supplements group|dietary supplements questionary
10163748|NCT03959631|Experimental|Intervention group|The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
10163749|NCT03959631|No Intervention|Control group|The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.
10163750|NCT03959306|Experimental|Group I|this group of patients will receive their standard anti-diabetic treatment in addition to 1800 mg of black seed oil soft gelatin capsule (900 mg twice daily) for three months
10163751|NCT03959306|Active Comparator|Group II|this group of patients will receive their standard anti-diabetic treatment only
10163752|NCT03959683|Active Comparator|Trilogy device|Trilogy Lithotrite to fragment urinary tract calculi in the kidney, ureter and bladder
10163753|NCT03959683|Active Comparator|ShockPulse-SE|ShockPulse-SE Lithotripsy System to fragment urinary calculi in the kidney, ureter and bladder
10163754|NCT03959540||Cohort 1|Standard of care (including L-DOPA) + starting opicapone
10163755|NCT03959540||Cohort 2|Standard of care (including L-DOPA)
10163756|NCT03959501|Experimental|Dapagliflozin|Dapagliflozin 10mg daily PO for 24 weeks
10163757|NCT03959501|Active Comparator|Sitagliptin|Sitagliptin 100mg daily PO for 24 weeks
10163758|NCT03959514|Experimental|AT247|Single subcutaneous injection 0.3 U/Kg
10163759|NCT03959514|Active Comparator|NovoRapid|Single subcutaneous injection 0.3 U/Kg
9527702|NCT03217981||2015|2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
10163760|NCT03959514|Active Comparator|Fiasp|Single subcutaneous injection 0.3 U/Kg
10163761|NCT03959254|Experimental|Intervention Group|Application of a protocol of active exercises for recovery after arthroscopic hip surgery, adapted to the femoroacetabular shock characteristics.
10163762|NCT03959254|Active Comparator|Control Group|Usual post-surgical general guidelines for hip interventions described by Gocen et al
10163763|NCT03959228|No Intervention|referencial diet|0.8 g/kg/day of protein
10163764|NCT03959228|Experimental|protein very poor diet with additional keto-analogs|0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.
10163765|NCT03959384|Experimental|Surfactant replacement (Curosurf)|"Broncho-alveolar lavage (BAL) with 25 mg / kg of Curosurf, diluted 1:10 with physiological solution, divided in two aliquots administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~Following supplementation of a dose of 25 mg / kg of Curosurf, diluted with physiological solution 1: 2 (1 ml = 40 mg of surfactant), given in two aliquots with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
10163766|NCT03959384|Placebo Comparator|Ambient Air|"Broncho-alveolar lavage (BAL) with air, administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).~Following supplementation of air given with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
10163767|NCT03959293|Experimental|FOLFIRI plus durvalumab|"Durvalumab: 1500 mg by 1-hour IV infusion. Every 4 weeks until progression~FOLFIRI (1 course every 2 weeks, until progression):~Irinotecan: 180 mg/m² by 2-hour IV infusion,~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
10163768|NCT03959293|Experimental|FOLFIRI plus durvalumab plus tremelimumab|"Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.~Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).~FOLFIRI (1 course every 2 weeks, until progression):~Irinotecan: 180 mg/m² by 2-hour IV infusion~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion~5-FU bolus: 400 mg/m² by 10-minutes IV bolus~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
10163769|NCT03959397|Experimental|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
10163770|NCT03959449|Experimental|Action Observation and Motor imagery|
10163771|NCT03959449|Active Comparator|Motor Imagery|
10163772|NCT03959449|Experimental|Exercise plus motor imagery and action observation|
10163773|NCT03959410||HPV-positive patients|Patients who are positive for HPV DNA test
10186430|NCT03735563|Experimental|Fentanyl|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
10163774|NCT03959267|No Intervention|Usual Care|Participants will continue with their usual medical care. Usual care may vary at different sites. Based on the investigator's preliminary data usual care can result in not GCRA referral, referral directly to testing, or referral to genetic counseling with an interpreter. The investigators will document usual care for participants from the sites randomized to usual care.
10163775|NCT03959267|Other|Telephone Genetic Counseling|Participants will receive telephone genetic counseling with the culturally adapted protocol and booklet
10163776|NCT03959215|Experimental|Usual care + Back in the Game|Smartphone-delivered cognitive behavioural therapy to support confidence to return to sport + usual post-operative physiotherapy rehabilitation
10163777|NCT03959215|Active Comparator|Usual care|Usual post-operative physiotherapy rehabilitation
10163778|NCT03959202|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
10163779|NCT03959202|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants in this group will also receive a Go4Life program book from the National Institute on Aging.
10163780|NCT03959280|Experimental|Tailored intervention|"In this group, participants will receive a comprehensive lifestyle program in addition to CPAP therapy which will include a supervised exercise program, diet interventions and behavioural counselling during 12 weeks.~Then, participants will follow a real-world maintenance program from weeks 12 to 24. It will include one telephone-based contact per month with the study coordinator. Participants will be encouraged to maintain their lifestyle modification during this phase."
10163781|NCT03959280|Active Comparator|Control|Participant in this group will benefit from routine CPAP therapy management from week 0 to 24.
10163782|NCT03959176|Experimental|Group 1|"The right eye will receive a sham drop followed by 1 drop of Tropicamide 1%/Phenylephrine 2.5% five minutes after the sham drop is administered. A one minute wait will occur followed by a second drop of Tropicamide 1%/Phenylephrine 2.5%.~The left eye will receive 2 drops of Brimonidine 0.2% followed by a five minute wait time. One drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a one minute wait time. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered."
10163783|NCT03959176|Experimental|Group 2|"The right eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered followed by a 15 second wait after which a sham drop will be administered.~The left eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a 15 second wait after which 2 drops of Brimonidine will be administered."
10163784|NCT03959150|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 po qd
10163785|NCT03959150|No Intervention|Observation|Observation
10163786|NCT03959007|Active Comparator|Control|Usual therapy and complete 3 questionnaire at 3 times during hospitalization : Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status
10163787|NCT03959007|Experimental|Experimental|9 consultations (3 x 3 sessions during hospitalization) of aesthetic care will be provided to patient include in experimental arm and 3 times questionnaires (Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status)
10163788|NCT03959020||Patients, undergoing anti-reflux surgery|Patients having undergone anti-reflux surgery at the Department of Surgery, Kolding Hospital, a part of Hospital Lillebaelt, from 1th January 2002 - 31th December 2013
10163789|NCT03959462|Experimental|Real tDCS|20 min of 1 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
10163790|NCT03959462|Sham Comparator|Sham tDCS|30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
10163791|NCT03958903|Experimental|Neurophysiological recording and stimulation of amygdala|Recording and stimulation of amygdala using Neuropace RNS devices at certain points through out the behavioral tasks.
10163792|NCT03959046|Experimental|GIST|"GIST is an alternative way of speaking to patients. In order for patients to get the gist, Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved."
10163793|NCT03959046|No Intervention|Usual Care|These are physician and patient participants that will communicate in their normal, unchanged way.
10163794|NCT03958864|Experimental|CC-90001 100 mg|100 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
10163795|NCT03958864|Experimental|CC-90001 200 mg|200 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
10163796|NCT03958864|Experimental|CC-90001 400 mg|400 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
10163797|NCT03958825|Active Comparator|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
10163798|NCT03958825|Experimental|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
10186431|NCT03735550||Group A age: 18-49|Women aged 18-49 who had breast ultrasound performed with a result of BI-RADS 4b, 4c or 5. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to breast ultrasound. The planned number of participants in the group: n=700 people.
10163799|NCT03958838|Experimental|Intervention Group|"Subjects will receive usual care from community health center staff. In addition, they will also receive a variety of community-level and individual-level interventions, categorized broadly into three levels.~At the community level, subjects will receive the 5 Key Diabetes Messages that Everyone Should Know and the 6 Modules of Basic Diabetes Education. At the individual level, subjects and their families will be invited to participate in group activities, co-organized by community health staff, CHC staff, and CSMG peer leaders. Subjects will receive in-person peer support through these group activities, with follow up through telephone calls and text messaging. For subjects that have poorly controlled diabetes or are experiencing emotional distress related to their diabetes, CSMG peer leaders will work closely with them to help them solve problems around their diabetes."
10163800|NCT03958838|No Intervention|Control Group|Subjects in the control group will receive usual care from community health center staff.
10163801|NCT03959111|Experimental|Ear stimulation (Location 1)|
10163802|NCT03959111|Experimental|Ear stimulation (Location 2)|
10163803|NCT03959072||Robotic Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
10163804|NCT03959072||Conventional (manual) Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
10163805|NCT03958942|Active Comparator|quadratus lumborum block|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
10163806|NCT03958942|Active Comparator|lumbar epideural block|received pre-emptive lumbar epidural block with 15 mL of 0.25% bupivacaine before induction of GA.
10163807|NCT03959124|Experimental|AD with DBS|Alzheimer's disease subjects with optimal medication therapy and with DBS treatment
10163808|NCT03959124|Active Comparator|AD without DBS|Alzheimer's disease subjects with optimal medication therapy and without DBS treatment
10163809|NCT03959124|No Intervention|Normal control|Matched aged and demographics subjects
10163810|NCT03958760||Diabetic patients with CVD, CKD or at risk|The group A include all diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
10163811|NCT03958760||Diabetic patients without CVD, CKD or at risk|The group B include all diabetic patients without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
10163812|NCT03958760||Non-diabetic patients with CVD, CKD or at risk|The group C included all non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
10163813|NCT03958760||Health controls|The group D included non-diabetic patients without established cardiovascular disease, chronic kidney disease, and not at high cardiovascular risk.
10163814|NCT03959059|Experimental|PKP of traditional procedure|traditional method of PKP
10163815|NCT03958851||patients with lupus nephritis|Lupus nephritis is diagnosed by either the presence of proteinuria (>0.5 g/day), active urinary sediment (with red blood cell, granular, tubular and/or mixed casts), or an unexplained rise in serum creatinine in patients with systemic lupus.
10163816|NCT03958851||systemic lupus patients without lupus nephritis|The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997).these group will be taken as a control group
10163817|NCT03958851||healthy individuals|a group of age and sex matched healthy individuals will be taken as a control group.
10163818|NCT03958786|Experimental|single arm|500 HIV-1 infected patients, aged 70 years and older
10163819|NCT03958773|Experimental|Cardiovalve treatment|Patients that implanted with the Cardiovalve device
10163820|NCT03958721|Experimental|Concurrent Adjuvant Capecitabine and Radiotherapy|
10163821|NCT03958708|Experimental|Treatment Arm|
10163822|NCT03958812||Gastric cancer|patients with definitive diagnosis of gastric cancer by pathology
10163823|NCT03958812||Breast cancer|patients with definitive diagnosis of breast cancer by pathology
10163824|NCT03958812||Benign gastric diseases|Gastritis or gastric ulcer
10163825|NCT03958812||Benign breast diseases|Hyperplasia of mammary glands or mastitis
10163826|NCT03958812||Normal|healthy volunteers
10163827|NCT03958669||Sorafenib treated HCC patients|No intervention is performed. This is an observational study.
10163828|NCT03958682|Experimental|experimental group|During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.Patients can receive timely diagnosis and appropriate treatment
10163829|NCT03958487|Experimental|executive/monitoring training|All participants will be part of the same group and their performance after treatment will be compared to their own performance prior to treatment (baseline)
10163830|NCT03958513|Placebo Comparator|Placebo|0.9% normal saline, 1.5 ml for 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
10163831|NCT03958513|Experimental|Intervention|0.25% Bupivacaine, 1.5 ml per 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
10163832|NCT03958617|Active Comparator|On condition|Ongoing thalamic deep brain stimulation
10163833|NCT03958617|Sham Comparator|Off condition|Switched off thalamic deep brain stimulation, sham stimulation
10163834|NCT03958526|Active Comparator|Active|Active stimulation over M1
10163835|NCT03958526|Placebo Comparator|Sham|Sham stimulation over M1
10163836|NCT03958448|Experimental|Short Group|In each side of the posterior region of the maxilla, one tissue level implant, 4 mm long and 4.1 mm in diameter, will be installed
10163837|NCT03958448|Experimental|Standard group|sinus floor elevation with will be performed using natural bovine bone graft as filler material and porcine dermis collagen membrane to cover the antrostomy. After 4 months of healing, one bone level implant, 10 mm long and 4.1 mm in diameter, will be installed into each augmented sinus.
10163838|NCT03958227|Experimental|''Manuel Therapy group''|This treatment group will be received Manuel Therapy techniques and exercise interventions.
10163839|NCT03958227|Experimental|''Exercise group''|This treatment group will be received only exercise interventions.
10163840|NCT03958305||LAPAROTOMY|Radical hysterectomy by laparotomy
10163841|NCT03958305||MINIMALLY INVASIVE SURGERY|Radical hysterectomy by minimally invasive surgery (Laparoscopy or Robotics)
10163842|NCT03958318|Experimental|Exercise|Multi-modal exercise program
10163843|NCT03958318|Experimental|Exercise plus nutritional suplementation|Multi-modal exercise program plus nutritional suplementation
10163844|NCT03958318|No Intervention|Control|No interventions
10163845|NCT03958292|Experimental|Patients undergoing routine cataract surgery|"Two eye drops containing PVP-Iodine instillation in the eye undergoing cataract surgery three times for three days before surgery.~Each patient was evaluated for conjunctival flora variation by means of two conjunctival swabs before starting the treatment and at the end of the treatment before the surgery."
10163846|NCT03958357||Treatment arm|Single arm study, 40 participants will undergo brachytherapy with the Advanced Gynecological Applicator Venezia Configuration
10163847|NCT03958461|Other|Calculus removement|Anti-infective treatment of teeth
10163848|NCT03958604|Experimental|Burst Spinal Cord Neurostimulation|Burst spinal cord stimulation. When this fails, tonic stimulation targeting the DRG wil be applied
10163849|NCT03958539|Active Comparator|Intervention arm|6 sites out of a total of 12 will act as the intervention sites. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to be provided with bespoke 3-D printed insoles.
10163850|NCT03958539|No Intervention|Control|6 sites out of a total of 12 will act as the control sites providing standard care. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to standard care
10163851|NCT03958279||primipara giving birth|"The investigators involve every primipara giving birth in a period of two years.~Exclusion criteria:~a) Unwilling to participate~b) Minors (under 18 years old)~c) Foetus mortus or perinatal death of the newborn~d) Admission of the newborn to the ICU~e) Unfamiliar with slovak language~f) Multiple pregnancy"
10163852|NCT03958500|Experimental|Comprehensive anastomotic testing|"All patients undergo:~Indocyanine green fluorescent angiography intraluminally and intraperitoneally~Air leak test~Methylene blue test"
10163853|NCT03958422|Experimental|Myocardin test group|Patients in cardiomyopeptidin group are given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) and intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI.
10163854|NCT03958422|No Intervention|Blank test group|Patients in blank test group aren't given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) .
10163855|NCT03958344|Experimental|Intraorbital injection of steroid|"2 mL of steroid will be ready for each injection session:~1 mL Triamcinolone (40 mg) + 1 mL Betamethasone (6 mg) = 2 mL~For Dacryoadenitis without myositis , 1 mL of this compound will be injected at lacrimal gland through 1 site of injection.~For Dacryoadenitis plus 1 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at the rectus muscle through 2 separate sites of injection.~For Dacryoadenitis plus 2 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at either recti muscles through 3 separate sites of injection."
10163856|NCT03958344|Active Comparator|Oral Steroid|"Each patient will receive oral Prednisolone, 1 mg/kg, for 5-7 days, followed by tapered dose in 12 weeks (according to a pre-defined table of oral administration dose).~Daily Omeprazole 40mg p.o and daily Calcium Supplement will also be recommended to avoid complications."
10163857|NCT03958214|Experimental|Recipe 4 Success|For 12 weeks, home visitors will stop delivering the usual practice Early Head Start home visits and deliver the Recipe 4 Success curriculum instead. At the end of 12 weeks, home visitors will resume usual practice Early Head Start home visits.
10163858|NCT03958214|Active Comparator|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
10163859|NCT03958188||Patients|"Patients who have undergone pre-operated computerized tomography (CT) imaging for a subsequently operated Neuro-endocrine tumor (NET).~Clinical data collected for each patients:~Age~Sex~Symptomatology (abdominal pain, diarrhea, carcinoid flush, digestive bleeding, weight loss, occlusive syndrome)~Blood Chromogranine A and urinary 5-hydroxyindoleacetic acid (5-HIAA)~Carcinoid valvulopathy"
10163860|NCT03958266||MyIBD Care - Study Group|Will have traditional face to face outpatient contacts replaced with a novel mobile phone application supported via a digital clinician portal
10163861|NCT03958370||Fitbit|
10163862|NCT03958201|Other|Protocol|Patients will have perioperative neuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed objectively at adductor pollicis with quantitative neuromuscular monitoring.
10163863|NCT03958253|Experimental|Lung Cancer Screening Toolbox|"WU Staff will train local screening staff using a train-the-trainer model three months prior to the intervention and will provide technical assistance on an ongoing basis.~During the 3 hour train-the-trainer session, the selected staff from the referral sites will learn about the program, receive an orientation to the toolbox elements, and discuss how to adapt the elements of the toolbox to their referral sites."
10163864|NCT03958162|Experimental|uniportal and tubeless video assisted thoracic surgery|lung biospy by the uniportal and tubeless video assisted thoracic surgery
10163865|NCT03958162|Experimental|transbronchial lung cryobiopsy|transbronchial lung cryobiopsy
10163866|NCT03958175||Patients with Parkinson's Disease|Patients with Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
10163867|NCT03958175||Patients without Parkinson's Disease = control group|Patients without Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
9977391|NCT01360944|Placebo Comparator|reference|once daily, 100microgram
10163868|NCT03958123|Experimental|Treatment Group 1: Cebranopadol|"Supratherapeutic dose (1600 μg) of cebranopadol:~Participants received placebo once a day for 2 days (Days -3 and -1); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 3 days; 900 μg once a day for 3 days; 1300 μg once a day for 3 days; 1600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
10163869|NCT03958123|Experimental|Treatment Group 2: Cebranopadol|"Therapeutic dose (600 μg) of cebranopadol:~Participants received placebo once a day for the first 11 days (Days -3, -1 and 1-9); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 14 days; and placebo once a day on the last dosing day.~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
10163870|NCT03958123|Experimental|Treatment Group 3A: Placebo and Moxifloxacin|"Placebo / Moxifloxacin:~Participants received placebo once a day for 31 days (Days -3, -1 and 1-29) and moxifloxacin 400 mg once on the last dosing day. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
10163871|NCT03958123|Experimental|Treatment Group 3B: Moxifloxacin and Placebo|"Moxifloxacin / Placebo:~Participants received placebo once a day for 2 days (Days -3 and -1); moxifloxacin 400 mg once for 1 day; and placebo once a day for the following 29 days. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.~Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
10163872|NCT03958084|Experimental|Massage group|The deep massage will be applied for three minutes in the ischiotíbial muscles, only in the left limb, towards the muscular fibers. The volunteers will be placed in a ventral decubitus position on the stretcher.
10163873|NCT03958084|Experimental|Ventosa therapy group|The negative pressure ventosa therapy slide winds will be applied for three minutes in the oval direction in the posterior region of the thigh to contemplate the full extent of the ischiotíbial muscles, only in the left limb. The volunteers will be placed in a ventral decubitus position on the stretcher.
10163874|NCT03958084|Experimental|Foam roller group|The foam roller is a self-applied intervention for three minutes where the volunteers will be positioned on bench press on the floor of the room, with the left thigh posteriorly on the foam roller and the leg extended, the right lower limb will be in flexion of hip and knee, only the right foot and the right and left hands will touch the ground. Volunteers will be instructed to move so that they move forward and backward, causing the roller to travel the full length of the hamstring muscles.
10163875|NCT03958084|Experimental|Lumbar mobilization group|Unilateral lumbar mobilization of grade III at the frequency of 2Hz at the joint L4 / L5 of the ipsilateral side of the limb tested. The frequency was guaranteed by a metronome set at 120 beats per minute. Three sets of 1 minute of mobilization were performed with a 30 second interval, totaling a time of 4 minutes and 30 seconds of intervention. The technique was performed with the patient in the ventral decubitus position.
10163876|NCT03958084|Experimental|Proprioceptive neuromuscular facilitation group|Patient in dorsal decubitus, the examiner lifted the participant's leg up to the referred maximum amplitude. He then asked the patient for an isometric contraction of the hamstring muscles against the researcher's resistance for 10 seconds. After contraction, the researcher asked the patient to relax for 10 seconds. Then the member is repositioned passively by the researcher until the new amplitude limit reached. The technique was performed in 2 sets of 4 repetitions with an interval of 1 minute, totaling in an approximate time of 4 minutes of intervention.
10163877|NCT03958084|No Intervention|Control group|The patient remained lying down in the ventral position for 4 minutes. the patient remained lying down in the ventral position for 4 minutes.
10163878|NCT03958032||Participants with gastric cancer|All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
10163879|NCT03957798|No Intervention|Control (Treatment as Usual)|TAU consists of inpatient substance abuse treatment, followed by referral to outpatient treatment. For those who live within the outpatient geographic catchment area of the treatment center, patients are subsequently admitted to outpatient levels of care at treatment center. For the non-opioid population (primarily marijuana), this consists of the intensive outpatient program counseling sessions starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress with 12 wks target length of service. For the opioid population, this consists of a specialty youth opioid program with group and individual counseling, relapse prevention medications treatment, psychiatric assessment and treatment, also starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress, with indefinite target length of service. For those not within the outpatient geographic catchment area, patients are referred to local continuing care and outpatient levels of care convenient to their homes.
10163880|NCT03957798|Experimental|Intervention (Treatment as usual + game)|
9974728|NCT05250232|Active Comparator|onlays conventional|onlays preparation design conventional as all cusps covered with shoulder finish line preparation
9974729|NCT05250219||patients for tonsils|40 patients for tonsils
9974730|NCT05250219||patients for appendixes|40 patients for appendixes)
9974731|NCT05250206|Experimental|Myopia Control Lens|
10163881|NCT03958058||Anti-borrelial antibiotic therapy|
10163882|NCT03958058||No antibiotics|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
10163883|NCT03957967||acute pain|Patient with acute pain
10163884|NCT03958396|Active Comparator|OSA Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea
10163885|NCT03958396|Active Comparator|Control (non-OSA) Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) no known obstructive sleep apnea presenting for any procedure requiring general anesthetic
10163886|NCT03957772|Active Comparator|Extrafascial injection|"Extrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with extrafascial injection of local anesthetic"
10163887|NCT03957772|Experimental|Intrafascial injection|"Intrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with intrafascial injection of local anesthetic"
10163888|NCT03958136|Experimental|Patients HR + and HER2-|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
10163889|NCT03958136|Experimental|Patients HER2 + with or without HR+|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
10163890|NCT03958136|Experimental|Patients triple negative (HR- and HER2-)|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
10163891|NCT03958097|Experimental|NK cell combined with PD-L1 antibody|"Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16), total NK cells infused at least 3×10^9 .~200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.~NK cells and PD-L1 antibody will be infused every 21 days until disease progression or unacceptable adverse events."
10163892|NCT03957980|Other|Telehealth Intervention First|The participants in this arm of the study received occupational therapy via telehealth in the first 12 weeks of enrollment, then received no other intervention for the duration of the study.
10163893|NCT03957980|Other|No Intervention First|The participants in this arm of the study did not receive an intervention in the first 12 weeks of enrollment, but received occupational therapy via telehealth during the second 12 weeks of enrollment.
10163894|NCT03957902|Experimental|Arm 1 (100 mg/24h)|
10163895|NCT03957902|Experimental|Arm 2 (300 mg/24h)|
10163896|NCT03957902|Experimental|Arm 3 (100 mg/12h)|
10163897|NCT03957850|Experimental|Cognitive Reappraisal Training Group|Cognitive Reappraisal Training group will perform 4 training sessions in Cognitive Reappraisal during which, behavioral responses, event-related potentials (ERPs) and eye-tracking data are collected.
10163898|NCT03957850|Active Comparator|Control Training Group|Control Training Group will perform 4 control sessions without Cognitive Reappraisal Training during which behavioral responses, ERP and eye-tracking data are collected.
10163899|NCT03957993|Experimental|Occupational Therapy via Telehealth|Participants in the telehealth-based model will undergo occupational therapy treatment via a telehealth-based video chat platform for the entire episode of care (generally 10-12 weeks in duration). The patient will use the video chat client to connect to his/her occupational therapist, and the therapist will conduct the session over this virtual connection.
10163900|NCT03957993|Active Comparator|Standard of Care Occupational Therapy|Participants in the standard of care model will undergo occupational therapy treatment via traditional in- person encounters in an outpatient clinic setting for the entire episode of care (generally 10-12 weeks). These children will receive routine occupational treatment via in-person sessions with an occupational therapist conducted in an outpatient clinic setting.
10163901|NCT03957915|Experimental|INA03|INA03 administration
10163902|NCT03958045|Experimental|Patients with Stage IV SCLC|Patients with extensive stage (IV) SCLC (small cell lung cancer)
10163903|NCT03957720|Experimental|homo-R778L|When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
10163904|NCT03957720|Experimental|R778L+truncation mutation|"When patients carrying R778L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
10163905|NCT03957720|Experimental|Homo-P992L|"When patients carrying Homo-P992L mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
10163906|NCT03957720|Experimental|P992L+truncation mutation|"When patients carrying P992L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form:DMSA:750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form:DMSA:35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
9527703|NCT03217981||2016|2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
10163907|NCT03957720|Experimental|T935M+other point mutations|When patients carrying T935M and other point mutations are in hospital, they randomly receive DMPS or penicillamine treatment; Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; Dosage Form: penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years; When being off hospital, they receive DMSA treatment or penicillamine. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
10163908|NCT03957720|Experimental|Presymptomatic patients with Wilson's disease|"According to different age group, they receive various dosage of Zinc Gluconate treatment.~Patient aged≤6 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:BID, Zinc Gluconate Duration: 5 years; Patient aged from 6 to 14 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years; Patient aged≥14 years,Dosage Form: Zinc Gluconate: 210mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years;"
10163909|NCT03957889||Student|
10163910|NCT03957889||Trainers|
10163911|NCT03957837||Steep Trendelenburg|Patients undergoing elective laparoscopic prostatectomy in steep Trendelenburg position (25 degrees head down position)
10163912|NCT03957837||Healthy controls|Healthy awake volunteers undergoing steep Trendelenburg position (25 degrees head down position)
10163913|NCT03957811|No Intervention|Controls|Subjects under treatment for diabetes will receive the standard treatment for their condition.
10163914|NCT03957811|Experimental|Intervention|Subjects under treatment for diabetes not diagnosed for diabetic foot will receive the standard treatment plus exercise on a vibrator platform for a period of 12 weeks.
10163915|NCT03957785|Experimental|Alter G treatment|All participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.
10163916|NCT03957785|Active Comparator|Traditional Gait Training|All participants practiced one session a day TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using FAC-tailored physiotherapist assistance, to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). Physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions.
10163917|NCT03957785|Active Comparator|Healthy Control|ll participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.The HC initially practiced the device at the same BWS and S administered to the patients. BWS and S were reduced progressively and increased, respectively, across the AlterG sessions in keeping with patients progresses.
10163918|NCT03957746|Experimental|3 sets of resistance exercise|
10163919|NCT03957746|Experimental|6 sets of resistance exercise|
10163920|NCT03957746|Experimental|9 sets of resistance exercise|
10163921|NCT03957746|No Intervention|Rest|
10163922|NCT03957694|Experimental|AMG531|
10163923|NCT03957473||Single Arm|Single Arm - Use of Indigo Aspiration System with CAT RX Aspiration Catheter (mechanical thrombectomy) in high thrombus burden acute coronary vessel occlusions
10163924|NCT03957447||patients exhibiting skin wounds|Within the framework of Taabo HDSS Cross-sectional community and health services surveys are performed before wound management intervention (main study and substudy 1) is implemented (baseline) and are continued at 6 monthly intervals thereafter. Surveys are done door-to-door. All patients with skin lesions (broken skin barrier) are enrolled, lesions are documented with help of a questionnaire and photographic documentation.
10163925|NCT03957447||patients identified in the survey and willing to participate|Each patient with a wound will be enrolled. Presumptive clinical diagnosis and empirical treatment, as well wound assessment, will be recorded at enrollment and at each follow-up visit. Additional laboratory testing done within the framework of the local health system will also be recorded.
10163926|NCT03957447||patients exhibiting Buruli ulcers < 2cm|Buruli ulcer patients fulfilling inclusion criteria will be offered thermotherapy instead of standard antibiotic treatment. Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
10163927|NCT03957460||continuous and noninvasive hemoglobin monitoring|Group receive the continuous and noninvasive hemoglobin monitoring during laparoscopic gastrectomy.
9671445|NCT05048394|Experimental|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand
10163928|NCT03957486|Experimental|Same group|arterial cannulation on same arm of continuous hemoglobin monitoring
9671446|NCT05048394|Experimental|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
9694857|NCT04784611|Experimental|Group 1 - OP-ENS Intervention|Participants will be matched with a peer health navigator. As part of this complex behavioral intervention, participants and peer health navigators will engage in a systematic process of barrier and strength identification, goal setting and action planning related to issues of healthcare access and quality. Participants and peers will meet at least monthly over the course of the 12-month study period (but frequency is determined by participant need). Given the nature of the disability and healthcare experience, we anticipate the needs and therefore frequency will fluctuate over the duration of the study period. Beginning in month 10, participants and peers will engage in a period of transition planning to ensure that participants have the strategies and supports in place to assume the role of their own health navigator.
10163929|NCT03957486|Placebo Comparator|Different group|arterial cannulation on different arm of continuous hemoglobin monitoring
10163930|NCT03957655|Experimental|SHED group|SHED transplantation via peripheral vein: 1x10E6 SHEDs/kg body weight administered via peripheral vein at week 0,4,8,12.
10163931|NCT03957655|No Intervention|Control|Standard medication for viral hepatitis and cirrhosis
10163932|NCT03957408|Experimental|Visual Stimuli|Participants will be presented various visual stimuli in which accommodative response is measured.
10163933|NCT03957538|No Intervention|Standard care|Standard consent and explanation
10163934|NCT03957538|Experimental|Virtual reality|Addition of VR headset
10163935|NCT03957603|Experimental|TPF-DM Combined with Medical Nutrition Therapy Intervention|Participants in the experimental group will be provided with an individualized dietary, nutrition recommendation and the additional Enteral Nutrition Suspension (TFP-DM, Diason 0.75 kcal/ml). Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
10163936|NCT03957603|Active Comparator|Medical Nutrition Therapy Intervention|Based on the standard care, Participants will receive an individualized dietary, nutrition recommendations with the application of food exchange porting. Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
10163937|NCT03957681|Experimental|KHK4827|
10163938|NCT03957681|Placebo Comparator|Placebo|
10163939|NCT03957564|Experimental|Patients receiving neoadjuvant chemotherapy.|"Compare the monitoring of CTC, ctDNA and cfDNA with the results of CT scan and the blood level of CEA ,CA19-9 and CA72-4 tumor markers to explore the clinical value of dynamic detection of CTC, ctDNA and cfDNA in neoadjuvant chemotherapy and operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer.~Explore the clinical value of different types of CTC in neoadjuvant chemotherapy and Operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer. CTC can be classified into three types: epithelial CTC, mesenchymal CTC, hybrids CTC.~Explore the consistency between plasma ctDNA and tumor related DNA in pathological tissues after operation.~To explore the relationship between the dynamic changes of plasma CTC, ctDNA and cfDNA levels and the prognosis of patients after operation."
10163940|NCT03957668|Experimental|PEG 3350|The content of each sachet of PEG 3350 (17 g powder) is dissolved in 240 mL of water, drink it once daily at bedtime, for a duration of 14 days.
10163941|NCT03957668|Active Comparator|Lactulax|15 ml of Lactulax syrup (containing 10 g of lactulose) is drunk with 240 ml of water once daily at bedtime, for a duration of 14 days
10163942|NCT03957421|Experimental|Aquatic exercise is more beneficial than land based exercise|use of aquatic exercise will be evaluated for individuals with stroke
10163943|NCT03957499|Placebo Comparator|the control group|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
10163944|NCT03957499|Active Comparator|Group dexamethasone/Bupivacaine:|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml).(
10163945|NCT03957499|Active Comparator|Group Magnesium sulphate/Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
10163946|NCT03957343|Experimental|Pacing and Planning App|The Pacing and Planning Program is a points system to aid individuals with an acquired brain injury/concussion in planning daily activities and managing symptoms. Activities are allotted various points, depending on the energy the task requires and the symptoms they create. Activities can include anything from grocery shopping to driving or watching TV, etc. Patients are allotted a number of points for a day, and therefore learn to sparingly perform activities. This results in a reduction of symptoms and improved recovery time.
10163947|NCT03957629|Active Comparator|TDF group|93 patients would receive treatment of oral medication of tenofovir disoproxil fumarate (TDF) 300mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
10163948|NCT03957629|Active Comparator|Combination group|93 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg once per week and meanwhile oral medication of tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
10163949|NCT03957759||COPD patients|
10163950|NCT03957551|Experimental|Cabozantinib and pembrolizumab|Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.
10163951|NCT03957291|Active Comparator|Povidine-Iodine|patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye before operation
10163952|NCT03957291|Active Comparator|chlorhexidine|patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye before operation
10163953|NCT03957161|Experimental|ACEi/ARB continuation|Intervention group will continue or start to take ACEi and/or ARBs
10163954|NCT03957161|No Intervention|ACEi/ARB withdrawal|The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs
10163955|NCT03957122|Experimental|individualized rTMS|Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
10163956|NCT03957122|Active Comparator|standard rTMS in responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
10163957|NCT03957122|Active Comparator|standard rTMS in non-responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.
10163958|NCT03957174|Experimental|Reboxetine|Single dose of 4mg
10163959|NCT03957174|Experimental|Rivastigmine|Single dose of 3mg
9974732|NCT05250180|Experimental|Intervention|animal assisted therapy
9974733|NCT05250180|Active Comparator|Control|Treatment as usual
10163960|NCT03957174|Placebo Comparator|Placebo|Single dose of placebo
10163961|NCT03957525|Experimental|Orthopaedic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
10163962|NCT03957525|No Intervention|Orthopaedic Control group|Gets written and oral preparation for surgery
10163963|NCT03957525|Experimental|Urologic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
10163964|NCT03957525|No Intervention|Urologic Control group|Gets written and oral preparation for surgery
10163965|NCT03957525|Experimental|General Paediatric Surgery Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
10163966|NCT03957525|No Intervention|General Paediatric Surgery Control group|Gets written and oral preparation for surgery
10163967|NCT03957395|Experimental|scs high-frequency|high-frequency stimulation
10163968|NCT03957395|Experimental|scs tonic|tonic stimulation
10163969|NCT03957395|Experimental|scs burst|burst stimulation
10163970|NCT03957395|Placebo Comparator|scs off|off stimulation
10163971|NCT03957239|Experimental|Cranberry Beverage|Four prepackaged juice boxes (4.23 oz each) containing a whole milled cranberry beverage for 2 weeks
10163972|NCT03957239|Placebo Comparator|Placebo Group|Four prepackaged juice boxes (4.23 oz each) containing a cranberry-flavored beverage for 2 weeks
10163973|NCT03957135|Experimental|Laparoscopic distal pancreatectomy|Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer
10163974|NCT03957135|Active Comparator|open distal pancreatectomy|Patients receiving open distal pancreatectomy for pancreatic tail and body cancer
10163975|NCT03956992|Experimental|Mouth gel|A mouth gel with hydroxyapatite
10163976|NCT03957226|Experimental|Trasnhumeral e-OPRA Implant|This arm includes patients with transhumeral amputation that will receive the e-OPRA implant system.
10163977|NCT03957356|Experimental|HLBLS-200|HLBLS-200, absorbent hemostactic powder, will be applied intraoperatively to stop blood oozing during hepatic resection.
10163978|NCT03957265|Experimental|Syncone|Tapered abutment connection
10163979|NCT03956927||patients|Insulin-dependent diabetic patients who have participated in a full TPE program (3 sessions)
10163980|NCT03957057|Experimental|Iron carboxymaltose group|Iron carboxymaltose group. Total dose of intravenous ferric carboxymaltose (Iroprem®) needed to correct anemia and replenish iron stores will be calculated using the Ganzoni formula (28) modified to include adjustment for baseline iron status: prepregnancy weight in kilograms X (15-baseline Hb) X 2.4 + 500. Fifteen is the target Hb in g/dL, 2.4 is a unit less conversion constant and 500 is the target iron stores in mg. The maximal dose administered in a single day will not exceed 15 mg/kg (current weight) or 1000 mg (for participants with body weight > 67 kg). If total calculated dose will exceed 15 mg/kg or 1000 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
10163981|NCT03957057|Experimental|Iron isomaltoside group|Total dose of intravenous iron isomaltoside (Monofer®) needed to correct anemia and replenish iron stores will be calculated as described above. The maximal dose administered in a single day will not exceed 20 mg/kg (current weight) or 1500 mg (for participants with body weight > 75 kg). If total calculated dose will exceed 20 mg/kg or 1500 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
10163982|NCT03957057|Active Comparator|Iron sulphate group|Iron sulphate group. Participants will receive oral ferrous sulphate (Tardyfer®) 160 mg daily for 6 weeks with instruction to take two tablets by mouth once daily 1 hour before meal. They will receive no additional iron supplementation.
10163983|NCT03956966|Placebo Comparator|saline|bilateral quadratus lumborum block using 0.9% normal saline
10163984|NCT03956966|Active Comparator|Bupivacaine|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25%
10163985|NCT03956966|Active Comparator|Bupivacaine and dexamethasone|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25% and dexamethasone
10163986|NCT03957109|Other|general anesthesia|general anesthesia
10163987|NCT03957109|Other|spinal anesthesia|spinal anesthesia
10163988|NCT03957044|Experimental|sensory integration group|This group was given the education of sensory integration with vestibular education.
10163989|NCT03957044|No Intervention|Control group|The control group was given the education of sensory integration without vestibular education.
10163990|NCT03957096|Experimental|SGN-CD47M|
10163991|NCT03956953|Experimental|Group 1: BMS-986165 Dose 1|Participants will receive Dose 1 on Day 1, and from Day 5 - 19.
9974734|NCT05250167||CKD patients stage 2|
9974735|NCT05250167||CKD patients stage 3a|
9974736|NCT05250167||CKD patients stage 3b|
10163992|NCT03956953|Experimental|Group 2: BMS-986165 Dose 2|Participants will receive Dose 2 on Day 1, and from Day 5 - 19.
10163993|NCT03956953|Placebo Comparator|Group 1: Placebo Dose 1|Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.
10163994|NCT03956953|Placebo Comparator|Group 2: Placebo Dose 2|Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.
10163995|NCT03957031||Cases|Patients with a pathological confirmation of GC diagnosis
10163996|NCT03957031||Control|Patients with confirmed absent of GC
10163997|NCT03957148|Experimental|SSB Education|The SSB reduction intervention consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
10163998|NCT03957148|Sham Comparator|Food Safety Education|The sham control (food safety education) consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
10163999|NCT03956732|Experimental|High protein yoghurt and vitamin D supplement|Subjects will receive high protein yoghurt and vitamin D tablets.
10164000|NCT03956732|Experimental|High protein yoghurt and placebo supplement|Subjects will receive high protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
10164001|NCT03956732|Experimental|Medium protein yoghurt and vitamin D supplement|Subjects will receive medium protein yoghurt and vitamin D tablets.
10164002|NCT03956732|Placebo Comparator|Medium protein yoghurt and placebo supplement|Subjects will receive medium protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
10164003|NCT03957317|No Intervention|Control|Subjects in this group do not receive an eye mask or ear plugs, and receive standard of care (including pain control modalities). The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
10164004|NCT03957317|Experimental|Intervention|Subjects in this group receive an eye mask and ear plugs in addition to standard of care for pain control. The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
10164005|NCT03956641|Experimental|experimental: observational cohort|Evaluation of the physical condition and the quality of life
10164006|NCT03956693|Experimental|HEADS: UP|HEADS: UP is group-based mindfulness intervention based on the original mindfulness based stress reduction course, but adapted for people affected by stroke.
10164007|NCT03956719|Experimental|Autologous adipose-derived mesenchymal stem cells|Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells
10164008|NCT03956823|Experimental|Telmisartan|generic name：telmisartan；dosage form：80 mg；dosage：80 mg；frequency：once a day；duration：June , 2019-June , 2021
10164009|NCT03956823|Active Comparator|Amlodipine|generic name： amlodipine；dosage form：5mg；dosage：5mg；frequency：once a day；duration：June , 2019-June , 2021
10164010|NCT03956667|Experimental|Experimental: Live Music|Live Music will be played during the required Emergency Department procedure.
10164011|NCT03956667|No Intervention|Control: No Live Music|There will be no music played during the required Emergency Department procedure.
10164012|NCT03956628|Experimental|experimental group|participants in experimental group receive intervention and experimental group consists of two sub groups, teachers and students.
10164013|NCT03956628|No Intervention|control group|participants in control group does not receive intervention and control group consists of two sub groups, teachers and students.
9671447|NCT05048277|Experimental|Single Arm Study|"The intervention will consist of one 60-minute long session conducted through NYU ZOOM. Each session will be between one parent and one study consultant. The session is goal-oriented and solution-focused. During the SSC, consultants will identify the participant's hope for the session and a specific modifiable goal. From this, the consultant will discuss the smallest-possible step participants can take toward overcoming their identified problem and work together in creating an Action Plan, which will present three specific actions the participant can take to accomplishing the session's established goals. Following completion of the two-week follow-up assessment, additional resources personalized to participants will also be provided (i.e., referrals for further services and online resources for parents/children). Ultimately, this intervention is a way to potentially jumpstart progress and facilitate hope and agency."
9671448|NCT05048524|Experimental|SLOG|
10164014|NCT03956771|Experimental|Real neurofeedback|Two sessions of neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
10164015|NCT03956771|Sham Comparator|Sham neurofeedback|Two sessions of placebo/control neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
10164016|NCT03956576|Active Comparator|Chronic Kidney Disease patients|"Forearm blood flow studies~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.~Renal clearance studies~Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.~Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.~[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.~Crossover design, so patients will receive both apelin and placebo infusion."
9671449|NCT05048433|Experimental|implementation strategy for active learning to promote physical activity|
9671450|NCT05048433|Active Comparator|Usual Implementation support|
9671451|NCT05048420|Experimental|Ramp lesion repair|
9671452|NCT05048420|Experimental|Anterior cruriciate ligament reconstruction|
9671453|NCT05048355|Experimental|Power Knee Mainstream Dynamic|
9671454|NCT05048355|Active Comparator|Passive MPK|
10164017|NCT03956576|Active Comparator|Healthy volunteers|"Forearm blood flow studies~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.~Renal clearance studies~Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.~Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.~[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.~Crossover design, so patients will receive both apelin and placebo infusion."
10164018|NCT03956875|Active Comparator|yoga|Yoga treatment
10164019|NCT03956875|Placebo Comparator|massage|massage
10164020|NCT03957083|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10164021|NCT03957083|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10164022|NCT03957083|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10164023|NCT03957083|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9694858|NCT04784611|No Intervention|Group 2 - Usual Care|Participants randomized to the usual care group will continue with their usual health and healthcare routines. Participants in the usual care group will receive a monthly newsletter with general interest information relevant to the disability community.
9974737|NCT05250167||CKD patients stage 4|
9974738|NCT05250167||Controls without CKD|
10164024|NCT03957083|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10164025|NCT03957083|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10164026|NCT03956797|Experimental|-15 degrees Celsius for 10 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds.
10164027|NCT03956797|Experimental|-15 degrees Celsius for 15 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds.
10164028|NCT03956888|Experimental|N-acetylcysteine treatment|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
10164029|NCT03956459|Other|Patients with a cancer|
10164030|NCT03956524|Experimental|Test group|Single dose of EuTCV will be administered intramuscularly
10164031|NCT03956524|Active Comparator|Comparator group 1|Single dose of Typbar-TCV™ will be administered intramuscularly
10164032|NCT03956524|Active Comparator|Comparator group 2|Single dose of Typhim Vi® will be administered intramuscularly
10164033|NCT03956433|Experimental|Docosahexaenoic Acid enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) to be consumed daily for 4 weeks.
10164034|NCT03956433|Experimental|Beta-glucan enriched pancakes|One portion of pancakes enriched with 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
10164035|NCT03956433|Experimental|Anthocyanin enriched pancakes|One portion of pancakes enriched with 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
10164036|NCT03956433|Experimental|DHA+BG enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
10164037|NCT03956433|Experimental|DHA+AC enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
10164038|NCT03956589|Experimental|Orkambi open-label arm|Open-label study: all subjects will receive Orkambi during 3 months.
10164039|NCT03956901|Experimental|Liberal Fluid Management|liberal fluid management: 500 ml bolus crystalloid after 4-8 ml/kg/h infusion during surgery total amount of crystalloid volume of fluid infused during gycnecologcy l surgery fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml cyristaloid/Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
10164040|NCT03956901|Experimental|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \ kg crystalloid infusion to be started~If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.~PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13."
10164041|NCT03956914|Experimental|DSW (deep sea water) group|DSW, 440 ml/day for 8 weeks
10164042|NCT03956914|Placebo Comparator|Placebo group|Placebo, 440 ml/day for 8 weeks
10164043|NCT03956537||Pedicle screw system alone|
10164044|NCT03956537||Pedicle screw system with cages|
10164045|NCT03956381||THR with OPS system-TriFit TS/Trinity combination|Hip prosthesis combination: TriFit TS stem/ Trinity cup implanted by Surgeon 1 via a posterolateral approach according to their standard of practice.
10164046|NCT03956381||THR with OPS system-MetaFix/Trinity combination|Hip prosthesis combination: MetaFix stem/ Trinity cup implanted by Surgeon 2 via a direct anterior approach according to their standard of practice.
10164047|NCT03956563|Active Comparator|Active treatment arm|Youlaser MT: sequential 10600+1540 nm with vaginal (2 passes) and intritus (1 pass) treatment
10164048|NCT03956563|Sham Comparator|Control arm|Youlaser MT: no laser emission with vaginal (2 passes) and intritus (1 pass) treatment
10164049|NCT03956420||Study group|Implemented ERAS (Early Recovery After Surgery) elements
10164050|NCT03956420||Control group|The control group will consist of patients treated during the study in accordance with the current standards used in the Department
10164051|NCT03956290|Experimental|TREAT pilot study|Metabolically unhealthy overweight or obese potential participants who pass an in-person screen will enroll in a 2-week run-in period when they will use the app, to assess meal patterns under habitual living conditions.
10164052|NCT03956303|Active Comparator|Plain Levobupivacaine (Chirocaine (% 0.5)|Levobupivacaine 8 mg (Chirocaine (% 0.5)) + 20 mcg fentanyl Chirocaine Plain
10164053|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 40|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40 Chirocaine Heavy 40
10164054|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 60|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 60 Chirocaine Heavy 60
10164055|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 80|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 80 Chirocaine Heavy 80
10164056|NCT03956329|No Intervention|Usual care, control arm|Usual care in which participants will not see a video intervention. This group will attend their influenza vaccination appointment as usual, without intervention. Participants will receive Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
10164057|NCT03956329|Experimental|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
10164058|NCT03956329|Experimental|Individualised Digital Intervention|Similar to the standardised digital intervention, however participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
10164059|NCT03956680|Experimental|Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)|
9974739|NCT05250102|Active Comparator|Pulse oximeter sensor readings|
10164060|NCT03956680|Experimental|Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study|
10164061|NCT03956680|Experimental|Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study|
10164062|NCT03956680|Experimental|Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab|
10164063|NCT03956680|Experimental|Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab|
10164064|NCT03956212|Experimental|erythema migrans patients treated with doxycycline|adult patients with erythema migrans will be treated with oral doxycycline
10164065|NCT03956264|Experimental|VR|"VR Installation 5 min before the drain removal and stop 10 min after the procedure.~If Pain assessed by numerical rating scale (NRS) > 4, administration of morphine."
10164066|NCT03956264|Active Comparator|Kalinox®|"Start of Kalinox® administration by inhalation with a facial mask 1 min before the drain removal and stop after the procedure according to the usual procedure of the service.~If Pain NRS > 4, administration of morphine."
10164067|NCT03956446|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
10164068|NCT03956446|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
10164069|NCT03956446|Other|Healthy controls|Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control. Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
10164070|NCT03956472|Experimental|Osteopathic group|LCS Drainage before altitude exposure
10164071|NCT03956472|Experimental|PEEP 10 cmH2O|10 min at rest
10164072|NCT03956472|Sham Comparator|Control group|Sham PEEP and fake osteopathic protocol
10164073|NCT03956251|Experimental|Combined Mineralized/Demineralized Putty Allograft|Ridge preservation with a Mineralized/Demineralized Putty allograft
10164074|NCT03956251|Active Comparator|Demineralized Putty Allograft|Ridge preservation with Demineralized Putty allograft
10164075|NCT03956199|Experimental|experimental pulpotomy|
10164076|NCT03956199|Active Comparator|Root canal treatment|
10164077|NCT03956017|Experimental|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
10164078|NCT03956017|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
10186432|NCT03735550||Group B age: 50 and above|Women aged 50 and above who had mammography and/or breast ultrasound performed (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa). Women were recruited if they had a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques. The planned number of participants in the group: n=2100 people.
10186433|NCT03735550||Group C 18-49; 50 and above|"Subgroup C1 (n=100 people): women aged 18-49 years, who underwent breast ultrasound with a result of BI-RADS 1 or 2.~Sub-group C2 (n=100 people): women aged 50 and above, who had mammography or breast ultrasound performed; with a result of BI-RADS 1 or 2 (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa).~Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques."
10186434|NCT03735524|Experimental|Exercise|Conventional rehabilitation
10186435|NCT03735498|Experimental|Psychological Intervention|"Qualitative interview will be conducted~7-item Generalized Anxiety Disorder measure will be completed by participants via mail correspondence or online~A psychoeducational component to address preparedness, manage expectations, and develop caregiving skills~A psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~A self-care component to promote caregiver health and well-being"
10186436|NCT03735485|Experimental|Group I|The control group. Participants in this group received only conventional physiotherapy. Number of the participants were 14.
10186437|NCT03735485|Experimental|Group II|The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
10186438|NCT03735485|Experimental|Group III|The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises. Number of the participants were 15.
10186439|NCT03735472||Aneurysm/Dissection|Thoraflex™ Hybrid
10186440|NCT03735459|Experimental|Patient reminder|"Patient Oriented SCORAD (PO-SCORAD): Assess severity of eczema.~Adherence Questionnaire (AQ): Assess adherence to eczema treatment plan provided to them by their healthcare provider.~Family Dermatology Life Quality Index (FDLQI): Assess impact of the participant's eczema on the family's quality of life.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 1, 2, and 4: Participants will complete PO-SCORAD and AQ.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
10186441|NCT03735459|No Intervention|No patient reminder/control|"Participants in arm 2 are not sent text messages, and will not be asked to complete questionnaires 1, 2, and 4 weeks post enrollment. Participants will be asked to complete questionnaires during enrollment and 6 weeks post enrollment.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
10186442|NCT03735446|Experimental|Prexasertib+MEC|"Cytarabine is administered intravenously on days 1-5.~Etoposide is administered intravenously on days 1-5.~Mitoxantrone is administered intravenously on days 1-5.~Prexasertib is administered intravenously on days 1, 3, and 5."
10186443|NCT03735433|No Intervention|81 mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive recommended 81mg ASA
10186444|NCT03735433|Active Comparator|162mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
9694859|NCT04784455|Experimental|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within 100 days of HSCT
10164079|NCT03955991|Experimental|R-CBSM|10 weeks of group intervention convene by a broadband connection for approximately 75-90 minutes. Intervention given prior to Influenza Vaccine.
10164080|NCT03955991|Active Comparator|Wait List Condition (WLC)|Persons assigned to this group will receive R-CBSM approximately 28 days after receiving the Influenza Vaccine.
10164081|NCT03955939|Experimental|LY3295668 Erbumine Part A|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
10164082|NCT03955939|Experimental|LY3295668 Erbumine Part B|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
10164083|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Cohort 1|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II).
10164084|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Continuation Part C|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
10164085|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Switch Part D|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
10164086|NCT03955809|Active Comparator|Ketamine 0.5 mg/kg|ketamin 0.5 mg/kg intraarticular
10164087|NCT03955809|Active Comparator|Ketamine 1 mg/kg|ketamin 1 mg/kg intraarticular injection
10164088|NCT03955809|Sham Comparator|% 0.9 Saline|% 0.9 NaCL intraarticular injection
10164089|NCT03955848|Experimental|ARM 1|NK cell infusion
10164090|NCT03955848|No Intervention|ARM 2|Follow up without treatment
10164091|NCT03956134|Experimental|Tapentadol Test Product 1 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
10164092|NCT03956134|Experimental|Tapentadol Test Product 2 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
10164093|NCT03956134|Experimental|Tapentadol Test Product 1 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
10164094|NCT03956134|Experimental|Tapentadol Test Product 2 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
10164095|NCT03956134|Active Comparator|Tapentadol PR Reference Product|Tapentadol PR tablet formulation given as single oral dose with 240 mL of still mineral water under fasting condition.
10164096|NCT03956160|Experimental|Intervention group|"For 12 months from the return home, patients in the intervention group will benefit from telephone support by a trained case-manager (number and frequency of contacts defined according to the patient's needs) and access to an Internet platform.~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon return home, including identifying and requesting the necessary health or social resources."
10164097|NCT03956160|No Intervention|Control group|"Patients randomized to the control group will receive the usual practices. As part of the study, they will be contacted for data collection upon their return home, at 6 months and 12 months by a clinical research associate.~Access to the internet platform and an interview with the case-manager will be offered at the end of the study to patients in the control group."
10164098|NCT03956108|Experimental|MRI/Fusion biopsies|Stockholm3+MRI+targeted biopsies
10164099|NCT03956108|Active Comparator|Systematic biopsies|PSA+systematic biopsies
10164100|NCT03955653|Active Comparator|RAO projection|Patients will be randomized to right anterior oblique (RAO) projection by fluoroscopy for the access to the femoral artery
10164101|NCT03955653|Active Comparator|AP projection|Patients will be randomized to anterior-posterior projection by fluoroscopy for the access to the femoral artery
10164102|NCT03955757|Experimental|Boot Camp Translation|Intervention communities will undergo the Boot Camp Translation process.
10164103|NCT03955757|Active Comparator|Control|Control communities will behave as usual
10164104|NCT03955796|Experimental|RayOne Hydrophobic Aspheric|Patient will receive the hydrophobic IOL during cataract surgery
10164105|NCT03955796|Experimental|RayOne Aspheric|Patient will receive the non-hydrophobic IOL during cataract surgery
10164106|NCT03955965||Emergency patients with medication reconciliation|All patients who beneficiated from medication reconciliation in the emergency department between November 2017 and April 2018
10164107|NCT03956173||Clamp group|24 patients with type 1 diabetes.
10164108|NCT03955887||Experimental|Patients with severe acute lung disease requiring mechanical ventilation
10164109|NCT03955887||Control|Patients receiving routine bronchoalveolar lavage for a pathology not suspected of acute infection
10164110|NCT03956121||Exposed group|Exposed group( with magnesium sulfate): fetuses aged 24 + 0AW to 32 + 0AW and benefiting from MgSO4 for neuroprotective purposes, with decision of extraction or spontaneous or induced labour
10164111|NCT03956121||Control group|Control group (without magnesium sulfate) : fetuses aged 32 + 1SA to 35 + 0SA without MgSO4, with extraction decision or spontaneous or induced labour
10164112|NCT03955926|No Intervention|Control group|kept fasted from midnight until surgery
10164113|NCT03955926|Experimental|NO-NPO group|drink carbohydrate beverage until 2 h before surgery
10164114|NCT03955744|Experimental|3D translabial ultrasound|3D translabial ultrasound with concurrent vaginal manometry
10164115|NCT03955575|Active Comparator|Liraglutide/placebo-colesevelam|Liraglutide as active and colesevelam as placebo
10164116|NCT03955575|Active Comparator|Placebo-Liraglutide/colesevelam|Liraglutide as placebo and colesevelam as placebo
10164117|NCT03955601|Experimental|TBI free Haploidentical HSCT|Recipients will receive a reduced intensity conditioning regimen of ''Fludarabine'' 30 mg/m2 IV daily from day -7 to -3, ''Cyclophosphamide'' 14.5-30 mg/kg IV daily on day -6 and -5 , ''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3; ''Busulphan'' IV 3.2 mg per kg/day in 02 divided doses on day -3 and day-2, ''Granulocyte Colony Stimulating factor primed Bone marrow harvest'' and/OR ''PBSC'' graft on day 0 and day +1 respectively and Graft versus host disease prophylaxis with ''post-transplant cyclophosphamide'' administered at a dose of 50mg/kg/day given daily on days +3 and +5 post-transplant and ''cyclosporine'' from day +5, ''mycophenolate mofetil'' from day+5 to day+35.
10164118|NCT03955952||Bariatric Surgery|Patients with type 2 diabetes with BMI >=30 that underwent bariatric surgery
10164119|NCT03955952||Non-Surgical Control|Matched non-surgical controls with type 2 diabetes and BMI >=30
9826444|NCT02418754|Experimental|REGN2176-3 (1 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
10164120|NCT03955588||Women undergoing invasive prenatal diagnostic procedures|For women requiring invasive prenatal diagnosis by chorionic villus sampling or amniocentesis, they will be offered the options of having either conventional cytogenetics or aCGH.
10164121|NCT03955666|Experimental|Cohort A (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
10164122|NCT03955666|Experimental|Cohort B (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
10164123|NCT03955731|Other|Single study arm|STEMI Patients treated with Magmaris resorbable magnesium scaffold
10164124|NCT03956004|Experimental|Experimental|Full decision aid, consisting of education on osteoarthritis and treatment options, preferences and values elicitation, and personalized risk/benefit estimates based on patient's response to patient-reported outcome measures.
10164125|NCT03956004|Active Comparator|Control|Education component of the decision aid only.
10164126|NCT03955770|Experimental|HFOT first then LFOT|
10164127|NCT03955770|Experimental|LFOT first then HFOT|
10164128|NCT03955705|Experimental|Nefopam|Nefopam: 20 mg (infuse at least 15 minutes) every 4-6 hours, max 120 mg/day
10164129|NCT03955705|Placebo Comparator|Normal saline solution|Normal saline or 0.9% Sodium Chloride (NaCl) or NSS
10164130|NCT03955562|Experimental|Intervention|Communities that receive a pedestrian footbridge.
10164131|NCT03955562|Experimental|Comparison|Communities that do not receive a pedestrian footbridge.
10164132|NCT03955692|Active Comparator|Active tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
10164133|NCT03955692|Sham Comparator|Sham tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
10164134|NCT03955718|Experimental|Motherly App|A smartphone app with an automated intervention that provides strategies to prevent maternal depression and to promote child development: (1) behavioral activation, (2) sleep hygiene, (3) physical activity, (4) social support, (5) nutrition, (6) prenatal care schedule, and (7) educational content.
10164135|NCT03955718|Active Comparator|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
10164136|NCT03955549|Experimental|Insight Enhancement Program (IEP)|The insight enhancement program is a dynamo-cognitive therapeutic modality with the main target of improving insight in psychotic patients as a means of improving their overall outcome.
10164137|NCT03955549|Experimental|Metacognitive Training for Psychosis (MCT)|The metacognitive training program, developed by Moritz et al. (Moritz & Woodward, 2007) targets cognitive biases putatively involved in the formation and maintenance of psychotic symptoms.
10164138|NCT03955549|Active Comparator|Treatment As Usual (TAU)|"Treatment as usual will be used as a control condition to assure ethicality of our procedure.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
10164139|NCT03955484||Patients who had benign prostatic hyperplasia|"Male patients presenting with lower urinary tract symptoms to urology outpatient clinic~According to the European Association of Urology Guidelines:~International prostate symptom score> 8 Prostate volume> 40 ml Q max <15 ml /sn Patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time Patients who have not undergone lower urinary tract surgery"
10164140|NCT03955406|Active Comparator|Conventional group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 6% with fresh gas flow rate 4 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 1% higher value than the EtAA concentration required to achieve 0.7 MAC. And after 10 minutes fresh gas flow rate will be reduced to 1L/min.
10164141|NCT03955406|Active Comparator|Fixed Fresh Gas Flow Rate group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 18% with fresh gas flow rate 1 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 2% higher value than the EtAA concentration required to achieve 0.7 MAC.
10164142|NCT03955354|Experimental|experimental arm|SHR1210 plus apatinib
10164143|NCT03955341|No Intervention|conventional selective caries removal without disinfection|After collecting the first sample of dentin, the cavity will be restored
10164144|NCT03955341|Other|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
10164145|NCT03955341|Other|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
10164146|NCT03955380|Active Comparator|Active Comparator: Contraloid 160 mg|160 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
9977392|NCT01360944|Active Comparator|reference, once daily|once daily
10164147|NCT03955380|Active Comparator|Active Comparator: Contralod 320mg|320 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
10164148|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 160 mg|160 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
10164149|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 320 mg|320 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
10164150|NCT03955393||LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|Twenty patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4 cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter>10 cm). RCC candidates to surgery will receive a single intravenous infusion of 18F-FAZA. Surgery will be scheduled within 1 week after infusion. PET and CT scanning of the abdomen will be planned before surgery.
10164151|NCT03955458|Experimental|FICB with EXPAREL|Group 1: Suprainguinal Fascia Iliaca Compartment Block (FICB) with EXPAREL and bupivacaine HCl
10164152|NCT03955458|Active Comparator|FICB with Standard of Care: ropivacaine|Suprainguinal FICB with continuous infusion of local anesthetic (ropivacaine) via catheter placed in the FIC.
10164153|NCT03955419|No Intervention|Control group|Participants in the control group will be fasted from midnight until surgery.
10164154|NCT03955419|Experimental|Study group|Participants will receive 800 mL of carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg). They will drink this beverage freely, starting from the evening before surgery until 2 hours before surgery.
10164155|NCT03955536|Active Comparator|Group A|Routine cardiac rehabilitation program (RCRP)atient education
10164156|NCT03955536|Experimental|Group B|routine cardiac rehabilitation program + virtual reality
10164157|NCT03955536|Experimental|Group C|RCRP + inspiratory muscle training
10164158|NCT03955328|Experimental|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
10164159|NCT03955315|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells)
10164160|NCT03955315|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
10164161|NCT03955315|Sham Comparator|Sham|Sham needle puncture (outside disc)
10164162|NCT03955523|Experimental|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation >5% VO2peak for at least 3 minutes of exercise.
10164163|NCT03955523|Experimental|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
10164164|NCT03955523|No Intervention|Control (doing nothing)|Non-exercise trial day The protocol of the non-exercise trial day is identical to that of the exercise trial day, except that exercise is substituted by 30 min of quiet sitting in a lounge area (e.g. reading, working or watching a movie on an electronic device) without further engagement with other people.
10164165|NCT03955159|Experimental|Experimental: Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
10164166|NCT03955159|Placebo Comparator|Placebo comparator|The placebo that will be used in the present study is maltodextrin, which is a food supplement based on carbohydrate powder.
10164167|NCT03955107|Other|Continuous Glucose Monitoring System|
10164168|NCT03955250|Experimental|Mobile After-Care Support (MACS) app|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and intervention.
10164169|NCT03955250|Active Comparator|Mobile app attention control|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and psychoeducation about illness.
10164170|NCT03955172|Experimental|Everolimus|
10164171|NCT03955224|Active Comparator|Basic Oral Care + active LLLT (experimental arm)|
10164172|NCT03955224|Placebo Comparator|Basic oral Care + inactive LLLT (control arm)|
10164173|NCT03955224|Other|Basic Oral Care (control arm)|
10164174|NCT03955120|Experimental|Sleep Apnea- Dayzz|The intervention group is also provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the adherence to CPAP. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device. The intervention group meets a CPAP technician at the sleep clinic, as detailed below in the Sleep Apnea TAU group
10164175|NCT03955120|Active Comparator|Sleep Apnea- Treatment as Usual|"The treatment as usual [TAU] group meets a CPAP technician at the sleep clinic, who provides the participant with a CPAP device and fits the mask. The will also receive a follow-up visit with the same technician for technical support, mask changes or alterations if needed after an initial 7 to 14-day at home CPAP trial."
10164176|NCT03955120|Experimental|Insomnia - Dayzz|The intervention group is provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the insomnia concerns, sleep symptoms, and achieve sleep goals. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device.
10164177|NCT03955120|Active Comparator|Insomnia - Treatment as Usual|"The treatment as usual [TAU] group, will receive standard treatment recommendations for their insomnia, including sleep hygiene suggestions, referral for supportive/non-medical treatments [e.g. relaxation therapies], and if needed hypnotics or other medications prescribed by the sleep clinic physician."
10164178|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with short hamstring|Anatomic anterior cruciate ligament with short hamstring graft
10164179|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with standard hamstring|Anatomic anterior cruciate ligament with standard hamstring graft
10164180|NCT03955510|Other|"Right-time eating / no alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will be asked to not drink alcohol for 1 week. Subjects will randomly be assigned to each eating pattern during the study period."
10164181|NCT03955510|Other|"Right-time eating / with alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
10164182|NCT03955510|Other|"Delayed-eating / no alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Subjects will be asked to not drink alcohol for 1 week."
10164183|NCT03955510|Other|"Delayed-eating / with alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
10164184|NCT03955497|Experimental|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
10164185|NCT03955497|Placebo Comparator|sodium hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
10164186|NCT03955094|Experimental|AMBU® AURAGAIN™ device|Assess feasibility of AMBU® AURAGAIN™ as an intubating device in paediatrics
10164187|NCT03955003|Experimental|Group Drumming|6 week one hour/week drumming sessions. The detailed intervention protocol was created in collaboration with board-certified music therapists. The music used in the intervention will include both recorded percussion music and the use of percussion instruments.
10164188|NCT03955003|Other|Attention Control Entertaining Educational Series|6 week one hour/week educational series. The educational group is largely intended to create an attention group control so group effect and time of the drumming intervention can be controlled.
10164189|NCT03955237|Active Comparator|non glucose infusion group|Drug: LR infusion LR solution without glucose; the patients with preoperative blood glucose level higher than 90 mg/dL.
10164190|NCT03955237|Active Comparator|Drug:1% Dextrose infusion group|Drug:LR+ 1% Dextrose infusion LR solution with % 1 glucose: the patients with preoperative blood glucose level between 60-90 mg/dL,
10164191|NCT03955237|Active Comparator|2% Dextrose infusion group|Drug:LR+ 2 % Dextrose infusion Lactate ringer (LR) solution with % 2 glucose; the patients with preoperative blood glucose level lower than 60 mg/dL,
10164192|NCT03954990|Placebo Comparator|Control Arm|Placebo tablets oral, 4 tablets once.
10164193|NCT03954990|Active Comparator|Treatment Arm|Will receive 4 tablets (2g) of metronidazole oral once.
10164194|NCT03955302|Experimental|Exercise|Patients in this group will perform the water exercise protocol, 3 times a week, for 12 weeks.
10164195|NCT03955302|No Intervention|Control|Patients in this group will not perform any type of exercise during the 12 weeks of the treatment.
10164196|NCT03954951|No Intervention|Control group|The clinicians in the control group will continue usual care without intervention. They will not receive the online course or performance feedback reports.
10164197|NCT03954951|Active Comparator|Intervention group|The primary care physicians will receive access to an online course on hypertension management based on the ACC/AHA and ESC guidelines. They will also receive feedback reports on their performance on hypertension management for 16 weeks.
10164198|NCT03955185|Experimental|Minimally invasive surgery|The patients will receive laparoscopic or robotic assisted radical hysterectomy with improved surgery details: 1) Uterine manipulator type Cup-shaped uterine manipulator is prohibited, uterus hanging wire is allowed. 2) Avoid tumor cells shedding into the pelvis: A. Cut the vagina with the transvaginal method, B. Cut the vagina after closed loop ligation of the vagina. After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
10164199|NCT03955185|Active Comparator|Open abdominal surgery|The patients will receive traditional radical hysterectomy.After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
10164200|NCT03954964|No Intervention|Control Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement.
10164201|NCT03954964|Experimental|Intervention Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement will receive additional education about the disposal of opioids.
10164202|NCT03954977|Experimental|Ultrasound vs Radiograph|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
10164203|NCT03955016|Experimental|Rehabilitation group|15 weeks pulmonary rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home-based rehabilitation.
10164204|NCT03955016|No Intervention|Control group|Usual care
10164205|NCT03954860|Experimental|No Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. No drainage tube was placed after operation.
10164206|NCT03954860|Active Comparator|Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Drainage tube should be placed after operation.
10164207|NCT03954873|Experimental|Hyperglycaemia + GLP-2|Glucose + GLP-2
10164208|NCT03954873|Active Comparator|Hyperglycaemia + Placebo|Glucose + saline
10164209|NCT03954873|Experimental|Hypoglycaemia + GLP-2|Insulin + glucose + GLP-2
10164210|NCT03954873|Active Comparator|Hypoglycaemia + Saline|Insulin + glucose
10164211|NCT03954873|Experimental|Euglycaemia + GLP-2|GLP-2
10164212|NCT03954873|Active Comparator|Euglycaemia + Placebo|
10164213|NCT03955276||Matched Therapy|Targeted therapy matched to each patient's genomic/immunophenotypic tumor profile (whereby oncogenic alterations are matched with targeted agents)
10164214|NCT03955276||Unmatched Therapy|General, unmatched therapy (standard of care)
10164215|NCT03954821||control group|control group in which all of them present pronated foot without tratment
10164216|NCT03954821||experimental group|Group in which they have been treated with prefabricated plantar insoles to stop pronation
10164217|NCT03954795|Active Comparator|Group 1: TAP Block|TAP Block performed from the petit triangle ( anterior axillary line and iliac crest.)
10164218|NCT03954795|Active Comparator|Group 2: OSTAP Block|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
10164219|NCT03954795|No Intervention|No Block|No interventions
10164220|NCT03954808|Experimental|Motor imagery training group|Children with Cerebral Palsy. Motor imagery training group will receive a traditional physiotherapy and motor imagery training within a specific program, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes MI training). The motor imagery training will be designed for the individual basis with standard protocols. All sessions will be performed in the clinic.
10164221|NCT03954808|Active Comparator|Cerebral Palsy control group|Children with Cerebral Palsy. Traditional physiotherapy control group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
10164222|NCT03954808|No Intervention|Typically developing control group|Age matched healthy individuals, with no treatment.
10164223|NCT03954912|Active Comparator|MAKO robotic assisted UKA|image base (MAKO) robotic assisted UKA
10164224|NCT03954912|Active Comparator|NAVIO robotic assisted UKA|imageless (NAVIO) robotic assisted UKA
10164225|NCT03954847||Lung cancer patients|Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment
10164226|NCT03954639|Experimental|Cohort 1, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
10164227|NCT03954639|Active Comparator|Cohort 1, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
10164228|NCT03954639|Experimental|Cohort 2, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
10164229|NCT03954639|Active Comparator|Cohort 2, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
10164230|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Unfed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Unfed.
10164231|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Fed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Fed.
10164232|NCT03954600|Other|NPT520-34 - SAD Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT520-34: 250 mg OR Single dose of orally administered placebo capsule(s) to match dose.
10164233|NCT03954600|Other|NPT520-34 - SAD Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT520-34: 500 mg OR Single dose of orally administered placebo capsule(s) to match dose.
10164234|NCT03954600|Other|NPT520-34 - SAD Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT520-34: 1000 mg OR Single dose of orally administered placebo capsule(s) to match dose.
10164235|NCT03954600|Other|NPT520-34 - MAD Cohort 1, Dose 1|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
10164236|NCT03954600|Other|NPT520-34 - MAD Cohort 2, Dose 2|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
10164237|NCT03954600|Other|NPT520-34 - MAD Cohort 3, Dose 3|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
10164238|NCT03954665|Active Comparator|Baseline Testing|Baseline testing for a 10km cycle time trial and a 30s Wingate cycle test.
10164239|NCT03954665|Experimental|Dietary Supplement: Exogenous Ketone Salt|Ketone salt supplementation (0.6-0.8g•kg-1•d-1) 7-days. Participants will perform two exercise performance tests (a 10km cycle time trial and a 30s Wingate cycle test on separate days) after supplementation.
10164240|NCT03954704|Experimental|Phase 1a, Part A - Dose Escalation|Part A will consist of dose escalation by an accelerated dosing design and a 3+3 dose escalation scheme. Participants will receive escalating dose levels GS-1423 of up to 45 mg/kg on Day 1 of each 2-week cycle (Q2W) until the participants meets study treatment discontinuation criteria or for up to 1 year.
10164241|NCT03954704|Experimental|Phase 1a, Part B - Flat Dose Regimen|Part B will consist of 3 adaptive cohorts. Based on PK, pharmacodynamics, and safety results from the Part A study, participants will be administered a flat dose of GS-1423 on Day 1 of each cycle QW, Q2W and/or every 3 weeks (Q3W) until the participant meets study treatment discontinuation criteria or for up to 1 year.
10164242|NCT03954704|Experimental|Phase 1b, Cohort 1 (Gastric Cancer)|"Safety run-in: A standard 3+3 dose escalation design will be used to determine the DLT and MTD or RP2D of GS-1423 in combination with mFOLFOX6. The planned starting dose of GS-1423 will be targeted to achieve the exposure at -1 dose of RP2D monotherapy (Q2W) determined from Phase 1a. GS-1423 will be administered in combination with mFOLFOX6.~Post safety run-in: Approximately 70 participants will be enrolled to receive GS-1423 at the dose level determined from the safety run-in period, in combination with mFOLFOX6 regimen.~Participants will receive GS-1423 on Day 1 of each 14-day cycle up to 2 years until PD, or unacceptable toxicity, substantial noncompliance with study procedures or study drug, study discontinuation or withdrawal from study. Participants will also receive mFOLFOX6 regimen Q2W for up to 12 cycles."
10164243|NCT03954704|Experimental|Phase 1b, Cohort 2 (Paired Biopsy)|Participants will receive GS-1423 at the dose level determined from Phase 1a Q2W until the participants meets study treatment discontinuation criteria or for up to 1 year.
10164244|NCT03954717||Participants in the Shepherd CAN DO Program|24 people with MS enrolled into the Shepherd CAN DO Program.
10164245|NCT03954717||Control Group-Shepherd (CG-S)|24 people with MS who are current patients of the MS Institute at the Shepherd Center.
10164246|NCT03954717||Control Group-iConquerMS (CG-iCMS)|24 iConquerMS members
10164247|NCT03954717||Support partners of CAN DO|24 support partners of the participants in the Shepherd CAN DO Program group
10164248|NCT03954717||CG-S support partners|24 support partners of the people with MS in the CG-S group.
10164249|NCT03954717||CG-iCMS|24 support partners of the people with MS in the CG-iCMS group
10164250|NCT03954730|Experimental|Eccentric Training Group|Eccentric training will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
10164251|NCT03954730|Active Comparator|Active Release Technique Group|Active release technique will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
10164252|NCT03954561|Experimental|endoscopist group|endoscopist-administered abdominal compression group
10164253|NCT03954561|Active Comparator|assistant group|assistant-administered abdominal compression group
9826445|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
10164254|NCT03954366|Other|Arm A - rucaparib and oral rosuvastatin|
10164255|NCT03954366|Other|Arm B - rucaparib and oral contraceptives|
10164256|NCT03954522|Experimental|Expérimental|psychologist interview and psychometrics scales
10164257|NCT03954678|Experimental|Exercise Group|Participants randomized to the activity intervention will aim for taking 10,000 steps per day and completing strength training exercises three times per week.
9826446|NCT02418754|Experimental|Intravitreal Aflibercept Injection (IAI) 2 mg|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
9826447|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg) to IAI 2 mg|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
9826448|NCT02418754|Experimental|IAI 2 mg to REGN2176-3 (3 mg:2 mg)|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
9826449|NCT02418819|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
9826450|NCT02418819|Experimental|PF-06412562 9mg|PF-06412562 9mg BID
10164258|NCT03954678|Active Comparator|Nutrition Group|Participants randomized to the nutrition intervention will consume a liquid over-the-counter nutrition supplement two times per day.
10164259|NCT03954548|Experimental|With CB-17-08 CADe|
10164260|NCT03954548|No Intervention|Without CB-17-08 CADe|
10164261|NCT03954535|Experimental|Intervention|9 sessions and website with entertainment features and resources
10164262|NCT03954535|Placebo Comparator|Control|website with entertainment features and resources
10164263|NCT03954496|Experimental|Active tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2.5mA, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
10164264|NCT03954496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
10164265|NCT03954652|Other|Cohort 1: Intellectual disability|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
10164266|NCT03954652|Other|Cohort 2 Retinal diseases|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
10164267|NCT03954652|Other|Cohort 3: Rare tumors in childhood|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
10164268|NCT03954756|Experimental|apatinib and PD-1|Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect
10164269|NCT03954457|Experimental|A-CWS Intervention|Participants received A-CWS Intervention.
9826451|NCT02418819|Experimental|PF-06412562 45mg|PF-06412562 45mg BID
9826452|NCT02418819|Placebo Comparator|Placebo|Placebo BID
9826453|NCT02418845|Experimental|SYM-1219|Administered orally
10164270|NCT03954457|Active Comparator|Standard Care Control|Participants received standard care.
10164271|NCT03954483|Experimental|Buspirone|Participants will receive buspirone 10 mg prior to experiments.
10164272|NCT03954483|Experimental|Triazolam|Participants will receive triazolam 0.25 mg prior to experiments.
10164273|NCT03954483|Placebo Comparator|Placebo|Participants will receive a placebo prior to experiments.
10164274|NCT03954418|Experimental|Intervention group|Participants will drink an artificially sweetened drink 2-4 hours before elective caesarean section.
10164275|NCT03954418|No Intervention|Control group|Participants in the control group will refrain from intake of artificial sweeteners.
10164276|NCT03954340|Active Comparator|1 iRemember Treatment|Subjects randomized to this arm of the study will undergo 20 EEG NFB treatments with the iRemember System for the treatment of MCI
10164277|NCT03954340|Sham Comparator|2 Sham Treatment|Subjects randomized to this arm of the study will undergo 20 SHAM treatments
10164278|NCT03954210|Experimental|Six-Week CBT-I Program|"CBT-I, six sessions, forty-five to sixty minutes in duration.~Session 1: set up sleep restriction and stimulus control, discuss strategies for how to stay awake to a prescribed hour and what to do with wake after onset sleep time, provide sleep hygiene education.~Session 2: determine if upward titration of total sleep time is warranted, review sleep hygiene.~Session 3: continue upward titration of total sleep time, cognitive therapy for negative sleep beliefs if indicated.~Session 4: continue upward titration of total sleep time, follow-up regarding negative sleep beliefs.~Session 5: continue upward titration of total sleep time, discuss relapse prevention.~Session 6: assess global treatment gains, discuss questions regarding relapse prevention."
10164279|NCT03954210|Active Comparator|Six-Week Sleep and Lifestyle Education Program|"Sleep and Lifestyle Education, six sessions, forty-five to sixty minutes in duration.~Session 1: Sleep education, Instruction/demonstration on stretching exercises.~Session 2: Education on environmental factors & sleeping positions that impact sleep.~Session 3: Education on lifestyle factors that impact sleep.~Session 4: Education on diet and sleep.~Session 5: Education on exercises and sleep.~Session 6: Discus maintaining achievements & preventing relapses."
10164280|NCT03954171|Other|Patients treated with platinum based-chemotherapy|
10164281|NCT03954054||Former therapeutic education participants|Semi-structured interviews with people who already completed the TPE programme
9826454|NCT02418845|Placebo Comparator|Placebo|Administered orally
9826455|NCT02418910||bipolar outpatients|Patients with Bipolar Disorder in any clinical state
10164282|NCT03954054||Intervention group (current therapeutic education participants)|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
10164283|NCT03954054||Control AUD (Alcohol Use Disorder) patients|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
10164284|NCT03954197|Experimental|Without injection group|no injection used as priming
10164285|NCT03954197|Active Comparator|hCG group|hCG used as priming
10164286|NCT03954197|Active Comparator|GnRHa group|GnRH agonist used as priming
10164287|NCT03954288||chronic otitis media|patients with chronic otitis media without cholesteatoma
10164288|NCT03954288||cholesteatoma|patients with chronic otitis media whose cholesteatoma
10164289|NCT03954288||control|patients scheduled to operation with diagnosis of other causes
10164290|NCT03954145|Active Comparator|PUMICING GROUP|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle.Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors"
10164291|NCT03954145|Experimental|SANDBLASTING GROUP|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
10164292|NCT03954028|Active Comparator|CTG Group|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the autogenous connective tissue graft (CTG) material will be randomized to transplant to one side of the arch.
10164293|NCT03954028|Active Comparator|ADM Group|The patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the commercial acellular dermal matrix (ADM) materials will be transplanted to the opposite side of the arch with CTG transplants.
10164294|NCT03954093|Sham Comparator|Sham stimulation|
10164295|NCT03954093|Active Comparator|Motor cortex stimulation|
10164296|NCT03954093|Experimental|MEG-localized stimulation|
10164297|NCT03953989|Experimental|Patients with hypertrophic cardiomyopathy|"Thestudy is articulated into Screening visit plus other 3 visits. One visit (V2 ) for dose titration. V0 screening eligibility, consent, Medical History, physical examination, BP, ECG, Echocardiography, Biochemistry (haematology, electrolytes, glycaemia, ALS and bilirubin, creatinine and urine-analysis) V1 Baseline PET scan, physical examination, vital signs, and drug supply (500 mg bid).~V2 physical examination, safety check, biochemistry, drug compliance and up-titration (750 mg bid), drug supply.~V3 (2 months)safety check ,drug supply, drug compliance V4 (4 months, end of treatment) repeat PET scan, physical examination, BP, ECG, drug compliance, safety.~Drug of the study Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die"
10186445|NCT03735407|Experimental|C-Scan procedure|Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
9977393|NCT01360957|Placebo Comparator|Water flavored placebo|to be given orally in a dosage of 30 ml trice daily for 60 days
10164298|NCT03953963|Experimental|Intra-Abdominal Mesenteric Fat Extraction Group|All enrolled patients will undergo the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery.
10164299|NCT03953924|No Intervention|Control group|No interventions were performed for the control patients during the study. While those in the control group were given conventional care ( nursing procedure, education about diet, exercise and so on)
9694860|NCT04784975||Preclinical Type 1 Diabetes|"Adolescents and young adults with preclinical diabetes (having at least 2 positive diabetes autoantibodies but who do not meet criteria for clinical diagnosis of type 1 diabetes).~There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health."
10164300|NCT03953924|Experimental|Intervention group|The patients in intervention group received conventional care, transtheoretical model-based (TTM-based) intervention and motivational interviewing (MI).
10164301|NCT03954275||Critically ill patients with a CrCl24h|Patients admitted to any intensive care unit (surgical, medical or cardiac) and having at least one 24h creatinine clearance measurement available.
10164302|NCT03953911|Active Comparator|Control: Mobile Clinic Only|The middle school assigned to the control arm will receive a visit by a mobile clinic every 6 months only. The school will follow normal protocol for HPV vaccination awareness. Parents will be made aware of the mobile clinic per normal school newsletters and mailers.
10164303|NCT03953911|Experimental|Mobile Clinic plus Educational Sessions|The middle school assigned to the Mobile Clinic every 6-mos or month plus Educational Sessions arm will receive visitation of a mobile clinic providing free HPV vaccination among other school-related vaccines once every 6-months or once a month. Parents will be made aware of the mobile clinic per normal school newsletters and mailers. In addition, parents will be provided with free weekly educational sessions about the HPV Vaccine as a cancer-prevention effort.
10164304|NCT03953950|Experimental|Combination of spironolactone and losartan|
10164305|NCT03953950|Active Comparator|Losartan Alone|
10164306|NCT03953833|Experimental|recombinant anti-HER2 humanized monoclonal antibody conjugate|Drug Name : Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection R & D code: B003 Drug Type : Biological Products
10164307|NCT03954262||TCI group|Group I received TCI at 5-6 ug/ml target effect concentration (Ce)
10164308|NCT03954262||bolus group|groups II received an induction bolus of propofol (2-2.5mg/kg).
10164309|NCT03953807|Experimental|Ozurdex|OZURDEX implant 700 μg
10164310|NCT03953885|Experimental|Fire needle group|Participants in experimental group will receive Fire needle therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
10164311|NCT03953885|Placebo Comparator|Fire needle placebo group|Participants in experimental group will receive Fire needle placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
10164312|NCT03953755|No Intervention|Control 1|no/mild tricuspid regurgitation - left-side surgery alone
10164313|NCT03953755|No Intervention|moderate TR - left-side surgery|moderate tricuspid regurgitation - left-side surgery alone
10164314|NCT03953755|Experimental|moderate TR - left-side surgery+TVS|moderate tricuspid regurgitation - left-side surgery+tricuspid valve surgery
10164315|NCT03953755|No Intervention|Control 2|tricuspid regurgitation - left-side surgery +tricuspid valve surgery
10164316|NCT03953794||Patients with inflammatory bowel disease|"Patients who have...~a diagnosis of ulcerative colitis or Crohn's disease as confirmed by a clinician~experienced a flare within the past 24 months as determined by a clinician~had quiescent disease for at least 3 months as determined by a clinician"
10164317|NCT03953768|Experimental|Patients undergoing device implantation|Patients undergoing device implantation with vagal nerve stimulator (VNS) for epilepsy
10164318|NCT03953781||group 1|25 participants, were treated by valproate (VPA) as a monotherapy till became seizure free at the last 8-weeks before post treatment check-point, with ages ranged from 18-43 years
10164319|NCT03953781||group 2|25 participants were treated by levetiracetam (LEV) with the same regimens of valproate as a monotherapy, with ages ranged from 20-45 years.
10164320|NCT03953586||bubble suction test and peristalsis in hydrosalpnix|. Group A: Women with unilateral or bilateral blockage of the distal end of the fallopian tubes with tubal distension.
10164321|NCT03953586||bubble suction test and peristalsis in normal tubes|Group B: Women with normal appearance of the fallopian tubes by HSG.
10164322|NCT03953664|Experimental|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
10164323|NCT03953664|Experimental|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
10164324|NCT03953664|Experimental|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
10164325|NCT03953677|Experimental|Dexmedetomidine|
10164326|NCT03953677|Placebo Comparator|Placebo|
9977394|NCT01360957|Experimental|Black cumin water extract as a traditional medicine|Black cumin water extract as a traditional medicine to be given orally in a dosage of 30 ml trice daily for 60 days
10164327|NCT03953729|Experimental|Group 1:Ibuprofeno|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
10164328|NCT03953729|Placebo Comparator|Group 2: Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
10164329|NCT03953651||Patients|Patients admitted in the emergency department presenting a myocardial oxygenation imbalance and are therefore at risk for Myocardial Infarction (MI) type 2.
10164330|NCT03953469|No Intervention|Placebo Group|"(a) Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating, or caffeine consumption.~b) will be given 1/4 tsp of blackstrap molasses placebo. Subjects may not consume caffeine or eat food during this time.~(c) blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
10164331|NCT03953469|Active Comparator|Group II|"Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating food, or caffeine consumption.~15 minutes after examination - will be given 1/8 tsp (900mg) of Passiflora incarnata solid extract by Wise Woman Herbals mixed with 1/8 tsp of blackstrap molasses to mask the taste.~blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
10164332|NCT03953495|Experimental|Better Together|Participants will be recruited with e-mail, print, and social media announcements and advertisements distributed through the professional contacts and networks of the investigators. The experimental group will consist of randomly assigned volunteers who meet the eligibility requirements (i.e., same-sex female couple over the age of 18 who lives in Central Appalachia).
10164333|NCT03953716|Experimental|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
10164334|NCT03953716|Placebo Comparator|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
10164335|NCT03953716|Experimental|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
10164336|NCT03953716|Active Comparator|Marvelon|1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
10164337|NCT03953378||"Group RA patients"|Patients with Rheumatoid Arthritis (RA) fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria.
10164338|NCT03953378||"Group PsA patients"|Patients with Psoriatic Arthritis (PsA) fulfilling the Classification for PsA (CASPAR) criteria.
10164339|NCT03953378||"Group Healthy donors"|Anonymous healthy donors from the Etablissement Français du Sang.
10164340|NCT03953612|Experimental|patients receiving PREG|Eligible participants will then be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) and randomly assigned to 2 doses of PREG (300/500 mg/day)over 8 weeks.
10164341|NCT03953612|Placebo Comparator|patients receiving placebo|Eligible participants will then be admitted to the Clinical Neuroscience Research Unit (CNRU) at the CMHC and randomly assigned to a placebo (PLA) treatment (N=20/group) over 8 weeks.
10164342|NCT03953430||study group|Patients with clubfoot recurrence undergoing Tibialis Anterior tendon transfer with a minimum age of three years from a prospective, consecutive database of patients with clubfoot treated with the Ponseti method.
10164343|NCT03953430||control group|healthy children of employees of our hospital
10164344|NCT03953261|Experimental|Curcumin|
10164345|NCT03953261|Placebo Comparator|Placebo|
10164346|NCT03953339|Active Comparator|no release|no release of the suprascapular nerve during arthroscopic repair of a rotator cuff tendon repair
10164347|NCT03953339|Experimental|release|arthroscopic release of the suprascapular nerve according to the established, standard technique during arthroscopic repair of a rotator cuff tendon repair
10164348|NCT03953391|Experimental|Tea-water|Tea before water
10164349|NCT03953391|Experimental|Water-tea|Water before tea
10164350|NCT03953573||Women post-delivery|
10164351|NCT03953456|Experimental|elafibranor 120mg followed by placebo|Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
10164352|NCT03953456|Placebo Comparator|placebo followed by elafibranor 120mg|Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
10164353|NCT03953521|Experimental|navigated|Positioning of the coil according to neuronavigation (Mylius et al., 2013, Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: Inter-rater reliability, accuracy, and influence of gender and Age, NeuroImage 78, 224-232).
10164354|NCT03953521|Active Comparator|F3|Positioning of the coil according to EEG (electroencephalography) electrode Position F3 (marking this Position on a head cap).
10164355|NCT03953196|Experimental|Cohort 1: Vaccine Challenge Imvanex|Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
10164356|NCT03953196|Experimental|Cohort 2: Vaccine Challenge Shingrix|Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
10164357|NCT03953196|Experimental|Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)|Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
10164358|NCT03953196|Experimental|Cohort 4: Antigen Challenge Candin|Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
10164359|NCT03953196|Experimental|Cohort 5: Skin Wounding Challenge|3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.
10164360|NCT03953300|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
10164361|NCT03953300|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
10164362|NCT03953404||septic shock|
10164363|NCT03953404||severe sepsis|
10164364|NCT03953404||sepsis|
10164365|NCT03953404||sirs positive, not septic|
10164366|NCT03953248|No Intervention|Non L-Carnitine|Subjects in this arm will receive standard treatment only (without LC). It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment
10164367|NCT03953248|Active Comparator|L-Carnitine|Subjects in this arm will receive standard treatment in addition to LC IV, as a dose of 1 g/8 hours
10164368|NCT03953326|Experimental|HeartPhone Intervention|Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.
10164369|NCT03952975|Other|follicular phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14). In light of this formula patients were classified into the follicular phase group (defined as <15 adjusted days, group A).
10164370|NCT03952975|Other|luteal phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14) [14]. In light of this formula, patients were classified into the luteal phase group (defined as ≥15 adjusted days, group B).
10164371|NCT03953235|Experimental|Phase 1|"GRT-C903~GRT-R904~nivolumab~ipilimumab"
10164372|NCT03953235|Experimental|Phase 2|"GRT-C903~GRT-R904~nivolumab~ipilimumab"
10164373|NCT03953365|No Intervention|without mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without prophylactic mesh
10164374|NCT03953365|Other|with mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with prophylactic mesh
10164375|NCT03953170|Active Comparator|Teduglutide|Teduglutide 0.05 g/kg/day
10164376|NCT03953170|Placebo Comparator|Placebo|Placebo
9671455|NCT05048290|Experimental|Group I (communication workshops, video, surveys)|Participants complete 2 communication workshops about conversational skills and development of a video about the summer student's research experience over 3 hours each during the second week of the summer research experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
10164377|NCT03953157|Experimental|Arm I (dietary intervention)|Patients receive a controlled anti-inflammatory diet over 12 weeks.
10164378|NCT03953157|Experimental|Arm II (exercise intervention)|Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
10164379|NCT03953105||Resusci Baby|Resusci Baby used for the simulated emergency scenario
10164380|NCT03953105||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
10164381|NCT03953001|Experimental|Buzzy|Buzzy was used during Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel.
10164382|NCT03953001|Active Comparator|Control|Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel only.
10164383|NCT03952884|Active Comparator|Leucine|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g leucine powder dissolved in 250 mL of water.
10164384|NCT03952884|Experimental|Leucine Peptide (Dileucine)|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g protein peptide powder dissolved in 250 mL of water.
10164385|NCT03953287|Experimental|Pharmacokinetic Study of Paracetamol.|"Detailed Description:~Twelve healthy young volunteers are recruited, and the experiments begin at 07:45 after an overnight fast. BMI and blod pressure are recorded and a catheter is inserted in an antecubital vein for blood samples.~At 08.00 participants take 500 mg paracetamol as a tablet with 200 ml tap water or a Paracetamol1523 capsule in random order. Subsequently, blood samples are taken every minute for 3 minutes the first hour, then every 10 minutes the following two hours. In addition, blood pressure and puls rate are measured every 20 minute the first hour, and then every 30 minutes.Side effects and time to the participants registrate any effect of the drugs are assessed in a prefabricated scheme.~The disadvantages associated with the experiment are sought monitored by adverse event registration which ends at the end of the trial. The trial day lasts 2 hours in which blood samples are taken as described above, and blood pressure and records are stored ."
10164386|NCT03953131|Experimental|Diagnostic (gallium Ga 68-DOTATATE PET/CT)|Patients receive gallium Ga 68-DOTATATE IV over a few minutes and, after 60 minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation therapy and 6 weeks after completion of radiation treatment.
10164387|NCT03953092|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
10164388|NCT03953092|Experimental|SAD Cohort 2|10 mg YG1699 or placebo
10164389|NCT03953092|Experimental|SAD Cohort 3|25 mg YG1699 or placebo
10164390|NCT03953092|Experimental|SAD Cohort 4|50 mg YG1699 or placebo
9826456|NCT02418949|Experimental|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
10164391|NCT03953092|Experimental|SAD Cohort 5|100 mg YG1699 or placebo
10164392|NCT03953092|Experimental|MAD Cohort 1|5 mg YG1699 or placebo
10164393|NCT03953092|Experimental|MAD Cohort 2|20 mg YG1699 or placebo
10164394|NCT03953092|Experimental|MAD Cohort 3|50 mg YG1699 or placebo
10164395|NCT03952819||Diabetic group,|The study was designed with 28 chronic hemodialysis patients (17 men, 11 women) receiving treatment at our hospital. Of the 28 hemodialysis patients, 14 had Type 2 diabetes mellitus. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
10164396|NCT03952819||Non-Diabetic group,|Of the 28 hemodialysis patients, the other 14 were not diabetic. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
10164397|NCT03952819||Control group,|The study was designed with 56 individuals; 28 healthy volunteers as a control group. Venous blood samples of the control group were obtained at the blood sampling unit by the healthcare personnel during morning hours following overnight fasting while they were sitting after being rested. The intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
10164398|NCT03952988|Experimental|Probiotic|
10164399|NCT03952988|Placebo Comparator|Placebo|
10164400|NCT03953222|Experimental|Experimental|A single group of people with Parkinson's disease will undergo real-time feedback intervention.
10164401|NCT03953209|Experimental|spironolactone 50 mg|Oral administration of spironolactone 50 mg once daily for 12 weeks
10164402|NCT03953209|Experimental|spironolactone 100 mg|Oral administration of spironolactone 100 mg once daily for 12 weeks
10164403|NCT03953209|Experimental|spironolactone 200 mg|Oral administration of spironolactone 200 mg once daily for 12 weeks
10164404|NCT03952936|Other|Mobility|Self comparison of data from pre-post intervention.
10164405|NCT03952949|Experimental|Default|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
10164406|NCT03952949|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read a brief education brochure before online grocery shopping.
10164407|NCT03952897||Group 1|Subjects treated with balneotherapy for 10 days, previously diagnosed with knee and/or hip osteoarthritis, and subjects previously diagnosed with rheumatoid arthritis.
10164408|NCT03952910|Experimental|Experimental group|Online pain education program will be accessible by the intervention group
10164409|NCT03952910|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
10164410|NCT03952858|Experimental|Telerehabilitation Group|Physiotherapist-supervised Telerehabilitation as home exercise in Groups. Participants in the intervention group receive supervised Telerehabilitation by an experienced physiotherapist two days a week during four weeks. A computer and a camera will be installed where the exercise should take place. It will make it possible for the physiotherapist to see how the participants follow the exercise program and for the participants to follow the physiotherapist instructions on the screen. The participants will be instructed in the use of computer and receive a written guide. After four weeks the participants will on their own continue the Otago exercise Program for another 4 weeks by video sessions and still together in their already established groups. Otago Exercise Program consist of a walking plan, balance exercises, and a set of leg muscle strengthening exercises all progressing in degree of difficulty.
10164411|NCT03952858|Active Comparator|Community Center group|"The Community Center Group will receive the traditional exercise programs offered in a Community Center for older people. The exercise program can vary dependent on the offer in the individual community center. Often the training consists of exercises carried out in a range of different training equipments such as exercise bikes, steppers, rowing machines etc. often supervised by a physiotherapist. At some community centers the training will be performed in groups on appointed times. Some citizens are offered one or two times instruction and hereafter they have to train on their own. Some times the citizens are offered few times of training in their own home and hereafter follow the offer at the community center for older people. Before discharge, at the hospital, their plan for rehabilitation will be completed.~Participants in the Community Center Group will be tested by the same instruments at baseline and after 4 and 8 weeks and at 6 months of follow-up."
10164412|NCT03952689|Experimental|Post cardiac surgery patients|For all patients, readings of the urine output from both the Serenno system and the collection bag (urinometer) (by camera) will be recorder every 10 minutes, for the duration of 24 hours.
10164413|NCT03952676|Experimental|Moving cupping intervention|Participants will received moving cupping therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
10164414|NCT03952676|Placebo Comparator|Moving cupping placebo control|Participants will received moving cupping placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
10164415|NCT03952741|Experimental|Cognitive Functional Therapy|The intervention is a targeted cognitive functional therapy and will be based on examination findings. It is behaviorally directed with a focus on normalizing mal-adaptive pain, cognitive and movement behaviors in a graduated manner. In the evaluation process it is considered whether the patient has adjusted to the back complaints in a positive way (confrontation, active coping, minimal avoidance behavior) or in a negative way (passive coping, fear and avoidance behavior). Work related issues will be a particular focus, with the aim of achieving close co-operation between the worker, the workplace and the worker's responsible health care provider.
10164416|NCT03952741|Active Comparator|Cognitive Patient Education and PT|The intervention in the second group will receive much training in cognitive coping techniques after the COPE LBP trial principles (Werner et al. 2010). The educational part of the COPE for new instructors with a PT background takes 2 days supervised by Werner and his group, with regular follow-up meeting with the project leaders, together with a psychologist trained in cognitive therapy
9671456|NCT05048290|Active Comparator|Group II (generic communication workshops, surveys)|Participants complete 2 generic communication workshops about networking and presentation skills over 3 hours each during the second week of the summer experience and 2-3 weeks before the conclusion of summer experience. Participants also complete surveys over 15 minutes each about their communication, their engagement with research, mentoring experience, and current career intentions, before participating in the workshop, after the second workshop and at 6 months after the conclusion of the summer experience.
9671457|NCT05048186||Decision Aid Arm|Participants in this arm will review educational material from the ADHD Decision Aid developed by the Cincinnati Children's Hospital Medical Center.
9671458|NCT05048186||Control Arm|Participants in this group will not receive any educational materials.
9671459|NCT05048472|Experimental|Intervention|Use of point of care viral load monitoring (Abbott PoC devices)
9974740|NCT05250089|Experimental|Emergency physicians|"Each participant will have to carry out two simulation sessions. The first simulation will correspond to the usual evaluation, that is to say it will take place on a day that will not be preceded by night duty during the three previous nights.~The second simulation will correspond to the assessment twenty-four hours after the end of a call, in the post-recovery period. The participant must therefore have performed a night shift the day before the day when the simulation takes place. This call must have a minimum duration of twelve hours on night shifts."
9974741|NCT05250076|Active Comparator|Intervention Group|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination (Posturarte® Olympic). To clean the participant's skin, cotton (MASMI®) will be passed with ethyl alcohol (Fergus®). Scissor (Maped®) will be used to cut the Kinesio Tape."
9974742|NCT05250076|No Intervention|Control Group|The participants will remain at rest in a supine position on a treatment table (Posturarte® Olympic) without inclination for 5 minutes.
9974743|NCT05250024|Experimental|UHMWP Cranioplasty|synthetic reconstruction of cranial defects using computer guided milled UHMWP implants
9974744|NCT05250024|Active Comparator|PEEK Cranioplasty|synthetic reconstruction of cranial defects using computer guided milled PEEK
9974745|NCT05250011||Single-cohort|Patients initiated on dapagliflozin according to the approved indication for heart failure with reduced ejection fraction (HFrEF) and current medical practice
9974746|NCT05249998|Experimental|Interventional group|"Patients will receive the usual care, with the intervention of the multidisciplinary team which defines with the patient the objectives of the stay and the inter-stay period, without specific therapeutic education on adapted physical activity, nutrition and eating behaviour."
9974747|NCT05249998|No Intervention|Standard care group|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
9974748|NCT05249972|Experimental|AKP02|cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
9974749|NCT05249972|Active Comparator|Enstilar|cutaneous foam (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
9974750|NCT05249972|Placebo Comparator|Placebo|cutaneous spray
9974751|NCT05249946|Experimental|Intervention group|"increasing provision of vegetables and sustainable fish in food offered in early childhood education and care (ECEC) and adjusting intake of meat and milk to reasonable levels to meet recommendations~advancing food education, reducing food waste and assessing the climate and financial impacts of the shift towards a more plant-based diet"
9974752|NCT05249946|No Intervention|Control group|Food supply and food education continue as usual.
9974753|NCT05249933|Placebo Comparator|Control group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 200ml warm water. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
9974754|NCT05249933|Experimental|Pronase group|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of two liters of polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at the hospital in the morning after an overnight fast (>8hours). Then they would be randomly assigned to the control group or pronase group randomly. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg dimethicone. And 25 minutes before swallowing the capsule, the patient was asked to take 20000 IU pronase Granules Combined with 1 g NaHCO3 dissolved in 200ml warm water to maintain the intragastric pH at 6 - 8. There is still have 800-1000ml water for gastric filling 10 minutes before swallowing the capsule.
9974755|NCT05249907|No Intervention|Control|No application will be made this group
9974756|NCT05249907|Experimental|VIBRATION GROUP|Vibration will be applied this group.
9974757|NCT05249907|Experimental|MASSAGE GROUP|Massage will be applied this group.
9974758|NCT05249881|Other|semaglutide|semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and long-term weight management. Semaglutide acts like human glucagon-like peptide-1 in that it increases insulin secretion, thereby increasing sugar metabolism
9974759|NCT05249803||Patients with COVID-19 pneumonia|These patients were admitted in ICU for management of Covid-19 pneumonia usual care was offered to all patients
9974760|NCT05249751||mild-moderate|Cases classified as mild-moderate fulfilled the following criteria: fever and respiratory symptoms, CORAD 1-5, and oxygen saturation (SpO2 92 percent),
9974761|NCT05249751||Severe|severe cases met the following criteria: fever and respiratory symptoms, CORAD 4-5, and oxygen saturation (SpO2 92 percent).
9974762|NCT05249738||Study Group|Patients followed up with a mechanical ventilator for 4 days or longer were included in the study group.
10164417|NCT03953066|Active Comparator|women with vaginal delivery|30 women with spontaneous vaginal delivery will be included in group 1 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
10164418|NCT03953066|Active Comparator|women with emergency cesarean section|30 women with emergency cesarean section will be included in group 2 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
10164419|NCT03953066|Active Comparator|women with elective cesarean section|30 women with elective cesarean section will be included in group 3serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
10164420|NCT03952715|Experimental|Evoked pain training|
10164421|NCT03952715|Experimental|Control|
10164422|NCT03952806|Experimental|Arm 1: BHV-3241- Experimental|
10164423|NCT03952806|Placebo Comparator|Arm 2: Placebo Comparator|
10164424|NCT03952754|Experimental|Group 2: Hip Hop Nutrition-Math Curriculum|The intervention group will receive an tailored program for ten weeks, meeting twice a week.
10164425|NCT03952754|Active Comparator|Group 1: Food Explorers Program|The control group will receive the usual care for nutrition program provided by the schools, called Food Explorers. The group will also be conducted ten weeks, meeting twice a week.
10164426|NCT03952845|Experimental|Intranasal Capsaicin|Separate patients will be given escalating doses of intranasal capsaicinoid spray
9671460|NCT05048472|No Intervention|Control|Use of the standard of care viral load monitoring (centralized viral load monitoring)
9671461|NCT05048225||Low-salt (LS) group|intake of < 5 g of salt per day
10164427|NCT03953118|Placebo Comparator|Placebo|
10164428|NCT03953118|Active Comparator|Azithromycin|
10164429|NCT03952442|Active Comparator|control group|
10164430|NCT03952442|Experimental|experimental group|
10164431|NCT03953352|Other|Radiotherapy treatment|
9974763|NCT05249738||Control Group|Patients followed up with mechanical ventilation for 3 days or less were included in the control group.
10164432|NCT03952832|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10164433|NCT03952520|Active Comparator|Standard Approach (SA)|The Standard Approach is a one-size-fits-all multifaceted implementation strategy that was systematically developed using Intervention Mapping.
10164434|NCT03952520|Experimental|Tailored Approach (TA)|The Tailored Approach includes an implementation strategy that will be tailored to match site-specific barriers to implementation of SNaP at that site.
10164435|NCT03952728||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention, consented to administrative data linkages, and were successfully linked to Medicare databases.
10164436|NCT03952728||Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education control arm, consented to administrative data linkages, and were successfully linked to Medicare databases.
10164437|NCT03952533|Experimental|ALA|"ALA Group will be composed of women allocated to the Treatment Group. These women will receive 2 tablets of Alpha lipoic Acid (ALA) as Dav® food supplement 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy) daily until delivery."
10164438|NCT03952533|No Intervention|Control|"Control Group will be composed by women allocated in the Control Group and will not receive any supplementation but the standard care."
10164439|NCT03952650|Experimental|1a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
10164440|NCT03952650|Experimental|1b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
10164441|NCT03952650|Experimental|2a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
10164442|NCT03952650|Experimental|2b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
10164443|NCT03952650|Experimental|3a|Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)
10164444|NCT03952650|Experimental|3b|Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)
10164445|NCT03952650|Placebo Comparator|4a|Receiving normal saline with 75 mg pyrimethamine day 0 post injection
10164446|NCT03952650|Placebo Comparator|4b|Receiving normal saline with 75 mg pyrimethamine days 2&amp;3 post injection
10164447|NCT03952650|Placebo Comparator|4c|Receiving normal saline with weekly chloroquineibuprofen (if necessary)
10164448|NCT03952650|Experimental|5a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)
10164449|NCT03952650|Experimental|5b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
10164450|NCT03952650|Experimental|6a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
10164451|NCT03952650|Experimental|6b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
10164452|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
9671462|NCT05048225||Normal-salt (NS) group|intake of 5 - 7.5 g of salt per day
9671463|NCT05048225||High-salt (HS) group|intake of 7.5 - 10 g of salt per day
9671464|NCT05048225||Very high-salt (VHS) group|intake of > 10 g of salt per day
9671465|NCT05048368|Experimental|Cohort A-Larotinib|Cohort A:Healthy participants with normal hepatic function （match to subjects with mild hepatic impairment_cohort B）
10164453|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Reveal®|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
10164454|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Endocuff Vision|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
10186446|NCT03735394|Experimental|Gingival Biotype|A Periodontal probe was used to differentiate between thick and thin biotypes and patients were classified into 3 possible categories of Gingival Biotype (A1, A2 and B) according to Müller & Eger (https://doi.org/10.1034/j.1600-051x.2000.027009621.x). On each group two measurements were taken on the most protruded lower and upper central incisor: 1/ a tangential radiographic film and 2/ an ultrasonic probe measurement with the PIROP Biometric scanner (G-scan) form Echoson
10186447|NCT03735381|Active Comparator|Intervention 1: pedometer|"Minimum intervention:~Use of pedometer watch from 12 to 32 GW~Recommendations of physical activity"
10164455|NCT03952338|Experimental|Nutrition Coupons|Participants in the FMNCP group will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets. To ensure participants receive all 16 coupon sheets, community partners will provide two coupon sheets per household during the first 1-6 weeks of the intervention. Participants in the FMNCP group will also be invited to participate in nutrition skill-building activities (e.g., cooking classes) offered by community partners throughout the intervention period, however participation is not required (this is consistent with the existing FMNCP).
10164456|NCT03952338|No Intervention|Control|No intervention provided. Participants will be eligible to participate in the BC Farmers' Market Nutrition Coupon Program during the next farmers' market season (i.e. one year following the current intervention).
10164457|NCT03952572|Experimental|CDOP regimen|cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.
10164458|NCT03952572|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
10164459|NCT03952546|Experimental|Treatment Arm|Saline-coupled bipolar sealer
10164460|NCT03952546|Active Comparator|Control Arm|Unipolar electrocautery
10164461|NCT03952455|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
10164462|NCT03952351|Experimental|CTCA with standard care|Patients will be referred for CT Coronary Angiography, ideally within 2 weeks of randomisation
10164463|NCT03952351|No Intervention|Standard care|
10164464|NCT03952507|Experimental|Group 1: JNJ-64417184|Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
10164465|NCT03952507|Experimental|Group 2: JNJ-64417184|Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
10164466|NCT03952507|Experimental|Group 3: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
10164467|NCT03952507|Experimental|Group 4: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
10164468|NCT03952507|Experimental|Group 5: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
10164469|NCT03952507|Experimental|Group 6: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
10164470|NCT03952416|No Intervention|Standard of Care (SOC)|The control group for this study will receive rehabilitation therapy that is recommended and provided by the current healthcare structure. The SOC group will receive therapy only from four therapists who are not trained and supervised in EMR. These therapists will be monitored (videotaped or observed) but will not be not asked to do anything differently with their patients. The investigators recognize that spillover of therapist EMR training to untrained therapists is a concern. Thus, the investigators will ask therapists in the EMR group to agree not to share any of the training with non-trained therapists over the course of the study, and the investigators will provide free EMR training to the non-trained therapists once the treatment phase of the study is complete.
10164471|NCT03952416|Experimental|Enhanced Medical Rehabilitation (EMR)|Patients in the EMR group will also receive the recommended rehabilitation therapy, but they will receive therapy only from four therapists who are trained and supervised in EMR. The therapy sessions will follow EMR protocol. EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation.
10164472|NCT03952481|Experimental|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
10164473|NCT03952390||control|healthy volunteers
10164474|NCT03952390||sepsis|patients with sepsis
10164475|NCT03952403|Experimental|Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
10186448|NCT03735381|Experimental|Intervention 2: pedometer+goal+reminds|"Maximum intervention:~Use of pedometer from 12 to 32 GW~Recommendations of physical activity~Information about get a goal of 11000 steps/day~Reminds the goal every two weeks."
10186449|NCT03735381|No Intervention|Control: without pedometer|Women receive some recommendations of physical activity during pregnancy. They do not use the pedometer during pregnancy
10164476|NCT03952403|Experimental|Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
10164477|NCT03952403|Experimental|Part 2-Arm B (HLX10+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
10164478|NCT03952403|Active Comparator|Part 2-Arm C (Carboplatin+Pemetrexed)|Participants will receive IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
10164479|NCT03952325|Experimental|Cohort 1, Arm A: Tesetaxel plus nivolumab|
10164480|NCT03952325|Experimental|Cohort 1, Arm B: Tesetaxel plus pembrolizumab|
10164481|NCT03952325|Experimental|Cohort 1, Arm C: Tesetaxel plus atezolizumab|
10164482|NCT03952325|Experimental|Cohort 2: Tesetaxel|
10164483|NCT03952325|Experimental|Cohort 3: Tesetaxel|
10164484|NCT03952273|Active Comparator|Combo|PCI with COMBO stent
10164485|NCT03952273|Active Comparator|BioMatrix Alpha|PCI with BioMatrix Alpha stent
10164486|NCT03952117|Active Comparator|Active tDCs|Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. The cathode will be positioned facing the primary motor cortex area and the anode over the contralateral supraorbital area.
10164487|NCT03952117|Sham Comparator|Sham tDCS|Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 10 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
10164488|NCT03952065|Experimental|PD1/PDL1 inhibitor infusion via neck artery|Interventional technique is used to localize neck artery to infuse the inhibitors directly into tumor.
10164489|NCT03952065|Experimental|PD1/PDL1 inhibitor infusion via peripheral vein|Routine peripheral vein infusion of PD1/PDL1 inhibitor is performed as control.
10164490|NCT03952000|Experimental|Experimental: Exercise|Exercise: Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1.
10164491|NCT03952000|No Intervention|No Intervention: Control|Participants will rest on day 1.
10164492|NCT03951922|Experimental|Therapeutic Horticulture Group|The therapeutic horticulture group will participate in a 6-week horticulture program meeting twice a week for an hour led by an occupational therapist incorporating plant-based activities and education on pain management techniques at a community farm.
10164493|NCT03951974|Experimental|Experimental|Participants in the experimental group will receive training in utilizing social regulation of emotion strategies in an individualized format. They will meet with an interventionist for 5 weeks (1 in-person session and 4 telephone sessions) for 1-1.5 hours each week, and keep a journal documenting their emotion challenges and regulation strategy use.
9671466|NCT05048368|Experimental|Cohort B-Larotinib|Subjects with mild hepatic impairment
10164494|NCT03951974|Other|Control|Participants in the control group will not receive training in utilizing social regulation of emotion strategies. While they will still meet with the interventionist on the same schedule and for approximately the same length of time, they will simply be asked to report the emotion regulation strategies that they naturally employ. They will also keep a journal documenting their emotion challenges and regulation strategy use.
10164495|NCT03952052|Other|Patient enrolled|Recurrent mutations determination
10164496|NCT03952156|Experimental|Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
10164497|NCT03952156|Experimental|Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
10164498|NCT03952156|Experimental|Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
10164499|NCT03952156|Experimental|Delayed Treatment Control|Delayed Treatment Control Arm
10164500|NCT03952156|Experimental|Expansion Phase First Dose level|Expansion Phase First Dose Level of HMI-102 delivered intravenously one time
10164501|NCT03952156|Experimental|Expansion Phase Second Dose level|Expansion Phase Second Dose Level of HMI-102 delivered intravenously one time
10164502|NCT03952247|Experimental|Single Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
10164503|NCT03952247|Active Comparator|Conventional Multi Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
9671467|NCT05048368|Experimental|Cohort C-Larotinib|Healthy participants with normal hepatic function （match to subjects with moderate hepatic impairment_cohort D）
9671468|NCT05048368|Experimental|Cohort D-Larotinib|Subjects with moderate hepatic impairment.
10164504|NCT03952013||Study group|"All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE~LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),~HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)~HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)"
10164505|NCT03952026||isolated pelvic fracture|Patients with an isolated pelvic fracture
10164506|NCT03952026||combined abodominal/pelvic injury|Patients with a combined injury of a pelvic fracture and an abdominal injury.
10164507|NCT03952104|Experimental|Experimental-Low Intensity Strength Training|Strength training (low intensity)
10164508|NCT03952104|Experimental|Experimental-Moderate Intensity Strength Training|Strength training (moderate intensity)
10164509|NCT03952104|Experimental|Experimental-High Intensity Strength Training|Strength training (high intensity)
9520256|NCT03279250|Experimental|Arm A (LHRHa, apalutamide)|Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
9520257|NCT03279250|Experimental|Arm B (LHRHa, apalutamide, abiraterone acetate)|Participants receive gonadotropin-releasing hormone analog and apalutamide as in arm A, abiraterone acetate PO QD, and prednisone PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
10164510|NCT03952104|No Intervention|Control|No intervention
10186450|NCT03735368|Placebo Comparator|Control|placebo oral capsule+ dexmedetomidine+topical anesthesia
10186451|NCT03735368|Active Comparator|Dexmedetomidine- Pregabalin|Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia
10186452|NCT03735355|Experimental|Balloon dilation|TTS balloon dilation
10186453|NCT03735355|Active Comparator|Surgery|Resection of the fibrostenotic area
10186454|NCT03735342|Experimental|Audio Recording|Participants receive a verbal discharge discussion with a provider, written discharge instructions and a re-playable audio recording of the discharge discussion with the discharging provider.
10186455|NCT03735342|No Intervention|Usual care|Participants receive a verbal discharge discussion with a provider and written discharge instructions.
10187856|NCT03722043|Experimental|Parenting Program|"All study participants will receive our parenting program curriculum. There will not be a control group.~The parenting program will include the topics of mindful parenting strategies, emotional regulation, positive discipline, and positive parenting/attachment. Participants will be provided skills to develop strategies for each of the modules. Each session will contain elements of group troubleshooting and practice in-session. Practice at home will be assigned so that participants can continue to practice and implement these skills and strategies in their homes.~The program is taken from a published, empirically based program called Everyday Parenting: A Professional's Guide to Building Family Management Skills written by Thomas Dishion, Elizabeth Stormshak, and Kathryn Kavanagh."
10187857|NCT03722004|Active Comparator|mOPV1 + fIPV 6 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
10187858|NCT03722004|Active Comparator|mOPV1 + fIPV 10 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
10187859|NCT03722004|Active Comparator|mOPV1 only|mOPV1 administered at 6, 10, and 14 weeks.
10187860|NCT03722004|Active Comparator|bOPV only|bOPV administered at 6, 10, and 14 weeks.
9671469|NCT05048407|Experimental|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
10187861|NCT03721991|Active Comparator|GABA|gamma Amino butyric acid (GABA) food supplement with 6 g per day
10187862|NCT03721991|Placebo Comparator|PLACEBO|Matching placebo capsules to GABA
10187863|NCT03721939|Experimental|FLEX Scoring Catheter plus DEB|The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
10187864|NCT03721913|Experimental|Intervention group|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
10187865|NCT03721913|No Intervention|Control group|The control group will not receive the intervention during the study.
10187866|NCT03721900|Experimental|SHX-001 Active Low Dose|Ketamine transdermal patch
10187867|NCT03721900|Placebo Comparator|Placebo|placebo transdermal patch
10187868|NCT03721900|Experimental|SHX-001 Active high dose|ketamine transdermal patch
10187869|NCT03721887|Experimental|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
10187870|NCT03721887|Sham Comparator|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
10187871|NCT03721874|Active Comparator|Dapagliflozin 10 mg|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days."
10187872|NCT03721874|Placebo Comparator|Placebo matching to dapagliflozin 10 mg|"Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days"
10187873|NCT03721848|Experimental|Healthy Community Clinic: NCD+MH|The arm of this study consists of a 28 session intervention, which are 45 minutes and meet 2-3 times a month providing health awareness on non-communicable diseases diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking; traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma.
10187874|NCT03721848|Active Comparator|Healthy Community Clinic: NCD|The arm of this study consists of a 24 session intervention, which are 45 minutes and meet 2 times a month providing health awareness on non-communicable disease diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking.
10187875|NCT03721848|No Intervention|Treatment as usual|This is treatment as usual where there is no intervention, but patients attend the clinic for treatment of non-communicable diseases.
10187876|NCT03721835|Other|Control femoral neck fracture system|This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture
10187877|NCT03721809|Other|macrophage activation syndrome secondary to bacterial sepsis|Patients hospitalized in medical intensive care for macrophage activation syndrome secondary to bacterial sepsis
10164511|NCT03952260|Active Comparator|Fasting clear fluid for 1 hour prior to anaesthesia|Fasting clear fluid for 1 hour prior to anaesthesia
10164512|NCT03952260|No Intervention|Fasting clear fluid for 2 hours prior to anaesthesia|Fasting clear fluid for 2 hours prior to anaesthesia
10164513|NCT03952169|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
10164514|NCT03952169|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
10164515|NCT03951987|Experimental|Treatment A: 4 ml CG5503|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) was administered as a 2 minutes infusion.
10164516|NCT03951987|Experimental|Treatment B: 4 ml CG5503; 5 g charcoal powder|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) with oral co-administration of charcoal (5 g charcoal were co-administered orally at 1, 0.5 hours and 10 minutes before the start of CG5503 infusion and 0.5, 1, 1.5, 2 and 4 hours thereafter)
10164517|NCT03951909|Experimental|Active intervention|Either Physiotherapy activity and awareness intervention (PAAI) or Teaching recovery techniques (TRT)
10164518|NCT03951909|Experimental|Waiting list|The same interventions as above will be hold for waiting lists participants, but after 6 to 8 weeks
10164519|NCT03952221|Active Comparator|Usual physiotherapy and continuous ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and continuous ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
10164520|NCT03952221|Active Comparator|Usual physiotherapy and pulsed ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and pulsed ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle) every working day for two weeks (10 occasions).
10164521|NCT03952221|Active Comparator|Usual physiotherapy and sonotens therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sonotens therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 0,5 W/cm2 SATA intensity, transcutanous electrical nerve stimulation) every working day for two weeks (10 occasions).
10164522|NCT03952221|Placebo Comparator|Usual physiotherapy and sham ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sham ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 0 MHz frequency, 0 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
10164523|NCT03951896|Experimental|PRP|"Interventions:~A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects."
10164524|NCT03951896|Placebo Comparator|Placebo|For the control group, same amount of blood was sampled and they were given a same amount of waiting time with the other group, with the resulting injection preparate being 2 ml's of 0,9% saline instead.
10164525|NCT03951662||With alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers with high bilirubin and AST levels.
10164526|NCT03951662||Without alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers without high bilirubin and AST levels.
10164527|NCT03951844|Experimental|Experimental group|Each participant is evaluated while wearing or not wearing the device.
10164528|NCT03951558|Experimental|Diet for calciuria prevention|placebo capsules and a strict eating plan will be given. The placebo will look similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz.
10164529|NCT03951558|Placebo Comparator|hydrochlorothiazide for calciuria prevention|recommendations for water intake and decrease in salt intake will be given.
9671470|NCT05048160|Experimental|6MW3211|"Dosage form: injection~Specification: 240 mg / 8 ml/Vial"
10164530|NCT03951831|Experimental|ADT Followed by Chemoimmunotherapy|"REGN2810 followed by chemoimmunotherapy:~Initiate degarelix 240mg SC once, followed by leuprolide acetate 22.5mg SC every 3 months.~Week 4 start cemiplimab (REGN 2810) 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.~Week 10 start docetaxel 75 mg/m2 every 21 days for up to 6 cycles."
10164531|NCT03951623|Active Comparator|treatment arm|Eligible subjects will be treated with planned dose of 100 mg, 200 mg and 300 mg HMPL-523 once daily for 8 weeks and 16 weeks open-label treatment.
10164532|NCT03951623|Placebo Comparator|placebo arm|Eligible subjects will be treated with HMPL-523 matching placebo once daily for 8 weeks and 16 weeks open-label treatment.
10164533|NCT03951714|Other|Reference|Control experience using marketed application to record medication intake without reminders from the app
10164534|NCT03951714|Experimental|Intervention|Full experience using marketed application, with all functionalities enabled
9977395|NCT01361022|Active Comparator|Brotizolam tablet|Brotizolam tablets 250mcg : at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
10164535|NCT03951857|No Intervention|Young men|Range of age is 20-35 years, young men (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
10164536|NCT03951857|No Intervention|Young women|Range of age is 20-35 years, young women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
10164537|NCT03951857|Experimental|Elderly women (control)|Range of age is 65-80 years, Elderly women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
10164538|NCT03951857|Experimental|Elderly obese women|Range of age is 65-80 years,Elderly obese women (BMI ≥25 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
10186456|NCT03735329|Experimental|Pulse oximetry monitoring|
10186457|NCT03735316|Experimental|B12a|Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
10164539|NCT03951688|Experimental|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
10164540|NCT03951688|No Intervention|Control Group|No intervention
10164541|NCT03951727|Other|Endovascular treatment for PAD|Single group study (1 arm)
10164542|NCT03951584||ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study cohort. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset, to evaluate the damage and prognosis of vestibular function.
10164543|NCT03951636|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant/abutment surface will be cleaned by copious irrigation with Chlorhexidine
10164544|NCT03951636|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant/abutment surface.
10164545|NCT03951636|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant/abutment surface.
10164546|NCT03951701|Experimental|observation cohort|Questionnaire to assess the supportive care needs
10164547|NCT03951740|Experimental|Group of cardiac patients|All patients completed the study wearing two wrist-worn activity trackers and the Oxycon mobile as reference method during a laboratory activity protocol.
10164548|NCT03951753|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
10164549|NCT03951753|Active Comparator|Semaglutide|Semaglutide administered SC
10164550|NCT03951753|Placebo Comparator|Placebo|Placebo administered SC
10164551|NCT03951571|Experimental|Anlotinib Gruop|
10164552|NCT03951571|Placebo Comparator|Placebo Group|
10164553|NCT03951597|Experimental|Combined therapy using Gemox, Lenvatinib and PD1|"Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~Lenvatinib (8mg/d), continuous use for 1 year.~PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
10164554|NCT03951545|Active Comparator|Mechanical group|Group of patients whose tibial sections will be performed using extramedullary mechanical sighting
10164555|NCT03951545|Experimental|Gyroscopic group|Group whose tibial sections will be performed using gyroscopic and accelerometric navigation (I-Assist) will be randomized
10164556|NCT03951519|Experimental|Water|
10164557|NCT03951519|Active Comparator|Physiological serum|
10164558|NCT03951428||All Participants|
10164559|NCT03951467|Experimental|Interventional arm|
10164560|NCT03951467|No Intervention|Controlled arm|Patients within this arm will be follow as usual care of the cardiologic unit
10164561|NCT03951415|Experimental|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
10164562|NCT03951506|Experimental|Experimental-Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
10164563|NCT03951506|Experimental|Experimental-conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
10164564|NCT03951350|No Intervention|Control (TAU)|Patients will follow the usual treatment provided by their GP (treatment-as-usual, TAU).
10164565|NCT03951350|Experimental|Lifestyle Modification Program (LMP)|It will consist of 6 weekly group sessions (lasting 90 minutes each).
10164566|NCT03951350|Experimental|Lifestyle Modification Program (LMP) + ICTs|It will consist of 6 weekly group sessions (lasting 90 minutes each).
10164567|NCT03951363|No Intervention|Qualitative Interview|Interviews: The investigators will enroll at least 10 adults 18 years or older with CKD (self-report).
10164568|NCT03951363|Other|Pilot Testing|Pilot Study: The investigators will enroll 30 adults at least 18 years old with mild to moderate CKD (documented estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2) who also have diabetes and/or hypertension.
10164569|NCT03951402|Experimental|CG5503 PR 100 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 100 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 1 tablet CG5503 PR and 1 placebo-tablet, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin 400 mg.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
10164570|NCT03951402|Experimental|CG5503 PR 200 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 200 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
10164571|NCT03951402|Placebo Comparator|Placebo|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
10186458|NCT03735316|Placebo Comparator|Placebo|Subjects will receive placebo
10186459|NCT03735303|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
10164572|NCT03951402|Active Comparator|Moxifloxacin 800 mg single dose|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); and 2 placebo-capsules, matching moxifloxacin on days 1 and 2; In the morning of Day 3, each participant received additionally 2 capsules each containing 1 tablet moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
10164573|NCT03951324||Expert Endoscopists|Experienced Endoscopists with significant user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
10164574|NCT03951324||None-Expert Endoscopists|Experienced Endoscopists with non-significant or beignner user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
10164575|NCT03951285|Experimental|NR|"One intervention includes healthy BMI-discordant monozygotic twin pairs, which both are treated with NR. With this unique model, the investigators obtain the information on how beneficial NR is in two different BMI classes (obese and leaner) with an identical genomic background.~The final dose for NR will be 1 g/day. The daily NR dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full NR dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
10164576|NCT03951285|Placebo Comparator|Placebo|"The second intervention includes monozygotic twins concordant for body weight. It's randomized which member of the twin pair is treated with NR while the other co-twin gets placebo.~The final dose for placebo will be 1 g/day. The daily placebo dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full placebo dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
10164577|NCT03951181|Experimental|LEAP-MS Intervention|This is a single arm study.
10164578|NCT03951155|Experimental|ADHD Group|Muscle Relaxation technique for behavioral management
10164579|NCT03951155|No Intervention|Tell Show Do Group|Tell Show Do Technique for behavioral management
10164580|NCT03951129||verbal group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal informing before hemodialysis catheter insertion
10164581|NCT03951129||verbal and video group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal and video informing before hemodialysis catheter insertion
10164582|NCT03951246|Experimental|Training Group|"Training Group recieved cognitive and Motor training included 6 sessions using the following training devices.~Dynavision D2 ® (USA) (https://products.dynavisioninternational.com/products/d2) presents a panel with 64 bulbs which take the form of five circles. The task of a participant is to press the bulb that is glowing as quick as possible. In the trial 8 modes will be used; they have different instructions which are aimed at visual-motor co-ordination, processing speed, inhibition, and shifting.~Fitlight Trainer ® (Canada) (https://www.fitlighttraining.com) consists of 7 clickers, and the tasks are similar to Dynavision ones.~NeuroTracker ® (Canada) (https://neurotracker.net) includes a task of multiple object training for working memory and attention enhancement."
10164583|NCT03951246|No Intervention|Control Group|Control Group didn't recieved any cognitive and motor training. They visited swimming pool and physical therapy.
10164584|NCT03951376|Experimental|Intervention|"The schools in this arm will implement the UPRIGHT programme (18 skills related to Mindfulness, Coping, Efficacy and Social and emotional learning) during a minimum of 18 sessions and a maximum of 24 in a period of 6 months, which will be conducted by teachers to adolescents of 1st grade (12-14 years of age).~Teachers will be trained by the UPRIGHT team at the beginning of the school year (3 months) and families will have a combination of face to face training and online training throughout the UPRIGHT platform."
10164585|NCT03951376|No Intervention|Control|Schools in the control arm have their usual curricula and are not provided of any intervention resources or support, apart from those in the common daily activities.
10164586|NCT03951337|Experimental|64Cu ATSM|pretherapeutic 64Cu-ATSM PET/CT scan
10164587|NCT03951298||Wolfram Syndrome Patients|Participant has confirmation of a WFS1 mutation OR Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old
10164588|NCT03951298||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
10164589|NCT03951168|Other|Routine Management|The patients were divided into routine diabetic health education management model group. Patients who meet the criteria for admission and discharge.
10164590|NCT03951168|Experimental|Standardized Management|The patients were divided into standardized diabetes health education management model group. Patients who meet the criteria for admission and discharge.
10164591|NCT03950999|Experimental|Study arm|Each subject underwent baseline assessment of pain reporting accuracy (FAST). Thereafter, the placebo response was assessed using tonic heat stimuli delivered at fixed temperature of 44, 46.5, and 48°C which evoke mild, moderate and severe pain sensations (in accordance). The stimuli were given in a pseudo-random order twice, once before receiving the placebo pill (a sugar pill) and once after, maintaining the same order as before.
10164592|NCT03951272|Experimental|Lyoplant® Onlay|All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study
10164593|NCT03951272|Active Comparator|DURAFORM™ Dural Graft Implant|All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study
10164594|NCT03950986|No Intervention|Control|Providers assigned to the control group will receive unmodified vaccine reminders (as they already appear in the VA EHR system). Separate reminders will appear for the different vaccines of interest.
10187878|NCT03721809|Other|bacterial sepsis/septic shock|Patients hospitalized in medical intensive care for sepsis / septic shock
9671471|NCT05048303|Experimental|Individualized Lutajet operative group|Arthroscopic modified individualized flexible Latarjet procedure with preservation of the coracoacromial arch. During the procedure, we perform coracoid osteotomy with preservation of coracoacromial arch, then split subscapular tendon, transfer the bone graft and fix it with double button under arthroscopy.
9671472|NCT05048121|Experimental|CLS02021 - Investigational Product arm|Cosmetic cream with proprietary cosmetic ingredient CLS02021.
9671473|NCT05048121|Placebo Comparator|PLC01021 - Placebo Control arm|Cosmetic cream, identical to the studied product but without cosmetic ingredient. Color, texture, scent and the packaging are identical as a IP.
10164595|NCT03950986|Experimental|Treatment|Providers in the treatment group will receive modified clinical reminders for the vaccines of interest. Reminders for the different vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
10164596|NCT03951090|Experimental|GARRT Arm|Participants in this arm complete an brief geriatric assessment, and the results of these assessments are given to providers with recommendations to address deficits identified by the geriatric assessment
10164597|NCT03951090|Active Comparator|Control Arm|Providers of participants of this group will not receive the results of the brief geriatric assessments. These participants will receive standard of care treatment
10164598|NCT03951259|Experimental|SM934 10mg|SM934 10mg（1 tablet）+Placebo（4 tablets）p.o. qd in combination with steroids
10164599|NCT03951259|Experimental|SM934 30mg|SM934 10mg（3 tablet）+ Placebo（2 tablets）p.o. qd in combination with steroids
10164600|NCT03951259|Experimental|SM934 50mg|SM934 10mg（5 tablet）p.o. qd in combination with steroids
10164601|NCT03951259|Placebo Comparator|Placebo|Placebo（5 tablets）p.o. qd in combination with steroids
10164602|NCT03951207|Experimental|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
10164603|NCT03951207|Experimental|Rosuampin 20/5mg|Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
10164604|NCT03951207|Active Comparator|Amlodipine/Atorvastatin 5/20mg|Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks
10164605|NCT03951038|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with saline added up to a volume of 80ml in total ) and the equal volume of 0.9% normal saline will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
10164606|NCT03951038|Experimental|Lateral TLIPB group|Participants in this group will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine, and combined with PCIA post-operatively. The regimen of the Lateral TLIPB is 0.2% 20 ml ropivacaine respectively and the regimen of PCIA is same with PCIA group.
10164607|NCT03951220||Group 1- Myeloma|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
10164608|NCT03951220||Group 2- MGUS|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
10164609|NCT03951220||Group 3- Healthy Volunteers|Participants will have the experimental combined MR imaging.
10164610|NCT03950830|Experimental|Treatment arm|Cisplatin 50mg/m2 day 1 and 2, every 3 weeks, Disulfiram 400mg daily, continuously
10164611|NCT03950960|Experimental|BMS-986256 +Itraconazole|
10164612|NCT03951051|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10164613|NCT03951051|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10164614|NCT03950843|Experimental|Experimental Group|"Patients assigned to this group are treated with 1 capsule of CKD-825 and 2 placebo capsules(the placebo of CKD-825)~The necessity of a dose titration is adjudicated every 2 weeks.~After unblinding at the end of Administration Period, only patients in experimental group are treated with 1 capsule of CKD-825 for additional 4 weeks of Extension Period."
10164615|NCT03950843|Placebo Comparator|Placebo Group|"Patients assigned to this group are treated with 3 placebo capsules (the placebo of CKD-825)~The necessity of a dose titration is adjudicated every 2 weeks"
9671474|NCT05048147|Experimental|CM Intervention Group|Cluster. RCT of 16 urban and rural communities. CHEWs will facilitate use of CF-CS and educate households on HAP exposure throughout the intervention period
10186460|NCT03735303|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
9671475|NCT05048147|No Intervention|Self-Directed Group|Receive information on CFCS use and education on HAP in 16 urban and rural communities; will not receive the CM intervention
9694861|NCT04784975||New Onset Type 1 Diabetes|Adolescents and young adults with a diagnosis of clinical type 1 diabetes. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
9977396|NCT01361022|Experimental|Lendormin tablet|Lendormin tablets 250mcg: at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
9977397|NCT01361035|No Intervention|No communication training|Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making
10164616|NCT03950947|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis and randomization to the intervention group, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug, CE0086).
10164617|NCT03950947|Sham Comparator|Sham-Control|In the presence of a significant right coronary artery stenosis, and randomization to the sham-procedure: right IMA will be selectively intubated using an appropriate catheter. Angiography of the RIMA and the pericardiacophrenic branch will be performed.
10164618|NCT03950778|Active Comparator|Septic patients receiving albumin replacement|Septic patients receiving albumin replacement 20 ml Inj Human Albumin 20% -3x100 ml- 3 day
10164619|NCT03950778|No Intervention|Septic patients not receiving albumin replacement|
10164620|NCT03950700|Experimental|Bupivacaine solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
10164621|NCT03950700|Placebo Comparator|Saline solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
10164622|NCT03950869|Experimental|Negative Expectations|Expectations on the severity and frequency of intrusions are increased while expectations on the controllability of intrusions are decreased.
10164623|NCT03950869|Experimental|Positive Expectations|Expectations on the severity and frequency of intrusions are decreased while expectations on the controllability of intrusions are increased.
10164624|NCT03950869|No Intervention|No Expectation Manipulation|Expectations on the severity and frequency of intrusions and on the controllability are neither increased nor decreased.
10164625|NCT03950921|Experimental|Patient Safety Display Arm|Patient Safety Display in patient room
10164626|NCT03950921|No Intervention|Control Arm|Usual Care
10164627|NCT03950635|Experimental|Group I (fiber-rich diet)|Patients consume a whole-foods, fiber-rich diet for 6 weeks.
10164628|NCT03950635|Experimental|Group II (ketogenic diet)|Patients consume a high fat, low carbohydrate (ketogenic) diet for 6 weeks.
10164629|NCT03950804||CHAPLE patients, without eculizumab treatment|Patients with suspected CHAPLE syndrome undergo flow-cytometry based CD55 surface staining of peripheral blood samples. Those patients with loss of CD55 protein expression are diagnosed with CHAPLE syndrome. A subgroup of the CHAPLE patients describe only mild symptoms and are not treated with eculizumab, but monitored closely for any disease progression.
10164630|NCT03950804||Control subjects- no intervention|Healthy subjects with no history of any chronic disease. All investigational analyses are performed on both the case and the control subjects. Therefore, the same type of biological specimens collected from the case group are collected from the control group simultaneously.
10164631|NCT03950804||Non-CHAPLE PILs|PIL patients with intact CD55 on flow-cytometry assesment undergo genetic testing to exclude a potential missense mutation in the CD55 gene that impairs its function while retaining protein expression. Overall, patients and their parents undergo exome sequencing as trios, and examined for potential gene mutations underlying their disease. Non-CHAPLE PILs are also examined by high-throughput investigation similarly to CHAPLE patients.
10164632|NCT03950804||CHAPLE patients on eculizumab|Among CHAPLE patients, there is a subgroup who receive eculizumab treatment. These patients are prospectively followed and biological samples collected at baseline as well as periodically under therapy. Eculizumab (Soliris) is being provided for CHAPLE patients on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to manufacturer's recommendations based on the weight of the patients.
10164633|NCT03950908|Other|Single bite|The single bite technique involved removing the forceps with its specimen after each individual biopsy.
10164634|NCT03950908|Other|Double bite|The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
10164635|NCT03950713|Experimental|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|Participants in the intervention group received the MBSR-T in addition to routine care.
10164636|NCT03950713|No Intervention|Routine care|The control group received the routine care provided in facilities, including routine check-ups at diabetes clinics as necessary.
10164637|NCT03950765|Experimental|Ecological Momentary Intervention|This group will receive three intervention prompts and three assessment prompts on their smartphone each day.
10164638|NCT03950687|Active Comparator|Control group A|intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
10164639|NCT03950687|Experimental|Experimental group B|intravenous administration, 0.5μg/kg, once a week, for 32 weeks
10164640|NCT03950687|Experimental|Experimental group C|"intravenous administration,~1μg/kg, once every two weeks, for 32 weeks"
10164641|NCT03950882|Experimental|PXL770|PXL770 500 mg once daily (QD) for 4 weeks
10164642|NCT03950882|Placebo Comparator|Placebo|placebo once daily (QD) for 4 weeks
10164643|NCT03950791|Experimental|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials.
10164644|NCT03950791|Placebo Comparator|Health Education|A 2-hour in-person informational session about general health education. Participants receive a list of resources in the community.
10164645|NCT03950596|Active Comparator|One acute resistance load exercise|One hundred volunteers will participate in one acute resistance load exercises to their quadriceps
10164646|NCT03950596|Active Comparator|Three acute resistance load exercises|One hundred volunteers will participate in three acute resistance load exercises to their quadriceps
10164647|NCT03950596|Active Comparator|Control Group|One hundred volunteers will participate in study as a control group
10164648|NCT03950661|Experimental|Forest|"Each subject is exposed to a 50 minute walk in a green location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
10164649|NCT03950661|Experimental|Urban|"Each subject is exposed to a 50 minute walk in a gray location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
10164650|NCT03950648|Experimental|Spatial Cognitive Training|map reading and route-learning skills
10164651|NCT03950505|Experimental|1|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
9520258|NCT03279224|Active Comparator|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
10164652|NCT03950531||COPD exacerbation without Bronchiectasis|COPD patients who have been in exacerbation period and have no bronchiectasis
10164653|NCT03950531||COPD exacerbation with Bronchiectasis|COPD patients who have been in exacerbation period and have bronchiectasis
10164654|NCT03950479||primiparous group|women who will give birth to their first baby
10164655|NCT03950453|Experimental|Parenting Mindfully for Health Nutrition (PMH)|Parenting Mindfully for Health (PMH) + nutrition and physical activity counseling to promote healthy eating and physical activity in parent and child.
10164656|NCT03950453|Active Comparator|Contact Control Nutrition (C+N)|Contact control intervention (C) + nutrition and physical activity counseling (N).
10164657|NCT03950388|No Intervention|Treatment as Usual|
10164658|NCT03950388|Experimental|Intervention|
10164659|NCT03950726||Study Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection through the same incision
10164660|NCT03950726||Control Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection who underwent standard laparoscopic resection
10164661|NCT03950518|Experimental|One-drug Regimes|Drug: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
10164662|NCT03950518|Experimental|Two-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride
10164663|NCT03950518|Experimental|Three-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride Levamisole Hydrochloride
10164664|NCT03950492|Experimental|OUD DBS|This is a single arm study. Participants will be followed in an inpatient service for two weeks to gather baseline data followed by DBS placement and up to 6 weeks inpatient for clinical stabilization and DBS titration. All participants will then be followed twice a week for 12 weeks in the outpatient setting and then once a week for a total of 52 weeks post-titration.
10164665|NCT03950427|Active Comparator|Videogame-based Physical Activity Group|"The videogame-based physical activity group, will play active videogames using the Kinect for Xbox 360 game system. Each videogame group will be facilitated by the study coordinator, the principal investigator or other study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
9520259|NCT03279224|Placebo Comparator|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
9520260|NCT03279211|Experimental|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
10164666|NCT03950427|Placebo Comparator|Sedentary Videogame Group|"The sedentary videogame group will play videogames while seated using the Xbox 360 game system (without the Kinect sensor). Each sedentary videogame group will be facilitated by study staff.~Participants in this group will also receive bupropion and counseling for smoking cessation."
10164667|NCT03950544|Experimental|only meropenem therapy,|this group is only meropenem therapy as a single antibiotic treatment
10164668|NCT03950284|Experimental|immediate loading with all on four technique in FFF|immediately loaded dental implants with the all-on-four technique in free vascularized fibular grafts
10164669|NCT03949998|Experimental|Dry Needling|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals.
10164670|NCT03949998|Active Comparator|Dry Needling + Manual Therapy|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals IN ADDITION TO manual therapy of the above muscles and/or cervical joint traction and/or mobilization as indicated.
10164671|NCT03949998|Active Comparator|Manual Therapy|Participants will receive manual therapy of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals and/or cervical joint traction and/or mobilization as indicated.
10164672|NCT03950141|Experimental|Apatinib and S1 group|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
10164673|NCT03950089||Patients with Central Serous Chorioretinopathy|
10164674|NCT03950089||Healthy patients|
10164675|NCT03950219||Intervention, Centre for Diabetes or local setting|Group-based course in diabetes education including 6 sessions of approximately 3 hours. Sessions are constructed around themes such as; diabetes knowledge and complication, mental health, diet, physical activity, Ramadan, medicine and include practical exercises such as blood sugar measurements, walking etc.
10164676|NCT03950219||Usual care|Usual care in 5 municipalities in the west area of Copenhagen
9520261|NCT03279211|Experimental|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
9977398|NCT01361035|Other|Cancer risk ommunication skills training|Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making
9977399|NCT01361061||patients with liver cirrhosis|
10164677|NCT03950193||premature child|Premature children evaluated during their 24 months follow up consultation
10164678|NCT03950258|Experimental|endovascular embolization|patients under the age of 18 years with arteriovenous shunts manifested by systemic or neurological manifestations will undergo endovascular embolization
10164679|NCT03950115|Active Comparator|Group 1|
10164680|NCT03950115|Active Comparator|Group 2|
10164681|NCT03950362|Experimental|Radiotherapy associated to immunotherapy|"Radiotherapy: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder~Concomitant administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)"
10164682|NCT03950154|Experimental|Arm 1:CIK|"Bevacizumab & Oxaliplatin & Capecitabine & PD1-T cells~Bevacizumab,7.5mg/kg,intravenousinfusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; PD1-T cells, 1x10^10 (10 billion),intravenous infusion,17; Q3W,after 6 cycles; Bevacizumab, 7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2;Oral administration,d1-14; PD1-T cells,1x10^10(10 billion),intravenous infusion,d17; Q3W, maintenance treatment."
10164683|NCT03950154|Active Comparator|Arm 2: Control|"Bevacizumab & Oxaliplatin & Capecitabine~Bevacizumab,7.5mg/kg,intravenous infusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; Q3W,after 6 cycles; Bevacizumab,7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2, Oral administration,d1-14; Q3W, maintenance treatment."
10164684|NCT03950180|Active Comparator|PCCI group|In addition to standard of care counseling the additional provision of the patient's specific Prostate Cancer Comorbidity Index score and life expectancy estimation was provided.
10164685|NCT03950180|No Intervention|Standard care|Standard of care was defined as prostate cancer counseling reflecting the best practices of a multidisciplinary team of urologists, radiation oncologists and medical oncologists.
10164686|NCT03950271|Experimental|SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine|trastuzumab + SHR-1210 + capecitabine + oxaliplatin for neoadjuvant chemotherapy 4-cycle.Then D2 radical surgery. The patients continued to receive capecitabine plus oxaliplatin for adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.
10164687|NCT03950206|Other|Women with endometriosis|Women undergoing laparoscopic surgery for endometriosis
10164688|NCT03950297|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6;
10164689|NCT03950323|Experimental|patients operated on for parotid tumor|All consecutive patients operated on for parotid tumor.
10164690|NCT03950310|Experimental|ELCA|On the antegrade delivery of the laser catheter after wiring, we used safe laser techniques and injected saline before and during the laser procedure at a 0.5 mm/sec catheter advancement rate. Whether to perform a retrograde laser method depended on each operator. After ablation by ELCA, patients undergo balloon dilation via standard techniques, and as appropriate, receive drug-eluting stent deployment.
10164691|NCT03950310|No Intervention|non ELCA|In non ELCA group, the conventional PCI procedure, including thrombus aspiration, POBA, and stent implantation was performed. The indication for aspiration was at the discretion of the physician based on angiographic, intravascular ultrasound, or optical coherence tomography/Optical Frequency-Domain Imaging.
10186461|NCT03735303|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
10186462|NCT03735303|Experimental|control group|no intervention was given
10186463|NCT03735277|Experimental|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters.
10186464|NCT03735264|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1)
10186465|NCT03735251||Left Ventricular Diastoic Dysfunction Classification|normal diastole pattern：E/A>1，DT 160~220 ms，S/D >1，AR 0.22-0.32m/sec，E/e'< 8 diastolic dysfunction pattern Impaired relaxation pattern：E/A< 1，DT > 220 ms，S/D > 1，AR 0.21-0.28 m/sec，E/e'<10 Pseudo-normalization pattern：E/A> 1，DT 150~210 ms，S/D < 1，AR ≥0.35m/sec，E/e'≥ 10 Restrictive pattern：E/A ≥ 2，DT < 150 ms，S/D <1，AR ≥0.25m/sec，E/e'≥10
10186466|NCT03735238||Lupus Patients|All lupus patients, regardless of if they are having an active flare
10186467|NCT03735225|Experimental|IV Dasiglucagon|Dasiglucagon 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
10186468|NCT03735225|Experimental|SC 0.6 mg Dasiglucagon|Dasiglucagon 0.6 mg administered SC as a single dose
10186469|NCT03735225|Placebo Comparator|IV Placebo|Placebo 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
10186470|NCT03735212|Experimental|Program Group|Participants in this group receive enhanced services as the intervention. These services include Motivational Enhancement, Incredible Years, and Contingency Management. Participants also receive case management services to support referrals to substance use.
10186471|NCT03735212|No Intervention|Control Group|Participants in this group receive services as usual.
10187879|NCT03721796||Arm 1 Physician/APP|Surgical, medical, and radiation oncologists and/or Advanced Practice Provider (APP)
9826457|NCT02418949|Placebo Comparator|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
9977400|NCT01361074|Experimental|In Vivo Exposure|
9977401|NCT01361074|Experimental|Augmented Reality Exposure|
9694862|NCT04784975||Long standing Type 1 Diabetes|Adolescents and young adults with type 1 diabetes for at least 2 years. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
9977402|NCT01361100|Experimental|Oncoral test|
10164692|NCT03950349||"Anterior cervical discectomy group"|
10164693|NCT03950128|Experimental|Mindfulness-Based Skills Training|This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The intervention is given over the course of three 50-minute sessions with homework between sessions.
10164694|NCT03950128|Active Comparator|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions.
10164695|NCT03950050|Experimental|Ambroxol|"Ambroxol therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
10164696|NCT03950063||Patients with Cutibacterium acnes bone infections|Patients with Cutibacterium acnes orthopedic material infections
10164697|NCT03949946||High-risk|Female participants confirmed to be BRCA1/2 or TP53 gene carriers
10164698|NCT03949946||Patients|Female participants confirmed to have invasive ductal carcinoma of the breast
10164699|NCT03950102|Experimental|SBRT|SBRT will be used as the primary bridging therapy for HCC patients on waitlist
10164700|NCT03949751|No Intervention|Control group|The participants of the control group will not get the local therapy in the investigator's preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative.
10164701|NCT03949751|Experimental|Therapy group|30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae.
10164702|NCT03950011||ERP|Any patient requiring oncologic surgery, including hysterectomy or curettage, posterior pelvectomy, conventional laparoscopic or assisted robotic surgery, or laparotomy for cervical or cervical cancer or ovarian cancer, body or cervix uterus and ovaries as well as benign pathologies or borderline malignancy.
10164703|NCT03949803|Experimental|Morning Chocolate|Test the if Chocolate Timing in the morning changes the metabolism
10164704|NCT03949803|Experimental|Evening Chocolate|Test the if Chocolate Timing before bedtime changes the metabolism
10164705|NCT03949803|Experimental|No Chocolate (Control)|Test the if no Chocolate Timing may affect the metabolism
10164706|NCT03949790|Active Comparator|Intercostal block with ESPB|Performed ESPB in VATs with intercostal nerve block
9694863|NCT04784975||Control|Adolescents and young adults without any evidence of diabetes or hyperglycemia. There is no intervention. Each group will complete a bone health assessment, a microbiome assessment and a glycemic assessment with the goal of better understanding the association between these different variables and bone health.
10164707|NCT03949790|Active Comparator|Intercostal block without ESPB|Not Performed ESPB in VATs with intercostal nerve block
10164708|NCT03949699|Other|Resistance Training|. Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down. Performance during exercise sessions will be monitored by study staff who will progress the participant to exercises of greater intensity (increasing number of repetitions, sets, or resistance load; on an individual basis over the 8-week intervention period according to the participant's level of readiness). This progression will also be guided by a strength training protocol. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise
10164709|NCT03949764|Experimental|HCV Positive Study Participants|Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).
10164710|NCT03949764|No Intervention|Control (Pike County)|After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.
10164711|NCT03949712|Experimental|Right motor cortex (M1) tSMS|tSMS will be applied to the right motor cortex for 30 minutes.
10164712|NCT03949712|Experimental|Left motor cortex (M1) tSMS|tSMS will be applied to the left motor cortex for 30 minutes.
10164713|NCT03949712|Sham Comparator|Sham tSMS|Sham tSMS will be applied to the left or right motor cortex (randomized) for 30 minutes.
10164714|NCT03949907|Other|Nutritional counseling alone|Nutritional counseling consists of a personalized dietary prescription with regular consultation by a registered dietitian and telephone interviews, as well as of the use of oral nutritional supplements, when necessary.
10164715|NCT03949907|Experimental|Supplemental parenteral nutrition plus nutritional counseling|Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.
10164716|NCT03949985||Estrogenic contraceptive users|
10164717|NCT03949985||Non-estrogenic contraceptive users|
10164718|NCT03949816|Experimental|patient-centered communication style|The patient-centered style is characterized by features such as empathetic communication, open questions, and uses an easily understandable language.
9694864|NCT04784494|Experimental|Magnetic Seizure Therapy|MST treatments will be administered using the MagPro XP MST with Cool TwinCoil.
9694865|NCT04784585|Experimental|Enhanced Education|Theory-driven intervention focused on providing information about dietary quality and goals
9977403|NCT01361152|Experimental|Fixed-bearing group|Fixed-bearing group
10164719|NCT03949816|Experimental|doctor-centered communication style|The doctor-centered style is defined by an authoritarian and goal-oriented communication. The doctor uses medical terms instead of lay language.
9977404|NCT01361152|Experimental|Mobile-bearing group|Mobile-bearing group
10164720|NCT03949816|Active Comparator|information letter|In the active control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
10164721|NCT03949608|Experimental|BASIC|"mon cœur, mon BASIC video viewing and installation in the own smartphone or tablet of the patient"
10164722|NCT03949608|No Intervention|Control|Usual care
10164723|NCT03949855|Experimental|Part A: Low Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.~Ten participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
10164724|NCT03949855|Experimental|Part A :High Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.~Ten participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~An adjustment (increase) in prescribed weekly dose may occur, per protocol, if indicated by pharmacokinetics (PK) assay results.~High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
10164725|NCT03949855|Experimental|Part B: Low Proteinuria Group - Belimumab and Rituximab|Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
10164726|NCT03949855|Placebo Comparator|Part B: Low Proteinuria Group - Placebo and Rituximab|Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab placebo weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
10164727|NCT03949855|Experimental|Part B :High Proteinuria Group - Belimumab and Rituximab|"Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~A higher dose of belimumab, per protocol, will be prescribed in high proteinuria participants, if indicated in Part A."
10164728|NCT03949855|Placebo Comparator|Part A :High Proteinuria Group - Placebo and Rituximab|"Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab placebo weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.~A higher dose of belimumab placebo, per protocol, will be prescribed in high proteinuria participants, if indicated in Part A."
10164729|NCT03949933|Experimental|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
10164730|NCT03949686|Sham Comparator|Saline + Placebo|Ultrasound guided 0.5 ml/kg saline injection to erector spinae plane
10164731|NCT03949686|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection to erector spinae plane
10164732|NCT03949842|Experimental|Subjects who inhaled non-ELLIPTA MITT|Subjects with moderate or severe exacerbation in the past year and history of use of inhaled non-ELLIPTA MITT of ICS/LABA/LAMA within a routine clinical practice setting in the 52-week retrospective pre-switch period.
10164733|NCT03949842|Experimental|Subjects receiving TRELEGY ELLIPTA SITT|Subjects will receive FF/UMEC/VI (100 microgram [mcg]/62.5 mcg/25 mcg), inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) in the 52-week prospective post-switch period.
10164734|NCT03949595||cases|women suffering from severe/massive obesity
10164735|NCT03949517|Experimental|68-Ga RM2+68-Ga PSMA11|68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
10164736|NCT03949517|Experimental|68-Ga PSMA11+68-Ga RM2|68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
10164737|NCT03949322|Experimental|Adapted Physical Activity Program|Patients in the experimental group take part in a program of Adapted Physical Activity lasting 6 weeks, with 2 sessions per week.
10164738|NCT03949569|Experimental|Arm 1|In this condition, children will interact with the therapy dog prior to the psychosocial stress task and with the stuffed toy dog prior to the prosocial behavior tests.
10164739|NCT03949569|Experimental|Arm 2|In this condition, children will interact with the stuffed toy prior to the psychosocial stress task collection and with the therapy dog prior to the prosocial behavior tests.
10164740|NCT03949426|Experimental|KPG-818|Dose escalation
10164741|NCT03949426|No Intervention|Placebo|Matching placebo
10164742|NCT03949413|Experimental|Pediatric balance scale|The Pediatric Balance Scale (PBS) includes fourteen items. Each item of subsets scored as 4, 3, 2, 1 or 0. Finally, the total test score was calculated
9827687|NCT02465073|Active Comparator|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management intervention to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted. Determine the effect on wound treatment outcomes using standard of care treatment
10164743|NCT03949400||Patients diagnosed with knee OA|Patients diagnosed with knee OA and assigned to undergo exercise therapy and education.
10164744|NCT03949348|Active Comparator|autologous fascia|Patients who underwent a transobturator sling placement using autologous rectus fascia
10164745|NCT03949348|Active Comparator|synthetic mesh|Patients who underwent a transobturator sling placement using synthetic mesh
10164746|NCT03949582|Experimental|Mycoprotein as in Soup|24 will be randomised to soup (12 caucasian and 12 south asian) in order to test raw mycoprotein. Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
10164747|NCT03949582|Experimental|Mycoprotein as in Mince|24 will be randomised to mince (12 caucasian and 12 south asian) in order to test processed mycoprotein (Quorn). Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
10186472|NCT03735186|No Intervention|Control|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
10164748|NCT03949439||Non-Frail|non-frail (frailty score 1~3) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
10164749|NCT03949439||Pre-Frail|Pre-frail (frailty score 4) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
10164750|NCT03949296|Active Comparator|Mindfulness Intervention|Mindfulness-Based Treatment for Insomnia intervention led by a certified instructor. It is adapted from the Mindfulness-Based Stress Reduction Curriculum developed by the Center for Mindfulness in Medicine, Health Care, and Society at the University of Massachusetts Medical School. It introduces the concept of mindfulness and provides the opportunity to practice it within sessions and during home practice. Participants learn about stress, and explore habitual behavioral, physical, emotional and cognitive patterns, as well as more effective responses to challenges and demands of everyday life. Each class includes mindfulness practice, group discussions, and practices and exercises related to the class topics. Participants receive home assignments with guided meditation and yoga practices.
10164751|NCT03949296|Placebo Comparator|Sleep Hygiene|Control group participants attend a 30-minute group counseling session on sleep hygiene. The session includes a handout from the Centre for Clinical Intervention in Australia that provides 15 sleep hygiene tips.
10164752|NCT03949374|Active Comparator|10mg of the generic formulation (rosuvastatin, ROVASRO®)|Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
10164753|NCT03949374|Active Comparator|10mg of the reference formulation (rosuvastatin, CRESTOR®)|Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)
10164754|NCT03949387|Experimental|FES Cycling Exercise|FES cycling will involve systematic, transcutaneous electrical stimulation of the leg muscles to produce leg-cycling movement. The intensity and duration of training will be prescribed based on guidelines for aerobic exercise training for persons with MS and from the American College of Sports Medicine, and will progressively increase across 24 weeks. Participants will be encouraged to actively cycle at a minimum cadence of ~40-50 rpm, at 40-60% VO2peak for between 10-50 minutes. The intensity of stimulation will be adjusted per leg muscle group based on sensory tolerance with the goal of maintaining pedaling action and target heart rate over the entire session. At each session, we will record the distance traveled, energy expended, power output, resistance, heart rate and rating of perceived exertion (RPE).
10164755|NCT03949387|Placebo Comparator|Passive Leg Cycling|Passive leg cycling will involve movement of the participant's legs by the cycle ergometer motor without electrical stimulation. The duration of training will follow the same schedule as the FES cycling condition and the same data will be recorded at each session. The passive cycling condition will include the same exposure with the training facility, the exercise equipment (i.e. RT300 cycles), and the research staff (i.e. social contact and attention) as with the FES cycling condition.
10164756|NCT03949556|Experimental|Intervention program - stress management program|This intervention program on stress management is developed to prevent suicidal ideation in medical students and residents.
10164757|NCT03949556|Active Comparator|Intervention program - health promotion program|This intervention program on health promotion is developed to prevent suicidal ideation in medical students and residents.
10164758|NCT03949556|Placebo Comparator|Control condition - general information|Participants will receive weekly emails and SMSs, over the same periods of time, with general information about health except mental health, e.g. prevention of melanoma, dental care….
10164759|NCT03949634|Experimental|PLD plus CTX sequential docetaxel or PTX|pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
10164760|NCT03949634|Active Comparator|DOX plus CTX sequential docetaxel or PTX|doxorubicin（DOX） 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
10164761|NCT03949257|Experimental|colonic TET and FMT|gut microbiota will be collected through the colonic TET after FMT
10164762|NCT03949530|Experimental|IDL-2965 Oral Capsule|IDL-2965 oral capsule, single and multiple doses
10164763|NCT03949530|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single and multiple doses
10164764|NCT03949452|Active Comparator|Subcostal Transversus Abdominis Plane catheter|This group includes patients who will receive subcostal Transversus abdominis plane block analgesia
10164765|NCT03949452|Placebo Comparator|Epidural catheter|This group includes patients who will receive epidural analgesia using a catheter technique
10164766|NCT03949309||Eligible patients|All eligible patients discharged from hospital for Acute Myocardial Infarction (AMI) or acute decompensation of Chronic Heart Failure (CHF)
10164767|NCT03949270|No Intervention|Usual Care|Patients in the usual care arm will not receive any text messages.
10164768|NCT03949270|Experimental|BETA-Text Intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
10164769|NCT03949231|Experimental|PD1/PDL1 inhibitor hepatic artery infusion|Interventional technique to place microcatheter in hepatic artery to infuse PD1/PDL1 inhibitor in 30 minutes.
10164770|NCT03949231|Experimental|PD1/PDL1 inhibitor vein infusion|Regular IV infusion of PD1/PDL1 inhibitor in 30 minutes.
9827688|NCT02465099|Active Comparator|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
9520262|NCT03279211|Other|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
10164771|NCT03949478|Placebo Comparator|Placebo|Patients will receive placebo for at least five days prior to the first blood flow study. They will continue to receive placebo until the baseline study is obtained after the postictal study has been completed.
10164772|NCT03949478|Experimental|Ibuprofen|Patients will receive ibuprofen 400 mg by mouth three times a day (po tid) for at least five days prior to the first blood flow study. They will continue to receive ibuprofen until the baseline study is obtained after the postictal study has been completed.
10164773|NCT03949478|Experimental|Nifedipine|Patients will receive nifedipine 10 mg po tid for 2 days, then 20 mg po tid, thereafter for at least five days prior to the first blood flow study. They will continue to receive nifedipine until the baseline study is obtained after the postictal study has been completed.
10164774|NCT03949543|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with large lunch intervention
10164775|NCT03949543|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with large dinner intervention
9520263|NCT03279198|Placebo Comparator|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
10164776|NCT03948945|No Intervention|before treatment|The patient with facial and neck photoaging did not receive laser treatment.
10164777|NCT03948945|Experimental|after treatment|The patient with facial and neck photoaging received Profile HaloTM mixed fractional laser treatment
10164778|NCT03948997|Experimental|Treatment group|Patients with port wine stains receive PDL (1.5-10ms, 11-12.5J/cm2) with a treatment range of approximately 10*10cm2
9520264|NCT03279198|Active Comparator|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
9520265|NCT03279198|Active Comparator|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
9520266|NCT03279198|Active Comparator|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
9520267|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
10164779|NCT03948997|No Intervention|No treatment group|Patients with port wine stains have not been treated with PDL treatment
10164780|NCT03949023||Standard of Care Cerebral Angiogram Group|Participants undergoing a standard of care cerebral angiogram.
10164781|NCT03949114|Experimental|test group|"1) Performing a weak debilitating phenotype screening on the patients before surgery;~(2) Do the early rehabilitation intervention process:"
10164782|NCT03949114|Active Comparator|Control group|1) Performing a weak debilitating phenotype screening on the patients before surgery; (2) Patients in the control group were treated according to the general nursing routine after neurosurgery;
9694866|NCT04784585|Experimental|Self-efficacy|Theory-driven intervention focused on providing skills to increase self-efficacy for following dietary goals
9694867|NCT04784585|Experimental|Motivation|Theory-driven intervention focused on providing skills to increase motivation for following dietary goals
9694868|NCT04784585|Experimental|Self-regulation|Theory-driven intervention focused on providing skills to increase self-regulation
9977405|NCT01361204|Experimental|Theanine|Experimental Comparator, theanine Taking 4 tablets of theanine two times daily for 16 days Placebo Comparator, sucrose Taking 4 tablets of sucrose two times daily for 16 days
9977406|NCT01361230|Experimental|Protocol|Using sedation monitoring and protocol
9977407|NCT01361230|No Intervention|Control|Standard practice
10164783|NCT03949010|Experimental|Kinesiotaping with space correction technique|
10164784|NCT03949010|Experimental|Kinesiotaping with muscle inhibition technique|
10164785|NCT03949010|Active Comparator|Home exercise program|
10164786|NCT03948984|Experimental|Therapeutic Music Session|
10164787|NCT03949101|Experimental|combined use of 1% atropine and 0.01% atropine|first week, use atropine sulfate 1% ophthalmic ointment every night before sleep; then use atropine sulfate 1% ophthalmic ointment once every week(Friday night before sleep is recommended) for half a year; then use atropine sulfate 0.01% eye drop every night before sleep for one year and a half.
10164788|NCT03949101|Active Comparator|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years.
10164789|NCT03949179||Pain and Disability Drivers Management model|Participating clinicians will use the PDDM model to guide assessment and treatment of their patients for a 6-weeks period.
10164790|NCT03949049|Experimental|Citacoline|Citacoline as neuroprotector
10164791|NCT03949049|Placebo Comparator|Placebo|Placebo
10164792|NCT03949127|Experimental|Exercise Group|The group who will exercise to manage pain.
10164793|NCT03949127|No Intervention|Control Group|The group who will not take part in any exercises and only have to do assessments.
10164794|NCT03949166|No Intervention|Fasting|After completion of an epidural block patients that agreed to participate in the study and were randomised to the fasting arm will be allowed to drink water and clear fluids during labor and delivery as accepted by the institute protocol.
10164795|NCT03949166|Experimental|Eating|After completion of an epidural block patients that agreed to participate in the study and were randomized to the eating arm will be allowed to eat during their labor and delivery. They will be provided with the list of food that was approved and accepted by the anesthesia team. They will be asked to try eating every 2 hours but if they feel lack of need to eat or any side effects preventing them to eat they can choose not to eat. When reaching full dilatation of 10cm they will ber asked to stop eating.
10164796|NCT03949205|Experimental|Leg Extension Isometric Training|Experimental group will perform leg extension isometric exercise.
10164797|NCT03949205|No Intervention|Control Group|Control group will be advised to maintain their work habits and not to change their routine activities, especially diet and physical activities.
10164798|NCT03949088|Experimental|Linear descending UF profile|2-step descending Na profile, linear descending UF profile 3 weeks (9 sessions)
10164799|NCT03949088|Experimental|Run-in & washout phases|constant Na concentration, constant UF rate 3 weeks (6+3 sessions)
10164800|NCT03949088|Experimental|Ascending/descending UF profile|2-step descending Na profile, ascending/descending UF profile 3 weeks (9 sessions)
9694869|NCT04784585|Active Comparator|Generic Risk Alert|A notification to alert participant of lapse risk, no additional intervention provided
10164801|NCT03948958|Experimental|TIVAD evaluation|TIVAD evaluation at port removal evaluation of catheter function, visualization of catheter tip, presence of thrombus material and sleeve and any device damage during linogram (contrast injection via TIVAD), tip and chamber content microbiological culture, macroscopic catheter and port chamber evaluation PROM: patient reported outcome measurements regarding TIVAD insertion, presence and removal
10164802|NCT03949062|Experimental|iR2|Participants received six 21-day cycles of ibrutinib, lenalidomide, and rituximab (iR2) treatment (21-day cycles).
10164803|NCT03948854|Experimental|Registered dietitian education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in person by a registered dietitian
10164804|NCT03948854|Experimental|On-line video program education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet using an on-line video program
10164805|NCT03948854|Experimental|Handout education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet by a printed handout
10164806|NCT03948854|Experimental|Dietitian-led group education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in a dietitian-led group setting
10164807|NCT03948841||Neuroendocrine tumor|Patients with liver metastasis from neuroendocrine tumor
10164808|NCT03948724|Experimental|Therapeutic patient education|Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize
10164809|NCT03948724|Active Comparator|Standard Care|Patient receive usual informations
10164810|NCT03948802||STROKE GROUP|Cerebral ischemic stroke patients treated.
10164811|NCT03948802||CONTROL GROUP|Ambulatory healthy patients
10164812|NCT03949075|Experimental|Enalapril treatment|
10164813|NCT03949075|Placebo Comparator|Placebo treatment|
10164814|NCT03948828|Other|Conventional treatment group|GnRHa combained with reverse addition therapy
10164815|NCT03948828|Experimental|Conventional treatment and Autologous NK cells therapy|GnRHa combained with reverse addition therapy and NK cell combined treatment group
10164816|NCT03948815|Experimental|Intervention room|An adaptable, person-centered, birthing room that is specially designed.
10164817|NCT03948815|Other|Control room|A regular standard birthing room
10164818|NCT03948685|Experimental|Carvedilol SR|Carvedilol SR 8mg, 16mg, 32mg
10164819|NCT03948685|Placebo Comparator|Placebo|Placebo
10164820|NCT03948750||Patients with Ocular Toxoplasmosis|
9694870|NCT04784585|Sham Comparator|No Intervention|No notification or intervention is delivered to the participant during lapse risk
10164821|NCT03948750||Patients without Ocular Toxoplasmosis|
10164822|NCT03948737|Active Comparator|Alpha-Tocopgerol|"Alpha-Tocopherol supplementation will be given orally for 4 weeks with doses adjusted by age.~5-8 years old: 200 mg daily, 9-13 years old: 400 mg daily and 14-18 years old 600 mg daily."
10164823|NCT03948737|Placebo Comparator|Control|Placebo is the drug with the same shape and color as the alpha-tocopherol supplementation.
10164824|NCT03948672|Active Comparator|Control-then-Intervention|In each intensive care unit assigned to the Control-then-Intervention arm, all participants who regularly access the ICUs will wear the wristband while at work for 5 months. The functionality of the wristband will not be disclosed to the healthcare providers. Handwashing compliance data will be automatically collected, but data will not be shared with the healthcare providers or hospital management teams. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from the sensor system. Then, all healthcare providers will be educated on the functionalities of the CleanHands system with real time reminders now turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection reduction. This phase will last for 5 months.
10164825|NCT03948672|Active Comparator|Intervention-then-Control|In each intensive care unit assigned to the Intervention-then-Control arm, all participants who regularly access to the ICUs will be educated on the functionalities of the CleanHands system with real time reminders turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection control. This phase will last for 5 months. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from sensor system installation and implementation. Then, the real-time reminder functionality of the wristband will be turned off and no more education will be provided. Handwashing compliance data will be automatically collected but will not be shared with the healthcare providers. This process will last for 5 months.
10164826|NCT03948789|Active Comparator|A Myomectomy|Removement of uterine fibroids by myomectomy
10164827|NCT03948789|Experimental|B MRgFUS-TUF|Removement of uterine fibroids by Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy (MRgFUS-TUF)
10164828|NCT03948594|Placebo Comparator|plain water|subject drink 250cc plain water
10164829|NCT03948594|Active Comparator|resource|subject drink 1 packet resource(237ml)
10164830|NCT03948529|Experimental|eltrombopag|Eligible patients will receive the investigational drug eltrombopag
9694871|NCT04784650|Other|Pre-dialysis population|Pre-dialysis population, consisting both Diabetes Mellitus (DM) and non-DM patients
9694872|NCT04784481|Experimental|Experimental Group|"The EG received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.~All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol"
10164831|NCT03948373|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
10164832|NCT03948373|No Intervention|Conservative measures|Patients who will receive conservative treatment based on hygienic-dietetic measures
10164833|NCT03948659||Cirrhotic patients in intensive care unit|
10164834|NCT03948360|Experimental|LIMB Phototherapy with SOC|Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.
10164835|NCT03948360|Experimental|LIMB Phototherapy without SOC|Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.
10164836|NCT03948620||Children whose mother prescribed antibiotics during pregnancy|"Children whose mother were prescribed an only monotherapy of macrolides or penicillins from 5 gestational weeks (GW) to delivery. A monotherapy is defined as one or more consecutive prescriptions for a single antibiotic (i.e. same drug substance) separated by no more than 30 days and uninterrupted by prescriptions for other antibiotic drug substances.~The investigators will also build a negative control cohort which includes children whose mother were prescribed an only monotherapy of macrolides or penicillins from 50 to 10 weeks before conception."
10164837|NCT03948607||Adult ADHD|Adult ADHD patients without current comorbidity and treatment.
10164838|NCT03948607||Healthy controls|Healthy controls without ADH, paired in age and gender.
10164839|NCT03948633|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination).
9694873|NCT04784481|No Intervention|Control Group|Conventional treatment. All participants were evaluated by physical examination COVID-19 diagnosed with positive RT-PCR at the beginning, and final of the protocol
9694874|NCT04784442|Experimental|ETC-1002 180mg|
10164840|NCT03948633|No Intervention|Control|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting).
10164841|NCT03948542||Outcome|Nerve conduction studies (NCV) Functional assessment according to Daniels and Worthingham
10164842|NCT03948477|Other|Pantoprazole/Placebo|Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2
10164843|NCT03948477|Other|Placebo/Pantoprazole|Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2
10164844|NCT03948503|Experimental|Mobilization with movement (MWM) group|Application of the Mulligan concept
10164845|NCT03948503|Placebo Comparator|Sham group|Sham treatment
10164846|NCT03948412|Experimental|Closed Incision Negative Pressure Wound Therapy (Prevena)|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. This is left in-situ for 7 days, unless clinically indicated.
10164847|NCT03948412|Active Comparator|Standard Dressings|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. Standard care wound dressings are applied for patients in this arm. These are changed as clinically appropriate whilst in hospital.
10164848|NCT03948308|Experimental|Interventional arm|blood sample before, during and after treatment for infection
10164849|NCT03948425|Experimental|Stroke|Clinical suspicion of hyperacute stroke (6 hours after onset of symptoms):Intervention 'spectral CT'
10164850|NCT03948399||STROKE GROUP|150 patients admitted to Stroke Unit with a diagnosis of acute ischemic stroke (IS) or transient ischemic attack (TIA)
10164851|NCT03948399||CONTROL GROUP|50 individuals admitted to hospital without diagnosis of acute cerebrovascular disease; with diagnosis of dizziness, epilepsy, sclerosis multiplex.
10164852|NCT03948555||Acute aortic dissection|stable patients with confirmed diagnosis of acute AD.
10164853|NCT03948555||Chronic aortic dissection|patients with diagnosis of chronic AD, being followed up in outpatient aortic clinic.
10164854|NCT03948451|Experimental|[14C]AZD5718 Oral Suspension|One 200 mg dose of [14C]AZD5718 Oral Suspension
10164855|NCT03948321|Experimental|Painless Photodynamic Therapy（P-PDT）|The painless photodynamic therapy（P-PDT）group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 400 J/cm2) after applying 20% 5-aminolevulinic acid（ALA）cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
9694875|NCT04784442|Experimental|ETC-1002 120mg|
10164856|NCT03948321|Active Comparator|Conventional Photodynamic Therapy（C-PDT）|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 100 J/cm2) after applying 20% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
10164857|NCT03948139|Other|Functional Bracing Group|In a presented abstract, the functional brace group has been to shown equivalent outcomes to the hip spica cast. Subject will be administered the functional brace without going to the operating room to be put under full anesthesia. Most cases will not require any sedation in this group (in some cases, light sedation may be needed). Brace will be used for up to 8 weeks post-administration, until adequate callous formation is confirmed.
10164858|NCT03948139|Other|Spica Cast Group|If subject is randomized into the hip spica cast group, subject will proceed to the operating room and be given general anesthesia to administer the spica cast. Cast will be used for up to 8 weeks, until adequate callous formation is confirmed.
10164859|NCT03948165||Distal Radial Approach|Distal transradial access will be performed on patients above 18 years of age, undergoing diagnostic and/or therapeutic coronary angiography, with palpable pulse at the level of the radial fossa, and these patients will be also subjected to the following tests: Allen maneuver and Barbeau maneuver; a positive Allen test was indication to perform the transradial access, while a type D Barbeau test will be a contraindication for it.
10164860|NCT03948243|Experimental|G.Glabra|single arm
9694876|NCT04784442|Experimental|ETC-1002 60mg|
10164861|NCT03948269|Experimental|Internet- and mobile-based group treatment|the therapy consists of 10 modules (15 hours in total) in groups of 8 participants each over a period of 10 weeks and one follow-up meeting (2 hours) 12 weeks after the 10th module (week 22). Each module is adapted from the previous literature on CBT rationale and will be conducted online on WeChat, a mobile social networking software with 1 billion users in 2018. First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging.
10164862|NCT03948269|Active Comparator|Face-to-face group treatment|10 modules will be conducted every weekend in the psychological counseling room of The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University.
10164863|NCT03948217|Active Comparator|L1|regimen L1 has overall higher intensity, higher color temperature and less light fluctuations
10164864|NCT03948217|Active Comparator|L2|regimen L2 has lower intensity, lower color temperature and more light fluctuations.
10164865|NCT03948256|Active Comparator|Control intervention|Prompt closure, based on best available scientific data
10164866|NCT03948256|Experimental|Experimental intervention|Gradual weaning, based on best available scientific data
10164867|NCT03947905|Experimental|Type of visit|Single arm, non-randomized crossover design. All patients will receive both types of visits virtual and physical, and after assessments are made, participants will be classified by physicians into low, moderate or high risk for intervention.
10164868|NCT03948126||travel medicine|Healthy adults originating from Sub-Saharan Africa, South America and the Caribbean and attending a travel medicine and international vaccination consultation in France.
10186473|NCT03735186|Experimental|Exercise|Participants will complete 60 min of treadmill exercise on day 1 (14:30-15:30). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
10186474|NCT03735173|Active Comparator|Pegged through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through a Subscapularis Peel (SP) manipulation.
10186475|NCT03735173|Active Comparator|Pegged through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through subscapularis tenotomy (ST) manipulation.
10186476|NCT03735173|Active Comparator|Keeled through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through a Subscapularis Peel (SP) manipulation.
10186477|NCT03735173|Active Comparator|Keeled through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through subscapularis tenotomy (ST) manipulation.
10186478|NCT03735160||Nasal intubation with pressure sensor|anesthetized patient with nasotracheal intubation
10186479|NCT03735147|Experimental|All children|Administration of live attenuated influenza vaccine (LAIV)
10186480|NCT03735134|Active Comparator|Control Group|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
10186481|NCT03735134|Active Comparator|Early colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
10186482|NCT03735134|Active Comparator|Late colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
10186483|NCT03735108||pregnancy loss group|the times of pregnancy loss more than or equal to twice
10186484|NCT03735108||normal control group|no history of pregnancy loss
10186485|NCT03735082|Experimental|apatinib+Paclitaxel+Carboplatin|apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle
10186486|NCT03735069|Experimental|IPT (Indirect pulp treatment) group|In this group, complete caries excavation from the dentin-enamel junction will be done. Caries near the pulp will be removed with caution until the remaining dentin shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material will be placed (Vitrebond; St.Paul, MN), followed by resin-modified glass ionomer (RMGI) build-up material (Vitremer; St. Paul, MN), and the final restoration of choice for MIH involved teeth; a preformed Stainless Steel Crown (SSC).
10186487|NCT03735069|Experimental|Cvek/partial pulpotomy group|"In this group, partial pulpotomy will be attempted first, inflamed pulp tissue will be removed until healthy pulp tissue is reached (2-4mm depth), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated twice if required; otherwise, cervical pulpotomy will be done.~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be placed in the pulp chamber (2-3mm thickness), a moist cotton pellet will be placed and Intermediate Restorative Material (IRM) to ensure setting. Patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
9977408|NCT01361243|Experimental|NOURISH+|Participants will receive a 6-week face-to-face intervention, NOURISH+. Weekly topics teach parents skills to role model and encourage healthy lifestyle behaviors for their children.
9694877|NCT04784442|Placebo Comparator|Placebo|
9694878|NCT04784416|Experimental|Transcranial Photobiomodulation (t-PBM)|
9694879|NCT04784416|Sham Comparator|Sham|
10186488|NCT03735069|Experimental|Cervical pulpotomy group|"In this group, a cervical pulpotomy procedure will be done where all pulp chamber tissue shall be removed until healthy pulp tissue is reached, as indicated by bleeding from all canals and arrest of hemorrhage upon pressure (for maximum 6 minutes).~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be mixed according to manufacturer instructions and will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with Intermediate Restorative Material (IRM), the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
10186489|NCT03735056|No Intervention|Group 1 (Usual care)|Receives usual care only.
10164869|NCT03948230|Active Comparator|Sodium chloride / Water|300mg sodium chloride consumed in a capsule on two occasions with 300ml water
10164870|NCT03948230|Active Comparator|Sodium chloride / no water|300 mg sodium chloride consumed
10164871|NCT03948230|Active Comparator|Sodium chloride / colored water|300mg sodium chloride consumed in a capsule on two occasions with 300ml coloured water
10164872|NCT03948230|Placebo Comparator|Placebo / water|Placebo consumed in a capsule on two occasions with 300ml water
10164873|NCT03948230|Placebo Comparator|Placebo / no water|Placebo capsule consumed
9977409|NCT01361243|Placebo Comparator|Wellness Group|"Participants will receive an in-person Family Wellness Night followed by 6 mailings of information regarding pediatric overweight and obesity."
9977410|NCT01361256|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
10164874|NCT03948230|Placebo Comparator|Placebo / coloured water|Placebo consumed in a capsule on two occasions with 300ml colored water
10164875|NCT03948087|Experimental|Vacuum Removable Rigid Dressing (VRRD)|Application of a Vacuum Removable Rigid Dressing (VRRD)
10164876|NCT03948087|No Intervention|Soft Dressing Control Group|Application of standard of care soft dressing (SD) intra-operatively.
10164877|NCT03948191|Active Comparator|Methylprednisolone(ivMP)|Methylprednisolone(ivMP) 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
10164878|NCT03948191|Experimental|99Tc-MDP|99Tc-MDP 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
10164879|NCT03947827|Active Comparator|Active|Minocycline will start at an oral dose of 100mg daily and will be increased after one week to 100mg twice daily.
10164880|NCT03947827|Placebo Comparator|Placebo|Placebo capsules will start at one capsule daily, and will be increased after one week to one capsule twice daily
10164881|NCT03948152|Active Comparator|Standard of Care|
10164882|NCT03948152|Experimental|Mask Advice Tool|
9694880|NCT04784156||All study patients|"All study patients will be in one group.~Interventions:~Procedure: Subtalar (Talocalcaneal) arthrodesis Device: DynaNail Mini"
10164883|NCT03947970|Experimental|[14C] CR845|Subjects will receive a single dose of [14C] CR845 IV solution administered as an IV bolus on Day 1.
10164884|NCT03948100|Experimental|Group I (dyadic yoga)|Patients and caregivers undergo dyadic yoga intervention session involving physical exercises and relaxation techniques over 60 minutes each for up to 15 sessions.
10164885|NCT03948100|Active Comparator|Group II (dyadic education)|Patients and caregivers undergo dyadic education program session focusing on strategies of how to manage patient and caregiver symptoms over 60 minutes each for up to 15 sessions.
10164886|NCT03947996|Experimental|Stretching|Stretching
10164887|NCT03947996|Experimental|Walking|Walking
10164888|NCT03947879|Experimental|L-glutamine|Treatment with L-glutamine for 3 months.
10164889|NCT03947879|Experimental|No L-glutamine|No L-glutamine for 3 months.
10164890|NCT03947775|Experimental|Immediate Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at baseline visit, dose #2 at month 2, and dose #3 at month 6.
10164891|NCT03947775|Active Comparator|Delayed Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at month 24, dose #2 at month 26, and dose #3 at month 30.
10164892|NCT03947944|Active Comparator|manifest refraction planning group|The subjects underwent SMILE using manifest refraction planning.
10164893|NCT03947944|Active Comparator|vector planning group|The subjects underwent SMILE using vector planning.
10164894|NCT03947801|Experimental|Greek Yogurt condition|3x 160g of 0% Plain Greek yogurt (~115 kcals, 17 g protein, ~11.5 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
10164895|NCT03947801|Placebo Comparator|Isoenergetic condition - Carbohydrate|3x 30g of isoenergetic CHO supplement (~115 kcal, 0.04 g protein, ~28.6 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
10164896|NCT03947814|Experimental|Part A: Normal renal function (control group)|Participants with normal renal function (glomerular filtration rate [GFR] greater than or equal to [>=] 90 milliliters per minute [mL/min]) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
10164897|NCT03947814|Experimental|Part A: Severe renal impairment or ESRD|Participants with severe renal impairment (GFR >=15 to less than [<]30 mL/min) who are not on dialysis or end stage renal disease (ESRD) (GFR <15 mL/min) not yet on dialysis will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
10164898|NCT03947814|Experimental|Part B (Optional): Mild renal impairment|Participants with mild renal impairment (GFR >=60 mL/min to <90 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
10164899|NCT03947814|Experimental|Part B (Optional): Moderate renal impairment|Participants with moderate renal impairment (GFR >=30 to <60 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
10164900|NCT03947697|Placebo Comparator|Control|Participants will receive stimulation only up to sensory level.
10164901|NCT03947697|Experimental|NMES|Participants will receive stimulation up to maximum tolerable level.
10164902|NCT03947697|Placebo Comparator|Resistance Training|Participants will receive exercise training with stimulation up to sensory level.
10164903|NCT03947697|Experimental|Resistance Training + NMES|Participants will receive exercise training with stimulation up to maximum tolerable intensity.
10164904|NCT03947645|Experimental|Ipsilesional stimulation|Ipsilesional stimulation
10164905|NCT03947645|Experimental|Contralesional stimulation|Contralesional stimulation
10164906|NCT03947593||Households with children under 13|Interviews conducted with the parent or guardian of a child or children under age 13.
10164907|NCT03947593||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own for five or more hours a week.
9694881|NCT04784195||Profesional acrobatics|Profesional Acrobatic Skyedivers as the cort group
10164908|NCT03947593||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
10164909|NCT03947593||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
10164910|NCT03947658|Experimental|Six weeks group|Prosthetic restoration started 6 weeks after surgical crown lengthening
10164911|NCT03947658|Experimental|Fourteen weeks group|Prosthetic restoration started 14 weeks after surgical crown lengthening
10164912|NCT03948178|Experimental|Levosimendan|Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.
10164913|NCT03947502|Experimental|Intervention Group with|Educational intervention in neurobiology of pain
10164914|NCT03947502|No Intervention|Control group|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
10164915|NCT03947554|Experimental|HRG80 Panax ginseng|Panax ginseng standardized to 63.4 mg of total ginsenosides taken orally once daily in the morning after a meal.
10164916|NCT03947554|Active Comparator|Panax ginseng|Panax ginseng standardized to 19.6 mg of total ginsenosides taken orally once daily in the morning after a meal.
10164917|NCT03947554|Placebo Comparator|Placebo|Placebo capsule containing brown sugar and rice flour, taken orally once daily in the morning after a meal.
10164918|NCT03947528|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
10164919|NCT03947528|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
10164920|NCT03947567|Experimental|Recombinant Human Coagulation FVIII|
10164921|NCT03947580|Experimental|Use of the Dvectis Single pad|The Dvectis Single Dynamic-directional pad is a basic model of the Dvectis product range that provides full functionality based on the dynamic-directional seating principle. The Dvectis Single pad is designed to steer muscle tension during sitting in deep-seated muscles. The Dvectis Single pad is intended to eliminate chronic lumbar spine pain by strengthening the stabilizing muscles.
10164922|NCT03947580|Experimental|Use of the Dvectis Double pad|The Dvectis Double Dynamic-directional pad is based on the Dvectis Single model, but in addition to its dual-chamber design, it provides seating with a more balanced load and a higher dynamic-directional effect. The Dvectis Double pad is designed to create and route muscle tension during sitting in deep-seated muscles. The Dvectis Double is also suitable for soft substrates (sofa, soft chair, etc.). The Dvectis Double Pad is intended to remove chronic lumbar spine pain by strengthening the stabilizing muscles.
10164923|NCT03947580|No Intervention|Use of no pad|Description is not needed
10164924|NCT03947515|Experimental|cancer group|
10164925|NCT03947515|Experimental|control group|
10164926|NCT03947346||survivors of neuroblastoma treated with nephrotoxic therapy|Upon enrollment, all subjects will receive a urine collection kit by mail. Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.
10164927|NCT03947736||patients with positive HER2 amplification|
10164928|NCT03947736||patients with negative HER2 amplification|
9520268|NCT03279172|Experimental|Group Direct Laryngoscope|direct laryngoscope (macintosh laryngoscope) is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Macintosh laryingoscope, BIS monitoring and tonometry would be used in Group Direct Laryngoscope.
9520269|NCT03279172|Experimental|Group videolaryngoscope|Videolaryngoscope is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Video laryingoscope, BIS monitoring and tonometry would be used in Group Video Laryngoscope.
9977411|NCT01361269|Experimental|Fosmidomycin and clindamycin treatment|All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
9977412|NCT01361282||Triple Procedure|All qualifying patients will have received DSAEK with concurrent cataract extraction and intraocular lens placement. Data collection will occur between 6-18 months post-operation.
10164929|NCT03947710|Experimental|High-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume high protein meals during their dialysis sessions for one week.
10164930|NCT03947710|Experimental|Low-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume low protein meals during their dialysis sessions for one week
10164931|NCT03947710|Experimental|No meals|Patients with End Stage Renal disease on maintenance hemodialysis will not consume meals during their dialysis sessions for one week
10164932|NCT03947359|Other|Participants with a thoracic diameter < 75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
10164933|NCT03947359|Other|Participants with a thoracic diameter >75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
10164934|NCT03947437|Experimental|Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
10164935|NCT03947437|Experimental|High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
10164936|NCT03947437|Experimental|TBD dose in patients|TBD μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in paucibacillary leprosy patients. Dose will be determined by safety and immunogenicity data from healthy participants.
10164937|NCT03947437|Placebo Comparator|Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
10164938|NCT03947242|Experimental|Pyrotinib + trastuzumab +Vinorelbine|Pyrotinib in Combination With Trastuzumab Plus Vinorelbine
9694882|NCT04784195||General active participations|Adults with meched caracteristics with the profesional acrobatics
10164939|NCT03947229|Active Comparator|Clopidogrel mono-therapy|After randomization, patients will receive clopidogrel monotherapy after DES implantation for 24 months.
10164940|NCT03947229|Active Comparator|Dual-antiplatelet therapy|Patients will receive dual antiplatelet consisting of aspirin and clopidogrel.
10164941|NCT03947372|Active Comparator|OA (open Appendectomy)|Open Appendectomy
10164942|NCT03947372|Experimental|LA (Laparoscopic Appendectomy)|Laparoscopic Appendectomy
10164943|NCT03947424|Experimental|Experimental 1|Long-pulse (LP) Er:YAG laser snoring treatment.
10164944|NCT03947424|Experimental|Experimental 2|Fotona SMOOTH mode Er:YAG laser snoring treatment.
10164945|NCT03947424|Sham Comparator|Control|Sham laser snoring treatment with no energy applied.
10164946|NCT03947450|Experimental|Autologous skin fibroblasts|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives autologous skin fibroblast whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives autologous skin fibroblasts."
10164947|NCT03947450|Placebo Comparator|Control|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives vehicle (placebo) whole stump injections.~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives a placebo."
10164948|NCT03947463|Experimental|PECS block group|20ml of 0.25% bupivacaine was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualised on the ultrasound screen. similarly, in Serratus plane block, ultrasound probe was placed over the mid-axillary region of the thoracic cage in a sagittal plane. Ribs were identified inferiorly and laterally, until the identification of the 3rd rib in the mid axillary line. 10 ml of 0.25% bupivacaine was infiltrated in between Serratus anterior muscle and Latissimus Dorsi muscle
10164949|NCT03947463|No Intervention|Control group|Patient were given multimodal analgesia without the regional block
10164950|NCT03947320|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
9520270|NCT03279159|Experimental|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
9694883|NCT04784130|Experimental|DHSMP core|Dietary Modification and Physical Activity
10164951|NCT03947398|Experimental|Treatment with BLIMP first|
10164952|NCT03947398|Active Comparator|Treatment with low-profile balloon first|
10164953|NCT03947489|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
10164954|NCT03947489|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
10164955|NCT03947411|Experimental|Oseltamivir Phosphate+Xiyanping injection|Oseltamivir Phosphate+Xiyanping injection treatment for 7-10 days
10164956|NCT03947411|Active Comparator|Oseltamivir Phosphate treatment only|Oseltamivir Phosphate treatment for 7-10 days
10164957|NCT03947138|Experimental|GC3107_Part1|Part 1 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
10164958|NCT03947138|Experimental|GC3107_Part2|Part 2 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
9977413|NCT01361295|Active Comparator|PVI with PVAC gold|Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
10164959|NCT03947138|Active Comparator|BCG SSI_Part1|Part 1 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
10164960|NCT03947138|Active Comparator|BCG SSI_Part2|Part 2 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
10164961|NCT03947073|No Intervention|Standard of Care|Subjects with newly diagnosed gestational diabetes are randomized to standard of care diabetes education.
10164962|NCT03947073|Experimental|Interactive Educational Application|Subjects with newly diagnosed gestational diabetes are randomized to standard of care plus an interactive educational application.
10164963|NCT03947047||Placenta Accreta|Women found to have abnormal placentation (any degree of placenta accreta) during the cesarean section.
10164964|NCT03947047||No Placenta Accreta|Women found to have normal placenta separation during the cesarean section.
10164965|NCT03947606|Experimental|Basic social support + communication + Ottawa guide|3 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
10164966|NCT03947606|Experimental|Basic social support + communication|2 in-person/telephone weekly sessions on providing decision social support and tips for good communication
9520271|NCT03279146|Active Comparator|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
9694884|NCT04784130|Experimental|DHSMP core plus|Dietary Modification, physical activity and medication adherence
9694885|NCT04784130|Active Comparator|DHSMP control|enhanced usual care-3 hours of education plus materials.
9977414|NCT01361295|Active Comparator|PVI with Cooled-RF|Patient for pulmonal vein isolation using the Cooled-RF catheter.
10164967|NCT03947606|Experimental|Basic social support + Ottawa guide|2 in-person/telephone weekly sessions on providing decision social support and decision support tools
10164968|NCT03947606|Experimental|Basic social support only|1 in-person/telephone weekly session on providing decision social support
10164969|NCT03947606|Experimental|Advanced social support + communication + Ottawa guide|5 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
10164970|NCT03947606|Experimental|Advanced social support + communication|4 in-person/telephone weekly sessions on providing decision social support and tips for good communication
10164971|NCT03947606|Experimental|Advanced social support + Ottawa guide|4 in-person/telephone weekly sessions on providing decision social support and decision support tools
10164972|NCT03947606|Experimental|Advanced social support only|3 in-person/telephone weekly sessions on providing decision social support
9520272|NCT03279146|Experimental|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
9520273|NCT03279146|Experimental|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
9520274|NCT03279133|Experimental|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
9694886|NCT04784351||Training|A subset of patients that are used to train the machine learning algorithm.
10164973|NCT03947268|Experimental|Short-course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation technique.
10164974|NCT03947034||Metabolic toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of metabolic toxicities(such as hyperammonemia) of patient treated by a drug, with a chronology compatible with the drug toxicity
10164975|NCT03946956|Active Comparator|Prebooking|Participants randomised to this arm receives a prebooked appointment to screening
10164976|NCT03946956|Placebo Comparator|Web based booking|Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
10164977|NCT03946956|Active Comparator|Pictured invitation|Participants randomised to this arm receives a pictured invitation to screening
10164978|NCT03946956|Placebo Comparator|Texted invitation|Participants randomised to this arm receives a classical texted invitation to screening
10164979|NCT03946943|Experimental|anlotinib + Toripalimab|Concurrent anlotinib and Toripalimab therapy, with Blood Draw and Tumor Specimen Collection for correlative studies
10164980|NCT03947086|Active Comparator|Active TDCS Group|Participants will receive active Transcranial Direct Current Stimulation (TDCS) (1.5 mA). Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
10164981|NCT03947086|Sham Comparator|Sham tDCS Group|Participants will receive sham TDCS. The protocol is identical for placebo stimulation, but the current will stop after 30 seconds from the start of stimulation. Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
10164982|NCT03947203|No Intervention|Pamphlet|Provided with only a pamphlet containing educational material about oral health
10164983|NCT03947203|Experimental|Social media|Provided pamphlet containing educational material about oral health and will have access to a private Facebook group, where we will share informational messages and content relating to oral health
10164984|NCT03947164|Other|Case group|"Case :~- Patient operated at Rennes University Hospital of anterior POP and / or posterior POP via vaginal and / or abdominal way.~POPs will be classified in stages 2-4 using the ICS classification;~Without urinary incontinence associated effort (eliminated by the interrogation);~Registered to a health insurance system;~Having received information on the protocol and giving informed written consent."
10164985|NCT03947164|Other|Control group|"Control:~Patient operated at the Rennes University Hospital for a vaginal or abdominal hysterectomy for a benign reason.~No POPs and no urinary incontinence eliminated during the interrogation and clinical examination.~Registered to a health insurance system;~Having received information on the protocol and giving informed written consent."
10164986|NCT03946787|Active Comparator|EMDR Therapy + TAU|"Patients will be submitted to 20 individual sessions of Eye Movement Desensitization and Reprocessing (EMDR) Therapy of 60 minutes each, combined to the Treatment as usual (TAU).~It's an eight-step process aimed at the traumatic events, also used to address current situations that evoke emotional disturbances so they do not trigger more symptomatic reactions. In addition, it is helpful to assist the patient in developing the specific skills and behaviors required for a healthy functional life.~Our group will adapt the EMDR protocol model specific for bipolar patients with a history of trauma, developed by Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma."
10164987|NCT03946787|Placebo Comparator|TAU (Treatment as Usual)|"Patients will receive the Treatment as Usual. TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service. Patients are expected to be euthymic (or with subsyndromal symptoms) with the same medication for at least 3 months.~Although the medications used by patients are relevant and taken into account in future analyzes, our group will not interfere with drug treatment. Thus, patients who require any type of drug intervention will be considered losses."
10164988|NCT03947723|Experimental|Low power|"These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of low."
10164989|NCT03947723|Experimental|1 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.
10164990|NCT03947723|Experimental|1.5 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5
10164991|NCT03947723|Experimental|2 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.
10164992|NCT03947125||knee applied group|the patients with buprenorphine patch applied to painful knee joint in knee osteoarthritic patients
10164993|NCT03947125||chest applied group|the patients with buprenorphine patch applied to anterior chest wall in knee osteoarthritic patients
10164994|NCT03946878|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10187880|NCT03721796||Arm 2 Patients|For each participating oncologist, we will may enroll up to three adult cancer patients presenting for consultation, since certain disease sites have a higher incidence in the HIV population.
10187881|NCT03721783||children with soft tissue lesions|All children who undergo cryoablation therapy for benign soft tissue lesions
9520275|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
9527704|NCT03217942|Experimental|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
9694887|NCT04784351||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
10164995|NCT03947008|Experimental|First Intuitive Eating Group (IE1)|IE1 will be the first group to participate in an intuitive eating program and will be required to attend five intuitive eating classes. The intuitive eating classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. This group will have an additional final assessment on the last day of the IE2's intuitive eating course. During the assessments, they will complete a questionnaire that will ask them about their body satisfaction and eating attitudes, and have their height and weight measured.
10164996|NCT03947008|Experimental|Second Intuitive Eating Group (IE2)|IE2 will be the second group to will participate in an intuitive eating program and will be required to attend 5 intuitive eating classes. The classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted on the same day as IE1 but they will take the 5 week course once the first group completes the class. This group will have an additional initial assessment on the day they begin their curriculum. The initial assessment will occur during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. During assessments, they will complete a questionnaire that will ask about body satisfaction and eating attitudes, and have their height and weight measured.
10164997|NCT03946852|Experimental|ARP arm|Patients will receive DCD after therapy after the abdominal reperfusion protocol.
10164998|NCT03946917|Experimental|JS001/regorafenib|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with regorafenib tablet
10164999|NCT03946657|Active Comparator|The Inhalation Group|Sevoflurane (1 minimum alveolar concentration [MAC]) were used in the Inhalation group for the maintenance of anesthesia.
10165000|NCT03946657|Active Comparator|The TIVA (total intravenous anesthesia) Group|Propofol infusion (4-8 mg/kg of total body weight/h) were used in the TIVA group.
10165001|NCT03946995|Experimental|Dry needling|Dry needling will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
10165002|NCT03946995|Active Comparator|Graston|Graston Technique will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
10165003|NCT03946982|Experimental|Low thoracic patient controlled epidural analgesia|
10165004|NCT03946982|Active Comparator|Lumbar epidural patient controlled epidural analgesia|
10165005|NCT03946982|Active Comparator|Low thoracic epidural morphine|
10165006|NCT03946982|Active Comparator|Lumbar epidural morphine|
10165007|NCT03946839||ICU Survivors|Patients with high risk of cognitive impairment who discharge from ICU
10165008|NCT03946839||Healthy Control|The control group have to be medically and cognitively healthy(MMSE ≥ 28). These individuals are recruited from the community and all attempts will be made to match them on age,sex and education to individuals recruited for groups of ICU Survivors.
10165009|NCT03947021|Experimental|BSPM-only group|Participants will only receive body-surface potential mapping (BSPM) with an extensive electrode set (256 electrodes).
10165010|NCT03947021|Experimental|CT+BSPM group|Participants will receive body-surface potential measurements (BSPM) and a CT scan. These data will allow for non-invasive reconstruction of electrical potentials at the heart surface.
10165011|NCT03946592|Placebo Comparator|Placebo group|Inject the Drug into submental fat via subcutaneous
10165012|NCT03946592|Experimental|DWJ211 group|Inject the Drug into submental fat via subcutaneous
10165013|NCT03946904|Experimental|preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. The lesion in this case was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
10165014|NCT03946904|Experimental|no preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG.the lesion in this case was prepared with high power laser setting first to ablate the enamel, dentin, and caries.
10165015|NCT03946865|Experimental|Hospitalized hematology/oncology cancer subjects|Hospitalized hematology/oncology cancer will participate in Reiki Therapy
10165016|NCT03946748|Experimental|REGN3918|"Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A.~Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B."
10165017|NCT03946709|Other|Muscle strength condition|
10165018|NCT03946709|Other|Muscle weakness condition|
10165019|NCT03946709|No Intervention|Control|
10165020|NCT03946644|Active Comparator|EVLA with keeping of security distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
10165021|NCT03946644|Experimental|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
10165022|NCT03946735|Experimental|Intervention study|Cognitive Behavioural Therapy for social anxiety
10165023|NCT03946735|Experimental|Social anxiety|
10165024|NCT03946475|Other|Intervention group|4 schools in 4 subdistrict which are divided into north and south Malang District. North area (Lawang and Singosari) and South area (Kepanjen and Gondanglegi).
10165025|NCT03946475|No Intervention|Control group|4 schools in 4 subdistrict which are divided into north (Sumberpucung), south (Lawang and Singosari), and east (Tumpang) Malang District.
10165026|NCT03946813|Experimental|Poor ovarian reserve|Infertile women with poor ovarian reserve
9527705|NCT03217942|Experimental|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
9694888|NCT04784273||All study patients|Device - DynaNail - Utilization of a novel dynamic compression pseudoelastic intramedullary nail
10165027|NCT03946722|Other|Standard downregulation with GnRH analogue|"Participants in this arm will be assigned to the routine IVF protocol currently being used in the investigators' IVF unit, as outlined below, with one week of downregulation. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Start progesterone (Norethisterone 5mg twice daily orally) on day 14 of downregulation cycle and continue for 11 days. Start GnRH analogue (Buserelin 0.5ml subcutaneously once daily) on day 21 of downregulation cycle and reduce to 0.2ml on day 1 of bleed. Baseline scan on day 1 - 5 of bleed and start oestrogen (Progynova 2mg three times daily orally). Serial scanning from day 10 until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
10165028|NCT03946722|Experimental|Prolonged downregulation with GnRH analogue|"Participants in this arm will be exposed to an additional five weeks of downregulation using a GnRH analogue. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Baseline scan on day 1-5 of bleed and administer GnRH analogue (Leuprorelin acetate 3.75 mg subcutaneously single injection). 28 days later administer second dose of GnRH analogue (Leuprorelin acetate 1.875 mg subcutaneously), and 21 days later start oestrogen (Progynova 2 mg three times daily orally). Serial scanning from day 10 of oestrogen until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
10165029|NCT03946826|Experimental|PDL+ Halometasone Cream group|PDL+ Halometasone Cream Halometasone Cream, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
10165030|NCT03946826|Experimental|PDL+Vaseline group|PDL+Vaseline Vaseline, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
10165031|NCT03946826|Active Comparator|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
10165032|NCT03946826|Placebo Comparator|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
10165033|NCT03946306|Active Comparator|Group 1|5,25% NaOCl with syringe needle irrigation alone
10165034|NCT03946306|Active Comparator|Group 2|5,25% NaOCl with syringe needle irrigation, activated with sonic system EDDY (VDW, Munich, Germany)
10165035|NCT03946319|Experimental|Personalized, Transdiagnostic Assessments|One or more times per day, participants in the Experimental Arm will be presented with a variable-length assessment based on the personalization algorithm. The assessment will include a dynamic number of questions based on personalized relevancy, engagement level, and assessment completion metrics. Questions are scored immediately upon submission, regardless of how many questions are answered. As questions are scored, the personalization algorithm takes the previous responses and response times into consideration when determining what and when to ask additional questions.
10165036|NCT03946319|Active Comparator|Monotopic Assessments|Once daily, participants in the Control Arm will be presented with the standard of care mental health surveillance assessments identified as relevant upon intake. The assessments will be scored in totality or not at all and have a fixed, predefined number of questions. No personalization of assessment will take place.
10165037|NCT03946696||Dementia|Observations of communication and interactions between people with dementia living in a care home and therapy-animals.
10165038|NCT03946683|Experimental|Cyberknife for Early Stage Breast Cancer|Cyberknife Robotic Radiosurgery will be utilized as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer.
10165039|NCT03946566||Acupuncture group|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
10165040|NCT03946566||Basic treatment group|Use basic treatments, such as western medicine.
10165041|NCT03946579|Other|Patient treated by adjuvant therapy|Self questionnaires of sexual health and quality of life (FSFI, QLQ-C30, BR23, ELD 15, HADS, GDS 15, BIS, FACIT)
10165042|NCT03946280|Other|Fluoroscopy Group|Patient undergoing common flutter (AFL) ablation procedure using conventional X-ray based fluoroscopy for for catheter tracking
10165043|NCT03946280|Experimental|3D Group|Patient undergoing common flutter (AFL) ablation procedure using the low X-ray 3D navigation technique for for catheter tracking
10165044|NCT03946449|Experimental|ARO-AAT Cohort 1|"Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 8 additional doses."
10165045|NCT03946449|Experimental|ARO-AAT Cohort 1b|"Administered on Day 1, Weeks 4 and 16, for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 8 additional doses."
10165046|NCT03946449|Experimental|ARO-AAT Cohort 2|"Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 8 additional doses."
10165047|NCT03946410|Active Comparator|Screening|Invitation to cardiovascular screening
10165048|NCT03946410|Placebo Comparator|Control|No invitation to cardiovascular screening
10165049|NCT03946267|Experimental|IFCG = Infracyanine Green stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 ml of low-concentration (0.5 mg/mL, 0.05%) IFCG injected over the macular area with the infusion line closed.
10165050|NCT03946267|Experimental|BBG = Brilliant Peel stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 mL BBG at a concentration of 0.25 mg/mL (0.025%) injected over the macular area with the infusion line closed.
10165051|NCT03946384||patients|Hemophilia B with p.Ile112Thr mutation on factor IX gene
10165052|NCT03946501||clinical research visit|
10165053|NCT03946436|Experimental|I-AVI|The I-AVI group were involved in a regular tennis training process, two times a week for one hour. Additionally right after the tennis lessons they played a Virtua Tennis 4 active video game for 20 minutes per participant. They use the playstation kinect console. The intervention lasted 6 months.
10165054|NCT03946436|Active Comparator|NO-AVI|The NO_AVI group were involved in a regular tennis training process, two times a week for one hour. The training process lasted 6 months.
10165055|NCT03946137|Experimental|Sample|"30 patients of both sexes aged between 0 and 6 years with chronic neurological involvement with respiratory complications.~Individual sessions of chest therapy every fifteen days for three months, in total 6 respiratory physiotherapy sessions of 30 minutes each were performed. And the postural hygiene workshops were given to the parents, this educational intervention was carried out at the beginning of the study, at 3 months and at 6 months from the beginning. Each intervention lasted 4 hours with theoretical and practical part."
10165056|NCT03946514|Experimental|losartan/hydrochlorothiazide group|
10165057|NCT03946514|Active Comparator|amlodipine/hydrochlorothiazide group|
10165058|NCT03946488|No Intervention|Inactive neuroprosthesis|
10165059|NCT03946488|Experimental|Active neuroprosthesis|
10165060|NCT03946293|Active Comparator|White bread|White bread 3 x 30 g, single serving
10165061|NCT03946293|Active Comparator|Wholegrain|Standard wholegrain, 3 x 30 g, single serving
10165062|NCT03946293|Experimental|Wholegrain Enzyme|Enzyme-treated wholegrain, 3 x 30 g, single serving
10165063|NCT03946254|Experimental|Intervention|THE EXPERIMENTAL GROUP WILL DEVELOP 20 WEEKS OF TRAINING TO IMPROVE THE MUSCLE CAPACITY. FOR THIS, FORCE EXERCISES WILL BE DEVELOPED IN GUIDED MACHINES.
10165064|NCT03946254|Experimental|Control|THE CONTROL GROUP WILL DEVELOP 20 WEEKS OF BALANCE AND BREATHING EXERCISES.
10165065|NCT03946371||Extubation Success|Patients who do not require re-intubation, upto 48 hours after a planned extubation in the adult intensive care unit.
10165066|NCT03946371||Extubation failure|Patients who required re-intubation within 48 hours after a planned extubation in adult intensive care unit.
9826458|NCT02418949|Active Comparator|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
10165067|NCT03946007||Patients with melanoma or NSCLC|Patients (age ≥18 years) with melanoma or NSCLC ≥2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG.
10165068|NCT03946358|Experimental|Atezolizumab and UCPVax|"Induction phase:~Atezolizumab 1200 mg intravenous (IV) every 3 weeks since day 1~UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase:~UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)~Atezolizumab 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
10186490|NCT03735056|Experimental|Group 2 (Usual care plus Support 1)|Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl & Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
10186491|NCT03735056|Experimental|Group 3 (Usual care plus Support 2)|Receives usual care plus Support 2 (i.e. MS Nurse Support plus Peer Support). In addition to receiving the MS Nurse Support (i.e. Support 1, as described in Group 2), this group will also receive peer support which will be provided by Peer Support Workers who are patients/carers with lived experience and who are recruited and trained to deliver peer support under supervision from experienced clinical psychologists. It will be delivered one-to-one, face-to-face (in a community setting or via Skype, based on participants' preferences). Patients in this group will be triaged to a Peer Support Worker by the MS Nurse during the 2-week MS Nurse Support session. The sessions will be scheduled to a convenient time between weeks 2-6 after diagnosis and each session will last up to 60 minutes.
10186492|NCT03735043|Experimental|ccNexfin ©|
10186493|NCT03735030|Experimental|human hCG|
10186494|NCT03735030|Active Comparator|recombinant hCG|
10186495|NCT03735004|Experimental|TES 60 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 60 Hz) current
10186496|NCT03735004|Active Comparator|TES 100 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 100 Hz) current
10186497|NCT03735004|Sham Comparator|TES with DC current|Transcranial electrostimulation (TES) with direct current (DC) only
10186498|NCT03734978||A blood group|prematurity with sepsis
10186499|NCT03734978||O blood group|prematurity with sepsis
10186500|NCT03734978||B blood group|prematurity with sepsis
10186501|NCT03734978||AB blood group|prematurity with sepsis
10186502|NCT03734952|Experimental|Group A|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program+Postoperative radiotherapy program
10186503|NCT03734952|Other|Group B|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program
10186504|NCT03734926|Experimental|Part 1|Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
10186505|NCT03734926|Experimental|Part 2 Cohort A|Participants with hepatocellular carcinoma.
10186506|NCT03734926|Experimental|Part 2 Cohort B|Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
9694889|NCT04784247|Experimental|Leiomyosarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
10165069|NCT03945994|No Intervention|Connecting People Control Group|CMHTs (Community Mental Health Teams) will continue to support people with mental health problems using their standard care.
10165070|NCT03945994|Experimental|Connecting People Intervention Group|CMHTs will receive training on how to implement Connecting People programme. They will receive implementation toolkit to improve their practice in contrast to standard care.
10165071|NCT03946085|Experimental|Lumega-Z group|Participants assigned the study supplement Lumega-Z.
10165072|NCT03946085|Active Comparator|AREDS2 group|Participants assigned the AREDS2 supplement
10165073|NCT03946085|No Intervention|Control|Participants are determined ocular normal after clinical examination and do not have retinal drusen.
10165074|NCT03946046|Experimental|Clinical targeting|Clinical localization method (observation and palpation of target muscles)
10165075|NCT03946046|Experimental|Ultrasonography targeting|Ultrason-guided method
10165076|NCT03946020|Active Comparator|Augmentation with autologous bone + DBBM|A layer of autogenous bone chips was placed on the implant surface. On top of this a layer of DBBM (Bio-Oss™, Geistlich®, Wolhusen, Switserland) was placed, thereafter covered with a collagen membrane.
10165077|NCT03946020|Experimental|Augmentation with DBBM|A layer of DBBM was placed on the implant surface and thereafter covered with a collagen membrane. Care was taken to make both augmentations as comparable as possible by weighting the used amount of graft material.
10165078|NCT03946189||P/F less than 100|Patients receiving mechanical ventilation with paO2/FiO2 less than 100
10165079|NCT03946189||P/F between 100 and 200|Patients receiving mechanical ventilation with paO2/FiO2 between 100 and 200
10165080|NCT03946189||P/F between 200-300|Patients receiving mechanical ventilation with paO2/FiO2 between 200 and 300
10165081|NCT03945851|Experimental|VNS + Rehabilitation|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The experimental arm for that study includes subjects whose stroke treatment via Vagal Nerve Stimulation (VNS) delivered during rehabilitation.
10165082|NCT03945851|Active Comparator|Control VNS|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The active control arm for that study included subject whose stroke treatment is rehabilitation (standard-of-care) with only a minimal amount of VNS at the start of each rehabilitation session.
10165083|NCT03945942|Other|Pediatric liver transplant patients|Using somatic and cerebral Near infrared spectroscopy devices
10165084|NCT03946033|Other|Single arm|All participants are included in the same arm. Immunoscore Colon Test is applied on a tumor sample and the result is kept secret. In the Multidisciplinary Meeting evaluating the adjuvant therapy of the participant, a first therapeutic decision is taken, then Immunoscore result will be disclosed and the Multidisciplinary Meeting will take a second decision.
9520276|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
10165085|NCT03945864|Experimental|antimicrobial synthetic bone graft|This group will have parenteral antibiotics and antimicrobial (silver ions) synthetic bone graft
10165086|NCT03945864|Active Comparator|parenteral antibiotics with pure synthetic bone graft|This group will have parenteral antibiotics and pure synthetic bone graft
10165087|NCT03945838||Breast cancer related lymphedema|All patients were included in the complete decongestive therapy programme. This therapy includes patient education, skin care, exercises, manual lymphatic drainage (self), and compression bandage therapy.
10165088|NCT03946163|Experimental|first group|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
10165089|NCT03946163|Placebo Comparator|second group|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
10165090|NCT03946150||P/FP Ratio|P/FP Ratio is calculated in ARDS Patients retrospectively and analyse whether this new formula with PEEP can appropriately diagnose the Severity of Oxygenation with different levels of PEEP.
10165091|NCT03946150||P/F ratio|P/F ratio is the current Berlin definition of ARDS in Calculating the severity of Oxygenation.
10165092|NCT03946176|Experimental|Symbiotic|HD patients with 7 weeks symbiotic administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
10165093|NCT03946176|Placebo Comparator|Placebo|HD patients with 7 weeks placebo administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
10165094|NCT03945877||English-speaking Community Members|Survey respondents
10165095|NCT03945877||Spanish-speaking Community Members|Survey respondents
10165096|NCT03945877||Arabic-speaking Community Members|Survey respondents
10165097|NCT03945916|Experimental|Dark chocolate|180g/d dark chocolate
10165098|NCT03945916|Placebo Comparator|Placebo|180g/d of artificial dark chocolate
10165099|NCT03945929|Experimental|Distraction1 group|Distraction-1 Group (Cards containing optical illusion pictures)
10165100|NCT03945929|No Intervention|Control|Control
10165101|NCT03945929|Experimental|Distraction 2 group|Distraction-2 Group
10165102|NCT03945682|Experimental|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
10165103|NCT03945682|No Intervention|Usual Standard of Care|Participants continue with usual care and existing therapy recorded in study diary
10165104|NCT03945799|Experimental|Anlotinib|Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
10165105|NCT03945656|Experimental|Insulin 287 followed by insulin glargine|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.~After run-in, participants will receive insulin 287 once a week (OW) for 6 weeks.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 12 days."
10165106|NCT03945656|Active Comparator|Insulin glargine followed by insulin 287|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.~After run-in, participants will receive insulin glargine U100 OD for 12 days.~After insulin glargine treatment, participants will receive insulin 287 OW for 6 weeks."
10165107|NCT03945669|Active Comparator|Intramedullary Nail|Intramedullary Nailing: Alignment will be obtained by closed or limited open reduction of the fracture. A standard reamed intramedullary nail is inserted. Access above the patella, through the patella tendon or parapatellar access is used according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. Patients are administered preoperative antibiotics (Dicloxacillin) 15 minutes before surgery commences. Postoperative antibiotics is administered by discretion of the surgeon based on individual patient considerations.
10165108|NCT03945669|Experimental|External Ring fixator|External Ring fixation: Closed or limited open reduction of the fracture is performed. A circular frame is attached on both sides of the fracture. Connection to the bone is obtained by hydroxyapatite coated half pins and/or k-wires with olives as needed according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. After applying the ring fixator alignment is assessed radiologically and corrected both peri- and postoperatively. Patients are administered preoperative antibiotics (Dicloxacillin) preoperatively 15 minutes before surgery commences. Following surgery antibiotics are continued until wounds, pin- and wire perforations are dry.
10165109|NCT03945708|Experimental|Treatment|Addition of whole blood adsorber to CPB circuit
10165110|NCT03945708|No Intervention|Control|Standard treatment
10165111|NCT03945734|Experimental|Expressive Helping|Participants complete four 20-minute writing/voice-recording sessions spaced one week apart. During the first week, the instructions will explain that cancer patients and survivors benefit from learning about other cancer survivors' experiences. They are told that the first three weeks of writing/voice-recording (writing/talking about their stress and coping at Week 1, deepest emotions about cancer at Week 2, self-affirmation and benefit finding at Week 3) are exercises designed to help them think about their cancer experiences and to prepare them to write/record the narrative they would share on Week 4. During Week 4, they are asked to write/record a narrative as if they are speaking to another Chinese person with cancer, adding advice and encouragements, and reminded that their writing/recording would be shared with other Chinese American cancer patients and survivors.
10165112|NCT03945695|Experimental|Pneumatic Vitreolysis|All included eyes will receive one intravitreal injection of filtered sulfur hexafluoride gas (SF6).
10165113|NCT03945630|Experimental|anterior Quadratus Lumborum Block (QLB)|"Anterior QLB will be performed in the sitting position. This block is also known as TQL- Transmuscular QLB or QLB 3. A convex transducer will be placed in a transverse position, in the posterior axillary line and tilted caudad until the 'shamrock sign' at L4 level will be obtained. An 80-110 mm SonoTAP (PAJUNK Medizintechnologie, Geisingen, Germany) will be inserted in-plane from the lateral end of the transducer and advanced until the needle tip will be inside the interfascial plane between the Quadratus Lumborum and the Psoas muscles. The successful needle placement will be confirmed by observing the spread of 5 mls 0,9%NaCl. Subsequently, 30 ml 0.5% ropivacaine with 100 mcg dexmedetomidine and adrenaline 1:200,000 will be injected. Satisfactory interfascial spread will be assessed by longitudinal probe orientation.~Following QLB, a spinal anaesthetic will be sited and a THA via posterior approach will be performed."
10165114|NCT03945630|Active Comparator|Standard of Care (no QLB)|A spinal anaesthetic will be sited and a THA via posterior approach will be performed.
10165115|NCT03945747||Control group|Individuals continue current treatment regimen with either standard insulin pump therapy or multiple daily insulin injections for the duration of the study.
10165116|NCT03945747||Hybrid closed-loop artificial pancreas system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a hybrid closed-loop system at the beginning of the study after initial labs and imaging studies are completed.
10165117|NCT03945747||Predictive low glucose suspend system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a predictive low glucose suspend system at the beginning of the study after initial labs and imaging studies are completed.
10165118|NCT03946215|Experimental|well-trained athletes|A cardiorespiratory stress test
10165119|NCT03945955|Experimental|Melatonin|
10165120|NCT03945955|Placebo Comparator|Placebo|
10165121|NCT03945331|Experimental|TESS|Transcutaneous Electrical Spinal Stimulation (TESS), used during all training sessions.
10165122|NCT03945331|Experimental|EES|TESS, used during the initial 6-month training period, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
10165123|NCT03945487|Experimental|Comprehensive treatment plus UC-MSC treatment|
10165124|NCT03945487|Other|Comprehensive treatment|
10165125|NCT03945461|Experimental|Gum chewing|Chew xylitol based, peppermint flavored gum for 30 minutes every two hours during the hours of 7 am to 9 pm, for the first 24 hours after your surgery
10165126|NCT03945461|No Intervention|Standard Care|Standard hospital management with no deviations from usual care
10165127|NCT03945474|Experimental|OMT|Patients will receive a standardized protocol of: condylar decompression, Still's technique for the sternocleidomastoid, hyoid rebalancing and thoracic inlet myofascial release.
10165128|NCT03945474|Sham Comparator|Sham|Patient will be treated in the supine position, with hands gently applied without pressure to the four areas: occiput, lateral cervical spine, hyoid area and thoracic inlet.
10186507|NCT03734913|Experimental|Part 1|Participants with advanced solid tumors including basal cell carcinoma and medulloblastoma, regardless of SMO or Gli1 alteration status.
10186508|NCT03734913|Experimental|Part 2 Cohort A|Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1 protein overexpression alteration.
10165129|NCT03945539|Experimental|JNJ-56136379 and Itraconazole|Participants will receive a single dose of JNJ-56136379 on Day 1 in Treatment Period 1 and itraconazole 200 mg once daily for 21 days starting on Day 34 along with a single dose of JNJ 56136379 on Day 38 in Treatment Period 2. JNJ-56136379 intake in Treatment Period 1 and the first intake of itraconazole in Treatment Period 2 will be separated by a washout period of at least 33 days. Study drug (JNJ-56136379 and itraconazole) intakes will be taken orally and under fed conditions.
10165130|NCT03945513|Experimental|LPRI424|
10165131|NCT03945526|Active Comparator|Astaxanthin|Astaxanthin supplementation will be given at 2 x 8mg for 7 days.
10165132|NCT03945526|Placebo Comparator|Control|A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation
10165133|NCT03945617|Experimental|Unified treatment protocol|This intervention group receives 16 sessions of CBT-based, individual psychotherapy using to the Unified Treatment Protocol for the treatment of emotional disorders by Barlow et al. (2011).
10165134|NCT03945617|No Intervention|Waitlist Control Group|Participants in the waitlist control group gain access to the Unified Treatment after a waiting period of 16 weeks
10165135|NCT03945604|Experimental|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity
10165136|NCT03945149|Active Comparator|Turmipure Gold™|30 subjects will be randomized under active arm and will receive Active Product at V1 and until V2 (5 weeks of treatment).
10165137|NCT03945149|Placebo Comparator|Placebo|30 subjects will be randomized under Placebo arm and will receive placebo Product at V1 and until V2 (5 weeks of treatment).
10165138|NCT03945253|Experimental|ASP8374-dose A|Participants will receive dose A of ASP8374 solution intravenously on day 1 of every 3-week cycle.
10165139|NCT03945253|Experimental|ASP8374-dose B|Participants will receive dose B of ASP8374 solution intravenously on day 1 of every 3-week cycle.
10165140|NCT03945058|Experimental|Experimental|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
10165141|NCT03945058|Sham Comparator|CONTROL|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 4weeks.
10165142|NCT03945227|Placebo Comparator|Arm A (consolidation only arm)|Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
10165143|NCT03945227|Experimental|Arm B (concurrent arm)|Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
10165144|NCT03945019|Experimental|CT-P13 SC|
10165145|NCT03945019|Placebo Comparator|Placebo SC|
10165146|NCT03945344|Experimental|Treatment A|Tiotropium with concomitant charcoal
10165147|NCT03945344|Experimental|Treatment B|Tiotropium without concomitant charcoal.
9826459|NCT02418949|Active Comparator|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
10165148|NCT03945370|Active Comparator|Intervention sequence 1|Ketone drink first - Placebo drink secondly
10165149|NCT03945370|Placebo Comparator|Intervention sequence 2|Placebo drink first - Ketone drink secondly
10165150|NCT03945383|Experimental|Treatment with IPL device|The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
10165151|NCT03945006||Multiple Sclerosis Patients with Incontinence|Multiple Sclerosis with incontinence 24-58 years of age and being volunteered.
10165152|NCT03945006||Multiple Sclerosis Patients without incontinence|Multiple Sclerosis without incontinence 24-58 years of age and being volunteered.
10165153|NCT03945279|Experimental|Cohort 1: BIIB100 Dose 1|Participants will receive single oral dose of BIIB100 on Day 1.
10165154|NCT03945279|Experimental|Cohort 2: BIIB100 Dose 2|Participants will receive single oral dose of BIIB100 on Day 1.
10165155|NCT03945279|Experimental|Cohort 3: BIIB100 Dose 3|Participants will receive single oral dose of BIIB100 on Day 1.
10165156|NCT03945279|Experimental|Cohort 4: BIIB100 Dose 4|Participants will receive single oral dose of BIIB100 on Day 1.
10165157|NCT03945279|Experimental|Cohort 5: BIIB100 Dose 5|Participants will receive single oral dose of BIIB100 on Day 1.
10165158|NCT03945279|Experimental|Cohort 6: BIIB100 Dose 6|Participants will receive single oral dose of BIIB100 on Day 1.
10165159|NCT03945279|Placebo Comparator|Cohort 1-6: Matching Placebo|Participants will receive single oral dose of matching placebo on Day 1.
10186509|NCT03734913|Experimental|Part 2 Cohort B|Participants with basal cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma with SMO or Gli1 protein overexpression alteration.
10165160|NCT03945201|Active Comparator|Standard of care|"Participants receive normal cardiac rehabilitation according to approved standard of care. They use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session."
10165161|NCT03945201|Experimental|Virtual walking trails|"Participants use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session. The treadmill is positioned in front of a vertically oriented high definition television screen showing Bionautica Trails, virtual walking trails created by Plas.md."
10165162|NCT03945396|Experimental|Multidisciplinary intervention + homeopathic medication|"Multidisciplinary intervention (diet, exercise program, motivational support) and Calcarea carbonica ostrearum 30c.~A single dose of Calcarea carbonica ostrearum 30C dissolved in a 30 ml bottle of 30% alcohol-distilled water. Patients will receive 8 drops PO three times per day prior agitation."
10165163|NCT03945396|Active Comparator|Multidisciplinary intervention + homeopathic placebo|"Multidisciplinary intervention (diet, exercise program, motivational support) and placebo.~Placebo will be prepared with 30% alcohol-distilled water only, in the same 30 ml bottle. Patients will receive 8 drops PO three times per day prior agitation."
10165164|NCT03945097||Letters|Education program focuses on learning letters.
10165165|NCT03945097||Language|Education program focuses on language comprehension.
10165166|NCT03945123|Experimental|Ginseng trial|compare experimental group to controlled group
10165167|NCT03945045|Experimental|SCV|TIVAD implanted through subclavian vein under real-time ultrasound guidance
9671476|NCT05048017|Experimental|Regorafenib plus PD-1 inhibitor|"Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF).~Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma.~Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers.~Pembrolizumab (Keytruda) the programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells."
9671477|NCT05047796|Experimental|Intervention Protocol|Visceral osteopathic techniques
10165168|NCT03945045|Experimental|IJV|TIVAD implanted through internal jugular vein under real-time ultrasound guidance
10165169|NCT03945084|Experimental|Experimental Arm|Patients assigned to experimental arm will receive Niraparib 300 mg or 200 mg daily (based on weight and platelet count) plus best supportive care (BSC), in 28-day cycles, until disease progression or unacceptable toxicity or death.
10165170|NCT03945084|Other|Control Arm|Patients assigned to control arm will receive best supportive care alone, until disease progression or death.
10165171|NCT03945188|Experimental|Etrasimod 2 mg|
10165172|NCT03945188|Placebo Comparator|Placebo|
10165173|NCT03944980|Experimental|Arm 1: CIK|"Docetaxel & PD1-T cells~Docetaxel,60mg/m2,intravenous infusion,d1; PD1-T cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
10165174|NCT03944980|Active Comparator|Arm 2: Control|"Docetaxel~Docetaxel,60mg/m2,intravenous infusion,d1; Q3W."
10165175|NCT03945071|Active Comparator|Puntal plug|Subjects will receive temporary punctal plug after intravitreal injection
10165176|NCT03945071|No Intervention|Non-Punctual plug|Subjects will not receive temporary punctal plug after intravitreal injection
9671478|NCT05047796|Sham Comparator|Sham Protocol|Simulated visceral osteopathic techniques
10165177|NCT03945266|Experimental|Intervention group|Participants receive the allocated intervention to help manage gestational weight gain that includes education on weight regulation, healthy eating, physical activity, and goal setting.
10165178|NCT03945266|Active Comparator|Control group|Participants do not receive the allocated intervention but self-monitor their behaviors, complete study tasks and receive prenatal care as normal.
10165179|NCT03945110|Experimental|Arm A|Patients in this Arm will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later.
10165180|NCT03945110|No Intervention|Arm B|Patients in this Arm will receive usual bladder care only.
10165181|NCT03945110|Experimental|Arm C|Patients in this Arm will be Spinal Urology Outpatients or Inpatients who are eligible for inclusion and experiencing significant urinary tract infection recurrence and/or complications. Patients will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later. Patients will be encouraged and supervised to self-administer iAluRil® intravesical instillations.
9671479|NCT05048056|Experimental|AK120 Regimen 1|AK120 Regimen 1- subcutaneous injection every 2 weeks for 30 weeks.
9671480|NCT05048056|Experimental|AK120 Regimen 2|AK120 Regimen 2- subcutaneous injection every 2 weeks for 30 weeks.
10165182|NCT03944889|Placebo Comparator|Placebo Topical|Placebo Cream, applied topically to trapezius muscle
10165183|NCT03944889|Active Comparator|Low Dose, Topical|Capsaicin Cream- low dosage, applied topically to trapezius
10165184|NCT03944889|Active Comparator|High Dose, Topical|Capsaicin Cream- higher dosage, applied topically to trapezius
10165185|NCT03944889|Placebo Comparator|Placebo, Intrafascial|Injection placebo(saline)- injected intrafascially into trapezius
10165186|NCT03944889|Active Comparator|Low Dose, Intrafacial|Injection Capsaicin formulation low dose- injected intrafascially into trapezius
10165187|NCT03944889|Active Comparator|High Dose, Intrafascial|Injection Capsaicin formulation higher dose- injected intrafascially into trapezius
10165188|NCT03944889|Placebo Comparator|Placebo, Intramuscular|Injection placebo (saline) - injected intramuscularly into trapezius
10165189|NCT03944889|Active Comparator|Low Dose, Intramuscular|Injection Capsaicin formulation low dose - injected intramuscularly into trapezius
10165190|NCT03944889|Active Comparator|High Dose, Intramuscular|Injection Capsaicin formulation higher dose - injected intramuscularly into trapezius
10165191|NCT03944915|Experimental|ARM 1|Induction Therapy
10165192|NCT03944915|Experimental|ARM 2|Radiation therapy with chemotherapy
10165193|NCT03945578|Active Comparator|Control Group|"This group performed a supervised Pelvic Floor Muscle Training (PFMT) protocol associated with a manual sham therapy (MST) sessions.~The PFMT protocol consisted of 20 sessions of 45-60 minutes each, twice a week, totalizing a five weeks treatment.~The MST protocol was performed once a week, during five weeks lasting approximately 15 minutes."
10165194|NCT03945578|Experimental|Experimental Group|"The experimental group performed the same PFMT protocol as the CG, but associated with a Visceral Manual Therapy (VMT) protocol.~The VMT sessions were held once a week, for five weeks. Each session lasted approximately 20 minutes."
10165195|NCT03944954|Experimental|Excitatory TMS|Combinations of THC and excitatory TMS.
10165196|NCT03944954|Experimental|Inhibitory TMS|Combinations of THC and inhibitory TMS.
9520277|NCT03279120|Placebo Comparator|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
9520278|NCT03279120|Placebo Comparator|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
10165197|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on dominant leg.
10165198|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Non-dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on non-dominant leg.
10165199|NCT03944993|Sham Comparator|Sham Therapy (Control)|Inactive Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes.
10165200|NCT03945032|Experimental|8 parents of a childhood cancer survivor|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
10165201|NCT03944824|Experimental|Exercise (Intervention) Arm|The 25 patients in this arm will receive an interventional exercise plan using resistance bands and once weekly visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
10165202|NCT03944824|Placebo Comparator|Control|The 25 patients in the control arm will not receive an interventional exercise plan or visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
10165203|NCT03944837|Experimental|Severe fetal congenital heart disease (CHD)|Mothers whose fetuses have a diagnosis of CHD will be exposed to 10-15 L/minute of oxygen while undergoing echocardiogaphy and MRI scanning
9671481|NCT05048056|Experimental|Placebo to AK120|Placebo subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 1, subcutaneous injection at Week16, after primary endpoint evaluation
9671482|NCT05047874||short-term (3 days) high-dose (1000 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone
9671483|NCT05047874||low-dose long-term (2x 40 mg) systemic methylprednisolone|retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone
9671484|NCT05047887|Experimental|Study group|Modified socket shield technique with autogenous dentin graft
9671485|NCT05047887|Active Comparator|Control group|Modified socket shield technique with alloplast
9671486|NCT05047861|Experimental|Study group|patients will receive the implant in the previously preserved socket using Socket shield technique with Alloplastic graft material
9671487|NCT05047861|Active Comparator|Control group|patients will receive the implant in the previously preserved socket shield with Autogenous dentin graft
9671488|NCT05047744|Experimental|Prosthesis Cohort|Surgery dual mobility Prosthesis
9671489|NCT05047965|Experimental|Diagnostic (standard MRI, Dixon MRI)|Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.
9671490|NCT05047848|Experimental|chidamide + fulvestrant|
9671491|NCT05048004||periprocedural oral anticoagulation|Oral anticoagulation will be continued without a periprocedural pause
9977415|NCT01361321||patients after GBR procedure|The study will comprise of patients who already underwent a routine Guided Bone Regeneration (GBR) procedure in order to augment a bony ridge before dental implant insertion. The patients will be followed up in order to determine bone quality and quantity formed after the usage of routinely used bone substitutes during GBR procedure.
10165204|NCT03945214|Experimental|Meditation group|Participants in the meditation intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks.
10165205|NCT03945214|Experimental|Healthy eating group|Participants in the healthy eating group will be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
9520279|NCT03279107|No Intervention|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
9520280|NCT03279107|Experimental|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
9520281|NCT03279107|Experimental|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
9977416|NCT01361334|Experimental|Pazopanib|Pazopanib treatment
9977417|NCT01361347|Placebo Comparator|placebo|"rice/soy/oat milkdrink, masked"
10165206|NCT03945214|Experimental|Mediation + Healthy eating group|Participants in the meditation + healthy eating intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks. They will also be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
10165207|NCT03945214|No Intervention|Waitlist control condition|Waitlist control group participants will continue their normal activities and not add any form of mediation during the study period.
10165208|NCT03944733|Active Comparator|Iron Intervention|IDA mothers will receive a 65 mg of iron (ferrous sulfate) daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
10165209|NCT03944733|Placebo Comparator|Placebo|IS mothers will receive 600 mg of gelatin daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
10165210|NCT03944746||SAMMC Emergency Medicine Residents|Emergency Medicine Residents from San Antonio Military Medical Center in San Antonio, Texas.
10165211|NCT03944746||University Hospital Emergency Medicine Residents|Emergency Medicine Residents from University Hospital in San Antonio, Texas.
10165212|NCT03944863||POEM + Antibiotic prophylaxis|Cefazolin: 2g or Amoxicillin - clavulanic acid: 1g x 3 during 7 days
10165213|NCT03944863||POEM + No antibiotic prophylaxis|
9671492|NCT05048004||no periprocedural oral anticoagulation|Pause of oral anticoagulation on the day of the intervention
10165214|NCT03944759|Active Comparator|GBM:( bupivacaine/magnesium sulphate)|"serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.~GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate"
10165215|NCT03944759|Active Comparator|GBN: ( bupivacaine/nalpuphin)|serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg.
10165216|NCT03944642|Experimental|Intervention|Participants will receive the standard prenatal care and invited to participate of a breastfeeding workshop during the third trimester of pregnancy, with active and intentional participation of the pregnant woman and her partner/relative; based on adult education methodology. In addition, women participants will have continuous support during their breastfeeding process, up to 6 months of the child's life, through a virtual support group (whats-app), where they will receive messages that promote their self-efficacy in relation to their ability to breastfeed and may ask questions that are related to breastfeeding. Professionals in this group will be train before delivering the intervention.
10165217|NCT03944642|No Intervention|Standard Care|This group will receive the standard pre and postnatal regular care, for mother and child. Professionals who provide direct care will maintain their usual attention.
10165218|NCT03944850|Experimental|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
10165219|NCT03944694||Delirious|Patients were delirious if CAM-ICU was positive within 24 hours from admission due to acute ischemic stroke.
10165220|NCT03944694||Non-delirious|Patients were delirious if CAM-ICU was negative within 24 hours from admission due to acute ischemic stroke.
10165221|NCT03944551|Experimental|Bubble CPAP|
10165222|NCT03944551|Other|Standard Therapy|
10165223|NCT03944499|Experimental|FS-1502|"Phase Ia:~Patients enrolled on the 1.2 and 2.0 regimens: FS-1502 monotherapy every 4 weeks with intravenous drip, 28 days as a cycle; Patients enrolled on the 3.0 regimens: starting from the 1.0mg/kg dose group, FS-1502 monotherapy every 3 weeks with intravenous drip, 21 days as a cycle;~Phase Ib:~FS-1502 monotherapy, the dose and frequency of administration for Stage Ib will be obtained according to Phase Ia (RP2D). All patients will continue treatment until no clinical benefit occurs, or intolerable toxicity occurs, or death occurs, or the investigator decides, or patients voluntarily withdraw from the study.~Study end is defined as the last patient's treatment ended or 2 years after the last patient's treatment began(depending on which happens earlier)."
10165224|NCT03944564|Active Comparator|Condition 1: sitting|Four hours of sitting condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
10165225|NCT03944564|Active Comparator|Condition 2: static standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
10165226|NCT03944564|Active Comparator|Condition 3: dynamic standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
10165227|NCT03944655|Active Comparator|Strepsils|
10165228|NCT03944655|Placebo Comparator|Placebo|
10165229|NCT03944681|Other|Droperidol group|Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus
10165230|NCT03944408|Experimental|A metal bare stent with 125I seeds|125I seeds fixed on the metal bare stent, then stent implantation
10165231|NCT03944408|Other|A metal bare stent|A metal bare stent implantation
10165232|NCT03944616|Active Comparator|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
10186510|NCT03734900|Placebo Comparator|Saline injection|Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
10186511|NCT03734900|Experimental|PRP injection|PRP injection into the study knee joint every 4 weeks for a total of 3 injections
9671493|NCT05047991|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV + Oxaliplatin|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-fluorouracil (5-FU), leucovorin(LV) and oxaliplatin intravenously on day 1 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
9977418|NCT01361347|Experimental|milk|cow's milk
9977419|NCT01361360||control|
9977420|NCT01361360||hypercapnia|
10165233|NCT03944616|Experimental|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
10165234|NCT03944330|Active Comparator|a treatment group|All study participants were provided with a standard hospital diet that provided B25-30 kcal/kg/day
10165235|NCT03944330|No Intervention|control group|All study participants were not intervened with diet
10165236|NCT03944369|Other|Observational Control|The observational control arm is an observational control group.
10165237|NCT03944369|Other|KB109|KB109 is a novel glycan.
10165238|NCT03944395|Other|Assisted Partner notification services|Voluntary assisted partner notification (VAPN) services will be offered at facilities according to a stepped wedge design. Once VAPN services are activated at a facility, HIV positive individuals will be offered four options (3 voluntary assisted partner notification options and 1 standard of care option) for inviting their contacts, which they can choose to accept or decline.
10165239|NCT03944421|Experimental|Red and Processed Meat|240 grams (raw weight) of red and processed meat every day for 2 weeks
10165240|NCT03944421|Experimental|Quorn|240 grams (uncooked weight) of Quorn every day for 2 weeks
10165241|NCT03944460|Active Comparator|Contraloid 4 mg|4 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165242|NCT03944460|Active Comparator|Contraloid 12 mg|12 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165243|NCT03944460|Active Comparator|Contraloid 36 mg|36 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165244|NCT03944460|Active Comparator|Contraloid 108 mg|108 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165245|NCT03944460|Active Comparator|Contraloid 320 mg|320 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165246|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 4 mg|4 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165247|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 12 mg|12 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165248|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 36 mg|36 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165249|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 108 mg|108 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165250|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 320 mg|320 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
10165251|NCT03944473|Active Comparator|neostigmine|Neostigmine is the acetylcholinesterase inhibitor most commonly used in pharmacologically reversing the effects of neuromuscular blockers [8]. Reversal of NMB is facilitated by increasing acetylcholine levels at nicotinic skeletal muscle-binding sites.
10165252|NCT03944473|Experimental|sugammadex|Sugammadex is a modified gamma-cyclodextrin, the first of a new class of drugs called selective relaxant binding agents, with an unusually high affinity for rocuronium. This medication offers an alternate mechanism of action to antagonize the effects of steroidal neuromuscular blockade agents.
10165253|NCT03944512|Experimental|Pravastatin|20 mg pravastatin daily
10165254|NCT03944512|Placebo Comparator|Placebo|Identical appearing daily placebo
10165255|NCT03944538|Experimental|Lifestyle Physical Activity|"The primary content of the website will be delivered through interactive video courses. The courses will be released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~The website Tracker feature will allow for tracking of daily step counts as well as setting goals and monitoring progress.~The one-on-one video chats will be conducted face to face through Zoom and will be semi-scripted. The chats will consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral changes based on social cognitive theory and current website content. The chats will occur at the same frequency as the video course release. For the second 6 months of the study, participants will be asked to maintain their usual activities."
10165256|NCT03944538|Active Comparator|General Wellness|The general wellness condition will focus on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the National Multiple Sclerosis Society. The delivery of the Internet materials and chat sessions will occur on the same schedule and frequency as the intervention condition, and will have a comparable time commitment. This condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. For the second 6 months of the study, participants will be asked to maintain their usual activities.
9977421|NCT01361373|Active Comparator|DOPAMINE|Sinemet up to 10 mg/kg/day
10165257|NCT03944525|Active Comparator|Intervention|Intervention consists of HFA using standard equipment at the department. A gas flow of 60L/min and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the pati ent or indication for intubation.
10165258|NCT03944525|Active Comparator|Control|Control consists of non-invasive CPAP ventilation support using a tight mask and standard respirator equipment of the Department of Emergency Medicine. A positive airway pressure of 5cm H2O and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.
9977422|NCT01361373|Placebo Comparator|Placebo|placebo
9977423|NCT01361386||1|
9977424|NCT01361399|Experimental|Arm 1|
10165259|NCT03944317|Active Comparator|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
10165260|NCT03944317|Active Comparator|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
10165261|NCT03944343|Sham Comparator|Reference product|Commercial cereals and a commercial yogurt
10165262|NCT03944343|Experimental|Test product A|Specific designed cereals A and yogurt
10165263|NCT03944343|Experimental|Test product B|Specific designed cereals B and yogurt
10165264|NCT03944343|Experimental|Test product C|Specific designed cereals C and yogurt
9826460|NCT02419001|Experimental|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:~Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
10165265|NCT03944343|Experimental|Test product D|Specific designed cereals D and yogurt
10165266|NCT03944291|Active Comparator|Unilateral PNB|Unilateral Pudendal Nerve Block
10165267|NCT03944291|Active Comparator|Bilateral PNB|Bilateral Pudendal Nerve Block
10165268|NCT03944304|Experimental|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
10165269|NCT03944278|Experimental|Thulium Device|1927 Laser Treatment
10186512|NCT03734900|Experimental|PL injection|PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
10186513|NCT03734887|Active Comparator|Private Feedback|Participants will receive a smart pill bottle that will collect data on their medication usage and provide real-time data about adherence to study staff. Study staff will provide participants with private feedback about adherence in the form of meeting with a pharmacist. Feedback will be provided at the start of the study. A semi-structured interviews will be performed among a random sub-sample of participants afterwards.
10186514|NCT03734887|Experimental|Social Network Intervention|Participants will receive the same treatment as the Private Feedback arm but they will additionally have Social Network Feedback. A biweekly feedback text messages will be sent to both the participant and a designated loved-one or friend of the participants for 12 weeks.
10186515|NCT03734874|Active Comparator|hesperidin|
10186516|NCT03734874|Placebo Comparator|control|
9826461|NCT02419001|Experimental|Period 1 - Treatment Sequence AC|"Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
10186517|NCT03734861|Experimental|BreatheSmart System|"BreatheSmart mobile application that tracks medication usage and sends real time reminders~HeroTracker sensor that counts dosage and monitors real-time medication adherence~CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)"
10186518|NCT03734861|Active Comparator|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
10186519|NCT03734848|No Intervention|Group 1|patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
10186520|NCT03734848|Active Comparator|Group 2|patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
10186521|NCT03734835|Active Comparator|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
10186522|NCT03734835|Placebo Comparator|control|no supplementation
10186523|NCT03734835|Active Comparator|flaxseed|30 grams flaxseed
10186524|NCT03734835|Active Comparator|hesperidin|1000 mg hesperidin as two capsules
10186525|NCT03734809|Experimental|pembrolizumab|"Total 51 weeks for 17 doses of pembrolizumab:~Neoadjuvant pembrolizumab-chemotherapy: 6 weeks (2 doses of pembrolizumab)~Concurrent pembrolizumab-chemoradiation: 9 weeks (3 doses of pembrolizumab~Maintenance pembrolizumab: 36 weeks (12 doses of pembrolizumab)"
10186526|NCT03734796||suspected NSTEMI|Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.
10186527|NCT03734770|Active Comparator|Subcutaneous progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
10186528|NCT03734770|Active Comparator|Vaginal progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
10186529|NCT03734757|Experimental|Trimodality|PET-CT with fluorocholine and MRI
10186530|NCT03734744|Experimental|Adults with Cystic Fibrosis|CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
10186531|NCT03734744|Experimental|Non-CF Controls with Low vitamin D|Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
10186532|NCT03734718|Active Comparator|Glucose-Dependent Insulinotropic Polypeptide|6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide
10186533|NCT03734718|Placebo Comparator|Placebo|Saline
10186534|NCT03734679|Experimental|Surveil drug coated balloon|
9826462|NCT02419001|Experimental|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:~[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
10165270|NCT03944226|Experimental|Beetroot|16 patients confirmed with a diagnosis of invasive ductal carcinoma who will undergo wide local excision surgery or mastectomy. All patients in the single arm will undergo a 5 day intervention drinking concentrated beetroot juice and 2 magnetic resonance imaging scan sessions pre and post intervention. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
10165271|NCT03944265|Experimental|Supportive care (treatment decision counseling session)|Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
10165272|NCT03944252|Experimental|A (avelumab)|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
10165273|NCT03944252|Experimental|B (cetuximab + avelumab)|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
9671494|NCT05047991|Active Comparator|Cohort 2: Nab-paclitaxel + Gemcitabine|The patients in cohort 2 will receive nab-paclitaxel and gemcitabine intravenously on day 1、day 8 and day 15 of every 28-day cycle until disease progression or unacceptable toxicity, or termination of the study due to other reasons.
10165274|NCT03944057|Experimental|ATG-010 + Dexamethasone|Open-label ATG-010 80mg plus Dexamethasone 20 mg
10165275|NCT03944070|Active Comparator|Intensive Treatment|The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
10165276|NCT03944070|Active Comparator|Standard Treatment|The participants will continue their preoperative treat and extend protocol .
10165277|NCT03944044|Other|Subcutaneous route first|The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.
10165278|NCT03944044|Other|Intravenous route first|The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.
10165279|NCT03944122|Experimental|continuous ultrasound|continuous ultrasound were applied to the patients
10165280|NCT03944122|Experimental|pulsed ultrasound|pulsed ultrasound were applied to the patients
10165281|NCT03944122|Experimental|placebo|placebo (sham) ultrasound were applied to the patients
10165282|NCT03944109|Experimental|SHR-1209|Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
10165283|NCT03944109|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
10165284|NCT03944135|Experimental|Experimental group|The sample consisted of 40 people: 20 in an experimental group. There were 5 men and 15 women.
10165285|NCT03944135|Active Comparator|Control group|The sample consisted of 40 people: 20 in a control group. There were 5 men and 15 women.
10165286|NCT03944239|Experimental|retinal pigment epitheliums transplantation|Transplant clinical-grade hESC derived retinal pigment epitheliums into subretinal of patients with retinitis pigmentosa.The dosage is 150000.
10165287|NCT03944031|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.
10165288|NCT03944083||ADHD with and without DMDD|ADHD with DMDD versus ADHD without DMDD. Observational study at referral and after 6 and 12 months.
10165289|NCT03944018|Experimental|Intervention with rehabilitation coordinator|
10165290|NCT03944018|No Intervention|Control|
10165291|NCT03944200|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
10165292|NCT03944200|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
10165293|NCT03943888|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex 15 minutes after rocuronium administration
10165294|NCT03943888|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex 15 minutes after rocuronium administration
10165295|NCT03943888|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex 15 minutes after rocuronium administration
10165296|NCT03943888|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) 15 minutes after rocuronium administration
10165297|NCT03944174||Single Trans-sacral Screw|
10165298|NCT03944174||Two Iliosacral Screws|
10165299|NCT03943940|Experimental|BM-MNC and UC-MSC|30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.
10165300|NCT03943940|Other|Stand medicines|30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines.
10165301|NCT03944213||MDD patients|
9977425|NCT01361399|Active Comparator|Arm 2|
10165302|NCT03944213||Healthy controls|
10165303|NCT03944096|Experimental|FMT+MTX|"FMT One FMT is performed at baseline by gastroscopic guidance. The same FMT is repeated 4 weeks later. The transplant consists of 50 g mixed feces obtained from 3-5 non-related healthy donors. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the recipient.~Drug: Methotrexate (MTX) Weekly methotrexate"
10165304|NCT03944096|Placebo Comparator|autologous FMT+MTX|"autologous FMT (the feces used in FMT is from participant themselves) One identical FMT is performed at baseline using gastroscopic guidance and is repeated 4 weeks later. The corresponding participant's feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the participant himself or herself.~Drug: Methotrexate (MTX) Weekly methotrexate"
10165305|NCT03943953|Experimental|Facial Palsy - Trial of ITG|In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
9977426|NCT01361399|Active Comparator|Arm 3|
10165306|NCT03943953|Experimental|Friends or relatives - Trial of ITG|In this arm of the trial friends or relatives of individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
10165307|NCT03943797|Experimental|Cultivated oral mucosal epithelial cell transplantation|Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
10165308|NCT03944005|Active Comparator|Study Group|Spinal Anesthesia + ACB continuous catheter+ iPACK + Sham LIA
10165309|NCT03944005|Sham Comparator|Comparator Group|Spinal Anesthesia + LIA + Sham Blocks
10165310|NCT03943979|Sham Comparator|Active Control group|This group will receive CT and sham tDCS each day, for four days.
10165311|NCT03943979|Active Comparator|Active group|This group will receive both CT and tDCS, each day, for four days.
10165312|NCT03943992|Experimental|YYD601 40mg|Esomeprazole magnesium Dihydrate.
10165313|NCT03943992|Active Comparator|Nexium 40mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
9671495|NCT05047809|Experimental|"Jingchuang Ointment(JCO) group"|"Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration. Besides, JCO was applied once a day on the wounds, last 3 months.~Jingchuang Ointment (JCO) is made by Chuang Song Zong Pharmaceutical Co., Ltd. (Taiwan)"
9671496|NCT05047809|Other|Regular treatment group|Ulcers were treated in this study using the four-step wound care guidelines, observation, rinsing, cleaning, and dressing, published by the Taiwan Food and Drug Administration.
10165314|NCT03943459|No Intervention|Control|20 Patients on placebo
10165315|NCT03943459|No Intervention|Atorvastatin|20 patients treated with atorvastatin 80 mg/day
10165316|NCT03943459|Experimental|Quercetin|20 patients treated with quercetin 500 mg/day
10165317|NCT03943628|Experimental|Familias Unidas|Consists of eight parent group sessions and four family sessions with the adolescent.
10165318|NCT03943628|Other|Community Practice|Consists of community practice.
10165319|NCT03943524|No Intervention|DrApp Without Interax-AI|There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
10165320|NCT03943524|Experimental|DrApp With Interax-AI|"There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (Interax-AI).~Intervention: Device: Medication Interaction System of Dr App (Interax-AI)"
10165321|NCT03943576|Experimental|GXCPC1|GXCPC1 contains 6.7×10^6 or 4×10^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL
10165322|NCT03943576|Active Comparator|hyaluronic acid|Hya Joint Plus synovial fluid supplement 3mL
10165323|NCT03943485|Active Comparator|Uterien Manipulator Arm|Patients in this group will receive a uterine manipulator during abdominal hysterectomy.
10165324|NCT03943485|No Intervention|Control|Patients in this group will receive standard abdominal hysterectomy without adoption of a uterine manipulator.
10165325|NCT03943537|Experimental|Intranasal Insulin (40 IU)|40 IU Novolin-R insulin will be administered one time using the ViaNase intranasal delivery device.
10165326|NCT03943784||Endoscopic Variceal Ligation|From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
10165327|NCT03943784||Propranolol Group|Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.
10165328|NCT03943654||Children living within study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live within the mobile pharmacy delivery area will receive illness assessments and treatment recommendations over the phone. Immediately following calls a nurse will conduct household visits to complete in-person assessments of the children. Illness progression will be tracked with a 8-12 day follow up call. The phone and in-person assessments will be compared to evaluate safety and accuracy of the healthline.
10165329|NCT03943654||Children living outside study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live outside the delivery area will receive illness assessments and treatment recommendations over the phone. Illness progression will be tracked with a 8-12 day follow up call.
10165330|NCT03943654||Children who are identified as having danger signs|Families who call the healthline service about a sick child and who are identified as having a danger sign will be directed to the nearest medical facility. Illness progression will be tracked with a 8-12 day follow up call.
10165331|NCT03943602|Experimental|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
10165332|NCT03943433|Active Comparator|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration at specific time points.
10165333|NCT03943433|Experimental|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration at specific time points.
10165334|NCT03943771|Experimental|Virtual modelization group|Patients having their kidney modelized in three dimensions on a software
9671497|NCT05047978|Active Comparator|A routine cow's milk-based infant formula|A routine cow's milk-based infant formula
9671498|NCT05047978|Experimental|A partially hydrolyzed cow's milk protein (PHP) infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
9671499|NCT05047666||Cases Group|Also called in our study 'Case-Positives'. These are those with respiratory symptoms suspected of COVID-19 that actually test positive (PCR).
9977427|NCT01361399|Placebo Comparator|Arm 4|
10165335|NCT03943771|Experimental|Printed modelization group|Patients having their kidney modelized and printed in three dimensions
9671500|NCT05047666||Symptomatic Control Group|Also called in our study 'Case-Negatives'. These are those with respiratory symptoms suspected of COVID-19 that actually test negative for SARS-CoV-2 but positive for any other pathogen included in our respiratory PCR-based panel.
9671501|NCT05047666||Healthy Control Group|At the community.
9671502|NCT05047614|Experimental|Study 1|Twelve patients in study group 1 receiving lumbar repositioning feedback training
9671503|NCT05047614|Experimental|Study 2|Twelve patients in study group 2 receiving transverses abdominis training
10165336|NCT03943771|Sham Comparator|Control group|No kidney model
10165337|NCT03943563|Other|single cohort|"There is only one cohort where each patient experiment the classic sequences as the standard of care and the DIXON sequences for the study."
10165338|NCT03943823|Active Comparator|Estrogen vaginal cream|
10165339|NCT03943823|Active Comparator|Trimo-San vaginal gel|
10165340|NCT03943862|Experimental|Intervention (2Share) + treatment as usual|"Study participants randomized to the experimental group receive the intervention (2Share) while maintaining their current treatment (treatment as usual). 2Share is a peer-led group intervention containing three two-hour sessions within two weeks plus an additional booster session four weeks later.~Fidelity to manual is rated in each session by study staff."
9671504|NCT05047614|Experimental|Study 3|Twelve patients in study group 3 receiving both lumbar repositioning feedback training and tranversus abdominis training
9671505|NCT05047614|Experimental|Control|Twelve patients in control group receiving conventional lumbar propriception physical therapy program .
9671506|NCT05047679|Experimental|Perioperative Pain Neuroscience Education|Patients in the experimental treatment group will receive Perioperative Pain Neuroscience Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
9671507|NCT05047679|Active Comparator|Perioperative Biomedical Education|Patients in the control treatment group will receive Perioperative Biomedical Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
10165341|NCT03943862|No Intervention|Treatment as usual|Participants randomized to the control group do not receive the group program but maintain their current treatment (treatment as usual).
10165342|NCT03943472|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA CAR-T cells to patients with multiple myeloma
10165343|NCT03943472|Experimental|anti-BCMA CAR-T+ Immune inhibitors|Administration of anti-BCMA CAR-T cells + Immune inhibitors to patients with multiple myeloma
10165344|NCT03943732|No Intervention|control|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays
10165345|NCT03943732|Experimental|Intervention|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
10165346|NCT03943420||Experimental Group|Therapy A : Basic treatment + Qianyang Yuyin Granules
10165347|NCT03943420||Negative Control Group|Therapy B : Basic treatment
10165348|NCT03943420||Positive Control Group|Therapy C : Basic treatment + Donepezil
10165349|NCT03943238|Experimental|Combined kidney/stem cell transplants and recipient's Tregs|Preparatory regimen including TLI, ATG after kidney transplantation followed by infusion of donor CD34+, T cell and recipient Tregs
10165350|NCT03943186||Ectoin Lozenges Honey Lemon|application of 1 Lozenge every three hours or as often as required, not more than 10 lozenges per day
10165351|NCT03943186||Hyaluronic acid/Icelandic moss Lozenges|application as often as required, not more than 6 lozenges per day
10165352|NCT03943394||Denovo MDS/ AML|"Patients with de-novo myeloid neoplasm either myelodysplastic syndrome and/ or acute myeloid leukemia which are diagnosed by complete blood count , blood film, bone marrow aspirate, bone marrow biopsy , immunophenotyping and bone marrow biopsy with these inclusion criteria • Myelodysplastic syndromes: the diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy : blast count must be < 20%;~• Acute myeloid leukemia with multilineage dysplasia: the diagnosis of AML-TLD must be confirmed by a bone marrow aspirate and/or biopsy NOTE: there must be evidence of >= 20% blasts on the review of the bone marrow aspirate and/or biopsy;"
10165353|NCT03943394||therapy related MDS/ AML|PCM1-JAK2 fusion gene detection in patients with therapy related Myelodysplastic syndrome / Acute myeloid leukemia patients
10165354|NCT03943199|Active Comparator|Metamizole sodium|1 gram intravenous, will be diluted in 0.9% physiological solution of 100 ml, applied for 30 minutes
10165355|NCT03943199|Active Comparator|Ketorolac|60 milligrams intravenously, it will be added to 20 ml with 0.9% physiological solution, it will be applied for 5 minutes
10165356|NCT03943199|Active Comparator|Lysine Clonixinate|100 milligram intravenously, diluted in 5% glucose solution of 100 ml, applied for 30 minutes
9671508|NCT05047497||less than 10 years working|workers who work in cement factories in a period of time less than 10 years
9671509|NCT05047497||from 10-15 years working|workers who work in cement factories in a period of time from 10-15 years
9671510|NCT05047497||more than 15 years working|workers who work in cement factories in a period of time more than 15 years
9671511|NCT05047419||Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 6 weeks post due date and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
9977428|NCT01361412|Experimental|ToleroMune Ragweed 4|
10165357|NCT03943199|Placebo Comparator|Placebo|20 milliliters of 0.9% physiological solution, will be applied for 5 minutes.
10165358|NCT03943251|Experimental|HEC113995PA•H2O tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
10165359|NCT03943251|Placebo Comparator|placebo tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
10165360|NCT03943407|Experimental|Zyclara/vehicle|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle.
10165361|NCT03943407|Experimental|Zyclara/Doxepin|All subjects will be treated with the topical antihistamine cream (Prudoxin, containing 5% doxepin hydrochloride, Healthpoint, San Antonio, TX) or a placebo cream. After removal, subjects will be treated with Zyclara cream
9671512|NCT05047419||Not Pregnant Participants with Asthma|Participants will be asked to use peak flow meter each day from enrollment to 9 months and send peak flow and FEV1 values to the research team via text message. Also, every 3 months participants will be asked to send in a PDF of the values from the peak flow meter app for the previous 7 days via email as a validation of the text message values.
9671513|NCT05047510|Experimental|Anti-GPC3-IRDye800CW Intraoperative Fluorescence|The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
10165362|NCT03943407|Experimental|Zyclara/Histamine/Cowage|All subjects will be treated with Zyclara cream, vehicle cream, histamine and cowhage
10165363|NCT03943407|Experimental|Zyclara/L-menthol/trans-cinnamaldehyde|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle. After removal, subjects will be treated with L/menthol and trans-cinnamaldehyde
10165364|NCT03943069|Experimental|Patient with PSP|Patient who will be admitted with primary spontaneous pneumothorax.
9826463|NCT02419001|Experimental|Period 2 - Treatment Sequence AC|"[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
10165365|NCT03943212|Experimental|Blood Flow Rate Reduction|Participants will have their hemodialysis blood flow rate reduced on their regular schedule.
10165366|NCT03943212|Sham Comparator|Control|Participants will continue to receive regularly-scheduled hemodialysis without any changes to the prescription.
10165367|NCT03943056|Experimental|Single Ascending Dose (SAD): Cohort 1A|Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1.
10165368|NCT03943056|Experimental|(SAD): Cohort 2A|Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1.
10165369|NCT03943056|Experimental|(SAD): Cohort 3A|Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal.
10165370|NCT03943056|Experimental|(SAD): Cohort 4A|Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1.
10165371|NCT03943056|Experimental|(SAD): Cohort 5A|Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1.
10165372|NCT03943056|Experimental|Multiple Ascending Dose (MAD): Cohort 1B|Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14.
10165373|NCT03943056|Experimental|(MAD): Cohort 2B|Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
10165374|NCT03943056|Experimental|(MAD): Cohort 3B|Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
10165375|NCT03943043|Experimental|gemcitabine oxaliplatin nab-paclitaxel|combination at different dose of gemcitabine, oxaliplatin and nab-paclitaxel
10165376|NCT03943355||Nonoperative management protocol with angioembolization|The nonoperative management (NOM) protocol with angioembolization (AE) presents a trend in dealing with trauma patients with blunt splenic injury (BSI). This study was designed to explore the adverse events and associated risk factors before and after protocol-based NOM of BSI over a 12-year period.
10165377|NCT03943108||Obese teenagers within the PAIDOS clinic|Obese children within the PAIDOS clinic, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
10165378|NCT03943108||Healthy children|Healthy children living in Mexico City, Mexico.
10165379|NCT03943108||Children with Type 2 Diabetes|Chjildren with Type 2 Diabetes attending the Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
10165380|NCT03943368|Experimental|Experimental: Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
10165381|NCT03943368|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
10165382|NCT03943134||Avive® Soft Tissue Membrane|Subjects with utilization of Avive® Soft Tissue Membrane on an impacted but intact nerve during a surgical procedure for one of the following targeted acute upper extremity traumas (selected injuries): Spaghetti Wrist, Distal Radius Fracture, Medial Epicondyle Fracture, Flexor Tenolysis at Wrist, and Ballistic Injuries in the Forearm and/or Hand.
10165383|NCT03943134||Standard Surgical Procedures - Control Arm|Subjects who have undergone surgical procedures for the same selected injuries, but without placement of a surgical implant on an impacted but intact nerve.
10165384|NCT03943121|Experimental|Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. Steroid-eluting stent were implanted in one side of ethmoid sinus and frontal sinus randomly.
10165385|NCT03943121|Sham Comparator|Without Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. The side without the stent is defined as the control side.
10165386|NCT03942874|Experimental|Treatment|Participants will complete baseline sessions and then complete treatment right away.
10165387|NCT03942874|Experimental|Waitlist Control|Participants will complete a baseline session and then wait for 10 weeks before starting treatment.
10165388|NCT03942861||Severe Ulcerative Colitis|Consecutive patients admitted as in-patients to the Department of Gastroenterology at four University Hospitals in Denmark, with acute severe UC defined as an affirmed diagnosis of UC according to well established criteria, combined with a Mayo score of 8 or more (i.e. severe disease activity) and the need for intravenous corticosteroid treatment will be screened for participation in the study after informed consent.
10165389|NCT03942679|Other|PRPinjection group|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 201
10165390|NCT03942679|Other|physiotherapy group|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks
10165391|NCT03942705||Kenyan Women|Women living in western Kenya will be asked to complete a self collected vaginal sample for HPV DNA screening and asked to undergo a second screening by VIA. As per Kenyan standard of care, vaccination against HPV will be offered to children/grandchildren (boys and girls) of women, and to the women themselves if age 26 or younger. The second vaccine dose (for children ages 9 through 14) and third doses (for children and adult women ages 15 through 26) will be administered at subsequent visits. There will be no requirement for HPV vaccination (of children or mothers up to 26 years of age) for participation in the study. Results of the screening will be returned to participants and they will be referred to receive standard care as applicable.
10165392|NCT03942913||dual therapy|including 1 antiplatelet treatment aspirin or clopidogrel associated with 1 anticoagulant treatment VKA or NOAC.
10165393|NCT03942913||triple therapy|"including 2 antiplatelet treatments (aspirin and clopidogrel) associated with 1 anticoagulant treatment VKA or NOAC.~In VKA class, 2 different drugs are commonly prescribed: warfarin and fluidinione. In NOAC class, 3 different drugs are commonly prescribed: rivaroxaban, apixaban, dabigatran."
10165394|NCT03942991|Active Comparator|2% Mepecaine-L|infiltration injection of 2% Mepivacaine
10165395|NCT03942991|Experimental|4% Artpharmadent|infiltration injection of 4% Articaine
10165396|NCT03942770|Active Comparator|Active Comparator: Group A (Intensive incentives)|"Group A will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will also have the opportunity to earn more incentives for providing negative results. For the first 3 weeks, these additional incentives will scale based on the number of consecutive days of sustained negative samples. For the remaining weeks incentives will be based on a randomized prize drawing."
10165397|NCT03942770|Active Comparator|Active Comparator: Group B (Prize-based incentives)|"Group B will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will only have the opportunity to earn more incentives based on a randomized prize drawing if they submit a negative sample."
10165398|NCT03942770|Sham Comparator|Sham Comparator: Group C (Intensive incentives)|Group C serves as a direct control group to Group A and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
10165399|NCT03942770|Sham Comparator|Sham Comparator: Group D (Price-based incentives)|Group D serves as a direct control group to Group B and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
10165400|NCT03942770|No Intervention|No Intervention: Group E (no incentives)|Group E will have no monitoring intervention, they will only complete assessment sessions.
10165401|NCT03942731||Experimental|83 adult outpatients at CHR Metz-Thionville with penicillin allergy label
10165402|NCT03942718|No Intervention|Control group|Participants will obtain no exercise program. After 12 weeks, the patients in the control group will be invited to participate in the training group.
10165403|NCT03942718|Experimental|Aerobic exercise group|Participants will obtain aerobic exercise only.
10165404|NCT03942718|Experimental|Anaerobic exercise group|Participants will obtain aerobic and anaerobic exercise respectively
10165405|NCT03942757||observation before educational program|100 preterm infant medical records will be studied in a first part of this observational study
10165406|NCT03942757||Observation after educational program|An educational program will be implemented in the unit after this first period. 100 preterm infant will be included in a second part of this observational study.
10165407|NCT03942900||Cohort LAND|Patients enrolled in OPTIMANAL clinical trial
10165408|NCT03942926|Experimental|Sirolimus|Patients in sirolimus group will receive sirolimus for 6 months.
10165409|NCT03942848|Experimental|intrathecal Ziconotide followed by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
10165410|NCT03942848|Placebo Comparator|intrathecal Ziconotide preceded by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
10165411|NCT03942809|Experimental|Effectiveness|Evaluate the Effectiveness in insertion success, insertion times, influence of respiratory, cardiac and cerebral circulation
10165412|NCT03942796|Active Comparator|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin
10165413|NCT03942796|Active Comparator|pulsed radiofrequency ablation of the dorsal root ganglion und|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion
9520282|NCT03279107|Experimental|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
9520283|NCT03279107|Experimental|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
9520284|NCT03279094|Experimental|Haploidentical stem cell transplantation|
9977429|NCT01361412|Experimental|ToleroMune Ragweed Regimen 3|
10165414|NCT03942887|Active Comparator|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg.
10165415|NCT03942887|Active Comparator|Rituximab plus low-dose cyclophosphamide|5.1.2. Cyclophosphamide Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
10165416|NCT03942978|Active Comparator|Longitudinal Equity Action Plan (LEAP)|Heart failure patients admitted with a principal diagnosis of heart failure to general medicine service and admitted to a general medicine pod that is randomized to the intervention arm.
10165417|NCT03942978|No Intervention|Standard Care|Heart Failure patients admitted to a general medicine pod at our institution, which is not randomized to intervention arm. Patients will be treated for their heart failure as per standard of care while admitted to the hospital.
10165418|NCT03942692||Children with anaphylactic reaction|Children who underwent an anaphylactic reaction between the 1st July 2014 and the 31st June 2016 treated in Paediatric Emergency Department of Femme-Mère-Enfant Hospital in Lyon in France.
10165419|NCT03942939|Experimental|A - TKA with short tourniquet time|50 arms: subjects will receive a tourniquet with a short tourniquet time during TKA surgery. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
10165420|NCT03942939|Active Comparator|B - TKA with tourniquet|50 arms: subjects will receive a tourniquet during TKA surgery.
10165421|NCT03942783|Active Comparator|Control Group|"The control group will receive a written work self-help information pack plus usual care. The pack includes published arthritis patient information booklets about work; a decision-tree flowchart; information about the UK Equality Act. The self-help information pack is mailed to the participants by the CTU following randomisation.~Usual care consists of: prescribed medication; attending Rheumatology clinics; referral to rehabilitation, as and when deemed necessary from the Rheumatology clinic, but not including work advice. Any rehabilitation required will be provided as normal, e.g. provision of exercise, self-management education, activities of daily living advice, psychosocial support."
10165422|NCT03942783|Experimental|WORKWELL Group|The same as the Control Group (i.e. self-help information pack, plus usual care) PLUS the WORKWELL intervention. This consists of, on average, 4.5 hours contact, including: a structured work assessment; identification of work-related barriers and priority problems; collaborative treatment planning with the participant; a range of self-management, work advice and job modifications appropriate to the individual participant's problems; goal setting and action planning; and a 30 minute telephone review to identify progress with goals at the end of treatment.
10165423|NCT03943004|Experimental|DFP-14927|DFP-14927: weekly IV infusion, 28 day treatment cycle
10165424|NCT03942822|Experimental|Chia supplemented group|8 weeks of 25 g/day of milled chia supplemented-isocaloric diet
10165425|NCT03942666|Experimental|Treatment A|Single administration of CHF 6532 Dose #1
10165426|NCT03942666|Experimental|Treatment B|Single administration of CHF 6532 Dose #2
10165427|NCT03942666|Experimental|Treatment C|Single administration of CHF 6532 Dose #3
10165428|NCT03942666|Experimental|Treatment D|Single administration of CHF 6532 Dose #4
10165429|NCT03942666|Placebo Comparator|Treatment E|Single administration of CHF 6532 Placebo
10165430|NCT03942666|Other|Treatment F|Part II: Administration of tablet of CHF 6532 b.i.d. for 10 days at one dose.
10165431|NCT03942640|Other|perineural injection group|"perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years~Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%.~Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves :~Suprascapular nerve.."
10165432|NCT03942640|Other|deepprolotherapy group|Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .
10165433|NCT03942601|Active Comparator|Group 1 - temsirolimus injection|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
10165434|NCT03942601|Active Comparator|Group 2 - temsirolimus and dexamethasone injection|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
10165435|NCT03942445|Experimental|Control patients|
10165436|NCT03942445|Experimental|Chronic ischemia|
10165437|NCT03942445|Experimental|Acute ischemia|
10165438|NCT03942471|Other|Intervention Mindfulness Based Stress Reduction|Six Modules each delivering an important principle of Mindfulness Based Stress Reduction
10165439|NCT03942471|No Intervention|Control Group|Wait Group - received no mindfulness teaching
10165440|NCT03942406|Experimental|BPZE1 Intranasal Prime, BPZE1 Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
10165441|NCT03942406|Experimental|BPZE1 Intranasal Prime, Placebo Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
10165442|NCT03942406|Experimental|Boostrix IM Prime, BPZE1 Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
10165443|NCT03942406|Active Comparator|Boostrix IM Prime, Placebo Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
10165444|NCT03942250|Experimental|Treated|Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks
10165445|NCT03942276|Placebo Comparator|Control|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks without perform exercise training.
10165446|NCT03942276|Experimental|Alternative training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of high intensity interval training.
10165447|NCT03942276|Experimental|Conventional training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of moderate intensity continuous training
9977430|NCT01361412|Experimental|ToleroMune Ragweed Regimen 2|
10165448|NCT03942380|Other|Cell-free tumor DNA|The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.
10165449|NCT03942380|Other|Identifying recurrence|The aim is to identify recurrence through serial monitoring patients with blood samples.
10165450|NCT03942341||Adult subjects with Down syndrome and Alzheimer Disease|"Patients will be included from the 6 centers of the Horizon 21 european consortium. Horizon 21 consortium consists of DS cohorts from Spain (the Down Alzheimer Barcelona Neuroimaging Initiative -DABNI). France (the TriAl 21 at Jérôme Lejeune Institute in Paris), the UK (The LonDowns consortium and Dementia in Down's Syndrome (DiDS) in Cambridge), the Netherlands (the Rotterdam DS cohort) and Germany (AD21 in Munich), with a combined total of more than 1,000 older participants with DS to pool data and bioresources to address current gaps in knowledge about AD in DS.~All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity."
10165451|NCT03942367|Experimental|Group A (Active Device Group)|Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients. Pre-configured stimulation intensity cannot be changed by the Patient.
10165452|NCT03942367|Sham Comparator|Group B (Sham Device Group)|Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation. Pre-configured stimulation intensity cannot be changed by the Patient.
10165453|NCT03942536||MNH Emergency Cohort|Participants will be either patients who have experienced a critical pregnancy-related, obstetric, or neonatal health emergency.
10165454|NCT03942536||Birth Planning cohort|Pregnant women who complete an initial Birth Plan through the HN program within Mfangano Island East and South Sub-locations.
10165455|NCT03942510|Experimental|High intensity eccentric training|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
10165456|NCT03942510|Experimental|High intensity eccentric training with blood flow restriction|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week.
10165457|NCT03942510|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
10165458|NCT03942510|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week.
10165459|NCT03942614|Experimental|Nordic pole walking|walking with a pair of poles customized to an individual's height and stride length
9671514|NCT05047367||single-group studies|A total of 149 patients diagnosed with CTS, 126 female and 23 male, were included in the study
10165460|NCT03942614|No Intervention|Control|usual daily routine and activities of daily living
10165461|NCT03942549||MUS Cohort|This cohort will undergo midurethral sling placement.
10165462|NCT03942354|Experimental|Intervention arm|A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.
10165463|NCT03942354|Active Comparator|Standard therapy|72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.
10165464|NCT03942237|Experimental|single-injection QLB (quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
10165465|NCT03942237|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
10186535|NCT03734640|Placebo Comparator|Guideline recommended standard monitoring|vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment
10186536|NCT03734640|Active Comparator|Low-intensity monitoring strategy|vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward
10186537|NCT03734627||Upper Gastrointestinal Surgery - Transit|
10186538|NCT03734627||Control - Transit|
9671515|NCT05047458|Experimental|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
9671516|NCT05047458|Experimental|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
9671517|NCT05047458|Experimental|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
10186539|NCT03734627||Upper Gastrointestinal Surgery - Gut Function|
10186540|NCT03734627||Control - Gut Function|
10186541|NCT03734614||Patients with adjuvant aspirin|After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
10186542|NCT03734614||Patients without adjuvant aspirin|After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
10186543|NCT03734575|Experimental|ClariCore System|Biopsy tissue, correlative spectral data, T2-weighted MR scans and ultrasound images acquired with the ClariCore System will be collected and recorded during standard practice transperineal biopsy.
10186544|NCT03734562|Experimental|Ablation|Substrate-based radiofrequency catheter ablation
9671518|NCT05047406|Experimental|Probiotic|2 oral mini-bottles daily of Bacillus clausii probiotic liquid containing 2 billion spores/bottle for 2 weeks before living donor liver transplantation surgery In addition, patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
9671519|NCT05047406|No Intervention|Control (No Probiotic)|patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
9671520|NCT05047276|Experimental|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
9671521|NCT05047484|Experimental|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo twice daily (BID) on Day 1 through Day 14 in a fasted state.
9977431|NCT01361412|Placebo Comparator|Placebo|Placebo
9527706|NCT03217760||Patients|The main aim of the study is to examine the patient's induced stress during endodontic treatment in order to offer customised solutions to lessen stress. The other aims is also to evaluate the patient's pain and discomfort during endodontic treatment.
9671522|NCT05047484|Experimental|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
9671523|NCT05047484|Experimental|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
9977432|NCT01361412|Experimental|ToleroMune Ragweed Regimen 1|
10165466|NCT03942432|Experimental|Patients with dysmetabolic iron overload syndrome|
10165467|NCT03942289|Experimental|Healthy controls|
10165468|NCT03942289|Experimental|Parkinson disease|
10165469|NCT03942575|No Intervention|No negative pressure wound therapy|Historical cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage and where negative wound pressure therapy has been omitted
10165470|NCT03942575|Experimental|Negative pressure wound therapy|Prospective cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage with negative wound pressure therapy
10165471|NCT03941951|No Intervention|Pre-intervention Cohort|Cohort of patients who have received either empirical or targeted treatment with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2016 to December 2019 will be included.
10165472|NCT03941951|Other|Intervention cohort|Cohort of patients with complex infections treated with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2010 to June 2021.
10165473|NCT03941951|No Intervention|Safety cohort|Cohort of patients with bacteremia due to carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, carbapenem-resistant enterobacteria, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus occurred in participating hospitals from 2017 to 2021 will be collected.
10165474|NCT03941977|Experimental|Surgery|Group evaluated with MRI and submitted to the percutaneous introduction of cannula for bone grafting
10165475|NCT03941938|Experimental|Cyanoacrylate|the anastomotic reinforcement with nebulized cyanoacrylate glue using the special short catheter device for open surgery or the laparoscopic catheter.
10165476|NCT03941938|Active Comparator|No reinforcement|No reinforcement will be applied on the anastomosis line
10165477|NCT03941925|Experimental|Prebiotic fructans|Prebiotic fructans. Prebiotic will be mixed into foods or drinks and consumed twice daily.
10165478|NCT03941925|Placebo Comparator|Maltodextrin|Maltodextrin. Maltodextrin will be mixed into foods or drinks and consumed twice daily.
10165479|NCT03941964|Experimental|Ventoclax + azacitidine or decitabine|Venetoclax (daily for 28 days), in combination with azacitidine or decitabine, beginning on Cycle 1 Day 1. Depending on investigator's choice, participants will receive either azacitidine for 7 days beginning on Day 1 of each 28-day cycle or decitabine for 5 days beginning on Day 1 of each 28-day cycle, as per institutional practice.
10165480|NCT03942107|Active Comparator|Group 1: RCT+post+core in 1 visit|the root canal treatment will be completed with 2Shape NiTi system as well as post and core application in the same visit prior to postoperative pain evaluation.
10165481|NCT03942107|Active Comparator|Group 2: after RCT, post and core in 2nd visit|after root canal treatment conducted with 2Shape NiTi system, the postoperative pain evaluation will be completed prior applying post and core for coronal restoration.
10165482|NCT03941990|Experimental|Nitrous oxyde|will inhale experimental treatment throughout the entire procedure (50% N2O - 50% 02)
10165483|NCT03941990|Placebo Comparator|Placebo|will inhale medical air throughout the entire procedure (22% O2 + N2 Q.S.)
10165484|NCT03942003|Experimental|Rhomboid|When applying the Rhomboid nerve block, the patient is tilted to the side position so that the corresponding breast is at the top. After T7 up to T10 sterile preparation of the C7 spinous projection, the convex probe shows a rhomboid muscle at the level of T5 and block is applied with 0.25% bupivacaine (20 cc), 2% lidocaine (10 cc) and 10 cc SF mixture.
10165485|NCT03942003|Experimental|Pectoral|The PEC I field block is performed by administering 10 cc of local anesthetic between the pectoralis minor and the major at the 2nd costal position. PEC II field block is performed using linear USG probe visibly in 3rd and 4th ribs while the patient is in supine position. In this block, a total of 20 cc 0.25% bupivacaine (10 cc), 2% lidocaine (5 cc) and 5 cc SF mixture were used to block the area between the pectoralis minor muscle and the serratus muscle
10165486|NCT03942003|Sham Comparator|Control|Infiltration analgesia was performed.
10165487|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Capsule|LY3154207 capsule (reference) administered orally, once.
10165488|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Tablet|LY3154207 tablet (test) administered orally, once.
10165489|NCT03942029|Experimental|Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole|LY3154207 (dose 1) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
10165490|NCT03942029|Experimental|Cohort 1 Part B - Placebo + Fluconazole|Placebo administered alone, orally, once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
10165491|NCT03942029|Experimental|Cohort 2 - LY3154207 (Dose 2) + Fluconazole|LY3154207 (dose 2) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
10165492|NCT03942029|Experimental|Cohort 2 - Placebo + Fluconazole|Placebo administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
10165493|NCT03942029|Experimental|Cohort 3 - LY3154207 + Fluconazole|LY3154207 (dose 2) administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
10165494|NCT03942029|Experimental|Cohort 3 - Placebo + Fluconazole|Placebo administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
10165495|NCT03942133|Experimental|entrance placement of adductor canal catheter|
9527707|NCT03217760||Young dentists practitioners.|The other aims are to evaluate the young dentist's induced stress and to examine and compare the patient's induced stress and the young dentist's induced stress.
9520285|NCT03279068||Without Pattern Interpretation|All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
10165496|NCT03942133|Experimental|middle point placement of adductor canal catheter|
10165497|NCT03941899|Other|QLB II|Quadratus Lomborum Blocck II type will be performed before robot-assisted laparoscopic radical prostatectomy
10165498|NCT03942146|No Intervention|Control group|No information on smoking cessation
10165499|NCT03942146|Active Comparator|Written information, GynOp|"When reporting being a current smoker in the health declaration on-line the participant receives the following written recommendation in the web-based health declaration You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended"
10165500|NCT03942146|Active Comparator|Doctor informed|"The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text  the patient smokes, recommend smoking cessation"
10165501|NCT03942146|Active Comparator|Written information, GynOp + doctor informed|A combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the participant is a smoker and instructed to recommend smoking cessation as in group 3.
10165502|NCT03941886|No Intervention|Non-intervention group|Participants receive routine prenatal care
10165503|NCT03941886|Experimental|Intervention group|Participants receive first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis in high-risk women.
10165504|NCT03942172|Experimental|SpotOn Balance|SpotOn Balance Glasses
10165505|NCT03942055||B-line score ≥7|"Patients with B-line score ≥7 at the end of the surgical procedure.~The Sonosite Edge II Ultrasound device will be used.~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
10165506|NCT03942055||B-line score <7|"Patients with B-line score <7 at the end of the surgical procedure.~The Sonosite Edge II Ultrasound device will be used.~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
10165507|NCT03942185|Experimental|Psoriasis with Blood heat syndrome group|Participants in Psoriasis with Blood heat syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Clearing heat and Cooling blood, such as Cool blood detoxification Decoction I，Cool blood and activating blood prescription compound, Cool blood detoxification Decoction II, Cool blood activating blood Decoction, Tufu drink, Xiaoyin Decoction and etc., two times per day for 8 weeks.
10165508|NCT03942185|Experimental|Psoriasis with Blood stasis syndrome group|Participants in Psoriasis with Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Promoting blood circulation and Removing blood stasis, such as Huoxue Sanyu Xiaoyin Decoction, Cool blood detoxification Decoction III and etc., two times per day for 8 weeks.
10165509|NCT03942185|Experimental|Psoriasis with Non-Blood heat or Blood stasis syndrome group|Participants in Psoriasis with Non-Blood heat or Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of syndrome differentiation therapy two times per day for 8 weeks.
10165510|NCT03942185|No Intervention|Healthy control group|No Intervention.
10165511|NCT03942198|Experimental|Oral Chinese medicine|Participants in experimental group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
10165512|NCT03942198|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
10165513|NCT03942068|Experimental|albumin-bound paclitaxel+apatinib|albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po
10165514|NCT03942081|Experimental|Ulcer Measurement and Photo Group|Diabetic patients with foot ulcers being seen in clinic.
10165515|NCT03942081|No Intervention|Healthy Control Group|Patients without foot ulcers being seen in the clinic.
10165516|NCT03942159||Donors|HLA-matched or haploidentical nursing relative donors
10165517|NCT03942159||Patients|recipients of allogeneic HSCT
10165518|NCT03941873|Experimental|Sitravatinib monotherapy|Two dose levels of sitravatinib as monotherapy, 80 mg once daily and 120 mg once daily, will be evaluated in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer. A modified 3+3 design will be used in the dose escalation to confirm recommended Phase 2 dose (RP2D)
10165519|NCT03941873|Experimental|Sitravatinib plus Tislelizumab|The combination dose escalation of sitravatinib (80 mg once daily and 120 mg once daily; modified 3+3 design) with tislelizumab (200 mg every 3 weeks, in both cohorts) will be evaluated in unresectable locally advanced or metastatic HCC or G/GEJ cancer participants . If the combination dose of 80 mg sitravatinib and 200 mg tislelizumab has been declared tolerable, the dose of sitravatinib will be escalated to 120 mg and tislelizumab will remain fixed at 200 mg. Approximately 12 to 24 evaluable participants will be treated. The dose of tislelizumab during dose escalation for the combination will be kept fixed at 200 mg
10165520|NCT03941873|Experimental|Anti-PD-1/PD-L1 Antibody Naïve or R/R HCC (Monotherapy)|
10165521|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive HCC(Combination)|
10165522|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant HCC|
9527708|NCT03217656||Mother-child birth cohort|
9977433|NCT01361425|Experimental|methildopa|pregnant women with stable severe pre-eclampsia will use methildopa (1,5g/day)
9977434|NCT01361425|Placebo Comparator|placebo|stable pregnant women with severe preeclampsia will use placebo
9977435|NCT01361503||Autism Spectrum Disorder (ASD)|
10165523|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive G/GEJ cancer|
10165524|NCT03942588|Experimental|High-intensity interval training|Twice-weekly supervised high-intensity interval treadmill training in a laboratory setting for 10 weeks.
9671524|NCT05047484|Experimental|Cohort 4: 200 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo BID on Day 1 through Day 14 in a fasted state.
9827689|NCT02465099|Experimental|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
10165525|NCT03942588|No Intervention|Control|Usual activities for 10 weeks
10165526|NCT03942458|Experimental|Vicagrel|Vicagrel 24mg loading followed by 6mg/day for 6 days
10165527|NCT03942458|Active Comparator|Clopidogrel|Clopidogrel 300mg loading followed by 75mg/day for 6 days
10165528|NCT03942315||Liver transplant in Hereditary Hemorrhagic Telangiectasia|Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
10165529|NCT03942523|Experimental|School Children|School children will be administered with behavioral change communication sessions as an intervention
10165530|NCT03941847|Experimental|music|The experimental group will benefit from musical listening during a classic period of induction of anesthesia
10165531|NCT03941847|No Intervention|silence|The control group will have a usual care.
10165532|NCT03941821||G/P treatment|Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment
10165533|NCT03941613|Experimental|Anterior temporal lobectomy|surgical treatment for mTLE
10165534|NCT03941613|Active Comparator|SEEG guided RF-TC|SEEG recording and minimal invasive treatment for mTLE
10165535|NCT03941717|Experimental|Mindfulness-Based Condition|Parents and children in the mindfulness intervention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of a mindfulness activity. There is a parent and child version of the mindfulness intervention. Both scripts were developed by Siegel and Bryson (2011), and include a parent and child version of a mindfulness activity targeting worries and anxiety. Adjustments to the child script were informed by the work of Petter and colleagues (2013). Adjustments to the parent script were informed by the work of Garland and colleagues (2015). This activity will last 5-minutes.
10165536|NCT03941717|Sham Comparator|Unfocused attention Condition|Parents and children in the unfocused attention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of an unfocused attention activity. There is a parent and child version of this activity. The parent version has been validated in other research with healthy adults as a control for a mindfulness intervention (Garland, Hanley, Farb, & Froeliger, 2015). This script was condensed in time from the original reading. The child version of the activity was developed for the current study, and was adapted from a mind-wandering script used for children aged 7-12 in past research (Spann, 2016). It was also informed by the unfocused attention script used for parents (Garland, Hanley, Farb, & Froeliger, 2015), and work by Cahn and Polich (2009). This activity will last 5-mintues.
10165537|NCT03941561|Experimental|S-1 for 9 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 9 months after D2 resection
10165538|NCT03941561|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
10165539|NCT03941795|Experimental|JS001(Toripalimab Injection) Combined With Axitinib|
10165540|NCT03941795|Experimental|JS001 alone|
10165541|NCT03941795|Active Comparator|Axitinib alone|
10165542|NCT03941665|Experimental|Gelronate|Tested new medical device
10165543|NCT03941665|Active Comparator|Aloevera|Current product used by the medical center
10165544|NCT03941522|Experimental|Intervention group (23-hour stay)|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
10165545|NCT03941522|No Intervention|Control group (conventional hospitalization)|Patients randomized to the group conventional hospitalization will be hospitalized as per the current conventional care after ileostomy closure.
10165546|NCT03941678|Experimental|Creatine|0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
10165547|NCT03941678|Placebo Comparator|Placebo|0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
10165548|NCT03941587|Active Comparator|Aflibercept + RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection + RF-PDT ( 6mg/m2 intravenous infusion of Verteporfin followed by laser light at a dose rate of 25 Joules/cm2) at baseline.~Aflibercept- 1st treatment (baseline) followed by minimum retreatment interval of 4 weeks (from Baseline to week 8) and then retreatment at intervals of 4 weeks pro re nata (PRN) retreatment( week 12-48). Primary endpoint at week 52.~RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.~At each visit, subjects will be assessed based on BCVA, ophthalmic examination and Optical Coherence Tomography (OCT)"
10165549|NCT03941587|Active Comparator|Aflibercept + sham RF-PDT|"Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection, at baseline. A minimum of 1 injection(baseline) followed by minimum pro re nata (PRN) retreatment interval of 4 weeks ( from baseline to week 8) and then a minimum of 4 weeks retreatment thereafter (week 12-48). Primary endpoint at week 52.~Sham RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.~At each visit, subjects will be assessed based on Best Corrected Visual Acuity (BCVA), ophthalmic examination and Optical Coherence Tomography (OCT)"
10165550|NCT03941756|Experimental|Group I (LVB)|Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.
9527709|NCT03217643|Experimental|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
9671525|NCT05047484|Experimental|Cohort 5: 120 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fed state.
9827690|NCT02465203|Other|Follow up from feeder studies|Follow up arm
9977436|NCT01361503||Controls|
10165551|NCT03941756|No Intervention|Group II (no intervention)|Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.
10165552|NCT03941496|Experimental|AZA Treatment|"In Phase Ib dose escalation stage, participants will receive subcutaneous (SQ) AZA once daily x 5 days. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). All participants receive standard of care antibiotics against tuberculosis.~Dose Escalation Strategy to identify the lowest dose of AZA that decreases DNA methylation and restores immune function is listed below. Proceeding to Phase IIa will proceed if stopping criteria are met at any of the steps below and FDA/IRB approval is obtained:~5 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~15 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~30 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals~50 mg/m^2 SQ once daily x 5 days for 8 individuals~75 mg/m^2 once daily x 5 days for 8 individuals"
10165553|NCT03941691|Experimental|Treatment Group|Experimental group is allocated to use novel fully degradable ventricular septal defect closure system manufactured by Shanghai shape memory alloy materials co. LTD.
10165554|NCT03941691|Active Comparator|Control Group|Control Group is allocated to use Interposition conveying device for ventricular septal defect closure produced by Shanghai shape memory alloy material co. LTD.
10165555|NCT03941808|Experimental|Drug|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
10165556|NCT03941808|Placebo Comparator|Placebo|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
10165557|NCT03941535|Experimental|Decreasing Daily Dose of Vitamin K|"This group of patients will receive a decreasing dose of Vitamin K IV:~Days 1-2 = 10mg/day (standard of care) Days 3-4 = 5mg/day Days 5-90 (or date of discharge, death, etc) = 2mg/day"
10165558|NCT03941535|Active Comparator|Standard of Care Dose of Vitamin K|This group of patients will be reviewed retrospectively and would have received Vitamin K IV at 10mg/day during their entire hospital course
10165559|NCT03941626|Experimental|CAR-T/TCR-T cells immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
10165560|NCT03941457|Experimental|anti-tumor response of BiCAR-NK cells (ROBO1 CAR-NK cells)|Patients with relapsed and refractory pancreatic cancer of ROBO1 expression will be treated with BiCAR-NK cells (ROBO1 CAR-NK cells).
10165561|NCT03941431|Experimental|Chinese medicine internal treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin granule two times daily after meals and moving cupping placebo therapy three times per week for 8 weeks.
10165562|NCT03941431|Experimental|Chinese medicine external treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin placebo granule two times daily after meals and moving cupping therapy three times per week for 8 weeks.
10165563|NCT03941431|Experimental|Chinese medicine treatment group|Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks.
10165564|NCT03941431|Experimental|Western medicine treatment group|Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks.
10165565|NCT03941431|Experimental|Integrated Chinese and Western Medicine Treatment Group|Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks.
10165566|NCT03941340|Experimental|[14C]-AST2818 80mg (oral solution)|Volunteers will receive 80 mg [14C]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.
10165567|NCT03941366|Other|Neoadjuvant Chemotherapy and Follow-up Surgery|All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.
10165568|NCT03941418|Experimental|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
10165569|NCT03941418|Placebo Comparator|Placebo|Patients will be administered with placebo as an addition to their standard therapy.
10165570|NCT03941067|Experimental|Pre-event massage|
10165571|NCT03941067|No Intervention|Control|
10165572|NCT03941145|Experimental|Exercise|Participants allocated to the intervention group will be asked to perform 2 exercise sessions per week for 6 weeks. Each session will involve 10 min of low-intensity cycling (25 W) interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 5% of body mass. The exercise intervention will be delivered on a commercially available cycle ergometer with software developed by CAR.O.L.
10165573|NCT03941145|No Intervention|Control|The effects of the intervention will be compared to a no-intervention control group recruited from the same workplace settings.
10165574|NCT03941002|Placebo Comparator|Clinical pressure support|The level of inspiratory pressure support will be selected by the attending physician
10165575|NCT03941002|Active Comparator|Reduced pressure support|The level of inspiratory pressure support will be reduced by 25%
10165576|NCT03941002|Active Comparator|Lowest pressure support|The level of inspiratory pressure support will be reduced by 50%
10165577|NCT03941028|Experimental|bone defects caused by trauma|Large bone defects (>6cm) caused by trauma
10165578|NCT03941028|Experimental|bone defects caused by infection|Large bone defects caused by chronic osteomyelitis
10165579|NCT03941028|Experimental|bone defects caused by tumor|Large bone defects caused by benign tumor
10165580|NCT03941327|Placebo Comparator|Control|Patients who provide consent for implant placement but do not receive the implant.
10165581|NCT03941327|Experimental|Interventional|Patients who provide consent for implant placement and do receive the implant.
10165582|NCT03941106|Experimental|Left aTMS|
10165583|NCT03941106|Experimental|Right aTMS|
10186545|NCT03734562|Active Comparator|Antiarrhythmic drug therapy|Antiarrhythmic drug therapy; amiodarone or sotalol
10186546|NCT03734549||technical success group|Technical success was defined as crossing the CTO and placement of a guidewire in the distal true lumen confirmed by angiography.
9827691|NCT02465216|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
10165584|NCT03941288|Active Comparator|Pharmacodynamics and clinical effects of cannabidiol|"Cannabidiol will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
10165585|NCT03941288|Placebo Comparator|pharmacodynamics and clinical effects of placebo|"Placebo will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
10165586|NCT03941314|Experimental|Supera® Peripheral Stent System|Femoro-popliteal arterial stenting with Supera® Peripheral Stent System as CE-marked by the manufacturer Abbott
10165587|NCT03941314|Active Comparator|EverFlex™ Self-Expanding Peripheral Stent System|Femoro-popliteal arterial stenting with EverFlex™ Self-Expanding Peripheral Stent System with Entrust™ Delivery System or as Protégé™ EverFlex™
10165588|NCT03941405|No Intervention|No treatment|No treatment.
10165589|NCT03941405|Experimental|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days.
9527710|NCT03217487|Experimental|Corneal epithelial autograft|Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
10165590|NCT03941171|Experimental|Group 1|PAO+usual+PRT
10165591|NCT03941171|Active Comparator|Group 2|PRT
10165592|NCT03941119|Experimental|Intervention|The intervention arm will receive a VR-therapy session every 24-72 hours of their stay in the hospital. Participants will view specially designed 360-degree VR films using a Virtual Reality head mounted display for a maximum of 20 minutes per session.
10165593|NCT03941119|No Intervention|Control|The control arm will not receive any VR-therapy sessions during their hospital stay.
10165594|NCT03941197|Experimental|Ready and Healthy for Kindergarten Family Literacy Program|Ready and Healthy for Kindergarten Family Literacy Program- 8 weekly parent child workshops with text message reminders
10165595|NCT03941054|No Intervention|Control arm|No intervention
10165596|NCT03941054|Experimental|Pressure Release|Digitopressure treatment of the Myosfascial Trigger Points
10165597|NCT03941223|Experimental|pectoral PECS II block|Ultrasound-guided PECS II block with ropivacaine 0.75% 20 ml (patients N = 75) + Parasternal ultrasound-guided block at T2, T4 levels with ropivacaine 0.375% 10 ml
10165598|NCT03941223|Active Comparator|Paravertebral nerve block|Ultrasound-guided paravertebral block with ropivacaine 0.75% 20 ml at T1-T2 and T3-T4 levels (10 ml each) (patients N = 75)
10165599|NCT03941210||HIV+/TB+|"Frozen samples and data from participants recruited in the ANRS 12095 CAMELIA clinical trial and the ANRS 12153 CAPRI NK study will be used for this study arm~All plasma samples were collected before any treatment during IRIS diagnosis and at W8 post TB treatment initiation"
10165600|NCT03941210||HIV+/TB-|"Participants included in this study arm will be HIV+ and TB-~One time collection of 5 ml of blood will be drawn in EDTA tube for each patient before starting cART and sent to the laboratory for protocol analysis"
10165601|NCT03941210||HIV-/TB+|"Participants included in this study arm will be HIV- and TB+~Collection of 5 ml of blood drawing in EDTA tube will be requested for each patient before starting TB drug treatment and after week 2 and 8 of treatment"
10165602|NCT03941210||HIV-/TB-|"Participants included in this study arm will be HIV- and TB-~Clinical examination to rule out overt evidence of TB and, whenever needed, routine TB testing as per national guidelines (sputum smear ± chest X-ray) in case of symptoms/clinical manifestations suggestive of TB."
10165603|NCT03941041|Experimental|Prenatal Yoga Practice|Pregnant women participating in a yoga course at least 12 session, each session in duration of 90 minutes.
10165604|NCT03941041|No Intervention|Regular Prenatal Care|Pregnant women being treated according to national guidelines
9527711|NCT03217487|Active Comparator|Limbal conjunctival autograft|Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD
10165605|NCT03940963|Active Comparator|AxoGuard® Nerve Cap|"Porcine derived extracellular matrix (ECM) based Nerve Termination Device~Implantation of appropriate diameter of AxoGuard® Nerve Cap at the time of surgery"
10165606|NCT03940963|Active Comparator|Standard Neurectomy|Standard surgical treatment for symptomatic neuroma entailing neuroma excision.
10165607|NCT03940976|Experimental|Afatinib|
10165608|NCT03940898|Active Comparator|study group-active rTMS|Participants in the study group received 100%MT(motor threshold) repetitive transcranial magnetic stimulation with the intermittent theta burst stimulation paradigm.
10165609|NCT03940898|Sham Comparator|control group-shame rTMS|Participants in the control group received rTMS pseudo-stimulation intervention. The stimulation head was inverted by 180 degrees or 90 degrees according to the model of the stimulation device to achieve pseudo-stimulation and the remaining stimulation parameters were consistent with the study group.
10165610|NCT03940781|Experimental|intervention group|We conducted a twice a week, 12-week-intervention of 'comprehensive rehabilitation'
10165611|NCT03940781|No Intervention|control group|We kept the patients for the waiting list until after completing baseline and 12-week measurement
10165612|NCT03940885|Active Comparator|Erector spinea plane block group|this group is planned for ultrasound-guided Transversus abdominis plane block
10165613|NCT03940885|Active Comparator|Transversus abdominis plane block|this group is planned for ultrasound-guided Transversus abdominis plane block
10165614|NCT03940885|Placebo Comparator|Control group|standard general anesthesia
9671526|NCT05047484|Experimental|Cohort 6: 240 mg ALXN2050/Placebo|Participants randomized to receive a single dose of ALXN2050 or placebo on Day 1 in a fasted state.
9827692|NCT02465216|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
10165615|NCT03940950|Experimental|SVF (Stromal Vascular Fraction) Group|Subjects with knee osteoarthritis (OA) will receive Autologous Adipose-Derived SVF (Stromal Vascular Fraction) cells
10165616|NCT03940950|Placebo Comparator|Placebo Group|Subjects with knee osteoarthritis (OA) will be treated with a placebo
10165617|NCT03940742|Experimental|Tirzepatide Control|Tirzepatide administered subcutaneously (SC) to participants with normal hepatic function
10165618|NCT03940742|Experimental|Tirzepatide Mild|Tirzepatide administered SC to participants with mild hepatic impairment
10165619|NCT03940742|Experimental|Tirzepatide Moderate|Tirzepatide administered SC to participants with moderate hepatic impairment
10165620|NCT03940742|Experimental|Tirzepatide Severe|Tirzepatide administered SC to participants with severe hepatic impairment
10165621|NCT03940664||neovascular group|patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
10165622|NCT03940664||non-neovascular group|patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.
10165623|NCT03940534|Active Comparator|Start with Mobile Device|
10165624|NCT03940534|Active Comparator|Start without Mobile Device|
10165625|NCT03940859||DEMAT|Patients with intramural hematoma in intracranial dissecting aneurysm treated by endovascular treatment will be recruited.
10165626|NCT03940807|Experimental|Ultra-long protocol group|All women will receive one intra-muscular administration of 11.25 mg Gonadotropin Releasing Hormone (GnRH) agonist (triptorelin acetate) on luteal phase of their menstrual cycle. Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period. Ovarian stimulation will be started after 90 days desensitization.
10165627|NCT03940807|Active Comparator|Long protocol group|All women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous application of 0.1mg of GnRH agonist (triptorelin acetate) started on luteal phase of their menstrual cycle. Ovarian stimulation will begin after 15 days desensitization.
10165628|NCT03940651|Experimental|Knee Arthroplasty|Surgery to replace the knee joint with prothetic joint
10165629|NCT03940651|Experimental|Hip Arthroplasty|Surgery to replace the hip joint with prothetic joint
10165630|NCT03940599|Experimental|Fitbit with visible screen|The first group will receive a FitBit with the screen visible, displaying their daily step count (the Step-Counter group).
10165631|NCT03940599|Experimental|Scale group|The second will receive a BodyTrace scale that will display and record their weight in kilograms and a FitBit with the screen covered as it was for the run-in period so their physical activity can be measured, but the only feedback they will receive is from the scale (the Scale group).
10165632|NCT03940599|Experimental|Step counter and scale|The third group will receive a BodyTrace scale and a FitBit with the screen visible (the Step-Counter and Scale group).
10165633|NCT03940599|Sham Comparator|Fitbit with screen covered|The remaining 5 participants will serve as normal controls and continue wearing the FitBit with the screen covered as it was during the run in period for the duration of follow up.
10165634|NCT03940638||Patients with septic non-union of the tibia|
10165635|NCT03940755||Critical Illness Survivors|Those intensive care unit(ICU) patients who survive from critical illness.
10165636|NCT03940768|Experimental|Lactobacillus plantarum 299v receivers|Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.
10165637|NCT03940768|Placebo Comparator|Placebo receivers|Sanprobi IBS placebo 2 capsules per day for 4 weeks.
10165638|NCT03940677|Other|Parkinson's disease patient|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination for motor and non motor symptoms
10165639|NCT03940677|Other|Healthy controls|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination
10165640|NCT03940612|Experimental|STP4 (product with probiotics)|Dietary Supplement: STP4
10165641|NCT03940612|Experimental|Placebo (product without probiotics)|Dietary Supplement: Placebo
10165642|NCT03940560|Experimental|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
10165643|NCT03940794|Experimental|Verbal instruction|"The participants will be instructed to contract the pelvic floor muscle with the following verbal instruction: (1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.Those who will not be able to contract will be taught by the ultrasound as biofeedback."
10165644|NCT03940716|Experimental|IntERact|"Participants randomized to this condition will receive behavioral therapy comprised of motivational interviewing, cognitive behavioral skills therapy, and care management. Youth will receive a total of six sessions, one delivered in the emergency department at the time of recruitment and five delivered over the five subsequent weeks after the ED visit (i.e., baseline). Participants will also receive a smartphone APP that will deliver intervention content between therapy sessions, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
10165645|NCT03940716|No Intervention|Enhanced Usual Care Condition|Participants randomized to this condition will receive a pamphlet with violence, mental health, and substance use resources.
10165646|NCT03940833|Experimental|anti-tumor response of BCMA CAR-NK-92|Patients with relapsed and refractory MM of BCMA expression will be treated with BCMA CAR-NK 92 cells.
10165647|NCT03940846||Maastro (Lung1)|Open source dataset available at TCIA.org. The cohort includes CT scans of 422 patients diagnosed with NSCLC.
10165648|NCT03940846||UCSF|A cohort of patients diagnosed with NSCLC at UCSF medical center. It includes CT scans of 165 patients.
10165649|NCT03940846||Radboud|A cohort of patients diagnosed with NSCLC at Radboud medical center. It includes CT scans of 255 patients.
10165650|NCT03940846||Stanford|Open source dataset available at TCIA.org. The cohort includes CT scans of 211 patients diagnosed with NSCLC.
10186547|NCT03734549||technical failure group|Technical failure was defined that guidewire could not crossing through the CTO nor reture to the true lumen by angiography.
10165651|NCT03940911|Other|anti-TNFα treatment and severe fatigue (FSS)|"See bellow (section Interventions) the full description for~Measurement of aerobic exercise on cycloergometer~Measurement of muscle mass by two-photon absorptiometry: specific study~Measurement of Isometric Muscle Strength~Blood sampling for measurement of cytokine levels in the blood~Measurement of sedentarity~Psychological impact~Fatigue mesurement~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
10165652|NCT03940911|Other|anti-TNFα treatment and with mild fatigue (FSS <4)|"See bellow (section Interventions) the full description for~Measurement of aerobic exercise on cycloergometer~Measurement of muscle mass by two-photon absorptiometry: specific study~Measurement of Isometric Muscle Strength~Blood sampling for measurement of cytokine levels in the blood~Measurement of sedentarity~Psychological impact~Fatigue measurement~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
10165653|NCT03940521||HIV-A infected patients|
10165654|NCT03940573|Experimental|Treatment|All patients fitted with the device.
10165655|NCT03940820|Experimental|anti-tumor response of ROBO1 CAR-NK cells|Patients will receive a single dose of ROBO1 CAR-NK cells without any conditioning chemotherapeutic regimen.
10165656|NCT03940872|Experimental|3PDQ self-questionnaire validation|200 patients will be included for this step in 10 French Parkinson expert centers.
10165657|NCT03940508|Experimental|MCI + IPT-A|Participants will receive the Making Connections Intervention (MCI) in addition to IPT-A for depression.
10165658|NCT03940508|Active Comparator|IPT-A Only|Participants will receive IPT-A for depression.
10165659|NCT03940274|Experimental|Intervention|Participants will undergo a walking program using a treadmill, a body-weight support system, and an assistive device.
10165660|NCT03940287|Experimental|Muscle Energy Technique and Conventional Physiotherapy|Muscle Energy Technique will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks, where each session of Muscle Energy Technique will be repeated for 3-5 repetitions.
10165661|NCT03940287|Experimental|Kinesiotaping and Conventional Physiotherapy|Kinesiotape application will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks
10186548|NCT03734549||had adverse events group|Patients had one of the adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization or amputation.at 12 months after procedures.
10186549|NCT03734549||had no adverse events group|Patients had none adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization and amputation at 12 months after procedures
10186550|NCT03734536|Other|REGENETEN™ Bioinductive Implant|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
10186551|NCT03734536|Other|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
10186552|NCT03734510|Active Comparator|hesperidin and flaxseed|
10186553|NCT03734510|Placebo Comparator|control|
10186554|NCT03734510|Active Comparator|flaxseed|
10186555|NCT03734510|Active Comparator|hesperidin|
10186556|NCT03734484|Experimental|Gram type infection-specific algorithm|The experimental arm will involve patients monitored by the Gram type infection-customized version of InSight.
10186557|NCT03734484|No Intervention|Standard treatment protocol|The control arm will involve patients treated with the regular diagnosis and treatment protocol for gram-type infection, where fluid cultures are run to determine infection type.
10186558|NCT03734471|Active Comparator|Traditional|
9977437|NCT01361516|Experimental|Intravenous sedation, General anaesthesia|IV sedation-ESWL under spontaneous respiration GA - ESWL under controlled respiration
10186559|NCT03734471|Experimental|Reactor Device|
10186560|NCT03734458|Experimental|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
10186561|NCT03734458|Experimental|Group B - PRF only with a CAF|Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
9977438|NCT01361529|Experimental|safty test|FLP,dose escalation,MTD
10186562|NCT03734458|Active Comparator|Group C - CTG with a CAF|Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
10186563|NCT03734445|Experimental|Vitamin supplement|Effervescent tablets containing Vitamin C, Vitamin D and zinc
10186564|NCT03734445|Placebo Comparator|Placebo|Effervescent tablets not containing Vitamin C, Vitamin D and zinc
10186565|NCT03734432|Experimental|Patients|IGAR-Breast TeleOp
10187882|NCT03721770||Relatives|Relative or adult companion (age <18 years) of a patient who died of cardiac arrest after organ removal request. A parent is defined as a close relative of the first degree: husband-wife, father-mother, son-daughter. Only one loved one is included per patient. Inclusion order of priority is husband-wife / father-mother / son-daughter.
10165662|NCT03940378|Experimental|One-drug Regimes|Basic drug : Anlotinib Hydrochloride Capsules
10165663|NCT03940378|Experimental|Two-Drug Regimens|Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
10165664|NCT03940339|Experimental|Suboccipital myofascial release|Treatment will be given for 3 minutes, 3 days per week for 4 weeks.
9671527|NCT05047133|Experimental|Early Adminstration of TXA + Intraoperative TXA|This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
9826464|NCT02419313|Active Comparator|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
10165665|NCT03940339|Active Comparator|Coventional Physiotherapy|Treatment will be given for 3 days per week for 4 weeks
10165666|NCT03940222|Experimental|I-BiT group|Amblyopic patients will play I-BiT games without patching.
10165667|NCT03940222|Placebo Comparator|Placebo group|Amblyopic patients will patch their dominant eye and they will play placebo I-BiT games.
10165668|NCT03940404||experiment|The patients whose treatment strategy containing anlotinib.
10165669|NCT03940248|Experimental|Early Stage Breast Cancer|Patients to be treated with Accelerated Partial Breast Irradiation utilizing pencil beam scanning proton therapy. Treatment will be delivered twice a day, at least 6 hours apart, over 5 treatment days.
10165670|NCT03940209|No Intervention|Usual care|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan including access to a physician network, case management resources, and other educational and health-focused resources and activities.
10165671|NCT03940209|Experimental|Basic needs navigation|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan (usual care) as well as a navigator for 6 months to address any unmet basic needs, provide instrumental and emotional social support, and improve self-management capabilities.
10165672|NCT03940235|Experimental|Stereotactic body Radiotherapy (SBRT) only|ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously.
10165673|NCT03940235|Active Comparator|Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)|ARM 2: salvage SBRT (as described for ARM 1) + 6-month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within one week before the start of SBRT.
10165674|NCT03940443||Ground Emergency Medical Services|Patients suffering TBI or acute MI and has been treated by GEMS dispatched by an emergency dispatch centre.
10165675|NCT03940144|Experimental|goal-directed fluid therapy|Stroke Volume variation (SVV)-guided fluid therapy
10165676|NCT03940144|Active Comparator|Conventional fluid therapy|Conventional fluid therapy such as CVP, MAP and urine-output guided fluid therapy
10165677|NCT03940300|Experimental|Adults with or risk for Type 2 Diabetes|All adult individuals with (non-insulin treated) or at risk for type 2 diabetes are in the treatment group and will receive prescriptions of fresh organic vegetables on a weekly basis for 10 weeks.
10165678|NCT03940391|Experimental|antihistamine combination|Participants in this group will get combination chlorpheniramine and midazolam injection for sedative endoscopy.
10165679|NCT03940391|Placebo Comparator|midazolam|Participants in this group will get only midazolam injection for sedative endoscopy
10165680|NCT03940430|Active Comparator|Lactoferrin in iron deficiency anemia|lactoferrin ( pravotin) 100mg twice daily
10165681|NCT03940430|Active Comparator|Ferrous sulfate in iron deficiency anemia|ferrous sulphate (hemojet)
10165682|NCT03940430|Active Comparator|Lactoferrin and ferrous sulfate in iron deficiency anemia|Lactoferrin 100 mg twice daily and ferrous sulfate
10165683|NCT03940482|Experimental|Single Arm|Subjects will act as their own controls
10165684|NCT03940170||vistacam|
10165685|NCT03940170||ICDAS II|
10165686|NCT03940170||Fissurotomy|
10165687|NCT03940118|Active Comparator|Catheter secretion suctioning|Secretions are aspirated with a catheter at -120 to -150 mBar
10165688|NCT03940118|Experimental|Secretion suctioning + hypertonic saline|Hypertonic saline is nebulized prior to aspiration of secretions.
9671528|NCT05047133|Other|Intraoperative only TXA|This group will only receive the intraoperative TXA.
10165689|NCT03940118|Experimental|Ins-exsufflation|Mechanical insufflation-exsufflation with device programmed at 50/-50 mmHg
10165690|NCT03940118|Experimental|Ins-exsufflation + Hypertonic Saline|Mechanical insufflation-exsufflation and hypertonic saline
10165691|NCT03940456||Inception cohort, former Elsinore pupils|640 former Elsinore pupils (330 female, 310 male). Aged 14 in 1965. Two earlier cross-sectional studies have been done in this group (in 1990 and 2000).
10165692|NCT03940469|Placebo Comparator|Control group|received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block.
10165693|NCT03940469|Active Comparator|Dexamethasone group|received 35ml levobupivacaine+8mg dexamethasone
10165694|NCT03940469|Active Comparator|Dexmeteomidine group|received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.
10165695|NCT03940183|Experimental|Trelagliptin succinate 100 mg|Tablets,100mg per tablet,oral, once a week, 100mg each time, continuous medication for a total of 24 weeks
10165696|NCT03940183|Placebo Comparator|Placebo Oral Tablet|Tablets,N/A,oral, once a week, one tablet each time, continuous medication for a total of 24 weeks
10165697|NCT03940079|Experimental|gross-motor group (GMG)|"The participants of GMG received motor-cognitive dual-task training. The sensors used by the participants were four different colored buttons. The participants wear a suit with two buttons on the shoulders and the other two fasten on the knees by velcros. To accomplish the tasks, the participants had to slap the correct colored buttons. The stretching of upper or lower limbs was demanding while slapping, so the participants of GMG received a training which required cognitive and motor functions at the same time.~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
10165698|NCT03940079|Active Comparator|fine-motor group (FMG)|"The participants of FMG received cognitive training only. Four colored sensors used by the participants were the keys on the keyboard of the laptop. The participants simply pressed correct colored keys by fingers to complete the tasks.~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
10165699|NCT03940053|No Intervention|Observation|Subjects only accept the routine treatment for underlying diseases.
10165700|NCT03940053|Experimental|Intervention|Based on the routine treatment for underlying diseases, subjects were administrated by arginine.
10165701|NCT03940040|Active Comparator|Usual Care|Patients will under go usual care ( pulmonary rehabilitation on room air or with nasal oxygen supplementation)
10165702|NCT03940040|Experimental|High flow nasal oxygen|Patients will undergo pulmonary rehabilitation with high flow nasal oxygen
10165703|NCT03939988|Active Comparator|Experimental group|In this study, immediately after the installation of the separators, the subjects of the experimental group will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
10165704|NCT03939988|Placebo Comparator|Placebo group|In the placebo group, the same procedures will be made, but the laser will be switched off.
10165705|NCT03939663|Placebo Comparator|placebo group|2 tablets vaginally
10165706|NCT03939663|Experimental|misoprostol group|400 mcg vaginally
10165707|NCT03939689|Active Comparator|Enzalutamide|
9977439|NCT01361542|Experimental|Anti TNF|Anti TNF alpha therapy including either infliximab or etanercept with data obtained before and after the study duration.
10165708|NCT03939689|Experimental|I-131-1095 in combination with enzalutamide|
10165709|NCT03939702|Active Comparator|Non-Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
10165710|NCT03939702|Active Comparator|Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
10165711|NCT03939741|Experimental|Group A|"Participants having a harvested total Adipose Derived Stem Cell (ADSC) count (in 5 ml SVF solution) more than 1 x 10^6.~Genetic: SVF containing Autologous Non Expanded ADSC."
10165712|NCT03939728||Chest radiography and lung ultrasound|All patients will be enrolled, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
10165713|NCT03939910|Active Comparator|Control arm|bupivacaine 0.25% for pudendal block
10165714|NCT03939910|Experimental|Intervention arm|ropivacaine 0.2 % for the pudendal block
10165715|NCT03939754||Adult attendance to Dedalo activities|Adult attended one Dedalo's activity
10165716|NCT03939754||Adult living in Vercelli|Adult aged 40-75
10165717|NCT03939832|Active Comparator|FiO2 0.5|
10165718|NCT03939832|Active Comparator|FiO2 1.0|
10165719|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on with MSM|
10165720|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on without MSM|
10165721|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment with MSM|
10165722|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment without MSM|
10165723|NCT03939884|Active Comparator|Voltaren Emulgel|
10165724|NCT03939884|Placebo Comparator|Non-medicinal Placebo|
10165725|NCT03939936|Active Comparator|Test Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
10165726|NCT03939936|Placebo Comparator|Control Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment.~Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
10165727|NCT03939650|Experimental|Diaana|"The patient fulfill Diaana~The resident physician reads the Diaana summary~The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
9977440|NCT01361581||ACD (acid-citrate-dextrose)|
10165728|NCT03939650|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
10165729|NCT03939923|Active Comparator|Group One|Group 1: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage).
10165730|NCT03939923|Active Comparator|Group Two|Group 2: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 2 (treatment) will receive reversal with Sugammadex (2mg/kg).
10165731|NCT03939715|Active Comparator|DermaPure|
10165732|NCT03939715|Active Comparator|Native Tissue|
10165733|NCT03939780|Experimental|Cohort 1|Subjects will be scanned twice (once with each of the tracers [18F]RO-948 and [18F]MK-6240)
10165734|NCT03939780|No Intervention|Cohort 2A|No PET scans will be done. Previous [18F]AV-1451 scans of selected aged matched older cognitively healthy controls (OC) subjects from the Baltimore Longitudinal Study of Aging (BLSA) study (IRB00047185) will be reanalyzed.
10165735|NCT03939780|Experimental|Cohort 2B1 - AD [18F]RO-948 and [18F]AV-1451|Alzheimer's Disease (AD) subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
10165736|NCT03939780|Experimental|Cohort 2B2 - AD [18F]MK-6240 and [18F]AV-1451|AD subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
10165737|NCT03939780|Experimental|Cohort 2B3 - OC [18F]RO-948 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
10165738|NCT03939780|Experimental|Cohort 2B4 - OC [18F]MK-6240 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
10165739|NCT03939637|Experimental|Eltrombopag|Patients randomized to eltrombopag will be treated for 12 weeks, with the possibility to continue therapy for up to 1 year depending on response.
10165740|NCT03939637|Active Comparator|Standard first-line therapy|"Subjects randomized to the standard therapy arm will receive one of three treatments at the discretion of the treating physician. Patients who previously failed standard management prior to study entry must be treated with a different agent than their original failed agent. e.g. Patient who failed steroids could receive either IVIg or anti-D if randomized to the standard treatment arm.~Standard therapy will be administered as commercially available drug.~Investigator may choose amongst the following:~IVIg: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)~Steroids: Prednisone/Prednisolone 4 mg/kg/day (Max 120 mg/day) x 4 days~Rho(D) Immune Globulin: Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)"
10165741|NCT03939975|Experimental|Study arm|"Patients with stable diseases or atypical progression to ICIs monotherapy would be additionally treated with incomplete thermal ablation along with ICIs therapy; and for those who with no lesions eligible for Incomplete ablation, ICIs would be given solely.~Others with complete or partial responses would keep on going with mono-ICIs therapy."
10165742|NCT03939871|Experimental|Single arm|Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.
10165743|NCT03939845|Active Comparator|TACE|
10165744|NCT03939845|Experimental|TACE+RT|
10165745|NCT03940027|Experimental|ropivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% ropivacaine with 10ml anhydrous alcohol
10165746|NCT03940027|Active Comparator|bupivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% bupivacaine with 10ml anhydrous alcohol
10165747|NCT03939793|Placebo Comparator|Usual Clinical Support|Participants will continue with their usual diabetes care provided by their clinic. Participants will receive a free wireless glucometer on the day of enrollment if they do not already have one.
10165748|NCT03939793|Active Comparator|DFI Alone|Participants will receive a free wireless glucometer on the day of enrollment if they don't already have one. To encourage habit formation, for the first 6 weeks of the trial, participants will be eligible for a daily lottery incentive for every day that they use their glucometer. Investigators will use an approach similar to what we have used in prior DFI trials: the lottery will provide infrequent large payoffs (a 1 in 100 chance of a US$50 reward) and more frequent small payoffs (an 18 in 100 chance of a US $5 reward). Participants who draw the winning lottery number, but did not check their glucose the day prior will receive an automated text or e-mail message informing them what earnings they would have won had they used their glucometer. After 6 weeks, investigators will terminate the lottery but continue to monitor patients' adherence to glucose self-monitoring.
10165749|NCT03939793|Experimental|Hybrid DFI CHW|Participants in the hybrid intervention will receive a wireless glucometer if they don't already have one and financial incentives just as in the DFI intervention. However, any individuals who have low adherence (no self-monitoring) or elevated glucose readings (>300 mg/dL) for >30% of days over any 2 week period in the first 12 weeks of the study will be assigned to receive ongoing community health worker (CHW) support for the duration of the 24-week study period.
10165750|NCT03940001|Experimental|arm|"Biological: Sintilimab For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1~Drug: Paclitaxel 50 mg/m^2 IV Q3W day 1, day 8 and day 15~Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15~Radiotherapy:~1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy"
10165751|NCT03939806||Oxytocin|This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
10165752|NCT03939806||Carbetocin|This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
10165753|NCT03940014||Pulmonary arteriovenous malformations|"Patients with hereditary haemorrhagic telangiectasia (HHT)-related Pulmonary Arteriovenous Malformations (PAVMs). For all patients, the final diagnosis of certain HHT the diagnosis can be made depending on the presence of four criteria known as the Curaçao criteria: 1) Spontaneous recurrent epistaxis 2) Multiple telangiectasias in typical locations 3) Proven visceral Arteriovenous Malformations (AVM) (lung, liver, brain, spine) 4) First-degree family member with HHT. If conditions three or four are met, a patient has definite HHT, while condition two is considered as possible HHT. All patients had a molecular diagnosis and all follow-up clinical assessments were available in the database."
9671529|NCT05047562|Active Comparator|Pilates Group|Participants will undergo 16 sessions, twice a week on alternate days through the following Pilates Method exercises: Pelvic Curl, Leg lift Supine, One leg circle modified and Hundred modified. There will be 4 sets of 5 repetitions in the first week, 6 repetitions in the second week, 7 repetitions in the third week, 8 repetitions in the fourth week, 9 repetitions in the fifth week, 10 repetitions in the sixth to eighth week.
10165754|NCT03939468||Observational Cohort|Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)
10165755|NCT03939481||Observational (non-study chemo, questionnaire, assessments)|Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
10165756|NCT03939494|Experimental|Telehealth Intervention|This arm receives 26 hours of telehealth encounters with a registered dietitian in conjunction with their normal clinic/program care.
10165757|NCT03939494|No Intervention|Standard of Care Control|This arm will participate in their normal clinic/program routine.
10165758|NCT03939507|Experimental|Intervention group|AEP score results were made available to the treating physician at each assessment visit.
10165759|NCT03939507|No Intervention|Control group|AEP scores were only made available at the end of follow-up.
10165760|NCT03939403|Experimental|7-days pill free interval|
10165761|NCT03939403|No Intervention|5-days pill free interval|
10165762|NCT03939572|Active Comparator|Accurate step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will simply display their accurate step count."
10165763|NCT03939572|Experimental|Deflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display a deflated step count."
10165764|NCT03939572|Experimental|Inflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display an inflated step count."
10165765|NCT03939572|Experimental|Accurate feedback + mindset intervention|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display their accurate step count. Additionally, participants in this arm will receive a meta-mindset intervention."
10165766|NCT03939416|Experimental|POLD concept treatment|Patients treated with rhythmic mobilizations according to the POLD concept, in addition to the standart treatment
10165767|NCT03939416|Active Comparator|CONTROL|Patients treated with the standart treatment
10165768|NCT03939611|Experimental|Foot Reflexology Group|Foot reflexology was performed to the reflexology group infants. Foot reflexology application (FRA) involved relaxation for the first 3-5 minutes and the last 2 minutes; the remaining 12-15 minutes included stimulation of the brain and digestive system organs. To ensure relaxation, rotation was performed by using the thumbs of the hand under the feet, cephalocaudally. The session of FRA included stimulating the brain and medulla spinalis (2 min), the solar plexus (1min), the stomach (2min), the liver (2min), the pancreas (2min), the gallbladder (1min), and the ileocecal valve and intestine (5min) reflex points. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
9827693|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
10165769|NCT03939611|Placebo Comparator|Placebo Foot Reflexology Group|Placebo foot reflexology was performed to the placebo group infants. Placebo foot reflexology application (PFRA) was constrained to ineffective touch without any stimulation and pressure. The aim of the PFRA was to create only a touch effect. It was applied by patted the foot by using the thumbs of the hand, for 20 minutes with the same rotation and to the same points as FRA. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
10165770|NCT03939559|Experimental|Balance Exercises Group|Balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks. After the four weeks, the exercises should be progressed in the last 4 weeks in the second training session
10165771|NCT03939559|Experimental|Dual Task Based Balance Exercises Group|Dual task based balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
10165772|NCT03939546|No Intervention|Control|The Control Arm will not receive any study intervention or placebo. The infants in this arm will receive standard NICU care.
10165773|NCT03939546|Active Comparator|B. infantis EVC001|Infants in the B. infantis arm will receive a once daily enteral feed of Evivo with MCT oil (8B CFU B. infantis EVC001) from Study Day 0 (by Day 10 of life) to hospital discharge, except on days when the infant is NPO.
10165774|NCT03939221|Experimental|intervention of infrared lamp and acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6(neiguan) and ST36(zusanli) for one minutes) for our patient for the cold limbs, pain control and constipation problems.
10165775|NCT03939325||first group|patient who exposed to frequency 60 shock wave per min
10165776|NCT03939325||second group|patient who exposed to frequency 80 shock wave per min
10165777|NCT03939325||third group|patient who exposed to frequency 100 shock wave per min
10165778|NCT03939156||Group 1 - before starting ET|women candidate to receive ET and interviewed before starting treatment
10165779|NCT03939156||Group 2 - within 1 year of ET|women interviewed within 1 years from beginning of ET
10165780|NCT03939156||Group 3 - between 4 and 6 years of ET|women interviewed after more than 4 years but no more than 6 years of ET
10165781|NCT03939338||Participates|
10165782|NCT03939312|Other|Atogepant 60mg|Taken orally once daily
10165783|NCT03939299|Experimental|OCT group|Patients, whose coronary chronic total occlusion lesion was successfully implanted stent, received optical coherence tomography imaging immediately and at 9-12 months after index procedure.
10165784|NCT03939429|Experimental|QPX2015|QPX2015, antibiotic
10165785|NCT03939429|Placebo Comparator|Placebo|Matched placebo
10165786|NCT03939377|Experimental|Osteopathy|Management will be centered on the skull, the sacrum, the cranio-sacral axis, the entire visceral abdominal and thoracic system.
10165787|NCT03939377|Placebo Comparator|Simulate|The simulated treatment will be characterized by placing the practitioner's hands on the patient in the areas tested without any intention of treatment.
10165788|NCT03939182|Experimental|Abexinostat and Ibrutinib|The investigational agents to be used in this study are ibrutinib and abexinostat. Ibrutinib will be administered once daily on a 28-day cycle. Abexinostat will be administered orally twice daily (approximately 4-6 hours apart) for 7 days a week given every other week on a 28-day cycle.
10165789|NCT03939247|Other|"Conventional PT treatment (CPT)"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching;
10165790|NCT03939247|Experimental|"CPT + Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an active Tecaretherapy is also provided during the sessions
9977441|NCT01361581||4% trisodium citrate|
10165791|NCT03939247|Sham Comparator|"CPT + Placebo Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an inactive Tecaretherapy is also provided during the sessions
10165792|NCT03939130|Experimental|Fructose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive fructose based beverage, prepared as a solution with 10% fructose, water and flavoring powder, totaling 1.0g / kg of body mass / day of fructose.
10165793|NCT03939130|Active Comparator|Glucose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive glucose based beverage, prepared as a solution with 10% glucose, water and flavoring powder, totaling 1.0g / kg of body mass / day of glucose.
10165794|NCT03939130|Experimental|Fructose-rich diet and exercise|The subjects will perform the same protocol described in the intervention Fructose-rich diet, except for the inclusion of the physical exercise. During the 4-week intervention, participants will perform three sessions a week of 60 minutes of aerobic exercise at 60% of VO2 peak on cycle ergometer.
10165795|NCT03939078||Vaginal Laser Intervention|Patients will be submitted to vaginal biopsy before and after three laser sections, and therefore will be their own comparative group to see the improvement associated with the laser effects.
10165796|NCT03938987|Experimental|CAR T cells|Patients with relapsed/refractory B-cell ALL or NHL.
10165797|NCT03939052|Experimental|Protein intake|Free amino acids vs. Glycomacropeptide (GMP)
10165798|NCT03939208|Experimental|Intervention (BRISC) Group|Clinicians randomly assigned to BRISC will implement a flexible intervention that, over four sessions, aims to assess and engage student clients, and identify and address student identified difficulties that are distressing and impacting academic performance/behavior, social, and overall functioning. BRISC uses an explicit, problem-solving structure and a range of techniques common to evidence-based practices (EBP) tailored to the identified needs of the student.
10165799|NCT03939208|Active Comparator|Services as Usual (SAU) Group|"Clinicians in the SAU condition will use a diverse array of treatment as usual strategies over four sessions that may include some directive, skill-building techniques common in EBPs, but, given findings from pilot studies and studies of mental health services as usual in community and school settings, are likely to be provided at an overall lower rate, and at lower intensity, than in BRISC or other EBP."
10165800|NCT03939624||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
10165801|NCT03939624||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
10165802|NCT03939065|Experimental|Insulin Pump and CGM|
10165803|NCT03939065|Other|Standard of Care and CGM|
10165804|NCT03939013|Experimental|Xpert HCV VL, sof/dac (local standard of care therapy)|Use of Cepheid GeneXpert HCV VL device as diagnostic tool to test for HCV RNA for diagnosis of chronic hepatitis C infection, for assessment of sustained virological response at 12 weeks post treatment completion
10165805|NCT03939039||Dyslipidemia|Genotype/phenotype correlation in patients with dyslipidemia
10165806|NCT03939273|Active Comparator|Active group|A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
10165807|NCT03939273|Placebo Comparator|Control group|A preoperative seven day course of placebo, consisting of pills and capsules identical in appearance and number to the active group
10165808|NCT03938922|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
10165809|NCT03939455|Experimental|Experimental|Participants will complete a brief tablet-based intervention, which includes watching a 5 minute educational video on the importance of HIV testing, and respond via tablet computer to the offer of an HIV test.
10165810|NCT03939455|No Intervention|Treatment as usual|Participants will be offered an HIV test by hospital staff, and will respond face-to-face.
10165811|NCT03938844||TLH with BURCH Colposuspension|the patients who underwent simultaneous burch copying with TLH was evaluated. In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
10165812|NCT03938844||TLH with Transobturatuar Tape (TOT)|In cases of simultaneous toting with TLH; In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
10165813|NCT03939091|Other|Ultrasonography|Renal Ultrasonography
10165814|NCT03939286|Other|movement group|intensified training (equipment, coordination, balance)
10165815|NCT03939286|Other|control group|continuation of physical activity as usual
10165816|NCT03938688|Other|Transfascial sutures for mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. Full thickness transfascial sutures will be placed circumferentially to secure the mesh using slowly absorbable no. 1 sutures. A total of at least six transfascial sutures will be placed universally for all patients with additional sutures allowed according to each surgeon's discretion. Additional bone or ligament sutures for mesh fixation will be allowed according to each surgeon's discretion.
10165817|NCT03938688|No Intervention|No mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. No fixation method will be used. Bone or ligament sutures for mesh fixation will not be allowed.
10165818|NCT03938805|Experimental|I-CBT|Internet-based cognitive behavioral therapy program including 1-week introduction, 2 weeks psycho education on Cardiovascular disease/insomnia, 6 weeks of sleep hygiene, stimulus control and sleep restriction
10165819|NCT03938805|Active Comparator|Control group|3 weeks internet-based sleep hygiene education
10165820|NCT03938896|Other|platelet rich plasma|It started with puncture of the vein and taking specific amount of autologous blood from the participantnearly a sample of 20 ml of venous blood (Co AY, 2012).The blood sample was put in a sterile tube containing an anticoagulant as sodium citrate.Then the blood sample wascentrifuged for 15 minutes at 1800 rpmwhich leads to separation of the plasma at the top layer from the packed RBCs at the bottom layer. The RBCs layer is removedthenanother centrifugationwas done at 3500 rpm for 10 minuteswhich leads to formation of a more concentratedplatelet layer after removal of PPP(Anitua et al., 2012).Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area.
10165821|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle.
10165822|NCT03938714|Active Comparator|CH( Conventional Hemorrhoidectomy)|Closed Conventional Hemorrhoidectomy
10165823|NCT03938714|Experimental|HS( Harmonic Scalpel)|Harmonic Scalpel Hemorrhoidectomy
10165824|NCT03938766|Other|PSMA PET/CT|Repeat PSMA PET/CT after ADT
10165825|NCT03939143|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
10165826|NCT03939143|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
9827694|NCT02465216|Placebo Comparator|Placebo|Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
10165827|NCT03938649|Experimental|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday"
9826465|NCT02419313|Active Comparator|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
10165828|NCT03938649|Experimental|SBRT|"RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)~5 fractions of weekly treatment. Once fraction per week."
10165829|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures
10165830|NCT03938818|Experimental|Tu'Washindi intervention|"Standard of care will include PrEP delivery according to the usual DREAMS procedures. The Tu'Washindi intervention includes the following components:~PrEP sensitization for men (community level).~Buddy Days (partner level).~Adherence support clubs (individual and peer levels)."
10165831|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
10165832|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
10165833|NCT03938883|Experimental|Ocular Bandage Gel (OBG)|Cross-linked Hyaluronic Acid 0.75%, regulated through CDRH (device). EyeGate Ocular Bandage Gel will be applied topically to both eyes (OU) four times a day. Ocular Bandage Gel use is discontinued once complete re-epithelialization has occurred in that eye.
10165834|NCT03938883|Other|Bandage Contact Lens (BCL)|standard-of-care post-operative intervention following PRK. BCL (Acuvue® Oasys plano lens) applied OU. Bandage contact lens use is discontinued once complete re-epithelialization has occurred in that eye.
10165835|NCT03938753|Experimental|Phonak Audéo M90-T|The Phonak Audéo M90-T is a Receiver-in-the-canal Hearing aid with direct connectivity functionality and a T-Coil from Phonak which will be fitted to the participants individual Hearing loss.
9826466|NCT02419469|Experimental|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
10165836|NCT03938636|Experimental|Subjects Free of Inflammatory Disease|The first arms is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
10165837|NCT03938636|Experimental|RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
10165838|NCT03938636|Experimental|Candidates for Initiation of, or Change to,|The third arm is designed to assess the efficacy of TUV global in clinically diagnosed subjects with active RA who are candidates for initiation of, or change to, a new anti-TNFα bDMARD therapy.
10165839|NCT03938948|Experimental|Treatment Arm|62 participants shall be enrolled
10165840|NCT03938779|Experimental|Pelvic Floor Muscle Training (PFMT)|Experimental group will perform for 4 months a PFMT
10165841|NCT03938779|Experimental|Pad test|The experimental and control group will perform the pad test twice. At the beginning of the evaluation and 4 months after the PFMT. The modified pad test, has the durability of a workout (2h30min)
10165842|NCT03938779|No Intervention|Kings Health Questionnaire|Kings Health Questionnaire to assess the impact of urinary incontinence on quality of life of women. Both groups will complete the questionnaire.
10165843|NCT03938779|No Intervention|perineometer|Both groups will perform perineometry at baseline and 4 months after
10165844|NCT03938623||Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
10165845|NCT03938623||Control|General Practitioners not using the patient-centered approach
10165846|NCT03938662|Experimental|S-Adenosyl methionine and choline|Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.
10165847|NCT03938662|Placebo Comparator|Placebo|Patients in will be administered with placebo once daily for 24 weeks.
10186566|NCT03734406|Experimental|Video group|"All subjects enrolled in the study group will be showed during the discharge process the video related to patient's condition (DVT vs AF), using it as a graphic support to doctor's verbal explanation of the diagnosed pathology and its possible complications.~For the purposes of the study we have selected two 3D videoclips, available on various internet sites and not covered by any copyright restrictions; these have been modified and shortened to make them suitable to use in our study setting.~The images contained show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.~The SIs will show the videos to patients on the institutional computer or, alternatively, on their personal smartphone / tablet. The videos were purposely left without audio content."
10186567|NCT03734406|No Intervention|Control group|"Patients of the control group will receive discharge explanations without the aid of any video.~The communication strategy in these cases won't be standardized, in order to leave the treating doctors free to express themselves in the way they are used to in their clinical practice, which is based solely on doctor's verbal and non-verbal communication skills."
10186568|NCT03734393|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 40
10186569|NCT03734393|No Intervention|HIVD-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and are randomized to participate in the full study arm, which includes research sample collection -enrollment 40
10186570|NCT03734393|No Intervention|HIVD-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group with limited data collection - enrollment 120
10165848|NCT03938389|Active Comparator|Valsartan|Valsartan 160 mg twice daily for 26 weeks
10165849|NCT03938389|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan (97/103 mg) twice daily for 26 weeks
10165850|NCT03938389|Placebo Comparator|Placebo|placebo (+/- amlodipine 2.5-5 mg twice daily if high blood pressure)
10165851|NCT03938467|Experimental|Antiseptic Cleanser|Standard prophylaxis will be administered by Irrisept patients as would individuals in the control group. In addition, these Irrisept study subjects will be supplemented with the use of Irrisept irrigation by the study surgeon during the patient's surgical procedure. Standard times for irrigation will include immediately after incision through the dermal layer, and immediately prior to implantation of any prosthetic components. Final irrigation will be performed just prior to closure of the deltopectoral interval.
10165852|NCT03938467|No Intervention|Standard of Care Prophylaxis|Standard prophylaxis includes use of chlorhexidine wipes (Sage cloth) the night before and morning of surgery on the surgical site over the anterior shoulder.
10165853|NCT03938571|Experimental|Standard DS|"Standard duodenal switch:~Sleeve gastrectomy over a 35 Fr bougie~Division of the duodenum 2-3 cm distally of the pylorus~Measurement of the small bowel. 100 cm common channel. 150 cm alimentary limb.~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~Entero-entero-anastomosis linear stapled and handsewn.~Division between the two anastomosis.~Closure of the mesenteric defects."
9671530|NCT05047562|Active Comparator|Segmental Stabilization Group|Participants will undergo 16 consultations, twice a week on alternate days through the following Segmental Stabilization exercises: multifidus in prone position, transverse abdomen in four supports, transverse abdomen in dorsal decubitus and transverse abdomen associated with multifidus in position orthostatic. There will be 4 sets of 10 repetitions of 10 seconds in all appointments.
10165854|NCT03938571|Active Comparator|SADI-DS|"Duodenal switch with Single anastomosis duodeno-ileostomy:~Sleeve gastrectomy over a 35 Fr bougie~Division of the duodenum 2-3 cm distally of the pylorus~Measurement of the small bowel. 250 cm alimentary limb/common channel.~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~Closure of the mesenteric defects."
10165855|NCT03938558|Experimental|Dance intervention group|"Dancers at beginners level~Dancers at advanced level"
10165856|NCT03938558|Active Comparator|Art intervention group|"Paint artists~Word artists~Film artists~Photographers"
10165857|NCT03938376||Potential Prostate Cancer|Biopsy naïve patients with rising Prostate Specific Antigen (PSA) results referred by their Urologist for a standard of care (SOC) biopsy.
10165858|NCT03938493||endotracheal intubation under general anesthesia|Adults who require endotracheal intubation for head and neck surgery under general anesthesia
10165859|NCT03938441|Experimental|Intermittent Fasting|Modified 5:2 intermittent fasting
10165860|NCT03938324|Experimental|PiCASO Intervention Group|Peer coaching intervention delivered by young adults with a childhood onset chronic condition and trained in coaching curriculum that includes motivational interviewing techniques and the benefits of peer relationships over a shared experience such as a chronic condition. The peer coach supports the AYA to identify their goals and feel a sense of success in making change towards goals within a supportive environment. This process involves goal-setting, development of self-discovery and accountability for changes in health behavior. The peer coach elicits the AYA's vision of optimal health and identifies the AYAs values. As the AYAs identify a vision of wellness and develop goals and action steps to progress towards that vision, the peer coach elicits the AYA's intrinsic motivation and activates skill development in self-advocacy and communication and empowers the AYA to take leadership in managing their condition.
10165861|NCT03938324|Sham Comparator|Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
10165862|NCT03938363|Experimental|Cervical Dystonia (CD)|Patients with cervical dystonia
9671531|NCT05047380||coccycodinia group|A total of 54 patients diagnosed with coccycodinia
10165863|NCT03938363|Placebo Comparator|Healthy Control CD|CD age- and sex-matched healthy control subjects
10165864|NCT03938363|Experimental|Blepharospasm (BS)|Patients with blepharospasm
10165865|NCT03938363|Placebo Comparator|Healthy Control BS|BS age- and sex-matched healthy control subjects
10165866|NCT03938545|Experimental|Regimen A-RVT-1401|Regimen A= RVT-1401 680 mg weekly for 12 weeks
10165867|NCT03938545|Experimental|Regimen B-RVT-1401|Regimen B= RVT-1401 340 mg weekly for 12 weeks
10165868|NCT03938545|Experimental|Regimen C-RVT-1401|Regimen C= RVT-1401 255 mg weekly for 12 weeks
10165869|NCT03938545|Placebo Comparator|Placebo|for 12 weeks
10165870|NCT03938285|Active Comparator|High Flux Hemodialysis|High Flux Hemodialysis with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment.
10165871|NCT03938285|Active Comparator|Extended Hemodialysis|Extended Hemodialysis with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment.
10165872|NCT03938285|Active Comparator|On Line Hemodiafiltration|On Line Hemodiafiltration with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
10165873|NCT03938285|Active Comparator|On Line Hemodiafiltration with an MCO membrane|On Line Hemodiafiltration with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
10165874|NCT03938051|Experimental|Experimental group|Multi-component intervention
10165875|NCT03938051|Experimental|Control group|treadmill walk
9671532|NCT05047393||Coccygodynia group|51 patients with a diagnosis of coccygodynia will be included in the study.
9671533|NCT05047081|Experimental|College Workshop Arm|Intervention
9671534|NCT05047081|Placebo Comparator|Placebo|Placebo
9671535|NCT05047003||Patients under evaluation for Suspected Concussion|Device: EyeBOX Model EBX-4 (Portable version)
9827695|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
10165876|NCT03938064|Active Comparator|Group Early start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries from the day of ovum retrieval (OR).
10165877|NCT03938064|Placebo Comparator|Group Late start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries 2 days after OR.
10165878|NCT03938532|Active Comparator|Control Arm|Infant will receive pressure regulated breaths, 40-60 breaths/min, PiP of 20-24cm of water as recommended by 2017 Neonatal Resuscitation Program (NRP) guidelines. Reading of the TV will be blinded from the providers as in routine clinical situations
10165879|NCT03938532|Experimental|Intervention Arm|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
10165880|NCT03937999|Experimental|Bezlotoxumab Arm|Single dose of Bezlotoxumab 10mg/kg iv over 60 minutes on Day 0
10165881|NCT03937999|No Intervention|No Bezlotoxumab|Control group who are eligible as per the inclusion/exclusion criteria to the Bezlotoxumab arm, but not given Bezlotoxumab (Day 0) .
10165882|NCT03938090|Placebo Comparator|Standard biventricular pacing|Cardiac resynchronization therapy (CRT) devices will be programmed as per standard biventricular pacing settings
10165883|NCT03938090|Active Comparator|Optimised MultiSite Pacing (MSP)|Cardiac resynchronization therapy (CRT) devices will be programmed as per optimal MSP programming settings; determined by greatest change in dP/dtmax and narrowest QRS duration.
10165884|NCT03938077|Experimental|S4E App intervention|"Youth will receive the S4E intervention via provided iPads. The intervention will last approximately 60. Content includes: (a) storytelling scenarios, (b) drug use and HIV/STI knowledge, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual and drug use risk behaviors and increase HIV self-testing, (e) Near Peer-youth communication, and (f) highlighting prevention principles. The youth will participate in a Near Peer-initiated prevention and risk reduction encounter which includes (a) reinforcement of HIV solutions that youth learned in the S4E app, (b) promotion of HIV self-tests, and (c) linkage to care and prevention services.~Youth have the option to take a HIV self-test. We will determine the acceptability of youth disclosing their results to their Near Peer and linkage to resources.~The research staff will also conduct in-depth qualitative interviews with both youth and Near Peer participants to assess feasibility and acceptability of S4E."
10165885|NCT03938220||fluid responders|fluid responder if stroke volume increases by > 10% after the fluid challenge
10165886|NCT03938220||fluid non responders|fluid responder if stroke volume increases by <= 10% after the fluid challenge
10165887|NCT03938129||Group 1|Pregnant women and their baby
10165888|NCT03938233|Active Comparator|DSME program delivered by community health volunteers|Randomisation will happen in 21 primary care units to offer DSME delivered by lay health workers to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
10165889|NCT03938233|Active Comparator|DSME program delivered by nurses|Randomisation will happen in 21 primary care units to offer DSME delivered by nurses (for comparative effectiveness) to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
10165890|NCT03938233|No Intervention|Usual care(no DSME program)|Randomisation will happen in 21 primary care units where no DSME will be offered to those newly diagnosed with diabetes and/or those having difficulties with self-managing their diabetes.These patients will continue with usual care and will be assessed as the control group.
10165891|NCT03938506||intubation using the endotracheal tube size of 6.0 or 8.0|Adult male patients who require endotracheal intubation using the endotracheal tube size of 6.0 or 8.0
10165892|NCT03938207||Dry eye syndrome|Dry eye syndrome patients were extracted from Taiwan Biobank.
10165893|NCT03938207||Health subjects|Health subjects were extracted from Taiwan Biobank.
10165894|NCT03938207||Sjögren's syndrome|Sjogren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
10165895|NCT03937843|Experimental|Arm with 2 cohorts|"Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I:~Within 7 days after registration, the patients will receive one infusion of carboplatin AUC (Area under the curve) 7 at day 1 of trial treatment, followed 3 weeks later by 12 x 2 Gy involved-node radiation therapy (RT). RT should ideally start on day 22 (range: day 19-25) from the date of carboplatin administration, preferably on a Monday.~Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I:~Within 7 days after registration, the patients will receive one cycle of etoposide 100 mg/m2/d + cisplatin 20 mg/m2/d at days 1 to 5 of trial treatment, followed 3 weeks later by 15 x 2 Gy involved-node radiation therapy. RT should ideally start on day 22 (range: day 19-25) from the date of chemotherapy start, preferably on a Monday."
10165896|NCT03938142||patients with chronic pain|
10165897|NCT03938259||Control group; patients without obstructive sleep apnea|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
10165898|NCT03938259||Patients with known obstructive sleep apnea|Children with OSA having adenotonsillectomy for obstructive apnea will receive opioids with evaluation of respiratory changes
10165899|NCT03938012||Lung and head and neck tumours|"Age 18 years or older~Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region~No other active malignancy within the past 24 months~Refractory disease"
10165900|NCT03938168||Pain patients|30 patients eligible for adhesiolysis because of chronic adhesion-related pain. Patients are recruited at the RadboudUMC, MUMC+ and Pantein hospital departments of surgery. These are patients with chronic pain after previous abdominal surgery who have been selected for operative treatment after evaluated with CineMRI. CineMRI is used to map adhesions. This technique has been established to provide insight in localization of adhesions in relation to the pain, and risk of bowel injury based on extensiveness of adhesions.
9977442|NCT01361581||unfractionated heparin (UFH)|
9977443|NCT01361646|Experimental|LC350189|
10165901|NCT03938168||Control group|The control group will comprise of 30 patients undergoing an abdominal reoperation during which adhesiolysis has to be performed for reasons other than chronic adhesion-related pain.
10165902|NCT03937934|Experimental|Subjects with long term health condition|Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton
10165903|NCT03937908|Experimental|2g CAP|Single administration of 2g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
10165904|NCT03937908|Experimental|4g CAP|Single administration of 4g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
10165905|NCT03937856|Experimental|Intervention group|Participant groups will include enrolled patients with rheumatic disease who use the smartphone mindfulness meditation application for 30 days.
10165906|NCT03937856|No Intervention|Control group|Usual care participants.
10165907|NCT03937765|Experimental|PRP|Intervention group will receive PRP instead of the standard of care for skin grafts. PRP Group-will remove surgical dressing post operative day 5. Donor site will be cleaned with soap and water daily and dressed with gauze daily until drainage stops.
10165908|NCT03937765|No Intervention|Control|Control group receiving the standard of care for skin grafts. Control Group-will remove gauze dressing post operative day 2 but leave adeptic. Donor site will be cleaned daily with soap and water. Gauze applied daily as needed for drainage and will be stopped when drainage stops. The adeptic, which forms a biologic dressing, will be removed by the patient over time as it lifts from the wound.
10165909|NCT03937700|Experimental|CPWalker Robotic-Assisted Gait Training|Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours
10165910|NCT03937869|Other|Single dose Solosec (secnidazole) 2g oral|Solosec 2 grams, oral
10165911|NCT03937518|Other|strontium ranelate|included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years,
10165912|NCT03937518|Other|physiotherapy|included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years
10165913|NCT03937492|Experimental|A group|In this group patients follow standard treatment after radius fracture plus GMI procol
10165914|NCT03937492|Active Comparator|B group|In this group patients follow standard treatment after radius fracture
10165915|NCT03937687|Placebo Comparator|Placebo|300 mg cellulose
10165916|NCT03937687|Experimental|Caffeine|300 mg caffeine
10165917|NCT03937687|Experimental|Caffeine Combination|150 mg caffeine with 100 mg Dynamine and 50 mg TeaCrine
10165918|NCT03937440|Experimental|Deep neuromuscular block group|
10165919|NCT03937440|Experimental|Moderate neuromuscular block group|
10165920|NCT03937531|Experimental|Retrograde-fill void trial (RVT)|Subjects will leave the operating room with a urinary catheter inserted. Subjects should be recovered from anesthesia effects (2-3 hours after surgery) before voiding trial. First, the bladder will be completely drained into the Foley bag then the bag will be detached from the catheter. The bladder will be back-filled with sterile water (300 mL). After the catheter is removed, subjects are expected to void at least 2/3 (200 mL) of the total instilled amount within 30 minutes of filling. Post-void residual (PVR) will be measured by both subtraction of the voided volume from 300cc and by using a bladder scanner.
10165921|NCT03937531|Active Comparator|Spontaneous void trial (SVT)|"Subjects will leave the operating room without a urinary catheter. Participants are allowed up to 6 hours after surgery for spontaneous voiding. After voiding, the voided volume will be noted. PVR will be measured using a bladder scanner.~In both groups, if PVR >=100 mL on a bladder scanner, an indwelling urinary catheter will be placed and the actual PVR will be documented. Subjects who failed voiding trial will be instructed to return to clinic within 2-4 days for the second void trial. Prophylactic antibiotics will NOT be given. The time to discharge will be measured for each subject. This will be determined by calculating the time between arrival to the PACU and the time of discharge using documentation from EPIC."
10165922|NCT03937427||CRS with Asthma|
10165923|NCT03937427||CRS without Asthma|
10165924|NCT03937609|Other|Standard dosing|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The control group will continue with 5 mg/kg IFX at week 2 and 6, followed by every 8 weeks.
10165925|NCT03937609|Experimental|Intervention group|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The intervention group will receive model based dosing of infliximab with 5mg/kg at various timepoints based on the dashboard model.
10165926|NCT03937752||Anal fistula|Patients with anal fistulas, no previous fistula procedures. Ultrasound investigation done as a part of surgical treatment, such as loose seton or fistulotomy.
10165927|NCT03937544|Experimental|CD19 CAR-T CELLS|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
9826467|NCT02419508|Experimental|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
10165928|NCT03937739||Group 1: Case group,|The patients who admitted to the general surgery for operation with inguinal hernia were the case group of this study.
10165929|NCT03937739||Group 2: Control group,|The patients who were admitted to the same hospital with such as eye, ear/nose/throat, dermatologic diseases or elective surgeries and did not have any inguinal hernia complaints, constipation and other chronic disease which could increase the intra abdominal pressure selected as control group.
10165930|NCT03937557|Active Comparator|men's hair count|
10165931|NCT03937557|Placebo Comparator|women's hair count|
10165932|NCT03937674|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
10165933|NCT03937505|Experimental|Dose-escalation|Dose-cohort escalation of single intravenous injection of IS-001 starting with 20 mg (n=8), escalating in 20 mg increments until optimal dose is determined.
10165934|NCT03937505|Experimental|Optimal dose-characterization|Single intravenous injection of IS-001 at the optimal dose will be administered to subjects assigned to the treatment group. Safety control subjects will not receive any study drug but will undergo robotic surgery and all associated safety assessment clinical trial procedures.
10165935|NCT03937726|Experimental|Boiled peanut Oral Immunotherapy|Desensitisation using boiled peanut
10165936|NCT03937726|Active Comparator|Conventional Oral immunotherapy|Desensitisation using defatted peanut flour
10165937|NCT03937349||sPTx group|Patients underwent subtotal parathyroidectomy due to severe secondary hyperparathyroidism
10165938|NCT03937349||TPTx+AT group|Patients underwent total parathyroidectomy with immediate autotransplantation of parathyroid tissue due to severe secondary hyperparathyroidism
10165939|NCT03937349||Control group|Patients with severe SHPT on conservative treatment (calcimimetics, active vitamin D analogues, phosphate-binders) who are likely to undergo surgery in a period of 12 months
10165940|NCT03937648|Experimental|COL-144 50mg|
10165941|NCT03937648|Experimental|COL-144 100mg|
10165942|NCT03937648|Experimental|COL-144 200mg|
10165943|NCT03937648|Experimental|COL-144 400mg|
10165944|NCT03937648|Placebo Comparator|Placebo|
10165945|NCT03937362||Clinical Response Evaluation|"Patients with operable esophageal squamous cell carcinoma who are planned to undergo neoadjuvant chemoradiotherapy according to the CROSS regimen (intravenous carboplatin AUC 2 mg/mL/min and intravenous paclitaxel 50 mg/m2 on days 1, 8, 15, 22 and 29 with concurrent 41.4 Gy radiotherapy given in 23 fractions of 1.8 Gy on 5 days per week) followed by surgery.~Patients will undergo a first clinical response evaluation (CRE-1) 4-6 week after completion of nCRT. In patients without histological evidence of residual tumor surgery will be postponed another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy."
10165946|NCT03937414|Experimental|SLNs were tested by the OSNA assay Intraoperatively|SLNs were tested by the OSNA assay Intraoperatively
10165947|NCT03937284||Parkinson's patients|Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
10165948|NCT03937284||Control group|Subject matched for sex, age and BMI
10165949|NCT03937401|Experimental|Patients treated with oxytocin during MRI-HIFU|
10165950|NCT03937297|Experimental|Arm 1|Six Arts intervention
10165951|NCT03937297|Experimental|Arm 2|Cognitive Stimulation Therapy (CST)
10165952|NCT03937297|Active Comparator|Arm 3|Usual care (control group)
10165953|NCT03937453||New-Onset Diabetes Mellitus|Diabetes Mellitus diagnosed within the past 12 months
10165954|NCT03937310||Surgical intervention for non-union|The investigation group will consist of cases undergoing surgical intervention for non-union
10165955|NCT03937310||Acute fracture fixation|The control group will consist of cases undergoing acute fracture fixation
10165956|NCT03937271||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
10165957|NCT03937271||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 revised Systemic lupus erythematosus criteria
10165958|NCT03937271||Rheumatoid Arthritis|Rheumatoid Arthritis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2010 ACR/EULAR Rheumatoid Arthritis classification criteria
10165959|NCT03937271||Systemic Sclerosis|Systemic Sclerosis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1980 ACR eSystemic Sclerosis criteria
10165960|NCT03937271||Ankylosing spondylitis|Ankylosing spondylitis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1984 Ankylosing spondylitis Modified New York criteria
10165961|NCT03937271||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min
10165962|NCT03937232|Active Comparator|Cross-Education|Cross education has been defined as the unilateral training of a limb with resisted exercise for the benefit of transferring strength to the contralateral (often injured or immobilized) limb. Participants randomized to cross-education will be provided with a hand-grip strengthener, adjusted to provide resistance at 70-80% of their maximum grip strength. They will be given written, illustrated instructions for performing grip strengthening exercises for their uninjured hand in a seated position with both forearms comfortably supported; this will be demonstrated during the teaching session. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
10186571|NCT03734380|Experimental|Laboratory-based gait retraining (LGR)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
10165963|NCT03937232|Active Comparator|Mirror Visual Feedback|Mirror visual feedback is the performance of movements with an uninjured hand in front of a mirror hiding the injured hand, thus creating the illusion of bilateral movement. Participants randomized to mirror visual feedback will be provided with a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization of exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete a three sets of 10 repetitions for finger flexion and extension (mimicking the fisting motion of the grip strengthening exercises) twice daily. A diary for tracking exercise completion and attendance for usual care will also be provided.
10165964|NCT03937232|Experimental|Cross-education + Mirror Visual Feedback|In this group, participants will perform the cross-education resistance exercise in front of the mirror, visualizing the performance of the resistance exercises. Participants randomized to cross education with mirror visual feedback will be provided with both a hand-grip strengthener and a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization hand grip strengthening exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
10165965|NCT03937232|Active Comparator|Usual Care|Participants randomized to usual care will be encouraged to attend the recommended rehabilitation, and provided with a diary for frequency of rehab attendance, and tracking any exercises completed at home.
10165966|NCT03937323||Group 1: Pancreatitis group|Patients with biliary pancreatitis
10165967|NCT03937323||Group 2: Control group,|Healthy volunteers
10165968|NCT03937336|No Intervention|Control Group|
10165969|NCT03937336|Experimental|Bike Intervention Group|A 1-month bike-based program (1 session/week)
10165970|NCT03937375||High PEEP|Use of high levels of PEEP with recruitment maneuvers
10165971|NCT03937375||Low PEEP|Use of low levels of PEEP without recruitment maneuvers
10165972|NCT03937388|Experimental|Cochlear implant recipients|
10165973|NCT03937167|No Intervention|Control|Standard treatment at Hospital Infanta Leonor with Endocrinology and Psyquiatry
10165974|NCT03937167|Experimental|Completers|Randomized to treatment AND complete treatment 14 sessions are needed
10165975|NCT03937167|No Intervention|Drop-out|Randomized to treatment BUT do not assist or do not complete treatment Less than 14 sessions
10165976|NCT03937206|Experimental|Low Dose|Low Dose (300mg TG Omega-3) - 1 capsule containing 1000mg NutriterraTM per capsule + 3 capsules containing 1000mg corn oil per capsule
10165977|NCT03937206|Experimental|Mid Dose|Mid Dose (600mg TG Omega-3) - 2 capsules containing 1000mg NutriterraTM per capsule + 2 capsules containing 1000mg corn oil per capsule
10165978|NCT03937206|Experimental|High Dose|High Dose (1200mg TG Omega-3) - 4 capsules containing 1000mg NutriterraTM per capsule
10165979|NCT03937206|Placebo Comparator|Placebo|Placebo (0mg TG Omega-3) - 4 capsules containing 1000mg corn oil per capsule
10165980|NCT03937193||Non-SMAS group|subjects in this group are not clinically diagnosed as superior mesenteric artery syndrome(SMAS).
10165981|NCT03937193||SMAS group|subjects in this group are clinically diagnosed as superior mesenteric artery syndrome(SMAS).
10165982|NCT03937258|Other|PF-04965842 single dose|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
10165983|NCT03937258|Other|PF-04965842 multiple doses|In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions.
10165984|NCT03937258|Other|Probenecid and PF-04965842|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
10165985|NCT03937180|Other|Usual care|Patients will receive 'usual care' left at the discretion of the treating general practitioner (GP). They are expected to follow the Belgian guidelines, which propose education of the patient about the harmful effects of chronic benzodiazepines and z-drugs ((z-)BZD) use, the alternatives, and the advice to discontinue (z-)BZD use. A stepped approach is recommended. First, a minimal intervention strategy such as a discontinuation letter or a short advice is applied. If unsuccessful, a brief intervention, which may span one or more consults, is recommended. During such an intervention, the GP will - based on the principles of motivational interviewing- assess the patient's readiness for change and match the appropriate intervention. A tapering scheme will be developed which typically consists of a 10-20% reduction in the daily dose of the (z-)BZD every 2-4 weeks.
10186572|NCT03734380|Experimental|Sensor-based gait retraining (SGR)|Subjects will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. The training schedule, duration, and intensity will be identical to those of the LGR group.
10186573|NCT03734380|Experimental|Walking exercise control (Ctrl)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups.
9827696|NCT02465372|Experimental|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
9671536|NCT05047211|Active Comparator|Oral Iron group|"Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks three times daily.~Intravenous placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride."
9671537|NCT05047211|Experimental|IV Iron group|"Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride.~Oral placebo will be given by mouth for a total of 6 weeks TID."
9827697|NCT02465372|No Intervention|Control|Standard practice.
9662149|NCT05130580|Active Comparator|Arm II (educational materials, standard of care consultation)|Patients receive newly-developed educational materials about breast reconstruction and attend a standard of care consultation visit with their plastic surgeon to discuss options for breast reconstruction surgery. At the end of the consultation visit, patients complete questionnaires about decision-making and psychological well-being. Within 4-6 weeks and 3-6 months after beginning the reconstruction process, patients also complete questionnaires about satisfaction with their breasts, body image, and psychological well-being, and undergo 2D and 3D imaging of the torso.
10165986|NCT03937180|Experimental|Blended care|Usual care is supported by the use of an interactive e-tool. The e-tool provides psycho-education about sleep and sleep medication, and exercises featuring cognitive behavioural techniques to enhance the self-management of the patient. It's purpose is to motivate patients to discontinue the use of (z-)BZD, to adapt alternative remedies and to support them in this process. The patient can grant the participating GP access to all his answers in the e-tool, making it possible to discuss their findings and experiences face-to-face. During consultations, the GP will also assess the patients' readiness for change and match the appropriate intervention. A tailored gradual taper of the (z-)BZD will be agreed upon, which typically consists of a 10-20% reduction in the daily dose every 2-4 weeks. Follow-up appointments are scheduled depending on the needs of the patient until the end of dose reduction.
10165987|NCT03937115|Experimental|Group S1|High level jump practice : more 4000 hours of practice during the last five years
10165988|NCT03937115|Experimental|Group S2|Amateur jump practice : less 4000 hours of practice during the last five years
10165989|NCT03937115|Experimental|Group C1|High level cycling practice: more 4000 hours of practice during the last five years
10165990|NCT03937115|Experimental|Group C2|Amateur cycling practice: less 4000 hours of practice during the last five years
10165991|NCT03937115|Experimental|Group T|Sedentary : less two hours of recreationally practice of sport by week
10165992|NCT03937076|No Intervention|intercostal block|patients will get intercostal block at the end of the surgery, control group
10165993|NCT03937076|Experimental|PECS II block|patients with get PECS II block at the end of the surgery, research group
10165994|NCT03936855|Active Comparator|Incremental filling technique|Glass ionomer in the pulp chamber and incremental filling technique using composite resin
10165995|NCT03936855|Experimental|Bulk Fill|Bulk fill composite resin filling all the cavity
10165996|NCT03936868||Tendon transfer for irreversible radial nerve palsy patient|Tendon transfer for irreversible radial nerve palsy patient who had irreversible damage to radial nerve due to trauma with different mechanism especially gun shot injury
10165997|NCT03936946|Experimental|Group 1--October Start Audio Content 1|This group will listen to audio content 1 daily for 28 days beginning in October, and then will receive no further intervention
10165998|NCT03936946|Other|Group 2--November Start Audio Content 1|This group will not be assigned to any interventions during the first month of the trial and will act as a passive control group at that time. They will be assigned to listen to audio content 1 daily for 28 days beginning in November.
10165999|NCT03936946|Sham Comparator|Group 3--October Start Audio Content 2|This group will listen to audio content 2 daily for 28 days beginning in October, and then will receive no further intervention.
10166000|NCT03936907|Experimental|Orally Disintegrating MGC-ODT Tablet|Administration of a single tablet of Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5mg THC and 5 mg CBD
10166001|NCT03936907|Active Comparator|Sativex®|Sativex® spray X 2 actuations (1 under the tongue and 1 inside the cheek administered within 2 min) - Reference Product [Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 5.4 mg THC and 5.0 mg CBD]
10166002|NCT03936972||ilizarov circular frame|46 participants with open tibia fracture Gustillo type III only
10166003|NCT03936972||Ex. Fix|47 participants with open tibia fracture Gustillo type III only
10166004|NCT03937050|Experimental|Intervention|A package of three interconnected educational/behavioural film-based interventions will developed for delivery at the cluster (clinic) level. The aim of the three components will be as follows: a) improving knowledge of GDM guidelines and skills among health providers involved in GDM management, b) raising awareness of GDM and the importance of screening among pregnant women and their family members, and c) improving confidence and skills in self-management of GDM among women diagnosed.
10166005|NCT03937050|No Intervention|Control|Usual care practices.
10166006|NCT03937089||Patients|Patients with persistent AF, who underwent a CA procedure in the Nancy hospital between January 2011 and April 2017, will be included in this retrospective study.
10166007|NCT03936803|Active Comparator|exercise group|Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD) and taking their standard medications in addition to aerobic interval training exercise .Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with heart rate (HR) at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum heart rate HR. The exercise session was terminated by 5 minutes cool-down
10166008|NCT03936803|Active Comparator|electro-acupuncture group|"Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD), and taking their standard medications In addition to electro acupuncture (EA) of (2 Hz, 4 mA) was applied at points of: liver 3 (LR3) ,liver 14 (LR14), gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
10166009|NCT03936816||GBS screened positive|150 patients that were screened positive by culture at 35-37 weeks gestational age.
10166010|NCT03936816||GBS unknown with risk factors|150 patients that were not screened for GBS and have risk factors for GBS prophylaxis.
10166011|NCT03936959|Experimental|LY3434172|LY3434172 administered IV
10166012|NCT03936842|Experimental|Single Arm|"Eligible patients who are referred to the one-stop diagnostic clinic with breast pain alone and have completed a clinical assessment will be given a patient information sheet inviting them to participate in the study. They will be met by the interviewing clinician at the same visit."
9826468|NCT02419508|Other|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
9974764|NCT05249712|Experimental|ADT with Darolutamide|"Pathological response rate after radical prostatectomy with dalotamide combined with androgen deprivation therapy (ADT) in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer.~Duration of treatment: 28-day cycle of darotamide treatment and 6 cycles of neoadjuvant therapy. ADT treatment continued during neoadjuvant therapy and was discontinued after surgery.~Adjusted dosing: When the serum testosterone concentration cannot be maintained at <50 ng/dL, the dose and type of ADT can be adjusted. Investigators can adjust the dose of darostatide according to the situation."
9974765|NCT05249686|Experimental|Manual Therapy + Dry Needling|
9974766|NCT05249686|Active Comparator|Manual Therapy|
9974767|NCT05249686|No Intervention|Control|The control group received only the dentist´s usual advice after endodontic surgery.
9974768|NCT05249673|Experimental|global postural reeducation|"global postural reeducation (GPR) interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
9974769|NCT05249673|Active Comparator|neck stabilization training|Each exercise session will be comprised of 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient.
9974770|NCT05249660|Experimental|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
9974771|NCT05249660|Active Comparator|Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
9974772|NCT05249647|Experimental|Instrument based fascial abrasion technique|IASTM using tools over Myofascial trigger points of the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place & the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping.
9974773|NCT05249647|Active Comparator|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
9974774|NCT05246124|Experimental|Intervention group|This study used Zumba dance exercise done 3 times a week during 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
9974775|NCT05246124|No Intervention|Control group|No intervention during 2-week self-isolation period
9974776|NCT05246046|Experimental|Tiotropium Easyhaler 10 microg/dose, Product variant J|Each subject will receive a single dose of 2 inhaled doses from Tiotropium Easyhaler Product variant J in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
10166013|NCT03936777|Experimental|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
10166014|NCT03936712|Experimental|Red Bull drink (RB)|Over the study, three participants were unable to complete all test sessions due to muscle pain or injury . Thus, 19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg) completed all test sessions
9974777|NCT05246046|Experimental|Tiotropium Easyhaler 10 microg/dose, Product variant K|Each subject will receive a single dose of 2 inhaled doses from Tiotropium Easyhaler Product variant K in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
10166015|NCT03936712|Placebo Comparator|Placebo drink|19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg)
10166016|NCT03936725||Chronic and non specific low back pain patients|Chronic and non specific low back pain patients
10166017|NCT03936582|Experimental|Treatment|All owners/managers of small businesses in 10 treatment neighborhoods will receive a request to support youth physical activity. The owners/managers will be able to direct support to specific programs, get recognized for their support, receive added information on the benefits of supporting such programs, have the oversight of an advisory board and interface with a local program representative
10166018|NCT03936582|Active Comparator|control|All owners/managers of small businesses in 10 control neighborhoods will will receive a request to support youth physical activity. None of the other components of the treatment arm (e.g., direct support to specific programs, advisory board) will be provided.
10166019|NCT03936569|Experimental|Marketed Stannous Fluoride Toothpaste|Brush twice daily
10166020|NCT03936569|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
10166021|NCT03936764|Other|Group 1|5 Preoperative Pulmonary Rehabilitation sessions / week during 3 weeks.
10166022|NCT03936764|Other|Group 2|3 Preoperative Pulmonary Rehabilitation sessions / week during 5 weeks.
10166023|NCT03936660|No Intervention|Control|Clinics in the control arm will be encouraged to follow guideline-based care.
10166024|NCT03936660|Active Comparator|Intervention|The cardiology clinics in the intensive educational intervention arm will receive guidance to develop an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
10166025|NCT03936517|Other|Prednisolone first; hydrocortisone second|Participant will receive 4 months of prednisolone in the first study period and 4 months of hydrocortisone in the second study period.
10166026|NCT03936517|Other|Hydrocortisone first; prednisolone second|Participant will receive 4 months of hydrocortisone in the first study period and 4 months of prednisolone in the second study period.
10166027|NCT03936543|Experimental|Extended axillary midline|Operator stands at the bedside on extended midline of the patient's lt. axilla during lt. internal jugular vein catheterization
10166028|NCT03936543|Active Comparator|Extended head midline|Operator stands at the bedside on extended midline of the patient's head during lt. internal jugular vein catheterization.
10166029|NCT03936556|Experimental|Marketed Stannous Fluoride Paste|Brush twice daily
10166030|NCT03936556|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
10166031|NCT03936595|Experimental|Core exercises protocol|Participants will perform 4 core exercises
10166032|NCT03936595|Experimental|Structural exercises protocol|Participants will perform 4 structural (Olympic lifting) exercises
10166033|NCT03936595|Experimental|Accentuated eccentric load exercises protocol|Participants will perform 4 exercises with eccentric loading
10166034|NCT03936595|Other|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
10166035|NCT03936491|Experimental|Methylphenidate|The subjects will receive methylphenidate according to their clinical symptoms
10166036|NCT03936491|Active Comparator|Atomoxetine|The subjects will receive atomoxetine according to their clinical symptoms
10166037|NCT03936621|Active Comparator|Group 1: Omega 3 Fatty Acid|Omega 3 fatty acids for 6 months and then off omega 3 fatty acids for the next 6 months. In the first 6 months, you will be asked to take one capsule of Omega 3 fatty acids with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks. In the next 6 months (Months 7 to 12), you will have a blood test for markers of inflammation at the end of Month 7 and at Month 9 and 12 to determine if the anti-inflammatory effects of Omega 3 acids are still there after you have stopped taking it.
10166038|NCT03936621|Placebo Comparator|Group 2: Control Arm|No Omega 3 fatty acids for the first 6 months followed by Omega 3 fatty acids for the next 6 months. You will be asked to have a blood test for markers of inflammation at Month 1, 3 and 6 for markers of inflammation to determine the natural variation of the levels of these markers without Omega 3 fatty acid supplements. In Month 7, you will be asked to take one capsule of Omega 3 with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks.
10166039|NCT03936504|Active Comparator|Control Group|Group received conventional exercise rehabilitation programs (CERP).
10166040|NCT03936504|Experimental|Experimental Group|Group received Tai Chi cardiac rehabilitation program(TCCRP).
10186574|NCT03734367|Active Comparator|Emotional abilities training program|Intervention program on emotional abilities that will be carried out for 10 hours distributed over 5 weeks, in two and a half hour session. The work methodology will be eminently practical, working in groups including real case analysis and interactive simulation
10186575|NCT03734367|No Intervention|Control group|Control group that will not receive the training program on emotional abilities but usual care.
10186576|NCT03734354|Experimental|1 mg dosing group|Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
10186577|NCT03734354|Experimental|2 mg dosing group|Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
10186578|NCT03734354|Experimental|4 mg dosing group|Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
10186579|NCT03734341|Experimental|EZ START Titration|"CPAP titration test performed with an auto CPAP device preset on incremental fixed pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with EZ START pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: auto-adjusting pressure (no wash-out period)."
10186580|NCT03734341|Active Comparator|APAP Titration|"CPAP titration test performed with an auto CPAP device preset on auto-adjusting pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with APAP pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: incremental fixed pressure (no wash-out period)."
10186581|NCT03734328|Active Comparator|connective tissue graft|"Drug:local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~5/0 silk suture"
10186582|NCT03734328|Experimental|connective tissue graft&PRF|"Drug: local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~-5/0 silk suture"
10186583|NCT03734302|Experimental|Multiple dose oral administration|1mg Once Daily (QD) , oral administration,14 consecutive days
9662150|NCT05130554|Experimental|XEN45|The effect of XEN45 surgery on patients with primary open-angle glaucoma
9662151|NCT05130541|Placebo Comparator|Control|Usual Care
9977444|NCT01361646|Active Comparator|Febuxostat|
10166041|NCT03936673|Experimental|atrophic kidney|Patients diagnosed with unilateral obstructed kidney with RRF 10% or less underwent application of percutaneous nephrostomy tube on affected side.
10166042|NCT03936686|Active Comparator|Children in grades 4 or 5|This group was comprised of participants that were in grades 4 or 5 in school.
10166043|NCT03936686|Active Comparator|Adolescents in grades 10 or 11|This group was comprised of participants that were in grades 10 or 11 in school.
10166044|NCT03936686|Active Comparator|College Age Participants|This group was comprised of participants that were sophomores or juniors in college/university that were non-health career majors.
10166045|NCT03936686|Active Comparator|Cardiac Rehab Adults|This group was comprised of participants that were adults over the age of 40 that had completed a phase II cardiac rehabilitation program.
10166046|NCT03936686|Active Comparator|General Adults|This group was comprised of participants that were adults over the age of 40 that had never attended an outpatient cardiac rehabilitation program before.
10166047|NCT03936647|Active Comparator|Standard conventional treatment (surgical or endovascular)|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
10166048|NCT03936647|Experimental|WEB embolization device|Endovascular treatment with WEB, including standard management of thrombo-embolic risk
10166049|NCT03936634||Newly Diagnosed (ND)|Recruited within 6 weeks of type 1 diabetes diagnosis. Age between 1 and <45 years
10166050|NCT03936634||Unaffected Family members (UFM)|"Participants who are not diabetic but have a first degree relative with type 1 diabetes diagnosed < 45 years of age.~Age between 1 and <45 years"
10166051|NCT03936751|Active Comparator|CPAP|Continuous positive airway pressure
10166052|NCT03936751|Sham Comparator|Nasal strips|Nasal Strips
10166053|NCT03936452|Experimental|Treatment arm|Sintilimab 200mg ivdrip D1 Peg-aspargase 2500U/m2 im D1 Anlotinib 12 mg po D1-14 repeat every three weeks
10166054|NCT03936283|Experimental|Lifestyle Intervention|
10166055|NCT03936283|No Intervention|Usual Care|
10166056|NCT03936127|Experimental|Transperineal (TP) Ultrasound (US) Targeted Fusion Biopsy|Transperineal (TP) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
10166057|NCT03936127|Active Comparator|Transrectal (TR) Ultrasound (US) Targeted Fusion Biopsies|Transrectal (TR) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
10166058|NCT03936426|Experimental|SARTATE|All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.
10166059|NCT03936322|Experimental|Pregnant women diagnosed with fetal myelomeningocele|Women subjects who are pregnant and diagnosed with myelomeningocele (MMC), also known as fetal spina bifida or neural tube defect, will undergo a minimally invasive fetoscopic repair of MMC.
10166060|NCT03936062||2nd Generation SUs|Reference group
10166061|NCT03936062||Sitagliptin|Exposure group
10166062|NCT03936348|Experimental|FB group|Participants who performed an exercise training program for 8 weeks using a nasal restriction device for inspiratory muscle training, called Feelbreathe®
10166063|NCT03936348|Experimental|ONB group|Participants who performed an exercise training program for 8 weeks with oronasal breathing without FB
10166064|NCT03936348|No Intervention|control group (CG)|Participants who received the standard medical recommendations for patients with COPD, but not participated in the exercise intervention program
10166065|NCT03936166|Experimental|Single Ascending Dose (Part 1)|
10166066|NCT03936166|Experimental|Multiple Ascending Dose (Part 2)|
10166067|NCT03936166|Placebo Comparator|Elderly Cohort (Part 3)|
10166068|NCT03936374|Experimental|BMS-986205 + Omeprazole|
10166069|NCT03936205|No Intervention|Control|
10166070|NCT03936205|Experimental|Dexmedetomidine|
10166071|NCT03936049||DPP-4 inhibitor|Reference group
10166072|NCT03936049||Liraglutide|Exposure group
9662152|NCT05130541|Experimental|Proning|Proning, rotating 90 degrees on long axis every 30 minutes - 2 hours
9662153|NCT05130515|Experimental|Treatment group|Niraparib 200mg po QD day1~21, Anlotinib 10mg po QD day1~14
9826469|NCT02419521|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
10166073|NCT03936153|Experimental|Abexinostat 80 mg bis in die (BID)|Abexinostat 80 mg BID
10166074|NCT03936400|Experimental|Randomized controlled trial|Experimental group receiving a couple-based intervention
10166075|NCT03936400|Active Comparator|Active comparator: control group|A control group that receives same but delayed couple-based intervention
10166076|NCT03936114|Experimental|SMART|
10166077|NCT03936296|Active Comparator|fusion arm|Patients in this arm will be undertaken standard transrectal prostate biopsy and MR guided MR-US fusion prostate biopsy
10166078|NCT03936296|Other|Standard arm|Patients in this arm will be undertaken only standard transrectal prostate biopsy
10166079|NCT03936179|Experimental|high dose radiochemotherapy|A total dose of 86 Gy to residual metabolic disease with concurrent chemotherapy
10166080|NCT03936140|Experimental|Iloprost 10|"Iloprost 10μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
10166081|NCT03936140|Experimental|Iloprost 20|"Iloprost 20μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
10166082|NCT03936140|Placebo Comparator|Distilled water|"Distilled water~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
10166083|NCT03936101||Prenatally Sequenced Group|750 trios with fetal structural anomalies who receive prenatal sequencing from the study
10166084|NCT03936101||No Prenatal Sequencing (Unsequenced) Group|350 trios with fetal structural anomalies who do not have prenatal sequencing
10166085|NCT03936036||2nd generation sulfonylureas|Reference group
10166086|NCT03936036||Linagliptin|Exposure group
9520286|NCT03279068||With Pattern Interpretation|"All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM."
10166087|NCT03936075|Experimental|intervention|treatment with the provision of 6 individual sessions of the Guided Imagery and Music method as a psychological supportive intervention, and psychometric questionnaires collection
10166088|NCT03936075|Placebo Comparator|control|standard care treatment with psychometric questionnaires collection and two individual counselling sessions, at baseline (week 1) and at the end (week 6)
10166089|NCT03936023||2nd Generation SUs|Reference Group
10166090|NCT03936023||Saxagliptin|Exposure Group
10166091|NCT03936010||DPP4i|Reference group
10166092|NCT03936010||Canagliflozin|Exposure group
10166093|NCT03935945|Experimental|Personalized Feedback Intervention (PFI)|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes.
10166094|NCT03935945|No Intervention|Attention-Control|Attention control information will be comparable in focus on health-related behaviors (e.g., nutrition, exercise). We will use behaviors in the attention control feedback that are not associated with study outcomes. Attention control feedback will have text and graphs that are similar in appearance and length (i.e., 20-30 minutes) to intervention feedback.
10166095|NCT03935828|Experimental|Topical Sinonasal Antibiotics|For topical antibiotics, the compounding pharmacy will use pre-determined doses using data extrapolated from oral and intravenous doses and data that has detailed the effect of the medication on solubility, pH, and particle properties. Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml, and Amphotericin B 20mcg/ml, all to be prescribed for 21 days, applied twice a day. Although the dosing schedule for these topical antibiotics has not been definitively studied, the majority of the data supports a range from two to three times daily for three to four weeks. Patients will be instructed by the pharmacist how to dissolve the cream, powder, or vial of antibiotic in saline, and to irrigate each nostril with 120 ml total. Doses will not be varied during the study period.
10166096|NCT03935828|Active Comparator|Oral Antibiotics|Oral antibiotics will be prescribed for 21 days, as available (albeit limited) evidence recommends antimicrobial therapy in CRS for at least 3 weeks. For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours, Levofloxacin 500 mg once daily, or Clindamycin 300 mg every 6 hours, as these are standard of care for treatment of Chronic Rhinosinusitis.
10166097|NCT03935997|Experimental|Step 1|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
10166098|NCT03935997|Experimental|Step 2|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
10166099|NCT03935997|Experimental|Step 3|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
10166100|NCT03935685|Experimental|mirtazapine in glioma patients treated with Temozolomide|Using the well-known Beck Depression Inventory, we will assess the changes in depression scores from baseline to after four and eight weeks of treatment with mirtazapine. We will also assess the change in nausea, vomiting, and weight at the same time points, and collect information on tolerability of mirtazapine throughout the course of the study.
10166101|NCT03935776|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend a 12-week intensive lifestyle programme.~The intervention includes weekly exercise class and educational workshops, serial blood pressure, body mass index, glucose and lipid measurements.~Weekly multidisciplinary team meetings and targeted and protocol pharmacotherapy to support lifestyle changes."
10166102|NCT03935776|Active Comparator|Standard Healthcare|The control group will receive information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
10166103|NCT03935841|Experimental|3-OHB orally|36 gram 3-OHB salt consumed orally
10166104|NCT03935841|Active Comparator|3-OHB intravenously|Variable amounts of 3-OHB salt given i order to replicate the same individual plasma concentrations measured during the experimental arm.
10166105|NCT03935672|Other|All trial participants|"Baseline plasma and saliva tests for future translational analysis~Baseline planning FDG PET CT scan~Patients will start their 6 weeks of CCRT within two to three weeks following the planning scans. Cisplatin chemotherapy will be administered. 33 daily fractions of radiotherapy will be delivered over 6 weeks.~A second FDG-PET-CT scan (iPET) and repeat plasma and saliva tests will be carried out after 2 weeks of CCRT (on RT days 9 - 12) and the iPET assessed for residual FDG-avid disease. The biological GTV will be re-outlined based on the residual avid region of the tumour on the second PET-CT (bGTV_iP)~At the end of treatment, plasma and saliva tests will be carried out at 4 weeks post treatment and again at the 3 month post-treatment PET-CT~Swallowing and QoL assessments will be repeated 4 weeks (+/- 2 weeks) after treatment and will be repeated at 6, 12 and 24 months post-treatment. The plasma and saliva samples will be repeated at 12 and 24 months"
10166106|NCT03935529|Experimental|Behavioural Acitivation|Behavioural Activation. Originally a component of cognitive behavioural therapy, Behavioural Activation is a structured psychotherapeutic approach which aims to (a) increase engagement in activities associated with pleasure or mastery, (b) decrease engagement in activities that maintain depression, and (c) problem solve barriers limiting access to reward or maintain aversive control. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
10166107|NCT03935802||primary non-metastatic breast cancer|primary non-metastatic breast cancer
10166108|NCT03935815|Active Comparator|Intervention|"Standard of care pain management plus quadratus lumborum nerve block.~Ropivicaine 0.25% 60 mL will be injected in the fascial plane between the quadratus lumborum muscle and transverses abdominus muscle."
10166109|NCT03935815|Sham Comparator|Control|Standard of care pain management plus a sham procedure.
10166110|NCT03935490||e-TREPP|Patients with strangulated inguinal hernia treated with e-TREPP
10166111|NCT03935659|Active Comparator|Standard gauze therapy|The control group will receive a standard sterile gauge dressing over the groin incision. The dressing will be removed on post-operative day #2 and the wound will be inspected for any complications, followed by daily dressing changes and wound inspections until discharge.
10166112|NCT03935659|Experimental|Negative Pressure wound therapy|The intervention group will receive a negative pressure dressing which will be applied in the operating room under sterile conditions. The brand of negative pressure dressing will be based on surgeon preference or center availability. The NPWT dressing will be removed on day 5 postoperatively or at discharge, whichever occurs first, and the groin wound inspected for any evidence of infection or dehiscence, and daily thereafter until discharge.
10166113|NCT03935568|Experimental|Single Dose Placebo|Patients randomized to receive Placebo
10166114|NCT03935568|Experimental|Single Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
10166115|NCT03935568|Experimental|Multiple Dose (Placebo)|Patients randomized to receive Placebo
10166116|NCT03935568|Experimental|Multiple Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
10166117|NCT03935880|Active Comparator|Cartiva Hemiarthroplasty|Cartiva implant
10166118|NCT03935880|Active Comparator|Cheilectomy|Bone spur removal
10166119|NCT03935984|Experimental|Treatment Group|All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging
10166120|NCT03935477||High risk surgery|those undergoing elective and emergency, high-risk surgery receiving arterial cannulation and urethral catheterisation as standard
10166121|NCT03935477||Critical Care|Emergency admissions to UCLH critical care unit receiving arterial cannulation and urethral catheterisation as standard
10166122|NCT03935503||Total Extraperitoneal Repair|Laparoscopic Total Extraperitoneal (TEP) method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
10166123|NCT03935503||Lichtenstein repair|Lichtenstein method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
10166124|NCT03935789|Experimental|BLAST|All participants in this study will be assigned to this group to participate in the BLAST intervention. The intervention will be a self-guided web-based platform using a self-management model to help support better engagement in everyday life activity
10166125|NCT03935516|Experimental|Flexed Elbow|The first group will be placed in a cast with the elbow bent.
10166126|NCT03935516|Experimental|Extended Elbow|The second will be placed in a cast with the elbow straight.
10166127|NCT03935555|Experimental|Oral - 50mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
10166128|NCT03935555|Experimental|Oral -100 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
9662154|NCT05130502|Experimental|Foam roller|Individuals perform Foam roller on bilateral legs and the muscles include Quadriceps, hamstring and gastrocnemius and soleus with a dynamic warm up program The investigators conduct the test for 2 sets and 60 seconds with 30 seconds rest period per muscle
10166129|NCT03935555|Experimental|Oral - 200 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
9662155|NCT05130502|Active Comparator|Kinesiotape|Individuals perform Kinesiotape on bilateral legs and the muscles include Quadriceps, hamstring and gastrocnemius and soleus with a dynamic warm up program The investigators conduct the kinesiotape per muscle and will wait for 45 minutes for bring out the effects.
10166130|NCT03935555|Experimental|Oral - 300 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
10166131|NCT03935581|Experimental|ExAblate 4000 System|ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
10166132|NCT03935464|Experimental|Intervention Arm|POC adherence testing by a urine TFV assay with feedback
10166133|NCT03935464|No Intervention|Standard of Care|Follow Kenya's PrEP guidelines on standard adherence counselling
10166134|NCT03935737||Full dose Chest X-Ray|Subjects will receive a full (standard) dose chest X-ray at Day 1.
10166135|NCT03935737||Low dose Chest X-Ray|Subjects will receive a follow up X-ray at at a lower dose within 3 months after the first dose.
10166136|NCT03935646|Experimental|Stimulant Medication|Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
10166137|NCT03935451|Placebo Comparator|Placebo|The placebo group will receive a similarly appearing full supply of a twice daily placebo oral tablet.
10166138|NCT03935451|Experimental|Experimental|The treatment arm will receive a full supply of twice daily 2.5 milligram (mg) dosing of apixaban beginning on the first day of hospital discharge.
10166139|NCT03935633|Experimental|First Dosage|The dose of CN128 is 20 mg/kg bw， bid.
10166140|NCT03935633|Experimental|Second Dosage|The dose of CN128 is 15 mg/kg bw， bid.
10166141|NCT03935438|Experimental|Patients after ACS|Patients after acute coronary syndrome undergoing cardiac rehabilitation.
10166142|NCT03935191||Group|Device: Dexcom CGM System
10186584|NCT03734276|Experimental|High intensity exercise|
10166143|NCT03935334|Experimental|Eptacog alfa, biosimilar (AryoSeven)|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
10166144|NCT03935334|Active Comparator|Novoseven|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
10166145|NCT03935386|Active Comparator|Standard Compression|Standard multi-layer compression dressing with no graft or biologic material added
10166146|NCT03935386|Active Comparator|Standard Compression with application of human allograft|standard compression with application of a cryopreserved skin allograft (TheraSkin)
10166147|NCT03935152|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 8 hours until delivery
10166148|NCT03935152|Placebo Comparator|Placebo|placebo by mouth every 8 hours until delivery
10166149|NCT03935035|Experimental|internet-Cognitive Therapy for PTSD|This is a single-arm study. All participants will receive the same therapist supported, internet-delivered intervention.
10166150|NCT03935113|Experimental|KT group|The paretic upper limb is a common consequence of stroke that increases activity limitation.
10166151|NCT03935204|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
10166152|NCT03935204|Placebo Comparator|Placebo|Participants in this arm would receive 1.0ml aluminium adjuvant.
10166153|NCT03935165|Experimental|Indocyanine Green arm|"All the patients to be enrolled have to meet the inclusion criteria. All enrolled patient is subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions are described.~Subsequently, 0.25 mg /(kg BW) Indocyanine Green is administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision is made, in order to identify the fluorescent lesions. All the lesions are described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged."
10166154|NCT03935217|Experimental|Solosec (containing 2 grams of secnidazole)|Orally administered as a single dose with applesauce. Upon completion of primary phase patients will receive the opposite treatment (placebo)
10166155|NCT03935217|Placebo Comparator|Placebo|Orally administered as a single dose with applesauce. Upon completion of primary phase patients will receive the opposite treatment (Solosec (containing 2 grams of secnidazole)
10166156|NCT03935295|Experimental|Botulinum Toxin|"The investigators plan to administer approximately 1000 U Dysport ® in the concave-sided paraspinal musculature of the major curve, based on an estimated total dose of 1000 U, the maximum allowable dose. The total dose per treatment session will not exceed 15 units/kilogram or 1000 units, whichever is lower. If two curves are equivalent within 3˚, both will be treated, however, the dosing (described above) will be divided equally across both curves.~There will be two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
10166157|NCT03935295|Placebo Comparator|Placebo|"Control patients will receive an injection of placebo specifically prepared as a control for this study. The same volumes as indicated in the experimental arm description will be injected.~These will be administered during two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
10166158|NCT03934996|No Intervention|Assesment Runners|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week.
10166159|NCT03934996|Experimental|Runners with educational training|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week with educational training about pelvic floor muscles.
10166160|NCT03935074||group 1|Patients who received intra-arterial chemotherapy as a first line treatment
10166161|NCT03935074||group 2|Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
10166162|NCT03935048|Experimental|Higher Protein, Low Glycemic Load with Potatoes|Higher Protein, Low Glycemic Load with Potatoes (HPLG-P): low- to moderate- glycemic load meals containing white potatoes. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
10166163|NCT03935048|Active Comparator|Higher Protein, Low Glycemic Load with Processed Potatoes|Higher Protein, Low Glycemic Load with Processed Potatoes (HPLG-PP): low- to moderate- glycemic load meals containing processed white potato products. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
10166164|NCT03935048|Placebo Comparator|Higher Protein, Low Glycemic Load - Control|Higher Protein, Low Glycemic Load (HPLG-C): low- to moderate- glycemic load meals containing control carbohydrate (e.g. rice, pasta). Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing control carbohydrate sources.
10166165|NCT03934944|Experimental|Phone application arm|Participants will have access to a educational video and foot alerts at weekly intervals to supplement usual Podiatry care and education.
9974778|NCT05246046|Active Comparator|Spiriva HandiHaler 18 microg/capsule|Each subject will receive a single dose of 2 inhaled Spiriva capsules via HandiHaler device in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
10166166|NCT03934944|Other|Usual care|Participants will have Podiatry care and education.
10166167|NCT03935061|Experimental|Mulberry juice|Two bottles (600 ml/bottle) of sanitized mulberry juice are delivered to the patients of the experimental group 20 days before the next clinic visit, with instruction to consume 50 ml of juice diluted with drinking water at room temperature. A reminder of the next clinic visit for continuous treatment is attached.
10166168|NCT03935061|No Intervention|Controlled|Patients of the controlled group are informed of their allocation results along with a reminder of the next clinic visit. On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
10186585|NCT03734276|Active Comparator|Control|
10186586|NCT03734224|Active Comparator|Group1: Adhesix|This group gets the Adhesix mesh in a normal open hernia operation.
10166169|NCT03935412|Active Comparator|ES Erector Spinae Plane Block|By the end of surgery parturient in the ESPB underwent bilateral ESPB at the level of T9 using a linear ultrasound (US) transducer (Phillips Saronno Italy) the transducer was placed vertically3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine 22-G short bevel needle (spinocan, B.Braun melsungen AG, Germany) was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml 0.5% bupivacaine was done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
10166170|NCT03935412|Sham Comparator|intrathecal morphine ITM|participant in the ITM group intrathecal injection of 10mg of hyperbaric bupivacaine 0.5 % in addition to 100 mcg of preservative-free morphine. Then, the parturient immediately placed in the supine position with 15° left tilt, and an oxygen mask was applied at 2 l.min-1. After ensuring sufficient anesthesia level, the surgical procedure was done with continuous hemodynamics monitoring and recording. While participants in the ITM group underwent sham blocks; Sham blocks consisted of a non-invasive ultrasound scan, while a blunt needle was gently pressed on both sides.
10166171|NCT03935373||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) primary or secondary SS; (2) aged between 20 and 75 years; (3) fulfilled the 2002 American-European Consensus Criteria for SS (AECG); (4) had no abnormal findings of immune, liver, kidney, or blood function evaluations. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; or (3) steroid pulse therapy within three months prior to the commencement of our study.
10166172|NCT03935373||Health subjects|Health subjects were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 41 and 63 years (which the age could match the SS patients enrolling in the SS-1 trial); (2) had no chronic inflammatory illness. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; (3) abnormal findings of immune, liver, kidney, or blood function evaluations; (4) total sleeping time insufficiency less than 6 hours before one day of enrollment; (5) ever took the conventional medicine or hormone within one month; (6) ever encountered the acute illness, allergy reaction, immune, or rheumatic disease within one month.
9827698|NCT02465437|Experimental|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
10166173|NCT03935022|Experimental|Black rice Venere|Healthy volunteers will receive the black rice Venere in a cross-over randomized clinical trial (after 7 days wash-out).
10166174|NCT03935022|Experimental|Black rice Artemide|Healthy volunteers will receive the black rice Artemide in a cross-over randomized clinical trial (after 7 days wash-out).
10166175|NCT03935022|Sham Comparator|Complete white rice|Healthy volunteers will receive the complete white rice in a cross-over randomized clinical trial (after 7 days wash-out).
10166176|NCT03935243|Experimental|equine assisted therapy|In the active intervention phase, patients participate twice a week in a equine assisted group therapy, while during the control phase they participate twice a week in a group that includes a non-specific and general activity program. After 15 therapy units in a study phase, the subjects will complete the 15 units of the other study phase (within-subject-design). All participants complete both study phases, with the order being randomized.
10166177|NCT03935243|Active Comparator|activating control phase|"In the present study, the interventions in the control phase are based on the sub-program Social Skills of the Integrated Psychological Treatment Program (IPT) for schizophrenic patients (Brenner et al., 1994, Roder et al., 1988, 2002)."
10166178|NCT03935347|Experimental|Treatment (cyclophosphamide, fludarabine, pembrolizumab)|Patients receive cyclophosphamide IV over 2 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -2, and pembrolizumab IV over 30 minutes on day -1. At least 24 hours later, patients receive autologous tumor infiltrating lymphocytes LN-145 IV on day 0, and receive aldesleukin IV over 30 minutes for up to 6 doses on days 1-4. Patients then continue receiving pembrolizumab IV over 30 minutes beginning on day 21. Cycles of pembrolizumab repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity.
10166179|NCT03935256|Experimental|Full Dose Chemo, Reduced Dose Chemo + RT, Full Dose Chemo|Week 1 : Cycle 1: Full Dose Carboplatin and Paclitaxel Week 4: Pelvic Radiotherapy Begins Cycle 2: Dose reduced Carboplatin and Paclitaxel Week 7 : Cycle 3: Dose reduced Carboplatin and Paclitaxel Weeks 10,13,16: Cycle 4-6: Full Dose Carboplatin and Paclitaxel
10166180|NCT03934892||lactate during CPB|check lactate levels routinely during cardiac operations with cardiopulmonary bypass, choose the peak lactate data
10166181|NCT03934853|Other|No arm|There is no arm for this study.
10166182|NCT03934918|Experimental|Treatment|Patients for IOL with intracervical balloon placed in the outpatient clinic and sent home
10166183|NCT03934918|No Intervention|Control|Patients for IOL admitted to Labor and Delivery
10166184|NCT03934866||Group A (LDCT)|"25,000 individuals who are at high-risk for lung cancer due to a significant smoking history.~Participants will receive at least 1 LDCT scan at baseline."
10166185|NCT03934931|Experimental|Facilitated Directly Observed Therapy (DOT)|Facilitated DOT arm participants will attend the Mulago Immune Suppression Syndrome (ISS) clinic on a weekly basis to ingest 3HP medication under direct observation. DOT will be defined as a designated clinic staff member observing ingestion of each dose of 3HP. Additionally, participants randomized to facilitated DOT will receive: 1) DOT cards with instructions to present directly to the pharmacy for a pharmacy-only visit, without the need to wait in the general queue; 2) Automated short message service (SMS) or phone call reminders at no cost to participants the day before each appointment, 3) A fixed level of reimbursement (~$5/visit) for each weekly visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
10186587|NCT03734224|Active Comparator|Group 2: Progrip|This group gets the Progrip mesh in a normal open hernia operation.
9974779|NCT05243979||Group (A)|40 patients with CKD (1-3) not on renal replacement therapy.
10166186|NCT03934931|Experimental|Facilitated Self-Administered Therapy (SAT)|Facilitated SAT participants will take their 1st dose of medication under direct observation and be given a 4-week 3HP supply to take weekly via self-administration. Participants will return to the Mulago ISS clinic after completing their 5th dose to review adherence data with the clinic pharmacy technician and receive 5 additional 3HP doses (doses 7-11). At the scheduled refill visit (dose 6) and end-of-treatment visit (dose 12) participants will ingest 3HP via direct observation. Participants will also receive: 1) Free automated SMS reminders or phone call reminders before each scheduled dose; 2) Weekly check-ins inquiring about side effects via two-way SMS with a follow-up phone call depending on participant response, 3) Fixed level of reimbursement (~$5/visit) for the refill/end-of-treatment visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
10166187|NCT03934931|Experimental|Patient Choice between facilitated DOT and facilitated SAT|Participants randomized to the Patient Choice between facilitated DOT and facilitated SAT arm will be offered a choice between arms 1 and 2. A research nurse will review each section of the decision aid with participants, discuss values and preferences, and, after addressing any questions, ask participants to select facilitated DOT or facilitated SAT. Participants will have the option to switch between DOT and SAT at any time. The reason for switching and time spent under each strategy will be recorded.
10166188|NCT03934879|Experimental|Gateway Academy|For this study, Gateway Academy students will participate in the FitClub intervention. They will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
10166189|NCT03934879|Active Comparator|Control School|Other comparable school will be added as a control school, in which regular school activities will be provided.
9974780|NCT05243979||Group (B)|40 persons with normal kidney function and GFR ( control ).
9520287|NCT03279055|Experimental|SHUTi|"Participants will be provided with an individual access code for SHUTi~SHUTi is delivered over 6 sessions, each taking 20-30 minutes~SHUTi is delivered by a virtual therapist~Participants will learn about the etiology and maintenance of their insomnia~Participants will learn how to maintain their sleep log~Participants will learn how to address lifestyle barriers that impact their sleep~Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom~Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior~Participants will be taught how to gradually expand their restricted sleep"
9520288|NCT03279042|Experimental|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
10166190|NCT03934970||Diabetic Neuropathy|Thirty Egyptian patients with type 2 diabetes mellitus complaining of symptoms suggestive of peripheral neuropathy including 12 males and 18 females with a mean of 50.90 ± 9.18.
9520289|NCT03279042|Active Comparator|Traditional corticotomy|Traditional corticotomy will be performed in this group.
9826470|NCT02419547|Other|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
10166191|NCT03934970||Healthy Control Subjects|Fifteen normal healthy Egyptian volunteers including10 males and 5 females with a mean age of 45.67±7.77 years.
10166192|NCT03934983||Trauma patients|Subject experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
10166193|NCT03934788|Experimental|Oxysoft|olifilcon C, daily disposable soft contact lens, 1 month
10166194|NCT03934788|Active Comparator|SiHy|olifilcon B, dialy disposable soft contact lens, 1 month
10166195|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°1|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and will be instructed to use them for six weeks.
10166196|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°2|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
10166197|NCT03935009|Active Comparator|Electric toothbrush N°1 with electric toothbrush N°2|Participants will receive an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
10166198|NCT03934827|Experimental|Part A|"Open label, preliminary phase~20 participants"
10166199|NCT03934827|Experimental|Part B|"Randomised, double blinded phase~100 participants"
10166200|NCT03934762|Active Comparator|Placebo|A placebo solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
9520290|NCT03279029|Experimental|patients with aortic valve disease (AVD).|
9520291|NCT03279029|Experimental|patients with left ventricular assist device (LVAD|
9826471|NCT02419573|Active Comparator|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
9974781|NCT05232019||Infertile females|No less than 20 years old who were attending our clinical center for the first time were enlisted
9977445|NCT01361646|Placebo Comparator|Placebo|
10166201|NCT03934762|Experimental|Natural aloe vera|A natural aloe vera solution (peel and leaf) will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
10166202|NCT03934762|Experimental|Aloe vera soup|An aloe vera soup solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
10166203|NCT03934801||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
10166204|NCT03934645||Not In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)=0
10166205|NCT03934645||In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)≥4
10166206|NCT03934580|Experimental|hallucinated meal|A breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated under hypnosis by participants for 15 minutes
10166207|NCT03934580|Active Comparator|real meal|A real meal (white bread plus ham and cheese with 250 ml still water) is consumed by participants in 15 minutes
10166208|NCT03934502|Experimental|Evobrutinib: Treatment Sequence A, B, C, D|Participant will receive single oral dose of evobrutinib after an overnight fast of at least 10 hours (Treatment A) for 3 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by 2 hours after start of low-fat meal (Treatment D) for 2 days. There will be 48 hours washout period between each treatment period.
9826472|NCT02419573|Active Comparator|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
10166209|NCT03934502|Experimental|Evobrutinib: Treatment Sequence B, D, A, C|Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.
10166210|NCT03934502|Experimental|Evobrutinib: Treatment Sequence C, A, D, B|Participant will receive single oral dose of evobrutinib 1 hour prior to a low-fat meal (Treatment C) for 3 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days followed by within 30 minutes after start of a light meal (Treatment B) for 2 days. There will be 48 hours washout period between each treatment period.
10166211|NCT03934502|Experimental|Evobrutinib: Treatment Sequence D, C, B, A|Participant will receive single oral dose of evobrutinib 2 hours after start of a low-fat meal (Treatment D) for 3 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by after an overnight fast of at least 10 hours (Treatment A) for 2 days. There will be 48 hours washout period between each treatment period.
10166212|NCT03934528|Experimental|Pilot Study|
10166213|NCT03934723|Active Comparator|Control|This arm will consist of healthy overweight and obese individuals who are physically inactive and do not have clinically diagnosed depression or depression symptoms.
10166214|NCT03934723|Experimental|Antidpressants|This arm will consist of healthy overweight and obese adults who are physically inactive and who are diagnosed with clinical depression and have been taking antidepressant medications for at least 1 year.
10166215|NCT03934515||Group A - etCO2|"At the end of the anaesthesia , as usual, the secretions are aspirated with a suction tube of 18 Fr of caliber (diameter 6 mm). When the tube is inserted into the endotracheal tube, before proceeding with the aspiration of the secretions, a capnometer is attached to its outer end, measuring the etCO2 value for 10-15 seconds. At the end of the measurement, authors proceed with the aspiration of the secretions as usual.~Authors then proceed with the laying of a NGT according to local protocols. Also in this case, once the NGT has been inserted, the etCO2 is measured at the end of the probe for 10-15 seconds. At the end of the measurement, the capnometer can be detached, as a standard procedure, and the NGT can be used as usual.~At the end of the procedure, therefore, for each patient, two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values recorded at the endotracheal level and the one recorded at the oesophageal level."
10166216|NCT03934515||Group B - pH|"At the end of the anaesthesia , once the NGT is inserted, the pH is measured by aspirating the gastric contents and measuring on specific litmus paper the pH values, both at a distance of 25 cm from the mouth (oesophageal site) and at a distance of 40 cm (gastric site).~At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at oesophageal level and a value at the gastric level."
10166217|NCT03934489|Experimental|PERSIST|Participants will receive Partnered Emotion Regulation Skills Intervention and Support.
10166218|NCT03934489|Active Comparator|Facilitated Peer Support|Participants will undergo a 12-week group intervention, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
10166219|NCT03934593|Experimental|Faith-Based (FB, BHT DSMS)|The BHT DSMD intervention strategies adapted Stanford DSMP in a spiritual context is used in this group. Participants in the FB group will participate in BHT DSMS, which includes a Health Sermon, a 6-session Health Bible Study with cooking demonstrations, the Stanford DSMP and a Diabetes Resource Seminar delivered by two trained church lay leaders.
10166220|NCT03934593|Active Comparator|Faith-Placed (FP, Stanford DSMP)|The traditional Stanford DSMP is conducted in this control group. Participants in the FP group will first attend a 7-session community health and safety curriculum as a partial attention control intervention, followed by the Stanford DSMP and Diabetes Resource Seminar facilitated by the local public health department.
10186588|NCT03734211|Experimental|Evolocumab|Evolocumab (Repatha®) will be administered subcutaneously once monthly in the abdomen, thigh, or upper arm for the duration of the treatment period (one year). The 420 mg evolocumab/placebo will be administered by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
9826473|NCT02419612|Experimental|Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo|Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
9826474|NCT02419612|Experimental|Glimepiride or Placebo|Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
9827699|NCT02465437|Experimental|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
10166221|NCT03934736|Experimental|HEPLISAV-B®|A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).
10166222|NCT03934710|Placebo Comparator|Placebo|Placebo
10166223|NCT03934710|Experimental|Serotonin agonist|13ug of serotonin agonist
10166224|NCT03934749||standard mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV using Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
10166225|NCT03934749||Lowenstein mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV without Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
10166226|NCT03934424|Experimental|Weight Stigma|Weight stigma, read a weight stigma article for 5-10 minutes on one day
10166227|NCT03934424|Other|Ethnic stigma|Ethnic stigma, read an ethnic stigma article for 5-10 minutes on one day
10166228|NCT03934450|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days
10166229|NCT03934450|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days
10166230|NCT03934450|Active Comparator|Primaquine Phosphate|Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days
10166231|NCT03934450|Placebo Comparator|Placebo|Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days
10166232|NCT03934476|Experimental|Ketogenic diet|"Ketogenic diet:~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~fat type intake recommendation:~natural fats~trans-FA reduction"
10166233|NCT03934476|Experimental|Exercise HIIT (High-Intensity Interval Training)|"Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
10166234|NCT03934476|Experimental|Ketogenic diet + Exercise HIIT|"Ketogenic diet:~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~fat type intake recommendation:~natural fats~trans-FA reduction~Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
10166235|NCT03934476|No Intervention|Control Group|The study subjects in this arm will undergo no dietary changes and no exercise intervention.
10166236|NCT03934411|Experimental|Tramadol treatment|
10166237|NCT03934411|Placebo Comparator|Placebo treatment|
10166238|NCT03934385|Experimental|Mental Rehearsal|Between-session rehearsal/retrieval exercises focused upon consolidating non-fear learning gained from exposures by prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditioned stimulus (i.e., spider) and unconditioned stimulus (e.g., bite/attack).
10166239|NCT03934385|Active Comparator|Control Rehearsal|Between-session rehearsal/retrieval exercises focused upon an unrelated, recent academic experience.
10166240|NCT03934216|Experimental|BMS-986165|
10166241|NCT03934216|Placebo Comparator|Placebo|
9827700|NCT02465437|Experimental|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
10166242|NCT03934203|Experimental|Treatment 1|
10166243|NCT03934203|Experimental|Treatment 2|
10166244|NCT03934203|Experimental|Treatment 3|
10166245|NCT03934203|Experimental|Treatment 4|
10166246|NCT03934242||New born group 1|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, before nurses formation on the newborn's bedding
10166247|NCT03934242||New born group 2|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, after nurses formation on the newborn's bedding
10166248|NCT03934281|Active Comparator|HAS dressing|"Patients included in the HAS dressing arm will receive the best available dressing according to the HAS recommendations. HAS is the french National Authority for Health (HAS) ."
10166249|NCT03934281|Experimental|Honey dressing|"the honey used in this study is the Melectis G dressing. This is a combination of thyme honey (99.8%) and hyaluronic acid (0.2%).~The patient will benefit from the honey dressing until complete healing and/or until the end of the study (maximum 12 months)."
10166250|NCT03934060|Experimental|Intervention|Supervised exercise training including specific strength training tools and general exercise contents (standard care), 2-3 times per week, 30 minutes per session
10166251|NCT03934060|No Intervention|Control|Supervised exercise training regarding general exercise contents (standard care), 2-3 times per week, 30 min per session
10166252|NCT03934047|Experimental|Group A|Group A: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
9827701|NCT02465437|Placebo Comparator|Placebo|Placebo bid on Days 1-84.
9827702|NCT02465437|Experimental|Part B Open-label|JBT-101 20 mg bid on Days 1-364
9827703|NCT02465450|Experimental|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
9827704|NCT02465450|Experimental|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
9827705|NCT02465450|Placebo Comparator|Placebo|Placebo once a day on Days 1-28.
10166253|NCT03934047|No Intervention|Group B|Group B: No Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
10166254|NCT03934021||Acute stroke patient group|"Consecutive patients diagnosed with acute ischaemic stroke during hospitalization in Prince of Wales Hospital will be recruited.~After an informed consent, stool will be collected from enrolled patients in their first bowel opening after hospitalization and stored in a freezer (-80 degree Celsius) within 24 hours for analysis. If a subject develops constipation, stool sampling will be facilitated by stool softener or laxatives. Stools samples will be stored at -80 degrees Celsius within 24 hours once it is collected.~Subjects will be followed up at 3 and 6 months after trial entry. NIHSS and mRS will be performed at each visit. Stool sample collection will be repeated in 6 months visit only."
10166255|NCT03934021||Control group|Age and disease matched subjects will be invited to join the study as the control. Stool will also be collected for the comparison of gut microbiota with acute stroke patients to look for evidence of gut dysbiosis in acute stroke. We shall match the control cohort with the stroke cohort in terms of age, gender, smoking status, medical co-morbidities including hypertension, hyperlipidaemia, diabetes, (atrial fibrillation), use of medications in particular metformin, proton pump inhibitors and aspirin.
10166256|NCT03934294|Experimental|Treatment group: specific acupuncture group(Acu)|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G.~Acupuncture doctor will disinfect the acupoints with alcohol and will perform acupuncture on the marked points with needle Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor."
10166257|NCT03934294|Placebo Comparator|Control group: non-specific acupuncture group (Con-Acu)|"Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related pathologies, and are not reported to improve digestive function.~Acupuncture doctor 1 will disinfect the marked acupoints with alcohol and will perform acupuncture on the marked points. Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor"
10166258|NCT03933995||Mesenchymal stem cell|Long-term follow up of Mesenchymal stem cell group
10166259|NCT03933943|Experimental|LY3361237|LY3361237 administered subcutaneously (SC)
10166260|NCT03933943|Placebo Comparator|Placebo|Placebo administered SC
10166261|NCT03933956|Experimental|Empagliflozin-treated|Oral empagliflozin tablets 10mg daily, taken for 30 days.
10166262|NCT03934008||Historical Control Group|All pediatric patients 0-6 years of age seen in the clinic within one year prior to the start of the intervention period
10166263|NCT03934008||Post-Intervention Group|All pediatric patients 0-6 years of age seen in the clinic for one year following the implementation of the motivational interviewed based tool
10166264|NCT03934151||intracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with intracorporeal technique
10166265|NCT03934151||extracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with extracorporeal technique
10166266|NCT03933917|Experimental|Large Volume Acute Normovolemic Hemodilution|All the participants will undergo Large Volume Acute Normovolemic Hemodilution.
10166267|NCT03934346|Other|Zinc transport kinetics|Three different amounts of dietary zinc are used in the creation of a standard curve for determining zinc absorption kinetics: 4 mg, 7 mg, and 15 mg of zinc.
10166268|NCT03934138|Active Comparator|Educated open label placebo|These subjects will undergo all the same procedures as in the control group. But before the placebo CTP, they will watch a short movie explaining placebo mechanisms. While applying the placebo cream, they will be told that the cream is inert (placebo), efficient to decrease pain caused by cold and the mechanisms seen in the movie will take place.
10166269|NCT03934138|Placebo Comparator|Conventional placebo|These subjects will watch a video on hand washing. While applying the placebo cream, they will be told that this cream is effective to decreased pain caused by cold.
10166270|NCT03934177|Experimental|Blueberry powder|4 weeks of supplementation of 24 g whole blueberry powder
10166271|NCT03934177|Placebo Comparator|Placebo powder|4 weeks of supplementation of 24 g placebo powder (maltodextrin)
10166272|NCT03934320|Other|FAMCAT|
10166273|NCT03934333|Experimental|A/B (BDA MDI/Pulmicort)|For each participant, the BDA MDI/Pulmicort Flexhaler DPI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP will be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
10166274|NCT03934333|Experimental|B/A (Pulmicort/ BDA MDI)|For each participant, the Pulmicort Flexhaler DPI / BDA MDI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP should be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
10166275|NCT03934229|Experimental|Group Active|Bifidobacterium animalis ssp. lactis 420 at 1*10^10 colony forming units (CFU) per day
9827706|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
10166276|NCT03934229|Placebo Comparator|Group Placebo|Placebo
10166277|NCT03934073|Experimental|DEXTRAIN|The DexTrain group sessions will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting dexterity components.
10166278|NCT03934073|Active Comparator|CONVENTIONNELLE|Conventional training involving stretching of the spastic muscles as well as a set of exercises conventionally used in the protocols of post-stroke rehabilitation (repeated movements, manipulation of objects).
9827707|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
10166279|NCT03934073|Other|CONTROLE|To compare the results of SMT and functional MRI.
10166280|NCT03933930|Experimental|Lactate-directed therapy|
10166281|NCT03933930|Experimental|Goal-directed therapy|
10166282|NCT03933982|Experimental|Pyrotinib plus Vinorelbine|
10166283|NCT03933891||Decompensated liver cirrhosis with TIPS|
10166284|NCT03933839|Experimental|PainCOACH|This group will take part in an 8-week pain coping skills training (PCST) intervention.
10166285|NCT03933839|No Intervention|Wait List Control|The other group will be the wait list group and will receive the pain CST program after completing all study measures.
10166286|NCT03933865|Other|Buprenorphine Maintained Patients|All participants will be maintained on buprenoprhine for the treatment of opioid use disorder. All participants will be exposed to all 8 study drug combinations
10166287|NCT03933592|Active Comparator|Thoracic epidural|thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
10166288|NCT03933592|Experimental|Serratus plane block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 min before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
10166289|NCT03933657|Experimental|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System-Peripheral is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions via atherectomy.
10166290|NCT03933527|No Intervention|control group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).
10166291|NCT03933527|Experimental|coffee group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make coffee rinses for 30 seconds, four times daily.
10166292|NCT03933527|Experimental|tea group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make tea rinses for 30 seconds, four times daily.
10166293|NCT03933644|Other|Ambu Aura Gain TM with gastric tube|
10166294|NCT03933644|Other|Ambu Aura Gain TM without gastric tube|
10166295|NCT03933631|Experimental|Pilocarpine, Prednisolone acetate and Ofloxacin|This group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
9671538|NCT05047120|Experimental|Intervention group|HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT to identify adaptive cognitions and make adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). Participants will undergo 4 sessions during inpatient rehabilitation admission, each lasting 30-60 minutes. Sessions will include brief assessments of pain intensity, adverse events, and between session practice. Participants in this group will also complete baseline, follow-up, and post-discharge assessments.
9671539|NCT05047120|No Intervention|Measures only|People who consent to the measures only and usual care group will be encouraged to continue using the health care services available to them to address their pain. This includes a Rehabilitation Psychologist who can offer nonpharmacological pain management strategies. Participants in this group will baseline, follow-up, and post-discharge assessments.
9671540|NCT05047029||Patients with cirrhosis|Patients with cirrhosis and transjugular intrahepatic portosystemic shunt implantation.
9671541|NCT05046743|Experimental|Colonic gas load|
9671542|NCT05046743|Sham Comparator|Sham|
9671543|NCT05046756|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
9671544|NCT05046756|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
9827708|NCT02465450|Placebo Comparator|Placebo BID|Placebo twice daily on Days 29-84.
10166296|NCT03933631|Active Comparator|Prednisolone acetate and Ofloxacin (standard of care)|This group will use only Prednisolone acetate and Ofloxacin, without pilocarpine.
10166297|NCT03933709|No Intervention|Follow-up Group (FG)|dietary surveillance and conventional therapy
10166298|NCT03933709|Active Comparator|Control Group (CG)|deworming and WHO diet
10166299|NCT03933709|Experimental|Intervention Group (IG)|deworming and the Nutritional Support System (NSS)
10166300|NCT03933683||Pathologic Group|Patients affected by Fecal Incontinence
10166301|NCT03933683||Control Group|Healty volunteers cohort
10166302|NCT03933800|Experimental|High flow nasal cannula (HFNC)|High flow nasal cannula therapy
10166303|NCT03933800|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure therapy
10166304|NCT03933761|Experimental|Pamiparib (BGB-290)|Drug: Pamiparib Oral capsules 60mg twice daily continuously Although treatment is continuous, a cycle is defined as 4 weeks or 28 days.
10166305|NCT03933787|Placebo Comparator|mannitol in a tablet|two tablets containing mannitol in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
10166306|NCT03933787|Active Comparator|Saxagliptin in a tablet|two tablets containing each 5 mg of Saxagliptin in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
10166307|NCT03933553|Experimental|Easy sleep complex essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
10166308|NCT03933553|Active Comparator|Lavender essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
10166309|NCT03933566||Ultrasound-Guided|Ultrasound-Guided Superficial Cervical Plexus Block
10166310|NCT03933566||Landmark-Based|Landmark-Based Superficial Cervical Plexus Block
9671545|NCT05046977|Active Comparator|Single tibial osteotomy|Single tibial osteotomy done to achieve correction
9671546|NCT05046977|Active Comparator|Double tibial osteotomy|Double tibial osteotomy done to achieve correction
9671547|NCT05046990||RAC evaluation|Patients older than 18 years without previous history of Hp infection or eradication undergoing a gastroscopy
9671548|NCT05046652||One bag of convalescent plasma therapy|Four patients had been administered one dose of 200 mL CP with an antibody titer of 1:320.
9671549|NCT05046652||Two bags of convalescent plasma therapy|Four patients had been administered two doses of 200 mL CP with an antibody titer of 1:320.
9826475|NCT02419690|No Intervention|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
10166311|NCT03933436|Experimental|Iodine|Iodine swabs.
10166312|NCT03933436|Active Comparator|Normal Saline|Saline flush.
10166313|NCT03933501|Experimental|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
10166314|NCT03933501|Placebo Comparator|FMUD|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
10166315|NCT03933501|Experimental|SRP + AM|Four sessions (1/week) of scaling and root planning, plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the last session of treatment and taken every 8 hours for 7 days.
10166316|NCT03933501|Placebo Comparator|SRP|Four sessions (1/week) of scaling and root planning, plus two distinct placebo pills prescribed on the last session of treatment and taken every 8 hours for 7 days.
10166317|NCT03933488|Experimental|TAK-994: Part A|TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.
10166318|NCT03933488|Experimental|TAK-994: Part B|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
10166319|NCT03933488|Experimental|TAK-994: Part C|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
10166320|NCT03933488|Experimental|TAK-994: Part D|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
10166321|NCT03933488|Experimental|TAK-994: Part E|TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
10166322|NCT03933475|Experimental|Intendu Active Brain Trainer Telerehabilitation Games|Use of telerehabilitation Games within the home environment
10166323|NCT03933397|Experimental|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home, what was needed during their past hospital and emergency department visits to treat pain and doses that have been effective and safe in the past.
10166324|NCT03933397|Experimental|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight.
10166325|NCT03933280|Active Comparator|Group P|nalbuphine/propofol group
10166326|NCT03933280|Active Comparator|Droup D|Nalbuphine/dexmedetomidine group
10166327|NCT03933605|Active Comparator|midazolam and palonosetron|0.05 mg/kg of midazolam i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
10166328|NCT03933605|Active Comparator|palonosetron|the same volume (0.05 mg/kg) of normal saline i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
10166329|NCT03933514||GAgP parents|Parents diagnosed with Generalized Aggressive Periodontitis
10166330|NCT03933514||GAgP children|Children from parents diagnosed with Generalized Aggressive Periodontitis
10166331|NCT03933514||Health parents|Parents diagnosed as periodontally healthy
9671550|NCT05046860|Experimental|Dalbavancine + Rifampicine|
9826476|NCT02419690|Active Comparator|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
10166332|NCT03933514||Health children|children from parents diagnosed as periodontally healthy
10166333|NCT03933332||Ventilator length of use|measured in days
9826477|NCT02419755|Experimental|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
10166334|NCT03933293|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection
10166335|NCT03933293|Placebo Comparator|placebo|Placebo, Q4W, subcutaneous injection
10166336|NCT03933345||People who use illicit opioids|The study will recruit an adult-age (18+) sample of 600 people who use illicit opioids (either heroin or prescription opioid analgesics without a doctor's prescription) in New York City using Respondent Driven Sampling.
10166337|NCT03933358||Euthyroid|
10166338|NCT03933358||Low T3|low triiodothyronine syndrome
10166339|NCT03933319|Experimental|PLD in combination with trastuzumab|"Trastuzumab: administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.~pegylated liposomal doxorubicin(PLD):administered at dose of 35mg/m2 IV once every 21 days."
10166340|NCT03933111|Experimental|patients with pancreatic solid neoplasms|Patients with pancreatic solid neoplasms are enrolled in this study and accept the test.
10166341|NCT03933267|Experimental|Group I|This group of participant will receive Cervical sensorimotor control training exercises. In addition to it conventional physical therapy protocol will be given.
10166342|NCT03933267|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol.
10166343|NCT03933241|Experimental|experiment group|nasal irrigation after transsphenoidal surgery for pituitary tumor
10166344|NCT03933241|No Intervention|matched group|without nasal irrigation after transsphenoidal surgery for pituitary tumor
10166345|NCT03933228||Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
10166346|NCT03933228||Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
10166347|NCT03933176|Experimental|Simplified restorative procedure|After selective carious tissue removal, the universal adhesive (Adper Universal; 3M ESPE, St. Paul, MN, EUA) will be applied on the cavity walls. The cavity will be restored using a single increment of Filtek One Bulk Fill (3M ESPE, St. Paul, MN, EUA).
10166348|NCT03933176|Active Comparator|Control|A thin layer of resin-modified glass ionomer (Ionoseal (Voco America Inc., Briarcliff Manor, NY, EUA) will be placed on the pulpal floor of the cavity. Then, the adhesive and composite will be used following the same directions defined for the experimental condition.
10166349|NCT03932929|Experimental|Scotchbond universal adhesive (etch-and-rinse)|Acid etch (enamel&dentin)+adhesive agent Intervention: Device: Adhesive agent
10166350|NCT03932929|Experimental|Scotchbond universal adhesive (selective-etch)|Acid etch (only enamel)+adhesive agent Intervention: Device: Adhesive agent
10166351|NCT03932929|Experimental|Scotchbond universal adhesive (self-etch)|Adhesive agent Intervention: Device: Adhesive agent
10166352|NCT03932955|Experimental|MC-19PD1 CAR-T Cells|
10166353|NCT03932838|Experimental|clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
10166354|NCT03932903|Experimental|Contextually-tailored Mobile Messages for Adherence|All participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
10166355|NCT03932903|No Intervention|No messages|All participants will also be micro-randomized to not receive messages on some days of the intervention (~40% of the time).
10166356|NCT03932916|Experimental|experimental group 1|HHT201 17mg injection
10166357|NCT03932916|Experimental|experimental group 2|HHT201 34mg injection
10166358|NCT03932916|Active Comparator|experimental group 3|Donepezil Hydrochloride oral tablet 5mg
9827709|NCT02465463|Experimental|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
10166359|NCT03932877||late-onset preeclampsia, group1|30 late-onset preeclampsia patients as group1 (gestational age≥34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
10166360|NCT03932877||Control, group 2|33 patients with normal pregnancies as group2 (gestational age≥34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
10166361|NCT03932877||early-onset preeclampsia, group 3|31 early-onset preeclampsia patients as group3 (gestational age<34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg considered mild, and higher values considered to being severe.
10166362|NCT03932877||Control, group 4|31 patients with normal pregnancies as group 4 (gestational age<34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
10166363|NCT03933033|Active Comparator|Group A|treated with platelet rich plasma
10166364|NCT03933033|Active Comparator|Group B|treated with Erbium Yag Laser
10166365|NCT03933033|Active Comparator|Group C|treated with both line of treatments
10166366|NCT03933059|Active Comparator|R&R Park City, Utah|This group will receive 12 daily individual sessions of CPT at the National Ability Center in Park City, Utah. They will also participate in daily recreational activities.
10166367|NCT03933059|Active Comparator|R&R Salt Lake City, Utah|This group will receive 12 daily individual sessions of CPT at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
10166368|NCT03933059|Active Comparator|Weekly Treatment Salt Lake City, Utah|This group will receive 12 individual sessions of CPT on a weekly basis at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
10166369|NCT03932864|Placebo Comparator|Single Ascending Dose of MGTA-145 or placebo|MGTA-145 or placebo dose escalation as single agent, single dose
10166370|NCT03932864|Placebo Comparator|Single Dose MGTA-145 or placebo plus plerixafor|MGTA-145 or placebo in combination with plerixafor, single dose
10166371|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor for 2 sequential d|MGTA-145 in combination with plerixafor on two consecutive days; single dose per day
10166372|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis
10166373|NCT03932825|Placebo Comparator|Air oxygen mixture|participants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration ~50%).
10166374|NCT03932825|Experimental|Nitrous oxide|Participants in this group inhale mixed 50% nitrous oxide and 50% oxygen.
10166375|NCT03932981|Experimental|Temozolomide|Chemotherapy by temozolomide
10166376|NCT03932994|Experimental|ACT on Health Intervention|Those assigned to ACT on Health will use the program over the next 8 weeks, completing weekly modules and coaching calls.
10166377|NCT03932994|No Intervention|Waitlist|Those assigned to the waitlist will simply wait 8 weeks. A second online assessment will be completed 8 weeks after baseline in both conditions (for a between condition comparison). After the second assessment, waitlist participants will gain access to ACT on Health.
10166378|NCT03933046|Experimental|children referred to PSG due to suspected SDB|
10166379|NCT03932942|Experimental|Point-of-care testing of respiratory pathogens on admission|Point-of-care testing of respiratory pathogens on admission. The subjects will receive the point-of-care testing of respiratory pathogens at pediatric emergency room. The results are ready within 1 one hour.
10166380|NCT03932942|No Intervention|Routine ED protocol|Diagnostic tests for respiratory pathogens will be obtained according to clinical judgement and tested on microbiological laboratory. The results are ready on the next office day.
10166381|NCT03933189|Active Comparator|Biomedical (BIOM) physical therapy|Six 60 minute PT sessions consisting of 15 minutes of education on topics such as ideal postural alignment (sitting, sleeping), maintenance of normal spinal curves, body mechanics, proper lifting techniques, home pain control via anti-inflammatory modalities such as ice; 15 minutes of manual therapy to region of pain (soft tissue and/or joint mobilization); 30 minutes of region specific exercises to address identified muscle imbalances -stretching and strengthening of the muscles local to the area of pain.
10166382|NCT03933189|Active Comparator|Biopsychosocial (BPS) physical therapy|"Six 60 minute PT sessions consisting of 15 minutes of pain neuro-science education, 15 minutes of Graded Motor Imagery (GMI) techniques, (a progressive program of visual and mental exercises consisting of laterality exercises, motor imagery and mirror therapy); 30 minutes of a general conditioning exercise program individualized for each participant based on initial examination findings and participant presentation consisting of:~A cardiovascular component which may include walking on a treadmill, stationary cycling, or a seated stepping machine.~A muscle strengthening component for extremities and trunk. A flexibility component for upper and lower extremity musculature."
10166383|NCT03933150|Other|ultrasoun guided caudal epidural injection|A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.
10166384|NCT03933150|Other|fluoroscopy guided caudal epidural injection|B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
10166385|NCT03932851||HBsAg(+) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA). The newborns born to HBV-infected pregnant women were divided into HBV DNA-negative group, low-viral group, and high-viral group according to HBV DNA status. The HBV infection status of these newborns was counted in July, and the different viral loads were tested. The impact of HBV mother-to-child transmission.
10166386|NCT03932851||HBsAg(-) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA).
10166387|NCT03933098|Experimental|Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
10166388|NCT03933098|Experimental|Test group B: Lot 2 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 2 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
10166389|NCT03933098|Experimental|Test group C: Lot 3 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 3 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
10166390|NCT03933098|Active Comparator|Test group D: Typbar TCV|"One dose of Typbar TCV will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
10166391|NCT03932890|Active Comparator|Lower Volume fluid bolus arm|The 'lower volume' (LV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the LV arm, the trigger will deliver 50mls over 10 mins at a rate of 300ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
9671551|NCT05047055||Single Group - 4 months moxifloxacin group|"Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Moxifloxacin (M)~Isoniazid, rifampicin, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by isoniazid, rifampicin, ethambutol and moxifloxacin daily for 2 months (2 HRZEM daily / 2HREM daily) - Duration 4 months~Drug dosages The Fixed-dose Combination (FDC) for HRZE(75/150/400/275mg) used under NTEP according to weight category will be used.~The patients enrolled in the study will receive an additional tablet of moxifloxacin(M) 400mg (body weight <64 Kg) / 600mg (body weight >65 Kg) along with the FDC both in the intensive and continuation phase."
9694890|NCT04784247|Experimental|High grade undifferentiated pleomorphic sarcoma|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal . Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
10166392|NCT03932890|Experimental|Higher Volume fluid bolus arm|The 'higher volume' (HV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the HV arm, the trigger will deliver 200mls over 10 mins at a rate of 1200ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
10166393|NCT03932812|Experimental|Options Counselor Health Educator Intervention Group|These individuals will receive the Options Counselor Health Educator Intervention
10166394|NCT03932812|No Intervention|Control|These individuals will receive the typical standard of care treatment from clinics
10166395|NCT03933124|Experimental|Virtual Reality Intervention group|"The intervention group includes 60 patients who will use Virtual Reality for postoperative pain. Participants will use Virtual Reality minimal 10 minutes, minimal 3 times a day on the second, third and fourth day after surgery, on the general ward.~20 participants will receive an Oculus Go immersive 3D nature videos, games, meditation videos, google earth experiences and sports games.~20 participants will receive a Relaxmaker with 2D nature videos~20 participants will receive CareVRx with 3D nature videos and meditation videos."
10166396|NCT03933124|No Intervention|Control group|The control group receives standard postoperative care.
10166397|NCT03932799||Washington|Workers in the Washington Department of Labor and Industries state fund insurance system.
10166398|NCT03932799||Ohio|Workers in the Ohio Bureau of Workers' Compensation state fund insurance system.
10166399|NCT03933137||Not prolonged length of stay|Living donor patients who had ≤ 6 days length of stay after laparoscopic nephrectomy procedure
10166400|NCT03933137||Prolonged length of stay|Living donor patients who had > 6 days length of stay after laparoscopic nephrectomy procedure
10166401|NCT03932773|Sham Comparator|Sham rTMS + CPT|30 minutes of sham repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) prior to each Cognitive Processing Therapy (CPT) session
10166402|NCT03932773|Active Comparator|Active rTMS + CPT|30 minutes of 1 Hz rTMS to rDLPFC prior to each CPT session
10166403|NCT03932773|Active Comparator|Active rTMS Alone|30 minutes of 1 Hz rTMS to rDLPFC at 1 session per week over 12 weeks
10166404|NCT03932565|Experimental|The fourth-generation CAR-T therapy|Clinical trial study of Interventional therapy sequential with the fourth-generation CAR-T cells (IL7 and CCL19 or / and IL12) targeting Nectin4/FAP in the treatment of advanced malignant solid tumors with Nectin4-positive .
10166405|NCT03932578|Active Comparator|Atropine group|Patients will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
10166406|NCT03932578|Active Comparator|Metoclopramide group|Patients in will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo
10166407|NCT03932487||AITD group|Thyroid antibody positive and hypothyroidism
10166408|NCT03932487||normal group|Thyroid antibody negative and hypothyroidism
10166409|NCT03932630|Experimental|Study intervention|
10166410|NCT03932630|Active Comparator|Control intervention|
10166411|NCT03932474|Experimental|SAMEUp|SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
10166412|NCT03932474|Placebo Comparator|Placebo|Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste.
10166413|NCT03932435|Experimental|TWLO_C → TWLO|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
10166414|NCT03932435|Experimental|TWLO → TWLO_C|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
9826478|NCT02419755|Experimental|Stratum 2: ALL and MLM|Participants in Stratum 2 [Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
10166415|NCT03932552|Active Comparator|Control|Personalized nutritional therapy
10166416|NCT03932552|Experimental|Exercise|Aerobic exercise + Personalized nutritional therapy
10186589|NCT03734211|Placebo Comparator|Placebo|The placebo is presented in an identical prefilled autoinjector. It is supplied as a sterile, single-use, preservative-free solution for subcutaneous injection in a disposable, spring-based prefilled autoinjector. The prefilled autoinjector contains a 1.0 mL deliverable volume of 1.1% (w/v) sodium carboxymethylcellulose, 250 mM proline, 10 mM acetate, and 0.01% (w/v) polysorbate 80, pH 5.0.
10186590|NCT03734198|Experimental|Ibrutinib + daratumumab|"Prephase (D-27 to D0): ibrutinib 420 mg/day~Cycle 1 (4 weeks): ibrutinib 420 mg/day from D1 to D28 + daratumumab 8 mg/kg D1 and D2, then 16 mg/kg at D8, D15, D22.~Cycle 2 (4 weeks): ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1, D8, D15 and D22.~Cycles 3 to 6 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1 and D15.~Cycles ≥ 7 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1."
10186591|NCT03734172||Paediatric diagnostic group|Paediatric diagnostic group
10186592|NCT03734159|Experimental|parasternal block|preoperative parasternal block by ropivacaine injection
10186593|NCT03734159|Placebo Comparator|physiological serum|sodium chloride injection
10186594|NCT03734146|Experimental|Aerobic exercise (AE)|Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
10186595|NCT03734146|Experimental|Resistance exercise (RE)|Engage in supervised resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 3 sets of 8-12 repetitions of 12 exercises for the major muscle groups.
10186596|NCT03734146|Experimental|Combined Resistance and Aerobic Exercise|Engage in supervised aerobic resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 30 min aerobic exercise at 50-80% heart rate reserve and 30 min of resistance exercise comprising 2 sets of 8-12 repetitions of 9 exercises for the major muscle groups.
10186597|NCT03734146|No Intervention|No training control|No exercise training. Participants will refrain from any moderate-vigorous exercise or resistance training for 8 weeks.
10186598|NCT03734133|Experimental|Foot orthoses|Different foot orthoses
10186599|NCT03734120||men|men undergoing routine semen analysis for infertility
10186600|NCT03734094|Experimental|Ceramic Barrier|The use of a ceramic barrier to induce bone formation during GBR
10186601|NCT03734094|Active Comparator|Titanium mesh|The use of a titanium mesh to induce bone formation during GBR
10186602|NCT03734081|Experimental|Gastric electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
10186603|NCT03734081|Experimental|Electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
10186604|NCT03734081|Experimental|Electrical stimulation with type 1 ODC|Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
10186605|NCT03734068||Chemoembolization|Chemoembolization Using LifePearl and Doxorubicin
10186606|NCT03734003|Experimental|Controllable infrared bioeffect system for cutaneous warts|"Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.~Common warts, plantar warts, and condyloma acuminata"
10186607|NCT03734003|Active Comparator|Liquid nitrogen cryotherapy for cutaneous warts|Liquid nitrogen crytotherapy at days 1, 15, 30.
10186608|NCT03733964|Experimental|Manual therapy|A group of 50 people using manual therapy as a treatment method.
10186609|NCT03733964|Experimental|PNF|A group of 50 people using PNF (Proprioceptive Neuromuscular Facilitation) as a treatment method.
10186610|NCT03733964|Experimental|Manual therapy + PNF|A group of 50 people using combination therapy - manual therapy and PNF.
10186611|NCT03733964|Experimental|Kinesiotherapy|A group of 50 people using traditional kinesiotherapy (exercises) as a treatment method.
10186612|NCT03733951|Experimental|KN046|
10186613|NCT03733938||teeth with failed root canal treatement|endodontic microsurgery will be performed for teeth with failed root canal treatment
10186614|NCT03733912||Pregnancy|Infertile women undergoing in vitro fertilization cycle got pregnancy successfully. The pregnancy persisted over 12 weeks.
10186615|NCT03733912||Non-pregnancy|Infertile women undergoing in vitro fertilization cycle failed to reach pregnancy.
10186616|NCT03733886|Active Comparator|Burst SCS|"In the active comparator the burst SCS system will be turned on according to randomisation.~A treatment period is a 2-week period where the patient receives either active treatment or sham. Each patient will go through 6 treatment periods (in total 12 weeks). A treatment cycle is a 4-week period with two treatment periods, one of active treatment and one of sham. Each patient will go through three treatment cycles."
10186617|NCT03733886|Sham Comparator|Sham|In the sham comparator the burst SCS system will be turned off according to randomisation.
10186618|NCT03733873|Experimental|desmopressin plus Suoquan|Drug1. name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months Drug2 name:Suoquan mixture form:liquid dosage:10ml/time frequence:bid duration:3 months
10186619|NCT03733873|Active Comparator|desmopressin|name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months
10186620|NCT03733860|Active Comparator|Cavernous sparing group|
10186621|NCT03733860|Other|Conventional technique group|
10186622|NCT03733834||SD therapy|SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
10186623|NCT03733834||NSD therapy|Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
10186624|NCT03733821||CUD patients on HF-rTMS treatment|Patients fulfilling the Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM 5) criteria for Cocaine Use Disorder undergoing a High Frequency rTMS protocol stimulating over the left dorsolateral prefrontal cortex (DLPFC).
10166417|NCT03932617||fluid responders|
9671552|NCT05046925||24-hour PACU group|closely monitor in post-anesthetic unit (PACU) and the stay time is less than 24 hours, then patients can be discharged to floor
9827710|NCT02465463|No Intervention|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
10166418|NCT03932617||fluid non responders|
10166419|NCT03932513|Experimental|Treatment A: inarigivir soproxil|Inarigivir 400 mg once per day for 6 weeks (2800mg/week).
10166420|NCT03932513|Experimental|Treatment B: inarigivir soproxil|Inarigivir 400 mg three times per week for 6 weeks (1200mg/week).
10166421|NCT03932747|Placebo Comparator|Placebo Creams|Measuring the skin before the application of the cream without urea (placebo), wait 3 hours and re-measure the hydration
10166422|NCT03932747|Active Comparator|Urea 5%|Measuring the skin before the application of the cream with urea (5%), wait 3 hours and re-measure the hydration
10166423|NCT03932747|Active Comparator|Urea 20%|Measuring the skin before the application of the cream with urea (20%), wait 3 hours and re-measure the hydration
10166424|NCT03932695|Active Comparator|High dose Milk peptides|2800mg of whey protein hydrolysates single dose
10166425|NCT03932695|Active Comparator|Low dose Milk peptides|1400mg of whey protein hydrolysate Single dose and 6 weeks intervention
10166426|NCT03932695|Placebo Comparator|Placebo|maltodextrin
10166427|NCT03932734||survey|
9827711|NCT02465489|Experimental|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
10166428|NCT03932591|Experimental|intervention|Inhibitory kinesio taping method will be used for intervention group. Y shaped, 34-40 cm length, 5 cm width, skin color kinesio tape will be applied on spastic gastrocsoleus muscle. The base of Y shaped tape will be strapped on calcaneus ( no stretch for first 5 cm) and the both legs of Y shaped tape will be strapped on gastrocnemius muscle medial and lateral head with 15% stretch.
10166429|NCT03932591|Sham Comparator|Control|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be applied on achilles tendon without stretch.
10166430|NCT03932721|Active Comparator|Evolocumabe|Patients with T2DM treated with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure) AND evolocumab (anti-PCsk9).
10166431|NCT03932721|No Intervention|Control|Patients with T2DM treated exclusive with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure).
10166432|NCT03932292|Active Comparator|Ectoin Mouth Wash|30 patients obtaining EML03 treatment
10166433|NCT03932292|Active Comparator|Supersaturated solution of calcium and phosphate ions|20 patients taking standard treatment (calcium phosphate mouth wash)
10166434|NCT03932604|No Intervention|Atrial sensing OFF mode|VDD-ICD programmed as atrial sensing Off mode
10166435|NCT03932604|Active Comparator|Atrial sensing ON mode|VDD-ICD programmed as atrial sensing ON mode
10166436|NCT03932149|Experimental|Experimental Group|Real stimulation
10166437|NCT03932149|Sham Comparator|Control Group|Sham stimulation
10166438|NCT03932396||Single group of subjects who fulfill the inclusion criteria|All the population condemned to a non-custodial sentence that is presented in the Service of Management of Penalties and Alternative Measures of the Center of Social Insertion (CIS) José Hierro CP Dueso during the study period (March 2019 and March 2021) , with ages between 18 and 79 years (approximately 1000 people / year) and willing to participate (signs the IC).
10166439|NCT03932409|Experimental|Pembrolizumab + Radiation Therapy + Pembrolizumab/Chemotherapy|Pembrolizumab given 7 days prior to radiation therapy (e.g., vaginal cuff brachytherapy) followed by three cycles pembrolizumab combined with Carboplatin/Paclitaxel chemotherapy
10166440|NCT03932526|Active Comparator|Vinorelbine + placebo group|92 enrolled patients will be assigned to receive oral vinorelbine plus placebo until disease progression or other criteria for administration termination.
10166441|NCT03932526|Experimental|Vinorelbine + Apatinib group|92 enrolled patients will be assigned to receive oral patatinib mesylate in combination with vinorelbine until disease progression or other criteria for administration termination.
10166442|NCT03932305|Placebo Comparator|Control|Patients taking inactive placebo tablets
10166443|NCT03932305|Experimental|Lutein|Patients taking lutein supplement
10166444|NCT03932253|Experimental|FCN-159|Preset 6 dose groups during the dose-escalation phase, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, and 6 mg, orally, continuous once a day for 21 days, followed by a 7-day break, 28 days is a cycle.
10166445|NCT03932214|Experimental|Infrared illumination group|The nurse uses the Accuvein® device to identify the veins before puncture.
10166446|NCT03932214|No Intervention|Control group|The nurse proceeds as usual (visual identification in the light of the room and palpation)
10166447|NCT03932422||Controlled Hypertensive Patients (CHP)|Hypertensive patients that have blood pressure less than 140 x 90 mmHg. This parameter must be evaluated by ambulatory blood pressure monitoring
10166448|NCT03932422||Resistant Hypertensive Patients (RHP)|Hypertensive patients that have blood pressure more than 140 x 90 mmHg and they use three antihypertensive medicines; or hypertensive patients that have blood pressure less than 140 x 90 mmHg, but they use four or more antihypertensive medicines. This parameter must be evaluated by ambulatory blood pressure monitoring.
10166449|NCT03932279||Stage IA-IIA cutaneous T cell lymphoma|
10166450|NCT03932279||Stage IIB and above cutaneous T cell lymphoma|
10166451|NCT03932279||CD30+ lymphoproliferative disorders|
10166452|NCT03932279||Plaque psoriasis with BSA>5% on routine phototherapy|
10166453|NCT03932279||Moderate to severe atopic dermatitis on routine bleach bath|
10166454|NCT03932279||Healthy controls|
10166455|NCT03932227|Other|Cardioskin-Holter|Subjects in the randomized group A, start by wear the Cardioskin during 24h, and after wear the Holter during 24h.
10166456|NCT03932227|Other|Holter-Cardioskin|Subjects in the randomized group B, start by wear the Holter during 24h, and after wear the Cardioskin during 24h.
10166457|NCT03932370||f-URS|
10166458|NCT03932370||mini-PCNL|
10166459|NCT03932084|Experimental|Control group|"During hospitalization:~Monitor subjects' blood glucose;~One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
10166460|NCT03932084|Experimental|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c<7% and LAGE<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
10166461|NCT03932383|Experimental|Modified CPAP|Single arm cohort study of modified mask
10166462|NCT03932669|Experimental|Nilotinib group|Patients with SCA and taking nilotinib treatment
10166463|NCT03932058||osteosarcoma|
10166464|NCT03932058||chondrosarcoma|
10166465|NCT03932058||enchondroma|
10166466|NCT03932188||Control|Individuals between 13-25 years old that do not meet criteria for any prodromal syndrome, any current or past psychotic disorder, or Cluster A personality disorder diagnosis
10166467|NCT03932188||Prodromal/Early psychosis|Individuals between 13-25 years old that meet diagnostic criteria for a prodromal syndrome or early psychosis
10166468|NCT03932344||SJIA patients on Kineret treatment|SJIA patients on Kineret treatment enrolled in the Pharmachild JIA registry
10166469|NCT03932175|Experimental|Intervention group|The multicomponent intervention will comprise three aspects on-top of usual care: i) Motivational interview to assess patient's adherence profile and to raise the compromise with the behaviour change towards NIV, physical activity and nutritional habits; ii) Bi-directional interaction between the study participants and clinical staff delivered by the MyPathway app, where specific clinical problems regarding NIV will be addressed as they arise; and iii) Motivational messages and educational material delivered via the MyPathway app regarding changes in physical activity and/or nutritional habits. As part of the behavioural intervention, goal setting for NIV adherence and life-style changes will be introduced to the MyPathway app in order for the participants to follow the advice.
10166470|NCT03932175|No Intervention|Control group|Patients will receive usual care according to guidelines on management of chronically ventilated patients, without any mHealth tool or behavioural intervention
10166471|NCT03932006|Experimental|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
10166472|NCT03932006|Experimental|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
10166473|NCT03932006|Active Comparator|Imrecoxib|Imrecoxib 0.1g twice a day,orally
10166474|NCT03931993|Placebo Comparator|Treatment Group 1|Six 1.0mL placebo injections (2% w/v L-tyrosine)
10166475|NCT03931993|Experimental|Treatment Group 2|Six 1.0mL injections of Grass MATA MPL 900, 2700, 8000, 8000, 8000, and 8000 SU
10166476|NCT03932266|Experimental|Experimental group|Drug: Endostar Drug: Cisplatin Drug: Docetaxel Radiation
10166477|NCT03932266|Other|Control group|Drug: Cisplatin Drug: Docetaxel Radiation
10166478|NCT03931915|Experimental|TAK-385|TAK-385 40 mg administered orally once daily before breakfast + Leuprorelin placebo administered subcutaneously once every 4 weeks
10166479|NCT03931915|Active Comparator|Leuprorelin acetate|TAK-385 placebo administered orally once daily before breakfast + Leuprorelin acetate 1.88 mg / 3.75 mg administered subcutaneously once every 4 weeks
10166480|NCT03932071|Experimental|experimental group|
10166481|NCT03932071|No Intervention|control group|
10166482|NCT03932110|Other|psoriasis vulgaris,|patients who have only psoriasis vulgaris
10166483|NCT03932110|Other|psoriatic arthritis|patients who have psoriatic arthritis
10166484|NCT03932110|Other|healthy control|healthy people
10166485|NCT03932097|Experimental|Parenting Now|Preventive Parenting Now digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
10166486|NCT03932097|Active Comparator|Active Control Materials|SAMHSA alcohol prevention materials for parents
10166487|NCT03931759|Active Comparator|Diabetes mellitus|patients with diabetes mellitus
10166488|NCT03931759|No Intervention|non-Diabetes mellitus|patients without diabetes mellitus
10166489|NCT03931733|Active Comparator|Music Therapy Intervention|Receiving one thirty minute music therapy intervention.
10166490|NCT03931733|No Intervention|Usual Care|Receiving usual care for a patient in the ICU during a 30 minute intervention.
10166491|NCT03931629|Active Comparator|CONVENTIONAL PHACO|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
10166492|NCT03931629|Active Comparator|FEMTOSECONDLASER (FLACS)|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
9671553|NCT05046925||24-hour ICU group|closely monitor in intensive care unit (ICU) and the stay time is less than 24 hours, even patients die within 24 hours in ICU
10166493|NCT03932019|Experimental|High dose group|Jitongning tablet,3tablets,bid,po
10166494|NCT03932019|Experimental|Low dose group|Jitongning tablet,2tablets,bid,po Jitongning tablet placebo,1tablet,bid,po
10166495|NCT03932019|Placebo Comparator|Placebo Comparator controlled group|Placebo Comparator: Jitongning tablet placebo,3tablets,bid,po
10166496|NCT03931707||Sick Neonatal Cohort, Sequencing|Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
10166497|NCT03931798|Experimental|Treatment|Healthy participants were administered the Visual Scanning Test
10166498|NCT03931772|Other|Automated Self-Hypnosis Intervention|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health. Participants will be provided the Amazon Alexa device to take home (necessary for using the program). After the lab visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they feel the urge to smoke). Furthermore, participants will be taking an at-home 15 minute survey at baseline, and then 1, 3, 6, 12 and 24 month follow-ups.
10166499|NCT03931668|Experimental|0.125mg single dose|single dose of TPN-672 0.125mg, 2 subjects
10166500|NCT03931668|Experimental|0.25mg single dose|single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)
10166501|NCT03931668|Experimental|0.5mg single dose|single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)
9826479|NCT02419807|Experimental|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
10166502|NCT03931668|Experimental|1mg single dose|single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)
10166503|NCT03931668|Experimental|2mg single dose|single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)
10166504|NCT03931668|Experimental|3mg single dose|single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)
10166505|NCT03931668|Experimental|4mg single dose|single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)
10166506|NCT03931616|Experimental|STEMO deployment|STEMOs are specialized stroke ambulances providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
10166507|NCT03931616|Active Comparator|Regular care|Regular prehospital care consists of normal ambulance care. In suspected life-threatening cases, an emergency physician is sent to the emergency scene in parallel.
10166508|NCT03932045|Experimental|SYB Filler (SF-01)|
10166509|NCT03932045|Active Comparator|Ellansé M|
10166510|NCT03931720|Experimental|anti-tumor response of BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|Patients with relapsed and refractory cancer of ROBO1 expression will be treated with BiCAR-NK/T cells (ROBO1 CAR-NK/T cells).
10166511|NCT03931863|Active Comparator|Group A|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
10166512|NCT03931863|Active Comparator|Group B|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
10166513|NCT03931863|Placebo Comparator|Group C|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
10166514|NCT03931850|Experimental|Dual guidance (ultrasound and neurostimulation)|This arm : patients will be received pudendal nerve block by dual guidance technique ( ultrasound and neurostimulation)
9826480|NCT02419924|Experimental|Experimental|Pelvic floor support device to treat refractory constipation.
10166515|NCT03931850|Active Comparator|ultrasound-guided only|This arm : patients will be received pudendal nerve block by ultrasound-guided only.
9826481|NCT02419937|Active Comparator|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
9826482|NCT02419937|Placebo Comparator|Placebo|Blinded subjects will be randomized to placebo
9827712|NCT02465489|Experimental|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
10166516|NCT03931538|Active Comparator|Culture Only|Physician receives only culture result
10166517|NCT03931538|Active Comparator|Guidance 4.0 PCR test only|Physician receives Guidance report only
10166518|NCT03931538|Active Comparator|Culture and Guidance 4.0 PCR test Group|Physician receives both results, gets Culture report immediately before Guidance
10166519|NCT03931538|Active Comparator|Guidance 4.0 PCR test and culture group|Physician receives both results, gets Guidance report immediately before culture
10166520|NCT03931967||MR-proADM|
10166521|NCT03931811|Experimental|Short wave diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.~SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device). Both groups took injections in the beginning of the therapy, 3rd week and 6th week, a total of 3 times. SWD or sham SWD therapy was given right after the injections, also for a total of 3 times."
10186625|NCT03733808|Active Comparator|Active rTMS treatment|Active High frequency rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. The stimulation protocol parameters will be set as follow: frequency of 15 Hz, of 100% of resting motor threshold (rMT), 40 trains, 60 pulses per train, 15 s intertrain-interval, 2400 pulses per session.
10166522|NCT03931811|Sham Comparator|Sham diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.~Sham SWD group took 20 minutes of SWD therapy with device not working(Enraf-Nonius, Curapuls 970 Short wave diathermy device)."
10166523|NCT03931928|No Intervention|Control group (Group 1)|All patients receive Placebo
10166524|NCT03931928|Experimental|Group 2|"Patients will receive (Z)-endoxifen dosed according to CYP2D6 genotype"
10166525|NCT03931928|Experimental|Group 3|Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening
10166526|NCT03931876|Placebo Comparator|Placebo|placebo
10166527|NCT03931876|Active Comparator|Active|AV-006
10166528|NCT03931824|Experimental|PRP group|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times."
10166529|NCT03931824|Sham Comparator|Placebo group|Injections containing saline were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used. To provide blindness, all injections were done using injectors coated with non transparent tape. All of the PRP injections were done by the same physician each time, with compliance to preventive measures against complications such as infections. Patients and the physician who applied the injection were blinded to the groups, and the solution was prepared by another researcher who was not blind to the groups.
10166530|NCT03931889|Active Comparator|Vitamin D3|Cholecalciferol 80,000 IU (2 capsules of 40,000 IU) per oral per week for consecutive 26 weeks.
10166531|NCT03931889|Placebo Comparator|Vitamin D3 placebo|Placebo (2 capsules) per oral per week for consecutive 26 weeks.
10166532|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 75 mmHg|Before skin incision
10166533|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 100 mmHg|Before skin incision
10166534|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 150 mmHg|Before skin incision
9671554|NCT05046691|Experimental|Intervention group|8-week .b Foundations course
10166535|NCT03931395|Experimental|Honey Plus Standard of Care|The Honey standard of care group will receive treatment as usual, alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic, plus 1 tsp of honey with every dose of acetaminophen. The Honey standard of care group will receive the first dose of honey in the recovery room with the administration of acetaminophen and will be provided with honey upon discharge.
10166536|NCT03931395|Active Comparator|Standard of Care|The standard of care group will receive treatment as usual (alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
10166537|NCT03931421|Experimental|experiment group|In this arm, patients are treated with B Cell Maturation Antigen (BMCA)-targeted CAR-T cells and the safety and efficacy will be observed.
10166538|NCT03931694||All patients with chronic pain follow in pain clinic|
10166539|NCT03931434|Active Comparator|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
10166540|NCT03931434|Placebo Comparator|Placebo|The Placebo does not contain any Aged Garlic Extract (AGE)
10166541|NCT03931343|Experimental|Thoracolumbar interfascial plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
10166542|NCT03931343|Active Comparator|Erectro spinae plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
10166543|NCT03931382|Experimental|Virtual Reality|In this arm, participants will receive 45 minutes of preparation using a simulated virtual reality experience designed in collaboration with Medical Imaging and Child Life Specialists.
10166544|NCT03931382|Active Comparator|Mock MRI|In this arm, participants will receive 45 minutes of preparation using the standard of care simulator, conducted by a Child Life Specialist
10166545|NCT03931382|Active Comparator|Booklet|In this arm, participants will receive 45 minutes of preparation using the standard of care MRI Preparation Booklet for non-sedated MRIs.
10166546|NCT03931564|Active Comparator|PRESERFLO Microshunt (formerly InnFocus Microshunt (IMS))|The intervention group will undergo PRESERFLO (formerly InnFocus) Microshunt implantation (IMS).
10166547|NCT03931564|Active Comparator|Trabeculectomy|The usual care/control group will undergo a standard trabeculectomy.
10166548|NCT03931499||Study cohort|Patients undergoing surgery under cardiopulmonary bypass
10166549|NCT03931512|Experimental|transcranial direct current stimulation|"20 minutes of transcranial direct current stimulation~1 mA on bi-hemispheric colocation with cathode on the left M1 and anode on the right M1"
10166550|NCT03931512|Sham Comparator|sham transcrial direct current stimulation|20 minutes positioning the electrodes on the scalp. Whith an initial increasing of the current intensity by 10 seconds, until 1mA and a ramp down from 20 seconds to reach zero.
10166551|NCT03931239|Experimental|Vaccination|DTPw-HB-Hib vaccine
10166552|NCT03931226||Departmental cohort|Department level of the Haute-Garonne through the use of the 'POMME' cohort (PrescriptiOns Medicines Mother Children)
10166553|NCT03931226||National cohort|"National level through the use of the EGB database (General Sample of Beneficiaries)"
10166554|NCT03931577|Experimental|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the use of C-reactive protein rapid testing.
9827713|NCT02465489|Experimental|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
10166555|NCT03931577|Experimental|Enhancement of communication skills|Continuous (on-site and monthly online training) illness-focused intervention with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
10166556|NCT03931577|Experimental|C-reactive protein + communication skills|Continuous (workshop and monthly web-based training) disease-focused intervention with C-reactive protein rapid testing and on-site and continuous (monthly online training illness-focused intervention) with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
10166557|NCT03931577|No Intervention|Usual care|Usual care.
10166558|NCT03931447|Experimental|Cohort 1: JNJ-72537634 Dose 1 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a single day (SD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1.
10166559|NCT03931447|Experimental|Cohort 2: JNJ-72537634 Dose 2 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a SD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1.
10166560|NCT03931447|Experimental|Cohort 3: JNJ-72537634 Dose 1 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a multiple day (MD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1 for 14 consecutive days.
10166561|NCT03931447|Experimental|Cohort 4: JNJ-72537634 Dose 2 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a MD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1 for 14 consecutive days.
10166562|NCT03931473|Experimental|Interceptor G2|Chlorfenapyr/alpha-cypermethrin
10166563|NCT03931473|Experimental|Royal Guard|Pyriproxyfen/alpha-cypermethrin
10166564|NCT03931473|Active Comparator|Interceptor|Alpha-cypermethrin
10166565|NCT03931317|Other|Latanoprostene bunod 0.024% QD|4 weeks of Latanoprostene bunod 0.024% QD, then a 2 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
10166566|NCT03931317|Other|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 2 Week washout, followed by 4 weeks of Latanoprostene bunod 0.024% QD
10166567|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
10166568|NCT03931525|Active Comparator|Radiofrequency Therapy without drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
10166569|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 15 days|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
10166570|NCT03931525|Active Comparator|Radiofrequency therapy without drug delivery 15 days|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
10166571|NCT03931135|Active Comparator|Dexamethasone|
10166572|NCT03931135|Active Comparator|Cyclizine|
10166573|NCT03931590|Experimental|Healthy Male Subjects|Single oral dose of 150 mg of [14C] omaveloxolone containing approximately 90 μCi as a capsule after an overnight fast of at least 10 hours.
10166574|NCT03931304||Cases group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
10166575|NCT03931304||Control group|Cytoreductive surgery alone
10166576|NCT03931018|Experimental|70 grams alcohol|"Males and Females: Alcohol 70 grams (220 ml Vodka Absolut®), single dose, oral administration~- 70 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
10166577|NCT03931018|Experimental|100 grams alcohol|"Males: Alcohol 100 grams (312 ml Vodka Absolut®), single dose, oral administration~- 100 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
10166578|NCT03931005|Experimental|Decision-Support|An electronic copy of a collaboration decision-support guide.
10166579|NCT03931005|Active Comparator|General Support|An electronic copy of general collaboration supports (a list of collaborative implementation strategies and their definitions)
10166580|NCT03931031||Cardiac Surgery Patients|Patients taking antiplatelet medication who are scheduled for elective cardiac surgery.
10166581|NCT03930901|Other|Intervention|Children in this group were examined for intestinal parasites and then treated accordingly. Then, health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), & nail clipper).
10166582|NCT03930901|No Intervention|Control|Children in this group were examined for intestinal parasites and then treated accordingly. They were follow up for 6 months.
10166583|NCT03931122|No Intervention|Group A - Weight Based Method|"Body Weight Based method: This is the conventional method for LMA size selection. The patient will be weighed and LMA size corresponding to their weight will be used as follows.~(LMA Size - 1 for up to 5 kg of body weight) (LMA Size - 1.5 for 5 to 10 kg of body weight) (LMA Size - 2 for 10 to 20 kg of body weight) (LMA Size - 2.5 for 20 to 30 kg of body weight) (LMA Size - 3 for 30 to 50 kg of body weight)"
10166584|NCT03931122|Experimental|Group B - Ear Size Based Method|"Ear Size Based method: External ear size will be measured by using a paper ruler and will be recorded in cm as follows:~Vertical length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W )~Based on these ear measurements, nearest smaller LMA size will be selected."
10166585|NCT03930927|Experimental|Self Assembling peptide|intervention
10166586|NCT03930927|Experimental|Fluoride|Comparator
10166587|NCT03930940|Experimental|RIC group|RIC treatment and regular treatment.
10166588|NCT03930940|Other|Control group|Regular treatment alone.
10166589|NCT03931096||children with congenital heart disease|Groupe 1: case: children with congenital heart disease aged 5 to 7 years.
10166590|NCT03931096||control children|Groupe 2: control children recruited in schools aged 5 to 7 years.
10166591|NCT03931044|Experimental|Image-Guided Robotic Gastrectomy|"The day before surgery, the ICG will be injected endoscopically into the submucosa of the four quadrants around the tumor (1.25mg/mL, 0.6mL x 4).~A modified total D2 gastrectomy - including the following lymph node stations: 1 - 7 + 8a, 9, 11p, 12a - will be performed in each patient.~The lymph node dissection will be performed using the Da Vinci Xi robotic system and the assistance of the near infrared technology to detect ICG fluorescence.~Even the resulting fluorescent lymph nodes outside the standard dissection plane will be retrieved. The lymph node stations will be sent to the pathologist in different containers and further subdivided according to fluorescence."
10166592|NCT03931044|No Intervention|Robotic Gastrectomy|Data from patients undergoing the same surgery without the ICG imaging procedure will be collected during the same study period.
10166593|NCT03930888||Patients with nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients nutritionally supported by nutritional supplements.
10166594|NCT03930888||Patients without nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients without special nutritional supplements.
10166595|NCT03930992|Experimental|1 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
10166596|NCT03930992|Active Comparator|2 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
10166597|NCT03930992|Experimental|3 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
10166598|NCT03930992|Active Comparator|4 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
10166599|NCT03931148|Experimental|Intervention|"After first consultation for diagnosis of neurodegenerative disorder :~Geriatric Assessment with specific neuropsychologic tests of decision making~fRMI~EEG High Resolution~Qualitative interview"
10166600|NCT03931369|Experimental|Tolvaptan test|15 MG pill administered tolvatan once, one day
10166601|NCT03930875||Control - No Obstructive Sleep Apnea with Aspirin|"The control group consist of patients with a negative diagnosis of OSA (based on a negative home sleep apnea test (REI) < 5 and attended sleep study, AHI < 5; or attended NPSG with an AHI < 5) and the patient is taking aspirin at a dose of 81 mg/day for at least a week prior to inclusion.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
10166602|NCT03930875||Arm 1- Obstructive Sleep Apnea with CPAP therapy and Aspirin|"Arm 1 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old, CPAP has been started within the last 2 years, and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
10166603|NCT03930875||Arm 2 -Obstructive Sleep Apnea with no CPAP & Aspirin|"Arm 2 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
10166604|NCT03930810||FIC1-deficiency and Bsep-deficiency|
10166605|NCT03930797|Experimental|Intimacy Enhancement|Participants attend four sessions (60-75 minutes) consisting of education and skills training to enhance physical and emotional intimacy.
10166606|NCT03930797|Active Comparator|Living Healthy Together|Participants attend four sessions (60-75 minutes) consisting of information and support across a range of breast cancer-related topics.
10166607|NCT03930758|Experimental|Uphill exercise before the meals|40 minutes of uphill treadmill exercise at +6o slope completed 1 hour before eating the meal
10166608|NCT03930758|Experimental|Uphill exercise after the meals|40 minutes of uphill treadmill exercise at +6o slope started 1 hour after eating the meal
10166609|NCT03930758|Experimental|Downhill exercise before the meals|40 minutes of downhill treadmill exercise at -6o slope completed 1 hour before eating the meal
10166610|NCT03930758|Experimental|Downhill exercise after the meals|40 minutes of downhill treadmill exercise at -6o slope started 1 hour after eating the meal
10166611|NCT03930758|Sham Comparator|Sedentary trial|A trial with no exercise
10166612|NCT03930823|Other|Interview|One to one interviews with older people from Turkish origin in Belgium
10166613|NCT03930654|Experimental|iPrEP Intervention|"iPrEP Intervention:~Women will receive the iPrEP intervention on an iPAD Air tablet device~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~iPrEP uses qualitative themes~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~Scales were modified (in some cases) for cultural competency and tailoring to women"
10166614|NCT03930654|Active Comparator|Usual Care|"Control Intervention:~Women will receive usual care~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~Social worker will offer a list of substance abuse treatment referral agencies"
10186626|NCT03733808|Sham Comparator|Sham rTMS treatment|Sham rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same procedures of active High frequency rTMS will be used.
10186627|NCT03733795||Control|'Healthy babies' to establish 'normal' blood flow in neonates.
10186628|NCT03733795||ECMO|Children undergoing extracorporeal membrane oxygenation for acute respiratory failure.
10186629|NCT03733795||Conventional|Neonates undergoing conventional treatment for acute respiratory failure.
10166615|NCT03930667|Active Comparator|clips|Closure of the appendix stump with hem-o-lok clips
10166616|NCT03930667|Experimental|knotting|Closure of the appendix stump with intracorporal knotting.
10166617|NCT03930693|Experimental|Normotensive pregnant women|Normotensive pregnant women
10166618|NCT03930693|Experimental|Hypertensive pregnant women|Hypertensive pregnant women
10166619|NCT03930693|Experimental|Normotensive non-pregnant women|Normotensive non-pregnant women
10166620|NCT03930693|Experimental|Hypertensive non-pregnant women|Hypertensive non-pregnant women
10166621|NCT03931161|Placebo Comparator|Placebo|Matching Placebo.
10166622|NCT03931161|Active Comparator|Evolocumab|Evolocumab Auto-Injector [Repatha]
10166623|NCT03930914|Other|Active Treatment to Sham|Subjects randomized to the sequence Active Treatment/Sham Treatment arm will be instructed to first use the Parasym (TM) TENS device as active treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as sham treatment for the second phase of the study.
10166624|NCT03930914|Other|Sham to Active Treatment|Subjects randomized to the sequence Sham Treatment/Active Treatment arm will be instructed to use the Parasym (TM) TENS device as sham treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as active treatment for the second phase of the study.
10166625|NCT03931278|Other|persons with Multiple Sclerosis (MS)|
10166626|NCT03931278|Other|Healthy controls|
10166627|NCT03930836|Active Comparator|control group|high/low dosage intervention, intensive or not (motor function rehabilitation)
10166628|NCT03930836|Experimental|interface group|high/low dosage intensive intervention using the interactive interface (motor function rehabilitation)
9520292|NCT03278990|Experimental|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
10166629|NCT03930706|Experimental|Group A|Group A will include all the patient that will start with progesterone ((P), Utrogestan®) supplementation after 7 days of E2 (Progynova®) intake and that will perform the FET (after 13 days of E2 and 6 days of P).
10166630|NCT03930706|Active Comparator|Group B|Group B will include the patients that will perform 14 days of E2 intake (Progynova®, 6 mg per day (2 mg every 8 hours) those patients will be asked to perform a supplementary blood test and ultrasound on day 14 of E2 intake, afterwards, they will start with P supplementation (Utrogestan®, 800 mg per day, 400 mg every 12 hours) from day 15 of E2 for 6 days and they will get their FET day 20 of the cycle (after 14 days of E2 and 6 days of P)
10166631|NCT03930589|Placebo Comparator|Standard of care|no intervention will occur in the standard of care arm
10166632|NCT03930589|Active Comparator|Remote Ischemic Conditioning|Remote ischemic conditioning using BP cuff on left arm
10166633|NCT03930862|Active Comparator|ball and socket|It is an attachment retaining implant overdentures to increase retention and stability of the denture
10166634|NCT03930862|Experimental|Locator attachment|attachment retaining implant overdentures
10166635|NCT03931083||Portable magnification device (Gynocular™)|The Gynocular™ examination will be performed following the steps involved in colposcopy as described in the IARC colposcopy manual. These steps include: visualization of the vagina, vulva and cervix following insertion of a speculum, magnified assessment after application of normal saline, examination of cervical vessel patterns using the red-free mode (or green filter), application of 5% acetic acid for 1 minute and finally assessment following application with Lugol's iodine. The findings of the live examination will be documented using the parameters of the Swede score. Each parameter is scored between zero and two. Treatment will be based on the results found at histopathology, unless the woman is also VIA positive in which case, after biopsy she will undergo routine treatment as per local guidelines. The results will be used to determine the optimal threshold for treatment in WLHIV.
10166636|NCT03931083||Testing for high risk HPV (HRHPV)|To reduce the number of examinations undergone by the study participant during the same day, HRHPV testing will be carried out at the time of the first gynecological examination by the VIA nurse (see next arm). Using specific single-use cervical cytobrush provided by GeneXpert, a specimen will be collected immediately prior to VIA examination. Cervical cytobrush specimens will be placed into ThinPrep PreservCyt (Cepheid, Sunnyvale, CA) immediately after collection. The HR-HPV testing of cervical specimens will be conducted by a GeneXpert™ machine (Cepheid, Sunnyvale, CA), which will be placed at the health facility and will be operated by a trained nurse in accordance with the manufacturer's instructions. Additionally, as part of the baseline clinical characteristics of the study participant, the study participant will undergo an STI test at the same time. The sample will be collected and tested using the same GeneXpertTM platform.
10166637|NCT03931083||Visual inspection with acetic acid (VIA)|VIA, which is standard of care for cervical cancer screening in Zambia, will be carried out using the methodology described by IARC. This is summarized as follows: visualization of the vagina, vulva and cervix following insertion of a speculum; assessment with the naked eye after application of normal saline; and further assessment after application of 5% acetic acid for 1 minute. This will be recorded as normal or abnormal by the assessor.
10166638|NCT03931083||Histopathological examination of tissue biopsies|All acetowhite lesions will be biopsied. When no lesion is seen, one biopsy is taken from each quadrant at the squamocolumnar junction. Biopsies will be sent and examined in a South African based lab. All histological slides will also be verified independently by an IARC trained pathologist at the end of the study. Histological endpoints are defined by the CIN classification system: CIN 1 affects only the lower third of the epithelium (mild dysplasia), CIN 2 involves two thirds of the epithelium and CIN 3 involves the full thickness (severe dysplasia and carcinoma in situ). These findings can be dichotomized by the Lower Anogenital Squamous Terminology into low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). All patients with CIN grade 2 that stained diffusely positive for p16 are considered as HSIL, all patients with CIN 3 are considered as HSIL. Expression of p16 will be visually assessed by immunohistochemistry.
10166639|NCT03930524|No Intervention|Assessment Only|Control
10166640|NCT03930524|Experimental|Early-college Universal|Prior to beginning their first semester of college, incoming students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
10166641|NCT03930524|Experimental|Early-college No Coach (automated email)|Students from the early-college universal arm, who flag on one of the self monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
10166642|NCT03930524|Experimental|Early-college Coach|Students from the early-college universal arm, who flag on one of the self monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
10166643|NCT03930524|Experimental|Later-college Universal|After beginning their first semester of college, students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
10166644|NCT03930524|Experimental|Later-college No Coach (automated email)|Students from the later-college universal arm, who flag on one of the self monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
10166645|NCT03930524|Experimental|Later-college Coach|Students from the later-college universal arm, who flag on one of the self monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
10166646|NCT03930303|Active Comparator|Multimedia Arm|
10166647|NCT03930303|No Intervention|Control|
10166648|NCT03930719||PSD|Patients fulfilling DSM-5 criteria of PSD within 7 days of admission.
10166649|NCT03930719||No PSD|Patients NOT fulfilling DSM-5 criteria of PSD within 7 days of admission.
10166650|NCT03930459|Experimental|Static cold storage (SCS)|Traditional method of organ preservation which involves flushing of cold preservation solution following complete dissection and interruption of blood supply to the donor organ. Although cold preservation slows metabolism by 10- to 12-fold, substantial anaerobic activity continues even at ice temperature. This lead to the generation of reactive oxygen species that are the basis of ischaemia-reperfusion injury, when the organ is re-exposed to oxygenated blood at the time of transplantation. This damage, exacerbated by any prior injury, limits the maximum safe preservation time of the donor organ.
10166651|NCT03930459|Experimental|Normothermic machine perfusion (NMP)|The main goal of NMP is to optimize graft preservation by mimicking physiological conditions. The perfused organ is supplied with nutrients and oxygen to maintain metabolic hemostasis. Under these conditions, ATP and glycogen reserves can be maintained or actively restored. At the same time, toxic products from the cellular milieu are continuously eliminated, so the cell-mediated injury phase of reperfusion injury can be minimized. Thus, ischemic injury is avoided and the activation of cell death cascades is prevented. This allows both hepatocellular and biliary protection.
10166652|NCT03930433|Active Comparator|Nebivolol group|Oral Nebivolol 5mg / day (2 weeks) -> 10mg / day (10 weeks)
10166653|NCT03930433|Placebo Comparator|Diltiazem group|Oral Diltiazem 90mg / day (2 weeks) -> 180mg / day (10 weeks)
10166654|NCT03930433|Placebo Comparator|Nebivolol+Diltiazem group|Oral Nebivolol 2.5mg / day + Oral Diltiazem 45mg / day (2 weeks) -> Oral Nebivolol 5mg / day + Oral Diltiazem 90mg / day (10 weeks)
10166655|NCT03930407||Hayman group|Who had undergone cesarean section within the last 6 months and received a The Hayman uterine compression suture for uterine atony.
10166656|NCT03930407||Control|Who had undergone cesarean section within the last 6 months and did not experience neither any complication nor any additional intervention
10166657|NCT03930511|No Intervention|PADL at the beginning of PR|First assessment of patients starting Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
10166658|NCT03930511|Experimental|PADL at discharge of PR|Assessment of patients at discharge of Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
10166659|NCT03930511|No Intervention|PADL at 6 months follow-up|Half-a-year reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
10166660|NCT03930511|No Intervention|PADL at 1 year follow-up|Yearly reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
10166661|NCT03930784||Participants|Divided for analysis as having suffered post-operative complications or not
10166662|NCT03930563|Experimental|Beetroot Juice Low|Subjects will consume beetroot juice containing 250mg inorganic nitrate and 20mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
9520293|NCT03278990|Sham Comparator|Control|In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
9520294|NCT03278977|Other|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
10166663|NCT03930563|Experimental|Beetroot Juice High|Subjects will consume beetroot juice containing 500mg inorganic nitrate and 40mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
10166664|NCT03930563|Active Comparator|Beetroot Juice Placebo|Subjects will consume beetroot juice devoid of inorganic nitrate and nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
10166665|NCT03930537|Active Comparator|Hip replacement with cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of cemented femoral component of hip prothesis.
10166666|NCT03930537|Active Comparator|Hip replacement with non-cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of non-cemented femoral component of hip prothesis.
10166667|NCT03930550|Experimental|Infrared guidance first|"In this arm the infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is without the infrared light"
10166668|NCT03930550|Active Comparator|Infrared guidance last|"In this arm NO infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is with the infrared light as guide"
10166669|NCT03930290||Pregnant patients|Pregnant patients in their 2nd trimester.
10166670|NCT03930225|Experimental|study group|"In the study group, both patients and their family members will be required to attend a weekly 1 hour long psycho-educational sessions. Moreover assessment sessions will be attended also.~The stigma directed intervention program"
10166671|NCT03930225|Other|control group|"In the control group, only Patients will attend the psycho-educational sessions.~Family members and patients will be required to attend the assessment sessions."
10166672|NCT03930368|Experimental|Intervened arm|as in a single-arm before-and after study, the only one arm will receive intervention of low GI diet with supplementation of RCS.
9520295|NCT03278977|Other|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
10166673|NCT03930238|Experimental|VA MapTrek|Veterans in the intervention group receive a Fitbit and access to VA MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required to enroll). Each week, Veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. Throughout each race, participants will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
10166674|NCT03930238|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to VA MapTrek or simply by giving the Veterans a Fitbit.
10166675|NCT03930329|Experimental|MBRP group|The mindfulness-based relapse prevention program consists of eight weekly 2-hour sessions. It combines mindfulness with evidence-based cognitive behavioural techniques that help participants to recognize internal and external triggers of their substance abuse, including smoking. Each session consists of mindful practices with cognitive exercises. The standardized treatment manual was published
10166676|NCT03930329|No Intervention|usual care|All participants in this trial will receive usual care, which consists of 8-12 weeks of counselling and drug treatment to help smokers quit. Data from the centre shows that approximately 50% of smokers are successfully abstinent from smoking at end of the program, as confirmed by the carbon monoxide breath test. This trial will only recruit those who successfully quitted smoking. During this 8-12 week program, written information about relapse prevention is given, including information for maintaining healthy lifestyles (e.g. diet/sleep/exercise/emotional control). Participants will receive follow-up phone interviews by trained smoking cessation counsellors at end of the program (week 8-12)
10166677|NCT03930251|No Intervention|Treatment as Usual|This is the standard coordinated specialty care treatment (without cognitive remediation) that is provided to OnTrackNY clients. This treatment involves psychiatric treatment, employment and educational support, substance abuse treatment, family education and support, CBT-informed individual psychotherapy, and cognitive health support services as needed.
10166678|NCT03930251|Experimental|Clinic-Based Cognitive Remediation|Clinic-based cognitive remediation consists of twice weekly group-based and clinician-led sessions.
10166679|NCT03930251|Experimental|Partial-Remote Cognitive Remediation|Partial-Remote cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
10166680|NCT03930472|Experimental|Voucher intervention F&V|Receiving $20 in vouchers at each of up to 4 markets ($80 total) that are good for F&V only
10166681|NCT03930472|Experimental|Voucher intervention SNAP|Receiving $20 vouchers at each of up to 4 markets that are good for any foods that SNAP/EBT benefits can be used for
10166682|NCT03930472|No Intervention|Waitlist control|Delayed intervention/waitlist control (who, at the final data gathering, will receive 5 x $20 in vouchers good at the WFfT 2019 and 2020 markets).
10166683|NCT03930173|Experimental|18F-fluciclovine PET/CT of the brain|"Arm includes participants with a known diagnosis of brain metastases who have undergone prior intracranial SRS and whose MRI brain scan is equivocal for radiation necrosis versus tumor progression.~Participants will undergo 18F-fluciclovine PET/CT of the brain. Qualitative and quantitative metrics will be documented at the time of image acquisition. Qualitative image assessment will be performed independently by 3 separate physicians."
10166684|NCT03930355||Transfused|Patients who received blood transfusion in the perioperative period
10166685|NCT03930355||Non transfused|Patients who did not receive blood transfusion in the perioperative period
10166686|NCT03930160||Mortality outcome|
10166687|NCT03930108||Mortality outcome|
10166688|NCT03930095|Experimental|Acceptance-Based Behavior Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
10166689|NCT03930095|Active Comparator|Non-directive Supportive Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
10166690|NCT03929965|Experimental|advanced solid tumors with FGFR alteration|
10166691|NCT03929770|Active Comparator|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
10166692|NCT03929770|Experimental|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
10166693|NCT03929783|Experimental|Diagnostic (CEM)|Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day.
10166694|NCT03930069|Active Comparator|misoprostol group|20 cases received 400 microgram prostaglandin E1 analogue, misoprostol, (Misotac®, 200 microgram, by SIGMA pharmaceutical industries, Alexandria, Egypt), intra-vaginally, 2 hr before operation.
10166695|NCT03930069|Active Comparator|vasopressin group|20 patients who had hysteroscopic guided intralesional vasopressin injection before hysteroscopic myomectomy
10166696|NCT03929809||Adult Single-sided deafness|Adult subjects with unilateral single-sided deafness at least 6 months (to ensure stability of hearing loss), but no greater than 10 years will be implanted with a MED-EL Synchrony Cochlear Implant.
10166697|NCT03930212|Experimental|Progesterone|received rectal progesterone suppositories 400 mg once daily
10166698|NCT03930212|Placebo Comparator|Control group|received placebo suppositories rectally once daily.
10166699|NCT03929952|Experimental|Chronic low back pain|
10166700|NCT03929939|Experimental|Lifestyle Modification Group|
10166701|NCT03929939|No Intervention|Control Group|
10166702|NCT03929848||female|female patient who is scheduled for laryngomicrosurgery
10166703|NCT03929848||male|male patient who is scheduled for laryngomicrosurgery
10166704|NCT03929861|Experimental|Fluconazole, period 1|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours
10166705|NCT03929861|Experimental|Fluconazole, period 2|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours
10166706|NCT03930043||Health Control|
10166707|NCT03930043||Non-gastrointestinal Lymphoma|
10166708|NCT03930043||Gastric Lymphoma|
10166709|NCT03930043||Intestinal Lymphoma|
10166710|NCT03929835|Experimental|Avidekel Oil|The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
10166711|NCT03929835|Placebo Comparator|Placebo|Patients in the control group will receive placebo oil containing olive oil and Chlorophyll.
10166712|NCT03930056|Experimental|C-Brace II Group|Subjects will be assigned a C-Brace II orthotic for use.
10166713|NCT03930056|Active Comparator|Traditional Group|Subjects will continue with their own KAFO (non C-Brace II) use.
10166714|NCT03930134|Experimental|sparse uterine suture|women who had a french ambulatory casarean section including a sparse uterine closure
10166715|NCT03930134|Active Comparator|one layer uterine closure|women who had a misgav ladach caesarean section section, including a one layer classical uterine closure
10166716|NCT03929991||Case|"All women admitted or already hospitalized with suspected or confirmed infection after C/S will be screened for inclusion in the study as a case. Case confirmation will be clinically established by an infectious disease expert.SSI post C/S will be classified as:~Superficial incisional surgical site infection,~Deep incisional surgical site infection,~Organ/space surgical site infection."
10166717|NCT03929991||Control|For each case, 3 patients undergoing the C/S on the same day and admitted to the same ward but not presenting Surgical Site Infection
10166718|NCT03929887||KORNERSTONE|"Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy (IgAN)~Participants enrolled in KORNERSTONE with a biopsy proven GN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
10166719|NCT03930147|Experimental|Passive phase, Pressure-Control Ventilation / ASV order|90 minutes of Pressure-Control Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Control Ventilation mode at the end of the intervention.
10166720|NCT03930147|Experimental|Passive phase, ASV / Pressure-Control Ventilation order|90 minutes of ASV, change to Pressure-Control Ventilation mode with 15 to 30 minutes of washout, 90 minutes of Pressure-Control Ventilation.
10166721|NCT03930147|Experimental|Active phase, Pressure-Support / ASV order|90 minutes of Pressure-Support Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Support Ventilation at the end of the intervention.
10166722|NCT03930147|Experimental|Active phase, ASV / Pressure-Support order|90 minutes of ASV, change to Pressure-Support Ventilation with 15 to 30 minutes of washout, 90 minutes of Pressure-Support Ventilation.
10166723|NCT03929926|Active Comparator|Group 1 (usual care)|receive usual care
10166724|NCT03929926|Experimental|Group II (outreach contact)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Eligible and interested patients receive an office visit at the JLCSP for shared decision-making and possible lung cancer screening.
10166725|NCT03929926|Experimental|Group III (outreach + Decision Counseling Program)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Patients then undergo a decision counseling session through a semi-structured Decision Counseling Program that includes a review of the mailed educational materials and completion of an interactive exercise intended to clarify personal preference related to screening options (to have LDCT or not to have LDCT). Patients interested in screening schedule an office visit at JLCSP for possible screening or are referred to their primary care physician for consultation.
10166726|NCT03929432|Active Comparator|Active tDCS (with Speech-Language Treatment)|tDCS Stimulation Dose: 1.5 mA for 20-mins
10166727|NCT03929432|Sham Comparator|Sham tDCS (with Speech-Language Treatment)|No tDCS stimulation
10166728|NCT03929731||Polypoidal Choroidal Vasculopathy RCT|Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T&E studies
10166729|NCT03929445|Active Comparator|AIR-Q group|the group which selected randomly to try AIR-Q device
10166730|NCT03929445|Active Comparator|I-LMA group|the group which selected randomly to try I-LMA device
10166731|NCT03929523|Experimental|HOPE group|hypothermic oxygenated perfusion
10166732|NCT03929523|Active Comparator|Control group|classic static cold storage
10166733|NCT03929419|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
10166734|NCT03929419|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
10166735|NCT03929562|Active Comparator|Brief advice|One brief advice session, resource brochure, standard of care, and an infographic about alcohol and surgical health at patient's pre-existing pre-operative clinical visit.
10166736|NCT03929562|Experimental|Health coaching|Two health coaching sessions, resource brochure, standard of care
10166737|NCT03929497|Experimental|Lu AF11167|
10166738|NCT03929640|Placebo Comparator|Ibuprofen and placebo|Oral administration of ibuprofen 600 mg tablet and placebo tablet every 6 hours
10166739|NCT03929640|Active Comparator|Ibuprofen and acetaminophen|Oral administration of ibuprofen 600 mg tablet and acetaminophen 650 mg tablet every 6 hours
10166740|NCT03929744|Experimental|LY3502970 (Part A)|Single dose of LY3502970 administered orally.
10166741|NCT03929744|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally.
10166742|NCT03929744|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
10166743|NCT03929744|Placebo Comparator|Placebo (Part B)|Multiple doses of placebo administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
10166744|NCT03929744|Experimental|LY3502970 (Part C)|Single dose of LY3502970 administered orally in each of two study periods.
10166745|NCT03929744|Experimental|LY3502970 (Part D)|Single dose of LY3502970 administered orally.
10166746|NCT03929744|Placebo Comparator|Placebo (Part D)|Single dose of placebo administered orally.
9827714|NCT02465489|Active Comparator|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
10166747|NCT03929744|Experimental|LY3502970 Formulation 1 (Part E)|Multiple doses of LY3502970 - formulation 1 administered orally.
10166748|NCT03929744|Experimental|LY3502970 Formulation 2 (Part E)|Multiple doses of LY3502970 - formulation 2 administered orally.
10166749|NCT03929653||Advanced Refractory Solid Tumors|Patients with advanced refractory solid tumors receive personalized therapy with the guidance of Molecular Tumor Board after the NGS(next generation sequencing).
10166750|NCT03929484|Experimental|Group A|Each patient will receive oxygen for 1 hour using a novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the standard nasal cannula alone (Period 2).
10166751|NCT03929484|Experimental|Group B|Each patient will receive oxygen for 1 hour using a standard nasal cannula alone (Period 1), followed by a 1-hour period of continued use of the novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 2).
10166752|NCT03929575|Placebo Comparator|Placebo of calcium|Participants will consume 250 mg of calcium
10166753|NCT03929575|Experimental|Rhodiola|Participants will consume 250 mg of Rhodiola
10166754|NCT03929575|Experimental|Rhodiola and Cordyceps|Participants will consume a combination of 250 mg of Rhodiola and 225 mg of Cordyceps
10166755|NCT03929510|Experimental|Period A|Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).
10166756|NCT03929510|Experimental|Period B|Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).
10166757|NCT03929666|Experimental|ZW25 + FP|ZW25 plus fluorouracil (5-FU) and cisplatin
9827715|NCT02465489|Active Comparator|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
10166758|NCT03929666|Experimental|ZW25 + mFOLFOX6|ZW25 plus 5-FU, leucovorin, and oxaliplatin
10166759|NCT03929666|Experimental|ZW25 + XELOX|ZW25 plus capecitabine and oxaliplatin
10166760|NCT03929666|Experimental|ZW25 + mFOLFOX6 with bevacizumab|ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab
10166761|NCT03929666|Experimental|ZW25 + CisGem|ZW25 plus cisplatin and gemcitabine
10166762|NCT03929406|Experimental|Brain Tissue Imprint|Evaluation and validation of the samples collected during the brain tissue imprint procedure using a CE marked Medical Device in patients presenting one of the following five disorders: Parkinson's disease (PD), essential tremor (ET), dystonia (DYS), Obsessive compulsive disorder (OCD) and Tourette Syndrome (TS).
10166763|NCT03929692|Other|Intervention Group|Intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects.
10166764|NCT03929692|Other|Control Group|Adolescents of same age as intervention group at follow-up examination that did not participate in health promotion program.
10166765|NCT03929276|Experimental|high-intensity laser therapy & exercises|High-intensity laser therapy application with iLux Laser device + exercise program
10166766|NCT03929276|Placebo Comparator|Shame laser & exercises|Sham high-intensity laser therapy application with iLux Laser device + exercise program
10166767|NCT03929276|Active Comparator|control - exercises only group|exercise program
10166768|NCT03929055|Active Comparator|venturi mask|oxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92%
10166769|NCT03929055|Active Comparator|HFNC|HFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min
10166770|NCT03929055|Active Comparator|CPAP|Helmet CPAP is set to obtain the same esophageal pressure variation during HFNC step
9827716|NCT02465515|Experimental|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
9827717|NCT02465515|Placebo Comparator|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
10166771|NCT03929224|Active Comparator|Bacitracin|Standard care: BAHA abutment incision is coated in bacitracin. A healing cap is placed over the abutment and left for a week. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment to the area for 2 weeks.
10166772|NCT03929224|Experimental|Medicinal honey and bacitracin|Standard care + MediHoney: Medi-Honey will be applied to the abutment site immediately after surgery in addition to the bacitracin. The healing cap will be placed on the BAHA site. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment and MediHoney daily to the area for 2 weeks.
10166773|NCT03929263|Experimental|Real-time fMRI neurofeedback|All participants will receive neurofeedback from the target region (no sham condition).
10166774|NCT03929354|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend the 12-week intensive lifestyle programme which includes healthy lifestyle change such as smoking cessation, healthy food choices and increasing physical activity levels, as well as management of cholesterol, diabetes, and blood pressure.~The 12-week programme will consist of 12 sessions of 2.5 hours each per week.~Each of the weekly sessions will incorporate an individualised meeting between the multidisciplinary healthcare team and each patient to review the progress and health goals.~The weekly sessions will also include a one-hour group exercise programme and an educational workshop."
10166775|NCT03929354|Active Comparator|Standard Care|Standard care is defined as giving information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
10166776|NCT03929107|Experimental|Intervention group|In this group, patients will be treated with Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T, and the safety and efficacy will be evaluated.
10166777|NCT03928990|Experimental|Experimental arm|
10166778|NCT03929094|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
10166779|NCT03929380|Experimental|10x10 squat protocol|
10166780|NCT03929380|Experimental|As Fast As Possible 100 squat protocol|
10166781|NCT03929185||Tumor affected|Patients affected by colorectal cancer who underwent to surgical resection in Sant'Anna Hospital in Cona (Ferrara)
10166782|NCT03929185||Control|Healthy people aged 20-35 years old without risk factors for colorectal cancers who voluntarily participated to the study
10166783|NCT03929328|No Intervention|Spontaneous breathing trial with T-piece|Patients were randomized to undergo a spontaneous breathing trial with T-piece that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
10166784|NCT03929328|Experimental|Spontaneous breathing trial with high flow oxygen therapy|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
10166785|NCT03929302|No Intervention|Brain Energy Metabolism and Sleep on cognition|In the phase-1 of the study, the investigator will be investigating the basic science of the relationship of sleep abnormalities, genes, brain energy metabolites variables with cognitive performance in three cohorts: cognitively normal adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
10166786|NCT03929302|Experimental|Dental Intervention to improve sleep and cognition|To investigate if MyTAP oral airway management with mouth shield will improve sleep and cognition in three cohorts: cognitively healthy adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
10166787|NCT03929159||Group A (biospecimen collection)|Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
10166788|NCT03929159||Group B (biospecimen collection)|Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
10166789|NCT03929146|Experimental|Liposomal Bupivacaine|Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
10166790|NCT03929146|Other|Interscalene Nerve Block|Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
10166791|NCT03929211|Experimental|CPI-613 and hydroxychloroquine|The initial phase of the study will be a dose escalation of hydroxychloroquine from 600 mg to 1,200 mg orally flat dose given 2 hours before the CPI-613 infusion on days 1-5 of every 28 days. CPI-dose will be 2,000 mg/m² and will not be escalated.
10166792|NCT03929341|Experimental|CCTA first approach with Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test and have Cardiac Link pathway activated for expedited cardiology referral.
10166793|NCT03929341|Experimental|CCTA first approach without Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test, but Cardiac Link pathway will not be activated.
10166794|NCT03929341|Active Comparator|Usual Care with Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, and have Cardiac Link pathway activated for expedited cardiology referral.
10166795|NCT03929341|Active Comparator|Usual Care without Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, but Cardiac Link pathway will not be activated.
10166796|NCT03929016|Experimental|Active DNDI-0690 male 10mg fasting|Single dose 10mg male fasting
10166797|NCT03929016|Placebo Comparator|Placebo male fasting|Single dose placebo male fasting
10166798|NCT03929016|Experimental|Active DNDI-0690 male 30mg fasting|Single dose 30mg male fasting
10166799|NCT03929016|Experimental|Active DNDI-0690 male 150mg fasting|Single dose 150mg male fasting
10166800|NCT03929016|Experimental|Active DNDI-0690 male 400mg fasting|Single dose 400mg male fasting
10166801|NCT03929016|Experimental|Active DNDI-0690 male 1200mg fasting|Single dose 1200mg male fasting
10166802|NCT03929016|Experimental|Active DNDI-0690 male 3600mg fasting|Single dose 3600mg male fasting
10166803|NCT03929016|Placebo Comparator|Placebo male fed|Placebo male fed
10166804|NCT03929016|Experimental|Active DNDI-0690 400mg male fed|Single dose 400mg male fed
10166805|NCT03929016|Placebo Comparator|Placebo female fasting|Placebo female fasting
10166806|NCT03929016|Experimental|Active DNDI-0690 1200mg female fasting|Single dose 1200mg female fasting
9827718|NCT02465528|Experimental|Inflammatory myofibroblastic tumor (IMT)|Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
9520296|NCT03278964|Active Comparator|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
10166807|NCT03929068|Active Comparator|carbidopa-levodopa|Each tablet of carbidopa-levodopa in this study will be equivalent to half of a standard carbidopa-levodopa 25/100mg tablet. Participants will take one tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
10166808|NCT03929068|Placebo Comparator|Placebo|Participants will take one placebo tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
10166809|NCT03928899|No Intervention|old guideline group|"Women randomized to the old guideline group will be followed up once-weekly by electronic fetal heart rate monitoring and biophysical profile until 40 weeks 0 days (unless a medical indication arises), when induction of labor was then offered."
10166810|NCT03928899|Experimental|new procedure group|"Women randomized to new procedure group will first undergo fetal weight ultrasound estimation at 38 weeks 0 days to 38 weeks 6 days of gestation, if the fetus is estimated to be LGA/macrosomia by ultrasound, women should have an elective induction of labor immediately (at 38 weeks 0 days to 38 weeks 6 days of gestation). On the contrary, if the fetus is estimated to be normal size, the pregnant women were then given a cervical assessment. If the Bishop score ≥6, women will have at least weekly follow-up visits with their doctors and unless a medical indication is present, continue pregnancy and have selective induction at 40 weeks 0 days of gestation. Whereas, if the Bishop score <6, women will be followed up until 41 weeks 0 days of gestation with a close assessment of fetal wellbeing through the cardiotocographic trace. And women who will not deliver by this gestational age will be admitted for labor induction. Certainly, medical indication should warrant delivery without delay."
10166811|NCT03929081|Experimental|Inference Based Approach (IBA)|The IBA treatment, a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly. The IBA model is based on the assumption that patients with OCD feel the need to perform compulsive acts because they misjudge the actual state of affairs, for example fearing that an appliance is on when it is visibly off. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the patient's attention from observable reality. IBA teaches patients how to defend themselves against the absorbing and confusing effect of obsessive reasoning processes and how to stay in touch with reality by actively relying on the sensory information of the very moment. As a consequence, the patient realizes that any compulsive act is superfluous and feels able to omit it.
10166812|NCT03929081|Active Comparator|Cognitive Behavior Therapy (CBT)|In the control condition, the patients will receive twenty 45-minutes sessions of CBT consisting of self-guided exposure in vivo with response prevention (ERP) and cognitive therapy (CT), both standardized according to evidence-based session-by-session protocols, containing standardized forms for exercises and homework assignments.
10166813|NCT03929081|No Intervention|No intervention (healthy controls)|The healthy control group will receive no intervention.
10166814|NCT03928977|Other|Confirmed TIA|Confirmed TIA at 3 months with standardized neurological expertise
10166815|NCT03928977|Other|Confirmed non-TIA|Not-confirmed TIA at 3 months with standardized neurological expertise
10166816|NCT03929198|Experimental|Intervention|The intervention group participated in a 6-week Pritikin diet, exercise program, and behavioral modification.
10166817|NCT03929198|No Intervention|Control|This group did not receive any intervention.
10166818|NCT03928938|Experimental|Electronic follow-up|Follow-up of cancer patients treated with immune checkpoint inhibitor therapy using electronic patient reported outcomes-tool
10166819|NCT03928834|Experimental|Adapted Nzira Itsva Intervention|Participants will be attending clinics that provide an enhanced adherence package to the adolescents consisting of viral load (VL) testing using DBS, including the Nzira Itsva(NI) intervention and low-cost genotyping and drug resistance monitoring
10166820|NCT03928834|No Intervention|Standard of Care( SOC)|Participants will be attending clinics that provide the standard of care (SOC) VL testing and management to adolescents
10166821|NCT03928795||neonates with acute acidosis|neonates with Cord blood gases measured immediately after birth inferior to 7.15
10166822|NCT03928795||neonates with a normal ph|neonates with Cord blood gases measured immediately after birth of at least 7.15
10166823|NCT03928756|Experimental|Within-participant randomization|Each day, each available participant will be randomly assigned to receive either: a push notification with tailored intervention content; a push notification with engaging, nontherapeutic content; or no push notification.
10186630|NCT03733782|Active Comparator|Modular enteral protein - Prosource|Subjects are patients admitted to the surgical intensive care unit and identified by one of the investigators as being appropriate for protein supplementation. Guidelines required that patients were: 1. Deemed ready to start enteral nutritional support by the attending physician within 72 hours of admission to the intensive care unit, 2. No contraindications to full enteral support, 3. No history of chronic liver disease, 4. Serum creatinine < 2.0 mg/dl.
9520297|NCT03278964|Experimental|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
9520298|NCT03278951|No Intervention|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
10166824|NCT03928860|Experimental|OMT Session and Doppler Ultrasonography|"OMT Session Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.~Doppler Ultrasonography Femoral artery diameter and flow evaluated by radiologist.~In the evaluation, the wall contour characteristics of the vessel to be examined were evaluated and the diameter was measured. Color doppler examination was performed to determine whether the vessel contained color filling, patency, flow direction and turbulence.~Peak systolic and end diastolic flow rates and flow pattern and flow rate were measured by spectral examination"
10186631|NCT03733782|No Intervention|Control group|The investigators used the electronic medical record to identify control subjects. These were patients admitted to the surgical intensive care unit who were in the ICU long enough to undergo testing of 24 hour urine nitrogen excretion from January to December 2016.8 As part of standard clinical practice, measurement of urine nitrogen excretion is performed in patients who are in the ICU and receiving nutritional support for more than one week.
10186632|NCT03733769|Experimental|TQL group|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
10186633|NCT03733756|Experimental|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
10186634|NCT03733756|Active Comparator|POEM involving longitudinal muscle|participants are operated POEM involving the whole layer of muscle, both circular and longitudinal muscle
10186635|NCT03733743|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
10186636|NCT03733704|Experimental|Healthy volunteers|Healthy volunteers
10186637|NCT03733691|Experimental|Ixazomib Only|The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
10186638|NCT03733691|Experimental|Ixazomib + Lenalidomide|"The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.~The prescribed dose administration of lenalidomide in this study is the same as the dose of the patient's front-line treatment taken in the last treatment cycle unless otherwise clinically indicated per investigator's discretion, taken orally on days 1-28 of a 28-day cycle. If patient was receiving lenalidomide at a higher dose than 10 mg, then the dose of lenalidomide on this study will be adjusted to 10 mg daily on days 1-28 of a 28-day cycle"
10186639|NCT03733678|Experimental|Free SARC, Free LARC, Recommendation|Free SARC, Free LARC, Sequential recommendation
9520299|NCT03278951|Experimental|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
10186640|NCT03733678|Experimental|Free SARC, LARC=500, Recommendation|Free SARC, LARC=500 CFA, Sequential recommendation
10186641|NCT03733678|Experimental|Free SARC, LARC=1000, Recommendation|Free SARC, LARC=1000 CFA, Sequential recommendation
10186642|NCT03733678|Experimental|Free SARC, LARC=2140, Recommendation|Free SARC, LARC=2140 CFA, Sequential recommendation
10186643|NCT03733678|Experimental|Free SARC, LARC=5000, Recommendation|Free SARC, LARC=5000 CFA, Sequential recommendation
10186644|NCT03733678|Experimental|Regular SARC, Free LARC, Recommendation|Regular price SARC, Free LARC, Sequential recommendation
10186645|NCT03733678|Experimental|Regular SARC, LARC=500, Recommendation|Regular price SARC, LARC=500 CFA, Sequential recommendation
9671555|NCT05046691|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
10186646|NCT03733678|Experimental|Regular SARC, LARC=1000, Recommendation|Regular price SARC, LARC=1000 CFA, Sequential recommendation
10186647|NCT03733678|Experimental|Regular SARC, LARC=2140, Recommendation|Regular price SARC, LARC=2140 CFA, Sequential recommendation
10186648|NCT03733678|No Intervention|Regular SARC, LARC=5000, Recommendation|Regular price SARC, LARC=5000 CFA, Sequential recommendation
10186649|NCT03733678|Experimental|Free SARC, Free LARC, No Recommendation|Free SARC, Free LARC, Simultaneous recommendation
10186650|NCT03733678|Experimental|Free SARC, LARC=500, No Recommendation|Free SARC, LARC=500 CFA, Simultaneous recommendation
10186651|NCT03733678|Experimental|Free SARC, LARC=1000, No Recommendation|Free SARC, LARC=1000 CFA, Simultaneous recommendation
10186652|NCT03733678|Experimental|Free SARC, LARC=2140, No Recommendation|Free SARC, LARC=2140 CFA, Simultaneous recommendation
10186653|NCT03733678|Experimental|Free SARC, LARC=5000, No Recommendation|Free SARC, LARC=5000 CFA, Simultaneous recommendation
10186654|NCT03733678|Experimental|Regular SARC, Free LARC, No Recommendation|Regular Price SARC, Free LARC, Simultaneous recommendation
10186655|NCT03733678|Experimental|Regular SARC, LARC=500, No Recommendation|Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
10186656|NCT03733678|Experimental|Regular SARC, LARC=1000, No Recommendation|Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
9520300|NCT03278951|Experimental|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
9520301|NCT03278938|Active Comparator|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
9671556|NCT05046678||Control|Periodontally healthy, non-smoking
9671557|NCT05046678||Smokers with periodontally healthy|Periodontally healthy, smoking
10186657|NCT03733678|Experimental|Regular SARC, LARC=2140, No Recommendation|Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
10186658|NCT03733678|Experimental|Regular SARC, LARC=5000, No Recommendation|Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
10166825|NCT03928717|Experimental|Text-Based Adherence Game|Participants in the experimental condition will receive the Text Based Adherence Game. They will receive semi-automated text messages sent by study staff throughout the trial period.
10166826|NCT03928717|Active Comparator|Standard of Care (SOC)|SOC participants will receive the Standard of Care Intervention which includes receiving a brief adherence counseling session and access to clinic resources, including counseling services, throughout the trial period.
10166827|NCT03928925|Active Comparator|BOUGIE|"For patients randomized to use of a bougie, the operator will use a bougie on the first attempt at intubation. If successful, an assistant will load an endotracheal tube over the bougie, and the operator (without removing the laryngoscope from the mouth) will guide the tube through the vocal cords to the desired depth in the trachea.~If the bougie is not successfully placed in the trachea or the endotracheal tube cannot be successfully advanced over the bougie on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
10166828|NCT03928925|Active Comparator|Endotracheal Tube with Stylet|"For patients randomized to use of an endotracheal tube with stylet, the operator will use an endotracheal tube containing a removeable, malleable stylet, on the first attempt at intubation.~Manipulation of the shape/curve of the endotracheal tube with stylet is at the discretion of the operator, however a straight-to-cuff shape and a bend angle of 25° to 35° is encouraged. The stylet will be left in place until the tube is advanced to the trachea.~If the endotracheal tube with stylet is not successfully placed in the trachea on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
10166829|NCT03929003|Experimental|Contingent|Participants in this arm will be required to meet CO goals in order to earn game-based rewards.
10166830|NCT03929003|Active Comparator|Non-contingent|Participants in this arm will submit CO verifications but will earn game-based rewards independent of meeting CO goals.
10166831|NCT03928626|Active Comparator|CRAVING REGULATION|"In the CRAVING REGULATION condition, participants will first read a brief essay about the adverse consequences of drinking alcohol. Then, participants may complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will be trained to use the information to inform the strategy they will use in the regulation of craving training (ROC-T). A single trial in the regulation of craving training will have two possible instructions: (a) STRATEGY: implement the strategy (bring to mind the negative facts from the essay) and (b) LOOK: to merely observe the image and allow natural responses to come. Participants will follow the instructions; followed by an alcohol-related picture, a brief delay, and will then rate their craving. Participants will then be instructed to use this strategy in daily life situations when they might drink."
10166832|NCT03928626|Placebo Comparator|CONTROL (NO REGULATION)|In the CONTROL condition, participants will first read a brief essay about a non-alcohol-related topic (e.g., color perception). Then, participants will complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will view images of objects that are unrelated to alcohol. Furthermore, participants in the control condition will not practice any strategy in the regulation of craving task (ROC-T). That is, in the CONTROL condition, participants would merely observe the image and allow natural responses to come (i.e., LOOK instruction) and rate how colorful is each item (this controls for task time and experiment setting).
10166833|NCT03929172|Experimental|AAVLP-HPV Vaccine Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
10166834|NCT03929172|Placebo Comparator|Placebo Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
10166835|NCT03928886|Experimental|Senographe Pristina patient-assisted compression model|Senographe Pristina is a commercial mammography medical device consisting of the Senographe Pristina FFDM system (2D) and Senographe Pristina DBT option (3D). Senographe Pristina includes the hardware and software components required for multi-modality functioning and is designed to improve patient experience, patient throughput, and radiographer experience. The system offers two compression modes - standard mode and the optional patient-assisted compression. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
10166836|NCT03928886|Active Comparator|Senographe Pristina standard compression mode (usual care)|Senographe Pristina standard mode
10166837|NCT03928873|Experimental|Low energy ESWT|"Low energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks)"
10166838|NCT03928873|Experimental|High energy ESWT|"High energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks)"
10166839|NCT03928873|Sham Comparator|Sham treatment|All participants will receive sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks.
10166840|NCT03928496|Experimental|Abobotulinumtoxina|300 units of abobotulinumtoxinA was reconstituted with 2.4 ml of 0.9% preservative free sterile saline so that each 0.1 ml contained 12.5 units of Abobotulinumtoxina 0.1 ml were injected into 31 sites of the head and neck
10166841|NCT03928496|Placebo Comparator|Placebo|0.9% preservative free sterile saline. 0.1 ml were injected into 31 sites of the head and neck
10166842|NCT03928444|Experimental|stem cells|one side of the face to be treated with intradermal stem cells
10166843|NCT03928444|Placebo Comparator|control|one side of face treated with intradermal saline
10166844|NCT03928951||Patients suffering from urinary infection|Patients consulting in one of Toulon - La Seyne sur Mer hospital emergency departments because of urinary infection
10166845|NCT03928548||Low Risk Malnutrition|Participants who are determined to be at low risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
10166846|NCT03928548||High Risk Malnutrition|Participants who are determined to be at high risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
10166847|NCT03928483|Experimental|Modified WW Food program|Participants will be assigned to a SmartPoints budget and number and types of ZeroPoint foods.
10166848|NCT03928691||Study group|pregnant women admitted to Women's Health Hospital , Assiut university during 2019-2020 will be counseled to participate in the study
10166849|NCT03928561|Experimental|1 - Active air cleaner then Placebo|Exposure to cat allergen in the presence of active air cleaners then placebo. 3-week wash-out period between the two exposures.
10166850|NCT03928561|Experimental|2 - Placebo then active air cleaner|Exposure to cat allergen in the presence of placebo then active air cleaners. 3-week wash-out period between the two exposures.
10166851|NCT03928340|Active Comparator|combined metformin and insulin|
10166852|NCT03928340|Other|Insulin only|
10166853|NCT03928353|Experimental|1: 18 g PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
10166854|NCT03928353|Experimental|2: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
10166855|NCT03928353|Experimental|3: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
10166856|NCT03928353|Experimental|4: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
10166857|NCT03928353|Experimental|5: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
10166858|NCT03928366|Experimental|Volunteers recibing propofol and remifentanil|Volunteers receive propofol to the loss of consciousness. Then they receive remifentanil during 12 min (pain stimuli in their finger also)
10166859|NCT03928249|Active Comparator|Grupo A|Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks
10166860|NCT03928249|Placebo Comparator|GRUPO B|group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks
10166861|NCT03928171|Experimental|Intra-abdominal pressure of 8 mmHg|The laparoscopy insufflator is set to a pressure of 8 mmHg
10166862|NCT03928171|Experimental|Intra-abdominal pressure of 12 mmHg|The laparoscopy insufflator is set to a pressure of 12 mmHg
9827719|NCT02465528|Experimental|Anaplastic large cell lymphoma (ALCL)|Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
9520302|NCT03278938|Active Comparator|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
10166863|NCT03928171|Experimental|Intra-abdominal pressure of 16 mmHg|The laparoscopy insufflator is set to a pressure of 16 mmHg
10166864|NCT03928145|Experimental|Chlorthalidone 25 mg + amiloride 20 mg|Chlorthalidone 25 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
10166865|NCT03928145|Active Comparator|Chlorthalidone 25 mg + amiloride 10 mg|Chlorthalidone 25 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
10166866|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 20 mg|Hydrochlorothiazide 50 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
10166867|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 10 mg|Hydrochlorothiazide 50 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
10166868|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 1|Benralizumab single dose administration subcutaneously
10166869|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 2|Benralizumab single dose administration subcutaneously
10166870|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 3|Benralizumab single dose administration subcutaneously
10166871|NCT03928275|Experimental|Intralesional IL-2 Treatment|CMM patients will received 4 treatments of intralesional Interleukin-2 two weeks apart over an eight week period.
10166872|NCT03928275|Experimental|Combination therapy: Intralesional IL-2 and BCG Treatment|CMM patients will receive 4 treatments of combination therapy intralesional Interleukin-2 and Bacillus Calmette Guerin two weeks apart over an eight week period.
10166873|NCT03928288|Experimental|Intervention|Cabergoline 0.5 mg PO twice weekly for 6 months
10166874|NCT03928288|Placebo Comparator|Placebo|Placebo capsule PO twice weekly for 6 months
10166875|NCT03928392|Experimental|SCUBA Dive with OT|Two SCUBA dives in conjunction with occupational therapy intervention. The occupational therapy intervention will take place on the beach or on the boat before/after the SCUBA dive. The intervention will consist of learning 3 different breathing techniques. Participants will also be educated about mindfulness principals. Additionally, participants will complete journaling activities between dives.
9520303|NCT03278860|Experimental|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
10166876|NCT03928392|Active Comparator|SCUBA Dive without OT|The group will engage in two SCUBA dives.
10166877|NCT03928535|Other|High-Flow Nasal Cannula|High-flow oxygen was applied immediately after extubation through specific nasal cannula.
10166878|NCT03928535|Other|Noninvasive Ventilation|Noninvasive Ventilation was applied immediately after extubation.
10166879|NCT03928613|Experimental|Mild Cognitive Impairment|"Clinical dementia rating 0 or 0.5~Diagnosed by physicians as mild cognitive impairment according to the criteria of International Working Group on Mild Cognitive Impairment"
10186659|NCT03733665||Heart failure patients|All patients in NICOR's National Heart Failure Audit will be matched to those in NHS Digital's HES database who have a 4-character primary diagnosis of I50.0-I50.9.
10186660|NCT03733652|No Intervention|Tenofovir|Patents are treated with oral tenofovir 300mg once per day for 48 weeks. Then, tenofovir will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be continued if HBsAg is positive.
9520304|NCT03278860|Experimental|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
9671558|NCT05046678||Non-smokers with gingivitis|Gingivitis, non-smoking
9827720|NCT02465528|Experimental|Glioblastoma (GBM)|Patients with GBM with a translocation involving the ALK gene
10166880|NCT03928405|Experimental|Virtual reality group|The subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT). The virtual reality group was trained with games selected from different categories such as balance and aerobic exercises with Nintendo Wii virtual reality device for 6 weeks, 1 session 30 min, 2 times a week. In the control group, no treatment was performed during this period and routine medical treatments were continued. In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control.
9671559|NCT05046678||Smokers with gingivitis|Gingivitis, smoking
10166881|NCT03928405|No Intervention|Control Group|The sociodemographic characteristics of the subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT).the control group was reevaluated at the end of the 6th week after the initial evaluation. After the study was completed, training was given to the volunteers from the control group.
10166882|NCT03928574||Ultrasound-Guided|Ultrasound-Guided Plane Block
10166883|NCT03928574||Conventional|Conventional Block
10166884|NCT03928301|Active Comparator|Wholetones Intervention|"Wholetones music to help participants sleep. Data collected after listening to the Wholetones music was compared to that collected both at Baseline, and after listening to the other music condition (i.e. Classical music).~Wholetones® 2Sleep is music that is designed to lull the listener into a deep, delta sleep, using frequency-enhanced music and precise tempos. Wholetones® differs from other musical genres in that it employs a proprietary method of tuning and layering the music with a unique frequency underlayment."
10166885|NCT03928301|Active Comparator|Classical Intervention|"Classical music was the additional music condition used to compare to both Baseline data and Wholetones data.~The classical music was selected based on the Mayo Clinic and NIH music recommendations for better sleep. More specifically, the classical music consisted of the following six pieces: Beethoven (i.e., Moonlight Sonata, first movement), Marconi Union (i.e., Weightless), Chopin (i.e., Nocturne No.2, Op.9), Ravel (i.e., Piano Concerto in G major, 2nd movement), and J.S. Bach (i.e., Prelude No.1)."
10166886|NCT03928132|Experimental|CPD Workshop on Depression and Diabetes|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
10166887|NCT03928132|Sham Comparator|CPD Workshop on Depression and Diabetes II|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
10166888|NCT03928197|Other|Healthy Volunteers|
10166889|NCT03928197|Other|Volunteers with Venous Insuficiency|
10166890|NCT03928431|No Intervention|vaginally delivered|A non-randomized reference group of vaginally delivered infants.
10166891|NCT03928431|Active Comparator|CS intervention|"A piece of gauze soaked with saline (0.9%) will be placed in the birth canal 2 hours before the CS by the study midwife, using sterile glows. Before the CS procedure begins, the gauze will be removed from the vagina and then immediately contaminated by a swab carrying maternal fecal microbiota. The swab is contaminated by introducing it 3 cm into the anal canal and by rotating it for 10-20 s.~Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding."
10166892|NCT03928431|Placebo Comparator|CS placebo|See above - the gauze will be exchanged to a clean gauze (soaked with saline). Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding.
10166893|NCT03928379|Experimental|LY3305677|LY3305677 administered SC
10166894|NCT03928379|Placebo Comparator|Placebo|Placebo administered SC
10166895|NCT03928210|Experimental|Digoxin|
10166896|NCT03928470|Experimental|EsoDuo Tab. 20/800mg|EsoDuo Tab. 20/800mg
10166897|NCT03928470|Active Comparator|Nexium Tab. 20mg|Nexium Tab. 20mg
10166898|NCT03927924|Experimental|High-intensity focused ultrasound|
10166899|NCT03927937|Experimental|AUTOTRANSPLANTATION TOOTH|
10166900|NCT03928106|Other|intervention|pharmacist responsible for enrollment will administer the following interventions: identifying the medication discrepancies make the recommendations to correct these discrepancies contact the physician to resolve these discrepancies
10166901|NCT03928106|Other|control|pharmacists will identify medication discrepancies no recommendation will be written by pharmacists to solve these discrepancies
10166902|NCT03927963|Placebo Comparator|propofol|
10166903|NCT03927963|Active Comparator|dexmedetomidine|
10166904|NCT03927976|Experimental|Path2Quit|After assessment eligibility, given consent, information about text messaging will be collected and participants enrolled in the Path2Quit culturally specific text message program and feedback will be collected on their experience.
10186661|NCT03733652|Active Comparator|Interferon alfa|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
9671560|NCT05046678||Non-smokers with periodontitis|Periodontitis, non-smoking
9671561|NCT05046678||Smokers with periodontitis|Periodontitis, smoking
9671562|NCT05046665|Other|Staging cohort|Eligible participants recruited to the staging cohort
9671563|NCT05046665|Other|Metastatic cohort|Eligible participants recruited from the metastatic cohort
9671564|NCT05046626|Experimental|nutritional counseling|Arm with intervention
9827721|NCT02465528|Experimental|Any other ALK-positive tumor|Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
10166905|NCT03927859|Active Comparator|Mailing Letter|Patients assigned to this arm, in which a letter is mailed out will receive 2 pamphlets in the mail. One pamphlet described the teleophthalmology program and the other pamphlet was designed by the Canadian Association of Ophthalmologists and describes what DR is and why screening is important. The letter will also contain contact information about the closest TOP to the area of the PCP practice.
10166906|NCT03927859|Active Comparator|Phone call|"Administrative staff on site of each practice will contact all patients assigned to this arm by a phone call.~The patient will be informed that they are calling from the family health practice that the patient belongs to. The reason for the call will be that the patient has been identified as somebody who is likely overdue for a screening test. Patients will be asked if they have had a screening test done recently, and if not, they will be offered an appointment. Patients that refuse an appointment, will be politely probed for reasons and attempts will be made to provide them with information on potential solutions to these barriers (e.g. patients working 9-5 on weekdays will be informed that they can access TOP on evenings). The call will also be used as an opportunity to inform patients about the importance of screening.Three attempts will be made to reach each patient. Only a single voicemail message will be left, when the possibility is available."
10166907|NCT03927859|Active Comparator|Mail + Phone call|Patients assigned to this arm will first have letters mailed out to them (identical to the ones mailed out in the letter only arm). A week later, the letter will be followed up by a phone call as per the phone only arm. Patients will be asked if they have already booked, and if not, will be provided with information about the program as per the phone call script in the phone only arm.
10166908|NCT03927859|No Intervention|Control|No intervention will be offered to patients in this arm.
10166909|NCT03928041|Other|single prospective study|All subjects who are entered into this trial will receive the EVOS Lumbar Interbody System (EVOS- HA).
10166910|NCT03928119|Experimental|public education and network construction|"Public education was conducted to evaluate the effectiveness on patients delay of ST-Segment Elevation Myocardial Infarction treatment.~Network construction was conducted to evaluate the effectiveness to minimize the medical delay of ST-Segment Elevation Myocardial Infarction treatment."
10166911|NCT03927898|Experimental|SBRT+Toripalimab|Participants received SBRT (BED>80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease.
10166912|NCT03927820||Patients Using Inhalers|Adult patient admitted to Vanderbilt University Medical Center (excluding surgery services) on a long acting inhaler or prescribed a long acting inhaler during admission.
10166913|NCT03927742|Experimental|Shade and application with UV message activated|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging activated
10166914|NCT03927742|Active Comparator|Shade and application without UV messaging|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging not activated
10166915|NCT03928093|Experimental|Pregabalin followed by placebo|The study has a crossover design. Participants in this arm will receive pregabalin during the first study treatment period for ten weeks and placebo during their second ten-week treatment period . The dose will depend on the participant's weight and phase of treatment period. Each treatment period consists of 4 weeks of escalating dose until the desired maximum , 4 weeks of active treatment and 2 weeks of titrating down.
10166916|NCT03928093|Experimental|Placebo followed by Pregabalin|Participants will receive placebo during the first treatment period of the study(10 weeks) followed by 10 weeks of pregabalin treatment . The dose will depend on the participant's weight and phase of the treatment period . Each treatment period consists of 3 phases: 4 weeks of escalating dose until the desired maximum, 4 weeks of active treatment and 2 weeks of titrating down.
10166917|NCT03927807|Experimental|repetitive hourly dose of oral misoprostol|The dose will be 10 microgram oral misoprostol that will be administered hourly up to 12 doses or till onset of regular uterine activity.
10166918|NCT03927807|Experimental|two hourly dose of oral misoprostol|The dose will be 20 microgram oral misoprostol solution that will be administered every 2 hours up to 6 doses or till onset of regular uterine activity.
10166919|NCT03928054|Experimental|"group 1 Kinesio Taping® KT"|Kinesio Taping® KT
10166920|NCT03928054|Experimental|" Kinesio Taping® with therapeutic alliance KT+AT"|Kinesio Taping® with therapeutic alliance
10166921|NCT03927872||cardioembolic stroke|
10166922|NCT03927872||non cardioembolic stroke|
10166923|NCT03928002|Experimental|4DFlow magnetic resonance imagery|2D MRI, essential for diagnosis and monitoring of PAH, with an additional 8 minutes for 4D flow
10166924|NCT03928002|Active Comparator|Cardiac catheterization|cardiac catheterization procedure using the Fick method; gold standard
10166925|NCT03928067|Experimental|TREK Study Abroad Program|On-screen personalized normative feedback (PNF) will contain information on the drinking behavior and attitudes about gender- and country-specific study abroad peers. Participants will view text-based tips and strategies and watch clips of prior student abroad students discussing how they met their cultural engagement goals while abroad (Sojourner Adjustment Feedback or SAF). Content focuses around the four aspects of positive sojourner adjustment (social interaction with host nationals, cultural understanding and participation, language development and use, host culture identification) and the two negative sojourner adjustment factors while abroad (i.e., social interaction with co-nationals, homesickness/feeling out of place). The intervention will also contain text- and video-based tips and strategies for protective strategies used abroad to limit experience of risk sex and sexual violence victimization.
10166926|NCT03928067|No Intervention|Control|"Control participants will receive a link to a general website offering study abroad advice (www.studyabroad.com) and will be asked to spend at least 20 to 30 minutes reviewing their institution's study abroad website content, including policies for drinking abroad. This control condition was selected as a form of treatment as usual as our conversations with study abroad personnel indicate this is the extent of typical information students receive about alcohol use abroad."
10166927|NCT03928015|Experimental|Adjunctive dronabinol|Dronabinol 5mg BID and adjusting within the range of 2.5mg - 10mg BID, as an adjunct to systemic analgesics
9827722|NCT02465567|Experimental|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
10166928|NCT03928015|Active Comparator|Systemic analgesics|Systemic analgesics only
10166929|NCT03928028|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
10166930|NCT03928028|Experimental|FBT w/ Parent-focused Cognitive Remediation Therapy|Family Based Treatment with Parent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of parent focused CRT followed Family Based Treatment over six months.
10166931|NCT03928028|Experimental|FBT w/Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of adolescent focused CRT followed by Family Based Treatment over six months.
10166932|NCT03927833|Active Comparator|Continuous Phototherapy|Continuous phototherapy
10166933|NCT03927833|Experimental|Cycled Phototherapy|Cycled phototherapy at timed intervals, dependent upon total serum bilirum (TSB) levels.
10166934|NCT03927755||Sub-xyphoid|Ultrasound views of the heart obtained using the sub-typhoid approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
10166935|NCT03927755||Para-sternal Long|Ultrasound views of the heart obtained using the parasternal long approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
10166936|NCT03927729|Experimental|Penthrox|Patients with moderate to severe post-traumatic acute pain will be included in the emergency room.
10166937|NCT03927768||200 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
10166938|NCT03927768||50 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
10166939|NCT03927677|Experimental|Cohort|Period 1: LC350189 200mg Day 1~ Day 4 qd, Period 2: Colchicine 0.6 mg Day 8 ~ Day 15 bid, Period 3 : LC350189 200mg (qd) + Colchicine 0.6 mg (bid) Day 16~ 19
10166940|NCT03927365|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
10166941|NCT03927365|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
10166942|NCT03927404|Experimental|Adaptive Vacuum test Prosthesis|The experimental socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
10166943|NCT03927560|Experimental|Robotic Assisted Percutaneous Coronary Intervention|
10166944|NCT03927352|Experimental|SCT630|"Participants received 80 mg SCT630 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg SCT630 until week 48."
9520305|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
9520306|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
9520307|NCT03278834|Experimental|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.~Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
10166945|NCT03927352|Active Comparator|adalimumab-EU source|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to SCT630 until week 48"
10166946|NCT03927456|Experimental|SHR6390 + Fulvestrant|Intervention Drug: SHR6390, Fulvestrant
10166947|NCT03927456|Placebo Comparator|Placebo + Fulvestrant|Intervention Drug: Placebo, Fulvestrant
10166948|NCT03927703|Experimental|SB206 12%|SB206 12% topically once daily
10166949|NCT03927703|Placebo Comparator|Placebo Comparator|Placebo topically once daily
10166950|NCT03927599||Advanced refractory tumor solid tumors patients|Patients with advanced refractory solid tumors carrying TP53 mutations and receive PARP-inhibitors in combination with the VEGFR-inhibitors therapy
10166951|NCT03927586|Experimental|cognitive training (COG group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each cognitive intervention session will last for 90 minutes. The COG group received computerized cognitive based training which include memory, executive function, visuospatial , language and attention trainings.
10166952|NCT03927586|Experimental|physical exercise training (PE group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each physical exercise intervention session will last for 90 minutes. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The PE group received multimodal exercise program which includes aerobic exercise, balance and muscle strength training.
10166953|NCT03927586|Experimental|sequential training (SEQ group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the SEQ group will first undergo physical exercise training for 45 minutes followed by 45 minutes of cognitive-based training. The participants will first perform 10 minutes of warm-up followed by 25 minutes of physical exercise, and end with 10 minutes of cool-down. The exercise intensity will be similar to the PE group. Following the physical exercise, the participants will take part in 45 minutes of cognitive training. The same tasks used in the COG group will be practiced.
10166954|NCT03927586|Experimental|dual-task training (Dual group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the DUAL group will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance. The 90 minutes of training session will be break up into 2 to 3 parts, and the participants can rest as needed.
10166955|NCT03927664||Peritoneal Tuberculosis|Patients diagnosed with peritoneal tuberculosis and who have undergone a computed tomographic examination
10166956|NCT03927573|Experimental|GEM3PSCA|Application of GEM3PSCA, a PSCA targeted bispecific antibody engaging T-cells
10166957|NCT03927482|Experimental|CARES mobile app|Participants in this arm will receive 12 weeks of text messages and use of the smart phone mobile app that provides support for alcohol risk reduction.
10166958|NCT03927482|Active Comparator|Alcohol Education|Those randomized to the control arm will be given access to an online alcohol education intervention; Check Your Drinking (CYD: www.CheckYourDrinking.net). CYD provides normative feedback on the user's drinking habits relative to his/her peers.
10166959|NCT03927469||Hospitalisation group|The patients who were hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
10166960|NCT03927469||Re-hospitalisation group.|The patients who were re-hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
10166961|NCT03927495|Experimental|Concurrent chemoradiotherapy and KN046|Participants in the Arm I will receive chemoradiotherapy and concurrent KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
10166962|NCT03927495|Experimental|chemoradiotherapy and sequential KN046|Participants in the Arm II will receive chemoradiotherapy and sequential KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
10166963|NCT03927508|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
10166964|NCT03927625|Experimental|Cohort 1|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.16 g/min for 60 minutes.
10166965|NCT03927625|Experimental|Cohort 2|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.31 g/min for 60 minutes.
10166966|NCT03927625|Experimental|Cohort 3|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The second cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.63 g/min for 60 minutes.
10166967|NCT03927625|Experimental|Cohort 4|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The third cohort of patients will receive ascorbate-meglumine at a dose administration rate of 1.25 g/min for 60 minutes.
10166968|NCT03927534|Experimental|Experimental|Mindful Eating program is apply face to face 7 sessions of 120 minutes/session. ME is apply in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
10166969|NCT03927534|No Intervention|Control|Treatment As Usual (TAU) in Primary Care (PC) is any kind of treatment administered by the GP to the patient with overweight and obesity. According to nutritional status, overweight or obesity, as well as the presence of co-morbidity, different actions can comprise the treatment offered at a PC level. For individuals presenting with overweight (BMI 25-29.9 kg/m2) but with no co-morbidities, PC teams organise care plans to enable them to achieve a normal BMI range (BMI 18.5-24.9 kg/m2). In case of suicide risk, severe social dysfunction or worsening of symptoms, it is recommended that patients are referred to mental health facilities.
10166970|NCT03927170|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
10166971|NCT03927170|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
10166972|NCT03927547|Experimental|Inclined Sleep|Inclined mattress at 15 degrees
10166973|NCT03927547|No Intervention|Flat Sleep|Plane mattress
10166974|NCT03927339||pre and post excercise group|
10166975|NCT03927391|Active Comparator|reference (normal) dose|Normal dose of enzalutamide (160mg once daily)
10166976|NCT03927391|Experimental|test (reduced) dose|Reduced dose of enzalutamide (120mg once daily)
10166977|NCT03927287||Radical prostatectomy (RP cohort)|Our institutional prostate cancer database was queried for all patients between 2000-2017 who had a biochemical recurrence (BCR) after radical prostatectomy (RP) (Total PSA>=0.2 ng/ml) and had at least one post-BCR free PSA ratio (FPSAR) blood test (RP cohort). FPSAR ascertainments were performed incidentally or reflexively (e.g. PSA in the range of 4-10 ng/ml, as per Institutional policy). If multiple FPSAR tests were performed, only the first FPSAR test was analyzed. otal PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
10166978|NCT03927287||Radiotherapy cohort|Our institutional database was queried or all patients between 2000-2017 who had a rising PSA after radiotherapy (RT) for intermediate- and high-risk prostate cancer, and at least one post-treatment free PSA ratio (FPSAR) blood test (RT cohort). As in the RP cohort, FPSAR was performed either incidentally or reflexively, and the first FPSAR test was used for the analyses. Total PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
10166979|NCT03927287||Biobank surgical cohort|To validate our findings in the two retrospective cohorts (RP and RT), we analyzed a third cohort of prospectively collected biobank specimens of patients who underwent RP and developed biochemical recurrence(Biobank cohort). The retrieved samples were batched and tested for FPSAR levels to determine the results in lower PSA ranges and also to account for intrinsic analyte measurements variability in the retrospective cohorts. For his cohort we used the Roche Elecsys analytical platform, according to the instructions of the manufacturer.
10166980|NCT03927300||Patients without Telemonitoring with ApTelecare Software|
10166981|NCT03927300||Patients with implementation of Telemonitoring with ApTelecare|
10166982|NCT03927196|Experimental|extended statin counseling group|Extended statins counseling. Patients are handed out information leaflets on the correction of risk factors, SMS reminders.
10166983|NCT03927196|No Intervention|convetional statin counseling group|Сounseling on the prevention of cardiovascular diseases and the use of drugs for this purpose
10166984|NCT03927326|Experimental|Local infiltration|Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.
10166985|NCT03927326|Experimental|Transversus abdominis plane block|Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.
10166986|NCT03927183|Other|Person-centred practice|Person-centred care
10166987|NCT03927313|Active Comparator|Standard of care anti-tubercular therapy|Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
10166988|NCT03927313|Experimental|Intensified anti-tubercular therapy|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days)."
10166989|NCT03927313|Experimental|Intensified anti-tubercular therapy plus aspirin|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),~Plus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)"
10166990|NCT03927222|Experimental|DC vaccination with Td preconditioning and GM CSF|This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant GM-CSF on overall survival of newly diagnosed GBM patients who have undergone definitive resection, are unmethylated, and completed standard temozolomide and radiation treatment. All enrolled patients will undergo a leukapheresis for the generation of DCs. Patients will then receive approximately 6 weeks of standard of care radiation therapy (RT) and concurrent TMZ. A single post-RT cycle of dose intensified TMZ (100 mg/m2/day for 21 days) will then be given. On day 23 (± 2 days) of the cycle, patients will receive the first of 3 pp65 DC vaccines every 2 weeks. All patients will receive up to a total of 10 DC vaccines
10166991|NCT03927235|Sham Comparator|the freezing time of 3s|Transbronchial cryobiopsy in the freezing time of 3s
10166992|NCT03927235|Experimental|the freezing time of 4s|Transbronchial cryobiopsy in the freezing time of 4s
10166993|NCT03927235|Experimental|the freezing time of 5s|Transbronchial cryobiopsy in the freezing time of 5s
10166994|NCT03927235|Experimental|the freezing time of 6s|Transbronchial cryobiopsy in the freezing time of 6s
10166995|NCT03926949|Active Comparator|Intervention group|Participants will receive parenteral nutrition (Olimel 7.6% E 1000 ml), infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
10166996|NCT03926949|Other|Control group|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively
10166997|NCT03927053||HIV infected youth who use marijuana only|
10166998|NCT03927053||HIV infected youth who use tobacco only|
10166999|NCT03927053||HIV infected youth who use tobacco and marijuana|
10167000|NCT03927053||HIV infected youth with no substance use|
10167001|NCT03927131|Experimental|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
10167002|NCT03927131|Active Comparator|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
10167003|NCT03927131|Active Comparator|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
10167004|NCT03927131|Experimental|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
10167005|NCT03927131|Experimental|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
10167006|NCT03927131|Experimental|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
10167007|NCT03927248|Experimental|Nivolumab and PAC-1|Patient will be accrued and started on dose 1 level of PAC-1 (500 mg). If no DLT is observed in first cycle of therapy (28 days), dose of PAC-1 will be escalated to 625 mg in second cycle of therapy for the same patient. If patient remains on study and has no dose limiting toxicities, then in third cycle, dose will be escalated to 750 mg and continue in following cycles, if no dose adjustment is needed because of toxicities. Nivolumab will be administered by IV infusion at a dose of 480 mg.
10167008|NCT03927040|Experimental|TEMT Administration|Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.
10167009|NCT03927066|Experimental|Healthy Volunteer|All Volunteers will be studied at rest and during experimental condition (lower body negative pressure)
10167010|NCT03926780|Active Comparator|Warfarin|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin by the regular starting dose with follow up of the INR to target (2-3)
10167011|NCT03926780|Experimental|Rivaroxaban|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban in a dose of 20 mg per day
10167012|NCT03926871|Experimental|Novices|They received ergonomic training after 1-2 days of hiring to do the work in the cutting room, and packaging sectors. They did not have experience in the refrigerator or butchers, so they had the minimum of information about tasks and risks.
10167013|NCT03926871|Experimental|Experienced|They received the same ergonomic training as the newbies, and should have been hired for more than 6 months in the company. In this period they had already acquired patterns of movement and self-protection to accomplish the tasks.
10186662|NCT03733639|Active Comparator|Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm Tisseel® surgeon dispenses the product all over the anastomosis. The rest of the surgical procedure is as usual."
10167014|NCT03926975|Experimental|Experimental: Scleral Lens|One eye will be randomly selected to wear a scleral lens for a 6-hour testing period.
10167015|NCT03926975|Active Comparator|Control: no lens|The contralateral eye will not wear a lens.
9671565|NCT05046951|Active Comparator|Web arm|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
9827723|NCT02465567|Experimental|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
10167016|NCT03926806|Active Comparator|Plain yoghurt|2x200g plain yoghurt/day for 12 weeks
10167017|NCT03926806|Experimental|Vitamin B yoghurt|2x200g yoghurt enriched with vitamins B for 12 weeks
10167018|NCT03926832|Experimental|Patients with Sarcoidosis|Participants with Sarcoidosis. This arm will complete baseline questionnaires assessing daytime sleepiness (Epworth Sleepiness Scale - ESS) and fatigue (Fatigue Assessment Scale - FAS). All participants will perform home polygraphy and will be treated with CPAP for three months if moderate-to-severe OSA has been diagnosed and re-assessed with the same questionnaires along with a complete analysis of CPAP adherence by analyzing the compliance report of the device.
10167019|NCT03926962|Experimental|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
10167020|NCT03926962|Placebo Comparator|Placebo|Visually matching placebo
9827724|NCT02465567|Experimental|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT009)
10167021|NCT03926936|Experimental|Low-grade uterine sarcoma|
10167022|NCT03926936|Experimental|low-grade endometrial carcinoma|
10167023|NCT03926936|Experimental|sex cord stromal tumors|
10167024|NCT03926936|Experimental|low-grade serous ovarian cancer|
10167025|NCT03927014||Preeclampsia|The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
9827725|NCT02465567|Experimental|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT003)
10167026|NCT03927014||Control|The control groups' samples will obtain during the routine obstetrical care examination in the third trimester of pregnancy.
10167027|NCT03926884|Experimental|Tea1 group|"This is the treatment group. This group will be taking 2 grams of the three-seeds mixture twice a day for three weeks."
10167028|NCT03926884|Placebo Comparator|Tea2 group|"This is the control group. This group will be taking 0.02 grams of the three-seeds mixture once a day for three weeks."
10167029|NCT03926663|Experimental|group Bupivacaine|Group B; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) as preincisional local infiltration of the nasal mucosa of the nasal septum ,injected once before surgical intervention
10167030|NCT03926663|Active Comparator|group Bupivacaine +Dexmedetomidine|group B+D; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa of the nasal septum,injected once before surgical intervention.
10167031|NCT03926793|Experimental|Cohort 1|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
10167032|NCT03926793|Experimental|Cohort 2|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
10167033|NCT03926793|Experimental|Open Label Extension|Eligible subjects may participate in the Open Label Extension (OLE) study for a period of 24 weeks.
10167034|NCT03926767|Experimental|Pain Neuroscience Education + orofacial and neck exercises|All participants in this arm will initially receive two additional sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
10167035|NCT03926767|Active Comparator|Orofacial and neck exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
10167036|NCT03926702|Experimental|Radiopharmaceutical administration|All participants receive radiopharmaceutical for positron-emission tomography (PET) study.
10167037|NCT03927092||Multiple Sclerosis patients|Patients that attended an annual patient education seminar at the investigators' university hospital were asked to fill out the Turkish version of the Multiple Sclerosis Knowledge Questionnaire
10167038|NCT03926455|Experimental|Typhax 0.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
10167039|NCT03926455|Experimental|Typhax 2.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
10167040|NCT03926455|Experimental|Typhax 10 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
10167041|NCT03926455|Active Comparator|Typhim Vi 25 mcg|Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
10167042|NCT03926455|Placebo Comparator|Placebo (saline)|Placebo control was administered IM Days 0 and 28 ( n=9)
10167043|NCT03926637||Study Participants|Participants with MS, including CIS will complete the MSPT at their standard of care visits.
10167044|NCT03926754|Active Comparator|Mirabegron|Active treatment arm (mirabegron)
10167045|NCT03926754|Placebo Comparator|Placebo|Placebo
10167046|NCT03926728|Experimental|Cohort A - 85µg CTH522-CAF01|Cohorts A will receive three IM vaccination of 85µg CTH522-CAF01. This cohort is divided into two groups: A1 will receive placebo at DAY 28 + Day 112 + Day 140, while A2 will receives placebo at Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
10167047|NCT03926728|Experimental|Cohort B - 85µg CTH522-CAF01+ TO CTH522|Cohort B will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 + Day 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional doses TO CTH522 (12µg) is administered in each eye. The rationale for this cohort is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results obtained.
10167048|NCT03926728|Experimental|Cohort C - 85µg CTH522-CAF01+ID CTH522|Cohort C will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted CTH522 at Day 28 + Day 12 and TO placebo at Day 140, while C2 will receive the same for Day 28 + Day 112, but TO CTH522 boost at Day 140. The two additional doses of non-adjuvanted CTH522 (24µg) is administered ID. The rationale for this cohort is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results obtained.
10167049|NCT03926728|Experimental|Cohort D - 15µg CTH522-CAF01|Cohort D is the same as cohort A except that the dose for CTH522-CAF01 is 15µg.
10167050|NCT03926728|Experimental|Cohort E - 85µg CTH522-CAF09b|Cohort E is the same as cohort A except that the adjuvant is CAF09b and not CAF01. The rationale for the A, D and E cohorts is to investigate the impact of the CTH522 dose and adjuvant on the immunogenicity results.
10167051|NCT03926728|Placebo Comparator|Cohort F - Placebo|Cohort F will receive only placebo in form of 0.9% NaCl saline.
10167052|NCT03926559|Experimental|Duramorph (Morphine)|2mg of Neuraxial Morphine given through epidural once after the patient has delivered.
10167053|NCT03926559|No Intervention|No intervention|Patient does not get any intervention.
10167054|NCT03926351|Placebo Comparator|Arm 1a; Placebo|Valid for the first 24 weeks of the study. Arm 1a: placebo, soft gelatine capsule containing 1000 mg olive oil, refined.
10167055|NCT03926351|Experimental|Arm 2a; Omega-3 capsules|Valid for the first 24 weeks of the study. Arm 2a; Omega-3, (1000 mg fill weight per capsule) containing omega-3 ethyl ester concentrate with a high proportion of DHA.
9826483|NCT02420015|Experimental|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
9826484|NCT02420015|Active Comparator|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
10167056|NCT03926676|Experimental|Grandio blocks|Nano hybrid composite blocks
10167057|NCT03926676|Active Comparator|E max|ceramic blocks
10167058|NCT03926377|Other|Clobetasol propionate treatment|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
10167059|NCT03926429||Patient with reactive arthritis|
10167060|NCT03926442|Experimental|Active1|Italian Herb in active breakfast meal
10167061|NCT03926442|Experimental|Active2|Cinnamon in active breakfast meal
10167062|NCT03926442|Experimental|Active3|Pumpkin Spice Mix in active breakfast meal
10167063|NCT03926442|Placebo Comparator|Placebo Comparator|Placebo Breakfast
10167064|NCT03926598||Patients/Caretakers Group|Patients with Type II Diabetes and caretakers of patients with Type II Diabetes.
10167065|NCT03926598||Certified Diabetes Educators Group|Diabetes educators who help patients manage their Type II Diabetes.
10167066|NCT03926598||Physician Group|Physicians who help patients manage their Type II Diabetes.
10167067|NCT03926598||Front Desk Staff|Front desk staff who work with physicians that treat Type II Diabetes.
10167068|NCT03926598||Nurses|Nurses who help patients manage their Type II Diabetes.
10167069|NCT03926572|Other|Patients with Pulmonary arterial hypertension|Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
10167070|NCT03926585||Responders|Patients in combination therapy due to persistent symptoms on L-thyroxin mono-therapy who experience a longtime effect of triiodothyronine treatment.
10167071|NCT03926585||Non-responders|Patients who have tried combination therapy due to persistent symptoms on L-thyroxin mono-therapy, but did not experience a longtime effect.
10167072|NCT03926507|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo 4 PET/CT scans over 10 minutes paired with standard of care MRI within 14 days prior to initial maximal tumor resection, within 7 days prior to initiation of radiation therapy, 28 days after the completion of radiation therapy, and 6 months after the completion of radiation therapy.
10167073|NCT03926390|No Intervention|Non bovine colostrun|Preterm received preterm formula
10167074|NCT03926390|Active Comparator|Bovine colostrum group|Preterm received bovine colostrum as trophic feeding
10167075|NCT03926286|Experimental|FMT for Sjogrens|FMT- active ingredient coming from participant's screening stool
10167076|NCT03926312|Experimental|Smart device-based rehabilitation|One month after myocardial infarction, patients will receive a smart band and a cellphone in order to transmit data on physical activity to electronic health record. A study nurse will periodically check compliance with recommended physical activity and intervene in the case of non-compliance.
10167077|NCT03926312|No Intervention|Control group|Patients will receive a guideline directed recommendation to increase physical activity to 30 minutes of moderate physical activity a week.
10167078|NCT03926403|Experimental|Hypnosis|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
10167079|NCT03926403|Active Comparator|conventional management|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
10167080|NCT03926481|Experimental|Obesity Only|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity who are 65 years and older.
10167081|NCT03926481|Experimental|Sarcopenia and Obesity|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity and sarcopenia who are 65 years and older.
10167082|NCT03926247|Other|Immigrant Well-being Project Intervention|Intervention
9671566|NCT05046951|Active Comparator|Print Arm|The Should I Screen print-based education (included with this IRB protocol) will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
10167083|NCT03926234||emergency triage patients|triage Level I triage Level II triage Level III triage Level IV
10167084|NCT03926338|Experimental|PD-1 inhibitor plus COX inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab) plus COX inhibitor (Celecoxib)
10167085|NCT03926338|Experimental|PD-1 inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab)
10167086|NCT03926546|Experimental|Individual ERP|Individual Exposure and Response Prevention for OCD
10167087|NCT03926546|Experimental|Group ERP|Group Exposure and Response Prevention for OCD
10167088|NCT03926364||Patients|Referred pain
10167089|NCT03926182|Experimental|Fasted AST2818 tablets following a period of fasting|
10167090|NCT03926182|Experimental|High-fat meal AST2818 tablets following a high-fat meal|
10167091|NCT03926416|Experimental|CodaVax-H1N1, low dose|Participants will receive a single dose of either CodaVax (5 x 10^3 PFU in 200 uL) and an intramuscular injection of placebo
10167092|NCT03926416|Active Comparator|Fluzone|Participants will receive an intranasal (IN) dose of placebo and an intramuscular (IM) dose of QuadriFlu- Tetravalent Influenza Vaccine (TIV) (Fluzone®)
10167093|NCT03926416|Experimental|CodaVax-H1N1, high dose|Participants will receive a single intranasal (IN) dose of CodaVax-H1N1 (1 x 10^5 PFU in 500 uL)
10167094|NCT03926416|Placebo Comparator|Placebo|Leibovitz's L-15 medium (IN) or saline (IM)
10167095|NCT03926221|Experimental|PBC_I plus TranS-C|The Parent Behavior Change Intervention (PBC-I) is a behavioral intervention intended to teach parent behavior change techniques to better support their adolescents to improve sleep health behavior. The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
10167096|NCT03926156|Experimental|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
10167097|NCT03926156|Active Comparator|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
10167098|NCT03925974|Experimental|HER2 overexpression|HER2 IHC 3+ or IHC2+ and ISH+
10167099|NCT03925974|Experimental|HER2 expression|HER2 IHC 2+ISH- or IHC 1+ and ISH+
10167100|NCT03925948|Experimental|Intervention|This is a one arm study with all participants enrolled into this arm.
10167101|NCT03925857|Experimental|Allocetra-OTS|Standard of Care (SOC) Drug: One dose Allocetra-OTS 140 140x106 /kg
10167102|NCT03925857|Experimental|Allocetra-OTS Two doses|Standard of Care (SOC) Drug: Two doses Allocetra-OTS 140 140x106 /kg
9671567|NCT05046912|Experimental|Clinical|Clinical participants with a primary diagnosis of psychosis or related disorder.
10167103|NCT03925987|Experimental|Exposure therapy|Participants complete 10 weekly sessions of a group-based exposure therapy class for anxiety disorders.
10167104|NCT03925870|Experimental|KN046 monotherapy|Eligible subjects will be enrolled and receive KN046 monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first.
10167105|NCT03925909|Experimental|Eriomin 200 mg|The volunteers will receive one capsule containing 200 mg eriocitrin
10167106|NCT03925909|Experimental|Eriomin 400 mg|The volunteers will receive one capsule containing 400 mg eriocitrin
10167107|NCT03925909|Experimental|Eriomin 800 mg|The volunteers will receive one capsule containing 800 mg eriocitrin
10167108|NCT03925909|No Intervention|Placebo|The volunteers will receive a capsule containing corn starch (placebo)
10167109|NCT03925896|Experimental|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
10167110|NCT03926078|Other|Patients under 18 years of age|Group A consists of patients that receive a chest radiography in the current work-up of PE.
10167111|NCT03926078|Other|Patients aged 18 years or older|Group B consists of patients that receive a CT scan in the current work-up of PE.
10167112|NCT03926000|Active Comparator|Pregabalin (PG)|Patients will receive 150 mg pregabalin one hour before the procedure.
10167113|NCT03926000|Placebo Comparator|Control placebo (C)|Patients will receive placebo tablet one hour before surgery.
10167114|NCT03925792|Experimental|Treatment Group|Lifestyle Medicine Group 1
9671568|NCT05046912|Active Comparator|Non-clinical|Non-clinical participants with no mental health diagnoses.
10167115|NCT03925792|Experimental|Waitlist Control Group|Lifestyle Medicine Group 2
10167116|NCT03925818|Experimental|B.I.D. TMPPI + Lactobacillus-10|pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
10167117|NCT03925818|Active Comparator|B.I.D. Bismuth|pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days
10167118|NCT03925714|Other|life style|life style control only
10167119|NCT03925714|Active Comparator|Metformin|Metformin 500 mg twice daily
10167120|NCT03925714|Experimental|Nigetella salivata|NS 450 mg twice daily
10167121|NCT03925779|Active Comparator|(Dexmedetomidine)Dex group|The patients will be administered a loading dose of i.v. dexmedetomidine 1 μg/kg over 10 min, followed by a continuous infusion of 0.2-1 μg/kg/h, titrated according to the sedation score, till the end of the procedure
10167122|NCT03925779|Active Comparator|Propofol-Remifentanil (P-R) group|Propofol will be started by a loading dose of 0.5 mg/kg over 3-5 minutes then a maintenance infusion of 25-75 μg kg/min. Remifentanil infusion will be started at 1 μg kg over one minute then and 0.01-0.1 μg kg/min.
10167123|NCT03925740|Experimental|MI Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.
9827726|NCT02465632|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
9827727|NCT02465632|Active Comparator|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
10167124|NCT03925740|Experimental|PreviDent Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.
10167125|NCT03925740|Active Comparator|1.23% APF Control Group|Regular application of APF for 4 minutes with high volume suction to the whole mouth.
10167126|NCT03925701|Experimental|vildagliptin|vildagliptin 50 mg twice daily
10167127|NCT03925701|Active Comparator|vildagliptin\metformin|vildagliptin\metformin twice daily
10167128|NCT03925558|Active Comparator|Probiotic formula|Lactobacillus strains
10167129|NCT03925558|Placebo Comparator|Placebo formula|Placebo
10167130|NCT03925662|Active Comparator|Folfox with avastin|Folfox with avastin only
10167131|NCT03925662|Experimental|Mebendazole|Folfox with avastin with mebendazole
10167132|NCT03925623||Commercial closure system|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with a standard two piece push and turn cap and asked to open this during 2 five minute trials.
10167133|NCT03925623||Physically based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped a novel closure that was designed using anthropometric data such that it disallows children from engaging the system and enables adults. Children will be asked to open this during 2 five minute trials.
10167134|NCT03925623||Cognitively based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with the design feature that was introduced as part of the physical intervention (above); however, this treatment is sized such that children should be able to engage it (if they understand how). In having these three treatments, we began to evaluate the paradigm which enables the design to work. (Do they fail to understand how?- Cognitive treatment fail- and or Can they not effectively manipulate the closure? --- Physical failure).
10167135|NCT03925571|Experimental|music-listening group|patient will listen to music during the dental surgery (1 to 1h30 hours).
10167136|NCT03925571|No Intervention|non music-listening group|patient will receive their dental intervention without music-listening.
10167137|NCT03925675|Experimental|Axumin (fluciclovine-F18) PET/CT scan|Axumin (fluciclovine-F18) PET/CT scan to evaluate possible glioma recurrence to help differentiate scar (fake recurrence) from true tumor recurrence
10167138|NCT03925337|Experimental|Arm-1 Standard Colonoscopy/AI-Assisted Combined Colonoscopy|Normal scope insertion and withdrawal first, followed by a second withdrawal with the research software running on a separate screen to catch any additional polyps missed during the first withdrawal.
10167139|NCT03925337|Experimental|Arm-2 AI-Assisted Combined Colonoscopy/Standard Colonoscopy|Normal scope insertion but first withdrawal with the research software running on a separate screen, followed by a second withdrawal without the research software running.
10186663|NCT03733639|Other|no Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm  noTisseel® surgeon performs the surgical procedure as usual."
10186664|NCT03733613||Healthy adults|Subjects will receive pre and post-test, in order to verify the test-retest reliability of the Somatosensory detector
9827728|NCT02465632|Placebo Comparator|Placebo topical gel|apply a thin layer of the gel to the face
9827729|NCT02465866|Experimental|Treatment A: CL-108 (Fasted)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
10167140|NCT03925493|No Intervention|Control Group Procedures (RPE based exercise)|Patients in the control group will follow standard exercise prescription protocols in CR. Exercise intensity will be guided by the patient's reported rating of perceived exertion (RPE). The modified Borg scale will be used by the patients to determine their RPE. Therefore, a scale of 1-10 will be used. The general goal will be to exercise between intensity level 3 or 4 (i.e. moderate intensity), per current program standards. Based on exercise levels achieved on the first day, patients will be given exercise recommendations for their 2nd session of CR and so forth. As the patients progress in CR, patients will increase their time, intensity, and mode of exercise as appropriate. Exercise progression will be guided by RPE and clinical assessment.
10167141|NCT03925493|Experimental|Exercise Test and Heart Rate Range|Patients randomly assigned to this group will complete a graded exercise test (GXT) per standard protocols. The researchers will obtain the patients peak heart rate from this stress test. Obtaining an accurate peak heart rate will allow for the calculation of a target heart rate range (THRR) using the Karvonen formula. Based upon the Karvonen formula, the THRR will be between 60-80% of the patient's heart rate reserve. The Karvonen formula can be calculated as follows ((peak heart rate - resting heart rate) X % intensity (0.6 or 0.8) + resting heart rate)). An example would be: (155 -75) X (.6) + 75) = 123; ((155 - 75) X (.8) + 75 = 139) THRR: 123 - 139. Patients will then adjust their exercise intensity to match this target heart rate range for the duration of their time in cardiac rehabilitation. Cardiac rehabilitation staff will provide feedback about heart rate when they are able.
10167142|NCT03925493|Experimental|Exercise Test, Heart Rate Range, and Heart Rate Monitor|"Patients randomly assigned to this group will also undergo a stress test (GXT) and exercise within a target heart rate range (THRR) during cardiac rehabilitation comparable to second arm of the trial. Additionally, they will receive a personal heart rate monitor (HRM). This monitor will consist of a polar heart rate chest strap and polar watch. Patients will be asked to wear this during cardiac rehabilitation and adjust their own exercise intensity. This will provide continuous feedback to the patient about their heart rate. Cardiac rehabilitation staff will also provide feedback when available.~The investigators are using the heart rate monitors because cardiac rehab staff are not always able to adjust exercise intensity for all patients, and telemetry is not always used."
9671569|NCT05046509||COVID_Patients|"Patient has been confirmed diagnosis Covid-19 disease by PCR~Patient aged 18 years and above"
9671570|NCT05046496|No Intervention|Observational arm|Patients recruited to this arm will undergo no intervention.
9671571|NCT05046496|Active Comparator|Interventional arm|Patients recruited to this arm will undergo intra-arterial digital subtraction angiography, with or without intra-arterial stent placement
9671572|NCT05046431|Active Comparator|EU Simponi|
9671573|NCT05046431|Experimental|BAT2506|
9671574|NCT05046405|Experimental|home-based remotely supervised tDCS|The intervention combines home-based tDCS (1 or 2 cycles of 15 daily sessions for 3 weeks/cycle at 2 mA for 30 minutes) with tele-health for remote supervision and e-health for self-monitoring of depressive symptoms.
9671575|NCT05046275||MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
9827730|NCT02465866|Experimental|Treatment B: CL-108 (Fed)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
9827731|NCT02465866|Active Comparator|Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
9827732|NCT02465866|Active Comparator|Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
10167143|NCT03925636|Experimental|Dietary therapy for C. difficile colonization|Dietary therapy intervention for this arm is the Specific Carbohydrate Diet.
10167144|NCT03925519||non-obese|non-obese diabetic patients (n= 25, BMI ≤ 30 kg/m2) were subjected to supervised aerobic exercise
10167145|NCT03925519||obese group|obese diabetic group (n= 25, BMI ≥ 30 kg/m2)
10167146|NCT03925545|Experimental|Unilateral|Implantation with the FluidVision AIOL in one eye during cataract surgery. Only one eye was treated.
10167147|NCT03925545|Experimental|Contralateral|Implantation with the FluidVision AIOL in the first eye during cataract surgery, followed by implantation with the AcrySof IQ monofocal IOL in the fellow eye during a subsequent cataract surgery
10167148|NCT03925363|Active Comparator|Active|Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)
10167149|NCT03925363|Sham Comparator|Control|Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).
10167150|NCT03925467|Experimental|proximal acupoints|Acupuncture needles will be administered at proximal acupoints
10167151|NCT03925467|Experimental|distal acupoints|Acupuncture needles will be administered at distal acupoints
10167152|NCT03925467|Placebo Comparator|sham acupoints|Sham acupuncture needles will be administered in the abdominal sham acupoints.
10167153|NCT03925194|Experimental|Anakinra|
10167154|NCT03925194|Placebo Comparator|Placebo|
10167155|NCT03925233||HER2+ Breast Cancer|
10167156|NCT03925233||ER+ Breast Cancer|
10167157|NCT03925233||Triple Negative Breast Cancer|
10167158|NCT03925285|Experimental|IV fluorescent tracer bevacizumab-800CW|Patients will be administered with 10 or 25 bevacizumab-800CW.
9827733|NCT02465931|Other|Comparison Condition|Paper and pencil informed consent
10167159|NCT03925220|Experimental|Substance Use Prevention Intervention|Parents will be given a handbook specific to the gender of their child that provides information and advice communication and substance use prevention. Parents will then participate in a one-hour session with an interventionist where the main points in the handbook will be reviewed and they will fill out an action plan on how to make changes in communication about substances with their child. The interventionist will also provide parents with a referral packet. Two weeks after the live session, participants will have a half-hour follow-up phone call with the same study interventionist. For the home-based component, parents will receive two messages each week with reminders and tips that reinforce the information covered in the handbook. Finally, participants will receive a magnet about the importance of family meals that they will be instructed to put on their refrigerators.
10167160|NCT03925220|Active Comparator|Nutrition, Physical Activity, and Weight Talk Comparison|"For the comparison condition, after the baseline assessment, parents will receive a handbook on nutrition and physical activity entitled: Healthy Eating & Physical Activity Across Your Lifespan: Helping your Child - Tips for Parents. This handbook, which is adapted from the handbook developed by the National Institute of Diabetes and Digestive and Kidney Diseases and the Weight Control Information Network, is approximately the same length as the intervention handbook and is available in English and Spanish. It is given with an insert on reducing weight talk and weight teasing in the family. Parents will also receive a magnet with a message about nutrition and exercise. To control for contact time, these participants will meet live with a study staff member two weeks after receiving the handbook, complete an action plan, and have the 30-minute call, as well as receive two text messages twice per week for 13 weeks with tips and reminders from the comparison handbook and insert."
10167161|NCT03925454||In-Centre Haemodiafiltration (ICHDF) Group|Participants undergoing ICHDF treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
10167162|NCT03925454||Home HaemoDialysis (HHD) Group|Participants undergoing HHD treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
10167163|NCT03925259|Active Comparator|Full-ACT|Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of eight modules in the Full-ACT arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all eight mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; self-as-context; values; and committed action.
10167164|NCT03925259|Experimental|ACT-SAC|"Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of seven modules in the ACT-SAC arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; values; and committed action.~The ACT-SAC condition removed the self-as-context module; therapists were instructed to avoid any reference to self-as-context or to support discussions regarding this process."
10167165|NCT03925168|Experimental|Experimental|Music therapy
10167166|NCT03925168|No Intervention|Control|No music therapy
10167167|NCT03925428|Experimental|Treatment (entinostat, molibresib)|Patients receive entinostat PO on days 1, 8, 15, and 22 and molibresib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10167168|NCT03925103|Experimental|3D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a three-dimensional display system
10167169|NCT03925103|Active Comparator|2D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a two-dimensional display system
10167170|NCT03925090|Experimental|Neoadjuvant and Adjuvant Toripalimab+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: Toripalimab Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT Other Names:anti-PD-1 antibody, JS001
10167171|NCT03925090|Placebo Comparator|Neoadjuvant and Adjuvant Placebo+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: placebo placebo 240mg every 2 weeks with a total of 2 cycles as neoadjuvant treatment; placebo 240mg every 3 weeks with a total of 8 cycles as adjuvant treatment 2 weeks after CCRT.
10167172|NCT03925155|Experimental|Chlorhexidine gluconate vaginal scrub|Use of chlorhexidine 4% vaginal scrub instead of current standard of care 10% povidone iodine vaginal scrub for cesarean sections
10167173|NCT03925155|Active Comparator|Povidone-iodine vaginal scrub|Current standard of care 10% povidone iodine vaginal scrub for cesarean sections
10167174|NCT03924999|Experimental|Combined decongestive treatment & Combined exercise|"Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 5 days a week, for 6 weeks (totally, 30 sessions).~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
10167175|NCT03924999|Experimental|Intermittent pneumatic compression & Combined exercise|"Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
9827734|NCT02465931|Experimental|Intervention condition|Digital informed consent tool
9827735|NCT02466009|Experimental|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast."
9827736|NCT02466087|Experimental|Mg Cl|500mg Mg Cl per day for 6 weeks
10167176|NCT03924999|Active Comparator|Combined exercise|All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
10167177|NCT03924960|Experimental|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
10167178|NCT03924960|Active Comparator|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
10167179|NCT03924960|Other|Control|Usual care control group
10167180|NCT03924921|Experimental|autogenic training|Autogenic training
10167181|NCT03924921|Experimental|wait list|usual care for 6 months Autogenic training after 6 months
10167182|NCT03925272|Experimental|Patients with Suppurated Hidradenitis|"Human biological samples :~Whole blood and derived products (DNA, RNA), urine, stool, saliva, tears, skin and mouth swabs, lesion samples: swab for microbiological analyzes, cutaneous biopsies (lesion skin and peri-lesional healthy skin), surgical lesion excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: Ethno-geographical, family and personal antecedents and current events in particular related to Verneuil's disease and any associated diseases (chronic auto-inflammatory ...)"
10167183|NCT03925272|Experimental|Patients with Alzheimer disease|"Human biological samples :~stool, blood (20 ml), nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: healthy or sick status,cognitive, memory and psychometric abilities evaluated by different tests example: MMSE (for Alzheimer's) and MST (minor memory disorders), Psychometric abilities assessed by the Geriatric Depression Scale GDS, Nutritional status assessed by the MNA test"
10167184|NCT03925272|Experimental|Patients with familial adenomatous polyposis|"Human biological samples :~whole blood (30 to 100 mL), optional stool collection~bio-clinical data: Age, Gender, Ethnicity, Personal and Family Medical History, Current Treatment, Type of PAF Mutation"
10167185|NCT03925272|Experimental|Patients with chronic inflammatory diseases (SPA, Crohn, ...)|"Human biological samples :~whole blood and derived products (DNA, RNA, PBMC, plasma, serum), (100 mL), stool; as part of the treatment, occasionally: lesions, urine, saliva, tears~Bio-clinical data :~Ethno-geographical origin, Personal and family history, History of the disease, Associated or concomitant diseases, Treatments in progress."
10167186|NCT03925272|Experimental|Healthy cases|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
10167187|NCT03925272|Experimental|Healthy cases relatives|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
10167188|NCT03925272|Experimental|Subjects vaccinated against COVID-19|"Human biological samples :~whole blood and derived products: serum, DNA, PBMCs, saliva, nasopharyngeal swab~Bio-clinical data :~ethno-geographical origin, family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases, specific history of otorhinolaryngology and broncho-pulmonary and treatments, specific COVID-19 history, risk factor for a severe form of COVID-19, symptoms of COVID-19 or positive test for SarsCov-2 positive"
10186665|NCT03733600||Glaucoma|All patients followed for either early or moderate forms of primary or secondary open-angle glaucoma who had undergone surgery for Xen alone or in combination with cataract surgery for phacoemulisation of the lens.
10186666|NCT03733587|Experimental|Cyclophosphamide and GX-I7|Cyclophosphamide and determined dose of GX-I7 of each cycle
9520308|NCT03278834|Placebo Comparator|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
9520309|NCT03278808|Experimental|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
9520310|NCT03278808|Active Comparator|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
9826485|NCT02420041|Active Comparator|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
9520311|NCT03278808|Other|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
9974782|NCT05229952|Experimental|Constant infusion of 13C2-oxalate|Subjects who have passed screening, will consume a low-oxalate, normal calcium controlled diet for 5 days total. On Days 3 and 4, subjects will collect two 24-hour urines. On Day 5, they will receive a carbon 13 oxalate infusion which will occur at a constant rate for 6 hours, in the fasted state, following a priming dose. Hourly urine and twice hourly blood samples will be collected during the 6 hours. Meals will be resumed at the end of the infusion and timed urine collections will take place at home until the next day. A DXA scan will be performed to assess body composition at another date.
9974783|NCT05227612|Experimental|Psilocybin + CBT|All participants will receive 12 sessions of cognitive-behavioral therapy (CBT) along with two psilocybin-drug sessions -- the first following the third CBT session (10mg of psilocybin, taken orally) and the second following the sixth CBT session (25mg of psilocybin, taken orally).
9974784|NCT05227456|Experimental|Etonogestrel implant|The participants will receive an etonogestrel 68mg implant
9974785|NCT05227040|Experimental|Nintendo Ring Fit Adventure Exergame Group|Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
9974786|NCT05227040|No Intervention|Control group|
9974787|NCT05226585|Active Comparator|In-person CBTi|CBTi of variable treatment length will be administered by trained study staff in-person.
9974788|NCT05226585|Active Comparator|Telehealth CBTi|CBTi of variable treatment length will be administered by trained study staff via HIPAA-compliant tele-video conference.
9974789|NCT05226585|Active Comparator|Internet CBTi|Self-paced CBTi of variable treatment length will be administered via Sleep Healthy Using The Internet (SHUTi).
9974790|NCT05226585|No Intervention|Waitlist Control|Treatment will be postponed by 12 weeks.
9974791|NCT05226442|Experimental|Argatroban|Continuous infusion of 0,3μg/kg/min to target an aPTT of 50-70sec and/or Hemoclot of 0,60 - 0,80 µg/mL
9974792|NCT05226442|Active Comparator|Unfractionated Heparin|Continuous infusion of Unfractionated Heparin to target an aPTT of 50-60 seconds and/or Anti-Xa level between 0.20 and 0.30 IU/ml and/or thrombin time >20sec.
9974793|NCT05225337|Experimental|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
9974794|NCT05225337|Experimental|Daily calorie restriction (CR)|25% energy restriction every day Diet counseling provided
9974795|NCT05225337|No Intervention|Control|Ad libitum food intake, no meal timing restrictions
9974796|NCT05224648|Active Comparator|TOF scan train of four ratio monitoring|recovery of train of four ratio after neostigmine administration
9974797|NCT05224648|Experimental|ITF device tetanus stimulation monitoring|recovery of tetanus 100 Hz and tetanus 50 Hz ratio after neostigmine administration
9974798|NCT05224154|Experimental|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO<=6ppm).
10186667|NCT03733574|Experimental|LY03005 cross-over to Pristiq® (Desvenlafaxine)|Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
9974799|NCT05224154|Active Comparator|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
9520312|NCT03278795|Active Comparator|PSV mode|PSV weaning group
9974800|NCT05223205|Experimental|Air group|Air tamponade after vitrectomy.
9974801|NCT05223205|Experimental|SF6 group|10% SF6 tamponade after vitrectomy.
9974802|NCT05222763|Experimental|Experimental: Interventional group|The web-supported interactive nursing program intervention will take 3 weeks. The first week of the training will begin with the patient's admission to the clinic. Shoulder and Arm Exercises, Lymphedema in the Arm and Prevention of Its Development, and qualitative study, the themes of misperception determined in this area will be emphasized. In the second week, they will be asked to continue their Shoulder and Arm Exercises training, to examine the Other Side Breast Examination Training and Adaptation Process to Life Activities, Skin Care and Post-Surgery Cancer Treatment and Breast Reconstruction. In the last week of the training, it will be requested to review the contents again. Correct perceptions that may emerge as a result of the qualitative study will be supported in the relevant parts of the training. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times).
9974803|NCT05222763|Active Comparator|Behavioral:|"The handbook developed within the scope of the Women's Return to Social Life After Mastectomy Project on the website of the Continuing Education, Research and Solidarity Association will be used on the website of the participants assigned to the control group."
9974804|NCT05220319|Placebo Comparator|Placebo|"100 ml of NaCl 0,9%, not containing corticosteroids, given at induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 100 ml of NaCl 0,9% will be administered at the beginning of CPB."
9974805|NCT05220319|Active Comparator|Methylprednisolone|"250 mg of methylprednisolone made up with 100 ml NaCl 0,9%, given at the induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 250 mg methylprednisolone will be administered at the beginning of CPB."
9974806|NCT05220137|Active Comparator|1|Core Session 1, Core Session 2, Module Choice, Final Session
9974807|NCT05220137|Active Comparator|2|Core Session 1, Core Session 2, Modified A-B-C, Final Session
9671576|NCT05046275||Non MCR syndroms|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
9827737|NCT02466087|No Intervention|Control|No intervention
9974808|NCT05220137|Active Comparator|3|Core Session 1, Core Session 2, Challenging Questions, Final Session
9974809|NCT05220137|Active Comparator|4|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Module Choice, Final Session
9974810|NCT05220137|Active Comparator|5|Core Session 1, Core Session 2, Problematic Patterns, Final Session
9974811|NCT05220137|Active Comparator|6|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Module Choice, Final Session
9974812|NCT05220137|Active Comparator|7|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Module Choice, Final Session
9974813|NCT05220137|Active Comparator|8|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Final Session
9974814|NCT05220137|Active Comparator|9|Core Session 1, Core Session 2, Challenging Beliefs, Final Session
9974815|NCT05220137|Active Comparator|10|Core Session 1, Core Session 2, Modified A-B-C , Challenging Beliefs, Module Choice, Final Session
9974816|NCT05220137|Active Comparator|11|Core Session 1, Core Session 2, Challenging Questions, Challenging Beliefs, Module Choice, Final Session
9974817|NCT05220137|Active Comparator|12|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Challenging Beliefs, Final Session
9974818|NCT05220137|Active Comparator|13|Core Session 1, Core Session 2, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
9974819|NCT05220137|Active Comparator|14|Core Session 1, Core Session 2, Modified A-B-C, Problematic Patterns, Challenging Beliefs, Final Session
9974820|NCT05220137|Active Comparator|15|Core Session 1, Core Session 2, Challenging Questions, Problematic Patterns, Challenging Beliefs, Final Session
9974821|NCT05220137|Active Comparator|16|Core Session 1, Core Session 2, Modified A-B-C, Challenging Questions, Problematic Patterns, Challenging Beliefs, Module Choice, Final Session
9974822|NCT05217030|Experimental|Animal Assisted Therapy|This group of patients with traumatic brain injury received AAT throughout the acute care hospitalization
9974823|NCT05217030|No Intervention|Control|This group of patients with traumatic brain injury did not receive AAT throughout the acute care hospitalization
9974824|NCT05216172|Experimental|AZD1656|AZD1656 100mg BD for 3 months
9974825|NCT05216172|Placebo Comparator|placebo|placebo 100mg BD for 3 months
9974826|NCT05216120|Experimental|Pemigatinib|Participants will be provided with a bottle of pemigatinib tablets on Day 1 of each cycle (one cycle = 21 days). A bottle contains 4.5 mg X 42 tablets total. Each pemigatinib bottle is sufficient for one cycle. Resupply will be provided as necessary on Day 1 of each cycle.
9974827|NCT05214066|Experimental|4-day ATG combined regimen|ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF (Mycophenolate mofetil), CsA (cyclosporin A) and MTX (methotrexate). All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
9974828|NCT05211024||Aim 1: Group A|Children and adolescent who are prior GOAL participants who have a normal echocardiogram at the 2 year endpoint and are no receiving secondary antibiotic prophylaxis
9974829|NCT05211024||Aim 1 Group B|Children and adolescent who have a normal echocardiogram at the start of the study
9974830|NCT05211024||Aim 2|Children and adolescent who are prior GOAL participants who have persistent latent RHD on echocardiogram at the 2 year endpoint.
9974831|NCT05210699|Experimental|Product usage order A B N C E D|Subjects will use each of the 5 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
9974832|NCT05210699|Experimental|Product usage order B C A D N E|Subjects will use each of the 5 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
9974833|NCT05210699|Experimental|Product usage order C D B E A N|Subjects will use each of the 5 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
9520313|NCT03278795|Experimental|VSV mode|VSV weaning group
9974834|NCT05210699|Experimental|Product usage order D E C N B A|Subjects will use each of the 5 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
9974835|NCT05210699|Experimental|Product usage order E N D A C B|Subjects will use each of the 5 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
9974836|NCT05210699|Experimental|Product usage order N A E B D C|Subjects will use each of the 5 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
9974837|NCT05206266|Experimental|Turmeric, then Turmeric+Black Pepper|Participants first receive Turmeric (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper) for 1 week. After a 1 week washout, participants then receive Turmeric at the previous amount plus Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper 300mg/subject daily) for 1 week.
10167189|NCT03925012|Experimental|Intervention|Child participants will attend the healthy lifestyle summer program for 4 weeks, five days per week. The summer intervention will include daily one-hour nutrition education, one-hour behavioral counseling, and 3 one-hour exercise sessions. These physical activities include flexibility, games, traditional fitness, and dancing. Counseling and school psychology students, registered dietitian/nutrition educators, and fitness specialists will lead the respective sessions. Parental guardians will participate in a two-hour weekly parental sessions that involve: 1)nutrition education with cooking demonstrations of healthy recipes; 2)behavioral counseling to learn effective parenting strategies on how to support their child's healthy nutrition and exercise habits and goals; and 3)exercise sessions where parents will engage in different physical activities and will receive fitness tips on how to promote an active lifestyle for the entire family.
10167190|NCT03925051|Experimental|CMAB807|60mg by subcutaneous injection once on the first day.
10167191|NCT03925051|Active Comparator|Prolia®|60mg by subcutaneous injection once on the first day.
10167192|NCT03925064||Diabetic pregnancies|Pregnant women with pregestational or gestational diabetes mellitus
10167193|NCT03925064||non-diabetic pregnancies|Pregnant women without pregestational or gestational diabetes mellitus
10167194|NCT03925038|Active Comparator|Treatment as Usual|Participants will receive psychotherapy (treatment as usual).
10167195|NCT03925038|Experimental|Augmented Care|Participants will receive augmented psychotherapy which includes use of an electronic media dashboard as part of treatment.
9671577|NCT05046210|Experimental|LHA group (EG)|"Behavioral: LHA intervention~Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day, whereas the participants in the EG also received 4 lessons from a LHA over 4 weeks."
10167196|NCT03924674|Active Comparator|Stepped Wedge Group 1: Sept. 2019 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
10167197|NCT03924674|Active Comparator|Stepped Wedge Group 2: Nov. 2019 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
9520314|NCT03278782|Experimental|Treatment (romidepsin, pembrolizumab)|Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
9671578|NCT05046210|Placebo Comparator|Leaflet group (CG)|"Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.~The participants in the CG received oral exercise intervention and leaflets only."
10167198|NCT03924674|Active Comparator|Stepped Wedge Group 3: Jan. 2020 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
10167199|NCT03924726|Other|Control and experimental (4 weeks MOP)|This is a split mouth study. At the experimental site in group 1, three Micro-osteoperforation (MOP) were made directly at the buccal cortical bone of extracted first premolars sites, at equidistance from the canine and second premolar under local anaesthesia. This group received four sessions of MOPs at an interval of 4 weeks.
10167200|NCT03924726|Other|Control and experimental ( 8 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 8 weeks.
10167201|NCT03924726|Other|Control and experimental (12 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 12 weeks.
10167202|NCT03924973|Experimental|Experimental group|"Children below the age of 3 in this group received 2 years of ESDM intervention for 12 hours per week, and then treatment as usual for the 3 following years.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community."
10167203|NCT03924973|Other|Control group|"Children in this group received treatment as usual delivered in the community for the 2 years of IDEA.~Participants will still receive treatment as usual delivered in the community during IDEA-2, in the 3 years following IDEA."
10167204|NCT03925116|No Intervention|usual care|"women who present for birth control to the gynecology office will see their physician in the usual fashion for review, counseling and contraception decision/initiation.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
9671579|NCT05046483||Diabetes Cohort|Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and diabetes mellitus type 1 or type 2 according to criteria of the German Diabetes Society (DDG) (HbA1c ≥ 6.5 % or orale glucose tolerance test), aged 18-80 years at inclusion into the study
9520315|NCT03278769|Experimental|Ventilator setting|Positive end-expiratory pressure , Tidal volume
9520316|NCT03278756|Experimental|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
10167205|NCT03925116|Experimental|Contraceptive pathway|"Women who present for birth control to the gynecology office will be recognized by the front desk and offered a tablet which which will:~collect relevant medical history~provide educational material on birth control options~provide a link to bedsider.com for further information~They will then discuss the tablet information/history with the medical assistant, who will answer any remaining questions. They will then see the physician/APN.~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
10167206|NCT03925129|Experimental|TENS|
10167207|NCT03925129|Sham Comparator|Sham TENS|
10167208|NCT03924908|Experimental|VRH|Virtual reality hypnosis
10167209|NCT03924908|Active Comparator|VR|Virtual reality
10186668|NCT03733574|Experimental|Pristiq® (Desvenlafaxine) cross-over to LY03005|Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
10186669|NCT03733561|Experimental|LY03003|LY03003
10186670|NCT03733561|Active Comparator|Neupro transdermal patch|Neupro transdermal 4 mg patch
10186671|NCT03733548|Experimental|Regulating Emotions Like An eXpert (RELAX)|Families at the Virginia Commonwealth University Center for Psychological Services and Development or Clark-Hill Institute for Positive Youth Development
10186672|NCT03733535|Experimental|Treatment|Benralizumab 30mg subcutaneous injection on study days 0, 28 and 56 and 1.0 L 129-Xenon/4-Helium mixture, twice per visit, on days 0, 14, 28 and 112.
10187883|NCT03721757|Other|Nivolumab, Surgery, Radiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with low risk criteria following surgery will be assigned to radiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and commencement of radiotherapy (1-2 weeks prior).~Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks).~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals"
10187884|NCT03721757|Other|Nivolumab, Surgery, Chemoradiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria following surgery will be assigned to chemoradiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and chemoradiotherapy (1-2 weeks prior).~Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21.~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals."
10187885|NCT03721744|Experimental|Napabucasin+Paclitaxel+Gemcitabine|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose).Paclitaxel 80 mg/m^2 will be administered intravenously. Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression based on RECIST 1.1 criteria
10187886|NCT03721744|Active Comparator|Standard of care treatment options|Patients will receive standard of care treatment options treatment, including Fluorouracil and Leucovorin, Gemcitabine, Onivyde plus Fluorouracil and Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region), or best supportive care (BSC) alone, one of which will be assigned by the investigator for each patient.
10187887|NCT03721718|Experimental|GLS-5300 with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
10187888|NCT03721718|Experimental|GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
10187889|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (3 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
10187890|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (2 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
10187891|NCT03721692|Experimental|RIC group|The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
10187892|NCT03721692|No Intervention|non-RIC group|The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
10187893|NCT03721679|Experimental|Poly-ICLC treatment combination aPD-1or aPD-1L1|"Weeks 1 and 2: Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM ONLY twice a week with a 48-72 hour interval between the two injections~Weeks 3-25:~Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND~ONLY 1 of the following regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows:~Nivolumab (Opdivo), OR~Pembrolizumab (Keytruda), OR~Cemiplimab (Libtayo) OR~Atezolizumab (Tecentriq) OR~Durvalumab (Imfinzi) Follow up: After completion of treatment subjects may be contacted by telephone at least twice over 12 months, or longer with patient consent, in order to inquire on their health status (e.g., in remission, progressive disease, on new cancer treatment)."
10187894|NCT03721653|Active Comparator|FOLFOXIRI + Bevacizumab|"(to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
10167210|NCT03924739|Experimental|Intervention group|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model.
9671580|NCT05046483||Normal Glucose Tolerance (NGT) Cohort|Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and normal glucose tolerance (HbA1c < 5.9 % and normal oral glucose tolerance test), aged 18-80 years at inclusion into the study
9974838|NCT05206266|Experimental|Turmeric+Black Pepper, then Turmeric|Participants first receive Turmeric+Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper at 300mg/subject daily) for 1 week. After a 1 week washout, participants then receive Turmeric daily at the previous amount for 1 week (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper).
9974839|NCT05204888|Active Comparator|Usual COPD care|The intervention : A pulse oximeter to record heart rate and pulse oximetry on a daily basis will be provided. A smart phone and charger will also be provided to answer a short questionnaire that queries daily respiratory symptoms plus enter heart rate and pulse oximetry data
10167211|NCT03924739|No Intervention|Control group|The control group will receive the conventional care provided by the study hospital.
10167212|NCT03924830|Active Comparator|Bulk without Surface Sealant|53 teeth will receive restorations using Bulk fill restoration without surface sealant
10167213|NCT03924830|Experimental|Bulk with Biscover|53 teeth will receive restorations using Bulk fill restoration with Biscover surface sealant
10167214|NCT03924830|Experimental|Bulk with Permaseal|53 teeth will receive restorations using Bulk fill restoration with Permaseal surface sealant
10167215|NCT03924609||Bone metastasis screening|The information about bone metastasis screening is retrospectively collected.
10167216|NCT03924687|Experimental|ACT group|ACT group: participants receiving the 8-week bibliotherapy intervention based on Acceptance and Commitment Therapy
10167217|NCT03924687|No Intervention|control group|Wait-list control condition: participants placed on a wait-list (and receiving the intervention following the 9 week duration of the intervention)
9974840|NCT05204888|Active Comparator|Usual COPD care with use of the myAirvo 3 integrated humidifier and flow generator.|The intervention is the myAirvo 3 humidifier with integrated flow generator delivered through the Optiflow™ + Duet nasal cannula.
9974841|NCT05198128|Experimental|Calcium intravenous infusion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
9974842|NCT05198128|Placebo Comparator|saline|0.9 % saline intravenous infusion
9974843|NCT05198115|Active Comparator|Aerobic group|The intervention consisted of aerobic exercise training, which was taught to participants face-to-face at a meeting. At the end of the session, we provided the intervention group with CDs and educational posters containing all the exercises
10167218|NCT03924544|Experimental|Decorin Group|26 patients will receive subconjunctival injection of 100 µg decorin 15 minutes before surgery, 1, 3, and 7postoperatively. A30-gauge needle was used to inject 100 µL of decorin. The needle was placed at the nasal margin of the superior rectus muscle
10167219|NCT03924544|Active Comparator|Mitomycin Group|MMC will then be applied in 26 patients to the sclera at a concentration of 0.3 mg/ml using cellulose sponges, which will be removed after 3 minutes followed by copious irrigation with balanced saline solution (BSS).
10167220|NCT03924648||premature ovarian insufficiency|Idiopatic premature ovarian insufficiency (POI), defined as loss of ovarian function and subsequent amenorrhea before the age of 40.
10167221|NCT03924648||Control|The investigators compared patients with POI to a cohort of age matched healthy controls recruited among women who visited the gynecology clinic for routine examination or from hospital workers. All volunteers for the control group had regular menstrual cycles and no concomitant health problems.
10167222|NCT03924596|Experimental|Luban Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
10167223|NCT03924596|Active Comparator|Uralyt-U Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)
10167224|NCT03924596|Experimental|Luban Uric acid|25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
10167225|NCT03924596|Active Comparator|Uralyt-U Uric acid|25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2
10167226|NCT03924713||Community Health Worker|"initial comprehensive health, behavioral, and social needs assessment;~development of an individualized 'action plan' to address identified needs;~linkage to necessary services and work with neighborhood-based health care and social services organization to address each individual's unique needs; and 4) provide follow-up support as needed."
10167227|NCT03924713||Usual Health Plan Services|1) receipt of other plan services besides the CHW program for which they are eligible.
10167228|NCT03924557|Active Comparator|Genotyping Intervention Supportive Care|For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.
10167229|NCT03924557|No Intervention|Delayed Genotyping Intervention Supportive Care|For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.
10167230|NCT03924622|Experimental|Group 1: Mepilex on Litter + AE Mattress + 30 degree backrest|Intervention: Mepilex
10167231|NCT03924622|No Intervention|Group 2: Without Mepilex on Litter + AE mattress + backrest|Intervention: Control (no Mepilex)
10167232|NCT03924622|Experimental|Group 3: Mepilex on VSB on AE mattress|Intervention: Mepilex
10167233|NCT03924622|No Intervention|Group 4: Without Mepilex on VSB on AE mattress|Intervention: Control (no Mepilex)
10167234|NCT03924622|Experimental|Group 5 Prolonged Field Care (PFC) - LiquiCell on Talon litter|Intervention: LiquiCell mat
10167235|NCT03924622|No Intervention|Group 6: PFC Without LiquiCell on Talon Litter|Intervention: Control (no LiquiCell)
10167236|NCT03924570|Experimental|Intervention|This arm will receive training in the use of the IPASS package to improve communications during hands off.
9974844|NCT05198115|Placebo Comparator|Eight Weeks of Aerobic Exercise|The control group was subjected to all the pre-and post-assessments but were not asked to perform the exercise intervention. Instead, we phone-called them to give a reminder for filling out the questionnaires.
9974845|NCT05193396|Placebo Comparator|Placebo|Placebo tablets
9974846|NCT05193396|Active Comparator|Hydrocortisone|hydrocortisone tablets
9974847|NCT05189171||CRC Standard of Care|Colorectal patients with confirmed liver metastasis that has have submitted tumor biopsy sample and receive standard of care therapy.
9974848|NCT05186935|Experimental|Single arm|This is a multi-center, pivotal, non-randomized, prospective, open-label clinical investigation.
9974849|NCT05178888|Experimental|Dose Escalation|Dose escalation of MRTX849 and palbociclib to determine maximum tolerated dose in combination.
9974850|NCT05178888|Experimental|Dose Expansion|Expansion cohorts may be implemented to ensure sufficient safety experience, pharmacokinetic data and early evidence of clinical activity of MRTX in combination with palbociclib.
9974851|NCT05172921||Exposed|High exposure to environmental pollutants
9974852|NCT05172921||Non-exposed|Low exposure to environmental pollutants
9974853|NCT05172336||Assisted reproductive technology (Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
9974854|NCT05172336||Assisted reproductive technology (Non-Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
9974855|NCT05172336||Spontaneous conception (SC)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
9974856|NCT05170334|Experimental|Binimetinib + Belinostat|Participants will receive binimetinib by mouth two times a day, every day during each cycle. Each cycle will last for 21 days. Participants will receive belinostat by intravenous infusion on days 1 through 5 of each cycle.
9974857|NCT05167903|Experimental|Time-restricted eating|Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm (8 h eating window with 16 h of fasting)
9974858|NCT05167903|Experimental|Normal Diet (ND)|The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum)
9974859|NCT05164549|Experimental|XR-Bup|Extended-Release Buprenorphine, monthly, 300mg or 100mg
9974860|NCT05164549|Active Comparator|Bup/Met|Standard of Care; either Buprenorphine (including Subutex, Suboxone & Espranor) or Methadone (Participant Preference).
9974861|NCT05164549|Experimental|XR-Bup + PSI|Extended-Release Buprenorphine, monthly, 300mg or 100mg + Personalised Psychosocial Intervention (PSI)
9974862|NCT05164549|Active Comparator|Bup/Met + PSI|Standard of Care; either Buprenorphine (including Subutex, Suboxone & Espranor) or Methadone (Participant Preference) + Personalised Psychosocial Intervention (PSI)
9974863|NCT05164289||Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
9974864|NCT05164289||EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
9974865|NCT05162274|Experimental|Group 1|Participants first received lazertinib(G001) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14~21days, they then received lazertinib(G002) 240mg in a fasting state morning for 1 day.
9974866|NCT05162274|Experimental|Group 2|Participants first received lazertinib(G002) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14~21days, they then received lazertinib(G001) 240mg in a fasting state morning for 1 day.
9974867|NCT05159128|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts|Healthy Japanese participants will receive JNJ-75105186 or matching placebo orally in Cohorts 1-3.
9974868|NCT05159128|Experimental|Part 2: Single Dose (SD) Cohort|Healthy Chinese participants will receive JNJ-75105186 or matching placebo orally in Cohort 4.
9974869|NCT05158634||Cerebral Palsy|"Inclusion Criterias: Being diagnosed with Cerebral Palsy. Volunteer. Be between the ages of 6-18. Being at level 1 and level 2 according to Gross Motor Function Classification System (GMFCS) (Level 1 and 2).~To have the cognitive skills to understand and apply the evaluation parameters.~Exclusion Criterias: Cognitive impairment of participants diagnosed with Cerebral Palsy. Participants diagnosed with Cerebral Palsy have vision or hearing problems. Participants diagnosed with Cerebral Palsy must have a history of trauma such as botox or muscle relaxation operation and/or fracture at least 6 months before participating in the study."
9974870|NCT05157698|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
9974871|NCT05157698|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
9974872|NCT05157698|Experimental|NB medication|Participants randomly assigned to this arm will receive 6 months of NB medication taken daily in pill form.
9974873|NCT05157698|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 6 months of placebo. Placebo will be inactive and taken daily in pill form.
9974874|NCT05155839|Experimental|MRG001|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG001 on Day 1 of every 3 weeks (21-day cycle).
9974875|NCT05154279|Active Comparator|intramyometrial Terlipressin|intramyometrial injection of Terlipressin in women undergoing laparoscopic myomectomy procedure
9974876|NCT05154279|Active Comparator|intramyometrial carbitocin|intramyometrial injection of Carbetocin in women undergoing laparoscopic myomectomy procedure
9974877|NCT05154279|Placebo Comparator|intramyometrial saline|intramyometrial injection of saline in women undergoing laparoscopic myomectomy procedure
9974878|NCT05153551|Experimental|PEARS assessment|
9974879|NCT05152485|Active Comparator|BIIB104 0.5 mg Reference Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release liquid-filled hard-shell capsule, orally, on Day 1 in the fasted state.
9974880|NCT05152485|Experimental|BIIB104 0.5 mg Test Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fasted state.
9974881|NCT05152485|Experimental|BIIB104 0.5 mg Test Formulation (Fed State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fed state.
10167237|NCT03924570|No Intervention|Control|Until randomization this arm will continue running hands offs per usual care.
10167238|NCT03924531|Experimental|Mindful Awareness Program|The group that received mindfulness training.
10167239|NCT03924531|Active Comparator|Health Promotion Program|The group that received the health information.
10167240|NCT03924505|Experimental|Implementation Manual and External Facilitation|This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.
10167241|NCT03924505|Active Comparator|Implementation Manual - only|This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.
10167242|NCT03924388|Experimental|Short-term transcutaneous spinal cord stimulation|"In Project 1, we will measure the immediate effects of one-hour mid-thoracic and/or lumbosacral transcutaneous stimulation on autonomic function.~In mid-thoracic stimulation, the self-adhesive cathode electrode with a diameter of 30 mm will be placed on the skin between the TVII and TVIII spinous processes (approximately corresponding to the T8 spinal segment) at the midline over the vertebral column. For lumbosacral stimulation, the cathode will be placed on the skin between the LI and LII spinous processes (approximately corresponding to the L2/3 to S4/5) at the midline over the vertebral column. Two self-adhesive anode electrodes with a size of 5 × 9 cm will be symmetrically located on the skin over the iliac crests. Before and immediately after the stimulation, the outcomes will be measured in 2 positions, supine and ~ 70° upright (adjusted by tilt-up table)."
10167243|NCT03924388|Experimental|Long-term transcutaneous spinal cord stimulation|"In Project 2, we will measure the effects of one-month stimulation (five one-hour stimulation sessions per week) of mid-thoracic and lumbosacral transcutaneous spinal cord stimulation on autonomic function.~The electrode placement and duration of stimulation will be identical to Project 1. The outcomes at each time point will be measured in two positions, supine and ~ 70° upright (adjusted by tilt-up table). The cardiovascular outcomes will be measured before, after the last stimulation session. Bladder and bowel function will be assessed weekly."
10167244|NCT03924388|Experimental|Project 3|For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.
10167245|NCT03924362|Active Comparator|Simultaneous Bilateral PCNL|Patients undergo simultaneous bilateral PCNL.
10167246|NCT03924362|Active Comparator|Unilateral PCNL|Patients undergoing unilateral staged PCNL.
10167247|NCT03924349|Experimental|ICG clip|Three clips are fixed in three directions (120 degrees apart) at the distal of the lesion (just distal) before surgery
10167248|NCT03924323|Experimental|Escitalopram 10 mg/day|Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion
10167249|NCT03924323|Placebo Comparator|Placebo|Matching oral administration of placebo once daily
10167250|NCT03924518|Experimental|granisetron group|3ml granisetron（3mg） will be diluted in 22 mL of 0.9% normal saline,and the granisetron diluted will be intravenously injected for at 10 minutes， every 8 hours for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
10167251|NCT03924518|Placebo Comparator|placebo group|Normal saline 25ml every 8h for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
10167252|NCT03924271|Experimental|ONCOLOGY|Patient with a cancer
10167253|NCT03924258|Experimental|HEART FAILURE|Patients with Heart Failure diagnosis
10167254|NCT03924297|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
10167255|NCT03924453||Pearl Powered by Proov|Participants are given hormone tests strips and a digital app and all instructions for use, collectively called the Pearl Power by Proov kit. The app will analyze hormonal test strip information to predict and confirm ovulation
10167256|NCT03924284||NPA positive|NPA specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
10167257|NCT03924284||NPA negative|NPA specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
10167258|NCT03924284||Saliva positive|Saliva specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
10167259|NCT03924284||Saliva negative|Saliva specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
10167260|NCT03924245|Experimental|Treatment (entinostat, olaparib)|Patients receive entinostat PO 1 week before starting combination therapy (day -7). Patients then receive entinostat PO on days 1, 8, 15, and 22, olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity
10167261|NCT03924206||Minimally invasive surgery with smoke evacuation system (SES)|minimally invasive surgical procedures during which a smoke evacuation device is used
10167262|NCT03924206||Minimally invasive surgery without SES|minimally invasive surgical procedures during which no smoke evacuation device is used
10167263|NCT03924206||Open surgery with SES|open surgical procedures during which a smoke evacuation device is used
10167264|NCT03924206||Open surgery without SES|open surgical procedures during which no smoke evacuation device is used
10167265|NCT03923881|Experimental|Study group|Patients with oral squamous cell carcinoma that have been included in ICON-study and are scheduled for treatment of neck
10167266|NCT03923868|Experimental|dose escalation in healthy subjects|
10167267|NCT03923868|Experimental|dose escalation in hyperuricemia patients|
10167268|NCT03923985|Active Comparator|Active Arm|1 tablet / day of probiotic containing 10 Mld L. crispatus during two months
10167269|NCT03923985|No Intervention|Control Arm|No treatment
10167270|NCT03924011|Sham Comparator|Control group|Receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
10167271|NCT03924011|Experimental|Treatment group|Receives PBMT (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
10167272|NCT03924089|Experimental|Oral nutritional supplement with probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics.~Physical activity recommendations."
10167273|NCT03924089|Experimental|Oral nutritional supplement without probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics.~Physical activity recommendations."
10167274|NCT03924089|Active Comparator|Individualized dietary recommendations|Individualized dietary recommendations. Physical activity recommendations.
10167275|NCT03924076|Experimental|Treatment Group|Received UHT milk + paraprobiotic Lactobacillus plantarum IS-10506 5 x 1010 CFU/day (125 mL) for 90 days
10167276|NCT03924076|Placebo Comparator|Placebo Group|Received UHT milk (125 mL) for 90 days
10167277|NCT03923816|Experimental|Group (R)|Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
9671581|NCT05046197||Work Package 1 - patients and carers|"Qualitative interview of 48 Patients, or their carers where the patient lacks capacity, who have had a ReSPECT form completed in the previous 6 months. To include:~12 patients living in care homes 12 patients living at home (nearing the end of their life) 12 patients living at home (not nearing the end of their life)"
9671582|NCT05046197||Work Package 1 - GPs|Qualitative interview of 30 General Practitioners who are involved in the ReSPECT process
10167278|NCT03923816|Experimental|Group (C)|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).
9974882|NCT05150509||Patients with Progressive Disease and without Progressive Disease|"Patients with Progressive Disease Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease.~Patients with without Progressive Disease Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease."
9520317|NCT03278756|Active Comparator|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
10167279|NCT03924141|Experimental|Third year nursing students - intervention|Third year nursing students will receive the intervention in de-escalation training
10167280|NCT03924141|No Intervention|Third year nursing students - control|Third year nursing students will receive no training in de-escalation
9520318|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
9520319|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
9520320|NCT03278730|Active Comparator|Para-Tyrosine intervention|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Tyrosine. Strength 500 mg. Oral dose form: hard capsule. Number of Dispensed at frequency of 3x2 g daily. Duration of administration: 4 to 7 days."
9671583|NCT05046197||Work Package 1 - Care home managers|Qualitative interview of 24 care home managers.
9671584|NCT05046197||Work Package 2 - Focus groups/interviews (Members of the Public)|Qualitative interview of 30 members of the public with an interest in healthcare regarding attitudes to the ReSPECT process.
10167281|NCT03924063|Other|conservative treatment|conservative treatment with physical therapy and non steroidal anti-inflammatory drugs
10167282|NCT03924115|Experimental|Group Total|This group of patients was chosen at random. They are patients who receive the full PST as intervention, that is, they receive a Smartphone with the AFAM-Health application with all the contents of the PST and data plan for 1 year.
9671585|NCT05046197||Work Package 2 - Focus groups/interviews (Health and Social Care Professionals)|Qualitative interview of 30 Non-GP Health and Social Care Professionals regarding attitudes to the ReSPECT process.
9671586|NCT05046197||Work Package 2 - Focus groups/interviews (Faith Leaders)|Qualitative interview of 8 faith leaders regarding attitudes to the ReSPECT process.
9671587|NCT05046197||Work Package 2 - Survey (Members of the Public)|Survey of 1000 members of the public to measure public awareness and acceptability of emergency care treatment plans
9974883|NCT05148312|Experimental|AQ001S 0.125 mg/2mL single-dose|AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.
10167283|NCT03924115|Experimental|Group Partial|This group of patients was chosen at random under the criteria of parity with group A. They are patients who receive partial PST as intervention, that is, they only receive video capsules reproduced in the CESFAM waiting room as educational content.
10167284|NCT03924115|No Intervention|Group Control|This group of patients is the control group, that is, they do not receive any type of intervention additional to the one they already receive from their CESFAM.
10167285|NCT03924050|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
10167286|NCT03924050|Placebo Comparator|Group Placebo combined with standard chemotherapy|
10167287|NCT03924024|Experimental|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
9671588|NCT05046197||Work Package 2 - Survey (GPs)|Survey of 1000 GPs to measure the views of GPs nationally regarding the use of emergency care treatment plans including ReSPECT, in primary care.
9974884|NCT05148312|Experimental|AQ001S 0.250 mg/2mL single-dose|AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.
9974885|NCT05148312|Experimental|AQ001S 0.500 mg/2mL single-dose|AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.
9974886|NCT05148312|Active Comparator|Budesonide inhalation suspension 1.0 mg/2 ml single-dose|Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.
10167288|NCT03923855|Experimental|BTL-899 Therapy Arm|
10167289|NCT03923842|Experimental|ARM A: Denosumab Treatment|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
10167290|NCT03923842|Active Comparator|ARM B Control Arm|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. At the end of the 6 cycles, if the patient is not progressing, can continue treatment with Gemcitabine alone.for 12 months
10167291|NCT03923946|Experimental|Intervention|Compassionate Imagery Intervention- up to three 1:1 sessions, up to one hour each with the primary researcher
10167292|NCT03923946|No Intervention|Control|Treatment as usual arm
10167293|NCT03923959|Active Comparator|Intervention|100 cc normal saline with 1g of tranexamic acid in solution
10167294|NCT03923959|Placebo Comparator|Placebo|100 cc normal saline
10167295|NCT03923894|Experimental|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
10167296|NCT03923894|Placebo Comparator|Placebo|Placebo 2.07 g/day for 8 weeks.
10167297|NCT03923712|No Intervention|Control Group|Participants randomly assigned to control group will be instructed to maintain their normal life habits with respect to physical activity and diet. During the 5 months of intervention participants from this group will receive at least one call from the researchers to be interested in their health status and inform them about the next evaluation appointment, as well as, an objectively evaluation of the main behaviours in the middle of intervention. Investigators will inform about the relevance of attending the full process and respecting the condition and rule as control. Participants from the control group will be freely offered the possibility to get involve in a similar intervention protocol at the end of the study in order to benefit from the potential positive effect of exercise.
9671589|NCT05046197||Work Package 3 - Patient records|Patient records of 413 patients within 12 CCGs in England who have had a ReSPECT form completed in the previous 12 months
10167298|NCT03923712|Experimental|Supervised exercise programme|5 months of supervised physical exercise program. The individualized and progressive Health periodization model will be applied establishing an initial individualizing period, as well as identifying any need or adaptation to apply during the exercise program. The physical exercise program will be applied in a period of progressive increase whose initial objective will be to reach the volume and intensity established by the international recommendations of physical activity (http://www.health.gov/paguidelines/) for this population. Briefly, a volume of 150 min/week of moderate-vigorous physical activity (60% -85% reserve heart rate) spread over a maximum of 5 days and including force work 2-3 days/week. The training load will progressively increase with a wave and flexible periodization.
10167299|NCT03923803||Chronic obstructive pulmonary disease|patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up
10167300|NCT03923634|Experimental|Princess® RICH|"Eligible subjects will be injected with Princess® RICH (this is an open-label study).~Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids."
10167301|NCT03924154|Experimental|RVT-1201|RVT-1201 600 mg immediate-release tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=24 [Anticipated])
10167302|NCT03924154|Placebo Comparator|Placebo|Matching placebo tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=12 [Anticipated])
10167303|NCT03923998|Experimental|Neoadjuvant chemoradiotherapy followed by surgery|Preoperative chemotherapy with concurrent radiotherapy followed by definitive surgery
10167304|NCT03923556|Experimental|Sugammadex|Sugammadex
10167305|NCT03923556|Active Comparator|Neostigmine|Neostigmine
9974887|NCT05143866|Experimental|Self-help CBT|Evidence based book detailing self-help program to follow plus Telephone support from a non specialist guide
10167306|NCT03923569|Other|Alzheimer's Disease patients group|This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease
10167307|NCT03923569|Other|Healthy control group|This group contains the 31 (anticipated) age and sex -matched healthy controls
10167308|NCT03923660|Experimental|Concentric-eccentric|Concentric-eccentric
10167309|NCT03923660|Experimental|Eccentric-concentric|Eccentric-concentric
9974888|NCT05142839|Experimental|EUS-CD|EUS-guided choledochoduodenostomy
10167310|NCT03923764|Experimental|Intervention group|1.3 g protein per kg bodyweight per day for 8 weeks
10167311|NCT03923764|Active Comparator|Kontrol group|habitual diet
10167312|NCT03923673|Experimental|Subjects with Heart Failure with Preserved Ejection Fraction|Subjects with Heart Failure with Preserved Ejection Fraction (HFpEF) will receive a minimally invasive treatment called a pericardiotomy.
10167313|NCT03923647||Laparoscopy and CT scan|Usage of laparoscopy after inflation of co2 infra umbilical
10167314|NCT03923621|Experimental|Experimental - EPSiT|Endoscopic Pilonidal Sinus Treatment
10167315|NCT03923621|Active Comparator|Control - excision|Excision treatment
10167316|NCT03923608||strength test|The maximum strength test of external shoulder rotators will be performed on 5 different tools with specific protocols.
10167317|NCT03923608||Endurance test|"Test designed by the Laboratory of Sports Physical Therapy (LAFIDE) of FCT / UNESP - Presidente Prudente, used in the prescription of training for gain of localized muscular endurance. Will be realized in the tools: Isokinetic dynamometer, elastic bands, pulley and halter.~The test will consist of the maximum possible repetitions (until fatigue) with loads of 70%, 80% and 90% of the maximum force (in different sessions)."
10167318|NCT03923829|Experimental|Zinc administration with scaling and root planing|systemic administration of Zinc cap of 50 mg elemental zinc as zinc sulphate, once a day for 12 weeks in addition to scaling and root planing
10167319|NCT03923829|Active Comparator|scaling and root planing|scaling and root planing
10186673|NCT03733522|Active Comparator|Rubber dam isolation|"Absolute isolation~local anesthesia~use of dental clamp and rubber dam~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
9520321|NCT03278730|Placebo Comparator|Placebo|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Placebo.. Strength N/A. Oral dose form: capsule matching to Tyrosine capsule. Number of Dispnsed an frequency 3x2 g daily. Duration of administration: 4 to 7 days."
10167320|NCT03923491|Experimental|Healthy Feeding, Healthy Eating|The experimental arm will receive three home over the first three months of the intervention.Visits will be conducted by a community health worker (CHW) trained in Motivational Interviewing. The home visits will include video-feedback on a meal; in-home cooking demonstrations; tailored text-messages, and mailed materials. During the last three months of the intervention, CHW will conduct monthly phone calls, together with mailed materials and text messages. The intervention will be tailored for families based on the child's appetitive traits and eating behaviors.
10167321|NCT03923491|Active Comparator|Reading and Readiness|The Reading and Readiness group will receive information on school readiness promotion. Materials will be adapted and delivered by the community health worker (CHW) with a similar dose and schedule as the intervention group (three home visits and three phone calls). During the home visits, the CHW will show a video that models early childhood caregiver-child activities and demonstrates simple methods to interact with their children. They will also send a video of themselves reading with a child, receive text-messages based on these materials as well as the print materials during the last three months of the intervention.
9671592|NCT05046145|Experimental|tDCS + speech therapy+ sham|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
9671593|NCT05046145|Experimental|sham + tDCS + speech therapy|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
10167322|NCT03923777|Other|Active Surveillance|Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor. Patients continue on this regimen, watching for tumor growth, up to 2 years on study or until rate or extent of growth leads to a shared decision to initiate treatment, whichever comes first.
10167323|NCT03923517|Experimental|YOD caregiver|The participants will be encouraged to use RHAPSODY for four weeks. After that they will have two individual MEET sessions with experts (social worker and psychologist).
10167324|NCT03923751||Polish Hospitals|Hospitals with anesthesia or intensive care practices
10167325|NCT03923478|Experimental|ABI-M201|"Cohort A: 1 capsule one time a day~Cohort B: 1- 5 capsules one time a day"
10167326|NCT03923478|Placebo Comparator|Placebo|"Cohort A: 1 capsule one time a day~Cohort B: 1-5 capsules one time a day"
10167327|NCT03923465|Active Comparator|EPP with EMD+BS|Using minimally invasive surgery, entire papilla preservation technique with the adjunctive use of amelogenins and bone substitutes
10167328|NCT03923465|Other|EPP without EMD+BS|Using minimally invasive surgery, entire papilla preservation technique without the adjunctive use of amelogenins and bone substitutes
10167329|NCT03923114|Other|Patient group with treatment response|PET/CT imaging of patients with response to GLP-1 receptor agonist treatment
10167330|NCT03923114|Other|Patient group without treatment response|PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment
10167331|NCT03923192|Other|ICDAS II|Visual tactile examination based on ICDASII scoring system
9974889|NCT05142839|Experimental|EUS-GEA|EUS-guided gastroenterostomy
10167332|NCT03923166|Experimental|pyrotinib+ capecitabine|
10167333|NCT03923348|Experimental|Leva Users|Subjects with pure urge urinary incontinence (UUI) or urge-predominant mixed urinary incontinence (U-MUI) who are candidates for pelvic floor physical therapy or other first line treatments for UUI/U-MUI use the leva® system twice-daily at home in addition to behavioral therapies for 8 weeks.
10167334|NCT03923205|Active Comparator|Control meal|The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.
9520322|NCT03278704|Other|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
10167335|NCT03923205|Active Comparator|The test meal|The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.
10167336|NCT03923361|Experimental|Propofol|
10167337|NCT03923387|Experimental|MynxGrip|MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
10167338|NCT03923387|Active Comparator|Manual compression|Manual compression hemostasis
10167339|NCT03923244|Experimental|cohorte 1|"Normal patient consultation schedule for cataract surgery with:~Preoperative appointment scheduled for the patient~Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
9671594|NCT05046080||Observational (medical record review)|Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.
9671595|NCT05046457|Experimental|3mg BCX supplement|One 3mg BCX capsule + one placebo capsule to be taken once per day for 8 weeks
10167340|NCT03923062|Experimental|G I A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
10167341|NCT03923062|Experimental|G I B(left side):will be treated by cryopeeling|left side of the patient's face will be treated by cryopeeling using Liquid Nitrogen.
10167342|NCT03923062|Experimental|G II A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
10167343|NCT03923062|Experimental|G II B (left side):will be treated by tranexemic acid|left side of patient's face will be treated by tranexemic acid(cyclokapron)
10167344|NCT03923153|Active Comparator|Inspiratory muscle training group|Inspiratory muscle training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
10167345|NCT03923153|Sham Comparator|Sham group|Sham group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
10167346|NCT03923218||Smoker patients with chronic periodontitis|Smoker patients with chronic periodontitis
10167347|NCT03923218||non-smoker patients with chronic periodontitis|non-smoker patients with chronic periodontitis
10167348|NCT03923218||periodontally healthy patients|periodontally healthy patients
10167349|NCT03923140|Experimental|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
10167350|NCT03923075|Active Comparator|Dexmedetomidine|"Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type body weight (Kg)/4 or body weight (Kg) X 0.25.~THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
10167351|NCT03923075|Placebo Comparator|0.9 % saline|"Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: body weight (Kg)/4 or body weight (Kg) X 0.25 THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
10167352|NCT03923257|Experimental|PRRT with 177Lu-DOTA-tyr3-OCTREOTATE|"177Lu-DOTA-tyr3-OCTREOTATE (177Lu-DOTATATE) and amino acid will be administered intravenously (IV) on Day 1 of each of four treatment cycles, 8 weeks apart.~This study will consist of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma. Children and adolescents with neuroendocrine tumor, pheochromocytoma or paraganglioma will not have had any previous endoradiotherapy with 90Y-DOTATOC, 131I-MIBG, or 177Lu-DOTATATE."
10167353|NCT03923101||Patients with Keratoconus|Aim is to include as many Keratoconus patients as possible with the intention to elucidate how the disease begins and develops during lifetime.
10167354|NCT03923335||high-risk group|patients with any of the four genes hypermethylated
10167355|NCT03923335||low-risk group|patients with none of the four genes hypermethylated
10167356|NCT03923127|Experimental|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
10167357|NCT03923231||Children <5 years|Children under the age of 5 years who are receiving atazanavir as part of clinical care
10167358|NCT03923231||Children 6-11|Children aged 6-11 years who are receiving atazanavir as part of clinical care
9671596|NCT05046457|Experimental|6mg BCX supplement|Two 3mg BCX capsules to be taken once per day for 8 weeks
9671597|NCT05046457|Placebo Comparator|0mg BCX supplementation|Two placebo capsules to be taken once per day for 8 weeks
9671598|NCT05045898|Experimental|Control group|plantar massage
9671599|NCT05045898|Experimental|Intervention group|plantar massage and textured insoles
9671600|NCT05045911|Experimental|Endoscopic Barbed-clips Suturing|Patients will be closed the mucosal defect after colorectal ESD using Endoscopic Barbed-clips Suturing.
9974890|NCT05141409||CAD-A|
9827738|NCT02466126|Experimental|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
9974891|NCT05141409||CAD-B|
10167359|NCT03923231||Adolescents 12-17|Adolescents aged 12-17 years who are receiving atazanavir as part of clinical care
10167360|NCT03923231||Pregnant women|Women who are at least 20 weeks gestation, who are receiving atazanavir as part of clinical care
10167361|NCT03923231||BMI < 18.5|Adults with a BMI of <18.5 kg/m2 who are receiving atazanavir as part of clinical care
10167362|NCT03923231||BMI >30|Adults with a BMI of >30 kg/m2 who are receiving atazanavir as part of clinical care
10167363|NCT03923179|Experimental|pyrotinib+Etoposide|
10167364|NCT03923413||patients with chronic heart failure without LVAD support|patients with chronic heart failure without LVAD support
10167365|NCT03923413||patients with end-stage heart failure with LVAD support|patients with end-stage heart failure with LVAD support
10167366|NCT03923088|Experimental|jacobson's progressive muscle relaxation technique|
10167367|NCT03923088|Experimental|audiovisual distraction technique|
10167368|NCT03923088|No Intervention|conventional|
10167369|NCT03923322|Experimental|Botanical Tincture|The 12-week study includes a 2-week screening, 8-week treatment, and 2-week withdrawal periods. A 2-week screening period will be used to establish the presence and persistence of trial entry criteria and train patients in the mode of data collection. Participants randomly assigned to the Botanical Tincture arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose. Participants who received Botanical Tincture during the study will be followed by a 2-week randomized withdrawal design to address the need for maintenance treatment to prevent sign or symptom recurrence. The participant will be randomly reassigned to receive either Botanical Tincture or placebo at a dosage of 2.5 ml once a day by mouth at any time during the day that they prefer.
10167370|NCT03923322|Placebo Comparator|Placebo|Participants randomly assigned to placebo arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose during the 8-week treatment period.
10167371|NCT03922984|Experimental|Glioblastoma Patients|Patients with histologically proven glioblastoma will undergo enhanced MRI with arterial spin labeling at weeks 0, 3, 6, 10, 18, 26, and 34 after beginning standard of care treatment.
10167372|NCT03923010|Experimental|Itraconazole|Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
9827739|NCT02466126|No Intervention|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
10167373|NCT03922932||Group A: PDR|This group will consist of 25 subjects with active proliferative diabetic retinopathy (PDR) and 25 subjects with treated PDR.
10167374|NCT03922932||Group B: NPDR|This group will consist of 50 subjects with severe non-proliferative diabetic retinopathy (NPDR), 50 subjects with moderate NPDR, and 50 subjects with mild NPDR.
10167375|NCT03922932||Group ME: Macular Edema|This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.
10167376|NCT03922932||Group C: DM without Retinopathy|This group will consist of 50 subjects with diabetes mellitus (DM) who do not have retinopathy.
10167377|NCT03922932||Group D: Healthy Controls|This group will consist of 40 subjects with healthy eyes who do not have diabetes.
10167378|NCT03922802|Experimental|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|"May receive up to 45 minutes of AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.~Intervention: Device: AIH prior to Noninvasive spinal stimulation during gait training"
10167379|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
10167380|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with sham transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
10167381|NCT03922815|Experimental|haemodynamic parametres-guided deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to disappearance of cilliary reflex; in the case of heart rate and/or arterial blood pressure increase by 20% a rescue dose of fentanyl 0,5 mcg per kilogram of body weight will be administered
10167382|NCT03922815|Experimental|SE-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weight of fentanyl in the case of heart rate and/or arterial blood pressure increase by 20%
10167383|NCT03922815|Experimental|AoA-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weightof fentanyl in the case of increase of SPI value > delta 15
10167384|NCT03922659|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
10167385|NCT03922659|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
10167386|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
10167387|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
9974892|NCT05138094|Active Comparator|Minimally invasive two-stage resection|Minimally invasive resection of the primary colorectal carcinoma and liver metastases in two stages. The liver metastases or the colorectal carcinoma can be resected during the first surgical procedure.
10167388|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
10167389|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
10167390|NCT03922711|Experimental|Pridopidine Dose 1|Dose 1 (oral capsule) for 12 weeks following 4 week dosage regimen titration period
10167391|NCT03922711|Experimental|Pridopidine Dose 2|Dose 2 for (oral capsule) for 12 weeks following 4 week dosage regimen titration period
10167392|NCT03922711|Placebo Comparator|Placebo|Matching placebo (oral capsule) for 16 weeks
10167393|NCT03922685|Active Comparator|Morning sedentary arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 11:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
10167394|NCT03922685|Active Comparator|Morning exercise arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 7:20 and 11:20, 3-ml blood samples were collected at 10-min intervals.After the 11:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
10186674|NCT03733522|Experimental|Relative isolation|"Relative isolation~no local anesthesia~use of cotton roll and saliva ejector~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
10167395|NCT03922685|Active Comparator|Evening sedentary arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 23:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
10167396|NCT03922685|Active Comparator|Evening exercise arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 19:20 and 23:20, 3-ml blood samples were collected at 10-min intervals.After the 23:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
10167397|NCT03922633|Experimental|Cohort 1 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167398|NCT03922633|Experimental|Cohort 1 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167399|NCT03922633|Experimental|Cohort 2 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167400|NCT03922633|Experimental|Cohort 2 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167401|NCT03922633|Experimental|Cohort 3 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167402|NCT03922633|Experimental|Cohort 3 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167403|NCT03922633|Experimental|Cohort 4 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167404|NCT03922633|Experimental|Cohort 4 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
10167405|NCT03922672|Experimental|Piano group|This group will consist of the adult with Parkinson's disease and their caregiver for a total of 14 pairs.
10167406|NCT03922919|Active Comparator|Cefotaxime or ceftriaxone group|free use of cefotaxime or ceftriaxone by the investigator
10167407|NCT03922919|Experimental|Cefotaxim group|Systematic use of cefotaxime
10186675|NCT03733509|Experimental|Intraoperative Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of Bupivacaine 0.25%.~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml of saline solution (NaCl 0.9%)."
10186676|NCT03733509|Active Comparator|Ultrasound Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of of saline solution (NaCl 0.9%).~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml Bupivacaine 0.25%."
9974893|NCT05138094|Experimental|Minimally invasive simultaneous resection|Minimally invasive resection of both the primary colorectal carcinoma and the liver metastases in one procedure.
10186677|NCT03733457|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
10186678|NCT03733444|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
10186679|NCT03733444|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
10186680|NCT03733444|Experimental|Placebo|Placebo to match will be administered as matching film-coated tablets for oral use once daily.
10186681|NCT03733431|Active Comparator|Standard dose vagal stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
10186682|NCT03733431|Active Comparator|High dose vagal stimulation|A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
10186683|NCT03733431|Sham Comparator|Sham stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
10186684|NCT03733405|Experimental|Postpartum Visit 6 Weeks|Participants will have a postpartum visit scheduled 6 weeks after birth
10186685|NCT03733405|Experimental|Postpartum Visit 2 and 6 Weeks|Participants will have postpartum visits scheduled 2 and 6 weeks after birth
10186686|NCT03733379|Placebo Comparator|Control|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
10186687|NCT03733379|Experimental|Probiotic|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.
10186688|NCT03733379|Experimental|Antibiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
10186689|NCT03733379|Experimental|Antibiotic + probiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.
10186690|NCT03733340|Experimental|Imipenem prophylaxis group|Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT
10186691|NCT03733340|No Intervention|Blank control group|Without antibacterial prophylaxis at the onset of condition of all-HSCT
10167408|NCT03922607|Experimental|Substudy 2: Group 2|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose D or matching placebo on Day 1 through Day 28
10167409|NCT03922607|Experimental|Substudy 2: Group 1|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 28
10167410|NCT03922607|Experimental|Substudy 1: Group 3|Participants, who are healthy volunteers, will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 14
10167411|NCT03922607|Experimental|Substudy 1: Group 2|Participants, who are healthy volunteers, will be administered with ABBV-157 dose B or matching placebo on Day 1 through Day 14
9974894|NCT05130723||Patients|Pediatric patients aged 2-18 years administered with fluconazole for the treatment or prophylaxis of invasive fungal infections.
10167412|NCT03922607|Experimental|Substudy 1: Group 1|Participants, who are healthy volunteers, will be administered with ABBV-157 dose A or matching placebo on Day 1 through Day 14
10167413|NCT03922906|Experimental|Motus Pure-Vu System|The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
10167414|NCT03922776|Experimental|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~at diagnosis, before chemotherapy (pre-CT)~after chemotherapy (post-ct)~Intervention : Collection of two blood samples (5mL)~before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~and then, after chemotherapy (post-CT), up to 3 months after enrollment"
10167415|NCT03922594||Cameroon|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
10167416|NCT03922594||China|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
10167417|NCT03922594||Ivory Coast|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex and severely disproportionate length or weight according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
10167418|NCT03922594||Sri Lanka|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
10167419|NCT03922594||Vietnam|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
10167420|NCT03922763|Active Comparator|Anatomically-matched cut|
10167421|NCT03922763|Active Comparator|Cutting guide|
10167422|NCT03922412|Active Comparator|plantar block|Short lasting sciatic nerve block (mepivacaine 1% 200mg) and long lasting plantar block (ropivacaine 0,5% 25mg + 2mg dexamethasone) with distal deep peroneal block (ropivacaine 0,5% 2ml).
10167423|NCT03922412|Active Comparator|Sciatic popliteal block|Long lasting sciatic nerve block (ropivacaine 0,5% 100mg + 2mg dexamethasone)
10167424|NCT03922490|Experimental|Knee Arthroscopy + Adipose Derived Stem Cells (ADSC)|Experimental Group: will undergo diagnostic knee arthroscopy with injection of adipose derived stem cells. Will also carry out all procedures associated with study (Physical Exam, Magnetic Resonance Imaging (MRIs), X-rays, Questionnaires).
10167425|NCT03922490|Other|Observation Cohort: Knee Arthroscopy|Observational Group: will undergo diagnostic knee arthscropy (No injection of adipose derived stem cells). Will also carry out all procedures associated with study (Physical Exam, MRIs, X-rays, Questionnaires).
10167426|NCT03922360|Active Comparator|Best Practices|
10167427|NCT03922360|Experimental|Best Practices + Financial Incentives|
10167428|NCT03922425|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
10167429|NCT03922425|No Intervention|Standard care|
10167430|NCT03923036||Metastatic colorectal cancer|"The French county Calvados registry of digestive cancers will allow to identify patients with a metastatic colorectal cancer diagnosed between 2004 and 2014.~Patients will be included if the cancer was diagnosed at the metastatic stage between 2004 and 2014 or non-metastatic before 2004 that became metastatic between 2004 and 2014 (synchronous and metachronous tumors)"
10167431|NCT03922399|Other|Laser and Surgery in patients with major burn scars|Evaluating patients with major burn scar after laser and surgical treatments Multiple-directions evaluation, including senior plastic resident, young resident, professional burn surgeons, senior nurse with burn scar, one non-medical patients(usually patients' family and friends)
10167432|NCT03922503|Experimental|Advanced- platelets rich fibrin with DFDBA|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
10167433|NCT03922503|Active Comparator|Collagen membrane and DFDBA|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
10167434|NCT03922438|Experimental|Cleft margin flap with anterior palatal closure|Usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.
10167435|NCT03922516|Other|Reporting order: Plain Film - ULDCT|"The plain film of half the participants (randomized) will be submitted for reporting by a radiologist as a first imaging method. After finishing this report, the same radiologist will assess the ULDCT of this participant. In this second report, the findings of both examinations will be summarized, and a second report will be filed.~Emergency physicians will first receive the report for the plain film of the chest and will be asked for the diagnosis and its probability. Next, the report for ULDCT will be presented to them. Again, diagnosis and probabilities will be documented."
10167436|NCT03922516|Other|Reporting order: ULDCT - Plain Film|"For half the participants (randomized) radiologists will first receive the data from ULDCT of the chest and write a report. Subsequently, they will receive the data from the plain film of the chest and may expand their report (explicitly separated).~Emergency physicians will first receive the report for the ULDCT of the chest and will be asked for probabilities of the nine most frequent diagnoses in chest-imaging plus other. Next, they will be presented with the report for the plain film and will again be asked to give an estimation of the probabilities for the same diagnoses as before."
10167437|NCT03922568||Density Gradient Centrifugation (DGC)|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
10167438|NCT03922568||Physiological ICSI (PICSI)|Semen processing is done by double layer DGC method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
10167439|NCT03922568||Magnetic Activated Cell Sorting (MACS)|Semen processing is done by double layer DGC method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
10167440|NCT03922867|No Intervention|Control Group|Subjects with receive standard of care for management of insomnia in subjects with fibromyalgia
10167441|NCT03922867|Active Comparator|Intervention Group|Subjects will receive standard of care and additionally complete the online cognitive behavior therapy program
10167442|NCT03922737|Active Comparator|In-person office visit|
10167443|NCT03922737|Active Comparator|Telehealth visit with provider|
10167444|NCT03922854||Mobile Monitor Group|Participants are recruited to this study if they have been monitored during their labour with a monica AN 24 monitor
10167445|NCT03922841||Subjects with pleural disease|"The subject must meet all of the following inclusion criteria to participate in this study.~Evidence of pleural disease on chest radiograph or bedside ultrasound or Computed Tomography regardless of underlying aetiology~No age or gender restrictions~Ability to provide informed consent"
10167446|NCT03922386|Other|JX model|Subjects implanted with an RA XFINE lead (JX model)
10167447|NCT03922386|Other|TX model|Subjects implanted with an RV XFINE lead (TX model)
10167448|NCT03922555|Experimental|ASTX727 (Cedazuridine + Cytidine Antimetabolite Decitabine)|-ASTX727 administered orally for 5 or 6 consecutive days every 28d cycle and will de-escalate to 4 consecutive days every 28 d cycle.
10167449|NCT03922555|Experimental|Expansion Cohort|"Oral ASTX727 will be administered daily for 4, 5 or 6 consecutive days~Surgical resection will take place 12 days (+/- 1 day) after initiation of treatment"
10167450|NCT03922542|Active Comparator|Accelerated|Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
10167451|NCT03922542|Active Comparator|Standard|Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes
10167452|NCT03922269||Transgender individual with a diagnosis of HIV|The participant self-identifies as transgender and/or has a current gender identity which differs from gender assigned at birth, is 18 years old or above, has a diagnosis of HIV infection and has been prescribed antiretroviral therapy.
10167453|NCT03922282|Experimental|Gasless BABA|BABA robotic-thyroidectomy that do not using carbon dioxide but using elevation of flap.
10167454|NCT03922282|Active Comparator|Classic BABA|BABA robotic-thyroidectomy using carbon dioxide.
10167455|NCT03922347|No Intervention|routine care|
10167456|NCT03922347|Active Comparator|Screening program including 2 consecutive tests|
10167457|NCT03922347|Active Comparator|Screening program with mobile health|
10167458|NCT03922373|Experimental|Benzonatate|
10167459|NCT03922295|Active Comparator|endoscopic double flap group|
10167460|NCT03922295|Active Comparator|endoscopic single flap group|
10167461|NCT03922113||Critically ill patients|Patients who spent a minimum of 48h in ICU
10167462|NCT03922113||Surgical patients|Patients who were scheduled for elective colorectal surgery
10167463|NCT03922113||Healthy subjects|Healthy volunteers
10167464|NCT03922152|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation and 2D-technique.
10167465|NCT03922009|Experimental|Virtual Reality group|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
10167466|NCT03922009|No Intervention|control group|General routine care
10167467|NCT03922048|Experimental|Cohort 1 Part A: HTX-011|Adolescents ≥12 to <17 years of age. A single dose of HTX-011 via instillation into the surgical site.
10167468|NCT03922048|Active Comparator|Cohort 1 Part A: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site.
10167469|NCT03922048|Experimental|Cohort 1 Part B: HTX-011|Adolescents ≥12 to <17 years of age. Dose to be determined from Cohort 1 Part A.
10167470|NCT03922048|Active Comparator|Cohort 1 Part B: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
10167471|NCT03922048|Experimental|Cohort 2 Part A: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
9671603|NCT05045976|Experimental|Experimental group|The experimental group will receive the web-based interactive self-management support intervention.
9671604|NCT05045976|No Intervention|Control group|The control group will receive usual care and regular patients education.
9827740|NCT02466230|Experimental|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
10167472|NCT03922048|Active Comparator|Cohort 2 Part A: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
10167473|NCT03922048|Experimental|Cohort 2 Part B: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
10167474|NCT03922048|Active Comparator|Cohort 2 Part B: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
10167475|NCT03922048|Experimental|Cohort 3: HTX-011|Children ≥3 to <6 years of age. Dose to be determined from Cohorts 1 and 2.
10167476|NCT03922048|Active Comparator|Cohort 3: bupivacaine HCl|Children ≥3 to <6 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
10167477|NCT03921983|Experimental|LTOT +|COPD patients with long term oxygenotherapy
10167478|NCT03921983|Active Comparator|LTOT -|COPD patients without chronic hypoxemia (no LTOT)
10167479|NCT03922230||Early esophageal cancer group|Pathological examination diagnosed as Early esophageal cancer.The ratio of male to female is 3:1, and the age is between 50 and 70 years old.
10167480|NCT03922230||Middle and advanced ES group|Pathological examination diagnosed as Middle and advanced esophageal cancer.
10167481|NCT03922230||Normal group|Confirmed as the normal by health checkups.
10167482|NCT03922178|Experimental|Elective coronary surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and anesthesiology wards. Subjects referred for elective coronary surgery will be prospectively included during the length of the study.
10167483|NCT03922061|Experimental|fIPV-dmLT|fractional-dose inactivated polio vaccine (fIPV) given intradermally with double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant
10167484|NCT03922061|Active Comparator|fIPV|fractional-dose inactivated polio vaccine (fIPV) given intradermally
10167485|NCT03921853|Active Comparator|Active comparator|Control group with obesity under Resistant Training
10167486|NCT03921853|Experimental|Experimental group with morbid obesity|Experimental group with morbid obesity under Resistant Training
10167487|NCT03921892|Other|In-person parenting education|Participants will complete two six-hour in-person parenting education sessions on two consecutive Saturdays
10167488|NCT03921892|Active Comparator|On-line parenting education|Participants will complete on-line parenting education at the times and locations of their choice over a two-week period.
10167489|NCT03921905||Patients with CAD|In this study will be included patients with stable CAD
10167490|NCT03922204|Experimental|MCLA-145|In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days
10167491|NCT03922191||Pediatric population|Infants diagnosed with cardiac post-surgery mediastinitis within the HUDERF Hospital within the last 20 years.
10167492|NCT03922191||Adult population|Adults diagnosed with cardiac post-surgery mediastinitis within the CHU Brugmann Hospital within the last 20 years.
10167493|NCT03922022|Experimental|EIM group|patients will go to different classes: (i) Hypertension basic exercise class (ii) Hypertension advanced exercise class (iii) diabetes basic exercise class (iv) diabetes advanced exercise class; if the patient has normal BMI AND reported some regular exercise, they will be prescribed the advanced level class. There is no control group for this pilot study
10167494|NCT03922074|Experimental|Non-anesthesiologist administered propofol|Sedation directed by an endoscopist in which the intravenous drugs are propofol and fentanyl . Target level sedation: moderate - deep.
10167495|NCT03922074|Active Comparator|Monitored anesthesia care|Sedation directed by an anesthesiologist in which the used intravenous drugs and target level sedation are chosen by the anesthesiologist.
10167496|NCT03921957|Experimental|stereotactic|
10167497|NCT03921684|Experimental|Neoadjuvant Treatment|All subjects will receive chemoradiation followed by chemotherapy and nivolumab as neoadjuvant treatment
10167498|NCT03921827|Experimental|EECP therapy|Half of the study sample will be allocated to EECP therapy (35 sessions) of 1-hour each. Acetazolamide challenged HMPAO-SPECT will be performed before randomization and repeated 2-months after the completion of EECP therapy. MRI of the brain would be performed after completion of EECP therapy to document any silent stroke.
10167499|NCT03921827|No Intervention|Best Medical Therapy|This group will receive the best medical therapy according to our institutional practice and as per the recommendations of American Stroke Association.
10167500|NCT03921840|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
10167501|NCT03921840|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
10167502|NCT03921632|Experimental|Education Program Effectiveness|Outpatients and inpatients from UNC Center of Excellence for Eating Disorders clinic
10167503|NCT03921879|Experimental|Stage 1 Dose Escalation|The dose escalation arm will use a modified 3+3 design to determine the maximum tolerated dose. or maximum tested dose.
10167504|NCT03921879|Experimental|Stage 2 Dose Expansion|The dose expansion arm will use the maximum tolerated dose to determine preliminary efficacy.
10167505|NCT03921801|No Intervention|Control|14-week control period.
10167506|NCT03921801|Experimental|Intervention|14-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback and home-based strength training session for plantarflexor muscles three times per week.
10167507|NCT03921801|No Intervention|Young adults - control|Outcome measures obtained at a single time point. The data is used to compare outcome measured between older and young adults.
10167508|NCT03921554|Experimental|Aicardi Goutières Syndrome patients receiving Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
10167509|NCT03921762|Experimental|Artis Active IOL|Artis Active IOLs (Artis Active Mid, Artis Active Plus) will be implanted in patients eyes during cataract surgery
10167510|NCT03921762|Experimental|AT Lara IOL|AT Lara IOLs will be implanted in patients eyes during cataract surgery
10167511|NCT03921736|No Intervention|Control Group|Control group consisted of 40 postmenopausal women with normal blood pressure.
10167512|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide|Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
10167513|NCT03921736|Experimental|Hypertensive women group receiving perindopril.|Patients received perindopril 4 mg/day p.o for 1 year.
10167514|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide and EPT|Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
10167515|NCT03921736|Experimental|Hypertensive women group receiving perindopril and EPT.|Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
10167516|NCT03921736|Experimental|Hipotensive women group receiving EPT.|Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.
10167517|NCT03921918|Other|Evaluation of Fluid Expression Technology|This study aims to provide important insights with respect to the safety, performance, and real-life usability of pumping technology
10167518|NCT03921697||Parkinson Disease Patients|"Patients with PD will be recruited at Fondazione Policlinico Universitario Gemelli and Fondazione Don Gnocchi ONLUS in Rome. All included patients will be affected by idiopathic PD. Clinical data will be acquired by a trained neurologist.~We will remotely monitor 300 patients through wearable sensors. Subjects will be instructed to wear the sensor for 14 consecutive days."
10167519|NCT03921645|Experimental|aerosol combined group|aerosol combined intravenous antibiotics group，amikacin 15mg/kg, qd
10167520|NCT03921645|No Intervention|No intervention group|this group follow the usual treatment without any intervention
10167521|NCT03922087||Control Group|The pregnancy women without any diseases.
10167522|NCT03922087||Disease Group|The pregnancy women with cardio-metabolic and endocrinic disorders such as gestational diabetes, obesity, hypertension, thyroid diseases, anemia and other cardio-metabolic diseases.
10167523|NCT03921749|Experimental|Focused shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be focused shock wave therapy (0.20 mJ/mm 2 )
10167524|NCT03921749|Experimental|Raidal shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be radial shock wave therapy (3 bar)
10167525|NCT03921658||Cohort 1 - Cross-sectional (within 2 years of diagnosis)|Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure
10167526|NCT03921658||Cohort 2- Prospective (from diagnosis)|Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)
10167527|NCT03922100|Experimental|Dose Escalation and Expansion (Phase I)|Dose escalation will be applied until one patient experiences first cycle DLT (Dose Limiting Toxicity) or 2 patients at any dose level experience non-DLT NCI CTCAE Grade ≥2 drug-related toxicity during the first cycle. Once the Maximum Tolerated Dose (MTD) is identified, a maximum of 10 additional patients will be enrolled (dose expansion).
10167528|NCT03922100|Experimental|AML FLT3 mutated (Phase II)|Cohort of AML FLT3 mutated patients. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
10167529|NCT03922100|Experimental|CMML (Phase II)|Cohort of patients with CMML. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
10167530|NCT03921931|Experimental|healthy volunteers|light stimulation
10167531|NCT03921931|Experimental|primary open angle glaucoma patients|light stimulation
10167532|NCT03921931|Experimental|age-related macular degeneration patients|light stimulation
10167533|NCT03921671|Experimental|Ramucirumab +carboplatin+ paclitaxel|All patient will receive the combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with recurrent and / or metastatic thymic carcinoma or thymoma B3 with area of carcinoma, in the first line.
10167534|NCT03921814|Experimental|Treatment with IPL device|This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual [5]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
9520323|NCT03278704|Experimental|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
9520324|NCT03278652||Patient with renal colic|
10167535|NCT03921710|Active Comparator|CAPA-IVM|Immature oocytes are culture in the new capacitation-IVM system.
10167536|NCT03921710|Active Comparator|Standard-IVM|Immature oocytes are cultured in the standard IVM system.
10167537|NCT03921593||Simultaneous Pancreas Kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Simultaneous Pancreas Kidney Transplant (SPK)
10167538|NCT03921593||Pancreas after kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Pancreas after kidney Transplant (PAK)
10167539|NCT03921593||Pancreas Transplant Alone Recipients|Patient affected by Insulin Dependent Diabetes Mellitus with hypoglycemia unawareness undergoing Pancreas Transplant Alone (PTA)
10167540|NCT03921567|Experimental|Group I|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
10167541|NCT03921567|Active Comparator|Group II|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
10167542|NCT03921567|Placebo Comparator|The control group|will be given opioids during surgery, opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
10167543|NCT03921463||caesarean section|
10167544|NCT03921463||vaginal delivery|
10167545|NCT03921476||Subjects on spironolactone for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
10167546|NCT03921476||Subjects on oral antibiotics for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
10167547|NCT03921528|Experimental|Cohort 1|Ambulatory Type 3 SMA
10167548|NCT03921528|Experimental|Cohort 2|Type 2 SMA / Non-Ambulatory Type 3 SMA
10167549|NCT03921528|Experimental|Cohort 3|Type 2 SMA
10167550|NCT03921489||Subchondroplasty in treating bone marrow edema|These patients will have calcium phosphate mineral compound injected into the bone marrow lesions.
10167551|NCT03921398||Patients with ESRD|Patients with history of biopsy-proven lupus nephritis (all classes of lupus nephritis)
10167552|NCT03921398||Patients with active lupus prior to treatment and no ESRD|Patients with biopsy-proven ACTIVE lupus nephritis
10167553|NCT03921398||Healthy individuals|Healthy individuals
10167554|NCT03921450|Experimental|Inhibitory repetitive transcranial magnetic stimulation (rTMS)|1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
10167555|NCT03921450|Active Comparator|Facilitatory intermittent theta burst stimulation (iTBS)|"Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.~total of 15 sessions in 3 weeks"
10167556|NCT03921450|Placebo Comparator|Placebo|1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
10167557|NCT03921450|No Intervention|Waiting group|This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm
10167558|NCT03921437|Experimental|decision support intervention|The intervention measures in this study were discussed with the nephrologist and CKD health teachers. Based on theoretical considerations, the experimental group provides decision support. Measures, including CKD Guardian as a decision-maker, and the use of e-book software to develop medical decision-assist tools, and the application and decision-making mode complemented by introduction and selection, including team discussions, option discussions, and decision-making conversations. The control group is introduced with traditional care instructions for routine care. The experimental group and the control group were referred to the CKD health teacher for the introduction of renal replacement therapy by the physician. The experimental group was guided by CKD Health Education to guide the patients to participate in the discussion, discuss the advantages and disadvantages of each treatment and guide patients to explore preferences. And value, supplemented by discussion and final decision.
10167559|NCT03921437|No Intervention|routine care|According to the nursing routine provide paper education.
10167560|NCT03921775|Experimental|Treatment group A|IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance
10167561|NCT03921775|Active Comparator|Treatment B|IV pumping of propofol at 120~150mg/kg/h for anesthesia induction and 3~12mg/kg/h for anesthesia maintenance
10167562|NCT03921606|Experimental|Experimental group|The experimental group will receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. However, the total time spent by the interventionist will not be more than that for a traditional MI with several long sessions. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up. The total time spent will be recorded and analysed.
10167563|NCT03921606|Other|Control group|The control group will receive individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese) in SOPCs. A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
10167564|NCT03921359|Experimental|Conventional physical training|Participants assigned to this arm will receive the conventional physical training.
10167565|NCT03921359|Experimental|SMARTfit training|Participants assigned to this arm will receive the SMARTfit training.
10167566|NCT03921086|Other|Hypertensive patients|Newly diagnosed or poorly controlled hypertensive patients will be initiated on appropriate therapy as per a specific algorithm.
10167567|NCT03921385||Single cohort - navigated cranial and spine surgery|
10167568|NCT03921268|Experimental|Treatment A|Dose A estimated delivered single dose of AZD1402 nebuliser solution administered via a nebuliser.
10167569|NCT03921268|Experimental|Treatment B|Dose B estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
10167570|NCT03921268|Experimental|Treatment C|Dose C estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
10167571|NCT03921294|Experimental|Single Arm|Patients with hemophilic pseudotumor will be treated with prophylactic emicizumab and assessed for improvement.
10167572|NCT03921346|Experimental|Arm A (mobile device app)|"Paramedics preparing drugs with the help of the mobile device app PedAMINES™.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of the mobile device app PedAMINES™."
10167573|NCT03921346|Active Comparator|Arm B (conventional preparation method)|"Paramedics preparing drugs with the help of conventional method.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of conventional method"
10167574|NCT03921372|Experimental|Normal Tension Glaucoma (NTG)|Patients with diagnosed NTG
10167575|NCT03921372|Experimental|Healthy Control Subjects|Subjects with no sign of glaucoma, Age and sex matched
10167576|NCT03921333|Active Comparator|Low dose plant extract|300 mg
10167577|NCT03921333|Active Comparator|Middle dose plant extract|500 mg
10167578|NCT03921333|Active Comparator|High Dose plant extract|700 mg
10167579|NCT03921333|Placebo Comparator|Placebo control|Cellulose microcrystalline
10167580|NCT03921177|Experimental|Multiple micronutrient supplement|Daily micronutrient supplement
10167581|NCT03921177|Placebo Comparator|Placebo|Daily identifcal placebo tablet
10167582|NCT03921112|Active Comparator|lung ultrasound|
10167583|NCT03921112|Active Comparator|x-ray, ABG, RSBI, Vetilator parameters|
10167584|NCT03921164||Patients scheduled for a neuroradiology procedure|Interventional neuroradiology procedure under general anesthesia requiring a continuous monitoring of mean arterial pressure and cardiac output, including electrocardiogram, pulsated oxygen saturation, endtidal CO2, respiratory rate, tidal volume and monitoring of neuromuscular function. In addition, for all patients, data from trans-oesophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.
9671605|NCT05045989|Experimental|Residence-based asymptomatic SARS-CoV-2 testing|The aim of the RB-TPP was to increase and maintain participation of students in regular COVID-19 testing in university residences. The R-TPP was delivered over 4 weeks in April-May 2021 and required asymptomatic students to take a saliva test for COVID-19, twice weekly for four weeks. This was combined with relaxed social restrictions within the residence during the study period (i.e., removing the need for 2 metre distancing between students living in the same residence), surge testing and enhanced support for students who were required to self-isolate (i.e., welfare and financial support).
9827741|NCT02466386|Experimental|SPD489|Participants will receive 5 milligrams (mg) of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 52 weeks.
10167585|NCT03921203||Type 2 diabetes patients|
10167586|NCT03921203||Healthy controls|
10167587|NCT03921125||Responders|
10167588|NCT03921125||Non responders|
10167589|NCT03921138||Benign laparoscopic hysterectomy|Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy
10167590|NCT03921034|Active Comparator|continuous ACB with IPACK block|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and IPACK block with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine
10167591|NCT03921034|Sham Comparator|continuous ACB with sham subcutaneous saline injection|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and a sham IPACK block with subcutaneous saline injection along the medial thigh
10167592|NCT03921099|No Intervention|Vancomycin only|Vancomycin 15-20mg/kg intravenous every 8-12 hours.
10167593|NCT03921099|Experimental|Vancomycin +Ascorbic acid|Vancomycin 15-20mg/kg intravenous every 8-12 hours. Ascorbic acid 1gm every 12 hours orally just before vancomycin by half an hour for seven days.
10167594|NCT03921021|Experimental|Telomelysin (OBP-301)|All patients will receive Telomelysin (OBP-301) at 2x10^12 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).
10167595|NCT03920917|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
10167596|NCT03920917|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
10167597|NCT03920943|Other|Core and TAT measurements|As part of the standard of care, flight paramedics will insert an esophageal or rectal temperature probe in patients meeting including criteria to enable continuous temperature monitoring. Paramedics will measure core temperature on at least two occasions, the first measurements made at least 5 minutes after insertion of the temperature probe, and also prior to departure from the sending facility.
10167598|NCT03920930|Experimental|Early-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached."
10167599|NCT03920930|Active Comparator|Late-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied after the preparation of the femur and tibia bone shortly before the prosthesis is inserted and during the retreat from the knee joint."
10167600|NCT03920956|Experimental|Experimental: 24-hour ABPM by Pharmacists|Patients will meet with the pharmacist to be equipped with a 24-hour ambulatory blood pressure monitor (ABPM). Patients will return the monitor for the pharmacists to download the results to send to their medical provider.
10167601|NCT03920579|Experimental|Sequence 1|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: D326, D337, D013(3 tabs, once)
10167602|NCT03920579|Experimental|Sequence 2|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 2(1 tab, once)
10167603|NCT03920579|Experimental|Sequence 3|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 1(1 tab, once)
10167604|NCT03920579|Experimental|Sequence 4|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: D326, D337, D013
10167605|NCT03920579|Experimental|Sequence 5|Period 1: D326, D337, D013(3 tabs, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: CKD-386 formulation 2(1 tab, once)
10167606|NCT03920579|Experimental|Sequence 6|Period 1: D326, D337, D013 (3 tabs, once)/ Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: CKD-386 formulation 1(1 tab, once)
10167607|NCT03920657|Experimental|Deferasirox|patients will be assigned to a fixed dose of 3.5 mg/kg/day of DFX FCT.
10167608|NCT03920709||Chronic HIV-1 infected subjects : 50 Viremic subjects|plasma HIV RNA > 500 copies/mL, treatment-naive or treated (failing) regardless of the cause of persistent viremia
10167609|NCT03920709||Chronic HIV-1 infected subjects : 50 Treated Aviremic subjects|< 50 copies/mL under treatment for at least 12 months
10167610|NCT03920709||Chronic HIV-1 infected subjects :10 Spontaneous Controllers|from the ANRS CO21 CODEX Cohort or not (5 last viral loads < 400 copies /ml)
10167611|NCT03920631|Experimental|Cohort 1: Microtransplantation (MST)|MST:Infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
10167612|NCT03920631|Experimental|Cohort 2/2b: MST + Nivolumab|"2: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day+14)~2b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day+14)."
10167613|NCT03920631|Experimental|Cohort 3/3b: MST + Nivolumab|"3: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day-1).~3b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day-1)."
10167614|NCT03920631|Experimental|Cohort 4: Expansion|Microtransplantation (Day 0) + nivolumab (at RP2D)
10186692|NCT03733327|Experimental|BUCYE|For PCNSL patients undergoing auto-HSCT，BUCYE conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/ day on days -3 and -2.
10186693|NCT03733288|Experimental|SLAMM|Multi-component intervention (Education and training sessions, Support emails, Team leader training)
10186694|NCT03733288|Experimental|SLAMM+|Multi-component intervention (Education and training sessions, Support emails, Team leader training, Height-adjustable workstation)
10186695|NCT03733275|Experimental|local anesthetic group|local aensthetic group receive preopetaive lidocaine spray and lidocaine-bupivacine mixture-soaked nasal pacing after nasal reduction surgery
10186696|NCT03733275|Placebo Comparator|control group|control group receive preoperative normal saline spray and normal saline-soaked nasal packing after nasal reduction surgery
10186697|NCT03733262||Hemodialysis Patients|There will be approximately 1,200 patients in the outpatient HD units from Toronto (300), Vancouver (200), Winnipeg (400) and Halifax (300). Based on a previous pilot study, it is assumed that 80% of patients have been prescribed at least one of the nine target drugs (i.e., n=960). Of those, it is assumed that 50% will be eligible for the study (i.e., n=480). Of eligible individuals, it is assumed 88% will initiate a De-prescribing Trial (Intervention Group), resulting in an anticipated cohort of n=420.
10186698|NCT03733249|Experimental|Rimiducid and Rivogenlecleucel|"Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)~No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy."
10186699|NCT03733236|Experimental|Active Stimulation|The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
10186700|NCT03733223||experimental group|The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions
10186701|NCT03733223||control group|The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.
10186702|NCT03733210|Experimental|Lymph Node-positive Tumor|Participants whose lymph nodes are positive for cancer
10186703|NCT03733210|Experimental|Lymph Node-negative Tumor|Participants whose lymph nodes are negative for cancer
10186704|NCT03733197|Experimental|Culture specific|"The culture-specific arm may entail FIT kits plus barbers as motivational interviewers."
9827742|NCT02466399|Experimental|POLAT-001|Latanoprost liposome ophthalmic injection
10167615|NCT03920904||Bupivacaine dosage in PIFB block|The pharmacokinetics of bupivacaine 0.25% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following a PIFB block will be determined by the collection of blood samples at predetermined time points.
10167616|NCT03920813|Experimental|Antitumor drugs|Mercaptopurine administered at standard dose for children with hematological neoplasms.
10167617|NCT03921008|Experimental|Paclitaxel and Radiation|"All patients will receive standard of care induction chemotherapy with 6 weekly cycles of paclitaxel at 80 mg/m^2. They will then receive 6 weekly cycles of paclitaxel at 80 mg/m^2 concurrently with radiation therapy. Patients will be receiving paclitaxel as part of their routine care, but in order to participate in this study, their induction chemotherapy regimen must be paclitaxel. Radiation therapy is 50.4 Gy in 28 fractions delivered within 7 weeks.~Standard of care surgery ideally within 6 weeks after completing concurrent chemotherapy and radiation therapy"
10167618|NCT03920878|Experimental|Aflibercept injected Pre- and Post-operatively|Pre- and Post-operative time of Aflibercept injections
10167619|NCT03920878|Active Comparator|Aflibercept injected intraoperatively|Intraoperative time of Aflibercept injection
10167620|NCT03920618|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
10167621|NCT03920618|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
10167622|NCT03920618|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
10167623|NCT03920891|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
10167624|NCT03920891|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
10167625|NCT03920748||Difficult laryngoscopy (Group D)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 3-4 are classified as difficult laryngoscopy ( Group D).
9671606|NCT05045924||Intervention group|20 patients with decompensated liver cirrhosis monitored using a wrist-watch wearable device, with associated smart weighing scales and blood pressure cuff, along with a smartphone application (including economic smartphone in those patients if not available), to facilitate home monitoring.
10167626|NCT03920748||Easy laryngoscopy (Group E)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 1-2 are classified as easy laryngoscopy ( Group E).
10167627|NCT03920839|Experimental|INCMGA00012 + gemcitabine/cisplatin|
9671607|NCT05045924||Control group|20 patients with decompensated liver cirrhosis receiving standard quality of care.
10167628|NCT03920839|Experimental|INCMGA00012 + pemetrexed/cisplatin|
10167629|NCT03920839|Experimental|INCMGA00012 + pemetrexed/carboplatin|
10167630|NCT03920839|Experimental|INCMGA00012 + paclitaxel/carboplatin|
10167631|NCT03920852|Experimental|Ruxolitinib cream|
10167632|NCT03920644|Experimental|DPI-386 Nasal Gel|Receives Active Nasal Gel 2 times per treatment day
10167633|NCT03920644|Placebo Comparator|Placebo nasal gel|Receives Nasal Gel 2 times per treatment day
10167634|NCT03920644|Active Comparator|TDS Patch|Receives one patch per treatment.
10167635|NCT03920735||Opportunistic infection|Immunocompromised or frail patients with an opportunistic infection
10167636|NCT03920735||Control group|Immunocompromised or frail patients with no opportunistic infection
10167637|NCT03920592|Experimental|Video watching|"All participants will watch 4 videos of potential everyday school situations, adapted for boys and girls.~Videos contain different levels of bullying (presence/absence) and virtual reality (presence/absence).~Every pupil will watch the 4 types of video content randomly."
10167638|NCT03920800||Conservative management - progression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, with progressive lesions or lesions remaining present after 2 years of follow-up.
10167639|NCT03920800||Conisation|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital by means of conisations.
10167640|NCT03920800||Conservative management - spontaneous regression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, who showed a spontaneous regression of the lesions during the 2 years follow-up.
10167641|NCT03920683||Diabete type 1 and 2|Data collection from patients treated in the diabetes department, in Pitié-Salpêtrière hospital, and adressed for a one-day hospitalization to assess cardiovascular comorbidities.
10167642|NCT03920605|Active Comparator|Peginterferon alfa group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
10186705|NCT03733197|Experimental|Control|Distribution of CRC screening brochures & FIT (Fecal Immunochemical Test) kits by barbers
9671608|NCT05046041|Experimental|Mifepristone + Misoprostol|200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
9671609|NCT05045742||Training|A subset of patients that are used to train the machine learning algorithm.
10167643|NCT03920605|Active Comparator|Combination group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week and meanwhile oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive treatment of oral TDF 300 mg once per day from 49 to 144 weeks.
10167644|NCT03920787|Experimental|Inositol|Administration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month
10167645|NCT03920787|Placebo Comparator|Placebo|Administration of placebo. 2 capsules every day for 1 month
10167646|NCT03920540|Experimental|GC1111|All subjects should receive the GC1111 for 52 weeks.
10167647|NCT03920540|Active Comparator|Comparator|All subjects should receive the comparator for 52 weeks.
10167648|NCT03920553|Experimental|Test Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it. No bleeding was observed after the frenectomy performed with laser. Then, commercially available Hiyaluronic acid was topically applied to the relevant area to completely cover the surgical field to the test group. Following the frenectomy performed with laser, no application was made to the control group patients.
9520325|NCT03278639|Experimental|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
10167649|NCT03920553|No Intervention|Control Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it.
10167650|NCT03920514|Active Comparator|GROUP 1|IUI 24 hours after hCGadminstration
10167651|NCT03920514|Active Comparator|GROUP 2|IUI 36 hours after hCG adminstration
10167652|NCT03920514|Active Comparator|GROUP 3|IUI 48 hours after hCG adminstration
10167653|NCT03920514|Active Comparator|GROUP 4|IUI at time of hCG adminstration
10167654|NCT03920501|Experimental|Tele-Critical Care|Tele-Critical Care + Audit & Feedback.
10167655|NCT03920501|No Intervention|Usual Care|Usual Care.
10167656|NCT03920371|Experimental|gamma camera imaging|hand held camera
10167657|NCT03920228|Experimental|Open label period|
10167658|NCT03920228|Placebo Comparator|Randomized period - Dosing A|
10167659|NCT03920228|Experimental|Randomized period - Dosing B|
10167660|NCT03920228|Experimental|Randomized period - Dosing C|
10167661|NCT03920150|Active Comparator|Control|5 ml alcoholic solution containing 24'000 IU vitamin D for 3 months
10167662|NCT03920150|Active Comparator|IMP|Vitamin D oily capsules containing 24'000 IU vitamin D for 3 months
10167663|NCT03920150|Active Comparator|IMP + loading dose|Vitamin D oily capsules containing 24'000 IU vitamin D for an individual number of weeks calculated with the formula: 40 x (100 - actual value [nmol/l] x body weight [kg] / 24'000 IU.
10167664|NCT03920137|Active Comparator|Active- UP-ST|The intervention will be the UP-ST therapy sessions. Treatment will be delivered using the new UP-ST protocol that will be developed in Phase I by integrating components of smoking cessation treatments (e.g. using the nicotine patch) with the theoretical model and treatment components of the existing UP treatment protocol, which includes both a therapist14 and patient12 manual. The UP-ST will maintain the same focus on transdiagnostic mechanisms of change as in the original UP, but will be adapted to integrate the smoking cessation focus and concurrent use of NRT. Thus, the investigators can successfully adapt and develop the new UP-ST to be delivered in eight 90-minute sessions and will be able to incorporate content from each of the 8 modules of the UP in the new UP-ST protocol.
10167665|NCT03920137|Experimental|Control- Standard|The Intervention will be the standard therapy sessions. Participants will receive a standard smoking cessation treatment based on the most recent clinical practice guideline from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence19. The investigative team has considerable expertise in developing and evaluating behavioral and pharmacological treatments for smoking cessation. Treatment will be delivered in eight, 90-minute sessions over an eight-week period.
10167666|NCT03920163|Active Comparator|Control|Stable , penetrating trauma patients undergoing laparotomy who receive standard post operative care
10167667|NCT03920163|Experimental|ERATS|Stable penetrating trauma patients undergoing laparotomy who receive enhanced recovery measures post operatively .
10167668|NCT03920345|Experimental|Treatment: Endoscopic ET on SI joint|New techniques have been developed and tested to expand the usefulness of minimally invasive spine surgery beyond disk herniation. This includes endoscopic electrothermic ablation which can be used to target SIJ-associated CLBP. A small retrospective study demonstrated significant improvements in Visual Analog Scale and Oswestry Disability Index from pre-operative levels in patients with CLBP associated with the SIJ for up to 21 months following the procedure. However, there has not yet been a prospective study to assess the efficacy of this procedure, and therefore, this is the aim of this study.
10167669|NCT03920241||MBSR group|Attendants to Mindfulness-Based Stres Reduction programs offered to the community by Complutense University
9520326|NCT03278639|Active Comparator|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
9520327|NCT03278587|Active Comparator|Community-based screening|
9520328|NCT03278587|Active Comparator|Cataract camp program|
10167670|NCT03920241||CCT group|Attendants to Compassion Cultivation Training programs offered to the community by Complutense University
10167671|NCT03920241||Control group|Control group matched by age, gender, and meditation experience.
10167672|NCT03920423|No Intervention|shallow depth|Radial arterial deth is shallow than the cutoff point that relative to results.
10167673|NCT03920423|Experimental|improved depth|Radial arterial deth is shallow than the cutoff point that relative to results, and increased by injection of saline to more than deep cutoff point.
10167674|NCT03920475||TAU (treatment as usual) group|Patients with depression, meeting inclusion criteria, who needed antidepressant treatment and received either sertraline or venlafaxine.
10167675|NCT03920319|Experimental|Bupropion|Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
10167676|NCT03920319|Placebo Comparator|Placebo|Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
10167677|NCT03920397|Experimental|Adipose tissue-derived stem/stromal cells|Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
10167678|NCT03920397|Experimental|Daily 2000 UI of daily oral cholecalciferol|To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.
10167679|NCT03920436|Experimental|Infrared water group|This group takes drinking water using a tumbler that emits far infrared rays at room temperature for 8 weeks.
10167680|NCT03920436|Sham Comparator|sham group|This group takes drinking water using a tumbler at room temperature for 8 weeks.
10167681|NCT03920085|Experimental|LifeScan BGMSs|OneTouch Verio, OneTouch Select Plus and OneTouch Ultra Blood Glucose Monitoring Systems (BGMSs) tested using subject capillary blood and compared to a reference instrument (YSI 2900).
10167682|NCT03920072|Other|Open label|All subjects will be administered subcutaneously burosumab every 4 weeks at the dosage defined in study UX023-CL303 or UX023-CL304 until December 2021 or when the drug becomes commercially available.
10167683|NCT03920124|Experimental|High intensity interval exercise|Completion of four separate step and walk-based high intensity interval exercise sessions, followed by completion of six week unsupervised (at home) high intensity interval exercise intervention
10167684|NCT03920449|Active Comparator|Botulinum toxin injection|
10167685|NCT03920449|Active Comparator|Posterolateral internal sphincterotomy|
10167686|NCT03920111|Other|Group 1 - Any status|Up to 3-4 healthy adults
10167687|NCT03920111|Other|Group 2 - FlaviPrime Naive|Up to 6-8 healthy adults who have never travelled to a flavivirus endemic area and are negative in screening tests for flavivirus immunity.
10167688|NCT03920111|Other|Group 3 - Flavivirus Exposed|Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
10167689|NCT03920059|Placebo Comparator|FD arm|MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.
10167690|NCT03920059|Active Comparator|CC Arm|MMF will be prescribed at a starting dose of 1.5 g/day. MPA-C0 (trough) level will be measured weekly and MMF dose will be increased by 500 mg/day every week until the MPA-C0 level ≥ 3 mg/L or the MMF dosage is 3000 mg/day. After achieving the targeted MPA-C0 level, the MMF dose adjustment will be allowed only if the MPA-C0 levels are lower than 3 mg/L for two consecutive monitoring visits. After week 12, MMF will be maintained at the same dose until week 48
10167691|NCT03920046||Effects of passive smoking on children|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents smoking.
10167692|NCT03919877|Other|Optimizing Diet for Glycemic Control|"All individuals will go through all the phases of the study.~Phase 1: Metabolic testing to determine insulin resistance status.~Phase 2: Participants follow their own diet while using the CGM (continuous glucose monitor). Participants are provided with 5-10 standardized foods to test during this phase.~Phase 3: Participants are provided with additional standardized foods and counseled to continue their own diet during this phase.~Phase 4: Participants are counseled on reducing or limiting the foods that caused glucose spikes and they are also counseled on macronutrient composition of their diet based on lipid profile. Participants use the CGM for another cycle of 2-3 weeks to assess effectiveness of the recommendations. Blood is drawn for analyses before and after this cycle."
10167693|NCT03919890|Experimental|ONO-7684 Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
10167694|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
10167695|NCT03919890|Experimental|ONO-7684 Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
10167696|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
10167697|NCT03919890|Experimental|ONO-7684 Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
10167698|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
10167699|NCT03920033|Experimental|Hypofractionated|65 Gy/ 26 fractions (fraction size 2.5 Gy)
10167700|NCT03920033|Active Comparator|Standard|66 Gy/ 33 fractions (fraction size 2 Gy)
10167701|NCT03919838|Active Comparator|Probiotics|Participants will receive two lozenges containing probiotic bacteria and cranberry.
10167702|NCT03919838|Placebo Comparator|Placebo - No probiotics|Participants will receive a control two lozenges containing no probiotic bacteria.
9520329|NCT03278587|Active Comparator|Community health worker program|
9520330|NCT03278587|No Intervention|No intervention|
9520331|NCT03278574|Experimental|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
10167703|NCT03919916|Experimental|Serratus plane block and patient controlled analgesia|"Initial local anaesthetic bolus of 0.4 ml/kg of 0.25% levobupivacaine. Subsequent continuous local anaesthetic infusion of 0.125% levobupivacaine~Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes"
10167704|NCT03919916|Active Comparator|Patient controlled analgesia only|Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes
10186706|NCT03733184||The Christie NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at The Christie NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
10167705|NCT03919786|Experimental|intervention group|"Durg：0.375% Ropivacaine and 1% lidocaine~topical local anesthesia of pulmonary vein with lidocaine+ropivacaine at the beginning and the end of surgery operation.~Block vagus nerve with lidocaine+ropivacaine 1ml after exposing the pleural apex"
10167706|NCT03919786|Placebo Comparator|normal saline group|Same volume of normal saline will be administrated
10167707|NCT03920020|Other|the concentric isokinetic exercise group|the concentric isokinetic exercise group will perform quadriceps and hamstring concentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
10167708|NCT03920020|Other|the eccentric isokinetic exercise group|the eccentric isokinetic exercise group will perform quadriceps and hamstring eccentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
9671610|NCT05045742||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
9671611|NCT05045781|Experimental|Eptinezumab 100 mg|
10167709|NCT03920020|Other|the control group|the control group will perform the standard exercise program predetermined by us consisting of stretching exercises and isometric strengthening (these exercises will be done at home, too) and the conventional physiotherapy program will be applied 3 times a week during 6 weeks.
10167710|NCT03919968|Experimental|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
10167711|NCT03919968|Active Comparator|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
10167712|NCT03919695|Experimental|structural and behavioral intervention|The KISOBOKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component changes the mode of work payment from cash to mobile money.
10167713|NCT03919695|Active Comparator|Screening and Referral|Brief feedback on AUDIT-C score, referral for alcohol counseling, and briefly discussion of the importance of HIV care engagement and adherence.
10167714|NCT03919955|Experimental|Atomoxetine and Oxybutynin|Participants will take Atomoxetine and Oxybutynin nightly for one month. Half doses will be given on the first three nights.
10167715|NCT03919955|Placebo Comparator|Placebo|Participants will take Placebos nightly for one month. Half doses will be given on the first three nights.
10167716|NCT03919721|Experimental|Learners receiving Applied Behavior Analysis therapy|All children enrolled in the study will already receiving therapy. Each BT-child pair will have worked together regularly for at least 3 months prior to the study.
10167717|NCT03919929|Active Comparator|Diet Intervention|Weight loss with dietary intervention
10167718|NCT03919929|Experimental|GLP-1 Intervention|Participants will take a daily oral tablet of semaglutide for 4 months.
10167719|NCT03919942|Experimental|OxyFlower gel|pericoronitis treatment with oxyflower gel.
10167720|NCT03919942|Experimental|Chlorhexidine gel|pericoronitis treatment with chlorhexidine gel.
10167721|NCT03919942|Placebo Comparator|Placebo gel|pericoronitis treatment with placebo gel.
10167722|NCT03919591|Other|Open Label Pilot|Open Label Pilot Study. All subjects will receive the viral challenge inoculum.
10167723|NCT03919812|Experimental|Vitamin D supplementation according to baseline Vitamin D|The intervention provided according to the participants' state of vitamin D sufficiency. vitamin D sufficient participants received 800 IU cholecalciferol (syrup containing 400 IU cholecalciferol per measuring spoon, Gracia Pharmindo, Indonesia) daily for 8 weeks, while those who had insufficient or deficient vitamin D level consumed 2000 IU daily. Compliance was systematically monitored using drug monitoring diary evaluated by researchers. Blood samples for the study objectives were taken at enrollment and after eight weeks of cholecalciferol supplementation during routinely scheduled visits to the clinic.
10167724|NCT03919578|Experimental|Hep B Batch 1|1 dose of 1 mL Hepatitis B Batch 1
10167725|NCT03919578|Experimental|Hep B Batch 2|1 dose of 1 mL Hepatitis B Batch 2
10167726|NCT03919578|Experimental|Hep B Batch 3|1 dose of 1 mL Hepatitis B Batch 3
10167727|NCT03919578|Active Comparator|Hep B (Bio Farma)|1 dose of 1 mL Hepatitis B (Bio Farma)
10167728|NCT03919656|Experimental|Dapagliflozin|Dapagliflozin 10 mg daily (orally)
10167729|NCT03919656|Placebo Comparator|Placebo|Matching placebo for dapagliflozin daily (orally). Does not contain active ingredient
10167730|NCT03919708||Enriched Population|Children between the ages of 2-8 who present to an eye clinic. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans and exam should be performed within a single visit. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
9520332|NCT03278574|Active Comparator|Complete ring|Mitral valve repair with complete rigid ring
9671612|NCT05045781|Experimental|Eptinezumab 300 mg|
9671613|NCT05045963||Observational (medical record review)|Patients' medical charts are reviewed retrospectively.
9671614|NCT05045859|Experimental|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning.
10186707|NCT03733184||Hampshire Hospitals NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at Hampshire Hospitals NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
10186708|NCT03733171|Active Comparator|Platelet rich plasma|endoscopic injection of PRP
10186709|NCT03733171|Placebo Comparator|CONTROL GROUP|diluted epinephrine
10167731|NCT03919708||Unenriched Population|Children between the ages of 2-8 who present to a general pediatric clinic, with no history of eye disorders or amblyopia. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans will be performed at a single visit, but the exam may require a follow up visit, depending on the availability of a pediatric ophthalmologist at the clinic at the time of study enrollment. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
9671615|NCT05045859|No Intervention|No Intervention: Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 15-weeks waiting period. At the end of that period received the exact intervention as the study group.
9671616|NCT05045755||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
10167732|NCT03919604||ECLS group|Patients with CF undergoing LUTX. Need for intraoperative extracorporeal life support
9671617|NCT05045755||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
9671618|NCT05045495||Healthy Volunteer|120 Healthy Volunteers will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
9671619|NCT05045495||CSID Case|50 CSID cases defined by being on Sucraid for at least 12 months will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
9827743|NCT02466399|Active Comparator|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
10167733|NCT03919604||Non-ECLS group|Patients with CF undergoing LUTX. No need for intraoperative extracorporeal life support
10167734|NCT03919760||NAVIGATE EPI|"This group of first episode psychosis patients is receiving NAVIGATE early psychosis intervention (EPI) as their regular clinical standard of care.~The project team is implementing NAVIGATE at several early psychosis intervention (EPI) programs in different geographic regions of Ontario. The team will recruit consecutive referrals to these programs in order to determine longitudinal change in functioning and symptoms (hypothesis #3).~Additionally, the primary data collected for these patients will be linked deterministically to data sources held at the Institute for Clinical Evaluative Sciences (ICES) via their unique health card number. Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
10167735|NCT03919760||Non-NAVIGATE EPI|"This group of first episode psychosis patients received early psychosis intervention other than NAVIGATE as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
10167736|NCT03919760||Non-EPI|"This group of first episode psychosis patients did not receive early psychosis intervention as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
10167737|NCT03919500|Experimental|Erythropoietin|Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
10167738|NCT03919500|Placebo Comparator|Normal saline|Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.
10167739|NCT03919682|Experimental|Training, Phase 1|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in April-May 2015
10167740|NCT03919682|Experimental|Training, Phase 2|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in November-December 2015
10167741|NCT03919682|No Intervention|Control|6 health centers served as controls and did not receive training during the study period
10167742|NCT03919630|Experimental|Cervical Thrust Mobilizations|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine.
10167743|NCT03919630|Active Comparator|Cervical Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
10167744|NCT03919513|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
10167745|NCT03919513|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
10167746|NCT03919552|Experimental|Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and carboplatin (AUC 5 on day 1) every three weeks for three cycles during radiotherapy.
10167747|NCT03919552|Active Comparator|Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during radiotherapy.
10167748|NCT03919565|Active Comparator|TDF group|80 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 144 weeks.
10186710|NCT03733158|Experimental|Normal airway|intubation in normal aurway condition
10186711|NCT03733158|Experimental|Tongue edema|intubation in Tongue edema condition
10167749|NCT03919565|Experimental|Peginterferon alfa group|40 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
10167750|NCT03919253|Experimental|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously; nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
10167751|NCT03919201|Sham Comparator|Control group|No exercise intervention
10167752|NCT03919201|Experimental|Resistance band exercise intervention|Exercise intervention group (resistance band exercise training for 12 weeks, 5x per week, for 60 minutes per day).
10167753|NCT03919240|Experimental|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells
10167754|NCT03919526|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/ CD22 CAR-T cells in the MRD-positive ALL patients.
10167755|NCT03919487||Back-to-back colonoscopy group|As I described the study method in the protocol, the experimental group will be a screening colonoscopy cohort with back to back method. In fact, this study is to evaluate the correlation between quality indicators of colonoscopy and adenoma miss rate (AMR), and intervention is a single arm for back-to-back colonoscopy.
10167756|NCT03919331|Experimental|Experimental|Every adult patient admitted to the medical intensive care unit for de novo acute hypoxemic respiratory failure, and placed under hign flow nasal canula (HFNC). Inclusion and exclusion criterion are listed elsewhere.
10167757|NCT03919383|Experimental|Lenvatinib Plus Toripalimab|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 21-day treatment cycles, and received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10167758|NCT03919448|Active Comparator|Zutrab® (Bevacizumab Richmond)|a single 1 mg/kg IV dose of Bevacizumab
10167759|NCT03919448|Active Comparator|Avastin®|a single 1 mg/kg IV dose of Bevacizumab
10167760|NCT03919448|Active Comparator|Cizumab®|a single 1 mg/kg IV dose of Bevacizumab
10167761|NCT03919084|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
10167762|NCT03919084|Experimental|THRIVE+|Enhanced screening-and-referral with motivational interviewing and patient navigation services
10167763|NCT03919058|Active Comparator|Regime 1: control regime|All participants start with the control regime, where baseline activity will be measured.
10167764|NCT03919058|Experimental|Regime 2: Sit regime/sit less regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
10167765|NCT03919058|Experimental|Regime 3: Sit less regime/sit regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
10167766|NCT03919058|Experimental|Regime 4: Exercise regime|The exercise regime is the final regime for all participants. This is comparable with the sit regime, but 1h of sitting is replaced with 1 exercise bout.
10167767|NCT03919461|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows. Etodolac:400mg PO bid for the entire intervention period, Propranolol (slow release): 20 mg PO b.i.d. for 5 preoperative days; 80 mg PO b.i.d. on the day of surgery; 40 mg PO b.i.d. for the first post-operative week and 20 mg PO b.i.d. for the second post-operative week.
10167768|NCT03919461|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
10167769|NCT03919396|Experimental|OrthoK|Group wearing Breath-O corrected orthokeratology lenses for 2 years
10167770|NCT03919396|No Intervention|SV Lenses|Group wearing spectacle with single vision lenses for 2 years
10167771|NCT03919318|Experimental|AH-Plus|
10167772|NCT03919318|Experimental|EndoSeal MTA|
10167773|NCT03919318|Experimental|Endosequence BC Sealer|
10167774|NCT03919227|Experimental|Group 1: empty bladder|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS.
10167775|NCT03919227|Active Comparator|Group 2: natural state of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS.
10167776|NCT03919357||Verbal|Passing of a specialized questionnaire on verbal disorders
10167777|NCT03919357||Non-verbal|Passing of a specialized questionnaire on non verbal disorders
10167778|NCT03919357||Attention|Passing of a specialized questionnaire on attention disorders
10167779|NCT03919357||Complaint about learning|Passing of a specialized questionnaire on learning disorders
10167780|NCT03919279|Experimental|active arm with active tVNS for 1 month|
10167781|NCT03919097||Control|No atrial arrhythmia post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
10167782|NCT03919097||Atrial fibrillation post ablation|Atrial arrhythmia (Atrial Fibrillation) post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
10167783|NCT03919097||Flutter recidive|Recidive of the flutter after ablation.
10167784|NCT03919097||Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, with previous antecedents of atrial fibrillation.
10167785|NCT03919097||No Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, without antecedents of atrial fibrillation.
10167786|NCT03919175|Experimental|Umbralisib+Rituximab|"A treatment cycle is defined as 28 consecutive days.~Umbralisib will be administered at 800 mg by mouth once daily on days 1-28 of cycles 1-24.~Rituximab will be administered at 375 mg/m2 by intravenous infusion on Cycle 1 Day 1 and may be administered at 375 mg/m2 by intravenous infusion or at 1400 mg by subcutaneous injection on days 8, 15, 22 of cycle 1, day 1 of cycles 2 to 6, then every 8 weeks starting on day 1 of cycle 7 until completion of 24 cycles of umbralisib (i.e. every other cycle for 18 cycles or 9 doses, for a total of 15 doses of rituximab), or until progression or intolerance."
10167787|NCT03919019|Experimental|Macuprev Group|patients taking oral supplementation (Macuprev) 2 capsules per day for 6 months
9671620|NCT05046015|No Intervention|non diabetic|Control Group of 20 non-diabetics. Skin measurements, evaluation of skin dryness and sampling of skin particles will be performed
9671621|NCT05046015|Experimental|moderate dryness-diabetic|"Experimental: Diabetics with moderate dryness. Intervention Group of 20 diabetics with moderate dryness~10% Urea foot lotion During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
10167788|NCT03919019|Placebo Comparator|Placebo Group|patients taking oral placebo 2 capsules per day for 6 months
10167789|NCT03919136||Primary Objective|Evaluation of the devices accuracy referenced to interventional (A-line) measurement.
10167790|NCT03919110||Genetically Undiagnosed SAID Patients (guSAID)|"adults and children, with different SAID of unknown pathogenesis, for which no specific mutations is identified and whose pathogenic mechanism remains unknown:~Still Disease,~Recurrent pericarditis,~Neutrophilic dermatosis,~Schnitzler,~Vasculitis (Kawasaki disease, Behçet disease, Takayasu arteritis),~Inflammation of unknown origin,~Chronic/recurrent osteitis."
10167791|NCT03919110||Parents of guSAID patients|Enrollment of parents of guSAID patients is justified by the TRIO genomic analysis (patient plus two parents) of the guSAID patients without known mutations. Indeed, the TRIO based whole-exome sequencing helps to facilitate the interpretation of genotypes and improve genetic explorations
10167792|NCT03919110||Monogenic SAID patients (mSAID)|This group of patients will serve as positive control to classify other diseases and encompass the following diseases: FMF, TRAPS, HIDS, and CAPS. Investigators aim at recruiting 50 patients per disease entity.
10167793|NCT03919110||Patient Free of inflammatory disorders control subjects|In order to set a reference / baseline for the identification of biomarkers the study will need non-inflammatory samples.
10167794|NCT03919409|Experimental|Part A: Cohort 1: TS-161 15 mg|Single dose of TS-161 15 mg or placebo in a fasted condition.
10167795|NCT03919409|Experimental|Part A: Cohort 2: TS-161 50 mg|Single dose of TS-161 50 mg or placebo which will be dosed first in a fasted condition, and then in a fed condition, with a washout period in between 2 dosing. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
10167796|NCT03919409|Experimental|Part A: Cohort 3: TS-161 100 mg|Single dose of TS-161 100 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
10167797|NCT03919409|Experimental|Part A: Cohort 4: TS-161 200 mg|Single dose of TS-161 200 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
10167798|NCT03919409|Experimental|Part A: Cohort 5: TS-161 400 mg|Single dose of TS-161 400 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
10167799|NCT03919409|Experimental|Part B: Cohort 6: TS-161 TBD|Single dose of TS-161 in a fasted condition. The dose level will be determined based on the results from the preceding cohorts.
10167800|NCT03919409|Experimental|Part C: Cohort 7: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
10167801|NCT03919409|Experimental|Part C: Cohort 8: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
10167802|NCT03919409|Experimental|Part C: Cohort 9: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
10167803|NCT03919006|Active Comparator|Periodontitis|"GCF, saliva and serum samples were taken before and after treatment from periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
10167804|NCT03919006|Active Comparator|Gingivitis|"GCF, saliva and serum samples were taken before and after treatment from gingivitis patients.~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
10167805|NCT03919006|Placebo Comparator|Periodontally healthy|GCF, saliva and serum samples were taken at baseline from periodontally healthy individuals.
10167806|NCT03918993||Group T|31 Patients with ED who receiving 5 mg/day of Tadalafil for 8 weeks.
10167807|NCT03918993||Group C|Thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up
10167808|NCT03918967|Experimental|CT-G11|CT-G11 Experimental Drug
10167809|NCT03918967|Experimental|CT-G20|CT-G20 Experimental Drug
10167810|NCT03918967|Placebo Comparator|CT-G11 Placebo|
10167811|NCT03918967|Placebo Comparator|CT-G20 Placebo|
10167812|NCT03918707||Prospective|The prospective group will consist of approximately 15 evaluable patients who will undergo rWGS sequencing in addition to standard of care genetic testing. Subjects in this study will be drawn from children admitted to the NICU at OSF HealthCare Children's Hospital of Illinois who meet inclusion criteria.
10167813|NCT03918707||Historical Control|The historical control group will consist of patients admitted to the NICU between January 1, 2016 and December 31, 2018 who received genetic testing at less than 4 months of age and fulfil eligibility criteria.
10167814|NCT03918616||PD + AD|Patients with newly-diagnosed (onset of suggestive symptoms not later than 3 months) Parkinson disease (PD) or Alzheimer disease (AD) with no previous specific treatment, no anti-inflammatory drugs assumed in the three months preceding the enrolment and no chronic inflammatory diseases or cancer.
10167815|NCT03918616||Control group|An age and gender matched control group (n=50) was formed, on a volunteer basis, by the spouse of the probands participating in the study.
9671622|NCT05046015|Experimental|severe dryness- diabetic|"Intervention Group of 20 diabetics with severe dryness 10% Urea foot ointment During the course of the study participants cleanse their feet once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® Fuss Salbe 10% Urea on both feet once daily in the evening by themselves."
9671623|NCT05045729||OHCA SPORTS|All OHCA, where the patient was engaged in sports at the time of the event
10167816|NCT03918837|Sham Comparator|Sham rTMS|"The investigators will perform sham rTMS at 30% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days. The coil will have a 180° rotation compared to the active coil position, thus making the magnetic field ineffective on the patient's cortex.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment.~All participants of this group will have the opportunity to undergo an active rTMS treatment right after the end of each one's participation in the study."
10167817|NCT03918837|Active Comparator|Active rTMS|"The investigators will perform active rTMS at 120% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days.~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment"
10167818|NCT03918590|Active Comparator|A single drop of nepafenac 0.3% suspension|A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
10167819|NCT03918590|Other|Patching|A light pressure patch applied for two hours
10167820|NCT03918590|Placebo Comparator|A single drop of preservative-free Artificial Tears|A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).
10186712|NCT03733158|Experimental|Pharyngeal obstruction|intubation in Tongue edema condition
10186713|NCT03733158|Experimental|Manual cervical inline stabilization|intubation in Manual cervical inline stabilization condition
10186714|NCT03733158|Experimental|Cervical collar stabilization|intubation in Cervical collar stabilization condition
10186715|NCT03733158|Experimental|Cervical collar stabilization and pharyngeal obstruction|intubation in Cervical collar stabilization and pharyngeal obstruction condition
10186716|NCT03733145|Experimental|Participants on ACE inhibitors|Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.
10186717|NCT03733145|Experimental|Participants on ARBs|Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.
10186718|NCT03733145|Experimental|Other Classes of Antihypertensive Agents|Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.
10186719|NCT03733106|Experimental|digital breast tomosynthesis|Tomosynthesis and two dimension digital mammography
10186720|NCT03733106|Active Comparator|control|standard two dimension digital mammography
10186721|NCT03733015|Active Comparator|cTBS group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. TBS refers to a rTMS protocol where pulses are applied in bursts of three, delivered at a frequency of 50 Hz and an inter-burst interval of 200 ms (5 Hz)."
10186722|NCT03733015|Active Comparator|High frequenct rTMS group|High frequency refers to a rTMS protocol where pulses are applied in at 10Hz frequency
10186723|NCT03733002|Experimental|AngongNiuhuang|Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
10186724|NCT03733002|Placebo Comparator|Placebo of AngongNiuhuang|Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
10186725|NCT03732989|Active Comparator|Control group: Non-interactive toy prototype|30 children will be given the same toy as participants in the experimental group, but without the interactive features (haptic feedback).
10186726|NCT03732989|Experimental|Experimental: Interactive toy prototype|30 children will be given the same toy as participants in the control group, but with the interactive features (haptic feedback).
10186727|NCT03732976|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
10186728|NCT03732976|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
10186729|NCT03732963|Placebo Comparator|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
10186730|NCT03732963|Active Comparator|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
10186731|NCT03732937||Control group|Pregnant ladies with no medical disorders from 16 weeks till term
10186732|NCT03732937||case group|Pregnant ladies with medical disorders from 16 weeks till term
10186733|NCT03732924|Experimental|Five minute rest|
10186734|NCT03732924|Active Comparator|Zero minute rest|
10186735|NCT03732911|Experimental|Intervention|Intervention arm
10186736|NCT03732885|Experimental|densah burs drilling group|maxillary sinus floor elevation during implant placement using Densah burs
10186737|NCT03732885|Experimental|Summers osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
10186738|NCT03732872||Patient with habits and having OSMF|Patients who had history of arecanut chewing habit in any form and composition and who were not undergone any treatment for their current condition i.e, OSMF
10186739|NCT03732872||Patients with habits and had no clinical symptoms of OSMF|Patients who had history of arecanut chewing habit in any form and composition and had no symptoms of OSMF clinically
10186740|NCT03732872||Healthy human volunteers|patients who reported no history of areacnut chewing habits and had no clinical symptoms of OSMF
10186741|NCT03732846|Experimental|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
10186742|NCT03732807|Experimental|Sequence A|Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
10186743|NCT03732807|Experimental|Sequence B|Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
10186744|NCT03732807|Experimental|Sequence C|Maintenance dose #1 given QD for 48 weeks
10186745|NCT03732807|Experimental|Sequence D|Maintenance dose #2 given QD for 48 weeks
10186746|NCT03732807|Experimental|Sequence E|Maintenance dose #3 given QD for 48 weeks
10167821|NCT03918746|Experimental|internet Attachment-Based Compassion Therapy (iABCT)|"The intervention will consist of an internet version of Attachment-Based Compassion Therapy (iABCT).~The length of the intervention will depend on the pace of each participant that will be advised to carry out one module per week, taking days between sessions to complete homework assignments. It is estimated that the online intervention can be completed in eight weeks, with a maximum period of ten weeks. However, each participant will be free to advance at his/her own pace. Formal telephone support will be not systematically provided, but participants will contact for technical assistance (i.e., web accessibility problems or forgotten password) if necessary."
10167822|NCT03918681|Experimental|Intervention Group|The experimental group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups experimental group participants will receive gait retraining cues to transition to a NRFS running pattern.
10167823|NCT03918681|No Intervention|Control Group|The control group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups control group participants will not receive any gait retraining cues and will only be instructed on standard of care return to run metrics to include volume, load, and duration of running.
10167824|NCT03918720|Experimental|Trekkers|
10167825|NCT03918720|No Intervention|Controls|
10167826|NCT03918785|Experimental|Rice Germ|"The Rice Germ was supplied in vacuum jars of a weight of 130 grams. These jars once opened, were stored in the refrigerator (-3-4°C). Together with cans, small containers were provided to act as dosers and served to determine the correct dose to be taken (25 grams, twice a day). The rice germ or placebo were continually taken every day twice a day (25 grams in the morning with breakfast and 25 grams in the afternoon as snacks) for 5 weeks. The rice germ was supplied by the company Acquerello (TenutaColombara, Livorno Ferraris, Vercelli, Italy)."
10167827|NCT03918785|Active Comparator|Control group|Active comparator, which consisted of an isocaloric wheat germ-based supplement. Characteristics of supplementation are the same of experimental group.
10167828|NCT03918655||Patient newly diagnosed with AML (prospectively)|Patient newly diagnosed with AML in Saint Antoine hospital or Tours University hospital in 2018 to 2020.
10167829|NCT03918655||Patient diagnosed with AML (retrospectively)|Patient diagnosed with AML in Saint Antoine hospital in 2015 to 2018
10167830|NCT03918694|Active Comparator|Experimental|Participants will receive Vit C tablets
10167831|NCT03918694|Placebo Comparator|Placebo|Participants will receive placebo tablets
10167832|NCT03918889|Experimental|dexmedetomidine|patients receive dexmedetomidine infusion
10167833|NCT03918889|Experimental|midazolam|patients receive midazolam infusion
10167834|NCT03918863|Experimental|Neuromuscular electrical stimulation|8-week exercise program, twice a week, with neuromuscular eletrical stimulation on vastus medialis and gluteus medius.
10167835|NCT03918863|Active Comparator|Exercise|8-week exercise program, twice a week.
10167836|NCT03918941|Experimental|Carey|
10167837|NCT03918941|Active Comparator|conventional information|
10167838|NCT03918603|Experimental|ultra-protective multimodal ventilation group|Patient will be diposed on ventral decubitus: one session at least more than 12 hours between inclusion and H48
10167839|NCT03918603|No Intervention|protective ventilation group|Patient will received usual care
10167840|NCT03918551|Other|Sequence AB|25 subjects assigned to the sequence AB will receive a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10167841|NCT03918551|Other|Sequence BA|25 subjects assigned to the sequence BA will receive a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10167842|NCT03918954|Active Comparator|Physical sensory room|In the inpatient ward there is a specifically designed room for calming down which a patient can request access to. In the room there is calming music, soft mats, nature themed wallpaper and calming visual lighting.
10167843|NCT03918954|Experimental|Virtual sensory room|The patients will have access to wireless virtual reality glasses during a session. The glasses will have a specially made protection that will be disinfected between each user, all users will also have the opportunity to choose a disposable cover for the glasses. The VR glasses are adjustable and adaptable to all types of head sizes and can be used with regular glasses. The application accessable in the VR glasses is called Calm Place, a virtual natural environment with day and night cycles, dynamic weather and associated soundscapes.
10167844|NCT03918733|Experimental|surgical treatment|surgical treatment of failed root canal treated teeth following secondary root canal treatment.
10167845|NCT03918733|Experimental|Non surgical retreatment|Non surgical retreatment of failed root canal treated teeth
10167846|NCT03918538|Experimental|The intervention group|"After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual.~The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers."
10167847|NCT03918538|No Intervention|The control group|Participants in the control group received regular medication education.
9671624|NCT05045651|Experimental|patient specific knee prosthesis|TKA with Gender Solution® posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
10167848|NCT03918473|Experimental|Mobilization with Movement|A weight- bearing mobilization directed to the talocrural joint in a standing position.
10167849|NCT03918473|Experimental|Thrust Mobilization|A high velocity, low amplitude thrust mobilization directed to the talocrural joint with the participant in a non-weight bearing position.
10167850|NCT03918382|No Intervention|Control group|First phase. 97 participants. This group will continue standard procedure regarding side effect registration and handling. When the 97 patients have been included and have finished their radiotherapy the second phase will be initiated.
10167851|NCT03918382|Experimental|PRO group|Second phase. 194 participants. This group will be assigned to the intervention which is weekly electronic Patient-Reported Outcomes. Patients report the symptoms (PRO) on a tablet before each weekly control visit. The clinician will use the patients PRO answers as part of the consultation. The PRO symptoms consist of head and neck relevant items fra PRO-CTCAE™ (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) and EORTC (European Organisation for Research and Treatment of Cancer) item library.
10167852|NCT03918499|Experimental|Treatment (pembrolizumab, cyclophosphamide, and IRX-2)|Participants receive pembrolizumab IV over 30 minutes on day 1. Participants also receive cyclophosphamide IV on day 1 and IRX-2 SC for 10 days starting on day 4 during cycles 1, 5, 9, 13, 17, 21, 25, 29, and 33. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease or unacceptable toxicity.
10167853|NCT03918395|Placebo Comparator|Placebo|Placebo beverage
10167854|NCT03918395|Active Comparator|Protein-Polyphenol supplement|Protein-polyphenol beverage
10167855|NCT03918291|Experimental|Addition of whole-body vibration to squat training|The addition of whole-body vibration to squat training (for 12 weeks, 3x/week). The mechanical stimulation parameters of the vibration consisted of the following: frequency of 35 to 40 Hz, amplitude of 4 mm and acceleration that ranged from 2.78 to 3.26 G
10167856|NCT03918291|Other|Squat training|Squatting exercises for 12 weeks, 3x/week
10167857|NCT03918265|Experimental|Efficiency of tacrolimus on autoimmune cytopenia|"A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
10167858|NCT03918317|Experimental|AirXpanders AeroFormtissue expander + Radiation therapy|AirXpanders AeroFormtissue expander in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate.
10167859|NCT03918174|Experimental|Dart Splint orthosis|The Dart-Splint orthosis allows oblique wrist motion along the Dart Throwing Motion (DTM) plane, thus inhibiting movement of the healing structures following surgery around the distal radius. This is a hinged orthosis that permits selective midcarpal mobilization along the plane of the DTM is a novel orthotic device that was developed in order to facilitate protected midcarpal motion.
10167860|NCT03918174|Experimental|The conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions.
10167861|NCT03918408|Experimental|Pulsed, accelerated|30 mW, 5 sec, 5 sec off, 10 minutes of illumination
10167862|NCT03918408|Active Comparator|Conventional|9 mW, continuous 10 minutes of illumination
10167863|NCT03918226|Other|Exploratory Laparotomy|Exploratory Laparotomy of patients presenting acute abdomen and whose diagnosis later on confirmed on histopathology to be tuberculosis
10167864|NCT03918057|Experimental|Cognitive-Behavioural Therapy Group|Participants receive 5 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
10167865|NCT03918057|Active Comparator|Treatment as Usual Group|Participants receive usual obstetric care and are placed on a wait-list until six months postpartum. All activities or efforts participants make to treat or improve their sleep on their own is recorded and coded. After the final assessment six months postpartum, participants have the option of receiving 1.5-hour sessions (for a total of 5 session) of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
10167866|NCT03918200||Study|Women with unexplained infertility
10167867|NCT03918200||Control|Fertile women who had normal physical and pelvic examination, regular menstrual cycles, don't use hormonal contraceptive, had one child at least.
10167868|NCT03918252|Experimental|Arm A Nivolumab Only|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
10167869|NCT03918252|Experimental|Arm B Nivolumab + Ipilimumab|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
10167870|NCT03918356|Experimental|Inclusion Body Myositis patients|Subjects with clinically or clinico-pathologically defined IBM will be included in this study. Patients with consistent clinical and laboratory features including ages 18 to 80 years, duration of symptoms> 12 months, serum creatine kinases (CK) no greater than 15 times upper limit of normal, prominent weakness of quadriceps and/or finger flexor weakness>shoulder abduction weakness along with some characteristic histopathological findings of endomysial inflammatory infiltrate, rimmed vacuoles and protein accumulation or 15-18 nm filaments will be considered as clinically or clinicopathologically defined IBM as proposed by the European Neuromuscular Center (ENMC IBM working group, 2013).
10167871|NCT03918356|Experimental|Idiopathic Inflammatory Myopathies patients|Subjects with more than 2 of the following criteria, symmetric proximal weakness, elevated CK, electromyography (EMG) suggesting myositis, muscles biopsy showing inflammatory changes, and typical skin rashes of dermatomyositis (DM) will be recruited as dermatomyositis and polymyositis (DM/PM) based on Bohan and Peter criteria.
9520333|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
9520334|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
10167872|NCT03918356|Placebo Comparator|control|Healthy controls without any known neuromuscular disorders and no family history of Amyotrophic lateral sclerosis (ALS) will be recruited for the study.
10167873|NCT03918005|Experimental|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
10167874|NCT03918005|Active Comparator|High glycemic load diet|Foods with high glycemic index or glycemic load (white rice, white bread, corn flakes, mashed potatoes, orange juice, banana, persimmon, grape, raisins, honey, sugar)
10167875|NCT03918109|Experimental|OTO-313|
10167876|NCT03918109|Placebo Comparator|Placebo|
10167877|NCT03917979|Experimental|Individual GIM|Participants are provided with a series of individual GIM sessions.
10167878|NCT03917979|Other|Waitlist Control|Participants complete an initial wait list period, then are provided with a series of Group GIM sessions.
10167879|NCT03918161|Experimental|MRE exam|Magnetic Resonance Elastography (MRE) exam associated with standard T1-weighted and T2-weighted sequences
10167880|NCT03918148||SGLT-2i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a SGLT-2 inhibitor:~dapagliflozin 10 mg, oral, once daily or canagliflozin 100 mg, oral, daily or empagliflozin 10 mg, oral, daily"
10167881|NCT03918148||DPP-4i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a DPP-4 inhibitor:~sitagliptin 100 mg, oral once daily or vildagliptin 50 mg, oral, twice daily or saxaglitpin 5 mg, oral, once daily or linagliptin 5 mg, oral, once daily or alogliptin 25 mg, oral, once daily"
10167882|NCT03918083|Other|5-pronged wellness approach|30-day assessment of daily exercise, mindfulness, sleep, social connectedness, and nutrition
10167883|NCT03917953|Experimental|Arm I|Patients receive transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
9671625|NCT05045651|Experimental|Unisex knee prosthesis|TKA with posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
9671626|NCT05045326|Experimental|Experimental: Intervention Group|Participants in the intervention group will receive an intensive motivational intervention with individual and group treatment for smoking cessation. The treatment, provided by trained professionals, will include psychological, psycho-educational support and pharmacological treatment advice.
9671627|NCT05045326|Placebo Comparator|Placebo Comparator: Brief Counselling|Participants in the placebo group will receive a brief intervention for smoking cessation.
10167884|NCT03917953|Sham Comparator|Arm II|Patients receive sham transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
10167885|NCT03918187|Experimental|bupivacaine|12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
10167886|NCT03918187|Active Comparator|nalbuphine|12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
10167887|NCT03918187|Active Comparator|midazolam|12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .
10167888|NCT03917914|Active Comparator|Bisoprolol|1.25, 2.5 or 5mg of bisoprolol daily
10167889|NCT03917914|Placebo Comparator|Placebo|1.25, 2.5 or 5mg of matched placebo daily
10167890|NCT03918135|Experimental|Paracetamol|Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 100 patients
10167891|NCT03918135|Experimental|İbuprofen|İbuprofen 400mg of ibuprofen (intrafen 400mg/4ml solution Gen ilaç sanayi,Turkey ) intravenous (IV) was given 100 patients
9826486|NCT02420041|Experimental|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
10167892|NCT03917888|Experimental|Lung ultrasound|Patients will be monitored for ventilator associated pneumonia using lung ultrasound combined with clinical features
10167893|NCT03917888|No Intervention|Chest x-ray|Patients will be monitored for ventilator associated pneumonia using chest x-ray and clinical features.
10167894|NCT03917940|Experimental|Omega 3 + glimepiride|group 1: 35 patients treated with (Omega - 3 1000mg / day oral plus glimepiride 2mg or 3mg /day.
10167895|NCT03917940|Placebo Comparator|Control|group 2: 35 patients treated with glimepiride 2mg or 3mg /day.
10167896|NCT03917849|Experimental|Heavy slow resistance training|"The program is performed 3 times per week using resistance equipment in a fitness center. Each session consists of three 2-legged loaded quadriceps and lower limb kinetic chain exercises. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 3 exercises.~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 times, 15-repetition maximum (15RM ), in week 1; 3 times, 12RM , in weeks 2 to 3; 4 times, 10RM , in weeks 4 to 5; 4 times, 8RM , in weeks 6 to 8; and 4 times, 6RM , in weeks 9 to 12."
10167897|NCT03917849|Experimental|Inertial flywheel resistance training|The program is performed 3 times per week using resistance equipment in a fitness center. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 12 repetition máximum (RM) with moment inertia 0.05 m² from week 1-6 and 8 repetition máximum (RM) with moment inertia = 0.10 m² from week 6-12.
10167898|NCT03917875|No Intervention|Control|
10167899|NCT03917875|Experimental|PFI|
10167900|NCT03917680|Experimental|Type III angioedema|White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
10167901|NCT03917680|Experimental|Idiopathic angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
10167902|NCT03917680|Experimental|Type I or II angioedema|White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.
10167903|NCT03917680|Experimental|Post IEC (conversion enzyme inhibitors) angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.
10167904|NCT03917680|Experimental|Histaminic angioedema|Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
10167905|NCT03917680|Other|Control|Healthy individuals, no angioedema.
10167906|NCT03917706||Congenital Heart Disease|Adults suffering from congenital heart disease, followed within the CHU Brugmann hospital, operated during childhood.
10167907|NCT03917862|No Intervention|Control|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques.
10167908|NCT03917862|Active Comparator|TDM-621|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques and will receive the TDM-621 for complementary hemostasis.
10167909|NCT03917784|Experimental|Curcumin and bioperine|This group will receive curcumin 500 mg and bioperine 5 mg oral dosing every 12 hours for 3 months
10167910|NCT03917784|Placebo Comparator|Placebo|This group will receive placebo (starch) 500 mg oral dosing every 12 hours for 3 months
10167911|NCT03917563|Experimental|Intervention group|WATCHMAN LAA occluder treatment
10167912|NCT03917771|Experimental|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery. Lower Limb measurement and care education
10167913|NCT03917771|Active Comparator|Usual follow-up|The usual follow-up will be carried out in GO consultation (0,1,6,12 months)
10167914|NCT03917732|Experimental|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
10167915|NCT03917732|Active Comparator|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
10167916|NCT03917758|Experimental|Diabetic patients|30 diabetic patients candidate to treatment with SGLT2i in add-on to metformin.
10167917|NCT03917797|Experimental|MSC treatment|Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
10167918|NCT03917797|Placebo Comparator|Placebo|Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
10167919|NCT03917719|Experimental|Dose 1|Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.
10167920|NCT03917615|Experimental|"after women health course"|The participants will be instructed to contract the pelvic floor muscle
10167921|NCT03917615|Active Comparator|"before women health course"|The participants will be instructed to contract the pelvic floor muscle
10167922|NCT03917693|Active Comparator|Phytin capsules|2.4 g phytin to be consumed daily for a period of 2 weeks. Participants will consume 2 test capsules containing phytin, 3 times a day with a meal for a period of 2 weeks.
10167923|NCT03917693|Placebo Comparator|Microcrystalline cellulose (MCC) capsules|2.4 g MCC to be consumed daily for a period of 2 weeks. Participants will consume 2 placebo capsules, each containing microcrystalline cellulose, 3 times a day with a meal for a period of 2 weeks.
10167924|NCT03917810|Active Comparator|MODSUG|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
10167925|NCT03917810|Experimental|LOWSUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
10167926|NCT03917810|Experimental|LOWCHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
10167927|NCT03917550|Experimental|Recovery (Transdiagnostic & self)|A longitudinal study conducted before has shown that self-compassion, unconditional self-acceptance, self-esteem and self concept clarity could be considered risk factors for the severity of the clinical symptoms in anxiety and depression. This is the main reason why this arm consists of the Transdiagnostic intervention program for emotional disorders plus a number of intervention techniques targeting the self-concepts mentioned before. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms. Moreover, additional intervention techniques targeting self-concepts will be used to improve participants' self.
10167928|NCT03917550|Active Comparator|Transdiagnostic|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
10167929|NCT03917641|Experimental|Patients after Oculoplastic surgery|"Each participant will use one compression with Khat leaves and another standard compression and will decide on which eye to use which compression.~The compressions will be used for 10 minutes per every waking hour in the first 2 days post-op.~The patient will take pictures of both his eyes in days 1,3 and 7 post operative days."
10167930|NCT03917459|Experimental|LCZ696|
10167931|NCT03917459|Active Comparator|Enalapril|
10186747|NCT03732807|Experimental|Sequence F|Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
9520335|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
9671628|NCT05045599|Experimental|Integration of Family planning in Maternal, Newborn and Child Health|Strengthening of capacity of LHWs and Health care provider in providing integrated services Ensure Sustained supplies are available Community Mobilization Infrastructure support to ensure privacy and confidentiality Improvement of data recording, reporting and use
10167932|NCT03917901|Experimental|Anxiety Sensitivity Training|The Anxiety Sensitivity training (AST) will provide: (1) psychoeducation on anxiety sensitivity and its consequences, (2) psychoeducation on the relationship between anxiety sensitivity and obesity-related health behavior correlates, and (3) concrete, evidenced-based strategies to reduce anxiety sensitivity.
10167933|NCT03917901|Placebo Comparator|Health Control|The Health Control (HC) will cover general health care, such as information on wearing sunscreen and regular attendance to doctor appointments. The HC will not provide any recommendations or education on mood, dietary, or physical habits.
10167934|NCT03917446||Euvolaemic|
10167935|NCT03917446||Hypovolaemic|
10167936|NCT03917537||HNSCC patients have used Nivolumab|Retrospectively analyze WGS information from cancer tissues from HNSCC patients have used Nivolumab
10167937|NCT03917368|Experimental|Ultrasound scan of the internal jugular veins|Hospitalised adult patients, requiring a scheduled central venous catheterisation and measurement of the central venous pressure as part of their usual care, will undergo a non-invasive ultrasound scan of the internal jugular veins (both side of the neck) synchronized with an ECG trace, to assess the jugular venous pulse. This procedure will be performed once throughout the study.
10167938|NCT03917498|Experimental|Single Pre-Operative Radiation Therapy with Delayed Surgery|Single Pre-Operative Radiation Therapy with Delayed Surgery
10167939|NCT03917524||no need for any adjuvant therapy|Patients with oral cavity squamous cell carcinoma post-surgery no need for any adjuvant therapy
10167940|NCT03917524||with risk factors|Patients with oral cavity squamous cell carcinoma post-surgery with major risk factor(s) or 2 minor risk factors Stratification by Risk factors, alcohol, betel nut chewing and cigarette use status
10167941|NCT03917576|Active Comparator|Normoglicamic group|Control normoglycaemic participants
10167942|NCT03917576|Active Comparator|Hyperglicaemic group|Control hyperglicaemic group
10167943|NCT03917576|Experimental|Experimental group|Experimental Type 2 Diabetes Mellitus Group
10167944|NCT03917628|Experimental|SCT630|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing SCT630
10167945|NCT03917628|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
10167946|NCT03917238|Other|Patients with T1D|gallium-68-exendin followed by a PET/CT scan (twice)
10167947|NCT03917602|Experimental|Patients with large macular holes|Patients suffering from large macular holes as documented by spectral domain OCT will undergo pars plan vitrectomy with human amniotic membrane insertion into the macular hole.
10167948|NCT03917420|Experimental|Tenofovir/Emtricitabine|Participants will take 5 once daily doses above noted combination tab at 200mg/300mg before each sampling visit
10167949|NCT03917264|Active Comparator|Tooth-borne treatment|Titanium curettes
10167950|NCT03917264|Experimental|Implant-specific treatment|Implant brush
10167951|NCT03917147||AUB in Post-Menopause|Abnormal Uterine Bleeding (AUB) in Post-Menopause
9520336|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 20 men and 20 women aged between 18-29 years
9520337|NCT03278535||age group 30-39years|CAREN-based gait analysis: 20 men and 20 women aged between 30-39years
9520338|NCT03278535||age group 40-49years|CAREN-based gait analysis: 20 men and 20 women aged between 40-49years
10167952|NCT03917147||Endometrial Thickening in post-menopause|Ultrasonographic detection of Thickened Endometrium in post-menopause
10167953|NCT03917147||Endometrial Thickening in pre-menopause|Ultrasonographic detection of Thickened Endometrium in pre-menopause
10167954|NCT03917147||Pharmacological history of Tamoxifen-related therapy regimens|Patients who had been treated with Tamoxifen
10167955|NCT03917173|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin
10167956|NCT03917173|Active Comparator|Comparator|Standard surgery
10167957|NCT03917069|Experimental|nab-paclitaxel + endostatin+ carboplatin|nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d
10167958|NCT03917069|Active Comparator|paclitaxel+carboplatin|paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d
10167959|NCT03917316||ADHD|
10167960|NCT03917316||Control|
9520339|NCT03278535||age group 50-59years|CAREN-based gait analysis: 20 men and 20 women aged between 50-59years
9520340|NCT03278535||age group 60-69years|CAREN-based gait analysis: 20 men and 20 women aged between 60-69years
9520341|NCT03278535||age group 70+|CAREN-based gait analysis: 20 men and 20 women aged between 70 years and older
9520342|NCT03278522|Active Comparator|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
9520343|NCT03278522|Active Comparator|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
9671629|NCT05045599|Active Comparator|Standard of care|
9671630|NCT05045625||Study Group|Twelve patients offered SCS for standard of care were also invited to participate in this study, in which a study electrode was temporarily placed intraoperatively and neuromonitoring was done per our routine standard-of-care
9671631|NCT05045560||antenatal diagnosis of anorectal malformation|Groupe 1 : antenatal diagnosis of anorectal malformation
10167961|NCT03917212||Patients|Patients with propionic acidemia, isovaleric acidemia, methylmalonic acidemia
10167962|NCT03917212||Controls|Healthy humans
10167963|NCT03917290|Experimental|Intervention|Upon clearance to RTP after concussion, participants randomized to NMT will complete training for 20-30 minutes, two times per week, beginning at RTP and continuing at this frequency for 8 weeks.
10167964|NCT03917290|No Intervention|Usual Care|Participants cleared to RTP in the usual care arm will return to sports and not undergo any intervention.
10167965|NCT03917342|Active Comparator|Control Group|EEG measure in 15 healthy women undergoing elective hysteroscopy under single shot spinal anesthesia. Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
10167966|NCT03917342|Active Comparator|Healthy parturients|EEG measure in 15 healthy parturients undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
10167967|NCT03917342|Active Comparator|Preeclamptic parturients|EEG measure in 15 parturients with preeclampsia undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
10167968|NCT03916991|Experimental|Neuromuscular Exercise|Neuromuscular Exercise
10167969|NCT03916991|No Intervention|Control|No intervention
10167970|NCT03916991|Sham Comparator|Sham Exercise|Sham Exercise
10167971|NCT03917303|Active Comparator|Adalimumab|Episodic adalimumab monotherapy as first line treatment for 6 months
10167972|NCT03917303|Active Comparator|Standard step-up care|Step-up care as first line treatment, starting with corticosteroids.
10167973|NCT03917329|Other|ACT and PBS group workshop|The intervention in this study is an Acceptance and Commitment Therapy (ACT) and Positive Behaviour Support (PBS) group workshop for parents and education staff of children with intellectual disabilities.
10167974|NCT03917251|Other|Right ventricular Pacemaker|Patients with right ventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
9671632|NCT05045560||postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound|Groupe 2 : postnatal diagnosis of anorectal malfiormation with associated anomalies on antenatal ultrasound
10167975|NCT03917251|Other|Biventricular Pacemaker|Patients with Biventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
10167976|NCT03917277|Experimental|Musculoskeletal ultrasound of the ankle|"see Intervention description"
10167977|NCT03917004|Experimental|hypotension group (group H )|particcipants in hypotension group are received controlled hypertension in the operation.
10167978|NCT03917004|No Intervention|control group (group C )|participants in cotrol group are received no controlled hypertension in the operation
10167979|NCT03917095|Active Comparator|Mesalazine conventional enema|Participants undergo the conventional enema of Mesalazine Enemas (4g) for one week.
10167980|NCT03917095|Experimental|Mesalazine TET enema|Participants undergo the TET enema of Mesalazine Enemas (4g) for one week.
10167981|NCT03917095|Active Comparator|Compound Glutamine conventional enema|Participants undergo the conventional enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
10167982|NCT03917095|Experimental|Compound Glutamine TET enema|Participants undergo the TET enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
10167983|NCT03917095|Experimental|Compound Glutamine and Mesalazine TET enema|Participants undergo the TET enema of Mesalazine(4g) and Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
9671633|NCT05045560||postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound|Groupe 3 : postnatal diagnosis of anorectal malformation with anormal antenatal ultrasound
10167984|NCT03916926|Experimental|"A simple medical strategy consisting of SDF"|The treatment will be bi-annual application (at baseline and 26 weeks) of topical 38% silver diamine fluoride (Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL) following manufacturer's instructions and guidelines published by UCSF (2016).
10167985|NCT03916926|Active Comparator|"A typical dental strategy consisting of ART + FV"|Atraumatic Restorative Treatment (ART) will be a modification of the approach used by Lo and colleagues (2006), and the cavity restored at baseline with resin reinforced glass-ionomer cement (GIC) (GC Corporation, Japan). Participants in this arm will also receive biannual topical fluoride varnish application (FluoriMax, Elevate) according to manufacturer's instructions.
10167986|NCT03917121|Experimental|Jet anesthesia|Local infiltration anesthesia delivered using Madajet XL® (MADA Medical Products, Inc., Carlstadt, NJ, USA) needle-free jet injector
10167987|NCT03917121|Active Comparator|Conventional infiltration anesthesia|Local infiltration anesthesia delivered using 25 gauged short needle attached, 1.8 ml carpule loaded standard metal dental syringe
10167988|NCT03917134|Experimental|cephalosporin + Metronidazole|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
10167989|NCT03917134|Placebo Comparator|cephalosporin + placebo|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
10167990|NCT03917225|Active Comparator|Active|
10167991|NCT03917225|Placebo Comparator|Placebo|
10186748|NCT03732807|Experimental|Sequence G|Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks
10186749|NCT03732781|Experimental|Radspherin|
10186750|NCT03732768|Experimental|Radspherin|
10186751|NCT03732755|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
10186752|NCT03732742|Experimental|TOF repair with preservation of PV|Surgical intervention by repair of Tetralogy of Fallot with preservation of pulmonary valve, recently interested has shifted to preserving the integrity of the pulmonary valve.
9671634|NCT05045417||Cases with SLE|"110 patients with SLE will be divided to :~40 patients with lupus nephritis~40 patients interstitial lung disease~30 SLE patients without internal organ affection)"
9671635|NCT05045417||control group|30 sex and age matched healthy individuals as a control group
10167992|NCT03916900|Experimental|Pulpotomy|"Group A (Experimental group) Pulpotomy:~The teeth will be anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain) by inferior alveolar nerve block.Under rubber dam isolation, pulpotomy will be performed with a large sterile round end bur in a high speed hand piece with copious irrigation; pulp tissue will be removed by a sharp spoon excavator to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet moistened with 2.5% NaOCL for 2 min and repeated if needed.~After hemostasis, Biodentine (Septodont, Saint Maur des Fausses, France) will be mixed according to the manufacturer's instructions and gently placed over the pulp to thickness of 2-3 mm.Biodentine will be covered by resin modified glass-ionomer and teeth will be restored using composite resin.A postoperative radiograph will be taken by parallel technique."
10167993|NCT03916900|Active Comparator|Root canal treatment|"Group B (control group) Root canal treatment:~The teeth were anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain).Under rubber dam isolation, root canal treatment will be performed in single visit.Working length will be determined using stainless steel k-files (Mani, Inc.) keeping 0.5 to 1.0 mm short of the apex using a RootZX apex locator (J. Morita, Irvine, CA) and confirmed radiographically. Mechanical preparation will be achieved by a crown-down technique using using the M-PRO system (IMD, Shanghai, China) and irrigation with 5 mL 2.5% NaOCl between instruments.Obturation will be done with gutta-percha (Meta Biomed Co. Ltd, Cheongwongun, Chungbuk, Korea) and resin sealer ADseal (Meta Biomed CO., LTD, Korea) using cold lateral condensation technique and restored with composite resin with a base of glass-ionomer cement. A postoperative radiograph will be taken by parallel technique."
10167994|NCT03917056|Experimental|Long needle group|Participants were treated with CAES using long needle.
10167995|NCT03917056|Experimental|Short needle group|Participants were treated with CAES using short needle.
9520344|NCT03278496|Experimental|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
9520345|NCT03278496|Experimental|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
9520346|NCT03278496|Active Comparator|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
9520347|NCT03278483|Active Comparator|Isoniazid|Diabetic patients with a positive TST of >10mm, will be randomly assigned to receive treatment with isoniazid 300mg Oral Tablet daily plus pyridoxine 50mg daily for six months
10167996|NCT03916822||ABMR|Biopsy-proven ABMR-Banff criteria, with or without Complement binding donor-specific anti-HLA antibodies
10167997|NCT03916822||TCMR|Biopsy-proven TCMR-Banff 1A, 1B, 2 and 3
10167998|NCT03916822||No Rejection|Biopsy-proven, or clinical criteria
10167999|NCT03917082|Experimental|standard of care endocrine therapy for two years|Standard of care adjuvant endocrine therapy for two years. for postmenopausal women, initial therapy will be aromatase inhibitor unless contraindicated, in which case tamoxifen may be used. For premenopausal and perimenopausal women, initial therapy will be tamoxifen unless contraindicated, in which case an lutenizing hormone releasing hormone (LHRH) agonist with / without aromatase inhibitor may be used.
10168000|NCT03917394||rHuEPO monotherapy group|rHuEPO was administrated during hospitalization period.
10168001|NCT03917394||iron sucrose monotherapy group|Iron sucrose was administrated during hospitalization period.
10168002|NCT03917394||rHuEPO combined with iron sucrose group|rHuEPO combined with iron sucrose was administrated during hospitalization period.
10168003|NCT03917394||control group|Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period.
10186753|NCT03732742|Experimental|TOF repair with trans-annular patch|Surgical intervention by repair of Tetralogy of Fallot with trans-annular patch, right ventricular hypertrophy, right ventricular dilatation and pulmonary vavle regurgitation has been recognized as one of the most important risk factors for both right and left ventricular performance after the repair of Tetralogy of Fallot.
10186754|NCT03732729|Experimental|Massage chair|lifestyle modification education(once)+ Using massage chair
10186755|NCT03732729|No Intervention|Control|lifestyle modification education(once)
9520348|NCT03278483|Active Comparator|Rifampin|Diabetic patients with a positive TST of >10mm, who wil be randomly assigned to receive treatment with rifampin 600mg Oral Tablets daily for three months
9520349|NCT03278470|Experimental|HL237 50mg|take oral tablet once
9520350|NCT03278470|Experimental|HL237 100mg|take oral tablet once
9520351|NCT03278470|Experimental|HL237 200mg|take oral tablet once
9520352|NCT03278470|Experimental|HL237 400mg|take oral tablet once
10186756|NCT03732716||Elderly with sarcopenia|50 patients aged 75 or older with sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
10186757|NCT03732716||Elderly without sarcopenia|50 patients aged 75 or older without sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
10186758|NCT03732703|Experimental|Sub-Protocol A1|Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
10186759|NCT03732703|Experimental|Sub-Protocol B1|Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
9520353|NCT03278470|Experimental|HL237 800mg|take oral tablet once
9520354|NCT03278470|Experimental|HL237 1200mg|take oral tablet once
10186760|NCT03732703|Experimental|Sub-Protocol C1|Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
9520355|NCT03278470|Experimental|HL237 1600mg|take oral tablet once
9520356|NCT03278444|Experimental|One-drug Regimes|Basic drugs therapy of HCC
9520357|NCT03278444|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
9520358|NCT03278444|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
9520359|NCT03278431|Active Comparator|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
10168004|NCT03917030|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
10168005|NCT03917030|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
10168006|NCT03917108|Active Comparator|retraction cord|
10168007|NCT03917108|Other|subgingival clamp|
10168008|NCT03917186|Active Comparator|Group sevoflurane|Administration under labelling conditions
10168009|NCT03917186|Experimental|Group desflurane|Administration under labelling conditions
10168010|NCT03917017|Experimental|Radiomics and Watson artificial intelligence|
10168011|NCT03916887|Experimental|golf training|10-week golf training program
10168012|NCT03916952||Healthy younger|All participants between 18 and 65 years of age that completed the test
10168013|NCT03916952||Healthy older|All participants > 65 years of age that completed the test
10168014|NCT03916718||Dementia|The target population includes patients seen at Ochsner Clinic Foundation, >=55 years old, diagnosed with dementia, and meeting other inclusion/exclusion criteria. this study will recruit subjects identified as high utilizers of the Ochsner System. This will be defined by >= 2 ED visits, >= 2 Hospitalizations, or some combination prior to baseline. We will co-variate by insurance plan.
9520360|NCT03278431|Experimental|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
9520361|NCT03278431|Experimental|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
10168015|NCT03916913|Experimental|Local therapy|Consolidation local radiotherapy
10168016|NCT03916744|Experimental|Giredestrant Dose Level 1|
10168017|NCT03916744|Experimental|Giredestrant Dose Level 2|
10168018|NCT03916744|Experimental|Giredestrant Dose Level 3|
10168019|NCT03916861|Experimental|Bioelectrical Impedance|The first group will be monitored by Inbody S20 analysis to measure fluid status. The Bioimpedance will be measured each time prior to hemodialysis session . The value of BIA measurement of more than 0.4 will be considered as edema.
10168020|NCT03916861|Active Comparator|Physicain-guided group|The fluid monitoring will be managed by physician-adjustment by physical examination and fluid balance record . The fluid balance (FB) is the total fluid administered minus the total fluids eliminated over a period of time.
9520362|NCT03278431|Experimental|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
9520363|NCT03278418|Experimental|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
9520364|NCT03278418|Active Comparator|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
9520365|NCT03278405|Experimental|Intervention Arm|Treatment with avelumab
9520366|NCT03278392|Experimental|Psychosocial challenge task|Participants will be assigned to complete the Trier Social Stress Test (TSST) immediately after consuming a standardized breakfast drink
9520367|NCT03278392|Sham Comparator|Placebo challenge task|Participants will be assigned to complete the placebo non-stress task immediately after consuming a standardized breakfast drink
9520368|NCT03278379|Experimental|Intervention Arm|Treatment with Avelumab
9520369|NCT03278366|Experimental|Dancing students|Students will participate in dance activities from a video with their teacher in class.
9520370|NCT03278366|No Intervention|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
10168021|NCT03916471|Experimental|S (SOLYX)|The Solyx™SIS System is an innovative mid-urethral sling single incision system consisting of a 9 cm long polypropylene mesh, whose mid-urethral portion (4 cm) is detanged to potentially resist deformation and to reduce irritation to the urethral wall. Snap-fit to delivery device tip allows for advanced placement control and, therefore, the tensioning through the forward and reverse functions performed with this delivery device.
10168022|NCT03916471|Experimental|O (OBTRYX II)|The Obtryx II System (Halo) is a transobturator sling designed to allow inter-operative adjustability with minimal tissue disruption. It consists of two delivery devices (one patient right and one patient left) and one mesh assembly. The mesh assembly is comprised of a polypropylene knitted mesh with dilator legs and a center tab. At the distal ends of the dilator legs there are association loops designed to be placed in the needle slot of the distal end of the delivery device. The disposable delivery device consists of a handle with a stainless steel needle. The needle is designed to facilitate the passage of the mesh assembly through bodily tissues for placement through the obturator foramen.
9520371|NCT03278353|Experimental|Conservative care|Exercise and manual therapy
9520372|NCT03278340|Experimental|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
9662156|NCT05130476|Experimental|NIRAF+ICGA|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
10168023|NCT03916757|Experimental|V-Boost recipients|In this open label study all eligible participants will receive daily tablet of V-Boost
10168024|NCT03916536|Active Comparator|Holmium Laser|holmium laser enucleation of the prosteate
10168025|NCT03916536|Active Comparator|Thulium Laser|Thulium laser enucleation of the prosteate
10168026|NCT03916536|Active Comparator|Bipolar Enucleation|Bipolar enucleation of the prosteate
10168027|NCT03916679|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
10168028|NCT03916523|Experimental|Group A|Infants in the group receive CPAP for respiratory support in the delivery room. In addition, they receive a total of 15 sustained lung inflations in the first 96 hours of life; 6 in the first day, 3 in the second day, 3 in the third day and 3 in the forth day of life.
10168029|NCT03916523|Experimental|Group B|Infants in the group receive CPAP for respiratory support in the delivery room. No sustained lung inflation will be applied.
10168030|NCT03916523|Active Comparator|Group C|Infants in this group are intubated in the delivery room and supported with mechanical ventilation.
10168031|NCT03916653|Experimental|Test group|Osseous resection using piezoelectric device
10168032|NCT03916653|Active Comparator|Control group|Osseous resection using conventional rotary instruments
10168033|NCT03916640|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation + injection of placebo (0.9% NaCl) to ensure double dummy.
10168034|NCT03916640|Active Comparator|Humulin® + Symlin®|Simultaneous, separate subcutaneous injections of human insulin and pramlintide.
10168035|NCT03916640|Active Comparator|Humalog®|Subcutaneous injection of insulin lispro + injection of placebo (0.9% NaCl) to ensure double dummy.
10168036|NCT03916588||Memory Care Unit Residents|Residents on a locked memory care unit in southeastern Louisiana will be enrolled. Engaged family members and staff will also consent to provide qualitative information on the resident.
10168037|NCT03916250|Experimental|PF-06700841 cream 0%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
10168038|NCT03916250|Experimental|PF-06700841 cream 0.1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
10168039|NCT03916250|Experimental|PF-06700841 cream 0.3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
10168040|NCT03916250|Experimental|PF-06700841 cream 1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
10168041|NCT03916250|Experimental|PF-06700841 cream 3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
10168042|NCT03916250|Experimental|White petrolatum|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
10168043|NCT03916328|Active Comparator|DMPA+ and TDF+|HIV-infected women on DMPA, and TDF containing ART.
10168044|NCT03916328|Experimental|DMPA+ and B/F/TAF+|HIV-infected women on DMPA, and B/F/TAF.
9671636|NCT05045508|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|
10168045|NCT03916328|Experimental|DMPA- and B/F/TAF+|HIV-infected women on non hormonal contraception, and B/F/TAF.
10168046|NCT03916562|Experimental|Healthy Participants|The investigators will determine how asymmetric walking constraints influence spatiotemporal coordination, energetic cost, and dynamic balance in healthy individuals. The investigators will manipulate spatiotemporal coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
10168047|NCT03916562|Experimental|Post-stroke Participants|The investigators will determine how different patterns of coordination during walking influence energetic cost and dynamic balance in people post-stroke. The investigators will manipulate coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
10168048|NCT03916315|Experimental|Transdiagnostic Treatment|Participants in this group will receive from 11 to 17 sessions of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
10168049|NCT03916315|No Intervention|Control group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 11-12 sessions will take place in the intervention group.
10168050|NCT03916692|Experimental|Standard Process - glucose balance|Standard Process - glucose balance formula (200 kcal)
10168051|NCT03916692|Experimental|Energy smart Carbohydrate blend|Energy smart carbohydrate blend (50 grams, 200 kcal)
10168052|NCT03916692|Active Comparator|Liquid Dextrose Control|Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 grams, 200 kcal)
9671637|NCT05045508|Placebo Comparator|Placebo (vehicle) nasal spray|
10168053|NCT03916367||Early Stage Lung Cancer|The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
10168054|NCT03916510|Experimental|Dosing schedules 1 to 6|"Dosing Group 1:~- Loading dose pre chemoradiation (CRT) - 1x10^12 viral particles (vp)~Dosing Group 2:~Loading dose pre CRT - 1x10^12 vp~Maintenance dose post CRT - 1x10^12vp~Dosing Group 3:~Loading dose pre CRT - 1x10^12vp~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 1x10^12vp~Maintenance dose post CRT - 1x10^12vp~Dosing Group 4:~- Loading dose pre CRT - 3x10^12vp~Dosing Group 5:~Loading doses pre CRT - 3x10^12vp~Maintenance dose post CRT - 3x10^12vp~Dosing Group 6:~Loading dose pre CRT - 3x10^12vp~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 3x10^12vp~Maintenance post CRT - 3x10^12vp"
10168055|NCT03916432|Experimental|Interventional group|HELIOS biodegradable polymer sirolimus-eluting stents
10168056|NCT03916354||appropriate GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is in the recommended normal range is in this group.
10168057|NCT03916354||excess GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is over the upper limit of the recommended normal range is in this group.
9671638|NCT05045339|Experimental|Exercise Group|Five different ball exercises were implemented for 35 minutes, 3 sessions per week for 2 months.
9671639|NCT05045339|No Intervention|Control Group|No exercises were performed in control group
9671640|NCT05045664|Active Comparator|Standard|Standard dose (24 Gy) involved site radiotherapy plus Rituximab
9671641|NCT05045664|Experimental|Experimental|ow-dose (4 Gy) involved site radiotherapy in combination with Obinutuzumab
9671642|NCT05045469|Active Comparator|group A (dian dao san group)|Herbal medicine (dian dao san) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
10168058|NCT03916354||insufficient GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is below the lower limit of the recommended normal range is in this group.
10168059|NCT03916406|Experimental|Sequence 1|midazolam alone followed by combination of PF 06835919 and midazolam
10168060|NCT03916406|Experimental|Sequence 2|PF 06835919 in combination with midazolam followed by midazolam alone
10168061|NCT03916380|No Intervention|Group A|Tacrolimus Extended Release + Midazolam
10168062|NCT03916380|Active Comparator|Group B|Tacrolimus Extended Release + Midazolam + Grapefruit Juice
9671643|NCT05045469|Placebo Comparator|group B( topical medicine without therapeutic effects)|Placebo (topical medicine without therapeutic effects) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
10168063|NCT03916393|Experimental|PF-06651600 Treatment A|Active pharmaceutical ingredient (API)solution in water
10168064|NCT03916393|Experimental|PF-06651600 Treatment B|API in sweetened solution
10168065|NCT03916393|Experimental|PF-06651600 Treatment C|API blend suspension in water
10168066|NCT03916393|Experimental|PF-06651600 Treatment D|API blend suspension in apple sauce
10168067|NCT03916393|Other|Bitrex (Registered) Treatment E|Positive control for bitterness
10168068|NCT03916445||gynecological cancer|all patients having a consultation doctor during the recruiting time
10168069|NCT03916445||chronic gynecological disease|all patients having a consultation doctor during the recruiting time
10168070|NCT03916705|Other|single study arm|All enrolled participants will undergo ultrasound evaluation and chiropractic low back spinal manipulation treatment.
10168071|NCT03916497||Group 1 : kidney transplant recipients (KTR)|
10168072|NCT03916497||Group 2 : hemodialysis patients|
10168073|NCT03916497||Group 3 : Control patients|
10168074|NCT03916211|No Intervention|routine treatment|Diabetic foot routine treatment without intervention
10168075|NCT03916211|Experimental|MSCs treatment|On the basis of routine treatment of diabetic foot, adipose stem cells will be added to treat diabetic foot
10168076|NCT03916172|Experimental|APT Treatment|Participants in this arm will receive the Open Door Approach to Parenting Teenagers (APT). It offers 6 weekly 50-minute appointments with an optional 7th review session.
10168077|NCT03916172|No Intervention|Waiting List|Participants in this group will be placed on a waiting list and will receive APT treatment after no longer than 25 weeks.
10168078|NCT03916159|Experimental|Extrauterine Placental Transfusion EPT|Intervention group
10168079|NCT03916159|Active Comparator|Delayed cord clamping DCC|Control group
10168080|NCT03916146|Experimental|Behavioral Parent Training|
10168081|NCT03916146|No Intervention|Control|
10168082|NCT03916133|Other|Intervention group|Included patients will undergo angiographic FDCT perfusion imaging.The study will be embedded in the standard procedure of pre-operative diagnostics and angiographic control after EC-IC bypass treatment of steno-occlusive disease and during pre-embolization mapping and embolization procedure. An informed consent will be acquired during consultations in the preparatory process of the different examinations and treatments
10168083|NCT03916068|Experimental|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO2) - 100% oxygen at 2.4 atmospheres ATA for 90 minutes, Monday-Friday for 30 sessions (six weeks)
10168084|NCT03916068|Active Comparator|Trental and Vitamin E|Trental (pentoxifylline), 400 milligrams three times a day in combination with Vitamin E, 400 international units orally twice daily for six months
10168085|NCT03915821|Experimental|Patients diagnosed as major depression according to DSM V|"All patients presented with major depression disorder not received ECT previously within 6 monthes, admitted to the study site ( Psychiatry department, in Assiut University Hospital, Assiut, Egypt). They Fulifilled will be recruited within 6 monthes duration .~The patients classified into group A comprised that will be treated with Unipolar ECT, and group B comprised that will be treated Biploar ECT."
10168086|NCT03915808|Experimental|Conjugated linoleic acid plus lifestyle counselling|supplementation of 3.2 g/day conjugated linoleic acid and receive education sessions regularly
10168087|NCT03915808|Placebo Comparator|Sunflower oil plus lifestyle counselling|supplementation of equivalent sunflower oil, and receive education sessions regularly
10168088|NCT03915990|Other|control group|60 healthy pregnant women will be included
10168089|NCT03915990|Active Comparator|controlled diabetics|30 diabetic pregnant women with controlled Diabetes (i.e. HbA1C less than 6.5 %)
10168090|NCT03915990|Active Comparator|uncontrolled diabetics|30 diabetic pregnant women with uncontrolled Diabetes (i.e. HbA1C equal or more to 6.5 %)
10168091|NCT03916107|Experimental|Levator muscle and tarsus resection|
10168092|NCT03916107|Active Comparator|Frontal muscle flap|
10168093|NCT03915964|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
10168094|NCT03915964|Experimental|Baricitinib High Dose|Baricitinib administered orally.
10168095|NCT03915964|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
10168096|NCT03915756|Experimental|With drain|Participants who received a drain during surgery
10168097|NCT03915756|No Intervention|Without drain|Participants who did not receive a drain during surgery
10168098|NCT03916016|Experimental|Intervention Group|The intervention group received enhanced integrated behavioral health care.
10168099|NCT03916016|Active Comparator|Control Group|The control group received care as usual only.
10168100|NCT03915938|Experimental|Group S-Ketamine|S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
10168101|NCT03915938|Placebo Comparator|Group Placebo|A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.
9671646|NCT05045521|Experimental|plyometric warm up group|set of active exercises used as warm up protocol.
9671647|NCT05045521|Experimental|resistance warm up group|warm up protocol on treadmill wearing weighted jacket
9671648|NCT05045521|Active Comparator|control|warm up protocol on treadmill without weights
9671649|NCT05045248|Experimental|Patients|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.
9671650|NCT05045391||pulmonary tuberculosis (smear-positive) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-positive)
10168102|NCT03915730|Experimental|Smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
10168103|NCT03915730|Experimental|Non-smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Never smoked patients were included into the nonsmoker group
10168104|NCT03915730|No Intervention|Smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
9520373|NCT03278340|Active Comparator|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
9671651|NCT05045391||pulmonary tuberculosis (smear-negative) patients|Patients with pulmonary tuberculosis (smear-positive). Diagnosis of chronic pulmonary aspergillosis among patients with pulmonary tuberculosis (smear-negative)
10168105|NCT03915730|No Intervention|Non-smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Never smoked patients were included into the nonsmoker group
10168106|NCT03915834||endovascular treatment group|
10168107|NCT03915743|Experimental|Palliative care|Specialized palliative care arm in a newly formed COPD outpatient clinic
10168108|NCT03915743|No Intervention|Usual care|Usual care in a standard pulmonary out-patient clinic. Treatment as described in national standards.
10168109|NCT03915847|Active Comparator|Single layer closure|
10168110|NCT03915847|Active Comparator|Double layer closure|
10168111|NCT03915847|Active Comparator|Doble layer closure with trimming|
9671652|NCT05045274|Active Comparator|dapagliflozin|(a) Dapagliflozin 10 mg once daily within 24 hours after PPCI for 3 month
10168112|NCT03915899|Experimental|WIN Intervention|WIN Intervention
10168113|NCT03915899|No Intervention|Standard of Care|No WIN intervention.
10168114|NCT03915912|Experimental|Mindfulness meditation|Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session. Patients will complete various Quality of Life questionnaires and distress measuring tools prior to initiating the mindfulness sessions, at the clinic visit following the mindfulness intervention, and ~2 months after completing the mindfulness intervention. Additionally, patients will be provided with supplemental materials including website references and guided audiotape meditations to guide their individual practice outside of the weekly guided sessions.
10168115|NCT03915886|Experimental|JNJ-0440 (Low Dose) or Placebo|Participants will receive single oral dose (low) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
10168116|NCT03915886|Experimental|JNJ-0440 (Medium Dose) or Placebo|Participants will receive single oral dose (medium) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
10168117|NCT03915886|Experimental|JNJ-0440 (High Dose) or Placebo|Participants will receive single oral dose (high) of JNJ-0440 or matching placebo under fed conditions.
10168118|NCT03916120||Postoperative Analgesic Failure|
10168119|NCT03916120||Postoperative Analgesic Success|
10168120|NCT03915782|Experimental|Remote Ischemic Conditioning (RIC) positive|Patients with remote ischemic conditioning
10168121|NCT03915782|Sham Comparator|Control group|The control group will receive a sham procedure (same procedure than Remote Ischemic Conditioning (RIC) with brachial cuff inflation to 30 millimeters (mm) of mercury (Hg) during 40 minutes).
10168122|NCT03916055|Experimental|Exposure and response prevention (ERP)|Therapist-guided and parent-guided internet-delivered exposure and response prevention (ERP)
10168123|NCT03916055|Active Comparator|Education on tics|Therapist-guided and parent-guided internet-delivered education on tics
9671653|NCT05045274|Placebo Comparator|conventional therapy|"Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
9671654|NCT05045443|Active Comparator|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea
9671655|NCT05045443|Placebo Comparator|Standard of nutritional care|Standard of nutritional support care
9671656|NCT05045287|Experimental|hypofractionated radiation therapy|receive chest wall and nodal irradiation at a dose of 43.5 Gy in 15 fractions over 3 weeks
10186761|NCT03732703|Experimental|Sub-Protocol D1|Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
10168124|NCT03916094|Experimental|HLX22 group|HLX22, at four dose levels (1, 3, 10, 25mg/kg), to be intravenously injected once every three weeks; Study drugs given until disease progression, one year of treatment, withdrawal from the study or death
10168125|NCT03915873||vWB patients|
10168126|NCT03915873||control|
10168127|NCT03915691|Active Comparator|Ripple Mapping|Intervention: Ripple Mapping guided catheter ablation of atrial tachycardia.
10168128|NCT03915691|Active Comparator|Conventional Mapping|Intervention: conventional catheter ablation of atrial tachycardia.
10168129|NCT03915704|Experimental|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed. The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
10168130|NCT03915704|Experimental|Shotblocker|ShotBlocker is a small, flat, yellow horseshoe-shaped plastic tool that is non-invasive, appropriate for every age group, does not have the characteristics of medication or adverse effects. ShotBlocker has short, blunt points that provide contact with skin on one side, and a hole that exposes the injection site in the middle of the tool. It is used by being held on the skin surface during injection. The pointed surface of the tool is placed on the administration area right before the injection
10168131|NCT03915704|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
10168132|NCT03915366|No Intervention|Standard of Care (SoC)|"Standard treatment for severe pneumonia and pneumonia in HIV-infected infants:~Ceftriaxone 80 mg/k/day or Ampicillin plus Gentamicin ampicillin 50 mg/kg, or benzylpenicillin 50,000 unit/kg im/iv every six hours plus Gentamicin 7.5 mg/kg/im or iv once a day Cotrimoxazole trimethoprim (TMP) 8mg/kg/dose + sulfamethoxazole (SMX) 40mg/kg/dose three times daily Prednisolone 2mg/kg during 7 days, plus 1mg/kg other 7 days, plus 0.5 mg/kg for 7 days"
10168133|NCT03915366|Experimental|Valganciclovir plus SoC|Treatment for cytomegalovirus (CMV) Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, and Standard or Care as described in Control Group
10168134|NCT03915366|Experimental|Tuberculosis Treatment plus SoC|"Treatment for tuberculosis Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
10168135|NCT03915366|Experimental|Tuberculosis Treatment plus Valganciclovir plus SoC|"Treatment for CMV and for tuberculosis. Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
10168136|NCT03915353||Experiment|No interventions
10168137|NCT03915353||Control|No interventions
10168138|NCT03915483|Experimental|tDCS group|one session of computerized change detection attentional filter exercise (selective attention) combined with real tDCS
10168139|NCT03915483|Sham Comparator|sham group|one session of computerized change detection attentional filter exercise (selective attention) combined with sham tDCS
10168140|NCT03915457|Experimental|Dry immersion Control Group|5 days of dry-immersion
10168141|NCT03915457|Experimental|Thigh Cuffs intervention|5 days of dry-immersion with thigh cuffs
10168142|NCT03915509|Experimental|Bioactive group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
10168143|NCT03915509|Active Comparator|Sandblasted group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
10168144|NCT03915444|Experimental|NabCG|nab-paclitaxel 125mg/m2 cisplatin 25 mg/m2 gemcitabine 1000 mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days
10168145|NCT03915561|Active Comparator|Study group|This group will be received intravenous injection with 10ml transparent mixture solution with 40mg Dynastat and 0.9% saline twice
10168146|NCT03915561|Placebo Comparator|Placebo|This group will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice
10168147|NCT03915665|Active Comparator|Standard treatment|Manual treatment One application of Chlorhexidine 1% gel
10168148|NCT03915665|Experimental|Comprehensive treatment|Supragingival biofilm removal with Erythritol air-powder Submucosal biofilm removal with Erythritol air-powder (30%-60% power)
10168149|NCT03915639|Experimental|Cocktail|Participants in Group Cocktail are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with the multimodal cocktail.
10168150|NCT03915639|Active Comparator|Ropivacaine|Participants in Group Ropivacaine are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with ropivacaine.
9520374|NCT03278327|Other|Endoscopic resection|
9671657|NCT05045027|Experimental|Basic science (MRI, metabolic imaging, tissue collection)|"AIM 1: Previous scan data from healthy subjects is collected and analyzed.~AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.~AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection."
10168151|NCT03915587|Other|Fluid Challenge|After defining fluid responders from non-responders in this single arm prospective trial, we will compare the predictive utility of non-invasive devices such as the CipherOx-CRI and IVC CI to currently employed indices (heart rate, systolic blood pressure, urine output and pulse pressure variability) to gauge the need for additional fluid and ongoing resuscitation.
10168152|NCT03915340|Other|Sequence ABAB|16 subjects assigned to the sequence ABAB will receive a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in Periods 1 and 3 and a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10168153|NCT03915340|Other|Sequence BABA|16 subjects assigned to the sequence BABA will receive a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in Periods 1 and 3 and a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10168154|NCT03915522|Experimental|Adductor Canal Block|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a single adductor canal block wiht 20cc of 0.5% Ropivacaine using ultrasound guidance .
10168155|NCT03915522|Placebo Comparator|Placebo Comparator|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a sham adductor canal block with 2ml of 1% subcutaneous lidocaine at the level of the adductor canal using ultrasound guidance.
10168156|NCT03915470|Experimental|XF-73|0.3 mL applications in each naris of 0.2% w/w XF-73 nasal gel for a cumulative dose of 6.0 mg of XF-73.
10168157|NCT03915470|Placebo Comparator|Placebo|0.3 mL applications in each naris of placebo to match XF-73 nasal gel.
10168158|NCT03915314||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
10168159|NCT03915314||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
10168160|NCT03915600|Experimental|Quinoa|Personalized diet added with quinoa
10168161|NCT03915600|Experimental|Flaxseed|Personalized diet added with Flaxseed
10168162|NCT03915600|Experimental|Quinoa and Flaxseed|Personalized diet added with quinoa and flaxseed
10168163|NCT03915600|No Intervention|Normal diet|Personalized diet without dietary supplement
10168164|NCT03915288|Experimental|Group continuous training at moderate intensity|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity - MICT (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Regarding the MICT training, this was done with fast walk or jog in endless band with the floor tilted to reach the desired intensity. Also by bicycle, rowing and elliptical. During the entire intervention the participants was monitored by a Polar Multisport RS800CX, oximetry and with the Borg scale to avoid exceeding the training intensity (60-80% FCM, 6 to 8 Borg)."
10168165|NCT03915288|Experimental|Group high Intensity Interval Training|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Concerning the HIIT training, it consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group, which we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%)."
10168166|NCT03915288|Active Comparator|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities. It is highlighted that in the institutions where the patients of the 3 groups attended, there is not a physical training area supervised by a professional. Therefore, the intervention protocol was not excluded or denied to the participants of the control group, but continuity and supervision was given for investigative purposes to its process and treatment. In addition, none of the 3 groups stopped their medical treatment or that of the other professionals that make up the interdisciplinary team.
10168167|NCT03915301||ESPB|Erector spinae plane block group
10168168|NCT03915301||Opioids|Opioid group
10168169|NCT03915093|Experimental|study group|receive educational nursing protocol
10168170|NCT03915093|Active Comparator|control group|receive routine hospital care
10168171|NCT03915262||Crohn's Disease|
10168172|NCT03915028|Experimental|Treated group by thermal cure|Treated group will benefit, within 6 weeks of the inclusion, from the thermal cure in one of the thermal establishments.
10168173|NCT03915028|No Intervention|Control group|Control group will receive a thermal cure after the end of the study
10168174|NCT03915015|Other|the study|Patients with a PPM or ICD getting a clinically indicated MRI
10168175|NCT03915002||Patients|"Steatohepatitis:~Alcoholic Steatohepatitis and Alcoholic liver disease~Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)"
9671658|NCT05044988|Experimental|HS-10342|Each subject will receive repeat doses (C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
9671659|NCT05045352|Active Comparator|Echogenic needle|venous access performed under ultrasound guidance with echogenic needles
10168176|NCT03915002||Disease control|Patients 18 years or older with a diagnosis of cholestatic liver diseases (primary biliary cholangitis or primary sclerosing cholangitis) or hepatotropic virus (hepatitis C or B virus), according to the current international guidelines.
10168177|NCT03915002||Control subjects|"Patients over 18 years old without a diagnosis of liver disease that for any other reason (i.e candidate to liver donor, patients with liver metastasis that require surgery, patients with any type of benign liver tumor or HCC in a healthy liver).~Patient over 18 years old with a documented alcoholic used disorder in their clinical records and without any evidence of liver disease."
10168178|NCT03914963|Experimental|Fibrin sealant treatment hemipelvis|•Drug: Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis).
10168179|NCT03914963|Placebo Comparator|Control hemipelvis|Other hemipelvis
10168180|NCT03914989|Experimental|Experimental group|Individuals in this group receive exposure to a higher concentration of essential oil fragrances nightly.
10168181|NCT03914989|Placebo Comparator|Active control group|Individuals in this group receive exposure to a lower concentration of essential oil fragrances nightly.
10168182|NCT03915080|Other|Oktokog alpha (Advate)|Personalized treatment according to individual PK using intravenous injection of oktokog alpha with dose and dose interval according to MyPKFIT and phenotypic evaluation.
10168183|NCT03915119|Experimental|VR Obstacle group|"Initial Visit: navigates a cluttered array of fixed and moving virtual obstacles to reach a way-point (goal) as fast and efficiently (avoiding obstacles) as possible. In each block, task difficulty (i.e., complexity) will increase linearly, regardless of success or failure (≥ 1 collision before reaching the goal).~Second (Training) Visit (randomized into two groups):"
10168184|NCT03915119|Experimental|Agility Group|"Initial Visit: Completes a soccer ball dribbling agility task in which they must dribble a soccer ball toward an artificial way-point, while avoiding artificial obstacles overlaid onto the real world via a Microsoft Hololens augmented reality display.~Second (Training) Visit"
10168185|NCT03915145|Experimental|Kinesio tape group|Kinesio tape application has been applied
10168186|NCT03915145|Sham Comparator|Sham group|Sham kinesio tape application has been applied
10168187|NCT03915145|Other|Control group|No intervention has been applied
10168188|NCT03914820|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
10168189|NCT03914820|Active Comparator|Comparator|Standard surgey without HIPEC CO2
10168190|NCT03914807|Active Comparator|Whole (3.25%) milk|
10168191|NCT03914807|Active Comparator|Reduced fat (1%) milk|
10168192|NCT03914898|Experimental|Nurse led intervention group|"The program was four sessions; It took about 1.5-2 hours. The intervention group was divided into two groups. The author who administered the intervention previously led nurse support groups, is also an active educator in psychiatry and mental health nursing, and has training in cognitive behavioral therapy.~The group sessions were based on cognitive restructuring techniques."
10168193|NCT03914898|No Intervention|Control Group|No intervention was applied to the control group during the study.
10168194|NCT03914976||patient who will have a high risk digestive surgery|patient who will have a high risk digestive surgery: esophagectomy, major hepatectomy> 3 segments, duodeno cephalic pancreatectomy
10168195|NCT03914937||Intervention Group: Virtual Reality|Patients will wear a virtual reality device in addition to standard lidocaine/novocaine numbing agent
10168196|NCT03914937||Control Group: Music|Patients will listen to music in addition to standard lidocaine/novocaine numbing agent
10186762|NCT03732703|Experimental|Sub-Protocol E1|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
10186763|NCT03732703|Experimental|Sub-Protocol Y1|Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)
10186764|NCT03732703|Experimental|Sub-Protocol Y2|Patients with Non-Actionable Genetic Abnormality receive Belantamab mafodotin in combination with ixazomib, pomalidomide and dexamethasone (IPd)
10186765|NCT03732703|Experimental|Sub-Protocol Y3|Patients with Non-Actionable Genetic Abnormality receive Selinexor in combination with ixazomib, pomalidomide and dexamethasone (IPd)
10186766|NCT03732690|Other|Diet High Protein (HP)|Diet High Protein (HP) : 30% protein, 40% carbohydrate and 30% fat
10186767|NCT03732690|Other|Diet Low Protein (LP)|Diet Low Protein (LP) : 10% protein, 55% carbohydrate and 35% fat
10186768|NCT03732651|Experimental|non-pulsatile blood flow|
10186769|NCT03732651|Experimental|pulsatile blood flow|
10186770|NCT03732625|Experimental|Raltegravir|Raltegravir (RAL) x 2 600mg QD (Total 1200mg QD)
10186771|NCT03732612||Control patients|"Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study."
10186772|NCT03732612||Study patients|"Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction."
10186773|NCT03732599|Active Comparator|Standard DALK|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
10186774|NCT03732599|Active Comparator|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
10186775|NCT03732586|Experimental|Omega 5 fatty acid supplement|20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid
9671660|NCT05045352|No Intervention|Non-Echogenic needles|venous access performed under ultrasound guidance with non-echogenic needles
10186776|NCT03732586|Placebo Comparator|PLACEBO|20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo
10168197|NCT03914781|Experimental|SPIN-SELF program|Offered access to the online SPIN-SELF program in addition to usual care
10168198|NCT03914781|No Intervention|Not Offered the SPIN-SELF program|Usual care
10168199|NCT03915171|Experimental|MSI-H|IHC/PCR tested as dMMR/ MSI-H
10168200|NCT03915171|Experimental|MSS|IHC/PCR tested as pMMR/ MSS
10168201|NCT03915197|Experimental|group 1|cohorts of infants with acute bronchiolitis
10168202|NCT03915054|Active Comparator|AREG-TRIGGER|"Per case (6mL) 5940 µL Basal Medium~60 µL IVM MIX Do not need to filtrate media."
10168203|NCT03915054|Active Comparator|CONTROL-TRIGGER|Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
10168204|NCT03915132|Experimental|VMAT plus Nimotuzumab|Patients receive Nimotuzumab weekly during radiotherapy .
9671661|NCT05045040|Experimental|Mobile-based empathic communication support program group|Patients will be provided an mobile-based empathic communication support program to promote ACP discussion for advanced cancer patients and physicians. The experimental group will also receive the usual care as is standard practice.
9671662|NCT05045040|No Intervention|Usual care group|Patients will receive the usual care. The usual care includes routine medical treatment and care by physicians, nurses, pharmacists, and others as well as support from the palliative care team and others as per the patient's situation.
10168205|NCT03915041|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
9671663|NCT05045209|Experimental|Virtual rehabilitation|Virtual pulmonary rehabilitation will be provided by a tablet with connection to a physiotherapist for monitored exercise sessions with educational videos provided on the tablet.
9671664|NCT05045131|Experimental|PVI+PWI, 6 months reassessment procedure, 3 year continued rhythm monitoring|Single arm experimental, observational study: All participants receive a single-procedure combined PVI + posterior wall isolation (PVI+PWI), loop recorder implantation, esophagoscopy, a mandated interventional reassessment /reablation procedure at six months and continuous rhythm monitoring for three years
10168206|NCT03915041|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
9671665|NCT05045118|Experimental|Intervention arm|Single-arm prospective, multiple assessment intervention study. Participants will receive a digital structured patient education material
9671666|NCT05045105||ICU physicians|Intensive Care physicians who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
10168207|NCT03914729|Active Comparator|Primary Closure|After pilonidal sinus is excised, subcutaneous fat and skin are closed in midline with a running suture
10168208|NCT03914729|Active Comparator|Gluteus Maximus Plasty Flap|After pilonidal sinus is excised, gluteus maximus fascia flaps will be mobilised, approximated in the midline and fixed with a running suture. Subcutaneous fat and skin are closed in midline with a running suture.
10168209|NCT03914911|Experimental|Study Arm|The radiologist will perform a routine ultrasonic guided biopsy procedure using the Smart Biopsy Device, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
10168210|NCT03914859|Other|Exposed|Urinary level of 1-hydroxypyrene, the most sensitive biomarker of PAH exposure greater than 0.1 μmol / mol creatinine
10168211|NCT03914859|Other|Not exposed|Urinary level of 1-hydroxypyrene, the most sensitive marker of PAH exposure below 0.1 μmol / mol creatinine
9671667|NCT05045105||Neurosurgeons|Neurosurgeons who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring
9671668|NCT05045053|Experimental|xiidra group|patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking
9671669|NCT05045053|No Intervention|control group|patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups
9671670|NCT05044858|Experimental|Midpoint transverse process block group|Patients will receive midpoint transverse process block after induction of general anesthesia and before surgical incision
9974895|NCT05128838|Experimental|RISE Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management.
9671671|NCT05044858|Sham Comparator|Sham group|Patients will receive general anesthesia and the same intervention steps will be performed i.e., the block under investigation but instead of local anesthetic a placebo (2ml normal saline) will be injected (sham block)
9974896|NCT05128643|Experimental|Population Ⅰ|At 0,1,6 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
9974897|NCT05128643|Experimental|Population II|At 0,1,4 months, 3 doses of experimental vaccine were injected into the deltoid muscle of the upper arm.
10168212|NCT03914755|Experimental|Cohort 1|50 mg twice daily on Days 1-13 and once daily on Day 14
10168213|NCT03914755|Experimental|Cohort 2|150 mg twice daily on Days 1-13 and once daily on Day 14
10168214|NCT03914755|Experimental|Cohort 3|300 mg twice daily on Days 1-13 and once daily on Day 14
10168215|NCT03914924|Active Comparator|Exercise Program|Ex: The participants will be submitted to only exercise sessions for 12 weeks.
10168216|NCT03914924|Experimental|Exercise and Lifestyle Education Program|ExLE: The participants will be submitted to exercise sessions and education classes for 12 weeks.
10168217|NCT03914846|Experimental|Cohort I (ultrasound)|Patients with skin lesions undergo at least 1 ultrasound during the consultation. Patients may undergo at most 2 additional scans after the standard of care approach for non-malignant lesions at the discretion of the radiation oncologist and/or dermatologist.
10186777|NCT03732573|Experimental|Intervention Group|This group will receive 9 text messages over 3 weeks. Messages will be based on goal-setting in the first week, goal-operating in the second week, and self-monitoring in the third week.
10186778|NCT03732573|No Intervention|Control Group|Participants in this group will receive no messages during the intervention period.
10168218|NCT03914846|Experimental|Cohort II (ultrasound)|Skin cancer patients who undergo surgery or radiation undergo 2-5 ultrasounds over a 1 year period (a baseline ultrasound scan may be performed prior to treatment, followed by 1 scan during and/or after radiation, and additional ultrasounds may be conducted [at the discretion of the treating physician] upon completion of radiation and/or surgery, at approximately 1, 6, and 12 month follow-up examinations).
9520375|NCT03278288|Experimental|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
10168219|NCT03914846|Experimental|Cohort III (ultrasound)|Participants with inflammatory skin disorders (psoriasis, eczema, alopecia, acne) undergo ultrasound at baseline and follow-up visits.
10168220|NCT03914768|Experimental|Immunomodulatory DC vaccine to target DIPG and GBM|Patients will receive immune modulatory treatment consisting of cyclophosphamide (200 mg/m2) and bevacizumab (15 mg/kg), before and after DC vaccine injection, respectively.
10168221|NCT03915236|Experimental|Group 1: MON4STRAT Strategy|
10168222|NCT03915236|Active Comparator|Group 2: Conventional treatment|
10168223|NCT03914690|Experimental|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
10168224|NCT03914690|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
10168225|NCT03914365|Active Comparator|Ultrasound-guided pudendal nerve block (PNB)|"Standard circumcision under general anaesthesia with ultrasound-guided pudendal nerve block.Pudendal nerve block patients will be positioned dorsally with the legs in the  frog  position (hips in abduction, knees flexed, sole of the feet together). An ultrasound-guided technique will be used as described previously. A linear probe will be positioned horizontally between the ischiatic tuberosity and the rectum. The ischiorectal fossa is then located between these two landmarks. Using a sterile tech-nique, an echogenic 22 gauge, 50 mm block needle will be inserted out of plane on the superior edge of the probe, midline between the ischiatic tuberosity and the rectum. After feeling two distinct fascial  clics  and confirmation of correct needle posi-tioning in the ischiorectal fossa under ultrasound, 0,2 mL/kg (max 10mL) of ropiva-caine 0,25% will be injected under real-time ultrasound-guidance after negative aspiration. The same technique will be repeated on the contralateral side."
10168226|NCT03914365|Active Comparator|Ultrasound-guided penile nerve block (DPNB)|Standard circumcision under general anaes-thesia with ultrasound-guided penile nerve block.Penile nerve block patients will be positioned in the supine position. An ultrasound-guided technique will be used as described previously. A linear probe will be placed transversely at the base of the penis while an assistant applies caudal traction to the penis. The penile neurovascular sheath is then located just above the corpus cavernosum. The dorsal penile nerve, dorsal penile artery and penile deep dorsal vein are visualized deep to Buck's fascia. Using a sterile technique, a 25 gauge, 1,5 inch needle will be inserted in-plane from lateral to medial so that the needle tip is placed into the penile neurovascular sheath, 0,1 mL/kg (max 4 mL) of ropivacaine 0,25% will be injected under real-time ultrasound guidance while retracting the needle so that the local anaesthetic solution spreads bilaterally filling the neurovascular space.
10168227|NCT03914586||Septic patients with AKI|Patients with sepsis /septic shock ( Sepsis III ) and AKI submitted to Continuous Renal Replacement Therapy with the adsorbing membrane oXiris.
10168228|NCT03914638|Experimental|Active|Active intervention arm. Treatment for 8 weeks per treatment period.
10168229|NCT03914638|Placebo Comparator|Placebo|Placebo arm. Treatment for 8 weeks per treatment period.
10168230|NCT03914456|Experimental|Body Weight Supported Treadmill Training|"The rehabilitation program consisted of five hours per day of the treatment, five times a week for two months (40 sessions). The treatment protocol included kinesiotherapy (passive and active mobilizations, muscle lengthening), BWSTT, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training. The duration of each event was approximately one hour.~The initial time of the treatment on the BWSTT was 20 minutes, and the modification of the time depended on the endurance and capability of each patient. Training charge began at 40% body weight supported and at treadmill speeds of at least 1.5 km per hour. The treadmill speed was increased progressively to 2.5 km per hour, and the level of weight supported was adjusted within sessions to achieve knee extension."
10168231|NCT03914339|Experimental|Test group|Eighteen periodontally compromised patients who will be given both orthodontic and periodontal treatment .
10168232|NCT03914339|Active Comparator|control group|Eighteen periodontally compromised patients will receive periodontal treatment alone .
10168233|NCT03914378||Discovery Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
10168234|NCT03914378||Discovery Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
10168235|NCT03914378||Validation Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
10168236|NCT03914378||Validation Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
10168237|NCT03914404|Experimental|Test group|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
10168238|NCT03914404|Experimental|Control Group|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
10168239|NCT03914482|Other|Patients at risk of FLD|Patients who choose to participate in the study that meet the inclusion criteria
10168240|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured dairy|
10168241|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured non-dairy|
10168242|NCT03914430|Experimental|Water|Energy-free control
9974898|NCT05128058|Experimental|Cohort 1|Subjects will be dosed with 50 mg Ritlecitinib on Day 1 and followed up till Day 3
9974899|NCT05128058|Experimental|Cohort 2|Subjects will be dosed with 200 mg Ritlecitinib on Day 1 and followed up till Day 3
9974900|NCT05124691|Active Comparator|Albendazole|Albendazole 400 mg single dose
10168243|NCT03914508|Experimental|Memory + Behavioral Weight Loss (M+BWL)|The M+BWL program will integrate memory interventions to the BWL program. The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
10168244|NCT03914547|Experimental|REDCHiP|REDCHiP uses 10- video-based telemedicine sessions to deliver T1D education, behavioral parent training, and problem-solving to enhance parents' knowledge and skills. Sessions last about 45-60 minutes each.
9974901|NCT05124691|Experimental|FDCx1. Albendazole and Ivermectin Fixed Dose Coformulation|Single dose of a tablet of FDC 400mg18mg or 400mg9mg. (i) For participants <45 kg of body weight at baseline: FDC of 400mg ALB 9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB18mg IVM
10168245|NCT03914547|Active Comparator|ATTN|ATTN uses 10- video-based telemedicine sessions to deliver general patient education specific to young children. Similar to REDCHiP, all ATTN sessions last 45-60 minutes.
10168246|NCT03914287|Experimental|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
10168247|NCT03914287|No Intervention|Control|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
10168248|NCT03914664||Tourette Syndrome|Adults (>18 years of age) with diagnosis of Tourette syndrome
10168249|NCT03914664||Healthy Control|Adults who are generally healthy with no known neurologic or psychiatric diagnoses
10168250|NCT03914677|Experimental|Mecamylamine Oral Tablet|Initial dose - mecamylamine 2.5 mg tablet po 3 hours prior to provocative testing; subsequent dose escalations as needed, to 5 mg and then 7.5 mg, using the same testing methodology.
10168251|NCT03914534|Experimental|Test Formulation of Valproic Acid|Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2
10168252|NCT03914534|Active Comparator|Reference Formulation of Valproic Acid|Valcote tablets 500 mg Single dose administered in dosing period 1 or 2
10168253|NCT03914352|Experimental|PD-1 antibody group|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
10168254|NCT03914352|Active Comparator|Controlled group|In this group entrolled patients were treated with TACE in the 30 days after hepatic resection.
10168255|NCT03914274|No Intervention|"Thermometer FTN Medisana, precision 0.18º C),"|"Temperatures were taken with an infrared thermometer FTN Medisana, precision 0.18º C.~The temperature will be taken into account to see if it will vary according to the socket used as the temperature is a favoring element of dermic injuries on the feet."
10168256|NCT03914274|No Intervention|Non-elastic tape measure|"Perimeter was measured with a flexible, non-elastic tape measure Lawton 18-0160, precision 1 mm.~The measurement of the feet perimeters will be taken into account to see if it will vary according to the socket used and related to injuries in the feet."
10168257|NCT03914274|No Intervention|Bascule|"Weight was measured using scales (Tanita UM-076, precision 0.1kg). The scale is used to control the weight of the participants in order to find out their body mass index since the weight can influence the appearance of lesions on the feet."
10168258|NCT03914274|No Intervention|Altimeter|"Height was measured using the weight rod of different scales SECA 704, precision 1 mm) The altimeter is used to measure the participants in order to find out their body mass index."
10168259|NCT03914274|Experimental|Socks|"Socks were of two types: technical socks, designed for high performance sports use Lurbel brand, models Tierra and Set, and non-technical socks for everyday use. The socks had different composition: Tierra:50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra; Set:75% cotton, 17% polyamide, 8% lycra and cotton: 98% cotton, 2% elastane.~Different socks were given to the participants to see if the different compositions influenced the appearance of injuries in a short route route and little difficulty"
10168260|NCT03914274|No Intervention|"Geographical Position System Garmin ETREX 20"|"The height range and the pace hikers were controlled with a Garmin ETREX 20X Geographical Position System"
10168261|NCT03914313|Experimental|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat Pro, in which the exoskeleton device is equipped with a VR screen. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Lokomat will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
10168262|NCT03914313|Active Comparator|Robotic treatment without VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Nanos, in which the exoskeleton device is equipped with a screen with a visual feedback (but not virtual reality). The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Nanos will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
10168263|NCT03914313|Active Comparator|Conventional treatment|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a conventional gait rehabilitation. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Beside conventional overground training for gait, motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
10186779|NCT03732560||Patients undergoing treatment with nivolumab and ipilimumab|
10186780|NCT03732560||Patients undergoing treatment with nivolumab|
10186781|NCT03732547|Experimental|'PolyIC plus PD-1 mAb' and 'PD-1 mAb'|"'PolyIC plus PD-1 mAb' group: PolyIC, 2mg, i.m., every other day, for three weeks. PD-1 mAb, 200mg, i.v., every three weeks.~'PD-1 mAb' group: PD-1 mAb, 200mg, i.v., every three weeks."
10168264|NCT03914599||Neurological Disorder|For all neurological disorder participants an electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy. For participants with a diagnosis of Charcot Marie Tooth (CMT) disease, they will have an additional Neuropathy Score to assess disease severity.
10168265|NCT03914599||Healthy Control|An electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy.
10168266|NCT03914248||Active large vessel vasculitis|PET/MR scan
10168267|NCT03913988|Active Comparator|LUCID DREAMING, STRESS REDUCTION, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~Psychoeducation regarding lucid dreaming, stress reduction, and sleep hygiene~Practice of lucid dreaming induction techniques~Guided visualization~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
10168268|NCT03913988|Active Comparator|LUCID DREAMING, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~Psychoeducation regarding lucid dreaming and sleep hygiene~Practice of lucid dreaming induction techniques~Guided visualization~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
10168269|NCT03913988|Active Comparator|SLEEP HYGIENE|"This group will meet for 2 online group sessions and 4 email communications. The 2 online group sessions will each last 1 hour and occur in weeks 1 and 12. The 4 email communications will occur in weeks 3, 5, 7, and 9 and consist of individual communication between each participant and the PI or co-investigator. Each email communication will require 10 minutes of participants' time.~The control group will be asked to engage in Sleep Hygiene techniques in which they adhere to a recommended protocol and record their adherence in a Sleep Hygiene Tracking Log, requiring 5 minutes per day.~Through the 2 online sessions and the individual email with the investigators, participants will have the opportunity to discuss their experience with adherence to the sleep hygiene program and tracking log. Investigators will help participants trouble shoot problems adhering to the sleep hygiene protocol."
10168270|NCT03914222|Other|CardioSpire Device|Patients blows into Respirix device or uses BIPAP machine for a few breaths solely to obtain signal.
10168271|NCT03914183|Other|Control|Standard of care arm - using insulin pen needles as previously prescribed
10168272|NCT03914183|Active Comparator|mCPN intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened The current research study has accordingly been designed to determine if a pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles."
9671672|NCT05044819|Experimental|Cannabidiol|Cannabidiol solution 100 milligrams per milliliter (mg/mL) will be administered orally at a dose level of 5 mg/kg/day for 1 week, then increase to 10 mg/kg/day by the participant or their caregiver twice each day (morning and evening).
10168273|NCT03913923|Experimental|BCD-217 and BCD-100|Patients will receive 4 blinded infusions of BCD-217 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
10168274|NCT03913923|Active Comparator|BCD-100 monotherapy|Patients will receive 4 blinded infusions of BCD-100 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
10168275|NCT03914131|Experimental|study group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals.~Dosage form:Capsule"
10168276|NCT03914131|Placebo Comparator|control group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~Dosage form:Capsule"
10168277|NCT03913897|Experimental|virtual reality group|The children in the groups were distracted by virtual reality goggles 2 minutes before venipuncture, until the process was over.
10168278|NCT03913897|Experimental|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
10168279|NCT03913897|No Intervention|control group|No intervention was made to children in the control group
10168280|NCT03914040|Experimental|IPSE program|IPSE is conceptually divided in two phases: 1) pre-immersion preparation, 2) immersion.
10168281|NCT03914040|No Intervention|Traditional course|Participants in the control group will receive the current face-to-face course.
9826487|NCT02420093|Experimental|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
9671673|NCT05044728|Experimental|Neoadjuvant Chemotherapy Immunotherapy stage|Patients with locally advanced non-small cell lung cancer and locally advanced thoracic esophageal squamous cell carcinoma who met the entry and discharge criteria will be enrolled. After detecting the functional subsets of peripheral CD8-positive T cells, the group was randomly stratified 1:1, respectively. Group A received immunotherapy 24 hours after chemotherapy, and group B received chemotherapy 24 hours after immunotherapy.
9671674|NCT05044741||Perforated group|
10168282|NCT03914118|Active Comparator|Preoperative modafinil + postoperative placebo|
10168283|NCT03914118|Active Comparator|Preoperative modafinil + postoperative modafinil|
10168284|NCT03914118|Placebo Comparator|Preoperative placebo + postoperative placebo|
10168285|NCT03914118|No Intervention|Control group|
10168286|NCT03914001|Other|NMIBC patients|eligible patients will undergo initial mpMRI before initial TURBT, then followed by second mpMRI and second resection TURBT after 4 weeks
10168287|NCT03914209||EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
10168288|NCT03913910||Lipogems|Lipogems injection in the internal orifice, mucosal, submucosal and muscular layer, in the fistula tract and external orifice.
10168289|NCT03914144||Normal Vaginal Delivery|The group of patients who achieved a normal delivery will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
10168290|NCT03914144||Insturmental Vaginal Delivery|The group of patients who underwent instrumental delivery (ventouse or forceps) will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
10168291|NCT03914144||Emergency Caesarean Section|Each patient will be recorded how many catheter episodes occurred during their labour and delivery.
10168292|NCT03914144||Elective Caesarean Section|We expect all patients in this group to have an indwelling catheter sited before their elective caesarean sections, however we will assess each patient individually to confirm whether they had a catheter for their delivery.
10168293|NCT03914092|Experimental|study group|female patients with vocal fold nodules undergoing intralesional steroid injection
10168294|NCT03914092|Active Comparator|control group|female patients with vocal fold nodules undergoing Smith Accent voice therapy
9671675|NCT05044741||Controlled group|
9671676|NCT05044663||NASH related cACLD|NASH related cACLD (Liver Stiffness ≥10 kPa).
10168295|NCT03914066|Experimental|Group treatment in primary care|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
10168296|NCT03913962|Experimental|Patient|Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor
10168297|NCT03913962|Active Comparator|Control|healthy children sex- and age-matched
10168298|NCT03913884|Experimental|Concentrated growth factor Group|Group I (test); in which CGF fibrin matrix was applied to the extraction socket
10168299|NCT03913884|Experimental|Non-Concentrated growth factor Group|Group II (control); in which CGF was not applied to the extraction socket
10168300|NCT03913871|Experimental|Telephone (text messages) support for healthy eating|Participants will receive average of 1-2 text messages per day for 4 weeks focused on health eating with the aim increasing consumption of fruits, vegetables and water; and a reduce intake of sugar sweetened beverages.
10168301|NCT03913871|Active Comparator|Telephone (text messages) support for physical activity|Participants will receive an average of 1-2 text messages per day for 4 weeks that offer physical activity and general health/wellbeing advice.
10168302|NCT03914235|Experimental|Tumescent anesthesia|A tumescent solution was prepared; consisting of 40 cc of 0.9% Saline Solution, 10 cc of 2% Lidocaine, 0.4 cc of Epinephrine (1: 1000) and 4 cc of 7.5% Sodium Bicarbonate. This solution was applied in the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc of tumescent solution was injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc of tumescent solution was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Subsequently, 20 minutes were waited for the epinephrine to cause vasoconstriction, and the asepsis of the limb was continued , sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
10186782|NCT03732521|Experimental|Intervention group|educational therapy
9671677|NCT05044663||Viral hepatitis (HBV / HCV) related cACLD|Viral hepatitis (HBV / HCV) related cACLD
9671678|NCT05044624|Other|Margin, Tumor-Free|
9671679|NCT05044637|Experimental|Primaquine (3.5mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
9671680|NCT05044637|Active Comparator|Primaquine (7.0mg x 7d)|Primaquine 7 days Standard blood schizontocidal therapy plus 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
9671681|NCT05044637|Active Comparator|Primaquine (7.0mg x 14d)|Primaquine 14 days Standard blood schizontocidal therapy plus 14 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (0.5 mg/kg).
9671682|NCT05044702|Experimental|Retro walking|Retro walking
9671683|NCT05044702|Active Comparator|conventional physical therapy|Conventional Physical therapy
10168303|NCT03914235|Active Comparator|Local anesthesia with tourniquet.|"Lidocaine 1% was applied to the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc were injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Afterwards, a pneumatic tourniquet was placed at the level of the forearm at 250 mmHg after exsanguination with a bandage from Esmarch. The asepsis of the limb was continued, sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.~At the end of the surgical procedure, it was closed by planes, a soft bandage was placed, the tourniquet was removed and the patient was taken to recovery."
10168304|NCT03913936|Experimental|NEWLY DIAGNOSED|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
10168305|NCT03913936|Experimental|SURVIVOR|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
10168306|NCT03913936|Experimental|LIVING WITH ADVANCED DISEASE|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
10168307|NCT03913858|Other|high-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
10168308|NCT03913858|Other|low-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
10168309|NCT03914027|No Intervention|Control|Patients allocated to the control group will follow the same procedure except for not using tele-rehabilitation.
10168310|NCT03914027|Experimental|Intervention|The intervention is the use of a tele-rehabilitation program during 12 weeks. The patient's training time will be registered automatically. The control group will receive standard treatment only.
10168311|NCT03913689|Other|StimRouter Neuromodulation System|Implant of the Bioness StimRouter Neuromodulation System in subjects with chronic pain of peripheral nerve origin
10168312|NCT03913650|Active Comparator|Nerve block(+)|patient accept nerve block for post-op pain control
10168313|NCT03913650|Sham Comparator|Morphine|patient received morphine for post-op pain control
10168314|NCT03913702|Active Comparator|Ketorolac|Assigned patients will receive a subacromial injection of ketorolac 60mg (2ml + 8ml lidocaine 1%)
10168315|NCT03913702|Active Comparator|Methylprednisolone|Assigned patients will receive a subacromial injection of methylprednisolone 80mg (1ml + 9ml lidocaine 1%)
10168316|NCT03913663|Active Comparator|study group|20 patient with hemineglect, minimum 6 months post stroke
9671684|NCT05044533||Cohort 1|Participants with atrial fibrillation (AF) experiencing a bleed
10168317|NCT03913663|Active Comparator|control group|20 patient with hemineglect, minimum 6 months post stroke
10168318|NCT03913624|Experimental|50 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 50 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
10168319|NCT03913624|Experimental|35 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 35 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
10168320|NCT03913624|No Intervention|Control group|Conventional treatment
10168321|NCT03913611|Other|Traditional Rehabilitation|In this arm, patients will undergo the standard rehabilitation protocol, with sling use for 6 weeks.
10168322|NCT03913611|Experimental|Accelerated Rehabilitation|In this arm, patients will undergo the accelerated rehabilitation protocol, with no sling use outside the immediate postoperative period.
10168323|NCT03913754||Lupus Patients with kidneys failure|Assessment of quality of life on everydays life trough questionnare
10168324|NCT03913754||Lupus Patients without kidneys failure|Assessment of quality of life on everydays life trough questionnare
9671685|NCT05044494||study group|non-prompt surgery after acute type a aortic dissection occurred
9974902|NCT05124691|Experimental|FDCx3. Albendazole and Ivermectin Fixed Dose Coformulation 3 days|Daily dose of a tablet of FDC 400mg18mg or 400mg 9mg for 3 days. (i)For participants <45 kg of body weight at baseline: FDC of 400mg ALB9mg IVM. (ii) For participants ≥45 kg of body weight at baseline: FDC of 400mg ALB 18mg IVM.
10186783|NCT03732521|No Intervention|Control group|usual clinical practice
9671686|NCT05044494||control group|prompt surgery after acute type a aortic dissection occurred
9671687|NCT05044689||Colorectal Cancer (Cases)|Based on the existing ARGO (African Colorectal Cancer Group) platform where a current colorectal cancer study is going on, 400 patients with a prior diagnosis and a new diagnosis will be recruited into this study.
10168325|NCT03913637|Experimental|Strategy Training|In addition to receiving everything in Enhanced Usual Care, participants will engage in 10 sessions over 5 weeks with a trained research interventionist. Participants will describe activities they do, no longer do, or have never done using the cards from the Activity Card Sort as a guide. The therapist will ask the participants to use this information to identify and prioritize activity-based goals to address in the remaining sessions. These sessions will take place in a location of the participant's choice and will last approximately 1 hour.
10168326|NCT03913637|Active Comparator|Enhanced Usual Care|Enhanced usual care will allow older adults to interact with services and support. All mental health treatment (e.g., medications that you may be taking) and psychotherapy (e.g. counseling or social services) will be documented and monitored. Furthermore, all participants assigned to Enhanced Usual Care will receive the same assessments as other participants. The close monitoring will track potential changes in symptoms (e.g., depressive symptoms), and participants will be referred to services as appropriate.
10168327|NCT03913806|Experimental|Treatment group|Bevacizumab-IRDye800CW
10168328|NCT03913793|Active Comparator|Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction with peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
10168329|NCT03913793|Active Comparator|Non-Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction without peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
10168330|NCT03913793|No Intervention|Control group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction, not enrolled into exercise program.
10168331|NCT03913403||Intervention|Participants will receive 2 ECHO's and 2 Blood Draws
10168332|NCT03913676|Experimental|Velibra|All treatment will be provided via the Velibra website: https://velibra.broca.io/en/registration/voucher. While the Velibra treatment is only six weeks long, participants will have free access to the program for 24 weeks. They can access this website as often as they would like. The Velibra program is self-guided, so participants determine how often they access the material (the program encourages participants to complete one of six sessions per week for six weeks).
10168333|NCT03913338|Other|Study group|LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.
10168334|NCT03913338|Other|Control group|LASIK only
10168335|NCT03913455|Other|Guadecitabine and Carboplatin|Each cycle = 28 days; Subjects receive 4 cycles
10168336|NCT03913494|Experimental|4 Week Snoozeal Use|Participants will take the device home and be required to use it for 20 minutes morning and night every day for at least 4 weeks. The SnooZeal records usage time to allow assessment of compliance.
10168337|NCT03913429|Active Comparator|Control Group|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml."
10168338|NCT03913429|Experimental|Study Group|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side."
10168339|NCT03913325|Experimental|PREVSAM model|
10168340|NCT03913325|Active Comparator|Treatment as usual|
10168341|NCT03913468||Received Ascorbic Acid IV|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who were treated within the first 24 hours of admission with the combination of IV ascorbic acid, IV thiamine, and IV hydrocortisone, with a duration of 4 days or until patient leaves the ICU.
10168342|NCT03913468||Control Group|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who did not receive any treatment with IV ascorbic acid.
10168343|NCT03913416|Experimental|3D|Surgery with surgeon trained using a 3D printed model of the pulmonary malformation.
10168344|NCT03913416|Other|Control group|Conventional surgery without training using a 3D printed model of the pulmonary malformation.
9520376|NCT03278288|No Intervention|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
9520377|NCT03278275|Experimental|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
9520378|NCT03278262||>= 70 letters|Baseline VA >= 70 letters
9520379|NCT03278262||36-69 letters|Baseline VA 36-69 letters
10168345|NCT03913312|Experimental|DAC combined with unrelated cord blood transplantation|Decitabine (DAC) 15mg/m2/d, d-7 to d-3;Ara-C 1000g/m2/q12h, d-2 to d-1.Single unrelated cord blood (TNC>1.5*107/kg), d0.
9520380|NCT03278262||<=35 letters|Baseline VA <=35 letters
9520381|NCT03278236|Experimental|TRF|
10168346|NCT03913546|Sham Comparator|Sham spinal manipulation|Participants in the 'sham' group will receive a sham mechanical thrust (force set at level 0) instead of an actual one. In the force level 0, no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition. Therefore, the subject does not distinguish between intervention or placebo.
10168347|NCT03913546|Experimental|Actual spinal manipulation|Participants in the actual actual spinal manipulative therapy (SMT) group will be assessed through the Activator basic method. SMT will be performed with the Activator IV Adjusting Instrument (Activator Methods International, Phoenix, AZ) varying the force level depending on the adjusted segment.
10186784|NCT03732508|Experimental|Irinotecan liposome plus SHR1316 plus fluorouracil|
9520382|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
9520383|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
10168348|NCT03913585|Experimental|Lifestyle intervention|The intervention group comprises ~4800 patients born 1959-1988, living in the municipalities of Haderslev or Middelfart, and affiliated to one of the participating GPs. No control group is included.
10168349|NCT03913520|Other|Congenital Heart Disease|Undergoing evaluation at 30 days
10168350|NCT03913533|Active Comparator|Control group|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
10168351|NCT03913533|Experimental|Intervention group|Heart rate assessment using Tap-based smartphone application At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
10168352|NCT03913780|Active Comparator|Group 1 (Medical record)|For group 1, participants do not have intervention as groups 2 and 3. This group consists of reviewing the medical history of the year 2000 to determine the variables of the study and then compare them with groups 2 and 3. This group of participants they were from the year 2000 and whose information will be strictly taken from their medical history was based on initial training with warm-up and walking, after that, aerobic training was performed from 50 to 70% of their maximum heart rate and they finished their session training with breathing exercises, coordination, balance and walking.
10168353|NCT03913780|Experimental|Group 2: Aerobic exercise + Strength training in MMSS|"For group 2, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more strength exercises for upper limbs with dumbbells, multi-strength equipment and Theraband.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
10168354|NCT03913780|Experimental|Group 3: Aerobic exercise + Strength training in MMII|"For group 3, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more the strength training for lower limbs with theraband, multi-strength equipment and exercises for activation of the sole-twin pump.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
10168355|NCT03913364|Experimental|Experimental Obese mothers|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
10168356|NCT03913364|Placebo Comparator|Placebo Obese mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
10168357|NCT03913364|Experimental|Experimental normal weight mothers|One portion (50g) of an ice-cream containing B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
10168358|NCT03913364|Placebo Comparator|Placebo normal weight mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
10168359|NCT03913507|Experimental|one group : patients with suspicion of cystic fibrosis|
10168360|NCT03913728|Experimental|Outcome of blood test provided|These patients are given the results of their drug level blood tests and treatment can be altered/ further advice can be provided as a result of this.
10168361|NCT03913728|No Intervention|Outcome of blood test not provided|The blood results for these people are not fed back to the patient or the clinical site.
10168362|NCT03913728|Experimental|Patients have a telephone interview|All patients are randomised for a second time; 20% (10) of them will have a semi-structured phone interview
10168363|NCT03913728|No Intervention|No telephone interview|All patients are randomised for a second time; 80% won't have a phone call and this will be as per standard care.
10168364|NCT03913572||REVOLVE|Patients that have agreed to be prospectively enrolled in the study and undergo Injection of adipose-derived stem cells into perianal fistula with the REVOLVE system
10168365|NCT03913572||Retrospective cohort|Patients that have undergone treatment of perianal disease without use of adipose-derived stem cell injection.
10168366|NCT03913260|Experimental|Part A: LY3375880 Formulation A|LY3375880 Formulation A administered subcutaneously (SC).
10168367|NCT03913260|Experimental|Part A: LY3375880 Formulation B|LY3375880 Formulation B administered subcutaneously SC.
10168368|NCT03913260|Experimental|Part A: LY3375880 Formulation C|LY3375880 Formulation C administered SC.
10168369|NCT03913260|Placebo Comparator|Part A: Positive Control|Positive Control (buffer matrix, only) administered SC.
10168370|NCT03913260|Experimental|Part B: LY3375880 Test 1|LY3375880 Test 1 Formulation administered SC.
10168371|NCT03913260|Experimental|Part B: LY3375880 Test 2|LY3375880 Test 2 Formulation administered SC.
10168372|NCT03913260|Experimental|Part B: LY3375880 Test 3|LY3375880 Test 3 Formulation administered SC.
10168373|NCT03913234|Experimental|Combination of Letrozole, Trastuzumab with Ribociclib|Phase IB (dose escalation of ribociclib with fixed dose of letrozole and Ribociclib) Phase II (ribociclib of RPIID with fixed dose of letrozole and ribociclib)
10168374|NCT03913351|Experimental|Lifestyle modification program|The dietary intervention program will be scheduled for 12 months, and conducted by a dietitian.The program aims to increase energy expenditure and reduce caloric intake, with an emphasis on long-term lifestyle and behavioural change. An exercise instructor will provide advice on physical activity. A mobile tracking device to monitor calories expenditure will be provided to each participant during they study period to encourage physical activity.
10168375|NCT03913351|No Intervention|Control|standard care of treatment, as in routine clinical practice
10168376|NCT03913221|Active Comparator|Low Dose Caffeine (5 mg/kg)|Within 24 hours of delivery, participants will receive low dose administration of Caffeine citrate.
10168377|NCT03913221|Active Comparator|High Dose Caffeine (10 mg/kg)|Within 24 hours of delivery, participants will receive high dose administration of Caffeine citrate.
10168378|NCT03913065||Included patients|Cardiac arrest patients from sites participating in the TTM-2 CT-substudy still unconscious 48 hours after cardiac arrest are routinely examined with head computed tomography as soon as possible after inclusion.
10168379|NCT03912922|Experimental|Sit regime|Subjects will follow the sit regime during four days. Each day consists of 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
10168380|NCT03912922|Experimental|Sit less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 3 hours walking, 4 hours standing and 8 hours sleeping.
10168381|NCT03912922|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours sitting, 1 hour walking, 1 hour standing, 1 hour exercise and 8 hours sleeping. The cycle session will be at approximately 60% maximal power. Exact cycling intensity and duration will be calculated to ensure equal total energy expenditure between the sitting less and the exercise regime.
10168382|NCT03912974|Active Comparator|Pretreatment with escitalopram|Pretreatment with escitalopram (10 mg for 7 days orally, 20 mg for another 7 days orally), followed by administration of psilocybin (25 mg orally) on the study day
10168383|NCT03912974|Placebo Comparator|Pretreatment with placebo oral capsule|Pretreatment with placebo, followed by administration of psilocybin (25 mg orally) on the study day
10168384|NCT03912857|Experimental|test group|"Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
10168385|NCT03912896|Experimental|Children with autism spectrum disorder|
10168386|NCT03912935|No Intervention|Sniffing position|Subject will be maintained in standard intubation position which is supine position with head elevation with head rest (foam donut).
10168387|NCT03912935|Experimental|Bed up head elevation position|Subject will be maintained at bed up 20-30 degree aiming alignment between the external auditory meatus with sternal notch
10168388|NCT03913013|Experimental|FFT with MCC App (FFT-MCC)|Youth in this study arm will receive 12 sessions of FFT (psychoeducation, communication skills training, and problem-solving skills training) with their parents and siblings. They and their parents will make regular mobile app ratings of mood, sleep, family functioning, stress, and perceived criticism. Children and parents will call into a voice-activated phone system and be asked to speak freely for 3-5 minutes about their health and family functioning. They will be guided through 12 lesson plans in which they practice skills such as active listening or identifying prodromal signs of episodes, paralleling what they are learning in sessions. The clinician will be able to set a weekly skill training assignment and observe the family's practice of the skill between sessions. They will adapt session content accordingly.
10168389|NCT03913013|Active Comparator|FFT with App Assessments only (FFT-Assess)|Youth in this condition will receive the same 12 sessions of FFT, but the app will be limited to daily and weekly assessments of their mood, sleep, stress, and family functioning. The app will not provide the skill training offered in the FFT-MCC condition.
10168390|NCT03912909|Active Comparator|Phase 1|Empagliflozin 10mg daily or placebo
10168391|NCT03912909|Placebo Comparator|Phase2|Empagliflozin 10mg daily or placebo
10168392|NCT03913182|Experimental|apatinib group|apatinib：500mg po Qd
10186785|NCT03732482|Placebo Comparator|RT groups|participants was given radiotherapy only,50Gy in 10 fractions over 2 weeks to metastases synchronously with 25Gy WBRT
10186786|NCT03732482|Experimental|Drug plus RT groups|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
10186787|NCT03732469|Experimental|Fentanyl/propofol + acetaminophen|In addition to the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol, one dose of 1300 mg of solid base rectal acetaminophen suppository (2 suppositories) will be administered at the end of oocyte retrieval.
10186788|NCT03732469|Active Comparator|Fentanyl/propofol only|Participants in this arm will receive the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol.
10186789|NCT03732443||Critical Ill Patients|Critically ill patients with a RASS ≥ 3. FAM-CAM and CAM-ICU will be administered.
10186790|NCT03732430|Experimental|Anti-PD-1 antibody|IBI308 200mg intravenous drip every three weeks following adaptive radiation therapy.
10186791|NCT03732417||Stroke patients|Control group included people with ischemic or haemorragic stroke in Terres de l'Ebre, Spain.
10186792|NCT03732417||Telematic model treatment of patients with Stroke|The intervention group included control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced.
10186793|NCT03732404|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
10186794|NCT03732404|Placebo Comparator|Placebo|The control group will receive plain water with the same volume and timing of treatment
10186795|NCT03732391|Experimental|single arm|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will come continued with the same schedule until unacceptable toxicity or disease progression
10186796|NCT03732378|Experimental|Omega-3|one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time)
10186797|NCT03732378|Placebo Comparator|Placebo|one capsule of 500 mg corn oil, along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time) were given to placebo group
9974903|NCT05119101|Active Comparator|Magnesium sulphate|patients will recieve Mg sulphate as loading dose of 4 g diluted in 200 ml normal saline intravenous over 10 minutes followed by 1 g/h infusion for 24 h.
10168393|NCT03913026|Experimental|Main intervention|Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.
10168394|NCT03913000|Experimental|ID-085 single dose|Administration of the study treatment 200 mg to renally impaired subjects will be done by severity, starting with group A (mild), and followed by group B (moderate), C (severe) and D (healthy subjects).
10168395|NCT03913156|Other|Part 1|Part 1 of the study will recruit subjects who are about to be introduced to a concentrated phe-free protein substitute (i.e. second stage protein substitute) for the first time.
10168396|NCT03913156|Other|Part 2|Part 2 of the study will recruit subjects who have already been introduced to a concentrated phe-free protein substitute (i.e. have already transferred from phe-free infant formula onto a second stage protein substitute). This group will be included to evaluate the acceptability of the study product in patients who have already moved onto a second stage protein substitute.
10168397|NCT03913052|Experimental|Injection|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine was performed once when the knee joint was in the supine position and the knee was in the extension.
10168398|NCT03912766||Transurethral Prostatectomy|male patients undergoing transurethral prostatectomy (TURP) for benign prostatic hyperplasia, routine surgical removal using resectoscope
10168399|NCT03912545||Trauma patients|Subjects experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
10168400|NCT03912545||Obstetric hemorrhage patients|Subjects experiencing obstetric hemorrhage such that viscoelastic testing is performed as standard of care is performed to assess coagulopathy.
10168401|NCT03912584|Other|Optical Coherence Tomographer|
10168402|NCT03912493|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. The conventional program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
10168403|NCT03912493|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
10168404|NCT03912571||Mild Cognitive Impairment (MCI)|Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
10168405|NCT03912571||Normal Cognition (NL)|Clinical Dementia Rating [CDR] of 0 or Global Deterioration Scale [GDS] of 1-2
10168406|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 1|
10168407|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 2|
10168408|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 3|
10168409|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 4|
10168410|NCT03912623|Active Comparator|3 weeks SPA Treatment|"3-week thermal cure:~Spa treatment harmonized in the different stations~Therapeutic education workshops and conferences common to all stations in the form of practical workshops during supervised lunches~Adapted physical activity, workshops are common to all spas and use an electric bike suitable for health (VELIS) with briefing and debriefing. An APA (Adapted Physical Activity) coaching consultation at the end of the cure for personalized post-cure programs and objectives is planned as well as a telephone or internet coaching during the 5 months post-cure (objectives and adaptation, motivation)~Maintenance of the usual treatment within 6 months post randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by the software Diascope and / or HAS~Information booklet for inclusion (French Association of Diabetics)"
10168411|NCT03912623|Sham Comparator|Discovery week end|"Maintenance of usual treatment within 6 months post-randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by Diascope and HAS software In addition, a discovery access to the baths of 2-3 days will be offered to patients. Finally, the information booklet on diabetes will be given at the inclusion (French Federation of Diabetics)."
10168412|NCT03912675|Experimental|RigeneraTM protocol|Teatment with Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol.
10168413|NCT03912675|Experimental|Control|Treatment with Integra® dermal substitute only.
10168414|NCT03912688|Experimental|single acupoint stimulation|
10168415|NCT03912688|Experimental|dual acupoints stimulation|
10168416|NCT03912688|No Intervention|no stimulation|
10168417|NCT03912597|Experimental|Virtual Reality [A]|Participants watch a 4-minute virtual reality video, on top of reading a brochure, then answer post-intervention questionnaires.
10168418|NCT03912597|Active Comparator|Brochure Waitlist Control [A]|Participants read an informational brochure about depression, then answer post-intervention questionnaires. After that, they will be given a chance to watch the VR video at the end of their participation session.
10168419|NCT03912597|Active Comparator|Standard Video Control [B]|Participants watch a 4-minute standard video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
10168420|NCT03912597|Experimental|Virtual Reality [B]|Participants answer pre-questionnaires, then watch a 4-minute virtual reality video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
9974904|NCT05119101|Active Comparator|Dexamedotomidine adjuvant to Magnesium sulphate|Patients will reccieve Mg sulphate as loading dose of 4 g diluted in 200 ml normal saline intravenous over 10 minutes followed by 1 g/h infusion for 24 h. in addition they will receive an intravenous infusion of dexmedetomidine .5 μg/kg diluted in 200 ml normal saline intravenous over 10 minutes followed by .15 μg/kg/hr infusion for 24 h.
10168421|NCT03912779|Experimental|C2Hear RLOs|C2Hear RLOs (https://www.youtube.com/C2HearOnline): nine (custom earmould) or eight (open fit hearing aid) multi-media learning clips covering practical and psychosocial components of owning a hearing aid, alongside user testimonials (n= 7). Participants asked to watch all relevant to their prospective hearing aid coupling (custom earmould or open fit), with no limit on number of views. A paper diary documented usage during the study duration.
9974905|NCT05118477|Experimental|AMS group|Patients randomised to the intervention group will receive the AMS; this will be connected to the dashboard and the alerting system. Clinical staff will have access to the dashboard and alerted accordingly for the assigned patients.
10168422|NCT03912779|Placebo Comparator|Printed hearing aid booklet|A 32-page printed A5 colour booklet, designed and written by local Audiology staff, supplied to all prospective hearing aid owners at the study centre as standard care. Same booklet supplied irrespective of hearing aid style (custom/open fit). All content conveyed via text and supporting pictures only. Participants assigned to the placebo comparator were asked to read the booklet once. A paper diary documented usage during the study duration.
10168423|NCT03912480|Experimental|Stem cells from human exfoliated teeth|"Basic treatment:~The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia).~Stem cell therapy:~Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight .~Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment.~Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed."
10168424|NCT03912727|Experimental|Alpha-lipoic acid|18 patients will receive alpha lipoic acid (thiotacidR) product with their standard therapy.
10168425|NCT03912727|Placebo Comparator|Control|18 patients will receive their standard therapy only.
10168426|NCT03912649|Experimental|RemovAid arm|"RemovAid arm -~All subjects have their implant removed by the RemovAid device"
10168427|NCT03912714|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy in therapy refractory ulcerative colitis patients after pre-operative endoscopic biopsies of the appendix
10168428|NCT03912714|Active Comparator|Non-active UC|Patients with non-active ulcerative colitis planned for surveillance colonoscopy will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
10168429|NCT03912714|Active Comparator|Healthy control|'Healthy control' patients (i.e. patients planned for colonoscopy for polyps) will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
10168430|NCT03912610||Health control group|5 health volunteer are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
10168431|NCT03912610||Knee osteoarthritis group|5 patients of knee osteoarthritis accompanied with depression or anxiety are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
10168432|NCT03912740|Active Comparator|Remifentanil Analgesia|Continuous intraoperative analgesia with remifenanil + 0.9% sodium chloride
10168433|NCT03912740|Active Comparator|Remifentanil and Dexmedetomidine Analgesia|Continuous intraoperative analgesia with remifenanil + dexmedetomidine
10168434|NCT03912194|Experimental|Early Withdrawal Exposure plus NAW Regulation Training|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) across the first 4 hours of abstinence over 4 separate sessions.
10168435|NCT03912194|Active Comparator|Early Withdrawal Exposure plus Relaxation Control Training|The development, application, modification, and repeated practice of relaxation strategies across the first 4 hours of abstinence over 4 separate sessions.
10168436|NCT03912194|Active Comparator|NAW Regulation Training Only|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) over 4 separate sessions involving smoking as usual.
10168437|NCT03912194|Active Comparator|Relaxation Control Training Only|The development, application, modification, and repeated practice of relaxation strategies over 4 separate sessions involving smoking as usual.
10168438|NCT03912402|Experimental|BCD-100|BCD-100 mg/kg Q3W
10168439|NCT03912376||Healthy Volunteer|Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history.
10168440|NCT03912389|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
10168441|NCT03912389|Placebo Comparator|Placebo|
10168442|NCT03912324|Experimental|Unipolar voltage subtraction map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury~Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure and Ablation time, and perfusion saline dose~Rhythm follow-up after the procedure in accordance with the study design."
10168443|NCT03912324|Experimental|CT myocardial thickness map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
10168444|NCT03912324|Active Comparator|Empirical PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
10168445|NCT03912220|Experimental|Nicotinamide Riboside|Experimental group of participants will receive Nicotinamide riboside at a dose of 900 mg twice a day orally.
9520384|NCT03278197|Experimental|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
10168446|NCT03912220|Placebo Comparator|Placebo|Study participants in the placebo arm will receive placebo pills that are similar in size and shape to the experimental group drug.
10168447|NCT03912246|Experimental|Healthy volunteers|"Human biological samples:~whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
10168448|NCT03912246|Experimental|Patients with neuro-meningeal infection|"Human biological samples:~Whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.~Extended collection of CSF~Bio-clinical data :~adjusted to the purpose of the searches will be collected"
10168449|NCT03912415|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
10168450|NCT03912415|Placebo Comparator|Placebo|
10168451|NCT03912285|Experimental|Amlodipine, losartan, and amlodipine plus losartan|"Period 1:~amlodipine 10mg will be administered orally once a day for 9 days.~Period 2:~losartan 100mg will be administered orally once a day for 9 days after 13 days of the washout period.~Period 3:~amlodipine 10mg once a day plus losartan 100mg once a day will be administered orally for 9 days after 6 days of the washout period."
10168452|NCT03912168|Experimental|Question Prompt List|
10168453|NCT03912168|Active Comparator|3 questions list|
10168454|NCT03912155||Patients|20 patients per presumed location of the epileptogenic zone (see experimental plan) for a total of 120 patients, including 30 minors. For patients, a MEG-EEG-SEEG examination during the SEEG exploration period.
10168455|NCT03912155||Controles|For the control population, 120 control subjects, including 30 minors, that is to say as many as patients. For control subjects, a MEG-EEG exam.
10168456|NCT03912142||Three dimensional transperineal ultrasound|"This is a single arm study. All women who delivered vaginally will be included in the study .~The planned interventions are:~Clinical vaginal and rectal examination Three dimensional transperineal ultrasound."
10168457|NCT03912129|Other|pediatric Evans Syndrome|Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
10168458|NCT03912038||Null or low consumption|No-intervention. The group consists of women who have reported a null or low consumption of non-caloric sweeteners during late pregnancy.
10168459|NCT03912038||Moderate consumption|No-intervention. The group consists of women who have reported a moderate consumption of non-caloric sweeteners during late pregnancy.
10168460|NCT03912038||High consumption|No-intervention. The group consists of women who have reported a high consumption of non-caloric sweeteners during late pregnancy.
10168461|NCT03912025||Mild hemodynamic CHD|"Mild severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses, as outlined in the European Society of Cardiology Section on Sports Cardiology consensus guidelines (Budts W, Borjesson M, Chessa M, van Buuren F, Trindade PT, Corrado D, Heidbuchel H, Web G, Holm J, Papadakis M. 2013).~They define functional parameters such as systolic function, oxygen saturation, rhythm disorders, elevated pressure or volume load, etc. to divide patients into 3 hemodynamic groups. Based on their model, we define mild CHD as ones falling into the group that can train at High Intensity exercise levels."
10168462|NCT03912025||Moderate hemodynamic CHD|"Moderate severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses. Based on their model, we define moderate CHD as those that can train at Moderate Intensity."
10168463|NCT03912116|Experimental|Amniotic Umbilical Cord Particulate Injection|100mg Amniotic Umbilical Cord Particulate in 8cc saline
10168464|NCT03912116|Placebo Comparator|Saline Injection|8cc saline
10168465|NCT03912012|Other|Children and adolescent with a history of type 1 diabetes|Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years. Glomerular hyper filtration and endothelial dysfunction will be evaluate.
9520385|NCT03278197|Other|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
9826488|NCT02420093|No Intervention|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
10168466|NCT03912103|Active Comparator|Interdiciplinary medication review intervention|The clinical pharmacist perform medication review and presents medication interventions orally and written to the physician. The physician perform the changes and inform the patient about the changes. 7 days after intervention the patient receives a follow up phone call from the pharmacist about the medication interventions. If the pharmacist during the follow up phone call identify any complications due to compliance/add on/deprescribing the pharmacist uses motivational conversation to come to a solution.14 days after the beginning of the intervention the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire and measured on a Likert scale (1-5). 30 days after the beginning of the intervention the pharmacist collect an updated medication history. Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group.
10168467|NCT03912103|No Intervention|Control group|Standard treatment without a medication review and follow up related to medication changes (standard treatment).14 days after the enrollment the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire measured on a Likert scale (1-5). 30 days after the enrollment the pharmacist collect an updated medication history.Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group
10168468|NCT03912051|Experimental|asymmetric balloon|Asymmetric air filled (max 25 cc, Leur lock syringe) epistaxis balloon
10168469|NCT03911817|No Intervention|IV vasopressor|Will receive IV vasopressor infusion only
10168470|NCT03911817|Active Comparator|Midodrine|Will receive midodrine in addition to IV vasopressor infusion
9827744|NCT02466412|Active Comparator|CHTP 1.1 M then mCC|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CHTP 1.1 M)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of mCC)."
10168471|NCT03912077|Experimental|Culturally Adapted Cognitive Behavioural Therapy|"Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) is an evidence-based psychological intervention manual developed by Devon Hinton, MD from Harvard University and Baland Jalal from University of Cambridge. It is a group therapy protocol that consists of 7 sessions.~It is a brief, feasible and culturally sensitive intervention that has a transdiagnostical approach. Detailed information about Syrian culture, idioms of stress, cultural differences, and psychological problems that Syrian refugee women have been facing and their needs, expectations and sensitivities are considered in the adaptation process. Examples, cultural metaphors and imageries that take part in the manual are adapted according to Syrian culture."
10168472|NCT03912077|No Intervention|Treatment as Usual|Control arm participants will receive routine social support and/or care according to ordinary practice of the non-governmental organization (treatment as usual). Also, they will receive baseline and post assessments according to the study schedule.
10168473|NCT03911986|Other|Immediate External Loop Recorder|Participants randomized to the Immediate External Loop Recorder group will be monitored for the duration of the first week of the study using the Novacor R-Test 4.
10168474|NCT03911986|Other|Delayed External Loop Recorder|Participants randomized to the Delayed External Loop Recorder group will be monitored for the duration of the second week of the study using the Novacor R-Test 4.
10168475|NCT03911726|Other|Healthy subjects|30 healthy subjects will undergo a single PET/MR-measurement.
10168476|NCT03911726|Experimental|First-episode, drug-naive patients with schizophrenia|20 first-episode, drug-naive patients with schizophrenia will undergo a single PET/MR-measurement.
10168477|NCT03911726|Experimental|Pretreated chronically ill patients with schizophrenia|90 pretreated chronically ill patients with schizophrenia will undergo a single PET/MR-measurement.
10168478|NCT03911765|Experimental|Executive Function cognitive training|20 hours of digital cognitive training targeting executive function.
10168479|NCT03911765|Active Comparator|Games|10 hours of computer games c available online which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc), followed by 10 hours of of digital cognitive training targeting executive function.
10168480|NCT03911882||Celergen Administration|The food supplement Celergen was administered to fibromyalgia patients following a protocol of a daily intake for the period of a total of 3 months (90 days)
10168481|NCT03911934|Active Comparator|Usual care|Usual care in the geriatric outpatient clinic.
10168482|NCT03911934|Experimental|Usual care plus polypharmacy intervention|Usual care in the geriatric outpatient clinic plus polypharmacy intervention. Polypharmacy intervention consists of a medication review by a physician from the Department of Clinical Pharmacology plus additional communication with patients' GPs before and after the visit in the outpatient clinic.
10168483|NCT03911921|Experimental|RSYYT decoction|RSYYT decoction Compound granules of traditional Chinese medicine
10168484|NCT03911921|Experimental|Astragalus membranaceus|one herb decoction Compound granules of one herb (Astragalus membranaceus)
10168485|NCT03911635|Experimental|Hypospadias in children|Distal shaft hypospadias at age of 12 years or less
10168486|NCT03911648||Group B;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% caudally, the maximum given volume was 20 ml. N=42
10168487|NCT03911648||Group L;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1% caudally, the maximum given volume was 20 ml. N=44
10168488|NCT03911804|Experimental|Bolus group|
10168489|NCT03911804|Active Comparator|Infusion group|
10168490|NCT03911895||patients with coronary artery diseas undergoing PCI|Effect of stent length on patients with coronary artery undergoing PCI
10168491|NCT03911674|Experimental|Oral stimulation|Oral stimulation protocol: manual stimulation of the oral sucking
10168492|NCT03911674|No Intervention|Control|No intervention
10168493|NCT03911947|Active Comparator|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
10168494|NCT03911947|Active Comparator|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
10168495|NCT03911947|Active Comparator|AB (actual bicarbonat level)|Measurment 4 times per day, ABA (acid-bases analyses)
10168496|NCT03911609|Experimental|Isometric (Static) Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
10168497|NCT03911609|Experimental|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
10168498|NCT03911427|Experimental|Powder Mix 1|Oat powder product, mixed with water
10168499|NCT03911427|Placebo Comparator|Powder Mix 2|Brown rice milk powder product, mixed with water
10168500|NCT03911440|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
10168501|NCT03911440|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
10168502|NCT03911583|Active Comparator|Control Group (CG)|Education, modifying diet and light physical activity (LPA)
10168503|NCT03911583|Active Comparator|Moderate physical activity group (MPA)|Education, modifying diet and moderate physical activity (MPA)
10168504|NCT03911583|Active Comparator|Intense physical activity group (IPA)|Education, modifying diet and intense physical activity (IPA)
10168505|NCT03911336|Experimental|Group A - test|Group A (Test) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
10168506|NCT03911336|Active Comparator|Group B - Control 1|Group B (Control 1) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3- day period, starting the regime at 2 PM on the day of the extraction.
10168507|NCT03911336|Active Comparator|Group C - Control 2|Group C (Control 2) - Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
10168508|NCT03911544|Active Comparator|TIVA anesthesia with BIS monitoring|The depth of anesthesia will be adjusted with the help of BIS monitoring.
9974906|NCT05118477|Active Comparator|Standard Care group|"Patients in the control group will also receive the AMS however this will not be connected to the ward dashboard and clinical staff will not be able to access these patient's continuous vital signs:~Patient will not appear on the ward dashboard~No alerting system will be given to staff"
10168509|NCT03911544|No Intervention|TIVA anesthesia without BIS monitoring|The depth of anesthesia will adjusted as in standard practice (clinical signs of poor anesthesia such as increase in blood pressure and/or heart rate, tearing and profuse sweating)
10168510|NCT03911570||Glucosamine Sulfate Group (GS Group)|GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
10168511|NCT03911570||Control Group|Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).
10168512|NCT03911310|Experimental|PET/CT 1: [18F]PSMA-11, PET/CT 2: [68Ga]PSMA-11|Patients in this arm will first receive the experimental radiotracer [18F]PSMA-11 PET/CT followed by the [68Ga]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
10168513|NCT03911310|Active Comparator|PET/CT 1: [68Ga]PSMA-11, PET/CT 2: [18F]PSMA-11|Patients in this arm will first receive the experimental radiotracer [68Ga]PSMA-11 PET/CT followed by the [18F]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
10168514|NCT03911245||Patients with age equal or older than 40 years|
10168515|NCT03911245||Patients with age less than 40 years|
10168516|NCT03911375|Experimental|Mindfulness Based Stress Reduction (MBSR)|Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.
10168517|NCT03911375|No Intervention|Control|Participants assigned to the control group will follow the usual treatment, according to their diagnosis.
10168518|NCT03911518|Active Comparator|Control|Incision and drainage.
10168519|NCT03911518|Experimental|Intervention|Loop drainage.
10168520|NCT03911557|Experimental|Patients with moderate to high tumor mutational burden|Patients with recurrent or refractory disease in solid tumors naïve to anti-PD-1/PD-L1 or anti-CTLA-4 immunotherapy and have moderate to high tumor mutational burden (TMB)
10168521|NCT03911531||Fetuses|DNA obtained from amniotic fluid samples
10168522|NCT03911531||Neonates|DNA obtained from neonatal blood samples
10168523|NCT03911414|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
10168524|NCT03911414|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700mg QD) based on age .
10168525|NCT03911479|Experimental|Bariatric Surgery Group|
10168526|NCT03911479|Other|Clinical Threatment|Convencional treatment in a public tertiary outpatients care unit
10168527|NCT03911362|Active Comparator|Lumbopelvic Stabilisation Exercises|Starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction
10168528|NCT03911362|Active Comparator|Pelvic Floor Exercises|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres and for slowly contracting muscle fibres,slow contraction by counting to ten hold for a count of ten, then gradually relax by counting to ten.
10168529|NCT03911271|Experimental|Loading dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
10168530|NCT03911271|Experimental|Low dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
10168531|NCT03911271|Placebo Comparator|Placebo|"In phase 1 (treatment phase), the participants (n=50) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
10168532|NCT03911193|Experimental|Cabozantinib|Elegible NSCLC patients with MET exon 14 skipping mutations or MET amplification will be treated with open label orally cabozantinib 60 mg/daily, cycles each 28 days.
10168533|NCT03911258|Experimental|Nasal flora in CF patient|
10168534|NCT03911024|Active Comparator|HIV|
10168535|NCT03911024|Placebo Comparator|General Health|
10168536|NCT03911232|Experimental|Enhanced recovery|rocuronium 2 effective dose at anesthesia induction sugammadex after skin incision and before extubation (total 2 mg/kg iv)
9671688|NCT05044689||Controls|We will select our 400 controls from two groups of participants who are free of cancer and gastrointestinal diseases. First, we will leverage community mobilization groups to identify and recruit a target group of 200 community-based population controls. Second, we will identify and recruit the remaining 200 controls from those seeking care in the Outpatient Health Center at OAU, which sees ~50-60 patients per day as part of routine care.
9671689|NCT05044260|Experimental|Direct Sinus elevation using SLA Kit|
10168537|NCT03911232|No Intervention|Conventional anesthesia|standard general anesthesia protocol (1 effective dose of rocuronium at anesthesia induction)
10168538|NCT03911037|Active Comparator|Standard Medical Therapy + G CSF Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required). G-CSF ( prefilled syringe) at the dosage of 5 μg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
10168539|NCT03911037|Placebo Comparator|Standard Medical Therapy + Placebo|"Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required).~Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered."
9974907|NCT05117190|Other|Facial Deformity|Face not the normal shape because of injury or illness.
10168540|NCT03910907||Standard of care|Men treated for mycoplasma according to standard of care
10168541|NCT03910907||Standard of care plus|Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers
10168542|NCT03911141|No Intervention|Control|Participants receive a daily text message stating whether or not they achieved their step goal on the prior day during the 12 months of intervention and 6 months of follow-up.
10168543|NCT03911141|Experimental|Gamification Intervention|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
10168544|NCT03911141|Experimental|Financial Incentive Intervention|"Participants are informed that each week that money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
10168545|NCT03911141|Experimental|Gamification and Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
10168546|NCT03911180|Experimental|PFN straight parallel blade|All patients with pertrochanteric fracture that is eligible will undergo PFNA with straight parallel blade.
10168547|NCT03911050|Experimental|Apple consumption|Each subject took apple blends 600 g (made from two apples with seed removal) in a single dose, and samples (urine and blood and feces) at different timepoints were collected following administration of apple blends.
10168548|NCT03911050|Placebo Comparator|Control group|Each subject took breakfast without any apple-related products in a single dose, and samples (urine and blood and feces) at different timepoints were collected following breakfast.
10168549|NCT03910946||diabetic and renal|all cases included in the study will be subjected to : Full clinical history to rule out active TB ( history of current prolonged cough, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue.) Chest x ray TST (tuberculin sensitivity test) : injecting a 0.1 mL of liquid containing 5 TU (tuberculin units) PPD (purified protein derivative) into the top layers of skin of the forearm and read skin tests 48-72 hours after the injection
10168550|NCT03911167||RG|RG: robotic group
10168551|NCT03911167||LG|LG:laparoscopic group,
10168552|NCT03911167||OG|OG：open group
10168553|NCT03910855|Experimental|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
10168554|NCT03910855|Active Comparator|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
10168555|NCT03911063|Experimental|Cognitive behavioral therapy (CBT)|
10168556|NCT03911063|Active Comparator|Placebo Talking Sessions|
10168557|NCT03910842|Experimental|CD19-TriCAR-T/NK（SILK）|CD19-TriCAR-T/SILK cells will be administered intravenously
10168558|NCT03911206|Experimental|Arm 1 : Inspirtory muscle training (IMT)|IMT exercises at home will gradually ramp up.
9974908|NCT05113927|No Intervention|Standard of Care|Lumpectomy with usual intraoperative margin assessment
9974909|NCT05113927|Experimental|Device|Imaging of all margins with investigational device
9974910|NCT05110443|Other|Main arm|Patients will perform a D-WB PET/CT scan as a substitute for their clinical PET.
10168559|NCT03911206|Experimental|Arm 2: Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
10168560|NCT03911206|Experimental|Arm 3: IMT and Exercise|a combination of arm 1 and arm 3
10168561|NCT03911206|No Intervention|Arm 4: Routine care|no interventions will occur in this group besides testing procedures and offering access to the study team in case asthma-related questions come up.
10168562|NCT03911219||CANKADO (Arm A)|CANKADO application as eHealth support system: Patients use CANKADO for regular symptom self-reporting in addition to standard of care symptom management.
10168563|NCT03911219||Control (Arm B)|Control arm without eHealth support: Patients recieve standard of care symptom management.
10168564|NCT03910699|Active Comparator|Two-row anastomosis|Colorectal anastomosis is created with a two-row circular surgical stapler
10168565|NCT03910699|Experimental|Three-row anastomosis|Colorectal anastomosis is created with a three-row circular surgical stapler
10168566|NCT03910790|Experimental|19 Gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle
10168567|NCT03910829|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
10168568|NCT03910829|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
10168569|NCT03910829|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
10168570|NCT03910803|Other|Brodalumab - Open Label|"Randomized subjects will be receiving Brodalumab (210 mg) administered by subcutaneous injection at the following visits: Baseline, week 1, week 2 and every two weeks thereafter, until Week 24.~Investigational Product not to be administer into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by Hidradenitis Suppurativa."
10168571|NCT03910959|Experimental|Animal-assisted therapy|Patients receive three weeks of two AAT sessions, each lasting ca 30 minutes.
10168572|NCT03910959|Active Comparator|treatment as usual|Patients receive three weeks of two control sessions, each lasting ca 30 minutes.
10168573|NCT03910595|Experimental|Mepitel Film Arm|This is a single arm trial where all patients will receive the intervention of Mepitel Film.
10168574|NCT03910608|Experimental|DLPFC+10 IPL|Stimulation of dorsolateral prefrontal cortex (DLPFC) 10 ms before inferior parietal lobule (IPL) presumes that the DLPFC to IPL input facilitates insula postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
10168575|NCT03910608|Experimental|IPL+10 DLPFC|Stimulation of IPL 10 ms before DLPFC presumes that the IPL to DLPFC input inhibits insula postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
10168576|NCT03910608|Experimental|IPL+4 DPLFC|Stimulation of IPL 4 ms before DLPFC is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula inhibits insula postsynaptic output by weakening the IPL to insula input, thereby impairing cognition response.
10168577|NCT03910608|Experimental|DLPFC+4 IPL|Stimulation of DLPFC 4 ms before IPL is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula potentiates insula postsynaptic output by strengthening the IPL to insula input, thereby improving cognition response.
10168578|NCT03910608|Experimental|DLPFC+4 MPFC|Stimulation of DLPFC 4 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
10168579|NCT03910608|Experimental|MPFC+4 DLPFC|Stimulation of MPFC 4 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
10168580|NCT03910608|Experimental|DLPFC+10 MPFC|Stimulation of DLPFC 10 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
10168581|NCT03910608|Experimental|MPFC+10 DLPFC|Stimulation of MPFC 10 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
10168582|NCT03910647|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
10168583|NCT03910647|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
10186798|NCT03732365|Experimental|Investigational Group|Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
10186799|NCT03732365|Active Comparator|Comparator Group|Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
10186800|NCT03732313|Active Comparator|Central toenail resection|Under local ring anaesthesua using xylocaine injection in base of big toe ,Surgical resection of the central part of toenail with underlying germinal matrix.the defect is sutures by prolene.
10186801|NCT03732313|Active Comparator|wedge toenail resection|Under local ring anaesthesiausing xylocaine injection around the base of big toe. Resect lateral wedge of toenail with removal of ingrown toenail and periungual skin. The wound is then sutured.
10186802|NCT03732300|Experimental|ASSIP + TAU goup|ASSIP psychotherapy intervention + treatment as usual (TAU)
10186803|NCT03732300|No Intervention|TAU|Treatment as usual
10186804|NCT03732287|Experimental|-5 degrees Celsius for 10 seconds|
10186805|NCT03732287|Experimental|-5 degrees Celsius for 20 seconds|
10186806|NCT03732287|Experimental|-10 degrees Celsius for 10 seconds|
10186807|NCT03732287|Experimental|-10 degrees Celsius for 20 seconds|
10186808|NCT03732274|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
10168584|NCT03910582|Experimental|Experimental group|Subjects in this group will be treated with personalized frozen-thawed embryo transfer. The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
10168585|NCT03910582|Active Comparator|Control group|Subjects in this group will be treated with routine frozen-thawed embryo transfer.The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
10168586|NCT03911011|Active Comparator|Fresh air|2 litres of fresh air
10168587|NCT03911011|No Intervention|no fresh air|no supply of fresh air
10168588|NCT03910634|Experimental|IMRT combined with carboplatin|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
10168589|NCT03910634|Placebo Comparator|IMRT combined with carboplatin and fluorouracil|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
10168590|NCT03910712|Experimental|Pyrotinib and trastuzumab plus aromatase inhibitor|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10168591|NCT03910712|Active Comparator|Trastuzumab plus aromatase inhibitor|Participants will receive trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10168592|NCT03911115||Bariatric surgery|Individuals that have undergone a gastric bypass (RYGB) or a sleeve gastrectomy (SG)
10168593|NCT03910881|Experimental|open-platform patient support system|Proof of concept testing of app
10168594|NCT03910725||Obesity|Patients with BMI >40 awaiting stapled bariatric surgery, without a history of or concomitant ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication, will be recruited prospectively from the bariatric surgery preoperative assessment clinics.
10168595|NCT03910725||Rheumatoid arthritis|Patients with RA without diagnosed or known ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication will be recruited prospectively from rheumatology clinics, prior to initiation of biologic or diseased modifying anti-rheumatic drugs.
10168596|NCT03910725||Dilated cardiomyopathy|TTNtv-positive and -negative DCM patients from the Royal Brompton Hospital biobank have provided informed consent to be contacted for research
10168597|NCT03910556||no complication|the patients who did not develop any kind of complication and no re-craniotomy
9671690|NCT05044754||SCAP|Patients with recurrent prostate cancer undergoing SCAP
10168598|NCT03910556||with complication (s)|the patients who developed at least one of non-neurological complication or required re-craniotomy
10168599|NCT03910543|Experimental|Patients with Cutaneous Sarcoidosis|Patients with cutaneous sarcoidosis that may also have also have internal organ sarcoidosis
10168600|NCT03910543|Experimental|Patients with Granuloma Annulare|Patients with granuloma annulare that is long-standing and/or widespread
10168601|NCT03910686|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
10168602|NCT03910686|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
10168603|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
10168604|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
10168605|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
10168606|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
10168607|NCT03910517||E-sport athletes|People aged 15-35 who engage in structured E-sport (e.g. community-based, pro team or educational setting).
10168608|NCT03910348|Experimental|Whole body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting (2-4mm peak to peak) on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Each patient received the vibrations under supervision using five different static positions: squat, deep squat, widestep squat, lunge, and hands-front lunge. The exercise programs for each experimental groups consisted of 20 to 60-minute sessions on three days per week for 24 weeks, and they were performed under the supervision.
10168609|NCT03910348|Experimental|High-impact exercise|Depending on their individual calcium and vitamin D intakes, each patient advised to receive supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D.
10168610|NCT03910348|No Intervention|Control|Depending on their individual calcium and vitamin D intakes, each patient received supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D. The demographic characteristics of the participants were obtained at the baseline assessment.
10168611|NCT03910361|Experimental|Evogliptin|evogliptin 5mg
10168612|NCT03910361|Active Comparator|Pioglitazone|pioglitazone 15mg
10168613|NCT03910322|Placebo Comparator|Placebo|Placebo arm. Similar trial product, but without Bif195 bacteria
10168614|NCT03910322|Experimental|Low-dose Bif195|Active trial product with minimum 15 billion CFU daily dose
10168615|NCT03910322|Experimental|High-dose Bif195|Active trial product with minimum 50 billion CFU daily dose
9671691|NCT05044754||HIFU|Patients with recurrent prostate cancer undergoing HIFU
9671692|NCT05044247|Experimental|ESP block|ESP block under mixed local anesthetics, betamethasone agent
9671693|NCT05044169|Experimental|Broncho-Vaxom|Intervention
9671694|NCT05044286||40 Transgender and Gender Diverse for World Café Conversation|We will host two world cafe conversations. The first (n = 20) will be specifically or black transgender and gender diverse adults (18+), who are HIV-negative, and have indications for PrEP. The second (n = 20) will be open to transgender and gender diverse adults, who are HIV-negative, and have indication for PrEP.
10168616|NCT03910296||Acceptance & Commitment Therapy|"Acceptance & Commitment Therapy (ACT) use acceptance, mindfulness, commitment, and behavior change strategies to increase psychological flexibility.~Each subject will participate for 6 sessions of Acceptance & Commitment Therapy (ACT).~ACT trains patients to reframe their unpleasant, negative, private events while encouraging personal values."
10168617|NCT03910335||LSS patients|"Case/control study: Patients from surgical departments awaiting surgery for LSS will will out the questionnaire.~Cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)"
10168618|NCT03910335||Non-LSS patients|Case/control study and cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)
10168619|NCT03910309||1 or 2 level TLIF candidates|Any subject determined to ALREADY be a candidate for 1 or 2 level transforaminal interbody fusion surgery
10168620|NCT03910504|Active Comparator|Rocuronium 0,3 mg/kg|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will be obtained single reduced dose of rocuronium (0,3 mg/kg) once intravenous bolus. The dose of rocuronium will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment. The drug will be diluited in a syringe with 20 ml of solution."
10168621|NCT03910504|Experimental|No rocuronium|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will not receive rocuronium, but normal saline will be administered by the anesthesiologist in charge of the patients. The dose of normal saline (20 ml in one syringe) will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment."
10168622|NCT03910205||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
10168623|NCT03910205||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
10168624|NCT03910205||Healthy patients with gingivitis|Systemically healthy patients with gingivitis
10168625|NCT03910205||Healthy patients with healthy gingiva|Systemically healthy patients with healthy gingiva
10168626|NCT03910374|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
10168627|NCT03910374|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
10168628|NCT03910127|Experimental|TQB2450 + Anlotinib (10 mg)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 10 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10168629|NCT03910127|Experimental|TQB2450 + Anlotinib (12 mg)|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10168630|NCT03910127|Placebo Comparator|TQB2450 + Placebo|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Placebo for Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10168631|NCT03910257|Experimental|nutrition education module|12 activities of the nutrition education module pre and post test
10168632|NCT03910257|No Intervention|control group|no intervention pre and post test
10168633|NCT03910010|Experimental|Experimental: placebos|Fibromyalgia participants will enter in an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
10168634|NCT03910010|No Intervention|Waitlist|Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
10168635|NCT03910010|No Intervention|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
10168636|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|42 patients will receive both electroacupuncture（HANS100A）therapy and routine rehabilitation training.
10168637|NCT03909958|Other|Routine rehabilitation training Group|42 patients will receive simple routine rehabilitation training.
10168638|NCT03910023|Active Comparator|Control group|The control group will perform home exercises alone
10168639|NCT03910023|Experimental|Spa group|The spa group will be proposed an additional spa treatment
10168640|NCT03910062||VA ECMO|Patients under VA-ECMO with a femoral reperfusion cannula.
10168641|NCT03910114||Dotarem Enhancement Group|
10168642|NCT03910114||Gadovist Enhancement Group|
10168643|NCT03910114||Magnevist Enhancement Group|
10168644|NCT03909984|Other|Intervention|All participants will be monitored for 2 months.
10168645|NCT03910049||Study group|The group will include all adult patients that will sign ICF and will be operated for total thyroidectomy regardless of the undelying disease
10168646|NCT03910140|Experimental|TILA-TACE group|
10168647|NCT03910192|Experimental|Mindfulness meditation coaching|Mindfulness-based coaching - participants will receive instructions on (a) mindfulness meditation and gentle mindful movement through home-based and in-class participation at the Southlake Cardiovascular Rehabilitation Clinic and (b) personal coaching support. The health coach will further assist participants through either face-to-face or telephone-based discussions. They will meet with the health coach at mutually-agreed upon on times for designated time periods.
10168648|NCT03910192|Active Comparator|dietary cardiovascular risk reduction coaching|Cardiovascular risk reduction education - No change to standard of care where participants will receive instructions (in person or by phone call) on how to integrate exercise and dietary changes in your lifestyle to reduce your risk of future cardiovascular events. These instructions will be centered around the DASH dietary practices.
10168649|NCT03910231|Placebo Comparator|Placebo|Placebo
10168650|NCT03910231|Experimental|15mg Tolvaptan|15mg Tolvaptan
10168651|NCT03910231|Experimental|30mg Tolvaptan|30mg Tolvaptan
10168652|NCT03909945|Experimental|Interventional arm|The intervention consisted in the daily administration, during 60 days, of a 796 mg tablet of aqueous extracts of leaves of Annona muricata between 08:00 AM and 09:00 AM.
10168653|NCT03910036|Experimental|PRP group|15 patients to constitute the PRP-group was injected intra-articularly with about 5 ml of PRP in the operated knee joint
10168654|NCT03910036|No Intervention|control group|The other fifteen patients were not injected and constituted control group.
10168655|NCT03910400|Experimental|MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
10168656|NCT03910400|Experimental|Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
10168657|NCT03910088|Placebo Comparator|control group|received conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours
10168658|NCT03910088|Active Comparator|Pregabalin|received the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours
10168659|NCT03910088|Active Comparator|Hydrocortisone|received the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
10168660|NCT03909919|Experimental|Heart Failure|Heart Failure patients Subjects diagnosed with heart faikure, who will receive the best treatment of clinical practice, will be recruited. They must be more than 70 years old.
10168661|NCT03909919|Active Comparator|Healthy Subjects|Healthy Subjects/ Match control Healthy subjects of the same age as people with heart failure.
10168662|NCT03909932||Patients enrolled in the cross-sectional study|Patients over 18 years old, consulting in neuro-urology department.
10168663|NCT03909906|Active Comparator|Euphytose®|Euphytose® 2 tablets 3 times per day for 14 days
9974911|NCT05109455|Experimental|Food supplement|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
10168664|NCT03909906|Placebo Comparator|Placebo|Matched placebo 2 tablets, 3 times per day for 14 days
10168665|NCT03909880|No Intervention|Control|Without kinesio tape on the forearm of subjects
10168666|NCT03909880|Placebo Comparator|kinesio taping with neutral tension|Kinesio tape with neutral tension on the forearm of subjects
10168667|NCT03909880|Experimental|kinesio taping with additional 20% tension|Kinesio tape with 20% additional tension on the forearm of subjects
10168668|NCT03909659|No Intervention|Control|Normal salt
10168669|NCT03909659|Experimental|Reduced-sodium added-potassium salt substitute|salt substitute
9974912|NCT05109455|Active Comparator|Comparator|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
10168670|NCT03909633||A: anesthesia group|Patients accepting endoscopy check under anesthesia will be included in this group as group A,will doing a series of tests
10168671|NCT03909633||B:Non-anesthesia group|patients undergoing endoscopy check without anesthesia will be included in this group as controls voluntarily,namely group B,will doing a series of tests
10168672|NCT03909568|Experimental|Third molar surgery|Split mouth comparison of effect of complete third molar removal vs coronectomy of contralateral third molar
10168673|NCT03909672|Experimental|Cupping therapy with 2 suctions|Participants in the intervention group will receive the application of cupping therapy with two acrylic type 1 cups with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally. This group will consist of the application of windsheets with 2 suctions for 10 minutes, once a week, for 10 weeks. The cups shall be secured by means of elastic bands.
10168674|NCT03909672|Placebo Comparator|Cupping Therapy sham|"The placebo group will receive the application of cupping therapy with 2 cups of acrylic type size 1 with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of applying the sham winds for 10 minutes, once a week for 10 weeks.~However, the cups will be made with small holes <2 mm in diameter to release the negative pressure in seconds. The cups will also be fixed by means of elastic bands."
10168675|NCT03909789|Active Comparator|plant based bioequivalent dietary nitrate supplement|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
10168676|NCT03909789|Placebo Comparator|placebo|The Placebo does not contain any nitric oxide supplement.
10168677|NCT03909581|Active Comparator|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization
10168678|NCT03909581|Active Comparator|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator
10168679|NCT03909802|Experimental|Experimental group|This arm will receive interventions consisting of self-management combined with family management programs.
10168680|NCT03909802|Placebo Comparator|Control group|Usual care refers to incorporating wound assessment, wound irrigation using NaCl, debridement, wound dressing, evaluation, and health education unmet with the self-and-family management of DFU program criteria in this study. All of the usual care will be performed and evaluated by the wound care nurses working at the selected clinics for this study.
9974913|NCT05107531||Parkinson's Patients with Motor Freezing|Individuals with Parkinson's Disease with motor freezing were included in this group.
10168681|NCT03909776|Active Comparator|IA group|Cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion.
10168682|NCT03909776|Sham Comparator|IV group|Cisplatin was given at 100-120 mg/m2 as 6-h infusions.
10168683|NCT03909841||DM|DM without DPN (Diabetic Peripheral Neuropathy)
10168684|NCT03909841||DPN|DM with DPN (Diabetic Peripheral Neuropathy)
10168685|NCT03909841||DPN-P|DM with DPN-P (Diabetic Peripheral Neuropathic Pain)
10168686|NCT03909555||Short-term intensive insulin therapy|Patients who used to participated in short-term intensive insulin therapy for 14 days when diabetes was newly diagnosed
10168687|NCT03909555||Routine diabetic therapy|Received routine diabetic therapy
10168688|NCT03909594|Experimental|Nerve Block with Bupivacaine an|Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
10168689|NCT03909594|Active Comparator|Nerve Block with Bupivacaine al|Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
10168690|NCT03909477||Cannabis Smoker|Participants in this group will be current or former cannabis smokers
10168691|NCT03909724|Active Comparator|TAS-102 (Lonsurf)|35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period.
10168692|NCT03909724|Experimental|High Dose Intermittent Sunitinib|700 mg once every 2 weeks.
10168693|NCT03909737|Experimental|Azithromycin to pregnant women and azithromycin to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week Expanded Programme on Immunization (EPI) visits
10168694|NCT03909737|Experimental|Azithromycin to pregnant women and placebo to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
10168695|NCT03909737|Experimental|Placebo to pregnant women and azithromycin to infants|Oral placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
10168696|NCT03909737|Placebo Comparator|Placebo to pregnant women and placebo to infants|Placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
10168697|NCT03909737|Experimental|No intervention to pregnant women and azithromycin to infants|No intervention to pregnant women and 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
9974914|NCT05107531||Parkinson's Patients Without Motor Freeze|Individuals with Parkinson's Disease without motor freeze were included in this group.
9974915|NCT05107531||Healthy Controls|Healthy individuals who did not have any neurological problems that would affect gait were included.
10168698|NCT03909737|Placebo Comparator|No intervention to pregnant women and Placebo to infants|No intervention to pregnant women and placebo to infants at 6 and 14 week EPI visits
10168699|NCT03909698||Hemodialysis patients on amoxicillin-clavulanic acid|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for amoxicillin-clavulanic acid."
10168700|NCT03909698||Hemodialysis patients on ceftazidim|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for ceftazidim."
10168701|NCT03909698||Hemodialysis patients on piperacillin-tazobactam|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for piperacillin-tazobactam."
10168702|NCT03909698||Hemodialysis patients on vancomycin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for vancomycin."
9974916|NCT05106387||REGN5459 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5459 in study R5459-RT-1944.
10168703|NCT03909698||Hemodialysis patients on teicoplanin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for teicoplanin."
10168704|NCT03909529|Experimental|Digoxin 250 micrograms (MCG) Oral Tablet|Administration of 20 mL of 25 mg / 5 mL singe dose Day 1 to Day 9 randomized to digoxin and Spironolactone treatment. On day 6, after overnight fasting of at least 10.00 hours, either digoxin or spironolactone will be administered orally for drug drug interaction evaluation
9671695|NCT05044286||20 Other Key stakeholders for World Café Conversation|We will interview 20 other key stakeholders including medical providers, HIV prevention specialists, outreach workers, PrEP navigators/educators.
10168705|NCT03909529|Experimental|Spironolactone 25 mg/ 5 mL S/F Suspension|Crossover administration of 20 mL of 25 mg / 5 mL Day 1 to Day 9 randomized to Spironolactone or digoxin treatment. On day 6, after overnight fasting of at least 10.00 hours, either spironolactone or digoxin will be administered orally for drug drug interaction evaluation
10168706|NCT03909607|Active Comparator|SDK 0.75 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 0.75mg/k
10168707|NCT03909607|Active Comparator|SDK 1.0 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.0mg/k
10168708|NCT03909607|Active Comparator|SDK 1.5 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.5mg/k
10168709|NCT03909464||Patients receiving neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving known neurotoxic agents. Common neurotoxic agents include vinca alkaloids (ie. vincristine), taxanes (ie. Taxol), platins (ie. Oxaliplatin) and some other drugs beyond these categories (ie. Bortezomib).~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~EORTC-QLQ CIPN20 Questionnaire~Michigan Neuropathy Screening Instrument Questionnaire"
10168710|NCT03909464||Patients receiving non-neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving agents with negligible or doubtful risk of neurotoxicity.~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~EORTC-QLQ CIPN20 Questionnaire~Michigan Neuropathy Screening Instrument Questionnaire"
10168711|NCT03909191||treatment-naïve|treatment-naïve patients with chronic HBV infection
10168712|NCT03909191||NAs treated CHB patients|CHB patients undergoing long-term NAs treatment
10168713|NCT03909308|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 45 min.
10168714|NCT03909308|Experimental|Beach Tennis session|The participants performed a beach tennis training session throughout 45 min.The session started with a standardized 5-minute warm-up consisting of basic techniques (i.e., serve, volley, forehand, and backhand) followed by three 12-minute beach tennis matches with 2-minute intervals between the games. We used regular beach tennis rules in the game, which was played on a regular beach tennis court (i.e., 16 m long by 8 m wide and net 1.70 m high).
10168715|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 0|"Carfilzomib at 20mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
10168716|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 1|"Carfilzomib at 27mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
10168717|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 2|"Carfilzomib at 36mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
10168718|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 3|"Carfilzomib at 45mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
10168719|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 4|"Carfilzomib at 56mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
10168720|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 5|"Carfilzomib at 70mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
10168721|NCT03909516|No Intervention|Standard of Care|"Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded."
9671696|NCT05044286||500 Transgender and Gender Diverse for Survey|We will survey 500 TGD adults (18+), who are HIV negative, and have indications for PrEP.
9827745|NCT02466412|Active Comparator|mCC then CHTP 1.1 M|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
10168722|NCT03909516|Active Comparator|Standard of Care + iovera° Treatment|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded.~Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events.~Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
10168723|NCT03909269||Haemodialysis and type 2 diabetes|On chronic haemodialysis and type 2 diabetes
10168724|NCT03909269||Control group|Type 2 diabetes and with eGFR above 60ml/min
10168725|NCT03909646|Active Comparator|Surgical excision|Standard surgical excision with 5 mm safety margin
10168726|NCT03909646|Active Comparator|Photodynamic therapy|PDT with application of methyl aminolevulinate (MAL) cream followed by two illuminations with a one-week interval
10168727|NCT03909646|Active Comparator|5% 5-Fluorouracil|5FU cream, which has to be applied by the patient twice daily for 4 weeks.
10168728|NCT03909152|Experimental|PR+ Granulosa cell tumor (This Arm is closed)|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days. This Arm is closed.
10168729|NCT03909152|Experimental|PR+ Low grade serous ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
10168730|NCT03909152|Experimental|PR+ Endometrioid endometrial cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
10168731|NCT03909152|Experimental|PR+ Granulosa cell ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart and anastrozole 1mg po QD in AM beginning Day 1 of Cycle 1. A Cycle is 28 days.
10168732|NCT03909373||Cohort|patients with carpal tunnel syndrome
10168733|NCT03909204|Other|LAPEC|Patients with cecal percutaneous catheter placement.
10168734|NCT03909360|Experimental|drainage|Placement of subhepatic drainage tube for laparoscopic cholecytetomy
10168735|NCT03909360|No Intervention|no drainage|no placement of subhepatic drainage tube for laparoscopic cholecytetomy
10168736|NCT03909256|Experimental|NUTRI-HAB|"The intervention group participates in a targeted rehabilitation program 'NUTRI-HAB' with a focus on eating problem after treatment for head and neck cancer. The program comprises:~a five day residential stay with patient education~a two day follow-up residential stay after 3 months~two telephone consultations with clinical dietitian between the two residential stays."
10168737|NCT03909256|No Intervention|Control group|"The control group receives no intervention other than usual care in the study period.~After 3 months, the control group will be offered participation in the same residential rehabilitation program as the intervention group parcitipated in."
10168738|NCT03909126|Experimental|Montreal Region of Quebec|Vaccination with Boostrix at time of gestational diabetes screening in a hospital setting
10168739|NCT03909126|No Intervention|Montérégie|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
10168740|NCT03909126|Experimental|Maurice Region|Vaccination with Boostrix of pregnant women receiving routine care at high volume clinic
10168741|NCT03909126|No Intervention|National Capital|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
10168742|NCT03909113|Experimental|amino acid based formula|amino acid based formula
10168743|NCT03909048|Experimental|Interactive Psycho-education|Interactive psycho-education using interactive dashboard.
10168744|NCT03909048|Placebo Comparator|Psycho-education|Non-interactive psycho-education not using interactive dashboard.
10168745|NCT03908996|Experimental|Profile by Sanford|All enrolled subjects are assigned to participate in the Profile by Sanford weight management program for a period of 12 months..Subjects will follow the Profile program and will be provided a nutritional plan which includes consuming Profile nutritional supplements and other food items. Subjects will work with a Profile lifestyle coach to develop a personalized nutrition plan, discuss their activity, and lifestyle behavior. Subjects on this research study will follow the Profile by Sanford weight loss and management plan as all Profile members. All enrolled subjects will collect and return a fecal specimen prior to beginning the Profile by Sanford weight management plan and again after 6 months of participation.
10168746|NCT03908983|Experimental|Implanted Patients|Implantation of Kalios Device
10168747|NCT03909035|Experimental|Medication therapy management|Medication therapy management by the community pharmacist in collaboration with the General Practitioners to the Optimizations of Prescriptions
10168748|NCT03909035|No Intervention|Usual pharmaceutical care|Usual pharmaceutical care provided by the community pharmacist (first level pharmaceutical analysis of the prescriptions)
10168749|NCT03909074|Experimental|Experimental group|36-71 months old children-experimental EV71 vaccine.
10168750|NCT03909074|Active Comparator|Vaccine-controlled group|36-71 months old children-control EV71 vaccine.
10168751|NCT03909074|Active Comparator|Age-controlled group|6-35 months old children-experimental EV71 vaccine.
10168752|NCT03908840|Experimental|TBI 302 Safety, Tolerability|5 Cohorts, Dose escalation TBI 302 will be formulated in 0.9% saline. TBI 302 in a syringe will be administered over approximately 1 hour under constant observation once per week for 4 weeks (on Days 1, 8, 15 and 22).
9974917|NCT05106387||REGN5458 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5458 in study R5459-RT-1944.
9974918|NCT05105308|Active Comparator|Family Assisted Diet (FAD)|This is a 20-session intervention with a child and the child's parents that consists of helping parents set goals around their child's renourishment; consider barriers to implementing proposed plans; thinking through strategies to avoid barriers; and providing ongoing support for plan implementation.
10168753|NCT03908957|Experimental|Ga68-Dolacga Injection|The healthy volunteer was injected with Ga68-Dolacga Injection iv and performed PET imaging for liver reserve evaluation.
10168754|NCT03908801|Experimental|Intervention|Specialized water dance intervention
10168755|NCT03908801|No Intervention|Control|No intervention
9977446|NCT01361698|Experimental|IMR program|The program is organised into 11 curriculum topic areas: recovery strategies, practical facts about mental illness, the stress-vulnerability model, building social support, using medication effectively, drug and alcohol use, reducing relapses, healthy lifestyle, coping with stress, coping with problems and symptoms, and getting your needs met in the mental health system. In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
10168756|NCT03908931|Experimental|MRI|
10168757|NCT03908892|Experimental|Combination group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, plus local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day, till paronychia relief or progression.
10168758|NCT03908892|Active Comparator|Control group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, till paronychia relief or progression.
10168759|NCT03908918|Experimental|Active group|Mobile-app delivered mindfulness intervention. Dosage: 4 times per week for 4 weeks
10168760|NCT03908918|Other|Waitlist control|Waitlist control - receiving the app after 6 months
10168761|NCT03908775|Active Comparator|Group VL|C-MAC Videolaryngoscope Patients intubated with C-MAC Videolaryngoscope
9826489|NCT02420210|Experimental|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10168762|NCT03908775|Active Comparator|Group DL|Direct Laryngoscope Patients intubated with Direct laryngoscope
10168763|NCT03908658|Active Comparator|Inspiratory Muscle Training and Nasal High Flow|Inspiratory Muscle Training will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Nasal High Flow will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
10168764|NCT03908658|Active Comparator|Inspiratory Muscle Training and Venturi mask|IMT will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Venturi mask will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
10168765|NCT03908827|Experimental|Active BMAC treatment|60 mL of bone marrow will be aspirated from the iliac crest of each subject in the active treatment group. The bone marrow aspirate (BMA) will be centrifuged using a single spin protocol such that the red blood cells are minimized and the total nucleated and platelet cells are concentrated into a 12 mL volume of bone marrow aspirate concentrate (BMAC).
10168766|NCT03908827|No Intervention|Wait List Control|Participants will continue with their usual treatment, inclusive of medications or conservative treatments and will continue with activity guidelines as previously provided by clinical staff whilst awaiting joint arthroplasty
10168767|NCT03908944|Active Comparator|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
10168768|NCT03908944|Experimental|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
10168769|NCT03908619|Active Comparator|TTP (Group A)|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
10168770|NCT03908619|Active Comparator|TTP (Group B)|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
10168771|NCT03908619|Active Comparator|TTP (Group C)|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
10168772|NCT03908619|Experimental|TTP (Group D)|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
10168773|NCT03908866|Experimental|PICC(Peripherally inserted central catheter)|Patients randomly assigned to receive a peripherally inserted central catheter(PICC).
10168774|NCT03908866|Active Comparator|CVC(Central venous catheter )|Patients randomly assigned to receive a centrally inserted central venous catheter(CVC).
10168775|NCT03908879|Experimental|Intraosseous (IO) catheter placement confirmation methods|All patients will undergo all three confirmation methods/procedures. Method 1 is a triage test and an index test. Method 2 is an index test. Method 3 is a reference standard. None of the procedures being performed in this study are regulated by the United States Food and Drug Administration.
10168776|NCT03908853||Patients|Subjects with painful bone metastases caused by primary breast cancer.
10168777|NCT03908853||Controls|Gender and age matched healthy volunteers.
10168778|NCT03908736|Other|Single-arm cohort|Baseline experimental measurements will be collected for each individual participant twice prior to zinc supplementation (0 month and 3 month time points). After zinc supplementation, experimental measurements will be collected for each individual participant at the 6 month and 9 month time points. The zinc intervention is zinc picolinate 15 mg once per day for 6 months.
10168779|NCT03908905||Intervention|
10186809|NCT03732261|Experimental|Intervention|Intervention Group: Women randomized to the intervention group will be given a 3month membership to a community based exercise program, a pedometer and individual dietary recommendations. They will be asked to attend a minimum of three 45 minute to 60 minute exercise sessions per week but no more than five and will gradually build to walk 10,000 steps per day. Childcare and breastfeeding support will be provided. Trained research assistants will lead all group sessions. Weekly workout volume will be calculated and weekly steps will be monitored by research assistants. For the dietary intervention, the women will be provided 6oz of plain yogurt fortified with vitamin D post workout for the 12-week intervention. If any yogurt is out of date (expired), we will dispose of the expired yogurt. Weekly monitoring for the consumption of the yogurt and energy intake will be conducted by face-to-face or telephone interviews by research assistants.
9827746|NCT02466425|Experimental|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
10168780|NCT03908554|Experimental|intervention|The WHPP was applied to the intervention group in the workplace for two times a week for five weeks. During the first 5 minutes of the session, breathing exercises, 20 minutes, PMR and 10 minutes, posture exercises were performed. PMR has progressed gradually to every session. The program is under control with a follow-up chart of what the participants do every day, and the participants were supported with various reminders (i.e., graphical leaflets on PMR techniques which also can be used as a guide while practicing at home).
10168781|NCT03908554|No Intervention|Control|Participants of the control group rested in a room for 40 minutes and were told that they could read every session.
9826490|NCT02420223|Experimental|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
10168782|NCT03908580|Experimental|Meditoxin®|Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.
10168783|NCT03908697|Experimental|Single cohort|All 20 participants will use ClearBlue and Mira monitors on first morning urine
10168784|NCT03908593|Active Comparator|One month of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month
10168785|NCT03908593|Experimental|Twelve months of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months
10168786|NCT03908528|Experimental|Chemotherapy plus Placebo for six Months|• Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus Placebo.
10168787|NCT03908528|Experimental|Chemotherapy plus alpha lipoic acid for six Months|• Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks in addition to oral 600 mg alpha lipoic acid (ALA) once daily.
10168788|NCT03908463||The patients who undergo percutaneous coronary intervention|The patients who undergo percutaneous coronary intervention will be enrolled.
10168789|NCT03908645|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
10168790|NCT03908645|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
10168791|NCT03908814|Experimental|Drug: LDP|"This is a dose-escalation trial, all participants will receive treatment with LDP. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.~Cohort 1: 0.1 mg/kg Cohort 2: 0.3 mg/kg Cohort 3: 1 mg/kg Cohort 4: 3 mg/kg Cohort 5: 10 mg/kg Cohort 6: 10 mg/kg"
10168792|NCT03908762|Experimental|iSage|The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose <70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.
10168793|NCT03908762|Active Comparator|Conventional Management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet. In the case of glargine or detemir (Basaglar, Lantus, Levemir) adjustments of 1 unit of insulin/day are made until the fasting blood sugars (2 of 3 consecutive values) are 80-130 mg/dl. In the instance of Toujeo or Tresiba, adjustments of 2 units are made every 5 days. Volunteers will have meters downloaded (or interviewed where necessary) to obtain data on fasting blood sugar and episodes of hypoglycemia (perceived or measured <70 mg/dl). The PCP is free to request glucose logs and set return appointments as needed to manage the patient.
10168794|NCT03908489|Experimental|intervention we want to test vital pulpotomy using garlic oil|interventional group as garlic oil pulpotomy dressed in zinc oxide powder
10168795|NCT03908489|Active Comparator|control or comparator as mta vital pulpotomy in primary molars|mta vital pulpotomy in primary molars
10168796|NCT03908424||CONTROL|Parturients who gave birth to a normal birth and did not receive epidural anesthesia.
10168797|NCT03908424||Normal Epidural|Parturients who gave birth to a normal birth with epidural anesthesia without an unintentional dural puncture.
10168798|NCT03908424||PDPH conservative treatment|Parturients who gave birth to a normal birth with epidural anesthesia and had an unintentional dural puncture, these women were treated conservatively.
10168799|NCT03908424||PDPH treated with Blood Patch|. Parturients who had a normal birth with epidural anesthesia and had an unintentional dural puncture and were treated with a blood patch following PDPH.
10168800|NCT03908606|Experimental|Periodontitis patients with diabetes type 2|scaling and root planing was administered to all patients. Serum samples were collected before and after treatment to assess hs-CRP levels. Glycated hemoglobin was measured before and after treatment
10168801|NCT03908606|Experimental|Periodontitis patients|scaling and root planing will be done to periodontitis patients. Serum samples were collected before and after treatment to assess hs-CRP levels.
10168802|NCT03908606|No Intervention|Healthy control group|We measured serum levels of hs-CRP in all healthy control subjects
10168803|NCT03908710|Other|home Home blood pressure levels in hypertensive participants|Only one arm. No control group.
10168804|NCT03908723|Experimental|all patients in the study|
9827747|NCT02466425|Placebo Comparator|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
9827748|NCT02466516|Experimental|SEL 6 mg|Selonsertib (SEL) 6 mg for 24 weeks.
10168805|NCT03908684||Head and Neck|
10168806|NCT03908684||Prostate|
10168807|NCT03908684||Rectum|
10168808|NCT03908684||Prostate Characterization|
10168809|NCT03908411|Active Comparator|Paratracheal pressure|Left Paratracheal pressure is applied by ultrasound transducer after confirmation of the location of the esophagus.
10168810|NCT03908411|Active Comparator|Sellick's maneuver|Conventional Sellick's maneuver is applied.
10168811|NCT03908671|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with advanced esophageal and non-small cell lung cancers
10168812|NCT03908450|Active Comparator|Control intervention|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
10168813|NCT03908450|Experimental|Experimental intervention|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
10168814|NCT03908229|Experimental|Trainee colonoscopy|"In the investigation arm colonoscopy will be performed by gastroenterology fellows. The fellows will always start the case and proceed generally until they are unable to make further progress despite coaching from the staff attending.~During the procedures with fellows, the staff attending will always actively participate in the entire procedure and assess for the presence of any lesions."
10168815|NCT03908229|Active Comparator|Experienced physician colonoscopy|In the control arm all colonoscopy will be performed by full-time board-certified gastroenterologists who have each done more than 5000 colonoscopy examinations.
10168816|NCT03908333|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
10168817|NCT03908203|Other|Treatment Arm|
10168818|NCT03908164|Experimental|Vaccination at <23+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy before 23+6 gestational weeks (GW). Although the time period for study group 1 is ≤23+6 no pertussis vaccine will be given in this study at less than 16 GW.
10168819|NCT03908164|Experimental|Vaccination at 24-27+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 24 and 27+6 gestational weeks.
10168820|NCT03908164|Experimental|Vaccination at 28-31+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 28 and 31+6 gestational weeks.
10168821|NCT03908242|Experimental|Salvianolic Acid A|2 anticipated doses are 90 mg and 180 mg.
9977447|NCT01361698|No Intervention|Treatment as usual|Patients randomised to the control group will get 'treatment as usual' only. This means individual adapted interdisciplinary treatment including medication, individual support, occupational therapy, psycho-education and group therapy.
10168822|NCT03908242|Placebo Comparator|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
10168823|NCT03908060|Experimental|Intravenous single-dose methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
10168824|NCT03908060|Active Comparator|Intravenous single-dose morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
10168825|NCT03908294||Chronic hepatitis C under antiviral treatment with DAA|Patients with chronic hepatitis C infection and planned DAA treatment are enrolled prospectively. Parameters of glucose metabolism and liver fibrosis are measured at baseline, during therapy and up to one year after end of treatment.
10168826|NCT03908372|Experimental|Induction chemotherapy(IC)+IMRT|Induction chemotherapy for two cycles, the patients with complete response will receive 60 Gy to the gross target volume of nasopharynx, partial response 64 Gy, and the absence of response will receive concurrent chemoradiotherapy as the same as CCRT arm
10168827|NCT03908372|Active Comparator|Concurrent chemoradiotherapy(CCRT)|cisplatin 100mg/m2 IV on d1 of each 21 days for two cycles at least and 70 Gy radiotherapy
10168828|NCT03908047||healthy volunteers|
10168829|NCT03908099|Experimental|Fit-For-Fertility program|The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
10168830|NCT03908099|Active Comparator|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months.
9977448|NCT01361724|Other|One on one with a PT|The participant will work one-on-one with a trained for PT for 3 days a week for four weeks.
10168831|NCT03908138|Active Comparator|RDD group|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
10168832|NCT03908138|Active Comparator|VDD group|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
10168833|NCT03908008|Active Comparator|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
10168834|NCT03908008|Experimental|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
10168835|NCT03908177|Experimental|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
9827749|NCT02466516|Experimental|SEL 18 mg|SEL 18 mg for 24 weeks.
10168836|NCT03908177|Active Comparator|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
10168837|NCT03908190|No Intervention|Treatment As Usual|Participants will receive treatment as usual within the VHA Women's Wellness Clinic including any appropriate treatment or treatments for their medical and psychosocial concerns as determined by their primary care teams.
10168838|NCT03908190|Experimental|Treatment As Usual Plus Personalized Support for Progress|In addition to treatment as usual, women will receive the Personalized Support for Progress intervention.
10168839|NCT03908281|Experimental|Fasted Exercise|Exercise training will be performed in the fasted state (i.e., before breakfast).
10168840|NCT03908281|Active Comparator|Postprandial Exercise|Exercise will be performed in the postprandial period (i.e., after breakfast)
10168841|NCT03908112|Active Comparator|Standard Community Concussion Care (SC)|Standard concussion care consists of physical and cognitive rest immediately following the injury for a brief period of time to allow symptoms to abate, followed by a gradual reintroduction of academic and physical activities, restricting activities at high risk for repeat brain injury (such as contact or collision sports) until a graded return to play protocol has been completed in a symptom-free manner.
10168842|NCT03908112|Experimental|SC plus Simple Convergence Procedures (SC+)|In addition to the treatment described for SC, participants in this group will be asked to work with the Brock String, which is a popular and simple therapy technique designed to improve convergence. A 3-phase, graded Brock String procedure has been developed for ICONICC.
10168843|NCT03908112|Experimental|SC plus Office-based Vergence/Accommodative Therapy (SC+VAT)|Office-based vergence accommodative therapy (OBVAT) is administered by a study certified therapist at weekly intervals (60-minute office visits with 55 minutes of therapy time), combined with procedures to practice at home for 15 minutes, 5 times per week.
10168844|NCT03908268|Active Comparator|CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Standard Children's Learning Center Program group.
10168845|NCT03908268|Experimental|FNI plus CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Family Nurture Intervention plus Standard CLC Program group.
10168846|NCT03908320|Experimental|Menstrual Cycle Timing|
10168847|NCT03908320|Active Comparator|Menstrual Cycle Monitoring|
10168848|NCT03908346|Other|Decision Aid for Surrogate Decision Makers|In this pilot trial all participants will be presented with the decision aid and queried as to the feasibility, acceptability and knowledge translation that is gained by exposure to the decision aid
10168849|NCT03908086||RA patients|Incident patients with rheumatoid arthritis as identified by the Danish National Patient Registry and the rheumatology registry, DANBIO.
10168850|NCT03908086||General population|All other adults, as Identified by the Civil Registration System. Patients who develop RA contribute person-years in the general population cohort until RA diagnosis
10168851|NCT03907865|Experimental|intense|Patients have been randomized to receive Softacort eye drops for 12 days 4 times daily followed by 2 days twice daily treatment resulting in a total time of 14 days
10168852|NCT03907865|Experimental|standard|Patients have been randomized to receive Softacort eye drops for 8 days 3 times daily followed by 3 days twice daily treatment resulting in a treatment time of 11 days total
10168853|NCT03907722||Genotypic variants|AA, AG and GG genotype
10168854|NCT03907930|Active Comparator|conventional|this arm will have both nephrostomy tube and ureteric catheter after completing the operation
10168855|NCT03907930|Active Comparator|tubeless|the arm will have only ureteric catheter rafter completing the operation
10168856|NCT03907839|Active Comparator|Endurance Training (ET)|endurance training for control group
10168857|NCT03907839|Experimental|ET+cognitive training(CT)|endurance training added to cognitive training for exprimental COPD group
10168858|NCT03907709||First Responders in In-Home Addiction Treatment Program|- First responders (individual who does or has worked as a police officer, fire fighter, corrections officer, military police, emergency medical technician, paramedic, parole or probation officer)
10168859|NCT03907800|Experimental|Nab-paclitaxel + Carboplatin ± Herceptin|
10168860|NCT03907787|Other|One-group pretest-posttest quasi-experimental design|50 subjects with moderate knee osteoarthritis were supplied for four weeks with two tablets/day, each containing 350 mg of standardized extracts of Zingiber officinale and Acmella oleracea.
10168861|NCT03907956|Experimental|INTERVENTION|The subjects included in the intervention group will be treated with Dry Needling with Fascial Winding Technique according to the original Four-Pole Carpal Dry Needling approach, which has already been validated recently by means of a first ultrasound study.
10168862|NCT03907956|No Intervention|CONTROL|The individuals of the control group will remain within the normal course of their waiting list status for CTS surgery, without receiving any extraordinary treatment to what is normally practiced in this situation.
9977449|NCT01361724|Other|Group exercise class|The participant will be in a group exercise class. That will meet 3 days a week for 4 weeks.
10168863|NCT03907852|Experimental|gavo-cel|gavo-cel
10168864|NCT03907852|Experimental|Lymphodepletion followed by gavo-cel|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by TC-210 T Cells
10168865|NCT03907852|Experimental|Phase 2 Dose|MPM, cholangiocarcinoma, and ovarian cancer will receive gavo-cel at the RP2D; NSCLC patients will receive gavo-cel at the RP2D or gavo-cel at the RP2D followed by anti-PD1
9520386|NCT03278197|Other|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
10168866|NCT03907813|Experimental|liposomal bupivacaine infiltration|Local infiltration of all wound layers with liposomal bupivacaine (Exparel(R)) 20 ml diluted with 70 ml of normal saline to 90 ml for patient with a BMI of 39 and under. If BMI is 40 or more the 20 ml of liposomal bupivicaine will be diluted to 150 ml by adding 130 ml of normal saline
10168867|NCT03907813|Placebo Comparator|Saline infiltration|Local infiltration of all wound layers with saline, using to match the amount. The amount of total fluid is divided into 4 and instilled with 1-2 ml at a time in between fascial layers after fascial closure. Each 1/4 will be instilled laterally (2) and on each side of the incision(2)- extra fluid is placed subcutaneously.
10186810|NCT03732261|No Intervention|Control|Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
10168868|NCT03908034|No Intervention|Uncontrollable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5 (Hong Kong dollars). Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
10168869|NCT03908034|Experimental|Uncontrollable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
10168870|NCT03908034|Experimental|Uncontrollable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5. Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
10168871|NCT03908034|Experimental|Uncontrollable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
10168872|NCT03907644|Experimental|Active FPS|We use Starstim AC (alternative current) -Stimulator R32. FPS protocol will be used with 20 minutes 2mAmp 6 Hz tACS to the middle frontal gyrus (DLPFC, F4 in EEG electrodes with 10-20 system measurement) and inferior parietal cortex (IPC, P4), as the main nodes of the frontoparietal network, in synchronous oscillation. The 4 return electrodes will receive 0.5 mAmp each around each active electrode (High Definition Montage). The electrodes are silver/silver chloride that are wet with conductive gel. We will use surface landmarks and EEG caps on the head to place the electrodes, which are held in place by head caps with holes indicating places for electrode positioning.
10168873|NCT03907644|Sham Comparator|Sham FPS|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
10168874|NCT03907995|Experimental|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
10168875|NCT03907618||Group 1 diagnosed with Diabetes Mellitus|Patients with Type 1 Diabetes Mellitus aged 18-40 years who had ovarian reserve with gynecological examination
10168876|NCT03907618||group 2 control group|Healthy volunteer patients aged 18-40 years who have no diagnosis of Type 1 Diabetes Mellitus and whose ovarian reserve is evaluated by gynecological examination
10168877|NCT03907683|Experimental|Random Messaging|Participants receive 0-5 messages/day from the Random AIM app. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages are selected randomly from three content domains: Move More (40%), Sit Less (40%), and Inspirational Quotes Unrelated to Movement (20%). Half of the messages are accompanied by images. Message selection and timing are determined randomly each night for the following day.
10168878|NCT03907423|Experimental|Rosuvastatin|DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients)
10168879|NCT03907423|Placebo Comparator|Control|DM-type 2 patient who will receive glimepiride-metformin combination (20 patients).
10168880|NCT03907696|Other|Intervention|The intervention arm participate in an educational program that aimed at reducing stigma
10168881|NCT03907696|No Intervention|control|regular curriculum with no addition educational contents
9827750|NCT02466516|Experimental|SEL 6 mg+SIM 125 mg|SEL 6 mg plus SIM 125 mg for 24 weeks.
10168882|NCT03907553||Health and Anemia|"individuals belonging to the Health and Anemia'' prospective population-based observational study (2003-2013) of all elderly residents (>65 years) in the municipality of Biella"
10168883|NCT03907553||Monzino|"individuals belonging to the Monzino Over 80 trial"
10168884|NCT03907345|Experimental|Exposure|Participants of this arm receive one 120-minute session of exposure treatment for spider fear.
10168885|NCT03907345|No Intervention|No Exposure|Participants of this arm receive no exposure or other adequate treatment.
10168886|NCT03907358||cataract in old age|
10168887|NCT03907358||cataract in young age|
10168888|NCT03907293||Phase-III Cardiac Rehabilitation|Eight weeks of supervised exercise sessions (one session per week).
10168889|NCT03907293||Phase-III and Phase IV Cardiac Rehabilitation|Twenty weeks of supervised exercise sessions (one session per week for first eight weeks [phase-III], session frequency determined by participant for remaining twelve weeks [phase-IV].
9977450|NCT01361724|Other|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
9827751|NCT02466516|Experimental|SEL 18 mg+SIM 125 mg|SEL 18 mg plus SIM 125 mg for 24 weeks.
9977451|NCT01361737||preeclampsia|"Control group: 86 healthy women not developing preeclampsia (PE)~Case group: 43 women developing PE"
10168890|NCT03907293||No Cardiac Rehabilitation|Participants who declined to take part in a cardiac rehabilitation programme.
10168891|NCT03907410|Experimental|Arm 1: Incentives, plus reminders & feedback (IRF)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 1 will receive the IRF intervention.~During the Observation period (Months 4-6), all the arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
10168892|NCT03907410|Active Comparator|Arm 2: Reminders & feedback ONLY|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 2 will receive ONLY reminders and feedback, without nominal financial incentives.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
10168893|NCT03907410|No Intervention|Arm 3 (Control)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).~During the Experiment period (Months 1-3), Arm 3 will not receive any component of the IRF intervention.~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
10168894|NCT03907280|Experimental|T1-T2-R-T3|
10168895|NCT03907280|Experimental|R-T1-T2-T3|
10168896|NCT03907280|Experimental|T2-R-T1-T3|
10168897|NCT03907592|Experimental|L-carnitine Group|Group participated in the training protocol and supplemented by 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout 24 weeks.
10168898|NCT03907592|Experimental|Leucine Group|Group participated in the training protocol and supplemented by 4000mg of L-leucine per day throughout 24 weeks.
10168899|NCT03907592|Experimental|Control Group|Group participated in the training protocol without any supplementation throughout 24 weeks.
10168900|NCT03907566||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals, and Turkish version of the Eating Assessment Tool.
10168901|NCT03907449||Symptoms of Strep Throat|"Any patient presenting with symptoms of pharyngitis~Fever~Sore throat~Swollen lymph nodes in neck~Redness of throat/tonsils~White/yellow patches on tonsils~Not currently on antibiotics"
10168902|NCT03907631||Acute Severe Ulcerative Colitis|Patients hospitalised for acute severe ulcerative colitis will be invited to participate. Participants will be treated at the discretion of their treating physicians as per standard of care. We expect some participants will undergo an endoscopic assessment, some participants will be treated with standard versus accelerated infliximab dosing, permitting comparisons, in addition to other treatment strategies.
10168903|NCT03907436|Sham Comparator|USDA diet arm|Participants will receive dietician counseling based on the USDA guidelines for Americans, 2010. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the Mediterranean arm.
10168904|NCT03907436|Experimental|Mediterranean diet arm|Participants will receive dietician counseling on a standard Mediterranean diet although they will not be told this diet is labelled as a Mediterranean diet. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the USDA diet arm.
10168905|NCT03907527|Experimental|Treatment (PRGN-3005 UltraCAR-T cells) IP Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IP administration with or without lymphodepleting chemotherapy.
10168906|NCT03907527|Experimental|Treatment (PRGN-3005 UltraCAR-T cells) IV Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IV administration with or without lymphodepleting chemotherapy.
10168907|NCT03907501|Experimental|Synbiotic|Two grams of organic Triphala powder (Banyan Botanicals, Inc.) with 1 capsule VSL#3® (VSL Pharmaceuticals, Inc.) probiotic taken with a few ounces of room temperature water in the morning and at bedtime for 8 weeks. Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.) and VSL#3® (VSL Pharmaceuticals, Inc.) capsules.
10168908|NCT03907501|Active Comparator|Probiotic|Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.). Subjects will take 2 grams of organic Triphala powder with a few ounces of room temperature water in the morning and at bedtime.
10168909|NCT03907501|Placebo Comparator|Placebo|Subjects will be provided both written and verbal instructions and given a kit containing placebo capsules. Subjects will be instructed to take 2 (inert) capsules with room temperature water in the morning and at bedtime.
10168910|NCT03907306|Experimental|Patients after open hemorrhoidectomy (study group)|Patients to whom during a post-operation period cold argon plasma and a standard treatment will be treated. Cold argon plasma will be applied during 4 minutes at one session on the 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 14th, 21nd, 30th day after operation. The usage of antibacterial and wound healing ointments daily.
10168911|NCT03907306|Active Comparator|Patients after open hemorrhoidectomy (control group)|Patients who during a post-operation period will be treated with a standard treatment.The usage of antibacterial and wound healing ointments daily.
10168912|NCT03907384|Experimental|Mat Pilates training|The MPT group participated in 3-one hour supervised training sessions per week for 12 weeks. All MP sessions were performed in nonconsecutive days. The MP sessions were divided into the following stages: initial warm up and stretching (10 min), general conditioning consisting of MP exercises (40 min) and stretching and cooling down (10 min). The participants performed 12 basic MP exercises (one set of 6-10 repetitions was performed per exercise). Breathing, a core principle of MP, was performed by forced but controlled inspirations and exhalations, while relaxing and contracting the abdomen, respectively. All sessions were supervised by a certified MP instructor.
10168913|NCT03907384|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
10168914|NCT03907514|Experimental|Intervention Group (IG)|"The adolescents in this group will use the FALE application through a smartphone in the waiting room before the dental appointment. When starting to answer the application, the adolescent will report his/her level of dental anxiety through the question, How do you feel about coming to see your dentist today?, and record his/her answer on a seven-point face scale. Then the participant will continue to answer the 12 other questions, and finally registers his/her anxiety level once more through the same question."
10168915|NCT03907514|No Intervention|Control Group (CG)|"Similarly to IG, the adolescents in this group will use the FALE application through a smartphone, but only to record their level of anxiety by answering the question How do you feel about coming to see your dentist today? using a seven-point face scale. Instead of continuing to answer the other questions, the application will guide him to wait for the one-minute interval (expected time to answer the questionnaire) and, once more, ask the same question regarding his/her feeling about the experience with the dentist."
10168916|NCT03907267|Experimental|Taurine|
10168917|NCT03907267|Placebo Comparator|Saline|
10168918|NCT03907254|Experimental|National Capital Region (NCR)|10-week longitudinal pre-post study, in which each participant will serve as their own control. Each participant will train a service dog using methods that facilitate a relationship between the trainer and dog for the gradual shaping of desired behavior. Self-report measures of behavioral symptoms will be given weekly throughout participation in this study. Biological measures, including blood collection, HR, BP, etc. will be collected at baseline, during the three-week training follow-up, during the six-week training follow-up, and at a three-month post-training follow-up. The researchers will also be collecting self-report assessments from the participant, observational reports from an Occupational Therapist (OT) and electronic health records to track healthcare utilization and social skills (i.e. communication).
10168919|NCT03907371|Experimental|Donepezil|Patients receive donepezil with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
10168920|NCT03907371|Placebo Comparator|Control|Patients receive placebo with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
10168921|NCT03907228|Experimental|RHT-3201|Lactobacillus rhamnosus IDCC 3201, Tyndallization (RHT-3201) (100 billion Colony Forming Units/sachet)
10168922|NCT03907228|Placebo Comparator|Placebo|Dextrose Anhydrous
10168923|NCT03906981||Caries free|6-9 year old caries free children
10168924|NCT03906981||Caries active|6-9 year-old caries active (>5 dmft/DMFT) children
10168925|NCT03907098|Experimental|endostar + chemotherapy|"Endostar 15 mg per square of BSA, continuous intravenous infusion 24 hours a day, continuous administration for 7 days, every three weeks.~Chemotherapy regimens are selected by physicians based on regular clinical decision."
10168926|NCT03907085|Active Comparator|High intensity laser therapy (HILT) + exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
10168927|NCT03907085|Placebo Comparator|Placebo HILT + exercise|Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
10168928|NCT03906929|Experimental|Pediatric forearm fracture|
10168929|NCT03906903|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, three per weekday, with a final result of 30 sessions in this modality with a 30 minutes Cognitive Stimulation after session.
10168930|NCT03906903|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 30 sessions, three per weekday with a 30 minutes Cognitive Stimulation afterwards.
10168931|NCT03907007|No Intervention|Sole Medication|Monitoring under current prescribed medication
10168932|NCT03907007|Active Comparator|Combined stimulation & medication|Concurrent usage of stimulation with the prescribed medication
10168933|NCT03907007|Active Comparator|Sole Stimulation|Alternating usage of stimulation to the prescribed medication
10168934|NCT03906877|Experimental|Injection laryngoplasty group (IL)|The patients in the first group will receive an IL of hyaluronic acid in the paralyzed vocal fold within a maximum of three months after the onset of symptoms. The Ear-Noise-Throat (ENT) physician will perform the injection in office, under topical anaesthesia.
10168935|NCT03906877|Experimental|Voice therapy group (VT)|Patients from the second group will be involved in 15 sessions of thirty minutes of voice therapy, twice a week, and will have to do home practice. Patients will have to record these training sessions. Initiation of this intervention should also take place within the first three months after the onset of symptoms. They will also receive an injection of physiological saline under the skin of the neck (sham of injection).
10168936|NCT03906877|Sham Comparator|Sham group|The patients of the third group will be treated following the traditional wait-and-see policy. They will receive an injection of physiological saline under the skin of the neck and will be seen during 15 sessions of 30 minutes, twice a week. Therefore, this will be a sham procedure for both IL and VT.
10168937|NCT03907059|Active Comparator|Omnivorous|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (whey) + 12 weeks of resistance training
10168938|NCT03907059|Experimental|Vegan|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (soy) + 12 weeks of resistance training
10168939|NCT03906955|Experimental|Efficacy for Lifestyle PA|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for lifestyle physical activity.
10168940|NCT03906955|Active Comparator|Efficacy for Work-life Balance|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for work-life balance.
10168941|NCT03906916|Experimental|Patients with suspicion of invasive candidiasis|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
10168942|NCT03907150||Pneumothorax|Pneumothorax
10168943|NCT03907150||Normal|Normal lung
10168944|NCT03907124|Experimental|Genetically-guided treatment arm|The active arm - where patients will receive genetically-guided treatment
10168945|NCT03907124|No Intervention|Treatment as usual (TAU) control arm|TAU is the control arm - where patients will continue to receive their usual treatment as before.
10168946|NCT03907215|Other|Treatment A and B|"On Day 1 and Day 2, subjects will EITHER receive:~a single dose of 50 mg ACT-541468 (Treatment A) on Day 1 and a single dose of ACT- 541468 placebo (Treatment B) on Day 2 OR~a single dose of ACT-541468 placebo (Treatment B) on Day 1 and a single dose of 50 mg ACT-541468 (Treatment A) on Day 2."
10168947|NCT03907215|Other|Treatment C, D, E, and F|"From Day 3 to Day 10, subjects will on each day receive:~• a single dose of 20 mg citalopram and EITHER a single dose of ACT-541468 placebo OR a single dose of 50 mg ACT-541468."
10168948|NCT03907163|Experimental|healthy subjects|
10168949|NCT03907163|Placebo Comparator|healthy volunteers|
10168950|NCT03907202|Active Comparator|KBP-089|"Three cohorts:~Cohort 1: starting dose 5 µg, maximum dose 20 µg, uptitration step 7 days, dose increment 5 µg~Cohort 2: starting dose 7.5 µg, maximum dose 60 µg, uptitration step 3 days, dose increment 7.5 µg~Cohort 3: starting dose 5 µg, maximum dose 120 µg, uptitration step 3 days, dose increment 5, 10, 15 and 20 µg"
10168951|NCT03907202|Placebo Comparator|Placebo|For all the cohorts, sentinel dosing for the first two patients will be performed 1:1 in a blinded manner.
10168952|NCT03907111|Experimental|Chitosan gauze|100cm^2 Gauze made by chitosan material. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
10168953|NCT03907111|Placebo Comparator|Traditional gauze|100cm^2 Gauze made by traditional cotton yarn. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
10168954|NCT03907020|Experimental|Meabolic Availabiliy of Barley|Healthy adult men
9671697|NCT05044559|Experimental|Continuous Positive Air Way Group|"Day 1: Use of CPAP between 10 and 12 cmH2O according to tolerance for 20 minutes two time a day at first day of post surgery bed mobility chest physiotherapy ,active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise. and vital was record after exercise.~Day 2: Active ROM exercise progress of 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time was increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
9671698|NCT05044559|Active Comparator|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
9671699|NCT05044429|Experimental|Intravenous Lidocaine|
10168955|NCT03906864|No Intervention|Control group|Usual care consisted of 2 half hourly therapy sessions per day from Monday to Friday and medical ward rounds 3 times a week. Multidisciplinary rounds were conducted every 2 weeks. Any specific goals or interventions were at the discretion of the managing team.
10168956|NCT03906864|Experimental|Intervention group|Intervention group had structured assessments and checklists (as part of the integrated care pathway) in addition to usual care.
10168957|NCT03906942|Experimental|Fun For Wellness (FFW)|Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks of 24 hr access to the FFW online intervention during data collection for this study. Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being and/or physical activity.
10168958|NCT03906942|No Intervention|Usual Care (UC)|Participants assigned to the UC group (i.e., UC participants) will proceed through the pre-operative weight management program provided by the center.
10168959|NCT03906825|Active Comparator|dietary supplement CEAG|The dietary supplements consists of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG).
10168960|NCT03906825|Placebo Comparator|Placebo|The Placebo does not contain any CEAG.
10168961|NCT03906721|Experimental|Conditioning & Open-Label Placebo (COLP)|Days 1 to 3 will include the acquisition phase where oxycodone will be prescribed on a schedule of 3-4 times per day and paired with open-placebo and smelling the essential oil. Days 4 to 6 will be the evoked phase, and patients will receive full oxycodone dosage on alternating days with open placebo and smelling the essential oil.
10168962|NCT03906721|Other|Treatment-as-usual|For the duration of the study, days 1 to 6, oxycodone will be prescribed on a schedule of 3-4 times per day.
10186811|NCT03732235||TACE+ systemic Bevacizumab|"TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.~Bevacizumab (5 mg/kg) therapy was initiated 15 days after first round of TACE and was repeated every two weeks, for a total of 8 cycles."
9671700|NCT05044429|Active Comparator|Transversus abdominis plane (TAP) block|
9671701|NCT05044429|Active Comparator|Quadratus Lumborum (QL) Block|
9671702|NCT05044143||Women who remained undelivered after their first episode of threatened preterm labor|Women admitted to the hospital due to their first episode of threatened preterm labor (i.e onset of spontaneous labor < 34 weeks gestation), who did not deliver prematurely as labor stopped (with or without interventions such as tocolysis). Those with a cervical length < 25 mm at the time of hospital discharge are eligible to participate in the study
10168963|NCT03906799|Experimental|Low OMT-28|Verum, low OMT-28
10168964|NCT03906799|Experimental|Middle OMT-28|Verum, middle OMT-28
10168965|NCT03906799|Experimental|High OMT-28|Verum, high OMT-28
10168966|NCT03906799|Placebo Comparator|Placebo|Placebo
10168967|NCT03906578|Active Comparator|Probiotic|Two sachets Vivomixx® containing 8 strains of life bacteria (9 x 10^11 CFU) in the evening for 8 weeks
10168968|NCT03906578|Placebo Comparator|Placebo|Two sachets placebo in the evening for 8 weeks
10168969|NCT03906786|Experimental|motivacional interviewing group|
10168970|NCT03906786|No Intervention|control group|
10168971|NCT03906851|Experimental|Activity and diet|"Multi-component, holistic model with a) physical activity, b) nutrition, and c) psychosocial work.~A: physical activity will be provided as a pedagogical tool in subjects Mathematics, Norwegian and English B: Focus on school meals and menus in school cafeteria C: Psychosocial work with focus on the associations between physical activity, nutrition and psychosocial health. Collaboration between schools and school health services"
10168972|NCT03906851|No Intervention|Control|Schools are required to perform teaching activities, school meals and school cafeteria menus as usual
10168973|NCT03906682|Experimental|RAP Club program|RAP Club is a 12-session universal prevention program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
10168974|NCT03906682|Active Comparator|Healthy Topics program|Like RAP Club, Healthy Topics is a 12-session program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
10168975|NCT03906773||Intervention|The investigators seek to conduct a pragmatic trial including 2 sister clinical sites to test an innovation using a patient portal framework for Advance Care Planning. The intervention site implemented the intervention (secure patient portal delivered pre-visit planning framework for Advance Care Planning communication). The presence of ACP and the quality of documentation will be assessed through post-intervention chart review. Practice level enrollment was sought for the trial, and the framework will be delivered to all patients during a period of roll out. About 250 patients will receive the intervention.
10168976|NCT03906773||control|The control site delivered usual care during the same period of roll out.
10168977|NCT03906838|Experimental|Regional Nerve Block|Subjects in the regional anesthesia cohort will have a regional anesthesia block and/or catheter placement administered according to current hospital policies and our established standard of care.
10168978|NCT03906838|No Intervention|No Regional Nerve Block|Subjects in the no regional anesthesia cohort will not get pre-operative regional anesthesia, and their surgery and anesthesia will be performed according to normal policies and standard of care in our hospital.
10168979|NCT03906552|Experimental|acupressure group|"2 neonates did not calm down before heel lancing; oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well.~Acupressure was performed when the mother was holding the neonate on her arm. For two minutes, acupressure was performed in the acupressure points (Kun Lun (UB60) and Taixi (K3). Each point was applied acupressure for 60 seconds, and heel lancing was performed right after this procedure. The acupuncture points that Kun Lun (UB60) and Taixi (K3) are on the side of the ankle."
10168980|NCT03906552|Experimental|masssage group|"oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~Foot massage was performed when the mother was holding the neonate on her arm. Each neonate was given foot massage for two minutes, and heel lancing was performed right after the massage."
9671703|NCT05044442|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
10168981|NCT03906552|No Intervention|control group|"oxygen saturation and heart rate values of 1 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~No application was made to theneonates in the control group before heel lancing procedure"
10168982|NCT03906630||Shoulder patients|
10168983|NCT03906591|Experimental|allogenic bone ring|
10168984|NCT03906591|Active Comparator|autogenous bone ring|
10168985|NCT03906669|Active Comparator|Letrozole|Letrozole 2.5mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
10168986|NCT03906669|Experimental|Letrozole and Prometrium|Letrozole 2.5mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
10168987|NCT03906669|Experimental|Tamoxifen and Prometrium|Tamoxifen 20mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
10168988|NCT03906656|Active Comparator|KAFO/SCO|Home use of 3 months with existing knee ankle foot orthosis (KAFO) or existing stance control orthosis (SCO)
10168989|NCT03906656|Experimental|C-Brace|Home use of 3 months with newly fitted C-Brace microprocessor-controlled stance and swing control orthosis.
10168990|NCT03906734|Experimental|alfieri technique + Septal myectomy|Septal myectomy plus mitral valve repair using alfieri stich
10168991|NCT03906734|Active Comparator|Subvalvular intervention + Septal myectomy|Septal myectomy plus subvalvular mitral valve intervention
10168992|NCT03906812|Active Comparator|Unmonitored floor admission|Participants in this arm will be admitted to an unmonitored floor bed.
10168993|NCT03906812|Active Comparator|Floor admission with telemetry|Participants in this arm will be admitted to a telemetry bed.
9520387|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
9520388|NCT03278158|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
9827752|NCT02466516|Experimental|SIM 125 mg|SIM 125 mg for 24 weeks.
9520389|NCT03278158|Experimental|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
10186812|NCT03732235||FOLFIRI+Bevacizumab|FOLFIRI consists of 5-FU administered as a 48-hour continuous infusion to a total dose of 3,200 mg/m2 without a bolus, leucovorin 200 mg/m2, irinotecan 165 mg/m2 Bevacizumab (5 mg/kg) therapy was repeated every two weeks, for a total of 8 cycles.
9974919|NCT05105308|Experimental|Feeling and Body Investigator_ARFID Division|This is a 20-session intervention with a child and the child's parents that consists of 4 components: 1) psychoeducation of somatic body sensations and sensory features of foods using playful characters (e.g., Aftertaste Anthony); 2) in-session exercises that expose family members to different body and food sensations so they can learn something new about their body and food; 3) body brainstorm worksheets that help them generalize what they learn in session to outside of treatment; and 4) Decision-tree practice worksheets that help them map body sensations to meanings and actions and to track explorations with food.
9974920|NCT05093166|Experimental|Urethral reduced functionality and/or lesions due to previous hypospadias treatment failure|"The first step consists in a small oral mucosa biopsy collection by surgeon under general anaesthesia. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where the epithelial cells will be isolated, expanded and prepared as final graft to be implanted.~The treatment for urethra reconstruction required a two stage urethroplasty:~First stage: application of Holour on the wound bed prepared according to standard surgery The penis will be immobilized for some days after this operation.~Second stage: surgical procedure for urethral tubularization and penile reconstruction according to standard surgical procedure.~The surgical procedures may be followed by a post-implantation treatment (if necessary) with corticosteroids and antibiotics."
9974921|NCT05090657|Other|Open label presurgical nasal decolonization|All patients presenting for surgery will be offered nasal decolonization with the combination product. After informed consent a nasal culture will be obtained followed by a 4-minute nasal decolonization treatment and a post-treatment culture. The intervention consists of swabbing the nose with a methylene blue/chlorhexidine gluconate solution followed by non-thermal nasal illumination with red light. There will only be a single treatment.
9974922|NCT05086952|Experimental|A-B-D-C|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
9974923|NCT05086952|Experimental|B-C-A-D|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
9974924|NCT05086952|Experimental|C-D-B-A|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
9974925|NCT05086952|Experimental|D-A-C-B|4-fold crossover design with 4 interventions, 4 intervention periods, and 4 intervention sequences. (according to Williams design [balanced for 1-period-carry-over]).
9974926|NCT05077007|Active Comparator|Percutaneous nephrolithotomy|patients suffering of pelvic renal stones underwent Percutaneous nephrolithotomy
9974927|NCT05077007|Active Comparator|Extracorporeal Shock Wave Lithotripsy|patients suffering of pelvic renal stones underwent Extracorporeal Shock Wave Lithotripsy
9974928|NCT05077007|No Intervention|control group|Healthy volunteers with negative history of renal stones or renal impairment to measure the level of urinary markers in their urine samples
9974929|NCT05073250|Experimental|Experimental arm|Enrolled patients will be administered IBI376 plus rituximab, induction therapy for 6 cycles (28-day cycle). Patients assessed as partial response (PR) after 6 cycles of induction therapy will receive another 6 cycles of IBI376 combined with rituximab induction therapy.
9974930|NCT05070403|Experimental|Afatinib Intervention|Participants will receive afatinib 40 mg once a day. Each cycle is 4 weeks. They will have CT imaging (and/or digital photography) done at baseline and every 8 weeks while on treatment. Participants will have a baseline and on-treatment (at 4 weeks) tumor biopsy, and a biopsy at disease progression if feasible. Patients may remain on treatment as long as they are deriving clinical benefit, until disease progression or intolerable toxicity.
9974931|NCT05063149|Active Comparator|Broncho-Vaxom treatment|Infants in this arm will be given 3,5mg bacterial lysate (OM-85) 10 days per month from 6 weeks after birth until 12 months of age.
9974932|NCT05063149|Placebo Comparator|Placebo|Infants in this arm will be given a placebo powder from a capsule that will be indistinguishable from the active study drug.
9974933|NCT05058742|Experimental|Nervus vagus stimulation|Non-invasive Nervus vagus stimulation called AuriStim Intermittent stimluation cycle of three hours of activity and three hours of rest, equating to four cycles of three hours of Stimulation in 24 hours) is performed. The stimulation is performed until the patient's condition is better and he or she isdischarged from OCU or transferred to normal ward or dies.
9974934|NCT05058742|No Intervention|Control|There is no Nervus vagus stimulation.
9974935|NCT05056324|Experimental|Intervention group|
9974936|NCT05056324|Active Comparator|Control group|
9974937|NCT05048342|Experimental|Arm 1|LOU064 open-label treatment taken orally for 52 weeks.
9974938|NCT05034562|Experimental|Diagnostic (gallium Ga 68-labeled PSMA-11, PET/CT, PET/MRI)|Patients receive gallium Ga 68-labeled PSMA-11 IV. 50-100 minutes after injection, patients then undergo a PET/CT scan or PET/MRI scan over 60 minutes.
9974939|NCT05031026|Active Comparator|donor group|where donors only will receive dexmedetomidine
9974940|NCT05031026|Active Comparator|recpient group|where recepients only will receive dexmedetomidine
9974941|NCT05031026|Placebo Comparator|control group|both donors and recipients will receive a placebo
9974942|NCT05029414|Experimental|Intervention group: EVT + BMT|Patients randomized to the EVT arm will undergo endovascular therapy (EVT) in addition to best medical treatment (BMT). All decisions regarding EVT device and EVT technique will be made by the treating physician.
9974943|NCT05029414|No Intervention|Control group: BMT|Patients randomized to the control arm will NOT undergo EVT but will get best medical treatment (BMT) including intravenous thrombolysis (IVT) or antiplatelet therapy if indicated under current international guidelines and according to routine clinical practice.
9974944|NCT05027919|Other|Within-subject design|All participants will undergo the same study design, which includes morphine stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).
10168994|NCT03906500|Experimental|Intervention|"The intervention consist of three main components.~School environmental component~The component targeting the high school environment consisted of two separate elements:~Revision of school alcohol policy~Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student components~The Student components consisted of three main elements:~Web-based education for the student committees organizing events where alcohol is sold and the student introduction committee~Pocket movie campaign~Social norms campaign~Parent components~The parent component consisted of three separate elements:~Parent Information Meeting~Parent Information Folder~Parent Information Website"
10168995|NCT03906500|No Intervention|control group|Control high schools was asked to continue business as usual and promised to receive the intervention in the school year starting in 2020
10168996|NCT03906513|Active Comparator|Active treatment|20 patients will be treated with active treatment (OMK2)
10168997|NCT03906513|Placebo Comparator|Placebo|10 patients will be treated with placebo (lubricant eye drops)
10168998|NCT03906396|Experimental|Intervention Group|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant for 6 weeks, 3 times per week. Games use for the activity are Sports Kinect and Sports Kinect 2. The activity can be performed in solo or in pairs with another participant. The game activity will be played only at the site chosen for this study.
10168999|NCT03906396|No Intervention|Control Group|No standard activity is provided for the participants. The participants will continue with their normal daily life activities.
10169000|NCT03906565|Experimental|utidelone|Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC
10169001|NCT03906383|Experimental|Remote Ischemic Conditioning|
10169002|NCT03906487|Experimental|Intimate partner violence|The women in this arm must have suffered at least two physical aggressions. They will be recruited in the study as part of their coming to the consultation of intentional injury of the medico-legal unit of the University Hospital Toulouse.
10169003|NCT03906487|Active Comparator|Control group|The women in this group are women who have never experienced domestic violence or have experienced a potentially traumatic event. These women will be recruited by a call for volunteers.
10169004|NCT03906409|Active Comparator|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
10169005|NCT03906409|Experimental|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
9671704|NCT05044442|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
10169006|NCT03906370||MS patients/cases|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
10169007|NCT03906370||Healthy subjects/controls|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
10169008|NCT03906422|Experimental|"A: 0.016 Nitinol"|"0.016 Nitinol (3M Unitek, Monrovia, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
10169009|NCT03906422|Experimental|"B: 0.016 Ormco 27oC NiTi"|"0.016 Ormco 27oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
10169010|NCT03906422|Experimental|"C: 0.016 Ormco 35oC NiTi"|"0.016 Ormco 35oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
10169011|NCT03906201|Experimental|Control Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment
10169012|NCT03906201|Experimental|Ecdysterone Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment
10169013|NCT03906032|Experimental|Intra-medullary hip Nail|Surgery
10169014|NCT03906032|Active Comparator|Sliding hip screw|Surgery
10169015|NCT03906305|Experimental|Dry needling in a myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into trigger point spastic muscle of the shoulder.
10169016|NCT03906305|Active Comparator|Dry needling in a non myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into a non trigger point spastic muscle of the shoulder.
10169017|NCT03906266|Active Comparator|nutric score|> 5 indicates high risk for malnutrition < 4 indicates low risk for malnutrition
10169018|NCT03906266|Placebo Comparator|adductor pollicis|< 20 mm indicates high high risk for malnutrition > 20 mm indicates low risk for malnutrition
10169019|NCT03906266|Placebo Comparator|SGA score|SGA 1 indicates no malnutrition SGA 2 indicates good diet SGA 3 indicates high risk for malnutrition
10169020|NCT03906266|Placebo Comparator|NRS 2002 score|> 3 indicates high risk for malnutrition
10169021|NCT03906058|Experimental|Anlotinib|
10169022|NCT03906474|Experimental|Group 1|A third blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to two blood-stage challenges in the VAC063 trial. Group 1 will be challenged in parallel with Groups 2 (undergoing a second challenge) and 3 (malaria-naïve controls).
10169023|NCT03906474|Experimental|Group 2|A second blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to one blood-stage challenge in the VAC063 trial. Group 2 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 3 (malaria-naïve controls).
10169024|NCT03906474|Experimental|Group 3|Malaria-naïve controls will receive a primary blood-stage controlled human P. falciparum malaria infection. Group 3 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 2 (undergoing a second challenge).
9671705|NCT05044442|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
10169025|NCT03906084|Active Comparator|Corticotomy facilitated orthodontics.|Corticotomy is carried out under local anesthesia in right side.
10169026|NCT03906084|Experimental|Corticotomy and low level laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
10169027|NCT03905980||Vaginal delivery|woman who terminate their pregnancy by vaginal delivery
10169028|NCT03905980||Cesarean delivery|woman who terminate their pregnancy by cesarean delivery
10169029|NCT03906097|Experimental|intervention|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
10169030|NCT03906097|No Intervention|control|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
10169031|NCT03905798||Lorazepam|Patients administered Lorazepam in accordance with the indication (for Status Epilepticus, SE) and have no history of using this drug
10169032|NCT03906045|Experimental|All patients|10 patients with moderate COPD and 10 patients with severe/very severe COPD inhale BGF followed by a breath hold of up to 10 seconds.
10169033|NCT03906188|Experimental|LitEmotion group|This group will play to LitEmotion video game.
10169034|NCT03906188|No Intervention|Control group|This group will no do receive any intervention with the video game
10169035|NCT03905785|Experimental|Parenting Intervention Group(Samarthan)|Parenting intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
10169036|NCT03905785|No Intervention|Wait list Control group|wait list control group was given no intervention for the trial period. They were offered sam intervention after the intervention was completed in experimental group.
10169037|NCT03906006|Experimental|ABP-671, Cohort 1-|ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
10169038|NCT03906006|Experimental|ABP-671, Cohort 2-|ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
10169039|NCT03906006|Experimental|ABP-671, Cohort 3-|ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
10169040|NCT03906006|Experimental|ABP-671, Cohort 4-|ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
10169041|NCT03905850|Experimental|Somapacitan 5/10/10 mg|One dose of somapacitan 5 mg/1.5 ml followed by two doses of somapacitan 10 mg/1.5 ml. Each dose will be followed by a 3 week observation period.
10169042|NCT03905850|Experimental|Somapacitan 10/5/10 mg|One dose of somapacitan 10 mg/1.5 ml followed by a 5 mg/1.5 ml dose followed by a 10 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
10169043|NCT03905850|Experimental|Somapacitan 10/10/5 mg|Two doses of 10 mg/1.5 ml somapacitan followed by a 5 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
9671706|NCT05044468|Experimental|Group A (liposomal bupivacaine)|Patients receive liposomal bupivacaine via injection into the intercostal nerve block.
9671707|NCT05044468|Active Comparator|Group B (lidocaine)|Patients receive lidocaine via injection into the pleuroscopy port incision sites and indwelling pleural catheter site.
9977452|NCT01361750|Experimental|gastirc tube group|conduit will be perfomed by narrowed gastric tube
10169044|NCT03905915|Other|Preoperative virtual reality session|Amsterdam Anxiety score recorded before VR session is followed by a 15 min VR session and finally Amsterdam Anxiety score is recorded after VR session
10169045|NCT03905954||Parkinson's Diagnosis|Usual care
10169046|NCT03906162|Experimental|Motivational interviewing|Experimental content + base intervention
10169047|NCT03906162|Active Comparator|Control intervention|Base intervention
10169048|NCT03905824|Experimental|Debridement and microfracture in LOC + Cells|Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.
10169049|NCT03905824|Active Comparator|Debridement and microfracture in LOC|Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus.
10169050|NCT03905837|Experimental|Lidocaine IV|Group 1: intravenous lidocaine and paravertebral saline (SF). In this group during intraoperative anesthetic maintenance, a continuous intravenous infusion of lidocaine at 1.5mg/kg/h until the end of surgery and perfusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1ml/kg/h will be administered.
10169051|NCT03905837|Experimental|Lidocaine PV|Group 2: intravenous SF and paravertebral lidocaine. During anesthesia maintenance, a continuous intravenous infusion of 0.9% SF and an infusion of 2% lidocaine will be administered through the intraoperative paravertebral catheter at a rate of 0.1 ml/kg/h.
10169052|NCT03905837|Active Comparator|no lidocaine|Group 3: intravenous remifentanil and paravertebral SF. During the maintenance of anesthesia, a continuous intravenous infusion of remifentanil at a rate of 0.1 mg/kg/min until the end of surgery and an infusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1 ml / kg / h.
10169053|NCT03905941|Experimental|Metformin then oral combined hormonal contraceptives|Subjects will take metformin 2000 mg/day for the first 6 months, followed by 6 months of oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg.
10169054|NCT03905941|Active Comparator|Oral combined hormonal contraceptives then metformin|Subjects will take oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg for the first 6 months, followed by 6 months of metformin 2000 mg/day.
10169055|NCT03906123|Experimental|NBP|DL-3-n-butylphthalide (NBP), soft capsule, 200mg Tid, po, for 48 weeks.
10169056|NCT03906123|Placebo Comparator|Placebos|Placebo, soft capsule, 200mg Tid, po, for 48 weeks.
10169057|NCT03905967|Experimental|Lenvatinib + TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib.
10169058|NCT03905967|Active Comparator|Lenvatinib|Lenvatinib alone
10169059|NCT03905772|Experimental|Voluntary exercise|The participants will perform 36 voluntary contractions of 20% of maximal voluntary isometrical contraction, 3 times per week for 8 weeks.
10169060|NCT03905772|Experimental|Wide pulse responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in responder in the acute fase."
10169061|NCT03905772|Experimental|Wide pulse non responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in non responder in the acute fase."
10169062|NCT03905772|Experimental|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
9826491|NCT02420223|No Intervention|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
9826492|NCT02420262|Experimental|IDegLira|
9671708|NCT05044546|Experimental|Aim 1 and secondary aim 2 (focus group)|Participants participate in focus group over 60-90 minutes. Participants who completed and dropped out of postpartum treatment also participate in a focus group.
9671709|NCT05044546|Experimental|Aim 3 Group I (BA)|Participants participate in smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
9826493|NCT02420262|Active Comparator|IGlar plus IAsp|
9671710|NCT05044546|Experimental|Aim 3 Group II (HW)|Participants participate in smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes once a week for 10 weeks to pilot test delivery via smartphone videoconferencing and to conduct process evaluation of technical issues in use of smartphones.
9671711|NCT05044546|Experimental|Aim 4 Group III (BA)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and BA counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
9826494|NCT02420327|Experimental|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
9826495|NCT02420327|Experimental|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
9826496|NCT02420327|Experimental|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
10169063|NCT03905447|Experimental|PC945|
10169064|NCT03905447|Other|Standard of Care|Standard of care anti-fungal medication
10169065|NCT03905681|Active Comparator|"Active TENS Group Group A"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. While the device is off, it will be set at the following settings: The selector switch will be set to 'Milli' or milliamperes, and the frequency dial will be rotated to 100 Hertz. The participant will be instructed to rotate both dials in a clockwise direction if more intensity is desired, or counter-clockwise if less intensity is desired. The participant will wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
9826497|NCT02420327|Experimental|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
9827510|NCT02458690|Experimental|eIMPACT|eIMPACT is a 12-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for cardiovascular disease risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers.
9827511|NCT02458690|Active Comparator|Usual Care|Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
9977453|NCT01361750|No Intervention|control group|conduit will be traditional subtotal stomach without any surgical modification
9977454|NCT01361763|Experimental|Dabigatran|
10169066|NCT03905681|Placebo Comparator|"Placebo TENS Group Group B"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. However, no electrical stimulation will be provided. The participant will also wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
10169067|NCT03905538|Experimental|[18F]FLT-PET/CT Arm|The experimental [18F]FLT-PET/CT will be completed before initiation of chemotherapy and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline [18F]FLT PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
10169068|NCT03905759|Active Comparator|colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
10169069|NCT03905759|Active Comparator|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
10169070|NCT03905759|Active Comparator|amiodarone|amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
10169071|NCT03905616|Experimental|healthy subjects|25 healthy subjects with a normal/corrected vision fitting to all of the inclusion/exclusion criteria. All the subjects will be tested on the same visual stimuli, leading to intrasubject comparison analyses of functional magnetic resonance imaging (fMRI) activity between conditions.
10169072|NCT03905577|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
10169073|NCT03905577|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
10169074|NCT03905577|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
10169075|NCT03905733||general anesthesia with rigid bronchoscopy|Patients 7 years or younger who undergo general anesthesia with rigid bronchoscopy
10169076|NCT03905746||acute decompensation group|patients admitted within 48 hours for acute decompensation of cirrhosis, with or without evidence of sepsis
10169077|NCT03905746||Pathological control group|patients with Chronic Liver Disease (CLD), also named stable cirrhotic patients, without any admission in the last 6 months for an acute event
10169078|NCT03905603|Experimental|ACTH (Cosyntropin), rhCG (Ovidrel)|ACTH (Cosyntropin) administered 250 mcg IV; rhCG (Ovidrel) administered 250 mcg IV
10169079|NCT03905499|Experimental|Robotic mediated therapy|Robotic mediated therapy with MJS (multi joint system) Tecnobody
10169080|NCT03905317|Experimental|Bevacizumab|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
10169081|NCT03905486|Active Comparator|G1: patients will receive pregabalin|pregabalin as a mono-therapy will be administered in increment doses for 3 months
10169082|NCT03905486|Active Comparator|G2: patients will receive pregabalin and milnacipran|pregabalin and milancipran as a combination therapy will be administered in increment doses for 3 months
10169083|NCT03905304|Experimental|Meditoxin|Meditoxin administered 200U~300U, single-dose administration.
10169084|NCT03905304|Active Comparator|Botox|Botox administered 200-300U, single-dose administration.
10169085|NCT03905629||Patients aged 75 years and older hospitalized as an emergency|Patients considered will be all patients aged 75 years and older (on the day of the index admission) hospitalized as an emergency (i.e. after visit to ED) between january 2017 and december 2017.
10169086|NCT03905278|Experimental|Parental guidance|"In the experimental condition, the two significant caregivers of the child or the individual caregiver receive the intervention composed of an informational booklet and a psychological intervention. The intervention consists of four sessions, centered on supporting the child in the context of parental cancer principally through communication.~Assessments are conducted at two periods : before and after the intervention."
10169087|NCT03905278|No Intervention|Waiting List group|"In the control condition, the participants receive the informational booklet before being registered in a waiting list for the psychological intervention. The intervention should ideally last two months.~Assessments are conducted at 9 weeks of interval."
9974945|NCT05027048|Experimental|Calcium chloride|"1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
10169088|NCT03905590|Experimental|periapical surgery with amniotic membrane|periapical surgery will be done and amniotic membrane will be placed over the defect before closure of flap
10169089|NCT03905590|Active Comparator|periapical surgery without amniotic membrane|periapical surgery will be done without the placement of amniotic membrane over the defect before closure of flap
10169090|NCT03905655|Placebo Comparator|Group 1|Three placebo tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
9671712|NCT05044546|Experimental|Aim 4 Group IV (HW)|Participants participate in 8-14 smoking cessation counseling over 15 minutes and health and wellness education counseling sessions over 45 minutes every 2-3 weeks till the end of the pregnancy. Following birth, participants also participate in 4 additional sessions within the first 6 weeks, then that last 4 evenly distributed across 10 weeks.
10169091|NCT03905655|Active Comparator|Group 2|Two 300 mg NTZ tablets and one placebo tablet administered orally in the morning and three placebo tablets in the evening in addition to continuing TDF, TAF or ETV therapy
10169092|NCT03905655|Active Comparator|Group 3|Two 300 mg NTZ tablets and one placebo tablet administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
10169093|NCT03905655|Active Comparator|Group 4|Three 300 mg NTZ tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
10169094|NCT03905551|Placebo Comparator|Standard Dialysis|Patients participated in a 7 months exercise trials receiving standard dialysis (at 37oC)
10169095|NCT03905551|Experimental|Cold Dialysis|Patients participated in a 7 months exercise trials receiving cold dialysis (at 35oC)
10169096|NCT03905512|Experimental|SEL-212|IV infusion of SEL-212 every 28 days for a total of up to 6 infusions of SEL-212.
9977455|NCT01361763|Active Comparator|Antiplatelets|
10169097|NCT03905512|Active Comparator|KRYSTEXXA|IV infusion of KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for a total of up to 12 infusions of KRYSTEXXA®.
9520390|NCT03278158|Experimental|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)
9826498|NCT02420353|Active Comparator|Somatropin|Somatropin of rDNA origin
10169098|NCT03905564|Experimental|Doxylamine succinate/pyridoxine hydrochloride|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination) administered with 250 mL of water (at room temperature) under fasting conditions.
10169099|NCT03905564|Active Comparator|Diclegis (Registered Trademark)|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets) administered with 250 mL of water (at room temperature) under fasting conditions.
10169100|NCT03905395|Active Comparator|Meditation and mindfulness intervention|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
10169101|NCT03905395|No Intervention|Control group|Women in the no intervention arm will receive no introduction to meditation and mindfulness - only questionnaires at the same time as the intervention group receives questionnaires.
10169102|NCT03905408|Experimental|50 mL Dextrose|50 mL of 50% dextrose
10169103|NCT03905408|Experimental|100 mL Dextrose|100 mL of 50% dextrose
10169104|NCT03905408|Experimental|150 mL Dextrose|150 mL of 50% dextrose
10169105|NCT03905408|Experimental|200 mL Dextrose|200 mL of 50% dextrose
10169106|NCT03905343|Experimental|A: endocrine therapy + ribociclib|
10169107|NCT03905343|Active Comparator|B: mono-chemotherapy|
10169108|NCT03905291|Experimental|MT921 60mg Group|MT921 60 mg
10169109|NCT03905291|Experimental|MT921 120mg Group|MT921 120 mg
10169110|NCT03905291|Experimental|MT921 150mg Group|MT921 150 mg
10169111|NCT03905291|Placebo Comparator|Placebo Group|Placebo
10169112|NCT03905239|Experimental|algorithm arm|Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
10169113|NCT03905239|No Intervention|no algorithm arm|Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.
10169114|NCT03905109|Experimental|ABX464|50 mg
10169115|NCT03905109|Placebo Comparator|Placebo|50 mg matching placebo
10169116|NCT03905122||continous veno-venous hemodialysis|to measure the fluid changes by using bioreactance method in continous veno-venous hemodialysis group
10169117|NCT03905122||hemodialysis|to measure the fluid changes by using bioreactance method in hemodialysis group
10169118|NCT03905200||coronary artery disease|Patients who were diagnosed with coronary heart disease at admission and planned to undergo coronary angiography
10169119|NCT03905187|Other|Control Group|Group received education only
10169120|NCT03905187|Other|Traditional CR Group|Group received cardiac rehabilitation including education and exercise
10169121|NCT03905187|Experimental|Stress-Modified CR Group|Group received cardiac rehabilitation including education, exercise and stress management
10169122|NCT03904992|No Intervention|Non-exposed|Subjects with access to nutritional counseling sessions every 30 days
10169123|NCT03904992|Experimental|Exposed|Subjects with access to the progressive web app in their smartphones.
10169124|NCT03905005||Pre-flexed reconstruction plate|Patients who undergo mandibular reconstruction using a pre-flexed osseosynthesis reconstruction plate along with free-tissue transfer for reconstruction of a mandibular continuity defect.
10169125|NCT03905005||Printed reconstruction plate|Patients who undergo mandibular reconstruction using a 3D-printed reconstruction plate made by selective laser melting (SLM), along with free-tissue transfer for reconstruction of a mandibular continuity defect.
10169126|NCT03905382|Other|Qualitaitve|Qualitaitve
10169127|NCT03905031|Experimental|InfraScanner 2000|All participants entered into the study will undergo at least one cranial scanning using the InfraScanner 2000 within 4 hours before or after CT scan. Patients will know the results of the CT scan but not of the InfraScanner 2000. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative.
9826499|NCT02420353|Placebo Comparator|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
10169128|NCT03904849|Active Comparator|Cannabidiol|Cannabidiol 6 mL of 100 mg/mL cannabidiol oral solution per day for 8 days
10169129|NCT03904849|Placebo Comparator|Placebo|Placebo 6 mL oral solution per day for 8 days
10169130|NCT03904979|Experimental|Therapeutic Writing Prompts|Participants will be given writing prompts that discuss events that have been perceived as stressful in their lives and how they may or may not have cultivated resilience and coping strategies because of it.
10169131|NCT03904979|Placebo Comparator|General Writing Prompts|"Participants will be given writing prompts that discuss neutral topics unrelated to their life stress, resilience, or coping."
10169132|NCT03904979|No Intervention|No Writing|Participants will not be given writing prompts during their prenatal care. They will be given blank journals that will NOT contain any instructions or writing prompts.
10169133|NCT03904810|No Intervention|Control|Subjects in this group do not received any intervention
10169134|NCT03904810|Active Comparator|Moderate Intensity Continuous Training ×3/wk|Subjects in this group will receive three sessions of Moderate-Intensity Continuous Training per week throughout the 8 weeks experimental period
10169135|NCT03904810|Active Comparator|High Intensity Interval Training×3/wk|Subjects in this group will receive three sessions of High-Intensity Interval Training per week throughout the 8 weeks experimental period
10169136|NCT03904810|Active Comparator|High Intensity Interval Training×2/wk|Subjects in this group will receive two session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
10169137|NCT03904810|Active Comparator|High Intensity Interval Training×1/wk|Subjects in this group will receive one session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
10169138|NCT03905369|Experimental|Decision aid, SDM booster and deliberation training|In the first arm, patients have COMBO, consisting of the decision aid, the SDM-booster, and the values deliberation training for physicians
10169139|NCT03905369|Active Comparator|Deliberation training|In the second arm, patients have the values deliberation training for physicians alone.
10169140|NCT03905213|Active Comparator|conventional gauze|Device is a conventional gauze and the change will be to the day 2 and 4 of surgery
10169141|NCT03905213|Experimental|polyurethane dressing|Device is a polyurethane dressing and the change will be to the day 7 of surgery
10169142|NCT03905213|Experimental|vacuum therapy dressing|Device is a vacuum therapy dressing and the change will be to the day 7 of surgery
10169143|NCT03904966|Experimental|ESWT+ Kinesiotaping|Low-dye Kinesio taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
10169144|NCT03904966|Sham Comparator|ESWT+Shamtaping|Sham taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
10169145|NCT03904966|Other|ESWT|Extracorporeal shock wave therapy for 5 sessions (5-week)
10169146|NCT03905044||CC|eyes with congenital cataracts
9671713|NCT05044403|Active Comparator|Conventional treatment|Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.
9671714|NCT05044403|Experimental|Extracorporeal support with haemoperfusion treatment|Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.
10169147|NCT03905018|Experimental|tadalafil|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the first will receive a single dose of tadalafil 20 mg orally
10169148|NCT03905018|Placebo Comparator|calcined magnesia (placebo)|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the second will receive 20 mg of calcined magnesia (placebo),after a single administration
10169149|NCT03904927|Experimental|Experimental Arm|The arm will be treated with combined chemotherapy and local therapy such as radiation, surgery or radiofrequency ablation.
10169150|NCT03904927|Active Comparator|Control Arm|The arm will be treated with chemotherapy alone.
10169151|NCT03905174|Active Comparator|Standard treatment|A porous collar for either distal or proximal femoral replacements
10169152|NCT03905174|Active Comparator|standard treatment + HA|A porous collar with hydroxyapatite (HA) for either distal or proximal femoral replacements
10169153|NCT03905174|Active Comparator|standard treatment + HA + autogenic cells|A porous collar with hydroxyapatite (HA) and stem cells for either distal or proximal femoral replacements
9671715|NCT05044390||lung transplantation|Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.
9671716|NCT05044364|Experimental|China clevidipine butyrate injection|Yangtze River Pharmaceutical Group Co., Ltd.
9671717|NCT05044364|Active Comparator|Original research clevidipine butyrate injection|Fresenius Kabi Austria Gmb H (Austria)
9694891|NCT04784247|Experimental|Vascular sarcomas (including angiosarcoma and epithelioid hemangioendothelioma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
10169154|NCT03905057|Sham Comparator|Sham ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), using a sham applicator which is highly similar to the active applicator except that the sham applicator does not emit shockwaves, twice a week (total of 6 weeks) without treatment interval. Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
10169155|NCT03905057|Active Comparator|Active ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks). Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
10169156|NCT03905070||Study Group|The study group consisted of people who had undergone bariatric surgery and who had at least 6 months after the operation.
10169157|NCT03905070||Control Group|The control group will consist of asymptomatic individuals whose BMI is 18-25 kg / m2 and has not participated in any exercise program in the last one year.
9520391|NCT03278158|Experimental|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
10169158|NCT03904901|Active Comparator|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, drink with water and drink before bed. Probiotics contain a dose of 10 9 CFU per capsule.
10169159|NCT03904901|Placebo Comparator|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
10169160|NCT03904953|Experimental|Study group|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
10169161|NCT03904953|Active Comparator|Control group|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
10169162|NCT03904836|Experimental|Tobramycin|Subjects with end-stage renal disease who have been involved in an intermittent hemodialysis program and who have suspected or diagnosed Gram-negative rod-type infection
10169163|NCT03904888|Other|l-TAPP without local anesthetics|These patients will undergo a laparoscopic surgery without local anaesthetics.
10169164|NCT03904888|Other|l-TAPP with local anesthetics|These patients will undergo a laparoscopic surgery with local anaesthetics.
10169165|NCT03904888|Other|r-TAPP without local anesthetics|These patients will undergo a robot-assisted surgery without local anaesthetics.
10169166|NCT03904888|Other|r-TAPP with local anesthetics|These patients will undergo a robot-assisted surgery with local anaesthetics.
10169167|NCT03904940|Experimental|Total Contact Insole Group|Ethyl vinyl acetate insole shaped in the cast of the patient's foot, every 6 months.
10169168|NCT03904940|Sham Comparator|Flat Insole group|Flat insole made the same material ethyl vinyl acetate, every 6 months.
10169169|NCT03904914||AIS group|Patients confirmed with adolescent idiopathic scoliosis (AIS)
10186813|NCT03732235||TACE|TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
10186814|NCT03732222|Experimental|Stretching the diaphragm muscle|The interventor places his hands on the last costal cartilages and the subject makes an inspiration and keeps his hands resisted in the expiration.
10186815|NCT03732222|Experimental|Impulse technique in rotation of cervical level 3 and 4|The thumbs position the head in a double chin and then place it with neutral flexion-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
10186816|NCT03732222|Experimental|Combined technique of diaphragm muscle stretch and cervical ro|combine both previous techniques.
10186817|NCT03732183|Experimental|Podcast SMART-3RP|"The mind body intervention is delivered by podcast and material posted online. All session content will be audio recorded into 15-min audio-recordings that will be delivered on a podcast platform. During the course of the 4-week program, one new podcast session will be delivered every day."
10186818|NCT03732170|Experimental|TotalFill® Bioceramic sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
10186819|NCT03732170|Active Comparator|AH plus® sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
10186820|NCT03732157||outpatient management of parathyroidectomy|
10186821|NCT03732157||conventional management of parathyroidectomy|
10186822|NCT03732144|Experimental|Connect Staff-based PA intervention|Sites receiving the Connect physical activity intervention will involve three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum.
10186823|NCT03732144|Other|Connect Health Curriculum Control|Sites receiving the general health curriculum control will also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff.
10186824|NCT03732105|Experimental|Radiotherapy|Patients in radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization. After radiotherapy, patients on the control arm will be actively monitored.
10186825|NCT03732105|Experimental|Apatinib|Patients in apatinib group will receive oral apatinib at an initial dose of 500mg daily until recurrence,death, patient withdrawal or unacceptable toxic effects.
10186826|NCT03732105|Experimental|Radiotherapy and apatinib|Patients in radiotherapy+apatinib group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50 Gy/25 fraction after randomization and after radiotherapy they will receive oral apatinib at an initial dose of 500mg/qd until recurrence,death,patient withdrawal or unacceptable toxic effects.
10186827|NCT03732105|No Intervention|Control group|Patients on the control arm will be actively monitored after randomization.
10186828|NCT03732092||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
10186829|NCT03732079||Research group|Women with early postpartum hemorrhage.
10186830|NCT03732079||Control group|Postpartum women without abnormal bleeding.
10186831|NCT03732066|Experimental|Intervention Group|The intervention group will receive usual text messages, personalized reminders and interactive responses.
10186832|NCT03732066|Other|Control Group|The control group will receive usual text messages only.
10169170|NCT03904823|Experimental|famitinib, HS-10296|
10169171|NCT03905161||Myasthenia patients|Danish patients with myasthenia gravis seen at the Department of Neurology, Rigshospitalet
10169172|NCT03904797|Experimental|e-PRO|EI service coordinators participated in a 90-minute training on the study protocol, to gain clearance to recruit families when they were being contacted to schedule their annual reviews of progress. The recruitment protocol was later modified in response to low enrollment, such that a designated EI staff member was paired with research staff to recruit participants. Eligible and interested caregivers visited the project website to create an account, confirmed study eligibility, provided informed consent and HIPAA authorization for abstracting select EI service use data, and completed a demographic questionnaire and the Young Children's Participation and Environment Measure (YC-PEM) e-PRO. Caregivers received immediate access to an online report summarizing their e-PRO responses to share with their child's EI team
10169173|NCT03904784||School withdrawal teenagers|The study is based on questionnaries, interview with teenagers and/or their familly
10169174|NCT03904680|Active Comparator|Methotrexate|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week for 3 months.
9974946|NCT05027048|Placebo Comparator|Saline placebo|"60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.~This intervention occurs IN ADDITION TO standard care with oxytocin 2 unit bolus and infusion at 7.5 units per hour which begins immediately after fetal delivery."
10169175|NCT03904680|Active Comparator|Methotrexate and Vitamin D|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week and Vitamin D intramuscular injections with the dose of 200,000 IU per month for 3 months.
10169176|NCT03904576|Experimental|Treatment (T)|
10169177|NCT03904576|Placebo Comparator|Reference Treatment (R)|
10169178|NCT03904589||Coronary Heart Disease|
10169179|NCT03904485||SPKT|patients with end-stage diabetic nephropathy got simultaneous pancreas-kidney transplantation
10169180|NCT03904485||RT|patients with end-stage diabetic nephropathy got single kidney transplantation
10169181|NCT03904511|Experimental|Low Dose Souroubea-Platanus|190 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
10169182|NCT03904511|Experimental|High Dose Souroubea-Platanus|380 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
10169183|NCT03904511|Placebo Comparator|Placebo|Inert placebo in an identical vegicap to the experimental treatment groups. Administered once daily for 14 days.
10169184|NCT03904667||Watson on oncology recommends surgery|
10169185|NCT03904667||Watson on oncology does not recommend surgery|
9826500|NCT02420379|Experimental|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
10169186|NCT03904706|Experimental|Audits only|"Formalized audit teams with monthly meetings at each facility.~Audit Intervention phases:~Identification of facility leadership (i.e physicians or leading health care providers) to be trained on best practices in obstetric and perinatal care in the implementation of the audits.~Training of identified audit leaders (main investigator is typically a physician)~a. 5-day training workshop to include: i. Day 1: maternal death and near misses, perinatal, neonatal deaths and morbidity outcomes ii. Day 2: 'Three-delay' framework and identifying modifiable factors iii. Day 3: data collection and setting up the audit system iv. Days 4-5: mentoring on the identification of the audit teams and initiating audit implementation~Creating audit team (composed of at least two obstetricians, 2 pediatricians plus the main investigator)~Establishing and launching the audit cycle (monthly meetings)~Annual re-certification of audit leaders"
10169187|NCT03904706|Experimental|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
10169188|NCT03904706|No Intervention|Control|Monthly outcome data will be collected from health facilities where no audits will be conducted. Data from this group will help evaluate the effectiveness of the intervention arms on perinatal and neonatal mortality.
10169189|NCT03904459||cases|Children with juvenile idiopathic arthritis
10169190|NCT03904459||controls|healthy children
10169191|NCT03904654|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 60-minute consecutive weekly MBCT group sessions.
10169192|NCT03904771|Active Comparator|Food for Mind -intervention group|Nutrition counselling + peer support
10169193|NCT03904771|Active Comparator|Befriending group -control group|Social activation + peer support
10169194|NCT03904719|Experimental|CM082 plus JS001|CM082 tablets 150mg is orally given once daily in a 28-day cycle, combinational JS001 240mg was given intravenously on day 1 once every 21 days.
10169195|NCT03904446|Experimental|Methylergonovine 0.2 mg|Standard Oxytocin Infusion at the time of Cesarean Section plus 0.2 mg of Intramuscular Methergine
10169196|NCT03904446|Placebo Comparator|Placebo (Normal Saline)|Standard Oxytocin Infusion at the time of Cesarean Section plus 1 milliliter (mL)of normal saline given intramuscular
9974947|NCT05023317|Experimental|Strengths-based linkage to alcohol care (SLAC)|SLAC is a behavioral intervention designed to link persons with substance use/misuse to a care or help option
10169197|NCT03904433|Experimental|1. Sunflower oil|Sunflower oil (30 g)
10169198|NCT03904433|Experimental|2. Caprylic acid|Caprylic acid (20 g) + Sunflower oil (10 g)
10169199|NCT03904433|Experimental|3. Caprylic acid + Glucose|Caprylic acid (20 g) + Sunflower oil (10 g) + Glucose (50 g)
10169200|NCT03904433|Experimental|4. Coconut oil|Coconut oil (30 g)
10169201|NCT03904433|Experimental|5. Coconut oil + Glucose|Coconut oil (30 g) + Glucose (50 g)
10169202|NCT03904433|Experimental|6. Coconut oil + Caprylic acid|Coconut oil (30 g) + Caprylic acid (20 g)
10169203|NCT03904745|Experimental|Atosiban used before embryo transfer|the patients in this group will be administered 6,75mg atosiban intravenously.
10169204|NCT03904745|No Intervention|Control group|the patients in this group will not be administered atosiban before embryo transfer.
10169205|NCT03904602|Experimental|Edema Wear|Edema Wear fuzzy wale compression garment worn on lower extremities continuously for 5 days or until discharge if less than 5 days.
10169206|NCT03904394|Placebo Comparator|Placebo Mouthwash|
10169207|NCT03904394|Active Comparator|Antibacterial Mouthwash|
9671718|NCT05044351|Experimental|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted thyroid lobectomy
10169208|NCT03904563|Experimental|Bevacizumab|All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with 6 courses of Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for 6 courses.
10169209|NCT03904758|Experimental|Monitoring of pH with Restech|The patients with EER randomized into this arm will undergo pH monitoring using Restech system
10169210|NCT03904758|Experimental|Monitoring of oesophageal impedance|The patients with EER randomized into this arm will undergo monitoring of oesophageal impedance
10169211|NCT03904732||Cohort 1|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for primary prevention
10169212|NCT03904732||Cohort 2|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for secondary prevention
10169213|NCT03904732||Cohort 3|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for primary prevention
10169214|NCT03904732||Cohort 4|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for secondary prevention
10169215|NCT03904732||Cohort 5|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for primary prevention
10169216|NCT03904732||Cohort 6|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for secondary prevention
10169217|NCT03904732||Cohort 7|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for primary prevention
10169218|NCT03904732||Cohort 8|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for secondary prevention
10169219|NCT03904407|Experimental|Probiotic|Lactobacillus probiotic capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
9671719|NCT05044351|Active Comparator|(B): Conventional surgery|Patients undergoing conventional thyroid surgery without NIRAF-assistance
9671720|NCT05044299|Active Comparator|Isoped mobilization with resistance load|Use of Isoped with movement at 3 levels of resistance load: zero, low, high, each condition lasts 3 minutes at 9 minutes total work
9671721|NCT05044299|Active Comparator|Isoped mobilization without resistance load|Use of Isoped with movement at zero resistance load lasts 9 minutes of work
9671722|NCT05044416|Experimental|VieScope|intubation with the VieScope laryngoscope
9671723|NCT05044416|Active Comparator|Videolaryngoscopy|intubation with videolaryngoscope
9671724|NCT05044208||No atrial fibrillation detected|In this cohort, AF is not detected in 7-day ECG monitoring or 2-years follow-up period
9671725|NCT05044208||Atrial fibrillation detected|In this cohort, AF is detected in 7-day ECG monitoring or 2-years follow-up period
9671726|NCT05044130|Active Comparator|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD~MR spectroscopy verified steatosis"
9671727|NCT05044130|Active Comparator|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD~MR spectroscopy verified no steatosis"
9671728|NCT05043935|Experimental|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
9671729|NCT05043935|Active Comparator|antimicrobial photodynamic therapy|Application antimicrobial photodynamic therapy in the defect
9671730|NCT05044026||JAK inhibitor naive|JAK-inhibitor-naive patients
9671731|NCT05044026||Pretreated patients|Patients pretreated for at least 8 weeks with one or more JAK-inhibitors (Jakavi® or otherwise)
10169220|NCT03904407|Placebo Comparator|Placebo|Matching Lactobacillus probiotic placebo capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
10169221|NCT03904537|Experimental|PD1-TIL combined with chemotherapy|Participants would received anti-PD-1 antibody-activated TILs after the final adjuvant chemotherapy.
10169222|NCT03904472|Experimental|Web-based CBTI|Participants will have 8 weeks to receive 6 therapy sessions. Content is dynamically driven by an animated therapist who guides the user through the program.
10169223|NCT03904641|Experimental|aPDT + ART group|In this group, both aPDT and ART will be performed.
10169224|NCT03904641|Experimental|ART group|In this group, only ART will be performed.
10169225|NCT03904628|Experimental|150 mg, BIW in every 28d|TG02 capsules were given orally at 150 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
10169226|NCT03904628|Experimental|200 mg, BIW in every 28d|TG02 capsules were given orally at 200 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
10169227|NCT03904628|Experimental|250 mg, BIW in every 28d|TG02 capsules were given orally at 250 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
10169228|NCT03904355|Active Comparator|Fiboroid group|Women with intramural myoma no reaching the cavity
10169229|NCT03904355|Active Comparator|Non fibroid group|Women without myomas
10169230|NCT03904290|Other|Pre-PFO closure|Subjects evaluated at 'baseline' prior to percutaneous closure of PFO, and re-evaluated at 3 months post percutaneous closure of PFO
10169231|NCT03904368|Active Comparator|Myomectomy group|women with intramural myoma not reaching endometrial cavity will undergo open myomectomy followed by ovarian stimulation for in vitro fertilization 6 months after the operation
10169232|NCT03904368|Active Comparator|Conservative group|women with intramural myoma not reaching endometrial cavity will undergo ovarian stimulation for in vitro fertilization
10169233|NCT03904303|Experimental|Geloprep|Novel and patented Polyethylene glycol 3350 mixture
10169234|NCT03904303|Active Comparator|Moviprep|Standard of care Polyethylene glycol 3350 mixture
10169235|NCT03904160|Sham Comparator|Nurse-lead group|Nurse-lead sessions for weight management. Ten sessions lasting 90 minutes each in three groups of 10-14 participants. Each session comprise education about healthy diet, psychoeducation and discussions.
10169236|NCT03904160|Experimental|Web-based group|Web-based weight management system with peer-based conversation possibility. Three groups of 10-14 participants who gather together for three nurse-lead sessions in the weeks 0, 5, and 12. The web-based program can be used for a year.
10169237|NCT03904160|Experimental|Web-based personal|Web-based weight management system with conversation possibility with the nurse for 12 weeks. Altogether 37 participants who can use the web-based weight management system for one year.
10169238|NCT03904186|Experimental|QUIT Treatment for Smoking Cessation and Distress Tolerance|Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
10169239|NCT03904186|Active Comparator|Time and Intensity-Match Control|Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.
10169240|NCT03904186|No Intervention|Standard of Care|At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
10169241|NCT03904342|Active Comparator|Sophie CBT|The Sophie Cognitive Behavioral Therapy (CBT) intervention is a tablet-based computerized CBT and self-management education intervention that consists of an evidence-based cognitive behavioral therapy self-management curriculum divided into 6 discrete modules. Patients will have up to 8 weeks to work through the modules on the tablet.
10169242|NCT03904342|Active Comparator|iHope CBT|iHope CBT is a telemedically-delivered CBT package. The iHope system comprises a HIPAA-compliant platform on which real, live, licensed clinicians provide cognitive behavioral therapy via video conferencing, phone calls, and text messaging. iHope will be delivered on subjects' preferred electronic device (mobile phone, laptop, tablet).
10169243|NCT03903978|Experimental|CORE condition|CORE is a 6-week web-based prevention programme whose main objective is to teach coping skills and strategies to cope with stressful everyday situations in order to improve resilience, promote self-efficacy and increase well-being. The intervention consists of 6 interactive modules designed for weekly sessions and organized in 6 dimensions: autonomy, self-acceptance, environmental mastery, purpose in life, positive relationships, and personal growth. Each module includes exercises to practice the proposed skills. The program includes multimedia elements: videos, audios, vignettes, images.
10169244|NCT03903978|Active Comparator|Healthy lifestyle|This program will provide information to promote a healthy lifestyle, on issues related to physical and mental health and physical activity, as well as diet and sleep management. The components of psychoeducation are based on the intervention protocol for depression (Castro, et al. 2015) based on low intensity psychological intervention models for mild or moderate depressive symptoms in primary care (Garcia-Herrera et al 2011; NICE, 2009; Nieuwsma et al 2012).
10169245|NCT03903978|No Intervention|Waiting List Control|Participants assigned to the Waiting List control group will be evaluated and monitored at the start of the study, 4 weeks, 8 weeks and follow-ups at 3 months. After the last follow-up evaluation, they will be given access to CORE training.
10169246|NCT03903952|Other|Papanicolaou smear result (control group)|women who did not have intraepithelial neoplasia as a result of smear
10169247|NCT03903952|Other|Papanicolaou smear result (study group)|women who have atypical squamous cells of undetermined significance (ASCUS) as a result of smear
10169248|NCT03904082|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4 vertebral level will performed preoperatively to patients in the ESP group (Group I).
10169249|NCT03904082|Active Comparator|Serratus Anterior Plane Block Group (SAP)|Single- shot ultrasound (Esaote Mylab30 )guided SAP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) the T4 vertebral level will performed preoperatively to patients in the SAP group( Group II).
10169250|NCT03904082|Placebo Comparator|Control Group|The Control group receive no intervetion ( Group III).
10169251|NCT03904108|Experimental|Ramucirumab|Ramucirumab 10 mg/kg IV day 1, every 3 weeks for 4 cycles
10169252|NCT03903913|Experimental|Dose Escalation Study|"Subjects will receive up to three inhaled doses of S- 1226. Each dose will be administered over a 2-minute treatment period (with a minimum 2-minute break between treatments) with a nebulizer as follows.~Three S-1226 formulations will be tested sequentially:~S-1226(4%) is composed of 3 mL PFOB and 4% CO2~S-1226(8%) is composed of 3 mL PFOB and 8% CO2~S-1226(12%) is composed of 3 mL PFOB and 12% CO2~Each formulation will be administered by inhalation for a period of 2 minutes.The nebulizer will be filled with 3 mL of PFOB. The nebulizer is connected to a compressed medical gas mixture consisting of either 4%, 8% or 12%, CO2. A driving pressure of 20 psi will be used, producing a gas flow rate of 9 L/min."
10169253|NCT03903913|Experimental|Daily Dosing Study|"Eligible subjects will receive S-1226 twice daily for 5 consecutive days. Subjects will receive up to three doses of S-1226 in the morning and afternoon, administered over three 2-minute periods with a Circulaire nebulizer, filled with one of the dosages outlined below, depending on the safety and tolerability data gathered from the dose escalation study for that particular subject.~S-1226(4%) is composed of 3 mL PFOB and 4% CO2~S-1226(8%) is composed of 3 mL PFOB and 8% CO2~S-1226(12%) is composed of 3 mL PFOB and 12% CO2"
10169254|NCT03903926|Experimental|Cohort one|5000 volunteers (6-35 months)-EV71 vaccine
10169255|NCT03903926|No Intervention|Cohort two|10000 unvaccinated volunteers (6-35 months)
10169256|NCT03903926|No Intervention|Cohort three|500 unvaccinated volunteers (36-71 months)
10169257|NCT03904277||No PFO|Research subjects who present no evidence of PFO - IE no appearance of saline contrast microbubbles within 3 cardiac cycles
10169258|NCT03904277||Small PFO|Research subjects who present evidence of having a small PFO or ASD - IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles
10169259|NCT03904277||Large PFO|Research subjects who present evidence of having a large PFO - IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.
10169260|NCT03903991||Thoracotomy|All patients needing pulmonary surgery under thoracotomy
10169261|NCT03904251|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT."
10169262|NCT03904030|Experimental|Anti-Gravity Treadmill rehabilitation|Patients in the intervention group are participating to the Alter G exercises (n=27). The groups are randomized, so after patients have signed consent, an envelop will be opened and there can be seen in which groups patients will participate.
10169263|NCT03904030|Active Comparator|Traditional rehabilitation|Traditional exercises with instructions are given to the patients (n=27) (as a control group).
10169264|NCT03904212|Active Comparator|Adipose tissue injection|Patients will be treated with freshly harvested autologous adipose tissue
10169265|NCT03904212|Placebo Comparator|Placebo|Patients will be treated with saline
10169266|NCT03903848|Experimental|Exercise session|One session of physical exercise
10169267|NCT03904225|Experimental|tegio|Tegio 60mg bid d1-28 q6wks was administered until disease progression, unacceptable toxicity,or over 12monthes within 3monthes after curative chemoradiation
10169268|NCT03904225|No Intervention|control|patients was oberved
10169269|NCT03904238|Experimental|CBT-H (Individual format)|Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
10169270|NCT03904238|Experimental|CBT-H (Group format)|Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
10169271|NCT03903835|Active Comparator|Control: Standard Care|Randomization between assignment to the control arm or the biomarker driven arm will be stratified on biomarker signatures, previous treatment, and fraction of ctDNA and will therefore occur after the results from the ctDNA profiling is obtained. Patients in the control arm will receive standard of care following national guidelines.
10169272|NCT03903835|Experimental|Treatment 1: Enzalutamide|Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature. Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment of Abiraterone or Enzalutamide.
10169273|NCT03903835|Experimental|Treatment 2: Abiraterone|Patients with an intact androgen receptor (AR) and without TP53 mutations will have an increased chance of being randomised to treatment of Abiraterone or Enzalutamide.
10169274|NCT03903835|Experimental|Treatment 3: Carboplatin|DNA-repair deficient patients will have an increased chance of receiving Carboplatin.
10169275|NCT03903835|Experimental|Treatment 4: Cabazitaxel|Patients with the TMPRSS2-ERG gene fusion will have increased chance of receiving chemotherapy at study onset.
10169276|NCT03903835|Experimental|Treatment 5: Docetaxel|Patients with the TMPRSS2-ERG gene fusion will have increased chance of receiving chemotherapy at study onset.
10169277|NCT03903835|Experimental|Treatment 6: Niraparib plus Abiraterone acetate plus Prednisone|DNA-repair deficient patients will have an increased chance of receiving the combination treatment with Niraparib plus Abiraterone acetate plus Prednisone.
10169278|NCT03903965||diabetic patients after cataract surgery|diabetic patients after cataract surgery
10169279|NCT03903965||non-diabetic patients after cataract surgery|non-diabetic patients after cataract surgery
10169280|NCT03903900|Experimental|Intervention group|Adults with chronic pain (n=48) matching the inclusion and exclusion criteria will be included.
10169281|NCT03903861|Experimental|Glucose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
10169282|NCT03903861|Experimental|Galactose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
10169283|NCT03903861|Experimental|Glucose and galactose|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
10169284|NCT03904056|Active Comparator|ETDRS-PRP group|Patients with proliferative diabetic retinopathy submitted to panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
10169285|NCT03904056|Experimental|ISQ-RP group|Patients with proliferative diabetic retinopathy submitted to retinal photocoagulation targeted to ischemic retina combined with intravitreal injection of ranibizumab (IVR) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
10169286|NCT03903887|Experimental|PD1-TIL combined with chemotherapy|Participants would receive anti-PD1 antibody-activated TILs after the final cycle of adjuvant chemotherapy.
10169287|NCT03904095|Active Comparator|Psoas compartment block group (PCB)|Single- shot ultrasound (Esaote Mylab30) guided PCB with 15 ml 0.25% bupivacain ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the PCB group (Group I).
10169288|NCT03904095|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the ESP group (Group II).
10169289|NCT03904095|Placebo Comparator|The Control group|The Control group receive no intervention ( Group III).
10169290|NCT03904004||Esophageal motility disorders|Individuals with sympmtoms related to esophageal motility disorders who receive a endoscopic or surgical treatment
10169291|NCT03903809|Experimental|HS-20039 Pegol-Sihematide|Pegol-Sihematide's starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 13 doses
10169292|NCT03903809|Active Comparator|ReHuman Erythropoietin Injection|ESPO(Recombinant Human Erythropoietin Injection) ESPO's starting dose was 6000 IU per week
10169293|NCT03903796|Experimental|HS-10234 25mg|HS-10234 + TDF placebo for up to 96 weeks
10169294|NCT03903796|Active Comparator|TDF 300mg|TDF + HS-10234 placebo for up to 96 weeks
10169295|NCT03903796|Experimental|Open-label HS-10234|All participants who complete the double-blind period (96 weeks) will be eligible to receive open-label HS-10234 until week 144 of the study.
10169296|NCT03903718|Experimental|MEDI8852 (dose 1) - part 1|Participants will receive a single intravenous infusion (IV) of MEDI8852 (dose 1)
10169297|NCT03903718|Sham Comparator|Placebo - part 2|Participants will received a single IV infusion of placebo ( matched to MEDI8852) on day 2
10169298|NCT03903718|Active Comparator|Oseltamivir (OS) 75 mg - part 2|Participants will receive 75 mg orally twice a day for 5 days starting at day 2
10169299|NCT03903718|Experimental|MEDI8852 (dose 2) - part 2|Participants will receive a single IV dose of MEDI8852 on day 2 (dose 2)
10169300|NCT03903718|Experimental|MEDI8852 (dose 1) - part 2|Participants will receive a single IV infusion of MEDI8852 on day 2 (dose 1)
10169301|NCT03903718|Experimental|MEDI8852 (dose 2) +OS 75 mg part 2|Participants will receive a single IV infusion of MEDI8852 (dose 2) on day 2 and 75mg of Oseltamivir twice a day for 5 days starting at day 2
10169302|NCT03903770|Experimental|Intervention|Upper extremity rehabilitation
10169303|NCT03903783|Active Comparator|Cefotaxime|
10169304|NCT03903783|Active Comparator|Ceftriaxone|
10169305|NCT03903757||Obese subjects with and without T2D|
10169306|NCT03903757||control subjects|
10169307|NCT03903679|Active Comparator|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway supreme during the septal surgery.
10169308|NCT03903679|Sham Comparator|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
10169309|NCT03903705|Experimental|VEGFR cohort:|Fruquintinib
10169310|NCT03903666|Experimental|Cohort|47 Down syndrome patients age from 4 to 16
10169311|NCT03903640|Experimental|Optune + Ipilimumab + Nivolumab|"Ipilimumab at 3 mg/kg IV over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.~Nivolumab at 1 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle for 4 cycles, then at 240 mg IV over 30 minutes on Days 1 and 15 of each 28-day cycle for up to 20 doses~Within 2 weeks of the start of ipilimumab (before or after), treatment with Optune will begin. All patients will be required to shave their heads to initiate array placement and Optune therapy.~Treatment may continue for up to 1 year"
10169312|NCT03903419|Experimental|68Ga-PSMA PET-CT and 18F-FDOPA PET-CT|Functional imaging: 68Ga-PSMA and 18F-FDOPA PET-CT Immunohistochemistry of initial chirurgical sample with determination of PSMA expression
10169313|NCT03903627|Experimental|Verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~(1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.~Those who will not be able to contract will be taught by the ultrasound as a biofeedback."
10169314|NCT03903614|Experimental|Sensory Motor Lateralization (SML)|This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
10169315|NCT03903614|Active Comparator|Conventional School-Based OT (CON)|This was a group of 8 junior high school students who received conventional school-based Occupational Therapy service for handwriting difficulty during the 2012-13 School Year. The participants received a like fitness exercises, fine motor speed training, and handwriting practice on their dominant hand instead.
10169316|NCT03903562|Experimental|V503|V503 administered as a 0.5 mL intramuscular injection at Day 1, Month 2 and Month 6.
10169317|NCT03903380|Active Comparator|MT treatment + Usual care exercise|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where usual care exercise protocol will be introduced.~The manual therapy protocol that will be used is the one proposed by Beltrán-Alacreu et al. (2015). The mentioned protocol consist of specific passive movements in the facet cervical joints, global mobilization of the cervical spine and high-velocity technique in the thoracic región."
10169318|NCT03903380|Experimental|MT treatment + Augmented reality (AR) exercises|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where AR will be applied as an exercise method.~The same manual therapy protocol will be used for both groups.~For this group, the Microsoft HoloLens Development Edition device will be used, which is a holographic device that allows us to interact with high definition holograms in its environment. The application that will be used will be the Roboraid software, this app is a shooter, which requires the cervical movement to move the pointer and be able to play."
10169319|NCT03903445|Experimental|MaPa Kids|"Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids) Parenting training for parents of children aged 2-9~Program length: 8 consecutive weekly sessions~Incentive: PHP 500 or approximately £7 per participant~Participants: N=15 per group"
10169320|NCT03903445|Experimental|MaPa Teens|"Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens) Parenting training for parents of children aged 10-17~Program length: 9 consecutive weekly sessions~Adult Incentive: PHP 500 or approximately £7 per participant~Child incentive: PHP 300 or approximately £4 per participant~Participants: N=15 per group"
10169321|NCT03903588||Normal|Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.
10169322|NCT03903588||Glaucoma|Eyes that have been diagnoses with Glaucoma
10169323|NCT03903588||Retinal Disease|Eyes that have been diagnoses with a Retinal Disease
10169324|NCT03903393||preeclamptic women|systolic blood pressure(BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg; hypertension diagnosed after 20 weeks gestation; new-onset hypertension with new-onset proteinuria or other signs/symptoms of preeclampsia after 20 weeks or chronic proteinuria with newonset hypertension.
10169325|NCT03903393||controls|Normal pregnant women
10169326|NCT03903471|Experimental|22G-ProCore Group|The experimental group with 22G-ProCore needle is expected to enroll 300 patients. The 22G-ProCore needle has a 1.5mm long groove 2.5mm above the needle tip, which is expected to have the advantage of taking more biopsy tissues than the 22G-Standard needle.
10169327|NCT03903471|Active Comparator|22G-Standard Group|The control group of 22G-Standard needle is expected to include 300 patients, and there is no groove above the needle tip compared with 22G-ProCore needle.
10169328|NCT03903367|Active Comparator|control|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
10169329|NCT03903367|Active Comparator|paravertebral block|Bilateral thoracic paraverteberal catheters will be inserted preoperative at level of T4 in order to block thoracic dermatomal levels from T3-T7 and 0.3ml/kg 0.25% bupivacaine bouls dose in each catheter maximum 20 ml in each catheter before induction and testing sensation bilaterally by pinprick and ice after 15-20min from injection then standard GA and after tracheal intubation continuous infusion of 0.1 ml /kg/h 0.25% bupivacaine in each catheter and stopped at the end of the operation , When HR or MBP increased ≥20% from base line readings, increamental dose of fentanyl will be given (2mcg /kg), the catheters will be removed after 24 h.
10169330|NCT03903458|Experimental|Tinostamustine and Nivolumab|Experimental drug combination arm
10169331|NCT03903302|Active Comparator|CS 1 I SAD|Single dose pharmacokinetics of CS1 I
10169332|NCT03903302|Active Comparator|CS 1 II SAD|Single dose pharmacokinetics of CS1 II
10169333|NCT03903302|Active Comparator|CS 1 III SAD|Single dose pharmacokinetics of CS1 III
10169334|NCT03903302|Active Comparator|CS 1 II MAD|Multiple dose pharmacokinetics of CS1 II
10169335|NCT03903484|Experimental|Deprescribing intervention|Included patient participants will meet with their clinical pharmacist to complete a survey about medication use and quality of life. Then working with the pharmacist, patients will prioritize medications that are no longer needed for discontinuing. A deprescribing plan will be created and the pharmacist will work with the patient to complete this plan. The patient will also be provided resources from the study toolbox to support the patients as they work through deprescribing the targeted drugs. Once the deprescribing plan is completed there will be a patient survey that will capture satisfaction with the deprescribing experience and patient quality of life.
10169336|NCT03903510|Experimental|Virtual Reality|Participants will experience Virtual Reality during their cast removal
10169337|NCT03903510|No Intervention|Standard of care|Participants will receive their usual standard of care treatment during cast removal
10169338|NCT03903575|Experimental|En Masse Retraction|Group treated by retracting the six anterior teeth simultaneously.
10169339|NCT03903575|Active Comparator|Two-Step Retraction|Group treated by retracting the canines incisors in two different steps.
9974948|NCT05023317|Active Comparator|Usual care|Usual care consists of brief intervention in primary care and/or standard referral to more intensive alcohol care (e.g., outpatient/inpatient, pharmacotherapy)
10169340|NCT03903432|Other|45 participants, in one center - Assuta|Patients with chronic sinusitis who are scheduled to undergo ESS at Assuta will be recruited and patients will sign an informed consent form for performing MRI (new protocol-without gadolinium injection) in addition to the routine CT.
10169341|NCT03903653|Active Comparator|Chemodenervation + Serial Casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection and weekly serial casting Intervention = Weekly Serial Casting AND Botulinum Toxin A injection (350-400 units per treated limb)
10169342|NCT03903653|Active Comparator|Chemodenervation without serial casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection. Intervention = Botulinum Toxin A injection (350-400 units per treated limb) alone.
10169343|NCT03903497|Other|NBI assessment using the WASP classification|
10169344|NCT03903276|No Intervention|Control|assessment of pain scale and functional capacity
10169345|NCT03903276|Experimental|Experimental|assessment of pain scale and functional capacity, TENS 30 minutes 3 sessions
10169346|NCT03903289|Experimental|Automated red cell exchange|Automated red cell exchange
10169347|NCT03903289|Active Comparator|Manual red cell exchange|Manual red cell exchange
10169348|NCT03903289|Sham Comparator|Simple red cell transfusion|Simple red cell transfusion
10169349|NCT03903549|Experimental|Brain uptake and kinetics in Parkinson patients|
10169350|NCT03903549|Experimental|Brain uptake and kinetics in healthy volunteers|
10169351|NCT03903549|Experimental|Dosimetry in healthy volunteers|
10169352|NCT03903250|Placebo Comparator|Sugar|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
10169353|NCT03903250|Experimental|A-GPC|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
10169354|NCT03903601||Ischemic changes|Patients with ischemic changes in the brain diagnosed by MRI
10169355|NCT03903601||No ischemic changes|Patients without ischemic changes in the brain diagnosed by MRI
10169356|NCT03903185|Active Comparator|HCV-infected patients with hematological malignancy|HCV-infected patients with hematological malignancy on maintenance chemotherapy
10169357|NCT03903185|Active Comparator|Control HCV-infected patients|Control HCV-infected patients without haematological malignancy or co-morbidities.
10169358|NCT03903029||Low-dose (10mg) rosuvastatin|Four statin benefit groups per 2013 ACC/AHA guideline in Korea
10169359|NCT03903224|Active Comparator|Combined PECS II and TTP blocks (PT)|"Modified Pectoralis block (PECS II) : Using ultrasound we proceed to inject 10 ml of bupivacaine 0.25% between the pectoral muscles and 10 ml under Pmm above the serratus muscle.~Transversus Thoracic Plane block : 10 mL bupivacaine (0.25%) is injected between the transversus thoracic muscle and the internal intercostal muscle between the third and fourth left ribs connecting at the sternum."
9974949|NCT05002881|Active Comparator|Moringa oleifera (E-HS-01)|One capsule to be taken stat
9974950|NCT05002881|Placebo Comparator|Placebo|One capsule to be taken stat
9974951|NCT05002049|Experimental|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the SEEDS project, and participants will be assessed at baseline and end-of-study.
10169360|NCT03903224|Active Comparator|Erector Spinae Block (E)|Using ultrasound an echogenic 22-G block needle is inserted in-plane in a cranial-to-caudal direction until contact is made with the T5 transverse process. A total of 30 bupivacaine 0.25% is then injected while seeing the fluid lifting the erector spinae muscle off.
10169361|NCT03902899|Experimental|Intervention-arm|"All endoscopists employed by 9 semi-randomly chosen hospitals in the Netherlands will be exposed to an educational intervention (oral presentation): an oral awareness training which will be delivered twice, first in 2014 and then in 2016/2017.~In total 38 endoscopists are included from these 9 hospitals."
9671732|NCT05043987|Experimental|Part A|"Part A will follow the standard 3+3 dose-escalation design and will be enrolled at dose levels of CPO102 at (0.5, 1, 1.8, 2.5, 3.5, 4.5, 5.5 mg/kg).~Each subject group will receive one dose of CPO-102 every 3 weeks (1 cycle=21 days=1 treatment). For each cohort, the decision whether to dose-escalate will be made once all patients have been enrolled into the cohort and the last patient enrolled has been followed for 21 days (3-week DLT observation period)."
9671733|NCT05043987|Experimental|Part B-Arm 1|Upon attaining a RP2D, Part B-Arm 1 will include approximately 15 patients with pancreatic cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
9671734|NCT05043987|Experimental|Part B-Arm 2|Upon attaining a RP2D, Part B-Arm 2 will include approximately 15 gastric (including gastric esophageal junction) cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
9671735|NCT05043948||Coronary Artery Disease_collateral flow grade 2|
9671736|NCT05043948||Coronary Artery Disease_collateral flow grade 0|
9671737|NCT05043948||Peripheral Artery Disease_collateral flow grade 2|
10169362|NCT03902899|No Intervention|Control arm|A random set of 100 endoscopists will be selected ass a reference group. These 100 endoscopists were unaware of the present study, and were thus blinded for their allocation.
10169363|NCT03903133|Other|vitamin E supplementation|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
10169364|NCT03902912|Experimental|prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
10169365|NCT03902925|Experimental|Group 1- Sub-tenon plus lidocaine jelly|Patients are going to be submitted to lidocaine 2% jelly topical anesthesia for 5 minutes then to sub-tenon injection of 2-4 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
10169366|NCT03902925|Active Comparator|Group 2- peribulbar|Patients are going to be submitted to peribulbar injection of 4-6 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
10186833|NCT03732053|Experimental|GPR Intervention Research group|A total of 135 subjects with AD in the mild or moderate phase participated in the study from which 90 pertain to research group.The intervention implemented to the patients with AD was the Global Postural therapy which lasted about 30-40 min in repeated sessions of 2 meetings per week by making 48 sessions in total during a six month period.
10186834|NCT03732053|No Intervention|Control Group|45 subjects of the study belongs to the control group which has not received the same treatment .
10186835|NCT03732040|Sham Comparator|standerd preventive measures|tooth brushing twice daily with fluoride tooth paste and dental flossing and mouthwash
10186836|NCT03732040|Experimental|miswak stick|use of miswak stick twice daily
10186837|NCT03732040|Experimental|Use of Miswak plus tooth brushing and tooth paste|use of miswak stick and tooth brush with fluoride toothpaste twice daily
10186838|NCT03732027|Active Comparator|Transversus Abdominis Block [TB] group|Patients will receive Surgical Transversus Abdominis Plane Block
10186839|NCT03732027|Active Comparator|Rectus Sheath Block [RB] group|Patients will receive Surgical Rectus Sheath Block
10186840|NCT03732001|Experimental|Anlotinib combined Docetaxel|patients treated with Anlotinib and Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
10186841|NCT03732001|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
10186842|NCT03731988|Experimental|5.5% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 5.5%, 350 µm ablation depth, level 1 coagulation and a single pulse
10186843|NCT03731988|Experimental|11% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 11%, 350 µm ablation depth, level 1 coagulation and a single pulse
9826501|NCT02420379|No Intervention|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
10186844|NCT03731988|Experimental|22% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 22%, 350 µm ablation depth, level 1 coagulation and a single pulse
9671738|NCT05043948||Peripheral Artery Disease_collateral flow grade 0|
10186845|NCT03731975|Active Comparator|CTZ Paste|Endodontic treatment with CTZ paste.
10186846|NCT03731975|Experimental|GP Paste|Endodontic treatment with Guedes-Pinto paste.
10186847|NCT03731962|Active Comparator|Developed Contrast Induced Nephropathy|Coronary Angiography
9826502|NCT02420639|Experimental|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
10186848|NCT03731962|Other|Without CIN|Coronary Angiography
9671739|NCT05043974|Experimental|Dry immersion|5 days of dry-immersion.
9826503|NCT02420691|Experimental|Treatment (ribociclib)|Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9826504|NCT02420873|Experimental|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
10169367|NCT03903107|Placebo Comparator|Conventional His Bundle Pacing|Patients in this arm will receive permanent his bundle pacing using conventional fluoroscopy technique
10169368|NCT03903107|Experimental|Fluoroless His Bundle Pacing|Patients in this arm will receive permanent his bundle pacing utilizing electroanatomic mapping system to eliminate or minimize fluoroscopic exposure
9520392|NCT03278158|Experimental|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
9520393|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
10169369|NCT03903146|Experimental|Intervention Group|This group of participants was assigned to receive the intervention by the bicultural/bilingual team of Peer counselor and Lactation Consultant. An intensive support intervention (1 prenatal visit, 1 in-hospital visit, 1 home postpartum visit, and free phone calls) were conducted individually to mothers participating until 6 months after the birth of the infant.
10169370|NCT03903146|No Intervention|Control Group|All participants in this group received traditional prenatal care in the clinic and received the usual educational material (in their proficient language) about breastfeeding during prenatal care provided by the Special Supplemental Nutritional for Women, Infants, and Children (WIC) program implemented in the clinics. Women were also able to receive one breastfeeding consultation during their hospital stay in the birthing center as part of the actual protocol established in the UK Chandler Hospital (Baby-friendly Hospital that includes support of breastfeeding during hospital stay). Women in the usual care group did not have any contact with the study IBCLC/PC.
10169371|NCT03903081|Experimental|100 mg single dose|It includes two groups, one group is pilot study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=2) . Another group is formal study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=8) or matching placebo (N=2)
10169372|NCT03903081|Experimental|300 mg single dose|Healthy subjects, receiving a single dose of 300 mg HEC110114 tablet (N=8) or matching placebo (N=2)
10169373|NCT03903081|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
10169374|NCT03903081|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC110114 tablet (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study
10169375|NCT03903081|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg HEC110114 tablet (N=8) or matching placebo (N=2)
10169376|NCT03903081|Experimental|1200 mg single dose|Healthy subjects, receiving a single dose of 1200 mg HEC110114 tablet (N=8) or matching placebo (N=2)
10169377|NCT03903081|Experimental|1600 mg single dose|Healthy subjects, receiving a single dose of 1600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
10169378|NCT03903081|Experimental|600 mg multiple doses|Healthy subjects, receiving 600 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
10169379|NCT03903081|Experimental|800 mg multiple doses|Healthy subjects, receiving 800 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
10169380|NCT03903081|Experimental|1000 mg multiple doses|Healthy subjects, receiving 1000 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
10169381|NCT03903211|Experimental|Cognitively normal individuals|Cognitively normal individualswill receive a single IV injection of [18F]PI-2620.
10169382|NCT03903211|Experimental|Subjects with Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment will receive a single IV injection of [18F]PI-2620.
10169383|NCT03903211|Experimental|Subjects with Alzheimer Disease|Alzheimer Disease Subjects with Alzheimer Disease will receive a single IV injection of [18F]PI-2620.
10169384|NCT03903172|Experimental|Binder Arm|Abdominal binder + standard of care postpartum pain management
10169385|NCT03903172|No Intervention|Standard of Care|Standard of care postpartum pain managment
9520394|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
9520395|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
10169386|NCT03902834|Experimental|Intervention|
10169387|NCT03902990|Experimental|Dual task|Treadmill training + cognitive tasks + standard exercise programme
10169388|NCT03902990|Active Comparator|Single task|Treadmill training + standard exercise programme
10169389|NCT03902990|Active Comparator|Control|Standard exercise programme
9671740|NCT05044091||ovarian/fallopian tube/primary peritoneal cancer patients|ovarian/fallopian tube/primary peritoneal cancer patients treated with PAPRi for more than four weeks
10169390|NCT03902977|Experimental|Arm A|quilting
10169391|NCT03902977|Active Comparator|Arm B|conventional suture
10169392|NCT03903068|Experimental|NEXALIN Stimulator Group|In this study, the group is the treatment group. Patients are randomly assigned to participate, and patients will be given current parameters for setting time and flow.
10169393|NCT03903068|Sham Comparator|Pseudo-Stimulator Group|In this study, the group is the control group. Patients are randomly assigned to participate, and patients will be given simulated electrical stimulation.
10169394|NCT03903003|Active Comparator|preoxygenation mask applied to the cesarean|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
10169395|NCT03903003|Active Comparator|high flow nasal oxygenation applied to the ceserian|In order to protect the mother from hypoxia, preoxygenation is performed with high flow nasal oxygenation mask before induction of anesthesia.
10169396|NCT03902873|No Intervention|usual compression|A group who get no real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
10169397|NCT03902873|Active Comparator|real-time audiovisual feedback|A group who get the real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
10169398|NCT03902587||Cervical Elastography|During each sonogram in which cervical lengths are measured, 5 additional cervical indices will be collected using Samsung's E-cervix technology. Each index will then be separated based on characteristics to create a nomogram for singletons, twins, and those with interventions already in place (i.e. cerclage and/or progesterone) at the time of their E-cervix assessment.
10169399|NCT03902652|Experimental|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
10169400|NCT03902652|Active Comparator|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
10169401|NCT03902678|Experimental|EUS - FNA for benign PVT by imaging|Intervention: Procedure/Surgery: EUS guided fine needle aspiration of portal vein thrombus
10169402|NCT03902886||cerebral palsy infants|gait analysis
10169403|NCT03902886||typically developed infants|gait analysis
10169404|NCT03902730|Other|Back Squat Variation One|In a randomized order, traditional back squat will be completed.
10169405|NCT03902730|Other|Back Squat Variation Two|In a randomized order, barefoot back squat will be completed.
10169406|NCT03902730|Other|Back Squat Variation Three|In a randomized order, box squat will be completed.
10169407|NCT03902730|Other|Back Squat Variation Four|In a randomized order, traditional back squat with chains will be completed.
10169408|NCT03902795||Group of 62 eyes|Group of 62 eyes with rhegmatogenous retinal detachment who underwent successful vitrectomy with SF6 tamponade
10169409|NCT03902847|Experimental|Motor imagery|All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but previously, a mental practice based on kinesthetic mental motor imagery was performed. To reinforce the process of motor imagery, a video with the exercises was shown to the subjects before performing the mental practice. All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
10169410|NCT03902847|Experimental|Action observation|"All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but prior to the real execution, a video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.~All the participants also received a booklet with written information about the indications and exercises to be practiced at home to ensure that the training program was performed properly. Each week, participants received messages to remind and motivate them to undertake the exercise program daily."
10169411|NCT03902847|Active Comparator|Control group|The subjects in this group received an intensive training program based on stabilization exercises of lumbo-pelvic region, which are common exercises used in rehabilitation of patients with chronic non-specific low back pain.
10169412|NCT03902535||Group I (geriatric and quality of life assessments)|Patients complete comprehensive geriatric and quality of life assessments within 1-4 weeks of treatment (either upfront surgery which may be followed by radiation with or without chemotherapy or upfront radiation which may include CRT) initiation (baseline), and at 1, 3, and 6 months following CRT completion.
10169413|NCT03902535||Group II (quality of life assessment)|Family caregivers complete quality of life assessment at baseline, and at 1, 3, and 6 months following patient radiation or CRT completion.
10169414|NCT03902769|Experimental|No allogeneic SCT|For standard or intermediate risk AML patients who achieved good rapid response, allogenic SCT will be excluded from treatment plan
10169415|NCT03902769|Active Comparator|Standard post induction therapy|For slow responding AML patients, post induction therapy will be provided according to treating physician discretion
10169416|NCT03902691|Experimental|Pegol-Sihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks.
10169417|NCT03902691|Active Comparator|ESPO (Recombinant Human Erythropoietin Injection）|ESPO administration 1 to 3 times per week.
10169418|NCT03902782|Experimental|ESP block|patients will receive an ultrasound guided ESP block (technique as described by Forero et al) under strict sterile conditions in the operating room area. After identifying the T5 transverse process (TP) and after infiltration of lidocaine 2% subcutaneously. A 22g 100mm block needle will be advanced under vision, in a cephalad to caudad direction, until the tip contacts the T5 TP. 20 ml of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be injected under the erector spinae muscle. A visible separation of the erector spinae muscle from the TP will be the sign of a successful block. A 20 ml syringe of Normal Saline will be given to the surgeon (unaware of the content) at the end of the surgery, for the intercostal nerve block as per standard present technique.
10169419|NCT03902782|Sham Comparator|ESP sham block|patients will receive an ultrasound guided sham ESP block under strict sterile conditions in the operating room area as described above. 20 ml of Normal Saline will be injected under the erector spinae muscle. A 20 ml syringe of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be given to the surgeon (blinded to the content) at the end of the surgery for the intercostal nerve block.
9520396|NCT03278132|Experimental|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
9520397|NCT03278080|Other|driving test|
10169420|NCT03902496|Experimental|Avulux Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
10169421|NCT03902496|Sham Comparator|Sham Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
10169422|NCT03902457|Experimental|test site|The sinus mucosa will be elevated and, at the test sites, a collagen membrane will be placed subjacent the sinus mucosa
10169423|NCT03902457|Experimental|control site|The sinus mucosa will be elevated and, at the control sites, a collagen membrane will not be placed subjacent the sinus mucosa
10169424|NCT03902548|Experimental|Brain uptake and kinetics in Alzheimer's patients|
10169425|NCT03902548|Experimental|Dosimetry in healthy volunteers|
10169426|NCT03902626||Physiotherapy students|Degree course
10169427|NCT03902626||Medical students|Degree course
10169428|NCT03902327|Experimental|NAC group|NAC for 12 weeks, 1.6 mg/day, 4x400 mg; a diet based on general recommendations for people with carbohydrate metabolism disorder
10169429|NCT03902327|Active Comparator|Control group|Placebo for 12 weeks and a diet based on general recommendations for people with carbohydrate metabolism disorder
10169430|NCT03902665|Experimental|Allogeneic hematopoietic stem cell transplantation|Day -6, -5 Thiotepa 5 mg/kg/day . Day -4 to -3 Busulfan i. v 3,2 mg/kg/day and fludarabine i.v. 50 mg/m2 /day Day -2 fludarabine i.v. 50 mg/m2 Day -1 Rest Day 0 Begin cyclosporine; Infusion of T cell replete bone marrow transplant Day 1 Begin mycophenolate mofetil Day 3 and 5 Cyclophosphamide 50 mg/kg IV and Mesna Day 6 G-colony stimulating factor
10169431|NCT03902366||AUD+/HCV+|"With current Alcohol Use Disorder and with HCV~About to initiate DAA therapy for HCV"
10169432|NCT03902366||AUD-/HCV+|"Without current Alcohol Use Disorder and with HCV~About to initiate DAA therapy for HCV"
10169433|NCT03902366||AUD+/HCV-|-With Alcohol Use Disorder and without HCV
10169434|NCT03902366||AUD-/HCV-|-Without Alcohol Use Disorder and without HCV
10169435|NCT03902379|Experimental|Supportive Care (CCI intervention)|Patients complete 3 modules of online CCI intervention.
9520398|NCT03278054|Active Comparator|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
10169436|NCT03902470|Experimental|Thoracic epidural anaesthesia for vats|"Patients in thoracic epidural (TE) group will pre-medicated using midazolam 3-4 mg intravenous (IV)and fentanyl 50 mcg intravenously(i.v.). Then patients will placed in the lateral decubitus position. An epidural catheter will be inserted between T3-T4 and T4-T5 for all thoracic procedures except sympathectomy and thymectomy. A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5% and 50 mcg of fentanyl.~The objective is to achieve sensory and motor block between C7 and T7 levels. At this level diaphragmatic respiration is maintained. The anaesthesia level will be monitored by warm-cold discrimination."
10169437|NCT03902470|Active Comparator|General anesthesia for vats|Patients will receive general anesthesia as follows, Premedication in the form of 3-4 mg midazolam (IV), induction of a anesthesia with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation and double endotracheal tube insertion will be facilitated with cisatracurium 0.1 mg/kg. and confirmation of it is position will made by fiberoptic bronchoscopy, Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose).After the end of the operation, anesthesia will be discontinued, the wound dressing will be applied, and extubation of the patient will be done after reversal of muscle relaxant by neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg) and extubation will be performed after complete neuromuscular recovery.
10169438|NCT03902275|Experimental|Quantra|Evaluation of bloodsamples using the Quantra and Multiplate device
10169439|NCT03902275|Active Comparator|Control|Evaluation of bloodsamples using the ROTEM and Multiplate device
10169440|NCT03902522|Experimental|Leronlimab (PRO 140)|Subjects will be on existing ART for one week followed by PRO 140 700mg weekly SC Inj. + existing ART for the next week. Subsequently, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
10169441|NCT03902444||Credo® Stent and NeuroSpeed® PTA balloon catheter|Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine
10169442|NCT03902756|Experimental|Flow-Volume loop guided endotracheal cuff inflation|Endotracheal cuff will be inflated by Flow-Volume loop guided until getting proper sealing.
10169443|NCT03902756|Active Comparator|Stethoscope-guided endotracheal cuff infration|Endotracheal cuff will be inflated by Stethoscope-guided until getting proper sealing.
10169444|NCT03902743|Experimental|Intervention group|Participants will receive an Anticipatory Care Plan
10169445|NCT03902743|No Intervention|Control group|Usual care
9520399|NCT03278054|Active Comparator|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
9520400|NCT03278054|Active Comparator|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
9520401|NCT03278041|Experimental|surgical reconstruction with submental flap|surgical reconstruction with submental flap
10169446|NCT03902405|Active Comparator|Active CEASAR Intervention|"Participants will be given the active CEASAR intervention where they will be trained to avoid cues associated with stimulant use and approach healthy cues based on the orientation of the images presented. Individuals will be asked to approach (pull in) portrait images and avoid (push away) landscape images. In the active condition, pushed pictures (landscape orientation) will exclusively be stimulant-use related pictures. Conversely, healthy images will be in the portrait orientation which will be pulled in."
10169447|NCT03902405|Placebo Comparator|Placebo CEASAR|In the control condition, stimulant use-related pictures will be randomized and equally divided into push (landscape) and pull (portrait) conditions.
10169448|NCT03902288|Experimental|Patients with type 2 diabetes|Patients with type 2 diabetes at early stages of type 2 diabetes (FSG: 7.1 15.8 mmol/L)
10169449|NCT03902288|Active Comparator|Healthy individuals|Healthy individuals match age and gender to the experimental group
10169450|NCT03902106|Active Comparator|beta2-agonist and exercise|Subjects undergo exercise training with administration of salbutamol (800 microgram in 12 hours x 2)
10169451|NCT03902106|Sham Comparator|placebo and exercise|Subjects undergo exercise training with administration of sham placebo
10169452|NCT03902340|Experimental|TENS|Treatment by non-pharmacological transcutaneous electric nerve stimulation (TENS)
10169453|NCT03902340|Active Comparator|level 2 systemic analgesic treatments|Treatment by level 2 analgesic pharmacological treatment indicated in the treatment of chronic nociceptive pain of moderate to severe intensity.
10169454|NCT03902353|Other|Adults without diagnosis of PH|Adults without diagnosis of PH carrying an heterozygous EIF2AK4
10169455|NCT03902184|Experimental|Cohort 1: Relapsed/refractory Sezary Syndrome|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
10169456|NCT03902184|Experimental|Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
10169457|NCT03902184|Experimental|Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
10169458|NCT03902236||Cystic fibrosis group|Children diagnosed with cystic fibrosis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
9826505|NCT02420873|Experimental|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
10169459|NCT03902236||Bronchiectasis group|Children diagnosed with bronchiectasis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
10169460|NCT03902236||Healthy group|Healthy children more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
10169461|NCT03902158|Experimental|Glasses|
10169462|NCT03902158|No Intervention|Distraction techniques|No glasses will be used
10169463|NCT03902197|Experimental|CD19 hsCAR-T|This cohort will be administrated by T cells transduced with lentivirus vectors expressing CD19 hsCAR
10169464|NCT03902249|Active Comparator|Dexamethasone group|Patients who received 0.15mg/kg of Dexamethasone in 8ml of saline
10169465|NCT03902249|Placebo Comparator|Placebo group|Patients who received the same volume of saline as the study group (8ml)
10169466|NCT03902223|Experimental|Enhanced Screening Protocol For Cardiac Sarcoidosis|Arm will be randomly assigned to undergo enhanced screening methods (ambulatory ECG and echocardiogram) at month 0 and month 24, as well as a phone call/chart review at month 12.
10169467|NCT03902223|Active Comparator|Routine Screening for Suspected Cardiac Sarcoidosis|Arm will be randomly assigned for the routine standard of care/no intervention with enhanced screening methods. They will be offered the EKG and symptom check at months 0 and 24, as well as a phone call/chart review at month 12.
10169468|NCT03902145||Intervention Group|Children previously in the intervention group received one egg per day for 6 months beginning when the child was between 6-9 months of age.
10169469|NCT03902145||Control Group|
10169470|NCT03902119|Experimental|INIBY tool|Patients will undergo a single treatment session consisting of applying a suboccipital muscle inhibition technique using the so-called INYBI tool. The treatment session will last approximately 5 minutes
9826506|NCT02420873|Experimental|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
10169471|NCT03902119|Active Comparator|Manual suboccipital inhibition|Patients will receive a single treatment session consisting of the use of the manual suboccipital muscles inhibition technique.The treatment session will last approximately 5 minutes
10169472|NCT03902002|Experimental|Group 1: matched healthy subjects|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
10169473|NCT03902002|Experimental|Group 2: subjects with mild hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
10169474|NCT03902002|Experimental|Group 3: subjects with moderate hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
9520402|NCT03278041|Active Comparator|maxillary obturator|maxillary obturator
9826507|NCT02420951|Experimental|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
9826508|NCT02420951|Active Comparator|No Injection|Will not receive injection of bupivacaine prior to catheter removal
9826509|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
10169475|NCT03902002|Experimental|Group 4: subjects with severe hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
10169476|NCT03901885|Other|Major women operated for deep endometriosis|Major women operated for deep endometriosis at the Lyon Sud Hospital Center (CHLS) of the Hospices Civils de Lyon (HCL).
10169477|NCT03902041||Treatment Group|The patients will receive Eltrombopag treatment after transplantation at d1.
10169478|NCT03902041||Control Group|The patients will not receive Eltrombopag treatment after transplantation.
10169479|NCT03901937|Placebo Comparator|Placebo|parenteral nutrition without ω-3 polyunsaturated fatty acid
10169480|NCT03901937|Experimental|ω-3 fatty acid|parenteral nutrition with ω-3 polyunsaturated fatty acid
10169481|NCT03902067|Experimental|UC-MSC|UC-MSC transplantation
10169482|NCT03902067|Placebo Comparator|Control Group|Routine treatment
10169483|NCT03901872||Acute Iliofemoral DVT|Suitable patients would be invited to take part in this trial as part of standard of care.
10169484|NCT03902054|Experimental|Experimental Group - High dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV
10169485|NCT03902054|Experimental|Experimental Group - Medium dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV
10169486|NCT03902054|Experimental|Experimental Group - Low dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of low dosage investigational sIPV
10169487|NCT03902054|Active Comparator|Control Group -commercialized sIPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV
9671741|NCT05043922|Experimental|CYH33|40mg daily
9671742|NCT05044000|Experimental|Heavy blanket|Patients will start with heavy blanket during 15 days
9671743|NCT05044000|Placebo Comparator|Non-heavy blanket|Patients will start with non-heavy blanket during 15 days
10169488|NCT03902054|Active Comparator|Control Group -commercialized IPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV
10169489|NCT03902171||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
10169490|NCT03902171||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
10169491|NCT03901846|Other|ColdZyme|"The study is intended to verify the method used to measure the duration of ColdZyme®.~Each participant will be his own control as samples are taken before application of ColdZyme and used as an internal control."
9671744|NCT05043961||study group|"Patients who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study.~Intervention:~Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles"
10169492|NCT03901976|Other|Bed Exit Detection On|prevention of fall by a true bed exit detection
10169493|NCT03902015|Experimental|Nuance Phone case|"Nuance Hearing has developed a technology enabling focused hearing. The Selective Noise Cancellation (SNC) technology consists of an advanced beam-forming algorithm that tones down the ambient sound by up to 15 decibels (dB) in order to focus on a primary audio source. The device consists of a special phone case(for iPhone) containing microphone array. Controlling the direction of focus is enabled through the use of a designated app. The user can place the phone case on his/hers table and can choose the direction of preferred listening, without having to ask the talker to hold the device."
10169494|NCT03902210|Experimental|Online Yoga|The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes (6 manufactured specifically for the cancer-afflicted patients instructed by Udaya yoga therapist, Jules Mitchell, MS). Patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes. Participants will be instructed to view a safety handout (see yoga safety & modifications handout) before gaining access to the Udaya video library. Yoga therapist, Jules Mitchell and PIs Huberty and Palmer will pre-approve Udaya videos that are appropriate for this population.
10169495|NCT03902210|Placebo Comparator|Podcast|The podcast control group will be asked to view 60 minutes per week of online podcast videos. The podcast videos will contain general cancer-related health education material. To match the online yoga group for time and attention, 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a daily log (see podcast group weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.
10169496|NCT03902132|Experimental|Core Stability exercises group|Core Stability exercises
10169497|NCT03902132|Active Comparator|Traditional low back physical therapy group|Traditional low back physical therapy management
9671745|NCT05043766|Experimental|PF614|Part A will utilize a randomized, open-label, multiple-ascending dose design with up to 3 separate dose groups of 8 subjects. Within each dose group, subjects will be randomized to receive repeated BID doses, planned to be 12 hours apart over a 5 day period, for a total of 9 doses. Dose escalation to Dose Groups 2 and 3 will follow a review of pharmacokinetic, safety and tolerability data up to Day 10 of the preceding group. The doses or dosing regimen for Dose groups 2 and 3 may be modified based on a review of the data.
9826510|NCT02421055||Group 2|Sleeve Gastrectomy
9826511|NCT02421094|Active Comparator|GR-MD-02|Active
10169498|NCT03901820|No Intervention|DrApp Without SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
10169499|NCT03901820|Experimental|DrApp With SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (SIMDA).
10169500|NCT03901677|Experimental|Tai-chi training|Tai-chi training performe as a group exercise. Duration for tai chi exercise will be 60 minutes for 2 days per week for 12 weeks. Each session includes 10 min warm-up and cool-down and 40 min Tai Chi exercises. During exercises, attention paid to correct positioning of the upper and lower extremity joints, and mentally concentration achieve. Slow and controlled movements will carry out by a specialized physiotherapist.
10169501|NCT03901859||Patients with ADHD|drug-naive patients with ADHD, aged 7-18 year old
9520403|NCT03278015|Experimental|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
9671746|NCT05043766|Active Comparator|Part B Compare Bioavailability and Bioequivalence|"Part B will utilize an open-label, single-dose, randomized, 4-way crossover design. Following confirmation of eligibility, subjects will be randomized to receive each of the single oral doses of study drugs (one at each treatment period).~PF614 100 mg administered under fasted conditions; PF614 100 mg administered under fed conditions; OxyContin 40 mg administered under fasted conditions; OxyContin 40 mg administered under fed conditions"
9974952|NCT05002049|No Intervention|Control Group (No intervention)|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
10169502|NCT03901859||Healthy Controls|drug-naive healthy controls, aged 7-18 year old
10169503|NCT03901703|Active Comparator|Dorsiflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their dorsiflexor muscles alongside standard functional progressive strengthening exercises.
10169504|NCT03901703|Active Comparator|Plantarflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their plantarflexor muscles alongside standard functional progressive strengthening exercises.
10169505|NCT03901703|Active Comparator|Dorsiflexor and Plantarflexor Muscle strengthening Group|The children in this group will receive functional exercises aiming to strengthen both their dorsiflexor and plantarflexor muscles alongside standard functional progressive strengthening exercises.
10169506|NCT03901924|Active Comparator|Volume Support Mode Mechanical Ventilation|Volume support mode ventilation is a spontaneous mode where a target goal volume is set on the ventilator. This ventilatory strategy is dependent on patients spontaneously breathing and triggering (or activating) the ventilator to support the breath. The ventilator adjusts the amount of pressure support to deliver with each breath (i.e. if the patient's tidal volume is greater than the set target volume, then the ventilator will decrease the amount of pressure support in the subsequent breath to try to achieve the goal volume and vice versa). The respiratory rate is not set in this mode of ventilation and is dependent on the patient. For patients randomized to this mode, the goal tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
10169507|NCT03901924|Active Comparator|Assist Control Mode Mechanical Ventilation|In assist control mode ventilation, the machine is programmed to deliver a set tidal volume and set respiratory rate. Patients can breathe over the set respiratory rate, but the volume of breath that they receive is fixed and delivered by the ventilator. For patients randomized to this mode, the tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
10169508|NCT03901898|Experimental|Training, audit, and reminders|An investigator will deliver a 20-30-minute briefing on intervention delivery to all staff at participating practices, followed by one-on-one audit training (1 hour) with the staff member responsible for conducting the audit. Each practice conducts an audit of their patients with diabetes to identify all people who have not attended retinopathy screening with the national programme. At 6 months, practices conducts a re-audit. Practice staff add electronic alerts to the records of eligible patients, to prompt GPs and nurses to remind patients. Practices are reimbursed at study entry with further payment following intervention cessation based on number of patients audited. Face-to-face verbal reminders are delivered by GPs and practice nurses to eligible patients attending for an appointment during the study period. All eligible patients receive a reminder phone call from a practice nurse and a GP-endorsed reminder letter accompanied by an information leaflet.
10169509|NCT03901898|Other|Wait list control|In control practices, the intervention will be delivered after 6 months. For the audit, administrators or practice nurses will use date restricted data extraction from the electronic medical record to capture data for the 12-month period prior to the intervention (study baseline) and 6 months after the study intervention period, during which they will have acted as control practices (follow-up). This will satisfy the baseline data collection prior to the delivery of the intervention to this group on study completion. This approach was chosen as collecting data at baseline (i.e. 6 months before intervention start) would constitute an intervention in those practices; knowledge of non-attenders would lead to a change in usual care as the control group would likely follow up patients immediately. Control practices will receive the same supports and training as intervention practices.
10169510|NCT03901651|Active Comparator|Standard colonoscopy|"Patients submitted for screening, surveillance or diagnostic colonoscopy. A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location. Polyps will be removed before the second procedure."
10169511|NCT03901651|Experimental|Retroview colonoscopy|"The same group of patients. A second colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the first colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
10169512|NCT03901794||With Clear Sight|record and observe the data including SVI, CI, SVR with clearSight during hemodialysis
10169513|NCT03901989|Active Comparator|zeolite|50 subjects receive the substance 3 times per day as powder
9671747|NCT05043779|Other|Preoperative Awake Airway Nasoendoscopy|only one arm
9671748|NCT05043818||IBD patients with depression|IBD patients with depression
10169514|NCT03901989|Placebo Comparator|cellulose|50 subjects receive the substance 3 times per day as powder
10169515|NCT03901716|Experimental|Sufentanil|Group S received sufentanil 0.1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
10169516|NCT03901716|Experimental|Fentanyl|Group F received fentanyl 1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
10169517|NCT03901716|Experimental|Remifentanil|Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
10169518|NCT03901599||Children between 5-10Kg|Children with a body weight between 5-10Kg
10169519|NCT03901599||Children between 10-20Kg|Children with a body weight between 10-20Kg
10169520|NCT03901599||Children between 20-40Kg|Children with a body weight between 20-40Kg
10169521|NCT03901612|Placebo Comparator|Saline solution|Post operative analgesia throw the thoracic Erector spinae catheter with saline solution and opioid rescue
10169522|NCT03901612|Experimental|Ropivacaine|Post operative analgesia throw the thoracic Erector spinae catheter with Ropivacaine 0.2% solution and opioid rescue
10169523|NCT03901638|Experimental|Tllsh2910 to placebo|Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
10169524|NCT03901638|Experimental|Placebo to Tllsh2910|Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks
10169525|NCT03901430|Experimental|Class|Group navigation model
10169526|NCT03901417|Active Comparator|Non-ablative Fractional Laser|Non-ablative fractional laser (brand name Fraxel Restore) only on one half of the face.
10169527|NCT03901417|Active Comparator|Non-ablative Fractional Laser Plus Microneedling|Non-ablative fractional laser (brand name Fraxel Restore) in combination with a microneedling device (SkinPen) on the other half of the face.
10169528|NCT03901495|Experimental|Diaana|"The patient fullfill Diaana~The resident physician takes connaissance of the Diaana summary~The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
10169529|NCT03901495|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
10169530|NCT03901781|Experimental|Cohort One|Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
10169531|NCT03901781|Experimental|Cohort Two|Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
10169532|NCT03901781|Experimental|Cohort Three|Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
10169533|NCT03901625|Active Comparator|ManualTB+Floss|Cleaning teeth with a manual toothbrush and a dental floss three times a day.
10169534|NCT03901625|Experimental|ManualTB+Waterjet|Cleaning teeth with a manual toothbrush and a waterjet three times a day.
10169535|NCT03901625|Experimental|Electric TB+Floss|Cleaning teeth with an electric toothbrush and dental floss three times a day .
10169536|NCT03901625|Experimental|Electric TB +Waterjet|Cleaning teeth with an electric toothbrush and a waterjet three times a day .
10169537|NCT03901742|Active Comparator|Standard Enteral Nutrition|Standard Enteral Nutrition: cow's milk based infant formula (Nidina, Nestlé, Barcelona, Spain).
10169538|NCT03901742|Active Comparator|Protein-enriched nutrition|Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain)
10169539|NCT03901742|Active Comparator|High Protein-enriched Nutrition|High Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain) supplemented with 2.6 g of protein/100 mL of formula. The source of the protein supplement would be a nonhydrolyzed protein cow's milk-based formula (Resource Protein Instant; Nestlé, Barcelona, Spain). Final composition 5.1 g/100 mL.
10169540|NCT03901768|Experimental|Group dexamethasone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection
10169541|NCT03901768|Experimental|Group triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
10169542|NCT03901768|Experimental|Group dexamethasone with triamcinolone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection. 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
10169543|NCT03901768|Placebo Comparator|Placebo group|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
10169544|NCT03901482|Experimental|STS101 Low Dose|STS101 (dihydroergotamine nasal powder), low dose
10169545|NCT03901482|Experimental|STS101 High Dose|STS101 (dihydroergotamine nasal powder), high dose
10169546|NCT03901482|Placebo Comparator|STS101 Placebo|STS101 Placebo
10169547|NCT03901365|Experimental|Group 1|Patient received manual therapy in addition neuroscience pain education sessions
10169548|NCT03901365|Active Comparator|Group 2|Patient received manual therapy in addition tradition education sessions
10169549|NCT03901586|Experimental|Patients who had Richter intervention|
10169550|NCT03901391||Retinitis Pigmentosa|
10169551|NCT03901508|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
9520404|NCT03278015|Experimental|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
9826512|NCT02421094|Placebo Comparator|Placebo|Placebo
9826513|NCT02421120|Experimental|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
9826514|NCT02421146|Sham Comparator|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
10169552|NCT03901508|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
10169553|NCT03901547|Other|Education and Documentation (Tier 1)|Education only. Participants who do not wish to enroll in the behavioral observation group are followed in the education only. This includes participation in a two week palliative medicine elective which is a part of the medical trainees training and training in the serious illness communication guide (SICG). Participants can opt out of the pre and post training confidence surveys, and simulated patient encounters. Electronic documentation of the SICG by these trainees will be monitored prospectively. Participants will be provided reminders and profile information on their own documentation rate of the SICG via email and have the ability to opt out of receiving emails if they wish.
10169554|NCT03901547|Other|Priming and additional measures (Tier 2)|Education and behavioral observation cohort. These participants must sign an informed consent to participate in this part of the study. In addition to all of Tier 1 activities, participants also complete psychological inventories at three time points to measure emotion regulation and burnout, and participate in a semi-structured interview.
10169555|NCT03901690|Experimental|Arm Betaglucin|It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.
10169556|NCT03901690|Active Comparator|Arm Imiquimod|51 individuals between the ages of 18 and 50 will receive 5% imiquimod.
10169557|NCT03901352|Experimental|Mirogabalin|"The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.~The patients with creatinine clearance (CLcr) 30 to < 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose"
10169558|NCT03901352|Placebo Comparator|Placebo|Placebo (14-weeks)
10169559|NCT03901326|Experimental|CTA/CT-FFR care group|If the subjects are randomly allocated to CTA/CT-FFR arm, they will be examined by DeepFFR for three major epicardial arteries. If CT-FFR value of one or more major coronary arteries is less than 0.75, ICA will be performed directly; if CT-FFR is 0.75-0.8 (including 0.8), physicians will decide whether to start intensive drug therapy or ICA; if CT-FFR value is more than 0.8, only drug therapy will be needed. The clinical management plan will be suggested including optimal medical therapy, ICA, PCI, CABG and other intervention according to the result of this non-invasive examination.
10169560|NCT03901326|No Intervention|routine clinically-indicated diagnostic care group|If the subjects are randomized to CID arm, attending physicians will decide next step of diagnosis and treatment, such as exercise ECG, stress cardiac echo, SPECT. According to the results of examination combined with risk factors assessment and clinical manifestations, physicians should provide recommendation whether the subjects would undergo ICA or not.
10169561|NCT03901287|Experimental|dual energy CT|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
10169562|NCT03901378|Experimental|Single Arm|Pembrolizumab 200mg IV day 1 with Carboplatin AUC 6 IV day 1 or Cisplatin 80mg/m2 day 1 with etoposide 100mg/m2 days 1-3 of 21 day cycle. Repeat 4-6 cycles to be followed by maintenance Pembrolizumab 200mg IV day 1 every 21 days until progression or intolerance for up to 2 years.
10169563|NCT03901274|Active Comparator|Clinical Services Support Condition|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework.
10169564|NCT03901274|Experimental|Patient-Centered Enhancements|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework. The clinicians in this condition will receive additional training on two Patient-Centered Enhancements (PCE).
10169565|NCT03901261|Experimental|Down syndrome patients|
10186849|NCT03731936||Model establishment and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to establish the facial based diagnostic model of coronary artery diseases, and to prospectively validate the diagnostic effectiveness of the model.
10186850|NCT03731897|Experimental|prolotherapy|"Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain."
10186851|NCT03731897|Placebo Comparator|control|"Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc.~Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection."
10186852|NCT03731884||Elapsed time of onset-of-pain-to-PCI <3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) prior to 3 hours from the onset of symptoms
10186853|NCT03731884||Elapsed time of onset-of-pain-to-PCI >3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) after at least 3 hours from the onset of symptoms
10186854|NCT03731845|Experimental|patient|
10186855|NCT03731832|Experimental|PId|Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
9520405|NCT03278015|Experimental|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
9671749|NCT05043818||IBD patients without depression|IBD patients without depression
10169566|NCT03901248||Normoglycemia|Participant with normal blood glucose level with No Intervention
10169567|NCT03901248||Impaired Glucose Tolerance|Participants with Impaired Glucose Tolerance blood glucose level with No Intervention
10169568|NCT03901248||Type 2 Diabetes|Newly diagnosed type 2 diabetes patients with No Intervention
10169569|NCT03900923|Experimental|98% pure CBD|98% pure CBD. The CBD will be 100mg/mL oral solution provided by Greenwich Biosciences, Inc.
10169570|NCT03901196||Interstitial Lung Disease|Ex : sarcoidosis, IPF
10169571|NCT03901040|Other|obese patient|we will perform endoscopic ultrasound botulinum toxin (100 IU)injection to gastric antrum of obese patient with BMI more than 30 will
10169572|NCT03900936||Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
10169573|NCT03901079||CTO BridgePoint system|"BridgePoint CTO System:~CrossBoss Catheter~Stingray LP Catheter~Stingray Guidewire and Extension Wire"
10169574|NCT03901014|Active Comparator|Baseline diet|1 week baseline diet
10169575|NCT03901014|Experimental|Very low carbohydrate diet|2 week very low carbohydrate ketogenic diet
10169576|NCT03901118|Experimental|chiauranib plus etoposide|Patients receive the combined treatment of chiauranib plus etoposide, 28 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Etoposide is given orally, 50mg once daily for 21 days, 7 days off, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
10169577|NCT03901118|Experimental|chiauranib plus paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
10169578|NCT03900962|Experimental|Slow-speed strength training|The slow-speed strength training group performed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds.
10169579|NCT03900962|Experimental|High-speed power training|During the first three weeks of training, the high-speed power training group completed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds. Thereafter, this group completed the concentric phase of five resistance exercises (squat, press-up, incline chest press, seated row and push-press) as fast as possible whilst still taking two seconds to complete the eccentric phase.
10169580|NCT03901209|Experimental|Laser osteotomy|The planned mid-face osteotomy (e.g. LeFort I) is performed using the CARLO osteotomy device, where a patient-specific intervention plan based on preoperative imaging is loaded on the system to allow the device to show and suggest a location for the osteotomy.
10169581|NCT03901222|Active Comparator|Bi-Anodal tDCS|Subjects will receive 20 min of bi-anodal tDCS
10169582|NCT03901222|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
10169583|NCT03901183|Experimental|Interventional|Participants receive a 8 week nutritional counseling with weekly group meetings to establish a plant-based diet.
10169584|NCT03901183|No Intervention|Control|Waiting list. Participants receive no intervention during study period, equal intervention is offered after the end of study.
10169585|NCT03901170|Experimental|letrozole|patients with letrozole
10169586|NCT03901170|No Intervention|control|patients without letrozole
10169587|NCT03901027|Experimental|Parents of children with chronic illnesses|psycho-educational intervention for parents
10169588|NCT03901157|Experimental|Active yogurt|Contains 120 g yogurt + 60 g oil-gel particles (containing 6 g oil) + 24 g water
10169589|NCT03901157|Active Comparator|Control yogurt|Contains 120 g yogurt + 54 g empty gel particles + 6 g oil in 24 g water
10169590|NCT03900988|Active Comparator|intravenous N-acetylcysteine (NAC) and oseltamivir|
10169591|NCT03900988|Placebo Comparator|intravenous 5% dextrose and oseltamivir|
10169592|NCT03901001|Active Comparator|oseltamivir and adjunctive sirolimus|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
10169593|NCT03901001|Placebo Comparator|oseltamivir alone|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
10169594|NCT03900910|Other|Gastric cancer prevention|13C-urea breath test and anti-H. pylori treatment for those who are tested positive.
10169595|NCT03900949|Experimental|Treatment (gemtuzumab ozogamicin, cytarabine, daunorubicin)|INDUCTION THERAPY: Cytarabine intravenously (IV) on days 1-7, daunorubicin IV on days 1-3 and midostaurin 50 mg orally (PO) twice daily (BID) on days 8-21. Gemtuzumab ozogamicin IV may be given either on days 1, or days 1 and 4 or days 1, 4 and 7. RE-INDUCTION THERAPY: Between days 14 and 21 of Induction Therapy, patients may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin per the treating physician. Patients may also undergo allogeneic stem cell transplantation (SCT) or receive consolidation therapy. CONSOLIDATION THERAPY: PATIENTS < 60 YEARS: high dose cytarabine (HiDAC) IV on days 1, 3, and 5 and gemtuzumab ozogamicin IV on day 1 of cycle 1 and midostaurin 50 mg PO BID on days 8-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. PATIENTS >= 60 YEARS: Same as above except cytarabine (MiDAC) IV on days 1, 3, and 5.
10169596|NCT03900871|Experimental|Experimental group|
10169597|NCT03900871|Placebo Comparator|Control group|
10169598|NCT03900858|Experimental|Isoniazid/ Rifapentine 3 times a week|Intervention：Isoniazid/ Rifapentine 3 times a week given by DOT oral Rifapentine (450mg) plus Isoniazid (400mg) for 12 doses
10169599|NCT03900858|No Intervention|No Intervention|No preventive treatment Follow up without intervention. Have already done.
10169600|NCT03900767|Experimental|Clinic-Level|"Clinics will receive the AAC intervention consisting of an EHR-based point of care alert that prompts clinic staff to Ask every patient about tobacco use, Advise tobacco using patients to quit, and Connect interested tobacco users to the Utah Tobacco Quit Line~Assigned Interventions = Electronic Health Record intervention AAC"
10169601|NCT03900767|Experimental|Phase I Group I (Continued EHR and text messages)|Patients receive a weekly text message for one month followed by a monthly text message over the next 5 months (i.e., 6 months of text messages following each tobacco users' clinic visit). All messages will include a motivational message, the Quit Line website, the Quit Line phone number, and simple two-touch response that directly connects interested tobacco users to the Quit Line.
10169602|NCT03900767|Experimental|Phase I Group II (Continued clinic-level EHR intervention only)|Patients receive continued clinic level EHR intervention only (CO).
10169603|NCT03900767|Experimental|Phase II Group I (Text messages, Counseling call)|Patients receive a monthly text message plus 2 brief telephone calls from patient navigators/health educators for 6-12 months following each tobacco user's clinic visit.
10169604|NCT03900767|Experimental|Phase II Group II (Text messages continued)|Patients receive a monthly text message for 6-12 months following each tobacco user's clinic visit that includes a simple one-touch response to directly connect to the Quitline.
10169605|NCT03900806|Experimental|Basic Cognitive Rehabilitation|The basic arm will consist of a brief cognitive training programme without individual guidance throughout the intervention, involving three to five sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks.
10169606|NCT03900806|Experimental|Extensive Cognitive Rehabilitation|The extensive arm will consist of a comprehensive training program, involving five to eight sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks. After the first session, each further session in the extensive group involves tailored therapy guidance . Cognitive strategy modules will be assigned by the therapist depending on the participants' cognitive profile and personal treatment goals.
10169607|NCT03900806|No Intervention|Waitlist control group|Participants in the waiting list control group will be offered the opportunity to follow the basic cognitive rehabilitation program after completion of the 26-week follow-up measurement.
10169608|NCT03900585|Experimental|Interval walking|Interval walking for 10 weeks, 150 minutes per week administered by an app on the patient's telephone.
10169609|NCT03900585|No Intervention|Control|Patients live as normal, though aerobe training restricted to a maximum of 30 minutes a week.
10169610|NCT03900663||Breast fed infants|
10169611|NCT03900663||Formula fed infants|
10169612|NCT03900663||vaginally delivered infants|
10169613|NCT03900663||Infants delivered by caesarean section|
10169614|NCT03900624|No Intervention|Methylprednisolone Arm|Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
10169615|NCT03900624|Experimental|Dexamethasone Arm|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
10169616|NCT03900637|Experimental|Arm I|"MammaPrint high risk :~Neoadjuvant chemotherapy : Adriamycin/Cyclophosphamide #4 followed by Docetaxel #4~MammaPrint low risk :~Premenopausal women : Letrozole 2.5mg PO QD + leuprorelin acetate 3.6mg SQ every 4weeks during 16 weeks (if needed, maximum for 24 weeks)~Postmenopausal women : Letrozole 2.5mg PO QD during 16 weeks (if needed, maximum for 24 weeks)"
10169617|NCT03900702|Active Comparator|Active Intervention|Gaze-driven games, played at home on PC with eye-tracker, to train resistance to attention distraction and speed of processing.
10169618|NCT03900702|No Intervention|Wait List Control|Wait list then cross over to active intervention.
10169619|NCT03900494|Active Comparator|Children treated with VHC 1|In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. We only compare the efficacy of the two VHC devices.
10169620|NCT03900494|Active Comparator|Children treated with VHC 2|In this group children are receiving salbutamol with valved holding chamber number 2. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria.
10169621|NCT03900650|Experimental|Alcoholic beverage|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%.
10169622|NCT03900650|Active Comparator|Non-alcoholic beverage|Participants will receive a beverage that does not contain alcohol (fruit juice only).
10169623|NCT03900650|Experimental|High provocation manipulation|Participants receive an experimental manipulation designed to evoke negative emotions such as frustration.
10169624|NCT03900650|Active Comparator|Low provocation manipulation|Participants receive an experimental manipulation that is designed to evoke neither positive or negative emotions.
10169625|NCT03900572|Experimental|HPV vaccine|Subjects receive 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
10169626|NCT03900572|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
10169627|NCT03900429|Placebo Comparator|Matching Placebo|Placebo Daily
10169628|NCT03900429|Active Comparator|80 mg MGL-3196|80 mg daily
10169629|NCT03900429|Active Comparator|100 mg MGL-3196|100 mg daily
10169630|NCT03900741|Experimental|Submerged healing|Bone regeneration of peri-implantitis defects following a submerged healing
10169631|NCT03900741|Active Comparator|Non-submerged healing|Bone regeneration of peri-implantitis defects following a non-submerged healing
10186856|NCT03731832|Experimental|PICd|Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.
10169632|NCT03900481|Experimental|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive
10169633|NCT03900559|Experimental|"NO-FEAR Airlines program with still images"|"Intervention group that uses NO-FEAR Airlines program with still images to carry out the exposure."
10169634|NCT03900559|Experimental|"NO-FEAR Airlines program with still and navigable images"|"Intervention group that uses NO-FEAR Airlines program with still and navigable images to carry out the exposure."
10169635|NCT03900559|No Intervention|Waiting list control group|"Participants of this group are able to access NO-FEAR Airlines program after 6 weeks of waiting period.~After that period, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (only still images or still + navigable images)."
10169636|NCT03900611|Experimental|Active stimulation|
10169637|NCT03900611|Sham Comparator|Sham stimulation|
10169638|NCT03900611|No Intervention|healthy control|
10169639|NCT03900676|Experimental|VB-1953 topical gel - 2% QD|VB-1953 topical gel - 2% QD
10169640|NCT03900676|Experimental|VB-1953 topical gel - 2% BID|VB-1953 topical gel - 2% BID
10169641|NCT03900676|Placebo Comparator|VB-1953 topical gel- 0% (Vehicle) QD|VB-1953 topical gel- 0% (Vehicle) QD
10169642|NCT03900676|Placebo Comparator|VB-1953 Vehicle|VB-1953 topical gel- 0% (Vehicle) BID
10169643|NCT03900351|Active Comparator|Group A: Study group|They will receive the Wii fit protocol of virtual reality games for 40 minutes, 3 times per week, for 8 weeks, in addition to the regular exercise rehabilitation protocol according to the criterion of Adams et al. (2012).
10169644|NCT03900351|Experimental|Group B: Control group|They will receive the regular exercise rehabilitation protocol only for 40 minutes, for 3 days per week, for 8 weeks.
10169645|NCT03900390|Experimental|Cross Ischemic Preconditioning Group|the ascending aorta of the CIP group will be crossclamped to cease the blood supply for 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions
10169646|NCT03900390|No Intervention|Control Group|The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation without Ischemic Preconditioning manoeuvre.
10169647|NCT03900377|Experimental|Lg-B-NHL or MCL|For previously untreated patients with Lg-B-NHL or MCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 0 (the day before Day 1 only in Cycle 1), and SyB L-0501RI will be intravenously administered at 90 mg/m^2/day on Day 1 and Day 2 of each 28-day cycle with up to 6 cycles.
10169648|NCT03900377|Experimental|DLBCL|For patients with recurrent or refractory DLBCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 1, and SyB L-0501RI will be intravenously administered at 120 mg/m^2/day on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles.
10169649|NCT03900455|Experimental|Hydrocellular polyurethane foam multilayer dressing|
10169650|NCT03900455|Active Comparator|standard preventive care|
10169651|NCT03900780|Experimental|PGT-A group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
10169652|NCT03900780|Active Comparator|Control group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
10169653|NCT03900520||Pneumonia group (PREVAIL-Pneumo)|Children aged 1-35 months with pneumonia or lower respiratory tract infection hospitalized or recommended for hospitalization
10169654|NCT03900520||Community group (PREVAIL-Community)|Children aged 1-35 years living in the community with no known systemic illness
10169655|NCT03900520||Economic group (PREVAIL-Econ)|PREVAIL-Pneumo-enrolled children hospitalized for pneumonia
10169656|NCT03900442|Experimental|PTX-100|IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles
10169657|NCT03900364|Other|robot-assisted partial nephrectomy|partial nephrectomy performed with the da Vinci Surgical System
10169658|NCT03900364|Other|laparoscopic partial nephrectomy|partial nephrectomy performed with conventional laparoscopic surgery
10169659|NCT03900312|Experimental|Intervention|The program consists of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices.
10169660|NCT03900325|Experimental|Nimacimab|2.5 mg/kg
10169661|NCT03900325|Placebo Comparator|Placebo|0.9% sodium chloride
10169662|NCT03900234||Residents of the single rural settlement|No interventions will be administered
10169663|NCT03900195|Experimental|Bottle PEP|Bottle PEP is a positive expiratory system that is applied via a tube of more than 5 mm of thickness and a bottle filled with water about 10 cms.
10169664|NCT03900195|No Intervention|Control|No interventions will be applied.
10169665|NCT03900091||Cases with clinical meningitis|Patients aged 0-12 years with suspected CNS infection, at the pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda.
10169666|NCT03900091||Control subjects|Patients aged 0-12 years, visiting the outpatient pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda, with fever clinically considered non-severe.
10169667|NCT03900039|Active Comparator|Conventional Polyethylene versus metal head|This is the more conventional group bearing surfaces
10169668|NCT03900039|Experimental|Conventional Polyethylene versus oxidized zirconium head|This group uses the more conventional polyethylene against the newer head
10169669|NCT03900039|Experimental|Newer Cross linked Polyethylene metal head|In this group we continued with the conventional polyethylene, but added in the new type of head (oxidized zirconium)
10169670|NCT03900039|Experimental|Newer Cross linked Polyethylene versus oxidized zirconium head|In this group, we added both the new head and the new polyethylene
10169671|NCT03900273|Experimental|Novel measures of cognition and everyday function|"No Practice Effects (NPE) cognitive battery~Miami Computerized Functional Assessment Scale (CFAS)~Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52."
10169672|NCT03900273|Active Comparator|Established measures of cognition and everyday function|"Preclinical Alzheimer's Cognitive Composite (PACC)~Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)~Functional Assessment Questionnaire (FAQ).~Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period.~Assessments will take place at baseline, week 12, and week 52."
10169673|NCT03900286|Experimental|Single Arm Study|Total Diet Replacement for 12 weeks, food reintroduction 6 weeks
10169674|NCT03900143|Experimental|Treatment - Tightra|Treatment group with the Tightra device
10169675|NCT03900260|Other|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
10169676|NCT03900078|Active Comparator|Control group|After subcuticular skin suture, patients receive standard dressing with adhesive wound tapes.
10169677|NCT03900078|Experimental|Incisional negative pressure group|After subcuticular skin suture, patients receive an incisional negative pressure dressing for 5 days.
10169678|NCT03899948|Experimental|Teacher Anxiety Program for Elementary Students (TAPES)|Teachers in the experimental condition attend a 6-hour training on the TAPES program. The teachers learn to implement a brief intervention (5 meetings) with the student and his or her parent, utilize classroom anxiety-reduction strategies, and apply relationship enhancement strategies to improve the relationship with the target student and parents.
10169679|NCT03899948|Active Comparator|Teacher Anxiety Training (TAT)|Teachers in this condition receive training about childhood anxiety and classroom anxiety-reduction strategies using a 3-hour typical teacher professional development training format.
10169680|NCT03900104|Experimental|Transcervical endometrial injection arm|Tracer injection performed by a transcervical catheter in endometrial cancer patients.
10169681|NCT03900104|Active Comparator|Cervical injection arm|Tracer injection was administered via the cervical route in endometrial cancer patients.
10169682|NCT03900013|Experimental|Injectable Platelet Rich Fibrin (i-PRF) with DFDBA|"In i-PRF assigned group, 10 cc of blood per intraosseous defect will be collected right after administering the anaesthesia and will be processed according to the technique proposed by Choukroun et al., 2017 (centrifuged at 700 rpm, for 2-3 minutes). The yellow part will be collected using a syringe and added to a cup that contains the bone grafting material.~The i-PRF consolidated bone graft will placed into the intraosseous defect."
10169683|NCT03900013|Active Comparator|Demineralized Freeze-Dried Bone Allograft (DFDBA) alone|After debridement and intraoperative recordings, in the control group, the bone graft material will be placed in the intraosseous defect without overfilling.
10169684|NCT03900182|Active Comparator|HBO treated group|Patients in the treated group were evaluated three - at baseline, after 6 weeks of HBOT and after 6 weeks of neuropsychological treatment or no treatment.
10169685|NCT03900182|Sham Comparator|crossover group|Patients in the crossover group were evaluated three times: baseline, after 6 weeks control period of no treatment, and after subsequent 6 weeks of HBOT
10169686|NCT03900065|No Intervention|Control group|No preconditioning of the flap.
10169687|NCT03900065|Experimental|Preconditioned group|Preconditioning of the flap prior to surgery.
10169688|NCT03900052|No Intervention|Naïve|Conventional cane with no instruction given
10169689|NCT03900052|Active Comparator|Scale training|Conventional cane, scale training, and instruction on proper cane use
10169690|NCT03900052|Active Comparator|Scale recall|Conventional cane with no further instruction or practice given
10169691|NCT03900052|Experimental|Haptics training|Haptic biofeedback cane with explanation and training.
10169692|NCT03900052|Experimental|Haptics recall|Haptic biofeedback cane with no further instruction or practice given.
10169693|NCT03900026|Placebo Comparator|Placebo Treatment|Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)
10169694|NCT03900026|Experimental|Evolocumab Treatment|Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)
10169695|NCT03900130|Experimental|Full group|"There is only one arm in this study. The group of 25 subjects all undergo a repeated measures 2 x 2 factorial design, fully crossed such that all subjects are tested under all four combinations of factors.~The intervention Preload amounts to two factors, caloric load and protein to carbohydrate ratio of the preload, both of which can take on two levels high or low."
10169696|NCT03899974|Experimental|70% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 70% high-amylose flour)
10169697|NCT03899974|Experimental|85% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 85% high-amylose flour)
10169698|NCT03899974|Active Comparator|Control bread|Mixed meal with 80g of available carbohydrates coming mainly from conventional bread
10169699|NCT03900117|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
10169700|NCT03899935||Group A: obese patients|Obese patients undergoing laparoscopic surgery for endometriosis
10169701|NCT03899935||Group B: non-obese patients|Non-obese patients undergoing laparoscopy for endometriosis
10169702|NCT03900000|Other|Short_Physiotherapy|one period of physiotherapy (8 weeks)
10169703|NCT03900000|Other|Long_Physiotherapy|two periods of physiotherapy (à 8 weeks)
10169704|NCT03900169||Stemi patient|Stemi patient who underwent Ppci
10169705|NCT03900156|No Intervention|comparison group|The CG received no extra care.
10169706|NCT03900156|Experimental|Intervention Group|Intervention Group, goal-setting with follow-up, will have a structured goalsetting interview using the Bangor Goal-Setting Interview ; once goals are identified and clearly expressed in accordance with SMART principles (specific, measureable, achievable, realistic, and timed)
10169707|NCT03899779|Active Comparator|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
10169708|NCT03899779|Experimental|Online hypnotherapy|12 weeks treatment with online hypnotherapy
10169709|NCT03899779|Active Comparator|Online psychoeducation|12 weeks treatment with online psychoeducation
10169710|NCT03899727||Pregnant group|pregnant women in the third trimester of pregnancy
10169711|NCT03899727||Non-pregnant group|middle aged women
10169712|NCT03899675|Experimental|Caffeine|Volunteers will ingest 300mg caffeine one hour before strength training.
10169713|NCT03899675|Placebo Comparator|Placebo|Volunteers will ingest 300mg placebo one hour before strength training.
10169714|NCT03899740||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
10169715|NCT03899909|Experimental|GLPG3121 SAD|Single doses of GLPG3121 at up to 6 dose levels in ascending order
10169716|NCT03899909|Placebo Comparator|Placebo SAD|Single doses of placebo
10169717|NCT03899909|Experimental|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 4 dose levels in ascending order
10169718|NCT03899909|Placebo Comparator|Placebo MAD|Multiple doses of placebo
10169719|NCT03899922||Uveitis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of uveitis of patient treated by a drug, with a chronology compatible with the drug toxicity
10169720|NCT03899818|Other|new generation DEB|drug-eluting balloon (DEB)
10169721|NCT03899818|Other|second generation DES|standard therapy with second generation drug-eluting stent (DES)
10169722|NCT03899831|Experimental|Function-Based Elopement Treatment (FBET)|Participants in this group will receive Function-Based Elopement Treatment (FBET) for 16 weeks.
10169723|NCT03899831|Active Comparator|Parent Education Program (PEP)|Participants in this group will take part in a parent education program (PEP) for 16 weeks.
10169724|NCT03899805|Experimental|Liposarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
10169725|NCT03899805|Experimental|Leiomyosarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
10169726|NCT03899805|Experimental|Undifferentiated Pleomorphic sarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
10169727|NCT03899662|Experimental|Cognitive and Physical Training|24 sessions (8 weeks, 3 times per week) of computer based 45 minute cognitive and 45 minute physical training.
10169728|NCT03899532|Experimental|Remote Ischemic Conditioning|"Remote ischemic conditioning will be performed using a standard manual blood pressure cuff. The pressure in the blood pressure cuff will be maintained at 30 mm of Hg higher than the patient's systolic blood pressure. 4 cycles of ischemic conditioning will be performed each day for a period of 7 days. Each cycle consists of 5 min of controlled upper limb ischemia (cuff up) followed by 5 min of reperfusion (cuff down). The total duration of the treatment cycle will be 40 min. The study protocol is based on our published literature in traumatic brain injury.~Blood samples will be collected at 0 hours (before randomization). Then the first 4 cycles of RIC (done consecutively) will be performed, blood samples will be taken at 6 hours post randomization and then at 24 hours post randomization. RIC cycles will then be performed on a daily basis followed by taking a blood sample once daily during the patients' length of stay up to a maximum of 7 days"
10169729|NCT03899532|Placebo Comparator|No Remote Ischemic Conditioning|Blood samples will be collected at 0 hours (before randomization). Blood samples will then be collected at 6 hours post randomization and 24 hours post randomization. These patients will not receive daily RIC therapy but will only have their blood drawn once daily during the patients' length of stay up to a maximum of 7 days.
10169730|NCT03899714|Active Comparator|Ankle evertors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the ankle evertors, the ice bag will be applied to the lateral side of the ankle encompassing the lateral malleolus.The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
10169731|NCT03899714|Active Comparator|Hip adductors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the hip adductors, the ice bag will be applied to the medial side of the thigh, covering the entire area from the groin, to just above the knee joint. The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
10169732|NCT03899961|Active Comparator|Oxytocin|Oxytocin 2.5 U i.v.
10169733|NCT03899961|Experimental|Carbetocin|Carbetocin 100 µg i.v.
10169734|NCT03899766||Animal Assisted Intervention|children interact and play with the expert of Animal Assisted Intervention (AAI) and his/her trained dog in the waiting room and then, are accompanied by a parent (as standard care) and the AAI in the venipuncture room during and immediately after the procedure
10169735|NCT03899766||Clowns|children interact and play with hospital clowns in the waiting room and then, are accompanied by a parent (as standard care) and the clown in the venipuncture room during and immediately after the procedure
10169736|NCT03899766||Musicians|children interact and play with a musician in the waiting room and then, are accompanied by a parent (as standard care) and the musician in the venipuncture room during and immediately after the procedure
10169737|NCT03899766||Non-clinical Conversation|children are accompanied by a parent in the waiting room and then in the venipuncture room during the procedure, thus receiving standard care
10169738|NCT03899753|Experimental|2-Octyl Cyanoacrylate and mesh|The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
10169739|NCT03899753|Active Comparator|2-Octyl Cyanoacrylate|The wound will be closed with just 2-Octyl Cyanoacrylate
10169740|NCT03899610|Experimental|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"Neoadjuvant treatment:~Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~Interval debulking surgery~Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
10169741|NCT03899558|Experimental|Intervention|HNHF device (intervention) + usual care
10169742|NCT03899558|No Intervention|Control|Usual care alone
10169743|NCT03899506||Olanzapine|Patients receiving 10 mg IM Olanzapine per the ED protocol
10169744|NCT03899506||Midazolam|Patients receiving 5 mg IM Midazolam per the ED protocol
10169745|NCT03899441|No Intervention|Control|Patients in the control arm will have pre-operative teaching from their physician and sign consent for surgery, as is the current standard of care at the investigators' institution.
10169746|NCT03899441|Experimental|Video arm|Patients in the intervention arm will watch two short animated video about minimally-invasive endometrial cancer surgery followed by focused pre-operative teaching from their physician. They will then sign consent for surgery.
10169747|NCT03899493||Primiparous & Multiparous|Women having borne at least one child > 20 weeks gestational age
9826515|NCT02421146|Active Comparator|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
9826516|NCT02421146|Sham Comparator|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
9826517|NCT02421146|Active Comparator|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
10169748|NCT03899493||Nulliparous|Women in whom this is their first pregnancy > 20 weeks who are anticipated to deliver
10169749|NCT03899545|Experimental|Serratus Plane Block|Serratus plane block will be applied after induction of general anesthesia.
10169750|NCT03899545|Active Comparator|Serratus Plane Block plus Pectoral I block|Serratus plane plus pectoral I block will be applied after induction of general anesthesia.
10169751|NCT03899337|Active Comparator|Standard of Care Arm (CHOP-R)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5"
10169752|NCT03899337|Experimental|Experimental Arm (CHOP-R + Acalabrutinib)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
10169753|NCT03899337|Experimental|Cohort 1 - Acalabrutinib Monotherapy - Platform Trial|Registration arm in platform study. Patients registered to Cohort 1 will receive 100 mg acalabrutinib monotherapy, twice daily, continuously from day 1 until disease progression, toxicity, patient choice or death.
10169754|NCT03899337|Experimental|Cohort 2 - CHOP-R + Acalabrutinib - Platform Trial|"Registration arm in platform study. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
10169755|NCT03899480|Experimental|Haploidentical Natural Killer Cells|Day -7 the subject will undergo inguinal lymph node biopsy & colonoscopy to obtain ileal & rectal biopsies. Blood samples will be obtained. PBMCs will be obtained to sort into CD4 subsets & measure frequencies of HIV RNA & DNA. On Day -1, the donor will undergo apheresis & donor cells will be obtained & incubated overnight. On Day 0 subjects will be infused with N-803 activated NK cells. Subjects will receive 1st dose of N-803 4 hrs after the infusion. Plasma will be obtained at 2, 4 & 12 hrs after. Subjects will return on Days 2, 4, 7, 10, & 14 for blood draw. Subjects will return Days 21 & 42 for blood work & to receive 2 additional doses of N-803, for a total of 3 doses. Subjects will be monitored for toxicity assessment by targeted physical exam & laboratory evaluations on Days 2, 4, 7, 10, 21, & 42. On day 49, we will perform lymph node biopsy & colonoscopy to obtain ileal & rectal tissues. The patient will then be followed until day 100 post infusion.
10169756|NCT03899246|Experimental|Capsaicin Arm|Single arm to receive eight percent topical capsaicin applied to up to 4 sites of recurrent pain over one hour on an every three month schedule. Participants in this arm will receive pretreatment with topical five percent lidocaine.
10169757|NCT03899454|Experimental|Extract administration|administration of a mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
9671750|NCT05043740|No Intervention|Control|Standard of care: management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
10169758|NCT03899454|Placebo Comparator|Control|Placebo
10169759|NCT03899363|Experimental|surgery|
10169760|NCT03899363|Active Comparator|custom thermoplastic orthosis|
10169761|NCT03899584|Active Comparator|Treatment with 4-aminopyridine|The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
10169762|NCT03899584|Placebo Comparator|Placebo oral capsule|Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
10169763|NCT03899168|Experimental|Social Tag Popularity|Popularity of Social Tags (antidepressants more popular vs. psychotherapy more popular)
10169764|NCT03899168|Experimental|Confidence in Prior Attitudes|Confidence in prior attitudes (high vs. low: recalling situations in which participants were confident or uncertain about their thoughts)
10169765|NCT03899168|Experimental|Source Credibility|Credibility of the source (tagging community: experts - many years of professional experience vs. novices - students in the first semester)
9826518|NCT02421172|Experimental|Period 1: CJM112 High Dose|Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
9826519|NCT02421172|Placebo Comparator|Period 1: Placebo|Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
9826520|NCT02421172|Placebo Comparator|Period 2: CJM112 High Dose (Period 1) / Placebo (Period 2)|Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on CJM112 High Dose in Period 1
10186857|NCT03731819|Experimental|Follow-up participants|Patients who met eligibility criteria. Participants are going to undergo Abbreviated PB MRI.
10186858|NCT03731793|Placebo Comparator|Placebo Group|Placebo. For 90 days one capsule/day.
10186859|NCT03731793|Experimental|Intervention Group|600 mg/day of non-animal Chondroitin Sulphate. One capsule/day for 90 days.
10186860|NCT03731780|Experimental|Personalized Treatment|Intervention by (standard preventive measures + targeting individual caries risk factors)
10186861|NCT03731780|Experimental|Chlorhexidine and Rremineralization|Intervention is (chlorhexidine + Remineralizing agent + standard preventive measures)
10186862|NCT03731780|Active Comparator|Control|standard preventative measures (tooth brushing, fluoride tooth paste, interdental cleaning)
10186863|NCT03731767|Other|Subject group|Distraction thrust manipulation of the talocural joint in supine position
10186864|NCT03731754|Active Comparator|Traditional Closure|Patients receive primary closure discontinuously for reconstruction of APR perineal wound
10186865|NCT03731754|Experimental|"Cross Closure"|"Patients receive cross closure for reconstruction of APR perineal wound"
10186866|NCT03731741|Experimental|treatment group|Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk).
10186867|NCT03731741|No Intervention|control group|Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes.
10187895|NCT03721653|Experimental|FOLFOXIRI + Bevacizumab + Atezolizumab|"Atezolizumab 840 mg iv over 30 minutes(60 minutes at the first infusion) day 1 followed by Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev and atezolizumab until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
10187896|NCT03721627|Experimental|Treatment group|Ledipasvir/sofosbuvir fixed dose combination tablet (90 mg ledipasvir, 400 mg sofosbuvir) once daily for 12 weeks for those 12-18 years, Wt 35 kg or more and half the dose (45 mg ledipasvir, 200 mg sofosbuvir) once daily for 12 weeks for those 6-11 years, Wt Less than 35 kg.
10187897|NCT03721614|Experimental|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|
10187898|NCT03721614|Active Comparator|Xience family Everolimus Coronary Stent Systems|
10187899|NCT03721601||Atrial fibrillation|Patients in atrial fibrillation as recorded by 3-lead Holter.
10187900|NCT03721601||Sinus rhythm|Patients in sinus rhythm as recorded by 3-lead Holter.
10187901|NCT03721588||Major depressive disorder|MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied.
10187902|NCT03721588||MDD and ADHD|MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied.
10187903|NCT03721575|Active Comparator|Scarpa's preserving hernio-abdominoplasty|Hernio-abdominoplasty is performed with preservation of Scarpa's fascia.
9671751|NCT05043740|Experimental|treatment|On top of Standard of care, Evolocumab (Repatha®) 140 mg or Alirocumab(Praluent) 75mg every two weeks: first subcutaneous injection at the time of randomization, followings during 12 months.
9826521|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 Low Dose (Period 2)|Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
9826522|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 High Dose (Period 2)|Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
10169766|NCT03899571|Active Comparator|5 days|oral oseltamivir 75 mg once daily for 5 days post-exposure
10169767|NCT03899571|Active Comparator|10 days|oral oseltamivir 75 mg once daily for 10 days post-exposure
10169768|NCT03899181|Active Comparator|1 Hz 2400 TNT Treatment|Intervention: TNT treatment intervention with 2400 total stimulations with the magnetic coil..
10169769|NCT03899181|Active Comparator|1 Hz 3600 TNT Treatment|Intervention: TNT treatment intervention with 3600 total stimulations with the magnetic coil.
10169770|NCT03899181|Sham Comparator|Sham TNT Treatment|This arm will have the sham treatment session. First we will assess the motor threshold intensity described above. Next, a sham coil is placed on each of 4 regions (2 lumbar & 2 sacral), and 600 stimulations will be given at each site in 2 trains, with a 5 minutes rest period between each site and 3 minutes between trains.
10169771|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Autoimmune Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
10169772|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Orthopedic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
10169773|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Neurologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
10169774|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Urologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
10169775|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Cardiac Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
10169776|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Renal Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
10169777|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Pulmonary Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
10169778|NCT03899402|Active Comparator|Control|Standard of care insulin will be used as an active comparator arm for 1/3 of patients (38 patients) for the entire duration of the study.
10169779|NCT03899402|Experimental|Dual Therapy|Once a week injection of Semaglutide (a GLP-1 receptor agonist) in addition to standard of care insulin for the first six months in 2/3 of patients (76 patients). Semaglutide is a clear, colorless solution that contains 2 mg of semaglutide in a 1.5 mL (1.34 mg/mL) pre-filled, disposable, single-patient-use pen injector. Semaglutide will be started at the 0.25 mg dose for the first two weeks, then increased to 0.5 mg at week 2, and then yet again increased to 1.0 mg at week 4.
10169780|NCT03899402|Experimental|Triple therapy|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of Dapagliflozin (an SGLT-2 inhibitor) added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)). Dapagliflozin will be started at 5 mg for one week, and then increased to 10 mg for the remainder of the study
10169781|NCT03899402|Placebo Comparator|Triple therapy control|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of the Placebo form of Dapagliflozin added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)).
10169782|NCT03899389||Acute Coronary Syndrome (ACS)|Patients with STEMI or NSTEMI infarction, who were admitted to the hospital with chest pain.
10169783|NCT03899389||Stable Angina (SA)|Patients with stable angina who were scheduled for conventional coronary angiography.
10169784|NCT03899389||Control Group (CON)|Healthy control group responding by age and gender to examined groups.
10169785|NCT03899597|Experimental|artificial contractions (ARTCON) group|All participating patients in the intervention (ARTCON) group will undergo oxytocin exposure in the form of a continuous intravenous infusion according to dosage guidelines of The Czech Society of Obstetrics and Gynaecology. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed in order for the assumed effects of physiological stress associated with labor to occur.
10169786|NCT03899597|Placebo Comparator|standard approach (SA) group|All participating patients in the control (SA) group will undergo placebo exposure in the form of a continuous intravenous infusion. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed.
10169787|NCT03899376|Active Comparator|Conventional radiotherapy|patients with gynecological cancer treated with adjuvant conventional radiotherapy
10169788|NCT03899376|Experimental|Volumetric modulated arc therapy|Patients with gynecological cancer treated with adjuvant VMAT radiotherapy
10169789|NCT03899324|Experimental|Group 1: Experimental Bumetanide|bumetanide with a titration period
10169790|NCT03899324|Placebo Comparator|Group 2: Placebo comparator|placebo intake identically to group 1
10169791|NCT03899129|Experimental|simultaneous working length control|• Using simultaneous working length control during root canal preparation using E-CONNECT S endomotor with integrated apex locator.
10169792|NCT03899129|Active Comparator|Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
10169793|NCT03899415|Experimental|TCR-Redirected T Cells|HBV antigen specific TCR redirected T cells
10169794|NCT03899207|Experimental|training +acupressure|In the training+acupressure group, 10 women were excluded from the study since they could not participate in acupressure application at different times, 2 women were excluded since they had menstrual irregularities and 4 women were excluded since they could not be contacted.
10169795|NCT03899207|Experimental|training|In the training group, 4 women were excluded since they did not participate in the reminder training, 1 woman was excluded since she had menstrual irregularities, 3 women were excluded since they wanted to withdraw from the study and 3 women were excluded from the study since they could not be contacted.
10169796|NCT03899207|No Intervention|control|In the control group, 4 women were excluded from the study since they could not be reached and 5 women were excluded since they did not agree to participate in the posttest.
10169797|NCT03899233|Active Comparator|Fractional CO2 laser combined with Tranexamic acid|one side of the face of all participants will be subjected to low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond for 3 sessions every 6 weeks. In addition to Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, on the 2nd and the 4th week of each laser session. With total treatment time for each patient of 4 months and another month free of sessions for followup.
10169798|NCT03899233|Active Comparator|Tranexamic acid alone|the other side of the face of all participants will be subjected Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, every 2 weeks for 4 months then another month free of sessions for followup.
10169799|NCT03899194|Active Comparator|escitalopram|Patients will only be treated with escitalopram from the minimum dosage.
10169800|NCT03899194|Experimental|escitalopram+ fish oil capsules|Patients will be treated with escitalopram from the minimum dosage and fish oil capsules according to direction for use.
10169801|NCT03898999||Older adult|Individuals belonging to the population group of the elderly (60 years or more)
10169802|NCT03899116||G50|The tourniquet cuff pressure will be deflated gradually by 50 mm Hg every 2 minutes till complete deflation.
10169803|NCT03899116||G100|The tourniquet cuff pressure will be deflated gradually by 100 mm Hg every 2 minutes till complete deflation.
10169804|NCT03899116||G0|The tourniquet cuff will be released till complete deflation.
10169805|NCT03899142|Experimental|human hepatitis B immunoglobulin|once, i.m.
10169806|NCT03898973|Other|Study Phase|Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)
10169807|NCT03898986|Experimental|MZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
10169808|NCT03898986|Experimental|DZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
10169809|NCT03899077|Active Comparator|Arm A|The standard hormonal treatment in combination with salvage radiotherapy is ADT by a LHRH agonist or antagonist for 24 weeks. LHRH agonists and antagonists include leuprolide, goserelin, triptorelin, and degarelix.
10169810|NCT03899077|Experimental|Arm B|Patients will receive 6 cycles (each cycle is 30 days) of the study drug (4x 60mg tablets daily in a single intake).
10169811|NCT03899038|Experimental|Deceasing|Spinal anesthesia with decreasing dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
9520406|NCT03277976||ThermoCool SmartTouch 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
9520407|NCT03277976||ThermoCool SmartTouch 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
9520408|NCT03277976||ThermoCool SmartTouch SF 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
10169812|NCT03899038|Active Comparator|Similar|Spinal anesthesia with similar dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
10169813|NCT03899311||PSMF cohort|The cohort is instructed to follow a protein-sparing modified fast diet and is given standard health care in the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital.
9520409|NCT03277976||ThermoCool SmartTouch SF 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
9520410|NCT03277963|Active Comparator|Absence of sleep apnea syndrome|Pain perception tests
9520411|NCT03277963|Experimental|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
9520412|NCT03277950|Experimental|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
10169814|NCT03899025|Other|Suspected scaphoid fracture|Patients with a suspected scaphoid fracture
10169815|NCT03898700|Active Comparator|coaching face to face|10, 1 hour sessions of face to face strength based coaching sessions
10169816|NCT03898700|Active Comparator|phone coaching|10, 1 hour sessions of strength based coaching via phone.
9520413|NCT03277950|Active Comparator|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
9520414|NCT03277950|Other|Healthy|Participants do not play virtual reality game.
9662157|NCT05130398|Experimental|the rVSVΔG-ZEBOV-GP vaccine|Participants of the experimental arm will receive a single intramuscular dose of ≥7.8 x 107 pfu of the rVSVΔG-ZEBOV-GP vaccine. In total, 80 participants will receive the experimental vaccine: 40 participants aged 6-12 years and 40 aged 1-5 years.
10169817|NCT03899051|Experimental|Test group|Papilla reconstruction would be done with platelet rich fibrin
10169818|NCT03899051|Active Comparator|Control group|Papilla reconstruction would be done with subepithelial connective tissue graft
10169819|NCT03898804|Experimental|BCI and FES|Surgical implantation of the device and testing for 13 months with an optional 5 year extension study.
10169820|NCT03898752|Experimental|Lifestyle intervention|Diet, omega-3 fish oil (1g daily), CoQ10 (100 mg/day) and a normal Multi-vitamin, Smoking cessation, weight loss, exercise,
10169821|NCT03898947||Tamoxifen users|Women undergoing therapy with Tamoxifen after surgery for breast cancer.
10169822|NCT03898947||Aromatase inhibitors|Women undergoing therapy with Aromatase Inhibitors after surgery for breast cancer.
10169823|NCT03898947||No treatment|Women who did not undergo any hormonal therapy after surgery for breast cancer.
10169824|NCT03899285|Experimental|Citalopram increase (group A)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of citalopram 20 mg for a length of 14 days. The total dose of citalopram will be 40 mg once daily.~Follow up will last 8 weeks in total."
10169825|NCT03899285|Placebo Comparator|Placebo (group B)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of placebo (a capsule without medication) for a length of 14 days. The total dose of citalopram will be 20 mg once daily.~Follow up will last 8 weeks in total."
10169826|NCT03899285|No Intervention|Observational arm (group c)|"Eligible patients to this arm are responders to citalopram. A diminution of at least 30% of the symptoms from baseline with the MADRS is required to enter this arm. At the end of the first phase, these patients will pursue their citalopram 20 mg for the rest of the study (=6 weeks). It's possible that in this group, the treatment approach may vary depending the physician.~Follow up will last 8 weeks in total."
10169827|NCT03898739|Active Comparator|traction therapy from neutral position|Patients in this group will receive traction decompression from neutral neck position with rope angle (0°)
10169828|NCT03898739|Active Comparator|traction therapy from lateral bending|patients will undergo traction decompression from (30°) lateral bending of the neck toward the non-affected side
10169829|NCT03898739|Active Comparator|traction from flexion with lateral bending and rotation|patients will be treated with traction decompression from (15°) neck flexion, (30°) lateral bending toward non- affected side and (15°) rotation to the affected side.
9662158|NCT05130398|Active Comparator|The Chikenpox or Varicella (Varilix) vaccine|The control arm consists of the chickenpox vaccine. Forty children will receive a single subcutaneous dose of Varilix, the active comparator vaccine, 20 aged 6-12 years and 20 aged 1-5 years
10169830|NCT03898609|Experimental|Low-fat diet|20% fat 20% protein 60% carbohydrate
10169831|NCT03898609|Experimental|Low-carbohydrate diet|45% fat 20% protein 35% carbohydrate
10169832|NCT03898791|Experimental|LY3295668 Erbumine Cohort A|LY3295668 erbumine administered orally.
10169833|NCT03898791|Experimental|LY3295668 Erbumine Cohort B|LY3295668 erbumine administered orally.
10169834|NCT03898791|Experimental|LY3295668 Part JP|LY3295668 erbumine administered orally.
10169835|NCT03898882||BMI 20 - 29.9 kg/m2|
10169836|NCT03898882||BMI > 30 kg/m2|
10169837|NCT03898596|Other|ECG Monitoring|ECG readings will be collected for neonatal patients who require or currently have UVC
10169838|NCT03898921|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
10169839|NCT03898921|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
10169840|NCT03898830|Experimental|eon™ FR 1064 nm device|Patient will be treated with the eon™ FR 1064 nm device
10169841|NCT03898765|Experimental|Experimental：Dry blood spot screening|
10169842|NCT03898687|Other|MAGMEN arm|Patients with melanoma of the extremities included in the protocol. SLNB will be performed with the addition of magtrace (SPIO) injection, 0.2 ml around previous scar. The patients will undergo MRI of the involved basin (Axilla-groin)and receive the SpIO injection the day before SLN biopsy. A separate SPIO MRI will be performed before the operation. All patients will receive all 3 methods for SLN identification as described in the protocol.
10169843|NCT03898674|Experimental|GDT feasibility|Patients undergoing microcirculatory goal directed therapy
10169844|NCT03898661|Experimental|local collagenase|Patients receiving local injection of collagenase into the esophageals stricture
10169845|NCT03898375|Experimental|VR-enhanced treadmill walking|Participants will be tested during 4 sessions of 20 minutes treadmill walking.
10169846|NCT03898505|Placebo Comparator|Placebo|Placebo powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour. Participants in the placebo group will ingest 1 scoop of the placebo material per day (30-35g). Placebo powder is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Placebo will be consumed once per day for 60 days.
10186868|NCT03731728|Experimental|Group CBT plus TAU|"Participants enrolled in the group CBT plus TAU arm of the study will receive a 2-hour session of group CBT every week for 14 weeks in addition to being wait-listed to receive treatment as usual."
10169847|NCT03898505|Experimental|Low Dose|All Participants randomized to the low dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 50 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the low dose group will ingest 1 scoop of this test product per day (30-35g). Low dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Low dose test product will be consumed once per day for 60 days.
10169848|NCT03898505|Experimental|High Dose|All Participants randomized to the high dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 200 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the high dose group will ingest 1 scoop of this test product per day (30-35g). High dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. High dose test product will be consumed once per day for 60 days.
10169849|NCT03898492|Other|Intervention|The participants in this group participated in exercise two times/week for 8 weeks
10169850|NCT03898492|No Intervention|Control|The participants in the control group were instructed to maintain their daily routines.
10169851|NCT03898635||Background group|The treatment regimen does not include linezolid throughout the treatment course.
10169852|NCT03898635||Background-linezolid group|Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.
10169853|NCT03898635||Linezolid initial group|Linezolid was in initial treatment regimen.
10169854|NCT03898453|Experimental|Group EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
10169855|NCT03898453|Other|Group Control : support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
10169856|NCT03898622|Active Comparator|Group with levothyroxine|Patients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. That meet the inclusion criteria. Levothyroxine 25 mcg (1/4 tablet of 100mcg) was administered in fasting the first month, the doctor evaluated with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 uim / L the second month increase to a dose of 50 mcg (1/2 tablet of 100mcg fasting, or similarly if the patient had a TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5u / L ) to complete three months of intervention.
10169857|NCT03898622|Placebo Comparator|Group Placebo|"atients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. that meet the inclusion criteria.~Placebo (1/4 tablet) was administered in fasting the first month, the doctor assessed with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 UM / L the second month increase at a dose (1/2 tablet fasting, or similarly if the patient had TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5 / month) to complete three months of intervention."
10169858|NCT03898570||Patients undergoing vascular surgery procedures|Patients will report outcomes via their smartphone.
9520415|NCT03277937|Experimental|Patients with gastric varices|Patients above 18 years old with gastric varices (GV) on the initial standard diagnostic upper endoscopy will be enrolled and treated using angiography in EUS-injection of coils + CYA. GV will be classified according to Sarin and Kumar classification. Only gastro-esophageal varices type II (GOV II) (fundal varices communicating with esophageal varices) and isolated gastric varices type I (IGV I) (fundal varices within a few centimeters of the gastric cardia) will be included. Gastro-esophageal varices type I (GOV I) will be excluded. Patients with active bleeding and history of previous bleeding due to GV (secondary prophylaxis) will be included as well as patients with high-risk GV suitable for primary prophylaxis according to Baveno VI consensus. T
10169859|NCT03898583|Experimental|Microarray patch A|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use
10169860|NCT03898583|Experimental|Microarray patch B|21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use
10169861|NCT03898583|Placebo Comparator|Vehicle|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance
10169862|NCT03898583|Active Comparator|Daivobet|21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use
10169863|NCT03898258||neurogenic bladder|individuals with chronic (≥12 months) neurogenic lower urinary tract dysfunction due to spinal cord injury (SCI)
10169864|NCT03898193|Other|Sequence Test-Reference (TR)|17 participants (total number of enrolled volunteers - 34) assigned to sequence TR will receive a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 1 and a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9662159|NCT05130385||Diabetic Retinopathy|Patients with various degree of diabetic retinopathy
9826523|NCT02421211|Experimental|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
9826524|NCT02421211|Experimental|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
10169865|NCT03898193|Other|Sequence Reference-Test (RT)|17 participants (total number of enrolled volunteers - 34) assigned to sequence RT will receive a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 1 and a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10169866|NCT03898544||Group primary TKA|Patients operated of primary TKA Stryker for knee osteoarthritis.
10169867|NCT03898544||Group TKA revision|Patients operated of a first revision of TKA for a mechanical failure, with the revision Stryker TKA
10169868|NCT03898518|No Intervention|Control Group|The control group was in the facility for all jump rope exercise sessions but did not participate in the exercise intervention.
10169869|NCT03898518|Experimental|Experimental Group|The experimental group performed the jump rope exercise intervention.
9662160|NCT05130385||Artery and vein occlusion|Patients with history of artery or vein occlusion (central or branch artery)
10169870|NCT03898427||Individuals with atopic dermatitis|Sensor technology and digital measures will be used to evaluate scratch and sleep in individuals with atopic dermatitis receiving standard of care treatments (SOC) who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
10169871|NCT03898401|Experimental|1 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169872|NCT03898401|Experimental|2 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169873|NCT03898401|Experimental|3 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169874|NCT03898401|Experimental|4 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169875|NCT03898401|Experimental|5 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169876|NCT03898401|Experimental|6 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169877|NCT03898401|Experimental|7 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169878|NCT03898401|Experimental|8 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169879|NCT03898401|Experimental|9 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169880|NCT03898401|Experimental|10 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169881|NCT03898401|Experimental|11 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
9662161|NCT05130385||Glaucoma|Patients with history of glaucoma (open-angle glaucoma, chronic angle closure glaucoma)
10169882|NCT03898401|Experimental|12 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
9662162|NCT05130385||Optic nerve neuropathy|Patients with history of various optic nerve neuropathies
10169883|NCT03898401|Experimental|13 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169884|NCT03898401|Experimental|14 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169885|NCT03898401|Experimental|15 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169886|NCT03898401|Experimental|16 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
9974953|NCT04999228|Experimental|Infliximab treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, infliximab will be used as first-line treatment
10169887|NCT03898401|Experimental|17 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169888|NCT03898401|Experimental|18 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169889|NCT03898401|Experimental|19 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169890|NCT03898401|Experimental|20 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169891|NCT03898401|Experimental|21 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169892|NCT03898401|Experimental|22 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169893|NCT03898401|Experimental|23 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169894|NCT03898401|Experimental|24 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169895|NCT03898401|Experimental|25 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169896|NCT03898401|Experimental|26 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169897|NCT03898401|Experimental|27PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10187904|NCT03721575|Active Comparator|Classical hernio-abdominoplasty|Hernio-abdominoplasty is performed with removalof Scarpa's fascia.
9662163|NCT05130385||Hereditary retinal diseases|Patients with history of various retinal dystrophies
10169898|NCT03898401|Experimental|28 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169899|NCT03898401|Experimental|29 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169900|NCT03898401|Experimental|30 PRp|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
10169901|NCT03898310|Experimental|Cranberry Extract Capsules|36mg of proanthocyanidins in cranberry capsules
10169902|NCT03898310|Placebo Comparator|Placebo Capsules|
10169903|NCT03898466|Experimental|Fluticasone Furoate|"Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
10169904|NCT03898466|Placebo Comparator|Matching Placebo|"Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
10169905|NCT03898167|Active Comparator|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator on behalf of Harris Health System.
10169906|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit|Participants receive a scripted telephone recall from a patient navigator on behalf of Harris Health System and receive a mailed HPV self-sampling kit with a pre-paid return envelope.
10169907|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit + Patient Navigation|Participants receive a scripted telephone recall and mailed self-sampling kit with a pre-paid return envelope. Within 3-5 days of the kit's mail-out, participants will receive a telephone call from a patient navigator to provide one-on-one education.
10169908|NCT03898141|Experimental|Animal-assisted placebo condition (AAPL)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream.~Additionally, they will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high de-gree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Therefore, the distance between participant and dog will always be the same. However, partici-pants will still be able to see the dog."
10169909|NCT03898141|Placebo Comparator|Placebo only (PO)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
10169910|NCT03898141|Experimental|Dog only (DO)|"Participants will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. During the experiment the dog will be lying in the room with some distance to avoid further physical interaction.~After the introduction of the dog, participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements"
10169911|NCT03898141|No Intervention|No dog, no placebo (ND)|Participants will participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements.
10169912|NCT03898011|Other|Sequence Test-Reference (TR)|14 participants (total number of enrolled volunteers - 28) assigned to sequence TR will receive a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 1 and a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10169913|NCT03898011|Other|Sequence Reference-Test (RT)|14 participants (total number of enrolled volunteers - 28) assigned to sequence RT will receive a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 1 and a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10186869|NCT03731728|Experimental|Group Exercise plus TAU|"Participants enrolled in the group exercise plus TAU arm of the study will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks in addition to being wait-listed to receive treatment as usual."
9974954|NCT04999228|Active Comparator|Corticosteroid treatment group|For newly diagnosed moderate to severe Pediatric ulcerative colitis, corticosteroids will be used as first-line treatment
10169914|NCT03898557|Experimental|Usual Care|"Participants randomized to this arm will receive a card with information to report results via WhatsApp, similar to the existing card used in the STAR program. This card will have a dedicated Usual Care WhatsApp number (different from the existing STAR program numbers).~Potential self-test recipients will be shown the WhatsApp card and instructed on how to anonymously report use of self-test to the WhatsApp number. Recipients will be instructed to message the WhatsApp number for the following reasons:~1. So study staff know the self-test recipients used the test and it went ok. 2. So study staff can help the self-test recipients understand the results of the test. 3. If the self-test recipients need support from study staff to access care and services."
10169915|NCT03898557|Experimental|Plan and Pledge|"Participants randomized to this arm will revive the Usual Care WhatsApp card and and a brief template to make a plan and make a pledge for test completion and results reporting, to take the HIV self-test. The card will include a dedicated Plan and Pledge WhatsApp number.~Potential self-tester recipients will be shown the WhatsApp card, including Plan and Pledge statements, and will be encouraged by STAR field staff to use the card in their own time to make a plan and sign the pledge as part of receiving the test kit and instructions for how to complete the card. Importantly, testers will be able to keep the card for themselves. There is no expectation to share the plan or the pledge signature with the STAR field staff who distribute self-tests. Field staff will clarify for self-tests recipients that the Plan and Pledge process and card do not change the confidentiality of testing in any way."
10169916|NCT03898206|Experimental|Prolonged sitting|Participants will remain seated for 5 h and instructed to reduce excessive movement, only rising from the chair to void.
10169917|NCT03898206|Experimental|Breaking up sitting with walking breaks|Participants will rise from the seated position every 30 min throughout the experimental period to walk on a motorised treadmill at a light intensity walking (as determined during the preliminary test) for 3 min. Participants will start walk on a treadmill at 30 min (so physical activity would be at 30-33 min), 60 min (physical activity will be at 60-63 min), 90 min (physical activity will be at 90-93 min), 120 min (physical activity will be 120-123 min), 150 min (physical activity will be at 150-153 min ), and 180 min (physical activity will be at 180-183 min) in the breakfast postprandial period and 30 min (physical activity will be 30-33 min), 60 min (physical activity will be at 60-63 min), and 90 min (physical activity will be at 90-93 min) in the lunch postprandial period. After performing walking activity, they will return to the seated position.
9826525|NCT02421224|Active Comparator|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
10169918|NCT03898245|Active Comparator|active tDCS|intervention : Intensity 2mA, 30minues, 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS
10169919|NCT03898245|Sham Comparator|sham tDCS|Intensity 2mA, 8 seconds (but looks same as an intervention 30mins), 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS (sham mode)
10169920|NCT03898271|Experimental|Virtual World Training|Synchronous PTSD training in a virtual world environment
10169921|NCT03898271|Active Comparator|Web-based Video Training|Asynchronous web-based PTSD training
10169922|NCT03898115|Experimental|CHG Bathing Implementation|In a step-wedged design, ICUs and BMT units will be enrolled into a educational program to improve knowledge/compliance with daily CHG bathing
10169923|NCT03898115|No Intervention|Control|In a step-wedged design, ICUs and BMT units will be enrolled over a rolling 4 month time frame; when not enrolled, this data will serve as control data
10169924|NCT03897933||Erector spinae plane block group (ESP)|Single- shot ultrasound guided ESP block with 30 ml 0.25% bupivacain at the T10 vertebral level will performed preoperatively to patients in the ESP group (Group I).
10169925|NCT03897933||non- blocked Group|consists of the patient group without any procedure
9520416|NCT03277898|Experimental|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
9520417|NCT03277898|Other|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).
9520418|NCT03277872|Active Comparator|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
9520419|NCT03277872|Active Comparator|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
9520420|NCT03277859|Experimental|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
9520421|NCT03277859|Active Comparator|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
9520422|NCT03277833|Experimental|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
9520423|NCT03277833|Placebo Comparator|Placebo|Placebo
9826526|NCT02421224|Experimental|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
10169926|NCT03898102|Experimental|Regorafenib treatment with Zn supplement|Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
10169927|NCT03898102|Active Comparator|Regorafenib treatment only|Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.
10169928|NCT03898336|Experimental|broad-spectrum micronutrients|broad-spectrum micronutrients description: capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
10169929|NCT03898336|Placebo Comparator|placebo|capsules containing placebo
10169930|NCT03897803||Group (I):juvenile dermatomyositis (JDM)|"Group (I): twenty children diagnosed to have juvenile dermatomyositis (JDM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.~."
10169931|NCT03897803||Group (II):idiopathic inflammatory myopathies(IIM)|"Group (II): twenty adults diagnosed to have idiopathic inflammatory myopathies(IIM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.~•"
10169932|NCT03897803||Group (III): juvenile control group|"20 healthy children matching age and sex as first control group to children with JDM .Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .~."
10169933|NCT03897803||Group (VI):adult control group|20 healthy adults matching age and sex as second control group to adults with IIM. Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .
10169934|NCT03897855|Other|Patient (TSPT-R)|Post Traumatic Stress Disorder
10169935|NCT03897855|Experimental|control|No Post Traumatic Stress Disorder
10169936|NCT03898024|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
10169937|NCT03898024|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
10169938|NCT03898024|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
10169939|NCT03898024|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
9826527|NCT02421224|Experimental|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
9826528|NCT02421224|Experimental|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
10169940|NCT03898024|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
10169941|NCT03897894|Experimental|Enhanced Service Package|"The enhanced service package provides 40 sequential sessions selected by CFS program staff in advance and implemented over a twelve-week period. Activities are meant to build upon and reinforce one another and are organized into seven psychosocial themes: 1) Building community: Our space together, 2) Emotional learning: My feelings, 3) Wellbeing and coping: Feeling good, 4) Social support: My friends and family, 5) Relating to others: Being a good friend, 6) Protection and boundaries: My safety, and 7) Building on strengths: All my supports. Each session takes approximately 1.5 - 2 hours to facilitate and will conclude with 1-1.5 hours unstructured free play time."
10169942|NCT03897894|Experimental|Basic Service Package|The basic service package offers a mixture of recreational and non-formal education activities over a twelve-week period. Each session lasts around 1.5 - 3 hours. Structured activities offered include basic literacy and numeracy lessons, life skills exercises, health and hygiene sessions, and traditional song and dance. Many activities are centered around various forms of play that enable expression and age-appropriate skill development. Unstructured free play and playground time is allocated throughout the daily session.
10169943|NCT03897894|No Intervention|Control|Waitlist control will receive delayed treatment of intervention after the primary assessment period.
10169944|NCT03897972|Active Comparator|Non-personalised general diet advice|Control group to receive non-personalised dietary advice based on general public health dietary recommendations for Northern Europe. Advice will be delivered to the participant via the eNutri web application.
10169945|NCT03897972|Experimental|Personalised diet advice|Intervention group to receive personalised dietary advice generated by the eNutri app from their actual dietary intakes and tailored according to their body mass index and food preferences. Advice will be delivered to the participant via the eNutri app web application and will be generated based on their adherence to an 11-item diet quality score suitable for Northern European populations.
10169946|NCT03897790||Patients under vasoconstrictor|Patients older than 65 years old and hypertensive, requiring vasoconstrictor (phenylephrine or Neosynephrine) during general anesthesia.
10169947|NCT03897686|Experimental|NOLTREX™, II-III grade OA|72 patients with II-III grade of gonarthrosis will randomised to receive PAHG
10169948|NCT03897686|Placebo Comparator|Placebo, II-III grade ОА|72 patients with II-III grade of gonarthrosis will randomised to receive saline solution
10169949|NCT03897959|Other|Kohli vs Foley Study|Compare various performance characteristics of two urinary catheters.
10169950|NCT03898089|Other|Core Exercise Group|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks.
10169951|NCT03898089|Experimental|Core Exercise plus Myofascial Relaxation Group|In addition to the core stabilization exercises myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks.
10169952|NCT03897647|Experimental|POCUS Patients|A bedside echocardiogram will be taken using a point-of-care pocket ultrasound (General Electric (GE) Vscan). Central venous pressure (right atrial pressure) and pulmonary capillary wedge pressure (left atrial pressure) will be collected from pulmonary artery catheters.
9974955|NCT04983407|Experimental|Phase 1b: batiraxcept+ nab-paclitaxel and gemcitabine|
9974956|NCT04983407|Experimental|Phase 2: batiraxcept+ nab-paclitaxel and gemcitabine|
9974957|NCT04983407|Active Comparator|Phase 2: nab-paclitaxel and gemcitabine alone|
10169953|NCT03897842|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
10169954|NCT03897660|Active Comparator|TG form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acidsesterified in a reconstitute triglyceride form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
10169955|NCT03897660|Active Comparator|EE form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in ethyl esters form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
10169956|NCT03897660|Experimental|MaxSimil (MAG form of omega-3)|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in MaxSimil® form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
10169957|NCT03897946|Experimental|Group A: Hepatitis B exposed, with birth dose|"The 100 HBV-exposed (born to HBsAg-positive mothers) infants who are already enrolled in the parent AVERT study will also be enrolled in the current study, as the HBV-exposed cohort (Group A). These exposed infants will not receive additional interventions on top of the AVERT study since they will already be receiving a birth dose vaccine through the AVERT study."
10169958|NCT03897946|No Intervention|Group B: Hepatitis B unexposed, no birth dose|"For the HBV-unexposed cohort in this study, the investigators will enroll 200 infants born to HBsAg-negative mothers. Half (100) of these infants will receive the routine three-dose series of HBV vaccine according to the standard EPI schedule in the DRC with no additional birth dose vaccine (Group B)."
10169959|NCT03897946|Experimental|Group C: Hepatitis B unexposed, with birth dose|"Group C will consist of the other half (100) of infants in the HBV-unexposed cohort who will receive four doses of HBV vaccine including a birth dose vaccine prior to the routine EPI schedule."
10169960|NCT03897764|Experimental|Superior Hypogastric Block group|The group which superior hypogastric block performed intraoperatively
10169961|NCT03897764|Placebo Comparator|placebo controlled group|The group which placebo used
10169962|NCT03897777|Experimental|Hypertension (Exercise Intervention)|Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.
10169963|NCT03897569||patellofemoral pain syndrome|twenty subjects with anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
10169964|NCT03897569||control|twenty-six asymptomatic subject will be recruited for this study and should have no pain or other relevant clinical symptoms in the lower quadrant
9520424|NCT03277820|Experimental|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
9520425|NCT03277820|No Intervention|Control group|No intake of Probactiol Mini
9520426|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
9520427|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
9826529|NCT02421224|Experimental|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
10169965|NCT03897868|Experimental|Experimental 1|HCP1803 High
9520428|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
9520429|NCT03277781||Current smokers|
9520430|NCT03277781||Ex-smokers|
9520431|NCT03277781||Coronary heart disease|
9520432|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
9520433|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
9520434|NCT03277755|Experimental|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
9662164|NCT05130385||Retinal detachment|Patients history of retinal detachment
9662165|NCT05130385||Age related macular degeneration|Patients with history of age related macular degeneration
9662166|NCT05130385||Retinal changes from arterial hypertension|Patients with history of arterial hypertension
10169966|NCT03897868|Experimental|Experimental 2|HCP1803 Middle
10169967|NCT03897868|Experimental|Experimental 3|HCP1803 Low
10169968|NCT03897868|Active Comparator|Active Comparator 1|HGP0904 High
10169969|NCT03897868|Active Comparator|Active Comparator 2|HGP0904 Low
10169970|NCT03897868|Active Comparator|Active Comparator 3|HGP0608
10169971|NCT03897868|Placebo Comparator|Placebo Comparator|Placebo
10169972|NCT03897465|Experimental|Lomatuell Pro|Lomatuell Pro® is a wound contact layer consisting of wide-meshed tulle, impregnated with a polymer matrix, which form a gel on contact with wound exudate to facilitate moist wound healing.
10169973|NCT03897465|Active Comparator|UrgoTul|UrgoTul® is a flexible contact layer with TLC healing matrix comprised of a conformable polyester mesh impregnated with hydrocolloid and petroleum jelly particles.
10169974|NCT03897543|Experimental|ABX196|IM injection of 0.1, 0.2, and 0.4 µg of ABX196
10169975|NCT03897907|Experimental|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
10169976|NCT03897907|Placebo Comparator|Control Education|This arm will provide education of basic knee anatomy and will not address maladaptive psychological behaviors.
10169977|NCT03897504|Experimental|feminizing genitoplasty using inner surface of the prepuce|Feminizing genitoplasty will be done using the prepuce as a pedicled tubularized flap to create the new vagina, the new vagina which the investigators create it from the prepuce will be sutured above to the native vagina after its separation from the urogenital sinus, and the remaining part of the urogenital sinus will be used to create the urethra, the remaining part of the prepuce will create the labia minora, clitoroplasty will be attempted in all patients.
10169978|NCT03897283|Experimental|Anlotinib + TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10169979|NCT03897478||Ischemic Stroke|"Ischemic stroke subjects presenting within 30 hours from symptom onset will have al PAX Gene Blood RNA tubes drawn upon arrival to the Emergency Department (if available) or hospital.~Biomarker blood draw"
10169980|NCT03897478||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn. Control group matched with ischemic stroke subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
10169981|NCT03897400||study group|women in reproductive age with crohn's disease
10169982|NCT03897400||control group|women in reproductive age without crohn's disease,
10169983|NCT03897517|Experimental|Proprietary Botanical Blend|Proprietary Botanical Blend - Dietary supplement with alpha amylase and sucrase inhibitory activity. 2 capsules
10169984|NCT03897517|Placebo Comparator|Placebo|Non/minimally nutritive nonactive material: rice flour. 2 capsules
10169985|NCT03897361|Experimental|CTNS-RD-04 Gene Therapy|This is a single arm study without randomization. Eligible subjects will receive the final product: CTNS-RD-04.
10169986|NCT03897426|No Intervention|Standard-of-care arm|Patients randomized to the Standard-of-care-arm were provided 60 minutes of RD time for consultation through in person visits.
9662167|NCT05130385||Uveitis|Patients with history of uveitis intermedia and/or posterior and/or pan-uveitis
10169987|NCT03897426|Experimental|Intervention arm|"Mediterranean Diet - Remote Coaching using a Mobile App.~Patients randomized to the intervention arm were allotted 60 minutes of RD time through a Mobile App (for remote consultation), given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD. Remote coaching by RD was the intervention."
10169988|NCT03897309|Experimental|Monovalent GI.1|Monovalent GI.1 tableted vaccine group
10169989|NCT03897309|Experimental|Monovalent GII.4|Monovalent GII.4 tableted vaccine group
10169990|NCT03897309|Experimental|Bivalent GI.1 and GII.4 vaccine group|Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine
10169991|NCT03897309|Placebo Comparator|Placebo|Placebo tablets
10169992|NCT03897738|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
10169993|NCT03897738|Placebo Comparator|Placebo|"Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~Placebo capsules are identical to Amberen and Smart B capsules."
10169994|NCT03897153|Experimental|Experimental:Diagnostic|Diagnostic Test: SONAS® Ultrasound Device
10186870|NCT03731728|No Intervention|Wait-listing for TAU|"Participants enrolled in the wait-listing for treatment as usual or TAU arm of the study will be wait-listed to receive individual therapy or counselling from an Addiction and Mental Health therapist as per current standard protocol for managing patients with MDD at Addiction and Mental Health Clinics of Edmonton Zone."
10186871|NCT03731689|No Intervention|Control group|Control group( Intrauterine patients) do not apply intrauterine lavage therapy or intrauterine gel-injection therapy after surgery.
10186872|NCT03731689|Experimental|Intrauterine lavage therapy group|Intrauterine lavage therapy group apply intrauterine lavage therapy after surgery.
10186873|NCT03731689|Experimental|Intrauterine gel-injection therapy group|Intrauterine gel-injection therapy group apply intrauterine gel-injection therapy after surgery.
10186874|NCT03731689|No Intervention|Healthy control group|Healthy control group 1)have regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity.2) had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.
9662168|NCT05130385||Healthy|Healthy age matched control subjects
10169995|NCT03897413|Experimental|Sequence 1|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fed state in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
10169996|NCT03897413|Experimental|Sequence 2|Participants received a single oral dose of 0.75 mg S-888711 in the fed state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
10169997|NCT03897413|Experimental|Sequence 3|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state in period 2, and a single oral dose of 0.75 mg S-888711 in the fed state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
10169998|NCT03897218|Placebo Comparator|Group 1|Patients consuming placebo (millet flakes) each day
10169999|NCT03897218|Experimental|Group 2|Patients consuming oatmeal flakes with a low dosage of prebiotic food supplements
10170000|NCT03897218|Experimental|Group 3|Patients consuming oatmeal flakes with a high dosage of prebiotic food supplements
10170001|NCT03897452|Experimental|Fentanyl for procedural pain|"A dose of Fentanyl 5 microgram/ml, 0.5 microgram/kg (anticipated medium pain) or 2 microgram/kg (anticipated strong pain) will be given prior to a painful procedure during NICU-care. Repeated doses or complementary analgesics will be administered according to pain assessment and clinical judgement.~This is not an RCT with several arms."
10170002|NCT03897010|Active Comparator|Silica-calcium phosphate composite Group|Participants underwent socket augmentation procedures and dental implant placement in a staged approach. Atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. Free gingival gingival graft (1.5 to 2 mm thick) was taken from the area between the first and second premolar, 5 mm from gingival margin. Bioactive porous SCPC dental bone graft granules in the size range 90-710 micron were mixed with saline and loosely packed in the extraction sockets as per the manufacturer. The grafted SCPC granules were covered with free gingival graft obtained from the palatal tissues and sutured to stabilize the grafting material in place.
10170003|NCT03897010|Placebo Comparator|Control Group|Participants underwent atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. The socket left to heal.
10170004|NCT03897114|Experimental|Cocoa group|The cocoa will be provided in sachets. The intervention will be carried out for 10 weeks. Cocoa is provided in a single daily dose of 5 g, which contains 83 mg of flavonoids per gram of cocoa (dose at which a prebiotic effect has been shown).
10170005|NCT03897114|Placebo Comparator|Placebo group|Maltodextrin will be supplied as a placebo, which will be provided in sachets. Athletes will take 5g of product per day.
10170006|NCT03896971|Experimental|Thrombopoietin mimetic plus immunosuppressive therapy|The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months. Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
9520435|NCT03277755|Experimental|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
10170007|NCT03896971|No Intervention|Immunosuppressive therapy|A comparative group will be collected retrospectively and treated with cyclosporin A alone as standard.
9520436|NCT03277742|Active Comparator|Control|This arm will receive the standard of care for patients with TB and DM2
9520437|NCT03277742|Experimental|Intervention|This arm will receive the community intervention
9520438|NCT03277716|Experimental|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
9520439|NCT03277677|Active Comparator|normal saline|
9520440|NCT03277677|Active Comparator|balanced solution|
9520441|NCT03277664|Experimental|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
9520442|NCT03277664|No Intervention|control group|"All the device-monitored adherence data were downloaded from the background database and calculated weekly. However, feedback and reminders were not given to the caregivers. Caregivers were also asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
10170008|NCT03897140|Experimental|Patients scheduled for an echocardiogram|Patients ≥18 years scheduled for an echocardiographic examination. This is a non-randomized, un-blinded, study in patients with an indication for an echocardiographic examination. Enrolled patients will be stratified into two groups based on known cardiac abnormalities to ensure a sufficient number of patients with cardiac abnormalities and into 3 strata of BMI: normal, overweight and obese.
10170009|NCT03896841||PCOS|premenopausal patients with PCOS
10170010|NCT03896841||control subjects|non-pregnant healthy control subjects
10170011|NCT03897166|Experimental|Trimodality Imaging|Positron Emission Tomography coupled with Computed Tomography computed coupled with Magnetic Resonance Imaging and whole-body Biphoton Absorptiometry
10170012|NCT03896867|Experimental|Anapod™ Humi-Therm Heated Humidification System|Patient warming will be provided via the Anapod™ Humi-Therm Heated Humidification System Breathing Circuit.
10170013|NCT03896867|Active Comparator|Bair Hugger™ Warming Blanket|Patient warming will be provided via the Bair Hugger™ Warming Blanket.
10170014|NCT03896906|Experimental|Group N|pre-oxygenation with High-flow nasal cannula
10170015|NCT03896906|Active Comparator|Group M|pre-oxygenation with simple mask
10170016|NCT03896802|Experimental|Low PEEP|PEEP 5 cmH2O
10170017|NCT03896802|Experimental|High PEEP|PEEP 15 cmH2O
10170018|NCT03896932|Experimental|minipooled- Intravenous immunoglobulin(MP-IVIG)|• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
10170019|NCT03897049|Experimental|TWC App|The intervention is a mobile app delivered sexual health promotion program designed specifically for transgender women. The mobile app will include more than 30 interactive activities including resource maps, PrEP and PEP content, and communication forums for connecting with other transgender women. The intervention/app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
10170020|NCT03897049|Active Comparator|General Health App|Participants will download a general health mobile app that contains sexual health information. The control mobile app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
10170021|NCT03897062|Active Comparator|Treatment group|Patients (n=64): 20mg tablets of suvorexant nocte daily for six months
10170022|NCT03897062|Placebo Comparator|Placebo group|Placebo control group: Patients (n=64): 1 placebo tablet nocte daily for six months in addition to treatment as usual
10170023|NCT03897023||Stable patient|Stable patients who admitted to ICU for observation.
10170024|NCT03896893|No Intervention|Standard of Care|Routine bathing and skin care as per hospital practice
10170025|NCT03896893|Experimental|1% chlorhexidine gluconate (CHG)|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays (total of 8 days CHG application)
10170026|NCT03896893|Experimental|Emollient therapy|Aquaphor skin cream applied from the neck down daily on weekdays (total of 8 days emollient application)
10170027|NCT03896893|Experimental|1% CHG plus emollient therapy|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays followed immediately by Aquaphor skin cream (total of 8 days CHG application plus emollient application)
10170028|NCT03896854|Experimental|CD19 positive relapsed or refractory acute myeloid leukemia|MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia
10170029|NCT03896672|Experimental|Treatment with Continuous Positive Airway Pressure|All patients will undergo to physiotherapeutic treatment based on the previous training of the physiotherapist
10170030|NCT03897101||MILD NE|"gestational age > 35 weeks and weight > 1800 gr~Apgar score < 5 at 10 minutes o need for cardiopulmonary resuscitation at 10 minutes or evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses~evidence of mild encephalopathy graded according to Sarnat&Sarnat neurological evaluation~normal amplitude integrated electroencephalography~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
10170031|NCT03897101||ISOLATED METABOLIC ACIDOSIS|"gestational age > 35 weeks and weight > 1800 gr~evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses~Normal Sarnat&Sarnat neurological evaluation~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
10170032|NCT03897101||HEALTY CONTROLS|"gestational age > 35 weeks and weight > 1800 gr Normal blood pH or base excess~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokiness will be evaluated"
10170033|NCT03896737|Experimental|Dara-VCd|"treatment period includes administration of four 28-day cycles of induction with Dara- VCd; then patients will undergo transplant and finally they will receive two 28-day cycles of Dara-VCd consolidation treatment.~The response will be assessed after each cycle. Patients in the first randomization will be stratified according to FISH (standard/missing vs high risk,defined as del17, t 4;14, t 14;16) and ISS (I vs II and III).~TREATMENT SCHEMA - INDUCTION Daratumumab: 16 mg/Kg given by IV infusion on days 1, 8, 15, 22, on cycles 1-2 and on days 1, 15 on cycles 3-4.~Bortezomib: 1.3 mg/m2 given SC injection on days 1, 8,15, 22; Cyclophosphamide: 300 mg/ m2 given orally or IV infusion on days 1, 8, 15, 22; Dexamethasone: 40 mg given orally or by IV infusion on days 1, 8, 15,22 Repeat for four 4-week induction cycles."
10170034|NCT03896737|Active Comparator|VTd|"treatment period includes administration of four 28-day cycles of induction with VTd; then patients will undergo transplant and finally they will receive two 28-day cycles of VTd consolidation treatment.~TREATMENT SCHEMA INDUCTION~ARM VTd:~Bortezomib: 1.3 mg/m2 given by SC injection on days 1, 4, 8, 11 of 28-day cycle; Thalidomide: 100 mg given orally on days 1-28. Dexamethasone: 20 mg given orally or by IV injection on days 1, 2, 3, 4, 8, 9, 10 and 11 of every 28-day cycle.~Repeat for four 4-week induction cycles."
10170035|NCT03896763|Experimental|Supine / CMV|Supine positioning and conventional mechanical ventilation
10170036|NCT03896763|Experimental|Prone / CMV|Prone positioning and conventional mechanical ventilation
9671752|NCT05043909|Experimental|Experimental Group (EG)|The students in EG received VR-based training for elderly oral health care at 2-week (Time 2), 4-week (Time 3), and 6-week (Time 4) follow-ups. The learning module was divided into three sessions according to the physical condition (1) Mild disability, (2) Semi-disability, (3) Total disability and oral condition, (1) wearing dentures, (2) missing teeth of the elderly. Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
9671753|NCT05043909|No Intervention|Control Group (CG)|The students in CG do not receive any of the interventions. However, the same VR-based curriculum of oral health care on dependency elderly were provided at the end of the study.
9671754|NCT05043753|No Intervention|Control group: Symphysis fundal height measurement|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNMs) using symphysis fundal height (SFH)
9520443|NCT03277651||liver fibrosis|liver biopsy proved
9520444|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
10170037|NCT03896763|Experimental|Supine / HVOF|Supine positioning and high-frequency oscillatory ventilation
10170038|NCT03896763|Experimental|Prone / HFOV|Prone positioning and high-frequency oscillatory ventilation
10170039|NCT03896776|Experimental|Community Based Organization (CBO) Delivery|"CBOs will be selected through a Request for Proposal (RFP) process. The RFP will describe research and KIU! delivery activities to be conducted as part of the study and allowable budget to carry out the activities. The RFP will ask CBOs to describe past experience providing HIV services for YMSM. Selected CBOs will recruit participants into the intervention and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the CBO delivery arm will receive baseline HIV and STI testing at a CBO. Participants will receive an at-home STI test kit at 12 Week Follow-up if testing is not provided at their CBO site."
10170040|NCT03896776|Experimental|Direct to Consumer (DTC) Delivery|"In the DTC arm, participants will be recruited online via paid social media advertising (e.g., Facebook, Instagram). Advertisements will target placements by age, gender, sexual orientation, racial background, likes that are relevant to YMSM (e.g., local LGBT organizations, out celebrities), and location (i.e., target county). Dating/sex-seeking apps (e.g., Grindr) will also be used to recruit YMSM, using a similar advertising approach as social media. These online recruitment strategies will be supplemented by referrals from local organizations and participant registries, and snowball recruitment. Study staff at Northwestern University will manage this recruitment process and encourage participants to complete each session of intervention content at baseline, 6 Week Follow-up, and 12 Week Follow-up.~Participants in the DTC delivery arm will receive at-home HIV and STI test kits at baseline. Participants will receive an at-home STI test kit at 12 Week Follow-up."
10170041|NCT03896919||cases|HLA-DQ mismatched recipient-donor pairs
10170042|NCT03896919||control|HLA-DQ matched recipient- donor pairs
10170043|NCT03896542|Experimental|Commercial video game|the group commercial video game received 30 minutes of conventional therapy plus 30 minutes of rehab training using Xbox Kinect-based games.
10170044|NCT03896542|Experimental|Rehabilitation video game|the group rehabilitation video game received 30 minutes of conventional therapy plus 30 minutes of rehab games.
10170045|NCT03896542|No Intervention|The control group|The control group received 30 minutes of conventional therapy
10170046|NCT03896698|Experimental|TUS treatment|AD patients with TUS treatment
10170047|NCT03896698|No Intervention|Non-TUS treatment|AD patients with Non-TUS treatment
10170048|NCT03896386|Other|Use of seizure diary|People diagnosed with epilepsy that lives with a dog that is able to anticipate the onset of a seizure. They will be ask to use a diary (bespoke smartphone app) to register the occurrence of seizures and the alerting behaviour of the dogs.
10170049|NCT03896412|Experimental|Detection of circulating tumor DNA|sampling of 20 ml of blood the day before surgery, the day after , 6 months after diagnosis and every 3 months thereafter until 18 months of follow up
10170050|NCT03896646|Experimental|Treatment (personalized radioembolization, SPECT/CT HIDA)|Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization.
10170051|NCT03896451|Other|GMK Sphere|"Patients receiving total knee replacement surgery with the device Medacta GMK Sphere"
9520445|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter <3 mm.
9520446|NCT03277612||C-Section|Infants delivered by C-section
10170052|NCT03896451|Other|GMK PS|"Patients receiving total knee replacement surgery with the device Medacta GMK PS"
10170053|NCT03896321|Active Comparator|Asprin|Patient will receive dual anti platelet asprin And clopidogrel
9520447|NCT03277612||Vaginal Delivery|Infants delivered by spontaneous vaginal delivery after C-section.
9520448|NCT03277599|Active Comparator|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
9520449|NCT03277599|Active Comparator|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
9520450|NCT03277586|Experimental|Probio'Stick|
9520451|NCT03277586|Placebo Comparator|Placebo|
10170054|NCT03896321|Active Comparator|Clopidogrel|Patient will receive dual anti platelet asprin And clopidogrel
10170055|NCT03896321|Active Comparator|Warfarin|Patient will receive oral anticoagulation
9520452|NCT03277573|Experimental|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
9520453|NCT03277573|Placebo Comparator|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
10170056|NCT03896321|Active Comparator|Novel oral anticoagulant|Patient will receive oral anticoagulation
10170057|NCT03896490|Experimental|ACT|
10170058|NCT03896490|Placebo Comparator|Control|
10170059|NCT03896594|Experimental|HL237 200mg|HL237 100mg 1 tablet twice a day
10170060|NCT03896594|Experimental|HL237 400mg|HL237 100mg 2 tablets twice a day
10170061|NCT03896594|Experimental|HL237 800mg|HL237 400mg 1 tablet twice a day
10170062|NCT03896334|Experimental|Isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training will train three times per week, during 24 weeks. They will perform a bout of isometric handgrip exercise: four sets of 2-min of isometric contractions (using alternate hands) at 30% of maximal voluntary contraction.
9527712|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:~The Mologic Biomarker Panel~PCT~CRP~Other inflammatory markers or pathogen detection that may augment the panels accuracy~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
10170063|NCT03896334|Sham Comparator|Control group|All participants randomized to control group will realize stretching and relaxation exercises, three times per week, during 24 weeks.
10170064|NCT03896373||Lupus erythematosus|Patients with inactive lupus erythematosus, active lupus erythematosus or newly diagnosed
10170065|NCT03896347||ViBone®|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
10170066|NCT03896347||Demineralized Bone Matrix|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
10170067|NCT03896347||Bone Morphogenetic Protein|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
10170068|NCT03896256|Experimental|Treatment Arm|Patients will be admitted to the hospital for a total of 5 full days from the time of admission until discharge. Ketamine infusion will be started on day 1. Adjustments to ketamine infusion will be made according to standard acute pain service protocol.
10170069|NCT03896282|Active Comparator|daycare facility|After surgery patient stay at daycare facility for mobilisation and stay until discharge or transfer to standard patient ward if nor discharged by 20.000
10170070|NCT03896282|Active Comparator|standard patient ward|After surgery patients are transferred to standard patient ward for mobilisation and stay until discharge.
10170071|NCT03896113|Experimental|Celecoxib|Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery will receive celecoxib 400 mg twice a day, for 15 days before the curative surgery for their endometrial cancer. The patients will undergo an endometrial biopsy at the inclusion and during the surgery.
10170072|NCT03896243||Uterine artery ligation (UAL)|"We would like toinvite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They would be evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
10170073|NCT03896243||Control Group:|"We would like to invite the patients to the hospital at least 6 months after C-section who delivered baby without any complication.~They would be also evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
9520454|NCT03277534|Experimental|Electrical stimulation|
9520455|NCT03277534|Sham Comparator|Control|
9520456|NCT03277521|Active Comparator|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
9520457|NCT03277521|Active Comparator|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
9520458|NCT03277521|Active Comparator|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
9520459|NCT03277508|Experimental|BCI robot assisted hand therapy|Brain-computer integration robot assisted hand therapy
9520460|NCT03277508|Active Comparator|CPM robot assisted hand therapy|Continue Passive Movement robot assisted hand therapy
9520461|NCT03277482|Experimental|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab* and radiation therapy~*q4 weeks durvalumab for 13 cycles or until progression"
9671755|NCT05043753|Experimental|intervention group: Symphysis fundal height measurement and point of care ultrasound.|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNM) using symphysis fundal height (SFH) and point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)
9671756|NCT05043896|Experimental|Combination therapy|Li-ESWT + tadalafil
10170074|NCT03896074|Experimental|Atezolizumab|Patients allocated to Arm A will be treated with atezolizumab administered intravenously at 1200 mg every 3 weeks given until disease progression, toxicity or patient refusal
10170075|NCT03896074|Experimental|Atezolizumab plus bevacizumab|Patients in the Arm B will receive atezolizumab administered intravenously at 1200 mg every 3 weeks plus bevacizumab intravenously at 15 mg/kg every 3 weeks given until disease progression, toxicity or patient refusal
10170076|NCT03896191||Stable, satisfied primary TKR|Participants who have a stable TKR (as assessed by the surgical team) and are satisfied with their knee replacement (as assessed by a questionnaire).
10170077|NCT03896191||Unstable, dissatisfied primary TKR|Participants who are dissatisfied with their TKR, with instability (including instability due to aseptic loosening) and consequently awaiting revision TKR.
10186875|NCT03731676|Active Comparator|Rotating platform total knee arthroplasty|These patients were randomly assigned to receive a rotating platform total knee arthroplasty.
10186876|NCT03731676|Active Comparator|Fixed bearing total knee arthroplasty|These patients were randomly assigned to receive a fixed bearing total knee arthroplasty.
10186877|NCT03731663|Experimental|Appetizing Food exposure group|Participants allocated to this group will watch a 3-minute video presenting a series of pictures of appetizing foods eaten in facilities in a tourist destination. An audio of a young adult describing herself eating these foods during a trip to London will be played.
9671757|NCT05043896|Sham Comparator|Single Therapy|tadalafil only
10170078|NCT03896269|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|"INDUCTION THERAPY: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. After 2-5 weeks, patients who do not achieve a CR/CRi/CRp, have acceptable or no toxicity, and have stable disease and no disease progression may receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients who achieve at least a HI response, receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 5-8 weeks, patients who do not show clinically significant disease progression or unacceptable toxicity may receive liposome-encapsulated daunorubicin-cytarabine for up to 12 additional cycles."
10170079|NCT03895892|Placebo Comparator|Water Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
10170080|NCT03895892|Experimental|Experimental 1|Ketone salts supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
10170081|NCT03895892|Experimental|Experimental 2|Ketone salts/caffeine supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
10170082|NCT03895905||Genotype of HR-HPV 16/18|Patients with genotype of HR-HPV 16/18 who underwent cervical biopsy with colposcopy
10170083|NCT03895905||Genotype of HR-HPV Non-16/18|Patients with genotype of HR-HPV non-16/18 who underwent cervical biopsy with colposcopy
10170084|NCT03896217|Active Comparator|Simvastatin|Simvastatin is part of the pharmacotherapeutic group of HMG-CoA reductase inhibitors (ATC-Code: C10A A01). Simvastatin is licensed within the EU for hypercholesterolemia and cardiovascular prevention but for this trial its use will be outside its licensed indication. Oral Simvastatin will be taken 40mg daily (one tablet in the evening) for 4 weeks and then at week 4 up titrated to 80mg daily (two tablets in the evening.
10170085|NCT03896217|Placebo Comparator|Placebo|Matched Placebo (one tablet in the evening) for 4 weeks and then at week 4 up titrated to two tablets daily in the evening.
10170086|NCT03896165|Experimental|Teaching Reiki|Parent-adolescent pairs will be in the study for a total of nine weeks from enrollment to the follow up visit. During Week 1, the parent will receive Reiki training, a poster with suggested hand positions and a commercially-available book about Reiki in the home. During Week 2 the parent will receive a Reiki booster session with a repeat of the training and may ask questions in the home. At the end of Week 4, measures will be repeated either in person or by phone. During Week 8, measures will be repeated, another hair sample obtained and the parent will participate in a qualitative interview. The qualitative interview will be administered in person by trained Ohio State University College of Nursing study staff as part of the interview session. Interviews will be audio recorded using a hand-held audio recording device. Audio recording is voluntary and participants can choose to not have their interview recorded and still be a part of the study.
10170087|NCT03895957|Experimental|Group 1: VR Mind+|Virtual Reality Exposure Therapy VR Mind+
10170088|NCT03895957|Experimental|Group 2: VR Mind|Virtual Reality Exposure Therapy VR Mind
10170089|NCT03895957|Active Comparator|Control group: CBT|Cognitive Behavioral Therapy
10170090|NCT03896126||Gastroparesis Patients|20 gastroparesis patient ages 20-49
10170091|NCT03896126||Healthy Controls|40 healthy controls ages 20-49
10170092|NCT03896178||Firefighters|
10170093|NCT03896178||Pilots|
10170094|NCT03896178||Police|
10170095|NCT03896178||Military personnel|
10170096|NCT03896178||Controls|Control group matched for geographic location (county), and year of diagnosis. Consisting of all other workers than the four specified groups.
10170097|NCT03895944|Experimental|iv low dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with low dose (1x10^6) in Leukemia or Lymphoma patients
10170098|NCT03895944|Experimental|iv middle dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with middle dose (3x10^6) in Leukemia or Lymphoma patients
9520462|NCT03277482|Experimental|Phase I Radiation Dose Evaluation|"Durvalumab~Tremelimumab* -- Start radiation dose from safety lead-in (level 0 or level -1) *q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
10170099|NCT03895944|Experimental|iv high dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with high dose (10x10^6) in Leukemia or Lymphoma patients
10170100|NCT03896139||VUMC EHR cohort|De-identified version of the electronic health record (EHR) at Vanderbilt University Medical Center (VUMC).
10170101|NCT03896139||Toxicity induced by kinase inhibitors in Vigibase database|Case reported in the World Health Organization (WHO) of toxicity or complication of patient treated by KIs, with a chronology compatible with the drug toxicity
10170102|NCT03896204|Experimental|telephone-supported group|
10170103|NCT03896204|Experimental|Other group|
10170104|NCT03896087|Experimental|clinical performance of the HCV DBS assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the for assays (medical devices) used for the qualitative and quantitative detection of Hepatitis C RNA.
10170105|NCT03896087|Active Comparator|comparison PQ marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
10170106|NCT03895983||Thrombus aspiration group|Will include 135 patients who will have PPCI with thrombus aspiration
9671758|NCT05043727|Experimental|Exer gaming treatment plan|Exer gaming treatment plan
9826530|NCT02421224|Experimental|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
9671759|NCT05043727|Active Comparator|conventional treatment plan|conventional treatment plan
9826531|NCT02421224|Experimental|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
10170107|NCT03895983||Standard PPCI group|Will include 135 patients who will have PPCI without thrombus aspiration
10170108|NCT03895788|Experimental|niraparib and brivanib|Subjects will be assigned into niraparib 100mg+brivanib 200mg, niraparib 200mg+brivanib 200mg, niraparib 200mg+brivanib 400mg, niraparib 200mg+brivanib 600mg dose group at the first day of the first cycle.
10170109|NCT03895918|Experimental|Delayed Group (delayed parental skills)|Participants continue medication adherence monitoring over 2 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
10170110|NCT03895918|Experimental|Early Group (early parental skills)|Participants continue medication adherence monitoring over 1 week and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
10170111|NCT03895918|Experimental|Late Group (late parental skills)|Participants continue medication adherence monitoring over 3 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
10170112|NCT03895879|Experimental|Intervention|Tocilizumab administered every 2 weeks
10170113|NCT03895879|Active Comparator|Control|Tocilizumab administered every week
10170114|NCT03895879|Active Comparator|Standard dose (screening < 15 mg/L)|Tocilizumab administered every week
9520463|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY with Tracker|"Standard pelvic MRI sequences will be obtained~MRI Tracker is used during catheter positioning with serial MR imaging during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
9520464|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY without Tracker|"Standard pelvic MRI sequences will be obtained~Standard process is used with serial MR imaging to evaluate catheter position during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
9520465|NCT03277456|Experimental|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
9520466|NCT03277443|Active Comparator|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.~Modified model surgical tecnique:~Obtain wax bite registration.~Record face-bow transfer.~Duplication of articulating model for surgical simulation.~Measure all casts and bases in standard model surgery fashion.~Fabricate intermediate splint & Final splint.~Condylar repositional splint."
9520467|NCT03277443|Experimental|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.~Computer-aided planning for study group:~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.~Pre-operative Fabrication of computer aided surgical splint:~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
9520468|NCT03277430|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
9520469|NCT03277430|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
9520470|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
9520471|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
9520472|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
9520473|NCT03277404|Experimental|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium' hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
9520474|NCT03277404|Active Comparator|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
9520475|NCT03277391|Active Comparator|Serratus anterior plane block|Deep serratus anterior plane block
9826532|NCT02421224|Experimental|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
10170115|NCT03895866||Group A|High-risk HPV persistent infection more than half a year and reversion
10170116|NCT03895866||Group B|High-risk HPV non-infection
10170117|NCT03895801|Experimental|Group A Experimental + active comparator|IFX-1 + reduced dose GC
10170118|NCT03895801|Active Comparator|Group B Placebo + active comparator|Placebo-IFX-1 + standard dose GC
10170119|NCT03895801|Placebo Comparator|Group C Experimental + placebo comparator|IFX-1 + Placebo-GC
10170120|NCT03895814|Experimental|Multi-baseline Step Training|"Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week protective step training period. Participants will also be assessed 2 months later at a follow-up visit."
10170121|NCT03895554||Normal volunteers|Normal, healthy volunteers with undergo cardiac PET stress testing.
10170122|NCT03895619|Experimental|Men living with HIV|Uptake of safer conception strategies among men living with HIV and/or their female partners
10170123|NCT03895489|Experimental|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
10170124|NCT03895489|Active Comparator|Stryker|Stryker Triathlon Total Knee prosthesis
10170125|NCT03895489|Active Comparator|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
10170126|NCT03895749|Active Comparator|Neo40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
10170127|NCT03895749|Placebo Comparator|Placebo|Per Capsule: Beet Juice concentrate, Carmine, Croscarmellose Sodium, D-Mannitol, Magnesium Stearate, Orange flavour, Silicon dioxide, Stevia rebaudiana leaf, Xylitol.
10170128|NCT03895476|Active Comparator|control group|palatal wound will not be protected with any material
10170129|NCT03895476|Active Comparator|group 1|palatal wound will be protected with Platelet rich Fibrin
10170130|NCT03895476|Active Comparator|group 2|wound will consist of collagen protection with the additional layer of cyanoacrylate surgical glue.
10170131|NCT03895476|Active Comparator|group 3|wound will consist of collagen protection with the application
10170132|NCT03895671|Experimental|AP-CML|Patient with Philadelphia chromosome positive CML in accelerated phase is defined by the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), ≥ 20% basophils in PB or BM, ≥ 30% blasts plus promyelocytes (with blasts <30%) in PB or BM, <100 x109/L platelets unrelated to therapy, or by clonal cytogenetics evolution (i.e., the presence of cytogenetic abnormalities other than the Philadelphia chromosome);
10170133|NCT03895671|Experimental|MBC-CML|Patient with Philadelphia chromosome positive CML in myeloid blast crisis is defined by the presence of ≥ 30% blasts in the bone marrow and/or peripheral blood or the presence of extramedullary disease.
10170134|NCT03895723|Experimental|Minimally Invasive surgery|the intevention of Minimally Invasive procedure contains laparoscopic and robotic liver resection
10170135|NCT03895723|Other|Open surgery|the open surgery means traditional open surgery for liver resection
10170136|NCT03895606||HIPEC|patients undergoing cytoreductive surgery and hyperthermic intraoperative chemotherapy due to carcinomatosis.
9520476|NCT03277391|Active Comparator|patient-controlled analgesia|patient-controlled analgesia: pump containing morphine (1mg/ml) and dehydrobenzperidol (50 mcg/ml).
9520477|NCT03277339|Experimental|Paroxetine|Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
9520478|NCT03277339|Other|Thermal cure|This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
9671760|NCT05043597|Experimental|Thrombus aspiration|
9671761|NCT05043597|No Intervention|control group|
9671762|NCT05043571|Experimental|Single arm|Single arm Phase I Clinical Trial
9671763|NCT05043844|No Intervention|Control|In the control group, an investigator performed only a pulmonary recruitment maneuver on the Trendelenburg position before the emergence of anesthesia.
10170137|NCT03895697|Experimental|Sequence 1|V2: Single fixed dose (sc injection) of dasiglucagon batch B then at V3: Single fixed dose (sc injection) of dasiglucagon batch A
10170138|NCT03895697|Experimental|Sequence 2|V2: Single fixed dose (sc injection) of dasiglucagon batch A then at V3: Single fixed dose (sc injection) of dasiglucagon batch B
10170139|NCT03895970|Experimental|Lenvatinib plus Pembrolizumab|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.~Pembrolizumab is a recombinant anti-human PD-1 monoclonal antibody."
10170140|NCT03895450|Experimental|Aerobic Exercise Protocol (AEP)|Symptom threshold will be determined at baseline and repeated every 3 weeks using the Buffalo Concussion Treadmill Test. Briefly, there will be an initial 4min warm up at 1.7mph. The protocol will start with treadmill speed se to 3.3 mph and 0.0% incline. Each subsequent minute, the incline will increase by 1.0% to a max of 15%. At 15% grade, if the participant is still able to continue, treadmill speed will increase by 0.4mph each minute. Heart rate (HR) and rating of perceived excretion (RPE Borg scale) will be measured every minute. The test will be terminated upon symptom exacerbation at which time HR and RPE will be recorded. Every 3 weeks the symptom threshold test will be repeated for all participants and exercise prescription will be adjusted accordingly.
10170141|NCT03895450|Placebo Comparator|Stretching Protocol (SP)|The exercise testing for the stretching protocol to determine exercise prescription will be the same as described above.
9520479|NCT03277326|Active Comparator|ISB|Interscalene brachial plexus block
9520480|NCT03277326|Active Comparator|aSSB|Anterior Suprascapular Block
9520481|NCT03277326|Active Comparator|pSSB|Posterior Suprascapular Block
9520482|NCT03277313|Experimental|Epoch 1|Pediatric patients with primary immunodeficiency disease (PIDD) who are on intravenous (IV) or non-HYQVIA subcutaneous (SC) treatment with immunoglobulin (IV-pre-treated, SC-pre-treated) will be enrolled and treated with HYQVIA subcutaneously with a dose or interval ramp-up period of up to six weeks.
9527713|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:~Patients being managed for potential infection~Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
9671764|NCT05043844|Experimental|Abdominal binder|In the abdominal binder group, a pulmonary recruitment maneuver was performed on the Trendelenburg position and the abdominal binder which had a standard height of 22 cm was placed on the abdomen of the patient before the emergence of anesthesia.
9671765|NCT05043467||Duvie(Lobeglitazone)|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
9671766|NCT05043831|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Subjects will be treated with DSLT
9671767|NCT05043831|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects will be treated with SLT
10170142|NCT03895502|Experimental|12-month Edoxaban|Edoxaban for 12 months
10170143|NCT03895502|Active Comparator|3-month Edoxaban|Edoxaban for 3 months
10170144|NCT03895437|Experimental|TOL-3021|TOL-3021 2 mg/mL
10170145|NCT03895437|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
10170146|NCT03895229|Experimental|Experimental Arm|Subjects will receive a single oral dose of Empagliflozin 10 MG Oral Tablet [Jardiance]
10170147|NCT03895138|Active Comparator|Standard Glucommander Protocol (SGP)|CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations
10170148|NCT03895138|Experimental|Optimized Glucommander (OGM)|CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol
10170149|NCT03895125|Experimental|[year1] PD group|
10170150|NCT03895125|Active Comparator|[year1] healthy control group|
10170151|NCT03895125|Experimental|[year2-3] freezer|
9520483|NCT03277313|Experimental|Epoch 2|"HYQVIA treatment at following intervals:~For intravenous (IV)-pre-treated participants: every 3 or 4 weeks, depending on participant's previous IV schedule.~For subcutaneous (SC)-pre-treated participants: every 3 or 4 weeks, at discretion of investigator and participant.~After one year in Epoch 2, anti-rHuPH20 binding antibody assay results during year will decide next steps in study:~Participants with anti-rHuPH20 antibody titer <160 at all time-points during study will complete the study completion visit at next possible occasion following 12-month visit.~Participants with anti-rHuPH20 antibody titer ≥160 during study and/or at last measurement will continue in Epoch 2 for additional 2 years of HYQVIA treatment and observation, and complete study completion visits at next possible occasion following 36-month visit.~Alternative treatment intervals, such as infusion every 2 weeks, may be considered for tolerability reasons, at discretion of investigator after informing sponsor"
9520484|NCT03277313|Active Comparator|Epoch 3|Approximately one year safety follow-up, if needed: for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a study drug related serious adverse event (SAE) or a related severe adverse event (AE) will be followed accordingly.
9520485|NCT03277287|Experimental|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
9520486|NCT03277287|Experimental|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
9520487|NCT03277287|No Intervention|Group C|No intervention
9520488|NCT03277235|Experimental|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
9520489|NCT03277235|No Intervention|Control|Usual care
9520490|NCT03277222|Active Comparator|IN insulin 40 IU|Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
9520491|NCT03277222|Placebo Comparator|IN Sterile Saline|Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks
9520492|NCT03277209|Experimental|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
9520493|NCT03277157|Experimental|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
9520494|NCT03277157|Placebo Comparator|Placebo|Placebo veggie capsule.
9520495|NCT03277144|Experimental|TST-TriStaple(3lines stapler)Technology|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device.
9671768|NCT05043584|Experimental|(A): NIRAF-assisted surgery|Patients undergoing NIRAF-assisted total thyroidectomy
9671769|NCT05043532|Active Comparator|Two passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of two passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
9826533|NCT02421224|Experimental|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
10170152|NCT03895125|Experimental|[year2-3] non-freezer|
10170153|NCT03895073||healthy|healthy volunteers' replies to questionnaire
10170154|NCT03895073||heart failure|heart failure patients' replies the questionnaire
10170155|NCT03895424|Experimental|Iron Fatty Acid Complex (IFAC)|The iron fatty acid complex encapsulated and administered to the participants
10170156|NCT03895424|Experimental|Micellarized iron fatty acid complex (MIFAC)|Micellarized form of the iron fatty acid complex which is enscapsulated and administered to the participants
10170157|NCT03895424|Active Comparator|Control Ferrous Sulfate|Ferrous sulfate that is provided in the form of a solution along with a capsule that contains the same amount of fat that is present in the other two arms.
10170158|NCT03895190|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
10170159|NCT03895190|Experimental|Experimental: Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
10170160|NCT03895177|Experimental|low kVp high mAs CT group|doing pancreatic CT with 80 kVp tube current with more than 500 mA tube current for the evaluation of pancreatic cancer resectability
10170161|NCT03895164|Placebo Comparator|Standard NE|Control Group will receive standard nutrition education package from primary health care.
10170162|NCT03895164|Experimental|Enhanced NE|Intervention Group will receive standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
10170163|NCT03895398|Experimental|nutrition and psychosocial intervention arm|"12 selected ECE centers will be selected to be the intervention group. ECE teachers will be trained on psychosocial and nutrition care for children and expected to deliver the information and parenting class to mother.~Community health officers will be trained on how to monitored the activities regularly and providing technical assistance to ECE teachers if needed.~mothers will received weekly parenting class. in the parenting class mothers will be informed on how to provide appropriate feeding and psychosocial stimulus to their children. nutrient dense food supplementation in the form of liver and fish floss will be prepared together and distributed.~underfive children will received nutrient dense food supplementation in the form of liver and fish floss and expected to be eaten everyday for 6 months"
10170164|NCT03895398|No Intervention|control arm|no intervention is given to this arm
10170165|NCT03895021|Experimental|Intervention|This multifaceted, adapted program focuses preventing falls through balance and strength exercises, teachings from guest experts (e.g., PT, Pharmacist, vision) and at-home safety education. Participants attended weekly 2-hour group sessions (8 -12 persons) over the course of 8 weeks delivered in Spanish by trained Hispanic/Latino personnel in two communities in Wisconsin.
10170166|NCT03895151|Experimental|Milk supplementation|"Children will receive 130 ml fresh milk, 6 days/week for 20 weeks (January-June 2019).~Milk will be provided and delivered by appointed supplier directly to school. Milk will be distributed with name of the student on the bottle - during break time.~Subjects must be consumed with supervision of the teacher at school during the break.~If they can not finish the milk at once, they can store it in the provided cool box. Student then can consume it again before they go home. Teacher have to record the remaining milk in each bottle that corresponds to every child name and record it in the provided form.~Prior to holiday, student will be given the milk according to school leave days.~Enumerators should collect the form every 3 days and make a recap in the provided form."
10170167|NCT03895151|Experimental|Food Based Recommendation (FBR) nutrition education|FBR group will received nutrition education delivered by trained teacher under the supervision of researcher/research assistant once a week. Those who received nutrition education is not only the recruited subjects but also includes their classmates.
10170168|NCT03895151|No Intervention|Control|Control group will receive standard nutrition education
9520496|NCT03277144|Active Comparator|OCT (other conventional techniques)|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples.
9520497|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
9977456|NCT01361776|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
9520498|NCT03277092|Experimental|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
9520499|NCT03277092|Active Comparator|Usual care group|Blood drawing performed traditionally
9671770|NCT05043532|Active Comparator|Three passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of three passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
9977457|NCT01361776|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
9977458|NCT01361776|Active Comparator|TBE vaccinte at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
10170169|NCT03895255|Active Comparator|IMA high ligation with routine SFM|Inferior mesenteric artery is ligated close to its origin. Splenic flexure is always mobilized.
10170170|NCT03895255|Experimental|IMA skeletonization and low ligation with selective SFM|Inferior mesenteric artery is ligated below the origin of left colic artery. Splenic flexure is mobilized only if needed.
10170171|NCT03895385|Experimental|Bimekizumab|Subjects randomized to this arm will receive a single dose bimekizumab followed by inactivated influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
10170172|NCT03895385|No Intervention|No Treatment|Subjects randomized to this arm will receive the influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
10170173|NCT03895242|Experimental|Group 1:First supine position,then prone position|First group was supine position then prone position.
10170174|NCT03895242|Experimental|Group 2:First prone position, then supine position|Second group was first prone position, then supine position.
10170175|NCT03895333||study group|women with hearing loss and osteoporosis will develop the study group.
10170176|NCT03895333||control group|women who have hearing loss but have no osteoporosis will constitute the control group.
10170177|NCT03895411|Experimental|Sotalol|Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc
10170178|NCT03895411|Active Comparator|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc
10170179|NCT03895346|Experimental|Mindfulness|Class meeting three times a week for six months, led by a certified mindfulness meditation instructor. Includes instruction and practice on techniques such as breathing, body scan, physical sensations, and yoga.
9520500|NCT03277079|Active Comparator|statin + ezetimibe|Low dose statin associated with ezetimibe
9520501|NCT03277079|Active Comparator|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
9520502|NCT03277053|Sham Comparator|control|Patients receive an ipad with no app.
9520503|NCT03277053|Experimental|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
9520504|NCT03277053|Experimental|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
9520505|NCT03277040|Experimental|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
9520506|NCT03277040|No Intervention|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
9520507|NCT03277001|Active Comparator|Enoxaparin|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
9520508|NCT03277001|Experimental|Rivaroxaban|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
9520509|NCT03276988|Other|Part B - Sequence A|Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
9671771|NCT05043519|Experimental|FAM-NP41 Fluorescence Imaging|The patients will be injected with FAM-NP41 preoperatively, and fluorescence imaging of cranial nerves will be evaluated after the craniotomy.
10170180|NCT03895346|Active Comparator|Brain Games and Puzzles|Class meeting three times a week for six months, led by a qualified instructor. Includes teaching and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
10170181|NCT03895294|Experimental|Health care under the strategic purchase-Clinical pathway|Health care under the strategic purchase and the Clinical pathway for the treatment of chronic Hepatitis C
9520510|NCT03276988|Other|Part B - Sequence B|Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
9520511|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
9520512|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
9826534|NCT02421354|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks for 8 doses and then once every 12 weeks thereafter. Treatment may continue for up to 4 years in the absence of disease progression or unacceptable toxicity.
9826535|NCT02421419|Active Comparator|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
9520513|NCT03276910|Experimental|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
9520514|NCT03276910|Experimental|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
9520515|NCT03276910|Placebo Comparator|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
9520516|NCT03276897|Experimental|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
9671772|NCT05043363||Observational cohort|"Patients with an established diagnosis of inflammatory bowel disease who have been identified as being 'at risk' by either their secondary care doctor or GP and now require endoscopic assessment for ongoing disease symptoms but are unable to access endoscopy services urgently.~Patients presenting directly to their GP practice with symptoms of anorectal disease (e.g. rectal bleeding or pain) or symptoms that would warrant referral to a hospital under a 2WW appointment according to NICE criteria~Recruited patients will undergo rectal examination in primary care with the LumenEye X1 with either contemporaneous or retrospective image review by a secondary care clinician. This will require a glycerine suppository to be administered. Patient feedback will be sought with a post-procedural questionnaire."
9671773|NCT05043506||Palbociclib + aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between September 1, 2016, and July 31, 2020.
9671774|NCT05043506||Aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated an aromatase inhibitor as first line therapy between January 1, 2010,, and July 31, 2020
9671775|NCT05043662||Urothelial carcinoma group|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice (N=80).
9671776|NCT05043662||Control group|Patients need to undergo CTU examination and being treated for benign diseases with ureteroscopy, but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD, CTU and cytology assay (N=30).
9671777|NCT05043649|Experimental|Camsirubicin + pegfilgrastim|Camsirubicin phase 1b dose escalating to determine MTD
9671778|NCT05043688|Experimental|Neoadjuvant Chemotherapy With SHR-1210|"Neoadjuvant Chemotherapy： Paclitaxel（Albumin Bound）100mg/m2, Day 1,8,15，Carboplatin AUC=5mg/ml/min，Day 1，SHR-1210 200mg，Day 1，every 3 weeks, 2 cycles.~Postoperative adjuvant treatment：SHR-1210 maintenance"
9671779|NCT05043688|Experimental|Neoadjuvant Radiochemotherapy With SHR-1210|"Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29，SHR-1210 200mg，Day 1,22, 5 cycles.~Radio therapy d1-23. Postoperative adjuvant treatment：SHR-1210 maintenance"
10170182|NCT03895294|Active Comparator|Usual care process prior strategic purchase-clinical pathway|Usual care process prior to the establishment of the strategic purchase and the Clinical Pathway
9671780|NCT05043688|Other|Neoadjuvant Radiochemotherapy Without SHR-1210|"Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29， 5 cycles.~Radio therapy d1-23. Postoperative adjuvant treatment：according to the recommendations of the guidelines and the investigators"
10170183|NCT03895112|Experimental|AVID200|intravenous in dose cohorts of 70mg/m2 or 180 mg/m2
9671781|NCT05043701|Experimental|Treatment|Patients will be treated with drugs based on functional profiling of autologous tumor cells in vitro
9671782|NCT05043558|Experimental|beprostaglandin sodium|
9671783|NCT05043558|No Intervention|control group|
10186878|NCT03731663|Sham Comparator|Control content watching group|Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
10186879|NCT03731650|Experimental|active comparator|
9671784|NCT05043480|Experimental|PEMF arm|In this single-arm study, all participants will be assigned to the intervention arm.
9826536|NCT02421419|Active Comparator|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
9826537|NCT02421419|Active Comparator|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
10186880|NCT03731650|Experimental|placebo|
10186881|NCT03731624||SLK|
10186882|NCT03731624||GVHD|
9520517|NCT03276884|Experimental|Experimental Infant Formula|Infant formula powder to be fed ad libitum
9520518|NCT03276884|Active Comparator|Control Infant Formula|Infant formula powder to be fed ad libitum
9520519|NCT03276858|Experimental|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
9520520|NCT03276858|Experimental|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
9520521|NCT03276858|Placebo Comparator|Placebo Oral Solution|Placebo oral solution, single-dose
9520522|NCT03276858|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
9520523|NCT03276858|Other|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
9520524|NCT03276845|Other|1|
10170184|NCT03895320|Experimental|Intervention Program|The intervention and control programs will consist of similar, but not identical components. The intervention will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the intervention program, the self-assessment ('Sexual Health Quiz'), score ('Sexual Health Score') and messaging ('Sexual Health Messaging') will pertain to sexual and reproductive health. For the intervention program, the self-assessment, will include a valid clinical prediction tool, established to predict STI positivity. Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen after the risk score. The program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
10170185|NCT03895320|Other|Control Program|The intervention and control programs will consist of similar, but not identical components. The Control Program will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the Control Program, the self-assessment ('Water Sugar Sweetened Beverages (SSB) Quiz'), score ('Water SSB Score') and messaging ('Water SSB Messaging') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment. However, based on the answers given on the control quiz, steps the control participant can take to meet the recommended daily intake of water and sugar sweetened beverages will be displayed on the screen after they complete the quiz. The control program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
10170186|NCT03895060|Experimental|autogenous ring blockls with GBR covered by collagen membrane|Vertical and horizontal ridge augmentation using autogenous onlay ring blocks combined with simultaneous guided bone regeneration using native collagen membrane in atrophic anterior maxilla.
10170187|NCT03895086|Experimental|Specific Physical Activity|Specific patient care in telephone coaching of fibromyalgia patients.
10170188|NCT03895086|Other|Classic Physical Activity|Classic patient care in common group of multipathological patients.
10170189|NCT03895008||Cardia gastric cancer|Cardiac gastric cancer is defined as a cancer center lies arising 2-5 cm from the gastric mucosa distal to the esophagogastric junction.
10170190|NCT03895008||Non-cardia gastric cancer|Non-cardia gastric cancer is defined as tumors originated from the gastric mucosa distal to the cardia.
10170191|NCT03894982||What is Asthma|"Reviewing asthma is a lung disease. There is no cure, but asthma can be well controlled so that your child can be healthy and join in all their favorite activities.~Asthma causes the airways (breathing tubes in the lungs) to get smaller, making it hard to breathe.Common symptoms of asthma are coughing, wheezing, chest tightness and trouble breathing.~These symptoms are ongoing and get better with asthma medicines."
10170192|NCT03894982||Triggers|Reviewing specifics around children with asthma have extra sensitive airways and many things around them can make their asthma worse. The things around your child that cause an asthma attack are called triggers. Triggers are different for each child. Your doctor can help you figure out your child's triggers. Try to keep your child away from their triggers, especially at home and at school where your child spends most of their time.
10170193|NCT03894982||Medications and Asthma Action Plan|Review what is an asthma action plan, how to use an asthma action and the medications listed on each individuals plan.
9520525|NCT03276832|Experimental|Treatment (pembrolizumab, imiquimod)|Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Courses repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity.
9520526|NCT03276819|Experimental|Cohort A|"Samples collection and Tobacco and alcohol status follow-up for patient with OPML:~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples"
9520527|NCT03276819|Experimental|Cohort B|"Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research"
9520528|NCT03276819|Experimental|Cohort C|Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research
9977459|NCT01361776|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
10170194|NCT03894943|Experimental|General|All subjects will undergo ordinary surgical treatment for their lumbar disc herniation. Experimentally, all subjects participating in the study will receive PET/CT scans and sensory testing as specified below.
10186883|NCT03731624||Dry eye|
10186884|NCT03731624||Control|
9520529|NCT03276806|Experimental|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
9826538|NCT02421510|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
9520530|NCT03276806|Active Comparator|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
9520531|NCT03276767|Experimental|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
9520532|NCT03276767|Active Comparator|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
9520533|NCT03276741|No Intervention|Control Group|Routine care during labor (authorized clear liquid diet).
10170195|NCT03894904|Experimental|Premixed Papaverine|2mL of the 50mL premixed syringe of papaverine as dispensed from pharmacy ( NaCl 0.9% inj 48.8 mL + papaverine 6mg+ heparin 100 units).
10170196|NCT03894904|Active Comparator|Heparin|2 ml of the 10 mL of 2 units/mL of heparin from the pressurized fast flush bag from the operating room.
10170197|NCT03894930|Experimental|Metta meditation|Eight-week, guided metta meditation training that is administered online
10170198|NCT03894930|No Intervention|Wait-list|Eight-week wait-list control with no training
9520534|NCT03276741|Active Comparator|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
10170199|NCT03894865|Experimental|urban school|Male students from selected urban schools undergo screening for idiopathic scoliosis
10170200|NCT03894865|Experimental|countryside schools|Male students from selected countryside schools undergo screening for idiopathic scoliosis
9520535|NCT03276728|Active Comparator|AMG 986 IV Dose Level A|or matching placebo
9520536|NCT03276728|Active Comparator|AMG 986 IV Dose Level B|or matching placebo
9520537|NCT03276728|Active Comparator|AMG 986 IV Dose Level C|or matching placebo
9671785|NCT05043402|Experimental|Combination navicixizumab + paclitaxel|Combination navicixizumab + paclitaxel: navicixizumab 3 mg/kg Q2W of a 28 day cycle (i.e., Days 1 and 15); paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28 day cycle
9520538|NCT03276728|Active Comparator|AMG 986 IV Dose Level D|or matching placebo
9520539|NCT03276728|Active Comparator|AMG 986 IV Dose Level E|or matching placebo
9520540|NCT03276728|Active Comparator|AMG 986 IV Dose Level F|or matching placebo
9520541|NCT03276728|Active Comparator|AMG 986 IV Dose Level G|or matching placebo
9520542|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A|or matching placebo - HV
9520543|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B|or matching placebo - HV
9520544|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C|or matching placebo - HV
9520545|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D|or matching placebo - HV
9520546|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E|or matching placebo - HV
9520547|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F|or matching placebo - HV
9671786|NCT05043402|Active Comparator|Paclitaxel monotherapy|Paclitaxel monotherapy: paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
9826539|NCT02421510|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
10170201|NCT03894852||AML|cases with denovo AML and t-AML
9671787|NCT05043402|Experimental|Navicixizumab monotherapy|Navicixizumab monotherapy: navicixizumab 3 mg/kg Q2W of a 28-day cycle (i.e., Days 1 and 15)
9826540|NCT02421510|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
10170202|NCT03894852||MDS|cases with denovo MDS and t-MDS
10170203|NCT03894839|Active Comparator|glutaraldehyde disinfection and microwave application|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
10170204|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and microwave application|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
9520548|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A - MAD|or matching placebo - HV
9520549|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B MAD|or matching placebo - HV
9520550|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C MAD|or matching placebo - HV
9520551|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D MAD|or matching placebo - HV
9520552|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E MAD|or matching placebo - HV
9520553|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F MAD|or matching placebo - HV
9520554|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-HEF|Heart failure patients with reduced ejection fraction
9520555|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-REF|Heart failure patients with preserved ejection fraction
9520556|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
9520557|NCT03276689|Experimental|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
9520558|NCT03276689|Experimental|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
9520559|NCT03276689|Experimental|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
9520560|NCT03276676|Experimental|All Enrolled participants|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
9520561|NCT03276663|Other|Formula fed group|Formula feeding regimen
9520562|NCT03276663|No Intervention|Human milk-fed group|
9671788|NCT05043493|Active Comparator|Injection (study) group|This group will receive platelet rich plasma (PRP) injection
10170205|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and microwave application|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
9520563|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
10170206|NCT03894839|Active Comparator|glutaraldehyde disinfection and ozone therapy|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
10170207|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and ozone therapy|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
10170208|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and ozone therapy|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
10170209|NCT03894826|Experimental|TREATMENT|Participants will be administered 230 mg/m2/day of oral Vorinostat [100 mg tablets] in addition to standard of care anti-seizure medication for a duration of 6 weeks.
10170210|NCT03894579|Experimental|SNK01|SNK01 infused weekly for 4 consecutive weeks
10170211|NCT03894709|Experimental|The family-centered care model|Interventions include a family-centered approach to interdisciplinary care and a family caregiving-training component to enhance family caregivers' competence in providing post-operative care and handling behavioral problems of adults with cognitive impairment. The interdisciplinary care model consists of geriatric consultation, continuous rehabilitation, and discharge planning. The family-centered approach involves family caregivers using a structured guide to assess the condition of the hip-fractured patient with cognitive impairment. Habits, daily routines, preferences, behavioral problems and environmental safety and stimuli are explored. The strengths, weakness, and resources of the family are assessed. The behavioral problems and symptoms to target are identified. Both the research nurse and the caregiver will then collaborate on a tentative plan to minimize the behavioral problems.
10170212|NCT03894709|No Intervention|Usual care|During hospitalization, patients receive health teaching for exercise while still in bed. Physical therapy usually starts only for those who received arthroplasty of hip replacement. Physical therapists train patients to use a walker and get in/out of bed through consultation. Usually, patients are discharged from the hospital without home assessment, nor are in-home programs provided for rehabilitation or nursing care. The usual care does not involve interdisciplinary care protocols, continuity of care, or specific care for hip-fractured patients with cognitive impairment.
10170213|NCT03894722|Placebo Comparator|Group I (control; saline only)|Control Group: Intraoperative irrigation with saline solution only.
10170214|NCT03894722|Experimental|Group II (0.5% concentration of PVP-I )|Experimental Group: Intraoperative irrigation with 0.5% concentration of PVP-I solution.
9520564|NCT03276624|Other|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
9520565|NCT03276598|Active Comparator|Amlodipine|One of the four monotherapy treatment periods.
9520566|NCT03276598|Active Comparator|Bisoprolol|One of the four monotherapy treatment periods.
9520567|NCT03276598|Active Comparator|Hydrochlorothiazide|One of the four monotherapy treatment periods.
9520568|NCT03276598|Active Comparator|Losartan|One of the four monotherapy treatment periods.
9520569|NCT03276598|Placebo Comparator|Placebo|Placebo treatment period.
9520570|NCT03276572|Experimental|All Subjects|A single dose of 225Ac-J591 will be given to subjects with documented progressive metastatic CRPC.
9520571|NCT03276559|Experimental|EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
9520572|NCT03276559|Placebo Comparator|Enhanced usual care arm|"The usual care arm indicates regular ICU support for informal caregivers (i.e. social work, chaplaincy) as recorded in the patient's medical record, a general information packet for informal caregivers, and a site-specific resource list.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone."
9520573|NCT03276546|Experimental|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
10170215|NCT03894722|Experimental|Group III (1% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 1% concentration of PVP-I solution.
10170216|NCT03894722|Experimental|Group IV (3% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 3% concentration of PVP-I solution.
10186885|NCT03731611|Active Comparator|Group A|umbilical cord milking will be done for preterm infants <34 gestational age without placental insufficiency
10186886|NCT03731611|Active Comparator|Group B|umbilical cord milking will be done for preterm infant <34 gestational age with placental insufficiency
9520574|NCT03276520|Experimental|ethyl glucuronide|subjects being screened with ethyl glucuronide
9826541|NCT02421588|Experimental|Arm A|lurbinectedin (PM01183)
9520575|NCT03276520|Active Comparator|ethanol|subjects being screened with ethanol
9520576|NCT03276455|Experimental|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
9520577|NCT03276442|Experimental|Healthy diet|'Low-fat dietary intervention' to be administered to participants
9520578|NCT03276442|Experimental|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
9520579|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
9520580|NCT03276416||150 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
9527714|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
9826542|NCT02421588|Active Comparator|Arm B|"pegylated liposomal doxorubicin~OR~topotecan"
10170217|NCT03894774|Experimental|Intensive InPatient Psychotherapy Treatment Group (IG)|Intensive non-pharmaceutical inpatient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic frame where patients live over the whole treatment (approximately a 1:1-ratio caregiver per patient is given) of 6 to 8 month treatment duration.
10170218|NCT03894774|Active Comparator|Waiting Control Group (WCG)|"Treatment as usual (mostly combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy).~Duration: At least 3 month to a maximum of 6 month."
10170219|NCT03894774|No Intervention|Healthy Control Group (HCG)|"Matched Pairs design to control for gender, age and handedness. HCG measurements are planned and conducted according to the exact durations of their matched inpatient pair of the IG.~Mandatory to control for effects of factors such as brain maturation."
10170220|NCT03894761|Other|Patients with Rotator Cuff Syndrome|The patients diagnosed with rotator cuff syndrome by clinical and magnetic resonance imaging.
10170221|NCT03894748|Experimental|MT10109L(Botulinum toxin type A)|
10170222|NCT03894748|Active Comparator|BOTOX® 50U(Botulinum toxin type A)|
9520581|NCT03276390|Active Comparator|Intervention study site|"Exposure to the intervention, which is the Northwestern Medicine (TM) Hispanic Kidney Transplant Program, a culturally targeted program for Hispanic potential recipients for transplant evaluation that is implemented into the 2 study sites.~The intervention study site will provide the intervention to its Hispanic patients.~The intervention study will will also provide the routine care (control arm) to all other patients.~For the purposes of this study, Hispanic potential recipients recruited into the study will be exposed to this intervention. Non-Hispanic Whites recruited into the study will not be exposed to this intervention."
9520582|NCT03276390|No Intervention|No intervention study site|Exposure to routine transplant evaluation at the two control sites.
9520583|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
9520584|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
9520585|NCT03276364||Shock|
9520586|NCT03276338|Experimental|Intervention|Participation in the HOLA intervention designed to prevention HIV
9520587|NCT03276338|No Intervention|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
9520588|NCT03276325|Placebo Comparator|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
9520589|NCT03276325|Active Comparator|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
9520590|NCT03276312|Experimental|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
9520591|NCT03276312|No Intervention|Control|Routine clinical practice
9520592|NCT03276299|Active Comparator|test 1|six minute walking test
9520593|NCT03276299|Experimental|test 2|six minute walking test
9520594|NCT03276299|Experimental|test with encouragement|six minute walking test
9520595|NCT03276299|Active Comparator|test without encouragement|six minute walking test
9520596|NCT03276286|Experimental|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
9520597|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
9520598|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
9826543|NCT02421601|Experimental|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
9826544|NCT02421666|Experimental|behavioral PNMI|eligible patients received patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care.
9520599|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
9520600|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
9520601|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
9520602|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
9520603|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
9520604|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
9520605|NCT03276208|Experimental|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
9520606|NCT03276208|Active Comparator|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
9520607|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
9826545|NCT02421666|No Intervention|control|eligible chronic HBV patients received standard care
9826546|NCT02421757|Experimental|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
10186887|NCT03731611|No Intervention|Group C|Immediate cord clamping for preterm infants <34 gestational age with placental insufficiency
10186888|NCT03731585|Experimental|Group I (psychological intervention)|Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
9520608|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
9520609|NCT03276182|Experimental|cataract patients|cataract patients undergoing phacoemulsification
9520610|NCT03276169|Experimental|Left atrial appendage closure group|
9520611|NCT03276169|Other|Radiofrequency ablation group|
9520612|NCT03276169|Experimental|LAAC combined with radiofrequency ablation group|
9520613|NCT03276156|Experimental|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
9520614|NCT03276143|Active Comparator|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
10186889|NCT03731585|Experimental|Group II (educational intervention)|Patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. Patients also complete questionnaires and participate in group sessions as in group I.
9520615|NCT03276143|Active Comparator|Apixaban|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
9520616|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
9974958|NCT04978168|Experimental|Implementation Core|During baseline Exploration, staff organizational surveys are collected. During Preparation, staff focus groups conduct needs assessment with system mapping of linkage points for screening, assessment, and referral, and the agencies/staff involved in these activities. During Implementation, sites use facilitated local change teams (LCT) provided with a core set implementation strategies to facilitate linkages between probation agencies and local community treatment providers. The LCTs identify barriers to change, approaches to overcome barriers, do goal selection using SMART (specific, measurable, achievable, relevant, timely) goals and evidence for medications, address stigma, and clarify needs/expectations/roles of probation officers and treatment providers, then choose and implement goals and strategies. Sustainability Phase: Facilitators work with LCTs for 12 months using a written action plan based on goal selection.
9974959|NCT04978168|Experimental|Randomized Trial of Peer Support Specialist Model|After Core implementation is complete, half of adult participants in probation who consent will be randomly assigned to a Peer Support Specialist (PSS) condition. PSS are assigned to adults diagnosed with OUD within 6 months of entry into probation, in addition to treatment as usual. PSS establish linkages to community providers (medical, mental health, substance use treatment); educate about recovery support services, transportation assistance, MOUD; provide experiential, non-clinical support to individuals with SUD; share skills, offer support for setting goals and navigating the recovery process); and provide referrals and support for treatment, housing, employment, drug court, and probation.
9974960|NCT04978168|Active Comparator|Randomized to Treatment as Usual|After Core Implementation is complete, half of adult participants in probation who consent will be randomly assigned to continue with usual care.
9974961|NCT04971148|Active Comparator|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level that matches patient peak tidal inspiratory flow
9974962|NCT04971148|Experimental|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.33 times of patient peak tidal inspiratory flow
9974963|NCT04971148|Experimental|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 1.67 times of patient peak tidal inspiratory flow
9974964|NCT04971148|Experimental|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set at the level that is 2 times of patient peak tidal inspiratory flow
9974965|NCT04967144||Carpal Tunnel syndrome|.Patients with carpal tunnel syndrome
9520617|NCT03276143|Experimental|BAY1213790 0.6 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
9520618|NCT03276143|Experimental|BAY1213790 1.2 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
9520619|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
9520620|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
9520621|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.
9520622|NCT03276130||Part A: Retrospective register study|To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population.
9520623|NCT03276130||Part B1: Survey to HTC|The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts.
9520624|NCT03276130||Part B2: Survey to PwH|All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey.
9520625|NCT03276104|Active Comparator|IOL repositioning group|
9520626|NCT03276104|Active Comparator|IOL exchange group|
9520627|NCT03276091|Experimental|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
9520628|NCT03276065|Experimental|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
9527715|NCT03217409|Experimental|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
10170223|NCT03894800|Active Comparator|Methoxyflurane (M)|"A session starts with a CPT - cold pressor test (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale metoxyflurane through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
10170224|NCT03894800|Active Comparator|Fentanyl (F1)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.025 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs.Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
10186890|NCT03731546|No Intervention|Group A|Placental insufficiency and ICC : Immediate cord clamping after delivery of the fetus in preterm infants with placental insufficiency
10186891|NCT03731546|Active Comparator|Group B|Placental insufficiency and DCC: Cord clamping 60 seconds after delivery of fetus in preterm infants with placental insufficiency
9520629|NCT03276065|Active Comparator|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
9520630|NCT03276039||25 patients with non-alcoholic fatty liver disease|
9520631|NCT03276039||25 patients with NAFLD and chronic HCV|
9520632|NCT03276039||20 healthy controls|
9520633|NCT03276013|Experimental|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
9520634|NCT03276000|Active Comparator|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
9520635|NCT03276000|Active Comparator|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
9520636|NCT03275987|Experimental|Mammography treatment|Mammography direct mail coupled with a financial incentive
9520637|NCT03275987|Active Comparator|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
9520638|NCT03275987|Experimental|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
9520639|NCT03275987|Active Comparator|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
9520640|NCT03275961|Experimental|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
9520641|NCT03275948|Experimental|whole grain|
9520642|NCT03275948|Other|refrence|white wheat based product
9520643|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
9520644|NCT03275922|Other|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
9520645|NCT03275922|Other|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
9520646|NCT03275909|Experimental|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
9520647|NCT03275909|No Intervention|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
9520648|NCT03275896|Experimental|Descemet Membrane Transplantation|Patients with severe, symptomatic Fuch's Endothelial Dystrophy (FED) will be offered Descemet Membrane Transplantation (DMT) for their condition.
9527716|NCT03217409|Active Comparator|Rosuvastatin|Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
9527717|NCT03217292|Experimental|Group S|"IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.~20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB."
9527718|NCT03217292|Active Comparator|Group T|IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
9527719|NCT03217435|Experimental|Cornea epithelial allograft|Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
9527720|NCT03217435|Active Comparator|Limbal conjunctival allograft|Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
9527721|NCT03217383|Experimental|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
9527722|NCT03217617|Experimental|Single arm|Gene transfer to treat SCID-X1
10186892|NCT03731546|Active Comparator|Group C|Normal placenta with DCC:Cord clamping 60 seconds after delivery of fetus in preterm infants without placental insufficiency
9520649|NCT03275844||Group 1|Children with congenital heart disease
9671789|NCT05043493|Placebo Comparator|Control group|This group will receive normal saline (NS) injection
9671790|NCT05043350|Experimental|Interventional group|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to oral famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
9671791|NCT05043350|Active Comparator|Control group|107 patients will receive standard drug therapy according to the treatment protocols of the National Committee of COVID-19 in addition to oral famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company)
9671792|NCT05043220|Experimental|Telemedicine|Telemonitoring via PPG (photoplethysmography) and PROM (patient reported outcome monitoring) via app
10186893|NCT03731533|Experimental|WellStart|WellStart is a 12-week virtual intensive therapeutic lifestyle program utilizing web-based encounters with physicians, dietitians, health coaches and additional resources.
9671793|NCT05043207|Experimental|uAud|Patients which hearing aid is fitted based on the audiometry obtained with user-operated automated audiometry.
9671794|NCT05043207|Active Comparator|control|Patients which hearing aid is fitted based on the audiometry obtained with traditional audiometry.
9671795|NCT05043181|Experimental|Homozygous Familial Hypercholesterolemia|
9671796|NCT05043194|Experimental|ursodeoxycholic acid arm|Premature infants who meet the inclusion criteria take preventive oral ursodeoxycholic acid on the 7th day after birth. ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
9671797|NCT05043194|Sham Comparator|the control arm|The control group was treated with UDCA after the occurrence of cholestasis.ursodeoxycholic acid capsules (Ursofalk, 250 mg/capsules), starting with oral administration of pharmacologic doses of 20-25mg/kg/d, twice daily, until they were discharged .
9671798|NCT05043233||Patients with Graves' disease|Graves' disease was diagnosed based on clinical symptoms and laboratory findings. The clinical symptoms included heat intolerance, fatigue, increased appetite, increased sweating, weight loss, muscle weakness, tremors, and diffusely enlarged thyroid glands. The laboratory results included increased serum concentrations of free thyroxine (FT4) and/ or free triiodothyronine (FT3), decreased basal thyroid-stimulating hormone (TSH) level, and TRAb positivity. All participants in this study would be treated with anti-thyroid drugs(MMI: methimazole) according to the 2016 ATA guildline.
9671799|NCT05043246||Basic diseases Patients/Healthy People|Hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease,Chronic Liver Diseases Patients
9671800|NCT05043025|Active Comparator|Neck extension group|The cricothyroid membrane is identified in a neck extended position.
9671801|NCT05043025|Experimental|Modified ramped position group|The cricothyroid membrane is identified in a modified ramped position.
9671802|NCT05043129||HIV infenction/AIDS|experimental group
9671803|NCT05043129||Healthy population|Control group
9671804|NCT05043675|Experimental|[18F]APN-1607|For the injection, subjects will receive a target dose of 0.1~0.15mCi/Kg [18F]APN-1607 as a bolus injection.
9671805|NCT05043272||Overweight population with basic diseases|Basic diseases include diabetes, hypertension.
9671806|NCT05043272||Overweight population with chronic liver diseases|Chronic liver diseases include chronic hepatitis ,liver cirrhosis, primary hepatocellular carcinoma.
9671807|NCT05043272||Healthy population|Control group
9671808|NCT05043116|Active Comparator|Vitamin D|Dietary supplement: 2000 IU Vitamin D3 daily dose (oral suspension) for one year.
9671809|NCT05043116|Placebo Comparator|Placebo|Oral suspension with no active substance, identical to the active suspension for one year.
9974966|NCT04967144||Control subjects|Healthy subjects
9974967|NCT04962360|Experimental|Nutritional standardized supplementation formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.
9974968|NCT04962360|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
9974969|NCT04962334|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
9974970|NCT04962334|Placebo Comparator|Placebo|Low caloric formula (Powder added to waster) without added vitamins and minerals
9671810|NCT05043415|Active Comparator|Immediate endoscopic necrosectomy|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Then in this group, endoscopic necrosectomy will be performed immediately following index EUS-guided drainage of the necrotic collection, during the same session
9671811|NCT05043415|Active Comparator|Step-up endoscopic intervention|Endoscopic ultrasound (EUS)-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. In this group, only EUS-guided drainage of the necrotic collection will be performed, and endoscopic necrosectomy will be performed at a separate session at a later time as needed.
9671812|NCT05043389|Experimental|Obstructive sleep apnea|myofunctional therapy program
9671813|NCT05043389|No Intervention|control|standard treatment
9671814|NCT05043610|Experimental|Cohort 1|In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.
9671815|NCT05043610|Active Comparator|Cohort 2 (Control Group)|In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment.
9671816|NCT05042921||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 21 months and the available data is collected retrospectively.
9671817|NCT05042921||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 21 months.
9671818|NCT05042960|Experimental|50% brightness group|Participants will be using a computer screen reducing screen brightness 50%.
10170225|NCT03894800|Active Comparator|Fentanyl (F2)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.05 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
9520650|NCT03275844||Group 2|Control healthy subjects
9520651|NCT03275818|Experimental|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:~Age ≥ 21: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days~Age ≥ 6 months and ≤ 20 years: 240 mg/m2 (for patients weighing > 10 kg) and 11.5 mg/kg (for patients weighing ≤ 10 kg) on days 1, 8 and 15 in cycles of 28 days"
10186894|NCT03731533|No Intervention|Usual Care|The control group will continue with usual care.
10186895|NCT03731520|Experimental|Assessing exercise behavior|determining exercise behaviour in patients with JIA by using specific scales
9520652|NCT03275805|Active Comparator|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will most likely begin the 12-week regiment at their first visit to our hip clinic.
9520653|NCT03275805|Experimental|6 weeks Pavlik Treatment Arm|This arm will receive treatment to normalization, but for no less than 6 weeks. Patients will begin their treatment around the time of their first visit to our designated hip clinic.
9520654|NCT03275792|Experimental|Admission/Intravascular Volume Expansion|"Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes~0.9% NS with 5% dextrose at 150% of standard maintenance volume~If urine output is <0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload~Oral fluids ad lib along with strict input/output documentation~Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload~Daily laboratory tests and in-person assessment until inpatient discharge criteria reached:~A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child~Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge."
9520655|NCT03275792|Active Comparator|Outpatient Observation|"Following standard emergency department (ED) care [volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs).~Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge~Additional health assessments as required~Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child"
9520656|NCT03275779|Experimental|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
9520657|NCT03275779|Experimental|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
9520658|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
9520659|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
9520660|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
9520661|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
9520662|NCT03275727|Experimental|A - iACT-BC experimental group|
9520663|NCT03275727|Other|B - Waiting list control group|
9520664|NCT03275714|Active Comparator|People With a Bipolar Affective Disorder|
9520665|NCT03275714|Active Comparator|Control subjects without a psychiatric disorder|
9520666|NCT03275701|Other|Triumeq|Single Arm, Open Label
9520667|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
9520668|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
9671819|NCT05042960|Experimental|Light App group|Participants in this group will use a modulating computer screen tone with flux or night shift app.
9671820|NCT05042960|No Intervention|Control group|Participants in this group will be a control with no change in screen features
9826547|NCT02421757|Placebo Comparator|Sham Device|Sham Device
9520669|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
9520670|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
9520671|NCT03275662|Experimental|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
9520672|NCT03275662|Experimental|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
9520673|NCT03275636|Experimental|Haploidentical donor|Peripheral blood stem cells from Haploidentical donor
9520674|NCT03275636|Active Comparator|partially matched unrelated donor|Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
10170226|NCT03894800|Placebo Comparator|NaCl (C)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
10170227|NCT03894683|Experimental|Melatonin|Melatonin (10 mg tablets) by oral root, ingested at bedtime for 6 months
9520675|NCT03275597|Experimental|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 3 days) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients > 30 kg Tremelimumab 300 mg via infusion (equivalent to 4 mg/kg) in one dose in patients >30 kg Weight-based dosing should be utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 4 mg/kg"
9826548|NCT02421887|Active Comparator|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
10170228|NCT03894683|Placebo Comparator|Placebo|Placebo tablets in the same shape as melatonin tablets, ingested the same as the melatonin tablets.
10170229|NCT03894670|Active Comparator|SmartBar™|The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
10170230|NCT03894670|Experimental|Standard mixed breakfast meal|The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
10170231|NCT03894475|Active Comparator|Sequence A|Patient would first perform an examination with handheld spirometer (AioCare), followed by measurements with the reference spirometer (MGC)
9826549|NCT02421887|Placebo Comparator|Placebo|
9520676|NCT03275584|Experimental|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
9520677|NCT03275571|Experimental|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
9520678|NCT03275558|Active Comparator|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
9520679|NCT03275558|Active Comparator|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
10170232|NCT03894475|Active Comparator|Sequence B|Patient would first perform an examination with the reference spirometer (MGC), followed by measurements with handheld spirometer (AioCare)
10170233|NCT03894631|Active Comparator|Phaco/KDB|Eyes needing glaucoma and cataract extraction will receive combined KDB and phacoemulsification in one eye of a patient
9520680|NCT03275558|Active Comparator|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
9520681|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI > or = 18.5 kg/m2)
9826550|NCT02421952||Single Cohort|All subjects will be asked to assess their pain and nausea using the visual analogue scales (VAS), the modified faces scale and the BARF scale as described below in the preoperative and postoperative areas.
9826551|NCT02422186|Experimental|Intranasal Esketamine plus Oral Antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
10170234|NCT03894631|Active Comparator|Phaco/Trabectome|Contralateral eyes needing glaucoma and cataract extraction will receive combined Trabectome and phacoemulsification in contralateral eye of the same patient
9520682|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
9520683|NCT03275519|Active Comparator|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
9520684|NCT03275519|Active Comparator|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
9527723|NCT03217448|Experimental|Dabigatran etexilate group|Subjects in this group will take Dabigatran etexilate for 6 months after randomization
9527724|NCT03217448|Active Comparator|Warfarin group|Subjects in this group will take Warfarin for 6 months after randomization
9974971|NCT04959019|Experimental|Immediate Exercise|immediate participation in 6-week exercise program (intervention)
9974972|NCT04959019|Other|Delayed Exercise|6-week delay (no-intervention control) prior to participating in exercise program
9974973|NCT04956224|Experimental|VLA2001|
9974974|NCT04955743|Experimental|Cohort 1: Melanoma|Participants who are melanoma (PD-1/PD-L1-experienced)
10170235|NCT03894644|Experimental|Group A: simulation training before instruments|Group A performed simulation training before the recognition of real surgical instruments.
10170236|NCT03894644|Active Comparator|Group B:instruments before simulation training|Group B performed the recognition of real surgical instruments without prior simulation training.
10186896|NCT03731507|Experimental|Range of motion in upper extremity|Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion
10186897|NCT03731494||Nickel oral hyposensitization treatment|The patients take capsules at different doses in nickel content until reaching the maximum dose of 1.5 mcg per week for a total of 12 months.
9671821|NCT05042973|Active Comparator|Active drug (Empagliflozin)|Empagliflozin 10 mg, 1 capsule per day
9671822|NCT05042973|Placebo Comparator|Inactive drug (placebo)|Placebo, 1 capsule per day
9520685|NCT03275506|Experimental|Pembrolizumab + Chemotherapy|"Arm B (n=60): 4 neo-adjuvant cycles of standard 3 weekly Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm B: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy.~In the arm B, patient will receive Pembrolizumab 200 mg until a maximum of 15 months in total from the beginning of the adjuvant therapy."
9520686|NCT03275506|Active Comparator|Chemotherapy alone|"Arm A (n=30): 4 neo-adjuvant cycles of standard 3 weekly carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm A: carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~- In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy."
9520687|NCT03275493|Experimental|Experimental: Cohort 1|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia
9520688|NCT03275493|Experimental|Experimental: Cohort 2|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.
9520689|NCT03275467|Experimental|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
9520690|NCT03275454|Experimental|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 intravenous (IV) infusion and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 every 2 weeks for approximately 21 weeks in Part A (based on time to complete 11 doses of study drug). There will be a 9-week safety follow-up/washout period after administration of the last dose of study drug in Part A. Participants who have been shown to benefit from BIVV009 treatment during Part A, will receive BIVV009 (based on weight) biweekly for up to 52 weeks of BIVV009 after Last Patient In (LPI) in part B.
9520691|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
9520692|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
9520693|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
9520694|NCT03275415|Active Comparator|Experimental|Curosurf + budesonide
9974975|NCT04955743|Experimental|Cohort 2: Renal Cell Carcinoma|Participants who are Renal Cell Carcinoma (PD-1/PD-L1 experienced).
9520695|NCT03275415|Placebo Comparator|Placebo|Curosurf + saline
9520696|NCT03275376|Experimental|Statin treated group|
9520697|NCT03275376|Placebo Comparator|Control group|
9520698|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
9520699|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
9520700|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
9520701|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
9520702|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
9974976|NCT04949789|Other|Placebo without Exercise|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
10186898|NCT03731481|Experimental|CHIP - Urban|Participants randomized by urban location of residence to receive CHIP Lifestyle Medicine program intervention.
9520705|NCT03275337|Experimental|Anodal tDCS|Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
9520706|NCT03275337|Experimental|Cathodal tDCS|Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
9520707|NCT03275337|Active Comparator|Sham tDCS|Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
9520708|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
9520709|NCT03275285|Experimental|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
9671823|NCT05042817|Active Comparator|Morphine|50 mg prilocaine + 2.5 mcg sufentanil + 100 mcg morphine (0.1ml)
9671824|NCT05042817|Placebo Comparator|NaCl 0.9%|50 mg prilocaine + 2.5 mcg sufentanil + 0.1 ml saline
10186899|NCT03731481|Experimental|CHIP - Rural|Participants randomized by rural location of residence to receive CHIP Lifestyle Medicine program intervention.
10186900|NCT03731481|Experimental|FPD2- Urban|Participants randomized by urban location of residence to receive FPD2 Lifestyle Medicine program intervention.
9520710|NCT03275285|Active Comparator|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
9520711|NCT03275272|Other|level of IGF-1 in infant|Measurment of blood level of IGF-1 In infants
9520712|NCT03275259|Experimental|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
9520713|NCT03275207|Placebo Comparator|control group|an equal volume of saline
9520714|NCT03275207|Experimental|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
9520715|NCT03275194|No Intervention|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
9520716|NCT03275194|Experimental|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
9520717|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
9520718|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
9520719|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
9826552|NCT02422186|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase using the same titration as Esketamine. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
9826553|NCT02422264|Experimental|dTpa Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 [DTPA (BOOSTRIX)-047] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
9826554|NCT02422264|Active Comparator|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 [DTPA (BOOSTRIX)-047], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
9520720|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
9520721|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
9826555|NCT02422290|Experimental|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
9826556|NCT02422511|Active Comparator|Well Baby Family History Only|Parents of newborns in well-baby units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
9520722|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
9826557|NCT02422511|Experimental|Well Baby Family History + Exome Sequencing|Parents of newborns in well-baby units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
9977460|NCT01361789|Active Comparator|COXIB|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
10186901|NCT03731481|Experimental|FPD2 - Rural|Participants randomized by rural location of residence to receive FPD2 Lifestyle Medicine program intervention.
10186902|NCT03731468|Active Comparator|dexmethasone group|8 mg dexamethasone will be added to local anaesthetics
9520723|NCT03275142|Experimental|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
9520724|NCT03275142|Active Comparator|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
9520725|NCT03275116|Active Comparator|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
9520726|NCT03275116|Active Comparator|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
9520727|NCT03275090|Active Comparator|Intralipid injectable product (MOFS)|20 preterm infants receive parenteral nutrition containing 20% MOFS lipid emulsion (Smoflipid ®)
9520728|NCT03275090|No Intervention|Pure Soybean oil lipid emulsion|20 preterm infants with sepsis receive the usual parenteral nutrition containing soybean oil based lipid emulsion (20% Intralipid ®) at daily increasing doses guided by serum triglycerides.
9520729|NCT03275077||Controls|Normal Healthy Volunteers
9520730|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
9520731|NCT03275064|Experimental|LNA043 40 mg Part B|LNA043 40 mg Part B
9520732|NCT03275064|Experimental|LNA043 20 mg Part B|LNA043 20 mg Part B
10186903|NCT03731468|Sham Comparator|control group|isobaric bupivacaine will be given on each side
9520733|NCT03275064|Experimental|LNA043 20 mg Part A|LNA043 20 mg Part A
9520734|NCT03275064|Placebo Comparator|Placebo Part A|Placebo Part A
9520735|NCT03275064|Placebo Comparator|Placebo Part B|Placebo Part B
9520736|NCT03275051|Experimental|All subjects|Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study. Subjects received OTL-300 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
9520737|NCT03275038|No Intervention|Control group|Maintain the original life style
9520738|NCT03275038|Experimental|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
9520739|NCT03275038|Experimental|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
9520740|NCT03275025|Experimental|YRA-1909 low dose|
10186904|NCT03731455|Experimental|Investigational and Comparator devices|Investigational (WISE Cortical Strip, WCS) and comparator (Subdural Strip Electrode, Ad-Tech Medical Instruments Corporation) devices will be used together.
10187905|NCT03721536|Active Comparator|low-flow anesthesia|Patients in low-flow anesthesia receive a fresh gas flow of 4 L/min for the first 10 minutes and were then maintain with a fresh gas flow of 0.75 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
9520741|NCT03275025|Experimental|YRA-1909 medium does|
9520742|NCT03275025|Experimental|YRA-1909 high dose|
9520743|NCT03275025|Placebo Comparator|YRA-1909 Placebo|
9520744|NCT03275012|Experimental|Group 1|Gabapentin + Morphine
9520745|NCT03275012|Placebo Comparator|Group 2|Placebo + Morphine
9520746|NCT03274973||Zomacton|
9520747|NCT03274960|Experimental|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
9520748|NCT03274960|No Intervention|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
9520749|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 Low dose TMS|Low level cerebellar TMS. Delivered once per day for 3 days.
9520750|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 High dose TMS|High level cerebellar TMS. Delivered twice per day for 5 days.
9520751|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 2 Sham|Sham cerebellar TMS. Delivered twice a day for 5 days.
9520752|NCT03274947|Active Comparator|Hypothesis 2 Protocol 1 Cerebellar TMS|Cerebellar TMS at 10Hz, 250 pulses.
9520753|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 1 Sham|Sham cerebellar TMS
9520754|NCT03274934|Experimental|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
9520755|NCT03274934|Experimental|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
9671825|NCT05042804|Experimental|Machine Learning Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, and they will also view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
9520756|NCT03274934|Experimental|Control group|Behavioral: No intervention, school counseling as usual
9520757|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
9520758|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
9520759|NCT03274908||Group|
9520760|NCT03274895|Experimental|PHMB 0.08% plus placebo|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
9520761|NCT03274895|Active Comparator|PPHMB 0.02% plus propamidine 0.1%|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
9520762|NCT03274882|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio of 1:0.5) was administered at 35 mg/m²/dose orally twice a day, within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period. This treatment cycle was repeated every 4 weeks until treatment withdrawal criteria are met.
9520763|NCT03274843|Experimental|Patient with stroke|
9520764|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
9520765|NCT03274817|Active Comparator|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
9520766|NCT03274817|Active Comparator|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
9520767|NCT03274817|Placebo Comparator|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
9520768|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
9520769|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
9527725|NCT03217500|Experimental|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
9527726|NCT03217500|Active Comparator|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
9527727|NCT03217500|Active Comparator|Simple removal|Simple removal of pterygium
9671826|NCT05042804|No Intervention|No Assistance|Clinicians in the Anesthesia Control Tower will review patient data using the electronic health record and using AlertWatch, but they will not view the machine learning display. They will then predict how likely the patient is to experience postoperative death and postoperative acute kidney injury.
9671827|NCT05042895|Active Comparator|PCO women|Group A will consist of 100 PCO infertile women
10170237|NCT03894462|Active Comparator|Zero Suicide Usual Care|"In Onondaga County, NYS aims to implement a countywide Zero Suicide Safety Net of providers who share enhanced protocols for clinical care, staff training, and data collection (improved EMR coding of suicidal behavior). Participating behavioral health systems have agreed to common protocols for clinical care, training, and data collection. Participating providers receive robust training in suicide prevention best practices. Because of the wide participation of mental health facilities in the NYS-OMH Zero Suicide project, most subjects who engage in outpatient treatment will receive that treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged."
9671828|NCT05042895|Active Comparator|unexplained infertile cases|group B will consist of 50-unexplained infertility.
9671829|NCT05042778|Experimental|Auricular branch of the vagus nerve|Indwelling fixed semipermanent needles embedded in a skin-colored adhesive tape will be used in active points around the vagus nerve stimulation area.
10170238|NCT03894462|Experimental|Zero Suicide Usual Care + ASSIP|"Patients in this treatment arm will receive ASSIP brief therapy in addition to being able to access any usual care as recommended by their provider.~ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan."
9671830|NCT05042778|Active Comparator|Lesser occipital nerve|Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used in active points around the lesser occipital nerve stimulation area.
9671831|NCT05042778|No Intervention|No intervention|No auriculotherapy will be applied.
9671832|NCT05042622|Experimental|Cytokine adsorber patients on ECMO|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
9671833|NCT05042622|Experimental|Cytokine adsorber patients with sepsis|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
9671834|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients on ECMO|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
9671835|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients with sepsis|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
9671836|NCT05042622|No Intervention|Control (subgroups)1|No filter will be installed into the ECMO in this study group (15 patients)
9671837|NCT05042622|No Intervention|Control (subgroups) 2|No filter will be installed into the patient with sepsis (15 patients)
9671838|NCT05042674|Other|Placebo, Ergothioneine 25mg, Ergothioneine 25mg for 1 week daily|Participants will consume placebo on first study day, consume 25mg of ergothioneine on second study day, then consume 25mg of ergothioneine daily for 1 week
9671839|NCT05042557||Sun Yat-sen University Cancer Center|
9671840|NCT05042557||hanghai Chest Hospital|
9671841|NCT05042557||Tianjin Cancer Hospital|
9671842|NCT05042557||Fudan University Shanghai Cancer Center|
9671843|NCT05042557||Anhui Cancer Hospital|
9671844|NCT05042557||Shandong Cancer Hospital|
9671845|NCT05042557||Hunan Cancer Hospital|
9671846|NCT05042557||Yunnan Cancer Hospital|
9671847|NCT05042557||Chinese Academy of Medical Sciences|
9671848|NCT05042713|Active Comparator|Wave One Gold|The Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
9977461|NCT01361789|Active Comparator|Dexamethasone|dexamethasone 8 mg iv
9520770|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked > 20 packs of cigarettes in a lifetime and who continue smoking every day.~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
9520771|NCT03274778|Experimental|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
10170239|NCT03894592|Active Comparator|Virtual Reality analgesia|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive the intervention which is a virtual reality headset providing immersive interactive content in the video format
10170240|NCT03894592|No Intervention|Control|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive no intervention
9826558|NCT02422511|Active Comparator|ICU Baby Family History Only|Parents of newborns in intensive care units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
10170241|NCT03894527|Active Comparator|Control|"Subjects with simple obesity will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
9520772|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
9520773|NCT03274752|Experimental|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
9520774|NCT03274752|Placebo Comparator|Placebo|Placebo oral capsule QD per os for 13 weeks
9520775|NCT03274739||Pregnant women|
9520776|NCT03274713|Experimental|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
9520777|NCT03274713|Experimental|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
9520778|NCT03274700|Active Comparator|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
9520779|NCT03274700|Placebo Comparator|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
9671849|NCT05042713|Active Comparator|One Flare and Wave One Gold file system|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
9671850|NCT05042713|Active Comparator|One Curve|The One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
9671851|NCT05042713|Active Comparator|One Curve with One Flare|The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the One Curve file (Size 25) will be used in the VDW endodontic motor (VDW) in continuous rotation at 300 rpm and 2.5 Ncm torque in accordance with the manufacturer's recommendations.
9826559|NCT02422511|Experimental|ICU Baby Family History + Exome Sequencing|Parents of newborns in intensive care units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
9974977|NCT04949789|Other|Placebo with Exercise|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
9974978|NCT04949789|Other|IP I|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
9974979|NCT04949789|Other|IP II|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
9974980|NCT04949789|Other|IP III|"2 Capsules to be taken 30 minutes before breakfast.~Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner.~On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption."
9826560|NCT02422940|Active Comparator|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
9520780|NCT03274687|Experimental|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy for 37 fractions over 7 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
9671852|NCT05042661|Experimental|acupuncture-like transcutaneous electrical nerve stimulation|"The experimental group received acupuncture-like transcutaneous electrical nerve stimulation three times a week for 4 weeks.~Invention and control groups are 4 weeks and 3 weeks respectively. Each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment"
9520781|NCT03274687|Experimental|Arm II (hypofractionated radiation therapy|Patients undergo hypofractionated radiation therapy for 25 fractions over 5 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
9520782|NCT03274674|Experimental|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
9520783|NCT03274674|Active Comparator|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
9520784|NCT03274648|Experimental|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
9520785|NCT03274648|Experimental|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
9520786|NCT03274648|Active Comparator|Habitual diet|habitual diet without supplementation
9520787|NCT03274635|Active Comparator|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
9520788|NCT03274635|Active Comparator|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
9520789|NCT03274635|Experimental|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
9520790|NCT03274635|Experimental|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
10170242|NCT03894527|Active Comparator|Metabolic Syndrome|"Subjects with metabolic syndrome will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
9520791|NCT03274635|Experimental|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
9520792|NCT03274635|Experimental|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
9520793|NCT03274622|Experimental|Impact Parent Training|Parents receive 22 1.5-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
9520794|NCT03274622|Placebo Comparator|No Impact|No parent coaching is provided
9520795|NCT03274609||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
9520796|NCT03274596|Active Comparator|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
9520797|NCT03274596|Placebo Comparator|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
9520798|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
9520799|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
9520800|NCT03274557|Active Comparator|Radiofrequency microtenotomy|Treatment of Achilles tendinose with radio-frequency microtenotomy
9520801|NCT03274557|Active Comparator|Phusical therapy|Supervised eccentric training
9520802|NCT03274544|Experimental|PROLUNG|Herbal formula treatment PROLUNG in additional to current therapy
9520803|NCT03274531|Experimental|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
9520804|NCT03274531|No Intervention|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
9520805|NCT03274427|Experimental|One-drug Regimes|Basic drugs therapy of HCC by TACE.
9520806|NCT03274427|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
9520807|NCT03274427|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
9520808|NCT03274414|Experimental|Unresectable paranasal sinus/nasal cavity malignancy|
9520809|NCT03274401|Active Comparator|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
9520810|NCT03274401|No Intervention|Control Arm|Standard of care
10170243|NCT03894189|Active Comparator|doxapram group (GROUP D)|The patients in this group will receive loading dose of (1 mg/kg) followed by an infusion of (1mg/kg/h)
9520811|NCT03274388|Experimental|Control|Intervention of protein-rich nutritional therapy and counseling
9520812|NCT03274388|Experimental|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
9520813|NCT03274362|Experimental|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
9520814|NCT03274362|No Intervention|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
9520815|NCT03274349|Active Comparator|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
9827512|NCT02458768|Experimental|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
10170244|NCT03894189|Active Comparator|theophylline group (GROUP T)|the therapeutic loading dose (5mg/kg) followed by an infusion of (0.5 mg/kg/h)
9520816|NCT03274349|Experimental|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
9520817|NCT03274336|Active Comparator|interview|questionnaire after face-to-face interview
10170245|NCT03894228||Biologics exposed cohort|Children born from mothers treated with biologic drugs (with or without immunomodulators) at any time during pregnancy or the three months before conception. Biologic drugs are IgG monoclonal antibodies able to cross the placenta.
10170246|NCT03894228||Immunomodulators exposed cohort|Children born from mothers treated with immunomodulators (without biologics) during pregnancy or the three months before conception.
9520818|NCT03274336|Placebo Comparator|brochure|questionnaire interview plus brochure
9520819|NCT03274336|Placebo Comparator|movie|questionnaire interview plus movie
9520820|NCT03274323|Experimental|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
9520821|NCT03274323|Active Comparator|trabeculectomy|Standard trabeculectomy
9520822|NCT03274310|Experimental|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
9520823|NCT03274310|No Intervention|Surveillance-only arm|No intervention solely surveillance messages
9520824|NCT03274297|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
9520825|NCT03274297|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
10170247|NCT03894228||Non-exposed cohort|Children born from mothers treated neither with biologic drugs nor with immunomodulators at any time during pregnancy or the three months before conception.
9520826|NCT03274297|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
9520827|NCT03274297|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
9520828|NCT03274284|Experimental|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
9520829|NCT03274258|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9520830|NCT03274245|Experimental|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
9520831|NCT03274245|No Intervention|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
9520832|NCT03274245|Experimental|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
9520833|NCT03274232|Experimental|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
9520834|NCT03274219|Experimental|bb21217 Experimental Arm|
9527728|NCT03217370|Other|all haematologists|"There will be only one arm: the haematologists will all be included in the interventional phase.~Interventions are: 1) rewriting guidelines to order blood components; 2) to show the last hemoglobin value on the orders for erytrocytes and the last platelet count on the orders dor thrombocytes and 3)implementation of a clinical decision support system in the electronic rodering of blood components to stimulate restrictive blood transfusion."
9520835|NCT03274206|Experimental|BLS-ILB-E710c|"Drug: BLS-ILB-E710c 1,000mg~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
9520836|NCT03274206|Placebo Comparator|BLS-ILB-E710c-placebo|"Drug: BLS-ILB-E710c-placebo~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
9520837|NCT03274193|Experimental|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
9520838|NCT03274193|No Intervention|Control|The control group will be asked not to participate in any exercise program during the course of the study.
9520839|NCT03274180|Experimental|Nursing consultation|travel preventive consultation was performed by nurse
10170248|NCT03894397|Experimental|Stimulation of left BNST|
10170249|NCT03894397|Experimental|Stimulation of right BNST|
10170250|NCT03894397|Experimental|Stimulation of bilateral BNST|
10170251|NCT03894397|Placebo Comparator|Stimulation OFF|
9520840|NCT03274180|No Intervention|Medical consultation|travel preventive consultation was performed by a doctor
9520841|NCT03274167|Experimental|Gabapentin|300 mg per day once daily before bedtime
9974981|NCT04920331|Experimental|Erenumab|Subjects with episodes of status migrainosus will receive a single dose of IV erenumab
9974982|NCT04912583|Active Comparator|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
10170252|NCT03894293||ventilator group|It's a observational study. Participants entry the Respiratory Care Center and are evaluated. If the participant meet the inclusion criteria, the first assessments will be collected. After the weaning training, the second assessment will be collected before the the endotracheal tube is removed.
9520842|NCT03274167|Placebo Comparator|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
9520843|NCT03274154|Experimental|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
9520844|NCT03274154|No Intervention|Untreated group|23 caucasian female subjects untreated
9520845|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
9520846|NCT03274141||RC Patients|RA patients managed with routine care(RC)
9520847|NCT03274128|Active Comparator|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
9974983|NCT04912583|Active Comparator|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
10170253|NCT03894111||living patients|living patients in intersivecare unit about 28 days
10170254|NCT03894111||deceased patients|deceased patients in intersivecare unit about 28 days
9520848|NCT03274128|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
9520849|NCT03274115|No Intervention|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
9520850|NCT03274115|Active Comparator|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
9520851|NCT03274102|Experimental|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
9520852|NCT03274102|Active Comparator|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
9520853|NCT03274102|Active Comparator|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
9520854|NCT03274089|Experimental|Kiosk intervention group|
9520855|NCT03274089|No Intervention|Nurse clinician control group|
9520856|NCT03274063|Active Comparator|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
9520857|NCT03274063|Sham Comparator|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
9520858|NCT03274050||patient group|Surgery with robot - all patients operated in pediatric surgery department with indication of robot in the routine care (all specialities).
9520859|NCT03274050||control group|Retroperitoneal coelioscopy - patient operated for pyeloplasty
9520860|NCT03274037|Experimental|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
9520861|NCT03274024|Experimental|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
9520862|NCT03274024|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C surgery
9977462|NCT01361789|Active Comparator|COXIB and dexamethasone|combination of coxib AND dexamethasone
10170255|NCT03894098|Active Comparator|Single shot regional popliteal and saphenous block|Standard of care traditional single shot popliteal / saphenous regional block for acute pain control after elective ankle surgery
10170256|NCT03894098|Experimental|High ankle block|High ankle block for acute pain control after elective ankle surgery
10170257|NCT03894124|Other|Study intervention|Pifeltro® (doravirine 100mg) daily dose for 7 days
10170258|NCT03894241|Experimental|Sedentary condition|
10170259|NCT03894241|Experimental|Moderate-intensity continuous training|
10170260|NCT03894241|Experimental|Cooperative-high-intensity interval training|
10170261|NCT03894384||Group:1|Gastric cancer patients
9520863|NCT03274011|Experimental|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
10170262|NCT03894384||Group:2|Patients with benign gastric diseases
10170263|NCT03894176||PTX3 concentration|First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL
10170264|NCT03894085|Experimental|GAD group|"General anxiety disorder(GAD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine (20-40mg) treatment for 4 weeks"
10170265|NCT03894085|Experimental|PD group|"Panic disorder(PD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine (20-40mg)treatment for 4 weeks"
10170266|NCT03894085|Experimental|SAD group|"Social anxiety disorder(SAD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine (20-40mg)treatment for 4 weeks"
10170267|NCT03894085|Experimental|OCD group|"Obsessive-compulsive disorder (OCD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine(40-80mg) treatment for 4 weeks"
9520864|NCT03273985|Experimental|Dry needling|
9520865|NCT03273985|Experimental|Ischemic compression|
9520866|NCT03273972|Experimental|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
9520867|NCT03273972|Other|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
10170268|NCT03894085|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
10170269|NCT03894137|Experimental|Grains of Paradise|
9520868|NCT03273959|No Intervention|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
9520869|NCT03273959|Experimental|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
10170270|NCT03894137|Placebo Comparator|Placebo|
10170271|NCT03894371|Other|Thermage|Subjects will undergo treatment with the Thermage FLX system using a 900 pulse, 4cm2 Total Tip to treat the face and neck and a 450 pulse, 0.25cm2 tip to treat the upper and lower eyelids.
10170272|NCT03894254|Experimental|Patients with subjective cognitive complaint or neurocognitive|: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study
10170273|NCT03894332||SBT Success|Patients took part of this cohort when succeeding the Spontaneous Breathing Trial (SBT).
10170274|NCT03894332||SBT Failure|"Patients took part of this cohort when failing the Spontaneous Breathing Trial (SBT).~SBT Failure is defined by one or more of the following criteria occurring during the SBT:~loss of ≥ 2 points of Glasgow Coma Scale~respiratory rate/ tidal volume ≥105 breaths/min/L~arterial partial pressure of oxygen ≤60 mmHg on inspired oxygen fraction (FiO2) ≥0.5 and/or pH <7.32 or a decrease in pH ≥0.07 units at the end of the SBT~systolic Blood Pressure <90 mmHg or ≥180 mmHg or increased by ≥20%~Heart Rate >140 beats/min or increased by 20%~onset of major heart arrhythmias, or electrocardiographic signs of cardiac ischemia~Respiratory Rate ≥35 breaths/min or increased by ≥50%~increased effort, respiratory distress (as indicated by diaphoresis, accessory respiratory muscles recruitment, facial signs of distress and/or paradoxical breath)"
10170275|NCT03894332||Extubation Success|Patients took part of this cohort when, after extubation, did not need continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours.
10170276|NCT03894332||Extubation Failure|"Need for continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours from extubation, as defined by:~Respiratory Rate >25 breaths/min for 2 hours~Heart Rate >140 beats/min or sustained increase or decrease >20%~clinical signs of respiratory muscle failure~arterial partial pressure of oxygen (PaO2) <80 mmHg on inspired oxygen fraction (FiO2) ≥50%~Arterial partial pressure of carbon dioxide >45 mmHg with pH <7.33"
9520870|NCT03273933|Active Comparator|10 children with DragONE only|
9520871|NCT03273933|Experimental|10 children with DragONE and SmartOne|
9520872|NCT03273920|Experimental|Robotic gastrectomy|Robotic distal gastrectomy with D2 nodal dissection
9520873|NCT03273920|Active Comparator|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 nodal dissection
9520874|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
9977463|NCT01361815|Other|H-Coil Deep TMS Treatment|
9977464|NCT01361828||Patients with choroidal neovascularization|CNV due to Age-Related Macular Degenerations and Myopia were included.
9520875|NCT03273881|Active Comparator|glucose solution and insulin|Participants will receive intravenous saline solution boosted with 5% glucose + 8 units regular insulin in a rate of 125 mL/h.
10170277|NCT03894345|Experimental|Open-label treatment with Prazosin|"Week 1 Day 1-3: 0.5 mg at bedtime Day 4-7: 1.0 mg at bedtime Week 2 Day 8-10: 2.0 mg at bedtime Day 11-14: 4.0 mg at bedtime Week 3 2 mg in the morning, 4 mg at bedtime Week 4 4 mg in the morning, 4 mg at bedtime Week 5 4 mg in the morning, 6 mg at bedtime Week 6 4 mg in the morning, 8 mg at bedtime~Dosage of Prazosin will be titrated at the discretion of the study physician."
10170278|NCT03894358|Active Comparator|FeFum and 7.5 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture
10170279|NCT03894358|Active Comparator|FeFum and 3 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture
9520876|NCT03273881|Active Comparator|glucose solution only|Participants will receive intravenous saline solution boosted with 5% glucose in a rate of 125 mL/h.
9520877|NCT03273868|Experimental|High velocity low amplitude manipulation|
9520878|NCT03273868|Sham Comparator|Sham manipulation|
10170280|NCT03894358|Active Comparator|FeFum and no prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate
10170281|NCT03894072|Active Comparator|HFHO-CPAP|This group will have HFHO before CPAP
9520879|NCT03273842|Experimental|PF-06881894|PF-06881894 6 mg SC
9520880|NCT03273842|Active Comparator|US-approved Neulasta|US-approved Neulasta 6 mg SC
10170282|NCT03894072|Active Comparator|CPAP-HFHO|This group will have CPAP and then HFHO
10170283|NCT03894280|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
10170284|NCT03894280|Active Comparator|Reference Product|SERETIDE DISKUS 250/50
10170285|NCT03893981|Experimental|Proprioception and Balance Training|Proprioception and Balance Program
10170286|NCT03893981|Experimental|Strengthening Training|Strengthening Program
10170287|NCT03894267|Experimental|Experimental Arm|"Self-adhesive silicone bordered foam dressing will be secured to the heels and sacrum.~Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.~Follow up 20 days"
10170288|NCT03894267|No Intervention|Control Arm|"Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.~Follow up for 20 days."
10170289|NCT03894046|Experimental|Part A|
10170290|NCT03894046|Experimental|Part B|
10170291|NCT03893994|Experimental|Stretching group|Posterior shoulder stretching exercises
10170292|NCT03893994|No Intervention|Control Group|No exercise will be applied
10170293|NCT03893968|Experimental|Informed by a doctor|Information by a doctor
10170294|NCT03893968|Experimental|Informed by an assistant nurse|Information by an assistant nurse
9520881|NCT03273816|No Intervention|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
9520882|NCT03273816|Experimental|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
9520883|NCT03273777|Experimental|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
9520884|NCT03273777|No Intervention|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
9520885|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
9520886|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
9520887|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
9520888|NCT03273712|Experimental|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
10170295|NCT03894007|Experimental|A: Experimental|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide + atezolizumab. In total seven courses of preoperative treatment. Response evaluations after course four.~Postoperatively, if pathologic complete response, patients receive 14 courses of adjuvant trastuzumab every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
10170296|NCT03894007|Active Comparator|B: Standard|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide. In total seven courses of preoperative treatment. Response evaluations after course four.~Postoperatively, if pathologic complete response patients receive 14 courses of adjuvant trastuzumab (combined with pertuzumab in case of high-risk disease features) every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
10170297|NCT03893877|Experimental|nasal cannula|device:nasal cannula will be applied to patients for oxygenation under deep sedation
10170298|NCT03893877|Active Comparator|nasal mask|device:nasal mask will be applied to patients for oxygenation under deep sedation
10170299|NCT03893890||No Treatment|Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in the EN3835-201 study, will be eligible for this study. The study will consist of up to two evaluations approximately 3 years after the first dose of study drug was received in the EN3835-201 study.
10170300|NCT03893695|Experimental|metastatic HCC|"Stage one - Dose de-escalation:~Each dose cohort will assess toxicity within the 28 days following the first dose of nivolumab and GT90001.~Stage two- the expansion cohort:~14 patients will be enrolled to the expansion cohort where one or no DLT takes place in planned study cohort."
10170301|NCT03893708|Experimental|Prenatal yoga|Each class will be outlined as follows: 1) opening greeting/intention setting, 2) pranayama (i.e., breathing exercises), 3) warm-up/sun salutations (i.e., flowing sequence), 4) yoga sequence (e.g., combination of sun salutations, vinyasa, and standing, seated, and/or balancing poses), 5) cool-down 6) Savasana (i.e., final resting pose), and 7) class closing. Meditation and breath awareness (e.g., linking each movement with breath) will be emphasized throughout each class. All classes will focus on safety and alignment and be appropriate for women during pregnancy by incorporating modifications to poses/exercises as necessary (e.g., yoga block, strap). Certified yoga instructors with a bachelors degree in a health related field and experience teaching pregnant women will instruct all yoga classes. Participants will be provided with a 'yoga during pregnancy' safety packet that includes a list of prenatal yoga poses that women may do at their own leisure at home.
10170302|NCT03893708|Active Comparator|Pregnancy education|Participants will be asked to attend a group-based pregnancy education group (similar to a birth education class). The class format will include a didactic portion followed by group discussion (N=12). The following evidence-based topics (based on the American College of Obstetrics and Gynecologists) to be discussed may include (but not limited to): financial management in preparation for baby, preparing for labor and delivery, transitioning into motherhood, sleep hygiene, and baby bonding. A labor and delivery nurse and certified Dula will instruct all classes.
10170303|NCT03893734|Active Comparator|methadone group|Patients in this group will receive a syringe of methadone at the induction of anesthesia and a syringe of saline at the end of anesthesia.
10170304|NCT03893734|Placebo Comparator|hydromorphone group|Patients in this group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
10170305|NCT03893591||Body mass index below 35|
10170306|NCT03893591||Body mass index 35 and above|
9520889|NCT03273699|Experimental|Mindfulness|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
9520890|NCT03273699|No Intervention|Control|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
10170307|NCT03893760||No Pulonary Hypertension|the presence of mean pulmonary pressures (PAPm) at the right heart catheterization < 25 mmHg
10170308|NCT03893760||Postcapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg and postcapillary wedge pressure (PCWP) >15 mmHg
9671853|NCT05042661|No Intervention|Control group:conventional therapy|The control group will receive routine care.
9671854|NCT05042856|Experimental|PanOptix|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
9671855|NCT05042388|Experimental|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Group intervention comprised of didactics and trainings in cognitive behavioral therapy relapse prevention skills and mindfulness meditation.
10170309|NCT03893760||combined postcapillary/precapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg, PAWP >15 mmHg and diastolic peak gradient (DPG - diastolic pulmonary pressure - PCWP) ≥7 mmHg and/or pulmonary vascular resistence (PVR) >3 WU, where available.
10170310|NCT03893786|Experimental|Robotic Treatment|"Fifteen patients with Parkinson's Disease will perform ten 45-minutes training sessions of the upper limb using the Armeo®Spring applied bilaterally, an electromedical device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upper limb training and it is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
10170311|NCT03893786|Active Comparator|Conventional Treatment|Fifteen patients with Parkinson's Disease will undergo ten 45-minutes training sessions of the upper limb with a traditional approach, performing the same excercises of the experimental group, i.e. flexo-extension of the wrist, prono-supination of the forearm, etcc.
9671856|NCT05042388|Active Comparator|Treatment-As-Usual (TAU)|Standard procedure for residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on issues related to mental health and substance use disorders; and medication counseling. No aspect of the treatment-as-usual services provided entails mindfulness training or components of mindfulness training.
9974984|NCT04911543|Experimental|Part A: [18F]-JNJ-70099731|Participants will receive an intravenous (IV) bolus injection of [18F]-JNJ-70099731 on Day 1 of Part A to investigate the total body bio-distribution and measure the radiation dosimetry of [18F]-JNJ-70099731.
9974985|NCT04911543|Experimental|Part B: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of [18F]-JNJ-70099731 on Day 1 of Part B to measure the uptake, distribution, and clearance of [18F]-JNJ-70099731 and to model the tissue specific kinetics of [18F]-JNJ-70099731 in the human brain with the appropriate arterial input function.
10170312|NCT03893604|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
10170313|NCT03893604|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
9520891|NCT03273686|Experimental|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
9520892|NCT03273686|No Intervention|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
9520893|NCT03273660|Experimental|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
9520894|NCT03273647|Experimental|surgery plus radiation|adjuvant radiotherapy is developed in this arm
9520895|NCT03273647|No Intervention|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
9520896|NCT03273634|Experimental|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
10170314|NCT03893851|Experimental|ICC-T|Interactions Competencies with Children - for Teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
10170315|NCT03893851|No Intervention|Control|The control schools do not receive any intervention
9520897|NCT03273634|Placebo Comparator|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
9520898|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
9520899|NCT03273595|Placebo Comparator|Control|
9520900|NCT03273595|Experimental|Experimental group|
9520901|NCT03273569|Experimental|Women with placenta accreta|PDI-UC protocol
9520902|NCT03273556|Experimental|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
9520903|NCT03273530|Experimental|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
9520904|NCT03273530|No Intervention|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
9520905|NCT03273530|No Intervention|Traditional Vocational Rehabilitation|general pre-vocational training and placement
9520906|NCT03273504|Experimental|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.~The placebo product will be applied in the same way, on the controlateral leg."
9520907|NCT03273491|Experimental|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
10170316|NCT03893669|Experimental|Group 1|NBP607 0.5ml
9520908|NCT03273491|Active Comparator|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
9520909|NCT03273465|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
10170317|NCT03893669|Active Comparator|Group 2|Agrippal 0.5ml
9520910|NCT03273465|Placebo Comparator|Placebo|Placebo capsules
9520911|NCT03273452|Experimental|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
9520912|NCT03273439|Experimental|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
9520913|NCT03273439|Sham Comparator|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
9520914|NCT03273400|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
9520915|NCT03273400|No Intervention|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
10170318|NCT03893552|Experimental|Patient with sleep disordered breathing symptoms|Patients referring to the clinic of sleep disorders will be asked to participate in this study. A negative expiratory pressure will be applied via a cough-assist attached to a facial mask.
10170319|NCT03893864|Experimental|Intervention Group (CoQ10)|Runner athletes > 50 years old, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions
10170320|NCT03893864|Active Comparator|Control Group|Runner athletes > 50 years old with the same characteristics as the Experimental arm, served as control group, maintaining the training sessions Both groups were evaluated before and after the month of intervention or no intervention.
9520916|NCT03273374|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
10170321|NCT03893630|Active Comparator|Control Group|Patients will receive standard of care.
9520917|NCT03273361|Experimental|Seated|Participants completed work tasks while seated.
9520918|NCT03273361|Experimental|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
9520919|NCT03273361|Experimental|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
9520920|NCT03273348|Other|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
9520921|NCT03273309|Active Comparator|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
9520922|NCT03273309|Active Comparator|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
9520923|NCT03273296|Active Comparator|Amoxicillin|
9520924|NCT03273296|Active Comparator|Azithromycin|
9520925|NCT03273296|Active Comparator|Vancomycin|
9520926|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
9520927|NCT03273231|Experimental|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
9520928|NCT03273231|Placebo Comparator|control group|0.9% saline solution
9520929|NCT03273218|Experimental|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
10170322|NCT03893630|Experimental|Acetylsalicylic Acid 81mg|Patients will receive low dose (81mg) acetylsalicylic acid (Aspirin).
10170323|NCT03893630|Experimental|Acetylsalicylic Acid 162mg|Patients will receive low dose (162mg) acetylsalicylic acid (Aspirin).
9520930|NCT03273218|Active Comparator|Judkins catheter|Judkins right and judkins left catheter
10170324|NCT03893747|Experimental|the first batch vaccine producted by 40 L reactor|500 subjects will be randomly received the first batch vaccine producted by 40 L reactor
9520931|NCT03273205|Experimental|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
9520932|NCT03273205|Sham Comparator|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
9520933|NCT03273192|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
9520934|NCT03273192|Active Comparator|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
9520935|NCT03273140|Experimental|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
9520936|NCT03273140|No Intervention|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
9520937|NCT03273127|Experimental|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
10170325|NCT03893747|Experimental|the second batch vaccine producted by 40 L reactor|500 subjects will be randomly received the second batch vaccine producted by 40 L reactor
9520938|NCT03273127|Placebo Comparator|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
10170326|NCT03893747|Experimental|the third batch vaccine producted by 40 L reactor|500 subjects will be randomly received the third batch vaccine producted by 40 L reactor
10170327|NCT03893747|Experimental|the first batch vaccine producted by 150 L reactor|500 subjects will be randomly received the first batch vaccine producted by 150 L reactor
9520939|NCT03273114|Experimental|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
9520940|NCT03273114|Active Comparator|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
9671857|NCT05042635|Experimental|Ixekizumab (4 weeks) + Jueyin Granules (12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin Granules was used in the 12-week traditional Chinese medicine treatment period.
10170328|NCT03893747|Experimental|the second batch vaccine producted by 150 L reactor|500 subjects will be randomly received the second batch vaccine producted by 150 L reactor
10170329|NCT03893747|Experimental|the third batch vaccine proudected by 150 L reactor|500 subjects will be randomly received the third batch vaccine producted by 150 L reactor
10170330|NCT03893578|Experimental|Interventional Arm|Access, delivery, and retrieval of the Conveyor system with correct positioning of the valve delivery system to facilitate correct positioning of the implant at the mitral location in patients with a failing bioprosthetic valve.
10170331|NCT03893721||malnourished under five children|children from 2 to 5 years with malnutrition
10170332|NCT03893721||well nourished under five children|children from 2 to 5 years without malnutrition
10170333|NCT03893526|Placebo Comparator|Placebo|Participants are subjected to a standardized meal
10170334|NCT03893526|Active Comparator|Entrestro|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
10170335|NCT03893526|Active Comparator|Sitagliptin|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
10170336|NCT03893526|Active Comparator|Entrestro + sitagliptin|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
10170337|NCT03893526|Active Comparator|Valsartan|206mg valsartan as one single dose followed by a standardized meal
10170338|NCT03893422|Experimental|WB-010|3 capsules administered twice daily with morning and evening meal for 12 weeks
10170339|NCT03893422|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 12 weeks
10170340|NCT03893422|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 12 weeks
10170341|NCT03893435|Experimental|Sacubitril/Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
10170342|NCT03893435|Active Comparator|Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Valsartan with an initial dose of 40 mg PO BID, with subsequent titrations to target maintenance dose of 160 mg BID as tolerated.
10170343|NCT03893539|Other|Robotic Bronchoscopy|The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.
10170344|NCT03893357||Positive for antiphospholipid antibodies|Patients tested positive for antiphospholipid antibodies
10170345|NCT03893357||Negative for antiphospholipid antibodies|Patients tested negative for antiphospholipid antibodies
10170346|NCT03893409||pulmonary function|
10170347|NCT03893409||biological sample detection outcome|
10170348|NCT03893474|Other|Control Arm|All investigations are the same in both arms, but patients within this arm will be seen in the hospital as per standard practice.
10170349|NCT03893474|Other|Study Arm|All investigations are the same in both arms, but patients within this arm will be seen in a community optometrist practice.
10170350|NCT03893344||Cases|patients with Multiple Sclerosis in different stages diagnosed clinically according to revised McDonald's criteria 2010
10170351|NCT03893344||Control|Healthy peaple
10170352|NCT03893227||Patients|Patients with chronic upper airway inflammation
10170353|NCT03893227||Healthy control|Healthy controls without chronic upper airway inflammation
10170354|NCT03893201||Venaseal|Patients that have undergone venaseal
10170355|NCT03893084|Experimental|Intervention|Preconception guidance prepared by reference to the guidelines published in the literature, women were given pre-pregnancy training.
10170356|NCT03893084|No Intervention|Control|The women in the control group were not given training, and routine practice was performed.
10170357|NCT03893643||pediatric population|Pediatric population aged 0 to 15 years with neurofibromatosis type 2
9520941|NCT03273101|Experimental|Intervention group|The sit-to-stand training is assisted by mechanical device
9520942|NCT03273101|Active Comparator|Control group|The sit-to-stand training is assisted by manual device
9520943|NCT03273088|Experimental|AryoGen Pharmed etanercept|Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.
9520944|NCT03273088|Active Comparator|Pfizer etanercept|Enbrel® (etanercept prefilled syringe produced by Pfizer Company) 25mg/0.5ml in prefilled syringe.
9527729|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
10170358|NCT03893097|Active Comparator|Praziquantel|Participants in this arm will receive one dose of PZQ at baseline at 40 mg/kg.
10170359|NCT03893097|Experimental|Artesunate-Mefloquine|Participants in this arm will receive the Artesunate-Mefloquine (fixed-drug)combination at 4 mg/kg artesunate and 8 mg/kg mefloquine at 3 consecutive days. This will be repeated twice; at week 6 and week 12.
9520945|NCT03273075|Active Comparator|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
9974986|NCT04911543|Experimental|Part C: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of [18F]-JNJ-70099731 on Day 1 of each period of Part C to determine the test-retest variability in the regional brain kinetics and binding properties of [18F]-JNJ-70099731.
10170360|NCT03893292||Preoperative cooled radiofrequency ablation|Patients who undergo cooled radiofrequency ablation within 4-8 weeks of their scheduled total knee replacement.
10170361|NCT03893214|Experimental|intervention group|Virtual reality exposure for acrophobia - this arm receives the virtual reality exposure intervention in the initial phase and has a four-week follow-up assessment.
10170362|NCT03893214|Placebo Comparator|waitlist control group|This arm watches a movie in the initial phase in order to control for effects of behavioral approach test that is done before and after the intervention and for time effects. In the second phase after four weeks, this arm receives the virtual reality exposure after collection of outcome measures.
10170363|NCT03893006|Experimental|UnAssisted (UA)|This term refers to driving a vehicle manually without any vehicle automation technology. It will serve as a baseline concerning behaviors, representations and neural results associated with unassisted automobile driving.
9520946|NCT03273075|Active Comparator|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
9520947|NCT03273075|Placebo Comparator|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
9520948|NCT03273075|Placebo Comparator|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
9671858|NCT05042635|Placebo Comparator|Ixekizumab (4 weeks) + Jueyin placebo Granules(12 weeks)|Subjects received Ixekizumab in the first 4 weeks (biologic treatment period); After the cessation of biologic treatment, only Jueyin placebo Granules was used in the 12-week traditional Chinese medicine treatment period.
10170364|NCT03893006|Experimental|Assisted (A)|This term refers to driving with warning technology which upon activation sounds an a warning when the vehicle is too close to the edge of the road (off-road warning , Navarro, Mars, & Hoc, 2007; Suzuki & Jansson, 2003) or too close to the vehicle in front of it (anti-collision warning; Lee, McGehee, Brown, & Reyes, 2002).
10170365|NCT03893006|Experimental|Shared Control (SC)|This term refers to shared tactical control between the driver and the automated assistive technology, both working simultaneously on the physical trajectory of the vehicle, laterally (Griffiths & Gillespie, 2005; Mulder, Abbink, & Boer, 2012) as well as longitudinal (Adell, Várhelyi, & Hjälmdahl, 2008).
10170366|NCT03893006|Experimental|Partly Autonomous (PA)|"This term refers to a situation where the lateral and longitudinal control of the driving are delegated to the automated assistive technology. It consists of a level of automatisation that today is possible to put into application and which often is referred to by the name Highly Automated Driving (Navarro, 2018). In this case, the driver is no longer the one who physically ensures the lateral and longitudinal control of the vehicle, but instead supervises the actions of the automated assistive technology."
10170367|NCT03893006|Experimental|Fully Autonomous (FA)|This term refers to a completely automated driving experience. The on-board technologies take over all the driving tasks for any driving situation.
10170368|NCT03893006|Experimental|Any Automation (AA)|This term refers to a situation where the drivers can choose the automation device of their choice among the five types presented above and can change it whenever they think it is good to do so.
10170369|NCT03893032|Experimental|Modafinil 200mg|single, 200 mg dose of modafinil
10170370|NCT03893032|Experimental|mixed amphetamine salts|single 10 mg dose of mixed amphetamine salts
10170371|NCT03893032|Placebo Comparator|placebo|placebo
10170372|NCT03893188||People asking for PrEP|All individuals aged >18 years asking for PrEP prescription at one of the participating centers will be asked to participate to the SwissPrEPared Study(consecutive ongoing recruitment). Only HIV negative individuals will be deemed eligible.
10170373|NCT03893136||Control group|The control group mainly consists of healthy volunteers. The whole blood is obtained and frozen to detect the corresponding biochemical markers in the futures. The vascular tissues are obtained from the deserted and free abdominal aorta conjugated to the renal artery in the kidney transplantation.
9520949|NCT03273062|Active Comparator|Study Period 1|"15 days of Tolcapone 200mg TID~OR~Placebo Comparator 15 days of Placebo pill TID"
9520950|NCT03273062|Placebo Comparator|Study Period 2|"15 days of Placebo pill TID~OR~Active Comparator 15 days of Tolcapone 200mg TID"
9977465|NCT01361841|Other|ophtalmic solution,|Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
9520951|NCT03273036|Active Comparator|epidural steroid injection|40 mg triamcinolone acetate 1 cc
9520952|NCT03273036|Placebo Comparator|placebo injection|no injection agent
9520953|NCT03273010|Experimental|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
9826561|NCT02422940|Active Comparator|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
9826562|NCT02423109|Experimental|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
9826563|NCT02423109|Active Comparator|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
9977466|NCT01361880|Other|Reduce infant mortality|The overall purpose of this study is to develop and evaluate a systematic approach to improve African-American parental behaviors specifically with regards to the infant sleep environment
9520954|NCT03273010|Active Comparator|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
9520955|NCT03272984|Experimental|ERAS group|Patients will undergo the ERAS programs.
9520956|NCT03272984|Other|SC group|Patients will undergo the SC group.
9520957|NCT03272971|Experimental|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
9520958|NCT03272945|Experimental|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
9520959|NCT03272945|Placebo Comparator|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
9520960|NCT03272919|Experimental|Arm 1: Investigational INF|Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow.
9520961|NCT03272919|Other|Arm 2: Standardized muscle stretching and strengthen|subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist
9520962|NCT03272906|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
9520963|NCT03272906|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
9520964|NCT03272880|Experimental|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
9520965|NCT03272867|Experimental|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
9520966|NCT03272867|Placebo Comparator|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
9520967|NCT03272854||Renal Transplant Recipients|A cohort or renal transplant recipients, all more than 1 year after transplantation at inclusion
9520968|NCT03272841||Transplant recipients|Renal, heart, lung, liver, small bowel, pancreas or combined transplant recipients
9671859|NCT05042323|Experimental|TF-CBT-Skills|Step 1: 4-5 sessions with stabilization/skill building Step 2: 4-5 sessions with narrative and cognitive processing
9520969|NCT03272815|Experimental|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
9520970|NCT03272815|Active Comparator|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
9520971|NCT03272802|Experimental|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:~Tab. Rilutek 50 mg PO q12hr on empty stomach.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
9520972|NCT03272802|Active Comparator|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.~Instructions:~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
9520973|NCT03272789|Other|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
9520974|NCT03272776||Protector Laryngeal Mask Airway|Patients undergoing anesthesia in which airway management includes a Protector Laryngeal Mask and fulfill the inclusion criteria of the study.
9520975|NCT03272750|Experimental|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
9826564|NCT02423122|Experimental|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
9520976|NCT03272750|Active Comparator|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
9520977|NCT03272750|Placebo Comparator|PLACEBO|2 placebo capsules + 1 placebo tablet
9826565|NCT02423122|Experimental|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
9520978|NCT03272711|Experimental|Vortioxetine plus cognitive training|Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
9520979|NCT03272711|Placebo Comparator|Placebo plus cognitive training|Placebo plus cognitive training 5 times weekly for 30 minutes a day
9520980|NCT05075460|Experimental|Tucidinostat, Azacitidine combined with CHOP|Tucidinostat, Azacitidine combined with CHOP
9520981|NCT05075460|Active Comparator|CHOP|CHOP
9520982|NCT05075447|Experimental|ADHD group|Child diagnosed with ADHD
9520983|NCT05075447|No Intervention|control group|Children without any diagnosis
9826566|NCT02423200|Experimental|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
9974987|NCT04902820|Experimental|PrEPTECH intervention recipients|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and an online pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine [200 mg]/tenofovir disoproxil fumarate [300 mg]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
9520984|NCT05075447|Experimental|ADHD+ODD/CD group|Child diagnosed with ADHD+ODD/CD
9520985|NCT05075473|Experimental|Segmental Stabilization|Segmental control over the primary stabilizers (TrA, deep multifidus, pelvic floor and diaphram) is maintained. Weight of body is minimized by using drawing in maneuver. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
9520986|NCT05075473|Active Comparator|General lumber stabilization exercises|It includes exercises in closed chain with low velocity as well as low load. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for about 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
9974988|NCT04902820|Active Comparator|Control resource-list only recipients|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
9974989|NCT04894812|Active Comparator|Group A|Neurodevelopmental Treatment. Total duration of treatment will be 20 minutes, 3 sessions per for 3 months
9974990|NCT04894812|Experimental|Group B|Neurodevelopmental Technique and Vestibular stimulation. Total duration of treatment will be 50 minutes (20 min NDT+ 30 MIN VS) 3 sessions per week for 3 months.
9974991|NCT04894799|Experimental|Vestibular stimulation|all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
9974992|NCT04894799|Active Comparator|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
10170374|NCT03893136||sham TA group|In the TA cohort, patients are divided into two groups mainly, sham TA group and scramble TA group. The sham TA group is the TA group who is given the traditional and classical intervention or treatment and so on.
9520987|NCT05075434|Experimental|Intervention Group|This group will receive the protocol prescribed by the health centre (calf stretching exercises, plantar fascia, proprioception exercises, ultrasound, magnet therapy and gait re-education and proprioceptive exercises for 40-45 minutes). In addition, you will receive 15 minutes of the instrumental technique of diacutaneous fibrolysis. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
9520988|NCT05075434|Active Comparator|Control Group|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
9520989|NCT05075525|Experimental|High Intensity Laser Therapy Group|Patients underwent High Intensity Laser Therapy (HILT) and exercise for 10 sessions
9520990|NCT05075525|Experimental|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Patients will be treated by transcutaneous electrical nerve stimulation(TENS), ultrasound (US) and exercise for 10 sessions
9520991|NCT05075525|Experimental|Ultrasound and Interferential Current Stimulation Group|Patients will be treated with ultrasound (US) ,interferential current stimulation and exercise for 10 sessions
9520992|NCT05075512|Experimental|experimental group|anlotinib combined with fulvestrant
9520993|NCT05075265||Methadone Group|adult patients undergoing cardiac surgery with extracorporeal circulation
9527730|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
9671860|NCT05042323|Active Comparator|TF-CBT-Narr|Step 1: 4-5 sessions with narrative and cognitive processing Step 2: 4-5 sessions with stabilization/skill building
9826567|NCT02423200|Experimental|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
10170375|NCT03893136||scramble TA group|Compared to sham TA group in the cohort, scramble TA group refers to TA patients who are given novel drugs or new drugs which are safe to treat other autoimmune diseases but have not been used to treat TA yet, or some new interventions and so on.
10170376|NCT03893110|Experimental|Instrumentation with Carbon/PEEK pedicle screw system|Posterior instrumentation using a Carbon/PEEK pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
10170377|NCT03893110|Active Comparator|Instrumentation with titanium pedicle screw system|Posterior instrumentation using a titanium pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
10170378|NCT03893123||Firefighters|
10170379|NCT03893162|Experimental|"Multi-strain probiotic BioKult"|4 capsules daily for 8 weeks
10170380|NCT03893162|Placebo Comparator|Placebo|4 capsules daily for 8 weeks
9662169|NCT05130372|Active Comparator|Static Stretching Group|The static stretching method was actively applied while standing.The person was positioned facing the wall, supporting the wall with both hands, with the dominant foot behind. The point where a feeling of tension in the plantar flexor muscles was created and held in this position for 30 seconds. Afterward, a 15-second rest break was given. After completing 3 repetitions (3x30sec) in total, measurements were started.
9662170|NCT05130372|Active Comparator|PNF Stretching Method Group|The person was positioned supine, and the ankle joint was dorsiflexed by the physiotherapist to the point where the tension was felt. Then, while the person was trying to push the foot towards the plantarflexion direction for 10 seconds, the movement was prevented by the physiotherapist and isometric contraction was achieved at 20% of the maximum voluntary contraction. After 10 seconds, the person was asked to relax slowly and passive stretching was applied to the plantar flexors for 20 seconds. The contract-relax technique was applied for 30 seconds and completed with 3 repetitions (3x30sec) with 15-second rest intervals.
9671861|NCT05042726|Experimental|cTBS First|The first course of treatment, participants are treated with cTBS for 2 weeks, a total of 10 times, then followed up for 8 weeks. The first course of treatment, participants are treated with pseudo-stimulation for 2 weeks, a total of 10 times, then followed up for 8 weeks.
10170381|NCT03893045|Experimental|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
10170382|NCT03893045|Active Comparator|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL)
10186905|NCT03731442|Experimental|Involved field irradiation|Patients after R0 surgery whose recurrence lesion larger than 5cm in diameter, or largest diameter was less than 5cm but with skip metastasis far from primary tumor or their time-to-recurrence longer than 16 months were assigned to involved field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 60Gy/2Gy/30f, and for lesions close to the thoracic stomach, the prescribed dose is 59.4-61.2Gy/1.8Gy/33-34f. Chest CT scan is planned at 50Gy. Radiation field should be modified according to the tumor response. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF (3-6mg) should be given after 48 hours of chemotherapy.If patients received postoperative chemotherapy of paclitaxel and platinum and went through local-regional recurrence within six months, it is allowed to deliver chemotherapy regimens in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
10186906|NCT03731442|Experimental|Elective field irradiation|Patients after R1/R2 surgery or R0 surgery with the recurrence lesion whose diameter was less than 5cm without skip metastasis far from primary tumor and time-to-recurrence shorter than 16 months were assigned to elective field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a simultaneously integrated boost up to 59.92-62.16Gy/2.14-2.22Gy/28f. For lesions close to the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a sequential boost of 10-12Gy/1.8-2Gy/5-7f. For patients whose planned thoracic stomach V50>50%, the dose should be lowered to 45Gy/1.8Gy/25f. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF should be given in need. If patients received postoperative chemotherapy of TP and went through local-regional recurrence within 6 months, chemotherapy regimens delivered in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
10186907|NCT03731429|Experimental|Intervention|Group that receives a 1 mg/kg single bolus of 2% IV lidocaine
9671862|NCT05042726|Experimental|Pseudo-stimulation First|The first course of treatment, participants are treated with pseudo-stimulation for 2 weeks, a total of 10 times, then followed up for 8 weeks. The first course of treatment, participants are treated with cTBS for 2 weeks, a total of 10 times, then followed up for 8 weeks.
9671863|NCT05042427||primigravida women|Weight management health literacy of primigravida women.
10186908|NCT03731429|Placebo Comparator|Placebo|group that receives 0.9% saline solution
9671864|NCT05042752|No Intervention|No intervention arm|Standard care of AHF on a patient admitted on a HAH unit consists in physical examination and basic complementary tests
9671865|NCT05042752|Experimental|Experimental arm|Clinical ultrasound on HAH admitted patient. Clinical handheld Ultrasound consists of inferior vena cava diameter measurement and lung ultrasound protocol in order to guided Diuretic Therapy
9671866|NCT05042453||Hysteropexy using Splentis via vaginal route|Non-fertile women ≥ 18 years with uterine descent (POP-Q ≥ 2) which are study-independently scheduled for hysteropexy with Splentis
9671867|NCT05042570|Experimental|Instrument Assisted Soft Tissue Mobilization|Group 1 (n=13): Each session will consist of 40 minutes. An additional 10 minutes of IASTM will be performed to the 30-minute NDT program.
9671868|NCT05042570|Experimental|Stretching Exercises|Group 2 (n=13): Each session will consist of 40 minutes. In addition to the NDT program applied for 30 minutes, 10 minutes of Stretching Exercises will be performed.
9974993|NCT04889898||ALS Patients|All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.
10170383|NCT03893019|Experimental|Dose Level 1: 1x10e5 MB-CART20.1 cells|3+3 patients will be treated with 1x10e5 MB-CART20.1 cells per kg body weight administered intravenously
10170384|NCT03893019|Experimental|Dose Level 2: 1x10e6 MB-CART20.1 cells|3+3 patients will be treated with 1x10e6 MB-CART20.1 cells per kg body weight administered intravenously
10170385|NCT03893019|Experimental|Dose Level 3: 1x10e7 MB-CART20.1 cells|3+3 patients will be treated with 1x10e7 MB-CART20.1 cells per kg body weight administered intravenously
10170386|NCT03892941|Experimental|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
9520994|NCT05075395|Experimental|Intervention|The PT/OT provider will assess whether the patient meets eligibility criteria. If the patient is eligible to participate, they will then introduce the study to the patient and their parent or guardian. If the patient is interested in participating, the PI or PIs research assistant (RA) will seek written informed consent. After informed consent is obtained, the PI or RA will begin pretest data collection. Then, the PT/OT provider will begin the therapy session with Paro. The PI or RA will remain in the room during therapy session to record field notes. When the therapy session is complete, the PI or RA will begin posttest data collection. The patient will remain in the study for up to 7 PT/OT sessions or until they are discharged from the PICU. The PT/OT providers will coordinate all subsequent therapy sessions with the PI/RA while the patient remains on the study protocol.
9527731|NCT03217526|Active Comparator|Ex Group|"EX: Standard exercise program (EX) (active range-of otion exercises, balance and mobility exercises) and walking training on the overground.~This rehabilitation program physiotherapist will be applied to participants for five days a week. Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be instructed to walk with verbal commands and encourage them to continue their walk at constant speed.The duration of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale."
9527732|NCT03217526|Experimental|Ex +WT Group|Ex: A standard exercise (SE) (active range-of otion exercises, balance and mobility exercises) WT: walking training on the treadmill (WT). This rehabilitation program physiotherapist will be applied to participants for five days a week.Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be trained on the treadmill.The duration of walking training and the speed of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale.
9527733|NCT03217344|Experimental|1-week|patients undergoing 1-week immobilization period
9527734|NCT03217344|Experimental|3-week|patients undergoing 3-week immobilization period
9527735|NCT03217474|Experimental|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
10170387|NCT03892941|No Intervention|Clinical routine|Mapping of the electrical input of the cochlear implant will be based on a one-size-fits-all, as is part of clinical routine.
10187906|NCT03721536|Active Comparator|normal-flow anesthesia|Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
9527736|NCT03217474|Active Comparator|GCV orally|Ganciclovir (GCV) orally only
9527737|NCT03217604|Placebo Comparator|Placebo|Placebo
9527738|NCT03217604|Experimental|PF-06852231|Single ascending doses of PF-06852231
9527739|NCT03217253|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9527740|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
9527741|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
9527742|NCT03217734|Placebo Comparator|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
9527743|NCT03217734|Active Comparator|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
9527744|NCT03217461|Experimental|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
9527745|NCT03217461|Active Comparator|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
9527746|NCT03217695|Experimental|Mindfulness-based Yoga Arm|"8-week period, 1x/week for 45-60 minutes/session. Sessions 1-2: Participants instructed to focus their attention on their breath, and the physical sensations in their bodies while holding the yoga postures, to develop sustained and focused attention. Sessions 3-4: exploring the sensorial qualities of physical sensation in the body whether pleasant or unpleasant and to notice thoughts and label them (e.g., planning, remembering), and to the same with emotions (e.g., worry, frustration, fear) to practice disengaging from automatic associative thinking. Session 6-8: Instructor will guide participants to allow sensations of discomfort or effort to be as they are and to bring awareness to automatic patterns of reactivity. The goal is to foster distress tolerance, provide opportunities for participants to practice self-care, and allow an opportunity to observe and respond skillfully, instead of react automatically, to unpleasant stimuli (sensations, emotions)."
9527747|NCT03217539|Experimental|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
9527748|NCT03217539|No Intervention|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
9527749|NCT03217318|Active Comparator|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
9520995|NCT05075343|Experimental|Custom foot orthoses (CFO)|Participants with a confirmed diagnosis of PsA and foot pain received and wore custom foot orthoses (CFO).
9520996|NCT05075148||Aneurysmal bone cyst|Patient aging from 0 to 30 years with diagnosis of aneurysmal bone cyst treated by percutaneous alcolisation or endovascular embolization.
9520997|NCT05075382||Pilot group|Group of 40 patients that will act as observationnal group for this study
9520998|NCT05075369|No Intervention|baseline Intraocular pressure|The participants will have their intraocular pressure measured with Goldmann Application Tonometry immediately prior to beginning the water drinking test.
9520999|NCT05075369|Active Comparator|Change in Intraocular pressure with Water drinking test|The participants will undergo the water drinking test as previously described, i.e. after drinking 800 mls of water over a 5 minute period, the intraocular pressure will be measured immediately after completion of ingestion, followed by intraocular pressure measurements every 15 minutes for 60 minutes, using etc Goldmann apllantion tonometer.
9521000|NCT05075304|Experimental|A low dose of BDB-001|6 patients administered low dose of BDB-001 injection
9521001|NCT05075304|Experimental|A intermediate dose of BDB-001|6 patients administered intermediate dose of BDB-001 injection
9521002|NCT05075304|Experimental|A high dose of BDB-001|3-6 patients administered high dose of BDB-001 injection
9521003|NCT05075356|Experimental|Single participant arm|"The iToBoS intervention is a total body imaging device, to image the total skin surface in order to detect and monitor for signs of skin cancer.~The imaging process involves laying down on a bed that has a framework of cameras arched over it. The imaging process takes less then 10 minutes, and requires the participant to lay in two different positions (face-up and face-down).~The study visit also includes individual dermoscopic images taken of certain moles on the skin. This is done in combination with a clinical skin examination. Participants are given the option of providing a saliva sample for genetic research. Participants are then asked to complete a series of questionnaires.~There a three visits in total (month 0, 6 and 12), in which these procedures are repeated (except for saliva sample)."
9521004|NCT05075499|Active Comparator|MS no immunomodulatory treatment|MS patients receiving no immunomodulatory treatment
9521005|NCT05075499|Active Comparator|MS Teriflunomide treatment|MS patients under treatment with Teriflunomide
9521006|NCT05075499|Active Comparator|MS Alemtuzumab treatment|MS patients under treatment with Alemtuzumab
9521007|NCT05075135|Experimental|3D-splint group|Patients wear the Swibrace 3D splint for 6 weeks of immobilization of the wrist for distal radius fractures, including the basis of the thumb for scaphoid fractures. X-rays after week 1, 3 and 6 are planned to document bone healing, together with weekly visits at the hand therapy unit to measure patient satisfaction and hand function. This results in 2-3 surgeon and 6 hand therapy visits at the Inselspital Bern, where regular check-ups on the patient's comfort in the splint are made.
9521008|NCT05075135|Active Comparator|Plaster cast group|"The control intervention is the same as the study intervention, but the participants wear the gold-standard plaster cast instead of the newly designed Swibrace 3D-splint."
9521009|NCT05075109|Experimental|High Frequency TENS|high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
9521010|NCT05075109|Experimental|Low Frequency TENS|low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks with task related training.
9521011|NCT05075109|Active Comparator|Task Related Training|postural control, shoulder mobilization, weight bearing exercises, functional activities that will comprise of simple tasks to more advanced movement patterns
9521012|NCT05074875||Cohort 1|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 1 subjects will undergo Visit 0 after informed consent is obtained. Eligible subjects will return for follow-up at Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks"
9521013|NCT05074875||Cohort 2|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 2 subjects will undergo Visit 1, within 4 (+/- 2) weeks of hospital discharge or outpatient infection, after informed consent is obtained. Eligible subjects will return for follow-up Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks."
9974994|NCT04889898||Listeners|Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.
9974995|NCT04889859|Active Comparator|long RL group|long Roux limb Roux-en-Y reconstruction
9974996|NCT04889859|Experimental|long BPL group|long biliopancreatic limb Roux-en-Y reconstruction
9974997|NCT04883606||All Participants|Retrospective data will be collected from participants who followed up at least 6 months before teduglutide initiation or intestinal failure associated with SBS-IF diagnosis and at least 6 months of follow-up after teduglutide treatment initiation.
9974998|NCT04880967||Standard Group|"Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected.~Participants of this cohort will not use the ICU Feel Better App."
9974999|NCT04880967||Experimental Group|Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected. Participants of this cohort will have the opportunity to use the ICU Feel Better App every day from the second day after admission to the ICU until the day of discharge from ICU.
9975000|NCT04863885|Experimental|Phase 1 Dose Level 1|Participants will be treated at dose level 1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 8 mg/kg IV will be administered days 1 and 8 every 3 weeks.
10170388|NCT03893240|Other|Participants with Late Onset Pompe disease|This is a multi-center, low-interventional study with a retrospective component in participants with LOPD. During a single study visit, assessments including but not limited to, liver health, neutralizing antibodies to SPK-3006 capsid and GAA, anti-GAA binding antibodies, GAA activity and GAA antigen levels will be performed. Additional information will be collected to provide retrospective evaluations relating to muscle and liver inflammation and/or injury. Historic data relating to Pompe disease will be collected from medical records. The retrospective and laboratory data collected may assist in providing baseline information for a future investigational gene therapy study.
10187907|NCT03721510|Active Comparator|Group 1A|HIV-uninfected volunteers receiving one IV infusion
9521014|NCT05074875||Cohort 3a|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled within ≤ 12 weeks of hospital discharge or outpatient COVID- 19 infection will undergo their first study visit at Visit 1 (Weeks 6-12)."
9521015|NCT05074875||Cohort 3b|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled ≥ 12 weeks from hospital discharge or outpatient COVID- 19 infection will undergo their first visit within 4 weeks before week 24. Subjects that are enrolled into Cohort 3 will be followed until Week 72."
9521016|NCT05074797||covid not diabetic with AKI|AKI in pt with covid_19 not diabetic
9521017|NCT05074797||AKI in covid_19 in diabetic|AKI in covid_19 in diabetic pt
9521018|NCT05074797||covid_19 in diabetic|covid_19 in diabetic without AKI
9521019|NCT05075031||300 Newborn feeding on Breast Milk or Artificial Milk Formula rom birth to about 2 months of age|The electronic patient record of 300 Newborn feeding on Breast Milk or Artificial Milk Formula from birth to about 2 months of age would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
9975001|NCT04863885|Experimental|Phase 1 Dose Level 2|Participants will be treated at dose level 2: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 10 mg/kg IV will be administered days 1 and 8 every 3 weeks.
9975002|NCT04863885|Experimental|Phase 1 Dose Level -1|If dose reduction is indicated, participants will be treated at dose level -1: Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks. Sacituzumab Govitecan 6 mg/kg IV will be administered days 1 and 8 every 3 weeks
9975003|NCT04863885|Experimental|Phase 2: Treatment at Maximum Tolerated Dose (MTD)|Participants will be treated at with Ipilumumab 3mg/kg + Nivolumab 1mg/kg IV day 1 every 3 weeks for 4 cycles, followed by Nivolumab 360 mg every 3 weeks plus the maximum tolerated dose of Sacituzumab Govitecan.
9975004|NCT04861987|Experimental|PCS6422 + Capecitabine|Fixed dose of PCS6422 combined with various doses of Capecitabine administered in 14 day cycles
9975005|NCT04857827|Experimental|QLS-101 ophthalmic solution 1.0%|Ophthalmic solution one time daily for 14 days (These patients will administer 2.0% QLS-101 for last 14 days of the study).
9975006|NCT04857827|Active Comparator|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution once daily dosing for 14 days followed by 14 days of twice daily dosing.
9975007|NCT04857827|Experimental|QLS-101 ophthalmic solution 2%|Ophthalmic solution once daily dosing for 14 days followed by 14 days of twice daily dosing.
9975008|NCT04853381|Experimental|1st Group: Traditional diet recommendations|Traditional diet recommendations will apply for 4 weeks.
9975009|NCT04853381|Experimental|2nd Group: Low FODMAP diet|Low FODMAP diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
9975010|NCT04853381|Experimental|3rd Group: Gluten-free diet|Gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
9975011|NCT04853381|Experimental|4th Group: Low-FODMAP gluten-free diet|Low-FODMAP gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
9975012|NCT04845568|No Intervention|Video|This is the control condition, which views a short video and online interactive game with psychoeducational material on healthy eating and consideration of future consequences.
9975013|NCT04845568|Experimental|Virtual Reality|This is the intervention condition, which participates in the virtual reality experience; the experience includes psychoeducational material on healthy eating and consideration of future consequences.
9975014|NCT04835857||Experimental-Arm|"For the same subject,~ViTrack wrist cuff is applied on one of the wrist~Standard Oscillometric cuff is applied to the brachial artery / wrist of the same arm~Auscultatory cuff is applied to the brachial artery of the same arm"
9975015|NCT04834518||Negative result at the first autoantibodies screening test|Participants will be invited to repeat the screening test at the age of 2-5 years old
9975016|NCT04834518||Positive result at the first or second autoantibodies screening test|"Participants will be monitored annually for risk of type 1 diabetes. (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated)~Families will attend diabetes-educational program emphasizing on DKA prevention~Stress assessment for the families involved and stress alleviating interventions when required."
9975017|NCT04832438|Experimental|9-ING-41 plus carboplatin|Patients will receive 9-ING-41 (15 mg/kg IV on Day 1 and Day 4) in addition to carboplatin (AUC 5 IV on Day 1) each of a 21-day cycle
9975018|NCT04832087||Cohort A|Participants with SBS who started Teduglutide after FDA approval (May 2019)
9975019|NCT04832087||Cohort B|Subjects who participated in any of the teduglutide pediatric clinical trial studies (TED-C13-003, TED-C14-006, SHP633-303, or SHP633-304) and subsequently started therapy with teduglutide
9977467|NCT01361893|Other|Lifestyle Counseling|Parents who qualify for the study will be asked to participate in the survey portion of the study. informed consent will be obtained. After completing the survey each parent will be asked if they would be willing to participate in and additional interview (focus group or semi-structured in-debth interview) at a later date.
9977468|NCT01361906|No Intervention|Untreated control|Untreated control
9521020|NCT05075031||300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year|The electronic patient record of 300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
9521021|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year|The electronic patient record of 300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
9521022|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 5 year up to 15 year|The electronic patient record of 300 child feeding on Artificial Milk Formula or any source of DHA from 5 year up to 15 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
9521023|NCT05075031||Control Group|"The electronic patient record of 150 infant and child patients who feed on only cow's milk which does not provide a rich source of DHA and did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the cohorts that feed on Breast Milk or Artificial Milk Formula~The electronic patient record of 150 adult patients from 15 years to 25 years who did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021"
9521024|NCT05074784|Active Comparator|Control Group|Tongue depressor exercise protocol for tongue strengthening for control group. Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
9521025|NCT05074784|Experimental|Intervention Group|IOPI exercise protocol for tongue strengthening for intervention group. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
9521026|NCT05074849|Experimental|Smart insoles + Education|Participants in this group will receive a 90-minute group session education on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch)
9521027|NCT05074849|No Intervention|Smart Insoles|Participants in this group will not receive a 90-minute group session education on foot self-care, but will receive foot care supplies, insoles and smart watch
9521028|NCT05074849|No Intervention|Usual Care|Participants will not receive foot self-care education or the use of insoles and smart watch.
9671869|NCT05042570|Active Comparator|Control|Group 3 (n=13): Each session will consist of 40 minutes. There will be no additional application to the NDT program, which is applied for 40 minutes, and it will be included as a control group in the study.
9975020|NCT04832074|Experimental|Dry Needling|"Dry needling will be performed with 'solid filiform needles'. The procedure is as follows: The participant will lie in the prone position. The overlying skin will be cleaned with antiseptic spray. The taut band and MTrP, will be localized manually.~After measuring the Pain Pressure Thresholds in this location and the control (located 3 cm lateral to the MTrP), the needle within its plastic guide tube will be placed over the MTrP. After a tapping movement to insert the needle, the needle will be moved to the muscle around the bundle and moved forward and backward to the tissue to elicit a small muscle twitch. After eliciting LTR, needling will be stopped. If no twitch were elicited, needling will stopped after two or three stellate movements"
9975021|NCT04832074|Sham Comparator|Sham Dry Needling|"The same approach will be used with the exception of piercing the skin. The guide tube will press against the tissue and the sham needle will be allowed to drop against the skin. The handle will be tapped briskly but not breaking the skin. The sham needle will stay within the guide tube and will be pressed against the skin twice so as to mimic the quick in and out technique."
9975022|NCT04831398|Active Comparator|Control|Time control experiment (CON). Nothing given to subject
9975023|NCT04831398|Placebo Comparator|Placebo|Placebo (PLA) is 10 sublingual sprays of a diluted (1 microliter/29ml filtered water) mint extract.
9975024|NCT04831398|Experimental|Melatonin|5mg commercially available melatonin (MEL) spray will be given sublingually.
9975025|NCT04816799|Experimental|START|START (startle adjuvant rehabilitation therapy) will be applied.
9975026|NCT04816799|No Intervention|Control|Subjects will train but without START
9975027|NCT04813107|Active Comparator|APL-1202 in combination with tislelizumab|
9975028|NCT04813107|Placebo Comparator|Tislelizumab alone|
9975029|NCT04812652|Experimental|Intervention group: Digitally distributed yoga|"Type of yoga: Physical yoga sequences that through scientific evaluation have proven to be effective and relevant for the target group. There will be 3 different programs during the 12-week-intervention Dose: twice weekly for 12 weeks; one yoga class live broadcasted and digitally distributed to the patient's computer or mobile device, and one class pre-recorded video for self-training.~Sequences: The yoga class will be 60 minutes including 10 minutes of final relaxation. Thereafter, a 5 minutes reflection will be offered.~Home Training: Instructions for yoga home practice will be standardized. The three yoga programs will be distributed in video-links for the participants to view at a time-point that suits them during the week. The recommendation will be to yoga at home once a week in addition to the digital yoga class in real time.~Participants are expected to use their own computer or mobile device."
9975030|NCT04812652|No Intervention|Control group: Regulare care|Receive regular care, including written standardized information about the importance of physical activity by their contact nurse or physiotherapist, when discharged from the hospital accordingly to the routines at the clinic.
9975031|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
9977469|NCT01361906|Experimental|Sensomotoric training|Treatment with Sensomotoric training
9977470|NCT01361932|Experimental|Video of ED Discharge Instructions|
9521029|NCT05074966|Experimental|mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
9521030|NCT05074966|Active Comparator|FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab：500 mg/m2, IV, d1, q2w Oxaliplatin： 85 mg/m2, IV d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
9521031|NCT05074927|Other|Cohort|All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France)
9521032|NCT05074836|Experimental|Formula Milk|"Formula milk designed for young children aged over 3 years;~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
9521033|NCT05074836|Active Comparator|Regular milk|"Regular milk (pure milk);~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
9521034|NCT05074836|Other|Control foods|"Grain foods: e.g., bread;~Dosage: 20-40 g/time;~Frequence: 2 times /day;~Duration: 12 months"
9521035|NCT05074992|Experimental|Ipilimumab|3mg/kg Ipilimumab IV infusion (day 1) given as a 21 day cycle for 2 cycles.
9521036|NCT05075096||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
9521037|NCT05075096||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
9521038|NCT05075096||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
9521039|NCT05074901|Experimental|digital behavioral intervention|Digital behavioral interventions to improve mood and decrease fatigue, sleep complaints and substance usage.
9521040|NCT05074901|No Intervention|e-diaries|Ecological momentary assessment based on e-diaries on a weekly basis to evaluate sleep/wake schedules, physical activity, substance usage and nutrition.
10170389|NCT03892824|Experimental|Vine™ Filter + OAC|Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study
9521041|NCT05074628|Experimental|Nitrofurantion|is the drug of choice for the treatment of infections caused by multidrug resistant pathogens.
9975032|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6 months
9975033|NCT04803604|Experimental|Basic social support + communication + 1 monthly follow up call|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
9975034|NCT04803604|Experimental|Basic social support + communication + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
9975035|NCT04803604|Experimental|Basic social support + Ottawa guide + 1 monthly follow up call|2 in-person/telephone weekly sessions on 1 coaching session on providing social support, decision support tools, and a single monthly follow-up call
10170390|NCT03893149|Experimental|Active-Start intervention|Supervised exercise training
9975036|NCT04803604|Experimental|Basic social support + Ottawa guide + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
9975037|NCT04803604|Experimental|Basic social support + 1 monthly follow up call|1 in-person/telephone weekly sessions on providing social support and a single monthly follow-up call
9975038|NCT04803604|Experimental|Basic social support + monthly follow up calls for 24 weeks|1 in-person/telephone weekly sessions on providing social support and monthly follow-up calls for 6 months
9975039|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + 1 monthly follow up call|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
9975040|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6
9975041|NCT04803604|Experimental|Advanced social support + communication + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
9975042|NCT04803604|Experimental|Advanced social support + communication + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
9975043|NCT04803604|Experimental|Advanced social support + Ottawa guide + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, decision support tools, and a single monthly follow-up call
9977471|NCT01361932|No Intervention|Control (usual standard of care)|
9977472|NCT01361945|Experimental|AUY922|Single Arm
10170391|NCT03893149|No Intervention|Control group|No-exercise
9521042|NCT05074628|Active Comparator|Calcium Hydroxide|Most commonly used intracanal medicaments . Antimicrobial activity of calcium hydroxide is related to the release of hydroxyl ions in an aqueous environment.
9521043|NCT05074602|Experimental|SHR8008|
9521044|NCT05074602|Active Comparator|Fluconazole|
9521045|NCT05074576|Experimental|Mulligan group|In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied.
9521046|NCT05074576|Other|Control group|Electroterapy agents are applied in the contro group
9521047|NCT05074589|Experimental|Treatment group A|Irinotecan liposome plus 5-fluorouracil, Leucovorin
9521048|NCT05074589|Active Comparator|Treatment group B|Placebo plus 5-fluorouracil, Leucovorin
9521049|NCT05074563|Active Comparator|Online REsOluTioN training|The active comparator arm will receive access to online REsOluTioN training to enhance resilience.
9521050|NCT05074563|Other|Control|The control arm will have no access to the online training.
9521051|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart|Astra-Zeneca vaccine 0.5 mL/dose
9521052|NCT05074368|Active Comparator|mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
9521053|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
9521054|NCT05074368|Active Comparator|The mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose
9975044|NCT04803604|Experimental|Advanced social support + Ottawa guide + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
9521055|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
9521056|NCT05074147|Experimental|3 weeks antibiotherapy|Patients are treated 3 weeks with appropriate antibiotics after antibiogram evaluation.
9975045|NCT04803604|Experimental|Advanced social support + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, and a single monthly follow-up call
9521057|NCT05074147|Experimental|6 weeks antibiotherapy|Patients are treated 6 weeks with appropriate antibiotics after antibiogram evaluation.
9521058|NCT05074199|Active Comparator|W-plasty|"The cosmetic appearance of scars closed in a in a zig-zag  fashion (W-plasty)."
9521059|NCT05074199|Active Comparator|Linear closure|"The cosmetic appearance of scars closed in a standard straight line fashion (linear closure)."
9521060|NCT05074186|Experimental|neurological thrombectomy device|Revascularization device is an investigational device.
9521061|NCT05074108|Experimental|Pilot study|Adapt and pilot a nutrition-based intervention. The program will take a holistic approach to educate participants about basic nutrition and cooking skills, sleep, and mindfulness strategies to enhance mental health.
9521062|NCT05074329|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
9521063|NCT05074329|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
9975046|NCT04803604|Experimental|Advanced social support + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, and monthly follow-up calls for 6 months
9975047|NCT04782063|No Intervention|No Intervention: Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
9975048|NCT04782063|Other|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
9975049|NCT04777981|Experimental|CBDRA60 supplement|Daily sublingual tablet containing 30mg Cannabidiol and 30mg Red Algae, a total of 60mg per dose. Participants will take 2 tablets per day, sublingually and with food, taken approximately and at least, 8 hours apart, daily for 28 days. Participants will be mailed a supply of pills by an overnight courier service.
9975050|NCT04777981|Placebo Comparator|Placebo|Control subjects will receive daily oral placebo tablets of identical appearance and taste containing no CBDRA60.
9975051|NCT04771598|Experimental|İntervention|Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
9977473|NCT01361958|Experimental|T1 received 0.625 mg NOMAC + 1.5 mg E2|
9977474|NCT01361958|Experimental|T2 received 1.25 mg NOMAC + 1.5 mg E2|
9977475|NCT01361958|Experimental|T3 received 2.5 mg NOMAC + 1.5 mg E2|
9521064|NCT05074043||covid19|covid 19 proven by clinical, PCR. not associated with mucor
9521065|NCT05074043||covid19 associated with mucor|covid19 associated with mucor proven by clinical, histopathological
9521066|NCT05074095||1|Patients with urogenital injuries
9521067|NCT05074095||2|Patients without urogenital injuries
9521068|NCT05073926||Persons with latent tuberculosis treated with 4 months rifampicin|Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months
9521069|NCT05073926||Persons with latent tuberculosis treated with 6-9 months isoniazide|Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6-9 months
9521070|NCT05074082||Flap reconstruction|Patients who had a flap formation as part of a multi-visceral extended resection for advanced pelvic (rectal, urological, gynaecological, sarcomatous origin) malignancy
9521071|NCT05073978||Case group|Case group with certain pregnancy outcome, e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
9521072|NCT05073978||Control group|Control group without certain pregnancy outcome,e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
9521073|NCT05073913|Other|Living kidney donors|complete vascular exploration before and one year after nephrectomy
9671870|NCT05042401|Experimental|Treatment group A|
9521074|NCT05073835|Experimental|Intervention|Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.
9521075|NCT05073835|Placebo Comparator|Control|Placebo administration, once weekly, subcutaneous injection.
9521076|NCT05073809||Group 1|Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status
9521077|NCT05073809||Group 2|Proven or suspected oral cavity cancer, amenable to intraoral examination
9521078|NCT05074004|No Intervention|control group|"No intervention was applied to the control group in this process.~be receiving treatment in Clinic Day Hospital~Volunteering to participate in research"
9521079|NCT05074004|Experimental|Psychoeducation|"be receiving treatment in Clinic Day Hospital~Volunteering to participate in research"
9521080|NCT05073965|Experimental|Intervention Group|Subject receive a 1000IU vitamin D supplement dose daily for 6 months
9521081|NCT05073965|Placebo Comparator|Placebo group|Subject receive a placebo daily for 6 months
10170392|NCT03893071|Experimental|Hydroxypropyl-β-cyclodextrin IV|Hydroxypropyl-β-cyclodextrin will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
10170393|NCT03892629|Experimental|Baduanjin exercise group|Participants in this group received Baduanjin exercise
9521082|NCT05068011||Spinal cord stimulation|Patients will receive differential target multiplexed spinal cord stimulation
9671871|NCT05042401|Experimental|Treatment group B|
9671872|NCT05042479|Experimental|Standard treatment then virtual reality then choice between the two|"Efficiency of VR will be evaluated for each patient across 3 potentially painful care-procedures :~For the first treatment, the child will benefit usual distraction and pain prevention techniques.~For the 2nd, the child will use a VR headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age and parental agreement.~For the 3rd treatment, the child will choose his/her favorite technique."
9671873|NCT05042414|Experimental|Breastmilk|Randomized intervention order.
9671874|NCT05042375|Experimental|camrelizumab + famitinib|
9671875|NCT05042375|Experimental|pembrolizumab|
9975052|NCT04771598|Other|Control|Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
9975053|NCT04763343|Experimental|Ketamine Treatment + CAMS Therapy|
9975054|NCT04763343|Placebo Comparator|Saline Placebo Treatment + CAMS Therapy|
9975055|NCT04761848|Experimental|Cilostazol|
10187908|NCT03721510|Active Comparator|Group 1B|HIV-uninfected volunteers receiving one IV infusion
9521083|NCT05066685||All Participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
9521084|NCT05066503|Active Comparator|Delirious subjects receiving active study product|Subjects will ingest an oral amino-acid containing nutritional supplement twice daily for up to 7 days.
9521085|NCT05066503|Placebo Comparator|Delirious subjects receiving placebo|Subjects will ingest a flavored, sweetened, inactive drink twice daily for up to 7 days.
9521086|NCT05066503|No Intervention|Non-delirious control subjects who receive no intervention|Subjects receive no intervention and are observed for 2-3 days.
9521087|NCT05057429|Experimental|Bioelectric Dressing on the Right Armpit and Standard Gauze Dressing on the Left Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the right armpit and will receive the standard gauze dressing for up to 8 weeks on the left armpit.
9521088|NCT05057429|Experimental|Bioelectric Dressing on the Left Armpit and Standard Gauze Dressing on the Right Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the left armpit and will receive the standard gauze dressing for up to 8 weeks on the right armpit.
9521089|NCT05051722||Cohort 1 - AUB / PMB|Women ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.
9521090|NCT05051722||Cohort 2 - Biopsy-provend EC or AEH or EIN|Women ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.
9671876|NCT05042375|Experimental|camrelizumab|
9671877|NCT05042297|Active Comparator|Combined Posterior and anterior ring fixation|Posterior ring fixation via a single posterior Sacroiliac screw or two Iliac wing plates. While anterior ring fixation was via a single para-symphyseal plate in Tile B2 injuries. Meanwhile, we used double superior and anterior symphyseal plates in Tile C1 injuries.
9671878|NCT05042297|Experimental|Isolated Posterior ring fixation|We used either two Sacroiliac screws in S1 and S2, or two Iliac wing plates.
9975056|NCT04761848|Placebo Comparator|Placebo|
9975057|NCT04760847|Experimental|Intermittent Fasting|Patients in Group A will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day.
9975058|NCT04760847|Active Comparator|Control|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast.
9975059|NCT04757571|Experimental|Paroxetine|Paroxetine 20 mg daily plus standard therapy
9975060|NCT04757571|Placebo Comparator|Placebo|Placebo tablet daily plus standard therapy
9975061|NCT04756076||Control|age and gender matched controls
9975062|NCT04756076||Pulmonary Hypertension Group|Pulmonary Hypertension Patients with Various Degree of Severity
9975063|NCT04753957|Active Comparator|Vaginal progesterone|200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery
9975064|NCT04753957|No Intervention|Control|No intervention, scheduled cesarean delivery
9975065|NCT04751071|Active Comparator|Roflumilast|Roflumilast 250 µg tablet plus standard therapy
9521091|NCT05051722||Cohort 3 - Cervix pathology|Women ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.
9521092|NCT05051722||Cohort 4 - Benign Uterine Pathology|Women with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All women enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.
9521093|NCT05051722||Cohort 5 - Healthy Control Women|Healthy women ≥45 years of age presenting for well-woman exams to serve as a control group. These women will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These women will not have known or clinically-suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.
9521094|NCT05065775|Experimental|Dexmedetomidine|Single intranasal 100 µg bolus dose of dexmedetomidine
9521095|NCT05051696|Experimental|Oncorine (H101) with or without radiotherapy|The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter>10cm.
9521096|NCT05068063|Experimental|Femoral Triangle + IPACK block|Patients randomized to receive a combination of femoral triangle block and active IPACK block
10170394|NCT03892629|Active Comparator|Instrument rehabilitation group|Participants in this group received rehabilitation by using tri-ball respiratory trainer
10170395|NCT03892629|Active Comparator|Baduanjin Exercise and Instrument Rehabilitation|Participants in this group received both instrument rehabilitation and Baduanjin exercise
10170396|NCT03892629|No Intervention|No Intervention|Participants in this group only received routine drug-treatment
9521097|NCT05068063|Active Comparator|Femoral Triangle block|Patients randomized to receive a combination of femoral triangle block and sham IPACK block
9521098|NCT05029141|Experimental|Chidamide+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.
9521099|NCT05029141|Placebo Comparator|Placebo+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group.
10170397|NCT03892902|Experimental|Treatment A (50 mg ACT-541468)|1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A.
10170398|NCT03892902|Experimental|Treatment B (100 mg ACT-541468)|2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B.
10170399|NCT03892902|Experimental|Treatment C (7.5 mg zopiclone)|2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo).
10170400|NCT03892902|Experimental|Treatment D (placebo)|2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D.
10170401|NCT03892694|Active Comparator|Treatment|MCS
9521100|NCT05029089|Experimental|Experimental: Entire Papilla Preservation Modified Technique (EPPMT)|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated (subperiosteal tunnel). Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. Microsurgical suturing technique with 7-0 materials was performed. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
9671881|NCT05042284|Experimental|NE PERT|Non-enteric coated pancreatic enzyme preparation containing 30,000U of protease.
9671882|NCT05042284|Placebo Comparator|Placebo|Similar appearing glucose capsules.
9671883|NCT05042336|Experimental|camrelizumab/lenvatinib combined with TACE|"Phase Ib trial： Ib-A group [camrelizumab q3w group]: TACE d1, camrelizumab 200mg, d1, 22, 43; Lenvatinib d7-43; Surgery d50; Group Ib-B [camrelizumab q2w group]: TACE d1, camrelizumab 200mg, d1, 15, 29; Lenvatinib d7-43; Surgery d50.~Phase II trial： The enrolled patients received camrelizumab/lenvatinib combined with TACE treatment (a relatively safer treatment plan based on phase Ib), and the first imaging efficacy evaluation was performed at 6-8 weeks to evaluate surgical resection"
9975066|NCT04751071|Placebo Comparator|Placebo|placebo tablet plus standard therapy
10170402|NCT03892694|Sham Comparator|Sham Control|Sham
10170403|NCT03892668|Experimental|tranexamic acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
10170404|NCT03892668|Active Comparator|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
10187909|NCT03721510|Active Comparator|Group 2|HIV-infected volunteers on ART receiving three or six IV infusions
10170405|NCT03892668|Placebo Comparator|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
10170406|NCT03892850|Experimental|nurse prescription|experimental group receiving pharmacological nurse prescription
10170407|NCT03892850|Active Comparator|medical prescription|control group receiving medical prescription
10170408|NCT03892863|Active Comparator|active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
10170409|NCT03892863|Sham Comparator|sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
10170410|NCT03892733|Experimental|Intervention|CHEKS (calorie health, education, knowledge and skills) intervention will educate participants about calories in fast-food and teach skills to select lower calorie fast-food items.
10170411|NCT03892733|No Intervention|Control|Participants will receive a brochure about healthier choices in fast-food restaurants.
10170412|NCT03892681|Other|contrast agents for liver MRI|
10170413|NCT03892837|Active Comparator|Control group|Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
10170414|NCT03892837|Experimental|PRP group|Procedure/Surgery: PRP PRP treatment following the conventional treatment Slow spray / inject autogenous PRP to cover the wound of stenosis. Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
10170415|NCT03892876|Experimental|Schizophrenia TS+ve|Schizophrenia patients who receive auditory high frequency Tetanizing Stimulation
10170416|NCT03892876|Sham Comparator|Schizophrenia TS-ve|Schizophrenia patients who receive sham comparator
9671884|NCT05042271||Meropenem: Patients who underwent TPE (Phase 1)|In phase 1, each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first therapeutic plasma exchange (TPE) and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
10170417|NCT03892876|Experimental|Control TS+ve|Healthy controls who receive auditory high frequency Tetanizing Stimulation
10170418|NCT03892876|Sham Comparator|Control TS-ve|Healthy controls who receive sham comparator
10170419|NCT03892811||Infants referred for swallow study|"This is a within-subjects intervention study where each infant in the study will receive all three conditions.~The three study conditions are bottle-feeding with 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple."
10170420|NCT03892525|Experimental|treatment|
10170421|NCT03892928|Placebo Comparator|Propofol group|2-5 mg/kg.h propofol during the whole colonoscopy
10170422|NCT03892928|Other|Dexmedetomidine group|0.1mcg/kg continuous infusion for 15min, 0.7-1mcg/kg.h during the whole colonoscopy
10170423|NCT03892590||Stable patient|Stable patients who admitted to ICU for observation.
10170424|NCT03892499|Experimental|Healthy Volunteers|Period 1: Single dose of olinciguat. Period 2: ITZ is dosed once daily (QD) for 10 days; a single dose of olinciguat is administered 1 hour after the fourth ITZ QD dose.
10170425|NCT03892603|Experimental|Strengthening exercises program|
10170426|NCT03892603|Experimental|Motor control exercises program|
10170427|NCT03892603|Active Comparator|Education and advice|
10170428|NCT03892447|Experimental|Alprostadil|Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
10170429|NCT03892447|Active Comparator|Sodium Ferulate|Sodium Ferulate 2~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
10170430|NCT03892551||patients admitted to emergency ward|all patients admitted to the emergency ward and awaiting triage are observed
10170431|NCT03892512|Active Comparator|dexmedetomedine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .
10170432|NCT03892512|Active Comparator|esmolol|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).
10170433|NCT03892486|Experimental|The high PUFA diet group|This will receive detailed nutritional recommendations and will consume at least 4 table spoons of olive oil or 30 grams of nuts daily for 12 weeks.
10170434|NCT03892486|No Intervention|Control group|The Control group will receive general nutritional recommendations based on Human Nutrition Recommendations for Polish Population.
10170435|NCT03892473|Experimental|Flexible Assertive Community Treatment (FACT)|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
10170436|NCT03892473|Active Comparator|Care as usual (CAU)|Active Comparator: CAU (Care as usual) Patients with SMI receiving usual care, meaning mostly medical treatment
10170437|NCT03892434|Active Comparator|Bevacizumab|
10170438|NCT03892434|Active Comparator|Dexamethasone|
10170439|NCT03892382|Active Comparator|Active rTMS|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
10170440|NCT03892382|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
10170441|NCT03892330|Experimental|liposomal doxorubicin|Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
10170442|NCT03892330|Active Comparator|doxorubicin|Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
10170443|NCT03892330|Active Comparator|pharmorubicin|Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
9527750|NCT03217318|Active Comparator|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
9527751|NCT03217331|Experimental|CRD-102 Treatment|CRD102 Treatment
10170444|NCT03892330|Active Comparator|pirarubicin|Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
9671885|NCT05042271||Meropenem: after TPE (Phase 2)|was similar to phase 1 except that the meropenem administration and PK studies were conducted >6 hours apart from the next TPE
9671886|NCT05042154|No Intervention|Standard of Care Cohort for COPD|Standard care patients will receive routine clinical management as per their treating physicians based on the GOLD Criteria.
9671887|NCT05042154|Active Comparator|WatchPAT Cohort|Consented patients will undergo group randomization to either standard AECOPD care or to the WatchPAT One cohort (WPC). The WPC will undergo a single night of in-hospital sleep apnea testing from 2200 to 0600 using the WatchPAT One, a portable and disposable home sleep apnea testing device (Itamar Medical, Israel [WPAT]).
9671888|NCT05042245|Experimental|ornithine aspartate granule group|Patients in this group will be given aspartate ornithine granules (3 g po tid, after three meals) and silymarin capsule simulant (140 mg po bid, before breakfast and dinner).
9671889|NCT05042245|Active Comparator|silymarin capsule group|Patients in this group will be given silymarin capsule (140 mg po bid, before breakfast and dinner) and aspartate ornithine granules simulant (3 g po tid, after three meals) .
9827513|NCT02458768|Active Comparator|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
9827514|NCT02459093|Experimental|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
9975067|NCT04736394|Active Comparator|Epirubicin hydrochloride group|intravesical instillation of Epirubicin hydrochloride
9975068|NCT04736394|Experimental|APL-1202 group|receive APL-1202 single-agent oral treatment
9975069|NCT04730648|Experimental|pcsk9 inhibitor group|patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.
9975070|NCT04730648|No Intervention|control group|Patients with comparable age, sex ratio, and BMI, but coronary arteries are relatively normal evaluated by coronary angiography. their blood and urine would be collected as the control group.
9975071|NCT04721132|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery during week 12.
9975072|NCT04720157|Experimental|177Lu-PSMA-617|Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
9975073|NCT04720157|Active Comparator|Standard of Care|For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order
9975074|NCT04720001||Experimental: Florbetaben F18 recipients|Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.
9975075|NCT04719000|Experimental|rhFSH+rhLH|Ovarian Stimulation with rhFSH+rhLH
9975076|NCT04719000|Active Comparator|rhFSH|Ovarian Stimulation with rhFSH
9975077|NCT04718155|Active Comparator|statin group|will receive atorvastatin for 48 hours
9975078|NCT04718155|Placebo Comparator|control|will receive placebo tablets for 48 hours
9975079|NCT04707313|Placebo Comparator|Placebo|
9975080|NCT04707313|Experimental|PF-06882961 40 milligrams (mg) twice daily (BID), standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID. Titration steps include: 10 mg BID, 20 mg BID, and 40 mg BID.
9975081|NCT04707313|Experimental|PF-06882961 80 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID.
9975082|NCT04707313|Experimental|PF-06882961 120 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID.
9975083|NCT04707313|Experimental|PF-06882961 160 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID, 120 mg BID, 140 mg BID and 160 mg BID.
9975084|NCT04707313|Experimental|PF-06882961 200 mg BID, standard titration|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID, 120 mg BID, 140 mg BID, 160 mg BID, 180 mg BID and 200 mg BID.
9975085|NCT04707313|Experimental|PF-06882961 120 mg BID, slow titration|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID.
9975086|NCT04707313|Experimental|PF-06882961 160 mg BID, slow titration|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg, 100 mg BID, 120 mg BID, 140 mg BID and 160 mg BID.
9977476|NCT01361958|Experimental|T4 received 2.5 mg NOMAC + Lactose|
10187910|NCT03721497|Active Comparator|Testosterone Undecanoate|Inj. Testosterone undecanoat (Nebido®), 1000 mg im preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
9671890|NCT05041998|Experimental|Unmodified Socket + 8 Socket Modifications in Random Order|The sequence of the 9 different interventions (original socket and 8 versions derived from it) is randomized for each participant. The number of participants is smaller than the number of possible permutations. Therefore the enacted ordering is randomly selected from the pool of possible orderings. Participants walk for less than 10 minutes with every socket type while data is being collected.
10170445|NCT03892577||Patients with advanced hepatobiliary tumors|"2000 patients with advanced hepatobiliary tumors will be enrolled and the enroll patients should be treat with any type of the following three treatment program:~Monotherapy or combination therapy with the targeted drug related to genetic variation of the subject;~Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib, apatinib, etc;~Immunotherapy or immunotherapy combined with targeted therapy."
10170446|NCT03892785|Experimental|Tocilizumab group|
10170447|NCT03892785|Active Comparator|Methotrexate group|
10170448|NCT03892408|Experimental|Optiflow|100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
9671891|NCT05042037|Active Comparator|Double-blind, placebo-controlled interventional study|Active treatment group will receive a 3-gram sachet of probiotics containing multi-strain of lactobacillus and Bifidobacterium 30 Colony Forming Unit x 109 to be taken twice daily for 12 weeks.
10170449|NCT03892408|No Intervention|Standard|standard anesthesia
10170450|NCT03892421|Experimental|Modified DHAP|Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.
10170451|NCT03892356||Concussion Group|Participants (age group 18-60) who presents to the emergency department in the University Health Network within 7 days of concussion
10170452|NCT03892356||Healthy Controls Group|Participants (age group 18-60) with no previous history of concussions who are age, education and sex-matched to the patients' group will be recruited from the community.
10170453|NCT03892122|Other|Propofol group|"Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient~. The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group"
9521101|NCT05029089|Active Comparator|Entire Papilla Preservation Modified Technique + EMD|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. 24%EDTA was applied on the exposed root surface for 2 minutes, than rinsed and EMD was applied. Vertical incision was closed with simple single sutures(7-0),whereas due to modification of the original technique additional sling suture was applied.
10170454|NCT03892122|Other|Dexmedetomidine group|For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.
10170455|NCT03892109|Active Comparator|Gingitrac|The gingitrac cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the selected abutment. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
9671892|NCT05042037|Placebo Comparator|Placebo|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 12 weeks.
10187911|NCT03721497|Placebo Comparator|Placebo|Inj. placebo preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
9521102|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft|Procedure:The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
9527752|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Activity and Lifestyle Questionnaires~Fat Mass Measurement"
9671893|NCT05041985|Experimental|group A (the Test group)|arm which received Diazepam 5 mg therapy for 7 days after whiplash
9671894|NCT05041985|No Intervention|group B (the control group)|a group which did not receive Diazepam 5 mg therapy
9827515|NCT02459093|Experimental|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
9975087|NCT04707313|Experimental|PF-06882961 200 mg BID, slow titration|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID, 120 mg BID, 140 mg BID, 160 mg BID, 180 mg BID and 200 mg BID.
9975088|NCT04705883|Other|Prasterone|10 patients will be treated using prasterone during 6 months.
9521103|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft+sCTG|Procedure: After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. sCTG taken form palate was sutured to the inner part of mucosa flap. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
9521104|NCT05037396||Brolucizumab|Participants received brolucizumab injection during the index period
9521105|NCT05011318|Experimental|Fatigue Manipulation|
9975089|NCT04695288||Fibromyalgia Syndrome|100 participants with a diagnosis of Fibromyalgia Syndrome according to the 2016 revised American College of Rheumatology diagnostic criteria.
9975090|NCT04695288||Control subjects|60 healthy participants do not meet the exclusion criteria of the study.
10170456|NCT03892109|Active Comparator|traxodent|The traxodent cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the tooth. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
10170457|NCT03892109|Experimental|Ultrapk cord|the cord packed into the gingival sulcus around the tooth
9521108|NCT05045586|Experimental|Modified Coronally Advanced Tunnel With Connective Tissue Graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
9521109|NCT05045586|Active Comparator|MCAT With Cross-linked Hyaluronic Acid in Addition to CTG|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with cross-linked hyaluronic acid. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
10170458|NCT03892109|Placebo Comparator|nocord|used directly in the tray
10170459|NCT03892226||1, no myocardial injury|normal troponin level (hs-troponin T ≤ 99. percentile, i.e. 14ng/ml)
9521110|NCT05039866||Subjects who received ST-920|Subjects who received ST-920 in clinical study ST-920-201
9521111|NCT05016323|Experimental|HR19042 Capsules|
10170460|NCT03892226||2, chronic myocardial injury|elevated, but stable troponin level; (hs-troponin T> 99. percentile and rise/fall ≤ 20% in the control)
10170461|NCT03892226||3, acute myocardial injury|dynamic troponin elevation; (hs-troponin T> 99. percentile and rise/fall >20% in the control)
9521112|NCT05016323|Placebo Comparator|Placebo|
9521113|NCT05046938|Experimental|intervention group|It was planned to apply 5 sessions of MI to the intervention group, and to follow-up 2 months after the interviews were completed.
9521114|NCT05046938|No Intervention|control group|No application will be made to the students in the control group, and at the end of the study, a seminar on food addiction and quality of life will be given to the students.
9521115|NCT05009784|Active Comparator|Short Traffic Sound|100 seconds of traffic sound
9521116|NCT05009784|Active Comparator|Medium Traffic Sound|200 seconds of traffic sound
9521117|NCT05009784|Active Comparator|Long Traffic Sound|300 seconds of traffic sound
9521118|NCT05009784|Experimental|Short Traffic and Bird Sound|100 seconds of traffic and bird sound
9975091|NCT04693689|Experimental|Conventional vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 0%."
9975092|NCT04693689|Experimental|Conventional vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 20%."
9977477|NCT01361984|Experimental|Brovana (nebulized arformoterol)|Brovana (nebulized arformoterol) treatment for 2 weeks
10187912|NCT03721471||Frail, non-frail|"Frail Group: Those individuals identified as frail by low hand-grip-strength and/or the Clinical Frailty Scale.~Non-frail Group: Those individuals identified as not frail by hand-grip-strength and/or the Clinical Frailty Scale."
10187913|NCT03721445||CPAP opponent|CPAP opponent: moderate to severe OSA patients who refused CPAP therapy after PSG study and CPAP titration test.
9521119|NCT05009784|Experimental|Medium Traffic and Bird Sound|200 seconds of traffic and bird sound
9521120|NCT05009784|Experimental|Long Traffic and Bird Sound|300 seconds of traffic and bird sound
9521121|NCT05009784|Experimental|Short Traffic and Water Sound|100 seconds of traffic and water sound
10187914|NCT03721445||CPAP acceptor|CPAP acceptor: moderate to severe OSA patients who accepted CPAP therapy after PSG study and CPAP titration test and had purchased a PAP at home for long term use.
9521122|NCT05009784|Experimental|Medium Traffic and Water Sound|200 seconds of traffic and water sound
9975093|NCT04693689|Experimental|Conventional vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 40%."
9975094|NCT04693689|Experimental|Conventional vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 60%."
9521123|NCT05009784|Experimental|Long Traffic and Water Sound|300 seconds of traffic and water sound
9977478|NCT01361984|Experimental|Serevent (Salmeterol dry powder inhaler)|Serevent (Salmeterol dry powder inhaler) treatment for 2 weeks
10170462|NCT03892278|Experimental|Aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
9671895|NCT05042024|Active Comparator|the SRP Group|Patients received conventional periodontal therapy including scaling and root planing as a full-mouth procedure, n=25.
9671896|NCT05042024|Experimental|the Arg Group|Patients received oral L-arginine aspartate (Yuria-Pharm, Ukraine) at a dose of 1 g t.i.d. for 10 days after conventional periodontal therapy, n=25.
10187915|NCT03721432|Experimental|Pregabalin group (P)|received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
9521124|NCT05004402||Primiparous women|Primiparous women after vaginal delivery
9521125|NCT05002478|Experimental|Prone Group|Turn patient in prone position after surfactant administration. After 6 hours turn patient in supine position and perform EIT and LUS.
9521126|NCT05002478|No Intervention|Supine Group|Leave patient in supine position after surfactant administration. After 6 hours perform EIT and LUS.
9521127|NCT04999891||Surgical Cohort|Elderly patients aged 65 and above who are planned for hip fracture surgery.
9521128|NCT04982497|Experimental|Video game based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 70 (±25) minutes long that will be administered at a rate of 1 per week with between-session homework.
9521129|NCT04982497|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
9521130|NCT04975620|Experimental|Franseen needle with three symmetric cutting edges|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using the Franseen needle (Acquire FNB needle; Boston Scientific): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
9521131|NCT04975620|Experimental|Multi-blade needle with three-prong tip with one tip longer than the other two|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using a multi-blade three-prong tip needle (Trident; Microtech): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
9521132|NCT04975581|Experimental|Rotator cuff repair Surgery with Augmentative patch|Open rotator cuff repair Surgery with additional application of augmentative human allograft patch
9521133|NCT04975581|Active Comparator|Rotator cuff repair surgery|Open Rotator cuff repair surgery
9521134|NCT04968379|Experimental|Ferric Carboxymaltose|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 5.0 mg/kg dose of FCM
9521135|NCT04968379|Experimental|Injectafer|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 7.5 mg/kg dose dose of FCM.
9521136|NCT04955951||polarized light group|group A (20 patients) will receive Polarized light therapy
9521137|NCT04955951||topical corticosteroid group|group B (20 patients) will receive topical corticosteroid therapy
9521138|NCT04964713||type 2 diabetes|T2DM was defined according to the WHO 2006 criteria. Assessing the left heart and right heart structure and function of T2DM by speckle tracking echocardiography.
9521139|NCT04964713||Prediabetes|According to the WHO 2006 criteria, combining impaired fasting glucose and impaired glucose tolerance as prediabetes. Assessing the left heart and right heart structure and function of prediabetes by speckle tracking echocardiography.
9671897|NCT05042024|Experimental|the Orn Group|Patients received oral L-ornithine aspartate (Farmak, Ukraine) at a dose of 3 g t.i.d. for 15 days after conventional periodontal therapy, n=25.
9671898|NCT05042089||pathological tumor stage 1-2 (pT1-2)|Stage pT1 and pT2 according to pathology results of patients who underwent partial or radical nephrectomy.
9671899|NCT05042089||pathological tumor stage ≥pT3a|Stage ≥pT3a according to pathology results of patients who underwent partial or radical nephrectomy.
10170463|NCT03892278|Experimental|Aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
10170464|NCT03892278|Active Comparator|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
10187916|NCT03721432|Placebo Comparator|Control group (C)|received placebo capsules sixty minutes prior to epidural insertion.
9521140|NCT04964713||normal glucose metabolism(NGM)|Assessing the left heart and right heart structure and function of NGM by speckle tracking echocardiography.
9521141|NCT04943432|Experimental|People who inject drugs|People who inject drugs recruited from a needle exchange program who will participate in a psychosocial intervention
9521142|NCT04953286|Other|Case group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients with Amyotrophic Lateral Sclerosis
9521143|NCT04953286|Other|Control group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients without neurological disease
9521144|NCT04962022|Experimental|Period 1|PF-07321332/ritonavir orally
9521145|NCT04962022|Experimental|Period 2|Itraconazole + PF-07321332/ritonavir orally.
9521146|NCT04941742||Active eosinophilic esophagitis|
9521147|NCT04941742||Eosinophilic esophagitis in remission|
9521148|NCT04941742||No eosinophilic esophagitis|
9521149|NCT04957134|Experimental|Electro-acupuncture with lifestyle intervention|Participants will receive electro-acupuncture combined with lifestyle intervention. Participants will receive the treatment of electroacupuncture 3 times a week to fulfill a 8-session treatment course.While the intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
9521150|NCT04957134|Placebo Comparator|Sham electro-acupuncture with lifestyle intervention|Participants will receive the treatment of sham electro-acupuncture 3 times a week to fulfill a 8-session treatment course, A superficial skin penetration (2-3 mm in depth) at nonacupoints will be performed in the sham acupuncture group, without needle manipulation for De qi. The internal output power cord of the electrical acupuncture stimulation instrument is interrupted.The intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
9521151|NCT04956679||Family members in the study|Community groups that meet the inclusion criteria
9521152|NCT04933669|Experimental|Imatinib neoadjuvant|Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.
9975095|NCT04693689|Experimental|Conventional vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive a conventional vaccine if its current adoption rate in the country is 80%."
9521153|NCT04897841|Placebo Comparator|control arm|The control arm will receive 30 mL of bupivacaine HCl plus 50 mL of saline injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
9521154|NCT04897841|Experimental|Intervention: liposomal bupivacaine|The intervention arm will receive 30 mL of bupivacaine HCl plus 30 mL of saline plus 20 mL of liposomal bupivacaine injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
9521155|NCT04878315|Experimental|Treatment sequence TRR|Participants will receive Capoten (T) in period 1 followed by Captopril (R) in period 2 followed by Captopril (R) in period 3.
9521156|NCT04878315|Experimental|Treatment sequence RTR|Participants will receive Captopril (R) in period 1 followed by Capoten (T) in period 2 followed by Captopril (R) in period 3.
9521157|NCT04878315|Experimental|Treatment sequence RRT|Participants will receive Captopril (R) in period 1 followed by Captopril (R) in period 2 followed by Capoten (T) in period 3.
9521158|NCT04889287|Experimental|Rosuvastatin and/or elinzanetant|The participants will receive each dose of rosuvastatin and/or elinzanetant together with 240 mL of non-sparkling water in total.
9521159|NCT04895384||Surgical Cohort|Placement of Edwards ClearSight and Masimo SET on patient intraoperatively.
9521160|NCT04878107|Experimental|SBRT/LDRT + Camrelizumab +Apatinib|SBRT（8Gy×3f） LDRT（2Gy×5f） Camrelizumab（200mg，q3w） Apatinib （250mg，qd）
9671900|NCT05042050|Experimental|A-iMAPS Intervention|Participants will receive six sessions of Attachment-focused iMAgery therapy for PSychosis. They will be randomised to different baseline lengths (two to five assessment sessions)
9521161|NCT04878107|Active Comparator|SBRT + docetaxel|docetaxel 75mg/m2 SBRT（8Gy×3f）
9975096|NCT04693689|Experimental|RNA vaccine, 0% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 0%."
9975097|NCT04693689|Experimental|RNA vaccine, 20% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 20%."
9521162|NCT04877821|Experimental|Sintilimab + Anlotinib + Chemotherapy|Experimental: Sintilimab + Anlotinib + Chemotherapy Participants receive Sintilimab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + (Nab paclitaxel weekly + carboplatin (Q3W) x 4 cycles followed by epirubicin + cyclophosphamide Q3W x 4 cycles) as neoadjuvant therapy prior to surgery. After surgery, those who exhibited residual disease were treated with capecitabine (1000-1250 mg/m2) given two-times a day for 1-14 days and cycled every 21 days for a total of 6-8 cycles.
10170465|NCT03892395|Active Comparator|Treatment group|"Supplementation for 2 years with one of the following treatments in capsule form:~Treatment group will receive: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined"
10170466|NCT03892395|Placebo Comparator|Control group|"Supplementation for 2 years with one of the following treatments in capsule form:~Control group will receive: Vitamin D, a daily capsule containing 10 µg/day vitamin D"
9521163|NCT04870255|Active Comparator|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
9521164|NCT04870255|Active Comparator|Dorsomedial Prefrontal Cortex (DMPFC)|The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
9521165|NCT04870255|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
9521166|NCT04856241|Experimental|Supported Implementation (Intervention)|Our supported implementation approach is designed to improve uptake of Prep-to-Play. The Prep-to-Play program consists of four components: dynamic warm-up, strength training, football fundamentals, and education. At the start of the intervention period, Prep-to-Play Physiotherapists will conduct a 3-hour workshop for coaches and influential players. Ongoing support will be provided via a range of strategies. Prep-to-Play Physiotherapists will attend training (two times) during and immediately post implementation to provide coaches with support (feedback on missing components, player technique, questions). Monthly Coaches Shed; Online drop-in session with education component to meet other coaches (peer support & networking) and ask questions. Refresher workshops will be run in pre-season 2022 for the teams who have received the intervention in 2021.
9521167|NCT04856241|Active Comparator|Unsupported implementation (Control)|"The unsupported implementation arm will be usual care. Access to the Prep-to-Play resources, including videos, downloadable manuals and posters, are freely available to coaches online. The online resources incorporate the same four concepts as described in the supported implementation - dynamic warm-up, strength exercises, football fundamentals, and education. In the control arm, no additional resources, education, or support will be provided."
9671901|NCT05041868|Experimental|Study group|The program comprises the practice of warm-up, muscle strengthening with free weights and with their own body weight against the action of gravity for the main muscular groups, balance control training, aerobic training, and relaxation exercises. The proposal consists of 3 weekly sessions, for 12 consecutive weeks.
9671902|NCT05042102|Experimental|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
9671903|NCT05042102|Experimental|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
9671904|NCT05042102|Experimental|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
9671905|NCT05042102|Experimental|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
10170467|NCT03892200|Experimental|Daily Mouth Care|The intervention being tested is a standardized educational and skill-building program for use in assisted living communities, which highlights that mouth care is infection control (e.g., can reduce pneumonia); includes techniques and products to clean and protect the teeth, tongue, gums, and dentures (e.g., the jiggle-sweep approach to remove plaque, use of an interdental brush instead of floss); provides strategies for care provision in special situations (e.g., broken teeth); and includes a toolkit of dementia-sensitive approaches for people who are resistant (e.g., refuse to open the mouth). It also includes information about potential dental emergencies and issues that merit assessment.
10170468|NCT03892200|No Intervention|Standard Mouth Care|Assisted living communities will continue to provide standard mouth care to all residents. Assisted living staff will not receive training or supplies in the control condition.
9671906|NCT05041595||Sick Cohort|Borreliosis Subjects - established diagnosis of early Borreliosis expressing EM Rash Borreliosis Subjects - expressing signs and symtoms consistent with suspicion of acute Borreliosis and under medical examination for Lyme disease
10170469|NCT03892213|Other|Benznidazole and E1224|Benznidazole and E1224
10170470|NCT03892083|Active Comparator|Anodal tDCS (M1)|tDCS applied over primary motor cortex. Dose: 1mA, 20 minutes
10170471|NCT03892083|Experimental|Anodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
10170472|NCT03892083|Experimental|Cathodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
10170473|NCT03892083|Sham Comparator|Sham tDCS|tDCS applied over the cerebellum Dose: 1mA, 20 minutes (30s ON)
10170474|NCT03892291||Civilian mTBI|Civilians with persistent symptoms from mTBI
10170475|NCT03892291||Civilian Control|Civilian healthy controls
10170476|NCT03892291||Active Duty Control|Active duty service member healthy controls
9521168|NCT04817085|Experimental|Visant Medical Canalicular Plug|Bilateral placement of the Visant Canalicular Plug inserted on Day 1
9521169|NCT04817085|Active Comparator|Commercially available canalicular plug|Bilateral placement of commercially available canalicular plug inserted on Day 1
9521170|NCT04831437|Experimental|Hypofractionated|EBRT 40Gy/15fr
9826568|NCT02423291|Experimental|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
10170477|NCT03892291||Active Duty mTBI|Active duty service members with persistent symptoms from mTBI who are referred for physical therapy due to their symptoms
9521171|NCT04831437|Active Comparator|Control Group|EBRT 45Gy/ 25fr
10170478|NCT03892317|Other|Medication adherence interventions|Pharmacist led medication adherence interventions which will be tailored to individual patient need
10170479|NCT03892148|Active Comparator|Standard|Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician
10170480|NCT03892148|Experimental|Protocol|use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network
10170481|NCT03892304||Adult women with Cystic Fibrosis|Cohort of 164 women diagnosed with Cystic Fibrosis (CF) who were patients at the Cystic Fibrosis Adult Referral Centre in Lyon, France in 2017 (compared to 155 in 2014). Women attending the CF adult centre in 2017 were asked to complete a written questionnaire.
9521172|NCT04824417|Active Comparator|Control|Oral itraconazole
9521173|NCT04824417|Experimental|Intervention|Oral voriconazole
10170482|NCT03892005||MOTIVATION HIP Total Hip System|All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MOTIVATION HIPTM Total Hip System in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.
10170483|NCT03892343||Transplant recipients|Patients undergoing live donor kidney transplant.
9521174|NCT04818866||Patients hospitalized for Covid-19|
9527753|NCT03217227||Patients with Stable Angina|"Patients will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Cardiac Catheterization~Activity, Lifestyle and Medication Compliance Questionnaires~Fat Mass Measurement~Retinal Photography (Optional)~I123 MIBG scan (Optional)"
9527754|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)~Passive Thermography (PT): 2 thermoscans of the following parts:~Both carotid artery on left and right of the neck.~Both superficial temporal artery on the left and right of forehead.~Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
10170484|NCT03892343||Non-transplanted|Patients on the deceased donor waiting list without prospect of a live donor transplant.
10170485|NCT03892135||Physicians|3 paediatricians and 3 rheumatologists
10170486|NCT03892135||Parents|Parents
10170487|NCT03892135||Children|Children
9527755|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
9527756|NCT03217188|Experimental|fractionated full dose re-irradiation|
9527757|NCT03217188|Experimental|hypofractionated palliative re-irradiation|
9527758|NCT03217071|Experimental|Pembrolizumab|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles, prior to surgery. Pembrolizumab will be administered via IV infusion for 30 minutes. Surgery will occur no later than 6 weeks following the last dose of pembrolizumab.
9527759|NCT03217071|Experimental|Pembrolizumab + Radiation|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles. Pembrolizumab will be administered via IV infusion for 30 minutes.Within the week (7 days +/- 3 days) following administration of the second cycle, a single 12 Gy dose of stereotactic radiation therapy (SRT) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur no later than 6 weeks following the last dose of pembrolizumab.
10170488|NCT03892252||before surgery|no intervention(s)
10170489|NCT03892252||after surgery|no intervention(s)
10170490|NCT03892252||Normal colonoscopy|People who were diagnosed by colonoscopy without colorectal cancer.
10170491|NCT03892096||Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer|A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled. It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
10170492|NCT03892044|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO BID on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10170493|NCT03891979|Experimental|Pembrolizumab + Antibiotics|Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.
10170494|NCT03892057|Experimental|Internet-based Positive Psychological Intervention|The investigator's culturally-tailored internet-based Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
9521175|NCT04800887|Active Comparator|Extended depth of focus intraocular lens|Eyes of patients implanted with extended depth of focus lens Tecnis Eyhance
9826569|NCT02423317|Active Comparator|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
9826570|NCT02423317|Experimental|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
9826571|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 1) Phase 1b|50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
9521176|NCT04800887|Active Comparator|Monofocal intraocular lens|Eyes of patients implanted with monofocal lens Tecnis ZCB00
9521177|NCT04769427|Experimental|PDO Max thread injection to nose|
9521178|NCT04779424||Primary Health Care Providers (PHCPs)|Any Belgian general practitioner (GP) (including those in professional training) currently working in primary care and any other primary health care providers (PHCPs) from the same GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP).
9521179|NCT04797325|Active Comparator|vedolizumab|
9521180|NCT04797325|Active Comparator|Standard treatment|
9521181|NCT04798911||Observational - phase 1|"Determination of Informational Needs (Months 0- 9)~Qualitative interviews with patients with SS~Interview transcriptions and thematic analysis"
9521182|NCT04798911||Observational - phase 2|"Phase 2 Development of the informational need instrument for SS [SS-INQ] (Months 9-32)~Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group~Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis~Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability"
9521183|NCT04784546||Mild COVID-19 Infection Group|Mild cases present with acute symptoms of respiratory tract infection and gastrointestinal complaints.
9521184|NCT04784546||Moderate COVID-19 Infection Group|Moderate patients experience pneumonia, they don't have clinically aberrant hypoxemia(O2 saturation is more than 90%) but they have positive findings on chest computerized tomography (CT) scans.
9521185|NCT04784546||Severe COVID-19 Infection Group|Severe patients present with pneumonia, they have hypoxemia (O2 saturation is less than 90%) and have positive findings on chest computerized tomography (CT) scans.
9521186|NCT04765358|Other|All Participants|All participants will be provided with a commercially available CGM system. Training and data collection for the study will be completed remotely. After initial CGM training (initiation of unblinded CGM use or initial training with virtual clinic) has been completed, participants will continue to be followed by the virtual clinic team for approximately six months. Psychosocial screening questionnaires are administered at enrollment and during follow up. The virtual clinical team member will follow up with the study participant if there is an elevated score on the psychosocial screening questionnaires. After the initial six months of follow up, participants who decide to continue to use CGM will be asked to extend follow up and complete questionnaires, submit HbA1c samples, and share data. During the extended follow up phase, participants will be able to contact the virtual clinic with questions or to request assistance as needed.
9521187|NCT04780464|Active Comparator|Standard doxorubicin|
9521188|NCT04780464|Experimental|Metronomic doxorubicin|
9521189|NCT04780464|Experimental|Metronomic oral cyclophosphamide + prednisolone|
9521190|NCT04779476||Control Group|No dressing material will be used post dental extraction
9521191|NCT04779476||Alveogyl Group|Alveogyl will be placed in the dental socket after extraction
9521192|NCT04779476||Cutanplast Group|Absorbable gelatin sponges contain will be placed in the dental socket after extraction
9521193|NCT04744181||cases|patients who fulfill the inclusion criteria
9521194|NCT04744181||controls|Patients who underwent cardiac surgery in 2019 and 2018
9521195|NCT04736862|Experimental|Continuous monitoring group|
10170495|NCT03892057|No Intervention|Attention Control Group|Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.
9521196|NCT04736862|Active Comparator|Intermittent monitoring group|
9521197|NCT04733560|Experimental|Pudendal nerve block|25 women will receive pudendal nerve blocks of 0.25% Bupivicaine 10ml administered vaginally prior to making any surgical incisions.
9521198|NCT04733560|Sham Comparator|Placebo|25 women will receive sham pudendal nerve blocks using normal saline. These will also be administed vaginally prior to making any surgical incisions.
9521199|NCT04729257|Other|Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
9826572|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 2) Phase 1b|50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
9826573|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 3) Phase 1b|80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
9977479|NCT01361997|Experimental|Chlorhexidine in isopropyl alcohol|This arm is composed of 545 hospitalized patients with suspected blood stream infection, to test 2% chlorhexidine gluconate in 70% isopropyl alcohol.
10170496|NCT03892070|Experimental|HMB GROUP|HMB Supplementation with 1.5 g of HMB taken twice daily. Supplementation will be provided for 12 weeks
10170497|NCT03892070|Placebo Comparator|PLACEBO GROUP|Mannitol 1.5 g twice daily. Supplementation will be provided for 12 weeks
9521200|NCT04729257|Other|Group B (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using digital tests.
10170498|NCT03892161|Experimental|Standard dose DRV/r|Standard dose DRV/r 800/100mg without Rifampicin
10170499|NCT03892161|Experimental|Standard DRV/r with Rifampicin|Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
10170500|NCT03892161|Experimental|Boosed ritonavir 200mg|Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
9521201|NCT04729257|Other|Group C1 (Norms + Validation, 18-49 years) + Group C2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using digital tests.
9975098|NCT04693689|Experimental|RNA vaccine, 40% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 40%."
9975099|NCT04693689|Experimental|RNA vaccine, 60% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 60%."
9977480|NCT01361997|Experimental|Isopropyl alcohol|This arm is composed of 572 hospitalized patients with suspected blood stream infection, to test 70% isopropyl alcohol.
9521202|NCT04729257|Other|Group D (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
9521203|NCT04729257|Other|Group E (Norms, 18-49 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
9521204|NCT04729257|Other|Group F (Norms, 80-95 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
9521205|NCT04717115||Genetic diagnosis|
9521206|NCT04705545|No Intervention|molar block|No additional anchorage reinforcements besides the banding first and second molar with and tying them together at the buccal tubes (also known as molar block)
9521207|NCT04705545|Experimental|TPA group|Bands are selected and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a transpalatal archwire.
9521208|NCT04705545|Experimental|Nance button group|Bands are selected and an alginate impression taken over the bands. Bands are replaced on the tooth and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a Nance button
9521209|NCT04706533||Covid-19|Patients with confirmed SARS-CoV-2 infection presenting specifically for Covid-19
9521210|NCT04706598|Experimental|Intravesical therapy group|"Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg. The recommended phase II dose(RP2D) to be decided after safety run-in.~The cycle is divided into an induction course and a maintenance course. The induction course is initiated 2 weeks after TURBT and repeat once a week for 6 weeks . After that, the maintenance course starts every 3 weeks. The maximum duration of dosing is 2 years."
9521211|NCT04706598|Active Comparator|Intravenous therapy group|Camrelizumab(SHR-1210) is administered on the first day (D1) of each treatment cycle (21 days) at a dose of 200 mg by 30-min intravenous infusion(the allowable error in infusion time is -5 min, +10 min). The maximum duration of dosing is 2 years.
9521212|NCT04713501|Experimental|PARTS|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
9977481|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 4%|Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
9521213|NCT04713098|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
9521214|NCT04713098|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
9671907|NCT05041595||Apparently Healthy|Apparently healthy subjects living in an area non-endemic for Lyme disease Apparently healthy subjects living in an area endemic for Lyme disease
10170501|NCT03892161|Experimental|Double dose DRV/r 1600/200mg QD|Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
10170502|NCT03892161|Experimental|Double dose DRV/r 800/100mg BD|Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
10170503|NCT03892174|No Intervention|Treatment protocol without adsorption|
10170504|NCT03892174|Active Comparator|Treatment protocol with adsorption|
10170505|NCT03891693|Experimental|Passeo-18 Lux and SUPERA® stent|Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty
9975100|NCT04693689|Experimental|RNA vaccine, 80% adoption rate|"Our survey follows a 2 x 5 between-subjects design. The two dimensions we vary are vaccine technology (conventional vs. RNA) and the hypothetical adoption rate of the new vaccine in the country (0%, 20%, 40%, 60%, 80%). We elicit subjects' willingness to receive the new COVID-19 vaccine given the vaccine technology and a hypothetical adoption rate of the new vaccine.~In this arm, we elicit subjects' willingness to receive an RNA vaccine if its current adoption rate in the country is 80%."
9826574|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 4) Phase 1b|150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
9521216|NCT04669561|Experimental|Single /arm|All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
9521217|NCT04664621|Experimental|HepQuant Testing|
9521218|NCT04647383|Experimental|OSA Cohort, Sequence A: Placebo + Lemborexant 10 mg|Participants with OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
9521219|NCT04647383|Experimental|OSA Cohort, Sequence B: Lemborexant 10 mg + Placebo|Participants with OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
9521220|NCT04647383|Experimental|COPD Cohort, Sequence C: Placebo + Lemborexant 10 mg|Participants with COPD will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
10170506|NCT03891667|Experimental|8 Week Disulfiram|Patients in this group receive disulfiram for 8 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg for week 3, and 500 mg daily for week 4 to week 8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
10170507|NCT03891667|Active Comparator|4 Week Disulfiram|Patients in this group receive disulfiram for 4 weeks followed by placebo capsules for 4 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg during week 3, and 500 mg daily during week 4. Placebo capsules are given during weeks 5-8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
10170508|NCT03891927|Experimental|olive group|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO ( high polypheol Extra virgin olive oil)
10170509|NCT03891927|No Intervention|non olive group|No intervention
10170510|NCT03891615|Experimental|Niraparib + Osimertinib|"Niraparib will be administered orally once daily~Osimertinib will be administered by mouth once daily"
10170511|NCT03891758|Experimental|BK1310|
10170512|NCT03891758|Active Comparator|ActHIB® and Tetrabik|
10187917|NCT03721419|Experimental|High Flow High Humidity device|High Flow High Humidity device arm subjects will be placed on a High Flow Airvo device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen. This device has its own flow generator built in.
9521221|NCT04647383|Experimental|COPD Cohort, Sequence D: Lemborexant 10 mg + Placebo|Participants with COPD will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
9521222|NCT04647591|Experimental|ENT Barotrauma incidence and link with risk factors|
9521223|NCT04643587|Experimental|CSL787 (SAD dose 1)|Inhalation by mouth of a nebulized aerosol in healthy subjects
9521224|NCT04643587|Experimental|CSL787 (SAD dose 2)|Inhalation by mouth of a nebulized aerosol in healthy subjects
9521225|NCT04643587|Experimental|CSL787 (SAD dose 3)|Inhalation by mouth of a nebulized aerosol in healthy subjects
9521226|NCT04643587|Experimental|CSL787 (SAD dose 4)|Inhalation by mouth of a nebulized aerosol in healthy subjects
9521227|NCT04643587|Experimental|CSL787 (MAD dose 1)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
9521228|NCT04643587|Experimental|CSL787 (MAD dose 2)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
9521229|NCT04643587|Experimental|CSL787 (MAD dose 3)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
9521230|NCT04643587|Placebo Comparator|Placebo|Inhalation by mouth of a nebulized aerosol
9521231|NCT04667156|Experimental|Sequence 1|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 traditional formulation (R) in the last period
9521232|NCT04667156|Experimental|Sequence 2|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 new formulation 2 (T2) in the last period
9975101|NCT04686487|Other|Stereotactic Ablative Radiotherapy|Stereotactic body radiation therapy delivered to the thick heart muscle at the point of obstruction
9975102|NCT04680780|Experimental|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 month
9975103|NCT04680780|Experimental|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months.
9521233|NCT04667156|Experimental|Sequence 3|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 1 (T1) in the last period
9671908|NCT05041738|Experimental|Intraoral Cryotherapy|
9826575|NCT02423343|Experimental|Galunisertib + Nivolumab - Non-small Cell Lung Cancer (NSCLC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
9975104|NCT04680780|Placebo Comparator|Control|Patients are allowed to eat ad libitum
10170513|NCT03891810|Experimental|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
10170514|NCT03891810|No Intervention|Control|This group was a wait list control group who received the treatment following the intervention period.
9521234|NCT04667156|Experimental|Sequence 4|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 2 (T2) in the last period
9521235|NCT04667156|Experimental|Sequence 5|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 traditional formulation (R) in the last period
9521236|NCT04667156|Experimental|Sequence 6|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 new formulation 1 (T1) in the last period
10170515|NCT03891797|Experimental|Cognitive Processing Therapy|12 sessions of group-based Cognitive Processing Therapy administered 1x/week for 90 minutes each session.
9521237|NCT04620551|Experimental|PD with DBS|Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.
9521238|NCT04626427|Experimental|WavelinQ™ EndoAVF System|The WavelinQ™ EndoAVF System is indicated for the cutting and coagulation of blood vessel tissue in the peripheral vasculature for the creation of an AVF used for HD. The device is intended to be used in patients suffering from chronic kidney disease requiring HD by physicians trained and experienced in endovascular techniques. The WavelinQ™ EndoAVF System will be used for these intended purposes as part of this clinical investigation according to its instructions for use (IFU).
9521239|NCT04630002|Experimental|Cohort 1: GSK3640254 then DRV/RTV then GSK3640254 + DRV/RTV|Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
9521240|NCT04630002|Experimental|Cohort 2: GSK3640254 then ETR then GSK3640254 + ETR|Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
9521241|NCT04630002|Experimental|Cohort 3: GSK3640254 then GSK3640254 + DRV/RTV + ETR|Cohort 3 will include 2 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 GSK3640254 (Treatment A), DRV/RTV (Treatment B), and ETR (Treatment C) will be administered.
9521242|NCT04580888|Experimental|Intervention arm|Assessment using an early transthoracic echocardiography (after 500 mL of fluids) to identify the hemodynamic profile responsible for the acute circulatory failure associated with sepsis / septic shock and to guide ongoing treatment (therapeutic algorithm) and monitor its efficacy and tolerance.
10170516|NCT03891797|No Intervention|Control|No treatment/treatment as usual. Participants will complete questionnaires at three time points with no intervention.
10170517|NCT03891940||Patient receiving Anterior Cervical Spine Surgery|"Patients who fulfill the criteria of anterior cervical spine surgery under general anesthesia~Aged from 20-80 years old"
10170518|NCT03891472|Experimental|Arm 1|
10170519|NCT03891823|Experimental|MitraClip|"Study of MitraClip in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
9521243|NCT04580888|Other|Control arm|Conventional management according to current standards of care based on SSC recommendations, including a standardized fluid resuscitation of 30 mL/kg.
9521244|NCT04615117||Study Group|Patients treated with Superior Capsular Reconstruction with Allomend
9521245|NCT04565041|Experimental|Social Support|
9521246|NCT04564976|Experimental|Social Support|
9521247|NCT04549493|Active Comparator|Trauma Management Therapy|1. Trauma Management Therapy (TMT; Turner, Beidel, & Frueh, 2005): TMT is a multicomponent behavioral treatment program designed to target various aspects of chronic PTSD - reducing emotional and physiological reactivity to traumatic cues, reducing intrusive symptoms and avoidance behavior, improving interpersonal skills and emotion modulation (e.g., anger control), and increasing the range of enjoyable social activities. In this investigation and in line with our previous publications, TMT will include virtual-reality augmented exposure (i.e. olfactory stimulation, heart rate, and skin conductance); group therapy to address sleep, anger, depression, and social isolation; homework assignments; and programmed practice. In the 3-week treatment program, each participant receives virtual-reality assisted exposure in the morning followed by in vivo exposure and group therapy (SER) each afternoon for a total of 29 sessions.
9521248|NCT04549493|Active Comparator|Prolonged Exposure|2. Standard Prolonged Exposure (PE; Foa, Hembree, & Rothbaum, 2007) consists of psychoeducation, imaginal exposure to trauma memories, in vivo exposure to situations that are avoided due to their association with the trauma, and emotional processing. The standard protocol consists of 12 imaginal exposure sessions, along with in vivo exposure/homework assignments and listening to a recording of the imaginal sessions at home during the evening.
9671909|NCT05041738|Active Comparator|Intracanal Cryotherapy|
9975105|NCT04679311|Experimental|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with 2 units of fresh frozen plasma that have been preselected to contain ACE activity ≥50 U/L
10170520|NCT03891823|Active Comparator|Medical Therapy|"Study of medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
9975106|NCT04679311|Placebo Comparator|Normal Saline|Subjects will be treated with normal saline 500 cc.
9975107|NCT04677491|Active Comparator|VVA-FSIAD ospemifene group|Women treated with ospemifene 60 mg/day
9975108|NCT04677491|Placebo Comparator|VVA-FSIAD placebo group|Women treated with placebo
10170521|NCT03891524|Experimental|Group A: JNJ-70033093 25 mg + Placebo BID|Participants will receive JNJ-70033093 25 milligram (mg) (1*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
10170522|NCT03891524|Experimental|Group B: JNJ-70033093 50 mg BID|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
10170523|NCT03891524|Experimental|Group C: JNJ-70033093 100 mg + Placebo BID|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
10170524|NCT03891524|Experimental|Group D: JNJ-70033093 200 mg BID|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID orally for 10 to 14 postoperative days.
10170525|NCT03891524|Experimental|Group E: JNJ-70033093 25 mg Once Daily + Placebo|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
10170526|NCT03891524|Experimental|Group F: JNJ-70033093 200 mg Once Daily + Placebo|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
10170527|NCT03891524|Experimental|Group G: JNJ-70033093 50 mg once daily + Placebo|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
10170528|NCT03891524|Active Comparator|Group I: Enoxaparin 40 mg Once Daily|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
10170529|NCT03891420|Experimental|Galidesivir|Galidesivir IV infusion
10170530|NCT03891420|Placebo Comparator|Placebo|Placebo IV infusion
10170531|NCT03891433|Active Comparator|Carbapenems group|Meropenem (1g intravenously every 8 hours or adjusted to renal function) or Ertapenem (1g intravenously every 24 hours or adjusted to renal function) by 10 days.
10170532|NCT03891433|Active Comparator|Piperacillin/tazobactam.|Piperacillin / Tazobactam (4.5gr intravenously every 6 hours or adjusted to renal function) by 10 days.
10170533|NCT03891602||Clinicians|Primary care clinicians (general internists, family physicians, nurse practitioners, physician assistants) who treat lung cancer screening eligible patients
10170534|NCT03891602||Smokers/Former Smokers|Current smoker or former smoker who has quit within the past 15 years
10170535|NCT03891628|Experimental|Modified ABC|Modified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
10170536|NCT03891628|Active Comparator|Modified DEF|Modified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
10170537|NCT03891732||MRI pathway|Plain biparametric MRI prostate applied to men with elevated PSA, on top of standard screening pathway using PSA and Prostate Health Index
10170538|NCT03891732||Standard screening pathway|Intervention: Using blood tests PSA and Prostate Health Index to screen men at risk of prostate cancer
10170539|NCT03891576|Experimental|Niraparib 200 mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg
9975109|NCT04661514|Experimental|Safety, Tolerability, and Treatment|On dosing day, each participant will receive 1 x 25 mg treatment bottle containing 5 x 5 mg oral capsules of psilocybin. The administration session will last approximately 4-6 hours and will be supported by a lead therapist and an assisting therapist.
9975110|NCT04660279|Other|Validate|D-WB PET/CT scans + arterial blood sampling.
9975111|NCT04641767||BIOTRABIS>18 - Pathologic patients|Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.
9975112|NCT04641767||BIOTRABIS>18 - Control patients|Group that includes adult control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
9975113|NCT04641767||BIOTRABIS<18 - Pathologic patients|Group of paediatric patients under study. This will recruit those who come to the emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).
9975114|NCT04641767||BIOTRABIS<18 - Control patients|Group that includes paediatric control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
9975115|NCT04619485|Sham Comparator|SHAM LASER|Group A: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to zero potence.
9975116|NCT04619485|Active Comparator|EFFECTIVE LASER|Group B: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to regular potence.
9975117|NCT04603677||Acute phase of SARS-CoV-2 infection|Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.
9975118|NCT04603677||Convalescent phase of SARS-CoV-2 infection|Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.
9977482|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 1%|Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
9977483|NCT01362010|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
9977484|NCT01362023|No Intervention|control|Control pupils follow their usual activities
9977485|NCT01362023|Experimental|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
10170540|NCT03891576|Active Comparator|Niraparib 300 mg|Niraparib will be administered every day as oral at a fixed dose of 300 mg
10170541|NCT03891576|Other|Niraparib 200mg/300mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg or 300 mg
10170542|NCT03891589|Experimental|Optimized CF with Taburia|The intervention groups consisted of promotion of optimized complementary feeding with home fortification (taburia) one sachet per week
10170543|NCT03891589|Experimental|Optimized CF only|The intervention groups consisted of promotion of optimized complementary feeding without home fortification (taburia)
10170544|NCT03891589|Experimental|Taburia|The intervention groups consisted of provision taburia home fortification three sachet per week
10170545|NCT03891589|No Intervention|Control|No intervention but gave a standard education from primary health center
10170546|NCT03891459|Experimental|spray+ group|"In spray+ condition, participants learned oxytocin materials on a self-paced basis and then intranasally administered with saline (but it was told as oxytocin). Participants were instructed to refrain from smoking or drinking (except water) for 2 h before the experiment. The spray was administered to each participant three times, and each administration consisted of one inhalation into each nostril. Participants took a rest (they were told it was a time period waiting for treatment to produce effects) for 10min and then performed the experimental tasks."
10170547|NCT03891459|Placebo Comparator|control group|"In control condition, the materials and procedure were same with the spray+ condition except the nasal spray was told as saline instead. Oxytocin materials used in current experiments were adopted from previous study"
10170548|NCT03891550|Experimental|SOF/VEL|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks
10170549|NCT03891498|Experimental|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
10170550|NCT03891407|Experimental|HIV Self-testing Group|Camp members will receive information about HIV self-testing from peer educators who will be nominated by you and other camp members in your camp. Camp members in the STEP project will receive pretest counseling and a 10 minute demonstration. They will receive 1 oral fluid HIV self-test kit to conduct the self-test at home or in a private location during the next 1 month and a phone number to call in case you need assistance when performing the self-test at home. They will also receive information about the nearest HIV Care and Treatment Center where they can seek a confirmatory HIV test and start HIV treatment in the event of a positive self-test result.
10170551|NCT03891407|No Intervention|Non-intervention Group|Camp members will be encouraged to seek HIV testing at the clinics.
10170552|NCT03891680|Experimental|Botox injection|
10170553|NCT03891680|Active Comparator|Genicular Radio frequency|
10170554|NCT03891719|Experimental|Changes in nose symmetry|- Direct anthropometric assessment (frontal, oblique, lateral and basal views) and three- dimensional observations of the nose preoperatively and postoperatively in order to evaluate the nostril symmetry, the angles, ratios of the nose and its relation to the face.
10170555|NCT03891316||Anaesthesiologists balanced|Anaesthesiologists performing balanced anaesthesia with sevoflurane.
10170556|NCT03891316||Anaesthesiologists TIVA|Anaesthesiologists performing only total intravenous anaesthesia.
10170557|NCT03891316||Surgeons|Surgeons working in the operating room while anaesthesia of the patients is randomly maintained with sevoflurane or propofol.
10170558|NCT03891316||Anaesthesiologists PACU|Anaesthesiologists working in the postoperative care unit.
10170559|NCT03891316||Anaesthesiologists outside the operating room|Anaesthesiologists working outside of the operating room, for example pain service or anaesthesiological walk-in clinic
10170560|NCT03891316||Physicians not exposed|Physicians not having contact with patients on wards/outpatient clinics after exposure with sevoflurane
10170561|NCT03891316||Patients|Patients having undergone sevoflurane anesthesia for elective surgery
9521249|NCT04549493|Active Comparator|Compressed Prolonged Exposure|3. Compressed PE consists of 10 standard PE sessions delivered on consecutive work days. The imaginal exposure sessions take place in the morning, with in vivo exposures assigned (not therapist accompanied) for the afternoons. Patients are instructed to listen to the recordings of the imaginal exposure each night. Being most concerned with having enough time for in vivo practice, Session 1 does not start on a Monday, allowing for two full weekends in order to maximize in vivo exposures. Both versions of PE average 36 total treatment hours.
9521250|NCT04577729|Experimental|Allogenic FMT group|Allogenic FMT group: patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
9521251|NCT04577729|Placebo Comparator|Autologous FMT group|Autologous FMT group: patients receiving their own stool in terms of sham FMT.
9521252|NCT04555967||Transcatheter aortic valve implantation|
9671910|NCT05041556||Case-control study of clinical outcomes|These are children who live in RTS,S implementation areas aged less than 5 years and who were eligible to have received RTS,S based on their date or birth and age, will be eligible to be recruited into the study. Cases will be recruited in sentinel hospitals of the ongoing malaria Vaccine Pilot Evaluation (MVPE). Control for a case will be a child who lives outside a 100-metre radius from the case, matched on date of birth (+/- 1 month of date of birth of the case)
9671911|NCT05041556||Case-control study of mortality outcome|These will be children who died of any cause excluding accidents or trauma, who are eligible to have received the RTS,S vaccine based on their date of birth and age. Cases will be recruited from the community-based mortality surveillance of MVPE. Control for a mortality case will be a live child who lives outside a 100 metre radius from the case with date of birth +/- 1 month of the date of birth of the case who are eligible to have received the RTS,S vaccine.
9671912|NCT05041881|Active Comparator|Trifocal IOL group|Patients implanted during cataract or refractive surgery with trifocal lens, which allowed to see for far, intermediate and near distance, but due to optic design having unwanted effect like optical phenomena and lower contrast sensitivity
9671913|NCT05041881|Active Comparator|Accommodating IOL group|Patients implanted during cataract or refractive surgery with accommodating lens, which allowed to see for far and should improve intermediate distance better than monofocal lens do.
9671914|NCT05041881|Active Comparator|Monofocal IOL group|Patients implanted during cataract or refractive surgery with standard monofocal lens, which allowed to see for far but patients do not experiences optical phenomena or low contrast sensitivity.
9671915|NCT05041751|Active Comparator|Arm I (trigger point injections)|Patients receive standard of care trigger point injections at baseline
9671916|NCT05041751|Experimental|Arm II (myofascial release)|Patients perform myofascial release for 10 minutes each day.
9521253|NCT04570358|Experimental|Static stretching|An 8-week home-based static stretching training for the calf muscles will be performed by group A. Altogether, 10 stretches are performed per leg 4 times a week.
10170562|NCT03891342|Experimental|Patients with sepsis/septic shock|Comaprison of fast or slow fluid bolus administration in patients with sepsis/septic shock 48hours before admission to ICU requiring fluid challenge as assessed by clinical examination
10170563|NCT03891342|Experimental|Major surgical patients|Comaprison of fast or slow fluid bolus administration in patients undergoing major surgery requiring fluid challenge as assessed by clinical examination
9521254|NCT04570358|No Intervention|Control|While group A performs the 8-week static stretching training, group B acts as control group performing its daily life activities as usual.
10170564|NCT03891277|Active Comparator|Ferrous succinate|Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
10170565|NCT03891277|Placebo Comparator|placebo|placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
10170566|NCT03891004|Experimental|Tissue Adhesives Only|For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
10170567|NCT03891004|Active Comparator|Subcuticular Suture Closure Method Only|For the suture arm we will only close the subcuticular layer. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
10170568|NCT03891082|Active Comparator|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border.The absorbable suture is fed posteriorly and vertically to enter the posterior wall of the uterine cavity at the same level as the upper anterior entry point.
10170569|NCT03891082|Active Comparator|Bakri balloon|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium.
9521255|NCT04570358|Experimental|Proprioceptive neuromuscular facilitation stretching|After group A has finished the 8-week static stretching training, group B starts with the 8-week home-based proprioceptive neuromuscular facilitation stretching training. Altogether, 10 stretches are performed per leg 4 times a week.
9521256|NCT04570358|No Intervention|Follow-up|While group B performs the 8-week proprioceptive neuromuscular facilitation stretching, group A is in its follow-up period performing its daily life activities as usual.
9521257|NCT04542096||Group1|Patients receiving invasive respiratory therapy (intubated)
9521258|NCT04542096||Group2|Patients receiving non-invasive respiratory therapy.
9521259|NCT04539522|Experimental|Three-dimensionally corrective exercise for scoliosis|Experimental group will perform three-dimensionally corrective exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home.For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
9521260|NCT04539522|Active Comparator|Conventional exercise|Control subjects will perform conventional exercise for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home. For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
9521261|NCT04535440||Rectal varices with bleed|
9521262|NCT04535440||Rectal varices without bleed|
9521263|NCT04521296|Experimental|DWJ1248|Camostat mesylate
9521264|NCT04521296|Placebo Comparator|Placebo|Placebo
9521265|NCT04494035|Experimental|AVATR-Toronto|Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
9521266|NCT04474704|Experimental|Cheetah® non-invasive cardiac monitoring system|Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 24 hours postpartum.
9521267|NCT04474704|Other|Standard of care|24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
9521268|NCT04479319||COVID-19 Pneumonia|"COVID-19 patients who have pneumonia on thorax CT~either Thorax CT + SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +"
9521269|NCT04479319||COVID-19, without Pneumonia|"COVID-19 patients who have not pneumonia on thorax CT~Thorax CT - SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-"
9521270|NCT04479319||Non COVID-19|"Patients with viral infection symptoms who is not diagnosed with COVID-19~either Thorax CT - SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 -"
9521271|NCT04483908||Cohort 1|"Disease survivors with a positive polymerase chain reaction (PCR) test > 12days (d) ago and no symptoms (~250 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
9671917|NCT05041764||PCR positive|samples that are positive for the detection of SARS-CoV2. The SARS-CoV2 sequence of positive samples is provided, together with an indication about patient's neigborhood, corresponding to one of the 21 different spots which wastewater was analyzed
9671918|NCT05041764||PCR negative|samples that are p negative for the detection of SARS-CoV2. T
9671919|NCT05041777||Prospective data collection, retrospective OCT image evaluation|From February 2017-June 2017 patients were included prospectively. OCT images were evaluated retrospectively in conjunction with clinical images. A deep learning algorithm is developed with use of this dataset including 676 OCT images.
10170570|NCT03891095|Experimental|Intranasal oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)
10170571|NCT03891095|Experimental|L-DOPA|L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)
10170572|NCT03891095|Placebo Comparator|Placebo|Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)
9521272|NCT04483908||Cohort 2|"Disease survivors with a positive PCR test 7 - 12d ago and no symptoms (~100 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
9521273|NCT04483908||Cohort 3|Subjects with PCR negative test > 5d (~100 participants). Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
9521274|NCT04483908||Cohort 4|"Anonymised blood sera from the Serumbank at the Kantonsspital Basel-Land (KSBL) taken during last years influenza period (~100 participants).~Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates."
9521275|NCT04495452||Study Participants|"We will be enrolling 200 participants, this will provide a large enough sampling to assure there are at least 25 patients with significant respiratory depression and 25 with insignificant respiratory depression.~The genetic data from participants with the most respiratory depression defined as having a 20-40% decrease from initial respiratory parameters will be compared with genetic data from participants with the least respiratory depression defined as having no change or less than 10% decrease from initial respiratory parameters."
9521276|NCT04467255|Active Comparator|group a|aerobic training
9521277|NCT04467255|Active Comparator|group b|endurance training
9521278|NCT04443504|Experimental|Intervention Group|
10170573|NCT03891303||Transfused group (TR)|Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
10170574|NCT03891303||Non-transfused (non-TR)|Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
9521279|NCT04443504|No Intervention|Waitlist Group|The waitlist group will receive the intervention 3 months after the intervention group.
9521280|NCT04437199|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
9521281|NCT04437199|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
9521282|NCT04419818||Left brain damaged patients|"A group of 20 left brain damaged (LBD) patients will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
9521283|NCT04419818||Right brain damaged patients|"A group of 20 right brain damaged (RBD) patients will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
9521284|NCT04419818||Healthy controls|"A group of 40 (20 young and 20 elderly) healthy controls (HC) will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
9521285|NCT04431466|Active Comparator|Standard of care|Standard of care (SOC) treatment
9521286|NCT04431466|Experimental|SOC plus ivermectin 100 mcg/kg|SOC plus ivermectin 100 mcg/kg
9521287|NCT04431466|Experimental|SOC plus ivermectin 200 mcg/kg|SOC plus ivermectin 200 mcg/kg
9521288|NCT04431466|Experimental|SOC plus ivermectin 400 mcg/kg|SOC plus ivermectin 400 mcg/kg
9671920|NCT05041777||Prospective data collection and OCT image evaluation|From January 2021-April 2021 patients were included prospectively. OCT images were evaluated prospectively in a clinical setting. The deep learning algorithm will be prospectively validated with use of this dataset including 287 OCT images.
9671921|NCT05041686|Experimental|CADISS® System|
9975119|NCT04593771|Experimental|Experimental group|80 healthy people were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD once.
9975120|NCT04593771|Other|control group|80 healthy people were randomly assigned to the experimental group and the control group. The control group was injected with BCG-PPD was marketed once.
9975121|NCT04593264|Active Comparator|Traditional Supervised Prehabilitation with a Physical Therapist|
10170575|NCT03890991|Experimental|SCOPE-DM only|Participation in SCOPE-DM programme without supply of glucometers and accessories
10170576|NCT03890991|Active Comparator|SCOPE-DM with 3 months' supply of glucometer|Participation in SCOPE-DM programme with 3 months' supply of glucometers and accessories
10170577|NCT03890991|Active Comparator|SCOPE-DM with 6 months' supply of glucometer|Participation in SCOPE-DM programme with 6 months' supply of glucometers and accessories.
10170578|NCT03890991|No Intervention|Control|Usual care by healthcare provider/ clinics of Tsao Foundation without participation in SCOPE-DM programme
9975122|NCT04593264|Experimental|Self-guided Home-based Prehabilitation|
9977486|NCT01362036|Experimental|TXA127 sc injectable|All cohorts will recieve TXA127; Cohorts receive either 300, 600, or 900 ug/kg daily
9671928|NCT05041647|Experimental|High CBD [25:1]|"1 dose (1 mL) of HIGH CBD~50 mg/ml CBD and 2 mg/ ml THC"
9521289|NCT04427904|Experimental|Bupivacaine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
9521290|NCT04427904|Active Comparator|Lidocaine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
9521291|NCT04416282|Experimental|Terlipressin + Albumin|Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
9521292|NCT04416282|Active Comparator|Albumin|i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
9521293|NCT04412941|Experimental|Treatment group|Myofunctional exercises + home oropharyngeal exercises + the rules of sleep hygiene
9521294|NCT04412941|Active Comparator|Control group|the rules of sleep hygiene
9521295|NCT04398030|Experimental|coil-reinforced soft polymer indwelling cannula|Participants in this arm are randomized into the coil-reinforced soft polymer indwelling cannula group and then switched to a soft Teflon indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
9521296|NCT04398030|Active Comparator|soft Teflon indwelling cannula|Participants in this arm are randomized into the soft Teflon indwelling cannula group and then switched to the coil-reinforced soft polymer indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
9521297|NCT04358328|Experimental|Intervention group|The patients in the intervention arm will receive the same care and treatment as is provided to all patients in the clinical setting, including the ERAS-concept. In addition to this they will be individually assessed by a physician with geriatric profile, dietician, physiotherapist and nurse and thereafter undergo appropriate interventions (CGA and care). The intervention team will have weekly meetings regarding the patients included in the study to evaluate how long the intervention should continue before surgery, a maximum time of eight weeks will be allowed for the intervention.
9521298|NCT04358328|Active Comparator|Control group|The patients in the control group will standard care and treatment which include assessment of surgeons, anaesthesiologists and, if needed, other specialized physicians. They will be treated according to the ERAS-concept in the pre- peri- and post operative phase.
9521299|NCT04377451|No Intervention|Control arm|The control group will be formed of 60 overweight or obese dengue patients receiving standard of care
9521300|NCT04377451|Experimental|Intervention arm|Two cohorts receive a 5-day course of metformin treatment. In the initial phase (cohort 1), 5 young adults and 5 children (age <16) will receive a low dose of metformin. In the second phase (cohort 2), 25 adult and 25 paediatric patients will receive a weight-based dose of metformin.
9521301|NCT04350294||Serious Mental Illness *RECRUITMENT IN THIS GROUP IS CLOSED|"Mothers with a serious mental illness*~*received hospitalisation, treatment or intervention from a secondary care (mental health) service in the last 5 years."
9521302|NCT04350294||Healthy Controls|Mothers with no history of mental illness, who have given birth since February 2021
9527760|NCT03217123|Experimental|Deep Brain stimulation|After the surgery, a random sequence of contact activations (0 [Nacc],1,2 and 3), including sham (-), was generated for each patient. Each contact was activated using 130 Hz, 60 ms, and 4.5 V for three months (the sham activation was 0 V) following the patient's individual sequence, separated by one month of washout with the generator turned off
9527761|NCT03217032|Experimental|YUVA-GT-F801|Gene transfer to treat Hemophilia A
9671929|NCT05041647|Experimental|Low CBD [5:1]|"1 dose (1 mL) of LOW CBD~10 mg/ml CBD and 2 mg/ ml THC"
9671930|NCT05041647|Placebo Comparator|Placebo|"1 dose (1 mL) of PLACEBO~No active ingredients"
9671931|NCT05041725|Experimental|remimazolam infusion|Intraoperative remimazolam infusion for postoperative sedation
9671932|NCT05041660|Experimental|VR ICT|Virtual-reality-based inhibitory control training done daily at home for 6 weeks.
9671933|NCT05041660|Sham Comparator|VR Sham ICT|"Virtual-reality-based sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
9671934|NCT05041660|Active Comparator|Non-VR ICT|Computerized inhibitory control training done daily at home for 6 weeks.
9975123|NCT04588545|Experimental|Radiation Therapy followed by 10 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 1 of 4 with 10 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
10170579|NCT03891108|Active Comparator|Treatment A: BMS-986231 Formulation A|Participants will be administered Treatment A: BMS-986231 Formulation A as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
10170580|NCT03891108|Experimental|Treatment B: BMS-986231 Formulation B|Participants will be administered Treatment B: BMS-986231 Formulation B as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
9671935|NCT05041660|Sham Comparator|Non-VR Sham ICT|"Computerized sham inhibitory control training (i.e., one that does not include a stop signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks."
9671936|NCT05041608||Subjects undergoing Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
9977487|NCT01362075|Experimental|Local infiltration analgesia|
9977488|NCT01362075|Active Comparator|Interscalene catheter|
10170581|NCT03891108|Experimental|Treatment C: BMS-986231 Formulation C|Participants will be administered Treatment C: BMS-986231 Formulation C as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
10170582|NCT03891108|Experimental|Treatment D: BMS 986231 Formulation D|Participants will be administered Treatment D: BMS 986231 Formulation D as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
9521303|NCT04341129|Experimental|Abbreviated MRI using Dotarem|Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. The shorter imaging times achieved with the abbreviated DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol using Dotarem® (Gadoterate Meglumine) by comparing the diagnostic accuracy of dynamic contrast-enhanced breast MRIs performed with an abbreviated protocol versus a full protocol.
9521304|NCT04350541|Experimental|Interval training|Interval training will consist of 10 minutes of warm-up between 40-50% of the peak oxygen consumption (VO2peak), followed by four to six repetitions of three-minute intervals between 80-90% of VO2peak and three minutes between 40-50% VO2peak and finally, five minutes of cooling down between 30-40% of VO2peak.
9521305|NCT04350541|Active Comparator|Continuous training|The continuous aerobic training will consist of 10 minutes of warm-up with intensity between 40 and 50% of VO2peak, 20 minutes of conditioning between 60 and 70% of VO2peak and 5 minutes of cooling down between 30 and 40% of VO2peak.
9521306|NCT04330950||Surgical Cohort|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
9521307|NCT04329312||Pulmonary arterial hypertension (PAH)|The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
10170583|NCT03890926||radioactive Iodine-125 seed implantation|All enrolled patients received the intervention previously as a conventional treatment.
10170584|NCT03891147|Experimental|Electro-acupunture (EA) group|"Patients will receive the treatment of electro-acupuncture with acupoints (i) Riyue (GB-24) ; (2) Danshu (B19) ; (3) Ganshu (B18) ; (4) Qimen (LR14) ; (5) Yanglingquan (GB34)~The EA will be conducted by using disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length). The needles are inserted at a depth of 10-30 mm vertically or obliquely into acupoints, on which electrical stimulation with continuous waves with 2 Hz and 100 Hz are delivered for 15 min for each frequency through an electrical acupuncture treatment instrument (Hwarto, SDZ-II). The intensities of stimulation are adjusted to a level at which patients feel most comfortable. Each session lasts for 30 minutes."
9521308|NCT04329312||PH due to left-heart disease (PH-LHD)|The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
9521309|NCT04329312||Chronic thromboembolic pulmonary hypertension (CTEPH)|The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
9521310|NCT04329312||PH due to emphysema (PH-LD-Emphys)|The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
9521311|NCT04329312||PH due to lung fibrosis (PH-LD-Fibr)|The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
9975124|NCT04588545|Experimental|Radiation Therapy followed by 20 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 2 of 4 with 20 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
9521312|NCT04329312||PH due to combined emphysema and fibrosis (PH-LD-CPFE)|The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
9671937|NCT05041504|Experimental|Intervention|Participants assigned to the intervention arm will receive the True North Peer Navigation intervention.
9975125|NCT04588545|Experimental|Radiation Therapy followed by 40 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 3 of 4 with 40 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
9975126|NCT04588545|Experimental|Radiation Therapy followed by 80 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 4 of 4 with 80 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
9977489|NCT01362088||CVVH patients|
9977490|NCT01362101|Active Comparator|Traditional behavioral intervention|
9521313|NCT04329312||No PH|The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
9521314|NCT04333862||Healthcare workers providing healthcare|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
9521315|NCT04333862||Healthcare workers staying at home|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
9671938|NCT05041504|Other|Active Waitlist Control|Participants assigned to the control arm will receive usual care and access to an online health resource library. After completion of the study, they will receive the True North Peer Navigation intervention.
9521316|NCT04333862||Hospitalized patients|To compare the infection rate of hospitalized patients versus healthcare workers
9521317|NCT04308291||MiniMed™ 780G System|Subject will use the MiniMed™ 780G System as per standard of care.
9521318|NCT04307355|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
10170585|NCT03891147|No Intervention|Usual care group|Participants randomized to usual care will continue regular follow up arranged by their visiting physicians in public or private sectors. Current usual care of these patients is limited to symptomatic treatment and dietary advice only during the follow-up session in out-patient clinic until the end of observation period (week 10).
10170586|NCT03891017|Experimental|vacuum casting|Vacuum casting will be performed using the Ottobock vacuum casting system. For our vacuum casting procedures, we will be following the protocols outlined in the Harmony Fabrication Quick Guide
10170587|NCT03891017|Active Comparator|hydrostatic casting|For the aqua casting system, we will be using an in-house manufactured device. This device will be created following guidelines from the PCAST Technical Manual
10170588|NCT03891134|Experimental|enriched Branched Chain Amino Acid intervention|enriched Branched Chain Amino Acid nutrition supplement 3.6 g twice a day for 5 weeks then withdrawal nutrition supplement for 12 weeks
10170589|NCT03890939|Experimental|BiPAP AutoSV Advanced System One|
10170590|NCT03890939|Experimental|Dreamstation BiPAP AutoSV|
10170591|NCT03890939|Active Comparator|ResMed S7 VPAP Adapt device|
10186909|NCT03731416|Placebo Comparator|GBR by xenograft|"Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~In the study group: bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~• The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
9521319|NCT04307355|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
9521320|NCT04264962|Experimental|Yang Yin Fu Zheng Jie Du therapy|
9521321|NCT04264962|Placebo Comparator|Routine medical care|
9521322|NCT04262115|Experimental|AM-EX|Participants in this group will be prescribed morning aerobic exercise.
9826576|NCT02423343|Experimental|Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
9826577|NCT02423408|Experimental|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
9671939|NCT05041634|Experimental|Single Group Pilot study pre/post|One group of 8 participants receiving 14 week intervention
9671940|NCT05041465|Experimental|French Green Clay Mask|
9671941|NCT05041465|Experimental|Rhassoul Clay Mask|
9521323|NCT04262115|Experimental|PM-EX|Participants in this group will be prescribed evening aerobic exercise.
9521324|NCT04282551|Experimental|oligosaccharide group 1|
9521325|NCT04282551|Experimental|oligosaccharide group 2|
9521326|NCT04282551|Placebo Comparator|placebo group|
9521327|NCT04261764|Experimental|TCM-FMD|"Fasting-Mimicking Diet Combined With a Dispelling Dampness Meal Replacement Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
9521328|NCT04261764|Placebo Comparator|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
9521329|NCT04254796|Experimental|TARA Training|
9521330|NCT04254796|No Intervention|Control|
9826578|NCT02423408|Placebo Comparator|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
9826579|NCT02423447|Active Comparator|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
9826580|NCT02423447|Active Comparator|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
9826581|NCT02423577|Experimental|FF-3 dry powder|FF-3
9521331|NCT04239040|Experimental|Relapsed or Refractory High Risk Neuroblastoma|"Tissue Collection of Cancerous cells during primary or clinically indicated surgical resection.~Manufacture and cryopreservation of vaccine. Treatment with vaccine, nivolumab and ipilimumab.~Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.~Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
9521332|NCT04214028||Maviret Participants|Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
9521333|NCT04190758||Patients with rheumatoid arthritis (RA)|Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
9521334|NCT04190758||Patients with psoriatic arthritis (PsA)|Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
9671942|NCT05041465|Experimental|Bentonite Clay Mask|
9826582|NCT02423577|Placebo Comparator|Placebo|
9975127|NCT04585009|Experimental|Cohort1:GSK3923868 50 micrograms (mcg)/ Placebo/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/Placebo/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
9521335|NCT04190758||Patients with undifferentiated arthritis|Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
9521336|NCT04190758||Patients with psoriasis|Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
9521337|NCT04190758||General population controls|General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
9521338|NCT04181047|Experimental|Virtual EMDR|Patients will receive 1 to 3 preparation sessions (which will include psychoeducation and preparation exercises before EMDR), followed by up to 12 EMDR sessions, delivered over encrypted Zoom videoconferencing. EMDR is an evidence based trauma therapy. These EMDR sessions will focus on the experiences, urges or negative thoughts associated with their suicidal thoughts. The sessions will be 90 minutes in length and occur twice per week. This group will also have access to usual psychiatric care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
9521339|NCT04181047|Active Comparator|Treatment as usual|This group will also have access to usual care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
9521340|NCT04229173|Other|MSA patients|"Patients with multiple system atrophy will be examined at baseline, 6 months and 12 months via the following procedures performed at all 3 visits:~a clinical examination;~blood and cerebrospinal fluid (CSF) (optional) sampling for the assessment of selected fluid biomarkers;~MRI for the assessment of brain volume, white matter integrity and cerebral iron deposition; DAT-SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography) for the assessment of presynaptic dopaminergic function"
9521341|NCT04229173|Other|Healthy volunteers|healthy. Controls will undergo an MRI scan at baseline, 6 months and 12 months, and a DAT-SPECT(Dopamine Transporter, Single Photon Emission Computed Tomography) scan at baseline and 12 months.
9521342|NCT04179409|Experimental|Casimersen|This arm will involve the treatment of boys with DMD who have a duplication of exon 45, for which casimersen will target skipping of this exon.
9521343|NCT04179409|Experimental|Eteplirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 51, for which eteplirsen will target skipping of this exon.
9521344|NCT04179409|Experimental|Golodirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 53, for which golodirsen will target skipping of this exon.
9521345|NCT04171063|Other|Bracing arm|Patients that will be using the thoracic compressor
9521346|NCT04159480|Experimental|Experimental - Cogito Companion|Those allocated to Experimental arm will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators. The Cogito mobile sensing platform passively gathers behavioral information through an individual's normal smartphone usage. Measurements of location, call, and text patterns are recorded.
9521347|NCT04159480|Active Comparator|Active Control|Participants randomized to the Active Control group will download MyCAP and have access to resources housed within this app for a three-month period post-consent. Participants will be provided information regarding the mHealth Tool apps, and provided basic information on how to download the apps. As noted above, participants will be provided biweekly surveys .
9671943|NCT05041582|Experimental|Real tDCS + Citalopram + Rehabilitation|"Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks~Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
9671944|NCT05041582|Sham Comparator|Sham tDCS + Citalopram + Rehabilitation|"Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks~Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS"
9671945|NCT05041582|Placebo Comparator|Real tDCS + Placebo + Rehabilitation|"Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks~Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
9671946|NCT05041582|Placebo Comparator|Sham tDCS + Placebo + Rehabilitation|"Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks~Placebo oral intake daily for 3 months, since 2 weeks before tDCS"
9671947|NCT05041348||liver cirrhosis with sarcopenia|In order to diagnosis sarcopenia, patients' muscle strength and physical function will be measured. Patients with sarcopenia will show the decrease of muscle strength and physical function.
9671948|NCT05041348||liver cirrhosis without sarcopenia|The decrease of muscle strength and physical function will not appear in patients.
9975128|NCT04585009|Experimental|Cohort 1:GSK3923868 50 mcg/ 100 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
9671949|NCT05041348||healthy group|No related diseases
9671950|NCT05041790|Experimental|Choline Alfoscerate|
9671951|NCT05041790|Placebo Comparator|Placebo|
9671952|NCT05041517|No Intervention|Control|No intervention
9671953|NCT05041517|Experimental|BOLT + 1 PTC|BOLT Training + 1 PTC Call
9671954|NCT05041517|Experimental|BOLT + 2 PTC|BOLT Training + 2 PTC Calls
9975129|NCT04585009|Experimental|Cohort 1:GSK3923868 50mcg/ 100mcg/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
9977491|NCT01362101|Active Comparator|Mindfulness behavioral intervention|
10170592|NCT03891225|Experimental|Amniotic Membrane implantation Arm|All consecutive patients undergone pancreaticoduodenectomy with high FRS will be treated with implantation of AM, by overlapping it over the pancreo-jejunal anastomosis.
10170593|NCT03891186|Experimental|Experimental Group|"Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the treatment as usual (TAU)."
10170594|NCT03891186|Active Comparator|Control Group|The control group will not participate in the MCT program. In both groups will be maintained the TAU.
9671955|NCT05041517|Experimental|BOLT + 4 PTC|BOLT Training + 4 PTC Calls
10170595|NCT03891069|Experimental|Interventional arm|Participants will be invited to play the five different Exergames, for a total of 5 minutes.
10170596|NCT03891030|Experimental|Checklist Based Box system|Pregnant mothers will receive scheduled person-centered health educations starting from: they are identified as suspected pregnant mother up to attending their third PNC visit. In between the first ANC and the third PNC drop out tracing mechanisms will be applied, for mothers who fail to utilize the recommended maternal health services.
10170597|NCT03891030|No Intervention|Routine maternal health care|Pregnant mothers in this arm will receive the usual routine maternal health care.
10170598|NCT03891212|Experimental|The prone group|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
10170599|NCT03891212|No Intervention|The supine group|Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
10170600|NCT03891238|Experimental|Avelumab Arm|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
10170601|NCT03890952|Experimental|Arm B Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients not undergoing salvage surgery
10170602|NCT03890952|Experimental|Arm A Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients undergoing salvage surgery
10170603|NCT03891173|Experimental|L-DOS47 in combination with cisplatin + vinorelbine|L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.
10170604|NCT03891173|Active Comparator|Cisplatin + vinorelbine alone|Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.
10170605|NCT03890965|Experimental|Experimental|Adult patients with chronic sequelae in the upper limb after neurological damage
10170606|NCT03890978|Experimental|intervention|The intervention group will receive EBF promotional messages from the time of discharge until 6 months post delivery.
10170607|NCT03890978|Other|control|the control group will receive child health care-related messages (except breastfeeding messages) from the time of discharge until 6 months post delivery.
10170608|NCT03890757||serratus anteriorblock|Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe
10170609|NCT03890835|Active Comparator|Mineral Trioxide Aggregate (MTA)|
10170610|NCT03890835|Experimental|Biodentine|
10170611|NCT03890848|Experimental|Wechat application intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
10170612|NCT03890848|Active Comparator|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
10170613|NCT03891056|Active Comparator|Gastric bypass|Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
10170614|NCT03891056|Active Comparator|Slevee gastrectomy|Twenty patients will be randomly assigned to perform a sleeve gastrectomy
10170615|NCT03890809|Experimental|Normal liver function|Single dose
10170616|NCT03890809|Experimental|Mild liver impairment|Single dose
10170617|NCT03890809|Experimental|Moderate liver impairment|Single dose
10170618|NCT03890809|Experimental|Severe liver impairment|Single dose
10170619|NCT03890692|Experimental|patients will undergo flexible nasoendoscopy|Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
10170620|NCT03891121|Experimental|Occlusal splint|Patients were treated with occlusal splint.
10170621|NCT03891121|Experimental|Botulinum toxin|Patients were treated with botulinum toxin injection.
9671956|NCT05041478|Experimental|Cold EMR with adjuvant STSC to margins|Standard cold EMR technique with adjuvant snare tip soft coagulation to defect margins
9671957|NCT05041478|Active Comparator|Cold EMR|Standard Cold EMR resection technique
10170622|NCT03891121|Experimental|Both|Patients were treated with occlusal splint and botulinum toxin injection together.
10170623|NCT03890783||Patients after surgery of oropharyngeal cancers|Patients after surgery of oropharyngeal cancers with soft palate with free flap reconstruction and adjuvant radiotherapy
10170624|NCT03891199|No Intervention|Control|Traditional THA.
10170625|NCT03891199|Active Comparator|Intervention|Robotic-arm assisted THA.
10170626|NCT03890640|Experimental|Ultrasound-guided TECI|After assessment of the epidural space using the loss of resistance technique with saline under ultrasound guidance, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
10170627|NCT03891043|Placebo Comparator|Group A, Placebo group|Placebo consisted in a pill of 100 micrograms of starch, to be taken twice a day.
10170628|NCT03891043|Experimental|Group B, Selenium group|Selenium consisted in a pill of 100 micrograms, to be taken twice a day.
10170629|NCT03890770|Experimental|Normal renal function|Single dose
10170630|NCT03890770|Experimental|Mild renal disease|Single dose
10170631|NCT03890770|Experimental|Moderate renal failure|Single dose
10170632|NCT03890770|Experimental|Severe renal failure|Single dose
10170633|NCT03890770|Experimental|End-stage renal disease requiring dialysis|Two single doses administered with washout
10170634|NCT03890341|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-64530440|Participants will receive single oral dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and midazolam 2 mg with under fed conditions (high fat meal) on Day 1 followed by JNJ-64530440 2,000 mg on Days 6 under fasted conditions ; JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg under fed conditions on Day 13; JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) from Days 14 to 18; single oral dose of JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg on Day 19 under fed conditions (high fat meal); and JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) on Days 20 to 22.
10170635|NCT03890302|Experimental|Cohort A|0.5 mg/kg study drug, or placebo, administered once
9521348|NCT04150354|Experimental|Participants allocated to Cogito Companion|Participants will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators.
10170636|NCT03890302|Experimental|Cohort B|2 mg/kg study drug, or placebo, administered once
10170637|NCT03890302|Experimental|Cohort C|4 mg/kg study drug, or placebo, administered once
10170638|NCT03890302|Experimental|Cohort D|8 mg/kg study drug, or placebo, administered once
10170639|NCT03890302|Experimental|Cohort E|Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).
10170640|NCT03890562|Experimental|Auricular acupressure for NAS infants|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
9521349|NCT04149899|Experimental|Study Treatment 1|WB007 Formulation 1
9521350|NCT04149899|Experimental|Study Treatment 2|WB007 Formulation 2
9521351|NCT04149899|Experimental|Study Treatment 3|WB007 Formulation 3
9521352|NCT04149899|Active Comparator|Timolol 0.5%|Timolol maleate ophthalmic solution, 0.5%
9521353|NCT04119271|Other|Breathe Easy at Home Kit Products|"Families will be provided with a Breathe Easy at Home Kit. These kits will include:~a HEPA filtered upright vacuum cleaner, a HEPA-filtered Air Purifier, a Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control, and a combination of safe products to locate and kill roaches."
9521354|NCT04075253|Experimental|VO2 peak test|All participants enrolled in the planned study on physical activity and ventricular arrhythmias and on baseline will complete an exercise treadmill test to determine VO2 peak
10170641|NCT03890393||patients with episodic headache|
10170642|NCT03890393||patients with chronic headache|
9521355|NCT04070300|Experimental|Interval training group|Aerobic interval training during 12 weeks 3 times a week.
10170643|NCT03890393||healthy controls|
10170644|NCT03890653|Experimental|Performance-Based Financing|At least one primary healthcare centre per ward and one General Hospital per selected LGA (in 50% of LGAs in each of the 3 states) and one secondary hospital per State will be contracted by the State Primary Health Care Development Agency ) , to deliver specified services at an agreed price. Selection of which services to focus on is based on priorities identified by the Federal Government of Nigeria and the states in 2010-2015. Initial prices for each service were based on shadow prices of providing the service and have been adjusted based on implementation experience.
10170645|NCT03890653|Experimental|Decentralized Facility Financing|In the other half of the LGA's in each treated state, at least one facility per ward will receive Decentralized Facility Financing (DFF) or equivalent financing that is not be linked to any service delivery targets. These payments would be made on a quarterly basis.
9521356|NCT04070300|No Intervention|Control group|No lifestyle recommendations. Usual daily life.
10170646|NCT03890653|No Intervention|Control|This is a pure control arm with no additional interventions.
10170647|NCT03890406|Experimental|Group D|Deep neuromuscular blockade
10170648|NCT03890406|Active Comparator|Group M|Moderate neuromuscular blockade
9521357|NCT04098445||Pediatric and young adult HSCT recipients|Prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).
9521358|NCT04046263|Experimental|Intervention|Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.
9521359|NCT04046172|Experimental|test group|intensive periodontal treatment (IPT)
9521360|NCT04046172|Sham Comparator|control group|Control periodontal treatment (CPT)
9521361|NCT04028414|Experimental|Early Weight Bearing|Patients with ankle fractures will be instructed to weight bear as tolerated (WBAT) while in a boot with a heel to toe normal gait and wean from walker or crutches to a cane or no support device. At the 6 week post op visit, patients with ankle fractures will be instructed to wean from the boot and continue full weight bearing as tolerated until full weight bearing is achieved. Patients with plateau fractures will be instructed to begin WBAT until full weight bearing is achieved.
10170649|NCT03890471|Experimental|Preoperative telephone call|Patients will receive routine preoperative counseling in the clinic plus a provider initiated telephone call 3 days before surgery.
10170650|NCT03890471|No Intervention|No preoperative telephone call|Patients will receive routine preoperative counseling in the clinic.
10170651|NCT03890549||obstructive sleep apnea group|The patients were diagnosed by thoracic and ENT (Eye-Nose-Throat) specialist through polysomnography.
9521362|NCT04028414|No Intervention|Delayed Weight Bearing|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
9521363|NCT03996720||severe sepsis|patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay
9521364|NCT03996720||sepsis|patients recover from sepsis without developing into organ dysfunction
9527762|NCT03217162|Experimental|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
9527763|NCT03217162|Active Comparator|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
9521365|NCT03995537||Patients with severe liver disease waiting liver transplant|Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.
9521366|NCT03982602|Experimental|Subjects on Ketogenic diet|Treatment with KD will consist of 4:1 [fat]: [protein + carbohydrate] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
9527764|NCT03216811|Experimental|nutraceutical|after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones
9527765|NCT03216759|No Intervention|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
9527766|NCT03216759|Experimental|intervention|"After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.~At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.~Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
10170652|NCT03890510|Active Comparator|Low PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 6~9% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
10170653|NCT03890510|Active Comparator|High PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 13~16% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
9527767|NCT03216733|Experimental|COMBO|PCI with COMBO stent
9527768|NCT03216733|Active Comparator|ORSIRO|PCI with ORSIRO stent
9527769|NCT03216889|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6 weeks of CBT-I.
9527770|NCT03216889|Active Comparator|Control|6 weeks of stretching and thinking games.
9527771|NCT03216837|Experimental|Cathodal Transcranial direct current stimulation|Cathodal tDCS
9527772|NCT03216837|Sham Comparator|Sham Transcranial direct current stimulation|Sham
9527773|NCT03216928|Experimental|Group 1|patients with good response to anti-TNF had a blood test
9527774|NCT03216928|Experimental|Group 2|patients with moderate or non-response to anti-TNF had a blood test
9527775|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
9527776|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
9527777|NCT03216863|Experimental|8 weeks Respiratory rehabilitation|
9975130|NCT04585009|Experimental|Cohort 1:Placebo / GSK3923868 100 mcg/ GSK3923868 250 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 100 mcg/GSK3923868 250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
10170654|NCT03890796|Experimental|Dementia Care Education and Activity Scheduling Group (DE&AS)|Will received both dementia care education and activity scheduling
10170655|NCT03890796|Sham Comparator|Dementia Care Education Group (DE)|Will received dementia care education
10170656|NCT03890627||Thoracic bio-reactance measurement of cardiac output|
9975131|NCT04585009|Experimental|Cohort 2:Placebo / GSK3923868 1000 mcg/ GSK3923868 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 1000 mcg/GSK3923868 3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
9527780|NCT03216980|Experimental|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
9527781|NCT03216980|Placebo Comparator|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
9527782|NCT03216980|Experimental|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
9527783|NCT03216980|Placebo Comparator|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
9527784|NCT03217019|Experimental|Guidewire|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion with guidewire-assist. (Catheter over guidewire)"
9527785|NCT03217019|Active Comparator|Direct|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion without guidewire-assist. (Catheter over needle)"
9527786|NCT03216876|Experimental|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
9527787|NCT03216876|Experimental|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
9527788|NCT03216876|Experimental|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
9527789|NCT03217058||Pre-implementation|The pre-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
10170657|NCT03890328|Experimental|RF group|radiofrequency-assisted spleen-preserving therapy group.
10170658|NCT03890328|No Intervention|CT group|Conventional Treatment of Blunt Splenic Injury group.
9521367|NCT03960827|No Intervention|Sedentary control|The control group does not engage in any acute exercise testing protocol.
9521368|NCT03960827|Active Comparator|Sedentary EE|Participants randomized to ET first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
9521369|NCT03960827|Active Comparator|Sedentary RE|Participants randomized to RT first engage in a single acute exercise test of Resistance Exerciser, consistent with their random assignment.
10170659|NCT03890588|Experimental|CKD enhanced clinical decision support (CKD-CDS Intervention)|Priority Wizard CDS tool is enhanced to incorporate chronic kidney disease(CKD) management. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CDS also provides CV risk factor management like the basic Priority Wizard present in the usual care arm.
9521370|NCT03960827|No Intervention|Highly Active EE|A comparison group of highly active EE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Endurance Exerciser (HAEE) participants are tested on a cycle ergometer.
9521371|NCT03960827|No Intervention|Highly Active RE|A comparison group of highly active RE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Resistance Exerciser (HARE) participants are tested via a bout of resistance exercise.
9521372|NCT03974204|Experimental|Cerebrospinal fluid and Blood sample collection|"Collection of cerebrospinal fluid and blood samples:~At initial diagnostic assessment;~1 month and 3 months after initial diagnostic assessment, for patients classified possible, probable or confirmed according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;~In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified lack of evidence according to EANO-ESMO classification."
10170660|NCT03890588|No Intervention|Usual Care|A basic Priority Wizard CDS tool for cardiovascular (CV) risk factor management (previously know as the CV Wizard) includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. Has no decision support specific to CKD care.
9521373|NCT03948048||septic shock|The critically ill children with septic shock (ss group)
9521374|NCT03948048||refractory septic shock with ECMO|The critically ill children with refractory septic shock with ECMO treatment
9521375|NCT03948048||refractory septic shock without ECMO|The critically ill children prediction model th refractory septic shock without ECMO treatment
9521376|NCT03919669|Experimental|All Subjects|"All subjects will complete PET imaging sessions evaluating the tau PET radioligand [18F]MK-6240 at baseline, as well as at 6, 12 and 24 months post-baseline.~If unable to complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may instead be scheduled, totaling a maximum of four time points."
9521377|NCT03921320|Active Comparator|Bilateral sympathectomy|Bilateral sequential (one surgical procedure) videothoracoscopic R4 sympathectomy
9521378|NCT03921320|Experimental|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the right (dominant) side
9521379|NCT03921320|Experimental|Contralateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the left (contralateral) side
9521380|NCT03917433|Experimental|Exposure with Tactile Feedback|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
9521381|NCT03917433|Experimental|Exposure with Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. The participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
10170661|NCT03890380|Experimental|Magneto Wire|Patients treated with Magneto Wire
9521382|NCT03917433|Experimental|Exposure with Tactile Feedback and Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world. Also, the participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
9521383|NCT03917433|Other|Virtual Reality Exposure Therapy Alone|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
9521384|NCT03920527|Active Comparator|Six months|Six months of itraconazole
9521385|NCT03920527|Experimental|12 months|12-months of itraconazole
9521386|NCT03918460|Experimental|Intervention|All patients enrolled are intended to be treated
9521387|NCT03918980|Experimental|Part 1 Dose A|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
10170662|NCT03890315||Neuropathic pain|Adult patients with upper extremity neuropathic pain due to radiculopathy Duration of >1 month Unilateral extremity pain will be recruited
10170663|NCT03890315||Control|Age and gender matched control patients will also be recruited to show whether differences exist in outcome measures.
9521388|NCT03918980|Experimental|Part 1 Dose B|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
9521389|NCT03918980|Experimental|Part 1 Dose C|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
9521390|NCT03918980|Experimental|Part 1 Dose D|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
10170664|NCT03890523|Experimental|Segmented Airway Stent for Gastro-Respiratory fistula|Segmented covered metallic airway stent modified with 3D printing was used for gastro-respiratory fistula.
10170665|NCT03890458|Experimental|Experimental|
10170666|NCT03890458|No Intervention|Control|
9975132|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ Placebo/ 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/Placebo/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
9521391|NCT03918980|Experimental|Part 1 Dose E|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
10170667|NCT03890575|Experimental|Airway Stent for Malignant Stricture|Patients with malignant stricture were implanted with covered metallic segmented stent modified with 3D printing.
9521392|NCT03918980|Experimental|Part 1 Dose F|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
9521393|NCT03918980|Experimental|Part 1 Dose G|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
9521394|NCT03918980|Experimental|Part 1 Dose H|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
9521395|NCT03918980|Experimental|Part 1 Dose I|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
9521396|NCT03918980|Experimental|Part 1 Dose J|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
9521397|NCT03918980|Placebo Comparator|Part 1 Placebo|(Single Ascending Dose) Healthy volunteers will receive a single dose of placebo.
9826583|NCT02423798|Other|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
9975133|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ 1000 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/Placebo. There will be at least 10 days of wash-out period between doses for each participant.
9975134|NCT04585009|Experimental|Cohort 2:GSK3923868 500mcg/ 1000mcg/ 3000mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
9975135|NCT04585009|Experimental|Cohort 3: Participants receivings repeated doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
9975136|NCT04585009|Experimental|Cohort 4: Participants receiving repeat doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
10170668|NCT03890263|Experimental|Opioid deprescribing and self-management|
10170669|NCT03890276|Active Comparator|HMS EL&C training without video|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will be able to: 1) distinguish normal and abnormal findings, 2) competently and confidently manage normal labor and birth to help prevent complications, 3) employ evidence-based practices, 4) rapidly identify and manage complications when they arise and 5) provide respectful care
10187918|NCT03721419|Active Comparator|Low Flow High Humidity Device|Low Flow High Humidity device arm patients will be placed on a Low Flow device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen.
9521398|NCT03918980|Experimental|Part 2 Dose K|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
9521399|NCT03918980|Experimental|Part 2 Dose L|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
9521400|NCT03918980|Experimental|Part 2 Dose M|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
9521401|NCT03918980|Experimental|Part 2 Dose N|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
9521402|NCT03918980|Experimental|Part 2 Dose O|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
9521403|NCT03918980|Experimental|Part 2 Dose P|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
9521404|NCT03918980|Placebo Comparator|Part 2 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo once daily for 12 days
9521405|NCT03918980|Experimental|Part 3 Dose Fasted|Healthy volunteers will receive a single dose of LOU064 given under fasting conditions followed by a single dose of LOU064 given after a high fat meal (cross-over design).
9521406|NCT03918980|Experimental|Part 3 Dose Fed|Healthy volunteers will receive a single dose of LOU064 given after a high fat meal followed by a single dose of LOU064 given under fasting conditions (cross-over design).
9826584|NCT02423980|Experimental|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
9975137|NCT04585009|Experimental|Cohort 5: Participants receiving repeat doses of GSK3923868|Participants with stable asthma will receive a planned repeat dosing of 3000 mcg (six capsules) GSK3923868 daily for 7 days
9975138|NCT04581057|Experimental|First CVE|
9975139|NCT04580953|Experimental|Treatment with CardiaCareTM RR2|
9975140|NCT04577755|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with complete response, partial response, or stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
9975141|NCT04576715|Experimental|TEaM Intervention Group|Dedicated Provider Education plus Information Technology Support. The IT support includes addition of an eMR concussion screening, followed by an alert to the provider, followed by a structured assessment / evaluation template.
9975142|NCT04576715|Active Comparator|Control Group|Standard medical protocol for the management of mTBI in children. This group will not receive interventional Provider Training on the TEaM concussion evaluation examination and utilization of the eMR template.
9975143|NCT04565899|Experimental|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
9521407|NCT03918980|Experimental|Part 4 Dose R|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
9521408|NCT03918980|Experimental|Part 4 Dose S|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
9521409|NCT03918980|Placebo Comparator|Part 4 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo twice daily for 12 days
9521410|NCT03918980|Experimental|Part 5 Formulation A|Healthy Volunteers will receive a single dose of LOU064 formulation A followed by a single dose of LOU064 formulation B (cross-over design).
9521411|NCT03918980|Experimental|Part 5 Formulation B|Healthy Volunteers will receive a single dose of LOU064 formulation B followed by a single dose of LOU064 formulation A (cross-over design).
10170670|NCT03890276|Experimental|HMS training with video supplementation|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will ALSO receive the training with interspersed with short video clips that that aim to improve understanding and skills acquisition ('Videos used to supplement live trainer'). Video supplementation is meant to standardize the cascaded training in the future as the training is offered at a much larger scale in low and middle income countries.
9521412|NCT03918980|Experimental|Part 6 Dose T|Subjects with atopic dermatitis will receive a twice daily dose of LOU064 for 4 weeks
9521413|NCT03918980|Placebo Comparator|Part 6 Placebo|Subjects with atopic dermatitis will receive a twice daily dose of placebo for 4 weeks
9521414|NCT03910218|Experimental|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring,Pre exposure prophylaxis (PrEP) eligibility screening,PrEP/non occupational post exposure prophylaxis(nPEP)services (labs, medication), healthcare planning/coordination, Motivational Interviewing (MI) counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
9521415|NCT03910218|Placebo Comparator|Usual care|Participants will receive the usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling,substance use treatment referrals,PrEP/nPEP referrals
9521416|NCT03905876|Other|assessment of psychological experience|Questionnaire
9521417|NCT03903120|Experimental|ASSIST|Study 1 and 2
9521418|NCT03903120|No Intervention|Delayed Control|Study 1 and 2
9521419|NCT03903120|Experimental|Massed ASSIST|Study 3
9671958|NCT05041452||Noncirrhotic portal hypertension (NCPH)|Patients with non-cirrhotic portal hypertension (NCPH) with pre-sinusoidal (e.g., porto-sinusoidal vascular disease, portal vein obstruction, congenital hepatic fibrosis, biliary diseases,), sinusoidal (e.g., sinusoidal destruction in the setting of acute hepatic injury, inflammatory or toxic fibrosis, non-alcoholic steatohepatitis), or post-sinusoidal causes (Budd-Chiari syndrome, sinusoidal obstruction syndrome).
9671959|NCT05041452||Cirrhotic portal hypertension|Patients with cirrhosis and portal hypertension.
9521420|NCT03903120|Experimental|Distributed ASSIST|Study 3
9521421|NCT03902509|Experimental|Pirfenidone|pirfenidone + basic treatment
10170671|NCT03890107||Pediatric tympanostomy tube patients|Patients diagnosed with otitis media and scheduled for tympanostomy tube placement will be imaged with the OtoSight
10170672|NCT03890120|Experimental|Blinded Phase: Cilofexor|Cilofexor for 96 weeks
9521422|NCT03902509|Other|Controll|with basic treatment and without pirfenidone treatment
9671960|NCT05041296||Chronic group|Chronic epilepsy with recurrent seizures
9671961|NCT05041296||Acute group|Epilepsy and short-term history of seizures
10170673|NCT03890120|Placebo Comparator|Blinded Phase: Placebo|Placebo for 96 weeks
9521423|NCT03874546|Experimental|Prognostic evaluation|Questionnaire at Day1, Day7 and 6 months.
10170674|NCT03890120|Experimental|Open-Label Phase: Cilofexor|Cilofexor for 96 weeks
10170675|NCT03890224|No Intervention|Control group|no home non-invasive ventilation (NIV), only hospital NIV
9521424|NCT03873480|Active Comparator|Intervention Arm|Participants randomized into the intervention group will receive an injection of 2.5 cc of 0.25% marcaine without epinephrine prior to the incision. The local anesthetic will be administered by the treating surgeon. All other aspects of the procedure will be kept in accordance with the standard of care for trigger thumb surgeries.
9521425|NCT03873480|No Intervention|Non-Intervention Arm|Those that are not randomized into the intervention group will receive the standard of care for a trigger thumb release, which is administration of 2.5 cc of 0.25% marcaine without epinephrine following completion of surgery. The local anesthetic will be administered by the treating surgeon.
9527790|NCT03217058||Post-implementation|The post-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
9671962|NCT05041296||Control group|Healthy participants
10170676|NCT03890224|Active Comparator|Non-targeted home NIV|Nocturnal home non-invasive ventilation (NIV)
10170677|NCT03890224|Active Comparator|Targeted home NIV|Nocturnal home non-invasive ventilation (NIV) with high monitoring
10170678|NCT03890224|Active Comparator|Rescue home NIV|home non-invasive ventilation (NIV) on demand
10170679|NCT03890094||Sufentanil and Midazolam|Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study.
9671963|NCT05041192|Experimental|Synaquell Group|Subjects will receive the dietary supplement, Synaquell, twice-daily during the hockey season.
9671964|NCT05041192|Placebo Comparator|Placebo Group|Subjects will receive the placebo twice-daily, during the hockey season.
9671965|NCT05041153|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib PO QD, Treatment repeats every 42 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
9671966|NCT05041127|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.
9521426|NCT03885401|Experimental|Enhanced care planning|The intervention consists of two components - enhanced care planning and clinical-community linkages. The enhanced care plan is created using MOHR (https://myownhealthreport.org). MOHR screens patients for unhealthy behaviors, mental health needs, and social needs. Patients identify the needs they would like to address and create a care plan, which they update quarterly. A clinical navigator and community health worker (CHW) help patients address their care plans using clinical-community linkages, which has four components. First, clinicians and clinical navigators have a resource registry identifying community programs and support - No Wrong Door (NWD) and https://navigator.aafp.org/. Second, MOHR shares information (care plans, patient narrative, and patient progress) across clinical and community team members. Third, MOHR supports messaging and video visits for team members and patients. Finally, MOHR sends care team members quarterly patient progress updates.
9521427|NCT03885401|No Intervention|Usual medical care|"Clinicians randomized to the control condition will continue to provide usual care. This includes current non-systematic assessment of health behaviors, mental health needs, and social needs. Neither clinicians nor patients will be eligible to receive CHW support or have access to NWD. Clinicians may refer some control patients to community programs as part of their current usual care. Control clinicians will be blinded as to which patients are included in the study. At the end of the study, the investigators will share with control clinicians our lessons learned, access to MOHR, and lists of useful community resources."
9671967|NCT05041270|Placebo Comparator|control group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
9671968|NCT05041270|Active Comparator|dexmedetomidine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)
9671969|NCT05041270|Active Comparator|nalbuphine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)
10170680|NCT03890055|Experimental|Clinical trial group|（Carboplatin/cisplatin + etoposide）+ （Anlotinib Hydrochloride 12 mg/day ，Each cycle was defined as 2 weeks on-treatment fol- lowed by 1 week off-treatment）, after 4-6 cycles of treatment, the treatment was continued with anlotinib until disease progression.
9521428|NCT03862066||Received Nivolumab|
9521429|NCT03862066||Nivolumab Naive|
9521430|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
9521431|NCT03877276|Experimental|5d Diet+Spinach Smoothie+Breakfast|5 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
9521432|NCT03877276|Experimental|3d Diet+Kale Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On the final day, participants will return to the study site and drink a prepared kale smoothie and be provided a breakfast meal.
9521433|NCT03877276|Experimental|3d Diet+V Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie with varying amounts of spinach and be provided a breakfast meal.
9521434|NCT03877276|Experimental|3d Diet+Blended Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended smoothie and be provided a breakfast meal.
9521435|NCT03877276|Experimental|3d Diet+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and be provided a breakfast meal.
10170681|NCT03890068|Experimental|anlotinib|anlotinib for maintenance treatment a dose of 12 mg once daily (day1-14 PO) in 21-day cycles
9521436|NCT03877276|Experimental|3d Diet+Sodium Oxalate Drink+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared sodium oxalate drink and be provided a breakfast meal.
10170682|NCT03889990|Other|healthy smokers|"Healthy smokers males, aged >18years, with >10 pack/years,receiving no medications~Intervention: the use of an IQOS"
9521437|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast w/ 24 Hr Urine|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a blended spinach smoothie and be provided a breakfast meal.
9671970|NCT05041413|Experimental|Moms Quit Intervention|12 weeks of the Moms Quit text message intervention
9671971|NCT05041413|Active Comparator|Text4Baby|12 weeks of Text4Baby messages
9826585|NCT02423993|Experimental|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
10170683|NCT03890198|Experimental|chimeric Antigen Receptor T cell|LCAR-C182A Cells
10170684|NCT03890159|Experimental|Computer Assisted Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours, and patients will progress to the difficulty level automatically. Their performance during this process (response time etc.) will be recorded.
10170685|NCT03890159|Experimental|Conventional Cognitive Rehabilitation|The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests.
10170686|NCT03890159|No Intervention|Waiting list controls|These patients will get no intervention as means of cognitive rehabilitation, but will get their usual treatments.
10170687|NCT03890237|No Intervention|Control|Business as usual, no intervention
10170688|NCT03890237|Experimental|Her Spaces|Starts in year 1; intervention package with 11-13 year old girls for 10 months; standard parental and community engagement. All programming ends after 10 months.
10170689|NCT03890237|Experimental|Act With Her|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
9521438|NCT03852862|Experimental|Serratus plane block with paravertebral block|Association of Serratus plane block and paravertebral block for anesthesia
9521439|NCT03852862|Active Comparator|paravertebral block alone|Paravertebral block for anesthesia
9521440|NCT03854370|Experimental|Baby shampoo|Baby shampoo used for surgical site prep
9521441|NCT03854370|Active Comparator|Peridex (Chlorhexidine)|Peridex used for surgical site prep
10170690|NCT03890237|Experimental|Act With Her + Asset Transfer|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; asset transfer for girls over 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
9521442|NCT03854370|Active Comparator|TechniCare (chloroxynel)|TechniCare used for surgical site prep
9521443|NCT03854370|Active Comparator|Betadine (Povidone- iodine)|Betadine used for surgical site prep
9521444|NCT03849651|Experimental|Transplant participants|"Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.~Cells for infusion are prepared using the CliniMACS system."
9521445|NCT03844087|Experimental|multiplanar neuromuscular training arm|The intervention arm will be involved in the training intervention outlined. Briefly, each participant will be asked to train on the TopSpin360 3 times per week for 3-5 sets for the duration of the study. Each set will take roughly 15-30 seconds to perform and training will take part during regularly scheduled training sessions.
9521446|NCT03832790||adolescents with type 1 diabetes|Adolescents ages 14-19 with type 1 diabetes
9521447|NCT03821883|Experimental|Aspirin group|Study patients assigned to Aspirin group will receive enteric coated aspirin (100 mg/day).
9521448|NCT03821883|Placebo Comparator|Control group|Study patients assigned to control group will receive placebo.
9521449|NCT03799705||History of VACTERL or congenital malformations|1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.
9521450|NCT03800017|Experimental|Hyperoxia|During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.
9671972|NCT05041283|No Intervention|Standard Preparation|Control arm; patients receive a standard support for bowel preparation consisting of a explanatory dialogue with a gastroenterologist and a brochure with a structurated description of bowel preparation and colonoscopy conduct
9671973|NCT05041283|Active Comparator|Phone-call Supported Preparation|In addition to standard preparation, patients receive a phone call every day starting at 3 days before colonoscopy in which a investigator explains key points of bowel preparation and patients can ask questions concerning bowel preparation and colonoscopy conduct.
10170691|NCT03890237|Experimental|Act With Her (simple)|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; does not include community-level systems strengthening. All programming ends after 10 months.
10170692|NCT03890211|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, the mother will be encouraged to provide KMC whenever possible. For hypothermic infants, if the temperature is not rising by ½°C per hour with KMC alone, the Infant Warmer will be offered as an addition. In these cases, the heat will be provided by placing the Infant Warmer over the infant's back while the mother provides KMC. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the Infant Warmer by being placed directly on the warmer as it lies flat. Use of hat and socks will be encouraged by additional clothes will only be added in addition to the warmer per caregiver request, as it reduces heat transfer.
10170693|NCT03890211|No Intervention|Control|Data such as infant temperature, date of birth, etc. will be collected from those who enroll in the control group. No experimental intervention will be administered.
10170694|NCT03889717|Experimental|400 iu|neonates who will receive vitamin d dose at 400 iu per day
10170695|NCT03889717|Active Comparator|1000 iu|neonates who will receive vitamin d dose 1000 iu per day
10170696|NCT03889808||Non immunosuppressed patients|without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.
10170697|NCT03889808||Patients with immunosuppressive therapy|Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.
10170698|NCT03889808||Patients with biologic agents|in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.
9671974|NCT05041283|Experimental|Chatbot Supported Preparation|In addition to standard preparation, patients receive an access to a chatbot which can be contacted via Whats App starting at 3 days before colonoscopy. The chatbot is programed to answer questions concerning bowel preparation and colonoscopy conduct.
9975144|NCT04563273|Experimental|Healthy people aged 18-45|Healthy people aged 18-45 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
9671977|NCT05041114|Other|Single|Implantation of motor neuroprosthesis medical device.
9521451|NCT03800017|Placebo Comparator|Healthy Controls|During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.
9527791|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
9671978|NCT05041244|Experimental|Interventional arm|NPWT will be delivered through devices (ActiVac and InfoVac) according to FDA protocol in conjunction with the polyurethane foams. Dressing changed will be on a weekly basis.
9671979|NCT05041244|Other|Control|Standard of care Participants will be given the standard care provided in specialist foot care clinics or in-patients.
10170699|NCT03889808||Patients with steroid treatment|Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.
10170700|NCT03889808||Healthy subjects|A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.
10170701|NCT03889821|Active Comparator|Child-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM).
10170702|NCT03889821|Experimental|Child- and Parent-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM). Parents also participate in 6 separate, individual sessions of Mindfulness Based Stress Reduction (MBSR).
10170703|NCT03889847|Experimental|silicone DLT|Fibreoptic intubation with silicone double lumen tube
10170704|NCT03889847|Experimental|PVC DLT|Fibreoptic intubation with PVC double lumen tube
10170705|NCT03890042|Active Comparator|Dienogest group|
10170706|NCT03890042|Active Comparator|Gynera group|
10170707|NCT03889886|Placebo Comparator|Vehicle|Vehicle
10170708|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (0.1%)|Low concentration of SDP-4
10170709|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Mid concentration of SDP-4
9521452|NCT03787966|Experimental|ATOPE-B|An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
9521453|NCT03787966|Active Comparator|ATOPE-I|An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
9521454|NCT03764995|Experimental|Abdominal Massage|
9521455|NCT03764995|Placebo Comparator|Placebo Ultrasound|
9521456|NCT03761394|Experimental|Intervention Group|Testing devices plus Cardea Solo device by Cardiac Insight for 14-day period.
9521457|NCT03761394|Active Comparator|Control Group|Only Cardea Solo device by Cardiac Insight for 14-day period.
9521458|NCT03761394|Experimental|Intervention Group for Extended Use|30-additional days of extended use of testing devices for adherence plus Kardia Mobile ECG device by AliveCor.
9521459|NCT03761394|No Intervention|Control Group for Extended Use|No device usage for 30-days following completion of the original 14-day period.
9521460|NCT03739905|Experimental|Blood Brain Barrier (BBB) Disruption|The ExAblate Model 4000 Type 2.0 System
9521461|NCT03752684|Experimental|Low Oxalate Diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a low oxalate diet to determine baseline oxalate values in urine and plasma.~Subjects will be colonized with Oxalobacter formigenes (Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
9521462|NCT03752684|Experimental|Moderately high oxalate/low calcium diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a moderately high oxalate/ low calcium oxalate diet to enhance dietary oxalate absorption.~Subjects will be colonized with Oxalobacter formigenes(Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
9521463|NCT03752684|Experimental|Oxalobacter formigenes|Subjects will ingest a liver preparation of O.formigenes
9521464|NCT03721120|Experimental|Liquid biopsy|Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.
9527792|NCT03216993|Experimental|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
9671980|NCT05040906|Experimental|H02+ Chemotherapy|Participants received six cycles of H02(375 mg/m2) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
9671981|NCT05040906|Active Comparator|Rituxan+Chemotherapy|Participants received six cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
9671982|NCT05040945|Active Comparator|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy
9671983|NCT05040945|Experimental|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy
10170710|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (3.0%)|High concentration of SDP-4
10170711|NCT03890003|Experimental|AID System Containing Insulin Lispro|The automated insulin delivery (AID) system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a PLGS algorithm, and a continuous glucose monitor (CGM) component.
10170712|NCT03889977|Experimental|Exercise|Resistance exercise 45 min following breakfast
10170713|NCT03889977|No Intervention|Control|No exercise (resting) following breakfast
10170714|NCT03889964||patients with stable COPD|
10170715|NCT03890016||snakebite victims|Victims of snakebite presenting to the Emergency Department of Jubilee Mission Medical College and Research Institute
10170716|NCT03889678||Peripheral IV|Patients with peripheral intravenous line in place undergoing elective surgery
10170717|NCT03889691||Control group|The control group consisted of patients who verbal explanation of the surgical procedure and the potential postoperative complications was given with a written informed consent document
10170718|NCT03889691||Study group|Participants in the study group asked to watch impacted lower third molar extraction video which was previously uploaded to the internet with their own device. This video includes only visual components of the surgery such as anesthesia, incision, extraction and suturing. Patients in the second group were also informed verbally about the surgical procedure-possible postoperative complications and was given with a written informed consent document.
10170719|NCT03889873|Experimental|Drinking; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
9521465|NCT03721120|No Intervention|Cytological or histological sampling|During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.
9521466|NCT03704207|Other|Nasal Nitric Oxide testing and collection of clinical data|Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data
9521467|NCT03698539||Down syndrome who stutter|"This group consists of individuals with Down syndrome who stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures and stutter frequency are investigated in this group."
9521468|NCT03698539||Down syndrome who do not stutter|"This group consists of individuals with Down syndrome who do not stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures are investigated in this group"
9521469|NCT03698539||Typically developing children who stutter|This group consists of typically developing children who stutter. They function as a control group to the individuals with Down syndrome.
9521470|NCT03698539||Typically developing children who do not stutter|This group consists of typically developing children who do not stutter. They function as a control group to the individuals with Down syndrome.
9521471|NCT03691519|Placebo Comparator|Placebo|"During the 18 months placebo-controlled period, participants will ask to consume 3 identical 1g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil) per day. During the following 18-month open-label extension period, placebo subjects are switched to active treatment.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment"
9521472|NCT03691519|Experimental|Omega-3 treatment|During the entire length of the study (that is, both the placebo-controlled and open-label extension periods), participants in the intervention (Omega-3 treatment) arm will ask to consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
9521473|NCT03680846|Other|CMM|Conventional Medical Management
9521474|NCT03680846|Active Comparator|HF10 + CMM|Addition of HF10 therapy to CMM
9521475|NCT03675919|Active Comparator|Control group|The control group will be provided a scale, a step counter as well as access to the online portal and will remain in routine care.
9521476|NCT03675919|Experimental|TeLIPro group|The TeLIPro group will be provided a scale, a step counter, a blood glucose meter with test stripes as well as access to the online portal and will get telemedical coaching.
10170720|NCT03889873|Experimental|Drinking; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
10170721|NCT03889873|Experimental|Drinking; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
9521477|NCT03650816||Alzheimer Disease|"Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
9521478|NCT03650816||Subjective Cognitive impairment|"Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
10170722|NCT03889873|Experimental|Drinking; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
10170723|NCT03889873|Experimental|Smartphone; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
10170724|NCT03889873|Experimental|Smartphone; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
9521479|NCT03626311|Experimental|AKBM-3031|4g/day (2 capsules BID)
9521480|NCT03626311|Placebo Comparator|Placebo|4g/day (2 capsules BID)
9521481|NCT03644160|Experimental|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity with a physiotherapist who has training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
9521482|NCT03644160|No Intervention|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
10170725|NCT03889873|Experimental|Smartphone; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
10170726|NCT03889873|Experimental|Smartphone; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
10170727|NCT03889925|Experimental|Autologous conditioned plasma group|Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.
10170728|NCT03889925|Experimental|Autologous conditioned plasma with hyaluronic acid group|Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.
10170729|NCT03890185|Experimental|A: Chemo+RT low dose|Chemo + Low dose RT: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin (CDDP) 75mg/m2 IV D1 and radiation therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for a total of 2 cycles every 21 days.
9521483|NCT03629080|Experimental|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
10170730|NCT03890185|Active Comparator|B: Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
10170731|NCT03890172||study group|in this group the investigators will be managing diabetic wounds with platelet rich plasma treatment.
9521484|NCT03629080|Placebo Comparator|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
9521485|NCT03629080|Experimental|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
9521486|NCT03629080|Placebo Comparator|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
10170732|NCT03890172||control group|In this group patients will receive the standard treatment in form of debridement and dressing twice weekly
10170733|NCT03889665|Experimental|Suspension training group|
10170734|NCT03889457||Patients with venous thromboembolic disease|Patients with deep vein thrombosis, superficial or muscular vein thrombosis, pulmonary embolism, over 18 years of age.
9527793|NCT03216772|Experimental|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using the Olympus PK Morcellator in PneumoLiner containment device
10170735|NCT03889470|Active Comparator|200 microgram NTG|200 microgram NTG through the radial sheath
10170736|NCT03889470|Placebo Comparator|Saline|Saline infusion through the radial sheath
10170737|NCT03889288|No Intervention|conventional management of postoperative pain|Patients who have had an aortic valve replacement surgery have a conventional management of pain after surgery. The pain is treated by morphine using a patient-controlled analgesia for the administration. Patients are recruiting prospectively or possibly retrospectively. The management is usual, nothing from the conventional care of patients change, only data will be collected.
10170738|NCT03889288|Experimental|Medical device - electronic-pain killer|In addition to the conventional management of postoperative pain, patients benefit from perioperative treatment sessions with medical device. Patients are recruiting prospectively.
10170739|NCT03889496|Other|Scheduled for (partial) pancreatectomy or Whipple procedure|I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan
10170740|NCT03889392||polycystic kidney disease|Adult autosomal dominant polycystic kidney disease patients who received kidney transplantation at Asan Medical Center between 1994 and 2018
10170741|NCT03889535|Active Comparator|Resin strip crowns|Current standard full coverage restoration provided for primary incisors. Please see intervention section for detailed description of technique.
9521487|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Prophylactic Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
9521488|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Preemptive Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
9521489|NCT03611569|Experimental|Lu AF82422|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
9521490|NCT03611569|Placebo Comparator|Placebo|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
10170742|NCT03889535|Experimental|Zirconia crowns|Experimental treatment under study. Zirconia crowns are an alternative restorative option. Please see intervention section for detailed description of technique.
10170743|NCT03889379|Experimental|Effects of Albuterol on Immune Cell Composition|This is a single subject repeated measure experimental design with each participant acting as his/her own control.
10170744|NCT03889483|Other|NeuroCatch™ Platform Assessment|All participants will undergo two NeuroCatch™ Platform Assessments.
9521491|NCT03605277|Experimental|Normal renal function|healthy volunteers with normal renal function
10170745|NCT03889431|Experimental|Capsule group|Group one received iodine capsule
10170746|NCT03889431|Experimental|Iodized salt group|Group two received iodized salt
9521492|NCT03605277|Experimental|Severe renal impairment|subjects with severe renal impairment
9521493|NCT03605277|Experimental|Moderate renal impairment|subject with moderate renal impairment
9521494|NCT03605277|Experimental|Mild renal impairment|subjects with mild renal impairment
9521495|NCT03590002|Experimental|Electronic ICU Medical Transfer Tool|ICUs allocated to the experimental arm will have access to the electronic Medical Transfer of Care Documentation Tool within the clinical information system (CIS) in order to prepare ICU transfer of care documents for the receiving medical care team.
9521496|NCT03590002|No Intervention|Dictated ICU Medical Transfer|Usual Care, ICUs in the control group will only have access to the dictation documentation system as the standard method to prepare ICU medical transfer documents. New ICU medical staff responsible for preparing transfer documents will receive the usual training on the dictation system.
9521497|NCT03581513|Experimental|IMR<40 and defer PCI|Patients whose IMR<40 undergo stent implantation after an interval of 7±2 days.
9521498|NCT03581513|Active Comparator|IMR<40 and immediately PCI|Patients whose IMR<40 undergo immediately stent implantation.
9521499|NCT03581513|Experimental|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo stent implantation after an interval of 7±2 days.
10170747|NCT03889626|Experimental|Apatinib|In this arm, patients will receive a daily oral treatment with Apatinib 500mg.
9521500|NCT03581513|Active Comparator|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation.
9662217|NCT05077046|Experimental|Control first arm|"Due to the counter-balanced design of this study all participants will experience both an interventional and a control period. Within the control first arm participants will be asked to execute the assessment trial / test battery with the control pen first. After a wash-out period, the participants will execute the same assessment trial / test battery with the intervention pen."
10170748|NCT03889626|Experimental|Capecitabine|In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.
10170749|NCT03889626|No Intervention|Observation|In this arm, no additional treatment will be given, and patients will be followed up at regular time
10170750|NCT03889561|Experimental|Improved Water Access, Promotion, and SSB taxes|Intervention parks will receive installation of water stations, multicultural water promotion campaign, and SSB taxes
10170751|NCT03889561|No Intervention|Control|SSB taxes
10170752|NCT03889587|Experimental|Innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibula bone flaps. In simultaneous innervated group, neurorrhaphy between the ilioinguinal nerve or fibula flap nerve with inferior alveolar nerve or great auricular nerve will be performed.~Intervention: Procedure: Innervation"
9662218|NCT05072067|Experimental|OBESE PATIENT|OverStitch™ Sx with a Single channel endoscop CO2 Insufflation, patient on decubitus dorsal, with intubate 3 to 7 sutures, from the antral ogiv to the cardia are done
9662219|NCT05067673|Placebo Comparator|Control group|Placebo dry needling
9662220|NCT05067673|Experimental|Experimental group|Dry needling
9662221|NCT05066646|Experimental|CT103A in relapsed and refractory multiple myeloma patients|CT103A autologous CAR-T cells will be infused at RP2D of 1.0 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
9662222|NCT05065554|Experimental|ACALABRUTINIB + RITUXIMAB/BIOSIMILAR|"Acalabrutinib and rituximab (or biosimilar) with be contained in the treatment regimen.~Acalabrutinib will be administered twice daily, with 28 consecutive days defined as a treatment cycle. Acalabrutinib will be administered for 48 cycles or until disease progression or unacceptable toxicity.~Rituximab will be administered on Days 1, 8, 15, and 22 of Cycles 1 and 4. Participants will have study visits every cycle for cycles 1-6, then every 3 cycles, with the next visit at Cycle 9, then C12, C15, etc.~Participants will continue acalabrutinib until disease progression or intolerable adverse effect develops. They will be followed for up to 2 years after completion of 48 cycles of treatment or until death"
9662223|NCT05049265|Experimental|JS007|
9975145|NCT04563273|Experimental|Healthy people aged 46-65|Healthy people aged 46-65 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
9975146|NCT04563273|Experimental|Healthy people aged 11-17.|Healthy people aged 11-17 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
9521503|NCT03545464|Experimental|Antihistamines + placebo of cortancyl|"- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.~Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally"
9671984|NCT05041205|Placebo Comparator|Placebo control group|placebo drink powder without active ingredients, 1 sachet per day with 50 ml water for 12 weeks
9671985|NCT05041205|Experimental|Beauty drink powder group|Beauty drink powder is the test article provide to participants, 1 sachet per day with 50 ml water for 12 weeks
9975147|NCT04563273|Experimental|Healthy people aged 6-10|Healthy people aged 6-10 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
9975148|NCT04552925|Active Comparator|Exercise Group|Exercise group will receive ROM exercises, stretching and anterior deltoid re-education exercises described by Levy et al. Subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
10170753|NCT03889587|Active Comparator|Non-innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibular bone flaps. In traditional noninnervated group, neurorrhaphy will not be performed.~Intervention: Procedure: Non-innervation"
10170754|NCT03889327|Experimental|Cognitive Feedback and Psychoeducation (CFP)|Participants assigned to the cognitive feedback and psychoeducation (CFP) treatment group will watch a brief video integrating both neuropsychological test feedback and psychoeducation. The computerized intervention will cover MS disease-related information, define objective cognition, explain neuropsychological assessment, and inform patients of their cognitive test performance outcomes. The CFP intervention will also define and explain perceived cognition and subjective measures of cognition, and compare objective performance on neuropsychological tests to a subjective measure of perceived cognition. The intervention will also discuss emotion, attention, and misattribution related to PCI. The proposed intervention will incorporate expert testimony on MS disease course and related symptomology and interpretations of neuropsychological test performance.
10170755|NCT03889327|Active Comparator|Healthy Eating Habits (HEH)|The control group, healthy eating habits (HEH) group, will watch a brief psychoeducational video of same length in time as the treatment group. The control intervention will include information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The proposed control intervention will include expert testimony from a nutritionist and expert dietician.
9975149|NCT04552925|Experimental|EMG-BF Group|EMG-BF group will receive the same exercises as with the other group, but deltoid re-education exercises were performed under the guidance of EMG-BF device. All subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
9975150|NCT04541108|Experimental|TAK-676, Carboplatin, 5-FU, & Paclitaxel|Patients with HNSCC who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-676, carboplatin, 5-fluorouracil (5-FU), or paclitaxel as single agents or in combination. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
10170756|NCT03889548|Experimental|Mental Imagery|
10170757|NCT03889548|No Intervention|Control|
10170758|NCT03889600|Experimental|REDD-CAT Recipient|The nurse care manager will incorporate the administration of the REDD-CAT to the patient as part of the standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
10170759|NCT03889301|Experimental|E-E Video|Watch E-E video that incorporates health and educational messages
10170760|NCT03889301|Active Comparator|Discussion|Structured discussion about depression and anxiety
10170761|NCT03889262|Active Comparator|Control Group|Participants in this group will receive only Neurodevelopmental therapy (NDT) based rehabilitation for 45 minutes in each session, twice a week, during 8 weeks, 16 sessions in total. Number of participants in this group is anticipated to be 20.
10170762|NCT03889262|Active Comparator|Study Group|After 16 sessions (8 weeks) of only Neurodevelopmental therapy (NDT) based rehabilitation, simulated hippotherapy treatment will be added to rehabilitation program of the same participants. Their NDT treatment will be reduced to 25 minutes whereas hippotherapy will be applied for 20 minutes in each session, 2 sessions a week, 8 weeks in total.
10170763|NCT03889652||Cataract group|"Group 1 includes patients who are planned for cataract extraction without any other preexisting retinal or optic nerve pathology that may affect the RNFL thickness.~OCT (investigation) before and after cataract extraction"
10170764|NCT03889652||Combined cataract and glaucoma group|Group 2 includes patients who are diagnosed with POAG controlled on medical treatment and have cataract and planned for cataract extraction only OCT is done before and after cataract extraction
10170765|NCT03889366|Experimental|NXP001 Oral Capsule|
10170766|NCT03889366|Experimental|NXP001 Oral Suspension|
10170767|NCT03889366|Active Comparator|Emend®|
10170768|NCT03889613|Experimental|all patients|All enrolled patients- prospective observation (all patients are followed using videocapsule)
10170769|NCT03888924|Experimental|BCG treated patients|a single dose of Bacille Calmette-Guerin vaccine
9521504|NCT03545464|Active Comparator|Association of antihistamines and cortancyl|"- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.~Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally"
9521505|NCT03545477|Experimental|Novel treatment, curved-walking training|It consists of 20 sessions of training (three times a week for seven weeks) composed by standard physical therapy and a novel approach to locomotion rehabilitation based on curved-walking training. Each session lasts about 90 minutes.
9521506|NCT03545477|Active Comparator|Usual care|It consists of 20 sessions of training (three times a week for seven weeks) of standard physical therapy and conventional straight-walking training. Each session lasts about 90 minutes.
9521507|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
10170770|NCT03888924|Placebo Comparator|Placebo treated patients|a single dose of placebo.
10170771|NCT03889041||Caregivers of children with EA-TEF|Caregivers of children with esophageal atresia and tracheoesophageal fistula will be included in the study.
9521508|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
9521509|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
9521510|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
9662224|NCT05045950|Experimental|WBRT-PRDR plus memantine.|Study patients will receive WBRT-PRDR within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique. Memantine should ideally start two days (or one day) prior to WBRT PRDR and must start no later than the fourth WBRT PRDR treatment and will continue for a maximum of 24 weeks (≈six months). Memantine will be administered as per standard institutional guidelines.
10170772|NCT03888872|Experimental|Group I|Group I (Study): will consist of 20 patients with diabetic neuropathy and will receive High tone power therapy in addition to selected physical therapy program (Wobble board training, AROM exercises for both UL & LL, gentle manual stretching exercises for both UL & LL and graduated gait training). for 10 sessions every other day, each session for 1.45 hours (60 minutes for HiTop and 45 minutes for selected physical therapy program).
10170773|NCT03888872|Experimental|Group II|Group II (Control): will consist of 20 patients with diabetic neuropathy and will receive selected physical therapy program only same as group I. For 10 sessions every other day, each session for 45 minutes.
10170774|NCT03888950|Experimental|early research PET-CT|The patient will undergo an early research PET-CT after 2 cycles of anti-PD1 (PET1) between the baseline PET-CT and the PET-CT at 3 months of initiation of treatment
10170775|NCT03889054|No Intervention|Control|Current clinical management
10170776|NCT03889054|Active Comparator|Structured health education program|Patient will be referred to a specific consultation to carry out this intervention.
10170777|NCT03888989|Other|Study Phase|Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
10170778|NCT03888846|Other|Colchicine|Colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
10170779|NCT03888846|Experimental|Topical Pentoxifylline Gel and Colchicine|Topical Pentoxifylline Gel administration in addition to the colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
10186910|NCT03731416|Active Comparator|GBR by xenograft ,autogenous bone|Intervention In the control group:first crestal incision then two vertical incisions by blade 15c,full thickness flap reflection, bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area(atrophic maxilla) then covered by a native collagen membrane which will be stabilized by tacks.Then The flap will then be closed using interrupted 4/0 resorbable sutures.
10186911|NCT03731403|Experimental|MI Varnish|
9521511|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
9521512|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
9521513|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
10170780|NCT03888963|Experimental|PRF|
10170781|NCT03888963|Sham Comparator|SHAM|
9521514|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
9662225|NCT05045638|Experimental|Rosuvastatin alone|
10170782|NCT03889145|Active Comparator|Telmisartan, Amlodipine|
10170783|NCT03889145|Active Comparator|Hydrochlorothiazide|
10170784|NCT03889145|Experimental|Telmisartan, Amlodipine, Hydrochlorothiazide|
10170785|NCT03889106||Lassa fever|
10170786|NCT03889236|Experimental|Fasting mimicking diet|5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.
10170787|NCT03889236|Experimental|Food supplement|4 capsules a day of the food supplement Endocalyx for 3 months.
10170788|NCT03889236|Placebo Comparator|Placebo|4 capsules a day of the placebo for 3 months.
10170789|NCT03888859|Experimental|Intravenous (i.v.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intravenous (IV) infusion
10170790|NCT03888859|Experimental|Intra-hepatic artery (i.a.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intra-hepatic artery (IA) infusion
10170791|NCT03888859|Experimental|Intratumoral Injections (i.t.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intratumoral injections (i.t.) infusion
10170792|NCT03889132||Premenopausal women with obesity|
9662226|NCT05045638|Experimental|Rosuvastatin + sotorasib|
10170793|NCT03889132||Postmenopausal women with obesity|
10170794|NCT03889132||Men with obesity|
10170795|NCT03889132||Premenopausal women without obesity|
10170796|NCT03889132||Postmenopausal women without obesity|
10170797|NCT03889132||Men without obesity|
10170798|NCT03889184|Experimental|rehabilitating meals-on-wheels service|the intervention group will for 8 weeks receive a rehabilitating meals-on-wheels service
10170799|NCT03889184|No Intervention|Usual care|the control group will receive usual care
10170800|NCT03889210|Active Comparator|HVMN ketone drink|HVMN ketone drink will be given in a total volume of 100 ml.
10170801|NCT03889210|Placebo Comparator|Placebo|Placebo will be given in a total volume of 100 ml.
10170802|NCT03889015|Active Comparator|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
10170803|NCT03889015|Experimental|probiotic yogurt|Probiotics are live microorganisms that confer oral health benefits by adhering to the oral mucosa and surface of teeth as a part of the biofilm thus preventing the adhesion, colonization, and proliferation of cariogenic bacteria inhibiting the formation of pathogenic plaque
10186912|NCT03731403|Active Comparator|Profluorid Varnish|
10186913|NCT03731390|Experimental|GR1405 injection 3 mg/kg|According to the patient's weight, the dose of this group is 3mg/kg.
10186914|NCT03731390|Experimental|GR1405 injection 10 mg/kg|According to the patient's weight, the dose of this group is 10mg/kg.
10186915|NCT03731390|Experimental|GR1405 injection 20 mg/kg|According to the patient's weight, the dose of this group is 20mg/kg.
9521515|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
9521516|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
10170804|NCT03889223|Active Comparator|The LDF neuraxial positioning technique|In the LDF neuraxial positioning technique, fifty participants were planned to lay down the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist. Volunteers jaw touch to chest and legs in abdominal flexion with hands are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
10170805|NCT03889223|Experimental|The SCF neuraxial positioning technique|In the SCF neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
9521517|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
9521518|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
10170806|NCT03888911|Experimental|High dose IQP-LU-104 (5120mg)|High dose treatment group
10170807|NCT03888911|Experimental|Low dose IQP-LU-104 (2560mg)|Low dose treatment group
10170808|NCT03888911|Placebo Comparator|Placebo|Placebo group
10170809|NCT03889080||SCN9A-group|Patients with SCN9A-associated small fiber neuropathy
10170810|NCT03889080||Skin biopsy|Patients with SFN confirmed with a decreased intra-epidermal nerve fiber density (IENFD)
10170811|NCT03889080||Control|Age- and gender-matched healthy controls
10170812|NCT03888898|Active Comparator|N95 Filtering Facepiece Respirator|control fit testing
10170813|NCT03888898|Experimental|Elastomeric Respirator|experimental rapid conversion fit testing and competency evaluations
10170814|NCT03888885|Experimental|Sport Education Group|Participants participated in the required physical education lessons which were delivered in a season of sport education model for 10 lessons.
10170815|NCT03888885|No Intervention|Control Group|Participants received no intervention treatment. They were asked to attend in normal physical education classes for the same period of time.
9527794|NCT03217084|Active Comparator|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
10170816|NCT03888651||Observational (questionnaires, quality of life assessment)|Patients complete questionnaires and quality of life assessments over 10-15 minutes at pre-surgery, after-surgery, at discharge, within 2-3 weeks after surgery, and within 90 days after surgery.
10170817|NCT03888820|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
9521519|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
9521520|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
9521521|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
10170818|NCT03888820|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
9521522|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
10170819|NCT03888677|Active Comparator|Standard|Standard FEC (F600, E60, C600) every 3rd week.
10170820|NCT03888677|Experimental|Tailored|Tailored FEC (F600, E75-90, C900-1200) every 3rd week.
10170821|NCT03888677|Active Comparator|Registered|Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.
10170822|NCT03888690|Active Comparator|With and then without VR|Virtual Reality with standardized procedures for first intervention, Standardized procedures for second intervention, without VR.
10170823|NCT03888690|Active Comparator|Without and then with VR|Standardized procedures without VR for first intervention, Virtual Reality with standardized procedures for second intervention.
10170824|NCT03888807|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees.
9521523|NCT03536520|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
10170825|NCT03888807|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees
10170826|NCT03888781||With Left Ventricular Remodeling|By Echocardiography
10170827|NCT03888781||Without Left Ventricular Remodeling|By Echocardiography
9521524|NCT03536520|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9521525|NCT03536455|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9521526|NCT03536455|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9521527|NCT03536429|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
10170828|NCT03888768|Active Comparator|ProPBM|Pre-operative: patient will be screened for iron deficiency and anemia and administered IV monofer Intra-operative:IV tranexamic Acid 1gm will be administered at the beginning of surgery and blood transfusion triggered by Allowable blood loss Post-operative: IV Iron monofer will be given to those with estimated blood loss >1L and subsequent post operative follow up till 6month
10170829|NCT03888768|No Intervention|Standard Care|patient will received standard hospital practise
10170830|NCT03888703|Experimental|Treatment|
10170831|NCT03888703|No Intervention|Control|
10170832|NCT03888664|Experimental|FRDA patients treated with gIFN|1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
10170833|NCT03888508|Experimental|SIT plus standard therapy|Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses such as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home Sensory integration kit will be prepared which consists of varying textures from soft to hard items (wool, jute, sand paper, velvet), picture cards, sensory brush, elastic band(Thera tube) and also usage of other home based items such as swings, sofa/bed, textured board, black board, wet chalks and paint. Each session would take approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 d Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving as a standard therapy
10170834|NCT03888508|No Intervention|Standard therapy alone|Standard therapy -Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving
10170835|NCT03888521|Experimental|Resound Relief|All participants are in the same group, and receive the same intervention - use of the Resound Relief smartphone app for 6 months
10170836|NCT03888573|Active Comparator|Stretch|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms.
10170837|NCT03888573|Active Comparator|Traction|Patients within Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
10170838|NCT03888729|Experimental|HCV treatment-naïve participants|HCV-infected individuals naïve to DAA therapy regimen; in this group we consider also HCV-infected individuals who have failed interferon-based therapy. Sofosbubir/velpatasvir (SOF/VEL) will be administered once daily for 12 weeks to eligible HCV treatment-naïve participants.
10170839|NCT03888729|Experimental|HCV treatment-experienced participants|HCV treatment-experienced participants, i.e.HCV-infected individuals with a history of virologic failure to SOF/LDV or other DAA-containing regimen. Sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) will be administered once daily for 12 weeks to eligible HCV treatment-experienced participants
10170840|NCT03888534|Experimental|Ixazomib|Ixazomib, injection, intravenously, once on Days 1, 4, 8, and 11 in a single 29-day treatment cycle in combination with multiagent reinduction therapy. Participants >= 1 year will receive the starting dose of 1.0 milligram per square meter (mg/m^2) and <1 year will receive the starting dose of 0.03 milligram per kilogram (mg/kg). The dose escalation phase will determine the MTD or RP2D of Ixazomib. Dose of Ixazomib will be escalated based on the observed safety and tolerability data.
10170841|NCT03888833||Veno arterial extracorporeal membrane oxygenation|
10170842|NCT03888586|Experimental|Dry Needling|Participants were administered trigger point dry kneedling technique 6 times for 1 month, once every 5 days. The subject was positioned prone and the arm position was slightly changed related with the muscle. After the skin inspection it was cleaned with the alcohol. .
10170843|NCT03888586|Experimental|Deep Friction Massage|Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
10170844|NCT03888456|Experimental|study|participants will receive a single touch intervention based on osteopathic assessment and treatment
10170845|NCT03888456|Sham Comparator|Control|participants will receive a single touch sham intervention mimicking the intervention
10170846|NCT03888430||Standard Oxygen|preoxygenation methods : Standard Oxygen
10170847|NCT03888430||High flow Oxygen|preoxygenation methods : High flow Oxygen
9521528|NCT03536429|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9521529|NCT03521466|Experimental|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
9521530|NCT03521466|No Intervention|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
9521531|NCT03529825|Experimental|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
9671986|NCT05041205|Placebo Comparator|cosmetic apparatus group|This group is designed for a cosmetic apparatus control group without consumption of placebo or test article. Together with the specified cleanser, the apparatus is used for daily facial cleaning, two times in the morning and evening for 12 weeks.
10170848|NCT03888430||Non invasive ventilation|preoxygenation methods : Non invasive ventilation
10186916|NCT03731390|Experimental|GR1405 injection 30 mg/kg|According to the patient's weight, the dose of this group is 30mg/kg.
10170849|NCT03888443||uCP children|15 Children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol twice separated from 2 to 4 weeks
10170850|NCT03888443||uCP children with botulinum toxin injections|5 children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol three times
9521532|NCT03529825|No Intervention|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
9521533|NCT03516591|Experimental|Dose Escalation (3+3 design)|A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level. AMV564 will be tested as a 14-Day CIV regimen (14-Day Continuous Intravenous Infusion Regimen).
9521534|NCT03516591|Experimental|Dose Expansion|Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.
10170851|NCT03888443||healthy volunteers (TDC children)|20 children aged from 6 to 17 (healthy volunteers) will realize the bimanual protocol once
10170852|NCT03888196|Experimental|Intervention Group|500 mg/day of Panax Ginseng. 2 weeks treatment
9521535|NCT03482089|Experimental|Cystoprostatectomy|(Open, laparoscopic or robot-assisted ) cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection; without adjuvant androgen deprivation therapy;
9521536|NCT03482089|Active Comparator|Radiotherapy|Radiotherapy by external beam radiotherapy (81 Gy，2.4-4 Gy per fraction over 4-6 weeks); with adjuvant androgen deprivation therapy for the least 3 years
9521537|NCT03475134|Experimental|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
9521538|NCT03466203|Experimental|LLF580|LLF580 every 28 days * 3
9521539|NCT03466203|Placebo Comparator|Placebo|Placebo to LLF580 every 28 days * 3
9521540|NCT03449576|Experimental|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
9521541|NCT03449576|Active Comparator|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
9521542|NCT03461120|Experimental|Treatment|Bupivacaine 0.3% [or ropivacaine 0.5%] infusion for 7 days via femoral and sciatic perineural catheters
9521543|NCT03461120|Other|Control|Bupivacaine 0.1% [or ropivacaine 0.2%] infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
10170853|NCT03888196|Placebo Comparator|Control Group|500 mg/day of Celulose. 2 weeks treatment
10170854|NCT03888625|Active Comparator|Group A: Conventional ILM peeling|peeling with complete removal of the internal limiting membrane (ILM)
10170855|NCT03888625|Active Comparator|GroupB: Inverted ILM Peeling|the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
10170856|NCT03888248|Active Comparator|Exercises|Daily muscle-strengthening exercises
10170857|NCT03888248|Experimental|Whole-body vibration + exercises|Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
10170858|NCT03888495|Experimental|Gender socialization (GS)|Gender socialization workshops raised awareness on gender, its social construction and inequality, notions of masculinity and femininity, division of labor, access and control over resources. The workshop also included skill-building sessions on effective communication and negotiation and relationship building.
10170859|NCT03888495|Experimental|GS + Financial literacy (FL)|Financial literacy workshops promoted knowledge and skills in budgeting, financial planning and accessing and using financial services and income generating activities.
10170860|NCT03888495|Experimental|GS + FL + Family planning|Family planning counseling was provided to couples by family planning providers from nearby facilities. Couples were encouraged to seek services in facilities of their choice. A voucher system provided financial support for the poorest couples.
10170861|NCT03888495|No Intervention|Control|Couples were interviewed at baseline, and will be interviewed at endline.
10170862|NCT03888313||Patients participating in the pretreatment group consultation|Patients who chosse to participate in a group consultation (with other patients also in the process of undergoing surgery for colorectal cancer).
10170863|NCT03888287|Experimental|Retrospective Phase|150 patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
10170864|NCT03888287|Experimental|Prospective Phase-Watch Rx system|150 patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
10170865|NCT03888287|Experimental|Retrospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
9671987|NCT05041205|Experimental|Beauty drink powder + cosmetic apparatus group|In this group, Beauty drink powder is consumed 1 sachet daily with 50 ml water and the cosmetic apparatus is used together with the specified cleanser for daily facial cleaning, two times in the morning and evening for 12 weeks.
9671988|NCT05041010|Experimental|Neu2000KWL|
9521545|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
9671989|NCT05041010|Placebo Comparator|Placebo|
9521546|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
9521547|NCT03417674|Experimental|Intervention group|Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
9521548|NCT03417674|No Intervention|Control group|Routine care.
9521549|NCT03411837||Dupilumab|Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
9521550|NCT03411239|Other|Interventional arm|Patients recruited will have OBC inserted under general anaesthesia and various pressure measured
9521551|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
9521552|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
9521553|NCT03400215|Active Comparator|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
10170866|NCT03888287|Experimental|Prospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
10170867|NCT03888326|Experimental|Robotic Rehabilitation plus 1x1 anodal tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.
10170868|NCT03888326|Sham Comparator|Robotic Rehabilitation plus sham tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.
10170869|NCT03888326|No Intervention|Standard of Care Rehabilitation|No additional therapy/treatment provided. The individual continues with their normal daily routine
10170870|NCT03888547|Experimental|OT-HAWP|"The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules:~Week 1: Sleep Hygiene Week 2: Fatigue Management Week 3: Cancer-related cognitive impairments Week 4: Stress Management Each session will last 1.5 hours (45 minutes of group education and 45 minutes of individual modifications and strategy recommendations."
10170871|NCT03888404||Underlying Cohort|"The study will recruit and follow a prospective cohort of women at risk of pregnancy for one year."
10170872|NCT03888404||Pregnancy Match Cohort, Pregnant Group|Women from the Underlying Cohort who become pregnant will be transferred into the Pregnancy Match Cohort to be followed for two years.
10170873|NCT03888404||Pregnancy Match Cohort, Not Pregnant Group|The study will also follow a comparison cohort of non-pregnant women from the Underlying Cohort, frequency matched to the pregnant participants on Desire to Avoid Pregnancy score and time at risk of pregnancy.
10170874|NCT03888339|Active Comparator|Control group - Commercially available high abutments|Commercially available 2.5mm high abutments
10170875|NCT03888339|Experimental|Test group - Modified shape abutments|Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
9521554|NCT03400215|Active Comparator|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
10170876|NCT03888300|Experimental|Patient Group|Patients with obstructive pulmonary diseases receiving standard physiotherapy treatment
10170877|NCT03888183|Placebo Comparator|salt solution without 0.15% HA|
9521555|NCT03384212|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
9521556|NCT03384212|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
10170878|NCT03888183|Active Comparator|preservative-free 0.15% HA|
10170879|NCT03888157||Liraglutide|Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.
10170880|NCT03888209|Experimental|Anodal tDCS|Patients will receive 20min anodal tDCS
10170881|NCT03888209|Sham Comparator|Sham tDCS|Patients will receive 20 minutes of Sham anodal tDCS
9521557|NCT03382977|Experimental|Dose Level 1|VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
9521558|NCT03382977|Experimental|Dose Level 2|VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
9521559|NCT03382977|Experimental|Dose Level 3|VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
9521560|NCT03382977|Experimental|Dose Level 4|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.
9521561|NCT03382977|Experimental|Dose Level 5|VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection
10170882|NCT03888170||Non-pregnant|Women aged 18-45 years old undergoing elective hysterectomy (either vaginal, laparoscopic, or open routes) for benign indications.
10170883|NCT03888170||Pregnant|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age.
9521562|NCT03364127|Active Comparator|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
9521563|NCT03364127|Placebo Comparator|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
9521564|NCT03384225|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
9521565|NCT03384225|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
9521566|NCT03383874|Placebo Comparator|Placebo|Participants will receive capsules containing placebo for 24-weeks.
10170884|NCT03888170||Pregnant with hypertension|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age with pregnancy complicate by chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, or superimposed preeclampsia.
10170885|NCT03888261|Active Comparator|Active Intervention:|Mind-body intervention (incl. Relaxation Response Resiliency Program & the Open and Calm Program)
9521567|NCT03383874|Experimental|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
9521568|NCT03339505|Active Comparator|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
9521569|NCT03339505|Placebo Comparator|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
9662227|NCT05043337|Experimental|Maternal voice|Recording the maternal voice in reading children's books, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored maternal voice, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
9662228|NCT05043337|Experimental|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Brahms Lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
9662229|NCT05043337|Experimental|Maternal voice combined with lullaby|Recording the maternal voice in reading children's books and giving mother listening to the lullaby at the same time, and recorded the sound for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group was explored Maternal voice combined with Brahms lullaby, which starts from 3 minutes before the procedure and ends ten minutes after the heel puncture.
9662230|NCT05043337|No Intervention|Control group|When the premature infants undergoing heel lance procedure , the control group was under routine care . Measuring with the Respiration , heart rate , oxygen saturation , and neonatal infant pain scale (NIPS ) were recorded 3 minutes before , during , 1st , 3rd , and 10th minutes after the heel lance puncture .
9662231|NCT05041829|Experimental|lowsodium|Participants in this arm will be guided to have low dietary sodium intake of <2.3 g/day (<100 mmol/day) for 4 weeks.
10170886|NCT03888261|No Intervention|No Intervention|No intervention (Study participants will receive routine clinical practice)
10170887|NCT03888144|Active Comparator|Oxycodone group|Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.
10170888|NCT03888144|Experimental|Ketorolac group|Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.
10170889|NCT03888118|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual ankle therapy and one hour therapy on the Luna EMG device.
9662232|NCT05041829|Active Comparator|highsodium|Participants in this arm will be guided to have low dietary sodium intake of ≥4 - <6 g/day (≥174 - <261 mmo/day) for 4 weeks.
9662233|NCT05041400|Other|Healthy subjects|"Evaluation carried out on a BIODEX S4 Pro isokinetic dynamometer after a standardised 10-minute warm-up on this same dynamometer .~The measurement range will be from 0° (full extension) to 90° of flexion for each knee, providing 91 degrees of measurement."
9662234|NCT05041101|Experimental|Treatment (grapiprant, eribulin mesylate)|Patients receive grapiprant PO BID on day 1-21 and eribulin mesylate IV over 5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9662235|NCT05039086||PDE5 inhibitors|Exposure group
9662236|NCT05039086||Endothelin receptor antagonists|Reference group
9662237|NCT05028725|Experimental|Esophageal Squamous Cell Carcinoma (ESCC) Cases|Each study participant will undergo esophageal sponge sampling using the 'EsophaCap' sponge device. Group 1 will include a safety-phase, which will consist of a lead-in cohort of 8 patients with ESCC. Subsequent recruitment of ESCC Cases (Group 1) will not commence until the Data Safety Monitoring Board (DSMB) has deemed the safety lead-in data appropriate for continuation. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
9662238|NCT05028725|Experimental|Non-ESCC, Esophageal squamous dysplasia (ESD) Cases|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
9662239|NCT05028725|Experimental|Non-ESCC, Control Group|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
9662240|NCT05028465|Experimental|EP combined with RFA|Endoscopic Papillectomy Combined with Endobiliary Radiofrequency Ablation
9662241|NCT05026814||Women with FGM/C|Women who requested clitoral reconstruction after FGM/C between 01/2013 until 04/2021 and underwent multidisciplinary care consisting of psychosexual care (PC) with or without CR. To be included the women had to attend at least one session with the psychologist as part of psychosexual care.
9521570|NCT03330795|Experimental|CD3/CD19 neg allogeneic BMT|All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
9521571|NCT03272672|Experimental|Braced|Össür Unloading Knee Brace used during walking protocol
10170890|NCT03888118|No Intervention|Control group|A four-week rehabilitation program (Monday to Friday) involving two hours of individual ankle therapy.
9521572|NCT03272672|No Intervention|Unbraced|Walking protocol without the use of brace
9521573|NCT03272698|Experimental|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
9521574|NCT03272698|Active Comparator|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
9521575|NCT03272659|Experimental|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
9521576|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
9521577|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
10170891|NCT03887923|Experimental|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
10170892|NCT03888131|Experimental|CHF 1535 100/6 µg pMDI|2 inhalations BID Total Daily Dose = 400/24µg
9521578|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
9521579|NCT03272633|Experimental|Cohort I (initial IHC within 42 days)|Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
9521580|NCT03272633|Experimental|Cohort II (initial IHC within 70 days or after relapse)|Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
9521581|NCT03320200|Experimental|CNS-focused treatment|Group of subjects receiving a 10 week CNS (Central Nervous System) -focused treatment program for frozen shoulder in addition to 5 days per week home treatment program
9826586|NCT02423993|Active Comparator|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
9826587|NCT02423993|Experimental|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
9826588|NCT02423993|Active Comparator|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
9521582|NCT03320200|Experimental|Standard Care Treatment|Group of subjects receiving a 10 week standard care treatment program for frozen shoulder in addition to 5 days per week home treatment program based on conventional physiotherapy
9521583|NCT03272594|Experimental|Breastfeeding|
9521584|NCT03272594|Active Comparator|24% oral sucrose|
9521585|NCT03272607|No Intervention|Control|All participants in the control arm will receive medication reconciliation at admission and discharge, and identical follow up, but no prioritized deprescribing list will be generated.
10170893|NCT03888131|Active Comparator|Symbicort® Turbohaler®|2 inhalations BID Total Daily Dose = 640/18µg
10170894|NCT03887793|Experimental|VACs intervention|Integrated healthcare delivery systems randomly assigned to this arm will participate in the Vaccinate Adolescents against Cancers (VACs) model for HPV vaccine QI. Specific QI activities will be chosen by healthcare system leadership and healthcare providers on the systems' QI teams.
10170895|NCT03887793|No Intervention|Wait list control|Integrated healthcare delivery systems randomly assigned to this arm will be placed on a waiting list to receive the intervention after the conclusion of the study period.
9521586|NCT03272607|Experimental|Intervention|"Participants in the intervention arm will be electronically screened using an electronic software MedSafer which will generate output of PIMs that will be brought to the attention of the CTU team via the unit pharmacist as deprescribing opportunities. (Note that in the case of multiple recommendations, they will be limited and prioritized so as to avoid overwhelming the treating team.) Based on their own expert medical judgement, in collaboration with the patient/caregiver and other relevant clinicians, a decision will be made to deprescribe if appropriate by the patient's in-hospital doctors."
9671990|NCT05040789|Experimental|Group 1|CoVLP Lot 1
10186917|NCT03731377|Experimental|Intubated group|Patient in this group will receive general anesthesia with endotracheal tube intubation to perform one lung ventilation. Patient will be paralyzed and controlled ventilation will be implied.
9521587|NCT03272568|Experimental|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
10170896|NCT03888014||Treatment group|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
9521588|NCT03272568|Experimental|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
9521589|NCT03272425|Experimental|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
9521590|NCT03272425|Experimental|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
10170897|NCT03888092|Experimental|Z650 , Single-arm|Z650 will be administered daily, at dose of 350 mg orally
10170898|NCT03887832|Experimental|SBSI intervention|Mothers is this arm will download the SMBI intervention app onto their smartphone. They will be shown a video from the app and how to share videos with others. After hospital discharge, mothers will receive a weekly media package (video, associated prompt(s), and activity) via the SMBI for six months.
10170899|NCT03887832|Active Comparator|Infant standard of care|Mothers in this arm will receive the standard of care for newborn and infants including education and a list of resources.
9521591|NCT03272425|Experimental|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
9521592|NCT03272425|Experimental|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
9521593|NCT03272490|Active Comparator|Medartis|Surgery using the Medartis Implant
9521594|NCT03272490|Active Comparator|Synthes|Surgery using the Synthes implant
10170900|NCT03887845||Open gastrointestinal surgery|All patients enrolled in this group would undergo open gastric and colorectal resection surgery.
10170901|NCT03887845||Laparoscopic gastrointestinal surgery|All patients enrolled in this group would undergo laparoscopic gastric and colorectal resection surgery.
10170902|NCT03887949|Active Comparator|VCV|Volume controlled ventilation
10170903|NCT03887949|Active Comparator|PCV|Pressure controlled ventilation
10170904|NCT03887949|Experimental|PCV-VG|Pressure controlled ventilation with volume guarantee
10170905|NCT03888040|Experimental|Blood Flow Restriction Training|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
10170906|NCT03888040|Experimental|Resistance Training Only|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training without blood flow restriction.
10170907|NCT03887975|Active Comparator|Percentage of force in monoplane occlusion|Different occlusal scheme evaluation using tscan
10170908|NCT03887975|Active Comparator|Percentage of force in lingualized occlusion|Different occlusal scheme evaluation using tscan
10170909|NCT03887689|Experimental|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
10170910|NCT03887897|Active Comparator|Airtraq|Airtraq laryngoscope
10170911|NCT03887897|Active Comparator|Macintosh|Macintosh laryngoscope
9521595|NCT03272516|Active Comparator|Control group|This group receives treatment as usual (TAU) from his/hers physician. This treatment is different for each physician, but mainly consists of cognitive therapy, personal interviews or antidepressants or anxiolytics.
10170912|NCT03887884|Experimental|CVT-301|Single inhaled dose of CVT-301 84 mg
9521596|NCT03272516|Experimental|Intervention group|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol..
9521597|NCT03272529||Patient-specific simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. This is in addition to standard prerequisite simulation training.
10170913|NCT03887884|Active Comparator|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
10170914|NCT03887650|Experimental|Liposomal Bupivacaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
10170915|NCT03887650|Active Comparator|Bupivacaine 0.5% with Adjuncts|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
9671991|NCT05040789|Experimental|Group 2|CoVLP Lot 2
9671992|NCT05040789|Experimental|Group 3|CoVLP Lot 3
10186918|NCT03731377|Experimental|Non-intubated group|Patient in this group will receive general anesthesia with laryngeal mask insertion. Patients in this group will not be paralyzed and keep spontaneous breathing to maintain one lung ventilation.
10186919|NCT03731364|Active Comparator|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (5 mg), was prepared at 0.05 mg/mL CA-008 (vocacapsaicin)
10170916|NCT03887754|Active Comparator|The Hyperbaric oxygen therapy group|This group consists of twenty autistic children received forty sessions of HBOT, the time of the session is one hour. The sessions were done at pressure 1.5 ATA (atmosphere absolute) and with 100% oxygen concentration, either in multiplace or monoplace chamber. The number of sessions per week allowed is five sessions per week, all participants were required to complete forty sessions within two months. After six months from the last session, another forty sessions would be taken in the same manner
10170917|NCT03887754|Active Comparator|The Risperidone group|"This group consists of twenty autistic children received Risperidone (dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more) for eight months.~The medication schedule in the initial 2 months was based on the child's weight and clinical response. Adjusting the total daily dose according to response and/or adverse effects, at the end of these eight months of treatment we began the discontinuation phase. In this phase, gradual placebo substitution occurs. The discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the last week in the eight months for the first week, followed by 50% of the last week for the second week, 25% of the last week for the third week, and placebo only by the fourth week."
10170918|NCT03887754|Active Comparator|The HBOT and Risperidone group|This group consists of twenty autistic children received HBOT as the HBOT group in addition to Risperidone as the Risperidone group in the same manner and duration
10170919|NCT03887754|Placebo Comparator|The Control group|This group consists of twenty autistic children received placebo in the form of multivitamins
10170920|NCT03887871|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
10170921|NCT03887871|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~Period 2: Harnal-D Tab. 1T"
10170922|NCT03887611||thyroid nodules|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of thyroid surgery or thyroid biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
10170923|NCT03887858|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
9521598|NCT03272529||Idealized simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models that incorporate the necessary anatomy, physiology, and pathology of an ideal training case. This is in addition to standard prerequisite simulation training.
9521599|NCT03272529||Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in this group in addition to the standard.
10170924|NCT03887858|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~Period 2: Harnal-D Tab. 1T"
10170925|NCT03887676|Active Comparator|Arbaclofen|
10170926|NCT03887676|Placebo Comparator|Placebo|
10170927|NCT03887637||Danoprevir Sodium triple therapy|"DNV(Danoprevir Sodium)/PegIFNα(Peginterferon α-2a)/RBV(Ribavirin) : (1) DNV : 100mg (one tablet) orally twice daily for 12 weeks. (2) PegIFNα: 180ug subcutaneous infection on abdomen or thigh once a week for 12 weeks. (3) RBV: 500mg (5 tablets) orally twice daily for 12 weeks in patients weighing less than 75kg; 600mg (6 tablets) orally twice daily for 12 weeks in patients weighing ≥75kg.~Dosing time: In the morning, participants will be instructed to take DNV and RBV with food or one hour after food. The drugs are not allowed to be cut or divided. The interval between DNV and RBV dosing time should be 12±2 hours."
10170928|NCT03887637||Sofosbuvir/ Velpatasvir therapy|Sofosbuvir/ Velpatasvir :500mg (two drugs in one tablet) orally once daily for 12 weeks.
9521600|NCT03272477|Active Comparator|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.~Adjuvant Therapy: Standard of care"
9521601|NCT03272477|Experimental|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.~Adjuvant Therapy: Standard of care"
10170929|NCT03887637||Ombitasvir/Paritaprevir therapy|Ombitasvir/Paritaprevir: Ombitasvir two tablets orally once daily for 12 weeks; Paritaprevir one tablet orally twice daily for 12 weeks.
10170930|NCT03887637||Grazoprevir/elbasvir therapy|Grazoprevir/elbasvir: 150mg (two drugs in one tablet) orally once daily for 12 weeks.
9521602|NCT03272581|No Intervention|Control Group|Control group followed routine basketball training and traditional strength training.
9521603|NCT03272581|Experimental|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
9521604|NCT03272438|Active Comparator|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
9521605|NCT03272438|Experimental|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
10170931|NCT03887637||Daclatasvir/Asunaprevir therapy|Daclatasvir (60mg)one tablet once daily and Asunaprevir (100mg)one tablet twice daily for 24weeks
10170932|NCT03887637||Danoprevir Sodium/Sofosbuvir therapy|Danoprevir Sodium: 100mg (one tablet) orally twice daily for 12 weeks;Sofosbuvir:400mg (one tablet) orally once daily for 12 weeks.
10186920|NCT03731364|Placebo Comparator|Placebo - Cohort 1|"Placebo for Cohort 1~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
9826589|NCT02424097|Experimental|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
9826590|NCT02424097|Active Comparator|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
10170933|NCT03887962|Experimental|Virtual Environment feedback|"Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a virtual path displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist."
9521606|NCT03272438|Active Comparator|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
10170934|NCT03887962|Active Comparator|Control|Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.
10170935|NCT03887585|Experimental|Achilles tendon lengthening|Surgery of percutaneous Achilles tendon lengthening by triple hemisection
10170936|NCT03887598||breast nodule|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of breast surgery or breast biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
9521607|NCT03272542|Experimental|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
9521608|NCT03272542|Placebo Comparator|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
10170937|NCT03887572||Pre-intervention/control|20 older adult patients (age 65 or older) will be recruited over 3 months prior to implementation of the unit-based MOVIN intervention.
10170938|NCT03887572||Post-intervention|20 older adult patients (age 65 or older) will be recruited over 3 months after MOVIN has been implemented on the unit for a period of 12-14 weeks.
9521609|NCT03272451|Experimental|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
9521610|NCT03272451|Active Comparator|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
10170939|NCT03887546|Experimental|Intervention group|"Intervention is administrated with Inspiratory Muscle Trainer. 20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the second week.~12 weeks, 5 days/week, 15 minutes/day."
10170940|NCT03887546|Active Comparator|Control group|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day
10170941|NCT03887416|Active Comparator|Dapagliflozin|"The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet [Farxiga] given once daily (film coated tablets, oral use).~Dapagliflozin 10 MG Oral Tablet [Farxiga] will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
9521611|NCT03272503|Experimental|Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)|Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
9521612|NCT03272503|Placebo Comparator|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
9521613|NCT03272555|Other|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
10170942|NCT03887416|Placebo Comparator|Placebo matching dapagliflozin|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
10170943|NCT03887403|Experimental|Multimodal Intervention|Multimodal Intervention Based on Person-centered Communication
10170944|NCT03887403|Active Comparator|Usual Care|Patients receive usual advices in primary health care centers
9527795|NCT03217084|Active Comparator|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
9527796|NCT03216941|Active Comparator|ketamine|assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
10170945|NCT03887390|No Intervention|Usual Care|Participants in this arm will receive care as usual.
10170946|NCT03887390|Experimental|Depression Medication Choice|Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.
10170947|NCT03887494|Experimental|Y-Strut Implant|Single interventional arm
10170948|NCT03887273|Experimental|Q-Cells dose level 1|One time surgical transplantation of Q-Cells dose level 1 unilaterally into spinal cord demyelinated lesion
10170949|NCT03887273|Experimental|Q-Cells dose level 2|One time surgical transplantation of Q-Cells dose level 2 unilaterally into spinal cord demyelinated lesion
9521614|NCT03272399|Experimental|H3-L6|High Omega-3, low Omega-6 diet
9521615|NCT03272399|Active Comparator|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
9521616|NCT03272152||Inflamed CD group|Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
10170950|NCT03887273|Experimental|Q-Cells dose level 3|One time surgical transplantation of Q-Cells dose level 3 unilaterally into spinal cord demyelinated lesion
9521617|NCT03272152||Non-inflamed CD group|Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
10170951|NCT03887468|Active Comparator|"EvoCit"|"Standardized hemodialysis treatments 3x4hours/week. Intervention: EvoCit procedure using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation."
10170952|NCT03887468|Active Comparator|"EvoHep"|"Control: EvoHep procedure using a heparin-grafted AN69ST dialyzer in combination with a conventional bicarbonate-based dialysate and standardized systemic anticoagulation using unfractionated heparin."
9521618|NCT03272152||Control group|Control ileal mucosa was obtained from healthy patients
9975151|NCT04541108|Experimental|MK-0482, MK-4830, & Pembrolizumab|Patients with HNSCC or STS who are scheduled for surgical biopsy or tumor resection surgery will be injected two to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of pembrolizumab as a single agent or in combination with MK-0482 or MK-4830. Each microdose is simultaneously injected in a columnar fashion through each of 8 needles into a single solid tumor or effaced metastatic lymph node.
9975152|NCT04538911|Experimental|Experimental group|80 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
9975153|NCT04538911|Other|control group|80 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
10170953|NCT03887325|Active Comparator|Maxipost|
10170954|NCT03887325|Placebo Comparator|Saline|
10170955|NCT03887364|Active Comparator|Group A-Diaphragmatic breathing exercise|Diaphragmatic breathing exercise
9521619|NCT03272126|Experimental|vitamin D bolus|vitamin D 160 000 IU given as bolus
9521620|NCT03272126|Experimental|vitamin D daily|vitamin D 4000 IU daily for 28 days
9521621|NCT03272126|Placebo Comparator|placebo|identical looking as vitamin d
9521622|NCT03272230|Experimental|bvFTD|"Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
9521623|NCT03272230|Experimental|Healthy control|"Healthy age, sex and education matched controls~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
9521624|NCT03272230|Experimental|Parkinson's disease without Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
9521625|NCT03272230|Experimental|Depression|"Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
9521626|NCT03272230|Experimental|Parkinson's disease with Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992). ICDs are closely related to use of dopaminergic medications.~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
9521627|NCT03272360||Chronic Pelvic Pain|
9521628|NCT03272360||Elective Tubal Ligation|
9521629|NCT03272269|Experimental|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
9521630|NCT03272269|Experimental|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
9826591|NCT02424149|No Intervention|Control|No preoperative phenazopyridine
9521631|NCT03272269|Experimental|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
9521632|NCT03272321|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
9521633|NCT03272321|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
9521634|NCT03272386||Observational study|Observational study with patients over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
9521635|NCT03272295|Experimental|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
9521636|NCT03272295|Experimental|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
9521637|NCT03272256|Experimental|IM156, Dose escalation|
9826592|NCT02424149|Experimental|Phenazopyridine|Preoperative phenazopyridine
9975154|NCT04535687|Experimental|Treatment group|Fluzoparib alone
9975155|NCT04534270|Experimental|Dapagliflozin treatment|
10170956|NCT03887364|Experimental|Group B-Icing and Airflow Stimulation|Icing and Airflow Stimulation
10170957|NCT03887312|Experimental|t-CETA|Telephone-delivered Common Elements Treatment Approach (t-CETA). t-CETA sessions of up to 30 minutes will be delivered 1-2 times per week for approximately 8-12 weeks. The number and content of sessions will be tailored to each child, thus there will be some variation.
9521638|NCT03272243|Active Comparator|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
9521639|NCT03272243|Active Comparator|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
9521640|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
9521641|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
9521642|NCT03272113|No Intervention|Control|"Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support.~Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week."
9521643|NCT03272113|Experimental|Intervention|Women will receive usual care as described above plus the SKIP-IT intervention
9521644|NCT03272087|Active Comparator|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
9521645|NCT03272087|Active Comparator|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
9521646|NCT03272204|Other|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
9521647|NCT03272204|Other|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
9521648|NCT03272334|Experimental|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
10170958|NCT03887312|Active Comparator|Médecins du Monde treatment as usual|Treatment as usual provided by Médecins du Monde. The number and content of sessions will vary depending on the needs of the child.
9521649|NCT03272334|Experimental|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
10170959|NCT03887507|Experimental|Experimental|There will be 3 Vojta therapy sessions conducted on 2 consecutive weeks with an interval of 7 dayssessions, on 1st, 7th and 14th days. Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling Réflex, and 1st phase and 2nd phase Rolling reflex. The relative or close person will be instructed to carry out an exercise protocol to do at home every day for 20 minutes during the 2-week study. All interventions will be made by the principal investigator.
10170960|NCT03887507|Active Comparator|Standard Therapy|The standard group shall perform 4 sessions of physiotherapy in the same period for two consecutive weeks, with one hour per session in its specialized MS association, on 1st, 3rd, 8th, 10th and 15th days. This will be applied by experienced physiotherapists during the treatment of people with MS. The program will consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept. Patients in this group will walk at least for 20 minutes per day during the study period.
9521650|NCT03272334|Experimental|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
10170961|NCT03887338|Other|NIV settings titration|Transnasal Fiberoptic Laryngoscopy will be used during ongoing NIV setting titration. Aim is to titrate NIV setting to be more optimal for laryngeal responses.
10170962|NCT03887208|Experimental|Autologous adipose derived stem cells|Autologous ADSC injection combined with laser therapy of the skin.
10170963|NCT03887208|Placebo Comparator|Placebo - Normal saline injection|Normal sline injection combined with laser therapy of the skin.
9521651|NCT03272074|Experimental|Egg Group (Group A)|Participants will consume one large egg per day for 12 weeks
9521652|NCT03272074|Active Comparator|Egg White Group (Group B)|Participants will consume equivalent amounts of egg whites for 12 weeks
9521653|NCT03271866|Other|metformin treatment|
9521654|NCT03271866|No Intervention|non-metformin treatment|
9521655|NCT03272022||women|never-pregnant women
9521656|NCT03272022||pregnant women|pregnant
10186921|NCT03731364|Active Comparator|CA-008 10 mg (0.1 mg/mL) Cohort 2|Cohort 2 (10 mg), was prepared at 0.1 mg/mL CA-008 (vocacapsaicin)
9521657|NCT03272061|Experimental|Aerobic-based exercise program|
9521658|NCT03272061|No Intervention|Control program|Maintenance of habitual physical activity levels
9521659|NCT03271918|Experimental|Study Group|This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
9521660|NCT03271918|No Intervention|Control Group|This group was followed, with clinical visits in same frequency of study group, but without intervention.
9521661|NCT03272009|Experimental|Treatment A|oral EYP001a
9521662|NCT03272009|Experimental|Treatment B|oral EYP001a
9521663|NCT03272009|Experimental|Treatment C|oral EYP001a
9521664|NCT03272009|Experimental|Treatment D|oral EYP001a
9521665|NCT03272009|Placebo Comparator|Treatment E|oral placebo
9521666|NCT03272009|Active Comparator|Treatment F|oral Entecavir
9521667|NCT03272009|Experimental|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
9521668|NCT03272009|Experimental|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
9521669|NCT03272009|Placebo Comparator|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
9521670|NCT03271879|Active Comparator|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
9521671|NCT03271879|Placebo Comparator|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
9521672|NCT03271983|Other|metronidazole gel 1|RLD gel
9521673|NCT03271983|Other|metronidazole gel 2|generic gel
10170964|NCT03887247|Active Comparator|E-Mail Alert|Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.
10170965|NCT03887247|No Intervention|As-Usual|As-usual (no email) approach.
10170966|NCT03887234|Active Comparator|Through the coracoid|The semitendinosus tendon graft goes through the 4.5 mm coracoid drill hole.
9521674|NCT03271983|Other|metronidazole cream|generic cream
9521675|NCT03271996|Experimental|Primary closure|Excision of sinus and paramedian closure according to modified Karydakis technique
9521676|NCT03271996|Experimental|Fistulectomy|Removal / fistulectomy by scalpels or trephines of primary and drainage orifices and healing of the wound by second intention
9521677|NCT03271853||SBS II|
9521678|NCT03271931|No Intervention|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
9521679|NCT03271931|Experimental|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
9521680|NCT03271931|Experimental|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
9521681|NCT03272048|Experimental|Low-Fear/Not-Temporary|
9521682|NCT03272048|Experimental|Low-Fear/Temporary|
9521683|NCT03272048|Experimental|High-Fear/Not-Temporary|
9521684|NCT03272048|Experimental|High-Fear/Temporary|
9521685|NCT03271944|Other|Single group 30 post menopause females.|
9521686|NCT03271970||Patients with conductive hearing loss|
9521687|NCT03271814|Experimental|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
9671993|NCT05040893|Experimental|Outpatient Physiotherapy Intervention|POETIC will test a patient-oriented, outpatient physiotherapy intervention tailored to each patient based on their symptoms, functional limitations, and goals. The intervention consists of eight one-on-one, supervised sessions delivered over 8 to 10 weeks, approximately one week apart. Each session will be approximately one hour long.
9521688|NCT03271814|Active Comparator|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
9521689|NCT03271814|Placebo Comparator|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
9521690|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
9521691|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
9521692|NCT03271905|Experimental|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
9521693|NCT03271905|Experimental|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
9521694|NCT03271905|Experimental|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
9521695|NCT03271736|Experimental|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
9521696|NCT03271736|Experimental|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
10170967|NCT03887234|Experimental|Around the coracoid|The semitendinosus tendon graft goes around the coracoid.
10170968|NCT03887195||students|The clinical sample is made up of 501 students (male and female) in the 4th year of medicine at Paris Descartes University, participating at the obligatory training module during the 2018-2019 academic year : this constitutes the entire population concerned by the intervention.
10170969|NCT03887221|Experimental|Safinamide 50mg|The subjects will receive 50mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
10170970|NCT03887221|Experimental|Safinamide 100mg|The subjects will receive 100mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
10170971|NCT03887260|Active Comparator|GA group|Patients will receive general anaesthesia for nephrectomy/NSS procedures via lumbotomy. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
9521697|NCT03271801|Active Comparator|Child Health Education|The child health education condition will participate in a family-based obesity treatment program for the first 40 minutes of each session, followed by 20 minutes designated to education about a child health topic. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time.
9671994|NCT05040750||moderate to severe COVID 19 patients|moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed
9671995|NCT05041166|Experimental|Protocol optimization cohort|Following the [13C]pyruvate injection, dynamic imaging and 3D volumetric imaging of volunteers in the first cohort (HP MRI protocol optimization, Aim 1) will be performed on the 3-T MRI scanner, using different [13C] RF excitation/detection coils.
9671996|NCT05041166|Experimental|Tissue reference cohort|The optimal setup will then be used for HP MRI of the second cohort.
9671997|NCT05040854||Healthy Subjects|Blood donors
9671998|NCT05040854||IBD patients - under biological therapy|Patients with IBD followed up in consultation on biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23.
9671999|NCT05040854||IBD patients - naive|Patients newly diagnosed with IBD and need for biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23,
9672000|NCT05041439|Experimental|Community health worker (CHW) group|Participants in the intervention arm will receive 5 one-on-one sessions over 6 months with a CHW, as well as a manual and written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
9672001|NCT05041439|No Intervention|Enhanced care condition (ECC)|Participants in this arm will receive 5 outreach calls at the same interval as the intervention arm, as well as written materials on child development. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers.
9672002|NCT05040828|Experimental|Early interventional treatment group|The patients in this group:oral drug therapy from onset of the low pollen stage (August 1st, 2020) to the end of the pollen stage (September 30, 2020). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
9672003|NCT05040828|Active Comparator|Post-onset treatment group|The patients in this group: oral drug therapy after the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020.). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
9672004|NCT05040828|Active Comparator|Control group|The patients in this group:Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
9672005|NCT05040737|Experimental|Study Arm|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
10170972|NCT03887260|Experimental|ESP group|Patients will receive general anaesthesia with ESP block for nephrectomy/NSS procedures via lumbotomy. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
9672006|NCT05040776|Other|Active|EP-7041 infusion 0.6 mg/kg/hr or 1 mg/kg/hr
9672007|NCT05040685|Experimental|Axillary mapping reverse|Application of axillary mapping reverse technique
9672008|NCT05040867|No Intervention|Control group (CG)|Participants will continue with their daily life and usual care.
9672009|NCT05040867|Experimental|Traditional periodization exercise group (TEG)|Participants will participate in a physical exercise program with a preplanned intensity progression.
9672010|NCT05040867|Experimental|Heart Rate Variability exercise group (HRVG)|Participants will participate in a physical exercise program guide by participants' daily heart rate variability to plan the intensity progression.
10170973|NCT03887182|Experimental|confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
10170974|NCT03887182|Experimental|suspected not confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
9672011|NCT05040672||Group I|All volunteer male employees of Libbs Pharmaceuticals residing in all Brazilian regions will participate in this research.An online questionnaire will be applied to assess research subjects understanding of prostate cancer and health habits.
9672012|NCT05040919||with an arrythmia|patient suffering from STEMI and presenting an arrythmia
9672013|NCT05040919||without an arrythmia|patient suffering from STEMI and not presenting an arrythmia
9672014|NCT05040815|Experimental|chemo-radiation treatment|"Radiotherapy with concurrent 5-fluorouracil and mitomycin-C combination treatment.~Radiotherapy consists of 5400 cGy delivered in 30 fractions over 6 weeks. The investigators will be using the current standard regimen for the study or no change in the current CCI treatment regimen. However, the radiotherapy target will be smaller than current practice since the investigators will be omitting prophylactic inguinal irradiation."
9672015|NCT05041179|Active Comparator|7.2 g of actives (3.6 g NAC and 3.6 g glycine) per day split in two doses (arm A)|"First dose (1.8 g NAC and 1.8 g glycine) consumed in the morning~Second dose (1.8 g NAC and 1.8 g glycine) taken in the evening"
9672016|NCT05041179|Active Comparator|4.8 g of actives (2.4 g NAC and 2.4 g glycine) per day split in two doses (arm B)|"First dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) consumed in the morning~Second dose (1.2 g NAC and 1.2 g glycine, +1.2 g placebo) taken in the evening"
9672017|NCT05041179|Active Comparator|2.4 g of actives (1.2 g NAC and 1.2 g glycine) per day split in two doses (arm C)|"First dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) consumed in the morning~Second dose (0.6 g NAC and 0.6 g glycine, +2.4 g placebo) taken in the evening"
9672018|NCT05041179|Placebo Comparator|Placebo control (7.2 g isomaltulose)(arm D)|"First dose (3.6 g isomaltulose) consumed in the morning~Second dose (3.6 g isomaltulose) taken in the evening"
9672019|NCT05040724|Experimental|Ivermectin|Ivermectin 3mg, on tablet. As a single dose of 400 µg / kg orally (rounded down to the nearest unit). T+ usual care
10170975|NCT03887182|Active Comparator|healthy volunteers|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic, multidisciplinary consultation
10170976|NCT03887156|Other|Arm 1|One arm
9672020|NCT05040724|Placebo Comparator|control|placebo of ivermectin administered in the same manner as the active drug in experimental arm + usual care
9672021|NCT05040542||Infant Cohort|Healthy infants aged from 0-36 months.This is an observational trial so no intervention will be provided, with exception of study assessments, including fMRI.
10170977|NCT03887169|Experimental|Methionine|
10170978|NCT03887130|Experimental|Vinorelbine-Capecitabine (arm A)|oral vinorelbine (OV) with capecitabine (CAP)
10170979|NCT03887130|Active Comparator|Gemcitabine-Paclitaxel (arm B)|gemcitabine (GEM) in combination with paclitaxel (PAC)
10170980|NCT03887130|Active Comparator|Gemcitabine-Docetaxel (arm C)|gemcitabine (GEM) in combination with docetaxel (DOC)
10186922|NCT03731364|Active Comparator|CA-008 15 mg (0.15 mg/mL) Cohort 3|Cohort 3 (15 mg), was prepared at 0.15 mg/mL CA-008 (vocacapsaicin)
10186923|NCT03731364|Placebo Comparator|Placebo - Cohorts 2 and 3|"Placebo - Cohorts 2 and 3~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
10186924|NCT03731325|Experimental|Episodic Future Thinking Group|The experimental group (N=20 families; N=40 total) will receive the Episodic Future Thinking (EFT) intervention. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now [Atance].
10186925|NCT03731325|Placebo Comparator|Healthy Thinking Group|The placebo group (N=20 families; N=40 total) will receive the Healthy Thinking (HT) intervention. HT encourages individuals to focus on the nutritional characteristics of food and the healthy benefits of physical activity.
10186926|NCT03731312||Study group|We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
10186927|NCT03731286|Active Comparator|Alpinia galanga|EnXtra: 2 capsules to be taken twice daily after breakfast and evening.
10186928|NCT03731286|Active Comparator|Composite (Alpinia galanga + Caffeine)|Composite: 2 capsules to be taken twice daily after breakfast and evening.
9672022|NCT05040542||Preschooler Cohort|Healthy preschooler aged from 37-72 months.This is an observational trial so no intervention will be provided, with exception of study assessments, including fMRI.
9672023|NCT05040646||Patients|Patients who follow the watch-and-wait program for rectal cancer.
9672024|NCT05040646||Experts|Surgeons, radiotherapists, medical oncologist and other medical personnel who are involved in the treatment of rectal cancer and the watch-and-wait program.
9826593|NCT02424175|Experimental|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
9975156|NCT04530552|Experimental|Treatment (apalutamide)|The first 40 patients taking part in this trial receive apalutamide PO QD TIW (on Monday, Wednesday, and Friday) for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Based on PSA levels of the first 40 patients, the next group of 40 patients receive apalutamide either QW or QD for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Patients may receive apalutamide for up to 4 to 12 weeks before prostate surgery (in the event surgery is delayed).
9975157|NCT04530019||MR Group|Following standard MRI-guided Brachytherapy, patients will have images analyzed for quantification of residual tumor versus fibrosis. We will pilot-test an endovaginal coil, a deflectable MR stylet, real-time planning software, and auto-segmentation of normal and tumor tissue.
9975158|NCT04502836|Experimental|preliminary psychological intervention|Participants in this group will receive a psychological intervention providing knowledge and tools for problems solving one hour prior to the ACTH LRH test.
9975159|NCT04502836|No Intervention|control group|Participants in this group will not receive any psychological intervention prior to the test.
9975160|NCT04498585|Experimental|Intervention|Participants who will be receiving standard ICU care and additionally the VR stimulation during their ICU stay.
9975161|NCT04498585|No Intervention|Control|Patients in the ICU who will be receiving standard ICU care during their ICU stay. Participants in this arm will not be receiving VR stimulation.
9975162|NCT04494867|Experimental|Core warming|Patients receive the Attune Medical Esophageal Heat Transfer Device (EnsoETM) and undergo core warming
10186929|NCT03731286|Placebo Comparator|Placebo|Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.
10186930|NCT03731208|Experimental|Intervention group|The patient assign to this arm receive the telerehabilitation program for 8-week after a knee operation
10186931|NCT03731169|Active Comparator|TDM Only|This is the standard of care trial arm. Patients receive voriconazole dosages according to the product monograph. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
10186932|NCT03731169|Experimental|Genotyping + TDM|After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
10186933|NCT03731143|Experimental|study arm|surgical opening the lower punctum using the pig tail probe and a scalpel followed by insertion of self retaining bicanalicular stent (FCI®; Paris, France).
10186934|NCT03731130||neoadjuvant short term radiation|Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.
10186935|NCT03731130||neoadjuvant long-term chemoradiation|Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire
10186936|NCT03731117|Experimental|FST|FUROSEMIDE STRESS TEST
10186937|NCT03731091|Experimental|Calcipotriene/ betamethasone dipropionate topical foam|Topical foam once daily for 4 weeks (28 days)
10186938|NCT03731091|Active Comparator|Enstilar®|Topical foam once daily for 4 weeks (28 days)
9521698|NCT03271801|Experimental|Skills Training|The skills training condition will participate in a family-based obesity treatment program for the first 40 minutes of each session followed by 20 minutes of experiential learning about meal stimulus control strategies. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time. In addition they will self-monitor the use the following stimulus control strategies: portion control, energy density and variety.
9521699|NCT03271658|Experimental|Intervention|Patient/family are randomized to either the active intervention (web based life support patient decision aid - eLSDA and decision coaching) or usual care comparison.
9521700|NCT03271658|No Intervention|Usual Care Comparison|Patients may also randomized to review current web based resources provided by the health region for seriously ill patients.
9521701|NCT03271775|No Intervention|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
10170981|NCT03887039||ADHD group|clinical examination
10170982|NCT03887039||normal group|clinical examination
10170983|NCT03886870|Experimental|Lifestyle and work intervention|Lifestyle intervention with work focus.
9521702|NCT03271775|Experimental|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
9521703|NCT03271775|Experimental|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
10170984|NCT03886870|Experimental|Lifestyle intervention|Lifestyle intervention without work focus.
10170985|NCT03886896|Experimental|Group A - lidocaine group|Group A: children receiving standard general anesthesia with intravenous lidocaine infusion 1,5 mg/kg for 5 minutes before induction of anesthesia. After 5 minutes, lidocaine infusion continued at rate of 1.5 mg/kg/h during operation, and discontinued before move the patients to PACU.
9826594|NCT02424253|Experimental|ZPL-3893787|30 mg ZPL-3893787 orally once daily for 8 weeks.
9826595|NCT02424253|Placebo Comparator|Placebo|1 capsule orally once daily for 8 weeks.
10170986|NCT03886896|No Intervention|Group B - control group|Group B: children receiving standard general anesthesia (involving fentanyl and sevoflurane) without lidocaine infusion
10170987|NCT03886844||Prolacta group|Infants, who received a human milk fortifier based on human milk (12/2015-11/2018), started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity
9521704|NCT03271827|Experimental|Apnoeic oxygenation group|Standard airway management + 3 L/min of oxygen by nasal cannula
10170988|NCT03886844||"Frauenmilch Supplement=FMS group"|Infants, who received a human milk fortifier based on bovine milk (05/2012-06/2015), started with an enteral intake of 100 ml/kg
9521705|NCT03271827|No Intervention|Standard care group|Standard airway management
9521706|NCT03271788|Experimental|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
9521707|NCT03271749|No Intervention|Conventional|The participants of this arm will receive the convencional pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
9521708|NCT03271749|Experimental|PROSM interventional|The participants of this arm will receive the PROSM protocol pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
9521709|NCT03271762|Experimental|MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW Device|MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
9521710|NCT03271762|Active Comparator|cardiac surgery|mitral valve repair in first intervention, valve replacement if repair not feasible
9521711|NCT03271437|Experimental|PC-trained therapists|
9521712|NCT03271437|Experimental|EMDR-trained therapists|
9521713|NCT03271450||Continuer at 90 Days: Dabigatran|
9826596|NCT02424344|Experimental|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
10186939|NCT03731091|Placebo Comparator|Placebo|Topical foam once daily for 4 weeks (28 days)
9521714|NCT03271450||Continuer at 180 Days: Dabigatran|
9521715|NCT03271450||Continuer at 270 Days: Dabigatran|
9521716|NCT03271450||Continuer at 90 Days: Apixaban|
9521717|NCT03271450||Continuer at 180 Days: Apixaban|
9521718|NCT03271450||Continuer at 270 Days: Apixaban|
9521719|NCT03271450||Continuer at 90 Days: Rivaroxaban|
9521720|NCT03271450||Continuer at 180 Days: Rivaroxaban|
9521721|NCT03271450||Continuer at 270 Days: Rivaroxaban|
9521722|NCT03271450||Continuer at 90 Days: Edoxaban|
9521723|NCT03271450||Continuer at 180 Days: Edoxaban|
9521724|NCT03271450||Continuer at 270 Days: Edoxaban|
9521725|NCT03271450||Continuer at 90 Days: Warfarin|
9521726|NCT03271450||Continuer at 180 Days: Warfarin|
9521727|NCT03271450||Continuer at 270 Days: Warfarin|
9521728|NCT03271450||Discontinuer at 90 Days: Dabigatran|
9521729|NCT03271450||Discontinuer at 180 Days: Dabigatran|
9521730|NCT03271450||Discontinuer at 270 Days: Dabigatran|
9521731|NCT03271450||Discontinuer at 90 Days: Apixaban|
9521732|NCT03271450||Discontinuer at 180 Days: Apixaban|
9826597|NCT02424344|Placebo Comparator|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
9521733|NCT03271450||Discontinuer at 270 Days: Apixaban|
9521734|NCT03271450||Discontinuer at 90 Days: Rivaroxaban|
9521735|NCT03271450||Discontinuer at 180 Days: Rivaroxaban|
9521736|NCT03271450||Discontinuer at 270 Days: Rivaroxaban|
9521737|NCT03271450||Discontinuer at 90 Days: Edoxaban|
9975163|NCT04494867|Active Comparator|Standard of Care|Patients receive standard temperature management and treatment
9521738|NCT03271450||Discontinuer at 180 Days: Edoxaban|
9521739|NCT03271450||Discontinuer at 270 Days: Edoxaban|
9521740|NCT03271450||Discontinuer at 90 Days: Warfarin|
10170989|NCT03886779|Active Comparator|Prolensa (Bromfenac Ophthalmic Solution) 0.07%|Bausch and Lomb, Rochester, NJ Dose: Subjects will instill one drop into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one days prior to surgery (Day 1), continue on the day of surgery plus 1 hour before surgery and for 14 days after surgery.
10170990|NCT03886779|Active Comparator|Ilevro® (nepafenac ophthalmic suspension ) 0.3%|Alcon Laboratories, Inc., Fort Worth, TX Dose: Subjects will instill one drop of test article into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one day prior to surgery (Day 1), continue on the day of surgery plus1 hour before surgery and for 14 days after surgery.
9521741|NCT03271450||Discontinuer at 180 Days: Warfarin|
9521742|NCT03271450||Discontinuer at 270 Days: Warfarin|
10170991|NCT03886948|Experimental|Prefilled Syringe (PFS) with LY3074828|PFSs containing LY3074828
9521743|NCT03271606|Experimental|ERAS group|The patients in this group receive enhanced measures perioperatively
9521744|NCT03271606|Active Comparator|Traditional group|The patients in this group receive traditional measures perioperatively
10170992|NCT03886948|Experimental|AutoInjector (AI) with LY3074828|AI containing LY3074828
10170993|NCT03886818|Experimental|PICO strategy|"Use of PICO™ device from the ankle surgery to the post-surgery day 7.~Use of usual care by simple dressings after post-surgery day 7 up to wound healing"
9521745|NCT03271710|Experimental|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
9521746|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
10170994|NCT03886818|Active Comparator|Standard of care|-Usual care by simple dressings after the ankle surgery until the wound healing.
10170995|NCT03886792|Experimental|Triggered Reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
10170996|NCT03886792|Sham Comparator|Social Interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
10170997|NCT03886922|Active Comparator|Glibenclamide and Levcromakalim|Participants will recieve levcromakalim/placebo infusion after glibenclamide administration
10170998|NCT03886922|Active Comparator|Glibenclamide and Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
10170999|NCT03886922|Sham Comparator|Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
10171000|NCT03887065|Experimental|Starting dose|Three to five patients will receive a daily dose of 1 mg/kg JM-4 (in normal saline) delivered via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
10171001|NCT03887065|Experimental|Intermediate dose of JM-4|Three to five patients will receive a daily dose of 4 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
10171002|NCT03887065|Experimental|High dose of JM-4|Three to five patients will receive a daily dose of 9 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
9521747|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
9521748|NCT03271515|No Intervention|conventional therapy|patients accept conventional radioactive and chemical therapy.
9826598|NCT02424357|Experimental|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
9826599|NCT02424357|Active Comparator|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
9521749|NCT03271515|Experimental|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
9521750|NCT03271502|Experimental|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
9521751|NCT03271502|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
9521752|NCT03271476|Experimental|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
9521753|NCT03271671|Active Comparator|PSV|Pressure support ventilation
9521754|NCT03271671|Experimental|NAVA|Neurally adjusted ventilator assist
9521755|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
9521756|NCT03271684|Experimental|intervention group|Will receive one session of up to one-hour per week over a six-week period in self-management in addition to their usual rehabilitation and workbook.
9521757|NCT03271684|Other|control group|Will receive booklet consist of home exercises and education besides the usual care
9521758|NCT03271697|Experimental|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
9521759|NCT03271697|Placebo Comparator|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
10171003|NCT03886831|Experimental|PRT543|PRT543 will be administered orally
10171004|NCT03887000|Experimental|MAGNESIUM|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
9521760|NCT03271632|Experimental|Single arm|CAR T cells to treat MM
10171005|NCT03887000|Experimental|PLACEBO|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
10171006|NCT03887013|No Intervention|CHD routine therapy|Patients with CHD will be treated with evidence-based therapy including antiplatelet drugs,beta-blockers,statins,angiotensin-converting enzyme inhibitor (ACEI),nitrates,etc. Percutaneous coronary intervention (PCI) could be performed if needed.
9521761|NCT03271541|Experimental|Bitopertin|"Part 1 - The main study - 16 weeks in total:~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
10171007|NCT03887013|Experimental|CHD routine therapy+Trimetazidine|Apart from the drug and PCI therapy mentioned above,patients will be given treatment of trimetazidine.
10171008|NCT03887078|Experimental|A. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
10171009|NCT03887078|Experimental|B. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
10171010|NCT03887078|Experimental|C. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
10171011|NCT03887078|Experimental|D. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
10171012|NCT03887078|Experimental|E. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
10171013|NCT03887078|No Intervention|F. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to usual care."
10171014|NCT03887078|Experimental|G. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
10171015|NCT03887078|No Intervention|H. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to usual care."
10171016|NCT03886987|Experimental|Device and Control|"Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml~Negative control: Blank patch Dose: Not applicable"
9521762|NCT03271593||All children admitted|All children admitted to hospital
9521763|NCT03271645|Experimental|Space from depression|Space from depression is an 8 module CBT-based intervention.
9521764|NCT03271645|Experimental|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
9521765|NCT03271645|Experimental|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
9521766|NCT03271645|Active Comparator|Face-to-face counselling|Face-to-face counselling
9521767|NCT03271411|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
9521768|NCT03271411|Experimental|Progressive counting (PC) arm|
9521769|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness >15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness >15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
9672025|NCT05040620|No Intervention|Placebo|controlling group who will receive traditional orthodontic treatment.
10171017|NCT03886935||Fontan patients|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
10171018|NCT03886935||Healthy biventricular controls|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
9826600|NCT02424383|Experimental|PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
9826601|NCT02424526|Active Comparator|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
9826602|NCT02424526|Active Comparator|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
9672026|NCT05040620|Experimental|Olive Oil|experimental group who will receive the local application of Olive Oil five times daily after teeth brushing
9826603|NCT02424539|Experimental|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
9975164|NCT04494113|Experimental|Treatment (triapine, surgical resection)|Patients receive triapine IV over 2 hours on day 1 in the absence of unacceptable toxicity. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion.
9826604|NCT02424539|Experimental|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
9975165|NCT04490993|Experimental|APL-1202 treatment|
9975166|NCT04490993|Placebo Comparator|Placebo|
9975167|NCT04465565|Experimental|Intravenous fluid administration|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will be treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 60 minutes. The fluids treatment will be initiated 90 minutes after the stimulation test will begin
9975168|NCT04465565|No Intervention|Control Group|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will not receive fluids intravenously during the stimulation test, unless it will be required due to safety reasons
9975169|NCT04454463||Adult patients with NAFLD|1500 patients 18 years and older at the time of enrollment.
9975170|NCT04454463||Pediatric patients with NAFLD|750 patients 2 years or older and up to 17 years old at the time of enrollment.
9975171|NCT04449861|Experimental|Durvalumab plus 4-6 cycles chemotherapy|Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.
9975172|NCT04422366|Experimental|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
9975173|NCT04422366|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
9975174|NCT04420624|Experimental|Colchicine|colchicine and standard therapy
9975175|NCT04420624|No Intervention|Comparator|standard therapy
9975176|NCT04409964|Experimental|opioid-free anesthesia|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
9975177|NCT04409964|Active Comparator|opioid anesthesia|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy.
9975178|NCT04404257|Experimental|ControlRad System|Participant will undergo Cardiac catheterization or electrophysiology implant procedures with the ControlRad system installed in Cath lab room 5
9975179|NCT04404257|Active Comparator|Without ControlRad System|Participant will undergo the cardiac catheterization or electrophysiology implant procedures per standard of care. Meaning, without the ControlRad system installed in Cath lab room 5.
9975180|NCT04395755||Infertile women who had the IVF treatment postponed or delayed|
9975181|NCT04391036|Experimental|High Eudragit® Film, then Low Eudragit® Film|High (12.8%) Eudragit® content vaginal film, then low (6.4%) Eudragit® content vaginal film
9975182|NCT04391036|Experimental|Low Eudragit® Film, then High Eudragit® Film|Low (6.4%) Eudragit® content vaginal film, then high (12.8%) Eudragit® content vaginal film
9975183|NCT04386837||Aphasics|Patients with a left MCA infarct due to CVA will be included in the study. Each subject will be administered an aphasia screening test less than 3 minutes in length. The same test will be administered by another clinician to the same patient within a maximum of 12 hours to assess the inter-rater reliability of the test.
9975184|NCT04377997|Experimental|Therapeutic Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation (LMWH for most subjects but UFH for those with morbid obesity or moderate to severe renal dysfunction as noted below) or standard of care anticoagulation. Those assigned to the therapeutic anticoagulation group will receive a higher dose of heparin."
9521770|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure [BP] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
9521771|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
9521772|NCT03271398||Adult victims of sexual assault|
10171019|NCT03887091|Experimental|Postwire© Virtual Education Cohort|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility.~In randomized into the Virtual Education Cohort:A video based, personalized web page will be created that has information related to the participants therapeutic clinical trial.~This web page will have videos of a research nurse explaining how to take study medication(s), how to fill out the study drug diary, and a description of the main side effects associated with the study drugs.~Clinic Visit Video Recording Cycle 1-4/Day 1~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7"
10171020|NCT03887091|No Intervention|No Video Intervention|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility~Participants randomized to the control cohort will follow standard of care procedures involving clinic visits that do not include the use of video or access to a personalized web page.~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7."
10171021|NCT03886883|Experimental|Exercise-induced hypoalgesia (EIH)|Exercise-induced hypoalgesia - isometric muscle contractions of the hand flexors
10171022|NCT03886883|Active Comparator|Static stretch (SS)|A static stretch of the knee flexors
10171023|NCT03886883|Sham Comparator|Rest|No intervention
10171024|NCT03886883|Experimental|Conditioning painful stimulus (CPM)|Conditioned pain modulation - cold pressure test
10171025|NCT03886961|Experimental|Lung Transplant Patients|For the first four weeks, lung transplant patients will not wear the Reflux Band. Use of the Reflux Band will subsequently commence in the next four weeks.
10171026|NCT03886766|Experimental|Sequence 1,2,3|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period C/ Visit 10: Efavirenz solution, 3 mg, oral administration (product 3)
9672027|NCT05040607||Primary Ciliary Dyskinesia (PCD)|"The first stage of the study:~Data of 20 PCD patients from the database recorded between 10 July 2015 and 10 January 2017.~The second stage of the study:~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent supervised inspiratory muscle training (IMT) at our research unit and airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017.~Data of 14 PCD patients who had lower inspiratory muscle strength from the same database underwent airway clearance techniques (ACT) as a home-based therapy for 6 weeks from the database recorded between 10 July 2015 and 10 January 2017."
9672028|NCT05040607||Healthy Group|Data of 20 healthy subjects from the database recorded between 10 July 2015 and 10 January 2017.
9521773|NCT03271398||Children who have been exposed to domestic abuse|
9521774|NCT03271398||Women with perinatal emotional complications|
9521775|NCT03271398||Teens with behavior problems and histories of abuse|
10171027|NCT03886766|Experimental|Sequence 2,3,1|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period B/ Visit 6: Efavirenz solution, 3 mg, oral administration (product 3) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
10171028|NCT03886766|Experimental|Sequence 3,1,2|Period A/ Visit 2: Efavirenz solution, 3 mg, oral administration (product 3) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
10171029|NCT03886805|Experimental|Dual task with variable- and fixed-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks. From the 1st to 12th week the participants were trained under variable-priority instructions (half the session was focused on balance motor task and half the session focused on cognitive task performance). From the 13th to 24th week) the participants performed dual tasks under fixed-priority instructions (simultaneous focus attention on balance and cognitive tasks). The motor tasks were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks will include activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, working memory, among other cognitive tasks.
9672029|NCT05040594|Experimental|Treatment A (right) B (left)|Subjects will receive PavéDerm J-Fill Soft Dermal Filler and Restylane® Lyft Lidocaine. One product will be randomized, per NLF.
9672030|NCT05040594|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane® Lyft Lidocaine and PavéDerm J-Fill Soft Dermal Filler. One product will be randomized, per NLF.
9521776|NCT03271398||Veterans with military-related trauma|
9521777|NCT03271398||Survivors of intimate partner violence|
9521778|NCT03271320||systemic sclerosis|patients with systemic sclerosis
9521779|NCT03271320||control|Healthy subjects
9521780|NCT03271333||patients with systemic sclerosis|
9672031|NCT05040217|Experimental|Gene transfer of AAV2-BDNF|Up to 12 subjects will receive open-label AAV2-BDNF
10171030|NCT03886805|Active Comparator|Dual-task with variable-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks (48 sessions). From the 1st to 24th week, the participants were trained under variable-priority instructions, in which they were asked to spend half the session focused on balance (motor task) and half the session focused on cognitive task performance. The motor tasks (gait and postural balance) of this protocol were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks included activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, rescue working memory, among other cognitive tasks.
10171031|NCT03886753||Ease|Subjects using Ease as standard treatment. Registry and PK sampling
9826605|NCT02424539|Placebo Comparator|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
9826606|NCT02424578|Experimental|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
10171032|NCT03886753||Dream|Subjects using Dream as standard treatment. Registry and PK sampling
10171033|NCT03886753||Soothe|Subjects using Soothe as standard treatment. Registry and PK sampling
10171034|NCT03886753||Shine|Those subjects using Shine as standard treatment. Registry and PK sampling
10171035|NCT03886597|Experimental|60 Arbequina Table Olives|Pharmacokinetics Study
9521783|NCT03271164|Experimental|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
9521784|NCT03271164|Active Comparator|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
9521785|NCT03271112|Other|Exercise program|Participation to the 12-wks exercise program
9521786|NCT03271281|Experimental|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT
9521787|NCT03271255|Experimental|Arm Apatinib|"Apatinib-FOLFIRI:~Apatinib Mesylate Tablets 500 mg po qd; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
9521788|NCT03271255|Active Comparator|Arm Bevacizumab|"Bevacizumab-FOLFIRI:~Bevacizumab Injection 5 mg/kg IV over 30 minutes,day 1; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
10171036|NCT03886597|Experimental|120 Arbequina Table Olives|Pharmacokinetics Study
10171037|NCT03886597|Experimental|60 Table Olives|Table Olives Nutritional Intervention
10171038|NCT03886597|No Intervention|Control|Control of Table Olives Nutritional Intervention
10171039|NCT03886480|Experimental|SaeboVR|Use of the SaeboVR for task specific upper extremity training
10171040|NCT03886623|Experimental|4-day systematic oral hygiene|The intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
9521789|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
9521790|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
9521791|NCT03271177|Experimental|7F Sheathless Guide Catheter|Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter
9521792|NCT03271177|Placebo Comparator|6F Sheath/Guide Catheter Combination|Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination
9521793|NCT03271294|Other|Exair transvaginal mesh surgery|This is a prospective study done in 80 consecutive subjects who underwent the Exair transvaginal mesh surgery from June 2013 to August 2015. The subjects were followed at 4 weeks, 6 months and 12 months post-operatively. All eligible subjects underwent a detailed urogynecologic history and examination including a Pelvic Organ Prolapse Quantification system assessment (POP-Q).
9521794|NCT03271229|Active Comparator|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
9521795|NCT03271229|Active Comparator|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
9521796|NCT03271359|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
9521797|NCT03271359|Experimental|Progressive counting (PC) arm|
9521798|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
9521799|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
9826607|NCT02424578|Experimental|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
9826608|NCT02424591|Active Comparator|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
9521800|NCT03271125|Experimental|Treadmill group|Participants in the experimental group received supervised treadmill training
9521801|NCT03271125|Active Comparator|Resistance group|Participants in the control group were treated with Resistance exercises.
9521802|NCT03271099|No Intervention|Usual Care|Usual care
9521803|NCT03271099|Experimental|Navigator|Patient navigator services provided as part of survivorship care plan
9521804|NCT03271086|Experimental|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
9521805|NCT03271086|Experimental|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
9521806|NCT03271073|Experimental|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
9521807|NCT03271060|Active Comparator|Lumbar spondylolisthesis1|
9521808|NCT03271060|Active Comparator|Lumbar spondylolisthesis 2|
9521809|NCT03271138|Active Comparator|Bifidobacterium Infantis NLS Super Strain|Participants in the probiotic period will take two capsules of Bifidobacterium infantis NLS super strain (Natren LIFE START®2) three times per day for three weeks. Each capsule contains 2 x 10^9 colony-forming units (CFU) of Bifidobacterium infantis NLS super strain, for a total daily dose of 12 X 10^9 CFU. The probiotic will be kept refrigerated during transportation and throughout the study period.
10171041|NCT03886623|Other|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
10171042|NCT03886532||Medical Marijuana|Those subject taking only medical marijuana as standard of care. Will collect registry data and collect blood samples.
10171043|NCT03886532||CBD only products|Those subjects taking only CBD products as standard of care. Will collect registry data and collect blood samples.
10171044|NCT03886389|Experimental|Carbohydrate/intervention group|Breast cancer patients receive 2 x preoperative carbohydrate loading [PreOP(TM)] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.
10171045|NCT03886389|No Intervention|Control group|Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.
10171046|NCT03886636|Experimental|Neuroscience pain education group|in Group 1, participants received Neuroscience pain education, manual therapy and a home exercise program.
10171047|NCT03886636|Experimental|Manual therapy group|in Group 2, participants received manual therapy and a home exercise program.
10171048|NCT03886636|Active Comparator|Control group|in Group 3, participants received home exercise program only.
10171049|NCT03886428|Experimental|100% Portion Size|Test meal with portion size 100% of baseline
10171050|NCT03886428|Experimental|125% Portion Size|Test meal with portion size 125% of baseline
10171051|NCT03886428|Experimental|150% Portion Size|Test meal with portion size 150% of baseline
10171052|NCT03886428|Experimental|175% Portion Size|Test meal with portion size 175% of baseline
10171053|NCT03886376|Experimental|Deep Massage|The deep massage was performed three times during a training week, after a physical training and before the swimming training
10171054|NCT03886376|Active Comparator|Superficial Massage|The superficial massage was performed three times during a training week, after a physical training and before the swimming training
10171055|NCT03886376|No Intervention|Control|The control group kept their normal routine of training. Immediately after the physical training the athletes were instructed to wait for 12 minutes (passive recovery) until the beginning of the swim training.
10171056|NCT03886402|Experimental|Treatment|Each subject will receive a single injection of autologous adipose-derived stromal vascular fraction (SVF) and will be monitored for 6 months
10171057|NCT03886441|Experimental|Prevention group|Participants inhaled beclomethasone propionate aerosol daily during chest radical radiotherapy (total dose 60GY).
10171058|NCT03886441|No Intervention|Traditional therapy group|Participants were not given daily inhalation of beclomethasone propionate when undergoing radical chest radiotherapy (total dose 60GY).
10171059|NCT03886688|Experimental|single ascending|Drug or placebo, oral, fast, single dose ascending
10171060|NCT03886688|Experimental|multiple ascending|Drug or placebo, oral, fast, multiple dose ascending
10171061|NCT03886688|Experimental|Food Effect|Drug or placebo, oral, fed or fast, single dose
9521810|NCT03271138|Placebo Comparator|Placebo|Participants in the placebo period will take two capsules of placebo three times per day for three weeks. The placebo capsules contain rice flour, hydroxypropyl and methylcellulose. The placebo will be kept refrigerated during transportation and throughout the study period.
9521811|NCT03270865|Experimental|Usability and Ergonomic Evaluation of Self-Positioning System|
9521812|NCT03270969|Experimental|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
9521813|NCT03270982||Comprehensive SRS Replacement|
9826609|NCT02424591|Placebo Comparator|Placebo|placebo group will have standard of care rather than ketamine infusion
10171062|NCT03886558|Experimental|Institution Group (n=14)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
9521814|NCT03270813|Experimental|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
9521815|NCT03270813|Sham Comparator|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
10171063|NCT03886558|Experimental|Community Group (n=16)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
9521816|NCT03270787|Placebo Comparator|Placebo Comparator|Placebo Comparator: controlled group Placebo,10pills,tid,po
9521817|NCT03270787|Experimental|Compound danshen dripping pills|Compound danshen dripping pills Compound danshen dripping pills ,10pills,tid,po
9826610|NCT02424630|Experimental|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
9826611|NCT02424630|Placebo Comparator|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
10171064|NCT03886545||caregivers with shoulder pain|
10171065|NCT03886545||Healthy subjects|
10171066|NCT03886675|Experimental|carbon-dioxide|Flushing of stent-grafts in TEVAR with carbon-dioxide
10171067|NCT03886675|Active Comparator|Saline|Flushing of stent-grafts with saline
10171068|NCT03886740|Experimental|Tympanostomy with tubes|Tympanostomy with pressure equalization tube placement with Ventilation (Tympanostomy) Tubes
10171069|NCT03886740|Experimental|Eustachian tube (ET) dilation|Eustachian tube (ET) dilation with ACCLARENT AERA® Eustachian Tube Balloon Dilation System
10171070|NCT03886727|Active Comparator|Rubber Dam|Isolation of single tooth using rubber dam
10171071|NCT03886727|Active Comparator|Cotton Roll|Isolation of quadrant using cotton rolls
10171072|NCT03886662|Experimental|LB-100 for Intravenous administration|Phase Ib: Escalating doses of LB-100 administered. Phase 2: Safe dose of LB-100 from phase Ib administered.
10171073|NCT03886363|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
10171074|NCT03886363|No Intervention|Wait-list control|Usual practice
10171075|NCT03886350||Patients with cystic fibrosis|Patients with CF whom follow-up is undertaken at University Hospital of Tours, France
10171076|NCT03886337|No Intervention|Control|The control arm will be surgical care according to usual practice with usual ambient lighting
10171077|NCT03886337|Experimental|Treatment Arm|The treatment arm will include surgical care according to usual practice with germicidal ambient lighting
10171078|NCT03886324|Experimental|DCB Treatment|Stricture patients treated by DCB
10171079|NCT03886311|Experimental|Talimogene laherparepvec, Nivolumab and Trabectedin|"This is an open label phase 2 study using known doses of TALIMOGENE LAHERPAREPVEC injected intratumorally, and NIVOLUMAB AND TRABECTEDIN given intravenously.~A total of 40 previously untreated and treated patients will receive TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks, NIVOLUMAB 240 mg IV over 30 min q 2 weeks and TALIMOGENE LAHERPAREPVEC intratumorally q 2 weeks according to tumor size (see Schematic of Study Design and Imlygic product information; www.accessdata.fda.gov). Patients in this study may continue treatment until significant disease progression (see below for criteria for discontinuation of therapy) or unacceptable toxicity occurs up to one year of therapy."
10186940|NCT03731078||Motor Functional Neurological Disorder|The cohort will consist of patients with clinically-established motor functional neurological disorder, which includes individuals with functional movement disorders and functional limb weakness. Individuals with functional movement disorders and/or functional limb weakness who also have psychogenic nonepileptic seizures will be included. Patients will receive CBT informed PT intervention. The physical therapy intervention will be usual care in FND and based on consensus recommendations, clinical trials and good practices.
9521818|NCT03271008|Active Comparator|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
9521819|NCT03271008|Active Comparator|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
9826612|NCT02424734|Experimental|Ceftaroline Fosamil|Ceftaroline Fosamil
10171080|NCT03886012|Experimental|Otoband efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to the effective power level. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
10171081|NCT03886012|Sham Comparator|Otoband sham efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to an ineffective power level, serving as a placebo. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
9521820|NCT03271008|Active Comparator|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
9521821|NCT03270839|Active Comparator|Responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
10171082|NCT03886116|Active Comparator|Exercise|"Patient randomized are required to squeeze a soft ball 10 times for a set. They are required to perform 3 sets of 10 squeezes each at a 1 Minute interval.~3 sets of exercises to be performed twice in the Morning and Evening, for a total of 6 weeks."
10171083|NCT03886116|No Intervention|No Exercise|Patient is not required to do any exercise.
10171084|NCT03886103|Experimental|Healthy volunteer|Single of 14C-PXL770
10171085|NCT03885947|Experimental|VPA expanded cord blood stem cells|"CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.~VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation"
9521822|NCT03270839|Placebo Comparator|Responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
9672032|NCT05040243|Experimental|Treatment Group|"On the basis of conventional acupuncture treatment combined with acupoint application of Yanqing Zhitong Ointment.~Acupuncture point:Weizhong,Shenshu,Dachangshu,Jaji,Ashi Acupoint application:Pain in the lumbar spine, Mingmen, Yaoyangguan, Shenshu (double), Ashi (6 points in total); Within 3 inches beside the spine on both sides of the waist, Shenshu (double), Dachangshu (double), Ashi (6 points in total); 3 inches away from the sides of the spine on both sides of the waist, Shenshu (double), Zhishi (double), Ashi (6 points in total).~Stick to each point for about 4 hours. If there is a burning sensation or obvious itching or other discomfort on the part after application, it can be removed in advance.~Three times a week( Monday, Wednesday, and Friday). Course of treatment: each course lasts for 2 weeks, a total of 2 courses of continuous treatment."
10171086|NCT03886077||Hepatitis C Negative Donor Hearts|Hearts for transplantation that are not infected with Hepatitis C. (Negative NAT)
10171087|NCT03886077||Hepatitis C Infected Donor Hearts|Hearts for transplantation that are infected with Hepatitis C. (Positive NAT).
9826613|NCT02424799|Experimental|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
9826614|NCT02424799|Experimental|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
10171088|NCT03886090|Experimental|motor skill practice + aerobic exercise|acute bout of aerobic exercise following motor skill practice
10171089|NCT03886090|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
10171090|NCT03886129||Participants with Transient Ischaemic Attack|"Inclusion Criteria:~Willing to participate~Capacity to consent~Aged >18 years~Able (in the Investigator's opinion) and willing to comply with all study requirements~A diagnosis of acute (≤7 days) TIA, made by a specialist that fulfils the 2009 American Heart Association definition of TIA~Good understanding of written and verbal English~Exclusion Criteria:~Unwilling to take part~Unable to consent~Aged <18 years~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~Female participants who are pregnant, lactating or planning pregnancy during the course of the study~Atrial fibrillation~Severe heart failure (Ejection Fraction <30%)~Severe respiratory disease~Inadequate bilateral transcranial Doppler windows~Carotid stenosis ≥70% (unilateral or bilateral)~Participant enrolled in an interventional research study.~Poor understanding of written and verbal English"
10186941|NCT03731065|Active Comparator|Fructose-maltodextrin ingestion|Ingestion of fructose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
10186942|NCT03731065|Experimental|Fructose-maltodextrin hydrogel ingestion|Ingestion of fructose and maltodextrin (glucose polymers) encapsulated in alginate-pectin hydrogel, drinks at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
9521823|NCT03270839|Active Comparator|Non-responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
9521824|NCT03270839|Placebo Comparator|Non-responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
9521825|NCT03270839|Active Comparator|Responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
9672033|NCT05040243|Sham Comparator|Control Group|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
10171091|NCT03886129||Healthy Control Participants|"Inclusion Criteria:~Willing to participate~Capacity to consent to the study~Aged >18 years~Able (in the Investigator's opinion) and willing to comply with all study requirements~Good understanding of written and verbal English~Exclusion Criteria:~Unwilling to take part~Unable to consent~Aged <18 years~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~Female participants who are pregnant, lactating or planning pregnancy during the course of the study~Atrial fibrillation~Severe heart failure (Ejection Fraction <30%)~Severe respiratory disease~Inadequate bilateral transcranial Doppler windows~Carotid stenosis ≥70% (unilateral or bilateral)~Participant enrolled in an interventional research study.~Poor understanding of written and verbal English"
10171092|NCT03886142|Active Comparator|radiofrequency|genicular nerves pulsed radiofrequency
10171093|NCT03886142|Active Comparator|intra-articular platelet rich plasma|injection of platelet rich plasma in the affected joint
10171094|NCT03886298|Experimental|radiofrequency splanchnic denervation|
10171095|NCT03886298|Active Comparator|retrocrural celiac denervation|
10171096|NCT03885882|Experimental|Cohort 1: E0302 Sustained Release (SR1) 1500 mcg|Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.
10171097|NCT03885882|Experimental|Cohort 2: E0302 Sustained Release (SR3) 1500 mcg|Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.
10171098|NCT03885882|Experimental|Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg|Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
10171099|NCT03885882|Experimental|Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg|Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
10171100|NCT03886207|Experimental|Warm water with ginger powder footbath|Participants who receive a warm water with added ginger powder footbath four times a week over a six-week period.
10171101|NCT03886207|Active Comparator|Warm water only footbath|Participants who receive a warm water only footbath four times a week over a six-week period.
10171102|NCT03885895|Active Comparator|Participants with freckles (one side of the face)|one randomized side of the face will be treated by Intradermal Tranexamic acid
10171103|NCT03885895|Active Comparator|Participants with freckles (other side of the face)|other side will be treated by Q switched KTP laser
10171104|NCT03886038|Active Comparator|RA patients on JAK inhibitors|RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDS/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
10171105|NCT03886038|Active Comparator|RA on synthetic or biological DMARDs|RA patients tretad with syntetic or bioloogial DMARDs for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
10171106|NCT03886038|Active Comparator|healthy controls|healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart
10171107|NCT03886051|Experimental|test group|Connective Tissue Graft before Orthodontic treatment
9521826|NCT03270839|Placebo Comparator|Responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
9521827|NCT03270839|Active Comparator|Non-responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
9521828|NCT03270839|Placebo Comparator|Non-responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
10171108|NCT03886051|Active Comparator|control group|Orthodontic treatment only
10171109|NCT03885869||Type 2 Diabetics|Type 2 diabetic individuals aged 30-65 years
10171110|NCT03885973|Experimental|Lactobacillus plantarum|1 bottle of fermented milk (100 g) containing probiotic Lactobacillus plantarum IS-10506 1.0x10^8 CFU will be given daily for three weeks.
10171111|NCT03885973|Placebo Comparator|Placebo|1 bottle of fermented milk (100 g) containing placebo will be given daily for three weeks.
10171112|NCT03886194|Active Comparator|Thrombolytic group|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip
10171113|NCT03886194|Experimental|Interventional treatment group|Interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
10171114|NCT03886233||Traditional Treatment for Autoimmune uveitis|Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
10171115|NCT03886233||Biological Treatment for Autoimmune uveitis|Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
9826615|NCT02424799|Experimental|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of ~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
9826616|NCT02424799|Experimental|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
9826617|NCT02424968|Experimental|Infusion of Allogeneic CD8+ Memory T-cells|All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).
9521829|NCT03270852|Experimental|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
9826618|NCT02425098|Experimental|High-dose Tetravalent Dengue Vaccine (HD-TDV)|High-dose Tetravalent Dengue Vaccine [HD-TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
10171116|NCT03886181|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
10171117|NCT03885856||single row repair technique|patients surgically treated for rotator cuff lesion by single row repair technique
10171118|NCT03885856||double row repair technique|patients surgically treated for rotator cuff lesion by double row repair technique
10171119|NCT03885843|Experimental|RDN Group|renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.
10171120|NCT03885843|Sham Comparator|Sham Group|renal artery angiography group, without any renal nerve stimulation, mapping or denervation
10171121|NCT03885778|Experimental|A-fasted dosing followed by fed dosing|Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing
10171122|NCT03885778|Experimental|B-fed dosing followed by fasted dosing|Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing
10171123|NCT03885830||Bosutinib|Subjects who have been prescribed or administered bosutinib (Bosulif) for treatment of chronic-phase CML for less than 12 months.
10171124|NCT03885830||Dasatinib|Subjects who have been prescribed or administered dasatinib (Sprycel) for treatment of chronic-phase CML for less than 12 months.
10171125|NCT03885830||Imatinib|Subjects who have been prescribed or administered imatinib (Gleevec) for treatment of chronic-phase CML for less than 12 months.
10171126|NCT03885830||Nilotinib|Subjects who have been prescribed or administered nilotinib (Tasigna) for treatment of chronic-phase CML for less than 12 months.
10171127|NCT03885687|Experimental|Exercise with Music Intervention|The Exercise with Music intervention is a recorded exercise playlist, which is tailored to a patient's individual physical abilities and music choices.
10171128|NCT03885687|Active Comparator|Active Control Group|The active control group will receive exercise brochure and will be advised to exercise at least twice daily.
10171129|NCT03885791|Experimental|Vaginal cryotherapy - intervention|"The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a slushy consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer."
10171130|NCT03885791|Placebo Comparator|Vaginal cryotherapy - control|The control group will be provided with an identical tube that is empty. An empty tube was chosen as the control because a tube with room-temperature liquid may still be perceived as cold. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home at room temperature.
10171131|NCT03885570||Groups/Cohorts|"1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete."
10171132|NCT03885440||Young adult, without OSAS|20<=Age<40 years old, apnea-hypopnea index(AHI)<5
10171133|NCT03885440||Young adult, with OSAS|20<=Age<40 years old, AHI>=5
10171134|NCT03885440||older adult, without OSAS|Age>=40 years old, AHI<5
10171135|NCT03885440||older adult, with OSAS|Age>=40 years old, AHI>=5
10171136|NCT03885739|Other|Patients with hip fracture|15 consecutive HF patients who were admitted to a single level 3 center and who report severe pain despite a standardized analgesia protocol. Patients were assessed by the Pain Service as part of a multidisciplinary care pathway and a Continuous Pericapsular Nerve Group blocks was offered as a component of a multimodal analgesic regimen.
9521830|NCT03270852|Active Comparator|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
9521831|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
9672034|NCT05040399|Other|Locking Compression Plates|Patients in whom we used Locking compression plates for sternal fixation
9521832|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
9521833|NCT03270735|Experimental|Treatment|Snake venom thrombin
9521834|NCT03270735|Placebo Comparator|Placebo|Snake venom thrombin simulant
10171137|NCT03885804|Sham Comparator|Quadratus lamborum dexmedetomidine intravenous group|Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
10171138|NCT03885804|Active Comparator|Quadratus lamborum dexmedetomidine perineural group|Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
9527797|NCT03216941|Active Comparator|olanzapine|assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
9527798|NCT03216707|Sham Comparator|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
9527799|NCT03216707|Active Comparator|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
10171139|NCT03885752|Active Comparator|the control group|
10171140|NCT03885752|Placebo Comparator|the gum group|
10171141|NCT03885583|Active Comparator|thoracic epidural group|patients in this group will receive ultrasound guided thoracic epidural block preoperatively for pain management, continuous infusion of 0.5% bupivacaine through epidural catheter during operation and early post-operative period
10171142|NCT03885583|Active Comparator|paravertebral group|patients in this group will receive ultrasound guided pararvertebral block preoperatively for pain management, continuous infusion of paravertebral bupivacaine 0.5% through paravetebral catheter during operation and early post-operative period
10171143|NCT03885674|Experimental|Reminder Interventions|Receive daily reminders from Kessler Foundation study personnel on when to take their medication.
10171144|NCT03885674|No Intervention|Standard Condition|This group will not receive reminders on when to take their medication from Kessler Foundation staff and will receive the usual and standard care.
10171145|NCT03885700|Experimental|intervention group|
10171146|NCT03885700|No Intervention|control group|
10171147|NCT03885609|Experimental|Treatment - toothwave brush|Subjects using the Silk'n ToothWave RF utilizing toothbrush
10171148|NCT03885609|Sham Comparator|Control - powered toothbrush|Subject using a regular powered toothbrush with no RF.
10171149|NCT03885635|Active Comparator|Hemiarch repair|Standard hemiarch repair with open distal anastomosis in the proximal arch without replacement of the head vessels.
10171150|NCT03885635|Active Comparator|Extended arch repair|Ascending aortic and arch replacement with or without head vessel re-implantation and single TEVAR device placement within 1 week.
10171151|NCT03885258|Experimental|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
10171152|NCT03885479||IBD patients|"Full history taking and examination~Colonoscopy, biopsy and histopathology to determine the extent of the lesion~An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)~Patients will be categorized into 3 groups (UC patients, Crohn disease patients and controls)~All of the following factors will be taken into consideration; type and duration of the treatment, age of diagnosis, BMI, smoking status and activity of the disease at the time of the study"
10171153|NCT03885479||Controls|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
10171154|NCT03885557|Experimental|Group I Experimental Dynamic oscillatory stretch(DOS)|Dynamic oscillatory stretch technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group.
10171155|NCT03885557|Active Comparator|Group II Static Stretching(SS) Group|Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group.
10171156|NCT03885466|Experimental|Nordic walking|Nordic walking exercise intervention, 3 times per week over 12 weeks
9527800|NCT03216707|Active Comparator|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
9527801|NCT03217149|Experimental|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
9527802|NCT03217149|Active Comparator|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
9672035|NCT05040399|Other|Wires|Patients in whom we used Sternal Wires for sternal fixation
10171157|NCT03885466|No Intervention|Control|Waiting list controls will be offered same Nordic walking intervention after 3 month follow-up measurements
9521835|NCT03270904|Experimental|Group 1 - Interventional Treatment|Participants in this group have been randomised to receive application of violet blue light administered by the hand held Microlight i:X device in addition to routine care of their foot ulcer. This intervention will be administered four times during the study.
9672036|NCT05040516||Group 1|"The planned procedures include: medical interview, physical examination with basic anthropometric measurements (age, height, body weight); biochemical tests including blood selenium, selenoproteins, renalase and creatinine levels; total antioxidant status (TAS), 24-hour Holter electrocardiography, polysomnography and echocardiography.~A 10 ml of venous blood sample will be collected by venopuncture. Laboratory tests will be performed using commercially available standardized tests."
9672037|NCT05040412|Experimental|Diabetic mellitus patients using insulin|The trachea will be intubated by direct laryngoscopy.
9521836|NCT03270904|No Intervention|Group 2 - Usual care|This group receive routine care and no additional intervention.
9672038|NCT05040412|Experimental|Diabetic patients using oral antidiabetic drug|The trachea will be intubated by direct laryngoscopy.
10171158|NCT03885336||Both-Quit Group|Couples in which both individuals smoke and both individuals would like to quit smoking.
10171159|NCT03885544|Active Comparator|Controlled lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet without red meat for 3 weeks.
10171160|NCT03885544|Experimental|Controlled unprocessed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with unprocessed red meat for 3 weeks.
10171161|NCT03885544|Experimental|Controlled processed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with processed red meat for 3 weeks.
10171162|NCT03885453||Panic Disorder / Agoraphobia|Patients with Panic Disorder / Agoraphobia as major diagnosis
10171163|NCT03885453||Depression|Patients with Depression as major diagnosis
10171164|NCT03885427|Experimental|oral ketamine|evaluate sedative,and analgesic effects
9826619|NCT02425098|Experimental|Tetravalent Dengue Vaccine (TDV)|Tetravalent Dengue Vaccine [TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^3 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
9826620|NCT02425111|Experimental|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
10171165|NCT03885427|Active Comparator|nebulized ketamine|evaluate sedative, and analgesic effects
9672039|NCT05040633|Experimental|Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by the Low Lever Laser Therapy.
10171166|NCT03885206|Experimental|Hospital|Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
10171167|NCT03885206|No Intervention|Municipal acute ward|Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
10171168|NCT03885232|Experimental|PIVOT with MI|Clinics with providers trained in the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing intervention (PIVOT with MI)
10171169|NCT03885232|Active Comparator|Control|Control-Care as usual
10171170|NCT03885219|Experimental|nab-paclitaxel and S-1|chemotherapy of Nab-Paclitaxel and S-1, repeat 21 days for up to 8 cycles. The following treatment including pancreatectomy, continuing same chemotherapy, S-1 maintenance therapy, or radiotherapy will be decided after discussion between physicians and patients.
10171171|NCT03885310|Experimental|DCB Treatment|Stricture patients treated by DCB
10186943|NCT03731065|Active Comparator|Glucose-maltodextrin ingestion|Ingestion of glucose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
10186944|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SLIGHT TISSUE DAMAGE|
10186945|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH MODERATE TISSUE DAMAGE|
10186946|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SUBSTANTIAL TISSUE DAMAGE|
10186947|NCT03731026|Other|Group 1|Patient will receive an IV injection of up to 200MBq 68Ga-RM2. Each patient will have torso PET/CT imaging at 2 timepoints. Alternate patients will have imaging at 1 and 2h post-injection then the next patientat 1 and 3h post-injection, with axillary gamma probe measurements (using a collimator) of 68Ga-RM2 at the same time points.
10186948|NCT03731026|Experimental|Group 2|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 2 scans will acquire LightPath® images of both intact and incised cancer specimens with varying parameters to optimise imaging.
10186949|NCT03731026|Experimental|Group 3|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 3 scans will acquire LightPath® images of intact and incised cancer specimens using a final and consistent imaging procedure.
10186950|NCT03731013|Experimental|Mediterranean diet (MedDiet)|
10186951|NCT03731013|Experimental|Physical activity (PA)|
10186952|NCT03731013|Experimental|Mediterranean diet and physical activity|
10186953|NCT03731013|No Intervention|Control|
10186954|NCT03731000|Experimental|PHIL® device|Using device
10186955|NCT03730935|Experimental|Intervention|Respiratory muscle endurance training (30 minutes of volitional hyperpnoea at a target ventilation of 60-70% of the individual maximal voluntary ventilation for 5 days per week for 4 weeks).
10186956|NCT03730935|Sham Comparator|Sham|Sham training will be performed 5 times a week for 4 weeks using a mock asthma inhaler filled with 5.5 mg lactose powder. Subjects will be instructed to inhale the powder according to inhaler instructions and to then perform one full inspiration to total lung capacity using custom-made, low resistance tubing, which elicits minimal resistance to breathing.
9521837|NCT03270748|Experimental|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day -6 through day -3) Fludarabine 40 mg/m2 per day for 4 days (from day -6 through day -3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
9521838|NCT03270800|Experimental|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
9521839|NCT03270800|Experimental|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
10171172|NCT03885128|Experimental|Vest arm|high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients
10171173|NCT03885128|Experimental|Quake arm|Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients
10171174|NCT03885349|Experimental|SBIP+ ADAPs-IMP|Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
10171175|NCT03885349|Active Comparator|SBIP+IMP|Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
10171176|NCT03885102|Experimental|Intervention|12 months intradialytic exercise intervention
10171177|NCT03885102|Active Comparator|Usual care|Usual care according to current guidelines
10171178|NCT03885284|Experimental|Dose Level 1|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 8-12 of cycle 6"
10171179|NCT03885284|Experimental|Dose Level 2|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 15-19 of cycle 6"
10171180|NCT03885180|Experimental|Extend anticoagulation group|Extended the duration anticoauglation to 12 months
10171181|NCT03885180|No Intervention|Stop anticoagulation group|Just stop oral anticoagulation like routine
10171182|NCT03885414|Experimental|OST-VRET + in-vivo transition program|One-session treatment (OST) VRET on-location with clinical psychologist (3 hours), followed by a therapist-guided, four-week online program encouraging transition to real-world, in-vivo exposure exercises.
10171183|NCT03885063|Experimental|Benjamin Rose Institute Care Consultation (BRI-CC)|
10171184|NCT03885063|No Intervention|No intervention|
9521840|NCT03270995|Experimental|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
9521841|NCT03270995|Active Comparator|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
9521842|NCT03270878|Experimental|Glasdegib Oral tablet then IV|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
9521843|NCT03270878|Experimental|Glasdegib IV solution followed by Oral tablet|Subjects will receive a 50 mg IV solution will be infused over approximately 1.25 hours in the fasted condition followed by washout in the first study period . Then in the second period, a single 100 mg oral tablet of glasdegib will be administered under fasted conditions
9672040|NCT05040633|Sham Comparator|Sham Low Level Laser Therapy + standard exercise therapy|This group of participants will first receive the standard therapy of strengthening and stretching exercises followed by a sham Low Level Laser Therapy (LLLT). The laser equipment will be deactivated and not switched on.
9826621|NCT02425306|Experimental|Arm A:6MHP + Montanide ISA-51|Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
9521844|NCT03270722|Experimental|patients with scleroderma and trouble swallowing|
9521845|NCT03270722|Experimental|patients with scleroderma but no trouble swallowing|
9521846|NCT03270722|Active Comparator|patients without scleroderma undergoing endoscopy|
10171185|NCT03884959|Experimental|HepaStem Infusion|A calculated dose based on patient's body weight will be administered via Permanent mesenteric Portal Access and Catheter for four times or a Transient Percutaneous Transhepatic Catheter for three times.
10171186|NCT03885388|Active Comparator|control arm|single methotrexate multicourse treatment MTX:MTX 0.4mg/kg•d, intramuscular, every two weeks
10171187|NCT03885388|Experimental|experimental arm|combination of methotrexate and actinomycin multicourse treatment, every two weeks MTX+ACTD:Act-d 0.6mg/m2 Day1,2 intravenous (IV) MTX 100mg/m2 IV Day1(after Act-d) MTX 200mg/m2 Ivgtt Day1(after MTX,500mlNS)
10171188|NCT03884933|Experimental|Mobile team community mental health services|
10171189|NCT03884933|No Intervention|Current clinical services|
10171190|NCT03885323|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with RF-utilizing powered toothbrush
9521847|NCT03270709|Experimental|HIV+ smokers|Vitamin D3 450,000 IU orally
9521848|NCT03270709|Active Comparator|HIV- non-smokers|Vitamin D3 450,000 IU orally
9521849|NCT03270709|Active Comparator|HIV+ non-smokers|Vitamin D3 450,000 IU orally
9521850|NCT03270709|Active Comparator|HIV- smokers|Vitamin D3 450,000 IU orally
9527803|NCT03216720|Active Comparator|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
9527804|NCT03216720|Active Comparator|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
10171191|NCT03885323|Placebo Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
10186957|NCT03730922|Experimental|A: Delayed-immediate reconstruction|"Primary Surgery: Skin sparing mastectomy (nipple sparing if appropriate) and axillary surgery according to guidelines or protocol. Reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix.~Delayed reconstruction: Final reconstruction with any reconstructive procedure - being it autologous or implant-based (one- or two-stage, +/- acellular dermal matrix (ADM)) - is performed 6-12 months after completion of chemotherapy and PMRT. Any contralateral procedure is allowed when doing the delayed surgery, but not in relation to the initial cancer surgery."
9521851|NCT03270696|Experimental|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
9672041|NCT05040633|Active Comparator|Standard Exercise Therapy|Trial participants in this group will only receive the standard exercise therapy. The exercise therapy will consist of strengthening and stretching exercises.
10171192|NCT03885297||Overweight/obese participants|Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan. Patients will additionally receive standard NHS Tier 3 lifestyle advice and support for the duration of the study. Lifestyle modification aimed at weight loss will be delivered by a dietician or other trained health care professional within individual sessions for a period of 6 months. Finally, all patients will be able to withdraw from treatment and/or the study at any point without giving any explanation. This will have no impact in their clinical management.
10171193|NCT03884686|Experimental|Web-based intervention|Patients allocated to intervention arm will have unlimited free access to a web-based education resource.
10171194|NCT03884686|No Intervention|Usual care|Patients allocated to usual care will receive all usual care and education opportunities.
10171195|NCT03885271|Experimental|Group A (Experimental group) Hall Technique|Clinical examination to assess the clinical inclusion criteria. Radiographic examination.The child will be positioned upright in the dental chair . The correct size of PMC for the tooth will be selected. The tooth will be rinsed and dried, and the PMC dried. The PMC will be filled with glass ionomer luting cement. The PMC will be placed evenly over the tooth and the child instructed to bite down firmly until the crown was pushed down over the tooth;If the child was unable or unwilling to bite down on the PMC, finger pressure will be used to seat the crown Extruded cement will be removed, and the child will be asked to keep biting on the Hall PMC until the cement sets and once cement sets, excess cement is removed, floss will be used to clear the aproximal contacts, and post-fitting instructions will be given (Innes et al. 2007).
10171196|NCT03885271|Active Comparator|Group B (control group) Formecresol Pulpotomy|Clinical examination to assess the clinical inclusion criteria. Radiographic examination. The teeth anesthetized, rubber dam isolation, Complete caries removal achieved with a sterile round steel bur in a slow- speed handpiece. Access to the pulp chamber performed using a sterile slow-speed round steel bur. The pulp amputation with a sterile diamond bur in a high-speed handpiece and pulpal debris removed with a sterile saline solution on a sterile cotton pledget. After pulp amputation haemostasis achieved using a sterile cotton pledget. Formocresol (FC) applied using a sterile cotton pledget for 5 minutes. After removal of the formocresol soaked cotton pledget, the pulp chamber rinsed with water using an air-water syringe. The pulp chamber dried with a sterile cotton pledget, followed by application of Zinc Oxide & Eugenol and zinc phosphate. Tooth preparation done to receive stainless steel crown.
10171197|NCT03884946|Active Comparator|Immediate Delivery|Participants randomized into the Immediate Delivery arm (n = 150) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
10171198|NCT03884946|Placebo Comparator|Delayed Delivery|Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
10171199|NCT03884881|Other|metagenomic next generation sequencing|Adjust medication for patients with severe pneumonia based on mNGS results
10171200|NCT03884881|Other|Conventional pathogen detection|Blood, bronchoalveolar lavage fluid (BALF), bronchial secretions samples will be collected and microbiologically tested prior to initial empirical antibiotic use.
10171201|NCT03884868|No Intervention|Control group|Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
10171202|NCT03884868|Experimental|Intervention group|In addition of the regular nursing visit: the nurse will use iconographies specially designed to communicate the risk of the different possible diagnoses and the complications of the colonoscopy. Because the risks are different according to sex and age, specific iconographies will be developed from the data available in the first screening round.
10171203|NCT03885076||Acute myeloid leukaemia|Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease. There is no intervention. This is an observational tissue collection study.
10171204|NCT03884738|Active Comparator|Concentric|Leg Curl Training
10171205|NCT03884738|Active Comparator|Eccentric|Nordic Hamstring Training
10171206|NCT03884738|Active Comparator|Neuromuscular Electrical Stimulation|Stimulation Training
10171207|NCT03884894||sepsis diagnosis by blood colture/molecular biology|fullterm/ preterm neonates hospitalized in NICU with suspect of sepsis
10171208|NCT03884790|Experimental|Surgical repair of long bone defects|The Patients in the study group will be surgically treated and the GreenBone Bone Substitute will be implanted
10171209|NCT03884803|Other|HealthyMoms web-based program|An on-line self-help psychoeducational website for new moms that includes educational learning modules and tools to prevent/reduce depression. .
10171210|NCT03884803|Other|Control group|No access to the intervention but to continue with standard care. Will complete the same questionnaires as the HealthyMoms group.
10171211|NCT03884764|Experimental|PRF on S3 + ganglion impar denervation|patients will receive pulsed radiofrequency on sacral root number 3 in conjunction with ganglion impar denervation by alcohol
10171212|NCT03884764|Active Comparator|ganglion impar denervation|patients will receive ganglion impar denervation by alcohol
9672042|NCT05040555|Experimental|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1~5.
10171213|NCT03884751|Experimental|CAR-GPC3 T Cells|The subjects are enrolled into 2 dose levels cohorts in sequence
9521852|NCT03270696|Experimental|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
9521853|NCT03270579|Experimental|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of [18F]JNJ-64511070.
10171214|NCT03885141|Placebo Comparator|Men - Placebo|Men - Placebo, 1 tablet if a wake up occurs
10171215|NCT03885141|Experimental|Men - Zolpidem 1.75 mg|Men - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
10171216|NCT03885141|Experimental|Men - Zolpidem 3.5 mg|Men - Zolpidem 3.5 mg, 1 tablet if a wake up occurs
10171217|NCT03885141|Placebo Comparator|Women - Placebo|Women - Placebo, 1 tablet if a wake up occurs
10171218|NCT03885141|Experimental|Women - Zolpidem 1.0 mg|Women - Zolpidem 1.0 mg, 1 tablet if a wake up occurs
10171219|NCT03885141|Experimental|Women - Zolpidem 1.75 mg|Women - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
10171220|NCT03885115|Experimental|Intervention|Participants randomly assigned to the experiential group (EG) will receive a 12-week structured exercise that will consist of two group fitness sessions (i.e. kickboxing, Zumba, fitness yoga, and other aerobic exercises) every week. Certified fitness instructors will lead each session and participants will learn strategies how to be more active during the daily routines at home. Parents or other relatives in the EG will participate in one 2-hour session every four weeks (total of 3 sessions) designed to help them support their children and entire family in being active and eat healthy at home. Parents will meet with a fitness instructor who will provide specific tips on how to increase physical activity at home as well as providing community resources to be active. A basic nutrition education and cooking demonstrations, and healthy recipes will be also provided to parents at these workshops. Data/assessments are collected, pre and post the 12 weeks intervention.
10171221|NCT03885115|No Intervention|Control|Participants randomly assigned to the control group (CG) will receive once a week recreational structured group play/game sessions led by trained BOUNCE interns/staff. The control group will receive 60 minute of structured free play sessions (i.e. recreational games) once a week for 12 weeks. Every 4 weeks, parents will be given (either sent home with their child or via email or mail) basic nutrition information, healthy recipes, and tips to promote physical activity at home as well as community resources to be active. Data/assessments are collected, pre and post the 12 weeks intervention.
10171222|NCT03884842|Active Comparator|dupilumab|"Dupilumab 300 mg subcutaneously (SC) every 2 weeks as an investigational drug. For those randomized to dupilumab, a loading dose of 600 mg will be given only at randomization/Visit 2.~Sterile dupilumab of will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total volume) to deliver 300 mg in 2 mL."
10171223|NCT03884842|Placebo Comparator|matched placebo|Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to deliver 2 mL.
10171224|NCT03884725|Active Comparator|fibrinogen concentrate|patients randomized to fibrinogen group receive intravenous infusion of drug prepared based on ROTEM measurement of maximum clot firmness (MCF)
10171225|NCT03884725|Placebo Comparator|control|patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF)
10171226|NCT03884972|Experimental|Cohort I (BTK-refractory)|Patients receive venetoclax PO QD beginning on day 1 for 5 weeks (cycle 1). Beginning in cycle 2, patients receive venetoclax PO QD and trabectedin IV over 3 hours on day 1. Cycles 2+ repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
10171227|NCT03884972|Experimental|Cohort II (BTK-intolerant)|Patients receive trabectedin IV over 3 hours on day 1 of a 3-week cycle (cycle 1), then receive venetoclax PO QD beginning on day 1 of a 5-week cycle (cycle 2). Beginning in cycle 3, patients receive trabectedin IV over 3 hours on day 1 and venetoclax PO QD every 3 weeks in the absence of disease progression or unacceptable toxicity.
10171228|NCT03884699|Other|Segmental maxillary lefort I re-positioning|Accuracy of the planned virtually re-positioned segmental Lefort I maxilla using a specifically designed patient implant, comparing the virtual plan to the actual postoperative position.
10171229|NCT03884673||DTG+3TC|These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).
10171230|NCT03884621|Experimental|EHP Group|The Enhanced post-discharge home-based care program (EHP) offers one coaching session upon hospital discharge and 12-week home follow-up (including 6 home visits, 6 telephone calls and 24-hour hotline) post hospital discharge to participants by an especially trained nurse case manager with the support of a clinical team. The five intervention protocols integrate with an individualized home-based rehabilitation training and self-care plan.
10171231|NCT03884621|No Intervention|Control Group|Usual discharge care and post-discharge care provided to all stroke patients discharged home.
10171232|NCT03884595||No SIRS|Children without clinical signs of SIRS, according to Goldstein criteria.
9672043|NCT05040178||Male and Female Adult and Pediatric Participants|Patients treated with carglumic acid for the treatment for hyperammonemia due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
9672044|NCT05040425|Experimental|Chinese herbal medicine treatment|
10171233|NCT03884595||SIRS|Children with clinical signs of SIRS, according to Goldstein criteria.
10171234|NCT03884595||Sepsis|Children with clinical signs of sepsis, according to Goldstein criteria.
10171235|NCT03884595||Severe sepsis|Children with clinical signs of severe sepsis, according to Goldstein criteria.
9527805|NCT03216668|Experimental|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks
9527806|NCT03216668|Active Comparator|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
9672045|NCT05040425|No Intervention|Non-Chinese herbal medicine treatment|
9672046|NCT05040464|Experimental|AZA group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg(W0)-80mg(W2)-40mg(W6) and then 40mg EOW and oral AZA capsules at a daily dose of 2.5 mg/kg
9672047|NCT05040464|Experimental|MTX group|Combination of sub-cutaneous administration of adalimumab at a dose of 160mg (week (W) 0)-80mg(W2)-40mg(W6) and then 40mg EOW and sub-cutaneous MTX 25mg once a week
9521854|NCT03270579|Experimental|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 and to model the tissue specific kinetics of [18F]JNJ-64511070 in the human brain with the appropriate arterial IF.
10171236|NCT03884595||Septic Shock|Children with clinical signs of septic shock, according to Goldstein criteria.
10171237|NCT03884582||HealthyVolunteers|
10171238|NCT03884491|Experimental|Vortioxetine|
10171239|NCT03884374|Experimental|African American Group|African Americans with knee osteoarthritis (OA).
10171240|NCT03884374|Experimental|Non-Hispanic White Group|Non-Hispanic whites with knee osteoarthritis (OA).
10171241|NCT03884257|Experimental|Passeo-18 Lux treatment group|These patients will be treated with the Passeo-18 Lux (Biotronik).
10171242|NCT03884257|Active Comparator|IN.PACT Admiral treatment group|These patients will be treated with the IN.PACT Admiral (Medtronic).
10171243|NCT03884231||Leads-only configuration|The leads-only configuration consists of at least one implanted lead protected with a lead protection boot, as well as an optional cranial burr hole cover. Any leads must be completely implanted with the surgical incision closed.
10171244|NCT03884231||Full system configuration|The full system configuration consists of at least one IPG, one lead, one extension, and an optional cranial burr hole cover. All devices must be completely implanted with the surgical incision closed.
10171245|NCT03884348||PAM-treated clarithromycin-resistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
10171246|NCT03884348||PAC-treated nonresistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
10171247|NCT03884361|Experimental|Vaginal Microbiome as result of aminocentesis|aginal Microbiome as result of aminocentesis by a blood and a vaginal samples that will taken before and after the aminocentesis
10171248|NCT03884517|Experimental|BAT8003 0.2mg/kg|BAT8003，0.2mg/kg，intravenous infusion, sample size 1-3
10171249|NCT03884517|Experimental|BAT8003 0.5mg/kg|BAT8003，0.5mg/kg，intravenous infusion, sample size 1-3
10171250|NCT03884517|Experimental|BAT8003 1mg/kg|BAT8003，1mg/kg，intravenous infusion, sample size 3
10171251|NCT03884517|Experimental|BAT8003 2mg/kg|BAT8003，2mg/kg，intravenous infusion, sample size 3
10171252|NCT03884517|Experimental|BAT8003 4mg/kg|BAT8003，4mg/kg，intravenous infusion, sample size 3
10171253|NCT03884517|Experimental|BAT8003 6mg/kg|BAT8003，6mg/kg，intravenous infusion, sample size 3
10171254|NCT03884517|Experimental|BAT8003 8mg/kg|BAT8003，8mg/kg，intravenous infusion, sample size 3
10171255|NCT03884517|Experimental|BAT8003 10mg/kg|BAT8003，10mg/kg，intravenous infusion, sample size 3
10171256|NCT03884517|Experimental|Amplification group|BAT8003，intravenous infusion，choose one proper dose from 0.2、0.5、1、2、4、6、8、10mg/kg
9521860|NCT03270410||Neonates|Babies born in Rennes University Hospital
9521861|NCT03270566|Experimental|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
9521862|NCT03270566|No Intervention|Usual hard water supply|The control group will receive their usual domestic water supply.
10171257|NCT03884322|Experimental|Prepod Group|Premature Infants (31 to 32 weeks gestation on entry to program), healthy who wear a prepod or elastic knit fabric pod with snaps essentially 24 hrs a day with brief breaks for bathing, exams, or parent skin to skin time. The intervention lasts 4 weeks
10171258|NCT03884322|Active Comparator|Control Group|Premature infants (31 to 32 weeks of age on entry to program), healthy who receive a joint compression exercise program approximately 10 minutes a day 5 days a week. The intervention lasts 4 weeks
10171259|NCT03884413||Breast cancer survivors|Study of spontaneous fertility outcomes following breast cancer history
10171260|NCT03884413||Control group|Study of spontaneous fertility outcomes in healthy volonteers population
10171261|NCT03884296|Other|Study Phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
10171262|NCT03884465|Experimental|Inhaled dry powder treprostinil (LIQ861)|Full study population receives inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg or 100μg capsule strengths.
10171263|NCT03884400||Subjects who have provided consent for specimen collection|Re-consent will not be required. This protocol allows distribution of the specimens following the terms agreed to by the subject in the original consent.
10171264|NCT03884192|Experimental|Sintilimab Arm|Sintilimab consolidation therapy
10171265|NCT03884192|No Intervention|Observation Arm|Observation
10171266|NCT03884218|Other|Thermal Comfort|Infra red thermal image
10171267|NCT03884244|Active Comparator|taking chewing gum patients|
9521863|NCT03270449|Experimental|Multidisciplinary intervention|The 10-week intervention will include twice weekly 1-2 hours sessions with multiple professional team members to undergo education and exercise sessions. The multidisciplinary team will consist of a rheumatologist, rheumatology nurse, dietitian, physiotherapist, a trained exercise therapist, a physiologist who specializes in pain management, a psychiatrist and a mental health clinician. All intervention team members have expertise in working with individuals with chronic pain conditions. General disease information, current best practices and techniques such as self-pain management, pacing, sleep hygiene, approach to a healthy lifestyle and weight loss will be discussed. The total number of hours for the 10 week intervention is 31 hours.
9527807|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
10171268|NCT03884244|No Intervention|no chewing gum|
10171269|NCT03884309|Experimental|Experimental Hydrolyzed Protein Infant Formula|hydrolyzed protein infant formula powder in cans
10171270|NCT03884478|Experimental|Alcohol + Stigma Coping PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
9521864|NCT03270449|No Intervention|Usual care|Usual care involves being referred to the local rheumatologist involved in the study. The rheumatologist and the rheumatology nurse will see the control group patients during a one hour one on one consultation appointment. During that time the patient's history will be taken, physical exam performed and investigations analyzed. If a diagnosis of fibromyalgia is confirmed, the rheumatologist and nurse will counsel the patient and provide resources for self directed management. Unless there is a concern of an alternative diagnosis, follow up will not be arranged.
10171271|NCT03884478|Experimental|Alcohol + Control PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
9672048|NCT05040321|Experimental|MIB-626|Subjects will either take MIB-626 or placebo tablet twice a day for 90 days. For those who receive MIB-626, we plan on giving subjects 1000mg of the drug, twice a day for 90 days. MIB-626 will be in two 500mg tablets.
10171272|NCT03884478|Other|Control PNF|Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use & Control) and Round 4 (Stigma-Coping & Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.
10171273|NCT03884530|Active Comparator|Ticagrelor ( Brilique) group|the group will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose, and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours) for 3 months
10171274|NCT03884530|Active Comparator|Aspirin Group|The group will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that for 3 months
10171275|NCT03884335|Active Comparator|epidural group|An epidural catheter was placed at L1-L2 level, and tested, prior to induction. Induction was performed intravenously with fentanyl (1.5mcg•Kg-1), propofol (1.5-2 mg•Kg-1), and rocuronium (0.6 mg•Kg-1). Orotracheal intubation was performed. Prior to skin incision 8 mL of 0.25% levo-bupivacaine were administered epidurally, and a continuous perfusion of 0.125% levo-bupivacaine at 5 mL was started.
10171276|NCT03884335|Experimental|TAP group|Bilateral Transversus abdominis plane blockade (TAP) was performed following induction of anaesthesia ( the same of epidural group) and prior to skin incision, the high-frequency lineal probe (Sonosite MicroMAXXTM) was placed midway between the costal margin and iliac crest, and transversus abdominis muscle located behind the rectus abdominis and below the IOM. 20 mL of LA (bupivacaine 0.375%) was administered via a 22 gauge Quincke spinal needle inserted in-plane on each side of the abdomen. A successful block was recorded if the plane was seen to expand with fluid under ultrasound vision.
10171277|NCT03884127||hyperlipidaemia|On the basis of the intervention of therapeutic sexual life style, a case control study was conducted on the intervention of oral ezetimibe tablet and orlistat capsule for 12 weeks and hyperlipidemia patients who persisted in the use of basic treatment.
10171278|NCT03883906|Experimental|Viral Specific T-cells (VSTs)|
10171279|NCT03883841||Study group|patients with iron deficiency anemia
10171280|NCT03883841||control group|normal pregnant patients
10171281|NCT03883880|Experimental|Epigallocatechin gallate|Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
10171282|NCT03883880|Experimental|Linoleic acid|Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
10171283|NCT03883880|Experimental|Capsaicin|Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
10171284|NCT03883815||Assesment treatment intensity|Assesment treatment intensity during neurodevelopmental therapy session and active video games therapy session
10171285|NCT03884062||DAAs-SVR.|annual incidence of HCC in chronic hepatitis C patients with advanced liver fibrosis (F3 and F4) after achieving DAAs-SVR.
10171286|NCT03884426||Patients with MVP|The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.
10171287|NCT03884426||Normal relatives|Related healthy patients, for an average of 6 individuals per family
10171288|NCT03883945|Placebo Comparator|Cohort 1 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
9521865|NCT03270592|Other|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
10171289|NCT03883945|Active Comparator|Cohort 1 - 0.033%|Subjects randomized to vehicle will receive AIV001 0.033% administration to the target area.
10171290|NCT03883945|Placebo Comparator|Cohort 2 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
10171291|NCT03883945|Active Comparator|Cohort 2 - 0.1%|Subjects randomized to vehicle will receive AIV001 0.01% administration to the target area.
10171292|NCT03883945|Placebo Comparator|Cohort 3 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
10171293|NCT03883945|Active Comparator|Cohort 3 - 0.3%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
10171294|NCT03883945|Placebo Comparator|Cohort 4 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
10171295|NCT03883945|Active Comparator|Cohort 4 - 1%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
10171296|NCT03883971|Experimental|3D model|patient is given 3D printed model of her fetus's face
10171297|NCT03883971|Placebo Comparator|picture|patient is given a fetal picture only.
10186958|NCT03730922|Active Comparator|B: Delayed reconstruction|"Primary surgery: Total mastectomy and axillary surgery according to guidelines or protocol.~Delayed reconstruction: 6-12 months after completion of PMRT: final recon-struction with any reconstructive procedure - being it autologous or implant-based (one-or two-stage, +/- ADM). Any contralateral procedure is allowed at any time point after PMRT has been delivered"
9521866|NCT03270605||CS with myomectomy|Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
9521867|NCT03270605||CS without myomectomy|Women having uterine myoma with pregnancy and delivered by CS without myomectomy
9521868|NCT03270553|Experimental|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
10171298|NCT03883919|Experimental|Group 1: Paricalcitol 75 mcg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 75 mcg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
10171299|NCT03883919|Experimental|Group 2: Paricalcitol 7 mcg/kg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 7 mcg/kg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
10171300|NCT03884010||Participants|Professional male soccer players from the second professional Mexican division
10171301|NCT03884101|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
10171302|NCT03884101|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
10171303|NCT03884387|Experimental|Use of a Patient Decision Aid|A Patient Decision Aid is used in this arm in the clinical encounter. A tool designed to facilitate shared decision making when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
10171304|NCT03884387|No Intervention|Usual counceling|Usual counseling in the clinical encounter, when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
10171305|NCT03883997||Participants|Professional male soccer players from the second professional Mexican division.
10171306|NCT03884114|Other|All participants|All participants are evaluated on a scenario of pediatric asthma exacerbation using three different evaluation tools: (i) the simulation game EfficAsthme developed to train individuals on the management of pediatric asthma exacerbations; (ii) a MCQ on the same subject developed for the purpose of the study and (iii) HF-simulation, considered as the gold-standard for its enhanced realism.
10171307|NCT03884036|Active Comparator|Vitamin D group|Vitamin D 200,000 IU (1 cc) IM
10171308|NCT03884036|Placebo Comparator|Control group|Normal saline 1 cc IM
10171309|NCT03883802|Experimental|Foxy-5|Arm will receive Foxy-5 as neo-adjuvant therapy prior to surgical removal of tumour and afterwards until initiation of FOLFOX 6 months regimen
10171310|NCT03883802|Active Comparator|Standard therapy|Surgical removal of tumour followed by 6 months FOLFOX regimen
10171311|NCT03884205||test group|patients with PTCL who receive GDPE/CEOPE as the first-line therapy strategy
10171312|NCT03884205||control group|patients with PTCL who receive CEOPE as the first-line therapy strategy
10171313|NCT03883984|Experimental|Cysteamine|Cysteamine Bitartrate plus standard asthma care
9521869|NCT03270553|Experimental|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
9521870|NCT03270462|Other|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
9521871|NCT03270202|Experimental|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
9521872|NCT03270202|Active Comparator|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
9527808|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
9672049|NCT05040321|Placebo Comparator|Placebo Tablet|Subjects will be randomized to receive either the placebo or MIB-626 tablets twice a day orally.
9672050|NCT05040347||PVTT group|The diagnosis of portal vein tumor thrombosis was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
10171314|NCT03883984|Placebo Comparator|Placebo Oral Tablet|Placebo plus standard asthma care
10171315|NCT03883789||Normal pregnancies|Participants who have normal uncomplicated pregnancies
10171316|NCT03883789||Pregnancies with complications|Participants who undergo pregnancy with liver disease or develop liver disease or other conditions
10171317|NCT03883958|Active Comparator|TPVB|
10171318|NCT03883958|Experimental|ESPB|
10171319|NCT03883932|Experimental|F3 Program|The F3 group will focus on the fatherhood role each session. The topic of children and parenting will be applied to each of the standard FVEP topics.
10171320|NCT03883932|Active Comparator|FVEP Program|A retrospective control group who received the standard FVEP will be included in this arm.
10186959|NCT03730909|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
10186960|NCT03730909|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
9521873|NCT03270397|Experimental|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
9521874|NCT03270397|No Intervention|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
9672051|NCT05040347||HCC group|The diagnosis of HCC was confirmed by clinical correlation using histologic features taken from liver biopsy as determined by a pathologist,and findings from image studies including ultrasound, computed tomography, and MRI, verified by a radiologist.
9672052|NCT05040347||control group|The presence of PVTT or HCC was confirmed by medical record review and all the recorded events were confirmed by a radiologist using imaging studies, ultrasound, contrast-enhanced, or MR.
9672053|NCT05040529||PLDRH|patients who underwent pure laparoscopic donor right hepatectomy
10171321|NCT03883776|Experimental|healthy volunteers and NET patients|"In the first part of the study, 6 healthy volunteers will receive a single intravenous single injection of Al18F-NOTA-octreotide, followed by whole-body PET/CT scans at various time points for an initial safety assessment and dosimetry study.~In the second part of the study, a single dose of Al18F-NOTA-octreotide will be intravenously injected in 6 patients with neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and initial efficacy assessment."
10171322|NCT03883763|Experimental|Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)|
10171323|NCT03883763|Active Comparator|Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)|
10171324|NCT03883672|Experimental|hematopoietic stem cell transplantation|Personality and transactional factors involved in the process and outcomes of hematopoietic stem cell transplantation
10171325|NCT03883737|Experimental|Group 1: PNM in pain knee|participants in whom PNM will be applied to the femoral nerve of the pain knee
10171326|NCT03883737|Experimental|Group 2: PNM in non-pain knee|participants in whom PNM will be applied to the femoral nerve of the non-pain knee
9672054|NCT05040529||ODRH|patients who underwent conventaional open donor right hepatectomy
9672055|NCT05040490|Experimental|SUG group|sugammadex as reversal drugs
10171327|NCT03883555||Optiflow tm|High flow nasal therapy (HFNT)
10171328|NCT03883555||Non invasive ventilation (NIV)|Non invasive ventilation (NIV)
10171329|NCT03883425||Case 1: formal home service recipients|Adults aged 65 or older living at home who receive formal home service (household, meal delivery, transportation, shopping) at least one a week
9672056|NCT05040490|No Intervention|NEO group|neostigmine as reversal drugs
10171330|NCT03883425||Case 2: formal home care recipients|Adults aged 65 or older living at home who receive formal home care (shower/bath nursing assistance, nursing care) at least once a week
9521875|NCT03270280|Placebo Comparator|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
9521876|NCT03270280|Experimental|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
9521877|NCT03270267||Patients with IBD|
9521878|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:~advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter~intubated or tracheostomy in place~echocardiography requested by the treating physician~intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
9672057|NCT05040503|Active Comparator|Patients without sepsis|patient without sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
10171331|NCT03883425||Control: free of formal home care or home service|Adults aged 65 or older living at home who do not receive formal home care or home service.
10171332|NCT03883321||CBSM|Patients included in this group participate in the CBSM program. They attend 10 sessions of stress management according to the CBSM program, 9 take place over 3 months and the tenth session takes place 3 months after the 9th session. The session is composed of relaxation and cognitive and behavioral therapy, which is carried out in groups of 8 to 10 patients
10171333|NCT03883321||Waiting list|"The CBSM group is compared to the waiting list group that does not benefit from the CBSM program. After completing their assessment in the waiting list group, patients in this group will be integrated into the CBSM group but will not be evaluated as such."
10171334|NCT03883308|Experimental|Treatment|Treatment group will receive 6 months of online, computerized, multi-domain cognitive training at home.
10171335|NCT03883308|Active Comparator|Active Control|The Active Control group will receive 6 months of online, computerized cross-word puzzles at home using the same platform as for the Treatment group.
10171336|NCT03883490||Bicuspid Aortic valve|Patients with a bicuspid aortic valve
10171337|NCT03883490||Tri-leaflet Aortic valve|Patients with a tri-leaflet aortic valve
10171338|NCT03883451|Experimental|Helmet type|football player helmet model
10171339|NCT03883529|Experimental|Women reviewing birth experience|Women who had their antenatal care provided at a high-risk antenatal clinic, will be offered to write about and review their birth experience about 6 weeks post-partum with a known midwife from antenatal care.
10171340|NCT03883503|Experimental|Beer alone|Consumption of beer (correlated for weight to reach a blood alcohol concentration of 0.8) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
9521879|NCT03270163|Experimental|Experimental|Magnetic and Transcutaneous electrical stimulation of quadriceps
9672058|NCT05040503|Experimental|Patients with sepsis|Patients with sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
9672059|NCT05040503|Experimental|Patients with septic shock|Patients with septic shock admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital
9672060|NCT05040503|Active Comparator|Healthy volunteers|
9521880|NCT03270488|Experimental|Laser Group|Laser application three times a week for 4 weeks.
9521881|NCT03270488|Placebo Comparator|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
9521882|NCT03270150|Experimental|BTL-899 Therapy Arm|BTL-899 therapy, 3 therapies
9521883|NCT03270241|Experimental|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
10171341|NCT03883503|Active Comparator|Beer and water|Consumption of beer and additional water (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of water, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
9521884|NCT03270293|Experimental|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:~zygomatic protuberance~nostril's angle~inferior margin of tragus~lip marionette lines~mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
10171342|NCT03883503|Active Comparator|Beer and stock|Consumption of beer and additional stock(correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
10171343|NCT03883503|Placebo Comparator|Water alone|Consumption of water alone (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
10171344|NCT03883438|Active Comparator|Coronally advanced flap and acellular dermal graft|In CAF group, after local anesthesia oblique beveled vertical incisions were made at the most mesial and distal line angles of the recessions. These two incisions were connected with an intra-sulcular and interdental sub-marginal incisions in order to create the external surgical papillae. Then the flap was elevated as a split-full-split approach. The apical portion of the flap was reflected as close to the periosteum as possible by mesio-distal and apical sharp dissection parallel to the mucosa to release residual muscle tension and extended beyond the muco-gingival junction to facilitate the passive coronal replacement of the flap over the defects. In both groups ADMG was used as a sub-epithelial graft considering the manufacturer's instructions. The graft was positioned at the level of cemento-enamel junction and extended to the surrounding bone in the apical direction with full closure of the exposed root surfaces.
10171345|NCT03883438|Experimental|Modified coronally advanced flap and acellular dermal graft|Test group received CAF avoiding vertical releasing incisions (mCAF).
10171346|NCT03883464|Experimental|Low fat intake|Patients who underwent cholecystectomy and were instructed to have a low fat diet.
10171347|NCT03883464|No Intervention|Regular diet|Patients who underwent cholecystectomy and were instructed to have a regular diet.
10171348|NCT03883399||Colorectal surgeons|Survey among Spanish colorectal surgeons
10171349|NCT03883659|Active Comparator|traditional paper hangouts group|patients use the traditional paper hangouts to conduct the home exercise program at home
10171350|NCT03883659|Experimental|smartphone group|patients use the smartphone to conduct the home exercise program at home
10171351|NCT03883711||Patients with acute coronary syndrome or myocardial injury|Incident consecutive patients presenting with acute coronary syndrome or myocardial injury
10171352|NCT03883373||Cortical group|Group of patient who had an alveolar bone graft with cancellous bone and a cortical block
10171353|NCT03883373||Cancellous group|Group of patient who had an alveolar bone graft with cancellous bone only
10171354|NCT03883620|Experimental|Cohort 1 (Initial Safety Cohort) 1 mg/kg|4 participants will be administered Dengushield at 1 mg/kg body weight as Intravenous injection.
10171355|NCT03883620|Experimental|Cohort 2 Experimental 3mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
10171356|NCT03883620|Placebo Comparator|Cohort 2 Placebo 3 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo and enrolled.
10171357|NCT03883620|Experimental|Cohort 3 Experimental 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
10171358|NCT03883620|Placebo Comparator|Cohort 3 Placebo 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
10171359|NCT03883620|Experimental|Cohort 4 Experimental 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
10186961|NCT03730896|No Intervention|standard care group|Normal manual therapy interventions Clinician will decide normal course of treatment
9521885|NCT03270189|Experimental|orthoptic treatment|Patients with cervical dystonia occuring only during handwriting.
9521886|NCT03270189|No Intervention|Controls|Patients without cervical dystonia.
9521887|NCT03270358|Experimental|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
9521888|NCT03270358|Other|patient without stenosis|Patient coming for their dialysis
9521889|NCT03270371|Experimental|MCO Dialysis|Theranova Dialyzer
9521890|NCT03270371|Active Comparator|Standard High Flux Dialysis|Standard High Flux Dialyzer
9521891|NCT03270254|No Intervention|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
9521892|NCT03270254|Active Comparator|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
9527809|NCT03216655|Experimental|traditional group|phone call
10171360|NCT03883620|Placebo Comparator|Cohort 4 Placebo 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
10171361|NCT03883477|Experimental|Endoscopic Release|12 patients recommended for surgical treatment of trigger finger will undergo endoscopic release.
10171362|NCT03883477|Active Comparator|Standard Open Release|12 patients recommended for surgical treatment of trigger finger will undergo standard open surgical release.
10171363|NCT03883347|Active Comparator|Group DEX|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.6 mcg / kg / h.
10171364|NCT03883347|Active Comparator|Group REMI|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.025 mcg / kg / min.
10171365|NCT03883633||Enrolled Participants|All participants enrolled will be tracked from initial assessment to study completion.
10171366|NCT03883685|Experimental|experimental group|40 subjects will be randomly allocated to receive probiotics pills for consecutive 8 weeks.
10171367|NCT03883685|Placebo Comparator|Control group|40 subjects will be randomly allocated to receive placebo pills for consecutive 8 weeks.
10171368|NCT03883295|Experimental|Control|root canal treatment will be initiated
10171369|NCT03883295|Experimental|NeoMTA Plus|vital pulp treatment using neomta plus will be used.
10186962|NCT03730896|Experimental|Dry needling|Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment
10186963|NCT03730870|Experimental|Pharmacogenomics report|Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.
10186964|NCT03730870|No Intervention|Control|"Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report (treatment-as-usual)."
10186965|NCT03730857|Active Comparator|olanzapine|olanzapine has a dose of 10 to 20 mg daily for 12 weeks
10186966|NCT03730857|Active Comparator|risperidone|risperidone at a dose of 4 to 6 mg daily for 12 weeks
10186967|NCT03730857|Active Comparator|paliperidone|paliperidone at a dose of 6 to 12 mg daily for 12 weeks.
10186968|NCT03730831|Experimental|Intervention|Narrative Exposure Therapy The Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed treatment and will be performed according to the manual of Schauer et al., 2011. In the NET the experiences experienced as traumatic are worked on and placed in the context of the entire life story.
10186969|NCT03730831|No Intervention|Control|Waiting List
10186970|NCT03730818|Experimental|Water-based Exercise Group|"The Water-based Exercise Group will compromise participants attending a 2 weekly exercise intervention each session lasting 1 hour for 12 weeks.~Each session will consist of:~10 minutes of warm-up: general mobilisation, walking, active stretching~40 minutes of global training: 20 minutes of endurance exercise and 20 minutes of resistance exercises targeting large main muscle groups involved in daily life activities (squats, lateral hip abduction, row, etc.) using body weight and elastic bands~10 minutes of cooling down: stretching, breathing exercises and relaxation Intensity will be monitored with the modified Borg Scale to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
10186971|NCT03730818|Active Comparator|Land-based Exercise Group|"The land-based exercise group will attend as well 2 weekly sessions lasting 1 hour each for 12 weeks.~Each session will consist of the same structure as the Water-based Exercise Group including:~10 minutes warm up~40 minutes of global training (20 minutes of endurance exercise and 20 minutes of resistance training)~10 minutes cool down. The exercises will be adapted from the water-based exercise group to match the requirements on the water-based exercise group. Intensity will be monitored with the Perceived Rate of Exertion Scale (modified Borg Scale, Borg 1982) to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
10186972|NCT03730805|Experimental|Intervention + open mindset|ASSIST-linked Brief Intervention plus prior induction of deliberative mindset
10186973|NCT03730805|Experimental|Intervention + closed mindset|ASSIST-linked Brief Intervention plus prior induction of closed mindset
9521893|NCT03270423|Active Comparator|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
9521894|NCT03270423|No Intervention|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
9521895|NCT03270423|Active Comparator|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
9521896|NCT03270423|No Intervention|Control VD|Adapted sport session 1h/week during 6 months
9521897|NCT03270384|Experimental|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
9826622|NCT02425306|Experimental|Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide|"Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
10186974|NCT03730805|Experimental|Intervention alone|ASSIST-linked Brief Intervention without prior induction of any mindset
10186975|NCT03730805|Experimental|Control + open mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of an open mindset is conduced.
10186976|NCT03730805|Experimental|Control + closed mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of a closed mindset is conduced.
9521898|NCT03270475|Experimental|Exercise|12-15 training sessions of 30 min over 4-5 weeks
9521899|NCT03269981|Experimental|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
9527810|NCT03216655|Experimental|new device group|wechat group
10171370|NCT03883646|Experimental|Mindfulness|Mindfulness
10171371|NCT03883646|Experimental|Relapse Prevention|
10171372|NCT03883646|No Intervention|Waitlist Control|
10171373|NCT03883646|No Intervention|Treatment as Usual|
10171374|NCT03883360|Experimental|Cannabidiol (CBD)|Participants receive CBD daily for 12 weeks.
10171375|NCT03883360|Placebo Comparator|Placebo|Participants receive vehicle not containing any drug daily for 12 weeks.
10171376|NCT03883698|Experimental|ESRD, alternate day dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 400 mg on alternate days. Total duration of treatment will be 12 weeks
10171377|NCT03883698|Experimental|ESRD, daily dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 200 mg daily doses. The total duration of treatment will be 12 weeks
10171378|NCT03883698|Active Comparator|Control|Participants with normal eGFR and hepatitis C virus infection and treated with sofosbuvir 400 mg daily dose. The total duration of treatment will be 12 weeks
10171379|NCT03883269|Experimental|Erythromycin 4%|Erythromycin 4% topical gel formulation, BID, 4 weeks
10171380|NCT03883269|Experimental|Clindamycin 1%|Clindamycin 1% topical lotion formulation, BID, 4 weeks
10171381|NCT03883269|Placebo Comparator|ethanol solution|70% topical ethanol solution, BID, 4 weeks
10171382|NCT03883334|Experimental|Immunomodulator group|Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.
10171383|NCT03883334|No Intervention|Control group|combine antiretroviral therapy only
10171384|NCT03883256|Active Comparator|high flow nasal cannula|Subjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
9672061|NCT05040477|Experimental|Experimental Group (1): Muscle energy techniques,Moist Hot pack and TENS.|"Experimental group included Moist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45C.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle.These pre and post intervention values were mentioned in questionnaire. The participants were administered with muscle energy technique (PIR) and data was collected again 2 and 4 weeks after the interventions."
10171385|NCT03883256|Active Comparator|nasal cannula|Subjects perform a constant-load exercise test with nasal cannula oxygen device.
10171386|NCT03883243|No Intervention|Control|Patients will only receive a brochure explaining the importance of physical activity with recommendations to improve it.
10171387|NCT03883243|Experimental|Telecoaching|Patients will receive a brochure explaining the importance of physical activity with recommendations to improve it. Next to this patients will receive the telecoaching intervention in which a coaching application linked to a step counter is installed on the patients smartphone, which will weekly give a new physical activity goal to improve the amount of steps per day for 8 weeks.
10171388|NCT03883100|Experimental|HQP1351|
10171389|NCT03882931|Experimental|TMS to left DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the left DLPFC and complete a visuomotor rotation task.
10171390|NCT03882931|Experimental|TMS to right DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the right DLPFC and complete a visuomotor rotation task.
10171391|NCT03882931|Sham Comparator|TMS Control|A Sham Theta Burst Transcranial Magnetic Stimulation will be delivered to the right/left DLPFC and complete a visuomotor rotation task.
10171392|NCT03882931|Experimental|FUS to right/left DLPFC|Low intensity Focused Ultrasound stimulation will be delivered to either the left or right DLPFC depending on the subject's DLPFC response during their functional MRI flanker task.
10171393|NCT03882957|Active Comparator|Video|videos of media tasks being completed
10171394|NCT03882957|Experimental|media multi-task|media tasks
10171395|NCT03882957|Experimental|sustained attention task|a cognitive task that trains sustained attention
10171396|NCT03882853|Active Comparator|Conservative exercise group (CEG)|Conservative exercise group
10171397|NCT03882853|Experimental|Tree pose added exercise group (TPAEG)|Tree pose added exercise group
10171398|NCT03883165|Experimental|high-intensity neck strengthening group|
10171399|NCT03883165|Experimental|low-intensity neck strengthening group|
10171400|NCT03883165|Other|Control group|
10171401|NCT03883022|Experimental|Vancomycin (V Group)|
10171402|NCT03883022|Active Comparator|Without Vancomycin (NV Group)|
10171403|NCT03882866|Experimental|3D-printed non-coplanar template|3D-printed non-coplanar template is used in this group.
10171404|NCT03882866|Active Comparator|3D-printed coplanar template|3D-printed coplanar template is used in this group.
10171405|NCT03883230||Patients with chronic wound|All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later.
10171406|NCT03883178|Experimental|Neurolysis|
10171407|NCT03882983|Experimental|Antria Cell Preparation Process|Safety will be evaluated by collection of vital signs, EKG, patient surveys, and assessments
10171408|NCT03883087|Experimental|HQP1351|
10171409|NCT03883061||mortality of sepsis|the study sample would be extracted from electronic health records in emergence departments. risk factor analysis and mathematical modeling would be performed to evaluate the significant and independent risk factors and predictive models.
10171410|NCT03883074|Experimental|GERDOff® Plus|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate Melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
10171411|NCT03883074|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
10171412|NCT03883035|Experimental|EAS-aided group|esophagogastroduodenoscopy examination with the assistance of automatic quality-control system
10171413|NCT03883035|No Intervention|control group|conventional standard esophagogastroduodenoscopy examination without the assistance of automatic quality-control system
10171414|NCT03882879|Experimental|Arm 1|Participants in Arm 1 will begin participation in 6 months of karate classes immediately after the pre-intervention study visits.
10171415|NCT03882879|Experimental|Arm 2|Participants in Arm 2 will continue their usual exercise routine for six months followed by karate classes for six months
10171416|NCT03883204|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
10171417|NCT03883204|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
10171418|NCT03883126|Active Comparator|Group A|Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
9521900|NCT03269981|Active Comparator|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
9521901|NCT03269942|Active Comparator|Endovascular Flow-Diversion|Implantation of flow-diversion device
10171419|NCT03883126|Active Comparator|Group B|Group B will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention.For the remaining 9 weeks they will not be required to submit breathalyzer samples.
10171420|NCT03883126|Sham Comparator|Group C|Group C will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting on time samples regardless of alcohol content.
9521902|NCT03269942|Active Comparator|Cerebral Revascularization|Cerebral revascularization procedure with trapping of aneurysm
9521903|NCT03269929|Experimental|Music therapy|
9521904|NCT03269929|Active Comparator|Midazolam|
10171421|NCT03883126|Sham Comparator|Group D|Group D will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will not be required to submit breathalyzer samples.
10171422|NCT03883126|No Intervention|Group E|Group E will have no intervention, they will only complete assessment sessions.
10171423|NCT03882840|Experimental|itNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
10171424|NCT03882723|Active Comparator|BiTrac MaxShield™ with standard elbow (FFM)|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
10171425|NCT03882723|Active Comparator|BiTrac™ Full Face with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
9521905|NCT03270098|Experimental|Aerobic Exercise|using traditional exercise equipment (i.e., treadmill, stationary bike) along with active-play video games (Xbox Kinect).
9521906|NCT03270098|Active Comparator|Stretching and Toning Exercise|
9521907|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
9521908|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
9521909|NCT03269877||Liver cirrhosis and hypersplenism|Patients proven to have Liver Cirrhosis and Hypersplenism based on clinical examination, Laboratory findings, and abdominal ultrasound examinaton
9826623|NCT02425306|Experimental|Arm C:6MHP + polyICLC + Montanide ISA-51|Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
9521910|NCT03269890|Experimental|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks per side. once before surgery
9521911|NCT03269890|Active Comparator|US-intermediate cervical plexus block|15 mL of 0.5% isobaric bupivacaine + Epinephrine 5 microgram/ ml. per side. once before surgery
9521912|NCT03269760|No Intervention|Control|Current practice of postoperative care without sleep medicine measures
9521913|NCT03269760|Experimental|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
9521914|NCT03269903|Experimental|Patients|Patients with malignant dysphagia treated with the HILZO stent
10171426|NCT03882723|Active Comparator|Respironics PerforMax with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
10171427|NCT03882723|Active Comparator|Philips Respironics AF531 with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
10171428|NCT03882593||Analysis of arterial filters during CPB|This is a clinical and observational study to investigate of blood cells addesion to surfaces of arterial filters during CPB and the impact in coagulations laboratory exams
10171429|NCT03882463|Experimental|insulin pump function|continuous glucose monitoring and then continuous glucose monitoring with the stop insulin pump function
10171430|NCT03882606|Other|SML implantation|prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation
10171431|NCT03882710|Experimental|metoprolol XR capsule|
10171432|NCT03882710|Placebo Comparator|placebo capsule|
10171433|NCT03882645|Experimental|CHH-diet arm|"During the 4-week intervention period, free meals conformed to CHH-diet will be provided 3 times per daily (breakfast, lunch, dinner). Different center offers different meals of different cuisines but all conformed to CHH-diet. The main nutrientional healthy goal of different cuisines will be achieved through specific nutrient targets, including fat, carbohydrate, protein, dietary fiber, sodium, potassium, magnesium and calcium."
10171434|NCT03882645|Other|local usual diet arm|During the 4-week intervention period, three meals per day (breakfast, lunch, dinner) will be provided free of charge in line with local dietary characteristics. The energy,protein, carbohydrate, as week as dietary fiber, sodium, calcium, magnesium and potassium will be kept the same as that in the run-in phase.
10171435|NCT03882814||Pethidine group / study group|Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
10171436|NCT03882814||control group|The patients who received placebo injection were included in the control group. Saline was given in placebo.
10171437|NCT03882619|Experimental|Calligraphy group|
10171438|NCT03882619|No Intervention|Treatment-as-usual group|
10171439|NCT03882567|Experimental|Electro Neuro adaptative Regulator|8 SCENAR sessions (twice a week) (30 min of duration) following the protocols for treatment several points in the body
10171440|NCT03882567|Sham Comparator|Sham Electro Neuro adaptative Regulator|8 Sham SCENAR sessions (twice a week) (30 min of duration), following the same protocol tan experimental group but the machine will be turn off 30 seconds after starting on the treatment.
10171441|NCT03882775|Experimental|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
10171442|NCT03882775|Active Comparator|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
10171443|NCT03882632|Experimental|Patients with Fecal Incontinence|Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
10171444|NCT03882762|Experimental|Group I - Cebranopadol 200 μg tablet|"Mild Renal Impairment:~PK evaluable non-dialyzed patients with mildly impaired renal function (eGFR = 60-89 mL/min/1.73 m2)"
10171445|NCT03882762|Experimental|Group II - Cebranopadol 200 μg tablet|"Moderate Renal Impairment:~PK evaluable non-dialyzed patients with moderately impaired renal function (eGFR = 30-59 mL/min/1.73 m2)"
10171446|NCT03882762|Experimental|Group III - Cebranopadol 200 μg tablet|"Severe Renal Impairment:~PK evaluable non-dialyzed patients with severely impaired renal function (eGFR = 15-29 mL/min/1.73 m2)"
10171447|NCT03882762|Experimental|Group IV - Cebranopadol 200 μg tablet|"Normal Renal Function:~PK evaluable participants with normal renal function (eGFR greater than or equal to 90 mL/min/1.73 m2)"
10171448|NCT03882515|Experimental|Experimental group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after myofascial release
10171449|NCT03882515|Sham Comparator|Sham group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after continuous surface slip technique
10171450|NCT03882515|Active Comparator|Control group|Evaluation and reassessment of asymptomatic individuals
9521915|NCT03270007|Experimental|Chemotherapy|
9521916|NCT03270007|No Intervention|Control|
9521917|NCT03269773|Experimental|FURESTEM-AD Inj.|hUCB-MSC 5.0x10^7 cells
9521918|NCT03269773|Placebo Comparator|Placebo|
9521919|NCT03269786||cirrhotic patients with esophagel varisces|Endoscopic band ligation or injection scelerotheraby will be done for all patients
9521920|NCT03270033|Active Comparator|Dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
9521921|NCT03270033|Active Comparator|Dexmedetomidine|50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
9521922|NCT03270033|Active Comparator|Dexamethasone and Dexmedetomidine|4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
9521923|NCT03269916|Experimental|IBD patients|IBD patients, 17-40 years old, female
9521924|NCT03269916|Other|healthy control|17-40 years old , female, without any gynecological disease
10171451|NCT03882476|Experimental|Experimental|The experimental arm will involve patients monitored by InSight.
10171452|NCT03882476|No Intervention|Control|The control arm will have no intervention and will involve patients with the usual standard of care.
9521925|NCT03269747|Active Comparator|Prednisone|Prednisone 40 mg daily for 7 days
9521926|NCT03269747|Placebo Comparator|Placebo|Placebo daily for 7 days
9521927|NCT03270137|Active Comparator|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
9521928|NCT03270137|Active Comparator|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
9521929|NCT03269864|Active Comparator|pedicled perforator flaps|"Once the perforator is identified, the flap will be designed around the perforator or perforators according to the location and size of the defect.~A tourniquet is inflated without prior exsanguination. This maneuver facilitates identification of perforators as they remain filled with the blood.~An exploratory incision along the margin of flap is made keeping the position of marked perforator in mind. The incision is made through the skin, subcutaneous tissue, deep fascia (sub-fascial approach) and the perforator vessel is directly visualized. The incision is initially always made from one side of the flap only to properly identify the perforator.~Careful and meticulous dissection is done in a blunt way isolating the perforator.~After deflation of the tourniquet, hemostasis is performed."
10171453|NCT03882788|Active Comparator|Volatile Anesthesia|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane.~Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
10171454|NCT03882788|Active Comparator|Narcotic based anesthesia|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose)."
10171455|NCT03882554|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
10171456|NCT03882450|No Intervention|Neonates with congenital cardiac disease (retrospective)|Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
10171457|NCT03882450|Active Comparator|Neonates with congenital cardiac disease (prospective)|Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
10171458|NCT03882502|Experimental|stimulation group|
10171459|NCT03882502|Sham Comparator|sham stimulation|
9521930|NCT03269864|Active Comparator|free perforator flaps|"A two-team approach is used for microvascular free tissue transfer. The first team starts exploring the limb for the recipient vessel. The second team simultaneously begins elevating the perforator flap and its vascular pedicle.~Microvascular anastomosis will be carried out under operating microscope for one artery and one or two accompanying veins."
9521931|NCT03269812|Experimental|laparoscopic operated group|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
9521932|NCT03269812|Experimental|non laparoscopic operated group|Under general anesthesia ,abdominal exploration ,removal of a ganglionic part by soav ,duhamel procedures and trans-anal pull through procedures.
9521933|NCT03270124|Active Comparator|No Resistance Exercise and No Activity Goal Arm|Blinded use of Fitbit with no daily activity goal and no resistance exercises
9521934|NCT03270124|Experimental|Resistance Exercise and Activity Goal Arm|Unblinded use of Fitbit with a daily activity goal (steps per day) and resistance exercises
9521935|NCT03269721||Never Smoker|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
9527811|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
9521936|NCT03269721||Smoker/Past smoker-No Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
10171460|NCT03882437|Experimental|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of three dose levels depending on the cohort.
10171461|NCT03882489||Cohort 1 : Height 150-165 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 1 includes patients whose the height is between 150 and 165 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 40 mg in the cohort 1 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 25 to 50 mg for cohort 1.
9521937|NCT03269721||Smoker/Past smoker-W/Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
10171462|NCT03882489||Cohort 2 : Height 166-180 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 2 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 45 mg in the cohort 2 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 30 to 55 mg for cohort 2.
9521938|NCT03269708|No Intervention|Control|Participants receive standard care in cardiac rehabilitation program
10171463|NCT03882489||Cohort 3 : Height 181-195 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 3 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 50 mg in the cohort 3 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 35 to 60 mg for cohort 3.
10171464|NCT03882541|No Intervention|Control group|headphones without music, without sedation
9521939|NCT03269708|Experimental|Knowledge transfer group|Participants receive standard care in cardiac rehabilitation program plus education regarding telomere length
9521940|NCT03269630||Clinic patients (Comprehensive Pulmonary Hypertension Center)|"Pulmonary hypertension patients (WHO group 1-5)~Systemic sclerosis patients without pulmonary hypertension~Mixed connective tissue disease patients without pulmonary hypertension"
9521941|NCT03269630||Outpatient right heart catheterization patients|-Outpatients undergoing right heart catheterization for any indication
9977492|NCT01362114|Experimental|Sihogayonggolmoryeo-tang extract|"name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'~standard code for item: 200005676~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
9521942|NCT03269630||Healthy controls|"Age>18~Not actively smoking~No chronic medical conditions"
9521943|NCT03269955|Experimental|application of TachoSil®|Fibrinogen/thrombin-coated collagen patch (TachoSil®) and fibrin glue are applied to the pancreas anastomosis site in pancreatoduodenectomy
9521944|NCT03269955|No Intervention|control|Only fibrin glue alone is applied to the pancreas anastomosis site in pancreaticoduodenectomy.
9672062|NCT05040477|Experimental|Experimental Group (2): Facets joint mobilizations, Moist Hot pack and TENS.|"Experimental group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Facet joint mobilization (UPA & SNAGS) and data was collected again 2 and 4 weeks after the interventions."
9672063|NCT05040477|Active Comparator|Control Group:Conventional Therapy (Stretching, strengthening , Moist Hot pack and TENS)|"Control group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Conventional (sustained stretching and isometric strengthening) physical therapy and data was collected again 2 and 4 weeks after the interventions."
9672064|NCT05040438|Experimental|Autologous NK cell infusion combined with HAIC|HAIC of 5-FU (500 mg/m2, Q4W) and cisplatin (15 mg/m2, Q4W) will be administered for up to 4 cycles to patients with locally advanced HCC. Subjects who achieved sustained SD or better based on the mRECIST criteria after 2nd cycle of HAIC will be enrolled to receive 1x10^9 cells VAX-NK/HCC infusion.
9672065|NCT05040191|Experimental|Control Group|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Nursing Fundamentals Skills Laboratory. The laboratory consists of 3 practice rooms, 1 control room and 1 analysis room. A video prepared by the researcher on the Simple Nasogastric Tube Application Model in line with the steps of Checklist for Teaching Nasogastric Tube Application Skills was watched and preliminary information was given. The questions were answered by allowing the students to ask questions."
9521945|NCT03269643|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
9521946|NCT03269643|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
9521947|NCT03269656||AGES-Reykjavik participants|Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.
9521948|NCT03269500||malnourished older people|The hospitalized elderly with swallowing and/or Mastication problems.
10171465|NCT03882541|Active Comparator|sedative group|headphones without music, with sedation
9521949|NCT03270046|Placebo Comparator|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
9521950|NCT03270046|Active Comparator|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
9521951|NCT03269513|Experimental|Intervention group|"Adolescent Obesity~The exercise program, nutritional counseling and oral health will last for five to three months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC).~The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week."
9521952|NCT03269513|No Intervention|Control group|
9521953|NCT03269461|Experimental|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
9521954|NCT03269461|Experimental|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
9521955|NCT03269461|Experimental|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
9521956|NCT03269604|Active Comparator|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
9521957|NCT03269604|Active Comparator|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
9521958|NCT03269604|Experimental|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
9521959|NCT03269799|Active Comparator|test group|vitamin C 500 mg oral capsule
9521960|NCT03269799|Placebo Comparator|control group|placebo
10171466|NCT03882541|Experimental|experimental group|headphones with music, without sedation
9521961|NCT03269591|Active Comparator|Pulsed electromagnetic field|magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
9521962|NCT03269591|Experimental|diclofenac tablets|(50 mg) few hours at the onset of menstruation for 3 months
9521963|NCT03269591|Other|Visual analogue scale|was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
9672066|NCT05040191|Experimental|Haptic Interactive Virtual Reality Simulation(Experiment 1 group)|Application in the Experiment-1 Group: After the theoretical lesson, the students in the Experiment-1 group were taken to the computer laboratory room where the haptic interactive virtual reality application was installed. The Nasogastric Tube Application with Haptic Interactive Virtual Reality Simulation was applied and explained by the researcher and preliminary information was given. The questions were answered by allowing the students to ask questions.
10171467|NCT03882684||Cancer patients|The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.
10171468|NCT03882684||Benign tumor and other disease patients|Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.
10171469|NCT03882671|Experimental|Monitoring Device|Subjects will be asked to wear up to 3 different noninvasive seizure detection devices including EpiTel EpiLog, Empatica E4, GeneActiv
10171470|NCT03882411|Experimental|Electronic shared decision making (eSDM) Tool|When a clinic's randomly allotted intervention period arrives, coronary heart disease patients in a given cluster of clinics will complete a web application, which delivers screening, behavioral activation and shared decision making (eSDM), and providers will receive a patient preference report generated from the application.
10171471|NCT03882411|No Intervention|Usual Care|In the year prior to the allocated intervention period, coronary heart disease patients will receive usual care from their providers.
10171472|NCT03882099||Pregnant women with pre-eclampsia|
10171473|NCT03882099||Pregnant women with eclampsia|
9521964|NCT03269591|Other|Progesterone blood level|Sample of blood was taken to detect the level of progesterone.
9521965|NCT03269591|Other|Menstrual symptom questionnaire|to assess symptoms of dysmenorrhea.
9521966|NCT03269487||Healthcare professionals in partner sites|NHS employee or student nurse involved in the delivery of care to patients on partner wards in which the PERFECTED ERP is being implemented.
9521967|NCT03269617|Placebo Comparator|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
9521968|NCT03269617|Experimental|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
9521969|NCT03269565|Experimental|Arm 1|BCD-100 1 mg/kg Q2W;
9521970|NCT03269565|Experimental|Arm 2|BCD-100 3 mg/kg Q3W.
9521971|NCT03269383|Sham Comparator|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
9521972|NCT03269383|Experimental|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
10171474|NCT03882099||Normotensive pregnant women|
10171475|NCT03882112|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
9521973|NCT03269422|Experimental|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
9521974|NCT03269370|Experimental|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
9521975|NCT03269370|Experimental|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
9521976|NCT03269370|Active Comparator|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)."
9521977|NCT03269370|No Intervention|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
9521978|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
9521979|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
9521980|NCT03269357|Other|Intervention|"Clinics randomized to intervention will provide structured LARC centered counselling"
9521981|NCT03269357|No Intervention|Routine counselling|Clinics randomized to routine counselling
9521982|NCT03269331||ARCC EBP Model|CTEP EBP Immersion Course
10171476|NCT03882112|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
9521983|NCT03269331||Control Group|No CTEP EBP Immersion Course
9521984|NCT03269071|Experimental|Treatment Cohort A|"See Study Description~TC-A: 0.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
9521985|NCT03269071|Experimental|Treatment Cohort B|"See Study Description~TC-B: 1.4 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
9521986|NCT03269071|Experimental|Treatment Cohort C|"See Study Description~TC-C: 2.8 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
9521987|NCT03269071|Experimental|Treatment Cohort D|"See Study Description~TC-D: 5.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
9521988|NCT03269123|Other|A device to relieve Blepharospasm|The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.
10171477|NCT03882164||Rejection|Patient undergone liver transplant with diagnosis of rejection within 10 days
10171478|NCT03882164||No-Rejection|Patient undergone liver transplant wothout diagnosis of rejection within 10 days
10171479|NCT03882398|Experimental|Experimental group|The experimental group (EG) participated in a once a week physical exercise program for 8 weeks. The session consisted of balance training, followed by aerobic endurance training with exercise peddlers. At the beginning of the program, each session lasted 25 minutes and progressed to 35 minutes, in the last two weeks
10171480|NCT03882398|Active Comparator|Control Group|The control group (CG) only performed routine balance exercises once a week (10 min)
9521989|NCT03269240|Experimental|LDHF plus m-Mentoring|"Participants will undergo pre-training assessment comprising multiple-choice questions and objective structured clinical examination (OSCE) using manikins. Training is divided into two 4-day low-dose sessions at the health facility or onsite training. Pre-training and immediate post-training assessments results will be compared. A score of ≥80% is acceptable competence (pass). During the one-month intervals between training sessions, participants practice using manikins to reinforce their competencies through simulation-based practices, facilitated by facility-based trained Peer Practice Coordinators (PPCs). The PPCs will also receive structured, monthly half-hour mentoring calls that will provide remote support, answering questions, providing guidance and reinforcing key messages. Acquisition of knowledge and clinical skills is measured."
9521990|NCT03269240|Active Comparator|Traditional training|The health providers will receive the same content of training in eight days, Off-site training, the way it's currently done in Nigeria. Both theoretical and practical through use of manikins - simulation. No reinforcement and further practice will take place once the participants are back in their work stations. Acquisition of knowledge and clinical skills is measured.
9521991|NCT03269201||Parkinson;s Disease|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
9521992|NCT03269201||Essential tremor|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
9521993|NCT03269201||Multiple system atrophy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
9672067|NCT05040191|Experimental|Haptic Interactive Computer Based Simulation(Experiment 2 group)|Application in the Experiment-2 Group: After the theoretical lesson, the students in the Experiment-2 group were taken to the laboratory room where the haptic interactive computer-based simulation was located. This computer-assisted simulation allows us to see the application on the computer screen while performing an application with a haptic arm. It gives feedback on hand manipulations similar to reality. It was explained by the researcher by applying the nasogastric tube application skill with haptic interactive computer-based simulation and preliminary information was given. The questions were answered by allowing the students to ask questions.
10171481|NCT03882138|Active Comparator|thin biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
10171482|NCT03882138|Active Comparator|thick biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
10171483|NCT03882190|No Intervention|group 1|
10171484|NCT03882190|Experimental|group 2|
10171485|NCT03882151|Experimental|Epilog Preop|patients receive Epilog preop analysis
9521994|NCT03269201||Normal Pressure Hydrocephalus|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
9521995|NCT03269201||DYSTONIA-focal, generalized and others|"Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia~.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia"
10171486|NCT03882359|Active Comparator|Definity|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of DEFINITY® 100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
10171487|NCT03882359|Experimental|MVT-100|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of MVT-100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
10171488|NCT03882086|Experimental|foot reflexology group|The intervention group was comprised of 30 women in the early postpartum period. Pretest data were collected on the 14th day postpartum. Then a total of four reflexology sessions were applied for 15 minutes in each foot, in the afternoons, every other day between postpartum 14th-20th day, as the women were available. And posttest data were collected on the 20th day postpartum at the end of the four-reflexology sessions.
10171489|NCT03882086|No Intervention|standard care group no reflexology|The control group of this study was comprised of 30 women in the early postpartum period who had sleep problem and gave vaginal birth. Pretest data were collected on the 14th day postpartum. On the 20th day postpartum, the posttest data were assessed during home visits. These women only received routine postpartum care from public health nurses but did not access the reflexology
10171490|NCT03882346|No Intervention|Control Group|Patients in Control Group will receive best supportive care for the disease.
10171491|NCT03882346|Experimental|Experimental Group|Patients in Experimental Group will receive LifeLiver treatment in addition to best supportive care for the disease.
10171492|NCT03882320|Experimental|Sublingual Patient Controlled Analgesia (PCA)|Sufentanil Sublingual Patient Controlled Analgesia (PCA)
10171493|NCT03882320|Active Comparator|Intravenous Patient Controlled Analgesia (PCA)|Oxycodone Intravenous Patient Controlled Analgesia (PCA)
10171494|NCT03882281|Experimental|A group|Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.
10171495|NCT03882281|Experimental|B group|Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.
10171496|NCT03882294|Experimental|Probiotics|Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10^10 CFU/bottle (80 ml)
10171497|NCT03882294|Placebo Comparator|Placebo|Subjects in placebo group will receive milk drink without LcS (80 ml).
10171498|NCT03882307|No Intervention|group1 (naive)|Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment
10171499|NCT03882307|Active Comparator|group2 (sustained responder)|Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens
10171500|NCT03882255|Experimental|Treatment Period 1: Ponesimod (2 mg)|Participants will receive a single dose ponesimod 2 milligram (mg) oral tablet under fed conditions on Day 1. Participants not fulfilling discontinuation criteria can continue to Treatment Period 2 after a washout period of at least 7 days and a maximum of 14 days.
10171501|NCT03882255|Experimental|Treatment Period 2:Ponesimod, Propranolol, Placebo Propranolol|Participants who do not fulfill any of discontinuation criteria will be randomized to 1 of 2 Treatments (Treatment A or B) on Day 1. Treatment A: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus placebo propranolol once daily from Day 1 to Day 19; Treatment B: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus 80 mg propranolol once daily from Day 1 to Day 19.
10171502|NCT03882242|Experimental|Intervention Program Facilitators|"Participants will learn about and deliver (facilitate) a prevention program In favor of Myself to school-children"
10171503|NCT03882333|Experimental|Acute exercise|Acute exercise (bicycle at stationary cycle).
10171504|NCT03882333|No Intervention|Rest|Rest (lying down or sitting in a chair) for 30 minutes, i.e. same time duration as in experimental arm.
10171505|NCT03882008|Experimental|Abatacept|Abatacept 125mg subcutaneous injection weekly for 24 weeks
10171506|NCT03882125|Experimental|Mindfulness|Assigned to a 6-week mindfulness-based relapse prevention course
10171507|NCT03881982|Experimental|PIMPERNEL Novel Electronic Log - intervention|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
10171508|NCT03881982|Other|PIMPERNEL Novel Electronic Log - control|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
10171509|NCT03882216|Experimental|test group pouch technique|free connective tissue graft augmentation using pouch technique
10171510|NCT03882216|Experimental|test group modified pouch technique|free connective tissue graft augmentation using modified pouch technique
9521996|NCT03269201||Cerebellar ataxia|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
9521997|NCT03269201||Progressive supranuclear palsy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
9521998|NCT03269201||Corticobasal degeneration|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
9521999|NCT03269201||Dementia with Lewy Bodies|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
9522000|NCT03269292||warm autoimmune hemolytic anemia|corticosteroid either oral form or intravenous followed by oral
9527812|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
9527813|NCT03216824|Active Comparator|Dressing|A dressing is maintained on the CVAD exit site.
9527814|NCT03216824|Experimental|No-Dressing|The CVAD exit site is not covered with a dressing.
9527815|NCT03216616|Experimental|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
9527816|NCT03216525|Active Comparator|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
10171511|NCT03881995|Active Comparator|iGlarLixi|Subjects will receive premixed Insulin glargine + lixisenatide once daily for 12 weeks
10171512|NCT03881995|Active Comparator|Insulin glargine|Subjects will receive Insulin glargine once daily for 12 weeks
10171513|NCT03882060|Experimental|rHuEPO|recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
10171514|NCT03882060|Placebo Comparator|Control|Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
10171515|NCT03881956|Other|Women with gestational diabetes|88 women with gestational diabetes (46 for the intervention group and 42 for the control group) were in the arm.
10171516|NCT03881943|Active Comparator|Ticagrelor|Ticagrelor 60mg BD for 3 months
10171517|NCT03881943|Active Comparator|Aspirin|Aspirin 100mg daily for 3 months
10171518|NCT03881930|Experimental|Experimental group|"Balance rehabilitation with modified visual input:~In experimental group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with modified visual input."
10171519|NCT03881930|Active Comparator|control group|"Balance rehabilitation with no modified visual input:~In control group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with no modified visual input."
10171520|NCT03881722|Active Comparator|thickened formula|
10171521|NCT03881722|Experimental|Mg alginate|
10171522|NCT03881735|Experimental|Cohort A (enasidenib, hematopoietic cell transplantation)|Patients receive enasidenib PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo a HCT 7-14 days after treatment. Within 30-100 days following the transplant, patients receive enasidenib QD. Treatment repeats every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
10171523|NCT03881735|Active Comparator|Cohort B (enasidenib)|Patients receive enasidenib PO QD. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
10171524|NCT03881826|Experimental|Haematological patients|
10171525|NCT03881826|Active Comparator|Healthy volunteers|
10171526|NCT03881774|Experimental|experimental arm|cord blood derived CAR T cells group
10171527|NCT03881904|Active Comparator|OCP Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
10171528|NCT03881904|No Intervention|Control Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.
10171529|NCT03881891|Experimental|Follow-app intervention arm|This arm will comprise of patients who are prompted to complete the PROMIS pain intensity scale through text/Short Message Service(SMS) or email mobile device notifications at pre-defined time intervals on Days 1, 3, 5 and 7 post-operatively.
10171530|NCT03881891|No Intervention|Standard care arm|This arm will comprise of patients who receive the usual care.
10171531|NCT03881839||patient in emergency department|
9527817|NCT03216525|Placebo Comparator|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
10171532|NCT03881761|Experimental|experimental arm|CAR-T cell group
10171533|NCT03881644|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigran infusion (0.4 mg/min) for 10 mins"
10171534|NCT03881644|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
10171535|NCT03881696|Experimental|Stage 1:Omalizumab as Monotherapy|"Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study."
10171536|NCT03881696|Experimental|Stage 1: Omalizumab OLE|"OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.~Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic."
9522001|NCT03269214|No Intervention|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
9522002|NCT03269214|Experimental|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
9522003|NCT03269175|Other|Experimental arm 15 years ago|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
9522004|NCT03269175|Other|Placebo arm, offered treatment at MS diagnosis or at Month 24|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
10171537|NCT03881696|Placebo Comparator|Stage 1: Placebo for Omalizumab as Monotherapy|"Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study."
10171538|NCT03881696|Experimental|Stage 2: Omalizumab|"Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:~Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR~Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
10171539|NCT03881696|Experimental|Stage 2: Omalizumab-Facilitated OIT|"OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy~Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
10171540|NCT03881696|Experimental|Stage 2: Omalizumab + Placebo OIT|"OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
10186977|NCT03730805|No Intervention|Control alone|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) without prior induction of any mindset is conduced.
9522005|NCT03269227|Experimental|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
9522006|NCT03269045|Other|Treatment with ORL-1B.|Pediatric patients with biotinidase deficiency.
9522007|NCT03269279|Experimental|Medical abortion arm|200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
9522008|NCT03269058|Experimental|Patients not treated with statins|
9522009|NCT03269058|Experimental|Patients treated with statins|
9522010|NCT03269149|Experimental|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
9522011|NCT03269149|Active Comparator|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
9522012|NCT03269318|Experimental|Personalised Medicine|Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
9522013|NCT03269318|No Intervention|Standard Care|Standard of care (Standard Care will be prescribed controller medication based on guidelines)
9522014|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
9522015|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
10171541|NCT03881696|Other|Stage 3: DBPCFC Based Treatment|"DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.~Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:~Long-term follow-up with dietary consumption of a food;~Long-term follow-up with avoidance of a food; or~Rescue OIT for a food.~The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will remain in Stage 3 until December 2023.~Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3."
10171542|NCT03881579|Other|Usual care|one random half of patients will receive usual care
9522016|NCT03268707|Experimental|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
9522017|NCT03268837|Experimental|Programmed Intermittent Bolus|
9522018|NCT03268837|Active Comparator|Continuous Infusion|
9522019|NCT03268798|Experimental|Wrist extension training|
10171543|NCT03881579|Experimental|intervention arm|one random half of patients will receive enhanced usual care (usual care plus nurse-led supportive care intervention)
10171544|NCT03881592||R-Clb patients|Patients treated with the combination of Rituximab + chlorambucil
9522020|NCT03268993|Other|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
9522021|NCT03268720|Other|healthy controls|FODMAP low diet gluten-free diet
9522022|NCT03268720|Other|NCGS patients|FODMAP low diet gluten-free diet
9522023|NCT03268928|Experimental|Story Starters Intervention|"Children will receive the the Story Starters intervention for six months. Each child will be visited by a trained Story Starter volunteer twice a week while the child is in preschool. The sessions will last 20 minutes and in each session the Story Starter volunteer and child will read books and play with toys. The Story Starter volunteers will keep a record of the number of sessions each child attends.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
10171545|NCT03881592||R-B patients|Patients treated with the combination of Rituximab + bendamustine
10171546|NCT03881592||Obi-Clb patients|Patients treated with the combination of Obinutuzumab + chlorambucil
10171547|NCT03881605|Experimental|MRI screening|Contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain at baseline, 4 months, 8 months and 12 months.
10171548|NCT03881605|No Intervention|Symptom-directed surveillance|Imaging of the brain will take place only if patients develop symptoms that are suggestive of brain metastases (e.g. headaches, vision changes, gait instability).
10171549|NCT03881657|Experimental|Intervention Group|The intervention group received a reverse colocated integrated behavioral health intervention or usual care
10171550|NCT03881657|Active Comparator|Control Group|The control group received behavioral health services only (usual care)
10171551|NCT03881878|Experimental|pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (420mg, IV)"
10171552|NCT03881878|Experimental|non-pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) :~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
10171553|NCT03881787|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
10171554|NCT03881787|Active Comparator|Cetuximab|Cetuximab,Erbitux 250mg/m2 single administration
10171555|NCT03881709|Experimental|The intervention group|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
10171556|NCT03881709|No Intervention|The control group|The control group will receive a health education about prostate biopsy.
10171557|NCT03881618|Experimental|electroacupuncture+auricular pressure|a group :electroacupuncture+auricular pressure for 20 minutes twice a week for 4 weeks
10171558|NCT03881618|Active Comparator|auricular pressure|b group :auricular pressure for 20 minutes twice a week for 4 weeks.
9522024|NCT03268928|Other|Wait-list Control|"Children in the wait-list control arm will continue to attend preschool as normal during the randomised controlled trial (RCT) and will receive the Story Starters intervention after the RCT has finished.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
9522025|NCT03268850|Experimental|LW-A|The Lost Wages A (LW-A) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a certain amount. This will also include standard of care.
9522026|NCT03268850|Experimental|LW-B|The Lost Wages B (LW-B) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a different amount. This will also include standard of care.
9522027|NCT03268694|Experimental|Cognitive and Emotion Processing Tasks|As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task
9522028|NCT03269006|Experimental|Inesfly Paint|Inesfly 5AIGRNG TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%). The formulation is vinyl paint with an aqueous base, with the active ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of active ingredients. Microcapsules range from one to several hundred micrometers in size.
9522029|NCT03269006|Experimental|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies.
9522030|NCT03269006|Experimental|ITN (KO-Tab 123)|impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin.
10171559|NCT03881553|Experimental|Premature Infants (NICU)|Premature infants receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
10171560|NCT03881553|Experimental|Opioid-Exposed Newborns (NICU)|Opioid-exposed newborns receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
10171561|NCT03881553|Experimental|Hospitalized Infants (PICU)|Infants receiving treatment in the Pediatric Intensive Care or Inpatient Unit will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
9522031|NCT03269006|Experimental|IRS (Delthamethrin)|indoor residual spraying with Delthamethrin in the living rooms
10171562|NCT03881540|Active Comparator|tDNA-MI group|Follow tDNA intervention and motivational interviewing counselling
10171563|NCT03881540|Active Comparator|tDNA-CC group|Follow tDNA intervention and conventional counselling
10171564|NCT03881540|Other|UC group|Follow a conventional diet with standard diabetes support and lifestyle education
10171565|NCT03881527|Experimental|Resection of the aortic valve leaflets with device|Patients in which the aortic valve has been resected using the nitinol blade
10171566|NCT03881527|Other|Resection of the aortic valve leaflets in standard fashion|Patients in which the aortic valve has been resected using a conventional blade or scissor
10171567|NCT03881813|Experimental|Fiber reinforced composite retainers|Fiber reinforced composite retainers were inserted in group 1 and were evaluated after every 3 months for a follow up period of 3 months.
10171568|NCT03881813|Experimental|Multistranded stainless steel retainers|Multistranded stainless steel retainers were inserted in group 2 and were evaluated after every 3 months for a follow up period of 3 months.
10171569|NCT03881969|Experimental|Financial incentive offered|Patient offered £100 incentive payment in initial trial invitation letter.
9522032|NCT03269006|No Intervention|Control|without any study interventions
9522033|NCT03269019||HIT-group|The patients with heparin-induced thrombocytopenia.
9522034|NCT03269019||HITTs-group|The patients with heparin-induced thrombocytopenia with thrombosis.
9522035|NCT03269019||Control group|The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.
9522036|NCT03268733|Experimental|Treatment group|45 PCOS patients will receive 5 mg folic acid
9522037|NCT03268733|No Intervention|control group|45 PCOS patients will receive no folic acid
9522038|NCT03268889|Experimental|treatment group|In this arm, patients would be given the regimen composed of Chidamide, Cyclophosphamide, epirubicin, Vincristine and Prednisone.
9522039|NCT03268967|Active Comparator|Structured Admission procedure|After implementation of a structured admission procedure to all ICU patients inspired by principles of Crisis Resource Management, Closed loop communication, action cards, and staff simulation training
9522040|NCT03268967|No Intervention|Standard Care|Randomly admission procedure to all ICU patients based on the clinicians' evaluation prior implementation of the intervention.
9522041|NCT03268915|Experimental|patient with idiopathic pulmonary fibrosis|
9522042|NCT03268785|No Intervention|Control|Previous admitted patients who were given conventional thyroidectomy combined with central neck lymph node dissection, without intra-operative nodes identification were enrolled into control group.
9522043|NCT03268785|Experimental|Experimental group|Newly admitted patients,from august 2016 to august 2018, who were given thyroidectomy combined with central neck lymph node dissection, with intra-operative identification of suspicious lymph nodes or parathyroid glands were regarded as experimental group.Intraoperative identification method includes Diff-quik staining and PTH test assay. 200 participants were planed for enrollment.
9522044|NCT03269162|Experimental|Jinfukang + Chemotherapy Group|
9522045|NCT03269162|Placebo Comparator|Chemotherapy Group|
10171570|NCT03881969|Experimental|No incentive. Payment not offered|Patient sent standard trial invitation letter with no offer of incentive payment.
9522046|NCT03268876||Epithelial ovarial cancer|Patients primary treated with primary surgery for advanced epithelial ovarian cancer (> stage IIa) at the participating institutions will be asked to participate.
9522047|NCT03268902|Experimental|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
10186978|NCT03730792|Experimental|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
10186979|NCT03730792|No Intervention|Usual Practice Control|"Participants experience standard or Usual Practices in new employee onboarding processes at their workplace."
10186980|NCT03730779|Experimental|O2 recieving|Patients who receive hyperoxia
10186981|NCT03730766|Experimental|Bismuth Plus triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
10186982|NCT03730753|Active Comparator|Control group|Continuous infusion + patient controlled epidural analgesia
10186983|NCT03730753|Experimental|Study group|Programmed intermittent epidural bolus + patient controlled analgesia
10186984|NCT03730740|Experimental|Lenalidomide|Administer the study drug in the following way with 28 days as one cycle. Lenalidomide 25mg Days 1-21 Dosing continues until disease progression is confirmed.
10171571|NCT03881267|Experimental|Human Autologous Homologous Skin Construct (SkinTE)|SkinTE, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a venous leg wound in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing and compression
10171572|NCT03881267|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on venous leg wounds in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing and compression
9522048|NCT03268902|Experimental|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
9522049|NCT03268902|Experimental|Nicotinamide only|Nicotinamide Placebo Placebo
9522050|NCT03268902|Placebo Comparator|No active treatment|Placebo Placebo Placebo
9522051|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
10171573|NCT03881280|No Intervention|Control group|Treatment as usual for 4 weeks
10171574|NCT03881280|Experimental|Intervention group|Education through the app for 4 weeks
9522052|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
10171575|NCT03881306|Experimental|D-TACE|D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
9522053|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
9522054|NCT03268863|Experimental|Virtual Reality|Google Cardboard Virtual Reality headset running an interactive game
9522055|NCT03268863|Sham Comparator|Control|Powered down Google Cardboard Virtual Reality headset
10171576|NCT03881254|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
10171577|NCT03881254|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
10171578|NCT03881423|Active Comparator|Deep block|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
9522056|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
9522057|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
9522058|NCT03268772|Experimental|PLD-IFO|pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
9522059|NCT03268603|Experimental|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules.
9522060|NCT03268564|Experimental|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~Viewing a promotion video and a demonstration video~Brief motivational interviewing through telephone~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~Viewing a promotion video and a demonstration video~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders"
10171579|NCT03881423|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
9672068|NCT05040165|Experimental|Failure time analysis|"The primary objective is to evaluate the durability of the investigational device over its intended use lifetime (i.e. warranty period), specifically relating to any defect in the TPE material. Additionally, to gather information on the rate of side-effects, i.e. skin rashes, sores, etc.~Secondary objectives relate to gather information on how amputees use the liner, specifically:~Intensity of use (days/week and hours/day)~Alternation; i.e. switching every other day between liners~Use of personal hygiene or cosmetic products~The following performance and safety aspects are to be verified:~• The ICEFORM line of devices are durable over their intended use lifetime."
9672069|NCT05040152|Experimental|Arm I (telephone-based intervention)|Participants receive weekly telephone-based weight loss intervention for 15 weeks, including dietary recommendations tailored to their current weight and weight loss target, home-based aerobic and resistance exercise, and weekly telephone counseling session over 30-45 minutes.
9672070|NCT05040152|Active Comparator|Arm II (education brochures)|Participants receive education brochures describing the American Institute for Cancer Research physical activity and dietary guidelines.
9672071|NCT05040139||Malone procedure|The percutaneous caecal access is performed surgically
9672072|NCT05040139||Percutaneous Endoscopic Caecostomy|The percutaneous caecal acces is performed endoscopically.
9672073|NCT05039801|Experimental|Part A (IACS-6274)|Patients receive IACS-6274 PO BID on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
9672074|NCT05039801|Experimental|Part B (IACS-6274, pembrolizumab)|Patients receive IACS-6274 PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
10171580|NCT03881189|Experimental|SUNEKOS ® 200|"The 1st intradermal treatment (T1i) with Sunekos ® 200 was carried out during the basal visit (T0), after basal evaluations planned by the study procedure, and then repeated 2 more times with an interval of 15 days (T2i and T3i)"
10171581|NCT03881293|Placebo Comparator|Placebo Lubricant Gel|5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
9522061|NCT03268577||Prevention (diet and activity tracking)|Patients complete the ASA24 about foods, cooking methods, and other aspects of diet every 2 months for up to 6 times, and complete ACT24 about activities and time reporting every 2 months for up to 6 times. Patients also complete DHQ-II questionnaires at the beginning and end of the study about the frequency and portion sizes of foods consumed over the past 12 months, provide a 7-day food checklist twice with the DHQ-II, and provide a 4-day food record twice, once every 6 months. Physical activity monitors are worn to measure movement at different intensity levels and sitting or standing periods, twice during the study with 6 months between each time they are worn.
9522062|NCT03268525|Active Comparator|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
9522063|NCT03268525|Placebo Comparator|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
9522064|NCT03268616|Experimental|Healthy Subjects|increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive.
9522065|NCT03268616|Experimental|Sever COPD Patients|increase the pressure support ventilation step by step, in order to decrease neural respiratory drive.
9522066|NCT03268317||Patients with chronic hepatitis C treated by DAAs|All subjects will be given the same treatment regimen which includes Sofosbuvir 400 mg orally/24 hours (pre-breakfast) and Daclatasvir 60 mg orally/24 hours after lunch with or without ribavirin for a total period of 12 weeks.
9522067|NCT03268642||Life-support Based Comprehensive Treatment Regimen group|"meet all the following conditions:~intravenous immune globulin;~large dose of glucocorticoids;~mechanical ventilation;~hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);~continuous renal replacement therapy."
9522068|NCT03268642||conventional therapy group|"meet one of the following conditions:~without/insufficient intravenous immune globulin;~without/with various doses of glucocorticoid ;~vasoactive drug;~without/delayed mechanical ventilation;~without/delayed hemodynamic support;~without/delayed continuous renal replacement therapy."
9522069|NCT03268655|Experimental|Ginger extract|Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
9522070|NCT03268655|Experimental|Placebo|Placebo, daily for 6 weeks, followed by 6 week washout.
9522071|NCT03268252||2x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given twice per year
9522072|NCT03268252||1x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once per year
9522073|NCT03268486||Triple monitoring|Pregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.
9522074|NCT03268369|Active Comparator|Control group|
9522075|NCT03268369|Experimental|Non lesional diurnal partial epilepsy|
9522076|NCT03268369|Experimental|Idiopathic generalized epilepsy|
9522077|NCT03268369|Experimental|Nocturnal frontal lobe epilepsy|
9522078|NCT03268369|Experimental|Epileptic patients with Vagus Nerve Stimulation (VNS)|
9522079|NCT03268512|Experimental|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
9522080|NCT03268512|Experimental|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
9522081|NCT03268512|No Intervention|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
9522082|NCT03268408||Intervention|"Intervention aimed at improving self-efficacy parenting which consists in sending to new parents, during the first year of life of their son, eight newsletters with advices and recommendations on child care and development (project Baby Newsletter)."
9522083|NCT03268408||Control|Usual care
9672075|NCT05039905|Experimental|99mTc-MSA-ICG injection|"99mTc-MSA-ICG injection~1mCi of 99mTc~1mg of MSA 0.1mg of ICG Total 1cc injection volume at 2 hours before the surgery"
9672076|NCT05039983|Experimental|EGCG application|We have chosen a dose of 880 umol/L as the lower limit for this phase I study by referring to previous studies. Six dose levels for EGCG were defined as following: 880, 1760, 2640, 3430, and 4400 umol/L per dose. Dose escalation proceeded according to a standard phase I design with three patients initially treated on each tier. If, on any dose tier of EGCG, two of three patients or two of six patients experienced a grade III or IV toxicity due to EGCG, dose escalation of EGCG would cease. The maximally tolerated dose (MTD) was defined as the highest dose with fewer than one-third of patients experiencing a dose-limiting toxicity (DLT) due to EGCG. EGCG solution was given continuously for 8 days before anti-tumor treatment.
9977493|NCT01362114|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
9977494|NCT01362153|Experimental|001|Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
9522084|NCT03268447|Active Comparator|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
9522085|NCT03268447|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
9672077|NCT05040074|Experimental|SQ-Kyrin TMVr Feasibility Study|Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.
9672078|NCT05040022|Active Comparator|Group pneumoperitoneum pressure 10|Pneumoperitoneum pressure at 10 mmHg
10171582|NCT03881293|Active Comparator|Lidocaine 2% Gel|5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
9522086|NCT03268291|Active Comparator|Standard outpatient observation|Outpatient management according to Ministry of health standards
9522087|NCT03268291|Experimental|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;~service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;~questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
9522088|NCT03268278|Active Comparator|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
9522089|NCT03268278|Placebo Comparator|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
9522090|NCT03268434|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
9522091|NCT03268434|Active Comparator|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
9522092|NCT03268382|Experimental|APR-246 + PLD|
10171583|NCT03881488|Experimental|Part 1 Dose Escalation|Escalating doses of CTX-471 depending on cohort at enrollment.
10171584|NCT03881488|Experimental|Part 2 Dose Expansion|Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)
10171585|NCT03881475||healthcare workers|Participants will participate in several sessions where they will complete the questionnaires. The questionnaires will be spaced: 0, 1 week, 6 months, 1 year and then at each occupational visit within 5 years.
10171586|NCT03881371|Experimental|Safinamide|Patient will receive film-coated Safinamide tablets orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
9522093|NCT03268395|Other|CO2 Measurement|Each subject will received simultaneous arterial blood gas CO2 and transcutaneous CO2 monitor assessments. The correlation of these two measurements will be compared.
9527818|NCT03216330||Case|"Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.~New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.~Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)~Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.~At least 18 years old"
9672079|NCT05040022|Placebo Comparator|Group neumoperitoneum pressure 14|Pneumoperitoneum pressure at 10 mmHg
9672080|NCT05039957|Active Comparator|A|
9672081|NCT05039957|Experimental|B|
9672082|NCT05039723|Experimental|Treatment|Treatment with Xeomin, Radiesse, and/or Belotero
10171587|NCT03881371|Placebo Comparator|Placebo|Patient will receive matching placebo orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
10171588|NCT03881384||ctDNA level|ctDNA level during neoadjuant chemotherapy
10171589|NCT03881176|Experimental|Active|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
9672083|NCT05039827|Experimental|MWM GROUP|Mobilization with movement with wrist extension
9672084|NCT05039827|Active Comparator|SOFT TISSUE MOBILIZATION GROUP|Parallel and perpendicular soft tissue massage at common extensor origin
9826624|NCT02425306|Experimental|Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide|"Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
9826625|NCT02425449|Experimental|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
9977495|NCT01362153|Experimental|002|Golimumab SC injection of 100 mg every 4 weeks through Week 20
9977496|NCT01362179||unstimulated BM donors|Observational (non-interventional) study.
9977497|NCT01362179||filgrastim-mobilized PBSC donors|Observational (non-interventional) study.
9522094|NCT03268629|Experimental|Mindfulness-Based Joyful Sleep|The proposed 'Joyful Sleep' program will be conducted weekly, 2 hours per session, 8 sessions, group-based in mindfulness. The content and skills are based upon MBSR, MAPs and Tai Chi. The proposed topics include: 1) mindfulness and insomnia, 2) mindful awareness of stress, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, 6) moving mindfulness meditation: the first taste of Tai Chi, 7) moving mindfulness meditation: the second taste of Tai Chi, 8) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, body scan meditation, sitting meditation, standing meditation, walking meditation, Taichi, and daily life meditation.
10171590|NCT03881397|No Intervention|Control (Track B assessed at Time 2)|A survey regarding tech use, health behaviors and well-being including physical activity, anxiety, and sleep
10171591|NCT03881397|Experimental|Online Family Media Use Plan (Track A)|The Online Family Media Use Plan group will receive a link to American Academy of Pediatrics Family Media Use plan at the end of the survey, which describes internet safety ideas for teens and parents to review and create together.
9522095|NCT03268629|Active Comparator|CBT-I|The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
9522096|NCT03268239|Other|MRI sequences|"There will be only one arm of patients with central nervous system inflammatory disease.~Each patient will be its own control. The usual and additional MRI sequences will be performed in all patients and the number of lesions obtained in usual sequences and additional sequences will be compared in the same patient."
9522097|NCT03268200|Experimental|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
9522098|NCT03268200|No Intervention|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
9522099|NCT03268226|Experimental|CHF5993|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
9522100|NCT03268161||Patients with anti-MAG neuropathy|Mutational analysis of clonal B cells
9522101|NCT03268174|Active Comparator|AO+Mist|AO+Mist
9522102|NCT03268174|Placebo Comparator|Placebo|Placebo
9672085|NCT05040061|Experimental|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
10171592|NCT03881397|Experimental|Media Use Resources Awareness (Track B assessed at Time 3)|Resources offered to parents and teens that include tools and data for safe technology use among teens
10171593|NCT03881111|Experimental|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
9522103|NCT03268187|Experimental|Self-Alert Training|Biofeedback-based Self-Alert Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
9522104|NCT03268187|Active Comparator|Relaxation Training|Biofeedback-based Relaxation Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
10171594|NCT03881111|Placebo Comparator|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
10171595|NCT03881410|Experimental|Shear-wave elastography-guided|
10171596|NCT03881410|Active Comparator|Convention ultrasound-guided|
10171597|NCT03881137|Experimental|Intervention|Geriatric assessment with management
10171598|NCT03881137|No Intervention|Control|Patients receiving supportive care and follow up according to routine practice
9522105|NCT03268148|Experimental|low level laser group|LaserPen is applied to the local point for 20 seconds where heel-lancing will be performed in the low level laser group.
9522106|NCT03268148|No Intervention|breast milk group|Subjects in breast milk group are given 5ml expressed breast milk by mouth using a syringe tube inserted to the participant's oral cavity over a 2-minute period before heel-lancing.
9522107|NCT03268070|Experimental|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
9522108|NCT03268070|Experimental|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
9522109|NCT03268070|Experimental|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
9522110|NCT03268070|Sham Comparator|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
9522111|NCT03268070|Experimental|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
9522112|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
9522113|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
9522114|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
9522115|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
9522116|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
9522117|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
9522118|NCT03268122|Active Comparator|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
9522119|NCT03268122|Active Comparator|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
9522120|NCT03267927|Experimental|Patient with OSA|
9522121|NCT03267745|Experimental|Amino Acid|Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
9522122|NCT03267745|Placebo Comparator|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 23.7g of excipient-matched placebo in water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
9522123|NCT03267719|Experimental|laser therapy|Erbium-laser therapy will be applied
9522124|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
9522125|NCT03267797|Experimental|Treatment group|Peripheral blood mononuclear cells (PBMCs) were administered into the uterine cavity of RIF patients in this group.
9522126|NCT03267797|Placebo Comparator|Control group|Phosphate buffer saline (PBS) as placebo was injected into the uterine cavity of RIF patients in this group.
10171599|NCT03881228|Experimental|Intervention|"at enrollment, caretakers will receive an educational booklet for caretakers explaining why IPT needs to be given~at enrollment and weekly for 24 weeks, caretakers will receive a children's storybook, with weekly installments, over the 6-month course of IPT as a non-monetary incentive~weekly, caretakers will receive short messages services (SMS) reminders delivered to the caretaker for the weekly pick-up."
10171600|NCT03881228|No Intervention|Standard of care|Routine care at the health facility
9522127|NCT03267979|Other|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
9522128|NCT03267732|Active Comparator|1|Pegilodecakin (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
9522129|NCT03267732|Active Comparator|2|Pegilodecakin (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
9522130|NCT03267849|Experimental|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure or decrease eye pressure, then will have images taken a second time
9522131|NCT03267810|Experimental|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
9522132|NCT03267810|Sham Comparator|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
9522133|NCT03267953|Experimental|First stage: Self-directed My Health CheckUp|Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
9522134|NCT03267953|Experimental|First stage: Minimally guided My Health CheckUp.|This group will also be invited to use the 12-week Internet-based stress management program, but they will additionally receive support via weekly telephone calls from a lay coach.
9522135|NCT03267953|Experimental|Second stage: High intensity Motivational Interviewing (MI)|After 6 weeks, response to the first stage programs will be assessed and only the non-responders will be randomized a second time to (a) continue with the first stage programs or (b) High-intensity MI. In addition to continued access to My Health CheckUp, participants in this group will also be supported with 6 weekly, telephone-based MI sessions.
9522136|NCT03268031||Glaucoma patients|Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
10171601|NCT03881449|Experimental|ABILIFY MYCITE Group|"If patients are assigned to the ABILIFY MYCITE treatment group, the patients and physician will initiate the system at the baseline visit, and continue to use the system for 3 months. At any time after the first 3 months, a patient and his or her doctor will have the opportunity to either discontinue or continue using ABILIFY MYCITE for the remainder of the trial (9 additional months; 12 months total) as long as clinically appropriate with the goal of measuring adherence to improve clinical decision-making and care.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
9522137|NCT03268031||Non-glaucoma participants|Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
9522138|NCT03267875|Experimental|single arm|Patients after aneurysm in the aorta, Men and women aged 18-100 (not including special populations), who are able to read understand and sign a written consent to participate in the research
9522139|NCT03267706|Active Comparator|Palliative Care Comprehensive Tool|Clinicians within the study will be randomly assigned and trained on the use of the Palliative Care Comprehensive Tool
9522140|NCT03267706|No Intervention|Usual Care|Clinicians within the study will be randomly assigned to usual palliative care (without the newly introduced tool)
9522141|NCT03267966|Experimental|Group A|Leeds Pathology Protocol (LEEPP)
9522142|NCT03267966|No Intervention|Group B|"Conventional method of pathological evaluation"
9522143|NCT03267901|Experimental|Walnut-Control|
9826626|NCT02425449|Experimental|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
9522144|NCT03267901|Experimental|Control-Walnut|
9522145|NCT03268057|Experimental|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
9522146|NCT03267771|Active Comparator|progesterone suppositories vaginal group|vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.
9522147|NCT03267771|Experimental|Dydrogesterone oral tablets group|20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.
9522148|NCT03267784|Experimental|Experimental: allo-APZ2-DFU|Application of IMP on patients wound
10171602|NCT03881449|No Intervention|Treatment as Usual (TAU) Group|"TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
9522149|NCT03267550|Experimental|remote programming system|
9522150|NCT03267602|Experimental|Continuous Positive Airway Pressure (CPAP) Therapy|
9522151|NCT03267537|Active Comparator|Conventional office-based CBT-I|CBT-I will be delivered by a licensed clinical psychologist in weekly sessions lasting up to 1 hour. There will be 6 CBT-I sessions over the course of therapy with the option of an additional 2 treatments if deemed necessary by the clinical psychologist.
9522152|NCT03267537|Experimental|Telemedicine based CBT-I|The treatment will be the exact same as the active comparator group, with the same clinical psychologist doing the office-based CBT-I, but will be administered through a telemedicine modality
9522153|NCT03267446|Experimental|Interventional group|Patients confirmed having one or more of the signs of morbidly adherent placenta will be examined by 3D Ultrasound and 3D power Doppler. Patients will then be prepared for the operation.Cesarean hysterectomy will be done with removal of the uterus and the placenta as one mass.Cases with focal invasion of the uterus will be given a trial for conservative management. The whole specimen will be sent for histopathological examination, and the determination of length and depth of invasion.
9522154|NCT03267628|Sham Comparator|Saline intrathecal as well as saline in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
9522155|NCT03267628|Active Comparator|Saline intrathecal as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
9522156|NCT03267628|Active Comparator|Intrathecal morphine as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
9522157|NCT03267628|Active Comparator|Intrathecal morphine as well as saline in Block|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
9522158|NCT03268018|Other|Single arm|
9522159|NCT03267654|Experimental|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
9522160|NCT03267654|Experimental|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
9522161|NCT03267654|Active Comparator|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
9527819|NCT03216330||Control|"Reproductive aged female with no suspected or diagnosed endometriosis.~Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.~At least 18 years old"
9527820|NCT03216317|Active Comparator|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
9527821|NCT03216317|No Intervention|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
9527822|NCT03216291|Active Comparator|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
9527823|NCT03216291|Active Comparator|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
9672086|NCT05040061|Active Comparator|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI consisted of similar activities, but they all omitted savoring practices. These activities included attending to any current thoughts and feelings, planning everyday activities, remembering and recording daily events, and anticipating important events.
9527824|NCT03216278|Experimental|Treatment A|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed
9527825|NCT03216278|Active Comparator|Treatment B|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed
9527826|NCT03216278|Experimental|Treatment C|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted
9527827|NCT03216278|Active Comparator|Treatment D|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted
9527828|NCT03216278|Experimental|Treatment E|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed
9527829|NCT03216278|Active Comparator|Treatment F|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed
9527830|NCT03216278|Experimental|Treatment G|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted
9527831|NCT03216278|Active Comparator|Treatment H|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted
9527832|NCT03216356|Experimental|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
9527833|NCT03216356|Active Comparator|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
9527834|NCT03216356|Active Comparator|CBT + I.E. + study pill|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
10186985|NCT03730727|Active Comparator|Control|A liquid meal replacement shake containing 500 kcal (55% kcals from carb, 30% fat, 15% protein) will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Two-hours after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
9522162|NCT03267342|Experimental|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
9672087|NCT05039697|Experimental|NBO group Normobaric Hyperoxia combined with endovascular mechanical thrombectomy|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30minutes after admission) at a ventilation rate of 10L/min using a sealed non-ventilating oxygen storagemask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
9527835|NCT03216473|Experimental|Neuronox|Botulinum Toxin Type A for injection
9975185|NCT04377997|Active Comparator|Standard of Care Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation or standard of care anticoagulation. Those assigned to the standard of care anticoagulation group will receive the normal dose of heparin as per the Mass General guidelines."
9672088|NCT05039697|Placebo Comparator|Control group Inhale air placebo plus endovascular mechanical thrombectomy|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%
9672089|NCT05039853|Experimental|A brief cognitive task-based based intervention|Participants will engage in a brief cognitive task including: a memory reminder procedure, playing the computer game, Tetris, on a smart-device using mental rotation.
9672090|NCT05039853|Placebo Comparator|Placebo activity|Participants will engage with a placebo activity: listening to a pod-cast for approximately 15 minutes on a smart-device.
9672091|NCT05039567|Experimental|optimal heart team group|Heart teams in this group will be established according to the optimal heart team protocol. Each team consists of two interventional cardiologists and two cardiac surgeons. Team members will be trained systematically before the heart team meeting.
9672092|NCT05039567|No Intervention|conventional heart team group|Heart teams in this group will be established according to the basic elements recommended by guidelines. Each team consists of an interventional cardiologist, a cardiac surgeon, and a non-interventional cardiologist. No team training will be held before the heart team meeting.
9672093|NCT05039658|Experimental|Single agent treatment arm with IBI110|IBI110 administered at RP2D
9672094|NCT05039658|Experimental|Combination treatment arm with IBI10 and sintilimab|IBI110 and sintilimab administered at RP2D
9672095|NCT05039762|Active Comparator|Extracorporeal anastomosis|Laparoscopic right hemicolectomy with Extracorporeal anastomosis in patients with colon cancer.
9672096|NCT05039762|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy with Intracorporeal anastomosis in patients with colon cancer.
9672097|NCT05039931|Experimental|GNC-035|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
9672098|NCT05039892|Experimental|All eligible subjects|
9672099|NCT05040100|No Intervention|Textbook Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images.
9672100|NCT05040100|Experimental|3D Model Cohort|Trainees underwent a 10-minute lecture using two-dimensional (2D) images of the mediastinum selected from standard textbook resources. The lecture carefully reviewed the mediastinal anatomy reflected in the prosected cadaver and provided a variety of 2D axial, coronal, and sagittal images. Upon completion of the didactic session, the 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
9672101|NCT05039580|Experimental|PD-1 monoclonal antibody group|PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age >=18 years, or age <18 years but weight >=40kg. While for patients age <18 years, the dose of PD-1 monoclonal antibody is 3mg/kg.
9672102|NCT05039463||PRP + HA|two injections of PRP (plasma rich in platelets ), in combination with HA (hyaluronic acid)
9672103|NCT05039463||HA alone|HA (hyaluronic acid)
9672104|NCT05039749|Experimental|Human Central Lighting (HCL) Room|This inpatient room was outfitted with lights that mimic the day/night cycle, thereby supporting circadian rhythm. Day time lights were automatically on during 0600 to 1900 and in use any time the patients would normally utilize their lights, with a goal of three hours of light exposure per day. The lights automatically transitioned to warmer toned evening lighting at 1900.
9672105|NCT05039749|No Intervention|Standard Hospital Lighting (SL) Room|The lighting in this room was standard florescent hospital lighting. The only changes in the lighting was the on/off settings normally associated with lighting.
9826627|NCT02425449|Experimental|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
9826628|NCT02425449|Experimental|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
9826629|NCT02425449|Experimental|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
9522163|NCT03267680|Experimental|Arm I (IRX-2)|Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
9522164|NCT03267680|Active Comparator|Arm II (placebo)|Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
9522165|NCT03267420|Experimental|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
9522166|NCT03267420|Active Comparator|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
9522167|NCT03267420|Active Comparator|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
9522168|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
9522169|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
9522170|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
9522171|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
10171603|NCT03881150|Experimental|Hybrid Cardiac Rehabilitation|"This intervention is adapted from the Cardiac Rehabilitation Delivery Model for Low-Resource Settings proposed by the International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. This program will be delivered by an exercise specialist (physiotherapist) and the principal purposes of the exercise sessions is to develop patient self-management related to the physical activity habit, and educate them how to monitor exercise intensity at home and in daily life. The program include 10 face-to-face exercise sessions and a transition to unsupervised phase using mobile technology.~Counseling is considered about physical activity, diet, smoking, and medication compliance."
10171604|NCT03881150|Active Comparator|Standard Cardiac Rehabilitation|The participants in the control group will receive the standard cardiac rehabilitation that is delivered in participating centers. These programs accounts with physicians, nurses, nutritionists and physiotherapists. The programs will be standardized in participating centers in accordance with currents guidelines (only 18-22 face-to-face exercise sessions). Differentially, this programs provide, group education sessions about physical activity, diet, smoking, and medication compliance (without counseling).
9522172|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
9522173|NCT03267368|Experimental|Comprehensive Care Program|Pulmonary rehab and smoking cessation program/intervention/assessment
9975186|NCT04346511|Experimental|Acupuncture|In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.
9975187|NCT04346511|Sham Comparator|Sham Acupuncture|Specially designed Sham acupuncture needles that are not actually penetrate the skin and activate the acupoint will be used in an identical procedure to RA. The patient would be able to feel light pressure at the site.
9522174|NCT03267355|Experimental|Gastrointestinal diseases|Endoscopic Ultrasound
9522175|NCT03267290|Experimental|Sonazoid- CEUS+CEMRI or CECT+CEMRI|Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
9522176|NCT03267316|Experimental|Dose escalation|Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04. [Completed December 2018]
9522177|NCT03267316|Experimental|Monotherapy (Q1W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W).
9522178|NCT03267316|Experimental|Monotherapy (Q1W/Q2W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W).
9522179|NCT03267316|Experimental|Combination - NSCLC|Subjects with NSCLC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (cisplatin/gemcitabine).
9975188|NCT04346394|Experimental|Yohimbine|The first visit in the study has no interventional drug. Yohimbine (5mg) is administered orally during visit two, during a head up tilt test, to manipulate the noradrenergic system to determine the association between OH and NP symptoms in those with PD. Yohimbine is not administered as a treatment in this study, but as a pharmacologic tool to study the adrenergic system.
9975189|NCT04336033|Experimental|Counseling + Renal Diet App|Subjects in the intervention group will receive an individualized dietetic counseling from the researcher aided with the newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients
9975190|NCT04336033|Placebo Comparator|Counseling + Printed Nutrition Pamphlet|Individualized dietetic counseling aided with printed nutrition pamphlet prepared by Ministry of Health, Malaysia
9522180|NCT03267316|Experimental|Combination - PDAC|Subjects with PDAC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine).
9522181|NCT03267316|Experimental|Combination - PDAC (1 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
9522182|NCT03267316|Experimental|Combination - PDAC (2,5 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
9522183|NCT03267381||Arm 1a|Stage III melanoma diagnosis (biopsy-proven lymph node positive (this is either clinically palpable or enlarged nodes detected by imaging, which are then biopsied and have macroscopic disease).
9522184|NCT03267381||Arm 1b|Stage III after sentinel node biopsy (microscopic disease diagnosed on sentinel node biopsy).
9522185|NCT03267381||Arm 2|Stage IV- will need to stratify by current treatment with immunotherapy, targeted therapy, none
10171605|NCT03881202|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
9522186|NCT03267303|Experimental|TS-091 5mg|
9522187|NCT03267303|Experimental|TS-091 10mg|
9522188|NCT03267303|Placebo Comparator|Placebo|
9522189|NCT03267563|Experimental|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
9522190|NCT03267563|Experimental|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
9522191|NCT03267563|Experimental|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
9522192|NCT03267329|Experimental|Duowell® Tab.|Once daily during 16 wks
9522193|NCT03267329|Active Comparator|Telmisartan|Once daily during 16 wks
9522194|NCT03267173|Experimental|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
9522195|NCT03267251|Active Comparator|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
9522196|NCT03267251|Experimental|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
9522197|NCT03267030|Experimental|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
9522198|NCT03266939|Placebo Comparator|Placebo|
9826630|NCT02425891|Experimental|Atezolizumab Plus Nab-Paclitaxel|Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
10171606|NCT03881358|Active Comparator|ortho-k lenses and thinner spectacles|participants using conventionally designed ortho-k lenses (target for 4.00D) and thinner spectacles during day time
9975191|NCT04328376|Experimental|Prospective FEMQT Group|Propositus patients with genetically proven LQTS and their relatives
9975192|NCT04327986|Experimental|1/Arm 1A|De-escalating doses of M9241 in combination with M7824
9522199|NCT03266939|Active Comparator|Active Medication|
9522200|NCT03267043|Active Comparator|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
9522201|NCT03267043|Experimental|Family Nurture Intervention (FNI)|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
9522202|NCT03267043|Active Comparator|Standard Care - Case Studies|Participants enrolled as case studies in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital. These participants will be those who fall outside the inclusion criteria.
9522203|NCT03267043|Experimental|FNI - Case Studies|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay. These fall outside the inclusion criteria but act as a comparator to the case studies of Phase 1.
9522204|NCT03267186|Experimental|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
9522205|NCT03267069||alcohol liver disease|Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.
9522206|NCT03267004|Experimental|Meal Order 1|Meal A will be served to participant in meal session 1 and Meal B in meal session 2.
9522207|NCT03267004|Experimental|Meal Order 2|Meal B will be served to participant in meal session 1 and Meal A in meal session 2.
9522208|NCT03267121|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
9522209|NCT03267199||patients with high MPV,PDW,PFT|patients with high MPV,PDW,platelet function test
9522210|NCT03267199||patients with normal or low MPV,PDW, PFT|patients with normal or low MPV,PDW,platelet function test
9975193|NCT04327986|Experimental|2/Arm 1B|De-escalating doses of M9241 in combination with M7824 and SBRT
10171607|NCT03881358|Experimental|newly designed ortho-k lenses|participants using newly designed ortho-k lenses for high myopia (target for full correction)
10171608|NCT03881319|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
10171609|NCT03881319|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
9522211|NCT03267095|Experimental|Study|.Patient in stduy Arm will receive music therapy sessions
9522212|NCT03267095|No Intervention|Control|Patient in control Arm will have cosuling for mother and follow up
10171610|NCT03881319|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
9522213|NCT03266965|Experimental|Histidine Intervention Group|A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.
9522214|NCT03267056||DCB arm|drug eluting balloon catheter
9522215|NCT03267017||Patient scheduled for surgery under general anesthesia|
9522216|NCT03266913|Active Comparator|Probiotic|Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
9522217|NCT03266913|No Intervention|No probiotic|Routine phototherapy
9522218|NCT03267082|Experimental|Evaluation the role of Laparoscopic management of perforated a|
9522219|NCT03266926||Postoperative Patients with premarin|Patients who undergo vaginal surgery at Sunnybrook Health Sciences Centre (SHSC) who require vaginal packing postoperatively and receive premarin vaginal cream coated packing.
9522220|NCT03266926||Postoperative Patients with bupivacaine|Patients who undergo vaginal surgery at Patients who undergo vaginal surgery (SHSC) who require vaginal packing postoperatively and receive bupivacaine soaked packing.
9522221|NCT03267160||Sepsis with cardiopulmonary failure|Patient with sepsis and also respiratory and heart involvement, confirmed by Hemodynamic parameters
9522222|NCT03267160||Sepsis without cardiopulmonary failure|Patient with sepsis without respiratory and heart involvement
9975194|NCT04327986|Experimental|3/Arm 2|RP2D of M7824 and M9241 in combination with SBRT
9975195|NCT04318314||Healthy and asymptomatic healthcare workers|Healthy and asymptomatic healthcare workers
9975196|NCT04300140|Experimental|Phase 1b: Batiraxcept + cabozantinib|Two dose levels of batiraxcept administered Q2W (once every two weeks) in combination with QD (once a day) cabozantinib will be evaluated.
9975197|NCT04300140|Experimental|Phase 2 Part A: batiraxcept + cabozantinib|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib will be evaluated.
9975198|NCT04300140|Experimental|Phase 2 Part B: batiraxcept + cabozantinib + nivolumab|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib and nivolumab.
10171611|NCT03881215|Experimental|Platelet Rich Plasma|PRP
10171612|NCT03881215|Active Comparator|intra-uterine balloon|
10171613|NCT03880942|Active Comparator|Informative Story Book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
10171614|NCT03880942|Placebo Comparator|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
10171615|NCT03880981|Active Comparator|Acetaminophen|Patients will receive 650mg PO Acetaminophen every 6 hours as needed for pain
10171616|NCT03880981|Active Comparator|Ibuprofen|Patients will receive 600mg PO Ibuprofen every 6 hours as needed for pain
10171617|NCT03881033|Placebo Comparator|P12|
9522223|NCT03266991|Experimental|RPT-INH|Participants treated with weekly rifapentine and isoniazid for twelve weeks.
9522224|NCT03266991|Active Comparator|control|Participants treated with daily isoniazid for six months
9522225|NCT03266692|Experimental|ACTR087 in combination with SEA-BCMA|
9522226|NCT03266705|Experimental|61 mgA tafamidis free acid soft gelatin capsule|
9522227|NCT03266705|Experimental|4x20 mg tafamidis meglumine soft gelatin capsule|
9522228|NCT03266718|Other|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
9522229|NCT03266718|Other|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
9522230|NCT03266744|Other|Main study group|"Patients will have repeat CT (Computerised Tomography) scans and WB-MRI (Whole Body Magnetic Resonance Imaging) every 12 weeks until disease progression. A baseline bone scan (99mTc-MDP) will be performed.~At the point of disease progression, a repeat bone scan will be obtained in addition to the CT and WB-MRI."
9522231|NCT03266744|Other|WB-MRI sub-study group|Patients will be given the opportunity to participate in a sub-study of WB-MRI reproducibility. This involves a repeat scan of the Whole Body Magnetic Resonance Imaging (WB-MRI) diffusion-weighted sequences. This will be shorter in duration than the full WB-MRI scan and will take place within one hour of completing the full WB-MRI scan.
9522232|NCT03266731|Experimental|use of aspirin and clopidogrel|
9522233|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
9522234|NCT03266562|Other|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
9522235|NCT03266822||Healthy control|
9522236|NCT03266822||RA patients on anti-TNF therapy|
9522237|NCT03266822||RA patients on anti-IL-6R therapy|
9527836|NCT03216473|Active Comparator|Botox|Botulinum Toxin Type A for injection
9522238|NCT03266679|Other|Patients receiving metacognition-based intervention|Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker & Klion) - weekly for a period of 12 months. No control/comparison group.
9522239|NCT03266666|Other|Intervention Arm - WellnessRX|This is a longitudinal outcome study. All participants will receive the class and grocery credit intervention.
9975199|NCT04300140|Experimental|Phase 2 Part C: batiraxcept alone|One dose level of batiraxcept administered Q2W will be evaluated.
9522241|NCT03266809||Breast Cancer Patients|"Eligible participants will be women aged 18 years or over who have the following main characteristics:~Early invasive breast cancer (stage I-III)~Due to start SAT (adjuvant or neoadjuvant chemotherapy +/- trastuzumab +/- pertuzumab)~WHO performance status 0-2."
9522242|NCT03266549|Experimental|Botulinum toxin augmented surgery group|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
9522243|NCT03266549|Active Comparator|conventional surgery group|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia.The standard correction tables will be used as a guide for the amount of muscle recession and, or resection
9522244|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
9522245|NCT03266835|Other|SoundBite™ Crossing System - Peripheral|This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
9522246|NCT03266653|Experimental|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
10171618|NCT03881033|Active Comparator|P7+5|
9522247|NCT03266614|Experimental|Recovery 4 US|This group receives a smartphone with the Recovery 4 US application and access to the application website.
9522248|NCT03266614|No Intervention|Services as usual|This group receives a smartphone but no access to the Recovery 4 US application.
9522249|NCT03266640|Experimental|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
9522250|NCT03266601|Experimental|Recombinant Human Interferon α-2b Spray|
9522251|NCT03266601|Active Comparator|Ribavirin|
9522252|NCT03266627|Experimental|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
9522253|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
9522254|NCT03266523||Control|The CONTROL (neutral) environment corresponds to the standard environment of the imaging waiting rooms
9522255|NCT03266523||Zen|The ZEN environment will represent a clean, minimalist nature
9522256|NCT03266523||Green|The GREEN environment will represent rural landscapes, undergrowth
9522257|NCT03266523||Sea|The SEA environment will represent lakes, ponds, seaside
9522258|NCT03266393|Experimental|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
9522259|NCT03266393|Experimental|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
9522260|NCT03266406|Experimental|Effect of hyaluronidase on IOP|
9522261|NCT03266510|Experimental|Inspiratory muscle strength training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be strong.
9522262|NCT03266510|Sham Comparator|Sham training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
10171619|NCT03881462|Experimental|Axillary nerve block|Axillary nerve block is performed in standardized manner and muscle force is measured before and after the block.
9522263|NCT03266211||Patients|People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.
9522264|NCT03266211||General practitioner|General practitioner of the Auvergne-Rhônes-Alpes region
10171620|NCT03880903|Experimental|normal saline with bronchdilator|will recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours
9522265|NCT03266159|Experimental|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
9522266|NCT03266159|Experimental|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
9522267|NCT03266159|Experimental|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
9527837|NCT03216408|Experimental|Neuronox|Botulinum toxin type A for Injection
9522268|NCT03266159|Experimental|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
9522269|NCT03266159|Experimental|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
9527838|NCT03216408|Active Comparator|Botox|Botulinum toxin type A for Injection
10171621|NCT03880903|Experimental|hypertonic saline with bronchodilator|will recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours
9672106|NCT05039918|Experimental|Intervention|"Following randomisation, infants will receive CT-optimal stimulation (gentle stroking) at a velocity of 3cm/s over the area which the infant will be stroked (10cm) for a duration of 10s applied proximally to the pain site prior to the heel prick. Location of the heel prick will be based on clinical judgement. There will be an inter-stimulus interval of approximately 1 second between the end of the touch and heel prick, and touch stimulation will be applied to the lower leg ipsilateral to the heel receiving the noxious stimuli. All infants will have cardio-respiratory monitoring during the intervention. All other environmental factors will be as standard care (e.g., temperature, lighting and sounds).~The heel prick will be performed by a member of the infants designated clinical team who have performed the procedures in a standardised manner according to the institutional and unit policy."
9672107|NCT05039918|No Intervention|Control|Infants who are randomised to the control group will receive standard care consistent with neonatal policy. The infant will undergo a heel prick in the incubator or crib in an identical fashion to the infants in the intervention group.
9672108|NCT05039814||AKI|patients suffered postoperative acute kidney injury
9672109|NCT05039814||Non-AKI|patients did not suffer postoperative acute kidney injury
9672110|NCT05039606|Experimental|the treatment group|Nedplatin combined with intensive radiotherapy group
9672111|NCT05039606|Active Comparator|the control group|Cisplatin was combined with the IMRT group
9672112|NCT05039528|Experimental|Intervention|Participants will receive the personalized OSA messages.
9672113|NCT05039528|Placebo Comparator|Control|Placebo participants will receive no treatment during the experiment.
9672114|NCT05039372|Experimental|training and consultancy|"Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered to the patients in this group at the first interview. Individual training will be given to the patient in line with the training guide prepared for the rheumatoid arthritis patient, and the guide will be shared after the training. In line with the theory of planned behavior in patients with rheumatoid arthritis, counseling service will be provided by the researcher to the extent of the training plan prepared for symptom management. At the end of the 3rd month, the patients will be interviewed face to face and the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Assessment Questionnaire will be administered again."
9672115|NCT05039372|No Intervention|control|"After obtaining written consent from the patients who agreed to participate in the study, the patients included in the control group were asked to continue their rheumatologist follow-up and their normal lives (hospital routine, daily life). Patients in this group will fill out the Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Evaluation Questionnaire at the first interview. After 3 months, data collection tools other than the Patient Identification Form will be applied to the patients and the training guide to be prepared for rheumatoid arthritis patients will be given."
9672116|NCT05039294|Experimental|intervention|provided the educational programs with all contents, and follow up after one month
9672117|NCT05039294|No Intervention|control|received no intervention, but assessed pre-post
9672118|NCT05039437|Experimental|MGF-4|Take two MGF-4 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-4 and other excipients.
9672119|NCT05039437|Experimental|MGF-7|Take two MGF-7 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-7 and other excipients.
9975200|NCT04292405||Heart Failure Patients|Simultaneous recordings of cardiac acoustic biomarkers (CABs) by the Wearable Cardioverter Defibrillator and the AUDICOR AM
9975201|NCT04288856|Experimental|Cohort A: BIIB078 First Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
9672122|NCT05039398|Active Comparator|Comparison group|
9672123|NCT05039398|Experimental|Telephone D&G|
9672124|NCT05039398|Experimental|Physical meeting D&G|
9672125|NCT05039216||patients initiating a biotherapy or a target treatment|Blood sampling
9672126|NCT05039216||patients with chronic inflammatory rheumatism, weakening osteopathy or mechanical pathology|Blood sampling
10171622|NCT03880903|Experimental|hypertonic saline only|will recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours
10171623|NCT03880890|Active Comparator|sphenoidotomy (group A)|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus
9672127|NCT05039502|Experimental|Retreatment system using in rotational motion|Previous root canal filling materials were removed with D1-D2-D3 retreatment files with using an endodontic motor in rotational motion
9672128|NCT05039502|Experimental|Retreatment system using in reciprocal motion|Previous root canal filling materials were removed with Reciproc 25 file with using an endodontic motor in reciprocal motion
9672129|NCT05039502|Experimental|Retreatment system using in additional rotational motion|Previous root canal filling materials were removed with XP-endo finisher r file with using an endodontic motor in rotational motion
9672130|NCT05039151||septic shock|50 patients with a diagnosis of septic shock established within 24 hours of admission with oedemas
9672131|NCT05039151||control|35 non-septic patients with oedema from another cause
9672132|NCT05039333||RUS (Surgical navigation, anatomy 3D-reconstruction)|single-arm study : prospective observational 1-arm (RUS group)
9975202|NCT04288856|Experimental|Cohort B: BIIB078 Second Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
9522270|NCT03266159|Experimental|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
9522271|NCT03266120|Active Comparator|Art Intervention|Participants randomly assigned to this arm will receive a hands-on art intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place indoors over a period of four weeks for a total of eight art sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
9522272|NCT03266120|Experimental|Gardening Intervention|Participants randomly assigned to this arm will receive a hands-on gardening intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place in a greenhouse over a period of four weeks for a total of eight gardening sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
9522273|NCT03266237|Experimental|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
9522274|NCT03266237|Experimental|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
9522275|NCT03266237|Experimental|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
9522276|NCT03266237|Experimental|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
9522277|NCT03266185|Experimental|45-minutes|45-minutes post-infusion cooling time
9522278|NCT03266185|Experimental|20-minutes|20-minutes post-infusion cooling time
9522279|NCT03266185|No Intervention|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
9522280|NCT03266133|Experimental|Sleep Education Intervention|This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.
9522281|NCT03266133|No Intervention|Routine Care|Usual care
9522282|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
9522283|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
9522284|NCT03266146|Experimental|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
9522285|NCT03266146|Experimental|48 Weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in glucocorticoid 48 weeks of treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
9522286|NCT03266432|Other|60 pregnant women|60 pregnant women diagnosed with placenta previa will take from them 3 blood samples : one pre intervention and two samples postintervention
9522287|NCT03266276|No Intervention|Treatment as Usual Control Group|Treatment as usual.
9522288|NCT03266276|Experimental|Intervention Group|Use of a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
9522289|NCT03266263|Experimental|automatic computer-led feedback|automated feedback for CPR quality provided by computers
9522290|NCT03266263|Active Comparator|instructor-led feedback|feedback for CPR quality provided by instructors
9522291|NCT03266224||Wryneck|those with a condition
9522292|NCT03266367||patients|NGAL and renal functions will be measured two hours after Percutaneous coronary intervention and two days later as a follow up
9522293|NCT03266367||Healthy Group|control group
9522294|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
9522295|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
9522296|NCT03266445|Active Comparator|FULL-BUPRENORPHINE|Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone
9522297|NCT03266445|No Intervention|LOW-BUPRENORPHINE (control)|Participants will be randomly assigned to have their daily dose of buprenorphine/naloxone reduced to 8mg on the day of surgery
9522298|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples, stool samples, and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 6 weeks duration but not more than 52 weeks.
9522299|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples, stool samples and intestinal biopsies from standard of care colonoscopy.
9522300|NCT03266081|Experimental|0.75% bupivacaine|
9522301|NCT03266055|Experimental|Blueberry powder|
9522302|NCT03266055|Placebo Comparator|Blueberry placebo powder|
9522303|NCT03265886|Experimental|Warm bupivacaine at (37°c)|Warmed bupivacaine at body temperature will be administered
9522304|NCT03265886|Active Comparator|Bupivacaine at operating room temperature (23°c)|Bupivacaine at temperature of 23°C will be administered
9522305|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
9522306|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
9522307|NCT03265925||Healthy|Healthy controls
9522308|NCT03265912||Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), mTBI (Mild Traumatic Brain Injury) patient group also called as Arm 1 in this study.
9522309|NCT03265912||Non Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study, Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), non-TBI (Non Mild Traumatic Brain Injury) patients also called as Arm 2 in this study.
9522310|NCT03265834|Experimental|Long course antibiotic therapy (28 days)|Antibiotic therapy for a duration of 28 days
9522311|NCT03265834|Active Comparator|Short course antibiotic therapy (≤10 days)|Antibiotic therapy for a duration of ≤10 days
9522312|NCT03265769|Active Comparator|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
9522313|NCT03265769|Active Comparator|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
10171624|NCT03880890|Active Comparator|sphenoid nasalization (group B)|sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
10171625|NCT03881072|Other|Ultrasounicelastography|Ultrasounicelastography:non-invasive, convenient and comprehensive evaluation method.
9522314|NCT03265977|Experimental|H56:IC31|5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56
10171626|NCT03880812|Experimental|Cost group|These patients reviewed total societal costs associated with carpal tunnel release.
9522315|NCT03265977|Placebo Comparator|Placebo|Normal saline, 0.5 mL IM, Days 0 and 56
9522316|NCT03265756||Healthy children|250 3D facial images of healthy children under 5yrs of age in the Democratic Republic of Congo (DRC).
9522317|NCT03265756||Suspected Pneumonia|50 young children (under 5 yrs) in hospital/clinics in Butembo DRC with suspected pneumonia
9527839|NCT03216590|No Intervention|Standard draping|Shoulder arthroscopy will be performed using standard draping with the shoulder exposed.
9527840|NCT03216590|Experimental|Compressive draping|After standard preparation similar to the no-intervention group, the shoulder will be draped with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA)
9527841|NCT03216486|Experimental|BPS804 Dose 1|BPS804 IV Infusion
9527842|NCT03216252|Other|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
9527843|NCT03216629|Experimental|Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will say sorry repeatedly. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
9975203|NCT04288856|Experimental|Cohort C: BIIB078 Third Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
9527844|NCT03216629|No Intervention|Not Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will remain silent. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
9527845|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
9527846|NCT03216564|Experimental|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
9826631|NCT02425891|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
9527847|NCT03216564|No Intervention|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
9527848|NCT03216434|Experimental|PTSD Diagnosed|Veterans exposed to combat and diagnosed with PTSD. MRI using DaTscan.
9527849|NCT03216434|Experimental|Designated Combat-Experienced Controls|Veterans exposed to combat, but never diagnosed with PTSD. MRI using DaTscan.
9527850|NCT03216304|Experimental|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
9527851|NCT03216304|Experimental|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
9975204|NCT04269668|Active Comparator|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
10171627|NCT03880812|No Intervention|No cost group|These patients did not review total societal costs associated with carpal tunnel release.
10171628|NCT03880968||inactive - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and assigned to sequential tapering group (A1).
9527852|NCT03216460|Other|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will participate in specific setpoint challenges, meal challenges, and exercise
9975205|NCT04269668|Experimental|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
10171629|NCT03880968||inactive - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and then assigned to discontinuation group (A2).
10171630|NCT03880968||low disease activity - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to sequential tapering group (B1).
10171631|NCT03880968||low disease activity - full dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.
10171632|NCT03880968||low disease activity - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to discontinuation group (B3).
10171633|NCT03880773|Experimental|Stapler|
10171634|NCT03880773|Active Comparator|ultrasonic shears|
10171635|NCT03880916|Experimental|Duloxetine group|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
9522318|NCT03265743||Patients with Cystic Fibrosis|Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
10171636|NCT03880916|Placebo Comparator|Placebo group|"Phase I (preemptive): 2weeks before operation (Placebo for 2weeks)~Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
9522319|NCT03266016|Experimental|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
10171637|NCT03880734|Experimental|study|Vitamin D.Generic name-Cholecalciferol (40,000 IU).Dose- 80,000. Dosage-2 capsule/week for consecutive 26 weeks
10171638|NCT03880734|Experimental|control|Placebo oral capsule.Dose 80,000.Dosage-2 capsules for consecutive 26 weeks
10171639|NCT03880851|Other|Hypofractionated image-guided radiotherapy|"Hypofractionated image-guided radiotherapy IGRT to a total dose of 60 Gy (20 fractions) is performed.~Weekly MRI are used to estimate volume/deformation changes of OAR and target volume.~Intervention: In case of a significant change of target volume or OARs (threshold based) the radiation treatment plan is adapted on individual MR-anatomy."
10171640|NCT03880877|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followed by Leucovorin (400 mg/m2 IV infusion over 2 hours), and fluorouracil (5-FU) (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle."
10171641|NCT03880877|Active Comparator|Regorafenib|Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.
10171642|NCT03880695|Experimental|Anlotinib+ Liposomal Doxorubicin|Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
10171643|NCT03880760|Experimental|Probiotics capsule|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
10171644|NCT03880760|Placebo Comparator|Placebo capsule|Taking 1 placebo capsule twice a day before meals for six months.
10171645|NCT03880630|Experimental|Chronic respiratory disease|Patients with chronic respiratory disease with inspiratory muscle weakness will be recruited for the study
10171646|NCT03880448|Experimental|Metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (metronidazole 500mg/8h/7days)
10171647|NCT03880448|Placebo Comparator|Placebo + periodontal surgery|Periodontal surgery + Placebo (cornstarch 500mg/8h/7days)
9826632|NCT02425956|Experimental|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
10171648|NCT03880656|Experimental|Autologous BM-MNCs High Dose|Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
10171649|NCT03880656|No Intervention|Observational Control|Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome. No autologous bone marrow mononuclear cells will be administered.
10171650|NCT03880656|Experimental|Autologous BM-MNCs Low Dose|Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
9522320|NCT03266016|Placebo Comparator|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
9522321|NCT03266016|Experimental|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
9522322|NCT03266016|Placebo Comparator|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
9522323|NCT03265951|Active Comparator|Ramelteon|Ramelteon 8 mg po at bedtime
9522324|NCT03265951|Placebo Comparator|Usual care|education brochure about sleep hygiene
9522325|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
10171651|NCT03880799|Experimental|Mindfulness Intervention|Newly diagnosed breast cancer patients who undergo a mindfulness session before their surgical appointment.
9522326|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
9522327|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
10171652|NCT03880838|No Intervention|No contact control|Participants are not contacted.
9522328|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
9522329|NCT03265782|Experimental|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
9522330|NCT03265782|Experimental|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
10171653|NCT03880838|Experimental|Letter|Participants are only contacted through a letter with a personal testimonial.
10171654|NCT03880838|Experimental|Link and no nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and no nudges.
10171655|NCT03880838|Experimental|Link and commitment nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a commitment nudge.
10171656|NCT03880838|Experimental|Link and prevention nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a prevention nudge.
10171657|NCT03880838|Experimental|Link and both nudges|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and both commitment and prevention nudges.
10171658|NCT03880838|Experimental|DVD and no nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and no behavioral nudges.
10171659|NCT03880838|Experimental|DVD and commitment nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a commitment nudge.
10171660|NCT03880838|Experimental|DVD and prevention nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a prevention nudge.
10171661|NCT03880838|Experimental|DVD and both nudges|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and both commitment and prevention nudges.
10171662|NCT03880838|Experimental|Link and DVD and no nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and no behavioral nudges.
10171663|NCT03880838|Experimental|Link and DVD and commitment nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a commitment nudge.
10171664|NCT03880838|Experimental|Link and DVD and prevention nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a prevention nudge.
10171665|NCT03880838|Experimental|Link and DVD and both nudges|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and both commitment and prevention nudges.
10171666|NCT03880435|Experimental|Hyalobarrier® gel endo|Application of Hyalobarrier® gel endo immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second-look hysteroscopy)
10171667|NCT03880435|No Intervention|No Hyalobarrier® gel endo|No application of Hyalobarrier® gel endo after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second- or third-look hysteroscopy)
10171668|NCT03880539|Other|BEZLO + SOC taper|Single arm of patients treated with BEZLO + SOC oral VAN pulse/taper.
10171669|NCT03880747||Vagus nerve preserving group|Patients who underwent vagus nerve-preserving distal gastrectomy for early gastric cancer
10171670|NCT03880721||Good prognosis|
10171671|NCT03880721||Poor prognosis|
9522333|NCT03266003|Other|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
9522334|NCT03266003|Other|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
10171672|NCT03880721||Recurrence|
10171673|NCT03880721||Not Recurrence|
9522335|NCT03265717|Experimental|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
9522336|NCT03265717|Experimental|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
9522337|NCT03265678||Arm|Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
10171674|NCT03880721||Survival|
9522338|NCT03265691|Experimental|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
9522339|NCT03265691|No Intervention|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
9522340|NCT03265847|Experimental|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
9522341|NCT03265847|No Intervention|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
9522342|NCT03265990|Experimental|Group A|Conventional haemrrhoidectomy,Ferguson technique
9522343|NCT03265990|Experimental|Group B|Ligasure haemorrhoidectomy
9522344|NCT03265470|Experimental|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
9522345|NCT03265470|Active Comparator|Fentanyl|Patients received intravenous infusion of fentanyl
10171675|NCT03880721||Death|
10171676|NCT03880604|Active Comparator|Triple tourniquets plus TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus1-gram tranexamic acid (10 ml) in 100 ml saline infusion
9522346|NCT03265444|Experimental|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery
9826633|NCT02426086|Experimental|Imetelstat 4.7 mg/kg|
9975206|NCT04267328||Patients having surgery|Older adults undergoing elective orthopedic surgery.
9975207|NCT04258826|Experimental|LY3154207|LY3154207 administered orally in one of two study periods.
9522347|NCT03265483|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
9522348|NCT03265483|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
9522349|NCT03265483|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
9522350|NCT03265483|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
9522351|NCT03265899|Experimental|Oxytocin|40 IU Oxytocin, intranasal application 30 min prior to the experiment
9522352|NCT03265899|Placebo Comparator|Placebo|sodium chloride solution, intranasal application 30 min prior to the experiment
9522353|NCT03265574|Experimental|Intervention|
9522354|NCT03265574|No Intervention|Standard care|
9522355|NCT03265587||Orientation 1|Nursing staff allocated to a bed space with orientation 1
9522356|NCT03265587||Orientation 2|Nursing staff allocated to a bed space with orientation 2
9522357|NCT03265587||Floater / Control group|Nursing staff not allocated to a bed space with an orientation.
9826634|NCT02426086|Experimental|Imetelstat 9.4 mg/kg|
9826635|NCT02426138|Experimental|Med. Tailored Meal Delivery, Usual Care + Choose Myplate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
9975208|NCT04258826|Placebo Comparator|Placebo|Placebo administered orally in one of two study periods.
9975209|NCT04258488|Experimental|Oral Factor Xa inhibitor|
9975210|NCT04258488|Active Comparator|Vitamin K antagonist|
9975211|NCT04256005|No Intervention|Control|Participants will attend the laboratory and complete no exercise. The participants will remain seated for the 29 minutes of the session.
10171677|NCT03880604|Active Comparator|Triple tourniquets plus placebo to TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
10171678|NCT03880487|Experimental|KP-1199|
10171679|NCT03880487|Placebo Comparator|Placebo oral capsules|
10171680|NCT03880487|Active Comparator|Oxycodone oral capsules|
10171681|NCT03880825|Other|Metformin Only|
10171682|NCT03880825|Other|Levoketoconazole Only|
10171683|NCT03880825|Other|Levoketoconazole + Metformin|
9522358|NCT03265795|Experimental|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
9522359|NCT03265509|Active Comparator|Glutamine|30 g/day Glutamine supplementation for three months
9522360|NCT03265509|Placebo Comparator|Fantomalt|30 g/day Fantomalt supplementation for three months
10171684|NCT03880383|Experimental|Group 1 - Coaching|"Upon enrollment to the study, parents in this group will have immediate access to the full intervention:~Coaching: Telephone contact with coaches, who will provide information, education and support about the child's development. Coaching will be adapted to family needs, situation, preferences and child's condition.~Online parent education: Parents will be provided access to empowering online tools, such as educational resources, chosen or developed by other parents and researchers.~Peer support tools: Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge."
9522361|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
9522362|NCT03265457||Normal people at same age|
9522363|NCT03265522|Experimental|"Group 1: ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=20)"
9522364|NCT03265522|Experimental|"Group 2: ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=20)"
9522365|NCT03265522|Placebo Comparator|Group 3: Standard Care (control) group|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention) (n=20)"
9522366|NCT03265561|Experimental|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
9522367|NCT03265561|Active Comparator|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
9522368|NCT03265418|Experimental|BioXmark liquid fiducial markers|Placement of 4 BioXmark liquid fiducial markers, standard treatment (chemo-radiotherapy followed by surgery or wait-and-see) with extra imaging to evaluate the behaviour of the markers before, during and after the radiotherapy
9522369|NCT03265431|Active Comparator|Control|Normal subjects without history of cardiac disease or arrhythmia
9522370|NCT03265431|Experimental|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
9522371|NCT03265431|Experimental|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
9522372|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
9522373|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
9522374|NCT03265626|Experimental|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
9522375|NCT03265626|Active Comparator|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
9522376|NCT03265626|Other|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.~-No intervention package but standard service will be maintained"
9522377|NCT03265639|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
9522378|NCT03265639|Experimental|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
9522379|NCT03265639|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
9522380|NCT03265548|No Intervention|Standard|Usual Direct view laryngoscopy
9522381|NCT03265548|Experimental|Intervention|Video laryngoscopy
9826636|NCT02426138|Active Comparator|Usual Care + Choose Myplate, Med. Tailored Meal Delivery|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
9826637|NCT02426476|Experimental|active HRVB training|Heart rate variability biofeedback training
9826638|NCT02426476|Sham Comparator|sham HRVB training|passive relaxation
9826639|NCT02426541|Experimental|Dapagliflozin|Dapagliflozin Once Daily 10 mg
9826640|NCT02426541|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
9826641|NCT02426580|Experimental|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
9522385|NCT03265392|Other|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
9522386|NCT03265392|Other|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
9522387|NCT03265392|Other|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
9522388|NCT03265392|Other|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
10171685|NCT03880383|Other|Group 2- Partial and delayed coaching|"Parents in this group will have delayed and partial access to coaching, at the end of the 18-month period. Parents in this group will have a one-time session with a developmental coach who can give them guidance about their child's development. Parents in this group will also then get access to online parent education and peer support tools, indefinitely, until the online platform is de-activated.~* Both arms/groups* will obtain usual care for their child, in addition and independent of full or partial coaching."
9522389|NCT03265392|Other|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
9522390|NCT03265392|Other|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
9522391|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
9522392|NCT03265353|Other|Moderate Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
9672133|NCT05039034||Low-risk Group|Low-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but without chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
9672134|NCT05039034||Mediate-risk Group|Mediate-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but meanwhile suffer from chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
9672135|NCT05039034||High-risk Group|High-risk Group is defined as the population with ≥3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), or population with history of stroke or/and transient ischemic attack.
9672136|NCT05039346||Brain Tumor|Patients who are diagnosed with a high grade glioma that is progressive and therapy resistance. Patients will have a KPS of 60 or less.
9672137|NCT05039346||Care Giver|"Should a patient be unable to answer, the care giver will step in and provide surrogate answers.~Additionally, at four weeks following the patient's death, the patient's care giver will be interviewed by utilizing a validated questionnaire."
9672138|NCT05039125|Active Comparator|40000HZ ultrasound cavitation|group A (n=15) received 40000HZ ultrasound cavitation, Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
9672139|NCT05039125|Active Comparator|2600HZ ultrasound cavitation|group B (n=15) received 2600HZ ultrasound cavitation. Treatment time was 30 minutes /sessions, 3 times/ week for two months. Both groups (A and B) received a low caloric diet (1200 Kcal/day). All participants had their medical treatment as prescribed by the physician.
10171686|NCT03880357|Experimental|Test Product|Betamethasone Scalp Suspension 0.064%;0.0005% (Taro Pharmaceuticals Inc.)
10171687|NCT03880357|Active Comparator|Reference Product|Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)
9522393|NCT03265353|Other|High Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
9522394|NCT03265613|Experimental|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
9826642|NCT02426580|No Intervention|Controlled group|Only conventional education every 3 months during routing clinical visit
9826643|NCT02426658|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.
9975212|NCT04256005|Experimental|105% VO2Peak|Participants will complete ten intervals at a work rate which equates to 105% VO2peak with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
10171688|NCT03880357|Placebo Comparator|Placebo|Vehicle of the test product (Taro Pharmaceuticals Inc.)
10171689|NCT03880396|Other|hypofractionated Rth with weekly cisplatin 40mg/m2|hypofractionated radioyherapy with weekly cisplatin 40mg/m2
10171690|NCT03880422|Experimental|Supportive care (diet, exercise, education)|Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
9672140|NCT05038865||Malocclusion group|500 12-19 year olds with malocclusion, defined as IOTN-DHC grade 3, 4 or 5. The adolescents are consecutively recruited new patients at three orthodontic centers; Center for Orthodontics and Pediatric Dentistry, Norrköping, Public Dental Service Östergötland; Department of Orthodontics, Folktandvården Stockholms län AB, Folktandvården Eastmaninstitutet, Stockholm, Sweden and Department of Orthodontics, Malmö University, Malmö, Sweden. Patients are examined at the first visit at the orthodontic department, before any orthodontic treatment is begun.
9522395|NCT03265652|Experimental|Intense Pulsed Light (IPL) therapy|Subjects with receive 10-15 intense pulsed light (IPL) pulses on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid. Following the administration of IPL pulses, subjects will undergo meibomian gland expression.
9522396|NCT03265652|Placebo Comparator|Sham therapy|Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
10171691|NCT03880370||group 1(group without low back pain)|Participants inclusion criteria an age 18 to 55 years of age who practice sports equal to greater than three hours per week who have not had low back pain or ciatalgia in the last 12 months.
10171692|NCT03880370||group 2 (low back pain group)|Participants inclusion criteria an age 18 and 55 years of age who practice sports equal to greater than three hours a week, with a history of at least one episode of low back pain and / or ciatalgia in the last 12 months lasting no longer than three months and diagnosis of hernia lumbar disc using MRI.
9522397|NCT03265080|Experimental|Part A|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.~Two dose levels of ADXS-NEO will be explored: 1 x 10 to the 9th power and 1 x 10 to the 8th power colony forming unit (CFU)."
9522398|NCT03265080|Experimental|Part B|Two dose levels of ADXS-NEO will be explored [i.e., 1 x 10 to the 8th power and 5 x 10 to the 8th power colony forming unit (CFU)] in combination with 200mg of pembrolizumab.
9975213|NCT04256005|Experimental|50% ∆ Gas Exchange Threshold|Participants will complete ten intervals at a work rate which equates to 50% ∆ GET with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
9975214|NCT04236388|Active Comparator|Dietary Ketone|Participants will consume three daily ketone drinks (one before each meal) for 2 weeks.
9522399|NCT03265080|Experimental|Part C|ADXS-NEO will be explored at 1 x 10 to the 8th power colony forming unit (CFU) in combination with 200mg of pembrolizumab in an expansion cohort.
9522400|NCT03265028||Intervention|Invited to take the TRACE e-learning.
10171693|NCT03880409|Active Comparator|2% lidocaine with 1:000,000 epinephrine|supplemental intraseptal injections using 0.8 mL 2% lidocaine with 1:000,000 epinephrine
10171694|NCT03880409|Active Comparator|4% articaine with 1:000,000 epinephrine|buccal infiltration of 1.8 ml 4% articaine with 1:000,000 epinephrine
9522401|NCT03265028||Control|Not (yet) invited to take the TRACE e-learning.
9522402|NCT03265067|No Intervention|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
9522403|NCT03265067|Experimental|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
9522404|NCT03265002|Placebo Comparator|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
9522405|NCT03265002|Experimental|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
10171695|NCT03880149|Experimental|Omega-3 supplementation|Omega-3 fatty supplementation and vitamin E. Each 1 g omega-3 capsule contain 600 mg omega-3 including 400 mg EPA + 200 mg DHA. Individual omega-3 dose will be determined according to the athlete's body mass, 1 g omega-3 / 15 kg body mass per day and vitamin E: 1 capsule of vitamin E (400 IU) for every five omega-3 capsules
9522406|NCT03265002|Active Comparator|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
10171696|NCT03880149|Placebo Comparator|Placebo|Medium-chain triglyceride (MCT) and vitamin E. Each MCT capsule contain 1 g, the dose will be 115 mg per kg body mass per day, and vitamin E: 1 capsule of vitamin E (400 IU) for every five MCT capsules
9522407|NCT03265002|Active Comparator|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
9522408|NCT03265236||Group1|Patients with early rheamatoid arthritis
9522409|NCT03265236||Group 2|patients with late rheamatoid arthritis
9522410|NCT03265236||Group 3|Healthy control
9522411|NCT03265288|Experimental|LAU-7b|Active drug fenretinide (as LAU-7b capsules)
9522412|NCT03265288|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
9672141|NCT05038865||No malocclusion group|175 12-19 year olds without malocclusion, defined as IOTN-DHC grade 1 or 2. Patients are consectively recruited adolescents examined at their general dentistry clinic.
9522413|NCT03265093|Active Comparator|experimental; Corticosteroid|Intralesional corticosteroid administration
9522414|NCT03265093|Experimental|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
9522415|NCT03265015|Experimental|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
9522416|NCT03265015|Active Comparator|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
9975215|NCT04236388|Placebo Comparator|Placebo|Participants will consume three daily placebo drinks (one before each meal) for 2 weeks. .
9672142|NCT05038878|Experimental|GnRH antagonist (Elagolix)|Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression
9522417|NCT03265106|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/ maximum dose: 1x10^6/kg / 1x10^7/kg administered to childhood patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
9522418|NCT03265340|Active Comparator|A|dTMS standard protocol 10 min session
9522419|NCT03265340|Active Comparator|B|dTMS standard protocol 20 min session
9522420|NCT03265340|Active Comparator|C|dTMS standard protocol 40 min session
9522421|NCT03265223|No Intervention|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
9522422|NCT03265223|Active Comparator|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
9522423|NCT03265223|Active Comparator|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
9522424|NCT03265054||re-thrombosis|adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
9522425|NCT03265054||no thrombosis recurrence|adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
9522426|NCT03265262|Experimental|Children receiving OFC during a diagnost|paediatric patients attending food allergy
9522427|NCT03265184|Experimental|intervention group|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
10171697|NCT03880331|Active Comparator|Aggressive Debridement|Aggressive and frequent debridement of fibrin and crust from the wound base down to pinpoint bleeding, both by the patient as part of daily wound care at home, and also by the clinician (either physician or experienced dermatologic surgery nurse) during follow-up visits. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return weekly until healed. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
10171698|NCT03880331|Active Comparator|Minimal Debridement|No debridement of fibrin by the patient or the clinician. Exceptions include debridement of dried crust or eschar. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return every two weeks until healed. In between visits at weekly intervals, the patient will be contacted by phone to determine if healing has occurred in between clinic visits11. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
10171699|NCT03880318|Other|spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies in spasmodic flat foot
9826644|NCT02426749|Active Comparator|Active Coil|Participants of this arm will receive active rTMS intervention (treatment).
9522428|NCT03265184|Placebo Comparator|placebo group|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
9522429|NCT03265210|Experimental|Relief|Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
9522430|NCT03265210|No Intervention|Referral|Referral for mental health based on clinical indication.
9522431|NCT03265197|Experimental|Intratympanic injection of drugs;|intervention by Intratympanic injection of drugs in two studied groups; group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
9522432|NCT03265197|Active Comparator|Data management of Intratympanic drugs|intervention by Manage data of two study group as blind statistical between group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
9522433|NCT03265301|Other|Office hysteroscopy|
9522434|NCT03265301|Other|Conventional hysteroscopy|
9522435|NCT03265327|Experimental|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
9522436|NCT03265327|Placebo Comparator|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
9522437|NCT03264976||Group 1|Patients without DR. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years.
9522438|NCT03264976||Group 2|"Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
9662242|NCT05024253|Experimental|patient is receiving Tranexemic acid (TXA )|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare TXA injection at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion at a dose of 5mg/kg/hour will be given until wound closure."
9662243|NCT05024253|Placebo Comparator|standard treatment (saline)|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare 50 ml of 0.9% saline or TXA at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion of saline will be given until wound closure."
9522439|NCT03264976||Group 3|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
9522440|NCT03264976||Group 4|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
9522441|NCT03264976||Group 5|"Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
9977498|NCT01362218|Experimental|Fixed Dose Combination Pill|A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
9522442|NCT03264950|Other|SIngle Arm|All patients undergo Elastography. This is a single arm study
9522443|NCT03264937|Experimental|Social-software management group|We set up a mini-program based on wechat application. We instruct warfarin therapy via social-software including dose adjustment, answer questions, remind monitoring INR et.al.
9522444|NCT03264937|No Intervention|Routine management group|This is the control group, Warfarin therapy was managed via traditional style without social software intervention.
9522445|NCT03264677|Experimental|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
9522446|NCT03264677|Experimental|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
9522447|NCT03264677|Experimental|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
9522448|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
9522449|NCT03264638|Experimental|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
9522450|NCT03264638|Experimental|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
9522451|NCT03264638|Active Comparator|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
9522452|NCT03264612|Active Comparator|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
9522453|NCT03264612|No Intervention|Non swimming group|no intervention
9522454|NCT03264729|Experimental|Isometric exercise|
10171700|NCT03880045|Active Comparator|Topical TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
10171701|NCT03880045|Active Comparator|placebo to TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus placebo to tranexamic acid
9522455|NCT03264729|Active Comparator|Isotonic exercise|
9522456|NCT03264729|Active Comparator|Walking|
9522457|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
9977499|NCT01362218|Active Comparator|Simvastatin|Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
10171702|NCT03880201||patient undergoing upper limb orthopaedic surgery|The study will be performed on patient undergoing upper limb orthopaedic surgery which will be performed under ultrasound guided supraclavicular block.
10171703|NCT03880162|Experimental|Study intervention|Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.
9522458|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
9522459|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
9522460|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
9662244|NCT05017675|Experimental|High fructose diet|Participants will receive dietary products high in fructose for 4 weeks.
9662245|NCT05017675|Experimental|High saturated fat diet|Participants will receive dietary products high in saturated fat for 4 weeks.
9662246|NCT05015413|Experimental|shock wave group|Group A will receive shockwave therapy 2 session per week for 6 weeks
9977500|NCT01362231|Experimental|GS-6624 125mg|
9977501|NCT01362231|Experimental|Experimental: GS-6624 200mg|
9977502|NCT01362257|Experimental|14C-GSK573719 Oral Solution|single dose of 1000µg
9977503|NCT01362257|Experimental|14C-GSK573719 IV Solution|single dose of 65µg
10171704|NCT03880162|Active Comparator|Control intervention|Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.
10171705|NCT03880253|Experimental|CTP-692 Low Dose or Matching Placebo|Once daily dosing
10171706|NCT03880253|Experimental|CTP-692 Mid Dose or Matching Placebo|Once daily dosing
10171707|NCT03880253|Experimental|CTP-692 High Dose or Matching Placebo|Once daily dosing
9522461|NCT03264820|Experimental|Patients with scleroderma and potential arterial disease|"The patients (33) will undergo a medical examination in order to analyse their medical history, parameters and check inclusion and non-inclusion criterions.~Then will be performed :~Visit 1 :~Biology report * (* Biological evaluation carried out in all healthy subjects and in subjects whose biological check-up dates more than 2 years,+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
9522462|NCT03264820|Experimental|Healthy volunteers|"The healthy volunteers (11) will undergo :~Visit 1 :~Biology report (+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
9522463|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
9522464|NCT03264846||Group 1|PCOS participants with periodontitis
9522465|NCT03264846||Group 2|PCOS participants with periodontally healthy
9522466|NCT03264846||Group 3|systemically healthy participants with periodontitis
9522467|NCT03264846||Group 4|systemically and periodontally healthy participants
9522468|NCT03264651|Experimental|oral enobosarm and anastrozole|9 mg of oral enbosarm and 1 mg of anastrozole daily
9522469|NCT03264885|No Intervention|Usual Care|The usual stand of care (UC) after community eye screening was to provide a GP referral letter and advice to attend a tertiary eye care facility most accessible to them
9522470|NCT03264885|Other|Incentive Care|In addition to the UC, those assigned to the ICS also received social and financial support to incentivise and improve compliance. All ICS participants were assisted with scheduling their tertiary care appointments, given telephone reminders, provided once-off transportation allowance and subsidy for their first tertiary eye-care consultation - while participants with mobility issues were assisted by volunteers.
9522471|NCT03264898||FIT Group|Fecal immunochemical tests will be completed.
9522472|NCT03264794|Experimental|trial group|Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
9522473|NCT03264794|Active Comparator|control group|Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
9522474|NCT03264768|Other|control|standard care in case collateral ventilation is observed (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post allocation.
9522475|NCT03264768|Experimental|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post intervention.
9522476|NCT03264963|Active Comparator|Control|
9522477|NCT03264963|Experimental|Intervention|
9522478|NCT03264781|Experimental|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
9522479|NCT03264781|Placebo Comparator|Placebo group|normal saline 0.5 ml IM single dose
9522480|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle > or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
9522481|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle < 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
9522482|NCT03264911|Active Comparator|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
9522483|NCT03264911|Placebo Comparator|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
9522484|NCT03264807|Active Comparator|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
10171708|NCT03879889|Experimental|Intervention|Intervention arm will include face-to-face counseling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of free NRT, referral to quit smoking hotline, monthly phone follow-up and two follow-up visits.
10171709|NCT03879889|No Intervention|Control|Smoking parents will be given standard advice on smoking cessation. They will be given an information leaflet showing standard information on the currently available smoking cessation service as well as a smoking cessation hotline.
10171710|NCT03879928|Placebo Comparator|Placebo for SAD|Placebo comparator for SAD
10171711|NCT03879928|Experimental|FM101 75 mg for SAD|Single ascending doses of FM101
9522485|NCT03264807|Experimental|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
9522486|NCT03264755|Active Comparator|cortical excitability in smokers|
9977504|NCT01362283||Hypertension|Subject who meet eligible criteria
9977505|NCT01362309|Placebo Comparator|Placebo|Inert filler in matched pill.
9522487|NCT03264755|Active Comparator|cortical excitability in nonsmokers|
10171712|NCT03879928|Experimental|FM101 150 mg for SAD|Single ascending doses of FM101
10171713|NCT03879928|Experimental|FM101 300 mg for SAD|Single ascending doses of FM101
10171714|NCT03879928|Experimental|FM101 600 mg for SAD|Single ascending doses of FM101
10171715|NCT03879928|Experimental|FM101 1200 mg for SAD|Single ascending doses of FM101
10171716|NCT03879928|Experimental|FM101 2400 mg for SAD|Single ascending doses of FM101
10171717|NCT03879928|Placebo Comparator|Placebo for MAD|Placebo comparator for MAD
10171718|NCT03879928|Experimental|FM101 150 mg (QD) for MAD|Multiple ascending doses of FM101
10171719|NCT03879928|Experimental|FM101 450 mg (QD) for MAD|Multiple ascending doses of FM101
9522488|NCT03264586|Active Comparator|Lidocaine-prilocaine cream|"Women who were assigned randomly to receive EMLA cream had a 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate pemetration thrug stratum corneum~EMLA cream was applied, 1 hour before the expected time of birth.~With the assistance at birth, the residue of cream was removed to prevent contact with the fetus, because sodium hydroxide, which is a component of the cream, can cause fetal eye irritation.~No additional anesthetic was applied if episiotomy was necessary.~Before commancement of perineal repair any residual cream was wiped off."
9522489|NCT03264586|Active Comparator|mepivacaine infiltration group|"In the mepivacaine group, 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
9522490|NCT03264534|Active Comparator|limbal relaxing incisions|Manually performed limbal relaxing incisions
10171720|NCT03879928|Experimental|FM101 600 mg (BID) for MAD|Multiple ascending doses of FM101
9522491|NCT03264534|Active Comparator|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
9522492|NCT03264872|Experimental|Peer-Enhanced Motivational Interviewing|Both dyad members, the target client and their peer support person, in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions with a trained counselor.
9522493|NCT03264872|Other|Waitlist Control|Delayed Treatment.
9522494|NCT03264625|Experimental|Treatment group|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
9522495|NCT03264625|Placebo Comparator|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
9522496|NCT03264716|Experimental|HepaSphere TACE (transarterial chemoembolization)|Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis. TACE using HepaSphere load with doxorubicin.
9672143|NCT05039203||Intervention group|Inpatients with an indwelling urinary catheter (IUC) at admission to a rehabilitation clinic for persons ≥65 years in Sweden. Intervention is removal of the IUC.
9672144|NCT05039203||Control group|Inpatients without an IUC at admission to a rehabilitation clinic for persons ≥65 years in Sweden
10171721|NCT03879928|Experimental|FM101 300 mg under fasted condition for FE|Food Effect of FM101
10171722|NCT03879928|Experimental|FM101 300 mg under fed condition for FE|Food Effect of FM101
9522497|NCT03264573|Active Comparator|stem cell, PRP|Adipose derived MSCs, versus Platelet rich plasma
9522498|NCT03264573|Active Comparator|Stem cell, Stem cell and PRP|Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma
9522499|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
9522500|NCT03264378|Experimental|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
9522501|NCT03264378|Active Comparator|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
9522502|NCT03264300|Active Comparator|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
9672145|NCT05038969|Experimental|A test|Test drug (Stomopral) 1 capsule contains 40 mg Enteric Coated Pellets of Esomeprazole
9672146|NCT05038969|Active Comparator|B reference|Reference drug (Nexium) 1 capsule contains 40 mg Esomeprazole
9672147|NCT05039229|Experimental|Nozzles (NZ)|Intervention with the aim of reducing bioaerosol exposure for the employees, targeting alteration of nozzles or nozzle function along the production line.
9672148|NCT05039229|Experimental|Cleaning of surfaces (CS)|Intervention with the aim of reducing bioaerosol exposure for the employees while cleaning their personal operating areas (work benches and part of production lines) during work operations or while cleaning floor areas.
9672149|NCT05039229|No Intervention|Control (CTR)|Work is to be carried out as usual without any intervention measures. Follow-up according to the same schedule as for the other intervention groups.
9826645|NCT02426749|Sham Comparator|Sham|Participants of this arm will receive sham rTMS intervention (treatment).
9826646|NCT02426918|Experimental|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
10171723|NCT03879876|Experimental|Human T Lymphoid Progenitor (HTLP) injection|Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines
10171724|NCT03880097||Research Biopsy|"The research biopsy is the same procedure as a standard of care percutaneous biopsy. A core (hollow) needle is inserted into the tumour tissue in order to collect tissue samples. The procedure is called a research biopsy as it is an additional procedure to the standard of care, used purely to collect tissue samples for research purposes."
10171725|NCT03879850||Propofol group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - i.v. Propofol - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
10171726|NCT03879850||Volatile group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - volatile anesthetic agent as Sevoflurane or Desflurane - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
9522503|NCT03264300|Active Comparator|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
9522504|NCT03264365|Experimental|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
9522505|NCT03264365|No Intervention|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
9522506|NCT03264547|Active Comparator|Arm A|"Trastuzumab + pertuzumab + Taxane*~*Taxane is chosen from the following; Docetaxel or Paclitaxel"
9522507|NCT03264547|Experimental|Arm B|Trastuzumab+ Pertuzumab + Eribulin
9522508|NCT03264287|Experimental|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Huatuo Brand needle (0.20*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3*40mm) will be used for GV20, LU5, LI11 and LI4.~2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
9522509|NCT03264287|Active Comparator|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.~Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Use the seed of Vaccaria segetalis ( Neck.)Garcke."
9527853|NCT03216551||The assumed selective lymph node dissection group|Patients with consolidation tumor ratios ≤ 0.5 tumors will be considered to have negative mediastinal metastasis. Patients with intraoperative lepidic predominant adenocarcinoma diagnosis will be considered to have negative mediastinal metastasis. Patients with an apical tumor will be considered to have negative inferior mediastinal lymph node metastasis. If both N1 nodes and visceral pleural invasion are negative, patients with peripheral non-apical-segment upper lobe tumors will be considered to have negative inferior medistinal lymph node metastasis. If N1 nodes are negative, patients with left superior segment tumors will be considered to have negative 4L lymph node metasis, and patients with left basal segment tumors will be considered to have negative superior mediastinal lymph node metastasis.
9527854|NCT03216395|Experimental|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
9527855|NCT03216395|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clips or pulse
9527856|NCT03216447|Experimental|Experimental Arm|Switch from Prograf to Advagraf on POD 15
9527857|NCT03216447|Active Comparator|Control Arm|Continue Prograf treatment
9527858|NCT03216239||Colectomy Group|Mean age 52.3 years (range:20-85), 82% females, and a mean duration of symptoms of 79.9 months in the colectomy group. The indication for colectomy was constipation (36%), diverticular disease (8%), bowel obstruction (8%), colorectal carcinoma (8%), colon polyps (6%), and other (34%).
9527859|NCT03216239||Control Group|Mean age of 49.9 years (range 18-88), 76% females, and mean duration of symptoms 77.6 months,
9527860|NCT03216421|Other|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
9527861|NCT03216421|Other|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
9527862|NCT03216538|Active Comparator|AS101 1% oral solution|Daily dose 0.4 ml administered orally
9527863|NCT03216538|Placebo Comparator|Placebo|Daily dose of 0.4 ml administered orally
10171727|NCT03879954|Other|OOP-IJV|Out of plane inetrnal jugular vein catetherization
10171728|NCT03879954|Other|IP-SSV|in plane supraclavicular subclavian vein catetherization
10171729|NCT03880071|Experimental|DBT + ACT group|- The experimental group (DBT+ ACT) led in Montpellier during 6 months.
10171730|NCT03880071|Other|DBT group|The control group (DBT) led in Geneva during 12 months.
10171731|NCT03880058|Active Comparator|SLI-F06|
10171732|NCT03880058|Placebo Comparator|Formulation Buffer|
10171733|NCT03879915||Prospective Dental Implant placement|Patients prospectively included and treated following current recommendations
10171734|NCT03879915||Retrospective Dental Implant placement|Patients retrospectively included, that did not benefit from current recommendations
10171735|NCT03880136|Experimental|Sequence 1|Period 1: CTP-543 with meal Period 2: CTP-543 without meal
9527864|NCT03216148|Experimental|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
9527865|NCT03216174|Experimental|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
9662247|NCT05015413|Experimental|low level laser group|Group B will receive low level laser therapy 2 session per week for 6 weeks
10171736|NCT03880136|Experimental|Sequence 2|Period 1: CTP-543 without meal Period 2: CTP-543 with meal
10171737|NCT03879980|Placebo Comparator|Non-QL block|The control (non-QL block) group only received fentanyl IV during surgery.
9522510|NCT03264235|Experimental|Group 1 Exoskeleton|Both training groups will undergo inpatient physical therapy of the same duration and intensity. Group 1 will complete stair training wearing the Keeogo Exoskeleton in inpatient physical therapy.
10171738|NCT03879980|Experimental|Bilateral QL block|The patients were in the semi-lateral supine position to show up the side to be blocked. Using USG and 1-6 MHz convex transducer placed in the transverse plane above the iliac crest at the level of the umbilicus. A Stimuplex® 20G 100-mm needle was advanced in anteroposterior direction toward the junction of tapered abdominal muscle layer and QL muscle, and 20 ml of 0.25% bupivacaine was deposited in the anterolateral border of QL muscle at the junction with the transversalis fascia reach outside the anterior layer of transversalis fascia. The lateral approach QL (type I) blocks were performed at both sides of patients. The total amount of bupivacaine was 100 mg for each patient
10171739|NCT03879993|Experimental|Exercise group|Exercise group was resistance training three times per week, during 45 to 60 minutes per day. Training program was composed by bench press, leg press 45°, lat pulldown, knee extension, dumbbell lateral raise, horizontal leg curl, triceps pulldown, seated calf raise, biceps curls and abdominal. Participants should complete 3 series with 8-12 repetitions of each exercise, which was supervised by trained research personnel. There were 60 seconds of interval between series and exercises were separated by a 120 seconds recovery period.
10171740|NCT03879993|No Intervention|Control group|Control group was not do any exercise during intervention period. Participants was asked to keep their habitual routine until finish the final evaluations.
9522511|NCT03264235|Active Comparator|Group 2 Traditional Therapy|Group 2 will complete traditional stair training in inpatient physical therapy.
9522512|NCT03264482|Active Comparator|THUVAP|thulium vaporization
9522513|NCT03264482|Active Comparator|M-TURP|monopolar transurethral resection
9522514|NCT03264209|Experimental|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
9522515|NCT03264209|No Intervention|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
9522516|NCT03264144|Experimental|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
9522517|NCT03264144|No Intervention|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
9522518|NCT03264313|Active Comparator|dTMS active|patients undergoing of dTMS real
9522519|NCT03264313|Sham Comparator|dTMS Sham|patients undergoing to placebo dTMS
9522520|NCT03264326|Experimental|BFR Group|Blood Flow Restriction Training with Eccentric Exercise Protocol
9522521|NCT03264326|Sham Comparator|Sham BFR Group|Sham Blood Flow Restriction Training with Eccentric Exercise Protocol
9672150|NCT05038995||Cow milk elimination group|The CME children will be eligible for the study if they (1) had a diagnosis of CMA by OFC, except children with known anaphylaxis (2) those on a CME diet or a specialized infant formula for at least three months (3) had reintroduced cow's milk for at least three months ago. Children who excluded other foods in addition to cows' milk in the first four years of life for ≥ three months and who currently introduced these foods for at least ≥ three months will be also enrolled in the CME group.
9977506|NCT01362309|Active Comparator|d-cycloserine 50 mg|50 mg d-cycloserine.
9522522|NCT03264443|Active Comparator|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
9522523|NCT03264443|Experimental|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
9522524|NCT03264430|Active Comparator|The ketamine group|The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
9522525|NCT03264430|Placebo Comparator|The control group|group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
9522526|NCT03264339|Experimental|Smal step|Small Step Program, comprising 3 treatment focus areas (Hand use, Mobility, Communication)
9522527|NCT03264222|Other|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
9522528|NCT03264118|Active Comparator|Control|Decontamination of furcation defect with scaling and root planing only.
9977507|NCT01362335||patients, that are having a routine surgical procedure.|
9977508|NCT01362361|Experimental|Arm A|mFOLFOX6 + BIBF 1120
9522529|NCT03264118|Experimental|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
9522530|NCT03264196|Active Comparator|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
9522531|NCT03264196|No Intervention|Conservative|Non-operatively managed Condylar Head Fracture
9522532|NCT03264274|Other|Aflibercept + DCE-US|Aflibercept: 4mg/kg IV every 2 weeks until discontinuation due to progression. DCE-US before treatment, and at 2 weeks and 8 weeks after the first Aflibercept administration.
9522533|NCT03264170|Active Comparator|Prediction of pregnancy outcome|Women will receive an individualised prediction score of the pregnancy being viable at the follow-up ultrasound generated from the prediction tool.
9522534|NCT03264170|No Intervention|Control|Women will not receive the prediction score
9522535|NCT03264105|Experimental|NovaPro™ Flow|NovaPro™ Flow Flowable Composite, Nanova Biomaterials company, USA
9977509|NCT01362361|Placebo Comparator|Arm B|mFOLFOX6+placebo
9977510|NCT01362387|No Intervention|Group 1|Women assigned to Group 1 will receive the standard post-abortion follow-up currently used at bpas and will be undertaken as usual by staff at the treating clinic
9977511|NCT01362387|Experimental|Group 2|Follow-up after medical abortion using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test.
9522536|NCT03264105|Active Comparator|Conventional resin-based flowable composite|Filtek™Supreme Ultra Flowable Restorative, 3M ESPE company, USA
9522537|NCT03264131|Experimental|Open-label, Multicenter, Single-Arm|This is a single-arm intervention where patients will receive concurrent therapy with BV+CHEP [(brentuximab vedotin; 1.8 mg/kg IV, on D1 every 21 days) (cyclophosphamide 750 mg/m^2 on D1; doxorubicin 50 mg/m^2 on D1, etoposide 100 mg/m^2 IV infusion on D1-3; prednisone 100 mg orally once daily on D1-5; cycle length every 21 days)] for 2 to 6 cycles of induction therapy. After 6 cycles of BV + CHEP, responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV, every 21 days) until disease progression, withdrawal due to toxicity or death.
9522538|NCT03264261|Experimental|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
9522539|NCT03264261|Active Comparator|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
9522540|NCT03264079|Experimental|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
9522541|NCT03264053|Experimental|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
9522542|NCT03264053|Active Comparator|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
10171741|NCT03880123|Experimental|Selinexor/Ixazomib|Patients will receive combination treatment with selinexor and ixazomib. The dose of ixazomib is fixed at 4 mg, whereas several different dose levels of selinexor may be evaluated. No patients will receive a placebo.
9522543|NCT03263754|Experimental|Intervention|
9522544|NCT03263754|Active Comparator|Control|
9522545|NCT03263858|Experimental|Cohort 1 and 2|
10171742|NCT03880032|Experimental|Cognitive Behavioral Therapy Intervention for Anxiety|Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
10171743|NCT03880032|No Intervention|Enhanced Usual Care|Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Transportation will be facilitated to assist participants in attending appointments and medically indicated ultrasounds will be paid for (as in the intervention group).
10171744|NCT03879967|Experimental|Allograft block graft|For lateral alveolar ridge augmentation, all patients will be treated with allograft block with guided bone regeneration. After a minimal healing phase of six months, implants would be placed in the augmented site. After a healing phase of about 4months, the implants would be loaded and then followed until the control appointment approximately 3 years later.
9522546|NCT03263897|Experimental|Active|Receiving insufflation during an acute episode of migraine in both visits
9522547|NCT03263897|Sham Comparator|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
9522548|NCT03263936|Other|Other|decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
9522549|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
10171745|NCT03879824|Experimental|Radial Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the radial artery (right radial artery only) during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary radial artery access during TAVI"
9522550|NCT03263884|Experimental|Real treatment group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. The coil produces small electric currents in the region of the brain just under the coil via electromagnetic induction.~The protocol used in this research includes 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses."
9522551|NCT03263884|Sham Comparator|Sham treatment group|Sham coil is used to mimic the clicking sound of the TMS coil and skin stimulation
9522552|NCT03263819||POTS|patients with postural orthostatic tachycardia syndrome diagnosis.
9522553|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
9522554|NCT03263910|Experimental|NPO-11|
9977512|NCT01362400|Active Comparator|ARM 1: IPI 504 + Docetaxel|Drug: IPI-504 plus Docetaxel
9522555|NCT03263910|Placebo Comparator|Placebo|
9522556|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
9522557|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
10171746|NCT03879824|Active Comparator|Femoral Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the contralateral femoral artery artery during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary femoral artery access during TAVI"
9975216|NCT04231942|Experimental|Group 1 (experimental): continuous using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS (at least 8 hours per day) for both lower extremities every day for 12 months, while change of GCS for the new one should be carried out at 6 months or early in case of stocking deterioration;"
9975217|NCT04231942|Experimental|Group 2 (experimental): intermittent using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS on both limbs during physical activity and long stasis events: any kind of sport activities, air travel of any duration, traveling on vehicles for more than 4 hours, walking for more than 2 hours, standing work for more than 4 hours) for 12 months, while change of GCS for the new one should be carried in case of stocking deterioration;"
9975218|NCT04231942|No Intervention|Group 3 (control): no use of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~The use of GCS will be possible on-demand when symptoms or risk factors appear after appropriate coordination with the Investigator"
9975219|NCT04216134|Experimental|Diagnostic (68GA-PSMA-11 PET)|Patients receive gallium Ga 68-labeled PSMA-11 IV over less than 1 minute, and then undergo PET over 60 minutes.
10171747|NCT03880175|Experimental|FCC DEB and Anti-stigma|
10171748|NCT03880175|Experimental|FCC DEB and HIV info|
9522558|NCT03263923|Experimental|Intervention group|Online intervention is cognitive behavioral skills' training and 4 weeks of online journaling. Participants receive cognitive behavioral skills training by online video, then participants must complete a 28 day online journal reflecting on the cognitive skills they have learned/used.
9522559|NCT03263923|Active Comparator|Comparison group|Comparator intervention is Reflective journaling training and 4 weeks of online journaling. Participants watch a reflective journaling video with specific instructions, and then the participants complete a 28 day journal using a different set of prompts to reflect on their days and describe how they handled various situations.
9522560|NCT03263975|Experimental|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
9522561|NCT03263975|Experimental|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
9522562|NCT03263741|Experimental|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 135 mg/m2, iv, 3h, at D1 ; S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
9522563|NCT03263962||With canrenone|Patients with canrenone
9522564|NCT03263962||Without canrenone|Patients without canrenone
9522565|NCT03263871|Experimental|Intervention|PTM202 and micro-nutrient sprinkles
9522566|NCT03263871|Other|Control|micro-nutrient sprinkles
9522567|NCT03263793|Experimental|Behavioral vocal training|12-week vocal training program will use maximum vocal function exercises targeting vocal deficits specific to Parkinson Disease.
9522568|NCT03263689|Experimental|Intervention|"ITM group were given~Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia~100 micrograms of preservative-free morphine."
9522569|NCT03263689|Active Comparator|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
9522570|NCT03264040||Observation|Patients with Mannosidosis disease or high-grade suspicion for Mannosidosis disease
9522571|NCT03263728|Experimental|Stress Cardiac MR|
9522572|NCT03264027|Experimental|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
9522573|NCT03264027|Active Comparator|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
9522574|NCT03263767|Experimental|LYMPHOID HEMOPATHY without ATG|patients with lymphoid hemopathy
9522575|NCT03263767|Experimental|MYELOID HEMOPATHY without ATG|patients with myeloid hemopathy
9522576|NCT03263767|Experimental|LYMPHOID HEMOPATHY witH ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
9522577|NCT03263767|Experimental|MYELOID HEMOPATHY with ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
10171749|NCT03880175|Experimental|FCC DEB and ART info|
9522578|NCT03264001|Experimental|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
9522579|NCT03264001|Experimental|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
10171750|NCT03880175|Experimental|FCC DEB and HIV-ART info|
9522580|NCT03263715|Experimental|Tocilizumab|Tocilizumab-based regimen (Tocilizumab Prefilled Syringe [Actemra] 162 mg s.c. administered weekly) on top of rapidly tapered Glucocorticoid [Glucocorticoids]
9522581|NCT03263715|Placebo Comparator|Placebo|Placebo [Placebos] and rapidly tapered Glucocorticoid [Glucocorticoids] treatment
10171751|NCT03880175|Experimental|FCC DEB and high coupon value|
10171752|NCT03880175|Experimental|FCC DEB and no info|
9522582|NCT03263650|Experimental|Cabazitaxel + Carboplatin|Cabazitaxel, Cabazitaxel and Carboplatin intravenously on day 1 of cycles 1-6. Prednisone by mouth twice daily on days 1-21 of cycles 1-6.
9522583|NCT03263650|Experimental|Olaparib Maintenance|Participants randomized to receive Olaparib by mouth twice daily on Day 1 of cycle 7.
9522584|NCT03263650|No Intervention|Observation Only|Participants randomized to observation only beginning cycle 7.
9522585|NCT03263676|Experimental|Icon reusable underwear|
9522586|NCT03263676|Placebo Comparator|Disposable pad|
9522587|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
9522588|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
9522589|NCT03263624|Experimental|Group (A)|fractional carbon dioxide laser plus tazarotene 0.1% cream
9522590|NCT03263624|Active Comparator|Group (B)|Tazarotene Cream 0.1%
9975220|NCT04213677|Experimental|Dapagliflozin|Dapagliflozin (Participants will receive dapagliflozin 10mg po qd).
10171753|NCT03880175|Experimental|FCC non-DEB and Anti-stigma|
9522591|NCT03263585|Active Comparator|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
9522592|NCT03263585|Active Comparator|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
9522593|NCT03263585|No Intervention|Control|Women in the control group get no intervention for six months.
9522594|NCT03263377|Active Comparator|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
9522595|NCT03263377|Other|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
9522596|NCT03263390||Bariatric Surgery|Subjects that have demonstrated extreme response to bariatric surgery.
9522597|NCT03263390||Anti Obesity Medications|Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.
9975221|NCT04213677|Placebo Comparator|Placebo|Placebo (Participants will receive placebo po qd)
9522598|NCT03263611|Placebo Comparator|placebo|subject will receive single intradiscal injection of placebo
9522599|NCT03263611|Experimental|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
9522600|NCT03263611|Experimental|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
9975222|NCT04213456|Experimental|Nutritional supplementation|Powder added to water,high protein and multi vitamin and minerals
9977513|NCT01362400|Placebo Comparator|Placebo + Docetaxel|Placebo plus Docetaxel
10171754|NCT03880175|Experimental|FCC non-DEB and HIV info|
10171755|NCT03880175|Experimental|FCC non-DEB and ART info|
10171756|NCT03880175|Experimental|FCC non-DEB and HIV-ART info|
10171757|NCT03880175|Experimental|FCC non-DEB and high coupon value|
10171758|NCT03880175|Experimental|FCC non-DEB and no info|
10171759|NCT03880175|Experimental|FCC control and Anti-stigma|
10171760|NCT03880175|Experimental|FCC control and HIV info|
10171761|NCT03880175|Experimental|FCC control and ART info|
10171762|NCT03880175|Experimental|FCC control and HIV-ART info|
10171763|NCT03880175|Experimental|FCC control and High coupon value|
10171764|NCT03880175|No Intervention|FCC control and no info|
10171765|NCT03879837|Experimental|Investigational Test Product|Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation
10171766|NCT03879837|Active Comparator|Reference Listed Drug|Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation
10171767|NCT03879837|Placebo Comparator|Placebo|Placebo pressurized metered dose inhaler, no active content
10171768|NCT03880006|No Intervention|Standard of care|Participants assigned to the Senegalese standard of care treatment for people living with HIV.
10171769|NCT03880006|Experimental|Case management|Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
10171770|NCT03879811|Experimental|MMR-Proficient Colorectal Cancer|"The first 3 subjects will receive oral TMZ at 150mg/m2 day 1 to 5 during cycle~1, followed by nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1 (i.e. Cycle 2 day 1). Nivolumab will continue for up for 2 years maximum. If confirmed that TMB increased in at least 2 of 3 subjects following 1 cycle of TMZ, then subsequent patients will continue to receive TMZ during cycle 1 only, and the original three participants will not be replaced. If it is determined that TMB did not increase following 1 cycle of TMZ, then subsequent patients will receive TMZ up to cycle 3, those first 3 patients will discontinue further Nivolumab and be replaced and an additional 6 patients will initially be enrolled. If confirmed that TMB increased in at least 1 of 6 subjects following 3 cycles of TMZ, then 12 more patients will be allowed to enroll for a total of 18 in stage I."
9522601|NCT03263611|Experimental|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
9522602|NCT03263481|Experimental|ERCP with intraductal secretin test|Subjects undergoing ERCP for biliary indication in which inadvertent pancreatic cannulation occurs will receive intraductal secretin testing using a one-time intravenous injection of 16 mcg of human secretin for injection administered over one minute.
9522603|NCT03263338|Active Comparator|Group A|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target.
9522604|NCT03263338|Experimental|Group B|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
9522605|NCT03263338|Experimental|Group C|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
9522606|NCT03263299|Active Comparator|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
9522607|NCT03263299|Active Comparator|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
9522608|NCT03263299|Active Comparator|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
9522609|NCT03263286|Experimental|HandSOME|The intervention is given to this group.
9522610|NCT03263572|Experimental|Treatment (blinatumomab, chemotherapy, ponatinib)|Patients receive blinatumomab IV nonstop on days 1-28 of cycles 1-5, and methotrexate and cytarabine intrathecally (by spinal tap) on days 1, 15, and 29 of cycles 1-4. Patients also receive ponatinib PO daily. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9522611|NCT03263247|Experimental|Visual Imaging Training|"Participants will receive visual imaging training to facilitate learning of written information.~Intervention: Visual Imaging Training in individual sessions"
9522612|NCT03263247|Active Comparator|Psychoeducation|"Participants will receive information about memory functioning and aging.~Intervention: behavioral: Psychoeducation in individual sessions"
9522613|NCT03263247|Experimental|Alphabet Search|"Participants will receive alphabet search training.~Intervention: Alphabet Search in individual sessions"
10171771|NCT03879785|Active Comparator|Self-Administration followed by Interviewer-Administered|
10171772|NCT03879785|Active Comparator|Interviewer-Administered followed by Self-Administration|
9522614|NCT03263260||implanted patients|Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
9522615|NCT03263312|Experimental|Fontan Patients|All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
9522616|NCT03263455|Experimental|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
9522617|NCT03263455|Sham Comparator|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
9662248|NCT05008536|Experimental|Anti-BCMA CAR-NK Cells|After preconditioning with chemotherapy, the Anti-BCMA CAR-NK Cells will be evaluated
10171773|NCT03879720|Active Comparator|Standard Endotracheal Intubation (SEI)|the patient will be positioned supine on the gurney for intubation, with eventual position in the standard semi-prone ERCP position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed, Propofol and Succinylcholine will be administered per standard of care and intubation will be accomplished by direct laryngoscopy or glidescope, with confirmation of endotracheal tube placement by auscultation.
10171774|NCT03879720|Experimental|Endoscope assisted endotracheal intubation [EAEI]|the patients will position themselves in the semi-prone position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed and Propofol will be administered per standard of care. Succinylcholine will not be administered and therefore the patient will not be paralyzed. The endotracheal tube will be positioned on the mid-distal aspect of the ultra-slim endoscope and the ultra-slim endoscope will then be advanced into the trachea under direct endoscopic visualization to the level of the carina. The anesthesiologist will then advance the endotracheal tube over the endoscope into the trachea, and its position above the carina will be simultaneously confirmed endoscopically with the ultra-slim endoscope.
10171775|NCT03879759|Experimental|Arm 1|NAC - Relapse Prevention (4 wks)
10171776|NCT03879759|Placebo Comparator|Arm 2|NAC - Relapse Prevention (4 wks)
9522618|NCT03263351|Experimental|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
9522619|NCT03263351|Active Comparator|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
9522620|NCT03263468|Experimental|Same sitting complete revascularization|After treatment of the IRA, subjects will undergo PCI of all suitable significant non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm).
9522621|NCT03263468|Active Comparator|Staged non-IRA PCI|Only the IRA will be intervened upon during the index primary PCI procedure. Staging of the non-IRA lesions will be performed 48 hours to 45 days after the primary PCI procedure. All suitable non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm) will be treated with PCI irrespective of whether there are clinical symptoms or evidence of ischemia.
9975223|NCT04213456|Placebo Comparator|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
9975224|NCT04206982|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
9662249|NCT05006170|Experimental|6 to below 10 kg weight band|Children with perinatal HIV infection whose weight from 6 kg to below 10 kg
9662250|NCT05006170|Experimental|10 to below 14 kg weight band|Children with perinatal HIV infection whose weight from 10 kg to below 14 kg
9662251|NCT05006170|Experimental|14 to below 20 kg weight band|Children with perinatal HIV infection whose weight from 14 kg to below 20 kg
9975225|NCT04206982|Active Comparator|Pulmonary vein isolation arm|
9975226|NCT04198337|Experimental|Endoscopic Full Thickness Resection|Resection of the gastric GIST by ESD techniques followed by endoscopic closure of defect with suturing or clips and loop
10171777|NCT03879707|Experimental|Experimental|Melatonin and magnesium for 14 days
10171778|NCT03879707|Placebo Comparator|Control|Placebo for 14 days
10171779|NCT03879694|Experimental|Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)|Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
10171780|NCT03879746|Active Comparator|tamsulosin group|the first group will include 40 patients treated with daily administration of tamsulosin 0.4 mg
10171781|NCT03879746|Active Comparator|paroxetine group|the second group will include 40 patients treated with daily administration of paroxetine 20 mg
10171782|NCT03879746|Active Comparator|combined group|the third group will include 40 patients treated with daily administration of tamsulosin 0.4 mg and paroxetine 20 mg
10171783|NCT03879746|Placebo Comparator|placrbo group|the fourth group will include 40 patients will be given placebo
9662252|NCT04991571|Experimental|Part 1|Participants will be administered with zibotentan once daily for 5 days.
9662253|NCT04991571|Experimental|Part 2: Treatment Sequence ABC|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment A; Treatment B; Treatment C) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
9662254|NCT04991571|Experimental|Part 2: Treatment Sequence BCA|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment B; Treatment C; Treatment A) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
9662255|NCT04991571|Experimental|Part 2: Treatment Sequence CAB|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment C; Treatment A; Treatment B) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
9662256|NCT04983901|Experimental|Group I (imipenem, cilastatin, relebactam)|Patients receive imipenem IV, cilastatin IV, and relebactam IV over 30-60 minutes q6h for 2 days for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h. Patients may continue to receive imipenem IV, cilastatin IV, and relebactam IV over 30-60 minutes for up to 14 days if clinically indicated by the assessment of the treating physician.
9662257|NCT04983901|Active Comparator|Group II (cefepime, meropenem, piperacillin/tazobactam)|Patients receive cefepime IV q8h for a minimum of 6 doses, meropenem IV q8h for a minimum of 6 doses, or piperacillin/tazobactam IV q6h for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h.
9662258|NCT04983134|No Intervention|Standard Intervention(SI)|the HealthStreet Standard Intervention to include a CHW referral to an accessible and acceptable lung cancer screening site to include a financial counselor (if needed), tobacco cessation and quit resources (if still smoking) and, additionally, will watch the Genentech lung cancer screening video with the CHW;
9662259|NCT04983134|Experimental|Enhanced CHW Intervention|After 1:1 randomization, 30 women will additionally receive a 6-hour four week Enhanced CHW Intervention (E-CHW-I) modelled on successful peer-partnered interventions and informed by Stages of Change theory, which will add to the SI, calls and texts (if appropriate) to help problem solve and encourage screening receipt and transportation to the screening (if needed);
9662260|NCT04982848||Talzenna treated group|Talzenna treated gBRCA Breast cancer patients in the real world setting in Korea
9662261|NCT04968899|Experimental|Experimental group|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21
9662262|NCT04968899|Active Comparator|Control|IVIg (1g/kg D1-D2) plus prednisone (1 mg/kg/day x 21 days (3 weeks))
9522622|NCT03263533|Experimental|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
9522623|NCT03263533|Experimental|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
9522624|NCT03263546|Experimental|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
9522625|NCT03263546|Active Comparator|Gold standard treatment|Cognitive behavioral therapy (CBT)
9522626|NCT03263494|Active Comparator|CGM|
9522627|NCT03263494|No Intervention|BGM|
9522628|NCT03263403|Experimental|Test Group|"44 participants will be randomly assigned to the test group for receiving the locally produced meningococcal vaccine Ingovax ACWY (Incepta)."
9522629|NCT03263403|Active Comparator|Comparator Group|44 participants will be randomly assigned to the comparator group for receiving 'Quadri Meningo' (BiO-MeD Private Limited).
9522630|NCT03263234|Active Comparator|Group 1|Group 1 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 1 starts the 8 week control period and ends with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED).
9522631|NCT03263234|Active Comparator|Group 2|Group 2 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 2 starts with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED) and ends with the 8 week control period
9522632|NCT03263234|No Intervention|Group 3. Control group|"Group 3 consists of elderly people with frailty living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are not having CALED installed.~This group serves as a control for:~Physiological or mental decline in participants during the study period~Seasonal variation"
9522633|NCT03263182||Nchelenge Facilities|Purposively selected health facilities based on criteria including: high demand for services, perceived need for support for quality improvement, and presence of a SBA to mentor.
9522634|NCT03263520|Experimental|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
9522635|NCT03263520|Active Comparator|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
9522636|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
9522637|NCT03263208|Experimental|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
9522638|NCT03263091|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
10171784|NCT03879668||eIPOS|The cohort will include all participants who are cared for by the participating specialist palliative home care teams when implementing eIPOS.
10171785|NCT03879668||Historic control|The cohort will include all participants that were cared for by the participating specialist palliative home care teams in the last 6 months before the implementation of eIPOS.
10186986|NCT03730727|Experimental|Immediate prior to meal|At approx. 8 am following an 8-10 hour overnight fast, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]). Immediately after completion of this bout, a liquid meal replacement shake containing 500 kcal will be administered. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion.
10186987|NCT03730727|Experimental|Immediate post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Immediately after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
9522639|NCT03263091|Placebo Comparator|Placebo (Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
9522640|NCT03263091|Experimental|Open-Label High Erythropoietin|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
9522641|NCT03262831|Experimental|Arm 1: Yoga|"Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga~Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.~The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel~During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
9522642|NCT03262831|Active Comparator|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
9522643|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:~Prolonged mechanical ventilation (longer than 96 hours)~Tracheostomy~Sepsis~Serious injury (burn)~Stroke (hemorhagic or ischemic)~Traumatic brain injury"
9522644|NCT03262857|Experimental|time of start of anesthesia|
9522645|NCT03262857|Experimental|intensity of anesthesia|
9522646|NCT03262948|Experimental|nab-paclitaxel plus carboplatin|nab-paclitaxel 260mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
9826647|NCT02426918|Experimental|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
9826648|NCT02426918|Placebo Comparator|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
9826649|NCT02427100|No Intervention|Control Group|Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
9826650|NCT02427100|Active Comparator|Intervention Group|Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.
9826651|NCT02427399|No Intervention|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
9826652|NCT02427399|Experimental|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
10171786|NCT03879590|Experimental|Budesonide and Doxophylline|Budesonide at the same dose in which the subject is currently treated (GINA step 3 or 4) plus doxophylline at a dose of 18 mg / kg per day
9522647|NCT03262948|Active Comparator|Paclitaxel plus carboplatin|paclitaxel 175 mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
9522648|NCT03262818|Experimental|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"Transvaginal ultrasound (US) prior to surgery~Immediately after the transvaginal US, US/PAI imaging will be performed~Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
9522649|NCT03262974||CML patients with MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
9522650|NCT03262974||CML patients without MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
9522651|NCT03263013||FMD patients|patients with a diagnosis of clinically definite FMD who have been assessed at the HMCS clinic, and who have completed protocol 07-N-0190.
9522652|NCT03263065|Experimental|Nopal added to test meal|test meal including nopal powder
9522653|NCT03263065|Experimental|Psyllium added to test meal|test meal including psyllium powder
9522654|NCT03263065|Experimental|Bran added to test meal|test meal including bran powder
9522655|NCT03263052||Tacrolimus XR|
9522656|NCT03263039|Other|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
9522657|NCT03263104|Experimental|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
9522658|NCT03263104|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
9522659|NCT03263169||WE Health Tapestry|Completion of baseline measures then enrolled in a community-based personalized care intervention that consists of four core elements: volunteer support, interprofessional care, technology, social network linkage
9522660|NCT03263169||Usual Care|Completion of baseline measures with six-month delayed community-based personalized care intervention: volunteer support, interprofessional care, technology, social network linkage
9826653|NCT02427399|Experimental|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
9975227|NCT04179110|Experimental|Pembrolizumab and Ramucirumab|Patients with progressive transitional cell carcinoma after treatment with an immune checkpoint inhibitor will receive Pembrolizumab and Ramucirumab.
9977514|NCT01362426||001|paliperidone palmitate Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
9522661|NCT03263156|Experimental|Intervention group|The intervention will involve two face-to-face consultation sessions and one follow-up phone call with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
9522662|NCT03263156|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
9522663|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
9522664|NCT03263000||Healthy|24 healthy volunteers (HVs)
9522665|NCT03263000||Patients|24 patients with blepharospasm
10171787|NCT03879590|Active Comparator|Low budesonide and Doxophylline|Reduced dose of inhaled budesonide (GINA step down) plus doxophylline to a dose of 18 mg / kg per day, maximum of 800 mg / day (Group B)
10171788|NCT03879681|No Intervention|No Intervention|
10171789|NCT03879681|Experimental|Jelly Snakes|
10171790|NCT03879460|Experimental|Open Label|Open label
10171791|NCT03879564|Placebo Comparator|control|0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
10171792|NCT03879564|Experimental|ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
10171793|NCT03879486|Experimental|PVPI intervention|rectal cleansing and disinfection of the needle tip at transrectal ultrasound guided prostate biopsy
10171794|NCT03879486|No Intervention|Control arm|controls at transrectal ultrasound guided prostate biopsy
10171795|NCT03879356|Other|Aluminum phosphide patients|effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
10171796|NCT03879382|Experimental|anti-CD19/BCMA CAR-T cells|Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
10171797|NCT03879421|Active Comparator|Group 1 (Epithelium-off accelerated CXL)|patients with corneal thickness > 400 µm (thinnest location) were assigned into Epi-off accelerated CXL procedure
10171798|NCT03879421|Active Comparator|Group 2 (Epithelium-on accelerated CXL)|patients with corneal thickness > 380 µm and < 400 µm thinnest location) were assigned into Epi-on Trans-epithelial accelerated CXL procedure
10171799|NCT03879343||Clinical group|Children aged six to eleven with clinical diagnosis of attention deficit / hyperactivity disorder were recruited for interview and completion of questionnaires
10171800|NCT03879343||Control group|Normally developing children aged six to eleven studying in local mainstream primary schools were recruited for completion of questionnaires
10171801|NCT03879174|Experimental|Pembrolizumab + Tamoxifen|Pembrolizumab (200mg IV every three weeks) + Tamoxifen (20 mg OD)
10171802|NCT03879148|Active Comparator|Erector spinae plane block (Group I)|The ultrasound (US) guided ESPB was performed under aseptic conditions at the level of T5 vertebrae using the GE Vivid Q® US device. A high frequency 12 MHz linear US probe was covered with a sterile sheath and placed longitudinally 2-3 cm lateral to the T5 transvers process. After visualizing trapezius, rhomboid major, erector spinae muscles superficial to the hyperechoic transverse process shadow respectively, a 22-gauge 50 mm block needle (Braun Stimuplex Ultra 360, Germany) was inserted in a cephalad to caudad direction. Once the needle tip had been placed within the interfacial plane below the erector spinae muscle, 2 mL of saline were injected to confirm the proper injection site, and then a 20 mL dose of 0.25% bupivacaine was injected. Patients received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit
10171803|NCT03879148|No Intervention|Control group (Group II)|Patients in control group only received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit.
10171804|NCT03879213|Experimental|Active|freeze-dried red raspberry powder (25 g) in active breakfast meal
10171805|NCT03879213|Placebo Comparator|Placebo|Placebo breakfast
10171806|NCT03879031||Outpatients with low back pain|"All outpatients with non-specific subacute or chronic low back pain will be submitted to a physical therapy program including:~information on pain mechanisms and the favorable nature of non-specific low back pain;~advice on positions, movements and activities recommended or advised against in people with low back pain, both at work and during leisure time;~active postural correction exercises, overactive muscles lengthening and weak musculature strengthening;~passive manual techniques, aimed at muscle relaxation and recovery of lumbar joint mobility.~A cluster of Clinical tests to measure lumbar stability will be administrated before the starting of the first session and at the ending of the last session of the physical therapy program."
10171807|NCT03879239|Active Comparator|Vibrant Capsule mode A|Vibrant Capsule mode A administered 5 times per week
10171808|NCT03879239|Active Comparator|Vibrant Capsule mode B|Vibrant Capsule mode B administered 5 times per week
10171809|NCT03879239|Placebo Comparator|Placebo Capsule|Placebo Capsule administered 5 times per week
10171810|NCT03879252|Experimental|Tooth brushing|
9522666|NCT03263000||Patients 2|24 patients with increased blinking alone.
10171811|NCT03879252|Active Comparator|Mouthwash|
10171812|NCT03879122|Active Comparator|ADT + Docetaxel|ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
10171813|NCT03879122|Experimental|ADT + Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
10171814|NCT03879122|Experimental|ADT + Ipilimumab / Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
10171815|NCT03879395||Cohort|Patients with stage IV malignant melanoma with abdominal metastasis (M1c) that underwent abdominal surgery with metastasectomy during the study period.
10171816|NCT03879070|Experimental|Intervention group|
9522667|NCT03262805|Placebo Comparator|Placebo|Placebo
9522668|NCT03262805|Active Comparator|Active|Lanconone(R)
10171817|NCT03879070|No Intervention|Control group|
10171818|NCT03879278|Other|Treatment 2 mg/kg|Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
10171819|NCT03879278|Other|Treatment 5 mg/kg|Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
10171820|NCT03879278|Other|Treatment 12.5 mg/kg|Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
10171821|NCT03879057|Experimental|Surufatinib 200mg/JS001 240mg|Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
10171822|NCT03879057|Experimental|Surufatinib 300mg/JS001 240mg|Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
9522669|NCT03262844|Placebo Comparator|Conservative treatment|Conservative physiotherapy, intermittent catheterization, or drug treatment for bladder or bowel dysfunction
9522670|NCT03262844|Experimental|Capsule surgery|Nerve root axial decompression surgery (Capsule surgery)
9522671|NCT03263143|No Intervention|Standard of Care|
9522672|NCT03263143|Other|Early Palliative Care Consultation|
9522673|NCT03262961|Active Comparator|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
9522674|NCT03262961|Placebo Comparator|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
9522675|NCT03262792|Placebo Comparator|Placebo|Microcrystalline cellulose
9522676|NCT03262792|Active Comparator|Andrographis Paniculata 150|Andrographis Paniculata 150 mg
9522677|NCT03262792|Active Comparator|Andrographis Paniculata 300|Andrographis Paniculata 300 mg
9527866|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
9527867|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
9527868|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
9527869|NCT03216213|No Intervention|Control|Vignette contains no extra information
9527870|NCT03216213|Experimental|Frame|Vignette is framed in a particular manner
9527871|NCT03216213|Experimental|Norms|Vignette contains extra information about norms
9527872|NCT03216213|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
9527873|NCT03215927|Placebo Comparator|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
9527874|NCT03215927|Experimental|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
9527875|NCT03215875|Experimental|Fed- 60mg ER Torsemide|Adult healthy subjects will be given standardized high-fat, high-calorie meal prior to dosing
9527876|NCT03215875|Experimental|Fasting- 60mg ER Torsemide|Adult healthy subjects will fast overnight (at least 10h) prior to dosing
9527877|NCT03215979|Experimental|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
9527878|NCT03215979|Placebo Comparator|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
9527879|NCT03215992|Other|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
9527880|NCT03215992|Other|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
9527881|NCT03215823||1. Easy endotracheal intubation|Easy endotracheal intubation
9527882|NCT03215823||2. Difficult endotracheal intubation|Difficult endotracheal intubation
9528204|NCT03212742|Experimental|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:~Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.~Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
9528205|NCT03212820|Experimental|Biologic drilling|drilling at low speed
9528206|NCT03212820|Active Comparator|conventional drilling|drilling at conventional or high speed
10171823|NCT03879200|No Intervention|Standard Individual care|Historical controls Individual care follows standard individual Swedish antenatal care, i.e.8-9 30 minutes appointments with a midwife during a normal pregnancy including information and regular pregnancy check-ups. Women are offered classes (3 x 2 hours) that provide preparation for birth and parenthood according to the same guidelines. Obstetricians and general practitioners have a consultant role.
10171824|NCT03879200|Experimental|Group antenatal care|Group antenatal care will follow the same guidelines as for individual care but with tailored content provided in language supported group sessions.
9528207|NCT03212664|Other|Exercise|Schroth-based physical therapy exercises for patients who agree to participate in exercises. Will be compared to observation-only treatment
9975228|NCT04173975|Experimental|With knee exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).~Each session will be 45 minutes long. Three time per week, for three weeks.~The patients allocated in this arm will perform the training wearing the BELK device."
10171825|NCT03878901|Sham Comparator|control group|Cotton Blanket Warming (CBW) starts 30 min preoperatively and then continues throughout the entire operation.
9522678|NCT03262467|Active Comparator|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
9522679|NCT03262467|Placebo Comparator|Aneurysmorrhaphy without external porous prosthesis|
9522680|NCT03262545|Experimental|experimental group|apatinib 500 mg p.o. once daily
9522681|NCT03262545|Placebo Comparator|control group|placebo p.o. once daily
9522682|NCT03262636|Other|Diagnostic value of Second Window ICG|"The primary study objective is to determine the diagnostic value of Second Window ICG (delayed, high dose IV administration of ICG) in the surgical resection of nervous system tumors.~The first objective is to determine safety/efficacy of high dose, delayed indocyanine green (second window ICG) during surgery of nervous system tumors."
9522683|NCT03262636|Other|Optimal timing and dose of SWG|"The second study objective is to calculate diagnostic test characteristics (sensitivity/specificity) of delayed, high dose indocyanine green (second window ICG) as a diagnostic aid during surgery of nervous system tumors.~The third study objective is to optimize timing and dose of second window Indocyanine Green during surgery of nervous system tumors, based on sensitivity/specificity."
9522684|NCT03262493|Experimental|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
9522685|NCT03262493|No Intervention|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
9522686|NCT03262688|Experimental|INL-001|Bupivacaine HCl collagen-matrix implant
9522687|NCT03262688|Active Comparator|Infiltration|Bupivacaine HCl infiltration
9522688|NCT03262558||Patients with ECC|No intervention
9522689|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
9522690|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
9522691|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
9522692|NCT03262506|Experimental|Cognitive Training|
9522693|NCT03262597|Experimental|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
9522694|NCT03262532||Experimental|Learning TEE manipulation with a Web-based TEE simulation module
9522695|NCT03262532||Control|Learning a TEE manipulation without the Web-based TEE simulation
9522696|NCT03262480|Active Comparator|Stroke volume optimization|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.
9522697|NCT03262480|Sham Comparator|Central venous pressure dynamic|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
9522698|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
9522699|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
9522700|NCT03262740|Experimental|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
9522701|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
9522702|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
10171826|NCT03878901|Experimental|warm group|"Warm according to different hypothermia risk for low risk ---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) continues throughout the entire operation.~moderate risk---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) and fluid warming continues throughout the entire operation.~high risk ----Forced-air warming(FAW) starts at least 30 min preoperatively, FAW and fluid warming continues throughout the entire operation."
9522703|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
9522704|NCT03262571|Experimental|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
9522705|NCT03262571|Placebo Comparator|Group B|Group B includes patients undergoing physical examination only.
10171827|NCT03879096|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
10171828|NCT03879226|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
9522706|NCT03262714|Experimental|Dancing|Elderly women randomized to the dance intervention programme.
9522707|NCT03262714|Experimental|Walking|Elderly women randomized to the walking intervention programme.
9522708|NCT03262714|Active Comparator|Stretching|Elderly women randomized to the stretching intervention programme.
9522709|NCT03262402|Experimental|HIV-infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
9522710|NCT03262402|Active Comparator|Non-HIV infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
9522711|NCT03262415||Study Cohort|30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
9522712|NCT03262727|Experimental|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
9522713|NCT03262766|Active Comparator|Acute intermittent hypoxia (AIH)|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
9527883|NCT03215849|Sham Comparator|Routine Medical Therapy|Routine Medical Therapy
9522714|NCT03262766|Experimental|AIH+ Upper extremity training|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
9527884|NCT03215849|Experimental|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
9527885|NCT03215849|Experimental|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
9672151|NCT05038995||Healthy group|Healthy children will ve eligible for the study if they (1) did not have CMA and other allergic diseases (2) who had never been on a diet throughout their lives.
9672152|NCT05038943|Experimental|SherpaPak|cardiac allografts recovered from donors after circulatory determined death using thoracoabdominal normothermic regional perfusion will be transported to the recipient center in Paragonix SherpaPak Cardiac Transport System
9672153|NCT05038748||ASD group|80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
9672154|NCT05038748||Sibling group|30 unaffected siblings of ASD youths
9672155|NCT05038748||TD group|40 healthy typical developing(TD) control from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007
10171829|NCT03879226|Experimental|PBMT + training/ placebo + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
9672156|NCT05038930|Experimental|Intervention protocol|"Phase 1. The patient will be positioned in a supine position for 20 minutes on the Sara Combilizer®. When necessary, the head of the patient can be elevated to a maximum of 30 degrees during the 20 minutes baseline measurements.~Phase 2. The patient will be positioned in a seated position for 10 minutes with the trunk and head elevated to at least 70 degrees.~Phase 3. The patient will be moved to the standing position for 20 minutes with an elevation angle of the Sara Combilizer of at least 70 degrees. If patients become haemodynamically unstable during the seated or standing position, they will be returned to the supine position, and the intervention will be terminated.~Phase 4. The patient is returned to the phase 1 position (supine). Further measurements are made for at least 20 minutes."
9672157|NCT05038930|No Intervention|Sedentary protocol|The sedentary protocol will follow the same four phases as the intervention protocol only the patient will remain in the supine position on the Sara Combilizer®. Ideally, no interventions will occur during the 70-minute protocol. If medications are given or other interventions are necessary, this will be registered.
9672158|NCT05038891||Digital Cervical Assessment performed first|A digital cervical exam will be performed by an experienced senior obstetrics and gynecology resident, using index finger and middle finger to measure the dilation and thickness of the cervix. This is the gold standard measurement utilized to assess the labor course. In this group, the digital cervical exam is done first, followed by a participant-performed ultrasound imaging assessment of the cervix.
9672159|NCT05038891||Ultrasound Assessment performed first|Ultrasound imaging will be first taught by an experienced RN, then self-performed by the participant in the presence of junior obstetrics and gynecology resident and the RN. The junior resident will ensure the ultrasound device is functioning properly and the images are saved. In this group, the participant-performed imaging assessment is done first, followed by a digital cervical exam performed by an experienced senior obstetrics and gynecology resident.
9672160|NCT05038670|Active Comparator|PERSONA|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet PERSONA system
9672161|NCT05038670|Active Comparator|Journey II|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Smith&Nephew Journey II system
9672162|NCT05038605|Active Comparator|Topical metronidazole|Topical application of metronidazole cream on the anal verge after surgery
9672163|NCT05038605|Active Comparator|Oral metronidazole|oral metronidazole 500 mg tablets after surgery
9672164|NCT05038605|No Intervention|Control|No metronidazole was received
9672165|NCT05038579|Experimental|Musiquence|Dementia group was involved in a 14-session customized cognitive stimulation program, using Musiquence.
9672166|NCT05038657|Experimental|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
10171830|NCT03879226|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
10171831|NCT03879226|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
9672167|NCT05039164|Experimental|Remote Training Strategy (RTS)|The RTS will be developed during Phase 1 of this 5-year project using an iterative process (Rapid Prototyping) to develop an online training platform. Investigators will train school staff from both conditions remotely on providing a brief in-service training to teachers on recognizing warning signs of excessive anxiety, depression, and disruptive behavior problems in children. Teachers will nominate students who might need Tier 2 services. Investigators will offer protected access to asynchronous training materials to school behavioral health staff (BHS). The materials will include didactic content, audio and visual examples, as well as treatment materials and resources. The RTS will also allow synchronous training and consultation for the implementation of EBPs by BHS supported by expert consultants and school personnel to coordinate services in a child-centered approach for students already receiving other services at school.
9522715|NCT03262766|Active Comparator|Sham AIH + Upper extremity training|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the sham AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training. Upper extremity training will be given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
9522716|NCT03262766|Sham Comparator|Sham Acute intermittent hypoxia|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
9522717|NCT03262142|Active Comparator|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
9522718|NCT03262142|No Intervention|Antibiotic-free treatment|
9522719|NCT03262077|Experimental|MB 1 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
9522720|NCT03262077|Experimental|MB 3 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
9522721|NCT03262077|Experimental|MB 5 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
9522722|NCT03262077|Experimental|MBS 1 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
9522723|NCT03262077|Experimental|MBS 3 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
9522724|NCT03262077|Experimental|MBS 5 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
10171832|NCT03879018|Experimental|Reinforcement Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For reinforcement training, participants will not see their hand or a cursor, but instead participants will receive target-specific binary feedback after each reach (i.e. based on running average of last 10 reaches to that target). Binary feedback indicates only whether the reach was successful or unsuccessful and provides no specific information about the location of the hand.
10171833|NCT03879018|Experimental|Standard Practice Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For standard practice, participants will be able to see a cursor that represents the position of the hand at all times and try to make straight reaches to the targets. This type of feedback provided specific information about the location of the hand.
10171834|NCT03878888|Experimental|Exparel use in TAP block|Exparel used in bilateral TAP block for open abdomen surgery
10171835|NCT03878888|No Intervention|no TAP block|these patients, N=20, did not received a bilateral TAP block for postoperative pain control. Instead, pain control involves PO/IV pain medications
9826654|NCT02427399|Experimental|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
9826655|NCT02427399|Experimental|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
10171836|NCT03879187|Experimental|High-fat diet|Participants underwent a 7 day high-fat, high-energy diet intervention with metabolic measurements before and after
10171837|NCT03878966|Experimental|Invasive Strategy group|Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .
10171838|NCT03878680||13-14 years age group|Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
10171839|NCT03878680||6-7 years age goup|Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
9522725|NCT03262090|No Intervention|control group|Subjects were randomly assigned to receive saline before skin incision
9522726|NCT03262090|Active Comparator|0.2ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
10171840|NCT03878940|Other|Primary care patients|All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent.
10171841|NCT03878953|Experimental|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
9522727|NCT03262090|Active Comparator|0.4ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
10186988|NCT03730727|Experimental|30-minutes post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Thirty-minutes after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
9522728|NCT03262090|Active Comparator|0.6ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
9522729|NCT03262090|Active Comparator|0.8ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
9522730|NCT03262090|Active Comparator|1.0ug/kg dexmedetomidine|Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
9522731|NCT03262311|Experimental|Hypoxia marker|Administration of a single dose of the hypoxia marker Pimonidazole
9522732|NCT03262207||testicular tumours|
9522733|NCT03262207||fertile|
9522734|NCT03262207||infertile|
9522735|NCT03262298|Experimental|anti-CD22 CAR-T|Patients will receive a full dose CART infusion at day 0.
9522736|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
9522737|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
9522738|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
9522739|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
9522740|NCT03262181|Experimental|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
9522741|NCT03262181|Sham Comparator|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
9522742|NCT03262337||Elderly Travelers|approximately 135 travelers with an age >= 60 years will be enrolled
9522743|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
9522744|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
9522745|NCT03262155||ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
9522746|NCT03262155||No ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
9522747|NCT03262116|Experimental|Bionic Pancreas - Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
9522748|NCT03262116|Experimental|Bionic Pancreas - Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
9522749|NCT03262116|Experimental|Bionic Pancreas - BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
9522750|NCT03262363|Experimental|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
9522751|NCT03262363|Placebo Comparator|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
9522752|NCT03262272|Experimental|Hemodialysis|patients treated by conventionnal hemodialysis
9522753|NCT03262272|Experimental|Hemodiafiltration post dilution|patients treated by HDF post-dilution
9522754|NCT03262376|Experimental|Mineral + vits + botanical A|Mineral and vitamin complex combined with Botanical A
9522755|NCT03262376|Experimental|Mineral + vits + botanical B|Mineral and vitamin complex combined with Botanical B
9522756|NCT03262376|Experimental|Mineral+vits +botanical A+Botanical B|Mineral and vitamin complex combined with Botanical A and Botanical B
9522757|NCT03262376|Placebo Comparator|Placebo|Cellulose crystalline placebo
9522758|NCT03262103|Experimental|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
9522759|NCT03262103|Experimental|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
9522760|NCT03262103|Experimental|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
9522761|NCT03262103|Experimental|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
9522762|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
10171842|NCT03878914|Experimental|Quick responders (Group A)|"Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.~CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group A (Total duration of therapy 8 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 2 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 2 weeks.~Wean off in 4 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
10171843|NCT03878914|Active Comparator|Slow responders (Group B)|"CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group B: (Total duration of therapy ≥ 12 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 4 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 4 weeks.~Wean off in 4-6 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
9522763|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
9522764|NCT03262168|Other|Study Group One|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
9522765|NCT03262168|Other|Study Group Two|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
9522766|NCT03262168|Other|Study Group One - phase 2|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
9522767|NCT03262168|Other|Study Group Two - phase 2|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
9522768|NCT03262051||Patient with acute inflammation (surgery)|patients undergoing hip surgery
9522769|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
9522770|NCT03262051||Patient with acute inflammation (SARS-CoV-2 infection)|patients with SARS-CoV-2 infection
9522771|NCT03262350|Experimental|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
10171844|NCT03879083|Experimental|With reproduction of palatal rugae|Participants will receive maxillary complete dentures with a reproduction of the patients's own palatal rugae to the palatal surface.
9522772|NCT03262350|No Intervention|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
9522773|NCT03261986|Other|Trident II acetabular cup|Subjects receive the Trident II acetabular cup and RSA beads and undergo a series of post-operative RSA exams.
9522774|NCT03261635|Active Comparator|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
9522775|NCT03261635|Experimental|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
9522776|NCT03261687|Experimental|Water Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
9522777|NCT03261687|Experimental|Land Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
9522778|NCT03261622|Active Comparator|Control arm|Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)
9527886|NCT03215836|Other|Obese Asthmatics|BMI >/= 30 and without metabolic syndrome
9826656|NCT02427477|Experimental|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
9826657|NCT02427477|Active Comparator|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
10171845|NCT03879083|Active Comparator|Without reproduction of palatal rugae (smooth surface)|Participants will receive maxillary complete dentures with smooth palatal surfaces without a reproduction of the patients's own palatal rugae to the palatal surface.
9522779|NCT03261622|Sham Comparator|Intervention arm|"Alternation of stimulation amplitude~Period - Stimulation amplitude 0.05 Volts (lowest possible)~Period - Stimulation amplitude - 50% of sensory threshold.~Period - Stimulation amplitude - 90% of sensory threshold."
10171846|NCT03879265||Study group|No intervention. Couples who come to the study center to carry out a PGT-A cycle will be selected. Only couples that will use their own gametes will be selected and the indication of PGT-A will be advanced maternal age, failure of implantation, repeat abortion, male factor or structural chromosomal alterations. The results of chromosomal status of the embryo will be compared using the NICS and the conventional invasive method (PGT-A).
9522780|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
9522781|NCT03261843|Active Comparator|posterior lumbar interbody fusion + platelet rich plasma|the addition of autologous platelet rich plasma to the bone graft
10186989|NCT03730714|Active Comparator|Ggroup LAM|Patients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
9522782|NCT03261843|Active Comparator|posterior lumbar interbody fusion|bone graft alone
9522783|NCT03261869|Experimental|Cold application|Cold applied after extraction of third molar tooth.
9522784|NCT03261869|No Intervention|No Cold application|Cold application is not advised after extraction of third molar tooth
9522785|NCT03261739|Experimental|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
9522786|NCT03261739|Placebo Comparator|Placebo|vehicle control
9522787|NCT03261700|Experimental|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care and red flags, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
9522788|NCT03261700|Active Comparator|Information and referral condition|This brochure-based intervention includes education about IPV, health effects of IPV, resources and referral options to address a wide-array of health and social issues associated with IPV, and safety planning. Participants randomized to this arm are offered resources and referrals to VA and community resources.
9522789|NCT03261765||Multiple repeat cesarean (four or more)|
9522790|NCT03261765||Fewer repeat cesarean (two-three)|
9522791|NCT03261570|Active Comparator|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
9522792|NCT03261570|Active Comparator|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
9522793|NCT03261921|Active Comparator|Dexamethasone group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + (0.1 mg/kg dexamethazone) caudally.
9522794|NCT03261921|Active Comparator|Dexmedetomidine group|In this group the Patients received 0.5 ml/kg of bupivacaine 0.25% + dexmedetomidine(1 mu/kg) caudally.
9522795|NCT03261921|Active Comparator|Combination group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + dexamethasone(0.1mg/kg) and dexmedetomidine (1 mu/kg) caudally.
9522796|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
9522797|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
9522798|NCT03261713|Experimental|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
9522799|NCT03261713|Active Comparator|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
9522800|NCT03261726|Experimental|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
9522801|NCT03261895|Experimental|Intervention group|Nurse-led Integrative health and wellness programme
9522802|NCT03261895|No Intervention|control group|usual diabetes care
9522803|NCT03261752||patient with cancer|blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
9522804|NCT03261752||healthy people|blood sample will be collected for comparison
9522805|NCT03261804||Group I:internal vaginal douching users|
9522806|NCT03261804||Group II: none internal vaginal douching users|
9522807|NCT03261778|Experimental|Acromion 2.0 Brace|
9522808|NCT03261778|Active Comparator|Mitella Sling|
9522809|NCT03261596|Experimental|100 mg solid tablets 2x/day for 3 days|Assess the efficacy (Cure Rate/CR) and safety of 100 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
9522810|NCT03261596|Experimental|Single dose 500 mg solid tablets|Assess the efficacy (Cure Rate/CR) and safety of 500 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
9522811|NCT03261908||wild genotype|Through next generation sequencing, distinguish wild genotype of simvastatin
9522812|NCT03261908||mutant genotype|Through next generation sequencing, distinguish mutant genotype of simvastatin
9522813|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.~Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
9527887|NCT03215836|Other|Obese Astmatics|BMI >/= 30 and with metabolic syndrome
9527888|NCT03215836|Other|Obese non-asthmatics|BMI >/= 30
9522814|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
9522815|NCT03261882||Foreign-born Mexican-Americans|
9522816|NCT03261882||US-born Mexican-Americans|
9522817|NCT03261882||non-Hispanic Whites|
9522818|NCT03261856||small intetsinal bacterial overgrowth|Glucose breath test, 75 g glucose in 250 ml water. Breath samples collected at baseline and every 15 min for 2 hours
9522819|NCT03261856||Fructose breath Test|Fructose breath test, 25 g fructose in 250 ml water. Breath samples collected at baseline and every 30 min for 3 hours
9522820|NCT03261856||Lactose Breath test|Lactose breath test, 25 g lactose in 250 ml water. Breath samples collected at baseline and every 30 min for 5 hours
9522821|NCT03261791|Experimental|Apatinib|Apatinib mesylate tablets 500 mg po qd.
9522822|NCT03261557|Experimental|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
9522823|NCT03261557|Active Comparator|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
9522824|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
9522825|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
9522826|NCT03261284|Experimental|DOAC group|Patients with elevated d-dimer levels was switched to DOAC (dabigatran 150mg, bid).
10186990|NCT03730714|Active Comparator|Ggroup LAMG|Patients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
10186991|NCT03730714|Active Comparator|Group CG|Patients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
9522827|NCT03261284|Experimental|Higher-INR group|Patients' target INR was adjusted from 1.5-2.5 to 2.0-3.0 by adding warfarin dose.
9522828|NCT03261284|No Intervention|Control group|Patients continue previous strategy without change.
9522829|NCT03261193|Sham Comparator|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
9522830|NCT03261193|Experimental|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
9522831|NCT03261505|Experimental|VGAIT|
9522832|NCT03261505|Sham Comparator|VGAIT Control|
9522833|NCT03261505|Active Comparator|Real Acupuncture|
9522834|NCT03261505|Placebo Comparator|Sham Acupuncture|
9522835|NCT03261206|No Intervention|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
9522836|NCT03261206|Experimental|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
9522837|NCT03261427|Experimental|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
9522838|NCT03261427|Active Comparator|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
9522839|NCT03261453|Experimental|Treatment|Patients randomized to treatment will receive the Elipse device.
9522840|NCT03261453|Sham Comparator|Control|Patients randomized to the control arm will receive the sham device.
9522841|NCT03261349|Experimental|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
9672168|NCT05039164|Active Comparator|Control Condition (CC)|School behavioral health staff (BHS) in the CC will be trained remotely on providing a brief in-service training to teachers tasked with nominating students on recognizing warning signs of excessive anxiety, depression, and disruptive behavior problems in children. Investigators will offer protected access to asynchronous training materials such as training modules that include didactic content, audio and visual examples, as well as treatment materials and resources, all of which can be viewed at the trainee's individual pace and convenience.
9672169|NCT05039060|Active Comparator|Group 1|Group 1: Modified MAC diet (first 3-weeks) followed by conventional diet (second 3-weeks)
9522842|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
9522843|NCT03261245||Controls|No hypertension disorder during pregnancy
9522844|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
9522845|NCT03261388||ABLE POWER Program|Participants on the Activity-Based Locomotor Exercise Program (ABLE) waitlist will be enrolled prior to beginning the ABLE program. This waiting period will allow outcomes to be compared (in the same participant) before receiving the intervention and after receiving the intervention.
9522846|NCT03261492|Experimental|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
9522847|NCT03261492|Active Comparator|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
9522848|NCT03261375|Experimental|Renal denervation (RDN) Group|
9522849|NCT03261375|Sham Comparator|Control Group|
9522850|NCT03261180|Experimental|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
9522851|NCT03261180|Active Comparator|Group II (regular diet)|Patients receive regular diet.
9522852|NCT03261466|Active Comparator|Active group Bifidobacterium breve BR03 and B632|This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
9522853|NCT03261466|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
9522854|NCT03261414|Experimental|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
10171847|NCT03878706||GLP1 and SGLT2i group|40 patients treated with a combination of liraglutide and empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
9522855|NCT03261414|Active Comparator|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
10171848|NCT03878706||GLP1 group|40 patients treated with liraglutide.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
10171849|NCT03878706||SGLT2i group|40 patients treated with empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
10171850|NCT03878706||Control group|40 patients treated with insulin and metformin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
10171851|NCT03878875||High Noise Exposure|One group (20, 10f:10m) with previous exposure i.e. nightclubs ++
9522856|NCT03261219|Experimental|Intrapulmonary Percussive ventilation|
9522857|NCT03261219|Active Comparator|Chest Physiotherapy vest|
9522858|NCT03261310|Experimental|Acetaminophen & Craniotomy|Drug: Acetaminophen 1000mg administered intravenously during craniotomy
9522859|NCT03261310|Placebo Comparator|Placebo & Craniotomy|Placebo administered intravenously during craniotomy.
9522860|NCT03261310|Experimental|Acetaminophen & Laminectomy|Acetaminophen 1000mg administered intravenously during laminectomy.
9522861|NCT03261310|Placebo Comparator|Placebo & Laminectomy|Placebo administered during laminectomy.
9522862|NCT03261401|Experimental|Part A: M5717|
9522863|NCT03261401|Placebo Comparator|Part A: Placebo|
9522864|NCT03261401|Experimental|Part B: M5717|
9522865|NCT03261401|Placebo Comparator|Part B: Placebo|
9522866|NCT03261401|Experimental|Part C: M5717|
9522867|NCT03261362|Placebo Comparator|Amino acid powder with all amino acids|amino acid powder 80 g oral Administration 1 week
9522868|NCT03261362|Active Comparator|Amino acid powder without BCAAs-reduced intake|Branched-chain amino acids reduced intake - amino acid powder lacking BCAAs 80 g oral Administration 1 week -
9522869|NCT03261661|Experimental|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
9522870|NCT03261661|Experimental|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
9522871|NCT03261661|Active Comparator|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
9522872|NCT03261661|Active Comparator|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
9522873|NCT03261271|Experimental|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
9522874|NCT03261271|Active Comparator|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
9527889|NCT03215836|Other|Non - obese asthmatics|BMI: lean > 20; Normal >/= 20 to <25; overweight </= 25 to < 30;
9527890|NCT03216005|Experimental|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
9527891|NCT03215888||Obese|Obese individuals undergoing bariatric surgery
9527892|NCT03215888||controls|matched non-obese controls
9527893|NCT03215862|Active Comparator|Control|
9522875|NCT03261141||study group sixty three children|"severity and character of dysphonia APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
9522876|NCT03261141||control group sixty three children|"severity and character of dysphonia (APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
9522877|NCT03261102|Active Comparator|Standard clinical care|"Adalimumab induction as per standard clinical care:~Week 0: 160 mg SC~Week 2: 80 mg SC~Followed by 40 mg SC every 2 weeks' maintenance therapy"
9522878|NCT03261102|Active Comparator|Active optimization|"Same as Standard clinical care Arm, except:~If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week~If ADAL trough >15 μg/ml, no dose escalation and continued standard of care dosing"
9522879|NCT03261128||Group D-FOG|Filling of a self-questionnaire before each chemotherapy cure
9522880|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
10171852|NCT03878875||Low Noise Exposure|Group (20, 10f:10m) with less exposure measured through NESI
9522881|NCT03260777||children with Alopecia Areata|
9522882|NCT03260777||children with tinea capitis|
9522883|NCT03260777||children with trichotillomania|
9522884|NCT03260777||children with tractional alopecia|
9522885|NCT03260829|Active Comparator|vitamin C injection|orthodontic traction with vitamin C injection
9522886|NCT03260829|Placebo Comparator|orthodontic traction|orthodontic traction without vitamin C injection
9522887|NCT03260855|Other|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
9522888|NCT03260985|Experimental|Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
9522889|NCT03260985|No Intervention|Delayed Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
9522890|NCT03260972|Active Comparator|Chloroprocaine arm|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
9522891|NCT03260972|Placebo Comparator|Normal saline arm|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
9522892|NCT03260803|Experimental|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
9522893|NCT03260803|Placebo Comparator|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
9522894|NCT03260998||diabetic patients type 1|electrocardiogram will be done for 60 children and adolescents with type 1 diabetes
9522895|NCT03260998||healthy persons|electrocardiogram will be done for 60 age and sex matched non diabetic children and adolescents
9522896|NCT03260816|Experimental|Internet-Delivered Parent Training|Families will receive weekly sessions of Internet-delivered Parent-Child Interaction Therapy (I-PCIT), a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
9522897|NCT03260816|Active Comparator|Referrals as Usual (RAU)|Families in the referrals as usual (RAU) group will be referred to services as usual in their Early Intervention exit interview, which includes a variety of clinic-based mental health services at local community agencies. At each assessment, the access and extent of participation in other services will be monitored.
9522898|NCT03260920|Experimental|Low Dose|
9975229|NCT04173975|No Intervention|Without exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).~Each session will be 45 minutes long. Three time per week, for three weeks.~The patients allocated in this arm will perform the training without any exoskeleton."
9975230|NCT04170296|Experimental|Cohort 1: Posterolateral Thigh|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
9975231|NCT04170296|Experimental|Cohort 2: Buttocks|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
9975232|NCT04167891||Patients admitted in the intensive care unit|Patients with return of spontaneous circulation after cardiac arrest regardless of initial rhythm, and admitted in intensive care unit for post cardiac arrest care
10171853|NCT03879005|Other|Renal scintigraphy|5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.
10171854|NCT03878771|Experimental|autologous Platelet rich fibrin in Orabase (PRF)|applied to oral ulcer and/or mucositis 3 times per day
9522899|NCT03260920|Experimental|Medium Dose|
9522900|NCT03260920|Experimental|High Dose|
9527894|NCT03215862|Experimental|Experimental|
9527895|NCT03215953|Active Comparator|Group A|cast shoe plus standard wound care
9672170|NCT05039060|Placebo Comparator|Group 2|Group 2: Conventional diet (first 3-weeks) followed by modified MAC diet (second 3-weeks)
9672171|NCT05038683|Experimental|HOT|Holbæk Obesity Treament
10171855|NCT03878771|Active Comparator|Clobetasol propionate 0.05%(Dermovate cream) in orabase|applied to oral ulcer and/or mucositis 3 times per day
10171856|NCT03878641|Experimental|Children in Grade 1 to 5 with literacy and language needs|The investigators intend to identify children in Grade 1 to 5 who demonstrate language-based learning difficulties. Using the two-stage screening, the investigators will identify children who produce substantial number of reading miscues and/or self-correct more less 25% of their miscues, and/or who present weaknesses in expressive language skills with a total CUBED score lower than grade-specific cut scores.
10171857|NCT03878810|Experimental|Exergaming, restless legs syndrome (+)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
10171858|NCT03878810|Experimental|Exergaming, restless legs syndrome (-)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
10171859|NCT03878810|No Intervention|Control, restless legs syndrome (+)|No specific intervention.
10171860|NCT03878810|No Intervention|Control, restless legs syndrome (-)|No specific intervention.
10171861|NCT03878784|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigrane infusion (0.4 mg/min) for 10 mins"
10171862|NCT03878784|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
10171863|NCT03878654|Experimental|Tauroursodeoxycholic Acid|TUDCA 1750 mg daily for 12 weeks
10171864|NCT03878628|Experimental|Adipose tissue-derived mesenchymal stem cells|Approximately 11 million ASCs in a 0.5 ml suspension
10171865|NCT03878992|Other|GHD|GHD patients will be studied two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two trial days are identical
10171866|NCT03878732||Caucasian female|
10171867|NCT03878732||Hispanic female|
10171868|NCT03878693|Experimental|A|Oral APAP and IV Fomepizole.
10171869|NCT03878693|Active Comparator|B|Oral APAP.
10171870|NCT03878719|Experimental|Safety Run-in Phase|"binimetinib taken twice daily (BID) and~encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol."
10171871|NCT03878719|Experimental|Expansion Phase|"binimetinib taken twice daily (BID) and~encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol."
10171872|NCT03878667|Placebo Comparator|No Diet|No diet or exercise or calcium intervention
10171873|NCT03878667|Experimental|High Calorie Diet|High calorie (2,600 calorie) diet and exercise and calcium
10171874|NCT03878667|Experimental|Low Carbohydrate/High Protein Diet|Low carbohydrate (63% protein, 7% carbohydrate, 30% fat) diet and exercise and calcium
9522901|NCT03261050||R61 (Phase 1)|In R61, participants are randomly assigned to either the treatment group or the wait-list condition. Participants assigned to the treatment group receive Counter Attitudinal Therapy (CAT). Participants in the treatment group are compared with participants in the wait-list condition. Participants will complete target and outcome measures at pretest and posttest, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. Additionally, at pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Electrocardiography (ECG) data will be collected at pre and post.
9527896|NCT03215953|Active Comparator|Group B|removable walker plus standard wound care
10171875|NCT03878667|Experimental|High Carbohydrate/Low Protein|High carbohydrate (15% protein, 55% carbohydrate, 30% fat) diet and exercise and calcium
10171876|NCT03878576|Active Comparator|REFERENCE: white bread - BGL0 [RP]|Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
10171877|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL2 [IP1]|Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
10171878|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL3 [IP2]|Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
10171879|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL4 [IP3]|Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
10171880|NCT03878329|No Intervention|standard of care|standard of care treatment
9527897|NCT03216018|Experimental|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
9528208|NCT03212677|Active Comparator|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
9672172|NCT05038683|Active Comparator|COT|Conventional Obesity Treatment
9672173|NCT05038774|Experimental|Interventional group|GPs of the Interventional group will receive (1 day) face to face education with structured educational material on strategies of hypertension management by a senior cardiologist.
9672174|NCT05038774|Active Comparator|Control group|GPs of the Control group will receive print version of education material (Structured educational material) on strategies of structured hypertension management.
9672175|NCT05038826||trial 1|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
9672176|NCT05038826||trial 2|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
9672177|NCT05038826||trial 3|RNA-polymerase-II inhibitor
9672178|NCT05038826||trial 4|Tyrosine kinases inhibitor
9522902|NCT03261050||R33 (Phase 2)|In R33, participants from wait-list condition are assigned to receive either Counter Attitudinal Therapy or Interpersonal Therapy. Participants will complete target and outcome measures at pretest and posttest, including a 6-month follow-up, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. At pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Additionally, thin-ideal valuation will be accessed outside the scanner at pre, post and follow-up. Similarly, binge food valuation will be accessed outside the scanner at pre, post, and follow-up and weeks 2, 4, and 6 during treatment for dose-response analysis. Electrocardiography (ECG) data will be collected at pre and post.
9522903|NCT03260907|Experimental|Electroacupuncture|The patients in this group received electroacupuncture using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
9522904|NCT03260907|Experimental|Acupuncture|The patients in this group received acupuncture without electric stimulation using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
10171881|NCT03878329|Experimental|remote home monitoring|use of telemedicine based remote home monitoring
9522905|NCT03261024|Active Comparator|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
9522906|NCT03261024|Active Comparator|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
9522907|NCT03260764|Experimental|group A|
9522908|NCT03260764|Placebo Comparator|group B|
9522909|NCT03260764|Experimental|group C|
9522910|NCT03260764|Placebo Comparator|group D|
10171882|NCT03878368|Experimental|Intervention|32 participants with moderate osteoarthritis will eat soup with the active ingredient once-a-day for 4 days-a-week for 3 months.
10171883|NCT03878368|Active Comparator|Control|32 participants with moderate osteoarthritis will eat soup without the active ingredient once-a-day for 4 days-a-week for 3 months.
9522911|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
9522912|NCT03261063|Experimental|Evera Implanted Group|
9522913|NCT03261011|Experimental|AK-104|Single-arm
9522914|NCT03260751|Experimental|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
9522915|NCT03260751|Placebo Comparator|Placebo|Placebo for 12 weeks
9672179|NCT05038826||trial 5|Tyrosine kinases inhibitor
9672180|NCT05038826||trial 6|Immune checkpoints + chemotherapy vs. chemotherapy + placebo
9672181|NCT05038462|Active Comparator|Maternal supplementation with Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
10171884|NCT03878615||Elective Hepatic Surgery|Patientes undergoing elective hepatic resection, managed according to departement routine.
10171885|NCT03878264|Experimental|Part 1|On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
10171886|NCT03878264|Experimental|Part 2|On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
10171887|NCT03878186|Experimental|Cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT). Participants will receive the usual care and 6 sessions of cognitive behavioral therapy
10171888|NCT03878186|Other|Usual Care (UC)|Participants will receive Usual Care only
9522916|NCT03260738|Experimental|"Robot Poppy group"|30 minutes of daily rehabilitation program (physical exercises dedicated to the mobility of the spine) supervised by Poppy robot during 3 weeks included in a 3hours daily (5 days a week) rehabilitation program.
9522917|NCT03260738|Active Comparator|Control group|Usual 3hours daily (5 days a week) rehabilitation program without robot during 3 weeks
9522918|NCT03260673||the diabetic group|patients with type 2 diabetes scheduled to undergo cataract surgery
9522919|NCT03260673||the control group|patients without diabetes scheduled to undergo cataract surgery
9522920|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals <40 kg the maintenance dose is 100 mg twice daily in oral form.~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
9522921|NCT03261115|No Intervention|Control group|Topical Anesthesia
9522922|NCT03261115|Experimental|Study group|No topical anesthesia
9528209|NCT03212677|No Intervention|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
10171889|NCT03878511|Experimental|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
10171890|NCT03878511|Placebo Comparator|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
10171891|NCT03878433|Active Comparator|Drug|Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast
9522923|NCT03260374||children with cochlear implant|"30 subjects whose age ranges from 2-6 years old who are implanted with Medel multichannel cochlear implant male and female will be included and will undergo:-~Electric compound action potential~Electric stapedial reflex threshold~Electric auditory brain stem response"
9522924|NCT03260439|Other|G1 (group BT)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Tramadol
9522925|NCT03260439|Other|G2 (group B or control)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Placebo
9522926|NCT03260712|Experimental|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem [25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
9522927|NCT03260478|Experimental|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
9522928|NCT03260478|Experimental|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
9522929|NCT03260465|Experimental|seleXys PC|seleXys PC cup combined with the optimys stem
9522930|NCT03260465|Active Comparator|RM|RM Pressfit vitamys cup combined with the optimys stem
9522931|NCT03260361|Experimental|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
9522932|NCT03260361|Other|usual practice|physiopathology and treatments
9522933|NCT03260335|Experimental|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
9522934|NCT03260543|Experimental|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
9522935|NCT03260543|Placebo Comparator|Placebo|Placebo for 12 weeks.
9522936|NCT03260400|Experimental|New Grafts|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the participant will have a shorter surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After another healing period, experiments with prosthetic control and sensory feedback will begin.
9522937|NCT03260400|Experimental|Existing Grafts|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The participant will have a short surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After a healing period, experiments with prosthetic control and sensory feedback will begin.
9522938|NCT03260569|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
9522939|NCT03260569|Placebo Comparator|Placebo|Nitrogen only, administered once during first 36 hours following admission
9522940|NCT03260556|Active Comparator|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
9522941|NCT03260556|Placebo Comparator|Placebos|Placebo titrated to three tablets three times a day
9522942|NCT03260621|Other|echocardiographic increase in left atrial pressure|
9522943|NCT03260621|Other|echocardiographic no increase in left atrial pressure|
9522944|NCT03260608|Experimental|Intervention|Telesupport: eight weekly phone calls of psychoeducation and support on the illness of their relatives. Patients will also receive printed materials on problematic behaviors about dementia.
9522945|NCT03260608|No Intervention|Control|No active intervention. Patients will only receive printed materials on problematic behaviors about dementia and no contact by the research team.
9522946|NCT03260452|Experimental|Patients|'Abdominal subcutaneous biopsies and Blood test'
9522947|NCT03260582|No Intervention|Control arm (n=50)|Patients randomized to the control arm will receive usual cardiac rehabilitation care post-myocardial infarction.
9522948|NCT03260582|Experimental|Intervention arm: LifePod arm (n=100)|In addition to usual cardiac rehabilitation care, patients randomized to the LifePod arm will receive access to the LifePod® support software for six months.
9522949|NCT03260517|Experimental|Treatment arm (Mdt Drug-Coated Balloon)|Medtronic Coronary Drug-Coated Balloon Catheter used for dilatation of the target lesion.
9522950|NCT03260686|Experimental|Video Guided Group|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician. In addition the participants will receive a personalised video guide of their exercises, filmed during their therapy session to use for independent practice when back on the ward.
9522951|NCT03260686|No Intervention|Treatment as usual|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician
9522952|NCT03260725|Experimental|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
9522953|NCT03260725|Active Comparator|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
9522954|NCT03260387||TPIAT|patients undergoing total pancreatectomy with islet autotransplant.
9522955|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
9522956|NCT03260309|Experimental|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
9522957|NCT03260309|Experimental|control group|Routine infusion therapy tactic
9522958|NCT03260283|Experimental|Group I|0.4 mgkg-1 of pethidine hydrochloride
9522959|NCT03260283|Experimental|Group II|2ml of ropivacaine (0.75%) with 15 mcg of fentanyl
9522960|NCT03260296||University students|university students who use smartphones
9522961|NCT03260062|Experimental|PEARLS|Participants in this arm will receive 10 1-hour weekly sessions of the PEARLS intervention
9522962|NCT03260062|Active Comparator|Control|Participants in this arm will receive 10 1-hour weekly sessions of the standard of care LSL Speech Therapy
9522963|NCT03260153|Experimental|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
9672182|NCT05038462|Placebo Comparator|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
9672183|NCT05038566|No Intervention|Comparator Baseline|The subject wears their usual partial hand prosthesis while performing functional outcome measures.
9672184|NCT05038566|Experimental|Pointdexter|The subject wears a modified version of their usual partial hand prosthesis. The modification replaces the usual index finger of the partial hand prosthesis with the investigational Pointdexter device. Subjects will either test out this hand configuration in the lab while performing functional outcome measures or at home in their daily lives for approximately four weeks.
9672185|NCT05038501||Comorbidities in Oncosurgery patients|Prevalence of comorbidities as Coronary artery disease, Hypertension , Diabetes Mellitus,Hypothyroidism and Corona Virus Infection will be studied in patients undergoing Oncosurgeries.
10171892|NCT03878433|Placebo Comparator|No Drug|2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo
9672186|NCT05038488|Experimental|MIB-626|Oral administration of MIB-626 substantially raises the intracellular NAD+ levels and activates signaling mechanisms that regulate inflammation and cell survival, downregulates the NLRP3 inflammasome, and attenuates the inflammatory response in a number of experimental models, and protects against tissue damage induced by pro-inflammatory cytokines.
9672187|NCT05038488|Placebo Comparator|Placebo Tablet|"A placebo control will be supplied. Participants randomized to placebo will receive matching tablet.~Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC."
10171893|NCT03878355|Experimental|radical endoscopic sinus surgery plus Draf 3 surgery|
10171894|NCT03878355|Experimental|radical endoscopic sinus surgery|
10171895|NCT03878355|Experimental|functional endoscopic sinus surgery|
10171896|NCT03878342|Active Comparator|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
10171897|NCT03878342|Experimental|No Radiotherapy|No Irradiation- Active surveillance
10171898|NCT03878225|Active Comparator|Ketone Mono Ester|"The ketone mono ester is commercially available dietary supplement beverage named H.V.M.N. Ketone Ester, marketed by HVMN Inc®. The KME beverage consists of water, D-β-hydroxybutyrate ester, stevia leaf extract, natural flavors, malic acid, potassium sorbate and potassium benzoate. The active ingredient is the D-β-hydroxybutyrate ester, with each dose containing 25g. Participants will be asked to ingest this 5 times daily for 3 days (72 hours), to a total of 15 doses during the study."
9672188|NCT05038488|Other|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
9672189|NCT05038384||Observational (survey)|Participants complete a survey over 20 minutes.
9672190|NCT05038397|Experimental|Therasphere|
9672191|NCT05038696|Experimental|Single arm|Single arm Phase I Clinical Trial
9672192|NCT05038254|Active Comparator|Arm I (standard of care)|Patients receive standard of care consisting of oncology care provided via telemedicine.
9672193|NCT05038254|Experimental|Arm II (standard of care, remote monitoring)|Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.
9672194|NCT05038280|Experimental|Let's Talk about Children intervention|Teachers, students, and parents in Finland, that take part in the LTC -intervention.
9672195|NCT05038280|No Intervention|Control group|The control group includes teachers who do not use the method in their work and students and parents who do not participate in the discussions.
9672196|NCT05038423|Active Comparator|A structured 12-week group walking program|Participants engaged in an evidence-based 12-week walking program.
9672197|NCT05038423|Experimental|A structured 12-week group walking program + 5RS|In addition to the 12-week group walking program, participants engaged in the 5R Shared Leadership Program, which implements a structure of shared leadership and strengthens the identity leadership skills of the appointed peer leaders.
9672198|NCT05038189|Experimental|Ankylosing Spondylitis|Study group
10171899|NCT03878225|Placebo Comparator|Placebo|The placebo beverage will consist of water added with a colorless, bitter flavor enhancer and a sweetening agent (Stevia) to approximate the taste of the KME beverage as closely as possible. The bitter flavor enhancer used is denatonium benzoate (Bitrex®). The placebo beverage will be delivered to patients in bottles identical to those used in the active arm. Patients, investigators and other caregivers will be blinded to treatment allocation until time of database unlock.
10171900|NCT03878238|Placebo Comparator|Placebo|
10171901|NCT03878238|Experimental|Probiotic|
10171902|NCT03878420|Experimental|PBM Treatment|The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
10171903|NCT03878420|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
10171904|NCT03878563||ascites with/without SBP|Cirrhosis with ascites and existing SBP or prior SBP
10171905|NCT03878563||ascites and decreased protein concentrati|Cirrhosis with ascites and decreased protein concentration <1,5 g/d
10171906|NCT03878563||ascites and normal protein concentration|Liver cirrhosis witha scites and protein concentration >1,5 g/d
10171907|NCT03878563||Liver cirrhosis without ascites|Patients with liver corrhosis without ascites
10171908|NCT03878563||Healthy controls without liver cirrhosis or other pathology|Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy
9672199|NCT05038189|Experimental|Non-radiographic Axial Spondyloarthritis|Study group
9672200|NCT05038189|Experimental|Healthy individuals|Control group
9522964|NCT03260153|Placebo Comparator|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
10171909|NCT03878303|Experimental|AC0058TA|AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID
10171910|NCT03878303|Placebo Comparator|Placebo AC0058TA|Placebo AC0058TA will be administered orally at the equivalent dose of investigational product
10171911|NCT03878290|Experimental|8-week RiSE|Participate in 8-week Resilience, Stress, and Ethnicity (RiSE) group based stress reduction program in which participants meet every week for approximately 2 hours for 8 consecutive weeks.
9522965|NCT03260140|Experimental|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
9522966|NCT03260140|No Intervention|usual care control|participant in this arm will continue with usual care
9522967|NCT03260179|Experimental|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
10171912|NCT03878290|No Intervention|Control|Treatment as usual
10171913|NCT03878069||ERT with ADA|Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen
10171914|NCT03878082|Active Comparator|propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
9522968|NCT03260179|Experimental|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
9522969|NCT03260179|Experimental|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
9522970|NCT03260166|Experimental|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
9522971|NCT03260010|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
9522972|NCT03259893|Active Comparator|Standard of care group 1|Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
9522973|NCT03259893|Experimental|Intervention group 2|The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
9522974|NCT03260049||1|there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
9522975|NCT03260049||2|there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
9522976|NCT03260049||3|there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
9522977|NCT03259984||Aim 1|This experiment will use the next generation sequencing reduced representation bisulfite sequencing to define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. The investigators will test the hypotheses that: (a) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (b) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (c) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance.
9522978|NCT03259984||Aim 2|This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and (b) Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise.
9522979|NCT03259984||Aim 3|This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes, (b) There is altered methylation of genes involved in inflammation and cytoskeletal structure.
9522980|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
9522981|NCT03260231|Active Comparator|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
9522982|NCT03260231|No Intervention|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
9522983|NCT03260114|No Intervention|Physical activity recommendations|Participants in this group will be advised to engage in physical activity recommendations from health authorities, i.e., 150 minutes per week of moderate intensity activity or 75 minutes per week of vigourous intensity activity or combination of both that results in same caloric expenditure.
9522984|NCT03260114|Active Comparator|PAI equal to or more than 100|Participants in this group will be advised to obtain a PAI score of 100 or more over a week.
9522985|NCT03260114|Active Comparator|PAI between 50 and 99|Participants in this group will be advised to obtain a PAI score between 50-99 over a week.
9522986|NCT03259906|Active Comparator|Osteosynthesis using a posterior plate|
9522987|NCT03259906|Active Comparator|Osteosynthesis using an anterior plate|
10171915|NCT03878082|Active Comparator|propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
10171916|NCT03878082|Placebo Comparator|IVPCA|pain control with IVPCA
9522988|NCT03259919|Experimental|Metformin|Metformin 850 mg x 2 daily
9522989|NCT03259919|Placebo Comparator|placebo|Placebo 1 tablet x 2 daily
10171917|NCT03877978||Severe traumatized patients|Severe traumatized patients with an Index Severity Score (ISS) ≥ 15 admitted to the trauma center of Edouard Herriot Hospital.
10171918|NCT03877796||Ovarian cancer patients|with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
9522990|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
9522991|NCT03259958|Experimental|Donepezil TDS|Corplex Donepezil TDS 5 mg/day followed by Donepezil TDS 10mg/day applied weekly for 5 consecutive weeks
9522992|NCT03259958|Active Comparator|Aricept|Aricept 5 mg/day followed by Aricept 10 mg/day once daily for 5 consecutive weeks
9522993|NCT03259971|Placebo Comparator|Placebo (for tic disorder)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
9522994|NCT03259971|Active Comparator|PS128 (tic disorder)|The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
9522995|NCT03259971|Placebo Comparator|Placebo (for Rett syndrome)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
9522996|NCT03259971|Active Comparator|PS128 (Rett syndrome)|The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
9522997|NCT03259932|Other|usual management|
9522998|NCT03259932|Experimental|physical training|
9522999|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
9523000|NCT03259997|Active Comparator|Probiotic supplement|
9523001|NCT03259997|Placebo Comparator|Placebo|
9523002|NCT03259854|Active Comparator|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
9523003|NCT03259854|Experimental|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
9523004|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
9523005|NCT03260075||ward cat|Patients and staff at wards that have a cat present
9523006|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
9523007|NCT03259828|Experimental|Adjuvant image-guided radiotherapy|Adjuvant radiotherapy with image guidance via cone beam computed tomography. Treatment is identical to the current standard of care.
9523008|NCT03259750||professional athletes|athlete who volunteered in this study that should be a member of a professional sport team, All athletes must complete self reported outcome instrument (FAAM-T)
9523009|NCT03259412|Experimental|Fish Oil|Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
9523010|NCT03259412|Placebo Comparator|Placebo|Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
9523011|NCT03259464|Experimental|BI 685509|Chinese & Japanese subjects
9523012|NCT03259464|Placebo Comparator|Placebo|Chinese & Japanese subjects
9523013|NCT03259477|Experimental|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
9523014|NCT03259477|Active Comparator|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
9523015|NCT03259529|Experimental|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
9523016|NCT03259529|Experimental|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
9523017|NCT03259529|Experimental|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
9523018|NCT03259516|Experimental|Nivo + FC|Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days
9523019|NCT03259516|Experimental|Nivo + LDAC + ATRA|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd
9523020|NCT03259516|Experimental|Nivo + LDAC + Sildenafil|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid
9523021|NCT03259516|Experimental|Nivo + Melphalan|Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days
9523022|NCT03259516|Experimental|Nivo + 5-aza|Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days
9523023|NCT03259360|Experimental|The Put It Out Project (POP):|a culturally tailored intervention developed for SGM young adults on Facebook
9523024|NCT03259360|Experimental|Tobacco Status Project (TSP):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
9523025|NCT03259594|Experimental|endophytic group|participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
9523026|NCT03259594|Sham Comparator|exophytic group|participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
9528210|NCT03212677|Placebo Comparator|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
9523027|NCT03259659||irritable bowel disease patient|Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
9523028|NCT03259659||healthy control|Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
10171919|NCT03877705|Experimental|Dissolving xylitol chewable tablets|Listerine ready tabs 3 times/day
10171920|NCT03877705|Active Comparator|Xylitol chewing gum|Trident original 3 times/day
9523029|NCT03259399||wild genotype|Detection of genotype will be carried out through next generation sequencing, distinguish wild genotype of enalapril
9523030|NCT03259399||mutant genotype|Detection of genotype will be carried out through next generation sequencing, distinguish mutant genotype of enalapril
9527898|NCT03216018|No Intervention|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
9527899|NCT03215914|Experimental|Subjects with type 1 diabetes using MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
9527900|NCT03215797|Active Comparator|phenylephrine and norepinephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of perioperative hypotension.
9527901|NCT03215797|Other|Norepinephrine and phenylephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion in postoperative time in case of hypotension
9527902|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
9527903|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
9527904|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
10171921|NCT03878017|Experimental|skin marking of clipped axillary LN|all eligible patients underwent skin marking of their clipped axillary LN post neoadjuvant chemotherapy to determine the retrieval rate of the clipped nodes
9527905|NCT03215693|Experimental|X-396 capsule|225mg once daily
9527906|NCT03216057|Experimental|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 grams of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega Rx Dr.Sears Zone labs Inc.
9527907|NCT03216057|Placebo Comparator|Placebo|Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
9527908|NCT03216070|Experimental|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
10171922|NCT03877718|Experimental|Arm 1: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)
9527909|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
9527910|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
10171923|NCT03877718|Experimental|Arm 2: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)
10171924|NCT03877718|Experimental|Arm 3: Sumatriptan succinate 100 mg|Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg
10171925|NCT03877718|Experimental|Arm 4: Promethazine HCl 18.75 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg
10171926|NCT03877718|Experimental|Arm 5: Promethazine HCl 37.5 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg
10171927|NCT03877718|Experimental|Arm 6: Placebo|Maximum dose within a 24 hour period: One capsule of placebo
10171928|NCT03878043||Patients without Readmissions|Patients with TSDH who were not readmitted within a 6-month time period following their initial visit.
10171929|NCT03878043||Patients with Readmissions|Patients with TSDH who were readmitted within a 6-month time period following their initial visit.
9527911|NCT03215602|Experimental|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension & leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
9528211|NCT03212677|Experimental|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 120 mg Fe per day) for 4 weeks.
9523031|NCT03259646|Experimental|Universal Education|Train providers to integrate screening, universal education, trauma informed counseling, and mobile health (mHealth) technology through the myPlan app safety decision aid in collaboration with local IPV programs as well as the integration of documentation and quality improvement templates and measures into clinical settings.
9523032|NCT03259646|No Intervention|Standard Practice|Standard clinical practice
9523033|NCT03259672|Active Comparator|Sevoflurane|
9523034|NCT03259672|Experimental|Desflurane|
9523035|NCT03259607|Experimental|Treatment A|Nicorette Extra Mint 2 mg Gum
9523036|NCT03259607|Active Comparator|Treatment B|Nicorette Mint 2 mg Gum
9523037|NCT03259607|Experimental|Treatment C|Nicorette Extra Mint 4 mg Gum
9523038|NCT03259607|Active Comparator|Treatment D|Nicorette Mint 4 mg Gum
9523039|NCT03259685|Active Comparator|Regular beverages|Sugar sweetened soft drinks
9523040|NCT03259685|Experimental|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
9523041|NCT03259685|Experimental|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
9523042|NCT03259542|Experimental|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
9523043|NCT03259438|Experimental|Qigong|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include guided instruction in the theory and background of qigong and healing. Practice will include gentle stretching and guided qigong movement as well as seated and lying down meditations. Participants will be asked to complete about 30 minutes a day of home assignments.
9523044|NCT03259438|Active Comparator|Healthy Living (CHIP + Pre-Train)|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) as well as core-stretching, strengthening, and light aerobic movements through a Pre-Train exercise program. Participants will be asked to complete about 30 minutes a day of home assignments.
9523045|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
9523046|NCT03259620|Experimental|CLS006|Furosemide Topical Gel, 0.125%
9523047|NCT03259620|Experimental|CLS006 Vehicle|Vehicle Topical Gel
9523048|NCT03259347|Experimental|Counter-attitudinal therapy|Counter-attitudinal therapy (CAT) is dissonance-based group intervention. CAT consists of behavioral, written, and verbal exercises in which participants discuss the costs of pursuing the thin ideal and behaviors that are used to pursue the thin ideal. The intervention is 8 sessions long (1-hr each) and is administered by a trained facilitator who uses an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
9523049|NCT03259347|Active Comparator|Educational-support group|The educational support group intervention that is representative of typical treatment groups offered at universities and community settings. For the current study, the educational support group was designed to match the dissonance group on treatment modality (group-based), duration (8 1-hr sessions), and use of an intervention script administered by a trained facilitator. In the intervention sessions, participants will be provided with a basic education about eating disorders, support for themselves and fellow group members, and learn mindfulness techniques.Participants will be asked to complete weekly homework assignments.
10171930|NCT03877952|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.
9523050|NCT03259295|Experimental|Skin tag removal initial|Removal of skin tags 1 cm or less using Digiclamp
9523051|NCT03259295|Experimental|Skin tag removal follow-up|Follow-up 2-3 months after skin tag removal.
9523052|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|
9523053|NCT03259230||Absence of HLH in patients diagnosed with malignancy|
9523054|NCT03259152|Experimental|Pre-Denosumab GctB|Specimens obtained during biopsy
9523055|NCT03259152|Experimental|Post-Denosumab GctB|Specimen after administration of Denosumab
9523056|NCT03258944|Experimental|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session
9523057|NCT03259256|Experimental|Allogeneic transplantation of human islet|Each subject may receive 1-3 transplantations of allogeneic human islets we will inject the least dose of 3,000 IEQ/kg body weight of the recipient. Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml.
9523058|NCT03259217|Experimental|stem cell product|stem cell transplant
9523059|NCT03259113|Other|Insertable cardiac monitor|All patients will undergo monitoring using an insertable cardiac monitor (single arm)
9523060|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
9523061|NCT03259269||Delamanid and companion WHO Group 5 drugs|
9523062|NCT03259191|Other|completely circumferential ARMS|
9523063|NCT03259191|Other|semi-circumferential ARMS|
9523064|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
9523065|NCT03259126|Experimental|SCUT|"Use of a Small Curtain under table (SCUT) placed under the cranial part of the angiographic table"
9523066|NCT03259126|No Intervention|Control|Control Group without the SCUT
9523067|NCT03258931|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
10171931|NCT03877965||Children with single ventricle congenital heart disease|Receiving digoxin per standard of care during the interstage period
9523068|NCT03258931|Active Comparator|Midostaurin|Midostaurin following salvage chemotherapy
9523069|NCT03259048||pediatric group|pediatric group from age of one day to eighteen years.
9523070|NCT03258957|Experimental|Fresh milk group|In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
9523071|NCT03258983||The Diet, Cancer and Health cohort|
10171932|NCT03877588|Other|Primary retroperitoneal sarcoma|All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition.
10171933|NCT03877835|Other|Ropivacaine|SSNB will be performed with 4 ml ropivacaine 5 mg/ml LSIB will be performed With 15 ml ropivacaine 7.5 mg/ml
10171934|NCT03877848||ACS and Non-ACS|"DAPT will be stopped at 30 days in non-ACS subjects while at ACS Patients it may be maintained for up to 3 months. In patients with ACS or with an ischemic event during the first 30 days, DAPT may be continued at the discretion of the investigator. In ACS patients DAPT should be continued for a maximum of 3 months. For patients with recurrent ischemic events duration of DAPT therapy will be at the discretion of the investigator.~Patients receiving long-term oral anticoagulation with either a Vitamin K inhibitor or a NOAC/DOAC will receive either single antiplatelet therapy with clopidogrel, or DAPT for 30 days (triple therapy) followed by single antiplatelet therapy with clopidogrel. Clopidogrel (75 mg QD) will be given to these patients post procedure for 6 months in stable patients and 12 months in ACS patients."
9523072|NCT03258918|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
9523073|NCT03259243|Placebo Comparator|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
10171935|NCT03877939||Non-pregnant patients|Patients with β-hCG test < 10 UI/L.
9523074|NCT03259243|Experimental|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
9523075|NCT03259243|Experimental|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
9523076|NCT03259243|Experimental|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
9523077|NCT03258840|Placebo Comparator|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
10171936|NCT03877939||Patients with viable pregnancy|Patients with β-hCG test > 10 UI/L whose pregnancy is confirmed between gestational weeks 6 and 8.
9523078|NCT03258840|Active Comparator|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
9523079|NCT03258801||Pirfenidone|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are treated with Pirfenidone as bridging therapy.
9523080|NCT03258801||Control|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are not treated with Pirfenidone.
9523081|NCT03258775|Active Comparator|250ml|
9523082|NCT03258775|Active Comparator|500ml|
9523083|NCT03258827|Experimental|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
9523084|NCT03258827|Placebo Comparator|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
9523085|NCT03258788||Non-Small Cell Lung Cancer|Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.
9523086|NCT03258684|Active Comparator|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
9523087|NCT03258684|Placebo Comparator|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
9523088|NCT03258892|Experimental|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
9523089|NCT03258892|Experimental|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
9523090|NCT03258697|No Intervention|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
9523091|NCT03258697|Active Comparator|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
9523092|NCT03258697|Experimental|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
9523093|NCT03258866|Experimental|group A|In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22).
9523094|NCT03258866|Experimental|group B|In group B, Rituximab was given with a single dose of 375mg/m2
9523095|NCT03258879|Experimental|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
9523096|NCT03258879|Active Comparator|Dural puncture epidural|Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.
9523097|NCT03258736|Other|Caudal block|Caudal block Marcaine
9672201|NCT05038540|Experimental|Virtual reality application|Application of virtual reality glasses during scaling and root planning to a quadrant.
9523098|NCT03258736|Other|ilionguinal/iliohypogastric block|ilionguinal/iliohypogastric block Marcaine
9523099|NCT03258749|Active Comparator|Formoterol|inhaled formoterol(4.5μg, bid)
9523100|NCT03258749|Experimental|Tiotropium|inhaled Tiotropium(18μg, qd)
9523101|NCT03258723|Experimental|Intervention|Highest risk pre-diabetic patients
9528212|NCT03212677|Experimental|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
9523102|NCT03258723|No Intervention|Control|Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited. ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups.
9672202|NCT05038540|Active Comparator|No application|No application of virtual reality glasses during scaling and root planning to a quadrant.
9672203|NCT05038371||Patients with neovascular age-related macular degeneration|This will include 10 subjects with a diagnosis of age-related macular degeneration.
9672204|NCT05038371||Controls|This group will comprise 10 participants who plan to undergo vitrectomy for macular hole, macular pucker, or vitreomacular traction, vitreous floaters or another condition unrelated to scarring.
9672205|NCT05038293|Experimental|Automated mouthpiece-based toothbrush|Under observation of study staff, participants assigned to the automated mouthpiece-based toothbrush will insert a properly fitted mouthpiece and use the automated device directly over the sink.
9672206|NCT05038293|Active Comparator|Manual toothbrush|Under observation of study staff, participants assigned to the manual toothbrush will be timed brushing their teeth directly over the sink using a pre-dispensed quantity of toothpaste on bristles dampened with water.
9672207|NCT05038072|Experimental|4 mg Triamcinolone Acetonide (TA)/ Suprachoriodal Injection|Suprachoroidal injection of 4 mg in 100 μL of TA was administered as a single injection.
9672208|NCT05038046|Experimental|TCM daycare model|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
9672209|NCT05038046|No Intervention|Control group|15 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
9672210|NCT05038007|Active Comparator|Control|Bupivacaine Hydrochloride in perioperative intercostal blockades
10171937|NCT03877939||Patients with biochemical pregnancy|Patients with β-hCG test > 10 UI/L and without sac observed.
9672211|NCT05038007|Experimental|Intervention|Liposomal bupivacaine in perioperative intercostal blockades
9672212|NCT05038267||Femous patients|Adults undergoing general anesthesia for an elective cardiac surgery requiring cardiopulmonary bypass
10171938|NCT03877939||Patients with ectopic pregnancy|Patients with β-hCG test > 10 UI/L whose sac is implantated outside the uterine cavity.
9672213|NCT05038319|Active Comparator|Cyanoacrylate injection and EUS guided coil and glue injection|The procedure would be performed under conscious sedation.The endoscope would be used to reach the site of Varices. In Conventional technique treatment with cyanoacrylate the injection was performed using a 23-G sclerotherapy needle catheter . One vial of N-butyl-2-cyanoacrylate (0.5 mL) was mixed with Lipiodol) in a 1:1 ratio, and injected intravesically as a 1 mL bolus. The injection was repeated until total hardening of the varix. In treatment with coil and cyanoacrylate once the gastric varix was identified, the total diameter of the vascular pseudotumor was measured and the puncture was made at the site of the widest varix. The puncture was performed using a 19 G needle . the size of the coil after release should not be greater than the caliber of the vessel. Following coil deployment, 2 mL of distilled water was injected, followed by one vial (0.5 mL) of N-butyl-2-cyanoacrylate mixed with Lipiodol in 1:1 ratio.
9672214|NCT05038319|Placebo Comparator|COIL and GLUE|"Cyanoacrylate injection, first published by Soehendra in 1986, remains the conventional treatment method.~Since coils were first used to treat ectopic varices by Levy in 2008(6), this technique has been increasingly implemented into clinical practice. However, its higher cost has been a limiting factor in more widespread use.~Depending on the ectasia of the varix the following coil was deployed: 8 mm x 20 cm, 10 mm x 20 cm, or 10 mm x 30 cm (Interlock-18 Fibered IDC Occlusion System,Cook)."
9672215|NCT05038410|Active Comparator|Wobenzym®|Medicinal product Wobenzym® containing Bromelain (67.5-76.5 mg) adjusted to 450 FIP units, Trypsin (32-48mg) adjusted to 24 µkat and Rutoside trihydrate (100mg).
9672216|NCT05038410|Placebo Comparator|PLACEBO|No active ingredients. The active ingredients will be substituted by microcrystalline cellulose.
9672217|NCT05038111||Dex|Dexmedetomidine infusion during the perioperative period
9975233|NCT04163887|Other|laparoscopic liver resection|Laparoscopy allows some surgical procedures to be performed through small incisions that enable the operator to access the abdominal cavity, often at the pubic area, and surgical instruments are introduced through these small incisions. This technique avoids large abdominal incisions and significantly reduces the duration of hospitalization.
9975234|NCT04163887|Other|open liver resection|standard of care
10171939|NCT03877939||Patients with clinical miscarriage|Patients with β-hCG test > 10 UI/L whose sac is implanted inside the uterine cavity, but non-viable pregnancy is confirmed before gestational week 8.
9523103|NCT03258671|Experimental|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
9523104|NCT03258671|Experimental|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
9672218|NCT05038111||Non-Dex|Did not have dexmedetomidine infusion during the perioperative period
9975235|NCT04156620|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
10171940|NCT03877861||Readiband Sleep Tracking - Patient|This group is comprised of 25 participants with a diagnosis of primary Grade IV glioma. A Readiband™ Sleep Tracker device will be provided to each participant, along with necessary instructions. Participantswill return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits.
10171941|NCT03877861||Readiband Sleep Tracking - Control|Aggregate fatigue data and sleep patterns for a group of 30 healthy controls procured from FatigueScience in a de-identified manner for data analysis purposes.
9523105|NCT03258528|Active Comparator|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
9523106|NCT03258528|Active Comparator|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.~Infants were fed while in their positions via feeding tube."
9523107|NCT03258515|Experimental|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
9523108|NCT03258515|Experimental|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
9523109|NCT03258515|Experimental|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
9523110|NCT03258515|Experimental|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
9523111|NCT03258515|Experimental|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
9523112|NCT03258515|Experimental|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
9523113|NCT03258372|Experimental|Cohort 1|Mifepristone 300 MG, 1 tablet
9523114|NCT03258372|Experimental|Cohort 2|Mifepristone 1500 MG, 5 tablets
9523115|NCT03258229|Experimental|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
9523116|NCT03258229|Placebo Comparator|Placebo|Placebo for 8 weeks
9523117|NCT03258333||Stented bioprosthesis|Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.
9523118|NCT03258333||Ozaki procedure|Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
9523119|NCT03258359|Experimental|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
9523120|NCT03258346|Experimental|Exercise and Pomegranate Juice|Exercise training with daily consumption of pomegranate juice containing polyphenols
9523121|NCT03258346|Placebo Comparator|Exercise and Placebo|Exercise training with daily consumption of pomegranate juice with polyphenols removed
9523122|NCT03258385|Active Comparator|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
9523123|NCT03258385|Placebo Comparator|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
9523124|NCT03258502|Experimental|RV521|RV521 drug substance in capsule for oral administration
9523125|NCT03258502|Placebo Comparator|Placebo|Micro-crystalline cellulose in capsule for oral administration
9523126|NCT03258424|Active Comparator|PTI-428|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
9826658|NCT02427607|Experimental|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) [NCT02307578]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
9523127|NCT03258424|Placebo Comparator|Placebo|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
9523128|NCT03258411|Active Comparator|Haas group (H)|Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)).
9523129|NCT03258411|Active Comparator|Hyrax (Hx)|Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)).
9523130|NCT03258411|Active Comparator|Miniscrew-supported (MHx)|Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx))
9523131|NCT03258255|Active Comparator|Pudendal block group in circumcision|Nerve stimulated pudendal nerve block performed under general anesthesia
10171942|NCT03877536|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
10171943|NCT03877549|Placebo Comparator|Placebo|10cc 0.0625% bupivacaine
10171944|NCT03877549|Experimental|Low Dose|4mg Dexamethasone + 10cc 0.0625% bupivacaine
9523132|NCT03258255|Active Comparator|Penil block group in circumcision|Penil block performed by surgeon under general anesthesia
9523133|NCT03258450|Experimental|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
9826659|NCT02427646|Experimental|ET BoNT-A treatment|ET participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
9826660|NCT02427646|Experimental|PD tremor BoNT-A treatment|PD participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
9975236|NCT04156620|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
9975237|NCT04138797|Experimental|Electrophysiological exploration & ECG Biosemi|
9523134|NCT03258450|No Intervention|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
9523135|NCT03258307|Active Comparator|omentectomy|Preoperative
9523136|NCT03258307|Other|Omentectomy|Postoperative
9523137|NCT03258307|Other|No omentectomy|Preoperative post operative
9523138|NCT03258268|Experimental|Standard of Care with DSS|"Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
9523139|NCT03258268|Active Comparator|Standard of Care without DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
9523140|NCT03258463||Time Period 1|Women who obtained an abortion from January 1 2012-December 31 2012
9523141|NCT03258463||Time Period 2|Women who obtained an abortion from May 1 2014-April 30 2015.
9523142|NCT03258476|Experimental|GXR and Mindfulness Skills|Guanfacine Extended Release (GXR) will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). GXR dosing will be flexible for the first 5 weeks of the study based upon patient response and tolerability to drug. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks.
9523143|NCT03258476|Active Comparator|Placebo and Mindfulness Skills|"Placebo will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). Placebo dosing will be flexible for the first 5 weeks of the study based upon patient response. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks."
9523144|NCT03258294|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
9523145|NCT03258294|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
9523146|NCT03258398|Experimental|Part 1: eFT508 plus avelumab dose finding Arm|subjects will receive eFT508 in combination with a fixed dose of avelumab
9523147|NCT03258398|Experimental|Part 2: eFT508 plus avelumab|subjects will receive eFT508 in combination with a fixed dose of avelumab
9523148|NCT03258398|Experimental|Part 2: eFT508 alone|subjects will receive eFT508 alone
9523149|NCT03258437|Experimental|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
9523150|NCT03258437|Placebo Comparator|Placebo|Placebo for 12 weeks.
9523151|NCT03258320|Experimental|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.~Procedure: radical prostatectomy surgery."
9523152|NCT03258320|No Intervention|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
9523153|NCT03258073|Experimental|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
9523154|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
9523155|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
9523156|NCT03258008|Experimental|Utomilumab + ISA101b|"Utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day 1.~ISA101b as an injection under the skin every 4 weeks for 3 doses. Participants receive 2 injections each time."
9523157|NCT03257956|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
9523158|NCT03257956|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
9523159|NCT03258489|Active Comparator|Transcutaneous nervous electric stimulation (TENS)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after TENS. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
9528213|NCT03212677|Experimental|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
9672219|NCT05038202|Experimental|Bencycloquidium Bromide|Bencycloquidium Bromide Nasal Spray (90μg per spray)：1 spray on each nostril, 4times per day, continuous treatment for 4 weeks (28days).
9672220|NCT05038202|Active Comparator|Mometasone Furoate Aqueous|Mometasone Furoate Aqueous Nasal Spray (50μg per spray)：2 sprays on each nostril, 1 time per day, continuous treatment for 4 weeks (28days).
9975238|NCT04129905|Experimental|Symptomatic HCM patients|30 subjects (25-26 sarcomeric, 4-5 Fabry).
9975239|NCT04129905|Active Comparator|Healthy controls subjects|10 subjects (matched in age and sex to HCM patients) to obtain reference values of endothelial dysfunction.
10171945|NCT03877549|Experimental|Higher Dose|8mg Dexamethasone + 10cc 0.0625% bupivacaine
9523160|NCT03258489|Active Comparator|Interferential electrical stimulation (IES)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after Interferential electrical stimulation (IES). The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
9523161|NCT03258489|Placebo Comparator|TENS and IES Placebo|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after of the TENS and IES placebo. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
9523162|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
9523163|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
9523164|NCT03258242|Experimental|Experimental: Keluo Xin Capsule|
9523165|NCT03258242|Placebo Comparator|Placebo Comparator: Placebo|
9523166|NCT03258086|Experimental|Blood sample|2ml blood sample of of blood will be taken for assessment of vitamin D
9523167|NCT03258047|Experimental|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
9523168|NCT03258099||wild genotype|Through next generation sequencing, distinguish wild genotype of capecitabine
9523169|NCT03258099||mutant genotype|Through next generation sequencing, distinguish mutant genotype of capecitabine
9523170|NCT03258060|Active Comparator|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
9523171|NCT03258060|Active Comparator|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
9523172|NCT03258034|Experimental|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
9523173|NCT03257930|Experimental|injection of ethanol|use of ethanol injection in the treatment of cystic thyroid nodule
9523174|NCT03258190|Experimental|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
9523175|NCT03258190|Placebo Comparator|Placebo|Participants were asked to take Placebo twice a day for 6 months
9523176|NCT03258021||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
9523177|NCT03258112|Other|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
9523178|NCT03258164|Experimental|ASC|
9523179|NCT03258164|Active Comparator|Control|
9523180|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein >2000 mg/d).
10171946|NCT03877809|Experimental|Open label trial|Sirolimus 0.5 mg tablets
10171947|NCT03877874||Asthmatic children|"Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily~Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)."
9523181|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
9523182|NCT03257943|Experimental|Ivermectin Lotion, 0.5%|One 10 minute application, under at-home use conditions
9523183|NCT03257943|Active Comparator|SKLICE (ivermectin) Lotion, 0.5%|One 10 minute application, under at-home use conditions
9523184|NCT03257943|Placebo Comparator|Vehicle of the Test product|One 10 minute application, under at-home use conditions
9523185|NCT03258203|Experimental|diet 1|diet with moderate in fat (40% energy) and protein(15%)
9523186|NCT03258203|Experimental|diet 2|diet with moderate in fat (40% energy) and protein(25%)
9523187|NCT03258203|Experimental|diet 3|diet with low in fat (20% energy) and protein(15%)
9523188|NCT03258203|Experimental|diet 4|diet with low in fat (20% energy) and protein(25%)
9975240|NCT04101461|Active Comparator|Group I: 27 mg elemental iron|will receive PharaFerro27; Devart Lab Company, Egypt; once daily starting at 12 -14 weeks until 37-38 weeks
9975241|NCT04101461|Active Comparator|Group II: 54 mg elemental iron|will receive two tablets of PharaFerro27; Devart Lab Company, Egypt; daily starting at 12 -14 weeks until 37-38 weeks
9523191|NCT03257982|Experimental|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
9523192|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
9523193|NCT03257670|Active Comparator|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
9523194|NCT03257670|Active Comparator|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
9523195|NCT03257722|Experimental|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
9528214|NCT03212677|Experimental|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving IHAT (containing 120 mg Fe per day) for 4 weeks
10171948|NCT03877874||Non-Asthmatic children|no intervention
9523196|NCT03257722|Experimental|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
9523197|NCT03257644|Experimental|Cohort 1|Ruxolitinib phosphate cream 0.5%.
9523198|NCT03257644|Experimental|Cohort 2|Ruxolitinib phosphate cream 1.5%.
9523199|NCT03257644|Experimental|Cohort 3|Ruxolitinib phosphate cream 0.75%.
9523200|NCT03257644|Experimental|Cohort 4|Ruxolitinib phosphate cream 1.5%.
9975242|NCT04100798|Experimental|Entire Papilla Preservation (EPP) technique|A minimally invasive surgical technique that involves using a vertical incision away from the defect area in order to preserve the integrity of the related interdental papilla and elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
9975243|NCT04100798|Active Comparator|Modified Minimally invasive Surgical Technique (M-MIST)|A minimally invasive surgical technique that involves using a horizontal interdental incision that extends to the buccal aspect of the two teeth adjacent to the intraosseous defect then elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
10171949|NCT03877731|Active Comparator|hypertrophic cariomyopathy, isolated septal myectomy|Patients with hypertrophic obstructive cardiomyopathy who will undergo isolated septal myectomy
9523201|NCT03257644|Experimental|Cohort 5|Ruxolitinib phosphate cream 0.75%.
9523202|NCT03257644|Experimental|Cohort 6|Ruxolitinib phosphate cream 1.5%.
9975244|NCT04096417|Experimental|Treatment (pemigatinib)|Patients receive pemigatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
9523203|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
9523204|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
9523205|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
9523206|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
10171950|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + edge-to-edge|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and edge-to-edge mitral valve repair (O. Alfieri technique)
9523207|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
9527912|NCT03215602|Active Comparator|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
9527913|NCT03215641|No Intervention|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
9527914|NCT03215641|Experimental|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
9975245|NCT04091022|Active Comparator|Diclofenac + DFMO|Participants in this arm will apply topical diclofenac to bilateral forearms once per day and topical DFMO to bilateral forearms once per day.
10171951|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + sliding plasty|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and posterior leaflet sliding plasty ( A. Carpentier technique)
10171952|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + chordae|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and secondary chordae transection
9527915|NCT03215654|Experimental|Sensitization Program (SP)|Include the concepts of mental health and mental disorder, healthy and risky behaviors of mental health, and use of health services. Duration 1 hour.
9527916|NCT03215654|Experimental|Mental Health Literacy Program (MHL)|MHL module contents are: 1) Our emotions. Definitions of mental health and mental disorders. Mental health multidisciplinary team network; 2) Healthy and risky behaviors of mental health; 3) Social skills and antisocial behavior, bullying and cyberbullying; 4) Anxiety, depression, self-harm, and suicidal behaviors; 5) Eating and behavioral disorders; 6) Substance abuse (alcohol and cannabis), an psychotic disorder. Duration 6 hours.
9527917|NCT03215654|Experimental|MHL more Stigma Reduction (ER)|Includes the six teaching units of MHL and a first contact presentation with lived experience of any mental disorder, who will be delivered by a voluntary member of Activament Catalunya Associació (http://www.activament.org/es), a non-profit group specialized in reducing stigma. Duration 7 hours.
9527918|NCT03215654|No Intervention|Control group|Control group will be a waiting list condition and they will receive the full program of 7h at the next year of academic course
9527919|NCT03215615|Active Comparator|Group NF + TE|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with nanofilled resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
9527920|NCT03215615|Active Comparator|Group NF + UA|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with nanofilled resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
9662265|NCT04936581||Open Total Mesorectal Excision|Patients undergoing open low anterior resection
9662266|NCT04936581||Laparoscopic Total Mesorectal Excision|Patients undergoing laparoscopic low anterior resection
9662267|NCT04936581||Robotic Total Mesorectal Excision|Patients undergoing robotic low anterior resection
9662268|NCT04936581||Transanal Total Mesorectal Excision|Patients undergoing transanal Total Mesorectal Excision (taTME)
9523208|NCT03257709|Active Comparator|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
9975246|NCT04091022|Placebo Comparator|Placebo + Placebo|Participants in this arm will apply placebo for topical diclofenac to bilateral forearms once per day and placebo for topical DFMO to bilateral forearms once per day.
9975247|NCT04090775|Other|Single arm. Subjects receiving treatment.|Cryosurgical freezing and intratumoral combination immunotherapy as determined by the proportion of patients achieving serum PSA decline from baseline of at least 50%.
9523209|NCT03257709|Active Comparator|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
9523210|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
9523211|NCT03257592|Experimental|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713
10171953|NCT03877731|No Intervention|Arterial hypertension + left ventricular hypertrophy|Patients with arterial hypertension with left ventricular hypertrophy whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
10171954|NCT03877731|No Intervention|Control|Patients without structural heart disease whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
10171955|NCT03877627|No Intervention|Negative 1|Patients in this arm will not undergo Pelvic and Peritoneal Lymphadenectomy.
9523212|NCT03257592|Experimental|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with [11C] DPA-713
9523213|NCT03257592|Experimental|Control|Normal volunteers will be imaged with [11C] DPA-713
9523214|NCT03257852|Experimental|ASP5094 Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
9523215|NCT03257852|Placebo Comparator|Placebo Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
9523216|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
9523217|NCT03257891|Experimental|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
9523218|NCT03257826|Experimental|surgery|Percutaneous Kirschner wire
9523219|NCT03257553|Experimental|intervention arm|do fecal calprotectin, doppler and ultrasound for each patient
9523220|NCT03257514|Active Comparator|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
9523221|NCT03257514|Placebo Comparator|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
9523222|NCT03257527|Experimental|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
9523223|NCT03257527|Active Comparator|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
10171956|NCT03877627|Experimental|Negative 2|Patients in this arm will undergo Pelvic and Peritoneal Lymphadenectomy.
10171957|NCT03877692|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg, 80mg after each severe BP
10171958|NCT03877692|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg, 60mg after each severe BP
9523224|NCT03257787|Experimental|Test of a new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation.
9523225|NCT03257774|Experimental|Test of three new adhesive strips|"The subjects test three new adhesive strips~adhesive strip A~adhesive strip B~adhesive strip C"
9523226|NCT03257800|Active Comparator|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
9523227|NCT03257800|Placebo Comparator|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
9523228|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
9523229|NCT03257423|Active Comparator|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
9975248|NCT04084080|Experimental|Exchange transfusion plus standard of care|Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months.
9975249|NCT04084080|Active Comparator|Standard of care|Randomized to standard of care
9523230|NCT03257423|Placebo Comparator|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
9523231|NCT03257423|Other|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
9523232|NCT03257423|Other|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
9523233|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
9523234|NCT03257540||Small Bone Intramedullary Nail|All study participants
9523235|NCT03257748|Experimental|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
9523236|NCT03257748|Experimental|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
9523237|NCT03257397|Experimental|left iTBS and right cTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC
9523238|NCT03257397|Active Comparator|left and right iTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)
10171959|NCT03877783|Experimental|group of intervention|"participants receive~personalized advice of a dietician about mediterranean diet~individualized training program,~recommendation about optimized pharmacological treatment as in high risk groups for cardiovascular diseases"
9523239|NCT03257488|Active Comparator|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
9523240|NCT03257488|Active Comparator|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
9523241|NCT03257306|Active Comparator|Magnetic double-J ureteric stent|Double-J ureteric stent removed using magnet
9523242|NCT03257306|Active Comparator|Standard double-J ureteric stent|Double-J stent removed using cystoscopy
9523243|NCT03257332||EDFI Cohort|Subjects should have received surgery for rectal cancer (low anterior resection).
9523244|NCT03257319|Experimental|inhaled morphine + IV placebo|Arm A: inhaled titration of morphine chlorhydrate+ IV placebo
9523245|NCT03257319|Placebo Comparator|IV morphine +inhaled placebo|Arm B:IV titration of morphine chlorhydrate + inhaled placebo
9523246|NCT03257462|Experimental|Cohort A|The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
9523247|NCT03257462|Experimental|Cohort B|Cohort B will begin enrollment after Cohort A has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
9523248|NCT03257462|Experimental|Cohort C|Cohort C will begin enrollment after Cohort B has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort C will be determined by an interim review of safety and PK/PD data from from Cohort A and B.
9523249|NCT03257293|Active Comparator|Routine Cystoscopy|
9523250|NCT03257293|Experimental|Modified Cystoscopy|
9523251|NCT03257280|Experimental|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
9975250|NCT04069299||Participants receiving PET scan|Participants with metastatic poorly-differentiated neuroendocrine carcinomas of the GI tract
10171960|NCT03877783|No Intervention|group of control|"participants receive~written information about the advantages of a healthy diet~written information about the advantages of physical activity,~medical treatment according to the latest version of the national guidelines issued by the Swedish Medical Product Agency"
9523252|NCT03257280|No Intervention|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
9523253|NCT03257241|Active Comparator|A arm (DA-90)|"Induction I:~DNR 90 mg/m2 D 1-3 in 30-60 min i.v. infusion~Ara-C 100 mg/m2 D 1-7 in 24 h i.v. infusion"
9523254|NCT03257241|Active Comparator|B arm (DAC)|"Induction I:~DNR 60 mg/m2 D 1-3 in 30-60 min i.v. infusion~cladribine 5 mg/m2 D 1-5 in 2 h i.v. infusion prior to Ara-C~Ara-C 200 mg/m2 D 1-7 in 22 h i.v. infusion."
9975251|NCT04068753|Experimental|Niraparib + dostarlimab|
10171961|NCT03877523|Experimental|Cocarnit|disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg
10171962|NCT03877679|Experimental|turmeric paste|Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).
10171963|NCT03877679|Active Comparator|Triamcenolone in orabase|Triamcenolone + na ploycarboxylate
9523255|NCT03257241|Active Comparator|A arm (CLAG-M)|Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
9523256|NCT03257241|Active Comparator|B arm (FLAG-IDA)|Fludarabine 30 mg/m2 in 30-min i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after fludarabine infusion on days (1-5). Idarubicin 8 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
9523257|NCT03257228||oral lichen planus and diabetes mellitus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
9523258|NCT03257228||oral lichen planus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
9523259|NCT03257228||healthy mucosa|Samples of healthy mucosa underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking mucosa samples.
9523260|NCT03257176|Experimental|Stepping Stones and Creating Futures|Receive the 21 session intervention
10171964|NCT03877614||Cardiovascular high-risk (disease) group|A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
9523262|NCT03257215|Active Comparator|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
9523263|NCT03257215|Active Comparator|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
9523264|NCT03257215|Placebo Comparator|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
9523265|NCT03257098|Experimental|allo-APZ2-CVU|Application of IMP on patients wound
9523266|NCT03257137|Experimental|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
9523267|NCT03257137|Experimental|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
9523268|NCT03257124|Experimental|AZD9291 in BM or LM cohort in T790M positive|"Brain metastasis cohort (BM cohort)~Leptomeningeal metastasis cohort (LM cohort)"
9523269|NCT03257072|Experimental|A: 50 Necator americanus L3 larvae|Mock infections with water at week 0 and 2, infection with 50 Necator americanus L3 larvae at week 4
9523270|NCT03257072|Experimental|B: 100 Necator americanus L3 larvae|Mock infections with water at week 0, infection with 50 Necator americanus L3 larvae at week 2 and 4
9523271|NCT03257072|Experimental|C: 150 Necator americanus L3 larvae|Infection with 50 Necator americanus L3 larvae at week 0, 2 and 4
9523272|NCT03257059|Experimental|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
9523273|NCT03257059|Experimental|No breakfast|Subject not given breakfast to test blood glucose response
9523274|NCT03256929|Experimental|depression participants - intervention|personalized diet intervention based on microbiota analysis and health status
9523275|NCT03256929|Experimental|depression participants - control|General information on nutrition and health
9523276|NCT03256929|Experimental|pre-depression participants - control|General information on nutrition and health for pre-depression participants
9523277|NCT03256929|Experimental|pre-depression participants - intervention|personalized diet intervention based on microbiota analysis and health status for pre-depression participants
9523278|NCT03257007|No Intervention|Usual Care|Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
9523279|NCT03257007|Active Comparator|Mindfulness|The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
9523280|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure < 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
9523281|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
9523282|NCT03257085|Experimental|Low-carbohydrate, high-fat|Participants adhering to low-carbohydrate, high-fat diet for 8 weeks.
10171965|NCT03877614||Cardiovascular Low-risk (control) group|Patient with only risk factors with ASCVD score<10% will be recognized as the comparison group
9523283|NCT03257085|Experimental|High-carbohydrate, moderate fat|Participants following high-carbohydrate, moderate-fat diet for 8 weeks.
9523284|NCT03256942|Experimental|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.~Single injection session, injections into the lips."
9523285|NCT03256942|No Intervention|No Treatment|
9523286|NCT03256981|Experimental|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.~Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 3."
9523287|NCT03256981|Active Comparator|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
9523288|NCT03256955|Other|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
9523289|NCT03257046|Experimental|1 mg ITI-214|Administered once daily for 7 days
10171966|NCT03877640|Active Comparator|Active EMSELLA treatment|6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology
10171967|NCT03877640|Sham Comparator|Sham EMSELLA treatment|6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology
9523290|NCT03257046|Experimental|3 mg ITI-214|Administered once daily for 7 days
9523291|NCT03257046|Experimental|10 mg ITI-214|Administered once daily for 7 days
9523292|NCT03257046|Experimental|30 mg ITI-214|Administered once daily for 7 days
9523293|NCT03257046|Experimental|90 mg ITI-214|Administered once daily for 7 days
9523294|NCT03257046|Placebo Comparator|Placebo|Administered once daily for 7 days
9523295|NCT03256890|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
9523296|NCT03256890|Active Comparator|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
9523297|NCT03256903|Experimental|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
9672221|NCT05038202|Experimental|Bencycloquidium Bromide with Mometasone Furoate Aqueous|Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray: For Bencycloquidium Bromide Nasal Spray(90μg per spray), 1 spray on each nostril, 4times per day. For Mometasone Furoate Aqueous Nasal Spray (50μg per spray), 2 sprays on each nostril, 1 time per day. If there is an overlap between the two drugs, use Bencycloquidium Bromide Nasal Spray first, and then mometasone furoate nasal spray should be used after an interval of more than 30 minutes.
10171968|NCT03878004|Experimental|Primary Group|135 people who will receive the vaccine in the therapeutic scheme
10171969|NCT03878004|Placebo Comparator|Placebo Group|45 people who will receive placebo in the therapeutic scheme
9523298|NCT03256903|Active Comparator|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
9523299|NCT03256877||All participants|Patients with haematuria.
10171970|NCT03877562|Experimental|Olanzapine plus CORT118335|Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.
10171971|NCT03877562|Placebo Comparator|Olanzapine plus Placebo|Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.
10171972|NCT03877497|Experimental|SBIRT-A|The screening, brief intervention and referral to treatment (SBIRT) will be adapted and used as the intervention in the experimental arm
10171973|NCT03877497|Active Comparator|INFO-C|The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT format via printed and audio-visual study material
10171974|NCT03877601|Experimental|Topical administration of bevacizumab-800CW|The tracer will be topically administered 5 minutes prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform).
10171975|NCT03877328|Experimental|Virtual Coach|BiotechCoachForAll
10186992|NCT03730701|Experimental|Prevention treatment group|Prevention program with 10 week blended intervention utilizing both a digital health app, group-sessions with peers and a interprofessional team of health-care workers chairing 5+1 themed group-sessions as support to change lifestyle habits in to a pattern of activities (behaviors and actions) in everyday life that can promote health and wellbeing and decrease risk for stroke. Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
9672222|NCT05038215|Experimental|multifactor intervention|The experimental group will receive adherence promotion techniques in addition to routine care.
9523300|NCT03256604||Fresh left-over sputum|All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples).
9523301|NCT03256721|Experimental|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
9672223|NCT05038215|Active Comparator|Control|The control group will receive routine care
10171976|NCT03877302|Experimental|reflexology group|In addition to providing routine nursing/midwifery care, foot reflexology was applied by the researcher to the pregnant women in the experimental group in the active phase of labor (dilatation 4 cm). By giving appropriate position to the pregnant women, the massage was done to both feet for totally 10 minutes including 5 minutes for each foot starting from right foot under the supervision of a doctor. Whereupon, the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. As reflex points of the feet for manual pressure in labor pain; 1: Solar Plexus, 2: Hypothalamus, 3: Pituitary, 4: Spleen, 5: Thyroid Gland, 6: Adrenal, 7: Intestine, 8: Spinal Cord 9: Uterus, Vagina, Ovaries and Fallopian Tubes were studied.
10171977|NCT03877302|No Intervention|Control Group|The control group received only routine treatment, care, and practices of the hospital. Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI FORM TX-I) were evaluated 2 times as in active (4-7 cm) and transition (8-10 cm) phases in the pregnant women in the control group. After the delivery, the Birth Satisfaction Scale was applied to the women by the researcher.
10171978|NCT03877471|Experimental|Low dosage|The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.
9523302|NCT03256721|Active Comparator|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
9672224|NCT05038228||NVAF High GI bleed risk|NVAF patients with a high risk of gastrointestinal bleeding
9672225|NCT05038449|Experimental|Colchicine group|"The colchicine treatment includes an initial dose of 1 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 6 days and 0.5 mg every 24 hours until the completion of 10 days of total treatment.~+ standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)."
9977515|NCT01362452|Experimental|Double Umbilical Cord Blood (UCB)|"Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation."
10171979|NCT03877471|Experimental|Medium dosage|The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.
10171980|NCT03877471|Experimental|High dosage|The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary.
10171981|NCT03877263|Other|OB/GYN physician-collected vaginal swab|"Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
9672226|NCT05038449|Placebo Comparator|Standard therapy group|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition).
9672227|NCT05038059|Active Comparator|1. Ethylene diammine tetra acetic acid group|samples will be rinsed with ethylene diamine tetra acetic acid group, which is the gold standard for final rinse and compares with the experimental group.
10171982|NCT03877263|Other|Patient-collected vaginal swab|"Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
10171983|NCT03877198|Experimental|CLiO2|Automated oxygen control by the CLiO2 algorithm
10171984|NCT03877198|Experimental|Oxygenie|Automated oxygen control by the Oxygenie algorithm
10171985|NCT03877315|Active Comparator|Stemmed|Subjects operated with stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
10171986|NCT03877315|Active Comparator|Non-Stemmed|Subjects operated with stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
10171987|NCT03877367|Experimental|Upper Extremity Group, Day 1|"Day 1: This group will receive a pre-test, upper extremity intervention, and post-test.~Day 2: This group will receive a pre-test, lower extremity intervention, and post-test."
10171988|NCT03877367|Experimental|Lower Extremity Group, Day 2|"Day 1: This group will receive a pre-test, lower extremity intervention, and post-test.~Day 2: This group will receive a pre-test, upper extremity intervention, and post-test."
10171989|NCT03877445|Other|Melasma Group exposed left half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
10171990|NCT03877445|Other|Melasma Group exposed right half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
10171991|NCT03877250||Non Small Cell Lung Cancer (NSCLC)|Participants with pathologically confirmed newly diagnosed or recurrent advanced NSCLC that is PD-L1 high by immunohistochemistry
9523303|NCT03256656|Experimental|Healthy subjects|
9523304|NCT03256656|Active Comparator|Patients with SCI|
9523305|NCT03256838|Experimental|Ferric citrate|Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).
9523306|NCT03256539|Experimental|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
10171992|NCT03877406|Active Comparator|Control group|up-titration of standard medication including monotherapy or combination of Metformin, Sulfonylurea, DPP4 inhibitor
10171993|NCT03877406|Experimental|Study group|addition of empagliflozin 10mg qd on standard oral antihyperglycemic agents
10171994|NCT03877393|Experimental|PRO-GFD|Probiotic supplementation + gluten-free diet
10171995|NCT03877393|Placebo Comparator|PLA-GFD|Placebo supplementation + gluten-free diet
9523307|NCT03256539|Placebo Comparator|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
9523308|NCT03256760|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
9523309|NCT03256760|Placebo Comparator|Placebo|Placebo
9523310|NCT03256747|Experimental|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
9523311|NCT03256747|Placebo Comparator|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
9523312|NCT03256669|Experimental|umbilical incision|neonates undergone surgery by umbilical incision
9523313|NCT03256682|Experimental|Mobile Video Counseling|Utilize mobile imaging equipment, receive a total of 4 stress management consultations every 50 minutes at a time, once a week.
9523314|NCT03256682|Active Comparator|Offline Counseling|Receive a total of 4 stress management counseling, once a week for 50 minutes each session.
9523315|NCT03256682|No Intervention|Selfcare|Use stress management materials to manage yourself.
9523316|NCT03256825|Other|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
9523317|NCT03256825|Other|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
9523318|NCT03256864|Experimental|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
9523319|NCT03256864|Experimental|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
9523320|NCT03256812|Experimental|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
10171996|NCT03877393|Experimental|PRO-GD|Probiotic supplementation + gluten-containing diet
10171997|NCT03877393|Placebo Comparator|PLA-GD|Placebo supplementation + gluten-containing diet
10171998|NCT03877172|No Intervention|Face-mask oxygen therapy|Oxygen delivered through a conventional face mask to keep saturation above 92%.
10171999|NCT03877172|Active Comparator|High-flow nasal cannula|High-flow nasal cannula delivered at 50 L/min and FiO2 adjusted to keep saturation above 92%.
10172000|NCT03877185||3-Injection-Protocol Group|Women in group A (3-Injection-Protocol Group) receive a bolus late luteal dose of Degarelix, a new long acting GnRH antagonist, a sole Elonva injection in the early follicular phase followed by the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to the individual response).
9523321|NCT03256812|Active Comparator|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
9523322|NCT03256643|Experimental|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
9523323|NCT03256643|Experimental|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
9523324|NCT03256643|Experimental|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
9523325|NCT03256617|Experimental|Provider training|
9523326|NCT03256500|Experimental|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
9523327|NCT03256500|Sham Comparator|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
9523328|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
10172001|NCT03877185||Multiple-Injection- Protocol Group|Women assigned to group B (Multiple- Injection- Protocol Group) are administered a single dose of Elonva (corifollitropin alfa) in the early follicular phase followed by daily GnRH antagonist doses, either fixed on day 6 of the stimulation cycle, or when 2 or 3 follicles over 12-14 mm are present. Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a, accordingly.
10172002|NCT03877146|No Intervention|Usual Care Control Condition|As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
10172003|NCT03877146|Experimental|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
10172004|NCT03877120|Sham Comparator|Dexmedetomidine|"Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.~Dosage form: DEX 0.2-0.7 mcg/Kg/min."
9523329|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
9523330|NCT03256513|Experimental|model controlling|an statistical model for periprocedural blood pressure control
9523331|NCT03256513|Active Comparator|conventional controlling|an conventional strategy for periprocedural blood pressure control
9523332|NCT03256487|Experimental|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
9523333|NCT03256487|Active Comparator|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
9523334|NCT03256708|Experimental|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
9523335|NCT03256708|Placebo Comparator|Placebo|Inactive ingredients
9523336|NCT03256591|Experimental|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
9523337|NCT03256591|No Intervention|Control|Participants receive training from facilitators for HBB training without simulation skills
9523338|NCT03256461|Experimental|Lactate clearance 10% target group|Lactate clearance falls by 10-percent every two hours.
9523339|NCT03256461|Experimental|Lactate clearance 20% target group|Lactate clearance falls by 20-percent every two hours.
9523340|NCT03256461|Placebo Comparator|Standard EGDT group|Refer to the Surviving Sepsis Campaign(SSC) 2012 sepsis guidelines within 6 h liquid resuscitation.
9523341|NCT03256331|Experimental|BEL-X-HG|3+3 dose escalation
9523342|NCT03256409|Experimental|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
9523343|NCT03256409|Experimental|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
9523344|NCT03256370||Infants with allergic diseases|allergic disease : atopic dermatitis or food allergy
9523345|NCT03256370||Healthy infants with atopic mothers|atopic mothers : mothers with asthma or allergic rhinitis or allergic dermatitis (diagnosed by doctors)
9523346|NCT03256370||Healthy infants with non-atopic mothers.|non-atopic mothers : mothers without history of asthma or allergic rhinitis or allergic dermatitis
9523347|NCT03256266||healthy controls|healthy controls
9523348|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
9523349|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
9523350|NCT03256279|Experimental|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
9523351|NCT03256279|Active Comparator|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
9523352|NCT03256084|Experimental|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
9523353|NCT03256383||Adult|Patients aged 18+ years
9523354|NCT03256383||Children 7 - 17|Patients aged 7 - 17 years
9523355|NCT03256383||Children <7|Patients aged under 7 years
9523356|NCT03256058|Active Comparator|Reinflation after early deflation|The tourniquet would be inflated immediately before incision and deflated after the use of the cement, and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation.The total time of tourniquet inflation is controlled within 90 minutes.
9523357|NCT03256058|Placebo Comparator|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
9523358|NCT03256110|Experimental|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
9523359|NCT03256110|No Intervention|Control|Patients and providers in this arm receive usual care.
9523360|NCT03256396|Experimental|Group E|PEEP set according to esophageal pressure measured
9523361|NCT03256396|No Intervention|Group C|PEEP set at 5 cm H2O
9523362|NCT03256123|Experimental|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
9672228|NCT05038059|No Intervention|2. Control group|no final irrigant will be used and evaluate the outcomes
9523363|NCT03256123|Placebo Comparator|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
9523364|NCT03256045|Experimental|Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay|Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
9523365|NCT03256149|Experimental|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
9523366|NCT03256149|Placebo Comparator|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
10172005|NCT03877120|Active Comparator|Diazepam|Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam
10172006|NCT03877003|Experimental|Egg Intake|Consumption of 3 eggs per day for breakfast during 4 weeks
9523367|NCT03256071|Experimental|Decitabine plus Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.
9672229|NCT05038059|Experimental|3. Experimental group|final irrigation of root canal will be done with ethanolic extract of sapindus mukorossi
9672230|NCT05038033|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy program adapted for the prevention of excessive weight gain. Involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
9672231|NCT05038033|Active Comparator|Cognitive-Behavioral Therapy (CBT)|The CBT program will match the delivery format and dose of the IPT program. There will be one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions.
9672232|NCT05037903|Experimental|Cognitive-behavioral therapy|Cognitive-behavioral therapy, including behavioral exercises and homework assignments.
10172007|NCT03877003|Experimental|Choline Supplement Intake|Consumption of choline supplement 1.5 tablets (approx. 400 mg) with breakfast for 4 weeks
10172008|NCT03877081|Experimental|Probiotics. Intervention patients|This patients will receive 2 doses of oral probiotics a day, for seven days
10172009|NCT03877081|Placebo Comparator|Placebo group|This patients will receive 2 doses of oral placebo a day, for seven days
9672233|NCT05037604||Cases|Patients diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
9672234|NCT05037604||Control|Patients not diagnosed with dermatoporosis. A clinical history, physical examination, and application of a previously validated diagnostic self-questionnaire were performed.
9672235|NCT05037890|Active Comparator|Plant sterol enriched margarine|20 grams plant sterol enriched margarine on a daily basis for a period of 6 months.
9672236|NCT05037890|Active Comparator|Plant stanol enriched margarine|20 grams plant stanol enriched margarine on a daily basis for a period of 6 months.
9672237|NCT05037890|Placebo Comparator|Control margarine|20 grams control margarine on a daily basis for a period of 6 months.
9672238|NCT05037773|Experimental|Group 1|In this condition, the intervention is administered immediately after the baseline.
9672239|NCT05037773|Experimental|Group 2 (waiting-list group)|This group is both a control and an experimental group. Indeed, the intervention (i.e., the same as for group 1) is administered but after a second baseline which is held after the completion of the Group 1. This condition will allow to check the specific efficiency of the intervention.
10172010|NCT03877107|Other|single cohort|Participants presenting at least 2/3 of symptom triad : gait disturbance, urinary symptoms and cognitive disturbance Ventricular enlargement non explained by cortical atrophy Cognitive capacity to understand the study and give informed consent (mini mental state > 13), speaking and reading french.
10172011|NCT03877068|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Patients will wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days. In addition, patients will undergo POC testing before meals and bedtime per hospital protocol. Insulin therapy will be titrated based on daily CGM printouts, which will include BG readings, glycemic excursions, hypoglycemia and severe hyperglycemia values throughout the day. Patients will wear a CGM in the current approved insertion site, the abdomen, and in the upper arm.
10172012|NCT03877068|Active Comparator|POC BG - Point-of-Care Blood Glucose monitoring|Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded in the electronic medical record (EMR) system. The research team together with the PCP team will adjust daily insulin orders based on POC readings (standard of care). In addition, patients will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, PCP or research teams).
10172013|NCT03877016|Active Comparator|TENS Eco2|TENS Eco2 is the classical device in patients with chronic neuropathic pain
9672240|NCT05037643|Experimental|Pre-emptive TIPS in Cystic Fibrosis Related Liver Disease and non-cirrhotic portal hypertension|"Patients with CFLD without cirrhosis were eligible for a pre-emptive TIPS, when early (asymptomatic) signs of portal hypertension. All procedures were performed under general anaesthesia by an experienced interventional radiologist. Depending on the patient's age and physiognomy, TIPS was created following a conventional transjugular technique as for adults or by a dedicated combined percutaneous transhepatic-transjugular (PIPS) approach for small children. Routinely, an expanded polytetrafluoroethylene-covered endoprosthesis was used for shunt creation. If the sheath could not be negotiated into the main portal vein, a self-expandable, non-covered stent was placed. We did not pursue a minimum gradient reduction.~Percutaneous liver biopsy was performed during TIPS procedure to confirm the diagnosis of fibrosis or cirrhosis."
9672241|NCT05037682|Other|Primary Care Practices|Dissemination and Implementation Research
9672242|NCT05037513|Active Comparator|CDC-PrEP|1 session PrEP education following CDC guidelines delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
9672243|NCT05037513|Experimental|SBCM-PrEP|Multi-session Strengths-Based Case Management intervention adapted for PrEP related educational content delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting
10172014|NCT03877016|Experimental|actiTENS|ActiTENS is a new TENS device, that seems less cotraining.
9523368|NCT03256071|Active Comparator|Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.
9523369|NCT03256175|Experimental|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
9523370|NCT03256175|Placebo Comparator|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
9523371|NCT03256292||testosterone, diet, and increased physical activity|Group receiving standard of care consisting of diet and regular exercise counseling + testosterone replacement therapy
9523372|NCT03256305|Experimental|"personalized rTMS+drug treatment"|"Received personalized rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks"
9523373|NCT03256305|Active Comparator|Traditional rTMS +drug treatment|Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
9523374|NCT03256357|Active Comparator|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
9523375|NCT03256357|Placebo Comparator|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
9523376|NCT03256318||Children in Sports and Rec|Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
9523377|NCT03256318||Comparison Children|Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
9523378|NCT03256214|Experimental|Closed suction system|Patients in mechanical ventilation were aspirated with closed suction system.
9672244|NCT05037578|Experimental|Project Grace|This intervention will be delivered through church-based multilevel activities by trained church leaders using religiously/ culturally-tailored study materials (sermon guides, responsive readings, educational games, brochures, educational/testimonial videos) packaged in a culturally-tailored. Intervention churches will receive the Project Grace Tool Kit and intervention implementation directions to seek cognitive screening. These churches will hold a Project Grace Kickoff event, where a sermon, and other tool kit materials will be distributed. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities over 4 months. Delivery of intervention components will coincide with existing, multilevel activities that occur in churches through: a) churchwide services, b) outreach ministry groups; and c) individual level activities (e.g., text/voice/email health promotion messages from church) over 4 months.
10172015|NCT03876899|Active Comparator|Evening Primrose Oil|
10172016|NCT03876899|Placebo Comparator|Placebo|
9523379|NCT03256214|Active Comparator|Open suction system|Patients in mechanical ventilation were aspirated with open suction system.
9523380|NCT03256188|Experimental|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
9527921|NCT03215615|Active Comparator|Group MH + TE|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with micro-hybrid resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
9527922|NCT03215615|Active Comparator|Group MH + UA|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with micro-hybrid resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
9528215|NCT03212677|Experimental|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
9528216|NCT03212859|Experimental|Coach2Move Intervention Group|Coach2Move Intervention Group
10172017|NCT03876925|Experimental|CT053PTSA|60-100mg
10172018|NCT03877042|Experimental|Experimental|Patients with end-stage knee disease need Total Knee Arthroplasty in both knees.
10172019|NCT03876912|Experimental|GnRH antagonist|Administration of GnRH antagonist (subcutaneous injection, 240 mg) after baseline 18F-PSMA 1007 PET/CT.Then 18F-PSMA 1007 PET/CT is repeated 3 weeks after ADT and at development of CRPC
10172020|NCT03876951|Experimental|vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery
10172021|NCT03876860|Active Comparator|Standard Dilator|Participants in control arm (active comparator) will receive standard vaginal dilator with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
10172022|NCT03876860|Experimental|Silicone Dilator|Participants in experimental arm will receive standard vaginal dilator with addition of silicone ring with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
10172023|NCT03876704|Experimental|High dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
10186993|NCT03730701|No Intervention|Standard treatment group|Usal care in Swedish primary health care. In addition a Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
9523381|NCT03256422|Experimental|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
9523382|NCT03256422|Active Comparator|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
9523383|NCT03256019|Active Comparator|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
9523384|NCT03256019|Active Comparator|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
9523385|NCT03255707|Experimental|Group A|50 patients will receive the gold standard occlusion therapy
9523386|NCT03255707|Experimental|Group B|50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
9523387|NCT03255811|Experimental|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
9523388|NCT03255694|Experimental|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
9523389|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - anodal|Transcranial direct current stimulation - anodal (positive) 1.5 millamps for 15 minutes
9523390|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - cathodal|Transcranial direct current stimulation - cathodal (negative) 1.5 millamps for 15 minutes
9523391|NCT03255837|Sham Comparator|Transcranial direct current stimulation (tDCS) - sham|Transcranial direct current stimulation - sham session 15 minutes
9523392|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
9523393|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
9523394|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
9523395|NCT03255889|Active Comparator|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
9523396|NCT03255889|Placebo Comparator|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
9523397|NCT03255863|Other|Questionnaire|Auto and hetero questionnaire
9523398|NCT03255876|Experimental|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
9523399|NCT03255876|Placebo Comparator|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
9523400|NCT03255681|Experimental|Split face study|Split face study with the left side of the face receiving PRP injections and the right side of the face receiving PRP with 0.1cc of 10% calcium chloride per 1mL of PRP. The volume of PRP will be used upon the discretion of the provider for treatment of the cosmetic facial deformity but will be in equal amounts for each side on every patient participating in the study.
9523401|NCT03255785|Experimental|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
9523402|NCT03255798|Other|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
9523403|NCT03255642|Active Comparator|Melatonin 2mg|4 weeks of 2mg of prolonged release Melatonin
9523404|NCT03255642|Placebo Comparator|ClonazePAM 0.5 MG|4 weeks of 0.5mg of rivotril
9523405|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
9523406|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
9523407|NCT03255759|Active Comparator|Molecular dx arm|Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
9523408|NCT03255759|No Intervention|Standard of care arm|Positive blood cultures are treated as per normal lab protocol (biochemical identification)
9523409|NCT03255954|Experimental|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
9523410|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
9523411|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
9523412|NCT03255629|Experimental|Treatment Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
9523413|NCT03255629|Placebo Comparator|Control Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
9523414|NCT03255616|Experimental|Healthy subjects|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
9523415|NCT03255616|Experimental|Low back pain patients|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
9523416|NCT03255603|Experimental|Modified potato starch|Modified potato starch is a resistant starch type IV and will be used as an experimental arm.
10172024|NCT03876704|Active Comparator|Conventional dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A，40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
9523417|NCT03255603|Experimental|Modified corn starch|Modified corn starch is a resistant starch type IV and will be used as an experimental arm.
10172025|NCT03876691||Do not resuscitate|Patients who are suggested to family about a do-not-resuscitate order treatment by physicians.
10172026|NCT03876756||PAUR (postpartum acute urinary retention)|patients presenting postpartum acute urinary retention.
9523418|NCT03255603|Experimental|Modified tapioca starch|Modified tapioca starch is a resistant starch type IV and will be used as an experimental arm.
9523419|NCT03255603|Placebo Comparator|Corn starch|Corn starch is digestible and will therefore will be used as a placebo control for the study.
9523420|NCT03255395|Experimental|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
9523421|NCT03255525|Active Comparator|Deep friction massage P50|In this group it was applied a pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
9523422|NCT03255525|Experimental|Deep friction massage P25|In this group it was applied the percentile 25, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
9523423|NCT03255525|Experimental|Deep friction massage P75|In this group it was applied the percentile 75, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
10172027|NCT03876756||Control|patients without postpartum acute urinary retention. This group was selected randomly, respecting a 1:1 matching criteria, including the year of delivery and the age of the patient at delivery.
10172028|NCT03876938|Active Comparator|aprepitant|aprepitant / dexamethasone/ ondansetron
9523424|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
10172029|NCT03876938|Experimental|olanzapine 10 mg|olanzapine 10 mg/dexamethasone/ ondansetron
10172030|NCT03876938|Experimental|olanzapine 5 mg|olanzapine 5 mg/dexamethasone/ ondansetron
9523425|NCT03255538|Experimental|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
9523426|NCT03255538|Experimental|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
9523427|NCT03255538|Experimental|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
9523428|NCT03255538|No Intervention|Control session|In this group, the participants will rest for 15 minutes
9523429|NCT03255369||Child exposed Zika virus proved|child born to mothers with proved zika virus in pregnancy by RT-PCR
9523430|NCT03255369||Child exposed to zika virus suspected|Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
9523431|NCT03255369||Normal Child|Normal child from mothers without Zika (IgG and IgM negative)
9523432|NCT03255226|Experimental|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
10172031|NCT03876782||IOLMaster group|IOL power for all cataract participants will be measured with IOLMaster and Verion
9523433|NCT03255408|Active Comparator|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
9523434|NCT03255408|Experimental|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
9523435|NCT03255408|Sham Comparator|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
9523436|NCT03255408|Placebo Comparator|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
9523437|NCT03255447|Experimental|Immunoadsorption therapy|Peptide GAM immunoadsorption therapy
9523438|NCT03255317|Experimental|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
9523439|NCT03255278|Experimental|Safety and portable study group|"12 persons who have got a single decreased dose (0.25 of the planned dose for regular administration) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: single GamTBvac vaccination (0.25 dose)."
9523440|NCT03255278|Placebo Comparator|Placebo safety study group|12 persons who have got a single dose of placebo (0.5 ml). The intervention for the Arm: Placebo administration (0.5 ml)
10172032|NCT03876626|Other|Provider Participants|Employees who work with medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as providers. Provider participants will receive access to a web based system that allows them to view information for their enrolled clients, securely message clients, and track medication refills. Providers will be asked to participate in a 30-day usability interview and a end-of-study assessment.
10172033|NCT03876626|Other|Patient Participants|Clients who receive medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as patients. Patient participants will be provided access to a mobile app that allows them to track their mood, stress, and medication adherence, access an anonymous online community, securely message providers, and receive medication refill alerts
10172034|NCT03876886|Active Comparator|AC-T(dose-dense)|A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）
9523441|NCT03255278|Experimental|Immunogenicity study group #1|"12 persons who will get a double sequential administration of the decreased dose (0.25 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.25 dose)."
9523442|NCT03255278|Experimental|Immunogenicity study group #2|"12 persons who will get a double sequential administration of the mean dose (0.5 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.5 dose)."
9523443|NCT03255278|Experimental|Immunogenicity study group #3|"12 persons who will get a double sequential administration of the maximum (regular) dose of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (1.0 dose)."
9523444|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
9523445|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
9523446|NCT03255343|Experimental|IMDENDRIM|
9523447|NCT03255330|Experimental|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
9523448|NCT03255330|Active Comparator|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
9523449|NCT03255473|Active Comparator|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
9523450|NCT03255473|Active Comparator|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
9523451|NCT03255356||Cohort|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
9827516|NCT02459119|Experimental|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
9523452|NCT03255499|Experimental|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
9523453|NCT03255499|Experimental|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
9523454|NCT03255499|Experimental|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
9523455|NCT03255499|Active Comparator|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
9523456|NCT03255577|Experimental|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
9523457|NCT03255486|Experimental|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
9523458|NCT03255265||Acute rejection|
9523459|NCT03255265||No acute rejection|
9523460|NCT03255239|Experimental|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
9523461|NCT03255239|Experimental|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
9523462|NCT03255239|Experimental|Suture repair|Ventral hernia repair using suture repair
9523463|NCT03255304|Experimental|health prime|
9523464|NCT03255304|Experimental|palatability prime|
9523465|NCT03255213|Experimental|Late Onset Pompe Disease who have tongue weakness|
9523466|NCT03255148|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
9523467|NCT03255148|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
9523468|NCT03255161|Experimental|Immediate communication education and support group|
9523469|NCT03255161|No Intervention|Waitlist|
9523470|NCT03255135|Experimental|HIFU|Patients with untreated recent diagnosed localized prostate cancer candidates of focal therapy.
9827517|NCT02459197|Active Comparator|T4P1001|
10172035|NCT03876886|Experimental|TP(dose-dense)|T: paclitaxel (PTX） P: carboplatin (CBP)
10172036|NCT03876600|Experimental|conventional hospitalization management.|"The patients who are randomized to have a conventional hospitalization for the pacemaker replacement have conventional management.~In this management patient come to hospital one day before this surgical operation and he is operated next day"
9523471|NCT03254862|Experimental|Group A: CSS & AsynS|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
9523472|NCT03254862|Experimental|Group B: CSS & AsynR|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
9528217|NCT03212859|Active Comparator|Usual Care|Usual care physiotherapy among older adults
9662269|NCT04931251|Other|Financial Navigation|includes a financial toxicity screening measure (COST), baseline and post-intervention surveys, and approximately 2-6 visits with a financial navigator to identify financial assistance resources
9827518|NCT02459197|Sham Comparator|Placebo|
9827519|NCT02459262|Active Comparator|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
9827520|NCT02459262|Placebo Comparator|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
9523473|NCT03254888||Low Grade group|"• 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy ,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) ."
9523474|NCT03254888||High Grade group|"• 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) ."
9523475|NCT03254888||Safety margin group|"• 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor),~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)."
9523476|NCT03254888||Control group|"• 50 (age and sex matched )control~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).."
9523477|NCT03254849|Experimental|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
9672245|NCT05037578|Active Comparator|Standard Control|Standard information churches will receive standard dementia education information. These churches will receive: a) non-tailored project materials collected from mental health organizations and b) standard community-based mental health screening events) coordinated by their Community Health Liaisons. These churches will receive all Project Grace Tool Kit materials and implementation training after the completion of assessments.
9672246|NCT05037695|Experimental|empagliflozin + OMT|empagliflozin 25mg - Daily - at least 15 days before the PCI procedure OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
9672247|NCT05037695|No Intervention|OMT|OMT - Optimized Medical Therapy - conventional drug therapy with oral antidiabetics and/or insulin plus use of anti-platelet, anti-hypertensive and lipid-lowering agents necessary to obtain adequate values for pressure, lipid control and glycemia, in accordance with international guidelines and protocols. Strategies to reduce Contrast-induced acute kidney injury will be used in both study arms
10172037|NCT03876600|Active Comparator|ambulatory management|"The patients who are randomized to have a ambulatory surgery for the pacemaker replacement have ambulatory management.~In the ambulatory hospitalization patients come to hospital and have a surgical operation the same day"
9672248|NCT05037591|Placebo Comparator|placebo A|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672249|NCT05037591|Placebo Comparator|placebo B|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672250|NCT05037591|Placebo Comparator|placebo C|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672251|NCT05037591|Placebo Comparator|placebo D|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672252|NCT05037591|Placebo Comparator|placebo E|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672253|NCT05037591|Placebo Comparator|placebo F|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672254|NCT05037591|Placebo Comparator|placebo G|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672255|NCT05037591|Placebo Comparator|placebo H|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672256|NCT05037591|Placebo Comparator|placebo I|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672257|NCT05037591|Placebo Comparator|placebo J|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672258|NCT05037591|Placebo Comparator|placebo K|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9827521|NCT02459275|Experimental|PEP uP Protocol|Participants will receive the PEP uP protocol with the pro motility agent. The intervention will be provided until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
10172038|NCT03876444|Experimental|Intervention arm|Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day
10172039|NCT03876444|Active Comparator|Control|Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day
10172040|NCT03876405|Experimental|sensory feedback|"A non-invasive air-mediated sensory feedback system embedded in the prosthesis socket.~Group description: Individuals with acquired forearm amputation."
10172041|NCT03876353|Other|Left Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
9523478|NCT03254849|Experimental|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
9523479|NCT03254914||Control Site|Measure Clinic Blood Pressure
9523480|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
10172042|NCT03876353|Other|Right Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
9523481|NCT03254875|Experimental|Intervention|Individually tailored nurse navigation
9523482|NCT03254875|No Intervention|Control|Usual care
9523483|NCT03254797|Experimental|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
9523484|NCT03254797|Active Comparator|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
9523485|NCT03254979|Experimental|Sequential engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a sequential engagement of professional categories, initiated in nursing, which finally involves the whole professional groups of the center (eg. physicians, etc), will be followed
9523486|NCT03254979|Active Comparator|Global engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a global strategy of engagement with the participation of all professionals from the beginning, will be followed
10172043|NCT03876665||Focus Group|"Active Duty Air Force, Army and Navy women diagnosed with PCOS.~Up to three focus groups per service branch will be conducted. Considering attrition for those who may volunteer and not show up for the FG session, the investigators will recruit up to 20 participants per site, with the goal of including a maximum of six participants per FG to maximize individual participation."
10172044|NCT03876314|Experimental|Physical Activity Condition (PAC)|Subjects will be asked to attend virtual exercise sessions 3 times a week for 1 year.
9523487|NCT03254823||Severe ME/CFS patients|patients with a clinical diagnosis of ME/CFS and are house or bed bound.
9523488|NCT03254823||Household controls|Healthy human participants who are either related/non-related to, living in the same household or in close proximity to, or providing care to the severe ME/CFS patient they are paired with. They are used as an environmental control.
9523489|NCT03254810|Experimental|SYN060|a single 0.57 mg/kg dose of SYN060
9523490|NCT03254810|Active Comparator|Adalimumab North American source|a single 0.57 mg/kg dose of adalimumab from North American source
10172045|NCT03876314|No Intervention|Usual Care Control (UCC)|Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
9523491|NCT03254810|Active Comparator|Adalimumab European source|a single 0.57 mg/kg dose of adalimumab from European source
9523492|NCT03255122|Experimental|Immediate treatment|Individuals in this condition will immediately receive I-CALM treatment, which draws on videoconferencing to remotely deliver real time cognitive-behavioral therapy for early child anxiety to families in their home.
9523493|NCT03255122|Other|Waitlist|Individuals in Waitlist will participate in an initial waitlist condition, and then after post-waitlist assessment will be offered the I-CALM intervention. Accordingly families in this condition receive Delayed I-CALM.
9523494|NCT03254927|Experimental|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
9523495|NCT03255044|Active Comparator|Lipophilic statin|Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
9523496|NCT03255044|Active Comparator|Hydrophilic statin|Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
9523497|NCT03254771|No Intervention|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
10172046|NCT03876730||Study group|3-18 aged children with cerebral palsy
10172047|NCT03876470||All Participants|All participants will receive HCV treatment as determined by their provider. HCV treatment is not assigned by the study.
10172048|NCT03876548|Experimental|Cadexomer Iodine Gel|Patients willy apply product to treatment site every other day for the next 28 days and cover with dressing or bandage.
10172049|NCT03876587|Experimental|Pyrotinib Maleate combine with Docetaxel|"Pyrotinib Maleate combine with Docetaxel should be administrate to all subjects.~Initial dose: Pyrotinib Maleate 400mg oral administration everyday plus Docetaxel 75mg per square of BSA every three weeks intravenous injection."
9523498|NCT03254771|Experimental|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
9528218|NCT03212924|Experimental|Pupillometry|"Measure of pupil dilatation while listening to speech (monosyllabic words) in quiet and in noise.~Evaluation of speech comprehension in quiet~Evaluation of speech comprehension in noise~Measure of cognitive functions with the MOCA (Montreal Cognitive Assessment)~Auto evaluation of listening effort in quiet~Auto evaluation of listening effort in noise"
9672259|NCT05037591|Placebo Comparator|placebo L|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9523499|NCT03254953|Experimental|Sequential Intervention|"in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
9523500|NCT03254953|Experimental|Simultaneous Intervention|"in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
9523501|NCT03254953|Experimental|Control (diet-tracking only)|"participants are asked to self-monitor their diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)"
10172050|NCT03876418|No Intervention|Usual Care|Patients undergo twice daily measurement of intra-abdominal pressure. Clinicians manage patients according to usual care.
10172051|NCT03876418|Active Comparator|Aggressive|Patients undergo aggressive surveillance (q6h) if intra-abdominal pressure is elevated as well as prevention and treatment according to protocol driven guidelines adapted from the World Society of the Abdominal Compartment. This may include nasogastric decompression, limiting fluid administration, drainage of ascites, paralysis and/or abdominal decompression.
9523502|NCT03254901||health care workers|health care workers in Assiut health directorate, Abutig central hospital, El-Quseya central hospital and Sahil selim central hospital in Assiut governorate .All of them will be screened for hepatitis C infection and interviewed about mode of transmission of infection
10172052|NCT03876431|Active Comparator|Traditional Exercise Group|Only traditional exercises will be performed in the early post-op period.
10172053|NCT03876431|Experimental|Easy-Flex Group|Easy-Flex group will be treated with the Easy-Flex device in addition to the traditional exercise program.
9523503|NCT03254966|Experimental|SHR0302 dose level 1|
9523504|NCT03254966|Experimental|SHR0302 dose level 2|
9523505|NCT03254966|Experimental|SHR0302 dose level 3|
9523506|NCT03254966|Experimental|SHR0302 dose level 4|
9523507|NCT03254966|Placebo Comparator|Placebo|
9523508|NCT03255005|Active Comparator|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
9523509|NCT03255005|Active Comparator|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
9523510|NCT03254992|Experimental|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
9523511|NCT03254992|Experimental|ASD - Tangible task|Experimental group using Keyboard with more real activity.
9523512|NCT03254992|Active Comparator|TD - Abstract task|Control group using Kinect with more virtual activity.
9523513|NCT03254992|Active Comparator|TD - Tangible task|Control group using Keyboard with more real activity.
9523514|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.~Patients will recieve treatment as per standard of care."
10172054|NCT03876509||Impedance Cardiography|Impedance Cardiography
9523516|NCT03255057|Experimental|Hemolung plus SOC IMV|Low-flow ECCO2R with the Hemolung Respiratory Assist System as an alternative or adjunct to standard-of-care (SOC) invasive mechanical ventilation (IMV)
9523517|NCT03255057|Active Comparator|SOC IMV|Standard-of-care (SOC) invasive mechanical ventilation (IMV) alone
10172055|NCT03876613|Active Comparator|Turkish music group|Rast makam
9523519|NCT03254550|No Intervention|Control phase|This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.
9528219|NCT03212885|Experimental|1|STN Monopolar Stimulation
9528220|NCT03212885|Experimental|2|rZI + STN stimulation
9528221|NCT03212703|Active Comparator|Waitlist control (WLC)|Observation surveys over an 8-week period.
9672260|NCT05037591|Placebo Comparator|placebo M|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672261|NCT05037591|Placebo Comparator|placebo N|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672262|NCT05037591|Placebo Comparator|placebo O|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672263|NCT05037591|Placebo Comparator|placebo P|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672264|NCT05037591|Placebo Comparator|placebo Q|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672265|NCT05037591|Placebo Comparator|placebo R|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672266|NCT05037591|Placebo Comparator|placebo S|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
10172056|NCT03876613|Active Comparator|classical western music|Vivaldi
10172057|NCT03876613|Active Comparator|soft rock music|Elvis presley
10172058|NCT03876613|Placebo Comparator|control group|No music
10172059|NCT03876561|Experimental|Prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 sessions per week before stoma closure and 1 sessions per week during 6 weeks following stoma closure. Complementary sessions are allowed if necessary.
10172060|NCT03876561|No Intervention|No intervention|No pelvic floor prehabilitation will be proposed before stoma closure. The pelvic floor prehabilitation will be proposed to patients suffering from LARS
10172061|NCT03876392|Experimental|magnetic resonance imaging|Detection of bone marrow metastases with magnetic resonance imaging
10172062|NCT03876834|Experimental|study group (group A)|Group (A) included 30 leukemic patients receiving chemotherapy in addition to training by inspiratory muscle trainer(IMT) for 4 weeks, 5 sessions /week
10172063|NCT03876834|No Intervention|control group (B)|Group (B) included 10 leukemic patients receiving chemotherapy only
10172064|NCT03876496|Experimental|SensableCareCare System|The Sensable®Care System uses pressure sensors and computer software to sense how patients are positioned on the bed in order to reduce bed falls. The Sensable®Care System Mattress has sensors embedded in them, which will be monitored by the nurses in the unit.
10172065|NCT03876340|Active Comparator|Current treatment|Patients will receive burn care treatment as dictated by the surgical team (current standard of care).
10172066|NCT03876340|Experimental|Algorithm-dictated treatment|Patients will receive burn care treatment as dictated by the treatment algorithm (PLOS ONE 13(11): e0206477.).
10172067|NCT03876639|Active Comparator|IPM_2/18|Application of formulation IPM_2/18
9523520|NCT03254550|Experimental|Intervention phase|This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.
9523521|NCT03254498|Active Comparator|Endocuff assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
9523522|NCT03254498|Placebo Comparator|Cap assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
9523523|NCT03254511|Experimental|enoxaparin|In the enoxaparin group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) with Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable (40 mg daily).
9523524|NCT03254511|Active Comparator|control|In the control group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) alone.
9523525|NCT03254524||Patients visiting an emergency department in New York State|
9523526|NCT03254446|Experimental|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
9523527|NCT03254446|Placebo Comparator|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
9523528|NCT03254537|Experimental|Mediterranean Organic|
9523529|NCT03254537|Experimental|Mediterranean conventional|
9523530|NCT03254745|Experimental|Pharmacist intervention|"Disease education (General education about rheumatoid arthritis in a verbal and written manner)~Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients' baseline health status)~Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status)~Advice on medication use (General counseling on medication use as well as patient centered counseling)."
9523531|NCT03254745|No Intervention|Usual care|Patients will not be counseled by pharmacist and will be allowed to take usual care.
9523532|NCT03254589|Experimental|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
9523533|NCT03254589|Active Comparator|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
9523534|NCT03254589|Experimental|Group 3|RA patients on long-term treatment (> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
9523535|NCT03254589|Active Comparator|Group 4|RA patients on stable treatment (> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
9523536|NCT03254784|Experimental|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
9523537|NCT03254784|Experimental|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
9523538|NCT03254784|Experimental|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
9523539|NCT03254784|Experimental|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
9523540|NCT03254784|Experimental|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
9672267|NCT05037591|Placebo Comparator|placebo T|placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms
9672268|NCT05037591|Experimental|sea grape extract A|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672269|NCT05037591|Experimental|sea grape extract B|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
10172068|NCT03876639|Active Comparator|PAR_2/18|Application of formulation PAR_2/18
10172069|NCT03876327|Experimental|PD patients that will receive FMT|fecal microbial transplantation once at the beginning of the study-15 patients.
10172070|NCT03876327|No Intervention|PD patients that will not receive FMT|do not receive treatment-35 patients.
10172071|NCT03876327|No Intervention|healthy people live with PD patients|do not receive treatment-50 participants.
9523541|NCT03254784|Experimental|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
9523542|NCT03254615|Experimental|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
10172072|NCT03876574|Experimental|Treatment|"Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention Hepatic artery infusion of gemcitabine and floxuridine the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired."
10172073|NCT03876288||People presenting with the Sx of Gp|People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.
9523543|NCT03254615|Experimental|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
9523544|NCT03254615|Experimental|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
9523545|NCT03254628|Experimental|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
9523546|NCT03254628|Experimental|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
9523547|NCT03254628|Active Comparator|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
9523548|NCT03254641||hypogondal men|men referred for hCG stimulation test
9523549|NCT03254706|Active Comparator|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
9523550|NCT03254706|Experimental|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
9523551|NCT03254706|Active Comparator|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
9523552|NCT03254706|Experimental|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
9523553|NCT03254680|Experimental|Turmeric Oil|stable dose of orally administered turmeric oil
9672270|NCT05037591|Experimental|sea grape extract C|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9826661|NCT02427672|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
9826662|NCT02427672|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
9826663|NCT02427737|Experimental|Comfort Talk® Training|In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
10172074|NCT03876145|Experimental|Minimal ovarian stimulation with rec-FSH|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 International Unit (IU) Gonal-f (Follitropin alfa, Merck Serono, Germany) after the seventh day.
9523554|NCT03254693|Active Comparator|1-step self-etch approach (SE)|According to the manufacturer's instructions.
9523555|NCT03254693|Active Comparator|selective enamel etching (SEE)|According to the manufacturer's instructions.
9523556|NCT03254693|Experimental|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
9523557|NCT03254693|Experimental|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
9523558|NCT03254576||Children at high-risk for obesity|Healthy-weight children (30th-75thBMI%) with two overweight/obese parents (BMI>25)
9523559|NCT03254576||Children at low-risk for obesity|Healthy-weight children (30th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
9523560|NCT03254433|Experimental|BAS+|As part of the main study, participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
9523561|NCT03254433|Placebo Comparator|SC|As part of the main study, participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
9523562|NCT03254407|Other|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
9523563|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
9523564|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
9523565|NCT03254160|Experimental|DNS-3379 (0.5mg)|
9523566|NCT03254160|Experimental|DNS-3379 (2.5mg)|
9523567|NCT03254160|Placebo Comparator|Placebo|
9523568|NCT03254121||Patients with SVR and developed HCC|HCV patients with SVR and developed HCC plus available tissue from HCC
9672271|NCT05037591|Experimental|sea grape extract D|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9523569|NCT03254251|Experimental|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
9523570|NCT03254251|No Intervention|No Exercise (CON)|N=21, No exercise for 12 weeks
9523571|NCT03254290|Experimental|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
9672272|NCT05037591|Experimental|sea grape extract E|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9523572|NCT03254290|Active Comparator|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
9523573|NCT03254030|Placebo Comparator|Inspection on withdrawal|Participants colonic mucosa will be examined only during withdrawal phase of the examination.
9523574|NCT03254030|Active Comparator|Inspection on insertion and withdrawal|Participants colonic mucosa will be examined during insertion and withdrawal phase of the examination
9672273|NCT05037591|Experimental|sea grape extract F|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672274|NCT05037591|Experimental|sea grape extract G|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9523575|NCT03254186|Experimental|Propranolol Hydrochloride|Two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks then will remain on a stable dose for six weeks. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
9523576|NCT03254186|Placebo Comparator|Placebo Oral Tablet|Identical placebo. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
9523577|NCT03254173|Active Comparator|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
9523578|NCT03254173|Placebo Comparator|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
9527923|NCT03215472|Experimental|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
9527924|NCT03215472|Experimental|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
9527925|NCT03215719|Experimental|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
9527926|NCT03216096|Experimental|3% DE-089 ophthalmic solution|
9527927|NCT03215745|Experimental|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
9527928|NCT03215745|No Intervention|Control group|Usual care
9672275|NCT05037591|Experimental|sea grape extract H|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672276|NCT05037591|Experimental|sea grape extract I|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9527929|NCT03215784|Placebo Comparator|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
9527930|NCT03215784|Experimental|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
9527931|NCT03215784|Experimental|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
9527932|NCT03215784|Experimental|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
9527933|NCT03215628|Active Comparator|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
9527934|NCT03215628|Experimental|Group B - TCEUS with HLM|Surgery of the aortic arc
9527935|NCT03215628|Active Comparator|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
9527936|NCT03215966|Experimental|Sequence A/B|Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
9527937|NCT03215966|Experimental|Sequence B/A|Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
9527938|NCT03215498|Experimental|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
9527939|NCT03215498|Experimental|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
9672277|NCT05037591|Experimental|sea grape extract J|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672278|NCT05037591|Experimental|sea grape extract K|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672279|NCT05037591|Experimental|sea grape extract L|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672280|NCT05037591|Experimental|sea grape extract M|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672281|NCT05037591|Experimental|sea grape extract N|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672282|NCT05037591|Experimental|sea grape extract O|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672283|NCT05037591|Experimental|sea grape extract P|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9523579|NCT03254303|Other|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
9523580|NCT03254303|Other|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
9523581|NCT03254303|Other|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
9523582|NCT03254199|Experimental|Experimental|
9523583|NCT03254199|Placebo Comparator|Placebo Comparator|
9523584|NCT03254277|Experimental|Group 1A|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg.
9523585|NCT03254277|Experimental|Group 1B|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
9523586|NCT03254277|Experimental|Group 1C|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
9523587|NCT03254277|Experimental|Group 2B|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
9523588|NCT03254277|Experimental|Group 2C|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
9523589|NCT03254277|Experimental|Group 1D|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
9523590|NCT03254277|Experimental|Group 2D|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
9523591|NCT03254277|Experimental|Group 1E|HIV-uninfected individuals will be administered a single 1 mL (approximately 150 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
9523592|NCT03254277|Experimental|Group 1F|HIV-uninfected individuals will be administered a single 2 mL (approximately 300 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
9672284|NCT05037591|Experimental|sea grape extract Q|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672285|NCT05037591|Experimental|sea grape extract R|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672286|NCT05037591|Experimental|sea grape extract S|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672287|NCT05037591|Experimental|sea grape extract T|given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms
9672288|NCT05037799||Group 1|body-weight < 50kg
10172075|NCT03876145|Experimental|Minimal ovarian stimulation with HMG|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) after the seventh day.
9523593|NCT03254381|Experimental|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
9523594|NCT03254381|Experimental|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
9523595|NCT03254368|Experimental|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
9523596|NCT03254368|Experimental|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
9523597|NCT03254368|Experimental|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
9523598|NCT03254368|Experimental|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
9523599|NCT03254368|Placebo Comparator|Placebo (D)|Placebo subcutaneous injection once every 3 days
9523600|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
9523601|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
9523602|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
9523603|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
9523604|NCT03254342||Major depressive disorder|There is no intervention/treatment in this study.
9523605|NCT03254342||Non-depressed individuals|There is no intervention/treatment in this study.
9523606|NCT03254082|Experimental|F-1000 (fontanelle flour)|Fontenel sorghum flour
9523607|NCT03254082|Experimental|Sumac|Sumac sorghum flour
9672289|NCT05037799||Group 2|50 kg ≤ body-weight < 100 kg
9672290|NCT05037799||Group 3|100 kg ≤ body-weight < 150 kg
9672291|NCT05037799||Group 4|150 kg ≤ body-weight < 200 kg
9672292|NCT05037487|Placebo Comparator|Placebo|Smoked placebo cannabis
9672293|NCT05037487|Experimental|20 mg CBD|Smoked cannabis with CBD
9672294|NCT05037487|Experimental|20 mg CBD + 20 mg THC|Smoked cannabis with CBD and THC
9672295|NCT05037487|Experimental|20 mg THC|Smoked cannabis with THC
9523608|NCT03254082|Experimental|Wheat|Wheat flour
9523609|NCT03254082|Experimental|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
9523610|NCT03254082|Active Comparator|Sucrose|Table sugar
9523611|NCT03254069|Experimental|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
9523612|NCT03254069|No Intervention|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
9672296|NCT05037526|Active Comparator|Dexcom G System|The Dexcom G6 or current version intended use is for the management of diabetes. It is a small flexible device that records interstitial glucose levels every 5 min and is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 or current version System results should be based on the glucose trends and several sequential readings over time. The system consists of a sensor, transmitter, receiver and mobile app.
9672297|NCT05037526|Active Comparator|Standard care of gestational diabetes with self monitoring blood glucose (SMBG)|SMBG (self-monitoring of blood glucose) is recommended for women with gestational diabetes that involves finger pricking up to six times daily.
9826664|NCT02427737|No Intervention|Control|MRI sites not trained in Comfort Talk®.
9523613|NCT03254056|Active Comparator|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
9523614|NCT03254056|Active Comparator|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
9523615|NCT03254004|Experimental|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
9523616|NCT03254043|Active Comparator|Treatment-as-Usual|Participants will routine methadone clinic care.
9523617|NCT03254043|Experimental|"Take-home Dosing using MedMinder Jon Electronic Pill Box"|Participants will receive 50% of their methadone dose in the morning in the clinic and 50% of their dose will be dispensed in an electronic pill box for participants to take at home later that day.
9523618|NCT03254043|Other|Choice Phase|"Participants will be allowed to select one final Treatment-As-Usual or the MedMinder Jon Electronic Pill Box for the final phase of the study."
9523619|NCT03254017|Experimental|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
9523620|NCT03253965|Experimental|Walking: Treadmill then Overground|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
9523621|NCT03253965|Experimental|Walking: Overground, then Treadmill|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
9523622|NCT03253913|Experimental|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
9523623|NCT03253991|Experimental|MRgFUS treatment|MRgFUS device treatment, thalamotomy
9523624|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
9523625|NCT03253939||Control group|Cytoreductive surgery alone
9523626|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
9523627|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
9523628|NCT03253731||Healthy Volunteers|15 healthy volunteers
9826665|NCT02427750|Experimental|Trivalent Influenza Vaccine|One injection of Agrippal®
9523629|NCT03253653|Experimental|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices.
9523630|NCT03253653|No Intervention|Control|A total of 25 adult make and female nonsmokers will be recruited as a control.
9523631|NCT03253718||Healthy Volunteers|Healthy Volunteers between 18 and 68 years of age
9523632|NCT03253861||control patients|patients without an infected pancreatic necrosis
9523633|NCT03253861||Case patients|patients with an infected pancreatic necrosis
9523634|NCT03253887|Experimental|Ethanol-lock therapy (ELT) Group|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters
9523635|NCT03253887|No Intervention|Control Group|This group did not receive the ethanol-lock, being only followed daily and treated according to the standard protocol in operation at this healthcare unit.
9523636|NCT03253536||entire cohort|none (observational study)
9523637|NCT03253900|Experimental|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
9523638|NCT03253640||Patients with HAI during hospital stay|Patients who meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
9523639|NCT03253640||Patients without HAI during hospital stay|Patients who do not meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
9523640|NCT03253575||Squamous Carcinoma of the Head and Neck (HNSCC)|"1st line metastatic/locally advanced~2nd line metastatic/locally advanced"
9523641|NCT03253575||Triple Negative Breast Cancer (TNBC)|1. Triple Negative Breast Cancer (TNBC) A 1st line metastatic/locally advanced B ≥2nd line metastatic/locally advanced
9523642|NCT03253575||Non-small Cell Lung Cancer (NSCLC)|1. Non-small Cell Lung Cancer (NSCLC) A ≥2nd line Stage 3B or 4
9523643|NCT03253575||Epithelial Ovarian Cancer (EOC)|1. Epithelial Ovarian Cancer (EOC) A 2nd line platinum-resistant Stage 3 or 4 B 2nd line platinum-sensitive Stage 3 or 4 C ≥3rd line platinum-sensitive Stage 3 or 4
9523644|NCT03253575||Colorectal Cancer (CRC)|1. Colorectal Cancer (CRC) A 1st line Stage 4 B Recurrent or progressive disease following treatment with both oxaliplatin- and irinotecan-containing regimens
9523645|NCT03253549|Experimental|SMArTVIEW|
9523646|NCT03253549|No Intervention|Standard Care|
9523647|NCT03253601|Experimental|Strategy Training: iADAPT Application|Participants will use the iADAPT mobile health application to supplement to in-person and remote intervention sessions.
9523648|NCT03253601|Active Comparator|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
9523649|NCT03253822|Experimental|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
9523650|NCT03253822|No Intervention|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
9523651|NCT03253822|No Intervention|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
9523652|NCT03253510|Experimental|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
9523653|NCT03253510|Active Comparator|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
9523654|NCT03253666||Nurses' Health Study|"See Detailed Description"
9523655|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
9523656|NCT03253523|No Intervention|Continued maximal medical management|
9523657|NCT03253523|Experimental|Surgical occipital nerve neurolysis|
10172076|NCT03876145|No Intervention|Mild ovarian stimulation with rec-FSH|The group of mild ovarian stimulation that will receive 150 IU Gonal-f (Follitropin alfa, Merck Serono, Germany) daily from Day 3 of the menstrual cycle.
9523658|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
9523659|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
9523660|NCT03253484|Experimental|NAFL-treated wounds|NAFL treated wounds
9523661|NCT03253484|No Intervention|Control|untreated control wound
9523662|NCT03253341|Experimental|Smart Aging Program|Participants will be enrolled into the Smart Aging Program.
9523663|NCT03253341|Active Comparator|Control Group|Participants will be enrolled into group that receives educational materials that reflect the current standard of care.
9523664|NCT03253471|Experimental|AL-611|
9523665|NCT03253471|Placebo Comparator|Placebo to Match AL-611|
9523666|NCT03253211||State|North Carolina
9523667|NCT03253211||SCD Patients|
9523668|NCT03253211||Providers|Primary care and emergency department clinicians
9523669|NCT03253211||Year|Baseline, year 2, year 3
9523670|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
9523671|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
9523672|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
9523673|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
9826666|NCT02427802|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
10172077|NCT03876145|No Intervention|Mild ovarian stimulation with HMG|The group of mild ovarian stimulation that will receive 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) daily from Day 3 of the menstrual cycle.
9523674|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
9523675|NCT03253328|Active Comparator|Active Arm N-acetyl cysteine (NAC)|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
9523676|NCT03253328|Placebo Comparator|Placebo Arm|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.
9523677|NCT03253419|Other|Home Safety Application|Use of Home Safety application as part of assessment for home safety. The only intervention is the use of the home safety application and identification of home safety issues by the patient using this application.
9523678|NCT03253874|Experimental|Intervention Site-LAC+USC Medical Center|In this arm or study site,new guidelines are disseminated to all residents attending and faculty physicians within the department of Ophthalmology and Anesthesiology. New guidelines call for the across the board elimination of pre-operative testing and visits for patients undergoing cataract surgery.
9523679|NCT03253874|No Intervention|Control Site--Harbor-UCLA Medical Center|In this arm or study site, patients will undergo standard of care for cataract surgery without any new guidelines.
9527940|NCT03215537|No Intervention|observation|No Intervention
9826667|NCT02427802|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
10172078|NCT03876197|Experimental|Autologous Adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia
9523680|NCT03253406|Experimental|Polar M400 + Facebook Group (PM400+FG)|Will be provided a Polar M400 to track physical activity and energy expenditure while also being included in a Facebook group wherein Social Cognitive Theory-based physical activity and nutritious eating tips will be provided twice weekly for 12 weeks.
9523681|NCT03253406|Active Comparator|Facebook Only Group (FG)|Included exclusively in a separate, but content-identical, Facebook group for 12 weeks.
10172079|NCT03876197|Placebo Comparator|Placebo|2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%
9523682|NCT03253380|Experimental|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
9523683|NCT03253289|Experimental|Meclizine 100 mg|Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).
9523684|NCT03253276|Active Comparator|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
9523685|NCT03253276|Placebo Comparator|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
9523686|NCT03253224|Placebo Comparator|Saline|Patient who received normal saline during the operation
9523687|NCT03253224|Experimental|Magnesium|Patient who received magnesium sulfate during the operation
9523688|NCT03253445|Experimental|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
9523689|NCT03253445|Placebo Comparator|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
9523690|NCT03253497|Active Comparator|Chlorhexidine- benzidamine|before 15 minute anesthesia induction Chlorhexidine-benzidamine spray will be administrated to oropharynx
9523691|NCT03253497|No Intervention|Control|before 15 minute normal salin will be administrated to oropharynx
9523692|NCT03253250|Active Comparator|Group A|The subjects will be treated by NAs (ETV, 0.5mg，qd；TDF，300mg，qd；ADV，10mg，qd）for 96 weeks
9523693|NCT03253250|Experimental|Group B|The subjects will be treated by peginterferon alfa-2a （135μg/week）combination with NAs(ETV\TDF\ADV) for 96 weeks.
9523694|NCT03253458|Experimental|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
9672298|NCT05037864||Ballet Dancer Group (Adolescent Ballet Dancers)|Adolescent ballet dancer student aged 7-17 years who have been actively attending a ballet dance school for at least 1 year will be form ballet dancer group. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. The assessment form, which includes demographic data such as, ballet duration(min/day), frequency (times/week) and continuity (year) will record by asking the parents. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
9672299|NCT05037864||Control Group (Sedentary Adolescents)|The control group (Sedentary Adolescent) of the study, are not ballet dance students who aged 7-17 years and have not experience in competitive sport or activity. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
10186994|NCT03730688|Experimental|Conventional and experimental compartment pressure measurement|Compartment pressure in the patients in this group will be measured using the conventional Intra-Compartmental Pressure Monitor System (Stryker) and using the newly-developed measuring device.
9523695|NCT03253354|Active Comparator|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
9523696|NCT03253354|Active Comparator|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
9523697|NCT03253354|Active Comparator|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
9523698|NCT03253354|Sham Comparator|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
9523699|NCT03253562|No Intervention|Healthy control|healthy volunteers not suffering from diabetes or hypertension
9523700|NCT03253562|No Intervention|diabetic hypertensive recently diagnosed patients|recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
9523701|NCT03253562|Other|Metformin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
9523702|NCT03253562|Other|Vildagliptin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
9523703|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
9523704|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation.
9975252|NCT04052334|Experimental|Infusion of Tumor-infiltrating lymphocyte|"Participants will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be generated. All participants will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS). Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB). All participants will receive not less than 10^9, and up to 1x10^12 T cells in ≥250 mL NS as an inpatient by intravenously (IV).~Eight (8) to sixteen (16) hours after completing the T cell infusion, all participants will receive high-dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an intravenous bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as tolerated."
9523705|NCT03253367||Current/former clozapine users|This group has only one visit.
9523706|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
9523707|NCT03253159|Experimental|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
10172080|NCT03875950|Experimental|Training intervention|In this cluster randomized control trial design, the experimental arm refers to the 12 study sites that are randomly assigned to receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
10172081|NCT03875950|No Intervention|Standard of care control|In this randomized cluster randomized control trial design, the no intervention arm refers to the 12 study sites that are randomly assigned not to receive the clinician training intervention. Instead, these study sites will receive the standard of care, which is no standardized patient actor training, for health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
9523708|NCT03253159|No Intervention|Control group|No special preparation before intravenous general anesthesia induction in the operative room
9523709|NCT03253198|Active Comparator|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
9523710|NCT03253198|Active Comparator|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
9523711|NCT03253185|Experimental|SC-007|SC-007 intravenous (IV) (various doses and dose regimens)
9523712|NCT03253770|Experimental|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
9523713|NCT03253770|Experimental|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
9975253|NCT04046536|Active Comparator|Active rTMS at the LDLPFC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left dorsolateral prefrontal cortex (LDLPFC).
9523714|NCT03253770|Experimental|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.~Intervention : paper cognitive aid in the hand of the leader during crises management."
9523715|NCT03253133|Experimental|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.~Intravenous chemotherapy protocol:~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
9523716|NCT03253042|Experimental|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
9527941|NCT03215537|Active Comparator|comprehensive intervention|preoperative: exercise counseling postoperative : symptoms counseling and pulmonary rehabilitation
9527942|NCT03215446|Active Comparator|propofol|
9527943|NCT03215446|Experimental|sevoflurane|
9975254|NCT04046536|Sham Comparator|Sham rTMS at the LDLPFC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LDLPFC.
9975255|NCT04046536|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
9975256|NCT04046536|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
9975257|NCT04043208|Experimental|Biofeedback|
9975258|NCT04043208|Placebo Comparator|Placebo|
9975259|NCT04039217|Experimental|Sample collection 2, 48, and 96 hours after first dose of Biktarvy|Participants in this study arm (Arm A) will provide biological specimens 2, 48, and 96 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
10186995|NCT03730675|Experimental|irradiation stent plus TACE|Portal irradiation stent placement will be performed before TACE procedures.
10172082|NCT03875937|Experimental|Tranexamic acid 1 gram intramuscularly|Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.
10172083|NCT03876119|Experimental|Intraarterial alteplase|"All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
9523717|NCT03253042|Sham Comparator|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
9523718|NCT03252977|Experimental|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
9523719|NCT03252977|Sham Comparator|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
9672300|NCT05037838||Patient undergoing a liver transplantation|Patients undergoing a liver transplantation and able to have a transesopahageal ultrasound
9672301|NCT05037565|Experimental|Treatment group|One group receive PHGG following study protocol (treatment group).
9672302|NCT05037565|No Intervention|Control group|This group will not receive PHGG
9672303|NCT05037461|Experimental|High-dose-high precision MR-guided radiotherapy|"Radiotherapy for pancreatic NET will be delivered in an image-guided, hypofractionated scheme of 5 fractions of 8 Gy, prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days 2 or 3 times a week with a maximum overall treatment time of 14 days on the 1.5T MR-Linac (Elekta Unity MR-Linac).~The Gross Tumor Volume (GTV) is defines as the pNET visible on pre-treatment CT and MRI scan. No clinical target volume (CTV) is used. The PTV is made by adding a 3mm margin to the GTV.~The treatment plan is a 9-14 field intensity modulated radiotherapy (IMRT) plan with dose prescribed to 95% of the PTV. While respecting the dose constraints to adjacent tissues"
9694892|NCT04784247|Experimental|Other soft tissue sarcomas (including synovial sarcoma and malignant peripheral nerve sheath tumor|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
9694893|NCT04784247|Experimental|Bone sarcomas (including osteosarcoma and chondrosarcoma)|Patients enrolled in the study will be treated initially with a 2 week run-in of lenvatinib 20 mg orally daily. Subsequently, they will start pembrolizumab 200 mg intravenously every 3 weeks (21-day cycles). Treatment will continue until progression or other indications for study withdrawal. Otherwise, treatment will be discontinued after a maximum of 35 cycles of pembrolizumab (approximately 2 years) or after achieving CR. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and approximately every 3 cycles (or every 9 weeks +/- 1 week) for the first 9 cycles (27 weeks), then every 4 cycles (or every 12 weeks +/- 1week). Patients who progress after having discontinued therapy after completing 2 years of treatment or after achieving confirmed CR may be eligible to reinitiate therapy for an additional 1 year (approximately 17 cycles).
9694894|NCT04784312|Experimental|9MW1411 injection|
9694895|NCT04784312|Experimental|9MW1411 injection placebo|
9694896|NCT04784338|Experimental|Virtual shared teaching kitchen program|Participants will participate in virtual shared medical appointments that utilize the teaching kitchen
9694897|NCT04784169|Experimental|free middle turbinate flap group|A free middle turbinate flap is used to repair the leakage
9694898|NCT04784169|Active Comparator|vascularized nasoseptal flap|A vascularized nasoseptal flap is used to repair the leakage
9694899|NCT04784377|Experimental|High laser group|
9694900|NCT04784377|Experimental|low laser group|
9694901|NCT04784377|Other|control group|
9694902|NCT04784039|Active Comparator|TEE-group|
10186996|NCT03730675|Active Comparator|Sorafenib plus TACE|TACE will be performed in patients randomized to Arm B, with sequential sorafenib.
9694903|NCT04784039|Active Comparator|DD-group|
9694904|NCT04784117||Subgroup 2016-2018|Subgroup before change of dispatcher protocol
9694905|NCT04784117||Subgroup 2019-2021|Subgroup after change of dispatcher protocol
9826668|NCT02427802|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
9523720|NCT03253016|Experimental|cervicall cerclage|to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
9523721|NCT03253016|Experimental|vaginal progesterone|to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
9523722|NCT03253016|No Intervention|contol|to test vaginal microbiome during pregnancies without cerclage or progesterone
9523723|NCT03253068|Experimental|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
9523724|NCT03253029|Experimental|Treatment|(arm 1) consume five scoops total per day of Pure Encapsulations Branched Chain Amino Acid powder on an outpatient basis (take 2 scoops both in the morning and afternoon and 1 scoop in the evening)
9523725|NCT03253029|Placebo Comparator|Control|(arm 2): control group (no BCAAs provided)
9523726|NCT03252730|Experimental|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
9523727|NCT03252795|Experimental|Uterus transplantation|
9523728|NCT03253107||responder in palliative chemotherapy|After initial chemotherapy, responder (complete remission, partial remission)
9523729|NCT03253107||non-responder in palliative chemotherapy|After initial chemotherapy, disease progression
9523730|NCT03253107||responder in adjuvant chemotherapy|complete cure and no recurrence at least 1 year after treatment
9523731|NCT03253107||non-responder in adjuvant chemotherapy|non-complete cure or recurrence within 1 year after treatment
9523732|NCT03252808|Experimental|TBI-1401(HF10) + Gem/nab-PTX|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
9523733|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
9523734|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary and meta)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
9523735|NCT03252782|Active Comparator|Functional Treatment|Acrylic Splint Herbst Appliance
9523736|NCT03252782|Active Comparator|Distalization Treatment|Mini-implant-borne Distal Jet Appliance
9523737|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
9523738|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
9523739|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
9523740|NCT03252886|Active Comparator|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
9523741|NCT03252886|Active Comparator|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
9523742|NCT03252717|Experimental|blood sample|Pre-treatment blood samples will be collected: 8 samples
9523743|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
9523744|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
9523745|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
9523746|NCT03252912|Experimental|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
9523747|NCT03253003|Experimental|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
9523748|NCT03252821|Experimental|High-intensity aerobic training group|High intensity interval training
9523749|NCT03252821|Active Comparator|Resistance training group|Muscle strengthening
9523750|NCT03252821|No Intervention|Control group|Usual care
9523751|NCT03252678|Experimental|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
9523752|NCT03252678|Active Comparator|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
9523753|NCT03252938|Experimental|Solid tumors|Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy (intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas) are not allowed)
9523754|NCT03252938|Experimental|Solid tumors + peritoneal carcinomatosis|Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
9523755|NCT03252938|Experimental|Solid tumors + chemotherapy|Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
9523756|NCT03252938|Experimental|Solid tumors + Avelumab/IMP321 therapy|"Avelumab and IMP321 as follows:~800 mg avelumab every 2 weeks i.v. (for a maximum of 24 cycles [48 weeks])~6 mg (cohort 1) or 30 mg (cohort 2) IMP321 every 2 weeks s.c. (for a maximum of 12 cycles [24 weeks])"
9523757|NCT03252951|Experimental|Eccentric Training|
9523758|NCT03252951|Experimental|Concentric Training|
9523759|NCT03252951|Experimental|Isometric Training|
9523760|NCT03252951|Active Comparator|Biofeedback|
9523761|NCT03252743|Experimental|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
9523762|NCT03252704|Experimental|High fiber - low fiber|Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top)
9523763|NCT03252704|Experimental|low fiber - high fiber|Treatment order described in arm title, conventional flour (low fiber muffin top)- resistant starch (high fiber muffin top)
10172084|NCT03876119|Placebo Comparator|Placebo|"The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
10172085|NCT03875989|Active Comparator|Arm A|
10172086|NCT03875989|Experimental|Arm B|
10172087|NCT03876158|Active Comparator|Prometra® Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refill #1, refill #2, refill #3) and will be compared to retrospectively collected pain (VAS) scores and drug doses from the last refill prior to peristaltic pump explant.
9523764|NCT03252769|Other|Self-sampling|Invitation to self-sample
9523765|NCT03252574|Other|Sequence AB|No mask, followed by AIR+ Smart Mask only (A), then AIR+ Smart Mask with micro-ventilator (B)
9523766|NCT03252574|Other|Sequence BA|No mask, followed by AIR+ Smart Mask with micro-ventilator (B), then AIR+ Smart Mask only (A).
10172088|NCT03876158|Other|Prior records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
10172089|NCT03876041|Active Comparator|dexamethasone group|this group will receive Dexamethasone: 0.1 to 0.3 mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
9523767|NCT03252665|Experimental|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
9523768|NCT03252665|Experimental|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
9523769|NCT03252665|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
9523770|NCT03252639||Patients with Renal Artery Stenosis|Patients with renal artery stenosis which may benefit from endovascular treatment will be recruited. Those patients who cannot benefit from this procedure will be excluded.
9527944|NCT03215459||Cardiopulmonary Exercise Test|A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
9527945|NCT03215212|Experimental|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
9527946|NCT03215212|Experimental|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
9527947|NCT03215212|Experimental|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
9527948|NCT03215108|Experimental|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
9527949|NCT03215108|Experimental|Conventional-CSEMS|Conventional-CSEMS (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
10172090|NCT03876041|Active Comparator|methylprednisolone group|this group will receive Methylprednisolone: 5-10mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
9527950|NCT03215134|Experimental|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
9527951|NCT03215394|Experimental|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
9527952|NCT03215394|Sham Comparator|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
9527953|NCT03215394|Other|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
9527954|NCT03215160|Experimental|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
10172091|NCT03875963|Experimental|Antibiotic loaded bone filler|Patients will undergo irrigation and debridement, surgical stabilization as required, and defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin]. The concurrent use of antibiotics is at the discretion of the treating physician.
9523771|NCT03252483|Active Comparator|HIV Only|Those randomized to the control group were offered only an HIV test.
9523772|NCT03252483|Experimental|Bundled HCV/HIV|Those randomized to the intervention group were offered both HCV and HIV test.s
10172092|NCT03875963|No Intervention|Standard of care|Current standard of care treatment for infected tibial defects or infected tibial nonunions includes treatment with irrigation and debridement, surgical stabilization as required, and defect management as required including placement of a polymethyl methacrylate spacer with or without antibiotics. A second procedure may or may not occur 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. Concurrent use of antibiotics is at the discretion of the treating physician.
9523773|NCT03252470||2D laparoscopic surgeries|Two-Dimensional Laparascopic Surgical Video System
9523774|NCT03252470||3D laparoscopic surgeries|Three-Dimensional Laparascopic Surgical Video System
9523775|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
9523776|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
9523777|NCT03252457|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
9523778|NCT03252457|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
9523779|NCT03252496|Experimental|Combination|250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
9523780|NCT03252496|Active Comparator|Crystalloid|250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
9523781|NCT03252509|Experimental|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
9523782|NCT03252444|Experimental|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
9523783|NCT03252444|Active Comparator|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
9523784|NCT03252418|Experimental|ascorbic acid|injection of 1 ml intamucosal ascorbic acid 3 times with 1 week interval
9523785|NCT03252418|Experimental|diode laser|photothermolysis by diode laser in one session
9523786|NCT03252288|No Intervention|No intervention|No intervention
9523787|NCT03252288|Experimental|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
9523788|NCT03252288|Experimental|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
10172093|NCT03876067|Experimental|Ozone Group|in which Ozone will be added to cold blood cardioplegia
10172094|NCT03876067|Placebo Comparator|Control Group|: in which in which only cold blood cardioplegia
9523789|NCT03252561|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
9523790|NCT03252561|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
9523791|NCT03252106|Experimental|Contour augmentation|
9523792|NCT03252171|Experimental|Experimental: CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen by infusion.
9523793|NCT03252171|No Intervention|No Intervention|
9523794|NCT03252366|Active Comparator|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
10172095|NCT03876249||RSV positive group|Children who had RSV infection within the first 60 days of life
10172096|NCT03876249||RSV negative group|Children without known RSV infection within the first 60 days of life
10172097|NCT03875976|Active Comparator|Fast Track Protocol|Patients treated using Fast Track Care Protocol
9523795|NCT03252366|Active Comparator|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
9826669|NCT02427841|Experimental|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
9523796|NCT03252405|Active Comparator|mask ventilation|induction is made with mask ventilation
9975260|NCT04039217|Experimental|Sample collection 4, 26, and 120 hours after first dose of Biktarvy|Participants in this study arm (Arm B) will provide biological specimens 4, 26, and 120 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
9523797|NCT03252405|Experimental|intravenous induction|induction is made with intravenous cannulation
9523798|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G1)|Low level laser therapy with energy dose of 18J will be applied on left brachial artery of the subject.
9523799|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G2)|Low level laser therapy with energy dose of 36J will be applied on left brachial artery of the subject.
9523800|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G3)|Low level laser therapy with energy dose of 54J will be applied on left brachial artery of the subject.
9523801|NCT03252184|Placebo Comparator|Phase 1 - Placebo low level laser therapy - 1 (G4)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
9523802|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
9523803|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
9523804|NCT03252184|Placebo Comparator|Phase 2 - Placebo low level laser therapy - 2 (G3)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
9523805|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
9523806|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3(G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
9523807|NCT03252379|Experimental|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
9523808|NCT03252379|Experimental|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
9523809|NCT03252379|Experimental|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
9523810|NCT03252119|No Intervention|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
9523811|NCT03252119|Experimental|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
9523812|NCT03252158|Experimental|Decrease less healthy item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove less healthy items in 20% of slots, then fill the empty slots with healthier items."
9523813|NCT03252158|Experimental|Decrease healthier item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove healthier items in 20% of slots, then fill the empty slots with less healthy items."
9523814|NCT03252132|Active Comparator|12-week resistance training|
9975261|NCT04039217|Experimental|Sample collection 24, 28, and 72 hours after first dose of Biktarvy|Participants in this study arm (Arm C) will provide biological specimens 24, 28, and 72 hours after the in-clinic dose of Biktarvy. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre-wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at one of the study visits.
9975262|NCT04010435|Active Comparator|Group A (r TMS group)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.
9975263|NCT04010435|Active Comparator|Group B (Galvanic stimulation)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo galvanic vestibular stimulation; in addition to designed vestibular rehabilitation exercises.
9694906|NCT04784260||Group A (normozoospermic): >15 mill/ml and >32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing, library preparation and bioinformatic analysis.
10172098|NCT03875976|Active Comparator|Standard Protocol|Patients treated using Standard Care Protocol
9523815|NCT03252132|No Intervention|No training|
10172099|NCT03876015||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
10172100|NCT03876184|Experimental|RMO FLi® Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 RMO FLi® Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
10172101|NCT03876184|Experimental|G&H G4 Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 G&H G4 Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
10172102|NCT03876184|Experimental|Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
10172103|NCT03876184|Active Comparator|Conventional superelastic Nickel Titanium|"This group has been allocated with conventional upper and lower round 0.014 superelastic Nickel Titanium archwires for a duration of 8 weeks."
10172104|NCT03876210|Other|Sequence A|"Period 1: PK101-001, PK101-002 / Period 2: PK101~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
9523816|NCT03252392||children with autism spectrum disorder|Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less)
9523817|NCT03252392||healthy non autistic age matched volunteers|children aged 3-12 years old never diagnosed to have autism spectrum disorder
9523818|NCT03252093|Experimental|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
10172105|NCT03876210|Other|Sequence B|"Period 1: PK101 / Period 2: PK101-001, P101-002~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
10172106|NCT03876002|Experimental|[18F]PBR06|To perform kinetic modeling using plasma-based (metabolite corrected plasma concentration) or reference region based methods or simplified quantification methods to assess the ability of [18F]PBR06 PET to measure microglial activation in brain.
9523819|NCT03252093|Placebo Comparator|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
9523820|NCT03252535|Experimental|Cellavita HD Lower Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
9523821|NCT03252535|Experimental|Cellavita HD Higher Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
9523822|NCT03252535|Placebo Comparator|Placebo Group|The participants randomized to this group will receive a total of 9 intravenous administrations divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
9523823|NCT03252262|Active Comparator|Jack Satter House|Residents of Jack Satter House who participated in the Vitalize 360 Program.
9523824|NCT03252262|Active Comparator|Center Communities of Brookline|Residents of Center Communities of Brookline who participated in the Vitalize 360 Program.
9523825|NCT03252262|Active Comparator|Simon C. Fireman|Residents of Simon C. Fireman who participated in the Vitalize 360 Program
9523826|NCT03252197|Experimental|New device group|participants who are tested performance for ultrasound guided cannulation using device
9523827|NCT03252197|Active Comparator|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
9523828|NCT03252210|Experimental|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.~Post Hoc Multiple Comparisons"
9523829|NCT03252249|Active Comparator|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy is the intervention.
9523830|NCT03252249|Active Comparator|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy is the intervention.
9523831|NCT03252275|Experimental|Intervention|Standard HBB and ECEB training with peer learning
9523832|NCT03252275|No Intervention|Control|Standard HBB and ECEB training only
9694907|NCT04784260||Group B (normozoospérmic): <15 mill/ml and <32% progressive mobility.|Analysis of the microbiome by extracting DNA from ejaculates, amplification of bacterial DNA with feeders aimed at the regions of the bacterial rRNA 16 S gene, sequencing,library preparation and bioinformatic analysis.
9523833|NCT03252327|No Intervention|routine care|Preterm infants in the control condition will receive only usual neonatal intensive care units (NICU) care
9523834|NCT03252327|Experimental|Multiple Sensory Integrations(1)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
9523835|NCT03252327|Experimental|Multiple Sensory Integrations(2)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
9694908|NCT04784325|Experimental|Women recruited from a general population subject to I/E criteria|All study participants will administer three blood collection modalities (2 TAP II, 1 ADx card, and phlebotomist-performed venipuncture).
9694909|NCT04784078|Experimental|dTRA group|
9694910|NCT04784078|Active Comparator|cTRA group|
9826670|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
10172107|NCT03875898|Experimental|150 g bread fortified (15 g mix fibre)|Volunteers will have to consume daily 150 g of a bread instead of usual bread during eight weeks
10172108|NCT03875898|Placebo Comparator|150 g unfortified bread|Volunteers will have to consume daily 150 g of an unfortified usual bread during eight weeks
10172109|NCT03875911|Active Comparator|Preoperative Subconjunctival injection of MMC|Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).
9523836|NCT03252327|Experimental|Multiple Sensory Integrations(3)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
9523837|NCT03252236|Experimental|Tai Chi|Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
9523838|NCT03252236|Active Comparator|Conventional exercise|Subjects in this group were trained with conventional exercises. Subjects were also asked to practice the exercises outside of the class 30 minutes at least once a week
9523839|NCT03252236|No Intervention|Control|No training was given to the subjects in this group
9523840|NCT03252080|Active Comparator|Education (Group A)|short-intensive education for one month
9523841|NCT03252080|Experimental|Education & holistic management(Group B)|short-intensive education for one month followed with holistic management for 6 months
9523842|NCT03252067|Experimental|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
9523843|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
9523844|NCT03252223|Active Comparator|Women with normal menses|
9523845|NCT03252223|Active Comparator|Women with Polycystic Ovary Syndrome|
9523846|NCT03251833||obese|Body mass index >30 Kilogram/m2
9523847|NCT03251833||non-obese|Body mass index <30 Kilogram/m2
9523848|NCT03251807|Experimental|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
9523849|NCT03251807|Experimental|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
9523850|NCT03251950|Experimental|Intervention group|15 week healthy eating and gardening curriculum to be implemented in Osage Nation Early Childhood Programs; 15 week healthy eating parenting curriculum to be implemented online to parents of enrolled children
9523851|NCT03251950|Other|Control group|Wait list control -- to receive intervention after serving as wait list group
10172110|NCT03875911|Active Comparator|Intraoperative subconjunctival injection of MMC|Intraoperative subjconjunctival injection of 0.1 mL of Mitomycin-C 0.01% (0.1mg/mL) to the site of trabeculectomy
10172111|NCT03875911|Active Comparator|Intraoperative topical application of MMC|Topical application of Mitomycin-C intraoperatively by applying a sponge soaked in 1mL of Mitomycin-C 0.02 mg/mL for 1 minute to the site of trabeculectomy
9523852|NCT03251677|Active Comparator|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
9523853|NCT03251677|Active Comparator|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
9523854|NCT03251690|Experimental|Switching TDF/FTC/EFV to TDF/FTC/RPV|Switching from Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day (once daily) to Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Rilpivirine 25 mg/day (once daily) Intervention: Tenofovir/Emtricitabine/Rilpivirine
9523855|NCT03251690|Active Comparator|Continuing TDF/FTC/EFV|Continuing Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day Intervention: Tenofovir/Emtricitabine/Efavirenz
9523856|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
9694911|NCT04784403||Students and workers at the University of Barcelona|"The study population will be randomly selected from the different groups of the University:~Students from the different centers and type of studies (undergraduate / graduate).~Administrative and service personnel.~Teaching and Research Staff."
10172112|NCT03875924||VWD BERHLINGO|Patients with constitutional von Willebrand Disease, of any severity, with or without inhibitor followed in one of the investigator centers
10172113|NCT03875872||Group propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
10172114|NCT03875872||Group inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
10172115|NCT03875833|Experimental|Collagen Nerve Wrap Conduit|
10172116|NCT03875833|No Intervention|Control|
10172117|NCT03875846||Intraoperative Hemodynamic Improvement|The primary outcome will examine the magnitude of change in the Toe-Brachial Index (TBI) between the beginning and the end of the procedure. The two measurements will be taken before- and after- vascular sheaths had been placed.
10172118|NCT03875768|Experimental|Intervention|Participants will track their daily dietary intake for six months using an app and will receive automated feedback daily via text message based on DASH nutrients. Participants in-need of coaching based on their adherence to the key nutrients in the DASH dietary pattern or engagement in the intervention will receive responsive digital coaching from Nourish registered dietitians.
10172119|NCT03875768|No Intervention|Control|Participants will receive information about the DASH dietary pattern and will track their daily dietary intake using an app for six months.
10172120|NCT03875521||12 hours|
10172121|NCT03875521||< 12hours|
10172122|NCT03875560|Experimental|Part A/Single Dose|IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
10172123|NCT03875560|Experimental|Part B/Cohort 1|IC14 4 mg/kg/day IV or placebo IV x 1 day.
10172124|NCT03875560|Experimental|Part B/Cohort 2|IC14 8 mg/kg/day IV or placebo IV x 1 day.
9523857|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
9523858|NCT03251794||threatened preterm labor|women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix
9523859|NCT03251781|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation
9523860|NCT03252002|Experimental|Single/multiple doses of 10 mg BAY1101042 or placebo|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
9523861|NCT03252002|Experimental|Single/ multiple doses of 20 mg BAY1101042 or placebo|Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
9826671|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
9523862|NCT03252002|Experimental|Single/ multiple doses of 30 mg BAY1101042 or placebo|Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
9523863|NCT03252002|Experimental|Single/ multiple doses of 40 mg BAY1101042 or placebo|Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
10172125|NCT03875560|Experimental|Part B/Cohort 3|IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
10172126|NCT03875560|Experimental|Part B/Cohort 4|IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
10172127|NCT03875807|Active Comparator|0 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 0 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
10172128|NCT03875807|Active Comparator|30 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 30 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
9523864|NCT03252002|Experimental|Single/ multiple doses of 50 mg BAY1101042 or placebo|Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
10172129|NCT03875677|Experimental|HD-tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the defined target area
10172130|NCT03875677|Experimental|Conventional tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
9523865|NCT03252002|Experimental|Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo|Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
10172131|NCT03875677|Sham Comparator|Sham HD-tDCS group|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect.
10172132|NCT03875625|Experimental|Morbid obesity- Bariatric surgery group|Morbid obese subjects who will consent to bariatric surgery
9523866|NCT03251885||women with preterm labor|pregnant women < 37 weeks of gestations with regular uterine contractions and > 3 cm dilation, > 80% effacement
9523867|NCT03251885||women with term pregnancy|pregnant women > 37 weeks of gestation
9523868|NCT03251742|Active Comparator|Fontan patient population|
9523869|NCT03251742|Sham Comparator|Healthy volunteers|
9523870|NCT03251859|Active Comparator|Standard ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
9523871|NCT03251859|Experimental|Reduced ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
9523872|NCT03251768|Experimental|Test group|"intervention: rHSA-GCSF 2.4 mg Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（2.4mg）will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle.After injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
9523873|NCT03251768|Active Comparator|Positive control group|"intervention: GCSF Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. (The minimum of usage was continuous 7 days ,The maximum of usage was continuous 14 days)"
9523874|NCT03251755|Experimental|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
9523875|NCT03251755|No Intervention|Control|Usually clinical practice
10172133|NCT03875625|Experimental|Morbid obesity-Dietitian led life style intervention group|Morbid obese subjects who will not consent to bariatric surgery but instead opt for dietitian led life style intervention
10172134|NCT03875625|Experimental|Mild obesity-Dietitian led life style intervention group|Mild- Moderate subjects assigned through a randomized controlled trial to the dietitian led life style intervention
10172135|NCT03875625|Experimental|Mild obesity-Conventional care group (control)|Mild- Moderate subjects assigned through a randomized controlled trial to conventional care
10172136|NCT03875781|Experimental|A: Modified Folfirinox|"Experimental : preoperative chemotherapy:~Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
10172137|NCT03875781|Active Comparator|B: Modified Folfirinox followed by Radiochemotherapy|Active comparator: preoperative chemotherapy : Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively FOLLOWED BY Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor
9523876|NCT03251716|Experimental|berberine adjunctive group|Only one treatment group in this study, without a preset control group,subjects who meet the criteria will entere the berberine adjunctive group
9523877|NCT03251976|Experimental|Intervention|video decision aid
9523878|NCT03251976|Active Comparator|Usual care|
9523879|NCT03251664||Anemic|Hemoglobin <11 g/l
9523880|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
9523881|NCT03251872|Experimental|Drug: Olaparib|Olaparib up to 400 mg BID (100 to 400 mg) for 16 weeks
9523882|NCT03251261||Specimen collection|
9523883|NCT03251586|Experimental|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523884|NCT03251586|Experimental|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523885|NCT03251586|Experimental|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523886|NCT03251586|Experimental|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523887|NCT03251586|Experimental|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523888|NCT03251586|Experimental|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523889|NCT03251586|Experimental|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523890|NCT03251586|Experimental|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
9523891|NCT03251274|Experimental|machine bathing group|structured machine bathing for 20-min duration at evening.
9523892|NCT03251274|Active Comparator|traditional bathing group|traditional bathing at evening.
9523893|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
9826672|NCT02427984||Controls|Patients free from hip devices
9826673|NCT02428192|Experimental|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
9523894|NCT03251404|Active Comparator|Knee Control original|The Knee Control program exercise program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
9523895|NCT03251404|Experimental|Knee Control+|The Knee Control+ is an extension of the original Knee Control exercise program offering a wider selection of exercises (to increase adherence) and more physically challenging exercises (adapted for athletes in the late teens and provide further stimuli to increase player performance and neuromuscular function). The program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
9523896|NCT03251599|Sham Comparator|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
9523897|NCT03251599|Active Comparator|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
9523898|NCT03251469|Active Comparator|Group 1|intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
9523899|NCT03251469|Placebo Comparator|Group 2|Intravenous normal saline, 100mg, preoperatively, single dose
9523900|NCT03251625|Placebo Comparator|To assess the effect of multistrain probiotics on abdominal|To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
9523901|NCT03251625|Placebo Comparator|To assess the efficacy of a multistrain probiotic supplement|To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre
9523902|NCT03251495|Experimental|Vaxchora Vaccination|Healthy subjects will receive a single dose of oral live cholera vaccine.
9523903|NCT03251547||NovoSeven|Non-hemophiliac patients experienced massive haemorrhage who was treated with recombinant activated factor VII
9523904|NCT03251365|No Intervention|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
9523905|NCT03251365|Experimental|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
9523906|NCT03251391|Experimental|Cardiac Rehabilitation Group|Participants randomized to this group will undergo cardiac rehabilitation program.
9975264|NCT04010435|No Intervention|Control (Group C)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo designed vestibular rehabilitation exercises.
10172138|NCT03875430||Perimenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
9523907|NCT03251391|Active Comparator|Control Group|Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
9523908|NCT03251339|Experimental|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
9527955|NCT03215160|Active Comparator|Classical Exercise Group|only classical exercises performed in the early post-op period
10172139|NCT03875430||Postmenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
9826674|NCT02428192|Experimental|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9523909|NCT03251339|Experimental|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
9523910|NCT03251300|Experimental|group A|daytime dosing of mirabegron
9523911|NCT03251300|Active Comparator|group B|nighttime dosing of mirabegron
9523912|NCT03251378|Experimental|3 mg Dose Escalation|3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
9523913|NCT03251378|Experimental|5 mg Dose Escalation|5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
9523914|NCT03251378|Experimental|Fruquintinib Expansion Cohort A|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.
9523915|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort B|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
9523916|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort C|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
9523917|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort D|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
9523918|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort E|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
9523919|NCT03251417|Experimental|Combination treatment|Combination treatment of irinotecan and apatinib.
9523920|NCT03251573||Normal cognitive function|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
9523921|NCT03251573||cognitive impairment|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
9523922|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
9523923|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
9523924|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
9523925|NCT03251443|Experimental|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
9523926|NCT03251560|Experimental|Fuke Qianjin capsule|Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
9523927|NCT03251560|Placebo Comparator|Placebo oral capsule|placebo pills, 2 pills each time,three times a day, orally, for 2months
9523928|NCT03251456|Experimental|Tertiary care|
9523929|NCT03251456|Active Comparator|Usual care|
9826675|NCT02428296|Experimental|Patients with PIK3CA gene mutation treated with Sirolimus|This is a single-arm, non-randomized, open-label study for the treatment of segmental overgrowth disorders (somatic PIK3CA gene mutation) with Sirolimus in thirty-nine patients.
10172140|NCT03875755|Experimental|Myo Inositol|The women will receive 2 caps of Myo Inositol with acid folic a day, until delivery
10172141|NCT03875755|Placebo Comparator|Placebo|The women will receive 2 caps of placebo (acid folic) a day, until delivery
10172142|NCT03875742|Other|"Ultraplex 360"|"This group will execute the first TAP block using Ultraplex 360 (Braun) and the second TAP block using  STIMUPLEX D SH, 30° (Braun)"
10172143|NCT03875742|Other|" STIMUPLEX D SH, 30°"|"This group will execute the first TAP block using  STIMUPLEX D SH, 30° (Braun) and the second TAP block using Ultraplex 360 (Braun)"
10172144|NCT03875404|Experimental|Deep Brain Stimulation subjects|
9523930|NCT03251612|Other|Treatment|1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.
9523931|NCT03251287|Active Comparator|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
9523932|NCT03251287|Placebo Comparator|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
9523933|NCT03251248|Experimental|First MSB11455 Then Neulasta|
9523934|NCT03251248|Experimental|First Neulasta Then MSB11455|
9523935|NCT03251001|Active Comparator|Control|Sites receiving a free gingival graft
9523936|NCT03251001|Experimental|Device - Acellular dermal matrix|Sites receiving acellular dermal matrix
9523937|NCT03251040|Other|Fibrin sealant|Single arm pilot study
9523938|NCT03251053|Experimental|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
9523939|NCT03251053|Other|Control regular cigarette smokers|Habitual smokers without EC use
9523940|NCT03251105|Active Comparator|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
9523941|NCT03251105|Active Comparator|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
9523942|NCT03251092|Active Comparator|SAD PTI-808 Active|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
9523943|NCT03251092|Placebo Comparator|SAD PTI-808 Placebo|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
9672304|NCT05037721|Experimental|gargling with green tea of stroke patients|Use fresh green tea (package date less than one month) sourced from the local market and serve in the form of soaked tea bags. 0.5% green tea refers to a tea bag soaked in 0.5g green tea, soaked in 100ml warm water for 5 minutes and let cool. Then, put each bottle of 15ml mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
9672305|NCT05037721|Active Comparator|gargling with water of stroke patients|Use water 15ml of mouthwash into a disposable opaque bottle, and give two bottles of mouthwash required daily at one time. Use 15ml twice a day, 30 minutes after breakfast and 30 minutes after lunch, each time for 30 seconds. Rinse mouth up and down for 30 seconds. Rinse mouth up and down, half sitting and lying down, and shake the head of bed for 30 degrees. After breakfast, the experimental group and the control group were instructed to clean their teeth according to routine procedures, and telephone reminders were provided to inform them to gargle.
9672306|NCT05037656|No Intervention|Control|Students in the control group will receive the standard health education curriculum.
9672307|NCT05037656|Experimental|Experimental|Students in the treatment group will receive the school-based classroom curriculum.
9672308|NCT05037539|Experimental|Injectable Fentanyl in Sublingual Route|Injectable Fentanyl in Sublingual Route that given after the first time Breakthrough Pain is occurred 50 mcg in sublingual route
9672309|NCT05037539|Active Comparator|Oral Morphine Syrup|Oral Morphine Syrup 2.5 ml ( 5 mg) in oral router that first time given after Breakthrough Pain is occurred
9672310|NCT05037383|Other|Study group|Each participant will be part of the same group, since the study is focusing on the motion and viewing of the operating staff. There are no patient records collected.
9672311|NCT05037370|Experimental|LASIK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
9975265|NCT04005521|Experimental|Preventive intervention|Patient will perform daily exercise: jaw and swallwing exercises, as well as are encouraged to eat and drink for as long as possible during treatment
9975266|NCT04005521|No Intervention|Control group|No intervention, only encouragement to eat and drink for as long as possible during treatment
9975267|NCT03998046|Active Comparator|Basic Resources and Services|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, and information about linkages to extant intensive lifestyle interventions in the community
9672312|NCT05037370|Experimental|PRK refractive surgery|Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
10172145|NCT03875469|Experimental|CT patients_Centargo_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
10172146|NCT03875469|Experimental|CT-patients_Stellant_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
10172147|NCT03875469|Experimental|CT-patients_Centargo_2|Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)
9672313|NCT05037357||nasopharyngeal carcinoma patients|Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers.
9672314|NCT05037318|Experimental|Stress arousal reappraisal|
10172148|NCT03875417||Group A|Patients who developed HCC recurrences after surgery and treated with re-resection, or microinvasive non-surgical means.
10172149|NCT03875417||Group B|Patients who did not develop recurrences after surgery.
10172150|NCT03875391|Experimental|Oxytocin and trauma film paradigm|Intervention: Drug: Oxytocin nasal spray
9523944|NCT03251092|Active Comparator|MAD PTI-808 Active|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
9523945|NCT03251092|Placebo Comparator|MAD PTI-808 Placebo|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
9523946|NCT03251092|Active Comparator|FE PTI-808 Active|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
9523947|NCT03251092|Placebo Comparator|FE PTI-808 Placebo|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
9523948|NCT03251092|Experimental|Part 2 PTI-808 + PTI-801 + PTI-428 Active|One cohort is planned where subjects will be randomized to either the triple active arm (dosed with PTI 808+PTI 801+PTI 428) OR placebo arm.
9523949|NCT03251092|Placebo Comparator|Part 2 matching Placebos|In all three cohorts in part 2, subjects will be randomized to active drug or placebo. The placebo arm for all cohorts consists of placebo capsules matching PTI-808+PTI-801+PTI-428.
9523950|NCT03251092|Experimental|Part 2 dual active arm PTI-801+PTI-428+ PTI-808 placebo|One cohort is planned where subjects are randomized to either 808 placebo + dual active arm (dosed with placebo matching PTI 808 plus PTI 801 + PTI 428) OR placebo arm.
9527956|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
10172151|NCT03875391|Placebo Comparator|Placebo and trauma film paradigm|Intervention: Drug: Placebos
10172152|NCT03875352|Experimental|Neutropenia patients|Patients with neutropenia were treated using the CHG and HMG technique.
10172153|NCT03875352|Experimental|No neutropenia patients|Patients with no neutropenia were treated using the CHG and HMG technique.
10172154|NCT03875274|Placebo Comparator|Ropivacaine group|Ropivacaine 0.375% 20 ml + Normal saline 2 ml via FICB
10172155|NCT03875274|Experimental|Ropivacaine and morphine group|Ropivacaine 0.375% 20 ml + Morphine 2 ml via FICB
10172156|NCT03875196|Experimental|Biyofeedback|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes
9523951|NCT03251092|Active Comparator|Part 2 dual active arm PTI-801+PTI-808+PTI-428 placebo|One cohort is planned where subjects are randomized to either 428 placebo + dual active arm (dosed with placebo matching PTI 428 plus PTI 808 and PTI 801) OR placebo arm.
9523952|NCT03251092|Active Comparator|Part 3 CF MAD PTI-808 + PTI-801 + PTI-428|In all cohorts in Part 3, subjects will be will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
9523953|NCT03251092|Placebo Comparator|Part 3 CF MAD PTI-808 placebo+PTI-801 placebo+PTI-428 placebo|In all cohorts in Part 3, subjects will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
9523954|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428|In cohorts 3 & 4 subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
9523955|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
9523956|NCT03251092|Placebo Comparator|Part 4 CF PTI-808 placebo + PTI-801 placebo + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
9523957|NCT03251066|Other|Test group|Proponent Nasal Spray Medical device
9523958|NCT03251235|Experimental|Treatment Group|Group receives four weekly sessions of CBT prior to experimental testing/ fMRI
9523959|NCT03251235|No Intervention|Waiting Group|Group receives four weekly sessions of CBT after experimental testing/ fMRI
10172157|NCT03875196|Experimental|Extracorporeal Magnetic Innervation|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes and the Extracorporeal Magnetic Innervation application was made for 20 minutes
10172158|NCT03875261|Experimental|Study arm|Participants are treated with the investigational medical product
10186997|NCT03730649|Active Comparator|Sulforaphane without light challenge|Participants with moderate photodamage and moderate intrinsic skin aging will apply sulforaphane (broccoli sprout extract) in jojoba oil nightly (without any UV or visible light irradiation) for up to 6 months and have up to 9 biopsies taken just before treatment and occurring at regular intervals during the study
9523960|NCT03251131|Experimental|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
9523961|NCT03251131|No Intervention|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
9523962|NCT03250923|Experimental|silver citrate complex and acemannan|This is a single arm open pilot trial. All participants will receive study drug.
9523963|NCT03251170|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
9523964|NCT03251170|Active Comparator|Fentanyl|2.5 mg/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
9523965|NCT03251222|Experimental|Dexmedetomidine group|Patients who will receive Dexmedetomidine intranasal prior the sedation with remifentanil
9523966|NCT03251222|Placebo Comparator|Placebo Concentrate|Patients will recive 0.9% NaCl
9523967|NCT03250910|Experimental|HIV/HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
9523968|NCT03250910|Experimental|HIV/HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
9523969|NCT03250910|Active Comparator|HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
9523970|NCT03250910|Active Comparator|HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
9527957|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
10186998|NCT03730649|Active Comparator|Sulforaphane with light challenge|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments and biopsies taken before and within 7 days after UV or visible light irradiation; one of the UV/visible light treated areas will be pre-treated with sulforaphane (broccoli sprout extract) for up to 28 consecutive nights and the other UV/visible light treated areas will be pre-treated with jojoba oil.
10186999|NCT03730623|No Intervention|Control group|Usual care. Conservative management of IC
10187000|NCT03730623|Experimental|Intervention|Supervised exercise
9523971|NCT03251183||Main group|Blood sampling Comprehensive Cardiovascular magnetic resonance (CMR) Transthoracic echocardiography (TTE) (EchoErgo) Invasive pressure-volume (PV) Loops Left ventricular (LV) biopsy
9523972|NCT03251183||Reproducibility group|Stress-perfusion Cardiovascular magnetic resonance (CMR)
9523973|NCT03251183||Age/gender matched control group|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
9523974|NCT03251183||Healthy volunteers|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
9527958|NCT03215225||Root canal treatment|
9527959|NCT03215264|Experimental|Single Arm|
9527960|NCT03215329||CPAP30|Alveolar recruitment maneuver with a continuous positive airway pressure (CPAP) at 30 cmH2O during 30 seconds
9527961|NCT03215329||PEEPsteps|Alveolar recruitment maneuver with a stepwise increase and decrease in positive end expiratory pressure from 5 to 20 cmH2O.
9527962|NCT03215303|Experimental|Continuous Positive Airway Pressure (CPAP)|Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
9527963|NCT03215303|Placebo Comparator|CONTROL|Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.
9527964|NCT03215251|Experimental|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
9527965|NCT03215251|No Intervention|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
9527966|NCT03215355|Experimental|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
9527967|NCT03215420|Experimental|Certain or probable Meniere's disease|
9527968|NCT03215407|Experimental|Intra-articular Tocilizumab|Tocilizumab, solution, 80mg intra-articular.
9527969|NCT03215407|Active Comparator|Intra-articular Compound Betamethasone|Compound betamethasone, solution, 14mg intra-articular
9527970|NCT03215381|Other|[11C]AZD1390 Microdose|[11C]AZD1390 single dose not exceeding 10 ug by IV bolus
9527971|NCT03215121|Active Comparator|One handed mask airway, switch to two hands|Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec
9527972|NCT03215121|Active Comparator|Two handed mask airway + jaw thrust|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec
9527973|NCT03215121|Active Comparator|Two handed mask airway, switch to one hand|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 20 sec and then switch to one hand + chin lift - 20 sec
9527974|NCT03215082|Experimental|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
9527975|NCT03215082|Active Comparator|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
9527976|NCT03214926|Experimental|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
9527977|NCT03214913|Other|EGDT Group|Early Goal Directed Therapy ：30ml/kg in the first bolus to have a CVP（central venous pressure） 8-12 mmHg and MAP（mean artery pressure ） 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenaline，red blood cell transfusion if necessary.
9672315|NCT05037318|Experimental|Worked examples|
9672316|NCT05037318|Experimental|Stress arousal reappraisal + Worked examples|
9975268|NCT03998046|Experimental|Coordinated Primary Care Population Management (C3PO)|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, information about linkages to extant intensive lifestyle interventions, and outreach MyChart messages that are tailored to each individual's pattern of self-weighing and progress towards their weight goal, and more intensive support from a primary care nurse based on self-weighing behavior and weight loss success.
9975269|NCT03992846|Experimental|Linzagolix 75 mg|
9975270|NCT03992846|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
9975271|NCT03992846|Placebo Comparator|Placebo|
9975272|NCT03981614|Experimental|Arm A (binimetinib, palbociclib)|Patients receive binimetinib PO BID on days 1-28 and palbociclib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9523975|NCT03250858|Placebo Comparator|Non-personalised advice|"Control group. Online (web-based) delivery of non-personalised dietary, weight and physical activity advice based on the UK general health guidelines.~This is an online trial and this arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non-personalised)."
9523976|NCT03250858|Experimental|Personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
9523977|NCT03251014|Experimental|YSS/salmon group|YSS followed by salmon
9523978|NCT03251014|Experimental|Salmon/YSS group|Salmon followed by YSS
9523979|NCT03250936||Trampoline group|Child patients with trauma due to trampoline from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
9523980|NCT03250936||Control group|Child patients with trauma related to sport from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
9523981|NCT03250949|No Intervention|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
9523982|NCT03250949|Experimental|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
9523983|NCT03250962|Experimental|SHR-1210-plus-Decitabine|Decitabine 10 mg/day, days 1-5; SHR-1210 200 mg, day 8, every 3 weeks.
9523984|NCT03250962|Experimental|SHR-1210|SHR-1210 200 mg, day 1, every 3 weeks.
9523985|NCT03250871|Placebo Comparator|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
9523986|NCT03250871|Experimental|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.~It is divided into three phases:~induction: attention of the patient fixed on an object or a part of the body,~the dissociation where the patient cuts off auditory, visual and tactile perceptions,~and finally the opening towards a hypnotic experience thanks to the imaginary."
9523987|NCT03251027|Experimental|Treatment (IM-SRT)|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
9975273|NCT03981614|Experimental|Arm B (trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may optionally crossover to Arm A.
9975274|NCT03972553|Other|Sugarbaker|For the Sugarbaker group, the bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
10172159|NCT03875248|Other|Arm 1. Blood pressure measurement compared to arterial line|Comparative blood pressure measurement with the investigational device and the invasive reference method (arterial line).
10172160|NCT03875248|Other|Arm 2. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in hypertensive patients with the investigational device and the non-invasive reference method (manual cuff).
9672317|NCT05037318|No Intervention|Control|
9975275|NCT03972553|Other|Keyhole|For the Keyhole group the stoma will be taken down and rematured through a cruciate incision (keyhole)
10172161|NCT03875248|Other|Arm 3. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in pregnant women with the investigational device and the non-invasive reference method (manual cuff).
10172162|NCT03875014||group 1|Bipolar hemiarthroplasty grop
9975276|NCT03970070|Experimental|Health service research (Periop-OSMT)|Patients and/or support persons/family caregivers complete Periop-OSMT session in-person or via telephone over 20-40 minutes before surgery and before hospital discharge and group telehealth session over 1.5-2 hours at weeks 1-3, 4, 5, 6, and 7 post discharge
9975277|NCT03967002|Experimental|Test group with corticotomy surgery|Orthodontic treatment and minimally invasive corticotomy surgery with piezoelectric device and surgical guide
9975278|NCT03967002|No Intervention|Control group without corticotomy surgery|Standard orthodontic treatment without surgery
9975279|NCT03965676|Other|Adult patients with a tophaceous gout|Adult patients with a tophaceous gout but no urate-lowering treatment or treatment but target not reached (target = uricemia < 360µmol/L).
9523994|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
9523995|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
9975280|NCT03951649|Experimental|Occipital Nerve block|"Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.~Site of injection will be cleaned with an alcohol swab.~5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.~After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved."
9975281|NCT03951649|Active Comparator|Oral Acetaminophen/Caffeine Group|Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)
10172163|NCT03875014||group 2|Total hip replacement dual mobility group
10172164|NCT03875170|Experimental|Proprioceptive neuromuscular facilitation|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility
10172165|NCT03875170|Active Comparator|Muscle stretching|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. It will be done for the hip, quadriceps and hamstring muscles with a voluntary antagonist activation to relax the agonist muscle.
10172166|NCT03875300|Experimental|Participants in the Intervention Group|Intervention Group - will undertake a programme of 7 x 2 hour group sessions, following the scripted 'Foodwise in Pregnancy' manual of nutrition information; practical cooking sessions; and information on low impact exercise.
9523996|NCT03251209|Experimental|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
9523997|NCT03251209|Experimental|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
9523998|NCT03251209|Active Comparator|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
9523999|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
9524000|NCT03250793|Experimental|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
9524001|NCT03250780|Experimental|Patients with extensive colitis|Patients with extensive colitis, for at least 8-10 years, already on the surveillance programme or newly referred whilst attending their outpatients IBD clinic at Leeds Teaching Hospitals NHS Trust will be screened by one of the research doctors who will be performing the surveillance colonoscopy.
9524002|NCT03250442|Other|Group A: Standard Dry Dressing|The standard dry dressing is comprised of nonadherent dressing, dry gauze, cotton undercast padding, compression, and immobilization.
9524003|NCT03250442|Active Comparator|Group B: Foam, Drape, and PrevenaTM|This arm is comprised of foam, drape, the PrevenaTM Device, compression, and immobilization.
9524004|NCT03250624|Experimental|CD5024 0.3% cream|Active drug
9826676|NCT02428309|Experimental|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
9826677|NCT02428309|Experimental|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
9826678|NCT02428309|Experimental|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
9524005|NCT03250624|Experimental|CD5024 cream placebo|Placebo of active drug
10172167|NCT03875300|No Intervention|Participants in the Control Group|Control Group - will continue with routine antenatal care, unchanged.
10172168|NCT03875066|Other|A to B|Subjects were involved in an control training program (A). After 2 weeks washout period, Subjects were trained using the other program (B).
10172169|NCT03875066|Other|B to A|Subjects were involved in an control training program (B). After 2 weeks washout period, Subjects were trained using the other program (A).
9672320|NCT05037253|Active Comparator|high dose|Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months.
9672321|NCT05037253|Active Comparator|Low dose:|Vitamin D therapy will prescribe for 3 months at a dosage of 2,000 IU/day.
9672322|NCT05037240|Active Comparator|Intervention Group|
10172170|NCT03874949|Active Comparator|SEALITE Regular|zinc oxide eugenol sealer
10172171|NCT03874949|Experimental|SEALITE Ultra|zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)
10172172|NCT03874962|Experimental|Routine oral cleaning and professional oral care group|"The subjects in Routine oral cleaning and professional oral care group were received about routine oral cleaning and professional oral care."
10172173|NCT03874962|No Intervention|Routine oral cleaning group|"The subjects in Routine oral cleaning group were received only routine oral cleaning, just maintain daily condition."
10172174|NCT03875157|Experimental|IBI318 DL1|
10172175|NCT03875157|Experimental|IBI318 DL2|
10172176|NCT03875157|Experimental|IBI318 DL3|
10172177|NCT03875157|Experimental|IBI318 DL4|
10172178|NCT03875157|Experimental|IBI318 DL5|
10172179|NCT03875157|Experimental|IBI318 DL6|
9524006|NCT03250559|Active Comparator|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.~Intervention: percutaneous nephrolithotomy."
9672323|NCT05037240|Placebo Comparator|Placebo|
9826679|NCT02428413|Active Comparator|Standard oxygen mask|Standard face mask to provide supplemental oxygen
9826680|NCT02428413|Active Comparator|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
10172180|NCT03875157|Experimental|IBI318 DL7|
10172181|NCT03875157|Experimental|IBI318 DL8|
10172182|NCT03875157|Experimental|IBI318 DL7b|
10172183|NCT03875157|Experimental|IBI318 DL8b|
10172184|NCT03875157|Experimental|IBI318 RP2D|
10172185|NCT03874832|Experimental|STS101 1.5 mg|STS101 (dihydroergotamine nasal powder), 1.5 mg
10172186|NCT03874832|Experimental|STS101 3.0 mg|STS101 (dihydroergotamine nasal powder), 3.0 mg
10172187|NCT03874832|Experimental|STS101 6.0 mg|STS101 (dihydroergotamine nasal powder), 6.0 mg
10172188|NCT03874832|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
10172189|NCT03874832|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
10172190|NCT03875053|Experimental|Monitoring device, Quality of Life Assessment, Questionnaire|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
10172191|NCT03874936|Experimental|A; Dexamethasone twice|24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.
10172192|NCT03874936|Experimental|B; Dexamethasone once|24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours
10172193|NCT03874936|Placebo Comparator|C; Placebo twice|placebo intravenous just before the operation and repeated after 24 hours
10187001|NCT03730597|Active Comparator|glenosphere 42|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 42. reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
10172194|NCT03874884|Experimental|177Lu-PSMA + olaparib|Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 4 cycles of treatment. An additional 2 cycles of treatment can be given based on clinical benefit achieved and toxicity experienced.
9524007|NCT03250559|Active Comparator|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.~Intervention: percutaneous nephrolithotomy."
9524008|NCT03250533|Experimental|LED 620 nm group (G-LED 620)|The LED device in the red light spectrum, with a wavelength of 620 nm, will be applied over the full extent of the wound.
9524009|NCT03250533|Experimental|LED 940 nm group (G-LED 940)|The LED device in the infrared light spectrum, with a wavelength of 940 nm, will be applied over the full extent of the wound.
9672324|NCT05037448|Other|Telehealth|Me & My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me & My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
10172195|NCT03874871||Function preserving gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.
9672325|NCT05037019|Experimental|Single fraction radiotherapy|Single fraction of 21 Gy stereotactic radiation therapy delivered to a single malignant lesion of the breast prior to any other treatment for breast cancer.
9672326|NCT05037006|Experimental|Group I-30|Inhalational anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
9672327|NCT05037006|Experimental|Group I-50|Inhalational anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
9672328|NCT05037006|Experimental|Group I-70|Inhalational anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
9672329|NCT05037006|Experimental|Group V-30|Intravenous anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
9672330|NCT05037006|Experimental|Group V-50|Intravenous anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
9672331|NCT05037006|Experimental|Group V-70|Intravenous anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
9672332|NCT05037435|Experimental|The pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
9672333|NCT05037435|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
9672334|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) low dose|The participants will receive the low dose of BCD-250
10172196|NCT03874871||Standard gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.
10172197|NCT03874923|Active Comparator|250 mL of fluid challenge|
10172198|NCT03874923|Experimental|500 mL of fluid challenge|
10172199|NCT03874819|Active Comparator|Control group|Conventional Hemodialysis using a high-flux dialyzer
10172200|NCT03874819|Experimental|Experimental group|Conventional Hemodialysis using a medium cut-of dialyzer
10172201|NCT03874806|Experimental|single|local anesthetic is delivered as a single bolus
10172202|NCT03874806|Active Comparator|continuous|local anesthetic is delivered as a continuous infusion
10172203|NCT03874780|Experimental|Treatment|Subjects treated with Botox (TM) with the Vibe investigational delivery system
9524010|NCT03250533|Experimental|Fixed diphasic current group (G-DF)|The electrical stimulation will be carried out with the fixed diphasic current of the Dualpex 071 equipment, being applied throughout the extension of the wound.
9524011|NCT03250533|No Intervention|Control group (G-C)|Volunteers from this group will not be submitted to treatment and will only be evaluated before, every 30 days, after the 12 week period and 30 days after the last evaluation. It is worth mentioning that, after the end of its participation, if the wound is not fully healed, the treatment will be offered with LED or diphasic current.
9524012|NCT03250390|Experimental|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
9524013|NCT03250390|Active Comparator|controls|The controls consisted of 2 groups: smokers and non-smokers.
9524014|NCT03250520|Experimental|glioma brain stem|
9524015|NCT03250520|Experimental|high grade recurrent brain tumor in the central nervous system|
9524016|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
9524017|NCT03250546|Experimental|Haplo-identical group|
9524018|NCT03250546|Active Comparator|HLA-9/10 MMUD group|
9672335|NCT05037188|Experimental|COVID-19 vaccine candidate (BCD-250) high dose|The participants will receive the high dose of BCD-250
9672336|NCT05037188|Experimental|Cohort 1/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
9672337|NCT05037188|Placebo Comparator|Cohort 1/Placebo|The participants will receive placebo
9672338|NCT05037188|Experimental|Cohort 2/COVID-19 vaccine candidate (BCD-250)|The participants will receive the selected dose of BCD-250
9672339|NCT05037188|Placebo Comparator|Cohort 2/Placebo|The participants will receive placebo
9672340|NCT05037162|Experimental|Arm 1 - CimetrA-1|CimetrA-1, with a total dose containing a combination of Curcumin 40 mg, Boswellia 30 mg and Vitamin C 120 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
9524019|NCT03250494|Active Comparator|group (I) (GI) (n=25)|
9524020|NCT03250494|Active Comparator|group (II) (GII) (n=25)|
10172204|NCT03874741|Experimental|Arm - Experimental|Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
10172205|NCT03874390|Experimental|ozone therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
10172206|NCT03874390|Active Comparator|initially periodontal therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
10172207|NCT03874585|Active Comparator|Standard Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange) and free nicotine replacement.
10172208|NCT03874585|Experimental|Enhanced Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange), free nicotine replacement, and the 6-week text messaging intervention.
10172209|NCT03874403|Experimental|NIVATS|Patients receiving Non-intubated VATS with DSA changes
10172210|NCT03874403|Other|Intubated VATS|Patients receiving intubated VATS with DSA changes
10172211|NCT03874533|Experimental|self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
10172212|NCT03874442|No Intervention|Controls|
10172213|NCT03874442|Experimental|CliniPup|
10172214|NCT03874598|Experimental|Ear acupuncture|
10172215|NCT03874598|Active Comparator|Psychoeducation|
10172216|NCT03874728||Older people at risk of falls|Older people at risk of falls
10172217|NCT03874507|Experimental|Technology-based therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive either virtual reality (VR) or augmented reality (AR) to improve clinical outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step.
10172218|NCT03874507|No Intervention|Standard of Care therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive physical therapy based on his/her providers recommendations to improve outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step
10172219|NCT03874559||Arm A|All patients enrolled will be placed in Arm A. Serum blood draw samples will be collected as well as additional data from medical records will be collected. This data includes demographic data, clinical information from notes, radiology images and reports, diagnostic test results, and procedure and pathology reports.
10172220|NCT03874429|Experimental|T2259|1 drop in each eye 2 to 4 times daily
10172221|NCT03874429|Active Comparator|Vismed Multi|1 drop in each eye 2 to 4 times daily
10172222|NCT03874416|Experimental|Specific rehabilitation of working memory|Specific rehabilitation of working memory according to hierarchized rehabilitation.
10172223|NCT03874416|Active Comparator|Control group|Non-specific rehabilitation of working memory, usual therapy.
10172224|NCT03874676||PEACE Rounds Clinicians|Nurses, physicians, care managers, chaplains, and other clinicians who attend PEACE rounds as part of their routine work in the hospital.
10172225|NCT03874637|Experimental|Treatment|Active therapy
9524021|NCT03250494|Placebo Comparator|group (III) (GIII) (control group) (n=25)|
9975282|NCT03922035|Experimental|Arm I (CBM588)|Patients receive standard peri-/post-transplant supportive care and CBM588 PO BID from day of admission to day 28 in the absence of disease progression or unacceptable toxicity.
9524022|NCT03250572||control group|
9524023|NCT03250572||NAFLD patients without hepatic fibrosis|
9524024|NCT03250572||NAFLD patients with hepatic fibrosis|
9524025|NCT03250507|Active Comparator|Bupivacaine|Patients will receive a TAP block with 60 mL 0.25% bupivacaine. this group will not receive Liposomal bupivacaine
9524026|NCT03250507|Active Comparator|Liposomal bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL saline.~this group will not receive bupivacaine. they receive only liposomal bupivacaine."
9524027|NCT03250507|Experimental|Liposomal bupivacaine and bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL 0.25% bupivacaine.~this group will receive the mixture of Liposomal bupivacaine and bupivacaine."
9975283|NCT03922035|Active Comparator|Arm II (standard of care)|Patients receive standard peri-/post-transplant supportive care.
10172226|NCT03874637|Sham Comparator|Sham Control|Sham Control
10172227|NCT03874520|Experimental|Video triage|The sick child will be assessed on video by the operator at the call-center.
10172228|NCT03874520|No Intervention|Telephone triage|The sick child will be assessed solely over the telephone by the operator at the call-center.
10172229|NCT03874611|Experimental|electrophysiological data from DBS|
10172230|NCT03874663||Oral HIV Self-testing|Evaluate the acceptability and performance of a directly assisted oral HIV self-testing (HIVST) in a youth population aged 14-24 in Nigeria
10172231|NCT03874650|Experimental|Activity Planning Group|"Those in the Activity Planning group receive training and practice in identifying realistic and safe activities in everyday life that may be enjoyable or rewarding to complete. They gain practice in scheduling activities and identifying and overcoming barriers to completion, such as memory problems, avoidance, sticking to habitual patterns and physical and transport issues.~The intervention will consist of weekly 1 hour group sessions over 8 weeks, as below:~Introduction to Group Therapy Identifying Enjoyable Activities The Automatic Pilot and Planning Pleasurable Activities Goal Review and Balancing Enjoyable and Routine Activities Identifying Solutions to Goal Attainment Increasing Mastery and Managing Fatigue Active Approaches to Engagement Relapse Prevention"
10187002|NCT03730597|Active Comparator|glenosphere 38 ECC|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 38 ECC reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
10187003|NCT03730584|Experimental|Patient with Hereditary Epidermolysis Bullosa|
10187004|NCT03730571|Experimental|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
9524028|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
10172232|NCT03874650|Experimental|Activity Engagement Group|"Individuals randomised to this arm will meet weekly for 8 weeks for 1 hour and engage in various potentially rewarding and meaningful social activities such as board games, crafting, and puzzles. Participants in this group will not receive specific training on activity scheduling or overcoming barriers to activity participation. Rather the aim is that participants gain experience of positive reinforcement from the activities and that this explicitly or implicitly challenges potentially negative predictions about such situations and encourages generalised increases in positive activity beyond the group setting. The group will cover activities such as board games, t-shirt making, puzzles, painting, pub quizzes, figurine painting, origami/paper-craft, and clay sculptures."
10172233|NCT03874650|Placebo Comparator|Waitlist Group|In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
10172234|NCT03874572|Experimental|Allogeneic mesenchymal stem/stromal cell therapy|Treatment with intra-glandular Injections of allogeneic adipose derived stem cells
10172235|NCT03874364|Active Comparator|Lidocaine gel, counselling, monitor|
10172236|NCT03874364|Active Comparator|Lidocaine gel, counselling, no monitor|
10172237|NCT03874364|Active Comparator|Lidocaine gel, no counselling, monitor|
10172238|NCT03874364|Active Comparator|Lidocaine gel, no counselling, no monitor|
10172239|NCT03874364|Placebo Comparator|Lubricating gel, counselling, monitor|
10172240|NCT03874364|Placebo Comparator|Lubricating gel, counselling, no monitor|
10172241|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, monitor|
10172242|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, no monitor|
10172243|NCT03874481||PCI|Patients who had stent
10172244|NCT03874338||Colchicine|
10172245|NCT03874338||Placebo|
10172246|NCT03874273|Experimental|crizotinib +|Patients with unresectable, relapsed or refractory inflammatory myofibroblastic tumor, receiving crizotinib
10172247|NCT03874286||Liver Transplant|Participants will obtain a liver biopsy at 4 months post transplant and 12 months post transplant.
10172248|NCT03874130|Active Comparator|Scopolamine|0.2 mg scopolamine HBr per dose
10172249|NCT03874130|Active Comparator|IV Scopolamine|4.0 μg/kg; 15 minute IV infusion
10172250|NCT03873922|Experimental|Ketogenic diet intervention|Ketogenic meals will be offered for the participants during the trial.
10172251|NCT03873922|No Intervention|Control group|Conventional hospital meals as usual will be offered during the trial.
10172252|NCT03874117|Other|Twice weekly hemodialysis|Participants will undergo hemodialysis twice per week.
10172253|NCT03874117|Other|Thrice weekly hemodialysis|Participants will undergo hemodialysis three times per week.
10172254|NCT03874195|Active Comparator|Control|"Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care - www.palliativedoctors.org; getpalliativecare.org; and Wikipedia Palliative Care https://en.wikipedia.org/wiki/Palliative care)."
10172255|NCT03874195|Experimental|Intervention|Intervention Arm subjects will receive access to PCforMe.
10172256|NCT03874247|Experimental|Pelubiprofen|
10172257|NCT03874247|Placebo Comparator|Pelubiprofen placebo|
10172258|NCT03874260|Experimental|statin / fenofibrate|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O
10172259|NCT03874260|Placebo Comparator|statin / fenofibrate placebo|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
10172260|NCT03873909|Active Comparator|Fruit Smoothie|Post-prandial study feeding 155-200 g mamey sapote mesocarp, 6 g of soybean oil , crushed ice and 150-200 g of water to reach a total volume of 450 mL. (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin).
10172261|NCT03873909|Active Comparator|Matrix-Free Shake|Post-prandial study feeding 2 g of carotenoid powder formula (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin), 37.5 g of sugar, 75 µg of citric acid, 6 g of soybean oil emulsified into 300 g of water using 3 g of soy lecithin as well as ca. 100 g of crushed ice, yielding a shake volume of 450 mL.
10172262|NCT03874143|Experimental|RCom equipped with a smartphone|
10172263|NCT03874143|No Intervention|RCom with paper-based system|
9524029|NCT03250468|Experimental|CBT-I|Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
9524030|NCT03250468|No Intervention|Wait-list control|The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
9524031|NCT03250403|Experimental|PRP injection|
9524032|NCT03250403|Active Comparator|medical treatment|
10172264|NCT03873935||Control|Healthy subjects
10172265|NCT03873935||Periodontitis|Patients with periodontal disease
10172266|NCT03873935||Cardiovascular|Patients with cardiovascular disease
10172267|NCT03873935||Periodontitis+Cardiovascular|People with both cardiovascular and periodontitis
10172268|NCT03874000|Experimental|Sintilimab plus Metformin Hydrochloride|Patients receive metformin hydrochloride 500mg orally (PO) twice daily (BID). Patients also receive Sintilimab 200mg intravenously (IV) in 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
10172269|NCT03874169||High-Risk of GI Bleed|Patients that have a high risk of having a gastrointestinal bleed upon admission into the ICU based on their medical history and symptoms. These patients will have a biosensor watch, the E4 wristband, placed on them to monitor their vital signs.
10172270|NCT03874026|Experimental|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
9524033|NCT03250481|Active Comparator|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
9524034|NCT03250481|Experimental|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
9524035|NCT03250611|Experimental|Occipito-Cervical Instability|Stabilization of the occipito-cervical junction by Occipital Condyle Screw (OCS) as a sole cranial anchor, with posterior bone graft.
9524036|NCT03250715|Experimental|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
9524037|NCT03250715|No Intervention|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
9524038|NCT03250728|Other|CDG with stroke-like history|
9524039|NCT03250728|Other|CDG without stroke-like history|
9524040|NCT03250455||CTA+CTP|
9524041|NCT03250455||CTA only|
9524042|NCT03250598|Experimental|Cohort A|
9524043|NCT03250598|Experimental|Cohort B|
9524044|NCT03250598|Experimental|Cohort C|
9524045|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
9524046|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
9524047|NCT03250650|Active Comparator|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
9524048|NCT03250650|Experimental|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
10187005|NCT03730545|Experimental|EIN group|Enteral formula including not only basic energy components, but also immune components such as omega-3 fatty acids, glutamine (Gln), arginine (Arg), and nucleotide.
9524049|NCT03250754||Pharmacological treatment group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a prophylactic treatment alone
9524050|NCT03250754||Electroacupuncture group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
9524051|NCT03250364|Experimental|Multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + multilayer bandage consisting of three layers. The first was a 100% cotton tubular bandage which will be directly placed on the skin to prevent any injury (Tubinylex TM). The second layer is a paddle with the purpose of unify and increase pressure (Emulsified Latex FoamTM 8mm, Thuasne, France); and the third layer of inelastic bandages (6, 8 and/or 10 cm Rosidal K Short Stretch Bandage, Germany). All the bandage layers will be placed from caudal to cranial in a circular disposition, overlapping in one third the previous layer for a correctly cover of the limb and not to leave open spaces. The cotton tubular bandage and the short-stretch bandage could be cleaned without losing their material properties."
9524052|NCT03250364|Experimental|Simplified multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + double compression bandage consisting of two layers, made up of a first rigid cotton bandage (11 cm Bande coton Short Stretch; Thuasne, France) and a second elastic bandage (BiflexTM 16 light; Thuasne, France). The two layers will be placed caudal to cranial in a circular manner, overlapping in one third the previous layer. The elastic bandage have squares drawn to help to the physiotherapist to control the stretch they given to the bandage. The two bandages could be cleaning without losing their properties. If there was any oedema concentration or a fibrous place, a paddle pad will be put in these places (Mobiderm TM, Thuasne, France)."
10172271|NCT03874208|Other|Patient group|To assess the predictive accuracy of comaScore evaluated in the day 7 - day 45 period post brain injury to predict unfavorable outcome at 1-year after the first insult in patients admitted in ICU after CA, TBI and aSAH, that remain comatose at least 7 days after brain injury.
10172272|NCT03874208|Other|Test group|MRI calibration in each center : test protocol compliance, data transfer procedures and quality of the MRI sequences
10172273|NCT03874156|Active Comparator|Intervention group|Atorvastatin 40 mg once daily
10172274|NCT03874156|Placebo Comparator|Placebo group|Matched placebo tablet once daily
10172275|NCT03873961|Experimental|High-intensity laser therapy|The participants received stretching and exercise guidance and underwent the BTL-6000 High Intensity Laser 12 W with 10 mm pen applicator high intensity laser procedures (mode = continuous, power = 7 W, dose = 120 J/cm2, total time= 7 min. 8 sec.) 3 times per week (total of 8 procedures).
10172276|NCT03873961|Active Comparator|Low-level laser therapy|The participants received stretching and exercise guidance underwent the LAS-Expert with laser shower applicator Low-level Laser therapy procedures (785 nm wavelength, 4,0 J/cm2, 35cm2, 6:40 min) 3 times per week (total of 8 procedures).
9672341|NCT05037162|Experimental|Arm 2 - CimetrA-2|CimetrA-2, with a total dose containing a combination of Curcumin 28 mg, Boswellia 21 mg and Vitamin C 84 mg in spray administration - divided in 4 separate doses given as an add on therapy, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
10172277|NCT03873753|Experimental|Oral cleaning|The oral cavity will be clean with gauze and mineral water three times a day.
10172278|NCT03873753|Active Comparator|No oral cleaning|The oral cavity will not be cleaned.
10172279|NCT03873974||Negative trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
10172280|NCT03873974||Positive trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
10172281|NCT03873766|Active Comparator|Intrapleural fibrinolytic therapy (IPFT)|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage~Protocol Image #1: After chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Intrapleural Medications (IPFT): The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day.~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion, a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
10172282|NCT03873766|Active Comparator|Surgery|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage: Chest tube placement~Protocol Image #1: Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Surgery: The surgical arm will have either open surgery or a VATS approach at the discretion of the surgeon~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
10172283|NCT03873714|Experimental|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
10172284|NCT03873883|Experimental|Dose Escalation- Monotherapy|Specified dose on specified days
10172285|NCT03873883|Experimental|EOS100850 and Pembrolizumab Combination Therapy|Specified dose on specified days
10172286|NCT03873883|Experimental|EOS100850 and SOC Combination Chemotherapy|Specified EOS100850 dose on specified days
10172287|NCT03873844|Experimental|CI Cognitive Therapy|The treatment will have 2 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily life.
10172288|NCT03873831|Active Comparator|Social Skills Control (A-A)|"The children in the A-A condition, a true control, will remain without a dog for the full 10 weeks."
10172289|NCT03873831|Experimental|Social Skills Dog (A-B)|"The A-B condition will involve standard instruction for 5 weeks (A), followed by 5 weeks of group instruction while a therapy dog is present in the room (B)."
10172290|NCT03873831|Experimental|Social Skills Dog (B-A)|"The B-A condition will be identical, except the first 5 weeks of instruction will include the dog, followed by 5 weeks of standard instruction with no dog."
10172291|NCT03873948||Control|Healthy patients
10172292|NCT03873948||Periodontitis|Patients with periodontal disease
10172293|NCT03873948||Cardiovascular|Patients with cardiovascular disease
10172294|NCT03873948||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
10172295|NCT03873662||Pediatric patients after out-of hospital cardiac arrest|Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication
10172296|NCT03873779|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental/submandibular area.
10172297|NCT03873610|Experimental|Stress and Symptom Management Program 1|
9528222|NCT03212703|Active Comparator|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
10172298|NCT03873610|Experimental|Stress and Symptom Management 2|
9528223|NCT03212898|Experimental|Intervention|Specific pharmacist-led anticoagulation care
9672342|NCT05037162|Placebo Comparator|Arm 3 - Placebo|Placebo, composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, total of 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
9672343|NCT05036993|Experimental|Intervention|Coaching
10172299|NCT03873896|Experimental|Blocked finger|The experimental arm will be the ring finger of the volunteer that is blocked (randomized either right or left hand) with a digital nerve block (described elsewhere in the submission). The skin wrinkle test (diagnostic test) will be applied to this arm
9672344|NCT05036993|Experimental|Control|Control, Coaching later
9524053|NCT03250364|Experimental|Cohesive bandage group|Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + cohesive bandage consisting of a single short-stretched layer that will be put directly on the subject skin and stick on itself (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States). It will be placed in a circular manner distal to cranial with a paddle pad in the elbow fold not to damage this moving part. This bandage will be reused twice in the same subject.
9524054|NCT03250364|Experimental|Adhesive compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + adhesive compression bandage consisting of an elastic bandage (BiplastTM Thuasne, France. Measures: 10cm x 2,5 m) which will put over a pre-tape bandage not to damage the skin. It will be placed in a circular disposition from distal to cranial. In each physiotherapy session, the bandage has to be replaced with a new one."
9672345|NCT05037136||Ablation|Participants recruited from the LoTO_CASA_AF trial (ClinicalTrials.gov Identifier: NCT04280042) who underwent either conventional catheter ablation or thoracoscopic surgical ablation to treat their long standing persistent AF with be asked to continue downloading data from their implanted loop recorder and monitor their heart rate and physical activity level (step count) using a wrist worn activity tracker.
10172300|NCT03873896|Active Comparator|Unblocked finger|The control arm will be the finger of the same volunteer that is not under the influence of digital nerve block. This will be the corresponding digit (the ring finger) on the opposite hand of the side that was blocked (determined by coin toss). The skin wrinkle test (diagnostic test) will be applied to this arm
9524055|NCT03250364|Experimental|Kinesiotaping bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + kinesiotaping bandage consisting of K-Active Tape. The k-tape will be pasted directly on the skin and put longitudinally in thin bands in a cranio-caudal disposition. The width of the bandage will be of 5cm, and will be cut in four bands that will cover all the upper limb cranial to caudal in a spiral way surrounded it. The bandage will be placed moving the limb into internal and external rotation for putting the skin in a little stretch without lengthen the tape."
9524056|NCT03250741|Active Comparator|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
9524057|NCT03250741|Placebo Comparator|Placebo|Placebo transdermal patches
9524058|NCT03250351|Experimental|Neurodynamic group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
9524059|NCT03250351|Active Comparator|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program consisting of physical therapy aimed at reducing postoperative edema, treatment of the scar, the muscle pain and / or joint and recovery and integration of the upper limb functional motor patterns plus instructions with printed material about lymphatic system, lymphedema, pain, movement & pain; etc…. (educational strategy). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
9524060|NCT03250286|Experimental|EUS-ERCP group|EUS is performed first, and when the examiner finds bile duct stone in the EUS examination, ERCP is performed to remove the stone.
9524061|NCT03250286|Active Comparator|ERCP group|ERCP without EUS is performed in all patients.
9524062|NCT03250260|No Intervention|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
9524063|NCT03250260|Experimental|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
9524064|NCT03250260|Experimental|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
9524065|NCT03250312|Active Comparator|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
9524066|NCT03250312|No Intervention|The control group|"The control group will wait in another room for approximately 30 minutes.~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
9524067|NCT03250325|Experimental|Split dose of 5x10^9 TBI-1301|Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.
9524068|NCT03250338|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
10172301|NCT03873688|Experimental|Experimental Group|Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
10172302|NCT03873688|Sham Comparator|Sham Group|In sham group, patients will perform expiratory muscle training at home for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device that the intensity of training will been setted 5 cm H₂O.
10187006|NCT03730545|Active Comparator|SEN group|Enteral formula including only basic energy components.
9524069|NCT03250338|Placebo Comparator|Placebo|Placebo following salvage chemotherapy
9524070|NCT03250221||Robotic or laparoscopic myomectomy|Women who received robotic or laparoscopic myomectomy
9524071|NCT03250065|Experimental|ETT Study Group|The Sensing ET Tube study Group
9524072|NCT03250026|Experimental|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
9524073|NCT03250026|Active Comparator|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
9524074|NCT03250208|Placebo Comparator|Control Group|Participants randomized to this group will take two placebo capsules daily during days 21-60.
9524075|NCT03250208|Experimental|Intervention group|The intervention in this study is a probiotic. Participants randomized to this group will take two capsules of a probiotic daily during days 21-60
9524076|NCT03250130|Experimental|Hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
9524077|NCT03250195|Other|PET/MRI|All participants will have a PET/MRI performed
10172303|NCT03873649||Patients with subacute or chronic hypersensitivity pneumonitis|"Procedures that each subject will undergo include:~Chest CT scan to determine extent of disease.~Pulmonary function testing to determine severity of disease.~Bronchoscopy with lavage.~Venipuncture."
10172304|NCT03873649||Healthy Controls|"Inclusion:~Adult between the ages of 18 and 80 years old.~Non-smoker or previous smoker quit >6months ago.~Able to understand the consent process and procedures involved in the study.~Exclusion:~Unable to understand the consent process or procedures involved in the study.~Pregnancy.~Suspicion of current infection or within the past 3 months.~Bleeding disorder or on anti-coagulants other than aspirin.~Any co-morbid condition that increases risk of bronchoscopy including but not limited to cardiac disease, uncontrolled hypertension, uncontrolled diabetes and/or morbid obesity."
10172305|NCT03873454|Active Comparator|Experimental Group|The experimental group listened to music and wore Sennheiser non-occlusive headphones
9524078|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
9524079|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
9524080|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
9524081|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
9524082|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
9524083|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
9524084|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
9524085|NCT03249805|Experimental|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
10172306|NCT03873454|Other|Control 1 with no music|This cohort wore non-occlusive earphones but did not listen to music
10172307|NCT03873454|Other|Control 2 with no music|The control 2 patients did not listen to music nor wore earphones.
10172308|NCT03873389||Ocrelizumab|All participants enrolled in the study. All participants will be receiving the treatment of interest (Ocrelizumab)
10172309|NCT03873363|Experimental|PS|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
10172310|NCT03873363|Active Comparator|CR|Implantation of a cruciate retaining Total Knee Arthroplasty.
10172311|NCT03873428|Other|FES PET|1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
10172312|NCT03873298|Experimental|COPD|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
10172313|NCT03873298|Experimental|IPF|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
10172314|NCT03873337|Experimental|NRT + Persistence Targeted Smoking Cessation in Schizophrenia|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling with a focus on task persistence.
10172315|NCT03873337|Active Comparator|NRT + Modified Clearing the Air|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling that does not focus on task persistence.
9524086|NCT03249805|Experimental|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
9524087|NCT03249987|Other|Electronic bladder diary|Participants will be asked to complete the electronic diary for three days before crossing over to the paper diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
9672346|NCT05036954||no arm|
10172316|NCT03873350|Experimental|Living kombucha|
10172317|NCT03873350|Placebo Comparator|Heat-sterilized kombucha|
10172318|NCT03873350|No Intervention|Water|
10172319|NCT03873597|Experimental|Tele-coaching + Usual Care|This group will undergo a 12 week physical activity tele-coaching intervention consisting of a step-counter and smartphone application, in addition to usual care. Usual care will also include sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
10187007|NCT03730532|Experimental|Randomised CBT|Cognitive Behavioural Therapy Guided Self Help
9524088|NCT03249987|Other|Paper bladder diary|Participants will be asked to complete the paper diary for three days before crossing over to the electronic diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
9524089|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
9524090|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
9524091|NCT03250078||FAMILIAL PANCREATIC CANCER and/or GENE MUTATION|An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
10172320|NCT03873597|No Intervention|Usual Care|This group will receive sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
9524092|NCT03249857|Experimental|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
9524093|NCT03249857|Active Comparator|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
9524094|NCT03249831|Experimental|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.~The minimally manipulated transplant product is manufactured using the CliniMACS device."
9524095|NCT03250156|Experimental|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
9524096|NCT03250156|Active Comparator|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
9524097|NCT03250156|No Intervention|No Training Control|This group will receive no intervention.
9524098|NCT03250143|Active Comparator|group A|Oral cyclosporine 3mg/kg/day (200mg/day) will be started.If there is no improvement in 1 week then escalating the dose maximum upto 5mg/kg/day.
9524099|NCT03250143|Active Comparator|group B|Oral azathioprine will be started at 1mg/kg/day.If there is no improvement in 1 week then escalating the dose maximum upto 100mg/day
9524100|NCT03249948|No Intervention|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
9524101|NCT03249948|Other|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
9524102|NCT03249948|Other|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
9524103|NCT03249961|Experimental|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
9524104|NCT03249961|Experimental|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
9524105|NCT03249974||Target group|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
9524106|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
9524107|NCT03249818|Other|HITT Device|HITT device to scan eyes of participants 3 times (30 seconds each) at time of admittance to hospital for diagnosed traumatic brain injury. If patient is still in hospital 2 weeks post-enrollment, a second set of 3 tests will be performed
9524108|NCT03249883|Active Comparator|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
9524109|NCT03249883|Active Comparator|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
9524110|NCT03250039|Experimental|Mass Balance|Cumulative recovery of radioactivity in urine and feces
10172321|NCT03873324|Experimental|CPL500036|"PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
9524111|NCT03250039|Experimental|Absolute Bioavailability|Oral absolute bioavailability
9524112|NCT03249896|Experimental|Intervention|Patients in the intervention arm will receive standard medical care and in addition to that, be given the Aina or Aina Mini device for self-monitoring of blood glucose (SMBG), the Habits-GDM mobile app, and a weighing scale.
9527978|NCT03214913|Other|Ruijin Group|"Ruijin Strategy therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR（heart rate） <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT（hematocrit） 25%~35%."
10187008|NCT03730532|Experimental|Randomised CAT|Cognitive Analytic Therapy Guided Self Help
9524113|NCT03249896|No Intervention|Control|"Patients in the control arm will receive standard medical care and only be given the Aina or Aina Mini device for SMBG.~Standard medical care involves one session of face-to-face education by a diabetes nurse educator and a dietician. Patients are initiated on capillary glucose monitoring. Subsequently, standard clinical care is provided by their obstetrician. Participation in this study will not increase the frequency of clinic visits. The frequency of SMBG will be as clinically indicated and not increased as a result of participation in this study. Should the obstetrician feels that insulin is required, it will be initiated and if necessary the patient will be referred to the endocrinology service for management of insulin therapy. In some patients, the clinician may decide to prescribe metformin."
9524114|NCT03250052|Experimental|Part A|Period 1(fimasartan) x 7days - Period 2(fimasartan + linagliptin) x 7days
9524115|NCT03250052|Experimental|Part B|Period 1(linagliptin) x 7days - Period 2(fimasartan + linagliptin) x 7days
9524116|NCT03249870|Experimental|Inotuzumab ozogamicin (INO)|
9524117|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
9524118|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
9524119|NCT03249740|Experimental|Experimental: Phase 1 - GB-102|Subjects will be assigned to 1 of 4 cohorts to receive a single intravitreal injection of up to 2.0 mg (50 μL) GB-102.
9672347|NCT05036824||COVID-19 patients|"Patients admitted to hospital with COVID-19, PCR+ SARS-CoV-2 infection administered thromboprophylaxis with tinzaparin.~Dosage: intermediate or therapeutic dose Frequency of tinzaparin administration: once daily Duration: Unknown"
9672348|NCT05036837|Experimental|OZOPROMAF_SEQ1|"OZOPROMAF consists of: local superficial anesthesia by application of EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (O2O3) mixture by 26Gx 1⁄2 - 0.45x13mm needle into mucosal margin surrounding bone exposure or around situs evidenced by CT scans.~Pain intensity and/or other symptoms are assessed at each visit and the day after by a questionnaire (numerical rating scale).~OZOPROMAF is applied on 7-15 days, depending on patient compliance, until the resolution (i.e. formation of sequestrum and clinical healing -T1).~Follow-up visits are scheduled to confirm healing at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5). Radiographic evaluations of bone healing are scheduled at T3/ T4/T5.~Positive outcomes~at T1/T2 clinical healing (no signs of acute phlogosis and no symptoms compatible with MRONJ);~at T3/ T4/T5 clinical healing and no radiological signs of MRONJ."
9672349|NCT05036772|No Intervention|Standard Practice|The control arm is supported according to the usual practice. The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography
9672350|NCT05036772|Experimental|Interventionnal|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
9672351|NCT05036759|Experimental|68Ga-FAPI, PET/MR|inject 68Ga-FAPI，and then perform PET/MR
9672352|NCT05036629|Experimental|MRI protocol|Feasibility and use of methods developed in clinical research protocols or cognitive: the reproducibility of the parameters of acquisition, of the design of the activation paradigms development and results according to people will be an important element for the future integration of these methods in clinical or cognitive research protocols.
9672353|NCT05036655|Active Comparator|Intervention: PGMP|Sites will implement a perioperative glycemic management pathway based on national guidelines and current evidence, with support of an implementation scientist team.
10172322|NCT03873324|Placebo Comparator|Placebo|PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
9672354|NCT05036655|Active Comparator|Non-intervention: usual care|Sites will perform usual perioperative glycemic management.
9826681|NCT02428478|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
9524120|NCT03249740|Experimental|Experimental: Phase 2 - GB-102|Low dose or high dose injected every 6 months
9524121|NCT03249740|Active Comparator|Active Comparator: Phase 2 - Aflibercept|Aflibercept 2 mg injected every 2 months
9524122|NCT03249701|Experimental|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
9524123|NCT03249701|Placebo Comparator|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
9524124|NCT03249701|Sham Comparator|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
9524125|NCT03249688|Other|Control|Regular health advice
9524126|NCT03249688|Experimental|Multidomain 1|Multidomain lifestyle
9524127|NCT03249688|Experimental|Multidomain 2|Multidomain lifestyle + medical food
9524128|NCT03249441|Experimental|Compassion-focused therapy|Compassion-Focused Therapy (CFT) Participants were taught the main compassion-focused exercises as outlined in 'The Compassion-Mind Guide to Ending Overeating: Using Compassion-Focused Therapy to overcome Bingeing and Disordered Eating' manual (Goss, 2011) over a ten session period (weekly for 2 hours), offered over a 3 month period. Self-criticism and shame were key foci across sessions. Participants in the CFT arm also received Treatment as Usual.
9672355|NCT05036525|Experimental|use HANBIO BarriGel|
9672356|NCT05036525|No Intervention|No anti-adhesive product|
9672357|NCT05036512|Placebo Comparator|Placebo|Placebo as a tablet or capsule with dose based off of preceding cohort's data.
9672358|NCT05036512|Experimental|GBT021601|GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.
9826682|NCT02428478|Active Comparator|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
9826683|NCT02428595|Experimental|Treatment|Eclipse™ System
10187009|NCT03730532|Experimental|Preference CAT|Cognitive Analytic Therapy Guided Self Help
10187010|NCT03730532|Experimental|Preference CBT|Cognitive Behavioural Therapy Guided Self Help
10172323|NCT03873740|Experimental|Single vaccine group A|This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
10172324|NCT03873740|Experimental|Single vaccine group B|This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
9524129|NCT03249441|No Intervention|Treatment as Usual|Treatment As Usual Treatment as usual was based in the Diabetes, Endocrinology and Metabolism Clinic in Galway University Hospital. The Weight Management Service provides assessment by a multi-disciplinary team of endocrinologists, dieticians, nurse specialists and clinical psychologists. Dietary advice is given by a specialist dietician regarding weight management, assessment by the Consultant Endocrinologist with possible medication for management of diabetes and weight, and participation in a healthy lifestyle education program.
9524130|NCT03249506||Cohort 1: Non-SGLT2i new Users|This is a retrospective cohort study identifying participants with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease using the Military Health System (MHS) over a 3-year period. Cohort 1 included participants with incident exposure of one or more non-sodium glucose co-transporter 2 inhibitor (SGLT2i) anti-hyperglycemic agent (AHA) therapy during the study period with no prior or subsequent SGLT2i exposure throughout the study period. New users are defined as participants whose first exposure to any non-metformin AHA medication occurs greater than or equal to (>=) 365 days after their start of observation in the database with no prior exposure to any medication within the same AHA medication class in the prior 365 days.
9524131|NCT03249506||Cohort 2: SGLT2i new Users|Cohort 2 included participants with incident SGLT2i exposure during the study period regardless of prior or concurrent exposure to one or more additional AHA therapy. New users are defined as participants whose first exposure to SGLT2i medication occurs >= 365 days after their start of observation in the database with no prior exposure to the same AHA medication class in the prior 365 days.
9524132|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
9524133|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
9524134|NCT03249402|Experimental|Oral Contraceptive Tablet + JNJ-42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
9524135|NCT03249350|Active Comparator|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
9524136|NCT03249350|Experimental|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
9524137|NCT03249558|Active Comparator|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
9524138|NCT03249558|Placebo Comparator|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
9524139|NCT03249558|Placebo Comparator|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
9524140|NCT03249480|Experimental|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
9524141|NCT03249363|Experimental|Group A - Pulsed PVP-I Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with Povidone-Iodine (PVP-I) diluted to a 3% concentration (30g/l) in 2 l of saline performed before applying the bone graft
9524142|NCT03249363|Active Comparator|Group B - Pulsed Saline Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with only 2 litres of saline solution (without povidone Iodine) performed before applying the bone graft
9524143|NCT03249662|Experimental|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
10172325|NCT03873740|Experimental|Sequential vaccination group A|One dose injection of EV71 inactived vaccines(Vero cells) on Day 0，following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
10172326|NCT03873740|Experimental|Sequential vaccination group B|One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0，following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
10172327|NCT03873155|Experimental|Mindfulness-based cognitive therapy|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.
10172328|NCT03873142|Experimental|Mindful parenting intervention|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in a mindful parenting intervention whilst the same variables are measured. Following the intervention, there will be an 8-week follow-up period, and mindful parenting groups will not run during this time.
10172329|NCT03873285|Experimental|Genodermatosis patients|Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
10172330|NCT03873506|Experimental|Mesenchymal Stem Cell|A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)
10172331|NCT03873220||Monitoring scratch in children|Sensor technology and digital measures will be used to evaluate scratch and sleep in children with atopic dermatitis who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
9524144|NCT03249662|Active Comparator|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
9524145|NCT03249623|Experimental|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
9975284|NCT03916549|Experimental|Group 1|The patients with bowel dysfunction following low anterior resection performed at least 1 year ago will undergo acupuncture. The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
9975285|NCT03898050|Experimental|A-P|Anterior - Posterior pad placement
9524146|NCT03249623|No Intervention|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
9524147|NCT03249311|Experimental|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
9524148|NCT03249311|Active Comparator|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
9524149|NCT03249311|Placebo Comparator|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
9524150|NCT03249571|Experimental|Flavonoid|Flavonoid supplement
9524151|NCT03249571|Placebo Comparator|Placebo|Placebo
9524152|NCT03249597||1. Suspected Infection.|Adult (≥18 years), non-trauma patient transported by the ambulance, who according to the EMS suffer from an infection.
9524153|NCT03249597||2. Control|Adult (>18 years of age), non-trauma patient immediately following the included patient with suspected infection, transported in the same ambulance but without infection.
9524154|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
9524155|NCT03249324|Experimental|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
9524156|NCT03249324|Active Comparator|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
9975286|NCT03898050|Experimental|A-L|Anterior - Lateral pad placement
9524157|NCT03249610|Experimental|Jindal Steel Pvt Ltd|Lifestyle intervention given
9524158|NCT03249610|Experimental|Maruti Udyog Ltd|Lifestyle intervention given
9524159|NCT03249610|No Intervention|Tata Capital|Control arm so no intervention given
9524160|NCT03249610|No Intervention|Powergrid Corporation|Control arm so no intervention given
9527979|NCT03215290|Experimental|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
9527980|NCT03215290|No Intervention|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
9975287|NCT03895580|No Intervention|Group 1|Medical nutrition therapy session with no further dietary counseling throughout the study.
9975288|NCT03895580|Experimental|Group 2|Medical nutrition therapy session plus in-store point-of-purchase (POP) education.
9975289|NCT03895580|Experimental|Group 3|Medical nutrition therapy session plus combined in-store/online point-of-purchase (POP) education.
10172332|NCT03873519|Experimental|Cold North|Group A: Cold color scheme, room facing North
10172333|NCT03873519|Experimental|Cold South|Group B:Cold color scheme, room facing South
10172334|NCT03873519|Experimental|Warm North|Group C: Warm color scheme, room facing North
9527981|NCT03215069|Experimental|Empagliflozin|Empagliflozin 10 mg PO daily
9527982|NCT03215069|Placebo Comparator|Placebo|Matched placebo PO daily
9527983|NCT03215199|No Intervention|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
9528224|NCT03212898|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
10172335|NCT03873519|Experimental|Warm South|Group D: Warm color scheme, room facing South
9524161|NCT03249285|Experimental|Peri profile yes|patient with genetic Perindopril profile, receiving Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
9524162|NCT03249285|Experimental|HCTZ profile yes|patient with genetic HCTZ profile, receiving HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
9524163|NCT03249285|Active Comparator|Peri no profile|patient with no genetic profile, receiving after randomisation Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
9524164|NCT03249285|Active Comparator|HCTZ no profile|patient with no genetic profile, receiving after randomisation HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
9524165|NCT03249428|Active Comparator|Nicotine Replacement Therapy & One-on-One Counseling|Standard NRT such as the nicotine patch, gum, inhaler, and/or lozenge as per participant liking and clinical indication deemed necessary by the expert smoking cessation nurse. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
9524166|NCT03249428|Active Comparator|Electronic Nicotine Delivery Systems & One-on-One Counseling|Electronic Nicotine Delivery Systems with nicotine. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
9524167|NCT03249519|Experimental|Standard Arm|Radiation therapy: 50.4 Gy Brachytherapy: 35-40 Gy Chemotherapy: Cisplatin weekly 40mg/m^2 (6 cycles) Hyperthermia: 10 times
9524168|NCT03249389|Experimental|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
9524169|NCT03249337|Active Comparator|Glanatec(R) 3 times a day|
9524170|NCT03249337|Active Comparator|Glanatec (R) 6 times a day|
9524171|NCT03249298|Active Comparator|Crystalloids|"Bolus of crystalloids~Bolus of 250 ml crystaloids will be infused regarding the measures"
9524172|NCT03249298|Active Comparator|Colloids|"Bolus of colloids~Bolus of 250 ml colloids will be infused regarding the measures"
9524173|NCT03249675||ARM 1|ARM 1: Retrospective Arm: Subjects tested with BNA in the past and have been diagnosed by their physician as having Post Concussive Syndrome. Study staff will contact the subjects and obtain Informed Consent. Study physicians will then review both BNA data and Clinical data. All relevant clinical data and all available BNA data will be shared with ElMindA. Subjects may be invited for an additional BNA follow up as part of the study.
9524174|NCT03249675||ARM 2|"ARM 2: Subjects will be prospectively enrolled in the study at the following time points when available:~Acute: within 2 weeks of injury~PCS: Subjects which sustained a concussion in the past 3 months or more, and are still experiencing symptoms related to the injury"
9524175|NCT03249259|Experimental|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
9524176|NCT03249259|Placebo Comparator|Control|Placebo (2 caps - 1 cap bid)
10172336|NCT03873233|Active Comparator|Volume Controlled Ventilation|Volume Controlled Ventilation with Aisys Carestation ventilator and normal endotracheal tube'
9524177|NCT03249194|Experimental|HCV+ Donor Kidney Recipient|"All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks."
9524178|NCT03249246||Infection only|The patients have only infection
10172337|NCT03873233|Active Comparator|Flow Controlled Ventilation|Flow Controlled Ventilation with Evone ventilator and Tritube
9524179|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
9524180|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
9524181|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
9524182|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
10172338|NCT03873441|Experimental|Computer Games-Aided Balance Training Group|The participants in CGR group will be asked to sit or stand (as per the screening result) on fixed & compliant surfaces; to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects using bi-manual grip gradually progressing to head rotations (mouse mounted on a cap worn by participant); finally using trunk movements as a part of experimental therapy protocol. While performing CGR; children will be standing on a thin pressure mat (placed over fixed or compliant surface). This will allow us to record the information of COP displacement [body sway] while CGR intervention implementation. This information will be used to quantify therapy dosage. The CGR Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
10172339|NCT03873441|Active Comparator|Conventional Balance Training Group|The control group will be receiving the conventional balance training for static and dynamic balance function improvement. The therapy will be provided in sitting or standing (as per the screening result) in a graded manner progressing from fixed surfaces to movable compliant surfaces. The Conventional Balance Training Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
9524183|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
9524184|NCT03248934|Experimental|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
9524185|NCT03248934|Active Comparator|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
9524186|NCT03249220|Experimental|CBMS|
9524187|NCT03249181|Experimental|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
9528225|NCT03212950|Experimental|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
9524188|NCT03249181|Active Comparator|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
9524189|NCT03249051|Experimental|Indirect Calorimetry|The energy need is being determined by using indirect calorimetry and if necessary, optimized by parenteral, enteral and additive parenteral nutrition.
9524190|NCT03249051|No Intervention|Standard Care|"This group receives nutrition supply according to the hospital routine (standard care)"
9524191|NCT03249064||Vitiligo untreated patients|
10172340|NCT03873051|Experimental|Challenge-Focused Program|This group will receive the challenge-focused group program
10172341|NCT03873051|Experimental|Rewards-Focused Program|This group will receive the rewards-focused group program
9524192|NCT03249064||Control. Patients without vitiligo|
9524193|NCT03249103|Placebo Comparator|Placebo|Up to 24 subjects will receive Placebo, NYX-2925 Low Dose, and NYX-2925 High Dose
9524194|NCT03249103|Experimental|NYX-2925 High Dose|Up to 24 subjects will receive High Dose of NYX-2925
9524195|NCT03249103|Experimental|NYX-2925 Low Dose|Up to 24 subjects will receive Low Dose of NYX-2925
9524196|NCT03249012|Experimental|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
9524197|NCT03249012|Experimental|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
9524198|NCT03249168|Experimental|case group|Duloxetine 60mg orally 12 hours before surgery
9826684|NCT02428608|Experimental|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
9826685|NCT02428699|Experimental|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
9826686|NCT02428699|Active Comparator|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
9826687|NCT02428855|Experimental|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen~Dasatinib, oral, daily, predetermined dosage per cycle~Radiologic Response Assessment every 2 cycles"
10172342|NCT03873090|Experimental|SBRT in 4 fraction|Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT
10172343|NCT03873246|Placebo Comparator|Placebo|
10172344|NCT03873246|Active Comparator|OC-01 0.1%|
10172345|NCT03873246|Active Comparator|OC-01 0.2%|
10172346|NCT03873077|No Intervention|intravenous analgesia|Patient receives intravenous analgesia: paracetamol 30 mg/kg, diclofenac 75 mg, clonidine 1 µg/kg and morfine 0,05 mg/kg
10172347|NCT03873077|Other|intravenous analgesia + LIA|Patient receives intravenous analgesia and a local infiltration analgesia in the knee
10172348|NCT03873064||patients with solid tumor|All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
10187011|NCT03730519|Active Comparator|Patients with refractory hypertension|Patients with refractory hypertension which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
10187012|NCT03730519|Active Comparator|Patients with highly variable BP|Patients with symptomatic highly variable blood pressure due to afferent baroreceptor failure which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
9524199|NCT03249168|Active Comparator|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
9524200|NCT03249077||Digital DPP enrolled|The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants.
9524201|NCT03249077||In-person DPP enrolled|In-person DPP participants will attend group sessions of ~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum,
9524202|NCT03249077||DPP not enrolled (usual care)|Access to usual care services without restrictions.
9524203|NCT03248869|Active Comparator|Current Daily Survey|need description
9524204|NCT03248869|Experimental|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
9524205|NCT03248856|Other|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
9524206|NCT03248856|Other|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
9524207|NCT03248856|Other|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
9524208|NCT03248856|Other|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
9524209|NCT03248895|Active Comparator|Immediate (I-med)|Participants allocated to the I-med group will take part in the mobile DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up
9524210|NCT03248895|Active Comparator|Delayed (D-med)|"Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up."
9524211|NCT03249025|Experimental|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
9524212|NCT03248908|Experimental|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
9826688|NCT02429115|Experimental|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
9826689|NCT02429115|Experimental|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
10187013|NCT03730506|Experimental|CBCT|
10187014|NCT03730506|Experimental|IOS|
10187015|NCT03730506|Active Comparator|desktop scanner|
9524213|NCT03248908|Active Comparator|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
10172349|NCT03873129|Experimental|A-CHESS|participant will be using the A-CHESS mobile app for 12 months
10172350|NCT03873025|Experimental|Pembrolizumab and CXD101|"Initial dose ('dose level 0'):-~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 20mg twice daily PO (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity.~Reduced dose level ('Dose level -1'; if >1 DLT observed at dose level 0):~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 given twice daily, 20mg in the morning and 10mg in the evening (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity."
9524214|NCT03248908|Experimental|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
9524215|NCT03248908|Active Comparator|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
9524216|NCT03249142|Experimental|ARM A Durvalumab/chemotherapy association|
9524217|NCT03249142|Experimental|ARM B Durvalumab/Tremelimumab/chemotherapy association|
9524218|NCT03249155|Experimental|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
9524219|NCT03249155|Active Comparator|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
9524220|NCT03248726|Experimental|Polyethylene glycol and bisacodyl|In order to decrease the dose and frequency of polyethylene glycol, we added bisacodyl at the night before examination to facilitate the action of polyethylene glycol given solely in the morning of examination.
9524221|NCT03248726|Active Comparator|Split-dose polyethylene glycol|The standard regimen of polyethylene glycol was used in this group. The participant of this arm receives polyethylene glycol in the evening before examination and the morning of examination .
10187016|NCT03730493|Experimental|Pictorial flashcard|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). Time was noted and kept for observation till 72 hours or removal in between.
9524222|NCT03249207|Active Comparator|IL-1Ra twice daily|
9672359|NCT05036551||Stage 2 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
9672360|NCT05036551||Stage 3 Knee osteoarthritis|The Visual Analogue Scale (VAS) was used to determine the severity of the pain. Tampa Scale for Kinesiophobia (TSK) was used to evaluate kinesiophobia. The functional state was evaluated using The Western Ontario and McMaster Universities Arthritis Index (WOMAC). The Arthritis Self Efficacy Scale was used to determine self efficacy perception.
9524223|NCT03249207|Placebo Comparator|Placebo twice daily|
9524224|NCT03248778|Experimental|disclosure-support counseling|
9524225|NCT03248778|No Intervention|Treatment as Usual|
9672361|NCT05036707|Active Comparator|1|Healthy Volunteer
10187017|NCT03730493|No Intervention|Comparison Group|In control group, standard care was given as per the hospital protocol.Time was noted and kept for observation till 72 hours or removal in between.
9524226|NCT03248752|Active Comparator|Group 1 - Self monitored|Fitbit use and reports details: Participants will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device and receive a Weekly Progress Report from Fitbit.
9524227|NCT03248752|Experimental|Group 2 - Partner monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device. Participant will also engage with their partner through the Fitbit application. They will have access to their partner's daily progress and be able to communicate through the application. They will also receive their partner's Weekly Fitbit Reports and have a weekly discussion about the Weekly Fitbit Report.
9524228|NCT03248804|Experimental|Soy Group|Subjects in the soy group were asked to participate in the Colorado Diet program and to consume 3 soy food items per day.
9524229|NCT03248804|Other|Non-soy Group|Subjects in the non-soy group were asked to participate in the Colorado Diet program and to avoid soy food products.
9524230|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
9524231|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
9524232|NCT03248817|Experimental|single shot|spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered
9524233|NCT03248817|Active Comparator|fixed infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred
9524234|NCT03248817|Active Comparator|variable infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure
9672362|NCT05036889|Experimental|MND|Subject's physician in this group will be using the Mind.Px report as a treatment reference for prescribing the subject's biologic.
9672363|NCT05036889|No Intervention|TAU|Treatment as usual. This group will have the biologic prescribed with results given to the physician at the end of the subject's participation and will not be used as a reference for the subject's treatment.
9826690|NCT02429115|No Intervention|Control|Will not receive peer mentoring.
9826691|NCT02429258|Experimental|Farxiga with metformin or insulin|Farxiga with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
9524235|NCT03248713|Active Comparator|Mifepristone|Mifepristone 600 mg/day in 2 tablets
9524236|NCT03248713|Placebo Comparator|Placebo|matching placebo in 2 tablets
10172351|NCT03872960|Experimental|Intervention Arm: Expedited transfer to a CAC|The intervention arm consists of activation of the pre-hospital triaging system currently in place for post-arrest STE patients. This involves pre-alert of the CAC and strategic delivery of the patient to the catheter laboratory (24 hours a day, 7 days a week). Patients will receive definitive post-resuscitation care: intubation and ventilation, where necessary, targeted temperature management, and goal directed therapies including evaluation and identification of underlying cause of arrest with access to immediate reperfusion if necessary. Prognostication will occur no earlier than 72 hours post-cardiac arrest to prevent premature withdrawal of life-sustaining treatment. Transfer times estimated from the 40-patient pilot are anticipated to be 100 minutes (median; IQR 75 to 113) from time of arrest to the designated centre.
9524237|NCT03248635||Focus group|Male and female adults age 40-75
9524238|NCT03248583|Experimental|Default|
10172352|NCT03872960|No Intervention|Control Arm: Current standard of care|The control arm comprises the current standard of pre-hospital advanced life support (ALS) care management for patients with ROSC following cardiac arrest of suspected cardiac aetiology. The patient is conveyed to the geographically closest emergency department. Management thereafter will be as per standard hospital protocols however as in the intervention arm, prognostication is to be delayed in trial patients until at least 72 hours post arrest.
9524239|NCT03248583|Active Comparator|Psychoeducation|
9524240|NCT03248583|Active Comparator|Incentive|
9524241|NCT03248544|Experimental|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
9524242|NCT03248544|Other|control|Control patients will not be received any intervention
9524243|NCT03248609|Experimental|Milano grapes|Unique grape varietal to test glycemic response.
9524244|NCT03248609|Active Comparator|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
9524245|NCT03248609|Active Comparator|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
9524246|NCT03248609|Placebo Comparator|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
9524247|NCT03248687|Experimental|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
9524248|NCT03248687|Active Comparator|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
9524249|NCT03248791|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
9524250|NCT03248791|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
9826692|NCT02429258|Placebo Comparator|Placebo with metformin or insulin|Placebo with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
9524251|NCT03248622||Anti-HBc positive|Anti-HBc positive
9524252|NCT03248622||HCV positive Cohort|HCV positive Cohort
9524253|NCT03249233|Experimental|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
9524254|NCT03249233|Experimental|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
9524255|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
9524256|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
9524257|NCT03248414|Experimental|Lactobacillus sakei|2 packs per day
9975290|NCT03884920||Group A Pre-diabetic placebo|Group of pre-diabetics receiving placebo BD for six weeks
9524258|NCT03248414|Placebo Comparator|Control|2 packs per day
9524259|NCT03248960|Experimental|iTreat Flu A+B Test and ellume.lab Flu A+B Test|"Upper respiratory tract samples from participants will be tested with:~iTreat Flu A+B Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); and viral culture."
9524260|NCT03248505|Placebo Comparator|Placebo TENS|TENS unit turned on, but with zero amplitude.
9524261|NCT03248505|Experimental|Conventional TENS|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude.
9524262|NCT03248505|Experimental|Burst TENS|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
9524263|NCT03248505|Experimental|Cryotherapy|1,5 Kg crushed ice pack
9524264|NCT03248505|Experimental|Burst TENS + Cryotherapy|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus an ice pack of 1,5 Kg.
9826693|NCT02429310|No Intervention|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
9975291|NCT03884920||Group B Pre-diabetic test|Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks
9975292|NCT03884920||Group C Diabetic test|Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks
10172353|NCT03872934||Turkish music group|Turkish music group (Saba or rast makam)
10172354|NCT03872934||classical western music|classical western music (vivaldi)
10172355|NCT03872934||soft rock music|soft rock music (elvis)
10172356|NCT03872934||control group (group not listening music)|control
10172357|NCT03872765|Other|Patients with chronic anal fissure|Use of laser in surgery of chronic anal fissure instead of the conventional surgical techniques.
10172358|NCT03872921|Experimental|norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg capsules, 6 capsules/day for 2 years
10172359|NCT03872921|Placebo Comparator|Placebo to norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg Placebo-capsules, 6 capsules/day for 2 years
10172360|NCT03872648||TW-VP (centralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC in a specialized clinic with a centralized structure
10172361|NCT03872648||TW-VP (decentralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC from different medical locations (decentralized structure)
10172362|NCT03872817|Experimental|Intervention ProLiSMentAl|"Experimental Group receive mental health literacy psychoeducational intervention called ProLiSMentAl that consist of 4 sessions of 90 minutes."
10172363|NCT03872817|No Intervention|Control Group|Control Group receive usual approach.
10172364|NCT03872687|Experimental|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size for 6 months.
10172365|NCT03872687|Active Comparator|interdental brushes|Subjects in this group will only receive interdental brushes 6 months.
10172366|NCT03872869|Active Comparator|Hip School|The participants in the Hip School were required to attend three 1.5 hour classes which were conducted by specially trained physiotherapists in premise at Lund University.
10172367|NCT03872869|Active Comparator|Tai Chi for arthritis (TCA)|The treatment intervention with TCA was scheduled in a group setting. Class size for Tai Chi groups was 8- 10 individuals. The group was led by a physiotherapist, specially trained in the concept, in premise at Lund University. The participants in the Tai Chi group were required to attend classes for 12-16 one- hour sessions, twice a week for the first four weeks and then once a week.
10172368|NCT03872869|No Intervention|Control group|
10172369|NCT03872661|Experimental|Drug and surgery|Neoadjuvant therapy followed by surgery. Neoadjuvant therapy included four drugs. IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles; bevacizumab was administered at a dose of 15 mg/kg; pemetrexed was given 500 mg/m^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles; carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles. Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
10172370|NCT03872674|No Intervention|standard oxygenation(nasal cannula)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
10172371|NCT03872674|Experimental|high-flow humidified oxygen-delivery system(OptiFlow THRIVE)|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
10172372|NCT03872622|Other|CD patients|New onset Crohn's disease patients
10172373|NCT03872622|Other|Healthy controls|Patients' family members and healthy subjects undergoing colonoscopy for non-research purposes
9524265|NCT03248505|Experimental|Conventional TENS + Cryotherapy|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude plus an ice pack of 1,5 Kg.
9524266|NCT03248661|Experimental|Intervention media condition|monthly social media contact will be used to keep people connected to the idea of completing a second screening test 12 months after their last one.
9524267|NCT03248661|No Intervention|control condition|this group will receive only a standard reminder for the annual repeat test, one month before the test due date
9524268|NCT03248999|Experimental|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
9524269|NCT03248323||pre-con|
9524270|NCT03248466|Placebo Comparator|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
9524271|NCT03248466|Experimental|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
9524272|NCT03248466|No Intervention|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
9524273|NCT03248453|Experimental|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
9524274|NCT03248453|No Intervention|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
9524275|NCT03248700|Experimental|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
9524276|NCT03248648|Active Comparator|Neostigmine group|At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
9524277|NCT03248648|Active Comparator|ketamine group|At the end of the surgery patients receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
9975293|NCT03878446|Experimental|0.24 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
9975294|NCT03878446|Experimental|0.20 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
9975295|NCT03878446|Experimental|0.16 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
10172374|NCT03872752|Experimental|Lay leader training in FL intervention|Community lay leaders from pre-existing community frameworks will undergo training in a manualized program that enables lay leaders to effectively disseminate food literacy skills through engaging visual and game-based tools in a food literacy workshop. Post training, lay leaders will implement the food literacy workshop in their communities.
10172375|NCT03872635|Experimental|CHO Drinking Grope|receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
9524278|NCT03248401|Experimental|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
9524279|NCT03248401|Active Comparator|Aspirin group|Aspirin 100 mg
9524280|NCT03248518|Active Comparator|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
9528226|NCT03212950|Active Comparator|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
9528227|NCT03212781|Experimental|intravenous iron|patients will receive intravenous iron as total dose infusion
9975296|NCT03878446|Active Comparator|0.035 mg/kg Norditropin®|Same treatment in main period (13 weeks) and extension period (39 weeks)
9524281|NCT03248518|Active Comparator|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
9524282|NCT03248518|Active Comparator|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
9524283|NCT03248336|Experimental|Vision therapy group|Twelve, 60-minute, weekly visits of office-based vergence/accommodation therapy will be administered by a trained therapist combined with procedures to practice at home (15 minutes, 5 times per week). This treatment sequence is a well-accepted approach for treatment of CI and has been successfully implemented in previous studies. Fifteen minutes of home-based therapy was prescribed to be performed 5 days per week, and compliance with home-based therapy was monitored at each visit by the therapist
9524284|NCT03248427|Experimental|Ribociclib + Letrozol|Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
9524285|NCT03248427|Other|Chemotherapy|Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
9524286|NCT03248375|Other|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
9524287|NCT03248362|Experimental|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
9524288|NCT03248362|Sham Comparator|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
9524289|NCT03248349||1|Pharmacokinetics
9524290|NCT03248271||Type 2 Diabetes, Insulin Naive|Study participants will be tested prior to and 3 and 6 months after starting insulin to manage their diabetes
9524291|NCT03248297|Experimental|Azithromycin and amoxicillin placebo|Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
9524292|NCT03248297|Experimental|Azithromycin + amoxicillin|Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
9524293|NCT03248297|Placebo Comparator|Usual Care|This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
9524294|NCT03248011|Experimental|Flexibility|Stretching exercise
9524295|NCT03248011|Experimental|Strength|Eccentric hamstring strengthening exercise
9524296|NCT03248011|Experimental|Neuromuscular|Balance exercise
9524297|NCT03248011|No Intervention|Control|No exercise
9524298|NCT03248245|Experimental|LOG-model schools|Experimental schools implement the LOG-model
9524299|NCT03248245|Active Comparator|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
9524300|NCT03248063|Active Comparator|Cloxacillin|Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion.
9524301|NCT03248063|Experimental|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion.
9524302|NCT03248050|Experimental|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
9524303|NCT03248050|No Intervention|Control pharmacy|
9524304|NCT03248180||Guided dose reduction (GDR)|Patients in the GDR group will be advised to reduce < 25% of their current dose of antipsychotic agents estimated on a weekly base and follow-up every 4 weeks for at least 12 weeks.
9524305|NCT03248180||Maintenance treatment group (MTG)|Patients in the MTG will be advised to stay on their current dose of antipsychotics throughout the observational period, follow-up every 12 weeks.
9524306|NCT03247972||Patients with PAD|
9524307|NCT03248102|Experimental|Patients with suspected appendicitis|Patients with suspected appendicitis Aged 5 and up to their 16th birthday on arrival to A&E
9524308|NCT03248193|Experimental|Healthy subjects|To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.
9524309|NCT03248193|Experimental|Cancer subjects|Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
9524310|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
9975297|NCT03878446|Active Comparator|0.067 mg/kg Norditropin®|Same treatment in main period (13 weeks) and extension period (39 weeks)
9975298|NCT03875690|Experimental|Experimental group|
9975299|NCT03875690|Placebo Comparator|Control group|
9524311|NCT03247907|Active Comparator|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
10172376|NCT03872635|No Intervention|Traditional fast Grope|fast on standard hospital protocol (8 hour fasting for solid and 4 hour fasting for clear liquid
10172377|NCT03872986|Experimental|SDF+Giomer|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Beautifil II restorative material
10172378|NCT03872986|Experimental|Giomer only|Beautifil II dental restorative material
10172379|NCT03872986|Experimental|SDF+GIC|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Equia forte
10172380|NCT03872986|Experimental|GIC only|Equia forte dental restorative material
9524312|NCT03247907|Active Comparator|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
9524313|NCT03247907|Active Comparator|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
9524314|NCT03247907|Active Comparator|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
9524315|NCT03247907|Active Comparator|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
9524316|NCT03247907|Active Comparator|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
10172381|NCT03872804|Experimental|Vitiligo patient|Patient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
10172382|NCT03872739|Experimental|distilled water|Oral distilled water at the rate of 3 mL/kg/h rate during undergoing enhanced computed tomography examination before 1-2 and after 4-6 hours
9524317|NCT03247907|Active Comparator|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
9524318|NCT03247907|Active Comparator|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
9524319|NCT03247998|Experimental|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, & David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
9524320|NCT03247998|Experimental|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
9524321|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
9524322|NCT03248206|Active Comparator|PNF exercise program group|The PNF home-program exercise group: perform grade 1&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
9524323|NCT03248206|Experimental|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
9524324|NCT03247920|Active Comparator|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
9524325|NCT03247920|Active Comparator|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
9524326|NCT03247946|Active Comparator|Intervention group|intervention: upright head position
9524327|NCT03247946|No Intervention|Control group|no feeding position instructions
9524328|NCT03248128|Experimental|Subjects receiving FF/VI in cohort A|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
9524329|NCT03248128|Active Comparator|Subjects receiving FF in cohort A|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
9524330|NCT03248128|Experimental|Subjects receiving FF/VI in cohort B|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
9524331|NCT03248128|Active Comparator|Subjects receiving FF in cohort B|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
9524332|NCT03247959|Experimental|Group A|Group A: Videogame distraction during extraction procedure
9524333|NCT03247959|Experimental|Group B|Group B: Video distraction during extraction procedure
9524334|NCT03247959|Active Comparator|Group C|group C: Verbatim during extraction procedure
9528228|NCT03212781|Active Comparator|oral iron|patients will receive oral iron
9975300|NCT03860038|Experimental|TJ202|
9528229|NCT03212911|Active Comparator|3-standard dose HBV vaccination group|participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months
10172383|NCT03872739|Placebo Comparator|Saline|intravenous saline hydration at the rate of 1 mL/kg/h rate during undergoing enhanced computed tomography examination before and after 12 hours
9524335|NCT03247933|Experimental|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
9524336|NCT03247933|No Intervention|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.~Clinical practice."
9524337|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
9524338|NCT03247881|Active Comparator|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
10172384|NCT03872856|Active Comparator|BP-ICAN|Participants in the BP-ICAN arm will receive a home blood pressure monitor to be used twice daily for 12 months. Participants' home blood pressure measurements will be shared with their provider and participants will receive a series of text messages including topics on the importance of managing hypertension, reminders to measure blood pressure with their device, and motivational messages on diet and exercise.
10172385|NCT03872856|No Intervention|Control|Participants in the control arm will receive care as usual for the treatment of hypertension
9524339|NCT03247868|Experimental|Botulinum toxin+SPRInt protocol|patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.
9524340|NCT03247855|Other|Minimal invasive coronary artery bypass graft|
9524341|NCT03247608|Experimental|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
9524342|NCT03247647|Experimental|Enhanced Intervention|Participants assigned to this arm will complete a personal values task before reviewing their personalized feedback (eCheckUpToGo).
9524343|NCT03247647|Placebo Comparator|Standard Intervention|Participants assigned to this arm will complete a writing task about the food they have eaten in the past 48 hours immediately before reviewing their personalized feedback (eCheckUpToGo).
9524344|NCT03247699|Other|"Basel phenotyping cocktail capsule"|
10172386|NCT03872700|Experimental|Intranasal fentanyl|2 mcg/kg INF, administered via intranasal route by atomizer syringe
9524345|NCT03247699|Other|"Basel phenotyping cocktail individual components"|
10172387|NCT03872700|Experimental|Placebo|0.04ml/kg of sterile water, administered via intranasal route by atomizer syringe
9524346|NCT03247712|Experimental|Treatment Cohort 1|Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
9524347|NCT03247712|Experimental|Treatment Cohort 2|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
9524348|NCT03247712|Experimental|Treatment Cohort 3|Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
9524349|NCT03247712|Experimental|Treatment Cohort 4|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
9975301|NCT03845296|Experimental|Treatment (rucaparib)|Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10172388|NCT03872830|Experimental|Experimental: group1|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
10172389|NCT03872830|Experimental|Experimental: group2|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
9524350|NCT03247491|Experimental|Experimental|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
9524351|NCT03247491|No Intervention|No intervention|Usual medical treatment (TAU) In this group the midwife will apply the usual treatment (childbirth education class in the third trimester of pregnancy).
9527984|NCT03215199|Active Comparator|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
9527985|NCT03215056|Experimental|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.~Dose of PENTHROX® should not exceed 6 mL in a single administration.~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 6 mL of methoxyflurane."
9528230|NCT03212911|Active Comparator|4-standard dose HBV vaccination group|participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months
9528231|NCT03212937|Experimental|Selinexor and ICE Chemotherapy|
9524352|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
9524353|NCT03247621|Experimental|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
9524354|NCT03247621|Placebo Comparator|Article|Participants will read a neutral article on their smartphones during the taste test
9524355|NCT03247621|Active Comparator|No Phone|Participants will not use their phones during the taste test
9524356|NCT03247777|Active Comparator|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
9524357|NCT03247777|Active Comparator|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
9524358|NCT03247660|Experimental|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
9524359|NCT03247660|Experimental|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
9524360|NCT03247660|Active Comparator|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
9524361|NCT03247595|Active Comparator|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
9524362|NCT03247595|Experimental|Magnesium Citrate Capsules|36 Magnesium citrate capsules
9524363|NCT03247725|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
9524364|NCT03247725|Experimental|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
10172390|NCT03872830|Experimental|Experimental: group3|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:188.5mg Volume:8ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
10172391|NCT03872830|Placebo Comparator|Experimental: group4|Generic name:Placebo; Placebo:normal saline Dosage form:Injection Dosage:4ml/injection Volume:10ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the placebo.
9524365|NCT03247725|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
9524366|NCT03247842|Active Comparator|suprascapular nerve RF|Eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups (Figure1); forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (PRF) followed by injection through the radiofrequency needle of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1)
9524367|NCT03247842|Active Comparator|suprascapular nerve block|and forty patients received fluoroscopically guided supra-scapular nerve injection of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.
9524368|NCT03247751|Experimental|one group|one group receiving NIDEK intraocular lens
9524369|NCT03247803|Experimental|Air-Q SP|air-Q Self-Pressurizing intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mecury Medical, Clearwater, FL, USA)
9524370|NCT03247803|Experimental|Williams Intubating Airway|Airway Intubator, Williams, Adult Female, Single Use, Molded Surlyn Plastic, 9 cm or Airway Intubator, Williams, Adult Male, Single Use, Molded Surlyn Plastic, 10 cm
9524371|NCT03247829||Patients with CardioMEMS and LVAD|Patients with CardioMEMS and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS
9524372|NCT03247478||invasive breast cancer|Patients with invasive breast cancer who underwent computed tomography (CT) reconstruction of axillary lymph node for assessment of lymph node response after NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis.
9524373|NCT03247465|Experimental|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
9826694|NCT02429310|Experimental|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
10172392|NCT03872973|Experimental|Training Group|Neuromuscular training will be performed in this group for 6 weeks.
10172393|NCT03872973|Experimental|Strobe Group|This group will perform neuromuscular training for 6 weeks with a strobe glasses.
10172394|NCT03872973|No Intervention|Control Group|This group will not perform any neuromuscular training program.
9524374|NCT03247465|No Intervention|"Group Control"|Trans aortic valve replacement with usual procedure
9524375|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
9524376|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
9524377|NCT03247452|Active Comparator|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
9524378|NCT03247452|Experimental|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
9524379|NCT03247439|Experimental|Cartiva|Synthetic Cartilage Implant
9524380|NCT03247361|Experimental|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.~Exercise: see group Combined aerobic/resistance exercise"
9524381|NCT03247361|Active Comparator|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.~Exercise: see group Combined aerobic/resistance exercise"
10172395|NCT03872596|Experimental|Part A: Sequence 1|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.~Treatment Period:~Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15."
9524382|NCT03247361|Sham Comparator|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
9826695|NCT02429427|Experimental|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
9524383|NCT03247283|Experimental|Single Oral Dose of BMS-986205|
9524384|NCT03247413|Experimental|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
9524385|NCT03247413|Placebo Comparator|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
9524386|NCT03247127|Other|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
9524387|NCT03247192|Experimental|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
9524388|NCT03247192|Experimental|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
9524389|NCT03247192|Placebo Comparator|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
9826696|NCT02429427|Placebo Comparator|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
9524390|NCT03247140|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
10172396|NCT03872596|Experimental|Part A: Sequence 2|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15."
9524391|NCT03247140|Experimental|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
9524392|NCT03247400|Active Comparator|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
9524393|NCT03247400|Active Comparator|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
9524394|NCT03247400|Placebo Comparator|Vehicle ointment|Placebo ointment applied onto limbs opposite to treated with active substances
9524395|NCT03247270|Experimental|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
9524396|NCT03247270|Experimental|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
9524397|NCT03247270|No Intervention|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
9524398|NCT03247153|Experimental|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
9524399|NCT03247179|Experimental|PTSD Coach Condition|PTSD Coach App
9524400|NCT03247179|No Intervention|Treatment as Usual Condition|Treatment as Usual
9524401|NCT03247374|Experimental|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
9524402|NCT03247374|Active Comparator|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
9524403|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
9524404|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
9524405|NCT03247244|Other|1|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD <0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC <0.3%, CBD <0.3%).
9524406|NCT03247244|Other|2|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC <0.3%, CBD <0.3%), A (THC 10%, CBD <0.5%), C (THC 0.6%, CBD 14%).
9524407|NCT03247244|Other|3|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD <0.5%), placebo D (THC <0.3%, CBD <0.3%), B (THC 8.6%, CBD 8.6%).
9524408|NCT03247244|Other|4|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC <0.3%, CBD <0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD <0.5%).
9524409|NCT03247257|Active Comparator|Group A: General Anesthesia|35 patients will be randomized to receive general anesthesia during their laparoendoscopic single site incision cholecystectomy.
9524410|NCT03247257|Active Comparator|Group B: Epidural Anesthesia|35 patients will be randomized to receive epidural anesthesia during their laparoendoscopic single site incision cholecystectomy.
9524411|NCT03247166|Experimental|Lower Back and Leg Pain Patients|Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System
9524412|NCT03247218|Experimental|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.~The study drug will be taken once a day per os, during one year."
9524413|NCT03247101|Experimental|Probiotics group|Miyarisan-BM (Clostridium Butyricum Miyairi) 40 mg po tid x 6 months
9524414|NCT03247101|Active Comparator|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
9524415|NCT03247101|Active Comparator|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
9524416|NCT03247075|Experimental|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
9524417|NCT03247075|Active Comparator|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
9524418|NCT03246789|Experimental|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
9524419|NCT03246789|Active Comparator|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
9524420|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
9524421|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
9524422|NCT03246919|Placebo Comparator|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
9524423|NCT03246919|Active Comparator|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
10187018|NCT03730415|Experimental|Viscoelastic (VE) guided transfusion|The intervention made in the VE guided transfusion group is that the VE results will be available to the treating physicians to guide transfusions based on VE results during their burn excision.
9524424|NCT03246802|Experimental|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
9524425|NCT03246893|Placebo Comparator|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
9524426|NCT03246893|Experimental|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
9524427|NCT03246854|Experimental|DBPR112|
9524428|NCT03246997|Other|Autumn Group|Intervention Group
9524429|NCT03246997|Other|Spring Group|Delayed Intervention
9524430|NCT03247062|Other|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.~The entire ICU population will be observed before and after intervention."
9524431|NCT03246776|Experimental|Halometasone Triclosan Cream|All subjects receive external Use of Halometasone Triclosan Cream
9524432|NCT03246867|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position.
9524433|NCT03246867|Experimental|Static stretching group|The participants in this group will receive static stretching in modified cross body position.
9524434|NCT03246867|Active Comparator|Control group|The participants in this group will receive no stretching. They will only be evaluated.
9524435|NCT03246763|Experimental|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
9524436|NCT03246763|Experimental|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
9524437|NCT03246763|Experimental|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
9528232|NCT03212755|Experimental|group 1|25 diabetic patients without diabetic nephropathy
9528233|NCT03212755|Experimental|group 2|25 type 2 diabetic patients with diabetic nephropathy
9826697|NCT02429778|Experimental|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
9528234|NCT03212755|Sham Comparator|group 3|25 healthy subjects
9528235|NCT03212313|Active Comparator|Healthy Subjects|Study dose of 120 mg
9528236|NCT03212313|Experimental|Mild Hepatic Impairment|Study dose of 120 mg
9528237|NCT03212313|Experimental|Moderate Hepatic Impairment|Study dose of 120 mg
10172397|NCT03872596|Experimental|Part A: Sequence 3|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15."
10172398|NCT03872596|Experimental|Part B: Sequence 1|Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
10172399|NCT03872596|Experimental|Part B: Sequence 2|Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
10172400|NCT03872557|Active Comparator|Tyrosine (TYR) depletion, then oral TYR|"TYR supplementation: Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before oral glucose tolerance test (OGTT). On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Visit 2. Placement of intravenous catheter for the collection of serial blood samples and an OGTT with supplementation with oral tyrosine supplement. To supplement the OGTT with Tyrosine, the contents of four (4) L-Tyrosine 500 mg capsule are given 45 minutes before the oral glucose solution is administered. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity."
10172401|NCT03872557|No Intervention|TYR depletion, then no oral TYR|"Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before OGTT. On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Subsequent Visit 3. This visit will consist of placement of intravenous catheter for the collection of serial blood samples and an OGTT without supplementation with oral tyrosine supplement."
9524438|NCT03246763|Experimental|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
10172402|NCT03872583|Experimental|Understanding MRI in MS (website)|Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
9524439|NCT03247114|Experimental|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
10172403|NCT03872583|Active Comparator|Control website|Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
10172404|NCT03872570|Active Comparator|phenylephrine|starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
9524440|NCT03247114|Experimental|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
10172405|NCT03872570|Active Comparator|norepinephrine|starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
10172406|NCT03872297|Placebo Comparator|Placebo supplement|Consumption of a non active food complement during 3 months.
10172407|NCT03872297|Active Comparator|Naticol supplement|Consumption of the active food complement during 3 months containing Naticol.
9524441|NCT03247114|Experimental|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
9524442|NCT03247114|Experimental|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
9524443|NCT03247114|Experimental|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
9524444|NCT03247114|Experimental|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
10172408|NCT03872310|Active Comparator|Active comparator|Within group
9524445|NCT03247114|Experimental|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
9524446|NCT03247114|Experimental|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
10172409|NCT03872310|Sham Comparator|Sham comparator|Within group
9524447|NCT03247114|Experimental|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
9524448|NCT03247114|Experimental|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
9524449|NCT03246984|Experimental|VasQ device implantation|
9524450|NCT03246698|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position. Additionally they will receive standard physiotherapy.
9524451|NCT03246698|Experimental|Static stretching group|"The participants in this group will receive static stretching in modified cross body position.~Additionally they will receive standard physiotherapy."
10172410|NCT03872505|Active Comparator|Chemotherapy + Durvalumab|Arm A: Carboplatin, Paclitaxel and Durvalumab
9524452|NCT03246698|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
9524453|NCT03246750|Experimental|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
9524454|NCT03246880|Experimental|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
9524455|NCT03246880|Active Comparator|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
9524456|NCT03246880|Active Comparator|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
9524457|NCT03246737||pregnant women|
10172411|NCT03872505|Experimental|Chemo + Durvalumab + Radiation Therapy|Arm B: Carboplatin, Paclitaxel and Durvalumab + Radiation Therapy
9524458|NCT03246971|Experimental|Wafermine™|
10172412|NCT03872245|Experimental|PENS T6 + Probiotics|The patients will receive Probiotics (Adomelle 1caps/12h) associated to PENS T6 during 10 weeks.
10172413|NCT03872245|Active Comparator|PENS T6|The patients will undergo PENS T6 during 10 weeks.
10172414|NCT03872362||Training dataset|No interventions
9524459|NCT03246971|Placebo Comparator|Placebo|
9524460|NCT03246945|Experimental|Study Arm|Patient-Parent Dyad receiving photography instructions prior to taking photographs of skin conditions
9524461|NCT03246945|No Intervention|Control Arm|Patient-Parent Dyad not receiving photography instructions prior to taking photographs of skin conditions
9524462|NCT03246555|Experimental|Fimasartan or Fimasartan/Hydrochlorothiazide|
9524463|NCT03246555|Active Comparator|Perindopril or Perindopril/Indapamide|
9524464|NCT03246620|Experimental|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
9524465|NCT03246620|Active Comparator|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
9524466|NCT03246620|Active Comparator|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
9524467|NCT03246659|Experimental|arm 1|111In-CP04
9524468|NCT03246659|Experimental|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
9524469|NCT03246685|Experimental|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
9516846|NCT03311672|Experimental|Cohort 1 - Immunotherapy Alone|Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
9524470|NCT03246685|Experimental|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
9524471|NCT03246711||Totally fasting|Fasting each day from sunrise to sunset the whole month
9524472|NCT03246711||Partially fasting|means fasting from sunrise to sunset part of the month
9524473|NCT03246711||Non fasting|women who did not fast at all
9524474|NCT03246594|Experimental|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.~Placement of oesophageal probe for temperature measurement"
9672364|NCT05036798|Experimental|Tislelizumab combined with Lenvatinib and GEMOX|"Chemotherapy regimen(GEMOX):~Gemcitabine 1g/m2,Oxaliplatin 100mg/m, D1, Q3W Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD~Receive at least 3 cycles of combined treatment, and perform imaging evaluation after 3 cycles of treatment. If surgical treatment is not possible, imaging evaluation will be performed every two cycles thereafter until surgical treatment is feasible. If more than 7 cycles are still not possible for surgical resection, enter Tislelizumab + Lenvatinib maintenance treatment until the disease progresses or the toxicity cannot be tolerated.~If patients undergoing R0 resection, start to receive Tislelizumab + Lenvatinib+Gemox regimen in 4-8 weeks after surgery for 7 cycles, and then entered Tislelizumab+Lenvatinib for 1 year or disease progression or toxicity cannot be tolerated"
9672365|NCT05036369|Experimental|Active capsule|The Vibrant non-biodegradable capsule administrated twice a week
10172415|NCT03872362||External validation1|No interventions
10172416|NCT03872362||External validation2|No interventions
9524475|NCT03246594|Experimental|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.~Intervention: Power limitation of RF generator"
9524476|NCT03246633|Other|Perceptual Training|Single-Arm study, all participants will receive educational training via online modules and will be assessed after completion of the training.
9524477|NCT03246581|Experimental|Test Product|tiotropium pMDI 2 inhalations
9524478|NCT03246581|Active Comparator|Commercial Product|tiotropium pMDI 2 inhalations
9524479|NCT03246516|Experimental|Questionnaire|Auto and hetero questionnaire
9524480|NCT03246412|Experimental|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
9524481|NCT03246412|No Intervention|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
9524482|NCT03246386|Experimental|Obese subjects|Subjects with a BMI>35 kg/m2
9524483|NCT03246386|Active Comparator|Non-obese subjects|Subjects with a BMI>18.5 and <25 kg/m2
9524484|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
9528238|NCT03212313|Experimental|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
10172417|NCT03872193|Experimental|Physio Therapy|We intervention this group some routine exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees.
9528239|NCT03212378||CHIP 1 - low risk patients|
9528240|NCT03212378||CHIP 2 - medium risk patients|
9528241|NCT03212378||CHIP 3 - high risk patients|
10172418|NCT03872193|Experimental|Virtual Reality|This group had physical therapy program plus virtual reality exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees. And virtual reality exercises were done for this group. Skiing,kayak, football,rafting and jumping activities were done in this exerciese.
10172419|NCT03872336|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg 80mg in succession after each severe BP
10172420|NCT03872336|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg 80mg in succession after each severe BP
10172421|NCT03872271|Experimental|Experimental|ileal pouch-anal anastomosis without diverting loop ileostomy
10172422|NCT03872271|Active Comparator|Control|ileal pouch-anal anastomosis with diverting loop ileostomy
9524485|NCT03246282|Experimental|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
9524486|NCT03246438|Experimental|Control|Colonoscopy only outreach and follow-up
9524487|NCT03246438|Experimental|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
9524488|NCT03246438|Experimental|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
9524489|NCT03246451|Placebo Comparator|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
9524490|NCT03246451|Experimental|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
9524491|NCT03246451|Experimental|Saline|Saline infusion (9mg/mL) on experimental days
9524492|NCT03246451|Experimental|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
9524493|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
9524494|NCT03246490|Other|All Participants|All participants complete the same study procedures, which involve drinking alcohol to a .08 blood alcohol level and walking short distances while their blood alcohol level is increasing to .08 and decreasing down to .00.
9524495|NCT03246360|Active Comparator|Intermittent administration of cloxacillin|
9524496|NCT03246360|Experimental|continuous administration of cloxacillin|
9524497|NCT03246321|Experimental|repetitive ePIPAC-OX|
9524498|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
9524499|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
9524500|NCT03246464|Placebo Comparator|Single-vision spectacles|
9524501|NCT03246464|Active Comparator|Orthokeratology lenses|
9524502|NCT03246334||Cohort|Case group: critically ill patients admitted >12 hours to the ICU. Control group: critically ill patients to the ICU <12 hrs, or to Post Anaesthesia Care Unit (PACU), or Medium Care or High Dependency Unit.
9524503|NCT03246256||Group 1|Patients with acute ischaemic stroke who were administered intavenous thrombolysis or patients with acute ischaemic stroke refusing intravenous thrombolysis; recall in both cases 60 to 90 minutes after the informed consent procedure
9826698|NCT02429778|No Intervention|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
9975302|NCT03838536|Experimental|Whole egg powder|Participants are given whole egg powder which contains high levels of the nutrients choline, lutein, and docosahexaenoic acid.
9524504|NCT03246256||Group 2|1st of 2nd degree relatives of patients with acute ischaemic stroke, who witnessed the informed consent procedure
9524505|NCT03246256||Group 3|Stroke patients with acute or subacute ischaemic stroke with a contraindication for intravenous thrombolysis
9524506|NCT03246256||Group 4|Patients without an ischaemic stroke but similiar risk factors (admitted to the Departement of Cardiology and Pneumology, Charité, Campus Benjamin Franklin, Berlin, Germany)
9524507|NCT03246256||Group 5|Patients with acute ischaemic stroke who were administered intavenous thrombolysis - recall 24 hours after the informed consent procedure
9524508|NCT03246217|Experimental|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
9524509|NCT03246217|Experimental|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
9524510|NCT03246217|Experimental|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
9524511|NCT03246243||Preterm infants|Group A will consist of preterm infants born < 37 weeks gestational age. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
9528242|NCT03212391|Experimental|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
9528243|NCT03212391|Experimental|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
9528244|NCT03212300|Active Comparator|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
9528245|NCT03212300|No Intervention|treatment as usual|standard treatment
9826699|NCT02429856|Active Comparator|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
9826700|NCT02429856|Active Comparator|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
9826701|NCT02429869|Experimental|Everolimus|
9975303|NCT03838536|Placebo Comparator|Egg white powder|The participants are given an egg white powder that does not contain the target nutrients (choline, lutein, and docosahexaenoic acid).
9524512|NCT03246243||Term infants with HIE or at risk of brain injury|Group B will consist of term infants admitted to the NICU for therapeutic hypothermia who are at risk of HIE; admitted with concern for neonatal stroke; seizures of unknown etiology; and those admitted who are at risk of abnormal neurodevelopment such as those with hypoglycemia or NAS. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
9524513|NCT03246243||Term infants healthy at birth|Group C will consist of healthy term infants from the community and term infants admitted to who had an initial uncomplicated postnatal course that will serve as the control group. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
9524514|NCT03246178|Other|MSD-HSCT|This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
9524515|NCT03246178|Experimental|HFD-HSCT|This group received treatment of haploid family donor - hematopoietic stem cell transplantation (HFD-HSCT).
9524516|NCT03246009|Experimental|single injection-1.8mg|rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day
9524517|NCT03246009|Experimental|single injection-2.1mg|rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day
9524518|NCT03246009|Experimental|single injection-2.4mg|rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day
9524519|NCT03246009|Experimental|multiple injection-1.8mg|rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
9524520|NCT03246009|Experimental|multiple injection-2.1mg|rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
10172423|NCT03872349|Experimental|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 7.1% from saturated fat; 20.7% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
9524521|NCT03246009|Experimental|multiple injection-2.4mg|rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
9524522|NCT03246399|Experimental|0.03mg SM04690|0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
9524523|NCT03246399|Experimental|0.07mg SM04690|0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
9524524|NCT03246399|Experimental|0.15mg SM04690|0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
9524525|NCT03246100|No Intervention|Control|These patients will receive no reminders from the health department and will receive usual care.
9524526|NCT03246100|Experimental|Autodialer R/R|Autodialer calls (up to 3 reminders)- with brief education message + practice name + practice phone #
9524527|NCT03246100|Experimental|Mail R/R|Mailed reminder (up to 3 reminders)-- with brief education message + practice name + practice phone #
9524528|NCT03246113|Experimental|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
9524529|NCT03245853|Other|Treatment|Treatment as per protocol, there is no placebo arm.
9524530|NCT03246139|Experimental|Action observation, imagery & execution|
9524531|NCT03246139|Active Comparator|Action observation|
9524532|NCT03246139|Active Comparator|Control treatment|
9527986|NCT03215056|Placebo Comparator|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.~Dose of normal saline should not exceed 10 mL in a single administration.~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
9527987|NCT03215017|Experimental|Transanal irrigation|Manual transanal irrigation to control bowel function.
10172424|NCT03872349|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 14.4% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
10172425|NCT03873415|Experimental|Formulation A|Dosage formulation and area of release varies between arms
9527988|NCT03215017|Active Comparator|Medication|Medication to control bowel function.
9527989|NCT03214835|Experimental|Brush biopsy for laryngeal lesion|Brush biopsy of the larynx - in addition to the standard biopsy
9527990|NCT03214835|Experimental|Brush biopsy for LPR|Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
9527991|NCT03214939|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
9527992|NCT03214809|Experimental|Thoracic ultrasound protocol|ABCDE algorithm with Thoracic ultrasound protocol
9527993|NCT03214809|No Intervention|No Thoracic ultrasound protocol|ABCDE algorithm without Thoracic ultrasound protocol
9528246|NCT03212352|Placebo Comparator|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
9524533|NCT03245944|Active Comparator|early angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who an early angioplasty intervention group that will undergo a routine Angioplasty at 6 weeks after AVF creation
10172426|NCT03873415|Experimental|Formulation B|Dosage formulation and area of release varies between arms
10172427|NCT03873415|Experimental|Formulation C|Dosage formulation and area of release varies between arms
10172428|NCT03873415|Experimental|Formulation D|Dosage formulation and area of release varies between arms
9524534|NCT03245944|Experimental|late Angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who a late angioplasty intervention group in which early Angioplasty will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent AVF immaturity
9524535|NCT03245970|Active Comparator|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
9524536|NCT03245970|No Intervention|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
9524537|NCT03246035|Active Comparator|Control Group (Standard Care)|The control group will receive outpatient follow-up, medication advice and lifestyle guidance as prescribed at discharge from the ED or hospital.
9524538|NCT03246035|Experimental|Intervention Group|The intervention will consist of contacting the patient 5 days post-discharge and arranging definitive outpatient follow-up and providing targeted medical and lifestyle advice based on deficient domains identified at baseline.
9524539|NCT03245983|Experimental|Patient willing to participate|
9524540|NCT03245996|Experimental|Subjects|Subjects with a cardiac pacemaker
9524541|NCT03245775|Experimental|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
9524542|NCT03245775|Experimental|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
10172429|NCT03873415|Experimental|Formulation E|Dosage formulation and area of release varies between arms
10172430|NCT03873415|Experimental|Formulation F|Dosage formulation and area of release varies between arms
10172431|NCT03873415|Experimental|Formulation G|Dosage formulation and area of release varies between arms
9524543|NCT03246087|Active Comparator|Acupuncture|Patients will receive acupuncture for plantar fasciosis. The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
9524544|NCT03246087|Experimental|Standard of Care|The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
9524545|NCT03246087|Experimental|Crossover|At the end of the study, patients in the Standard of Care group whom are still experiencing pain and symptoms will be rolled into the acupuncture treatment arm of the study.
9524546|NCT03245866||Aneurysmal Subarachnoid hemorrhage|Patients suffering from a ruptured cerebral aneurysm are included in the study.
9524547|NCT03245788|Experimental|Lay Navigation|Patients with even MRN.
9524548|NCT03245788|No Intervention|Usual Care|Patients with odd MRN.
9524549|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
10172432|NCT03873415|Experimental|Formulation H|Dosage formulation and area of release varies between arms
10172433|NCT03873532|Experimental|Active group|300 mg of surufatinib is given by oral administration once a day (QD) every 3 weeks;
9524550|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
9524551|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
9524552|NCT03245697||Lactating mothers|Lactating mothers recruited in Galicia (NW Spain)
9524553|NCT03245879|Active Comparator|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
9524554|NCT03245879|Active Comparator|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
9524555|NCT03245879|Active Comparator|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
9524556|NCT03245905|Experimental|Chidamide|Chidamide should be given at a fixed time with fixed dosage
9524557|NCT03245710|Experimental|Zhibai Dihuang powder|Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks
9524558|NCT03245710|Placebo Comparator|placebos|Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks
9524559|NCT03245814|Experimental|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
9524560|NCT03245814|No Intervention|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
9524561|NCT03245684|Experimental|Pressure Support Ventilation|"after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.~assessment of inflammatory response during PSV"
10172434|NCT03873532|Active Comparator|Control group|In each 3-week cycle, Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID) for 2 weeks, followed by 1 week rest period (equivalent to 2500 mg/m2 total daily dose).
10172435|NCT03872219|Placebo Comparator|Placebo|The children will receive and they are exposed daily to harmless materials that look and feel like the biodiversity intervention materials.
10172436|NCT03872219|Experimental|intervention arm|The children will receive and they are exposed daily to materials of high microbiological biodiversity.
10172437|NCT03872323|Active Comparator|Endovascular treatment|
10172438|NCT03872323|Active Comparator|Open surgery|
9524562|NCT03245684|Active Comparator|Controlled Mechanical Ventilation|patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol
9524563|NCT03245658|Experimental|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
9524564|NCT03245658|No Intervention|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
9524565|NCT03245671|Active Comparator|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
9524566|NCT03245671|Active Comparator|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
9524567|NCT03245515|Experimental|BMS-986195|A single oral solution dose of BMS-986195
9524568|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
9524569|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
9524570|NCT03245567|Experimental|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
9524571|NCT03245567|Experimental|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
9524572|NCT03245554|Experimental|placebo and propranolol|We used propranolol and placebo as an control drug to treat with patients.
9524573|NCT03245606||Patients with Non Alcoholic Fatty Liver Disease|"Patients (240) will undergo a medical examination in order to analyse their medical history and check inclusion and non-inclusion criterions.~Then will be performed:~a liver biopsy~an abdominal MRI~a transient elastography"
9524574|NCT03245476|Active Comparator|manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
9524575|NCT03245476|Active Comparator|education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
10172439|NCT03872232|Experimental|Ezetimibe/Rosuvastatin and Telmisartan|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin and Telmisartan for 8 weeks."
10172440|NCT03872232|Active Comparator|Ezetimibe/Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin for 8 weeks."
10172441|NCT03872232|Active Comparator|Telmisartan|"60 subjects will be assigned and the subjects will be administered Telmisartan for 8 weeks."
10172442|NCT03872258|Active Comparator|Control|Counseling on physical activity
10172443|NCT03872258|Experimental|Intervention|Add an intensive program of combined exercise for 6 months and use during this period a Smartband, in order to encourage and increase physical activity and decrease sedentary lifestyle
9524576|NCT03245632||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
9524577|NCT03245632||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
9524578|NCT03245541|Experimental|Durvalumab + SABR|Durvalumab + Stereotactic Ablative Body Radiotherapy
9524579|NCT03245177|Experimental|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
9524580|NCT03245216|Experimental|aerobic exercise + motor skill practice|acute bout of aerobic exercise before motor learning
9524581|NCT03245216|Active Comparator|rest + motor skill practice|seated rest before motor learning
9524582|NCT03245229|Experimental|Treatment A|In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h
9524583|NCT03245229|Experimental|Treatment B1|25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12
9524584|NCT03245229|Experimental|Treatment B2|"In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h.~Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17."
9524585|NCT03245164|Experimental|Physiotherapy group exercises|This group continued physiotherapy group exercises for 12 weeks.
9524586|NCT03245164|Experimental|Basketball program|Basketball educaiton was presented for 12 weeks.
9524587|NCT03245164|No Intervention|Control group|This group did not continue any physical activity regularly.
9524588|NCT03245203|Experimental|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
10172444|NCT03872167|Active Comparator|MANUAL|Manual titration of non-invasive mechanical ventilation using polysomnography and randomized
10172445|NCT03872167|Active Comparator|AUTOMATIC|Automatic titration of the non-invasive mechanical ventilation using the same device in an automatic mode with assured volume and pressure support.
10172446|NCT03872154|Experimental|Intervention|"In this group (intervention), physicians will conduct checklist-guided shared decision making to determine the patient's code status. Additionally, physicians will be given a decision aid, which they are told to use to illustrate impact and outcome of in-hospital cardiac arrests.~Ancillary project (patients considered as futile): In this group (intervention), physicians will conduct checklist-guided communication."
9524589|NCT03245203|Active Comparator|Control group|neoadjuvant CRT for consecutive 5 weeks
9524590|NCT03245385|Experimental|Treatment with topical halobetasol spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
9524591|NCT03245086||Transanal hemorrhoid dearterialization (THD)|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing transanal hemorrhoid dearterialization (THD).
9524592|NCT03245086||Ferguson hemorrhoidectomy|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing Ferguson hemorrhoidectomy.
9524593|NCT03245333|Experimental|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
9524594|NCT03245333|Other|Stage 1-negative control|observed only for 52 weeks.
9524595|NCT03245333|Experimental|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
9524596|NCT03245333|Other|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
9672366|NCT05036369|Placebo Comparator|Placebo|The placebo capsule is a white colored, softgel biodegradable capsule filled with soybean oil, beeswax and Calcium Carbonate, Gelatin, Glycerin or Titanium dioxide which is visually similar to the Vibrant active capsule
9672367|NCT05036382||Experimental Group|A group that receives an incentive message one month after the start of the experiment
9672368|NCT05036382||Control Group|A group that does not receive an incentive message (for equity, incentive messages will be sent in the last month of the experiment)
9672369|NCT05036564|Experimental|Study population - PCNSL|"Patients (pts) with clinical and radiological suspicion of PCNSL or with confirmed diagnosis of PCNSL will be enrolled to the protocol. They will represent the Study population"
9672370|NCT05036564|Other|Control|"Pts with suspicion of secondary CNS lymphoma, that includes subjects with DLBCL and involvement of the CNS at presentation in association with systemic disease, or subjects with systemic DLBCL and CNS relapse during or after primary therapy.~Pts with histological diagnosis of systemic DLBCL at high risk of CNS relapse according to Institutional guidelines and patients with histological diagnosis of systemic high grade B cell lymphoma, according to 2017 WHO classification;~pts affected by neurological disorders that are usually differential diagnosis of PCNSL (i.e. neurodegenerative and neuroinflammatory disorders, toxic or infective encephalitis, other primary CNS tumors)."
9672371|NCT05036694|Other|Ambulatory HIV positive patients|Ambulatory HIV positive patients with signs and symptoms of TB, and Ambulatory HIV positive patients with advanced disease and CD4 less than 200 cell.
9524597|NCT03245307|Experimental|Treament|In phase A, subjects receiving a single 30 mg oral dose of Nifedipine controlled-release tablets and wash-out for 2 days,a single 3 mg oral dose of warfarin tablets and wash-out for 12 days, then apatinib 750 mg once daily with a single 30 mg oral dose of Nifedipine controlled-release tablets co-administered on day 6 ,a a single 3 mg oral dose of warfarin tablets co-administered on day 9.
9524598|NCT03245437|Experimental|Oxytocin with SCST|Oxytocin with SCST (active condition)
9672372|NCT05036304|Active Comparator|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
9672373|NCT05036304|Experimental|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park).
10172447|NCT03872154|No Intervention|Usual Care|In this group (control), physicians will conduct code status discussions as usually.
9672374|NCT05036460|Active Comparator|Ultrasonography + direct visualization|To detect using ultrasonography assisted direct visualization.
10172448|NCT03872141||patients with stage I-III breast cancer|Patients with Stage I-III breast cancer who will receive paclitaxel or docetaxel treatments as part of their standard of care adjuvant or neoadjuvant therapy are eligible for this study.
9524599|NCT03245437|Sham Comparator|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
9524600|NCT03245437|Placebo Comparator|Placebo with SCST|Administration of Placebo with active psychosocial treatment
9524601|NCT03245437|Placebo Comparator|Placebo with HM|Administration of Placebo with control psychosocial treatment
9527994|NCT03214874|Active Comparator|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
9527995|NCT03214874|Experimental|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
9672375|NCT05036460|Experimental|Direct visualization|To detect using direct visualization.
9672376|NCT05036447|Experimental|DM1-Ex|Moderate-heavy resistance exercise of one leg in DM1-patients
9672377|NCT05036447|No Intervention|DM-Rest|Control leg (i.e. no exercise) in DM1-patients
9672378|NCT05036447|Experimental|Ctrl-Ex|Moderate-heavy resistance exercise of one leg in healthy participants
9672379|NCT05036447|No Intervention|Ctrl-Rest|Control leg (i.e. no exercise) in healthy participants
10172449|NCT03872128|Active Comparator|patients receiving 300mg PREG|30 patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
9524602|NCT03245450|Experimental|Eribulin mesilate plus irinotecan hydrochloride|In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m^2 or 40 mg/m^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m^2 or 125 mg/m^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
9524603|NCT03245294|Active Comparator|Lumbar ESI with paramedian approach|Lumbar ESI with paramedian approach
10172450|NCT03872128|Active Comparator|patients receiving 500mg PREG|30 patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
10172451|NCT03872128|Placebo Comparator|placebo|30 patients randomly assigned to receive a placebo daily.
9524604|NCT03245294|Active Comparator|Lumbar ESI with midline approach|Lumbar ESI with midline approach
9524605|NCT03245281|Experimental|Diuretic Suspension (DS)|
9524606|NCT03245281|Experimental|Diuretic Increase (DI)|
9524607|NCT03245281|Experimental|Diuretic and Medication Suspension (DMS)|
9524608|NCT03245190|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
9524609|NCT03245346|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
10172452|NCT03872024|Experimental|Morbidly obese adult patients|Only one group of patients in the study: morbidly obese adult patients who will have an examination with the XXL probe prototype of the FibroScan 630 Research Model
9524610|NCT03245346|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
9524611|NCT03245359|Active Comparator|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
9524612|NCT03245359|Experimental|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
9524613|NCT03245047|Experimental|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
10172453|NCT03871933||AECOPD|acute exacerbation of COPD
10172454|NCT03871933||stable COPD|
10172455|NCT03872076|Experimental|Plyometric exercises|The subjects included in the experimental group will carry out an intervention using plyometric exercises and isometric exercises with elastic band for the quadriceps muscle. Each session will last 15 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
10172456|NCT03872076|Active Comparator|Isometric exercises|The subjects included in the experimental group will carry out an intervention of isometric exercises with elastic bands for the quadriceps muscle. Each session will last 8 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
10172457|NCT03872050||Rosacea|Patients who have been diagnosed with rosacea
10172458|NCT03872050||Migraine|Patients who have been diagnosed with migraine
10172459|NCT03871881||Atrial septal defect|Patients with an open atrial septal defect, diagnosed in childhood
10172460|NCT03871881||Ventricular septal defect|Patients who had surgical closure of a ventricular septal defect in childhood
9524614|NCT03245047|Placebo Comparator|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
9524615|NCT03245255|Experimental|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
9524616|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
9524617|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
9524618|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
9524619|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
9524620|NCT03245073|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
9524621|NCT03245073|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
10172461|NCT03871881||Healthy control|Healthy, young adults matched on age, gender and education
10172462|NCT03871972|Experimental|UCB injection group|This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm.
10172463|NCT03871894|Active Comparator|Control arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy as per the standard enteral nutritional practice in a critical care setting in cirrhotics till the period admitted in ICU(Intensive care unit) 35-40 Kcal/Kg IBW/day; 1.5-2g protein per kg per day.
10172464|NCT03871894|Experimental|Intervention arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy based on indirect calorimetry measurements till the period admitted in ICU(Intensive care unit)
9524622|NCT03245060|Experimental|Intervention: immediate SFBT|The Intervention arm will receive up to six Adapted Solution Focused Brief Therapy (SFBT) sessions immediately post randomisation. The sessions will be spaced over 3 months. Participants will also receive all usual care.
9524623|NCT03245060|Other|Intervention: delayed SFBT|The wait-list control arm will receive the same intervention (Adapted Solution Focused Brief Therapy, SFBT) as the intervention arm, but after a delay of six months. Participants will also receive all usual care.
10172465|NCT03871842|Active Comparator|active tDCS|20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
9524624|NCT03245021|Other|Open-Label|Opdivo - Single-arm open label study
9524625|NCT03245034|Experimental|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
9524626|NCT03245138|Experimental|endoscopic third ventriculostomy|endoscopic third ventriculostomy for the treatment of iNPH
9524627|NCT03245138|Active Comparator|ventricular peritoneal shunt|Insertion of a ventriculo-peritoneal Shunt for the treatment of iNPH
9524628|NCT03244982|Active Comparator|Full-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
9524629|NCT03244982|Experimental|Half-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
9524630|NCT03244956|Experimental|patients with RAS mutation|
9524631|NCT03244956|Experimental|patients with BRAFV600E mutation|
9524632|NCT03244787|Experimental|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
9524633|NCT03244787|No Intervention|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
9524634|NCT03244813|Experimental|Adapted physical activity|
9524635|NCT03244813|No Intervention|Standard care|
9524636|NCT03244878|Experimental|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
9524637|NCT03244878|No Intervention|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
9524638|NCT03244891|Experimental|Studied subjects|"Each subject will be studied during two sequential phases:~before fluid challenge~after fluid challenge~During each phase, the subjects will be studied at:~baseline - spontaneously breathing~head down position - spontaneously breathing~baseline - positive pressure ventilation~head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
9524639|NCT03244774|Experimental|Apatinib plus POF|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and POF. Cohort 2: apatinib 375 mg per day and POF. Cohort 3: apatinib 500 mg per day and POF. Cohort 4: apatinib 625 mg per day and POF. Cohort 5: apatinib 750 mg per day and POF.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase)~If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
9524640|NCT03244735|Experimental|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
9524641|NCT03244631|Active Comparator|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
9524642|NCT03244631|Active Comparator|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
9524643|NCT03244748||Group 1|Patients underwent ablation and continued having amiodarone after the procedure
9524644|NCT03244748||Group 2|Patients underwent ablation and not having amiodarone after the procedure
9524645|NCT03244683|Other|Intervention|Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
9524646|NCT03244683|Other|Nutrition Counseling alone|Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.
9524647|NCT03244930|Experimental|Arm 1|Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
9524648|NCT03244709|Experimental|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.~Week 24. TCZ tapering every 8 weeks as follows:~1 injection every 2 weeks~1 injection every 3 weeks~1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
9524649|NCT03244761||The standard HFT|The high-flow oxygen was delivered via tracheostomy using a standard HFT.
10172466|NCT03871842|Sham Comparator|sham tDCS|20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
10172467|NCT03871998|Experimental|Interventional arm|Skin barrier protection in the first 2 months of life.
9524650|NCT03244761||The modified HFT|The high-flow oxygen was delivered via tracheostomy using a modified HFT.
9524651|NCT03244657|Experimental|Q12W group|
9524652|NCT03244657|Experimental|TAE group|
9524653|NCT03244605|Experimental|Rehabilitation training plus TCM|"Rehabilitation training include aerobic exercise training and Liu Zi Jue lung exercises, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.The patient will take TCM granules for 3 months."
9524654|NCT03244605|Placebo Comparator|Rehabilitation education plus placebo|"Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.~The patient will take placebo granules for 3 months."
9524655|NCT03244943|Other|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
9524656|NCT03244592|Active Comparator|Minocycline|200 mg/day
9524657|NCT03244592|Placebo Comparator|Sugar Pill|Matched placebo
9524658|NCT03244579|Experimental|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
9524659|NCT03244579|Experimental|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
10172468|NCT03871998|No Intervention|Control arm|Standard skincare advice. No moisturiser in the first 2 months.
9524660|NCT03244579|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
9524661|NCT03244514|Experimental|Intervention group|"Implementation of the cardiovascular surgery AKI bundle~discontinuation of all nephrotoxic agents when possible~optimization of volume status and hemodynamic parameters~close monitoring of serum creatinine, fluid balance and urinary output~avoidance of hyperglycemia~considerations of alternatives to radiocontrast agents~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~avoidance of HES, gelatin, and chlorid-rich solutions"
9524662|NCT03244514|No Intervention|Control group|The patients will receive standard of care (according to each center)
9524663|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
9524664|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
9524665|NCT03244267|Active Comparator|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
9524666|NCT03244267|Experimental|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
9524667|NCT03244319|Experimental|Edoxaban|
9524668|NCT03244319|Active Comparator|Warfarin|
9524669|NCT03244553|Experimental|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
9524670|NCT03244332|Experimental|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
9524671|NCT03244332|Experimental|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
9524672|NCT03244306|Experimental|Autologous CD22-specific CAR T-cells expressing EGFRt|
9524673|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
9524674|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
10172469|NCT03872037|Active Comparator|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
10172470|NCT03872037|Experimental|Selective removal of caries and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
10172471|NCT03872011|Experimental|Vitamin C,thiamine,hydrocortisone|"The combination of vitamin C, thiamine, hydrocortisone :~Vitamin C 2g every 6 hours x 5-days Thiamine 200mg every 12 hours x 5-days Hydrocortisone 200mg as a continuous infusion x 5-days"
10172472|NCT03872011|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
10172473|NCT03871855|Experimental|A:SHR-1702 Dose Escalation|SHR-1702 given intravenously (IV).
9524675|NCT03244371|Experimental|Co infected HIV and HCV patients|
9975304|NCT03835182|Active Comparator|Ultrasound group|Thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The ultrasound group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and ultrasound 1MHz frequency (ten minutes) applied to the lower back, abdominal and lower back muscle strengthening exercises.
10172474|NCT03871855|Experimental|B:SHR-1702 Dose Expansion|SHR-1702 given intravenously (IV).
9524676|NCT03244176|Other|Open-label|Avelumab - Single-arm open label study
9524677|NCT03244228|Experimental|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
9524678|NCT03244228|Experimental|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
9524679|NCT03244228|Experimental|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
9524680|NCT03244228|Experimental|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
9524681|NCT03244228|Experimental|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
9524682|NCT03244345|Experimental|Epileptic patient|
9524683|NCT03244397|Experimental|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
9524684|NCT03244397|Active Comparator|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
9524685|NCT03244527|Experimental|BCAA group|Participants in the BCAA group take 40g of BCAA supplement before each aerobic exercise session. The interventions include 24 aerobic training sessions. Accordingly, the participants intake 960g of BCAA during a 8-week intervention period.
9524686|NCT03244527|Placebo Comparator|Control group|Participants in the control group take 40g of placebo before each aerobic training session. The placebo has the same caloric as the BCAA supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
9524687|NCT03244215|Experimental|The study group|"The intervention to be evaluated is the patient response and compliance to best medical treatment and prevention of recognized stroke risk factors and the recurrence of stroke and TIA in the study group and its relation to the incidence of blood biomarkers.~The Nurse practitioners at the stroke ward will withdraw blood and collect urine samples from all the subjects. All the subjects from the study group will have 2 follow up visits (1 month and at 1 year) at HGH and one telephonic follow up at 3 months. The blood samples will be used to monitor blood inflammatory biomarker levels. At the beginning of the study, all subjects will have an MRI scan to assess plaque volume (this MRI scan will be ordered as part of the standard of care as per the policies applied to all stroke patients). MRI scans will be repeated at one year to assess any progression or regression in the plaque volume of the subjects.~No drugs will be administered to the patients for the purpose of our study."
9524688|NCT03244215|Other|Control|The control group will have blood work done to assess their blood inflammatory biomarkers but not the corneal confocal imaging.
9524689|NCT03244280|Other|MOB015B|
9524690|NCT03244423|Placebo Comparator|Group 1|In control group will receive normal saline,
9524691|NCT03244423|Active Comparator|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
9524692|NCT03244423|Active Comparator|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
10172475|NCT03871855|Experimental|C:SHR-1702 and Camrelizumab Dose Escalation|SHR-1702 and Camrelizumab given intravenously (IV).
10172476|NCT03871855|Experimental|D:SHR-1702 and Camrelizumab Dose Expansion|SHR-1702 and Camrelizumab given intravenously (IV).
9527996|NCT03215043|Experimental|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
9527997|NCT03215043|Experimental|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
9527998|NCT03215043|Experimental|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
9527999|NCT03215043|Placebo Comparator|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
9528000|NCT03214822|No Intervention|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
9528001|NCT03214822|Experimental|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
10172477|NCT03872115|Experimental|Setting 1|PDVibe2 set to high frequency and low amplitude
10172478|NCT03872115|Experimental|Setting 2|PDVibe2 set to high frequency and medium amplitude
10172479|NCT03872115|Experimental|Setting 3|PDVibe2 set to high frequency and high amplitude
9524693|NCT03244501|Experimental|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
9524694|NCT03244501|Experimental|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
9524695|NCT03244501|Sham Comparator|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
10172480|NCT03872115|Experimental|Setting 4|PDVibe2 set to medium frequency and low amplitude
9524696|NCT03244358|Experimental|Epalrestat|Epalrestat added to standard treatment
9524697|NCT03244137||Pulmonary rehabilitation|The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
9524698|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
9524699|NCT03244462|Experimental|Oral BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845~single oral dose of BAY1834845 + i.v. BAY1834845~single oral dose of BAY1834845 under fed conditions"
9524700|NCT03244462|Experimental|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845+ i.v. BAY1834845~single oral dose of BAY1834845~single oral dose of BAY1834845 under fed conditions"
9524701|NCT03244462|Experimental|Oral Methotrexate|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX)~single oral dose of MTX + single oral dose of BAY1834845"
9524702|NCT03244462|Experimental|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX) + single oral dose of BAY1834845~single oral dose of MTX"
9524703|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
9524704|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
9524705|NCT03244540|Experimental|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
9524706|NCT03244540|Experimental|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
10172481|NCT03872115|Experimental|Setting 5|PDVibe2 set to medium frequency and medium amplitude
10172482|NCT03872115|Experimental|Setting 6|PDVibe2 set to medium frequency and high amplitude
10172483|NCT03872115|Experimental|Setting 7|PDVibe2 set to low frequency and low amplitude
9672383|NCT05036499|Experimental|Personalized Feedback Intervention (PFI)|Personalized Feedback Intervention targeting pain-related anxiety for hazardous drinkers with chronic pain
9672384|NCT05036499|No Intervention|Assessment Only|Assessment only, no active treatment elements
9672385|NCT05036642|Experimental|Stroke Survivors|Stroke survivors with upper extremity motor impairments
9672386|NCT05036863||Patients with multiple myeloma|
9672387|NCT05036330||Observational (evaluation, examination, questionnaire)|Patients undergo speech and swallow evaluation by speech pathologist or study staff member and examination of TEP and laryngectomy stoma. Patients also complete questionnaires over 30 minutes about use the ProvoxLife HME system, symptoms, ability to communicate, exercise and physical activity levels, and quality of life at baseline and 3 months post-ProvoxLife.
9672388|NCT05036213|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
10172484|NCT03872115|Experimental|Setting 8|PDVibe2 set to low frequency and medium amplitude
9524707|NCT03244540|Experimental|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
9672389|NCT05036213|Placebo Comparator|concentrated beet root juice with depleted nitrate content|The placebo treatment is also beetroot juice provide by the same company (BEET IT, James White Drinks, Ipswich, UK), but it does not contain any inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
9672390|NCT05036239|Experimental|Exercised|One bout of 50 eccentric biceps curls
9672391|NCT05036239|No Intervention|Control|No eccentric biceps curls
9672392|NCT05036005|Experimental|Ontruzant + Pertuzumab (optional) + Chemotherapy|"All patients will receive 6 cycles of Ontruzant® i.v. q21d in combination with standard chemotherapy with or without pertuzumab, at the discretion of investigator's decision. Initial dose of Ontruzant® i.v. will be 8 mg/kg b.w. followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d. Clinical and bioptic tumor assessment will be performed during baseline and during surgery.~Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent. A safety follow-up is planned for 30 days after the last administration of study medication."
9672393|NCT05035953|Experimental|Edaravone|Edaravone Dexborneol injection
9672394|NCT05035953|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
10172485|NCT03872115|Experimental|Setting 9|PDVibe2 set to low frequency and high amplitude
10172486|NCT03871725|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
10172487|NCT03871985|Experimental|Lavage combined with aspiration|Intermittent subglottic secretions lavage combined with aspiration
10172488|NCT03871985|Active Comparator|Pure aspiration|Intermittent subglottic secretions aspiration
10172489|NCT03871738|Experimental|Proprioception training|The subjects included in the experimental group will carry out a protocol of proprioception exercises. Each session will last 25 minutes, taking place during 2 sessions a week, in a period of 4 weeks. All interventions will be made before the training session.
9524708|NCT03244072|Active Comparator|Treatment group|Intracameral injection of moxifloxacin solution after cataract surgery
9524709|NCT03244072|Placebo Comparator|Placebo group|Intracameral injection of placebo after cataract surgery
9524710|NCT03244241|Active Comparator|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
9524711|NCT03244241|No Intervention|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
10172490|NCT03871738|No Intervention|Control|The subjects included in the control group will not receive intervention and will continue to carry out their daily life in the same way as they have done up to now.
9524712|NCT03244124|Active Comparator|SET (Self-Etching)|50 teeth will receive restorations using Self-Etching Application Strategy
9524713|NCT03244124|Experimental|SEE (Selective Enamel Etching)|50 teeth will receive restorations using Enamel Etching Application Strategy
9524714|NCT03244124|Experimental|ERDry (Etch&Rinse Dry)|50 teeth will receive restorations using Etch&Rinse Dry Application Strategy, leaving dentin dry (but not overdry)
9524715|NCT03244124|Experimental|ERWet (Etch&Rinse Wet)|50 teeth will receive restorations using Etch&Rinse Wet Application Strategy, leaving dentin wet
9524716|NCT03244085|Experimental|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
9524717|NCT03244085|Experimental|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
9524718|NCT03244085|Experimental|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
9524719|NCT03244098|Experimental|Transition Assistance Program (TAP)|
9524720|NCT03244098|No Intervention|Standard of Care|
9524721|NCT03244046|Active Comparator|Physiotherapy (Phys)|12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
9524722|NCT03244046|Experimental|Somatic Experiencing + phys|12 sessions of psychotherapy (somatic experiencing) and 12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
9524723|NCT03243942|Experimental|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
9524724|NCT03243968||Ischemic patient - IP|25 participants with myocardial ischemia detected by scintigraphy and normal coronarography
9524725|NCT03243968||Control group - CG|25 healthy non-ischemic individuals
9524726|NCT03243903|Experimental|needle-free insulin injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
9524727|NCT03243903|Active Comparator|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
9524728|NCT03243890|Experimental|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
10172491|NCT03871777|Active Comparator|Vegetarians|Healthy vegetarians (vegans and lacto-ovo vegetarians) 18 and 50 years formed this arm.
10172492|NCT03871777|Sham Comparator|Omnivores|Healthy omnivores with similar characteristics of vegetarians (age, body mass index, gender and physical activity levels) formed this arm
10172493|NCT03871621|Experimental|Previous diabetic medical treatment & Dapagliflozin|Previous diabetic medication add on SGLT2 inhibitor (Dapagliflozin 10 mg) daily for 6 months
10172494|NCT03871621|Active Comparator|Previous diabetic medical treatment & standard care|Previous diabetic medication with drug adjustment by standard diabetes care except SGLT2 inhibitors for 6 months
9524729|NCT03243890|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
9524730|NCT03243916|Experimental|combination|TACE plus cyber knife
9524731|NCT03243929|Experimental|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
9524732|NCT03243929|Other|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
9524733|NCT03244111|Active Comparator|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
9524734|NCT03244111|Active Comparator|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
9524735|NCT03244202|Experimental|Decision Aid Plus Counselling|Participants will use a decision aid to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing. After using the decision aid the participants will speak with a genetic counsellor over the phone about their choice.
9524736|NCT03244202|Active Comparator|Genetic Counselling Only|Participants will a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
9524737|NCT03244033|Experimental|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
9524738|NCT03244033|Active Comparator|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
9524739|NCT03243994|Experimental|COPD|Patients with COPD without Cor Pulmonale
10172495|NCT03871790||Participants with colorectal cancer|Participants with colorectal cancer ongoing surgery older than 18 years old.
9524740|NCT03243994|Experimental|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
9524741|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
9524742|NCT03243955|Active Comparator|TEAS|True acupoint locations for placement of TENS unit pads
9524743|NCT03243955|Sham Comparator|Placebo|non-acupoint locations for placement of TENS unit pads
9524744|NCT03243851|Experimental|Temozolomide+metformin|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Metformin :~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th ~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
9524745|NCT03243851|Placebo Comparator|Temozolomide+placebo|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Placebo:~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
9524746|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
9524747|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
9524748|NCT03243760|Experimental|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
9524749|NCT03243760|Experimental|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
9524750|NCT03243760|Experimental|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
10172496|NCT03871790||Participants with pancreatic cancer|Participants with pancreatic cancer ongoing surgery older than 18 years old.
10172497|NCT03871660|Other|Patients with diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
9524751|NCT03243760|Experimental|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
9524752|NCT03243760|Experimental|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
9524753|NCT03243760|Experimental|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
9524754|NCT03243760|Experimental|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
9524755|NCT03243760|Experimental|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
9524756|NCT03243760|Experimental|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
9524757|NCT03243760|Experimental|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
9524758|NCT03243760|Experimental|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
10172498|NCT03871660|Other|Patients without diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
9672395|NCT05036083|Experimental|Diagnostic (CEM, DBT, medical record)|Patient receive iodinated contrast agent IV and undergo CEM. Patients who have not undergone DBT as part of their screening or diagnostic imaging within 3 month, undergo DBT. Patients medical records are reviewed.
10172499|NCT03871582||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
9524759|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
9524760|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
9524761|NCT03243708|No Intervention|Usual Care|Control: Standard order set without risk calculator (usual care)
9524762|NCT03243708|Active Comparator|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
9524763|NCT03243825|Experimental|chemo/brachytherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) and brachytherapy before radical hysterectomy.
9524764|NCT03243825|Active Comparator|chemotherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) before radical hysterectomy.
9524765|NCT03243526|Placebo Comparator|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
9524766|NCT03243526|Experimental|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
10172500|NCT03871699|Experimental|Iron Reposition|The selected patients will receive 1g of ferric carboxymaltose applied intravenously after dilution in 100ml of crystalline solution. the infusion time will be around 15 minutes realized at the moinhos the vento infusion center.
9524767|NCT03243799|Experimental|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.~Group psychoeducation."
9524768|NCT03243799|No Intervention|Control Group|Usual clinical care
9524769|NCT03243812|Active Comparator|SS genotype group|"Sickle cell patients with SS genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
9524770|NCT03243812|Active Comparator|SC genotype group|"Sickle cell patients with SC genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
9524771|NCT03243812|Active Comparator|control group|"Healthy subjects. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
9524772|NCT03243552|Active Comparator|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
9524773|NCT03243552|Experimental|Social Skills|All participants will receive 16-week manualized social skills training.
9524774|NCT03243500|Sham Comparator|Group C|"2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase powder 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
9524775|NCT03243500|Active Comparator|Group A|"5 mg atracurium 2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
9524776|NCT03243591|Active Comparator|Livionex gel|Brushing area of mucositis with Livionex gel for 30 days
9524777|NCT03243591|Active Comparator|Aquafresh gel|Brushing area of mucositis with Aquafresh gel for 30 days
9524778|NCT03243565|Active Comparator|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
9524779|NCT03243565|Placebo Comparator|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
9524780|NCT03243617|Active Comparator|AO+Mist|Cosmetic Product AO+Mist
9524781|NCT03243617|Placebo Comparator|Placebo|Placebo
9524782|NCT03243695|Experimental|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
9524783|NCT03243695|Active Comparator|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
9524784|NCT03243682|Active Comparator|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
9524785|NCT03243682|Active Comparator|Standard Shock Wave Lithotripsy|standard unidirectional approach
9524786|NCT03243643|Experimental|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
9524787|NCT03243669|Active Comparator|Fujinon standard|
9524788|NCT03243669|Active Comparator|Fujinon HD|Fujinon high-definition
9524789|NCT03243669|Active Comparator|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
9524790|NCT03243669|Active Comparator|Olympus standard|
9524791|NCT03243669|Active Comparator|Olympus HD|Olympus high-definition
9524792|NCT03243669|Active Comparator|Olympus VC|Olympus virtual chromoendoscopy
10187019|NCT03730415|No Intervention|Standard practice transfusion|The standard practice transfusion group will receive the current standard transfusion practice during their burn excision, which is based solely on physician preference using standard lab values.
10187020|NCT03730402|Active Comparator|bupivacaine block|laparoscopic assisted plane block of standardized dose of bupivacaine plain
9524793|NCT03243669|Active Comparator|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
9524794|NCT03243669|Active Comparator|Pentax standard|
9524795|NCT03243669|Active Comparator|Pentax HD|Pentax high-definition
9524796|NCT03243669|Active Comparator|Pentax VC|Pentax virtual chromoendoscopy
9524797|NCT03243669|Active Comparator|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
9524798|NCT03243487|Experimental|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
9524799|NCT03243487|Active Comparator|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
10172501|NCT03871803|Active Comparator|Arm A|"Controlled Withdrawal of Beta-blockers and Cardiopulmonary Exercise Testing (CPET) Patient will be assessed for chronotr0pic incompetence by CPET. If the patient exhibits chronotropic incompetence, we will reduce half dose of previous beta-blocker.~A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day.~After second CPET, the patient will introduce the half-dose of beta-blocker and will be evaluated in 3 days. If clinical stability, the patient will introduce the previous dose of beta-blocker A third CPET will be performed at 15-day"
10172502|NCT03871803|Active Comparator|Arm B|"Cardiopulmonary Exercise Testing (CPET) and Controlled Withdrawal of Beta-blockers Patient will be assessed for chronotropic incompetence by CPET.If the patient exhibits chronotropic incompetence, a cardiologist will evaluate clinically the patient and the heart rate in 3 days and will be assessed by CPET at 15-day.~After second CPET, the patient will reduce half dose of previous beta-blocker. A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day."
9524800|NCT03243539|Experimental|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
10172503|NCT03871920||intervention|any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist
9524801|NCT03243721|Experimental|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
9524802|NCT03243721|Experimental|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
9524803|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
9524804|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
9524805|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
9524806|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
9524807|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
9524808|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
9524809|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
9524810|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment. Determine if the Control group of subjects asthma has progressed any different from those subjects treated with BT.
9524811|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
9524812|NCT03243123|Experimental|Passive mobilization|Upper limb passive mobilization assisted with robotic device
9524813|NCT03243461|Experimental|Temozolomide + Valproic acid|E.g. Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), [10 mg/kg/d] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
9672396|NCT05036174|Experimental|Diphenhydramine|Topical 5% diphenhydramine ointment applied at knee joint at a dose of 2 g three times a day for 7 days
9672397|NCT05036174|Placebo Comparator|Placebo|Vehicle (placebo) ointment applied at knee joint at a dose of 2 g three times a day for 7 days
9826702|NCT02429934|Active Comparator|Abatacept also known as Orencia also known as CTLA4Ig|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
10172504|NCT03871946||Experimental group|"Experimental group subjects with impaired fasting glucose (IFG) (Group 1) underwent an oral glucose tolerance test (OGTT), and patients with levels > 140 mg/dL at the 2nd hour were excluded because they were diagnosed with impaired glucose tolerance"
10172505|NCT03871946||control group|The control group (Group 2) comprised 73 patients whose fasting blood glucose level was <100 mg/dL and who agreed to participate in the study.
10172506|NCT03871504|Experimental|submaximal isometric exercise.|submaximal isometric exercise will be performed.
10172507|NCT03871504|No Intervention|Quiet rest.|Subject will rest in seating position for a period that mimics the exercise time.
10172508|NCT03871712|Experimental|Motivational Interview (MI)|In the MI arm, a NAV case worker will meet the participants after the baseline assessment (electronic questionnaires) and randomisation and conduct the MI. The NAV case-worker will either meet (or call) again after a few weeks (anticipated 2-4 weeks) and conduct another MI.
10172509|NCT03871712|Active Comparator|Stratified vocational advice intervention (SVAI)|A trained physiotherapist will call the participants after the baseline assessment and randomisation. The SVAI intervention will be stratified due to the participants risk of long term sick leave estimated by the Orebro Screening Questionnaire and The Keele STarT MSK Tool. The low/moderate risk group will receive 1-2 phone calls, and the high risk group will be followed up 2-4 times. The follow-up can include face to face Meetings bewteen the Physical therapist and the participant, and also the employer and general practitioner when needed. The intervention will include an assessment of the participants obstacles for returning to work and help to develop and implement an action plan to overcome obstacles. The physical therapists' will cooperate with other health care providers and employer when needed.
9524814|NCT03243201|Experimental|Colloidal Silver|The colloidal silver arm will administer intranasal colloidal silver, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day (8 mcg of silver per day), for 28 days.
9826703|NCT02429934|Placebo Comparator|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks
9524815|NCT03243201|Placebo Comparator|Purified Water|The placebo arm will administer intranasal purified water, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day, for 28 days.
9524816|NCT03243435||Native 1,5 Tesla breast MRI group|From all patients a 1,5 Tesla MRI of the breast will be obtained
9524817|NCT03243214|Active Comparator|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
9524818|NCT03243214|Sham Comparator|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
9524819|NCT03243266||CBC/Diff Reference Interval|Hematology routine diagnostic test
9524820|NCT03243227|Experimental|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
9672398|NCT05035914|Experimental|Experimental: anlotinib+mXELIRI|"Dose-escalation phase:~A: anlotinib 8 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~B: anlotinib 10 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~C: anlotinib 12 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~Dose-expansion phase:~anlotinib RP2D, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;"
9672399|NCT05035979|Experimental|TCM comprehensive treatment group|Participants in the TCM treatment group will receive BaiDi Quzhi granule two times daily after meals, Ju Yin cream therapy three times per week for 8 weeks.
9672400|NCT05035979|Active Comparator|TCM internal treatment group|Participants in the TCM internal treatment group will receive Baidi Quzhi granule two times daily after meals and Ju Yin placebo therapy three times per week for 8 weeks.
9672401|NCT05035979|Active Comparator|TCM external treatment group|Participants in the TCM external treatment group will receive Baidi Quzhi placebo granule two times daily after meals and Ju Yin cream therapy three times per week for 8 weeks.
9672402|NCT05035979|Placebo Comparator|Placebo group|Participants in the placebo group will receive Baidi Quzhi placebo granule two times daily after meals, Ju Yin placebo therapy three times per week for 8 weeks.
9672403|NCT05036252||Participants with HER2-positive breast cancer|Participants with HER2-positive breast cancer who have developed mild cardiotoxicity during HER2-targeted therapy, defined by a decline in LVEF > 10% to < 53% without symptoms of clinical heart failure (NYHA class III or IV), will be eligible for participation in this study.
9672404|NCT05036161||Predicting treatment failure of Nasal High Flow in newborns|newborns with respiratory distress treated with NHF
9672405|NCT05036161||Predicting treatment failure of Continuous Positive Airway Pressure in newborns|newborns with respiratory distress treated with CPAP
9827753|NCT02466555|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
9524821|NCT03243227|Active Comparator|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
9524822|NCT03243188||Participants|Cancer patients with palliative care needs (+/- their carers)
9672406|NCT05036031||EASL-CLIF ACLF patients|
9672407|NCT05036031||APASL ACLF patients|
9672408|NCT05036031||Non-ACLF patients|
9672409|NCT05035966||Prediabetes|In the case-control study, prediabetes was diagnosed according to the diagnostic criteria recommended by the WHO in 1999. Prediabetes was defined as impaired fasting glucose (FPG ≥6.1 mmol/L and <7.0 mmol/L, and 2-h post-glucose load <7.8 mmol/L) and/or impaired glucose tolerance (FPG <6.1 mmol/L, and 2-h post-glucose load ≥7.8 mmol/L and <11.1 mmol/L). In the nested case-control study, new-onset prediabetes was defined as FPG ≥6.1 mmol/L and <7.0 mmol/L.
9524823|NCT03243149|Sham Comparator|False Feedback|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. False feedback (sham) shows a thermometer that indicates false feedback consisting of noise.
9524824|NCT03243149|Active Comparator|View Condition|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. View condition shows a thermometer that indicates true activation of ventromedial PFC minus amygdala but the participant is asked not to attempt neuroregulation.
9524825|NCT03243149|Experimental|Free Regulate|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. Free regulate shows a thermometer that indicates true activation of ventromedial PFC minus amygdala while the participant attempts neuroregulation.
9524826|NCT03243383|No Intervention|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
9524827|NCT03243383|Experimental|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
9524828|NCT03243383|No Intervention|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
9524829|NCT03243162|Experimental|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
9524830|NCT03243162|Active Comparator|Education|Education program consisting of weekly phone calls.
9524831|NCT03243331|Experimental|Gedatolisb + PTK7-ADC|
9524832|NCT03243344|Experimental|Surgiflo|Using Surgiflo® (Absorbable Gelatin Hemostatic) for the post-operative haemostasis in endonasal surgery.
9524833|NCT03243344|Experimental|Floseal|Using Floseal® (Absorbable Gelatin Hemostatic) containing human thrombin for the post-operative haemostasis in endonasal surgery
9524834|NCT03243344|Experimental|Algosteril|Using Algosteril® (Hemostatic Sterile Wick) for the post-operative haemostasis in endonasal surgery
9524835|NCT03243344|No Intervention|Abstention|Not using device for the post-operative haemostasis in endonasal surgery
9524836|NCT03243422|Active Comparator|Successful aging education intervention|Individual sessions on healthy aging topics
9524837|NCT03243422|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
9524838|NCT03243175|Experimental|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
9524839|NCT03243175|Experimental|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
9524840|NCT03243175|No Intervention|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
10172510|NCT03871712|No Intervention|Usual follow-up|This arm will be the control group receiving usual NAV follow-up. The other two groups will also receive usual NAV follow-up additionally to the interventions.
9524841|NCT03243357|Experimental|TF Adaptive (First Apical Binding File)|Endodontic treatment(teeth with periapical periodontitis&radiolucence).Local anesthesia (4%Articaine with1:100,000 epinephrine),isolation with rubber dam&standard access cavity preparation.Using 2.5 %sodium hypochlorite,canal negotiation,glide path,coronal flaring with Sx(ProTaper),determining working length&first apical binding file.Intervention: Root canal instrumentation:TF Adaptive system with enlargement of the root canal performed with up to 3 files larger than the diameter of the initial apical file. Irrigation2.5%NaOCl&EDTA (Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, obturation: gutta-percha&epoxy resin sealer.
9524842|NCT03243357|Other|TF Adaptive (Control)|In the control group,endodontic treatment (teeth with periapical periodontitis&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length&glide path. Root canal instrumentation:TF Adaptive system according to the protocol recommended by the manufacturer.Irrigation 2.5% NaOCl & EDTA(Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
10172511|NCT03872063|Experimental|Myofascial|Each session will last 17 minutes, taking place for 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the technique of myofascial induction and eccentric exercises will be performed.
10172512|NCT03872063|Active Comparator|Eccentric|Each session will have a duration of 9 minutes, taking place during 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the eccentric exercises will be performed.
10172513|NCT03871517|Experimental|Indobufen|Drug: Indobufen and aspirin mimetic Day 1: The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : Indobufen 100mg + aspirin mimetic The second time: indobufen 100mg
10172514|NCT03871517|Active Comparator|Aspirin|Drug: Aspirin and Indobufen mimetic Day 1:The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : aspirin 100mg+ Indobufen mimetic, The second time: indobufen mimetic.
10172515|NCT03871686|Experimental|Experimental Group|Participants will be asked to complete a brief online program over a 4 to 8-week period. Each week participants will be asked to complete one session of the program online. There are four sessions.
9524843|NCT03243396|Experimental|Health-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in a community setting from Community Health Volunteers.
9524844|NCT03243396|Experimental|Education-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in their school setting from teachers employed by their school.
9524845|NCT03243019|Experimental|SIROLIMUS|
9524846|NCT03243110||Asthmatics requiring breathing test|"Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.~Participants must be 1 to 85 years old."
9524847|NCT03242902|Experimental|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
9524848|NCT03242902|Experimental|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
9524849|NCT03242850|No Intervention|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
9524850|NCT03242850|Experimental|Intervention group|
9524851|NCT03243032|Experimental|Local Anesthetic Group 1|Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
9524852|NCT03243032|Placebo Comparator|Local Anesthetic Control|Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
9524853|NCT03242811|Experimental|Examination by MRI|MRI scan of knee, ankle and wrist
9524854|NCT03242993|Experimental|treatment group|"all patients successfully enrolled will be assigned to the treatment group:~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol"
9524855|NCT03242967|Experimental|Vadadustat|Oral tablet
9524856|NCT03242967|Active Comparator|Darbepoetin alfa|subcutaneous or intravenous
9524857|NCT03242876|Placebo Comparator|Control meal|Control will be 109 g white bread and 200 mL water. The glycaemic response to the test meal will be compared to the response of the control meal.
9524858|NCT03242876|Experimental|Test meal|Test will be 109 g white bread and 200 mL water containing 3.819 g citric acid and 119 mg malic acid adjusted to pH 3.2. The glycaemic response to this meal will be compared to that of the control meal.
9524859|NCT03242824|Experimental|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
9524860|NCT03243006|Placebo Comparator|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
9524861|NCT03243006|Active Comparator|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
9524862|NCT03243006|Active Comparator|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
9524863|NCT03243097|Experimental|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
10172516|NCT03871686|No Intervention|Control Group|Participants will receive no intervention from the investigators. Participants may continue services as usual as provided by Children's Brain Tumor Foundation.
10172517|NCT03871530|Experimental|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
10172518|NCT03871530|Experimental|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
10172519|NCT03871530|Experimental|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
10172520|NCT03871530|Experimental|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
9524864|NCT03242746||Control group|"The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume"
9524865|NCT03242746||LEEP group|"The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume~Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit~Estimation of cone dimensions/volume~Calculation of the proportion of volume/length excised"
9528002|NCT03214965|Active Comparator|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
9672410|NCT05035966||Healthy control|In the case-control study, healthy control was defined as FPG <6.1 mmol/L and 2-h post-glucose load <7.8 mmol/L. In the nested case-control study, healthy control was defined as FPG <6.1 mmol/L.
9672411|NCT05035888|Active Comparator|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
10172521|NCT03871530|Experimental|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
10172522|NCT03871530|Experimental|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
10172523|NCT03871530|Experimental|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
10172524|NCT03871530|Experimental|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
10172525|NCT03871530|Experimental|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
9524866|NCT03242837|Experimental|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
10172526|NCT03871530|Experimental|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
10172527|NCT03871530|Experimental|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
9524867|NCT03242837|Active Comparator|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
9524868|NCT03242720|Active Comparator|Active Positive Airway Pressure|Active positive airway pressure for treatment of Obstructive Sleep Apnea
9524869|NCT03242720|Sham Comparator|Sham Positive Airway Pressure|Sham positive airway pressure for treatment of Obstructive Sleep Apnea
9524870|NCT03242915|Experimental|Pembrolizumab/Carboplatin/Pemetrexed|Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks
9524871|NCT03242733||Hip fracture patients|Fasted elderly patients scheduled for hip fracture surgery except exclusion criteria are enrolled.
9524872|NCT03242980|No Intervention|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
9524873|NCT03242980|Experimental|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
10172528|NCT03871530|Experimental|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
10172529|NCT03871530|Experimental|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
10172530|NCT03871530|Experimental|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
10172531|NCT03871673|Active Comparator|Cornstarch|Ingestion of cornstarch, the standard treatment for hepatic GSD.
9524874|NCT03242785|Experimental|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
9524875|NCT03242785|No Intervention|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
9524876|NCT03242707|Experimental|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
9524877|NCT03242707|Active Comparator|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
9524878|NCT03242681|Experimental|Endoscopy Assisted Probing|Endoscopy Assisted Probing
9524879|NCT03242681|Active Comparator|Simple Probing|Simple Probing
9524880|NCT03242629|Active Comparator|oral group|
9524881|NCT03242629|Experimental|enema group|
9528003|NCT03214965|No Intervention|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
9528004|NCT03214848|No Intervention|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
9528005|NCT03214848|Experimental|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
9528006|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
9528007|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
10172532|NCT03871673|Experimental|Sweet Polvilho|Ingestion of sweet polvilho, the starch in study.
10172533|NCT03871569|Active Comparator|telemedecine nursing home|One buccodental teleexpertise at the completion day and a second buccodental teleexpertise at the end of study
9528008|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
10172534|NCT03871569|No Intervention|control nursing home|Only one buccodental teleexpertise at the end of study
10172535|NCT03871361|Experimental|Abatacept 125 MG/ML Prefilled Syringe|"Participants will inject the drug at home on a weekly basis. Participants will receive the syringes on the visit dates, supplying them for the period until the next visit. At baseline, participants will be explained and shown how to inject the drug themselves.~Subject will have to stop all concomitant immunosuppressive drugs at baseline, e.g. Corticosteroids, Methotrexate, Mofetil Mycophenolate, Azathioprine, Tacrolimus, Sirolimus or Cyclosporin. Other drugs can be continued. In case of recurrence in the abatacept group, the study will end for that subject.~Patients treated with abatacept (ORENCIA) may receive concurrent vaccinations, except for live vaccines. Live vaccines should not be given concurrently with abatacept or within 3 months of its discontinuation."
10172536|NCT03871413|Active Comparator|Manual repositioning maneuver|Diagnostics and treatment of BPPV with manual repositioning maneuvers. In case of posterior canal involvement, Epley's maneuver will be used. In case of horizontal canal involvement, the log roll maneuver will be used.
10187021|NCT03730402|Active Comparator|liposomal bupivacaine block (Exparel 266 milligram Per 20 ML)|laparoscopic assisted plane block of standardized dose of bupivacaine plain
9528009|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
9528010|NCT03214796||Albumin infusion|Patients with decompensated cirrhosis and an indication for routine human albumin infusion
9524882|NCT03242668|Experimental|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
9524883|NCT03242382|Experimental|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
9524884|NCT03242447|Experimental|e-Practice Self-Regulation (e-PS-R)|e-Practice Self-Regulation (e-PSR) is the treatment condition. e-PS-R is a 'blended learning' intervention, combining online and face-to-face instruction. e-PS-R aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
10172537|NCT03871413|Experimental|Treatment in mechanical rotational chair (TRV-chair)|"Diagnostics and treatment of BPPV with the use of a TRV chair. In case of posterior canal involvement, Epley's maneuver will be used with the addition of 10 kinetic impulses in each position.~In case of horizontal canal involvement, the log roll maneuver will be used with the addition of 10 kinetic impulses in each position."
9524885|NCT03242447|Active Comparator|Video Health Group|The Video Health Group is the control counterfactual condition. Youth assigned to the control group will view a video on a non-sexual health topic (the hazards of smoking).The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes. The informational video uses both narration and interviews to educate viewers on the dangers that cigarettes pose.
9524886|NCT03242460|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
9524887|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
9524888|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
9524889|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
9524890|NCT03242499|Experimental|Active|Lovastatin 80mg per day for 48 weeks.
9524891|NCT03242499|Placebo Comparator|Placebo|Placebo 80mg per day for 48 weeks.
9524892|NCT03242616|Experimental|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)~Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th…. cycle after then.)~Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose~Dexa 4mg po bid on D0-2"
9524893|NCT03242616|Active Comparator|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
9524894|NCT03242538|Experimental|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
9524895|NCT03242551|Experimental|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
9524896|NCT03242473|Experimental|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
10172538|NCT03871400|Other|NanoMetalene/PEEK|
10172539|NCT03871400|Other|NanoMetalene/Allograft|
10172540|NCT03871218|Active Comparator|Test Group|Hyaluronic acid application group. After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. The cross-linked HA package containing 20 mg/ml Na-hyaluronate, stored at room temperature, was opened, and the protective cap of the syringe was removed.
9524897|NCT03242473|Experimental|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
9524898|NCT03242512|Experimental|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
9524899|NCT03242512|Experimental|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
9524900|NCT03242512|Experimental|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
9524901|NCT03242655|Experimental|HCV GET-UP (Group Intervention)|HCV GET-Up (Group Evaluation and Treatment Uptake)
9524902|NCT03242655|No Intervention|Control|Individual onsite HCV treatment at a primary care center
9524903|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
9524904|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
9524905|NCT03242603|Experimental|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
9524906|NCT03242317|Experimental|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
9524907|NCT03242330|Experimental|Two-piece subperiosteal implant|The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body.
9524908|NCT03242330|Active Comparator|Single-piece subperiosteal implant|The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery.
9528011|NCT03214731|Experimental|low dose Art|25mg bid Artesunate and standard of care was given to patients
9524909|NCT03242564|Experimental|Active Device|"Active Device: Vevazz LED red light therapy system~Vevazz LED red light therapy system is a treatment regimen using the Vevazz LED device for fat removal using LED red light therapy."
9524910|NCT03242369|Experimental|PEG group|100 patients undergoing colonoscopy.
9524911|NCT03242369|Experimental|SBS group|100 patients undergoing colonoscopy
9524912|NCT03242369|Experimental|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
9524913|NCT03242369|Experimental|PICO group|100 patients undergoing colonoscopy.
10172541|NCT03871218|No Intervention|Control Group|In the control group (CG), HA was not applied to the recipient or the donor site.
9524914|NCT03242291|Active Comparator|conventional resin-based flowable composite|
9524915|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|
9524916|NCT03242343|Experimental|VasQ device implantation|"Main study cohort: Prospective, multi-center, single-arm, open label, enrolling patients referred to surgical creation of new brachiocephalic fistula (BCF). The VasQ will be applied to the AV fistula in all patients. The primary effectiveness endpoint for this trial will be measured at 6 months and compared to a performance goal (PG). Safety will compare descriptively between AE rates for Steal, Infection, Aneurysm and Seroma. Patients will be followed up for an additional 18 months for a total of 2 years. Additionally, this trial has several secondary endpoints.~Supplementary study cohort: 15 patients will be prospectively enrolled which are referred to surgical creation of a new forearm arteriovenous fistula. VasQ will be applied to the AV fistula in all patients. Patients will be followed in the same manner as in the Main study cohort, however, the data will be reported separately and not be part of the analysis sets for the study primary and secondary endpoints."
10172542|NCT03871322|Active Comparator|Vitamin D group|vitamin D supplementation - time to fracture healing
10172543|NCT03871322|Active Comparator|Vitamin D and K2 group|Vitamin D and K 2 supplementation - time of fracture healing
10172544|NCT03871322|Placebo Comparator|Placebo group|Placebo - time to fracture healing
9524917|NCT03242486|Experimental|toric intraocular lens|toric intraocular lens is implanted to all subjects
9524918|NCT03242161|Experimental|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
9827754|NCT02466646|Active Comparator|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
9524919|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
9524920|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
9672412|NCT05035888|Experimental|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
9672413|NCT05036200|Experimental|four pulsed dye laser sessions were administered every eight weeks in the 21 patients|
9672414|NCT05035719||Group 1|Cardiac patients
9672415|NCT05035745|Experimental|Patients with refractory solid tumors|Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of patients with refractory solid tumors to determine the RP2D.
9524921|NCT03242070|Experimental|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
9524922|NCT03242070|No Intervention|Control Group|No specific intervention will be provided to the control group participants
9524923|NCT03242083||Primary atrophic AMD|
9524924|NCT03242083||Secondary atrophic AMD|
9524925|NCT03242200|Other|Mobile Health App|Participants will be prompted to complete questionnaires.
9524926|NCT03242213|No Intervention|Usual Care|Standard of Care
9524927|NCT03242213|Active Comparator|Mobile App|Standard of Care and Mobile App
9524928|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
9524929|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
9524930|NCT03241979||laryngeal microsurgery|
9524931|NCT03242226|Experimental|two spectacles|
9524932|NCT03242226|Active Comparator|single vision spectacles|
9528012|NCT03214731|Experimental|high dose Art|50mg bid Artesunate and standard of care was given to patients
9528013|NCT03214731|Placebo Comparator|placebo|Placebo and standard of care was given to patients
9528247|NCT03212352|Experimental|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
9672416|NCT05035875||40 COPD patients|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
9672417|NCT05035875||40 healthy individuals|all participants were subjected to : history - clinical examination - spirometry - ultrasound evaluation of diaphragmatic function
9672418|NCT05035849|Active Comparator|Group A|Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks.
9827755|NCT02466646|Experimental|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
10172545|NCT03871478|Active Comparator|Lidocaine|Buffered lidocaine 1% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
10172546|NCT03871478|Active Comparator|Bupivacaine|Bupivacaine 0.5% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
10172547|NCT03871478|Active Comparator|Lidocaine and Bupivacaine|"Buffered lidocaine 1% with epinephrine 1:200,000 and bupivacaine 0.5% with epinephrine 1:200,000 injected sequentially.~Injected at the start of every Mohs excision stage"
10172548|NCT03871439|Experimental|PF-05221304 Formulation A|
10172549|NCT03871439|Experimental|PF-05221304 Formulation B|
10172550|NCT03871387|Experimental|Deep Block Group|"Continuous Rocuronium infusion during surgery~Maintain TOF = 0 & PTC= 1~2~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
10172551|NCT03871387|Active Comparator|Moderate Block Group|"Continuous Rocuronium infusion during surgery~Maintain TOF 1~2~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
10172552|NCT03871127||Left main coronary disease|
10172553|NCT03871192|Experimental|FACET JOINT UNDER CT GUIDANCE|Injection of the facet joint under computed tomography guidance
9524933|NCT03242044|Experimental|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
10172554|NCT03871192|Active Comparator|NERVE BLOCK UNDER CT GUIDANCE|Injection of the nerve under computed tomography guidance
10172555|NCT03871192|Experimental|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|Injection of the facet joint under fluoroscopy guidance
9524934|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
9524935|NCT03242239|Experimental|ALT02|
9524936|NCT03242239|Active Comparator|EU-licensed Herceptin|
9524937|NCT03242239|Active Comparator|US-licensed Herceptin|
9524938|NCT03242031|Experimental|1 session|
9524939|NCT03242031|Active Comparator|4 sessions|
9524940|NCT03241875|Placebo Comparator|placebo|Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
9524941|NCT03241875|Experimental|pregabalin|patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
9524942|NCT03241875|Experimental|gabapentin|patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.
9524943|NCT03241901|Active Comparator|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):~tablet for 5-14kg;~tablets for 15-24 kg;~tables for 25 - 34kg and~tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
9524944|NCT03241901|Experimental|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
9524945|NCT03241953|Experimental|debridement made by ultrasonic tips|mechanical debridement made by ultrasonic polyetheretherketone coated tips developed for implant surface and combined air-flow debridement
9524946|NCT03241953|Active Comparator|implants were debrided with standard plastic curettes|dental implants were debrided with standard plastic curettes, debridement made by combined klorhegsidin rinse
9524947|NCT03242187|Experimental|Trans-anal TME (TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
9524948|NCT03242187|Active Comparator|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
9524949|NCT03242057|Experimental|NI-NAVA|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.~ABG or CBG to be obtained at 4 hrs. post extubation~NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
9672419|NCT05035849|Active Comparator|Group B|Patients in group B were given acarbose and metformin for the first two weeks, and then were treated with sitagliptin and metformin for the second two weeks.FGM was used to monitor glycemic variations during the whole four weeks.
10172556|NCT03871192|Active Comparator|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|Injection of the nerve under ultrasound guidance
10172557|NCT03871192|Experimental|FACET JOINT UNDER ULTRASOUND GUIDANCE|Injection of the facet joint under ultrasound guidance
10172558|NCT03871192|Active Comparator|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|Injection of the nerve under computed ultrasound guidance
10172559|NCT03871309||Tigertriever|Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.
9524950|NCT03242057|Active Comparator|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~ABG or CBG to be obtained at 4 hrs. post extubation~NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
9528248|NCT03212443|Sham Comparator|Group A|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
9672420|NCT05035576|Active Comparator|400 mg OPN-019|
10172560|NCT03871452|Active Comparator|ABS in external bleeding|Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
10172561|NCT03871452|Active Comparator|Repetition of ABS stopped bleeding|Repetition of ABS stopped bleeding
9524951|NCT03241992|Experimental|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
9524952|NCT03241992|No Intervention|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
9524953|NCT03241849|Other|Modified surgical technique for placenta accreta|
9524954|NCT03242122|Active Comparator|CHO Control 1 Glucose|25 g glucose
9524955|NCT03242122|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
9524956|NCT03242122|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
9524957|NCT03242122|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
9524958|NCT03242122|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
9524959|NCT03242122|Active Comparator|CHO Control 2 Glucose|25 g glucose
9524960|NCT03242005|Experimental|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
9524961|NCT03241914|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
9524962|NCT03241914|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
9524963|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
10172562|NCT03871205|Experimental|Vaccinated group|Neoantigen loaded-DC vaccination will be performed with 6 doses in total, once per week, adjacent lymph-node injection.
9524964|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
9524965|NCT03241784|Experimental|Treatment arm|All subjects are enrolled in the one arm consisting of infusions of autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth/kg and subcutaneous injections of Interleukin-2 at a dose of 2x10 to the fifth IU/m2 three times a week.
9524966|NCT03242096|Experimental|Sirolimus coated balloon|Treatment of in-stent restenosis with a sirolimus coated balloon
9524967|NCT03242096|Active Comparator|Paclitaxel coated balloon|Treatment of in-stent restenosis with a paclitaxel coated balloon
9524968|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
9524969|NCT03241888|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
9524970|NCT03241888|Active Comparator|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
9524971|NCT03241888|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
9524972|NCT03241797|Experimental|Patients who suggested having AIP|Patients who suggested having AIP and underwent EUS-FNA biopsy by using a standard 22-gauge aspiration needle were enrolled between January 2013 and May 2017.
9524973|NCT03241472|Experimental|Lertozole|oral tablets 5 mg start from third day cycle for 5 days
9524974|NCT03241472|Active Comparator|clomiphene plus N- acetyl cystiene|clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
9524975|NCT03241420||Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
10172563|NCT03871101|Active Comparator|Scalpel|Soft tissue incision with scalpel in second- stage implant surgery.
10172564|NCT03871101|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz H mode, 10% water and 10% air) in second-stage implant surgery.
9524976|NCT03241420||Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
9524977|NCT03241628||Dressing Glove|"Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.~The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes."
9524978|NCT03241446|Experimental|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
9524979|NCT03241446|Experimental|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
9524980|NCT03241446|Experimental|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
9528249|NCT03212443|Active Comparator|Group B|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
10187022|NCT03730402|Placebo Comparator|saline block|laparoscopic assisted plane block with placebo saline injection
9524981|NCT03241433|Active Comparator|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
9524982|NCT03241433|Active Comparator|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
9524983|NCT03241433|Active Comparator|No exercise|No excercise training will be done
9524984|NCT03241511|Experimental|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
9524985|NCT03241511|No Intervention|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
10172565|NCT03871231|Experimental|Unpinning Termination Therapy Arm|Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
10172566|NCT03871036|Experimental|Tremelimumab 75 (R1)|"Run-in phase-1 (R1): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 75 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
10172567|NCT03871036|Experimental|Tremelimumab 225 (R2)|"Run-in phase-2 (R2): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 225 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
9524986|NCT03241563|Active Comparator|without triamcinolone|sodium Deoxycholate without triamcinolone
9524987|NCT03241563|Active Comparator|with triamcinolone|sodium Deoxycholate with triamcinolone
9524988|NCT03241524|Experimental|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
9524989|NCT03241745|Experimental|Nivolumab|Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
9524990|NCT03241602|Active Comparator|group of Pulmonary recruitment & Intraperitoneal libocai|
9524991|NCT03241602|Active Comparator|Group of Intraperitoneal lidocaine|
9524992|NCT03241602|Active Comparator|Group of pulmonary recruitment|
9524993|NCT03241602|No Intervention|group receive passive exsufflation through port|
9524994|NCT03241537|No Intervention|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
9524995|NCT03241537|Active Comparator|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
9524996|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
9524997|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
9524998|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
9524999|NCT03241680|No Intervention|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
9525000|NCT03241680|No Intervention|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
9525001|NCT03241680|No Intervention|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
9525002|NCT03241680|Active Comparator|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
9525003|NCT03241576|Experimental|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
9525004|NCT03241576|Active Comparator|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
9525005|NCT03241693|Other|control group|Physiotherapy students
9525006|NCT03241693|Experimental|experimental group|Physiotherapy students
9525007|NCT03241641|Experimental|Maintaining TAF monotherapy|- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
9525008|NCT03241641|Active Comparator|Switching from TDF to TAF|"Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks~Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks"
9525009|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 1: 1 to < 6 years of age|Patients will receive an intravenous (IV) loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
9528250|NCT03212456|Experimental|Opioid-free|The patients of this group will receive opioid-free anesthesia
9672421|NCT05035576|No Intervention|Standard of Care (SOC)|
9827756|NCT02466646|Experimental|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
9827757|NCT02466659|Experimental|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
9827758|NCT02466659|No Intervention|Observation|To observe as one kind of standard care for IXT.
9525010|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 2: 6 to < 12 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
9525011|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 3: 12 to < 18 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
9525012|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 4: 6 to < 12 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
9525013|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 5: 12 to < 18 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
9525014|NCT03241719|Experimental|Treatment|Subjects who receive transplantation and undergo IL-2 treatment
9525015|NCT03241407|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
9525016|NCT03241407|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min. During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
10172568|NCT03871036|Experimental|Tremelimumab vs Tremelimumab+Durvalumab (R3)|"Run-in phase-3 (R3): n=2 x 3 patients will be randomized over 2 arms:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45~OR~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 75 mg on day 1 of cycles 2-5~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
9525017|NCT03241706|Placebo Comparator|Controls-saline|Each subject from Group 1 will undergo a metabolic study where saline is infused so as to not stimulate liver glucose uptake and glycogen deposition.
9525018|NCT03241706|Active Comparator|Controls-high fructose|A second group of control subjects will undergo a single metabolic study using a higher dose of fructose (6.5 mg/kg/min).
9525019|NCT03241706|Active Comparator|Controls-low fructose|Each subject from Group 1 will undergo another metabolic study where fructose (1.3 mg/kg/min) is infused so as to stimulate liver glucose uptake and glycogen deposition.
9525020|NCT03241394||Lean|Individuals with Body Mass Index (BMI) = 18.5 - 25.0 Kg/m2
10172569|NCT03871036|Experimental|Tremelimumab 300 (R4)|"Run-in phase-4 (R4): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 300 mg once on day 1 of cycle 2~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
9525021|NCT03241394||Obese with MS|Individuals with BMI ≥ 30.0 Kg/m2 and metabolic syndrome (MS) MS was defined as the presence of three or more of the following criteria: 1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 2) serum triglycerides ≥ 150 mg/dL, 3) high density lipoprotein-cholesterol (HDL-C) < 40 mg/dl in men and < 50 mg/dl in women, 4) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg or antihypertensive drug treatment, 5) fasting glucose ≥ 100 mg/dL
9525022|NCT03241394||Obese without MS|Individuals with BMI ≥ 30.0 Kg/m2 but not MS
9525023|NCT03241498|No Intervention|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
9525024|NCT03241498|Experimental|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
9525025|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
9525026|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
9525027|NCT03241095|No Intervention|Control|
9525028|NCT03241095|Sham Comparator|Sham OMT|
9525029|NCT03241095|Active Comparator|OMT|
9525030|NCT03241303|Experimental|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
9525031|NCT03241303|Placebo Comparator|Placebo Oral tablets|180 mg. 2 weeks.
9525032|NCT03241303|Experimental|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
10172570|NCT03871036|Experimental|Tremelimumab 750 (A)|"Arm A:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
9525033|NCT03241303|Placebo Comparator|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
9525034|NCT03241147|Experimental|Subjects with severe renal impairment (Group A)|
9525035|NCT03241147|Experimental|Healthy subjects (Group B)|
9525036|NCT03241147|Experimental|Subjects with moderate renal impairment (Group C)|
9525037|NCT03241147|Experimental|Subjects with mild renal impairment (Group D)|
10172571|NCT03871036|Experimental|Tremelimumab+Durvalumab (B)|"Arm B:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 300 mg once on day 1 of cycle 2~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
10172572|NCT03871036|Experimental|Tremelimumab without paclitaxel (C)|"Arm C (control arm):~• tremelimumab 750 mg on day 1 of cycles 1-5 and then every 12 weeks until week 41"
9525038|NCT03241277|Experimental|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
9525039|NCT03241277|Experimental|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
9525040|NCT03241277|Active Comparator|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
9525041|NCT03241134|Experimental|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
9525042|NCT03241134|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
9525043|NCT03241225|Experimental|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
9525044|NCT03241225|Active Comparator|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
9525045|NCT03241199|Experimental|Imatinib Mesylate|imatinib 400mg daily
9525046|NCT03241264|Experimental|Module A|Lyophilized Formulation
9525047|NCT03241264|Experimental|Module B|Frozen Formulation
9525048|NCT03241238|Other|Regular Brownie|Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
9525049|NCT03241238|Other|Psyllium Brownie|For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
10172573|NCT03871062|Active Comparator|topical anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
10172574|NCT03871062|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
10172575|NCT03871114||OLP patients|fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks
10172576|NCT03871114||Control group|
10187023|NCT03730389|Experimental|EPVL Group|In treatment group, patients were given one to three sessions of External Physical Vibration Lithecbole therapy in two weeks. These patients were also instructed to drink a minimum of 2500 ml water daily and take more exercise.
10187024|NCT03730389|No Intervention|Traditional Group|patients with 4-10mm ureteral stone, were treated by traditional treatment methods, including drinking a minimum of 2500 ml water daily and taking more exercise.
10187025|NCT03730376|No Intervention|Control|Participants in the control group will be given a hypothetical scenario about carpal tunnel syndrome and asked to make a treatment decision for that hypothetical patient.
10187026|NCT03730376|Experimental|Intervention|Participants in the intervetion group will be given a hypothetical scenario about carpal tunnel syndrome as well as information about the cost of treatment and asked to make a treatment decision for that hypothetical patient.
10187027|NCT03730363|Experimental|Pentamidine + ICE|Pentamidine, Ifosfamide, Carboplatin, and Etoposide (ICE) by IV Infusion.
9525050|NCT03241238|Other|β-glucan Brownie|For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later
9525051|NCT03241108|Experimental|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
9525052|NCT03241108|Placebo Comparator|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
9525053|NCT03241355|Active Comparator|prebiotic inulin-type fructan|
9525054|NCT03241355|Placebo Comparator|placebo maltodextrin|
9525055|NCT03241329||Case : endometriosis|Infertile patients with endometriosis that is the only cause of their infertility
9525056|NCT03241329||Control : tubal factor|infertile patients with tubal factor that is the only cause of their infertility
9525057|NCT03241160||Children with cerebral palsy|Children with a diagnosis of spastic cerebral palsy aged between 2 to 12 years who will be referred by pediatric neurologists will be included. Children under the age of 24 months, and used any medicine and/or oral appliances that could affect the chewing performance, will be excluded. Chewing evaluation will be performed.
9525058|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
9525059|NCT03241251||parents children pediatric cancer|Screening questionnaire psychosocial risk factors
9525060|NCT03241212|No Intervention|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
9525061|NCT03241212|Experimental|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
9525062|NCT03241316||district-level representative rural survey|Approximately 4,800 adults in 60 villages across Thailand and Lao PDR to study health and antimicrobial resistance (AMR)-related behaviour in breadth.
9525063|NCT03241316||village-level social network census|Approximately 4,800 adults across 6 villages in rural Thailand and Lao PDR that are exposed to AMR awareness activities to study health behaviour within social networks.
9528014|NCT03214718|Experimental|CML patients treated with imatinib 400 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) by flowctytometry for each newly diagnosed chronic phase chronic myeloid leukemia (CML) patients treated with imatinib 400 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene level and the sokal score of the patients and deep molecular response of the patients after one year .
9528015|NCT03214718|Active Comparator|CML patients treated with nilotinib 600 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) for each newly diagnosed chronic phase chronic myeloid leukemia ( CML) patients treated with nilotinib 600 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene, the sokal score and deep molecular response of the patients after one year .
9528016|NCT03214757||group with dilated cardiomyopathy without anemia|
9528017|NCT03214757||group with dilated cardiomyopathy with anemia|
9528018|NCT03214692|Experimental|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
9528019|NCT03214783||Coronary artery disease (CAD) group|Patients enrolled with at least one coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
9528020|NCT03214783||No CAD group|Patients enrolled without coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
9672422|NCT05036057||COPD patients and their proxies|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
9672423|NCT05035446|Experimental|single-incision plus one-port laparoscopic surgery(SILS + 1)|It requires an auxiliary small incision and one more port to perform laparoscopic gastrectomy
10172577|NCT03870932|Experimental|Motor imagery rehabilitative group (MIG)|"All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to feeling and self-perceiving the execution of the movement. More than the quantity of repetition, the quality of the movement, free from pain, was important."
9826704|NCT02430090|Experimental|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.~Injection Surgical anaesthesia~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
9528021|NCT03214471|No Intervention|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
9528022|NCT03214471|Experimental|Intervention|usual care + BARI-LIFESTYLE intervention
9672424|NCT05035446|Other|conventional laparoscopic surgery(CLS)|It requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy
9672425|NCT05035342|Experimental|Fecal microbiota Transplant (FMT)|Fecal microbiota Transplant (FMT) prepared from the stools of healthy donors diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min) and manufactured in capsules (n=50 capsules corresponding to approximately 50 grams of stool; 25 two days in a row).
9672426|NCT05035342|Placebo Comparator|Placebo of FMT|FMT vehicle (solution of saline (NaCl 0.9%)) with 80% glycerol (storage in the same conditions as preparation for FMT experimental group) administered at the same volume and same time point as the experimental group.
9672427|NCT05035355|Experimental|weaning protocol group|spontaneous breathing trial (SBT)-based protocol-directed weaning combined with the high-flow nasal cannula group
9672428|NCT05035355|No Intervention|routine SBT weaning group|
9672429|NCT05035394|Active Comparator|Cataract|Cataract surgery as stand alone. Cataract surgery will be performed in a standardized fashion.
9672430|NCT05035394|Active Comparator|KDB|Cataract surgery combined with Kahook Dual Blade Glide goniotomy. The goniotomy will be performed at the end of cataract surgery through the temporal cataract incision.
9672431|NCT05035394|Active Comparator|Istent|Cataract surgery combined with iStent Inject W. The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.
9672432|NCT05035589||TCZ|The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
9672433|NCT05035589||Control|50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab
10172578|NCT03870932|Active Comparator|Control rehabilitative Group (CG)|The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.
10172579|NCT03870958|Experimental|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
9525064|NCT03241069|Experimental|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
9525065|NCT03241069|Experimental|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured 5 minutes later)
9525066|NCT03241069|Experimental|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver 5minutes later.)
9525067|NCT03241069|Experimental|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
9525068|NCT03241043|Experimental|Envarsus - Advagraf|
9525069|NCT03241043|Active Comparator|Advagraf - Envarsus|
9525070|NCT03241004|Experimental|Intensive Care Unit|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
9525071|NCT03241004|Experimental|Operating Room|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol and inhalational anesthetics will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
9525072|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
9525073|NCT03241017|Experimental|Durvalumab|Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).
9525074|NCT03240770|No Intervention|14 Day Tray + Sham|Trays worn at 14 day intervals + Sham
9525075|NCT03240770|Experimental|7 Day Tray + Sham|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
9525076|NCT03240770|Experimental|5 Day Tray + Sham|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
9525077|NCT03240770|Experimental|7 Day Tray + VPro5|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
9525078|NCT03240770|Experimental|5 Day Tray + VPro5|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
9525079|NCT03240757|Active Comparator|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
9525080|NCT03240757|Experimental|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
9525081|NCT03240809|Experimental|Cohort 1|(ages 12 to <18 years): 140 mg SC dose of brodalumab
9525082|NCT03240809|Experimental|Cohort 2|(ages 6 to <12 years): 70 mg SC dose of brodalumab
9525083|NCT03240874|Experimental|Usability - Focus Group|"Mobile Application Usability Testing: SweetMama Focus Groups~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
9525084|NCT03240874|Experimental|Usability - Individual Testing|"Mobile Application Usability Testing: SweetMama Individual Testing~Individual testing: Women with a confirmed intrauterine pregnancy (any gestational age) or who are up to 4 weeks postpartum, with gestational diabetes mellitus or type 2 diabetes mellitus, will be recruited to use SweetMama for 2 weeks and provide feedback."
9525085|NCT03240874|Experimental|Feasibility - Pilot Randomized Trial, SweetMama arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, SweetMama arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to receive SweetMama care will be oriented to use of SweetMama and will then use the intervention (messages, library, goal setting, and appointment reminders) throughout pregnancy and the first 8 weeks postpartum, at which point they will undergo surveys and interviews."
9525086|NCT03240874|No Intervention|Feasibility - Pilot Randomized Trial, usual care arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, usual care arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to usual care will be undergo entry and exit surveys (at 6-8 weeks postpartum) but will not interact with SweetMama."
9528251|NCT03212456|Active Comparator|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
10172580|NCT03870958|Active Comparator|Control|Children allocated to this group will receive the same dietary advices and brushing instructions described in the control arm.
9525087|NCT03240744|Experimental|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
9525088|NCT03240718|Experimental|Laser treated HSc scar|Co2 laser treatment
10172581|NCT03871153|Other|Treatment|Neoadjuvant chemotherapy(Durvalumab, Paclitaxel, Carboplatin), radiation and immunotherapy (durvalumab) followed by surgical resection followed by adjuvant immunotherapy (durvalumab)
9525089|NCT03240718|No Intervention|Control scar|Standard care
9525090|NCT03240796|Experimental|minimal invasive surgery and secondary IOL implantation|
9525091|NCT03240796|Active Comparator|traditional cataract surgery and secondary IOL implantation|
9525092|NCT03240822|Experimental|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
9525093|NCT03240887|Experimental|Peer Group Connection (PGC)|Ninth-grade participants are assigned to small groups of 10-14 students that attend weekly peer group outreach sessions led by older peer leaders.
9525094|NCT03240887|No Intervention|Business as usual|Ninth grade students remain in their regularly scheduled school classes or activities during PGC outreach times.
9525095|NCT03240679|Active Comparator|EMR with Extracelluar Matrix|Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive Extracellular Matrix to the defect site
9525096|NCT03240679|No Intervention|EMR|assess baseline dysphagia (Mellow-Pinkas scale and Mayo Dysphagia Questionnaire). Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive standard of care.
10172582|NCT03871010||Neutropenia patients, Dept. of Haematooncology|Patients with neutropenia from the Department of Haematooncology were included in this group.
9525097|NCT03240705|Experimental|Gratitude journaling|Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
9525098|NCT03240705|No Intervention|No intervention|Students proceed with their surgical clerkship as is standard in our institution.
9525099|NCT03240939|Active Comparator|Dutasteride&Tadalafil|Dutasteride 0.5 mg capsule and Tadalafil 5 mg Tablet, single dose
9525100|NCT03240939|Experimental|YY-201|YY-201 capsule, singe dose
9525101|NCT03240913|Experimental|Treatment Group|
9525102|NCT03240913|Placebo Comparator|Non Treatment Group|Conventional information
9525103|NCT03240900|Experimental|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
9525104|NCT03240900|Placebo Comparator|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
10172583|NCT03871010||No neutropenia patients, Dept. of Haematooncology|Patients without neutropenia from the Department of Haematooncology were included in this group.
10172584|NCT03871010||No neutropenia patients, other clinical depts.|Patients with neutropenia from the other clinical departments of the University Hospital Ostrava were included in this group.
9525105|NCT03240783|Experimental|Arm 1|Betamethasone OR Dexamethasone Injectable CT - fluoroscopic guided transforaminal lumbar epidural steroid
9525106|NCT03240783|Experimental|Arm 2|Normal Saline Flush, 0.9% Injectable Solution CT - fluoroscopic guided transforaminal lumbar epidural normal saline
9525107|NCT03240783|Experimental|Arm 3|"Dexamethasone Oral Tablet:~Oral dexamethasone 15 day tapered dosing is as follows: (i) days 1-5, 4 mg morning and evening, (ii) days 6-10, 2 mg morning and evening, and (iii) days 11-15, 1mg morning and evening."
10172585|NCT03870906|Experimental|WhatsApp interaction|Individual and group chat interactions.
10172586|NCT03870906|Placebo Comparator|Text message|Regular text messages with similar frequency to those in the Intervention group.
9525108|NCT03240783|Other|Arm 4|Sham Injection and/or oral placebo: CT/fluoroscopic guided (parameters set to zero) transforaminal lumbar sham (needle placement down to muscle and no injection of any fluid) AND placebo oral tablets taper.
9525109|NCT03240835||CCRT±NACT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
9525110|NCT03240978|Experimental|High intensity intervention|Exercise intervention at 70 to 80% of estimated heart rate maximum for 12 weeks.
9525111|NCT03240978|Experimental|Moderate intensity intervention|Exercise intervention at 50 to 70% of estimated heart rate maximum for 12 weeks.
9525112|NCT03240978|No Intervention|non-exercise group|Participants will not receive any type of exercise training.
9525113|NCT03240848|Experimental|artificial intelligent clinic|"Procedure: the initial diagnosis from artificial intelligent clinic Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in artificial intelligent clinic, participants in group A went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
9525114|NCT03240848|Active Comparator|normal clinic|"Procedure: the initial diagnosis from normal clinic Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in normal clinic, participants in group B went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
9525115|NCT03240965||Volunteers <60 years|Volunteers, who are able to consent to participation in the study, as control.
10172587|NCT03870984|Experimental|wNUTS, low-caloric diet plus nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
10172588|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
10172589|NCT03870854|Experimental|PEFA targeted substrate ablation|Use of PEFA strategy to identify and target VT isthmuses.
9525116|NCT03240965||Volunteers >60 years|Volunteers, who are able to consent to participation in the study, as control.
9525117|NCT03240965||Stroke patients|Stroke patients with supratentorial stroke, who are able to consent to participation in the study.
9525118|NCT03240926|Experimental|Loop Band|Measure accuracy of vital sign measurements
10172590|NCT03871088|Active Comparator|Eicosapentaenoic acid (EPA)|Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).
9525119|NCT03240627|Experimental|LH-8 cutaneous solution|LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp:
9525120|NCT03240627|Placebo Comparator|Placebo cutaneous solution|Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp:
9525121|NCT03240640|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
9525122|NCT03240640|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
9525123|NCT03240614|Active Comparator|BMI <30 no lung disease|Patients with a BMI <30 with no lung disease
9525124|NCT03240614|Active Comparator|BMI <30 with lung disease|Patients with a BMI <30 with lung disease
9525125|NCT03240614|Active Comparator|BMI 30-35 with no lung disease|Patients with a BMI between 30 and 35 with no lung disease
9525126|NCT03240614|Active Comparator|BMI 30-35 with lung disease|Patients with a BMI between 30 and 35 with lung disease
9525127|NCT03240614|Active Comparator|BMI >35 with no lung disease|Patients with a BMI> 35 with no lung disease
9525128|NCT03240614|Active Comparator|BMI >35 with lung disease|Patients with a BMI> 35 with lung disease
9525129|NCT03240432|Active Comparator|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
9525130|NCT03240432|No Intervention|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
9525131|NCT03240497|Experimental|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
9525132|NCT03240497|Experimental|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
9525133|NCT03240497|Experimental|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
9826705|NCT02430090|Experimental|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.~Indications:~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
10172591|NCT03871088|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).
10172592|NCT03871088|Active Comparator|EPA/DHA combination|EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.
10172593|NCT03870867||Seniors who have fallen|Emergency department patients over the age of 65 who present to the emergency department after a fall.
10172594|NCT03871244|Experimental|Restrictive arm (intervention)|Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.
10172595|NCT03871244|Active Comparator|Standard care arm (comparator)|Clinical teams will follow their usual transfusion practices.
10172596|NCT03870945|Experimental|Dose level 1 with 1x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
9525134|NCT03240497|No Intervention|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
9525135|NCT03240367|Experimental|coutery|Stapler bloom will be stopped with cautery
9525136|NCT03240367|No Intervention|clips|Stapler bloom will be stopped with clipping
9525137|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has undergone spine fusion (SF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
9525138|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
9525139|NCT03240484||Spine Fusion Only Group|Any patient who has had spine fusion only (no hip replacement surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
10172597|NCT03870945|Experimental|Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
10172598|NCT03870828||Study group IPAF|"Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.~The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry"
10172599|NCT03870828||Control group CTD-ILD|Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)
9525140|NCT03240393|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
9525141|NCT03240393|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mgBID
9525142|NCT03240393|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
9826706|NCT02430090|Experimental|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
9525145|NCT03240471|Experimental|One week of plaster cast|One week of plaster cast after a non-reduced distal radius fracture.
9525146|NCT03240471|Other|Control; four-five weeks of plaster cast|Four-five weeks of plaster cast after a non-reduced distal radius fracture, usual care.
9525147|NCT03240549|No Intervention|conventional therapy group|Treatment with previous regimen of combined chemotherapy
9525148|NCT03240549|Experimental|bevacizumab group|Adding bevacizumab to the previous regimen of combined chemotherapy
9525149|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
9525150|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
9525151|NCT03240445|Experimental|Period 1|ODM-203 dosed after food
9525152|NCT03240445|Experimental|Period 2|ODM-203 dosed before food
9525153|NCT03240445|Experimental|Periods 3-6|ODM-203 dosed as a tablet or dispersion
9672434|NCT05035537|Experimental|Group 1 (PGDT)|Group 1(PGDT, intervention group) where minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide a goal directed fluid administration protocol
9525154|NCT03240315||COPD subjects|Subjects with GOLD stage I-IV COPD
9525155|NCT03240380|Experimental|joint crisis plan|Subjects benefit from a joint crisis plan and the process of its negotiation in addition to the usual in-patient or out-patient care.
9525156|NCT03240380|Active Comparator|crisis card|Subjects benefit from a crisis card in addition to the usual in-patient or out-patient care.
9525157|NCT03240562|Sham Comparator|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
9525158|NCT03240562|Experimental|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
9525159|NCT03240354|Experimental|Saline|Use of saline to inflate cuff of endotracheal tube
9525160|NCT03240354|Active Comparator|Control|Use of air to inflate cuff of endotracheal tube
9525161|NCT03240276|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
9525162|NCT03240276|Active Comparator|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
9525163|NCT03240328|Experimental|CAR-T therapy|Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
9525164|NCT03240289|Other|Texting|Texting group
9528023|NCT03214458|Other|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
9528024|NCT03214536|Experimental|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
9672435|NCT05035537|No Intervention|Group 2 (control)|Group 2 (control) managed according to local and international best practice guidelines using standard hemodynamic monitoring
9672436|NCT05035381|Experimental|Experiment Group|
9672437|NCT05035498|Active Comparator|Phenylephrine group|Phenylephrine infusion simultaneous with spinal anesthesia
9672438|NCT05035498|Experimental|Norepinephrine group|Norepinephrine infusion simultaneous with spinal anesthesia
9525165|NCT03240159|Active Comparator|Deg-24mg|"Single dose of Degarelix 24mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
9525166|NCT03240159|Active Comparator|Deg-16mg|"Single dose of Degarelix 16mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
9525167|NCT03240159|Active Comparator|Deg-12mg|"Single dose of Degarelix 12mg, on day 24th of previous luteal face cycle.On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
9525168|NCT03240146|Active Comparator|Study Group|Subjects in this group will receive an active pulsed shortwave therapy device.
10172600|NCT03870828||Control group ILD|Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).
10172601|NCT03871075|Experimental|IPC + exercise|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy.
10172602|NCT03871075|Experimental|"IPC + no exercise control"|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
10172603|NCT03871075|Active Comparator|sham control + exercise|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy.
9525169|NCT03240146|Placebo Comparator|Control Group|Subjects in this group will receive a placebo pulsed shortwave device that it does not emit energy.
9525170|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
9525171|NCT03240120|Experimental|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
9525172|NCT03240107|Active Comparator|levator resection|20 patients who will undergo levator aponeurosis resection technique
9525173|NCT03240107|Active Comparator|levator tucking|20 patients who will undergo two point fixation levator tucking technique
9525174|NCT03240055|Experimental|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
9525175|NCT03240055|Placebo Comparator|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
9525176|NCT03240042|Experimental|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
9525177|NCT03240042|Other|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
9525178|NCT03240198||COPD|
9525179|NCT03240198||Controls|
9525180|NCT03240224|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9525181|NCT03240224|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525182|NCT03240224|Experimental|Combination therapy|"In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm), then drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525183|NCT03240224|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9525184|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
9525185|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
9525186|NCT03240302|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte using a standard ICSI petri dish.
9525187|NCT03240302|Active Comparator|PICSI Procedure|The PICSI procedure is based on a selection of mature spermatozoa with CD44 receptors and their injection into the oocyte using the PICSI petri dish that has been coated with hyaluronic acid on its bottom.
9525188|NCT03240237|Experimental|CCM therapy|Optimizer SMART
9525189|NCT03240263|Experimental|Inspiratory muscle training|High intensity inspiratory muscle training
9525190|NCT03240263|Sham Comparator|Sham endurance training|Sham inspiratory muscle training at low intensity
9525191|NCT03239912|Experimental|Twin-block group|Functional treatment will be applied using the Twin-block appliance.
9525192|NCT03239912|Experimental|Twin-block combined with low level laser|Functional treatment will be applied using the Twin-block appliance combined with low level laser.
10172604|NCT03871075|Active Comparator|"sham control + no exercise control"|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
10172605|NCT03870841|Experimental|PC945|PC945 5mg once daily
9525193|NCT03239977|Experimental|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
10172606|NCT03870815||CABG|Patients with CAD who undergoing CABG
10172607|NCT03870815||PCI|Patients with CAD who undergoing PCI with second-generation DES
10172608|NCT03871023|Active Comparator|Simple dressing|Standard, waterproof dressing applied to wound
10172609|NCT03871023|Active Comparator|PICO Dressing|Negative Wound pressure applied second cohort
10172610|NCT03871023|Active Comparator|PREVENA Dressing|Negative wound presure applied to third cohort
10172611|NCT03870776|Placebo Comparator|Placebo|Patients will receive the placebo during 42 days.
10172612|NCT03870776|Experimental|MAP4343 group B|Patients will receive daily dose 1 during 42 days.
9525194|NCT03239977|Placebo Comparator|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
9525195|NCT03240029|Experimental|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
9525196|NCT03240029|Other|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
9525197|NCT03239782|Experimental|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of ~0.5 kg.~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
9525198|NCT03239795|Experimental|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
9525199|NCT03239795|No Intervention|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
9525200|NCT03239691|Experimental|ACT-709478 - Single dose administration|Up to 16 subjects with photosensitive epilepsy will be studied across a maximum of 4 dose levels. Each dose level will initially be investigated in cohorts of 4 subjects undergoing a fixed sequence of study treatment administration in fed condition
9525201|NCT03239691|Placebo Comparator|Placebo|Placebo will be administered on two study days
9525202|NCT03239951|Experimental|Device|Temporary implant (iTind)
9525203|NCT03239808|Experimental|Experimental group|76 patients who start RRT with the incremental HD regimen.
9525204|NCT03239808|Active Comparator|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
9525205|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
9525206|NCT03239847|Experimental|EndoPhys Sheath and Radial Arterial Line|This group of patients will have both the EndoPhys sheath and the radial arterial line placed during surgery.
9525207|NCT03239847|Experimental|EndoPhys Sheath|This group of patients will only receive the EndoPhys sheath during surgery.
9525208|NCT03239704|Experimental|Telemedicine Follow-Up and Telemedicine Monitoring|
10172613|NCT03870776|Experimental|MAP4343 group C|Patients will receive daily dose 2 during 42 days.
10172614|NCT03870594||diabetic|patients suffer from diabetes mellitus
10172615|NCT03870594||non diabetic|patients free from diabetes with normal blood glucose level
9525209|NCT03239704|Active Comparator|Minimal Intervention|
9525210|NCT03239860|Experimental|Dose 1 GNbAC1|Monthly IV
9525211|NCT03239860|Experimental|Dose 2 GNbAC1|Monthly IV
9525212|NCT03239860|Experimental|Dose 3 GNbAC1|Monthly IV
9525213|NCT03239743|Experimental|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
9525214|NCT03239743|Active Comparator|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
9525215|NCT03239821|Sham Comparator|Placebo - deflated balloon|
9525216|NCT03239821|Placebo Comparator|Placebo - inflated balloon|
9525217|NCT03239821|Active Comparator|Codeine - delfated balloon|
9525218|NCT03239821|Active Comparator|Codeine - inflated balloon|
9528025|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
9528252|NCT03212586|Experimental|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
9525219|NCT03239964|Active Comparator|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
9528026|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
9528027|NCT03215173|Experimental|Fit After Baby Group|Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
9672439|NCT05035433|Experimental|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
9672440|NCT05035433|Experimental|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
10172616|NCT03870633||Observational (medical chart, interview)|Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
10172617|NCT03870607|Experimental|Prebiotics and probiotics group|This group will receive standard nutritional guidance from the institutional routine and prebiotics in combination with probiotics, starting one week before the start of Ch-RT and daily throughout the treatment up to 6 to 8 weeks post Ch-RT at the time of evaluation response (primary outcome).
10172618|NCT03870607|No Intervention|Control group|This group will lead nutritionally based just before starting Ch-RT.
10172619|NCT03870542||Deceased donor kidney transplantation|Patients receiving kidney transplants from deceased donor in the participating centers during the study period
9672441|NCT05035667||Observational (questionnaires)|Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.
9672442|NCT05035706|Experimental|Treatment (biopsy, biospecimen collection)|Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.
9672443|NCT05035628|Experimental|Cardiopulmonary exercise training group|Cardiopulmonary exercise intervention will include aerobic exercise, resistance and respiratory exercises, three sessions per week for 2 months
9672444|NCT05035628|No Intervention|control group|Control group with no intervention.
9672445|NCT05035563|No Intervention|Traditional communication management (Pre-intervention)|"Traditional communication practices are maintained, which consists of reporting the patient's medical conditions or specific requirements of the case, between the health team and the family.~According to the social and administrative conditions of each centers, medical telephone information is provided on the conditions of the patients."
9672446|NCT05035563|Experimental|Early and integral communication strategy (EICS) (Post-intervention)|"EICS that includes a bundle of various strategies that allow to favor communication and contact between family members, patients and health team.~That considers the delivery of: (1) Receive timely and understandable information; (2) Receive visits, companionship, and spiritual assistance"
9826707|NCT02430311|Experimental|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
10172620|NCT03870581|Experimental|AI-SMART group|Participants' warfarin therapy were guided by an AI-based miniprogram embedded in the Wechat social software.
10172621|NCT03870581|Active Comparator|Human-SMART group|Participants' warfarin therapy were guided by an human-based miniprogram embedded in the Wechat social software.
10172622|NCT03870789||Retrospective|The Investigators will examine data from 1-year prior to paramedic implementation of the Hamilton Early Warning Score tool.
10172623|NCT03870789||Prospective|The Investigators will examine data from 1-year after paramedic implementation of the Hamilton Early Warning Score tool.
10172624|NCT03870711|Experimental|group A|10% lidocaine spray
10172625|NCT03870711|Placebo Comparator|group B|sterile water
10172626|NCT03870646|Experimental|Hypertonic saline|Nebulized hypertonic saline of NaCl (7%) in combination with hyaluronic acid
10172627|NCT03870646|Placebo Comparator|Isotonic saline|Nebulized isotonic saline of NaCl (0,9%)
9525220|NCT03239964|Active Comparator|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
9525221|NCT03240094|Experimental|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
9525222|NCT03240094|No Intervention|Usual care|Participants in the control group receive usual care.
9525223|NCT03239756|Experimental|60 mg single dose cohort|patients would receive a 60 mg single dose of TK006.
9525224|NCT03239756|Experimental|120 mg single dose cohort|patients would receive a 120 mg single dose of TK006.
9525225|NCT03239756|Experimental|180 mg single dose cohort|patients would receive a 180 mg single dose of TK006.
9525226|NCT03239756|Experimental|120 mg Q4W cohort|patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.
9525227|NCT03239678|Active Comparator|group A|100% Oxygen
9525228|NCT03239678|Experimental|group B|30% Oxygen.
9826708|NCT02430311|Experimental|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
9826709|NCT02430337|Experimental|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
9525229|NCT03239678|Experimental|group C|21% Oxygen
9525230|NCT03239678|Experimental|group D|40% Oxygen
9525231|NCT03239678|Experimental|group E|60% Oxygen
9525232|NCT03239678|Experimental|group F|80% Oxygen
9525233|NCT03239938|Experimental|Modern pain neuroscience approach|Modern pain neuroscience approach
10172628|NCT03870516|Placebo Comparator|Valve replacement according to guideline parameters|One group will be referred for surgery according according to indications for mitral valve replacement in European guidelines for valvular heart diseases published in 2017 and will have speckle tracking echocardiography before surgery and 6 months later for comparison.
9525234|NCT03239938|Active Comparator|Usual care evidence-based physiotherapy|Usual care physiotherapy
10172629|NCT03870516|Active Comparator|Early valve replacement|The other group will include patients with severe asymptomatic mitral regurgitation who have left atrial or left ventricular dysfunction according to speckle tracking echocardiography and will be referred to surgery, then speckle tracking echo will be performed 6 months later.
10172630|NCT03870503|Active Comparator|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
10172631|NCT03870503|Active Comparator|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mc sublingual misoprostol
9525235|NCT03239886|Experimental|Discontinuation|All subjects will discontinue imatinib
9525236|NCT03239834||OncAlert RAPID test in oral cavity biopsy patients.|Patients at an intermediate and high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oral Cavity.
9826710|NCT02430337|Active Comparator|SafeCare-as-usual|SafeCare as it is usually delivered
10172632|NCT03870503|Active Comparator|Carbetocin|The patient will be received Carbetocin 100 mic gm IV
10172633|NCT03870490|Experimental|Healthy Subjects|VNRX-5133 + cefepime
10172634|NCT03870464||Prospective arm|Quality of Life questionnaires EORTC-QoL30 and Euro EQ-5D-5L questionnaires are distributed. Blood samples are collected consecutively during ICI and at a follow-up period of one year. CT-scans extended of thorax, abdomen and the lower extremities are performed at baseline and at 6 months. MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.Prospective registration of irAEs are registered during ICI and for one year of follow-up.Enrolment period 1th of April 2018- 31th of January 2020.
9525237|NCT03239834||OncAlert RAPID test in oropharyngeal biopsy patients.|Patients at an intermediate to high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oropharnyx
9525238|NCT03239834||OncAlert RAPID test in clinical decision to biopsy.|Patients at a lower level of clinical risk for HNSCC and not scheduled for an immediate biopsy. Patients will be offered medical management and have an initial RAPID test. All patients will return within 1-3 months for follow-up test and a possible biopsy if clinically indicated.
9525239|NCT03239626|Experimental|POHIM-RT|adjuvant hypofractionated IMRT for cervical cancer patients
9525240|NCT03239717|Placebo Comparator|Whey protein powder|Participants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
9525241|NCT03239717|Experimental|Experimental|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
9525242|NCT03239652|Experimental|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
9525243|NCT03239925|Experimental|Experimental group|all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
9525244|NCT03239925|Placebo Comparator|Control group|these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode
10172635|NCT03870347||Biliary Dilation Cohort|Patients referred for endoscopic evaluation of biliary dilation
9525245|NCT03239600|Experimental|Part I & II: GSK2618960 2 milligram per kilogram (mg/kg)|GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)
9525246|NCT03239600|Placebo Comparator|Part II: Placebo|Placebo will be administered IV with MTX
9525247|NCT03239561|Experimental|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
9525248|NCT03239769|Active Comparator|conventional access group (CA)|A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized. Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided. Finally, CLND was performed. The strap muscles were re-approximated with No.1 silk suture. The full-thickness skin was closed with interrupted monofilament.
10172636|NCT03870477|Other|THP Hip Fracture Plating System|THP Hip Fracture Plating System in Intracapsular and Intertrochanteric Femur Fractures
10172637|NCT03870685|Active Comparator|TAP block with Exparel|Patients will receive immediate postoperative bilateral 2-quadrant TAP block with Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by the anesthesia team.
10172638|NCT03870685|Active Comparator|Surgical Site Infiltration of Exparel|Patients will receive surgical site infiltration of Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by surgeon.
9525249|NCT03239769|Experimental|aesthetic principles access group (APA)|The key difference focused on the disposal incision using aesthetic principles, which are depicted below. The incision was protected by Vaseline ointment. Excessive skin traction was avoided to prevent the injury on the skin edge. Bleeding was stanched with a low-power bipolar coagulation device. The surgical field does not have to be pulled in every direction to show the full operation field. The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures. Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues. The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
9525250|NCT03239769|Experimental|minimally invasive access group (MIA)|With the MIA approach, a shorter incision of between 3 and 4 cm was created. The procedure used the Harmonic scalpel as an auxiliary device. First, the isthmus was divided. Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization. The RLN and parathyroid glands were carefully dissected. Third, the superior pole of the thyroid gland was disconnected. Finally, CLND was performed. The closure procedure for the incision was similar to that for APA.
9525251|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
10172639|NCT03870269|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
9525252|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
9525253|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
9525254|NCT03239327|Experimental|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
9525255|NCT03239327|No Intervention|control group|For the control group mothers enrolled will receive nothing.
9525256|NCT03239418|Experimental|EyeStim Group|Receive an active NMES treatment to the targeted muscles controlling eyelid function.
9525257|NCT03239418|Sham Comparator|Control Group|Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.
9525258|NCT03239301|Active Comparator|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
9525259|NCT03239301|Active Comparator|Robotic Rehabilitation + Conventional Rehab|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. A
9525260|NCT03239314|Active Comparator|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
9525261|NCT03239314|Active Comparator|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
9525262|NCT03239639|Experimental|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
9525263|NCT03239639|Sham Comparator|Wait list control|The intervention is not provided.
9525264|NCT03239353|Active Comparator|1.5 mg ETV XR tablet|
9525265|NCT03239353|Active Comparator|3 mg ETV XR tablet|
9525266|NCT03239353|Active Comparator|6 mg ETV XR tablet|
9525267|NCT03239353|Placebo Comparator|Placebo-to-match 1.5 mg ETV XR tablet|
9525268|NCT03239353|Other|0.5 mg ETV IR tablet|
9525269|NCT03239119|Experimental|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
9525270|NCT03239119|Experimental|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
10172640|NCT03870269|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
10172641|NCT03870256|Active Comparator|TA plus misoprostol|Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm
10172642|NCT03870256|Active Comparator|Carbetocin|Patient receives 100 mic gm carbetocin IV
9525271|NCT03239119|Placebo Comparator|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
9525272|NCT03239119|Placebo Comparator|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
9528028|NCT03215173|Active Comparator|Text4Baby Control Group|Receive text messages from the free Text4Baby program.
9528253|NCT03212586|Placebo Comparator|Dose escalation Placebo|Dose 1 to 9 of matching placebo
10172643|NCT03870308|Experimental|Deep Brain Stimulation subjects|
9525273|NCT03239275|Experimental|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017*0.025 stainless steel archwire.~Right and left bracket head mini-screw (1.6*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
9525274|NCT03239275|Active Comparator|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
9525275|NCT03239379|Placebo Comparator|Placebo|Normal saline
9525276|NCT03239379|Experimental|BNZ132-1-40|PEGylated BNZ-1 for Injection
9525277|NCT03239132|Experimental|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks, as well as meditation educational materials.
10172644|NCT03870321|Experimental|Core training|The subjects who are in the experimental group will carry out the Core training routine
10172645|NCT03870321|No Intervention|Control|The subjects who are in the control group will not receive intervention and will continue with their daily routine and training
9525278|NCT03239132|Active Comparator|Control|The control will receive meditation educational materials.
9525279|NCT03239236|Experimental|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
9525280|NCT03239236|Experimental|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
9525281|NCT03239236|Experimental|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
9525282|NCT03239236|Experimental|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
9525283|NCT03239457||Heberprot P treatment|Patients with diabetic foot ulcers treated with Heberprot P
9525284|NCT03239210|Active Comparator|Ondansetron (OND)|24 mg/day for 4 weeks
9525285|NCT03239210|Placebo Comparator|Placebo (PL)|Placebo pill
9525286|NCT03239444|Other|Assigned Intervention|Device: Foresight ICE System The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird console. The Foresight ICE system will be used in guiding the physician during the trans-septal puncture and provide physiological information during the course of the procedure.
9975305|NCT03835182|Active Comparator|Short wave diathermy group|The short wave diathermy group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The short wave diathermy group will be treated with a hotpack (20minutes), transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and short wave diathermy at a frequency of 27.12MHz (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
9975306|NCT03835182|Other|Control group|The control group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The control group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
10172646|NCT03870412|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle.
9525287|NCT03239262|Experimental|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
9525288|NCT03239262|Experimental|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
9525289|NCT03239366|Active Comparator|Active arm|Active product 'BioK+ 100% probiotic: Bio-K+50B® probiotic will be administered orally for a period of 12 weeks. Dose: two (2) capsules of 50 billion (B) colony forming units (CFU) providing a dosage of 100 billion CFU per day
9525290|NCT03239366|Placebo Comparator|Placebo arm|Placebo product (without the 3 strains of bacterias) will be administered orally for a period of 12 weeks. Dose: Two (2) capsules of Placebo per day
9525291|NCT03239288|Placebo Comparator|Control digestible carbohydrate|Control baked breakfast bar
9525292|NCT03239288|Experimental|Test resistant starch type 4|Test baked breakfast bar
9975307|NCT03826030|Sham Comparator|Sham tDCS + mCIMT|Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
9975308|NCT03826030|Active Comparator|2 mA tDCS + mCIMT|2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
9525293|NCT03239249|Experimental|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
9525294|NCT03239249|Active Comparator|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
9525295|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
9525296|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
9525297|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
9525298|NCT03239392|Experimental|BNZ-1|IV PEGylated BNZ132-1-40
9525299|NCT03239158|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9525300|NCT03239158|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525301|NCT03239158|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525302|NCT03239158|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9525303|NCT03239171|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9975309|NCT03826030|Active Comparator|4 mA + mCIMT|4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
9975310|NCT03809013|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
9525304|NCT03239171|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525305|NCT03239171|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525306|NCT03239171|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9975311|NCT03807765|Experimental|Nivolumab followed by stereotactic radiosurgery (SRS)|480 mg Nivolumab will be given intravenously every 4 weeks, followed by SRS the week after the initial dose of Nivolumab.
9975312|NCT03795428|Experimental|Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose|Pemziviptadil (PB1046) Injection: Regardless of dose assignment, all subjects will be up-titrated in 0.2 mg/kg weekly increments, beginning with 0.4 mg/kg at Week 1, to the target dose of 1.2 mg/kg or higher depending on safety and tolerability.
9975313|NCT03785249|Experimental|Phase 1 Dose Exploration|Dose escalation of MRTX849 to determine maximum tolerated dose
10172647|NCT03870165|Active Comparator|Salmon|After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
9525307|NCT03239223|Experimental|Dose 1 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
9525308|NCT03239223|Experimental|Dose 2 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
9662270|NCT04928157|Experimental|CPAP|Use of CPAP, a device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
9662271|NCT04928157|No Intervention|Control|No CPAP use, otherwise usual care
9662272|NCT04922593|Experimental|LY03010 treatment group|"LY03010 (paliperidone palmitate) is a pharmaceutical equivalent drug product to the listed drug (LD) product INVEGA SUSTENNA. The chemical name is (±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3yl)piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4oxo-4Hpyrido[1,2-a]pyrimidin-9-yl hexadecanoate. Its molecular formula is C39H57FN4O4 and its molecular weight is 664.89 g/mol.~LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection. In LY03010 treatment group, all subjects will receive the first dose of 351 mg IM injection on Day 1 in the deltoid muscle, followed by five (5) monthly dosing of 156 mg IM injection in the gluteal muscle with the last dose on Day 141."
9525309|NCT03239184|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9525310|NCT03239184|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525311|NCT03239184|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
9525312|NCT03239184|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9525313|NCT03239535|Experimental|Mesenchymal stem cells|Mesenchymal stem cells, Intramuscular injection
9525314|NCT03239535|Placebo Comparator|Normal saline|Normal saline, Intramuscular injection
9525315|NCT03239431||Asthma group|Patients with asthma
9525316|NCT03239080|Active Comparator|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
9525317|NCT03239080|Placebo Comparator|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
9525318|NCT03238937|Other|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
9525319|NCT03238937|No Intervention|no intervention|Patients without phrenic nerve stimulation
9525320|NCT03238898|Active Comparator|botulinum toxin type A|Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
9525321|NCT03238898|Placebo Comparator|Normal saline|The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
9525322|NCT03238872|Experimental|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
9525323|NCT03238872|Active Comparator|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
9525324|NCT03238833|Experimental|luteal ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.
9525325|NCT03238833|Active Comparator|follicular ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.
9525326|NCT03238859|Experimental|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
9525327|NCT03238859|Sham Comparator|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
9525328|NCT03238846|No Intervention|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
9525329|NCT03238846|Experimental|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
9826711|NCT02430389|Experimental|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
9826712|NCT02430389|Placebo Comparator|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
9975314|NCT03785249|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
9975315|NCT03785249|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849
9525330|NCT03238846|Experimental|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
9525331|NCT03238820|Experimental|The robot group|Patients undergo robotic gastric gastrointestinal stromal tumors resection.
9525332|NCT03238807|Experimental|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
9525333|NCT03238807|No Intervention|Control Group|Control Group
9525334|NCT03238768|Experimental|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
9525335|NCT03238768|Active Comparator|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
9525336|NCT03239405||SCS|Treated via suction callibrated system
9826713|NCT02430480|Experimental|1/Arm 1- Enzalutamide and Goserelin|Patients will have an multi-parametric magnetic resonance imaging (mpMRI) guided biopsy, then receive enzalutamide and goserelin subcutaneous (SC) treatment for 6 months followed by a second mpMRI examination.
9525337|NCT03239405||Bougie|Treated with multiple tubes & bougie
9525338|NCT03238950|Other|Porcine Group|Training conducted on Porcine model
9525339|NCT03238950|Other|Synthetic|Training conducted on synthetic model
9525340|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
10172648|NCT03870165|Experimental|Isolated mixture|After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
10172649|NCT03870425|Placebo Comparator|MINCED-SKEWED|Minced meat administered with a skewed protein distribution pattern
10172650|NCT03870425|Experimental|MINCED-EVEN|Minced meat administered with an even protein distribution pattern
9525341|NCT03239054|Experimental|Study Group|Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.
9525342|NCT03239054|Other|Control Group|"The control group will be provided with the ACOG Pamphlet entitled Exercise during pregnancy and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled."
9525343|NCT03239041|Active Comparator|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.~The social navigation team will function as follows:~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
9525344|NCT03239041|No Intervention|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
9525345|NCT03239028||Danish National Birth Cohort|
9525346|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
9525347|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
9672447|NCT05035550|Experimental|Non-Deceptive Placebo|The NDP group was informed that the purpose of the study was to test a mind-body intervention that might help participants deal with the stress and anxiety that they are feeling during the pandemic. The intervention included two videos that introduced the effects of non-deceptive placebos, followed by a presentation on up-to-date non-deceptive placebo research. The participants then received instruction on how they would take their non-deceptive placebos for the next two weeks. Participants were asked to complete daily pill-taking adherence surveys (~5 min) and weekly at midpoint (1-week) and endpoint (2-week).
9672448|NCT05035550|No Intervention|No-Treatment Control|The Control group did not receive an intervention. Instead, participants were informed that the purpose of the study was to track individual psychological and physical health over longer time periods in the context of the pandemic. Participants were asked to complete weekly questionnaires at midpoint (1-week) and endpoint (2-week).
9672449|NCT05035758|No Intervention|Control Goups|The control group (A) receives standard exercise therapy that is part of the rehabilitation at the center and no additional intervention
9672450|NCT05035758|Experimental|Transcendental Meditation|The intervention group (B) receives transcendental meditation sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
9672451|NCT05035758|Experimental|Yoga|The intervention group (C) receives yoga sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
9672452|NCT05035485|Active Comparator|Phenylephrine group|Rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred
9672453|NCT05035485|Experimental|Norepinephrine group|Rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred
10172651|NCT03870399|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
10172652|NCT03870373||Test Subject|neonatal patients undergoing complex cardiac surgical procedures
10172653|NCT03870295|Experimental|Patients suffering from polyneuropathies|Type C fibre conduction velocity determination in patients suffering from polyneuropathy
10172654|NCT03870295|Active Comparator|Control patients|Type C fibre conduction velocity determination in control patients
10172655|NCT03870282|Experimental|9h 15m Goal|
10172656|NCT03870282|Experimental|"9h 15m Goal | Texts B"|
10172657|NCT03870282|Experimental|"9h 15m Goal | Texts A"|
10172658|NCT03870282|Experimental|"9h 15m Goal | Texts A&B"|
10172659|NCT03870282|Experimental|"9h 15m Goal | Incentive B"|
10172660|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts B"|
10172661|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A"|
10172662|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A&B"|
10172663|NCT03870282|Experimental|"9h 15m Goal | Incentive A"|
10172664|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts B"|
10172665|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A"|
10172666|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A&B"|
10172667|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B"|
9525348|NCT03238742|Experimental|Intervention Group|100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
9525349|NCT03238742|Placebo Comparator|Placebo group|normal saline 200 mL every 12 hours for 5 days
9525350|NCT03238729|Experimental|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
10172668|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts B"|
10172669|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts A"|
10172670|NCT03870282|Experimental|"9h 15m Goal | Incentives A&B | Texts A&B"|
9525351|NCT03238729|Active Comparator|Standard of Care|Patients will be provided standard literature on heart failure management.
9525352|NCT03238716|Experimental|Electric DN, NM Re-ed, Exercise|
9525353|NCT03238716|Active Comparator|NM Re-ed and Exercise|
9525354|NCT03238703|Experimental|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
9525355|NCT03238690|Experimental|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
9525356|NCT03238521|Active Comparator|classical pedicle finder|Spinal osteosynthesis with classical pedicle finder
9525357|NCT03238521|Experimental|pedicle finder with impedancemetry|Spinal osteosynthesis with pedicle finder with impedancemetry
9525358|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
9525359|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
9525360|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
9525361|NCT03238365|Active Comparator|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
9525362|NCT03238365|Experimental|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
9525363|NCT03238573||optical enhancment endoscopy|
9525364|NCT03238599|Experimental|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
9525365|NCT03238404|Experimental|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
9525366|NCT03238404|Active Comparator|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
9525367|NCT03238625|Active Comparator|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
9525368|NCT03238625|Placebo Comparator|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives two injections:~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
9525369|NCT03238664|Experimental|Arm A (laparoscopic HIFU, RARC)|Patients undergo pre-HIFU CEUS, standard of care biopsy of the bladder tumor, laparoscopic HIFU, and post-HIFU CEUS. Patients then undergo standard of care RARC.
9525370|NCT03238664|Active Comparator|Arm B (RARC)|Patients undergo standard of care RARC.
9525371|NCT03238456|Experimental|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
9525372|NCT03238456|No Intervention|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
9525373|NCT03238508||Immediate stenting group|Conventional stenting immediate after the re-opening of infarct-related artery during primary PCI
9525374|NCT03238508||Deferred stenting group|Elective stenting following cooling down of infarct- related artery for several days after restoration of epicardial coronary blood flow during primary PCI
9525375|NCT03238378|Experimental|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
10172671|NCT03870282|Experimental|Personal Goal|
10172672|NCT03870282|Experimental|"Personal Goal | Texts B"|
10172673|NCT03870282|Experimental|"Personal Goal | Texts A"|
10172674|NCT03870282|Experimental|"Personal Goal | Texts A&B"|
10172675|NCT03870282|Experimental|"Personal Goal | Incentive B"|
10172676|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts B"|
10172677|NCT03870282|Experimental|"Personal Goal | Incentive B | Text A"|
10172678|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts A&B"|
10172679|NCT03870282|Experimental|"Personal Goal | Incentive A"|
10172680|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts B"|
10172681|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A"|
9525376|NCT03238430|Experimental|Ropivacaine infiltration|Continuous infiltration of local anesthetics + PCA morphine.
9525377|NCT03238430|Experimental|intrathecal morphine|Rachianalgesia + PCA morphine
10172682|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A&B"|
9525378|NCT03238430|Active Comparator|morphine PCA|PCA morphine alone
9525379|NCT03238482|Active Comparator|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
9525380|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
9525381|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
9525382|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
9525383|NCT03238391|Experimental|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
9525384|NCT03238391|Sham Comparator|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
9525385|NCT03238586|Experimental|WELL Program|Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.
9525386|NCT03238586|No Intervention|Standard of Care|Five-week standard of care program.
9525387|NCT03238469|Experimental|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
9525388|NCT03238469|No Intervention|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
9525389|NCT03238612|Experimental|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
9525390|NCT03238612|Placebo Comparator|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
9672454|NCT05035472|Active Comparator|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
9672455|NCT05035472|Experimental|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
9826714|NCT02430818|Experimental|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
10172683|NCT03870282|Experimental|"Personal Goal | Incentive A&B"|
10172684|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts B"|
10172685|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts A"|
10172686|NCT03870282|Experimental|"Personal Goal | Incentives A&B | Texts A&B"|
10172687|NCT03870191|Active Comparator|Twin Block Group|This group will receive twin block injections.
10172688|NCT03870191|Active Comparator|Trigger Point Injection Group|This group will receive trigger point injections.
10172689|NCT03870087||Robotic PCI|All subjects treated with CorPath GRX during the PCI procedure.
10172690|NCT03870113|Experimental|Vaccinated group|Patients will be vaccinated with autologous mature dendritic cells-loaded with HPV 16/18 E6/E7, DC vaccine will be injected into the adjacent lymph-node 6 times, once a week.
10172691|NCT03870126|Placebo Comparator|Flavored Beverage Mix 1|Flavored still beverage
10172692|NCT03870126|Experimental|Flavored Beverage Mix 2|Flavored still beverage with polyphenols, concentration 1
10172693|NCT03870126|Experimental|Flavored Beverage Mix 3|Flavored still beverage with polyphenols, concentration 2
10172694|NCT03870126|Experimental|Flavored Beverage Mix 4|Flavored still beverage with caffeine
10172695|NCT03870217||Cochlear implant users with Nucleus and AB devices|Speech recognition will be evaluated after poor electrodes are turned off.
10172696|NCT03870100|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
10172697|NCT03870100|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
10172698|NCT03870100|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
10172699|NCT03870100|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
10172700|NCT03870100|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
10172701|NCT03870139|Active Comparator|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the dominant lower limb) and supraorbital cathode (ipsilateral to the dominant lower limb)."
10172702|NCT03870139|Experimental|Combined stimulation 1|"Active peripheral electrical stimulation (PES_sensorial) combined with active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
10172703|NCT03870139|Active Comparator|Peripheral stimulation|"Active peripheral electrical stimulation (PES_motor).~PES: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
9525391|NCT03238274||Arm 1|Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
10172704|NCT03870139|Experimental|Combined stimulation 2|"Active sensorial peripheral electrical stimulation (PES_sensorial) combined with active motor peripheral electrical stimulation (PES_motor)~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level~PES_motor: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
9525392|NCT03238274||Arm 2|Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
9525393|NCT03238274||Arm 3|Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
9525394|NCT03238287|Active Comparator|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
9525395|NCT03238287|Active Comparator|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
10172705|NCT03869957|Experimental|Intervention group|We will use ~0.8-0.9 g/kg/day of Clinoleic® (80% olive oil/20 soybean oil) + 0.2-0.1 g/kg/day [Omegaven® ](100% fish oil), to cover the proposed amount of n-3 PUFAs for 7 days. The infusion rate should not exceed 0.5 ml Omegaven® / kg body weight / hour = 0.05 g fish oil / kg body weight / hour. The intervention group will return to PN without n-3 PUFA after 7 days.
10172706|NCT03869957|No Intervention|Control group|Will be administering ~1.0 g/kg/d the lipid emulsion Clinoleic® (80% olive oil/20 soybean oil) without n-3 PUFAs.
9525396|NCT03238261|Experimental|Chemotherapy and concomitant radiotherapy|
9525397|NCT03238261|Active Comparator|Radiotherapy|
9525398|NCT03238638|Experimental|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.~Cohort 1: Acquired Resistance Cohort~Treat upon emergence of acquire resistance~Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease~Progressive disease on recent scans~Intercurrent therapy is allowed~Cohort 2: Suboptimal Benefit Cohort~Treat subop. mal response/benefit, BEFORE emergence of acquired resistance~Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)~Ongoing stable disease on recent scans~Both cohorts will receive pembrolizumab and epacadostat."
9525399|NCT03238313|Experimental|Plan A|Plan A is the treatment condition. It is a 23-minute video that is designed to promote effective contraceptive use, use of dual methods of protection (condom use and prescription birth control use), and HIV/STI testing in African/American and Latina young women.
9525400|NCT03238313|Active Comparator|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a 17-minute video, but contains no information about reproductive health. Instead, the video teaches about the harms of cigarettes.
9525401|NCT03238248|Experimental|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
9525402|NCT03237949|Active Comparator|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
9525403|NCT03237949|Experimental|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
9525404|NCT03238131|Active Comparator|IVM annually (standard treatment)|The comparator (standard treatment) IVM 200 µg/kg body weight given at 0, 12 and 24 months plus vitamin pills at 6 and 18 months.
9525405|NCT03238131|Experimental|IVM plus ALB twice annually|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, 24 months
10172707|NCT03869879|Active Comparator|Feedback-assisted physical therapy|During a visual feedback session, therapists will spend 30min per session using the Mobility Rehab system for gait training with patients. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
10172708|NCT03869879|Placebo Comparator|Traditional physical therapy|During a regular session, patients with gait impairment will work on gait with the following tasks for 30min: weights on ankles, dual tasks, UE support, partial body weight support, speed challenges, obstacles, and head turning. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
10172709|NCT03870009|Experimental|ARDS patients|All the patients will be evaluated with the same procedure, as the study relates to evaluation of the diagnostic performance of a semi-automated method to detect cyclic hyperinflation on CT scan
10172710|NCT03870178|Active Comparator|Active tDCS|Anodal tDCS over trunk motor cortex representation. Intensity: 2mA Time: 20 minutes
10172711|NCT03870178|Sham Comparator|Sham tDCS|Anodal tDCS over trunk motor cortex representation. Itensity: 2mA Time: 20 minutes (30s ON)
9525406|NCT03238131|Active Comparator|IVM plus ALB once annually|IVM 200 µg/kg plus ALB 800 mg given at 0, 12, 24 months plus vitamin pills at 6 and 18 months.
9525407|NCT03238131|Active Comparator|IVM twice annually|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months
9525408|NCT03238066|Experimental|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.~If HDR BT is chosen:~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT~If PDR BT is chosen:~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
9525409|NCT03238079|Experimental|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
9525410|NCT03237962|Experimental|High Flow Nasal Cannula|Patients are randomly assigned into High flow nasal cannula group for the exercise training
9525411|NCT03237962|Experimental|Nasal Cannula|Patients are randomly assigned into nasal cannula group for the exercise training.
9525412|NCT03238092|Active Comparator|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
9525413|NCT03238092|No Intervention|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
9525414|NCT03238092|Experimental|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
9525415|NCT03238118|Experimental|Attention bias modification training|For attention-toward-positive, stimuli are colour-pictures of 16 angry and 16 happy faces (half female). Each happy face is presented 10 times, and each angry face presented 80 times across trials, balanced across the different positions in the 3 × 3 matrix. This yielded 160 training trials (two blocks of 80 trials). Children had to mouse-click on the happy face within the 3 × 3 matrix of angry faces as quickly and as accurately as possible. The matrix disappeared after the child mouse-clicked on the correct face and the next trial began.
9525416|NCT03238118|Placebo Comparator|Attention Control Training|For attention-training-control, stimuli are 20 colour-pictures of individual birds and flowers used in prior visual-search tasks with children. Children mouse-clicked on the bird presented amongst flowers as quickly and accurately as possible. Other task parameters were similar to the attention-toward-positive task (160 training trials). No performance feedback is given in either condition.
9525417|NCT03238118|Placebo Comparator|Psychoeducation|Psychoeducation is an intervention that is characterized by informing the participant of their irritability symptoms. The goal is to teach participants how to understand their symptoms, explain their treatment modalities, recognize signs that may lead to a possible crisis, and provide tips and strategies on how to deal with irritability.
9525418|NCT03238144|Other|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
9525419|NCT03238157|No Intervention|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
9525420|NCT03238157|Active Comparator|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
9525421|NCT03238105|Experimental|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
9525422|NCT03238105|Experimental|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
9525423|NCT03238222|Experimental|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) with a trained physiotherapist.
10172712|NCT03870022|Other|18-80 years of age|Single day study collecting 1 paired breath sample from each subject using two non-invasive breath sampling devices, as well as collecting participant responses to user documentation questions and rating scales.
10172713|NCT03869775||control group|no additional disease
9525424|NCT03238222|No Intervention|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
9525425|NCT03238209|Experimental|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
10172714|NCT03869775||working group-1|additional disease only DM and no cardıovascular autonomous neuropathıa
10172715|NCT03869775||working group-2|additional disease only DM and pozitif cardıovascular autonomous neuropathıa
10172716|NCT03869814||Non-cancer|900 asymptomatic individuals without prior history of cancer
10172717|NCT03869814||Cancer|900 individuals with confirmed malignancy
9525426|NCT03237936|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
9525427|NCT03238183|Active Comparator|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
9525428|NCT03238183|Placebo Comparator|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
9525429|NCT03237910|Experimental|AMSA-CPR|The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
9525430|NCT03237910|Active Comparator|Standard-CPR|The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines
9525431|NCT03237975|Experimental|Be the Expert for Your Own (BEYO)|BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
9525432|NCT03237975|Active Comparator|Routine health education|To neutralize the effect of extra attention from the facilitator, participants in control group will receive routine health education on topics related to type 2 diabetes. Contents for the routine education will be based on the national guideline of basic public health service for diabetes and specific implementation protocols in each community. Participants in control group will receive 5-weekly education packet at the same time with participants in intervention group. The patients will not be given any strengths-based information, but they are free to discuss their disease status with nurses or physicians at their regular follow-up appointments.
9525433|NCT03238014|Experimental|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
9525434|NCT03238014|Active Comparator|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
9525435|NCT03237988|Active Comparator|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
9525436|NCT03237988|Active Comparator|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
9525437|NCT03237988|Active Comparator|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
9525438|NCT03238027|Experimental|Ph1a D1: 1 mg/kg SNDX-6352|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
10172718|NCT03869996|Active Comparator|fast track total knee arthroplasties|patients treated using fast track care protocol
10172719|NCT03869996|Active Comparator|standard care total knee arthroplasties|patients treated using standard care protocol
9525439|NCT03238027|Experimental|Ph1a D2: 3 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
9525440|NCT03238027|Experimental|Ph1a D3: 6 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
9525441|NCT03238027|Experimental|Ph1a D4: 10 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 10 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
9525442|NCT03238027|Experimental|Ph1b D1: 1 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg SNDX-6352 dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.
9826715|NCT02430818|Experimental|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
10172720|NCT03870061|No Intervention|Control|
10172721|NCT03870061|Experimental|Treatment|This arm receives the full New Incentives' conditional cash transfer program (All Babies Are Equal Initiative).
9525443|NCT03238027|Experimental|Ph1b D2: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
9528029|NCT03214770|Experimental|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
9672456|NCT05035524|Active Comparator|Sodium Bicarbonate|Adjuvant SB treatment Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group
9672457|NCT05035524|Placebo Comparator|Placebo|Placebo
9672458|NCT05035238|Active Comparator|Arm 1|3 μg / 0.5 mL
9672459|NCT05035238|Active Comparator|Arm 2|4,5 μg / 0.5 mL
9672460|NCT05035251||experimental|patients with a condition
9672461|NCT05035251||control|patients without condition
9672462|NCT05034900|Active Comparator|Chest Physiotherapy Group|Patients in this group will perform comprehensive chest physiotherapy program two times a day, 7 days a week for 8 weeks at their homes.
9672463|NCT05034900|Experimental|OPEP device + Chest Physiotherapy Group|In addition to the same physiotherapy program applied to the controls, patients in this group will also use OPEP device two times a day, 7 days a week for 8 weeks at their homes.
9672464|NCT05034965|Active Comparator|deep injection of hyaluronic acid fillers|Each female will receive filler injection deep to the muscle (supraperiosteal) on one side of the face.
9672465|NCT05034965|Active Comparator|superficial injection of hyaluronic acid fillers|Each female will receive filler injection at superficial level to the muscle (subcutaneous) on the contralateral side(same dose and same site).
9672466|NCT05035108|Experimental|extensive hepatectomy patient|hiHep bioartificial liver therapy
9694912|NCT04784286|Active Comparator|Telemedicine 30-day follow-up visit|"The Center for Connected Care will arrange for 30-day post-op telemedicine visits via a secured video application. When there is a telemedicine visit, the Center of Connected Care will connect the patient and then page the midlevel provider and dietitian after the electronic rooming process is complete & the patient is ready.~A survey about post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-op care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for care outside of the direct medical costs, along with an open question asking for comments & feedback about their overall experience with their follow-up appointment."
9694913|NCT04784286|Active Comparator|In-person 30-day follow-up visit|"Standard practice of having bariatric surgery patients follow up with the bariatric surgery midlevel providers as well as with dietitians within 30-days after their bariatric procedure. The bariatric surgery midlevel providers are staffed and supported by our bariatric surgeons in case if they have questions or concerns.~Participants will be contacted via telephone and will be surveyed about their post-operative care visits within 7-14 days after that visit. The survey will focus on the following aspects: baseline familiarity with technology, patients' satisfaction with the post-operative care they received, patients' preference of in-person vs telemedicine visits, patients' estimation of additional costs for their care outside of the direct medical costs, along with an open question that will ask patients to provide comments and feedback about their overall experience with their follow-up appointment."
9694914|NCT04784104|Experimental|Supraclaviculer block|The coronal oblique supraclavicular block will be applied to the first group with ultrasound guidance using a 22G 50 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.) Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
9694915|NCT04784104|Experimental|Infraclaviculer block|The lateral sagittal infraclavicular block will be applied to the second group with ultrasound guidance using a 22G 100 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.). Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
9694916|NCT04784000|Experimental|AT-527 550 mg + carbamezepine|
9694917|NCT04784000|Experimental|AT-527 1100 mg + carbamezepine|
9694918|NCT04783688|Experimental|Experimental Group|All subjects will snorkel using the same FFSMs.
9694919|NCT04783870|Experimental|Dapagliflozin|Dapagliflozin 10 mg PO QD
9694920|NCT04783870|Placebo Comparator|Control|Placebo PO QD
9694921|NCT04783974||Patients assuming SSRI|Patients treated with dental implants and assuming selective serotonin reuptake inhibitors
9694922|NCT04783974||Patients assuming PPI|Patients treated with dental implants and assuming proton pump blockers
9694923|NCT04783974||Patients assuming Anti-inflammatory drugs|Patients treated with dental implants and assuming anti-inflammatory drugs
9694924|NCT04783974||Patients assuming Anti-hypertensive drugs|Patients treated with dental implants and assuming anti-hypertensive drugs
9694925|NCT04783974||Control group - Patients not assuming the studied drugs|Patients treated with dental implants and not assuming any of the following drugs: selective serotonin reuptake inhibitors, proton pump blockers, anti-inflammatory drugs, anti-hypertensive drugs
9694926|NCT04783649||High risk group|Women in the age group between 25 and 65 years old without prior history of malignancy referred to colposcopy
9525444|NCT03238027|Experimental|Ph1b D3: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
9525445|NCT03237832|Placebo Comparator|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
9525446|NCT03237832|Placebo Comparator|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
9525447|NCT03237832|Placebo Comparator|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
9525448|NCT03237832|Placebo Comparator|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
9525449|NCT03237832|Placebo Comparator|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
9525450|NCT03237767|Experimental|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
9525451|NCT03237767|Experimental|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
9525452|NCT03237663|Experimental|One enteric capsule|
10172722|NCT03870048|Active Comparator|tDCS effects on pain and fatigue|tDCS Block: The participant will receive tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
10172723|NCT03870048|Placebo Comparator|Sham effects on pain and fatigue|Sham block: Identical to the tDCS block, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
10172724|NCT03869918|No Intervention|Usual Care|Participant is assigned to undergo standard of care.
10172725|NCT03869918|Experimental|Exercise Group|If the participant is assigned to the exercise group, she will either exercise at home or take a class at the participating facility under the supervision of an instructor.
9525453|NCT03237663|Experimental|Two enteric capsule|
9525454|NCT03237676|Experimental|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
9525455|NCT03237676|Active Comparator|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
9525456|NCT03237637|Active Comparator|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
9525457|NCT03237637|Experimental|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
9525458|NCT03237598||male|young (≥18 and ≤45), adult (45~60), and old (>60) , n=1960
9525459|NCT03237598||female|young (≥18 and ≤45), adult (45~60), and old (>60) , n=2348
10172726|NCT03869918|No Intervention|Observational Group|If a subject is eligible, but does not want to exercise, she will be in a third group that is an observation group.
9528030|NCT03214770|Active Comparator|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
9528031|NCT03214575|Active Comparator|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
9528032|NCT03214575|Experimental|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
9672467|NCT05035160||Group 1|Pregnant and postpartum birthing persons with perinatal pathology.
9672468|NCT05035160||Group 2|Healthy pregnant and postpartum birthing persons.
9672469|NCT05035160||Group 3|Healthy non-pregnant persons (healthy volunteers).
9672470|NCT05035056|Other|CT Coronary Angiogram with quantitative characterization of plaque|
9672471|NCT05035069|Experimental|Ciprofol|
10172727|NCT03869931|Experimental|Fenofibrate|(Refer to intervention)
10172728|NCT03869671|Experimental|PrEP uptake/adherence intervention|A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
9672472|NCT05035069|Active Comparator|Propofol|
10172729|NCT03869671|Active Comparator|Harm reduction standard of care|Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
9525460|NCT03237689|Experimental|Hydrocortisone|Low dose hydrocortisone (10mg orally)
9525461|NCT03237689|Placebo Comparator|Placebo|Placebo tablets, made of starch 1500 powder
9525462|NCT03237715||Breast fed cohort|
9525463|NCT03237715||Formula fed cohort|
10172730|NCT03869762|Experimental|Denosumab & Enzalutamide|"120mg subcutaneous injection on Day 1 of every four week cycle, for a maximum of 24 cycles, or until clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason.~160mg PO daily; (4 x 40 mg capsules) until confirmed clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason)"
9525464|NCT03237806|No Intervention|Baseline|In this phase, patients were sedated to the level of Ramsay 6 before Deep sedated or Light sedated
9525465|NCT03237806|Experimental|Deep sedation|In this Arm, patients were sedated to the level of Ramsay 5(Deep sedated) by Midazolam IV continuously
9525466|NCT03237806|Experimental|Light sedation|In this Arm, patients were sedated to the level of Ramsay 3(Light sedated)by Midazolam IV continuously
9525467|NCT03237741|Experimental|Treatment Sequence 1: ABC1D1|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
9525468|NCT03237741|Experimental|Treatment Sequence 2: ABC2D2|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
9525469|NCT03237741|Experimental|Treatment Sequence 3: BAC1D1|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
9525470|NCT03237741|Experimental|Treatment Sequence 4: BAC2D2|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
9975316|NCT03785249|Experimental|Pilot Phase 1b Combination with Pembrolizumab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
9975317|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
9525473|NCT03237585|Experimental|i) Intervention arm- Receive Gender Centre's RRS package|
9525474|NCT03237585|No Intervention|No intervention|
9525475|NCT03237520|Experimental|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
9525476|NCT03237520|Active Comparator|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
9525477|NCT03237728|Experimental|0.06mg/kg,KB and Placebo|Group A:0.06mg/kg,Q8h,Day1-Day7
9525478|NCT03237728|Experimental|0.12mg/kg,KB|Group B:0.12mg/kg,Q8h,Day1-Day7
9525479|NCT03237728|Experimental|0.24mg/kg,KB|Group C:0.24mg/kg,Q8h,Day1-Day7
9525480|NCT03237728|Experimental|Placebos|Group D:Placebos,Q8h,Day1-Day7
9672473|NCT05035147|Experimental|Low dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8 q3w
9672474|NCT05035147|Active Comparator|High dose strength: albumin-bound paclitaxel + gemcitabine|albumin-bound paclitaxel 125mg/m2+ gemcitabine1000mg/m2:day1,8,15 q4w
10172731|NCT03869827||IUGR|All birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea with isolated intrauterine growth restriction at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2016.
10172732|NCT03869827||Control|To each of these children with intrauterine growth restriction is matched a control child: the child without intrauterine growth restriction of the same gestational age whose date of birth is consecutive to that of the case.
10172733|NCT03869801|Active Comparator|ESP Block|
10172734|NCT03869801|Active Comparator|QLB block|
9525481|NCT03237754|Experimental|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
9525482|NCT03237754|Sham Comparator|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
9525483|NCT03237793|Active Comparator|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal**) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15)
9525484|NCT03237793|Placebo Comparator|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment. (n=15
9694927|NCT04783649||Population sample|A population sample of women in the age group between 25 and 65 years old from several primary healthcare facilities to primary cervical screening
10172735|NCT03869736|Experimental|Nitrous Oxide 50% or 25%|Nitrous oxide at an inhaled concentration of 50% or 25%
10172736|NCT03869736|Sham Comparator|Placebo|Oxygen-air mixture
10172737|NCT03869749|Experimental|Learning to BREATHE Plus|It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
10172738|NCT03869749|Active Comparator|Health and wellness|It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
10172739|NCT03869723||Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
10172740|NCT03869723||Virtual planning|Fibula free flap in mandibular reconstruction using preoperative virtual planning, cutting guides and osteosynthesis plates. Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
10172741|NCT03869983|Active Comparator|Active Comparator|Omnipaque™ (iohexol) Injection, 755 mg/mL iohexol (350 mgI/mL)
10172742|NCT03869983|Experimental|Experimental|CE-Iohexol Injection, 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL
10172743|NCT03869554|Experimental|Renal disease|detection of Fabry disease
10172744|NCT03869359|Experimental|Group A|Gluten-free diet with placebo powder vs Gluten-free diet with gluten powder
10172745|NCT03869359|Experimental|Group B|Gluten-free diet with gluten powder vs Gluten-free diet with placebo powder
10172746|NCT03869346||GG|wild-type homozygote (CYP3A4*1/*1, GG)
10172747|NCT03869346||GA|mutant heterozygote (CYP3A4*1/*1G, GA),
10172748|NCT03869346||AA|mutant homozygote (CYP3A4*1G/*1G, AA)
10172749|NCT03869411|Experimental|aerobic exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness. The aerobic exercise group will arranged to the supervised aerobic dance program, it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
10172750|NCT03869411|Experimental|home exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness.The home exercise group will give the exercise recommendation based on ACSM's guideline, and it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
10172751|NCT03869411|Active Comparator|health control group|This study will recruit subjects without type 2 diabetes and the age matched to the diabetes groups.
10172752|NCT03869463|Experimental|EF/PS CCT|This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function & processing speed.
10172753|NCT03869463|Active Comparator|Verbal CCT|This group will complete verbal-focused computerized cognitive training.
10172754|NCT03869463|Placebo Comparator|Waitlist Control|This group will not receive cognitive training during study participation.
10172755|NCT03869476|Experimental|BioscoreSMP cohort|
10172756|NCT03869593||Patients presenting E. coli and S. aureus bacteremia|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
10172757|NCT03869489|Experimental|Anodal left dorsolateral prefrontal cortex tDCS stimulation|
10172758|NCT03869489|Experimental|Anodal right dorsolateral prefrontal cortex tDCS stimulation|
10172759|NCT03869489|Sham Comparator|Sham tDCS stimulation|
10172760|NCT03869242|Experimental|Experimental treatment arm|RT with concomitant TMZ and NovoTTF-200A for 6 weeks followed by up to 24 months of maintenance TMZ in combination with NovoTTF-200A.
10172761|NCT03869242|Active Comparator|control arm|RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with NovoTTF-200A.
10172762|NCT03869619||All enrolled patients|All patient who signed the consent form for participation to the study
10172763|NCT03869528|Active Comparator|5 sprays|5 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
10172764|NCT03869528|Experimental|10 sprays|10 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
10172765|NCT03869424|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.
10172766|NCT03869424|No Intervention|No-treatment control group|Participants do not receive the nasal spray.
10172767|NCT03869294||LAPC or MPC patients with GS first-line chemotherapy|
10172768|NCT03869567|Experimental|Cone beam CT|A cone beam CT wll be performed just after thrombectomy on patients with acute ischemic stroke
10172769|NCT03869255||Hospitalized patients|Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
10172770|NCT03869255||Community patients|"People coming to donate blood in Etablissement Français du Sang will be included and a nasal swab will be performed"
10172771|NCT03869385|Experimental|Albumin group|Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
10172772|NCT03869385|No Intervention|Control group without albumin:|The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.
10172773|NCT03869281||PTA|patients who underwent their first deceased donor PTA, or second deceased donor PTA if their first graft was explanted within a week, at the IRCCS San Raffaele Hospital between 2 January 2005 and 31 December 2017
10172774|NCT03869281||Controls|outpatients with T1D attending the Endocrinology Unit at IRCCS San Raffaele Hospital and patients listed for a first deceased donor PTA
10172775|NCT03869307|Experimental|Shoulder strengthening exercises|Progressive heavy shoulder strengthening exercises three times weekly and advice on load and pain management. Exercise sessions are supervised twice a week corresponding to 32 supervised exercise sessions during the 16 weeks.
10172776|NCT03869307|Active Comparator|Shoulder stability exercises|Recommendations of shoulder stability exercises which are to be performed unsupervised (e.g. at home) three times weekly and advice on load and pain management. Three supervised sessions are offered during the 16 weeks, and exercises are primarily performed unsupervised at home.
10172777|NCT03869320|Experimental|ACT-1004-1239|ACT-1004-1239 will be given as a single oral dose under fasting conditions. Eight doses are planned with a starting dose of 1 mg. The ADME characteristics and absolute bioavailability using a 14C-radiolabeled microtracer will be evaluated as part of the SAD, after the first 3 cohorts have been performed.
10172778|NCT03869320|Placebo Comparator|Placebo|Matching placebo will be given as a single oral dose under fasted conditions. Matching placebo for the oral and intravenous administration of the 14C-radiolabeled ACT-1004-1239 will also be available.
10172779|NCT03869320|Experimental|Food-effect subpart: ACT-1004-1239|ACT-1004-1239 will be given under both fasted (first period) and fed (second period) conditions. The food effect will be evaluated after the first 3 cohorts have been performed.
10172780|NCT03869320|Placebo Comparator|Food-effect subpart: Placebo|Matching placebo will be given under both fasted (first period) and fed (second period) conditions.
10172781|NCT03869398|No Intervention|Control arm: No pre-op medications|patients undergoing total thyroidectomy are started on calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID immediately postoperatively. No pre-operative medications are given
10172782|NCT03869398|Experimental|Intervention arm: Tums and Calcitriol pre-op|patients start calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
10172783|NCT03869268|Active Comparator|No Drug|"Patients will be randomised to receive no drug for the first medication period (10 days).~Patient will then be allocated to receive ticagrelor 90mg twice daily for the second medication period (10 days)"
10172784|NCT03869268|Active Comparator|Ticagrelor 180 mg|"Participants will be randomised to receive loading dose of ticagrelor 180 mg on the last day of the first medication period (10-14 days).~Participants will then be allocated to receive no aspirin but a loading dose of ticagrelor 180 mg on the last day of treatment for the second medication period (10-14 days)."
10172785|NCT03869268|Active Comparator|Aspirin 20mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
10172786|NCT03869268|Active Comparator|Aspirin 20 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
10172787|NCT03869268|Active Comparator|Aspirin 75 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
10172788|NCT03869268|Active Comparator|Aspirin 75 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days)."
10172789|NCT03869268|Active Comparator|Aspirin 300 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 300 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
10172790|NCT03869268|Active Comparator|Aspirin 300 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10-14 days) plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 300 mg once daily for the second medicaion period (10-14 days)."
10172791|NCT03869203|Experimental|Enhanced recovery after surgery (ERAS) patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the ERAS perioperative care.
10172792|NCT03869203|No Intervention|Control patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the traditional perioperative care.
10172793|NCT03869229|Active Comparator|osteoarthritis of the knee|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
10172794|NCT03869229|Active Comparator|osteoarthritis of the hip|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
10172795|NCT03869229|Active Comparator|osteoarthritis of the glenohumeral joint|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
10172796|NCT03869047|Active Comparator|quadratus lumborum block(dexmedetomidine+bupivacaine)|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine ,total volume 20 ml.
10172797|NCT03869047|Active Comparator|quadratus lumborum block(bupivacaine)|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20%.
10172798|NCT03869164|Experimental|ValmpClamp Arm|
9525485|NCT03237442|Experimental|group 1|
9525486|NCT03237442|Active Comparator|group 2|
9525487|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
9525488|NCT03237429||cancer patients|The first study population will represent patients scheduled for surgery for a new diagnosed cancer pathology
9525489|NCT03237429||non-cancer patients|The second study population will represent patients scheduled for surgery not for cancer disease
10172799|NCT03869086|Experimental|SLOW anthocyanin metabolisers|Participants will be prospectively recruited to the SLOW anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
10172800|NCT03869086|Experimental|FAST anthocyanin metabolisers|Participants will be prospectively recruited to the FAST anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
9525490|NCT03237533|Active Comparator|Study Group|in this group patients will be treated with Dexamethasone local application
9525491|NCT03237533|Active Comparator|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
9525492|NCT03237572|Experimental|Arm A: 1st dose of pembrolizumab after HIFU|Pembrolizumab (200 mg) administered intravenously, days 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
10172801|NCT03869099||Sindh|
10172802|NCT03869099||KPK|
9525493|NCT03237572|Experimental|Arm B: 1st dose of pembrolizumab before HIFU|Pembrolizumab (200 mg) intravenously, days 1, 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
9525494|NCT03237325|Experimental|SGX942|Patients are randomized 1:1 active/placebo.
9525495|NCT03237325|Placebo Comparator|Placebo|Patients are randomized 1:1 active/placebo.
9672475|NCT05034913|Experimental|Photography to Measure Children's Height, Wrist Circumference, and Abdominal Circumference|Subjects will be given instructions on how to take two photographs at home and submit them securely. Subjects will also be given instructions on how to measure height, wrist circumference, and waist circumference and submit this data to the research team.
9672476|NCT05034783|Experimental|[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/ CT scan|Patients of Insulinoma PET/CT imaging: In two consecutive days each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4, respectively.
9672477|NCT05034926||Cohort 1|Participants with locally advanced or metastatic (stage IIIB-IV) non-small cell lung cancer (NSCLC)
10172803|NCT03869099||Punjab|
10172804|NCT03869099||Balochistan|
10187028|NCT03730350|Experimental|Hypnosis|Prior to surgery, a member of the pain psychology team will guide patients through a clinical hypnosis session aimed at preparing for surgery by reducing anxiety and introducing relaxation and self-soothing strategies that can be used after surgery for adaptive coping. They will also be provided with a recording of this hypnosis script to use at home, and it will be recommended that they listen to the recording on the two days prior to surgery. Following surgery, a clinician from the pain psychology team will visit the patient in hospital on post-operative day one or whenever they are able to be seen prior to hospital discharge, in order to guide them through a clinical hypnosis session targeted at increasing comfort and pain relief.
10187029|NCT03730350|No Intervention|Standard Care|This control group will receive standard care pre- and post-surgery. After the completion of their one-month trial, control participants will be offered access to the hypnosis recordings, as well as an in-person hypnosis session.
10187030|NCT03730311|Experimental|Elpida 120 mg once weekly|elsulfavirine 120mg or placebo orally once weekly for 4 weeks
10187031|NCT03730311|Experimental|Elpida 200 mg once weekly|elsulfavirine 200mg or placebo orally once weekly for 4 weeks
10187032|NCT03730311|Experimental|Elpida 280 mg once weekly|elsulfavirine 280mg or placebo orally once weekly for 4 weeks
10187033|NCT03730298|Experimental|American Ginseng|American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months
10187034|NCT03730298|Placebo Comparator|Placebo|Placebo: 1 cpr twice a day orally for 3 months
10187035|NCT03730285|Active Comparator|Telemedicine|Discharge with telemedicine contact to emergency nurse, doctor, and municipality
10187036|NCT03730285|No Intervention|Control|Standard care with 24-48 h observation at emergency unit
10187037|NCT03730233|Active Comparator|Tension-free|Hiatal hernia repair by tension-free mesh closure
10187038|NCT03730233|Active Comparator|Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
9525496|NCT03237312|Other|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
9525497|NCT03237312|Other|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
9525498|NCT03237611|Experimental|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards
9525499|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
9525500|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
9525501|NCT03237455|Experimental|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
9525502|NCT03237455|Active Comparator|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
9525503|NCT03237507||Chemotherapy Group|chemotherapy treatment（S-1 and Oxaliplatin） for patients until disease progress
9525504|NCT03237507||Chemotherapy plus HIPEC Group|Hyperthermic Intraperitoneal chemoperfusion（HIPEC）with Paclitaxel more than 2 cycles and plus chemotherapy
9525505|NCT03237416|Experimental|BAY1841788/Healthy subjects|Period 1: intake of Midazolam and Dabigatran etexilate at day 1 followed by Period 2: intake of Darolutamide at days 1-11 (twice daily), intake of dabigatran etexilate at days 3 and 9, intake of Midazolam at day 9
9525506|NCT03237247||Benign|cases with benign biliary stricture
9525507|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
9525508|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
9525509|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
9525510|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
9525511|NCT03237338|Experimental|Insomnia-ture acupuncture|"True acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
9525512|NCT03237338|Sham Comparator|Insomnia-sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
9525513|NCT03237468|Experimental|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
9975318|NCT03785249|Experimental|Pilot Phase 1b Combination with Afatinib|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
9525514|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
9525515|NCT03237104||acute spondylolysis|Athletes who meet the inclusion criteria and consent to participate in the pilot study will be referred directly to PT care for 2 times per week until cleared to return to sport.
9525516|NCT03237546|Active Comparator|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
9525517|NCT03237546|Active Comparator|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
9525518|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
9525519|NCT03237039|Other|X-ray examination, fall-risk and gait|simultaneous acquisition in upright position of two full-body radiographic images, one in the coronal plane and one in the sagittal plane. In addition, 40 out of 160 subjects will undergo fall-risk assessment and gait cycle analysis evaluation.
9525520|NCT03237052|Experimental|model|model aided decision
9525521|NCT03237052|Active Comparator|non-model|real-world psychiatrist decision
9525522|NCT03237078|Experimental|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
9525523|NCT03237624|Experimental|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
9525524|NCT03237624|Placebo Comparator|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
9525525|NCT03237117|Experimental|GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. Additionally, these patients are co-treated with growth hormone (GH).
9694928|NCT04783935|Experimental|Mavenclad®|
9694929|NCT04783831||Biodegradable stent|
9975319|NCT03785249|Experimental|Phase 2 Combination with Cetuximab|Phase 2 evaluation of the clinical activity of MRTX849 in combination with cetuximab in patients with CRC
9975320|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab in NSCLC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with NSCLC
9975321|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab in PDAC|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with pancreatic adenocarcinoma (PDAC)
9975322|NCT03774069|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
9975323|NCT03774069|Active Comparator|Control group- medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
9975324|NCT03772717|Experimental|VitalStim400|"The stimulation devices used in this study are VitalStim 400, electrical neuromuscular stimulators, which have been used in multiple previous clinical studies for modulation of pain and have received FDA approval. The (2) electrodes for the device will be placed on the subjects left cervical (neck) region. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.~Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters."
9975325|NCT03772184|Active Comparator|cervical inversion|
9975326|NCT03772184|No Intervention|no cervical inversion|
9975327|NCT03749057|Other|rivaroxaban|15-20 mg rivaroxaban daily
10187039|NCT03730194|Experimental|Melatonin Only|Participants in this arm will take 3 mg of melatonin 30 minutes before bedtime.
10172805|NCT03869008|Sham Comparator|Sham Device Group|"15 patients will be randomized to the Sham device for the first half of the treatment window then switch to the gammaCore Sapphire device (study device) for the rest of the study.~The Sham device will look exactly like the gammaCore Sapphire device but will not deliver non invasive vagus nerve stimulation."
10172806|NCT03869008|Experimental|gammaCore Sapphire (Study Device) Group|15 patients will be randomized to the gammaCore Sapphire device for the full length of the treatment window.
9672478|NCT05034887|Experimental|Trastuzumab Deruxtecan (T-DXd)|One cycle is 21 days, with T-DXd repeated 3 cycles before surgery as the neo adjuvant treatment.
9672479|NCT05035121|Experimental|milk supplement|The milk group provided 200 mL milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
10172807|NCT03868865|Experimental|Integrative mind-body-medicine group program|The 66 hour program encompasses mindfulness training, yoga, moderate exercise, nutrition, naturopathic self-help strategies, cognitive restructuring and acupuncture for the management of side effects caused by chemotherapy.
9525526|NCT03237117|Active Comparator|non-GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the GH group, only that no GH is added.
9525527|NCT03237117|No Intervention|positive control group|35 infertile women undergoing their first oocyte donation attempt are included as a positive control group. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the non-GH group, with no GH added.
9525528|NCT03237208|Active Comparator|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
9525529|NCT03237208|Sham Comparator|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
9525530|NCT03237494||Participants at risk for hATTR and participants diagnosed with hATTR|Participants 18 years of age or older
9525531|NCT03237260|Experimental|Vedolizumab 300mg|vedolizumab open label
9525532|NCT03237273|Experimental|Single|All patients will undergo ultrasound scan using the HEAD-US Scoring System by a non-imaging specialist
9525533|NCT03237351|Active Comparator|Conventional therapy group|Patients in Conventional therapy group were received fluid therapy: intraoperative transfusion volume=maintenance fluids+deficit replacement+restoration of losses and with heart rate, mean arterial pressure, urine measurement ect.
9525534|NCT03237351|Experimental|Low value of PPV group|Patients in low value of PPV group were received fluid therapy according to PPV (3% ≤PPV < 5%) .
9525535|NCT03237351|Experimental|High value of PPV group|Patients in high value of PPV group were received fluid therapy according to PPV (5% ≤PPV < 8%) .
9975328|NCT03740958|Experimental|Argatroban combined with rt-PA|Drug: Argatroban combined with rt-PA Argatroban as a 100 ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
10172808|NCT03868852|Experimental|Radiotherapy plus apatinib mesylate|All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
9672480|NCT05035121|Experimental|soy milk supplement|The soy milk group provided 200 mL soy milk two times per day. The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
9672481|NCT05035121|Placebo Comparator|control|The participants joined the resistance exercise training program, three times per week (30 min/time) during 12 weeks.
9672482|NCT05034757|Experimental|Hyaluronate|HA injection
9672483|NCT05034757|Experimental|HA + ESWT|HA + ESWT
9672484|NCT05034718|Active Comparator|Control Arm|Completion of nurse powerform and data collection only.
9975329|NCT03740958|Active Comparator|rt-PA|Drug: rt-PA Intravenous throbolysis with 0.9mg/kg rtPA.
10172809|NCT03869021|Active Comparator|Computer guided surgery|A surgical guide is 3d printed to guide through the surgery, the patients of this group will have the distraction surgery by a guide designed by Mimics 19.0, Materialise NV,Belgium
10172810|NCT03869021|Other|No surgical guide (free hand surgery)|control group added to investigate the effect of surgical guide
10172811|NCT03868878|Experimental|Capoeira training group|The experimental protocol for Capoeira program lasted 12 weeks and was performed twice a week with duration of 60 minutes each with warm-up, basic movements in the modality, and 20 minutes with theoretical instructions related to Capoeira and musicality.
10187040|NCT03730194|Experimental|Bedtime Bank Only|Participants in this arm will utilize the Bedtime Bank, a behavioral sleep intervention.
9525536|NCT03237390|Experimental|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9525537|NCT03237091|Experimental|bihemispheric transcranial pulsed current stimulation (tPCS)|
9525538|NCT03237091|Experimental|unihemispheric transcranial pulsed current stimulation (tPCS)|
9975330|NCT03739437|Experimental|Mobile Contingency Management|
9975331|NCT03739437|Active Comparator|Standard Care|
9975332|NCT03738202|Experimental|Intervention|Multifaceted intervention package will be implemented at textile mills in the intervention arm.
9975333|NCT03738202|No Intervention|Control|No intervention will be provided to mills in the control arm.
9525539|NCT03237091|Experimental|bihemispheric transcranial direct current stimulation (tDCS)|
9525540|NCT03237091|Experimental|unihemispheric transcranial direct current stimulation (tDCS)|
9525541|NCT03237091|Active Comparator|sham-control|
9694930|NCT04783831||Non-biodegradable stent|
9975334|NCT03730948|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
9525542|NCT03237182|Experimental|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
9525543|NCT03237182|Active Comparator|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
9525544|NCT03237000|Experimental|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
9525545|NCT03237026||Cohort A|Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.
9525546|NCT03237026||Cohort B|Validation cohort will be recruited in the next 24 months of the study period .
9525547|NCT03236818|Other|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
9525548|NCT03236948|Experimental|WfWI Intervention|Women receive the WfWI intervention. This comprises of three main components. First, a social empowerment and health intervention. Second a livelihood strengthening intervention, including numeracy training, and vocational training. Third, a cash transfer conditional on attendance at the intervention to cover costs of attendance and provide start-up capital. The intervention is delivered over 12 months.
9525549|NCT03236948|No Intervention|Control|
9672485|NCT05034718|Experimental|Intervention Arm|Completion of nurse powerform, data collection and physician alert/powerform with score calculation and recommendations.
9672486|NCT05034861|Experimental|cCTG|cCTG group, that will undergo a following process: EFW and Doppler assessment biweekly, and instead of additional weekly Doppler-only assessment, the patients will be provided with an electronic cCTG device at no cost (Carebits). Women will be asked to apply Carebits device at least twice weekly for at least 30 minutes (e.g. Mondays-Thursdays) with minimum 72 hours interval in case of 2 sessions per week. The trace will be examined by an independent centre, available 24 hours daily. The person examining the trace is trained or already specialized in Obs&Gynae. In case of situation requiring medical intervention, the patient will be immediately contacted by phone and advised to self-refer to the nearest Antenatal Unit. In case of normal trace, a full report will follow within 30 minutes after last reading of the trace.
9672487|NCT05034861|Active Comparator|Doppler|Doppler group, that will undergo a standard process of antenatal care in case of FGR. The EFW will be assessed biweekly. In case of positive end-diastolic flow in UA, Doppler assessment (MCA PI, UA PI, DV PI, Ut PI) will be provided on a weekly basis. In case of deterioration to AEDF/REDF, further management will depend on clinical situation and the patient will be excluded from the study group (applies to both arms).
9672488|NCT05034575|Experimental|Novice and experienced medical personnel|Participants will be asked to complete two tasks each taking approximately 10 minutes while wearing eye-tracking technology to understand focus of gaze during laryngeal endoscopy and stroboscopy interpretation.
9672489|NCT05034458|Experimental|Diet|Patients will do biologic treatment and will do Crohns Disease Exclusion Diet for 12 weeks.They will be monitored periodically by interview and physical examination by physician and nutritionist, laboratory, fecal calprotectin.
9672490|NCT05034458|No Intervention|Control|Patients with normal treatment
9672491|NCT05034705|Active Comparator|Active comparator: Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
9672492|NCT05034705|Experimental|Experimental: Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
10172812|NCT03868878|Sham Comparator|Control group|While the Capoeira group performed the entire class, the Control group performed only the final part (20 minutes) with musicality - singing and touch of typical instruments - and theoretical instructions related to Capoeira.
10187041|NCT03730194|Experimental|Combination (Melatonin+Bedtime Bank)|Participants in this arm will take 3 mg melatonin 30 minutes before bedtime and utilize the Bedtime Bank, a behavioral sleep intervention.
9672493|NCT05034848|Other|PAD group|PAD patients, diagnosis after undergoing an echo-doppler in the Vascular Medicine Department of Orleans regional Hospital
9975335|NCT03711318|Experimental|Short-term treatment with buprenorphine|Short-term treatment with buprenorphine
9975336|NCT03686488|Experimental|TAS 102 and Ramucirumab|TAS 102 (Lonsurf) and Ramucirumab 10 MG/ML Intravenous Solution (CYRAMZA) administered concurrently.
9975337|NCT03685188|Experimental|Oxycodone group|PCIA is formulated at 0.4 mg/ml of oxycodone.
9975338|NCT03685188|Active Comparator|Sufentanil group|PCIA is formulated at 2 μg/ml of sufentanil.
9975339|NCT03680859||Diabetic|Participants with a primary etiology of diabetic gastroparesis
9975340|NCT03680859||Idiopathic|Participants with a primary etiology of idiopathic gastroparesis
9975341|NCT03680859||Post-fundoplication|Participants with a primary etiology of post-Nissen fundoplication gastroparesis
9525550|NCT03236844|Experimental|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
9525551|NCT03236844|Experimental|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
9525552|NCT03236766|Other|No intervention|
9975342|NCT03680859||Diabetic with Normal Emptying|Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying
9975343|NCT03680859||Idiopathic with Normal Emptying|Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying
10172813|NCT03869138|Experimental|Virtual-reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
10172814|NCT03868917|No Intervention|ultrasound group|The participants have continuous thoracic paravertebral block performed using only the ultrasound approach.
10172815|NCT03868917|Experimental|pressure measurement group|The participants have continuous thoracic paravertebral block performed using the ultrasound-guided approach combined with pressure measurement techniqueduring needle advancement.
10172816|NCT03869060|Experimental|Inoculated Group|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) given as a single dose [0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL)] inoculated subcutaneously.
10172817|NCT03869125||Obstructive sleep apnoea group|Blood pressure measurement
10172818|NCT03869073|Experimental|Low Dose|This treatment arm will receive the highest dose of evolocumab currently marketed and approved: 420mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
10172819|NCT03869073|Experimental|High Dose|This treatment arm will receive double the highest dose of evolocumab currently marketed and approved: 840mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
10172820|NCT03869073|Placebo Comparator|Placebo|This treatment arm will receive saline solution. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
10172821|NCT03868969|Experimental|Fosfomycin|Fosomycin tromethamine, one sachet for 21 days
9525553|NCT03236805|Experimental|Ketamine IV|
9525554|NCT03236805|Active Comparator|Morphine IV|
9525555|NCT03236896|Active Comparator|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
9525556|NCT03236896|Active Comparator|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
9525557|NCT03236831|Other|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
9525558|NCT03236974|Active Comparator|Standard arm|Fulvestrant, 500 mg
9525559|NCT03236974|Experimental|AZD9496|250 mg bd taken orally for 5-14 days
9525560|NCT03236922|Active Comparator|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
9525561|NCT03236922|Active Comparator|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
9525562|NCT03236792|Experimental|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
9525563|NCT03236883|Experimental|GEM plus GPBSC|Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)*10^8/kg
9525564|NCT03236883|Other|Gemcitabine|
9525565|NCT03236883|Other|GPBSC|
9525566|NCT03236961|Active Comparator|Intravenous & per oral antibiotics|Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
9525567|NCT03236961|Active Comparator|Per oral antibiotics|Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
9525568|NCT03236636|Experimental|Icaritin|Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
9525569|NCT03236636|Active Comparator|HUACHANSU PIAN|HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
9525570|NCT03236753|Experimental|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
9525571|NCT03236753|Sham Comparator|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
9525572|NCT03236610|Experimental|tenofovir|
9525573|NCT03236610|Active Comparator|tenofovir plus entecavir|
9525574|NCT03236649|Experimental|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
9525575|NCT03236649|Active Comparator|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
9525576|NCT03236740|Active Comparator|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
9525577|NCT03236740|Active Comparator|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
9525578|NCT03236701|No Intervention|Control|usual diet
9525579|NCT03236701|Experimental|Intervention|egg white instead of meat or fish in two meals twice a week for three months
9525580|NCT03236675||EML4-ALK|ALK positive patients
10172822|NCT03869112|Experimental|Physical activity intervention|Physical activity group will be given a FitBit device to monitor their PA, especially steps count Step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home based intervention.
10172823|NCT03869112|Experimental|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
9525581|NCT03236675||T790M EGFR|T790M positive patients
9525582|NCT03236727|No Intervention|Control|Data of SSEPs (amplitude and latency) before dexmedetomidine infusion.
9525583|NCT03236727|Active Comparator|Dexmedetomidine|Data of SSEPs (amplitude and latency) after dexmedetomidine infusion.
9525584|NCT03236987|Active Comparator|Clarithromycin 1000 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Clarithromycin (500 mg twice daily)"
9525585|NCT03236987|Experimental|Azithromycin 250 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Azithromycin (250 mg once daily)"
10172824|NCT03869112|No Intervention|Usual care|Usual care group will have the standard follow up care by rehabilitation clinic without being in any physical intervention.
10172825|NCT03868995|Sham Comparator|Sham injection|Dextrose water injection to subcutaneous layer at tender point
9525586|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
9525587|NCT03236467|Experimental|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
10172826|NCT03868995|Experimental|Tendon injection|Dextrose water injection to injured tendon
9525588|NCT03236402||Early young adult (20 years - 30 years)|Adults who were in the age group of 20 - 30 years was the first group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 20-30 years.
9525589|NCT03236402||Middle age adult (31 -50 years)|Adults who were in the age group of 31-50 years were in second group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 31-50 years.
9975344|NCT03680859||Post-fundoplication with Normal Emptying|Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying
10172827|NCT03868813||Interview with People with Diabetes|One-on-One interview with people with diabetes
10172828|NCT03868813||Interview with Health Coaches|One-on-One interview with health coaches
9525590|NCT03236402||Late adult (51 years - 65 years)|Adults who were in the age group of 51-65 years were in third group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 51-65 years.
9525591|NCT03236402||>65 years|Adults who were in the age group of >65 years were in fourth group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of >65 years.
9525592|NCT03236493|Experimental|PF-06700841|Multiple ascending doses of PF-06700841
9525593|NCT03236493|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
9525594|NCT03236597|No Intervention|Usual Desk|participants will work at their usual desk for four weeks.
9525595|NCT03236597|Experimental|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of 30 minutes per day for four weeks (Participants will sign up for a total of 30 minutes each day). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to up to 10 people over the four week period).
9525596|NCT03236441|Active Comparator|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
9525597|NCT03236441|Sham Comparator|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
9525598|NCT03236558|Experimental|Patients with diabetes|T1D patients with blood collection
9525599|NCT03236584|Active Comparator|lamivudine adefovir|
9525600|NCT03236584|Experimental|tenofovir|
9525601|NCT03236571|Experimental|Rehabilitation Program|It will consist of 2 sessions of 40 minutes per week, for 12 weeks on ergometric bicycle. Each session of 40 min will include 5 minutes of warm-up, 5 minutes of recovery and 6 sequences of 5 min. Each 5-minute sequence will alternate between 4 minutes of pedaling at a load corresponding to the 1st ventilatory threshold (determined in the initial maximum cardiorespiratory effort test) and 1 minute of pedaling at a load corresponding to 2nd ventilatory threshold (determined in the initial maximum cardiopulmonary stress test).
9975345|NCT03680820||Ages 5-9, gastroparesis|Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)
10187042|NCT03730181|Experimental|Single Arm Rifapentine and Isoniazid|Single arm, open label and exposure-controlled. Intervention is rifapentine given in a new fixed dose combination once-weekly, in combination with isoniazid for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years in whom LTBI treatment is indicated. The protocol allows for parallel enrolment of children into cohorts 1 and 2, simultaneously, using a predetermined modeled initial dose for each cohort, separately. Similarly, cohorts 3 and 4 will be enrolled in parallel, using modeled doses for each cohort, based on data from cohorts 1 and 2 and historical data from TBTC trials.
9525602|NCT03236623|Experimental|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
9525603|NCT03236623|No Intervention|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
9525604|NCT03236454|Active Comparator|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
9525605|NCT03236454|Sham Comparator|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
9525606|NCT03236532|Experimental|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
10172829|NCT03868800|Other|SDM-DC|All adult patients with kidney failure referred to a department of renal medicine at one of the four hospitals from the 1st of October 2016 to the 31st of May 2018 were offered the intervention and invited to participate in the study. The inclusion criterion was an estimated glomerular filtration rate below 20 ml/min and based on a clinical judgement made by the contact doctor and/or the contact nurse about the decline in the Estimated glomerular filtration rate to continue. Exclusion criteria were patients who had decided on conservative management, patients with a living donor and a set date for transplantation and patients not able to participate in the intervention due to cognitive impairment. The use of an interpreter was not an exclusion criterion.
10172830|NCT03868553||Under-10|
9525607|NCT03236532|Placebo Comparator|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
9525608|NCT03236363|Experimental|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
9525609|NCT03236363|No Intervention|Control|No intervention
9525610|NCT03236363|Experimental|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
9525611|NCT03236337|No Intervention|Control|No intervention
9525612|NCT03236337|Experimental|MOVI intervention|- MOVI-da Fit! is a high intensity interval training intervention that consists on: a) 4 h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
9525613|NCT03236324|Placebo Comparator|TFP block with saline|Placebo bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with 40 mL saline, single shot
9525614|NCT03236324|Experimental|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with local anesthesic of Bupivacaine-epinephrine [0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)], single shot
9525615|NCT03236415|Active Comparator|Xience Drug Eluting Stent|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery disease
9525616|NCT03236415|Active Comparator|ABSORB Bioresorbable Vascular Scaffold|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery diseasee
9525617|NCT03236376|Experimental|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
9525618|NCT03236376|Active Comparator|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
9525619|NCT03236480||COPD|Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled
10172831|NCT03868553||Under-12|
10172832|NCT03868553||Under-16 female|
10172833|NCT03868553||Under-16 male|
9525620|NCT03236480||healthy control|People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study
9525621|NCT03236350|Experimental|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
10172834|NCT03868566|Experimental|SNP-612 dose1|dose1 once a day orally for 12 weeks
10172835|NCT03868566|Experimental|SNP-612 dose2|dose2 once a day orally for 12 weeks
10172836|NCT03868566|Experimental|SNP-612 dose3|dose3 once a day orally for 12 weeks
10172837|NCT03868566|Placebo Comparator|SNP-612 placebo|placebo once a day orally for 12 weeks
10172838|NCT03868644|Experimental|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
10172839|NCT03868644|Experimental|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
9525622|NCT03236350|Sham Comparator|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
9525623|NCT03236298|Active Comparator|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
9525624|NCT03236298|Active Comparator|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
9525625|NCT03236389|Experimental|Collar Wearing|subjects will wear collar during MRI testing
9525626|NCT03236090|Active Comparator|Outpatients with refractory ascites|20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
9525627|NCT03236090|Active Comparator|Patients hospitalized because bacterial infection|30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
9525628|NCT03236285|Experimental|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
9525629|NCT03236285|Experimental|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
9525630|NCT03236285|Experimental|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
9525631|NCT03236285|Experimental|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
9525632|NCT03236142|Active Comparator|Standard Duodenal Switch (DS)|
9525633|NCT03236142|Experimental|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
9525634|NCT03236233|Experimental|Single dose - healthy subjects|
9525635|NCT03236233|Experimental|Repeat dose - healthy subjects|
9525636|NCT03236233|Experimental|Single dose - subjects with asthma|
9525637|NCT03236220|Experimental|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
9525638|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
9525639|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
9528033|NCT03214549|Active Comparator|gull wing preparation veneers|intervention: gull wing preparation in laminates veneers proximal margin of the preparation is placed toward the lingual .The area of the proximal margin between the contact area and the gingival papilla is placed even further to the lingual. This preparation design helps to hide the margin when the restorations are viewed from an angle.
10172840|NCT03868644|Experimental|VCT and Condoms|Youth are offered both VCT and condoms.
10172841|NCT03868644|No Intervention|Control|No intervention is provided (beyond the standard available HIV prevention services within the area)
9528034|NCT03214549|Active Comparator|conventional preparation veneers|intervention: conventional preparation in laminates veneers preparation of veneers without lingual extension of preparation in mesial and distal areas
10172842|NCT03868696|Sham Comparator|MUA with sham ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with sham ultrasound (screen concealed from participants)
10172843|NCT03868696|Experimental|MUA with active ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with active ultrasound (screen concealed from participants)
9528035|NCT03214653|Active Comparator|Propofol|Those who received target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50.
9528036|NCT03214653|Active Comparator|Sevoflurane|Those who received sevoflurane 1,5-2% as maintenance agent of anesthesia.
9528037|NCT03214679|Experimental|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
9528038|NCT03214679|Active Comparator|Usual Care|Usual care represents the current procedure after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
9826716|NCT02430870|Experimental|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
9826717|NCT02430870|Experimental|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
9826718|NCT02430870|Placebo Comparator|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
9525640|NCT03235895|Experimental|Internet based|"Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.~Followed by one day face to face CME activity"
9525641|NCT03235895|Active Comparator|Face to Face|Three days face to face Conventional CME educational materials
9525642|NCT03235895|No Intervention|Wait listed|No CME activity will be given
9525643|NCT03235947|Experimental|Fosfomycin disodium|"Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.~Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours."
9525644|NCT03235947|Active Comparator|Trimethoprim / Sulfamethoxazole|"Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.~Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm."
10172844|NCT03868527||Hematological diseases|Cohort of patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital
9525645|NCT03236272||case group|patients with ARDS
9525646|NCT03236272||control group|patients Without ARDS
9525647|NCT03236051|Experimental|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
9525648|NCT03236051|Active Comparator|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
9525649|NCT03236064|Experimental|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
9525650|NCT03235882||observational group|"Infants born 24-32 weeks.~Inclusion criteria:~Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:~a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or~a nasogastric tube inserted as part of routine management of preterm infants.~Written informed consent has been obtained"
9525651|NCT03236259|Active Comparator|Brainport high dose|
9525652|NCT03236259|Active Comparator|Brainport low dose|
9525653|NCT03236259|Placebo Comparator|Placebo|Maltodextrin
9525654|NCT03236116|Experimental|Almond Group|Participants will consumed almonds every day for 6 months, but will not be allowed to consume any other nuts or nut products.
9525655|NCT03236116|Experimental|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nuts or nut products.
9525656|NCT03236181|Other|Saturated Fat/SFA|30 grams saturated fat (SFA) in the form of heavy whipping cream will be provided to subject in a mixed meal shake
9525657|NCT03236181|Other|Monounsaturated Fat/MUFA|30 grams monounsaturated fat (MUFA) in the form of olive oil will be provided to subject in a mixed meal shake
9525658|NCT03236181|Other|Polyunsaturated Fat Linoleic/PUFA|30 grams high linoleic polyunsaturated fat (PUFA) in the form of high linoleic sunflower oil will be provided to subject in a mixed meal shake
9525659|NCT03236181|Other|Polyunsaturated Fat Omega-3/LCn3|30 grams high omega-3 polyunsaturated fat (LCn3) in the form of fish oil will be provided to subject in a mixed meal shake
9525660|NCT03236155|Active Comparator|1 prescription|Receives 90 pills in single prescription at discharge from hospital
9525661|NCT03236155|Active Comparator|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
9525662|NCT03236129|Experimental|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
9525663|NCT03236129|Active Comparator|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
9525664|NCT03235856||Keratoconus patients|This study involves a retrospective analysis of data recorded during routine clinical follow-up of keratoconus patients. As such, the impact for the patient is minimal as no additional tests need to be performed
9525665|NCT03235921|Other|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
9525666|NCT03235921|Other|control group|no drug given to the patients in control group
9694931|NCT04783766|Experimental|CK-3773274 for Single Ascending Dose (SAD) Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274
9525667|NCT03236207|Experimental|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
9525668|NCT03236207|Active Comparator|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
9525669|NCT03235973|Experimental|Fludarabine-Cladribine-Busulfan conditioning regimen|
9525670|NCT03235869|Experimental|Radiation Therapy + Durvalumab|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions) Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
9525671|NCT03236025|Experimental|Experimental group|Video+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. The videos which presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy, will be sent in sequence through the smart phone to the participants in the experimental group.
9525672|NCT03236025|Active Comparator|Conditional control group|Text-message+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. Text-message contains the same content with videos and will be sent in the same frequency with the videos through the smart phone to the participants in the Conditional control group.
9525673|NCT03236025|Placebo Comparator|Placebo control group|Participants in the control group will be given a one-sentence smoking cessation advice during the baseline assessment. A leaflet showed the information related to the smoking cessation will be allocated to them at the same time.
9525674|NCT03236103|Other|Subjects with VAD in place|Adult patients with VAD in place who are admitted to the hospital for acute medical illness. The investigators will provide clinical recommendations to the subject's primary care provider.
10172845|NCT03868735|Experimental|CleanSweep Closed Suction System|Device that includes balloon sweeping technology
10172846|NCT03868735|No Intervention|Standard in-line suction device|In-line suction device already in on intubated patients with an endotracheal tube
10172847|NCT03868462|Other|Optical Coherence Tomography (OCT)|
9525675|NCT03236012|Experimental|Botulinum Toxin Therapy|"Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.~We plan to conduct an open label study of Botox, up to 400 units, in amputees who have failed treatment with a topical antiperspirant."
9525676|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
9525677|NCT03235804|No Intervention|Control Group|Those assigned to the Control group will be asked to maintain their usual dietary intake over 12 weeks. Participants' usual dietary intake is expected to reflect the North American dietary pattern (i.e. ~15% of total energy intake coming from protein, ~50% from carbohydrate and ~35% from fat).
9525678|NCT03235804|Experimental|High-Protein Group|Those assigned to the High-Protein group will be asked to maintain their usual dietary intake and consume a nutritional supplement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
9525679|NCT03235843|Active Comparator|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
9525680|NCT03235843|Placebo Comparator|Rate Adaptive Pacing OFF|DDI-pacing
9525681|NCT03235830|Active Comparator|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
9525682|NCT03235830|Experimental|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
9525683|NCT03235570|Experimental|Pemigatinib|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
9525684|NCT03235609|Active Comparator|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
9525685|NCT03235609|Active Comparator|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
9525686|NCT03235635||Preterm|newborn infants were born with a gestational age of less than 32 weeks
9525687|NCT03235635||Late preterm|newborn infants were born with a gestational age of greater than 32 weeks and less than 36 weeks
9672494|NCT05034653|Experimental|Intermittent Fasting Healthy Plate (IFHP)|Dry fasting from dawn to dusk for two days a week (Monday and Thursday) and Healthy Plate for the rest of the week. Female participants were discouraged from fasting during their menstruation period.
9672495|NCT05034653|Active Comparator|Healthy Plate|Practice the Healthy Plate concept in at least one meal every day
9672496|NCT05034302||Recordings|Selection criteria include individuals between the ages of 18-85 years, no major chronic illness that impair mobility and able to complete activities of daily living without assistance. We will recruit approximately equal number of men and women and 30% of the sample will be racial or ethnic minorities.
9672497|NCT05034237|Experimental|ND;YAG 1064 NM LASER|monthly sessions of laser hair removal
9672498|NCT05034666|Active Comparator|Before education|"Before alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is before applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
9672499|NCT05034666|Active Comparator|After education|"After alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is after applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
9672500|NCT05034679||Vaciinated|First group patients who vaccinated and measure the AMH before and up to 9 months after vaccination.
9672501|NCT05034679||Infected patients by covid-19 and not vacinated|Second group patients who were infected by Covid-19 ant therefor were not vaccinated
9525688|NCT03235635||full-term|newborn infants were born with a gestational age of greater than or equal to 37 weeks
9525689|NCT03235674|Experimental|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
9525690|NCT03235674|No Intervention|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
9525691|NCT03235596|Experimental|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
9525692|NCT03235466|Active Comparator|Voice Therapy|(Group 1) will undergo active training in behavioral cough suppression and laryngeal relaxation exercises, but will not receive HRVB. Traditional cough suppression and laryngeal relaxation exercises include pursed lip breathing, swallowing (water, lozenge, gum, ice chips), sustained semi-occluded voicing, discussion and mitigation of triggers, maintaining a cough journal, addressing muscle tension dysphonia if indicated, and developing prophylaxis suppression and laryngeal relaxation based on stimulability. Participants in Group 1 will receive handwritten guidance indicating exercises to practice at home.
9528039|NCT03214627|Experimental|Anemia Control Model IV iron and ESA|"Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period"
10172848|NCT03868501|Experimental|High Working memory load: n-back task|During the intervention, each participant of this group will finish the 3-back task.
9525693|NCT03235466|Active Comparator|Voice Therapy and Heart Rate Variability Biofeedback|Voice therapy as described in Arm 1. HRVB involves measure respiratory rate, heart rate, body temperature and skin conductance. Participants are guided through reduced breathing rate until a resonant frequency is attained. HRVB breathing simulates resonance between the baroreflex rhythm and respiration based rhythm, increasing heart rate variability and baroreceptor sensitivity. Evidence suggests HRVB improves autonomic regularity. We propose this novel modality to address centrally regulated hypersensitivity that perpetuates coughing.
9525694|NCT03235466|Active Comparator|Heart Rate Variability Biofeedback|HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
9525695|NCT03235687|Experimental|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
9525696|NCT03235687|No Intervention|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
9525697|NCT03235531|Experimental|CIWA Protocol/BZD and Valproate|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool.~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.~The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
9525698|NCT03235531|Active Comparator|CIWA Protocol Only|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
9525699|NCT03235648|Experimental|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
9525700|NCT03235492|Experimental|SmartAlbu|If a participant agrees, after obtaining informed consent, the investigator will measure and record temperature, blood pressure, heart rate, height and weight. The participant will be given detailed instruction on how to hold the container and will be asked to spit (or deposit) their saliva up to the indicated line. The procedure will be performed twice to study the reproducibility of the test. The participant will then be asked to have a standard blood draw of 2-3 mls of blood into a vacutainer tube for analysis of HbA1c at the central lab and 1-2 mls of blood for glycated albumin for assay analysis, and a finger stick for point of care HbA1c measurement.
9525701|NCT03235661|Experimental|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
9525702|NCT03235661|Active Comparator|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
9525703|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
10172849|NCT03868501|Experimental|Low Working memory load: n-back task|During the intervention, each participant of this group will finish the 1-back task.
9525704|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
9525705|NCT03235440|Experimental|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
9525706|NCT03235583|Other|MotionPod Validation|Medical device validation
9525707|NCT03235700|Experimental|Adenosine followed by nicorandil|
9525708|NCT03235700|Experimental|Nicorandil followed by adenosine|
9672502|NCT05034679||Not infected nor vacinated|Ptients who who were not infected nor vacinated by Covid-19.
9672503|NCT05034315|Experimental|Whole egg consumption|
9672504|NCT05034315|No Intervention|No egg control|
9672505|NCT05034380|Active Comparator|Lean|males aged 18-30 years with BMI < 25
9672506|NCT05034380|Experimental|Overweight/Obese|males aged 18-30 years with BMI >= 25
9672507|NCT05034276|Experimental|MORE-VR|Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.
10172850|NCT03868683|Other|Glucose Reference 1|Glucose solution containing 30 g of glucose
10172851|NCT03868683|Other|Glucose Reference 2|Glucose solution 2 containing 30 g of glucose
10172852|NCT03868683|Other|Glucose Reference 3|Glucose solution 3 containing 30 g of glucose
10172853|NCT03868683|Experimental|Sucrose|Sucrose solution containing 30 g of sucrose
10172854|NCT03868683|Experimental|Regular Bake beans in tomato sauce|Bake bean in tomato sauce with high levels of sucrose (37%)
10172855|NCT03868683|Experimental|Bake beans in tomato sauce, reduced sugar|Bake bean in tomato sauce with medium levels of sucrose (29.9%)
9525709|NCT03235453|Experimental|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
9525710|NCT03235453|Experimental|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
9525711|NCT03235778|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:11.78mg Volume:0.50ml Frequency:Once Duration:30min A total of 10 subjects, 2 subjects served as pre-test groups, given to the test drug；the remaining 8 subjects,6 received the test drug and 2 received the placebo.
9525712|NCT03235778|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:23.56mg Volume:1.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
9525713|NCT03235778|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
9525714|NCT03235778|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
9672508|NCT05034419|Experimental|Active stimulation|Patients undergoing cardiac surgery will be randomized to active low level tragus stimulation for 30 min (pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz). Stimulation will be provided using the Parasym device.
10172856|NCT03868683|Experimental|Bake beans in tomato sauce, low GI|Bake bean in tomato sauce with low levels of sucrose (18.5%)
10172857|NCT03868436|Other|Methoxyflurane (MEOF)-active treatment|single arm study all subjects will be treated with Methoxyflurane 3 mL
9525715|NCT03235778|Experimental|group5|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:164.92mg Volume:7.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
9525716|NCT03235778|Experimental|group6|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
10172858|NCT03868488|Experimental|Visual imagery tasks group|During the intervention, each participant of this group will be asked to create visual mental images.
9525717|NCT03235778|Experimental|group7|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:377.00mg Volume:16.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
9525718|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
9525719|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
9525720|NCT03235401||Pulmonary Arterial Hypertension patients|
9525721|NCT03235752|Experimental|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
9525722|NCT03235752|Experimental|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
10172859|NCT03868488|Experimental|Auditory imagery tasks group|During the intervention, each participant of this group will be asked to create auditory mental images.
10172860|NCT03868722|Experimental|Treatment arm|Treatment with Acalabrutinib and Venetoclax is initiated within 14 days after randomization.
9525723|NCT03235752|Placebo Comparator|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
9525724|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
9525725|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
9525726|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
9694932|NCT04783766|Placebo Comparator|Placebo comparator for SAD Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator
10172861|NCT03868722|No Intervention|Observation arm|Observation period is initiated within 14 days after randomization.
10172862|NCT03868514||TiLOOP Bra Pocket|Medical Device
10172863|NCT03868774|Active Comparator|rTMS standard|Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)
10172864|NCT03868774|Active Comparator|rTMS accelerated model|Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)
10172865|NCT03868475|Experimental|Vacuum-assisted percutaneous excision|"Patients will undergo vacuum-assisted percutaneous excision (VAPE). The intervention group will have post-procedure imaging the same day to confirm complete excision.~The intervention group will then have imaging at 6, 12, and 24 months as per the radiology algorithms for following suspicious lesions (BIRADS 3 category). If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The intervention group will also be seen in clinic at 1 month with no imaging and then at 6, 12, and 24 months to correspond to the imaging visits."
10187043|NCT03730168|Experimental|study group and control group|"Two groups; study group included 30 diabetic male patients who where trained by circuit weight training program in the form of sets of resistance exercises (in the form of dumbbells and sand bags) for the muscles of lower limb and upper limb .The training sessions were performed 3 days per week for a period of 12 weeks. All patient were on their prescribed routine medications .~The control group were on there prescribed medications only ."
9525727|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
9525728|NCT03235193|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
9525729|NCT03235193|Active Comparator|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
9525730|NCT03235375|Experimental|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl <20ml/min will receive MEDI0382 administered subcutaneously
9525731|NCT03235375|Experimental|Group 2: Severe and ESRD Subjects|Subjects with CrCl >20 and < 30 ml/min will receive MEDI0382 administered subcutaneously
9525732|NCT03235375|Active Comparator|Group 3: Healthy Subjects|Subjects with CrCl >90 ml/min will receive MEDI0382 administered subcutaneously
9525733|NCT03235375|Experimental|Group 4: Moderate Renal Disease|Subjects with CrCl > or equal to 30 and < 60 mL/min will receive MEDI0382 administered subcutaneously
9525734|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
9525735|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
9525736|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
9525737|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
9525738|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
9525739|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
9826719|NCT02430870|Experimental|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
9525740|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
9525741|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
9525742|NCT03235297||Healthy subjects|Healthy subjects
9525743|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
9525744|NCT03235232|Experimental|BREMEN eye drops|1 drop in affected eye(s), each 12 hours for 8 weeks.
9525745|NCT03235232|Active Comparator|Combigan®|1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.
9525746|NCT03235167|Experimental|CpG DNA|CpG DNA concentrate
9525747|NCT03235167|Placebo Comparator|placebo|placebo concentrate
9525748|NCT03235245|Active Comparator|ARM A: Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.
9525749|NCT03235245|Experimental|ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.
9525750|NCT03235388|Experimental|Intervention|Audit filter implementation in hospital
9525751|NCT03235388|No Intervention|Control|Routine care
9525752|NCT03235323|Experimental|ECP group|Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
9525753|NCT03235323|No Intervention|Control group|Patients of Control group received routine medicine treatment postoperatively
9672509|NCT05034419|Sham Comparator|Sham stimulation|Patients undergoing cardiac surgery will be randomized to sham stimulation for 30 min. The Parasym device will be placed on the patient's tragus, but no current will be delivered.
9525754|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
9672510|NCT05034640||Conventional Multiport Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had multiport video assisted thoracoscopic surgery for pediatric pneumothorax.
9525755|NCT03234998|Experimental|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks.
9525756|NCT03234998|Active Comparator|cognitive dual-task training|Participants in the cognitive dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks.
9525757|NCT03234946|No Intervention|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
9525758|NCT03234946|Experimental|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
9525759|NCT03234933|Experimental|Mobility Tracker|"Each patient will be provided by the research team staff with a new mobility tracker~The standard pre-operative assessment, surgical procedure and post-operative care will still be done~Measurements of each patient (steps, distance and calories) will be obtained by the research staff"
9525760|NCT03235076|Experimental|Subjects with mild renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
9525761|NCT03235076|Experimental|Subjects with moderate renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
9525762|NCT03235076|Experimental|Subjects with severe renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
9525763|NCT03235076|Experimental|Matched healthy subject group|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
9975346|NCT03680820||Ages 5-9, gastroparesis-like syndrome|Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
10172866|NCT03868475|Active Comparator|Open surgical excision|"Patients will undergo standard open surgical excision.~The control group will then have follow up imaging at 12 and 24 months as per the usual radiology algorithms following excision of a lesion. If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The control group will also be seen in clinic at 1 month with no imaging and then at 12 and 24 months to correspond to the imaging visits."
10172867|NCT03868449|Experimental|Question Prompt List|Participants will be given a Question Prompt list that has been developed by the research team
9975347|NCT03680820||Ages 10-17, gastroparesis|Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)
9525766|NCT03234959|Experimental|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
9525767|NCT03234959|Active Comparator|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
9525768|NCT03235037|Other|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
9525769|NCT03235362|Experimental|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
9525770|NCT03235362|Experimental|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
9525771|NCT03235362|Experimental|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
9661855|NCT03891771|Experimental|Telemonitoring sensors|Patients allocated to this arm will receive a complex sensor platform aimed at detecting falls at home, nocturia and several environmental variables, including carbon monoxide concentrations, humidity and temperature. The system also includes a panic button that can be used to request assistance in emergencies.
9661856|NCT03889834|Experimental|Autotransfusion: blood stored at 4 ° C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days
9661857|NCT03889834|Experimental|Autotransfusion: blood stored at -80°C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days
9661858|NCT03889834|Other|Controls not transfused|no transfusion
9672511|NCT05034640||Single Port Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had single port video assisted thoracoscopic surgery for pediatric pneumothorax.
9975348|NCT03680820||Ages 10-17, gastroparesis-like syndrome|Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
9975349|NCT03655340||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
9975350|NCT03655340||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
9975351|NCT03655028|Experimental|RAS-music group|Home-based, exercise program augmented with rhythmically auditory stimulation enhanced music
10172868|NCT03868449|Active Comparator|3 questions list|Participants will be given 3 questions from the AskShareKnow method
10172869|NCT03868761|Other|Single Arm|21 male and female teenage participants will be randomized to one of three varying baseline assessment periods of two, four, or six weeks. Multiple baseline is a type of single-case experimental design (SCED) that is a time- and cost-effective method for evaluating efficacy of a new treatment, Sonoma Rises. The randomization of participants to baseline periods of varying lengths enables assessment of whether symptom changes occur when, and only when, the intervention is applied.
9661859|NCT03887143||Arterial ischemic stroke in patients less than 18 years old|"Patients < 18 years old~Suspected or confirmed cerebral infarction~With recanalization treatment in the acute phase: intra-venous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy~Patients treated between January 2015, 1st and May 2018, 31st"
10172870|NCT03868748|Placebo Comparator|Placebo|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the placebo treatment arm will consume one placebo capsule per day for 12 weeks
10172871|NCT03868748|Experimental|Low Dose, 12 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the low dose treatment arm will consume one 150 mg beta-arbutin capsule per day for 12 weeks.
10172872|NCT03868748|Experimental|High Dose, 4 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the high dose treatment arm will consume one placebo capsule per day for 8 weeks followed by one 400 mg beta-arbutin capsule per day for 4 weeks.
10172873|NCT03868397|Experimental|Liver MRI|In this study, MRI refers to phase-contrast 4D flow sequence.
10172874|NCT03868293|Experimental|Drug-Resistant Epilepsy (temporal lobe)|Pulsed low intensity focused ultrasound
10172875|NCT03868306||Iron deficiency anaemia|Microcytic hypochromic anaemic patients with serum ferritin less than 12 Ng /ml
10172876|NCT03868306||Beta thalassemia Trait|Microcytic hypochromic anaemic patients with HBA2 more than 3.2 %
10172877|NCT03868280|Active Comparator|Supine Positioning, Fracture Table|During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
10172878|NCT03868280|Active Comparator|Lateral Positioning, Free drape|During the lateral positioning phase, patients will be placed in lateral position after anaesthetic has been provided. A beanbag will be placed below the patient, and the patient will be safely turned to a lateral position. The beanbag will be inflated, the leg will be prepped, and a free drape will be applied. No traction will be used. Alternatively, some participating sites may use stulberg positioners rather than an inflatable beanbag, based on hospital preference. This positioning mirrors the positioning utilized for the direct lateral, posterior or posterolateral approach to a total hip arthroplasty or hemiarthroplasty
10172879|NCT03868072|Experimental|Reference/Test|"Period 1: XELJANZ 5Mg Tablet 1T~Period 2: Chong Kun Dang Tofacitinib Tablet 1T"
10172880|NCT03868072|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tofacitinib Tablet 1T~Period 2: XELJANZ 5Mg Tablet 1T"
10172881|NCT03868124|Experimental|Implant Group 1|G2TR intraocular implant containing Travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
10172882|NCT03868124|Experimental|Implant Group 2|G2TR intraocular implant containing Travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
10172883|NCT03868124|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
10172884|NCT03868371|Active Comparator|1. high - 2. low|These are the patients receiving a high phosphorous containing meal in the first trial day, and a low phosphorous containing meal in the second trial day.
10172885|NCT03868371|Active Comparator|1. low - 2. high|These are the patients receiving a low phosphorous containing meal in the first trial day, and a high phosphorous containing meal in the second trial day.
10172886|NCT03868176||Experimental: reminder SMS before appointment|SMS before appointment detailing the date of consultation and exams to be performed before
10172887|NCT03868176||Active comparator: standard of care|
10172888|NCT03868137|Placebo Comparator|Placebo|3 doses of placebo identical to study drug will be given to patients starting 1 day before IUD insertion
10172889|NCT03868137|Experimental|Ibuprofen|3 doses of Ibuprofen 800 mg will be given to patients starting 1 day before IUD insertion. Patient will take 800 mg Ibuprofen at noon and 8 PM day before IUD insertion and at 8 AM on the day of IUD insertion.
10172890|NCT03868098|Active Comparator|Crisaborole 2% (application rate A, B, C)|Crisaborole (Marketed drug)
10172891|NCT03868098|Placebo Comparator|Placebo ointment (vehicle)|Placebo
10172892|NCT03868111|Experimental|Sufentanil|Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.
10172893|NCT03868111|Experimental|Remifentanil|Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.
10172894|NCT03868189|Experimental|electroneuromyography|
10172895|NCT03868189|Placebo Comparator|control|
10172896|NCT03868241|Experimental|Bactiguard-coated Devices|Patients will receive endotracheal tube, central venous catheter and urinary cather coated with gold, silver and palladium (Bactiguard coating)
10172897|NCT03868241|Placebo Comparator|Control|Shelf endotracheal tube, central venous catheter and urinary cather available at each intensive care unit without any type of coating designed to prevent infection
10172898|NCT03868228|Experimental|Treatment with PIPAC|Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
10187044|NCT03730155|Experimental|CCT intervention|CCT intervention. 8 weeks with 2 hours session every week. Homework approx. 25 min. of meditation daily.
10187045|NCT03730155|No Intervention|Control waitlist|No treatment given. Participants only answer questionnaire packages.
9525772|NCT03235362|Experimental|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
10172899|NCT03868007|Experimental|RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent RIC twice daily for 14 days.And the RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
10187046|NCT03730142|Experimental|WXFL10030390 tablet|"WXFL10030390 continuous oral dosing (0.1 mg once a day)~WXFL10030390 continuous oral dosing (0.2 mg once a day)~WXFL10030390 continuous oral dosing (0.4 mg once a day)~WXFL10030390 continuous oral dosing (0.7 mg once a day)~WXFL10030390 continuous oral dosing (1.1 mg once a day)~WXFL10030390 continuous oral dosing (1.4 mg once a day)~WXFL10030390 continuous oral dosing (1.7 mg once a day)"
9525773|NCT03235362|Experimental|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
9525774|NCT03235362|Experimental|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
9525775|NCT03234920|Placebo Comparator|Group 1- Control Group|Placebo The placebo will be 200 ml of fruit juice twice a day. Placebo will be provided for 12 weeks
9525776|NCT03234920|Experimental|Group 2 - Treatment group|HMB Supplementation with 1.5 g of HMB dissolved in 200 ml of fruit juice and taken twice daily. Supplementation will be provided for 12 weeks
9525777|NCT03235141|Experimental|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
9525778|NCT03235141|Active Comparator|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
9525779|NCT03234894|Other|SiteSeal Endovascular|"After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.~There is a secondary metric as to patient reported pain on a 1-10scale."
9525780|NCT03234868|Experimental|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
9525781|NCT03234868|Active Comparator|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
9525782|NCT03234868|Experimental|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine & MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled & sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
9525783|NCT03234868|Active Comparator|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine & MAZAK CNC machine:~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
9525784|NCT03234855||LMD|Physician uses LMD during procedure.
9525785|NCT03234816|Experimental|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
9672512|NCT05034510|Active Comparator|Low frequency 80 Hz then short pulse width 30 usec stimulation|Each participant will undergo to low frequency stimulation for 4 weeks, then will switch to short pulse width stimulation paradigm for 4 weeks according to the crossover design.
9672513|NCT05034510|Active Comparator|Short pulse width 30 usec then low frequency 80 Hz stimulation|Each participant will undergo to short pulse width stimulation paradigm for 4 weeks, then will switch to low frequency for 4 weeks according to the crossover design.
9672514|NCT05034549|No Intervention|Control|
10187047|NCT03730129|Experimental|Ig replacement|Subjects will receive Hizentra 0.4 mg/kg subq once weekly.
9672515|NCT05034549|Experimental|Noninvasive ventilation|
9975352|NCT03655028|Active Comparator|Control group|Home-based, exercise program without rhythmically auditory stimulation enhanced music
10172900|NCT03868007|Sham Comparator|sham-RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent sham-RIC twice daily for 14 days.And the sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
10172901|NCT03868202|No Intervention|Premenopausal women|Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.
10172902|NCT03868202|Active Comparator|Postmenopausal women|Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
9672516|NCT05034445||Sputum group|Sputum samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (sputum 1000X)
10172903|NCT03867968|Experimental|TIPS Intervention|The Traumatic Brain Injury Positive Strategies (TIPS) program, is a comprehensive educational and training resource to help families. The web-based product will include: (a) the Training Center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the TBI Resource Center, an extensive library of educational materials, information, and resources about childhood TBI.
9975353|NCT03649880|Experimental|Diagnostic (FMISO, PET/MRI or PET/CT)|Participants receive ¹⁸F-fluoromisonidazole IV and 1.5 - 2 hours later undergo PET (Positron Emission Tomography) /CT (Computed Tomography) or PET/MRI (Magnetic Resonance Imaging) over 20-40 minutes and a retest examination within 7 days. Participants may undergo 2 more PET/MRI scans no sooner than every 4 weeks.
10172904|NCT03867968|Active Comparator|Control|An existing website related to traumatic brain injury.
10172905|NCT03868358|Active Comparator|Real Stimulation|Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
10172906|NCT03868358|Placebo Comparator|Sham Stimulation|Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
10172907|NCT03867955||Patients who have a neurosurgical intervention|Patients who have a neurosurgical intervention will be included. They will have a collection of datas.
10172908|NCT03868215||Patients with endoscopically removed malignant polyps|Patients with endoscopically removed malignant polyps
10172909|NCT03868033|Experimental|Continuous Denosumab|Continuous anti-resorptive therapy by Denosumab for 2 years
10172910|NCT03868033|Experimental|Zoledronic acid to Denosumab|treat with Zoledronic acid for one year and then shift to Denosumab for another one year
10172911|NCT03868033|Experimental|Continuous Zoledronic acid|Continuous anti-resorptive therapy by Zoledronic acid for 2 years
10172912|NCT03868033|Experimental|Zoledronic acid to observation|"treat with Zoledronic acid for one year and then close follow up by bone turn over marker.~resume another dose of Zoledronic acid if elevated CTX level above normal range"
10172913|NCT03868046||Patients treated with ICIs.|All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
10172914|NCT03868319|Experimental|control group|nonprotective ventilation with a tidal volume of 9 ml kg-1 PBW with ZEEP
10172915|NCT03868319|Experimental|LPV group|a tidal volume of 6 ml kg-1 PBW with a 7 cmH2O level PEEP
10172916|NCT03867929||STUDY|Patient with serum 25-Hydroxy vitamin D level <27.32
10172917|NCT03867929||CONTROL|Patient with serum 25-Hydroxy vitamin D level >27.32
10172918|NCT03867942|Active Comparator|monolayer group|monolayer of Gemigliptin/Rosuvastatin
10172919|NCT03867942|Experimental|bilayer group|bilayer of Gemigliptin/Rosuvastatin
10172920|NCT03867994|Experimental|Group (A)|included 49 patients who received high dose statin (80 mg atorvastatin) 12 hours before CC and 40 mg just before CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
10172921|NCT03867994|Experimental|Group (B)|included 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continued for 24 hours after the CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
10172922|NCT03867994|Experimental|Group (C)|included 47 patients who did not receive any medications but only hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization
10187048|NCT03730077|Experimental|18F-MISO PET/CT Test Retest|Up to 5 of the 30 intended subjects will participate in a test-retest group that will undergo a second 18F-FMISO scan. Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
9975354|NCT03635749|Active Comparator|DAPT + immediate high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.
9525786|NCT03234816|Experimental|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
9525787|NCT03234816|Experimental|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
9525788|NCT03234803|Experimental|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
9525789|NCT03234803|Active Comparator|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
9525790|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
9525791|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
10172923|NCT03867877|Experimental|Periodized Training with Motor Practice|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
10172924|NCT03867877|Experimental|Simple Periodized Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and 60-75% of subjects' maximum strength for the hypertrophy day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down
10172925|NCT03867617|Experimental|Study group|Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients
10172926|NCT03867617|Active Comparator|Control group|Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients
9525792|NCT03234842|Experimental|Proton|Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
10172927|NCT03867760|Experimental|Intervention Group|Participants will use the recorded hypnosis intervention (RHI) at home for 28 days.
9525793|NCT03234842|Active Comparator|Photon|Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
9525794|NCT03234777|Experimental|Whiteboard animation video|3 minute video on treatment, management of pediatric acute gastroenteritis
9525795|NCT03234777|Sham Comparator|Regular video|3 minute video on hand washing for infection control
9525796|NCT03234712|Experimental|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
9525797|NCT03234595|Experimental|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
9525798|NCT03234543|Experimental|Remote Ischemic Conditioning|The RIC intervention consists of 5 minutes of inflation of a pneumatic tourniquet placed mid-thigh followed by 5 minutes of deflation, repeated for 3 cycles. The pressure used will be 250 mmHg for the pre-operative intervention. Subsequent tourniquet pressures will be 50 mmHg above the patient's systolic blood pressure.
9525799|NCT03234543|Sham Comparator|No Remote Ischemic Conditioning|The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
9525800|NCT03234673|Experimental|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
9525801|NCT03234673|Experimental|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
9525802|NCT03234673|Experimental|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
9672517|NCT05034445||Tissue group|Clinical data review to obtain corresponding tissue samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (tissue 1000X)
10172928|NCT03867760|Active Comparator|Attention Control Group|Participants will use a recorded relaxation intervention at home for 28 days.
9525803|NCT03234621|Experimental|conventional tidal group|provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
9525804|NCT03234621|Experimental|low tidal group|provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
9525805|NCT03234621|Experimental|high tidal group|provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
9525806|NCT03234647|Experimental|AHF patients|AHF patient treatment with the Doraya catheter
9525807|NCT03234530||WTC responders|WTC Health Program participants
9525808|NCT03234530||Urban workers|Control group of urban workers in NYC not exposed to the dust from the WTC
9525809|NCT03234725||LCI out group|The whitdrawal of the colonoscop happen in LCI mode.
9525810|NCT03234725||WL (white light) out group|The whitdrawal of the colonoscop happen in WL mode.
9525811|NCT03234517|Experimental|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
9525812|NCT03234517|Active Comparator|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
9694933|NCT04783766|Experimental|CK-3773274 for Multiple Dose (MD) Cohort|Subjects will receive multiple doses of CK-3773274
9525813|NCT03234452|Experimental|Lactoflorene plus|10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day
9525814|NCT03234452|Placebo Comparator|Placebo Lactoflorene plus|Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.
9525815|NCT03234426|Experimental|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
9525816|NCT03234426|Placebo Comparator|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
9525817|NCT03234257|Other|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
10172929|NCT03867539|Active Comparator|Control Group; Bupivacaine + opioids|"This is the standard of care arm. This group will receive pre-operative opioid education and standard of care, which consists of an injection of 10cc bupivacaine (plus ~1cc epinephrine and bicarbonate) into the carpal tunnel and overlying skin pre-operatively, and a post operative prescription for opioids (oxycodone/acetaminophen 5/325). Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies."
9525818|NCT03234634|No Intervention|Group 1: patients with good collateral|
9525819|NCT03234634|Experimental|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
9525820|NCT03234634|No Intervention|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
9525821|NCT03234491|Active Comparator|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
9975355|NCT03635749|Other|DAPT + delayed high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.
9975356|NCT03635749|Other|Aspirin+immediate high-intensity statin|This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.
9975357|NCT03635749|Placebo Comparator|Aspirin+delayed high-intensity statin|This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.
9975358|NCT03633955|Active Comparator|Standard therapy|This Arm will accrue patients receiving standard therapy (e.g. chemotherapy for leukemia).
9975359|NCT03633955|Experimental|Immunotherapy|The other Arm will include patients receiving immunotherapy
9975360|NCT03630159|Experimental|Tisagenlecleucel+Pembrolizumab|
9975361|NCT03607370|No Intervention|Group 1|The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy
9525822|NCT03234491|Active Comparator|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
9525823|NCT03234491|Active Comparator|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
9528040|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
9528041|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
9528042|NCT03214562|Experimental|Treatment (venetoclax, FLAG-IDA)|See detailed description.
9528043|NCT03214510|Experimental|Arm I (TAE)|Patients undergo placement of thoracic epidural catheter before surgery. Patients receive hydromorphone hydrochloride and bupivacaine via thoracic epidural catheter every 10 minutes or 3 hours as needed. Patients may receive fentanyl and bupivacaine or plain bupivacaine via thoracic epidural catheter.
9694934|NCT04783766|Placebo Comparator|Placebo comparator for MD Cohort|Subjects will receive multiple doses of placebo comparator
9694935|NCT04783909||PEX|42 eyes with PEX syndrome and coexisting cataract
9694936|NCT04783909||Control|38 eyes with cataract only
9694937|NCT04783753|Experimental|EDP-514 and Itraconazole interaction (Part 1)|
9694938|NCT04783753|Experimental|EDP-514 and Carbamazepine interaction (Part 2)|
9694939|NCT04783753|Experimental|EDP-514 and Quinidine interaction (Part 3)|
9694940|NCT04783727|Experimental|Experimental arm|The individualised treatment durations defined by the RNA transcriptomic signature-based model
9694941|NCT04783727|No Intervention|Control arm|The locally accepted standard duration of treatment based on the WHO recommendation for treatment of MDR-TB patients
9525824|NCT03234556|Active Comparator|Arm I (SR-Bx)|Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
9525825|NCT03234556|Experimental|Arm II (MRI, MRUS-Bx, SR-Bx)|"Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.~If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.~If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx."
9525826|NCT03234244|Active Comparator|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
9525827|NCT03234244|Active Comparator|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
9525828|NCT03234244|Experimental|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
9525829|NCT03234699|Experimental|Single Group|
9672518|NCT05034445||Plasma group|Clinical data review to obtain corresponding plasma samples from more than 30 newly diagnosed advanced NSCLC patients with 520 Panel sequencing (plasma 10000X)
9672519|NCT05034588||Intensiv care patients after acute kidney injury|Patients with condition after intensive care stay and acute kidney injury and subsequent convalescence (without preexisting underlying cardiac disease or other disease with potential cardiac involvement).
9672520|NCT05034588||Intensiv care patients without kidney injury|Patients with condition after intensive care stay and subsequent convalescence (without kidney injury and preexisting underlying cardiac disease or other disease with potential cardiac involvement).
9672521|NCT05034224|Sham Comparator|Sham|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is kept deflated.
9672522|NCT05034224|Active Comparator|Coronary sinus occlusion|The index of microvascular resistances will be measured while a balloon placed in the coronary sinus is inflated.
9672523|NCT05034406|Experimental|Lidocaine group|A total amount of 6 mL of 2% lidocaine was injected at the three trocar insertion sites (2 mL at each insertion site) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
9672524|NCT05034406|Experimental|Levobupivacaine|Total amount of 6 mL of 0.5% levobupivacaine was injected at the three trocar insertion sites (2 mL at each) prior to incision and 10 mL of 2% lidocaine was injected at the end of procedure, under the direct visualization of laparoscope, below and around the defect of the peritoneum at the site of varicocele.
9672525|NCT05034406|No Intervention|Control group|No local or peritoneal administration of any local anesthetic prior, during and after the surgical procedure
9672526|NCT05034146|Experimental|68Ga-FAPI PET/CT in malignant tumors|Investigators select subjects from patients who have underwent whole-body 18F-FDG PET/CT scan for suspected or confirmed malignancy, or suspected recurrence and metastasis after treatment for malignant tumors, focusing on malignant tumors with low FDG uptake including glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases. Then the subjects receive whole-body 68Ga-FAPI PET/CT scan with time interval of one to four week.
9672527|NCT05034107|Experimental|Persons with dementia|Persons who have been diagnosed with dementia by their physicians and in nursing homes. Persons with dementia who have at least one symptom of BPSD and willing to participate in this study. These participants will be exposed to diffused Ylang-Ylang aromatherapy.
9672528|NCT05034185||Patients with one or more polyps detected|"During colonoscopy, the Clinician inspect for the presence of polyps as per routine clinical practice with the CAD EYE function turned off. When a polyp is encountered, the Clinician will make a prediction on the histology based on the white light and BLI features of the polyp with and without optical magnification, as per routine clinical practice. Following this, the CAD EYE function will be switched on and the Clinician will take note of the CADx prediction for the same polyp, which will be either neoplastic or hyperplastic.~In addition, other polyp features such as the size and location will be recorded, which is similar to what is performed in routine clinical practice. The polyp will be resected and sent for pathological examination, which will form the gold standard for the diagnosis of polyp histology."
9672529|NCT05034211|Active Comparator|Programmed intermittent Bolus Epidural technique|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered every 60 minutes via an epidural catheter placed for labor analgesia on L2-L3/L3-L4 level
10172930|NCT03867539|Experimental|Experimental Group: Exparel, no opioids|This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of ~5cc of Exparel (liposomal bupivacaine), ~5cc of bupivacaine, and ~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
9525830|NCT03234439|Experimental|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
9672530|NCT05034211|Active Comparator|Provider administered bolus epidural technique on patient request|10ml ropivacaine 0,2% and 1,5 mcg/ml fentanyl, will be administered by the provider on patient request
9525831|NCT03234439|No Intervention|Waitlist Control|The waitlist control group will gain access to the myStrength platform 60 days following the start of the study.
9694942|NCT04783636|Other|A|After a single administration of PT105R (leuprorelin acetate 3.75mg), a single administration of PT105 (leuprorelin acetate 3.75mg)
10172931|NCT03867786|Experimental|Exercise Condition|Participants will undergo a 40 minute exercise protocol
10172932|NCT03867786|Active Comparator|Video Control Condition|Participants will view a 40 minute nature video
9525832|NCT03234283|Experimental|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
9525833|NCT03234400|Experimental|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
9525834|NCT03234400|Experimental|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
10172933|NCT03867773|Experimental|4-hour Time restricted feeding|4-h TRF subjects will consume food ad libitum between 3pm and 7pm (4-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 3pm (20-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
10172934|NCT03867773|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits. Controls will visit the research center at the same frequency as the TRF groups (for outcome measurements).
9525835|NCT03234400|Experimental|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
9525836|NCT03234231|No Intervention|Control Group|This group receive nothing during the study period.
9525837|NCT03234231|Experimental|Intervention Group|A 3-month supervised tooth brushing programme will be provided to the students. An oral health education talk with written material delivered to the carers and the students
9975362|NCT03607370|Experimental|Group 2|The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy
10187049|NCT03730077|Experimental|18F-MISO PET/CT|The investigators anticipate enrolling up to 30 subjects who will undergo 18F-FMISO PET/CT.Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
9525838|NCT03234478||GBA mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
9525839|NCT03234478||non-mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
9525840|NCT03234478||GBA mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
9525841|NCT03234478||non-mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
9525842|NCT03234348|Experimental|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
9525843|NCT03234348|Placebo Comparator|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
9525844|NCT03234660|Experimental|Dexmedetomidine|dexmedetomidine infusion
9525845|NCT03234660|Placebo Comparator|control|placebo infusion
9525846|NCT03234504||Normal healthy volunteers|
9525847|NCT03234322|Experimental|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
9525848|NCT03234322|No Intervention|Control group|In the control group the routine health check is conducted.
9525849|NCT03234270|Experimental|F35 pilots|
9525850|NCT03234270|Active Comparator|F15 pilots|
9525851|NCT03234296|Active Comparator|Antibiotic treatment|Ertapenem 1 g x 1 intravenously for 3 days, followed by per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days, duration of treatment 7 days.
9525852|NCT03234296|Active Comparator|Placebo|Intravenous placebo once a day for 3 days, followed by per oral placebo for 4 days with similar p.o. tablets as in the antibiotic group.
9525853|NCT03234387||Cystic fibrosis (CF) with established CF-related diabetes|"Cystic fibrosis (CF) with established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat) and, where possible, diagnostic genotyping~Established CFRD in accordance with the most recent American Diabetes Association positional statement]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:~2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)~Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)~Glycated hemoglobin ≥ 48 mmol/mol~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
9525854|NCT03234387||Cystic fibrosis (CF) without established CF-related diabetes|"Cystic fibrosis (CF) without established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired~No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; [110]).~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
9525855|NCT03234387||Healthy controls|Age- and gender-matched healthy control participants.
9525856|NCT03234205|Experimental|MRI scan during free respiration|
9525857|NCT03234192|Active Comparator|Therapeutic ultra sound|
9525858|NCT03234192|Active Comparator|Astym Treatment Technique|
9525859|NCT03234192|Active Comparator|Graston Treatment Technique|
9525860|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
9525861|NCT03233828|Experimental|Intralesional IL-2 Injection|Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
9525862|NCT03233828|Placebo Comparator|Saline Injection|Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
9525863|NCT03234049|No Intervention|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
9525864|NCT03234049|Experimental|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
9525865|NCT03233919|Experimental|CORIC|"Comprehensive remote ischaemic conditioning (CORIC) will be induced using an automated RIC device:~Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
9525866|NCT03233919|No Intervention|Non-CORIC|Controls did not undergo comprehensive remote ischaemic conditioning.
9525867|NCT03233841||Living non-HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have not undergone hematopoietic stem cell transplantation (HSCT).
9525868|NCT03233841||Living HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have undergone hematopoietic stem cell transplantation (HSCT).
9525869|NCT03233841||Deceased Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are deceased (including patients who may or may not have undergone hematopoietic stem cell transplantation).
9525870|NCT03234140||"Group Genome Wide Association Studies"|"Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :~PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396~RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441~FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229~MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178~MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321~Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data."
9525871|NCT03234140||"Group EPIC"|"Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).~The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals."
9525872|NCT03234062|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
9525873|NCT03234062|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
9525874|NCT03234062|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
9525875|NCT03234062|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
9525876|NCT03234062|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
9525877|NCT03234062|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
9525878|NCT03234075||Control group|Patients supported without regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region and French Center region
9525879|NCT03234075||Intervention group|Patients supported with the regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region
9525880|NCT03233932|Active Comparator|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
9525881|NCT03233932|Experimental|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
9525882|NCT03233880|Active Comparator|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
9525883|NCT03233880|Placebo Comparator|placebo group|- Matching placebo orally, single dose
9525884|NCT03234088|Other|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
9525885|NCT03233984|No Intervention|Leaflet only|Women will only receive a leaflet about endocrine disruptor at home.
9525886|NCT03233984|Active Comparator|non immersive program|In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
9525887|NCT03233984|Experimental|immersive program|In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
9525888|NCT03234127|Other|Atherosclerosis- resistance|FH Patient without atherosclerosis
10187050|NCT03730064|Experimental|Bipolar depressed|
9525889|NCT03234127|Other|Control|FH patient with atheroclerosis
9525890|NCT03234127|Other|the related population without familial hypercholesterolemia|No FH patient
9525891|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
9975363|NCT03599791|Experimental|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
9975364|NCT03599791|Active Comparator|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
9525892|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
9525893|NCT03233971||Older adults|
9525894|NCT03233971||Caregivers|
9525895|NCT03233893|Experimental|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
9525896|NCT03233893|Active Comparator|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
9975365|NCT03599791|Active Comparator|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
9975366|NCT03593629|No Intervention|Standard of Care|Participants receive standard of care for PrEP, including 3-months of PrEP supply and HIV testing at clinic every three months
9975367|NCT03593629|Experimental|Blood-based HIV self-testing|Participants receive 6-months of PrEP supply and blood-based HIV self-tests for quarterly HIV testing.
9975368|NCT03593629|Experimental|Oral fluid HIV self-testing|Participants receive 6-months of PrEP supply and oral fluid HIV self-tests for quarterly HIV testing.
9525897|NCT03233997|Experimental|FT21018 Group|7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
9525898|NCT03233997|Experimental|FT21033 Group|7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
9525899|NCT03233997|Experimental|FT21034 Group|7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
9525900|NCT03233997|Experimental|FT21035 Group|7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
9525901|NCT03234153|Experimental|Durvalumab and Tremelimumab|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
9525902|NCT03234023|Active Comparator|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
10172935|NCT03867773|Experimental|6-hour Time restricted feeding|6-h TRF subjects will consume food ad libitum between 1pm and 7pm (6-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 1pm (18-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
10172936|NCT03867695|Experimental|Serratus Block|"At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.~Under ultrasonography assistance, block will be performed at the fifth rib in the midaxillary line. Local anesthetic will be injected either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of ropivacaine will be prepared identically by the central pharmacy, without any possible identification of the product."
9525903|NCT03234023|No Intervention|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
9975369|NCT03556020|Experimental|High Dose Group|Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
9525904|NCT03233906|Active Comparator|Chia Seeds|10% of a participants total kcal estimated needs given in chia seeds everyday for 8 weeks.
9525905|NCT03233906|No Intervention|Control|Habitual diet with avoidance of high fiber and high omega-3 fatty acid foods.
9525906|NCT03233776|Experimental|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
9525907|NCT03234010|Experimental|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
9525908|NCT03234010|Experimental|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
9525909|NCT03234010|Experimental|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
9525910|NCT03234010|Experimental|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
9694943|NCT04783636|Other|B|After a single administration of PT105 (leuprorelin acetate 3.75mg), a single administration of PT105R (leuprorelin acetate 3.75mg)
9694944|NCT04783922||Benign Hematoma|Patients (having novel image markers or clinical features) suggestive of a benign hematoma relatively , that is having relatively good prognostic outcome and less likely to expand.
9694945|NCT04783922||Malignant Hematoma|Patients (having novel image markers or clinical features) suggestive of a malignant hematoma relatively, that is more likely to expand and have poor prognostic outcome.
9694946|NCT04783623||Non-recurrence group|
9694947|NCT04783623||Recurrence group|
9694948|NCT04784026||Healthy Control Group|Healthy children who come to Afyonkarahisar Ege Youth and Sports Club Association for the purpose of sports, newly registered and between the ages of 6-18 will constitute the control group of the study.
9694949|NCT04784026||Case Group|The sample of the study will be inpatient and outpatient pediatric patients between the ages of 6-18 who have been diagnosed with cancer in the Pediatric Hematology-Oncology Clinics of Afyonkarahisar Health Sciences University Health Application and Research Center Department of Pediatrics.
10172937|NCT03867695|Placebo Comparator|Placebo Block - Control Group|"Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution. Under ultrasonography assistance, placebo will be injected at the fifth rib in the midaxillary line, either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of sterile saline will be prepared identically by the central pharmacy, without any possible identification of the product."
10172938|NCT03867604|Sham Comparator|Sham injection|Subcutaneous injection at upper trapezium muscle level
9525911|NCT03233802|Experimental|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
9525912|NCT03233802|Active Comparator|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
9525913|NCT03233802|Active Comparator|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
9525914|NCT03233672|Other|Hypo-fractionated postoperative IMRT-SIB|All patients underwent combined, intensified and modulated radiotherapy for five days a week with the following doses: 62.5 Gy to the prostate bed and 45 Gy to pelvis nodes in 25 fractions.
9525915|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
10172939|NCT03867604|Experimental|Fascia injection|Fascia injection, below upper trapezium muscle
10172940|NCT03867799|Experimental|Nivolumab and Relatlimab|Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks
9525916|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
9525917|NCT03233516||Cases with clinical CAP|Children 1-59 months at Sachs' Children and Youth Hospital with clinical CAP (both severe and non-severe) according to WHO-criteria.
9672531|NCT05033977|Experimental|Center-based Exercise|"patients did exercises with a physical therapist in a clinic 3 days and 45 minute in a week for 6 weeks.~The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings."
10172941|NCT03867669|Experimental|Single Patient Room|Patients randomized to this arm will be admitted to a NICU single patient room.
10172942|NCT03867669|Placebo Comparator|Open Bay|Patients randomized to this arm will be admitted to the open bay NICU Unit.
10172943|NCT03867656|Experimental|GLP-2|Glucagon-like peptide 2
10172944|NCT03867656|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
10172945|NCT03867656|Placebo Comparator|Placebo|Saline
10172946|NCT03867578|Other|Exploratory Phase - Standard CT Imaging and HR-MRI|The goal is to test several different novel Magnetic Resonance sequences to determine which gives the best visualization of peritoneal disease.
10172947|NCT03867578|Other|Testing Phase- Conventional and HR-MRI and Ultrasound|Patients will undergo conventional and HR-MRI imaging as well as abdominal ultrasound to define the performance of these methods.
10172948|NCT03867565|No Intervention|No nutritional diagnosis|Patients without nutritional diagnosis get SOC
10172949|NCT03867565|Experimental|Nutritional diagnosis|Patients with nutritional diagnosis get nutritional intervention by dietitian.
10172950|NCT03867591|Experimental|Gastro-AD® Group|The participants randomized to this group 1 g of Gastro-AD® powder per sachet + flavoring agents.
10172951|NCT03867591|Placebo Comparator|Placebo Group|Participants in this arm will take a sachet containing maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
10172952|NCT03867513||mTBI cases|Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
10172953|NCT03867513||Acute trauma controls|Non-head trauma controls matched for age and sex with the mTBI group
10172954|NCT03867864|Experimental|Group A|Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
10172955|NCT03867864|Other|Group B|The group B will wear the necklace without essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace with essential oil for last 4 weeks (the sixth to ninth weeks).
10172956|NCT03867851|Experimental|IBsolvMIR|Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
10172957|NCT03867851|Active Comparator|Heparin|Heparin treatment according to clinical praxis.
10187051|NCT03730038|Experimental|Pitavastatin treatment|Treatment of pitavastatin 4 mg qd for 12 weeks
10172958|NCT03867708||patients with residual shunt|patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
10172959|NCT03867708||patients without residual shunt|patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
9525918|NCT03233516||Control subjects|Children 1-59 months at Sachs' Children and Youth Hospital treated for a minor orthopedic (elective (e.g. hand surgery) or acute) or minor surgical disease, e.g. minor trauma (excluding e.g. appendicitis, major burns, major trauma).
9525919|NCT03233646|Experimental|Case|500 patients with MCI and/or AD, PD, multiple sclerosis, and Huntington's disease.or other neuro-degenerative disease
9525920|NCT03233646|Active Comparator|Controls|Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD/PD/MS/Huntington's Disease or other neuro-degenerative disease.
9525921|NCT03233581|Experimental|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
9525922|NCT03233581|Active Comparator|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
9525923|NCT03233685|Experimental|Experimental Group|Subjects will perform a visual training for 12 weeks
9525924|NCT03233685|Active Comparator|Control Group|Subjects will perform the normal training routine for 12 weeks
9525925|NCT03233750|Experimental|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
9525926|NCT03233750|Active Comparator|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
9975370|NCT03556020|Experimental|Low Dose Group|Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
9975371|NCT03526432|Experimental|Bevacizumab + Atezolizumab|
9975372|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
9525930|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
10172960|NCT03867721|Experimental|Ventilator PB560 (Covidien)|The non-dedicated (NON-DED) set comprised a ventilator for MPV (PB560) using a single active tubing with an exhalation valve. A custom-made arm support and plastic mouthpiece were used.
10172961|NCT03867721|Experimental|Ventilator Trilogy (Philips Respironics)|The dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
10172962|NCT03867812|No Intervention|Fasting + alcoholic drink|No food (0 calories) but 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
10172963|NCT03867812|Experimental|SOBAR bar + alcoholic drink|One 70g bar (210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
10187052|NCT03730038|Active Comparator|Life-style modification|
9525931|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
9672532|NCT05033977|Experimental|Home-based exercise|Patients did exercises at home every day and 3 times per day. The exercise programe included strenghtening and streching exercises. Strenghtening exercises for lower extremity and streching exercises for hamstrings.
9672533|NCT05033873|Experimental|Group A: Universal Exercise Unit Therapy (UEU)|This experimental group will be given universal exercise unit therapy.
9525932|NCT03233399|Active Comparator|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
9525933|NCT03233399|Active Comparator|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
9525934|NCT03233607||Antepartum Patients|Includes antepartum patients receiving prenatal care at the Broadway Practice who plan to deliver at Allen Hospital in New York City (NYC). On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
9672534|NCT05033873|Experimental|Group B: Sling Exercise Therapy (SET)|This experimental group will be given sling exercise therapy
9672535|NCT05033873|Other|Group C: Control Group|Control group will be given routine physical therapy
9975373|NCT03502330|Experimental|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
9975374|NCT03502330|Experimental|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
9975375|NCT03502330|Experimental|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
9975376|NCT03502330|Experimental|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
9975377|NCT03502330|Experimental|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
10172964|NCT03867812|Active Comparator|Control food + alcoholic drink|48.5g of General Mills Chexmix (Honey Nut Flavor, 210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
10172965|NCT03867812|Active Comparator|Full meal + alcoholic drink|Stouffer's Bistro Crostini 5 Cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie (635 calories total) followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
10172966|NCT03867630||Runoff Group|Runoff group are the patients whose images were shown root shadow by contrast media.
10172967|NCT03867630||Nonrunoff-Transforaminal group|Nonrunoff-Transforaminal group are the patients whose images are not shown root shadows by contrast media, so additional transforaminal blocks are done.
10172968|NCT03867630||Nonrunoff-NonTransforaminla group|Nonrunoff-NonTransforaminal group are the patients whose images are not shown root shadows by contrast media, but no additional transforaminal blocks are done.
10172969|NCT03867747|Experimental|Cardiac Radiosurgery|25 Gy in a single fraction
9672536|NCT05034120|Experimental|MB:Single arm|10 subjects will be enrolled in this arm. The subjects will take a single dose XZP-3621 tablet after a low-fat meal and perform excretion collection consistently.
9672537|NCT05034120|Experimental|FE:Arm A|Cycle1 Day1: fasting; Cycle2 Day10: High-fat meal; Cycle3 Day19: Low-fat meal
10172970|NCT03867474|Experimental|Intervention (MBSR)|Mindfulness-Based Stress Reduction (MBSR) - Intervention Arm
10172971|NCT03867474|No Intervention|Control - Usual Care|Control
10172972|NCT03867461|Active Comparator|Group A|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group A: Initial Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-80 mmHg, End tidal CO2 38-40 mmHg."
10172973|NCT03867461|Active Comparator|Group B|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group B: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg,"
10172974|NCT03867461|Active Comparator|Group C|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group C: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 24-26 mmHg, Subsequent Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg,"
10172975|NCT03867461|Active Comparator|Group D|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group D: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-100 mmHg, End tidal CO2 24-24 mmHg,"
10172976|NCT03867097|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
10172977|NCT03867097|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
10172978|NCT03867136|Experimental|PZA sensitivity guided ultra-short all Oral Regimen|The PZA sensitivity guided ultra-short regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of levofloxacin, linezolid, cycloserine, pyrazinamide, and clofazimine. Then based on molecular PZA drug sensitivity results, patients will be in divided into two sub-groups: pyrazinamide-susceptible (PZA-S) patients and pyrazinamide-resistant (PZA-R) patients. The Regimen for PZA-S patients, consisting of levofloxacin, linezolid, cycloserine, and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week). PZA-R sub-group regimen, consisting of levofloxacin, linezolid, cycloserine, and clofazimine given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week)
10172979|NCT03867136|Active Comparator|Standardized Shorter Regimen|WHO standardized shorter regimen group consists of 36-44 weeks with two phases of treatment. The first is an intensive phase of 16 weeks (extended up a maximum of 20 or 24 weeks in case of lack of smear conversion at the end of 16 or 20 weeks), and included moxifloxacin, amikacin, prothionamide, pyrazinamide, high-dose isoniazid, ethambutol and clofazimine. This is followed by a continuation phase of 20 weeks with the following agents: moxifloxacin, pyrazinamide, ethambutol and clofazimine.
10172980|NCT03867071|Experimental|erythropoietin (EPO) group|
9525935|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：~Clinical diagnosis of Posner-Schlossman Syndrome~Able to communicate with doctor and understand this study~Exclusion criteria:~Not be able to communicate with doctor and understand this study~One or more authorized investigators think he or she will suffer from any severe risks from the study"
9672538|NCT05034120|Experimental|FE:Arm B|Cycle1 Day1: High-fat meal; Cycle2 Day10: Low-fat meal; Cycle3 Day19: fasting
9975378|NCT03502330|Experimental|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
9975379|NCT03502330|Experimental|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
9975380|NCT03502330|Experimental|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
9672539|NCT05034120|Experimental|FE:Arm C|Cycle1 Day1: Low-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: High-fat meal
9975381|NCT03502330|Experimental|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
9672540|NCT05034120|Experimental|FE:Arm D|Cycle1 Day1: fasting; Cycle2 Day10: Low-fat meal; Cycle3 Day19: High-fat meal
9672541|NCT05034120|Experimental|FE:Arm E|Cycle1 Day1: High-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: Low-fat meal
10172981|NCT03867071|Placebo Comparator|Placebo (PLA) group|
10172982|NCT03867279|Experimental|Flossing|The subjects included in this group will perform a protocol of reeducation exercises plus the application of the Flossing technique. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
10172983|NCT03867279|Active Comparator|Reeducation exercises|The subjects included in this group will carry out a protocol of reeducation exercises. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
10172984|NCT03867370|Experimental|Group A|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
10172985|NCT03867370|Experimental|Group B (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.
10172986|NCT03867370|Active Comparator|Group C (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
10172987|NCT03867175|Experimental|Arm 1 Stereotactic Body Radiation Therapy/Pembrolizumab|3-10 treatments of SBRT/ pembrolizumab IV for 30 minutes every 3-4 weeks for 1 year at doctor's discretion.
9672542|NCT05034120|Experimental|FE:Arm F|Cycle1 Day1: Low-fat meal; Cycle2 Day10: High-fat meal; Cycle3 Day19:fasting
10172988|NCT03867175|Experimental|Arm 2 Pembrolizumab|Patients receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
10172989|NCT03867253|Active Comparator|ORY-2001 Low dose|0.6mg ORY-2001 capsule
10172990|NCT03867253|Active Comparator|ORY-2001 High dose|1.2mg ORY-2001 capsule
10172991|NCT03867253|Placebo Comparator|Placebo|Placebo capsule
10172992|NCT03867214|Experimental|Experimental|"Receiving TXA, Study group~Tranexamic acid, Study group tranexamic acid 1g,~intravenous injection, pre-operationally"
10172993|NCT03867214|Placebo Comparator|Placebo Comparator|"Normal saline, Control group~Not receiving tranexamic acid, Control group Normal~saline 100mL, intravenous injection, pre-operationally"
10172994|NCT03867292|Experimental|Myofascial|The subjects that include the experimental group will receive an intervention through myofascial therapy of crossed hands and electrotherapy
10172995|NCT03867292|Active Comparator|Electrotherapy|The subjects that are included in the experimental group will receive an intervention through electrotherapy
10172996|NCT03867396|Active Comparator|Cochlear Implant and Hearing Aid|Subject wears a hearing aid on the contralateral side of the cochlear implant. Subject will use a clinic-loaned Naida hearing aid for listening tests.
10172997|NCT03867396|Active Comparator|Cochlear Implant alone|Subject only uses the cochlear implant; hearing on the contralateral side is unaided.
10172998|NCT03867396|Experimental|Cochlear Implant and CROS|Subject wears the CROS device on the contralateral side of the cochlear implant. Subject will use a clinic-loaned CROS device.
9525936|NCT03233477||cataract|"Inclusion criteria：~Clinical diagnosis of age-related cataract~Prepare for cataract operation~Open angle and intraocular pressure is normally at anytime~No family history of glaucoma~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
9826720|NCT02430870|Experimental|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
10172999|NCT03867331|Experimental|5 microgram VLPM01|5 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
10173000|NCT03867331|Experimental|15 microgram VLPM01|15 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
10173001|NCT03867331|Experimental|30 microgram VLPM01|30 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
10173002|NCT03867331|Experimental|Controlled Human Malaria Infection (CHMI) Phase|Infectivity Control Participants, n=6
10173003|NCT03867058||Cochlear implant users with Nucleus and AB devices|"Temporal processing acuity will be compared using electrodes or electrode configurations that create broad versus sharp spatial excitation.~Speech recognition will be compared in the same group of subjects using electrode-dependent focused versus monopolar stimulation."
10173004|NCT03867123|Experimental|Arm 1 (chemoradiation phase)|"Radiotherapy (RT) + temozolomide (TMZ) + 2-OHOA (during Concurrent phase - duration 6 weeks)*:~2-OHOA will be initiated at the start of the concurrent phase and will be administered on a continuous daily basis together with TMZ and RT for 6 weeks at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~RT will be administered only during the concurrent phase, consisting of fractionated focal irradiation administered using 1.8- 2 Gy/fraction, daily for 5 days/week for 6 weeks, for a total dose of up to 60 Gy.~TMZ will be administered during the concurrent phase at a starting dose of 75 mg/m2/day given daily for 6 weeks.~* One extra week may be allowed."
10173005|NCT03867123|Experimental|Arm 2 (maintenance phase)|"TMZ + 2-OHOA (during Maintenance phase with TMZ 200 mg/m2/day at Cycle 2 - duration 8 weeks):~2-OHOA will be initiated on day 2 of Cycle 2 of the maintenance phase, when TMZ 200 mg/m2/day is given and administered on a continuous basis for two 28-day cycles. 2-OHOA will be administered at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~TMZ will be administered at 200 mg/m2/day given daily the first 5 days for two 28-day cycles (if no toxicity is seen). In case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery.~Both arms will be followed by a 4-week safety follow-up"
10187053|NCT03730025|Experimental|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
9528044|NCT03214510|Experimental|Arm II (TAP)|Patients undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block. Patients receive plain bupivacaine and liposomal bupivacaine via TAP block.
9672543|NCT05034055|Experimental|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
9672544|NCT05034003|Experimental|zirconia crowns|Zirconia crowns placed on primary incisor teeth
10173006|NCT03867162|Experimental|Live Attenuated Tularemia Vaccine|0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4
9672545|NCT05034003|Experimental|composite strip crowns|composite strip crowns placed on primary incisor teeth
9672546|NCT05034003|No Intervention|Control tooth|Caries-free primary incisor tooth
9672547|NCT05034198|No Intervention|Stakeholder Input|Behavioral health staff (BHS) will be asked to complete two semi-structured qualitative interviews and a set of surveys. The first interview will be about perceived barriers and facilitators on utilizing a remote training platform. The second interview will cover perceived feasibility and acceptability of the proposed training, consultation, and the implementation of evidence-based practices. The surveys will ask about the perceived acceptability, appropriateness, and feasibility of the remote training platform.
9672548|NCT05034198|No Intervention|Asynchronous Training|Mental health trainers with expertise in the treatment of externalizing and internalizing behavior disorders will video-record the training modules and produce them using lecture capture technology (i.e., showing speaker and Power Point slides on a split screen). Each training module will be approximately 45 minutes long. BHS will be given a procedures manual with instructions on how to access the video-recorded training modules on-demand.
9672549|NCT05034198|Experimental|Synchronous Training|After completing the first mini-trial, Investigators will develop manuals and procedures for the synchronous (interactive) portion of the training. The specific components of the synchronous remote training, as well as session length and frequency, will be determined by the results of preliminary studies and Aim 1 of the proposed study. Research team consultants will provide remote consultation to BHS. The synchronous consultation will be conducted using a video-conferencing platform, and will have two main components: didactics and coaching.
9672550|NCT05033834||Group A|People received any registered COVID-19 vaccination
9672551|NCT05033834||Group B|People developed COVID-19 infection after partial or full vaccination with any registered COVID-19 vaccine
9672552|NCT05033795|Experimental|Water A|2 L of water A per day
9672553|NCT05033795|Other|Water B|2 L of water B per day
9672554|NCT05033665|Active Comparator|Euhydrated|Afternoon urine osmolality < 800 mmol/kg or urine specific gravity < 1.020.
9672555|NCT05033665|Experimental|Underhydrated|Afternoon urine osmolality ≥ 800 mmol/kg or urine specific gravity ≥ 1.020.
10173007|NCT03867149|Other|patient with first thalamic infarct|Patient with first thalamic infarct, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
9672556|NCT05033691|Experimental|Early SRS treatment with SoC|Stereotactic surgery (SRS) to the brain metastases and continuation of Osimertinib, at 2 month (8 weeks) post Osimertinib start
9672557|NCT05033691|Active Comparator|SoC Tagrisso treatment only|continuation of osimertinib alone
9672558|NCT05033769|Experimental|Eribulin|Arm A. Eribulin 1.23 mg/m^2, administered as an injection on day 1 and 8 q 21d for a maximum of 4 therapy cycles
9672559|NCT05033769|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m^2, administered as an injection on day 1, 8 and 15 q21d for a maximum of 4 therapy cycles
9975382|NCT03490045|Experimental|Intervention Condition|Postpartum women and their infants will be randomly assigned to the treatment condition and receive a diaper incentive for their participation.
9975383|NCT03490045|Active Comparator|Comparison Condition|Postpartum women and their infants will be randomly assigned to the control condition and will receive a conditional cash transfer of equivalent value of the diapers provided to the intervention group.
9975384|NCT03473782||Voiding Diary|
9975385|NCT03473782||Urodynamics Correlation Study|
9672564|NCT05033938|Active Comparator|Early Mobilization|Post-operatively subjects receive a removable wrist splint that can be taken off for early wrist mobilization
10173008|NCT03867149|Other|healthy subject matched with control|Healthy subject matched with control, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
9672565|NCT05033938|Active Comparator|Late Mobilization|Post-operatively subjects receive a splint and are not instructed to not move their wrist till the 2 week follow up visit.
9672566|NCT05034133|Experimental|Study arm|Patients with limited stage small cell lung cancer receive durvalumab with chemotherapy (Etoposide and Cisplatin) for receive 6 cycles, and then receive thoracic radiotherapy.
9672567|NCT05033899|Experimental|group E: ERAS group|36 non-insulin dependent diabetic patients will undergo lumbar decompression surgery following ERAS protocol.
9672568|NCT05033899|No Intervention|group C: conventional group|conventional perioperative care.
9672569|NCT05033860|Experimental|Intervention group|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and questionnaire surveys were conducted afterwards.
9672570|NCT05033860|No Intervention|Control group|Questionnaire surveys were conducted without leaflets distribution.
9672571|NCT05033951||Cohort 1|Patients who start NIV in the first two months after the first visit to the HMV
9672572|NCT05033951||Cohort 2|Patients who do not start NIV in the first two months after the first visit to the HMV.
9975386|NCT03453268|Other|1: Interventional (drug reduction)|"STEP DOWN strategy.~Proposition of reduction of the number of antihypertensive medication according to:~the systolic blood pressure levels,~co-morbidities"
9975387|NCT03453268|Other|2: Control|Usual treatment
9975388|NCT03447912|Experimental|Intervention Condition|Fourteen communities will be assigned to the intervention.
9525937|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：~Both eyes involved~Open angle~Progressive glaucomatous optic neuropathy~Specific visual field loss of glaucoma~Intraocular pressure above the up limit of normal people~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
9975389|NCT03447912|No Intervention|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
9525938|NCT03233620|Other|working age patients|Prospective cohort of 250 patients.
10173009|NCT03867409|Experimental|Concordant virtual human|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
9525939|NCT03233490|Experimental|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
9525940|NCT03233490|Experimental|CPR training intervention|CPR training without web course
9525941|NCT03233321|Experimental|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
9525942|NCT03233321|No Intervention|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
9525943|NCT03233451|Experimental|Interventional group|Subjects receive guided psycho-behavioral intervention once a week for 8 weeks. After 8 weeks, the subjects will receive monthly psychological counseling for 7 months.
10173010|NCT03867409|Experimental|Dis-concordant virtual human|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
9525944|NCT03233451|No Intervention|control group|Subjects will receive usual care and be contacted as same frequent as the intervention group.
10173011|NCT03867409|Experimental|Concordant text|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
10173012|NCT03867409|Experimental|Dis-concordant text|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
9525945|NCT03233269|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
9525946|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
9525947|NCT03233282|Other|Cognitive Fatigability|
9525948|NCT03233282|Other|Physical Fatigability|
9525949|NCT03233373||Otolaryngology Clinic Patients|Healthy subjects with no present complaints of nasal obstructions. Patients visiting the clinic, once consented, will be asked which nostril they breathe better from. They will then be asked to perform 3-4 normal respiration cycles through their nose which will be recorded using our thermal imaging device, the Seek CompactPro thermal imager
10173013|NCT03867240|Experimental|Gabapentin|Gabapentin is a common neuropathic medication used in the treatment of chronic pain. Gabapentin will be given preoperative and continued for 5 days postoperatively.
9525950|NCT03233334|Experimental|Purpose Project Group|Group receiving Purpose Project intervention.
9525951|NCT03233412|Other|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
9525952|NCT03233412|Experimental|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
9975390|NCT03445221|Active Comparator|Group I|Patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 5 days before surgery.
9975391|NCT03445221|Active Comparator|Group II|Patients will continue preoperative oral conventional diet.
9525953|NCT03233347|Experimental|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and dacarbazine IV over >= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 30 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.
9975392|NCT03429140|Experimental|Group 1 - Gel-One|Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3
9975393|NCT03429140|Placebo Comparator|Group 1 - Saline Placebo|3 ml saline placebo one time injection at visit 3
9525954|NCT03233295|Experimental|Vitamin D deficiency|
9525955|NCT03233243|Experimental|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
9525956|NCT03233243|No Intervention|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
9525957|NCT03233386||Condition 1|Mexico City Cohort
9525958|NCT03233386||Condition 2|Monterrey Cohort
9525959|NCT03233386||Condition 3|Guadalajara Cohort
9525960|NCT03233165|Experimental|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er:YAG laser"
9525961|NCT03233165|Experimental|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er,Cr:YSGG laser"
9525962|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
9525963|NCT03233178||Liraglutide|Patients initiation liraglutide
9525964|NCT03233178||Sitagliptin|Patients initiating sitagliptin
9525965|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
9525966|NCT03233113|Active Comparator|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
9525967|NCT03233113|Experimental|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
9525968|NCT03233087||Top third of subjects based levels of selected biomarker.|
9525969|NCT03233087||Middle third of subjects based levels of selected biomarker.|
10173014|NCT03867240|Placebo Comparator|Placebo|Control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group.
9525970|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
9525971|NCT03233152|Experimental|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
9525972|NCT03233061|Active Comparator|NO|NON OBESE WOMEN GROUP ( same age and same physical activities ) cardiorespiratory exercise testing with evaluation of peak oxygen uptake, heart rate and maximal cycling power output. Cardiorespiratory functioning is assessed during household activities such as ironing,cleaning floor,walking and climbing stairs.
9525973|NCT03233061|Experimental|OB|OBESE GROUP cardiorespiratory exercise testing with evaluation of peak oxygen uptake,heart rate and maximal cycling power output.Cardiorespiratory functioning is assessed during household activities such as ironing, cleaning floor, walking and climbing stairs
9525974|NCT03233100|Experimental|FMT group|
9525975|NCT03233035|Placebo Comparator|placebo group|Intranasal placebo pulverisation
9525976|NCT03233035|Active Comparator|Ketamine group|Intranasal ketamine pulverisation
9525977|NCT03232905|Experimental|PF-06651600|Multiple ascending doses of PF-06651600
9525978|NCT03232905|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
9525979|NCT03232918|No Intervention|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
9525980|NCT03232918|Experimental|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
9525981|NCT03232866|Experimental|Experimental group|(n = 20) will practice Pilates exercises
10173015|NCT03867019||Subjects with BPPV|"Patients diagnosed with BPPV, who meet the following criteria:~Main complain of spinning sensation (Vertigo) when changes are made in head position relative to gravity.~Positive Dix-Hallpike / Supine Roll Test, confirmed by presence of nystagmus."
10173016|NCT03867019||Subjects without BPPV (Control group)|Patients who do not suffer from dizziness / spinning sensation (Vertigo), and do not meet the exclusion criteria in the study.
10173017|NCT03867045|Experimental|mRCC treated with cabozantinib|Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
10173018|NCT03866980|Experimental|AK105 plus Carboplatin and Pemetrexed|Subjects receive AK105 200 mg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
9525982|NCT03232866|No Intervention|Control group|(n = 20) will not carry out the intervention
9525983|NCT03232996|Experimental|Experimental Group|Computer Game based balance and walk rehabilitation
9525984|NCT03233022|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
9525985|NCT03233022|Active Comparator|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
9525986|NCT03233022|Active Comparator|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
10173019|NCT03866980|Placebo Comparator|Placebo plus Carboplatin and Pemetrexed|Subjects receive placebo intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
10173020|NCT03867006|No Intervention|control group|Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).
10173021|NCT03867006|Experimental|protein group|Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
10173022|NCT03867006|Experimental|protein and carbohydrates group|Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
10173023|NCT03866993|Experimental|AK105 plus Carboplatin and Paclitaxel|Subjects receive AK105 200 mg intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
9525987|NCT03233022|Placebo Comparator|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
9525988|NCT03233022|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
9525989|NCT03232957|Experimental|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
9525990|NCT03232957|Experimental|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
9525991|NCT03232957|Experimental|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
10173024|NCT03866993|Placebo Comparator|placebo plus Carboplatin and Paclitaxel|Subjects receive placebo intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
9525992|NCT03233048|Experimental|ORBERA™ Intragastric Balloon|Participants will have the ORBERA™ Intragastric Balloon inserted for 6 months. In addition, participants will have ongoing visits with a physician, dietitian, and psychologist before the balloon is inserted, while its in place, and for 6 months after the balloon is removed, for a total of approximately 1 year.
9525993|NCT03233126|Experimental|KRN23|
9525994|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
9525995|NCT03232879|Experimental|Experimental 1|Motor Imagery
9826721|NCT02430870|Experimental|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
9826722|NCT02430870|Experimental|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
10173025|NCT03866954|Experimental|Intravenous administration of EE-TP|Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
10173026|NCT03866928|Experimental|Stiripentol|
9525996|NCT03232879|Experimental|Experimental 2|Action Observation
9525997|NCT03232879|No Intervention|Control Group|No intervention
9525998|NCT03232970|Experimental|FPD group|This group will undergo three months of weekly lectures to incorporate more fiber in their diet.
9525999|NCT03232970|No Intervention|FPD Control group|This group will receive all the assessments before, during and after the three months program period but will not attend the weekly lectures.
9528045|NCT03214614|Experimental|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
9528046|NCT03214614|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension
9528047|NCT03214614|Experimental|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
9528048|NCT03214614|Placebo Comparator|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
10173027|NCT03866850||Cochlear implant users with late-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration).~Examine neural spatial excitation patterns with long and short phase duration. Measure speech recognition using long and short phase duration stimulation patterns."
10173028|NCT03866850||Cochlear implant users with early-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration) and compare that with the late-onset group.~Examine neural spatial excitation patterns with long and short phase duration within the non-leaky phase duration range.~Measure speech recognition using long and short phase duration stimulation patterns."
9526000|NCT03232762|Active Comparator|Diet A|high proportion of calories from refined grains as a carbohydrate source
9526001|NCT03232762|Active Comparator|Diet B|a high proportion of calories from whole grains
9526002|NCT03232814|Experimental|Group-based walking|Participants will engage in one supervised outdoor group-based walking session per week for the 8 week program.
9526003|NCT03232788|Experimental|Test group|Bone regeneration with autogenous bone + scaffold.
9526004|NCT03232788|Active Comparator|Control group|Bone regeneration with autogenous bone + collagen membrane.
9526005|NCT03232775|Other|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
9526006|NCT03232775|Other|Control|Control: Physical Exam without Visual Pedagogy and Structure
9526007|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
9526008|NCT03232632|Experimental|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
9526009|NCT03232697|Other|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
9526010|NCT03232697|Other|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
9826723|NCT02430870|Placebo Comparator|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
10173029|NCT03866746|Active Comparator|Group A|received aflibercept injections alone
9526011|NCT03232697|Other|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
10173030|NCT03866746|Experimental|Group B|received 3 aflibercept injections followed by micropulsed laser
9526012|NCT03232697|Other|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
10173031|NCT03866863||HFME births.|All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2017.
9526013|NCT03232710|Experimental|pilot study group|
9526014|NCT03232710|Experimental|group 1 (under fasting condition)|
9526015|NCT03232710|Experimental|group 2 (under fasting condition)|
9526016|NCT03232710|Experimental|group 3 (under fed condition)|
9526017|NCT03232710|Experimental|group 4 (under fed condition)|
9526018|NCT03232502|No Intervention|Control|
9526019|NCT03232502|Experimental|Intervention|
9526020|NCT03232528|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
9526021|NCT03232528|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
9526022|NCT03232723|Other|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
9526023|NCT03232619|Experimental|CD19-CART with a murine scFv|All enrolled patients in this arm will receive CD19-CART with a murine scFv.
9526024|NCT03232619|Experimental|humanized CD19-CART|All enrolled patients in this arm will receive humanized CD19-CART.
9526025|NCT03232554|Experimental|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
9526026|NCT03232554|Experimental|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
9526027|NCT03232554|Active Comparator|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
9526028|NCT03232515|Experimental|Intervention group|Evaluation,estimation and modification of the dry weight by BIVA.
9526029|NCT03232541|Other|Standard care (A)|Standard care (A) with neutral communication (A1) or positive communication (A2)
9526030|NCT03232541|Placebo Comparator|Sham acupuncture (B)|Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
9526031|NCT03232541|Experimental|Genuine acupuncture (C)|Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
9826724|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle QD|Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
9826725|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle BID|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
9526032|NCT03232450|Active Comparator|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
9526033|NCT03232450|Other|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
9526034|NCT03232372|Experimental|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
9526035|NCT03232372|Experimental|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
9526036|NCT03232372|Experimental|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
9526037|NCT03232424|Experimental|NovoTTF-200A + Temozolomide Chemoradiation|NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
9526038|NCT03232385|Experimental|MR-US Fusion Arm|Clear Guide SCENERGY, MR-US
9526039|NCT03232385|Active Comparator|EM Fusion or No Fusion Arm|
9526040|NCT03232398|Active Comparator|Apixaban|Apixaban Oral Tablet [Eliquis]
9526041|NCT03232398|Active Comparator|Warfarin|Warfarin - Vitamin K antagonist
9526042|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
9526043|NCT03232307|Experimental|Treatment (ibrutinib, rituximab, lenalidomide, dexamethasone)|Participants receive ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also receive rituximab IV on days 1, 8, 15 and 22 in course 1 and 2, on day 1 of course 3-8, and then on day 1 of every other 28-day course, lenalidomide PO on days 1-21, and dexamethasone PO weekly. Treatment with rituximab repeats every 28 days for 2 years, with lenalidomide for 1 year, and with dexamethasone for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9526044|NCT03232359||SPE/HELLP group|This group included 24 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of pre-eclampsia, HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
9526045|NCT03232359||TTP/HUS group|This group included 13 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of TTP/HUS. HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
9526046|NCT03232359||Control group|This group included 20 pregnant women (gestational age of >20 weeks) having normal pregnancy with normal blood pressure and platelet count.
9526047|NCT03232346|Experimental|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
9526048|NCT03232346|Experimental|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
9526049|NCT03232268|Experimental|HLA-mismatched microtransplantation|HLA-mismatched microtransplantation without immunosuppressive treatment
9526050|NCT03232229||Tennis players|
9526051|NCT03232476|Other|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
9526052|NCT03232216|Experimental|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
9526053|NCT03232216|Placebo Comparator|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
9526054|NCT03232216|Experimental|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
9526055|NCT03232216|Placebo Comparator|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
9526056|NCT03232320|Experimental|MEDITOXIN|
9526057|NCT03232320|Placebo Comparator|Placebo|
9526058|NCT03232047|Experimental|Combined cognitive training|The training is combined executive function and memory training. The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
9526059|NCT03232047|No Intervention|Waiting-list group|Participants in the control condition will conduct the same training as the intervention group after a 26-week waiting period. During the 26-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
9526060|NCT03231982|Experimental|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
9526061|NCT03231982|Active Comparator|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
9694950|NCT04783805||Spontaneous HSIL regression|Patients that have spontaneous regression of HSIL throughout follow-up. Patients in this group will be further classified into 3 subgroups: total resolution (no colposcopic lesion, normal pathology by biopsy and cytology, and negative HPV for the HPV type initially detected); partial resolution (regression of colposcopic lesion, negative cytology and biopsies, but persistence of the initial hrHPV detected); and lesion regression (HSIL no longer detected, but persistent LSIL in either cytology, histology or colposcopy).
9526062|NCT03232034|Placebo Comparator|Calcium Citrate|Calcium citrate (1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
9526063|NCT03232034|Active Comparator|Milk Mineral Supplement|Milk mineral supplement (equating to 1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
9526064|NCT03232034|Experimental|Milk mineral supplement plus Whey Protein Hydrolysate|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
10173032|NCT03866694|Experimental|BRIGHT|Building Resilience through Intervention: Growing Healthier Together (BRIGHT) weekly home-based intervention from the third trimester of pregnancy through 6 months postpartum. A licensed clinician meets with mother and infant to promote attunement and optimal parent-child interactions. Additionally, the mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic
9526065|NCT03232125|Experimental|Ramosetron group|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
9526066|NCT03232125|Placebo Comparator|Placebo group|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
9526067|NCT03232021|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
9526068|NCT03232021|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
9526069|NCT03232021|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
9526070|NCT03232255|Experimental|Treatment Group|
9526071|NCT03232112|Active Comparator|Exenatide 2 MG Injection|Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
9526072|NCT03232112|Placebo Comparator|BD PosiFlush (saline)|The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
9526073|NCT03232086|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
9526074|NCT03232086|Active Comparator|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
9975394|NCT03414385|Experimental|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for ~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
10173033|NCT03866694|Active Comparator|STAR/TAU+|The mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic.
10173034|NCT03866837|Active Comparator|Study group A: GOS|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) and galacto-oligosaccharides (GOS), 7.5 mg.
9526075|NCT03232151|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
9526076|NCT03231956||Group 0|Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
9526077|NCT03231956||Group 1|Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
9526078|NCT03231956||Group 2|Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
9526079|NCT03231956||Group 3|Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
9526080|NCT03232190|Experimental|INTNIC|NICU Intervention Group Web Application Infants < 32 weeks
9526081|NCT03232190|No Intervention|CNIC|NICU Control Group No Web Application Infants < 32 weeks
9526082|NCT03232190|No Intervention|CMAT|Maternity Unit Control Group No Web Application Infants > 37 weeks
9526083|NCT03232177|Experimental|Anagre Cap.|twice a day
9526084|NCT03232008|Experimental|Experiment A- experimental|3g Canderel in 250ml water
9526085|NCT03232008|No Intervention|Experiment A- control|3g of maltodextrin in 250 ml of water
9526086|NCT03232008|Experimental|Experiment B- experimental|3g Canderel + 35g Lyle's Golden Syrup in 250 ml water
9526087|NCT03232008|No Intervention|Experiment B- control|3g Lyle's Golden Syrup + 35g of maltodextrin in 250 ml of water
9526088|NCT03232099|Experimental|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
9526089|NCT03232099|Active Comparator|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
9526090|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
9526091|NCT03231930|Experimental|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
9526092|NCT03231839|Placebo Comparator|Caloric restriction (control)|daily reduction of caloric intake aimed at 400 kcal/day
9526093|NCT03231839|Active Comparator|No red meat|daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
9526094|NCT03231839|Active Comparator|Increased fiber intake|daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
9526095|NCT03231761|Experimental|Service user testimonial videos|Videos with service user testimonials about depression and psychosis
9526096|NCT03231761|Active Comparator|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
9526097|NCT03231761|No Intervention|No video|Participants do not observe any videos prior to the assessment
9975395|NCT03368144|Experimental|ClearLumen II Peripheral Thrombectomy System|Patients treated with the ClearLumen II Peripheral Thrombectomy System
10173035|NCT03866837|Active Comparator|Study group B: bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), bovine lactoferrin (bLF), 1.0 g.
10173036|NCT03866837|Active Comparator|Study group C: GOS + bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), galacto-oligosaccharides (GOS), 7.5 mg, and bovine lactoferrin (bLF), 1.0 g.
9526098|NCT03231787|Experimental|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
9526099|NCT03231787|No Intervention|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
9528049|NCT03214484|Active Comparator|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
9672573|NCT05033587|Experimental|AK105 injection with anlotinib and radiotherapy|"AK105 200mg intravenously (IV) on day 1 of each 21-day cycle until disease progression or treatment intolerance, the dose can not be adjusted.~Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.~The conventional radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy."
9672574|NCT05033925|Placebo Comparator|Placebo|receive a plasebo capsule 2 doses per day
10173037|NCT03866837|Placebo Comparator|Study group D|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) alone, with no galacto-oligosaccharides (GOS), and no bovine lactoferrin (bLF).
10173038|NCT03866681|Experimental|Patients cohort|A total of 40 patients with refractory classic PNH will be included and will be intervened by a combined therapy including sirolimus and low-dose warfarin
9672575|NCT05033925|Experimental|FADA 800 mg/day|receive FADA capsules twice a day (each 400 mg)
9672576|NCT05033925|Experimental|FADA 2000 mg/day|receive FADA capsules twice a day (each 1000 mg)
9672577|NCT05033496||Newborn infants|Newborn infants born in our medical center
9672578|NCT05033730|No Intervention|Standard care: Control (Group A)|Patients who are scheduled for elective surgical upper airway surgery will be given General Anesthesia by an anesthesiologist who is the principal investigator and the surgical procedures will be done by the same ENT surgeon. IV Induction of Anesthesia with Propofol Target controlled infusion (TCI), Remifentanil Target controlled infusion (TCI) and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed endotracheal tube after direct laryngoscopy. After intubation by a Suitable size Endotracheal tube, they will be mechanically ventilated using Volume Controlled Ventilation (VCV) with 40% Oxygen and minute ventilation adjusted to keep ETCO2 of 40 mmHg or less, and a PEEP of 5 cmH2O.
10173039|NCT03866915||Patients undergoing elective surgery|All patients older than 18 years undergoing elective surgery that receive a preoperative visit by anesthesiologists in which Aortic pulse wave velocity measurement and the 6 minutes walking test (6MWT) is carried out
10173040|NCT03866629||Lifitegrast 5%|Patients will receive lifitegrast 0.5% eye drops twice daily 4 weeks prior to cataract surgery.
9672579|NCT05033730|Experimental|Intervention Group: (Group B)|General Anesthesia will be induced with IV Induction of Anesthesia by an anesthesiologist with Propofol (Target controlled infusion), Remifentanil (Target controlled infusion), and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed Tritube after direct laryngoscopy. They will be mechanically ventilated using Flow Controlled Ventilation (FCV) with 40% Oxygen, Flow rate:13L/Min., Peak Airway Pressure (15 cmH2O), and a PEEP of (5 cmH2O) to keep ETCO2 of 40 mmHg or less. The anesthesia will be maintained with Intravenous Infusion of Propofol, Remifentanil (TCI) to keep BIS 40-60.
9672580|NCT05034081|Experimental|group A|to know the effect of post-bariatric body contouring surgery on weight loss and metabolism
9672581|NCT05034081|No Intervention|group B|compare this group of patients with group A to detect weight changes and metabolic changes without any post-bariatric intervention
9672582|NCT05033314|Experimental|Rivaroxaban thromboprophylaxis|
9672583|NCT05033314|Placebo Comparator|Placebo|
9672584|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa simplex|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
9672585|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of junctional epidermolysis bullosa|"Female patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
9975396|NCT03363035|Experimental|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily
10173041|NCT03866720|Active Comparator|Carbohydrate rich breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
10173042|NCT03866720|Experimental|Whey protein enriched breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
10173043|NCT03866720|No Intervention|Extended morning fast|Participants will extend their overnight fast until the ad libitum lunch is provided.
10173044|NCT03866876||Hôpital Femme Mère Enfants births|
9526100|NCT03231722|Active Comparator|mFOLFOX6 + Panitumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
9526101|NCT03231722|Experimental|mFOLFOXIRI + Panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by~Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
9526102|NCT03231813|Experimental|SLS irritation model and Treatment|SLS induced irritation on two sites each on forearms and back Emollient cream treatment
9526103|NCT03231813|Placebo Comparator|SLS irritation model and No Treatment|SLS induced irritation on two sites each on forearms and back No treatment
9526104|NCT03231813|Sham Comparator|Sham irritation and Treatment|Sham irritation (water) on two sites each on forearms and back Emollient cream treatment
9526105|NCT03231813|No Intervention|Sham irritation and No Treatment|Sham irritation (water) on two sites each on forearms and back No treatment
9526106|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
10173045|NCT03866733|Active Comparator|Narcotics group (group N)|intervention: injection of boluses of intra venous Narcotics (fentanyl) in the dose of (3-5 mcg/kg) during the surgery after induction of anesthesia. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till 48 hours after surgery. NSAID every 12 hrs if there is no contraindication and iv acetaminophine igm/6hrs.
9526107|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
9526108|NCT03231683|Active Comparator|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
9526109|NCT03231683|Placebo Comparator|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
9975397|NCT03363035|Experimental|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily
10173046|NCT03866733|Experimental|Erector spinea block group (group B)|intervention: after induction our intervention will be the performance of ultrasound guided bilateral continous Erector spinea block with insertion of catheters then 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 8 ml/h. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till extubation and iv acetaminophine igm/6hrs.
9526110|NCT03231657|Experimental|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:~sFlt1/PlGF ratio >38: pre-eclampsia risk~sFlt1/PlGF ratio >85: pre-eclampsia~ISSHP pre-eclampsia definition + ratio >210: severe PE~ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio >600: consider deliver"
9526111|NCT03231657|No Intervention|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
9526112|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
9526113|NCT03231631|Experimental|Education plan and adherence to exercise|"Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.~It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
9526114|NCT03231631|No Intervention|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
9526115|NCT03231644||FD/MAS Patients|Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.
9526116|NCT03231605|Experimental|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
9526117|NCT03231605|Active Comparator|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
10173047|NCT03866941||synthetic cannibinoids users|
10173048|NCT03866824|Experimental|PRP group|
9526118|NCT03231618|Experimental|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
9526119|NCT03231618|Experimental|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
9526120|NCT03231592|Experimental|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
9526121|NCT03231592|Active Comparator|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
9975398|NCT03363035|Active Comparator|enoxaparin|Enoxaparin 1mg/kg twice daily SC twice daily
9975399|NCT03349762||Observational 1|Radiotherapy or Chemotherapy
10173049|NCT03866824|Active Comparator|reference treatment|
9526122|NCT03231384|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
9526123|NCT03231384|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
9526124|NCT03231514|Placebo Comparator|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
9526125|NCT03231514|Active Comparator|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate & Placebo for effects of supplement. All participate in the exercise intervention.
9526126|NCT03231514|Experimental|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet & placebo) and placebo control group (vs. ketogenic & supplement). All participate in the exercise intervention.
9526127|NCT03231514|Experimental|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
9526128|NCT03231566|Active Comparator|Usual education control group (CG)|The CG received the traditional hospital preoperative program, which was consistent with current preoperative TKA protocols. The CG received education covering anatomy of the knee joint, information about the joint replacement surgery, what to expect when they were admitted for surgery, what to expect immediately after surgery, pain medications, postoperative rehabilitation/physical therapy, etc. The CG received a hospital-based booklet with this information.
9526129|NCT03231566|Experimental|Experimental group (EG)|The EG underwent an additional 30-minute group PNE program, followed by the usual preoperative education program from the hospital. The PNE program used in this TKA study was an adaptation of the PNE program developed for LS. The educational program was designed to be delivered by a physical therapist in a group session to patients prior to their TKA.
9526130|NCT03231436|Experimental|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
9526131|NCT03231436|Active Comparator|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
9526132|NCT03231423|Experimental|DRAIN PLACEMENT|Effects of drainage
9526133|NCT03231423|No Intervention|DRAIN NOT PLACED|Effects of not using drain
9526134|NCT03231488|Experimental|Mindfulness intervention|
10173050|NCT03866811|Experimental|Intervention arm|The intervention consists of a brief contraception educational video and then the 10-week texting intervention which consists of 30 automated, personalized and interactive texting algorithms (3 texts per week).
10173051|NCT03866811|No Intervention|Control arm|Patients randomized to the control arm will receive the current standard discharge instructions provided in the investigator's ED.
9526135|NCT03231488|Active Comparator|Control intervention (unfocused attention)|
9526136|NCT03231501|Experimental|single arm|This is a single arm study. It is an open-label study. The intervention is eptinib succinate.
9526137|NCT03231553|Experimental|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.~Receive MiQuit text message cessation programme."
9526138|NCT03231553|No Intervention|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
9526139|NCT03231540|Experimental|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
9526140|NCT03231540|No Intervention|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
9526141|NCT03231267||"Carrierof Ec-BLSE/EPC or Kp-BLSE/EPC"|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
9526142|NCT03231267||Non-Carrier of Ec-BLSE/EPC orKp-BLSE/EPC|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
9526143|NCT03231358|Experimental|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
9526144|NCT03231358|No Intervention|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
9526145|NCT03231280|Experimental|SB-061|SB-061
9526146|NCT03231280|Placebo Comparator|Placebo|Placebo
9526147|NCT03231254||Chinese patients with OSA|
9526148|NCT03231254||Canada patients with OSA|
9526149|NCT03231319|Active Comparator|fascia iliaca compartment block+ IV-PCA|
9526150|NCT03231319|Active Comparator|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
9526151|NCT03231319|Placebo Comparator|IV PCA only|
9526152|NCT03231332|Experimental|H.pylori Eradication index|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with Clarythromycin-containing eradication therapy
9526153|NCT03231332|No Intervention|Control|Microbiome diversity detection in Participants Without H.pylori Eradication therapy
9526154|NCT03231332|Active Comparator|H.pylori Eradication comparative|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with high dose Amoxicillin and bismuth containing eradication therapy
9526155|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
9526156|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
9526157|NCT03231163|Placebo Comparator|No Music|
9526158|NCT03231163|Experimental|Relaxing Classical Music|
10173052|NCT03866577|Experimental|Part A|Healthy volunteers will receive a single ascending dose of M254 or placebo
10173053|NCT03866577|Experimental|Part B|Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
9526159|NCT03231163|Experimental|Self-Selected Relaxing Music|
9526160|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
9526161|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
10173054|NCT03866577|Experimental|Part C|ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
9526162|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
9526163|NCT03231202|Experimental|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.~The study does not interfere with local diagnostic work-up and treatment protocols."
9526164|NCT03231202|No Intervention|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
9526165|NCT03231137|Experimental|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
9526166|NCT03231137|Experimental|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
9526167|NCT03231137|Experimental|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
9526168|NCT03231137|Experimental|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
9526169|NCT03231137|No Intervention|Control|Spontaneously healed socket
10173055|NCT03866577|Experimental|Part D|ITP patients will receive repeated doses of M254
9526170|NCT03231176|Experimental|Varlitinib and Capecitabine|
9526171|NCT03231215|Placebo Comparator|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
9526172|NCT03231215|Active Comparator|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
9526173|NCT03231072|Experimental|Electrical Impedance Tomography record|Electrical Impedance Tomography monitoring of the pleural effusion evacuation.
9528050|NCT03214484|Active Comparator|computer|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
9528051|NCT03214445|Experimental|resin composite with nanofiller.|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
9528052|NCT03214445|Active Comparator|sealant based on resin|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
9528053|NCT03214445|No Intervention|Control|The restorations were evaluated without treatment about defective restoration that was considered clinically acceptable.
9528254|NCT03212417|Other|Interventional trial without phases-supportive care.|This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
9528255|NCT03212625|Experimental|Urea cream 20%|144 patients spread urea cream (urea 20%)
9528256|NCT03212625|Placebo Comparator|Placebo|144 patients spread placebo cream (urea 0%)
9528257|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
9528258|NCT03212495|Active Comparator|dexmedetomidine (D group)|intraarticular administration of dexmedetomidine at the end of surgery
9528259|NCT03212495|Active Comparator|neostigmine (N group)|intraarticular administration of neostigmine at the end of surgery.
9528260|NCT03212469|Experimental|Patients with head and neck squamous cell carcinoma|
9528261|NCT03212469|Experimental|Patients lung cancer|
9528262|NCT03212469|Experimental|Patients with oesophagus cancer|
9528263|NCT03212573|Experimental|ERAS protocol|ERAS protocol includes early oral intake (6 hours after surgery), early deambulation (6h after surgery) and multimodal analgesia (port-sites infiltration with Bupivacain 0.5% combined with postoperative intravenous analgesia)
9528264|NCT03212573|Active Comparator|Standard care|Oral intake and early deambulation begins 24h after surgery and analgesia consists in only intravenous drugs
9528265|NCT03212534|Experimental|Prediction Algorithm|
9528266|NCT03212534|No Intervention|Control|
9526174|NCT03231111|No Intervention|traditional group|
9526175|NCT03231111|Experimental|Multimedia group|
9526176|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
9526177|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
9526178|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
9526179|NCT03230981|Experimental|Healthy subjects|Optical imaging of the cornea in healthy subjects
9526180|NCT03231124|Experimental|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
10173056|NCT03866889|Experimental|Strength|Maximum strength protocol based on a Maximum Repetition (1RM). The aim of the application of the training is to produce an increase in strength based on training with high loads (80% 1RM), individually and covering the muscles of the lower extremity (quadriceps, hamstrings, gluteus maximus).
10173057|NCT03866889|Active Comparator|Normal activity|The subjects included in the control group will perform the same physical activity to improve the strenght until the beginning of the study. The exercises will be done in the same conditions and with the same period (4 days / week)
10173058|NCT03866772|Active Comparator|MISOPROSTOL|"oral misoprostol, 50 microgram, every 4 hours~Repeat treatment every 4 hours until active labour begins: regular painful contractions (≥ 3 in 10 min), cervical dilatation ≥ 3 cm~maximal number of doses: 6~Oxytocin infusion can be initiated 4 hours after the last dose of Misoprostol.~Failure of induction will be considered if no cervical change nor uterine contractions have begun during 24 hours of treatment.~Electronic fetal monitoring should be performed for 30 min after administration of misoprostol and 60 min after any tachysystole."
9526181|NCT03231124|Placebo Comparator|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
9526182|NCT03231046|Experimental|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
9526183|NCT03231046|Active Comparator|EM Fusion or No Fusion Arm|
9526184|NCT03231020||Adherent Group|Parent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
9526185|NCT03231020||Non-Adherent Group|Parent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
9526186|NCT03231033|Experimental|Pioglitazone|Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
9526187|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
9526188|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
9526189|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
9526190|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
9526191|NCT03230721|Active Comparator|ThuLEP group|Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
9526192|NCT03230721|Active Comparator|Monopolar enucleation group|Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
9526193|NCT03230721|Active Comparator|HoLEP group|Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
9526194|NCT03230786|Placebo Comparator|Placebo|Placebo QD for 12 weeks as add-on to metformin
9526195|NCT03230786|Experimental|15µg KBP-042 QD|Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin
9526196|NCT03230786|Experimental|30µg KBP-042 QD|Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin
9526197|NCT03230786|Experimental|50µg KBP-042 QD|Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin
9526198|NCT03230825|Experimental|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
9526199|NCT03230825|Sham Comparator|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
9526200|NCT03230929|Experimental|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
9526201|NCT03230851|Experimental|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
9526202|NCT03230851|Experimental|aspirin 100mg/2d therapy|Group2: aspirin ;
9526203|NCT03230851|Experimental|aspirin 100mg/3d therapy|Groups3: aspirin ;
9526204|NCT03230851|Experimental|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
9526205|NCT03230851|Experimental|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
9526206|NCT03230851|Experimental|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
9526207|NCT03230851|Experimental|indobufen 100mg bid therapy|Group7: 100mg bid
9526208|NCT03230760|Experimental|treatment|
9526209|NCT03230695|Active Comparator|Active stimulation + robotic therapy|"Active transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
9526210|NCT03230695|Sham Comparator|Sham stimulation + robotic therapy|"Sham transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
9526211|NCT03230773|Experimental|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
9526212|NCT03230773|Experimental|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
9526213|NCT03230773|Experimental|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
9526214|NCT03230773|Experimental|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
10173059|NCT03866772|Active Comparator|DOUBLE BALLOON|"Insertion of the DBD as instructed by the manufacturer, removal after 6 hours.~Artificial rupture of membranes (AROM) if suitable + IV oxytocin administration~If AROM cannot be performed- oxytocin infusion will be initiated at first.~If Bishop <3 after DBD removal, clinical evaluation and lag time before considering other methods for ripening is suitable and is up to the physician on call."
10173060|NCT03866772|Active Comparator|MISOPROSTOL+DOUBLE BALLOON|
9526215|NCT03230773|Experimental|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
9526216|NCT03230773|Experimental|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
10173061|NCT03866551|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
9526217|NCT03230799|Active Comparator|traditional cataract surgery|
9526218|NCT03230799|Experimental|minimal invasive lens surgery|
9526219|NCT03230682||major depressive disorder|
10173062|NCT03866395|No Intervention|Control Group|drug therapy according to the guidelines
10173063|NCT03866395|Experimental|Ivabradine Group|drug therapy according to the guidelines + Ivabradine 5 mg twice a day
10173064|NCT03866369|Experimental|Experimental|IMP Under investigation
9526220|NCT03230812|Experimental|Experimental: carnitine intervention (in all participants)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
9526221|NCT03230955|Experimental|Psychological and psycho-educational support|The intervention group (IG) [that will receive telephone-based assistance to quit (including psychological and psycho-educational support and pharmacological treatment advice, if required) provided by trained nurses who will proactively call at one week, 15 day, a month, 3, 6 and 12 months after discharge, plus the calls made by the patients during the process]
9526222|NCT03230955|Active Comparator|Control Group|The control group (CG) [that will receive only a brief counselling session after discharge]
9526223|NCT03230656|Experimental|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:~working memory strategies~executive function program~divided attention program~environmental changes~identification of problematic cognitive-communication situations"
9526224|NCT03230656|Active Comparator|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:~- Same cognitive-communication therapy is administered"
9526225|NCT03230903|Experimental|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
9526226|NCT03230903|Sham Comparator|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
9526227|NCT03230734|Experimental|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
10173065|NCT03866369|Placebo Comparator|Placebo to Match|
9526228|NCT03230734|Experimental|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
9672586|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa dystrophic|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
10173066|NCT03866330|Active Comparator|osteoarthritis of the knee|Intraarticular injection of WJMSC
9526229|NCT03230968|No Intervention|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
9826726|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 4.0% QD|Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
10173067|NCT03866330|Active Comparator|osteoarthritis of the hip|Intraarticular injection of WJMSC
10173068|NCT03866330|Active Comparator|osteoarthritis of the glenohumeral joint|Intraarticular injection of WJMSC
10173069|NCT03866304|Experimental|Picosecond Laser|Treatment with investigational wavelengths of the S2 laser for tattoo removal.
10173070|NCT03866616|Active Comparator|Control (usual care)|"Behavioral: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
10187054|NCT03730025|Active Comparator|Auscultation without NeoTapAS|Pediatric resident responsible for HR assessment will mentally calculate the HR based on auscultation (by counting the number of beats in 6 seconds and multiplying by 10) and will verbally communicate the calculated HR.
9526230|NCT03230968|Active Comparator|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
9526231|NCT03230604|Active Comparator|Bulk-Fill composite Class I, II and V cavities|Restorative with Filtek Bulkfill composite in class I, II and V Restorative with Tetric N Ceram composite in class I, II and V
9526232|NCT03230604|Active Comparator|Z 350 xt Composite|Restorative with Z 350 xt composite in class I, II and V
9526233|NCT03230552|Experimental|Video group|Residents assigned to this group will watch an instructional surgical video prior to LSO surgery.
9526234|NCT03230552|No Intervention|No video group|Residents assigned to this group will not watch an instructional surgical video prior to LSO surgery.
9526235|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
9672587|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of Kindler syndrome|Female patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
9672588|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa simplex|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
9672589|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of junctional epidermolysis bullosa|"Male patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
9672590|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa dystrophic|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
9672591|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of Kindler epidermolysis bullosa|Male patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
9672592|NCT05033405|Experimental|Experimental:Neuro Linguistic Programming|One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field.
9526236|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
9672593|NCT05033405|No Intervention|control group|No NLP was applied on the control group patients.
9672594|NCT05033327|Other|Nutrition and Exercise App|The exercise and nutrition app intervention will be provided to study participants. The app offers self-directed and supervised (virtual) programming to support nutrition and exercise self-management. Each participant follows a program that has been tailored to their overall health, physical function, and needs.
9672595|NCT05033522|Experimental|AlloStim®|AlloStim® is a formulation of living allogeneic Th1-like cells with anti-CD3/CD28 microbeads attached derived from precursors purified from healthy screened blood donors that are differentiated and expanded ex-vivo. AlloStim® is formulated at 10-7 cells/ml in 0.5ml for ID administration and 3ml for IV administration
9672596|NCT05033522|Active Comparator|Physician's Choice|Physician's Choice is either palliative FOLFOX4 chemotherapy plus best supportive care or best supportive care alone.
9672597|NCT05033457||unilateral biportal endoscopy technique group|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group
9672598|NCT05033457||percutaneous endoscopic transforaminal discectomy group|Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group
9672599|NCT05033509||ECMO and AKI|
9672600|NCT05033197|Experimental|CBBS intervention group|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
9672601|NCT05033392|Experimental|Toripalimab group|Toripalimab is administrated with160mg and repeated every 2 weeks.
9672602|NCT05033249||Normal|Alvarado Score 4 - 7 Normal according to the initial computed tomographic evaluation
9672603|NCT05033249||Patient|Alvarado Score 4 - 7 Acute appendicitis according to the initial computed tomographic evaluation
9672604|NCT05034016|Experimental|HM experimental group|Intraocular implant test product
9672605|NCT05034016|No Intervention|Natural observation control group|Natural observation of the disease changes, no surgical intervention
9672606|NCT05033444|Experimental|PRV-002|"A single dose of PRV-002 will be administered to each study participant in this arm on study Day 1 at the following dose levels:~Cohort 1: 9.66 mg~Cohort 2: 19.38 mg~Cohort 3: 38.7 mg."
9672607|NCT05033444|Placebo Comparator|Placebo comparator|A single dose of placebo comparator will be administered to each study participant in this arm on study Day 1. Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
9672608|NCT05033340|Placebo Comparator|SS1-P2b|"Primary efficacy endpoint:~• Proportion of subjects with endoscopic response at Week 14~Secondary efficacy endpoint:~• Proportion of subjects with clinical remission CDAI at Week 14"
9694951|NCT04783805||Conization|Women who have cervical conization for any reason during follow-up. Patients in this group will be further classified according to indication criteria: failure to meet criteria for conservative management or persistence of HSIL after 24 months of follow-up.
9975400|NCT03349762||Observational 2|Huaier Granule & Radiotherapy or chemotherapy
9526237|NCT03230669|No Intervention|Control|this arm receives treatment as usual and no intervention.
9526238|NCT03230669|Experimental|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
9526239|NCT03230942|Experimental|Patient education program|Pre-operative education and pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
9526240|NCT03230942|Active Comparator|Control - only pos-op rehabilitation|Pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
9526241|NCT03230708|Experimental|Erythrocytes derived MPs containing MTX|Suspension of erythrocytes derived MPs containing MTX, qd×6, 6 units MPs a time , Two courses.
9526242|NCT03230708|Active Comparator|convention drugs|Chemotherapeutic drugs, biologicals or traditional Chinese medicine.Dosage form, dosage, frequency and duration according to respective medicine instructions.
9526243|NCT03230539|Experimental|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
9526244|NCT03230539|Experimental|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
9526245|NCT03230539|Experimental|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
9526246|NCT03230487|Experimental|BI 1015550|
9526247|NCT03230487|Placebo Comparator|Placebo|
9526248|NCT03230565|Active Comparator|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
9526249|NCT03230565|Active Comparator|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
9526250|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
9526251|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
9526252|NCT03230435||Anorexia nervosa|Treatment settings as usual.
9526253|NCT03230435||Healthy controls|No interventions.
9526254|NCT03230331||STN DBS|Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN)
9526255|NCT03230331||CONTROL|Parkinson's disease (PD) patients received optimized medical treatment according to published evidence based guidelines
9526256|NCT03230474|Active Comparator|group 1|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
9672609|NCT05033340|Placebo Comparator|SS2-I|"Primary efficacy endpoints:~Proportion of subjects with endoscopic response at Week 14~Proportion of subjects with clinical remission CDAI at Week 14~Secondary efficacy endpoints:~Proportion of subjects with clinical remission PRO2 at Week 14~Proportion of subjects with clinical response CDAI at Week 14~Proportion of subjects with endoscopic response and clinical remission CDAI at Week 14~Proportion of subjects with endoscopic remission at Week 14"
9526257|NCT03230474|Active Comparator|group 2|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
9526258|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
9526259|NCT03230500|Experimental|Computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
9526260|NCT03230500|Active Comparator|Free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
9526261|NCT03230305||Elderly cancer patient cohort|"Aged 70 years or over~With solid cancer irrespective of the stage~Pre-screened or screened for at least one ongoing clinical trial in the center~Informed oral consent (patient, his/her legal representant, trustworthy person or family member)~Social security affiliation"
9526262|NCT03230383|Experimental|Cohort 1_90mg and Matching Placebo|
9526263|NCT03230383|Experimental|Cohort 2_300mg and Matching Placebo|
9526264|NCT03230383|Experimental|Cohort 3_900mg and Matching Placebo|
9526265|NCT03230383|Experimental|Cohort 4_1800mg and Matching Placebo|
9526266|NCT03230383|Experimental|Cohort 5_3000mg and Matching Placebo|
9526267|NCT03230383|Experimental|Optional Cohort 6_TBD mg and Matching Placebo|
9526268|NCT03230383|Experimental|Optional Cohort 7_TBD mg and Matching Placebo|
9526269|NCT03230344|Active Comparator|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
9694952|NCT04783610|Experimental|Study subjects for vHIT- and VOG-measurements|Each study subject is his/hers own comparator at different phases of ethanol consumption.
9694953|NCT04783818||One Stage Reconstruction With Adjuvant Radiotherapy|
9526270|NCT03230344|Experimental|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
9526271|NCT03230461|Experimental|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
9526272|NCT03230461|Experimental|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
9526273|NCT03230461|Experimental|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
9526274|NCT03230227|Active Comparator|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
9526275|NCT03230227|Active Comparator|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
9526276|NCT03230513|Active Comparator|Self Epley Manoeuvre|Self Epley Manoeuvre.
9526277|NCT03230513|Active Comparator|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
10173071|NCT03866616|Experimental|Intervention (group sessions)|Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
10173072|NCT03866356|Experimental|Intervention group|The intervention group received care according to the SICP (Table 2). One of the researchers gave each participant one-on-one education in line with SICP. They were also provided with the booklet that had been prepared in accordance with SICP. The participants were phoned every week for eight weeks and offered counseling within the scope of SICP and then were reevaluated at the end of eight weeks (Post-intervention). The participants were followed from the eighth to the twelfth week without any intervention (4-week post-intervention).
10173073|NCT03866356|No Intervention|Control group|The control group received no intervention during the eight-week intervention period. The control group received standard care. The women were given no educational materials.
10173074|NCT03866525|Experimental|Dose escalation and dose expansion|"A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion.~In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts."
10173075|NCT03866291||ESBL carrier|"This cohort is followed for a year with additional selective ESBL cultures after 1, 3, 6 and 12 months. In the end of the year a questionnaire is handed in to the study group.~Sera is donated after 4-6 weeks and in year."
10173076|NCT03866291||Non ESBL-carrier|No further rectal cultures. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
10173077|NCT03866343|Active Comparator|Low AGE diet|Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
10173078|NCT03866343|Other|High AGE diet|Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
10173079|NCT03866421||Kidney transplanted patients|"Number of patients: 16~Patients on the waiting list for kidney transplantation with a living donor. The patients are screened with an OGTT before participation in the study, thereby excluding patients with diabetes mellitus.~Patients in this group are examined three times (baseline (before transplantation) and after three and twelve months after transplantation).~Same interventions as in the control Group.~Including/ Exclusion criteria are listed under the section Eligibility"
10173080|NCT03866421||Control group|"Number of patients: 16~Participants in this group are matched on age and BMI according to the kidney transplanted patients.~Participants are screened with an OGTT before participation since only persons with normal glucose tolerance may be included in the study.~Furthermore, participants have to have normal kidney function.~Participants in this group are only examined once. Same interventions as in the kidney transplanted patient group"
10173081|NCT03866408|Active Comparator|Immediate weight loss - placebo|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
10173082|NCT03866408|Placebo Comparator|Deferred control group - placebo|After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
10173083|NCT03866408|Active Comparator|Immediate weight loss - pioglitazone|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
10173084|NCT03866408|Active Comparator|Deferred group - pioglitazone|"After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period.~At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone."
10173085|NCT03866473|Experimental|Retilux Photobiomodulation|670nm wavelength device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device).
10173086|NCT03866473|Sham Comparator|Sham Light Device|Broad spectrum light device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device)
10173087|NCT03866486||IVUS-guidance group|The patients who underwent drug-eluting stents implantation with IVUS guidance.
10173088|NCT03866486||Angiography-guidance group|The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS.
10173089|NCT03866447|Active Comparator|vitamin D versus placebo|This group will be treated by topical Vitamin D analogue (Calcipotriol) versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
10173090|NCT03866447|Active Comparator|Adapalene versus placebo|this group will be treated by topical Adapalene (0.1%) versus versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
10173091|NCT03866252|Experimental|Treatment Arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
10173092|NCT03866252|Active Comparator|Control Arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
10173093|NCT03866317|Experimental|Secukinumab|Secukinumab 300 mg injection at week 0, 1, 2, 3, 4, then every 4 weeks until week 12
10173094|NCT03866161||CPAP group|Obstructive sleep apnea patients treated with continuous positive airway pressure
9526278|NCT03230409|No Intervention|Phase 1, Retrospective|Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
9526279|NCT03230409|Experimental|Phase 2, Prospective|"Four nurse-led interventions were implemented after Phase 1:~Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.~Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.~Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.~Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits."
9526280|NCT03230396|Placebo Comparator|Placebo|"Commercially-available chewing gum not supplemented with vitamins. Contains: Sugar; Dextrose; Gum Base; Corn Syrup; Natural and artificial flavors; artificial colors; carnauba wax; resinous glaze; neotame; butylated hydroxytoluene.~For saliva collection phase: No placebo is used. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
9526281|NCT03230396|Experimental|Vitamingum Sport|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (1250 IU); ascorbic acid (15 mg); cholecalciferol (100 IU); dl-tocopherol acetate (7.5 IU); thiamine mononitrate (375 microg); riboflavin (425 microg); niacinamide (5 mg); calcium d-panothenate (2.5 mg); pyroxidine HCl (500 microg); cyanocobalamin (1.5 microg); folic acid (100 microg); biotin (11.25 microg).~For saliva collection phase: Subjects will chew 2 pieces for 30 min. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
9526282|NCT03230396|Experimental|Vitamingum Immunity|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (2000 IU); ascorbic acid (62.5 mg); cholecalciferol (200 IU); dl-tocopherol acetate (20 IU); niacinamide (10 mg); calcium d-panothenate (10 mg); pyroxidine HCl (1 mg); cyanocobalamin (5 microg); folic acid (200 microg); biotin (75 microg); zinc sulfate (2.5 mg); sodium selenite (17.5 microg); chromium picolinate (60 microg); and potassium iodide (40 microg).~For saliva collection phase: Subjects will chew 1 pieces for 30 min. For blood collection phase: Subjects will chew 1 piece at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
9526283|NCT03230422|Experimental|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
9526284|NCT03230422|Experimental|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
9526285|NCT03230253|Experimental|Sequential training group|Exercise training for 30 minutes followed by 30 minutes of cognitive-based intervention
9526286|NCT03230253|Experimental|Dual training group|Exercise training simultaneously combined cognitive-based intervention for 60 minutes
9526287|NCT03230253|Active Comparator|Control training group|non-aerobic exercise (e.g., stretch, range of motion exercise...) and unstructured cognitive rehabilitation programs (e.g., reading newspapers, playing board games...) for 60 minutes
9526288|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
9526289|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
9694954|NCT04783818||Two Stage Reconstruction With Adjuvant Radiotherapy|
9694955|NCT04783818||Autologous Reconstruction With Adjuvant Radiotherapy|
9694956|NCT04783818||One Stage Reconstruction Without Adjuvant Radiotherapy|
10173095|NCT03866265|Active Comparator|Supplement Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a food supplement capsule (containing 0.125 g of FGE-Salmon-PLs) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the food supplement will now be administered the placebo capsules for 28 days (a placebo capsule per day)"
10173096|NCT03866265|Placebo Comparator|Placebo Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a placebo capsule (containing 0.125 g of glycerin) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the placebo capsules will now be administered the food supplement capsules for 28 days (a food supplement capsule per day)"
10173097|NCT03866005|Placebo Comparator|Placebo Arm - Standard Treatment|50 subjects with center-involved diabetic macular edema (CI-DME) and scheduled for treatment with intravitreal injection of anti-VEGF agents will receive softgel placebo containing canola oil, 2 capsules per day during the study duration
10173098|NCT03866005|Experimental|Experimental Arm - 2 DiVFuSS formula softgel capsules|50 subjects receiving two DiVFuSS softgels per day
10173099|NCT03866005|Experimental|Experimental Arm - 4 DiVFuSS formula softgel capsules|50 subjects receiving 4 DiVFuss softgels per day
10173100|NCT03866018|Experimental|Adapted physical activity|Patients will participate in an adapted physical activity workshop.
9526290|NCT03230357|Experimental|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
9526291|NCT03230201|No Intervention|Blank control|do not receive Lymph node dissection during surgery.
9526292|NCT03230201|Experimental|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
9526293|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
9526294|NCT03230279|Active Comparator|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
9526295|NCT03230279|Active Comparator|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
9526296|NCT03230370|Experimental|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly, one group can be used as the control group of the other one."
9526297|NCT03230370|Experimental|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly,one group can be used as the control group of the other one."
9526298|NCT03230240||HIPEC|Patients with carcinomatosis or other peritoneal surface malignancy
9526299|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
9526300|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
10173101|NCT03866213||Quantitative Measurement of Bilirubin|Bilirubin content of the neonate will be measured by the following: BiliSpec, laboratory spectophotometric bilirubinometer (Reichert UNISTAT), and transcutaneous bilirubinometer. The infant may or may not be receiving phototherapy treatment at the time of sample measurement.
10173102|NCT03865992|Experimental|Arm I (nanoemulsion curcumin)|Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.
10173103|NCT03865992|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.
10173104|NCT03866057||1 study group|All patients hospitalized in 4 intensive rehabilitation Structures of Don Gnocchi Foundation during the enrollment period, suffering from acute (within 30 days) ischemic or emorragic stroke
10173105|NCT03865888|Active Comparator|Cyclosporins 0.05 % treated eyes|Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
9526301|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
9526302|NCT03230162|Experimental|sildenafil citrate|50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.
9526303|NCT03230162|Experimental|low molecular weight heparin|50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow < 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily > 170 kg 75 u/kg/day
9526304|NCT03229954|Experimental|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
9526305|NCT03229954|Active Comparator|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
9526306|NCT03229993|Experimental|OCT guided PCI|
9694957|NCT04783818||Two Stage Reconstruction Without Adjuvant Radiotherapy|
10173106|NCT03865888|Active Comparator|Tacrolimus 0.03% treated eyes|Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months
10173107|NCT03865901||Non-diabetic pregnant women|Non-diabetic women with singleton pregnancy undergoing screening for gestational diabetes who provide plasma samples for testing with the Mellitus GCD59 Test
10173108|NCT03865849|Active Comparator|Conventional radiofrequent treatment|The patient is placed in a supine position on a fluoroscopy table with the index knee flexed 10-15°. The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 10 mm active tip
10173109|NCT03865849|Active Comparator|Cooled radiofrequent treatment|The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 100 mm long, 17 G RF cannula/introducer with an 18 G cooled probe/electrode with a 4 mm active tip (Halyard/Coolief).
9526307|NCT03229993|Experimental|OCT guided medicine|
9526308|NCT03229993|No Intervention|SPECT guided PCI|
9526309|NCT03229993|No Intervention|SPECT guided medicine|
9526310|NCT03230123|Experimental|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
9526311|NCT03230123|Placebo Comparator|Diet alone|The control group will receive diet counseling during six months.
9526312|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
9694958|NCT04783818||Autologous Reconstruction Without Adjuvant Radiotherapy|
9526313|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
9526314|NCT03230045|Experimental|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
9526315|NCT03230045|Sham Comparator|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
9526316|NCT03229980|Active Comparator|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
9526317|NCT03229980|Active Comparator|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
9526318|NCT03230097|Experimental|BI 409306|
10173110|NCT03866044||Parkinson's Disease (PD)|"Patients with Parkinson's Disease meeting the following criteria:~Inclusion criteria:~Aged 18 or more.~Clinically established or probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of other neurologic or psychiatric disease~Pacemaker or other implanted electronic devices~Claustrophobia"
9526319|NCT03230097|Placebo Comparator|Placebo|
9526320|NCT03230084|Experimental|Urine PDG test|Urine pregnanediol 3-glucuronide (PDG) test strip
9526321|NCT03229746|Experimental|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
9526322|NCT03229746|Active Comparator|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
9526323|NCT03229746|Active Comparator|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
9526324|NCT03229668|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
9526325|NCT03229668|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
9526326|NCT03229668|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
9526327|NCT03230006|Active Comparator|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
9526328|NCT03230006|Placebo Comparator|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
10173111|NCT03866044||Healthy participants|"Healthy participants age- and sex-matched to the PD group.~Inclusion criteria:~Age- and sex-matched to PD group (aged 18 or more)~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of neurologic or psychiatric disease~Pacemaker or other implanted electronic devices~Claustrophobia"
10173112|NCT03866096|Experimental|Experimental|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training and a CORE strengthening program
10173113|NCT03866096|Active Comparator|Control|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
10173114|NCT03866083|Experimental|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
10173115|NCT03866083|Active Comparator|Stadard Medical treatment|Stadard Medical treatment
9526329|NCT03229876|Experimental|CD19-UCART|All patients will be treated with 1 injection of CD19-UCART. Three escalating dose-levels (5x10^6/kgBW, 7x10^6/kgBW, 10x10^6/kgBW) of CD19-UCART will be evaluated using a 3+3 design. Each CD19-UCART injection will be administered at Day 0.
9526330|NCT03229850|Other|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
9526331|NCT03229850|Other|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
9826727|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% QD|Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
10173116|NCT03866122|Experimental|Neonatal Temperature Monitor|One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.
10173117|NCT03865823||anal Fistula|patient with anal fistula with indication to surgical treatment
9526332|NCT03230058|Experimental|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
9526333|NCT03230058|Placebo Comparator|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
10173118|NCT03865875|Experimental|Multimodal Prehabilitation Program|"Pretreatment exercise program and nutrition program~-The prehabilitation intervention will include the following components: (1) a standardized fitness program and (2) nutritional counseling and optimization. Patients are enrolled in the program within 8 weeks of being diagnosed and continued until operation"
10173119|NCT03865862|Experimental|Experimental|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
9526334|NCT03229642|Experimental|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
9526335|NCT03229642|Sham Comparator|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
9526336|NCT03229902|Experimental|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
9526337|NCT03229707|Active Comparator|group 1 Color matching using Vita 3D master|"Outcome Name: Color Matching measured by :~Modified (USPHS) criteria"
9526338|NCT03229707|Experimental|group 2 Color matching using digital photography|"Outcome Name: Color Matching measured by Digital Photography using (Photoshop)~Software:~0 to 1: no difference in perception~1 to 2: only perceptible to a trained observer~2 to 3.5: perceptible difference~3.5 to 5: marked difference"
9526339|NCT03230019|Active Comparator|chest tube|VATS with chest tube placement
9526340|NCT03230019|Experimental|two-lumen catheter|VATS with two-lumen catheterization
10173120|NCT03865862|Active Comparator|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
9694959|NCT04783506||Suicidal Behavior|Adolescents who have suicidal behavior, which for this study, is defined by a recent (within 3 months of enrollment) suicide attempt or suicidal ideation warranting urgent evaluation.
9826728|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% BID|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
9975401|NCT03349762||Observational 3|Huaier Granules
9975402|NCT03332420||Observational 1|Huaiqihuang Granule
9975403|NCT03332420||Observational 2|Standard treatment+Huaiqihuang Granule
9975404|NCT03332420||Observational 3|Standard treatment
9975405|NCT03327805|Experimental|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 4 weeks prior to and during the testing period.
9975406|NCT03327805|Placebo Comparator|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 4 weeks prior to and during the testing period.
10173121|NCT03866109|Experimental|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
10173122|NCT03866070|Experimental|Experimental|The subjects that are part of the experimental group will carry out the intervention thought the performance of strengthening exercises of the shoulder and scapula, and capsular stretches.
10173123|NCT03866070|Active Comparator|Control|Subjects that are part of the control group will perform shoulder strengthening exercises exclusively.
9975407|NCT03280732|Experimental|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
9526341|NCT03229694|Experimental|Tracleer (or Bosentan)|Tracleer (Tracleer 125Mg Tablet) was administered orally at two hours before surgery and six hours after surgery
9526342|NCT03229694|Placebo Comparator|Placebo|Placebo was administered orally at two hours before surgery and six hours after surgery
9526343|NCT03229720|Active Comparator|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
9526344|NCT03229720|No Intervention|Normal Dental Environment Group|Normal Dental Environment without any distractions.
9526345|NCT03229681|Experimental|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
9526346|NCT03229681|Active Comparator|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
9526347|NCT03230136|Experimental|Multimodal cardioprotection therapeutic strategy|
9526348|NCT03230136|Active Comparator|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
9672610|NCT05033340|Active Comparator|SS3-M|"Primary efficacy endpoints:~Proportion of subjects with clinical remission CDAI at Week 52~Proportion of subjects with endoscopic response at Week 52~Secondary efficacy endpoints:~Proportion of subjects with clinical remission CDAI at Week 52 among subjects in clinical remission CDAI at SS3-M baseline (defined as Week 14 or EI-Week 6 Visit)~Proportion of subjects with endoscopic response at Week 52 among subjects in endoscopic response at SS3-M baseline~Proportion of subjects with corticosteroid-free clinical remission CDAI at Week 52 among subjects receiving corticosteroids at SS3-M baseline~Proportion of subjects with endoscopic remission at Week 52~Proportion of subjects with clinical remission PRO2 at Week 52"
9672611|NCT05033704|Experimental|(Group A)|"Twenty-four of the 48 patients will receive an intraoperative intravenous infusion of 5% human plasma protein fraction PPF, (A group). PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).~Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl."
9672612|NCT05033704|No Intervention|(Group RS)|24 patients will receive an intraoperative intravenous infusion of crystalloids (0.9 % normal saline and/ or Lactated Ringer's solution) (RS group). Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl.
9672613|NCT05033535|Experimental|S086|
9672614|NCT05033535|Placebo Comparator|Olmesartan medoxomil|S086 PLCEBO
9672615|NCT05033366||Proov test strip users that record results with the Proov app|Participants using Proov test strips along with the Proov app who have logged at least one complete cycle will be asked to complete an online survey about fertility test results and current/previous pregnancy status. They will also be asked cycle history (irregular vs regular, cycle length), fertility testing (partners semen analysis results, AMH level, HSG results), possible fertility medications taken or prescribed, age, race, smoking status, and BMI.
9672616|NCT05033418|Experimental|IPRP + CBT-I|Interdisciplinary Pain Rehabilitation Program + Cognitive Behavioral Therapy for Insomnia (IPRP + CBT-I)
9672617|NCT05033418|Active Comparator|IPRP-UC|Interdisciplinary Pain Rehabilitation Program Usual Care (IPRP-UC)
9672618|NCT05033210|Other|Control Group|The control group will receive Psychological First Aid (PFA) and Care as Usual (CAU)
9672619|NCT05033210|Experimental|Treatment Group|The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2), in addition to Psychological First Aid (PFA) and care as usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress (K10 > 15.9) at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.
9672620|NCT05033171|Experimental|Study group|"Patients with scoliosis induced surgical indication (Cobb-degree>45).~Posterior screw-rod fixation segmentdesis~Before the implantation, right after the implantation and after the in situ bending 3D scanning of the rod using Artec Eva Spider type manual 3D scanner will be performed. Scanning is possible from a more than 60 cm distance, so that means the operational area stays sterile.~EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery (as in the actual clinical protocal)."
9672621|NCT05033145|Experimental|AZVUDINE|"Experimental:~AZVUDINE 1mg tablet~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment, for up to 14 days"
9672622|NCT05033145|Placebo Comparator|AZVUDINE placebo|"Control:~AZVUDINE placebo~Intervention:~AZVUDINE placebo tablet, 5 tablets QD + standard treatment, for up to 14 days"
9975408|NCT03268213|Experimental|Fecal microbial transplantation|Treated with fecal microbial transplantation
9975409|NCT03246958|Experimental|Nivolumab alone for two weeks|Ipilimumab will be administered via IV infusion, starting two weeks after Nivolumab
9975410|NCT03246958|Experimental|Ipilimumab alone for two weeks|Nivolumab will be administered via IV infusion, starting two weeks after Ipilimumab
9526349|NCT03229811|No Intervention|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
9526350|NCT03229811|Active Comparator|ESRD education + ACP|Standard ESRD education + conservative kidney management and advance care planning education
9526351|NCT03229928||Stakeholder Advisory Panel|The investigators will recruit 2 parents of children with IDD, 2 special education teachers, and 2 behavior health professionals to assist with the development and initial testing of the upgraded MOCHA application features to test usability.
9526352|NCT03229928||Primary Participants|The study primarily involves recruitment of clinically referred minor patients with IDD and their parents and teachers. Parents and teachers of 10 patients with IDD and co-morbid behavior problems will be asked to collect data via the MOCHA application on the frequency, antecedents,consequences, and other correlates of specific behavioral concerns.
9526353|NCT03229928||Sensor Wearing Participants|These will be the same participants from aim 2. All participants will be offered the opportunity to wear the sensors and provide and chose which ones they would prefer to wear. Two participants will be asked to wear the sensor for 48 hours in order to pilot test the feasibility of syncing sensor and MOCHA application data collection.
9526354|NCT03229967||Exploration Cohort|Up to 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines, will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period. ITS (internal transcribed spacer) DNA may also be used to characterize fungal communities.
9526355|NCT03229967||Validation Cohort|Up to 10 VLBW infants enrolled from the Le Bonheur Children's Hospital NICU. Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines willl be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA sequencing after conclusion of initial enrollment period.
9526356|NCT03229967||Well Baby Cohort|40 Well Baby Infants have been enrolled and may be used for secondary analysis of microbial community composition of the meconium.
9526357|NCT03229733|Experimental|Experimental group|Patients randomized to the experimental group participate in exergames training with Kinect. The supervised OT chooses different games according to the patient's needs and abilities. During therapy patients are at sitting position. The game program will be adjusted when patients got improvement. After 30 minutes of exergames training, participants will receive a 30-minutes of traditional occupational therapy.
9526358|NCT03229733|Active Comparator|Control group|Patients in the control group will receive individually tailored traditional occupational therapy consisting of the similar movement and dose as the experimental group doing by using the traditional equipment, such as climbing bar.
10173124|NCT03865797|Experimental|Experimental|Before carrying out each session of the intervention, each subject included in the experimental group will have a sports bandage on both ankles. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
9526359|NCT03229824|Experimental|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
9526360|NCT03229824|No Intervention|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
9526361|NCT03230071|Placebo Comparator|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
9526362|NCT03230071|Experimental|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
10173125|NCT03865797|Active Comparator|Control|The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
9526363|NCT03230071|Experimental|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
9526364|NCT03230071|Experimental|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
9526365|NCT03229785|Experimental|Human Umbilical Cord Blood Plasma|Six intravenous infusions of human umbilical cord blood plasma (HUCBP) during a twelve month study period. The amount of HUCBP being infused on each occasion is 50 mL.
9526366|NCT03229772|Other|Subjects indicated for dynamic nuclear medicine scanning|The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit.
9526367|NCT03229798|Active Comparator|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
9526368|NCT03229798|Experimental|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
9526369|NCT03229798|Experimental|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
9526370|NCT03229798|Experimental|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
9526371|NCT03229798|Experimental|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
9526372|NCT03229798|Experimental|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
9672623|NCT05033067|No Intervention|Usual Care|
10173126|NCT03865784|Experimental|Experimental|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises with tension and stretching will be performed
10173127|NCT03865784|Active Comparator|Control|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises technique will be performed without tension or stretching
9526373|NCT03229655|Experimental|Sequential stent addition|ERCP with sphincterotomy and stent placement is initially performed, then additional stents are placed across the stricture during sequential ERCPs, without stent removal/exchange or stricture dilation.
9526374|NCT03229655|Active Comparator|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
9526375|NCT03229889|Active Comparator|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
10173128|NCT03865706|Experimental|Inulin 32 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (16g twice daily) for a minimum of 7 days.
9526376|NCT03229889|Active Comparator|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
9526377|NCT03229889|Active Comparator|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
9526378|NCT03229889|Placebo Comparator|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
9526379|NCT03229603|Other|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
9528054|NCT03214523|Experimental|Sleep Education|The intervention will be a brief education of the importance of sleep and healthy sleep habits. Subjects will also receive a standard sleep brochure on healthy sleep (which will also be given to the other arm).
9528055|NCT03214523|No Intervention|Sleep Brochure|Subjects will receive a one page hand out on healthy sleep habits.
9528056|NCT03214354|Experimental|Non-myeloablative conditioning|Non-myeloablative conditioning
9528057|NCT03214497|Active Comparator|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
9528058|NCT03214497|Placebo Comparator|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
9528059|NCT03214393||Pre-Eclampsia|pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler
9528060|NCT03214601|Experimental|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
9528061|NCT03214328||Determination of causes of fetal death|Both the extensive and selective protocols will be applied to each case of IUFD recruited, so that each case will serve as its own control. For each case, determination of cause from either protocol will be performed in a blind manner with respect to the other protocol.
9528062|NCT03214133|Experimental|Epicatechin Dose Response|This arm will investigate varying doses of epicatechin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
10173129|NCT03865706|Experimental|Inulin 16 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (8g twice daily) for a minimum of 7 days.
9528063|NCT03214133|Placebo Comparator|Epicatechin-rich cocoa on performance|Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
9528064|NCT03214172||Cancer-associated thrombosis|Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
9528065|NCT03214042|Experimental|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
9528066|NCT03214107|Active Comparator|Full snack given before exercise|A snack containing ~0.5g of carbohydrates per kilogram of body weight will be given 5 minutes before exercise
9528067|NCT03214107|Active Comparator|Distributed snack over exercise period|A snack containing ~0.5g of carbohydrates per kilogram of body weight distributed this way will be given: ~40% given 5 minutes before exercise, ~30% after 20 minutes of exercise and the last ~30% after 40 minutes of exercise.
9528068|NCT03214315||Prostatectomy|Visceral adipose tissue specimen sample
10173130|NCT03865706|Placebo Comparator|Placebo|Critically ill adults who are receiving broad-spectrum antibiotics will also receive placebo oral suspension for a minimum of 7 days.
10173131|NCT03865771|Experimental|EPILEPSY GROUP|"Patients with typical BECTS (benign group) or atypical BECTS or ECSWS (severe group)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography (standard of care procedure): 2h wake and whole night~Sleep diary"
10173132|NCT03865771|Other|CONTROL GROUP|"Patients hospitalized for non neurologic illness (diabetes, nephropathy, chronic intestinal disease)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography : 2h wake and whole night~Sleep diary"
9528267|NCT03212339|Experimental|Mothers with children <3 years of age|Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
9526380|NCT03229616|Experimental|BUCY+VP-16|For DLBCL patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/day on days -3 and -2.
9526381|NCT03229616|Active Comparator|BUCY|For DLBCL patients undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
9526382|NCT03229369|Active Comparator|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
9526383|NCT03229369|Experimental|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
9526384|NCT03229408|Experimental|Salsalate-Treated Lean PCOS without IR|n=15
10173133|NCT03865758|Experimental|IN2L enhanced therapy|The intervention to be delivered is the use of the IN2L computer system to deliver video, music, and exercises to patients receiving physical and occupational therapy. Therapists will select the specific IN2L that will be most appropriate given each person's rehabilitation goals and personal preferences.
9526385|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS without IR|n=15
9526386|NCT03229408|Experimental|Salsalate-Treated Lean PCOS with IR|n=15
9526387|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS with IR|n=15
9526388|NCT03229408|Experimental|Salsalate-Treated Obese PCOS|n=15
9526389|NCT03229408|Placebo Comparator|Placebo-Treated Obese PCOS|n=15
9526390|NCT03229356|No Intervention|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
9526391|NCT03229356|Active Comparator|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
9526392|NCT03229356|Active Comparator|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
9526393|NCT03229395||patients with Cushing's syndrome|Patients were selected by the PI at the diagnosis.
9526394|NCT03229395||control patients|Selected patients are matched for age and sex.
9526395|NCT03229447|Active Comparator|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
9526396|NCT03229447|Experimental|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
9526397|NCT03229330|Experimental|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
9526398|NCT03229330|Active Comparator|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
9526399|NCT03229460|Active Comparator|standard low flow therapy|In the standard low flow therapy is applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more.
9526400|NCT03229460|Experimental|high flow nasal oxygen therapy|In the high-flow-oxygen group is passed through a heated humidifier and applied continuously through large-bore binasal prongs, with a gas flow rate of 30-60 liters per minute . The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an Spo2 of 92% or more.
9526401|NCT03229460|Placebo Comparator|Noninvasive ventilation|In the noninvasive-ventilation group is delivered to the patient through a face mask that was connected to an ICU ventilator,with pressure support applied in a noninvasive ventilation mode. The Fio2 or PEEP level (or both) were then adjusted to maintain an Spo2 of 92% or more.
9526402|NCT03229434|Experimental|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in a widely pristine area with moderate intensity (Rating of perceived exertion: ~ 11-15).
9526403|NCT03229434|Active Comparator|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: ~ 11-15).~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
9526404|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
9526405|NCT03229291|Experimental|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
9526406|NCT03229291|Experimental|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
9526407|NCT03229291|Experimental|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
9672624|NCT05033067|Experimental|Intervention (P3-BC) Usual Care|intervention + usual care group. In addition to receiving usual care, patients will have access to the aid and related materials before consultation with the physician about cystectomy and urinary diversion.
9526408|NCT03229291|Placebo Comparator|Vehicle|Vehicle solution applied once per day for 14 days
9526409|NCT03229551|Experimental|Xylitol|This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
9672625|NCT05033158|Other|Cancer patients|Level of antibodies against SARS-CoV-2 will be measured in these patients
9672626|NCT05033106|Active Comparator|Eyes with IVI bevacizumab|0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye
9672627|NCT05033106|Active Comparator|Eyes with IVI ranibizumab|A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant
9672628|NCT05033015|Experimental|Test|Mouth rinse containing enzymes
9526410|NCT03229551|Active Comparator|Control|This arm is the standard of care saline irrigation solution.
9526411|NCT03229577|Experimental|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga workshop is a nationally-recognized program focused on teaching yoga-based breathing techniques.
10173134|NCT03865758|No Intervention|Usual OT and PT services without IN2L|The intervention to be delivered is physical therapy and occupational therapy to improve functioning.
10173135|NCT03865472|Experimental|Arm I (rTMS)|Patients undergo rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
9526412|NCT03229577|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a nationally-recognized program focused on teaching mindfulness techniques.
9526413|NCT03229577|Experimental|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
9526414|NCT03229577|No Intervention|Control|The control group will receive no intervention.
9526415|NCT03229343|Experimental|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
9526416|NCT03229343|No Intervention|standard|pneumological consultation performed at M0, M3 and M6
9975411|NCT03192345|Experimental|Dose Escalation SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses
10173136|NCT03865472|Sham Comparator|Arm II (sham rTMS)|Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
10173137|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
9526417|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
9526418|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
9526419|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
9526420|NCT03229265|Experimental|Patiromer|
9526421|NCT03229096|Experimental|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
9526422|NCT03229031|Experimental|ES135|
9526423|NCT03229031|Placebo Comparator|Placebo|
9526424|NCT03229070|No Intervention|Control Group|Control Group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) and assessments at discharge
9526425|NCT03229070|Experimental|Interval effort group|Interval effort group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
9526426|NCT03229070|Experimental|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
9526427|NCT03229161|Experimental|IWT-group|The IWT-group follows the standardized GDM care program for GDM patients at OUH and is prescribed to a 6-week non-supervised IWT-program consisting of 3 IWT sessions per week of 40-50 minutes each.
9526428|NCT03229161|No Intervention|Con-group|The con-group follows the standardized GDM care program for GDM patients at OUH
9526429|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
9526430|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
9526431|NCT03229174|Experimental|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
9526432|NCT03229174|Other|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
9526433|NCT03229005|Active Comparator|A1 thick-high|group with thick tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
9975412|NCT03192345|Experimental|Dose Expansion SAR439459 monotherapy|SAR439459 administered intravenously every 3 weeks in a 21-day cycle with the previously determined recommended doses as the patients will be randomized to 2 different doses
9526434|NCT03229005|Experimental|A2 thick-low|group with thick tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
9526435|NCT03229005|Active Comparator|B1 thin-high|group with thin tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
9526436|NCT03229005|Experimental|B2 thin-low|group with thin tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
9526437|NCT03229226||2016 OPPE|All faculty participating in yearly ongoing professional Practice evaluation were eligible for enrollment
9526438|NCT03229148|Active Comparator|General anaesthesia|In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
9526439|NCT03229148|Active Comparator|Conscious Sedation|In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
9975413|NCT03192345|Experimental|Dose Escalation SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 2 weeks in a 14-day cycle or every 3 weeks in a 21-day cycle with escalating SAR439459 doses and cemiplimab
9526440|NCT03229564|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
9526441|NCT03229525|Active Comparator|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
9526442|NCT03229525|Sham Comparator|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
9526443|NCT03229187||neoadjuvant chemotherapy|
9526444|NCT03229239|Experimental|corneal stroma implantation|implant the corneal stroma to the diseased cornea of keratoconus patients
9526445|NCT03228979|Active Comparator|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
9526446|NCT03228979|No Intervention|Control group|Patients will receive standard post stroke care for 1 year
9526447|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
9526448|NCT03229135||Group B|Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
9526449|NCT03229135||Group C|Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
9526450|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
9526451|NCT03228992|Active Comparator|Ibuprofen|Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
9526452|NCT03228992|Placebo Comparator|Placebo|Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.
9526453|NCT03229278|Experimental|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
9975414|NCT03192345|Experimental|Dose Expansion SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 3 weeks in a 21-day cycle with previously determined SAR439459 doses and cemiplimab
9975415|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
9975416|NCT03181633|Experimental|ACH-0144471|All participants will receive ACH-0144471 during the treatment period.
9526454|NCT03229018|Other|voxel size|200 μm and 300 μm Voxel Sizes
9526455|NCT03228953|Experimental|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
9526456|NCT03228953|No Intervention|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
9526457|NCT03228927||twin A|Sampling of the facial and fecal microbiome
9526458|NCT03228927||twin B|Sampling of the facial and fecal microbiome
9526459|NCT03228940|Experimental|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
9526460|NCT03228901|Experimental|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
9526461|NCT03228901|Placebo Comparator|Placebo|Matched nasal spray
9526462|NCT03228810||Men >18 years old with metastatic prostate cancer|
9526463|NCT03228797|Active Comparator|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
9526464|NCT03228797|Active Comparator|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
9526465|NCT03228797|Active Comparator|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
9526466|NCT03228628|Experimental|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
9526467|NCT03228628|Placebo Comparator|Placebo|will inhale medical air (22% O2 - 78% N2)
9526468|NCT03228745|Experimental|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
9526469|NCT03228745|No Intervention|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
9526470|NCT03228550|Experimental|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
9526471|NCT03228550|Experimental|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
9526472|NCT03228550|Experimental|Placebo and exercise|Placebo supplement and aerobic exercise
9672629|NCT05033015|Active Comparator|Placebo|Control, same content as test, without enzymes
9672630|NCT05032924|Experimental|PPR group|Receive PRP injection only (PRP form Regen Kit BCT 1)
9672631|NCT05032924|Placebo Comparator|HA group|Receive HA injection only (HYAJOINT Synovial Fluid Supplement, active ingredient: Sodium Hyaluronate 25 mg, package: 2.5 mL per syringe)
9672632|NCT05032963|Active Comparator|Undisturbed Sleep|8 hours sleep - Subjects randomized to the undisturbed sleep will be instructed to go to sleep at 11pm, and awoken at 7am.
9672633|NCT05032963|Experimental|Restricted Sleep|4 hours sleep - Subjects randomized to the restricted sleep will be instructed to go to sleep at 3am and awoken at 7am.
9672634|NCT05032729|Placebo Comparator|Placebo beverage|"Flavor~Non-nutritive sweetener~Color added to match whey appearance"
9672635|NCT05032729|Experimental|Higher tryptophan beverage|"2.7g high Glycemic Index Carbohydrate~40g whey~0.855g tryptophan~660mg theanine~53mcg 5'AMP~Non-nutritive sweetener~Flavor"
9672636|NCT05032729|Experimental|Lower tryptophan beverage|"2.7g high Glycemic Index Carbohydrate~30g whey~0.641g tryptophan~660mg theanine~53mcg 5'AMP~Non-nutritive sweetener~Flavor"
9672637|NCT05032781|Experimental|Intra-arterial neuroprotective substances|"Cold saline, minocycline, and magnesium sulfate to be infused intra-arterially immediately after thrombectomy via the internal carotid artery. A dose escalation design will be used, as described above in Study Description."
9672638|NCT05033002|No Intervention|Treatment as Usual Group|This group will receive treatment as usual which means that no formal stigma reduction intervention will be provided. At the end of the follow-up period, this group will be invited to view the Labda Siku Moja stigma reduction intervention without follow-up.
9672639|NCT05033002|Experimental|Stigma Intervention Group|This group will participate in a 5 week intervention. Each week, intervention group participants will watch one ethnodrama segment of the Labda Siku Moja stigma reduction intervention followed by a guided debrief using motivational interviewing.
9672640|NCT05032911||Asymptomatic participants|Asymptomatic subjects should not present any pain in the cervical region during the last 3 months and no previous treatment for neck pain in order to be included in the study.
9975417|NCT03169998||GDFT group|The fluid infusion is to be performed, in accordance with GDFT protocol, on the basis of cardiac index (CI), stroke volume index(SVI) and stroke volume (SV) in addition to invasively measured arterial pressure by Vigilio / FloTrac Monitor.
9526473|NCT03228550|Experimental|Placebo and non-exercise|Placebo supplement and non- exercise
9526474|NCT03228823|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
9526475|NCT03228823|Active Comparator|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
9826729|NCT02431260|Experimental|INCB054329 Monotherapy|
9526476|NCT03228732|Placebo Comparator|Placebo 1|"Visit 1:~Study Day 1: Hyperinsulinemia/ euglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
9526477|NCT03228732|Placebo Comparator|Placebo 2|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
9526478|NCT03228732|Active Comparator|Fluoxetine|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine~Visit 2:~same as visit 1"
9526479|NCT03228732|Active Comparator|DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with DHEA~Visit 2:~same as visit 1"
9526480|NCT03228732|Active Comparator|Fluoxetine and DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine and DHEA~Visit 2:~same as visit 1"
9526481|NCT03228654|Experimental|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
9526482|NCT03228654|Active Comparator|Purohit's technique|Vaginal hysterectomy using Purohit's technique
9526483|NCT03228667|Other|Cohort 1|"Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.~1a - Non-small cell lung cancer~1b - Small cell lung cancer~1c - Urothelial carcinoma~1d - Head and neck squamous cell carcinoma~1e - Merkel cell carcinoma~1f - Melanoma~1g - Renal cell carcinoma~1h - Gastric cancer~1i - Cervical cancer~1j - Hepatocellular carcinoma~1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer"
9526484|NCT03228667|Other|Cohort 2|Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
9526485|NCT03228667|Other|Cohort 3|Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
9526486|NCT03228667|Experimental|Cohort 4|Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
9526487|NCT03228667|Experimental|Cohort 5|Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
10173138|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
9526488|NCT03228888|Experimental|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
10173139|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
9526489|NCT03228888|Experimental|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
9526490|NCT03228602|Active Comparator|healthy subjects|
9526491|NCT03228602|Experimental|obese|
10173140|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters;~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
10187919|NCT03721380|Experimental|BDRC|At the time of assignment to the counseling intervention arm of the study, there will be an initial meeting between the subject and the assigned counselor. As described in the counseling manual, this initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach.
9526492|NCT03228602|Experimental|obese diabetic|
9526493|NCT03228602|Experimental|obese diabetic who are going to be operated on|25 of a sleeve gastrectomy and 25 of a Y gastric bypass
9526494|NCT03228706|Experimental|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
10187055|NCT03730012|Experimental|Gilteritinib plus Atezolizumab|Participants will be treated with gilteritinib once daily for the phase 1 portion of the study to establish the recommended dose for the phase 2 portion. In the phase 2 portion, the participants will be treated with gilteritinib once daily at dose determined by the phase 1 portion of the study. Atezolizumab will be administered once every 2 weeks for the phase 1 and 2 portions of the study. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria; whichever occurs first.
10187056|NCT03729986||Healthy adults|Healthy subjects without exercise habit that can cooperate with the measurements of this study, loaded inspiratory muscle test.
9526495|NCT03228706|No Intervention|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
9526496|NCT03228719|Active Comparator|Control Group|Standardized Outpatient Physical Therapy after TKR
9526497|NCT03228719|Experimental|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
9526498|NCT03228589|Experimental|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
9526499|NCT03228589|Placebo Comparator|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
9526500|NCT03228641|Experimental|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
9526501|NCT03228771|Active Comparator|PRGF/ATV|"Group I (PRGF/ATV) : It was included 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin loaded in PRGF derived fibrin scaffold then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.~Intervention: Atorvastatin drug loaded in platelets rich in growth factors (PRGF)."
9526502|NCT03228771|Active Comparator|ATV gel|Group II (ATV gel) : Will include 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin in methyl cellulose gel then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
9526503|NCT03228771|No Intervention|Empty socket|Group III Empty socket( control) : Will include 10 patients undergoing single tooth extraction then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
9526504|NCT03228615|Experimental|Shared Decision Making Intervention|
9975418|NCT03169998||Control group|Patients in whom the surgery was conducted without the use of EV1000/ FloTrac monitoring among those who had undergone laparoscopic hepatobiliary or pancreatic surgery in the past.
9975419|NCT03160521|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
9526505|NCT03228615|No Intervention|Usual Care Group|
9526506|NCT03228485||MyBPH Care|All patients enrolled in this study.
9526507|NCT03228524|Experimental|D-aspartato+ET|Patients will be administered oral D-aspartate (2660 mg once daily) for 6 weks. Moreover, patients will receive therapeutic exercise.
9526508|NCT03228524|Placebo Comparator|Placebo+ET|Patients will be administered oral placebo for 6 weks. Moreover, patients will receive therapeutic exercise.
9526509|NCT03228576||TREVISE|
9526510|NCT03228511|Experimental|Formerly Arm Label|
9526511|NCT03228498|Experimental|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day~concomitant administration"
9526512|NCT03228498|Placebo Comparator|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only~concomitant administration"
9526513|NCT03228472|Experimental|real stimulation|Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
9526514|NCT03228472|Placebo Comparator|sham stimulation|"Patients will be treated as in the Real stimulation arm, but no electrical or magnetic stimulation will be induced."
9526515|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
9526516|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
9526517|NCT03228147|Experimental|Supportive Care (nutrition supplement)|Patients receive 10 different nutrition supplements PO and complete questionnaires based on each sample in a single session over 60-90 minutes.
9528069|NCT03214185|Experimental|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
9975420|NCT03160521|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
9975421|NCT03160521|Placebo Comparator|Placebo|Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
9975422|NCT03157960|Experimental|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
9975423|NCT03157960|Experimental|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
9526518|NCT03228459|Experimental|Mobile Unit Follow-up Group|In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
9526519|NCT03228459|No Intervention|Electronic Medical History Follow-up Group|Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.
9526520|NCT03228368||Atezolizumab (MPDL3280)|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
9526521|NCT03228316|Experimental|the study group one|20 patients with superior hypogastric plexus block
9526522|NCT03228316|Experimental|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
9526523|NCT03228758|Active Comparator|Anterior Orientation|"The anterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 11 o'clock to 3 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
9526524|NCT03228758|Active Comparator|Posterior Orientation|"The posterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 5 o'clock to 6 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
9526525|NCT03228199|Other|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
9526526|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
9526527|NCT03228407|Active Comparator|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
9526528|NCT03228407|Active Comparator|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
9526529|NCT03228407|Placebo Comparator|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
9526530|NCT03228849|Active Comparator|Conservative Treatment|Patients were treated with 6 weeks with splinting and were then started on physical therapy for 2 weeks.
9526531|NCT03228849|Active Comparator|Surgical Treatment|Patients were treated with the new suture anchor technique and after 6 weeks were started on physical therapy for 2 weeks.
9526532|NCT03228446|Experimental|Young subjects|Working memory training & attentional filter training for participants (18-30 years)
9526533|NCT03228446|Experimental|Old subjects|Working memory training, attentional filter training and no training (control) for participants (60-80 years)
9526534|NCT03228862|Experimental|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
10187057|NCT03729973|Active Comparator|Group (K)|"Group (K) (n=25): patients nebulized ketamine 50 mg(milgram) (1ml) plus 4ml normal saline.So total volume (5ml).~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized 1ml ketamine (Ketalar 50mg/VI Solution for Injection) by compressor nebulizing for 15 minutes."
9526535|NCT03228862|Experimental|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
10187058|NCT03729973|Active Comparator|Group (M)|"Group M(n=25) : patients nebulized isotonic magnesium sulfate 250mg (3ml)( 50% Magnesium Sulfate Injection)plus 1ml normal saline.~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
9526536|NCT03228862|Experimental|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
9526537|NCT03228225|Experimental|Tele cardiac rehabilitation|Following a standard intake process, patients will begin exercise in the institute and will gradually over a period of 6 months reduce the number of institution visits and will concomitantly increase the number of home \ community exercise sessions. During the entire period we will monitor program, coach and fine-tune the exercise program. Weekly exercise data will be securely transmitted to the rehabilitation team (heart rate zones, duration of exercise and type, step count, caloric expenditure, blood pressure and patients reported impressions)
9526538|NCT03228329|Other|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
9526539|NCT03228342|Experimental|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
9526540|NCT03228342|Experimental|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
9526541|NCT03228303|Active Comparator|Chronic phase CML treated by nilotinib|Newly diagnosed
9526542|NCT03228303|Active Comparator|Chronic phase CML treated by imatinib|Newly diagnosed
9526543|NCT03228160|Experimental|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
9526544|NCT03228160|Sham Comparator|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
9526545|NCT03228238|Experimental|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
10173141|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster:high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
9526546|NCT03228238|Experimental|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
10173142|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
10173143|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
9526547|NCT03228238|Experimental|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
9526548|NCT03228238|Active Comparator|Control group|Control subgroup : Standard medication for Variant angina only
9526549|NCT03228355|Active Comparator|Levcromakalim|
9526550|NCT03228355|Placebo Comparator|Saline|
9526551|NCT03228381|Experimental|BOSS Device|Patients who are undergoing open chest cardiac surgery via sternotomy will receive the BOSS device to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.
9526552|NCT03228277|Experimental|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
9526553|NCT03228264|Experimental|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
9526554|NCT03228264|Active Comparator|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
9526555|NCT03228134|Experimental|Hanxiao treatment group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
9526556|NCT03228134|Sham Comparator|Hanxiao control group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
9526557|NCT03228134|Experimental|Xuxiao treatment group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
9526558|NCT03228134|Sham Comparator|Xuxiao control group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
9526559|NCT03228121|Experimental|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
9526560|NCT03228121|Experimental|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
9826730|NCT02431273|Experimental|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
9826731|NCT02431273|Experimental|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
9826732|NCT02431273|Experimental|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
9826733|NCT02431364|Placebo Comparator|Placebo|Participants received matched placebo tablets to verdinexor tablets orally once daily on Days 1 and 3.
9826734|NCT02431364|Experimental|Verdinexor 5 mg|Participants received verdinexor 5 milligrams (mg) (2 tablets of 2.5 mg each) orally once daily on Days 1 and 3.
9826735|NCT02431364|Experimental|Verdinexor 10 mg|Participants received verdinexor 10 mg tablet orally once daily on Days 1 and 3.
9826736|NCT02431364|Experimental|Verdinexor 20 mg|Participants received verdinexor 20 mg tablet (2 tablets of 10 mg each) orally once daily on Days 1 and 3.
9826737|NCT02431364|Experimental|Verdinexor 40 mg|Participants received verdinexor 40 mg tablet (4 tablets of 10 mg each) orally once daily on Days 1 and 3.
9526561|NCT03228108|Experimental|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~fosfomycin 3 g orally 2 hours before prostate biopsy, or~pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
9526562|NCT03228108|Active Comparator|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
9826738|NCT02431455|Active Comparator|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
9526563|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
9526564|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
9526565|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
10173144|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
10173145|NCT03865615|Experimental|Oxytocin First|Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.
9526566|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
9526567|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
9526568|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
9526569|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
9526570|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
9661860|NCT03875287|Experimental|Decitabine and Cedazuridine|Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.
9826739|NCT02431455|Experimental|No Incentive Spirometry|No incentive spirometer provided
9826740|NCT02431468|Experimental|Bryostatin 1 20ug|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
10173146|NCT03865615|Experimental|Placebo First|Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.
10173147|NCT03865550|Placebo Comparator|Placebo|
10173148|NCT03865550|Active Comparator|Ketamine|
10173149|NCT03865745|Experimental|Korean Red Ginseng|Product: Red ginseng Everytime 1 pack(3g/day)
10173150|NCT03865563|Experimental|Pancreatic adenocarcinoma|Participants with resectable, borderline-resectable or locally-advanced pancreatic adenocarcinoma will receive pancreatic retrograde venous infusion of gemcitabine/lipiodol
10173151|NCT03865693|Experimental|scarmbler treatment group|Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The experimental participants were received scarmbler therapy 10 times for 2 weeks. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
10173152|NCT03865693|Sham Comparator|sham treatment group|conservative management without scarmbler therapy
9975424|NCT03157960|Experimental|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
10173153|NCT03865680|Experimental|MI varnish|MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
9975425|NCT03157960|Experimental|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
9975426|NCT03157960|Experimental|Fructose|Participant will receive a drink containing 35 g of fructose
10173154|NCT03865680|Active Comparator|Duraphat Fluoride varnish|Duraphat Fluoride: varnish 5% sodium fluoride varnish (Colgate, New York, N.Y.). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
9526571|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
9526572|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
9526573|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
9672641|NCT05032911||Neck pain patients|Patients with neck pain should have an intensity of pain of at least 3 points out of 10 on a Visual Analog Scale and a neck pain duration of at least 3 months of evolution. Neck pain could be from nonspecific mechanical origin, associated with whiplash or with a previous medical diagnosis of degenerative or inflammatory alterations of the cervical spine, associated or not with headache and pain in the shoulder region or the upper limb.
9694960|NCT04783506||At Risk for Mood Disorders|Adolescents at risk for mood disorders, which for this study, is defined by either personal history of anxiety disorder or substance use disorder or a history of trauma, or a first degree relative with a history of a mood disorder or suicidal history.
9694961|NCT04783506||Healthy Control|Healthy adolescents with no lifetime history of any psychiatric or substance use disorders or a history of trauma. Additionally, no first-degree family member with a history of a mood disorder or suicidal history.
9694962|NCT04783493|Active Comparator|ACTIVE|In the active group, non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold, this determined by abdominal muscle contractions, found from single pulses, applied gradually every 10 seconds until the contractions appear. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds.
9694963|NCT04783493|Placebo Comparator|PLACEBO|In the placebo group, a coil will be allocated in the T2-T3 thoracic region, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated. To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS).
9694964|NCT04783571|Experimental|Schizophrenia|Adult outpatients with a diagnosis of schizophrenia.
9694965|NCT04783571|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use.
9694966|NCT04783558|Experimental|Adapted NAS tool Intervention|Pregnant women in this condition will receive the adapted mobile-based NAS instructional tool and TAU. Women in this condition will go through the NAS instructional tool at least once during pregnancy, with their choice of going through the modules gradually while waiting at the OAT clinic to receive their dose, or by scheduling a time to review the modules. Participants will have free online access to the tool throughout their third trimester as well as through 12-weeks postpartum so they can access the modules at any time, and as many times as desired, including after giving birth.
9826741|NCT02431468|Experimental|Bryostatin 1 40ug|Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
10173155|NCT03865576||Thomas Jefferson University|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
10173156|NCT03865576||Honor Health in Phoenix|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
9826742|NCT02431468|Placebo Comparator|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
9975427|NCT03157960|Experimental|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
10173157|NCT03865576||Emory University Hospital in Atlanta|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors"
9526574|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
9526575|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
9526576|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
10173158|NCT03865576||University of Washington|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device. .~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors and lumbar puncture"
10173159|NCT03865732|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
10173160|NCT03865732|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
9526577|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
9526578|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
9526579|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
9526580|NCT03228082|Experimental|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
9526581|NCT03228082|No Intervention|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
9526582|NCT03227913|Active Comparator|Good chewing ability|
9526583|NCT03227913|Experimental|Impaired chewing ability|
9526584|NCT03228030|Experimental|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
9526585|NCT03228030|Placebo Comparator|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
9526586|NCT03227783|Active Comparator|Real tDCS|"Constant weak electric currents through scalp via two electrodes will be delivered.~Current intensity: 2mA, 20min/day"
9526587|NCT03227783|Sham Comparator|Sham tDCS|"a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects~Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
9528070|NCT03214185|Active Comparator|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
9528071|NCT03214146|Experimental|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.~*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
9528072|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
9672642|NCT05032768||Severe radiation dermatitis|RTOG/EORTC grade 2 and above
9672643|NCT05032768||No or mild radiation dermatitis|RTOG/EORTC grade 0 or 1
9672644|NCT05033028|No Intervention|Treatment-as-Usual|Participants will receive the same treatment as if they had not joined the study
10173161|NCT03865459|Experimental|Video group|The video group watched relaxing video with a ceiling mounted television during the whole cystoscopy.
10173162|NCT03865459|No Intervention|Control group|The control group received the standard treatment from a surgical technician who works in the cystoscopy during the whole procedure.The control group didn't watch relaxing video during the procedure.
9672645|NCT05033028|Experimental|Smartphone with dose changes after using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days play a 2-4 minute game.
9826743|NCT02431533|Experimental|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
10173163|NCT03865537|Experimental|Cold snare & Eleview injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Eleview
10173164|NCT03865537|Experimental|Cold Snare & Placebo injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Placebo
10173165|NCT03865537|Active Comparator|Hot snare & Eleview injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Eleview
9526588|NCT03227965|Other|ELITE|
9526589|NCT03227952|Active Comparator|Active treatment|Vibrotactile sensory stimulation
9526590|NCT03227952|Sham Comparator|Sham|Identical device. No vibration
9526591|NCT03227796|Experimental|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
10173166|NCT03865537|Active Comparator|Hot snare & Placebo injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Placebo
9526592|NCT03227796|Experimental|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
9526593|NCT03227796|Experimental|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
9526594|NCT03227796|Experimental|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
9526595|NCT03227796|Experimental|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
10173167|NCT03865641|Experimental|Virtual reality intervention|Experimental group : virtual reality intervention
9526596|NCT03227796|Experimental|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
9526597|NCT03227796|Experimental|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
9526598|NCT03227796|Experimental|Cohort 8 Healthy Volunteers Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers
9526599|NCT03227796|Placebo Comparator|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
10173168|NCT03865641|No Intervention|Control group|conventional rehabilitation without virtual reality intervention
10173169|NCT03865654|Experimental|Surveillance Mammography Communication Tool|"Conduct 30 telephone-based patient interviews~4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography~Perform cognitive testing of the communication tool"
10173170|NCT03865433|Experimental|Exercise Group|Intervention: aerobic exercise Subjects in the exercise group will be prescribed exercise at a target heart rate (THR) of approximately 80% of the achieved heart rate during the Buffalo Concussion Treadmill Test (BCTT). They will be given this prescription in writing to provide to their athletic trainer. Subjects will complete 30 minutes of daily exercise (including 5 minutes of warm up and 5 minutes of cool down) on an exercise bike or walking and supervised by an athletic trainer. This program may be modified by increasing heart rate threshold 5-10 beats per minute per week by the athletic trainer as the heart rate for symptom exacerbation increases.
10173171|NCT03865433|Placebo Comparator|Placebo/Stretching|Intrvention: stretching program Subjects assigned to the Stretching/Placebo group will be given a stretching protocol and instructions to report to their athletic trainer on a daily basis as soon as possible. . Subjects will then complete a 15-25 minute stretching program under supervision by the athletic trainer or other designated research personnel. The stretching protocol will be progressive and will change weekly as subjects continue their recovery.
10173172|NCT03865368|Experimental|Active Whole Body Vibration Training|Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
10173173|NCT03865368|Active Comparator|Control Group|The same exercises as the aWBVT group were performed on the vibration platform, with the vibration application turned off
9526600|NCT03227796|Placebo Comparator|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
9526601|NCT03227796|Placebo Comparator|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
9526602|NCT03227796|Placebo Comparator|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
9826744|NCT02431533|Placebo Comparator|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
10173174|NCT03865511|Experimental|TAGRISSO® 80mg (Osimertinib)|"Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.~Tumor biopsies performed at baseline and clinical progression. ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial."
10173175|NCT03865355||Cohort 1 / High grade Glioma|"Cohort 1:~Histologically confirmed high-grade glioma (grade III and grade IV (glioblastoma (GBM)))~Planned treatment (surgery followed by radiation therapy (RT) alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
10173176|NCT03865355||Cohort 2 / Low grade Glioma|"Cohort 2:~Histologically confirmed low-grade (grade I/II) glioma~Planned treatment either expectant monitoring or surgery followed by RT alone or Chemotherapy alone or a combination of RT/Chemotherapy"
9526603|NCT03227796|Placebo Comparator|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
9526604|NCT03227796|Placebo Comparator|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
9526605|NCT03227796|Placebo Comparator|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
9526606|NCT03227796|Placebo Comparator|Cohort 8 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
9526607|NCT03227731|Active Comparator|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
9826745|NCT02431559|Experimental|Phase 1, Dose Level 0a|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W [equivalent to 450 mg Q4W] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.
10173177|NCT03865355||Cohort 3 / Conditionally healthy volunteers|"Cohort 3:~No oncological disease was diagnosed~Planned treatment (reconstructive surgery after craniofacial trauma)"
10173178|NCT03865199|Experimental|Intervention Group|The intervention arm will view a digital story on a tablet created by the research team, then respond to a writing prompt. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
10173179|NCT03865199|No Intervention|Control Group|The control group will receive care as usual at the abortion clinic. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
9826746|NCT02431559|Experimental|Phase 1, Dose Level 0b|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
10173180|NCT03865186|Experimental|intervention group|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
9826747|NCT02431559|Experimental|Phase 1, Dose Level +1|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
9826748|NCT02431559|Experimental|Phase 2|Subjects received the MTD determined in Phase 1 (Dose Level +1), comprising PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
9826749|NCT02431572|Experimental|Metastatic Melanoma to the Brain (Cohort A)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
9826750|NCT02431572|Experimental|Primary Brain Tumor (Cohort B)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
9526608|NCT03227731|No Intervention|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation
9526609|NCT03227939|Experimental|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
9526610|NCT03227939|Active Comparator|LSG Group|LSG only
9526611|NCT03227718||athletic background|ex-gymnasts
9526612|NCT03227718||control|age-matched non-gymnastics background
9526613|NCT03227809|Experimental|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
9526614|NCT03227809|Experimental|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
9526615|NCT03227809|No Intervention|Control|Parents receive treatment as usual of incoming university student parents
9526616|NCT03227900|Active Comparator|Lidocaine|LIdocaine dissolved in water for injections
9526617|NCT03227900|Placebo Comparator|Placebo|Water for injections
10173181|NCT03865186|Experimental|control group|no intervention was applied to the control group
10173182|NCT03865264|Active Comparator|Living Liver donor|"Recovery enhancement program:~At least 6 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
10173183|NCT03865264|Active Comparator|Living Kidney donor|"Recovery Enhancement Program~At least 4 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
10173184|NCT03865264|No Intervention|Living Kidney donor (Control)|"Subjects maintain the same lifestyle without practicing physical training, relaxation skills or nutritional drink before and after the surgery.~To control post-op pain, subject will use medication per standard of care, including PCA pump."
10173185|NCT03865251|Experimental|experimental group|Kinesiology tape application to dominant leg during lying and standing positions
10173186|NCT03865134||Laser Group|Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
10173187|NCT03865134||Anti-VEGF Group|Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
9526620|NCT03227978|Experimental|PCL mesh group|Intervention: The participants will be received thoracoscopic bullectomy and abrasion of pleura, then PCL mesh will be applied over the lung.
9975428|NCT03150329|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO BID on days 1-5 and 8-12 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
9526621|NCT03228043|Experimental|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
9526622|NCT03228043|Placebo Comparator|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
9526623|NCT03227991|Active Comparator|Safety Planning Intervention|SPI is a personalized approach that focuses on early identification of warning signs and execution of systematic steps to manage suicidal thoughts, created collaboratively by the patient and clinician.
9526624|NCT03227991|Active Comparator|Risk factors and Warning signs|Patients will receive a generic suicide risk factors and warning signs information handout.
9526625|NCT03227744|Active Comparator|Enrolled in group therapy|Patients in the group therapy arm will be enrolled in group therapy and be issued surveys.
9526626|NCT03227744|Placebo Comparator|Not enrolled in group therapy|Patients in control arm will be issued surveys
10173188|NCT03865134||Regrese Group|Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
10173189|NCT03865290|Experimental|Healthy Control Ondansetron 8 mg|Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
9526627|NCT03227926|Experimental|Screening Phase|"Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the molecular eligibility of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared molecularly eligible for the Trial Phase."
10173190|NCT03865290|Experimental|Diabetic (DM) gastroenteropathy Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
10173191|NCT03865290|Experimental|Non-ulcer dyspepsia (NUD) Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
9526628|NCT03227926|Experimental|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
10173192|NCT03865290|Placebo Comparator|Healthy Control Placebo|Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
10173193|NCT03865290|Placebo Comparator|Diabetic (DM) gastroenteropathy Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
10173194|NCT03865290|Placebo Comparator|Non-ulcer dyspepsia (NUD) Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
10173195|NCT03865342|Experimental|Noom Coach DPP|Individuals will receive special instructions on how to use the app and will self-monitor their weight, exercise and receive daily DPP core content through the app over 16 weeks plus guidance from a coach, and will thereafter receive post-core DPP content up to 52 weeks.
10173196|NCT03865342|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the DPP curriculum."
10173197|NCT03865225|Sham Comparator|Control group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes sham-biofeedback over a period of three days
10173198|NCT03865225|Active Comparator|Treatment group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes biofeedback sessions over period of three days
9526629|NCT03227770|Active Comparator|regular hemodialysis|Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.
9526630|NCT03227770|Experimental|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment once every two week
9526631|NCT03227679|Active Comparator|Metabolism-Informed Care (MIC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) recommendations were guided by Nicotine Metabolism as measured by the Nicotine Metabolite Ratio. Ultimately, after being educated about smoking cessation medication efficacy and side-effects, the participant could decide to take any medication for which they were medically cleared, but the recommendation was made based on rate of Nicotine Metabolism.
9526632|NCT03227679|Active Comparator|Guideline-Based Care (GBC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) was co-selected from those they were medically able to receive after educating participants about smoking cessation medication efficacy and side-effects.
10173199|NCT03865160|Active Comparator|Atropine eye drops, 0.01%|Atropine eye drops, 0.01%, both eyes at bedtime
9526633|NCT03227822|Experimental|Short spot stenting|Short spot stenting
9526634|NCT03227822|Experimental|Long lesion stenting|Long lesion stenting
9526635|NCT03228004|Experimental|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
9526636|NCT03227705|Active Comparator|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
9526637|NCT03227705|Experimental|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
9526638|NCT03227887|Active Comparator|Good chewing ability|
9526639|NCT03227887|Experimental|Impaired chewing ability|
9526640|NCT03228056|Experimental|uniportal VATS lobectomy|"uniportal VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
10173200|NCT03865160|Placebo Comparator|Placebo (NaCl 0.9%) eye drops|Placebo (NaCl 0.9%) eye drops, both eyes at bedtime
10173201|NCT03864939|Experimental|dHAM|dHAM wrap is placed during RRP.
9526641|NCT03228056|Active Comparator|two-ports VATS lobectomy|"two-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
9526642|NCT03228056|Active Comparator|three-ports VATS lobectomy|"three-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
9526643|NCT03227874|Experimental|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
9526644|NCT03227874|Experimental|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
9526645|NCT03227666|Experimental|Intervention Group|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
9526646|NCT03227666|No Intervention|Control group|The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
9526647|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
9526648|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
9526649|NCT03227640|Active Comparator|stripping|standardized laparoscopic stripping technique
9975429|NCT03143816|Active Comparator|Technosphere insulin (TI, Afrezza) -Treatment arm|Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG ( post prandial blood glucose)
10173202|NCT03864939|Placebo Comparator|Standard|A standard RRP is performed.
10173203|NCT03864991|No Intervention|Routine Care|This group will be followed up for routine care, maintaining a standard log book for documenting blood sugar and insulin dosages per advice and explanation by doctors, nurses and nutritionists.
9975430|NCT03143816|No Intervention|Insulin Aspart ( Novolog) -Control arm|Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals.
9975431|NCT03143322|Experimental|Systemic treatment + SBRT|Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
10173204|NCT03864991|Active Comparator|e-device for step count (fit-bit)|This group will receive e-device for step count (fit-bit) in addition to routine care.
10173205|NCT03864991|Active Comparator|e-messages for log book|This group will receive daily e-messages for maintaining log book in addition to routine care.
9526650|NCT03227640|Experimental|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
9526651|NCT03227627|Experimental|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
9526652|NCT03227627|Active Comparator|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
9526653|NCT03227497|Active Comparator|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).~Treatment arm includes 56 g of whole walnuts daily."
9526654|NCT03227497|No Intervention|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
9526655|NCT03227484|Active Comparator|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
9672646|NCT05033028|Experimental|Smartphone with dose changes before using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days to play a 2-4 minute game.
10173206|NCT03864991|Active Comparator|e-messages for log book & fit-bit|This group will receive e-device for step count (fit-bit), daily e-messages for maintaining log book for blood sugar, insulin dosages and step count in addition to routine care.
9526656|NCT03227484|Placebo Comparator|Placebo|Matching placebo tablet once daily over 8 weeks
9526657|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
9526658|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
9526659|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
9526660|NCT03227367|Experimental|Test group|Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
9526661|NCT03227367|Other|control group|Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
9826751|NCT02431572|Experimental|Primary Brain Tumor (Cohort C)|"Chemoradiation~Assess inflammation (PBR PET)~Follow Patients"
9975432|NCT03143322|No Intervention|Systemic treatment|Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression…)
9975433|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
9526662|NCT03227419|Experimental|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
9526663|NCT03227419|Experimental|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
9526664|NCT03227393|No Intervention|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
9526665|NCT03227393|Experimental|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
9526666|NCT03227510||HCC Cases (Group 1)|This group will include 63 subjects and the diagnoses will be based on clinical examination, laboratory tests such as (Liver Function tests, Alpha-fetoprotein , Ultrasound, and biopsy in some cases if possible (Depends on the patients and their financial issues).
9526667|NCT03227510||Chronic Liver Diseases (group 2)|This group will be including 31 patients, and the diagnoses will be based on laboratory such as (liver function tests, viral markers, AFP,) and by ultrasound findings (shrunken liver, coarse echo-pattern, attenuated hepatic vein and finding nodular surface)
9526668|NCT03227510||Healthy Volunteer (group 3)|"It will include 32 subjects that serve as control group.~These all patients and control groups will be subject the following parameters: Biochemical tests such as (Liver function tests, viral markers, serum AFP, CBC, Kidney functions and others) and circulating MicroRNAs levels of all these subjects."
9526669|NCT03227380|Other|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
9526670|NCT03227562|Other|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
9526671|NCT03227562|Other|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
9526672|NCT03227341|Other|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
10173207|NCT03865056|Experimental|High-Flow Nasal Cannula|
9526673|NCT03227341|Other|patients with partially controlled asthma|8 week pulmonary rehabilitation program
9526674|NCT03227328|Active Comparator|Treatment Arm A|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
10173208|NCT03865056|Experimental|Noninvasive ventilation|
9526675|NCT03227328|Experimental|Treatment Arm B|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
9526676|NCT03227432|Experimental|Nivolumab + Elotuzumab|"22 patients will be entered, If > 4 patients achieve at least a partial response (PR) within 4 cycles an additional 18 patients will be treated.~Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5"
9526677|NCT03227432|Experimental|Nivolumab+Elotuzumab+Pomalidomide+Dexamethasone|"Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5~Pomalidomide will be administered for 21 days per cycle~Dexamethasone will be administered weekly"
9526678|NCT03227549|Experimental|Direct Superior Approach|The intervention being tested is the surgical approach.
9526679|NCT03227549|Active Comparator|Posterior Approach|
9528073|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
9672647|NCT05033028|Experimental|Focus group with Study Physicans|Study physicians asked to participate in a focus group session or 1:1 interviews if unable to attend the focus group during year one of the study and once annually towards the end of years 2, 3, 4, and 5 of the study
10173209|NCT03865277|Other|standard radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy
10173210|NCT03865277|Experimental|dose-escalated radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy
10173211|NCT03865277|Experimental|escalated radiochemoth., carbon boost, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)
9826752|NCT02431598|Active Comparator|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
10173212|NCT03865277|Other|standard radiochemotherapy, oxic|HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy
10173213|NCT03865277|Other|standard radiochemotherapy (70 Gy)|HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.
10173214|NCT03865004|Placebo Comparator|Placebo|
10173215|NCT03865004|Active Comparator|Paracetamol|
9526680|NCT03227575|Experimental|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
9526681|NCT03227575|Experimental|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
9526682|NCT03227575|No Intervention|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
9526683|NCT03227276|Placebo Comparator|Placebo|
9526684|NCT03227276|Experimental|Litramine|
9526685|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
9526686|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
9826753|NCT02431598|Active Comparator|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
10173216|NCT03865004|Active Comparator|Dexketoprofene|
10173217|NCT03864913|Experimental|Randomized SQ vs IM|Subjects randomized to either SQ or IM testosterone injections follow study protocol.
10173218|NCT03864913|Experimental|Non-randomized SQ|Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.
10173219|NCT03864913|Experimental|Non-randomized IM|Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.
10173220|NCT03865147|Experimental|Phase 1 open, pilot phase|A pilot group of 10 patients who will receive Tri-Solfen only (non-randomised) once, prior to debridement
10173221|NCT03865147|Experimental|Phase 2 - Tri-Solfen|A group of 20 patients who will receive EMLA cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by a single application of Tri-Solfen.
10173222|NCT03865147|Active Comparator|Phase 2 - Standard Care|A group of 20 patients who will receive EMLA Cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by standard of care post-operative analgesia.
10173223|NCT03865147|Experimental|Phase 3 - Tri-Solfen|A group of 20 patients who will receive two applications of Tri-Solfen (2mL/10cm2), once prior to debridement and once on completion of the procedure.
10173224|NCT03865147|Active Comparator|Phase 3 - EMLA|A group of 20 patients who will receive EMLA Cream (60-minute application) prior to surgical debridement
10173225|NCT03865121|Experimental|Nicotine Nasal Spray 10 MG/ML|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
10173226|NCT03865108|Experimental|Pessary and Progesterone|Women already receiving a pessary in addition to the standard progesterone through the TOPS trial will undergo ultrasound imaging and cervical speculum examination for information collection.
10173227|NCT03865108|Placebo Comparator|Progesterone only|Women already receiving the standard progesterone only will undergo ultrasound imaging and cervical speculum examination for information collection.
10173228|NCT03865069|Active Comparator|automated oxygen control with VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) with automated pressure control (Volume Guarantee®).
10173229|NCT03865069|Active Comparator|automated oxygen control without VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) without automated pressure control (Volume Guarantee®).
10173230|NCT03864822|Experimental|Active tDCS|30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA
10173231|NCT03864822|Placebo Comparator|Sham tDCS|30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes
10173232|NCT03864887||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
10173233|NCT03864887||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
9526687|NCT03227523||subjects with copd|
9526688|NCT03227523||subjects without pulmonary disease|
9526689|NCT03227406|No Intervention|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
9526690|NCT03227406|No Intervention|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
9526691|NCT03227406|Experimental|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
9526692|NCT03227406|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
9526693|NCT03227146|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
9526694|NCT03227133|Experimental|Single arm|Psychiatric interview, Neuropsychological evaluations, cardiovascular risk assessment
9526695|NCT03227185|Experimental|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
9526696|NCT03227185|Experimental|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
9526697|NCT03227120|Experimental|Prehabilitation Exercise|Receives Prehabilitation exercise program for three times a week for eight weeks of direct outpatient exercise instruction.
9526698|NCT03227120|No Intervention|Control|Receives the usual standard of care which is a one time Strength and Flexibility written home exercise program provided during total joint education pre-surgery class.
9526699|NCT03227094|Other|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
9526700|NCT03227094|Experimental|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
9526701|NCT03227094|Experimental|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
9526702|NCT03227237||Case group|Introduction was given about research and researcher to participants. Got the assent from participants, consent from parents and collected baseline data (demographic variable, specific IPR variable) from the participants. Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants.Participants were asked to fill out IPR related information of pre delinquent period with paper & pencil mode of technique. It took for each group of participants about 40 minutes. Collected data regarding conduct variables from parents with interview technique. On each day 8-16 participants were covered.
9526703|NCT03227237||Control group|Introduction was given about research and researcher to participants. Confirmed telephonic consent from Parents.Collected baseline data (demographic variable, specific IPR variable) from the participants.Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants. Participants were asked to fill out IPR related information of their past life from before 2 years with paper & pencil mode of technique. It took for each group of participants about 40 minutes. On each day 8-20 participants were covered Got the written consent form parents and collected data regarding conduct variables from parents with interview technique.
9526704|NCT03227068|Experimental|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
9526705|NCT03227068|Experimental|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
9526706|NCT03227198|Experimental|Intramyocardial injection of stem cell|Intramyocardial injection of autologous bone marrow mononuclear cells in patients with Heart Failure
9526707|NCT03227198|Placebo Comparator|Placebo|Placebo intramyocardial injection in patients with Heart Failure
9526708|NCT03226860|Experimental|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
9526709|NCT03226860|Active Comparator|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
10173234|NCT03864887||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
9526710|NCT03226977|Experimental|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
9526711|NCT03226977|Active Comparator|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
9526712|NCT03227055||CKD|Children and adolescents with stage G1-G4 CKD, age 3 to 18 yr
9526713|NCT03226964|Experimental|High flow nasal oxygen|(Optiflow; Fisher & Paykel, Auckland, New Zealand)
9526714|NCT03226964|Active Comparator|Nasal prongs|
9526715|NCT03226951|Experimental|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
9526716|NCT03226873|Experimental|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
9526717|NCT03227016|Experimental|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
9526718|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
9526719|NCT03226834|Active Comparator|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
9526720|NCT03226834|Experimental|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
9526721|NCT03226782|Active Comparator|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
9526722|NCT03226782|Active Comparator|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
9526723|NCT03226730|Experimental|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
10173235|NCT03864887||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
10173236|NCT03864978|Experimental|Rifaximin-EIR 800 mg BID for 10 days|2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
9528074|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
9672648|NCT05033028|Experimental|Focus group with Clinicians|Clinicians asked to participate in a 1:1 interview and a separate focus group at roughly the same time. Prior to the first structured interview with our study team, you will participate in a 1-hour training and familiarization session with the SOAR system using synthetic or training data.
9672649|NCT05032989|Experimental|Extraction of distoangular and vertically positioned 3rd molar using cowhorn forcep|Extraction with new technique
10173237|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 30 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
10173238|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 10 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
10173239|NCT03864978|Placebo Comparator|Two placebo tablets BID for 30 days|2 x placebo tablets twice a day for 30 days
10173240|NCT03864835|Experimental|Moderate intensity aerobic exercise|All subjects will undergo DXA and CRF measurement (relative VO2max) under the supervision of an American College of Sports Medicine (ACSM)-certified fitness professional and study physician at the Penn State PM&R Research Laboratories. Subjects selected for the interventional pilot trial will receive a FitBit Charge2 HR and be instructed on how to use a FitBit Hear Rate monitor, Fitbit application, Fitbit website, and Fitabase (secure data management platform utilized by >400 clinical trials). Participants will record their daily food and beverage intake through the Fitbit app. Individualized feedback will be provided by a registered dietician (RD). Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist.
10173241|NCT03864809||psoriasis patients|sleep disturbance
10173242|NCT03864809||atopic dermatites patients|sleep disturbance
10173243|NCT03864809||control|sleep disturbance
9672650|NCT05032989|Active Comparator|Extraction of distoangular and vertically positioned 3rd molar via conventional method|Extraction with the conventional technique
10173244|NCT03864783|Experimental|Curcumin (Meriva®)|Meriva® 500 mg tablet (contains 100 mg curcumin) Dosage: 2 tablets twice daily for 42 days (+/- 3 days)
10173245|NCT03864783|Placebo Comparator|Placebo|Placebo. Dosage: 2 tablets twice daily to mimic Meriva® tablets.
10173246|NCT03865017|Experimental|Regulatory T cells|Biologicals: Autologous Regulatory T cells (1.7*10^5 cells/kg, i.v) other name: GB301
10173247|NCT03865017|Placebo Comparator|Placebo|Saline+cell suspension solution infusion
10173248|NCT03864666|Other|Sequence 1|Treatment RTRT
10173249|NCT03864666|Other|Sequence 2|Treatment TRTR
10173250|NCT03864718||complex anal fistula|
10173251|NCT03864679|Experimental|Exercise|Subjects will perform a cycling tests
10173252|NCT03864497||Orthotopic liver transplantation candidates|No intervention, imaging test and risk stratification as part of routine clinical care.
10173253|NCT03864757|Experimental|UVFP correction surgery|Short-term implantation of VOIS and evaluation of voice quality and glottal closure.
10187059|NCT03729973|Active Comparator|Group (L)|"Group (L) (n=25): patients nebulized lidocaine 2% 100mg .So total volume (5ml). In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
10173254|NCT03864770|Experimental|Extracorporeal shock wave therapy and general physical therapy|In this arm, the subjects will receive the intervention of extracorporeal shock wave therapy and general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
9526724|NCT03226730|Experimental|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
10173255|NCT03864770|Active Comparator|Only general physical therapy|In this arm, the subjects will only receive the intervention of general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
9526725|NCT03226730|Experimental|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
9526726|NCT03226730|No Intervention|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
9526727|NCT03226925|Experimental|Healthy volunteers on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
9526728|NCT03226925|Experimental|Cancer patients on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
9526729|NCT03226925|Experimental|Planning with patients on ventilation|Planning 4D-CT will be performed with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different ventilation modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
9526730|NCT03226743|Experimental|Intervention Group|collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network
9526731|NCT03226743|No Intervention|Control Group|treatment as usual in German health care system
9526732|NCT03226886||All patients|"In London renal cell carcinoma patients undergo nephrectomy at centres for urological oncology, including the Royal Marsden, Guy's and St Thomas', St Georges, Charing Cross and Kings Hospitals. It is not uncommon for the same patients to undergo palliative resection for metastatic sites of disease. The majority of tissue from these resections does not undergo routine histopathological examination. As such, it is ethically feasible to use these specimens for laboratory research in the presence of patient consent. Practically, these specimens are often large, thereby offering considerable scope for a range of molecular analyses.~CAPTURE Sub-study:~We plan to enrol patients/participants into three groups:~Group A: patients with confirmed or suspected COVID-19 and a history of cancer Group B: patients without a history of COVID-19 infection and a history of cancer Group C: Hospital staff with or without a history of COVID-19"
9526733|NCT03226821|Experimental|Tesamorelin|Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.
9526734|NCT03226600|Active Comparator|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
9526735|NCT03226600|Experimental|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
9526736|NCT03226587|Experimental|Blue light|Each subject will be undergo a whole body exposure to blue light (453 nm wavelength) for 30 minutes.
9526737|NCT03226587|Placebo Comparator|Control exposure|Each participant will also undergo a control examination, where the body will be covered with a light tight foil during blue light exposure for 30 minutes.
9526738|NCT03226626|Active Comparator|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
9526739|NCT03226626|Experimental|TAAD + IVAD|Both subcutaneous tumescent anesthesia & antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
9526740|NCT03226613|Experimental|Patients with suspected or known oropharyngeal cancer|Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
9526741|NCT03226574|Experimental|RTX epidural injection|Epidural injection of 1.5mL/min RTX under the guidance of epidurogram.
9526742|NCT03226561|Active Comparator|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
9672651|NCT05033093|Active Comparator|Ah Plus|All samples will be filled with Ah Plus root canal sealer and gutta percha
9672652|NCT05033093|Active Comparator|I Root SP|All samples will be filled with I Root SP root canal sealer and gutta percha
10173256|NCT03864380||Person running a marathon|"Exams performed before (1 month maximum) and after the marathon (1 hour maximum) :~Color retinography Optical Coherence Tomography - Angiography (OCT-A) Blood pressure measurement"
10173257|NCT03864549|Experimental|probiotic femina II|research group will receive the probiotic formula Femina II (2 capsules/day) until delivery.
9526743|NCT03226561|No Intervention|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
9526744|NCT03227614|No Intervention|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
10173258|NCT03864549|Placebo Comparator|Placebo|control group will receive a placebo (2 capsules/day) until delivery.
10173259|NCT03864471|Experimental|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
9526745|NCT03227614|Experimental|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
9526746|NCT03226405|Experimental|Patient Navigation Program|"The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.~The Patient Navigation Program include~Education,~Appointment reminders,~Help with insurance,~Transportation,~Navigating the Cancer Center,~Assisting in finding appropriate child care,~Interpreting,~Connecting the patient to psychosocial and/or palliative care teams,~Physically escorting the patient to appointments"
9526747|NCT03226405|Active Comparator|Standard of Care|"The patients will receive enhanced usual care,~This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
10173260|NCT03864471|Active Comparator|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
10173261|NCT03864484|Experimental|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, participants watch a video using the iPad Application displaying positive word stimuli.
9526748|NCT03226444|Experimental|0.005% Lacripep|0.005% Lacripep ophthalmic solution
9526749|NCT03226444|Experimental|0.01% Lacripep|0.01% Lacripep ophthalmic solution
9526750|NCT03226444|Placebo Comparator|placebo|placebo solution
9526751|NCT03226431|Experimental|ARINA-1|Ascorbic acid (ARINA-1) (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
9526752|NCT03226496|Experimental|Intervention Group|This group receives a brief motivational interviewing session about PrEP
10173262|NCT03864484|Active Comparator|Usual rehabilitation|The control group receives usual rehabilitation.
9526753|NCT03226496|No Intervention|Control Group|This group receives standard of care clinic based counseling about PrEP
9526754|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
9526755|NCT03226535|Experimental|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
9526756|NCT03226535|No Intervention|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
9672653|NCT05033093|Active Comparator|GuttaFlow Bioseal|All samples will be filled with GuttaFlow Bioseal canal sealer and gutta percha
10173263|NCT03864341|Experimental|Homelessness Prevention Services|
9526757|NCT03226483|Experimental|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
9526758|NCT03226379|Other|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~Health system strengthening~Delivery of a co-designed education program tailored to frontline healthcare workers~Implementation of an algorithm for HIV-related meningoencephalitis~Infectious diseases/AHD mentorship and laboratory capacity building"
9672654|NCT05032677|Experimental|Conventional Epidural Technique|
9672655|NCT05032677|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
9672656|NCT05032664|Experimental|Intervention Group|Home-based aromatherapy programme
9672657|NCT05032664|Other|Control Group|Wait-list control
9826754|NCT02431598|Active Comparator|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
10173264|NCT03864263||Children with HBsAg-positive patients|Children from a father or mother who are infected with HBV
10173265|NCT03864263||Children without a family history of HBV|Children without a family history of HBV infection
10173266|NCT03864250|Experimental|Tacrolimus monotherapy|
10173267|NCT03864250|Active Comparator|Tacrolimus combined with hormone therapy|
10173268|NCT03864393|Experimental|Multimodal overground locomotor training|Individuals with Parkinson's Disease that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 12-week multimodal exercise training intervention performed twice per week.
10173269|NCT03864328|Experimental|RVT-1601 Low Dose|
10173270|NCT03864328|Experimental|RVT-1601 Mid Dose|
10173271|NCT03864328|Experimental|RVT-1601 High Dose|
10173272|NCT03864328|Placebo Comparator|Placebo|
10173273|NCT03864601|Experimental|14C-JNJ-56136379|Participants will receive a single oral 25 milligram (mg) dose of 14C-JNJ-56136379 on Day 1 under fed conditions.
10173274|NCT03864523|Experimental|XAMNPIO|Pioglitazone 15 mg tablets 2/day during 2 years
10173275|NCT03864354||Participants|Participants were adults with a diagnosis of asthma, treated using a standardized Osteopathic Manipulative Treatment protocol.
10173276|NCT03864588|Placebo Comparator|Control|Anesthesiologist preforms ultrasound guided adductor canal block post-operatively
10173277|NCT03864588|Experimental|Intervention|Surgeon preforms inter-operative adductor canal block
10173278|NCT03864575|Experimental|Combination Group|Celecoxib 400 mg/d Nivolumab 240 mg q2w
10173279|NCT03864458|Experimental|KHK7791 A|Patients take KHK7791 low dose BID.
10173280|NCT03864458|Experimental|KHK7791 B|Patients take KHK7791 middle dose BID.
10173281|NCT03864458|Experimental|KHK7791 C|Patients take KHK7791 high dose BID.
9526759|NCT03226418|Experimental|Group I|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine intravenously (IV) on days 1-7 and idarubicin over 10-15 minutes on days 1-3 (7+3), or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Gemtuzumab or midostaurin are added to 7+3 as per the standard of care. Treatment continues for 1 course in the absence of unacceptable toxicity.~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours twice daily (BID) on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression, unacceptable toxicity."
9526760|NCT03226418|Experimental|Group II|"LOW-INTENSITY: Patients receive venetoclax in combination with azacitidine or decitabine or other standard of care low-intensity therapy such as azacitidine or decitabine alone or in combination with FLT3 inhibitor such as midostaurin, low-dose cytarabine in combination with glasdegib.~Venetoclax dose varies depending on drug interaction with antifungal agents. Given daily continuous for >= 3 months orally. Glasdegib dose is 100 mg oral daily.~Decitabine IV over 1-3 hours daily for 5-10 days. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant. Azacitidine IV infusion over 10 to 40 minutes days 1 -7. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant."
10173282|NCT03864458|Experimental|KHK7791 D|Patients start at KHK7791 high dose and can down titrate weekly ,based on a GI tolerability question.
10173283|NCT03864458|Placebo Comparator|Placebo|Patients take Placebo BID.
10173284|NCT03864367||Device|This group will use the MWeST lift device along with regular physical therapy. The lift device is the Prism Medical FGA-700 Bariatric Floor Lift including a sling to assist in walking.
9526761|NCT03226522|Experimental|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
9526762|NCT03226522|Active Comparator|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
9526763|NCT03226522|Placebo Comparator|Placebo|Placebo tablets taken by mouth for 5 weeks.
9528075|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
9528076|NCT03214237||Participants|Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study
9528077|NCT03214289|Experimental|Fecal Microbiota Transplantation (FMT)|"Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.~Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.~Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected."
9827759|NCT02466958|Active Comparator|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
10173285|NCT03864367||Control|This group will only receive regular physical therapy.
10173286|NCT03864432|Experimental|25mg SAD|
10173287|NCT03864432|Experimental|50mg SAD|
10173288|NCT03864432|Experimental|100mg SAD|
10173289|NCT03864432|Experimental|50mg Multiple dosing|
10173290|NCT03864315|Experimental|Vitiligo|30 Patients with Vitiligo
10173291|NCT03864302|Experimental|Motor Imagery|"The intervention group is informed about the concept of motor imagery (MI) for performance enhancement and are instructed in using the modified PETTLEP framework for TURB (table 1).(18) The intervention group performs a MI training session (MITS) prior to each VR simulation procedure.~Table 1: PEELP framework:~Physical: Sitting in front of the simulator, aloud to touch and move the scope Environment: Simulated sounds from the OR, including electrical device feedback from devices and vital measures Task: Four standardized TURB cases Timing: Each MI session is temporal to a simulated TURB case, max. 10 minutes Learning: Think aloud the major steps of the procedure using Emotions: Imagine the emotions when the surgery progresses and when an adverse event occurs Perspectives: Internal perspective thinking then I…"
10173292|NCT03864302|No Intervention|Control|The control group proceeds directly to standard VR-simulator training.
10173293|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody positive)|
10173294|NCT03864185|Placebo Comparator|Placebo group (IgG4 autoantibody positive)|
10173295|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody negative)|
10173296|NCT03864198|Other|Genante (Tm)|Genante tablets One tablet in the morning and one tablet in the evening for 3 months
10173297|NCT03864237|Experimental|Alcohol texts|Participants assigned to this arm will receive a text message each day for 10 weeks, containing factual information about campus drinking norms.
10173298|NCT03864237|Placebo Comparator|Attention control|"Participants assigned to this arm will receive a text message each day for 10 weeks, containing this day in history facts."
10173299|NCT03864172|Placebo Comparator|Usual intake + placebo fruit juice|Placebo fruit flavoured juice powder
10173300|NCT03864172|Active Comparator|Usual intake +SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF)
10173301|NCT03864172|Active Comparator|Adequate calcium +fruit juice placebo|Placebo fruit flavoured juice powder added with 600 mg calcium to meet RNI intake
10173302|NCT03864172|Active Comparator|Adequate calcium + SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF) and 600 mg calcium to meet RNI intake
9826755|NCT02431637|Experimental|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
10173303|NCT03864159|Experimental|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time.The intervention through the suction cups will consist of its application and produce increased flexibility of the hamstring musculature. The technique will be performed with the subject in prone position, on the stretcher, while the physiotherapist will be placed next to the member to be treated. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
9526764|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
9526765|NCT03226340|Experimental|S-amlodipine + Chlorthalidone|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
10187060|NCT03729973|Active Comparator|Group (C)|"Group (C) (n=25): patients nebulized normal saline(0.9%). 5ml .In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
10187061|NCT03729934|No Intervention|Control|This arm receives no treatment control.
9526766|NCT03226340|Active Comparator|S-amlodipine + Telmisartan|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
9526767|NCT03226327|Experimental|hypertension patients|
9526768|NCT03226197|Experimental|Study group|Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
9526769|NCT03226210|Experimental|NovoRapid group (group Asp)|
9526770|NCT03226210|Experimental|Prandilin group (group Lis)|
9526771|NCT03226054|Other|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
9526772|NCT03225937|Experimental|Cohort A|Trastuzumab and lapatinib
9526773|NCT03225937|Experimental|Cohort B|Pertuzumab and Trastuzumab-emtansine
9526774|NCT03226080|Placebo Comparator|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
9526775|NCT03226080|Active Comparator|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
9526776|NCT03226041|Experimental|retroperitoneoscopic urologic surgery|All included patients will undergo retroperitoneoscopic renal or adrenal surgery with the transcutaneous carbon dioxide monitor.
9526777|NCT03226002|Active Comparator|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
9526778|NCT03226002|Active Comparator|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
9526779|NCT03225911|Experimental|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
9526780|NCT03225911|Experimental|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
9526781|NCT03225911|Experimental|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
9526782|NCT03225976|Experimental|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
9526783|NCT03225976|Experimental|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
9526784|NCT03225976|Sham Comparator|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
9526785|NCT03225976|Experimental|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
9526786|NCT03225924|Experimental|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
9526787|NCT03225898|Experimental|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
9827760|NCT02466958|Placebo Comparator|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
9526788|NCT03225898|Active Comparator|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
9526789|NCT03226119|Experimental|HTLV Infected (n=50)|Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)
10173304|NCT03864159|Active Comparator|Foam roller|The intervention will be carried out before starting the training session. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
9526790|NCT03226119|Experimental|Neurological Disorders (n=100)|Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica
9672658|NCT05032586|No Intervention|control groups: without wearing virtual reality headsets|"Before dressing, the child was given paracetamol, which is routinely used to prevent pain. The child was reminded that they would be with their family during the procedure, and either the mother or father was taken to the dressing room during dressing. After the standard burn dressing was applied to the patient by the healthcare personnel in the burn center treatment room, oxygen saturation and heart rate measurements were made again after the procedure and recorded in the Application Registration Form. Before and after the procedure, the patients were asked about the pain and anxiety levels felt during dressing and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
9672659|NCT05032586|Experimental|experimental groups|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
9672660|NCT05032365|Experimental|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
9672661|NCT05032365|Active Comparator|Conventional|Two hours period where the FiO2 delivered will be conventionally adjusted by the healthcare personnel based on SpO2 values obtained from the patient.
9672662|NCT05032378||People with movement disorders|Adults with acquired movement disorders secondary to neurological injury.
9672663|NCT05032378||Professionals|Professionals providing physical or occupational therapy to participants with acquired movements disorders.
9672664|NCT05032261||Group 1: surviving Patients|Patients surviving within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
9672665|NCT05032261||Group 2: Deceased patients|Patients deceased within 5 days of the date of ICU admission for circulatory shock and receiving norepinephrine
9672666|NCT05032391|Experimental|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is lyophilized and supplied with 2.5 ml of citrate bicarbonate buffer added for reconstitution before oral administration.
9672667|NCT05032391|Placebo Comparator|Diluent is a sterile solution (Citrate Bicarbonate Buffer)|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
9672668|NCT05032287|Active Comparator|tamsulosin|tamsulosin 0.4 mg once daily
9672669|NCT05032287|Placebo Comparator|Placeb|Placebo once daily
9672670|NCT05032404|Experimental|BNT103|All participants receive BNT103. BNT103 provides 10 sessions over approximately 10 weeks.
9672671|NCT05032430|Experimental|ATIENDE|Mindfulness-based parental stress reduction intervention
9672672|NCT05032430|Active Comparator|Modified Health Enhancement Program|Attention-matched comparator group designed to influence health and well-being that does not include mindfulness as an active ingredient
9672673|NCT05032534|Active Comparator|Newly developed cone for 6 weeks the currently used cone for 6 weeks|Starts off with treatment with the newly developed cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
9672674|NCT05032534|Active Comparator|Currently used cone for 6 weeks the newly developed cone for 6 weeks|Starts off with treatment with the currently used cone for transanal irrigation for 6 weeks and are then instructed to crossover to the contrary system, the currently used, for additional 6 weeks.
9672675|NCT05032326|Other|OXYTOCIN Treated cohort|babies treated with Oxytocin during the OTBB3 study
9672676|NCT05032326|Other|Untreated cohort|babies not included in the OTBB3 study and therefore never treated with Oxytocin
9672677|NCT05032482|Other|Investigational Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
9975434|NCT03128996|Experimental|RIC Prep Regimen & GVHD Prophylaxis|Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
9672678|NCT05032482|Other|Investigational Treatment 2|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
9672679|NCT05032638|Experimental|Experimental Group|Subjects with motor impairment will work closely with an occupational therapist to identify a goal and select activities that they will work on at home to improve the function of their affected arm.
9672680|NCT05032547|Experimental|Primary Care Online Emotion-Regulation Treatment|The youth component in the experimental condition will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as mindfulness practice and acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective responding to their children's and their own emotions.
9975435|NCT03122847||Patients|30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated
9526791|NCT03226093|Experimental|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
9526792|NCT03226171|Experimental|Dose-adjusted SK-1403|
9526793|NCT03225885|Active Comparator|Printed Handout|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as a printed gestational age specific handout about prematurity.
9526794|NCT03225885|Experimental|Multimedia Information|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as have bedside access to iPad multimedia information regarding prematurity.
9526795|NCT03226145|Active Comparator|Patients|"80 Patients : 40 FC 40 IBS-C~Will have MRI Motility and High Resolution Manometry~Then will have:~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo~Both agents will have their matched placebo dispensed alongside the active product of the other agent.~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
9526796|NCT03226145|Active Comparator|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
9526797|NCT03226236|Experimental|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
9526798|NCT03226132|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
9672681|NCT05032547|Active Comparator|Supportive Treatment|The intervention will be delivered in a blended treatment format combining asynchronous therapist-guided online modules (text/videos/audio/messaging function) with a synchronous session delivered over video-link.
9526799|NCT03226132|Active Comparator|Repeated Contact|Repeated Contact
9526800|NCT03225950||Chronic periodontitis donors|"Donors are medically healthy.~Slow to moderate attachment loss and bone destruction.~Good correlation between etiological factors and serverity of attachment loss."
10173305|NCT03864068|Placebo Comparator|Placebo Treatment bid|Women with PCOS (N = 30) will receive the daily placebo (maltodextrin and inulin) in an identical fashion as the active study group and will be monitored the same.
10173306|NCT03864068|Experimental|Active Treatment with Inositol 1gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 1000 mg of myo-inositol and 25 mg of d-chiro-inositol) over the initial 3 mos RCT period.
9526801|NCT03225950||Aggressive periodontitis donors|"Donors are medically healthy.~Rapid attachment loss and bone destruction.~Familial aggregation.~No correlation between etiological factors and serverity of attachment loss."
10173307|NCT03864068|Experimental|Active Treatment with Inositol 2 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 2000 mg of myo-inositol and 50 mg of d-chiro-inositol) over the initial 3 mos RCT period.
10173308|NCT03864068|Experimental|Active Treatment with Inositol 3 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 3000 mg of myo-inositol and 75 mg of d-chiro-inositol) over the initial 3 mos RCT period.
10173309|NCT03863912|Active Comparator|Disney|watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
10173310|NCT03863912|Other|Control|fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
10173311|NCT03864133|Other|Omidria|Phenylephrine/Ketorolac (1%/0.3%) will be administered to all participants enrolled into the study.
9526802|NCT03225950||Control donors|"Donors are medically healthy.~No sign of inflammatory conditions."
9526803|NCT03225872||Osteosarcoma patients and family members|Osteosarcoma patients and family members
9526804|NCT03225846|Experimental|WVE-120102 (2 mg) or placebo|
9526805|NCT03225846|Experimental|WVE-120102 (4 mg) or placebo|
9526806|NCT03225846|Experimental|WVE-120102 (8 mg) or placebo|
9526807|NCT03225846|Experimental|WVE-120102 (16 mg) or placebo|
9526808|NCT03225846|Experimental|WVE-120102 (32 mg ) or placebo|
9526809|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
9526810|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
9526811|NCT03225716|Experimental|Ibrutinib + Ulocuplumab|"Ibrutinib administered orally once daily~Ulocuplumab administered intravenously 2-4 times per cycle for Cycles 1-6"
9526812|NCT03225690|Placebo Comparator|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
9526813|NCT03225690|Active Comparator|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
9526814|NCT03225690|Active Comparator|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
9827761|NCT02467075|Active Comparator|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
10173312|NCT03863951||Patients with poststroke depression|No intervention
10173313|NCT03863951||Patients without poststroke depression|No intervention
10173314|NCT03863990||Patients with PAH|Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.
10173315|NCT03863925|Experimental|Propofol Target Controlled Infusion Group (Group T)|Patients in group T underwent anesthesia with Propofol (dosage form: 10mg/mL) target controlled infusion by Schnider model, starting at concentration of effect site (Ce) of 1.5 mcg/mL and titrating to achieve Observer's Assessment of Alertness/Sedation (OAA/S) Scale level 3 (responds only after name called loudly or repeatedly). Patients were paralyzed with suxamethonium (dosage form: 20mg/mL; dosage: 1mg/kg) once adequate sedation level achieved. TCI was stopped once the psychiatrist applied electroconvulsive stimulation to patients' bilateral frontal regions. Assisted ventilation with bag-valve-mask device by experienced anesthesiologists was began since patients were sedated until adequate spontaneous respiration was regained after each single electroconvulsive therapy (ECT) session. Every patient receive total six to twelve ECT sessions, and each ECT session was conducted one day apart.
10187062|NCT03729934|Experimental|Ketone Ester|This arm receives 25 g ketone ester.
9526815|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
9526816|NCT03225677||Patients with Cirrhosis|Patients with a diagnosis of cirrhosis will have a blood draw and muscle biopsy will be performed.
9526817|NCT03225677||controls|control group should have serum ALT and AST within normal range and a blood draw and muscle biopsy will be performed
9526818|NCT03225560|Experimental|Smart Phone Application|A novel smart phone application available for both Apple iOS and Google Android platforms with capabilities to populate the phone calendar with automated reminders/notifications at the appropriate times prior to the colonoscopy.
9526819|NCT03225560|Active Comparator|Traditional Paper Instructions|Traditional paper instructions for bowel preparation
9526820|NCT03225729|Experimental|CRYOBEAUTY MAINS ET DECOLLETE|"CRYOBEAUTY MAINS ET DECOLLETE is a new technology conceived to treat solar lentigo.~One side left, or right of neckline and/or hands is attributed to this device according to randomization protocol."
9526821|NCT03225729|Active Comparator|Liquid nitrogen|Liquid nitrogen is a classic cryotherapy device. One side, either left or right of neckline and/or hands are attributed to this device according to randomization protocol.
9526822|NCT03225703|Active Comparator|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
9526823|NCT03225703|No Intervention|Non exercise Leg|Randomly assigned non-exercise, control leg.
9526824|NCT03225664|Experimental|Treatment (trametinib, pembrolizumab)|Patients receive trametinib PO QD 14 days prior to cycle 1 and days 1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9526825|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
9526826|NCT03225794||Controls|Adults living in rural area of Cameroon, not infected with simian foamy viruses
9526827|NCT03225794||Simian Foamy virus infection|Adults living in rural area of Cameroon, infected with simian foamy viruses
9526828|NCT03225417|Experimental|Experimental group|"Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.~Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.~Starting Dose of Ixazomib according to phase I."
9526829|NCT03225417|Other|Control group|Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
9526830|NCT03225612|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
9526831|NCT03225768|Experimental|Guided Training|
9526832|NCT03225638|Other|Group 1|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (upper limit) strength thigh injection of 0.65ml of saline solution (0.9%)
9526833|NCT03225638|Other|Group 2|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (lower limit) strength thigh injection of 0.65ml of saline solution (0.9%)
9526834|NCT03225469|Experimental|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
9526835|NCT03225469|No Intervention|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
9526836|NCT03225521|Experimental|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
9526837|NCT03225456|Experimental|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
9526838|NCT03225456|Placebo Comparator|Placebo|Participants will received match placebo, again in two doses in a single session
9526839|NCT03225495|Active Comparator|Standard Implant|
9526840|NCT03225495|Experimental|Ultra-narrow Implant|
9526841|NCT03225391|Experimental|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
9526842|NCT03225391|Experimental|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
9526843|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
9526844|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
9526845|NCT03225651|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
9526846|NCT03225651|Experimental|Psychological therapy and rehabilitation|Psychological therapy Rehabilitation in 3 months
9526847|NCT03225352|Experimental|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
9526848|NCT03225352|Experimental|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
9526849|NCT03225352|Experimental|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
9526850|NCT03225352|Experimental|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
9526851|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.~The following interventions will be carried out:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
9526852|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.~Interventions:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
9526853|NCT03225339|Experimental|Lifestyle Intervention|The intervention includes the use of Low Energy Diet replacement products in combination with physical activity, followed by gradual introduction of food, and increasing physical activity. Behavioural support for the lifestyle intervention will also be provided.
10173316|NCT03863925|Active Comparator|Propofol Bolus Group (Group B)|Patients in group B underwent anesthesia with bolus of propofol for sedation, and the dosage raged between 0.75 to 1.5 mg/kg to achieve at least OAA/S scale level 3. Dosage of suxamethonium, application of electroconvulsive stimulation, ventilation maneuver, frequency of ECT session, and number of total ECT sessions were same as patients in group T.
10173317|NCT03863821|Experimental|HHHFNC group|Practice 6 MWT with HHHFNC
10173318|NCT03863821|No Intervention|non-HHHFNC group|Practice 6 MWT without HHHFNC
10187063|NCT03729934|Experimental|Ketone Salt|This arm receives 25 g ketone salt.
10187064|NCT03729921|Active Comparator|gastric variceal obturation|gastric variceal obturation
9526854|NCT03225339|No Intervention|Usual Care|This will be based on current clinical practice aiming to reduce diabetes symptoms and complications, and general recommendations on diet and physical activity.
9526855|NCT03225326|Experimental|Computer controlled 4% articaine delivery by Anaeject|
9526856|NCT03225326|Active Comparator|Conventional 4% articaine delivery by carpule syringe|
9526857|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
9526858|NCT03225261|Experimental|Citrus extract|Citrus extract
9526859|NCT03225261|Placebo Comparator|Placebo|Maltodextrin
9526860|NCT03224949||Healthy controls|
9526861|NCT03224949||Alcoholic hepatitis|
9526862|NCT03224949||Alcoholic steatosis|
9526863|NCT03224949||Alcoholic cirrhosis without HCC|
9526864|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
9526865|NCT03224949||Alcoholic cirrhosis with HCC|
9526866|NCT03225014|Active Comparator|Physical Therapy|
9526867|NCT03225014|Active Comparator|ARP Wave Therapy|
9526868|NCT03225300|Experimental|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
9526869|NCT03225248|Experimental|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
9526870|NCT03225248|Active Comparator|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
9526871|NCT03225066|Experimental|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
9975436|NCT03087994|Experimental|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
9526872|NCT03225027|Experimental|Patients with schizophrenia|Emotional judgment task, post-experimental questionnaire, recognition task, detection task, questionnaire CAPE-42, trait emotional intelligence questionnaire and positive and negative syndrome scale.
9526873|NCT03225027|Experimental|Few psychotic experiences|Healthy participants with few psychotic experience. Participants with the lowest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
9526874|NCT03225027|Experimental|Several psychotic experiences|Healthy participants with several psychotic experiences. Participants with the highest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
10187065|NCT03729921|Experimental|gastric variceal ligation|gastric variceal ligation
10187066|NCT03729908|Experimental|Animal assisted mindfulness based intervention|"The intervention is the AAMI. Trained animals that live in the Therapie-Tiergarten of REHAB Basel will function as therapy animals. Trained psychologists will lead the AAMI."
9526875|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
9526876|NCT03224988||Normal Adults|
9526877|NCT03224988||MCI Adults|
9526878|NCT03225105|Experimental|M3541 + Palliative Radiotherapy (RT)|
9528078|NCT03214003|Experimental|SIB group|Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).
10187067|NCT03729908|Active Comparator|Anti-stress program|The active control intervention consists of the same program, however without the inclusion of animals (Anti-Stress program, ASP).
10173319|NCT03863808|Experimental|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
10173320|NCT03863808|Active Comparator|Strengthening and Core Stability|"Following assessment 12 sessions over 6 weeks will start, focusing on strengthening exercises of the transversus abdominis and lumbar multifidus muscles (Angela Searle, 2015).~Exercises will be graduated according to the patient pain tolerance."
9526879|NCT03225053|Experimental|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
9526880|NCT03225235|Experimental|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:~tumor (RS) = 1.5~Late rectal and bladder complications = 3.0~early rectal and bladder complications = 10.0."
10173321|NCT03864445|Experimental|KHK7791|Patients take KHK7791 BID and can down titrate, based on a GI tolerability question.
9526881|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
9526882|NCT03225092|Experimental|PRP Injection|Ultrasound-guided platelet rich plasma injection
9526883|NCT03225274|Experimental|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
9526884|NCT03225274|No Intervention|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
9526885|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
9526886|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
9526887|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
9526888|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
9526889|NCT03225209|Experimental|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:~WK1-WK12 (5 MR/DAY)~WK13-14 (4 MR/DAY)~WK 15 (3 MR/DAY)~WK 16 (2 MR/DAY)~WK 17-18 (1 MR/DAY)~WK 19-24 (No MR)"
9526890|NCT03224975|Experimental|patients|Patient who was burned will have fMRI.
9526891|NCT03224975|Active Comparator|control group|Healthy volunteers (control group) will have fMRI.
9526892|NCT03224936||DISE group|All patients in this study group will receive a propofol PSI controlled DISE (drug induced sleep endoscopy).
9526893|NCT03224923|Experimental|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~Those with a positive genetic test (presence of CYP2C19*2 or CYP2C19*3), will receive 60mg Ticagrelor twice daily~Those with a negative genetic test (absence of CYP2C19*2/*3) will receive 75mg clopidogrel once daily"
9526894|NCT03224923|Active Comparator|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
9526895|NCT03224689|Experimental|PEEK Femoral|Subjects with a primary diagnosis of end-stage symptomatic primary knee osteoarthritis who require a uni-lateral knee prosthesis and have been evaluated as appropriate candidates for a total knee arthroplasty by the Investigator will be invited to take part in this clinical investigation.
10173322|NCT03864445|Placebo Comparator|Placebo|Patients take Placebo BID.
10173323|NCT03863977|Active Comparator|Dex4 group|After the surgery, the patients in this group will receive 4 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
10173324|NCT03863977|Active Comparator|Dex8 group|After the surgery, the patients in this group will receive 8 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
10173325|NCT03863977|Active Comparator|control group|After the surgery, the patients in this group will 1mg/kg of 0.5% bupivacaine in the TAP block.
10173326|NCT03863886|Experimental|Crohn's Disease|20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
10173327|NCT03863886|Experimental|Ulcerative Colitis|20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
9526896|NCT03224702|Experimental|M6495|
9526897|NCT03224702|Placebo Comparator|Placebo|
9526898|NCT03224806|Other|Wholegrain bread|
9526899|NCT03224806|Other|White bread|
9526900|NCT03224806|Other|15% fiber-rich bread|
9526901|NCT03224806|Other|30% fiber-rich bread|
10173328|NCT03863886|Experimental|Non-IBD Controls|20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
10173329|NCT03863938|Experimental|Tegoprazan 50mg under fasting condition|Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day
10173330|NCT03863938|Experimental|Tegoprazan 50mg before the meal|Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day
9526902|NCT03224897|Active Comparator|Cathodal tDCS|
9526903|NCT03224897|Active Comparator|Anodal tDCS|
9526904|NCT03224897|Sham Comparator|Sham tDCS|
9526905|NCT03224715|Experimental|Actinic Cheilitis patients|
9526906|NCT03224611|No Intervention|Control group|"The flexible LMA is inserted using index finger technique"
9526907|NCT03224611|Active Comparator|Light wand group|The flexible LMA is inserted using light wand as a stylet
9526908|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
9526909|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
9526910|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
10173331|NCT03863938|Experimental|Tegoprazan 50mg after the meal|Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day
9526911|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
9526912|NCT03224884|Active Comparator|Interscalene block|Patients randomized to receive an interscalene block .
9526913|NCT03224884|Experimental|Supraclavicular block|Patients randomized to receive a supraclavicular block.
9694967|NCT04783558|No Intervention|Treatment-as-Usual (TAU)|Pregnant women in this condition will receive care as usual that involves continued enrollment in OAT and continued obstetric care. We will also provide them with a printed handout containing information on NAS and local resources. Participants in the TAU condition will not receive iPads with accompanying modules, however the handout constitutes more information than they normally receive.
10173332|NCT03863847|Active Comparator|Online Neurofeedback|This intervention entails online feedback of pain-related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
10173333|NCT03863847|Sham Comparator|Online Sham Neurofeedback|This intervention entails online sham feedback of non-pain related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
9526914|NCT03224559||Sham Stimulation|subject receives minimal transcranial electrical stimulation
9526915|NCT03224559||Left Side Stimulation|transcranial electrical stimulation on the left side of the head.
9526916|NCT03224663|Experimental|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
9526917|NCT03224663|Experimental|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
9526918|NCT03224793|Experimental|BIIB059 20 mg|Participants will receive single subcutaneous (SC) dose of 20 milligram (mg) BIIB059 or matching placebo on Day 1.
9526919|NCT03224793|Experimental|BIIB059 50mg|Participants will receive single SC dose of 50 mg BIIB059 or matching placebo on Day 1.
9526920|NCT03224793|Experimental|BIIB059 150mg|Participants will receive single SC dose of 150 mg BIIB059 or matching placebo on Day 1.
9526921|NCT03224793|Experimental|BIIB059 450mg|Participants will receive single SC dose of 450 mg BIIB059 or matching placebo on Day 1.
9526922|NCT03224637|Active Comparator|radiofrequency group|radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
9526923|NCT03224637|Active Comparator|conventional group|the patients received conventional paracetamol and non steroidal antiinflammatory
9526924|NCT03224858|Experimental|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
9526925|NCT03224858|Active Comparator|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
9526926|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
9526927|NCT03224572|Experimental|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
9526928|NCT03224572|Placebo Comparator|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
9526929|NCT03224741|Placebo Comparator|Information|
9526930|NCT03224741|Active Comparator|Active Choice|
9526931|NCT03224741|Experimental|Monetary incentive|
9526932|NCT03224871|Experimental|Nivolumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Nivolumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks.
9526933|NCT03224871|Experimental|Pembrolizumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Pembrolizumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks.
9526934|NCT03224468|Active Comparator|Medical Marijuana Arm|This group can begin using medical marijuana immediately.
9526935|NCT03224468|No Intervention|Waitlist Control Arm|This group agrees to wait 3 months before using medical marijuana.
9526936|NCT03224832|Experimental|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
9526937|NCT03224832|Experimental|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
9526938|NCT03224845|Experimental|Cognitive behavioural skills training|
9526939|NCT03224845|No Intervention|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
9526940|NCT03224494|Other|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
10173334|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 minutes|Blood test
9672682|NCT05032469|Experimental|Refloxology Intervention|The first foot reflexology was applied to the intervention group for 30 min (20 min on the right foot, 10 min on the left foot) on the first postoperative day (24 h after the surgery). On the second postoperative day, 30 min of foot reflexology was applied to the patients who decided to chest tube removal (CTR). After the foot reflexology applied by the researcher, CTR was performed by the doctor within 10 min. Immediately after CTR, the patient's pain and anxiety level during CTR was measured. At the 15th minute after CTR, the pain and anxiety level of the patients was measured, their satisfaction with the reflexology application was measured. Then, the patients were asked to describe the pain and feelings and thoughts during CTR, 1 hr after CTR, pain level was measured, and they were asked to express their feelings and thoughts about the reflexology application.
9672683|NCT05032469|No Intervention|Standart Care|Participants in the control group will receive standart postoperative care.
9672684|NCT05032300|Active Comparator|focused shockwave therapy|Patients will receive 6 sessions of focused shockwave therapy.
10173335|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 7 minutes|Blood test
10173336|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 15 minutes|Blood test
10173337|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 30 minutes|Blood test
10173338|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1 hour|Blood test
10173339|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1.5 hours|Blood test
10173340|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2 hours|Blood test
10173341|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2.5 hours|Blood test
10173342|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 hours|Blood test
10173343|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3.5 hours|Blood test
10173344|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4 hours|Blood test
10173345|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4.5 hours|Blood test
10173346|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 5 hours|Blood test
10173347|NCT03864003|Experimental|Experimental group|Participants randomized to the experimental group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a Community Health Worker.
10173348|NCT03864003|Active Comparator|Control Group|Participants randomized to the control group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a non-Community Health Worker (undergraduate student in Speech, Language, and Hearing Sciences).
9526941|NCT03224494|Other|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
9526942|NCT03224481|Experimental|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
9526943|NCT03224481|No Intervention|Control group|Participants in the control group will not receive additional reminders.
10173349|NCT03863860|Experimental|Fluzoparib capsules, 50mg per capsule|Fluzoparib capsules, PO
10173350|NCT03863860|Placebo Comparator|Placebo capsules, 50mg per capsule|Placebo capsules, PO
10173351|NCT03864016|Other|Standard group|
10173352|NCT03864016|Experimental|Pupillometry group|
10173353|NCT03863899|Experimental|Nerve block|ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)
10173354|NCT03863899|Active Comparator|Local infiltration|local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)
10173355|NCT03863834|Experimental|Treatment arm|Subjects receive the RFAL treatment
10173356|NCT03863691|Active Comparator|amisulpride group|300 mg of the atypical antipsychotic drug amisulpride
10173357|NCT03863691|Placebo Comparator|placebo group|Similar looking capsules for placebo control
10187068|NCT03729895|Experimental|patients with OSAS in different degrees|OSAS patients will be treated with an adjustable oral appliance and evaluated with cone-beam computed tomography and polysomnography.
9526944|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
9526945|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
9526946|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
9526947|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
9526948|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
9526949|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
9526950|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
9526951|NCT03224247|Active Comparator|Transverse splitting|transverse cutting and/or pulling of lower uterine segment during lower segment cesarean section.
9526952|NCT03224247|Active Comparator|Vertical splitting|vertical splitting,of lower uterine segment during lower segment cesarean section.
9526953|NCT03224273|Experimental|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
9526954|NCT03224273|Active Comparator|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
9526955|NCT03224117|Placebo Comparator|Placebo|SQ injection
9526956|NCT03224117|Experimental|DWJ211_0.5%|SQ injection with DWJ211 0.5%
9526957|NCT03224117|Experimental|DWJ211_1%|SQ injection with DWJ211 1.0%
9526958|NCT03224117|Experimental|DWJ211_2%|SQ injection with DWJ211 2.0%
9526959|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.~The dosing of all antibiotics will be adjusted according to creatinine clearance."
9526960|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
9526961|NCT03224078||adult Emergency Department Patients|adult patients that were treated with any condition in one of the participating emergency departments in 2016 (n≈680.000 cases)
9526962|NCT03224442|Experimental|PRF with immediate implants|Immediate implants placed and covered with two prf layers
10187920|NCT03721380|Other|TAU|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs.
9526963|NCT03224442|Active Comparator|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
9526964|NCT03224208|Experimental|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle until disease progression.~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
9526965|NCT03224338|Experimental|: Dolutegravir (DTG)|
9526966|NCT03224143|Experimental|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the object (doll or cube) to the patient.~The nurse leaves the patient alone with the object.~Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the object."
9526967|NCT03224143|Active Comparator|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the cube to the patient.~The nurse leaves the patient alone with the cube.~Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the cube."
9526968|NCT03224065|No Intervention|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
9526969|NCT03224065|Experimental|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
9526970|NCT03224169|Experimental|Intervention|Directly observed hand hygiene
9526971|NCT03224169|No Intervention|Control|No directly observed hand hygiene
9526972|NCT03224156||Dilated Cardiomyopathy|
9526973|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
9526974|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
10187921|NCT03721367||Urea Cycle Disorders|
9526975|NCT03224429|Other|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
9526976|NCT03224429|Other|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
9526977|NCT03224260|Experimental|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
9526978|NCT03224260|Experimental|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
9526979|NCT03224260|Experimental|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
9526980|NCT03224364|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC
9526981|NCT03224364|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
9526982|NCT03224221|Experimental|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
9526983|NCT03224221|Active Comparator|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
9526984|NCT03224312||Primary aldosteronism|screened, confirmed and subtyped according to the guidelines.
9526985|NCT03224312||Essential hypertension|screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion
9672685|NCT05032300|Active Comparator|control|Patients in the control group will be treated using the home therapy protocol only.
9827762|NCT02467075|Placebo Comparator|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
10173358|NCT03863873|Active Comparator|PRP Injection Group|PRP Preparation: 16 ml of blood was obtained from each patient using special PRP kits (GD medical pharma, Dutch company). The blood was collected on citrated tubes with a mixing ratio of 9:1 by volume. Tubes underwent 1st centrifugation at speed of 3000 rpm (704g) for 3 minutes (to separate red blood cells from plasma). Plasma was then removed by syringe and then placed into another sterile tube with no anticoagulant and then underwent 2nd centrifugation at speed of at 4000 rpm (1252g) for 15 min. The supernatant platelet-poor plasma was then removed leaving 2 ml of PRP pellets in the sediment, and suspend the PRP pellets by gentle shaking of the tube. PRP is activated by adding 200 μl of 0.025 calcium chloride(Dhurat and Sukesh, 2014).
10173359|NCT03863873|Active Comparator|Steroid injection Group|A single injection of methylprednisolone acetate 40 mg/ml using a technique similar to that described for the PRP injection
10173360|NCT03863743|Other|Control|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. Patient will undergo treating physician's standard of care for total hip or knee replacement. Patient will receive bladder scans in PACU, upon admission to the nursing unit, and prior to discharge (post-void).
10173361|NCT03863743|Experimental|Experimental|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. If considered high risk (determined by IPSS), then patient Patient will undergo integrated care pathway that avoids narcotics. Bladder volume will be measured in PACU, after admission to the nursing unit, and prior to discharge from the hospital (post-void).
10173362|NCT03863730|Experimental|Profermin Plus®|Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
10173363|NCT03863730|Active Comparator|Fresubin®|Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator.
10173364|NCT03863652||Snuffboxer|Patients undergoing percutaneous coronary intervention via snuffbox approach
9526986|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
9526987|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
9526988|NCT03224013|Active Comparator|Hyperopic LASIK with crosslinking|group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking
9526989|NCT03224013|Active Comparator|Hyperopic LASIK only|group 2: hyperopic customized LASIK only
9526990|NCT03224039|Experimental|Intranasal sufentanil|"Treatment arm to include~Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose~Normal saline 1ml intravenous (IV) push x 1 dose"
9526991|NCT03224039|Active Comparator|Intravenous morphine|"b. Treatment B:~Normal saline 0.3 mL IN x 1 dose~Morphine 0.1 mg/kg IV push x 1 dose"
9526992|NCT03224416|Experimental|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
9526993|NCT03224416|Placebo Comparator|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
9526994|NCT03224416|Sham Comparator|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
9526995|NCT03223948|Active Comparator|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
9526996|NCT03223948|Active Comparator|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
9526997|NCT03223948|Active Comparator|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
9526998|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
9526999|NCT03223792|Active Comparator|Control|
9527000|NCT03223792|Experimental|Investigational|
9527001|NCT03223818|Experimental|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
9527002|NCT03223818|No Intervention|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
9527003|NCT03223779|Experimental|TAS-102|"Photon treatments will be performed on a linear accelerator~Photon SBRT will be given during TAS-102 dosing~TAS-102 dosing occurs on days 1 through 5 and 8 through 12~TAS-102 tablets should be taken twice a day orally"
9527004|NCT03223831|Active Comparator|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
9527005|NCT03223831|Active Comparator|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
9527006|NCT03223935|Active Comparator|Roasted snacks|Corn nuts
9527007|NCT03223935|Experimental|Roasted chickpeas|Chickpeas
9527008|NCT03223935|Experimental|Roasted yellow peas|Yellow peas
9527009|NCT03223935|Experimental|Roasted pinto beans|Pinto beans
9527010|NCT03223935|Experimental|Roasted soybeans|Soybeans
10173365|NCT03863561||Waiting room sample|Patients with type 1 or type 2 diabetes attending an LMC Diabetes & Endocrinology specialist clinic in Ontario completed the SCPI in the waiting room while attending their usual appointment with their healthcare provider.
10173366|NCT03863561||DSME Intervention|Patients with poor glycemic control (A1C >8.0%) were enrolled into a diabetes self-management education (DSME) program. The SCPI was completed at their first and last visit and and their individual results were incorporated into the care paths that were then customized for that participant. The patient met with a diabetes educator five to seven times over the course of three to four months.
9527011|NCT03223935|Experimental|Roasted almonds|Almonds
9527012|NCT03223701|Other|Treatment group|The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.
9527013|NCT03223714|Experimental|Conbercept|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
10173367|NCT03863405|Experimental|Metformin Group|850 mg metformin twice daily for six months in addition to standard therapy
9527014|NCT03223714|Sham Comparator|Conbercept or sham|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
9527015|NCT03224000|Experimental|MRI Guided Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
10173368|NCT03863405|Active Comparator|Control Group|placebo in addition to standard therapy for rheumatoid arthritis
10173369|NCT03863587|Experimental|HLX12 group|HLX12 are given intravenous infusion 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
9827763|NCT02467166|Experimental|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
10173370|NCT03863587|Active Comparator|Cyramza (Ramucirumab) group|Ramucirumab are given intravenous infusion of Cyramza 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
10173371|NCT03863574|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
9527016|NCT03224000|Active Comparator|Standard-of-Care Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
9527017|NCT03223675|Experimental|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
9527018|NCT03223922|Experimental|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy|Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
9527019|NCT03223844|Experimental|Healthy subjects|Measurement of Dextroamphetamine Sulfate-induced dopamine release and synthesis before and after amphetamine sensitization.
9527020|NCT03223688|Experimental|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training. Said therapists assisted the caregivers in improving their nurturing and parenting skills with their children, as well as their techniques with regards to influencing them.
9527021|NCT03223688|Experimental|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
9527022|NCT03223688|Active Comparator|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
10173372|NCT03863574|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
9527023|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
9527024|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
9527025|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
9527026|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
9527027|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
9527028|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
9527029|NCT03223636||Healthy Volunteers|Healthy Volunteers
9527030|NCT03223961|Experimental|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
9527031|NCT03223961|Experimental|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
9527032|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score < 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
9527033|NCT03223571||Controls|Healthy people with no history of neurological pathologies
9527034|NCT03223506|Experimental|Paracetamol arm|Administration of 10 mg/ml of paracetamol
9527035|NCT03223740|Experimental|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
9527036|NCT03223740|Active Comparator|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
9527037|NCT03223558|Experimental|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
9527038|NCT03223558|Active Comparator|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
10173373|NCT03863574|Placebo Comparator|Placebo|Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
10173374|NCT03863379||Neurodisabled persons|Persons with various neurodisabilities
10173375|NCT03863379||Control group|Able bodied persons
10173376|NCT03863392|Experimental|oral|patients undergoing induction of labour using misoprostol oral solution
10173377|NCT03863392|Experimental|vaginal|patients undergoing induction of labour using vaginal misoprostol
10173378|NCT03863678|Experimental|Neurodevelopmental therapy|Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.
10173379|NCT03863678|Experimental|Neurodevelopemental therapy and dry needling therapy|Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.
10173380|NCT03863418|Experimental|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG (10 billion Colony Forming Units/CAPSULE)
9527039|NCT03223896|Active Comparator|Group A|max 8 mg/per day naloxone nasal spray
9527040|NCT03223896|Active Comparator|Group B|max 16 mg/per day naloxone nasal spray
10173381|NCT03863418|Placebo Comparator|placebo|maltodextrin
9527041|NCT03223532|Active Comparator|PrePex Day 7 FRP|"Standard PrePex procedure, 1 week after device placement foreskin and device are removed.~*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision"
9527042|NCT03223532|Experimental|PrePex Day 0 FRP|On the day of device placement the foreskin is removed, the device is removed 1 week later.
9527043|NCT03223519|Experimental|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
9527044|NCT03223519|Placebo Comparator|Placebo|
9527045|NCT03223519|Active Comparator|Ibuprofen|
9527046|NCT03223519|Active Comparator|Magnesium|
9527047|NCT03223519|Active Comparator|Vitamin C|
9527048|NCT03223402|Experimental|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
9528079|NCT03214003|Active Comparator|BID group|Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).
10173382|NCT03863639||Pre-Eclampsia|15 English-speaking women with severe pre-eclampsia
10173383|NCT03863639||Control|15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age
10173384|NCT03863535|Experimental|Intravitreal conbercept+Panretinal coagulation|
10173385|NCT03863535|Active Comparator|Panretinal coagulation|
9527049|NCT03223467|Active Comparator|Biliopancreatic diversion|Study participants will undergo biliopancreatic diversion which is a type of bariatric surgery where a part of the stomach are removed and the remaining stomach is attached to a distal segment of the small intestine.
9527050|NCT03223467|Active Comparator|Gastric sleeve|Study participants will undergo sleeve gastrectomy which is a restrictive form av bariatric surgery where the size of the stomach is reduced.
10173386|NCT03863665|Experimental|Telemetric Bluetooth home BP monitors|Telemetric Bluetooth home BP monitors will be provided to participants during their inpatient stay or clinic visit, and will commence 3- times-daily readings immediately. The BP monitoring team will assess BP readings daily and advise medication adjustments to achieve a target BP of <120/80 mm Hg
10173387|NCT03863665|No Intervention|Standard clinical care|Standard clinical care including usual BP treatment, without home monitoring, undertaken in the clinical care setting
10173388|NCT03863626|Active Comparator|Frusemide IV shots = group A|Frusemide as IV shots
9527051|NCT03223467|Active Comparator|Gastric bypass|Study participants will undergo gastric bypass which is a type of bariatric surgery where a small pouch of the stomach is created and attached to a segment of the small intestine.
9672686|NCT05032417|Active Comparator|EBNPG knowledge-focused training (knowledge-only group)|The knowledge-focused training includes didactic information about the content of the EBNPG related to nutrition care for individuals on dialysis. This training contains information that is typically shared with RDNs when an EBNPG is released, and in this instance, includes a free webinar developed by the Academy and NKF that provides an overview of EBNPGs, as well as a presentation of the specific EBNPG developed.
10173389|NCT03863626|Active Comparator|Frusemide IV infusion = group B|Frusemide as continuous IV infusion
9672687|NCT05032417|Experimental|EBNPG knowledge-focused training plus an implementation toolkit (comprehensive group)|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
9672688|NCT05032456|Experimental|Virtual Reality Group|Investigators used Oculus Quest All-in-one Virtual Reality Gaming Headset (128 GB) VR system. Before the intervention, the investigators introduced the equipment and instructed study participants on how to wear and activate the headsets. The laboring women who enrolled in the virtual reality group first wore the headsets in early labor (Cervical dilation 3 cm) for 20 minutes. The patients were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the images of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance. The second implementation of virtual reality headsets was after the epidural analgesia in the active phase of labor for another 20 minutes (Cervical dilation 6-7cm).
9672689|NCT05032456|No Intervention|Control Group|For participants randomized to the control group, virtual reality headsets were not used and the clinic's standard of care in laboring women was followed. Participants in this group filled out a visual pain rating scale both in the latent and active phases of labor.
10173390|NCT03863717|Experimental|Arm Endurance Exercise Training Group|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
10173391|NCT03863717|Active Comparator|Control Group|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
10173392|NCT03863275|Other|No intervation|Children between the ages of 7 and 12 diagnosed with class II dental classification, who attend the Leonardo Da Vinci School after carrying out an intraoral and extraoral photography study and diagnostic impressions with study models accepting participation in the study, Children over the age of 12 who have an agreement according to the results of medical care. Patients with Pierre Robin syndrome or any form of cleft.
10187922|NCT03721354|Experimental|NAVA vs PSV -TCCD|Ultrasound evaluation, using trans cranial doppler technique will be performed to evaluate the cerebral blood flow speed (average/systolic speed) near the point of emergency, in the middle tract and at the bifurcation of M1 bilaterally, at the end of every ventilation trial (NAVA and PSV).
9527052|NCT03223467|No Intervention|No intervention|Study participants that do not want to undergo surgical treatment.
9672690|NCT05032235|Experimental|Group A|
9672691|NCT05032235|Experimental|Group B|
9672692|NCT05032235|Experimental|Group C|
9672693|NCT05032248|Experimental|tacrolimus|group I (Colchicine and topically applied Tacrolimus),
9672694|NCT05032248|Placebo Comparator|placebo|group II (Colchicine and topically applied Placebo),
9672695|NCT05032612|Experimental|PBM Therapy|
9672696|NCT05032612|Sham Comparator|PBM Sham|
9672697|NCT05032170||Locator Group|The participant has a mandibular overdenture supported by two implants with locator attachments. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
9672698|NCT05032170||Bar Group|The participant has a mandibular overdenture supported by two implants with a dolder bar attachment. The implants are scanned with each of two intraoral scanners both with and without the use of artificial landmarks. The implant scans are analyzed in terms of scanning accuracy (trueness and precision) by comparison with a reference model (3D implant positions in the working cast of the immediately loaded overdenture).
9672699|NCT05031832||HIV-negative|
9672700|NCT05031832||HIV-positive|
9527053|NCT03223220|Experimental|Study Drug|Will receive Ketamine infusion, and Midazolam (Versed).
9527054|NCT03223220|Placebo Comparator|Placebo|Will receive Normal saline infusion and Midazolam (Versed).
9527055|NCT03223376|Active Comparator|fruquintinib+paclitaxel|treatment arm (fruquintinib+paclitaxel) : Fruquintinib once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
9527056|NCT03223376|Placebo Comparator|placebo+paclitaxel|control arm (placebo+paclitaxel): Fruquintinib placebo once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
9527057|NCT03223454|Experimental|biological amnion loaded with hAECs|Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
9527058|NCT03223454|Placebo Comparator|biological amnion|Biological amnion is placed into uterine cavity immediately after TCRA.
9527059|NCT03223454|Experimental|intravenous infusion of hAECs|intravenous infusion of 100 million hAECs immediately after TCRA
9527060|NCT03223454|Experimental|intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity immediately after TCRA.
9527061|NCT03223454|Experimental|hydrogel loaded with hAECs|Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
9527062|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
9527063|NCT03223363|Experimental|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
9527064|NCT03223363|Other|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
9527065|NCT03223389|Experimental|10 gastric bypass operated patients|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
9527066|NCT03223389|Experimental|10 healthy control subjects|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
9527067|NCT03223415|Experimental|Experimental arm|Detection and isolation of C. difficile carriers
9527068|NCT03223415|No Intervention|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
9527069|NCT03223194|Experimental|Cohort 1|1.5 x 10^12 vg/kg of AT342 delivered intravenously one time
9672701|NCT05032131|Experimental|Experimental|"Group 1:~Patients treated by sirolimus since at least 6 months (but still disabled)~Group 2:~Patients currently (for at least 3 months) without specific treatment for inclusion myositis"
9672702|NCT05031754||Infants with atopic dermatitis|Infants with atopic dermatitis
9672703|NCT05031754||Infants without atopic dermatitis|Infants without atopic dermatitis
9672704|NCT05031910|Experimental|Arm I (VR/3D-CEPs, standard treatment)|Prior to surgery (day 0-13), patients undergo virtual reality 3D tumor resection via VR/3D-CEPs. Patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29 and a 3D model of true tumor is created and imported into the virtual reality environment.
10173393|NCT03863275|Experimental|Myofunctional apparatus|Boys and girls between 7 and 12 years skeletal class II, for the study group the individuals will be selected from the UNICIEO postgraduate clinic of orthopedic clinic orthodontics after conducting a full clinical case study exposed to a board of specialist teachers in orthodontics, where by means of several diagnostic methods a skeletal class II is confirmed that involves a treatment with myofunctional apparatus SN1; patients presenting syndromes that generate craniofacial alterations, patients with previous orthopedic treatment, patients with signs of condyle lesions, patients with Pierre Robin syndrome or any form of slit will be excluded.
9672705|NCT05031910|Active Comparator|Arm II (standard treatment)|Prior to surgery (day 0-13), patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29.
10173394|NCT03863236|Active Comparator|regular diet|The control group (group 1) will continue their regular diet.
10173395|NCT03863236|Active Comparator|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support two weeks before the operation and the nutritional support will continue 10 days after the operation.
10173396|NCT03863613|Active Comparator|Pessary group|A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
9672706|NCT05031728|Experimental|CPT Group|Cognitive Processing Therapy (CPT) is employed. Each patient will attend 12 individual sessions with the therapist. The sessions will be on the weekly basis. The standard manual of CPT (Resick et al., 2016) is going to be employed.
9672707|NCT05031923|Experimental|SMV and antimicrobial photodynamic therapy|Application SMV and antimicrobial photodynamic therapy in intrabony defect
10187923|NCT03721315|No Intervention|Control|This group will receive the standard of care for this condition.
9527070|NCT03223194|Experimental|Cohort 2|6.0 x 10^12 vg/kg of AT342 delivered intravenously one time
9527071|NCT03223194|Experimental|Cohort 3|1.5 x 10^13 vg/kg of AT342 delivered intravenously one time
9527072|NCT03223194|No Intervention|Delayed-Treatment Control|Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.
9527073|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
9527074|NCT03223259|Other|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
9527075|NCT03223233||No secondary suture|The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
9527076|NCT03223233||Secondary suture|The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
9527077|NCT03223285|Experimental|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
9527078|NCT03223285|Sham Comparator|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
9672708|NCT05031923|Active Comparator|SMV application|Application SMV in intrabony defect
9672709|NCT05031936|Active Comparator|Touhy needle group|cervical medial branch block using touhy needle
9527079|NCT03223142|Experimental|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received cryoablation immediately followed by radiofrequency ablation
9527080|NCT03223168|Experimental|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
9527081|NCT03223545|Experimental|Mindfulness-based cognitive therapy delivered by telephone|
9527082|NCT03223545|Placebo Comparator|Usual Care (UC)|
9527083|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
9527084|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
9527085|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
9527086|NCT03223129|Other|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
9527087|NCT03223129|Other|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
10173397|NCT03863613|Active Comparator|Cerclage group|Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
9527088|NCT03223129|Other|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
9527089|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
9527090|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
10173398|NCT03863613|Active Comparator|Pessary plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
10173399|NCT03863613|Active Comparator|Cerclage plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
10173400|NCT03863600||Midwife-led continuity of care|Women receiving midwife-led model of care though the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
9527091|NCT03223064|Experimental|PSMA PET-CT and USPIO MRI|
10173401|NCT03863600||Regular care|Women receiving regular maternal care through the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
10173402|NCT03863366|Experimental|Prucalopride|1mg prucalopride capsule
10173403|NCT03863366|Placebo Comparator|Placebo|Lactose placebo capsule
10173404|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-1)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-1 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
10187924|NCT03721315|Experimental|Intervention|This group will receive additional education along with their designated health support person prior to hospital discharge. This intervention does not include drugs/or devices.
10187925|NCT03721302||Main Study Clinical Sepsis|Clinical and Antimicrobial Assessments
10187926|NCT03721302||Microbiology Sub study|Clinical and Antimicrobial Assessments
9527092|NCT03223116|Experimental|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
9527093|NCT03223077||Acute Campylobacter|We will enroll 150 patients with acute Campylobacter infection. Our microbiology laboratory will inform us of a culture or PCR positive case of Campylobacter infection as soon as that test result is available.
9527094|NCT03223103|Experimental|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
9527095|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
9527096|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
9672710|NCT05031936|Placebo Comparator|Quincke needle group|cervical medial branch block using quincke needle
9527097|NCT03223025|Experimental|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
9527098|NCT03223025|Active Comparator|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
9527099|NCT03222843|Experimental|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
9527100|NCT03222843|Experimental|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
10173405|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-2)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-2 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
10173406|NCT03863327||Acute severe 3-vessel disease or critical left main stenosis|"Severe 3-vessel disease: >/=75% stenosis in all three major coronary vessels (or equivalents in the case of anatomic variants or preexisting bypass) with an acute culprit lesion (TIMI<3) or~Left main stenosis > 50% (see Smith review paper for reference): acute left main culprit of any TIMI score, or any lesion of the left main with TIMI<3 or~Any other cardiac catheterization findings prompting initiation of emergent coronary artery bypass grafting within the next 120 hours"
10173407|NCT03863327||No evidence of acute coronary occlusion|"At least three sequential negative cardiac biomarkers within 24 hours of presentation~cardiac catheterization showing no culprit lesion.~Angiogram showing an acute culprit lesion but both no occlusion (TIMI 2 or greater) and troponins not exceeding the cutoff above~If positive troponin values present but no angiography, then the patient must have echocardiography showing no wall motion abnormality and troponin values less than the above cutoff~If the patient has insufficient data to classify into one of these categories, the patient must be excluded from the study as they cannot be classified as ACO or non-ACO. For example, patients with extremely high troponin but no culprit seen on cath may have acute occlusion with complete autolysis of thrombus, myocarditis, spasm, etc. Thus the investigators cannot classify them as NO ACO when the possibility of ACO remains and cannot be disproven."
10173408|NCT03863132|Active Comparator|TAVR Group|Patients will be treated by transcatheter aortic valve repair (TAVR).
10173409|NCT03863132|No Intervention|Medical Treatment Group|Patients will receive optimal medical treatment alone.
10173410|NCT03863249|Active Comparator|The exCELLigence system|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics selected by 'the exCELLingence' system will be started at the second SRP visit."
10173411|NCT03863249|Active Comparator|Origen|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics agents selected by 'Origen' laboratories analysis will be started at the second SRP visit."
10173412|NCT03863249|Active Comparator|Echevarne|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit."
10173413|NCT03863171||Ocular ischemia syndrome|Patients with ocular ischemia syndrome
10173414|NCT03863171||Control|Patients with age-related macular degeneration
9827522|NCT02459275|No Intervention|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
9672711|NCT05032027|Experimental|Probiotic group|Probiotic( recieving Probiotic at the first day of chemoradiotherapy daily)with radiotherapy and Chemotherapy Intervention
9527101|NCT03222843|Placebo Comparator|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
9527102|NCT03222843|Placebo Comparator|Arm 4|oral placebo at an initial dose of 5 mg once daily
9672712|NCT05032027|No Intervention|placebo group|placebo( one times a day)with radiotherapy and Chemotherapy Intervention
9672713|NCT05032027|No Intervention|healthy control group|healthy control group
9672714|NCT05032001|Experimental|Metformin|Metformin 1.7-2.5mg per day during twelve weeks
9672715|NCT05032001|Experimental|Metformina + IDDP-4|Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day
9975437|NCT03087994|Active Comparator|girls with obesity|participants in this group will only receive nutrition guidance once during the study
10173415|NCT03863431|Active Comparator|High-fat diet|"Participants will consume a diet rich in fat (approximately 65% of total energy) and low in carbohydrate for 14 days.~Measurements will be made at 0, 7 and 14 days."
10173416|NCT03863431|Active Comparator|High-carbohydrate diet|"Participants will consume a diet rich in carbohydrate (approximately 70% of total energy) and low in fat for 14 days.~Measurements will be made at 0, 7 and 14 days."
10187069|NCT03729882|Other|EUS-guided gallbladder drainage|"In one arm, Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) will be performed by using a 3,8 mm therapeutic echoendoscope and a lumen apposing metal stent ( Hot AXIOS™ Stent and Electrocautery Enhanced Delivered System; Boston Scientific Corporation, Natick, MA, USA) after conventional biliary drainage with self-expandable metallic stents during endoscopic retrograde cholangiopancreatography (ERCP).~All procedures will be performed under general anesthesia."
10187070|NCT03729882|Other|Non EUS-guided gallbladder drainage|"In the other arm, patients will undergo conventional biliary drainage with self-expandable metallic stent placement during ERCP evaluation without prophylactic EUS-GBD and will be considered as a Non EUS-guided gallbladder drainage.~All procedures will be performed under general anesthesia."
10187071|NCT03729856|Experimental|B5 week,intervention,follow-up|Participants will undertake their usual activities for the 5 week baseline period. Participants will begin the 16 week intervention period at week 6 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 22, participants will have no contact with intervention personnel during the 5 week follow-up period.
10187072|NCT03729856|Experimental|B8 week,intervention,follow-up|Participants will undertake their usual activities for the 8 week baseline period. Participants will begin the 16 week intervention period at week 9 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 25, participants will have no contact with intervention personnel during the 5 week follow-up period.
10187073|NCT03729856|Experimental|B11 week,intervention,follow-up|Participants will undertake their usual activities for the 11 week baseline period. Participants will begin the 16 week intervention period at week 12 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 28, participants will have no contact with intervention personnel during the 5 week follow-up period.
10187927|NCT03721289||Cohort 1|All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
10187928|NCT03721289||Cohort 2|All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
10187929|NCT03721263|Experimental|ASLAN004 Single Ascending Dose|"Up to 10 dose levels are planned.~ASLAN004 by IV route: 0.1 mg/kg (Cohort 1), 0.3 mg/kg (Cohort 2), 1 mg/kg (Cohort 3), 3 mg/kg (Cohort 4) and 10 mg/kg (Cohort 5), 20 mg/kg (Cohort 6 [optional]).~ASLAN004 SC route: 75 mg (Cohort 7), 150 mg (Cohort 8), 300 mg (Cohort 9), and 600 mg (Cohort 10 [optional])."
10187930|NCT03721250||thoracic epidural|patients receiving thoracic epidural
10187931|NCT03721237|Experimental|EBC-assisted|A nasogastric tube, equipped with esophageal and gastric balloons, will be inserted in each patient enrolled in the study. After definitive catheter positioning has been obtained, Esophageal ballon calibration will be run in volume-controlled ventilation, pressure support ventilation and sigh + pressure support ventilation.
10187932|NCT03721224||Children with psychogenic cough|children who were examined by Pediatric Respiratory Disease specialist and diagnosed as having a psychogenic cough.
10187933|NCT03721224||control subjects|children who were referred to pediatrics clinics and do not have a chronical disease.
10187934|NCT03721211|Experimental|[11C]Martinostat|"Subjects will be administered [11C]Martinostat, which is synthesized on site at the MGH Martinos Imaging Center~All subjects will undergo an MR-PET scan of the thorax, including the breasts, to determine tumor uptake~All subjects will be scanned using [11C]Martinostat during an imaging session on a Siemens Biograph mMR integrated MR-PET scanner~PET imaging will begin concomitant with radiotracer administration"
10187935|NCT03721198|Active Comparator|Acidulated phosphorous flouride|Acidulated phosphorous flouride used once at the first of the study
10187936|NCT03721198|Experimental|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish (CLINPRO XT ) is used once at the first of the study only
10187937|NCT03721185|Active Comparator|LC|Lypolitic cream with hypocaloric diet and physicial activity in 51 patients
10187938|NCT03721185|Placebo Comparator|NLC|Hypocaloric diet and physicial activity alone in 51 patients
10187939|NCT03721159||Group I|30 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease.
10187940|NCT03721159||Group II|30 Generalized chronic periodontitis subjects without coronary heart disease.
10187941|NCT03721159||Group III|30 Systemically healthy patients with no chronic periodontitis or coronary heart disease.
10187942|NCT03721094|Other|Immersive virtual reality|Completing the procedures in immersive virtual reality
10187943|NCT03721094|No Intervention|Conventional virtual reality|Completing the procedures in conventional virtual reality
10187944|NCT03721081|Placebo Comparator|Na Cl 0.9%/Epi 1:200000|Subcutaneous infiltration of Na Cl 0.9%/Epi 1:200000
10187945|NCT03721081|Active Comparator|Lidocaine 1%/Epi 1:200000|Subcutaneous infiltration of Lidocaine 1%/Epi 1:200000
9528268|NCT03212339|Experimental|Mothers with children 3-5 years of age|Dyads of mothers with children between the ages of 3 and 5 years will be attending Brief Dyadic Intervention (BDI) sessions at Child Witness to Violence and/or the SPARK Center with their child and an individual therapist. Dyads will be offered the 10 session therapeutic intervention.
9975438|NCT03087994|Active Comparator|girls with normal weight|participants in this group will only receive nutrition guidance once during the study
10187946|NCT03721055|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
10187947|NCT03721029|Experimental|Intraoperative nerve monitoring|Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
9975439|NCT03078192|Experimental|Training Set - PVD, Isolated Left Heart Failure, Isolated Lung Disease|Patients with Pulmonary Vascular Disease (10 subjects), isolated left sided heart failure (10 subjects), and isolated lung disease(10 subjects) will undergo Xe MRI scans with GE-141, Hyperpolarized 129Xenon gas to develop diagnostic criteria for optimizing the sensitivity and specificity of XeMRI for the diagnosis of PVD
9826756|NCT02431650|Experimental|OZ439|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
9672716|NCT05032001|Experimental|Metformina + ISGLT-2|Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day
9672717|NCT05032118|Experimental|Ketamine|Intravenous ketamine will be initiated following aneurysm securement at 0.5mg/kg/h and will be titratable by 0.2mg/kg/h every 20min to a Richmond Agitation Sedation Scale (RASS) goal of 0 to -1 (or as otherwise clinically indicated). Ketamine boluses will be available at 0.5mg/kg every 1hr as needed for inadequate sedation or breakthrough agitation. An additional 0.5mg/kg bolus may be utilized prior to initiating the ketamine infusion, or as needed at the discretion of the clinician. The maximum ketamine infusion dose will be limited to 4mg/kg/h. A fixed-dose propofol infusion at 10mcg/kg/min will simultaneously be administered to minimize the potential psychomimetic side effects of ketamine. This sedation paradigm will continue for up to 10 days post-bleed or until the study participant no longer requires sedation, whichever occurs earlier. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
10173417|NCT03863444|Active Comparator|Control Group|Routine Care
10173418|NCT03863444|Experimental|Intervention Group|Routine Care + Prenatal Preparation Education
10173419|NCT03863301|Experimental|MR-guided single dose preoperative PBI|
9827523|NCT02459418|Experimental|Afolia - US Gonal-f® (Sequence A) Arm|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
10173420|NCT03863223|Experimental|A|Pyrotinib Plus trastuzumab and docetaxel
10173421|NCT03863223|Placebo Comparator|B|Placebo plus trastuzumab and docetaxel
10173422|NCT03863314|Active Comparator|In-Person Simulation|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
10173423|NCT03863314|Experimental|Virtual Simulation|Participants will experience virtual simulations of different workplace scenarios such as medical error and workplace harassment via Virtual Reality headset.
10173424|NCT03863145|Experimental|1|Part 1 (Dose Escalation): 100 mg daily.
10173425|NCT03863340|Experimental|short interruptions of work tasks|randomly start with or without short interruptions on the first experimental day and without or with them on the second experimental day
10173426|NCT03863197|Experimental|Intervention group|During a 12-week period children receive 3-4 sessions of progressive strength training per week on top of the usual care. All children will be provided with an individualized training program and supporting equipment. One or 2 session per week will be performed under supervision of the physical therapist, whilst the remaining sessions will be performed at home. Progression is closely monitored by the principal investigator and training programs are adjusted if necessary.
10173427|NCT03863197|No Intervention|Waitlist-control group|The waitlist-control group will continue their usual care without additional treatment for 12-weeks, followed by a 12-week period of progressive supervised home-based strength training.
10173428|NCT03863093|Experimental|An erythritol powder|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
10173429|NCT03863093|Active Comparator|ultrasonic instrumentation|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
10173430|NCT03862846|Experimental|Group|REN001 Low Dose
10173431|NCT03863002|No Intervention|Standard Medical Treatment|Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS]).
10173432|NCT03863002|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.
10173433|NCT03862872|Experimental|Anti-Aging Formula|4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
10173434|NCT03862872|Active Comparator|Control Fish Oil|4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
10173435|NCT03862872|Placebo Comparator|Inert Placebo|4 capsules daily of 1040 mg each of corn oil for 90 days.
10173436|NCT03862976|Experimental|computerized cardiotocography|computerized cardiotocography
10173437|NCT03862976|Active Comparator|standard cardiotocography|standard cardiotocography non stresstest
10187074|NCT03729843||CBCT and intraoral digital radiography|simulated bone defects will be detected and measured by 2 techniques using CBCT and using intraoral digital radiography and the all measurements will be compared with the gold standard real measurements on the dry jaws
9528269|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
10173438|NCT03862950|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
10173439|NCT03862950|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
10173440|NCT03862794|Experimental|high total and high broad spectrum prescribing letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
10173441|NCT03862794|Active Comparator|high total and high broad spectrum prescribing control|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
10173442|NCT03862794|Experimental|high total prescribing only intervention letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
10173443|NCT03862794|Active Comparator|high total prescribing control letter|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
10173444|NCT03862794|Experimental|moderate total prescribing and high broad spectrum letter|social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
10173445|NCT03862794|No Intervention|moderate total prescribing and high broad spectrum control|GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.
10173446|NCT03862963|Active Comparator|Standard of Diabetes Care|Standard of diabetes care in the Marshall Islands
9672718|NCT05032118|Active Comparator|Standard of Care|Intravenous titratable propofol will be initiated as needed per current standard of care, which generally consists of initiating the infusion at 10-20mcg/kg/min with titration parameters of 5-10mcg/kg/min every 5-10min for a RASS goal of 0 to -1 (or as otherwise clinically indicated). Propofol boluses are available at 10-20mg (or higher dosages if clinically required) every 15min as needed for inadequate sedation or breakthrough agitation. The maximum infusion dose is generally limited to 50mcg/kg/min. If the RASS goal is not met with this sedation regimen, additional agents will be at the discretion of the intensivist.
10173447|NCT03862963|Experimental|Lifestyle Intervention|Plant-based, whole foods diet with moderate exercise
10173448|NCT03863015|Active Comparator|Tocilizumab|A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
10173449|NCT03863015|Placebo Comparator|Isotonic saline|A one hour infusion of isotonic saline
10173450|NCT03862937|Experimental|Experimental|The experimental group will perform 12 weeks of strength training twice a week associated with whey protein supplementation.
10173451|NCT03862937|Placebo Comparator|Placebo|The placebo group will perform 12 weeks of strength training twice a week associated with maltodextrin supplementation.
10173452|NCT03863054||>40% wound area reduction after 1 month|Subjects to continue with standard practice for the next 12 weeks, or until the wound has completely healed.
10173453|NCT03863054||<40% wound area reduction after 1 month|Subjects to be fitted with NATROX™ after 1 month, over a period of 12 weeks or until the wound has completely healed.
10173454|NCT03862703|Experimental|Experimental group|PTSD Help intervention combined with care as usual.
10173455|NCT03862703|No Intervention|Control group|Care as usual.
10173456|NCT03863028||Novice|Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB
9672719|NCT05031819|Experimental|Practice Facilitation to support TASSH integration (group A).|Components of the PF strategy include: (a) establishment of a steering committee of key stakeholders (ministry of health, state primary care agency, AIDS control agency, patient advocates) to provide leadership and guide integration of TASSH into HIV care platform; (b) training of the HIV nurses on TASSH protocol; and (c) training of practice facilitators, who will serve as coaches, provide support, and performance feedback to the PHC nurses on TASSH implementation.
10173457|NCT03863028||Intermediates|Residents who have performed 10 to 30 TURBs.
10173458|NCT03863028||Experienced|Consultants with experience in the procedure defined as more than 100 TURBs.
10173459|NCT03862690||Participants with Type 2 Diabetes Mellitus|A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.
10173460|NCT03863548||Continuation of antithrombotic drugs|operation carried out without stopping anticoagulants
10173461|NCT03863548||Stop anti thrombotic drugs|operation performed with stopping the anticoagulants
10173462|NCT03862768|Experimental|Surgery following imatinib|Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
9672720|NCT05031819|Sham Comparator|TASSH only (group B)|HIV nurses based at Group B facilities will be trained on the 5As counseling approach strategy (Ask, Assess, Advise, Assist, and Arrange) and referral for the participants to the health center. However, they will not receive practice facilitation from the POFs. Participants attending PHC randomized to Group B will receive standard care offered by the facility.
9527105|NCT03222817|Experimental|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
10173463|NCT03862768|Active Comparator|Imatinib escalation or sunitinib|Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs. There is no high-level evidence to suggest which method is better. So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
10173464|NCT03862443|Experimental|Fixed Incentive|Eligible to earn a weekly payment during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will win $5; high adherence threshold (brushing twice per day for 14 days in a week) will win $10.
9527106|NCT03222960|Experimental|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
10187075|NCT03729804|Experimental|KRD Arm|Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary
9527107|NCT03222960|Experimental|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
9527108|NCT03223051|Experimental|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
10187076|NCT03729804|Experimental|VRD Arm|Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary
9527109|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
9527110|NCT03223012||Participants included in the AbbVie care program|Participants receiving adalimumab included in the AbbVie care patient support program.
9527111|NCT03222986||Sepsis with organ failure|Patients have organ failure
9527112|NCT03222986||Sepsis without organ failure|Patients have no organ failure
9527113|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
9527114|NCT03222804|Active Comparator|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
9527115|NCT03222804|Active Comparator|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
9527116|NCT03222804|Active Comparator|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
9672721|NCT05031962||CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Implant-based breast reconstruction following mastectomy using the CELLIS Breast matrix
9672722|NCT05031884||MGIR3-US group|using MGIR3-US to do ultrasonic examinations.
9672723|NCT05031884||control group|using conventional B-mode ultrasound to do ultrasonic examinations.
9672724|NCT05031871|Experimental|Treatment group A|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
9527117|NCT03222856|Experimental|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
9527118|NCT03222908|No Intervention|Control: Prescriptive Advice|Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
9527119|NCT03222908|Experimental|Intervention1: Contract Agreement|Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
9527120|NCT03222908|Experimental|Intervention2: Implementation Intentions|Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.
9527121|NCT03222622|Experimental|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
9527122|NCT03222622|Experimental|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
9527123|NCT03222622|Experimental|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
9527124|NCT03222622|Placebo Comparator|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
10173465|NCT03862443|Experimental|Drawing Incentive|Eligible to earn a weekly drawing entry with different winning probabilities during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
9527125|NCT03222557|Experimental|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
9527126|NCT03222557|Sham Comparator|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
10173466|NCT03862443|No Intervention|Control - Delayed Incentive|No rewards during the first 2-months, but information on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app. After the Month 2 follow-up visit, may opt to participate in a delayed 2-month open label extension to earn the same monetary rewards the fixed incentive intervention group could earn Baseline through Month 2. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
9528080|NCT03213873|Experimental|HiBalance|The HiBalance program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in PD. The training will be conducted as a progressive individually adjusted group program in order to challenge the specific balance disorder of every participant and endorse progression. The intervention will be performed for an hour, 2 times/week in groups of six to eight participants for a total of 10 weeks and one home training session on their own.
9528081|NCT03213873|Active Comparator|Speech therapy|The control group will receive a group treatment (2 times/w for 10 w + 1 home training session) consisting of speech and communication therapy performed by a speech therapist. This intervention will be performed in a sitting position. The speech and communication treatment will aim at increasing vocal loudness and improving articulatory precision. Level of difficulty is gradually increased by progressing from using loud voice and clear speech in short and automatized utterances, to using the same technique in more complex sentences and situations. The group format is used to practice techniques in communicative situations and also to introduce increasing level of multitasking by combining speech training with cognitively more challenging tasks in the group training.
9528082|NCT03214016|Experimental|Pilates method group|The participants will do Mat Pilates.
9528083|NCT03214016|Active Comparator|Aerobic training group|The participants will do aerobic exercise on treadmill.
9528084|NCT03214159|Experimental|group 1|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg"
9528085|NCT03214159|Experimental|group 2|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg"
9528086|NCT03213925|Experimental|RT|"After clinical response, breast magnetic resonance imaging (MRI) is performed and analyzed by two independent radiologists. Complete image response is defined by no enhanced tumor visible on any serial images.~Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region."
9528087|NCT03214302|No Intervention|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
10173467|NCT03862781|Other|Intra-corporeal|Right Hemicolectomy
9528270|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
10173468|NCT03862781|Other|Extra-corporeal|Right Hemicolectomy
10173469|NCT03862677||Patients with (suspicion of) primary EOC|
10173470|NCT03862677||Patients with recurrent EOC|
10173471|NCT03862573|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during the dental procedure
10173472|NCT03862573|No Intervention|Control (Standard of Care)|Participants are distracted with Standard-of-Care by dentists and/or parents.
10173473|NCT03862456|Experimental|azythromycin + periodontal surgery.|Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days).
10173474|NCT03862456|Active Comparator|metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days).
10173475|NCT03862898|Experimental|lumbar stabilization group- thoracic|Lumbar stabilization and thoracic mobilization in a closed kinetic chain (LSTMC) group performed this exercises from the least to the largest painless motion amplitude and accordingly divided into three phases. The first phase lasted for two weeks, the second three and the last third phase, also for three weeks, and a total of 8 weeks.
10173476|NCT03862898|Active Comparator|lumbar stabilization group|Lumbar stabilization in a closed and opened kinetic chain (LSCO) group also performed exercises from the least to the largest painless motion amplitude in three phases.
10173477|NCT03862586|Experimental|N-acetyl cysteine|Twenty two infertile women with the onset of endometrial preparation for evaluating genes expression, received 1200 mg of oral N-acetyl cysteine for at-least six weeks before starting ovarian stimulation
10187948|NCT03721029|Active Comparator|Control Cohort|Patients that undergo standard of care robotic-assisted radical prostatectomy.
9527127|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
9527128|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
9527129|NCT03222544|Experimental|Photodynamic Therapy|The photosensitizer, methylene blue, is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of seven times.
9527130|NCT03222544|Active Comparator|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of seven times.
9527131|NCT03222739|Other|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
10173478|NCT03862586|Placebo Comparator|Placebos|Eighteen infertile women with the onset of endometrial preparation for evaluating genes expression, received placebo effervescent tablet for at-least six weeks before starting ovarian stimulation
10173479|NCT03862651|Experimental|Cangrelor|Cangrelor, 0.75 μg/Kg/min, a cangrelor infusion will be started in addition to SOC when the P2Y12 inhibitor has been discontinued after the need for surgery has been determined. The infusions (cangrelor or matching placebo) will continue throughout the pre-operative period
9527132|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
9527133|NCT03222726|Active Comparator|exercise group|6000 steps/day or 40,000 steps/week
9527134|NCT03222726|Other|less-exercise group|less than 6000 steps/day or 40,000 steps/week
9527135|NCT03222791|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
9527136|NCT03222791|Other|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
9527137|NCT03222700||robotic thyroidectomy group|
9826757|NCT02431650|Active Comparator|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
9826758|NCT02431676|Active Comparator|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
9527138|NCT03222700||open thyroidectomy group|
9527139|NCT03222765|Placebo Comparator|Placebo|"Placebo~Lifestyle modification (diet and physical activity recommendations)"
9527140|NCT03222765|Experimental|Metformin|"Metformin~Lifestyle modification (diet and physical activity recommendations)"
9527141|NCT03222765|Experimental|Linagliptin|"Linagliptin~Lifestyle modification (diet and physical activity recommendations)"
9527142|NCT03222765|Experimental|Linagliptin and Metformin|"Fixed dose combination of Linagliptin and metformin~Lifestyle modification (diet and physical activity recommendations)"
9527143|NCT03222635|Experimental|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal or high-risk mucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.
9527144|NCT03222596|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
9527145|NCT03222596|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
9527146|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
9527147|NCT03222492|Experimental|Cohort 1: 0.6 mg/kg brentuximab vedotin|"This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
9672725|NCT05031871|Experimental|Treatment group B|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
9527148|NCT03222492|Placebo Comparator|Cohort 1: placebo|"0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
9527149|NCT03222492|Experimental|Cohort 2: 1.2 mg/kg brentuximab vedotin|"This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
9672726|NCT05031871|Experimental|Treatment group C|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
9672727|NCT05031871|Experimental|Treatment group D|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
9826759|NCT02431676|Experimental|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
9826760|NCT02431676|Experimental|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
9527150|NCT03222492|Placebo Comparator|Cohort 2: placebo|"1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
9527151|NCT03222492|Experimental|Cohort 3: 1.8 mg/kg brentuximab vedotin|"This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
9527152|NCT03222492|Placebo Comparator|Cohort 3: placebo|"1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
9527153|NCT03222674|Experimental|Single arm|CAR T cells to treat AML
10173480|NCT03862651|No Intervention|placebo|patients will receive only standard of care, in which the P2Y12 inhibitor is discontinued after the need for surgery has been determined and a placebo infusion is administered
10173481|NCT03862430|Experimental|NVX 108|NVX-108 infusion in conjunction with Radiation Treatment and temozolimide
10173482|NCT03862430|Placebo Comparator|Placebo|Placebo Saline infusion in conjunction with Radiation Treatment and temozolimide
10173483|NCT03862521|Experimental|Low carbohydrate diet group|Low carb diet, carbohydrates make up 30-40% of total daily calories.
9527154|NCT03222479|Experimental|treatment arm|All individual is instructed to use the application we developed for 4 weeks
9527155|NCT03222466|Experimental|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
9527156|NCT03222466|No Intervention|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
9527157|NCT03222453|Experimental|Intervention Patient|Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.
9527158|NCT03222453|No Intervention|non-intervention Patient|No treatment
9527159|NCT03222687|Experimental|therapy group|Immunosuppressive therapy included tacrolimus and prednisone.
9527160|NCT03222518|Active Comparator|Parcetamol Group|The patient receives an envelope containing Paracetamol 1000 mg at the dose of 3 times / day + follow-up sheet + appointment card.
9527161|NCT03222518|Active Comparator|NSAID Group|The patient receives an envelope containing NSAID 20 mg piroxicam twice daily / day + follow-up sheet + appointment card.
9527162|NCT03222518|Active Comparator|NSAID + Paracetamol Group|The patient receives an envelope containing NSAID 20 mg piroxicam at a dose of 2 times/day + Paracetamol 1000 mg at a dose of 3 times / day + follow-up sheet + appointment card.
9527163|NCT03222440|Experimental|SHR-1210+ Radiotherapy|Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
9527164|NCT03222401|No Intervention|Control Group|Control subjects will not receive an infusion or placebo
9527165|NCT03222401|Experimental|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
9527166|NCT03222401|Experimental|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
9527167|NCT03222401|Experimental|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
9527168|NCT03222375||Autism|Individuals with autism will have either Image converter (iSQUED™) for Hysteresis of Spiral Autowaves, Sound converter (sSQUED™) for Drift of Spiral Autowaves or Electromagnetic converter (eSQUED™) for Annihilation Autowave reverberator.
9527169|NCT03222154|No Intervention|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
9527170|NCT03222154|Placebo Comparator|Placebo|20 volunteers who received simulation of the application of shock wave therapy
9527171|NCT03222154|Experimental|Experimental|20 volunteers who received shock wave therapy
9527172|NCT03222388||IIEF5 paper-electronic|
9527173|NCT03222388||IIEF5 electronic-paper|
9527174|NCT03222388||IIEF15 paper-electronic|
9527175|NCT03222388||IIEF15 electronic-paper|
9527176|NCT03222388||IIEF5 electronic-electronic|
9527177|NCT03222388||IIEF15 electronic-electronic|
9527178|NCT03222206|Experimental|Salsalate|17 patients received continuous medication with salsalate 2g/day after run-in period
9527179|NCT03222206|Placebo Comparator|Placebo|17 patients received continuous medication with Placebo 2g/day after run-in period
9527180|NCT03222076|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients continue nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9527181|NCT03222076|Experimental|Arm B (ipilimumab, nivolumab)|Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9528088|NCT03214302|Experimental|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
9528089|NCT03213990|Other|Continuous Infusion|The prescribed Beta-lactam is administered by a continuous infusion.
10173484|NCT03862521|Experimental|Very low carbohydrate diet|Very low carb diet, carbohydrates make up 20-29% of total daily calories.
9527182|NCT03222076|Experimental|Arm C (ipilimumab, nivolumab)|Patients receive ipilimumab and nivolumab as in Arm B. Patients undergo post-treatment biopsy on day 1 of week 7, then receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks up to 2 years in the absence of disease progression or unacceptable toxicity.
10173485|NCT03862638|Experimental|Yoga Therapy|Yoga therapy session lasted for 60 minutes consisting physical posture, Breath work, Relaxation, guided meditation, chants and combination techniques for groups sessions.
9527183|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
9527184|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
9527185|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
9527186|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
9527187|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
9527188|NCT03222323|Experimental|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
9975440|NCT03078192|Experimental|Test Set - Pulmonary Vascular Disease|92 subjects being evaluated for undergoing right heart catheterization for evaluation of PAH or other cardiac or pulmonary disease for testing of diagnostic accuracy of XeMRI for diagnosis of PVD
9527189|NCT03222323|Active Comparator|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
9527190|NCT03222323|Placebo Comparator|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
9527191|NCT03222323|Active Comparator|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
9527192|NCT03222271|Active Comparator|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:~Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).~Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.~Respiratory rate (RR): 10-12 breath/minute."
9527193|NCT03222271|Experimental|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:~Patient's height in cm..~Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).~Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O~Minimum and maximum Pressure Support (PS) :8-16~Respiratory rate :10-12 breath/min."
9527194|NCT03222089|Experimental|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
9527195|NCT03222089|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
9527196|NCT03222284|Experimental|Group 1|"N=10 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 7 Day 28"
9527197|NCT03222284|Experimental|Group 2|"N=20 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 28"
9527198|NCT03222362||patients 85 years and above|120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
9527199|NCT03222297||test group|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
9527200|NCT03222297||control group|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
9527201|NCT03222310|Experimental|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
9975441|NCT03074227|Active Comparator|Allogeneic faecal transplantation|Faecal transplantation of donor stool
9975442|NCT03074227|Placebo Comparator|Autologous faecal transplantation|Faecal transplantation of own stool
9975443|NCT03053687|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
9975444|NCT03053687|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
9975445|NCT03045276|Active Comparator|Arm 1 - No Feedback, Minimum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos. They will receive compensation to encourage real-time adherence reporting. Subjects will also be able to log into a personal dashboard with a visual display of their weekly adherence performance and educational resources related to their primary disease. Every month, participants will receive a text encouraging them to visit their personal dashboard. The dashboard is able to track usage of the modules by individual. Parents/legal guardians will have access to these same educational materials via their own portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
10173486|NCT03862508|Experimental|Experimental|Five Plyometric exercises
10173487|NCT03862508|No Intervention|Control|Subjects included in the control group will not receive any intervention
9527202|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
9527203|NCT03222167|Experimental|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
9527204|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
9527205|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
9527206|NCT03222219||low implant stability quotient|dental implant insertion with low torque values
9527207|NCT03222219||medium implant stability quotient|dental implant insertion with medium torque values
9527208|NCT03222219||high implant stability quotient|dental implant insertion with high torque values
9527209|NCT03222102|Experimental|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
9527210|NCT03222102|No Intervention|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
9527211|NCT03222193|Experimental|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
9672728|NCT05031845||COVID-19 positive, Hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
9672729|NCT05031845||COVID-19 positive, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
9672730|NCT05031845||COVID-19 negative, not hospitalized with ARDS|"Patients with chest imaging at the time of the first COVID-positive PCR test will have their first LDCT within 3 to 4 months after COVID 19 diagnosis. A second LDCT between 3 to 6 months after the initial LDCT.~Patients without chest imaging at the time of the first COVID-positive PCR test or with a negative COVID PCR test will have their first LDCT within 2 weeks to 1 month after their recovery from COVID 19, or testing. A second LDCT may be performed between 3 to 6 months after the initial LDCT."
9672731|NCT05031793|Experimental|Collaborative Care of TCM and Western Medicine|
9672732|NCT05031793|Active Comparator|Western medicine|
9672733|NCT05031858|Experimental|Vojta Therapy|Reflex turn first phase: Patient positioned supine with legs flexed 30º-45º. The pectoral area is stimulated for five minutes on each side x 2 consecutive times. Total 20 minutes per session.
9672734|NCT05031858|Active Comparator|Control Group|.Inspiratory techniques, mucociliary clearance techniques (expiratory). Use of inspiratory and expiratory incentives. Employment of mechanical assistants
9672735|NCT05031689|Placebo Comparator|SPF 30 and Placebo|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
9672736|NCT05031689|Active Comparator|SPF 30 and pharmaceutical formulation with green banana peel|In Study Group, in addition to the SPF 30 sunscreen, a pharmaceutical formulation containing the extract of the green banana peel will be used.
9672737|NCT05031676|Experimental|group 1|Intervention consists at induction : direct intravenous lidocaine 1.5 mg/kg; clonidine 2 μg/kg in 250 ml of isotonic saline, started as soon as the venous route is taken and over a period of approximately 15 minutes; magnesium sulfate 50 mg/kg in the same isotonic saline as clonidine.
9672738|NCT05031676|No Intervention|group 2|In classic induction: fentanyl at a dose of 2 µg/kg. Following induction in all patients consisted of the administration of propofol 2-3 mg/kg in titration, rocuronium 0.6 mg/kg, ketamine 0.5 mg/kg, methylprednisolone 120 mg.
10173488|NCT03862612|Active Comparator|Erector Spinae Plane Block|This group will receive an Erector Spinae Plane Block under ultrasound guidance while under General Anaesthesia
10173489|NCT03862612|Experimental|Serratus Anterior Plane Block|This group will receive a Serratus Anterior Plane Block under ultrasound guidance while under General Anesthesia
10173490|NCT03862534|Experimental|CAF|After the restoration of the enamel patients were treated with a CAF
10173491|NCT03862534|Experimental|CAF + CTG|After the restoration of the enamel patients were treated with a CAF + CTG
10187077|NCT03729791|Experimental|actual tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
9527212|NCT03222063|Experimental|Experimental group|"Experimental Group:~Experimental group consists of 30 hospitalized children.In Experimental group after taking pretest on 1st day play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. Though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. The play interventions were administered for 1 hour daily for continuous 5 days.Post test assessment of anxiety was done on 5th day."
9527213|NCT03222063|No Intervention|Comparison group|Comparison Group: 30 hospitalized children were selected by purposive sampling in comparison group. Pretest anxiety was measured on 1st day . No intervention was administered. only usual medical and nursing care was administered to the hospitalized children. Post test assessment of anxiety was done on 5th day.
9527214|NCT03222050|Experimental|electronic toy group|Distraction technique was given by electronic toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
10187949|NCT03720990|Experimental|Cholic acid|Participants will be treated with cholic acid 10 mg/kg body weight.
9527215|NCT03222050|Experimental|key toy group|Distraction technique was given by key toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
9527216|NCT03222050|Experimental|Simple toy group|Distraction technique was given by simple toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
9527217|NCT03222050|No Intervention|control group|Routine care was given during immunization and no intervention was given
10173492|NCT03862547|Experimental|Men with ED and diabetes|"A peripheral blood sample from the cubital vein~A collection of peripheral blood from the routinary cubital vein for hormone dosage and metabolic evaluation~An introverted cavernous infiltration of Prostaglandin E1 to achieve erection (Aprostadil);~A blood sample from both the corpus cavernosum and the cubital vein, once the erection is achieved Baseline interaction of prostaglandin E1 on the concentration of NGF released in the medium and on the expression of its receptors Evaluation of NGF and Cytokine levels Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs"
10173493|NCT03862599|Sham Comparator|Standard care + sham ESWT|Cialis and Vacuum pump + sham Extra-corporeal shockwave therapy (ESWT)
10173494|NCT03862599|Active Comparator|Standard care + active ESWT|Cialis and Vacuum pump + active Extra-corporeal shockwave therapy (ESWT)
9527218|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
9527219|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
9527220|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
9527221|NCT03222180|Experimental|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
9527222|NCT03222180|No Intervention|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
9527223|NCT03221790|Experimental|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
9527224|NCT03221816|Placebo Comparator|Placebo Oral Tablet|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.~The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
9527225|NCT03221816|Experimental|Experimental group (Tenavit®)|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
9527226|NCT03221855|Active Comparator|Domperidone|Domperidone 10mg every 8 hours for 7 days.
9527227|NCT03221855|Placebo Comparator|Placebo|Placebo 10mg every 8 hours for 7 days.
9527228|NCT03221920|Experimental|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
9527229|NCT03221920|No Intervention|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
9527230|NCT03221933|Experimental|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
9527231|NCT03221933|Experimental|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
9527232|NCT03221894||Conventional therapy with herbs|Patients were treated with conventional therapy with Chinese herbal medicine (GRAPE granules).
10173495|NCT03862417|Experimental|Schroth exercise group|Will attend 5 1-hr long individual sessions to learn Schroth exercises and the home program. A 30-min. daily home program of 3 to 4 exercises will be progressed by the certified Schroth therapist using an algorithm. Patients will attend weekly 1-hr long group therapist-led exercise classes for 3 months. At each group class, adequate exercise performance will be assessed using the checklist. An algorithm guides the prescription of exercises intensity and progression from static to dynamic depending on the participant's ability. Prescription begins with Sitting on a Ball. If performed adequately, a more challenging exercise is attempted. The 3 most challenging exercises performed adequately as per the checklist will be prescribed with a detailed handout.
10173496|NCT03862417|No Intervention|Control group|Observation without treatment or with previously prescribed pain medication is the current standard for adults with degenerative scoliosis not planning surgery.
10173497|NCT03862560|Experimental|Experimental group|Female soccers that perform a strength training
10173498|NCT03862560|No Intervention|Control group|Female soccers that do not perform a strength training
10173499|NCT03862404|Placebo Comparator|Control group|Patients in this group receive Normal Saline injection in the inter pleural space
10173500|NCT03862404|Experimental|Experimental group|Patients in this group receive Bupivacaine 0.25% + Epinephrine 5 mcg/ml injection in the inter pleural space
10173501|NCT03862391|Active Comparator|Postsurgical Pain|pain is defined as unpleasant sensation that can range from mild, localized discomfort to agony.
10173502|NCT03862391|Active Comparator|Postanesthesia nausea and vomiting|nausea defined as feeling of sickness or discomfort in the stomach that may come with an urge to vomit.
9527233|NCT03221894||Conventional therapy alone|In conventional therapy group, donepezil was the commonly used ChEI(cholinesterase inhibitor) to treat mild to severe AD patients. Memantine, a NMDA(N-methyl-D-aspartate ) antagonist, was given to moderate and severe AD patients. The dose of donepezil ranged from 5 to 10 mg once a day according to patients.
9527234|NCT03221868|Experimental|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
9527235|NCT03221868|Active Comparator|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
9527236|NCT03222011|Active Comparator|Standard endoscopic therapy|Single endoscopic dilatation
9527237|NCT03222011|Experimental|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
10173503|NCT03862313|Experimental|active-rtACS arm|Active rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
10173504|NCT03862313|Sham Comparator|sham-rtACS arm|Sham rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
9527238|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
9527239|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
9527240|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
10173505|NCT03862248|Experimental|High-Dose Isoniazid|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
10173506|NCT03862248|Experimental|High-Dose Rifampicin|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
10173507|NCT03862248|Active Comparator|World Health Organisation (WHO) regimen|WHO levofloxacin-strengthened regimen (6EHRZLfx)
10173508|NCT03861988|Experimental|Open label ketamine|Patients will receive an intravenous ketamine infusion during surgery.
9527241|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
9527242|NCT03221907|Experimental|GLA5PR GLARS-NF1 & Pregabalin placebo|GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
9527243|NCT03221907|Active Comparator|GLA5PR GLARS-NF1 placebo & Pregabalin|GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
9527244|NCT03221881|Experimental|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
9527245|NCT03221946|Active Comparator|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
9672739|NCT05031338||SX-One MicroKnife with ultrasound guidance|Carpal Tunnel Release using the SX-One MicroKnife with ultrasound guidance
9672740|NCT05031338||Traditional mini-open technique without ultrasound guidance|Carpal Tunnel Release using the traditional mini-open technique without ultrasound guidance
10173509|NCT03861988|Experimental|Double blind ketamine|Patients will receive an intravenous ketamine infusion during surgery.
10173510|NCT03861988|Placebo Comparator|Double blind placebo|Participants will receive placebo (normal saline infusion) during surgery.
10173511|NCT03862105|Experimental|Health App with Provider Monitoring/Care|30 patients enrolled by the study team will receive notifications through a mobile health app (Twistle) before and after surgery. Patient Reported Outcome data will be collected through patient responses in this app and timely clinician feedback will be provided to patients to prevent complications and readmission.
10173512|NCT03862235||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
10173513|NCT03862235||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
10173514|NCT03862235||Sedentary control|"This group were sedentary men without cardiovascular disease.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
10173515|NCT03861975|Experimental|Breast Cancer-Related Lymphedema Measurements|Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.
10173516|NCT03862222||Cognitively normal - low risk|Adults aged 55-80 without subjective memory complaints, family history of Alzheimer's disease, or genetic risk for Alzheimer's disease.
10173517|NCT03862222||Cognitively normal - high risk|Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer's disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer's disease
10173518|NCT03862222||mild cognitive impairment|Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
10173519|NCT03862222||mild dementia|Adults aged 55-80 with mild dementia due to probable Alzheimer's disease.
9528090|NCT03213990|Other|Intermittent infusion|the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
9826761|NCT02431741|Experimental|Mepilex Transfer Ag|Non controlled investigation
9527246|NCT03221946|Experimental|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
9527247|NCT03221946|Other|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
10173520|NCT03862274||CLN2 Natural History Control Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are untreated or not receiving cerliponase alfa.
10173521|NCT03862274||CLN2 Treatment Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
10173522|NCT03862326|Other|Group Training|Group Training of the women with incontinence - with 5-8 women in each group. This is also Usual Care
9527248|NCT03221985|Other|Questionnaires|
9527249|NCT03221998|Experimental|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
9527250|NCT03221998|Placebo Comparator|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
10173523|NCT03862326|Experimental|Individual training|Individual pelvic floor exercises one-to-one with the physiotherapist
9527251|NCT03221699|Placebo Comparator|control|Formula without ZnO
9527252|NCT03221699|Active Comparator|intervention|Formula with ZnO
9527253|NCT03221569|Experimental|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
9527254|NCT03221569|Active Comparator|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
9527255|NCT03221803|Experimental|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
9527256|NCT03221803|Active Comparator|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
9527257|NCT03221686|Placebo Comparator|Control|Total daily protein intake: 1.5 g protein/kg body weight
9527258|NCT03221686|Active Comparator|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
9527259|NCT03221725|Experimental|sacrospinosus fixation group|The group which sacrospinous fixation was performed
9527260|NCT03221413|Experimental|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
9527261|NCT03221413|Experimental|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
9527262|NCT03221504|Active Comparator|Antibiotic therapy for 10 days|After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
9527263|NCT03221504|Experimental|Antibiotic therapy for 7 days|After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
9527264|NCT03221426|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
9528091|NCT03213964|Experimental|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.~Lymphodepletion with Cyclophosphamide and Fludarabine."
9528092|NCT03213977|Experimental|Arm I:R-DA-EPOCH|Protocol involves 8 cycles.
9528093|NCT03213977|Experimental|Arm II:R-DA-EPOCH + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
10173524|NCT03862326|Experimental|Individual training with biofeedback|Individual pelvic floor exercises one-to-one with the physiotherapist but with ultrasound used as biofeedback, and to check if the women are contracting the right muscles.
10173525|NCT03862287|Active Comparator|Intrathecal Lidocaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
10187078|NCT03729791|Active Comparator|sham tDCS|sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
10187079|NCT03729778|Active Comparator|HIV+|One time administration of Prevnar-13 vaccine to HIV+ participants
9527265|NCT03221426|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
9527266|NCT03221426|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion Day 1 Q3W PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
9527267|NCT03221426|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
9527268|NCT03221556|Active Comparator|Engagement-Focused Care Coordination|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
9527269|NCT03221556|Active Comparator|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
9527270|NCT03221465|No Intervention|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
9527271|NCT03221465|Active Comparator|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
9527272|NCT03221465|Experimental|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
10173526|NCT03862287|Active Comparator|Intrathecal Bupivacaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
10173527|NCT03862053|Active Comparator|Manuka honey eyedrops|optimel manuka eyedrops 10 ml used as directed in a CAC (Conjunctival allergen challenge) study
9527273|NCT03221491|Experimental|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
9527274|NCT03221491|Experimental|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
9527275|NCT03221491|Experimental|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
9527276|NCT03221478|Active Comparator|Kinesio Taping placebo and exercises|kinesio placebo and exercises
9527277|NCT03221478|Experimental|Kinesio Taping and exercises|kinesio with tension and exercises
9527278|NCT03221478|Experimental|Kinesio Taping with tension|Kinesio Taping with tension
9527279|NCT03221530|Experimental|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
9528094|NCT03213977|Active Comparator|Arm III:R-CEOP90|Protocol involves 8 cycles.
10173528|NCT03862053|Placebo Comparator|Normal saline 0.9% eyedrops|sterile normal saline eyedrops used as directed in a CAC (conjunctival allergen challenge) study
10173529|NCT03862196|Experimental|Intervention|Participants will receive 2 tailored text messages weekly from a trained counselor during 3 months.
10173530|NCT03862196|No Intervention|Control|Participants will receive standard of care: pre and post counseling after being diagnosed with HIV
9527280|NCT03221530|Active Comparator|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
9527281|NCT03221543|Experimental|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
9527282|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV/HIV co-infected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
9527283|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV monoinfected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
9527284|NCT03221634|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
9527285|NCT03221608|Active Comparator|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
9527286|NCT03221608|Experimental|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
9527287|NCT03221361|Active Comparator|Thermoplastic resin group|Thermoplastic complete denture placement is done
9527288|NCT03221361|Placebo Comparator|conventional acrylic resin group|conventional acrylic resin complete denture placement is done
9527289|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
9527290|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
10173531|NCT03862378||Group One|All patients underwent gastric or colorectal cancer surgery in the participating centers will be included. Clinical data, drainage cytokine levels will be recorded.
9527291|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ).
10173532|NCT03862365||Polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.
10173533|NCT03862365||Polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.
9527292|NCT03221179|Experimental|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
9527293|NCT03221179|Placebo Comparator|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
9527294|NCT03221088|Experimental|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
9527295|NCT03221088|Experimental|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
9527296|NCT03221088|No Intervention|Negative control group|Untreated Control Group
9527297|NCT03221101|No Intervention|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
9527298|NCT03221101|Active Comparator|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings~PS mode~IPAP according to clinical and hemodynamic tolerance~EPAP according to air trapping~RR around 12/ min.~LOT for SaO2 > 90%~Monitoring with capnometry for settings validation"
9527299|NCT03221348|Experimental|Open label treatment|Study drug (CHO-H01) administered on Day 1 of 28 day cycles up to 6 cycles total.
9527300|NCT03221452|Other|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
9527301|NCT03221114|Experimental|Positive Psychological Intervention|Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
9527302|NCT03221114|No Intervention|Wait list control|Receipt after the active treatment group has completed the positive psychological intervention.
10173534|NCT03862365||Diabetic polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.
10173535|NCT03862365||Diabetic polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.
10173536|NCT03862365||Carpal tunnel syndrome with pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.
10173537|NCT03862365||Carpal tunnel syndrome without pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.
10173538|NCT03862001|Experimental|LungCARE Group|The intervention group will receive the LungCARE intervention
10173539|NCT03862001|No Intervention|Comparison Group|The comparison group will receive usual care.
10173540|NCT03862352||Coronary artery perforation (iatrogenic)|Any coronary artery perforation defined according to the Ellis criteria.
10173541|NCT03862079|Experimental|Arm I (TGD + FMT)|Patients receive piperacillin-tazobactam PO TID and nystatin QID. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
10173542|NCT03862079|Experimental|Arm II (FMT)|Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
10173543|NCT03862079|Active Comparator|Arm III (standard therapy)|Patients receive standard of care.
10173544|NCT03862014|Experimental|SDF only|SDF will be applied on molars with MIH
9527303|NCT03221439|Experimental|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
9527304|NCT03221439|Active Comparator|Manual Therapy and Exercise|The active comparator will be the combination of manual therapy and motor control exercises.
9527305|NCT03221335|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
9527306|NCT03221166|Experimental|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
9527307|NCT03221166|Active Comparator|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
9527308|NCT03221374|Experimental|Mindfulness Based Stress Reduction|Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
9527309|NCT03221374|No Intervention|Waitlist|Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.
9527310|NCT03221296|Experimental|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
9527311|NCT03221296|No Intervention|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
9527312|NCT03221283|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center.
9527313|NCT03221283|Experimental|Music therapy group|Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
9527314|NCT03221231|Experimental|N-acetylcysteine|
9527315|NCT03221231|Placebo Comparator|Placebo|
9527316|NCT03221231|Active Comparator|Healthy controls|
10173545|NCT03862014|Active Comparator|SDF+ARR|SDT+ARR will be applied on molars with MIH
10173546|NCT03862183||dyslipidemia in hypertension|
10173547|NCT03862183||hypertension|
10173548|NCT03861949|No Intervention|Conventional|preoxygenation done with 100% oxygen in supine position
10173549|NCT03861949|Experimental|Positive-pressure|preoxygenation done with 5 cmH2O CPAP (continuous positive airway pressure) in supine position with 100% oxygen
10173550|NCT03861949|Experimental|Head-up|preoxygenation done in 25 degree head-up position with 5 cmH2O CPAP with 100% oxygen
10173551|NCT03862209|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
10173552|NCT03862209|No Intervention|Standard care|Health care settings and their providers randomised to the control condition receive usual care: participant will gain standard care; ambulatory care, day hospitals or hospital admission.
10173553|NCT03862092|Experimental|Patients with acute abdominal pain|Salivary VZV-DNA PCR was performed in patients who visited the emergency room due to acute abdominal pain.
10173554|NCT03861884||Cognitive assessments|Neurocognitive assessments, Birmingham Cognitive Screen
9527317|NCT03221205|Sham Comparator|Sham CPAP|Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
9527318|NCT03221205|Experimental|Therapeutic CPAP|Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
9528095|NCT03213977|Active Comparator|Arm IV:R-CEOP90 + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
9528096|NCT03213951||Prostate cancer|Gleason grade group 1-5 on prostate biopsy or prostate cancer recurrence.
9528097|NCT03213782|Experimental|Experimental group|Nature based sounds are administered via head phones continuously for 20 minutes.
9672741|NCT05031325|Experimental|Endoscopic submucosal dissection with Purastat|To compare of the risk of bleeding after endoscopic submucosal dissection, after ESD, application of Purastat gel (not a drug but a device with CE mark) with a catheter of a gel on the resected area to cover the whole surface of mucosal resection.
10173555|NCT03861884||MRI at 3T|Brain Imaging: MRI at 3T
10173556|NCT03861884||MRI at 7T|Brain imaging: Ultrahigh Field MRI at 7T
10173557|NCT03861923|Experimental|Dry needling and exercise|
10173558|NCT03861923|Sham Comparator|Sham dry needling and exercise|
9528098|NCT03213782|No Intervention|Control group|Usual routine care was continued
9528099|NCT03214276|Active Comparator|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
9672742|NCT05031325|No Intervention|Comparative arm without Purastat|After endoscopic submucosal dissection (ESD) and hemostasis, if the patient is randomized in the comparative group, no gel will be applied on the resected area that will remain like this without intervention (common practice)
9826762|NCT02431754|Experimental|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
9527319|NCT03221621|Active Comparator|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
9527320|NCT03221621|Experimental|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
10173559|NCT03861910||extensively hydrolyzed casein formula+LGG|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
9527321|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
9527322|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
9527323|NCT03221153|No Intervention|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
9527324|NCT03221153|Experimental|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
9527325|NCT03221023|Experimental|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
10173560|NCT03861910||extensively hydrolyzed whey formula;|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
9527326|NCT03221023|Placebo Comparator|Saline|These patients will receive intrawound saline + IV antibiotics alone
9527327|NCT03221010|Experimental|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
9527328|NCT03221010|Active Comparator|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
9527329|NCT03221270|Experimental|tACS Treatment & tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 20 minutes twice daily during 5 consecutive days of stimulation. 10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.
9527330|NCT03221270|Sham Comparator|Sham tACS Treatment & Sham tACS Maintenance|10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation. 10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation once weekly for 8 weeks of maintenance stimulation.
9527331|NCT03221270|Other|Sham tACS Treatment & tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 40 minutes once weekly for 8 weeks of maintenance stimulation.
9527332|NCT03221270|Other|tACS Treatment & Sham tACS Maintenance|10 Hz (alpha) tACS with a peak-to-peak amplitude of 2 mA for 20 minutes twice daily during 5 consecutive days of stimulation. 10 seconds of ramp in to 1 minute of 10 Hz (alpha) tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation once weekly for 8 weeks of maintenance stimulation.
9527333|NCT03221062|Experimental|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
9527334|NCT03221062|Experimental|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
9527335|NCT03221062|Experimental|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
9527336|NCT03221075||Invasive Aspergillosis|
9527337|NCT03220932|Experimental|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
9527338|NCT03220932|Active Comparator|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
9527339|NCT03221049||chronic hepatitis B patients|ultrasound and radiomics
9826763|NCT02431754|Placebo Comparator|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
9527340|NCT03221049||patients with liver space occupying lesions|ultrasound and radiomics
9527341|NCT03221049||patients undergo ablation|ablation, ultrasound and radiomics
9527342|NCT03220997|Experimental|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
10173561|NCT03861910||hydrolyzed rice formula|subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
10173562|NCT03861910||soy based formula|subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
10173563|NCT03861910||amino-acid based formula|subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
10173564|NCT03862144|Experimental|Netupitant/Palonosetron & Dexamethasone|"Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.~Dexamethasone 12 mg will be added on day 1 only of each cycle."
10187080|NCT03729778|Active Comparator|HIV Negative Controls|One time administration of Prevnar-13 vaccine to HIV Negative Control participants
9527343|NCT03220997|No Intervention|Standard Care|"Standard fasting instructions will given to mother:~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
9527344|NCT03221036|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.
9527345|NCT03221036|Placebo Comparator|Induction Phase: Placebo|Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.
9527346|NCT03221036|Experimental|Maintenance Phase: Vedolizumab 300 mg|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.
9527347|NCT03221036|Placebo Comparator|Maintenance Phase: Placebo|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.
9527348|NCT03220919|Experimental|Weight-based|Weight-based insulin insulin titration regimen
9527349|NCT03220919|Placebo Comparator|Glucose level-based|Glucose level-based insulin titration regimen
9527350|NCT03220815|Experimental|Biologic drilling drilling at low speed|
9527351|NCT03220815|Active Comparator|conventional drilling drilling at high speed|
9527352|NCT03220984|Experimental|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
9527353|NCT03220633|Experimental|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
9527354|NCT03220633|Placebo Comparator|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
9527355|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
9527356|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
9527357|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
10173565|NCT03861858|Experimental|DBT-A|The standard treatment to be delivered to all participants is DBT-A, which is a treatment model adapted from DBT. DBT-A is an adaptation for adolescents with emotion dysregulation and BPD features (Miller, Rathus, & Linehan, 2007; Rathus & Miller, 2015). DBT-A involves weekly individual therapy with the adolescent, weekly multifamily skills group in which adolescents and family members participate, as needed phone coaching, and weekly consultation team for the therapists.
9527358|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
9527359|NCT03220828|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
9527360|NCT03220828|Experimental|Intervention Group VR|Interventional arm will use technology based distractions (Virtual Reality)
9527361|NCT03220841|Active Comparator|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
9527362|NCT03220841|Experimental|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
9527363|NCT03220659|Placebo Comparator|Standard settings|Usual pacing programming
9527364|NCT03220659|Experimental|Multi-point pacing|MPP programming
9527365|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
9527366|NCT03220880||Intranasal dexmedetomidine|Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
9527367|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
9527368|NCT03220802|Experimental|Test group|participants receive a daily dose of OMNI-BiOTiC PPI for three months
9527369|NCT03220867|Experimental|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
9527370|NCT03220867|Experimental|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
9527371|NCT03220724|Experimental|Part A: Group 1|Participants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
9527372|NCT03220724|Experimental|Part A: Group 2|Participants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
9527373|NCT03220724|Experimental|Part A: Group 3|Participants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
10173566|NCT03861767|Experimental|SPRY: Metformin LD-SC|"LD-SC (low-dose, short course)~Participants take Metformin ER 500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
10187950|NCT03720964||presbycusis affected patients|affected by a more severe age related hearing loss than expected according to the norm ISO 7029
9527374|NCT03220724|Placebo Comparator|Part A: Group 4|Participants will receive placebo at Months 0, 2, 4, 8, and 12.
9527375|NCT03220724|Experimental|Part B: Group 5|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4, 8, 12, and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
9527376|NCT03220724|Experimental|Part B: Group 6|Participants will receive CH505TF at Month 0; CH505TF and CH505w53 at Month 2; CH505TF, CH505w53, and CH505w78 at Month 4; CH505w53 and CH505w78 at Month 8; CH505w78 at Months 12 and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
9527377|NCT03220724|Experimental|Part B: Group 7|Participants will receive CH505 M5 (admixed with GLA-SE) at Months 0, 2, 4, 8, 12, and 16.
9527378|NCT03220724|Placebo Comparator|Part B: Group 8|Participants will receive placebo at Months 0, 2, 4, 8, 12, and 16.
9527379|NCT03220672|Experimental|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
9527380|NCT03220620||GDT Group|receives goal-directed therapy
9527381|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
9527382|NCT03220971||proposed cross-section study|"100 subjects with NAFLD/NASH and negative anti-HCV Ab~50 subjects with HCC and negative anti-HCV Ab~50 subjects with HCC and positive for genotype-1 HCV~50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV~50 controls with all negative for NAFL, NASH and HCV"
9527383|NCT03220971||proposed longitudinal study|"50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR~10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR~10 HCC patients and positive for genotype-1 HCV with SVR~10 HCC patients and positive for genotype-1 HCV without SVR~50 chronic hepatitis C but not NAFLD patients with SVR~10 chronic hepatitis C but not NAFLD patients without SVR"
9527384|NCT03220789|Experimental|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
10173567|NCT03861767|Experimental|SPRY: Metformin LD-IC|"LD-IC (low-dose, intermediate course)~Participants take Metformin ER 500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
10173568|NCT03861767|Experimental|SPRY: Metformin LD-LC|"LD-LC (low-dose, long course)~Participants take Metformin ER 500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
10173569|NCT03861767|Experimental|SPRY: Metformin ID-SC|"ID-SC (intermediate-dose, short course)~Participants take Metformin ER 1000 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
10173570|NCT03861767|Experimental|SPRY: Metformin ID-IC|"ID-IC (intermediate-dose, intermediate course)~Participants take Metformin ER 1000 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
10173571|NCT03861767|Experimental|SPRY: Metformin ID-LC|"ID-LC (intermediate-dose, long course)~Participants take Metformin ER 1000 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
10173572|NCT03861767|Experimental|SPRY: Metformin HD-SC|"HD-SC (high-dose, short course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
9527385|NCT03220789|Active Comparator|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
9527386|NCT03220555|Experimental|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
9527387|NCT03220555|Active Comparator|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
9527388|NCT03220334|Experimental|Apply platelet rich plasma to the artificial gastric ulcer|
9527389|NCT03220334|Placebo Comparator|Apply normal saline to the artificial gastric ulcer|
9527390|NCT03220347|Experimental|CC-90010 in patients with solid tumors and NHL|Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.
9527391|NCT03220529|Active Comparator|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
9527392|NCT03220529|Active Comparator|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
9527393|NCT03220529|Active Comparator|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
9527394|NCT03220529|Active Comparator|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
9527395|NCT03220529|Active Comparator|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
9527396|NCT03220256|Experimental|Lamotrigine tolerance|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks.
9527397|NCT03220399|Experimental|NVP-1603-1 (P)|"Drug: NVP-1603-1~1capsule, oral dosing"
9527398|NCT03220399|Experimental|NVP-1603-2(T)|"Drug: NVP-1603-2~1Tablet, oral dosing"
9527399|NCT03220399|Experimental|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
9527400|NCT03220360|Experimental|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
10173573|NCT03861767|Experimental|SPRY: Metformin HD-IC|"HD-IC (high-dose, intermediate course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
10173574|NCT03861767|Experimental|SPRY: Metformin HD-LC|"HD-LC (high-dose, long course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
9527401|NCT03220360|Experimental|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
9527402|NCT03220360|Experimental|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
9527403|NCT03220386|Other|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
9527404|NCT03220243|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
9527405|NCT03220321|Active Comparator|IPS e.max hybrid abutment crown|
9527406|NCT03220321|Experimental|VITA Enamic hybrid abutment crown|
9527407|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
9527408|NCT03220295|Placebo Comparator|Placebo - Dose 1|Dose Escalation of Placebo
9527409|NCT03220295|Experimental|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
9527410|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
9527411|NCT03220295|Experimental|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
9527412|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
10173575|NCT03861767|Placebo Comparator|SPRY: Placebo|Participants are randomized to receive dose matched placebo to take daily for either short-, intermediate-, or long-course.
10173576|NCT03861598|Experimental|Cohort 1|Carvedilol orally with standard chemotherapy starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
9527413|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
9527414|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
9527415|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
9527416|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
9527417|NCT03220295|Placebo Comparator|Placebo - Dose 2|Dose Escalation of Placebo
9527418|NCT03220295|Placebo Comparator|Placebo - Dose 3|Dose Escalation of Placebo
9527419|NCT03220295|Placebo Comparator|Placebo - Dose 4|Dose Escalation of Placebo
9527420|NCT03220295|Placebo Comparator|Placebo - Dose 5|Dose Escalation of Placebo
9527421|NCT03220269||Out-of-hospital cardiac arrest (OHCA)|An OHCA is defined as cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
9527422|NCT03220269||In-hospital cardiac arrest (IHCA)|An IHCA is defined as cessation of cardiac mechanical activity that occurs inside of the hospital setting and is confirmed by the absence of signs of circulation.
9527423|NCT03220308|Other|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
9527424|NCT03220308|Experimental|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
9527425|NCT03220438|Active Comparator|TMS|rTMS
9527426|NCT03220438|Sham Comparator|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
9527427|NCT03220425|Experimental|Insulin detemir|
9527428|NCT03220425|Active Comparator|NPH insulin|
9527429|NCT03220542|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
9527430|NCT03220542|Experimental|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
9527431|NCT03220542|Active Comparator|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
9527432|NCT03220451|Experimental|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
9527433|NCT03220516|Experimental|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
9527434|NCT03220516|Experimental|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
9527435|NCT03220516|Experimental|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
9528100|NCT03214276|Placebo Comparator|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
10173577|NCT03861611|Experimental|Ketorolac + Educational Intervention|Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
10173578|NCT03861611|Experimental|Ibuprofen + Educational Intervention|Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
10173579|NCT03861611|Experimental|Diclofenac + Educational Intervention|Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
10173580|NCT03861572|Experimental|Isokinetic eccentric group|The isokinetic eccentric training will be carried out with the volunteers positioned seated on the dynamometer with the apparent axis of the ankle joint rotation aligned with the dynamometer's axis of rotation. Movement will be executed in the angular velocity of 30°·s-1. Ankle range of motion (ROM) will be standardized for all participants in 50º, which shall respect each individual's maximal dorsiflexion amplitude. The 50° eccentric training ROM will start from each subject's 80% of the maximal dorsiflexion. This procedure will be used to ensure that all subjects perform training on the same plantar flexor muscular length, which should promote the same level of muscular requirement among the participants. This methodology was recently used by GEREMIA and VAZ (2016) study.
10173581|NCT03861572|Active Comparator|Traditional eccentric training|Participants will be engaged in an intervention program consisting of 12 weeks of traditional eccentric training. The training will be carried out with the volunteers at gym in stand position. Concentric phase will be realized with both legs and the eccentric one only with one of them. Training progression will be the same from de isokinetic eccentric group. The same periodization from eccentric group will be used to permit us a posteriori comparison between groups. Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions. Each training session will comprise the same specific warming protocol for the ankle joint from the eccentric training.
10173582|NCT03861741|Experimental|Participants|All participants will be screened through complete clinical evaluations, genetic tests and imaging modalities (TTE and MRI) for the presence of newly Non Syndromic-Thoracic Aortic Diseases. Demographic and clinical data from all participants will be collected using case report forms, and by accessing their medical records. Data on imaging investigations will be obtained from TTE and MRI. Blood samples will be used for the purpose of isolation of genetic material and subsequent whole exome sequencing along with the analysis of selected loci. Additional citrated blood samples and plasma will be collected and stored for the potential analysis of circulating microvesicles and miRNA.
9527436|NCT03220490|Experimental|Short term: interval no-interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day."
9527437|NCT03220490|Experimental|Short term: No-interval interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner."
9527438|NCT03220490|Experimental|Long term: interval no-interval eye|"In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
9527439|NCT03220490|Experimental|Long term: No-interval interval eye|"In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
9527440|NCT03220503|Experimental|Group (A)|consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.
9527441|NCT03220503|No Intervention|Group (B)|consists of 25 patients will receive frozen embryo without endometrial scratching as control group.
10173583|NCT03861715||Single Dose antagonist Degarelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.
10173584|NCT03861715||Multidose antagonist Ganirelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.
9527442|NCT03220152|Experimental|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
9527443|NCT03220464|Experimental|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
10173585|NCT03861832|Experimental|Nutraceutical, KB220Z|A nutraceutical pill containing pro-dopamine precursors
10173586|NCT03861832|Placebo Comparator|Placebo|A placebo that looks the same and is in a similar bottle
9527444|NCT03220282|Active Comparator|Donor milk|Pasteurized donor breast milk
9527445|NCT03220282|Placebo Comparator|Preterm infant formula|Preterm formula determined by clinical practice
9527446|NCT03220165|Experimental|Treatment|MGL-3196
9527447|NCT03220126|Experimental|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
9527448|NCT03220126|Experimental|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
9527449|NCT03220126|Experimental|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
9527450|NCT03220126|Experimental|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
9527451|NCT03220100|Experimental|Stepped Palliative Care|All participants will receive palliative care Participants will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) every six weeks FACT-L scores will be used to determine which patients need to step up to every 6 week palliative care visits Patients on step 1 of the intervention will have a palliative care visit every 9 weeks Patients on step 2 of the intervention will have a palliative care visit every 6 weeks
9527452|NCT03220191|Experimental|palbociclib tablet with/without PPI|palbociclib tablet formulation alone in period 1 + palbociclib tablet formulation plus rabeprazole in period 2
9527453|NCT03220113|Experimental|Dexamethasone,Lidocaine,Thiamine cohort|"Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.~De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles."
9527454|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
9527455|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
9527456|NCT03219879|Experimental|Telephone-administered continuation therapy|Cognitive-behavioral continuation therapy (T-CT) delivered over the telephone by trained psychotherapist
9527457|NCT03219879|Active Comparator|Usual care|Treatment as usual
9527458|NCT03219788|Placebo Comparator|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
9527459|NCT03219788|Active Comparator|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
9527460|NCT03219788|Active Comparator|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
9527461|NCT03219957|Experimental|AT-527|
9527462|NCT03219957|Placebo Comparator|Placebo|
9527463|NCT03219853|Experimental|Lower selenium-status|
9527464|NCT03219853|Experimental|higher selenium|
9527465|NCT03219762|Experimental|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
9527466|NCT03219931|Active Comparator|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
9527467|NCT03219931|Active Comparator|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
9527468|NCT03219931|Placebo Comparator|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
9527469|NCT03219931|Placebo Comparator|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
9527470|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
9527471|NCT03219801|Experimental|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
9527472|NCT03220009|Active Comparator|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients undergo active surveillance for 1 year."
9527473|NCT03220009|Experimental|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
9527474|NCT03219983|Active Comparator|Interscalene Block|Ultrasound guided interscalene catheter will be placed and a 30 ml .5% ropivacaine will be given pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
9528101|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
9528102|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
10173587|NCT03861520||16-24 weeks Pregnant womes|Pregnant Women at (16-24) weeks of gestation for mid trimester anomaly scan with one sonographic fetal soft marker or more.
10173588|NCT03861650|Experimental|Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
9527475|NCT03219983|Active Comparator|Deep soft tissue/surgical site injection|A total volume of 100ml will be comprised of 60ml of 0.9% normal saline + 20ml 0.5% bupivacaine + 20ml liposomal bupivacaine will be injected into the deep soft tissue using an 18 or 20 gauge needle prior to or after prosthesis insertion
9527476|NCT03219918|Active Comparator|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
9527477|NCT03219918|No Intervention|NO EndoRings|Colonoscopy is performed conventionally without any caps
9527478|NCT03220061|Experimental|experimental|music therapy was used in the study for 30 minutes
9527479|NCT03220061|No Intervention|control|usual care was given to participant in control group
9527480|NCT03219996||non-survivor group|
9527481|NCT03219996||survivor group|
9527482|NCT03219944|Experimental|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
9527483|NCT03219944|Active Comparator|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
9527484|NCT03219905|Experimental|Kinesio-taping Group|Therapeutic Kinesio-taping
9527485|NCT03219905|Sham Comparator|Control Group|Sham Kinesio-taping
9527486|NCT03219749|Experimental|Exercise Intervention|Exercise training will take place three times per week for six weeks and involve both aerobic and resistance exercise.
10173589|NCT03861650|Sham Comparator|Saline|Sham or placebo drug in the control group
9527487|NCT03219736|Active Comparator|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
9527488|NCT03219736|Active Comparator|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
9527489|NCT03220074|Other|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
9527490|NCT03219814|Experimental|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
9527491|NCT03219814|Active Comparator|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
9527492|NCT03219814|No Intervention|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
9527493|NCT03219814|No Intervention|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
10173590|NCT03861481|Experimental|Rozanolixizumab|Subjects will be randomized to receive predefined subcutaneous doses of rozanolixizumab at a specified frequency
9528103|NCT03213808||anaphylaxis|anaphylaxis
9528104|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
9528105|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
10173591|NCT03861481|Placebo Comparator|Placebo|Subjects will be randomized to receive predefined subcutaneous doses of placebo at a specified frequency
9527494|NCT03219710|Active Comparator|Arm A|"Patient on control group (ODA) with weight category of 15-40 kg will receive:~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;~The patient on control group with weight category of > 40 kg will receive:~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
9527495|NCT03219710|Experimental|Arm B|"weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)~Weight category of > 40 kg in study group will receive:~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant & Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
9527496|NCT03219554|Experimental|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
9527497|NCT03219541|Active Comparator|Interventional Automated mobile phone text|"Subjects will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention. During the intervention, participants will receive a text question at the end of every day asking you How many cigarettes have you smoked today?"
9527498|NCT03219541|Placebo Comparator|Control Texts|The intervention will consist of a 3-day pre-quit period and then a 4-week post-quit period. Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
9527499|NCT03219515|Experimental|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
9527500|NCT03219515|Placebo Comparator|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
9527501|NCT03219593|Experimental|Apatinib Group|take apatinib orally (500mg/d, once a day, continuously)
10173592|NCT03861637|Active Comparator|drug : ESA for p correction of PTA|ESA (Aranesp or mir-CERA) injection 1 mg per kg sc every week for 1 year to correct PTA to level between 12-13g/dl.
10173593|NCT03861637|Active Comparator|ara or cera|ESA (Aranesp) 1mg/ kg (or equivalent doses) of MIR-CERA injection for 1 year to correct PTA to level between 13-15g/dl.
9527502|NCT03219580|Active Comparator|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
9527503|NCT03219580|Placebo Comparator|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
9527504|NCT03219398|Active Comparator|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
9527505|NCT03219398|Active Comparator|12-14 mmHg|Patients receive higher pneumoperitoneum pressure
9527506|NCT03219463|Experimental|Regular Exercise Group|at least 30 minutes of moderate to vigorous activity at least 3 times per week. Will recieve 3 grams of ginger for 8 weeks.
9527507|NCT03219463|Active Comparator|Non Regular Exercise Group|at least 30 minutes of moderate to vigorous activity 1-2 times per week. Will recieve 3 grams of ginger for 8 weeks.
9527508|NCT03219606|Experimental|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
9527509|NCT03219697|Experimental|Parenting education program|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits
9527510|NCT03219697|No Intervention|Control|Receive regular health care
10173594|NCT03861819|Experimental|VIIT Intervention|This is a single-arm trial. The intervention itself proceeds as follows: After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total.
10173595|NCT03861507|Other|Patient|Patient undergoing standard care prostate high dose rate brachytherapy.
10173596|NCT03861468|No Intervention|Usual care|Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
10173597|NCT03861468|Active Comparator|Early care|A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
10173598|NCT03861585|Experimental|semantic group|"Half of the participants (named the semantic group) perform a semantic categorisation task."
10173599|NCT03861585|Experimental|emotional group|"Half of the participants (named the emotional group) perform an emotional evaluation task."
9527511|NCT03219619|Experimental|Cap group: Cap-EGD|Undergoing cap-assisted esophagogastroduodenoscopy
9527512|NCT03219619|Active Comparator|Duo group: Duo|Undergoing side-viewing duodenoscope
9527513|NCT03219476|Experimental|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
10187951|NCT03720964||controls|not affected by age related hearing loss according to the norm ISO 7029
10173600|NCT03861494|Other|Enhanced Stroke Education|This group of participants will receive enhanced education provided by the Stroke Coordinator at the time of discharge. The enhanced education session will last 30 minutes with the participant.
9527514|NCT03219359|Experimental|Experimental|Hematopoietic Stem Cell Transplant followed by maintenance Vedolizumab
9527515|NCT03219671|Experimental|nivolumab plus ipilimumab|nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
9528106|NCT03213821|Experimental|high protein intake|Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight)
9528107|NCT03213821|Active Comparator|GFR based protein intake|Study participants will receive GFR based protein diet to preserve renal function.
10173601|NCT03861494|Other|Usual Stroke Education|This group of participants will receive the usual stroke education provided by the usual Neuroscience Registered Nurse throughout the hospitalization and at the time of discharge.
10173602|NCT03861624|Experimental|Intramedullary nailing|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures via Intramedullary nailing with standard SIGN nail.
10173603|NCT03861624|Active Comparator|External Fixation|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures External Fixation with uniplanar Dispofix external fixator.
9528108|NCT03213847|Other|Participants with carpal tunnel syndrome|Participants diagnosed with carpal tunnel syndrome; will be evaluated with Doppler ultrasound and superb microvascular imaging (SMI) ultrasound. The results of these two evaluations will be compared between each other in according to severity of carpal tunnel syndrome (severity will be determined by electromyography studies)
9528109|NCT03213834|Active Comparator|Thoracoscopy Arm|Consisting of chest thoracoscopy
9528110|NCT03213834|Active Comparator|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
9528111|NCT03213886|Experimental|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
9528112|NCT03213886|Active Comparator|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
9528113|NCT03213860|Active Comparator|eye mask|
9528114|NCT03213860|No Intervention|Control|
9528115|NCT03213769|Active Comparator|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
10173604|NCT03861546|Experimental|Healthy lifestyle Shared Medical Appointment (SMA) program|South Asian (SA) adults with prediabetes and Type 2 Diabetes (T2D) that are 'information rich' and have variation in background characteristics will be identified. Dyads (spouses, parent/adolescent or young adult child, peers) will participate in a 16-week culturally-tailored, community-informed pre-post SMA intervention to improve health behaviors.
10173605|NCT03861806|Experimental|PAS true|Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
10173606|NCT03861806|Sham Comparator|PAS sham|Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
10173607|NCT03861663|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
9528116|NCT03213769|Placebo Comparator|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
9528117|NCT03213756|Experimental|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
9528118|NCT03213756|No Intervention|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
9528119|NCT03213730|Experimental|Experimental group|Standard care + 3D-MOT protocol.
9528120|NCT03213730|Active Comparator|Active control group|Standard care + visual attention task (2048 online game)
9528121|NCT03213730|No Intervention|Control group|Standard care alone
9528122|NCT03213743|Other|before dexmedetomidine|We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
9528123|NCT03213444|Active Comparator|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
9528124|NCT03213444|Active Comparator|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
9528125|NCT03213600|Active Comparator|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
9528126|NCT03213600|Sham Comparator|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
9528127|NCT03213522|Active Comparator|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
9528128|NCT03213522|Active Comparator|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
9528129|NCT03213639|Experimental|study group|Patients will take esomeprazole single dose of 40 mg orally once a day
9528130|NCT03213639|Placebo Comparator|control group|Patients will take an inert tablet similar in appearance, color and consistency
9528131|NCT03213613|Experimental|Adaptive Attention Training|The training group will engage in 15 hours of at-home training on a novel iPad-based adaptive attention training program ('Engage'). Individuals will complete thirty 30-minute sessions over six weeks. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely and analyzed over secure online servers to ensure that participants are completing training as scheduled and to deal with any unexpected road-blocks in training.
9826764|NCT02431793|No Intervention|Usual Care|Employ the standard of care, no intervention
9827764|NCT02467179|Active Comparator|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
9672743|NCT05031364|Experimental|Consultation-Based Training on BIACA|Community mental health clinicians will be given online one-on-one training and consultation in the BIACA (Behavioral Interventions for Anxiety in Children with Autism; e.g., Wood et al., 2020) CBT program. Clinicians will be provided with weekly 30-minute video-conference-based consultation sessions with an expert in BIACA. These consultation sessions are manual-driven and utilize a Practice-Based Coaching format, in which a trained consultant meets weekly with clinicians to provide practice-based feedback (cf. McLeod et al., 2018). Consultation meetings include agenda setting, case material review, planning for the next treatment session, and a meeting summary. Relevant online training materials (e.g., demonstration videos of CBT sessions; corresponding written session materials) developed in the context of a NIMH R34 grant available on meya.ucla.edu (1R34MH110591) will also be provided to clinicians for each upcoming therapy session.
9672744|NCT05031364|Active Comparator|Usual Care Augmented by Self-Instruction Resources for CBT for Autism|Community mental health clinicians in this arm will provide any therapy, counseling, and/or behavioral treatment procedures they deem appropriate for each participating child. Clinicians randomized to this arm will be given immediate access to CBT-for-autism self-instruction materials that are already freely available to any clinician at meya.ucla.edu (see Consultation-Based Training on BIACA arm, above), to supplement their usual clinical care, if they so choose, until they complete their Usual Care/Self-Instruction participation and are offered direct training and weekly consultation in BIACA.
9672745|NCT05031273|Experimental|Residents moving into a congregate-living development with more features that support healthy living|Residents moving into a congregate-living development designed for older adults with more design and amenities features in the building, site, and/or neighbourhood that support physical activity, healthy eating, and social connections.
9672746|NCT05031273|No Intervention|Residents living in a standard congregate-living development|Residents living in a standard community-based congregate-living development designed for older adults.
9672747|NCT05031377|Experimental|Experimental Arm: Integrated Intervention|Receive an integrated exercise and cardiovascular health education programme (HE programme)
9672748|NCT05031377|Sham Comparator|Control|Receive usual care
9672749|NCT05031481|Experimental|VENUS 20 + 0,064|Venus association vaginal cream, single dose.
9672750|NCT05031481|Experimental|VENUS 20 + 1|Venus association vaginal cream, single dose.
9672751|NCT05031481|Experimental|VENUS 20 + 4|Venus association vaginal cream, single dose.
9672752|NCT05031481|Active Comparator|Butoconazole nitrate 100 mg|Butoconazole nitrate vaginal cream, single-dose containing 100 mg.
9672753|NCT05031299|Active Comparator|Control group (Standard care)|Participants in the control group will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors for 3 months.
9672754|NCT05031299|Experimental|Intervention group 1 (Application)|Participants will will be additionally provided with a health-promotion application for self-management for 3 months.
9672755|NCT05031299|Experimental|Intervention group 2 (Devices)|"Participants will be additionally provided with wearables and devices for 3 months including:~A weighing scale (assessing also body composition) device~A smartwatch/wristband to assess physical activity but also sleep pattern."
9672756|NCT05031611|Experimental|Intuitive Eating Treatment|"The intervention was a novel 10-week program aimed at promoting IE through pre-recorded videos, reading material, and bi-weekly discussion sessions. The intervention introduced the following modules sequentially: Unconditional Permission to Eat, Reliance to Hunger and Fullness Cues, Body-Food Choice Congruence, Gentle Nutrition, and Joyful Movement.~Every other week, a new module was introduced. Participants were taught the concept of this module through video and reading, then prompted to practice it over the week. On opposite weeks, the module last introduced was discussed in greater detail through video, and participants were given the opportunity to discuss amongst one another and have all questions answered by the researchers."
9672757|NCT05031611|No Intervention|Waitlist Control|Waitlist control group participants completed a series of questionnaires at the beginning and end of a 10-week interval, to compare changes in those who completed the intervention versus those who did not. This group was subsequently invited to participate in the intervention after their time on the wait-list.
9672758|NCT05031403|Experimental|Stroke (Telerehabilitation)|Exercise therapy with telerehabilitation system
9672759|NCT05031403|Other|Stroke (Home Exercise)|Exercise therapy with brochure
9672760|NCT05031403|Experimental|Multiple Sclerosis (Telerehabilitation)|Exercise therapy with telerehabilitation system
9672761|NCT05031403|Other|Multiple Sclerosis (Home Exercise)|Exercise therapy with brochure
9672762|NCT05031403|Experimental|Parkinson Disease (Telerehabilitation)|Exercise therapy with telerehabilitation system
9672763|NCT05031403|Other|Parkinson Disease (Home Exercise)|Exercise therapy with brochure
9672764|NCT05031312|Active Comparator|inferior oblique anterior nasal transposition|Group A for inferior oblique anterior nasal transposition 2mmx2mm posterior and nasal to inferior rectus insertion to control vertical deviation especially large angle vertical deviation and V pattern with more potent postoperative effect in unilateral and bilateral cases
9672765|NCT05031312|Active Comparator|inferior oblique myectomy|Group B for inferior oblique myectomy to control vertical deviation but not of large angle which lead to residual inferior oblique overaction
9672766|NCT05031390|Experimental|Physiotherapist-led training|Physiotherapy-led training of patients with FAIS
9672767|NCT05031663|Experimental|Almonds|The almond group will receive 15% of their daily energy intake in the form of almonds
9672768|NCT05031663|Placebo Comparator|Pretzel|The placebo group will receive an isocaloric carbohydrate based pretzel snack
9672769|NCT05031559|Experimental|Episodic Future Thinking|
9672770|NCT05031559|Experimental|Compassion|
9527516|NCT03219411|Active Comparator|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
9527517|NCT03219411|Placebo Comparator|Placebo|Placebo administered orally as capsules three times daily over 12 weeks
9672771|NCT05031559|Sham Comparator|Control|
9672772|NCT05031572|Other|conventional caloric restriction diet|(DCR protocol): lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet
10187952|NCT03720951|Experimental|Group I(Pudendal n.)|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
9672773|NCT05031572|Other|Intermitent fasting|Fasting for two days (non-consecutive) out of seven, with the fasting days separated by at least one day.
9672774|NCT05031533|Experimental|Assigned Interventions|"Radiation therapy: Dose-painting radiation~Systemic treatment: Choose a systemic treatment plan according to the patient's genetic testing status~(1) Chemotherapy~Squamous cell carcinoma: Paclitaxel 135mg/m2 D1 + Cisplatin 25mg/m2 D1-3, every 21 days, a total of 2-4 cycles.~Non-squamous cell carcinoma (adenocarcinoma, large cell carcinoma): Pemetrexed 500mg/m2 d1 + Cisplatin 75 mg/m2 d1-3, a total of 2-4 cycles.~(2) Targeted therapy: According to the patient's genetic testing status, molecular targeted therapy such as EGFR-TKI and ALK inhibitors can be selected; (3) Immunotherapy: According to the patient's genetic testing status, immunotherapy such as PD1/PD-L1 inhibitors can be selected;"
9672775|NCT05031260|No Intervention|Control group|The individuals in the control group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum.
9672776|NCT05031260|Experimental|Experimental group|The individuals in this group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum. Instead, they will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
9672777|NCT05031247|Experimental|Community Navigator Social Support|More intensive case management and weekly check-ins with older adults. The Community Navigator will be focused on increasing social contact and connection for older adult refugees and immigrants. Those who receive the intervention will be offered up to ten (30-minute-long) meetings with a Community Navigator and access to up to three group sessions over a 3-month period, alongside the standard services they receive for enrollment with the organization.
9672778|NCT05031247|No Intervention|Program Support as Usual|Standard program support will be provided to participants enrolled. These services are offered to all enrolled in the program and may include, but is not limited to the following: financial assistance services, case management, healthcare access services, employment and tax services, education services, citizenship and immigration services, community services and civic engagement, and refugee services.
9672779|NCT05031455|Experimental|Dupilumab|Time 0 - 600mg subcutaneous Week 1 - 300mg subcutaneous Week 3 - 300mg subcutaneous Week 5 - 300mg subcutaneous
9672780|NCT05031455|Placebo Comparator|Placebo|Time 0 - 600mg subcutaneous Week 1 - 300mg subcutaneous Week 3 - 300mg subcutaneous Week 5 - 300mg subcutaneous
9672781|NCT05031650|Active Comparator|openCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with a T-piece resuscitator with 8 cm H2O pressure and 0.30 fiO2. The heart rate (HR) and preductal saturation (SpO2) will be evaluated every 30 seconds. Individually, the following steps will be done according to the situation:~If the HR > 120 / min and SpO2 not measured yet or be in the target range: The pressure will be continue as 8 cmH2O.~If the HR between 100-120 but SpO2 below the target range or not measured yet : First the pressure will be increased to 10 cm H2O; than fiO2 will be increased gradually if the patient will not respond to 10 cmH2O pressure. Pressure will be reduced to 8 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
9672782|NCT05031650|Active Comparator|standardCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with T-piece resuscitator at 6 cmH2O pressure and 0.30 fiO2. HR and preductal saturation will be evaluated every 30 seconds. The following steps will be performed according to the situation:~If the HR > 120 / min and SpO2 be in the target range or not measurable yet: The pressure will be continue as 6 cmH2O.~If the HR between 100-120 but SpO2 below the target range or not measured yet : The pressure will increased up to 8 cm H2O. FiO2 will be increased gradually if the patient will not respond to 8 cmH2O pressure. Pressure will be reduced to 6 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
10173608|NCT03861429|Experimental|Me & My Wishes Intervention/Group 1|In Group 1 (early intervention group) NHs, video recording, editing, and viewing will occur within three months of baseline.
9672783|NCT05031520|Experimental|Intervention group|Participants will be identified by review of the cardiac catheterization laboratory schedule each day by the principal investigator, a co-investigator, or a research coordinator. Participants with no obstructive CAD and completed microvascular testing will undergo a research CCTA.
9672784|NCT05031234|Active Comparator|Group with morphine|conventional general anaesthesia with morphine
9672785|NCT05031234|Experimental|Group without opiates|general anaesthesia without opiates
9672786|NCT05031221|Experimental|Yoga + behavioral weight loss|In person and virtual yoga + 150 minutes of moderate-to-vigorous physical activity/week + weekly instruction on dietary strategies for weight loss
9672787|NCT05031208|Experimental|Vagus nerve stimulation|Invasive vagus nerve stimulation
9672788|NCT05031208|Experimental|Transcutaneous vagus nerve stimulation|Cymba concha stimulation
9975446|NCT03045276|Active Comparator|Arm 2 - Feedback, Maximum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos, and will have web access to the educational modules through their portal. Every month, participants will receive a text encouraging them to visit their portals. In contrast to Arm 1, they will receive their weekly performance results by text to their phone with tailored feedback. In Arm 2, subjects will receive a larger incentive if they perform their desired treatment behavior. Incentive notification will be texted to participants. Similarly to Arm 1, parents/legal guardians will have access to the same educational materials via their own WTH portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
9672789|NCT05031208|Sham Comparator|Sham vagus nerve stimulation|No vagus nerve stimulation
9672790|NCT05031117|Experimental|Conventional Epidural Technique|
9672791|NCT05031117|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
10173609|NCT03861429|Other|Me & My Wishes Wait-list control/Group 2|In Group 2 (delayed sharing) NHs, residents will be on a wait-list; after the delayed start, their video will be produced and viewed within three months.
10173610|NCT03861455|Experimental|dupilumab group|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
10173611|NCT03861455|Placebo Comparator|placebo group|patient receive placebo
10173612|NCT03861754|Experimental|Lifestyle modification|intensified Behavioural Modification (iBM) group receiving lifestyle counselling
9672792|NCT05031143|Active Comparator|SCTA injection (n=6 eyes)|Suprachoroidal Trimacinolone Acetonide injection 4mg/0.1ml, single dose, follow up for 6 months.
9672793|NCT05031143|No Intervention|Non-injected eyes (Standard Treatment) (n=6 eyes)|Non-injected eyes on systemic steroids (standard treatment) and follow up for 6 months
9672794|NCT05031013||Dialysis patients|Dialysis patients
9672795|NCT05030909|Experimental|transdiagnostic group protocol|The study will run two gender-specific treatment groups (8 participants each) recruited from the community, with one individual session (for information, consent and initial data collection) and 5 group sessions. Both groups will receive the same intervention.
9672796|NCT05031052|Experimental|Normothermic machine perfusion (NMP)|End-ischemic NMP will be performed immediately after arrival of the allocated and static cold stored ECD kidney graft. The study protocol aims a duration of 4 hours. Machine perfusion will be performed with a combination of patient's blood group matched packed red blood cells (RBC) and a special manufactured solution with the currently only certified device in Europe (XVIVO - KidneyAssist®). After 4 hours of perfusion and viability assessment, the kidney allograft will be disconnected from the device immediately prior to transplantation and flushed with three litres of Custodiol HTK solution via the renal artery. Then transplantation will be performed in typical method.
9672797|NCT05031052|Active Comparator|Statical cold storage (SCS)|Conventional method kidney transplantation of statical cold stored and transported ECD kidney allograft. The allocated kidney allograft will be flushed with Custodiol HTK solution during back table preparation with the aim of immediate implantation into recipient.
9672798|NCT05030779|Experimental|Treatment of SLE|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
9672799|NCT05031091||Case: patients with confirmed leprosy|diagnosed or followed up in French Guiana between the beginning of 2006 and the end of 2022
9672800|NCT05031091||Control: patient with a dermatological condition not clinically suspicious of leprosy|Any patient, of any age, consulting for a dermatological pathology not clinically suspicious of leprosy during a dermatological consultation by a practitioner of the Cayenne Hospital
9672801|NCT05031156|Active Comparator|non-splinting of OT Bridge system|Leaving the dental implants abutments solitary followed by denture pick up
9672802|NCT05031156|Experimental|splinting of OT Bridge|Splinting of implants abutments using titanium wire then followed by denture pick up
10173613|NCT03861754|Experimental|Lifestyle modification and exercise 1|"Intensified Behavioural Modification and exercise from 0 to 3 months (CWT1) group:~Lifestyle counselling 3 months Exercise intervention from 0 to 3 months"
9672803|NCT05030935|Experimental|Intervention Group|This group will be able to use the mHealth App.
9672804|NCT05030935|No Intervention|Control group|The Instructions Manual consists of a hard copy of the mHealth App bibliographical content. In addition, a calendar that can be used as a reminder for patient position switching is present and a hard copy explanation of the scale which can be used by the caregiver and through handwriting, determine the need for support surfaces.
9672805|NCT05030662|Experimental|Experimental:Walking stick exercise|"The experimental:Walking stick exercise~Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~The video clip of walking stick exercise is available to the patients.~The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
9672806|NCT05030662|No Intervention|Control group: conventional physical therapy.|"Perform bed mobility and transfers with the least amount of assistance while maintaining appropriate weight bearing (WB) precautions.~Ambulate with an assistive device for 25-100 feet and ascend/descend stairs to allow for independence with household activities while maintaining appropriate WB.~Verbalize understanding of post-operative activity recommendations/precautions including use of proper positioning of the lower extremity, range of motion and strengthening exercises."
9672807|NCT05030675|Experimental|Treatment (fostamatinib)|Patients receive fostamatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles (week 24) in the absence of disease progression or unacceptable toxicity.
9672808|NCT05030883|Experimental|unreliable source|In this condition participants receive a news message from an unreliable source
9672809|NCT05030883|Experimental|reliable source|In this condition participants receive a news message from an reliable source
9672810|NCT05030883|Experimental|no source|In this condition participants receive a news message without a source
9672811|NCT05031104|Active Comparator|Control group|Patients in this group undergone a standard exercise program.
9672812|NCT05031104|Experimental|LLT group|Patients in this group undergone a standard exercise program as the control group in addition to the LLT.
9672813|NCT05031039||Female Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians females that have unilateral or bilateral cleft lip and palate deformity
9672814|NCT05031039||Male Egyptian subjects with Cleft Lip and Palate Deformity|Egyptians males that have unilateral or bilateral cleft lip and palate deformity
9672815|NCT05031065||Women undergoing radiation treatment after lumpectomy for breast cancer.|There is no specific study intervention being used. Samples will be collected from participants undergoing standard of care radiotherapy at pre-specified timepoints.
9694968|NCT04783350|Experimental|Transcranial alternating current stimulation (tACS)|Participants (Ps) will undergo 20min of daily home-based tACS intervention at 40Hz over the left angular gyrus for 4 weeks by trained administrators (As) (phase 1). In case of cognitive and mental improvement participants will undergo further 10 weeks of 20 minutes session of tACS daily (phase 2). Additionally, those P/A pairs who completed the 14 weeks of home-based tACS intervention and express an interest in an open label extension may be enrolled in further 34 weeks of 20 minutes tACS sessions.
9975447|NCT03004131|Experimental|fixed drug combination|MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet
9975448|NCT03004131|Placebo Comparator|Placebo|Nasal spray with no active dose plus Placebo tablet
10173614|NCT03861754|Experimental|Lifestyle modification and exercise 2|"Intensified Behavioural Modification and exercise from 6 to 9 months (CWT2) group:~Lifestyle counselling 3 months Exercise intervention from 6 to 9 months"
10173615|NCT03861754|No Intervention|Control Group|Control group, no intervention, only measurements and questionnaires
10173616|NCT03861299|Experimental|Awake craniotomy|Cortical stimulation is performed with a bipolar electrical stimulator. The Boston naming test and repetition of words is done in cooperation with a neuropsychologist/linguist, who will inform the neurosurgeon of any kind of speech arrest or dysarthria. When localizing the motor and sensory cortex, the patient is asked to report any unintended movement or sensation in extremities or face. Functional cortical areas are marked with a number. When the tumour margins or white matter is encountered or when on regular neuronavigation the eloquent white matter tracts are thought to be in close proximity, subcortical stimulation (biphasic currents of 8-16 mA, pulse frequency 60 Hz, single pulse phase duration of 100 microsec., 2-second train) is performed to localize functional tracts.
9672816|NCT05030948|Experimental|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. They will take place at community partner sites during times when all participants can attend. In case of adverse weather, indoor locations are available through community partners. Walks will reflect participant goals and abilities, initially lasting 10 minutes, with 5-minute stretching warm-up and 5-minute cool down exercises, for a total of 20 minutes. Walk duration will increase by 5 minutes/week to at least 30 minutes with program content delivery time decreasing to accommodate increased walk times within the 1-hour session. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
9672817|NCT05030948|No Intervention|Attention Control|"If assigned to this group, participants will take part in 1-hour group (5-6 participants) sessions delivered twice a week for 3 months. The sessions will be with a trained Community Health Worker or qualified staff that will involve reviewing education topics in Spanish related to adult health. They will take place at community partner sites or remotely during times when all participants can attend. In case of adverse weather, indoor locations, or remote options will be available. Upon completing the 3 months of education sessions, for the next 3 months, they will receive educational booster sessions delivered every other week via phone calls/text messaging."
9672818|NCT05030753|Experimental|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
9672819|NCT05030753|Active Comparator|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
9672820|NCT05030987|Experimental|RDN|Renal Denervation
9672821|NCT05030987|Sham Comparator|Sham|Sham Procedure
9672822|NCT05030558|Experimental|Interventional group|The web-supported interactive nursing program intervention will last 4 weeks. In the first week of the training, the identity and causes of the disease, which is one of the sub-dimensions of the perception of illness, will be emphasized, and the themes of misperception determined in this field through qualitative study will be emphasized. In the second week, they will be asked to look at training sessions that discuss perceptions of the illness's timeline and consequences. In the last two weeks of the training, they will be asked to attend the trainings for the control of Fibromyalgia symptoms. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times). Data collection forms will be applied to the intervention group 3 times before starting the web-based interactive nurse program, at the end of the program (in the 1st month) and then at the end of the 2nd month.
9672823|NCT05030558|Active Comparator|Control Group|"The Fibromyalgia patient booklet of the Turkish Physical Medicine and Rehabilitation Association will be available in pdf format on the website of the participants assigned to the control group. Participants in this group will be able to access other trainings after the end of the study, if they wish.~Data collection forms will be applied to the control group 3 times in total, before the start of the study, in the 1st month and the 2nd month of the study."
9672824|NCT05030714|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Visual Field Analyzer and with the custom head-mounted device.
9672825|NCT05031169|Experimental|A-PRF|Surgical treatment A-PRF membrane
9672826|NCT05031169|Active Comparator|SCTG|Surgical treatment with SCTG
9672827|NCT05030701||cancerous patients|
9672828|NCT05030701||non cancerous patients|
9672829|NCT05030727|Other|Evaluation of intraoperative NGAL levels in terms of acute kidney injury in geriatric patients|only one group
9975449|NCT03004131|Active Comparator|active control|fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)
9527518|NCT03219489|Experimental|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
9694973|NCT04783194|Active Comparator|Dexamethasone + bupivacaine in bilateral TiPVB in lumbar spine surgery|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
9694974|NCT04783194|Active Comparator|Bupivacaine in bilateral TiPVB in lumbar spine surgery|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
9694975|NCT04783532|Experimental|Telehealth Mindfulness Program|Telehealth mindfulness sessions
9827765|NCT02467179|Experimental|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
9527519|NCT03219489|No Intervention|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
10173617|NCT03861299|Active Comparator|Craniotomy under general anesthesia|Trephination and tumour resection are performed without any additional neuro-psychological monitoring or brain mapping, guided by STEALTH-neuronavigation.
10173618|NCT03861312|Experimental|Neck Laterality|It was done with 20 images of necks and 4 seconds for each image in the Vanilla program of the tablet application.
9672830|NCT05030623|Experimental|Tadalafil|
9672831|NCT05030623|Placebo Comparator|Placebo|
9672832|NCT05030636|Experimental|EX starts at 9:30 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 9:30 am.
9672833|NCT05030636|Experimental|EX starts at 11:00 am|A warm-up, 30 min at 70% VO2 max and a cool-down performed at 11:00 am.
9672834|NCT05030636|No Intervention|No EX|Control condition. A choice of 30 minutes sedentary activities.
9672835|NCT05030610|Experimental|Intervention Group|Participants, along with a support person, will complete 12 weekly sessions of the BeatIt-ASD intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
9672836|NCT05030649|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
9672837|NCT05030649|Active Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
9672838|NCT05030545|Experimental|Eplerenone Treatment|Eplerenone (50-100mg daily, as tolerated by blood pressure and potassium) for 6 months
9672839|NCT05030220||Phase 1|51 subjects with serum levels of testosterone, free testosterone, and sex hormone binding globulin as well as the SpCuV from the cultures obtained in clinic, immediately pre-operative skin cultures, and incised wound cultures.
10173619|NCT03861312|Experimental|Foot Laterality|It was done with 20 images of feet and 4 seconds for each image in the Vanilla program of the tablet application.
10173620|NCT03861403|Experimental|All Solid Tumors|"Phase 1b, Part 1 Dose Escalation: TRX518 + CTX Combination (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Assigned dose of cyclophosphamide administered intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle~Phase 1b, Part 2 Dose Escalation: TRX518 + CTX + avelumab in (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide administered at the MTD from Part 1 intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle"
9672840|NCT05030220||Phase 2|Subjects enrolled to help determine if preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty and if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.
9672841|NCT05030168|No Intervention|Placebo|Twice weekly hemodialysis program plus regular protein diet (1.0 g/kg/day) every day
9672842|NCT05030168|Experimental|Ketosteril|Incremental hemodialysis program, starting from once weekly hemodialysis/hemodialysis filtration(HDF) plus low protein diet (0.6 g/kg/day) and ketoanologues 0.12g/kg/day supplementation on non-dialysis days and regular protein diet (1.0-1.2 g/kg/day) on dialysis day
9672843|NCT05030285|Experimental|Intervention|People who are randomised into the intervention arm will undergo 6 weekly psychotherapy sessions
9672844|NCT05030285|No Intervention|Control|People who are randomised into the control arm will undergo usual care
9672845|NCT05030415|Experimental|Ixekizumab|ixekizumab 80 mg injection, 160 mgs injected subcutaneously on week 0, 80 mgs injected subcutaneously every two weeks
9672846|NCT05030337|No Intervention|Manual oxygen control|Standard ventilation with inspired oxygen concentration adjusted manually as per unit's protocol.
9672847|NCT05030337|Other|Closed-loop automated oxygen control|Ventilation with Oxygenie software (closed-loop automated oxygen control system), adjusted by clinical staff as necessary
9527520|NCT03219450|Experimental|NeoVax|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134."
9672848|NCT05030181|Active Comparator|kinesiotaping and exercise|'I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
9672849|NCT05030181|Active Comparator|exercise|1-month home exercise program.
9672850|NCT05030532|Experimental|EVERYbody Project: Expert facilitator version|"This gender inclusive, dissonance-based body image program was created from focus group feedback. Based on the Body Project, the program retains key dissonance activities while expanding the inclusivity focus (e.g., expanding the gender focus, exploring diversity within appearance ideals, critically discussing the impact of limited diversity representation in cultural appearance norms).~Around 10% of content from the previous trial was modified to form the current intervention. Changes focused on enhancing diversity-focused content. College students with body image content interest completed two days (16 hours) of training on the program manual, group management, and conducting inclusive conversations. Post training, students self-assessed their facilitation readiness and were evaluated by two trainers on facilitation expertise. Peer leaders with sufficient expertise were invited to facilitate EVERYbody Project groups."
9672851|NCT05030532|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists, and (2) The Mask You Live In. Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.~Peer facilitators received brief (1 hour) training on the video group manual."
9672852|NCT05030402|Experimental|Maitland group|44 patients receives tens, SW, Maitland, and exercises. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
9672853|NCT05030402|Active Comparator|Control group|44 receives tens, SW, conventional physiotherapy and exercises as treatment. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
10173621|NCT03861403|Experimental|Advanced Triple Negative Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
9672854|NCT05030389|Experimental|Adapted Physical Activity (APA)|Participants receive a web-based adapted physical activity (APA) during 12 weeks, on the basis of three at-home sessions a week
9672855|NCT05030389|Experimental|Adapted Physical Activity + Bright Light Exposure (APA + BLE)|Participants receive a web-based APA program during 12 weeks on the basis of three at-home sessions a week, supplemented by a bright light exposure (BLE) during 12 weeks, on the basis of five at-home sessions a week
9672856|NCT05030389|Experimental|Galvanic Vestibular Stimulation (GVS)|Participants receive Galvanic Vestibular Stimulation (GVS) during two weeks, on the basis of five at-home sessions a week
9672857|NCT05030389|Active Comparator|Health Education program (HE)|Participants receive a web-based health education program (HE) during 14 weeks, on the basis of one at-home session a week
9672858|NCT05030493||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
9672859|NCT05030493||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg mFOLFOX6 + bevacizumab combination therapy, once every two weeks
9672860|NCT05030116|Experimental|Experimental group|
9672861|NCT05030116|Active Comparator|Control Group|
9672862|NCT05030246|Experimental|Surufatinib 250mg/Toripalimab 240mg|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody（Toripalimab） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
9672863|NCT05030155|Experimental|Patients with FFS=0 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336
9672864|NCT05030155|Placebo Comparator|Patients with FFS=0 - Placebo|Placebo of Mepolizumab every 4 weeks until D336
9672865|NCT05030155|Experimental|Patients with FFS≥1 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336 and placebo of Azathioprine 1mg/kg/day from D126 until D360 and placebo of cyclophosphamide/mesna at D1, D15, D28, D56, D84 and D112
9672866|NCT05030155|Placebo Comparator|Patients with FFS≥1 - Placebo|Placebo of Mepolizumab every 4 weeks until D336, cyclophosphamide and mesna at D1, D15, D28, D56, D84 and D112 and Azathioprine 1mg/kg/day from D126 until D360
9672867|NCT05030259||patients with fasciotomy|
9672868|NCT05030259||patients without fasciotomy|
9672869|NCT05030142|Experimental|Mechanical thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
9672870|NCT05030142|Active Comparator|Active Comparator|Best medical treatment alone (usual care)
9672871|NCT05030090|Active Comparator|Control group|"Consulted by the dietitian using communication software (Line) or telephone.~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~The nutrition care plan period will be three months."
9672872|NCT05030090|Experimental|Nutrition care plan group A|"Consulted by the dietitian using communication software (Line) or telephone.~Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~3.The nutrition care plan period will be three months."
9672873|NCT05030090|Experimental|Nutrition care plan group B|"Consulted by the dietitian using communication software (Line) or telephone.~Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement and powdered supplement 1 and nutritional products and powdered supplement 2~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~The nutrition care plan period will be three months."
9672874|NCT05030480||Chronic kidney disease|eGFR values of less than 60 mL/min/1.73 m2
9672875|NCT05030480||Non-Chronic kidney disease|eGFR values more than 60 mL/min/1.73 m2
9672876|NCT05029934|Active Comparator|EndoClot group|patients who are being provided with EndoClot adhesive spray after polyp resection
9672877|NCT05029934|Sham Comparator|Conrol group|no further prophylactic bleeding prevention after polyp resection
9672878|NCT05030012|Experimental|Automated Control (OAM)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.
9672879|NCT05030012|Active Comparator|Manual Control (Manual)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be manually adjusted by clinical staff to keep infants' oxygen saturation between 90-95%.
10187081|NCT03729765|Experimental|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
9672880|NCT05030064|Experimental|Intestinal flora capsule(FMT)|The group includes 27patients.They will receive 16 capsules of intestinal bacteria each time, once a week, 4 times in a row.Each capsule contains 200mg of fecal bacteria.
9672881|NCT05030064|Placebo Comparator|Placebo group|The group includes 27patients.They will receive 16 Placebo capsules each time, once a week, 4 times in a row.
9672882|NCT05029700|Experimental|Combined exercise group|Combined training consists of trunk stabilization training and aerobic training.
9672883|NCT05029700|Active Comparator|Control group|Aerobic training was given to the control group.
9975450|NCT03000101|Experimental|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
9975451|NCT03000101|Placebo Comparator|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
10173622|NCT03861403|Experimental|Advanced Hormone Receptor+/Endocrine Refractory Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
9672886|NCT05029791|Other|Metastatic melanoma|Patients with stage III or IV melanoma eligible for an immunotherapy or targeted therapy
10173623|NCT03861403|Experimental|Advanced Metastatic Castration-Resistant Prostate Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
10173624|NCT03861403|Experimental|Advanced Platinum-Resistant Ovarian Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
9672887|NCT05029752|Other|Vendys II Device|Your participation in this study will be over after your blood vessel health is measured 1 time with the Vendys II device
9672888|NCT05030129|Experimental|Ergoloid mesylates (EM) and 5-hydroxytryptophan (5-HTP)|Ergoloid mesylates (EM) 1 mg three times daily and 5-hydroxytryptophan (5-HTP) 100 mg three times daily for 4 weeks
10173625|NCT03861416|Experimental|Unifuzol® 1.4% 500 ml|Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days
10173626|NCT03861416|Experimental|Unifuzol® 1.4% 250 ml|Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days
9672889|NCT05030129|Placebo Comparator|Placebo|2 placebo capsules three times daily for 4 weeks
9672890|NCT05030129|Experimental|Ergoloid mesylates (EM) and placebo|Ergoloid mesylates (EM) 1 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
9672891|NCT05030129|Experimental|5-hydroxytryptophan (5-HTP) and placebo|5-hydroxytryptophan (5-HTP) 100 mg three times daily and 1 placebo capsule three times daily for 4 weeks.
9672892|NCT05029986|Experimental|All participants|This is a single-arm trial. All participants will receive (1) a control condition (socialization phase, 2 weeks) and (2) an intervention condition (speech breathing intervention, 4 weeks). Group sessions will take place once a week, and participants will be instructed to practice their exercises every day at home during the study duration.
10173627|NCT03861416|Placebo Comparator|Placebo 500 ml|Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.
9672893|NCT05029908||TMD disorders|"75 patients with temporomandibular disorder (TMD) who will apply to the outpatient clinic of Istanbul Physical Therapy and Rehabilitation Training and Research Hospital will be included in our study. Ethics Committee approval was obtained from Bakırköy Sadi Konuk Training and Research Hospital before starting the study and a voluntary consent form will be signed by the patients before the evaluation.~In this cross-sectional study; 75 participants aged 18-65 years who has temporomandibular joint (TMJ) complaints for more than 3 months and has the cognitive ability to understand test instructions will be included. Patients with a history of previous TMJ operation, muscle, neurological or rheumatic disease that may affect TMJ, and a history of facial/cervical trauma or neoplasia will excluded from the study."
9672894|NCT05029804|Experimental|Intervention Group|"After the initial assessment, patients in this group will be educated by the researcher on walking exercise by using the transtheoritical model. The data will be collected from the patients in the experimental group at baseline, 1st, 3rd, and 6th months of the programme.~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains include questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
9672895|NCT05029804|No Intervention|Control|"No intervention will be applied to this group. The data will be collected from the patients in the control group at baseline, 1st, 3rd, and 6th months.~The data will be collected by using Exercise Stages of Change Questionnaire, Exercise Processes of Change Scale, Pedometer, Patient Compliance in Type 2 Diabetes Mellitus Treatment Scale, and patient identification that includes five domain. These domains included questions about the patients' sociodemographic characteristics, habits, knowledge of diabetes and its treatment, exercise status, and the evaluation of the metabolic control variables."
9672896|NCT05029570|Experimental|Conduction System Pacing and AV node ablation|Atrioventricular node ablation and subsequent conduction system pacing
10187082|NCT03729765|No Intervention|standard care|The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.
9672897|NCT05029570|No Intervention|Medical treatment for rate control of AF|Pharmacological rate control based on clinical practice guidelines
9672898|NCT05029544|Active Comparator|intervention group 1|dynamic taping and standard rehabilitation program
10187083|NCT03729752|Active Comparator|Healthy Volunteer|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
10187084|NCT03729752|Experimental|Viremic HIV-infected|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
9975452|NCT02999152|Experimental|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
10187085|NCT03729752|Experimental|Suppressed HIV-infected|A PET-MR scan following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
9975453|NCT02999152|Experimental|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
9975454|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
9975455|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
9975456|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
10173628|NCT03861351|Experimental|Mini WELL Toric Ready intraocular lens|
9672899|NCT05029544|Active Comparator|intervention group 2|Kinesio taping and standard rehabilitation program
9672900|NCT05029544|Other|Control group|No taping on shoulder, only standard rehabilitation program
9672901|NCT05029583|Experimental|routine screening group|consists of 4 clusters randomized into Group 1 (includes different clinic sites from Group 2)
9672902|NCT05029583|Active Comparator|physician-driven screening group|consists of 4 clusters randomized into Group 2 (includes different clinic sites from Group 1)
9672903|NCT05029531|Experimental|intervention/treatment|
9672904|NCT05029453|Experimental|Experimental Group|apatinib combine with chemotherapy. Apatinib: initial dose: 500mg,oral,once a day, after meal ( try to take the medicine at the same time each day) Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
9672905|NCT05029453|No Intervention|Control Gtoup|chemotherapy Recommended chemotherapy: docetaxel(60/75 mg/m2, d1, q3w)、albuminbound paclitaxel(125mg/m2, d1, d8, q3w) or (260mg/m2, d1, q3w)。
9672906|NCT05029492|Active Comparator|Diet group|Giving a low caloric diet
9672907|NCT05029492|Experimental|Visceral manipulation with diet group|Giving visceral manipulation added to a low-calorie diet
9672908|NCT05029635|Active Comparator|treatment arm|Eligible subjects will be treated with planned dose of 300 mg HMPL-523 once daily for 24 weeks
9672909|NCT05029635|Placebo Comparator|placebo arm|Drug: Placebo HMPL-523 matching placebo will be oral administrated once daily for 24 weeks.
9672910|NCT05029778|Experimental|Experimental L-arginine 3 g and L-citruline 2 g|Drug: L-arginine 3g and L-citruline 2g, Food supplement, PO , for 24 h, until birth
9672911|NCT05029778|Experimental|placebo|Placebo 3g ( starch ) PO for 24 h. until birth
9672912|NCT05029765|Placebo Comparator|Healthy diet Arm|Healthy diet (WHO recommendations) + placebo
9672913|NCT05029765|Placebo Comparator|Mediterranean diet Arm|Mediterranean diet + placebo
9672914|NCT05029765|Active Comparator|"Mediterranean diet plus Arm"|Mediterranean diet + Biopolis-MIX42 (1 capsule per day containing 10^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium long).
9672915|NCT05029648||Cohort|Simple cohort
10173629|NCT03861364|Active Comparator|High Propofol|High Propofol induction dose
10173630|NCT03861364|Active Comparator|Low Propofol|Low Propofol induction dose
10187953|NCT03720951|Experimental|Group II(Sacral n.)|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
9672916|NCT05029596|Active Comparator|Heparin Group|"Participants will receive the UTSW standard of of care for PICC line maintenance.~All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws."
9672917|NCT05029596|Experimental|Normal Saline Group|Participants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.
9672918|NCT05029193|Experimental|Stroke survivors - Mindfulness intervention|Participants who have had a stroke who are receiving the mindfulness intervention immediately after enrollment (no wait period).
9672919|NCT05029193|No Intervention|Stroke survivors - Waitlist control|Participants who have had a stroke who are assigned to the waitlist.
9672920|NCT05029193|Experimental|Caregivers - Mindfulness intervention|Participants caring for someone who have had a stroke and receiving the mindfulness intervention immediately after enrollment (no wait period).
9672921|NCT05029193|No Intervention|Caregivers - Waitlist control|Participants caring for someone who have had a stroke assigned to the waitlist.
9672922|NCT05029440|Experimental|Electromagnetic and Exercise Group|Pulsed Electromagnetic Field (PEMF) PEMF was administered to the whole body using a 1.8×0.6m mat Exercise Program Exercise program to facilitate bone health
9672923|NCT05029440|Active Comparator|Laser and Exercise Group|Pulsed High Intensity Laser Therapy (HILT) HILT was administered to lumbar region and femoral head using Exercise Program Exercise program to facilitate bone health
9672924|NCT05029440|Active Comparator|Exercise Group|Exercise Program Exercise program to facilitate bone health
9672925|NCT05029258||Locally advanced cervical cancer patients treated with standard of care chemoradiation|
9672926|NCT05029115||SGLT-2 inhibitor administration group|The group who administrated SGLT-2 inhibitor for hypoglycemic medication
9672927|NCT05029115||control|The group who are not administrated SGLT-2 inhibitor
9672928|NCT05029362|Other|Beta testing group|
9672929|NCT05029076|Experimental|Liraglutide injection + Victoza|Subjects receive liraglutide injection in the first cycle and Victoza in the second cycle.
9672930|NCT05029076|Experimental|Victoza +Liraglutide injection|Subjects receive Victoza in the first cycle and liraglutide injection in the second cycle.
9672931|NCT05029375|Experimental|immediate parental involvement|Parental involvement in training is parallel to children's training
9672932|NCT05029375|Experimental|delayed parental involvement|Parental involvement in training will be given at the end of the children's training
9672933|NCT05029323|Active Comparator|Conventional HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to conventional HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; aprovocation phase of further 10 min after 300 micrograms NTG sublingual spray."
9672934|NCT05029323|Experimental|Fast HUTT|"All patients with unexplained syncope at initial evaluation with indication to perform a Head up tilt test (HUTT) randomized to fast HUTT protocol characterized by a stabilization phase of 5 min in the supine position; a passive phase of 10 min at a tilt angle of 60 degrees; a provocation phase of further 10 min after 300 micrograms NTG sublingual spray."
9672935|NCT05029401|Experimental|Single dose IMP (DMX-1002)|"Stage 1 (open label): treatment at one of 4 ascending dose levels (3, 6, 9 or 12 mg/kg)~Stage 2 (blinded): MTD/TTD established in Stage 1 vs placebo (proof of concept)"
9672936|NCT05029401|Placebo Comparator|Matching Placebo|Placebo using capsules identical to the IMP (DMX-1002)
9672937|NCT05029388|Experimental|Aerobic Exercise|This experimental group will receive aerobic exericse. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The aerobic exercise training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
9672938|NCT05029388|Experimental|High Intensity Interval Training|This experimental group will receive high intensity interval training. This group will be led by a certified personal trainer with at least three years of experience in guiding adolescents in group exercises. The HIIT training will be conducted in the fitness room of a local sports center that is hosted by the Leisure and Cultural Services Department in Hong Kong.
9672939|NCT05029388|No Intervention|Control Group|This group will not take part in aerobic exercise and HIIT training programme. Participants will be given an exercise diary or logbook to keep track of their exercise habits (i.e., record the type of exercise/activity, hours, and intensity of exercise/activity every day) throughout the intervention periods.
9672940|NCT05029232|Active Comparator|ambulant patient with DMD|patient that walk alone or with minor assist
9672941|NCT05029232|Active Comparator|non ambulant patient with DMD|patient need wheel chair
9672942|NCT05029297|Experimental|CAPSAICIN 0.75 mg/g topical solution applicable in roll-on|CAPSAICIN 0.75 mg / g topical solution applicable in roll-on: 4 applications per day for 8 weeks.
9672943|NCT05029297|Active Comparator|CAPSAICIN 0.075% cream|CAPSAICIN 0.075% cream (ARAFARMADOL® 0.075% cream): 4 applications per day for 8 weeks.
9672944|NCT05029167|Active Comparator|Restrictive PaO2 and low normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
9672945|NCT05029167|Active Comparator|Restrictive PaO2 and high normal MAP|Patients receiving PaO2 9-10 kPa (68-75 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
9672946|NCT05029167|Active Comparator|Liberal PaO2 and low normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 63 mmHg during targeted temperature management (36 hours) after OHCA.
9672947|NCT05029167|Active Comparator|Liberal PaO2 and high normal MAP|Patients receiving PaO2 13-14 kPa (98-105 mmHg) and MAP 77 mmHg during targeted temperature management (36 hours) after OHCA.
9672948|NCT05029037|Experimental|Group A|80 patients randomized to group A will receive two doses (High) of vitamin C intravenously, twice a day for seven days.
9672949|NCT05029037|Placebo Comparator|Group B|80 patients assigned to group B will receive two doses of Dextrose 500 mL, twice a day for seven days.
9672950|NCT05028998||Veterans with Opioid Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~Additionally, we will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews."
9672951|NCT05028998||Veterans with Alcohol Use Disorder receiving care through the Veterans Health Administration|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
9672952|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
9672953|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Medicaid Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
9672954|NCT05028998||Patients with Opioid Use Disorder for whom Market Scan Commercial Insurance Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
9672955|NCT05028998||Patients with Alcohol Use Disorder for whom Market Scan Commercial Claims data is available|"Pre-existing medical records data for these individuals will be part of our Aim 1 and Aim 2 large quantitative database.~We will not be recruiting any of these individuals for Aim 3 qualitative interviews."
9672956|NCT05028998||Patients with Opioid Use Disorder receiving care outside of Veterans Health Administration|We will be recruiting 30 of these individuals to participate in our Aim 3 qualitative interviews.
9672957|NCT05028998||Opioid Use Disorder Treatment Providers who provide treatment in the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
9672958|NCT05028998||Opioid Use Disorder Providers who treat outside the Veterans Health Administration|We will be recruiting 15 of these individuals to participate in our Aim 3 qualitative interviews.
9672959|NCT05028998||Opioid Use Disorder Treatment and Policy Decision Makers|We will be recruiting 20 of these individuals to participate in our Aim 3 qualitative interviews.
9672960|NCT05028959|Experimental|Female athletes|highly trained subjects
10173631|NCT03861026|Experimental|Intervention group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
10173632|NCT03861026|No Intervention|Control group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design."
10173633|NCT03861104|Active Comparator|group watched video|"patients will watch the medical video before filling out the spielberger state anxiety inventory at the time of nasal packing removal.~intervention is watching informative video."
9672961|NCT05028959|Experimental|Leisure sport women|recreational sportswomen practicing regular physical activity
9672962|NCT05028894||IPF|Participants diagnosed with idiopathic pulmonary fibrosis
9672963|NCT05029245|Experimental|Sinovac 2 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
9672964|NCT05029245|Active Comparator|Sinovac 2 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of Coronavac vaccine 2 dosage at least 1 month before enrollment will received Intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
9672965|NCT05029245|Experimental|Aztrazeneca 1 dosage followed by Comirnaty® 6 microgram Intradermal|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received Intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
9672966|NCT05029245|Active Comparator|Aztrazeneca 1 dosage followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of ChAdOX1 Cov-19 vaccine 1 dosage at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
9672967|NCT05029245|Experimental|Naive vaccine followed by Comirnaty® 6 microgram Intradermal|Patients who had no history SAR-CoV vaccine before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
9672968|NCT05029245|Active Comparator|Naive vaccine followed by Comirnaty® 30 microgram Intramuscular|Patients who had no history SAR-CoV vaccine before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
9672969|NCT05029245|Experimental|Any history of vaccination with Anti-RBD< 650AU/ml followed by Comirnaty® 6 microgram Intradermal|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intradermal Comirnaty® vaccine 6 microgram 2 dosage by 28 days interval
9672970|NCT05029245|Active Comparator|Any history of vaccination with Anti-RBD <650AU/ml followed by Comirnaty® 30 microgram Intramuscular|Patients who had history of any SAR-CoV vaccine at least 1 month before enrollment will received intramuscular Comirnaty® vaccine 30 microgram 2 dosage by 28 days interval
9672971|NCT05029063|Experimental|Experimental|Rivaroxaban 10mg OD
9672972|NCT05029063|Placebo Comparator|Control|Identical Placebo 10mg OD
9672973|NCT05029310|Experimental|All patients use both patiromer and tacrolimus|Pharmacokinetic investigation of tacrolimus performed in bothe the presence and absence of patiromer for all patients.
9672974|NCT05028907|Experimental|group one (cases with inflamatory punctal stenosis treated with steroids and antibiotics)|patients with inflammatory punctal stenosis were treated by steroids and antibiotics and evaluated by anterior segment optical coherence tomography before and after treatment
9672975|NCT05028907|Placebo Comparator|control group|patients with inflammatory punctal stenosis received only preservative free tear substitutes
9672976|NCT05028985||early COPD patients|younger than 50 years with 10 or more pack-years smoking history and any of these abnormalities: 1) early airflow limitation (post-bronchodilator forced expiratory volume in the first second(FEV1)/forced vital capacity(FVC) < lower limit of normal), 2) compatible CT abnormalities, 3) rapid decline in FEV1 (≥60 ml/yr).
9672977|NCT05028985||Healthy people|healthy without any disabling, physical, neurological, or mental disease and were excluded living in a nursing home.
9672978|NCT05028803|Experimental|Phenylbutyrate|Volunteers will recieve 5 grams of Sodium Phenylbutyrate daily for 3 weeks (21 days). Sodium Pheburane will come in granuale form and 5 grams will be dosed every day.
9672979|NCT05028686||Hospitalized heart failure cohort|Patients hospitalized with heart failure
9975457|NCT02959944|Experimental|Ibrutinib + Prednisone|"Ibrutinib (420 mg) given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. The 420 mg dose was adjusted for cytochrome P450 [CYP] inhibitors or hepatic dysfunction as applicable.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
10173634|NCT03861104|No Intervention|group without video|patients will fill out the spielberger state anxiety inventory without watching the video at the time of nasal packing removal
9672980|NCT05028868||Large artery atherosclerosis(LAA)|
9672981|NCT05028868||Cardiogenic stroke(CS)|
9672982|NCT05028868||Penetrating artery disease(PAD)|
9672983|NCT05028868||Other etiology(OE)|
9672984|NCT05028868||undetermined etiology(UE)|
9672985|NCT05028712|Experimental|Visual Information Training|
9672986|NCT05028712|Experimental|Multimodal Training|
9672987|NCT05028855||sCAS patients|Investigators plan to enroll 850 patients of symptomatic cerebral atherosclerotic stenosis (sCAS) for cerebral autoregulation assessment to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.
9672988|NCT05028842||Non Cirrhotic|Non Cirrhotic
9672989|NCT05028842||Compensated Cirrhotics|Compensated Cirrhotics
9672990|NCT05028842||Decompensated Cirrhotics|Decompensated Cirrhotics
9672991|NCT05028647|Active Comparator|VR treatment|5 subjects per country aged 13-16 treated with VR supported (Oculos) program, one hour a day for 5 days
9672992|NCT05028647|Active Comparator|AR treatment|5 subjects per country aged 10-13 treated with AR supported (tablet) program, one hour a day for 5 days
9672993|NCT05028647|No Intervention|control age 13-16|dyslexic subjects aged 13-16 not randomized to active treatment
9672994|NCT05028647|No Intervention|Control age 10-12|dyslexic subjects aged 10-12 not randomized to active treatment
9672995|NCT05028556|Experimental|Y101D|Y101D in subjects with Metastatic or Locally Advanced Solid Tumors
9672996|NCT05028452|Other|Internet based support|Internet based support for informal caregivers to individuals who are undergoing treatment for head and neck cancer.
9672997|NCT05028270||Balloon technology|The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. The common carotid artery and internal carotid artery will be received laterally. After whole-body heparinization, micro-catheter and guide wire technology are used. In the figure below, the proximal end of the 4mm super-form occlusion ball is marked far away from the eye, plugged and sealed, and the guide tube is pushed around in the internal carotid artery. When the occlusion is finished, the internal carotid artery and the ophthalmic artery are not accompanied far away, and the plot is good. The guiding catheter drives the injection of drugs, topotecar, and topotecan for 5 minutes (the suction balloon is opened and blocked, and the infusion is continuous) to complete the infusion.
9672998|NCT05028270||Microcatheter technology|The tip of the Marathon microcatheter is placed at the opening of the ophthalmic artery. After the contrast agent is confirmed by hand, the chemotherapeutic drugs The femoral artery is introduced after the patient is fully anesthetized. First, the 5F-VETERBRAL is introduced under the guidance of the guidance. Maphalan, carboplatin, and topotecan are injected sequentially for 30 minutes. Make sure that the tip position of the catheter is not maintained during the injection process. verb: move. After the operation is completed, the blocking balloon is pulled out under the guidance of the guide wire, the arterial sheath is removed, and the femoral artery puncture point is pressed to stop bleeding.
9672999|NCT05028478|Experimental|Single Arm|"Four planned CN202 dose level of 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg~Subjects will receive CN202 by intravenous infusion (IV) on Day 1 of each cycle (once every 2 weeks) for up to 24 months"
9673000|NCT05028296|Experimental|Patients Scheduled for Standard of Care Upper Endoscopy|
9673001|NCT05028335|Other|Group G1|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + placebo gel
9673002|NCT05028335|Experimental|Group G2|Home bleaching treatment (Carbamide Peroxide (PC) 22%) + 1.5% Potassium Oxalate gel
9673003|NCT05028322|Active Comparator|Intra-muscular vaccination (Group 1)|This group corresponds to the use of the vaccine as used in the current recommendations.
9673004|NCT05028322|Active Comparator|Intra-dermal vaccination group without application of IMIQUIMOD cream (Group 2)|Administration mode change for Intra-dermal vaccination. ( Instead of Intra-musculaire ) , to have a comparative with the experimental group.
10173635|NCT03861195||Da Vinci Robotic Surgical System|
10173636|NCT03861195||conventional laparoscopic surgery|
9673005|NCT05028322|Experimental|Intra-dermal vaccination group with application of IMIQUIMOD cream (Group 3)|"Intra-dermal vaccin administration, with an immunity booster few minutes before by IMIQUIMOD application cream.~Experimental group."
9673006|NCT05028543|Placebo Comparator|conventional TLH|women that will be subjected to conventional Total laparoscopic hysterectomy
10173637|NCT03861247|Active Comparator|Control group|
10173638|NCT03861247|Experimental|Intervention group|
10173639|NCT03861169|Experimental|Viscoeleastic delivery & trabeculotomy|Patients with open angle glaucoma and cataract
10173640|NCT03861156|Experimental|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
10173641|NCT03861130||Kawasaki disease|Kawasaki disease affected childrens
10173642|NCT03860974|Experimental|Serratus Plane (single injection)|A single injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL on each side for bilateral surgery)
10173643|NCT03860974|Active Comparator|Paravertebral (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery)
9673007|NCT05028543|Experimental|TLH with prior uterine artery clipping at its origin|women that will be subjected to TLH with prior uterine artery clipping at its origin
10173644|NCT03861182|Other|Adult Healthy Volunteers|
10173645|NCT03861182|Other|Neonates|
10173646|NCT03861208|Experimental|diet|high fiber high protein foods served in childcare centers are offered for meals and snacks
10173647|NCT03861208|Other|usual diet|foods representing the usual diet in childcare centers are offered for meals and snacks
9673008|NCT05028283|Experimental|participants|patients with atrophic acne scars on the cheeks who will reviewing the dermatological clinics at the Dermatology and Venereology Hospital at least 69 patients they will be undergo fat grafting for one session and will be follow up for 6 months after the procedure
9673009|NCT05028348|Experimental|Selinexor, pomalidomide and dexamethasone (SPd)|"Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) or 60 mg (3 20 mg tablets) once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.~Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.~Patients ≤75 years:~o Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion.~Patients > 75 years:~Dexamethasone will be given as an oral 20 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion."
9827524|NCT02459418|Active Comparator|US Gonal-f® - Afolia (Sequence B) Arm:|During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
9827525|NCT02459587|Experimental|Crisis Line Facilitation (CLF)|Crisis Line Facilitation
9827526|NCT02459587|Placebo Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care
9673010|NCT05028348|Active Comparator|Elotuzumab, Pomalidomide and Dexamethasone (EloPd)|"Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.~Pomalidomide will be given as an oral 4 mg dose once a day (QD) on Days 1 to 21 of each 28-day cycle.~Patients ≤75 years:~Dexamethasone 28 mg PO + 8 mg IV on days of elotuzumab dosing~Dexamethasone 40 mg PO on non-elotuzumab days (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion.~Patients >75 years:~Dexamethasone 8 mg PO + 8 mg IV on days of elotuzumab dosing~Dexamethasone 20 mg PO on non-elotuzumab dosing weeks (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion."
9673011|NCT05028231||Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|
9673012|NCT05028244|Experimental|Intervention group|Selected patients undego lower extremity ultrasound for diagnosis of deep vein thrombosis 2 times per week (mondays and thursdays) in a period of 3 weeks (21 days) of follow up
9673013|NCT05028244|No Intervention|control group|This group only undergo the first ultrasound assesment to discard previos thrombosis not detected during hospitalization or ambulatory
9673014|NCT05028218|Experimental|TQB3824 tablets|TQB3824 tablets orally administrated orally on Days 1-21 of each 21-day treatment cycle. Dose escalation of TQB3824 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
9673015|NCT05028192||Rectal cancer after neoadjuvant treatment|Rectal cancer patients, ycTNM stage II, III, and IV (AJCC 8th), clinically stratified in the pre-cachectic or cachectic stage according to Fearon K et al. definition. That will be subject to curative intent resection or palliative surgery through any approach (open, laparoscopic, or robotic).
10173648|NCT03860948|Experimental|Savolitinib Test Preparation|The subjects in this arm will receive Test preparation (T). T is dry granulation savolitinib tablets.
10173649|NCT03860948|Experimental|Savolitinib Reference Preparation|The subjects in this arm will receive Reference preparation(R). R is wet granulation savolitinib tablets.
9673016|NCT05028192||Control group|Patients who will undergo programmed abdominal surgery through any approach type for no neoplastic or inflammatory disease.
9673017|NCT05028179|No Intervention|Standard Care (comparator)|Patients will receive standard care
9673018|NCT05028179|Experimental|Standard Care plus AI platform (EchoGo)|Patients will receive standard care plus their Echocardiogram will be sent to Ultromics for AI assessment. The report from the assessment will be sent to the clinician, and utilised to inform the patients further care.
9673019|NCT05029024|Active Comparator|Intervention group|Patients allocated to the intervention group received standard care plus a guided 30-minute mindful breathing session which consisted of four breathing exercises done consecutively in one-to-one manner. The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes. Guidance was given by one of the two research assistants, who were medical doctors. They were trained by one of the co-investigators, who was a palliative care physician, certified in mindfulness training.
9673020|NCT05029024|Placebo Comparator|Control group|Patients in the control group received standard care alone.
9694976|NCT04783415|Experimental|Treatment (ublituximab, acalabrutinib, umbralisib)|"Patients receive ublituximab IV over 90 minutes-4 hours on days 1, 8, and 15 of cycle 1 and days 1 of cycles 2-6. Patients also receive acalabrutinib PO BID and umbralisib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ublituximab IV on day 1 on cycles 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30. Patients also receive acalabrutinib Po BID and umbralisib PO QD on day 1-28. Treatment repeats every 28 days for 24 cycles in the absence of disease progression of unacceptable toxicity."
9694977|NCT04783129|Experimental|Face-to-face group|Face-to-face group (FFG), in which participants, in groups of 10 persons, followed a multidisciplinary health education program composed of 10 monthly face-to-face lectures
9694978|NCT04783129|Active Comparator|Remote group|Remote group (RG), in which individuals followed 10 monthly remote lectures
9694979|NCT04783129|Sham Comparator|Control group|Control group (CG), in which participants followed no education program (lectures)
9694980|NCT04783402|Experimental|e-OTCAT|The experimental group will receive the e-OTCAT program that consists of a 12-week videoconference-based occupational therapy intervention at the same time women with breast cancer receive chemotherapy.
9694981|NCT04783402|Other|Control Group|At the beginning of chemotherapy, the participants allocated to the control group will only receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care for these patients.
9827527|NCT02459665|No Intervention|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
10173650|NCT03861065|Experimental|Tertiary Wound Closure|In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
10173651|NCT03861065|Active Comparator|Historical Wound Closure|"The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure)."
10173652|NCT03861260|Other|Rigid Cystoscopy and Urethral dilatation|Rigid cystoscopy, performed under General Anaesthetic, followed by intervention of urethral dilatation with Hagar dilators.
10173653|NCT03861260|Other|Flexible cystoscopy and Glycosaminoglycan Layer replacement|Flexible cystoscopy, under Local Anaesthetic, followed by the intervention, which is 6 installations of Ialuril (a Glycosaminoglycan Layer replacement)
10173654|NCT03860896|Experimental|GB004|GB004 for oral administration daily
10173655|NCT03860896|Placebo Comparator|Placebo|Placebo for oral administration daily
10173656|NCT03861013|Experimental|Intervention group|Participation in a multidimensional stress prevention program (GeDStress).
9527521|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
10173657|NCT03861013|No Intervention|Wait-list control group|Participants on the wait-list control group will not receive any treatment between the baseline and last follow-up. After the study has ended, they have the option to participate in the program.
10173658|NCT03860870|Experimental|Clenbuterol|Subjects ingest 80 micrograms of clenbuterol tablets
10173659|NCT03860870|Placebo Comparator|Placebo|Subjects ingest placebo tablets
10173660|NCT03860857|Experimental|Age 60-65 ApoE e4+|Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
10173661|NCT03860857|Experimental|Age 66-70 ApoE e4-|Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
10173662|NCT03860857|Experimental|Age 66-70 ApoE e4+|Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
10173663|NCT03860857|Experimental|Age 71-75 ApoE e4-|Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
10173664|NCT03860857|Experimental|Age 71-75 ApoE e4+|Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
9673021|NCT05028881||HIV positive|No interventions
10173665|NCT03860857|Experimental|Age 76-80 ApoE e4-|Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
9673022|NCT05028881||HIV uninfected|No interventions
9673023|NCT05027880|Experimental|Single-session Intervention of Growth Mindset for Anxiety (SIGMA)|The SIGMA intervention group will adapt the SSI-GP protocol in two ways: (a) by introducing the growth mindset of emotions rather than personality and (b) providing an experiential process of negative emotion change. SIGMA also consists of five components: (a) an introduction to emotions and the brain for conveying a scientific understanding of emotion and growth mindset of negative emotions; (b) stories and testimonials from high-school-aged youths who described their beliefs that people's negative emotion states (e.g., anxiety, depression, and stress) are malleable, and how these mindsets influence their coping with anxiety; (c) emotion changing experience induced by short videos; (d) common questions and misconceptions about growth mindset; and (e) self-persuasion writing exercises in which the participants write notes to younger students about the growth mindset of emotion.
9673024|NCT05027880|Experimental|Single session on growth mindset of personality (SSI-GP)|The SSI-GP intervention group will use the intervention protocol of Project Personality (https://osf.io/a9uv2/). The investigators will translate it into Chinese using bilingual native English and Chinese speakers. The key potent elements of SSI-GP consist of five components [17, 40, 41]: (a) an introduction to the brain about the potential of neuroplasticity and behavioural change; (b) written testimonials from older, high-school-aged youths of their belief in change of personality; (c) additional vignettes written by older youths about how growth mindset of personality helped them succeed following setbacks; (d) overview of common questions and misconceptions about growth mindset; and (e) an exercise of writing notes to younger students about the malleability of people's personality traits.
9673025|NCT05027880|Active Comparator|Active control group: Support therapy (ST)|The control condition will be a structurally similar web-based session of supportive therapy. The goals of supportive therapy are to encourage the client to identify and express feelings and to share their emotions-both positive and negative-with close others. ST group does not teach or emphasize specific skills or beliefs. The active control group includes the same number of reading and writing activities as do the SIGMA and SSI-GP interventions. Also, to mirror the intervention groups as closely as possible, supportive therapy will include vignettes written by older, high-school-aged youths, who describe times when they benefited from sharing their feelings with friends or family members.
9673026|NCT05028439|Experimental|RAF combined with gemcitabine and S-1 group|Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with gemcitabine and S-1 within 1 month after RFA.
9673027|NCT05028439|Placebo Comparator|RFA-only gruop|Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
9673028|NCT05028426||Traditional method of care|Patients managed according to the traditional care protocol without an enhanced recovery program
9673029|NCT05028426||Some elements of a fast-track program|operative and postoperative techniques were modified according to a fast-track program
9673030|NCT05028426||Full enhanced recovery program|Patients were managed in an enhanced recovery program (elements of the previous fast-track program were modified and preoperative education was added)
10173666|NCT03860857|Experimental|Age 76-80 ApoE e4+|Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
10173667|NCT03860857|Experimental|Age 81-85 ApoE e4-|Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
10173668|NCT03860857|Experimental|Age 81-85 ApoE e4+|Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
10173669|NCT03860597|Active Comparator|Memantine|
10173670|NCT03860597|Placebo Comparator|Placebo|
10173671|NCT03860766|Sham Comparator|Sham Group (G-S)|The LED will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
10173672|NCT03860766|Experimental|50J Infrared LED Group (G-50J)|The LED with a wavelength of 940nm, 50J power, will be applied throughout the quadriceps and hamstrings bilaterally, just before the strength training protocol.
9673031|NCT05028036|Experimental|Personalized lifestyle intervention|The intervention consists of a personalized lifestyle treatment program to address specific lifestyle issues.
9673032|NCT05028777||Patients diagnosed with left ventricular thrombus|All patients diagnosed with left ventricular thrombus through different imaging modalities (echocardiography, CT or MRI) and who have been diagnosed and/or treated at the Inselspital or another site of the Insel Gruppe.
9673033|NCT05028127|Experimental|Bimekizumab dosage regimen 1|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 1 during the Treatment Period.
9673034|NCT05028127|Experimental|Bimekizumab dosage regimen 2|Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 2 during the Treatment Period.
9673035|NCT05028049||Sufentanil-analgesia in plain area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plain area patients.
9673036|NCT05028049||Remifentanil-analgesia in plain area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plain area patients.
10173673|NCT03860766|Experimental|240J Infrared LED Group (G-240J)|The LED with a wavelength of 940nm, 240J power, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
9673037|NCT05028049||Sufentanil-analgesia in plateau area patients|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
9673038|NCT05028049||Remifentanil-analgesia in plateau area patients|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia in plateau area patients.
9673039|NCT05027893|Active Comparator|Active Comparator: The first tested group|Patients orally received film-coated tablets with either 400 mg of moxifloxacin. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
9673040|NCT05027893|Active Comparator|Active Comparator: The second tested group|Patients orally received film-coated tablets with either 400 mg of cefixime. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
9673041|NCT05027893|Placebo Comparator|Placebo Comparator: The control group|One third of patients received placebo-tablets containing indifferent substances with no antimicrobial action (99% microcrystalline cellulose, 0.5% silicon dioxide and 0.5% magnesium stearate, which were of the same colour and overall appearance as the used antibiotics. Film-coated tablets were administered for the first five days postoperatively, once a day, in a double-blind manner. All patients were evaluated at the postoperative follow-ups on the first, second and seventh postoperative day.
10173674|NCT03860766|Experimental|Progressive dose infrared LED group (G-50-240J)|The LED with a wavelength of 940nm, initial energy of 50J with an increment of 38J each week to the final energy of 240J, will be applied throughout extension of the quadriceps and hamstrings bilaterally, immediately prior to the performance of the strength training protocol
10173675|NCT03860831|Experimental|intranasal (IN)|"Group IN will receive nasal ketamine+midazolam mixture by mucosal atomisation device: midazolam (0.2 mg/kg) +ketamine (5mg/kg).~the calculated dose will be equally divided into the two nostrils by the parents"
9673042|NCT05028114|Experimental|Part 1 (Formulation Optimisation)|Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided 30 minutes after study drug administration. There will be 4 different formulations of the study drug and participants will be randomised to one of 4 sequences. There will be a washout of 2 days between each administration.
10173676|NCT03860831|Active Comparator|intramuscular (IM)|"Group IM will receive intramuscular administration of liquid ketamine +midazolam mixture:midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.~Mild to moderate restraint was done with the help of the parents during drug administration."
10173677|NCT03860545||non-AKI|patient without acute kidney injury (AKI) during perioperative observation period
9673043|NCT05028114|Experimental|Part 2 (Placebo Assessment)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants are randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods."
9673044|NCT05028114|Experimental|Part 3 (Titration Tolerability)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants will be randomised to either study drug or the matching placebo."
9673045|NCT05027984|Experimental|Intermediate lesion OCT-based management|"At OCT analysis, lesion features prompting intervention instead of conservative approach will be the following:~FCT <75 µm, plus at least 2 of 3 other OCT criteria of plaque vulnerability (i.e., MLA <3.5 mm2, lipid arc with circumferential extension >180°, and the presence of macrophages).~The presence of intracoronary thrombus at a non-culprit site, irrespective of the presence of other vulnerability criteria, may prompt treatment with DES, at the operator's discretion.~All lesions fulfilling these interventional criteria will be treated with an OCT guided DES implantation in order to achieve an optimal stent implantation.~In presence of a MLA <2.0 mm2, best cut-off showing correlation with fractional-flow reserve positive functional (FFR) assessment, clinical decision whether to treat the lesion will be based on FFR assessment irrespective of the presence of other criteria of vulnerability. Alternatively authors will have the option to treat the lesion with a DES."
10173678|NCT03860545||AKI|patient with diagnosis acute kidney injury (AKI) established during perioperative observation period
10173679|NCT03860506|Experimental|PSI-697|
10173680|NCT03860506|Placebo Comparator|Placebo|
10173681|NCT03860818|No Intervention|Control Arm|Usual Care
10173682|NCT03860818|Experimental|Intervention Arm|Technology-enabled pharmacist intervention
10173683|NCT03860519|Experimental|Intervention Group|"The components of the intervention unique to the treatment group include: 1) access to the Propeller Health Asthma App on his/her phone, which includes tracking of ICS and SABA usage; 2) receipt of NorthShore Connect physician alerts (these will be sent by the asthma nurse on behalf of the NS physician) if he/she has poor adherence ie missed 4 consecutive days of all of his/her controller medication dosages and their sensor has sent heartbeat to application OR at risk alerts if a patient transitions to a not well controlled or poorly controlled status (defined by the NHLBI guidelines); and 3) monthly phone calls with a nurse from his/her asthma doctor's office to review ICS and SABA usage reports (provided by Propeller Health on their Propeller Health dashboard)."
9673046|NCT05027984|Active Comparator|Intermediate lesion physiology-based management|The iFR/FFR/RFR measurements will be obtained using a coronary-pressure guidewire. For FFR, hyperemia will be induced with the administration of intravenous adenosine, in accordance with the clinical practice at each participating center. Lesion features prompting intervention instead of conservative medical approach will be the following: iFR ≤0.89, or FFR ≤0.80.(32) All lesions fulfilling these interventional criteria will be treated with an FFR guided DES implantation. PCI will be performed with the aim of achieving a post-stenting FFR ≥0.90 (i.e. optimal FFR result). If post-stenting FFR was <0.90 a further post-dilation of the stent could be performed and if FFR remained at <0.90, a pullback of the wire to identify another possible pressure drop and/or a subsequent stent implantation at least 5 mm from the stent will be performed according to physician's preference.
9673047|NCT05028010|Experimental|Training|There will be one arm, intervention group.
9673048|NCT05027854|Experimental|Stimulation|TMS or tES, depending on experiment
9673049|NCT05027854|Sham Comparator|Sham|Corresponding sham TMS or tES
9673050|NCT05028023|Experimental|Pediatric patients with tracheal stenosis undergoing tracheal balloon dilatation|Pediatric patients with severe to median acquired tracheal stenosis undergoing tracheal balloon dilatation, and the effects of apneic oxygenation on regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, and arterial oxygen partial pressure PaO2
10173684|NCT03860519|Experimental|Control Group|The control group will not receive access to view the contents of the Propeller Health Asthma App on his/her phone, NorthShore Connect alerts for missing ICS or overuse of SABA, or for his/her asthma doctor (the asthma nurse will be viewing this information on behalf of the asthma doctor) to view his/her ICS and SABA use on the Propeller Health dashboard until after the 3-month study has been completed.
10173685|NCT03860532|Active Comparator|HMPL-011 tablets|A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2)
10173686|NCT03860532|Active Comparator|HMPL-011 capsules|A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6)
10173687|NCT03860792|Experimental|Ketogenic Diet|Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein as energy). The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily. Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
10173688|NCT03860792|Active Comparator|Therapeutic Lifestyles Changes Diet|Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet. The diet consists of 20-35% fat, 50-60% carbohydrate, and ~15% protein as energy. Fat intake will comprise <7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy. Cholesterol consumption will be ≤200mg per day. Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
10173689|NCT03860662|Active Comparator|Spastic hemiplegia , Botox|Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
9673051|NCT05028088|Experimental|Child-Pugh A|"Diaphragm ultrasound scan before induction of anesthesia.~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
9673052|NCT05028088|Experimental|Child-Pugh B|"Diaphragm ultrasound scan before induction of anesthesia.~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
10173690|NCT03860662|Other|Spastic hemiplegia, Baclofen|Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.
9673053|NCT05028088|Experimental|Child-Pugh C|"Diaphragm ultrasound scan before induction of anesthesia.~Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.~When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg).~Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation."
9673054|NCT05028153|Active Comparator|Antibiotics|Azithromycin (10mg/kg) administered via oral suspension for 3 consecutive days
9673055|NCT05028153|Placebo Comparator|Placebo|Placebo with no active substance administered via oral suspension for 3 consecutive days
9673056|NCT05028140|Experimental|Piemonte association|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 tablet Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
9673057|NCT05028140|Active Comparator|Empagliflozin|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
9673058|NCT05028140|Active Comparator|Pioglitazone|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 tablet of piglitazone, oral."
9673059|NCT05027594|Experimental|Dose Escalation Part|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
9673060|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 single agent|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
9673061|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 in combination with dexamethasone|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
9673062|NCT05027620|Experimental|Home training|Participants train 3 times weekly in their home environment with help of a digital training app, over a 10-week period.
9673063|NCT05027828||patients using olaparib only|
9673064|NCT05027828||patients using olaparib combined with bevacizumab|
9673065|NCT05027672|Active Comparator|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|At the time of randomisation, patients in this arm receive a second dose of Sputnik V (rAd5) vaccine component two.
9673066|NCT05027672|Experimental|Gam-COVID-Vac / ChAdOx1 nCoV-19|At the time of randomisation, patients in this arm receive Astra Zeneca's vaccine (ChAdOx1 nCoV-19) as a second dose.
9673067|NCT05027672|Experimental|Gam-COVID-Vac / Gam-COVID-Vac (rAd26)|At the time of randomisation, patients in this arm receive a second dose of a repeat of the first component of the Sputnik V vaccine (rAd26) as a second dose.
9673068|NCT05027672|Experimental|Gam-COVID-Vac / mARN-1273|At the time of randomisation, patients in this arm receive as a second dose the vaccine produced by Moderna (mRNA-1273).
9673069|NCT05027737|Experimental|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
9673070|NCT05027737|No Intervention|Traditional closure (control)|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo a standardized reversal of their diverting loop ileostomy. The latter will be performed with a stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia and will be performed no earlier than 12 weeks following their index surgery.
9673071|NCT05027438|Experimental|COAST + Deprescribing|CBT-I with simultaneous sedative-hypnotic deprescribing delivered through a digital platform
9673072|NCT05027750|Experimental|Intervention|The selected womens were associated with obesity risk factors about obesity (overweight) or obese and between 18-49 years old) and randomly assigned to the experimental group. Obesity training consisting of a total of five sessions structured according to Theory of Planned Behavior was scheduled for the intervention group. Each session lasted for approximately 30 minutes.
9673073|NCT05027750|No Intervention|Control|The control group of the Randomized Controlled Trial (RCT) was composed of 39 womens (between 18-49 years old) randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between ≥30.0 according to the risk rating scales. A standard obesity training consisting of a single session was scheduled for the control group.
9673074|NCT05027659|Experimental|intervention|This study was carried out with two groups. Virtual reality glasses were used for the intervention group.
9673075|NCT05027659|No Intervention|control|No application was made to the control group, standard procedure was followed.
9673076|NCT05027555|Experimental|Multisensory training group|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
9673077|NCT05027555|Active Comparator|Conventional training group.|The intervention is a 50-minute session and 2-sessions/week, totaling 6 weeks
9673078|NCT05027516|Active Comparator|Rocephine®|ceftriaxone 1g + lidocaine 35mg; intramuscular injection
9673079|NCT05027516|Active Comparator|Rocephine® + Azithromycin|ceftriaxone 1g + lidocaine 35mg intramuscular injection + azithromycin 2g orally
9827528|NCT02459665|Other|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
10173691|NCT03860714||study group|400 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China].We do the neuropsychological tests,MMSE,CCI，CDR,QoR-40,GDS,CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，NRS once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
10173692|NCT03860571|Placebo Comparator|Placebo|
10173693|NCT03860571|Experimental|BT-11|
10173694|NCT03860441|Experimental|Intervention group|Participants in the intervention group received 24 sessions of computerized cognitive training, with a total time of 960 min.
10173695|NCT03860441|Active Comparator|Active control group|Participants in the control group attended activities separate activities, such as learning about healthy lifestyle, had cooking and other social lessons for the same amount as the intervention group performed cognitive training.
9673080|NCT05027412|Experimental|En Bloc TURBT with Collins Loop|"If the patient is randomized to the TURB group, it will be carried out with a Collins loop, with bipolar energy.~After randomization, demographic data (age, sex, exposure to tobacco, occupational risk), symptoms prior to randomization (micro or macrohematuria, LUTS) and laboratory data (urinary cytology, hemoglobin and serum creatinine) will be collected. Finally, the physical characteristics of the lesion will be noted in the cystoscopy immediately prior to the intervention: size, location (s) and appearance of the tumor. After the intervention, the type of procedure (TURB / TUB), the duration of the procedure from when the resector is inserted until the urinary catheter is placed, and complications according to the Clavien-Dindo scale will be recorded. In your first post-surgical check-up, the days of hospital stay and the time of bladder catheterization will be collected."
9673081|NCT05027412|Active Comparator|Conventional TURBT|The TURB will be carried out with bipolar current according to the traditional technique.
9673082|NCT05027581|Experimental|Chondrochymal® group|Subjects will be IA injected at the target knee with 3 mL of Chondrochymal® containing 5.0 x 107 BM-MSCs in lactated Ringer's solution at Day 1.
9673083|NCT05027581|Active Comparator|Hya-Joint Plus Synovial Fluid Supplement|Hya-Joint Plus Synovial Fluid Supplement containing 60 mg/3 mL of hyaluronic acid will be IA administrated into the subject's target knee at Day 1.
9673084|NCT05027334|Experimental|Interventional arm|Participants will be asked to use a designed mobile app to monitor their blood sugar levels
9673085|NCT05027321|No Intervention|Control|control
9673086|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring|1-hour consultation with a hypnopractor just before the examination
9673087|NCT05027321|Experimental|Conversational Hypnosis|conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
9673088|NCT05027321|Experimental|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|1-hour consultation with a hypnopractor just before the examination and conversational hypnosis support during the examination by a radiology technician and a radiologist specifically trained
9673089|NCT05027295|Active Comparator|Continuous UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of continuous UVA light for 7.5 minute exposure time
9673090|NCT05027295|Active Comparator|Pulsed UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of pulsed UVA light for 15 minute exposure time
9673091|NCT05027776|Experimental|Experimental: 2-doses Group|Subjects aged 9-14 years, received 2 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 6-month schedule.
9673092|NCT05027776|Experimental|Experimental: 3-doses Group|Subjects aged 9-19 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
9673093|NCT05027776|Active Comparator|Acitve Group|Subjects aged 20-26 years, received 3 doses of q-HPV vaccine, which was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 2，6-month schedule.
9673094|NCT05027711|Experimental|A|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
9673095|NCT05027711|Experimental|B|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
9673096|NCT05027711|Experimental|C|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT). If a BED of ≥ 100 Gy cannot be achieved using an ITV concept (e.g. due to OAR constraints), patients will be treated in arm C using MRgSBRT with the highest achievable dose as deemed appropriate by the treating radiation oncologist
9673097|NCT05027126|Active Comparator|Group A: Dexketoprofen (Stadium®)|Reference Drug Pharmaceutical Form: Tablets Dosage: 25 mg Administration way: oral
9673098|NCT05027126|Experimental|Group B: Fixed dose Dexketoprofen-Vitamin B Complex|Fixed dose combination: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin, Thiamine,and Pyridoxine. Administration way: oral
9673099|NCT05027373|Experimental|SSGJ-613|
9673100|NCT05027373|Placebo Comparator|Placebo|
9694982|NCT04783337|Experimental|HR-pQCT (high resolution computertomograph)|"This arm is the inverventional group for all collected cases. No other arms are available as comparator or control. All patients are treated the same.~Description of the intervention in the section Intervention."
10173696|NCT03860675|Active Comparator|persons with Multiple Sclerosis (MS)|
10173697|NCT03860675|Placebo Comparator|Healthy controls|
9694983|NCT04783168|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting.
9827766|NCT02467192|Experimental|Low dose CT|All patients will have Thoracic CT scan
10173698|NCT03860389|Experimental|Exercise effects on anxiety|An exercise programme will be administered 3 times a week for up to an 16 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will involve aspects of fundamental movement skills and will be fun for the students to participate in.
9673101|NCT05027386|Experimental|Apatinib Mesylate combined with IT Regimen|"The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.~Combination therapy phase: Apatinib (orally once daily continuously in a 21-day cycle) was combined with IT regimen (repeated every 3 weeks) for up to 6 courses of treatment.~Apatinib:~<25Kg：0.25g，po，qd； 25Kg≤wight<40Kg：0.425g，po，qd； 40Kg≤wight<50Kg：0.5g，po，qd.~IT regimen:~Temozolomde：150mg/m2，iv 90min，d1-5，（1h before irinotecan）； Irinotecan: 50mg/m2，iv 90min，d1-5.~Monotherapy maintenance phase: Apatinib is administered as a monotherapy until tumor progression, patient withdrawal, or toxicity becomes intolerable."
9673102|NCT05027178|Experimental|Chiropractic care for Ischemic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
9673103|NCT05027178|Experimental|Chiropractic care for Hemorrhagic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
9673104|NCT05027152|Experimental|traditional resistance exercises|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise.
9673105|NCT05027152|Experimental|repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
9673106|NCT05027191||Sevoflurane|This group will receive sevoflurane as the maintenance inhalational anesthetic.
9673107|NCT05027191||Desflurane|This group will receive desflurane as the maintenance inhalational anesthetic.
9673108|NCT05027529|Experimental|VA-ECMO and CytoSorb|standard ICU care WITH CytoSorb
9673109|NCT05027529|Placebo Comparator|VA-ECMO only|standard ICU care WITHOUT CytoSorb
9673110|NCT05027035|Active Comparator|Surgical plication|Surgical plication of the diaphragm
9673111|NCT05027035|Active Comparator|Mechanical ventilation|Non-invasive ventiatilatory support
9673112|NCT05027165||Observational group|"In this cohort, 40 NSCLC patients with indication for chemoradiotherapy followed by durvalumab maintenance treatment (standard of care) will be consecutively recruited.~Comprehensive characterization of all patients includes immunophenotyping of peripheral blood mono-nuclear cells, ctDNA as well as gut/saliva microbiome analyses and will be performed before, after 15 fractions of radiotherapy, at the end of concurrent chemoradiotherapy as well as 3-, 6- and 12 months after start of durvalumab.~18F-FDG-PET/CT will be performed 5-10 d before start of radiotherapy, 6 weeks, 6 months,12 and 24 months after the end of radiochemotherapy. Lung function will be asssed before start of radiotherapy, at the end and 6 weeks after chemoradiotherapy as well as 3-, 6- and 12, 18, 24months after start of durvalumab."
9673113|NCT05027243|Experimental|bilateral temporomandibular joint arthroscopy|
9673114|NCT05026970|Active Comparator|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
9673115|NCT05026970|Active Comparator|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
9673116|NCT05026970|Active Comparator|Biofeedback+Kegel|Biofeedback (6 sessions) Kegel exercises (twice daily)
9673117|NCT05026853|Experimental|PRO Integration into Clinical Practice|PRO scores will be shared with patients and healthcare providers (HCPs) via an emailed report card
9673118|NCT05026853|No Intervention|Usual Care|Patients and HCPs will not receive an emailed PROMIS score report. PROMIS scores, however, will be available in the EMR as usual.
9673119|NCT05026762|Experimental|Treatment|
10173699|NCT03860688|Experimental|Teduglutide + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
9673121|NCT05026658|Experimental|Visibly Digital Acuity Product|
9673122|NCT05026658|Experimental|ETDRS Visual Acuity Lane Test|
10173700|NCT03860584|Experimental|MFGM-enriched full-fat dairy milk|Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at ~10-times that in full-fat dairy milk.
10173701|NCT03860584|Placebo Comparator|Soy phospholipid/lecithin milk|Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.
9673125|NCT05026918|Active Comparator|Group A|all the components of Manual Chest Physiotherapy wer performed on the patients of this group. MCPT was done few hours before meals and it was made sure that nothing was in patient's mouth while doing chest physiotherapy. MCPT includes postural drainage, percussion and vibrations. Chest Physiotherapy was done thrice a day for 30 minutes and there were 21 sessions a week.
9673126|NCT05026918|Experimental|Group B|all the components of Active Cycle of Breathing techniques (ACBT) were performed on the patients of this group. ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique. These were performed thrice a day for 30 minutes and for 21 sessions a week.
9673127|NCT05026333|Experimental|High Stress Group|Group of high stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
9673128|NCT05026333|Experimental|Low Stress Group|Group of low stress participants based on cutoff scores on the Perceived Stress Scale (PSS) and the STAI - State Anxiety Scale.
9673129|NCT05026372|Experimental|Mindfulness + Compassion (MC)|For participants randomized to the MC condition will focus on compassion and creating positive emotions. This session will include techniques such as guided visualizations and a loving kindness meditation that are intended to facilitate connection with their partners. During this session, couples will also learn the ground rules of mindful and compassionate listening and sharing, as they will be asked to engage in an emotional disclosure task. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
10173702|NCT03860493||Study group|Only patients who might benefit from intraoperative fluorescent tissue perfusion assessment according to the primary surgeon will be enrolled in the study. The patients will be screened and consent during their office visit with their surgeon at the Cleveland Clinic Foundation. Each surgeon will follow the standard Open surgical protocol of his/her subspecialty, and will comply with the following additional steps according to the type of surgery:
10173703|NCT03860636||Fresh Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at three different points during their treatments.~The day they receive their HCG trigger,~The day of transvaginal oocyte retrieval (TVOR) and~The day of embryo transfer (ET)."
9673130|NCT05026372|Experimental|Mindfulness + Gratitude (MG)|Session 2 for participants randomized to group MG will focus on gratitude. Participants will be taught to reflect on things, events, and people which they are grateful for via a gratitude meditation. Couples will share their experiences of practicing gratitude. The instructor will remind the couple of ground rules prior to the emotional disclosure exercise and facilitate if necessary during the sharing. Each member of the couple will take turn in sharing with and listening to their partner. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
10173704|NCT03860636||Frozen Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at two different points during their treatments.~The day we coordinate with embryologist (day of progesterone +/-1)~The day of embryo transfer (ET)."
10173705|NCT03860480|Active Comparator|ESP with Bupivacaine 0.5%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of bupivacaine at a concentration of 0.5% with epinephrine 1:200 000 will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
10173706|NCT03860480|Sham Comparator|ESP with Saline 0.9%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of a placebo solution (normal saline) will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
9673131|NCT05026372|Experimental|Mindfulness + Value-Based Living (MV)|Session 2 for participants randomized to group MV will focus on learning strategies to live life according to their values. They will first engage in a reflection exercise to help identify their values, and then complete a worksheet. Couples will brain storm together strategies to ensure that their lives reflect their self-identified values. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
9673132|NCT05026372|No Intervention|Attention Control (AC)|For participants randomized to the AC condition, both sessions will focus on discussing issues and themes that emerge for couples, such as communication and perceived supportiveness. Utilizing a reflective listening approach, the interventionist will focus on encouraging participants to share concerns related to their daily experiences. Unlike in the MC, MG, and MV groups, the interventionist will not offer advice, support (other than reflective listening) or any other tools to participants. Additionally, the interventionist will not probe for deep emotional disclosure. Please see the appendix for the session outline. We believe a control group that discusses daily relationship-related concerns serves as an excellent comparison condition in this study since it is viewed as credible by participants and equates for time and attention as well as nonspecific treatment effects such as those provided through social interactions.
9673133|NCT05026359|Experimental|Bilateral ankle coordination training group|Exercise training of bilateral ankle coordination training group consisted of 30 minutes of bilateral ankle coordination training 3 days per week for 4 weeks (total 12 sessions)
9673134|NCT05026359|No Intervention|General rehabilitation intervention group|Exercise training of walking and balance training consisted of 30 minutes of general rehabilitation intervention group 3 days per week for 4 weeks (total 12 sessions)
9673135|NCT05026398|Experimental|Fenfluramine|Drug: Fenfluramine - 15mg twice daily oral solution for seven days
9673136|NCT05026398|Placebo Comparator|Placebo|Placebo - 15mg twice daily oral solution for seven days
9673137|NCT05026840||IADPSG|
9673138|NCT05026840||WHO '99|
9673139|NCT05026593|Active Comparator|Sintilimab+EP|During each 21-day cycle, participants receive Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
9673140|NCT05026593|Experimental|IBI110+Sintilimab+EP|During each 21-day cycle, participants receive IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). After the induction phase, participants will begin maintenance therapy with IBI110 PR2D intravenously (IV) Day 1 PLUS Sintilimab 200 mg intravenously (IV) Day 1 every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or other protocol-allowed reasons, whichever occurs first.
9673141|NCT05026554||CHE|Adults with moderate to severe chronic hand eczema
9673142|NCT05026554||Healthy Volunteers|Healthy adults
9673143|NCT05026619|Placebo Comparator|Control|Receives a fact sheet on diabetes in Singapore
9673144|NCT05026619|Experimental|Fertility-related information|Receives accurate information on age-related fertility
10173707|NCT03860649|Experimental|Nordic Walking|The patient walk program consists of 3 moments: warm up, walk and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.
10173708|NCT03860649|Experimental|Jogging|This group will undergo 24 Dance sessions. Aquatic therapy patients will receive deep water running intervention with the use of flotation vests. The exercises will consist of: immersion, balance, strength, agility, and movement within the water. The intensity of the classes will be measured in each moment and by the Borg Scale of Perceived Exertion.
9673145|NCT05026619|Experimental|Policy-related information|Receives accurate information on local policy initiatives related to age at marriage and childbearing
9673146|NCT05026567|Active Comparator|Reference Product A|Reference Product A
9673147|NCT05026567|Experimental|Experimental B|Experimental B
9673148|NCT05026567|Experimental|Experimental C|Experimental C
9673149|NCT05026567|Experimental|Experiment D|Experiment D
9673150|NCT05026294|Experimental|Experimental group I|The experimental group received plyometric training
9673151|NCT05026294|Experimental|Experimental group II|The experimental group received flat feet rehabilitation training
9673152|NCT05026294|No Intervention|Control group|The Control group didn't receive intervention
9673153|NCT05026346||Healthy|Healthy subjects, wothout shoulder pathology
9673154|NCT05026346||Rotator cuff tears|Patients after arthroscopic reconstruction of rotator cuff
9673155|NCT05026125|Active Comparator|Group 1|3 μg/kg (Ideal Body Weight) of Remifentanil
9673156|NCT05026125|Experimental|Group 2|3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil
9673157|NCT05025995|Experimental|Serious health game|Children played a serious health game with Garfield promoting health behavior, such as less intake of energy dense snacks, drink more water, and exercise more often.
9673158|NCT05025995|Experimental|control|Children in this condition did not play a serious health game and were in control condition.
9673159|NCT05026229|Experimental|Dasatinib, Vincristine and Prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
9673160|NCT05026229|Experimental|Dasatinib, Methotrexate and Cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
9673161|NCT05026060||Patients with arterial disease|Minor patients with acute or chronic arterial disease: diagnosis of Moyamoya, diagnosis of sickle cell disease, acute or chronic arterial infarction.
9673162|NCT05026203|Experimental|Ketamine|
9673163|NCT05026203|Placebo Comparator|Midazolam|
9673164|NCT05026073||Group 1 Endometrial Cancer:|Women with histological diagnosis of cancer of the endometrium (any type) undergoing hysterectomy
9673165|NCT05026073||Group 2 Endometrial Hyperplasia:|Women with histological diagnosis of endometrial hyperplasia (with or without atypia) undergoing hysterectomy
9673166|NCT05026073||Group 3 Controls:|Healthy women undergoing hysterectomy for a benign reason
9673167|NCT05026255|Experimental|mechanically ventilated intensive care patients.|Observational data collected for patients in intensive care under mechanical ventilation.
9673168|NCT05025943|Experimental|Standard lifestyle intervention + omega-3 fatty acid enriched diet|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI) + omega-3 fatty acid enriched foods
9673169|NCT05025943|Active Comparator|Standard lifestyle intervention|American Heart Association Target Diet/Standard Lifestyle Intervention (SLI)
9673170|NCT05026268|Experimental|Intracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice with the intracorporeal anastomosis performing.
9673171|NCT05026268|No Intervention|extracorporeal anastomosis|A laparoscopic right colectomy will be performed according to the surgeons standard practice.
9673172|NCT05026242|Experimental|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
9673173|NCT05026242|Active Comparator|Control|Participants will be provided with isocaloric snacks
9673174|NCT05026307|Experimental|Pterygium|Simple surgical excision of pterygium withe bare sclera
9673175|NCT05026216|Experimental|Single-arm study|Using CCH-ases on bilateral buttocks and thigh injections. No placebo being used.
9673176|NCT05025969||Glioma|(20 grade II gliomas, 20 grade III gliomas and 20 glioblastomas)
9673177|NCT05025969||Brain metastasis|"The brain metastasis cohort consists of 80 patients, including 30 patients for whom the matched primary tumour is available"
9673178|NCT05026190|Other|azoospermic patients|
9673179|NCT05026034||Training Cohort|Inpatients with HF requiring >24 hours IV diuretics
9673180|NCT05026034||Cohort A|Patients undergoing serial, clinically indicated RHC. To investigate if measures derived by the CPM wearable device correlate with invasive measures of cardiopulmonary haemodynamics (PCWP).
9673181|NCT05026034||Cohort B|Patients receiving haemodialysis. To investigate if changes in measures derived by the CPM wearable device correlate with B-lines on LUS and changes in B-lines before and after haemodialysis and with volume of fluid removed during haemodialysis
9673182|NCT05026034||Cohort C|Patients receiving inpatient intravenous diuretic treatment for heart failure. To investigate if changes in measures derived by the CPM wearable device system correlate with B-lines on lung ultrasound and weight before and after treatment for HF.
9673183|NCT05025982||Group of partecipants|we combined two surgical techniques in the same group of patients
9673184|NCT05025930|Experimental|endoscopic surgical instrument control system (SP1000: single- port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (SP1000)
9673185|NCT05025930|Active Comparator|Comparator: endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (IS3000)
9673186|NCT05025904|Experimental|Real-time fMRI neurofeedback (rt-fMRI NFB)|The duration of a session was approximately a half-hour. The course duration was 8 sessions. The preferred frequency was once a week, however, the schedule was flexibly adjusted for patients' convenience.
9673187|NCT05025904|Active Comparator|Сognitive behavioral therapy (CBT)|The duration of a session was approximately an hour/hour and a half. The course duration was 8 individual and 8 group sessions and included home assignments. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience and for improving benefits of the treatment.
9673188|NCT05025904|Active Comparator|EEG neurofeedback (EEG NFB)|"The duration of a session was approximately a half-hour. The course duration was 16 sessions. The preferred frequency was twice a week, however, the schedule was flexibly adjusted for patients' convenience.~Group was preliminarily aborted for lack of time and participants in order to assign more patients to the abovementioned arms."
9673189|NCT05025696|Experimental|Intervention|Blacksoap(R) applied whole body twice daily
9673190|NCT05025696|Placebo Comparator|Control|Johnson and Johnsons Baby Soap applied whole body twice daily
9673191|NCT05025657|Experimental|Program|
9673192|NCT05025657|Placebo Comparator|Control|
9673193|NCT05025813|Experimental|Arm A|"Neoadjuvant Pembrolizumab 4 cycles, 200mg IV Q3W followed by interval restaging:~If restaging imaging positive will have Radical Neck Resection followed by Pembrolizumab 17 cycles, 200mg IV Q3W +/- External Beam Radiotherapy (if >10% viable tumour cells at resection) If restaging imaging negative will have Mapping biopsy. If biopsy positive will proceed to Radical Neck dissection followed by Pembrolizumab 17 cycles 200mg IV, Q3W If biopsy negative will proceed to Pembrolizumab 17 cycles 200mg IV, Q3W"
9673194|NCT05025592||cTACE/DEB-TACE-HAIC+regorafenib±anti-PD1 antibody|patients will receive the combination treatment of cTACE/DEB-TACE plus HAIC and combined with regorafenib and anti-PD1 antibody or not. The anti-PD-1 antibody will be used depended on the contraindications or wishes of patients.
9673195|NCT05026411|Other|Orthodontic patients|Magnetic resonance images will be taken from 20 individuals with eating disorders before fixed orthodontic treatment, 12 months of orthodontic treatment and 6 months after orthodontic treatment finished
9673196|NCT05025839||C healthy|Healthy control group
9673197|NCT05025839||C pneum|Control group of patients who were hospitalised and diagnosed with pneumonia ( COVID-19 pneumonia excluded)
9673198|NCT05025839||Mild|Outpatients presenting to the hospital with COVID-19
9673199|NCT05025839||Moderate|In-patients with COVID-19 not requiring ICU admission
10173709|NCT03860649|Experimental|Dance|This group will undergo 24 Dance sessions inspired by Forró dance rhythm and Samba dance rhythm. Classes will be divided into four stages: Joint warm up and stretching on the chairs; strengthening, balance and rhythm exercises with the support of the barre; exercises inspired by the Samba and Forró dance (Brazilian ballroom dance) basic steps; and Final cool down. The intensity of the classes will be measured according to the beats per minute (BPMs) of the songs used in each moment and by the Borg Scale of Perceived Exertion.
9673200|NCT05025839||Severe|Patients with COVID-19 admitted to the ICU
9673201|NCT05025891|No Intervention|Arm 1: control|Patients continue consultations as usual in HDJA or at UMIT.
9673202|NCT05025891|Experimental|Arm 2: teleconsultation alone|Patients are directed to the tele-monitoring platform without specific accompaniment.
9673203|NCT05025891|Experimental|Arm 3: teleconsultation and mediation|Patients are referred to the tele-monitoring platform with specific support with mediation.
9694984|NCT04783168|Active Comparator|Arm II (usual care, Fitbit)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting. Patients also receive a Fitbit to monitor step count
9694985|NCT04783168|Experimental|Arm III (usual care, Fitbit, Fitbit app)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and walking in the postoperative setting. Patients also receive a Fitbit device, install and use the Fitbit app on a smartphone. Postoperative step goals are as follows: Postoperative day (POD) 1: 25% of baseline. Subsequent days will be increased by 10% until patient reaches baseline daily step number. Five automatic daily reminders (delivered by the Fitbit Inspire HR^TM device itself) to meet a minimum of 250 steps an hour. Postoperatively, patients will be invited to participate in a private group with a leaderboard that consists of step numbers of other participants in the study in an anonymous fashion.
9694986|NCT04783441|Active Comparator|Continuous glucose monitoring (CGM)|Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
9694987|NCT04783441|Placebo Comparator|Self monitoring of blood glucose (fingersticks)|The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.
9694988|NCT04783142|Other|High-fiber, low-protein diet|Participants will consume a high-fiber, low-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
9694989|NCT04783142|Other|Low-fiber, high-protein diet|Participants will consume a low-fiber, high-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
9694990|NCT04783454|Experimental|Intervention|"single (online) educational video on how the prevention program is designed and general advice on (how to adopt) a healthy lifestyle~12-week training program: 2 sessions of 60 minutes per week, with the focus of the first session on cardiovascular exercises, and the focus of the second session on mobility and strengthening exercises"
9694991|NCT04783454|No Intervention|control|no intervention (wait and see approach)
9673204|NCT05025917|Experimental|Shatavari|1000 mg per day shatavari root powder (2 x 500 mg opaque capsules; equivalent to 26,500 mg fresh weight shatavari). Ingested in the morning, daily for 6 weeks.
9673205|NCT05025917|Placebo Comparator|Placebo|1000 mg per day magnesium stearate powder (2 x 500 mg opaque capsules). Ingested in the morning, daily for 6 weeks.
9673206|NCT05025852||Metformin exposed in utero|Offspring of mothers who were exposed to metformin during pregnancy in the MiTy trial.
9673207|NCT05025852||Placebo exposed in utero|Offspring of mothers who were not exposed to metformin during pregnancy in the MiTy trial.
10173710|NCT03860649|Experimental|Pilates Training|"Classes composed of three phases: Warming up, main part and back to calm. Warming up will begin with pre-Pilates training exercises for 5 minutes (eg. breathing exercises, hip joint mobilization, shoulder girdle, etc.), the main part of the lesson will be the Pilates training drill sequence for the beginner level that will be conducted for 50 minutes in which all exercises will be performed on the floor.~The sequence of the eighteen exercises of the main part of the lesson is described in the table below. Back to Calm: will be carried out for 5 final minutes with standing exercises with the subject reclining on the wall to reconnect the subject with orthostatic posture.~In the each of the phases of the lesson will be shown to the subject the table of BORG with the objective of measuring the intensity of perceived exertion, using the Borg Scale of Perceived Exertion."
9673208|NCT05025748|Experimental|Health services research (ASQ brochure)|Patients receive ASQ brochure and complete questionnaires over 30 minutes at baseline, over 10 minutes pre-clinic visit, and over 30 minutes post-clinic visit.
9673209|NCT05026515||4 years and under|Children coming at dental appointment, aged 4 years and under
9673210|NCT05026515||5 to 6 years|Children coming at dental appointment, aged 5 to 6 years
9673211|NCT05026515||7 years and over|Children coming at dental appointment, aged 7 years and over
9673212|NCT05026892||moderate to severe|patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with moderate to severe or severe form of covid-19
9673213|NCT05026892||begining to moderate|Patients with known inflammatory rheumatism, auto-immune or auto-inflammatory diseases (as define in the inclusion criteria) with begnin to moderate or moderate form of covid-19
9673214|NCT05025644|Experimental|Preoperative Transesophageal Echocardiogram (TEE) PG under anesthesia <50mmHg (Group A)|"Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG under DBT stress test at 5, 10, 15 and 20 mcg/kg/min or until a PG ≥ 50mmHg is achieved, will be recorded.~Post-CPB (post-myectomy) echocardiographic parameters: PG at DBT peak dose (DBT-pd) will be recorded.~If LVOT PG post myectomy are >16 mmHg, the surgeon will be advised, for surgical management considerations."
9673215|NCT05025644|Experimental|Preoperative PG under anesthesia ≥ 50mmHg (Group B)|"Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG without DBT stress test will be recorded.~Post-CPB (post-myectomy) echocardiographic parameters: PG at 5, 10, 15, 20 mcg/kg/min DBT stress test or until the postoperative provocable PG is >16 mmHg will be recorded."
9673216|NCT05025527|Experimental|bpMRI|Man receive the bpMRI for Prostate cancer screening
9673217|NCT05025527|Active Comparator|PSA|Man receive the PSA blood test for Prostate cancer screening
9673218|NCT05025579|Experimental|Exercise group|Considering the protocol suggested in the literature and by examining exercise samples for geriatric individuals, an exercise protocol was created. The first week started with aerobic exercises with a total of 120 minutes, and the next week increased to 160 minutes . A 6-week exercise program was planned and applied 4 days a week in which the intensity was increased gradually. People 's heart rate, blood pressure and respiratory frequency exercise program implementation before and after was recorded in the evaluation form.
9673219|NCT05025202|Experimental|IET|Participants allocated to this arm performed 4 weeks of isometric wall squat exercise training, 3 times per week.
9673220|NCT05025202|Sham Comparator|Sham|Participants allocated to this arm performed 4 weeks of isometric wall squat training, but the training prescription was intentionally provided at an insufficient intensity to achieve any physiology stimulus.
9673221|NCT05025202|No Intervention|No intervention control|Participants allocated to this arm did not perform any exercise and were required to maintain usual daily habits.
9673222|NCT05025215|Experimental|Group A： Precise|The experimental group accepts improved precise aerosol inhalation nursing program，which was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc. This group is planned to enroll 100 patients.
9673223|NCT05025215|Experimental|Group B：Traditional|The control group accepts traditional aerosol inhalation nursing method. This group is planned to enroll 100 patients.
9673224|NCT05025254||PD patients|This is an observational study. The PD patient group will consist of participants who self-report that they have a diagnosis of Parkinson's disease
9673225|NCT05025254||Healthy controls|This is an observational study. The healthy control group will consist of participants who self-report that they do not have a diagnosis of Parkinson's disease
9673226|NCT05025189|Active Comparator|Table Grape|Subjects will consume 4 weeks of (two servings) of standardized Freeze-Dried Whole Table Grape Powder
9673227|NCT05025189|Placebo Comparator|Beige Diet|Subjects will consume 4 weeks of a beige diet (low in fiber and low in polyphenols)
9673228|NCT05025319||Taditional Grid|Patients imaged with traditional grid
9673229|NCT05025319||Virtual Grid|Patients imaged with virtual grid
9673230|NCT05025566||Psychotic disorders|
9673231|NCT05025566||Depressive disorders|
9673232|NCT05025566||Bipolar disorders|
9673233|NCT05025566||Anxiety disorders|
9673234|NCT05025566||Autism spectrum disorders|
9673235|NCT05025566||Eating disorders|
9673236|NCT05025566||Healthy volunteers|
9673237|NCT05025553|Other|Gut mobilization|Polyethylene Glycol (PEG) at the dose of 6.9 g/d once a day for 6 months.
9673238|NCT05025488|Experimental|CALR mutated|peptide-based vaccine in patients with myeloproliferative neoplasm (myelofibrosis and essential thrombocythemia) with CALR mutations
9673239|NCT05025358|Experimental|LP-118|"An accelerated titration for the first two dose cohorts (50mg and 100mg) followed by classic 3+3 design for the rest of dose cohorts (200mg, 300mg, 400mg and 500mg) will be used in this study."
10173711|NCT03860350|Active Comparator|Aged Garlic Extract|The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
10173712|NCT03860350|Placebo Comparator|Placebo|The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
10173713|NCT03860415|Experimental|Probiotic|Vivomixx
9673240|NCT05025501|Experimental|Intervention group|"Subjects in this group will receive the Famliy based Executive Function Training  program in aiming to reduce ADHD symptoms and improve the executive function."
9673241|NCT05025501|No Intervention|Waiting group|"Subjects in this group will not receive the Famliy based Executive Function Training  program during the study period."
9673242|NCT05025306|No Intervention|control group|only atraumatic extractions were done, honey was not applied
9673243|NCT05025306|Experimental|experimental group|ziziphus honey was applied into the sockets after tooth extractions in experimental group
9673244|NCT05025228||Paracetamol IV|Patients with femur fracture that received an initial analgesic treatment with paracetamol intravenously (IV).
10173714|NCT03860415|Placebo Comparator|Placebo|
10173715|NCT03860454||Lamin DCM (LMNA+)|Adults with known pathogenic lamin (LMNA+) gene mutation.
9673245|NCT05025228||Paracetamol OR|Patients with femur fracture that received an initial analgesic treatment with paracetamol orally (OR).
9673246|NCT05025176||Surgery requiring Invasive arterial pressure monitoring|Patients undergoing elective surgery that requires Invasive arterial pressure monitoring as standard of care.
9673247|NCT05025072|Experimental|Test IMP|Hydroxycarbamide dispersible tablets (20 x 50 mg)
9673248|NCT05025072|Active Comparator|Reference IMP|Hydroxycarbamide film-coated tablet (1000 mg)
9673249|NCT05025033|Experimental|PD-1 antibody combined with apatinib and chemotherapy|PD-1 antibody: 200mg intravenous drip every 3 weeks; Apatinib: 250mg/day; Chemotherapy: Irinotecan: 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel: 150mg/m2, intravenous drip once every 3 weeks.
9673250|NCT05025137|Experimental|Flexi-Bar group|Participants in the Flexi-Bar group performed a 60-minute Flexi-Bar exercise every week for 12 consecutive weeks.
9673251|NCT05025137|Experimental|Multi-Component exercise group|Participants in the Multi-Component exercise group performed a 60-minute Multi-Component exercise every week for 12 consecutive weeks.
9673252|NCT05025098|Active Comparator|Standard therapy|"This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined).~Standard treatment for AML patients is Azacitidine + Venetoclax.*~*Only if venetoclax is available to the study at the time-point of study start. If venetoclax is not available AML patients will receive Azacitidine alone similar to MDS patients.~Standard treatment for MDS is Azacitidine."
9673253|NCT05025098|Experimental|Precision therapy|This study is a randomization between treatment principles, not treatments, i.e., standard therapy vs precision therapy (tumor board determined). The precision therapy arm will receive standard therapy + tumor board decided precision therapy. The tumor board decided precision therapy can in principle be any therapy with marketing authorization in Norway.
9673254|NCT05024669|No Intervention|Control Group|where no desensitizer application was done,
9673255|NCT05024669|Experimental|Group GL|applied with Gluma dentin desensitizer
9673256|NCT05024669|Experimental|Group SF|applied with Shieldforce desensitizer
9673257|NCT05024669|Experimental|Group TC|applied with Telio CS desensitizer
9673258|NCT05024786||control group|
9673259|NCT05024786||CQI group|
10173716|NCT03860454||Wild types DCM (DCMwt)|Adults with heart muscle failure but normal (wild-type) LMNA gene (DCMwt).
10173717|NCT03860454||Healthy Volunteers (HV)|Matched healthy volunteers (HV).
10173718|NCT03860402||Pre-warmed drug|Pre-warmed (38°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
10173719|NCT03860402||Room temperature drug|Room temperature (20°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
10173720|NCT03860363||Treatment Group|Patients selected to participate.
10173721|NCT03860337|Experimental|Alginate then Control|This group will be given the alginate then the control sausages
10173722|NCT03860337|Experimental|Control then Alginate|This group will be given the control then alginate sausages
9673260|NCT05024682|Experimental|conventional pulsed radiofrequency|
9673261|NCT05024682|Experimental|pulse dosed pulsed radiofrequency|
9673262|NCT05024916|Experimental|Intervention|Participants will receive the dietary intervention. Participants will take 1 serving of blueberries/day.
9673263|NCT05024916|Active Comparator|Control|Participants will receive a placebo. Participants will take 1 serving of placebo/day.
9673264|NCT05024799|Experimental|F-P group|the combination of fentanyl and propofol
9673265|NCT05024799|Experimental|F-D group|the combination of fentanyl and dexmedetomidine
9673266|NCT05024799|Experimental|B-P group|the combination of butorphanol and propofol
9673267|NCT05024799|Experimental|B-D group|the combination of butorphanol and dexmedetomidine
9673268|NCT05024825|Experimental|Gabapentin|Patients in the gabapentin group will receive gabapentin preoperatively, one time dose of 10 mg/kg PO (maximum dose 600 mg) and will resume scheduled doses postoperatively of PO gabapentin, 300 mg PO every 8 hours, in addition to acetaminophen and ibuprofen for 7 days postoperative. Acetaminophen 15mg/kg PO (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; gabapentin, 10 mg/kg standing every 8 hours (22).
9673269|NCT05024825|Active Comparator|Hydrocodone|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
9673270|NCT05024851||Patients with Psychogenic pruritus|
9673271|NCT05024851||Patients with Neuropathic Pruritus|
9673272|NCT05024721|Experimental|HIP2101|Taking HIP2101+HPP2102 once daily for 2 weeks.
9673273|NCT05024721|Active Comparator|RLD2101|Taking RLD21012101+HPP2101 once daily for 2 weeks.
9673274|NCT05024955||Observational (interview, discussion)|Participants attend an interview over 45-60 minutes and/or a focus group over 1.5 to 2 hours.
9673275|NCT05024981|Active Comparator|Classic reeducation|
9673276|NCT05024981|Experimental|Classic reeducation + videographic feedback|
9673277|NCT05024734|Experimental|Epirubicin|"Patients in that PDOs show highest response to this drug in-vitro will be treated with Epirubicin.~If no significant drug selection can be performed in-vitro, Epirubicin will be the default for instillation."
9673278|NCT05024734|Experimental|Mitomycin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Mitomycin.
9673279|NCT05024734|Experimental|Gemcitabine|Patients in that PDOs show highest response to this drug in-vitro will be treated with Gemcitabine.
9673280|NCT05024734|Experimental|Docetaxel|Patients in that PDOs show highest response to this drug in-vitro will be treated with Docetaxel.
9673281|NCT05024695|Experimental|Implant Group|
9673282|NCT05024604||study group|women receiving mini pills as a method of contraception with symptoms not diagnosed with us
9673283|NCT05024604||Control group|women attending to office hysteroscopy unit and not taking hormonal therapy
9673284|NCT05024838||Spinal anesthesia|The investigators retrospectively collected the electronic medical record of patients receiving spinal anesthesia from July 1, 2018, to Dec 31, 2018. Patients less than 18 years old were excluded from this study.
9673285|NCT05024942||Severe aortic stenosis patients undergoing TAVR|Severe aortic stenosis patients undergoing TAVR will be stratified according to LUS evaluated pulmonary congestion before and after TAVR
9673286|NCT05024591||same as study population|Use of AI-based CADe/x by breast radiologists
9673287|NCT05024578|Sham Comparator|Sham|In the sham condition, participants will wear the EEG headband monitor (DREEM2, Dreem, Paris, France) for 1 week, but the sound stimulation feature will be deactivated.
9673288|NCT05024578|Experimental|Auditory Stimulation|In the active experimental condition, participants will complete 1 week of slow oscillation (SO) stimulation with the EEG headband monitor (DREEM2, Dreem, Paris, France) in the form of auditory stimuli (100ms pink noise pulses, i.e., below the waking threshold as established in prior work) sent on the ascending phase of the SO during N3 sleep.
9673289|NCT05024435|Experimental|Nasogastric Tube|
9673290|NCT05024435|Experimental|Lisacath|
9673291|NCT05024630|Experimental|RDN+PVI group|The experimental group received renal artery cryoablation and pulmonary vein cryoablation. Pulmonary vein cryoablation was first followed by renal artery cryoablation.
9673292|NCT05024630|Sham Comparator|PVI only group|The control group received pulmonary vein cryoablation alone. To ensure single blindness, the control group received femoral artery puncture and renal arteriography after cryoablation.
9673293|NCT05024461|Experimental|Patient with an indication for a COVID19 test|The persons included will be those who have an indication for a COVID 19 test and who present themselves at the Cayenne hospital and during the screening missions organised by the Red Cross and Médecin du Monde during the COVID 19 epidemic in the territory
9673294|NCT05024448|Active Comparator|Prednisone|Prednisone, 60mg/d, for 10 days
9673295|NCT05024448|Placebo Comparator|Placebo|
9673296|NCT05024500|Experimental|ADRSNet protocol|ARDSnet protocol is the current, standard of care for ARDS. Its used by setting PEEP and the fraction of inspired oxygen (FiO2) to achieve the oxygenation goal (SpO2 ≥ 93% - accepting the range of 90-96%)
9673297|NCT05024500|Experimental|Driving Pressure (DP)|setting PEEP after performing a modified alveolar recruitment maneuver followed by a decremental PEEP titration electing the level correspondent to the lowest driving pressure.
9673298|NCT05024500|Experimental|Electrical Impedance Tomography (EIT)|After performing a modified alveolar recruitment maneuver, the PEEP decremental titration guided by the EIT will be set at the level above the intersection of the curves representing relative alveolar overdistention and collapse.
9673299|NCT05024487|Experimental|Experimental group|The correlation between blood pressure level, dermal resistance level, and subjective symptoms caused by triggered AD below the level of the lesion will be performed in a group of SCI people.
9673300|NCT05024617||trigger finger stage 1-2-3|Volunteer patients between 35-65 years old diagnosed with Stage 1, Stage 2 and Stage 3 trigger finger based on the Froimson Classification were included in the study. Exclusion criteria include paediatric trigger finger, trigger thumb, concomitant de'Quervain tenosynovitis, carpal tunnel syndrome, or Dupuytren's contracture, neurological or rheumatological diseases, chronic pain syndromes, pregnancy and patients with treatment history of related finger/fingers
9673301|NCT05024877|Experimental|Hetrombopag treatment group|stanozolol 2mg tid + Hetrombopag (started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
9673302|NCT05025436|Experimental|Acupoint Laser Group|Each subject in the experimental group was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/- 10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, pause 2 After two weeks, the two groups crossed over and carried out 4 weeks of intervention.
9673303|NCT05025436|No Intervention|Control Group|Each subject in the control group was given the same main acupoints (5 acupoints) and constitution matching acupoints (1-2 acupoints) without energy acupoint care (therapeutic dose is 0 joules per acupoint), three times a week, after 4 weeks After a two-week suspension, the two groups crossed over for another four-week intervention.
9673304|NCT05024968|Experimental|Treatment (sintilimab)|The study drug is sintilimab. The first dose of study treatment should start on Day 1 of Cycle 1. For the rest of the treatment cycles, the study treatment can be administered 3 day before or 3 days after the scheduled day of administration. Treatment can be delayed for up to 1 week if the administration day is on a holiday or if the subject is otherwise unavailable.
9673305|NCT05024409|Experimental|Orthotic + Occupational Therapy|
9673306|NCT05024409|Active Comparator|Occupational Therapy alone|
9673307|NCT05024526|Experimental|edaravone dexborneol group|
9673308|NCT05024526|Active Comparator|edaravone group|
9673309|NCT05024370||Multiparas, planned cesarean section|Multiparas having a planned cesarean section at the departement of Obstetrics and Gynecology in Herning Hospital. Uncomplicated pregnancy that makes early discharge possible.
9673310|NCT05024565|Experimental|prolonged intravenous infusion of β-lactams Antibiotics|Administer according to the PK/PD optimized regimen with the goal of increasing T>MIC. (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
9673311|NCT05024565|No Intervention|short-term intravenous infusion of β-lactams Antibiotics|The daily allowable dose is calculated according to the creatinine clearance rate. The carbapenems, cephalosporins and β-lactamase inhibitor compound preparations are administered in accordance with the dosage and usage required by the instructions, and the injection is generally 30 minutes.
9673312|NCT05024422|Active Comparator|Administration of Cabergoline|one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days
9673313|NCT05024422|Active Comparator|Administration of Vitamin B6|200 mg X 3 per day for a week
9673314|NCT05024357|Experimental|Dasatinib for 1 year|After the allo-HSCT treatment, the patients in this group will continue to take dasatinib orally for 1 year.
9673315|NCT05024357|Experimental|Dasatinib for 6 months|After the allo-HSCT treatment, the patients in this group will receive dasatinib for 6 months.
10173723|NCT03860376||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
10173724|NCT03860324|No Intervention|Control-group|No peripheral nerve block
10173725|NCT03860324|Experimental|Single-shot erector spinae plane block|The patient is positioned in lateral decubitus. The anesthesiologist uses a linear high-frequency probe in a longitudinal direction laterally to the mid-sagittal plane at the level of L4 until the transverse process is identified and, more superficial, the erector spinae muscle. A 22G needle of 80mm is introduced in-plane craniocaudally towards the transverse process of L4 until its tip is in the plane deep to the erector spinae muscle. Single-shot block with 30ml of ropivacaine 0,5% + adrenaline 100mcg
9673316|NCT05025046||Ultrasound findings of thyroid nodules classified as type 3 and 4a of TIRADS|
9673317|NCT05024344|Active Comparator|ESP Group|One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-
9673318|NCT05024344|Sham Comparator|Sham Group|One 30mL syringe containing 30mL of preservative free normal saline
9673319|NCT05024331||Pediatric physicians|"Assigned Interventions~Prediction of the first date of recovery period with given data about chemotherapy of pediatric patients who diagnosed solid tumor at Samsung medical center during 2010-2018~Sees the result of the prediction algorithm.~Change or maintain their prediction values.~Participate in the usability questionnaires."
9673320|NCT05024318|Active Comparator|SABR plus nephrectomy|Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.
9673321|NCT05024318|Experimental|Pembrolizumab followed by SABR after cycle 1 plus nephrectomy|Pembrolizumab 200 mg (flat dose) will be administered as a 30 minute IV infusion every 21 days for 3 cycles. Patients will receive 1 cycle of pembolizumab prior to SABR followed by an additional 2 cycles of pembrolizumab (1 cycle is 21 days). Patients will undergo nephrectomy 9-12 weeks after commencement of treatment.
9673322|NCT05024175||CARv3-TEAM-E T cells|"Eligibility to participate on this study if enrolled on study 20-532 and received infusion of CARv3-TEAM-E T~The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol~Medical History/Physical Exam~Blood Test~Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.~Tumor biopsy.~Data Collection~Biobanking"
9673323|NCT05023915|Active Comparator|diammonium glycyrrhizinate enteric-coated capsule + high-dose dexamethasone|Diammonium glycyrrhizinate enteric-coated capsule orally at a dose of 150mg tid for 3 months, combining with dexamethasone (given orally at a dose of 40 mg qd for 4 days). Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
9673324|NCT05023915|Active Comparator|High-dose dexamethasone|Dexamethasone orally at a dose of 40 mg qd for 4 days. Patients who do not respond to the treatment may receive another cycle of high-dose dexamethasone therapy with an interval of 10 days.
9673325|NCT05024136|Active Comparator|Placebo|Subjects take 30 mins aromatherapy of Limon essential oil per time, a total of 3 times for the month.
9673326|NCT05024136|Experimental|Experimental|Subjects take 30 mins aromatherapy of vetiver essential oil per time, a total of 3 times for the month.
9673327|NCT05024123|Placebo Comparator|Placebo|
9673328|NCT05024123|Experimental|Experimental|
9673329|NCT05024110|Experimental|Group I|GI received high-intensity exercise training.
9673330|NCT05024110|Experimental|Group II|GII received moderate-intensity exercise training.
9673331|NCT05024071|Experimental|Swiss Ball|Swiss ball practice can create an unstable environment, promote the recovery of muscle function and develop joint stability. It can train the muscle groups in chest, abdomen, back, buttocks and legs, which play an important role in maintaining body balance and improving athletes' body.
9673332|NCT05024071|Experimental|Balance Plate|The balance board can exercise athletes' waist explosive force and body balance ability in an unstable state.
9673333|NCT05023941|Active Comparator|Medicine Group|Start orally take Acetazolamide 2 days before entering the hypoxic room.
9673334|NCT05023941|Active Comparator|RIPC Group|Start RIPC training twice daily, 6 days before entering the hypoxic room.
9673335|NCT05023941|Experimental|Rapid RIPC Group|Start RIPC training forth daily, 3 days before entering the hypoxic room.
9673336|NCT05023941|Experimental|Combined Group|Medicine + Rapid RIPC
9673337|NCT05023941|No Intervention|Control Group|Subjects do not receive specific interventions before entering the hypoxic room.
9673338|NCT05024266|Experimental|Tislelizumab + Albumin Paclitaxel + Carboplatin|Tislelizumab 200mg d1, Albumin Paclitaxel 260mg/m2 d1, Carboplatin AUC5 d1, Q3W
9673339|NCT05024201|Experimental|experimental group for effect of therapeutic touch|Therapeutic touch was applied to the experimental group for three days every other day.
9673340|NCT05024201|No Intervention|control group for effect of therapeutic touch|No application was applied to the control group. Only pretest and posttest were done.
9673341|NCT05024084|Active Comparator|Group Sevoflurane|The patients in this arm will be given Sevoflurane (2-3%) as volatile anesthetic throughout the duration of anesthesia.
9673342|NCT05024084|Active Comparator|Group Desflurane|The patients in this arm will be given Desflurane (7-8%) as volatile anesthetic throughout the duration of anesthesia.
9673343|NCT05023928|Experimental|Tumor antigen-sensitized DC vaccine|"Tumor antigen-sensitized vaccine is administrated, 1-week interval, totally 2 times.~2-week later, Neo-antigen DC vaccine is administrated, 2-week interval, totally 5 times."
9673344|NCT05024240|Experimental|Patient group|20 patients with cerebellum disorders, who suffer from stability disorders and with specific 3 Hz tremor
9673345|NCT05024240|Active Comparator|Control group|20 healthy age-matching probands without any neurological disorders and stability issues
9673346|NCT05024149|Experimental|Healthy group|Subjects in this group will not undergo acupuncture intervention. For participants in the healthy control group, the IRT examination of the measurement sites will last for 3 minutes, with one thermal image taken every 10s. In the Healthy group, there will be two visits, and the first visit will be considered as the screening stage (i.e., demographic data recording, medical history taking, physical examination report review and recording on the day of enrollment) and the second visit will be considered as the detection stage (i.e., the day of enrollment). At the second visit, the subjects received the Self-rating depression scale (SDS), HAMD, and then the infrared thermographic images to be acquired.
9673347|NCT05024149|Experimental|MDD electroacupuncture intervention group|
9673348|NCT05024149|Experimental|MDD waiting-list group|In this study, we used a waiting list control group. During the 4 weeks follow-up period, participants from the MDD waiting-list group had no contact with participants from the MDD EA intervention group and no access to the EA intervention. After the 4 weeks follow-up period, patients in the waiting list group received access to the EA intervention.
9673349|NCT05024019|Experimental|Study group|The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy.
9673350|NCT05024019|No Intervention|Control group|The control group received radiotherapy alone.
9673351|NCT05023954||A|A longitudinal observational study looking at the pregnancy journey of 200 women Bloods taken for sepsis biomarkers including a genomic sepsis-test throughout the pregnancy journey
9673352|NCT05023954||B|A consecutive collection of data from 100 pregnant women with suspected sepsis Bloods taken for Sepsis Biomarkers including a genomic sepsis-test throughout the sepsis episode
9673353|NCT05023889|Other|open label|single open arm label
9673354|NCT05023824|Experimental|alpha-blocker withdrawal|receives 5-ARI monotherapy
9673355|NCT05023824|Experimental|5-ARI withdrawal|receives alpha-blocker monotherapy
9673356|NCT05023824|Active Comparator|combination therapy|receives alpha-blocker and 5-ARI
9673357|NCT05023902|Active Comparator|Pilates|The Pilates Mat exercise group followed an eight-week exercise program. The exercise protocol of this study was designed by the researchers (Table I). According to previous reports, 6 to 8 weeks of Pilates training has positive effects on physical and psychological health (Akbas, Unver, 2021; Bavli & Koybasi, 2016; Pourvaghar, Bahram, Sharif & Sayyah, 2014; Rogers & Gibson, 2009). As the program advanced, 20-cm diameter mini soft balls, Pilates rings, 65 cm diameter soft gymnastic balls, and rubber bands were used in this order as materials in Pilates exercises. After an initial warm-up exercises at a slow pace for 10 minutes, Pilates exercises with and without equipment were performed for 40 minutes. The exercises ended with a 10- minute recovery and stretching exercises for relaxation of all muscle groups
9673358|NCT05023902|Experimental|NIA Dance|NIA includes nine basic movement forms, 13 principles, and 52 basic moves. The nine movement forms were derived from martial arts, dance arts, and the healing arts of the Alexander Technique, Feldenkrais Method, and Yoga (Rosas & Rosas, 2004). The 13 principles specify areas related to fitness, personal growth, and lifestyle. Centered on the joy of movement, they focus on, for example, being sensitive to personal rhythms, making the correct movement choices, and experiencing positive changes in daily life. The moves of NIA are used to engage all body areas, improve fitness, and facilitate self-healing.
9673359|NCT05023863|Active Comparator|Alpha Lipoic Acid Group (intervention group)|35 patients will receive radiation therapy with or without platinum-based chemotherapy in addition to alpha lipoic acid 600 mg tablets twice daily (throughout the radiotherapy period). .
9673360|NCT05023863|Placebo Comparator|Control Group|35 Patients will receive radiation therapy with or without platinum-based chemotherapy in addition to placebo tablets twice daily (throughout the radiotherapy period)
9673361|NCT05023746||Clinically diagnosed as non-small cell lung cancer samples|
9673362|NCT05023798||ATD Cohort 1|The first iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment.
9673363|NCT05023798||ATD Cohort 2|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673364|NCT05023798||ATD Cohort 3|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673365|NCT05023798||ATD Cohort 4|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673366|NCT05023798||ATD Cohort 5|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673367|NCT05023798||ATD Cohort 6|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
10173726|NCT03860324|Active Comparator|Single-shot fascia iliaca block|The patient is positioned in dorsal decubitus. The anesthesiologist uses a linear high-frequency probe in a transversal direction, below the crural arch so as to identify the femoral artery. Afterwards the probe is moved laterally to find the iliac muscle and its fascia. A 22G needle of 80mm is introduced in-plane latero-medially until its tip is below the fascia iliaca (between the muscle and its fascia). Single-shot block with 40ml of ropivacaine 0,2%.
9673368|NCT05023798||ATD Cohort 7|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673369|NCT05023798||ATD Cohort 8|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673370|NCT05023798||ATD Cohort 9|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673371|NCT05023798||ATD Cohort 10|The next iteration of the sensor will be tested and results compared to the gold-standard laboratory measuring equipment. The prototype will be tested on a cohort of 3-5 patients.
9673372|NCT05023590|Active Comparator|cryo ablation|cryo ablation of left atrium during mitral valve open chest intervention
9673373|NCT05023590|Active Comparator|radio frequency ablation|radio frequency ablation of left atrium during mitral valve open chest intervention
9673374|NCT05023538|No Intervention|Usual care|No intervention
9673375|NCT05023538|Experimental|Low-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-30min/training session, 3x/week, 6 months
9673376|NCT05023538|Experimental|High-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-50min/training session, 3x/week, 6 months
9673377|NCT05023538|Experimental|Low-volume high-intense exercise|exercise at 50-85%VO2peak; 20-30min/training session, 3x/week, 6 months
9673378|NCT05023564||Early onset dementia|Dementia patients with onset age lower than 65y/o
9673379|NCT05023564||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
9673380|NCT05023564||Oldest old dementia|Dementia patients with onset age older than 85y/o
9673381|NCT05023564||Cognitive normal control|Normal Aging with normal cognitive function
9673382|NCT05023382||Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily.
9673383|NCT05023499||With glutamine supplementation|perioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
9673384|NCT05023499||Without glutamine supplementation|no glutamine use
9673385|NCT05023616|Experimental|Real-time home CPR training|Online real-time home CPR(cardiopulmonary resuscitation) training will be provided to participants
9673386|NCT05023616|Active Comparator|Conventional CPR training|Conventional CPR training will be provided to participants
9673387|NCT05023694||Newborn reanimated video recordings|Newborns, requiring stabilization at birth in Delivery Room, prior authorization by verbal and written informed consent
9673388|NCT05023460|Active Comparator|Paresthesia-free (burst) ONS|"Implanted lead and impulse generator (IPG), paresthesia-free (burst) active stimulation.~Lead implanted subcutaneously over greater occipital nerves. Implanted IPG capable of providing paresthesia-free stimulation continuously."
9673389|NCT05023460|Placebo Comparator|Placebo|Implanted lead and IPG, deactivated.
9673390|NCT05023668||Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy|Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy
9673391|NCT05023473|Active Comparator|PENG block+ morhine|the participants will receive PENG block before being attached to morphine PCA
9673392|NCT05023473|Active Comparator|MORPHINE|The participants will be given morphine PCA without PENG block
9673393|NCT05023408|Experimental|Intralesional Bleomycin|Intralesional Bleomycin has been given to palmo plantar warts. Generic name: Bleomycin Dose: 1mg/1ml (0.1%) Frequency: every 2 weekly for 6 weeks.
9673394|NCT05023408|Experimental|Cryotherapy|Cryotherapy has been given to palmo plantar warts. Frequency: every 2 weekly for 6 weeks
9673395|NCT05023304|Experimental|Group A Dextenza|
9673396|NCT05023304|Active Comparator|Group B Topical Prednisolone|
9694992|NCT04783311|Experimental|Phase 1 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
9694993|NCT04783311|Experimental|Phase 1 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
9694994|NCT04783311|Experimental|Phase 2 - EuCorVac-19 Low dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
9694995|NCT04783311|Experimental|Phase 2 - EuCorVac-19 High dose group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
10173727|NCT03860298|Experimental|NaviFUS System|FUS treatment for 10 minutes
9694996|NCT04783311|Active Comparator|Phase 2 - Placebo comparator group|Healthy adults received two intramuscular doses (0.5mL per dose) with 3-week interval
9694997|NCT04783103|Active Comparator|Active adTMS|Subjects in the treatment arm receive 20 sessions of real adTMS . The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
9694998|NCT04783103|Sham Comparator|Sham adTMS|Subject in the control/Placebo/Sham arm receive 20 sessions of sham adTMS. The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
9694999|NCT04783038|Active Comparator|Distance Reiki|Subjects will be scheduled for once a week session of distance Reiki for 4 weeks.
9695000|NCT04783038|Sham Comparator|Sham Reiki|Subjects will be scheduled for once a week session of Sham distance Reiki for 4 weeks.
9695001|NCT04783038|No Intervention|Standard of Care|Subjects will not receive any Reiki treatment
9695002|NCT04783025|Experimental|Intervention Group (IG)|The participants in the IG will receive BGCTS, a blended training programme
10173728|NCT03860142||full-term child born|use of a new scale to rate the severity of food disorders on full-term child born
9673397|NCT05023421||Problematic media use of children with CP|The participants in the current study were parents of children with CP aged 4-18 years. They were recruited at the Hacettepe University Physical Therapy and Rehabilitation Faculty Cerebral Palsy and Pediatric Rehabilitation Unit and Special Education and Rehabilitation Centers. The inclusion criteria were having a child with CP aged 2-18 years without severe cognitive problems, being a primary caregiver.
9673398|NCT05023434||Awake Craniotomy|
9673399|NCT05023434||Healthy Volunteers|
9673400|NCT05023447|Experimental|BRIDGE Intervention (+Service as Usual)|The brief, intensive assessment and integrated formulation (BRIDGE) intervention is delivered over 3-6 months and has a three-fold focus: Firstly, an intensive (post-randomisation) assessment, taking up to two sessions, including BPD symptoms, co-presenting difficulties, neurodevelopmental profile, life events history and psychosocial functional impact. Secondly, up to 16 sessions of Cognitive Analytic Therapy (CAT). Thirdly, development of a shared formulation with a multi-agency group; further development of the shared formulation with the young person, using CAT principles (Reformulation, Recognition and Revision) and, where clinically applicable, their family and service-providers.
9673401|NCT05023447|Active Comparator|Service as Usual|For participants randomised to Service-As-Usual (SAU), a routine letter of their participation will be shared with their service provider(s), including the GP. SAU, likely to range from social services, mentalhealth services, forensic services to no intervention will be mapped and described for each participant. Treatment fidelity to SAU will therefore not be assessed, but the nature and intensity of SAU in different contexts will be described in detail through the qualitative process evaluation.
9673402|NCT05023577|Experimental|CL group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levoflaxacin 0.5 g qd for 14 days
9673403|NCT05023577|Experimental|LM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levoflaxacin 0.5 g bid for 14 days
9673404|NCT05023577|Active Comparator|CM group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
9673405|NCT05023356||Contact vital signs monitoring|Routine monitors with cables
9673406|NCT05023356||Non-contact vital signs monitoring|Camera
9673407|NCT05023291|Other|test group|All patients who give their consent for this study will participate in the test group and will therefore receive the injection with 18F-FDG and images (PET / CT) will be made of the resection piece.
9673408|NCT05023785|Experimental|Cardio-Oncology Rehabilitation (CORE)|Participants in the CORE group will have (1) 2 HIIT sessions (1 facility- and 1 home-based) and 1 home-based MICT session, (2) CV risk factor management, and (3) behavioural support for the first 6 months. The behavioural support will continue for CORE participants from months 7-24. Behavioural support includes professionally guided and peer-enhanced exercise behavioural support based on behaviour change stage theories. CORE participants will be provided a wrist-worn heart and physical activity monitor to use throughout the 24-month observation period. After the supervised 6 month exercise period, participants will be asked to maintain a PAI Score of ≥100 for the remainder of the study period via the PAI Health App.
9673409|NCT05023785|No Intervention|Standard of Care 1 (CON1)|Participants in the CON1 group will receive standard medical care only.
9673410|NCT05023785|Active Comparator|PAI Group (PAI)|Participants in the PAI group will be asked to download the same PAI Health application as CORE participants and be challenged to meet and maintain a weekly PAI Score ≥100 throughout the 24-month follow-up period.
9673411|NCT05023785|Active Comparator|Exercise Guidelines for Cancer Survivors (ExGL)|Participants in the ExGL group will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated weekly physical activity guidelines for cancer survivors (i.e. 90-150 minutes of moderate to vigorous-intensity physical activity).
9673412|NCT05023785|No Intervention|Standard of Care 2 (CON2)|Participants in the CON2 group will receive standard medical care only.
9673413|NCT05023278|Placebo Comparator|Placebo|Subjects in placebo arm will receive inactive placebo capsule daily for 7 consecutive days starting on day of primary arthroplasty surgery.
9673414|NCT05023278|Experimental|Venlafaxine|Subjects in venlafaxine arm will receive venlafaxine 37.5mg daily for 7 consecutive days starting on day of primary arthroplasty surgery.
10173729|NCT03860142||premature child born|use of a new scale to rate the severity of food disorders on premature child born
10173730|NCT03860012|Experimental|Folic Acid 800 mcg once weekly|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
9673415|NCT05023265|Experimental|SBRT for Medically Inoperable RCC|35-40 Gy in five fractions (7-8 Gy/day)
9673416|NCT05023772|Experimental|Experimental Treatment of Laser Interstitial Thermal Ablation Therapy and Stereotactic Radiosurgery|Patients will undergo laser interstitial thermal ablation and CT guided stereotactic radiosurgery via intensity-modulated radiation therapy on different dates within a one to fourteen day window. The order of treatment is at the treating physicians discretion.
10173731|NCT03860129|Other|ISO|Drug name: Isoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (0.5 Vol%)
9673417|NCT05022914||1|Patients affected by biochemical relapse after radical prostatectomy undergoing staging PSMA-PET/CT and baseline blood sample for miRNA panel assessment.
9673418|NCT05022888|Active Comparator|myofascial pain syndrome|Patients diagnosed with myofascial pain syndrome Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
9673419|NCT05022888|Active Comparator|Healthy volunteers|Healthy volunteers Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
9673420|NCT05023187|Experimental|Social and Cognitive Online Training Group (SCOT)|A group of participants randomly assigned to a social-cognitive online training through individual cognitive training sessions and group sessions to improve social functioning.
10173732|NCT03860129|Other|SEVO|Drug name: Sevoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (1.0 Vol%)
10173733|NCT03860129|Other|DES|Drug name: Desflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (3.0 Vol%)
10173734|NCT03859947||Patients with acute bronchiolitis|
10173735|NCT03860311|Experimental|Bladder Ultrasound|The bladder ultrasound group will undergo point-of-care ultrasound upon enrollment, and bladder ultrasound will be repeated every 30 minutes, unless the patient's bladder is full at time of initial scan.
10173736|NCT03860311|Active Comparator|Standard of Care|Bladder (Urethral) Catheter group. The standard of care group will undergo placement of a urethral bladder catheter to allow retrograde filling of the bladder.
9673421|NCT05023187|Active Comparator|Control Group (CON)|A group of participants randomly assigned to receive an active control intervention to compare performances with the experimental group.
9673422|NCT05023239|Sham Comparator|control group|patients will receive sham block by 10 ml of normal saline (5 mL in each side) as a control.
10173737|NCT03860116|Experimental|Intervention group|participants in this arm receive the APP-based case management service and standard-of-care followup service.
9673423|NCT05023239|Experimental|UG-SZM Group|The patients will be receive bilateral Ultrasound-Guided Suprazygomatic Maxillary (UG-SZM) Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine
9673424|NCT05022875|Experimental|Experimental app intervention|The complete Healthcare CEO app will be used for intervention in the experimental group.
10173738|NCT03860116|Active Comparator|control group|participants in the control arm receive standard-of-care followup service
10173739|NCT03860220|Active Comparator|NEWSTATIN TS|Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)
10173740|NCT03860220|Placebo Comparator|CADUET|Dual therapy (Amlodipine + Atorvastatin 5/10mg)
10173741|NCT03860207|Experimental|Hu3F8-BsAb|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
10173742|NCT03860194|Experimental|Supp group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Supp group were provided with Protison with High Protein 51(Original Flavor) containing supplements in addition to their regular daily meals to achieve 1.5 g protein/kg (BW)/day on the basis of this guideline."
9673425|NCT05022875|Sham Comparator|Control app intervention|"Participants in the control group will only install the CEO's Profile and Health Tracking interfaces of the Healthcare CEO app."
9673426|NCT05023213|Experimental|Warna-Warni Waktu intervention|Participants in this condition will be asked to view six, approximately five minute videos (each with a number of associated short, interactive reinforcer activities), at a pace of one video per day, for 6 days.
9673427|NCT05023213|No Intervention|Waitlist control condition|These participants will no be contacted during the intervention timeframe.
9673428|NCT05023200||Population|Adults (age ≥18 years) identified by their treating clinician as having lower limb cellulitis that requires intravenous or oral antibiotic treatment either from the hospital or another service based outside of the hospital, which will conduct ongoing follow-up regardless of location.
9673429|NCT05022953|Experimental|Digital Story Group|"Digital Story Group: One of the researchers gave the experimental group participants a 15-minute briefing on how to perform digital storytelling. She also told them not to talk to the control group participants about the content of the briefing. She created a Pixton account (https://edu.pixton.com/educators/) and a class named Isolation. She sent the link (https://join.pixton.com/x5xb6) to the experimental group participants. She asked them to click on the link and make stories out of their knowledge of isolation in four weeks."
9673430|NCT05022953|No Intervention|Control Group|Control group participants did not go through any training in isolation.
9673431|NCT05023018|Experimental|Patients with high-grade meningioma|30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma
9673432|NCT05022992|Experimental|Resistance Training Session|Resistance training. Heavy resistance training. 10 reps x 3 set of upper- and lower-body resistance exercises
9673433|NCT05022992|No Intervention|Control|Control activity. None-exercising. 30 min of rest
9673434|NCT05023226|Placebo Comparator|LPVS group|The general ventilator setting.
9673435|NCT05023226|Experimental|LPVS + RM group|Recruitment maneuver.
9673436|NCT05023122|Experimental|vitamin D3 + calcium|vitamin D3 (cholecalciferol) 800 IU QD and calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
9673437|NCT05023122|Active Comparator|calcium only|only calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
9673438|NCT05022966||Older people|
9673439|NCT05022940||TBI rehabilitation|All individuals with mild, moderate or severe TBI registered into rehabilitation.
9673440|NCT05022823|Active Comparator|Standard of Care|Group A (Control). Home decongestive exercise regimen + daytime use of a compression sleeve (12 hours per day)
9673441|NCT05022823|Experimental|DPRE + compression sleeve during exercise|Group B. Decongestive Progressive Resistance Exercise + compression sleeve use during exercise + daytime use of a compression sleeve (12 hours per day)
9673442|NCT05022823|Experimental|DPRE + AC garment during exercise|Group C. Decongestive Progressive Resistance Exercise + Adjustable Compression (AC) garment use during exercise + daytime use of a compression sleeve (12 hours per day).
9673443|NCT05022576|Experimental|PSMA PET/CT guided biopsy arm|Ga-68 PSMA PET/CT imaging is now routinely done in patients with prostate cancer with biochemical recurrence, response evaluation and even in patients with clinical suspicion of prostate cancer. In the present study, we aim to plan robotic arm-assisted Ga-68 PSMA guided transgluteal prostatic biopsies.
9673444|NCT05022446||Observational (survey)|Participants complete survey over 5-10 minutes.
9673445|NCT05022680|Experimental|Participants were used app to record their diet and steps every day|Experimental group was the mHealth with peer led to improved their physical activity during pregnancy. Participants received app to record and monitor their physical activity every days and using it until childbirth.
9673446|NCT05022680|No Intervention|non-mhealth|control group was the traditional prenatal care during pregnancy.
9673447|NCT05022498|No Intervention|Control 1|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
9673448|NCT05022498|No Intervention|Control 2|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
10173743|NCT03860194|No Intervention|Diet group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Diet group were instructed to consume ordinary high protein foods to achieve 1.5 g protein/kg body weight (BW)/day on the basis of this guideline, and suggested to equally distribute their meal time."
10173744|NCT03860025||Single dislocation.|Patients with a single postoperative hip dislocation without subsequent revision surgery.
9673449|NCT05022498|Experimental|Exercise 1|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
9673450|NCT05022498|Experimental|Exercise 2|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
9673451|NCT05022745|Experimental|ERAS group|Posterior lumbar interbody fusion Multimodal, multidisciplinary patient care.
9673452|NCT05022745|Active Comparator|Standard group|Posterior lumbar interbody fusion Standard treatment pre-, per-, and post-operative
9673453|NCT05022771|Experimental|Single Ascending Doses Cohort 1a|Subjects will receive either Dose level 1 of PMG1015 or Placebo
9673454|NCT05022771|Experimental|Single Ascending Doses Cohort 1b|Subjects will receive either Dose level 2 of PMG1015 or Placebo
9673455|NCT05022771|Experimental|Single Ascending Doses Cohort 1c|Subjects will receive either Dose level 3 of PMG1015 or Placebo
9673456|NCT05022771|Experimental|Single Ascending Doses Cohort 1d|Subjects will receive either Dose level 4 of PMG1015 or Placebo
10173745|NCT03860025||Recurrent dislocation.|Patients with two or more postoperative hip dislocations without subsequent revision surgery.
10173746|NCT03860025||Revision due to dislocation.|Patients with one or more postoperative hip dislocations with subsequent revision surgery due to recurrent instability.
9673457|NCT05022771|Experimental|Single Ascending Doses Cohort 1e|Subjects will receive either Dose level 5 of PMG1015 or Placebo
9673458|NCT05022771|Experimental|Single Ascending Doses Cohort 1f|Subjects will receive either Dose level 6 of PMG1015 or Placebo
9673459|NCT05022537|Experimental|Treatment (retrograde nephrostomy)|
9673460|NCT05022537|Active Comparator|Control Group ( antegrade nephrostomy)|
9673461|NCT05022732|Placebo Comparator|Control formula|Excipients and gum arabic in tablet
9673462|NCT05022732|Active Comparator|Experimental formula|Polyglucosamine L112 (750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients)
9673463|NCT05022433||Shukla|Shukla is a birth weight based formula to determine the insertional depth of the UVC
9673464|NCT05022433||UN-1|UN-1 is a body surface based formula to determine the insertional depth of the UVC
9673465|NCT05022420||Salivary gland biospy,|100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease.
9673466|NCT05022420||muscular biopsy,|muscular biospy use for the diagnosis of muscular auto-immune disease.
9673467|NCT05022420||neuro muscular biospy|neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease
9673468|NCT05022420||temporal arteries biospy|temporal arteries biospy uses for the diagnosis of giant cell arteritis
9673469|NCT05022628|Experimental|Therapy arm|donafenib
9673470|NCT05022706|Experimental|Adolescents living with HIV|"cART directly observed therapy (DOT) for participants at risk of or with a history of non-adherence~monthly home visits by trained health promoters~ongoing support in navigating the health system, including accompaniment to appointments and assistance enrolling in public health insurance~monthly peer support groups"
9673471|NCT05022797|Experimental|Glucarpidase, methotrexate, R-CHOP|Glucarpidase 2000Units per dose. IV. Bolus injection over 5 minutes. Administered 12 hours following after each HDMTX cycle, for a maximum of 3 cycles.
9673472|NCT05022407||Cohort 1 (SARS-CoV-2 uninfected)|Participants who test negative on the SARS-CoV-2 rapid test and are not considered at risk of COVID-19 or who have a negative RNA-PCR SARS-CoV-2 test result at baseline.
9673473|NCT05022407||Cohort 2 (SARS-CoV-2 infected)|Participants who test positive on RNA-PCR SARS-CoV-2.
9673474|NCT05022407||Cohort 3 (SARS-CoV-2 exposed)|Participants who have a positive SARS-CoV-2 rapid test result and are not considered to be at risk of active COVID-19 infection or have a negative RNA-PCR SARS-CoV-2 test.
9673475|NCT05022381|Other|Preoperative and Postoperative Pain Level|The preoperative pain level, hip function and quality of life of patients who underwent radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerve in chronic hip pain will be compared with the postoperative pain level, hip function and quality of life of these patients.
9673476|NCT05022368|Experimental|Oral Safety Device|"patients on which the device LabraGuard is used."
9673477|NCT05022394|Experimental|Treatment (sapanisertib, nivolumab)|Patients receive PO QD on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9673478|NCT05022290|Experimental|Single-syringe technique|Patients in this arm will receive adenosine in a single syringe, diluted with normal saline up to 20 ml. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
9695003|NCT04783025|Active Comparator|Control Group (CG)|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staff.
9695004|NCT04782986|Experimental|Pan-intestinal capsule endoscopy|PillCam Crohn's capsule protocol
9673479|NCT05022290|Active Comparator|Double-synring technique|Patients in this arm will receive adenosine using a double syringe, the first syringe contains only adenosine and the second syringe contains only normal saline 20 ml. Both syringes are connected to each other, and to the patient's IV portal with a stopcock. The administration must be done by two nurses one after another, adenosine syringe is injected first, then follow by normal saline. The dosage of adenosine is according to the recommendation of ACLS guidelines, which recommended 6 mg as the first dose and 12 mg as the subsequent dose if SVT can not be terminated by the first dose.
9673480|NCT05022277|Experimental|Phone-based intervention Plus SMS messages|
10173747|NCT03860025||Controls.|Matched patients without postoperative hip dislocation or revision of any reason.
10173748|NCT03859986|Experimental|ALX-101 Gel 5%|ALX-101 Gel 5% applied topically twice daily for 56 days
10173749|NCT03859986|Placebo Comparator|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle applied topically twice daily for 56 days
10173750|NCT03860090|Active Comparator|AXILLARY VEIN ACCESS|This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.
10173751|NCT03860090|Active Comparator|CEPHALIC VEIN ACCESS|This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.
10173752|NCT03859934|Active Comparator|Melatonin|10 mg melatonin each day 1 hour before bedtime for 3 months
9673481|NCT05022277|Experimental|SMS messages only|
9673482|NCT05022277|No Intervention|Control|
9673483|NCT05022303|Placebo Comparator|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
9673484|NCT05022303|Experimental|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
9673485|NCT05022043|Active Comparator|EOS|
9673486|NCT05022043|No Intervention|NO-EOS|
9673487|NCT05022030|Experimental|Arm A|mCapOX (capecitabine+oxaliplatin) plus cetuximab
9673488|NCT05022030|Active Comparator|Arm B|mFOLFOX6 (fluorouracil+leucovorin+oxaliplatin) plus cetuximab
9673489|NCT05022212|Active Comparator|LACTIN-V|"LACTIN-V contains a naturally occurring human vaginal strain of Lactobacillus (L.) crispatus CTV- 05. At a potency of 2 x 109 cfu/dose, it is preserved in powder formulation, and applied by a vaginal applicator.~Women will receive the study product for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
9673490|NCT05022212|Placebo Comparator|Placebo|"A matching placebo formulation without L. crispatus CTV-05 is supplied in an identical applicator containing just the powder formulation.~Women will receive the placebo for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
9673491|NCT05022316|No Intervention|Control Arm|Control clinics will not receive an intervention.
9673492|NCT05022316|Experimental|Intervention Arm|Intervention clinics will have the CDS tools turned on in their EHR.
9673493|NCT05021965|Experimental|group 1: have two weeks of at-home tooth bleaching|Participants will receive two weeks of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) for the maxillary anterior teeth.
10173753|NCT03859934|Placebo Comparator|Placebo|Placebo each day 1 hour before bedtime for 3 months
9673494|NCT05021965|Experimental|group 2 : have two sessions of in-office tooth bleaching|Participants will receive two sessions（with a 1- week interval ） of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
9673495|NCT05021965|Experimental|group 3 : one week of at-home and then have one session of in-office tooth bleaching|Participants will receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%) and then receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%)for the maxillary anterior teeth.
9695005|NCT04782986|Active Comparator|Conventional colonoscopy|Same-day colonoscopy under propofol sedation
10173754|NCT03859908|Experimental|Iodine-Povacrylex Alcohol|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
10173755|NCT03859908|Active Comparator|Chlorhexidine Alcohol|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
10173756|NCT03860077|Experimental|Very Low Nicotine Content Cigarettes|
10173757|NCT03860077|Active Comparator|Normal Nicotine Content Cigarettes|
10173758|NCT03859921|Experimental|Dydrogesterone group|Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.
10173759|NCT03859921|Placebo Comparator|Placebo group|Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.
10173760|NCT03859518||patients with Vitiligo|
10173761|NCT03859518||control|
10173762|NCT03859856||women with Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus
10173763|NCT03859856||women without Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control
10173764|NCT03859583|Experimental|Capsaicin|4 tsp of cayenne pepper in a 60g omelette
10173765|NCT03859583|Placebo Comparator|Control|60 g omelette
10173766|NCT03859830|Experimental|Artis Dialysis System|One midweek HDF session for a duration of 4 hours.
10173767|NCT03859830|Active Comparator|AK200 Ultra S|One midweek HDF session for a duration of 4 hours.
10173768|NCT03859570|Experimental|Pentoxifylline|Pentoxifylline and standard of care therapy
10173769|NCT03859570|Placebo Comparator|Placebo|Placebo and standard of care therapy
10173770|NCT03859531||CF patients planned to receive Orkambi|CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy
10173771|NCT03859687|Experimental|Intervention group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) plus a liquid oral vitamin A supplementation
10173772|NCT03859687|Experimental|Control group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) only, 'No vitamin A supplementation'
9673496|NCT05021965|Experimental|group 4 : one week of in-office and then have one session of at-home tooth bleaching|Participants will receive one session of in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) and a week later receive one week of at-home tooth bleaching with 10% Carbamide peroxide(Opalescence PF 10%)for the maxillary anterior teeth.
9673497|NCT05021887|Experimental|Test Product|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
9673498|NCT05021887|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK
9673499|NCT05021939|No Intervention|Control Group|No treatment will be given to the control group. Evaluation will be done at the at the baseline and 8th week.
9673500|NCT05021939|Experimental|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
9673501|NCT05021939|Experimental|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
9673502|NCT05022108|Experimental|Antihistamine test|The forearm was sensitized at four points (A, B, C and D). Point A: positive control sensitized with a drop of histamine at a concentration of 10 mg / Ml. Point B: histamine was applied and immediately after, the alpha bisabolol gel with a concentration of 0.5%. Point C: histamine and gel with 2.5% alpha-bisabolol were applied. Point D was sensitized with a drop of histamine and 5.0% alpha-bisabolol gel. The test reading at each point occurred 15 minutes after the procedure.
9673503|NCT05021952|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
9673504|NCT05021952|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
9673505|NCT05021874|Active Comparator|Physiotherapeutic procedures: magnetotherapy|Magnetotherapy is a pulsating, non-homogeneous magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) will be applied using an elliptical applicator with a beam width of approx. 5 cm. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
9673506|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-led therapy|Magneto-led therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and LED diodes with the wavelength of 860 nm were applied using an elliptic magnetic-light (IR) applicator with a diameter of 5 [cm] containing 47 infrared diodes. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
9673507|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-laser therapy|Magneto-laser therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and a low-energy laser with infrared wavelength of 808 [nm] (max. power 300 mW) was applied. The dose was set to increase from 3,0 J/cm2 to 5,0 J/cm2 and the total dose applied per each patient from this subgroup was 40 J/cm2. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
9673508|NCT05021874|Active Comparator|Physiotherapeutic procedures: manual therapy of soft tissues|Manual therapy of soft tissues will include: post-isometric relaxation of the masseter, cellular and tissue mobilization with Kibler fold, masseter trigger point therapy. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
9673509|NCT05022186|Experimental|Group receiving Cannabidiol|These patients will receive cannabidiol 5% without other medication for cognition and depression
9673510|NCT05022186|Experimental|Group receiving Homotaurine|These patients will receive Vivimind (homotaurine) without other medication for memory and depression
9673511|NCT05022186|No Intervention|Control group|These patients will not receive treatment
9673512|NCT05022160|Experimental|Group P|Patients in this group will receive bilateral pudendal nerve block after spinal anesthesia- before starting the surgery
9673513|NCT05022160|Placebo Comparator|Group C|Patients in this group will only receive spinal anesthesia before starting the surgery
9673514|NCT05022199|Experimental|Study Arm: SPY fluorescent angiography|
9673515|NCT05022199|No Intervention|Historic Control Arm: Urinary diversion without the use of SPY|This arm consists of 215 historic controls who have undergone urinary diversion at UVA from 2015-2020 without the use of SPY fluorescent angiography
9695006|NCT04783051|Active Comparator|IPTp-SP|The IPTp-SP group will be pregnant women who will receive the standard regimen recommended by the Malaria National Control Program (MNCP) at week 16, 28, 32 and 36 of their pregnancy
10173773|NCT03859882|Experimental|Caffeine|Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day
10173774|NCT03859882|Placebo Comparator|placebo|in 2 administration (08:00 and 14:00) per day
10173775|NCT03859843|Active Comparator|PRP|
10173776|NCT03859843|Active Comparator|Chemical peeling (Salycilic acid)|
10173777|NCT03859843|Active Comparator|Chemical peeling (Jessenr's solution)|
10173778|NCT03859596||MGB/OAGB|Consequent group of patients who underwent MGB/OAGB
10173779|NCT03859778||pharmacy students|
9673516|NCT05021757||Disrupt CAD III PAS Cohort|Patients in the CathPCI Registry who undergo a PCI procedure using a Shockwave C2 Coronary IVL catheter and meeting the eligibility criteria will be included in the PAS cohort. A minimum of 150 patients with 30-day follow-up will be included in the PAS cohort.
9673517|NCT05021627|Experimental|Cardiac autonomic nerve modification|
9673518|NCT05021627|Active Comparator|Pacemaker|
9673519|NCT05021822|Active Comparator|Block Group|
9673520|NCT05021822|No Intervention|Control Group|
9673521|NCT05021770|Experimental|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined with thiotepa, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 200mg will be used for phase II trial (RP2D).~Orelabrutinib: 150mg or 200mg orally daily. Thiotepa: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
9673522|NCT05021770|Experimental|Phase II|"Participants will receive orelabrutinib and thiotepa at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.~Orelabrutinib: RP2D (150 mg or 200 mg qd) Thiotepa:Sintilimab: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)."
9673523|NCT05021588|Experimental|Group A:dexamethasone|
9673524|NCT05021588|Experimental|Group B: prednisolone or methyl prednisolone according to D-dimer levels.|
9673525|NCT05021588|Experimental|Group C: prednisolone or methylprednisolone and anticoagulants according to the flexible protocol.|
9673526|NCT05021497|Experimental|Global Positional Re-education|Global Positional Re-education
9673527|NCT05021497|Active Comparator|Conventional Physical Therapy Program|Conventional therapy will consist of a combination of manual techniques
9673528|NCT05021406|Experimental|Carvedilol+ NUCs therapy|Patients randomized to Carvedilol combined with NUCs group during the previous 2-year treatment of RCT study; Patients showed the progression of esophageal varices in NUCs group during the 2-year treatment of RCT study. Based on nucleoside analogue (NUCs), carvedilol will be added to the patients. Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
9673529|NCT05021406|No Intervention|NUCs therapy|Continuing take single or combined nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
9673530|NCT05021484|Active Comparator|Felzartamab|9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
9673531|NCT05021484|Placebo Comparator|Placebo|9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
9975458|NCT02959944|Placebo Comparator|Placebo + Prednisone|"Placebo given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
9975459|NCT02959463|Experimental|Cohort 1 (hemithoracic radiation therapy, pembrolizumab)|Patients undergo hemithoracic radiation therapy. After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9673532|NCT05021666|Experimental|Group A1|PB-718 vs placebo
9673533|NCT05021666|Experimental|Group A2|PB-718 vs placebo
9673534|NCT05021666|Experimental|Group A3|PB-718 vs placebo
9673535|NCT05021666|Experimental|Group A4|PB-718 vs placebo
9673536|NCT05021666|Experimental|Group A5|PB-718 vs placebo
9673537|NCT05021666|Experimental|Group A6|PB-718 vs placebo
9673538|NCT05021666|Experimental|Group B1|PB-718 vs placebo
9673539|NCT05021666|Experimental|Group B2|PB-718 vs placebo
9673540|NCT05021666|Experimental|Group B3|PB-718 vs placebo
10173780|NCT03859635|Active Comparator|Ultrasound guided Liposomal Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
9673541|NCT05021666|Experimental|Group B4|PB-718 vs placebo
9673542|NCT05021796||Nurses|"Including criteria: (1) registered nurses, (2) nurses undergoing a training for asthma telecounseling, (3) age 21 or more.~Excluding criteria: (1) nurses with previous training for asthma counseling, (2) nurses who do not take care of patients with asthma, (3) Pregnant women"
9673543|NCT05021679|Experimental|AMP Implementation|
9673544|NCT05021692|Experimental|Intervention|Intervention group: Pregnant women with preeclampsia who receive a web-based support program based on the Health Promotion Model in addition to routine clinical care will form the intervention group.
9673545|NCT05021692|No Intervention|Control|Pregnant women who receive routine clinical care applied to pregnant women with preeclampsia will constitute the control group.
9673546|NCT05021575||2020|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2020.
9673547|NCT05021575||2019|Data on outpatient care, hospitalisation and cardiovascular mortality were collected for the year 2019.
9673548|NCT05021445|Experimental|plates based exercise|This will consists of 12 elderly participants who receive intervention protocol of Plates- based exercises program in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
9673549|NCT05021445|Active Comparator|conventional treatment|this will consists of 12 elderly participants who will receive intervention protocol of Conventional balance training exercises in which total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
9673550|NCT05021783||Patients|Patients with Axial SpondyloArthritis
9673551|NCT05021718|Experimental|Intervention group (IG)|A total of 35 patients in IG received different back and hip strengthening exercises five times a week for six weeks. They were also instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
9673552|NCT05021718|Active Comparator|Control group (CG)|The remaining 35 patients were allocated to CG. The patients in CG were treated with Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks, followed by hot moist compression for the next three weeks. Moreover, they were instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
9673553|NCT05021523|Experimental|HEAT group|Participants are doing passive and active heat exposures
9673554|NCT05021523|Sham Comparator|CON group|Participants are doing sham altitude exposures
9673555|NCT05021419|Active Comparator|Standard Arm|"Active Comparator: Standard Arm~Both the current the European society of cardiology guidelines and National Institute of Health and Care Excellence currently advise that chronic stable heart failure patients with severely impaired left ventricular systolic function should initially be optimized as follows:~Visit 1: ACEi/ARB and Low Betablocker commenced Visit 2: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 3: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 4: Switch ACEi/ARB to Entresto 100mg Visit 5: Modify Entresto dose to 200mg Visit 6: MRA Added Visit 7: MRA up-titrated Visit 8: SGLT2i started"
10173781|NCT03859635|Active Comparator|Ultrasound guided Standard Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
10173782|NCT03859635|Active Comparator|Surgeon Infiltration|At the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
10173783|NCT03859648|Experimental|Bone Conduction Implant|All subjects will be implanted with the bone conduction implant.
9673556|NCT05021419|Experimental|Streamlined protocol arm|"Patients are optimized according to the accelerated protocol adapted from and based on the principles proposed by Prof McMurray and Prof Packer (Circulation 2021;143:875-877)~Visit 1: Low Dose Beta Blocker started, SGLT2i started + Entresto 100 mg bd started~Visit 2: MRA Added if renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 3: MRA up-titrated if BP and renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)~Visit 4+: Betablocker increased if BP and pulse rate permit. Further visits may be required to facilitate a gentle up-titration of betablockers."
9673557|NCT05021380||Group|50 generally healthy children diagnosed with dental pain as symptomatic irreversible pulpitis (SIP) or symptomatic apical periodontitis (SAP) aged from 6 to 12 years old will be included to the GROUP.
9673558|NCT05021731|Active Comparator|3-month Isoniazid plus Rifampicin|Daily isoniazid 300 mg plus rifampicin 600 mg for three months
10173784|NCT03859479|Experimental|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
10173785|NCT03859479|Active Comparator|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
10173786|NCT03859713|Experimental|PT followed by Switching to CBT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will switch to 8 weekly sessions of cognitive behavioral therapy (CBT) as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
10173787|NCT03859713|Experimental|PT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will receive 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
10173788|NCT03859713|Experimental|CBT followed by Switching to PT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
10173789|NCT03859713|Experimental|CBT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
10173790|NCT03859726||Compliance group|6hLC≥10% NIRS Sublingual microcirculation
10173791|NCT03859726||Non compliance group|6hLC<10%
10173792|NCT03859440|Experimental|DSiHy (test lens)|
9673559|NCT05021731|Experimental|3-month Isoniazid plus Rifapentine|Weekly isoniazid 900 mg plus rifapentine 900 mg for 12 weeks
9673560|NCT05021731|Experimental|4-month Rifampicin|Daily rifampicin 600 mg for four months
9673561|NCT05021549|Active Comparator|nasal prong.|the apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong.
9673562|NCT05021549|No Intervention|conventional|the conventional preoxygenation group (30 patients)
9673563|NCT05021354|Experimental|Lateral epicondylalgia|It is established a plan of treatment base on the evidence for dry needling, stretching and eccentric exercise in the patient with lateral epicondylalgia. This is done in two sessions, one session every 10 days and with a duration of about 45 minutes.
9673564|NCT05021367|Experimental|TQB3823 tablets|Subjects receive TQB3823 in the first cycle for a total of 28 days , a single dose on Day 1. Day 2 to Day 7 are the elution period, and the continuous doses are from Day 8 to Day 21. From the second cycle, continuous treatment for 28 days is as a treatment cycle.
9673565|NCT05021094|Experimental|POI patients who taking Kuntai capsule|Patients in this group will take Kuntai capsule orally, 4 capsules each time, 3 times a day, and take the medicine for 3 courses.
9673566|NCT05021094|Active Comparator|POI patients who accepting hormone therapy|The estrogen and progesterone sequential regimen was adopted. The drug was estradiol tablets/estradiol didroxyprogesterone tablets (Femoston). Red tablets (estradiol, 2mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and 3 courses of treatment were taken.
9673567|NCT05021094|Experimental|POI patients who taking Kuntai capsule combined with hormone therapy|Kuntai capsule was taken at the same dose as Kuntai group on the basis of hormone therapy for 3 courses.
9673568|NCT05021094|Experimental|Subclinical POI patients who taking Kuntai capsule|Subclinical POI patients in this group which with Kuntai capsule intervention. This group is a self-controlled experiment before and after treatment
9673569|NCT05021016|Experimental|"Group 1: Vaccine"|150 volunteers who will be vaccinated with the EpiVacCorona vaccine with two doses spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9673570|NCT05021211||Low Egg Consumers|Participants who consume fewer than 1 whole egg per week
9673571|NCT05021211||Moderate Egg Consumers|Participants who consume 5-9 whole eggs per week
9673572|NCT05021211||High Egg Consumers|Participants who consumes great than or equal to 14 whole eggs per week
9673573|NCT05020925|Experimental|SHR-1701 plus Famitinib|SHR-1701+Famitinib for R/M NPC failure after platinum-based chemotherapy and anti PD-1/PD-L1 antibody therapy
9673574|NCT05021263|Experimental|Magnesium Group|The magnesium group (Mg) will receive a bolus of 50 mg/kg of IV magnesium prior to incision and an infusion of 15 mg/kg/hr, with no preoperative oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
9673575|NCT05021263|Active Comparator|Pregabalin Group|The pregabalin group (Pb) will receive preoperative pregabalin and no IV magnesium bolus and infusion. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
9673576|NCT05021263|Placebo Comparator|Control Group|The control group (Ct) will receive saline solution and no IV magnesium or oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
9673577|NCT05021289|Experimental|Guided İmagery|• participants were given one session of guided imagery.
9673578|NCT05021289|No Intervention|control group|No intervention was applied on the control group patients.
9673579|NCT05021120|Experimental|Intervention/treatment|Experimental
9673580|NCT05021159||Methotrexate Group|20 acute lymphocytic leukemia patients receiving MTX treatment (3- 5 mg/ cm2)
9673581|NCT05021159||Healthy control group|20 healthy pediatric subjects not receiving any treatment
9673582|NCT05021302|Placebo Comparator|Kegel exercises group|20 women in this group
9673583|NCT05021302|Experimental|Electromagnetic stimulation group|20 women in this group
9695007|NCT04783051|Experimental|ISTp-US-Py|The ISTp-US-Py group will comprise pregnant women who will be screened monthly from the beginning of the 2nd trimester with ultra-sensitive -RDT and who will be treated with Pyramax® if the test is positive
9695008|NCT04783116|Experimental|Plant stanols (3g/day)|Consumption of plant stanol chews
9695009|NCT04783116|Placebo Comparator|Control|Consumption of placebo chews (without plant stanols)
9975460|NCT02959463|Experimental|Cohort 2 (palliative radiation therapy, pembrolizumab)|Patients undergo palliative radiation therapy over 1-3 weeks to only the region of palliation (a region that does not include the entire side of the chest or thorax). After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
10173793|NCT03859440|Active Comparator|Silicone hydrogel soft contact lens CE-marked for daily use|
10173794|NCT03859492||Intermediate or high-risk breast cancer subjects|Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)
9695010|NCT04782752|Experimental|Experimental: Radiation|"Patients will be differentiated into 4 groups:~Patients with end-stage interstitial lung disease (ILD) and suspected stage I (up to 4 cm) primary lung cancer~Patients with end-stage lung disease other than ILD (e.g. emphysema/COPD, cystic fibrosis and pulmonary hypertension) and suspected stage I (up to 4 cm) primary lung cancer~Patients with multifocal primary lung cancer (e.g. multifocal adenocarcinoma) in the absence of nodal metastasis and distant metastasis.~Patients with isolated pulmonary metastasis in the absence of other sites of malignancy (primary and metastatic).~For this study, different doses will be used for each different group depending on their tumour size. The first 3 patients will start with a dose of 4 Gy, for the ILD group, or 8 Gy, for the non ILD group. The doses are then increased incrementally until the dose limiting toxicity is reached."
9695011|NCT04782622||Apatinib+Camrelizumab|treated with apatinib+camrelizumab
9695012|NCT04782960|Active Comparator|20 patients receive Subconjunctival bupivacaine of the end of the surgery|20 patients receive Subconjunctival bupivacaine in the end of operation and monitoring postoperative pain score
9673584|NCT05021276|Experimental|ruxolitinib+basiliximab|Patients with grade 3-4 steroid-refractory aGVHD receive combined therapy of basiliximab and ruxolitinib.
9673585|NCT05021172|Experimental|Arm I (Passport to Health booklet, ePrognosis)|Participants receive Passport to Health booklet and complete ePrognosis before scheduled primary care visit.
9673586|NCT05021172|Active Comparator|Arm II (usual care)|Participants receive usual care before scheduled primary care visit.
9673587|NCT05021250|Experimental|Lipiodol marking|HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH.
9673588|NCT05021341|Active Comparator|Berberine|500 mg of Berberine
9673589|NCT05021341|Active Comparator|Dihydroberberine 200|200 mg of Dihydroberberine
9673590|NCT05021341|Active Comparator|Dihydroberberine 100|100 mg of Dihydroberberine
9673591|NCT05021341|Placebo Comparator|Placebo|Maltodextrin
9673592|NCT05021068||COPD Patients|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
9673593|NCT05021068||Control Group|"The respiratory functions of the participants will be measured in accordance with the ATS-ERS criteria. After measurement; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), inspiratory capacity (IC), vital capacity (VC) parameters will be recorded.~Spinal structure and mobility will be evaluated with the Spinal Mouse device in the sagittal and frontal planes in standing and sitting positions. For the sagittal plane, the measurements were first in the neutral, then in the maximum flexion and extension positions, for the frontal plane; neutral, right and left lateral flexions will be performed.~Patients will be asked to mark the level of activity that causes dyspnea on the Medical Council Research Scale (MMRC) Dyspnea Score."
9673594|NCT05021315|Experimental|Iodine group|50 women who received preoperative vaginal cleansing with 10% povidone iodine.
9673595|NCT05021315|No Intervention|Control group|50 women who did not receive preoperative vaginal cleansing even with tap water.
9673596|NCT05020964|Experimental|Experimental Arm|Trastuzumab and Pyrotinib
9673597|NCT05021042||Acute mastitis (MA)|Lactating women with confirmed acute mastitis
9673598|NCT05021042||Subacute mastitis (SAM)|Lactating women with confirmed subacute mastitis
9673599|NCT05021042||Control (CT)|Lactating women with the absence of acute or subacute mastitis symptomatology.
9673600|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors > 5 cm)|Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
9673601|NCT05020860|Active Comparator|Triple Negative Breast Cancer (for tumors < 5 cm)|Paclitaxel IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
9673602|NCT05020860|Active Comparator|HER2-Positive Breast Cancer|Paclitaxel IV plus Trastuzumab IV plus Pertuzumab IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV administered (4 cycles total)
9673603|NCT05020860|Active Comparator|Hormone Receptor Positive Breast Cancer|Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)
9673604|NCT05020886||Healthy|
9673605|NCT05020886||Stroke|
9673606|NCT05020561|Experimental|Arm 1 - Group and Individual|Participants in this experimental Arm 1 will receive the 3 group sessions followed by 4 to 5 individual coaching sessions via phone calls that last 60 minutes each.
9673607|NCT05020561|Experimental|Arm 2 - Group only|Arm 2 will receive only the first 3 Life coach sessions (group session).
9975461|NCT02959021|Active Comparator|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
9673608|NCT05020561|No Intervention|Arm 3 - Routine care|Arm 3 will receive routine care by the Breast clinic team for the entire course of the study.
9673609|NCT05020821|Active Comparator|Single-shot interscalene block with intravenous dexmedetomidine|participants receiving single-shot interscalene block with intravenous dexmedetomidine
9673610|NCT05020821|Experimental|Continuous interscalene brachial plexus block|participants receiving continuous interscalene brachial plexus block
9975462|NCT02959021|Experimental|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
9975463|NCT02903823|Experimental|Baclofen injection at designated spinal level|Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
10173795|NCT03859804|Experimental|Group 1|In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
9673611|NCT05020704|Experimental|empagliflozin|empagliflozin 10mg once daily
9673612|NCT05020704|Placebo Comparator|Placebo|matched placebo
9673613|NCT05020808|Sham Comparator|Nonessential amino acid formulation (NEAA)|"Novel non-essential amino acid blend dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.~Product Number: NEAA56812"
9673614|NCT05020808|Active Comparator|Plant Protein Isolate (PPI)|"Plant protein isolate (Fava bean) dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.~Product Number: FP2011273"
9673615|NCT05020548|Active Comparator|pressure 10|mask ventilation with peak inspiratory pressure of 10 cmH2O
9673616|NCT05020548|Active Comparator|pressure 15|mask ventilation with peak inspiratory pressure of 15 cmH2O
9673617|NCT05020548|Active Comparator|pressure 20|mask ventilation with peak inspiratory pressure of 20 cmH2O
9673618|NCT05020626||Controls|
9673619|NCT05020626||Mild cognitive impairment|
9673620|NCT05020626||AD dementia|
9673621|NCT05020483|Experimental|FEIBA Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive activated prothrombin complex concentrate (aPCC) FEIBA to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
9673622|NCT05020483|Placebo Comparator|Placebo Group|Pediatric patients ≤15 kg of weight, undergoing cardiac surgery with cardiopulmonary bypass will receive a placebo to be incorporated into standard treatment of post-bypass coagulopathic bleeding.
9673623|NCT05020782|Experimental|Intervention Arm|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
9673624|NCT05020613|Other|Early group|Patients whose catheters are removed within the first 48 hours after surgery will form the early group.
9673625|NCT05020613|Other|Late group|Patients whose catheters are removed after the first 48 hours of surgery will form the early group.
9673626|NCT05020600||Patients with fibromyalgia|Patients diagnosed with fibromyalgia according to American College of Rheumatology 2016 criteria
9673627|NCT05020522|Other|MRI scan|Mp-MRI, LI-MRI, plasma DNA methylation signature (optional)
9673628|NCT05020834|Experimental|Functional Electrical Stimulation Group|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
9673629|NCT05020834|Experimental|TheraTogs Group|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
9673630|NCT05020639|Experimental|TQB3820 tablets|TQB3820 tablets are administrated orally on Days 1-28 of each 28-day treatment cycle. Dose escalation of TQB3820 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data.
9673631|NCT05020730|Experimental|PTM-001 400 mg daily for 12 weeks|
9673632|NCT05020730|Placebo Comparator|Placebo daily for 12 weeks|
9673633|NCT05020366|Experimental|PrO-PEAR|This group will receive the optimized PrO-PEAR intervention (in addition to usual care).
9673634|NCT05020366|Active Comparator|Enhanced Usual Care|This group will serve as the control group and only receive a report of their child's performance and adherence to World Health Organization recommendations based on baseline data.
9673635|NCT05020418|Experimental|Cardiac Device Cohort|This study is open to any adult VA patient with data about a cardiac device procedure performed in the electrophysiology laboratory entered into the national VA EHR. During FY 20-FY 24, we anticipate that this will include approximately 9,000 patients per year, or a total of 50,000 patients. In addition, cases that were previously accessed and used to develop the infection monitoring system, and the quality metric monitoring system, may also be included. This includes all patients entered in the VA Clinical Assessment Reporting and Tracking - Electrophysiology Cohort (CART-EP) database during the period from 2006-2016, and all VA patients who received a cardiac device procedure during the period from 2010-2019. This includes another approximately 50,000 patients, for a total of 100,000 patients.
9673636|NCT05020431|Experimental|One arm|One arm nonrandomized clinical trial
9673637|NCT05020379|Sham Comparator|Group N|"The patients in Group N will not receive any intervention. Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol. The pain intensity will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS are the simple and most commonly used scales.11 The numerical scale is most commonly 0 to 10, with 0 being no pain and 10 being the worst pain imaginable."
9673638|NCT05020379|Experimental|Group ESPB|The patients in the group ESPB will be placed in sitting pozition. A convex probe ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS)
9673639|NCT05020275||Blood samples|Blood samples for further assays
9673640|NCT05020262||Test Group|Using PI/PC reconstruct raw data
9673641|NCT05020262||Control Group|Using Idose4/Cardiac Image reconstruct raw data
9673642|NCT05020223|Experimental|MTA pulpotomy|Usuing MTA as capping material for cervical pulpotomy as a treatment option for deep carious primary teeth with signs and symptoms of reversible pulpitis in presence of pulp exposure
9673643|NCT05020223|Experimental|MTA direct pulp capping|Using MTA as capping material in case of trearment of deep carious primary teeth with signs and symptoms of reversible pulpitis with presence of pulp exposure
9673644|NCT05020223|Experimental|MTA indirect pulp capping|Using MTA as indirect capping material for treatment of deep carious primary teeth with signs and symptoms of reversible pulpitis
9673645|NCT05020041|Experimental|Intervention|"The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers, or manipulation of objects to maintain COVID-19 sanitary and safety protocols.~The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers."
9673646|NCT05020041|No Intervention|Control|The schools participating in the control group will receive an online educational talk aimed at promoting healthy habits and the benefits of physical activity inside and outside the school environment.
9673647|NCT05020028|Experimental|CBD Group|The first cohort will receive 50mg cannabidiol Orally Disintegrating Tablets (CBD ODT), three times daily.
9673648|NCT05020028|Placebo Comparator|Placebo Group|Cohort 2 will receive the same instructions, but with the placebo Orally Disintegrating Tablets (ODT) instead.
9673649|NCT05020067|Experimental|SPLS-IMRT|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%
9673650|NCT05020067|No Intervention|C-IMRT|The entire parotid gland was delineated as an OAR, and V36 (the percentage volume receiving 36 Gy or more) in the entire parotid gland was constrained to be less than 40%
9673651|NCT05020340|Experimental|Intervention|External cephalic version
9673652|NCT05020340|No Intervention|Control|ECV will not be performed.
9673653|NCT05020184|Active Comparator|Cimetidine|Cimetidine 800mg orally twice daily
9673654|NCT05020184|Placebo Comparator|Placebo|Placebo capsule orally twice daily
9673655|NCT05020171|Experimental|intervention group|group focus on lower limb strength training with a seated robotic device
9673656|NCT05020171|Active Comparator|control group|physiotherapy group as usual, not focused on strength training
9673657|NCT05020093|Experimental|Injection molding|cavity design, packing technique, bonding technique
9673658|NCT05020093|Active Comparator|Incremental packing|cavity design, packing technique, bonding technique
9673659|NCT05019898|Experimental|Diagnostic Test: pupillometry|
9673660|NCT05019911||Patients with COPD alone|In the cross-sectional part, the group of patients with COPD alone will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
9673661|NCT05019911||Patients with COPD combined with sleep apnea hypopnea syndrome|In the cross-sectional part, the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
9673662|NCT05020210||Sivelestat Sodium group|Patients treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
9673663|NCT05020210||Conventional treatment group|Patients not treated with Sivelestat Sodium/Normal Saline after the diagnosis of ARDS
9673664|NCT05020119|Experimental|Low dose of neoantigen-based cell therapy (N=3+3)|(1±20%) × 109cells/200 mL every 14 days for 10 doses
9673665|NCT05020119|Experimental|Medium dose of neoantigen-based cell therapy (N=3+3)|(3±20%) × 109cells/200 mL every 14 days for 10 doses
9673666|NCT05020119|Experimental|High dose of neoantigen-based cell therapy (N=3+3)|(9±20%) ×109cells/400 mL every 14 days for 10 doses
9673667|NCT05019937|Experimental|Multifaceted implementation strategy|Schools randomized to this arm will be exposed to a multifaceted implementation strategy, which contains five implementation components
9673668|NCT05019937|Active Comparator|Single implementation strategy|Schools randomized to this arm will be exposed to a single implementation strategy, which contains one implementation component
9673669|NCT05020288|Experimental|Orelabrutinib|Orelabrutinib 50mg po qd
9673670|NCT05020301|Experimental|Control group|Participants who have never practiced mindfulness
9673671|NCT05020301|Experimental|Beginner Practitioner|Participants with less than two years of mindfulness practice
9673672|NCT05020301|Experimental|Advanced Practitioner|Participants with more than two years of mindfulness practice
9673673|NCT05020002||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
9673674|NCT05020002||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
9673675|NCT05020002||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
9673676|NCT05019859|Active Comparator|Intervention|low carb diet
9673677|NCT05019859|No Intervention|Control|traditional low fat diet
9673678|NCT05020106||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
9673679|NCT05020106||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
9673680|NCT05020106||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
10173796|NCT03859804|Active Comparator|Group 2|In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
10173797|NCT03859505|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
10173798|NCT03859505|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) active.
9673681|NCT05020106||Cognitively normal controls|Individuals with normal cognitive function
9673682|NCT05019768|Active Comparator|sCXL|Standard protocol of Dresden Riboflavin-VEPTGS solution applied every 2 mins during UV UVA fluence of 3mW/cm2 UVA Irradiation time 30 minutes
9673683|NCT05019768|Experimental|aCFXL|"Accelerated custom fast CXL protocol. The protocol has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin con-sumption rate and the corneal thickness at its thinnest point.~Riboflavin-VEPTGS solution: Epithelial lavage before UV UVA fluence of 1.8 ±0.9 mW/cm2 UVA Irradiation time 10 ± 1.5 minutes"
9673684|NCT05019755|Experimental|A(First period) to B(Second period) order|"A: Oral Administration of IN-A002(IN-115314) in fasting status~B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~There will be a wash out period of 7days between period"
9673685|NCT05019755|Experimental|B(First period) to A(Second period) order|"B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet~A: Oral Administration of IN-A002(IN-115314) in fasting status~There will be a wash out period of 7days between period"
9673686|NCT05020080|Experimental|ECR MEP conditioning - Stroke|MEP operant conditioning of ECR in stroke survivors
9673687|NCT05020054|Active Comparator|Intervention Tecartherapy|"The procedures will be performed with Tecartherapy equipment, with the equipment Nèartek®- IBRAMED- Industria Brasileira de Equipamentos Eletromédicos.~The treatment will be carried out once a week, totaling 10 sessions, by two dermato-functional physiotherapists. During the sessions, all volunteers will be positioned in dorsal decubitus and the applicator positioned in the abdominal region, the therapy will be dynamic and simultaneously the professional must assess the local temperature.~The parameters used will be:~Area of 300cm², 1MHz, Capacitive Mode: 60mm Disc: Default 100W Time of 10 minutes, keeping temperature at 42°C Resistive Mode: 60mm Disc: Default 110W Time of 10 minutes, keeping temperature at 42ºC. The total treatment time is 20 minutes."
9673688|NCT05020054|Placebo Comparator|Placebo Tecartherapy|the therapy took place with the equipment turned off
9673689|NCT05019794|Experimental|Gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) with FGFR2 amplification|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
9673690|NCT05019794|Experimental|GC or GEJ with FGFR1/FGFR2/FGFR3 fusions/rearrangements and activating mutations|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
9673691|NCT05019794|Experimental|Solid tumors[Exclude GC,GEJ,CHOL,UC]with FGFR1/FGFR2/FGFR3 fusions/rearrangements and mutations|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off (every 4 weeks as one treatment cycle).
9673692|NCT05019820|Active Comparator|Sarcopenia and osteoarthritis group|Women aged 45-65 years diagnosed with sarcopenia and knee osteoarthritis
9673693|NCT05019820|Other|Without osteoarthritis and sarcopenia group|Women aged 45-65 years without a diagnosis of knee osteoarthritis and sarcopenia
9673694|NCT05019807|Other|WhatsApp group|The arm receives education information about diabetes and its complications, diet and physical activities through WhatsApp.
9673695|NCT05019807|Other|Control group|The arm does not received any education information.
9673696|NCT05019989|Experimental|Intervention group: on diet and physical activity|"Individual advice on diet and on physical activity Kitchen courses to teach basic Mediterranean and macrobiotic recipes (two 1-day course plus ten 3-h courses associated with common dinner) (15-20 participants at a time) Fortnightly common lunch or dinner (50-60 participant at a time) Basic gymnastic course (twelve - monthly- 2-hour courses)~Study newsletter, with scientific information, kitchen recipes, study facilities~Periodic conferences on diet and health~Periodic reinforcement meetings with common meals, gymnastic sessions, and dancing, after the first year~Periodic body weight assessment (weekly self-measurement and monthly measurement at the study center)~Discounted rate for advanced kitchen courses~Psychological support groups"
9673697|NCT05019989|Experimental|Control group: only public recommendations on lifestyle|"Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~Dissemination of the information on the study by media~Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
9673698|NCT05019508||High Risk for Gestational Diabetes Mellitus (GDM)|"High risk women screened with HbA1c at initiation of prenatal care who were not diagnosed with Type 2 Diabetes Mellitus or Early GDM.~These women will have Fetal Cardiac Function Parameters at their 20 week anatomy scan (E/A ratio, IVS, MPI). At their 24-28 week routine GDM screening, we will repeat the HbA1c and will repeat the E/A ratio, IVS, MPI. If women have a growth scan for any reason between 32 and 36 weeks, E/A ratio, IVS, and MPI will be repeated at those times."
9673699|NCT05019625||Single biofluid collection|We will ask eligible volunteers to provide a single urine sample and undergo a single blood draw.
9673700|NCT05019625||Serial biofluid and muscle function testing|We will ask eligible volunteers to provide a urine sample, a blood sample, and undergo standard muscle function tests once every six months over a two-year period, and undergo pulmonary function tests and electrocardiogram once per year for two years.
9673701|NCT05019625||Biofluid and muscle tissue biopsy|We will ask eligible volunteers to provide a urine sample and undergo a muscle biopsy once.
9673702|NCT05019625||Ultrasound and myography testing|We will ask eligible volunteers to provide a single urine sample, a single blood draw, and undergo ultrasound and electrical impedance myography studies once.
9975464|NCT02887040|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
9673704|NCT05019586||Helicobacter pylori resistance|Patients with treatment resistance to Helicobacter pylori treatment registered at GI-unites from 1990-2012 and included from 2010 to 2012. These patients were treated with a triple therapy of levofloxacin, amoxicillin and proton inhibitor for 10 days
9673705|NCT05019586||Newly diagnosed Helicobacter pylori|Patients with newly diagnosed Helicobacter pylori infection from 2010-2012.These patients were treated with a triple therapy of clarithromycin, amoxicillin and proton inhibitor for 10 days
9673706|NCT05019586||Previously eradicated Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
9673707|NCT05019586||Never Helicobacter pylori infection|Patients with previously Helicobacter pylori infection included from 2010-2012.
9673708|NCT05019469|Experimental|Single arm of study|Single Arm. During each study session the participant undertakes 4 walking/activity circuits. During each circuit the participant receives either continuous cueing, responsive cueing (delivered in response to gait freezing), no cueing and no device. The ordering of the interventions/circuits are systematically alternated for each participant.
9673709|NCT05019599|No Intervention|normal controls|subjects with normal renal function
9673710|NCT05019599|Experimental|CKD_Low protein diet|CKD patient with low protein diet (<0.8g/kg/BW)
9673711|NCT05019599|Active Comparator|CKD_normal protein diet|CKD patient with normal protein diet
9673712|NCT05019690|Experimental|Apatinib Combined With Albumin-Bound Paclitaxel|Participants will receive apatinib combined with albumin-bound paclitaxel until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
9695013|NCT04782960|Placebo Comparator|20 patients receive Subconjunctival placebo in the end of operation|20 patients receive Subconjunctival placebo in the end of operation and monitoring postoperative pain score
9695014|NCT04782557|Experimental|EUS-guided PVA and HVA|Patient will undergo EUS-guided PVA and HVA
10173799|NCT03859284|Active Comparator|flowable resin-composite|"3M flowable composite is a conventional restoration to treat anterior carious cervical lesions. considered to be the gold standard of the flowable composites.~other names: ''flowable composite ''"
9673713|NCT05019651|Experimental|Single Arm- Apollo Wearable System|Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
9673714|NCT05019781|Experimental|KT group|Participants were received single session therapeutic tape application for one week.
10173800|NCT03859284|Experimental|self-adhering flowable|intervention one is moist bonding self adhering flowable composite that binds to tooth without an adhesive system
10173801|NCT03859284|Experimental|self-adhering flowable with adhesive|intervention two moist bonding self adhering flowable composite that binds to tooth with the aid of adhesive system to improve the clinical performance
9673715|NCT05019781|Placebo Comparator|Placebo group|Participants were received single session placebo tape application for one week.
9673716|NCT05019781|No Intervention|Control group|No intervention.
10173802|NCT03859297|Experimental|Rumination-Focused CBT|RF-CBT is a manual-based treatment for prevention of depression, includes focus on ruminations, mental habits, concreteness training, and mindfulness.
10173803|NCT03859297|No Intervention|Treatment as Usual|Participants are allowed to continue any therapy outside of the treatment study.
10173804|NCT03859297|Active Comparator|Relaxation-based therapy|RelaxT includes an active comparison treatment that can be used to monitor and modify physiological responses to stress
10173805|NCT03859271|Experimental|brief motivational interviewing|Participants will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
10173806|NCT03859271|Placebo Comparator|Placebo Control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
9673717|NCT05019612||single-group/one cohort|Women with endometriosis, having the clinical indication for laparoscopic endometriosis excision
9673718|NCT05019573|Experimental|Black tea group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of black tea samples twice a day with main meals for the 4 weeks of the treatment.
9673719|NCT05019573|Placebo Comparator|Placebo group|Volunteers meeting inclusion/exclusion criteria will be given an appropriate number of placebo tea samples twice a day with main meals for the 4 weeks of the treatment.
9673720|NCT05019183|Experimental|Experimental arm|Patients in the experimental arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) during which they will be able to move freely in a virtual environment.
9673721|NCT05019183|Other|Control arm|Patients in the control arm will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) without being exposed to a virtual environment.
9673722|NCT05019300||COVID-19 patients discharged from critical care units|Adults over 18 years of age who have been hospitalized after COVID-19 diagnosis in the critical care units of Red Salud UC Christus who have been cognitively evaluated with Montreal Cognitive Assessment (MoCA) days prior to their discharge. All patients with a previous history of confirmed neurocognitive or psychotic disorders, prior to hospital admission, were excluded.
9673723|NCT05019118|Experimental|Intervention/treatment|"Dairy foods made with UNICLA milk Participants (n = 45) ingested UNICLA milk and dairy products (yogurt and cheese) for three months.~UNICLA milk is characterised by an improved nutritional composition, obtained by modifying cow's diet, feeeding the dairy cows with a sufficient and balanced ration, which recreates the fatty acid profile of the spring.~This ration includes pastures, high-quality forages and, among other components, a significant amount of flax seeds, which constitute a source of unsaturated fatty acids such as omega-3 and selenised yeast, as a source of organic selenium.~Consequently, UNICLA milk and dairy products are naturally enriched in selenium and ω-3 PUFA.~The daily intake reflects the usual consumption habits, being the recommended amounts of 200 ml of milk and 125 g of yogurt per day and 400g of fresh cheese per week"
9673724|NCT05019118|Placebo Comparator|Conventional milk|"Participants (n = 45) ingest milk and conventional dairy products daily for 3 months.~Daily intake reflects usual dairy consumption habits in real life conditions, without forcing or inducing increased consumption. Therefore, the recommended amounts are 200 ml of milk and 125 g of yogurt per day and 400 g of fresh cheese per week"
9673725|NCT05019248||vaccination prior to first cladribine exposition|
9673726|NCT05019248||vaccination shortly after first cladribine exposition|
9673727|NCT05019248||vaccination prior to second cladribine exposition|
9673728|NCT05019248||vaccination following completion of cladribine treatment|
9673729|NCT05019248||vaccination in patients with RRMS not subjected to cladribine|
9827529|NCT02459665|Active Comparator|Group 3|After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
9827530|NCT02459665|Active Comparator|Group 4|After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
9673730|NCT05019417|Experimental|Glycerol phenylbutyrate treatment|"Name of the Investigational Medicinal product: Glycerol phenylbutyrate [GPB] (Ravicti oral liquid 1.1 gr/1 ml; manufacturer Horizon Pharma USA).~Dosage of GPB will follow the dosage in use for children with urea cycle disorder.~Initial dose: 5.0 gr (4.5 ml)/ meter square divided by three time a day. An escalating schedule dose of GPB will be used until normal serum T3 levels are reached.~Initial dose: 5 gr/square meter body surface area (BSA). Second visit: 10 gr/square meter BSA~The dose raising will be stopped if one of the following condition is reaches:~Clinically significant side effects~Reaching the PAA serum toxic threshold of 500 µg/ml~Reaching the maximal dose of GPB that is in use in urea cycle disorder: 12.4 gr (11.2 ml)/ meter square BSA divided by three times a day.~Duration of study: 4 months"
9673731|NCT05019287|Experimental|Menstrual blood stem cell secretome group|Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment
9673732|NCT05019287|Placebo Comparator|Control group|Intravenous saline injection (Placebo)+Routine treatment
9673733|NCT05019157|Experimental|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic under the supervision of the specialized staff for familiarization with the intervention. and then the participants will proceed with the telerehabilitation program at their homes. Participants will undergo an exercise - based program 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down, with the use of wearable sensors.
9673734|NCT05019157|Active Comparator|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer 3 times/week, comprised of 10' warm up exercises, 40' aerobic, resistance and balance exercises and 10' cool down.
9673735|NCT05019157|No Intervention|Usual care group|Patients will not undertake any exercise based intervention and will only follow their usual medication treatment .The patients will wear the accelerometer for the 12 week study duration and visit the corresponding outpatient cardiac clinic every 4 weeks to upload the recorded data. The patients will also receive educational phone videoconference sessions every week for physical activity, diet/nutritional and smoking cessation counseling.
9673736|NCT05019482|Experimental|University-based 8-weeks intervention to promote Physical Activity (PA)|Experimental group: 8-weeks program of Physical Activity constructed by users during a design-based innovative workshops before the beginning of the interventions .
9673737|NCT05019482|No Intervention|Control Group|Control group: No intervention, only two measurement times
9673738|NCT05019456|Experimental|Vaccine|Participants who elect to receive the vaccine
9673739|NCT05019443|Active Comparator|Conventional balloon predilation|the target lesion can be prepared according to standard clinical practice using SC balloons sized 0.8-1:1. Stenting using a drug-eluting stent (DES) is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
9673740|NCT05019443|Experimental|Scoring balloon predilation|the target lesion must be prepared with a scoring balloon (SC) inflated 3 times at nominal pressure. To allow the scoring balloon to cross the lesion, it might be necessary to predilate with a small compliant balloon. The size of the scoring balloon to be used for is based on the size of the vessel. Stenting using a DES is performed and the inflation pressure for delivery is noted, as well as the expected balloon diameter at that pressure. 2 enhanced stent imaging acquisitions (StentBoost or equivalent depending on the X-ray system used), are acquired in 2 orthogonal views. Post dilatation can be performed at operator discretion followed by a final acquisition of 2 similar orthogonal views with enhanced stent imaging. Intravascular imaging is left to the operator's discretion and is encouraged
9673741|NCT05019378|Experimental|autologous SVF treatment|Three milliliter of cell suspension injection containing 1.0E8 SVF cells into the knee joint
9673742|NCT05019378|No Intervention|Placebo group|No treatment
9673743|NCT05019365||Participants with previous HER2 breast cancer|
9673744|NCT05019365||Healthy Volunteers|
9673745|NCT05019040|Experimental|PA1010 5 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 5 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
9673746|NCT05019040|Experimental|PA1010 10 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 10 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
9673747|NCT05019040|Experimental|PA1010 20 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 20 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
9673748|NCT05019274|Experimental|Culinary Medicine|Series of 6 virtual group Culinary Medicine sessions delivered monthly for 6 months
9673749|NCT05019274|Active Comparator|Nutrition Education|Series of 6 standard of care nutrition visits delivered by clinic dieticians. These are a mix of individual and group sessions.
9673750|NCT05018923|Experimental|RBMD group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
9673751|NCT05018923|Active Comparator|RAMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and tetracycline 0.5 g qid for 14 days
9673752|NCT05019326|Experimental|Andrographis extract|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
9673753|NCT05019326|Experimental|Boesenbergia extract|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
9827531|NCT02459795|Experimental|Test product|Ingenol Mebutate (Perrigo)
9827532|NCT02459795|Active Comparator|Reference product|Ingenol Mebutate (Reference)
10173807|NCT03859245|Experimental|Experimental group|Subjects in the experimental group will receive clinically prescribed meal plans designed to facilitate prolonged benign dietary ketosis (BDK) purposed at glucose regulation, improved insulin sensitivity and restored metabolic flexibility. Photobiomodulation therapy, via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
9673754|NCT05019326|Other|Standard supportive treatment|Standard supportive treatment, as recommended by guideline from Ministry of Public Health, Thailand, there will be no antivirus given in this asymptomatic group
9673755|NCT05019014||Neurodegenerative disease|Participants with a diagnosis of Probable Alzheimer's Disease, prodromal Alzheimer's Disease, Frontotemporal Dementia, Mild Cognitive Impairment, Dementia with Lewy Bodies, mild and moderate/severe TBI, and familial or sporadic ALS per El Escorial Criteria or individuals with known gene mutations associated with ALS.
9673756|NCT05019014||Age-matched controls|Healthy participants with no diagnosis.
9673757|NCT05019079|Experimental|electroacupuncture group|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation was stopped 30min later.
9673758|NCT05019079|No Intervention|control group|The patient underwent routine anesthesia without acupuncture treatment
9673759|NCT05019131|Experimental|Intervention arm|"Training: The investigators will develop a training for providers that addresses the following topics: Stress & positive coping mechanisms; Unconscious bias awareness and mitigation; Person-centered maternity care; Dealing with difficult situations; and Teamwork and communication;~Peer support and mentorship: The investigators will identify what works best for these groups in terms of group composition, size, and how the groups want to interact.~Leadership engagement: To ensure leadership buy in, support and sustainability of the intervention, the investigators will engage leadership of the County.~Embedded champions: To facilitate ongoing engagement, the investigators will identify local leaders, and invite them to training where they will be taught how to facilitate peer support groups and serve as champions."
9673760|NCT05019131|No Intervention|Control arm|Will not receive any training during the intervention period
9673761|NCT05018988|Experimental|Oral vitamin D3 spray|10µg/day for 12 weeks (BetterYou ltd.)
9673762|NCT05018988|Placebo Comparator|Placebo Comparator|Xylitol (BetterYou ltd.)
9673763|NCT05018962|Experimental|Cutting balloon followed by paclitaxel coated balloon|
9673764|NCT05018936|Experimental|treatment group|Hetrombopag would be started with 5mg/day. The dosage would be increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The maximum dosage is 15mg/day.
9673765|NCT05018897|Experimental|To Share or Not to Share|"Manualized, peer-led, strategic disclosure program to guide participants in disclosing suicidality, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
9673766|NCT05018897|Active Comparator|Peer Support|"Peer-led support group, held in group format, consisting of six sessions, each one hour in duration, once per week.~Pre-survey, post-survey, and 3-month follow-up survey"
9673767|NCT05019001|Other|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
9673768|NCT05019001|Other|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
9695015|NCT04782843||Cohort|"he retrospective cohort studied includes all the patients included in a previous study carried out in our center, the objective of which was to study the diagnostic performance of the HEP score in surgical intensive care.~The cohort studied is made up of all patients admitted for surgical resuscitation between October 2011 and October 2013 and validating the following criteria:~Inclusion criteria: any adult patient (age ≥ 18 years), admitted to surgical intensive care, treated with heparin (UFH or LMWH), and suspected of TIH by a clinician in the department according to the criteria of the SFAR 2002.~Non-inclusion criteria: minor patients, pregnant women and adults incapable."
9695016|NCT04782583||CAS|
9695017|NCT04782583||TEMOIN|
9695018|NCT04782765|Experimental|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
9695019|NCT04782544|Active Comparator|Treatment|5 grams of buttermilk powder daily for 10 weeks, oral.
9695020|NCT04782544|Placebo Comparator|Placebo|5 grams of milk powder (10% buttermilk powder, 90% anhydrous milk fat) daily for 10 weeks, oral.
9695021|NCT04782570|Experimental|Verum TMS|ITBS (intermittent Theta Burst Stimulation) over left frontal cortex
9695022|NCT04782570|Sham Comparator|Sham TMS|Sham TMS over left frontal cortex
9695023|NCT04782804|Active Comparator|Capecitabine|Capecitabine as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
9695024|NCT04782804|Experimental|Capecitabine+PD-1 Antibody（Tislelizumab）|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery. PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
9695025|NCT04782713|Other|PCP Evaluation of Smart PSA Screening Guidelines|Completing surveys at baseline, 3, 6, 9 and 12 months
9695026|NCT04782934|Experimental|YANG system group|
9695027|NCT04782882|Experimental|intervention group|In the first session of the researcher (S.K.), the participants were explained the effects of anxiety and stress on the treatment in simple terms for 5 min. Then, information was given about the effects of laughter therapy and progressive muscle relaxation on the body. Laughter therapy was applied for 15-20 min. Then, the lights were turned off and progressive muscle relaxation exercises were performed for 15-20 min under candlelight and accompanied by music. The procedures were received as a group (2-6 people) in 3-4 face-to-face sessions.
9673769|NCT05018702|Experimental|ARX788|
9673770|NCT05019313||COVID 19 positive patients|"COVID19 positive patients with hypoxemic acute respiratory failure hospitalized in intensive care unit.~This study evaluates diaphragmatic contractility with ultrasound, blood gas analytical parameters during weaning from invasive mechanical ventilation"
9673771|NCT05019196||fMRI，functional reorganization, functional connectivity, functional rating scale|low-grade glioma patients healthy controls
9673772|NCT05018663||Prospective enrollment|All subjects will be enrolled prospectively. Subjects will be included in the study after eligibility is assessed and informed consent is obtained. The slide scanner will scan the slides on site and the images will be securely saved and sent for interpretation by the AI software at a different location. The results of the AI interpretation of the slides will be blinded to the on-site procedure team including the endoscopist and cytopathologist until the final pathology report is complete.
9673773|NCT05018689|Active Comparator|Aevidum curriculum|Curriculum: Aevidum has developed a 5-lesson 3-hour mental health curriculum that can be broken up and integrated into existing school health curricula. The study team in partnership with the Executive Director of Aevidum will collaborate with schools to implement the curriculum to their 9th grade students.
9673774|NCT05018689|Active Comparator|Aevidum curriculum + club|Curriculum + club. Schools assigned to the curriculum plus club will also start an Aevidum club at their school. Club basic processes and ideas for events are housed on the Aevidum website. Schools will select faculty and student leaders who will participate in a kickoff web-based training at the start of the academic year. The training is led by current Aevidum student leaders at schools with successful clubs. This is a standard orientation process that Aevidum has run for many years in-person, but has been adapted to a virtual format with the COVID-19 pandemic.
9673775|NCT05019092|Experimental|Screening|Ultrasound (US) examination of lower limbs 48 hours after admission and again after 3-5 days (5-7 days after the admission)
9673776|NCT05019092|No Intervention|Control|Ultrasound (US) examination according to the clinical evaluation of risk factors for deep vein thrombosis (DVT) and life-threatening bleeding, based on the standard of care (SOC) of the enrolling institution.
9673777|NCT05018715||coronary heart disease|A total of 300 patients with CHD WHO were hospitalized in the First Affiliated Hospital of Xinjiang Medical University from August 2021 to February 2022 were selected, all of whom met the DIAGNOSTIC criteria of CHD formulated by the World Health Organization (WHO) and excluded diseases such as highly severe valvular disease and congenital heart disease
9673778|NCT05018715||Healthy person|.A total of 300 healthy subjects from the First Affiliated Hospital of Xinjiang Medical University during the same period were selected as controls.
9673779|NCT05018741||Liver transplant|
9673780|NCT05018624|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
9673781|NCT05018624|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through IM Apps
10173808|NCT03859245|Active Comparator|Control group|Subjects in the control group will follow current dietary protocol (Standard American Diet- SAD). Photobiomodulation therapy,via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
10173809|NCT03859232|Experimental|Delta Dry® Pantaloon Group|
10173810|NCT03859232|Active Comparator|Cotton Padding Group|
10173811|NCT03859362|Experimental|Ertapenem in urosepsis|Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min.
10173812|NCT03859375||2 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint two of a predefined area of the skin.
9673782|NCT05018325|Active Comparator|Arm 1: Colonoscopy 6 minute withdrawal time|-Undergo colonoscopy with the standard 6-minute withdrawal time followed by a tandem colonoscopy of at least another 6-minute withdrawal time.
9673783|NCT05018325|Experimental|Arm 2: Colonoscopy 9 minute withdrawal time|-Undergo a 9-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time.
9673784|NCT05018325|Experimental|Arm 3: Colonoscopy 12 minute withdrawal time|-Undergo colonoscopy with a 12-minute withdrawal time followed by a tandem colonoscopy with at least the standard 6-minute withdrawal time
10173813|NCT03859375||3 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint three of a predefined area of the skin.
10173814|NCT03859180|Experimental|Focused breathing intervention group|Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
10173815|NCT03859180|No Intervention|Control group|The participants randomized to this group with not be required to perform any additional behaviors for the six week period of the study. After completing post-tests they will be taught how to perform focused breathing for the self-management of anxiety.
9673785|NCT05018286|Experimental|Apraglutide subcutaneous (SC) injections, once weekly|Peptide analogue of Glucagon-like Peptide 2 (GLP-2)
9673786|NCT05018312|Experimental|Modified Collaborative Assessment (MCA)|The patients allocated to this arm will receive assessment inspired by therapeutic/collaborative assessment, as a pre-treatment to the standard psychotherapeutic treatment they will receive in the clinic.
9673787|NCT05018312|Active Comparator|Assessment as usual (AAU)|The patients allocated to this arm will receive standard assessment offered in the clinic, before proceeding to the standard psychotherapeutic treatment they will receive in the clinic.
9673788|NCT05018637|Experimental|WJ-MSC group|intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
9673789|NCT05018637|Active Comparator|Teriparatide group|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
9673790|NCT05018949||Patients who have undergone LL angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
10173816|NCT03859817||Patients with albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
10173817|NCT03859817||patients with normo albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
9673791|NCT05018377|Active Comparator|Raj'z catheter|
9673792|NCT05018377|Active Comparator|NAVI catheter|
9673793|NCT05018364||cases|measure serum erythropoietin level
9673794|NCT05018364||controls|measure serum erythropoietin level
9673795|NCT05018468|Experimental|ventilation with an anatomical facial mask|Intervention group 1: Patients in this group undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
9673796|NCT05018468|Experimental|ventilation with a nasal mask|Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. Ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
10173818|NCT03859349|Active Comparator|Systematic Sampling|Patients will undergo systematic sampling of lymph node stations in the mediastinum with a minimum sampling of 3 stations: 4R, 4L and 7, as is the standard of care. Other stations may be included at the endoscopist's discretion. CLNS is not used for this arm.
9673797|NCT05018559|Experimental|Intervention group nursing care|Participants receive a co-created physical activity intervention called BuG lesson (German: 'Bewegt und Gesund'-Stunde; English: PA and health lesson).
9673798|NCT05018559|No Intervention|Control group nursing care|Participants do not receive any treatment in addition to their vocational education and training curriculum.
9673799|NCT05018559|Experimental|Intervention group automotive mechatronics|Participants receive a co-created physical activity intervention called tutoring system.
9673800|NCT05018559|No Intervention|Control group automotive mechatronics|Participants do not receive any treatment in addition to their vocational education and training curriculum.
9673801|NCT05018546|Experimental|Gravity Irrigation|RIRS under Gravity irrigation
9673802|NCT05018546|Experimental|Pressure Irrigation|RIRS under Pressure irrigation.
9673803|NCT05018234|Experimental|Treatment|
9673804|NCT05018494|Experimental|Group A|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
9673805|NCT05018494|Active Comparator|Group B|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
9673806|NCT05018390|Experimental|OMT|Osteopathic manipulative treatment : participants will receive low-amplitude tissue mobilizations on peripheral, vertebral, cranial and/or visceral articular systems.
9673807|NCT05018390|Sham Comparator|Sham|Participants will be applied gestures that look like actual osteopathic manipulations but are not therapeutic.
9673808|NCT05018390|No Intervention|Test-retest|Participants will undergo the two eye movement measurements, but will not receive any (actual or sham) treatment. 30 minutes will elapse between the two measurements.
9673809|NCT05018429||nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
9673810|NCT05018429||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles) during the operation.
9673811|NCT05018182|Experimental|Neoadjuvant chemotherapy|4 cycles of neoadjuvant chemotherapy with FOLFOXIRI + operation + 5 cycles of adjuvant chemotherapy with XELOX
9673812|NCT05018572|Experimental|"Personalised internet-based treatment I am"|"Personalised internet-based treatment I am."
9673813|NCT05018572|No Intervention|Treatment As Usual|Treatment in primary care / Treatment As Usual (TAU), which is medical treatment
9673814|NCT05018260|Experimental|GCMRT|Attention bias modification: participants will receive gaze-contingent feedback according to their viewing patterns on disgusted and neutral faces
9673815|NCT05018260|Experimental|attention control|Attention control modification: participants will receive gaze-contingent feedback according to their viewing patterns on rounded and sharp geometric shapes
9673816|NCT05018247|Active Comparator|Urgent revascularization with Optimal Medical Therapy|Revascularization will be performed via either Percutaneous Coronary Intervention or Coronary Artery Bypass Graft, and the selection of the specific procedure will be at the discretion of the patient and their physician(s). Patients will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
9695028|NCT04782882|No Intervention|Control group|The control group then received routine care
9827533|NCT02459795|Placebo Comparator|Placebo product|Placebo gel
9827534|NCT02459899|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
9827535|NCT02459899|Experimental|Sotagliflozin 75 mg|Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
10173819|NCT03859349|Experimental|Selective Targeted Sampling|"Patients will first undergo endosonographic assessment of 3 mediastinal lymph node stations (i.e. 4R, 4L, and 7) using the four criteria of the CLNS. Lymph node stations that exhibit a CLNS >1/4 will be biopsied as is standard of care. Lymph node stations with CLNS ≤ 1/4 will be marked as not requiring biopsy but will be biopsied nevertheless, so that there is no deviation from the standard of care. Other stations may be included at the endoscopist's discretion."
10173820|NCT03859141|Experimental|Experimental group-phase Ⅰ|Quadrivalent influenza vaccine
10173821|NCT03859141|Experimental|Experimental group-phase Ⅲ|Quadrivalent influenza vaccine
10173822|NCT03859141|Active Comparator|Control group 1-phase Ⅲ|Trivalent influenza vaccine (contains B/Victoria strain)
10173823|NCT03859141|Active Comparator|Control group 2-phase Ⅲ|Trivalent influenza vaccine (contains B/Yamagata strain)
9673817|NCT05018247|Other|Optimal Medical Treatment with delayed revascularization|OMT without revascularization for a minimum of approximately 105 days if clinically stable. At their first follow-up visit (Day 105±20), patients will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. Patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter and will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
9673818|NCT05018533|Experimental|Cohort 1|TAKC-02 0.15mg Single dose
9673819|NCT05018533|Placebo Comparator|Placebo (to Cohort 1)|
9673820|NCT05018533|Experimental|Cohort 2|TAKC-02 0.5mg Single dose
9673821|NCT05018533|Placebo Comparator|Placebo (to Cohort 2)|
10173824|NCT03859310||Normal|no glaucoma or retinal pathology or corneal conditions
10173825|NCT03859310||Glaucoma|diagnosis of glaucoma
9673822|NCT05018533|Experimental|Cohort 3|TAKC-02 1.5mg Single dose
9673823|NCT05018533|Placebo Comparator|Placebo (to Cohort 3)|
9673824|NCT05018533|Experimental|Cohort 4|TAKC-02 5mg Single dose
9673825|NCT05018533|Placebo Comparator|Placebo (to Cohort 4)|
9673826|NCT05018533|Experimental|Cohort 4.5 *optional|TAKC-02 10mg Single dose
9673827|NCT05018533|Placebo Comparator|Placebo (to Cohort 4.5) *optional|
9673828|NCT05018533|Experimental|Cohort 5|TAKC-02 15mg Single dose
9673829|NCT05018533|Placebo Comparator|Placebo (to Cohort 5)|
9673830|NCT05018533|Experimental|Cohort 6|TAKC-02 Multiple dose (low)
9673831|NCT05018533|Placebo Comparator|Placebo (to Cohort 6)|
9673832|NCT05018533|Experimental|Cohort 7|TAKC-02 Multiple dose (high)
9673833|NCT05018533|Placebo Comparator|Placebo (to Cohort 7)|
9673834|NCT05018195|Active Comparator|Benign|Women who receive surgery for benign lesions including leiomyoma, adenomyosis, or ovarian cysts. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
9673835|NCT05018195|Experimental|Endometrial cancer|Women who receive surgery(staging or cytoreductive surgery) for endometrial cancer. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
9673836|NCT05018065|Active Comparator|50 women previously diagnosed with mild - medium Covid-19 and had ambulatory care|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
9673837|NCT05018065|Active Comparator|51 women having no Covid-19 history|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)
9673838|NCT05018130|Experimental|Bio-integrative|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm bio-integrative cannulated screws.
9673839|NCT05018130|Active Comparator|Metallic|Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm metallic cannulated screws.
9673840|NCT05018169|Experimental|BA-A|Teens will participate in BA-A. BA-A is a 12-session manualized treatment that utilizes established BA strategies and incorporates common mental health treatment adaptations for young people with ASD.
9673841|NCT05018000|Active Comparator|Arm 1: Enhanced usual care|Participants in this arm will receive their usual care plus a Financial Resource Sheet. The financial resource sheet lists and describes existing organization and community resources available to KP members.
9673842|NCT05018000|Experimental|Arm 2: Brief financial navigation intervention|Participants in this arm will receive their usual care, and the Financial Resource Sheet described in Arm 1, plus one (1) cycle of financial navigation (total cycles: 1; total length: 6 months). In each intervention cycle participants will get at least one (1) phone call with a CAFÉ Financial Navigator, the navigator will talk with participants to identify financial questions or concerns. The navigator will create a personalized plan for each participant. Participants can request extra support from the navigator for up to 6 months.
9673843|NCT05018000|Experimental|Arm 3: Extended financial navigation intervention|Participants in this arm will receive their usual care, a Financial Resource Sheet and the brief intervention described in Arm 2 (i.e., one (1) cycle of financial navigation). Plus, they will receive two (2) additional cycles of financial navigation (total cycles: 3; total length: 6 months).
9673844|NCT05018143|Experimental|STARS|The investigators will deliver an online intervention focused on safety planning (STARS). The intervention content includes life skills interactive modules across 14 domains, a goal tracker, referral to community resources, and scheduling of peer mentoring sessions.
9673845|NCT05018143|Active Comparator|Control Condition|The investigators will deliver an in-person therapeutic session where participants can develop an individualized safety plan for use during a suicidal crisis, focusing on adaptive coping, addressing barriers or ambivalence, and strengthening their self-efficacy.
9673846|NCT05017987|Active Comparator|Sequence A=Reference-Test|"T(Test drug): ATB-101 R1(Reference drug1): ATB-1011 R2(Reference drug2): ATB-1012~First stage: co-administration of R1 and R2, single dose and then Washout: 7days and then Second stage: administration of T, single dose"
9673847|NCT05017987|Active Comparator|Sequence B=Test-Reference|First stage: administration of T, single dose and then Washout: 7days and then Second stage: co-administration of R1 and R2, single dose
9673848|NCT05017896||Normal Perfusion|
9673849|NCT05017896||Low Perfusion|
9673850|NCT05017909|Experimental|Experimental Group 1|3-week web-based education group
9673851|NCT05017909|Experimental|Experimental Group 2|3-week face to face education group
9673852|NCT05017909|Active Comparator|Control Group|Uneducated group
9827536|NCT02459899|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
10173826|NCT03859310||Retina|diagnosis of AMD, DR or other retinal pathology
10173827|NCT03859310||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
10173828|NCT03858998|Experimental|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
10173829|NCT03858998|Other|Control|Current routine HIV care in Tanzania.
10173830|NCT03859401|Experimental|Control - Experimental Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Control-Experimental Arm will undergo the Control Admission first, utilizing an artificial pancreas (AP) controller that does not anticipate exercise (rMPC - naïve model predictive control), followed by the Experimental Admission, which will utilize an AP controller that has the ability to anticipate exercise (EnMPC - ensemble model predictive control). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
9673853|NCT05017961|Active Comparator|Autograft|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group an autograft will be used to fill the void. For the purpose of autologous grafting, cancellous strips of bone will be harvested from the posterior superior iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s). This will be the control arm.
9673854|NCT05017961|Other|Allograft only|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) will be used to fill the void. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
9673855|NCT05017961|Other|Allograft combined with BMAC|Following definitive fracture reduction a bone defect often remained in the substance of the calcaneus beneath the reduced posterior facet. In this group a cryopreserved allograft bone (Musculoskeletal Tissue Foundation, New Jersey, NJ) combined with BMAC will be used to fill the void. For the purpose of BMAC preparation, bone marrow will be collected from iliac crest or proximal tibia. It shall be applied wherever bone loss exists as a result of the incident fracture or subsequent bone debridement(s).
9673856|NCT05017974|Experimental|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement (MBSR+PS)|The study intervention is standard mindfulness-based stress reduction (MBSR), which will be delivered through 8 weekly 2.5-hour sessions via video conferencing to groups of 20-30 pregnant and non-pregnant people. MBSR also consists of a 2.5-hour orientation session, a 30-minute private interview with the instructor, and an all-day retreat, all conducted via video conferencing. The supplemental prenatal sleep content will be delivered through 6-8 30-minute sessions via video conferencing either individually or to small groups, and draws material from mindfulness-based therapy for insomnia, mindfulness-based childbirth and parenting program, and cognitive behavior therapy for prenatal insomnia.
9673857|NCT05017974|Other|Treatment as Usual|The control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy, with the exception of asking participants to refrain from participating in non-study mindfulness practice. Use of non-study treatment will be tracked.
9673858|NCT05017766||A) Urinary tract infection|Processing of residual urine for proteomic, metabolomic and transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH) analysis, flow cytometry analysis (FACS), immunophenotyping. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties (Highly sensitive mass spectrometry, whole genome sequencing), expression of virulence factors, genomic alterations of bacterial species, metabolism, surface molecule expression, gene expression levels, cytokine levels, immune cell biology, antibiotic concentration (chromatography/mass spectrometry). Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included. First, a pilot study from randomly selected patients within each bacterial species group (n=50, each) is done.
9673859|NCT05017766||B) Pneumonia|Processing of residual samples (tracheal secretion, bronchioalveolar lavage (BAL)) for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
9673860|NCT05017766||C) Deep-seated infections|Processing of intraoperative material residual samples for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
9673861|NCT05017766||D) Controls for A), B) and C)|Control samples result from patients with a suspected infection (infection sites A), B) or C), in which no microbiological confirmed infection has been diagnosed. Storage at biobank
9673862|NCT05017766||E) Clinical controls for A), B) and C) without obtained samples|For clinical controls, clinical characteristics of patients with detection of target pathogens in their routine samples (but which could not be included for sample analysis in this study) will be assessed.
9673863|NCT05017766||F) Cohort with analysis whether the application of Article (Art) 34 HFV can avoid a bias|Since part of the data and samples in this study are collected with the representative consent of the ethics committees, it is investigated whether the application of Art. 34 HFV prevents selection bias with respect to the study population. For this purpose, differences between the actual study population using Art. 34 HFV and the study population with provided research consent will be descriptively investigated in terms of the prevalence of multi-resistant germs and other available population characteristics.
9673864|NCT05017714|Experimental|Active plus SOC|
9673865|NCT05017714|Placebo Comparator|Placebo plus SOC|
9827537|NCT02459899|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.
9827538|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
10173831|NCT03859401|Experimental|Experimental - Control Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Experimental-Control Arm will undergo the Experimental Admission first, utilizing an artificial pancreas (AP) controller that has the ability to anticipate exercise (EnMPC), followed by the Control Admission, which will utilize an AP controller that does not have the ability to anticipate exercise (rMPC). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
9673866|NCT05018039|Experimental|Collaborative care model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider (psychologist or psychiatrist) and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments with the physiotherapist and/or occupational therapist (usual care)."
9673867|NCT05018039|No Intervention|Usal Care|"Current usual care within musculoskeletal outpatients involves an initial patient assessment by a physiotherapist or occupational therapist (or both) to determine the needs and goals of the patient in relation to their musculoskeletal condition. Clinicians also help to inform, educate, and empower patients to self-manage their rehabilitation where possible.~Following this initial assessment, patients are provided with a plan of their therapy treatment. The therapist(s) progress patients exercise, as appropriate. Therapy is most often a 1:1 session but can also include group classes. Physical therapy involves exercise and education, while occupational therapy focuses on practical strategies to perform daily tasks.~If the therapists feel that patients require additional support for their mental health problems, they can request this support via the General Practitioner or the hospital mental health services."
9673868|NCT05017597|Experimental|Fatigue management|"Prescribed exercises by Physical Therapy Problem-Solving Sessions to resume activities that ther person needs to do, wants to do or is expected to do.~Four online educational modules: What is Cancer-Related Fatigue? Nutrition, Sleep Hygiene and Exercise"
9673869|NCT05017636|Active Comparator|Treatment groupThorck Shock Wave Ibramed (terapia ESWT)- fat cell death|The shock wave treatment was performed on the left side of the abdomen
9673870|NCT05017636|No Intervention|Without intervention.|no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group no shockwave treatment was performed on the right side of the abdomen, which was specified as a control group without intervention.
9673871|NCT05017844|Placebo Comparator|KSR-001-04|KSR-001-04 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
9673872|NCT05017844|Experimental|KSR-001-02|KSR-001-02 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
9673873|NCT05017844|Experimental|KSR-001-03|KSR-001-03 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
9673874|NCT05017792|Other|1- Before vaccination:|"To detect:~COVID-19 IgG/IgM Rapid Test~COVID-19 IgG/IgM by quantitative method(ELISA).~D-dimer"
9673875|NCT05017792|Other|2-7 days after the first dose|Measuring D-dimer
9673876|NCT05017792|Other|3-Before the second dose:|To detect IgG and IgM To detect the level of Covid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
9673877|NCT05017792|Other|4-After 3 months from the second dose:|To detect the level ofCovid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
10173832|NCT03859011|Experimental|Acupuncture|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks), then no acupuncture between 10 weeks and 6 months. After treatment is completed, final measurement instruments are applied at 6 months. Questionnaires will be readministered at 2.5 and 6 months.
9673878|NCT05017792|Other|5-After 6 months from the second dose:|To detect the level ofCovid 19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.
9673879|NCT05017454|Experimental|sodium valproate group|Group 1 will be treated with the optimized sodium valproate-loaded nanospanlastic dispersion, twice daily on the affected areas of the scalp for 3 months
9673880|NCT05017454|Active Comparator|topical steroid group|Group 2 will be treated with the marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
9673881|NCT05017753|Active Comparator|Control group|Standard-of-care medical treatment.
9673882|NCT05017753|Experimental|Intervention group|Thoracentesis in addition to standard-of-care medical treatment.
9673883|NCT05017870|Experimental|KSR-001-01|Participants received KSR-001-01 for 6 days.
9673884|NCT05017870|Experimental|KSR-001-02|Participants received KSR-001-02 for 6 days.
9673885|NCT05017870|Experimental|KSR-001-03|Participants received KSR-001-03 for 6 days.
9673886|NCT05017870|Placebo Comparator|KSR-001-04|Participants received KSR-001-04 for 6 days.
9673887|NCT05017311|Active Comparator|Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted as non-responders to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
9827539|NCT02459964|Experimental|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
9673888|NCT05017311|Placebo Comparator|Allocation by Predictive Biomarker Algorithm; Placebo|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted to respond to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
9673889|NCT05017311|Active Comparator|Random Allocation; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
9673890|NCT05017311|Placebo Comparator|Random Allocation; Placebo|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
9673891|NCT05017688|Other|Patient population|"The population of the study will be adult patients with GI-aGVHD grade III to IV undergoing MaaT013 treatment through named-patient use program ATUn (Early Access Program).~Blood and stool samples will be collected at each visit to analyse the gut microbiota and the immune cells."
9673892|NCT05017337||BASILICA-A|"Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) patients recruited both retrospectively and prospectively.~Pre- and post-operative (4 w and 12 m) blood samples taken from prospectively recruited patients. Post-operative pathological FFPE tissue samples obtained from all recruited patients."
9673893|NCT05017337||BASILICA-C|"Patients undergoing capsule related surgery (any-grade of capsular contracture, irradiated and unirradiated capsules) recruited prospectively.~Pre- and post-operative (4 w) blood samples taken from all patients. Intra-operative tissue sampling (capsular washings, 2 samples of ADM and 2 samples of non-ADM capsule) from all patients."
9673894|NCT05017337||BASILICA-N|"Implant naive patients undergoing implant insertion surgery recruited prospectively.~Pre- and post-operative (4 w and 12 m) blood samples taken from all patients."
9673895|NCT05017519||Nuclear family type|The husband and wife with baby (aged less than 5 months) and with or without children (2-5)
9673896|NCT05017519||Extended family type (three-generation family)|The husband and wife with baby (aged less than 5 months), children (2-5), and grandparents aged > 65 years old
9673897|NCT05017259|Experimental|low carbohydrate trial|The energy distribution was carbohydrate 10%, protein 40-50%, fat 40-50% in the LC trial.
9673898|NCT05017259|Active Comparator|high carbohydrate trial|The energy distribution was carbohydrate 60-65%, protein 30-40%, fat 5-10% in the HC trial.
10173833|NCT03859011|Placebo Comparator|"Usual care"|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments) for 6 months. Questionnaires will be readministered at 2.5 and 6 months. After the control phase the participants will continue usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks, 8.5 months), then no acupuncture between 8.5 months and 12 months.
10173834|NCT03859050|Experimental|LPS arm|
9673901|NCT05017350|Experimental|Radiofrequency ablation group|hemostasis using radiofrequency ablation for track bleeding
9673902|NCT05017467|Experimental|vss|Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery
9673903|NCT05017467|Experimental|QuickDASH , VAS|, Quick Disabilities of Arm Shoulder and Hand functional score (QuickDASH) and Visual Analogue Scale (VAS) test was used to determine overall hand function, activities of daily living, work performance, pain, aesthetics, and satisfaction with hand function
9673904|NCT05017480|Experimental|CBP-201 Dose|CBP-201 Dose subcutaneous (SC) injection
9673905|NCT05017480|Placebo Comparator|Placebo|subcutaneous (SC) injection
9673906|NCT05017285|Other|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
9673907|NCT05017285|Experimental|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum.
9673908|NCT05017376||group A|small optical zone
9673909|NCT05017376||group B|large optical zone
9673910|NCT05017428|Experimental|Low Dose|The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide.
9673911|NCT05017428|Experimental|Medium Dose|The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide.
9673912|NCT05017428|Experimental|High Dose|The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide.
9673913|NCT05017428|Placebo Comparator|Placebo|In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour.
9673914|NCT05017077|Experimental|Telemonitoring|To evaluate the feasibility and efficacy of a new model of tele monitoring in pediatric population in advanced heart failure, we will enroll 20 patients in advanced NYHA/Ross class in waiting list for Heart Transplant. An home telemonitoring capable to detect vital parameters as heart rate, body temperature, blood pressure, oxygen saturation, breathe frequency, weight, arrhythmias and cardiac index may offers to physician valuable information able to strictly monitoring the clinical status of patients
9673915|NCT05017207||Patient with periampullary cancer and pancreaticoduodenectomy|Only one group of patient with periampullary cancer
9673916|NCT05017272|Active Comparator|Opioid Addiction Recovery Support (OARS)|Data collected post-implementation of OARS in conjunction with medication for opioid use disorder (MOUD) at study sites.
10173835|NCT03859154||Viper bite victims|Snakebite victims in whom the snake has been brought and positively identified as Viperidae AND simultaneous aPTT has been sent AND consenting to be part of the study
10173836|NCT03859154||Nonvenomous snakebite|"age and gender matched victims of snake bite in whom the culprit snake brought along has been identified as a non venomous one.~AND consenting to be part of the study"
10173837|NCT03859102|No Intervention|ERAS Control/non-ERAS group|Standard usual care after cardiac surgery.
10173838|NCT03859102|Experimental|ERAS group|"Enhanced Recovery After Cardiac Surgery. Pre-op carbohydrate drink, Lansoprazole and Gabapentin.~Intra-operative: IV Paracetamol, Dexamethasone, Ondansetron, Local Anaesthetic to wounds.~Post-op: Gabapentin PO, Paracetamol IV then PO, Ondansetron IV for 24hrs. Opiate sparing. Early extubation, early mobilisation, early removal of invasive devices. Early discharge."
10173839|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
10173840|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
10173841|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
9673917|NCT05017272|No Intervention|Treatment as Usual|Data collected at baseline before OARS in conjunction with MOUD is implemented at study sites.
9673918|NCT05017220|Experimental|Nature-based stimulation program|Participants will receive a single intervention with a duration of 30 minutes based on a multisensorial nature-based stimulation
9673919|NCT05017220|Other|Control intervention|Participants will be involved in a placebo task for 30 minutes
9673920|NCT05017168|Experimental|CT-P63|Single Ascending Dose
9673921|NCT05017168|Placebo Comparator|Placebo|Single Ascending Dose
9673922|NCT05017142||Patient population|Children, adolescents and adults diagnosed with an IBrainD before age 18, who are born, treated or living in Switzerland
9673923|NCT05017103|Experimental|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
9673924|NCT05017155|Active Comparator|Lamotrigine|When on the lamotrigine treatment arm, the participant will commence at lamotrigine 25mg (milligram) daily for two weeks; then increase to 25mg twice daily for two weeks; then increase to 50mg daily for one week; then increase to 100mg in the morning, 50mg at midday and 50mg at night for one week; then increase to 100mg in the morning, 50mg at midday and 100mg at night for two weeks.
9673925|NCT05017155|Active Comparator|Mexiletine|When on the mexiletine treatment arm, the participant will commence at mexiletine 100mg daily for two weeks; then increase to 200mg daily for two weeks; then increase to 200mg twice daily for one week; then increase to 200mg three times a day for one week; then remain on 200mg three times a day for two weeks.
9673926|NCT05017116|Experimental|Part A，single dose group|Subjects will receive single dose RBD1016/placebo on D1 combined with antiviral drugs during the study period.
9673927|NCT05017116|Experimental|Part B, multiple dose group|Subjects will receive two doses of RBD1016/placebo on D1 and D29 combined with antiviral drugs during the study period.
9673928|NCT05017181||BioVal|BioVal is a single site validation study to determine the histological correlates underpinning signals derived from 13C-pyruvate HYP-MRI in men with known prostate cancer scheduled for prostatectomy.
9673929|NCT05017181||ProVal|ProVal is a single site, prospective, longitudinal observational cohort study to determine the prognostic value of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known early prostate cancer on active surveillance.
9673930|NCT05017181||TecVal|TecVal is a multi-site validation study to determine the inter-site repeatability and intra-site reproducibility of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known prostate cancer.
9673931|NCT05017194|Experimental|Emodepside 5 mg|
9673932|NCT05017194|Experimental|Emodepside 10 mg|
9673933|NCT05017194|Experimental|Emodepside 15 mg|
9673934|NCT05017194|Experimental|Emodepside 20 mg|
9673935|NCT05017194|Experimental|Emodepside 25 mg|
9673936|NCT05017194|Experimental|Emodepside 30 mg|
9673937|NCT05017194|Active Comparator|Albendazole|
9673938|NCT05017194|Placebo Comparator|Placebo|
9673939|NCT05016739|Experimental|CADISS System|
9673940|NCT05016830|Sham Comparator|Sham bilateral transcranial direct current stimulation|Sham bilateral transcranial direct current stimulation consisted of 2 milliamperes (mA) of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex, but the stimulation was turned off after 30 seconds. On Sham Stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
9673941|NCT05016830|Experimental|Bilateral transcranial direct current stimulation|Bilateral transcranial direct current stimulation consisted of 2 mA of current from the anodal electrode in the amblyopic primary visual cortex to the cathodal electrode located in the fellow primary visual cortex and the stimulation was on for 20 minutes. On stimulation onset, the participant's fellow eye was occluded and the participant performed a reading task for 20 minutes.
9673942|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 10mcg|Two applications of 10mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
9673943|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 25mcg|Two applications of a vaccine composed of a recombinant S1 antigen 28 days apart
9673944|NCT05016934|Experimental|A vaccine composed of a recombinant S1 antigen 50mcg|Two applications of 50mcg of a vaccine composed of a recombinant S1 antigen 28 days apart
9673945|NCT05016934|Placebo Comparator|Placebo|Two applications of placebo 28 days apart
9673946|NCT05017064|Experimental|Cryotherapy group|An intraoral ice pack will be placed on the mucosal groove during root canal treatment.
9673947|NCT05017064|Placebo Comparator|Control group|No ice pack will be used.
9673948|NCT05016908||Biofluid collection|Eligible volunteers will be asked to provide a single urine sample and undergo a single blood draw.
9673949|NCT05016999|No Intervention|Control|Volunteers in this group will not take any products.
10173842|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
10173843|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
9673950|NCT05016999|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
9673951|NCT05016648||PEARS patients|Patients who underwent the personalized external aortic root support procedure at the AMC. Cerebral monitoring measurements (NIRS, EEG, TCD and blood pressure) are used for the study.
9673952|NCT05016869|Experimental|Experimental|fruquintinib plus capecitabine
9673953|NCT05016973|Experimental|RC48-ADC+ Triplizumab|RC48-ADC on days 1 every 21 days plus triplizumab on days 1 every 21 days
9673954|NCT05016713|Active Comparator|Intervention group 1|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
9673955|NCT05016713|Active Comparator|Intervention group 2|Chlorhexidine mouthwash is added to the previous oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.
9673956|NCT05016713|Placebo Comparator|Control group|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
9673957|NCT05016674|Experimental|Laser-assisted liposuction|Laser-Assisted Liposuction with the LipoLife system.
9673958|NCT05016544|Experimental|Inetetamab+Pyrotinib|Dose Escalation and Dose Expansion: Inetetamab in combination with Pyrotinib in HER2 mutant or amplified participants with advanced or metastatic NSCLC
9673959|NCT05016635||Sub-arachnoid Hemorrhage Patients|
9673960|NCT05016492|Experimental|Digital game group|The digital game group received the standard 4-week course of rehabilitation but with an additional 30-min interactive digital game training session per week.
9673961|NCT05016492|Active Comparator|Standard rehab group|The standard rehab group received the standard 4-week course of rehabilitation delivered in one 30-min session per week.
9673962|NCT05016466||Group I. Patients with DLCO <80%.|Patients with DLCO <80% will be followed at baseline and once a year during the study
9673963|NCT05016466||Group II. Patients with DLCO ≥ 80%.|Patients with DLCO ≥80% only will be followed at baseline and year 5.
9673964|NCT05016557|Experimental|Mycoprotein|Bolus ingestion of mycoprotein providing 25g protein
9673965|NCT05016557|Experimental|Spirulina|Bolus ingestion of spirulina providing 25g protein
9673966|NCT05016557|Experimental|Chlorella|Bolus ingestion of chlorella providing 25g protein
9695029|NCT04782635|Experimental|AI group|"Care givers will be selected through permuted block.~They will be explained the procedure of intervention and written consent will be asked.~Mobile application will be installed in their mobile.~They will be explained the working of mobile application~Application will make a standard diet plan for the child according to the requirements of the child~Then the child will use the application for one month.~After one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application.~Nutritional status of the patient will be monitored including weight, height, clinical signs, dietary history and will be updated in application.~Then patient will follow the application for one month~After another one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application and nutritional status will be measured"
9695030|NCT04782635|Other|usual care group|"Caregivers (Mothers/fathers/guardians) will be selected through permuted block.~Patient weight, height, clinical signs will be noted.~Caregivers will be handed over pamphlet regarding dietary instructions on discharge.~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted including weight, height, clinical signs and dietary history.~Patient will leave hospital with no added dietary instruction.~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted weight, height, clinical sign, and dietary history."
9696456|NCT04766775|Other|Application of Silver Diamine Fluoride onto the carious teeth surfaces|The patients will receive Silver Diamine Fluoride (SDF) treatment to the carious primary teeth. These are teeth with no sign or symptom, radiographically the deepest layer of the caries lesion does not involve the pulp, the inter-radicular area appears normal). Procedure: apply vaseline, isolate the tooth with a cotton roll, remove the food debris, and gross plaque on the tooth cavity with a spoon excavator, dry the tooth, apply the SDF (a clear, colorless solution) onto the tooth cavity. This application lasts for one minute. Take the urine and hair sample to assess the silver and fluoride levels. Take the urine sample before the SDF treatment, in the first and second 24 hours after the SDF treatment. Take the hair samples before the SDF treatment, followed by days 7,14,30,60,75, and 90 after the SDF treatment. Send the hair and urine samples to the laboratory to assess the silver and fluoride levels. If caries remains active, restore the SDF treated after the day 90 review.
9696457|NCT04766762|Experimental|Acupuncture combined with placebo group|Patients in this group will receive acupuncture combined with placebo.
9696458|NCT04766762|Other|Sham acupuncture combined with medication group|Participants in this group will receive sham acupuncture plus flunarizine hydrochloride.
9696459|NCT04767139||pre-intervention group|mothers included for the pre-intervention assessment of contraceptive prevalence rate in the selected health centers
9696460|NCT04767139||post intervention group|mothers included for the post-intervention assessment of contraceptive prevalence rate in the selected health centers
10173844|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
10173845|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
9975465|NCT02887040|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for 104 weeks. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
9673967|NCT05016141|No Intervention|no intervention|Participants will be observed for 12 months. Participants will use the Health in Motion app to set goals and keep track of their health and health events, including falls. These participants will NOT receive the education modules or the exercise program.
9673968|NCT05016141|Experimental|digital fall prevention program|Participants will complete the Health in Motion digital fall prevention program for 12 months. This program consists of education modules (modified from the Matter of Balance Program) and exercises based on a digital translation of the Otago Exercise Program.
9673969|NCT05016154|Experimental|Online group CBT intervention|Online group CBT delivered via Microsoft Teams (a secure web-based video conferencing platform) in 10 weekly workshops of 60-75 minutes.
9673970|NCT05016154|Active Comparator|SilverCloud guided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are also contacted by the SilverCloud support team which offers them guidance and support while using the app.~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
9673971|NCT05016154|Active Comparator|SilverCloud unguided|"The SilverCloud app is a set of programs and courses that can be completed on a phone, tablet or computer. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.~Silvercloud uses principles borrowed from both a popular type of counseling called Cognitive Behavioral Therapy (CBT) and Mindfulness. Each module takes approximately 40minutes to complete. Students are encouraged to complete at least one module per week."
9673972|NCT05016154|Active Comparator|Mood Flow|The Moodflow app is a mood tracker and journal that helps students figure out what changes their mood. Students are encouraged to use the app as they see fit, although guidelines to using the app are provided.
9673973|NCT05016128|Experimental|S-ketamine|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
9673974|NCT05016128|Placebo Comparator|Saline|a 0.25 mg/kg bolus and 0.125 mg/kg/h via intravenous infusion during surgery
9673975|NCT05016115||physiotherapy students|Totally 120 physiotherapy students at a non-governmental university in Istanbul participated in this study.
9673976|NCT05016206|Experimental|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants received all 3 doses of danicopan in ascending fashion over 3 periods:~Treatment A (Period 1): Danicopan 400 milligrams (mg) and moxifloxacin-matching placebo.~Treatment B (Period 2): Danicopan 800 mg and moxifloxacin-matching placebo.~Treatment C (Period 3): Danicopan 1200 mg and moxifloxacin-matching placebo."
9673977|NCT05016206|Placebo Comparator|Control Arm (EFG and IJK)|"Participants received 1 of 2 treatment sequences (Treatment Sequence EFG or Treatment Sequence IJK) over 3 periods:~Treatment E (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin-matching placebo.~Treatment F (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin 400 mg.~Treatment G (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin-matching placebo.~Treatment I (Period 1): Danicopan-matching placebo (400 mg) and moxifloxacin 400 mg.~Treatment J (Period 2): Danicopan-matching placebo (800 mg) and moxifloxacin-matching placebo.~Treatment K (Period 3): Danicopan-matching placebo (1200 mg) and moxifloxacin 400 mg."
9673978|NCT05016388|Experimental|Collaborative Multidimensional Model (CMD)|The teams in the CMD group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the CMD training and the CMD will be installed in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
9673979|NCT05016388|Other|Standard Model (SM)|The teams in the SM group will be composed each of at least a MD, a psychologist, and a social worker. The teams will receive the SM training and the SM will be set in the primary health care (PHC) center. Then, the participants with depression who enter treatment for depression in their respective PHC center, will be enrolled and evaluated by an external team, blind to the interventions at the beginning, three and six months after.
9673980|NCT05016219|Active Comparator|Active Intervention plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
9975466|NCT02876302|Experimental|Paclitaxel (12weeks)|"Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
9975467|NCT02876302|Experimental|Ruxolitinib with Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~16 patients will be randomized from the Run-In 7 days of Ruxolitinib~The drug will be administered at a pre-determine dosage"
9975468|NCT02876302|Experimental|Ruxolitinib and Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively~32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel~The drug will be administered at a pre-determine dosage"
9673981|NCT05016219|Active Comparator|Active Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
10173846|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
9673982|NCT05016219|Active Comparator|Placebo Light plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
9673983|NCT05016219|Placebo Comparator|Placebo Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
9673984|NCT05016414|No Intervention|Control|4 days of strict bed rest
10173847|NCT03859219|Placebo Comparator|Placebo in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
10173848|NCT03859219|Placebo Comparator|Placebo in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
10173849|NCT03859219|Placebo Comparator|Placebo in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
10173850|NCT03859037|Experimental|Umbilical cord milking|One group will have umbilical cord milking and will ba assessed for blood pressure,oxygen saturation and heart rate by monitor
9673985|NCT05016414|Experimental|Lower body negative pressure|4 days of strict bed rest with nightly lower body negative pressure at -20mmHg
9673986|NCT05016427|Experimental|VT301(low dose)|VT301 low dose: 8.5x10^4 cells/kg
9673987|NCT05016427|Experimental|VT301(high dose)|VT301 high dose: 1.7x10^5 cells/kg
9673988|NCT05016102|Other|Control condition|30 min to watching exercise-related video
9673989|NCT05016102|Other|Aerobic exercise condition|20 minutes of moderate-intensity exercise on treadmill
9673990|NCT05016102|Other|Resistance exercise condition|One set of 15 repetition 9 muscle exercises dumbbell squat with chair, dumbbell right/left foot lunge, sit-up, push-up, back muscle with superman, dumbbell right/left bicep curl, dumbbell calf raise.
9673991|NCT05016440|Active Comparator|Lisinopril|10mg Lisinopril tablets
10173851|NCT03859037|Placebo Comparator|Immediate cord clamping|One group will have immediate cord clamping and will be assessed for bloob pressure,heart rate,oxygen saturation by monitor
10173852|NCT03859115|Active Comparator|preanesthesia-TENS|Patients in preanesthesia-TENS group receive TENS for 30 minutes at one arm before anesthesia.
10173853|NCT03859115|Sham Comparator|preanesthesia-sham|Patients in preanesthesia-sham group receive sham stimulation for 30 minutes at one arm before anesthesia.
10173854|NCT03859115|Experimental|sevoflurane-TENS|Patients in sevoflurane-TENS group receive TENS for 30 minutes at one arm under sevoflurane anesthesia.
10173855|NCT03859115|Active Comparator|sevoflurane-sham|Patients in sevoflurane-sham group receive sham stimulation for 30 minutes at one arm under sevoflurane anesthesia.
10173856|NCT03859115|Experimental|propofol-TENS|Patients in propofol-TENS group receive TENS for 30 minutes at one arm under propofol anesthesia.
10173857|NCT03859115|Active Comparator|propofol-sham|Patients in propofol-sham group receive sham stimulation for 30 minutes at one arm under propofol anesthesia.
9673992|NCT05016440|Placebo Comparator|Sugar pill|sugar pill
9673993|NCT05016375||T2DM|Individuals with T2DM.
9673994|NCT05016336|Experimental|strategy-based cognitive training + social interaction|The experimental group received twelve 60 minutes sessions of strategy-based cognitive training. (i.e., training in mnemonic memory strategies). We chose to train multiple strategies instead of a single one in effort to reach larger training gains. each session began with engaging conversations between the researcher and participants. After each practice trial, participants were encouraged to share their ideas/stories/associations or visual images (mnemonic uses) in turn. All other participants were allowed to give feedback relating to what can be learned from each mnemonic use or give their own ideas on how they think it can be improved.
9673995|NCT05016336|Active Comparator|social interaction|The social interaction control group received the same number of group meetings but without the strategy training. Meetings content consisted of providing tools for making social connections, providing tools for interpersonal communication and raising the participant's sense of personal well-being through group contact.
9673996|NCT05016349|Experimental|All trans-retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral All trans-retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
9673997|NCT05016349|Experimental|Mifepristone, Cannabidiol (Epidiolex) , All trans-retinoic acid and tamoxifen|Patients will receive oral Mifepristone daily for 4 weeks ,after which daily oral All trans-retinoic acid, tamoxifen and Cannabidiol (Epidiolex) is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
9673998|NCT05016349|Experimental|Mifepristone , All trans-retinoic acid, Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, All trans-retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
10173858|NCT03859076|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
9673999|NCT05016349|Experimental|9 cis retinoic acid, Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 9 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
9674000|NCT05016349|Experimental|Mifepristone, 13 cis retinoic acid , Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
9674001|NCT05016349|Experimental|9 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral 9 cis retinoic acid and Mifepristone daily for 2 weeks ,after which daily oral Cannabidiol (Epidiolex) is added to the regimen for 2 weeks , after which daily oral tamoxifen is added to the regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
9674002|NCT05016349|Experimental|13 cis retinoic acid , Mifepristone Cannabidiol (Epidiolex) and tamoxifen|Patients will receive oral Mifepristone, 13 cis retinoic acid and Cannabidiol (Epidiolex) daily for 4 weeks ,after which daily oral tamoxifen is added to the regimen , a. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.
9674003|NCT05016349|Sham Comparator|Standard therapy|Patients will receive the approved standard therapy
9674004|NCT05016180|Placebo Comparator|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
9674005|NCT05016180|Experimental|Ropivacaine|Before the induction of anesthesia, Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
9674006|NCT05016362||Group A|blepharoplasty with repositioning of the nasal fat pad to the central arcus marginalis of the superior orbital rim during surgery.
9674007|NCT05016362||Group B|blepharoplasty with repositioning of the nasal fat pad to orbitoglabellar groove during surgery.
9674008|NCT05016063|Experimental|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR T cells
9674009|NCT05016076|Active Comparator|Dexamethasone|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
9674010|NCT05016076|Placebo Comparator|Placebo (0.9% sodium chloride)|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
9674011|NCT05016076|Active Comparator|Inspiratory pressure (10 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
9695031|NCT04782739||Description of PMTCT service provision and uptake at healthcare facilities|Aggregated data will be collected from all 1560 public healthcare facilities in Zimbabwe on key indicators including antenatal testing and treatment of HIV and syphilis, and management of HIV-exposed and HIV-positive infants. Data will be collected from March 2015 (5 years prior to the pandemic) to the end of the study, to explore trends over time.
9827767|NCT02467387|Experimental|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
9975469|NCT02869009|Experimental|clopidogrel plus aspirin group|the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
9975470|NCT02869009|Experimental|aspirin group|the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.
9975471|NCT02855697|Experimental|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
9975472|NCT02807597|Experimental|Phase I Dose Level 1: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.05 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
9975473|NCT02807597|Experimental|Phase I Dose Level 2: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.075 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
9975474|NCT02807597|Experimental|Phase I Dose Level 3: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.1 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
9674012|NCT05016076|Active Comparator|Inspiratory pressure (15 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
9674013|NCT05016076|Active Comparator|Inspiratory pressure (20 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
9674014|NCT05016076|Active Comparator|Inspiratory pressure (25 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
9674015|NCT05016076|Active Comparator|Video intubating stylet|A tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved.
9674016|NCT05016076|Active Comparator|Video laryngoscopy|A tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients.
9674017|NCT05016076|Active Comparator|Direct laryngoscopy|Tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
9674018|NCT05016076|Active Comparator|Goal-directed hemodynamic therapy|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2.61 In brief, if cardiac index < 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is < 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
9674019|NCT05016076|No Intervention|Usual care (control)|Subjects allocated to the control group are hemodynamically managed as per anesthesiologist preference. Typically, isolated hypotension (20% decrease in mean arterial pressure below baseline or < 60 mmHg) is treated by single or consecutive boluses of norepinephrine 5 or 10 μg. If hypotension persists, repeat boluses of ephedrine 4 mg will be administered until mean arterial pressure is above 60 mmHg. If hypotension is accompanied by signs of hypovolemia (urine output < 0.5 ml·kg-1·hr-1 and/or an increase in heart rate > 20% above baseline), crystalloid or colloid fluids will be given until urine output and/or heart rate are normalized. If hypotension persists despite volume challenge, norepinephrine will be used.
9674020|NCT05016089|Experimental|Simplified Pilates exercise group (SPEG)|The participants in the SPEG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks. Each participant will undertake a total of 24 exercise sessions.
9674021|NCT05016089|Other|Wait-list control group (WLCG)|The participants in the WLCG will participate in the 16-style simplified Pilates exercise sessions (about 60 minutes each) in a group (about 10 participants in each group) twice a week for 12 weeks after two scheduled assessment sessions and a waiting period of 12 weeks in between. Each participant will undertake a total of 24 exercise sessions.
9975475|NCT02807597|Experimental|Phase I Dose Expansion: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I dose escalation portion)~9 patients will be enrolled (6 invasive ductal carcinoma and 3 DCIS)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
9674022|NCT05016193|Experimental|Intervention Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~Participants will be asked to wear the Axem Home prototype headband when doing their daily upper-extremity rehabilitation exercises at home.~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once per week."
9827768|NCT02467387|Placebo Comparator|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
9975476|NCT02807597|Experimental|Phase II: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I portion)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
9975477|NCT02763956|Experimental|Gelstix|The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.
9975478|NCT02763956|Placebo Comparator|Placebo|Intradiscal saline solution (1 mL NaCl 0.9%) injection.
9674023|NCT05016193|Active Comparator|Control Group|"Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist.~Participants will be asked to keep track of how many minutes of rehabilitation they have completed as per standard care.~Participants will perform a short motor assessment while wearing the Axem Home prototype headband once at the beginning of the study and again at the end of the study during the clinical assessment sessions."
9674024|NCT05015933|Experimental|Refill at home|Patients will have one pump refill at home instead of at the hospital.
9674025|NCT05016050|Experimental|Digital therapeutic|Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.
9674026|NCT05015920|Experimental|Mobilization,harvest,transduction,conditioning,treatment,engraftment|Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.
9674027|NCT05015868|Experimental|IDENTIFICATION OF THE CAUSE OF THE EPILEPSY AND OF THE EPILEPTOGENIC ZONE (sequential approach)|"Step1: standard of care.~acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data~complete neuropsychological assessment~genetic tests through Next generation sequencing epilepsies panel, or exome~Step 2: experimental~- combined Electroencephalogram-Functional brain magnetic resonance imaging registration.~Step 3: experimental~In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~execution of High Density-Electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone(PI, Italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
9975479|NCT02710097|Experimental|Active THC and Placebo Ethanol|
10173859|NCT03859076|Active Comparator|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
10173860|NCT03859206|Experimental|empyema patients having medical thoracoscopy|"patients having empyema will undergo medical thoracoscopy as follow :~With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.~the intervention : is breaking the septation within the loculated empyema"
10173861|NCT03859206|No Intervention|tube thoracostomy in patients with empyema|after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.
9527522|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide + Pembrolizumab|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5~Pembrolizumab will be administered starting on Week 12 Day 78 and for up to 2 years"
9527523|NCT03219346|Experimental|Oral hygiene|
9527524|NCT03219385|Experimental|Treatment with the Mirabilis System|
9527525|NCT03219645|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
9527526|NCT03219645|Placebo Comparator|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
9527527|NCT03219125||Group 1 (cases)|occurence of incident major osteoporotic fracture less than 12 weeks
9527528|NCT03219125||Group 2 (controls)|no history of fragility fracture
9527529|NCT03219177|Experimental|Patient education group|
9527530|NCT03219177|Active Comparator|Control- Standard of care counseling|
9527531|NCT03218969|Experimental|Study period 1|"Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by~Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by~Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3)."
9527532|NCT03218969|Experimental|Study period 2|"Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by~Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by~Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9)."
9527533|NCT03219008|Experimental|Depression/underload 1|This group would be treated with fluoxetine from the minimum dosage.
9527534|NCT03219008|Experimental|Depression/underload 2|This group would be treated with fluoxetine combined with cognitive behavior treatment
9527535|NCT03219008|Experimental|Depression/underload 3|This group would be treated with fluoxetine and amfebutamone from the minimum dosage.
9527536|NCT03219008|Experimental|Depression/underload 4|This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.
10173862|NCT03858972|Experimental|Tesetaxel (oral) and capecitabine (oral)|"Cohort 1: Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.~Cohort 2: On Cycle 1, Day -1, either a single morning dose of capecitabine at 825 mg/m2 (Cohort 2A) or 1,250 mg/m2 (Cohort 2B). On Cycle 1, Day 1, a single dose of tesetaxel (27 mg/m2), followed 2 hours later by capecitabine (825 mg/m2), followed by an evening dose of capecitabine (825 mg/m2). Capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the morning dose on Day 2 through evening dose on Day 14 of Cycle 1. Starting with Cycle 2, tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle."
9674028|NCT05015907|Experimental|Selective supraclavicular nerve block|After induction of anesthesia, the anesthesiologist sterilizes the skin of the area to be punctured. In the test group, an Ultrasound-guided selective supraclavicular nerve block is performed using 0.5% Ropivacaine 0.1mL/kg (Maximum dose: 5mL).
9674029|NCT05015907|Active Comparator|Control|The nerve block is not performed in the control group.
9674030|NCT05015972|Experimental|CTA30X UCAR-T treatment|CD19+ R/R B Hematologic Malignancies patients be treated with a single dose of CTA30X UCAR-T cells. Total dose of(5-30)*10E6/kg cells will be administered at Day 0
9674031|NCT05015946|Experimental|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
10173863|NCT03858959|Experimental|HYBENX® Oral Tissue decontaminantTM (HBX)|HYBENX® Oral Tissue decontaminantTM is a concentrated aqueous solution of sulfonated aromatics and free sulphates. Once placed onto susceptible organic material, the product instantly absorbs free and electrostatically bonded water, denaturing the molecular structure of the organic matter. Biofilm is expected to be especially sensitive to the disruptive action of HBX solution by virtue of its porous structure and high water content.
9674032|NCT05015959||mortality outcomes|mortality classification into preventable, potentially preventable and non-prevenatable
9674033|NCT05016037|Other|Lexically Based Speech Intelligibility Recast|Speech recasts are likely to improve speech intelligibility in Down Syndrome. The goal of this study is to induce change in speech intelligibility in order to study phonological, acoustic and suprasegmental sequelae of improvements in speech.
9674034|NCT05015790|Experimental|use of virtual reality Bliss Solution|in the experimental arm the patient will receive the usual practice associated with a virtual reality session (20 minutes renewable) in a world chosen with the patient beforehand
9674035|NCT05015790|No Intervention|current practice, without Bliss Solution|patient will receive the usual practice, local anesthesia
9674036|NCT05016011|Experimental|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.
9674037|NCT05016011|Active Comparator|Marrow cellution (standard treatment)|Patients will undergo marrow cellution surgical procedure.
9674038|NCT05015660|Experimental|left bundle branch pacing|
9674039|NCT05015660|Active Comparator|Right ventricular pacing|
9975480|NCT02710097|Experimental|Active THC and Active Ethanol|
10173864|NCT03858959|Active Comparator|Chlorhexidine Digluconate CorsodylTM (CHX)|Chlorhexidine Digluconate CorsodylTM Dental Gel 1% is an antiseptic gel with cationic nature, effective against a wide range of Gram positive and negative bacteria, favourable to the plaque control and oral inflammation prevention.
10173865|NCT03858946|Sham Comparator|Simple trapeziectomy|Simple trapeziectomy with two sham incisions for primary thumb carpometacarpal osteoarthritis
10173866|NCT03858946|Experimental|Weilby|Ligament reconstruction interpositions arthroplasty modo Weilby for primary thumb carpometacarpal osteoarthritis
10173867|NCT03858933|Experimental|Limbic Modulation Index Neurofeedback|"This arm of the study will undergo a novel neurofeedback treatment, targeting downregulation of deep limbic structures, specifically the amygdalae.~Participants in this arm will complete 15 neurofeedback sessions."
10173868|NCT03858933|Active Comparator|Alpha/Theta Neurofeedback|"This arm of the study will undergo a proven PTSD neurofeedback treatment, alpha/theta regulation, during which participants will try various mental strategies to increase the presence of theta waves.~Participants in this arm will complete 15 neurofeedback sessions."
10173869|NCT03858777|Active Comparator|Sarcoidosis patients without evidence of active myocarditis|A single blood draw.
10173870|NCT03858777|Experimental|Sarcoidosis patients with evidence of active myocarditis|Two blood draws 2 months apart.
10173871|NCT03858777|Active Comparator|Acute ST elevation myocardial infarction (STEMI)|Three blood draws, baseline, 6 hours and 24 hours.
10173872|NCT03858777|Placebo Comparator|Healthy controls|A single blood draw
10173873|NCT03858725|Experimental|D569/CKD-374 5mg|"Period 1: D569 Tab. 1T~Period 2: CKD-374 5mg Tab. 1T"
10173874|NCT03858725|Experimental|CKD-374 5mg/D569|"Period 1: CKD-374 5mg Tab. 1T~Period 2: D569 Tab. 1T"
10173875|NCT03858660||Elderly|Healthy elderly No intervention.
10173876|NCT03858738||group A: women aged 25-49 years|"Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5.~Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device."
10173877|NCT03858738||Group B: Women aged 25-49 years or 50 ≥|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 1 or 2.Thermography examination was performed with the use of Braster device.
9527537|NCT03219008|Experimental|Atypical 1|This group would be treated with fluvoxamine from the minimum dosage.
9827769|NCT02467465|Experimental|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
9975481|NCT02710097|Experimental|Placebo THC and Active Ethanol|
9975482|NCT02710097|Placebo Comparator|Placebo THC and Placebo Ethanol|
9975483|NCT02709954|Experimental|Active THC and Placebo Ethanol|
9674040|NCT05015582|Experimental|Treatment|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C~Intraop: Use of upper body and lower forced air warming intra-operative at 32 and 42˚C respectively and IV fluids with hotline fluid warmer set at 42˚C"
9674041|NCT05015582|Active Comparator|Control Group|"Preop: Use of full body forced air warming pre-operative at ambient (32˚C) for at least 30 minutes and fluids from warmed cabinet set at 45˚C~Intraop: Use of upper body forced air warming intra-operative at ambient (32˚C) and IV fluids at room temperature"
9674042|NCT05015556|No Intervention|Casting|Casting of the distal radius for 6 weeks
9674043|NCT05015556|Active Comparator|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
9674044|NCT05015738|Other|Traditional diabetes education|"The subjects and activities were applied to the control group, who received traditional diabetes education, between 8:00 and 10:00 with the classical method, which lasted 2 hours, for 10 weeks. The training was completed by the researcher with the verbal narration method. Diabetes Achievement Assessment Test with question and answer method was administered to the students at the beginning and end of the application. These questions were the same questions asked to the experimental group. Interaction of groups with each other was limited. Students were informed about this and their consent was taken.At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels."
9674045|NCT05015738|Experimental|Diabetes Education supported by digital tools|The subjects included in the course content were given between 10:00-12:00 with the animation supported method, which lasted for 2 hours. The animations were created by the researchers to reflect all guidelines for diabetes. The scenario of the animation video was prepared in line with the training content. Storyboards in videos and animations were created with the collaboration of researchers and experts in their fields (software specialists, computer programmers). The animation video was voiced in Turkish by a professional actor. Animations are 2 minutes each and a total of 18 minutes long. The 'Kahoot' application, a Web 2.0 tool, was used to apply Diabetes Achievement Evaluation Test. At the end of the course, students' opinions were taken through the form developed by the researchers. Instructional Materials Motivation Survey (IMMS) was used to measure to student' motivation levels.
9674046|NCT05015530||Test Medical Device|Healsea Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
9674047|NCT05015855|Placebo Comparator|OBGYN-PrEP|OBGYN-PrEP has 4 parts: (1) prioritize PrEP; (2) train providers in PrEP and intervention; (3) identify PrEP-appropriate women through a risk screen; and (4) monitor progress and fidelity to protocol.
9674048|NCT05015855|Experimental|NP-PC PrEP|NP-PC PrEP incorporates the standard of care and practices in OBGYN-PrEP but enhances access to additional skilled providers, as the PrEP provider burden is shifted to a Nurse Practitioner (NP) who will use a sexpositive approach to deliver PrEP services via telemedicine
9674049|NCT05015764|Experimental|Reprieve Cardiovascular System|
9674050|NCT05015764|Active Comparator|Standard of Care|
9674051|NCT05015595|Active Comparator|Memantine|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of Memantine up to 20mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Memantine will be reduced at 10mg/day due to safety reasons before the end of treatment (T5)."
9674052|NCT05015595|Placebo Comparator|Placebo|"For thirty-two-week double-blind up-titration treatment period (from T0 to T4) each patient will receive a daily administration of placebo 20 mg/day.~Subsequently, each patient will undergone to a double-blind down-titration treatment period for eight-weeks (from T4 to T5). At T4, the dose of Placebo will be reduced at 10mg/day, following the study protocol, before the end of treatment (T5)."
9674053|NCT05015543|Experimental|Patients paticipating in the Personal Training Program|The study patients complete two training sessions per week (60 minutes each) under supervision (16 weeks)
9674054|NCT05015725||Treated hypothyroidism|Patients with treated hypothyroidism
9674055|NCT05015621|Active Comparator|study group|all subjects will receive study treatment in 21-day cycle, Surufatinib 250mg, QD and Toripalimab, 240mg, IV drip, Q3W, D1, the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first
9674056|NCT05015621|Other|control group|FOLFIRI group subjects will receive study treatment in 14- day cycle, Irinotecan: 180 mg/m^2, iv drip over 30～90 minutes, on Day 1; Calcium folinate: 400 mg/m^2, iv drip for about 2 hours, given upon completion of infusion of Irinotecan on Day 1; 5-FU: 400 mg/m^2, iv bolus, given upon completion of infusion of Calcium folinate on Day 1, followed by 2400 mg/m^2 continuously iv drip for 46～48 hours.
9674057|NCT05015647|Experimental|LP group|LP group (n=17) was prescribed high calories/low proteins diet (30 Kcal/kg and 0.6-0.7gr/kg respectively) supplemented with commercial protein free products (protein content <2%).
9674058|NCT05015647|Active Comparator|NP group|NP group (n=18) was prescribed high calories/normal proteins diet (30 kcal/kg and 0.8 gr/kg respectively)
9674059|NCT05015465||70 patients with juvenile SLE.|Anterior segment OCT for juvenile SLE patients.
9674060|NCT05015465||70 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
9674061|NCT05015777|Experimental|Intervention Group|Participated in the exercise programme
9674062|NCT05015777|No Intervention|Control Group|Were advised not to change anything about their current lifestyle, and in particular not to undertake any new structured physical activity.
9674063|NCT05015842|Experimental|Kinesio Tapping plus Conventional Physical Therapy - Experimental Group|"Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).~The KT was applied to the back once a week with a treatment duration of 2 weeks. Each KT was applied for continuous three days and the next KT was applied after a break of two days. Each participant in the experimental group was assessed for any allergy reaction of the skin to KT."
9975484|NCT02709954|Experimental|Active THC and Active Ethanol|
10173878|NCT03858738||Group C: Woman aged 50 years or over|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
9674064|NCT05015842|Other|Conventional Physical Therapy alone - Control Group|Both groups received conventional physical therapy treatment consisting of therapeutic exercise, heat therapy and manual therapy. All the patients received manual therapy techniques that including joint mobilization and therapeutic exercise that including piriformis stretching as well as bridging exercises to strengthen the core stability muscles (i.e., strengthening of transverses abdominis, erector spinae and lumbar multifidus).
9674065|NCT05015699|Experimental|HT Supreme|Device: HT Supreme ( R&D by Sinomed, Tianjin, China) Drug: 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system interventions
9674066|NCT05015517|Active Comparator|ESPB Group|This group will receive ultrasound-guided erector spinae plane block and subarachnoid block.
9674067|NCT05015517|Active Comparator|FIB Group|This group will receive supra-inguinal fascia iliaca block and subarachnoid block .
9674068|NCT05015829||Classical low-flow low-gradient aortic stenosis|LVEF<50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
9674069|NCT05015829||Paradoxical low-flow low-gradient aortic stenosis|LVEF>50% SVi < 35.0 mL/m2 Aortic mean gradient < 40 mmHg AVA < 1.0 cm2.
9674070|NCT05015816|Experimental|Group A: Time series|Individuals at high risk of developing melanoma will be invited to attend for sequential TBP imaging, full body skin examination by a Dermatologist and completion of a case report form (CRF) every three months for two years. At the end of the study participants will also be invited to complete a feasibility questionnaire
10173879|NCT03858673||Ligations group|VTH via the Tsuzi method with residual uterine ligament ligation (ligations group)
9674071|NCT05015816|No Intervention|Group B: Baseline cohort|All patients who undergo standard care and are selected for total body photography (TBP) imaging will be invited to consent to this group. Any individuals who have had previous TBP imaging will also be eligible to enter Group B of this study. A baseline CRF will be completed and a participant feasibility questionnaire. There will be no additional images taken for the purposes of the study and no additional clinic visits in relation to this part of the study. However, individuals who consent to Group B will also agree to share any future TBP images taken in the department over the next two years so that any sequential images can also be included in the analysis
9674072|NCT05015491|Experimental|Noom Healthy Weight Program|"The Noom platform uses a cognitive behavioral approach to weight loss that integrates set content with interaction with live coaches to support client efforts at behavior change. The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. It has 52 weeks of curriculum with 1-3 articles to read per day (Reading level: Grade 6-8)."
9674073|NCT05015894|Experimental|NNC0480-0389|All participants will be administered a single s.c. dose of 18 mg NNC0480-0389
9674074|NCT05015673|Experimental|SEP-363856 25mg|SEP-363856 25 mg given orally
9674075|NCT05015673|Experimental|SEP-363856 50mg|SEP-363856 50mg given orally
9674076|NCT05015673|Placebo Comparator|Placebo|Placebo given orally
9674077|NCT05015374|Placebo Comparator|placebo|Compared the difference of changes in psychometrics between Astaxanthin users and placebo group.
9674078|NCT05015374|Active Comparator|Astaxanthin|Compared the difference in adverse effects between Astaxanthin users and placebo group.
9674079|NCT05015400|Experimental|Fluid Increase|The increased fluid intervention arm will begin on day 2 after the onset of bleeding (day 1) of their phase 1 menses through day 5. For the increased fluid intake intervention, participants will a) consume an additional 64 oz (1.89 L) of plain water only on top of habitual fluid intake and b) aim to at least urinate 5 times per day.
9674080|NCT05015400|No Intervention|Fluid Habitual|The fluid habitual non-intervention arm will a) maintain normal fluid intake volume and beverage choices and a) urination frequency.
9674081|NCT05015361|Experimental|Treatment group A/B|Treatment group A: Remimazolam Tosilate Treatment group B: Remimazolam Tosilate
9674082|NCT05015361|Active Comparator|Treatment group C|Treatment group C: Propofol Injection.
9674083|NCT05015348|Experimental|O3A arm|participants of this arm will be provided with omega-3 PUFA
9674084|NCT05015348|Placebo Comparator|placebo arm|participants of this arm will be provided with same amount of palm oil as placebo
9674085|NCT05014997||Patient|30 male patients with Klinefelter syndrome who were not previously given testosterone replacement.
9674086|NCT05014997||Control|30 healthy control subject without diagnosis of any chronic disease
9674087|NCT05015075|Experimental|CR group|participants who have exercise-based cardiac rehabilitation program after PM.
9674088|NCT05015075|Placebo Comparator|non-CR group|participants who have only routine regular follow-up after PM instead of CR program
9674089|NCT05015153|Experimental|Intervention group|20 sessions of Pulmonary rehabilitation will be performed over a period of 3 months
9674090|NCT05015153|No Intervention|Control group|No Pulmonary rehabilitation
9674091|NCT05015010|Experimental|Alectinib|The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 96 weeks. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
9674092|NCT05015166|Experimental|Internet delivered self-help program with therapist support|"The intervention consists of 8 therapist-supported self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which they send to their therapist and receive feedback within a few days.~The treatment is based on principles from affect-focused psychodynamic psychotherapy."
10173880|NCT03858673||Without ligations group|Traditional VTH without residual uterine ligament ligation (without ligations group)
9527538|NCT03219008|Experimental|Atypical 2|This group would be treated with fluoxetine + cognitive behavior treatment
9975485|NCT02709954|Experimental|Placebo THC and Active Ethanol|
9975486|NCT02709954|Placebo Comparator|Placebo THC and Placebo Ethanol|
10173881|NCT03858829|Experimental|fear of movement scale|
9674093|NCT05015166|Active Comparator|Internet delivered self-help program without therapist support|The intervention consists of 8 self-help modules delivered over 8 weeks on a secure online platform. Modules consist of texts and video followed by exercises which the participants are encouraged to try. The treatment is based on principles from affect-focused psychodynamic psychotherapy.
9674094|NCT05015166|No Intervention|Waitlist|Participants will receive no intervention for 8 weeks.
9674095|NCT05015140|Experimental|experiment group|"The first day before the application of music to each of the 15 patients in the experimental group (D-1) 'Patient Identification First evaluation will be made by filling the form and then the Richard Campbell Sleep Questionnaire . The day before transplant (D-1) Starting from 10 days, calm music including nature sounds determined by the music therapist will be played using mp3 player. The Richard Campbell Sleep questionnaire will be filled again on the 10th day (D + 10) after the transplant."
9674096|NCT05015140|No Intervention|control group|"- The day before the transplant (D-1) for each of the 15 patients in the control group, first 'Patient Identification Form' and then 'Richard The first evaluations will be made by filling the Campbell Sleep Questionnaire, and standard treatment and care interventions will be given to the patients in this group.~The sleep questionnaire was filled out again on the tenth day (D + 10) after the transplant without any intervention."
9674097|NCT05015036||Minimally invasive surgery of the lumbar spine with ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
9674098|NCT05015036||Minimally invasive surgery of the lumbar spine|Minimally invasive surgery of the lumbar spine
9674099|NCT05015322|Active Comparator|subacromial injection|ultrasound (US)-guided subacromial injection
9674100|NCT05015322|Active Comparator|acromioclavicular joint and subacromial injection|ultrasound (US)-guided acromioclavicular joint and subacromial injection
9674101|NCT05015322|Active Comparator|suprascapular nerve block|ultrasound (US)-guided suprascapular nerve block
9674102|NCT05015244|Experimental|Von Willebrand Disease Type 2B patient with neurological symptoms|evaluation of patients using 3T (Tesla) Magnetic Resonance Imaging (MRI) and series of neuropsychological tests that cover virtually all cognitive domains.
9674103|NCT05015049||Neonatal population - hypertensive disorder of pregnancy|All babies born to a woman with a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
9674104|NCT05015049||Neonatal population - no hypertensive disorder of pregnancy|All babies born to a woman without a hypertensive disorder of pregnancy (HDP) and admitted to a neonatal unit in England and Wales between 1st January 2012 and 31st December 2020
9674105|NCT05015192|Experimental|NH102 3mg|NH102 3mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9674106|NCT05015192|Experimental|NH102 9mg|NH102 9mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9674107|NCT05015192|Experimental|NH102 20mg|NH102 20mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9674108|NCT05015192|Experimental|NH102 40mg|NH102 40mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9674109|NCT05015192|Experimental|NH102 60mg|NH102 60mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9674110|NCT05015192|Experimental|NH102 80mg|NH102 80mg, tablet, orally, once on Day 1 or NH102 placebo-matching tablet, orally, once on Day 1. NH102 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9674111|NCT05015179|No Intervention|Control|Laparoscopic partial nephrectomy is performed with an intraoperative ultrasound (US) control
9674112|NCT05015179|Experimental|Experimental|Underwent Laparoscopic partial nephrectomy with the aid of the mixed reality model
9674113|NCT05015205|Experimental|MET Group|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The exercises were performed 3 times per week for 4 weeks.
9674114|NCT05015205|Experimental|Control Group|Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. The exercises were performed 3 times per week for 4 weeks.
9674115|NCT05015062|Experimental|Mobile-based intervention with standardized incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive standardized compensation for performing the work.
9674116|NCT05015062|Experimental|Mobile-based intervention with performance-based incentive|Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive performance-based compensation for performing the work.
9527539|NCT03219008|Experimental|Atypical 3|This group would be treated with fluvoxamine + lithium from the minimum dosage.
9674117|NCT05015062|No Intervention|Control without intervention|Participants will not receive the mobile-based intervention
9674118|NCT05014945|Experimental|Atelocollagen group|After obtaining informed consent for the study, epidural nerve block was performed. The patient is asked to return to the outpatient clinic of the pain center after 2 weeks. At this time, when the NRS of back pain does not improve by more than 50% compared to before the epidural nerve block and the cross-sectional area of the multifidus muscle using ultrasound is 5 cm2 or less, final enrollment is decided. The evaluation of the cross-sectional area and thickness of the multifidus muscle using ultrasound is performed with the patient prone, and the cross-sectional area of the multifidus muscle is measured at the same position as the level of the lesion on MRI.
9674119|NCT05014958|Experimental|40 hz frequency exercise group|Individuals in this study group will receive exercise training at 40 hz frequency on whole body vibration device.
9674120|NCT05014958|Experimental|25 hz frequency exercise group|Individuals in this study group will receive exercise training at 25 hz frequency on whole body vibration device.
9674121|NCT05014958|Active Comparator|0 hz frequency exercise group|Individuals in this study group will receive exercise training at 0 hz frequency on whole body vibration device.
9674122|NCT05014711|Experimental|remifentanil group|After enrollment, remifentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
9674123|NCT05014711|Active Comparator|fentanil group|After enrollment, fentanil will be used for analgesia. Duration of mechanical ventilation, incidences of adverse events, interval from SBT to extubation, dosages and costs of analgesics and sedatives drugs will be observed.
9674124|NCT05014685|Experimental|RA group|
9674125|NCT05014685|Experimental|RAM group|
9674126|NCT05014685|Experimental|RAB group|
10173882|NCT03858556||Patients with lumbar disc herniation|"3times(baseline, 1weeks, 2weeks) of Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion in inpatients with lumbar intervertebral disc herniation hospitalized at Korean medicine hospital.~-Integrative Korean medicine treatment Procedure/Surgery: Chuna manipulation Drug: Herbal medicine Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s) Other: Other intervention(s)"
9674127|NCT05014685|Active Comparator|RABM group|
9674128|NCT05014763|Active Comparator|CTG from deep palate|The connective tissue graft harvested from the deep palate during flap elevation for implant placement
9674129|NCT05014763|Experimental|CTG from tuberosity|The connective tissue graft harvested from the tuberosity
9674130|NCT05014893|No Intervention|Control|Control group, without specific treatments
9674131|NCT05014893|Experimental|Cognitive training|This group receives treatments to improve cognitive function.
9674132|NCT05014880|Placebo Comparator|ICR (Intensive Cardiac Rehabilitation)|"20 patients will be randomly assigned to the standard of care group, which will receive the standard health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR group."
9674133|NCT05014880|Experimental|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|"20 patients will be randomly assigned to the Time-Restricted Eating (TRE) group which will be asked to limit the number of hours they eat in a day to 10 hours in addition to receiving the standard of care health and nutritional wellness guidelines that are required of UCSD's 9-week ICR program, referred to as the ICR x TRE group."
9674134|NCT05014906|Active Comparator|minocycline, azelaic acid|minocycline vs minocycline in comination with 15% azelaic acid for treatment of rosacea
9674135|NCT05014906|Experimental|azelaic acid|45 mg oral minocycline vs 45 mg oral minocycline plus 15% azelaic acid in the treatment of facial rosacea
9674136|NCT05015309|Experimental|SH3765 tablet|Daily oral administration of SH3765 tablet
9674137|NCT05014828|Experimental|Safety Run in Stage and Combination Assessment|lenvatinib + tislelizumab
9674138|NCT05015387|Active Comparator|SI group|Patients with periodontitis received subgingival instrumentation.
9674139|NCT05015387|Experimental|SI+PACNs group|Patients with periodontitis received subgingival instrumentation and subgingival application of collagen hydrogels with proanthocyanidins.
9674140|NCT05015387|No Intervention|Healthy controls|The no-treatment control group consisted of systemically healthy individuals with healthy periodontal state.
9674141|NCT05014477||Patients experiencing device embolization after left atrial appendage occlusion|Device embolization following either surgical or interventional left atrial appendage occlusion
9674142|NCT05014490|Experimental|Exib (Test)|A single oral dose of the test product Exib 120 mg etoricoxib film-coated tablets.
9674143|NCT05014490|Active Comparator|Arcoxia® (Reference)|A single oral dose of the reference product Arcoxia® 120 mg etoricoxib film-coated tablets.
9674144|NCT05014503|Experimental|Adaptive version of the therapeutic game|The adaptive therapeutic game will use a game-entry level that is based on the individual visual perceptual profile of the child. Children with higher visual perceptual capacities will be able to start the game at a higher entry level compared to children with lower visual perceptual capacities. Thereby, the entry level will also be different for the different games. In addition, the adaptive game uses an in-game adaptivity system that has been developed using artificial intelligence (more specifically, reinforcement learning): this means that the game can adjust the difficulty automatically, based on the game-behaviour and success of the child. Children learning fast, will more quickly move to higher difficulty levels compared to children learning slower. Thereby, this in-game adaptivity also enables children to return to lower difficulty levels when a difficulty level is too high.
10173883|NCT03858556||Normal|"baseline Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion.~-No treatment"
10173884|NCT03858751|Placebo Comparator|Placebo|Placebo capsule before bedtime
10173885|NCT03858751|Experimental|LTM1201AZ|LTM1201AZ capsule before bedtime
9674145|NCT05014503|Active Comparator|Non-adaptive version of the therapeutic game|The non-adaptive therapeutic game will use the same, lowest entry level for all children. During game play, a fixed stepwise increase in difficulty will be built in, not adjusted to the gaming behaviour or success of the child. All children will follow the same, gradual approach in difficulty and a fixed number of trials is set for each difficulty level. To prevent extreme frustration however, a safety margin is integrated by preventing the difficulty level to increase further when a child has more than a predefined number of unsuccessful trials. Likewise, the stepwise increase in difficulty level will only continue after a fixed, predefined number of successful trials. A child will also never return to a lower difficulty level, once a difficulty level is reached.
9674146|NCT05014516||Single arm|Those participants who have experienced a documented case (documented by positive COVID19 test and/or clinical history) mild or severe COVID19 infection including those with symptoms and those who were hospitalized with COVID19 infection, all of whom are within 3 months post recovery
9674147|NCT05014581|Experimental|Pre-emptive vasopressor|Pre-emptive continuous infusion of norepinephrine during intubation
9674148|NCT05014581|No Intervention|No vasopressor|No pre-emptive administration of vasopressors
9674149|NCT05014308|Experimental|piezocision group|piezocision surgical procedure was done according to Dibart's et al,
9674150|NCT05014308|Experimental|fiberotomy group|the fiberotomy procedure followed Edward's et al
9674151|NCT05014308|No Intervention|control group|no intervention
9674152|NCT05014594|Active Comparator|Group A (Dapaglifozin)|Group A will receive oral Dapaglifozin (10 mg/day) along with standard medical therapy for 6 months
9975487|NCT02703207|Active Comparator|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
9975488|NCT02703207|No Intervention|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
9975489|NCT02703207|No Intervention|OSA and comorbid COPD|Eligible elderly (age >/=60yrs) Veterans with moderate to severe Overlap Syndrome.
10173886|NCT03858751|Experimental|LTM1201AT|LTM1201AT capsule before bedtime
10173887|NCT03858751|Experimental|LTM1201AG|LTM1201AG capsule before bedtime
9975490|NCT02691338||patients undergoing thrombectomy|150 anesthetized patients undergoing intra-arterial catheterization for thrombectomy after CVA. The patients will be recruited at the Rambam Health Center, Haifa, Israel. The patients will undergo EEG recording during the procedure, without changing patient's standard treatment care. The EEG recording will continue after the procedure for four hours approximately, while the patients are admitted to intensive care unit (ICU).
10173888|NCT03858751|Experimental|LTM1201AD|LTM1201AD capsule before bedtime
10173889|NCT03858569|Active Comparator|Oxytocin|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus
10173890|NCT03858569|Active Comparator|Oxytocin plus uterine massage|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus and transabdominal uterine massage will be performed.
10173891|NCT03858920||General Responder Cohort (GRC) WTC Responders|General Responder Cohort (GRC) and who have chosen to undergo annual medical monitoring and treatment of their WTC-related conditions at Mount Sinai's Irving J. Selikoff Center for Occupational and Environmental Medicine (SCOEM), which is directed by Dr. M. Crane
10173892|NCT03858920||General Responder Cohort (GRC) Non WTC Responders|Members of the World Trade Center General Non Responder Cohort.
10173893|NCT03858608|Experimental|Counterweight Plus|"Total Diet Replacement phase (0-12 weeks) 825-853kcal/day low energy liquid diet (LELD) for 12 weeks Food Reintroduction phase (13-18 weeks) Wk 13: 400kcal/d LELD + 1 low-fat meal/day (c. 360-400 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1000kcal/day Wk 15: 200kcal/d LELD + 2 low-fat meals/day (c. 720-800 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1200kcal/day.~Wk 17: 3 low-fat meals per day (c.1080-1200 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1400kcal/day.~Weight maintenance phase (wks 19-52) Low-fat healthy eating weight loss maintenance intervention [target below 30% energy from fat, with flexibility to optimise individual compliance, to a maximum of 35%]"
10173894|NCT03858608|Active Comparator|Usual asthma care|Usual asthma management
9674153|NCT05014594|Placebo Comparator|Group B (Placebo)|Group B will receive placebo of Dapaglifozin along with standard medical therapy for 6 months
9695032|NCT04782739||Neonatal admissions at Harare Children's Hospital|Individual-level patient data will be collected on all neonates admitted for care at Harare Children's Hospital, including on patient characteristics, clinical status at presentation and outcomes. Data will be collected from February 2019 to the end of the study, to explore trends over time.
9695033|NCT04782739||Qualitative study|Qualitative study of 20 pregnant/lactating women accessing routine PMTCT services and 10 community healthcare workers from the Mabvuku and Kuwadzana Polyclinics. The estimated enrolment of 30 participants given in the study design section above refers to participants from this group only.
9695034|NCT04782505|Experimental|Cohort 1 (Part 1)|DWJ1248 100mg (100mg 1tab) PO
9695035|NCT04782505|Experimental|Cohort 2 (Part 1)|DWJ1248 200mg (100mg 2tab) PO
9695036|NCT04782505|Experimental|Cohort 3 (Part 1)|DWJ1248 300mg (100mg 3tab) PO
9695037|NCT04782505|Experimental|Group A (Part 2)|DWJ1248 100mg 2tab PO - Wash out - DWJ1248 200mg 1tab PO
9695038|NCT04782505|Experimental|Group B (Part 2)|DWJ1248 200mg 1tab PO - Wash out - DWJ1248 100mg 2tab PO
9975491|NCT02691338||Control - healthy individuals|20 health individuals under general anesthesia or sedation for other surgery or procedures. They will undergo EEG recording during the surgery/ procedure, to validate the sensitivity of the EEG to the effect of the anaesthetic medications.
9696461|NCT04766749|Experimental|Experimental|40 minutes before PCI by the nurse to the patient RIPC operation (RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times), and then do regular PCI operation
9975492|NCT02686411||Observational (survey)|Patients and caregivers complete surveys over 5-10 minutes before and after care in the PCU.
9975493|NCT02681549|Experimental|pembrolizumab plus bevacizumab|
9975494|NCT02666183|Experimental|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
10173895|NCT03858855|Experimental|Group I (bergamot essential oil)|Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
10173896|NCT03858855|Experimental|Group II (chamomile essential oil)|Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
10173897|NCT03858855|Experimental|Group III (ginger essential oil)|Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
10173898|NCT03858855|Active Comparator|Group IV (almond essential oil)|Patients inhale 7 drops of almond essential oil and complete journal as in group I.
10173899|NCT03858842||PF-ILD and SSc-ILD patients|PF-ILD and SSc-ILD patients
10173900|NCT03858790|Experimental|Experimental|Subjects' PINS spinal cord stimulator randomized to this arm is on always
10173901|NCT03858790|Sham Comparator|Control|Subjects' PINS spinal cord stimulator randomized to this arm is off for a week
10173902|NCT03858803|Active Comparator|FM2 first, LAST delayed|Parent intervention, Families Matter 2 (FM2), immediate, adolescent intervention, Living as a Safer Teen (LAST), delayed six months
9674154|NCT05014529||Control group|Polysomography show AHI less than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
9674155|NCT05014529||OSA without CPAP group|Polysomography show AHI greater than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.
9674156|NCT05014529||OSA with CPAP group|Polysomography show AHI greater than 15 events/h and participants receive CPAP more than 6 months.
9674157|NCT05014633|Experimental|EI skills training|Individuals in the intervention group received the pertinent training. The duration of the training for the intervention group was 16 hours (four four-hour sessions). The whole training process lasted for one month. EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
9674158|NCT05014633|No Intervention|Control|Individuals in the control group did not receive any training
9674159|NCT05014555||Group A Non-biologic Group|Participants on treatment regimen of mesalamine monotherapy or thiopurine monotherapy, or corticosteroids.
9674160|NCT05014555||Group B Anti-TNF Group|Participants on treatment regimen of maintenance montherapy of infliximab (at least 8 every 8 weeks), golilumamb (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly), or combination therapy of anti-TNF therapy as described above along with either 15mg of methotrexate or azathiprine at least 1.0mg/kg or 6MP 0.5mg/kg.
9674161|NCT05014555||Group C Ustekinumab Group|Participants on treatment regimen of ustekinumab monotherapy or combination therapy with methotrexate or azathioprine.
9674162|NCT05014555||Group D Vedolizumab Group|Participants on vedolizumab monotherapy or combination therapy with methotrexate or azathioprine.
9674163|NCT05014373|Active Comparator|Experimental: Favipiravir + Best supportive Care|Favipiravir (or Avigan) 1800 mg tablet 2x a day on Day 1 then 800 mg 2x a day from Day 2 to maximum of Day 14
9674164|NCT05014373|Placebo Comparator|Comparator: Best Supportive Care|Best supportive care or Standard Treatment includes oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases
10173903|NCT03858803|Active Comparator|FM2 and LAST simultaneous|Parents participate in Families Matter 2 (FM2) and adolescents in Living as a Safer Teen (LAST) intervention immediately following the baseline assessment.
9674165|NCT05014347||Health Care Professionals|Health Care Professionals (HCP) working in PancreatoBiliary Endoscopy and EUS Division of IRCCS San Raffaele (both endoscopists and nurses)
9674166|NCT05014347||"Expert patients"|a set of at least 30 outpatients undergoing EUS, who already underwent this procedure at least once
9674167|NCT05014347||Patients|100 consecutive patients undergoing EUS
9674168|NCT05014386|Active Comparator|Ahmed Glaucoma Valve Implantation|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
9674169|NCT05014386|Active Comparator|Ologen augmentation group|In addition to what is planned for the other Arm;, a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure.
9674170|NCT05014126|Experimental|Pain, Stress, & Emotions Class|No active or placebo comparator will be used. This is a single-arm study design.
10173904|NCT03858803|Active Comparator|Comparison arm|Comparison arm in which both parents and adolescents will be offered their respective interventions following the final assessment. Following the final assessment parents will be offered the Families Matter (FM2) intervention and youth the Living as a Safer Teen (LAST) intervention as an ethically justified service.
10173905|NCT03858881|Active Comparator|PROJECT PERSONALITY|
10173906|NCT03858881|Experimental|VR PERSONALITY PROJECT|
9674171|NCT05014009|Experimental|FIFA11+ and multidirectional training (MD)|Participants in the MD group will take part in an 8-week NMT intervention known to reduce the risk of sports injury and expected to improve COD movement strategies.
9674172|NCT05014009|Active Comparator|FIFA11+ and linear sprint training (LS)|Participants in the LS group will take part in an 8-week NMT intervention, which is known to reduce the risk of sports injury but is unlikely to improve COD movement strategies and is expected to improve linear sprint performance.
9674173|NCT05014100|Experimental|The treatment group|Orelabrutinib 150mg once daily in a 28-day cycle. Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days
9674174|NCT05014048|Active Comparator|vitamin D3|20 mikrog vitamin D3 daily, 3 months
9674175|NCT05014048|Placebo Comparator|Placebo|Placebo
9674176|NCT05013957||Retrospective analysis|Methylome of existing neuroendocrine tumor samples from the biobank of Basel University Hospital will be evaluated
9674177|NCT05013957||Prospective analysis|Methylome analysis of tumor samples of neuroendocrine tumor patients undergoing an operation or biopsy will be prospectively evaluated
9674178|NCT05013970|Other|Knee osteoarthritis|Patients with mild to moderate osteoarthritis who suffer from persistent knee pain treated with catheter-directed geniculate artery embolization
10173907|NCT03858881|Placebo Comparator|SHARING FEELINGS PROGRAM|
10173908|NCT03858543|Experimental|Fractional laser treatment & Poly-L Lactic Acid (Sculptra)|One Fractional laser treatment on half of the body with Sciton Laser and Scluptra
10173909|NCT03858543|Active Comparator|Fractional laser treatment|One Fractional laser treatment on half of the body with Sciton Laser
10173910|NCT03858530|Experimental|All Patients Enrolled|All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.
10173911|NCT03858582|Experimental|Arm A|Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles.
9975495|NCT02666183|Active Comparator|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose ~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
9674179|NCT05014152|Experimental|Single group|"This study is specially designed according to its age range and customized/non-customized range, and meets the requirements of ISO 80601-2-56 test population (table). Comply with the age range and population requirements of ISO 80601-2-56, as well as clinical and subject trials, including news to the population over five years old, and hopefuls must account for at least 30% of the total and less than 50% of the total.~Each subject uses Q-temp-w1 to measure axillary temperature and obtains 3 temperature values, and at the same time uses a reference body temperature patch (Omron thermometer MC-171W) to measure the other side axillary temperature, and 1 is measured Temperature value data. Perform clinical efficacy analysis based on the measurement results. The main evaluation indicators of the trial include clinical bias, limits of agreement, and clinical repeatability."
9674180|NCT05014191||Radiation therapy in frog leg position|
9674181|NCT05014191||Radiation therapy in straight leg position|
9674182|NCT05014035|Experimental|Exercise Intervention|
10173912|NCT03858582|Experimental|Arm B|Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles.
9527540|NCT03219008|Experimental|Atypical 4|This group would be treated with fluvoxamine + lithium + physical treatment
10173913|NCT03858582|Experimental|Arm C|Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles.
10173914|NCT03858465|Active Comparator|25 mg of ephedrine|participants who will receive intravenous 1,25mg/min ephedrine during 20 minutes (total dosage is 25 mg of ephedrine).
9674183|NCT05014165||Ancillary-Correlative (Cord Blood collection)|Accrue patients with ALL and AML who indicate having banked cord blood at birth through the COG Project:EveryChild (APEC14B1)
9674184|NCT05013788|Experimental|Treatment|
9674185|NCT05013788|Active Comparator|Control Group|
9674186|NCT05013918||Hospitalized people in Nursing Home|
9674187|NCT05013658|Active Comparator|junior|their anesthesia experiences are between 1 months and 1 year,
9674188|NCT05013658|Active Comparator|senior|Their anesthesia experiences are more than 4 years
9674189|NCT05013866|Active Comparator|Repair of resin Z350|Repair with Z350 on resin composite proximal
9674190|NCT05013866|Experimental|Repair of Tetric Evo Ceram Bulkfill|Repair with Tetric Evo Ceram on resin composite proximal
9674191|NCT05014178||Adult CKD stage 1-5 participants|"Age greater than or equal to 18 years~Estimated GFR < 90 mL/min/1.73m²"
9674192|NCT05014178||Adult transplanted participants|• Age greater than or equal to 18 years
9674193|NCT05014178||Adult dialysis participants|"Age greater than or equal to 18 years~More than 3 months duration of therapy"
9674194|NCT05014178||Adult ADPKD|• Age greater than or equal to 18 years
9674195|NCT05014178||Adults treated for nephrolithiasis|• Age greater than or equal to 18 years
9674196|NCT05014178||Adult healthy controls including kidney donors|"Age greater than or equal to 18 years~Lack of kidney disease, heart failure, liver cirrhosis and peripheral"
9674197|NCT05013814||Children with unilateral cerebral palsy|
9674198|NCT05013814||Typically developed children|
9674199|NCT05013593|Experimental|Symptomatic RCE|Bladder symptomatic group receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
10173915|NCT03858465|Active Comparator|0,3 mg of phenylephrine|participants who will receive intravenous 0,015mg/min phenylephrine during 20 minutes (total dosage is 0,3mg of phenylephrine).
10173916|NCT03858504|Experimental|Yoga Group|The yoga program will include breathing exercises, different postures, and meditation. The yoga will be performed in groups. The program will be supervised a physical therapist for two times in a week for eight weeks . A session will be fifty minutes (5-10 minutes: warming-up, 20-25 minutes: postures, 10-15 minutes: cooling down).
10173917|NCT03858504|Active Comparator|Home Exercise Group|Home exercise program will consist of trunk strengthening exercises. The patients will be asked to check the exercise days. Patients will be contacted with telephone once a week.
10173918|NCT03858426||Children with eosinophilic esophagitis|"Inclusion criteria:~Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus > 15 eos / CGA)~And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids~Exclusion criteria:~Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)~Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids)."
10173919|NCT03858452|Active Comparator|Pelvic floor muscles training group|Pelvic floor muscles exercises twice a day for 30 min
10173920|NCT03858452|Active Comparator|Diaphragm muscles training group|Breathing exercises twice a day for 30 min
9696462|NCT04766749|No Intervention|Control|A standard cuff is placed on the patient's thigh by the nurse 40 minutes before PCI but it is not inflated. PCI is performed 40 minutes later
10173921|NCT03858452|Active Comparator|Abdominal muscles training group|Abdominal muscles exercises twice a day for 30 min
10173922|NCT03858478|Experimental|Biktarvy arm|one tablet of BIKTARVY including [TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) ] one tablet once a day for 48 weeks
9674200|NCT05013593|Experimental|Healthy RCE|Healthy group without bladder symptoms receiving red clover extract containing the two isoflavones formononetin and biochanin A. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening with a meal)
9674201|NCT05013593|Placebo Comparator|Symptomatic PL|Bladder symptomatic group receiving placebo
9674202|NCT05013593|Placebo Comparator|Healthy PL|Healthy group without bladder symptoms receiving placebo
9674203|NCT05013853|Active Comparator|Resin Z350 of proximal posterior teeth|Restorative with Z350 composite of proximal caries lesions or restorations replacement
10173923|NCT03858309|Experimental|Breathing Group 1|Arm 1 will receive an 8-week intervention that consists of a set of breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
10173924|NCT03858309|Active Comparator|Breathing Group 2|Arm 2 will receive an 8-week intervention that consists of slow breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
10173925|NCT03858491|Experimental|Cobicistat|Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).
9674204|NCT05013853|Active Comparator|Resin Tetric N Ceram Bulkfill of proximal posterior teeth|Restorative with Tetric N Ceram Bulkfill composite of proximal caries lesions or restorations replacement
9674205|NCT05013853|Experimental|Resin Fill Up! of proximal posterior teeth|Restorative with Fill Up! composite of proximal caries lesions or restorations replacement
10173926|NCT03858699||Individuals with stroke|Participants in sub-acute and chronic phases post-stroke (>1 month post-stroke) will be recruited for participation in this study.
10173927|NCT03858699||Adult control participants|Even age distributions will be recruited in the adult control group, stratified under 40 years old and over 40 years old.
10173928|NCT03858387||Meropenem|Critically ill patients who require meropenem therapy
10173929|NCT03858387||Imipenem|Critically ill patients who require imipenem therapy
10173930|NCT03858595|Experimental|Intervention|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. Investigators will train our study participants (high-risk pregnant women) on how to use Salu Health Gauge to measure BP as well as how to charge them. Trained FFWs will visit the households weekly and synchronize the device with a tablet computer to collect the stored data. The FFWs will measure the weight of the participants using a digital weighing scale at enrollment and on a monthly bases thereafter. Investigators will keep monitoring up to termination of pregnancy. in any health issue arises, our health worker will ensure that an appropriate referral is made to a tertiary care facility. This intervention will be in addition to the conventional antenatal and postnatal care."
10173931|NCT03858595|No Intervention|Control group|All those women randomized to the control arm will receive conventional antenatal and postnatal care only. Investigators will collect the outcome data from the households and/or the health centers by follow-up visits or over phone. Investigators will consell participants, women both in the control group, to make at least four antenatal visits. In addition, Investigators will provide counselling about eating healty and keeping physically active during pregnancy. Investigators will provide general nutrition education on taking balanced energy and protein diet.
10173932|NCT03858218||Pediatric cancer survivors group|Childhood cancer survivors refers to those who have completed cancer treatment for at least six months, the pediatric cancer survivors must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese.This group will be required to fill in the questionnaires set.
10173933|NCT03858218||Healthy children group|Healthy children must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese. This group will be required to fill in the questionnaires set.
10173934|NCT03858413||Chronic kidney disease stage V|No intervention
10173935|NCT03858413||Chronic kidney disease stage III|No intervention
10173936|NCT03858101||PKU subjects|
10173937|NCT03858101||Age and sex-matched non-PKU comparison subjects|
10173938|NCT03858192|Experimental|Elective colorectal surgery|Patients who are expected to undergo a major colorectal surgery procedure will be recruited to this study preoperatively and followed-up until three months postoperatively.
10173939|NCT03858192|Experimental|Emergency abdominal surgery|Patients who are admitted as an emergency and undergo abdominal surgery will be recruited from general surgery wards either preoperatively or within 48 hours of surgery. They will be followed-up until three month postoperatively.
10173940|NCT03858192|Experimental|Medical patients|Patients admitted under general medicine with an infection will be recruited from general medicine wards within 48 hours of admission. They will be followed-up until three month post-admission
10173941|NCT03858270|Experimental|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
10173942|NCT03858270|Placebo Comparator|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
9674206|NCT05013723||Intervention|Patients who received casirivimab-imdevimab antibody infusion
9674207|NCT05013723||Control|Matched control group who did not receive MAb, matched on diagnosis date, age, gender and Utah COVID-19 Risk Score
9674208|NCT05013697|Experimental|Experimental group 1|"Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib (4-6 cycles).~Maintenance treatment: TQB2450 injection+Anlotinib."
9674209|NCT05013697|Experimental|Experimental group 2|Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection (4-6 cycles). Maintenance treatment: TQB2450 injection.
9674210|NCT05013710||Plan A Health|Founded in 2018, Plan A Health, Inc seeks to address health care disparities in rural communities by improving access to reproductive and sexual care. Beginning April 2021, the first Plan A mobile health clinic opened, serving five counties in the Mississippi Delta. The care team in the clinic includes a community health worker, nurse practitioner, volunteer providers, residents, and a collaborating physician.
10187954|NCT03720925|Experimental|TDI treatment|"The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and from between 3 to 6 months after the TDI treatment ."
9674211|NCT05013710||Just the Pill|Just The Pill offers telemedicine appointments by phone or online for sexual and reproductive health needs that is delivered to the patient's home. The organization is also opening a mobile health clinic that will deliver care directly to communities.
9674212|NCT05013515|Experimental|Salivary Gland Carcinomas|Patients with Salivary Gland Carcinomas were given Surufatinib .
9674213|NCT05013606|Experimental|Active Treatment: Hydrogen water|Hydrogen pills mixed in a water glass that is ingested up to five time a day for 30 days.
10187955|NCT03720912|Experimental|Online Family Education Modules|Patients will receive online family education modules.
9674214|NCT05013606|Placebo Comparator|Placebo: Inactive pill|Inactive pills mixed in a water glass that is ingested up to five time a day for 30 days.
9674215|NCT05013671|Active Comparator|residents with BPPV|
9674216|NCT05013671|Other|residents without BPPV|
9674217|NCT05013684|Active Comparator|Older adults with BPPV|
9674218|NCT05013684|No Intervention|Older adults without BPPV|
9674219|NCT05013762|Active Comparator|Speed-biased complex motor skill training|"Participants will perform 400 complex movements per day over 4 days over a one-week period. The task requires participants to navigate their hand through a track projected on the surface of a table with a width of 5cm. Participants receive adaptive score based on their movement time. ."
9674220|NCT05013762|Other|Accuracy-biased complex motor skill training|The accuracy-biased group receives a dose equivalent intervention with a emphasize on accuracy. The width of the track projected on the table is narrower (less than 2cm) and the adaptive score received are based on their accuracy to say within the boundary of the track.
9674221|NCT05013749|Active Comparator|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
9674222|NCT05013749|Active Comparator|Partial myometrial resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesicouterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
9975496|NCT02666183|Active Comparator|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
10187956|NCT03720912|No Intervention|Control|Patients will not receive any intervention.
9674225|NCT05013489|Experimental|Mindfulness, compassion and intercare based Intervention|An Eight week mindfulness and intercare group online program.
9674226|NCT05013489|No Intervention|Waiting list|Psychological support if needed. No other intervention.
9674227|NCT05013450|Experimental|Dupilumab + anti-PD-1/PD-L1 (SOC)|Patients will continue SOC immunotherapy with PD-1/PD-L1 blockade following progression of disease, and three q3w cycles of dupilumab will be administered
9674228|NCT05013203||Aseptic (uninfected) Revision Spine Surgery|Aseptic revision for indications including but not limited to hardware failure, adjacent segment pathology, radiculopathy, instability, cord compression.
9674229|NCT05013203||Spine Surgery for Degenerative Disease|Primary degenerative pathology surgery where a disc sample is extracted to enable spinal decompression or fusion. The potential primary surgeries include but are not limited to microdiscectomy, laminectomy, and lumbar and cervical fusion
9674230|NCT05013203||Septic (infected) Revision Spine Surgery|Spine surgery for known infection specifically: epidural abscess or septic revision. Epidural abscess must be managed surgically for inclusion. Septic revision cases include any surgery to address infected hardware from a previous spinal surgery.
9674231|NCT05013060|Active Comparator|The mixture of probiotics and microcapsulated sodium butyrate|One billion of the following strains: Bifidobacterium lactis FloraActive 32269, Bifidobacterium longum FloraActive 32946, Bifidobacterium bifidum FloraActive 32043, Lactobacillus rhamnosus FloraActive 19070-2, Lactobacillus acidophilus FloraActive 32418 and 150 mg microcapsulated sodium butyrate, and 64 mg fructooligosaccharides
9674232|NCT05013060|Placebo Comparator|Placebo|Maltodextrin
9674233|NCT05013398|Experimental|The Together Webinar Programme (TTP-Webinar)|Participants receive the six weekly session TTP-Webinar intervention.
9674234|NCT05013398|No Intervention|Waitlist condition|Participants do not receive any intervention as part of waitlist condition. Note: Following the collection of measures at the follow-up time point, participants assigned to the waitlist condition were offered four TTP-Webinar groups to sign up to.
9674235|NCT05012969|Experimental|intervention|HipStop bandage for 12 weeks to prevent dislocation of the hip
9674236|NCT05012969|No Intervention|control|normal procedure after dislocation of hip which is information on movement restrictions
9674237|NCT05013112|Placebo Comparator|Placebo group|Patients receive no additional therapy.
9674238|NCT05013112|Experimental|Metformin group|Patients receive metformin 500mg twice daily from discharge.
10173943|NCT03858257|Experimental|High flow nasal oxygen|The gas temperature will commence at the 'High' setting (ranges 30-32º Celsius) and titrated downwards if the patient complains of irritation. The gas flow rate will commence at 30 liters per minute prior to sedation administration and be titrated up to 70 liters per minute as tolerated by the patient after sedation has been administered. The fraction of oxygen in the gas will be commenced at 50% (same as that delivered from 6 liters per minute via facemask) and can be titrated upward according to patient requirements (i.e. increased if there is evidence of hypoventilation, airway obstruction or inadequate oxygenation, decreased during use of diathermy). Anesthesia Assistants at the site will be provided with training in the use of this mode of oxygen delivery prior to study commencement.
10173944|NCT03858257|Other|Standard oxygenation|Supplemental oxygen through a facemask with the flow rate chosen by the clinician responsible for sedation as per their standard practice. The oxygen flow rate is typically commenced at 6 liters per minute and can be titrated up to 15 liters per minute.
10173945|NCT03858374|Experimental|Experimental group|Patients in experimental group were transferred by air-suspending mattress.
10173946|NCT03858374|Active Comparator|control group 1|Patients in control group 1 were transferred by slide board.
9674239|NCT05013112|Experimental|Empagliflozin|Patients receive Empagliflozin once daily from discharge.
9674240|NCT05013164|Experimental|Folinic Acid + Behavioral Therapy|Children receiving folinic acid and behavioral therapy. Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks.
9674241|NCT05013164|No Intervention|Behavioral Therapy|Children received only behavioral therapy for 12 weeks.
9975497|NCT02616302|Experimental|Weight ≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
9674243|NCT05013034|Placebo Comparator|Placebo (Current Standard of Care)|Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
9674244|NCT05013034|Experimental|Basiliximab|Basiliximab in addition to Current Standard of Care for SARS-CoV2 hypoxemic pulmonary diease
9674245|NCT05013151|Experimental|Date consumption|Consumption of 6 dates a day until 41 weeks of gestation
9674246|NCT05013151|Experimental|Castor oil consumption|One time consumption of 60 CC of Castor oil
9674247|NCT05013151|No Intervention|Control Group|
9674248|NCT05013268|Experimental|Tislelizumab plus TP regimen as neoadjuvant therapy for local advanced cervical carcinoma|"Experimental:~Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin The subjects enrolled in this trial will receive tislelizumab 200mg ivgtt d1, paclitaxel (175mg/m2 ivgtt d1) or docetaxel (75mg/m2 ivgtt d1), cisplatin (75mg/m2 ivgtt d1) or carboplatin (AUC=5 ivgtt d1). The regimen will be repeated every 3 weeks for 3 cycles. Chemotherapy regimen will be selected by investigators.~Subjects will be enrolled serially."
9674249|NCT05013320|Active Comparator|Dexmedetomidine only|dexmedetomidine is administered during the surgery
9674250|NCT05013320|Experimental|Combined dexmedetomidine and glycopyrrolate|glycopyrrolate and dexmedetomidine are administered during the surgery
9674251|NCT05013372|Other|Dose-escalation|Dose -1：0.1×10E+6/kg Dose 1：0.25×10E+6/kg Dose 2：0.5×10E+6/kg Dose 3：1.0×10E+6/kg Dose 4：2.0×10E+6/kg
9674252|NCT05013021|Other|Sedentary participants|"Series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT).~These measurements consist of physiological measurements (VO2max), neuromuscular capacities (force-speed profile), autonomic nervous system responses (heart rate variability) and blood markers (lactate, CK, cytokinases, µRNA)."
9674253|NCT05012956|Active Comparator|POP group|Pelvic organ prolapse patients enrolled for sacrocolpopexy surgery at UZ Leuven.
9674254|NCT05012956|Active Comparator|Control group|Patients assigned to gynecologic laparoscopic surgery, other than sacrocolpopexy, at UZ Leuven.
9674255|NCT05012904|Experimental|Parent Support Group|From 10 minutes before the procedure until 10 minutes after the procedure, a parent provided support to their child. To provide support, parents held children on their laps, holding the extremity from which the blood was drawn, holding the children's hands, and communicating with their children during the process in the child's room. The parent support intervention was coordinated by the nurse involved in conducting the study.
9674256|NCT05012904|No Intervention|Control Group|Routine venipuncture procedure was performed on the control group. From 10 minutes before the procedure until 10 minutes after the procedure, the parent was present in their child's room but did not participate in the procedure. The standard parent presence procedure was coordinated by the nurse involved in conducting the study.
9674257|NCT05013125|No Intervention|Conventional Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo usual colonoscopy as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
10173947|NCT03858374|Active Comparator|control group 2|Patients in control group 2 were transferred by bedsheet.
10173948|NCT03858244||IS with SDB|Idiopathic scoliosis with untreated and treated sleep-disordered breathing
10173949|NCT03858244||IS without SDB, controls|Idiopathic scoliosis without sleep-disordered breathing, control group
10173950|NCT03858127||Male infants born <32 weeks gestation|
9674258|NCT05013125|Active Comparator|ENDO-AID assisted Colonoscopy - ENDO-AID assisted Colonoscopy|Patients will undergo ENDO-AID assisted colonoscopy with all polyps treated as per usual practice, followed back to back by ENDO-AID assisted colonoscopy
9674259|NCT05012930|Experimental|Study Provided Diet - Meat|A group of complementary foods provided to participants by researchers.
9674260|NCT05012930|Experimental|Study Provided Diet - Plant|A group of complementary foods provided to participants by researchers.
9674261|NCT05012930|Experimental|Study Provided Diet - Dairy|A group of complementary foods provided to participants by researchers.
9674262|NCT05012930|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
9674263|NCT05012579|Experimental|TAPS delivered by Cala device|Two 40-minute TAPS sessions daily for 28 days, recommended as once in the morning and once in the evening.
10173951|NCT03858179|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
10173952|NCT03858179|Experimental|PBMT + training/ placebo + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
9674264|NCT05012683|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
9674265|NCT05012683|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
9674266|NCT05012501||PVT group|（1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2) In accordance with the diagnostic criteria of portal vein thrombosis in the 2015 European Society of Hepatology Clinical Practice Guidelines: Hepatic Vascular Diseases. Color ultrasound, CT, MRI, and other imaging studies confirmed the presence of portal vein thrombosis and the specific location of the thrombosis.
9674267|NCT05012501||without PVT group|(1) Patients with cirrhosis diagnosed in accordance with the 2019 Guidelines for the Diagnosis and Treatment of Cirrhosis;(2)Color ultrasound, CT, MRI, and other imaging studies confirmed the absence of portal vein thrombosis and the specific location of the thrombosis.
9674268|NCT05012852|Experimental|VagiVitalAC|
9674269|NCT05012852|No Intervention|No treatment|
9674270|NCT05012592|Active Comparator|Intervention Group|Health Awareness Program To Reduce Malnutrition and Helminth Infestation Among Primary School children
10173953|NCT03858179|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
10173954|NCT03858179|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
9674271|NCT05012592|No Intervention|Comparison group|No Intervention during intervention period
9674272|NCT05012514|No Intervention|Control- Without intervention|The participants have the right side of the abdomen as a control without inversion
9674273|NCT05012514|Active Comparator|LLLT- With intervention|The participants received the LED PBMT treatment with associated red and infrared wavelengths sequentially on the left side of the abdomen
10173955|NCT03858153|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
9674274|NCT05012553|No Intervention|no education about self and peer assesment|Stoma care skills of the group who did not receive self- and peer-assessment training will be evaluated.
9674275|NCT05012553|Experimental|education of self and peer assesment|Stoma care skills of the group who received self and peer assessment training will be evaluated.
10173956|NCT03858153|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
10173957|NCT03858166|Active Comparator|Standard group|6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy.
10173958|NCT03858166|Experimental|Adjusted group|6mg PEG-rhG-CSF was administrated subcutaneously when ANC < 1000/mm3 after chemotherapy.
10173959|NCT03858062|Active Comparator|Open loop|14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
10173960|NCT03858062|Experimental|Closed loop|4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
10173961|NCT03858114|Experimental|Mild-to-moderate physical activity|Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
9674276|NCT05012839||Complicated appendicitis|The development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
9674277|NCT05012839||Non-complicated appendicitis|No development of complicated appendicitis, diagnosed during appendectomy or by pre-operative image study
9674278|NCT05012566|Experimental|Hyaluronic Acid filler and Botulinum Toxin group|"Hyaluronic Acid filler:~Juvederm Volbella: it will be used in the softer soft tissue, beacuse its reology is the softest~Juvederm Volift: it will be used in malar area, because its reology is intermediate between the three products~Juvederm Voluma: il will be used unstructured area bacause it has the best rheologic characteristics in the reintegration of loss of tissue.~The differents products are going to use in different areas, depending on the area of the paralysis.~Botulinum Toxin:~Vistabex (50U/vial): it is going to be used in the controlateral area of the paralysed face, in order to relax muscle hyper-tonicity.~Dosage and administration steps will be selected according to the clinical situation."
9674279|NCT05012566|No Intervention|Control group|The control group will undergo at the same examinations of the treated group but it will not be subjected to any treatment.
9674280|NCT05012748|Experimental|Ketogenic diet|The participants are instructed to follow a ketogenic diet consisting of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant.
9674281|NCT05012748|No Intervention|Normal western diet|The participants are instructed to follow a normal western diet without emphasising any particular macronutrient.
9674282|NCT05012787|Experimental|SCB-2019 Group|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
9674283|NCT05012787|Placebo Comparator|Control Group|Havrix and Placebo
9674284|NCT05012709|Experimental|intervention group|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
9674285|NCT05012709|No Intervention|control group|The TAU group received usual routine care.
9674286|NCT05012800|Experimental|COVID-19 Vaccines in older adults|Healthy people between the ages of 60 and 80 inoculated coronavirus vaccine on day 0 and day 21, respectively.
9674287|NCT05012800|Experimental|COVID-19 Vaccines in young adults|Healthy people between the ages of 20 and 59 inoculated coronavirus vaccine on day 0 and day 21, respectively.
9696463|NCT04766736||Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
10173962|NCT03858114|Active Comparator|Cultural group program|Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
10173963|NCT03858439|Experimental|Intervention|Single arm study. All participants will receive dietary intervention.
9674288|NCT05012475|Experimental|Participants|The study involves a pre-intervention phase (4 weeks long), followed by a cause and effect training phase (1 week long), followed by an intervention phase (12 weeks long), and ending with a post-intervention phase (4-weeks long) for a total of 5-6 months from start to finish.
9674289|NCT05012774|Experimental|Aim 1, Sentence Training: Sentence Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed whole sentence feedback following an attempt to lipread each sentence.~Participants receive pre- and post-training tests."
9674290|NCT05012774|Experimental|Aim 1, Sentence Training: Word Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed whole word feedback following an attempt to lipread each sentence. Word feedback is for correct words and words that are perceptually similar but incorrect responses.~Participants receive pre- and post-training tests."
9674291|NCT05012774|Experimental|Aim 1, Sentence Training: Consonant Feedback|"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading.~This arm gives printed consonant word feedback following an attempt to lipread each sentence. Word feedback is for correct words, but only the consonants are given as feedback for words that are perceptually similar but incorrect responses.~Participants receive pre- and post-training tests."
9674292|NCT05012774|No Intervention|Aim 1, Sentence Training: No Training Control|Participants receive only the pre- and post-training tests.
9674293|NCT05012774|Experimental|Aim 2, Nonsense Word Training|Participants train to lipread nonsense words that name nonsense pictures. Participants receive pre- and post-training tests.
9674294|NCT05012774|Experimental|Aim 3, Audiovisual Nonsense Word Training|"Participants train to recognize audiovisual spoken nonsense words that name nonsense pictures and are presented in speech-shaped noise. The paradigm is the same as in Aim 2.~Participants receive pre- and post-training tests."
10173964|NCT03857958|Experimental|FCSEMS|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In FCSEMS group, patients are inserted with Fully covered self-expandable metal stent (FCSEMS) bilaterally for malignant hilar biliary stricture via endoscopic retrograde cholangio-pancreatography.
10173965|NCT03857958|Active Comparator|Plastic stent|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In plastic stent group, patients are inserted with plastic stents bilaterally for malignant hilar biliary stricture.
9674295|NCT05012774|Experimental|Aim 3, Audiovisual Sentence Training|"Participants receive the same training paradigm from Aim 1 with the most effective feedback type from Aim 1. But the sentences are audiovisual and in speech-shaped noise.~Participants receive pre- and post-training tests."
9674296|NCT05012696|Experimental|Sequence A: Non-invasive ventilation - High flow nasal cannula|Once participants are extubated they will receive one hour of Non-invasive ventilation followed by one hour of high-flow nasal cannula.
9674297|NCT05012696|Experimental|Sequence B: High flow nasal cannula - Non-invasive ventilation|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of Non-invasive ventilation
9674298|NCT05012449|Experimental|Arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with the arthrography-assisted joystick technology.
9674299|NCT05012449|No Intervention|No arthrography-assisted joystick technology.|Adolescent transitional ankle fracture who were treated with open or close reduction .
9674300|NCT05012670|Experimental|[14C]-Paxalisib Capsule|Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).
9674301|NCT05012657|Experimental|Prosthesis|Patient is temporarily fit with Point Partial partial finger prosthetic system
9674302|NCT05012436|Experimental|YHD1119 75mg, 150mg NF|CLcr (mL/min/1.73m2) >= 60 Period 1 : YHD1119 75 mg Period 2 : YHD1119 150 mg NF
9674303|NCT05012436|Experimental|YHD1119 75mg|60 > CLcr (mL/min/1.73m2) >= 30 Period 1 : YHD1119 75 mg Period 2 : NA
9674304|NCT05012423|Placebo Comparator|SAD Cohorts 1 to 7: Participants Receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo.
9674305|NCT05012423|Experimental|SAD Cohorts 1 to 7: Participants receiving ECC0509|Participants in each SAD cohort will be randomized to receive 1 of 7 escalating doses (1 mg, 4 mg, 10 mg, 20 mg, 40 mg, 60 mg, or 80 mg).
9674306|NCT05012423|Placebo Comparator|MAD Cohorts 1 to 3: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
9674307|NCT05012423|Experimental|MAD Cohorts 1 to 3: Participants receiving ECC0509|Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (8 mg, 20 mg, or 40 mg) for 14 days.
9674308|NCT05012384|Experimental|Vergence exercises|Orthoptic vergence exercises
9674309|NCT05012384|Placebo Comparator|Generic treatment|
9674310|NCT05012215|Experimental|Paravertebral|Ultrasound-guided thoracic paravertebral block
9674311|NCT05012215|Active Comparator|Caudal|Caudal block
9674312|NCT05012293|Experimental|Experimental: Fatigue Manipulation|
9674313|NCT05012137|Experimental|SASIS-FICB|All subjects will be enrolled in the experimental group and receive an Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
9674314|NCT05012345|Experimental|4 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 4 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
9674315|NCT05012345|Experimental|6 Weeks cast immobilisation|Patients with fracture distal radius ( indicated for conservative treatment) will stay in a below-elbow cast for 6 weeks. Following immobilisation, treatment will be the same for both groups, in which additional physiotherapy after removal of the cast is advised and exercises to train wrist function will be given. As extra structured advice programmes may cause no extra benefit for the patient, this was not generally prescribed. However, during FU visits, patients will be asked if they were treated by a physiotherapist. If this is the case, details on the number of sessions per week and the total number of weeks the patient received physiotherapy, will be collected.
9975498|NCT02616302|Experimental|Weight ≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
9695041|NCT04782518||Participants with PD|Adults with Parkinson Disease. This is an observational study without an intervention.
9695042|NCT04782908|Experimental|Transcatheter tricuspid valve edge-to-edge repair|Patients will undergo transcatheter tricuspid valve edge-to-edge repair (TTVR) and hemodynamic characteristics will be analysed on a multimodal approach using cardiac magnetic resonance imaging and pressure volume loop analysis before and after TTVR.
9695043|NCT04782596|Experimental|One-centimeter resection|In the study subjects enrolled into this study arm, one-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
9695044|NCT04782596|Experimental|Two-centimeter resection|In the study subjects enrolled into this study arm, two-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
10173966|NCT03858088||Training set|Cohort of consecutive liver transplants performed in 2016-2017 from 14 liver transplant centers in Italy
10173967|NCT03858088||Validation set|Cohort of consecutive liver transplants performed in 2016-2017 from 2 liver transplant centers in the United Kingdom
10173968|NCT03858075|Experimental|Single ascending doses with BLU-782|
10173969|NCT03858075|Placebo Comparator|Single ascending doses with placebo|
9695045|NCT04782479||in the air|the position of the practitioner's hand holding the tube was placed in the air while the assistant pulling back the stylet.
10173970|NCT03858075|Experimental|Multiple ascending doses with BLU-782|
9695046|NCT04782479||on the cheek of a manikin|the position of the practitioner's hand holding the tube was placed on the cheek of a manikin while the assistant pulling back the stylet.
9695047|NCT04782388|Experimental|Staccato alprazolam|Study participants will receive Single dose of Staccato alprazolam on Day 1 of the Treatment Period.
9695048|NCT04782388|Placebo Comparator|Staccato placebo|Study participants will receive placebo on Day 1 of the Treatment Period.
9695049|NCT04782284|Experimental|Comprehensive swallowing rehabilitation|
9695050|NCT04782284|Active Comparator|Swallowing education|
9695051|NCT04782336|Experimental|Group A (Sample Collection - Symptomatic Patients)|The patient will be completing or has completed a SOC Influenza A/B and/or COVID-19 and/or RSV test on the day of study.
9695052|NCT04782336|Experimental|Group B (Sample Collection - Asymptomatic Patients)|To enable the participation of site's who do not routinely providing SOC testing.
9695053|NCT04782141|Experimental|Positioning the trunk and upper limb to improve the coordination the hand.|The study investigated the effects of the trunk and upper limb positioning on improving wrist and hand coordination.
9695054|NCT04782076|Experimental|Dabigatran + Selpercatinib|Dabigatran as single dose administered orally on Day 1 followed by a single dose of dabigatran coadministered with a single dose of selpercatinib on Day 8 orally.
9695055|NCT04782089|Experimental|Camrelizumab+Fluzoparib|
9695056|NCT04782245|Experimental|Treatment group Daplagliflozin|
9695057|NCT04782245|Placebo Comparator|Control group|
9695058|NCT04782375|Experimental|Treatment Arm A|discontinue antiviral treatment
9695059|NCT04782375|Active Comparator|Treatment Arm B|continue antiviral treatment
10173971|NCT03858075|Placebo Comparator|Multiple ascending doses with placebo|
9695060|NCT04782115|Experimental|1.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
9695061|NCT04782115|Experimental|1.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 1.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
9695062|NCT04782115|Experimental|2.0mg RC28-E injection Q8|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 3 consecutive times; From then on to the 48th week, the patients were visited every 4 weeks and given medicine every 8 weeks.
9975499|NCT02616302|Experimental|Weight >30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
10173972|NCT03858075|Experimental|Food effect of BLU-782 taken with food|
10173973|NCT03858075|Experimental|Food effect of BLU-782 taken without food|
10173974|NCT03857971|Other|Coronary OCT imaging of non flow-limiting lesion|Coronary OCT imaging will be performed of fractional flow reserve (FFR) negative lesions to assess plaque morphology.
10173975|NCT03858296|Experimental|Emotional awareness|4 modules of emotional awareness training
9975500|NCT02616302|Experimental|Weight >30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
10173976|NCT03858296|Experimental|Cognitive reappraisal|4 modules cognitive reappraisal training
10173977|NCT03858296|Experimental|Awareness + reappraisal|4 modules emotional awareness and cognitive reappraisal training
9975501|NCT02615184|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 weeks.
9975502|NCT02615184|Experimental|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 weeks.
9975503|NCT02615184|Experimental|Maintenance of Healed EE: Dexlansoprazole 30 mg|Participants on Dexlansoprazole 60 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
10173978|NCT03857997||Patients|
10173979|NCT03857997||Parents|
10173980|NCT03857789|Other|Regular care|Participant will be received by Healthcare professional (HCP). The HCP will administer a questionnaire. The HCP will discuss the results.
9527541|NCT03219008|Experimental|Anxiety/somatization 1|This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage.
9674316|NCT05012319|Experimental|treatment arm|"Nitric Oxide Nasal Spray Enovid"
9674317|NCT05012319|Placebo Comparator|Placebo|Placebo
9674318|NCT05012007|No Intervention|Control arm: No Reminder|Usual care
9674319|NCT05012007|Experimental|Automated phone reminder|Standard reminder via phone (audiocare)
9674320|NCT05012007|Experimental|Text reminder|Standard reminder via text (VEText)
9674321|NCT05012033||Group A|Patients started acutely on high dose prednisolone (>30mg for any inflammatory condition)
9674322|NCT05012033||Group B|Patients on longer term anti-inflammatory doses of prednisolone to treat any medical condition warranting their use, including post COVID.
9674323|NCT05012033||Group C|Patients receiving multiple high doses of methylprednisolone or dexamethasone in association with oral prednisolone.
9674324|NCT05011968|Experimental|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce (soil, water, harvesting time)
9674325|NCT05011968|Experimental|Experimental: intervention group|The intervention group was assigned to biofortificated Iodine crop lettuce.
9674326|NCT05012189|Active Comparator|Oseltamivir|Nursing homes randomized to receive oseltamivir for treatment and chemoprophylaxis for influenza.
9674327|NCT05012189|Experimental|Baloxavir|Nursing homes randomized to receive baloxavir for treatment and chemoprophylaxis for influenza.
9674328|NCT05011877||Acute Hypercapnic Respiratory Failure patients with Sleep Disorders|Acute Hypercapnic Respiratory Failure patients with Sleep Disorders
9674329|NCT05011877||Acute Hypercapnic Respiratory Failure patients without Sleep Disorders|Acute Hypercapnic Respiratory Failure patients without Sleep Disorders
9674330|NCT05011942|Placebo Comparator|normal saline control arm|ii. normal saline used after initial skin incision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point.
9674331|NCT05011942|Active Comparator|Irrisept irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects
9674332|NCT05011825|Experimental|Pregnant Moms' Empowerment Program|The PMEP is a 5-session program, delivered prenatally. The first three sessions address violence and mental health and the final two sessions address labor/delivery, infant health and early parenting.
9975504|NCT02615184|Experimental|Maintenance of Healed EE: Dexlansoprazole 15 mg|Participants on Dexlansoprazole 30 mg treatment arm in Healing Period will receive half dose, dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
9674333|NCT05011825|No Intervention|Control|Control group participants received information about community resources, but did not receive any study-related intervention.
9674334|NCT05011955|Experimental|Mindfulness, compassion and intercare based Intervention|Four week, one hour peer week, online group intervention plus home work based on mindfulness, compassion and intercare based programs.
9674335|NCT05011955|Active Comparator|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work based on psychoeducation about stress, anxiety, selfcare and effective communication.
9674336|NCT05011955|Other|General curricular intervention|All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.
9674337|NCT05011838|Experimental|A multi-component intervention to improve hypertension care and control|The intervention will be implemented in Commune 2. It will integrate activities related to 1) Health services redesign, 2) Clinical staff training and 3) Patient and community engagement. The intervention activities will be implemented by health services staff with technical assistance from the investigation team.
9674338|NCT05011838|No Intervention|Routine Care|The Commune 6 was selected as control area, where routine care will be delivered.
9674339|NCT05011916|No Intervention|Control group|Patients in the control group received 0.1% fluorometholone eye drops (0.1% fluorometholone + 0.05% tacrolimus eye drops for patients after corneal transplantation). The patients applied 0.1% fluorometholone eye drops 4 times daily for 10 weeks. Patients were instructed to continue with their usual ophthalmic medication regimens, such as topical antibacterial and antiviral drugs.
9674340|NCT05011916|Experimental|Low-concentration group|Patients in the low-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
9674341|NCT05011916|Experimental|Medium-concentration group|Patients in the medium-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
9674342|NCT05011916|Experimental|High-concentration group|Patients in the High-concentration group applied 4mg/ml KDR2-2 suspension eye drops 4 times daily for 6 weeks. The rest of the medication regimen is the same as the control group.
9696464|NCT04766736||Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)|The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
10173981|NCT03857789|Experimental|New care|Participant will be received by Healthcare professional (HCP). The social robot will administer a questionnaire. The HCP will discuss the results.
10173982|NCT03858023|Experimental|Hippotherapy|Children in hippotherapy arm will participate in hippotherapy (30 min/sessions, twice a week, 15 weeks)
10173983|NCT03858023|No Intervention|Control|Children in control group will not receive hippotherapy
10173984|NCT03857854|Experimental|treatment group|pirfenidone group
10173985|NCT03857854|Placebo Comparator|placebo group|control group
9674343|NCT05011903|Experimental|PFI+CDF with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) and Cross-tailored Dynamic Feedback (CDF) related to alcohol use and related sexual behavior. They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
9674344|NCT05011903|Experimental|PFI+GHI with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior, and generic health information (GHI). They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
9674345|NCT05011903|Experimental|PFI-only with no diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior. They do not complete weekend diary surveys.
9674346|NCT05011903|No Intervention|Control|Participants in this condition get no intervention and do not complete weekend diary surveys.
9674347|NCT05011747|Active Comparator|single-site VT group|Viscotrabeculotomy is performed through a superonasal triangular scleral flap.
9674348|NCT05011747|Active Comparator|two-site VT group|Viscotrabeculotomy is performed through a superonasal and an inferotemporal triangular scleral flap.
9674349|NCT05011786||Open repair group|children with inguinal hernia who were repaired with open high ligation of the hernia sac through an inguinal incision.
9674350|NCT05011786||Laparoscopic repair group|children with inguinal hernia who were repaired laparoscopically by closing the the PPV at the level of internal ring with a purse string suture
9674351|NCT05011760|Experimental|PET|[C-11]NPA PET Scan
9674352|NCT05011591|Experimental|swimming economy|This is a study based on a comparative clinical trial (effect of an imposed V and/or SR on the swimming economy of swimmers or para-swimmers). This longitudinal study is carried out on a representative sample of swimmers and para-swimmers selected for their potential at the Paris 2024 Olympic and Paralympian Games. Following a standardized warm-up, all swimmers will perform intermittent swimming tests of progressive velocity in a 50 m indoor pool in their swimming specialty with or without an imposition of the SR to adopt. During the trials, the swimmers and para-swimmers will be equipped with inertial measurement units, as well as a heart rate monitor and tissue oximeters. The swimming and non-swimming phases will also be filmed continuously. Gas exchanges will be recorded 2 minutes after the warm-up and during the 7 minutes of passive recovery. Micro blood samples will be taken from the earlobe at the end of the warm-up and at 1, 3, 5 and 7 minutes of recovery between each trial.
9674353|NCT05011539||Ovarian cancer|The patients with ovarian cancer
9674354|NCT05011539||Control group|
9674355|NCT05011799|Experimental|Arm I (health education)|Participants attend 1-2 monthly peer educator-led education sessions about PCA genetic testing over 3 hours each for 18 months.
9674356|NCT05011799|Active Comparator|Arm II (cancer educational materials)|Participants receive mailed informational materials about PCA risk, family history, and genetic testing.
9674357|NCT05011604|Other|Implant Failure|Early peri-implantitis and failed osseointegration.
9674358|NCT05011630||IAA group|Intraabdominal abscess (IAA) is defined as either a turbid discharge from the intraoperatively placed drain or a postoperative fluid collection managed by CT-guided placement of drains with documental bacteriological culture.
9674359|NCT05011630||Non-IAA group|No IAA formation
9674360|NCT05011773|Experimental|Deep brain stimulation|"All patients have already undergone deep brain stimulation. Results compared on and off stimulation."
9674361|NCT05011461|Experimental|Almond Oil|Almond Oil Pressed Cold
9674362|NCT05011461|Active Comparator|Topical Retinol|Retinol Lotion 0.5%
9674363|NCT05011487|Experimental|osimertinib plus chemotherapy|Osimertinib (80mg/qd) po. for 60 days with two cycles of Pemetrexed (500 mg/m2) to be administered with cisplatin (75mg/m2) on Day 1 of every 3-week cycle for 2 cycles
9674364|NCT05011643||Symptomatic statin users|Statin users with self-reported muscle symptoms
9674365|NCT05011643||Asymptomatic statin users|Statin users without muscle symptoms
9674366|NCT05011643||Non-statin using controls|Participants not using statins
9674367|NCT05011695|Active Comparator|1. Group ESWT treatment|"6000 SWT Easy device will be used for ESWT treatment. The plantar fascia of the patients will be applied once a week for 3 weeks. In each application, 2400 beats, 2.0 bar pressure and 12 frequency doses of ESWT will be applied"
9674368|NCT05011695|Active Comparator|2. Group transverse friction massage|Transverse friction massage will be applied to the plantar fascia of the patients for 3 weeks, 3 days a week, on Mondays, Wednesdays, and Fridays, with a break for 1 day and 15 minutes each. Transverse friction massage, when the patient is in the supine semi-lying position, the big toe will be dorsiflexed and in this position, it will be applied in the direction that will be transverse to the plantar fascia.
9695063|NCT04782115|Experimental|2.0mg RC28-E injection as needed|In the loading phase (from week 0 to week 16), the study eye will receive intravitreal injection of 2.0mg RC28-E every 4 weeks, for 5 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
9975505|NCT02607319|Experimental|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
9975506|NCT02607319|No Intervention|No intervention group|Control group receiving standard care.
9975507|NCT02576574|Experimental|Arm A: Avelumab|
9695064|NCT04782115|Experimental|control group|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of Conbercept every 4 weeks, for 3 consecutive times;In the as needed (pro re nata,PRN)phase (from then on to week 48), the study eye will receive the same dose on an PRN schedule based upon the physician assessment in accordance with pre-specified criteria.
10173986|NCT03857737|Experimental|ESD group|This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.
10173987|NCT03857737|Active Comparator|Surgery group|This group include patients who are going to undergo surgery for early gastric cancer.
10173988|NCT03857724|Experimental|prolapse surgery|
10187957|NCT03720899|Experimental|NicoBloc|NicoBloc participants will be provided with NicoBloc to use during counseling sessions and will test smoking their conventional cigarette with NicoBloc.
9674369|NCT05011695|Active Comparator|3. Group exercise group|Stretching the plantar fascia and gastrocsoleus muscles of the patients, towel picking exercises with the foot intrinsic muscles, heel drop exercises will be given. All stretching and exercises will be applied once a day, 5 days a week, for 3 weeks. Plantar fascia stretching exercises will be performed with a physiotherapist; While the patient is lying in the supine position, 30 seconds of stretching will be performed using the windlass (windlass) mechanism (toes are brought to dorsi flexion). This stretch will be repeated 3 times. Gastrocsoleus stretching exercises will be studied with a physiotherapist. In the supine position, the gastrocsoleus muscles will be stretched for 10 seconds and stretching will be performed with 10 repetitions. Towel collection exercises for the foot intrinsic muscles will be practiced in 3 sets, 15 repetitions per day. Heel drop exercise will be applied in 3 sets of 15 repetitions per day.
9674370|NCT05011617|Experimental|MAC group|Electroacupuncture was performed for two consecutive days before surgery (2 daily 30-min sessions) by a licensed acupuncturist at 4.0 mA using an alternating frequency of 2 and 100 Hz (every 1.5 seconds) (LH-202, Huawei, Beijing, China). Acupoints included bilateral Yunmen (LU2), Zhongfu (LU1), Lieque (LU7), and Neiguan (PC6). On the day of surgery, electroacupuncture started upon the completion of a loading dose of dexmedetomidine, was suspended when CPB started (to avoid interference with electrocardiogram recording) and continued until the end of surgery.
9674371|NCT05011617|No Intervention|IGA group|Anesthesia was induced with propofol (2.0-3.5 μg/mL) by target control infusion and 0.3-0.5 μg/kg sufentanil. Tracheal intubation was facilitated by rocuronium (1.0 mg/kg). Anesthesia was maintained using isoflurane at 0.7-1.0 minimal alveolar concentration in a gas mixture of oxygen and air and remifentanil (0.05-0.2 μg·kg-1·min-1) by intravenous injection pump. Sufentanil dose was totally 2.5-4.0 μg/kg. Muscle relaxation was achieved using 1/3-1/4 of the induction dose every 40-60 min based on a train of four. Mechanical ventilation with 80% O2 in air was used. Tidal volume (7-8 mL/kg) and respiratory rate (10-12/min) were adjusted according to PETCO2 to achieve normal ventilation (PETCO2 35-45 mmHg).
9674372|NCT05011500|Experimental|Starting with closed mask|Patient 1-8, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using a closed mask. For the next 5 fractions these patients will receive radiotherapy using an open mask. For the 5 fractions after that these patients will receive radiotherapy using no mask. This schedule repeats for the rest of their treatment.
9674373|NCT05011500|Experimental|Starting with open mask|Patient 9-16, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using an open mask. For the next 5 fractions these patients will receive radiotherapy using no mask. For the 5 fractions after that these patients will receive radiotherapy using a closed mask. This schedule repeats for the rest of their treatment.
9674374|NCT05011500|Experimental|Starting with no mask|Patient 17-24, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using no mask. For the next 5 fractions these patients will receive radiotherapy using a closed mask. For the 5 fractions after that these patients will receive radiotherapy using an open mask. This schedule repeats for the rest of their treatment.
9674375|NCT05011552|Experimental|The intervention group|
9674376|NCT05011552|Placebo Comparator|The control group|
9674377|NCT05011669|Experimental|Latuda® 40mg/d|
9674378|NCT05011669|Experimental|Latuda® 80mg/d|
9674379|NCT05011422|Experimental|ex vivo αβ-TCR/CD19 depleted haplo-hematopoietic stem cell infusion (HSCT)|"Patients will undergo standard of care conditioning regiment prior to HSCT~On Day 0, patients will undergo infusion of the ex vivo αβ-TCR/CD19 depleted haplo-HSCT from a stimulated peripheral stem cell source per institutional standard of care. Patients whose graft has a residual CD20+ count > 1.0 x 105 will receive a single infusion of rituximab on Day +1 at a dose of 375 mg/m2."
9674380|NCT05011383|Experimental|ATM|Patients with castration resistant prostate cancer which contains ATM alterations are treated with high dose testosterone
9674381|NCT05011383|Experimental|CDK12|Patients with castration resistant prostate cancer which contains CDK12 alterations are treated with high dose testosterone
9674382|NCT05011383|Experimental|CHEK2|Patients with castration resistant prostate cancer which contains CHEK2 alterations are treated with high dose testosterone
9674383|NCT05011305|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
9674384|NCT05011305|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
9695065|NCT04782193|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
9975508|NCT02576574|Active Comparator|Arm B: Platinum-containing chemotherapy regimen|"Platinum-containing chemotherapy regimen: Investigator's choice platinum containing chemotherapy regimen to be administered consisting of one of the following:~Non-squamous tumor histology~Pemetrexed (500 milligram per meter square [mg/m^2]) +cisplatin (75 mg/m^2) or Pemetrexed (500 mg/m^2) + carboplatin (AUC 6 mg/mL*min)~Squamous tumor histology~Paclitaxel (200 mg/m^2) +carboplatin (AUC 6 mg/mL*min)~Gemcitabine (1250 mg/m^2)+ cisplatin (75 mg/m^2)~Gemcitabine (1000 mg/m^2 )+carboplatin (AUC 5 mg/mL*min)"
9975509|NCT02576574|Experimental|Arm C: Avelumab|
9527542|NCT03219008|Experimental|Anxiety/somatization 2|This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.
9527543|NCT03219008|Experimental|Anxiety/somatization 3|This group would be treated with mirtazapine + SNRIs from the minimum dosage.
9674385|NCT05011305|Placebo Comparator|Placebo|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).
9674386|NCT05011019|Experimental|AL2846 Capsules|"During the dose escalation phase, patients enrolled in the group will first receive a single fasting administration（AL2846 capsules 120-150mg，oral）. The observation period is 3 days. If dose-limited toxity (DLT) does not occur, they will continue to receive multiple consecutive fasting administrations (120mg-150mg，once a day，oral ),every 28 days as a treatment cycle.~During the dose expansion phase, patients will receive multiple consecutive fasting administrations (AL2846 capsules，120mg-150mg, oral ), every 28 days as a treatment cycle."
9674387|NCT05011110|Experimental|GraduSOX (left leg) & Sigvaris (right leg)|Half of participants will wear a GraduSOX compression stocking on their left leg whilst wearing a Sigvaris compression stocking on their right leg.
9674388|NCT05011110|Experimental|GraduSOX (right leg) & Sigvaris (left leg)|Half of participants will wear a GraduSOX compression stocking on their right leg whilst wearing a Sigvaris compression stocking on their left leg.
9674389|NCT05011097|Experimental|Y150|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with Y150 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
9674390|NCT05011175||Individuals with Parkinson's Disease|Individuals that have been diagnosed with Parkinson's Disease will be enrolled to participant in the survey research.
9975510|NCT02562599|Experimental|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin~Interventions:~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .~Radiation: Intensity-modulated radiotherapy (IMRT)"
10173989|NCT03857802|Experimental|Sleep hygiene intervention|In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. After 3 months, at the next health check, the quality of sleep questionnaire will be carried out together with the blood extraction.
9674393|NCT05010928|Experimental|Tea mouthwash group|
9674394|NCT05010928|No Intervention|Control group|
9674395|NCT05011227|Experimental|Camrelizumab and chemotherapy combined with endoscopic surgery|Camrelizumab and chemotherapy combined with endoscopic surgery
9674396|NCT05011344|Experimental|Exposed hospital staff|"Hospital health care or non-health care staff willing to participate in the study:~Healthcare personnel (physician, nurse, caregiver) who have worked for a minimum of 2 weeks since March 1, 2020 in a care unit dedicated to the management of patients confirmed or suspected of COVID-19 infection, in the participating centers: intensive care units, emergency rooms, radiology, COVID-19 units;~Staff (physician, technician) who have worked for a minimum of 2 weeks since March 1, 2020 in the AP-HM laboratories handling samples from patients confirmed or suspected of having COVID-19 infection."
9674397|NCT05011344|Other|'Non-exposed' hospital workers|Hospital health care worker (physician, nurse, caregiver) willing to participate in the study who has not worked since March 1, 2020 in an intensive care unit or emergency department or other department dedicated to the management of patients confirmed or suspected of having COVID-19 infection.
9674398|NCT05011045||Observational (neurocognitive assessment, questionnaires, MRI)|Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.
9674399|NCT05011032|Other|Control Group|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
9674400|NCT05011032|Experimental|Non-diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
9674401|NCT05011032|Experimental|Diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
9674402|NCT05010980||retrospective|For the retrospective part of the study, the existing echocardiographic database will be used to retrieve data. The database query includes the last 2 years.
9674403|NCT05010980||prospective|For the prospective part of the study, patients will be included who have the clinical indication for cmr and scintigraphy due to suspected cardiac amyloidosis and fulfill the inclusion criteria.
9674404|NCT05011331|Experimental|MedCline Shoulder Relief System|Patients who will receive the MedCline Shoulder Relief System pillow
9674405|NCT05011331|Active Comparator|Control|Patients who will not receive the MedCline Shoulder Relief System pillow
9674406|NCT05010902||Multiple sclerosis|Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis
9674407|NCT05010889||Achalasia patients|Patients schedule to undergo POEM for treatment of symptomatic achalasia. The diagnosis of achalasia was based on high resolution manometry, barium esophagram, and upper endoscopy.
9674408|NCT05010941||Hypotension prediction index|prediction of hypotension events
9674409|NCT05010954|Experimental|LXI-15028 50mg group(n=200)|
9674410|NCT05010954|Active Comparator|Lansoprazole 30mg group (n=200)|
10173990|NCT03857802|No Intervention|No sleep hygiene intervention|In the no intervention group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.
10187958|NCT03720899|Active Comparator|Nicotine Lozenge|Participants who receive nicotine lozenge will use the lozenge in session and will discuss the effects of using the lozenge in session.
9674413|NCT05010876|Experimental|standard care + C1 inhibitor|The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.
9674414|NCT05010876|Experimental|standard care + Icatibant + C1 inhibitor|"The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.~The icatibant will be used in a single injection of 30 mg subcutaneously, preferably in the abdominal region. These doses correspond to the doses usually used in the treatment of conditions in which icatibant is indicated."
9674415|NCT05010876|Placebo Comparator|standard care + placebo|
9674416|NCT05010707|Active Comparator|Transdermal estradiol plus spironolactone|"Starting dose will be 100 mcg/24hrs Plan to increase by 100 mcg/24hrs every month to a max dose of 400 mcg/24hrs Goal is to achieve a serum estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose."
9674417|NCT05010707|Active Comparator|Daily sublingual estradiol plus spironolactone|"Starting dose will be 2 mg daily Plan to increase every month by 2 mg daily Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels.~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
9674418|NCT05010707|Active Comparator|Twice daily sublingual estradiol plus spironolactone|"Starting dose will be 1 mg twice daily Plan to increase every month by 2 mg daily divided BID Goal is to achieve serum estradiol level between 100-200 pg/mL mL and to suppress testosterone to cisgender female levels~All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.~Spironolactone will be started at 50 mg daily and will increase to standard dose."
9674419|NCT05010668|Experimental|Cryoablation in combination with Sintilimab plus lenvatinib|
9674420|NCT05010681|Experimental|Lenvatinib plus Sintilimab|
9674421|NCT05010525|Experimental|ATG-016-20mg|20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
9674422|NCT05010525|Experimental|ATG-016-35mg|35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
9674423|NCT05010525|Experimental|ATG-016-50mg|50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
9674424|NCT05010525|Experimental|ATG-016-65mg|65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study
9674425|NCT05010863||Patients with early gastric cancer|
9674426|NCT05010863||Patients with advanced gastric cancer|
9674427|NCT05010863||healthy person|
9674428|NCT05010863||Patients with colorectal cancer|
9674429|NCT05010863||Liver cancer patients|
9674430|NCT05010863||Breast cancer patient|
9674431|NCT05010863||Patients with atrophic gastritis|
9674432|NCT05010538||Sarecycline|Eligible patients will be prescribed with commercially available sarecycline at a dosage of 1.5 mg/kg/day and followed for 12 weeks post initiation of treatment.
9674433|NCT05010616|Experimental|Three-dimensional digital simulation with fixed appliance|The records will be obtained at the first visit, which will be one week before placing brackets. At the second visit, the orthodontic appliances will be applied; then assessments will be taken after 15 minutes of showing the patient the digital simulation of their teeth alignment at the end of orthodontic treatment.
9674434|NCT05010499|Active Comparator|Femoral nerve block|Patients will receive femoral nerve block (20 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
9674435|NCT05010499|Active Comparator|Fascia iliaca block|Patients will receive fascia iliaca block (40 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe
9674436|NCT05010577|Experimental|BX004-A|Participants will be randomized to receive standard dose of nebulized bacteriophage
9674437|NCT05010577|Placebo Comparator|Placebo|Participants will be randomized to receive nebulized placebo
9674438|NCT05010603||Families with a history of Alzheimer's Disease|Families with two or more family members affected with Alzheimer's Disease
9674439|NCT05010603||Un-related, non-demented controls|Un-related, non-demented healthy controls over age 55
9674440|NCT05010603||Individuals with Dementia (Alzheimer's Disease)|Individuals with dementia over the age of 65
9674441|NCT05010317|Experimental|Group receiving the mindfulness and acceptance intervention|This group will under go six sessions of the mindfulness and acceptance based therapy. These sessions will be delivered in six weeks, utilizing 2 hours every week. This will be in addition to the standard of care (clinic based counselling).
9674442|NCT05010317|Active Comparator|Control group|This group will continue receiving the usual clinic based care (counselling) only.
9674443|NCT05010434|Experimental|Sintilimab and Bevacizumab Combined with Radiotherapy|
9674444|NCT05010356|Experimental|Healthy control subjects|Healthy control subjects undergoing a hyperinsulinemic euglycemic clamp
9674445|NCT05010356|Experimental|Breast cancer survivors|Breast cancer survivors undergoing a hyperinsulinemic euglycemic clamp
9674446|NCT05010447|Experimental|Study Group|Participants receive the Virtual Coach App for one week at the beginning of their therapy and one week towards the end of their therapy.
9674447|NCT05010291|Experimental|Standard of Care (SOC) messaging|Participants randomized into this arm will receive standard voice call reminders + the Standard of Care (SOC) text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include the SOC text
9674448|NCT05010291|Experimental|Loss aversion messaging|Participants randomized into this arm will receive standard voice call reminders + loss aversion text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include loss aversion framing.
9674449|NCT05010291|Experimental|Social norms messaging|Participants randomized into this arm will receive standard voice call reminders + social norms text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include social norms framing.
9674450|NCT05010291|Experimental|Altruism messaging|Participants randomized into this arm will receive standard voice call reminders + altruism text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include altruism framing.
9674451|NCT05010369|Experimental|non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
9674452|NCT05010369|Experimental|hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
9674453|NCT05010369|Experimental|squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
10173991|NCT03857672|Experimental|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT arm will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). The participants will undergo 6 weekly sessions each lasting 30-40 minutes.
9674454|NCT05010369|Experimental|reactive|patients diagnosed with a reactive (non-cancerous) lymph node
9674455|NCT05010369|Experimental|other|none of the above. Other cancer and non-cancer conditions
9674456|NCT05010330||healthy control|healthy people
9674457|NCT05010330||lung cancer|patients diagnosed with lung cancer
9674458|NCT05010252|Experimental|Cycled Light|It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies over 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
9674459|NCT05010252|No Intervention|Dim light|no intervention
9674460|NCT05010135||Healthy Subject|Aged 60 and over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.
9674461|NCT05010135||Vertebral fracture subjects|"Aged 60 or over. Male or Female. Able to give consent, and attend the assessment centre for the balance and gait weight distribution assessment.~Have been diagnosed by doctors to have the vertebral fracture"
9674462|NCT05010200|Experimental|Cohort 1 - Primary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC.
9674463|NCT05010200|Experimental|Cohort 2 - Secondary treatment cohort|Patients receive the personalized genomic vaccine (PGV) and Poly-ICLC, and CDX-301
9674464|NCT05010200|Experimental|Cohort 3 - Expansion treatment cohort|An expansion cohort if the treatment of all 3 together has not triggered a safety stopping event.
9674465|NCT05010239|Active Comparator|Intervention group|Patients in the intervention group will receive a 30-minute MBST session by a palliative care physician trained in mindfulness practice. The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing. Outcomes will be measured at baseline and at minute 30.
9674466|NCT05010239|Placebo Comparator|Control group|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
9674467|NCT05010187|Experimental|Behavioral: Motivational Interview (MI)|Participants will complete a brief motivational interview focusing on determinants of women's alcohol use, including a focus on normative perceptions as well as motives for drinking.
9674468|NCT05010187|Active Comparator|Behavioral: Health Coaching (HC)|Participants will complete a brief health coaching interview and session focusing on educational modules.
9674469|NCT05010395|No Intervention|Control|Individuals in this arm did not receive a letter.
9674470|NCT05010395|Experimental|Arm 1: Basic Letter|Individuals received a letter with information about the benefits of enrolling, the February 15th sign-up deadline, the HealthCare.gov website, and the call center phone number.
9674471|NCT05010395|Experimental|Arm 2: Action|"Individuals in this arm received a letter that emphasized only minimal marginal effort is required; and used adjectives and verbs connoting action (e.g., almost done, quick, act now, and fast)."
9674472|NCT05010395|Experimental|Arm 3: Action, Implementation|Individuals in this arm received a letter similar to Arm 2, but with the addition of a calendar that draws attention to the February 15th deadline; and provided fill-in blanks in which the recipient can write the planned month, day, and time when they intend to enroll.
9674473|NCT05010395|Experimental|Arm 4: Action, Implementation, Picture|Individuals in this arm received a letter similar to Arms 2 and 3, but with the addition of an image of then HealthCare.gov Chief Executive Officer Kevin Counihan
10173992|NCT03857672|No Intervention|Usual Care|The study therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their pain. The study therapist will emphasize the importance of completing the outcome assessments. The treatments usual care participants actually received will be assessed at 6 and 12 weeks.
10173993|NCT03857932|Experimental|SLNB and non-slns resection|"Participants only receive SLNB~preoperative CT lymphography~SLNB with stained non-SLN resection~SLNB with ARM dissection"
10173994|NCT03857932|Experimental|SLNB group|Participants only receive SLNB
10173995|NCT03857685||Proliferation in an in-vitro model|An in-vitro model is used to study lens epithelial cell proliferation
9674474|NCT05010395|Experimental|Arm 5: Norm|"Individuals in this arm received a letter that included the following social norm sentence: Americans are enrolling but you haven't joined them."
9674475|NCT05010395|Experimental|Arm 6: Norm, Pledge|"Individuals in this arm received a letter that included a statement, to be checked in agreement, that I pledge to Get Covered at Healthcare.gov."
9674476|NCT05010395|Experimental|Arm 7: Loss Aversion|"Individuals in this arm received a letter that warned You risk paying a fee of $325 or 2% of your income-whichever is higher."
10173996|NCT03858036|Active Comparator|Epi-OFF CXL|The Epi-ON treatment will be performed without removal of the corneal epithelium. Ricrolin+will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-ON treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-ON treatment.
10173997|NCT03858036|Active Comparator|Epi-ON CXL|The Epi-OFF treatment will be performed with removal of the corneal epithelium before the first dose of riboflavin is administered. Ricrolin+ will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-OFF treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-OFF treatment.
9674477|NCT05010395|Experimental|Arm 8: Kitchen Sink|Individuals in this arm received a letter that includes all behavioral dynamics except for the pledge (due to space limitations).
9674478|NCT05010278||Latarjet|Patients followed up 6 months after a Latarjet procedure
9674479|NCT05010382|Experimental|Test group|Hybrid surface dental implant
9674480|NCT05010382|Experimental|Control group|moderately rough surface implant
9674481|NCT05009940|Experimental|Gradusox then Sigvaris compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Gradusox compression stockings applied to both legs.~After a washout period, the second intervention received are Sigvaris compression stockings applied to both legs."
9674482|NCT05009940|Experimental|Sigvaris then Gradusox compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Sigvaris compression stockings applied to both legs.~After a washout period, the second intervention received are Gradusox compression stockings applied to both legs."
9674483|NCT05009745|Experimental|Intervention|"The intervention will be PGT-A strategy involving trophectoderm biopsy and comprehensive chromosome screening (CCS) using Next Generation Sequencing (NGS). All embryos will be frozen after the biopsy procedure and transferred in a subsequent frozen-thawed embryo transfer. Embryo selection for transfer will be based on morphological criteria and the genetic screening result.~Only euploid embryos or mosaic euploid embryos deemed suitable to be transferred will be replaced into the uterus in a subsequent frozen-thawed embryo transfer cycles."
9674484|NCT05009745|No Intervention|Control arm|Women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection, or a frozen-thawed embryo transfer as first line over a fresh embryo transfer, if clinically indicated. Embryo selection for transfer will be based on morphological criteria.
9674485|NCT05010057|Experimental|New Zealand blackcurrants (NZBC)|1 NZBC capsule (containing 300 mg active cassis containing 105 mg of anthocyanins, i.e. 35-50 % delphinidin-3-rutinoside, 5-20 % delphinidin-3-glucoside, 30-45 % cyanidin-3-rutinoside, 3-10 % cyanidin-3-glucoside), consumed in the morning, for 12 days.
9674486|NCT05010057|Placebo Comparator|Placebo (PLA)|1 placebo capsule (containing 300 mg microcrystalline cellulose M102), consumed in the morning, for 12 days.
9674487|NCT05010031|Experimental|radiation|Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases).
9674488|NCT05010044|Experimental|Participants received MBCT once a week for 8 weeks|Participants received MBCT once a week for 8 weeks. At the same time, the drug therapy for psoriasis was used .
9674489|NCT05010044|Active Comparator|Active comparator|Only the drug therapy for psoriasis was used .
9674490|NCT05009823||Stabilization phase|"The dietetic treatment is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
9674491|NCT05009823||Transition phase|The child is assigned to one the therapeutic regimen depending on the treatment received during the stabilization phase and the results of the appetite test.
9674492|NCT05010096|Experimental|Arm I (elimusertib, copanlisib)|Patients receive Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 4 and 18. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
9674493|NCT05010096|Experimental|Arm II (elimusertib, copanlisib)|Patients receive elimusertib PO BID on days 1-3 and 15-17, and copanlisib IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may continue to receive elimusertib PO BID and copanlisib IV at the discretion of the treating physician.
9674494|NCT05010083|Experimental|diet and lifestyle program|
9674495|NCT05009901|Experimental|Alpha Lipoic Acid|alpha lipoic acid PO 600 mg daily for 8 weeks
9674496|NCT05009901|Placebo Comparator|Placebo|placebo PO daily for 8 weeks
9674497|NCT05010109||Ancillary-Correlative (SPECT/CT, stress test, biospecimen)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
9674498|NCT05009953|Experimental|Cohort 1: Irinotecan Liposome Injection + 5-FU/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or termination of the study for other reasons.
9674499|NCT05009953|Experimental|Cohort 2: Irinotecan Liposome Injection + SG001 + 5-Fu/LV|The patients in cohort 1 will receive irinotecan liposome injection combined with SG001, 5-Fluorouracil (5-FU) and Leucovorin (LV) intravenously on days 1 of every 14-day cycle until disease progression or unacceptable toxicity, or until 24 months is reached, or the study is terminated for other reasons.
9674500|NCT05009888||Adult KCL IoPPN Staff|Freely consenting Adult KCL Staff attending King's College London, IoPPN, Denmark Hill site will all have an antibody test on finger prick blood. The antibody test will give a rapid result for the presence of IgG or IgM antibodies to COVID-19
9674501|NCT05009914|Experimental|cardiac denervation group|In this group, patients undergoing CABG will receive the procedure of our new way of cardiac denervation, excision of Marshall ligament and Waterstone fat pad.
9674502|NCT05009914|No Intervention|controlled group|In this group ,patients undergoing CABG will not receive the procedure of cardiac denervation.
9695066|NCT04782167|Experimental|BRACE protocol|Researcher give Brace protocol to one group
9695067|NCT04782167|Experimental|Proprioception training|Researcher give proprioception protocol to one group
9695068|NCT04782453|Experimental|ToQuit|Participants from the ToQuit intervention arm will receive the messages on their mobile phones for 8 weeks. The messages will be sent for 3-4 days a week.
9695069|NCT04782453|Other|Control|Participants from the control group will be sent the details of other functional tobacco helplines in India.
9695070|NCT04782128|Experimental|intravitreal 1.0mg RC28-E injection Q8|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
9695071|NCT04782128|Experimental|Experimental: intravitreal 1.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
9695072|NCT04782128|Experimental|Experimental: intravitreal 2.0mg RC28-E injection Q8|Subjects received 2.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
9695073|NCT04782128|Experimental|Experimental: intravitreal 2.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
9695074|NCT04782232||Patients with failing/absence of the right heart|Patients with acute or chronic, conservatively uncontrollable heart failure of varying pathogenesis, graded as stage III or IV according to NYHA, with an anticipated need for short-term to long-term right ventricular or biventricular support.
9695075|NCT04782349|Experimental|study group (A)|
9695076|NCT04782349|Experimental|study group (B)|
9695077|NCT04782349|Other|control group|
9695078|NCT04782206|Active Comparator|group 1|superior hypogastric plexus block
9695079|NCT04782206|Active Comparator|group 2|pulsed radiofrequency at S3 nerve root + superior hypogastric plexus block
9695080|NCT04782102|Experimental|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
9695081|NCT04782102|No Intervention|Care-as-usual|Care-As-Usual: all other kinds of interventions are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory (Chisholm et al., 2000; Roick et al., 2001)
10173998|NCT03857906||IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease Intra-Aortic Ballon Pump insertion 1-6 hours prior to surgery
9695082|NCT04782024|Placebo Comparator|Placebo|
9695083|NCT04782024|Experimental|7-Keto 50mg|
9695084|NCT04782024|Experimental|7-Keto 25mg|
9695085|NCT04782258|Experimental|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
9695086|NCT04782258|Experimental|Tolvaptan Tablets|Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later based on weight if able to swallow tablets.
9695087|NCT04782440|Experimental|Telerehabilitation|
9695088|NCT04782440|Active Comparator|Home exercise|
9695089|NCT04782037|Experimental|L-methylfolate supplementation|Children under 1 year of age in group A will receive 3 drops (90mcg) of L-methylfolate calcium) while those older than 1 year of age will be given 5 drops (150mcg) daily fior 5 days
9695090|NCT04782037|Placebo Comparator|distilled water|Subjects in Group B will receive equal amount of distilled water as placebo (i.e. 3 drops to <1yr age and 5 drops to >1 yr.
10173999|NCT03857906||No-IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease No IABP
9674503|NCT05009719|Experimental|Prophylactic|The patients with high risk of relapse of disease and full donor chimerism after allo-HSCT without signs of the disease will be include in this group.
9674504|NCT05009719|Experimental|Preventive|The patients with persisted minimal residual disease or cytogenetic relapse after allo-HSCT will be include in this group.
10174000|NCT03857919|Experimental|TearCare|Subjects will have heat applied to the eyelids for 15 minutes followed by manual expression of the meibomian glands.
10174001|NCT03857919|Active Comparator|LipiFlow|Subjects will have heat and pressure applied to the eyelids for 12 minutes.
9674505|NCT05009693|Experimental|white light intervention group|Between the second and the eighth days of the application phase, the patients in the intervention group were administered a standard white light at 10,000 Lux intensity by an independent nurse (RA1) in their home environment using a Litebook Elite light source (The Litebook Company Ltd., Medicine Hat, AB). The distance between the light source and the patient's face was set at 50 cm, and the intensity of the light for each patient was checked using a Lux Meter. The intervention was applied between 07:00 and 10:00 in the morning for 30 minutes without interruption, and it was continued for seven successive days. The light application procedure was followed based on the previous studies on oncology patients. The second and third evaluations of the fatigue status of patients were completed on the 9th and 21st days.
9674506|NCT05009693|No Intervention|Control group|
9674507|NCT05009810|Experimental|astaxanthin 4 mg|The astaxanthin 4 mg will be taken 1 capsule once daily for 2 months.
9674508|NCT05009810|Experimental|astaxanthin 6 mg|The astaxanthin 6 mg will be taken 1 capsule once daily for 2 months.
9674509|NCT05009810|Placebo Comparator|Placebo|The placebo will be taken 1 capsule once daily for 2 months.
10174002|NCT03857698|Experimental|Evaluation of pain|The patient's pain will be evaluated by VAS (visual analog scale) at the end of the treatment, at the end of the treatment and at the end of the 3 months follow-up. For this, a 10 cm long line will be drawn. 0: painless and 10: the most severe pain is described and the patient will be asked to mark the value corresponding to the pain (rest, activity and night pain) on the scale.
10174003|NCT03857698|Experimental|Evaluation of joint range of motion|The flexion and extension range of motion of the knee joints of the patient will be measured in the prone position using a universal goniometer before and after the training.
10174004|NCT03857698|Experimental|Assessment of balance|Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
10174005|NCT03857698|Experimental|Evaluation of functional performance|A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
10174006|NCT03857698|Experimental|Lumbar lordosis angle assessment|During the test, patients will be asked to stand upright in a comfortable position. In the evaluation of the lumbar lordosis, the inclinometer will first be fixed to the T12-L1 backbone and then to the L5-Sl backbone and the angular values in both measurements will be collected and recorded as lordosis angle.
10187959|NCT03720886|Experimental|rhPTH（1-34） 28.2μg|Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
10187960|NCT03720886|Experimental|rhPTH（1-34） 56.5μg|Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
9527544|NCT03219008|Experimental|Anxiety/somatization 4|This group would be treated with mirtazapine + SNRIs + physical treatment.
9674510|NCT05009849|Experimental|Exercise I|Yogic and Routine Exercises (referred to as exercise I) Phase I: 1-7 days (Minimum attendance 4 days), Phase II: 8 - 14 days (Minimum attendance 4 days), Phase III: at 6-9 months or 12-15 months 1 year up gradation of exercises at 6-9 month or 12-15 months 1 year (Depending upon compliance to phase II exercises) Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months Exercise evaluation will be done at 6-9, 12-15, 30-33, 48-51 and 66-69 months
9674511|NCT05009849|Active Comparator|Exercise II|Objective assessment at baseline, 14 days, 6-9, 12-15, 18-21, 36-39 and 54-57 months
9674512|NCT05009576|Active Comparator|vac with silver|wounds of patients will be covered with a vac dressing with single layer of Ag+ hydrocolloid dressings. Such pattern of dressing will be followed in every change of dressing in 48 hours.
9674513|NCT05009576|Active Comparator|simple VAC without silver alginate|wounds of patients will be covered with VAC dressings only. Such pattern of dressing will be followed in every change of dressing in 48 hours.
9674514|NCT05009472|Experimental|Cleft Lip and Palate Patient|Cleft patient with transverse maxillary constriction and anteroposterior deficiency
9674515|NCT05009329|Experimental|Phase 1 Dose Exploration|Dose escalation of JAB-21822 to determine maximum tolerated dose
9674516|NCT05009329|Experimental|Phase 1 Dose Expansion|Conditionally required
9674517|NCT05009316|Experimental|Questionnaires|Patients will answer online surveys containing different questionnaires that will evaluate psychosocial variables as well as pain variables.
9674518|NCT05009407||HOSTS|patients ongoing corneal transplantation procedure which a full-thickness cornea from the host is replaced by a graft from a donor
10187961|NCT03720886|Active Comparator|teriparatide acetate(Teribone™)|Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.
10187962|NCT03720873|Experimental|EGFR-TKIs and Anlotinib|Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d
9674519|NCT05009407||DONORS|grafts from donors that would be analyzed
9674520|NCT05009550|Active Comparator|Erector spinae plane block group (ESP)|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group. Then standard sedation method is applied to all patients.
9674521|NCT05009550|Other|Control Group|This Group was received no intervention.Standard sedation method is applied to all patients.
9674522|NCT05009641|Experimental|carnitine2|2000 mg L-carnitine per day for 24 weeks
9674523|NCT05009641|Active Comparator|carnitine|1000 mg L-carnitine per day for 24 weeks
9674524|NCT05009641|No Intervention|control|no supplementation
9674525|NCT05009342|Experimental|Below-knee soft resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts three layers of jersey supplemented by strips of soft resins to be unrolled along the leg after immersion in warm water~Duration to ankle immobilization with soft resin boot : 21 days."
9674526|NCT05009342|Other|Below-knee rigid resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts one layer of jersey and then one layer of foam composed by strips of cotton wool to be unrolled supplemented by strips of rigid resins to be unrolled along the leg after immersion in warm water.~Duration to ankle immobilization with soft resin boot : 21 days."
9674527|NCT05009615|Experimental|Green coffee extract|Nutraceutical containing a decaffeinated green coffee extract rich in phenolic compounds (hydroxycinnamates). Participants received powdered sachets containing 300 mg of GC extract twice daily for 8 weeks
10174007|NCT03857698|Experimental|Evaluation of knee functionality|It will be measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). There are three subgroups, namely pain, stiffness and function. A total of 24 questions (pain 5 questions, 2 questions of malfunction and 17 questions of function) and the scale answered by patients are completed in approximately 5 minutes. The scale is a 5-point Likert-type scale (0 = none 1 = mild 2 = moderate 3 = severe 4 = very severe). The score range for the subgroup of pain is 0-20, for the subgroup group 0-8 and for the subgroup of function is 0 - 68. The total WOMAC score is obtained by the sum of these 3 points and the maximum total WOMAC score is 96. There is a linear ratio between the scores obtained from the WOMAC index and the presence of symptoms. The high scores were associated with severe symptoms, more disability and poor health status, whereas low scores indicated that symptoms, pain, and functionality were good.
10174008|NCT03857698|Experimental|Assessment of lower extremity muscle endurance|The patient will be asked to sit on the chair as fast as possible, so that the chair, which has a 46 cm height, will be crossed in the chest. The stopwatch is started with the command given to the patient and stopped in 30 seconds. The number of repetitions will be recorded.
9674528|NCT05009615|Experimental|Beta-glucan|Nutraceutical containing a oat beta-glucan. Participants received powdered sachets containing 2.5 g of BG twice daily for 8 weeks
9674529|NCT05009615|Experimental|Green coffee + Beta-glucan|Nutraceutical containing both green coffee extract and beta-glucan. Participants received powdered sachets containing 2.5 g of BG plus 300 mg of GC extract twice daily for 8 weeks
10174009|NCT03857776|Other|Open dialogue about CAM|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
10174010|NCT03857776|Other|Standard care|Standard care including referral to a homepage about complementary alternative medicine
9674530|NCT05009498|Placebo Comparator|Placebo group|Patient will receive a placebo dosing, identical in appearance and at the same intervals as the interventional dose
10174011|NCT03857373||Renal Cancer|Patients identified with RCC
9674531|NCT05009498|Active Comparator|Vitamin D3 supplementation group|Patient will receive high-dose Vitamin D3 supplementation in capsule form, identical in appearance and at the same intervals as the placebo dose
10174012|NCT03857568|Experimental|SHR0410 group|SHR0410 will be dosed
10174013|NCT03857568|Experimental|Placebo|Placebo will be dosed
10187963|NCT03720860||Sepsis|Patients admitted to the intensive care unit with sepsis
9674532|NCT05009433|Experimental|Pregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). The program will be also based on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise."
9674533|NCT05009433|Active Comparator|Pregnant MICT group|The moderate intensity continuous training (MICT) program will be implemented based on the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the recommendations on physical activity and exercise during pregnancy and postpartum period published by the American College of Obstetricians and Gynecologists (2020). During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the MICT program and to provide feedback to the project coordinator as to possible recommendations of the obstetric care provider regarding the exercise.
10187964|NCT03720860||Surgery|Patinets subjected to major surgery and then admitted to the intensive care unit
10187965|NCT03720860||Non-inflamed|Otherwise healthy patients admitted to the intensive care unit because of intoxication.
10187966|NCT03720834||Patients|Questionnaire on risk perception
9527545|NCT03219008|Experimental|treatment as usual(TAU)|The investigators recommend therapy strategies according to accessible methods.
10187967|NCT03720834||Clinicians|Questionnaire on risk perception
10187968|NCT03720808|Experimental|Balloon Blowing|Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
9674534|NCT05009433|Sham Comparator|Pregnant standard care group|During the study, the participant will be under standard obstetric care on her own. She is obliged to inform her obstetric care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to taking part in the study tests.
9674535|NCT05009433|Experimental|Nonpregnant HIIT group|"The high intensity interval training (HIIT) program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020) and on the High-Intensity Interval Training for Cardiometabolic Disease Prevention report by American College of Sports Medicine (2019).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
9674536|NCT05009433|Active Comparator|Nonpregnant MICT group|"The moderate intensity continuous training program will be implemented according to the World Health Organization guidelines on physical activity and sedentary behavior (2020).~During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests."
9674537|NCT05009433|Sham Comparator|Nonpregnant standard care group|During the study, the participant will be under standard health care on her own. She is obliged to inform her health care provider about participation in the HIIT Mama study and to provide feedback to the project coordinator as to possible contraindications to exercise or taking part in the study tests.
10174014|NCT03857399|Experimental|Arm-1|Patients will be assigned to receive intravenous local caspofungin (70 mg on day 1 and 50 mg once daily),If the study therapy was well tolerated but fever persisted for four or more days and the patient's clinical condition deteriorated, the dosage could be increased to 70 mg once daily.For patients who have no evidence of baseline or breakthrough fungal infection, study therapy was administered until the absolute neutrophil count was at least 500 per cubic millimeter and for up to 72 hours thereafter. The onsite investigator determined the duration of therapy for patients with baseline or breakthrough fungal infections; however,it was recommended that treatment be given for at least 14 days and for at least 7 days after neutropenia and symptoms resolved.
9674538|NCT05009563|Experimental|Inpatients with RT-PCR proven SARS-CoV-2 infection|Inpatients with real-time reverse-transcriptase polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection of the Department of Pulmonology of Semmelweis University who will undergo whole-body FDG-PET/CT
9674539|NCT05009563|Active Comparator|patients undergoing FDG-PET/CT for oncological indication|Age- and gender-matched group of patients undergoing FDG-PET/CT for oncological indication in the same time period
9674540|NCT05009654|Experimental|carnitine + leucine|1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
9674541|NCT05009654|Placebo Comparator|leucine|4000 mg L-leucine per day for 24 weeks
9674542|NCT05009420|Experimental|Avocado|Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
10174015|NCT03857399|Active Comparator|Arm-2|Patients will be assigned to receive intravenous original caspofungin (70 mg on day 1 and 50 mg once daily),the therapeutical duration is 4 Days.
9674543|NCT05009446|Experimental|Preoperative radiotherapy and chemotherapy|Preoperative radiotherapy and chemotherapy plus endoscopic surgery
9674544|NCT05009238|Experimental|Group (A)|Group (A): will receive lumbar stabilization exercises
10174016|NCT03857633||Pre Dialysis (CKD Stage 4/5)|Patients recruited from low clearance clinic with advanced CKD (stage 4/5). Patients will undergo Cardiac MRI 1 - With Gadolinium Contrast at the time of recruitment and Cardiac MRI 2 - With Gadolinium Contrast at time of commencement on renal replacement therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
10174017|NCT03857633||Haemodialysis Dialysis (CDK Stage 5d)|Patients started on Haemodialysis will have Cardiac MRI 3 - With Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
9674545|NCT05009238|No Intervention|Group (B)|Group (B): will be control group.
9674546|NCT05009173|Active Comparator|Stylet-in|Lumbar puncture performed keeping the stylet inside the needle until the practitioner reaches the appropriate location.
9674547|NCT05009173|Active Comparator|Stylet-out|The practitioner remove the stylet once he/she has passed the skin and moves the needle forward with the stylet.
9674548|NCT05009121||Czech adult people after stroke|Czech adult people after stroke will be asked basic questions about present feelings according to their condition using a questionnaire. Then they will be tested by the Box and Block Test in only one session. Video of their performance will be obtained. The Box and Block Test will be done during their regular rehabilitation by occupational therapist.
9674549|NCT05009095|Experimental|The Listening Program® with bone conduction headphones|"The Listening Program ® Spectrum music requires a person listen to psycho-acoustically modified classical music online using specialized Waves ™ headphones. The headphones transmit sound through bone conduction which provides another mode of perceiving sound (https://advancedbrain.com). The Listening Program ® can be carried out in the home environment with either the base schedule, two fifteen minute sessions at least 30 minutes apart, or a condensed schedule for 30 minutes.~Bone conduction allows the listening experience to go deeper into the vestibular system which is purported to reduce stress, help regulate the fight or flight response, and allow the listener to achieve a state of calm and relaxed alertness. This theory is based on the function of the vagus nerve, the 10th cranial nerve, which has branches that extend to the eardrum. Stimulation of the vagus nerve stimulates the parasympathetic nervous system (Allen, 2008)."
9674550|NCT05008978|Experimental|Test 1|
9674551|NCT05008978|Experimental|Test 2|
9674552|NCT05008978|Experimental|Test 3|
9674553|NCT05008978|Experimental|Test 4|
10174018|NCT03857633||Peritoneal Dialysis (CDK Stage 5d)|Patients started on Peritoneal Dialysis will have Cardiac MRI 3 - Without Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
10174019|NCT03857711|Active Comparator|Conventional CABG|Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)
10174020|NCT03857711|Active Comparator|CABG+ PVI|CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)
10174021|NCT03857711|Active Comparator|CABG+ PVI+amiodarone|CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)
9674554|NCT05008978|Experimental|Test 5|
9674555|NCT05009017||Biosimilar group|
9674556|NCT05009017||Originator group|
9674557|NCT05009082|Active Comparator|Arm 1|Chemotherapy followed by maintenance with niraparib
9674558|NCT05009082|Active Comparator|Arm 2|Chemotherapy in combination with bevacizumab followed by maintenance with bevacizumab and niraparib
9674559|NCT05008874||Males with AMN|Adult males with confirmed diagnosis of ALD and symptoms of AMN.
9674560|NCT05009108||Czech adult patients after a stroke|Czech adults patients after a stroke will be asked to fill in a informed agreement and as well to answer short questionnaire. Then they will be tested by the Purdue Pegboard Test in only one session. Video of their performance will be obtained as well.
9975511|NCT02489448|Experimental|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
9975512|NCT02456012|Experimental|The D group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
9975513|NCT02456012|Experimental|The S group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
9975514|NCT02456012|No Intervention|The C group|The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.
9975515|NCT02451436|Active Comparator|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
9975516|NCT02451436|Active Comparator|Study Skills Control Group|The control group will receive four sessions of study skills training.
9975517|NCT02389803|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
9975518|NCT02389803|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
9975519|NCT02349893|Experimental|RFA treatment|RFA treatment performed with CelonProSleep plus device
9975520|NCT02342665|Experimental|Copanlisib (BAY80-6946)|Dose escalation/safety evaluation cohort and objective tumor response (OR) expansion cohort
9975521|NCT02250157|Experimental|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
9975522|NCT02250157|Experimental|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
9975523|NCT02225405|Experimental|Treatment (cisplatin, docetaxel, nintedanib)|"RUN-IN PHASE: Patients receive induction therapy comprising cisplatin IV over 2 hours on day 1, docetaxel IV over 1 hour on day 1, and nintedanib PO BID from day 2 of course 1 to day 7 of course 3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~EXPANSION PHASE: Patients receive single-agent nintedanib PO BID on days 1-28. Patients then receive 3 courses of induction chemotherapy and undergo surgery as above. Treatment continues even if patients experience disease progression, unless treatment is judged to be not in the best interest of the patient by the treating physician."
9975524|NCT02215187|Experimental|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
9975525|NCT02215187|Sham Comparator|Attention Control|Attention/social contact control. Health education (non-skill focused).
9977516|NCT01362452|Experimental|Single Umbilical Cord Blood (UCB)|"Single UCB unit arm does not start enrollment until Dose Level A2 in the double UCB unit arm has been deemed safe.~Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation"
9977517|NCT01362465|Experimental|Cardiac Resynchronization Therapy (CRT)|Implanting device to measure delays between paced chambers in heart failure patients.
9977518|NCT01362478||Case group|
9977519|NCT01362478||Control group|
9977520|NCT01362504||Clinical sepsis|
9977521|NCT01362504||Proven sepsis|
9977522|NCT01362504||Control group|healthy neonates
9977523|NCT01362543|Active Comparator|Stress Management|
10174022|NCT03857711|Active Comparator|CABG+amiodarone|CABG+class III antiarrhythmic drug- amiodarone, group, n=70
10174023|NCT03857490|Experimental|Intervention|Lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 minutes per session) for 8 weeks.
9674561|NCT05009056|Experimental|postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
9674562|NCT05009056|Active Comparator|Presurgical computer guided functional appliance|Using the software, 3D digitized mandible will be virtually repositioned in ideal centric relation through accurate adjustment of the condyle in its glenoid fossa. Patients' dental casts will be scanned, and digitized into a virtual 3D model and superimposed to the CT cuts into the virtual plan software environment in order to produce preoperative CAD/CAM splint on the adjusted centric occlusion. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
9674563|NCT05009199|Experimental|[18F]MNI-444|After a wash-out of caffeine of at least 24 hours, each participant will receive a single injection of [18F]MNI-444 followed by brain PET imaging of up to 90 minutes to establish baseline A2A receptor binding.
9674564|NCT05008952|Active Comparator|Control group|The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent < 25% (male) or < 35% (female), and up to 1 other risk factor among the following: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
9674565|NCT05008952|Experimental|Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent > 25% (male) or > 35% (female).
9527546|NCT03218943|Active Comparator|APRV ventilation|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
9527547|NCT03218943|Active Comparator|BiPAP ventilation|They will start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
9674566|NCT05008952|Active Comparator|Metabolic Syndrome|Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( > 30 kg/m2) and 2 or more of the following risk factors: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
9674567|NCT05009186|Other|Covid-19 group|We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test
9674568|NCT05008939|Experimental|sevoflurane|Those with 1-hour inhalation of 1% sevoflurane/30% oxygen
9674569|NCT05008939|Placebo Comparator|placebo|Those with 1-hour inhalation of 30% oxygen
9674570|NCT05008744||Patients presenting with TTTS|Pregnant persons between 16 and 36 weeks of pregnancy with a diagnosis of twin to twin transfusion syndrome
9674571|NCT05008770||Older adults without sarcopenia|Healthy volunteers aged 65+ years who do not fulfill diagnostic criteria for sarcopenia, according to the revised European Working Group on Sarcopenia in Older People (EWGSOP2)
9674572|NCT05008861|Experimental|FMT with anti-PD-1/PD-L1 treatment|
9674573|NCT05009212|Experimental|ESt group|Endoscopic stricturotomy
9674574|NCT05009212|Active Comparator|EBD group|Endoscopic balloon dilatation
9674575|NCT05008523|Experimental|Opioids and Police Safety Occupational Risk Reduction Training|Provides occupational risk reduction training for police in 49 slides including 8 filmed videos (police officers, MDs, SSP staff, a person in recovery). The training is delivered online with secure access only for enrolled study participants.
9674576|NCT05008523|Active Comparator|COVID Occupational Risk Reduction Training|The COVID-19 and Police Safety training (Control only) includes 22 slides, also narrated by a professional voice narrator.
9674577|NCT05008640||Study group (all subjects)|All subjects belonged to the same study group, regardless of symptoms, disease diagnosis or state. Furthermore, there was no stratification of the population by sex, age, race or disease severity.
9674578|NCT05008705|Experimental|Intervention|Patients allocated to this arm will be submitted to intervention (protein supplementation plus neuromuscular electrostimulation).
9527548|NCT03218956|Experimental|Protein intake|Dietary supplement: Protein intake
9674579|NCT05008705|Placebo Comparator|Placebo|Patients allocated to this arm will be submitted to a placebo intervention (isocaloric supplement plus sham for neuromuscular electrostimulation).
9527549|NCT03219203|Experimental|Arm A: Single dose hepatitis B vaccine|Single dose of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at entry
9674580|NCT05008406||Preclinical medical students|
9975526|NCT02087865|Active Comparator|Donepezil HCL|Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
9975527|NCT02087865|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks.
10174024|NCT03857490|Placebo Comparator|Control|Lower leg immerse in a thermoneutral water bath (33°C), 4 times per week, 45 minutes per session for 8 weeks.
10174025|NCT03857516||Recipients of cardiac resynchronization therapy|Consecutive patients with de novo implantation of a cardiac resynchronization defibrillator or pacemaker.
10174026|NCT03857425|Experimental|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks
9674581|NCT05008406||Clinical medical students|
9975528|NCT02087865|No Intervention|Control Group|Participants without a family history of AD will undergo the study evaluations but will not receive any study drug
9975529|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
9975530|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
9975531|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
9975532|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
9975533|NCT01909934|Experimental|Brentuximab vedotin|1.8 mg/kg IV infusion
9977524|NCT01362543|Active Comparator|Cognitive restructuring|
10174027|NCT03857425|Experimental|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
9674582|NCT05008679|No Intervention|Control|patients with heart failure to receive standard HF therapy
9674583|NCT05008679|Experimental|Oseltamivir|patients with heart failure to receive oseltamivir (at a dose of 75 mg twice daily) for 1 month in addition to standard HF therapy
10174028|NCT03857425|Experimental|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
9674584|NCT05008614|Experimental|Erector spinae plane block group (ESP group)|"Patients receiving continuous unilateral ESP block.~Interventions:~Procedure: Ultrasound-guided unilateral ESP block via catheter placement for continuous infusion Drug: Ropivacaine 0.75% Injectable Solution Device: 21-gauge 85 mm perineural catheter, 18-gauge 100 mm stimulator needle (Silverstim, Vygon, Ecouen, France)"
9674585|NCT05008614|Active Comparator|Thoracic epidural analgesia group (TEA group)|"Patients receiving thoracic epidural analgesia.~Interventions:~Procedure: Fluoroscopy-guided thoracic epidural analgesia Drug: Ropivacaine 0.75% Injectable Solution Device: 17-gauge Tuohy needle (FlexTip Plus®, Teleflex Medical, USA)"
9674586|NCT05008666|Experimental|L-DEP, Sintinimab+Chidamide, Sintinimab+Azacitidine|"【L-DEP】~L-asparaginase: 2000U/m2 d5, im~Doxorubicin liposome: 25mg/m2 d1, ivd~Etoposide: 100mg/m2 d1, d8, d15, ivd~Methylprednisolone: 15mg/kg/day d1-3, 0.75mg/kg/day, d4-7, 0.25mg/kg/day, d8-14, ivd~【Sintinimab+Chidamide】~Sintinimab: 200mg，d1,ivd,q21d Chidamide：30mg biw, continued oral~【Sintinimab+Azacitidine】~Sintinimab:200mg，d1, ivd, q21d Azacitidine:75mg/m2, d1-d7, ih, q28d"
9674587|NCT05008458||children with febrile seizures|
9674588|NCT05008458||febrile children without seizures|
9674589|NCT05008458||healthy control children|
9674590|NCT05008731|Experimental|Group 1|botulinum toxin: 100 units (0.5ml) in 1 injection
9674591|NCT05008731|Placebo Comparator|Group 2|Placebo: 0.5 ml in 1 injection
9674592|NCT05008718|Active Comparator|38% SDF group|38% silver diamine fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
9674593|NCT05008718|Placebo Comparator|5% NaF group|5% sodium fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
9674594|NCT05008588|Experimental|Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment|Intranasal of 160 μl of conditioned medium
9674595|NCT05008588|Experimental|Umbilical cord mesenchymal stem cells treatment|Intra-parenchymal transplantation of 1-2x10^6 UC-MSCs
9674596|NCT05008588|Active Comparator|Standard treatment (control)|Neurologic and Neutrophic Drugs
9674597|NCT05008367|Active Comparator|Treatment A|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
9674598|NCT05008367|Active Comparator|Treatment B|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
9674599|NCT05008367|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
9975534|NCT01547117|Experimental|High Sodium Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
9977525|NCT01362556|Placebo Comparator|Sodium Chloride|Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
10174029|NCT03857347|Experimental|Brief Psychoeducation Intervention|2 group session psychoeducation intervention feasibility study
9674602|NCT05008549|Experimental|First Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence.
9674603|NCT05008549|Experimental|Second Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
9674604|NCT05008549|Experimental|Third Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
9674605|NCT05008549|Experimental|Fourth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
10174030|NCT03857763|Experimental|Apatinib+Paclitaxel+Cisplatin+RT|Apatinib：250mg,po,qd, d1-35; Paclitaxel：50mg/m2 iv, d1，8，15，22，29; Cisplatin: 30mg/m2 iv, d1，8，15，22，29; Radiotherapy：41.4Gy/23f , 1.8Gy/f，5 f/w
9674606|NCT05008549|Experimental|Fifth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
10174031|NCT03857386||PECS group|Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach
9674607|NCT05008549|Experimental|Sixth Product Order: order not stated to protect study blinding|Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence
9674608|NCT05008471|Experimental|Intervention group|The recommended target energy for NPC radiotherapy patients is 25-30kcal/(kg·d), in addition，the intervention group begins with an additional 50% daily energy increase during the peri-radiotherapy.
9674609|NCT05008471|No Intervention|Conventional group|Unlike the intervention group,conventional group should be treated according to the consensus of experts on standardized nutrition management.
9827770|NCT02467465|Experimental|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
9674610|NCT05008302|Experimental|To improve the coordination of the wrist and hand after stroke in three age groups.|The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
9674611|NCT05008380|Experimental|Standard of care + prone positioning|Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.
9674612|NCT05008380|No Intervention|Standard of care|Standard of care
9674613|NCT05008029|Experimental|In situ immobilization|Immobilization without reducing the radius fracture and above-elbow casting.
9674614|NCT05008029|Active Comparator|Reduction under general anesthesia|Radius closed reduction under general anesthesia and above-elbow casting. Percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block if needed.
9674615|NCT05008068|Experimental|PRF alone|
9674616|NCT05008068|Active Comparator|PRF in addition to Simvastatin|
9674617|NCT05008016||Procalcitonine analysed|The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement
9674618|NCT05008159|Experimental|The EMBOLDEN program|3 month community-based mobility and healthy aging intervention
9674619|NCT05008159|No Intervention|Usual care|
9674620|NCT05008198||Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
9674621|NCT05008315|Experimental|deep and superficial tissue mobilization group|include deep and superficial tissue mobilization
9674622|NCT05008315|Active Comparator|superficial tissue mobilization group|superficial tissue mobilization
9674623|NCT05008315|Placebo Comparator|control group|Sham (very light hand touch on the same location as the other two groups but without any treatment intention)
9674624|NCT05008315|Other|vaginal delivery group|education session
9674625|NCT05008042|Active Comparator|Mecobalamine 5 mg/ml|The active substance of vitamin B12 given in the study is Mecobalamin 5mg / ml 2 ml ie 10 mg and is given intramuscularly.
9674626|NCT05008042|Placebo Comparator|NaCl 9mg/ml|Placebo substance given in the study is Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) given intramuscularly.
9674627|NCT05008211|Experimental|Intervention|"There will be a respiratory team, same as the usual care, responsible for patients requiring domiciliary NIV in the intervention group.~The IMB model-based intervention of this study is a six-week program consisted of a one-hour face-to-face home visit in the first week, two 20-minute telephone follow-ups in the second and fourth weeks, and a half-hour face-to-face follow-up at hospital in the sixth week, and a telephone consultation hotline during office hours.~There are three major components including information, motivation and behavioral skill interventions as proposed by the IMB model and will be deliberately arranged in the different sessions."
9674628|NCT05008211|Placebo Comparator|Control - usual care|There is a respiratory team of health care professionals responsible for patients requiring domiciliary NIV. The team is led by a Medical Consultant and with respiratory nurse(s) as team members who are responsible for assisting patients or their family to initiate domiciliary NIV and teaching the relevant technical skills. The nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems such as leakage and pressure sore in hospital before discharge. Commercial leaflet or booklet according to the choice of ventilator with information of the ventilator, interface, accessories and the ventilator company will be provided to the patient.
9674629|NCT05008263||Patients with viral chronic liver disease at primary diagnosis|Patients with primary diagnosis of viral hepatitis B and hepatitis C who was referred for liver biopsy. All patients underwent liver shear wave elastography and dynamic liver scintigraphy evaluating liver physical and functional changes shortly prior to liver biopsy procedure.
9674630|NCT05008419|Experimental|Discourse Treatment|Biweekly discourse treatment sessions.
10174032|NCT03857386||Control group|Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation
10174033|NCT03857438||Bipolar Mania|Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
9674631|NCT05008419|No Intervention|Treatment as Usual|No treatment. Participants will engage in their usual care.
9674632|NCT05008237|Experimental|Cisplatin plus docetaxel|"D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Treatment will be continued until disease progression or unacceptable toxic effects."
9674633|NCT05008146|Experimental|PET|[C-11]NOP-1A
9674634|NCT05007977|Experimental|Treatment order: placebo, low dose, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
9674635|NCT05007977|Experimental|Treatment order: placebo, high dose, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
9674636|NCT05007977|Experimental|Treatment order: low dose, placebo, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
9674637|NCT05007977|Experimental|Treatment order: low dose, high dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
9674638|NCT05007977|Experimental|Treatment order: high dose, placebo, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
9674639|NCT05007977|Experimental|Treatment order: high dose, low dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
9975535|NCT01547117|Experimental|Low Sodium Dietary Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
9674640|NCT05008094||Genetic testing cohort (Phase 1)|Group of Croatian Parkinson's disease patients who will be tested with whole-exome sequencing in target Parkinson's genes.
9674641|NCT05008094||Drug-naive Parkinson's disease patients (Phase 2)|Drug-naive Parkinson's disease patients that will be prospectively followed in the two-year period for each patient.
9674642|NCT05008094||Control group (Phase 2)|Control patients who do not have neurodegenerative diseases. The control group will perform the same measurement as the drug-naive Parkinson's disease patients.
9674643|NCT05008250|Experimental|study group|Metoprolol tartrate (25 mg twice per day, orally) plus TMYXP (40 pills twice per day, orally). the treatment duration is 8 weeks.
9674644|NCT05008250|Placebo Comparator|control group|Metoprolol tartrate (25 mg twice per day, orally) plus placebo (40 simulated pills twice per day, orally). The treatment is 8 weeks.
9674645|NCT05007938|Experimental|Icotinib + Befotertinib|"Icotinib（125 mg orally, three times daily）~Befotertinib（25 mg orally, three times daily）"
9527550|NCT03219203|Active Comparator|Arm B: 3-dose series of hepatitis B vaccine|3-dose series of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at month 0, 1, and 6
9674646|NCT05007912||Orvil Group|Group that used the Orvil (circular stapler) for esophagojejunostomy
9674647|NCT05007912||Linear Group|Group that used the linear stapler for esophagojejunostomy
9674648|NCT05007795|No Intervention|Programmatic MDR TB treatment regimen|Conventional MDR-TB laboratory tests. Sputum culture (and smear microscopy) will be evaluated monthly during the treatment period (and 6 monthly during the follow-up period) for the conventional arm.
9674649|NCT05007795|Experimental|Sequence based resistance testing and individualized treatment|Sputum extracted for targeted sequencing and drug resistance profile provided to clinician for individualized treatment.
9674650|NCT05007743|Active Comparator|Stimulation of inner tragus|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
9674651|NCT05007743|Sham Comparator|Stimulation of ear lobe|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
9674652|NCT05007808|Experimental|G001 Topical Gel|G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
9674653|NCT05007808|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
9674654|NCT05007717|Experimental|Data-informed Stepped Care (DiSC) arm|At intervention sites, HCW will assign ALHIV to different levels or intensity of HIV services depending on their current and anticipated health care needs. The stepped care framework is designed to be flexible, to accommodate variable individual and social support services available at each facility.
9674655|NCT05007717|No Intervention|Standard of care|Sites randomized to the control arm will continue with standard of care approaches for adolescent clinic visits (usually 1-3 monthly visits) regardless of health care needs and additional support as needed.
9975536|NCT01431508|Experimental|Losartan 50 mg / HCTZ 12.5 mg|Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.
9975537|NCT00871351|Experimental|Ezetimibe + Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
9674658|NCT05007678|No Intervention|Standard of Care|The usual care will be offered as per current advice on management of hospitalised patients.
9674659|NCT05007678|Active Comparator|leflunomide|Patients admitted to the hospital COVID-19 positive and within 2 weeks of symptoms' onset will be treated with loading dose of 100 mg leflunomide for 3 days, followed by 20 mg once daily. Participants with ALT/AST levels 2 times above upper limits of normal reference range will receive 10mg instead of 20mg.
9674660|NCT05007587|Experimental|Lenvatinib，Then HAIC of mFOLFOX regimen|Cohort1：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.
9674661|NCT05007587|Experimental|Lenvatinib，Then HAIC of ROX regimen|Cohort2：Participants were treated with 8mg lenvatinib (weight<60kg) or 12mg lenvatinib (weight>60kg) orally once daily on days 1 through 21, and HAIC regimen was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
9674662|NCT05007457|Experimental|Experimental Group|telerehabilitation
9674663|NCT05007457|Active Comparator|Control group|Standard treatment
9674664|NCT05007860||No active therapy|Age ≥18 years and CLL/SLL (WHO criteria). We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, active therapy, treating physician intent to initiate CLL/SLL therapy within ≤2 months, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
9674665|NCT05007860||BTK inhibitor therapy (continued)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is continued through vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
9975538|NCT00871351|Active Comparator|Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
9975539|NCT00871351|Active Comparator|Rosuvastatin|Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
9975540|NCT00832455|Experimental|Montelukast|
10174034|NCT03857438||Healthy Control|showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
10174035|NCT03857464|Other|Crossover Arm One|Hospital wards in this arm will use C. DIFF QUIK CHEK COMPLETE® for near-patient testing for the first phase of the crossover. For the second phase of the crossover, Arm One will utilize standard operating procedure testing for C. difficile infections using the centralized testing facilities.
10174036|NCT03857464|Other|Crossover Arm Two|Hospital wards in this arm will utilize testing for C. difficile infections using the centralized testing facilities in phase 1 and will switch to using C. DIFF QUIK CHEK COMPLETE® for near-patient testing in phase 2 of the crossover design.
10174037|NCT03857815|Experimental|SBRT in combined with anti-PD-1 antibody|HCC Patients will be received stereotactic body radiation therapy (SBRT) to primary lesions or metastatic lesions, such as liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
9674666|NCT05007860||BTK inhibitor therapy (interrupted)|Age ≥18 years, CLL/SLL (WHO criteria), and active therapy with a BTK inhibitor which is interrupted at time of vaccination. We excluded patients with known HIV or primary immune deficiency disorder, known active progression of CLL/SLL, prior cytotoxic chemotherapy within ≤1 year, CD20 monoclonal Ab within ≤6 months, or any prior bendamustine or fludarabine. We excluded patients who received PCV13 within ≤2 years, or within 2-5 years with nonprotective titers for ≥50% of PCV13-specific S. pneumonia IgG titers.
9674667|NCT05007535||HD-IVUS-guided primary PCI|Prospective, single arm, observational
9674668|NCT05007431||Women asylum seekers|
10174038|NCT03857581|Experimental|Clozapine Arm|
10174039|NCT03857581|Active Comparator|Olanzapine Arm|
10174040|NCT03857412|Sham Comparator|Non capsular polishing|No capsular polishing taking place during cataract surgery
9674669|NCT05007600|Experimental|trial group|Participants in the experimental group received an 8-week intensive (Monday to Friday) online interactive course.
9674670|NCT05007600|No Intervention|Control group|Participants in the control group consumed 8 weeks of unidirectional online video and audio programs (such as from YouTube).
9674671|NCT05007366|Active Comparator|Real-time gait biofeedback (RTGBF)|The RTGBF regimen delivers biofeedback that cues a personalized target to normalize vertical ground reaction force (vGRF) of each limb.
10174041|NCT03857412|Active Comparator|Capsular polishing|Capsular polishing taking place during cataract surgery
10187086|NCT03729726|Experimental|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model will include: a mandatory school-year program that offers after-school programming 4 days a week, including 120 hours of education (direct instruction & homework support), 30 hours of health (social emotional learning & sexual health), and 15 hours of student advocacy; an optional, 4-week summer program that offers 120 hours of programming each summer, including 16 hours of health (social emotional learning - service learning), 104 hours of project-based learning and enrichment (project-based learning in STEM - 64 hours) and enrichment (i.e., field trips, career speakers, and arts and crafts opportunities- 40 hours); and an optional parent engagement program, which will offer monthly parent workshops and quarterly events.
9674672|NCT05007366|Sham Comparator|Sham real-time gait biofeedback (Sham RTGBF)|The Sham RTGBF regimen will receive biofeedback that cues their habitual step length determined during the accommodation period on the first session of treadmill walking.
9674673|NCT05007730|Experimental|Intervention Arm|
9975541|NCT00812006|Experimental|A|Treatment Sequence A: rizatriptan, rizatriptan, placebo
9975542|NCT00812006|Experimental|B|Sequence B: rizatriptan, placebo, rizatriptan
10187087|NCT03729726|No Intervention|Control|
9975543|NCT00812006|Experimental|C|Sequence C: placebo, rizatriptan, rizatriptan
9674677|NCT05007665||Chronic Liver Diseases Patients/Healthy People|Chronic hepatitis (B OR C) , autoimmune hepatitis, liver cirrhosis, primary hepatocellular carcinoma
9674678|NCT05007496|Experimental|AV-COVID-19 (0.1 mcg S-protein)|DCL previously incubated with 0.1 mcg spike protein
9674679|NCT05007496|Experimental|AV-COVID-19 (0.33 mcg S-protein)|DCL previously incubated with 0.33 mcg spike protein
9674680|NCT05007496|Experimental|AV-COVID-19 (1.0 mcg S-protein)|DCL previously incubated with 1.0 mcg spike protein
9695091|NCT04782297||Titan HD Catheter|The Titan HD Catheter is a double lumen catheter that provides 2 dedicated (arterial/venous) access lumens. Each lumen is connected through an extension line with female luer connectors. The arterial and venous catheter lumens connect to a hub to facilitate connection of extension tubes with clamps intended to prevent air/fluid communication and control fluid flow through the catheter. At the proximal end of the extension tubes are female Luer fittings to provide a needleless connection. The clamps and the sleeves are color-coded red for the arterial lumen and blue for the venous lumen. Each catheter has a cuff which is intended to be positioned underneath the skin at the skin exit to aid in securing the catheter and to provide a barrier to minimize the risk of infection. Each lumen is connected through an extension line with female Luer connectors. The transition between lumen and extension is housed within a molded hub.
9695092|NCT04782297||Hemo-Flow Catheter|The Hemo-Flow® Catheter has two lumens (one arterial lumen, one venous lumen) comprised of a biocompatible polymeric material that contains radiopaque filler to allow radiographic imaging of the distal tips to ensure proper placement into the superior vena cava. The arterial lumen is utilized to withdraw blood from the patient and the venous lumen returns the blood to the patient after treatment
9695093|NCT04782297||Hemo-Cath LT Catheter|"The Hemo-Cath® LT Catheter is designed for continuous extraction of a patient's blood and reinfusion of filtered blood. It has two lumens: the arterial lumen is utilized to withdraw blood from the patient and the venous lumen returns the blood to the patient after treatment. In order to increase filtering efficiency, the tip of the extraction (inflow) lumen is separated from the reinfusion (outflow) lumen, minimizing the reentry of dialyzed blood from the venous return into the arterial inflow (recirculation). This separation is achieved with a step-tip design."
9695094|NCT04782310|Experimental|Group Pregabalin|Patients will receive oral Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
9695095|NCT04782310|Experimental|Group Duloxetine|Patients will receive oral duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
9975544|NCT00777582|Experimental|Treatment A|300mg bid (twice daily) tablet dose
10187088|NCT03729713|Experimental|Intervention|Computerized Cognitive Rehabilitation
9975545|NCT00777582|Experimental|Treatment B|400 mg twice daily (bid) capsule dose
10174042|NCT03857360|Active Comparator|Pentabiocel|Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
10174043|NCT03857360|Placebo Comparator|Placebo|Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
9674681|NCT05007444|Placebo Comparator|Placebo comparator|Patients in the placebo group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
10174044|NCT03857308|Experimental|Mindfulness Training|
10174045|NCT03857308|Active Comparator|Reappraisal Training|
9674682|NCT05007444|Active Comparator|Active comparator P2Et|Patients in the P2Et group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
9674683|NCT05007548|Experimental|Ga68-Dolacga Injection|Ga68-Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
9674684|NCT05007626||zero to six Exo|
9674685|NCT05007613|Experimental|cabozantinib plus atezolizumab|cabozantinib 40mg PO QD atezolizumab 1200mg IVD 30-60mins Q3W
9674686|NCT05007353|Experimental|Structured Lifestyle Intervention|Structured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation.
9674687|NCT05007353|Experimental|Self-Guided Intervention|General health information provided to participants.
9674688|NCT05007314|Experimental|Human Science|Arm 1 will include university graduates that hold at least a science undergraduate degree (or equivalent) in human science, including psychology, neuroscience, human biology, or medicine.
9674689|NCT05007314|Active Comparator|Natural or non-science|Arm 2 will include university graduates from non-human or non-scientific fields such as engineering, history, language studies, or law.
9674690|NCT05007288|Experimental|RET Treated Eye Plus INhance Group|Participants randomized to receive the restorative eye treatment (RET) intervention on either the left or right eyelid will administer the RET cream on the eyelid daily for 4 consecutive weeks prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
9674691|NCT05007288|Experimental|RET Untreated eye Plus INhance Group|Participants randomized to not receive the RET intervention will not receive any intervention prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
9674692|NCT05006989|Experimental|Intervention Group|Participants will be provided pre-made whole blueberry freeze-dried powder to be consumed.
9674693|NCT05006989|Placebo Comparator|Placebo Group|Participants will be provided placebo powder to be consumed.
9674694|NCT05007158||pocket infection|Patients with isolated pocket infection were diagnosed in the presence of local signs of inflammation (one or more of erythema, pain, warmth, swelling, induration, tenderness, or fluctuation), wound dehiscence, hardware protrusion or pus discharge at the pocket in the absence of systemic findings.
9674695|NCT05007158||CIED systemic infection|Patient s with a CIED systemic infection, diagnosed as the presence of pocket infection accompanied by bacteraemia or echocardiographic finding suggestive of infective endocarditis, but not fulfilling the Duke criteria.
9674696|NCT05007158||Lead-associated infective endocarditis|Patients with infective endocarditis, diagnosed according to modified Duke criteria
9674697|NCT05007158||control group|CIED Patients presenting for elective device exchange or planned lead revision between without local or systemic infections were selected as controls
9674698|NCT05007119|Active Comparator|Control Group|"It includes participants receiving conventional physical therapy for low back pain female patients for a period of 6 months.~McKenzie extension exercise Protocol Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
9674699|NCT05007119|Experimental|Experimental Group|"Group (A) Involves participants receiving cupping therapy along with conventional physicla therapy for a period of 6 months .~Moist Heat Pack for 10 mins McKenzie Extension Exercise Protocol"
9674700|NCT05006911|Experimental|PBOHB|Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac to evaluate safety and efficacy to improve uncorrected near vision in healthy presbyopic patients
9674701|NCT05007197|Experimental|Intervention Group|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people.~Group-specific diabetes trainings were completed in two training sessions. Each training session lasted an average of one and a half hours and a fifteen minute break was given.~The auditory group in the intervention group, calling by phone; visual group by SMS and WhatsApp tactile group, reminder alerts were made by phone+SMS+WhatsApp."
10174046|NCT03857334|Experimental|Arm A|
10174047|NCT03857334|Active Comparator|Arm B|
10174048|NCT03857503||Coronary Lesion Assessment with iFR|Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will undergo a screening angiogram to assess eligibility. Eligible patients will be those with at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual assessment of angiogram.
10187089|NCT03729713|Sham Comparator|Placebo|Video game
9674702|NCT05007197|No Intervention|Control Group|The learning modality of the control group were determined and standard group training was provided with the education booklet.
10174049|NCT03857269|Experimental|Acupoint Massage group|Choose Chinese medicine acupuncture points： Shenting, Baihui, Sishencong, Diwei, Chengling, Fengchi, Fengfu，Zusanli and Sanyinjiao，32 points per acupressure.32 times per acupoint.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
10174050|NCT03857269|Experimental|Aromatherapy group|Make a 5x5cm bag and put a cotton ball in the bag and the bag is clipped to the patient's collar.Dispense 10% lavender essential oil, 2-3 drops a day in cotton balls.Cotton ball replacement daily. Intervention frequency will be monday to saturday per week for 6 months.（n=30）
9674703|NCT05006898|Experimental|PBO Investigational drug|Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
10174051|NCT03857269|Experimental|Acupoint Massage and Aromatherapy group|At the same time as the acupressure, the essential oil is applied to the collar and begins to sniff.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
10174052|NCT03857269|No Intervention|Blank control group|The group selects elderly people with MCI who do not receive intervention after informed.Participate in routine activities of Nursing homes.
10174053|NCT03857282|Active Comparator|Aerobic Exercises|Bicycling Exercise (lower Limb)
10174054|NCT03857282|Experimental|Tai Chi Exercises|Tai Chi Exercises (yang 24 Postures)
10174055|NCT03857204|Experimental|performing US scans for fetal weight assessment.|
10174056|NCT03856957|Experimental|Endocuff colonoscopy|Colonoscopy performed with Endocuff
10174057|NCT03856957|Placebo Comparator|Conventional colonoscopy|Colonoscopy performed without any device
10174058|NCT03857009||Symptomatic|No intervention.
10174059|NCT03857009||Asymptomatic|No intervention.
10174060|NCT03857113||PSMA-radioguided surgery|Tc-99m-PSMA combined with a gamma probe, guidance of the surgical resection of recurrent PC lymph node metastases
10174061|NCT03856892|Experimental|Active intervention|Intensive breath-based Hatha yoga program (more breath, more hours of practice)
10174062|NCT03856892|Active Comparator|Active Control|Less intensive practice on body (not breath) based yoga practices
10174063|NCT03856892|No Intervention|Passive control|No intervention is followed other than daily duties while in the same environment as both of the active groups.
10174064|NCT03857139|Experimental|NRT smoking Cessation Intervention|All participants will be provided with the Nicotine Patch as an intervention
10174065|NCT03857035|Experimental|Piezosurgery group|"One side of the patients will be randomly selected and labeled as experimental group. In experimental group, impacted third molar will be extracted using piezosurgery."
10174066|NCT03857035|Placebo Comparator|Rotary Instruments Group|"The other side will be accepted as control group. In the control group, impacted third molar will be extracted using conventional rotary instruments."
10174067|NCT03857152|Other|Patient receiving CESM|Patients will receive CESM in addition to normal standard treatment.
10174068|NCT03856853|Experimental|treatment group|pirfenidone group
10174069|NCT03856853|Placebo Comparator|placebo group|placebo group
10174070|NCT03857126||Pregnancy volunteer subjects|"Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology.~Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors."
10174071|NCT03857191||Patients already treated for OSA|The first group involves patients already diagnosed and treated for sleep apnea that will follow the nutritional psychocomportemental rehabilitation
10174072|NCT03857191||Patients with a high OSA risk|This group concerns patients with a high OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
10174073|NCT03857191||Patients with a low OSA risk|This group concerns patients with a low OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
10174074|NCT03857022|Experimental|Enhanced External Counterpulsation|"Subjects of Heart failure with 'Enhanced External Counterpulsation therapy"
10174075|NCT03857022|No Intervention|"No 'Enhanced External Counterpulsation"|"Subjects of Heart failure without 'Enhanced External Counterpulsation therapy"
10174076|NCT03857100|Active Comparator|Intervention|Receives letter and report
10174077|NCT03857100|No Intervention|Control|Does not receive letter and report
10174078|NCT03856983|No Intervention|Control group|Control group who will do usual rehabilitation.
10174079|NCT03856983|Experimental|Experimental group|Experimental group who will do usual rehabilitation and visualization of point-light human actions
10174080|NCT03857061||COPD Patients|This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.
10174081|NCT03856905|Active Comparator|Physical therapy group|The children in this group will receive the conventional physical therapy program (CPTP). It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neuro-developmental techniques, and gait training. The total program will be conducted for 1 h, three sessions/week for 12 weeks.
10174082|NCT03856905|Experimental|Extra-corporeal shock wave therapy group|The children in this group only will receive the extra-corporeal shock wave therapy (ESWT). An electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG) will be used. The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode, one session/week for 12 weeks. The treatment is painless and does not require any kind of anesthesia or the use of analgesic drugs
9674704|NCT05006898|Active Comparator|Pilocarpine|Pilocarpine was instilled in the other oye.
9674705|NCT05006898|Active Comparator|Brimonidine|Brimonidine was instilled in the other eye.
9674706|NCT05007210|Experimental|Prenatal massage therapy group|Prenatal massage therapy for prenatal attachment, physiological and psychological distress, maternal and fetal well-being.
9674707|NCT05007210|No Intervention|Control group|Pregnant women in the control group were interviewed twice (once a week for 30th and 34th week) by the same massaging midwife. No additional attempt was made except for filling out the forms and evaluating the biophysical profile by the obstetrician in these interviews. The massaging midwife's phone number was given to the pregnant women in both groups if they want to reach anytime. A phone number was set for the study, and this phone number was used by the massaging midwife. This service has been provided for pregnant women to reach her whenever they want.
9674708|NCT05007262|Experimental|Tangningtongluo tablets|Tangningtongluo tablets, 4 tablets one time,tid,po, taken after meals.The patients will receive drugs for 24 weeks continuously. After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI） and Angiotensin Receptor Blocker（ARB） drugs will be continued to use as the original treatment protocol.
9674709|NCT05007262|Active Comparator|Calcium dobesilate capsules|Calcium dobesilate capsules, 1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.After 24 weeks, the researchers will decide whether to continue depend on the patient condition and willingness. The maximum medication time is up to 48 weeks.Basic treatment: According to the comprehensive objectives of China Type 2 Diabetes Guidelines (2020 Edition) .The Angiotensin-Converting Enzyme（ACEI ）and Angiotensin Receptor Blocker （ARB） drugs will be continued to use as the original treatment protocol.
9674710|NCT05007184|No Intervention|Control Arm (Arm 1)|Participants will experience an unmodified version of NUSMart, which replicates the traditional shopping experience of online grocery stores.
9674711|NCT05007184|Experimental|Warning Label Arm (Arm 2)|Similar to Arm 1 except that products are labeled with Chilean warning FOP labels.
9674712|NCT05007184|Experimental|Nutri-Score Arm (Arm 3)|Similar to Arm 1 except that products are labeled with NutriScore FOP labels.
9674713|NCT05007171|Experimental|Very low calorie diet|Use of very low calorie diet in hospital for 3 weeks
9674714|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and Quadrivalent adjuvanted influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the quadrivalent adjuvanted influenza vaccine (FLUAD® Quadrivalent) simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
9674715|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and high-dose quadrivalent influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the (Fluzone® HD Quadrivalent) influenza vaccine simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
9674716|NCT05006846||Cohort 1|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between February 18, 2020, to May 25, 2020.
9674717|NCT05006846||Cohort 2|Primary care physicians (PCPs) and their patients used the intervention (OARS) for 4 weeks. They completed 2 interviews to obtain their feedback on the acceptability and feasibility of using OARS in a primary care setting. Data for this cohort was collected between July 17, 2020, to August 31, 2020.
9674718|NCT05007249|Other|Overweight or obese minors with intellectual disability|
9674719|NCT05007223||1. Experimental: doxycycline|Given doxycycline and assessment of skin
9674720|NCT05007223||2. No Intervention: Healthy Controls|Control subjects to assess if there is baseline difference in the skin microbiome
9674721|NCT05006937|Active Comparator|laser dusting|"In the dusting arm, the ureteroscope will be advanced into the kidney or ureter over an access wire without an access sheath in place. The identified stone will be dusted using a 200 micron Moses laser fiber at a setting of 0.3-0.6 J and 50-120 Hz using the Moses 2.0 laser system. Stone dusting will continue until the surgeon feels the fragments are all negligible in size and would be able to pass. One small piece will be extracted for analysis and the remainder will be left to pass spontaneously. If there is no evidence of injury or swelling of the ureter at the conclusion of the case a stent will be omitted."
9674722|NCT05006937|Active Comparator|basketing|In the Basketing arm, a ureteral access sheath (UAS) will be placed per standard fashion. The ureteroscope will be introduced into the kidney and the stone fragmented at a setting of 0.8-1.0 J and 6-15 Hz. The resultant fragments will be basket extracted through the sheath for analysis. All fragments will be removed until no residual stone remains. At the time of UAS removal the ureter will be inspected. If there is no evidence of ureteral injury or swelling then a stent will be omitted.
9674723|NCT05007002|Experimental|Robot-based therapy|Chronic stroke patients receiving robot-based therapy
9674724|NCT05007132|Experimental|Arm A|Trifluridine/tipiracil, 35 mg/m² body surface area (BSA), twice daily, orally on days 1-5 and 8-12 Panitumumab at 6 mg/kg bodyweight, intravenous infusion on days 1 and 15
9674725|NCT05007132|Active Comparator|Arm B|Trifluridine/tipiracil, 35 mg/m² body surface area, twice daily, orally on days 1-5 and 8-12 Bevacizumab at 5 mg/kg bodyweight, intravenous infusion on days 1 and 15
9674726|NCT05007054||Percutaneous coronary intervention|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months.
9674727|NCT05007054||Coronary artery bypass grafting|The left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. Te procedure was performed by surgeons experienced in onpump or of-pump surgery at the operator's discretion.
10174083|NCT03856905|Experimental|Functional electrical stimulation group|"The children in this group will receive the functional electrical stimulation (FES). The FES will be applied by using the WalkAide system (Innovative Neurotronics, Austin, TX, USA).~The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait."
10174084|NCT03856866|Experimental|Hydroxychloroquine|Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
10174085|NCT03856866|Placebo Comparator|Placebo|Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
10174086|NCT03856970|Experimental|Part 1: Healthy Volunteers|Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).
10174087|NCT03856970|Experimental|Part 2: Healthy Volunteers|Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).
10174088|NCT03856970|Experimental|Part 3: Healthy Volunteers|"Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).~Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42)."
10174089|NCT03857217||Post-cardiotomy patients|Patients submitted to cardiac surgery
10174090|NCT03856814||Patients with varicose veins|Patients with varicose veins, indicative for treatment with EndoVenous Laser Ablation (EVLA) using the ELVeS® Radial® 2ring slim fiber or Surgery (ligation/stripping) according to the standard of care of the participating investigators.
10174091|NCT03856827|Experimental|IW-6463|IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food
10174092|NCT03856827|Placebo Comparator|Placebo|Matching placebo tablets administered orally
10174093|NCT03856801|Experimental|Whole-body vibration in normoxia condition|Training session in normoxia condition
10174094|NCT03856801|Experimental|Whole-body vibration in hypoxia condition|Training session in hypoxia condition
10174095|NCT03856736|Experimental|MIAT|Composite of the execution of moderated-intensity aerobic training (MIAT) twice week.
10174096|NCT03856736|Experimental|Control|Consisting of two session per week of different activities, such as body relaxation, low-intesity/volume of aerobic exercise to mimic sham group.
9674728|NCT05007054||Medical therapy|Patients with neither PCI nor CABG treatment were allocated to the MT alone group. For medical therapy, antiplatelet medication, statins, renin-angiotensin system blockade, β-blockers, and nitrate were used.
9674729|NCT05006768|Experimental|T test|Test drug (Barcimiant) 1 tablet contains 4 mg Baricitinib
9674730|NCT05006768|Active Comparator|B reference (first dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
9674731|NCT05006768|Active Comparator|B reference (second dose)|Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib
9674732|NCT05006469|Experimental|BAd treatment|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, >70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
9674733|NCT05006703|Experimental|Intervention group|Access to digital intervention
9674734|NCT05006703|No Intervention|Control group|Usual care group
9674735|NCT05006755|Experimental|control group|the group of primary molar teeth that will be treated in furcal perforation with Mineral Trioxide Aggregate
9674736|NCT05006755|Experimental|experimental group|the group of primary molar teeth that will be treated in furcal perforation with Biodentine
9674737|NCT05006664|Experimental|Brentuximab Vedotin (Adcetris) in Combination with CHEP|Single arm, open label, Brentuximab Vedotin (Adcetris) in Combination with CHEP
9674738|NCT05006742|Active Comparator|CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
9674739|NCT05006742|Active Comparator|FB-CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
9674740|NCT05006586||RVF|All patients having undergone repair for rectovaginal fistula
9674741|NCT05006612|Active Comparator|Group 1 ((Serratus Anterior Plane Block SAPB)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%.
9674742|NCT05006612|Active Comparator|Group 2 ((Serratus Anterior Plane Block SAPB combined with Modified Pectoral Nerve Block)|N=3o Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 20 ml levobupivacaine 0.25%and Modified Pectoral Nerve Block with injection of 10 ml levobupivacaine 0.25%between the two pectoralis muscles, after that, the probe was turned toward the axilla, and as the serratus anterior muscle was recognized above the third and fourth ribs, 10 mL of levobupivacaine 0.25% was injected above this muscle
9674743|NCT05006729||RURAL cohort study|A longitudinal research project in ten rural counties in Alabama, Kentucky, Louisiana, and Mississippi enrolling approximately 4,600 participants from these communities, examining several different aspects of their health, including heart and lung function.
10187090|NCT03729700|Experimental|Almond supplementation|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
10187091|NCT03729700|No Intervention|Control snack|The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products.
9674744|NCT05006560|Experimental|Usual care rehabilitation and aftercare|Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.
9674745|NCT05006560|Experimental|Rehabilitation and aftercare (aligned)|"Participants receive the standard inpatient pulmonary rehabilitation followed by an internet based 12-week rehabilitation aftercare program.~During rehabilitation, participants already get familiarized with components of the after care program."
9674746|NCT05006508|Experimental|Usage of tool|Participants get access to the tool and use it regularly
9674747|NCT05006508|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool and get no further follow-up. Their development of type 2 diabetes or development of HbA1c is tracked via clinical registries.
9674748|NCT05006651|No Intervention|Laryngoscope|Intubation with traditional laryngoscope
10187092|NCT03729687|Experimental|LARCT-US|Short Course Radiation Therapy (5 x 5 Gy in 1 week, scRT) followed by 4 cycles of Pre-operative Chemotherapy using capecitabine and oxaliplatin (CAPOX) and Surgery in High-risk Rectal Cancer
9674749|NCT05006651|Active Comparator|McGrath MAC|Intubation with video laryngoscope
9674750|NCT05006651|Active Comparator|Trachway|Intubation with video stylet
9674751|NCT05006521|Experimental|KN-002 for SAD (Part 1)|Up to 6 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
9674752|NCT05006521|Placebo Comparator|Placebo for SAD (Part 1)|Up to 6 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
9674753|NCT05006521|Experimental|KN-002 for MAD (Part 2)|Up to 4 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
9674754|NCT05006521|Experimental|Placebo for MAD (Part 2)|Up to 4 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
9674755|NCT05006495|Experimental|C3 laminectomy with C4-6 laminoplasty|Cervical myelopathy patients who underwent C3 laminectomy with laminoplasty.
9674756|NCT05006495|Active Comparator|C3-6 laminoplasty|Cervical myelopathy patients who underwent C3-6 laminoplasty.
9674757|NCT05006677||non-vitamin K antagonist oral anticoagulants (NOACs)|
9674758|NCT05006677||vitamin K antagonists (VKAs)|
9674759|NCT05006677||antiplatelet agents|
9674760|NCT05006677||non-antithrombotic therapy|
9674761|NCT05006547||Young adults|18<age<35
9674762|NCT05006547||Middle aged adults|50<age<65
9674763|NCT05006690|Experimental|Telerehabilitation Training Group|"In the telerehabilitation group, an individualized rehabilitation program according to the principles of spinal stabilization exercises will be applied via video conference, 3 days a week, 1 hour, online in real-time, accompanied by a physiotherapist, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
9674764|NCT05006690|Experimental|Face-to-Face Training Group|"In the face-to-face training group, an individualized rehabilitation program according to the principles of spinal stabilization exercises will be applied in the clinic under the supervision of a physiotherapist for 1 hour, 3 days a week, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
9674765|NCT05006690|Experimental|Home-Based Training Group|"In the home exercise group, patients will be asked to perform individualized spinal stabilization exercises at home, 3 days a week, for 8 weeks.~In the first session, informative training about the disease (pathophysiology of spondyloarthritis, its course, physical structures it covers, etc.), pain management training (information about the relationship between pain, muscle spasm, stress, depression, methods that can be used for coping with pain, etc.), exercise. The importance of exercise training (trunk stabilization, anatomy) and aims will be given within the scope of patient education."
9674766|NCT05006625||Adolescents and Young Adults|Adolescents and Young Adults Seeking HIV Treatment and Prevention
9674767|NCT05006625||Service Providers|Service Providers for Adolescents and Young Adults Seeking HIV Treatment and Prevention
9674768|NCT05006391|Experimental|Tele-Coaching (Online) Community-Based Exercise|This study involves two phases: a six month online Community-Based Exercise Intervention (Phase 1), followed by a six month Follow-Up Monitoring Phase (Phase 2).
9674769|NCT05006300|Experimental|Group 1|One application of Topialyse Baume Barrière per day
10187093|NCT03729674||Biosimilar|Exposed group
9674770|NCT05006300|Experimental|Group 2|Two applications of Topialyse Baume Barrière per day
9674771|NCT05006274||Group 1-Traditional soft tissue balance|Patients in group 1 will receive traditional, manual soft-tissue balancing during surgery. For the purpose of the study, the balance will be quantitatively assessed at the end of the case, by means of surgeon-blinded VERASENSE measurements before and after cementation.
9674772|NCT05006274||Group 2-Soft tissue balance using VERASENSE|For the patients in Group 2, intra-operative sensor feedback will be used in creating a quantitatively balanced knee (VERASENSE, OrthoSensor Inc.). Thereby, a quantitatively balanced knee is characterized by a mediolateral load differential below 15lbs at 10-45-90 degrees of flexion.
9674773|NCT05006131||Patients who are at high-risk for pancreatic cancer|Patients that meet the eligibility criteria based on CAPS3 or updated national pancreatic cancer screening guidelines
9674774|NCT05006287|Experimental|Non-Vitamin K Oral Anticoagulant (NOAC) Group|Anticoagulation with a NOAC (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)
9674775|NCT05006287|Active Comparator|Warfarin Group|Anticoagulation with warfarin to target INR 2.5
9674776|NCT05006222|Active Comparator|ERT group|The participants are enrolled in this group whose get enzyme replacement therapy
9674777|NCT05006222|No Intervention|non-ERT group|The participants are enrolled in this group whose not get enzyme replacement therapy
9674778|NCT05006157|Experimental|ViaOne device|ViaOne device will be used for percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac
10187094|NCT03729674||Originator (legacy) drug|Reference group
10187095|NCT03729661|Experimental|Breath hold|Patients who receive a breathhold CT- and treatment
10187096|NCT03729635|Experimental|PIFB performed to treat PSP|Pectoral-intercostal fascial plane block (PIFB) is performed on patients with severe post-sternotomy pain (PSP) after coronary artery bypass graft surgery (CABG).
10187097|NCT03729622|Active Comparator|Immediate Intervention|Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
9674779|NCT05006638|Placebo Comparator|control group|will receive the traditional supportive treatment according to (PCC-ASUH) protocol
9674780|NCT05006638|Active Comparator|case group|will receive the traditional supportive treatment plus administration of ILE (20%) 1.5 ml/kg as a bolus over 2-3 minutes. Followed immediately by an infusion of 20 % lipid emulsion at a rate of 0.25 mL/kg/min. After 3 minutes of this infusion rate, response to the bolus and initial infusion should be assessed. If there has been a significant response, the infusion rate can be adjusted to 0.025 mL/kg/min with monitoring of blood pressure, heart rate, and other available hemodynamic parameters during the infusion with a maximum dose of 10 mL/kg
10174097|NCT03856658|Experimental|Floxuridine (FUDR) via HAI pump|Once enrolled, patients will undergo surgical placement of the HAI pump. This can be accomplished using minimally invasive or open techniques with an anticipated hospital stay of approximately 3-5 days. Prior to discharge from the hospital or at the first postoperative visit the pump is filled with FUDR according to the following equation: 0.12 mg/kg/d (using ideal body weight). This fill initiates day 1 of a 4-week cycle. The chemotherapy is infused by the pump continuously over 14 days. On day 15 (+/-4 days), the remaining chemotherapy is removed from the pump which is refilled with heparinized saline (30,000 units). This remains for an additional 2 weeks until the pump is refilled with FUDR at the start of the next cycle. Treatment is continued for a maximum of 6 cycles or as limited by toxicity. This regimen has been utilized with an acceptable safety profile in the setting of colorectal liver metastases.
10174098|NCT03856762|Experimental|Traditional Jiangnan diet|Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
10174099|NCT03856762|Experimental|Mediterranean diet|Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
9674781|NCT05006027||Percutaneous coronary intervention using a 7-Fr thin wall sheath via the snuffbox approach|patients with coronary artery disease who planned to perform PCI using 7-Fr thin wall sheath via the snuffbox approach
9674782|NCT05006105|Experimental|PPG-based mHealth on smartphone|Participants used PPG-based mHealth on a smartphone for 6 months. Participants were asked to perform two spot-check measurements and additional measurements in case of symptoms. The use of PPG-based mHealth on a smartphone was initiated on the day of insertable loop recorder insertion.
9674783|NCT05006105|Experimental|PPG-based mHealth on smartwatch|Participants used PPG-based mHealth on a smartwatch for 6 months. Participants were asked to wear the smartwatch continuously (except during battery charging). The use of PPG-based mHealth on a smartwatch was initiated on the day of insertable loop recorder insertion.
9674784|NCT05006001||Case|Cases were defined as patients with an event of renal impairment during follow-up, such as acute kidney injury.
10174100|NCT03856762|Experimental|Current Shanghai diet|Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
10174101|NCT03856606|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will not be asked to perform interval exercise.
9674785|NCT05006001||Control|Cases were defined as patients without an event of renal impairment during follow-up, such as acute kidney injury.
9674786|NCT05006001||Exposure|Exposure was defined as patients with colchicine and NSAIDs combination therapy.
9674787|NCT05006001||Non-Exposure|Non-Exposure was defined as patients with other gout therapy.
9674788|NCT05006365|Experimental|Transcranial Pulse Stimulation|Investigators will use a single-blind randomized controlled trial design with two-armed repeated measures. The trial design complies with the Consolidated Standards of Reporting Trials (CONSORT) statement. The first arm is the Intervention Group (Transcranial Pulse Stimulation) (TPS group)
9674789|NCT05006365|Active Comparator|Waitlist Control Group|Second arm is the waitlist control group.
9674790|NCT05006118|Experimental|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of [12C]-rodatristat ethyl and [14C]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
9674791|NCT05006209|Active Comparator|One visit root canal treatment with CHX|The teeth were treated in one-visit (OV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
9674792|NCT05006209|Active Comparator|Two visit root canal treatment with CH|The teeth were treated in two visit (TV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
9674793|NCT05005910|Experimental|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours) then vonoprazan 20 mg oral once daily for 28 days
9674794|NCT05005910|Active Comparator|PPIs|PPIs IV infusion for 72 hours then oral PPIs twice per day for 28 days
9674795|NCT05005923|No Intervention|Periodontal healthy|
9674796|NCT05005923|Active Comparator|Periodontitis Stage III Grade B|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
9674797|NCT05005923|Active Comparator|Periodontitis Stage III Grade C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
9674798|NCT05006066||Healthy volunteers - Pain-Free|"Each participant will be stimulated with 4 temporal summation stimulation conditions:~continuous thermal (1 stimulation of two minutes)~repetitive thermal (30 stimulations of 1 second)~continuous mechanical (1 stimulation of two minutes)~repetitive mechanical (30 stimulation of 1 second)"
9674799|NCT05006235|Active Comparator|Salbutamol Group|included babies who had received nebulized B2 agonist salbutamol (0.15 mg/kg) + 4ml normal saline
9674800|NCT05006235|Active Comparator|Epinephrine Group|included babies who had received nebulized epinephrine (0, 05 ml/Kg) + 4ml normal saline
9674801|NCT05006235|Placebo Comparator|Saline Group|include babies who had received nebulized 0.9% saline
9975546|NCT00777582|Experimental|Treatment C|400mg bid (twice daily) tablet dose
9975547|NCT00739050|Experimental|1|Arm 1: Drug
9975548|NCT00739050|Placebo Comparator|2|Arm 2: Placebo
9674803|NCT05005936||Ancillary-Correlative (ABUS, WBUS)|Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline, mid-treatment and pre-surgery (end of treatment).
9674804|NCT05005884|Active Comparator|oral phenolics intake|Prescription of oral phenolics 250 mg two times daily
9674805|NCT05005884|Placebo Comparator|placebo caplet intake|Prescription of oral phenolics 250 mg two times daily
9674806|NCT05005689|Active Comparator|Mouthwash|Fluoride mouthwash (0.05%; 225ppm) 10ml for 1 minute daily
9674807|NCT05005689|Experimental|Tooth Mousse|"Tooth Mousse Plus (Recaldent™ CPP-ACP [casein phosphopeptide (CPP)-amorphous calcium phosphate (ACP)] and Sodium Fluoride 0.2% w/w; 900 ppm).~Tooth creme; 2ml smear daily"
9674808|NCT05005611|Placebo Comparator|Placebo|
9674809|NCT05005611|Experimental|Probiotics-1|
9674810|NCT05005611|Experimental|Probiotics-2|
9674811|NCT05005611|Experimental|Probiotics-3|
9674812|NCT05005494|Active Comparator|Magnesium sulfate IV|10 patients scheduled for thyroidectomy
9674813|NCT05005494|Placebo Comparator|Placebo|10 patients scheduled for thyroidectomy
9674814|NCT05005858|Experimental|Autograft|"The filler used in ridge splitting is autologous bone block harvested from mandible~Interventions:~Procedure: ridge splitting~Procedure: bone core biopsy~Device: dental implant placement~Measurement: clinical measurement with Williams probe~Micro-CT analysis~Histomorphometric measurements"
9674815|NCT05005546|Experimental|Experimental: Yoga|
9674816|NCT05005546|Experimental|Experimental: Laughter Yoga|
9674817|NCT05005546|No Intervention|Control|
9674818|NCT05005702|Experimental|study group|Patients were assigned to inspiratory muscle training (IMT) for 6 weeks. During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training. The inspiratory load was set at 40% of maximal inspiratory pressure. The training session was supervised at the hospital.
9674819|NCT05005715|Active Comparator|Dexmedetomidine group|After the induction of anesthesia, the dexmedetomidine group received intravenous dexmedetomidine at a loading dose of 1µg/kg for 10 min, followed by a maintenance dose of 0.5µg/kg/h until the end of surgery.
9674820|NCT05005715|Placebo Comparator|Control group|After the induction of anesthesia, the control group received intravenous normal saline at the same loading volume for 10 min, followed by the same volume until the end of surgery.
9674821|NCT05005624||Validation group 1 (VG-1)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.1 logMAR (Snellen 20/25)
9674822|NCT05005624||Validation group 2 (VG-2)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.4 logMAR (Snellen 20/50)
9674823|NCT05005624||Validation group 3 (VG-3)|20 participants with binocular Uncorrected Near Visual Acuity (UNVA) 0.7 logMAR (Snellen 20/100)
9674824|NCT05005637|Experimental|Anti Tuberculosis Therapy|"Dosage form: ATT fixed-dose combination (FDC). FDC intensive phase containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), while FDC continuation phase containing rifampicin-isoniazid.~Dosage: according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets.~Frequency: Intensive phase: once daily. Continuation phase: 3 times/week. Duration: 6 months (2 months of FDC intensive phase + 4 months of FDC continuation phase)"
9527551|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
9527552|NCT03219151|Experimental|eMAR game|Participants provided access to eMAR simulator game in advance of simulated return-demonstration; also receive normal education pre-work related to eMAR administration
9527553|NCT03219151|Active Comparator|Normal pre-work|Participants receive normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
9674825|NCT05005637|Active Comparator|Oral Steroid|Dosage form: Oral prednisone Dosage: 1 mg/kgBW/day (max 60 mg/day) Duration: until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
9975549|NCT00687531|Experimental|Mometasone Furoate|Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
9975550|NCT00654628|Experimental|1|Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks
9674828|NCT05005767|Placebo Comparator|Placebo group|ten patients with sites suffering from mild chronic periodontitis sites will be treated with scaling and root planing (SRP) only
9674829|NCT05005767|Active Comparator|test group|Ten patients with sites suffering from mild chronic periodontitis. sites will be treated with scaling and root planing (SRP) and subgingival application of Frankincense extract gel
9674830|NCT05005455|Active Comparator|bevacizumab with old manufacturing process.|
9674831|NCT05005455|Experimental|bevacizumab with new manufacturing process.|
9674832|NCT05005598||pediatric population|pediatric population of CHU of Nancy, France.
9674833|NCT05005741|Experimental|Beinaglutide|
9674834|NCT05005741|Active Comparator|Dulaglutide|
9674835|NCT05005780|Experimental|µ-alpha oscillation coupled ipsilesional 100 Hz triplet bursts|µ-rhythm (The µ rhythm frequency band is defined by activity falling between 8 and 13 Hz and recorded by scalp electrodes over the sensorimotor cortex during waking neural activity) negative peak triggered TMS of ipsilesional primary motor cortex, consisting of 400 triple pulses at 100 Hz, delivered at a mean inter-triple pulse interval of 3.0 s. Stimulation intensity: 100% resting motor threshold.
9674836|NCT05005780|Active Comparator|contralesional 1 Hz rTMS|1200 stimuli to the contralesional primary motor cortex at 1 Hz. Stimulation intensity: 115% resting motor threshold.
9674837|NCT05005468|Experimental|Camrelizumab Combined With Famitinib|Drug: Camrelizumab Drug: Famitinib
9674838|NCT05005468|No Intervention|Observation|Observation
9695096|NCT04782310|Experimental|Group Pregabalin& Duloxetine|Patients will receive single dose of Pregabalin 75mg + duloxetine 30mg two hour preoperatively, 75mg pregabalin 12 hour postoperative and then will continue pregabalin twice per day +duloxetine once after breakfast for one week.
9674839|NCT05005416|Experimental|GOALS Intervention|The experimental arm is an 8-week cognitive-behavioral based physical therapy (PT) intervention for chronic spine pain. The manualized intervention utilizes a hybrid tele-rehabilitation delivery model. GOALS comprises an initial in-person evaluation (60 min) by a research physical therapist, followed by 6 remote treatment sessions (30-45 min each) conducted by the same physical therapist once a week by telephone. A second in-person evaluation is conducted at the midpoint of the GOALS intervention to assess progress and advance the participant's home exercise program.
9674840|NCT05005416|Active Comparator|Usual Care Physical Therapy|The control arm is Usual Care physical therapy (PT) at a local Federally Qualified Health Center (FQHC), which offers PT services at 4 outpatient clinics across San Diego county. Participants in the Usual Care group attend an initial PT evaluation at a FQHC Physical Rehabilitation Clinic. The frequency and type of PT intervention are then determined by the treating physical therapist in accordance with standard clinical practice at the FQHC.
9674841|NCT05005819|Experimental|[18F]APN-1607|Participants will receive an IV bolus injection of [18F]APN-1607, followed by PET brain imaging.
10174102|NCT03856606|Experimental|Prolonged sitting with interval exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will be asked to perform interval exercise every hour on the hour.
9674842|NCT05005377|Experimental|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
9674843|NCT05005377|Experimental|Socket Preservation with Freeze-Dried Bone Allograft|the extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
9674844|NCT05005325|Active Comparator|Experimental group(Male)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
9674845|NCT05005325|Experimental|Experimental group(Female)|Participants will be included in the study after screening from inclusion criteria. Each participant will perform FMS during a single session before competition as pre testing. It consists of 7 movement tasks and 3 clearance screens. Movement task will include deep squat, hurdle step, inline lunge, shoulder mobility, active straight-leg raise, trunk stability push-up and rotary stability. Five of the 7 tasks (hurdle step, inline lunge, shoulder mobility, active straight-leg raise and rotary stability) will be performed on both right and left sides. In addition to these, 3 clearance screen will assess the presence of pain with shoulder internal rotation/flexion, end range spinal flexion and end range spinal extension. Participants will be instructed for each task performance and will perform 3 attempts for each task.
9674846|NCT05005169|Experimental|intrapartum streptococcal B detection by PCR|The automatons will be installed by the laboratory in the delivery rooms and used delocalized by the obstetrical teams. Verification and validation of results will be ensured by the microbiology laboratory team, according to the recommendations and procedures already in use for off-site biology.
9674847|NCT05005169|Active Comparator|"intrapartum streptococcal B detection by SGB culture strategy"|
9674848|NCT05005117|Experimental|Laparoscopic operation|Laparoscopic emergency colon resection
9674849|NCT05005117|Active Comparator|Open operation|Open emergency colon resection
9674850|NCT05005065|Experimental|Treatment AB|Participants will be randomized to receive IN-C005 Y mg (Treatment A) and IN-A001 Y mg (Treatment B) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
9674851|NCT05005065|Experimental|Treatment BA|Participants will be randomized to receive IN-A001 Y mg and IN-C005 Y mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
9674852|NCT05005065|Experimental|Treatment CD|Participants will be randomized to receive IN-C005 Z mg (Treatment C) and IN-C005 X mg (Treatment D) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
9674853|NCT05005065|Experimental|Treatment DC|Participants will be randomized to receive IN-C005 X mg and IN-C005 Z mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.
9695097|NCT04782011|Experimental|ATC/DDD arm|The intervention is the introduction of the ATC/DDD including the training of healthcare workers on its importance and usage in monitoring antibiotic use. The unit of intervention will be a health facility. Antibiotic prescriptions and antibiotic utilization records for adult patients (in-patients and ambulatory) from the selected facilities will be enrolled in the study.
9695098|NCT04782011|No Intervention|Control arm|The health care workers will continue with standard practice. However, the research team will collect data on antibiotic prescriptions and antibiotic utilization for adult patients (in-patients and ambulatory) from the selected facilities. The data will be compared with that of the intervention arm.
9695099|NCT04781998|Experimental|liraglutide 3 mg (Saxenda®) once-daily|
9695100|NCT04781985|Experimental|suprapubic cystolithotomy|Extraction of the vesical stone via open exploration of the bladder.
9695101|NCT04781738||patients with history of vascular ring who didn't have corrective surgery|patients with history of vascular ring who didn't have corrective surgery
10187098|NCT03729622|Placebo Comparator|Delayed Intervention|Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
10187099|NCT03729583|Active Comparator|Control group|The control group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme without breathing retraining All patients were medically stable and referred by their caring respiratory consultant
9674854|NCT05005156|Active Comparator|Active vaccine Ad5-nCoV|two dose of active vaccine Ad5-nCoV
9674855|NCT05005156|Placebo Comparator|Placebo for Ad5-nCoV vaccine|one dose of placebo for Ad5-nCoV vaccine
9674856|NCT05004909|Active Comparator|1 Fingertip Unit 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 1 fingertip unit of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
9674857|NCT05004909|Experimental|2 Fingertip Units 0.05% Tretinoin|Subjects were randomized to receive the instructions to use 2 fingertip units of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
9674858|NCT05005130|Experimental|TASKPEN|a package of integrated HIV/NCD services
9674859|NCT05005091|Active Comparator|oral carbohydrate|the patients drunk oral carbohydrate two hours ago preoperatively
9674860|NCT05005091|No Intervention|no oral carbohydrate|the patients did not drink oral carbohydrate preoperatively
9674861|NCT05005143||Paroxysmal AF ablation|Patients with standard indications to paroxysmal AF ablation
9674862|NCT05005208|Experimental|Rehabilitation Group|PD subjects will be going through a rehabilitation program based on an Irish dance with the support of the technological platform SI-ROBOTICS
9674863|NCT05004974|Experimental|Sintilimab with Pemigatinib|Sintilimab combined with Pemigatinib every 3 weeks (Q3W): Sintilimab is administered every 3 weeks (200mg, IV), Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
9674865|NCT05005013|Experimental|Active tDCS + Mindfulness|
9674866|NCT05005013|Sham Comparator|Sham tDCS + Mindfulness|
9674867|NCT05004948|Active Comparator|Resistance exercise group|This group has conducted a resistance exercise program (50-60% of 1RM, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
9674868|NCT05004948|Active Comparator|Aerobic exercise program|This group has conducted an aerobic exercise program ( 50-70% maxHR, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
9674869|NCT05004948|No Intervention|Metformin group|This group received only metformin without any exercise intervention.
9674870|NCT05005000|Experimental|MFAT|
9674871|NCT05005000|Active Comparator|Steroid (Control)|
9674872|NCT05004922||ICSI in upper cavity|Embryo transfer into the upper cavity
9674873|NCT05004922||ICSI in midcavity|Embryo transfer into the midcavity
9674874|NCT05004753|Experimental|Artemisinin 500mg|The dose regimen will be in cycles. In a cycle a subject will receive Artemisinin 500 mg capsule once daily plus SOC on Day 1 to Day 5 followed by 5 days off (no dosing of Artemisinin) or SOC alone. A subject can have a total of consecutive 3 cycles maximum. Here SOC is Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division)
9674875|NCT05004753|Active Comparator|Standard of Care|Standard of Care as per CLINICAL MANAGEMENT PROTOCOL: COVID-19, Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division) Mild Patients: HYDROXYCHLOROQUINE Moderate Patients: Dexamethasone - OD for 05
9674876|NCT05004883|Experimental|Regulation of Cues Enhanced Treatment|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning, and it will be combined with aspects of BWL to capitalize on the strengths of both treatments.
9674877|NCT05004883|Active Comparator|Behavioral Weight Loss|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
9674878|NCT05004883|Active Comparator|Nutrition, Stress Management, and Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
9674879|NCT05005234|Experimental|GFH925|"Phase I Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design.~Phase I Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently.~Phase 2 Subjects with advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy."
9674880|NCT05004792|Active Comparator|Intervention|Access to DermLoop Learn IT platform
9674881|NCT05004792|No Intervention|Control group|No access to DermLoop Learn
9674882|NCT05005195|Other|Abdominal CT Scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer.
9674883|NCT05004818|Sham Comparator|sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
9674884|NCT05004818|Experimental|GVS stimulation coupled with inverse phase rotatory chair stimulation|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. The rotatory chair was activated in sinusoidal harmonic acceleration protocol in inverse phase to galvanic vestibular stimulation.
9674885|NCT05004519|Experimental|Opioid free anesthesia|"Dexmedetomidine 0,5 microgrammes/kg of ideal body weight (IBW) + magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~Dexmedetomidine 0,4- 0,8 microgrammes/kg of IBW/h;Lidocaine 2% 49ml+ Ketamine 50mg: 1ml/10kg of IBW/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ KgTBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;dexmedetomidine: 0,4-0,8 microgramme/kg/h;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence~Stop dexmedetomidine;Stop sevorane;1 ml of NaCL 0,9%;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Lidocaïne 2% 49ml + Ketamine 50 mg: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
9674886|NCT05004519|Experimental|Multimodal anesthesia|"magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~Remifentanil 0,2-0,4 microgrammes/kg/min of ideal body weight; Saline 0,9%: Infusion at 1ml/10kg of ideal body weight/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ Kg TBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;remifentanil 0,2-0,4 microgrammes/kg/min;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence~Stop remifentanil;Stop sevorane;1 ml of morphine 10mg/ml;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Salne 50ml: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
9674887|NCT05004623|Other|Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device. Lymph node dissection in each hemipelvis should be performed as standard if no sentinel lymph node is detected. Decision of proceeding with complementary lymph node dissection after sentinel lymph node detection is a surgeon decision, according to his/her usual practice.
9674888|NCT05004415|Experimental|AT-527 550 mg (R07496998)|
9674889|NCT05004610|No Intervention|standard of care|Patients will receive the standard of care infusion (balanced crystalloids)
9674890|NCT05004610|Experimental|treatement group|half molar sodium lactate infusion 15 µmol/Kg/min
9674891|NCT05004441|Experimental|First-line treatment|"First-line treatment: Fruquintinib Combined With mFOLFOX6/FOLFIRI for twelve cycles.~Maintenance treatment: Fruquintinib and Capecitabine"
9674892|NCT05004779|Experimental|human stem cell media apply lesion|human media apply after non ablative laser treatment
9674893|NCT05004779|Sham Comparator|control condition lesion|normal saline apply after non ablative laser treatment
9674894|NCT05004766|Experimental|virtual reality apply|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
9674895|NCT05004766|No Intervention|control condition|Each patient participated in the control condition, during which he or she performed RAGT with no distraction for the same amount of time spent doing therapy in VR.
9674896|NCT05004714||Head Start Staff|Head Start staff including teachers, family advocates, directors, and others
9674897|NCT05004714||Head Start Children with Asthma|Children enrolled in Head Start program with physician diagnosed asthma
9674898|NCT05004597|Experimental|infants longitudinally received three dimensional photo|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months
9674899|NCT05004636|No Intervention|No_Mg|Ctrl Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will not receive Mg (the intervention) in the block; instead they will receive 0.3mL of sterile saline.
9674900|NCT05004636|Experimental|Mg|Treatment Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will receive 150 mg Mg (0.3 mL-the intervention) in the block.
9674901|NCT05004545|Experimental|group 1 Profol Infusion to CABG patients to check lactate level|Propofol infusion according to bodyweight will be given to check lactate level on CPB
9527554|NCT03218904|Experimental|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
9674902|NCT05004545|Active Comparator|sevoflurane will be given to group 2 to check lacate level|Sevoflurane MAC % will be given to CABG patients to check lactate level
9674903|NCT05004493||Plasma arm|Patients receiving plasma as one of the main replacement fluids
9674904|NCT05004493||No Plasma|Patients receiving saline and/or 5% albumin as the replacement fluid.
9674905|NCT05004324|Experimental|Furestem-AD Inj.|"Investigational product name: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL~baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).~After 12 weeks, Experimental group will receive placebo."
9674906|NCT05004324|Placebo Comparator|Placebo|"Placebo~baseline (0week) Placebo comparator group will receive placebo.~After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL)."
9674907|NCT05004480|Experimental|Surgical Mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill while wearing surgical mask
9674908|NCT05004480|Experimental|Non mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill without wearing surgical mask
9674909|NCT05004558|Experimental|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
9674910|NCT05004363|Active Comparator|Lokelma|Lokelma therapy
9674911|NCT05004363|Placebo Comparator|Control|Placebo
9674912|NCT05004298|Other|Animal assisted terapy|The program structure will aim to influence the 6 specific factors, described in the Multifactorial Model of Positive Mental Health of Dr. Lluch, which are: F1-Personal Satisfaction, F2-Prosocial Attitude, F3-Self-control, F4-Autonomy, F5- Problem Solving and Self-actualization and F6 Interpersonal Relationship Skills. For this reason, direct contact exercises with the dog will be designed and defined to work on them.
9674913|NCT05004285|Other|MRI / [F-18]Florastamin|MRI and [F-18]Florastamin PET/CT are performed for each subject.
9674914|NCT05004168|Experimental|SPF evaluation|Healthy male or female subjects with Fitzpatrick Skin Type of II-IV were included in the SPF study
9674915|NCT05004064|Experimental|Acalabrutinib and rituximab|Patients with untreated mantle cell lymphoma will receive acalabrutinib and rituximab for up to six cycles. Each cycle will comprise of acalabrutinib 100mg twice daily orally for 28 days and rituximab 375mg/m2 IV on day 1 (+/1 3 days) of every cycle.
9674916|NCT05004220||Group 1|Group 1 consists of first time donors undergoing all 8 tracked plasmaphereses.
10174103|NCT03856580|Experimental|Self-injection|Participants will be trained on how to self-inject (intramuscular, gluteal muscle) an inert version of injectable cabotegravir. The inert substance is intended to mimic injectable cabotegravir as closely as possible (e.g., injection equipment, location of injection, volume of injection is identical to injectable cabotegravir). Specifically, participants will self-inject their choice of 300mg vitamin B12 or saline (3ml fluid) every 2 months for a total of 6 months (for a total of 4 injections). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as instructions on how to self-inject, FAQs about self-injection, study contact information, etc..
10174104|NCT03856580|Experimental|"Injection by HCP at drop-in clinics"|"Participants will report to a drop-in clinic, where a healthcare provider will inject them with an inert version of injectable cabotegravir. Visits will take <10 minutes, and participants will be able to come whenever they want (when their injection is due) during clinic drop-in hours, which will be staggered in 2-hour windows during each week day. The inert substance that will be injected is intended to mimic injectable cabotegravir as closely as possible (described above). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as drop-in clinic hours, directions to the drop-in clinic site, study contact information, etc..."
9674917|NCT05004220||Group 2|Group 2 consists of first time donors undergoing only last 4 plasmaphereses, serving as control for the first 4 donations.
9674918|NCT05003856|Experimental|Treatment (RFA)|Patients undergo ultrasound guided RFA over 1-2 hours.
9674919|NCT05003973|Experimental|home-based anti-resistance exercise|
9674920|NCT05003973|Experimental|usually care|
9674921|NCT05003999|Experimental|Intermittent catheterization starting with a hydrophilic catheter (HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter i.e. SpeediCath ® (Coloplast A/S, Humlebæk, Denmark)
9674922|NCT05003999|Active Comparator|Intermittent catheterization starting with a non-hydrophilic catheter (non-HPC)|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter i.e. Self-Cath ® (Coloplast A/S, Humlebæk, Denmark); Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
9674923|NCT05004090||children with ND|children with neurodevelopmental disabilities (ND) age between 3 and 24 months (chronologically or corrected in the case of children born preterm).
9674924|NCT05004090||Typical developed children (TD)|children with typical development age between 3 and 24 months (chronological).
9674925|NCT05004103|Experimental|Skin microbiome evaluation|Female healthy volunteers applied cosmetic products (cleanser and moisturizer cream), the diversity of skin microbiome will be examined before and after using the products
9674926|NCT05004142|Experimental|FCN-437c with Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
9674927|NCT05004142|Experimental|FCN-437c in combination with Letrozole + Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
9674928|NCT05004194|Experimental|Cold water caloric stimulation|50 cc of ice-cold water irrigation into the right ear at 1-2 cc/second, once per participant.
9674929|NCT05003869|Experimental|Intraoperative resection of intrauterine scar tissue by TCRA|Study group: patients took the bladder lithotomy position, routinely disinfected vulva and vagina, and laid sterile towel and sheet.pliers Clamp the front lip of the cervix, explore the depth of the uterine cavity, dilate the cervical canal one by one, place the endoscopy, and examine the uterine cavity.After the scar tissue contracted on one side, the scar tissue was disintegrated at the boundary between the intima and scar tissue. The scar tissue was removed with the annular electrode, and a balloon was placed after surgery to prevent re-adhesion.Complete adhesion release is defined as a return to normal shape of the uterine cavity with bilateral uterine angles exposed.
9674930|NCT05003869|No Intervention|No scar tissue resection group|During the operation, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips with needle-like electrodes, and scar tissue was not excised.
9674931|NCT05003726|Experimental|Non-pharmacological group including KM|Non-pharmacological treatment including Korean medicine will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
9674932|NCT05003726|Active Comparator|Pharmacological group|Pharmacological treatment will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
9674933|NCT05003505||Women with cervical cytology (TCT) abnormalities|In the enrollment, women who have undergone cervical cytology (TCT) examination for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months, 12 months and 24 months.
9674934|NCT05003765|No Intervention|Saline injection (CTRL)|Arm 1- 50 Patients-Control Group (CTRL): No Block (Saline) Post-operatively patients will receive 20 mL of Saline (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
9674935|NCT05003765|Experimental|SPIP Block|Arm 2-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
9674936|NCT05003765|Experimental|SPIP Block + Magnesium|Arm 3-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine + 200mg of magnesium sulfate (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
9674937|NCT05003765|Experimental|SPIP Block + Magnesium + Buprenorphine|Arm 4-50 Patients-Post-operatively patients will receive bilateral SPIP blocks by injecting 20 mL of 0.25% bupivacaine+ 200mg of magnesium sulfate + buprenorphine (300mcg) (on each side) between the pectoralis major and external intercostal muscle aponeurosis at 2 cm lateral to the right and left of the sternal edge, corresponding to the fifth rib.
9674938|NCT05003375||Multiple Sclerosis (MS)|People with MS diagnosis, aged 18-55 years, Relapsing Remitting type, EDSS < 6.0, normal vision (if necessary corrected), Dutch speaking.
9674939|NCT05003375||Healthy Controls (HC)|Healthy controls without relevant health conditions (diabetes, thyroid diseases, neurological disorders), non-pregnant, aged 18-55 years, normal vision (if necessary corrected), Dutch speaking.
9674940|NCT05003479|Experimental|candidate vaccine|
9674941|NCT05003479|Placebo Comparator|Placebo|
9674942|NCT05003739|Experimental|Logica Mirror|Since the trial is not comparative, the only arm implies the use of the investigational device (Logica Mirror femoral stem)
9674943|NCT05003570|Experimental|Remifentanil|Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml) + 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase).
9674944|NCT05003570|Active Comparator|Fentanyl|Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase).
9674945|NCT05003713|Experimental|Part 1: SAD Cohorts A through F CORT125236|Cohorts will receive a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 20-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose level and dose regimen (whether to split the dose) will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT125236 dose from the previous cohort in a fasted or fed state; the dose level, dose regimen, and prandial state will be determined after evaluation of safety and PK data from previous cohorts.
9674946|NCT05003713|Placebo Comparator|Part 1: SAD Cohorts A through F Placebo|Cohorts will receive a single dose of placebo matching CORT125236 lipid capsule formulation by mouth on Day 1. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
9674947|NCT05003713|Experimental|Part 2: MAD Cohorts A through D CORT125236|Cohorts will receive once- or twice-daily doses of CORT125236 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose level, dose schedule, and prandial state for each cohort will be determined after evaluation of safety and PK data from Part 1 and preceding Part 2 cohorts.
10187969|NCT03720808|Experimental|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
9674948|NCT05003713|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT125236 lipid capsule formulation by mouth for 14 days. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
9674949|NCT05003713|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg (20 mg + 5 mg) tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT125236 and the prandial state will be determined after evaluation of safety and PK data from Part 1. Part 3 of the study is optional.
9674950|NCT05003297||patients whom were hospitalized for 3 days or less|
9674951|NCT05003297||patients hospitalized for more than 3 days|
9674952|NCT05003635|Active Comparator|AFT+ EVEBRA device (intervention arm)|"Before and after the AFT surgery, patients are required to wear the EVEBRA expansion device for a total duration of 4 weeks. Thereafter patients will receive a PexyBra over the reconstructed breast.~Pre-operatively patients are required to wear the device for a total of 200 hours."
9674953|NCT05003635|No Intervention|AFT without EVEBRA device (control arm)|Patients will receive the AFT treatment for total reconstruction without the requirement of wearing the EVEBRA device.
9674954|NCT05003492|Active Comparator|Combination Therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
9674955|NCT05003492|Sham Comparator|Standard Therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
9674956|NCT05003427|Experimental|68Ga-FAPI-04 PET/CT|The patients were injected with 55.5-148 MBq (1.5-4mCi) of 68Ga-FAPI-04 in one dose intravenously and underwent SPECT/CT scan 30-90 min later.
9674957|NCT05003466|Experimental|candidate vaccine|
9674958|NCT05003466|Placebo Comparator|Placebo|
9674959|NCT05003518|Experimental|Condition 1: Low Personalisation+Low Frequency|The intervention will have low levels of personalisation and one message a day will be sent to participants.
9674960|NCT05003518|Experimental|Condition 2: High Personalisation+Low Frequency|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname) and one message a day will be sent to participants.
9674961|NCT05003518|Experimental|Condition 3: Low Personalisation+High Frequency|The intervention will have low levels of personalisation and three messages a day will be sent to participants.
9674962|NCT05003518|Experimental|Condition 4: High Personalisation+High Frequency|The intervention will have high levels of personalisation and three messages a day will be sent to participants.
9674963|NCT05003518|Experimental|Condition 5: High Personalisation+Low Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
9674964|NCT05003518|Experimental|Condition 6: Low Personalisation+High Frequency+Gamification|The intervention will have low levels of personalisation, contains gamified progress updates, and three messages a day will be sent to participants.
9674965|NCT05003518|Experimental|Condition 7: High Personalisation+High Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and three message a day will be sent to participants.
9674966|NCT05003518|Experimental|Condition 8: Low Personalisation+Low Frequency+Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and one message a day will be sent to participants.
9674967|NCT05003518|Experimental|Condition 9: High Personalisation+Low Frequency+Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and one message a day will be sent to participants.
10174105|NCT03856580|No Intervention|Control group|Participants will make an appointment when their injection is due to report to our clinic to complete injections. Visits and the injection protocol will follow similar procedures to HPTN-083/084. Participants will not have access to the mHealth adherence app.
10174106|NCT03856671|Experimental|oral antibiotics+mechanical bowel preparation|Liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. A combination of neomycin 1g and metronidazole 0.2g every 6 hours was also administrated. Enteroclysis was conduted for patients on surgical morning.
10174107|NCT03856671|No Intervention|simple mechanical bowel preparation|Only liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. Enteroclysis was conduted for patients on surgical morning.
9674968|NCT05003518|Experimental|Condition 10: Low Personalisation + High Frequency + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and three message a day will be sent to participants.
9674969|NCT05003518|Experimental|Condition 11: High Personalisation + High Frequency + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and three message a day will be sent to participants.
9674970|NCT05003518|Experimental|Condition 12: Low Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
9674971|NCT05003518|Experimental|Condition 13: High Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
9674972|NCT05003518|Experimental|Condition 14: Low Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three message a day.
9674973|NCT05003518|Experimental|Condition 15: High Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three messages a day.
9674974|NCT05003518|Experimental|Condition 16: Low Personalisation+Low Frequency+Gamification|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
10174108|NCT03856710|Active Comparator|Group 1 (Self-gripping Mesh),|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive self-gripping mesh
10174109|NCT03856710|Active Comparator|Group 2 (Stapled Mesh)|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive stapled mesh
10187100|NCT03729583|Experimental|Active group|The active group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme with breathing retraining exercises. All patients were medically stable and referred by their caring respiratory consultant
9674975|NCT05003648|Placebo Comparator|Placebo|Participants will be on the placebo arm for 2 months and will then cross over to the pramipexole arm for 2 months
9674976|NCT05003648|Active Comparator|Pramipexole|Participants will be on the pramipexole arm for 2 months and will then cross over to the placebo arm for 2 months
9674977|NCT05003232|No Intervention|Control group|
9674978|NCT05003232|Experimental|Optimal MAP group|
9674979|NCT05003284|Experimental|acupressure wristband|On the day before the surgery, the patients in the experimental groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the experimental group patients went to surgery, the PC6 acupressure point was determined for the patients. Immediately after the experimental group patients were taken to the wards after surgery, wristbands were placed on both wrists. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
9695102|NCT04781738||patients with history of vascular ring who underwent corrective surgery|patients with history of vascular ring who underwent corrective surgery
9975551|NCT00604812|Experimental|Panel A Rizatriptan|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
9975552|NCT00604812|Placebo Comparator|Panel A Placebo|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
9674980|NCT05003284|Placebo Comparator|placebo wristband|On the day before the surgery, the patients in the placebo groups were introduced to the wristband and given an explanation regarding how it should be used. Approximately 30 minutes before the placebo group patients went to surgery, the PC6 acupressure point was determined for the patients. Right after their surgery, patients in the placebo group were fitted with a wristband that looked the same as the acupressure wristband but did not have an acupressure application head. İt was stated to the patients that the wristbands should remain on for 24 hours. The wristband was removed at the end of the 24th hour.
9674981|NCT05003596|Experimental|Steroid Group|Patients receive 21 tablets of 4 mg methylprednisolone to be taken by mouth over a 6 week taper. Patients will be advised to not take other anti-inflammatory medications like NSAIDs.
9674982|NCT05003596|Active Comparator|Control Group|Patients will recieve standard treatment that focuses on mobilization and stabilization using common techniques like buddy taping and splinting. Pain control will be managed using non-NSAID medications like Tylenol or opioid narcotics when deemed medically necessary.
9674983|NCT05003700|Experimental|HAIC(RALOX) plus Lenvatinib and Camrelizumab|Hepatic arterial infusion of oxaliplatin and raltitrexed every 3 weeks. Lenvatinib 8 mg once daily (QD) oral dosing. Camrelizumab 200mg intravenously every 3 weeks.
9674984|NCT05003154|No Intervention|Conventional management group|Received conventional management based on Guidelines for GDM in China
9674985|NCT05003154|Experimental|Digitalized management group|Reveived conventional management and digitalized management
9674986|NCT05003219||ERAS group|patients received posterior cervical open-door laminoplasty under ERAS mode
9674987|NCT05003219||Conventional group|patients received posterior cervical open-door laminoplasty under routine perioperative management mode
9674988|NCT05002933|Experimental|Insulin glargine 300 U/ml|Insulin glargine 300 U/ml once daily for 24 weeks. Participants may continue for an additional 12 week extension period or switch to other anti-diabetic treatment, insulin dose will be adjusted according to the recommended dose titration algorithm
9674989|NCT05002907||General adult population living along the Maroni River in French Guiana and Suriname|General adult population living along the Maroni River in French Guiana and Suriname, upstream from Apatou. All adults (men and women) 18 years or older of both sexes will be able to participate in the study, in French Guiana and Suriname. Participation will be based on volunteering and signing informed consent. The acceptability and diversity of recruitment will be improved by seeking community support through community leaders and local associations and through appropriate communication (radio spots, posters in health centers and public establishments) before the survey .
9674990|NCT05003206|Experimental|PD,DBS|Patients with idiopathic PD before and after DBS surgery
9674991|NCT05003063|Active Comparator|Donepezil|5mg Donepezil will be administered in pill form.
9674992|NCT05003063|Placebo Comparator|Placebo|5mg placebo will be administered in pill form.
9674993|NCT05003193|Experimental|Using a pedometer|The pedometer will be given to the intervention group to evaluate the activity level and to encourage a walk , it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days.
9674994|NCT05003193|No Intervention|Not using a pedometer|The control group will not be given a pedometer.Patients in the control group will only be instructed to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days.
9674995|NCT05002842|Experimental|Immediate Intervention|Those in the immediate intervention arm will begin the LovingKindess Meditation practice upon enrollment.
9674996|NCT05002842|Experimental|Delayed Intervention|Those in the deferred intervention arm will commence the LovingKindness Meditation practice intervention approximately 3 weeks (post 3 -week survey) after enrollment and participate three weeks thereafter.
10174110|NCT03856632|Active Comparator|Risk Factor Modification (RFM)|A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner. The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
10187101|NCT03729531|Active Comparator|Conventional|The perivascular tissue is stripped off when harvesting the vein, and saline will be used to distend the vein to check for leakage.
9674997|NCT05002920||cleft patients received alveolar bone grafting|alveolar bone grafting was performed when the cleft patients were aged around 9 years old. CBCT was used to analyze the bone mineral density of grafted tissue.
9674998|NCT05003180|Active Comparator|Surgical|"Surgical stabilization with posterior fixation. Brace treatment will not be used postoperative. Early ambulation after surgery is encouraged. Surgery is to be performed within 2 weeks from the injury. The choice of supplier and brand of implants are based on the preference of each participating center.~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
9674999|NCT05003180|No Intervention|Non-surgical treatment|"No surgical stabilization is performed. Early ambulation after treatment randomization is encouraged. Brace treatment is not required, but a standard three-point hyperextension brace may be offered up to 3 months for pain relief. The choice of supplier and brand of brace are based on the preference of each participating center. The brace will only be used upon mobilization. Brace use will be estimated by the patient at the 3-4 months follow-up.~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
9675000|NCT05002855||Enhanced Recovery After Surgery (ERAS)|
9675001|NCT05002855||Conventional Recovery Strategy (pre-ERAS)|
9675002|NCT05002751||Cohort 1|1. Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2009 clinical stages IB2/IIA with positive para-aortic nodes, or FIGO 2009 clinical stages IIB/IIIB/IVA with positive pelvic or para-aortic lymph nodes (PALN). Pelvic or PALN nodal status confirmed by PET/CT scan or fine needle biopsy or extra peritoneal biopsy or laparoscopic biopsy. The PALN must be inferior to the T12/L1 interspace.
9695103|NCT04781712|Experimental|Self-management using mHealth|Self-management (physical activity, sleep, exercise, education, etc.) using mHealth
9695104|NCT04781712|No Intervention|Exercise using brochure|Only exercise using brochure
9675003|NCT05002894|Experimental|exercise group|This group included twenty six post-menopausal women. They will participate in Pilates exercise, medical standard care for fatigue and advices to deal with fatigue. The Pilates exercises consisted of a set of 10 movements: bridging; hundred; roll up; one leg circle (both ways); single straight leg stretch; single leg kick; side kick up and down; side kick circles; rest position (stretch and relaxation); and curling ,women were instructed to perform 30 min per session, 3 sessions per week, for 8 weeks.
9675004|NCT05002894|Experimental|standard care group|Each post-menopausal woman in both groups will receive a medical standard care for post-menopausal fatigue.
9675005|NCT05003128|Experimental|LED screen|
9675006|NCT05002634|Experimental|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
9675007|NCT05002647||exposure group|Data from electronic clinical pharmacist records of two infectious disease hospitals
10174111|NCT03856632|Experimental|RFM plus Liraglutide|In addition to RFM, Liraglutide will be administered. Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
9675008|NCT05002647||Non-exposure group A|Data from medical records of the hospital with no clinical pharmacy.
9675009|NCT05002647||Non-exposure group B|Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy
10174112|NCT03856489||Patients|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 10 am.
9675010|NCT05002660|Experimental|Group 1 (Intervention)|"For Change Club members (CCM) only: CCM will participate in meetings of the Change Club weekly for six months and continue implementation of a change to the community environment for up to an additional 24 months. Change Club members will also be asked to recruit 10 or more friends and family members (FFM) to participate in the research study.~In addition, 100 community residents (CR) will be recruited into the study. Family members, friends and community residents do not participate in the Change Club, but may hear about Change Club activities in their community."
9675011|NCT05002660|Experimental|Group 2 (Control)|Control group participants will participate in no intervention activities during the 4-year research study.
9675012|NCT05002725|Experimental|PENG|An ultrasound guided PENG catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
9675013|NCT05002725|Active Comparator|Femoral Block|An ultrasound guided Femoral Nerve catheter will be inserted. 20ml of 1.5% lidocaine will be administered.
9675014|NCT05002712|Experimental|Heavy resistance training|Group A
9675015|NCT05002712|Experimental|Contrast strength training|Group B
9675016|NCT05002712|Active Comparator|Elastic resistance training|Group C
9675017|NCT05003050|Experimental|Meditation Based Group|8 sessions weekly for 8 weeks Each session for 1hour Sessions on line (virtual) Self-care tools and techniques, mindfulness and meditation
9675018|NCT05003050|Experimental|Energy Therapy (Pranic Healing)|8 Sessions Weekly sessions for 8 weeks Each session 1 hour Pranic Healing (Energy Therapy)
9675019|NCT05003050|No Intervention|Stanrd of Care Group|Routine medical care and appointments
9695105|NCT04781842|Experimental|Boxing Club Group|Participation in a weekly boxing program designed for people with Parkinson Disease
9695106|NCT04781842|No Intervention|Control group|No changes to regular physical activity during the study period
9695107|NCT04781764||glioma patients|glioma patients with routine surgery
9695108|NCT04781569||Patients with S. aureus infection|
9695109|NCT04781569||healthy participants|
9695110|NCT04781608|Experimental|Intervention group|Gains access to the digital intervention program
9695111|NCT04781608|No Intervention|Wait-list- control group|Does not gain access to the intervention (until end of study)
9695112|NCT04781933|Active Comparator|Treatment with Combo|3 dietary supplements will be given
9695113|NCT04781933|Placebo Comparator|Treatment with Placebo|3 placebos will be given
9695114|NCT04781595|Active Comparator|Watermelon|Watermelon powder containing 3 g of L-citrulline.
9695115|NCT04781595|Active Comparator|Beetroot|Beetroot powder containing 8 mmol of nitrate.
9695116|NCT04781595|Active Comparator|Watermelon + beetroot|Watermelon powder containing 3 g of L-citrulline and Beetroot powder containing 8 mmol of nitrate.
10174113|NCT03856489||Nurses|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 7:30 am.
10174114|NCT03856385|Experimental|Mindful Walking|Four weekly 60 minute sessions of mindful walking.
10174115|NCT03856385|No Intervention|Control|Weekly email messages encouraging physical activity.
9695117|NCT04781595|Placebo Comparator|Placebo|Maltodextrin
10174116|NCT03856372|Experimental|Hypofractionated|42.5 Gy / 16 fractions, 2.66 Gy per fraction, 5 fractions weekly
9695118|NCT04781868|Experimental|Multi-nutrient supplement|
9695119|NCT04781868|Placebo Comparator|Placebo supplement|
9695120|NCT04781634|Experimental|prime CAR- T cells|Patients will be be treated with CD19 and CD22 prime CAR- T cells
9695121|NCT04781803|Experimental|Arm 1|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.
9695122|NCT04781803|No Intervention|Arm 2|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day +5 of the transplant, mycophenolic acid 1 gram orally (2 tablets of 500 mg) from day +5 post-transplant and post-transplant cyclophosphamide (PT-CY) at 50 mg/kg per day on days +3 and +4
9695123|NCT04781673|Active Comparator|Ketamine|"Infusion initiation: 0.1 mg/kg/hr Max: 0.3 mg/kg/hr Recommended titration: 0.1 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
9695124|NCT04781673|Active Comparator|Lidocaine|"Infusion initiation: 1 mg/kg/hr Max: 2 mg/kg/hr Recommended titration:0.25 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
10174117|NCT03856372|Active Comparator|Conventional|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
10174118|NCT03856697|Experimental|Abivertinib Maleate Capsules+ Placebo Gefitinib Tablets|Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Placebo Gefitinib Tablets (250 mg orally, once daily), in accordance with the randomization schedule.
9675020|NCT05002673|Experimental|SLEEPERONE|
9675021|NCT05002673|Experimental|COMFORTIN|
9675022|NCT05002491|Experimental|High protein feeding|Two isocaloric feeding phases of 2 weeks followed by an ad-libitum feeding phase of 3 months
9675023|NCT05002517|Experimental|Tociliziumab group|Patients assigned to this arm will receive an intravenous dose of tocilizumab. Patients weighing 75 kg or more will receive 600 mg. Those weighing less than 75 kg will receive 400 mg.
10174119|NCT03856697|Active Comparator|Gefitinib Tablets+ Placebo Abivertinib Maleate Capsules|Placebo Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Gefitinib Tablets(250 mg orally, once daily), in accordance with the randomization schedule.
10174120|NCT03856411|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
9675024|NCT05002517|Active Comparator|Metilprednisolone group|Patients in this arm will receive a daily intravenous dose of 250 mg methylprednisolone for 3 days.
9675025|NCT05002426||The type and orientation of Rouviere sulcus|"open type, fused type or absent type"
9675026|NCT05002309|Experimental|Psychotherapy|Cognitive-behavioural therapy
9675027|NCT05002309|Experimental|Pharmacotherapy|Antidepressant medication
9675028|NCT05002205||COVID-19|exposed cohort with a diagnosis of COVID-19 in the last 6 months
10174121|NCT03856411|Placebo Comparator|Group Placebo combined with standard chemotherapy|
10174122|NCT03856554|Experimental|Patients indicated for TLIF|Patients with lumbar degenerative spondylolisthesis, indicated for TLIF surgery
9675029|NCT05002205||no history of COVID-19|non-exposed cohort without a diagnosis of COVID-19. Tested for COVID-19 because of symptoms at the same time (+/- 1 month) as the exposed cohort.
9675030|NCT05002179|Experimental|Treatment group|"Treatment group, 3 x 2 Echinaforce chewable tablets (EC, 3x800mg) daily during prevention and 5 x 2 EC (5x800mg) during acute viral Respiratory tract infection vRTIs"
9675031|NCT05002179|No Intervention|Control Group|"No treatment Comparison group. Participants are free to take none or any preventive measure. Participants are requested not to take any Echinacea products"
9675032|NCT05002270|Experimental|Arm A0, JAB-21822 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-21822 will be administered alone to determine the MTD and RP2D
9675033|NCT05002270|Experimental|Arm A1, JAB-21822 monotherapy, Phare 2, Dose Expansion|JAB-21822 will be administered alone at RP2D in selected cancer type patients to evaluate the preliminary antitumor activity.
9675034|NCT05002270|Experimental|Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion|JAB-21822 will be administered together with Cetuximab in mCRC patients to evaluate the preliminary antitumor activity.
9675035|NCT05002140|Experimental|XRD-0394 40 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
10174123|NCT03856541|Experimental|SHR-A1403 Dose Escalation|SHR-A1403 given intravenously (IV).
10174124|NCT03856502|Experimental|group that received dexamethasone (DLSA)|The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
10174125|NCT03856502|Active Comparator|group without dexamethasone (LSA)|The control group of 30 patients ASA status 2 or 3 received 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
9675036|NCT05002140|Experimental|XRD-0394 80 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
9675037|NCT05002140|Experimental|XRD-0394 160 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
10174126|NCT03856463|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay patient navigator who will provide information regarding early advance care planning, documentation of goals of care, and coordinating home-based care. The intervention arm will also receive usual care as provided by their local oncologists.
10174127|NCT03856463|Active Comparator|Control Group Arm|The control group will receive usual care as provided by their local oncologists.
9675038|NCT05002140|Experimental|XRD-0394 (Dose TBD)|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT. A single biopsy will be performed in each subject (either after RT alone or after XRD-0394 and RT).
9675039|NCT05002361|Active Comparator|Treatment A+B|24 mg dexamethasone i.v. perioperatively
9675040|NCT05002361|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively
9675041|NCT05002582||patients with hematological diseases|to clarify the intestinal carriage rate of carbapenem-resistant Organisms (CRO) in patients with hematological diseases
9675042|NCT05002283|Experimental|Study group|the patients undergo free gingival graft harvest from the palate using a patient specific guide
9675043|NCT05002686|Experimental|Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection|
9675044|NCT05002036|Active Comparator|HA-GB|eyedrop containing hyaluronic acid and gingko biloba (Trium eyedrops, Sooft srl)
9675045|NCT05002036|No Intervention|No treatment|no treatment for iatrogenic dry-eye
10174128|NCT03856424|Other|Modality 1 - Washout - Modality 2 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
10174129|NCT03856424|Other|Modality 1 - Washout - Modality 3 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
10174130|NCT03856424|Other|Modality 2 - Washout - Modality 1 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
9675046|NCT05002296|Active Comparator|traditional physical therapy program|
9675047|NCT05002296|Experimental|rotatory upper cervical manipulation to both sides|
9675048|NCT05001984|Active Comparator|Intervention group|In addition to high-intensity statin and antiplatelet treatment, patients will receive treatment of alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks
9675049|NCT05001984|No Intervention|Control group|Patient will have high-intensity statin and antiplatelet treatment.
9675050|NCT05001971|Experimental|Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
9675051|NCT05002166||Children aged less than 18 years with a confirmed diagnosis of IBD.|"All patients admitted with inflammatory bowel disease will be subjected to:~History: including name, age ,sex ,family history, consanguinity, history of rectal bleeding, mucus or blood in the stool, diarrhea, abdominal pain ,vomiting ,nausea and loss of appetite.~Examination: including general examination, chest, cardiac, abdominal and neurological examination~Investigation:including labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope."
9675052|NCT05001997|Active Comparator|Diet A - Lactose free probiotic yogurt|Plain flavoured lactose free probiotic yogurt (contains Lactobacillus acidophilus and Bifidobacterium lactis)
9675053|NCT05001997|Placebo Comparator|Diet B - Lactose free yogurt (non-probiotic)|Plain flavoured lactose free yogurt (contains only starter cultures)
9675054|NCT05001893||The use of a mixture of BonAlive® putty and autologous bone|A retrospective case-controlled study will be created to compare the use of a mixture of BonAlive® putty and autologous bone to autologous bone alone for clinical safety and efficacy.
9675055|NCT05002101|Active Comparator|zinc group|The children were randomized to receive daily zinc sulphate. The elemental zinc dose was 3 mg/ day to children whose weight is less than 10 kg and 7 mg/ day to children whose weight is 10 kg or more.
9675056|NCT05002101|Placebo Comparator|placebo group|The placebo was non-nutritious and vitamin-free, designed to be identical to the zinc syrup in colour, odour, consistency and taste. Zinc and placebo syrups were packaged in similar bottles.
10174131|NCT03856424|Other|Modality 2 - Washout - Modality 3 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
10174132|NCT03856424|Other|Modality 3 - Washout - Modality 2 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
9675057|NCT05001906|No Intervention|Control group|The control group (CG) will consist of pregnant women with standard prenatal care, who attending theoretical classes on childbirth (CG, n = 35). The control group will not exercise. The sedentary participants will continue their regular daily activities and life habits.
9675058|NCT05001906|Experimental|Exercise group|The exercise group (EG) will consist of pregnant women who will attend theoretical classes and prenatal exercises in the program of psychophysical preparation for childbirth (EG, n = 35). The experimental group will exercise for 45 minutes, three times a week.
9675059|NCT05001919|Placebo Comparator|collagen membrane|10 sites treated with surgery and bone graft and collagen membrane as GTR
9675060|NCT05001919|Experimental|Concentrated growth factor membrane|10 sites treated by surgery +bone graft and concentrated growth factor membrane as GTR
9675061|NCT05001763|Placebo Comparator|Placebo|Glucose, 2mg, tablet.
9675062|NCT05001763|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment.
9675063|NCT05002114|Placebo Comparator|Placebo Group|Does not get active topical CBD. Instead, gets an identical placebo-containing topical agent.
9675064|NCT05002114|Experimental|Active Group|Does get active topic CBD.
9675065|NCT05001750|Experimental|continuous antibiotic use until the EVD is removed|continuous antibiotic use until the EVD is removed. Nafcillin 1-2 grams every 6 hours (depending on weight) until the EVD is removed. If penicillin allergic Doxycycline 100mg every 12 hours until the EVD is removed.
9675066|NCT05001750|No Intervention|antibiotics for a total of twenty-four hours|antibiotics for a total of twenty-four hours Nafcillin 1-2 grams every 6 hours (depending on weight) for a total of 24 hours. If penicillin allergic Doxycycline 100mg every 12 hours for a total of 24 hours.
10174133|NCT03856424|Other|Modality 3 - Washout - Modality 1 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
9675067|NCT05001789|Experimental|Active|Working memory training with task-difficulty increasing across sessions
9675068|NCT05001789|Active Comparator|Sham|Working memory training with task-difficulty remaining constant across sessions.
9675069|NCT05001854|Experimental|Fludrocortisone|"100 μg every 6 hours of fludrocortisone per os~A pharmacokinetic study is performed in this arm"
9675070|NCT05001854|Placebo Comparator|Control|100 μg every 6 hours of placebo per os
9675071|NCT05001659|Other|computer simulator|training students ACLS by one computer simulator
9675072|NCT05001659|Other|mannequin simulator|training students ACLS by one mannequin simulator
9675073|NCT05001672|Experimental|TAF arm|"54 patients will be randomized into TAF arm*. TAF 25 mg QD will be initiated 7 days before bDMARDs, and continued for up to 144-weeks.~*for patients received rituximab (anti-CD20 monoclonal antibody) will be enrolled into TAF arm, and TAF 25 mg QD will be initiated 7 days before rituximab, and continued for up to 144-weeks. Max 20 rituximab patients will be recruited."
9675074|NCT05001672|Other|Observation arm|54 patients will be randomized into observation arm initially. These patients will be closely monitored their HBV status (including qHBsAg and HBV DNA) for 48 weeks. TAF 25 mg QD will be initiated for 144 weeks in the presence of HBV reactivation, or after 48 weeks of observation.
10174134|NCT03856333|Other|traditional treatment|30 minutes of conventional TENS, 20 minutes of hotpack, 8 minutes of therapeutic ultrasound and isotonic, isometric, stretching and relaxation exercises 2 weeks, 5 days in a week.
10174135|NCT03856450|Active Comparator|Control-arm group|The control-arm group will consist of healthy volunteers with no known prior trauma in the wrists. The diagnostic truth for subjects in the control-arm will be no fracture and the treatment truth will be no treatment.
9675075|NCT05001581|Active Comparator|Treatment with biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps augmentation after its tenodesis
9675076|NCT05001581|Active Comparator|Treatment without biceps augmentation|Complete repair of ISP if possible with partial SSP repair and biceps tenotomy
9675077|NCT05001542|Experimental|Experimental Arm|VR simulation exercise with a digital follow-up component to help assess the physiological and psychological indicators of moral distress
9675078|NCT05001607|Other|Study trial|All participants will perform pulmonary blockade on an intubating manikin using 4 different methods: Endobronchial intubation with an endotracheal tube; Bronchial blocker attached to the outside of an endotracheal tube; Double lumen endotracheal tube; and Intraluminal placement of bronchial blocker.
9675079|NCT05002348|Experimental|Acupoint Laser Group|In the experimental group, the laser pen was turned on, and the acupoint stimulation was performed for about 3-5 minutes. Each acupoint was performed once a day. The patient wore goggles and observed the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
9675080|NCT05002348|No Intervention|control group|In the control group, the laser pen does not turn on the energy. The acupoint stimulation is performed for about 3-5 minutes, and each acupoint is performed once a day. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat, and blood pressure) with a physiological monitor. Oxygen), if the patient has any discomfort, the procedure will be stopped, and the patient's defecation status will be recorded/evaluated every day for up to 10 days (including Saturdays and Sundays). The post-test questionnaire will be conducted on the day of discharge, and the phone will be followed within one month after discharge. Inquire about the follow-up situation.
9675081|NCT05001438|Active Comparator|Hidro alone|The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
9675082|NCT05001438|Experimental|Hidro + MUA|"The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.~After the Hidrodilatation the patient is sedated and then a Movilization of the glenohumeral joint is performed."
9675083|NCT05001412|Experimental|Cohort one|Extensive SCLC patients who are Peripheral type or tumor vascular invasion grade one or less.
9675084|NCT05001412|Experimental|Cohort two|Extensive SCLC patients who are central type or tumor vascular invasion grade two to three.
9675085|NCT05001776|Active Comparator|Endovenous laser ablation without anticoagulants|Endovenous laser ablation without using of any anticoagulant
9675086|NCT05001776|Active Comparator|Endovenous laser ablation with short-term anticoagulant|Endovenous laser ablation and subsequent 7 days of subcutaneous fondaparinux sodium
9675087|NCT05001776|Active Comparator|Medical treatment|45 days of subcutaneous fondaparinux sodium
9675088|NCT05001490|Experimental|Experimental group|
9675089|NCT05001490|No Intervention|Control group|
9675090|NCT05001321||Training Group|Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis. And a model will be constructed based on deep learning.
9675091|NCT05001321||Internal Validation Group|Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.
9675092|NCT05001321||External Validation Group|Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.
9675093|NCT05001633|Experimental|Intervention|modified media content experience
9675094|NCT05001633|Active Comparator|Control|media content experience
9975553|NCT00604812|Experimental|Panel B Rizatriptan|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
9675097|NCT05001464||Reflectance Pulse Oximeter|The participants wear reflectance pulse oximeter for continuous monitoring when carrying out PSG . Oxygen desaturation index (ODI), average blood oxygen saturation, minimum blood oxygen saturation, percentage of blood oxygen saturation less than 90% in the whole recording time (TS90%), fastest heart rate, slowest heart rate and average heart rate are recorded by reflectance pulse oximeter.
9675098|NCT05001334|Experimental|Kangaroo care|The mothers of the experimental group who accept to participate in the research are given training on how to make kangaroo care and what to pay attention to.
9675099|NCT05001334|No Intervention|Control group|The mothers of the control group who accept to participate in the research are NOT given any extra training other than routine breastfeeding and care of a newborn.
9675100|NCT05001529|Experimental|Group A|Subject with severe asthma, treated with anti IL5R antibodies
9675101|NCT05001529|No Intervention|Group B|Subject with severe asthma, treated with conventional therapy
9675102|NCT05001243|Experimental|Experimental PBOHB|Pilocarpine, brimonidine, Oxymetazoline combined with Hyaluronic Acid and Bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
9675103|NCT05001243|Active Comparator|Pilocarpine 5 mgs|Pilocarpine was instilled in the other oye.
9675104|NCT05001243|Active Comparator|Brimonidine 0.5 mgs|Brimonidine was instilled in the other eye.
9675105|NCT05000879|Experimental|MMB for Moms|Subjects will receive digital delivery of Mindful Mood Balance for Moms for 12 weeks. Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
9675106|NCT05000879|No Intervention|Waitlist Control|Subjects will be unconstrained in the types of treatments or other wellness activities they could receive while participating in the study.
9695125|NCT04781790||Patients with Bone marrow failure|Standard of care of patients with bone marrow failure
9675107|NCT05000944|Experimental|breakfast omission (BO)|No breakfast will be provided until the lunch time at ~12:30. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
10174136|NCT03856450|Experimental|Test-arm group|The test-arm group will consist of subjects who present with a wrist injury and initial SOC X-ray imaging results show a confirmed or suspected distal radius or scaphoid fracture, for which additional diagnostic imaging shall be ordered. Diagnostic truth for subjects in the test-arm will be the per-subject clinical diagnosis and the treatment truth will be the per-subject treatment received.
9675108|NCT05000944|Experimental|early-morning breakfast consumption (EM-BC)|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at ~08:30 for EM-BC. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
9675109|NCT05000944|Experimental|mid-morning breakfast consumption (MM-BC).|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at ~10:30 for MM-BC (i.e., two hours after EM-BC). Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
9675110|NCT05001191|Experimental|Gentle Human Touch Group|
9675111|NCT05001191|No Intervention|Control group|
9675112|NCT05000918|Experimental|OPH group|Participants should eat a pack of OPH once a day for 28 days. The dosage of the OPH is 11.74 g/day.
9675113|NCT05001100|Active Comparator|Traditional rehabilitation|32 subjects will undergo a virtual motor-reality training during the post-surgical rehabilitation period with VRSS
9675114|NCT05001100|Experimental|Rehabilitation with virtual reality|32 subjects with demographic characteristics similar to the subjects of the Vrrs arm will undergo the habitual rehabilitative physiotherapy.
9675115|NCT05001061|Active Comparator|Sublingual Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive sublingual Misoprostol 800 micrograms every 4 hours up to five doses
9675116|NCT05001061|Active Comparator|Vaginal Misoprostol for termination of first trimester missed abortion|Patients diagnosed as first trimester missed abortion will receive vaginal Misoprostol 800 micrograms every 4 hours up to five doses
9675117|NCT05001217|Experimental|Chinese herbal medicine treatment plus conventional medication|"Participants will receive integrated medicine treatment combining Chinese herbal treatment, given in the form of granules, and conventional medication for 32 weeks. Patients will be differentiated into 4 subgroups based on their Chinese medicine pattern, and receive herbal treatment accordingly. An existing clinical pathway will guide the diagnosis and treatment of the Chinese medicine patterns. The four pattern subgroups are as follows:~1) the Phlegm-heat stirring Wind subgroup; 2) the Spleen-and Kidney-Yang subgroup; 3) the deficiency of Liver- and Kidney-Yin subgroup; and 4) the Qi deficiency and stasis of Blood subgroup~To resemble actual clinical practice, minor adjustment of herbal treatment will be possible and also adhere to the mentioned clinical guideline. The dosage of each herbal drug will follow the instructions of China Pharmacopeia."
9675118|NCT05001217|Active Comparator|Conventional medication|Conventional medication for Parkinson's disease include levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
9675119|NCT05001204|Experimental|68Ga-NOTA-RM26 PET/CT|Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection of 55.5-148 MBq (1.5-4 mCi) of 68Ga-NOTA-RM26.
9675120|NCT05001178||Class I horizontal grower|
9675121|NCT05001178||Class I normal grower|
9675122|NCT05001178||Class I vertical grower|
9675123|NCT05001178||Class II horizontal grower|
9675124|NCT05001178||Class II normal grower|
9675125|NCT05001178||Class II vertical grower|
9675126|NCT05001178||Class III horizontal grower|
9675127|NCT05001178||Class III normal grower|
9675128|NCT05001178||Class III vertical grower|
9675129|NCT05001269|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
9675130|NCT05001152|Experimental|Ozanimod|A maximum of 10 healthy adult participants (i.e., sensory panelists) will complete a maximum of 20 taste assessment days, with at least 4 panelists required to evaluate the taste characteristics of ozanimod on each taste assessment day.
9675131|NCT05001087||Patients registry|"Non-interventional, multicentre, retrospective and prospective registry. In order to increase the sample size and the validity of the Registry, patients who were diagnosed with myeloma since 1st January 2019 will also be included retrospectively, once their informed consent has been obtained by the enrolling centre. Being a registry, patients will be enrolled consecutively according to their appointments at the centre, at the discretion of their doctor and only once the patient has signed the informed consent form.~Also patients participating in interventional or other observational studies can be enrolled. In case of patients enrolled in interventional trials, only baseline and survival data can be collected for the period in with the patient is in interventional trial.~The data will be collected using an electronic data capture (EDC) platform. Hospital visits are planned every 6 months."
9675132|NCT05001074|Experimental|de novo cohort, extended release tacrolimus|de novo cohort, extended release tacrolimus
9675133|NCT05001074|Active Comparator|de novo cohort, immediate release tacrolimus|de novo cohort, immediate release tacrolimus
10174137|NCT03856346||Phaco-vitrectomy|
10174138|NCT03856099|Experimental|TTAC-0001|TTAC-0001 with dose assigned to each dose group will be administered
10174139|NCT03856034|Experimental|Fetoscopic repair|
9675134|NCT05001074|Experimental|conversion cohort, extended release tacrolimus|conversion cohort, extended release tacrolimus
9675135|NCT05001074|Active Comparator|conversion cohort, immediate release tacrolimus|conversion cohort, immediate release tacrolimus
9675136|NCT05001048|Experimental|Low Altitude|Participants will be assessed at an altitude of <1050m.
9675137|NCT05001048|Experimental|Early Acclimatization to High Altitude|Participants will be assessed on day 2 or 3 of a high-altitude expedition at 3,800m.
9675138|NCT05001048|Experimental|Late Acclimatization to High Altitude|Participants will be assessed on day 9 or 10 of a high-altitude expedition at 3,800m.
9675139|NCT05001165|Experimental|Intervention|Patients with perceived gaps in performance measures for guideline-directed medical therapies for heart failure with reduced ejection fraction will be chart-reviewed and called impromptu to receive point of care medication titration or reintegration into routine heart failure clinic. Patients lost to follow-up may be better identified using the HFrEF panel management tools.
9675140|NCT05001165|No Intervention|Usual Care|A control group of patients with HFrEF will receive routine primary and cardiology care as currently indicated in routine scheduled clinic grids. Patients are at the discretion of their primary care and cardiology clinicians regarding whether further HFrEF optimization is warranted. While panel management data is available to all clinicians, clinical workflows and responsibilities do not encourage the use of panel data or response to performance measurement for HFrEF.
9675141|NCT05000983|Active Comparator|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
9675142|NCT05000983|Experimental|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
9675143|NCT05000892|Experimental|Sintilimab + Carboplatin + Nab-paclitaxel|"Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
9675144|NCT05000970|Experimental|TRIO PLUS tablet and nurse at day 3|Virtual nurse encounter at 3 days
10174140|NCT03855982||myocarditis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
9675145|NCT05000970|Experimental|TRIO PLUS Tablet and nurse at day 3 and 7|Virtual nurse encounter at 3 days and 7 days
9675146|NCT05000970|Placebo Comparator|TRIO PLUS Group|No encounter
9675147|NCT05001126|Experimental|HIFT 1x/week|HIFT exercise performed one time per week.
9675148|NCT05001126|Experimental|HIFT 2x/week|HIFT exercise performed two times per week.
9675149|NCT05001126|Experimental|HIFT 3x/week|HIFT exercise performed three times per week.
9675150|NCT05001035|Experimental|Zinc carbonated hydroxy apatite|Toothpaste to be added on white spot lesions in dental enamel
9675151|NCT05001035|Experimental|Bioactive glass|Toothpaste to be added on white spot lesions in dental enamel
9675152|NCT05001035|Experimental|Poly amido amine|Resinous material to be painted on white spot lesions in dental enamel
9675153|NCT05001035|No Intervention|Control|No material to be added
9675154|NCT05001009|Active Comparator|No then high patient engagement|First stage: No patient engagement Second stage: High patient engagement
9675155|NCT05001009|Active Comparator|No then low patient engagement|First stage: No patient engagement Second stage: Low patient engagement
9675156|NCT05001009|Active Comparator|No then no patient engagement|First stage: No patient engagement Second stage: No patient engagement
9675157|NCT05001009|Active Comparator|Low then high patient engagement|First stage: Low patient engagement Second stage: High patient engagement
9675158|NCT05001009|Active Comparator|Low then low patient engagement|First stage: Low patient engagement Second stage: Low patient engagement
9675159|NCT05001009|Active Comparator|Low then no patient engagement|First stage: Low patient engagement Second stage: No patient engagement
9675160|NCT05001295|Experimental|Physical Activity|
9675161|NCT05001295|Placebo Comparator|Daily Live|
9675162|NCT05001113|Experimental|the subxiphoid approach thoracoscopic thymectomy|The subxiphoid approach thoracoscopic thymectomy is performed in enrolled patients.
9675163|NCT05001113|Active Comparator|the lateral intercostal approach thoracoscopic thymectomy|The lateral intercostal approach thoracoscopic thymectomy is performed in enrolled patients.
9675164|NCT05000853||Patients with iron deficiency|
9675165|NCT05000853||Patients without iron deficiency|
9675166|NCT05000827|Experimental|PSMA PET/CT based indication for ePLND:|"Node-negative PSMA PET/CT [N0] and M0: do not perform ePLND~Node-positive PSMA PET/CT [N1] and M0: perform ePLND"
9675167|NCT05000827|Active Comparator|Nomogram-based indication for ePLND (standard of care)|Nomogram-based indication for ePLND (conform current EAU guidelines)
10174141|NCT03855956|Experimental|KB174 Arm|KB174 is a novel mixture of oligosaccharides.
9675168|NCT05000528|Experimental|Therapeutic education|
9675169|NCT05000528|Active Comparator|Individualized consultation|
9675170|NCT05000619|Experimental|Outreach Postcard|This group receives a postcard with a stock image on the front and a message encouraging regular visits to manage health on the back.
9675171|NCT05000619|Experimental|Humorous Postcard|This group receives a postcard with with a cartoon image and a visit-related joke on the front and a humorous message on the back, with additional information about why visits are important, and what to expect at the appointment.
9675172|NCT05000619|Experimental|Physician Letter|This group receives a personalized letter signed by a physician with information about why visits are important, and what to expect at the appointment.
9675173|NCT05000619|No Intervention|No-contact Control|This group will not receive a study mailer during the trial.
9675174|NCT05000554|Experimental|Locally advanced gastric cancer|Patients with locally advanced gastric cancer who can receive PD-1 monoclonal antibody combined with neoadjuvant chemotherapy
9675175|NCT05000567|No Intervention|Control Group|No intervention.
9675176|NCT05000567|Experimental|Experimental Older group|12 week strength training program: Nordic Hamstring Exercise
9675177|NCT05000567|Experimental|Experimental Younger group|12 week strength training program: Nordic Hamstring Exercise
10174142|NCT03855956|Other|Maltodextrin Arm|Maltodextrin is a commercially available easily digestible polysaccharide.
10174143|NCT03856060|Experimental|Group I (questionnaires, videos)|Patients complete questionnaires and watch a video portraying a physician using a standard EHR and then another portraying a physician using an integrated model of EHR during communication over 35 minutes.
10174144|NCT03856060|Experimental|Group II (video, questionnaire)|Patients complete questionnaires and watch a video portraying a physician using an integrated model of EHR and then another portraying a physician using a standard EHR during communication over 35 minutes.
9675178|NCT05000723||PJI patients|"Patients (older than 18 years) with PJI of a total hip replacement treated at University Hospitals Leuven.~Diagnosis of PJI of the hip is made based on the EBJIS 2021 criteria. Patients will receive standard of care."
9675179|NCT05000749|Experimental|DBT-SG plus VHA treatment as usual|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
9675180|NCT05000749|Active Comparator|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
9675181|NCT05000489||Minors 1|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
9675182|NCT05000489||Minor 2|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
9675183|NCT05000489||Spina Bifida|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Spina Bifida clinic
9675184|NCT05000489||Pulmonology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the pulmonology clinic
9675185|NCT05000489||Endocrinology 1|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type I Diabetes
9675186|NCT05000489||Endocrinology 2|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type II Diabetes
9675187|NCT05000489||Rheumatology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Rheumatology clinic
9675188|NCT05000489||Gastroenterology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Gastroenterology clinic
9675189|NCT05000489||Neurology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Neurology clinic
9675190|NCT05000489||Cardiology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Cardiology clinic
10174145|NCT03856151|Active Comparator|Group 1|"For Group 1, each subject will receive Treatment 1# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 2#.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks."
9675191|NCT05000489||Hematology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Hematology clinic
9675192|NCT05000489||Nephrology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Nephrology clinic
9675193|NCT05000489||Oncology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Oncology clinic
9675194|NCT05000476|Other|Nurse Education and Environmental Regulation|Clinical nurses will be given training on delirium risks, diagnosis, prevention and management. In order to implement the interventions, environmental arrangements will be made in the intensive care units in the light of the training given, and the nurses will record which attempts are made during the day with the daily follow-up form.
9675195|NCT05000476|Experimental|Eye mask and earplugs|"Patients will be monitored for 3 days starting from their hospitalization.~Along with the regulations, each patient will be assisted by the intensive care nurses for 3 days between 23:00 p.m. - 06:00 a.m. for the use of eye mask and earplugs."
9675196|NCT05000476|No Intervention|Control|With the adjustments made, theywill receive the usual care for 3 days.
9675197|NCT05000775|Experimental|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
9675198|NCT05000775|Placebo Comparator|Placebo|Placebo
9675199|NCT05000684|Experimental|JS004 200 mg in combination with toripalimab 240 mg was administered every 3 weeks as planned|
9675200|NCT05000606|Experimental|A home visit program|A home visit program including five visits over three months were performed.
9675201|NCT05000606|Other|Control|No other intervention was applied to the control group other than the standard education given in the outpatient clinic
9675202|NCT05000814||cDLT|patients using conventional double lumen tube
9675203|NCT05000814||VDLT|patients using Vivasight DLT
9675204|NCT05000801|Experimental|DC vaccine|Vaccination with autologous or HLA-matched donors' WT1/TERT/survivin loaded DCs plus follow-up care.
10174146|NCT03856151|Active Comparator|Group 2|"For Group 2, each subject will receive Treatment 2# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 1#.~Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks."
10174147|NCT03856021|Active Comparator|Microfracture|
9675207|NCT05000762||Patients with diabetes mellitus|Patients with type 2 diabetes mellitus
9675208|NCT05000593|Experimental|stem cell treating group|Intra-articular injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 1 week for a total of 3 times.
9675209|NCT05000593|Sham Comparator|control group|Intra-articular injection of normal saline was performed once every 1 week for a total of 3 times.
9675210|NCT05000697|Experimental|Arm 1 - 5FU + Oxaliplatin|1) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by mFOLFOX6 or XELOX for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
9675211|NCT05000697|Active Comparator|Arm 2 - 5FU Only|2) RT (54Gy) plus daily concomitant capecitabine 825mg/m2 bid, followed by capecitabine 2000mg/m2/day for 14 days in a 21 days cycle for 4 cycles (12 weeks), starting 1 week after radiotherapy ended;
9675212|NCT05000411|Experimental|Experimental group|
9675213|NCT05000411|Placebo Comparator|Control group|
9695126|NCT04781829|No Intervention|Control|Critically ill patients with pneumonia will be treated with an antibiotic strategy at the discretion of the treating clinician
9695127|NCT04781829|Experimental|Interventional|Critically ill patients with pneumonia will be treated with an antibiotic strategy based on results from the BioFire Pneumonia Panel
9695128|NCT04781959|Active Comparator|5 Days of Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy.
10174148|NCT03856021|Active Comparator|Microfracture with Bone Marrow Aspirate Concentrate|
10174149|NCT03856294|Experimental|Rikkunshito|Rikkunshito: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
10174150|NCT03856294|Placebo Comparator|Placebo|Placebo: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
9675214|NCT05000307|Experimental|Volunteers, infected with COVID-19|
9675215|NCT05000398|Active Comparator|exercise with a physiotherapist|Participants will exercise with a physiotherapist. 4 times a week for 8 weeks
9675216|NCT05000398|Experimental|home program|The same exercises will be given to the participants as brochures. 4 times a week for 8 weeks
9675217|NCT05000372|Experimental|68Ga-grazytracer PET/CT in participants before immunotherapy|Participants who have not undergone immunotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 1 h.
9675218|NCT05000372|Experimental|68Ga-grazytracer PET/CT in participants after immunotherapy|Participants post-immunotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 1 h.
9675219|NCT05000385||Healthy|healthy complete dentition
9675220|NCT05000385||Dental caries|complete dentition with bilateral dental caries (ICDAS 4,5 or 6)
9675221|NCT05000385||Occlusal contacts|occlusal contacts are lost bilaterally due to extraction, changing dentition or orthodontic anomalies; no dental caries
9675222|NCT05000385||Dentures|patients with dentures, no caries and/or missing occlusal contacts on remaining teeth
9675223|NCT05000203|Experimental|Specific intervention for fear of childbirth|"Online education intervention Participants randomly assigned to the experimental group will be informed by telephone call of their inclusion in the first phase of the trial.~Participants in the intervention group will be encouraged to attend routine consultations with their midwife and obstetrician, as well as to take advantage of the group maternal education that participants usually develop in their health center.~Specific intranatal support~An experimental group will be carried out with a specific support intervention in the obstetric-gynecological emergency area that will supplement the one usually provided to all pregnant women.~At the end of the participant's stay within the emergency area due to hospital discharge, admission to the ward, or the end of the pregnancy, the collaborating midwife will fill out an online form designed to monitor the care offered. Said form will also be completed at the end of the work shift if the participant's care continues."
9675224|NCT05000203|Active Comparator|Routine intervention for fear of childbirth|"Usual care~Participants randomly assigned to the control group will be informed by telephone call of their inclusion in the first phase of the trial. The process under study will be explained in detail, resolving any doubts at that time.~Regular intranatal support~The participants in the control group will not be identified as pregnant women with fear of childbirth, and will receive the usual care in the obstetric-gynecological emergency area."
9675225|NCT05000034|Experimental|Patients|
9675226|NCT05000073|Experimental|Experimental Arm|
9675227|NCT05000073|Active Comparator|Control arm|
9675228|NCT05000112||Patients with mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is seen on surface of the vaginal mucosa, the patient is diagnosed with mesh exposure.
9675229|NCT05000112||Patients without mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is not seen on surface of the vaginal mucosa, bimanual examination will be performed to confirm no foreign body can be feeled on surface of the vaginal mucosa. Then the patient belong to this group.
9675230|NCT05000086|Experimental|99Tc methylene diphosphonate|99Tc-MDP was applied as follows: for each course of treatment, 99Tc-MDP 22 mg (5.5mg/set, four sets) was injected intravenously once a day for 7 successive days, one course every 4 weeks until week 24.
9675231|NCT04999995||HFrEF|Patients admitted with acutely decompensated HFrEF without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
9675232|NCT04999995||HFpEF|Patients admitted with acutely decompensated HFpEF without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
9675233|NCT04999995||Non-HF Dyspnea|Patients admitted with acute dyspnea without evidence of HF and without serum creatinine elevation > 2.5 mg/dl (220 micromol/L).
9675234|NCT05000099||phone calls|patients choosing phone calls as preferred communication technique
9675235|NCT05000099||video call|patients choosing video calls as preferred communication technique
9675236|NCT05000008|Experimental|Aerobic Exercise Group|Moderate Intensity Aerobic Exercises
9675237|NCT05000008|Experimental|Resistance Exercise Group|Moderate Intensity Resistance Exercises
9675238|NCT05000359|Other|AYA Text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
9675239|NCT05000190|Experimental|250 mg citicoline|Opaque capsule
9675240|NCT05000190|Placebo Comparator|0 mg citicoline|Opaque capsule matched in appearance to the active capsule
9695129|NCT04781959|Active Comparator|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
10174151|NCT03856008|Experimental|Exercises focused on flexor muscles.|Flexor cervical stabilization exercises will be applied.
10174152|NCT03856008|Experimental|Exercises focused on extensor muscles.|Extensor cervical stabilization exercises will be applied.
10174153|NCT03856008|No Intervention|Control.|No intervention will be applied.
10174154|NCT03856281|Experimental|Intervention Group A|LymphAssist IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
10174155|NCT03856281|Experimental|Intervention Group B|Sequential IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
10174156|NCT03856268||ARM 1: 'Surgical Menopause' Group|Premenopausal women having an oophorectomy.
10174157|NCT03856268||"ARM 2: Drug-Induced Menopause'"|Premenopausal women with gonadal suppression
10174158|NCT03856268||'Comparative (Control)' Group|Premenopausal women with regular cycles.
9675241|NCT05000255|Experimental|Intervention 1: According to DGP|For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of post-COVID-19 patients (DGP, 2020). The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients)
9675242|NCT05000255|Active Comparator|"Intervention 2: According to Cacioppo E.A.S.E."|The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. This psychological intervention will be applied to both groups of patients (non-Covid/Covid patients), too. The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions.
9675243|NCT05000255|No Intervention|Care as Usual; Standard psychological Support|The patients receive standard care from the psychologists, as is usual in this unit. No intervention is carried out.
9675244|NCT05000060|Experimental|1 week restart|Restart of mono or dual antiplatelet therapy one week post injury in TICrH patients
9675245|NCT05000060|Active Comparator|3 week restart|Usual Care for restart of mono or dual antiplatelet therapy after TICrH at clinician's discretion
9675246|NCT05000281|Experimental|NSAID|Standard of care pain medication regimen with NSAIDs.
9675247|NCT05000281|No Intervention|No NSAIDs|Standard of care pain medication regiment with no NSAIDs
9675248|NCT05000047||All participants|All participants will have bilateral impressions taken with both methodologies.
9675249|NCT04999943|Active Comparator|Hypomemylating agent monotherapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle)
9675250|NCT04999943|Experimental|Combined cellular immunotherapy（eDC）with Hypomemylating agent therapy|Azacitidine 100mg/ times. d × for 10 days (28 days for one cycle) or Decitabine 25mg/ times. d × 5 days ( 28 days is one cycle) with Dendritic Cell (DC) Vaccination Expressing WT1/hTERT/Survivin
9675251|NCT04999592|Active Comparator|No prophylaxis (placebo)|"Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted.~Administer antibiotics in response to infection."
9675252|NCT04999592|Experimental|Prophylaxis|Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
9675253|NCT04999683|Experimental|ITIS diet|anti-inflammatory (ITIS) diet for 14 days
9675254|NCT04999787|Experimental|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
9675255|NCT04999787|Placebo Comparator|Placebo|
9675256|NCT04999579|Active Comparator|Complete denture|Conventional complete denture without supporting devices
9675257|NCT04999579|Experimental|Ultra suction retained complete denture|Conventional complete denture with ultra suction device
9675258|NCT04999800|Experimental|Pembrolizumab combined with Anlotinib|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week, combined with Pembrolizumab 200 mg iv on day 1, and every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated
9675259|NCT04999657|Active Comparator|Active|Device: Non-invasive low-frequency tibial nerve stimulator
9675260|NCT04999657|Sham Comparator|Sham|Device: Non-invasive low-frequency tibial nerve stimulator (same device operation without real current output)
9675261|NCT04999878|Experimental|treatment group|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
9675262|NCT04999813|Experimental|Comprehensive intensive intervention|On the basis of routine management, carry out individualized cerebrovascular risk factor assessment and comprehensive intervention in a medical-nursing cooperation model, and require corresponding control indicators to be achieved. A comprehensive intervention team is established by specialized medical staff to monitor blood pressure, heart rate, exercise and other data through smart wearable devices, and automatically upload them to the cloud platform, conduct comprehensive data analysis every week, timely feedback and online reminders, establish health management files, and improve the target population The blood-brain tube risk factor control and self-management ability.
9675263|NCT04999813|No Intervention|Routine management|Only routine management was carried out for the subjects without special intervention.
9675264|NCT04999605|Experimental|AK112|AK112 injection
9675265|NCT04999670|Active Comparator|Single suture, knot above fascia|Fascia sutured with #1 polysorb braided absorbable suture, with the knot being superficial to the fascia, starting at the left angle of the fascial incision and closed in a continuous fashion. The contralateral angle is grasped with a kocher clamp and the suture is then tied behind the angle ensuring adequate closure.
9675266|NCT04999670|Active Comparator|Two sutures, knot above fascia|Fascia sutured using #1 polysorb braided absorbable suture with a superficial knot, starting at the left angle and closed in a continuous fashion until the suture is above the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is tied behind the right angle with a superficial knot and run across in a continuous fashion to meet the opposing suture which are then tied together.
9695130|NCT04781686|Experimental|First-line treatment|"First-line treatment: Apatinib plus Camrelizumab combined with Docetaxel and S1 for six cycles.~Maintenance treatment: Apatinib and Camrelizumab"
9695131|NCT04781920||Patients having undergone an Anterior Cruciate Ligament (ACL) reconstruction|Patients having undergone an ACL reconstruction will be included.
10174159|NCT03855930||micturition induced PLP|"10 Patients with chronic post amputation micturition induced PLP.All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.~All patients will go through functional MRI study"
9675267|NCT04999670|Active Comparator|Two sutures, buried knots below fascia|Fascia sutured using #1 polysorb braided absorbable suture with a buried knot below the fascia starting at the left angle and closed in a continuous fashion until the suture overlies the right rectus abdominis muscle belly. A second #1 polysorb braided absorbable suture is then tied behind the right angle with a buried knot below the fascia and run across in a continuous fashion to meet the opposing suture which are then tied together.
9675268|NCT04999930|Experimental|Group A|with aerochamber
9675269|NCT04999930|Experimental|Group B|without aerochamber
9675270|NCT04999722|Active Comparator|APP group|Participants with diabetes who had access to a mobile APP
9675271|NCT04999722|Placebo Comparator|Control Group|Diabetes participants who accepted the traditional management model
9675272|NCT04999826||Observational (questionnaire, biospecimen collection)|Participants complete questionnaires over 10 minutes and undergo blood, urine, saliva, and fecal samples collection.
9675273|NCT04999540|Experimental|Tucidinostat + Fulvestrant|"Patients receive 30 mg Chidamide twice per week. Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only.~Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
9675274|NCT04999774||School-age children|"Each SAC will be asked to supply fecal and blood samples for testing with:~Stool microscopy~Baermann method~Real-time PCR for S. stercoralis~Lateral flow rapid test~ELISA serology (NIE/SsIR and IgG Ratti)"
9675275|NCT04999696|Experimental|Laparoscopic radical hysterectomy|
9675276|NCT04999696|Active Comparator|Laparotomic radical hysterectomy|
9675277|NCT04999501|Experimental|65 - 75 years|All volunteers aged 65 - 75 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
9675278|NCT04999501|Experimental|85 years and over|All volunteers over the age of 85 will be subjected to 12 weeks of full body resistance exercise training (3 times per week).
9675279|NCT04999345|Experimental|Experimental Group|Provide resistance and aerobic exercise
9675280|NCT04999345|Placebo Comparator|Control Group|Health education and gross range of motion exercise for upper and lower extremities
9675281|NCT04999293||The Elderly Undergoing Percutaneous Coronary Intervention|Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
9675282|NCT04999150|Active Comparator|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected.~Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed . The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed.~A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)."
9675283|NCT04999150|Experimental|Micro-Osteoperforation|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced ~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed.~A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)."
9675284|NCT04999410|Experimental|Long-HITT|Long work bout durations (4 minutes) on cycle ergometers or home trainers
9675285|NCT04999410|Active Comparator|Medium HIIT-L|Medium duration work bouts (2 minutes) with intensity matched to the Long-HITT intensity
9675286|NCT04999410|Active Comparator|Medium HIIT-H|Medium duration work bouts (2 minutes) with intensity at 30% of the difference between Wmax and mean TT power outputs
9675287|NCT04999410|Active Comparator|Short HIIT|Short duration work bouts (30 seconds) with intensity at 50% of the difference between Wmax and mean TT power outputs
9675288|NCT04999332|Experimental|Perioperative chemotherapy with LOTS|"LOTS as one cycle:~Leucovorin (30 mg) twice daily per oral, day 1 to 7; Oxaliplatin (85 mg per square meter) intravenously, day 1; Docetaxel (40 mg per square meter) intravenously, day 1; S-1 (35 mg per square meter) twice daily per oral, day 1 to 7~Pre-operative part:~Four cycles of LOTS every two weeks~Operative part:~Curative gastrectomy or gastroesophagectomy plus D2 lymphadenectomy~Post-operative part:~Four cycles of LOTS every two weeks"
9675289|NCT04999280|Experimental|Fiber Croissant (FIBCRO) Group|Daily consumption at breakfast for 2 weeks of a fiber-enriched croissant
9675290|NCT04999280|Active Comparator|Control Croissant (CONCRO) Group|Daily consumption at breakfast for 2 weeks of a control croissant
9675291|NCT04999449|Experimental|Pharmacokinetic|Participants receive 1 dose of Scopolamine 0.4 mg delivered via a intranasal nebulizer developed by Creare LLC.
9675292|NCT04999449|Experimental|Chair|Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.
9675293|NCT04999059||Participants with Fabry Disease|This is a long-term follow-up study of participants who previously received AVR-RD-01 (single dose administration) in the AVRO-RD-01-201 treatment study. No investigational product will be administered in this study.
9675294|NCT04999098|Active Comparator|treatment group 1: Echinaforce Forte (EFF) Tablets (chewed)|"1st arm (EFF group): Slowly sucking 1 Echinaforce Forte tablet (1 tablet: 1'200mg EF) until dissolution Dose 1. Another 2 X 1 EF Forte tablets (total of 2 tablets: 2'400 mg EF) is taken one-by-one Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Forte tablets."
9695132|NCT04781660|Experimental|Implantable Alginate Hydrogel|All patients will be treated with Implantable Alginate Hydrogel
9975554|NCT00604812|Placebo Comparator|Panel B Placebo|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
10174160|NCT03855930||non micturition induced PLP|10 Patients with chronic post amputation with PLP and without post amputation micturition induced PLP All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.All patients will go through functional MRI study
9675295|NCT04999098|Active Comparator|treatment gorup 2: Echinaforce Chewable (EFC) Tablets (chewed)|"2nd arm (EFC group): Slowly sucking 1 x 3 Echinaforce Chewable tablets (total 3 tablets: 1'200mg EF) until dissolution Dose 1. Another dose of 2 x 2 & 1 x 3 EF Chewable tablets (total 7 tablets: 2'800mg EF) are slowly sucked Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Chewable tablets."
10174161|NCT03855930||healthy volunteers|10 healthy volunteers. All patients will go through functional MRI study
10174162|NCT03856177|Experimental|Neutral|A neutral mood induction will include reading a dull text while listening to non-evocative music for 5-15 minutes.
10174163|NCT03856177|Experimental|Evocative|A mood induction procedure will be utilized. The procedure consists of a combination of re-experiencing an autobiographical sad personal event while listening to their choice of one of four sad music selections commonly used in mood induction. Visual analogue scale ratings will assess momentary sadness prior to, following, and at subsequent time points around the mood induction procedure.
10174164|NCT03856242|No Intervention|No intervention|It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
9675296|NCT04999098|Active Comparator|treatment group 3: Echinaforce Tincture (EFT, gargling)|"3rd arm (EFT group): Gargling of 2 x 19 drops of Echinaforce tincture (1'200 mg EF) is diluted in 2 x35 mL water Dose 1. Another dose of 3 x 30 drops of Echinaforce tincture (2'800 mg EF) diluted in 3 x35 mL water for 15 sec each Dose 2, gargled for 15 sec and swallowed after swab sampling, which is repeated after gargling of the second dose of EF Tincture."
9675297|NCT04999033||Inpatient|This study is a cross-sectional study and no intervention will be involved
9675298|NCT04999124|Other|Type 2 Diabetes Mellitus patients|
9675299|NCT04999462|Experimental|Full-fat fermented dairy|1 serving per day of full-fat yogurt and full-fat fermented cheese
9675300|NCT04999462|Active Comparator|Low-fat fermented dairy|1 serving per day of low-fat yogurt and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
9675301|NCT04999462|Placebo Comparator|Non-dairy, non-fermented foods|2 servings per day of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
9675302|NCT04999176|Experimental|Rivaroxaban|Oral Rivaroxaban (10 mg once daily) for 30 days post-operative
9675303|NCT04999176|Active Comparator|Enoxaparin|Subcutaneous Enoxaparin (40 mg once daily) for 30 days post-operative
9675304|NCT04999007|No Intervention|Control|Whether the patients in the control arm will receive a temporary ileostomy depends on surgeons' experience.
9675305|NCT04999007|Experimental|Intervention|Whether the patients in the intervention arm will receive a temporary ileostomy depends on the risk of anastomotic leakage calculated by the artificial intelligence algorithm.
9675306|NCT04998968||Patients with permanent hypoparathyroidism after total thyroidectomy|Patients with permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region. Permanent hypoparathyroidism is defined as treatment with Calcium and/or vitamin D more than 12 months after surgery.
10174165|NCT03856242|Active Comparator|Tamsulosin|This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
9675307|NCT04998968||Patients without permanent hypoparathyroidism after total thyroidectomy|Patients without permanent hypoparathyroidism after total thyroidectomy for benign thyroid disease. These patients should be operated between 2005-2015 in Uppsala-Örebro healthcare region.
9675308|NCT04999046|Experimental|FUS treatment|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals. The FUS exposure area will be the epileptogenic focus which is individually different and determined by standard clinical practice previously.
9675309|NCT04999046|Sham Comparator|Sham treatment|Sham treatment is to mimic the FUS treatment procedure but without any energy. The ISPTA will be 0 W/cm2, duration: three repeating 5-minute sham exposures with two 5-minute intermission intervals.
9675310|NCT04999189|Experimental|Patients using mobile applications|Patients diagnosed with type 2 diabetes will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
9675311|NCT04999189|No Intervention|Control group|Patients will receive treatment from medical staff (as usual).
9675312|NCT04998955|Experimental|MST group|Exercise intervention, 20 supervised MST sessions
9675313|NCT04998955|No Intervention|Control group|IRD patient controls
9675314|NCT04998942|Experimental|Experimental|
9675315|NCT04998942|Placebo Comparator|Placebo comparator|
9675316|NCT04998903||Stem cell transplant with Graft versus host disease|Patients who following hematopoietic stem cell transplant suffered from graft versus host disease and presented with pulmonary infiltrates.
9695133|NCT04781621|Experimental|Robotic Gait Training|Patients in the Robotic Gait Training (RGT) group will receive 90 minutes per week of RGT once patients are deemed clinically appropriate as defined by being able to tolerate standing for 15 minutes without orthostatic intolerance. The duration of treatment will span the patient's length of stay in inpatient rehabilitation. The Ekso Bionics Ekso GT™ robotic exoskeleton will be used for RGT.
9695134|NCT04781621|Active Comparator|Usual Care Gait Training|Usual Care (UC) gait training including body weight-supported treadmill training (BWSTT) and conventional overground walking.
9675317|NCT04998890|Experimental|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program A 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure training (one adventure day camp (2 sessions) and adventure activities in the beginning of each workshop). One session per week, 3 hours for each session. A variety of cognitive behavioral skills were taught in lectures and these skills were practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework were used in the intervention program.
9675318|NCT04998890|No Intervention|Control group|No intervention of the adventure-based cognitive behavioral program
9675319|NCT04999137|Experimental|Intravenous vitamin C 1.5g + intravenous vitamin B1|intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
9675320|NCT04999137|Experimental|Intravenous Vitamin C 3g + intravenous vitamin B1|Intravenous vitamin C (3 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
9675321|NCT04999137|No Intervention|Usual Care|Usual care
9675322|NCT04998877||Heart Failure with Preserved Ejection Fraction|
9675323|NCT04998877||Healthy Volunteers|
9675324|NCT04998656|Active Comparator|Werewolf FLOW 50 Group|The Werewolf FLOW 50 electrocautery device will be used during surgical treatment for patients assigned to this group.
9675325|NCT04998656|Placebo Comparator|Control Group|No electrocautery device will be used during surgical treatment for patients assigned to this group.
9675326|NCT04998734||Chronic pain|Patients with chronic non-cancer pain referred to secondary and tertiary care
9975555|NCT00604812|Experimental|Panel C Rizatriptan|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
9975556|NCT00604812|Placebo Comparator|Panel C Placebo|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
10187102|NCT03729531|Experimental|No-touch|The vein will be harvested by frequency electrotome and the perivascular tissue will be preserved, the vein will not be distended.
9675327|NCT04998630|Experimental|A (4Hz)|ESWT frequency 4Hz washout period: 1 week
9675328|NCT04998630|Experimental|B (8Hz)|ESWT frequency 8Hz washout period: 1 week
9675329|NCT04998565|Experimental|Routine care|Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.
9675330|NCT04998565|Experimental|Routine care plus EA|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Electrical acupuncture on body acupoints"
9675331|NCT04998565|Experimental|Routine care plus TENS|"Routine care for early postpartum breast engorgement, including reverse pressure technique over areola, along with hand expression of breastmilk.~plus: Transcutaneous electrical nerve stimulation on breasts"
9675332|NCT04998552|Experimental|SBRT (Cyberknife)|5-10 Gy/fraction. Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
9675333|NCT04998552|Active Comparator|IMRT|1.2-3 Gy/fraction up to 40 fractions. 15 mins daily (M-F) for a total of 28 sessions (5.5 weeks).
9675334|NCT04998760|Experimental|ATG-008 + Chemotherapeutics|ATG-008: Oral, 30 mg QD+Paclitaxel: 175 mg/m2, intravenous infusion >3 h, Day 1, Q3W; ATG-008: Oral, 30 mg QD+Carboplatin: AUC = 5, intravenous infusion >1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion >1h, Day 2, Q3W ; ATG-008: Oral, 30 mg QD+Doxorubicin hydrochloride liposome, 40 mg/m2, Day 1; Q4W;
9675335|NCT04998760|Experimental|ATG-010 + Chemotherapeutics|"perimental: ATG-010 + Chemotherapeutics ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Paclitaxel: 175 mg/m2, intravenous infusion >3 h, Day 1, Q3W; ATG-010: Oral, 80 mg QW, Day~1/week of treatment cycles +Carboplatin: AUC = 5, intravenous infusion >1 h, Day 1, Q3W or Cisplatin: 75 mg/m2, intravenous infusion >1h, Day 2, Q3W ; ATG-010: Oral, 80 mg QW, Day 1/week of treatment cycles +Doxorubicin hydrochloride liposome, 40 mg/ m2, Day 1; Q4W;"
9675336|NCT04998526|Experimental|Experimental group|After routine drug treatment is given to hypertension patients, the cold gel pack will be applied to the nape for 3 minutes.
9675337|NCT04998526|Placebo Comparator|Placebo group|After routine drug therapy is given to hypertension patients, the gel pack kept at room temperature will be applied to the nape for 3 minutes.
9675338|NCT04998526|No Intervention|Control group|Routine drug treatment will be given to hypertension patients and no application will be made.
9675339|NCT04998591|Experimental|Fasting group|Participants will be councelled and accompanied to follow a fasting regime of 7 days in an outpatient setting under medical supervision.
9675340|NCT04998591|No Intervention|Waiting list|This group maintains their individual diet during the whole time of the study. In case that the first cycle of In-Vitro-Fertilization fails, they are offered a fasting intervention before a next cycle.
9675341|NCT04998825|Experimental|Proteoglycan F group|"Taking Proteoglycan F~Dosage of Proteoglycan F: 50mg/day~Used time: 24 weeks"
9675342|NCT04998825|Placebo Comparator|Control group|"Taking Placebo (Dextrin)~Dosage of Placebo: 50mg/day~Used time: 24 weeks"
9975557|NCT00536380|Experimental|5-mg Desloratadine|5-mg Desloratadine once daily
9675343|NCT04998721|Experimental|Maternal Infant Dyadic Care|Perinatal collaborative care and Promoting First Relationships-Brief
9675344|NCT04998721|Active Comparator|Control|Perinatal collaborative care only
9675345|NCT04998695|Experimental|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
9675346|NCT04998695|Active Comparator|Sunflower oil|Intake of 45 g/d of sunflower oil as the only source of oil in the diet
9675347|NCT04998773|Active Comparator|Group Bilateral|32 patients, bilateral active TBS stimulation, Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Continuous TBS in right DLPFC
9695135|NCT04781777|No Intervention|Control group|Dexmehtasone and local anesthetics in carpal tunnel syndrome
9675348|NCT04998773|Active Comparator|Group Unilateral|32 patients, unilateral left DLPFC active TBS stimulation. Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
9675349|NCT04998773|Placebo Comparator|Group Placebo|32 patients, bilateral sham TBS stimulation. Will receive an intensive-spaced protocol of Sham Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
9675350|NCT04998513|Active Comparator|Medical Management Alone Arm|Antibiotics, steroids, fluids
9675351|NCT04998513|Active Comparator|Surgical Arm|Incision and drainage
9675352|NCT04998474|Experimental|FRAME-001 personalized vaccine|"Prospective, single arm, multi center, open-label, phase II clinical trial.~Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs."
9675353|NCT04998461||Obese patients with normal renal function|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~Body Mass Index (BMI) > 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
9675354|NCT04998461||Obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2~Body Mass Index (BMI) > 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
9675355|NCT04998461||Non-obese patients with impaired renal function|"estimated Glomerular Filtration Rate (eDFG) < 60 ml/min/1.73 m2~Body Mass Index (BMI) between 18 and 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
9675356|NCT04998461||Non-obese patients with normal renal function (control group)|"estimated Glomerular Filtration Rate (eDFG) ≥ 60 ml/min/1.73 m2~Body Mass Index (BMI) between 18 and 30 kg/m2~Microalbuminuria / creatinuria ≤ 3mg / mmol and / or proteinuria < 0.15 g/24h"
9675357|NCT04998383|Experimental|HVNI|High velocity nasal insufflation (Fisher &Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort
9675358|NCT04998383|Experimental|Noninvasive ventilation|Respiratory assistance is provided by a NIV either Puritan Bennet 840 (Covidien, U.S.A.), EngströmCarestation (GE Healthcare, Finland) or Hamilton-G5 (Hamilton Medical, Germany), will be used for conventional non-invasive ventilation via an oronasal mask that helps patients to cope with their Breathlessness. Settings will be adjusted based on the clinical assessment of the respiratory therapist as per standard practice.
9675359|NCT04998370||Study cohort|The study population consists of patients admitted to an academic tertiary care center due to an aneurysmal subarachnoid hemorrhage. The primary objective of the study focuses on patients included with external ventricular drain (EVD), while secondary objectives consider patients with both EVD and lumbar drain (LD) as well as patients without any drainage system.
9675360|NCT04998292|Experimental|Low level laser therapy|
9675361|NCT04998292|Active Comparator|Control|
9675362|NCT04998435|Active Comparator|ESPB group|Erector Spinae Plain Block
9675363|NCT04998435|Active Comparator|PV group|Paravertebral Block
9675364|NCT04998838|Experimental|Tenofovir Disoproxil Fumerate|Pregnant women (&gt;=20 weeks of gestation) will be treated with TDF if clinically eligible; newborns will receive birth dose vaccine (and HBIG if eligible). Non-eligible women will be treated according to normal practices; newborns will still receive birth dose vaccine.
9675365|NCT04998149|No Intervention|standard care|The control group subjects will receive standard of care during labor using pillows and wedges as positional devices.
9675366|NCT04998149|Experimental|Peanut ball intervention|The experimental group will receive peanut ball as positioning device during labor
9675367|NCT04998071|Active Comparator|ROUTINE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.25% bupivacaine 0.4 ml/kg. in each side.
9675368|NCT04998071|Active Comparator|ALTERNATIVE DRUG - CONCENTRATION QLB|The patients will receive bilateral posterior quadratus lumborum block using 0.125% bupivacaine 0.4 ml/kg. in each side.
9675369|NCT04998357|Experimental|Transplantation|Endovascular infusion
9675370|NCT04998448||Cases|women aged 18 to 50 years, premenopausal, with polycystic ovary syndrome
9675371|NCT04998448||Controls|women aged 18 to 50 years, premenopausal, without polycystic ovary syndrome.
9675372|NCT04998123|Sham Comparator|Sham Stimulation|
9675373|NCT04998123|Experimental|ISP Stimulation|
9675374|NCT04998123|No Intervention|Perpheral Stimulation|
9675375|NCT04998175|Experimental|iNPH cohort|The patients diagnosed of iNPH.
9975558|NCT00536380|Experimental|10-mg Desloratadine|10-mg Desloratadine once daily
9975559|NCT00536380|Experimental|20-mg Desloratadine|20-mg Desloratadine once daily
9675376|NCT04998344|Experimental|Inactivated influenza vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
9675377|NCT04998344|Active Comparator|Inactivated polio vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
9675378|NCT04998045|Experimental|Intervention arm|Youth aged 15-24 years Intervention: screening and brief intervention for substance use
9675379|NCT04998227||suspect acute coronary syndrome|"Subjects with the diagnosis of suspected acute coronary syndrome (ACS), age between 20 to 80.~Exclusion criteria: pregnant women, patients with end-stage renal disease (eGFR <15 mL/min/1.73 m2), cardiogenic shock."
9695136|NCT04781777|Active Comparator|Insulin group|insulin added to dexamehtasone and local anesthetics
9975560|NCT00521599|Experimental|MF DPI 2 x 100 mcg BID|2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
9975561|NCT00521599|Experimental|MF DPI 1 x 200 mcg BID|1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
9975562|NCT00521599|Placebo Comparator|Placebo|2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
9975563|NCT00496834|Experimental|1|Losartan or Losartan/HCTZ
9675380|NCT04998253|Experimental|Group 1: Sevofruorane (Svofast)|"Experimental group: will receive sedation with sevoflurane with an infusion rate to maintain MAC of 0.7 and fentanyl 1mcg /kg/hour.~Inhalation sedation The AnaConda device (Sedana Medical, Ireland) is placed between the endotracheal tube and the ventilator circuit. The anesthetic infusion line is attached to a syringe, from where the anesthetic (sevoflurane) will be delivered to said device. The sample line will be taken to the anesthetic gas analyzer whit the Carescape B450 multiparametric monitors (General Electric, Finland) for MAC control. The anesthetic gas outlet port will be attached to the absorbent material container."
9975564|NCT00496834|Active Comparator|2|Carvedilol or Carvedilol/HCTZ
9675381|NCT04998253|Active Comparator|Group 2: Propofol (Diprivant)|"Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.~For both groups, the doses will be titrated to maintain a RASS score between -3 to -4 in both groups.~Both groups will receive cisatracurium (Nimbex) as a continuous infusion of 3 to 5mcg / kg/min for 48 hours. We will maintain sedation for both groups with the same scheme for 48 hours, after which the drugs used for sedation will be modified at the discretion of the intensive care physicians."
9675382|NCT04998097|Experimental|experimental (iTBS group)|device: Magstim Rapid2 Stimulator
9675383|NCT04998097|Sham Comparator|sham group|device shame Magstim Rapid2 Stimulator
9675384|NCT04998500|Experimental|GH intervention - control intervention|Participants will receive daily subcutaneous injections of growth hormone for 7 days. Approximately 1-4 months later, the participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant).
9675385|NCT04998500|Experimental|Control intervention - GH intervention|Participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant). Approximately 1-4 months later, the participants will receive daily subcutaneous injections of growth hormone for 7 days.
9675386|NCT04998019|Experimental|PositiveLinks|Participants from clinics randomized to PL will get the patient smartphone app; clinic staff will receive the provider portal and provider smartphone app, the provider online LMS (learning management system), and the research assistant will use the administrative website to enroll participants. Patients randomized to PL will use it for 12 months or more; they can opt to use it as long as it is available during the study(access depending on enrollment date).
9675387|NCT04998019|No Intervention|Usual Care|Participants from clinics randomized to Usual Care (UC) will receive usual clinic retention and medication adherence support services for 12M. Based on site assessments, and descriptions from the clinics, the UC condition ranges from having no ancillary support to only case management, to Ryan White funding and comprehensive services (adherence support, patient navigation, mental health, substance abuse, dental services and food banks)
9675388|NCT04998214||control group non cirrhotic|compare liver function 1m after COVID-19 and that at beginning of infection
9675389|NCT04998214||cirrhotic patients|compare liver function 1m after COVID-19 and that at beginning of infection
9675390|NCT04997954|Experimental|MediCabilis CBD Oil|MediCabilis CBD Oil to be taken no more than 7ml/day orally based from participants' individual 14 day titration period completed at the beginning of the trial. The frequency of the drug intake can range between once and three times a day depending on the outcome of the 14 day titration period. Titration period allows participants to gradually increase study drug intake in order to find appropriate dose for participants without or with minimal undesired side effects. The treatment will last no more than 6 months.
9675391|NCT04997967|Experimental|Ketofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Will receive Ketofol (ketamine: propofol concentration 1:4) prepared in 50 ml syringe containing dextrose 5% (each ml contained 8 mg propofol and 2 mg ketamine), administered as following; 5 ml of ketofol as loading then infusion titrated till targeted RSS score.
9675392|NCT04997967|Active Comparator|Propofol group|Patients undergoing urgent therapeutic ERCP for severe cholangitis, with American Society of Anaesthesiologist (ASA) Grade II - III. Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
9675393|NCT04997980||Amiodarone group|Patients who did receive amiodarone during the attempt of resuscitation
9675394|NCT04997980||NO Amiodarone|Patients who did receive amiodarone during the attempt of resuscitation
9675395|NCT04997824|Experimental|Artificial Intelligence-based atrial fibrillation catheter ablation|catheter ablation
9675396|NCT04997824|Active Comparator|typical atrial fibrillation catheter ablation|catheter ablation
9675397|NCT04997837|Experimental|PD-1 inhibitor and chemoradiotherapy|"PD-1 inhibitor+CapeOX/SOX/FOLFOX for 6 weeks, followed by chemoradiotherapy; 6 weeks of PD-1 inhibitor and CapeOX/SOX/FOLFOX for 6 weeks after chemoradiotherapy, followed by PD-1 inhibitor, till 12 months after chemoradiotherapy.~PD-1 inhibitor Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.~Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~Chemoradiotherapy Radiotherapy: 1.8 Gy/fx, 45-50.5Gy Chemotherapy: Capecitabine 625mg/m2 bid orally with radiotherapy; OR Tegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy."
9975565|NCT00442897|Experimental|1|
9975566|NCT00442897|Active Comparator|2|
9975567|NCT00423579|Experimental|Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment
9975568|NCT00423579|Active Comparator|Ezetimibe/Simvastatin placebo + Simvastatin 40 mg|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.
9675398|NCT04997837|Active Comparator|Chemotherapy|"Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator.~CapeOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.~SOX:~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off.~FOLFOX:~Oxaliplatin 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.~5-FU 2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W."
9675399|NCT04997928||Group 1 (n=20; with mild symptoms)|"Group 1 (n=20; with mild symptoms)~Covid positive patients with mild symptoms who required to be hospitalized,~Symptomatic (fever, cough, weakness, joint pain, etc.) new patients who apply to the Covid clinic for the first time,~Patients with stable vital signs and/or SpO2 ≥92% in room air, no radiological signs of lung involvement or mild pneumonia,~Patients who have not been started on steroid therapy and who have not yet received anticoagulant therapy."
9675400|NCT04997928||Group 2 (n=20; with moderate symptoms)|"Group 2 (n=20; with moderate symptoms)~Patients who are positive for Covid 19 and admitted to the covid clinic for the first time;~Radiologically moderate pneumonia findings and/or SpO2=88-92% in room air,~Patients who have not been started antiviral, steroid, and anticoagulant treatment."
9675401|NCT04997928||Group 3 (n=20; with severe symptoms)|"Group 3 (n=20; with severe symptoms)~Patients who are currently hospitalized in the Covid clinic,~Patients with radiological findings of severe pneumonia or ARDS and/or high FiO2 requirement due to respiratory failure.~Patients of this group may have received antiviral, anticoagulant, and/or steroid and/or biologic agent treatment."
9675402|NCT04997928||Group 4 (n=20; Control group)|"Group 4 (n=20; Control group)~The control group will be composed of healthy adult individuals applying to adult allergy outpatient clinics on a voluntary basis.~Patients who have not been previously diagnosed with Covid-19 and have not vaccinated against Covid-19,~The control patients will be matched with the study groups according to age, gender, and BMI."
9675403|NCT04997850|Experimental|TACE + lenvastinib + sindilimab/carrelizumab|The patients with body weight ≥ 60kg were treated with oral lenvastinib within 3 days (the initial dose was 12mg QD for patients with body weight < 60kg, the initial dose was 8mg QD for patients with body weight < 60kg). After 1-2 weeks of treatment, the patients received the first TACE treatment (3 days before TACE), and continued to take oral lunvastinib 3 days after TACE. Within one week after TACE treatment, 200 mg of sindilimab was given intravenously once every three weeks (every 21 days as a cycle) or 200 mg of carrelizumab was given intravenously once every three weeks (every 21 days as a cycle).
9675404|NCT04997850|Active Comparator|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
9675405|NCT04997655||Upper Transabdominal Plain Block|All patients in this group are routinely administered general anesthesia. After extubation, the subcostal transverse abdominis area block was directed laterally along the rectus abdominis muscle by finding the linea alba under the xiphoid region under ultrasound guidance with a 22G echogenic block needle, and 20 ml (8 ml 0.5% bupivacaine, 7 ml prilocaine) into the fascia between the rectus abdominis and transverse abdominis muscles. , 5 ml of saline) drug mixture will be performed by the anesthesiologist in charge of that day, who is not aware of the observational measurement to be made, if there is an indication, as a blind practitioner.
9675406|NCT04997655||Opioid analgesia|All patients in this group are routinely administered general anesthesia. Apart from this, in the other group, which does not have peripheral nerve block and only routine opioid analgesia is considered sufficient, only routine peroperative USG diaphragm measurements will be recorded observationally.
9675407|NCT04997889|Experimental|artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
9675408|NCT04997889|Active Comparator|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
9675409|NCT04997720|Other|Training|The course will be theoretical-practical, lasting eight hours, divided into two meetings with a theoretical class and practical exercises in microsurgery of increasing complexity. The course will also have an initial and final evaluation.
9675410|NCT04997603|Other|Athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
9675411|NCT04997603|Other|Non-athletes wearing an accelerometer continuously for 2 weeks|High school students: 50% male, 50% female
9675412|NCT04997772||1|Gaucher disease patients > 18 years old.
9675413|NCT04997746||educational pharmaceutical guidelines|Qualified listening of participants; General pharmaceutical educational guidelines on the use of medicines; Manufacture and supply of medicine organizer boxes.
9695137|NCT04781946|Experimental|Treatment Arm|Endoscopic pneumatic balloon dilation (PBD), gastric peroral endoscopic myotomy (G-POEM) and Roux-en-Y gastric bypass (RYGB) will be used for the management of post-LSG GSS using a predefined treatment algorithm.
9695138|NCT04781751|No Intervention|dexamethasone|dexamethasone with local anesthetics injected for carpal tunnel relief
10174166|NCT03856242|Active Comparator|TURP|This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).
9675414|NCT04997746||Nursing Educational Guidelines|"Nursing educational guidelines; Qualified listening to participants to resolve doubts related to their comorbidities and aging, bringing comfort in relation to their anxieties.~Nursing interventions will occur through verbal educational guidelines given individually and according to the reality of each participant assessed by the research, based on the nursing diagnoses obtained from the North American Nursing Diagnosis Association - NANDA-I (definitions and classification 2018- 2020) 11th edition."
9675415|NCT04997746||Nutritional Educational Guidelines|Obtaining anthropometric measurements (weight, in kilograms, height (in meters), knee height, arm and calf circumference (in centimeters) to trace the participant's nutritional profile and, subsequently, personalized and appropriate nutritional guidelines will be carried out for each situation The calculation of the Body Mass Index (BMI) must be performed by dividing the weight (W) in kilograms (kg) by the square of the height (H) in meters (m) and indicates the individual's nutritional status. The BMI for the elderly (LIPSCHITZ, 1994 apud TAVARES et al., 2015) determines underweight less than or equal to 22kg / m2, adequate or eutrophic weight between 22 and 27kg / m2 and overweight result greater than or equal to 27kg / m2 .
9675416|NCT04997551|Active Comparator|Colchicine|EC Experimental group: colchicine for 2 weeks orally added to standard treatment.
9675417|NCT04997551|Placebo Comparator|Placebo|Control group: placebo for 2 weeks added to standard treatment.
9675418|NCT04997707|Active Comparator|P group|75-100 µg/kg/min propofol
9675419|NCT04997707|Active Comparator|BA group|25ug/kg/min propofol and 0.2% below corrected-to-age- half MAC of sevoflurane
9675420|NCT04997785|Experimental|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
9675421|NCT04997785|Active Comparator|Intravenous Morphine|Dosage of intravenous morphine was determined according to 0.1 mg per kg; EPs were instructed to aim to reduce the pain by 50% or per patient request.
9675422|NCT04997798|Experimental|Dalpiciclib in combination with letrozole and trastuzumab plus pyrotinib|Receiving intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) and oral pyrotinib (400 mg po QD, Q3W) for six cycles plus oral Dalpiciclib (150 mg QD x 21 Q4W) and oral Letrozole (2.5 mg po QD for 20 weeks)
9675423|NCT04997876||Study Group|Biomarkers from presurgical OCTs are diagnosed
9675424|NCT04997590|Experimental|Umbilical cord blood mononuclear cells group|Umbilical cord blood mononuclear cells (cell number 1×108/2mL), once every two weeks, 3 times in total.
9675425|NCT04997590|Active Comparator|Staphylococcal Enterotoxin C group|Staphylococcal enterotoxin C (2mL), once every two weeks, 3 times in total.
9675426|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane|Control arm
9675427|NCT04997421|Active Comparator|CVVHDF with Oxiris®-AN69 membrane + Hemoadsorption using HA380|Intervention arm
9675428|NCT04997863|Experimental|Sericin hydrogel sheet impregnated with EBN extract|Apply sericin hydrogel sheet impregnated with EBN extract on one-half of the donor site once daily for 8-12 hours per day for 6 months.
10174167|NCT03856112|Experimental|Arm I (ixazomib, venetoclax, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, venetoclax PO QD on days 1-28 and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10174168|NCT03856112|Active Comparator|Arm II (ixazomib, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9675429|NCT04997863|Placebo Comparator|Placebo hydrogel sheet|Apply placebo hydrogel sheet on another half of the donor site once daily for 8-12 hours per day for 6 months.
9675430|NCT04997408|Active Comparator|Study Arm|Mobile device-assisted rehabilitation
9675431|NCT04997408|Active Comparator|Control Arm|In-person therapist-supervised rehabilitation
9675432|NCT04997486|No Intervention|Control|Subjects will consume all meals/snacks during a ~15-h daily eating period (~9-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
9675433|NCT04997486|Experimental|TRE isocaloric|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
9675434|NCT04997486|Experimental|TRE ad libitum|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting) without any other dietary advice.
9675435|NCT04997564|Experimental|non-cirrhotic patients|patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment
9675436|NCT04997564|Other|cirrhotic patients|patients will be received TAF once daily for 64 weeks. In this study, after week 64, and patients will continue NUC treatment but pay by themselves.
9675437|NCT04997330|Experimental|Active rTMS|Bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
9675438|NCT04997330|Placebo Comparator|Sham rTMS|Sham bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC
10174169|NCT03856112|Experimental|Arm III (ixazomib, venetoclax, dexamethasone)|PI-refractory patients receive ixazomib citrate, venetoclax and dexamethasone as Arm I.
9675439|NCT04997525|Active Comparator|Natural cycle|These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer
9675440|NCT04997525|Active Comparator|Estradiol and progesterone|These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6
9675441|NCT04997525|Active Comparator|Gonadotropin|These women will receive daily gonadotropin injection before embryo tranfer. Ovulation will be stimulated using hCG injection.
9695139|NCT04781751|Active Comparator|Insulin group|insulin with local anesthetics and dexamehtasone injected for carpal tunnel relief
9975569|NCT00394355|Experimental|Group 1|MF DPI 400 mcg once a day (QD) in the evening (PM)
9675442|NCT04997512|No Intervention|Standard of care|Participants are returned to the care of their usual diabetes care provider following randomisation. They will donate blood and urine samples as well as completing diabetes specific questionnaires at 0 and 6 months. They will also wear a blinded glucose sensor (freestyle Libre PRO) for a two week period at month 6.
9675443|NCT04997512|Experimental|Intervention arm|Participants will be randomised at baseline. They will provide blood and urine samples at months 0 and 6 as well as fill in diabetes specific questionnaires. They will receive education surrounding hypoglycaemia at baseline from a diabetes specialist nurse. They will wear a freestyle libre device which is changed every two weeks for a period of 6 months. At weeks 2,4,12 and 24 they will have their diabetes medication adjusted by the diabetes specialist nurse/diabetes doctor according to their blood glucose profiles, analysed from the data generated by freestyle libre.
9675444|NCT04997473|Experimental|App Group|Participants will be receiving an addiction model based mobile health (mHealth) weight loss intervention with coaching for a total of 4 months duration
9675445|NCT04997447|Experimental|Intervention group|Two weeks of daily step reduction (limited to 2000 steps per day) followed by four weeks of supervised gym-based exercise rehabilitation (twice per week strength training and twice per week cycle endurance training)
9675446|NCT04997447|No Intervention|Control group|Continued monitoring of habitual daily step count without structured intervention. Classic control.
9675447|NCT04997317|Active Comparator|Phase 0: Group A|"Cycle 1: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group A patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
9675448|NCT04997317|Active Comparator|Phase 0: Group B|"Cycle 1: 4.5 GBq 177Lu-DOTATOC (≈200 μg) will be administered once intravenously.~Cycle 2: 4.5 GBq 177Lu-DOTA-JR11 (300-1300 μg) will be administered once intravenously (following a cross-over design).~Cycle 3 and Cycle 4 will be performed for group B patients with 7.4 GBq 177Lu-DOTATOC (clinically established amount of activity). Cycle 3 and 4 are standard of care (i.e. not part of the study)."
9675449|NCT04997317|Active Comparator|Phase I/II|3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
9675450|NCT04997278|Experimental|Coordinated Reset- Spinal Cord Stimulation|All subjects will undergo spinal cord stimulation (SCS) implantation and will be optimized on standard SCS (sSCS) settings using the standard clinical protocol, including paresthesia mapping, threshold finding, and adjustment of stimulation parameters to provide reduction in pain. Therapeutic sSCS will be maintained for a minimum of one month prior to baseline assessment. Following a washout period of three hours assessments will be performed and Coordinated Reset- spinal cord stimulation (CR-SCS) will be enabled by means of a firmware upgrade. Personnel from Boston Scientific will perform this upgrade. The simulator will then be programmed to deliver CR-SCS. At the end of one month of CR-SCS (with stimulation parameters similarly held constant for the last 7 days), baseline assessment will be repeated after a three hour washout period. Finally, a firmware downgrade will be performed by Boston Scientific Personnel, and patients will be treated with sSCS at their previous settings.
9675451|NCT04996979|Placebo Comparator|Control|Only standard care
9675452|NCT04996979|Experimental|Intervention group|The PENG block was performed for intervention group with local anaesthetic solution composed of 20 ml of ropivacaine 0.5%.
9675453|NCT04997291|Experimental|Dexrazoxane|
9675454|NCT04997122|Experimental|Olive pomace oil|Intake of 45 g/d of olive pomace oil as the only source of oil in the diet
9675455|NCT04997122|Active Comparator|High-oleic sunflower oil|Intake of 45 g/d of high-oleic sunflower oil as the only source of oil in the diet
9675456|NCT04997434|Experimental|Intervention|After 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. The patient will have 15 to 20 minutes to carry out an artistic activity, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session.
9675457|NCT04997434|No Intervention|Control|The questionnaires and VAS will be offered to the control group at the beginning of the wait, then after 30 minutes of waiting under usual conditions.
9675458|NCT04997343|Experimental|MS patients|All MS patients will undergo clinical and neurophysiological evaluation at baseline (T0). The baseline will consider the radiological data of disease activity obtained from the most recently performed MRI according to clinical practice. These evaluations will be repeated according to clinical practice in patients taking DMT or every 6 months, in a stable condition or according to the indication of the treating neurologist in case of disease reactivation. A one-year neurophysiological, clinical and radiological observation is foreseen. Healthy subjects will undergo only the neurophysiological evaluation at baseline.
9675459|NCT04997343|Other|Healthy controls|Healthy subjects will undergo only the neurophysiological evaluation at baseline.
9675460|NCT04997213|Experimental|Interventional group|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and were individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
9695140|NCT04781504|Experimental|standard care + moderate-intensity continuous exercise training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 70-85% peak HR - 35min Cool-down: 60-70% peak HR - 15min
9975570|NCT00394355|Experimental|Group 2|MF DPI 200 mcg QD PM
9527555|NCT03218904|Experimental|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3-single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
9675461|NCT04997213|Active Comparator|Control group|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first were commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
9675462|NCT04997304|Experimental|AirDuo and ProAir|This trial includes using the inhaler (AirDuo®) Digihaler™ and rescue inhalers (ProAir®) Digihaler™.
9675463|NCT04997083|Experimental|cleft lip and palate patients|Cleft patients with transverse maxillary constriction and anteroposterior deficiency
9675464|NCT04997252|Experimental|high-risk and oligometastatic prostate cance|Neoadjuvant therapy with apalutamide in combination with luteinizing hormone-releasing hormone analogues
9675465|NCT04996953||165 patients with insomnia|
9675466|NCT04996966|Placebo Comparator|control|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
9675467|NCT04996966|Experimental|MSCs injection|In the MSCs injection group, 1×10^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
9675468|NCT04996615||high risk population|women at high risk of breast cancer undergoing enhanced MRI
10174170|NCT03856125|Experimental|PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
10174171|NCT03856125|Sham Comparator|Sham PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of sham percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
10174172|NCT03856073|Experimental|Novice|Anesthesiologists without experiment of manufacturing bronchoscopy.
10174173|NCT03855891|Experimental|Study group|A group of patients with blood tests
9675469|NCT04996992||Parkinson's disease|The cohort includes patients with Parkinson's disease who underwent MRgFUS pallidothalamic tractotomy (PTT).
9675470|NCT04996940|Experimental|Tobacco then Menthol|Current menthol smokers will be randomized to session order and complete a 30 minute ad libitum session with each product (tobacco e-cigarette and menthol e-cigarette).
9675471|NCT04996940|Experimental|Menthol then tobacco|Current menthol smokers will be randomized to session order and complete a 30 minute ad libitum session with each product (menthol e-cigarette and tobacco e-cigarette).
9675472|NCT04996576|Active Comparator|intranasal injection approach sphinopalatine ganglion block|Then in one nasal side (intranasal injection group) will be chosen randomly (right or left) by closed envelopes method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia and 2 ml saline will be injected in the same place in the other nasal side (to prevent surgeon expectation of intra nasal group by seeing injection site in one side only) by surgeon assistant who will be blind for the injection content.
9675473|NCT04996576|Active Comparator|infrazygomatic approach sphinopalatine ganglion block|"In the side saline only given by the intranasal injection A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
9675474|NCT04996745|Experimental|Intervention Group|Patients randomized to the intervention group of the RCT will be given tablet-based education. The first clinic follow-up visit will consist of screening for consent, providing a QR code for Orthokids, and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will be provided with the tablet for repeat education, with Orthokids and the post-intervention questionnaire will be distributed. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care.
9675475|NCT04996745|No Intervention|Control Group|"Patients randomized to the control group of the RCT will receive the standard clinic experience. This group will not be exposed to any education enrichment about their child's fracture except for the physician's explanation within the exam room.~The first clinic follow-up visit will consist of screening for consent and conducting the pre-intervention questionnaire. The pre-intervention questionnaire has two sections with questions pertaining to demographics and orthopedic knowledge. The second clinic follow-up visit will consist of conducting the post-intervention questionnaire. The post-intervention questionnaire has two sections with questions pertaining to orthopedic knowledge and satisfaction with care."
9675476|NCT04996550||Carvedilol group|Treated with Carvedilol
9675477|NCT04996550||Metoprolol succinate group|Treated with Metoprolol succinate
9675478|NCT04996849||Observational (data collection)|Patients undergo data collection every 6 months for up to 15 years.
9675479|NCT04996810|Experimental|PROTOXIN (Phase I/II)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
9675480|NCT04996810|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
9675481|NCT04996836|Experimental|BC diagnosis and Omics|"Participants will be offered:~Liquid biopsy of ctDNA and targeted NGS (BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, NF1, EPCAM, SMARCA4, CDK12);~Whole-genome RRBS"
9675482|NCT04996836|No Intervention|BC diagnosis and standard of the care|Participants will not be offered targeted NGS or whole-genome RRBS but will receive their usual clinical care
9975571|NCT00394355|Active Comparator|Group 3|Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)
10174174|NCT03855865|Experimental|Rapastinel|Rapastinel (450 mg prefilled syringe, weekly intravenous IV administration).
10174175|NCT03855865|Active Comparator|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
10174176|NCT03855865|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
10174177|NCT03855852|Active Comparator|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
9675483|NCT04996680|Experimental|Blood flow restriction group|patients in this group will undergo a standard strength training program combined with an occlusion cuff. The cuff will reduce the amount of blood flow and therefore increase the metabolic stimulus. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
9675484|NCT04996680|Sham Comparator|Sham group|patients in this group will undergo the same standard strength training program as the BFR-group, combined with an occlusion cuff but pressurized so there is no significant effect on the lower limb blood flow. The cuff will be used only during one quadriceps exercise, 2 times a week for 12 weeks.
9675485|NCT04996680|Active Comparator|Control group|patients in this group will undergo the same standard strength training program as the BFR-group and placebo-group, but without a tourniquet.
9675486|NCT04996784||Normal weight|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI).The normal weight group will contain 15 patients with a 18.5 ≤ BMI ≤ 25 kg/m2.~Each group will be divided in two subgroups (female/ male)"
9675487|NCT04996784||Obese|"The patients (n=30) will be stratified into 2 groups based on their body mass Index (BMI). The obese group will contain 15 patients with a BMI ≥ 30 kg/m2.~Each group will be divided in two subgroups (female/ male)"
9675488|NCT04996524|Experimental|epidural analgesia group|
9675489|NCT04996524|No Intervention|systemic analgesia group|
9675490|NCT04996914|Experimental|TACE+SBRT.|If a patient is eligible to participate in the project according to the in- and exclusion criteria, the patient will assigned to 1-2 sessions of TACE followed by SBRT within one month from last TACE session .
10174178|NCT03855852|Experimental|Xenograft and A-PRF|Placing the implant with xenograft and A-PRF at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
9675491|NCT04996667|Active Comparator|Interventional Radiology Arm (Invasive Cohort)|"Interventional radiology (IR) will perform a right heart catheterization (RHC) as part of a planned IR procedure.~Bedside apical 4 chamber view (RV:LV ratio) will be recorded using an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform.~The Butterfly iQ+ (one possible ultrasound device which may be used) is a single-probe, whole-body ultrasound device.~After initial measurements, inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The same measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
10174179|NCT03855839||Healthy participants|Participants will be ask to perform a repetitive upper limb task while posture is being monitored.This will be done while wearing a posture shirt, compression shirt or no shirt.
10174180|NCT03855761|Experimental|Intervention group|Experimental Occupational Therapy services
9675492|NCT04996667|Active Comparator|Non-intervention Arm (Non-invasive Cohort)|Vitals including O2 amount and modality, blood pressure, pressor name, dose, and rate will be recorded. If the patient is intubated, the name, dose, and rate of sedation and analgesia will be recorded. If the patient is not intubated, name and dose amount of sedation will be recorded. Arterial blood gas will be obtained if an A-line is placed. Bedside apical 4 chamber view will be recorded (RV:LV ratio) with an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. This data will be obtained before, during iNO administration, and after iNO has been withheld for 2 minutes.
9675493|NCT04996563|Experimental|Video|A brief educational video on POP will be sent electronically to participants randomized to the video group. Participants will view the video within one week prior to their consultation visit.
10174181|NCT03855761|Active Comparator|Comparison group|Treatment as usual
9975572|NCT00394355|Active Comparator|Group 4|ML 10 mg QD PM
9975573|NCT00359216|Experimental|Mometasone furoate nasal spray|
9675494|NCT04996563|No Intervention|No video|Participants assigned to this group will not be sent the educational video to view.
9675495|NCT04996602|Experimental|1.85GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
9675496|NCT04996602|Experimental|7.40GBq of 177Lu-PSMA-617|The patients were intravenously injected with the dose about 7.40GBq (200 mCi) of 177Lu-PSMA-617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
9975574|NCT00359216|Placebo Comparator|Placebo nasal spray|
9675497|NCT04996589||Lean subjects|BMI 18.5-22
9675498|NCT04996589||Obese subjects|BMI>30
9675499|NCT04996732||All Cancers|subgroups according to cancer sites
9527556|NCT03219229||Prepubertal children|Healthy 7-11 year old girls and boys.
9675500|NCT04996459||Tislelizumab group|
9675501|NCT04996485|Experimental|Experimental group №1 (Secukinumab )|Secukinumab - subcutaneous injections into the shoulder according to the schedule of 0,1,2,3 weeks, then injections 1 time in 3 months up to 52 weeks of therapy.
9675502|NCT04996485|Experimental|Experimental group №2 (Ustekinumab)|Ustekinumab - subcutaneous injections in the shoulder on schedule 0; 1 month, then every 2 months up to 52 weeks of therapy.
9675503|NCT04996485|Experimental|Experimental group №3 (Dupilumab)|"Dupilumab - subcutaneous injections in the shoulder:~for patients weighing from 15 to <30 kg: initial dose - 600 mg (2 injections of 300 mg), then 300 mg every 4 weeks; for patients weighing from 30 to <60 kg: initial dose - 400 mg (2 injections of 200 mg), then 200 mg every 2 weeks; for patients weighing 60 kg or more: the initial dose is 600 mg (2 injections of 300 mg), then 300 mg every 2 weeks."
9675504|NCT04996485|Active Comparator|Control group (Symptomatic therapy)|symptomatic therapy with emollients + systemic retinoids
9695141|NCT04781504|Experimental|standard care + high-intensity interval training|2 days/week Warm-up: 60-70% peak HR - 10min Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals) Cool-down: 60-70% peak HR - 10min
9975575|NCT00189280|Experimental|imiqimod 5% cream|
9975576|NCT00166504|Experimental|Vytorin|Ezetimibe 10 mg/Simvastatin 20 mg
9975577|NCT00166504|Active Comparator|Atorvastatin|Atorvastatin 10 mg
10187103|NCT03729505|Active Comparator|Pyloric injection of magnesium sulfate and lidocaine mixture|After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine
9675505|NCT04996433|Experimental|Cognitive Behavioral Analysis System of Psychotherapy (CBASP)|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
9675506|NCT04996433|Active Comparator|Behavioral Activation (BA)|Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
9675507|NCT04996290|Active Comparator|PENG + LFCN block|"The participants in this group received a combined regional technique just before surgery:~Pericapsular nerve group (PENG) block~Lateral femoral cutaneus nerve (LFCN) block"
9675508|NCT04996290|No Intervention|No regional anesthesia|Control group
9675509|NCT04996888|Experimental|with AI preoperative automatic reminder system|After receiving regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions, the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time.
9675510|NCT04996888|No Intervention|without AI preoperative automatic reminder system|The patients in the control group accept colonoscopy routinely without AI based preoperative automatic reminder system. All patients will receive regular instructions at the time of their appointment to discuss colonoscopy and education about colonoscopy provided by one nurse, including the importance of bowel preparation, the side effects of the agents used, and the exact preparation instructions.
9675511|NCT04996472|Experimental|Sensitivity to phonological rules: Adults|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern
9675512|NCT04996472|Experimental|Sensitivity to semantic category cues: Adults|Arm 1. Referential cue during OR learning.
10174182|NCT03855800|Experimental|Clinical Follow-up|"Participants not undergoing surgery will be assigned to the Clinical Follow-up study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. All participants in the Clinical Follow-up group will be contacted yearly for a telephone interview until they undergo surgery, die, receive a diagnosis that excludes them from the study, or for 3 years, and interval medical records will be obtained and reviewed. During follow-up results of clinically indicated follow-up imaging studies will be abstracted"
9675513|NCT04996511|Experimental|Colorectal Surgery Patients|
9675514|NCT04996537|Experimental|Micro-video with pressure injury(PI) education|"The experimental group's flipped education and training courses adopt a digital learning method and provide a digital learning platform. Log in according to personal account and password, and learn the curriculum units planned by the researcher in order: Prevention and management of stressful injury care as the main axis, enter the digital platform The provided video audio-visual digital teaching materials, combined with clinical situational learning, are equipped with basic knowledge learning, in-class test questions, and unit review, and can open courses for self-study anytime and anywhere, regardless of time and space constraints."
9675515|NCT04996537|Active Comparator|NIS with PI education|At the login interface of the Nursing Information System (NIS) used by the nursing staff daily, a link to the lecture notes (PDF file) of the course on prevention of stress injury is attached, and the nursing staff can view or download them according to their needs. Learn. At the same time, it provides a digital learning platform to download the self-study course handouts (PDF files) and complete the basic demography, pre-test, and post-test data on the platform.
9675516|NCT04996303|Other|Routine|Routine steroid administration group
9675517|NCT04996303|Other|Pulse|Steroid pulse therapy group
9675518|NCT04996186||Patients enrolled|Patients with Multiple sclerosis, with an age older than 18 years old and symptoms of fecal incontinence or chronic constipation
9675519|NCT04996225|Experimental|Group (A): (study group)|Group (A): (study group) 15 patients received aerobics exercises and balancing exercises in addition to relaxation exercises for 4 weeks, 3sessions/week.
9675520|NCT04996225|Placebo Comparator|Group (B): (Control group)|2-Group (B): (Control group) 15 patients received relaxation exercises in the form of physical relaxation exercise for 4 weeks, 3 sessions/week. the participants who received aerobics exercises and balancing exercises in addition to relaxation exercises (experimental group A), showed significant decrease in anxiety and dizziness more than (placebo group B)
9675521|NCT04996277|Experimental|Fractional Flow Reserve|Patients with FFR ≤ 0.8 will undergo PCI Patients with FFR > 0.8 will be treated with medication For study purposes, all patients will undergo OCT (subject's treatment strategy will be based on FFR results, e.g., stent-implanted OCT).
10174183|NCT03855800|Other|Surgical|"Participants scheduled for surgical resection after their initial clinical evaluation will be assigned to the Immediate Surgery study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. Participants in the Immediate Surgery group will be followed until the surgical pathology of their pancreatic cyst is known."
10174184|NCT03855488|Experimental|Standard cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively
9675522|NCT04996277|Experimental|Optical CoherenceTomography|Patients with MLA < 4.5mm² will undergo PCI Other patients will be treated with medication For study purposes, all patients will undergo FFR (subject's treatment strategy is based on OCT results; reference to FFR results is not recommended)
9675523|NCT04996277|Experimental|angiography|Appropriate treatment (implantation of stents) will be given according to the evaluation of the physician.
9675524|NCT04996420|Experimental|Clearsight|hemodynamic monitoring and goal directed fluid therapy guided by clearsight
9975578|NCT00101972|Experimental|RAV12|
9975579|NCT00017953|Experimental|Lifestyle Intervention|Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.
9975580|NCT00017953|Active Comparator|Diabetes Support and Education|The diabetes support and education arm provides group sessions on diabetes management and social support.
9975581|NCT01342978||oropharyngeal cancer case|208 oropharyngeal cancer cases were enrolled
10174185|NCT03855488|Experimental|Imagery enhanced cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively while engaging in imagery
9675525|NCT04996420|Other|Control|hemodynamic monitoring blinded and silenced, no goal directed fluid therapy. Fluid therapy based on clinical evaluation and mean arterial pressure by non-invasive monitoring
9675526|NCT04996251|Experimental|subcutaneous infiltration pre-incision|Marcaine (bupivacaine) injected in the umbilical port site subcutaneously, while in the other 4 sites injection under direct visualization
9675527|NCT04996251|Experimental|subcutaneous infiltration post-incision|local anesthetic infiltrated subcutaneously at the end of the procedure after trocar removal and after skin closure with suture
9675528|NCT04996498|Active Comparator|Group A (Oxytocin group):|30 women will undergo a hysteroscopic myomectomy with the use of 10 IU of oxytocin for every 1000 ml of the distending medium (1,5% Glycine ).
9675529|NCT04996498|Placebo Comparator|Group B (Placebo group):|30 women will undergo hysteroscopic myomectomy with the use of a sterile bacteriostatic water ampule in the distending medium (1,5% glycine).
9675530|NCT04996407|Active Comparator|survival thermal blanket|Patient will be using survival thermal blanket as substitute for perforated blanket with forced air warmer during anesthesia
9675531|NCT04996407|Active Comparator|draping fabric|Patient will be using draping fabrics as substitute for perforated blanket with forced air warmer during anesthesia
9675532|NCT04996446|Experimental|Alpps plus Tislelizumab group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
9675533|NCT04996446|Active Comparator|Alpps group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
9675534|NCT04996329|Experimental|comprehensive smoking cessation intervention group|Early health warning intervention combined with brief smoking cessation intervention Early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD
9675535|NCT04996329|Active Comparator|brief smoking cessation intervention group|brief smoking cessation intervention only
9675536|NCT04996121|Experimental|XZP-5955 tablets|XZP-5955 tablets
9675537|NCT04995991|Experimental|RRT rhythm only|10 RRT rhythm only sessions of 60 minutes, twice a week under the supervision of a trainer
10174186|NCT03855488|Placebo Comparator|Neutral Control Condition|Listen to descriptions of neutral scenarios
9675538|NCT04995991|Experimental|RRT rhythm + visual cue|10 RRT rhythm + visual cue sessions of 60 minutes, twice a week under the supervision of a trainer
9675539|NCT04995991|No Intervention|No intervention|5 weeks no intervention period
9675540|NCT04996238|Other|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid will be collected just before the first vaccination (T1: pre-vaccination) and between 14 and 30 days after the second vaccination (T2: post-vaccination)
10174187|NCT03855826|Experimental|Nifekalant Hydrochloride|Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.
10174188|NCT03855826|Active Comparator|Amiodarone|The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
9675541|NCT04996108||Participants with recurrent pericarditis (RP)|Patients aged 16 or over with (1) RP, diagnosed by a clinician, meeting the European Society of Cardiology (ESC) diagnostic criteria, and (2) where the aetiology of the RP is defined as idiopathic (i.e. there is no other aetiology identified, such as infective, malignant, post cardiac injury, as part of an autoimmune condition, as part of another known auto-inflammatory disease).
9675542|NCT04996108||Participants with systemic auto-inflammatory diseases (disease controls)|Patients aged 16 or over with a systemic auto-inflammatory disease, diagnosed by a trained specialist.
9675543|NCT04996108||Healthy volunteers (healthy controls)|Sex, ethnicity and aged matched healthy individuals who do not have a personal history of pericarditis or systemic auto-inflammatory disease.
9675544|NCT04996108||Relatives of individuals with recurrent pericarditis (familial controls)|First degree relatives of participants meeting the criteria for, and included in the study as, RP cases, who are aged 16 or over.
9695142|NCT04781582|Active Comparator|Lung volume reduction surgery arm|Bilateral videothoracoscopic lung volume reduction surgery by wedge resection. Unilateral procedures are possible in case of severe adhesions or intraoperative instability. In these cases a staged approach with contralateral LVRS within 3 months is possible.
9695143|NCT04781582|Active Comparator|Bronchoscopic lung volume reduction arm|Primarily unilateral bronchoscopic lung volume reduction by endobronchial valves. If a bilateral procedure is feasible it must be performed within 3 months after the first intervention.
9695144|NCT04781374|Experimental|Neratinib|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.~- Neratinib-once daily with 28 consecutive days defined as a treatment cycle"
9695145|NCT04781361||Isotonic fluid|"Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:~Dextrose 5% in 0.9% NaCl,~Intravenous fluid containing NaCl between 131 to 154 mmol/L"
9527557|NCT03219138|No Intervention|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
9527558|NCT03219138|Experimental|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
9695146|NCT04781361||Hypotonic fluid|"Group, received hypotonic maintenance fluid containing NaCl < 130 mmol/L such as:~Dextrose 5 % in 0.02 % NaCl,~Dextrose 5% in 0.033 % NaCl~Dextrose 5% in 0.045 % NaCl~Intravenous fluid containing NaCl < 130 mmol/L"
9695147|NCT04781348|Experimental|Platelet Rich Plasma plus fat grafting|Group will receive Platelet Rich Plasma plus fat grafting
9695148|NCT04781348|Experimental|Fat grafting|Group will receive only fat grafting
9975582|NCT01342978||partner or spouse of case|110 partners of patients with oropharyngeal cancer were enrolled
9675545|NCT04995913|Experimental|Computer-based (PC) online CBT program (Web version of the EASE Online Program)|The Web version of the EASE Online Program delivers the online CBT program through the Program website. It includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy.
9675546|NCT04995913|Experimental|Smartphone-based (App) online CBT program (App version of the EASE Online Program)|The App version of the EASE Online Program delivers the online CBT program through a smartphone application. The program content and system functions are the same as those of the Web version.
9675547|NCT04995913|Other|Waitlist control group|The Waitlist control group will receive the service of the Web version of the EASE Online Program after the two experimental groups completed the service.
9675548|NCT04995744|Other|Patients with closed Neer type 4 proximal humerus fractures|patients aged 50-75 years with closed Neer type 4 proximal humerus fractures
9675549|NCT04995822||EUROSTEM femoral stem|All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)
9675550|NCT04995861|Active Comparator|Group A (adductor canal only)|Will recieve adductor canal block only
9675551|NCT04995861|Active Comparator|Group AB (adductor canal + IPACK)|Will recieve both adductor canal block and IPACK
9675552|NCT04995848|Experimental|Telepalliation group|"The intervention group will participate in the telepalliation program. The patients will lent a tablet during the RCT study to access the TelePal.dk platform an video consultations. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:~They stop being followed by the Palliative Team due to lack of symptoms~They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:~The project nurse or the clinical responsible doctor at the patients' home OR~A district nurse under video supervision by the project nurse or the clinical responsible doctor~Death of the patient"
9675553|NCT04995848|No Intervention|Conventional palliation program|"The control group will follow a conventional palliation program. The patients will participate from the time they are referred to palliative care, and are enrolled in the telepalliation program for up to six months or until:~They stop being followed by the Palliative Team due to lack of symptoms~They are diagnosed with delirium based upon clinical guidelines and the Confusion Assessment Method (CAM). The assessment of delirium will be done by either:~The project nurse or the clinical responsible doctor at the patients' home OR~A district nurse under video supervision by the project nurse or the clinical responsible doctor~Death of the patient"
9675554|NCT04995731||Women with pre or peri-menopausal abnormal uterine bleeding or post menopausal bleeding|Eligible women presenting to Women's Health hospital with pre or peri-menopausal AUB or PMB will be prospectively enrolled after obtaining their informed consent. AUB will be deﬁned by symptoms of heavy menstrual bleeding, inter-menstrual bleeding, meno-metrorrhagia, irregular menses, or other AUB among women aged ≥40 years who are not in menopause. Peri-menopausal bleeding will be defined as vaginal bleeding after 6 months of menopause after the age of 40 years. Postmenopausal status will be defined as the absence of menstruation for at least 12 months after the age of 40 years, where any pathological condition of amenorrhea is excluded.
9675555|NCT04995809||EPRIMM study participants|
9975583|NCT01342978||control|A convenience group of 106 non-cancer controls were enrolled at some study sites at cancer screening events
10174189|NCT03855475|Experimental|Aerobic exercise|Exercise training
9975584|NCT01342991|Active Comparator|Milligan-Morgan Haemorrhoidectomy|Control arm
9675558|NCT04996160|Experimental|Cohort 1 -(without Ph+ / Ph like mutation)|Dose expansion phase-10 subjects in Cohort 1, 100 mg/m2/daily palbociclib on Days 1 to 5; 11 to 15; and 21 to 30, in combination with chemotherapy. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17.
9975585|NCT01342991|Experimental|Laser Haemorrhoidectomy|This new method of haemorrhoidectomy is being compared to the standard Milligan-Morgan Haemorrhoidectomy.
10174190|NCT03855475|Active Comparator|Stretching|Control
10174191|NCT03855787|Active Comparator|Ureteral stent group|A ureteral stent will be placed after ureteroscopy.
10174192|NCT03855787|Active Comparator|No ureteral stent group|A ureteral stent will not be placed after ureteroscopy.
10174193|NCT03855553|Experimental|FBT|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
9977526|NCT01362556|Active Comparator|Sodium Bicarbonate|Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
10174194|NCT03855553|Experimental|CBT-E|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
10174195|NCT03855644||Pelvic fracture patients|(1) 1<Age<80, and Chinese residents living in China more than 3 years; (2) Hemoglobin value less than 100g/L during hospitalization; Not suffered from pelvic fracture within 3 months; Not suffer from pathological fractures of the pelvis caused by malignant tumors; without chronic anemia and coagulopathy; accept blood transfusion
10174196|NCT03855540||Study group|Adult patients with documented paroxysmal, nonvalvular atrial fibrillation with CHA2DS2-VASc score > 2 (for females > 3) and sinus rhythm at the time of inclusion. In total 100 patients will be included.
10174197|NCT03855540||Control group|"Patients without a history of palpitations or irregular heart rhythm. AFib will be excluded with the help of 7 days ECG Holter and ECG event recorder monitoring. In total 100 patients will be included.~Propensity matching according to the:~CHA2DS2-VASc parameters~LVEF: preserved (<40%), mid-range (40-49%) and reduced (>50%)~Presence of diastolic dysfunction~Glomerular filtration rate: (≥1,5 ml/s), (1,4-1 ml/s) and (0,9-0,5 ml/s)~Drugs: ACE-I/ARB, betablockers, digoxin, amiodarone~BMI: (<30kg/m2), (30-39kg/m2) and (≥40kg/m2)~Smoking (>5 cigarettes per day)"
10174198|NCT03855631||Kabuki syndrome/ unaffected parents|Intervention on primary cultured cells from 4 patients with KS and sex match parents
10174199|NCT03855683|Experimental|Group therapy (Unified Protocol)|Participants experiencing stress, anxious, and/or depressive symptoms will receive 8 sessions of Unified Protocol for Emotional Disorders lasting for 90 minutes each. Includes psycho-education about (mal)adaptive emotion regulation, cognitive and behavioral tools to reduce symptoms of stress, anxiety, and/or depression.
9675559|NCT04996160|Experimental|Cohort 2-(Ph+ / Ph like ALL subtypes):|Dose escalation phase- 12 subjects in Cohort 2, Palbociclib dose escalation will begin at 75 mg/m2/day, on Days 1 to 5; 11 to 15; and 21 to 30, and escalate or de escalate. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17. Subjects with Ph+ / Ph-like mutation will receive a tyrosine kinase inhibitor (TKI or KI, either dasatinib or ruxolitinib).3 on 3 dose escalation with 2 dose levels.
9675560|NCT04995770|Experimental|Praise Text Messages|"The text message praise intervention lasted for 6 months. Each week, transplant coordinators, masked from who enrolled in the study or to which condition participants were randomized, prepared a list of all patients in the study age group whose laboratory blood tests indicated that immunosuppressant medications were within the expected range. A researcher reviewed the list to identify whether any of patients were currently assigned to the intervention, and if so, sent text message praise via REDCap's text message function. We rotated through 14 standardized text messages each week. Examples of messages included: Your labs look very good. Super job taking your meds! and Your labs look great! Thanks for putting in the effort to take care of your health!."
9675561|NCT04995770|No Intervention|Usual Care|Participants in the usual care arm did not receive any praise text messages. All participants continued to receive usual care from the multidisciplinary liver transplant team, including phone calls and follow-up care when laboratory blood tests indicated that immunosuppressant medications were outside of the expected range.
9675562|NCT04996017|Experimental|Arm A|atezolizumab 1200mg every 21 days
10174200|NCT03855462|Experimental|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with silicon oil medium-chain triglycerides (MCT) as tamponade agent :~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~MCT ablation after 4 to 6 weeks (after effective retinopexy)"
10174201|NCT03855813|Other|Test-retest reliability|Patients with knee osteoarthritis will perform the 30 seconds chair stand test as a self test twice at home to evaluate intra rater reliability. Same patients will be tested with the same performance test by a physical therapist to evaluate the inter rater reliability.
9675563|NCT04996017|Placebo Comparator|Arm B|Placebo will be supplied by the sponsor and will be identical in appearance to atezolizumab and will comprise the same excipients but without atezolizumab every 21 days
10174202|NCT03855657||Inflammatory Bowel Disease Patient|Patient with confirmed diagnosis of Inflammatory Bowel Disease
10174203|NCT03855657||Healthy control|Controls (non-IBD) will comprise individuals undergoing colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms, and friends and spouses or partners of patients at Prince of Wales Hospital or Alice Ho Miu Ling Nethersole Hospital, or any individuals who are interested to participate in this study.
9675564|NCT04995783||Ulcerative Colitis|
9675565|NCT04995783||Crohn's Disease|
9675566|NCT04995783||Rheumatoid Arthritis|
9675567|NCT04995783||Psoriasis|
10174204|NCT03855657||Healthy relatives of Inflammatory Bowel Disease patient|Relatives or household members of both patients with IBD or other diseases and controls will be recruited.
10174205|NCT03855501|Active Comparator|Mineral trioxide aggregate|The root canals were gently instrumented with K-files and copious irrigation was done with 2.5% sodium hypochlorite(NaOCI) by means of a 30 gauge endodontic irrigating needle . After drying with large sterile paper points, calcium hydroxide(CH) paste was mixed with saline and applied to the root canal with a lentulo spiral filler at low speed. A cotton pellet was used to gently compress CH into the root canal and its placement was examined radiographically before placing ZOE as temporary restoration into the access cavity. After one week, CH was removed from the canal by using both the files and the irrigation with 2.5% NaOCI and 17% ethylenediaminetetraacetic acid (EDTA). A final irrigation was made with 2% chlorhexidine (CHX) before obturation. Following drying the root canal with sterile paper points, MTA was placed with a MTA Endo Gun into the apical portion of canals with a minimum 4-mm thickness and adapted to the canal walls with an endodontic hand plugger.
10174206|NCT03855501|Active Comparator|Calcium hydroxide|After using the same biomechanical root canal preparation protocol, the root canal was filled to working length with CH paste. Both clinical and radiographical examinations were performed to evaluate the barrier formation and periapical healing. When a continuous hard tissue barrier was observed apically on radiographs that was verified by clinical probing and complete or significant periapical healing was noticed, the root canal was obturated and coronary restorations were completed as done in MTA group
10174207|NCT03855566|Other|Intervention|Enrolled participants will receive the intervention.
9675568|NCT04995783||Control|
9675569|NCT04995757|Experimental|MicroPort NeuroTech Stentretriever|
10174208|NCT03855722|Experimental|RIPC|RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
9675570|NCT04995757|Active Comparator|Solitaire FR|
9675571|NCT04995926|Experimental|Labial mucosa epithelium grafting for corneal limbus substitution.|Surgery for treating limbal stem cell deficiency using a strip of the lip oral mucosa with trimmed off the substantia propria and grafted as a circular corneal limbus substitute.
9675572|NCT04995705|Experimental|Experimental Group Based ACT|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. This consisted of 2.5 hour sessions over 5 consecutive weeks.
9675573|NCT04995705|Active Comparator|Waitlist Control Group -|Stroke survivors and individuals with brain injury were randomised into an adapted acceptance and commitment therapy (ACT) group-based intervention. Participants within the waitlist control arm of the study had to wait six weeks before they were offered the same intervention as the intervention arm. They received treatment as usual.
9675574|NCT04995952|Experimental|Gross motor training activity|Gross motor training activity It includes training of motor components of child grossly
9675575|NCT04995952|Experimental|Trunk targeted training|In this training group the particpiants were given the exercises that were focused the truck muscles
9675576|NCT04995653|Experimental|Cohort 1 - Open Label Study|Vancomycin & SER-155
10174209|NCT03855722|Sham Comparator|Sham-RIPC|Sham-RIPC will consist of setting a tourniquet to donor thigh without inflating it and keeping it in place for 35 min. Sham-RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
10174210|NCT03855774|Other|Polymorphisms|Classification of sleep disorders prevalence through polymorphisms
9675577|NCT04995653|Experimental|Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study|Vancomycin & SER-155 OR Vancomycin placebo & SER-155 placebo
9675578|NCT04995718|Experimental|IPET: Intelligent physical exercise training during working hours|Workplace physical exercise
9675579|NCT04996394||NMBAs|
10174211|NCT03855514|Active Comparator|NuShield|NuShield® is a sterile, dehydrated placental allograft
10174212|NCT03855514|No Intervention|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
9675580|NCT04995666|Experimental|Hearing Aid|Participants will wear Phonak rechargeable Audeo hearing aids
9675581|NCT04995679|Other|Patient whit osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery with metaphyseal sleeves
9675582|NCT04996082||Systemic sclerosis group|Patients with systemic sclerosis
9675583|NCT04996082||No Systemic sclerosis group|Patients without systemic sclerosis
9675584|NCT04995250|Experimental|Corrective exercise training for knee Osteoarthritis|
10174213|NCT03855579|Experimental|Levosimendan|Intraoperative infusion of Levosimendan
10174214|NCT03855579|Active Comparator|Milrinone|Intraoperative infusion of Milrinone
9675585|NCT04995302|Active Comparator|Microneedling and Amnion Bilayer|Microneedling is a dermaroller procedure that uses small needles to prick the skin. Amnion bilayer is used as an additional therapy after microneedling therapy.
9675586|NCT04995302|Placebo Comparator|Microneedling|Microneedling is a dermaroller procedure that uses small needles to prick the skin.
9675587|NCT04995627|Active Comparator|Salt (NaCl)|"12 grams (12 capsules) of NaCl per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
9675588|NCT04995627|Placebo Comparator|Placebo|"12 capsules of placebo per day~Note: participants will be treated with active and placebo comparator (N-of-1 trial design)"
9675589|NCT04995562|Experimental|Oxygen with nasal cannula|6 infants on oxygen with nasal cannula
9675590|NCT04995562|Experimental|HFNC, CPAP, or RAM cannula|6 infants currently requiring respiratory support with high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) or RAM cannula
9675591|NCT04995471|Experimental|In presence RRT - prototype software|10 biweekly in presence sessions of 45 minutes supervised by a trainer
9675592|NCT04995471|Experimental|In presence RRT - online platform|10 biweekly in presence sessions of 45 minutes supervised by a trainer
9675593|NCT04995471|Experimental|Tele-RRT - prototype software|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
9675594|NCT04995471|Experimental|Tele-RRT - online platform|10 biweekly telerehabilitation sessions of 45 minutes supervised by a trainer
9675595|NCT04995471|No Intervention|No intervention|5 weeks no intervention period
9675596|NCT04995601|No Intervention|Standard of Care|Participants will receive DVT prophylaxis using standard intermittent pneumatic compression during postoperative care after total joint replacement.
9675597|NCT04995601|Experimental|Recovery Force MAC|Participants will receive DVT prophylaxis using the RF Health MAC during postoperative care after total joint replacement.
9675598|NCT04995367|Experimental|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke|The participants will carry out tests for the evaluation of the functionality of the BCI system integrated to the T-FLEX device. The test consists of 1 session that includes four conditional experiments. Real Movement, Continuous Stationary Therapy, Motor Imagery Detection with Visual Stimulation, and Motor Imagery Detection with Tactile Stimulation.
9675599|NCT04995354|Experimental|EGF loaded Hydrogel (Gp I)|30 patients will receive EGF loaded Hydrogel (Intervention 1) to be applied three times a day for 1weeks.
9675600|NCT04995354|Active Comparator|Hydrogel alone ( Gp II)|30 patients will receive Hydrogel alone (Intervention 2) to be applied three times a day for 2 weeks.
9675601|NCT04995354|No Intervention|Control (Gp III)|30 patients will receive the standard of care treatment (Control) which includes benzydamine mouthwash, increased hydration, topical analgesics and antifungals.
9675602|NCT04995263|No Intervention|Pre-intervention, control group|A basal measurement of primary and secondary outcomes of the target population, prior to the implementation the intervention. Estimated duration 3 months, n = 30.
9675603|NCT04995263|Experimental|Post-intervention, SUEÑA half bundle, active group 1|"Post-intervention, environmental and behavioral modifications in patient care interventions.~Implementation of components 1 through 4 of SUEÑA intervention in the entire PICU unit. All participants will be exposed to the intervention. Estimated duration: 3 months, n = 30."
9675604|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA half bundle plus, active group 2|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment.~Participants will be randomized to receive SUEÑA components 1 through 5 Estimated duration: 6 months, n = 30"
9977527|NCT01362569||predialytic renal insufficiency|Patents without renal replacement therapy
9977528|NCT01362569||hemodialysis/hemofiltration patients|patients undergoing regular hemodialysis/hemofiltration
10174215|NCT03855423|Experimental|Tocotrienol-rich Fraction (TRF)|Pre-operative patients will be receiving TRF at different doses assigned to them in a cohort of 3 patients at each level.
10187104|NCT03729505|Active Comparator|Pyloric injection of saline|After sleeve gastrectomy, the pylorus is injected with normal saline
10187105|NCT03729492|Other|CTEPH/CTED work-up|
10187106|NCT03729479|Experimental|Experimental: DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
9675605|NCT04995263|Experimental|Post-intervention, randomization for SUEÑA full bundle, active group 3|"Randomization for full SUEÑA bundle: environmental and behavioral modifications in patient care interventions plus sleep informed treatment and personalized psychoeducation.~. Participants will be randomized to receive SUEÑA components 1 through 6. Estimated duration: 6 months, n = 30"
9675606|NCT04995549|Experimental|Measures using Cutiscan® CS 100|
9675607|NCT04995458|Experimental|Composite-ceramic|To assess the clinical performance and survival of posterior composite-ceramic implant-supported crowns
9675608|NCT04995458|Active Comparator|Monolithic zirconia|To assess the clinical performance and survival of posterior monolitihic zirconia implant-supported crowns
9675609|NCT04995328|Experimental|Radiation Care Gel application|Radiation Care® gel is instructed to use on the target skin area accepted radiation therapy twice daily.
9675610|NCT04995497|Experimental|Erector Spinae Plane Block-Administration of Lidocaine|Bilateral ultrasound guided erector spinae plane catheter placement for the administration of lidocaine. Dose will be 2 mg/kg ideal body weight. Bolus will be divided equally between the two ESP catheters. This is followed by lidocaine infusion via ESP catheter at 2 mg/kg/hr for 48 hours after catheter placement.
9675611|NCT04995497|Active Comparator|Intravenous-Administration of Lidocaine|Sham block procedure (catheter will be taped to subjects skin). Subject will receive a bolus of lidocaine at 2 mg/kg ideal body weight. This is followed by lidocaine infusion via intravenous route at 2 mg/kg/hr for 48 hours after sham catheter placement.
10174216|NCT03855410|Experimental|S4E App intervention|Participants in the S4E group will receive the tobacco modules via iPads in a private room. The intervention will last approximately 20 minutes. Content includes the theoretically driven components of S4E: (a)Storytelling scenarios, (b) an introduction video, tobacco use knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent tobacco use, (e) clinician-youth communication, and (f) highlighting prevention principles. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
10174217|NCT03855410|Experimental|Attention-Matched Control|Participants in the Attention-Matched Control group will receive a portable document format (PDF) version of the tobacco module content, an enhancement to the care they would receive should they not join the study. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
9675612|NCT04995640||CILCA patients|Subject with a CILCA and a thoracic cardiovascular disease requiring treatment. Both open cardiovascular repair and endovascular treatment (TEVAR) will be included.
10174218|NCT03855527|Experimental|Silver Diamine Fluoride (SDF) group|Atraumatic restorative technique will be performed. Then the cavities will be dried with a gentle flow of compressed air. One drop of silver diamine fluoride (Advantage Arrest Silver Diamine Fluoride 38% - Bottle) will be dispensed into a dappen dish. A micro brush will be bent, dipped into SDF and dabbed on the side of the dappen dish to remove excess liquid before application. SDF will be applied directly to affected tooth surface and dried with gentle flow of compressed air for 1 minute. Excess SDF will be removed with cotton roll. Teeth will be restored with glass ionomer cement (GC Fuji IX).
10174219|NCT03855527|Active Comparator|Chlorhexidine group|Atraumatic restorative treatment will be performed. Then, the cavities will be disinfected by placing a cotton pellet soaked in chlorhexidine solution (Consepsis®2% Chlorhexidine Antibacterial Solution) for 1 minute, air dried and restored using glass ionomer cement.
10174220|NCT03855527|Sham Comparator|Atraumatic Restorative Treatment without Disinfection|Cavities will be cleaned according to the ART approach.The cavity will be enlarged if needed using sterile hatchet.The carious dentin will be removed with excavators starting at the enamel-dentine junction. The unsupported thin enamel will be fractured off with the hatchet. The caries will be removed carefully until firm dentin is reached (physically resistant to hand excavation). The cavity will be cleaned with wet cotton pellets. Cavities will be restored immediately using conventional glass ionomer cement. All the cavities in the 3 groups will be temporary restored with glass ionomer cement handled according to manufacturer's instructions, however acid etching will not be carried out in order to make sample collection easier following the experimental period.
10187970|NCT03720808|Experimental|Coughing|Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
9675613|NCT04995575||all MINDACT patients who relapse|
9675614|NCT04995393|Active Comparator|Glove|A heated glove containing water.
9675615|NCT04995393|Active Comparator|Blanket|A heated blanket.
9675616|NCT04995393|Active Comparator|Gel pack|A heated gel pack.
9675617|NCT04995172||Observational (CT-assisted bronchoscopy, chart review)|Patients undergo RP-EBUS bronchoscopy per standard of care. If the study staff cannot reach the target lesion or is unable to determine a diagnosis, patients undergo bronchoscopy using mobile CT imaging. Patients' medical records are also reviewed for up to 6 months.
9675618|NCT04995146||Retrospective 3 months cohort (admitted stroke patients)|
9675619|NCT04995146||"Prospective pre-implementation standard of core care quality measures cohort"|
9675620|NCT04995146||"Prospective post-implementation standard of core care quality measures cohort"|
9675621|NCT04995133|Experimental|Colistin Arm|Intravenous administration of 6.75 x 106 Units Colistin for 30 minutes
9675622|NCT04995159|Experimental|Poststent SAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with SAPT strategy
9675623|NCT04995159|Active Comparator|Poststent DAPT treatment cohort|receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with DAPT strategy
9675624|NCT04994847||APOE Unimpaired Observational Trial|300 participants who are cognitively unimpaired; Yearly procedures: blood draw Every Two Year Procedures: cognitive and clinical assessments, CSF collection, MRI, and Tau and Amyloid PET scans
9675625|NCT04994990|Experimental|Left Side of Face Receiving Double Dose|
9675626|NCT04994990|Experimental|Right Side of Face Receiving Double Dose|
10174221|NCT03855397|Experimental|Microneedles|Application of microneedle patch, 30G hypodermic needle (positive control) and flat patch (negative control) in the lip, buccal, tongue, palatal and gingival mucosa for pain and safety assessment
10174222|NCT03855293|Other|Study group|rhexis protection shield
10174223|NCT03855293|No Intervention|Control group|regular surgery
10174224|NCT03855124||healthy participants|Participants will be ask to perform a repetitive upper limb task while posture and muscle activity is being monitored.This will be done while wearing a posture shirt or without a shirt
10174225|NCT03855345|Experimental|Control group|In this group, the participants will be submitted to the conventional treatment. The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
10174226|NCT03855345|Experimental|aPDT group|In this group, besides the conventional treatments, patients will also receive aPDT. aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F & A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
10174227|NCT03855306|Experimental|A Test|Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide
10174228|NCT03855306|Active Comparator|B Reference|Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide
10174229|NCT03855384|Experimental|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
10174230|NCT03855384|Placebo Comparator|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
10174231|NCT03855332|Placebo Comparator|Placebo|"All participants will undergo three phases in random order:~The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily"
10174232|NCT03855332|Experimental|Sildenafil|25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily
10174233|NCT03855332|Active Comparator|Cilostazol|50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)
10174234|NCT03855358|Experimental|TQB2450 Injection and Anlotinib Hydrochioride Capsules|
10174235|NCT03855254|Experimental|Positive communication|
10174236|NCT03855254|No Intervention|Control (neutral communication)|
10174237|NCT03855254|Experimental|Negative communication|
10174238|NCT03855241|Active Comparator|Informational Sheet|Persons picking up an opioid prescription will receive an informational sheet that describes how to properly dispose of leftover opioid medications
10174239|NCT03855241|Active Comparator|Drug Disposal Kit|Persons picking up an opioid prescription will receive a drug disposal kit (DisposeRx Drug Disposal kit) and instructions on how to use it
10174240|NCT03855241|No Intervention|No intervention|Persons picking up an opioid prescription will receive no additional information or materials on disposal.
10174241|NCT03855280|Experimental|APVO101|
10174242|NCT03855267|Placebo Comparator|Group A|Propofol 20 mg/ml, recommended anesthesia induction dose of 0.1~0.125 ml/kg, anesthesia maintenance pump speed of 0.2~0.5ml/kg/h. keep bispectral index within 40 # 60
10174243|NCT03855267|Active Comparator|GroupB|EP1:3, that is, 10ml etomidate was mixed with 30ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
10174244|NCT03855267|Active Comparator|Group C|EP1:1, that is, 20ml etomidate was mixed with 20ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
10174245|NCT03855267|Active Comparator|Group D|EP3:1, that is, 30ml etomidate was mixed with 10ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
10174246|NCT03855202|Experimental|infusion froup 1|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
10174247|NCT03855202|Experimental|infusion group 2|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
10174248|NCT03855202|Experimental|infusion group 3|PS,dose is 70mg/kg
9675627|NCT04994951|Experimental|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
9675628|NCT04994951|Active Comparator|control group|Topical steroids. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
9675629|NCT04994834|Experimental|Intervention|Probiotics
10174249|NCT03855202|Placebo Comparator|Placebol|0.9% sodium chloride installation after 24 hours
9675630|NCT04995068||Included patients|See inclusion and exclusion criteria
9977529|NCT01362569||peritoneal dialysis patients|patients undergoing peritoneal dialysis
9675631|NCT04995081|Active Comparator|Allogeneic HB-adMSCs.|"Biological/Vaccine: Allogeneic HB-adMSCs~Allogeneic HB-adMSCs will be administered intravenously to study participants who qualify.~Other Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells."
9675632|NCT04995081|Placebo Comparator|Placebo|"Placebo will be administered intravenously to study participants who qualify.~Other Names: Sterile Saline Solution 0.9%"
9675633|NCT04995198||Participants with at least one germline pathogenic/likely pathogenic variant|
9675634|NCT04995198||Participants with at least one variant of uncertain significance|
10174250|NCT03854916|Experimental|Caminemos Juntas App|Participants use the Caminemos app.
10174251|NCT03854916|Active Comparator|World Walking App|Participants use the World of Walking App.
9675635|NCT04994769|Experimental|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling
9675636|NCT04995016|Experimental|Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma|Neoadjuvant pembrolizumab plus axitinib
9675637|NCT04994821|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), (Soterix Medical mini-CT tDCS stimulator)
9675638|NCT04994821|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
9675639|NCT04994821|Experimental|Active tDCS with Cognitive Reappraisal (CR)|Active Transcranial Direct Current Stimulation (tDCS) (Soterix Medical mini-CT tDCS stimulator), and Cognitive Reappraisal (CR)
10174252|NCT03855371|Experimental|Decitabine plus arsenic trioxide|decitabine: 20mg/m2/d, intravenously, d1-d5, q4w arsenic trioxide: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
10174253|NCT03854955|Experimental|iScribes|Device-based scribing service used for dictation and documentation.
10174254|NCT03854955|No Intervention|Traditional Dictation|Standard dictation and documentation methods used.
10174255|NCT03855176|Active Comparator|1-dose group|Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
10174256|NCT03855176|Experimental|2-dose group|Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
10174257|NCT03855319|Experimental|SMR neurofeedback training to MCI|"A sensorimotor/theta neurofeedback training consisted of 20 individuals sessions, twice a week during 11 weeks maximum. For each subject, NF was planned and conducted by a neuropsychologist experienced in neurophysiology an neurofeedback. Each session lasted 1h10 minutes and was conducted as follows:~Preparation and installation of the electrodes, verification of the impedance, adjustement of the calibration.~NF training (tasks and video described below)(45minutes)~Feedback and debriefing about the session (15 minutes)"
9675640|NCT04994899||Interview & Depression Screening|
9675641|NCT04994756||Stroke|
9675642|NCT04994756||Thrombectomy|
9675643|NCT04994756||Aneurysm|
9675644|NCT04994925|Active Comparator|Control ready meal|Control supermarket brand ready meal with high energy density
9675645|NCT04994925|Experimental|Test ready meal with low energy density|Slimming world test ready meal with low energy density
9675646|NCT04994912|Experimental|EI-001|IV infusion
9675647|NCT04994912|Placebo Comparator|Placebo|IV infusion
9675648|NCT04994886|Experimental|Targeted Epidural Spinal Stimulation|"Participants will undergo a surgery for Targeted Epidural Spinal Stimulation (TESS). The neurostimulation system will be used to manage blood pressure instability.~Patients will then proceed to one month of an intensive device configuration protocol to configure the TESS settings of their investigational device to regain hemodynamic stability. After the intensive device configuration phase, daily supervised at-home hemodynamic TESS will be tested for 5 sessions per week for two weeks. Thereafter, and up to 10 months post-implant, patients will have a minimum of 5 TESS supported at-home sessions per week and one laboratory visit per month during a long-term at-home hemodynamic TESS phase. Finally, patients will have to undergo additional testing during a configuration of additional TESS programs phase. During this phase TESS configurations for hemodynamic stability, respiratory function, trunk stability and spasticity will be tested."
10174258|NCT03855007|Experimental|Iguratimod|The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
10174259|NCT03854968|Experimental|Quality control|The participants home mechanical ventilator will be tested in order to performe a quality control
9675649|NCT04994860|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
10174260|NCT03855072|Experimental|Customized plate fixation|"Customized Plate fixation of Vertical Ramus Osteotomy after Mandibular Setback~- intervention:~All cases will undergo one surgery under general anesthesia.~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~The customized fixation plate is positioned to fix the proximal and distal segment together"
10187107|NCT03729479|Experimental|Experimental: very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
10187971|NCT03720808|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
10187972|NCT03720769|Experimental|Step-by-Step|
9675650|NCT04994860|Active Comparator|Sildenafil|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple three times a day (t.i.d.) oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 2 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
9675651|NCT04994860|Experimental|BIA 5-1058 and Sildenafil|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple t.i.d. oral doses of sildenafil (Revatio® 1 x 20 mg film coated tablet) approximately 2 hours before or after each meal (breakfast, lunch and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and sildenafil (Revatio® 1 x 20 mg film coated tablet) and remained fasted for at least 4 hours post-dose. Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
9675652|NCT04995185|Experimental|PET/CT imaging|Intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole
9675653|NCT04994678|Experimental|Virtual Reality Training Group|VR training system will be setup in multidisciplinary lab of Foundation University Institute of Rehabilitation Sciences Foundation University Islamabad. Display will be provided on 55 inch LED TV with audio feedback. Display will be at height of 5 feet from floor and at distance of 6 feet from Subject. The Virtual reality based training group will receive a game based virtual reality training via XBOX 360 or wii fit balance games. Particiapants will be required to physically move to move avatar on screen to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week for 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
9675654|NCT04994678|Active Comparator|Moderate Aerobic Exercise Training Group|Moderate aerobic exercise training will be provided using motorized tread mill and stationary/recombinent cycle. Treatment will be provided for 30-50 minutes 3 times a week for 6 weeks.
9675655|NCT04994613|No Intervention|Control Group|The patient will be reserved a standard room in the preoperative area of main campus. This room will not include any additional sensory equipment. The child will be allowed to use any comfort items the family brought with them or offered a hospital iPad, as is current practice for all outpatient surgery patients.
9675656|NCT04994613|Experimental|Sensory Adaptive Environment Group|One of the three dedicated adaptive sensory rooms in the preoperative area of main campus will be set up by nursing and child life staff in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli. The equipment may include a portable popcorn tube with fiberoptic cart, handheld marble panel, color changing floor tiles, other sensory friendly objects, and individual sensory toys. This room will be set up prior to the patient's arrival the day of surgery and reserved for their use.
9675657|NCT04994626|Experimental|Ibrutinib Combined With Rituximab|"Induction therapy: Ibrutinib 560mg administered oral once a day of each 21-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.~Maintenance therapy: Ibrutinib 560mg administered oral once a day of each 56-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 56-day cycle for 6 cycles."
9675658|NCT04994743|Experimental|Cohort 1: CORT113176 150 mg|Participants will receive CORT113176 150 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days.
9675659|NCT04994743|Placebo Comparator|Cohort 1: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
9675660|NCT04994743|Experimental|Cohort 2: CORT113176 300 mg|Participants will receive CORT113176 300 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Progression from Cohort 1 to 2 will be done based on safety and tolerability outcome from Cohort 1 and only after Cohort 1 has received study drug for ≥7 days.
9675661|NCT04994743|Placebo Comparator|Cohort 2: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
9675662|NCT04994743|Experimental|Cohort 3: CORT113176 ≥300 mg|Participants will receive CORT113176 ≥300 mg not to exceed 450 mg lipid capsule formulation by mouth once daily under fed conditions for 14 days. Cohort 3 is optional, and progression from Cohort 2 to 3 be done based on safety and tolerability outcome from Cohort 2 and only after Cohort 2 has received study drug for ≥7 days.
9675663|NCT04994743|Placebo Comparator|Cohort 3: Placebo matching CORT113176|Participants will receive placebo matching CORT113176 capsule by mouth once daily under fed conditions for 14 days.
9675664|NCT04994353|Experimental|Supplementation|"Three days before the intervention, every subject was informed to maintain their normal diet, physical activities, and enough sleep (6-8 hours/day). All subjects fasted 10-12 hours before the intervention. An intravenous cannula was inserted into the cubital vein to provide access to repeated glucose measurement. Peripheral vein whole blood samples were taken for analysis of glucose concentration using a commercially available FreeStyle Optium glucose monitoring system (Abbot Laboratories, Chicago, Illinois, USA) .For the first week, we measured blood glucose to a meal without any intervention and use those data as a baseline. After that, blood glucose was measured at 0, 30, 60, 90, and 120 minutes after intervention and meal. After intervention, the subjects maintain daily predefined ready-meal (470 kcal). The supplementation formulas are food grade, purchased from PT. Lautan Natural Krimerindo (Mojokerto, Jawa Timur, Indonesia)."
9675665|NCT04994366||Intervention Group|The cohort receiving Thank you cards during their stay.
9675666|NCT04994366||Control Group|The cohort not receiving thank you cards during their stay.
9695149|NCT04781231|Experimental|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
9977530|NCT01362569||acute renal failure|patients with acute renal failure
9675667|NCT04994340||Children|From a cross-sectional perspective, children will fill out questionnaires related to their subjective physical activity levels (PAQ-C), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of children through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
10174261|NCT03855072|Active Comparator|maxillomandibular fixation|"Mandibular Setback by Vertical Ramus Ostotmy fixed with Maxillomandibular fixation~- intervention:~All cases will undergo one surgery under general anesthesia~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint"
10174262|NCT03855163|Experimental|Inspection visits|Regulatory tool to ensure enterprise compliance with legal requirements
10174263|NCT03855163|Experimental|Guidance workshops|Regulatory tool applied to inform and advise enterprises on legal requirements and how to realize compliance with such requirements
10174264|NCT03855163|Experimental|Online risk assessment tool|Regulatory tool applied to aid enterprises in conducting written objectives concerning health, environment and safety activities
9675668|NCT04994340||Adolescents|From a cross-sectional perspective, adolescents will fill out questionnaires related to their subjective physical activity levels (PAQ-A), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of adolescents through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
9675669|NCT04994327|Experimental|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
9675670|NCT04994327|Placebo Comparator|Control bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
10174265|NCT03855163|No Intervention|Control group|The Labour Inspection Authority will not preform any intervention activities in enterprises assign to the control group
10174266|NCT03854864||Oncologists|French oncologists
10174267|NCT03855033|Experimental|Media Aware Sexual Health - High School|Students received the web-based Media Aware Sexual Health - High School program.
10174268|NCT03855033|No Intervention|Typical Health Education Programming|Students received their regular health education programming not related to sexual health education.
10174269|NCT03854981|Placebo Comparator|Standard Care|If subjects are assigned to this group they will not be provided materials to increase exercise participation. Subjects will however be asked to participate in the standard education sessions that are provided to all bariatric surgery patients. This standard care includes meetings with a nutritionist, psychologist, and bariatric surgeon.
9675671|NCT04994405|No Intervention|Standard Pressure|The extremity tourniquet used during hand surgery for these participants will be the standard pressure of 250 mmHg.
9675672|NCT04994405|Experimental|Lower Tiered Pressures|The study intervention is the inflation of the extremity tourniquet to a pressure lower than the standard pressure of 250 mmHg during hand surgery for these participants determined by tiered guidelines based on systolic blood pressure (SBP).
9675673|NCT04994418|Experimental|Arm 1. Recommended sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300mg) from whole food while consuming placebo from pills
9675674|NCT04994418|Experimental|Arm 2. High sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300 mg) from whole food while consuming high sodium from pills (3400 mg)
9675675|NCT04994418|Experimental|Arm 3. High sodium and high fructose diet|7 day consumption of high fructose drink (200g) and recommended sodium (2300 mg)from whole food while consuming high sodium pills from pills (3400 mg)
9675676|NCT04994704|Experimental|Propofol group|Propofol based total intravenous anesthesia
9675677|NCT04994704|Active Comparator|Remimazolam group|Remimazolam based total intravenous anesthesia
9675678|NCT04994314|Active Comparator|orthodontic primer containing calcium fluoride nanoparticles|Fixed appliance for ten maxillary teeth and the contralateral mandibular teeth will be bonded using orthodontic primer containing calcium fluoride nanoparticles
10174270|NCT03854981|Active Comparator|Exercise + Standard Care|Subjects will be asked to exercise 5 days/week for 30 min/day at an intensity of 65-85% of their measured HRmax. Walking will be the main type of exercise. In addition to this training program, subject's will participate in the standard education sessions that are provided to all bariatric surgery patients.
10174271|NCT03854851|Experimental|NALDEBAIN|In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery.
9675679|NCT04994314|Placebo Comparator|Control primer|Fixed appliance for ten maxillary teeth (contralateral to experimental ten side)and the contralateral mandibular teeth will be bonded using conventional primer (TransbondTM XT orthodontic primers (3M-Unitek, Monrovia, USA)
9675680|NCT04994548||Cirrhotic patients or with portal hypertension|Patients with early esophageal cancer
9675681|NCT04994639|Experimental|HPI group|Managing intraoperative hemodynamic condition under the HPI guidance
9675682|NCT04994639|No Intervention|Standard care group|Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
9675683|NCT04994275||Patients admitted to undergo a major elective surgery|
9675684|NCT04994184||Perforated duodenal ulcer|MORBIDITY AND MORTALITY
10174272|NCT03854851|Active Comparator|MORPHINE|In group MORPHINE, subjects will receive morphine as needed after surgery.
10187973|NCT03720769|Active Comparator|Enhanced care as usual|
9675685|NCT04994652|Experimental|Videolaryngoscope|Intubation attempted with C-MAC videolaryngoscope
9675686|NCT04994652|Active Comparator|Standard laryngoscope|Intubation attempted with standard laryngoscope
9675687|NCT04994301||Patient with Cystic Fibrosis|Patients (male, female) age 5-11 with confirmed diagnosis of Cystic Fibrosis. These patients will begin clinically prescribed FDA-approved Trikafta therapy.
9675688|NCT04994262|Experimental|Intervention Group|"Patients in the intervention group will be given a lozenge with menthol at the 30th, 60th and 90th minutes after extubation and it will be explained that they should be dissolved in the mouth without swallowing, and the patients will be kept under observation during this time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. These parameters will be evaluated just before the menthol lozenge application at the 30th, 60th and 90th minutes.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded.~Second postoperative day: The comfort level of the patients will be evaluated using the General Comfort Scale Short Form."
9675689|NCT04994262|No Intervention|Control Group|"Patients in the control group will be followed up according to their routine clinical procedures. Since there is no procedure or intervention in the clinical procedures, only the patients will be followed up. Patients in the control group will be followed up with the same forms at the same time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded hourly.~Second day after surgery: The comfort level of the patients will be evaluated and recorded using the General Comfort Inventory Short Form."
9675690|NCT04994379|Experimental|1 mA tDCS|Participants receive the stimulation with an intensity of 1 mA.
9675691|NCT04994379|Experimental|1.5 mA tDCS|Participants receive the stimulation with an intensity of 1.5 mA.
9675692|NCT04994379|Sham Comparator|Sham tDCS|Participants receive the sham stimulation (zero electric current after a short initial increase).
9675693|NCT04994574|Experimental|tiotropium/olodaterol|
9675694|NCT04993963|Experimental|Cycle Ergometery Training (Prehabilitation)|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown) Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion <13 on Borg scale
9675695|NCT04993963|Active Comparator|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
9675696|NCT04994041|Experimental|Pelvic floor muscle plus adductor strengthening|pelvic floor muscle plus adductor strengthening
10174273|NCT03855098|Other|Fruit and Vegetable biomarkers|Each participant will consume the test foods over different weeks
10174274|NCT03854994|Experimental|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-5x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes Frequency: total one time
10174275|NCT03854890|No Intervention|Lymphadenectomy without indocyanine green injection|Laparoscopic lymphadenectomy will be performed in a standard way.
10174276|NCT03854890|Experimental|Lymphadenectomy with indocyanine green injection|Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.
10174277|NCT03854799|Experimental|CHEMORADIOTHERAPY PLUS AVELUMAB|"CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70"
9675697|NCT04994041|Active Comparator|Pelvic floor muscle exercises|pelvic floor muscle exercises
9675698|NCT04994197||Diagnosis group of patients with urothelial cancer|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as urothelial carcinoma in this study will be assigned to this group
9675699|NCT04994197||Diagnosis group of patients with benign urinary diseases|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as benign urinary diseases in this study will be assigned to this group
9675700|NCT04994197||Recurrence diagnosis group with urothelial cancer|Patients who were diagnosed with non-muscle invasive urothelial carcinoma within two years and diagnose as recurrent urothelial carcinoma in this study will be assigned to this group
9675701|NCT04994197||Recurrence diagnosis group with benign urinary diseases|Patients who were diagnosed with non-muscle invasive urothelial carcinoma within two years and diagnose as benign urinary diseases in this study will be assigned to this group
9675702|NCT04993885|Experimental|Treatment group|Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag
9675703|NCT04993989||Pharmacy based survey|Patients received a questionnaire, which was filled out and returned to the Contract Research Organization (CRO) or, alternatively to the pharmacy.
9675704|NCT04994236|Experimental|Hepatic Artery Infusion Chemotherapy|Subjects assigned to this arm will receive chemotherapy via catheterizations placed into the hepatic artery.
9675705|NCT04994054|Experimental|silkworms (Bombyx mori L.) pupae extracts group|This group takes silkworms (Bombyx mori L.) pupae extracts for 12 weeks.
10174278|NCT03854812|Active Comparator|Group M|magnesium sulphate as adjuvant to propofol
9675706|NCT04994054|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
9675707|NCT04994223|Experimental|Group A(combined anticoagulation plus antithrombotic therapy group)|group A patients would be receiving rivaroxaban and aspirin as experimental group to see the efficacy of rivaroxaban in peripheral arterial disease.
9675708|NCT04994223|Active Comparator|Group B( antithrombotic therapy alone group)|group B patients would be those receiving traditional antithrombotic therapy as usually given n Peripheral Arterial Disease.
10174279|NCT03854812|Active Comparator|Group F|fentanyl as adjuvant to propofol
10174280|NCT03854825||AKI|patients with postoperative AKI defined by KDIGO
10174281|NCT03854825||no AKI|patients without postoperative AKI defined by KDIGO
10187974|NCT03720756|Experimental|Subjects WITH nickel-sensitivity|Subjects on nickel-free diet who have a positive patch-test result, indicating nickel-sensitivity.
9675709|NCT04993846||Pancreatic cancer patients - Explorative phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments. An oral microbiota (dental plaque) sample will be collected and a periodontal and dental assessment will be performed, before any therapeutic procedure, together with orthopantomography
9675710|NCT04993846||Healthy controls - Explorative phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
9675711|NCT04993846||Pancreatic cancer patients - Validation phase|Pancreatic cancer patients evaluated at the Pancreatic Surgery Unit of the Pancreas Institute of the University of Verona will be enrolled. Fifteen PC patients per stage will be selected (15 Stage I/II, Stage III, Stage IV). Patients may have been scheduled for surgery or for biopsy for future systemic treatments.
9675712|NCT04993846||Healthy controls - Validation phase|Age-matched (+- 5 years) healthy controls referring to the Odontostomatology Unit for oral procedure according to clinical practice, with a recent (not longer than 12 months) cross-sectional abdominal imaging excluding gastrointestinal cancers.
9675713|NCT04993846||IPMN patients controls - Validation phase|Patients suffering from IPMNs evaluated at outpatients clinics or scheduled for surgery.
9675714|NCT04993872|Experimental|BIC/FTC/TAF|Development phase 4: Biktarvy®
9675715|NCT04994028|Active Comparator|Conventional treatment|Conventional treatment that include behavioral and life style modification and dyspnea prevention education
9675716|NCT04994028|Experimental|conventional treatment with volume Spirometry and deep breathing|Conventional treatment along with volume Spirometry and deep breathing exercise
9695150|NCT04781231|Active Comparator|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
9695151|NCT04781231|Other|Usual management of anxiety|
10174282|NCT03854877|Experimental|Health behaviour intervention|Personalised health behaviour e-health intervention. The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to promote health habits. Based on personal needs participants can choose tasks for physical activity, relaxation, healthy eating, sleep etc. They get regular feedback, tasks and support from their personal trainer via phone and computer.
9695152|NCT04781270|Experimental|mFOLFOXIRI+Bev|"Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks as the first-line treatment.~Drug: mFOLFOXIRI plus Bevacizumab Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
9695153|NCT04781270|Active Comparator|mFOLFOX6+Bev|"Patients will receive mFOLFOX6 plus bevacizumab once every two weeks as the first-line treatment.~Drug: mFOLFOX6 Plus Bevacizumab mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
9695154|NCT04781205|Experimental|Intervention|Members of clinics randomized into intervention arm will be consented on a blood test for DNA evaluation (up to WGS), a single feces sample for microbiome analysis and tentative agreement to ware monitors of various vital signs of body function
9695155|NCT04781205|No Intervention|Usual care|No intervention at all
9695156|NCT04781101|Experimental|conventional therapy|conventional therapy
9695157|NCT04781101|Experimental|RoboGait®|Group 1 (n = 13) received conventional therapy (65 min, 2 days/week ×8) and group 2 (n = 13) received 25 minutes of robot-assisted gait training (RoboGait®) in addition to conventional therapy (40 min, 2 days/week ×8).
9695158|NCT04781413|Experimental|Experimental|"The phase I trial is a dose escalation design with standard 3+3 followed by expansion cohorts.~Level Nab-PTX S-1 Sintilimab~80 mg/m2 80mg/m2 200mg~100 mg/m2 80mg/m2 200mg~120 mg/m2 80mg/m2 200mg~We start at level 1. The recommended dose (RD) is defined as dose equal to the maximum tolerated dose (MTD). If 1 of three patients experiences dose-limiting toxicities (DLT), three more patients will be enrolled at the same dose level. The MTD is defined as the dose level at which two or more of three patients, or at least two of 4-6 patients, have DLTs during one cycle."
9695159|NCT04781218||Participants enrolled in the registry|Participants enrolled in the registry will include school community members including students, parents, staff, etc.
9695160|NCT04781439|No Intervention|non-switching|control group
9695161|NCT04781439|Experimental|IV-to-PO conversion within 48-72 hours|early switching
10174283|NCT03854877|No Intervention|Control group|Only before and after measurements
10174284|NCT03854942|Other|First Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
9695162|NCT04781439|Experimental|IV-to-PO conversion after 72 hours|late switching
9695163|NCT04781075|Experimental|TAP Block with Exparel|TAP Block with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of bupivacaine diluted in 55 mL of normal saline
9977531|NCT01362569||post renal transplantation|patients after renal transplantation
10174285|NCT03854942|Other|Second Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET
10174286|NCT03854942|Other|Third Arm|7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
10174287|NCT03854786|Active Comparator|Oxyjun|Oxyjun- 400 mg OD after breakfast
9695164|NCT04781075|Active Comparator|TAP Block with bupivicaine|TAP Block with 30 mL (5mg/mL) of bupivacaine diluted in 70 mL of normal saline
9977532|NCT01362569||healthy controls|control group
10174288|NCT03854786|Placebo Comparator|Methyl Crystalline Cellulose|Methyl Crystalline Cellulose- 400 mg OD after breakfast
9675717|NCT04994119|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5-1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
9675718|NCT04994119|Experimental|Warfarin|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received a single dose of racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
9675719|NCT04994119|Experimental|BIA 5-1058 and Warfarin|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received a single concomitant dose of BIA 5-1058 400 mg (4 x 100 mg tablets) and racemic warfarin (Coumadin® 5 x 5 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay. Subjects were required to return for out patient visits.
9675720|NCT04993859||Male Cancer Survivors with DVSS Score ≥ 9|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
9675721|NCT04993859||Female Cancer Survivors with DVSS Score ≥ 6|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
9675722|NCT04993859||Male Cancer Survivors with DVSS Score < 9|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
9675723|NCT04993859||Female Cancer Survivors with DVSS Score < 6|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
9675724|NCT04993937|Active Comparator|Control group|Control group will follow their daily routine activities.
9675725|NCT04993937|Experimental|Experimental group|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
9675726|NCT04993950|Experimental|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
9675727|NCT04993950|Active Comparator|SNAGS with thoracic postural correction techniques|active as well as therapist-facilitated stretches.thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
10174289|NCT03854643|Experimental|Pilates group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
9675728|NCT04993833||Patients|Patients with risk of cerebral edema.
9675729|NCT04993833||Healthy Control|Staff/Faculty who interact with patients at the enrolling site.
9675730|NCT04993586|Experimental|Group A|
9675731|NCT04993586|Experimental|Group B|
9675732|NCT04993586|Experimental|Group C|
10174290|NCT03854643|Experimental|Control group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
9675733|NCT04993586|Experimental|Group D|
9675734|NCT04993586|Experimental|Group E|
9975586|NCT01343017|Other|Increased tidal volume (IVT)|In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
10174291|NCT03854565||Mild ARDS|patients have mild ARDS according to Berlin definition
9675737|NCT04993625|Experimental|Avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|
9675738|NCT04993729|Experimental|T89 low-dose group|Subjects in this group will take three T89 capsules and one Placebo capsule each time by oral administration three times daily for 5 days.
10174292|NCT03854565||Moderate ARDS|patients have moderate ARDS according to Berlin definition
9675739|NCT04993729|Experimental|T89 high-dose group|Subjects in this group will take four T89 capsules each time by oral administration three times daily for 5 days.
9675740|NCT04993729|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will take four placebo capsules each time by oral administration three times daily for 5 days.
10174293|NCT03854565||Severe ARDS|patients have severe ARDS according to Berlin definition
10174294|NCT03854708|Experimental|3 pmol/kg*min pancreatic polypeptide|3 pmol/kg*min of pancreatic polypeptide was intravenously infused.
9675741|NCT04993482||type 2 diabetes mellitus group|124 adults with type 2 diabetes mellitus will be included
9675742|NCT04993482||control group|124 control adults will be included
9675743|NCT04993690|Experimental|Phase I Dose Escalation|Dose Escalation and determination of MTD; multiple dose levels of LP-168 to be evaluated
9675744|NCT04993690|Experimental|Phase I Dose Expansion A|CLL/SLL patients treated with prior regimens.
9675745|NCT04993690|Experimental|Phase I Dose Expansion B|CLL/SLL patients with no prior therapy.
9675746|NCT04993690|Experimental|Phase I Dose Expansion C|MCL patients treated with prior regimens.
9675747|NCT04993690|Experimental|Phase I Dose Expansion D|WM patients treated with prior regimens.
9675748|NCT04993690|Experimental|Phase I Dose Expansion E|MZL patients treated with prior regimens.
9675749|NCT04993781|Experimental|eSTEPS Clinical Decision Support|Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
9675750|NCT04993781|No Intervention|Usual Care|Usual primary care practices regarding exercise-related fall prevention planning
10174295|NCT03854708|Experimental|10 pmol/kg*min pancreatic polypeptide|10 pmol/kg*min of pancreatic polypeptide was intravenously infused.
9675751|NCT04993508|Experimental|Arm A|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm A will undergo only targeted MRI/US fusion-guided biopsies. Men with PI-RADS 3 and PSAD > 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
9675752|NCT04993508|Active Comparator|Arm B|Men with PI-RADS 4/5 or PI-RADS 3 in conjunction with PSAD ≥ 0.15 that are randomized into arm B will undergo targeted MRI/US fusion-guided biopsies and systematic biopsies (standard of care). Men with PI-RADS 3 and PSAD > 0.15 with negative biopsy results will receive a follow-up MRI annually and PSA every 6 months for 3 years. In case of upgrade to PI-RADS 4/5, men will be re-biopsied. Men with PI-RADS 4/5 without cancer diagnosis or with clinically insignificant cancer in the subsequent biopsy will be offered an additional MRI inbore biopsy. If MRI inbore biopsy is negative or with clinically insignificant cancer, men will be followed-up with MRI annually and PSA every 6 months for 3 years. In the case of persistent PI-RADS 4/5, men will be re-biopsied.
9675753|NCT04993508|Other|Arm C|Men with PI-RADS 3 in conjunction with PSAD < 0.15 will not be biopsied, but followed-up with MRI annually and PSA every 6 months for 3 years.
9675754|NCT04993508|Other|Arm D|Men with PI-RADS 1 or 2 will not be biopsied, but followed-up with PSA every 6 months for 3 years. A control MRI will be performed after 3 years. At any time, a follow-up can be performed in case of clinical suspicion of PCa or a relevant PSA increase (> 1.0 ng/ml/a).
9675755|NCT04993742|Experimental|MOMS Intervention|"Women that are currently in the Mentors Offering Maternal Support (M-O-M-S) research program as well as pregnant women entering prenatal care in the first trimester, who are not in the M-O-M-S program may participate in the study.~Arms Assigned Interventions Experimental: M-O-M-S Intervention M-O-M-S intervention is 10, 1 hour prenatal mentored support groups~No Intervention: Routine Prenatal Care Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines"
9675756|NCT04993820|Experimental|Physical Activity (PA)|Combination of aerobic exercise and muscle strengthening exercise.
9675757|NCT04993820|Active Comparator|Education Control (CON)|No exercise group.
9675758|NCT04993391|Experimental|40mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
9675759|NCT04993391|Experimental|80mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
9675760|NCT04993391|Experimental|160mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
9675761|NCT04993391|Experimental|240mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
9675762|NCT04993391|Experimental|320mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
9675763|NCT04993807|Experimental|Shared decision-making tool|Participants in this arm will view a shared decision-making tool while they are undergoing consultation to have an atrial fibrillation ablation.
9675764|NCT04993794|Active Comparator|XueBiJing|XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group, Tianjin, China, batch No. 1603231) 100ml Xuebijing injection every 12 h (q12h) for 60 min
9675765|NCT04993794|Placebo Comparator|Normal saline|0.9% saline every 12 h (q12h) for 60 min
9675766|NCT04993547|Experimental|Parents present, peers present|The children are accompanied by their parents during the COVID-19 testing, and a visible covid-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
9675767|NCT04993547|Active Comparator|Parent present, peers absent|The children are also accompanied by their parents, but a covered COVID-19 swab test waiting line is set-up whereby the children are unable to observe their peers being tested.
9675768|NCT04993547|Active Comparator|Parents absent, peers present|Parents are absent during the COVID-19 testing, and a visible COVID-19 swab test waiting line is set-up enabling the children to observe their peers being tested.
9675769|NCT04993547|Active Comparator|Parents absent, peers absent|Parents are absent, and a covered COVID-19 swab test waiting line is set-up whereby the children are not able to observe their peers being tested.
9675770|NCT04993612||No pulmonary Hypertension|
9675771|NCT04993612||pulmonary Hypertension Group 1|
9675772|NCT04993612||pulmonary Hypertension Group 2|
9675773|NCT04993612||pulmonary Hypertension Group 3|
9675774|NCT04993612||pulmonary Hypertension Group 4|
9675775|NCT04993612||pulmonary Hypertension Group 5|
9675776|NCT04993521|Active Comparator|bilateral superficial cervical plexus block (BSCPB)|Analgesia obtained by a ultrasound guided cervical plexus block using lidocain
9675777|NCT04993521|Active Comparator|local wound infiltration (LWI)|Analgesia obtained by local wound infiltration of lidocain
10174296|NCT03854708|Placebo Comparator|Placebo|0.9 % saline solution was intravenously infused.
10174297|NCT03854760|Experimental|anesthesiologist with limited experiment|Anesthesiologists with limited experiment of bronchoscopy.
10187975|NCT03720756|Active Comparator|Subjects WITHOUT nickel-sensitivity|Subjects on nickel-free diet who have a negative patch-test result, indicating they do NOT have nickel-sensitivity.
9675778|NCT04993261|Experimental|Diagnostic (dual energy CT scan)|Patients undergo one dual energy CT scan during scheduled CT scan.
9675779|NCT04993209|Experimental|NDV-HXP-S 1μg (Stage A)|"Stage A:~Stage A will be the first use of the product in humans. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β.The scientific justification for these decisions will be approved by the regulatory agency before choosing Alternative (A) 1 or 2 and progression to the next stage, either B1 or B2."
9675780|NCT04993209|Experimental|NDV-HXP-S 3μg (Stage A)|"Stage A:~Stage A will be the first use of the product in humans. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β.The scientific justification for these decisions will be approved by the regulatory agency before choosing Alternative (A) 1 or 2 and progression to the next stage, either B1 or B2."
9675781|NCT04993209|Experimental|NDV-HXP-S 10μg (Stage A)|"Stage A:~Stage A will be the first use of the product in humans. A dose escalation will be performed with an interval of two days between each dose in a blinded form. The aim is to verify the product safety and support the decision on the dose selection among three alternatives, 1 μg, 3 μg and 10 μg, based on the immune response evaluation. These results will also explore the response against two variants of concern in SARS-CoV-2: γ and β.The scientific justification for these decisions will be approved by the regulatory agency before choosing Alternative (A) 1 or 2 and progression to the next stage, either B1 or B2."
9675782|NCT04993209|Placebo Comparator|Placebo (Stage A)|The stage A is designed as a non-inferiority test comparing the three different doses and using placebo as a control.
9675783|NCT04993209|Experimental|NDV-HXP-S parental vaccine in 3 consecutive lots (Stage B) - Group B1a|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 18-59 years old, no prior exposure to SARS-CoV-2."
9675784|NCT04993209|Active Comparator|Active Vaccine Control (Stage B) - Group B1a|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 18-59 years old, no prior exposure to SARS-CoV-2."
9675785|NCT04993209|Experimental|NDV-HXP-S parental vaccine (Stage B) - Group B1b|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 18-59 years old, with or without prior exposure to prior exposure to SARS-CoV-2."
9675786|NCT04993209|Active Comparator|Active Vaccine Control (Stage B) - Group B1b|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 18-59 years old, with or without prior exposure to SARS-CoV-2."
9675787|NCT04993209|Experimental|NDV-HXP-S parental vaccine (Stage B) - Group B1c|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1c: 18-59 years old, with prior exposure to SARS-CoV-2."
9675788|NCT04993209|Active Comparator|Active Vaccine Control (Stage B) - Group B1c|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1c: 18-59 years old, with prior exposure to SARS-CoV-2."
9675789|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage B) - Group B1d|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 18-59 years old, vaccinated more than 6 months ago."
9675790|NCT04993209|Active Comparator|Active Vaccine Control simple dose (Stage B) - Group B1d|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 18-59 years old, vaccinated more than 6 months ago."
9675791|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage B) - Group B1d (60 years or more)|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 60 years or more, vaccinated more than 6 months ago."
9675792|NCT04993209|Active Comparator|Active Vaccine Control simple dose (Stage B) - Group B1d (60 years or more)|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1d: 60 years or more, vaccinated more than 6 months ago."
9675793|NCT04993209|Experimental|NDV-HXP-S variant γ vaccine (Stage B) - Group B1e|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1e: 18-59 years old, without prior exposure to SARS-CoV-2."
9695165|NCT04781023|Experimental|Intervention (Colpofix)|intravaginal gel with carboxymtheyl beta-glucan and polycabophil
9695166|NCT04781023|No Intervention|Control|No intervention (standard of care)
9975587|NCT01343017|Other|Normal tidal volume (NVT), with PEEP|In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
10187108|NCT03729479|Experimental|Experimental: DASH diet and extra support|"Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
9675794|NCT04993209|Experimental|NDV-HXP-S variant β vaccine (Stage B) - Group B1e|"Stage B1 (Group B1, B1b, B1c, B1d and B1e) aims to compare the experimental parental vaccine with an active vaccine control in terms of homotypic immunogenicity.~Participants of this group B1e: 18-59 years old, without prior exposure to SARS-CoV-2."
9675795|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants in 3 consecutive lots (Stage C) - Group C1a|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).~Participants of this group C1a: 18-59 years old, without prior exposure to SARS-CoV-2."
9675796|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C1b|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).~Participants of this group C1b: 18-59 years old, with prior exposure to SARS-CoV-2."
9675797|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C1c|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).~Participants of this group C1c: 18-59 years old"
9675798|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C1c (60 years or more)|"Stage C1 (Groups C1a, C1b and C1c) is complementary to Stage B1 and seeks to assess an immune response of the variant-based vaccine with the best heterotypic immunogenicity (Hel) among those assessed in Stage B1 (Vaccines γ and β).~Participants of this group C1c: 60 years or more"
9675799|NCT04993209|Experimental|NDV-HXP-S variant γ vaccine (Stage B) - Group B2a|"Stage B2 (Group B2a) aims to assess the homotypic and heterotypic response induced by each of the vaccines based on variants.~Participants of this group B2a: 18-59 years old, with prior exposure to SARS-CoV-2."
9675800|NCT04993209|Experimental|NDV-HXP-S variant β vaccine (Stage B) - Group B2a|"Stage B2 (Group B2a) aims to assess the homotypic and heterotypic response induced by each of the vaccines based on variants.~Participants of this group B2a: 18-59 years old, with prior exposure to SARS-CoV-2."
9675801|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants in 3 consecutive lots (Stage C) - Group C2a|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2a: 18-59 years old, no prior exposure to SARS-CoV-2."
9675802|NCT04993209|Active Comparator|Active Vaccine Control (Stage C) - Group C2a|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2a: 18-59 years old, no prior exposure to SARS-CoV-2."
9675803|NCT04993209|Experimental|NDV-HXP-S vaccine based on variants (Stage C) - Group C2b|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2b: 18-59 years old, with or without prior exposure to SARS-CoV-2."
9675804|NCT04993209|Experimental|Active Vaccine Control (Stage C) - Group C2b|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2b: 18-59 years old, with or without prior exposure to SARS-CoV-2."
10174298|NCT03854682|Experimental|Surgical|Radiofrequency microtenotomy (RF): A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
9675805|NCT04993209|Experimental|NDV-HXP-S parental vaccine (Stage C) - Group C2c|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2c: 18-59 years old, with prior exposure to SARS-CoV-2."
9675806|NCT04993209|Active Comparator|Active Vaccine Control (Stage C) - Group C2c|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2c: 18-59 years old, with prior exposure to SARS-CoV-2."
9675807|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage C) - Group C2d|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2c: 18-59 years old, with prior exposure to SARS-CoV-2."
9675808|NCT04993209|Experimental|Active Vaccine Control simple dose (Stage C) - Group C2d|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2c: 18-59 years old, vaccinated more than 6 months."
10174299|NCT03854682|Active Comparator|Non-surgical|Strength training: Consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
10187109|NCT03729479|Experimental|Experimental: very low carb, ketogenic diet and extra support|"Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
10187110|NCT03729466|No Intervention|Control group|There will be no intervention for 8 weeks
9675809|NCT04993209|Experimental|NDV-HXP-S parental vaccine simple dose (Stage C) - Group C2d (60 years or more)|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2c: 60 years old or more, vaccinated more than 6 months."
9675810|NCT04993209|Experimental|Active Vaccine Control simple dose (Stage C) - Group C2d (60 years or more)|"Stage C2 (Groups C2a, C2b, C2c and C2d) will make a direct comparison between the experimental vaccine based on the variant selected in Step B2 and an active vaccine control.~Participants of this group C2c: 60 years old or more, vaccinated more than 6 months."
9675811|NCT04993365|Experimental|Experimental Group1|440 participants (including 220 subjects aged 18~59 years and 220 subjects aged 59 years and above ) will receive the first dose of COVID-19 vaccine and quadrivalent influenza vaccine on day 0, and the second dose of COVID-19 vaccine and PPV23 on day 28.
9675812|NCT04993365|Experimental|Experimental Group 2|440 participants (including 220 subjects aged 18~59 years and 220 subjects aged 59 years and above ) will receive the first dose of COVID-19 vaccine on day 0 and the second dose of COVID-19 vaccine on day 28.
10174300|NCT03854773|Active Comparator|Erector spinae block (Group ESPB)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
10174301|NCT03854773|Active Comparator|Thoracal paravertebral block group (Group TPVB)|In group B, TPVB will be performed. US probe will be placed 2-3 cm laterally following the visualization T5 spinous process in sagittal orientation. The ribs and transverse processes will be visualized as hyperechoic structures. The costotransverse ligament will be visualized in the superior, and the pleura in the anterior region. Using in plane technique, the block needle will be inserted in the cranio-caudal direction until the costotransverse ligament will be passed. For confirmation of correct position of the needle, 5 ml saline will be injected. After the negative aspiration of cerebrospinal fluid, blood and air; 20 ml of 0.25% bupivacaine will be performed and it will be seen of moving downwards of the pleura during the injection
9675813|NCT04993365|Experimental|Experimental Group 3|440 participants (including 220 subjects aged 18~59 years and 220 subjects aged 59 years and above ) will receive quadrivalent influenza vaccine on day 0 and PPV23 on day 28.
9675814|NCT04993131|Experimental|Liver transplant|The patients will be transplanted according to standard procedures by the institutional protocol. Median time of surgery is 7 hours and 20 minutes. Each surgical procedure will be performed by specialists at the Rikshospitalet liver transplantation team, which consists of seven specialists at the unit. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Complete clearance of the lymphatic tissue around the hepatoduodenal ligament. Frozen section is obtained from the distal end of the common bile duct. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
9675815|NCT04993404|Experimental|Cohort A：Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
9675816|NCT04993404|Experimental|Cohort B：Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
9675817|NCT04993404|Experimental|Cohort C：Normal Hepatic Function|Participants with normal hepatic function matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index) will be administered a single oral dose of Jaktinib Hydrochloride Tablets.
9675818|NCT04993404|Experimental|Cohort D：Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 11, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
9675819|NCT04993118|Experimental|Integrated Neuromuscular inhibition technique|Experimental group received Integrated neuromuscular inhibition technique. At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. M If pain was reproduced the pressure was maintained over the active trigger point as the position of ease was identiﬁed. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of iINIT.Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
9695167|NCT04781049|Experimental|TPLA (Trans-Perineal Laser Ablation of Prostate)|Participants who undergo Trans-Perineal Laser Ablation of Prostate
9695168|NCT04781049|Active Comparator|TURP (Trans-Urethral Resection of Prostate)|Participants who undergo the standard treatment, namely Trans-Urethral Resection of Prostate
9695169|NCT04781036|No Intervention|Normal feet|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography"
10174302|NCT03854773|Other|Control group (Group C)|Patients in control group will be only received fentanyl via a patient controlled analgesia (PCA) device.
10174303|NCT03854669|Experimental|Assessing pain reporting accuracy|Subjects will undergo pre-operative evaluation of their pain reporting accuracy ability in order to assess its relation to post-operative acute pain and analgesic consumption
10174304|NCT03854721|Experimental|VAX014|Intravesical VAX014 (dose: 3.33x10^10 - 9.0x10^11 recombinant bacterial minicells (rBMCs)), given once per week for Weeks 1-6
10174305|NCT03854539|Experimental|Active Stimulation 0.5|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
10174306|NCT03854539|Sham Comparator|Sham Stimulation|0.5mA intermittent transdermal stimulation of the aurical vagus stimulation5 Hz 30 seconds on/30 seconds off for five cycles
9675820|NCT04993118|Active Comparator|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
9675821|NCT04993326|Other|Intervention|"emPOWERed to Change~Online Courses:~4 Critical Step to Manage Diabetes modules~Step 1 Learn about diabetes~Step 2 Know your diabetes ABCs~Step 3 Learn how to live with diabetes~Step 4 Get routine care to stay healthy Diabetes + COVID-19 Protection and Prevention modules~Introduction to understanding COVID-19 and the risks specific to T2DM~Learn preventive and protective measures to avoid COVID-19~COVID-19 Vaccine education and Discussion guide~Community resource guide to access COVID-19 testing and vaccination Stress Management modules~Understanding of the relationship between diabetes and stress~Learn stress management techniques for diabetes Ongoing Program Support: Motivation for participation, medication adherence, accountability and peer-to-peer interaction and support (bi-weekly text messages & private and closed Facebook community support group with peers and professionals)"
9675822|NCT04993326|No Intervention|Control|Usual Standard of Care as deemed by participants provider(s)
9675823|NCT04993339|No Intervention|Standard Surgery|Participants in this group undergoing standard of care reparative surgery will not receive additional intervention
9675824|NCT04993339|Experimental|Standard Surgery with OOC|Participants in this group undergoing standard of care reparative surgery will receive OOC as an additional intervention
9675825|NCT04993092|Experimental|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
9675826|NCT04993092|Active Comparator|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
9675827|NCT04993222|Experimental|Sequence TR|6 healthy subjects assigned to the sequence TR were administrated intravenously for 120 mins with the test product of amphotericin B liposome for injection in period 1 and the reference product of AmBisome® in period 2.
10174307|NCT03854539|No Intervention|No Stimulation|0.0 mA (sham) intermittent transdermal stimulation of the aurical vagus stimulation, 0 Hz 30 seconds on/30 seconds off for five cycles
9675828|NCT04993222|Experimental|Sequence RT|6 healthy subjects assigned to the sequence RT were administrated intravenously for 120 mins with the reference product of AmBisome® in period 1 and the test product of amphotericin B liposome for injection in period 2.
9675829|NCT04993079|Experimental|Clotild®|"Subjects presenting an acute ischemic stroke due to M1 or middle cerebral artery (MCA) bifurcation occlusion, eligible for Endovascular Thrombectomy (EVT) based on neuro-interventionist and/or neurologist investigators' opinion will be eligible. Twenty (20) patients will be initially enrolled. Up to 100 patients will be enrolled following an analysis of the data of the first 20 enrolled patients by a data safety monitoring board (DSMB) and its' recommendation to proceed with the study.~Sixty clots will be retrieved and analysed in a group of participants for which Clotild® is used as neurovascular guidewire."
10174308|NCT03854539|Experimental|Active Stimulation 1.0|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles.
9675830|NCT04993144|Active Comparator|Active|"Participants received the real intervention of TBS (cTBS 600) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).~*cTBS = continuous theta burst stimulation"
9675831|NCT04993144|Sham Comparator|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).
9675832|NCT04993144|No Intervention|Normal control|No intervention.
9675833|NCT04993469|Experimental|Genital sensation and sexual functioning assessment|"Genital sensation testing with clinical assessment and self-examination questionnaire.~Sexual functioning testing with questionnaires."
9675834|NCT04993105|Experimental|B (exercise + graston):|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surf and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restriction was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
9975588|NCT01343030||Patients with implants|Patients with silicone implants and fat grafting.
10174309|NCT03854539|Experimental|Active Stimulation 0.25|0.25 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
10174310|NCT03854435|Experimental|Heart rate assessed by using a stethoscope (auscultation)|Heart rate will be assessed by using a stethoscope (auscultation) in newborn infants immediately after birth
10174311|NCT03854435|Active Comparator|Heart rate assessed by palpation of the umbilical cord|Heart rate will be assessed by palpation of the umbilical in newborn infants immediately after birth
10174312|NCT03854383|Sham Comparator|Misoprostol alone|Enrolled women will receive 25 πg of misoprostol which will be placed intravaginally 4 hourly, maximum up to 5 doses
10174313|NCT03854383|Active Comparator|Isosorbide mononitrate with misoprostol|Enrolled women will receive 25 πg of misoprostol together with 40 mg isosorbide mononitrate which will be placed intravaginally 4 hourly, maximum up to 5 doses
10174314|NCT03854513||-Group 1 (anuric)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output less than 100ml / day
10174315|NCT03854513||Group 2 (good UOP)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output 400ml / day or more
10174316|NCT03854292||Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopic electrocoagulating roller ball
9675835|NCT04993105|Active Comparator|A (exercise only)|Exercises only. Patients will be given gastrocnemius stretching, plantar fascia stretching, myofascial release and then graston will be given as sham treatment for 10 minutes after applying cream (applying graston on skin but not giving enough pressure).
9675836|NCT04993235||Sotos Syndrome|Children and adolescents with Sotos Syndrome
9675837|NCT04993235||Beckwith-Wiedemann Syndrome|Children and adolescents with Beckwith-Wiedemann Syndrome
9675838|NCT04993235||Control group|Adolescents with typical development
9675839|NCT04993573||Caregivers|Caregivers who work with older patients will be included. They will have a questionnaire
10174317|NCT03854292||Laparoscopic tubal disconnection|Coagulation of the mid isthmus region of the affected Fallopian tube, with the bipolar forceps. using direct current that was no greater than 25 Watts.
9675840|NCT04993573||Older|Older 65 people who live alone in their house will be included. They will have Individual interviews.
10174318|NCT03854630|Active Comparator|Standard dose (20µg)|Three doses of 20µg HBV vaccine given intramuscularly at week 0, 4, 24.
10174319|NCT03854630|Experimental|Double dose (40µg)|Three doses of 40µg HBV vaccine given intramuscularly at week 0, 4, 24.
9675841|NCT04993378||GC patients receiving immunotherapy|
9675842|NCT04992819|No Intervention|Control Group|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. Experiment is about labeling breast milk by time of day before giving it to babies. There is no extra intervention during feeding. The breastmilk of the control group patients will be given without matching according to the clinical routine practice.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
10174320|NCT03854617|Experimental|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
9675843|NCT04992819|Experimental|Chronobiological Approach Nutrition Model|"Preterm infants in NICU are fed with breast milk and bottle. Although the date is written on expressed breast milk, it is usually not given by checking its suitability for the time of day. The milk of the intervention group patients will be matched circadian and given to the babies. Intervention group's breast milk is labeling by time of day before the each feeding. In the intervention group, a label containing the time of expressed breastmilk will be affixed. Circadian matched milk will be provided at each feeding.~intervention is;n the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.~Demographic data, anthropometric measurements (weight, height, head circumference of all babies will be recorded in the Baby Monitoring Form created by the researcher."
9675844|NCT04993248|Experimental|Intervention|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
9675845|NCT04993248|No Intervention|Control|Usual intervention
9675846|NCT04993417|Experimental|Mime Therapy along with EMS|MT Group: Mime Therapy along with EMS
9675847|NCT04993417|Experimental|Motor imagery technique along with EMS|MIT Group: Motor imagery technique along with EMS
10174321|NCT03854617|Active Comparator|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period.
10174322|NCT03854591||Gunshot related injury|Patients admitted to orthopaedic trauma service with gunshot related injury
9675848|NCT04993456||POAF group|the patients will have atrial fibrillation following the cardiac surgery
10174323|NCT03854409|Experimental|Part A - Deltoid Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
10174324|NCT03854409|Experimental|Part A - Gluteal Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
10174325|NCT03854409|Experimental|Part A - Deltoid Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
9675849|NCT04993456||non-POAF group|the patients will have no atrial fibrillation following the cardiac surgery
10174326|NCT03854409|Experimental|Part A - Gluteal Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
10174327|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (X)|Participants will receive a single dose of aripiprazole LAI.
9675850|NCT04993638||EUROSCUP MOBILE cementless|107 who received cementless version of EUROSCUP MOBILE
9675851|NCT04993638||EUROSCUP MOBILE cemented|40 who received cemented version of EUROSCUP MOBILE
9675852|NCT04992858|Experimental|CT053PTSA|60 mg/d, starting on the first day
9675853|NCT04992975||Alzheimer's disease|"Patients with Early Onset Alzheimer's disease (with known cerebrospinal fluid Amyloid/tau status) during prodromal or mild phase will have MRI of the brain at 7T, neurocognitive assessments, and blood test to check APOe status.~Repeat neuroimaging and neurocognitive tests after one year."
9675854|NCT04992975||Control group|"Age and gender matched individuals with normal cognition will have MRI of the brain at 7T, neurocognitive assessments and blood test to check APOe status.~Repeat neuroimaging, neurocognitive tests after one year."
9675855|NCT04993014|Active Comparator|Cohort 1, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 positive CTCs at baseline
9675856|NCT04993014|Experimental|Cohort 1, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 positive CTCs at baseline
9675857|NCT04993014|Active Comparator|Cohort 2, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 negative/absent CTCs at baseline
9675858|NCT04993014|Experimental|Cohort 2, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 negative/absent CTCs at baseline
10174328|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (Y)|Participants will receive a single dose of aripiprazole LAI.
10174329|NCT03854409|Experimental|Part B - Gluteal Site: Group 2|Participants will receive a single dose of aripiprazole LAI.
10187111|NCT03729466|Experimental|Intervention group|clinical pilates will be given to the intervention group for 8 weeks
9675859|NCT04993040|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
9675860|NCT04992806||patients accepted hip arthroscopy|patients with hip diseases and accepted hip arthroscopy in Peking University Third Hospital
9675861|NCT04992910|Experimental|Functional Electrical Stimulation|
9675862|NCT04992910|Active Comparator|Standard Therapy|
9675863|NCT04992897||REN-Medication combinations|"all evaluable treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
9675864|NCT04992897||Consistent efficacy|"all users that performed at least 2 evaluable treatments. In order to isolate the effect of REN treatments, this dataset considered only treatments where REN was used as a standalone treatment.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes).~'Evaluable treatment' defined as a treatment in which pain levels were reported at baseline and post 2 hours."
9675865|NCT04992897||Treatment intensity distribution|"all treatments.~'Treatment' defined as a REN treatment of at least 20 minutes (the nominal duration is 45 minutes)."
9675866|NCT04992897||Safety|all reported treatment/device-related adverse events (AEs) within the time period.
9675867|NCT04992988|Experimental|Toripalimab+CCRT|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy.~Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 3 weeks after CCRT"
9675868|NCT04992962|Experimental|CBD/CBN|Participants will receive a 28-day supply of CBD/CBN sublingual tablets to be taken 3 times a day for 28 days.
9675869|NCT04992962|Experimental|CBD/THC|Participants will receive a 28-day supply of CBD/THC sublingual tablets to be taken 3 times a day for 28 days.
9675870|NCT04992962|Placebo Comparator|Placebo|A placebo sublingual tablet to be taken three times a day for 28 days
9675871|NCT04992871||Patient population|Children, adolescents and adults diagnosed with cerebral palsy who are born, treated or living in Switzerland
10174330|NCT03854357|Experimental|Additional Isolated Subscapularis Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
10174331|NCT03854357|Active Comparator|Standard Post-Operative TSA Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
10174332|NCT03854487|Experimental|Mirror therapy|
10174333|NCT03854487|Sham Comparator|Sham mirror|
10174334|NCT03854487|Active Comparator|Covered mirror|
10174335|NCT03854344|Experimental|Group 1|Liposomal Bupivicaine (266mg/20ml) will be diluted into Lactated Ringer solution (280 ml) and injected once intra-operatively subcutaneously before donor site harvesting
10174336|NCT03854344|Active Comparator|Group 2|Lidocaine (50 mg/50 ml) will be diluted into Lactated Ringer (1000ml) and injected once subcutaneously before donor site harvesting
10174337|NCT03854279|Experimental|Bizact|Tonsillectomy will be done With the Bizact device
9675872|NCT04992715|Experimental|Metastatic Non-Small Cell Lung Cancer|"Subjects with metastatic non-small cell lung cancer will be recruited as per protocol inclusion/exclusion criteria and will undergo [99mTc]-anti-PDL1 single-domain antibody ([99mTc]-NM-01) SPECT/CT imaging.~[99mTc]-NM-01 SPECT/CT images will be compared to immunohistochemistry PD-L1 expression results."
9675873|NCT04992741|Experimental|Experimental|Health Belief Model Based Motivational Interview Group The application will be made by the researcher who has been trained in motivational interviewing techniques. Motivational interviews based on Health Belief Model will be made by telephone to mothers who have daughters studying in high school. There will be 3 interviews with mothers based on the benefits, barriers, sensitivity and severity perception structures of the Health Belief Model regarding HPV infection and vaccination, and each interview will last 15-20 minutes. One week after each interview, the questionnaire/scale forms will be sent via whatsapp and applied.
9675874|NCT04992741|No Intervention|other|The control group will remain subject to the routine process without any intervention.
9675875|NCT04992702|Experimental|Animated Video|The information in the ACL animated video (https://vimeo.com/281721823) was displayed as a story of a typical athlete who sustained an injury and how this could be prevented through evidence-based prevention strategies.
9675876|NCT04992702|Active Comparator|Web-based Article|The active control group received commonly accessed information from a WebMD web-based article on ACL injury prevention.
9675877|NCT04992702|Placebo Comparator|Placebo control|The placebo control group intervention received an educational video from the CDC about concussions that is comparable in duration to that of the ACL video (https://youtu.be/fSRWF44wgn8).
9675878|NCT04992728||Male Prostate Patients|Adult male patients with fair to good performance status and who (1) have undergone an MRI of the prostate for suspected or known prostate cancer and/or (2) are planning to undergo radical prostatectomy for prostate cancer.
9675879|NCT04992507|Experimental|Arm I (surgical resection with TIVA)|Patients undergo surgical resection with TIVA.
10174338|NCT03854279|Active Comparator|Electro-scissor|Tonsillectomy will be done With electro-scissors
10174339|NCT03854305|Experimental|PRV-6527|Oral administration, 2X daily for 12 weeks
10174340|NCT03854305|Placebo Comparator|Placebo|Oral administration, 2X daily for 12 weeks
10174341|NCT03854396|Active Comparator|Intravaginal prasterone insert|Nightly intravaginal prasterone insert for 24 weeks
10174342|NCT03854396|Placebo Comparator|Intravaginal placebo insert (Witepsol H-15)|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks
10174343|NCT03854266|Experimental|Catheter directed thrombolysis|Low dose alteplase (4/8 milligram) will be infused over 2 hours locally in the pulmonary arteries at the site of the thrombus through an infusion catheter with sideholes (Unifuse, AngioDynamics, US)
10174344|NCT03854266|Active Comparator|Unfractionated heparin|Initial dose of unfractionated heparin is 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time is 1.5-2.3 times control value.
10187112|NCT03729440||corrosive patients|
9675880|NCT04992507|Active Comparator|Arm II (surgical resection with inhaled volatile anesthetics)|Patients undergo surgical resection with inhaled volatile anesthetics.
9675881|NCT04992663|Experimental|Intervention group (VR-group)|"The participants randomised into this group are offered the BirthVR intervention during Labour.~The VR group receives a VR information moment during labour and the possibility to exercise with the VR glasses and they receive VR during labour from the moment they are in active labour and use VR as much as they prefer. After labour, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated and participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5).~As soon as VR does not serve as adequate pain relief during labour and a women requests additional pain medication this will be offered according to local protocol."
9675882|NCT04992663|No Intervention|Care as usual group|Patients randomised to the care as usual group will be offered pain medication during labour according to the local protocol, and on maternal request only. Postpartum participants receive the WDEQ-B questionnaire and PROM and PREM (ICHOM; T3, T4, T5)
10174345|NCT03854240|Active Comparator|Classic block (Group C)|In group C, classic technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and multifidus muscles. Between these muscles, block needle will be inserted within in plane technique in a lateral-to-medial direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
9675883|NCT04992364||Positive Clinical Performances|Subjects show positive clinical performances regarding burnout syndrome
9675884|NCT04992364||Negative Clinical Performances|Subjects show negative clinical performances regarding burnout syndrome
9675885|NCT04992377|Experimental|R-EPOCH plus IBR for RT|
9675886|NCT04992325||Patients with type 2 diabetes mellitus|The patients with previous diagnosis of type 2 diabetes mellitus, without signs of diabetic retinopathy
9675887|NCT04992325||Healthy subjects|Healthy subjects without actual and previous ocular diseases
9675888|NCT04992468|Experimental|GnRH-a+rhCG|Ovulation triggering with GnRH-a+rhCG
9675889|NCT04992468|Active Comparator|GnRH-a|Ovulation triggering with GnRH-a
9675890|NCT04992533|Active Comparator|Long-duration tourniquet|Tourniquets inflated before arthroscopic exploration and deflated after high tibial osteotomy
9675891|NCT04992533|Experimental|Short-duration tourniquet|Tourniquet should be inflated before arthroscopic exploration and deflated immediately after the exploration
9675892|NCT04992611|Experimental|Circadian-Aligned Sleep Extension|A sleep extension period that roughly conforms to a given participant's circadian phase (i.e., fits the schedule of a Morning Lark vs. Night Owl).
9675893|NCT04992611|Experimental|Circadian-Misaligned Sleep Extension|A sleep extension period that does not conform to a given participant's circadian phase. In other words, this condition asks Morning Larks to extend their sleep by sleeping in later, or asks Night Owls to extend their sleep by going to bed earlier.
9675894|NCT04992390|Experimental|Immediate intervention arm|Immediate access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome).
9675895|NCT04992390|Experimental|Delayed intervention arm|Usual care for 4 weeks including completing a daily count of the number of their intrusive memories in week 4 (primary outcome), followed by access to the brief digital imagery-competing task intervention plus symptom monitoring for 4 weeks.
9675896|NCT04992299|Experimental|Mindfulness-Based Intervention|6-week group intervention, Learning to BREATHE, an adolescent mindfulness-based intervention derived from mindfulness-based stress reduction
9675897|NCT04992299|Active Comparator|Cognitive-Behavioral Therapy|6-week group intervention, the Blues Program, a cognitive-behavioral intervention for adolescents with elevated symptoms of depression
9675898|NCT04992299|Other|Health Education|6-week group program providing didactic information on adolescent health topics
9675899|NCT04992351||WALANT group|WALANT was used exclusively as anesthesia method for the operation
9675900|NCT04992351||control|tourniquet with regional or general anesthesia was used for the operation
9675901|NCT04992559|Experimental|Toripalimab Arm|Toripalimab consolidation therapy
9675902|NCT04992481|Experimental|1. professional mechanical tooth cleaning (PMTC)+fluoride varnish|This arm constituted of randomly selected 30 participants. In this group professional mechanical tooth cleaning (PMTC)+fluoride varnish were performed.
9675903|NCT04992481|Experimental|2. PMTC+fluoride varnish+gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+gaseous ozone therapy were performed.
9675904|NCT04992481|Experimental|3. PMTC+fluoride varnish+domestic octenidin mouth rinse|This arm contituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse were applied.
9675905|NCT04992481|Experimental|4. PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy|This arm constituted of randomly selected 30 participants. In this group PMTC+fluoride varnish+domestic octenidin mouth rinse+ gaseous ozone therapy were performed.
9675906|NCT04992481|No Intervention|Control group|Control group not subjected to any prophylactic program constituted of randomly selected 30 participants.
9675907|NCT04992572|Active Comparator|General anesthesia|"Patients under this group will be undergoing lumbar decompression surgery with general anesthesia:~General Anesthesia: Medically induced unconsciousness that suppresses reflexes and requires intubation (a tube inserted through the mouth and into the airway) to assist in breathing."
9675908|NCT04992572|Active Comparator|Monitored Anesthetic Care (MAC)/Local|"Patients under this group wil be undergoing limbar decompression surgery with Monitored Anesthetic care, (MAC)/Local.~Local + MAC: Local anesthetic (lidocaine) injected into the site of the incision/dissection with additional IV medication (Propofol) to achieve a state in which the patient is generally aware, but relaxed."
9675909|NCT04992091|Experimental|CONSTRUCTIVE DEBRIEFING|interventional group
9675910|NCT04992091|No Intervention|traditional debriefing|noninterventional group
10174346|NCT03854240|Active Comparator|Modified block (Group M)|In group M, modified technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
9675911|NCT04992585|Experimental|PTBD with primary metal stent implantation|PTBD with primary metal stent implantation is performed in the same session as a one step-procedure
9675912|NCT04992585|Active Comparator|PTBD with secondary metal stent implantation|PTBD with secondary metal stent implantation is performed as a two step-procedure with metal stent implantation 3 to 7 days after previous percutaneous transhepatic biliary drainage and insertion of a plastic catheter
9675913|NCT04992156||Patients cohort|Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FES PET/CT before the initiation of Palbociclib was included.
9675914|NCT04992182|Experimental|Inactivated vaccine booster|One standard IM CoronaVac dose (0.5 mL)
9675915|NCT04992182|Experimental|mRNA vaccine booster|One standard IM BNT162b2 dose (0.3 mL)
9675916|NCT04992182|Experimental|Viral vector vaccine booster|One standard IM ChAdOx1 dose (0.5 mL)
9675917|NCT04992182|Placebo Comparator|Placebo|Saline solution IM (0.3 mL)
9675918|NCT04992442|Experimental|TAK-935 300 mg + [14C]TAK-935 50 μg + [14C]TAK-935 300 mg|TAK-935 3×100 mg, tablets, orally, once on Day 1, followed by [14C]TAK-935 50 micrograms (μg) [approximately 1 μCi], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]TAK-935 300 mg (approximately 100 μCi) solution, orally, once on Day 1 of Treatment Period 2.
9675919|NCT04992286|Experimental|people aged 65 years or more|men or women, age Superior to 65 years
9675920|NCT04992130|Experimental|Intervention cohort|Pre-season supplementary neurologic training program
9675921|NCT04992130|No Intervention|Control cohort|Usual pre-season training program
9675922|NCT04992078|Experimental|Robotic-Unicompartmental Knee Replacement (R-UKR)|NAVIO/CORI Surgical System
9675923|NCT04992078|Active Comparator|Conventional-Unicompartmental Knee Replacement (C-UKR)|Non-robotic conventional instrumentation
9675924|NCT04992117||Unplanned-extubation in the ICU|Patients with unplanned extubation in the ICU
9675925|NCT04992052|Active Comparator|Treatment arm|This arm will have bone wax applied to the exposed cancellous surfaces of the bone.
9675926|NCT04992052|No Intervention|Control Arm|This arm will serve as the control group. Bone wax will not be used in this group.
9675927|NCT04992143|Experimental|TACE combined Tilelizumab and Sorafenib|TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)
9675928|NCT04992169|Experimental|Smartphone App with Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their video and are taught to score their own performance/fidelity through question prompts built into the app. When they are finished, the app will offer feedback and follow-up lessons based on the PRT strategies they have not demonstrated consistently.
9675929|NCT04992169|Experimental|Smartphone App without Video Self-Scoring Functionality|In this condition, after parents video-record their delivery of the intervention, they watch their own video but do not score their performance.
9675930|NCT04992039|No Intervention|Control Arm|Participants of this arm will not receive the total WHO HEARTS package as an intervention. These participants will be screened in the designated area for universal BP screening via A&D arm-in device. Their diagnosis will be confirmed by measuring their BP by a Medical Officer via an Omron desktop oscillometer. The Medical Officers and UHC nurses of the control sites will be trained up on BP measurement using standard techniques, patient registration, data collection, etc.
9675931|NCT04992039|Experimental|Intervention Arm|Participants of this arm will receive all the components of WHO HEARTS technical package components as an intervention.
9675932|NCT04992026|Experimental|ADT plus abiraterone + surgery|After 6 cycles of first-line treatment (Androgen deprivation therapy + abiraterone acetate along with prednisone) , patients will receive robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection (ePLND) within 9 months of being diagnosed. The ADT+abiraterone treatment will be maintained after surgery.
9675933|NCT04992026|Active Comparator|ADT plus abiraterone|Patients will be only treated with Androgen deprivation therapy + abiraterone acetate along with prednisone. Prostatectomy won't be performed.
9695170|NCT04781036|Experimental|Foot odor without pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography~Apply 4% chlorhexidine for 1 month~Re-evaluate their feet at time of treatment finish and 2 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
9695171|NCT04781036|Experimental|Foot odor with pitted keratolysis|"Swab their feet to analyze foot microbiome via 16s DNA sequencing~Collect their socks to analyze metabolomics via gas chromatography~Apply 4% chlorhexidine for 1 month~Re-evaluate their feet at time of treatment finish and 2 months after treatment finish. The forementioned methods (swab and collect their socks) will be applied on their feet again.~The microbiome and metabolomics will be analyzed to evaluate the difference of microbe and substances after treatment."
9975589|NCT01343069|No Intervention|before surgical checklist|
9975590|NCT01343069|Active Comparator|after implementation surgical checklist|
9975591|NCT01343121|Other|sample collection|"This is a single arm study. Patients will be seen on day 1, 8, 15 and 22 and will have the following samples collected:~Pre gemcitabine urine sample~Blood sample 30 minutes post Gemcitabine infusion~Urine and blood sample 2 hours post Gemcitabine infusion"
9975592|NCT01343134||Retinal detachment cohort|
9975593|NCT01343147|Other|Deep hyperthermia|Microwave diathermy
9975594|NCT01343147|Other|Superficial hyperthermia|Hot packs
9975595|NCT01343173|Experimental|Patients|
9527559|NCT03219073|Sham Comparator|SHAM tDCS|SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
9527560|NCT03219073|Active Comparator|Active tDCS with a tDCS device|Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
9527561|NCT03219112|Experimental|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
9675934|NCT04991675|Active Comparator|pelvic floor muscle exercises|Exercises were taught in the supine position, as described by Kegel (1948), and it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
10174347|NCT03854422|Active Comparator|Left Position during colonoscopy|Left position, the patient will be in the left-side position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.Moreover, process recall, sedation amounts and pain scale will be measured after the procedure..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent (midazolam) used during the process is paid attention to be equal. All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
10174348|NCT03854422|Active Comparator|Left Supine Position during colonoscopy|Left Supine position, the patient will be in the left and supine ( after splenic flexura) position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.
10174349|NCT03854422|Active Comparator|Dynamic position during colonoscopy|Dynamic position, the patient will be stared as left position during colonoscopy period. If necessary, change of position and pressure will be allowed at any time. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent used during the process is paid attention to be equal. The use of midazolam as an anesthetic agent was planned.All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
10174350|NCT03854149||Adults with CHD & non-valvular atrial arrhythmias|Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)
9527562|NCT03219112|No Intervention|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
9527563|NCT03219190|Experimental|LST High School Online|Provided with the prevention program, consisting of e-learning modules and classroom sessions.
9527564|NCT03219190|No Intervention|Treatment as Usual (Control)|Standard health education
9527565|NCT03218982|Experimental|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
9527566|NCT03218982|No Intervention|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
9527567|NCT03219060|Experimental|Intervention group|MI based four individual sessions
9527568|NCT03219060|Active Comparator|Control group|Brief advice following 5As
9527569|NCT03218930|Other|Social marketing intervention|Participants will receive a total combination of four interventions.
9527570|NCT03219047|Experimental|Cohort 2 (Co-trial cohort)|Patients receive ibrutinib at standard dose and schedule through an ongoing MD Anderson clinical trial. Patients that respond to ibrutinib but experience relapse or disease progression receive treatment based on the results of the PDX models as in Cohort 1 if they are available. Patients who experience relapse after treatment with ibrutinib are moved to Cohort I if the PDX models are not ready.
9527571|NCT03219047|Experimental|Cohort I (Traditional cohort)|Patients who have previously received ibrutinib, acalabrutinib, PI3K inhibitor ACP-319, or BTK inhibitor BGB-3111 receive treatment through ongoing clinical trials at MD Anderson or standard of care. At the same time, previously collected tissue is used to develop PDX models and suitable drugs/regimens are tested in the PDX models. Patients then receive treatment based on the results of the PDX models through another clinical trial or standard of care.
9527572|NCT03219086|Active Comparator|Group M|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
9527573|NCT03219086|Active Comparator|Group P|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
9527574|NCT03219242|Experimental|Caiman device|Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device
9527575|NCT03218735|Experimental|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
9527576|NCT03218735|Active Comparator|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
9675935|NCT04991675|Active Comparator|diaphragmatic breathing exercises|Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
9675936|NCT04991636|Experimental|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
9675937|NCT04991792|Experimental|Standard Infant Formula with synbiotics (CS-born)|CS born infants, randomized to receive infant formula with synbiotics
9675938|NCT04991792|Experimental|Standard Infant Formula with prebiotics (CS-born)|CS born infants, randomized to receive infant formula with prebiotics
9675939|NCT04991792|Active Comparator|Control Group 1: Standard Infant Formula (CS-born)|CS born infants, randomized to receive standard infant formula without synbiotics
9675940|NCT04991792|Active Comparator|Control Group 2 : Standard Infant Formula (VD-born)|VD born infants, receiving standard infant formula without synbiotics (self-selected for formula-feeding = non-randomized)
9675941|NCT04991792|No Intervention|Reference Group 1: Breastfed (CS-born)|CS-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
10174351|NCT03854162|Active Comparator|FREEHAND|For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
9675942|NCT04991792|No Intervention|Reference Group 2: Breastfed (VD-born)|VD-born infants, receiving exclusive breast-feeding with mother's own breast milk (non-randomized)
9675943|NCT04992000|Experimental|4-free app + PHN intervention|"The intervention group was received initial education, 4-free apps, and followed by PHN interventions.~Education, app, and PHN intervention"
9675944|NCT04992000|Experimental|4-free app alone|The apps alone group received the initial education and the 4-free Apps.
9675945|NCT04992000|No Intervention|education|Standard care group received just the initial education.
9675946|NCT04991727||PEEP|The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway.Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed.Pulmonary ultrasound was performed. The PEEPgroup was given the first RM (pulmonary retraction) with pressure maintained at 40cmH2O for 30s, followed by a 7cmH2O PEEP to maintain mechanical ventilation, and the RMS was repeated every 30 minutes until the end of surgery
9675947|NCT04991727||ZEEP|"The patient was admitted to the operating room, and routine ECG monitoring was performed. The patient was placed in supine position, and ultrasound lung examination was performed. The images of the patient were saved and the score of lung ventilation area was recorded. The induction of general anesthesia was started, and endotracheal intubation was performed after 3min of preoxygenation (100% O2) to establish a safe and effective artificial airway. Mechanical ventilation was performed after endotracheal intubation, and a second time was performed immediately after endotracheal intubation was completed~On pulmonary ultrasound, patients in the ZEEP group maintained normal mechanical ventilation throughout the operation without PEEP or RMS"
9675948|NCT04991649|Experimental|ACT Group|One two-weekly 2-hour of positive parenting program plus a four-weekly 2-hour group ACT program and routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
9675949|NCT04991649|Other|Treatment-as-usual (TAU) Group|Routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
9675950|NCT04991857|Experimental|The technology-based family-centered empowerment program for heart failure (T-FAME-HF)|The T-FAME-HF is a 16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits. The Program includes 3 four-week phases, which followed by 2 bi-weekly telephone visits. Each phase is designated with a specified goal of care to guide the disease management activities. Commenced with the home visit by the team nurse for each phase, patients' condition and self-care will be assessed. A goal-setting approach will be used to enhance disease monitoring, symptom recognition and response, and treatment compliance. A mobile apps (T-FAME) will be installed in participants' smart-phone and supports the prescribed actions for goal attainment.
9675951|NCT04991857|Active Comparator|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by another team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
9695172|NCT04781153|Experimental|Immediate intervention (A)|Subjects will receive the full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) immediately after baseline.
9975596|NCT01343186|Other|Arm 1|
9975597|NCT01343186|Other|Arm 2|
9975598|NCT01343186|Other|Arm 3|
9975599|NCT01343186|Other|Arm 4|
10174352|NCT03854162|Active Comparator|PILOT|The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
10174353|NCT03854162|Active Comparator|PARTIAL GUIDE|The only non-guided step is implant insertion, that is, all drilling happens through the SMART Guide surgical template. After having prepared soft tissue access, the guide is placed, and all drillings are performed through it, according to the surgical protocol. Here the depth of the bony bed is also determined, as the sleeve does not allow the drill to move any deeper than planned. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
10174354|NCT03854162|Active Comparator|FULL GUIDE|"The SMART Guide surgical template is used for all steps of the operation, including the insertion of the implant. Apart from this, the procedure is exactly the same as described under partial guide."
9527577|NCT03218631|Other|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
9527578|NCT03218709|Experimental|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
9527579|NCT03218709|Experimental|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
9527580|NCT03218709|Active Comparator|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
9527581|NCT03218709|Placebo Comparator|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
9527582|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
9527583|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
9527584|NCT03218579|No Intervention|No intervention|No intervention after antibiotic treatment.
9527585|NCT03218579|Active Comparator|Probiotic microbiome rehabilitation|Probiotic treatment after antibiotic treatment.
9527586|NCT03218579|Active Comparator|Bacteriotherapy microbiome rehabilitation|Bacteriotherapy after antibiotic treatment.
9527587|NCT03218657|Experimental|experimental group|the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
9527588|NCT03218657|Other|control group|the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
9527589|NCT03218696|Experimental|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
9975600|NCT01343212||newly diagnosed HCC|"Subjects with newly diagnosed untreated hepatocellular carcinoma (HCC) will be enrolled.~Subjects with the following conditions will be excluded:~liver cancer other than HCC, treated HCC, post major abdominal surgery, contraindications to liver tumor biopsy, contraindications to local percutaneous treatment of liver tumors, low quality ARFI measurement"
9975601|NCT01343225|Active Comparator|atripla|comparator
9527590|NCT03218696|Placebo Comparator|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
9527591|NCT03218813|No Intervention|Control cohort ('before' group)|Control cohort ('before' group): eligible patients will receive treatment as usual (TAU) and will complete all outcome measures.
9527592|NCT03218813|Experimental|Intervention cohort ('after' group)|Eligible patients will receive the pharmacist-led intervention and will complete all outcome measures.
9527593|NCT03218644|Active Comparator|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
9527594|NCT03218644|Experimental|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
9527595|NCT03218774|Other|Home Group|
9527596|NCT03218774|Experimental|Center Group|
9527597|NCT03218553|Experimental|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
9527598|NCT03218553|Placebo Comparator|placebo|Standard cares plus postoperative administrations of placebo
9527599|NCT03218852|Experimental|prednisone and cyclophosphamide|"prednisone(0.5mg/kg/day*6 months)~cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
9527600|NCT03218852|Experimental|prednisone alone|"prednisone(0.5mg/kg/day*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
9527601|NCT03218800|Active Comparator|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
9527602|NCT03218800|Experimental|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
9527603|NCT03218865|Experimental|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
9527604|NCT03218865|Active Comparator|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
9675952|NCT04991597|Experimental|Left Forearm Injection Sites Cooled, Right Forearm Injection Sites at Room Temperature|Palmar aspect of participants left forearm will have a cold compress pack placed on it. The palmar aspect of the right forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
9675953|NCT04991597|Experimental|Right Forearm Injection Sites Cooled, Left Forearm Injection Sites at Room Temperature|Palmar aspect of participants right forearm will have a cold compress pack placed on it. The palmar aspect of the left forearm will have a room temperature compress pack placed on it. Each forearm will be injected with 1mL of lidocaine with epinephrine buffered with sodium bicarbonate. Each forearm will be injected once with the experimental ratio (3:1) and once with the standard control ratio (9:1). Injections will be administered in a randomized order.
9675954|NCT04991714|Experimental|Sucrose|10% solution in water
9675955|NCT04991714|Experimental|Sucrose + Reb M|10% sucrose + 60 mg/L Rebaudioside M
9675956|NCT04991714|Experimental|Sucrose + Lactisole|10% sucrose + 30 mg/ L Lactisole
9675957|NCT04991714|Experimental|Sucrose + Reb M + Lactisole|10% sucrose + 60 mg/L Rebaudioside M + 30 mg/ L Lactisole
9675958|NCT04991584|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy Option 1:Amoxicillin+Tetracycline+Furazolidone+Vonoprazan fumarate or Esomeprazole Option 2: Amoxicillin+Furazolidone+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 3: Amoxicillin+Tetracycline+Levofloxacin+Vonoprazan fumarate or Esomeprazole Option 4: Amoxicillin+Clarithromycin+Levofloxacin+Vonoprazan fumarate or Esomeprazole Three options are selected according to the actual situation.
9675959|NCT04991831||Post Exablate Neuro Thalamotomy for Tremor Associated with Tremor Dominant Parkinson's Disease|This is a post Exablate Neuro Thalamotomy registry. No intervention is performed under this registry protocol.
9675960|NCT04991623|Experimental|Kinesiology taping|Apply a kinesiology taping on the abdominal muscles plus conventional physiotherapy
9675961|NCT04991623|Active Comparator|Physiotherapy Group|Apply a conventional physiotherapy
9675962|NCT04991844|No Intervention|Control group|The control group did not receive any intervention, but met at three timepoints to complete study questionnaires and provide anthropometric measurements,
9675963|NCT04991844|Experimental|Intervention Group|This group received the study intervention protocol.
9675964|NCT04991870|Experimental|Group 1 (CB-NK-TGF-betaR2-/NR3C1- )|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 8 doses in the absence of disease progression or unacceptable toxicity.
9675965|NCT04991870|Experimental|Group 2 (CB-NK-TGF-betaR2-/NR3C1-, resection)|Patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes on days 0, 7, and 14. Patients undergo standard of care surgical resection on day 15. Beginning 2 weeks after surgery, patients receive CB-NK-TGF-betaR2-/NR3C1- intratumorally over 5-10 minutes weekly for up to 5 doses (total of 8 doses) in the absence of disease progression or unacceptable toxicity.
10174355|NCT03854175|Active Comparator|Sildenafil group|40 women are give sildenafil citrate 25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle, in addition to oral 2mg of estradiol valerat 6-8 hourly from the day 2-14 of the menstrual cycle
10174356|NCT03854175|Active Comparator|estradiol group|40 women are given oral estradiol valerate tablets 2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium in addition to placebo in the same way as sildenafil
10174357|NCT03853915|Experimental|FDG PET Scan|[F-18] - FDG PET Scan and blood sample to measure HPV DNA
9675966|NCT04991909|Experimental|Treatment group A|
9675967|NCT04991909|Placebo Comparator|Treatment group B|
9675968|NCT04991610|Active Comparator|Adult male|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
9675969|NCT04991610|Active Comparator|Adult female|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
9675970|NCT04991545|No Intervention|Group A: control group (intubation without IRD/IRRIS device)|Group A = control group (intubation without IRD/IRRIS device) (15 subjects) The first operator experienced with video-laryngoscopy intubation will do the endotracheal intubation after induction of anesthesia.
9675971|NCT04991545|Experimental|Intervention group using Infrared (Active IRD/ IRRIS) device|Group B = intervention group using Infrared active IRD/IRRIS device (15 subjects) Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients. After confirming lack of discomfort during application of the IRRIS/IRD device, anesthesia will be induced
9675972|NCT04991532||Dasatinib group|the CML patient treated with dasatinib
9675973|NCT04991532||Imatinib group|the CML patient treated with imatinib
9675974|NCT04991389|Experimental|Phase 1 - Contrast 129Xe MRI ages 5-18|The research team will collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Phase contrast MRI of inhaled gas. (4) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
9675975|NCT04991389|Experimental|Phase 2 - Contrast 129Xe MRI ages 3-18|The research team plans to collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
10174358|NCT03854201|Experimental|Personalized Exercise Counseling (PEC)|The Personalized Exercise Counselling intervention includes 3 face-face counseling sessions and 4-6 phone calls during six months. In addition, the participants are provided with the ExSed® interactive accelerometer to record their physical activity 24/7 from which they will receive personal daily feedback on their smart phone, which is provided to each person not having a suitable one of their own to be used during the 6-month intervention period.
9675976|NCT04991272|Active Comparator|warming group|Warming group patients are applied prewarming with bair-hugger (43'C)(warm touch, COVIDIEN, full body blanket) for 10 minutes in the preanesthetic unit prior to induction of anesthesia. During operation, prewarmed intravenous fluid which was stored in the warming cabinet for more than 8 hours is connected and infused. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
9675977|NCT04991272|No Intervention|no warming group|No warming group patients are not applied prewarming devices. Intravenous fluid stored in room air is connected and infused during the operation. Forced air blanket (warm touch, COVIDIEN, upper body blanket) with 38'C is applied for all patients during the operation.
9527605|NCT03218748|Experimental|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.~Fidelity to manual: rated by a research assistant who is present during the group session"
9675978|NCT04991181|Experimental|BIA 5-1058|Capsules; 400 mg; single dose; oral administration.
9675979|NCT04991324|Experimental|weekly supplementation|Weekly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 3500 IU per day, as comedication to the usual treatment during 6 months.
9675980|NCT04991324|Active Comparator|monthly supplementation|Monthly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 800 IU per day, as comedication to the usual treatment during 6 months.
9975602|NCT01343225|Experimental|darunavir ritonavir raltegravir|experimental
10174359|NCT03854201|No Intervention|Control-arm|The participants only take part in the study measurements at baseline and the three follow-up time points. They will be provided personal written information by the UKK Institute on their blood sugar and lipid profiles, objectively measured physical activity (light, moderate, vigorous), standing, sedentary behaviour and sleep, and the three fitness tests measuring flexibility, muscular strength and cardiorespiratory fitness.
10174360|NCT03853941|No Intervention|Control|Patients in the control group will receive treatment as usual.
10174361|NCT03853941|Experimental|Experimental|The experimental group will receive clinical treatment as usual, however, the healthcare professionals treating them will have received training on how to enhance patient adherence via the use of a motivationally supportive communication style. Thus, the style/language healthcare professionals use to convey usual treatment recommendations may differ.
10174362|NCT03853954|Experimental|Methoxyflurane|Dosage form: inhalation Dosage: 3 mL methoxyflurane per inhaler, to be self-administered Frequency: maximum one inhaler (3 mL) per patient Duration: <15 minutes
10174363|NCT03853980|Experimental|Rotational fractional resection (RFR)|Single treatment of skin resection (removal of loose skin)
10174364|NCT03854214|Active Comparator|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc) with stimulation on.
10174365|NCT03854214|Sham Comparator|Passive Cycling|The passive cycling group will use the same RT300 ergometer with stimulation off.
10174366|NCT03853850|Experimental|Intervention|Participating mothers will receive mobile phone text messages during their babies' first 6 months of life. Messages will educate mothers on breastfeeding and proper infant feeding.
10174367|NCT03854097|Experimental|Active PAD group|-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
10174368|NCT03854097|Experimental|Placebo PAD group|-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
10174369|NCT03854097|Experimental|Healthy Volunteers|-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
10174370|NCT03854071|Other|Group 1|Heart failure patients with preserved ejection fraction
10174371|NCT03854071|Other|Group 2|Heart failure patients with reserved ejection fraction
10174372|NCT03854071|Other|Group 3|Patients with pulmonary hypertension
10174373|NCT03854071|Other|Group 4|Patients with acute myocardial infarction
9527606|NCT03218748|No Intervention|Control group|Treatment as usual (TAU)
9527607|NCT03218722|Experimental|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
9675981|NCT04991324|No Intervention|control group|Usual treatment without vitamin D supplementation.
9675982|NCT04991402||Pregnant women living with HIV initiating Dolutegravir (DTG) in pregnancy (iDTG)|Pregnant women living with HIV not on antiretroviral therapy (ART) at their 1st antenatal care visit and initiating DTG-based ART in pregnancy.
9675983|NCT04991402||Pregnant women living with HIV already on DTG-based ART prior to pregnancy (cDTG)|Pregnant women living with HIV already on DTG-based ART prior to pregnancy and continuing DTG use through pregnancy.
9675984|NCT04991402||HIV uninfected pregnant women|Pregnant women not living with HIV
9675985|NCT04991376||Vancomycin|Critically ill patients who suffered from sepsis, treated with vancomycin.
9675986|NCT04991376||Gentamicin|Critically ill patients who suffered from sepsis, treated with gentamicin.
9675987|NCT04991376||Other antibiotic groups|Critically ill patients who suffered from sepsis, treated by other antibiotic groups except for vancomycin or aminoglycoside (gentamicin).
9675988|NCT04991454|Other|end-stage pulmonary arterial hypertension .|subjects with end-stage PAH that currently on the waitlist for lung transplant
9675989|NCT04991454|Other|following pulmonary arterial hypertension subjects|Following pulmonary arterial hypertension subjects upto 24 months
9975603|NCT01343238|Experimental|Diet|12 week diet modification intervention by dietician
9975604|NCT01343238|Experimental|Exercise|12 week physical exercise modification intervention by physical therapist
9975605|NCT01343238|Experimental|Diet and Exercise|12 week diet and exercise behavioral modification by dietician and physical therapist
10174374|NCT03854071|Other|Group 5|Patients with suspected but not treated coronary artery disease
10174375|NCT03854071|Other|Group 6|Healthy Volunteers
10174376|NCT03853993|Experimental|Experimental group-phase I|Quadrivalent influenza vaccine
10174377|NCT03853993|Experimental|Experimental group-phase III|Quadrivalent influenza vaccine
10174378|NCT03853993|Active Comparator|Control group-1-phase III|Trivalent influenza vaccine (contains B/Victoria strain)
9675990|NCT04991441|Experimental|Control|Participants will follow their usual or normal diet for 5 months (CON) followed by an Controlled Dietary Sodium Restriction (INT) diet for 2 months. During the sodium restricted diet, participants will be provided with 2 meals and snacks daily, for 30 days (Month 5 - days 1-30) and 1 meal and snacks daily, for 30 days (Month 6 - days 31-60). These meals should meet the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDQOI) guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
9675991|NCT04991441|Experimental|Intervention|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
10174379|NCT03853993|Active Comparator|Control group-2-phase III|Trivalent influenza vaccine (contains B/Yamagata strain)
10174380|NCT03853863|Experimental|minimalist shoes walking group (MSW)|Subjects in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., in-school walking training with minimalist shoes).
9675992|NCT04991519||Stroke Survivors|Participants have had a left-hemisphere stroke with or without aphasia, or a stroke elsewhere in the brain causing aphasia. They are given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
9675993|NCT04991519||Controls|Participants are matched to aphasia cohort in age, educational background, race, and gender but have no history of brain injury. They are also given a series of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses, plus an MRI.
9675994|NCT04991428|Experimental|Active trancranial direct current stimulation|Active stimulation for 15 minutes
9675995|NCT04991428|Sham Comparator|Sham stimulation|Similar set-up but no actual stimulation
9675996|NCT04991220|Experimental|preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
9675997|NCT04991311|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
9675998|NCT04991415|Experimental|Treatment|30 minutes of manual therapy three times a week for two weeks (six total sessions).
9675999|NCT04991415|No Intervention|Control|No intervention
9676000|NCT04991207|Experimental|BIA 5-1058|Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5 1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
9676001|NCT04991207|Active Comparator|Bosentan|Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple (twice daily [b.i.d.]) oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
9676002|NCT04991207|Experimental|BIA 5-1058 and Bosentan|Treatment Period 3: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple b.i.d. oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single concomitant dose of BIA 5 1058 400 mg (4 x 100 mg tablets) and bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
9676003|NCT04991064|Other|AB arm|participants allocated to this arm receive treatment A first, followed by treatment B.
9676004|NCT04991064|Other|BA arm|participants allocated to this arm receive treatment B first, followed by treatment A.
9676005|NCT04990947||Bariatric surgery (Roux-en-Y Gastric Bypass)|Patients who are eligible for RYGB
9676006|NCT04990947||Lifestyle group|Patients with a BMI > 30 who will start a lifestyle program
10174381|NCT03853863|Active Comparator|traditional shoes walking group (TSW)|Subjects in the TSW group will be given a pair of protective shoes with arch support while following the same wearing pattern as the MSW group (i.e., in-school walking training with protective shoes).
10174382|NCT03854084|Experimental|Intervention group|The cranial osteopathic techniques
10174383|NCT03854084|Sham Comparator|control group|Control group
10174384|NCT03854188|Experimental|Acupuncture treatment|Patients diagnosed with chronic pelvic pain will be offered acupuncture treatment as an adjuvant therapy to standard of care treatment.
9676007|NCT04990960|Active Comparator|Physiotherapist|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements and actively worked on AWS cords with gentle extensions and / or energetic detachment maneuvers. No self-treatment methods were offered and required of the subject.
9676008|NCT04990960|Experimental|Self-treatment|The Physiotherapist worked on adhered breast scars, stiffness in neck and arm movements. During each session the patient was also assessed and trained in self-treatment exercises assigned to treat their cords. Subjects were trained to perform self-treatment extension exercises with four exercises selected by the Physiotherapist
9676009|NCT04991038|Experimental|DAISe Thrombectomy Device|Mechanical Thrombectomy with DAISe
9975606|NCT01343238|No Intervention|Control|Standard procedure
10174385|NCT03854045|Experimental|Home-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the home with 2 clinicians present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR but are not eligible for Medicaid reimbursement.
10174386|NCT03854045|Active Comparator|Clinic-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the clinic with 1 clinican present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR and eligible for Medicaid reimbursement.
9527608|NCT03218722|Placebo Comparator|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
9676010|NCT04991038|Active Comparator|Stent Retriever|Mechanical Thrombectomy with TREVO or Solitaire Device
9676011|NCT04991142||Persons with Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c greater than or equal to 6.5%
9676012|NCT04991142||Persons with Pre-diabetes|Venous blood draw of fasting HbA1c greater than or equal to 5.7% and less than 6.5%
9676013|NCT04991142||Persons without Pre-diabetes or Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c less than 5.7%
9676014|NCT04990999|Experimental|Vestibular Root Extraction|
9676015|NCT04990999|Active Comparator|Atraumatic extractions using periotomes followed by conventional forceps|
9676016|NCT04991233|Experimental|Endoscopic surgery|Endoscopic surgery group
9676017|NCT04991233|Active Comparator|Suboccipital craniotomy surgery|Suboccipital craniotomy surgery group
9676018|NCT04991155|Experimental|PART 1 (400 mg BIA 5-1058)|Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3): Part 1: 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 1, 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 2, and 400 mg BIA 5-1058 as four (4) 100 mg tablets in Period 3.
9676019|NCT04991155|Experimental|PART 2 (800 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 2: 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 1, 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 2, and 800 mg BIA 5-1058 as eight (8) 100 mg tablets in Period 3."
9676020|NCT04991155|Experimental|PART 3 (1200 mg BIA 5-1058)|"Each subject was orally administered a single oral dose of BIA 5-1058 on D1 (dosing day) on three different occasions (Period 1, Period 2 and Period 3):~Part 3: 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 1, 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 2, and 1200 mg BIA 5-1058 as twelve (12) 100 mg tablets in Period 3."
9676021|NCT04991246|Experimental|Students, teachers,administrative staff from the medical school of Paris-Saclay University|Students,teachers,administrative staff from the medical school of Paris-Saclay University
9676022|NCT04991363|Experimental|Patients|
9676023|NCT04990973|Experimental|Mediterranean Diet and then AAD|Healthy participants that are randomized to the MedDiet followed by a 4-week washout and a crossover to the AAD.
9676024|NCT04990973|Experimental|Average American Diet (AAD) and then Mediterranean Diet|Healthy participants that are randomized to AAD followed by a 4-week washout and a crossover to the Mediterranean Diet.
9676025|NCT04991259|Experimental|Preemptive CRRT|In patients randomized to early CRRT, CRRT would be initiated within 12 hours of randomization.
9676026|NCT04991259|Active Comparator|Standard Medical Treatment|"In patients randomized to SMT group, CRRT would be initiated as per the existing standard protocol.~in patients with worsening hyperammonemia despite two sessions of plasma-exchange~patients meeting renal indications (hyperkalemia, volume overload, oliguria or metabolic acidosis etc)."
9676027|NCT04991298|Active Comparator|Group M|patients will be premedicated with the undiluted IV formulation of Midazolam
9676028|NCT04991298|Active Comparator|Group F|patients will be premedicated with the undiluted IV formulation of fentanyl citrate
9676029|NCT04991194|Experimental|BIA 5-1058 1200 mg (Part I)|Subjects received 1200 mg of BIA 5-1058 once a day (od), in fasting conditions, for 10 days
9676030|NCT04991194|Experimental|BIA 5-1058 400 mg (Part II)|Subjects received 400 mg of BIA 5-1058 od, in fasting conditions, for 10 days.
9676031|NCT04991012|Experimental|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
9676032|NCT04991012|Active Comparator|Triamcinolone (Substance) therapy side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
9975607|NCT01343290|Experimental|001|Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods
9975608|NCT01343303|Experimental|001|JNJ-39439335 2 x 5 mg tablets once daily for 21 days
9975609|NCT01343303|Experimental|002|JNJ-39439335 2 x 25 mg tablets once daily for 21 days
9975610|NCT01343303|Other|003|Naproxen 500 mg capsule every 12 hours for 21 days
9975611|NCT01343303|Placebo Comparator|004|Placebo Placebo tablet/capsule every 12 hours for 21 days
9975612|NCT01343316||Transgastric tube|Nasogastric (NG tube)
9975613|NCT01343316||Transpyloric tube - Tiger2|Self-propelled by paristaltic waves of the stomach
9975614|NCT01343316||Transpyloric tube - Syncro BlueTube|Magnetically placed
9676033|NCT04990856|Experimental|Experimental arm|Blood flow of the tumor experimented
9676034|NCT04990830|Experimental|Inhalation Treatment|"Treatment: Inhaled Low molecular weight heparin + Standard COVID-19 treatment,~Inhaled Low molecular weight heparin (4000 IU given twice a day for 10 days)"
9676035|NCT04990830|Other|Control Group|Treatment: Standard COVID-19 treatment
9676036|NCT04990882||Low Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of less than 30 studies.
9975615|NCT01343329|Experimental|Subjects Receiving Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.
9975616|NCT01343329|Active Comparator|Subjects receiving Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
9975617|NCT01343342|Experimental|capsules omega-3|Omega-3 supplementation (3g EPA+DHA/d)
9975618|NCT01343381|Active Comparator|Hepalean Heparin|
9975619|NCT01343381|Active Comparator|PPC Heparin|
9975620|NCT01343394|Experimental|Biologic; Autologous Cell Injection|
9975621|NCT01343420|Active Comparator|Dog Hair Extract, ALK-Abelló, Inc.|
10174387|NCT03853967|Experimental|screening|participants performed lung cancer screening by Low Dose CT scan
9676037|NCT04990882||Intermediate Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 30 studies and less than 300 studies.
9676038|NCT04990882||High Experience Group|Nuclear medicine physicians or radiologists with a prior experience with 68Ga-FAPI PET/CT of more than 300 studies.
9676039|NCT04991090|Experimental|escalation|The gross tumor volume (GTV) was defined as gross disease determined on MRI scans. The clinical target volume (CTV) was defined as the GTV plus areas considered at significant risk of harboring microscopic area. The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost. The planning target volume (PTV) was generated by adding an 8-mm margin around the GTV, GTVnd, and CTV in all directions. Doses of 58 Gy, 50 Gy, and 45 Gy were delivered to PTV-GTVnd, PTV-GTV, and PTV-CTV at 25 fractions, respectively. The dose of the normal organs at risk was constrained to the following criteria: bowel bag, V50 ≤ 5%; bladder, V50 ≤ 50%; femoral heads, V50 ≤ 5% .
9676040|NCT04990869|Experimental|COPD-NR|COPD patients receiving Nicotinamide Riboside
9676041|NCT04990869|Placebo Comparator|COPD-placebo|COPD patients receiving placebo
9676042|NCT04990869|Experimental|Control-NR|Lung-healthy controls receiving Nicotinamide Riboside
9676043|NCT04990869|Placebo Comparator|Control-placebo|Lung-healthy controls receiving placebo
10174388|NCT03854006|Active Comparator|Freeze cycle: 240 s - TTI <75 s or 2x240 s - >75 s|"In the first group freeze duration is 240s if TTI (time-to-isolation) is < 75 s. In case of TTI>75s a 240s bonus freeze is applied.~If no TTI could be documented, a single 240 s freeze cycle is applied in this group in case of balloon temperature -40°C (degrees Celsius) after 60 s."
9676044|NCT04990544|Experimental|Adult Group 2a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
9676045|NCT04990544|Experimental|Adult Group 2b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
9676046|NCT04990544|Experimental|Adult Group 2c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28.
9676047|NCT04990544|Placebo Comparator|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
9676048|NCT04990544|Experimental|Elderly Group 2d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
9676049|NCT04990544|Experimental|Elderly Group 2e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
9676050|NCT04990544|Experimental|Elderly Group 2f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
9676051|NCT04990544|Placebo Comparator|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
9676052|NCT04990648|Experimental|Buzzy group|Buzzy ® was placed on the left arm deltoid muscle site and kept there for 30 seconds. After 30 seconds, Buzzy ® was taken 1 cm up and MMR vaccine injection was administered to the left deltoid muscle site. After the vaccine injection, Buzzy ® was taken to the injection site and kept for another 30 seconds.
9676053|NCT04990648|No Intervention|Control group|MMR vaccine injection was administered to the left deltoid muscle without any intervention or application to the injection site.
10174389|NCT03854006|Active Comparator|Freeze cycle: TTI+120 s|In the second group freeze duration is TTI (time-to-isolation) +120 s. If no TTI could be documented, a single 180 s freeze cycle is applied in this group in case of balloon temperature -40 °C after 60 s.
10174390|NCT03853785|Active Comparator|Intralesional MMR vaccine|Intralesional Mumps, measles and rubella (MMR) vaccine in genital warts
10174391|NCT03853785|Active Comparator|intralesional candida antigen|intralesional candida antigen in genital warts
10174392|NCT03853785|Active Comparator|Topical Podophyllin|Topical Podophyllin in genital warts
10174393|NCT03853655|No Intervention|Control arm|Patients in this arm will be observed and kept under active follow-up after surgery for the primary.
9676054|NCT04990622|Experimental|Dietary flavonoid group|"Participants will be encouraged to consume 2 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 2 weeks, above what they already consume each day, typically.~Berry fruits (~120g) e.g. blueberries, raspberries, strawberries, blackberries, blackcurrants, mixed berries~2 large squares of dark chocolate (at least 70% cocoa)~4-5 cups of tea (black or green) or coffee (normal or decaf varieties)~1 large glass of red wine* (250ml)~1 portion of leafy green vegetables such as spinach or cabbage (~70g)~1 glass (250ml) of fresh orange or grapefruit juice (not from concentrate)"
9676055|NCT04990622|No Intervention|Control group|Participants will be given no instructions regarding adding food items to their diet. They will be encouraged to continue their diet as normal for 2 weeks.
9676056|NCT04990609|Experimental|Neoadjuvant chemotherapy (NAC) plus Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA)|
9676057|NCT04990713|Placebo Comparator|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with saline placebo. Local anesthetic administered will be ropivacaine 0.2%.
9676058|NCT04990713|Experimental|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients randomized to this group will receive the intercostal block with local anesthetic and the serratus plane block with local anesthetic. Local anesthetic administered will be ropivacaine 0.2%.
9676059|NCT04990791|Other|Aspirin 20mg|Aspirin 75 mg OD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD
9676060|NCT04990791|Other|Asprin 75mg|Aspirin 75 mg OD for 14(-2) days then aspirin 75 mg OD plus rivaroxaban 2.5 mg BD for 14(-2) days then aspirin 20 mg BD plus rivaroxaban 2.5 mg BD
10174394|NCT03853655|Experimental|Study arm|Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.
10174395|NCT03853720|Experimental|Intervention arm|combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
9676061|NCT04990674|Experimental|REMOTION + TAU|
9676062|NCT04990674|Active Comparator|TAU|
9676063|NCT04990557|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
9676064|NCT04990557|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 1 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment.~A total of 2 x 10^7/kg PD-1and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
9676065|NCT04990557|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) and ACE2 gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1/ACE2 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.~A total of 4 x 10^7/kg PD-1 and ACE2 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
9676066|NCT04990570||Pediatric day-case surgical patients, encountered via Virtual clinic from June 2020 till July 2021|"Pediatric patients, with age ranging from 1 month-14 years, with day-case surgical problems, encountered during the era of Covid-19 pandemic.~Telemedicine, in the form of Virtual clinic, was utilized to address this distressing problem, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship & encounter."
9676067|NCT04990570||Control group comprising of patients scheduled to the OPD clinic from June 2019 till June 2020|Cases of office OPD appointments in the period from June 2019 till June 2020 will be included as a control group
9676068|NCT04990726||Observational (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline, 1 (optional), 3, 6, 12, 18, and 24 months.
9676069|NCT04990700|No Intervention|Control Group|Includes patients undergoing routine thoracotomy
9676070|NCT04990700|Experimental|Intervention Group|The group that will undergo 1 cm partial rib resection during thoracotomy.
9676071|NCT04990752||The ulinastatin group|In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. The recommended dosage of ulinastatin is 300,000 IU, q8h (Continuous administration for more than 5 days).
9676072|NCT04990752||The control group|In the control group, patients were treated with conventional treatment without ulinastatin.
9676073|NCT04990661|Experimental|Intervention group (massage group)|intradialytic massage for lower extremity was applied to the intervention group in three sessions a week and a total of six sessions for two weeks
9676074|NCT04990661|No Intervention|Control group|not administered except nursing interventions in the HD unit.
9676075|NCT04990765|Experimental|Virtual Reality Cognitive Behavioral Therapy (VRCBT)|The VR exposure is performed to induce alcohol craving during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.
9676076|NCT04990765|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.
9676077|NCT04990583|Experimental|Carium Condition|Participants assigned to the Carium condition will receive a single session intervention and receive 12 months of access to the Carium adherence application.
9676078|NCT04990583|Active Comparator|Control Condition|Participants assigned to the Control condition will receive a single session intervention only.
9676079|NCT04990466|Experimental|Active Vaccine|IIBR-100 (VSV-ΔG) vaccine at 10 to the 8th strength in prime/boost separated by 28 days
9676080|NCT04990466|Active Comparator|Active Comparator|A currently approved vaccine for COVID-19 administered in prime/boost separated by 28 days
9676081|NCT04990453|Other|RPD frameworks fabricated from PEEK material|14 patients received extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
10174396|NCT03853889|Active Comparator|preepidural ONSD|The diameter of the optic nerve sheath to be measured(ONSD) with the help of ultrasonography before epidural anesthesia(pre epidural ONSD). The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
9975622|NCT01343433||Control group|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. Patients in the other two rooms are only exposed to environmental light
10174397|NCT03853889|Experimental|post epidural ONSD|The diameter of the optic nerve sheath to be measured with the help of ultrasonography Immediately after epidural anesthesia(post epidural ONSD) (T1), 15 minutes (T2), 30 min (T3), 60. min (T4) epidural anesthesia. The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
10174398|NCT03853928|Experimental|Probiotics|50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .
9676082|NCT04990453|Other|RPD frameworks fabricated from Co-Cr|14 patients received extracoronal precision attachment RPD frameworks fabricated from Co-Cr material using casting machine
9676083|NCT04990271|Experimental|Conbercept intravitreal Injection|
9676084|NCT04990362|Experimental|MD + Seed oil|"Pomegranate oil + Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Pomegranate oil in a glass bottle of 30ml Dietary Supplement: Mediterranean dietary protocol~Intervention:~Mediterranean diet, Pomegranate oil"
9676085|NCT04990362|Active Comparator|MD|Mediterranean Diet 30 patients Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol Intervention: Mediterranean diet
9676086|NCT04990180|Experimental|Shared Decision Making Intervention|The intervention is a shared decision making consultation supported by a patient decision aid and decision coaching for healthcare professionals.
9676087|NCT04990414|Experimental|CBT for voices and dissociation|24 sessions of Cognitive Behavioural Therapy (CBT) over a 6-month period treatment window.
10174399|NCT03853928|Placebo Comparator|Placebo|5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly). Duration of treatment Continuous, 1 cycle per month. Continuous treatment will be carried out from randomization to the development of the primary event or until the end of the study.
10174400|NCT03853681|Other|additional blood sampling|
9676088|NCT04990349|Experimental|Extracorporeal normoxemia|"After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%.~The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg.~PO2 postoxygenator is monitored at least twice a day by the nurse.~If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after.~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~Intervention will be applied for 7 days after randomization."
9676089|NCT04990349|Active Comparator|Extracorporeal hyperoxemia|"After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%.~The objective is to maintain PO2 postoxygenator higher than 300 mmHg.~PO2 postoxygenator is monitored at least twice a day by the nurse.~If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed.~Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg.~Intervention will be applied for 7 days after randomization."
9676090|NCT04990232|Placebo Comparator|Standard of care|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days.
9676091|NCT04990232|Experimental|Immunotherapy|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive IV anakinra 200 mg three times daily (every eight hours) or sc rhIFNγ 100 μg once every other day. More precisely, patients randomized for hyper-inflammation will receive anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. Patients having immunoparalysis will receive IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days. Especially for patients with creatinine clearance lower than 30 ml/min anakinra will be given half dose (i.e. 100 mg three times daily). Creatinine clearance is calculated by the Cockcroft Gault equation [(140-age in years)/ (72 x serum creatinine in mg/dl) for men; this is multiplied by 0.85 for women.
9676092|NCT04990076||Patients planned for hysterectomy with a myometrial lesion of more than 1 cm.|
9676093|NCT04990193|Active Comparator|Control group|Children in the control group received the conventional physical therapy protocol which was designed to improve axial stability and trunk steadiness during standing and walking.
10174401|NCT03853603|Placebo Comparator|Placebo|Maltodextrin
10174402|NCT03853603|Active Comparator|Santa herba extract|Santa herba extract
9676094|NCT04990193|Experimental|Study group|The children in the study group received the conventional protocol given to the control group. Moreover, they wore TheraTog orthotic undergarment with its strapping system eight hours every day for twelve consecutive weeks.
10174403|NCT03853707|Experimental|Arm A (ipatasertib, carboplatin, paclitaxel)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10174404|NCT03853707|Active Comparator|Arm B (ipatasertib and carboplatin)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10174405|NCT03853707|Experimental|Arm C (ipatasertib, capecitabine, atezolizumab)|Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10174406|NCT03853525|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with BAY207543 is investigated.
10174407|NCT03853525|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with vaseline is investigated.
10174408|NCT03853668|Active Comparator|aerobic exercise group|"aerobic exercises (intervention) on treadmill for 10 weeks, 3 times/week for duration of 30-45 min/session.~Exercise intensity is 50-65%of maximal heart rate (MHR)"
10174409|NCT03853668|Experimental|aerobic and resisted exercise|combined resisted and aerobic exercises (intervention) for 10 weeks (circuit weight training and treadmill training respectively) 2 times/week for a duration of 30-45 min/session Exercise intensity is 50-65%of maximal heart rate (MHR) for aerobic part and 50% of 1 repetition maximum (1RM) for resistance part.
10174410|NCT03853746|Experimental|Ocrelizumab|All participants will receive Ocrelizumab
10174411|NCT03853408||First Admission|Cholecystectomy during first admission
10174412|NCT03853408||Second Admission|Cholecystectomy during second admission
9676095|NCT04990063|Experimental|adoptive TKC transfer combined with chemotherapy|NK cells and γδT cells are isolated from the patients' PBMCs obtained before standard chemotherapy and then co-cultured ex-vivo. Patients will receive multiple TKC treatments under administration, 3 weeks/cycle. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators. TKC cells are transfused to patients in a dosage escalated manner. Dose escalation starts at 1×10^8 cells/kg (based on the whole body weight). After the safety assurance of the initial administration, the next course, up to 8 courses, is resumed and the dose maybe increased subsequently at the discretion of the investigators, or reduced for safety reason.
9676096|NCT04990115|Active Comparator|rotation|root canal preparation performed using rotating instruments
9676097|NCT04990115|Active Comparator|reciprocation|root canal preparation performed using reciprocating instruments
9676098|NCT04989881|Experimental|Da Vinci Simulator|Participants will undergo a single session of training using the da Vinci Simulator
9676099|NCT04989881|Active Comparator|Laparascopic training box|Participants will undergo a single session of training using a laparoscopic training box
9676100|NCT04990089||VIVO|Patients in which VIVO is used.
9676101|NCT04990154|Experimental|experimental group|The experimental group received a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
9676102|NCT04990154|No Intervention|control group|the control group maintained their usual lifestyles
9975623|NCT01343433||Treatment group (bright light therapy)|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. During our study, light therapy will be applied with instrument 'Litepod' (manufactured by Goodlite, Donker Curtiusstraat 7/407, Amsterdam), which gives an intensity of 10000 lux at a distance of 22 centimetres.Patients will receive bright light therapy for three hours in the morning, from eight o'clock till eleven o'clock.
9676103|NCT04989985|Active Comparator|Active Comparator|"SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
10174413|NCT03853564|Experimental|Video-Feedback Group (VFG)|Dyads of mothers and their infant with developmental disability who are exposed to the video-feedback intervention focused on different domains of mother-infant quality of interaction (number of sessions: 6).
9676104|NCT04989985|Experimental|Experimental|"Sinitlimab + SOX； SOX: Oxaliplatin+S-1~Sinitlimab: 200mg, ivdrip, d1, q3w;~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40~60mg Bid, d1~14, q3w;~Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 4-6 cycles."
9676105|NCT04990037|Experimental|CAN04 and FOLFIRINOX|Subjects will receive bi-weekly doses of CAN04 in combination with FOLFIRINOX given as standard regimen.
9676106|NCT04989998|Experimental|Hip7 Software on Kick/ CORI platforms|Subjects will receive total hip arthroplasty surgery using Hip7 on Kick or CORI platform utilizing R3 Polarstem implants.
9676107|NCT04989998|Active Comparator|Conventional procedures with standard, manual instrumentation and digital templating techniques|Subjects will receive total hip arthroplasty surgery using conventional procedures with standard instrumentation and digital templating techniques utilizing R3 Polarstem implants.
9676108|NCT04989959|Experimental|Pre-Surgical|Patients with suspected RCC planned for surgery
9676109|NCT04989959|Experimental|Metastatic|Patients with metastatic ccRCC
9676110|NCT04990375|Sham Comparator|active vs. sham tDCS to reduce early relapse|We compare 5 sessions of active tDCS (2 mA) vs. 5 sessions of sham tDCS (0 mA) to observe if tDCS can reduce early relapse (2-week follow-up). The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
9975624|NCT01343446||Patients with Diabetes|Patients with diabetes suffer from sleep impairment or not
9975625|NCT01343472|Experimental|WISP supervision|Parolee supervised under WISP parole model.
9676111|NCT04990375|Other|tDCS alone vs. combined tDCS with ICT to reduce early relapse|We compare 5 sessions of active tDCS alone vs. 5 sessions of tDCS combined with alcohol ICT vs.5 sessions of tDCS combined with neutral ICT vs. 5 sessions of sham tDCS to observe whether tDCS is better combined than alone to reduce early relapses (2-week follow-up). For all active and sham tDCS conditions there is 15-second ramping up and down and the session lasts 20 minutes. Patients are watching a documentary during the application of tDCS alone and there are two types of ICT combined with tDCS: one alcohol ICT (8 alcohol images associated to nogo response, 8 sport images associated to go response, 8 neutral images associated to nogo response and 8 neutral images associated to go response) and one neutral ICT (the same 16 neutral images).
9676112|NCT04990375|Sham Comparator|Craving|We compare scored craving before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
9676113|NCT04990375|Sham Comparator|Working memory|We compare reverse memory span before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
9975626|NCT01343472|Active Comparator|Parole-as-usual|Parolees supervised under Washington State's parole-as-usual
9975627|NCT01343498|Experimental|BEZ235|
10174414|NCT03853564|Sham Comparator|Phone-Call Group (PCG)|Dyads of mothers and their infant with developmental disability who are not exposed to the video-feedback intervention, instead they receive phone calls focused on obtaining descriptions of different domains of infant behavioral development (number of sessions: 6)
9975628|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs treatment|Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
9975629|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs and hUC-MSCs therapy|Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
9975630|NCT01343524||all subjects|all subjects who are enrolled in an industry-sponsored study that utilizes a sponsor-supplied spirometer.
9975631|NCT01343537|Experimental|Monitoring|
9975632|NCT01343550|Experimental|Creativity group for persons diagnosed with BPD|
9975633|NCT01343563|Active Comparator|Low frequency to High|For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
9676114|NCT04990375|Sham Comparator|Depressive symptoms|We compare scored BDI-II before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
9676115|NCT04990167|Experimental|Tiotropium arm|"Subjects on this arm will start the study on tiotropium for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on the prescribed asthma controller medication."
9676116|NCT04990167|Active Comparator|ICS arm|"Subjects on this arm will start the study on the prescribed asthma medication for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on Tiotropium."
9676117|NCT04990245||patients with ulcerative colitis|patients with ulcerative colitis and planned endoscopy as part of routine care
9695173|NCT04781153|Experimental|Delayed intervention (B)|"Subjects will receive a full mouth disinfection treatment protocol (scaling and rootplaning of all periodontal pockets with adjunctive use of chlorhexidine mouthwash) 3-4 weeks after baseline. The delayed intervention will enable the study team to explore the effect of the participants change in behavior due to participation in a research project, and furthermore how change in oral hygiene habits might affect the lung function."
9695174|NCT04781166|Experimental|Intervention|Participants will be immediately assigned to the intervention.
9695175|NCT04781166|Other|Waitlist control|Participants will complete measures before and after a waitlist equivalent to the duration of the intervention, to assess whether change is observed with time and repeated assessment. After the waitlist control, participants will be provided the opportunity to take part in the intervention. In this RDICT design, the pre- post- treatment data will be included in analyses.
9695176|NCT04781491|Experimental|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Subjects receive a 90-minute Forest Therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
9695177|NCT04781491|No Intervention|Waiting list|Subjects don't receive any therapy but are offered the same treatment after trial is finished.
9695178|NCT04780906|Sham Comparator|Sham first (group 1)|Performs the first round of test with the sham comparator than with the experimental wrist taping
9695179|NCT04780906|Experimental|Wrist taping first (group 2)|Performs the first round of test with the experimental wrist taping than with the sham comparator
9695180|NCT04781335|Active Comparator|Dexycu|
9695181|NCT04781335|Active Comparator|Standard Care Post operative drops|
9975634|NCT01343563|Active Comparator|High frequency|Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
9975635|NCT01343602|Experimental|mod. Constraint-Induced Movement Therapy|CIMT at home is applied in the patients' home over the course of four weeks including (i.e. 20 consecutive days) 2 hours of daily training together with an instructed non-professional coach (e.g. family member) applying shaping techniques.
9975636|NCT01343602|Other|Therapy as usual|Patients in this arm will receive usual care dose-matched to the intervention group (250-300 minutes).
9975637|NCT01343615|Active Comparator|carotid stenting|
9975638|NCT01343615|Active Comparator|carotid endarterectomy|
9975639|NCT01343628|Placebo Comparator|Placebo, Atomoxetine|
9975640|NCT01343628|Active Comparator|Atomoxetine, Placebo|
9975641|NCT01343641|Experimental|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
9975642|NCT01343641|Placebo Comparator|Placebo|Inactive Pill used as a comparator
9975643|NCT01343654|Experimental|Text messaging|Participants randomized to this arm will receive a mobile phone if needed, and the 12 week personalized text messaging/EMA intervention
10174415|NCT03853824|Other|Intervention arm|Patients randomised to increased postoperative surveillance.
10174416|NCT03853824|Other|Control arm|Patients randomised to usual postoperative care.
9695182|NCT04780867|No Intervention|Routine vaccination (Control)|
9695183|NCT04780867|Experimental|Delay vaccination (Experimental)|
9695184|NCT04780945|Experimental|Olaparib monotherapy|Patients, irrespective of BRCA status, will be treated with olaparib tablet 300 mg bid
9695185|NCT04781114|Experimental|JS002|Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);
9695186|NCT04781114|Placebo Comparator|Placebo|Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);
9695187|NCT04780997|Experimental|Virtual Realty|Microsoft Xbox Kinect® was used for virtual reality exercises
9827540|NCT02459964|Active Comparator|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
9975644|NCT01343654|Active Comparator|Treatment as usual|Participants randomized to this arm will receive treatment as usual in the ID clinics and in the communities for nonadherence and drug use problems
9975645|NCT01343680|Active Comparator|10U/l heparin|
9975646|NCT01343680|Experimental|normal saline|
9975647|NCT01343706|Experimental|BI 409306 dose 1|Solution for oral administration
9975648|NCT01343706|Experimental|BI 409306 dose 2|Solution for oral administration
9975649|NCT01343706|Experimental|BI 409306 dose 3|Solution for oral administration
9975650|NCT01343706|Experimental|BI 409306 dose 4|Solution for oral administration
9975651|NCT01343706|Experimental|BI 409306 dose 5|Immediate release solid oral dosage
9975652|NCT01343706|Experimental|BI 409306 dose 6|Immediate release solid oral dosage
9975653|NCT01343706|Experimental|BI 409306 dose 7|Immediate release solid oral dosage
9975654|NCT01343706|Experimental|BI 409306 dose 8|Immediate release solid oral dosage
9975655|NCT01343706|Experimental|BI 409306 dose 9|Immediate release solid oral dosage
10174417|NCT03853642||Single-arm trial|Patient receiving blood sampling, spirometry and Feno
9676118|NCT04990024|Experimental|Mediterranean Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on Mediterranean diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
9676119|NCT04990024|Experimental|High protein/Low Carbohydrate Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on HP/LC diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
9676120|NCT04990024|Active Comparator|Low Fat Diet|50 participants will be randomized to this arm. The intervention consists of 5 individual (visits 1,3,5,7,9) and 8 group (visits 1,2,3,4,5,6,7,8) educational sessions on low fat diet in patients on Liraglutide, over a period of 24 weeks. Dietary assessments and adherence questionnaires will be held on several visits to assess adherence.
9676121|NCT04989868|Experimental|Trans-Nasal Afferent Loop Decompression Arm|Patients will receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
9676122|NCT04989868|Active Comparator|No Trans-Nasal Afferent Loop Decompression Arm|Patients will NOT receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
9676123|NCT04989920|Experimental|CIMT (Constraint-Induced Movement Therapy)|Therapy intervention: This arm will deliver the signature Constraint-induced therapy protocol for 60 hrs of training over a two-week period.
9676124|NCT04989920|No Intervention|Delayed (Control) intervention group|"Subjects randomized to the delayed intervention group will receive the usual and customary services provided by their personal health care system."
9676125|NCT04990011|Experimental|BioXclude amnion chorion membrane|
9676126|NCT04989933|Active Comparator|ESP 20 ml|Ultrasound-Guided erector spinae plane block with 20 ml of 0.25% bupivacaine
9676127|NCT04989933|Active Comparator|ESP 30 ml|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine
9676128|NCT04989855|Experimental|Fruquintinib plus Tislelizumab|Fruquintinib 5mg QD d1-d14, Q3W; Tislelizumab 200mg IV Q3W d1
10174418|NCT03853590|Active Comparator|Laparoscopic Adjustable Gastric Band|Subjects who elected to undergo Laparoscopic Adjustable Gastric Band intervention were examined prior to surgery and at 2, 3, 6 months after operation.
10174419|NCT03853590|Experimental|Roux-en-Y gastric bypass surgery|Subjects who elected to undergo Roux-en-Y gastric bypass surgery were examined prior to surgery and at 2, 3, 6 months after operation.
10174420|NCT03853538|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
9676129|NCT04989790|No Intervention|Baseline/Pre-implementation|Usual PICU care
9676130|NCT04989790|Active Comparator|Intervention/Post-implementation|PICU Up! is a multifaceted, inter-professional pathway that is integrated into routine PICU practice to safely optimize early and progressive patient mobility.
10174421|NCT03853538|Active Comparator|Women_Hemiface Vaseline|Adult women receive the test product randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
10187113|NCT03729414|Active Comparator|mucopexy with Doppler artery ligation|Doppler guided hemorrhoidal artery ligation and mucopexy: Group of patients with III degree hemorrhoids treated by THD or AMI device is introduced into the anal canal. The terminal branches of the rectal artery are detected by the Doppler 2-3 cm above the dentate line. The tip of the instrument is tilted and arteries ligated with a figure-of-eight suture inserted using a special needle-holder. After the haemorrhoid artery ligation, the suture is continued with 3/5 sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all artery ligations (6 ligations
10187114|NCT03729414|Experimental|mucopexy without Doppler artery ligation|Non Doppler guided hemorrhoidal artery ligation and mucopexy: A lubricating gel is applied to the tip of the THD or the AMI device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. the mucopexy will start at two o'clock and repeated at 4, 6 8, 10, 12, in clockwise direction
10187115|NCT03729375|Experimental|10cc Patients|Intervention: Group 1 will receive 10cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
10187116|NCT03729375|Active Comparator|20cc Patients|Intervention: Group 2 will receive 20cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
10187117|NCT03729336|Experimental|PEEZY specimen|All subjects will use PEEZY to give a urine specimen.
10187118|NCT03729336|Placebo Comparator|CATHETER specimen|All subjects will use CATHETER (performed by their clinician) to give a urine specimen, following PEEZY use.
10187119|NCT03729323|Experimental|Experimental: Motivational Interviewing|INTERVENTION GROUP: In this group, Diabetics and Hypertensives will attend two Nursing Consultation sessions based on the assumptions and techniques of Motivational Interviewing with a certified nurse with specific 20-hour theoretical and practical training for this approach style.
10187120|NCT03729323|Active Comparator|Nursing Consultation|CONTROL GROUP: In this group, Diabetics and Hypertensives will attend two conventional nursing consultation sessions aimed at self-care, with a untrained nurse for the use of motivational interviewing, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in Diabetes Mellitus and Arterial Hypertension and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
10187121|NCT03729310|Other|Propel Implant|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
9676131|NCT04989608|Other|patients having suffered to transient ischemic accident|
9676132|NCT04989608|Other|healthy volunteers|
9676133|NCT04989634|Active Comparator|standard care|In the early pregnancy ( 8-12 weeks of pregnancy ) , a group education on dietary weight management will be carried out according to the current medical system and the regulations of our hospital , followed by routine prenatal examination . According to the corresponding diagnosis and treatment guidelines, examinations and follow-up interventions will be carried out if the metabolic diseases are occurred during pregnancy.
9676134|NCT04989634|Experimental|dietary and weight management|A randomized controlled trial in pregnant women will be initiated at 8-12 weeks of gestation util delivery. The intervention contents included health education , nutritional analysis and individualized dietary guidance combined with mobile medical treatment and face-to-face teaching during the early , middle and late pregnancy stages.
9676135|NCT04989842|Active Comparator|Intervention group 1|webbased aftercare
9676136|NCT04989842|No Intervention|Control group|care as usual
9676137|NCT04989842|Active Comparator|Intervention group 2|webbased aftercare
9676138|NCT04989842|Active Comparator|face-to-face aftercare|face-to-face aftercare
9676139|NCT04989764||perioperative chemotherapy vs. adjuvant therapy in gastric ca patients|
9676140|NCT04989764||perioperative chemotherapy group vs. adjuvant chemotherapy group|
9676141|NCT04989712|Experimental|20 minutes MVPA|20 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 40 minutes from the start of the testing session following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
9676142|NCT04989712|Experimental|4 x 5 mins MVPA|4 bouts of 5 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 30 minutes from the start of the testing session and repeated at 60 mins, 90 mins and 120 mins following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
9676143|NCT04989712|Experimental|Uninterrupted sitting - No exercise, sitting session (control).|A sitting only exposure, glucose solution to be consumed at 0 mins.Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point
10174422|NCT03853577|Active Comparator|Psilocybin|
9676144|NCT04989751||LGMD patients|
9676145|NCT04989673||Exposed group (GE)|Pregnant women with symptomatic dengue fever, confirmed biologically between the presumed date of conception and the date of delivery.
9676146|NCT04989673||Unexposed group with fever (GNEF)|Pregnant women presenting a febrile syndrome not due to the dengue virus between the presumed date of conception and the date of delivery, excluding malaria, rubella, toxoplasmosis, chickenpox, listeriosis, CMV infection and primary HIV infection.
9676147|NCT04989673||Unexposed group without fever or dengue (GNES)|Pregnant women exhibiting neither febrile syndrome nor asymptomatic dengue fever between the presumed date of conception and the date of delivery.
9676148|NCT04989504|Active Comparator|Arm I (standard of care)|Patients receive standard of care skin management during radiation therapy for up to 6 weeks.
9676149|NCT04989504|Experimental|Arm II (Mepitel Film)|Patients receive Mepitel Film applied to breast or chest wall every week before radiation therapy for up to 6 weeks.
9676150|NCT04989465|Experimental|Experimental Group|450 Participants (including 150 subjects aged 2~17 years, 150 subjects aged18~60 years and 150 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd will be collected venous blood about 3.0~3.5 ml.
9676151|NCT04989465|Placebo Comparator|Control Group|150 Participants (including 50 subjects aged 2~17 years, 50 subjects aged18~60 years and 50 subjects aged 61years and older ) received one dose of 23-valent pneumococcal polysaccharide vaccine manufactured by Chengdu Institute of Biological Products will be collected venous blood about 3.0~3.5 ml.
9676152|NCT04989413|Active Comparator|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|Cannabidiol + Cannabigerol + Tetrahydrocannabinol in the maximum dosage of 133/66/4mg, divided in 2 doses of 66.5/33/2mg a day for 12 weeks. Each drop contain CBD/CBG/THC 1.66/0.8/0.05 mg, and medication will be titrated up as follow: day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drrops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day
9676153|NCT04989413|Placebo Comparator|Placebo|"Placebo capsules will be titrated up as follow:~day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day"
9676154|NCT04989556|Active Comparator|Arm I (standard symptom management)|Patients receive standard symptom management by palliative care team once every 4 weeks for 12 weeks. Patients and caregivers also may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
9676155|NCT04989556|Experimental|Arm II (weekly provider-initiated remote contact)|Patients in Phase I immunotherapy trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact every week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
9676156|NCT04989556|Experimental|Arm III (weekly provider-initiated remote contact)|Patients in Phase I non-immunotherapy clinical trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact once a week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
9676157|NCT04989530|Active Comparator|Low energy level of ESWT|
9676158|NCT04989530|Active Comparator|medium energy level of ESWT|
9676159|NCT04989530|Active Comparator|high energy level of ESWT|
9676160|NCT04989777|No Intervention|Control group|Patients with AMI and shock stage B were received Standardized treatment
9676161|NCT04989777|Experimental|IABP group|Patients with AMI and shock stage B were received Standardized treatment and IABP treatment
10174423|NCT03853577|Placebo Comparator|Placebo|
9676162|NCT04989569|No Intervention|control|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the control group will not be given to the dietitians for adjusting the diet formula according to the patient's body composition.
9676163|NCT04989569|Experimental|nutritional intervention|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the intervention group will be given to the dietitians for adjusting the diet formula according to the patient's body composition.
9676164|NCT04989335|Experimental|Bisantrene combined with Fludarabine and Clofarabine|"Bisantrene 250 mg at final concentration of 0.5 mg/mL will be administrated by intravenous (IV) infusion, delivered by a controlled-rate programmable pump via a central line over 2 hours.~Fludarabine (generic) and Clofarabine (generic) are commercially available as injection for intravenous infusion.~The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence:~First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2~Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes~Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours."
9676165|NCT04989361|Experimental|Microneedle side|Apply soluble hyaluronic acid microneedle eye mask to the periorbital area after normal facial cleansing and skin care every night for 20 days. Press and hold for 3 minutes, and then remove it after 1 h. Every 2 days for the next 20 days, and every 3 days for the last 21 days. Follow-up time: every 20 days during the treatment period, and follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
9676166|NCT04989361|Active Comparator|Non-fractional laser side|The patient received non-ablative fractional laser treatment once. Follow-up time: follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
9676167|NCT04989400|Experimental|ulipristal group|received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017,Then women had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
9676168|NCT04989400|Placebo Comparator|placebo|received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy
9676169|NCT04989296|Experimental|Level of NF-κB translocation in lymphocyte in children with psoriasis and in comparison group|The analysis of the relative count of cells with NF-κB translocation in the lymphocyte populations the group of patients with psoriasis and in the comparison group.
9676170|NCT04989296|Experimental|Level of NF-κB translocation in lymphocyte in children with psoriasis, based on the type of therapy|Determination of the level of NF-kB translocation in lymphocyte populations in patient groups depending on the type of therapy: Group 1 - patients receiving basic and external therapy; Group 2 - patients receiving methotrexate; and Group 3 - patients receiving therapy with biological drugs.
9676171|NCT04989296|Experimental|Severity of psoriasis based on level of NF-κB translocation in psoriasis who received biologics|Assessment of the level of NF-kB translocation in lymphocyte populations, assessment of PASI and BSA, assessment of the effectiveness of biological drugs in patients with psoriasis. Identification of patients in the stage of regression of the disease and in the progressive stage.
9676172|NCT04988997|Active Comparator|Vurolenatide 50 mg/PBO|50 mg biweekly SC administration, PBO alternate weeks
9676173|NCT04988997|Active Comparator|Vurolenatide 100 mg/PBO|100 mg biweekly SC administration, PBO alternate weeks
9676174|NCT04988997|Active Comparator|Vurolenatide 50/50 mg|50 mg weekly SC administration
9676175|NCT04988997|Placebo Comparator|Placebo|PBO - weekly SC administration
9676176|NCT04989088|Experimental|Left theta/beta and right beta/theta NF training|
9676177|NCT04989088|Placebo Comparator|Sham NF training|
9676178|NCT04988984||Suspected TB|Patient suspected of TB undergoing diagnostic testing.
9676179|NCT04989192|Other|CT scanner 1|Patients will undergo imaging on scanner 1.
9676180|NCT04989192|Other|CT scanner 2|Patients will undergo imaging on scanner 2.
9676181|NCT04989192|Other|CT scanner 3|Patients will undergo imaging on scanner 3.
9676182|NCT04989127||group 1|platelet-rich fibrin placed into the socket of the extracted tooth.+ Augmentin 1 gr tablet prescribed 3 times a day
9676183|NCT04989127||group 2|platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.
9676184|NCT04989127||group 3|platelet-rich fibrin placed into the socket of extracted tooth + Clin 150 mg capsule prescribed 4 times a day
9676185|NCT04989127||group 4|platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.
9676186|NCT04989127||control group|platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.
9676187|NCT04989166|Active Comparator|Nano-curcumin|80mg of Nano-curcumin daily
9676188|NCT04989166|Placebo Comparator|Placebo|Placebo
9676189|NCT04989140|Experimental|IxaPD|Ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle , pomalidomide 25mg qd day 1~21 of every 28-day cycle, Dexamethasone 40 mg (20 mg for patients >75 years of age) was given on days 1, 8, 15, and 22 of every 28-day cycle.
9676190|NCT04989114|No Intervention|standard care|In this arm, oxygen inhalation will be provided without positive end expiratory pressure
9676191|NCT04989114|Experimental|nasal continuous positive airway pressure|In this arm, positive end expiratory pressure will be provided by nasal continuous positive airway pressure
10174424|NCT03853694|Active Comparator|Group 1 (Standard of Care Group)|150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
10174425|NCT03853694|Experimental|Group 2 (Duramorph + EXPAREL TAP)|50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
10174426|NCT03853694|Experimental|Group 3 (EXPAREL TAP)|EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.
9676192|NCT04989036|Experimental|CALCIUM HYDROXIDE™|Non-setting Calcium hydroxide Pulpotomy capping agent. Deepak. Promotion Industrial Park, Bari Brahmana, Jammu - 181133 India form : powder and liquid. application : Calcium hydroxide was mixed with saline to a thick consistency immediately before use. The paste was carefully placed on the pulp stump surface 2-3 mm thick over a small sterile wet cotton with a small condenser, and the excess material was scraped off.
9676193|NCT04989036|Experimental|Biodentine ™|Biodentine ™ Pulpotomy capping agent. Calcium Silicate-Based Material.Septodent®, Saint-Maurdes-Fosses, France form: capsule and liquid. application: According to the instructions of manufacture, Biodentine ™powder and liquid were mixed to achieve a creamy consistency, by mixing a single-unit powder part and 5 drops of a single-unit liquid part for 30 seconds by mixing device . Final mixing and adjustment were done manually to obtain the desired consistency for each case
9676194|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (80% limb occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
9676195|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
9676196|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (60% of the limb complete occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
9827541|NCT02460172|Active Comparator|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
10174427|NCT03853902|Experimental|Mindfulness Program Online|Online 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
10174428|NCT03853902|Active Comparator|Mindfulness Program Face-to-Face|In-person 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
10174429|NCT03853239|Active Comparator|face mask crossover nasal ventilation|
10174430|NCT03853239|Active Comparator|nasal ventilation crossover face mask|
10174431|NCT03853265|No Intervention|Control|
10174432|NCT03853265|Experimental|Virtual Reality|Simulated dental office visit
10174433|NCT03853382|Experimental|Cognitive Analytic Informed Brief Therapy|
10174434|NCT03853382|No Intervention|Treatment As Usual|
10174435|NCT03853304|Experimental|Quadruple-Fortified Salt (QFS)|Salt fortified with iron, iodine, folic acid, and vitamin B12
10174436|NCT03853304|Experimental|DFS + Folic acid|Salt fortified with iron, iodine, and folic acid
10174437|NCT03853304|Experimental|DFS + Vitamin B12|Salt fortified with iron, iodine, and vitamin B12
10174438|NCT03853304|Active Comparator|Double-fortified salt (DFS)|Salt fortified with iron and iodine
10174439|NCT03853512|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
10174440|NCT03853512|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
10174441|NCT03853447||Diagnostic imaging|"The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including~Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM.~Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP.~Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria."
10174442|NCT03853278|Experimental|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
9676197|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (max of 4/10 pain).
9676198|NCT04988945|Experimental|Durvalumab + Tremelimumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD) and 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
9676199|NCT04989153||non-atrophic gastritis|No atrophic gastritis, The OLGA-0 group;OLGA :Operative Link on Gastritis Assessment)
9676200|NCT04989153||mild-moderate atrophic gastritis|The OLGA I-II group;OLGA :Operative Link on Gastritis Assessment)
9676201|NCT04989153||severe atrophic gastritis|The OLGA III-IV group;OLGA :Operative Link on Gastritis Assessment)
9676202|NCT04989153||gastric cancer|gastric cancer
9676203|NCT04989270||Patients undergoing Cesarean section|Group of patients undergoing Cesarean section between Jan'2015 to Dec'2019
9676204|NCT04989062||Healthy children|Apparently healthy children at Year 1 to Year 6 in the primary school in Taiwan. Exclusion criteria are children with metal implant or splint, pacemaker implantation, limb defect or injury and pregnant.
9676205|NCT04989257|Experimental|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
9676206|NCT04989257|Active Comparator|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
10174443|NCT03853278|No Intervention|No intervention control group|The control group will receive health education leaflets.
10174444|NCT03853460|Active Comparator|epidural group|ULTRASOUND GUIDED thoracic epidural at T 12 WILL BE INSERTED before anaesthesia induction
10174445|NCT03853460|Active Comparator|quadus lumborum group|bilateral ultrasound guided quadratus lumborum catheter will be inserted before anaesthesia induction
9676207|NCT04988932|Experimental|Administration of iNO in SAH patients with severe vasospasm|iNO is started at a dose of 1 parts per million (ppm) and increased stepwise to 2 ppm, 5 ppm, 12 ppm, 25 ppm, until a maximum dose of 40 ppm is reached.
10174446|NCT03853421|Experimental|Dose cohort 3 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
9676208|NCT04989010|Experimental|89Zr-NY005 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3 mCi) labeled anti-CLDN18.2 mAbs (89Zr-NY005)
9676209|NCT04989348|Placebo Comparator|Antagonist group|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
9676210|NCT04989348|Active Comparator|PPOS group|"Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.~Gonadotrophin (human menopausal gonadotrophin or recombinant FSH) injections will be started. Ovarian response will be monitored by transvaginal scanning with or without serum hormonal level. Human chorionic gonadotrophin (hCG 1,000 IU) and GnRH agonist (decepepty 0.2mg) will be given for triggering of final maturation when at least 3 follicles reach >17mm in diameter. Blood will be checked for serum estradiol and progesterone levels. Transvaginal USS-guided oocyte retrieval will be performed 36 hours after the trigger."
9676211|NCT04988919|Experimental|4D dietary supplement|Multi-ingredient supplement containing a proprietary blend with 150mg of caffeine, and other ingredients including vitamins, electrolytes, and BCAA blend (150mg).
9676212|NCT04988919|Placebo Comparator|placebo|flavored water (raspberry lemonade Crystal Light®)
10174447|NCT03853421|Experimental|Dose cohort 6 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
10174448|NCT03853421|Experimental|Dose cohort 9 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
10174449|NCT03853434|Experimental|Embolization|After angiography all metastases with poor/moderate vascularization will be embolized with acrylic glue in the treatment group.
10174450|NCT03853434|No Intervention|No embolization|After angiography all metastasis with poor/moderate vascularization will not be embolized with acrylic glue in the control group
10174451|NCT03853291|Experimental|PICT Workbook|PICT Workbook components will include: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set.
9676213|NCT04989205||HAP - group|The target group was individuals who engaged in regular or daily cannabis use, and who were motivated to quit cannabis. The formal inclusion criteria was a Severity of Dependence Scale (SDS) score ≥4 and being ≥16 years old. Exclusion criteria was polydrug use where cannabis was not the predominating substance of use and psychiatric comorbidity that was perceived as too severe to handle at the community-based centers .
9676214|NCT04988620|Experimental|Whole Blood stored for 15-21 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 15-21 days
10174452|NCT03853291|Active Comparator|Information Pamphlet|Informational pamphlet about pain in dementia and a link to the Alzheimer's Association website.
10174453|NCT03853356||Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)|
10174454|NCT03853395|Active Comparator|Control Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will not receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant.
10174455|NCT03853395|Experimental|Experimental Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant. They will be able to act accordingly.
10174456|NCT03853629||CF|"Age 1-17~Diagnosis of Cystic Fibrosis~Living in or around London"
9676215|NCT04988620|Active Comparator|Whole Blood stored for less than 7 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for less than 7 days. We aim at using as fresh as possible.
9676216|NCT04988620|Active Comparator|Whole Blood stored for 8-14 days|CPD Whole Blood leukoreduced with a platelet-sparing filter and stored cold for 8-14 days. This group may be added if deemed of interest after interim analysis.
10174457|NCT03853629||Controls|"Age 1-17~Healthy~Living in or around London"
10174458|NCT03853252|Other|Skin biopsy|
10174459|NCT03853499||Successful vacuum extraction|Patients for whom vacuum extraction was successful
9676217|NCT04988620|Active Comparator|Standard Blood Component|This group may be added for comparison if deemed of interest after interim analysis.
9676218|NCT04988633|Experimental|Intervention CFG App|
9676219|NCT04988633|Experimental|Control Group|
9676220|NCT04988776|Active Comparator|group A|Patients received ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
10174460|NCT03853499||Failed vacuum extraction|Patients who had an emergency caesarean section after failed vacuum extraction
10174461|NCT03853200|Experimental|Group I|QMix the solution under investigation which includes CHX EDTA and detergent QMix Root Canal Irrigant
9676221|NCT04988776|Active Comparator|group B|patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
9676222|NCT04988581|Experimental|Intensively Integrated Care of Microvascular Risk Factors|intensively integrated care of microvascular risk factors (glycated hemoglobin [HbA1C], urinary albumin-to-creatinine ratio [ACR], blood pressure [BP], estimated glomerular filtration rate [eGFR], uric acid [UA] and low-density lipoprotein cholesterol [LDL])
9676223|NCT04988581|No Intervention|Usual Care of Microvascular Risk Factors|Usual care among patients with diabetes
9676224|NCT04988542|Experimental|Sleep supplement|Circadian Wellness sleep SL strip nightly for 30 days.
9676225|NCT04988542|Placebo Comparator|Control Group|Participants in the control group will have no intervention and no change in their usual daily routine or supplements. They will be asked to not take any sleep aid supplement during the study period.
9676226|NCT04988594|Experimental|Premium probiotic yogurt|Participants receive 300 g/d of yogurt with concentrated and freeze-dried probiotic cultures for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
9676227|NCT04988594|Experimental|Conventional yogurt|Participants receive 300 g/d of conventional yogurt for 12 weeks. Also, the nutritional recommendations of the American Diabetes Association (ADA).
9676228|NCT04988594|Experimental|no fermented dairy|Participants followed the American Diabetes Association (ADA) recommendations without including fermented dairy.
9676229|NCT04988724|Experimental|Intervention|Intervention group that receive 30 min exercise training twice weekly in 12 weeks
9676230|NCT04988815|Experimental|Ropeginterferon alfa-2b|Eligible subjects will receive ropeg subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards until week 104. In patients achieving a clinical or molecular response at 24 months (week 104), treatment with ropeg will be continued until disease progression.
9676231|NCT04988828|Active Comparator|Control|"deep squat~1min*6repetitions"
9676232|NCT04988828|Experimental|Whole body vibration group|"deep squat on a whole body vibration platform with 30Hz and 4mm amplitude~1min*6repetitions"
9676233|NCT04988711|Experimental|Hb Oxymeter|Hb mesurment
9676234|NCT04988607|Experimental|osimertinib plus bevacizumab|Osimertinib 80 mg (QD) in combination with Bevacizumab (15 mg/kg) (Q3W)
9676235|NCT04988607|Active Comparator|osimertinib|All patients randomized into this will only receive Osimertinib 80mg (QD)
9676236|NCT04988854|Experimental|Positive Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a positive facial expression (positive video)
9676237|NCT04988854|Experimental|Neutral Condition|Children were exposed to a video of adult models eating a single piece of raw broccoli whilst showing a neutral facial expression (neutral video)
10174462|NCT03853200|Active Comparator|Group II|it involves use of two irrigant solutions, 17%EDTA+2%Chlorhexidine
10174463|NCT03853200|Active Comparator|Group III|17% EDTA with no antibacterial activity . the control group
10174464|NCT03853174|Active Comparator|ET|Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
10174465|NCT03853174|Other|RT|Resistance training were prformed. Intensity was gradually increased.
9676238|NCT04988854|Experimental|No-Food Control Condition|Children were exposed to a video of adult models putting pens away whilst showing a neutral facial expression (no-food control video)
9827542|NCT02460172|Active Comparator|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
9827543|NCT02460263|Placebo Comparator|In-Center|Staff administered treatments in-center using the device
9827544|NCT02460263|Experimental|In-Home|Patient administered treatments in-home using the device
10174466|NCT03852823|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
10174467|NCT03853148|Active Comparator|Otago|The Otago exercise program consists of the following: 1) A series of warm-up exercises, 2) Select exercises from the 17 Otago exercises which challenge the participant's strength and balance for up to 30 minutes, three times a week, 3) A walking program for up to 30 minutes, three times a week. Each Otago will be tailored for each participant's ability level.
9676239|NCT04988750|Experimental|FUS + re-RT or FUS + SRS|"The SRS treatment will be administered for 3 consecutive days (one fraction of 7-9 Gy per day; total dose 21-27 Gy), including SRS treatment 1 (SRS 1), SRS treatment 2 (SRS 2), and SRS treatment 3 (SRS 3). At the SRS 1 and SRS 3, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system.~cRT will be administered for 5 consecutive days within one week, and a full course is two weeks (one fraction of 3-4 Gy per day; total dose: 30-40 Gy), including cRT treatment 1 to cRT treatment 10 (cRT 1-cRT 10). At the cRT 1, cRT 3, cRT 6, and cRT 8, the patients will be shaved their hair at first, and the patient registration will be performed for the neuronavigation system according to the instruction of the system."
9676240|NCT04988646|Experimental|Acyclovir Tablet|Participants received Acyclovir Tablet 200 mg or 400 mg with 240 mL of water
9676241|NCT04988646|Active Comparator|Zovirax® Tablet|Participants received Zovirax® Tablet 200 mg or 2x200 mg with 240 mL of water
9676242|NCT04988737|Experimental|CDS Group|Clinicians complete tasks using the CDS prototype. Briefly, the clinician scans the barcode on the syringe label immediately prior to medication administration. The scan triggers the CDS to display a dosing window with pertinent patient-specific information and/or alert(s) when necessary to prevent a medication error (ME) prior to the medication being administered. Medication data are then sent from the CDS application to the patient's anesthesia record for automatic documentation in real-time, eliminating the need to manually document the medication in the Anesthesia Information Management System (AIMS). When necessary, the CDS application generates alerts to prevent medication errors. Upon receiving an alert, the anesthesia clinician may accept the alert and revise the action that generated the alert, or override the alert and continue with the planned action.
9676243|NCT04988737|No Intervention|Control Group|Clinicians complete tasks using the conventional medication administration and documentation workflow in anesthesia.
10174468|NCT03853148|Active Comparator|Otago + Gentle yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the Otago+GYYB group each exercise and their perceived benefits.
9676244|NCT04988516|Experimental|Virtual Reality Distraction|Use of Virtual Reality (VR) during MRI exam
9676245|NCT04988516|Active Comparator|Standard Treatment|Standard Treatment used at the radiology department
9676246|NCT04988529|Experimental|Smartphone-based supported serious game intervention|Group that receives the smartphone-based serious game intervention and receives technical support
9676247|NCT04988529|No Intervention|Waiting list control|Group that does not receive any treatment
9676248|NCT04988425|Experimental|TNFα monoclonal antibody group|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
9676249|NCT04988425|Active Comparator|Methylprednisolone group|Injection of 500mg of methylprednisolone immediately after admission before surgery.
10187122|NCT03729310|Other|Nasopore soaked with triamcinolone|"This packing' is a sponge-like material which dissolves while releasing triamcinolone, which is another type of steroid. Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA."
10187123|NCT03729297|Experimental|cabozantinib|cabozantinib 60 mg tablets OD
9676250|NCT04988425|Placebo Comparator|Control group|Injection of the same volume of saline immediately after admission before surgery.
9676251|NCT04988477|Experimental|Chronic care for tobacco use|Quarterly brief provider interventions about tobacco and 3 quarterly proactive outreach calls to connect patients to telephone cessation counseling and facilitate obtaining cessation medication.
9676252|NCT04988100|Experimental|Patients who undergo Splenic artery ligation|If inclusion criteria are met, these group of patients will undergo splenic artery ligation .
9676253|NCT04988100|Active Comparator|No splenic artery ligation|If inclusion criteria are met, these group of patients will not undergo splenic artery ligation.
9676254|NCT04988204|Experimental|Treatment Arm|Patients enrolled in 1 year program
9676255|NCT04988217|Experimental|Part 1a: Interferon alpha 2b 2.5 MIU|Nebulized interferon alpha 2b 2.5 MIU every 12 hours during 10 days (20 doses total)
9676256|NCT04988217|Experimental|Part 1b: Interferon alpha 2b 5 MIU|Nebulized interferon alpha 2b 5 MIU every 12 hours during 10 days (20 doses total)
9676257|NCT04988217|Placebo Comparator|Part 1: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
9676258|NCT04988217|Experimental|Part 2: Interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1)|Nebulized interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) every 12 hours during 10 days (20 doses total)
9676259|NCT04988217|Placebo Comparator|Part 2: Placebo|Nebulized placebo every 12 hours during 10 days (20 doses total)
9676260|NCT04988191|Experimental|Toripalimab combined with bevacizumab and chemotherapy|
9676261|NCT04988230|Experimental|Time Restricted Feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
9676262|NCT04988230|Active Comparator|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
9676263|NCT04988243|Other|Prospective and retrospective study of subjects undergoing aortic valve surgery|This study is a prospective / retrospective, multicenter, and observational study after listing. The researchers can initially determine that they can be enrolled in the study according to the history diagnosis of the subjects. After fully informed, they sign informed consent form. After the evaluation of the researchers, they meet the TAVR selection requirements, and register the subjects in multiple centers at the same time
9827545|NCT02460380|Active Comparator|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
9975656|NCT01343706|Experimental|BI 409306 dose 10|Immediate release solid oral dosage
10174469|NCT03853148|Active Comparator|Otago + GYYB + Behavioral activation|This condition will incorporate OEP and GYYB as above and will also include behavioral activation to address motivation and affect. Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities. Each participant outlines general values and specific behaviors that 'demonstrate' each value, compiling a list of the latter. This list is then used to generate 10 to 20 highly defined values-based, reinforcing activities. Next, this list is combined with the activities outlines in Otago and GYYB and this master list is used to schedule these values-based activities for the next two days.
9676264|NCT04988438||esophageal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (Chicago 3 score)."
9676265|NCT04988438||anorectal manometry|"The patients who has previously mentioned symptoms will underwent to manometry monitoring of esophageal and anorectal disorders.~For this investigation we have proven normal and standardized manometric values on previous investigations by other authors, so the control group is not needed. We know the normal manometric values (London protocol)."
9676266|NCT04988139|Active Comparator|Intervention group|traditional rehabilitation programs with additional individualized educational training
9676267|NCT04988139|No Intervention|Control group|traditional rehabilitation programs without additional individualized educational training
9676268|NCT04988126||Patient Group|Patient with Covid 19 Pneumonia
10174470|NCT03853148|Experimental|Caregiver Gentle yoga & yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the GYYB group each exercise and their perceived benefits.
9676269|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ ChAdOx1 nCoV-19|Heterologous: Gam-COVID-Vac C1/ ChAdOx1 nCoV-19
9676270|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / Gam-COVID-Vac C1|Heterologous: ChAdOx1 nCoV-19 / Gam-COVID-Vac C1
9676271|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ BBIBP-CorV|Heterologous: Gam-COVID-Vac C1/ BBIBP-CorV
9676272|NCT04988048|Active Comparator|BBIBP-CorV / Gam-COVID-Vac C1|Heterologous: BBIBP-CorV / Gam-COVID-Vac C1
9676273|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / BBIBP-CorV|Heterologous: ChAdOx1 nCoV-19 / BBIBP-CorV
9676274|NCT04988048|Active Comparator|BBIBP-CorV / ChAdOx1 nCoV-19|Heterologous: BBIBP-CorV / ChAdOx1 nCoV-19
9676275|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ mRNA-1273|Heterologous: Gam-COVID-Vac C1/ mRNA-1273
9676276|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / mRNA-1273|Heterologous: ChAdOx1 nCoV-19 / mRNA-1273
9676277|NCT04988048|Active Comparator|BBIBP-CorV / mRNA-1273|Heterologous BBIBP-CorV / mRNA-1273
9676278|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ Gam-COVID-Vac C2|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C2
9676279|NCT04988048|Active Comparator|ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19|Homologous: ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19
9676280|NCT04988048|Active Comparator|BBIBP-CorV / BBIBP-CorV|Homologous: BBIBP-CorV / BBIBP-CorV
9676281|NCT04988048|Active Comparator|mRNA-1273 / mRNA-1273|Homologous: mRNA-1273 / mRNA-1273
9676282|NCT04988048|Active Comparator|Gam-COVID-Vac C1/ Gam-COVID-Vac C1|Homologous: Gam-COVID-Vac C1/ Gam-COVID-Vac C1
9676283|NCT04988334|Active Comparator|FAST|12 weeks of FAST, 2/week 45 minute sessions with half hour per week of education, same group of men and women
9676284|NCT04988334|Placebo Comparator|wait control|12 weeks of usual activity prior to intervention, same group of men and women
9676285|NCT04988347|Experimental|Spirulina|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
9676286|NCT04988347|Placebo Comparator|Placebo|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
9676287|NCT04988451|Experimental|ASL Services - Adult ASL Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
9676288|NCT04988451|Experimental|ASL Services - Child Language Development|Presence (or absence, across 6-week periods) of ASL services designed to support improvement in ASL fluency
9676289|NCT04988165|Experimental|Treatment arm|
9676290|NCT04988269||Patients (Cases)|"Adult consecutive patients that visited the Emergency Department of LAIKO General Hospital of Athens, Greece from May to July 2021 due to confirmed COVID-19 and related symptomatology.~Blood sampling on the day of admission (one time point) and saliva sampling at 4 different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day)."
9676291|NCT04988269||Healthy Controls|Age and gender matched healthy individuals without COVID-19. Blood sampling (at day 1) and saliva sampling at different time points (0.800, 12.00, 18.00,22.00) the next day (all sampling in one day-day 2).
9676292|NCT04988061|Experimental|Counselling arm|Educating and Counselling are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
9676293|NCT04988061|No Intervention|standard arm|The information about hearing screening results and an appointment date are provided as a routine by either nurses or nurse assistances who perform the screening test.
9695188|NCT04781062|Experimental|Breast Cancer Stage T1 Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed T1 breast cancer, patients will undergo a second peripheral blood and urine collection after primary breast cancer surgery."
9827546|NCT02460380|Placebo Comparator|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
9676294|NCT04988256|Active Comparator|Cyclosporine|"All Patients start with 5 mg/kg/day (3 mg/kg/day if renal impairment) PO divided bid for 7 days (or IV if patient is NPO)~If complete resolution, stop cyclosporine and monitor closely for relapse~a. If patient relapses, give 5 (3 if renal impairment) mg/kg/day PO divided bid PO for 7 days~i. If down-trending, start oral taper regimen~ii. If not down-trending, switch to steroid arm~If >25% improvement and labs are down-trending, start the oral taper regimen.~If 0-25% improvement, give 5 (3 if renal impairment) mg/kg/day PO divided bid for 3 days~If down-trending, start oral taper regimen~If not down-trending, switch to steroid arm~If no improvement or up-trending labs at 7 days, switch to steroid arm~Oral Taper Regimen set as 3 mg/kg PO divided bid for 14 days, then 2 mg/kg PO divided bid for 20 days. If renal impairment, oral taper regimen set as 2 mg/kg PO divided bid for 14 days, then 1 mg/kg PO divided bid for 20 days"
9676295|NCT04988256|Experimental|Corticosteroids|"All Patients start with 500 mg IV Methylprednisolone for 3 days~1. If >25% improvement (must be >25% in all involved organs), start the taper regimen 2. If 0-25% improvement (in ≥1 involved internal organ), give 500 mg IV Methylprednisolone for 4 days~If no improvement, switch to cyclosporine arm of treatment~If 0-25% improvement, give 500 mg IV Methylprednisolone for 3 days~i. If labs are down-trending, start the taper regimen~ii. If labs are not down-trending, switch to cyclosporine arm of the study~c. If >25% improvement, start the taper regimen~Taper Regimen set as:~125 mg IV Methylprednisolone x3 days~1.2 mg/kg PO prednisone x1 week~1 mg/kg PO prednisone x1 week~0.8 mg/kg PO prednisone x1 week~0.6 mg/kg PO prednisone x1 week~0.4 mg/kg PO prednisone x1 week~0.2 mg/kg PO prednisone x1 week~0.1 mg/kg PO prednisone x1 week~0.05 mg/kg PO prednisone x1 week"
9676296|NCT04988373|Experimental|Single aligner appliance|Modified aligner appliance with NiTi springs
9676297|NCT04988373|Active Comparator|Traditional fixed appliances|MBT-prescription of metallic brackets.
9676298|NCT04987905|Experimental|Experimental Group|"In the study, for 60 minutes once a week for 8 weeks the MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice). In addition to these, nurses will be required to keep a diary of the program. This app contains basic mindfulness exercises and does not pose any health risks to practitioners. While the MIND-BE program is carried out in the online environment, the cameras of the nurses in the experimental group will be turned on and the researcher who made the application will be able to see each nurse."
9676299|NCT04987905|No Intervention|Control Group|No intervention will be made to the control group, only the data will be collected at the same time as the study group. After all data are collected (after the 12th week), the training content will be explained to the nurses in the control group and the MIND-BE program will be started for them as well. In this way, both groups will benefit from this program.
9676300|NCT04987996|Experimental|GR-MD-02 + pembrolizumab|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
9676301|NCT04987996|Placebo Comparator|Pembrolizumab Monotherapy|4 mg/kg placebo in combination with standard pembrolizumab treatment.
9676302|NCT04988282|Active Comparator|Steroid|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
9676303|NCT04988282|Other|control|standard symptom-relief therapy (since there is no current standard therapy for post-COVID Interstitial Lung Disease, patients in this arm will be commenced symptom-relief therapies including bronchodilators, inhaled corticosteroids, non-steroid anti-inflammatories, cough relievers, and long-term oxygen if the patient has respiratory failure)
9676304|NCT04988360|Experimental|Group A: HMD first|Those assigned to group A will use the head-mounted display (HMD) VR intervention first. Caregivers will be trained to use the HMD-system and asked to use that system for the duration of T1 (weeks 1 & 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 & 4), they will then be trained to use the tablet-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. All throughout T1 and T2, the participant dyad will complete personal reflections each instance a session occurs (5 sessions/week). Each session is expected to include 24 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
10174471|NCT03853096|Experimental|Subcutaneous cefazolin arm|"A patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison.~Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route."
10174472|NCT03853161|Experimental|Vapotherm arm|Preterm infants in this arm will be given respiratory support of heated humidified high flow via Precision Flow Vapotherm, Exeter, USA
9695189|NCT04781062|Active Comparator|Benign Breast Lesion Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed benign lesion, no other samples will be collected."
9827547|NCT02460562|Active Comparator|PMMA resin|A denture base will be made with PMMA resin as a standard material.
9827548|NCT02460562|Experimental|PMMA resin & S-PRG filler|A denture base will be made from PMMA resin & S-PRG filler for subject to wear.
9975657|NCT01343706|Experimental|BI 409306 dose 11|Immediate release solid oral dosage
10187124|NCT03729284|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
9527609|NCT03218839|Experimental|HIV+ PrePex|PrePex male circumcision device
9527610|NCT03218501|Active Comparator|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
9676305|NCT04988360|Experimental|Group B: Tablet first|Those assigned to group B will use the tablet VR intervention first. Caregivers will be trained to use the tablet-system and asked to use that system for the duration of T1 (weeks 1 & 2). At the end of T1 they will be asked to complete standardized questionnaires and will participate in a semi-structured interview about their experiences. At the beginning of T2 (weeks 3 & 4), they will then be trained to use the HMD-system, which will be used for the duration of T2. At the completion of T2, the dyad will again complete the same standardized questionnaires and will participate in a semi-structured interview about their experiences. All throughout T1 and T2, the participant dyad will complete personal reflections each instance a session occurs (5 sessions/week). Each session is expected to include 24 minutes of VR exposure. Each session throughout T1 and T2 is to be video-recorded by the caregiver-participant so that reactions and interactions can later be analyzed.
9676306|NCT04987983|Experimental|Experimental SLP-R|Infant placed in a SLP-R on the researcher's lap. Infant body positioned on side-lying position on the right side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
9676307|NCT04987983|Experimental|Experimental SLP-L|Infant placed in a SLP-L on the researcher's lap. Infant body positioned on side-lying position on the left side of it's body. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands).
9676308|NCT04987749|Active Comparator|Active|"Participants received the real intervention of TBS (iTBS 600) over the right inferior frontal gyrus for 8 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
9676309|NCT04987749|Sham Comparator|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the right inferior frontal gyrus for 8 weeks (2 days/week).
10174473|NCT03853161|Experimental|NIPPV arm|Preterm infants in this arm will be given respiratory support of Nasal Intermittent Positive Pressure Ventilation via the Leoni Plus neonatal ventilator
10174474|NCT03853057|Experimental|non-invasive ventilation|Non-invasive positive pressure at different body positions: sitting - supine - prone - right lateral and left lateral.
10174475|NCT03853135||Behçet group|Forty two patients diagnosed to have Behçet disease fulfilling the International Study Group Criteria for Behçet disease in whom measurement of serum endocan levels will be performed.
10174476|NCT03853135||control group|including 42 age and sex matching healthy volunteers as control group in whom measurement of serum endocan levels will be performed.
9676310|NCT04987684|Other|Standard of Care|
9695190|NCT04780971|Other|Post-PCI intra-coronary physiological and OCT measurements|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
9695191|NCT04780919|Experimental|Treatment Group (A)|Group of patients with Achilles tendinopathy which are treated by focused extracorporeal shockwave therapy once a week for 5 weeks. ESWT parameters: 0,12 mJ/mm2, 10 Hz, 1300 shocks.
9695192|NCT04780919|Sham Comparator|Sham Group (B)|Group of patients with Achilles tendinopathy in which sham extracorporeal shockwave therapy is applied once a week for 5 weeks. Total applications are 5, applicated weekly. Sham ESWT parameters are same as in Group A (0,12 mJ/mm2, 10 Hz, 1300 shocks) but with modified applicator which does not allow wave transmission.
9695193|NCT04780880||Youth football players|Young footballers aged 10-16 training and playing for a Polish football club.
9695194|NCT04780659|Experimental|Vaccination with Comirnaty according to standard of care treatment|All study participants will receive Comirnaty according to current approval.
9695195|NCT04780594||Pre-pandemic COVID-19 group (PreCOVID)|All patients who underwent surgery from 13th January until 29th February 2020, which are considered free of COVID-19 patients, therefore pre-pandemic period.
9695196|NCT04780594||Pandemic COVID-19 group (COVID)|All patients who underwent surgery from 11th March 2020 until 15th May 2020, which were done during the first wave of the pandemic crisis.
9695197|NCT04780633|Experimental|Precede-Proceed based Training Program|The experimental group is the group in which five training sessions interventions are applied.
9695198|NCT04780633|No Intervention|Control group|The control group is the group in which have no educational intervention.
9695199|NCT04780620|Experimental|Parent Intervention Group|The parent intervention group will undergo 8 weekly, manualized group sessions, with between 6 and 10 parent participants. Sessions are structured and follow an agenda including check-in and review of home practice, discussion of a skill or strategy, and review and assignment of home practice. Group sessions are held weekly for 1.5 hours and include both didactic, discussion, and practice elements, as well as assigned home practice.
9695200|NCT04780620|No Intervention|Usual Care Group|Parents in the usual care condition will be involved in their adolescent's care as is standard in our clinical program. With adolescent consent, parents are invited to participate in a single, 2-hour orientation session for parents/caregivers that provides information about depression, as well as the role of sleep, diet, and exercise in improving mood. Based on adolescent preference, parents can also attend regular psychiatric appointments with their adolescent, in which they will receive further information about depression and may receive and provide information about their adolescent's depression symptoms and response to psychosocial and pharmacological interventions. This control condition will allow us to determine whether the parent intervention is more effective than a relevant clinical alternative.
9975658|NCT01343706|Experimental|BI 409306 dose 12|Immediate release solid oral dosage
10174477|NCT03852732|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
9676311|NCT04987814|Experimental|Elderly patients suspected of sarcopenia|
9676312|NCT04987736||COVID-19 (RT-PCR +ve) patients|
9676313|NCT04987632|Experimental|Letrozole combined with acupuncture and Du Meridian moxibustion group|Letrozole combined with acupuncture and Du Meridian moxibustion was taken from 3-5 days of menstrual period (spontaneous menstruation or progesterone withdrawal bleeding). The acupuncture treatment was 3 times / week, with an interval of 2-4 days, 12 times a week, 30 minutes each time; Du Meridian moxibustion is 20 minutes each time, once a week, four times a week. The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. If not pregnant, the subjects received letrozole for up to 4 cycles to induce ovulation with acupuncture plus Du Meridian moxibustion.
9676314|NCT04987632|Active Comparator|Letrozole group|Letrozole was taken 3-5 days after menstruation (spontaneous menstruation or progesterone withdrawal bleeding). The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. In the absence of pregnancy, subjects were treated with letrozole for up to four cycles.
9676315|NCT04987788|Experimental|Motívate group|Participants will engage with an app on an iPad, smartphone or computer.
9676316|NCT04987788|Active Comparator|Control Group|Participant receive a link to watch a general health information video.
9676317|NCT04987619|Experimental|BJR|70 mL of beetroot juice (BEET It Sport®; James White Drinks Ltd., Ipswich, UK)
9676318|NCT04987619|Placebo Comparator|PLA|70 mL of blackcurrant beverage Capri-Sun.
9676319|NCT04987853||Acute COVID patients|Patients in the acute phase of the course of the disease
9676320|NCT04987853||Long Covid Patients|Patients with chronic symptoms after a previous Covid-19 (4-12 weeks)
9676321|NCT04987853||Postcovid patients|Patients with chronic symptoms after a previous Covid-19 (more than 12 weeks)
10174478|NCT03852979|Experimental|neo-adjuvant chemotherapy|The patients are given weekly paclitaxel 80 mg/m2 + carboplatin AUC=2 (or AUC=6 per three weeks) during 12 weeks/4 courses followed by conization if tumor size is reduced to <2 cm
9676322|NCT04987866|Experimental|group Vibration|The participants who were chose an opaque envelope containing yellow paper represented the vibration group (Group V). After 1 min of pre-treatment with the vibration device on the intravenous catheter trace, we manually injected 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunterand. Also asked the patients whether they had any discomfort. After the propofol injection, pain scores were observed during propofol injection and 20 seconds after the injection, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and after 20 seconds rocuronium injection.
9676323|NCT04987866|No Intervention|group Control|The participants who were chose an opaque envelope containing red paper represented the group control (Group C).Only propofol and rocuronium were given to these patients. propofol injection made manually 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Patients were observed during and after the injection of propofol for 20 seconds. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunter. During the injection of propofol, we also asked the patients whether they had any discomfort. After the propofol injection for 20 seconds, pain scores were observed, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and 20 seconds after the rocuronium injection.
9676324|NCT04987541|Active Comparator|Active|"Participants received the real intervention of TBS (iTBS 1200) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).~*iTBS = intermittent theta burst stimulation"
10174479|NCT03852745|Other|Cognitive Behavioral Therapy|Online cognitive behavioral therapy intervention for 2 hours a week for 12 weeks.
10174480|NCT03853031|Active Comparator|LVEDA guided intraoperative fluid therapy|Patients in TEE group will be given crystalloid fluids during surgery guided by LVEDA cm2 to be maintained between 10 -18 cm2 , if LVEDA < 10 cm2 then 200ml colloid bolus will be given and increase in LVEDA noted.
9676325|NCT04987541|Sham Comparator|Sham|Participants received the sham intervention of TBS (sham-coil) over the left dorsolateral prefrontal cortex for 4 weeks (5 days/week).
9676326|NCT04987658|Experimental|Group 1 Olanzapine/ 5 mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 5mg (Range: 5-20mg Olanzapine/samidorphan 5mg)
9676327|NCT04987658|Experimental|Group 2 Olanzapine/ 10mg Samidorphan|Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 10mg (Range: 5-20mg Olanzapine/samidorphan 10mg)
9676328|NCT04987463|Experimental|Vigabatrin arm|Vigabatrin in capsules co-administered with placebo in liquid.
9676329|NCT04987463|Experimental|Rapamycin arm|Rapamycin in liquid co-administered with placebo in capsules.
9676330|NCT04987593|Experimental|Intervention|Four probiotic strains to be consumed once daily
9676331|NCT04987502|Experimental|Virtual reality treatment|Virtual reality immersion with 3D audio and visual rendering (8 weekly sessions)
10174481|NCT03853031|Active Comparator|CVP guided intraoperative fluid therapy|Patients in CVP group will be given crystalloid fluids during surgery guided by CVP values to be maintained between 10 -16 cms of water H2O ,if CVP value < 10 cms H2O then 200 ml colloid bolus will be given and increase in CVP value noted.
10174482|NCT03852966|Experimental|CBT-i/ADHD|Behavioral treatment for sleep problems in ADHD
9676332|NCT04987502|Active Comparator|Standard treatment|Counselling Relaxation techniques Sound enrichment
9676333|NCT04987450||Study population|Plasma levels of SIRT-1, IL-6, FGF-23, sclerostin, calcium, phosphate, PTH and urine excretion of total protein, albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients receive three intravenous daily pulses of methylprednisolone of 500 mg followed by oral prednisone 0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the steroid treatment.
9695201|NCT04780542|Experimental|Clinician-Guided iCBT|Both help-seeking students recruited from university clinics and non-help-seeking students recruited from needs assessment survey and outreach will receive internet delivered cognitive behavioral therapy guided by clinicians
9676334|NCT04987567|Active Comparator|Antioxidant docosahexaenoic acid (DHA)|"Antioxidant docosahexaenoic acid (Tridocosahexaenoin-AOX ® 70%) 50mg/kg/day:~50mg/kg/day so:~> = 13-17kg: 2 pearls (700mg DHA) every day, once or twice daily (od or bd)~> = 18-24kg: 3 pearls (1050mg DHA) every day, od or bd~> = 25-30kg: 4 pearls (1400mg DHA) every day, bd (2-0-2)~> = 31-36kg: 5 pearls (1750mg DHA) every day, bd (2-0-3)~> = 37-43kg: 6 pearls (2100mg DHA) every day, bd (3-0-3)~> = 44-49kg: 7 pearls (2450mg DHA) every day, three times a day (td) (3-1-3)~> = 50kg: 8 prearls (2800mg DHA) every day, td (3-2-3)."
9676335|NCT04987567|Placebo Comparator|Placebo|"Olive oil 50mg/kg/day so:~> = 13-17kg: 2 pearls every day, once or twice daily (od or bd)~> = 18-24kg: 3 pearls every day, od or bd~> = 25-30kg: 4 pearls every day, bd (2-0-2)~> = 31-36kg: 5 pearls every day, bd (2-0-3)~> = 37-43kg: 6 pearls every day, bd (3-0-3)~> = 44-49kg: 7 pearls every day, three times a day (td) (3-1-3)~> = 50kg: 8 prearls every day, td (3-2-3)."
9676336|NCT04987554|Experimental|AM3 supplementation group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
9676337|NCT04987554|Placebo Comparator|Control Group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
9676338|NCT04987255|Active Comparator|Free visit|Free visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
9676339|NCT04987255|Experimental|Guided visit|Guided visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
9676340|NCT04987255|Other|Guided visit for individuals after stroke|This arm is specific for individuals with motor disability after stroke (non randomized condition)
9676341|NCT04987242|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days
9676342|NCT04987242|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Two doses may be evaluated under two Study Parts: Part 1 (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days; Part 2 (3 capsules thrice daily (TID) for a total of 9 capsules per day) will be evaluated for 7 days
10174483|NCT03852849|No Intervention|routine care group|Medical institutions will provide patients routine care according to the national program standard.
10174484|NCT03852849|Experimental|medicine intervention group|The dosage of 400 mg EFV will be used in the antiviral therapy.
9676343|NCT04987268||Current-smoking|exposure: smoking
9676344|NCT04987268||Smoking-cessation|exposure: smoking cessation
9676345|NCT04987268||non-smoking|exposure: none
9676346|NCT04987151|Experimental|Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
9676347|NCT04987151|Experimental|Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking,
9676348|NCT04987151|Experimental|Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups
9676349|NCT04987151|No Intervention|Control Group|All the patients in the wait-list control group will receive one of the three trainings immediately after the intervention.
9676350|NCT04987190||all cleft patients divided into unilateral and bilateral groups|One group of cleft patients received the alveolar bone graft surgery
9676351|NCT04987086|Experimental|PSMA PET Arm|The PSMA PET arm received PSMA PET and enhanced CT at the same time in the diagnosis of the patients with suspected renal cancer.
9676352|NCT04987398||Intubation for respiratory reasons|All patients who were intubated for respiratory reasons (i.e. acute respiratory distress syndrome, pneumonias, pleural effusions for example)
9676353|NCT04987398||Intubation for neurological reasons|All patients who were intubated for neurological reasons (i.e. stroke, intracranial bleeding, cervical fracture with tetraparesia for example)
9676354|NCT04987398||Intubation for other reasons|All patients who were intubated for other reasons than respiratory or neurological (i.e. intubation before surgery, cardiac arrest, hemodynamic instability and polytraumatism without respiratory distress or neurological pathology necessitating intubation)
9676355|NCT04987125|Experimental|Dyspnea Neuroscience education|
9676356|NCT04987125|Active Comparator|Usual care|
10174485|NCT03852849|Experimental|consolidated intervention group|Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
9676357|NCT04987411||Hemorrhagic group|Patients with bleeding confirmed with eFAST or CT.
9676358|NCT04986943||ABTHERA Advance without Wittmann patch|Patients with necrotizing pancreatitis that require an open abdomen after their initial operation will be treated with ABTHERA ADVANCE only, without the use of Wittmann patch.
10174486|NCT03853005|Placebo Comparator|Group A (controlled group)|They will not receive HVHDF treatment
10187125|NCT03729284|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
9676359|NCT04987034||Direct and indirect PPG measurements|Measuring the portalsystemic pressure gradient in patients directly using the EchoTip® Insight™ and indirectly through the HVPG procedure.
9676360|NCT04986878|Active Comparator|Single shot adductor canal block|Following sterile preparation and draping, an ultrasound survey of the medial thigh was performed, halfway between the superior anterior iliac spine and the patella. The superficial femoral artery has been identified beneath the sartorius muscle in a short-axis view, with the vein just inferior and the saphenous nerve just lateral to the artery. A 20 Gauge, 120 mm, non-cuttings tip echogenic needle (SonoPlex STIM, Germany) needle was introduced in-plane, and 2 to 3 mL of LA bolus (0.25 % Bupivacaine) was used to confirm proper needle placement in the adductor canal near the saphenous nerve. Then, a bolus of 20 ml of Bupivacaine 0.25 % was injected through the needle
9975659|NCT01343706|Placebo Comparator|Placebo|Solution for oral administration
9676361|NCT04986878|Active Comparator|Continuous adductor canal block|a catheter was secured in place using Tegaderm. The catheters were connected to a pump that infused local anesthetic, 20 mL of 0.25 % bupivacaine, followed by 48 hours of continuous infusion of 0.125 % bupivacaine at 5 mL/h.
9676362|NCT04986891||subjects before first chemotherapy cycle with no neuropathy|at least 75 consecutive subjects sent for an evaluation before 1st chemotherapy cycle (TNSc score equal to 0 which means no neuropathy);
9676363|NCT04986891||subjects with stable CIPN condition after chemotherapy completion|subjects sent for an evaluation due to stable CIPN condition (CIPN defined as TNSc > or = 1) after chemotherapy completion (at least 2 months off treatment).
9676364|NCT04987060|Other|Intrastromal Fresh Human Lenticule Implantation|The aim of this study is to investigate the effect of intrastromal fresh corneal lenticule implantation using Smile module surgery after PK with primary objective to increase visual acuity by reducing irregular astigmatism according to high K values. The stromal pocket diameter was 8 mm, 2mm super incision, 140-µm cap thickness and fresh lenticular implantation is performed.
10174487|NCT03853005|Active Comparator|Group B (HVHDF group)|They will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours. The survival status of all of the subjects were followed up at 28 days after being diagnosed as severe sepsis.
10174488|NCT03852940|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
10174489|NCT03852940|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
9527611|NCT03218501|Active Comparator|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
9676365|NCT04986982|Experimental|Opicapone|
9676366|NCT04986982|Placebo Comparator|Placebo|Opicapone and placebo capsules will be identical in size, colour, taste and appearance. The packaging and labelling will not allow for any distinction between test and reference drug.
9676367|NCT04986995|Experimental|Opicapone|50 mg hard capsules
9676368|NCT04987073|Experimental|patients with CYP24A1 mutation|
9676369|NCT04987346|Experimental|Treadmill walking|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
9676370|NCT04986969|Active Comparator|real-time, face-to-face, video-conferenced CBT (vcCBT)|vcCBT is cognitive behavioral therapy that consists of eight face-to-face video-conferencing sessions via tablet computers lasting approximately 45 minutes each.
9676371|NCT04986969|Active Comparator|self-administered internet-based CBT (iCBT)|iCBT is self-directed cognitive behavioral therapy using an interactive internet program, MoodGYM, which does not include direct interactions with a therapist.
9676372|NCT04987528||Patients with pulmonary fibrosis|"All ICU patients for which one of the non-invasive criteria of pulmonary fibrosis is reached :~Typical CT scan patterns (reticulation and/or bronchiectasia)~Serum PIIINP above 16 µg/L~BAL PIIINP above 9 µg/L"
9676373|NCT04987528||Patients without pulmonary fibrosis|All ICU patients for which none of the non-invasive criteria of pulmonary fibrosis are reached.
9676374|NCT04986774|Experimental|Rescue Intracranial Stenting (RIS)|RIS in Acute Ischemic Stroke caused by intracranial large vessel occlusion
9676375|NCT04986813|Active Comparator|Group Tranexamic Acid|50 patients were given 1 gram of Tranexamic acid (TXA) intravenously pre-operatively. Intravenous TXA was administered, at the time of start of surgical incision.
9676376|NCT04986813|Placebo Comparator|Control group|50 patients were kept as a control group and were not given TXA.
9676377|NCT04986644|Experimental|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
9676378|NCT04986644|Active Comparator|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
9676379|NCT04986826||Healthy master athletes|
9676380|NCT04986826||Genotype positive phenotype negative transthyretin amyloidosis|
9676381|NCT04986826||Phenotype positive transthyretin amyloidosis|
9676382|NCT04986761|Experimental|Workflows|Digital and conventional workflows for treatment of implant single crowns
9676383|NCT04986761|Experimental|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
9676384|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - within-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS on a visual working memory task in aged HV
9676385|NCT04986787|Experimental|Entrainment with personalized bi-focal fronto-parietal synchronized tACS in HV - cross-frequency|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized cross-frequency fronto-parietal tACS stimulation on a visual WM task in aged HV
9676386|NCT04986787|Experimental|Cerebellar rTMS to modify the effects of cortico-cortical, fronto-parietal tACS in HV|double-blind, randomized, sham-controlled, cross-over trial assessing the effects of cerebellar stimulation on individualized fronto-parietal tACS stimulation during a visual WM task in aged HV
9676387|NCT04986787|Experimental|Neuromodulation protocol in MCI patients (precise protocol to be chosen on results of previous arms)|double-blind, randomized, sham-controlled, cross-over trials assessing the effects of individualized fronto-parietal tACS stimulation or a combination of rTMS-tACS on a visual working memory task in MCI patients
9676388|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of small volume (≤ 30 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
9676389|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of large volume (> 30 and ≤ 100 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
9676390|NCT04986800|Experimental|Intervention Group|Participants in the Intervention Group will receive 10 sessions of the PROACTIVE Parent intervention.
9676391|NCT04986384|Active Comparator|Active Treatment Group|Patients will be instructed to use the anti-pruritic spray for four weeks starting from the day which informed consent was signed in active treatment group. A follow-up visit will be on week 2 for a mid-term review.
9676392|NCT04986384|Active Comparator|Wait-list Control Group|Patients will be instructed to start the treatment after two weeks from the day which consent was signed and for a duration of two weeks in wait-list control group. A follow-up visit will be on week 2 for a mid-term review and for the dispense of treating material.
9527612|NCT03218501|Placebo Comparator|Placebo|Placebo is to be administered orally once daily for 2 weeks
9527613|NCT03218540|Experimental|SVV group|Fluid management protocol
9676393|NCT04986553||50 subjects, male and female, at least 18 years of age|50 subjects who are candidates for surgery using the Arthrex Clavicle Plate for treatment of clavicle fractures.
9676394|NCT04986436|Experimental|HS-10360|Either single or multiple doses of varying dose levels
9676395|NCT04986436|Placebo Comparator|Placebo|
9676396|NCT04986865|Experimental|ATG-101|"Dose Escalation Phase:~Will be conducted with an enhanced PDx cohort.~Dose Expansion Phase:~Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled."
9527614|NCT03218540|Active Comparator|CVP group|Fluid management protocol
9527615|NCT03218475|Experimental|MR Guided Focused Ultrasound|
9676397|NCT04986410||Myocardial Perfusion examination|
9676398|NCT04986345|Experimental|Rest, HIIT-4, HIIT-10|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.~This arm's sequence of intervention is : 1-Rest; 2- HIIT-4 and 3- HIIT-10."
9975660|NCT01343706|Placebo Comparator|Placebo 2|Immediate release solid oral dosage
9975661|NCT01343719|Experimental|BI 661051 low dose, low|solution for oral administration, single dose
9975662|NCT01343719|Experimental|BI 661051 low dose, medium|solution for oral administration, single dose
9975663|NCT01343719|Experimental|BI 661051 low dose, high|solution for oral administration, single dose
10174490|NCT03853122|Active Comparator|Best current practice exercise programme|"Therapeutic physical exercise, best current practice:~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group)."
10174491|NCT03853122|Experimental|Experimental exercise programme|"Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages):~Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly"
9676399|NCT04986345|Experimental|Rest, HIIT-10, HIIT-4|"Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.~This arm's sequence of intervention is : 1- Rest; 2- HIIT-10 and 3- HIIT-4."
9676400|NCT04986501|Experimental|MucoPEG|Arm being compared to against Biotene
9676401|NCT04986501|Active Comparator|Biotene|Arm being compared against MucoPEG
9676402|NCT04986462||patients with bursal-side partial-thickness rotator cuff tears|Patients with bursal-side partial-thickness rotator cuff tears who underwent arthroscopic surgery and was followed up at Peking University Third Hospital.
9676403|NCT04986254||Benzylpenicillin|ICU patients receiving benzylpenicillin for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
9676404|NCT04986254||Ceftriaxone|ICU patients receiving ceftriaxone for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
10174492|NCT03853018|No Intervention|Control group|The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
10174493|NCT03853018|Experimental|CWAT intervention group|The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
9527616|NCT03218462|Experimental|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
9527617|NCT03218462|Experimental|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
9676405|NCT04986254||Meropenem|ICU patients receiving meropenem for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
9527618|NCT03218436|Active Comparator|CAP cohort|Cold Atmospheric plasma intervention
9676406|NCT04986254||Piperacillin/tazobactam|ICU patients receiving piperacillin/tazobactam for confirmed/suspected community-acquired pneumonia, ventilator-associated pneumonia, aspiration pneumonia or a clinically-diagnosed lung infection (n = 20)
9975664|NCT01343719|Experimental|BI 661051 medium dose, low|solution for oral administration, single dose
9975665|NCT01343719|Experimental|BI 661051 medium dose, medium|solution for oral administration, single dose
9975666|NCT01343719|Experimental|BI 661051 medium dose, high|solution for oral administration, single dose
9975667|NCT01343719|Experimental|BI 661051 high dose, low|solution for oral administration, single dose
9975668|NCT01343719|Experimental|BI 661051 high dose, medium|solution for oral administration, single dose
9975669|NCT01343719|Experimental|BI 661051 low dose|tablet
9975670|NCT01343719|Experimental|BI 661051 medium dose|tablet
9975671|NCT01343719|Placebo Comparator|Placebo|solution for oral administratrion
9975672|NCT01343732|No Intervention|healthy volunteeres|this arm will undergo only EEG measurement
9975673|NCT01343732|Active Comparator|real - low frequency|this arm will receive DTMS treatment with low frequency
9676407|NCT04986319||Adequately sun-exposed healthy population|Healthy coastal fishermen of Cox's Bazar district of Bangladesh
10174494|NCT03853018|Experimental|CWAT + motivation intervention group|Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
10174495|NCT03853083|Experimental|Hypoxi Equipment|
9676408|NCT04986319||Inadequately sun-exposed healthy population|Healthcare workers of the selected hospitals of Dhaka, Bangladesh
10174496|NCT03853083|Active Comparator|Recumbent Bicycle|
10174497|NCT03852914|Experimental|Experimental: Sodium Hyaluronate 2%|Each patient will receive a single injection of SH2%
9676409|NCT04986267||ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
9676410|NCT04986475|Experimental|Music Therapy|Music therapy was applied during the non-stress test.
10174498|NCT03852771|Experimental|Treatment|All participants will receive the intervention
9676411|NCT04986475|No Intervention|Control|A routine non-stress test was performed.
9676412|NCT04986280||Single Arm|Arm 1 - All patients will undergo PET/CT with 18F-PSMA-1007
9676413|NCT04986670|Experimental|NutriCare|The oncology care team will provide participants with nutrition toolkit involving printed educational materials, a nutrition prescription, referral to registered dietitians (RDs) for remotely-delivered medical nutrition therapy counseling, and home-delivery of medically tailored meals.
9676414|NCT04986670|Active Comparator|NutriTool|The oncology care team will provide participants with a nutrition toolkit involving printed educational materials.
9676415|NCT04986332|Experimental|"GROUP COPD"|100 participants, 50 males and 50 females with COPD and multiple chronic conditions
9676416|NCT04986332|Active Comparator|"GROUP HF"|100 participants, 50 males and 50 females with HF and multiple chronic conditions
9676417|NCT04986332|Active Comparator|"GROUP HEALTHY PARTICIPANTS"|"100 healthy participants or control group which will be compared to Group A and Group B by age and sex"
9676418|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction Without Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
9676419|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction With Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
9676420|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction Without Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
9676421|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction With Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
9676422|NCT04986241||Healthy sedentary Without Statin|Sedentary and healthy participant without use of statin; Without statin in the last 6 months.
9676423|NCT04986241||Healthy sedentary With Statin|Participant with dyslipidemia and sedentary with current use of statin.
10174499|NCT03852875|Experimental|Education|Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
10174500|NCT03852875|Sham Comparator|Control|Patients in the Control arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will NOT receive feedback on their intake exercise stress test.
9676424|NCT04986241||Healthy physically active Without Statin|Healthy, physically active participant without use of statin; Without statin in the last 6 months.
9676425|NCT04986241||Healthy physically active With Statin|Participant with dyslipidemia and physically active with current use of statin.
9676426|NCT04986488||Without delirium|
9676427|NCT04986488||With delirium|
9676428|NCT04986306||clinical tumor stage 1-3 (cT1-3) and nodal stage 1 (cN1) breast cancer patients|Patients who will undergo neoadjuvant chemotherapy were asked to participate in this study. Informed consent will be given. Clip will be placed over the positive lymph node by surgeon which was proven by fine-needle aspiration cytology. After completion of neoadjuvant chemotherapy, surgery of the breast and the axilla was executed in the same session. Different surgeons performed the procedure.
9676429|NCT04986228|Experimental|Digital aftercare|The group with the new digital aftercare is compared with the active control group with regular aftercare.
9676430|NCT04986228|Active Comparator|Treatment-as-usual (TAU)|The group with regular aftercare (TAU) serves as an active control group.
9676431|NCT04985994||Tuberculosis Patients|"Diagnosed with pulmonary TB after detailed history collection, clinical examination, and laboratory assessment (sputum culture positive).~Aged 18 years or above.~Willing to participate in the study."
9676432|NCT04985994||Healthy Volunteers|"Healthy subjects with no symptoms or history of pulmonary TB~Negative sputum culture~Matched for sex and age (±5 years) with the TB patient group."
9676433|NCT04986007|Experimental|digital Cognitive Behavioral Therapy for Insomnia|Following baseline evaluation, participants in this group will receive 8 weeks of digital Cognitive Behavioral Therapy for Insomnia delivered using Sleep Healthy Using the Internet (SHUTi). After the interim assessment, participants will then crossover to 8 weeks of active monitoring.
9676434|NCT04986007|No Intervention|Waitlist Control|Following baseline evaluation, participants in this group will undergo weekly monitoring of insomnia and suicidal ideation for 8 weeks. Participants will continue whatever treatments they are currently receiving, but will receive no specific instructions or behavioral interventions for insomnia. After the interim assessment, participants will then crossover to receive digital Cognitive Behavioral Therapy for Insomnia.
9676435|NCT04985877|Experimental|Sarcopenia group|Yakult light 300 supplementation with sarcopenia patient
10174501|NCT03852758|Experimental|Outdoor Exercise|2 sessions of outdoor exercise per week
10174502|NCT03852758|Experimental|Indoor Exercise|2 sessions of indoor exercise per week
10174503|NCT03852797|Active Comparator|Ketamine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
10174504|NCT03852797|Active Comparator|Ketamine + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
9676436|NCT04985877|No Intervention|Non sarcopenia group|no intervention to sarcopenia patient
10174505|NCT03852797|Active Comparator|Propofol|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
10174506|NCT03852797|Active Comparator|Propofol + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
9676437|NCT04985877|No Intervention|Control group|no intervention to non-sarcopenia people
9676438|NCT04985890|Experimental|UB-421 monotherapy|Subjects will receive 10 mg/kg UB-421 weekly infusion for 8 weeks.
9676439|NCT04985890|Experimental|UB-421 + chidamide combination therapy|Subjects will receive 10 mg/kg UB-421 weekly infusion and 10 mg chidamide twice a week administration for 8weeks.
9676440|NCT04986059|Experimental|Pre-event massage|
9676441|NCT04986059|No Intervention|Control|
9676442|NCT04986215||Benign pancreatic space occupying group|
9676443|NCT04986215||Malignant pancreatic space occupying group|
9676444|NCT04986124||MDD patients|No intervention.
9676445|NCT04986137||Group 1|Acute kidney injury due to acute tubular necrosis
9676446|NCT04986137||Group 2|Acute kidney injury due to prerenal azotemia
10174507|NCT03852797|Active Comparator|Etomidate|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
10174508|NCT03852797|Active Comparator|Etomidate + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
10174509|NCT03852420|Experimental|Treatment with the LUMINIZE RF Balloon Catheter|Subjects undergoing cardiac ablation procedure LUMINIZE™ RF Balloon Catheter System.
10174510|NCT03852628|Active Comparator|2mg Buprenex and 380mg Vivitrol|"2mg Buprenex and 380mg Vivitrol~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)"
10174511|NCT03852628|Placebo Comparator|Placebo|"Placebo (SL pill qd, IM injection q4weeks)~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)"
10174512|NCT03852641|Experimental|Bolus gavage feeds|Bolus gavage feeds over 15-30 minutes
10174513|NCT03852641|Experimental|Continuous feeds|Continuous feeds over 2.0 hrs
10174514|NCT03852615|Experimental|Ovarian torsion|Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that went through laparoscopic ovarian de-torsion surgery
10174515|NCT03852615|Other|No ovarian torsion|Control group - Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion and went through laparoscopic surgery, however no ovarian torsion has been demonstrated
10174516|NCT03852329|Experimental|Navigated|Lateral skull base navigation intervention is applied
10174517|NCT03852303|Active Comparator|ivermectin once a year|Ivermectin one dose per year and anti-epileptic treatment
10174518|NCT03852303|Experimental|ivermectin 2 times a year|Ivermectin one dose 2 times a year and anti-epileptic treatment
10174519|NCT03852303|Experimental|ivermectin 3 times a year|vermectin one dose 3 times a year and anti-epileptic treatment
10174520|NCT03852602||Group Control|Analgesic application15 minutes before the end of the treatment will constitute the control group.
9527619|NCT03218436|No Intervention|Control cohort|no intervention
9676447|NCT04986137||Group 3|Acute kidney injury due to hepatorenal syndrome type 1
9676448|NCT04986111|Experimental|Linear skin closure with wound drain|Reduce fluid collection and dead space by inserting drain into the subcutaneous layer using the wound closure method previously used in the experimental center. The linear suture has a relatively quick time to stitch out.
9676449|NCT04986111|Active Comparator|Purse-string skin closure with negative pressure wound therapy|Close the wound with a purse-string suture which is better in terms of surgical site infection but known to take a long time for wound healing, and use negative pressure wound therapy to help granulation of tissues and help healing.
9676450|NCT04986020||Parkinson disease|Participants with a clinical diagnosis of Parkinson's disease
9676451|NCT04986020||Control|Controls
9676452|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor: the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
9676453|NCT04986163|Active Comparator|non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|non invasive analgesia monitoring with ANSPEC-PRO and MEDSTORM the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
9676454|NCT04986163|Active Comparator|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE|non-invasive analgesia monitoring with MEDSTORM and MEDASENSE the monitoring will be done in different periods. In each period the two monitors will monitoring the pain in a serial way. Period 1: awake patient, Period 2: sedated patient with propofol, Period 3 : monitoring during standardized pain stimulus; Period 4: monitoring during surgery
9676455|NCT04985799|Active Comparator|Gynecare TVT Exact sling|Participants who are planning surgery for SUI are randomized to have placement of Gynecare TVT Exact sling and followed postoperatively for 1 year.
9676456|NCT04985799|Active Comparator|Neomedic KIM sling|Participants who are planning surgery for SUI are randomized to have placement of retropubic Neomedic KIM sling and followed postoperatively for 1 year.
9676457|NCT04985786|Experimental|AUD Intervention|Risk behavior specific intervention, targeting alcohol drinking
9676458|NCT04985786|Active Comparator|AUD Control|Non-risk behavior specific intervention, targeting cognitive exercises
9676459|NCT04985786|Experimental|AUD & SZ Intervention|Risk behavior specific intervention, targeting alcohol drinking
9676460|NCT04985786|Active Comparator|AUD & SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
9676461|NCT04985786|Experimental|SZ Intervention|Risk behavior specific intervention, targeting medication non-adherence
9676462|NCT04985786|Active Comparator|SZ Control|Non-risk behavior specific intervention, targeting cognitive exercises
10174521|NCT03852602||Group preemptive|Patients who underwent analgesic 15 minutes after the induction of general anesthesia .
10174522|NCT03852368|Experimental|The Effects of Light Exercise in Executive Functions|The effects of light exercise in executive functions of adolescents
9676463|NCT04985786|No Intervention|HC Control|Healthy control subjects will participate in fMRI assessments only
9676464|NCT04985864|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
9676465|NCT04985864|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
9676466|NCT04985591|Experimental|liposuction group|
9676467|NCT04985591|Placebo Comparator|Other plastic surgery group|
9676468|NCT04985617|Experimental|Warmed Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
9676469|NCT04985617|No Intervention|Room Temperature Fluids|When patients recovered from the effect of anesthesia, awakened and were able to switch to normal spontaneous breathing, they were taken from the sober unit to the service or intensive care unit, and subsequent follow-ups were carried out by the researcher in these units. The IV fluid given to the patients in the control group was given at room temperature without heating and without intervention
9676470|NCT04985721|Experimental|Pamiparib and Tiselizumab|
9676471|NCT04985578|Experimental|Dry needling Group|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
9676472|NCT04985578|Placebo Comparator|Sham dry needling|The experimental extremity will be assigned randomly and will receive a single treatment session of TrP sham dry needling as follows: the therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, sham dry needling technique will be performed on the TrP for 60 seconds with a needle without tip.
9676473|NCT04985578|No Intervention|Control|No Treatment will be perfomed in this group
9975674|NCT01343732|Active Comparator|real - high frequency|this arm will receive DTMS treatment with high frequency
9975675|NCT01343732|Sham Comparator|sham - low / high frequency|this arm will receive DTMS sham treatment with low or high frequency
10174523|NCT03852368|Experimental|The Effects of Moderate Exercise in Executive Functions|The effects of moderate exercise in executive functions of adolescents
10174524|NCT03852368|Experimental|The Effects of Heavy Exercise in Executive Functions|The effects of heavy exercise in executive functions of adolescents
9676477|NCT04985747|Experimental|Polished palate|Participants will receive maxillary complete dentures with smooth palatal surfaces without modification.
10174525|NCT03852654|Experimental|treatment|
10174526|NCT03852485||Normal|no glaucoma or retinal pathology or corneal conditions
10174527|NCT03852485||Glaucoma|diagnosis of glaucoma
9676478|NCT04985747|Experimental|Roughened palate|Participants will receive maxillary complete dentures with roughened palatal surfaces
9676479|NCT04985747|Experimental|Open palate|Participants will receive maxillary complete dentures with opened palatal surfaces
9695202|NCT04780542|Active Comparator|Treatment as usual|Help-seeking students recruited from university clinics will remain on waitlist until they receive treatment as usual. Non-help-seeking students recruited from needs assessment survey and outreach will be referred to university health clinic.
9695203|NCT04780542|Active Comparator|Self-guided iCBT|Help-seeking students recruited from university clinics will receive self-guided internet delivered cognitive behavioral therapy while on waitlist. Non-help seeking students recruited from needs assessment survey and outreach will receive the self-guided version of internet delivered cognitive behavioral therapy.
10174528|NCT03852485||Retina|diagnosis of AMD, DR or other retinal pathology
10174529|NCT03852485||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
9695204|NCT04780750|Active Comparator|Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)
9695205|NCT04780750|Active Comparator|Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks|Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\m2 every 3 weeks)
9695206|NCT04780854|Active Comparator|Metformin group|1 gm metformin tablet administered twice daily for 3 months
9695207|NCT04780854|Placebo Comparator|Metformin-free|1 placebo tablet administered twice daily for 3 months
9695208|NCT04780815|Experimental|myBluTM Formulation 1|
9695209|NCT04780815|Experimental|myBluTM Formulation 2|
9827549|NCT02460575|Experimental|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
10174530|NCT03852446|Experimental|Part 1: Single Ascending Dose|
10174531|NCT03852446|Experimental|Part 2: Bioavailability and Food Effect|"Single dose of Indoximod HCL (F2) formulation under fasting conditions~Single dose of Indoximod HCL (F2) formulation under fed conditions~Single dose of Indoximod base formulation under fasting conditions"
10174532|NCT03852407|Experimental|Fludarabine-Melphalan-Cyclophosphamide|FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.
10174533|NCT03852407|Experimental|Fludarabine-Melphalan-thymoglobulin|FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.
10174534|NCT03852563|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
9676480|NCT04985656|Experimental|Pevonedistat 20 mg/m^2 + Decitabine 35 mg + Cedazuridine 100 mg|Pevonedistat 20 mg/m^2, 60-minute intravenous (IV) infusion, once daily, on Days 1, 3, and 5 in each 28-day cycle in combination with decitabine 35 mg and cedazuridine 100 mg tablets, orally, once daily on Days 1 through 5 in each 28-day cycle up to 30 months.
9676481|NCT04985513|No Intervention|Group N|Stopping ventilation during cardiopulmonary bypass
10174535|NCT03852563|Active Comparator|Women_Hemiface Vaseline|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
10174536|NCT03852589|Active Comparator|C-MAC Videolaryngoscope|C-MAC Videolaryngoscope: An intubating device that is used for endotracheal intubation. Proseal laryngeal mask airway will be inserted with C-MAC Videolaryngoscope
10174537|NCT03852589|Active Comparator|Blind|Proseal laryngeal mask airway will be inserted with digital finger
10174538|NCT03852498|Experimental|Lenti-D Drug Product|Participants received a single intravenous (IV) infusion of Lenti-D Drug Product at a dose of > or = 5.0*10^6 CD34+ cells/kilogram (kg) (autologous CD34+ cell-enriched population that contains cells transduced with lentiviral vector encoding ABCD1 cDNA for human adrenoleukodystrophy protein, suspended in a cryopreservative solution) following myeloablative conditioning with busulfan and fludarabine on Day 1.
10174539|NCT03852251|Experimental|AK104|AK104 IV every 2 weeks (q2w)
9676482|NCT04985513|Active Comparator|Group V|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
9676483|NCT04985734|Experimental|Patients under diagnostic work-up|
9676484|NCT04985435|Active Comparator|Choice group|50 patients will be randomized to the choice group, they will view a neutral information video on anti TNF and Filgotinib and will be given the opportunity to choose between these two treatments
9527620|NCT03218449||1/NC|noninfective complication
9527621|NCT03218449||2/IC|infective complication
9676485|NCT04985435|Active Comparator|Randomization group anti TNF|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with antiTNF
9676486|NCT04985435|Active Comparator|Randomization group Filgotinib|A total of 50 patients will be randomized to the randomization group: 25 of those will start treatment with Filgotinib
9676487|NCT04985487||Brolucizumab|Patients prescribed with brolucizumab in the approved indication
9676488|NCT04985344|Experimental|Propranolol|Patient will receive oral propranolol
9676489|NCT04985344|Placebo Comparator|Placebo|Patient will receive oral placebo
9676490|NCT04985526|Experimental|Polymorphic light eruption patients|PLE patients subjected to MED testing and photoprovocation
9676491|NCT04985526|Other|Healthy subjects|Normal healthy subjects
9676492|NCT04985448||Conbercept|In clinical treatment and research, the applied doses of Conbercept in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Conbercept ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
9676493|NCT04985448||Ranibizumab|In clinical treatment and research, the applied doses of Ranibizumab in patients with retinopathy of prematurity have been reduced compared with adults, mostly half of the adult dose. The commonly used exposure dose of intravitreal injection of Ranibizumab ophthalmic injection is 0.25mg/0.025ml.In addition, possible exposure doses are but not limited to 0.15mg/0.15ml, 0.1mg/ 0.1ml, 0.2mg/0.2ml, etc.
9676494|NCT04985448||Laser Treatment|
9676495|NCT04985474||Pulmonary resection|
9676496|NCT04985292|Experimental|Probiotic|10^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
9676497|NCT04985292|Placebo Comparator|Placebo|Inactive substance packaged to be identical to active treatment
9676498|NCT04985279|Active Comparator|Standard clinical practice|"Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation using skin markers.~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine.~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~A usability questionnaire regarding the procedure will be completed."
9676499|NCT04985279|Experimental|Position and Angle Marking System (PAMS)|"PAMS will be attached to the ultrasound probe.~Lumbar ultrasound scan will be performed to identify the desired needle insertion site, followed by demarcation by gentle pressing PAMS into the simulated patient's back to create skin indentations.~The angulation of the ultrasound probe will be adjusted to optimise the image of the simulated patient's lumbar spine, and the angle read off a graduated scale.~The ultrasound probe will be removed and needle insertion simulated by touching the tip of a blunt needle to the patient's back, at the desired angle.~A usability questionnaire regarding the procedure will be completed."
9676500|NCT04985370|Experimental|Pain neuroscience education plus exercise|Three sessions of pain neuroscience education plus exercise.
9676501|NCT04985370|Active Comparator|Exercise alone|Exercise alone without pain neuroscience education.
9676502|NCT04985539||PD de novo|Observational.
9695210|NCT04780711||Diagnostic Group|Demographic data, symptoms for TMJ of the students will be recorded. Physical examination will be included range of motion of temporomandibular joint, right and left TMJ lateral range of motion, whether there is a gradual opening, during deflection and deviation during the opening and subluxation for palpation and measurements. Opening and closing clicks, crepitation and popping will be recorded during palpation. Deep palpation of the skin, masseter and temporal muscles will be determined, posture analysis will be recorded and dental interventions, missing teeth, orthodontic treatments and bruxism histories will be taken. An appropriate diagnosis will be determined for students who are found to have pathology as a result of all these examinations and information about this diagnosis will be provided.
9975676|NCT01343745|Placebo Comparator|Placebo|Placebo pMDI
9975677|NCT01343745|Experimental|Low dose|BDP/formoterol pMDI low dose
10174540|NCT03852251|Experimental|AK104 and chemotherapy|"AK104 IV every 2 weeks (q2w)~oxaliplatin IV 85 mg/m2 q2w~capecitabine 1000 mg/m2，twice a day (bid) for day 1 to day 10 per cycle"
9676503|NCT04985422|Experimental|Experimental group: Smartphone-based daily ecological momentary intervention (EMI)|"The experimental group receives 4 weeks of smartphone-based daily EMI. Participants are prompted 6 times a day (with an interval of at least 30 minutes between each digital prompt), on a daily basis over the 4-week period. Within 15 minutes of the digital prompt, participants are to first complete a brief (1-2 minutes) momentary survey (ecological momentary assessment [EMA]), and subsequently select 1 out of 5 personalised intervention actions of interest to complete in the moment (time to complete spans from 1 minute to 5 minutes).~The interventions are brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done in the moment. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).~Participants could also use the platform at any other times to redo intervention actions when preferred. Individualised reports for the EMI completed are provided."
9676504|NCT04985422|Other|Control group: Smartphone-based weekly-delivered information|"The control group receives 4 weeks of smartphone-based weekly-delivered information. The smartphone system (SMS + Qualtrics) as well as the contents of the interventions are identical to those provided to the EMI group. Rather than interventions delivered in the moment on a daily basis over the 4-week period, participants in the control group are provided with a new set of information on a weekly basis over the 4-week period (4 sets in total, 1 new set each week). Participants in the control group are also required to complete a brief 5-minute assessment within 3 days.~The information includes brief simple behavioural actions (mostly 1-2 minutes, up to 5 minutes) which could be done anytime. Simple action tasks include guided breathing, mindful walking, and mindful sound hearing (etc.).~Participants could complete any intervention of interest in the information provided at any time throughout the 4-week period."
10174541|NCT03852199||Case Group|Our study was performed with 30 healthy individuals at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. The FS of the knee joint was measured with a Pressure Biofeedback Device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN), a device similar to a sphygmomanometer. To correlate the outcomes of biofeedback device, simultaneously, a surface electromyography (EMG) data of M. Quadriceps femoris muscle activation levels from the individuals were recorded.
10174542|NCT03852355|Active Comparator|Radiofrequency|bilateral 3rd occipital nerve RF under fluoroscopic guidance
10174543|NCT03852355|Active Comparator|Systemic steroid|received systemic steroids oral prednisolone tablet, 10 mg/day.
10174544|NCT03852238||Cases: patients with hepatocellular carcinoma on non-cirrhotic|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
9676505|NCT04985552|Experimental|ciNPT|
10174545|NCT03852238||Control: patients without hepatocellular carcinoma|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
10174546|NCT03852212|No Intervention|Control Group|The control group did not received any treatment
9676506|NCT04985552|Active Comparator|Conventional tape dressings|
10174547|NCT03852212|Experimental|Manipulation|Experimental group received the osteopathic maneuver and the blood value were measured at baseline, after 2,5 and 10 minutes.
10174548|NCT03852225||OHCA patients|Patients resuscitated for out-of-hospital cardiac arrest of non-traumatic origin and investigated by intra-arrest echocardiography.
9676507|NCT04985396|Experimental|Platelet Rich Plasma (PRP) group|The PRP will be prepared based on the Sengodan et al, 2020 study.
9676508|NCT04985396|Active Comparator|Steroid group|"Steroid group will be treated with steroid injection. In this group, 2ml of Inj. Depo-Medrol 80 mg (Methylprednisolone) along with 1 ml lignocaine (0.25%) will be loaded in 5cc syringe and then the cocktail will be injected into medial calcaneal tuberosity at the most tender point using an aseptic technique as mentioned by Nishanth et.at,2018.~After the procedure, participants will be advised not to involve in any kind of rigorous activity with the affected foot for at least two days and then gradually return to their regular activities. All patients will be counseled to follow up in the next visit at 3 months and 6 months. The end-line information will be again recorded at 3 months and 6 months."
10174549|NCT03852186|Active Comparator|Cognitive behavioral therapy|Manualized group-based cognitive behavioual therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
9676509|NCT04985253||Operable breast neoplasm cohort|Operable breast cancer (OBC) ER +/Her2 neg or triple negative breast cancer patients diagnosed and treated at Tata Memorial Centre, Mumbai from 01 Jan 2010 to 31 Dec 2013 with a five-year follow up or events within the 5 years.
9676510|NCT04985669|Experimental|prucalopride group|prucalopride group will receive prucalopride 2 mg once daily
9676511|NCT04985669|Active Comparator|Lubiprostone group|lubiprostone group will receive lubiprostone 8 microgram twice daily
9827550|NCT02460575|Placebo Comparator|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
10174550|NCT03852186|Experimental|Acceptance and commitment therapy|Manualized group-based Acceptance and Commitment therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
10174551|NCT03852381|Experimental|Spinal Cord Stimulation|"At baseline, the following data will be recorded: standard-of-care questionnaire scores, neuroimaging (fMRI, MEG), psychophysical testing (QST), accelerometer sleep and activity data.~The trial will proceed as follows:~Day 1-4: Paresthesia-based SCS (PB-SCS)~Day 5-8: No SCS (placebo)~Day 9-12: PF-SCS~Neuroimaging and psychophysical testing will be conducted at the end of the trial, and will be assessed 6-months post-implantation of the SCS device along with adverse effects. A decision to implant the SCS system will be made based on reduction of patient pain intensity by 50% in PB-SCS and/or PF-SCS modes, but not with placebo SCS.~Based on the response in the trial, the patient will either not be a candidate for an SCS implant, or they will receive one of the four modes upon implantation (PB-SCS, or one of the three PF-SCS: Burst, High Frequency, High Density)."
10174552|NCT03852108|Experimental|Group comfort care|Socio-aesthetic care
10174553|NCT03852108|No Intervention|Group control|Conventional care
10174554|NCT03852121|Experimental|Intervention group|Participants will receive bibliotherapy without withdrawing from the usual care. They will be asked to read the designated manual (consists of eight chapters) within a recommended period of time (over 8 weeks). Weekly telephone coaching will also be provided to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves. An orientation will be organized before the first session. Two booster sessions will be organized during the study.
10174555|NCT03852121|No Intervention|Control group|The participants in the control group will only receive usual care provided by the community health professionals.
10174556|NCT03852095||minor trauma|Child from 1 to 18 years old suffering an isolated minor trauma presenting at the hospital emergency services.
10174557|NCT03852173|Experimental|"Intervention group Wasserschulen"|Schools receive refillable drinking bottles for all school children and drying racks for each classroom. Schools receive special project educational material and informational material and one training session for teachers. The intervention will be implemented during one school year (2018/2019), but schools can use the material and bottles also after ending of the intervention period.
10174558|NCT03852173|No Intervention|Control group|No intervention (usual education). Schools do not receive any project material. Schools got the information that they are part of a study on drinking and eating habits of third grade elementary school children.
10174559|NCT03852147|Active Comparator|Control group|hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.
9676512|NCT04985565|Experimental|Treatment (dietary intervention, radical prostatectomy)|Patients participate in the Mediterranean diet for 6 days per week for 4 weeks before undergoing standard of care radical prostatectomy.
10174560|NCT03852147|Experimental|Experimental group|perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.
10174561|NCT03852160|Experimental|Esketamine + Oral Antidepressants|Participants will receive esketamine as nasal spray (28 milligram [mg] [initial dose for elderly participants 65-74 years of age] on Day 1 and then uptitrated to 56 mg on Day 4, 56 mg [initial dose for adult participants aged 18-64 years and may be used for all age groups throughout the study] or 84 mg [maximum uptitrated esketamine dose]) twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral anti depressants (AD) (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
10174562|NCT03852160|Active Comparator|Placebo + Oral Antidepressants|Participants will receive matching placebo as nasal spray twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral AD (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
9676513|NCT04985240|Experimental|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
9676514|NCT04985240|Experimental|Experimental: intervention group|The intervention group was assigned to biofortificated Molibdenum crop lettuce.
9676515|NCT04985357||Breast Cancer|Diagnosis of stage III or IV breast cancer
9676516|NCT04985357||Lung Cancer|Diagnosis of stage III or IV lung cancer
9676517|NCT04985357||Acute myelogenous leukemia (AML)|Diagnosis of acute myelogenous leukemia.
9676518|NCT04985357||Multiple Myeloma|Diagnosis of relapsed multiple myeloma
9676519|NCT04985500|Experimental|ESP group|Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.
9676520|NCT04985500|Experimental|PIF group|Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.
9676521|NCT04985500|No Intervention|No Block group|Patient will not receive block.
9676522|NCT04985266|Active Comparator|Standard endocrine therapy|"Standard endocrine therapy will continue for up to 24 months on trial.~Standard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane)."
9676523|NCT04985266|Experimental|Palbociclib and fulvestrant|"Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.~Palbociclib will be given orally once a day on days 1-21 of each 28 day cycle.~Fulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit."
9676524|NCT04985149|Other|Grup 1; participants with fibromyalgia|Participants with fibromyalgia
9676525|NCT04985149|Other|Grup 2: patients without fibromyalgia|Patients without fibromyalgia
9676526|NCT04985006|Experimental|Moderate intensity aerobic exercise|each subject will undergo running in medium intensity.
9676527|NCT04985006|Active Comparator|High intensity aerobic exercise|each subject will undergo running in high intensity.
9676528|NCT04985201|Experimental|Simvastatin + Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
9676529|NCT04985201|Active Comparator|Irinotecan|received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles)
9676530|NCT04985123||Silicone Block patients|All subjects who received a successful penile implantation with the Silicone Block by the surgeons at the centers in this study.
9676531|NCT04984850|Experimental|Intervention plus usual care|
9676532|NCT04984850|No Intervention|Usual care only|
10174563|NCT03851913|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
10174564|NCT03851913|No Intervention|control group|no neo-adjuvant treatment before operation
10174565|NCT03851874|Active Comparator|Gastric bypass bariatric surgery|Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity
10174566|NCT03851874|Active Comparator|Sleeve gastrectomy bariatric surgery|Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity
10174567|NCT03851978|Experimental|Pharmacist Vaccine Education|
9676533|NCT04985162|Experimental|Intervention|Intervention group (n=10) received differential learning based physiotherapy program: 3 times a week ordinary physiotherapy, 2 times a week differential learning based on physiotherapy, total 3 weeks
9676534|NCT04985162|Active Comparator|Control|Control group (n=10) received ordinary physiotherapy program 5 times a week, total 3 weeks
9676535|NCT04984954|Experimental|Experimental group|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
9676536|NCT04984954|Placebo Comparator|Placebo group|The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.
10174568|NCT03851900|Experimental|Teethmate Desensitizer (TM)|Calcium phosphate biomimetic material that forms hydroxyapatite from tetracalcium phosphate and dicalcium phosphate anhydrous and plug the dentin tubules causing remineralization and dentin hypersensitivity relief.
10174569|NCT03851900|Active Comparator|Clearfil SE Bond 2 (SE)|Two-step self etch adhesive resin treating dentin hypersensitivity b covering a film layer after light-curing.
10174570|NCT03851900|Placebo Comparator|Distilled water|Distilled water with no desensitizing components.
9676538|NCT04984759|Experimental|Primaquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤5 days old will be recruited into the primaquine arm. They will receive primaquine 0.5 mg/kg daily for 14 days directly observed in the clinic.
10174571|NCT03851809|Experimental|neurologic intensive care in acute brain injury|With the guidance of Taiwan Neurosurgical Society and Taiwan Neurological Society, patients in the control group were given the consistent treatment. (http://www.neurosurgery.org.tw/nsr/tbi/main.htm and http://www.stroke.org.tw/guideline/guideline_1.asp). The intensive treatments were established according to the traumatic brain injury treatment guidelines and spontaneously intracerebral hemorrhage general treatment principles from these two society in Taiwan.
9676539|NCT04984759|Experimental|Tafenoquine in mature milk (mother-child pairs)|24 women who are breast feeding infants or young children > 14 days will be recruited into Arm 2. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic. We will begin with recruiting 2-4 women breastfeeding young children ≥12 months old.
9676540|NCT04984759|Experimental|Tafenoquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤ 5 days old will be recruited into Arm 3. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic.
9676541|NCT04984980|Experimental|combined treatment group|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab Gemcitabine: 1000mg/m^2, iv, d1, d8, q3w Oxaliplatin: 100mg/m^2, iv, d1, q3w Sintilimab: 200mg, iv, d1, q3w Bevacizumab: 5mg/kg, d1, q3w
9676542|NCT04984863|Experimental|magnetically controlled capsule endoscopy|magnetically controlled capsule endoscopy to evaluate the efficacy of the treatment of gastroesophageal varices
9676543|NCT04984967|Experimental|Insertion of peripheral venous catheter with micro-guide|
9676544|NCT04984967|Other|Classic insertion of peripheral venous catheter, without micro-guide|
9676545|NCT04984720|Experimental|Smart phone based digital app arm|Digital smartphone application which tracks migraine and to offers pill reminders for medication adherence and community blog and disease related educational material for migraineurs will be given to the patients
10174572|NCT03851991|Active Comparator|arbidol|200mg, three times per day, for 2-5 Days.
10174573|NCT03851991|Placebo Comparator|Placebos|two capsules, three times per day, for 2-5 Days.
10174574|NCT03851887|Experimental|treatment group|TAI combine SBRT
9527622|NCT03218176|Active Comparator|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
9676546|NCT04984720|Active Comparator|Paper and pen diary arm|Clinic based education and traditional paper-pen diary will be administered in tracking headache parameters
10174575|NCT03851770|Other|refractory epilepsy patients|All patients belong to the refractory epilepsy group. Intervention: Characterization of Vagus nerve stimulation: Evoked potentials (EP) are recorded using an EEG/EP digital acquisition system
10174576|NCT03852056|Placebo Comparator|MFP Fluoride toothpaste|Commercially available, monofluorophosphate (MFP) toothpaste. Fluoride level is 0.76%
10174577|NCT03852056|Experimental|Stannous Fluoride Toothpaste|New toothpaste containing 0.454% stannous fluoride.
10174578|NCT03851835|Experimental|Ondansetron Oral Solution|Ondansetron Oral Solution (4mg/5mL solution) - Dose = 0.15mg/kg. One dose every 8 hours (q8h). Six doses over 48 hours.
10174579|NCT03851835|Placebo Comparator|Placebo Oral Solution|Compounded Placebo Oral Solution to match experimental arm
10187126|NCT03729219|Experimental|ETVAX|Contains inactivated Tetravalent ETEC vaccine, 10 ug Double-mutant heat-labile toxin (dmLT) and effervescent power for oral solution administered twice 14 (plus minus 7) days intervals.
10187127|NCT03729219|Placebo Comparator|Placebo|Effervescent power for oral solution administered wice 14 (plus-minus 7) days intervals
10187128|NCT03729206|Experimental|Sublingual microscopy|
10187129|NCT03729193||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 soccer players.
9676547|NCT04985175|Experimental|QPL group|receive 2-pages ESRD QPL leaflets, circle the questions they want to ask before consultation. encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
9676548|NCT04985175|No Intervention|Usual care group|without receiving provision of QPL encourage asking questions with doctor during consultation. receive the nurse-led coaching of shared decision-making (SDM)
9676549|NCT04985110|Experimental|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
9676550|NCT04985110|Placebo Comparator|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
9676551|NCT04985019|Experimental|I (Prepectoral)|VR treatment group Participants received the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for panic disorder.
9676552|NCT04985019|No Intervention|II (Subpectoral)|Waiting list Participants in a waiting list.
9676553|NCT04985045||Control group|Healthy women will be included
9676554|NCT04985045||Cerebral palsy group|Women with cerebral palsy will be included
9676555|NCT04984746|Experimental|No Intervention: (control group)|No Intervention: (control group) The control group was assigned to lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
9676556|NCT04984746|Experimental|Experimental: intervention group|Experimental: intervention group To the intervention group was assigned the biofortificated Molibdenum lettuce and Iodine lettuce.
9676557|NCT04984707|Experimental|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.The applied dosage cohorts are 3mg, 12mg, 48mg and 96mg.
9676558|NCT04984707|Placebo Comparator|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.
9676559|NCT04985097|Active Comparator|Experimental group|Half an hour of active visual training per day for a period of 20 consecutive days with the Optictrain software
9676560|NCT04985097|Sham Comparator|Control group|Half an hour of using a videogame without specific stimuli to improve visual performance (Fun Kid Racing 3.53 for Android) per day for a period of 20 consecutive days
9676561|NCT04984824|No Intervention|No nap group|No nap opportunity will be given in this condition.
9676562|NCT04984824|Experimental|10 minute nap|Participants will be given a 10 minute nap.
9676563|NCT04984824|Experimental|30 minute nap|Participants will be given a 30 minute nap.
9676564|NCT04984824|Experimental|60 minute nap|Participants will be given a 60 minute nap.
9676565|NCT04984694|Experimental|Computerized virtual reality training programs group (Hot-Plus group)|Participants who are in Hot-Plus group will divide several small groups which will be 4 persons with mild cognitive impairment. Participants will receive computerized virtual reality training program by Hot-Plus as a group activity for one hour, once a week for 12 weeks.
9676566|NCT04984694|Active Comparator|Social interaction group|The participants in the social interaction group will come as a group for social interaction one hour weekly for 12 weeks.
10187130|NCT03729193||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 basketball players.
10187131|NCT03729193||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 volleyball players.
9676567|NCT04984694|No Intervention|Control group|The control group will maintain regular activities.
9676568|NCT04984473|Sham Comparator|Sham arm|Perform inspiratory muscle training at 2% maximal inspiratory pressure for 12 weeks.
9676569|NCT04984473|Active Comparator|Non-sham arm|Perform inspiratory muscle training at 40% maximal inspiratory pressure for 12 weeks.
9676570|NCT04984252|Active Comparator|Only Active components|15 minutes, once
9676571|NCT04984252|Sham Comparator|Inactive components|15 minutes, once
9676572|NCT04984252|Placebo Comparator|Distraction group|15 minutes, once
9676573|NCT04984460||life-style counseling|"A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd."
9676574|NCT04984226|Experimental|Veverimer|6 grams daily
9676575|NCT04984226|Experimental|Sodium Bicarbonate|0.5mEq/kg lean mass daily
9676576|NCT04984226|Placebo Comparator|Sodium bicarbonate placebo|cornstarch
9676577|NCT04984226|Placebo Comparator|Veverimer placebo|Microcrystalline cellulose
9676578|NCT04984551|Experimental|Arm I: ECHO Participants (ECHO clinics, workshop, education)|Participants participate in online ECHO clinics over 1 hour twice monthly for 12 months and in-country workshops twice per year. Participants also receive 5 core lectures through an internet-based professional education curriculum.
9676579|NCT04984551|Experimental|Arm II: Patients (questionnaire, medical chart review)|Patients complete 3 in-person or phone questionnaires over a total of 20 minutes every 3 months for 2 years about their symptoms, emotional and physical well-being, and their experience and satisfaction with outpatient oncology care. Patients' medical charts are reviewed for data collection. Patients complete a 15 minute interview in person or phone about the care they received by their physician at baseline, end of month 4 and month 12.
9676580|NCT04984551|Experimental|Arm III: Caregivers (questionnaire)|Caregivers complete an in-person or phone questionnaire over 5 minutes up to 8 times about their experience and satisfaction with the cancer care their family member has received. Caregivers complete a 15-minute interview in person or by phone their family member received by their physician.
9975678|NCT01343745|Experimental|High dose|BDP/Formoterol pMDI high dose
9676581|NCT04984304|Experimental|Mild cough|Mild cough only slightly worsening the quality of life (VAS 1-3)
9676582|NCT04984304|Experimental|Moderate and severe cough|Moderate and severe cough that significantly worsen the quality of life (VAS 4-10)
9676583|NCT04984408|Experimental|Arm 1: BBIBP-CorV|Study Arms 1 will have two groups: group 1 - HIV-uninfected receiving BBIBP-CorV; group 2 - HIV-infected receiving BBIBP-CorV .
9975679|NCT01343758|Active Comparator|5% dextrose in normal saline|This group will receive a bolus of normal saline that contains 5% dextrose
9975680|NCT01343758|No Intervention|Normal Saline Bolus|
10187132|NCT03729193||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 archers.
10187133|NCT03729193||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 kickboxers.
9676584|NCT04984408|Experimental|Arm 2: Flu Quadrivalent|Study Arms 2 will have two groups: group 1 - HIV-uninfected receiving Flu Quadrivalent; group 2 - HIV-infected receiving Flu Quadrivalent. The Flu Quadrivalent is recommended as a single dose for adults, the second and the booster doses for Arm 2 will be placebo.
9676585|NCT04984408|Experimental|Arm 3: BBIBP-CorV and Flu Quadrivalent (Co-administration)|Arm 3 will have 1 group - HIV-uninfected co-administration group receiving both study vaccines.
9676586|NCT04984200||AB|
9676587|NCT04984642|Experimental|healty subject|
9676588|NCT04984434|Experimental|Experimental: Single Arm|
9676589|NCT04984577|Experimental|Compound Edaravone Injection-Low dose|
9676590|NCT04984577|Experimental|Compound Edaravone Injection-High dose|
9676591|NCT04984577|Active Comparator|Edaravone Injection|
9676592|NCT04984577|Placebo Comparator|Placebo Injection|
9676593|NCT04984525|Experimental|Part 1 Cohort 1 MAD HV: SYNB1934 (3 x 10^11 live cells)|HV subjects receive SYNB1934 (3 x 10^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
10174580|NCT03852134|Experimental|MOCC Group|The OB provider will hold the baby at/below the placenta, provide warmth, stimulate the baby and suction the mouth/nose for 30 secs.S/He will then clamp and cut the cord about 5 cm from the the introitus (vaginal deliveries) or from the abdominal incision (C-Sections) before handing the baby with the long-cut cord to the neonatal team to resuscitate/ stabilize the baby. A member of the neonatal team will milk the long-cut cord slowly 1 time from the cut end toward the infant over 10 secs before clamping and cutting the cord 1-2 cm from the umbilical stump. The neonatal team will provide PPV to the baby (during the milking process) if the baby is not breathing. If the baby is breathing during the milking process the team will continue the stabilization as per standard NRP practice.
10174581|NCT03852134|Active Comparator|DCC group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
9676594|NCT04984525|Experimental|Part 1 Cohort 2 Crossover HV: SYNB1934 (6 x 10^11 live cells)|HV subjects receive SYNB1934 (6 x 10^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 7-day washout period HV subjects receive SYNB1618 (6 x 10^11 live cells), at least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
9676595|NCT04984525|Experimental|Part 1 Cohort 3 MAD HV: SYNB1934 (1 x 10^12 live cells)|HV subjects receive SYNB1934 (1 x 10^12 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
9676596|NCT04984525|Experimental|Part 1 Cohort 4 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
9676597|NCT04984525|Experimental|Part 1 Cohort 5 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
9676598|NCT04984525|Experimental|Part 2 Crossover with PPI vs No PII|HV subjects receive SYNB1934 (at or below the MTD from Part 1) with PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 14-day washout period HV subjects receive SYNB1934 (at or below the MTD from Part 1) without PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
9676599|NCT04984447|Experimental|Feasibility of TNIB catheter|The feasibility of using the TNIB catheter to obtain microscopic images of the intestine. Healthy adult volunteers, and healthy pregnant women in their 2nd trimester of pregnancy will be enrolled, and their upper gastrointestinal tract will be imaged by the TNIB device
9676600|NCT04984187|Other|Laser group|High Intensity Laser Therapy only , this group will receive laser for 4 weeks three times /week
9676601|NCT04984187|Other|Exercise group|Exercise , selected physiotherapy exercises will receive for 4 weeks ,3times/week
9676602|NCT04984187|Experimental|High intensity laser grouo|High intensity laser plus exercise will receive the selected exercises and laser 4 weeks, 3 times/week
10174582|NCT03851718|Experimental|Acupuncture Procedure|Acupuncture is a type of Traditional Chinese Medicine (TCM) therapeutic approaches involving the insertion and manipulation of fine needles in specific points. Mothers in acupuncture group will be given three standardized sessions of acupuncture within 5 weekdays, preferably on 3 consecutive days.
9676603|NCT04984265|Experimental|Stereotactic Body rRadiotherapy (SBRT)|SBRT targeting the area of the circuit of Ventricular Tachycardia
9676604|NCT04984278|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Study dependent: Each spray delivers 100 microliters (μL) of nabiximols. A pre-determined number of sprays, but no less than 4 sprays, of nabiximols will be self-administered by participants as an oromucosal spray, under supervision of trial staff during 2 study visits to the trial site after they temporarily discontinued treatment with prescribed nabiximols (Sativex) as part of their regular medication.
9676605|NCT04984278|Placebo Comparator|Placebo|Placebo to match nabiximols is presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray delivers 100 μL containing no active ingredients.
9676606|NCT04983758||PHP|
9676607|NCT04983758||Moderate PCP|
9676608|NCT04983758||Severe PCP|
9676609|NCT04983992||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
9676610|NCT04983992||control group|People suffered from excessive lateral pressure syndrome with conservative treatment
9676611|NCT04983836|Experimental|Serratus Block|
9676612|NCT04983836|Other|Paravertebral Block|
9676613|NCT04984070|Experimental|PCOS treatment|Lifestyle intervention, oral contraceptive pills and metformin will be given to improve the symptoms of PCOS patients, such as obesity, hyperandrogegism, and insulin resistance, and to compare the different psychological status in PCOS.
9676614|NCT04983940|Experimental|Jatenzo Arm|Participants in this group will receive Jatenzo for 26 consecutive weeks.
9676615|NCT04984122|Other|Control|GA group intravenous 2-3 μ/kg fentanyl followed by 2 mg/kg propofol. were administered for anesthesia induction. After a laryngeal mask insertion anesthesia was maintained by inhalation of sevoflurane in an oxygen (60%) and nitrous oxide (40%) mixture to maintain a minimal alveolar concentration (MAC) of 0.8%-1.3%.
9676616|NCT04984122|Other|Study|In the LA group, after positioning of the patient, injection 2% 1:1000.000 (2 % lidocaine with 1:100.000 epinephrine) was injected submucosally with a 27-gauge needle tip at 3,6,9,12 o'clock locations of the ectocervix.
9676617|NCT04983849|Active Comparator|hydrogel metronidazole 25%|metronidazole hydrogel in adjunct to non surgical periodontal therapy
9676618|NCT04983849|Active Comparator|scaling and root planing|the only use of scaling and root planing
9676619|NCT04984109|Sham Comparator|Control group|Patients will receive preoperative US-guided will receive sham PENG with an injection of just 1mL saline.
9676620|NCT04984109|Experimental|PENG Group|Patients will receive preoperative US-guided will receive real PENG with an injection of 20mL of bupivacaine 0.25%+ 0.2mg/mL dexamethasone.
9676621|NCT04984018|Experimental|Chidamide plus Camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
9676622|NCT04983966|Experimental|Desflurane group|General anesthesia with volatile agent of desflurane
10174583|NCT03851718|Active Comparator|Power pumping|Power pumping is a pumping strategy that mimics normal infant cluster feedings by repeatedly emptying mother's breast very frequently in an effort to increase breast milk supply. As there is no standardized protocol of power pumping, one of the most popular recommendations will be adapted as the study power pumping instruction. It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days.
9676623|NCT04983966|Active Comparator|Remimazolam group|Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
9676624|NCT04983784|Experimental|The Effectiveness of Walking on Sleep ,Depression and Quality of Life on intervention|"experimental group:~intervention home-style walking exercises~performed 12 weeks of 30 minutes walking exercise 2-3 times per week~assess on at baseline and 12 weeks"
9676625|NCT04983784|Experimental|No intervention group reaction|"control group:~no intervention~Routine care and follow-up~assess on at baseline and 12 weeks"
9676626|NCT04983745|Experimental|Experimental|niraparib and dostarlimab
9676627|NCT04984135||Enrolled patients|Patients fulfilling the study criteria were included.
9676628|NCT04984057|Experimental|PS is stopped when the pressure is equal between bPDA and aPDA|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
9676629|NCT04984057|Active Comparator|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
9676630|NCT04983537|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
10174584|NCT03852069|Placebo Comparator|Placebo|16 g maltodextrin/day + recipes based on vegetables poor in inulin-type fructans
9676631|NCT04983537|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
9676632|NCT04983537|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
9676633|NCT04983641|No Intervention|Control - No Pre-Visit Message|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were not sent any reminder e-mails or MyChart messages concerning PROMIS form completion at any timepoint prior to their scheduled clinic visit.
9676634|NCT04983641|Experimental|E-mail Arm|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patients in this arm were sent an initial reminder e-mail message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patient's did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder e-mail message.
9695211|NCT04780529|Experimental|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
10174585|NCT03852069|Experimental|Inulin|16 g inulin/day + recipes based on vegetables rich in inulin-type fructans
10174586|NCT03852043|Experimental|High-intensity interval training|
10174587|NCT03852043|Active Comparator|Moderate-intensity continuous training|
10174588|NCT03851939|Experimental|treatment group|Transarterial Chemoinfusion (TAI) Combine Toripalimab
10174589|NCT03851848|Experimental|Joint mobilization (JM) group|The Maitland mobilization technique will target three main joints of the affected foot in order to facilitate major ankle and foot movements: (1) Talocrural joint Anterior-posterior (AP) mobilization will be performed to enhance ankle dorsiflexion ROM; (2) first metatarsal phalangeal joint (FMTP) AP glide will be performed to facilitate big toe extension ROM; (3) subtalar joint traction will be performed to increase both foot eversion and inversion ROM, and lateral glide will be performed to reinforce inversion ROM.
10174590|NCT03851848|Experimental|Myofascial release (MFR) group|The MFR technique will be performed as a direct trigger point release followed by deep soft tissue release for the calf muscles (gastrocnemius and soleus) and the plantar fascia .
10174591|NCT03852017|Experimental|Mindfulness Audio Program|Mindfulness Audio Program is a daily audio-session, which teaches emotional self-regulation skills through the adoption of mindful awareness practices into one's life
10174592|NCT03852017|Active Comparator|Music Audio Program|Music Audio Program is a daily audio session of peaceful and relaxing music
10174593|NCT03852030|Experimental|Mindfulness text/email message|"Weekly MBSR specific text or email messages related to course teachings were sent.~TYPES OF MESSAGES INCLUDED: Non-reaction; Non-Judgment; Awareness; Loving Kindness; Acceptance."
9676635|NCT04983641|Experimental|"Digital Patient Portal MyChart Arm"|o Patients were assigned PROMIS forms in the domains of Depression (PROMIS-D) and Pain Interference (PROMIS-PI) in addition to Upper Extremity Function (PROMIS-UE) and/or Physical Function (PROMIS-PF). These forms were available for remote completion in each respective patient's MyChart portal at 1 week prior to their clinic appointment. Patient's in this arm were sent an initial reminder MyChart message at 1 week prior to their scheduled clinic visit regarding PROMIS form completion. If patients did not fill out PROMIS forms by 3 days prior to their visit, they were sent a second reminder MyChart message.
9676636|NCT04983550|Experimental|Group A: SG001 + doxorubicin hydrochloride liposome injection|Two-thirds of the patients will be randomly assigned to group A to receive SG001 240 mg, IV, every 2 weeks (1 cycle every 4 weeks), and doxorubicin hydrochloride liposome injection 40 mg/m^2, IV, every 4 weeks (1 cycle).
10174594|NCT03852030|Placebo Comparator|Health promotion text/email message|Weekly general/informational texts or emails about healthy living and lifestyle were sent. TYPES OF MESSAGES INCLUDED: Diet; Exercise; Sleep; Illness; Stress.
10174595|NCT03852030|No Intervention|No text/email message|No texts or emails were sent. There are no examples or descriptions for these messages, because no messages were sent to this group.
9676637|NCT04983550|Active Comparator|Group B: doxorubicin hydrochloride liposome injection|One-third of the patients will be randomly assigned to group B to receive doxorubicin hydrochloride liposome injection 40 mg/m^2, IV, every 4 weeks (1 cycle).
9676638|NCT04983381|Experimental|Education Group|Participants were grouped as; those who were given information about vaginal examination in the training group (n=40) and those who were not given information about vaginal examination in the control group (n=40).
10174596|NCT03851861|Experimental|Mediterranean Diet|Participants will be given individualized diet education on the Mediterranean diet and instructed to follow the diet for the 5-week intervention period. Individualized diet education will be administered by a licensed, registered dietitian nutritionist (RDN) followed by weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
9676639|NCT04983381|No Intervention|Control Group|Women were not given information about vaginal examination in the control group
9676640|NCT04983667|Experimental|Orange|Zinc-AA, Tablet, 30 mg. PO, Once Daily for up to one year
9676641|NCT04983667|Placebo Comparator|Green|Placebo, Tablet, 30 mg. PO, Once Daily for up to one year.
9676642|NCT04983524|Experimental|Propolis|intervention intracanal medicament
9676643|NCT04983524|Active Comparator|Calcium Hudroxide|Gold standard intracanal medicament
9676644|NCT04983693|Experimental|Dementia-friendly Worship Service|Caregiver and persons living with dementia dyads attending six dementia-friendly worship services in person or online.
9676645|NCT04983563|Experimental|Actigraphy|
9695212|NCT04780672|Active Comparator|Molixan|30 mg/ml solution for intravenous and intramuscular injection. Pharmacotherapeutic group: Metabolic agent. ATC code: V03AX - other medicinal products
9695213|NCT04780672|Placebo Comparator|Placebo|"Sol. of NaCl (Sodium chloride) - 0.9% Pharmacotherapeutic group: Regulators of water-electrolytic balance and acid-base balance.~ATC: B05CB01 Sodium chloride"
9695214|NCT04781088|Experimental|Treatment (paclitaxel, lenvatinib, pembrolizumab)|Patients receive paclitaxel IV over 1 hour on days -15 and -8 and lenvatinib PO QD on days -15 to 0. Beginning cycle 1 day 1, patients receive lenvatinib PO QD, pembrolizumab IV over 30 minutes on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles with pembrolizumab repeats every 3 weeks for up to 2 years, and cycles with paclitaxel and lenvatinib repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
10174597|NCT03851952|Other|Optilume DCB|Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
9695215|NCT04780581|Active Comparator|RECOVERY|intermediate-dose dexamethasone (6mg/24h - 10 days)
9695216|NCT04780581|Experimental|BOLUS|high-dose methylprednisolone bolus (250mg/4h - 3 days)
9695217|NCT04780646|Experimental|Nature therapy in urban nature|Subjects receive a 90-minute nature therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.
9695218|NCT04780646|Active Comparator|City Walk|Subjects receive a 90-minute city walk through urban sourroundings once per week for 8 weeks with a city guide, who talks about city architecture and gives information about the history of the surroundings.
9695219|NCT04780646|No Intervention|Waiting List|Subjects don't receive any therapy.
9695220|NCT04780958|Other|Study population|During the study period, babies born at this hospital with a gestational week of <30 were included .
9827551|NCT02460666|Experimental|Tai-Chi Chih Classes|Participants will engage in 12 weekly 60 minute Tai-Chi-Chih classes.
9827552|NCT02460666|Active Comparator|Health Education and Wellness Classes|Participants will engage in 12 weekly 60 minute Health Education and Wellness classes.
10174598|NCT03852004|Experimental|Osteopatic treatment|An osteopatic treatment will be realised by osteopath
10174599|NCT03852004|Placebo Comparator|simulated osteopathic treatment|A simulated ostepathic treatment will be realised by osteopath
10174600|NCT03851731|Experimental|Naltrexone|Subject received a single intranasal dose of 2 mg naltrexone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
10174601|NCT03851731|Experimental|Naloxone|Subject received a single intranasal dose of 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
10174602|NCT03851731|Experimental|Naltrexol|Subject received a single intranasal dose of a combination of 2 mg naltrexone and 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
10187134|NCT03729193||table tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 table tennis athletes.
9676646|NCT04983615|Experimental|fentanyl-based sedation group|
9676647|NCT04983615|Active Comparator|midazolam-based sedation group|
9676648|NCT04983706|Experimental|MRI/Ultrasound Fusion Saturation Biopsy|
9676649|NCT04983355|Experimental|Peptidyss|"Dietary supplement : fish hydrolysate~The experimental product is a dietary supplement composed of a hydrolysate of fish containing low molecular weight peptides (4 capsules/day providing 1,4 g of fish hydrolysate)"
9676650|NCT04983355|Placebo Comparator|Placebo|The placebo product containing mainly silica is presented in the same form as the active product, so that people handling the product cannot distinguish both formula (4 capsules/day)
9676651|NCT04983095|Active Comparator|Standard treatment|ADT and local RT to de novo patients
9676652|NCT04983095|Experimental|SBRT+Standard treatment|SBRT to all PSMA+ lesions in addition to ADT and local RT to de novo patients
9676653|NCT04983186|Experimental|Participants|Participants wear the Empatica E4 wearable sensor and use the smartphone applications developed by the research team.
9676654|NCT04983121|Experimental|combine treatment group|This study adopts a single-arm, multi-center, open design. As per the initial plan, 30 stage II-III human epidermal growth factor receptor 2(HER2)-positive breast cancer patients who have received neoadjuvant therapy containing trastuzumab and pertuzumab and have been assessed as stable disease (SD) during the neoadjuvant treatment (an increase of 0-20%), disease progression (PD), inoperable or failing to meet the breast-conserving requirements will be enrolled to receive pyrotinib combined with Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) neoadjuvant therapy. The main purpose of the study is to observe the efficacy and safety of pyrotinib combined with ARX788 neoadjuvant treatment in stage II-III HER2-positive breast cancer.
9676655|NCT04983147|Experimental|health belief model based training manuel|"A training manual entitled Do Not Stay Silent Towards Obesity was prepared by the researcher to guide women in obesity management by affecting their beliefs on obesity in a positive way."
9676656|NCT04983147|Experimental|powerpoint presentation with computer|The presentation prepared based on the Health belief model was used in group training.
9676657|NCT04983147|Experimental|video for obesity based on health beliefs|In the literature; It is explained that the educator's use of representations such as video is more effective than verbal expression and reading, and facilitates learning both by hearing and seeing.For this reason, videos that will create awareness about the subject in the trainings were prepared by the researcher and used in the trainings.
10174603|NCT03851757|Active Comparator|waist-shaped interdental brush|waist-shaped interdental brush, use four times per interdental space
10174604|NCT03851757|Active Comparator|cylindric interdental brush|cylindric interdental brush, use four times per interdental space
9676658|NCT04983147|Experimental|successful patients in obesity management|Real-life stories of people who could manage obesity before and thought themselves healthier compared to their previous condition were shared with the group. People were invited to the trainings who had obesity before and managed to lose weight and trainings were given in the affective field.
9676659|NCT04983147|Experimental|Post-training follow-up|"After the trainings given to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days.It will be made by phone call."
9676660|NCT04983290|Experimental|intervention|The participating subjects belonging to the experimental group, will receive at home a set of foods with modified textures that allow the patient to feed for the observation period of 4 months, will also be followed by the dietary service of the center and by personnel identified within the protocol in order to verify compliance, liability and information regarding the evaluation scales involved in the project.
9676661|NCT04983290|No Intervention|control|The control group will continue with its own feeding for the entire observation period of the experimental group.
9676662|NCT04983160|Active Comparator|Allopurinol|
9676663|NCT04983160|Placebo Comparator|Placebo|
9676664|NCT04982861|Experimental|Cefixime trihydrate 100 mg/5 mL dry syrup|Cefixime trihydrate 100 mg/5 mL dry syrup was dissolved by 20 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
9676665|NCT04982861|Active Comparator|Suprax® 100 mg/5 mL dry syrup|Suprax® 100 mg/5 mL dry syrup was dissolved by 33 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
9676666|NCT04982744||Patients affected by Li Fraumeni and Li Fraumeni Like syndromes|The group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes
9676667|NCT04983043|Experimental|Low dose group|Low dose Qishenyiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
10174605|NCT03851679||pregnancy woman|woman who are submitted to elective Cesarean Section in spinal anesthesia
9676668|NCT04983043|Experimental|High dose group|High dose Qishenyiqi Dripping Pills, 3 bags, take orally after meals, 3 times a day
9676669|NCT04983043|Placebo Comparator|Placebo group|Qishenyiqi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day
9676670|NCT04982757|Experimental|Depression - DMPFC target to (for non-responders) LPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the DMPFC. Partial responders will receive another 5-day course delivered to the DMPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the LPFC.
10174606|NCT03851432|Experimental|Janagliflozin 25 mg plus metformin|Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
10174607|NCT03851432|Experimental|Janagliflozin 50 mg plus metformin|Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
10174608|NCT03851432|Placebo Comparator|Placebo/Janagliflozin plus metformin|In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.
10174609|NCT03851692|Active Comparator|60s (group E)|Intravenous cannulation was released either 60 s following loss of lid reflex in group E
10174610|NCT03851692|Active Comparator|90 or 120 s (groupe L)|Intravenous cannulation was released either 90 or 120 s following loss of lid reflex in group L
10174611|NCT03851575|Active Comparator|Control arm|Usual guideline therapy
9676671|NCT04982757|Active Comparator|Depression - LPFC target to (for non-responders) DMPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the LPFC. Partial responders will receive another 5-day course delivered to the LPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the DMPFC.
9676672|NCT04982757|Experimental|OCD - DMPFC target to (for non-responders) LPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the DMPFC. Partial responders will receive another 5-day course delivered to the DMPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the LPFC.
9676673|NCT04982757|Active Comparator|OCD - LPFC target to (for non-responders) DMPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the LPFC. Partial responders will receive another 5-day course delivered to the LPFC. Non-responders will be crossed over to receive a 5-day course of rTMS delivered to the DMPFC.
9676674|NCT04982978|Active Comparator|PMT Threat Appraisal|The PMT present group will include an 8-minute informational video that explains the current research and health risks associated with vaping, within the context of a threat appraisal focus (Perceived Vulnerability and Perceived Severity). During this video intervention, the severity and vulnerability of vaping among young adults, both in the short and long-term health effects will be presented. In addition, the video will explain the negative impact of vaping and focus the attention of the participants on the lack of research and information that currently exists on popular vaping products and the potentially devastating impact it can have on the health of young adult populations.
9676675|NCT04982978|Sham Comparator|Nutrition and Lifestyle Control|"The PMT absent group will feature an 8-minute nutritional information video as an attention control strategy titled, Vaping Health Effects. During this video intervention, the general risks and benefits of nutrition and lifestyle will be presented. The focus of this video will be on how a balanced diet and proper lifestyle choices (i.e., adequate sleep, diet, etc.) can benefit the participants lives in the short-term and long-term."
9676676|NCT04982874|Experimental|Furosemide 40 mg tablet|volunteers received Furosemide 40 mg tablet with 240 mL of water
9676677|NCT04982874|Active Comparator|Lasix® 40 mg Tablet|volunteers received Lasix® 40 mg tablet with 240 mL of water
9676678|NCT04982705|Experimental|[Part 1.1] IDG-16177|6 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
9676679|NCT04982705|Placebo Comparator|[Part 1.1] Placebo of IDG-16177|2 subjects in each cohort (Cohort 1-5). The SAD study (Part 1.1) will consist of 5 cohorts of 8 healthy subjects who will be randomised to receive a single oral dose of IDG-16177 or placebo (6 active treatments and 2 placebo/3:1 ratio). Subjects in Cohort 4 will participate in a food-effect study.
9676680|NCT04982705|Experimental|[Part 1.2] IDG-16177|8 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo.
9676681|NCT04982705|Placebo Comparator|[Part 1.2] Placebo|2 subjects in each cohort (Cohort 6-8). The MAD study (Part 1.2) will consist of 3 cohorts of 10 healthy subjects (8 active treatments and 2 placebo/4:1 ratio), each receiving an oral dose of IDG-16177 or placebo (QD).
9676682|NCT04982705|Experimental|[Part 2] IDG-16177|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
9676683|NCT04982705|Placebo Comparator|[Part 2] Placebo|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator.
10174612|NCT03851575|Experimental|Accelerated arm|Accelerated treatment of endocarditis
10174613|NCT03851354|Other|Ultrasound meal accomodation test|ultrasound guided gastric dynamics test for tolerance of enteral feeding, 500 ml of water with protein (glutamine or casseinate) wil be administrated
10174614|NCT03851562|Experimental|Alprostadil 20 micrograms|1 μg / kg patient weight up to a maximum of 60 μg
9676684|NCT04982705|Active Comparator|[Part 2] Sitagliptin|This part will consist of 3 separate arms of 8 patients per arm. Each arm will receive one of the following treatments: IDG-16177, placebo or DPP-4i as comparator (1:1:1 ratio).
9676685|NCT04982809|Active Comparator|Betamethasone group|
9676686|NCT04982809|Active Comparator|Dexamethasone group|
9676687|NCT04982809|Active Comparator|Prednisolone group|
9676688|NCT04983303|Experimental|TICK-B group as intervention group|TICK-B group: The children will receive a picture as they want. They will be asked to trace and color the pictures that need coloring. After the procedure, the child will take his or her picture which he colored during the procedure.
9676689|NCT04983303|Experimental|Coughing trick|Coughing trick: Children in this group will be taught how to cough during the procedure. coughs with start moderate force and then coughs again which coincides with a needle procedure, such as venipuncture for example.
9676690|NCT04983303|Experimental|Balloon inflation group as intervention group|Balloon inflation group: In this group, the children will receive a balloon colored as their favorite, and they will be asked to inflate the balloon before starting the venipuncture procedure.
9676691|NCT04983303|No Intervention|Standard care provided group as control group|Standard care provided group as the control group
9527623|NCT03218176|Experimental|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
10174615|NCT03851562|Placebo Comparator|Placebo (physiological saline solution)|Placebo (physiological saline solution)
10174616|NCT03851289|Experimental|test (PRF-CS)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and calcium sulfate was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
10174617|NCT03851289|Active Comparator|control (PRF-X)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and xenograft (MinerOss® X) was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
10174618|NCT03851640|Experimental|HC-1119|80mg;
10174619|NCT03851640|Placebo Comparator|placebo|80mg;
9676692|NCT04982900|Experimental|EGFR-TKI Treatment Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of Furmonertinib on the day of baseline follow-up. Patients in the treatment group should take Furmonertinib (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of Furmonertinib for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
10174620|NCT03851341|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
10174621|NCT03851341|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
10174622|NCT03851653|Experimental|Lifestyle Intervention Group (LIG)|Participants from this group will receive a cognitive-behavioral intervention addressing weight loss and lifestyle habits such as hypocaloric diet, moderate exercise, smoking and alcohol avoidance, and sleep hygiene. This behavioral intervention will be combined with the usual treatment for OSA, i.e. CPAP.
9676693|NCT04982900|Placebo Comparator|Control Arm|After randomization, the enrolled patients in this arm should be completely free from the risk of perioperative complications or recovered from the effects of complications, usually no earlier than 4 weeks after surgery but no more than 10 weeks after surgery, before receiving baseline follow-up and starting oral administration of placebo on the day of baseline follow-up. Patients in the treatment group should take placebo (80 mg each time) orally on an empty stomach before breakfast once a day. The medicine should be taken about the same time each day, by swallowing the whole tablet with water, without crushing or chewing. Patients should maintain oral administration of placebo for 6 consecutive months, unless there is disease progression, death, new anti-tumor therapy received or intolerance of investigational drugs.
9676694|NCT04982835|Experimental|M6-C Artificial Cervical Disc|The M6-C is an investigational device composed of two outer and inner endplates made of titanium with a polycarbonate urethane nucleus (plastic center) and a polyethylene fiber annulus (strong thread-like binding). Around the polyethylene annulus is a polyurethane sheath (plastic cover). The outer endplates have keels to anchor the disc to bone. The outer endplates and keels are both coated with a titanium plasma spray. The M6-C is provided in two heights (6mm and 7mm) and four footprints (Medium, Medium Long, Large, Large Long).
9676695|NCT04982835|Active Comparator|Ant. Cervical Discectomy & Fusion (ACDF)|"ACDF will be performed using one of three FDA approved anterior cervical plate system and corticocancellous allograft bone. The three plating systems used in this study are:~Medtronic Sofamor/Danek Venture Anterior Cervical Plate System~DePuy Synthes: SKYLINE Anterior Cervical Plate System~Stryker Aviator Anterior Cervical Plating System"
9676696|NCT04982965|Experimental|Active THC|Participants will be administered 400mg of vaporized cannabis (5.1%) before pain testing and fMRI.
9676697|NCT04982965|Placebo Comparator|Placebo THC|Participants will be administered 400mg of vaporized cannabis (<.1%) before pain testing and fMRI.
9676698|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 1）|Healthy subjects receive sinele dose of HEC116094
9676699|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 2）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
10174623|NCT03851653|No Intervention|Control group|Participants from the control group will not receive any type of intervention apart from the usual care (CPAP).
10174624|NCT03851250|Experimental|MRx-4DP0004|"MRx-4DP0004 is a Live Biotherapeutic Product containing 10^9 to 10^10 Colony Forming Units.~Participants randomised to this arm will take 2 capsules twice daily at approximately 12 hour intervals for 12 weeks."
10174625|NCT03851250|Placebo Comparator|Placebo|"Participants randomised to this arm will take 2 capsules of placebo twice daily at approximately 12 hour intervals for 12 weeks.~All participants will receive placebo in a single blind manner for two weeks in addition to the 12 weeks of double blind treatment."
10174626|NCT03851367|Experimental|Sling suspension therapy|3-week duration of exercises using red cord and consisting of 15 sessions for 30 minutes each.
10174627|NCT03851367|Active Comparator|Swiss ball therapy|3-week duration exercise for trunk muscles strengthening and posture improvement consisting of 15 sessions for 30 minutes each.
10174628|NCT03851419||People living with HIV|People living with HIV (ART naive or on ART)
10174629|NCT03851419||People not infected with HIV|HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
9676700|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 3）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
10174630|NCT03851315||LBBAP group|patients received left bundle branch area pacing
10174631|NCT03851315||traditional RVP group|Age and sex-matched patients received traditional right ventricular pacing
10174632|NCT03851172|Experimental|Nepafenac and cyclopentolate|Nepafenac 1 mg eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
10174633|NCT03851172|Experimental|Ketorolac and cyclopentolate|Ketorolac 0.5% eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
10174634|NCT03851172|Placebo Comparator|Cyclopentolate and saline 0.9%|Cyclopentolate eye drops two times before surgery and saline 0.9% eye drops two times before cataract surgery
10174635|NCT03851536|Experimental|Transvaginal Ultrasound Guided ET|Transvaginal ultrasound is used to guide ET
10174636|NCT03851536|Experimental|Transabdominal Ultrasound Guided ET|Transabdominal ultrasound is used to guide ET
10174637|NCT03851549|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)
10174638|NCT03851224|Active Comparator|control group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with no graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
10174639|NCT03851224|Active Comparator|study group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with autogenous bone graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
10174640|NCT03851224|Active Comparator|study group 2|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced withxenograft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
9676701|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 4，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC116094 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
9676702|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 5）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
10174641|NCT03851393|Experimental|Peptest™ analysis of saliva pepsin|Induction of cough with inhaled citric acid and measurement of saliva pepsin following citric acid cough challenge using the peptest lateral device
9676703|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 6）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
9676704|NCT04982913|Experimental|Single dose of HEC116094（Part A, Cohort 7）|Healthy subjects receive sinele dose of HEC116094 or matching placebo
9676705|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 1）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
9676706|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 2）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
9676707|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 3）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
9676708|NCT04982913|Experimental|Mulltiple doses HEC116094（ Part B, Cohort 4）|Healthy subjects receive multiple doses of HEC116094 or matching placebo
9676709|NCT04982913|Experimental|The interaction with Oseltamivir of HEC116094（ Part C）|Healthy subjects received HEC116094 in cycle 1, Oseltamivir in cycle 2, and a combination of HEC116094 and Oseltamivir in cycle 3.There are washout periods between the first cycle and the second cycle and between the second cycle and the third cycle
9676710|NCT04983225|Experimental|1×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10^6 cells/periodontal defect site.
9676711|NCT04983225|Experimental|5×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 5×10^6 cells/periodontal defect site.
9676712|NCT04983225|Experimental|1×10^7 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site.
9676713|NCT04983225|Experimental|2×10^7 cells/two sites group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, two locations in total, and the total cell injection volume is 2 × 10^7 cells/2 periodontal defect sites.
9676714|NCT04983225|Experimental|3~4×10^7 cells/three or four sites group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, three or four locations in total, and the total cell injection volume is 3 × 10^7 to 4 × 10^7 cells/3 to 4 periodontal defect sites.
9676715|NCT04983225|Placebo Comparator|Saline solution group|Saline solution: 0.6mL/periodontal defect site.
9676716|NCT04983004|Experimental|experimental group (tele-rehabilitation)|"Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability.~The intervention is used by the communication software to interact with each other in real time. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment."
9676717|NCT04983004|Active Comparator|control group (bedside rehabilitation)|Each patient will go on a treatment with 10 sections, and each section is 15 or 30 minutes depends on patient's ability. It is carried out by the bedside therapist. The treatment plan and treatment method are set according to the individual's movement needs, and the individual's movement instructions are clearly given during treatment.
10174642|NCT03851276|Other|Patients with 3-vessels diseased referred to CABG surgery|Patients with 3-vessel disease (with or without left main involvement) for which the regular and conventional Heart Team has made already the decision to refer the patient for CABG treatment.
10174643|NCT03851042|Experimental|Virtual Reality Head set in PACU|Use of VR Headset in PACU post hysterectomy for up to 4 hours.
10174644|NCT03851042|Active Comparator|No intervention|Routine PACU care post hysterectomy for up to 4 hours
10174645|NCT03851055|Active Comparator|intervention group|will receive zinc supplementation
10174646|NCT03851055|No Intervention|Control group|Patients will receive placebo only
10174647|NCT03851198|Experimental|Mild Cognitive Impairment patients|Subjects diagnosed with mild cognitive impairment, who will receive the best treatment of clinical practice, will be recruited. They must be more than 60 years old.
10174648|NCT03851198|Active Comparator|Healthy Subjects/ Match control|Healthy subjects of the same age as people with mild cognitive impairment.
10174649|NCT03851666|Placebo Comparator|12 weeks daily administration Placebo|Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
9676718|NCT04982887|Experimental|Experimental Group|
9676719|NCT04982887|No Intervention|Control Group|
9676720|NCT04983017|Active Comparator|Dietary supplements|Dietary supplements are either (1) designated as Generally Recognized As Safe (GRAS) by the Food and Drug Administration or (2) compounds at similar concentrations to those found in foods.
9676721|NCT04983017|Placebo Comparator|Placebo|Placebo-matched formulations
10187135|NCT03729193||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 runners.
9527624|NCT03218176|Experimental|Distal single upper limb|Laying a single tourniquet on the forearm
9676722|NCT04982939|Experimental|Experimental Group-Sintilimab in combination with SOX|Preoperative treatment: three cycles of sintilimab in combination with SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX, Sintilimab up to one year.
9676723|NCT04982939|Active Comparator|Active Comparator-SOX|Preoperative treatment: three cycles of SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX.
9676724|NCT04983277||Diabetes|patients with diagnosed Diabetes Mellitus
10174650|NCT03851666|Experimental|12 weeks daily administration Cereal 1|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 1).~The daily dose administrated is 15 grams."
10174651|NCT03851666|Active Comparator|12 weeks daily administration Cereal 2|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 2).~The daily dose administrated is 15 grams."
9676725|NCT04982523|Experimental|Online Mental Health Program Group|The online mental health program of 8 sessions is provided. Data collection was collected pre-, post-, and one month after the program.
9676726|NCT04982523|No Intervention|Control Group|"Data collection was collected three times for three months. No intervention was provided during the study.~If they wanted, they were provided the online mental health program same as the experimental group after data collection."
9676727|NCT04982562|Other|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
9676728|NCT04982536|Experimental|VMCore Biopsy System|The VMCore biopsy needle will used to collect up to 10 tissue samples.
9676729|NCT04982536|Active Comparator|Standard of Care Biopsy Needle|The urologist will use his/her standard biopsy needle to collect up to 15 tissue samples.
9676730|NCT04982692|Experimental|Intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
9676731|NCT04982692|Placebo Comparator|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
9676732|NCT04982432|Experimental|Orismilast|Orismilast tablet, oral administration, multiple titrated doses twice daily, 10 mg up to 40 mg, morning and evening, 16 weeks treatment.
10174652|NCT03851159|Placebo Comparator|No Intervention: HIV-negative|HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
10174653|NCT03851159|Experimental|Intervention: HIV-|HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
9676733|NCT04982549|Experimental|Durvalumab + platinum-based chemotherapy and radiation|"All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:~cisplatin/etoposide carboplatin/paclitaxel pemetrexed/cisplatin pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
9676734|NCT04982510|Experimental|Thermoplastic tray definitive impression|
9676735|NCT04982510|Active Comparator|Conventional tray definitive impression|
9676736|NCT04982640|Experimental|Yoga|12-week program, 60 minutes, twice weekly group-delivered Iyengar yoga
10174654|NCT03851159|Placebo Comparator|No Intervention: HIV+|HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
10174655|NCT03851159|Experimental|Intervention: HIV+:|HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
9676737|NCT04982640|Active Comparator|Standard Exercise|12-week, 60 minutes, twice weekly group-delivered aerobic exercise (e.g., walking) program
9676738|NCT04982627|Experimental|Brief Negotiation Interview Chatbot (BNI Chatbot)|Participants will receive a link to register for the chatbot. Following registration, they will complete the initial chat, which includes instructions for the entire study. The chatbot will then guide the participant through multiple BNIs focused on the goal of bup engagement, with the following steps: 1) Raise the Subject/Establish Rapport; 2) Enhance Motivation; 3) Provide & Elicit Feedback; and 4) Negotiate a Plan. The chatbot then reminds the participant of their reasons why they might engage in OUD treatment based on their responses to Steps 2 & 3, and their negotiated plan. The chatbot will electronically connect participants to a treatment provider of their choice, based on available options.
9676739|NCT04982627|Active Comparator|Standard Care (OUD Education & Referral Resources)|• SC: The RA will provide participants with an electronic link, which provides OUD and bup education, and lists OUD treatment options and descriptions and locations, including bup prescribers. After reviewing, participants will be asked to choose from among the list of and a referral will be made based on the receiving treatment providers' procedures. These participants will not have access to the BNI chatbot. However, the referral facilitation, the electronic link will direct participants to a short Feasibility, Acceptability and Satisfaction (FAS) Assessment to obtain feedback on the process.
10174656|NCT03851471|Experimental|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
10174657|NCT03851263|Experimental|Evolocumab|All subjects are treated with evolocumab 140mg every 2 weeks (q2w) starting on day 1 and ending on day 1071 (week 153).
10174658|NCT03851146|Experimental|LeY CAR T cells|"One arm study consisting of 3 + 3 dose escalation study design (see below) followed by dose expansion phase at determined MTD.~Dose level : Target Number LeY CART cells infused *~-1 (if needed): 1 x 10e8~2 x 10e8~5 x 10e8~1 x 10e9~5 x 10e9~Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocols~Treatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells."
10174659|NCT03850990|Experimental|Placebo group|In the first visit, this group will learn about placebo pills from a video and will be placebo pills to take twice a day for 8 weeks. They will be asked to take the pills in conjunction with following the weight-loss protocol.
10174660|NCT03850990|Experimental|No placebo group|In the first visit, this group will learn about placebo pills from a video but will not be given placebo pills. They will follow the weight-loss protocol without placebo pills.
9527625|NCT03218176|Experimental|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
9676740|NCT04982601|Experimental|Yoga Group|Yoga-based exercises were performed by a physiotherapist has Yoga training, by consisting of 10-person groups, 6 weeks, 3 days in a week for a total of 18 sessions. Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises and lasts about one hour. Especially combined movements with upper extremity and neck movements and breathing exercises were used in breathing exercises. In the warm-up exercises, the muscles were extended by giving exercises especially for stretching the muscles. In this way, asanas were prepared. Asanas Ardra kati cahkrasana, padahastasana, trikosana, sasankasana, varaksana poses have been performed. Asanas were modified and applied according to the patient's condition. Relaxation exercises were used both after breathing exercises and at the end of the exercise program. With relaxation, the patients were allowed to leave their muscles relaxed with the whole body relaxation
9676741|NCT04982601|No Intervention|Control Group|No kind of intervention has been applied to control group they awaited for therapy procedure for 6 week. They have assessed at the end of the 6 weeks.
9676742|NCT04982380|Experimental|Experimental group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
9676743|NCT04982380|Placebo Comparator|Control group|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
9676744|NCT04982328||NAFLD|patients diagnosed with NAFLD and hospitalized due to the severe COVID-19
9676745|NCT04982328||non-NAFLD|patients hospitalized due to the with severe COVID-19 without NAFLD
9676746|NCT04982302||Non-surgical periodontal treatment NSPT|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets in 2 or 4 appointments
9676747|NCT04982315|Experimental|Standard Acupuncture|Participants randomized to standard acupuncture will receive 8-15 acupuncture treatments over 3 months.
9977533|NCT01362582|No Intervention|Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Subjects in the control group receive Best Supportive Nutritional Care. BSNC is defined as nutritional consultation and recommendation by experienced ecotrophologists."
10174661|NCT03851445|Other|Lung-MAP Screening|This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.
9676748|NCT04982315|Experimental|Enhanced Acupuncture|Participants randomized to enhanced acupuncture will receive 12-21 acupuncture treatments over 6 months.
10174662|NCT03850938|Experimental|Conventional Kyphoplasty|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon.
9676749|NCT04982315|No Intervention|Usual Care|Participants assigned to the usual care arm will not receive acupuncture and will be asked to not get acupuncture over the one-year course of the study.
9676750|NCT04982341||HFNC/prone|awake patients with COVID-19 and severe acute respiratory failure receiving HFNC in prone position
9676751|NCT04981990|Active Comparator|Single lung ventilation|Using double lumen endotracheal tube and lung isolation
9676752|NCT04981990|Active Comparator|Two lung ventilation|Using conventional single lumen endotracheal tube and intermittent two lung ventilation
9676753|NCT04982263||Mild cases|Patients with confirmed COVID-19 and with mild disease
10187136|NCT03729193||field tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 field tennis athletes.
9676754|NCT04982263||Severe cases|Patients with confirmed COVID-19 and with severe disease
9676755|NCT04982016|No Intervention|Control group|There is no treatment before anesthesia induction.
9676756|NCT04982016|Experimental|Crystal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml carbonated Ringer's solution was infused (infusion time >10min).
9676757|NCT04982016|Experimental|Colloidal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml colloidal fluid was infused (infusion time >10min).
9676758|NCT04981899|Experimental|Main arm|"Patients will receive 6 cycles of nivolumab at the fixed dose of 40 mg, with subsequent assessment of response by PET-CT. Patients with CR will proceed to ASCT.~Patients with <CR after nivolumab monotherapy will be treated with 2 cycles of a combination of nivolumab at the fixed dose 40 mg, ifosfamide, carboplatin and etoposide (NICE-40), with subsequent PET-CT assessment."
9676759|NCT04981938||Lobectomy with angioplasty|81 patients who underwent lobectomy with pulmonary artery reconstruction during oncologic lung resection from January 2001 to December 2020
9676760|NCT04981925|Experimental|MBSR treatment|
9676761|NCT04981951|Experimental|Dexmedetomidine and Bupivacaine|Patients will be given Dexemtomidine ( the intervention) added to the Bupivacaine
9676762|NCT04981951|No Intervention|Bupivacaine alone|patients will be given Bupivacaine alone
9676763|NCT04981977|Experimental|Care Transitions Intervention|Patient participants in this arm will receive the Care Transition Intervention.
9676764|NCT04981977|Experimental|Care Transition Intervention and Peer Support|Patient participants in this arm will receive the Care Transition Intervention.
9676765|NCT04981977|Other|Usual Care|Patient participants in this arm will receive the usual discharge/transition care provided by the hospital.
10174663|NCT03850938|Active Comparator|Kyphoplasty with Rotary Cutter|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration, which may induce a cavity with barriers pushed by balloon dilatation. Then, the structure of the cavity is destroyed by a rotary cutter. Finally, the cement is injected, which may effectively interdigitates with the healthy cancellous bone.
9676768|NCT04981886|Experimental|Group 1: Normal tension glaucoma subjects with thin corneas|NTG subjects with CCT ≤ 540 nm will be randomized to receive either netarsudil or bimatoprost.
9676769|NCT04981886|Experimental|Group 2: Normal tension glaucoma subjects with thick corneas|NTG subjects with CCT > 540 nm will be randomized to receive either netarsudil or bimatoprost.
9676770|NCT04982055|Experimental|Intravenous group|
9676771|NCT04982055|Active Comparator|Subcutaneous group|
9676772|NCT04982159||Invasive Fusariosis|Patients hospitalized with an invasive fusariosis diagnostic in the stablished period of study.
10174664|NCT03851029|Experimental|Tai chi|(Yang 24 postures) Moderate intensity HRR (40%-60%)
9676773|NCT04982068|Experimental|Adult Group 1a|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28
10174665|NCT03851029|Active Comparator|Aerobic Training|Elliptical Moderate intensity HRR (40%-60%)
9676774|NCT04982068|Experimental|Adult Group 1b|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28
9676775|NCT04982068|Experimental|Adult Group 1c|Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28
9676776|NCT04982068|Placebo Comparator|Adult Placebo|Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28
9676777|NCT04982068|Experimental|Elderly Group 1d|Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28
9676778|NCT04982068|Experimental|Elderly Group 1e|Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28
9676779|NCT04982068|Experimental|Elderly Group 1f|Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28
9676780|NCT04982068|Placebo Comparator|Elderly Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
10174666|NCT03850977||Patients and controls|Patients diagnosed with chronic pancreatitis or cirrhosis and healthy controls
10174667|NCT03850925|Experimental|Picosecond laser|Intervention: four consecutive sessions of 1,064-nm picosecond laser at 3-week intervals
9676781|NCT04982185||Deep block|Deep neuromuscular block before initial (V1) vagal stimulation.
9676782|NCT04982185||Moderate block|Moderate neuromuscular block before initial (V1) vagal stimulation.
9676783|NCT04982133|Active Comparator|Fortification adjusted according to urea|Fortification adjusted according to urea with FM 85 at 4% and oligopeptides. In this arm, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.
10174668|NCT03850925|Active Comparator|Fractional laser|Intervention: four consecutive sessions of nonablative fractional laser at 3-week intervals
10174669|NCT03850964|Active Comparator|Pazopanib|Pazopanib 50mg oral daily dosing [two 25mg capsules]. If after 3mths primary endpoint not achieved, and safety is maintained, consideration for advance in dose to up to 100mg daily
10174670|NCT03850964|Placebo Comparator|Placebo oral capsule|Placebo
9676784|NCT04982133|Experimental|Individualized fortification according to the nutritional characteristics of breast milk|"Individualized fortification according to the nutritional characteristics of the mother's own milk or pasteurized milk taken by the premature infant.~In this arm, fortification is adjusted based on the macronutrient analysis of breast milk or donated twice weekly."
9676785|NCT04982276|Experimental|AK104 and AK109|AK104 IV every 2 weeks (q4w) AK109 IV every 2 weeks (q4w)
9676786|NCT04982276|Experimental|AK104 and AK109 combined with chemotherapy|AK104 IV every 2 weeks (q4w) AK109 IV every 2 weeks (q4w) PTX iV 85mg/m2 day1 day8 day15(q4w)
9676787|NCT04981691|Experimental|anti-MESO CAR-T cells|"The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d from day-4 to day-2. Subjects will be treated with six administrations of anti-MESO CAR-T cells three times weekly (Monday-Wednesday-Friday) for two weeks. In the first week, total 1×109 or 3×109 will be infused, the second week is to plan three times consecutive infusions of 1x109 or 3×109 anti-MESO CAR-T cells each time.~Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated.~Interventions:~Drug: anti-MESO CAR-T cells~Drug: Fludarabine~Drug: Cyclophosphamide"
10174671|NCT03850860||empirical antibotherapy currently used|patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy
10174672|NCT03850860||another empirical antibotherapy|patients having had a vancomycin and cefepime combination as empirical antibiotherapy
10187137|NCT03729167|Experimental|Scaling and root planing|Teeth that have been given a prognosis of hopeless and treatment planned for extraction will be scaled and root planed with various non-surgical instruments prior to extraction. The teeth will then be photographed and assessed for remaining hard accretion deposits to determine the effectiveness of the instruments.
9527626|NCT03218176|Active Comparator|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
9676788|NCT04981743|No Intervention|group 1|Twenty five patients will be administered only the standard treatment regimen according to Ministry Of Health, and Population management protocol for COVID-19 patients (November 2020).
9676789|NCT04981743|Active Comparator|group 2|Twenty five patients will be administered a single dose (900mg) of Nigella Sativa capsule twice daily plus standard therapy
9676790|NCT04981743|Active Comparator|group 3|Twenty five patients will be administered a single dose (2000 IU) of vitamin D3 tablet once daily plus standard therapy
9676791|NCT04981743|Active Comparator|group 4|Twenty five patients will be administered a single dose (900 mg) of Nigella Sativa capsule twice daily, and single dose of vitamin D3 tablet (2000 IU) once daily plus standard therapy.
9676792|NCT04981782||healthy subjects|"No intervention~Infants will be measured at different time points. At the age of 3,4,6 and 9 months."
9676793|NCT04981782||torticollis group|"No intervention~Infants will be measured at their visit to a Chiropractor. Before and after treatment."
9676794|NCT04982120|Experimental|Repris Needle|Reprise sheath and needle
9676795|NCT04981600|Active Comparator|Laser Group|Grade II-III hemorrhoids present a special challenge to surgeons since aggressive surgery exposes the patient to several per- and postoperative complications. Therefore new techniques have been developed and one of the most popular contemporary technique is laser hemorrhoidectomy. By this technique a laser probe is inserted above the dentate line and advanced to the apex of the cushion and several shots are delivered while pulling out the probe gradually. The idea is to compromise the vascular flow of corpus cavernosum recti, hence shrinking the hemorrhoidal cushion.
9676796|NCT04981600|Active Comparator|RF (Radiofrequency) Group|Another recent and similar method is radiofrequency coagulation which depends on transmitting radiofrequency waves to tissue. This transmission results in conversion of radiofrequency waves into heat and causes coagulation necrosis in corpus cavernosum recti. The necrosis leads to fibrosis of the surrounding vessels and consequently cushion shrinkage is achieved.
9676797|NCT04981561|Experimental|100 microgram GATE-251|GATE-251, 100 microgram tablet, PO, Single Dose with 28 day follow up
9676798|NCT04981561|Experimental|1 mg GATE-251|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up
9676799|NCT04981561|Experimental|3 mg GATE-251|GATE-251, 3 mg tablet, PO, Single Dose with 28 day follow up
9676800|NCT04981561|Experimental|10 mg GATE-251|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up
9676801|NCT04981561|Experimental|25 mg GATE-251|GATE-251, 25 mg tablet, PO, Single Dose with 28 day follow up
9676802|NCT04981561|Experimental|50 mg GATE-251|GATE-251, 50 mg tablet, PO, Single Dose with 28 day follow up
9676803|NCT04981561|Experimental|100 mg GATE-251|GATE-251, 100 mg tablet, PO, Single Dose with 28 day follow up
9676804|NCT04981561|Experimental|1 mg GATE-251 with CSF collection|GATE-251, 1 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
9676805|NCT04981561|Experimental|10 mg GATE-251 with CSF collection|GATE-251, 10 mg tablet, PO, Single Dose with 28 day follow up, with CSF collection
10174673|NCT03850821|Experimental|Connect Social Mechanisms Intervention|"The primary components of the intervention included: Get-to-know-you sessions aimed specifically at providing youth guided social opportunities to foster friendships, group belonging, and social skills, and novel socially-oriented 'PA sessions' infused within the daily time slot that ASPs' allocated towards recreation. Drawing from theoretical models of motivation, and the investigators' previous ASP studies, key essential elements were identified for facilitating improvements in targeted PA social mechanisms (i.e., friendships, group belonging, and staff connection) and included: 1) social-emotional goal-oriented support, 2) collaborative/cooperative play centered on friendship and informal fun; 3) equal treatment/access, and; 4) inclusive and engaging."
9676806|NCT04981561|Placebo Comparator|Placebo|Placebo tablet, PO, Single Dose with 28 day follow up
10174674|NCT03850821|No Intervention|Typical ASP curriculum wait-list control|No intervention was implemented within the active wait-list control condition, which served as the typical ASP curriculum control/comparison. After completion of the 8-week intervention (12 weeks including baseline and post-intervention data collection), the control condition received the social mechanisms curriculum as a token of appreciation for participating in measurement.
10174675|NCT03850834|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|
9676809|NCT04981964|Experimental|Conventional physical therapy plus forward walking|25 minutes of the forward walking training program It is based on methods as described by Grecco et al. (2013) The children were instructed to walk at a comfortable, self-selected speed during the first and final five minutes of the session and encouraged to increase the speed during the other 15 minutes.
10174676|NCT03850834|Placebo Comparator|Placebo Enteric-coated Tablets|
10174677|NCT03850886|Experimental|Niacinamide group|Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
9676810|NCT04981964|Experimental|Conventional physical therapy plus backward walking|25minutes of the backward walking training It is based on methods as described by Davis (1992) Firstly, the subject is asked to take a step backwards within the parallel bar and can support him or herself with the unaffected hand as required. The therapist provides help to move the subject's leg in the correct pattern, preventing subject from moving the leg back in full extension, when the subject can move the leg back with the correct pattern, the therapist gradually reduces the amount of assistance. Secondly, as the movement components have been practiced and the subjects has taken over actively with only slight help, the therapist facilitates walking backward within the parallel bars. Thirdly, the subject walks backwards actively away from the parallel bars. Finally, the distance and speed of walking backwards is progressively increased.
9676811|NCT04981652|Experimental|Whole Milk|Participants randomly assigned to the whole milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two whole milk experimental beverages (250 mL each serving, 3% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
10174678|NCT03850886|Active Comparator|Control group|diabetes management including metformin or Sulphonylurea
10174679|NCT03850899||Cases|Heavy drinkers with alcoholic hepatitis
10174680|NCT03850899||Controls|Heavy drinkers without significant liver disease
10174681|NCT03850899||Donor|Healthy non-drinkers
10174682|NCT03850873|Experimental|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m to 120mg once daily
10174683|NCT03850769|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 4 cycles.
9695221|NCT04780568|Experimental|Treatment (osimertinib, tegavivint)|Patients receive osimertinib PO QD on days 1-28 and tegavivint IV on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive osimertinib PO QD on days 1-28. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
9695222|NCT04780984|Placebo Comparator|Placebo|Placebo, 2mL
9676812|NCT04981652|Experimental|Skim Milk|Participants randomly assigned to the skim milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two skim milk experimental beverages (250 mL each serving, 0% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
9676813|NCT04981652|Experimental|Almond Beverage|Participants randomly assigned to the almond beverage condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two almond experimental beverages (250 mL each serving) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to ~150% of their habitual levels.
9676814|NCT04982042|Experimental|Post COVID-19 Outpatient Pulmonary Rehabilitation Program|The outpatient Pulmonary Rehabilitation Program will be carried out at the Pulmonary Rehabilitation Laboratory, consisting of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
9676815|NCT04982042|Active Comparator|Post COVID-19 Home Pulmonary Rehabilitation Program|The Home Pulmonary Rehabilitation Program will be carried out at the patients' homes, consisting of the same combination of aerobic and strengthening exercises, lasting 12 weeks, 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance. Patients will be monitored weekly via whatsapp.
9676816|NCT04981548||raised intracranial pressure|more than 200 mmH2O
9676817|NCT04981548||the normal intracranial pressure group|more than 80 mmH2O and no more than 200 mmH2O
9676818|NCT04981405||Patients hospitalised to clinics of First Pavlov State Medical University of Saint - Petersburg|450 cases - patients hospitalised with COVID-19 450 control - patients hospitalised without COVID-19 in the same period (surgical, oncological, cardiological, ophthalmologic, gastroenterological departments)
9676819|NCT04981405||Patients referred to Medical Institute named after Berezin Sergey for computed tomography|Cases - patients with pneumonia confirmed after computed tomography. Controls - patients without pneumonia after computed tomography.
9695223|NCT04780984|Experimental|Group 1 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~8 µg, 2.0 mL, 4 µg/mL"
9695224|NCT04780984|Experimental|Group 2 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~16 µg, 2.0 mL, 8 µg/mL"
9695225|NCT04780984|Experimental|Group 3 Tiotropium Bromide Inhalation Solution|"Treatment Dose (µg) Volume (mL) Concentration (µg/mL)~24 µg, 2.0 mL, 12 µg/mL"
9695226|NCT04780984|Active Comparator|Spiriva Respimat|5 ug, 2 actuations, 2.5 µg/actuation
9695227|NCT04780737||Prophylactic cholecystectomy|Patient who undergo resection of primary ileal neuroendocrine tumor and contemporarly cholecystectomy
9975681|NCT01343784|Active Comparator|Standard Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects will be discharged without a catheter if the voided amount is more than 200ml, or 2/3rds of the infused volume (300ml).
9975682|NCT01343784|Experimental|Force of Stream Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects in the FOS group will be discharged home without a catheter if they are able to void any amount and report an FOS of at least 50% their typical FOS based on a visual analog scale
9975683|NCT01343810|Experimental|Meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The experimental arm will be randomly assigned to practice meditation immediately following the emotional stress task in the lab during the post-MBSR lab visit.
9975684|NCT01343810|Active Comparator|No meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The active comparator arm will be randomly assigned to not practice meditation, but rather listen to a non-meditative audio track of equal length, immediately following the emotional stress task in the lab during the post-MBSR lab visit.
9975685|NCT01343836|Experimental|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte implantation) injection with eccentric exercises
9975686|NCT01343836|Placebo Comparator|Saline injection|Intratendinous saline injection with eccentric exercises
9975687|NCT01343849||Suspected Breast cancer subjects|
9975688|NCT01343862|Experimental|D- Cycloserine|
9975689|NCT01343862|Placebo Comparator|sugar pill|
9975690|NCT01343875||surgery, biceps tear|
9975691|NCT01343914||Cohort|
9975692|NCT01343927|Active Comparator|Yoga|12 weeks of weekly yoga classes plus 40 weeks of either drop-in classes or home practice.
9975693|NCT01343927|Active Comparator|Physical Therapy|15 individual physical therapy treatment sessions over 12 weeks plus 40 weeks with either 5 booster sessions or home practice.
9975694|NCT01343927|Active Comparator|Education|"The Back Pain Helpbook which gives exercises and tips for self-care pain management."
9676820|NCT04981483|Experimental|Any age and parity with placenta accreta spectrum|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle[outside in-in out then out in-in out] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
9676821|NCT04981457|Active Comparator|patients who recieve misoprostol alone|Group A (n =30 ) will receive only vaginal Misoprostol 800mcg (4 tablets Cytotec 200mcg ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or uterine contractions or bleeding assessed by the same doctor who made evaluation at the beginning.
10187138|NCT03729154|Experimental|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
9676822|NCT04981457|Active Comparator|patients who recieve misoprostol and iso sorbide mononitrate|Group B (n =30 ) will receive combined vaginal Misoprostol 800mcg (4 tablets Cytotec ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or start of uterine contractions or bleeding. with Isosorbide-5-mononitrate (20 mg). Effox 20 mg )once at the beginning with misoprostol until reaching cervical ripening or start of and uterine contractions assessed by the same doctor who made the evaluation at the beginning.
9676823|NCT04981314|Experimental|Treatment with echinacea|EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
9676824|NCT04981314|Placebo Comparator|Placebo|Hard caplets indistinguishable from EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
9676825|NCT04981366|No Intervention|Control group (CTRL)|Patients allocated to this arm will not receive any intervention.
9676826|NCT04981366|Experimental|Caloric Restriction associated to exercise training plus protein supplementation (CREX+PTN)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus protein supplementation.
9676827|NCT04981366|Placebo Comparator|Caloric Restriction associated to exercise training plus isocaloric placebo (CREX+PLA)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus isocaloric placebo.
9676828|NCT04981860|Experimental|Treatment naïve participants First Group L|Treatment naïve participants randomized to receive Betadine on the left eye and Avenova on the right Eye
9676829|NCT04981860|Experimental|Treatment naïve participants Second Group R|Treatment naïve participants randomized to receive Avenova on the left eye and Betadine on the right Eye
9676830|NCT04981860|Experimental|Participants undergoing intravitreal injection First Group L|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group L are patients that are having intravitreal injections and will receive betadine in the left eye and Avenova in the right eye.
9676831|NCT04981860|Experimental|Participants undergoing intravitreal injection Second Group R|Participants undergoing intravitreal injection will receive betadine in the eye that is receiving injections and Avenova in the other eye. Group R are patients that are having intravitreal injections and will receive betadine in the right eye and Avenova in the left eye.
9676832|NCT04981353|Active Comparator|group 1|:(group 1) will be putted in sitting position and disinfecting her back. A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal direction
9676833|NCT04981353|Active Comparator|group 2|(group 2) patients will receive pethidine 25mg doses if NRS >4.
9676834|NCT04981327|Experimental|Experimental|After a conventional course of 7 days of Apixaban 10mg BID, Apixaban 2.5mg BID during 3 months.
9676835|NCT04981327|Active Comparator|Standard|After a conventional course of 7 days of Apixaban 10 mg BID, Apixaban 5 mg BID during 3 months.
9676836|NCT04981340|Experimental|Standard urotherapy + Diaphragmatic breathing exercises+ pelvic floor exercises|Diaphragmatic breathing exercises will be demonstrated by a qualified physiotherapist. Exercises will be done in lying and sitting positions respectively. In supine, with the lower extremities supported over a pillow and hands positioned on the abdominal muscles, children will be asked to inhale the air through the nose, bulge the abdomen outwards as much as possible, hold their breath for a few seconds, and then exhale slowly through pursed lips. The same exercise will be then performed in both side-lying positions and in a sitting position in front of the mirror. Children will be instructed to watch the anterior abdominal wall movement during inspiration and to repeat the same action while seated on the toilet to initiate voiding. They will be asked to perform the diaphragmatic breathing exercises daily at home.
9975695|NCT01343940|Experimental|Dulce family partner intervention|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services."
9975696|NCT01343940|Active Comparator|Safety intervention|Participating family is assigned a safety specialist who will provide the parent with guidance, equipment and instruction to reduce risk of newborn injury during transport (car seat) and while sleeping (Pack-and-Play).
9975697|NCT01343953|Experimental|Cord Blood Transplantation|
9975698|NCT01343979||positive|Patients with clinically suspected H1N1 infection confirmed by positive H1N1 PCR
10174684|NCT03850756||1: No smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers"
10187139|NCT03729154|No Intervention|Treatment as Usual|Participants in the Treatment as Usual condition will receive behavioral and counseling services typically provided by their preschool.
9676837|NCT04981340|Active Comparator|Standard urotherapy|Standard urotherapy will start with the education of the children and their parents about the normal function of the bladder and external urinary sphincter and the nature of their voiding disorder. The importance of regular fluid intake (200 ml 5-6 times per day) and regular voiding will be explained. Special voiding and defecation diaries that a child has to fill out at home will be provided. An optimal voiding posture will be demonstrated in front of a mirror: a sitting position, with feet supported, hips abducted and abdominal muscles relaxed.
9676838|NCT04981496||Study A: ILR implantation|These are participants attending hospital for a clinically indicated ICD/CRT-D implantation or box change who will undergo rapid atrial and ventricular pacing to simulate arrhythmias and RV lead noise simulation and have an ILR implanted during their procedure.
9676839|NCT04981496||Study B: ICD implantation|These are participants attending hospital for a clinically indicated ICD/CRT-D implantation or box change who will undergo rapid atrial and ventricular pacing to simulate arrhythmias and RV lead noise simulation who will not have an ILR implanted.
9676840|NCT04981496||Study C: VT Ablation|These are participants having a clinically indicated VT ablation who we will record ventricular arrhythmias during the procedure.
9676841|NCT04981496||Study D: Exercise Treadmill Test|These are participants who already have a cardioverter defibrillator implanted who can safely exercise and bring up their heart rate.
9676842|NCT04981496||Study E: Spontaneous Arrhythmias|These are participants who already have a cardioverter defibrillator implanted and come into hospital with an atrial or ventricular arrhythmia.
9676843|NCT04981262|Experimental|Stimulance|4 weeks intervention with Stimulance for all participants
9676844|NCT04981262|Experimental|Stimulance 6 months|6 months intervention
9676845|NCT04981262|No Intervention|No intervention|6 months control group
9676846|NCT04981470|Experimental|Investigational Device|Subjects implanted with the baroloop device
9676847|NCT04981379|Active Comparator|Hydroxychloroquine + Favipiravir|Hydroxychloroquine 2x200 mg 5 days and favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
9676848|NCT04981379|Active Comparator|Favipiravir + Placebo (Hydroxychloroquine)|Favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine ) 2x200 mg (5 days)
10187140|NCT03729141|Experimental|Added Cholesterol|
9676849|NCT04981379|Active Comparator|Hydroxychloroquine + Placebo (Favipiravir)|Hydroxychloroquine 2x200 mg (for 5 days) + placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)
9676850|NCT04981379|Placebo Comparator|Placebo (Favipiravir) + Placebo (Hydroxychloroquine)|Placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine) 2x200 mg (5 days)
9676851|NCT04981522|Experimental|Active Treatment (AT): PM+ intervention|Active Treatment (AT) group will receive 05 sessions of indigenously adapted problem management plus (IA-PM+) intervention.
9676852|NCT04981522|No Intervention|Delayed Treatment Control (DTC): Treatment as usual|Delayed Treatment Control (DTC) group will receive routine treatment until the last follow-up.
9676853|NCT04981392|Experimental|Multi-component intervention to promote COVID-19 vaccination|"The intervention will include the following components:~An online library of brief videos depicting local PCPs responding to common questions & concerns about the COVID-19 vaccine with link to be disseminated to patients by text message~Automated PCP text messaging to unvaccinated patients with evidence-based recommendations for COVID-19 vaccination~Educational materials for PCPs to support their conversations with patients about the COVID-19 vaccine"
9676854|NCT04981392|No Intervention|Control|Eligible patients seen at a study clinic randomized to the control group will receive usual care with no text messaging intervention. Providers at a study clinic randomized to the control group will be not be invited to attend the education session or sent any educational materials.
9676855|NCT04981704|Experimental|Part 1: Itraconazole/Poziotinib Drug-drug interaction (DDI)|On Day 1 of Treatment period 1, a single oral dose of 8 milligrams (mg) poziotinib will be administered. On Day 1 of Treatment Period 2, 200 mg itraconazole oral solution will be administered twice a day (BID) followed by 200 mg itraconazole oral solution once daily (QD) for 7 consecutive days (Day 2 to Day 8) with a single oral dose of 8 mg poziotinib coadministered on Day 4.
9676856|NCT04981704|Experimental|Part 2: Phenytoin/Poziotinib DDI|On Day 1 of Treatment period 1, a single oral dose of 16 mg poziotinib will be administered. In treatment period 2, an oral dose of 100 mg phenytoin will be administered three times daily (TID) for 17 consecutive days (Day 1 to Day 17) with a single oral dose of 16 mg poziotinib coadministered on Day 14.
9676857|NCT04981704|Experimental|Part 3: Paroxetine/Poziotinib DDI|On Day 1 of Treatment Period 1, a single oral dose of 8 mg poziotinib will be administered. On Day 1 and Day 2 of Treatment Period 2, an oral dose of 20 mg paroxetine will be administered BID followed by 20 mg paroxetine QD for 9 consecutive days (Day 3 to Day 11) with a single oral dose of 8 mg poziotinib coadministered on Day 7.
9676858|NCT04981769||Patients|Patients presenting to clinical sites for Covid-19 testing who are 2 years of age or older.
9695228|NCT04780737||On-demand cholecystectomy|Patient resected for primary ileal neuroendocrine tumor, treated with cholecystectomy in a different operation and only if needed, for the development of biliary stone disease
9695229|NCT04780412|Active Comparator|Misoprostol Group|
9695230|NCT04780412|Placebo Comparator|Placebo Group|
9695231|NCT04780347|Experimental|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel combined with capecitabine
9975699|NCT01343979||negative|Patients with clinically suspected H1N1 infection and negative H1N1 PCR
10187141|NCT03729141|Active Comparator|No Added Cholesterol|
9676859|NCT04980937||Patients with perineal nerve damage after ski injury|Retrospectively aquired patients from insight in medical records. All patients with perineal nerve damage after ski injury in the time period of question were enrolled. Inclusion required operative management of the injury interns of microsurgical reconstruction of peroneal nerve.
9676860|NCT04981210||suspect LOPD|
9676861|NCT04982198|Experimental|TKA assisted with ROSA® Knee System|TKA assisted with ROSA® Knee System
9676862|NCT04982198|Active Comparator|TKA with conventional surgical instrumentation|TKA with conventional surgical instrumentation
9676863|NCT04981080||Symptom of voiding dysfunction|Women with lower urinary tract symptoms including voiding symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
9676864|NCT04981080||No symptom of voiding dysfunction|Women with lower urinary tract symptoms but without cystocele or voiding symptoms who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
9676865|NCT04982094|Experimental|Mental Health First Aid and Relationship Building Training (MHFA+RBT)|Mental Health First Aid training in conjunction with Relationship Building Training.
9676866|NCT04982094|Active Comparator|Mental Health First Aid (MHFA only)|Mental Health First Aid training alone.
9676867|NCT04982211|Experimental|Propranolol and standard trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
9676868|NCT04982211|Placebo Comparator|Placebo and standard trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to writing (Treatment 1) or reading aloud a trauma narrative.
10174685|NCT03850756||2: No smokers with risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers"
9676869|NCT04982211|Active Comparator|Propranolol and mismatch trauma memory reactivation group|Oral propranolol will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
9676870|NCT04982211|Placebo Comparator|Placebo and mismatch trauma memory reactivation group|Oral placebo will be administered 60 minutes prior to a memory reactivation procedure involving variations in the contexts where the trauma memory reactivations occur.
9676871|NCT04981106|Experimental|Elastic Band Exercise|"All the participants were subjected to walking training and a standard postoperative care and exercise protocol until discharged from the hospital. During discharging, all the participants in both groups were provided with explanation and illustration about how to perform the exercises. In order to prevent any problem, the participants in both groups were recommended to start the at-home rehabilitation programs, which incorporate knee movement exercises, to be ready 2 weeks (14 days) after the surgery and they were asked to continue their current exercise programs thus far.~The patients in intervention group were recommended to do, in addition to the at-home exercise program given to the patients in control group, elastic band exercises and researchers showed them how to use the elastic bands by making use of instructions."
10174686|NCT03850756||3: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers~Also tobacco consumption will be measured"
10174687|NCT03850756||4: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers~Also Tobacco consumption will be measured"
9676872|NCT04981106|No Intervention|Exercise|The patients in control group were recommended to maintain only an at-home exercise program incorporating knee flexion and extension exercises.
9676873|NCT04981197|Experimental|Baduanjin exercise group|The Baduanjin exercise group received a 12-week Baduanjin exercise programme.
9676874|NCT04981197|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
9676875|NCT04981093|Experimental|Group Dexamethasone|"Group dexamethasone patients received intravenous injection after anesthesia induction~Injection 0.15mg/kg dexamethasone (2ml）"
9676876|NCT04981093|Placebo Comparator|Group Saline|Group Control patients were also given 2ml of normal saline intravenously after induction of anesthesia
9676877|NCT04981054||cystocele with repairment|women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
9676878|NCT04980989|Experimental|Mobile software|Patient with early breast cancer were followed-up by mobile software for the first six months. At six months they crossed-over to be followed-up by telephone calls for the next six months.
9676879|NCT04980989|Active Comparator|Telephone calls|Patient with early breast cancer were followed-up by telephone calls for the first six months. At six months they crossed-over to be followed-up by mobile software for the next six months.
9676880|NCT04980950|Experimental|gastric cancer patients (immunonutrition)|Experimental gastric cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
9676881|NCT04980950|Active Comparator|gastric cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
9676882|NCT04980950|Experimental|colorectal cancer patients (immunonutrition)|Experimental colorectal cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days.
9975700|NCT01343992|Active Comparator|Bedrest|Patients will rest in bed ten minutes after the embryo transfer.
10174688|NCT03850600|Experimental|Diet-CD|dietary intervention: 8-10 weeks of diet intervention
10174689|NCT03850600|No Intervention|No-Diet-CD|Usual diet with no intervention
9676883|NCT04980950|Active Comparator|colorectal cancer patients (standard nutrition)|These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days.
9676884|NCT04981028||Patients with acute episode of thrombotic thrombocytopenic purpura (TTP)|Any adult patients with a suspected diagnosis of TTP (defined by low platelets and anaemia with evidence of red cell breakdown) and confirmed by a low ADAMTS13 enzyme level <10%
9676885|NCT04981028||Healthy volunteers|Non-blood relative / friend / carer
9676886|NCT04981028||Patients with known diagnosis of TTP|Any adult patients with a previously confirmed diagnosis of TTP (more than 12 months ago) based on an ADAMTS13 enzyme level <10% at initial diagnosis
9676887|NCT04981015||Women with lower urinary tract symptoms|Women with lower urinary tract symptoms without cystocele were included.
10174690|NCT03850600|No Intervention|No-Diet-Control|Unaffected controls at the same gestational stage will follow usual diet and no intervention
9676888|NCT04981184|Other|Gait and balance measurement|"Gait analysis with surface electromyography measurement: surface electromyography signals (of affected and non-affected legs), gait and stance parameters are collected while the patient walks for 30 seconds on the treadmill with integrated sensor equipment (for measuring the force distribution).~Balance analysis with Biodex balance system SD: measurements of postural stability, fall risk, limits of stability, sensory integration are collected."
9676889|NCT04980924||Pulmonary Embolism without reccurence or complication|Pulmonary Embolism without reccurence or complication
9676890|NCT04980924||Pulmonary Embolism with reccurence or complication|Pulmonary Embolism with reccurence or complication, in particular occurrence of pulmonary hypertension.
10174691|NCT03850470||Patients with Musculoskeletal Pain|Subjects reporting for care with complaints of musculoskeletal pain will be examined and a diagnosis and plan of care will be established. The accuracy of the clinical examination will be compared to pathology detected by MRI
9676891|NCT04980898|Experimental|Electrical stimulation wound management system|Two daily electrostimulation sessions using the WoundEL® device on wound two for 30 minutes at an adjustable intensity, between 5 and 42 milliampere and chosen by the patient.
9676892|NCT04980898|Active Comparator|Standard of care|Use of dressings appropriate to the stage of healing according to French recommendations for the management of leg ulcers.
9676893|NCT04980963|Experimental|Full Treatment|Steps of the Intervention Condition. Following an in-person session in which a pretest assessment is completed, each member of the intervention group will participate in three face-to-face sessions with the interventionist at the student's campus or at the interventionist's office to complete the CST component of the intervention. Taking into consideration available psychoeducational assessment data, functional assessments from other agencies, and the participant's self-report regarding the functional difficulties that result from his or her ASD-related cognitive impairments, Scherer's (2012) Matching Person and Technology (MPT) protocol will guide the CST assessment. For purposes of the CST component of this intervention, the technological platform for cognitive accommodations will be an iPad II that is provided to each intervention-group participant at no charge (including wireless access if needed). The interventionist will provide training in the use of the iPad if necessary.
10174692|NCT03850561|Active Comparator|Coenzyme Q10 200|Coenzyme Q10 200mg/day for 3 months
10174693|NCT03850561|Active Comparator|Coenzyme Q10 400|Coenzyme Q10 400mg/day for 3 months
10174694|NCT03850639|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
10174695|NCT03850639|No Intervention|Wait list control|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 4 weeks.
10174696|NCT03850548||Prosthetic joint infection with Cutibacterium acnes|Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
10174697|NCT03850626||Immunotherapy Trees|Patients allergic to tree pollen
9695232|NCT04780347|Active Comparator|Capecitabine|Capecitabine
10174698|NCT03850626||Immunotherapy Grass|Patients allergic to grass pollen
10174699|NCT03850626||Immunotherapy Mites|Patients allergic to HDM
9695233|NCT04780373||Development cohort|
10174700|NCT03850652|Active Comparator|Prebiotic (Synergy-1)|Prebiotic (Synergy-1) + Iron supplement
9695234|NCT04780373||Validation cohort|
9827553|NCT02460679|Experimental|EPI-589|Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
10174701|NCT03850652|Placebo Comparator|Maltodextrin|Placebo (Maltodextrin) + Iron Supplement
10174702|NCT03850483|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
10174703|NCT03850483|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
10174704|NCT03850483|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
10174705|NCT03850483|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
10174706|NCT03850483|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
10174707|NCT03850483|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
10174708|NCT03850483|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
10174709|NCT03850483|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
10174710|NCT03850483|Experimental|PF-06700841 3% cream BID|PF-06700841 3% cream applied twice daily (BID)
10174711|NCT03850613|Experimental|Intervention arm|Participants in the intervention arm download the E-painting mobile app and use this app to make their own painting.
10174712|NCT03850730|Experimental|Pazopanib|Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
10174713|NCT03850717||Traditional Chinese Acupuncture|"Use traditional acupuncture, stronger, deeper, harder-acupuncture"
9676894|NCT04980963|Active Comparator|Abbreviated Treatment|Steps of the Control Condition. Following an in-person session in which the pretest assessment is completed, each member of the control group will participate in two telephone or Skype sessions with the interventionist to discuss her or his needs for electronic cognitive supports. An abbreviated version of Scherer's (2012) MPT assessment will be administered via telephone or Skype in the first of these virtually-administered sessions. In the second telephone or Skype session, the interventionist will summarize the results of the abbreviated MPT assessment, suggest a variety of cognitive enhancement apps for tablet computers or smart phones that the control group participant can consider.
9676895|NCT04980885|Experimental|AK117+Azacitidine|"Phase Ib: Subjects will receive different doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;~Phase II: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
9676896|NCT04980508|Active Comparator|Patients that had COVID-19 and were treated as outpatients|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
10174714|NCT03850717||Japanese Acupuncture|"Use traditional shallow, lighter acupuncture, softer-acupuncture"
10174715|NCT03850392|Active Comparator|ice|"16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day).~Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle."
9676897|NCT04980508|Active Comparator|Patients who were hospitalized due to COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
9676898|NCT04980508|Active Comparator|Patients who did not have COVID-19|Patients underwent diagnostic evaluation including IIEF-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of testosterone, luteinizing hormone, follicle stimulating hormone, and prolactin measured in the morning (07-11 am). The relaxation degrees of cavernosal smooth muscles were calculated from the corpus cavernosum electromyography results.
10174716|NCT03850392|Active Comparator|CO2|16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
10174717|NCT03850392|No Intervention|contralateral non-treated knees|16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
9695235|NCT04780503||Intubation Group/ Non-Intubation Group|Intubation group: Patients who failed noninvasive mechanical ventilation and who underwent endotracheal intubation Non-Intubation Group: Patients whose noninvasive mechanical ventilation is successful and endotracheal intubation is not applied
9975701|NCT01343992|Experimental|No bed rest|Patients will not rest after the embryo transfer.
10174718|NCT03850587|Experimental|YYC301-1 & Celocoxib placebo|"YYC301-1 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex)."
10174719|NCT03850587|Experimental|YYC301-2 & Celocoxib placebo|"YYC301-2 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)"
10174720|NCT03850587|Experimental|YYC301-3 & Celocoxib placebo|"YYC301-3 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)"
10174721|NCT03850587|Active Comparator|YYC301 placebo & Celecoxib|Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
10174722|NCT03850405|Experimental|Chocolate|20 patients (matched per gender) undergoing a diet which includes 25g of dark chocolate (70%), i.e. ca. 145 kcal per day
10174723|NCT03850405|No Intervention|Control|20 patients (matched per gender) undergoing a low-fat dietary regimen
10174724|NCT03850665|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
10174725|NCT03850665|Active Comparator|Anterolateral approach|Anterolateral Approach surgery to replace the hip.
10174726|NCT03850665|Active Comparator|Posterolateral approach|Posterolateral Approach surgery to replace the hip.
10187142|NCT03729128|Experimental|dextromethorphan and memantine (DM+MM)|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on dextromethorphan 30mg/day and memantine 5mg/day combination (DM+MM) for 12 weeks.
10187143|NCT03729128|Placebo Comparator|Placebos|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on placebos for 12 weeks.
10174727|NCT03850535|Experimental|Dose-Escalation Phase|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet [ELN] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
10174728|NCT03850535|Experimental|Post-Consolidation Phase|Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.
9676899|NCT04980625|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
9676900|NCT04980625|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days from thrombolysis. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
9676901|NCT04980690|Experimental|Phase Ia - Dose escalation(Acceleration Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~Acceleration Stage: The initial increasing dose is 0.025 mg/kg, and the dose is increased in 100% increments. Each dose group will enroll 1 subject."
9676902|NCT04980690|Experimental|Phase Ia - Dose escalation(3+3 Stage)|"Phase Ia is an open, non-random, single-arm dose escalation design.~3+3 Stage: The dose is increased in 30%-50% increments between adjacent dose groups, and the increment is determined by the investigator and the sponsor based on the safety data obtained in the previous period.Each dose group will enroll 3 to 6 evaluable subjects (evaluable: at least complete the DLT observation period), and this period continues until the maximum tolerated dose (MTD) is reached."
9676903|NCT04980690|Experimental|Phase Ib - Dose extension|"Phase Ib is an open, non-random, single-arm, multi-center research design.~When phase Ia is transformed into 3+3 stage, a certain dose group meets the conditions for increasing the next dose group (after the DLT observation period of the last subject in the dose group has passed, the safety assessment of the current dose group will be completed) , The dose extension study of this dose group can be carried out, and 6 evaluable (evaluable: at least 2 cycles of dosing and observation) subjects with advanced malignant tumors who have failed standard treatments will be included in this dose group."
9676904|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group A)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group A: Recurrent or metastatic triple-negative breast cancer that failed standard treatment."
9676905|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group B)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group B: Locally advanced/metastatic non-small cell lung cancer without driver gene mutations that failed standard treatment."
9676906|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group C)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group C: Recurrent or metastatic head and neck squamous cell carcinoma that failed standard treatment."
10174729|NCT03850535|Experimental|Expansion Phase: Favorable/Intermediate-Risk AML|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
9676907|NCT04980690|Experimental|Phase IIa - Clinical Exploratory Stage(Group D)|"The Phase IIa is planned to be divided into four indication groups, all of which are open, non-randomized, two-stage, single-arm research design.~Group D: Recurrent or metastatic peripheral T-cell lymphoma that failed standard treatment."
9676908|NCT04980677|Other|Children|Tangiball (Autism, Neurotypical group) - 20 minute play sessions with digital toy
9676909|NCT04980586||Non-OSA Groups|Participants with apnea-hypopnea index < 5 events per hour of sleep.
10187144|NCT03729089|Experimental|Modified Biophysical Profile scan|Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea.
9676910|NCT04980586||Mild OSA Group|Participants with apnea-hypopnea index > 5 < 15 events per hour of sleep.
9676911|NCT04980586||Moderate OSA group|Participants with apnea-hypopnea index > 15 < 30 events per hour of sleep.
9676912|NCT04980586||Severe OSA Group|Participants with apnea-hypopnea index > 30 events per hour of sleep.
9676913|NCT04980716|Experimental|The early intervention group|"The early intervention group: evaluation and intervention based on impedance cardiography results at multiple timepoints. Specific intervention measures include:~cardiovascular drug treatment: based on the increase and decrease of the Golden Triangle~ACEI, perindopril tert-butyrate 4mg qd~β receptor antagonist, metoprolol succinate 47.5mg qd~Spironolactone 20mg qd~Drugs to improve myocardial metabolism: trimetazidine hydrochloride 35 mg bid~Other therapeutic drugs include: loop diuretics, ARNI, sinus node If current selection specific inhibitors, statins, antiplatelet aggregation and nitrate drugs, etc.~Exercise intervention: exercise prescription based on the initial cardiopulmonary exercise test results."
9695236|NCT04780503||Dying patients / Surviving patients|Dying patients :Patients with in-hospital mortality presenting with acute respiratory failure Surviving patients: Patients presenting and surviving due to acute respiratory failure
10174730|NCT03850535|Experimental|Expansion Phase: High-Risk AML|Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
10174731|NCT03850132|Experimental|FAM-SOTC-PL|Grief responses, levels of vulnerability, measured using the Adult Attitude to Grief scale (AAG), a self-administered questionnaire
9676914|NCT04980716|No Intervention|The control group|This group will be under observation. When cardiovascular events (including ischemic cardiomyopathy, heart failure, arrhythmia requiring treatment, pericardial disease requiring treatment, valvular disease, etc.) happen, a cardiovascular specialist assessment and intervention will be given.
9676915|NCT04980703|Experimental|Grain moxibustion|Grain moxibustion +standard care
9676916|NCT04980703|Sham Comparator|Sham grain moxibustion|Sham grain moxibustion +standard care
9676917|NCT04980703|Other|Wait-list control|Standard care
9676918|NCT04980729|Experimental|the template-guided group|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction using a modular hemipelvic prosthesis.
9676919|NCT04980729|Active Comparator|the traditional operation group|In the traditional operation group (n = 14), acetabulum was manually reconstructed using a modular hemipelvic prosthesis by the surgeon's experience.
9676920|NCT04980729|Sham Comparator|the validation group|In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without acetabulum reconstruction.
9676921|NCT04980547|Experimental|ACUMED® Scapholunate Repair System|All participants in this trial will undergo the surgical RASL procedure using the ACUMED® Scapholunate Repair System.
9676922|NCT04980664|Experimental|Integrated intervention strategies|
9676923|NCT04980768|Other|Root canal treatment|Root canal treatment will be provided to all the participants with the diagnosis of apical periodontitis.
9676924|NCT04980443|Experimental|FIT positive individuals|FIT-positive individuals of whom we will collect blood samples and who will undergo a colonoscopy after blood sampling.
9676925|NCT04980859|Experimental|Zebutinib Combined With CIT arm|Zebutinib Combined With FCR( under 60 years of age) or BR (over 60 years of age )
9676926|NCT04980794|Experimental|Parent-Child Intervention|This is a four-dose intervention that includes psychoeducational modules and communication coaching administered through community organizations over the course of four weeks. Both participating adults and the participating child receive materials to review each week, paired with weekly contact from a family coach.
9676927|NCT04980794|Active Comparator|Self-study intervention|This is a four-dose intervention that include written self-study materials to review, paired with weekly contact with a family coach. Both participating adults receive self-study materials; the participating child does not receive separate materials.
9676928|NCT04980755|Experimental|Phase one|"Participants will be asked to attend four weekly sessions of Body Reprogramming via group video call.~Each session will include up to 8 patients and will consist of a 25-30 minute live presentation"
9676929|NCT04980755|Experimental|Phase two|We anticipate that participant sin phase two will complete the same intervention, but it may be somewhat modified following participant feedback in phase one.
9676930|NCT04980430||Primary Care and Ophthalmology clinic patients|Participants will be recruited from primary care and ophthalmology clinics in New York City
9676931|NCT04980651|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
9676932|NCT04980651|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
9676933|NCT04980404|Experimental|Dose Escalation Inqovi|"Study will follow a standard '3+3' dose escalation design:~Initial group of 3 participants will receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 42 day cycle/dose-limiting toxicity (DLT) period.~Additional enrollment, dosage and study cyles will be determined by number of dose-limiting toxicity (DLT) that occur in initial group"
9676934|NCT04980404|Experimental|Recommended Phase 2 Dose Expansion (RP2S) Inqovi|Once the Recommended Phase 2 Dose Expansion (RP2S) is established, 10 additional participants will be enrolled and receive Inqovi (decitabine/cedazuridine) on days 1-3 of a 28 day study cycle.
9676935|NCT04980261|Active Comparator|Control Group (ORIF + autograft)|The patients will receive the current gold standard to treat long bone defects.
9676936|NCT04980261|Experimental|Treatment Group (ORIF + FD BHA/Secretome composite)|The patients will receive a novel bone substitute following the ORIF procedure.
9676937|NCT04980170|Experimental|clindamycin group|Patients who take Clindamycin after Dental implants
9676938|NCT04980170|Experimental|Amoxicillin With Clavulanic Acid group|Patients who take Amoxicillin With Clavulanic Acid after Dental implants
9676939|NCT04980183|Experimental|Arthroscopic surgical robot assisted navigation and positioning for cruciate ligament reconstruction|Patient undergoes cruciate ligament reconstruction with robot-assisted navigation and positioning under arthroscopic surgery
9676940|NCT04980183|Active Comparator|Conventional arthroscopic cruciate ligament reconstruction|The patient undergoes conventional arthroscopic cruciate ligament reconstruction
9676941|NCT04980131|Experimental|Group C|Group C were received PPSF with pointed lotus-style regulator
9676942|NCT04980131|Experimental|Group B|Group B were received PPSF with Flat ended lotus root regulator
10174732|NCT03850158|Experimental|Interventional Arm, ICG and NIR imaging|NIR fluorescence imaging is performed after white light laparoscopy. 0.3mg/kg bodyweight of ICG is administered i.v. All suspected lesions are removed and labeled whether they are seen in WL or NIR imaging or both. Evaluation is performed after the histological analysis of the lesions.
9676943|NCT04980131|No Intervention|Group A|Group A were received traditional PPSF
9676944|NCT04980105|Experimental|Platelet-rich plasma arm|
9676945|NCT04980105|Active Comparator|Hyaluronic acid arm|
10174733|NCT03850314|Experimental|Glycine|Glycine total daily dose of 150mg/kg divided three times daily with meals (powder dissolved in 1 cup of water) for 12 weeks.
9676946|NCT04980105|Active Comparator|Methylprednisolone acetate arm|
9676947|NCT04980248|Experimental|ALXN1850|Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.
9676948|NCT04980274||Group 1|Patients with SOFA score < 2 on admission
9676949|NCT04980274||Group 2|Patients with SOFA score equal to or > 2 on admission and who improved after 48 hours of treatment
9676950|NCT04980274||Group 3|Patients with SOFA score equal to or > 2 on admission and who did not improve after 48 hours of treatment
9676951|NCT04980196||(1) URODYNAEMICS GROUP|30 patients allocated for group (1) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed. And to urodynamic studies were performed before surgical intervention and then corrective procedures for POP had been done uroflowmetry and cystometry. All participants were followed-up with same questionnaire and clinical examination after 12 weeks post -operatively
10174734|NCT03850119|Experimental|Intradermal Nanofat|This side of the scar received intradermal injection of nanofat during the closure of the donor site.
10174735|NCT03850119|No Intervention|Control|This side of the scar received no injection.
10174736|NCT03850301|Experimental|Etifoxine then XBD173|
10174737|NCT03850301|Experimental|XBD173 then Etifoxine|
10174738|NCT03850184||Mental Health Professionals|Psychiatrists, Psychologists, Nurses working with patients with mental disorders
9676952|NCT04980196||(2)NON URODYNAMICS GROUP|30 patients allocated for group (2) had been thoroughly evaluated by history and examination. A standardized questionnaire was obtained to evaluate the symptoms of stress urinary incontinence, urge urinary incontinence and obstructive symptoms. Clinical staging of pelvic organ prolapse by POP Q Staging .Ultrasound examination had been also carried out to rule out any pelvic pathology. Patients had completed a 3-day bladder diary (frequency volume chart) to assist in arriving at an urodynamic diagnosis. Urinalysis was performed and then corrective procedures for POP had been done.All participants were followed-up with same questionnaire and clinical examination after 12 weeks post-- operatively
9676953|NCT04980209||Ultrasonic and c-arm combination group|Ultrasound and c-arm were combined to evaluate intraoperatively conditions
9676954|NCT04980209||c-arm group|c-arm group was used to evaluate intraoperatively conditions
9676955|NCT04980118|Placebo Comparator|Control group|Individual nutritional intervention.
9676956|NCT04980118|Experimental|Experimental group|Individual nutritional intervention with two groupal sessions and physical activity.
9676957|NCT04980144|Experimental|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks (28 days).
10174739|NCT03850080|Experimental|Autologous Conditioned Serum|Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
10174740|NCT03850106|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose)
10174741|NCT03850106|Active Comparator|Indus810|Indus810 ( 500mg/d)
10174742|NCT03850262||patients with posterolateral corner trauma of the knee|
9676958|NCT04980144|Active Comparator|HA group|Participants in HA group will be administered one drop of 0.1% Sodium hyaluronate artificial tears (preservative free) six times per day for 4 weeks (28 days).
9676959|NCT04980339||ASO group|All participants with TGA/TBA after ASO
9676960|NCT04980066|Experimental|sticky bone and EDTA|treatment of gingival recession using sticky bone after root surface biomodification with EDTA
9676961|NCT04980066|Active Comparator|Sticky bone|treatment of gingival recession using sticky bone
9676962|NCT04980300|Experimental|Expanded Intervention|Virtual consultation sessions with a physical therapist, focusing on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis.
9676963|NCT04980300|Active Comparator|Brief Intervention|Web-based resources on knee osteoarthritis, including an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis.
9676964|NCT04980053|Experimental|Back Massage|"Back massage will be initiated in the first 2 hours after birth and it will be performed every 6 hours for 15 minutes until the mother is discharged from the hospital. After the mother's outfits are removed and the mother is situated in a suitable position, the back of the mother will be massaged by euphlorage, petrissage, friction methods. Then, the participants breast will be milked by hand every 3 hours and will be measured in the breast milk storage bag and delivered to the baby nurses until the 5th-7th day."
9695237|NCT04780360|Experimental|Cayanoacrylate tissue adhesives|thin layers of high viscosity blend of n-butyl and 2-octyl cayanoacrylate tissue adhesive will be applied and rinsed with saline at least three times with interval of at least 30 seconds
9695238|NCT04780360|Active Comparator|Silk suture material|interrupted knots
10174743|NCT03850171|Experimental|ExEarly|Patients completing the exercise training concurrent to anthracycline chemotherapy treatment during months 1 to 3
10174744|NCT03850171|No Intervention|ExStandard|Patients will be encouraged to continue with their regular physical activity routine and will be medically managed as per standard of care by their Cardiologist and Oncologists.
9676965|NCT04980053|Experimental|Breast Massage|Breast massage will be initiated in the first 2 hours after delivery and it will be practised every 6 hours until being discharged. After the researcher washes her hands, the participant's outfits are removed and she is situated in a sitting position, the massage will be practised on both breasts for 10 minutes by the researcher herself. After the mother's breast will be milked by hand every 3 hours and the milk obtained from the breast will be measured in the breast milk storage bag and delivered to the baby nurses.
9676966|NCT04980053|No Intervention|Control Group|No intervention will be made to the control group, standard hospital procedures will be applied and the relevant forms will be filled out. Until the mother is discharged from the hospital, the amount of milk obtained from the mother will be measured every 3 hours by the researcher.
10174745|NCT03850197||TMM followed by EarPopper + Tympanometry|"Participants will be asked to complete the tubomanometry (TMM) then EarPopper plus tympanometry tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize Eustachian tube (ET) pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
9676967|NCT04980092||Post-ICU group|Observational foolow-up
9676968|NCT04980079|Active Comparator|group A -undergo primary ureteroscopy URS|Thirty children with calicular anuria will undergo primary ureteroscopy URS
9676969|NCT04980079|Active Comparator|the group B(30 patients) will undergo deferred ureteroscopy URS|group B (30) patients will be admitted to do urinary drainage through the insertion of a double-J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done
9676970|NCT04980313|Experimental|Xenogenic collagen matrix|Volumetrically stable xenogenic collagen matrix
10174746|NCT03850197||EarPopper + Tympanometry followed by TMM|"Participants will be asked to complete the EarPopper plus tympanometry then TMM tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize ET pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
9676971|NCT04980313|Active Comparator|Autogenous connective tissue graft|Autogenous connective tissue graft obtained from the tuberosity area
9676972|NCT04980365|Other|Mindfulness and Gratitude|Participants will be asked to use either the app Mindfulness Coach or the app Grateful daily for 10 minutes for 14 days.
9676973|NCT04980365|Other|Control|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
9676974|NCT04980378||Simplify Disc|Extended follow-up of IDE Subjects treated at two continuous levels with the Simplify Cervical Artificial Disc during IDE G150206
9676975|NCT04980001|Experimental|FOCUS TIC-COM arm|"Health care providers will be trained in FOCUS TIC-COM through professional development and from this group the investigators plan to recruit participants for the surveys about the training, intervention feasibility and acceptability. Health care providers will be encouraged to implement FOCUS TIC-COM will all of their pediatric patients who are overweight/obese.~Parents / Caregivers of children who are overweight or obese will be recruited into the study after exposure to the intervention. Only those exposed to the intervention will be recruited to participate in the study which includes one survey and focus groups."
9676976|NCT04979975|Experimental|Placebo|placebo matching UB-621
9676977|NCT04979975|Experimental|UB-621 low-dose|low-dose of UB-621
9676978|NCT04979975|Experimental|UB-621 high-dose|high-dose of UB-621
9676979|NCT04979663|Experimental|experimental group|Combination of Gemox, Donafenib and Tislelizumab
9676980|NCT04979650|Active Comparator|The intervention group|The intervention group will receive 1 gram of methylprednisolone succinate within 500 ccs of normal saline within 5 hours.
9676981|NCT04979650|Placebo Comparator|The control group|The control group will receive 500 g of normal saline without methylprednisolone succinate.
9676982|NCT04979611|Other|Patients will undergo 68Ga-NOTA-exendin-4 PET/CT imaging|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. PET/CT imaging will be performed at 30-60 min post-injection.Visual and semiquantitative method will be used to assess the PET/CT images.
9676983|NCT04979819|Experimental|Multiple Sclerosis|Patients with multiple sclerosis will perform the UULEX and fill in the other mentioned parameters. Validity and reliability of the UULEX will be measured.
9676984|NCT04979715|Experimental|intervention group|"From the first postoperative day, with the approval of the surgeon performing the operation, the postoperative exercise program will be started once a day under the supervision of a physiotherapist during the stay of the participants in the hospital.~At the same time, participants will be directed to moderate intensity aerobic exercise (walking, jogging…) for 150 min/week. Information will be given on the importance of physical activity and increasing the level of physical activity. In addition, a brochure containing explanatory information about the postoperative physiotherapy program after breast surgery will be given to the participants."
9676985|NCT04979715|Active Comparator|control group|The patients in the control group will be informed about the postoperative physiotherapy program and patient education will be provided by the physiotherapist before the operation. Within the knowledge and approval of the surgeon performing the operation, preoperatively, respiratory control, diaphragmatic breathing, relaxation exercises, passive-active assistive-active range of motion exercises are shown by the physiotherapist, and patient education is provided with information about possible postoperative complications and what needs to be considered. will be given.
9676986|NCT04979676|Experimental|Cognitive Therapy|Experimental group subjected to active individual psychotherapy based on helping adolescents adopt a more realistic perspective on social events, by focusing on clues from those events and acting based on the social information thus gathered. Assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
10174747|NCT03850210|Experimental|Short Splint|
10174748|NCT03850210|Active Comparator|Traditional, Long Splint|
10174749|NCT03850327|Experimental|BIOMONITOR III|
10174750|NCT03849989|Experimental|Hailey Hailey|"Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy.~Skin biopsy specimens will be taken before and after lasertherapy at three time points.~Before treatment:~Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction~Immediately after treatment of the treated area:~2 mm punch for histopathology~Six weeks after treatment:~Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy"
10174751|NCT03849963|Experimental|Hyperpolarized [13C]pyruvate|Hyperpolarized stable isotope injection ([13C]pyruvate) during magnetic resonance spectroscopic imaging
10174752|NCT03849950|Experimental|SMARTCare|"Training in self-management support (SMS) strategies for ambulatory nursing staff~A web-based self-management education (I-Can-Manage Cancer) for patients~Telephone-based, nurse-led health coaching~Optional end of study patient interview (sub-study)"
10174753|NCT03849950|Active Comparator|Control|1. Training in self-management support (SMS) strategies for ambulatory nursing staff
9676987|NCT04979676|Experimental|Compassion-focused Therapy|Experimental group subjected to active individual psychotherapy based on developing compassionate mind skills, which in turn sustain exposing and acting in social events with a compassionate attitude towards oneself and others (instead of focusing on a critical and threat-based attitude). Assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
9676988|NCT04979676|Experimental|Acceptance and Commitment Therapy|Experimental group subjected to active individual psychotherapy based on developing skills for acceptance, defusing, and focusing on the present moments, which in turn sustain acting in social events in line with ones valued actions instead of prioritizing the avoidance of negative internal experiences). Assessed at pre-intervention, post-intervention (i.e., 10 to 12 weeks later), 12-weeks follow, and 24-weeks follow-up.
9676989|NCT04979676|Placebo Comparator|Waiting-list control|Group of participants with a main dignosis os social anxiety disorder not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
9676990|NCT04979676|Placebo Comparator|Normative control|Group of participants without any psychiatric diagnosis not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
9676991|NCT04979689|Experimental|Intensive physical therapy|Intensive session
9676992|NCT04979689|Other|Non intensive physical therapy|Non intensive session
9676993|NCT04979585|Experimental|Experimental|Patients with untreated advanced mucosal melanoma
9676994|NCT04979936|Active Comparator|early laparoscopic cholecystectomy|early laparoscopic cholecystectomy
10174754|NCT03849976||Experimental group|Patients accompanied to the operating room by a stretcher bearer trained in therapeutic communication
9676995|NCT04979936|Active Comparator|percutaneous cholecystostomy|percutaneous cholecystostomy first followed by delayed laparoscopic cholecystectomy
9676996|NCT04979845|Experimental|Telerehabilitation|
9676997|NCT04979845|Active Comparator|Video exercise|
9676998|NCT04979702|Active Comparator|Active Control|Patients will have access to our online exercise resources throughout the 12-week intervention.
9676999|NCT04979702|Experimental|Experimental: mHealth technology assisted exercise counselling (mHealth)|Participants will complete a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 4 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
9677000|NCT04979793|Active Comparator|Placebo|Oral placebo, 3 grams milk powder sachet, taken once daily
9677001|NCT04979793|Experimental|Daily L-citrulline|L-citrulline, 3 grams L-citrulline sachet, taken once daily
9677002|NCT04979884|Experimental|cyclosporine|patients will receive cyclosporine + (standard care treatment (± anticoagulant± antibiotic± antipyretic± steroid) according to Alexandria university hospitals protocol )
9677003|NCT04979884|Active Comparator|Standard of care treatment|patients will receive standard treatment (antiviral ± anticoagulant± antibiotic± antipyretic± steroid± interleukin ) according to Alexandria university hospitals protocol.
10174755|NCT03849976||Control group|Patients accompanied to the operating room by a stretcher bearer not trained in therapeutic communication
10174756|NCT03849872|Experimental|Part 1 Absolute Bioavailability|Single oral dose of 10 mg ONO-5788 capsule followed by iv infusion 100 μg/ 41 kBq (1.1 μCi) [14C]-ONO-5788 in 6 healthy male subjects.
10174757|NCT03849872|Experimental|Part 2 Mass Balance|Single oral dose of 10 mg [14C]-ONO-5788 capsule containing 4.1 MBq (111 μCi) [14C]-radioactivity in 6 healthy male subjects.
10174758|NCT03849885|No Intervention|Standard Skin Prep|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
10174759|NCT03849885|Experimental|Experimental Skin Prep with BPO|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~Following the CHG wipes, patients will be prepped with 5% BPO gel applied directly to the biopsy site.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
10174760|NCT03849898||Mandibular Fracture|"Elderly patients of > 60 years who present a mandibular fracture~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice"
9695239|NCT04780451|Experimental|Omega|
9695240|NCT04780451|Placebo Comparator|Placebo|
10174761|NCT03849859|Active Comparator|Single plastic stent|Deployment of single plastic stent
10174762|NCT03849859|Active Comparator|Multiple plastic stents|Deployment of multiple plastic stent
9677004|NCT04979832|Experimental|Local administration of GM-CSF, fosfomycin and metronidazole in the pouch|"Local administration of 50 micrograms GM-CSF, 400 milligrams fosfomycin and 100 milligrams metronidazole in the pouch.~In a Phase A of the trial, this will be applied as a single dose during endoscopy of the pouch. In Phase B of the trial, this will be applied as a first dose during endoscopy of the pouch, followed by 6 further daily doses for a total of 7 doses."
9677005|NCT04979923|Experimental|Lidocaine group|
10174763|NCT03850028|Other|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
10174764|NCT03849924|Experimental|Self-affirmation|Participants assigned to the self-affirmation intervention condition will undergo a self-affirmation intervention in the form of a questionnaire at time point one (one week after the intervention). This is a brief intervention that involves forming self-affirming implementation intentions. Implementation intentions are formulated plans that encourage one to link critical situations with appropriate behavioural responses. In this study participants are encouraged to write out the stem and their response to the stem from the four options.
10174765|NCT03849924|Experimental|Self-affirmation 'booster'|Participants assigned to this condition will undergo the self-affirmation intervention described above twice, in comparison to just once, in the form of a questionnaire at time points one (one week after the intervention) and two (two weeks after the intervention).
10174766|NCT03849924|No Intervention|Control|Participants assigned to the control condition will not undergo a self-affirmation intervention. Instead they will still complete the same questionnaire as participants in the intervention conditions but without the self-affirmation intervention included (normally included on the last page of the questionnaire).
10174767|NCT03849846||Adults with low socio-economic status|Four focus groups will be conducted with adults with low socioeconomic status recruited through community centres in the Québec City area.
10174768|NCT03849833|Other|Vitamin D3 supplementation|All participants will be selected for treatment with cholecalciferol, vitamin D3 supplementation and included in this single arm
10174769|NCT03849794|Experimental|Experimental group|Chiropractic Care Plus Physiotherapy
10174770|NCT03849794|Active Comparator|Control group|Physiotherapy
10174771|NCT03849807|Experimental|Experimental group|Chiropractic care
9677006|NCT04979923|Placebo Comparator|Salbutamol group|
9677007|NCT04979923|Active Comparator|Beclomethasone plus salbutamol|
9677008|NCT04979767||Sepsis|I. ≥ 50 years with ≥ 2 chronic comorbidities II. Highly suspected bacterial infection based on clinical or radiologic evidence III. ≥ 2 systemic inflammatory response syndrome (SIRS) criteria IV. Actual/anticipated admission to intensive care unit (ICU) V. Anticipated length of hospital stay ≥ 5 days
9677009|NCT04979767||Control|I. ≥ 50 years with ≥ 2 chronic comorbidities II. No suspected bacterial infection III. Actual/anticipated admission to intensive care unit (ICU) IV. Anticipated length of hospital stay ≥ 5 days
10174772|NCT03849807|Active Comparator|Control group|Usual health care
10174773|NCT03849781|Active Comparator|Intervention|NeoBeat will be placed on all newborns immediately after birth to assess the heartrate for at least 5 minutes, or longer if the newborn needs resuscitation. Intervention subjects will have a visible display of the heart rate on the NeoBeat, to guide healthcare providers in further management of the newborn.
10174774|NCT03849781|No Intervention|Standard Care|NeoBeat will be placed on the newborn to collect information on heart rate, but heart rate is not displayed to the healthcare providers. If the newborn is in need of resuscitation to initiate spontaneous respiration, the baby will be transferred to the resuscitation bay. According to recommendations the heart rate should be assessed and positive pressure ventilation initiated within one minute of life. Standard care is to assess heart rate by conventional ECG and/or pulse oximetry, alternatively auscultation of the heart.
10174775|NCT03849508|Active Comparator|phenylephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of phenylephrine started at an initial rate of 0,5mcg/kg/ min. The rate will be adjusted according to maternal systolic blood pressure.
9677010|NCT04979897||Intensive care unit stay during high bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a high bed occupancy in the pandemic
9677011|NCT04979897||Intensive care unit stay during low bed occupancy in the COVID-19 pandemic|Adult patients (≥18 years old) who are mechanically ventilated for at least 48 hours in one of the participating ICUs during a low bed occupancy in the pandemic
9677012|NCT04979559|Experimental|mHealth apps|The participants in this arm will receive information regarding mobile health applications used for screening and early intervention of the prediabetic states.
9677013|NCT04979559|Active Comparator|Standard care|The participant in this arm will receive regular practice or standard care of screening and early intervention of prediabetic state.
9677014|NCT04979598||Acute unilateral vestibular deafferentiation|Patients suffering from acute dizziness due to a unilateral vestibular deafferentiation.
9677015|NCT04979468|Other|ARM A|Participants in Arm A will be randomized to switch to DTG/3TC 50/300 mg QD until week 48 (early switch).
9677016|NCT04979468|Other|ARM B|Participants in Arm B will continue the INSTI-based ART regimen until week 48, and then will be switched to DTG/3TC through week 96 (delayed switch).
9677017|NCT04979494||Post cardiac surgery|Patients admitted to ICU right after cardiac surgery with or without cardiopulmonary bypass, usually with cardiac shock.
9677018|NCT04979494||Sepsis and septic shock|Patients admitted to ICU with the major complication of sepsis or septic shock.
9677019|NCT04979494||Control|Patients admitted to ICU for post-surgery monitor in case of complications due to their baseline health condition(e.g. coronary artery disease, hypertension and so on), but without severe shock.
9677020|NCT04979481|Experimental|BRAVE Intervention Arm|The BRAVE campaign included 3-5 text messages per week, including 1 role model video per week and a related image.
9677021|NCT04979481|Active Comparator|STEM Control Arm|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image.
9677022|NCT04979195||Group 1|patients with stable renal function.
9677023|NCT04979195||Group 2|Patients who developed AKI.
9677024|NCT04979520|Experimental|Brodalumab treated moderate-to-severe HS patients|Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.
9677025|NCT04979299|Experimental|wheelchair group|"Patients included in the  wheelchair  group will be asked to sit in a wheelchair during the interview;"
9677026|NCT04979299|No Intervention|Control group|Patients included in the control group will sit in a regular chair during the interview.
9677027|NCT04979117||Participants with plantar fasciitis|"Participants with the diagnose of plantar fasciitis; typical anamnesis (exacerbating pain by the first steps in the morning or after rest and with prolonged standing).~The emerge of local point tenderness over the heel and proximal fascia due to the pressure applied by the physician.~Thickening of the plantar fascia greater than 4 mm in ultrasonographic evaluation. measurement"
9677028|NCT04979117||Volunteers who has not foot complaints.|Volunteers who were not diagnosed with Plantar Fasciitis and without foot or heel pain when taking the first steps in the morning, with plantar fascia thickness less than 4 mm, painless, symptom-free and which had no additional rheumatic disease.
9677029|NCT04979429|Experimental|PePS|4 sessions of telephone CBT-based pain self-management in addition to standard perioperative care.
9677030|NCT04979429|No Intervention|Standard Care|Standard perioperative care.
9677031|NCT04979273|Active Comparator|Control Group|Patients within control group will be given adrenaline 1:20.000 injection, followed by thermocoagulation or hemoclip
9677032|NCT04979273|Experimental|Dextrose group|Patients within this group will be given adrenaline 1:20.000 injection, followed by dextrose 40% spray
9677033|NCT04979221|Experimental|Cyproheptadine and usual care|"Patients allocated to the intervention group will receive cyproheptadine within 6 hours after randomization, at a dose of 8mg every 8 hours for 10 days.~Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution."
9677034|NCT04979221|No Intervention|Usual care|Usual care (diagnostic testing, antibiotic administration, fluid resuscitation, hemodynamic management, and ventilatory support) will be applied in accordance with the clinical practice of each institution.
9677035|NCT04979104|Experimental|SL Cementless|Since the trial is not comparative, the only arm implies the use of the investigational device (SL cementless femoral stem)
10174776|NCT03849508|Experimental|Norepinephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of norepinephrine tartrate started at an initial rate of 0,1mcg/kg/min. The rate will be adjusted according to maternal systolic blood pressure.
10174777|NCT03849612|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
9677036|NCT04979351|Experimental|Abdominal Massage Group|Abdominal massage for 15 minutes twice a day application.
9677037|NCT04979351|No Intervention|Placebo Group|Abdominal massage was not applied.
9677038|NCT04979234|Experimental|Interventional|Endoscopic gastric reduction
9695241|NCT04780269|Experimental|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group.
9695242|NCT04780269|Experimental|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix.
9695243|NCT04780438|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following catheter ablation.
9695244|NCT04780438|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following catheter ablation.
9695245|NCT04780386|Experimental|NVP-1805|NVP-1805
9695246|NCT04780386|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1 and NVP-1805-R2
9695247|NCT04780243|No Intervention|Pre-intervention group|Pre-intervention group: women participated during the base line assessment will be labeled as Pre-intervention group
9695248|NCT04780243|Experimental|postintervention group|Postintervention group: women participated after the intervention was initiated will be labeled as postintervention group.
9695249|NCT04780217|Experimental|Phase 1 Part A|T3011 Single Agent Dose Escalation in participants with solid tumors
9695250|NCT04780217|Experimental|Phase 1 Part B|Dose Escalation of Combination T3011 + pembrolizumab in participants with solid tumors
9695251|NCT04780217|Experimental|Phase 2a Arm A|RP2D T3011 + pembrolizumab in participants with NSCLC
9695252|NCT04780217|Experimental|Phase 2a Arm B|RP2D T3011 + pembrolizumab in participants with advanced solid tumors with metastasis in either liver and/or lung
9695253|NCT04780165|Experimental|Single-arm|
9695254|NCT04780178|Experimental|TACTICs|Our ACT intervention will include 6 weekly 1-hour telephone sessions and 1 booster session offered 1 month after session 6 designed to increase psychological flexibility through practice of one or more of the six skills in each session. Although these are ideally spaced 1 week apart, participants will have up to 12 weeks to complete the 6 sessions. Each session will include guided mindfulness practice that encourages non-judgmental awareness of the present moment to increase psychological flexibility; brief (10-minute) study-provided audio recordings will enable participants to practice mindfulness at home. Caregivers will also identify deeply-held values to serve as a guide when choosing how to spend limited time or energy and will set values-based action goals each week. A booster session will be provided one month after session 6 to reinforce skills learned.
9695255|NCT04780178|No Intervention|Minimally Enhanced Usual Care|All caregivers randomized to the mEUC group will receive a mailed packet containing 1) a letter from the Co-PIs thanking them for participating, 2) printed selections from of the NIH Alzheimer's caregiving website (https://www.nia.nih.gov/health/alzheimers/caregiving), and 3) a listing of Alzheimer's Association sponsored support groups closest to the caregiver's home address. Caregivers will also receive a brief phone call from the research coordinator to verify receipt of the packet. Since this is a usual care group with a minimally-enhanced component, it will be up to the mEUC participants to decide whether or not to engage with these intervention materials.
9827771|NCT02467491|Other|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
10174778|NCT03849521||Asymptomatic group|Group with asymptomatic patients with carotid atherosclerosis.
9677039|NCT04979507|Experimental|Experimental Group|
10174779|NCT03849521||Symptomatic group|Group with symptomatic patients with carotid atherosclerosis.
10174780|NCT03849664|Experimental|Cytoflavin®|Patients of group I will receive the experimental drug Cytoflavin®, manufactured by POLYSAN (Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Cytoflavin® solution(Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered IV for 7 days, and Cytoflavin® enteric-coated tablets (Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered for 25 days (in total 32 days of treatment).
10174781|NCT03849664|Placebo Comparator|Placebo|Patients of group II will receive placebo (manufactured by POLYSAN, Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Placebo solution will be administered IV for 7 days, and placebo enteric-coated tablets will be administered for 25 days (in total 32 days of treatment).
10174782|NCT03849742|Experimental|Heath services research (Uber rides)|Patients receive Uber rides to and from scheduled radiotherapy appointments for up to 6 months.
10174783|NCT03849729|Active Comparator|Phentermine|Low-calorie diet + Phentermine Capsules 15 mg po by 6 weeks, one time a day before bariatric surgery.
9677040|NCT04979507|Active Comparator|Control group|
9677041|NCT04979455||Exertional heat illness|Participants who experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
9677042|NCT04979455||Control|Participants who do not experience an atypical elevation in thermal strain or an EHI undergoing strenuous physical exercise.
9677043|NCT04979390|Experimental|Treatment group|
10174784|NCT03849729|Placebo Comparator|Placebo|Low-calorie diet + Placebo Capsules po by 6 weeks, one time a day before bariatric surgery.
9677044|NCT04979208||Acute myocardial infarction (AMI) cohort|Adult patients with recent acute myocardial infarction admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis all recent AMI patients less than 24 hours old diagnosed by emergency physicians on the basis of suggestive clinical symptoms and electrocardiogram (ECG) criteria, cared in the 30 emergency units and 19 mobil intensive care unit, with a coronary angiography or a percutaneous coronary intervention (PCI) realized in the 11 cathlabs in Aquitaine
9677045|NCT04979208||Stroke cohort|Adult patients with recent stroke admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis recent ischemic or hemorragic stroke patients with brain imaging managed in one of the 14 participating hospitals in Aquitaine (7 stroke units and 7 primary care centers).
10187145|NCT03729089|No Intervention|Current standard of care|The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy.
9677046|NCT04979026|No Intervention|active ankle pumping without any reminders|In group 1, active ankle pumping exercise for the operative limb was performed without any reminder during hospitalization and at home after being discharged.
10187146|NCT03729076|Experimental|Crystalloid|Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.
10187147|NCT03729076|Active Comparator|Colloid|Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.
9677047|NCT04979026|Active Comparator|intermittent pneumatic compression|In group 2, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
9677048|NCT04979026|Experimental|active ankle pumping with a regular watch alarm|In group 3, in addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge. The watch was continuously used until the 14th day when the patients returned to the hospital for examination.
9677049|NCT04979013|Experimental|Smoking Abstinence|14-day Smoking Abstinence
9677050|NCT04978675|Experimental|Diagnostic (F-18 rhPSMA-7.3, PET/MRI)|Patients receive F-18 rhPSMA-7.3 IV and after approximately 60 minutes of uptake time, will undergo PET/MRI over 60 minutes. Patients with evidence of F-18 rhPSMA-7.3 disease in the first PET/MRI scan undergo a second F-18 rhPSMA-7.3 PET/MRI at 6 months after the second dose of standard hormonal therapy.
9677051|NCT04978636|Active Comparator|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The investigator will investigate the effect of continuous low tidal volume ventilation with hyperoxia avoidance (using FiO2 of 0.21) on PPCs and 30-day mortality compared to low-tidal volume ventilation (with FiO2 of 0.21) or apnea during CPB.
9677052|NCT04978636|Active Comparator|Continuous low tidal volume ventilation with using FiO2 of 1.0|The investigator will investigate the effect of low tidal volume lung ventilation with hyperoxia avoidance (FiO2 of 0.21) on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or apnea during CPB.
10187148|NCT03729063|Experimental|Twice daily expired CO measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
10187149|NCT03729063|Active Comparator|Control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
10187150|NCT03729050|Experimental|Intervention with rehabilitation coordinator|
10187151|NCT03729050|No Intervention|Control|
10187152|NCT03729037|Experimental|Serious game|Intervention: CPR self-training with serious game.
10187153|NCT03729037|Active Comparator|Training video|Intervention: CPR self-training with Keynote presentation with the addition of voice-over narration.
9677053|NCT04978636|Active Comparator|Apnea|The investigator will investigate the effect of apnea during on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or hyperoxia avoidance (FiO2 of 0.21) during CPB.
10187154|NCT03729011|Active Comparator|Volatile anesthesia group|
10187155|NCT03729011|Active Comparator|TIVA group|
10174785|NCT03849560|Experimental|Grippol® Quadri|"Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
9677054|NCT04978714||Women with cystocele|All women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair
10174786|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Yamagata lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
10174787|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Victoria lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
10174788|NCT03849534|Active Comparator|Soft occlusal appliance|Individually casted appliances
10174789|NCT03849534|Active Comparator|Jaw exercises|Resistance exercises to do twice a day
9677055|NCT04978974|Experimental|Patients with type 2 Diabetes mellitus and Hypertension|patients with type 2 diabetes mellitus and hypertension were selected by using purposive sampling technique to apply stress management program
9677056|NCT04979039||normal pregnancy|Adult pregnant women scheduled for cesarean section under spinal anesthesia
9677057|NCT04978805|Experimental|Progressive Relaxation Exercise|A total of 56 sessions of progressive relaxation were performed, 7 days a week for 8 weeks. Each session is set as fifty minutes
9677058|NCT04978805|No Intervention|Control group|Routine maintenance will be applied
9677059|NCT04978896|Experimental|Intervention group: Stress-coping Program|Participants will complete an 8-day self-guided programme on stress-coping delivered via a mobile-phone application with daily exercises guided by cognitive-behavioural principles.
9677060|NCT04978896|Active Comparator|Control group|Participants will complete an 8-day self-guided programme on cooperation delivered via a mobile-phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
9677061|NCT04978844|Active Comparator|I-WotCH|I-WotCH- Inner World of the Child- is a novel innovative therapy developed in our clinic. The therapy is based on modern concepts of early childhood developments emphasizing themes related to emotional regulation, processes of socialization, observational research on interpersonal and behavior as well as recent developments on affiliative neuroscience. More specifically, the therapist, through play, identifies themes and emotions the child is preoccupied with. The therapist then assists the child in naming these emotions, validating them, exploring their nature and consequences. The therapists discussed ways of managing and self-regulating these emotions. These methods would include behavioral techniques, the ability to enlist help from others and reframing. In addition, the therapy will address dealing with complexed emotions and enhancing symbolic play and joyfulness.
9677062|NCT04978844|Active Comparator|Dyadic therapy|"Child parent psychotherapy: CPP consists of joint parent-child sessions that focus on the child's free play and spontaneous parent-child interaction. The CPP therapist acts to translate the developmental and emotional meaning of a child's emotions and actions to the parent. The target of treatment includes the both the child's and the caregiver's adaptive conflicts, including a parent's difficulty in providing sensitive and developmentally appropriate care. CPP fosters parent-child activities that foster mutual pleasure, interpersonal trust and understanding. In the purpose of this study only mothers will be included."
9677063|NCT04978844|No Intervention|Control|Healthy control.
9677064|NCT04978623||Patient with CIDP|CIDP, is an acquired chronic inflammatory neuropathy characterised by : progressive symmetrical weakness of the proximal and to a lesser extent distal muscles of the lower and/or upper limbs, altered sensitivity and a decrease/abolition of the osteotendinous reflexes. The condition can be relapsing (30% of cases), chronically progressive (60%), or monophasically with total subsequent recovery (10%). Cranial nerve involvement is possible (5-30% of cases). Neuropathic pain as well as respiratory muscle and sub-clinical central nervous system involvement are described.
10174790|NCT03849534|Active Comparator|Counseling|Just information at the first visit
10174791|NCT03849482||Parotid Gland Neoplasms|"Preoperative Assessment of Parotid Gland Neoplasms with:~Clinical Evaluation;~Fine Needle Aspiration Cytology;~Multiparametric Magnetic Resonance Imaging.~Postoperative Collection of Final Histopathological Diagnosis"
9827772|NCT02467504|Active Comparator|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
10174792|NCT03849703|Experimental|Full Intervention #1|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the coparenting curriculum before the romantic relationships curriculum.
10174793|NCT03849703|Experimental|Full Intervention #2|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the romantic relationships curriculum before the coparenting curriculum.
9975702|NCT01344018|Active Comparator|Surgery alone|En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.
10174794|NCT03849703|Other|Partial Intervention #1|Participants will receive the romantic relationships curriculum along with the control curriculum.
10174795|NCT03849703|Other|Partial Intervention #2|Participants will receive the coparenting curriculum along with the control curriculum.
10174796|NCT03849677||Omnivore|
10174797|NCT03849677||Vegan|
10174798|NCT03849599|Experimental|PRV-300|Subjects in this arm will receive the study drug, PRV-300, via IV infusion, followed by an 8-week follow-up period.
10174799|NCT03849599|Placebo Comparator|Placebo|Subjects in this arm will receive placebo via IV infusion, followed by an 8-week follow-up period.
10174800|NCT03849547|Experimental|App training group|Subjects in App training group will receive App Balance training via smartphone application.
9677065|NCT04978623||Patient with MMNCB|Patients with MMNCB are at the crossroads between chronic demyelinating neuropathies and motor neuron diseases, the latter for which they constitute a differential diagnosis. The disease usually presents asymmetrically and affects the upper limbs more frequently. The course of the disease is unpredictable, and may be limited to one or two motor nerves or progress to other motor nerves in the contralateral upper limb and possibly the lower limbs. In all cases, the motor deficit is asymmetrical, multi-truncular in distribution, and is usually accompanied by cramps and fasciculations, and eventually by amyotrophy. Osteotendinous reflexes are usually diminished or abolished in the affected areas, but they may also be preserved in the initial attacks. There is no sensory deficit, although some patients occasionally present with paresthesias, and exceptionally with damage to the cranial nerves (especially CN XII).
10174801|NCT03849547|Active Comparator|Home training group|Subjects in Home training group will receive Home Balance training advised by physical therapist.
9677066|NCT04978623||Patient with Anti-MAG|Anti-MAG is a demyelinating neuropathy characterized clinically by a chronic progressive distal and symmetrical predominantly sensory involvement. This neuropathy belongs to the group of symmetrical acquired demyelinating neuropathies (Distal Acquired Demyelinating Neuropathy (DADS)) which is distinguished from PIDC by: 1. an essentially distal and rather sensitive clinical involvement (unlike PIDC which is proximal and distal with predominantily motor involvement); 2. a strong association with a monoclonal gammopathy of the IgM type (67% of DADS vs 22% of PIDC according to Katz et al, 3. a poor therapeutic response to first line of immunosuppressive drugs (in contrast to PIDC which generally responds well). Certain electrophysiological parameters, such as the demonstration of demyelinating damage with accentuated slowing of distal nerve conduction, make it possible to distinguish anti-MAG neuropathy from CIDP.
9677067|NCT04978623||Patient with L-S|Lewis-Sumner syndrome is an acquired demyelinating polyradiculoneuritis characterised by distal asymmetric upper and lower limb weakness and motor dysfunction that develops in adulthood. It is considered a variant of chronic inflammatory demyelinating polyradiculoneuritis. It has a prevalence of 1-9 per 1,000,000. The diagnosis is made with electroneuromyography (ENMG) which shows marked and persistent conduction blocks, in at least two nerves, having an asymmetric topography, mainly affecting the upper limb, outside the usual areas of compression. Lower limb blocks are much rarer (anterior tibial nerve), and are always located below the fibular neck.
10174802|NCT03849547|No Intervention|Control group|Control group will receive only education of ankle injury prevention related information.
9677068|NCT04978792|Experimental|Self-compassion Intervention|The intervention will include 14 self-compassion exercises completed over a 3-week period. The intervention will include methods of psychoeducation, meditation, and self-compassion exercises similar to Beshai et al.'s (2020) self-compassion-based intervention. The psychoeducation will focus on self-compassion, the meditations will be kindness and loving meditations and self-compassion breaks. The self-compassion exercises will be based on the writing exercises available on Neff's self-compassion website.
9677069|NCT04978792|Active Comparator|Control Group|The active control will also include 14 exercises completed over a 3-week period. The 14 exercises will comprise of a psychoeducation video, writing exercises, video/audio-guided relaxation, and journal entries. The same psychoeducation video used in the intervention will be shown to participants, however, the other exercises will be altered to focus on factual information and not focused on self-compassion. The exercises will be matched to the self-compassion exercise so that similar exercises are completed in parallel time with the intervention.
9677070|NCT04979000||Cases|Patients with a confirmed diagnosis of sinonasal cancer.
9677071|NCT04979000||Controls|Patients being seen for benign conditions at Johns Hopkins.
10174803|NCT03849573|Experimental|Mindfulness-based stress reduction + Hormone Therapy Education|
10174804|NCT03849573|Active Comparator|Hormone Therapy Education + Overall Health Education|
9677072|NCT04978766|Experimental|Interactive Book Reading Group|Participants in this arm will take baseline measures, will receive the intervention and will take posttest measures.
9677073|NCT04978766|No Intervention|Control Group|Participants in this arm will take baseline and posttest measures. For ethical purposes, they will receive the intervention after posttest measures are taken.
9677074|NCT04978857|Experimental|Virtual reality headset|
9677075|NCT04978948||Myasthénie|Blood samples will be collected
9677076|NCT04978948||Myopathie inflammatoire (Myosite)|Blood samples will be collected
9677077|NCT04978948||Neuropathie autoimmune|Blood samples will be collected
9677078|NCT04978948||Néphropathies autoimmunes|Blood samples will be collected
9677079|NCT04978948||Hépatite auto-immune|Blood samples will be collected
9677080|NCT04978948||Pancréatite auto-immune|Blood samples will be collected
9975703|NCT01344018|Experimental|Preoperative radiotherapy followed by en-bloc surgery|3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions
10174805|NCT03849365|Experimental|TOOKAD VTP|TOOKAD is administered as part of focal VTP under general anaesthetic. TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
10174806|NCT03849495|Experimental|Group A|"Period 1: D745~Period 2: CKD-370"
10174807|NCT03849495|Experimental|Group B|"Period 1: CKD-370~Period 2: D745"
10174808|NCT03849404|Experimental|AVT02 100mg/mL (Adalimumab Biosimilar)|Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
10174809|NCT03849404|Experimental|EU-Humira 100mg/mL (Adalimumab Originator)|Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48
10174810|NCT03849755|Other|PEPPER/Control|Group with intervention applied (PEPPER system) during the first three months and then, after wash -out period, swap to control group (using standard bolus calculator) for the next 3 months.
10174811|NCT03849755|Other|Control/PEPPER|Group without intervention applied (using standard bolus calculator) during the first three months and then, after wash -out period, swap to intervention group (using PEPPER system) for the next 3 months.
10174812|NCT03849391|Experimental|Skate group|This group takes Skate Skin extract for 12 weeks
10174813|NCT03849391|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
10174814|NCT03849417||Late-life Depression|Patients aged over 60 years old with severe depression
10174815|NCT03849417||Late-life Depression (ECT)|Patients aged over 60 years old with severe depression who are referred for treatment with electroconvulsive therapy
10174816|NCT03849417||Healthy Controls|Healthy volunteers over 60 years old who will form a comparison group
10174817|NCT03849352|Other|Lifestyle Arm|Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology
10174818|NCT03849209|Experimental|Stylet Slow-Pull Technique group|In patients randomized to the stylet slow-pull techniques an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
9677081|NCT04978948||Purpura Thrombopénique Immunologique|Blood samples will be collected
9677082|NCT04978948||Dermatose bulleuse|Blood samples will be collected
10174819|NCT03849209|Active Comparator|Standard Suction Technique group|In patients randomized to the standard suction technique an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed with the use of a 10-mL suction syringe.
10174820|NCT03849339|Experimental|Group 1|"Period 1: D635~Period 2: CKD-387"
10174821|NCT03849339|Experimental|Group 2|"Period 1: CKD-387~Period 2: D635"
9677083|NCT04978948||Thyroïdite autoimmune|Blood samples will be collected
9677084|NCT04978948||Sclérose en plaque|Blood samples will be collected
9677085|NCT04978948||Sclérose latérale amyotrophique|Blood samples will be collected
10174822|NCT03849222|Active Comparator|Ca(OH)2 Apexification|Apexification was performed with calcium hydroxide. calcium hydroxide dressing was applied directly against the open apex .The canals were back filled with Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
10174823|NCT03849222|Experimental|Ca(OH)2 Apexification with apical matrix|Treated by condensation of calcium hydroxide dressing against an internal matrix , a piece (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy) was gently compacted toward the apex before insertion of Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
10174824|NCT03849222|Active Comparator|MTA Apexification|Apexification was performed with MTA as apical plug. A 3-5 mm thickness of MTA using a hand plugger was applied as apical plug and verified radiographically. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
10174825|NCT03849222|Experimental|MTA Apexification with apical matrix|An internal (apical) matrix was used as a base for condensation of MTA apical plug, a pieces of (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy)were compacted toward the apex with premeasured suitable size schilder plugger. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
10174826|NCT03849183|Experimental|Nitroglycerin|Nitroglycerin 5mcg/kg (0.5cc) is subcutaneously injected before radial artery cannulation.
10174827|NCT03849183|Active Comparator|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation.
10174828|NCT03849287|Experimental|Group 1|"Period 1: CKD-333, formula I~Period 2: CKD-333, formula II~Period 3: CKD-330, D090"
10174829|NCT03849287|Experimental|Group 2|"Period 1: CKD-333, formula I~Period 2: CKD-330, D090~Period 3: CKD-333, formula II"
10174830|NCT03849287|Experimental|Group 3|"Period 1: CKD-333, formula II~Period 2: CKD-330, D090~Period 3: CKD-333, formula I"
10174831|NCT03849287|Experimental|Group 4|"Period 1: CKD-333, formula II~Period 2: CKD-333, formula I~Period 3: CKD-330, D090"
10174832|NCT03849287|Experimental|Group 5|"Period 1: CKD-330, D090~Period 2: CKD-333, formula I~Period 3: CKD-333, formula II"
9677086|NCT04978948||Polyarthrite Rhumatoïde|Blood samples will be collected
9677087|NCT04978948||Spondylarthrite axiale|Blood samples will be collected
9677088|NCT04978948||controls|Patients without autoimune desease* Blood samples will be collected
9677089|NCT04978922|Experimental|TelEPOC with Machine Learning (ML)|"Hospital with an active telemonitoring programme of readmitted COPD patients (TelEPOC) after application of an artificial intelligence system (Machine Learning: ML).~* TelEPOC: The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own."
9677090|NCT04978922|No Intervention|TelEPOC without ML|Hospitals with an active telemonitoring programme of readmitted COPD patients (TelEPOC) without the application of an artificial intelligence system (Machine Learning: ML).
9677091|NCT04978935|No Intervention|Control group|In the control group (n=40), interventions for the position, mobilization and spirometry of the patient are applied to all patients in the clinic where the study was conducted. However, these applications are not made in accordance with a certain order and protocol. Shoulder exercises are not routinely taught to patients. In the study, no additional application will be made to the control group other than the routine treatment and care practice of the clinic.
9827773|NCT02467504|Placebo Comparator|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
9827774|NCT02467621|Experimental|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
9827775|NCT02467621|Placebo Comparator|Normal saline|Saline (0.9%)
10174833|NCT03849287|Experimental|Group 6|"Period 1: CKD-330, D090~Period 2: CKD-333, formula II~Period 3: CKD-333, formula I"
9677092|NCT04978935|Experimental|Intervention|Care protocol will be applied to the study group (n=40), starting from the first day spent in the intensive care unit.Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises. The bed head of the patient will be raised 30°-45° in line with the application steps. In the study, the patient's in-bed and out-of-bed mobilization will be provided by considering the mobilization application steps, and the patient will be asked to stay out of bed for two hours on the 0 th day after surgery. The patient will be asked to stay out of bed for six hours from the first postoperative day until discharge. After the thoracotomy, the conditions that the doctor considers as complications will be recorded.The time of chest tube removal and the day of discharge will be recorded. In the study, the use of spirometry and shoulder exercises will be carried out by taking into account the implementation steps of the care protocol.
9677093|NCT04978688|Experimental|Relugolix|Participants received relugolix 40 milligrams (mg) alone for 6 weeks.
9677094|NCT04978688|Experimental|Relugolix + E2/NETA|Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks.
10174834|NCT03849144|Experimental|Therapy dog activity|Interact with visiting therapy dogs for 15 minutes on two Fridays
9677095|NCT04978753|Experimental|treatment|Anlotinib (12mg/time (BSA≥1.6 m2) or 10mg/time (BSA<1.6 m2), once a day orally, taking two weeks and stopping for one week) combine with Almonertinib (110mg, orally once a day)
9677096|NCT04978961|Experimental|Focused Acceptance and Commitment Therapy (FACT)|"Focused Acceptance & Commitment Therapy (FACT): FACT is a brief type of cognitive behavioral therapy that helps patients reduce disability through increased acceptance, reconnection with values, and reduced unhelpful control/coping strategies. Patients randomized to the intervention group received FACT per the study manual, delivered by an integrated Behavioral Health Consultant (BHC). Patients had one individual visit (30 minutes) and three consecutive weekly group visits (one hour) followed by a booster visit two months later. These classes (group visits) were rolling, not cohort-driven, meaning new and returning patients will be attending together. After the individual BHC visit and each class, patients had behavioral homework to complete."
9677097|NCT04978961|Active Comparator|Enhanced Treatment as Usual (ETAU)|"Patients randomized to the Enhanced-Treatment As Usual (ETAU) group received enhancement of usual primary care via 1-page (2-sided) educational handouts on four topic areas: Sleep, Pacing, Relaxation and Goal Setting. All topics have an evidence base in standard Cognitive Behavioral Therapy treatment of pain. One handout per assessment visit was given to each patient. Patients will continue to see their primary care clinicians and have access to all routine clinical services throughout the study."
9677098|NCT04978610|Experimental|Intervention (Immediate)|Participants in the intervention group will begin their 6-week vACT sessions first and complete baseline, the weekly surveys during intervention, post, one month follow-up, and three month follow-up.
9677099|NCT04978610|Other|Control (Waitlist)|Upon the intervention group's completion of the 6-week long vACT, the control group will then enroll into their own 6-week long ACT intervention. The research protocol for the second 6-week long ACT intervention will mirror the protocol with the original 6-week long ACT intervention, except for one change: participants will NOT complete an additional baseline questionnaire prior to starting the 6-week ACT therapy group. The rest of the protocol remains the same. Namely, before each session, each participant will be required to fill out a short survey on their stress and pain throughout previous week. At the conclusion of the final session, participants will follow the complete post-intervention battery of surveys, which mirrors the baseline measures plus the inclusion of satisfaction surveys assessing the effectiveness of the virtual therapy intervention. Participants will complete the post-intervention follow up battery of questionnaires at 1 and 3 months post-intervention.
9677100|NCT04978649|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
9677101|NCT04978649|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
9677102|NCT04978883||pSS-ILD|diagnosis of pSS-ILD was based on abnormal HRCT and PFTs
9677103|NCT04978883||pSS non-ILD|pSS patients after exclusion of pSS-ILD and concomitant pulmonary diseases were considered as pSS non-ILD
9677104|NCT04978597|Experimental|Opicapone|OPC will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
9677105|NCT04978597|Placebo Comparator|Matching placebo|Matching placebo will be taken orally once daily in the evening at least 1 hour after the last daily dose of L-DOPA/DDCI (considered the bedtime dose).
9677106|NCT04978350|Experimental|Educational Workbook Arm|Participants in the Educational Workbook Arm will receive an electronic PDF version of an educational workbook via email on cascade screening in families with Lynch Syndrome. Genetic counselors will introduce the workbook to enrolled patients with Lynch Syndrome. Patient participants will use the activities and information in the workbook to communicate about Lynch Syndrome with family members.
9677107|NCT04978545|Experimental|calciumhydroxide|Participants received calciumhydroxide as an intracanal medicament for a one week period
10174835|NCT03849144|Active Comparator|Low impact physical activity|Participate in 15-minute low impact physical activity on two Fridays
9677108|NCT04978545|Experimental|chlorhexidine|Participants received chlorhexidine gel as an intracanal medicament for a one week period
10174836|NCT03849313|Experimental|AVT02 100mg/mL|Biosimilar Adalimumab AVT02
10174837|NCT03849313|Active Comparator|EU-Humira 100mg/mL|EU Approved Adalimumab originator Humira
9527627|NCT03218176|Experimental|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
10174838|NCT03849313|Active Comparator|US-Humira 100mg/mL|US licensed Adalimumab originator Humira
10174839|NCT03849196|Experimental|2L PEG-Asc|2L PEG-Asc for bowel preparation
9677109|NCT04978285||Postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. Anaemia will be defined according to the World Health Organisation definition (males Hb <130 g/L, and female Hb <120 g/L).
9677110|NCT04978285||No postoperative anemia|All patients enrolled in the RELIEF trial in which a postoperative Day 1-3 hemoglobin concentration was measured. No anaemia will be defined according to the World Health Organisation definition (males Hb ≥130 g/L, and females Hb ≥120 g/L).
9677111|NCT04978584|Experimental|Treatment (uLTRA, CHOP)|"COHORT I (SMART STOP): Patients receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~COHORT II (uLTRA-CHOP): Patients who achieve a complete response to the Smart Stop in Cohort I, receive rituximab IV over 4-6 hours on day 1, acalabrutinib PO BID on days 1-21, lenalidomide QD on days 1-10, and tafasitamab IV over 2 hours on days 1, 8, and 15. Treatments repeat every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, vincristine IV over 15 minutes on day 1, and prednisone PO QD on days 1-5. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progr"
9677112|NCT04978571|Experimental|Active Neurostim Device|Patients in this group will receive the active devices for the initial 4 study weeks.
9677113|NCT04978571|Sham Comparator|Sham Neurostim Device|Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.
9677114|NCT04978467|Experimental|single arm|All participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
9677115|NCT04978194|Experimental|Online group|"Online group: online university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included:~9- video capsules (one per week)~An exchange room on each video on a private discord group"
9677116|NCT04978194|Experimental|Hybrid group|"Hybrid group: hybrid university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included: 10 lessons of 2 hours including~The viewing of the videos~A time of exchange between students, and with the teacher"
9677117|NCT04978194|No Intervention|Control group|Control group: No intervention, only two measurement times of 9 weeks apart. Nothing has changed.
9677118|NCT04978207|Experimental|Multilevel, religiously-culturally tailored COVID-19 testing and linkage to care|Church-based COVID19 promoted with a religiously-culturally tailored Faithful Response COVID19 Toolkit delivered by church health workers (trained in an enhanced communication style) through multilevel church outlets (e.g., sermon guide, responsive reading, church bulletin inserts, automated text messages) and linkage to care delivered by community health workers who also conduct contact tracing; inclusive of 2 church-based COVID-19 testing events at each participating site.
9677119|NCT04978207|Active Comparator|Standard COVID19 information (non-tailored) attention control arm|Standard COVID-19 information that has not been tailored delivered by trained church health workers via a toolkit; inclusive of 2 church-based COVID19 testing evens at each participating site.
9677120|NCT04978441||Type 1 diabetes mellitus (T1DM)|"Males or females above 18 years old~Patients with a prior medical history diagnosis of T1DM~Patients who are using a continuous glucose monitor (CGM or FGM)"
9677121|NCT04978532|Experimental|Guided Imagery Group|One minute before venipuncture and during venipuncture, the children in the guided imagery group listened to a voice recording prepared in a studio. This voice recording named 'Stroll in the Forest' helped the children to imagine that they are strolling in a forest and guided them.
9677122|NCT04978532|Other|Control Group|No intervention was performed to reduce pain in the control group.
9677123|NCT04978311|Experimental|Mirror therapy (MT) priming with task-specific training|
9677124|NCT04978311|Active Comparator|Mirror therapy priming with impairment-oriented training|
9677125|NCT04978311|Active Comparator|Control therapy|
9677126|NCT04978233||MUHC COVID-19 patients|COVID-19 infected patients, newly diagnosed at the RI-MUHC
9677127|NCT04978077|Experimental|High fat test meal first, high carbohydrate test meal second|Consumption of a high fat challenge first, consumption of a high carbohydrate challenge after two weeks wash out
10174840|NCT03849196|Active Comparator|1L PEG-Asc & 'Bisacodyl 10Mg Suppository|1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation
9677128|NCT04978077|Experimental|High carbohydrate test meal first, high fat test meal second|Consumption of a high carbohydrate challenge first, consumption of a high fit challenge after two weeks wash out
9677129|NCT04977960|No Intervention|Reference group|"Patients randomized to the Reference Group will receive the standard-of-care treatments, according to institutional procedures in force:~Dexamethasone i.v. 6 mg die for consecutive 5 days~Methylprednisolone i.v. 40 mg bid for consecutive 10 days~Low-molecular-weight-heparin i.v. at standardized dose of 70 UI/kg twice~Remdesivir i.v. 200 mg in bolus (1st day) then 100 mg die for 4 days; remdesivir will be used only in patients supported with low-flow nasal cannula oxygen or Venturi mask~Antibiotic therapy:~azithromycin: 500 mg/die per os for 5 days~ceftriaxone: 2 g i.v. die for 8 days"
9677130|NCT04977960|Experimental|Experimental Group|Patients randomized in the Experimental Group will receive canrenone as add-on therapy to standard-of-care treatments. Different starting doses of i.v. canrenone will be administrated in a single or double infusion per day, for 7 days, according to the serum concentration of potassium at randomization
9827776|NCT02467777|Active Comparator|Forced Air|Bair Hugger
10174841|NCT03849157|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
9527628|NCT03218176|Experimental|Distal single lower limb|Laying a single tourniquet on the calf
9677131|NCT04978155||Echo group|All the patients (n=90) who had an AVF creation with preoperative venous identification by the surgeon at CHU de TOULOUSE (echo group).
9677132|NCT04978155||Control|All the patients (n=93) who had a native AVF placed during the year 2019 without having received immediate preoperative ultrasound and therefore there was no alteration in the surgical project in relation to that planned at the time of the consultation
9677133|NCT04978038|Experimental|mRNA-1273 Vaccine|Eligible participants will be vaccinated with the mRNA-1273 (Moderna COVID-19 Vaccine). A .5ml dose of the vaccine will be administered intramuscularly.
9677134|NCT04978038|Active Comparator|Pneumococcal Prevnar-13|Eligible participants will be vaccinated with Pfizer Prevar-13 (pneumococcal vaccine) in a blinded manner such that the vaccination with mRNA-1273 will be mimicked. That is, a .5ml dose of the vaccine will be administered intramuscularly. After completion of the study participants in the control arm will be offered a third dose of mRNA-1273 if our data shows that a third dose is effective in boosting the immune response.
9677135|NCT04978090|Experimental|Enteroatmospheric fistula (EAF) management solution|Participants will receive a custom fitted device designed to isolate EAF effluent independent of negative pressure wound therapy (NPWT) utilizing 3D printing technology to design a participant-matched device that more easily and effectively separates the participant's fistula and any emanated intestinal contents surrounding the wound.
9677136|NCT04978025|Experimental|Silver Group|"Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
9677137|NCT04978025|Placebo Comparator|Placebo Group|"Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days~By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days."
9677138|NCT04978103|Experimental|Single Arm|Hundred postmenopausal women were enrolled and received therapeutic dose of Gum Arabic (0.5 gm/kg/day) and followed for 12 weeks then the intended outcomes will be compared before and after completion of the study
9677139|NCT04977921|Experimental|Elsiever clinical skill platform|
9677140|NCT04977999|Active Comparator|Eccentric training|Eccentron (BTE Technologies, Inc.) training
9677141|NCT04977999|Experimental|Aquatic training|Hydroworks aquatic training
9677142|NCT04977778|Active Comparator|Fatty Acids Compounds (FAG)|Individuals taking FAG mouthwash
9677143|NCT04977778|Active Comparator|Stannous Fluoride (SF)|Individuals taking SF mouthwash
9677144|NCT04977674|Experimental|A: Visit 1) Naltrexone + Ketamine, Visit 2) Placebo + Ketamine|"Participants randomly assigned to arm A:~VISIT 1) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~VISIT 2) Placebo before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
9677145|NCT04977674|Experimental|B: Visit 1) Placebo + Ketamine, Visit 2) Naltrexone + Ketamine|"Participants randomly assigned to arm B:~VISIT 1) Placebo before the administration of ketamine 0.5mg/kg.~VISIT 2) Naltrexone 50mg before the administration of ketamine 0.5mg/kg.~Study visits are separated by 14-28 days."
9677146|NCT04977804|Active Comparator|Eccentric only training|This is the experimental control; where this group will be used as the standard active comparison condition.
9677147|NCT04977804|Experimental|Eccentric plus blood-flow restriction|This is the experimental condition involving the eccentric resistance training with blood flow restriction.
9677148|NCT04977973|Experimental|Intervention group: Body Image|Participants will complete a 9-day self-guided programme on body image delivered via a mobile phone application with daily exercises informed by cognitive-behavioural and self-compassion principles.
9677149|NCT04977973|Active Comparator|Control group|Participants will complete a 9-day self-guided programme on cooperation delivered via a mobile phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
9677150|NCT04977908|Experimental|Fully closed-loop system with ultra-rapid Lispro insulin|"The fully closed-loop system (CamAPS HX) will consist of:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm~Cloud upload system to review CGM/insulin data.~Participants will use ultra-rapid Lispro insulin in the closed-loop system"
9677151|NCT04977908|Active Comparator|Standard insulin pump therapy with CGM|"Participants will use their own insulin pump and usual insulin throughout this study period.~The CGM will be the Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)"
9677152|NCT04978012|Experimental|Combination of Fluzoparib and Camrelizumab|Fluzoparib,150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w
9677153|NCT04977843|Experimental|E-BAL|E-BAL carried out within 48 hours
9677154|NCT04977843|No Intervention|Conservative/Control|Standard of care management
9677155|NCT04977856|Experimental|Guided ICBT|Participants in guided ICBT will receive internet-delivered CBT with therapist support. The treatment consists of 8 online modules with interactive features such as videos and illustrations, delivered over a maximum of 10 weeks. The main treatment focus is behavioral activation. The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The caregiver's program also consists of 8 chapters, including psychoeducation about depression and how to support their adolescent in treatment. The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support.
9677156|NCT04977856|Experimental|Self-guided ICBT|The self-guided arm is identical to the guided arm, however without the therapist support. To ensure patient safety, there will be clear instructions to the patients and primary caregivers on how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
9677157|NCT04977856|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical, or a combination of both. The content of TAU and the treatment techniques used will be monitored.
9827777|NCT02467777|Active Comparator|Conductive Warming|VitaHeat
9677158|NCT04977869|Active Comparator|RIC+Standard medical treatment|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days after mechanical thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
10174842|NCT03849157|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
10174843|NCT03849118|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.
10174844|NCT03849170|Experimental|Psychological Intervention|Six session intervention, each session 20-25 minutes in length. Stress inoculation technique-based intervention. Participants will be taught stress coping skills and relaxation skills such as self-efficacy statements, imagery, relaxation breathing, relaxation scripts, thought stoppage, cognitive reframing, positive self-talk, goal setting, event planning, and preparing for competition
10174845|NCT03849170|Placebo Comparator|Health Intervention|Six session intervention, each session 20-25 minutes in length. Participants will be taught relevant health and nutrition guidelines and practice using a food diary app (MyFitnessPal). Nutrition and health content will include such topics as reading Canadian food labels, vitamins and supplements, effects of alcohol on performance and recovery, vegetarian vs. omnivore diets, and hydration & performance.
10174846|NCT03848975|Experimental|Simulation training for ECV|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the Control group for VE : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
9677159|NCT04977869|Placebo Comparator|Sham RIC+Standard medical treatment|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days after mechanical thrombectomy. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
9677160|NCT04977882|Experimental|Abdominal drainage|19 Fr abdominal drainage placed intraoperatevely in right paracolic gutter
9677161|NCT04977882|Experimental|Postoperative antibiotico-prophylaxis|postoperative antibiotico-prophylaxis with Ceftriaxone 2gr and Metronidazole 1.5gr
9677162|NCT04977882|No Intervention|Control group|No drainage nor postoperative antibiotico-prophylaxis
9677163|NCT04977596||Group PNETs|The investigators retrospectively analyzed data for patients who underwent contrast-enhanced MDCT for the evaluation of G3 PNETs at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 12) between January 2011 and May 2019, patients with G3 PNET who underwent MDCT at the First Affiliated Hospital of Zhejiang University School of Medicine (n = 4) and the Military Medical University of Air Force (The Fourth Military Medical University) (n = 4) between January 2013 and October 2018
9677164|NCT04977596||Group PDAC|Patients with PDAC who underwent MDCT at the Second Affiliated Hospital of Zhejiang University School of Medicine (n = 58) from February 2014 to August 2015.
9677165|NCT04977570|Experimental|SYHA1805|subjects will be randomized to receive multiple ascending doses of SYHA1805 tablets.
9677166|NCT04977570|Placebo Comparator|Placebo|subjects will be randomized to receive the matching placebo tablets.
9677167|NCT04977661|Active Comparator|Group1|Group I (n = 34) received 400 IU Vitamin E (Vitamin E 400 IU®, MEPACO Pharmaceutical Company, Sharqia, Egypt) twice daily for 3 month
9677168|NCT04977661|Active Comparator|Group2|Group II (n =34) received 250 mg Ursodeoxycholic acid (Ursofalk 250 mg®, MINAPHARM Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
9677169|NCT04977661|Active Comparator|Group3|Group III (n = 34) received 400 mg sustained release (SR) Film-Coated Tablets of pentoxifylline (Trental 400 mg®, SANOFI Pharmaceutical Company, Cairo, Egypt) twice daily for 3 months
9677170|NCT04977739||those with a condition|
9677171|NCT04977739||those without a condition|
9677172|NCT04977700|Experimental|Intervention Group|Participants will be enrolled on a rolling basis and participate in SS for 4 months in the intervention condition. After pretesting, participants will receive sun protection messages from SS through emails/comments based on algorithm results from their profile and activity data. All participants will complete posttest survey 4 months from randomization.
9677173|NCT04977700|No Intervention|Control Group|A small control group will be included to see if a no-treatment control condition is acceptable to users and estimate follow-up rates for planning a randomized trial. Participants will be enrolled on a rolling basis and will complete a pretest at randomization. All participants will complete a posttest survey 4 months from randomization.
9677174|NCT04977622||Primary Progressive MS (PPMS)|Clinically definite MS patients with identified primary-progressive disease onset, within 10 years of diagnosis
9677175|NCT04977622||Non-neurological controls (HC)|Age and sex matched to the PPMS patients
9677176|NCT04977713|Experimental|Acupressure group|In the acupressure uterine contractions were checked before the care application began. Acupressure was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
9827778|NCT02467842|Experimental|NBP607-QIV|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
10174847|NCT03848975|Experimental|Simulation training for VE|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the the control group for for ECV : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
9677177|NCT04977713|Experimental|Shower Group|The shower group, uterine contractions were checked before the care application began. A shower was applied when the women's cervical dilation reached 4-5 cm, 6-7 cm and 8-10 cm. This method was applied 18 times during uterine contractions. The application stopped at the end of each contraction and resumed once another contraction started. No application was performed between contractions.
10174848|NCT03849014|Active Comparator|Dynamic Hip Screw|Dynamic Hip Screw is used for internal fixation of fractures of the certain types of hip fractures. The implant assembly consisting of a lag screw, a side plate, and cortical screws that fix the side plate to the proximal femoral shaft.
10174849|NCT03849014|Active Comparator|Proximal Femoral Nail|The Proximal Femoral Nail offers osteosynthesis for the several types of hip fractures. It consists of an anatomically curved nail, double neck screw, and two locking screws for distal end.
10174850|NCT03849027|Experimental|Methoxyflurane|"Inhaled methoxyflurane once-off dose of 3 ml will be administered via the inhaler at each dosing visit .~Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®)."
10174851|NCT03849027|Sham Comparator|Sham Methoxyflurane|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test
9677178|NCT04977713|No Intervention|Control group|The women in the control group underwent routine hospital care. They were administered neither pharmacological nor nonpharmacological methods to reduce labour pain.
10174852|NCT03848897|Experimental|Non falling elderly|
10174853|NCT03848897|Experimental|Falling elderly|
9677179|NCT04977726|Experimental|STRIVE - Simulation Training for Resilience in Various Environments|
9677180|NCT04977726|Sham Comparator|Control|
9677181|NCT04978051|Active Comparator|Standard of Care (SoC)|
9677182|NCT04978051|Experimental|SoC + Icatibant|
9677183|NCT04977427|Active Comparator|Prednisolone Arm|Standard post-cataract surgery therapy arm; acts as control in each patient.
9677184|NCT04977427|Active Comparator|Dextenza Arm|Investigational arm to compare the effectiveness of the Dextenza insert to standard therapy.
9677185|NCT04977336|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
9677186|NCT04977336|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
9975704|NCT01344031|Experimental|Arm A (anastrozole and Akt inhibitor MK2206)|"Patients receive anastrozole PO on days 1-28. Beginning in course 2, patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
10174854|NCT03848897|Experimental|Non falling patients with Parkinson's disease|
9527629|NCT03218176|Experimental|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
9677187|NCT04977336|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
9677188|NCT04977544|Active Comparator|drug only|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
9677189|NCT04977544|Experimental|vert combine with drug|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
9677190|NCT04977258|Active Comparator|Control group|Only treadmill aerobic exercise with 60 min recovery in supine position.
9677191|NCT04977258|Experimental|Controlled hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water predetermined intake.
9677192|NCT04977258|Experimental|Ad Libitum hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water intake in an uncontrolled manner.
9677193|NCT04977401|Sham Comparator|Group Glycerol|Submucosal injection using glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
9677194|NCT04977401|Active Comparator|Group Gel ORISE|Submucosal injection using ORISETM gel during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
9677195|NCT04977219||Prism Adaptation Training;|Patients who received prism adaptation training for treatment of spatial neglect during their inpatient rehabilitation admission
9677196|NCT04977219||Standard Care|Patients who received standard treatment of spatial neglect during their admission
9677197|NCT04977440||standard protein|
9677198|NCT04977440||high protein|
9677199|NCT04977505||Pushlock|Patients with recurrent shoulder dislocation received surgery fixed by pushlock
9677200|NCT04977505||Gryphon|Patients with recurrent shoulder dislocation received surgery fixed by Gryphon
9677201|NCT04977518||Patients diagnosed during 2008-2011|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2008-2011
10174855|NCT03849261|Experimental|Group 1|"Period 1: D635~Period 2: CKD-387"
10174856|NCT03849261|Experimental|Group 2|"Period 1: CKD-387~Period 2: D635"
10174857|NCT03849079|Experimental|Hyponut|
10187156|NCT03728998|Other|PLR & Clearsight measurements|All patients 16years or older presenting to the ED with uncomplicated sepsis (see inclusion and exclusion criteria) will undergo a Passive Leg Raise (PLR, non-invasive) and multiple measurements by the Clearsight non-invasive hemodynamic monitoring system. Followed by a fluid challenge (common practice; non interventional)
10187157|NCT03728959|Experimental|Liquid meal (Nutridrink)|Liquid meal (Nutridrink)
10187158|NCT03728959|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
9677202|NCT04977518||Patients diagnosed during 2012-2015|Patients diagnosed with definite and probable infective endocarditis defined according to the modified Duke clinical criteria during 2012-2015
9677203|NCT04977284|Experimental|TCSCS|
9677204|NCT04977492||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
9677205|NCT04977492||control group|People suffered from excessive lateral pressure syndrome with conservative treatment.
9677206|NCT04977557|Other|single arm|"its a quasi experimental study where single group is used (self controlled clinical trial).~clinical features were compared before iand after intervention"
9677207|NCT04977609|Experimental|VR+MUSIC|Upper limb repetitive training activities through the imitation of movements (i.e., unscrew the cap of a bottle, pour water into a glass, drink water from a glass, sugaring coffee, placing an object in a box) synchronized with a musical accompaniment (i.e., a selection of classical music pieces). Participants will wear a VR headset (Gear VR, Samsung) through which they will observe egocentric 180° 3D videoclips shot from a first-person perspective, as if the patient himself was performing the movement, while listening to music.
10174858|NCT03848819|Other|Control pursed lip breathing|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe adopting the pursed lip breathing technique. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
10187159|NCT03728959|Experimental|GLP-2|Glucagon-like peptide-2
9677208|NCT04977609|Experimental|VR|Upper limb repetitive training activities through imitation of movements, without any musical accompaniment. Participants will wear a VR headset through which they will observe egocentric 180° 3D silent videoclips.
9677209|NCT04977609|Active Comparator|TAU|Treatment as usual (TAU). Patients will be engaged in upper limb repetitive training activities through traditional physiotherapy rehabilitation.
9677210|NCT04977531||6 months less|Stroke onset less than 6 months
10187160|NCT03728959|Experimental|Placebo (saline)|Placebo (saline)
9677211|NCT04977531||6 months to 2 years|Stroke onset between 6 months and 2 years
9677212|NCT04977531||over 2 years|Stroke onset over 2 years
9677213|NCT04977323|Experimental|TICK-B group as intervention group|TICK-B group: The children will receive the pictures they want. They will be asked to trace and color the pictures that need coloring. The nurse will color with children during the procedure. And after the procedure, the child will take his or her picture which he colored during the procedure.
9677214|NCT04977323|Experimental|Watching cartoons|Watching cartoons: In this group, children will watch cartoons as they like. Watching will continue until the procedure is complete.
9677215|NCT04977323|Experimental|Group listening to music|Listening to music: In this group, children will listen to cartoon music as they like. Listen will continue until the procedure is complete.
9677216|NCT04977323|No Intervention|Standard care provided group as control group|Control group. The kids in this group will be allowed to keep their family near. The routine blood taking
9677217|NCT04977089||Ischemic heart disease patients .|Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.
9695256|NCT04779931|Experimental|Convoy-Pal Intervention|Intervention participants will be sent Convoy-Pal equipment and materials. The equipment can simply be removed from the box, plugged in, and turned on to start. Research staff will provide technical support as needed during the trial. Convoy-Pal is 12-week intervention that uses the Routinify platform to deliver self-management tools and palliative care resources in the participants' home. The platform includes a tablet, charging stand, and smart watch, with additional options for mobile phone access and a website portal.
9695257|NCT04779931|Active Comparator|Waitlist Control|Participants will complete baseline assessments and will be recontacted at 11 weeks to complete follow up assessments at week 12. Participants will receive a $25 gift card for each assessment ($50 total). If they would like to try the intervention at that time, we will send them Convoy-Pal equipment and materials. They will then have 12 weeks to use the tool.
9695258|NCT04779814||Cohort 1|Demipulse®/Aspire HC® (30 adult subjects)
10187161|NCT03728946|Experimental|Liposomal Bupivacaine Interscalene Block|Liposomal bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
9695259|NCT04779814||Cohort 2|Demipulse®/Aspire HC® (30 pediatric subjects)
9695260|NCT04779814||Cohort 3|Aspire SR® (30 adult subjects)
9695261|NCT04779814||Cohort 4|Aspire SR® (30 pediatric subjects)
9695262|NCT04779814||Cohort 5|SenTiva® (30 adult subjects)
9695263|NCT04779814||Cohort 6|SenTiva® (30 pediatric subjects)
9695264|NCT04780308||1 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 1 lateral K-wire
9695265|NCT04780308||1 medial 2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 1 medial 2 lateral K-wire
9695266|NCT04780308||2 medial 1 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 medial 1 lateral K-wire
9695267|NCT04780308||2 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 2 lateral K-wire
9695268|NCT04780308||3 lateral K-wire|Pediatric Gartland Type 3 supracondylar humeral fractures fixed by 3 lateral K-wire
9695269|NCT04780126||COVID-19 pneumonia patients|Patients over 18 years of age who are admitted to the hospital and whose main diagnosis and reason for staying is COVID-19 pneumonia will be included.
9695270|NCT04780191|Experimental|Active MyoRegulator® treatment|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
10187162|NCT03728946|No Intervention|Bupivacaine Interscalene Block|Bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
9677218|NCT04977388|Active Comparator|Northera™ (Droxidopa) (Treatment A)|Northera (Droxidopa) (Treatment A) will be provided to adult subjects as a capsule with 100mg, 200mg, or 300mg of Northera (Droxidopa) contained within gelatin color capsules (sky blue and white, size 0) based on findings from the dose titration visit. These capsules are physically indistinguishable from the Treatment B (placebo) capsules. Frequency of administration (by mouth) will be twice daily for six weeks.
9677219|NCT04977388|Placebo Comparator|Placebo (Treatment B)|Empty gelatin color capsules (sky blue and white, size 0) filled with cellulose microcrystalline and physically indistinguishable from Treatment A capsules. Frequency of administration (by mouth) will be twice daily for six weeks
9677220|NCT04977206|No Intervention|No Intervention|Patients receiving usual care
9677221|NCT04977206|Experimental|Intervention|Patient's receiving care following nurse education on mutual goal-setting
9677222|NCT04977128|Experimental|Experimental：89Zr-KN035 injection|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
10174859|NCT03848819|Experimental|pNIV|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe via the VitaBreath device. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
10174860|NCT03849066||Part 1: Cross-Sectional PRSA|This will be a cross-sectional analysis of 300 children with neurological impairment and polypharmacy.
10174861|NCT03849066||Part 2: Longitudinal PRSA|This will be a 12-month prospective cohort study of 50 children with neurological impairment and polypharmacy.
10174862|NCT03848962||Subjects for observational study|Various conditions & healthy subjects
10174863|NCT03849092|Experimental|Financial incentive|3 municipalities will receive 120.000 DKK for financial incentives.
9677223|NCT04976920||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation."
9677224|NCT04976985|Experimental|Interventional Group receiving Osteopathic Manipulative Therapy (OMT)|70 patients with chronic migraine who consent to OMT will receive four standardized osteopathic manipulative treatment protocol over the course of twelve weeks at week 0,2,6,10. MIDAS and HIT-6 Questionnaires will be obtained at time of consent prior to first treatment and again at the conclusion of treatment period of twelve weeks.
9677225|NCT04976985|Other|Control Group with Standard of Care|70 patients with the diagnosis of migraine headache who are receiving the standard of care medications will complete a MIDAS and HIT-6 questionnaire at week 0 and week 12. A new prophylactic medication may be started at time of initial questionnaires and the patient can be on up to two prophylactic medications, with no changes during the 12 week period.
9677226|NCT04976998||patients|those with symptoms of CTS
10174864|NCT03849092|Experimental|Campaigns|3 municipalities will receive 120.000 DKK for campaigns.
10174865|NCT03849092|No Intervention|Control|"6 clean control municipalities perform their smoking cessation activities as usual. They wont receive any financial resources. These muncipalities have not been randomly selected but have been matched (by number of smokers attending the smoking cessation groups in the municipality in 2017, the year before the intervention). 3 of them are Campaing Control group and 3 are Finacial Incentives Control group."
9677227|NCT04976998||control group|normal people those with no symptoms of CTS
9677228|NCT04977011|Experimental|experimental group|30 minutes music intervention for 3 days on bedside
9677229|NCT04977011|No Intervention|control group|usually care
9975705|NCT01344031|Experimental|Arm B (Akt inhibitor MK2206 and anastrozole)|"The RPTD of Akt inhibitor MK2206 with anastrozole is determined after 3 courses, administered as in Arm A.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
9975706|NCT01344031|Experimental|Arm C (Akt inhibitor MK2206 and fulvestrant)|"Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, fulvestrant IM on day 1and day 15 of course 1 and then on day 1 of each course in each subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
10174866|NCT03849053|Experimental|Mézières method|
10174867|NCT03849053|Active Comparator|Control Group|
10174868|NCT03848637|Experimental|Group 1|"Period 1: D387 (reference drug)~Period 2: CKD-387 (test drug)"
10174869|NCT03848637|Experimental|Group 2|"Period 1: CKD-387 (test drug)~Period 2: D387 (reference drug)"
10174870|NCT03848611|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
10174871|NCT03848767|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
9975707|NCT01344031|Experimental|Arm D (Akt inhibitor MK2206, anastrozole, fulvestrant)|"Patients receive Akt inhibitor MK2206 PO as in Arm A, anastrozole PO on days 1-28 and fulvestrant IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
10174872|NCT03848806|Experimental|HAT1 topical|HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
10174873|NCT03848806|Active Comparator|Calcipotriol|Calcipotriol topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
9677232|NCT04977102|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
9677233|NCT04977102|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
9677234|NCT04977193|Experimental|Treatment group|
9677235|NCT04977115|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
9677236|NCT04977115|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
9677237|NCT04977141||Under-represented minority|Non-English speaking and/or non-White
9677238|NCT04977141||Non-under-represented minority|English-speaking and/or White
9677239|NCT04976803||Group A|Deceased patients with archival tissue
9677240|NCT04976803||Group B|Living patients with archival tissue
9677241|NCT04976803||Group C|Living patients without archival tissue
9677242|NCT04976816|Experimental|A1 peri-levator betamethasone injection|patients with isolated thyroid-related upper lid retraction who will be given the Peri-levator injection of betamethasone suspension
9677243|NCT04976816|Experimental|A2 Peri-levator triamcinolone acetate injection|patients with isolated thyroid-related upper lid retraction who will be given Peri-levator injection of triamcinolone acetate
9677244|NCT04976816|Experimental|B1 Peri-levator and retrobulbar betamethasone injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of betamethasone suspension
9677245|NCT04976816|Experimental|B2 Peri-levator and retrobulbar triamcinolone acetate injection|patients with thyroid-related upper lid retraction and proptosis who will be given Peri-levator and retrobulbar injection of triamcinolone acetate
10174874|NCT03848884|Experimental|Adherence monitoring and education|
10174875|NCT03848936||adult cerebral palsy patients|>18 age cerebral palsy diagnosed patients evaluated with a survey.
10174876|NCT03848793|Other|HS-20004 or placebo treatment (Low dose)|HS-20004 or placebo SC once daily (Low dose)
9677247|NCT04976673|Experimental|photodynamic therapy side|On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2
9677248|NCT04976673|Active Comparator|Steroid side|on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
10174877|NCT03848793|Other|HS-20004 or placebo treatment (median dose 1)|HS-20004 or placebo SC once daily (median dose 1)
10174878|NCT03848793|Other|HS-20004 or placebo treatment (median dose 2)|HS-20004 or placebo SC once daily (median dose 2)
10174879|NCT03848793|Other|HS-20004 or placebo treatment (high dose)|HS-20004 or placebo SC once daily (high dose)
10174880|NCT03848624|Experimental|Cycling Group|Intention driven motor-assisted voluntary cycling with electrical stimulation
9677249|NCT04976660|Experimental|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-4 is determined
9677250|NCT04977076|Active Comparator|Interrupted NOAC use (group 1)|Patients in group 1 will receive standard care. Therefore, DOAC use will be interrupted at least 24 hours in advance of ICA or PCI. Based on the renal clearance, last DOAC intake may be extended to 48 hours prior to the procedure [Table 2]. After the procedure, patients will continue using their DOAC as usual.
9677251|NCT04977076|Experimental|Uninterrupted NOAC use (group 2)|In group 2, all patients will continue to use their specific DOAC as usual. This means that no adjustments of DOAC use will be made before and after ICA or PCI. After the procedure patients will continue to use DOAC from the next planned dose.
9695271|NCT04780191|Sham Comparator|Sham MyoRegulator® treatment|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
10174881|NCT03848598||Responders|Patients suffering from patellar tendinopathy who have complete pain resolution after performing isometric exercises.
10174882|NCT03848598||Non-responders|Patients suffering from patellar tendinopathy who do not have complete pain resolution after performing isometric exercises.
10174883|NCT03848702|Experimental|Healthy volunteers|All volunteers wore the DRFB
10174884|NCT03848702|Experimental|Patients with DRF|All patients wore the DRFB
10174885|NCT03848741|Placebo Comparator|Non-exercise control with placebo|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the β-hydroxy β-methylbutyrate (HMB) Plus Vitamin D (VitD) capsules.
10174886|NCT03848741|Experimental|Non-exercise control with HMB+VitD|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
9677252|NCT04976751|Experimental|Electrophysiological treatment group|Two electrodes covered the two acupoints of Zhongliao and Huiyang, one electrode covered the three acupoints of Zhongji, Guanyuan and Qihai, and two skin paste electrodes covered the three acupoints of Sanyinjiao, and connected the electric stimulation therapy instrument for 30 minutes. The intensity was based on the patient's tolerance. 4 weeks before the course of treatment, the treatment was performed once a day, 3 times a week.In the last 4 weeks, 20 times were performed twice a week.Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
9677253|NCT04976751|No Intervention|Regular treatment group|Fluoroquinolones and alpha blockers were administered according to the patient's symptoms.
10174887|NCT03848741|Active Comparator|Resistance exercise training with placebo|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the HMB + VitD capsules.
10174888|NCT03848741|Experimental|Resistance exercise training with HMB+VitD|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
9677254|NCT04976764||liver cirrhosis with cirrhotic cardiomyopathy|
9677255|NCT04976764||liver cirrhosis without cirrhotic cardiomyopathy|
9677256|NCT04977154||Trainers|
10174889|NCT03848585|Experimental|Pilloxa Pillbox|
9677257|NCT04976959|Experimental|Parkinson's patients|Parkinson's patients who will receive a high fiber supplement
9677258|NCT04976959|No Intervention|Control subjects|no supplement will be given
9677259|NCT04976972|Experimental|Robotic-Total Knee Replacement (R-TKR)|NAVIO/CORI Surgical System
9677260|NCT04976972|Active Comparator|Conventional-Total Knee Replacement (C-TKR)|Non-robotic conventional instrumentation
9677261|NCT04977050||Intervention Site|All miners in the New Mexico intervention mine site who will be administered nasal swabs for antigen testing every other work shift, and serological testing 3 months.
9677262|NCT04977050||Controled site|All miners in the Wyoming Control mine site who will be administered serological testing 3 months.
9677263|NCT04976543|Experimental|Anticoagulation group|low molecular weight heparin subcutaneously every 12ths for 6 months or for 14 days followed by warfarin orally with a initial dosage of 3mg daily for 5.5 months
9677264|NCT04976543|No Intervention|control group|no anticoagulation therapy
10174890|NCT03848585|Sham Comparator|Non active Pilloxa Pillbox|
10174891|NCT03849001|Experimental|Exercise Conditions|"Participants will undergo four Exercise Conditions (i.e., light intensity leg cycling, moderate intensity leg cycling, vigorous intensity leg cycling, and a seated, quiet rest) in a randomized, counterbalanced order."
9677265|NCT04976608||Group 1|The BCVA of eyes is greater than 0.6
10174892|NCT03848559|Experimental|Airway device placement|airway device is placed during the dive
10174893|NCT03848494||Gastroesophageal reflux disease|Patients submitted to primary minimally invasive surgery for gastroesophageal reflux disease or hiatus hernia
9677266|NCT04976608||Group 2|The BCVA of eyes is from 0.1 to 0.6
9677267|NCT04976608||Group 3|The BCVA of eyes is less than 0.6
9677268|NCT04976829||adult (≥ 18 years) inpatients (hospitalised ≥ 48h)|
9677269|NCT04976855|Placebo Comparator|Part I: Placebo|Healthy volunteers will receive placebo once daily for 7 days.
9677270|NCT04976855|Experimental|Part I: INDV-2000|Healthy volunteers will receive INDV-2000 once daily for 7 days.
9677271|NCT04976855|Placebo Comparator|Part II: Placebo|Healthy volunteers will receive placebo once daily for 28 days.
9677272|NCT04976855|Experimental|Part II: INDV-2000|Healthy volunteers will receive INDV-2000 once daily for 28 days.
9677273|NCT04976855|Experimental|Part III: INDV-2000 + SUBOXONE|Participants with opioid use disorder will receive SUBOXONE sublingual (SL) film for 6 days during the run-in period. Participants will then receive SUBOXONE SL film alone for 2 days, then SUBOXONE SL film and INDV-2000 for 7 days followed by INDV-2000 dosing alone for 4 days.
9677274|NCT04976842|Active Comparator|Opioid-free anesthesia|Opioid free anesthesia protocol for urological procedurs
9677275|NCT04976842|Active Comparator|Opioid-based anesthesia|Opioid based anesthesia protocol for urological procedures
9677276|NCT04976907||Perioperative patients|Patients undergoing perioperative assessment of vital signs.
9677277|NCT04976413|Experimental|Experimental|Experimental arm will receive eight phase EMDR treatment using standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12 -14 weeks . Follow up will be conducted after 12 weeks of treatment completion.
9677278|NCT04976413|Active Comparator|Control|Control group will receive treatment as usual (supportive counselling) for 12 -14 weeks
9677279|NCT04976465||combined with aPL(+)|the antiphospholipid antibodies appear in blood at least once
9677280|NCT04976465||combined with aPL(-)|the antiphospholipid antibodies never appear in blood
9975708|NCT01344044|Active Comparator|BCI treatment|BCI treatment will commence during the week of the Baseline.
9677281|NCT04976348||Consenting participants|All subjects aged ≥16 years referred to the cardiology outpatient clinic of the MUMC+ for heart failure like symptoms (as stated in the ESC 2016 Guidelines) and/or for cardiac screening are eligible for inclusion.
9677282|NCT04976400|Experimental|test group|Semi-individualized total knee arthroplasty
9677283|NCT04976400|Active Comparator|Control group|Zimmer standard prosthesis total knee replacement
9677284|NCT04976569|Experimental|DBS Regulation Group|All participants will receive STN-DBS sleep regulation.
9677285|NCT04976881|No Intervention|Usual Care|Usual care includes: 1) no specific materials to promote medication reconciliation, reproductive planning, or patient education on diabetes self-management within the context of preconception care, 2) variable physician preconception counseling without any EHR notifications or counseling support; and 3) no specific patient support or prompts to promote healthy behaviors post-visits.
9677286|NCT04976881|Active Comparator|PREPARED Strategy|Our PREPARED strategy will utilize health information and consumer technologies to 'hardwire' preconception care and promote diabetes self-management among reproductive-aged, adult women with T2DM in primary care. PREPARED will leverage electronic health record technology at clinic visits to: [1] promote medication reconciliation and safety, [2] prompt provider preconception counseling, and [3] deliver low literacy print tools to reinforce counseling and promote diabetes self-care. Post-visit, text messaging will be used to: [4] encourage healthy lifestyle behaviors.
9677287|NCT04976504||Oxygen reserve index|Male and female patients aged 18 to 80 years with ASA physical status I to III scheduled for elective surgery with planned arterial catheter placement before induction of general anesthesia and did not match the exclusion criteria.
9677288|NCT04976478||observation group|All patients will be treated with Nimotuzumab combined with radiotherapy.
9677289|NCT04976582|Experimental|interventional group|experimental group in which dry needling with conventional physical therapy treatment modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
9677290|NCT04976582|No Intervention|control group|control group in which kinesiotaping with conventional physical therapy treatment (modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
9677291|NCT04976517||non-diabetes group|patients who underwent heart tranplantation without diabetes
10174894|NCT03848728|Experimental|Intervention Clinics|SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
10174895|NCT03848728|No Intervention|Control Clinics|Optimized country standard of care
9677292|NCT04976517||pre-transplant diabetes group|patients who underwent heart tranplantation with diabetes before the transplantation
9677293|NCT04976517||post transplant daibetes group|patients who underwent heart tranplantation without diabetes until after the transplantation
9677294|NCT04976439||Age|
9677295|NCT04976439||Grade|
9677296|NCT04976439||Tumor location|
9677297|NCT04976439||Stage|
9677298|NCT04976439||Lymphovascular invasion|
9677299|NCT04976114|No Intervention|Control group|Standard of care
9677300|NCT04976114|Experimental|story book|Parents read a book with the chid previous to surgery.
9677301|NCT04976114|Experimental|video|Parents watch a video with the chid previous to surgery.
9677302|NCT04976114|Experimental|both instrument|Parents read a book and watch a video with the chid previous to surgery.
10174896|NCT03848507|Experimental|20% Albumin|Administration of 3ml per kg bodyweight of 20% albumin within 30 min during cystectomy.
10174897|NCT03848546|Experimental|PDA|Intervention group: receives the personalized dietary advice
9677303|NCT04976335|Active Comparator|Versawrap|
9677304|NCT04976335|No Intervention|No Versawrap|
10174898|NCT03848546|Active Comparator|Control|Receives the general advice (two flyers containing information about fiber intake)
10174899|NCT03848533|Experimental|melatonin plus metformin|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before bedtime) per 90 days."
10174900|NCT03848533|Active Comparator|metformin plus placebo|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate homologated placebo once a day in the night (before bedtime) per 90 days."
9677305|NCT04976140|Experimental|Low dose group|The investigational product is intravenously administered according to the planned dose.
9677306|NCT04976140|Experimental|Intermediate dose group|The investigational product is intravenously administered according to the planned dose.
9677307|NCT04976140|Experimental|High dose group|The investigational product is intravenously administered according to the planned dose.
9677308|NCT04976361|Experimental|Diabetic Patients with PDR|PRP for each diabetic patient included in this study.
9677309|NCT04976075||Adults|Patients of 18 or more years old
9677310|NCT04976075||Pediatrics|Patients less than 18 years old
9677311|NCT04976205|Experimental|TMI/TMLI|"The standard planning optimization for TMI/TMLI preview a two-free-breathing-CT scan without contrast will be performed for simulation at day -15(-10) to the BMT. The same day a WB-MRI will be acquired for lymph-nodes delineation. WB-MRI scans will be performed using a 1.5T MR scanner. The two CT will be co-registered to the WB-MRI.~CTV will be manually defined as the bones excluding mandible and hands (CTVBones), the spleen (CTVSpleen), and lymph nodes (CTVLN) using both MRI and CT images. The day -3 (4) to the BMT, further two-CT series will be acquired and co-registered to the first CTs for dose verification. Pre-treatment quality assurance (QA) will be performed the day before the treatment using the standard internal procedure.~The treatment will be performed the day before the BMT."
9677312|NCT04976088|Experimental|Group A Test|Test product: treated once a day (morning) with the medicated plaster containing 140 mg Diclofenac Sodium for seven days Diclofenac Sodium 140 mg medicated plaster
9695272|NCT04780074|Active Comparator|Standard product (SP): USP CoQ10 powder, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
10174901|NCT03848533|Experimental|melatonin plus placebo|"It will be indicate homologated placebo once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before sleep) per 90 days."
10174902|NCT03848390|Experimental|Modified Time-restricted Feeding|
10174903|NCT03848390|Active Comparator|Conventional diet|
10174904|NCT03848520||Total Knee Arthroplasty|Internal Registry of Patients having a TKA and with a high (>=9) activity-scale score at anytime between preoperatively and now.
9677313|NCT04976088|Active Comparator|Group B Reference|Reference product: treated once a day (morning) with the medicated plaster containing DIEP 180 mg, Flector® for seven days Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®
9677314|NCT04976088|Placebo Comparator|Group C Placebo|Placebo: treated once a day (morning) with the placebo plaster for seven days
9677315|NCT04975854|Experimental|Virtual Reality Exposure|Participants complete three 30-40-minute sessions of exposure administered via a virtual reality headset. The exposure involve exposure to various heights and height cues in the virtual city environment. Experimental group also attends 20-minute online information session (prerecorded video).
9677316|NCT04975854|Other|Control|Control group attends a single 20-minute information session (prerecorded video) about general principles of exposure therapy and anxiety before the start of the study, but receives no exposure-based intervention.
10174905|NCT03848351|No Intervention|Control Group|70 patients not receiving oral hygiene instructions or devices and continuing with their routine oral hygiene habits
10174906|NCT03848351|Active Comparator|Test Group|"70 patients receiving intense oral hygiene instructions assisted by specific software or devices as well as oral hygiene (OH) tools (electric toothbrush, interdental floss, toothpaste) Thus, interventions will consist of.~Oral Hygiene Instruction (OHI)~Professional supragingival scaling and polishing"
10174907|NCT03848338|Other|Pilot Group|Intra and Post-operative Electrocochleography
9677317|NCT04975945|Experimental|Local|Participants will receive single-time intra-operative intra-dermal ceftriaxone (15-20mg/kg diluted in 10 ml normal saline)
10174908|NCT03848442|Experimental|UPART intervention group|A 1-group pretest-posttest design was conducted. Outcomes were evaluated on four occasions; twice during baseline separated by six weeks and immediately following a 12-week 'uptime' participation intervention and after a further 12 weeks (follow-up).
10174909|NCT03848572|No Intervention|Usual care|Patients will enter standard 12-month clinical follow-up
10174910|NCT03848572|Experimental|Re-Score strategy|Patients will enter a novel strategy of 12-month follow with repetitive assessment of PRECISE-DAPT score at 3-month intervals
10174911|NCT03848650|Experimental|Opsens Medical OptoWire|Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
10174912|NCT03848182|Experimental|Gemcitabine with TT vaccine booster|Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT
9677318|NCT04975945|Active Comparator|Parenteral|Participants will receive parenteral ceftriaxone (15-20mg/kg) for prolonged duration as per local protocol
9677319|NCT04975763|Experimental|Soybean Oil|Consumption of study foods each day made with soybean oil
10174913|NCT03848468|Active Comparator|CH(conventional Hemorrhoidectomy)|conventional hemorrhoidectomy
10174914|NCT03848468|Experimental|LH (Ligasure Hemorrhoidectomy)|Ligasure hemorrhoidectomy
10174915|NCT03848780|Experimental|Desflurane Group|Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
10174916|NCT03848780|No Intervention|Control Group|No pharmacological preconditioning was implemented
9677320|NCT04975763|Placebo Comparator|Palm Oil|Consumption of study foods each day made with palm oil
10174917|NCT03848234|Experimental|A Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
9677321|NCT04975932||Study group: TACE+ICIs|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs
9677322|NCT04975932||Control group: TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
9975709|NCT01344044|Other|Wait-list control|BCI treatment will commence 8 weeks after Baseline
10174918|NCT03848234|Placebo Comparator|B Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
9677324|NCT04975776|Experimental|Sleep restriction therapy|Four group sessions delivered at the participants' primary health care centers once a week for 3 weeks and again after a 4-week pause. The first session will last for 2 hours and the other sessions for 1 hour.
9677325|NCT04975776|Active Comparator|Sleep hygiene|Participants in the active comparator group will receive a brochure with sleep hygiene advice from the primary health care center at baseline.
9677326|NCT04975971||Dextenza recepient|A Retrospective Review DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery
9677327|NCT04975568|Experimental|Therapeutic Exercise Controlled Through App With face-to-face|3 months treatment using app for HTEP and 6 people therapeutic exercise group every 15 days
10174919|NCT03848104||bone and joint infection treated with cefoxitin|patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
10174920|NCT03848117|Active Comparator|(DTF massage & Mill's manipulation)(Group 1)|For any given subject in group 1, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in 1st group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
10187163|NCT03728933|Experimental|2 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
9677328|NCT04975568|Active Comparator|Therapeutic Exercise Controlled Through App|3 months treatment using app for HTEP
9677329|NCT04975529|Experimental|Intervention Arm|Participants in intervention schools received access to daily, online after school programming, including live sessions with sports providers (via Zoom; rotating to provide exposure to multiple sports over the course of the intervention), weekly team meetings with a health coach (via Zoom), text-messages via the Remind app, and monthly delivery of Activity Kits with sports equipment, activity books, fresh produce, and incentives directly to their homes over 6-months.
9677330|NCT04975529|Experimental|Comparison Arm|Participants in comparison schools received access to the Game on Philly app with workout and sports content that could be used asynchronously, and received one activity kit delivery with sports equipment and a self-guided activity book at the start of the program.
9677331|NCT04975542|Experimental|Treatment Group|
9677332|NCT04975542|Sham Comparator|Sham Group|
9677333|NCT04975685|Experimental|TAU + SMART|Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
10174921|NCT03848117|Active Comparator|( Taping & MWM) (Group 2).|For any given subject in group 2, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
10174922|NCT03848273||Ischemic|questionnaire, physical-neurological examination, labor investigations, EEG
10174923|NCT03848273||Hemorrhagic|questionnaire, physical-neurological examination, labor investigations, EEG
10174924|NCT03848273||Control|questionnaire, physical-neurological examination, labor investigations, EEG
10174925|NCT03848364|Experimental|Hip Hop Stroke 2.0 intervention group|"Students in 4th and 5th grade will receive the intervention, Hip Hop Stroke 2.0, disseminated and implemented by local Stroke Centers - uses a framework of Child-Mediated Health Communication to make children stroke literate and then empower these stroke literate students with the tools required to successfully communicate actionable stroke knowledge (recognition of stroke symptoms and the urgency of calling 911) to their parents and grandparents at home."
10174926|NCT03848169|Experimental|Experimental group|Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.
10174927|NCT03848169|Sham Comparator|Control Group|Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.
9677334|NCT04975685|Sham Comparator|TAU + Sham training|Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
9677335|NCT04975685|No Intervention|TAU (treatment-as-usual)|Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
9677336|NCT04975711|Experimental|Sequence 1|Period 1: RLD2104 Period 2: HIP2105
9677337|NCT04975711|Experimental|Sequence 2|Period 1: HIP2105 Period 2: RLD2104
9677338|NCT04975724|Experimental|Group A Liposom Forte|Liposom Forte (2 ampoules of 28mg/2 ml) for 30 days + citalopram (10mg) for 90 days
9677339|NCT04975724|Placebo Comparator|Group B Placebo|Placebo (2 ampoules of 2 ml) for 30 days + citalopram (10mg) for 90 days
9677340|NCT04975633|Experimental|BodyPort Cardiac Scale|Patient will receive the Bodyport scale
9677341|NCT04975633|No Intervention|Control|Patients will receive usual care and no Bodyport scale
9677342|NCT04975659|Active Comparator|Nocebo|"We informed subjects in the N group a negative suggestion, using the following script: During the local anaesthetic injection, you are going to feel a sharp prick at your back; this is usually the painful part of the procedure"
9677343|NCT04975659|Placebo Comparator|Placebo|"We informed subjects in the P group a positive suggestion, using the following script: We will administer some local anaesthetic to numb your back; this will allow the procedure to be more comfortable and tolerable for you."
9677344|NCT04975503||Young Women|Young women, aged 18 to 50 years, with documented atherosclerotic cardiovascular disease
9677345|NCT04975503||Older Women|Older women, aged >50 years, with documented atherosclerotic cardiovascular disease
9677346|NCT04975477||Training cohort|A cohort was used to develop the novel score for predicting liver decompensation
9677347|NCT04975477||Validation cohort|A cohort was used to validate the performance of novel score for predicting liver decompensation
9677348|NCT04975477||Exploratory cohort|A cohort was used to study the diagnostic value of novel score for clinically significant portal hypertension
9695273|NCT04780074|Experimental|Investigational product 1 (IP1): CoQ10 in soybean oil, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
9677349|NCT04975451|Experimental|ADCb|Anlotinib (anlotinib 12mg qd p.o. d1-14/21day/cycle)and Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve [AUC] 6, intravenously every 3 weeks) for six cycles
9677350|NCT04975373|Other|study group|study group women in this group will receive intrauterine hyaluronic acid injection after operative hysteroscopy
9677351|NCT04975373|No Intervention|control group|women will not receive hyaluronic acid after operative hysteroscopy
9677352|NCT04975230|Experimental|Sleep Self-Management|The Sleep Self-Management Intervention involves an initial 50-minute face-to-face interactive session in a private location. Participants are asked to extend time in bed by 1 hour and consistently maintain the extension on both weekends and weekdays. Bedtimes and waketimes will be assessed to ascertain which time is most modifiable for the participant's lifestyle and routine. There will be weekly follow-ups and in-person 3-week booster sessions. Sleep reports generated by the actigraphy will be shared with participants with brief action planning and goal setting to address progress towards goal achievement. A need to revise plans for future weeks will be the booster sessions' major goal.
9677353|NCT04975230|No Intervention|Diabetes Self-Management Education|The Attention Control arm will receive Diabetes Self-Management Education at the initial consultation visit via in-person contact at T1. There will be weekly follow-ups and in-person 3-week sessions. A Diabetes Self-Management Tracking Form will be used to monitor the weekly acquisition of information and plans for the 6-week intervention and at the 3-month and 6-month data points.
9677354|NCT04975386|Active Comparator|spinal anesthesia|
9677355|NCT04975386|Active Comparator|lumbar plexus+sacral plexus block|
9677356|NCT04975360|Experimental|Caffeine|Administration of a time-controlled, pulsatile-release caffeine formulation (160 mg caffeine) at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
9677357|NCT04975360|Placebo Comparator|Placebo|Administration of a placebo formulation at 22:30. Participants are kept awake until 03:00 and then given a 4-hour sleep opportunity.
9677358|NCT04975490||SAPIENT = Sepsis ACLF patients|
10174928|NCT03848078|Other|Optical Coherence Tomography arm|In the intervention arm, OCT imaging is performed which will take about 3 minutes. The decision on the most adequate treatment strategy will be based directly on the OCT diagnosis, but only when there is certainty about the presence of BCC and BCC subtype according to the OCT diagnosis. A 'safety' biopsy will be performed after the OCT scan. In patients where the OCT diagnosis leaves doubt or it is certain that there is no BCC, a biopsy will be taken anyway and the treatment decision will be based on the result of this punch biopsy.
9677359|NCT04975490||PROACT = Portal mediators as ACLF Targets|
9677360|NCT04975490||ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts|
9677361|NCT04975243|Experimental|Unwanted Fine Facial Hair|Up to three (3) treatments with GentleMax Pro/ GentleMax Pro Plus TM for Laser Hair Removal
9677362|NCT04975282||Bottle Feeding|The bottle feeding method was being used in the NICU (1 January -31 December 2018).
10174929|NCT03848078|No Intervention|Regular care arm|In patients assigned to regular care, the result of punch biopsy will always be used to decide which treatment is most adequate. Therefore, a next consultation will be planned to discuss the outcome of the biopsy and the intended treatment strategy.
10174930|NCT03848065|Experimental|V114-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of V114 on Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
10174931|NCT03848065|Experimental|V114-IM|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
10174932|NCT03848065|Active Comparator|PCV13-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of pneumococcal 13-valent conjugate vaccine (PCV13) at Visit 1, 2, 3 and 5(approximately 3, 4, 5, and 12 to 15 months of age).
10174933|NCT03848299|Experimental|Experimental: Single Arm|All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.
10187164|NCT03728933|Experimental|3 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
10187165|NCT03728933|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
9677363|NCT04975282||Cup Feeding|The cup feeding method was being used in the NICU (1 January -31 December 2019).
9677364|NCT04975113|Experimental|Exercise group|Patients were given a progressive neuromuscular exercise program that included stabilization of the knee and hip joint . Green color elastic band was used in resistant exercises. When subjects used the green color Thera-Band®, they started with an easy length and increased relative to the Omni Scale .
9677365|NCT04975113|Experimental|Exercise and Taping group|"Patients in this group received the same exercises given in the exercise group for 12 weeks. In addition to these exercises, mechanical correction tape (5cm, Kinesio Tex Gold®) was applied for the knee and foot."
9677366|NCT04974983||A|Treatment without bevacizumab
9677367|NCT04974983||B|Treatment with bevacizumab
9677368|NCT04975022|Experimental|T group|
9677369|NCT04975022|Active Comparator|R group|
9677370|NCT04975126|Experimental|CatInfo tool + Face-to-face discussion with physician|audio-visual presentation (CatInfo tool) before face-to-face informed-consent discussion with the physician
9677371|NCT04975126|No Intervention|Face-to-face discussion with physician only|face-to-face informed-consent discussion with the physician only
9677372|NCT04975178|Experimental|MTBVAC|"Both MTBVAC and BCG vaccines are administered by intradermal route in the left deltoid region. One 0.05 mL reconstituted dose of MTBVAC will be defined based on the phase IIa results.~MTBVAC is manufactured by Biofabri. MTBVAC is formulated (1.5 - 8.5 x104 CFU/dose, 1.5 - 8.5 x105 CFU/dose or 1.5 - 8.5 x106 CFU/dose (to be selected) and presented as a lyophilised pellet in 20 dose vials (0.05 mL/dose, after reconstitution with sterile water for injection). MTBVAC vaccine will be released and distributed by BIOFABRI, and imported to the sites following approval by the local regulatory authority. MTBVAC vials should be stored in the site pharmacy between -20°C and -40ºC. A single vaccine vial will be used for each participant."
10174934|NCT03848130|Active Comparator|Knee Taping with Home Exercises (Group 1)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into knee taping group.Each subject in first group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
10174935|NCT03848130|Active Comparator|Lateral wedge insoles with Home Exercises (Group 2)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into lateral wedge insole group.Each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
9677373|NCT04975178|Active Comparator|BCG|"BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.~One 0.05 mL reconstituted dose of BCG contains 2.5 x 105 CFU. The control vaccine will be the BCG vaccine available and recommended in South Africa at time of the trial.~BCG vaccine produced by AJ Biologics (formerly Staten Serum Institute) is the only BCG vaccine (Danish strain) currently licensed for routine use in South Africa. The recommended BCG injection volume for newborn infants (0.05 mL, after reconstitution with BCG diluent) contains approximately 2.5 x 105 CFU (range 1-4 x 105 CFU). BCG vaccine vials should be stored in the site pharmacy at 2-8ºC."
9677374|NCT04975048|Experimental|Group A|Group A was consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. And it was first assigned egg yolk intervention during intervention period 1, and then macronutrient equivalent control during intervention period 2
9677375|NCT04975048|Other|Group B|Group B was also consisted of 16 rs2236513/rs2297508/rs4925119 C/G/G carriers and 16 AA/CC/AA homozygotes. It was first assigned macronutrient equivalent control during intervention period 1, and then egg yolk during intervention period 2
9677376|NCT04975750|Experimental|Problem solving intervention|Problem solving as developed by Nexu and colleguages. First-line managers are trained in the problem solving intervention (1 1/2 day). Thereafter, they apply the problem-solving in 2 - 5 meetings (about 30 - 45 min each) with employees at risk of future sick leave due to common mental disorders.
9677377|NCT04975750|Active Comparator|Care as usual|First-line managers participate in a 3 hour lectur including a brief overview about worker health, occupational stress and the mismatch model and self-efficacy. Thereafter, they provide care-as-usual to employees at risk of future sick leave due to common mental disorders.
9677378|NCT04975035|Experimental|Zolodine group|
9677379|NCT04974931|Active Comparator|Patients applied with PREVENA system|This arm relates to the group of participants applied with PREVANA system post reversal of colostomy/ileostomy.
9677380|NCT04974931|No Intervention|Patients applied with conventional dressings|This arm relates to the group of participants applied with conventional dressings post reversal of colostomy/ileostomy
9677381|NCT04975412||acne vulgaris group (cases)|Filipino patients, aged 18-25 years old with diagnosis of Acne Vulgaris
9677382|NCT04975412||control group|healthy Filipino patients, aged 18-25 years old
10187166|NCT03728907|Active Comparator|Audiologist-adjusted first|This arm will complete the field trial with the audiologist-adjusted fitting first, followed by the user-adjustment fitting.
10187167|NCT03728907|Experimental|User-adjusted first|This arm will complete the trial with the user-adjusted fitting first followed by the audiologist-adjusted fitting.
9677383|NCT04975165|Experimental|Staged total knee arthroplasty|Staged replacement of both knees in two separate surgeries.
9677384|NCT04975165|Experimental|Simultaneous total knee arthroplasty|Simultaneous replacement of both knees in a single surgery.
9677385|NCT04975321|Active Comparator|Nu Smile Zirconia crown|Anterior primary teeth which received a NuSmile zirconia crown as a final restoration
9677386|NCT04975321|Active Comparator|Nu Smile pre veneered crown|Anterior primary teeth which received a NuSmile pre veneered crown as a final restoration
9677387|NCT04975321|Active Comparator|Composite strip crown|Anterior primary teeth which received a composite strip crown as a final restoration
9677388|NCT04975074|Experimental|Anemia Correction Group|Continue to take the current medication orally at the current dose
9677389|NCT04975074|Experimental|Anemia uncorrected group|Continue to take the current medication orally at the current dose
9677390|NCT04974918|Experimental|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of Lip defects|participants will be chosen according to liable age and information will be given about complications
9677391|NCT04975009|Experimental|PTSD group|Participants will be screened and diagnosed using typical screening procedures and diagnostic criteria (e.g., the clinically administered PTSD scale). Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
9695274|NCT04780074|Experimental|Investigational product 2 (IP2): Q-Gel hydrosoluble/bioenhanced CoQ10, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
9695275|NCT04780074|Experimental|Investigational product 3 (IP3): Qunol Mega Ubiquinol, softgels|100 mg per softgel; dosage: 2 softgels - 200 mg total CoQ10
9527630|NCT03218241|Experimental|PRT0064445 Dose 1|Dose 1 versus Placebo
9527631|NCT03218241|Experimental|PRT064445 Dose 2|Dose 2 versus Placebo
9677392|NCT04975009|Experimental|Healthy control group|Participants will be healthy adults without a history of psychiatric illness. Participants also screened for contraindications for MRI. The learning paradigm inside the MRI scanner occurs over 3 days. The first two days are consecutive (back-to-back) and the third MRI visit is 1 month later. Participants are asked to look at a screen and listen to simple tones over headphones, while the experimenter measures brain activity and physiological measures of arousal (e.g., sweating from sensors on the hand). These visits will be scheduled within two weeks from the baseline and assessment visit.
9677393|NCT04974905|Other|patients with infrainguinal arterial occlusive disease after failed antegrade approach|
9677394|NCT04974957|Experimental|SHR-1701+BP102|
9677395|NCT04975087||Patients group|Individuals with primary Sjögren's syndrome
9695276|NCT04780074|Experimental|Investigational product 4 (IP4): HydroQsorb Coenzyme Q10, hard capsules|100 mg per capsule; dosage: 2 capsules - 200 mg total CoQ10
9695277|NCT04779853||Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM|serum samples will be taken and tested by enzyme-linked immunoassay (ELISA) using the SAVYON SeroPertussisTM kits (Savyon Diagnostics Ltd, Israel).
9695278|NCT04779892|Experimental|CMAB008|
9695279|NCT04779892|Active Comparator|Remicade|
9695280|NCT04780152|Experimental|tDCS arm|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
9695281|NCT04780152|Placebo Comparator|Control arm|Participant receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS) + fluoxetine (10 mg daily 2 weeks followed by 20 mg daily).
9695282|NCT04780282|Experimental|Scapular Stabilization Group|In the study, Adalar Water Sports Club (AWSK) takes places with its A team players; 15 players aged from 16-25 as the scapular stabilization group. The players in the scapular stabilization group will be applied scapular stabilization exercises for 8 weeks, 3 days a week in company with a physiotherapist. As stabilization exercises for the players; 1)Squatting while sliding a towel on the wall, 2)Wall push-ups with one leg extension, 3)Cross squat, 4)Pulling elastic band while squatting on one leg, 5)Double-leg squatting
9695283|NCT04780282|No Intervention|Control group|
9695284|NCT04779918|Other|OviTex Reinforced Tissue Matrix|This is a single-arm study. All study subjects will receive OviTex.
9695285|NCT04779970|Experimental|Caucasian patients|Cessation of treatment
9695286|NCT04779970|Active Comparator|non-Caucasian patients|Cessation of treatment
9695287|NCT04779840||period 2011|
9695288|NCT04779840||period 2018|
9695289|NCT04779827|Experimental|Egalitarian Networks of Homogeneous Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
9695290|NCT04779827|Experimental|Egalitarian Networks of Diverse Populations|Egalitarian networks are characterized by equal connectivity for all participants in an online network for information exchange. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
9527632|NCT03218241|Experimental|PRT064445 Dose 3|Dose 3 versus Placebo
9695291|NCT04779827|Experimental|Centralized Networks of Homogeneous Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices."
9695292|NCT04779827|Experimental|Centralized Networks of Diverse Populations|"Centralized networks have a small number of influential individuals, called hubs, with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected influencers. Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices."
9695293|NCT04779827|Experimental|Independent Control of Homogeneous Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition share similar baseline demographic characteristics, attitudes, or behavioral choices.
9695294|NCT04779827|Experimental|Independent Control of Diverse Populations|Independent control condition does not have online networks. Participants in this condition are not put into online networks. Participants only respond to questions by themselves. All participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
9695295|NCT04779749||COVID positive <20 weeks|Case groups 1 will include pregnant patients infected by SARS-CoV2 before 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
9695296|NCT04779749||COVID positive >20 weeks|Case groups 2 will include pregnant patients infected by SARS-CoV2 after 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
9695297|NCT04779749||Control|Patients not infected by SARS-CoV2 during pregnancy during the period starting on February 1st 2020 and ending on November 30th 2020
9695298|NCT04779762|Experimental|Group 1|Standard induction regimen of Ustekinumab with the Crohn's disease exclusion diet (CDED)
9695299|NCT04779762|Active Comparator|Group 2|Standard induction regimen of Ustekinumab as above without diet
9695300|NCT04779684|Experimental|ACP by proxy pilot intervention group|All participants are included in the intervention group
9695301|NCT04779671|Experimental|VR group|
9695302|NCT04779671|Active Comparator|control group|
9527633|NCT03218241|Experimental|PRT064445 Dose 4|Dose 4 versus Placebo
9677396|NCT04974827|Experimental|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 5 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
9677397|NCT04974970|Experimental|Peanut allergenic extract|injected peanut extract.
10174936|NCT03848130|Active Comparator|Traditional Physiotherapy with Home Exercises (Group 3)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into traditional physiotherapy group.Each subject in third group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
10174937|NCT03848247|Experimental|Control group|Participants will be injected with 0.5ml Isotonic saline into a neck muscle
9677398|NCT04974723||Patients Treated with Abaloparatide|Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period.
9677399|NCT04974723||Patients Treated with Teriparatide|Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period.
9677400|NCT04974762|Active Comparator|Wound infiltration|Standard intervention - surgical infiltration with local anesthetics
9677401|NCT04974762|Experimental|Truncal blocks|Truncal block for anesthetics
9677402|NCT04974541|Experimental|Cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial care plus Heart Health Yoga
9677403|NCT04974541|Active Comparator|Cardiac rehabilitation with standard psychosocial care|Subjects will participate in 12-weeks of cardiac rehabilitation with standard psychosocial education component
9677404|NCT04974853|Experimental|Ayurveda Formulation|Patients with hypercholesterolemia treated with Ayurveda formulation, Cardio-Complement
9677405|NCT04974450|Experimental|Trigona Honey|The intervention will be given by oral route in a form of liquid of 70-gram trigona honey once daily for 8 weeks
9677406|NCT04974450|Active Comparator|Control|The intervention will be given by oral route in a form of liquid of 70-gram artificial honey once daily for 8 weeks
9677407|NCT04974944|Experimental|Camrelizumab + Apatinib|On Day 1 and Day 15 of each 28-day cycle, participants receive an intravenous (IV) infusion of camrelizumab 200 mg Plus an oral apatinib 250 mg once daily. Apatinib will be administered 250 mg once every other day when completing twice tumor assessement. All treatments are administered until disease progression or unacceptable toxicity.
9677408|NCT04974944|Active Comparator|Paclitaxel + Cisplatin/Carboplatin + Bevacizumab|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH bevacizumab 15 mg/kg). All treatments are administered until disease progression or unacceptable toxicity.
9677409|NCT04974580|Experimental|CoachingOnlyArm|Phone Coaching; no Digital Coaching, no NRT: This arm will receive only the two phone counseling calls which all other arms will receive.
9677410|NCT04974580|Experimental|DigitalArm|Phone Coaching + Digital Coaching; no NRT: This arm will receive digital content (text messages with links to online materials) in addition to to the two phone counseling calls which all arms will receive.
9677411|NCT04974580|Experimental|CoachingNRTArm|Phone Coaching + NRT; no Digital Coaching: This arm will receive Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
9677412|NCT04974580|Experimental|DigitalNRTArm|This arm will receive digital content (text messages with links to online materials) AND Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
9677413|NCT04974606|Experimental|Coffeeberry 100 mg beverage|Appearance-matched to the other beverages
9677414|NCT04974606|Experimental|Coffeeberry 300 mg beverage|Appearance-matched to the other beverages
9677415|NCT04974606|Placebo Comparator|Placebo beverage|Appearance-matched to the other beverages
9677416|NCT04974606|Active Comparator|Caffeine 75 mg beverage|Appearance-matched to the other beverages
9677417|NCT04974632|Other|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
9677418|NCT04974814|Placebo Comparator|control group|in this group patients will not receive statin before primary PCI
9677419|NCT04974814|Active Comparator|atorvastatin group|in this group patients will receive 80 mg atorvastatin single dose before primary PCI
9677420|NCT04974814|Active Comparator|rosuvastatin group|in this group patients will receive 40 mg rosuvastatin single dose before primary PCI
9677421|NCT04974658|Active Comparator|The block group (ISP)|After aseptic preparation of the injection area, the needle will be introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of 0.25% bupivacaine and 2 mg of dexamethasone on each side will be injected for each block.
9677422|NCT04974658|Placebo Comparator|control group (C)|No block will be performed
9677423|NCT04974736|Experimental|iEHR + Navigator|
9677424|NCT04974736|No Intervention|Usual Care Control|Usual care delivery in pediatric primary care offices.
9677425|NCT04974281|Other|PD-1+TACE+Len|PD-1 Antibody and Lenvatinib Plus TACE
9677426|NCT04974385|Experimental|Liposomal Bupivacaine|Experimental group will receive ISNB with admixed LB (10 mL) and 0.5% bupivacaine (10 mL) total of 20 mL.
9527634|NCT03218241|Experimental|PRT064445 Dose 5|Dose 5 versus Placebo
9527635|NCT03218371||study group (Indentation)|Eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed with scleral indentation. (Exposure)
9677427|NCT04974385|Active Comparator|Non-liposomal Bupivacaine|Comparator group will receive ISNB with 20 mL of 0.5% non-liposomal bupivacaine
9677428|NCT04974294|Active Comparator|PPV23|
9677429|NCT04974294|Active Comparator|PCV13|
9677430|NCT04974294|Placebo Comparator|Saline placebo|
9677431|NCT04974411||Infection|Patients diagnosed with infection but did not reach the sepsis marker.
10174938|NCT03848247|Experimental|Neck pain|Participants will be injected with 0.5ml NGF into the a neck muscle
10174939|NCT03848091||Antibiotic pretreatment|patients having had an antibiotic pretreatment before a one-step exchange arthroplasty
10174940|NCT03848156||CRSwNP AERD allergic|Patients suffering from chronic rhinosinusitis with nasal polyps, allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
10174941|NCT03848156||CRSwNP AERD non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
10174942|NCT03848156||CRSwNP non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy - biopsy for RNA sequencing
9677432|NCT04974411||sepsis|The patient was diagnosed with sepsis but did not develop septic shock
9677433|NCT04974411||sepsis shock|The patient was diagnosed with sepsis shock
9677434|NCT04974372||HT group|Patients have echocardiography examination before and after heart transplantation.
9677435|NCT04974372||Control group|healthy volunteers who had no history of hypertension, diabetes mellitus, renal failure or other organic diseases based on physical examinations, biochemical tests, electrocardiogram, echocardiography were enrolled as control group
10174943|NCT03848156||CRSwNP allergic|Patients suffering from chronic rhinosinusitis with nasal polyps with allergy - biopsy for RNA sequencing
9677436|NCT04974502|Experimental|Non-smoker group|
10174944|NCT03848039|Experimental|Gardasil-9|Intramuscular Gardasil-9 vaccination at 0, 2 and 6 months.
9677437|NCT04974502|Experimental|Smoker group|
9677438|NCT04974320||MINOCA|All patients diagnosed with MINOCA in precision cohort (NCT04044066) will be included.
9677439|NCT04974320||acute myocardial infarction (AMI）|All patients diagnosed with acute myocardial infarction（AMI）in precision cohort (NCT04044066) will be included.
9677440|NCT04974320||unstable angina (UA)|The patients diagnosed with unstable angina（UA) in precision cohort (NCT04044066) will be selected according to the matching method.
10174945|NCT03848039|Placebo Comparator|Placebo|Placebo injection at 0, 2 and 6 months
10174946|NCT03847753||Danish population|The cohort includes all those born in Denmark between 1900-2015, and who resided there in the period of 2000-2016.Whether they received a diagnosis of one of the following mental disorders will be ascertained: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Eating Disorders, Neurotic Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders The risk of receiving a later diagnosis of one of the following types of general medical conditions will then be estimated: Circulatory, Endocrine, Pulmonary and Allergy, Gastrointestinal, Urogenital, Musculoskeletal, Hematological, Cancer, Neurological
10174947|NCT03848000|Experimental|Exercise Programme and NHS Standard Care|Exercise and NHS standard care.
9677441|NCT04974320||MINOCA （multi-center）|The patients diagnosed with MINOCA in multi-center cohort will be included.
9677442|NCT04974021||Participants|HFrEF patients undergoing iron therapy with intravenous carboxymaltose (FCM). FCM administered dosage as per clinical routine. FCM administration is repeated no sooner than 3 months than last therapy, based on repeat ferritin and transferrin saturation levels.
9677443|NCT04974242|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
10174948|NCT03848000|Active Comparator|NHS Standard Care only|Alcohol addiction counselling.
10174949|NCT03847740|Experimental|Right Isometric Thumb Force (ITF) handle|
10174950|NCT03847740|Experimental|Left Isometric Thumb Force (ITF) handle|
9677444|NCT04974242|No Intervention|Waiting-list control|Continue on the waiting list for rotator cuff repair surgery, as per usual care.
9677445|NCT04974190|Active Comparator|Patients treated with actual device with actual solution|
9677446|NCT04974190|Placebo Comparator|Patients treated with actual device with placebo solution|
9677447|NCT04974255|Experimental|Operated Patients|Measurement of fibrosis degree and Anti-tTG levels
9677448|NCT04974268|Experimental|Exercise and nutritional program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal (non-mandatory), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
9677449|NCT04974268|No Intervention|Control Group|Control group will receive recommendations for aerobic unsupervised exercise 150 min per week, standard dietary recommendations (Mediterranean diet pattern and 1800 Kcal diet), manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
9677450|NCT04974203|Experimental|CT Value <25|Patients with CT value <25
9677451|NCT04974203|Experimental|CT Value 25+|Patients with CT value of 25 or higher
9677452|NCT04974203|Experimental|Negative|Patients with negative PCR test result
9677453|NCT04974060|Experimental|Remifentanil intervention|After the satisfactory analgesia and sedation, remifentanil will continuously infuse an escalating dose in the sequence of 0.02, 0.04, 0.06, and 0.08 μg/kg/min, each dose infusion lasting at least 30 minutes.
9695303|NCT04779645|Experimental|GRA (REMD-477) Group|Once weekly, subcutaneous injection of 70mg REMD-477 (in 1 mL solution) for up to 12 weeks.
9695304|NCT04779645|Placebo Comparator|Placebo Group|Once weekly, subcutaneous injection of 1mL saline solution for up to 12 weeks.
10174951|NCT03847779|Experimental|Non-neuropathy|"Type 2 diabetic without neuropathy:~Negative findings on Semmes-Weinstein monofilament~Neuropathy symptom score (NSS) <3~Negative findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~pedometer during 4 days~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
9677454|NCT04974229||acute non-specific low back pain|patients with acute low back pain of (< 6 weeks) were consecutively included with or without radiating pain, aged 18 to 60 years with a pain-free episode for at least 3 months before the onset of their current back pain. They were also required to be able to read and understand the Dutch language.
9677455|NCT04974073|No Intervention|control group|with traditional western medicine treatment based on underlined disease
9677456|NCT04974073|Experimental|PHY606|PHY606 7.5gm BID for 3 months
9677457|NCT04974073|Other|Healthy group|PHY606 7.5gm BID for 2 days
9677458|NCT04974112||General Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
9677459|NCT04974112||Thoracic Surgery|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
9677460|NCT04974112||orthopedics|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
9677461|NCT04974112||Gastroenterology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
9677462|NCT04974112||Respiratory|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
9677463|NCT04974112||Neurology|This study was conducted in parallel in many Class-A hospitals across the country. Special researchers were assigned by the research unit to collect patient information using SGA and NRS2002 and other data measurement tools.
9677464|NCT04973969|Other|study group|The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.
9677465|NCT04973787||axSpA|Patients with clinical diagnosis of axialSpondyloarthritis according to ASAS criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
9677466|NCT04973787||RA|Patients with clinical diagnosis of Rheumatoid arthritis according to 2010 ACR/EULAR classification criteria, with indication for bDMARD (Portuguese Rheumatology Society Guidelines)
9677467|NCT04973787||Control|Healthy participants, e.g. with no clinical diagnosis of rheumatic inflammatory disease, crossed by age, gender and diet profile
9677468|NCT04973865||Disease Population|50 Patients who have chronic diseases, such as cardiovascular, will consider as high risk, those who have more than two number of CAD risk factor will categorize as mild and patients have less than two risk factor of CAD will consider as low risk factor. (ACSM risk stratification guide lines)
9677469|NCT04973865||Healthy|30 Healthy individual with no cardiac diseased.
9677470|NCT04973995||Patients with shoulder pain who received ER lag sign|
9677471|NCT04973995||Patients with shoulder pain who received External rotation resistence strength test|
9677472|NCT04973995||Patients with shoulder pain who received Patte's test|
9677473|NCT04973995||Patients with shoulder pain who received Errsair test|
9677474|NCT04973995||Patients with shoulder pain who received speed test|
9677475|NCT04973995||Patients with shoulder pain who received Yergason test|
9677476|NCT04973995||Patients with shoulder pain who received backward traction test|
9677477|NCT04973995||Patients with shoulder pain who received Cui's test|
9677478|NCT04973904|Experimental|PD-1+Paclitaxel+Cisplatin+Bevacizumab|"Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 (Q3W)~Bevacizumab 7.5mg/kg IV every 3 weeks (Q3W)"
9677479|NCT04973410|Other|Group A|FFR negative/non-significant (>0.80) and IMR negative (<25)
9677480|NCT04973410|Other|Group B|FFR negative/non-significant (>0.80) and IMR positive (>25)
9975710|NCT01344044|Experimental|BCI pilot arm|This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.
9975711|NCT01344070|Active Comparator|Reference formulation of each drug|Innovator formulation
9975712|NCT01344070|Active Comparator|generic formulation a|one of the several generic formulations in the market, randomly selected for each drug
9975713|NCT01344070|Active Comparator|generic formulation b|second of the several generic formulations in the market, randomly selected for each drug
9975714|NCT01344070|Active Comparator|generic formulation c|third of the several generic formulations in the market, randomly selected for each drug
9975715|NCT01344083|Experimental|T1210|
9975716|NCT01344083|Active Comparator|Olopatadine hydrochloride|
9677481|NCT04973644|Experimental|Internet + Digital Hospital-remote home management mode|Remote monitoring devices+Internet management platform, dietary recommendations, exercise supervision, web education, information pushing, doctor-patient interaction.
9677482|NCT04973644|No Intervention|the traditional management mode|Routine dietary and exercise recommendations, education as well as monitor in the clinic.
9975717|NCT01344109||Breast cancer patients|Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)
9975718|NCT01344109||Healthy volunteers|Adult women without a cancer diagnosis.
9975719|NCT01344122|Active Comparator|KPI training only|Study sites randomized to this arm will receive a knowledge, perceptions and information (KPI) training for community correctional and treatment staff to address knowledge, perceptions, and information regarding local resources about MAT.
9677483|NCT04973462|Active Comparator|Triazavirin group|Patients will take the standard treatment COVID-19 + Triazavirin 250mg three times daily for 7 days]
9677484|NCT04973462|Active Comparator|Oseltamivir group|Patients will take the standard treatment COVID-19 + Oseltamivir 75 mg twice daily for 7 days]
9677485|NCT04973839|Experimental|Video optimizing expectations before PMR (unguided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided)
10174952|NCT03847779|Experimental|Neuropathy|"Type 2 diabetic with neuropathy~Positive findings on Semmes-Weinstein monofilament~Neuropathy symptom score (NSS) >3~Positive findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~pedometer during 4 days~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
9677486|NCT04973839|Experimental|Video optimizing expectations before PMR (guided)|watching a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided)
9677487|NCT04973839|Active Comparator|Neutral video before PMR (unguided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided),
9677488|NCT04973839|Active Comparator|Neutral video before PMR (guided)|watching a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided)
9677489|NCT04973423|No Intervention|CALM|Tight control of inflammatory activity by calprotectin.
9677490|NCT04973423|Other|CALM + IRM|Tight control of inflammatory activity by calprotectin associated with transmural evaluation.
10174953|NCT03847779|Experimental|Controls|"matched for age, sexe and BMI with diabetic patients.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
10174954|NCT03847766|Experimental|PRO-based follow-up|Patients will receive a questionnaire every 3 months. The PRO questionnaire is used as decision aid together with other available clinical data to decide whether the patient needs a visit or not. Hence, patients only visit the outpatient clinic if there is a clinical need or a patient's wish. The actual response for each questionnaire automatically results in a colour code (green, yellow or red). A red or yellow response indicates that the patient needs to be contacted. A green colour indicates no need for a visit. Based on an overview of the questionnaire and the patient's blood samples a physician decides whether this patient should have a telephone consultation or the patient needs to be seen in the clinic.
9677491|NCT04973618|Experimental|APVO436|CD123 and CD3 epsilon bispecific antibody
10174955|NCT03847766|Experimental|PRO-based telephone consultations|Patients receive an electronic questionnaire every 3 months prior to a scheduled telephone consultation.The PRO questionnaire is used as dialogue support during the telephone consultation. The actual response for each item automatically results in a colour code (green, yellow or red). A red response indicates that the patient has a problem; a yellow colour indicates a potential problem, while a green colour indicates no problems.
9677492|NCT04973722|Experimental|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
9677493|NCT04973722|Active Comparator|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
9677494|NCT04973813|Experimental|Guideline + Active Choice + action&coping planning (GA+)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning.
10174956|NCT03847766|No Intervention|Usual outpatient follow-up visits|Patients in the control group will continue to have usual scheduled outpatient follow-up visits at the hospital initiated by the physician every 3 months. These patients do not use the clinical PRO questionnaire, but complete the research questionnaires.
10174957|NCT03847883|Active Comparator|0.6 mg/kg Ateplase|Low dose 0.6 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke (n = 26 in cohort A)
10174958|NCT03847883|Active Comparator|0.75 mg/kg Ateplase|Low dose 0.75 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A)
9677495|NCT04973813|Experimental|Guideline + Active Choice (GA)|Participants received a web-based intervention consisting of information (including the national physical activity guideline) and several assignments. Assignments included: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
9677496|NCT04973813|Experimental|Guideline + Information (GI)|Participants received the national physical activity guideline, and information about pros and cons of physical activity, and possible barriers to physical activity.
9677497|NCT04973813|Other|Guideline (G)|Comparison arm. Participants received the national physical activity guideline.
9677498|NCT04973501|Experimental|Manual physiotherapeutic correction (MFK) Method|The MFK was chosen for our clinical experience- it was developed in Czech Republic.The MFK Method consists of five established steps: anamnesis, assessment, diagnoses, treatment and checkup. In the course of all those steps, the computer MFK System software is used. This software allows us to display and visualize the patient´s functional muscle imbalance at the day of the assesment based on the assessment of muscle strength by manual muscle tests. Hereafter the physiotherapist performs muscle test and records results in the software. Then, the software visually describes the patient´s imbalance at the day of the assessment. Based on these diagnostic maps and the software suggestions the therapist chooses the body areas where the therapeutic techniques may be applied.
9695305|NCT04779697|Experimental|GLP-1a|GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
9677499|NCT04973501|Experimental|Dynamic Neuromuscular Stabilization (DNS) Method|Dynamic Neuromuscular Stabilization (DNS) is a neurophysiological rehabilitative approach encompassing a set of functional tests assessing the quality of postural stabilization patterns and a treatment approach based on developmental kinesiology models. DNS diagnosis is based on comparison of the individual's postural stabilization pattern to the developmental stabilization pattern of healthy infants. The assessor uses DNS evaluation sheet to screen client's posture in 11 developmental positions if the patient can perform them all. If not, only the tests that the patient can perform sufficiently and safely serve for functional assessment. The strategy of DNS manual treatment is to utilize only those functional exercises in developmental positions that are the most suitable for the specific client. The goal is to improve spinal and joint stability by focusing on the global stabilization system consequently improving quality of movement and mobility.
9677500|NCT04973592||Child with Blunt Abdominal Trauma|
9677501|NCT04973527|Experimental|LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
9677502|NCT04973709||Delirium with dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
9677503|NCT04973709||Dementia without Delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
9677504|NCT04973709||Delirium without Dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
9677505|NCT04973709||No dementia, No delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
9677506|NCT04973488|Experimental|Treatment arm|In the treatment arm, Therapeutic plasma exchange will be conducted in the first 24 hours after being admitted into the intensive care unit, after which convalescent plasma from donors that have had COVID-19 will be transfused
9677507|NCT04973488|No Intervention|Control arm|In the control arm, patients will receive standard COVID-19 treatment
9677508|NCT04973735|Experimental|30mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
9677509|NCT04973735|Experimental|150mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
9677510|NCT04973735|Experimental|600mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
9677511|NCT04973735|Experimental|1200mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
9677512|NCT04973735|Experimental|2400mg LY-CovMab|LY-CovMab is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
9677513|NCT04973735|Placebo Comparator|Placebo|Placebo is diluted with 0.9% sodium chloride to a total volume of 250 mL for IV infusion
9677514|NCT04973878|Experimental|Group A|EGD performed before the Colonoscopy
9677515|NCT04973878|Experimental|Group B|Colonoscopy performed before the EGD
9677516|NCT04973761|Other|Strip composite crowns|
9677517|NCT04973761|Experimental|Zirconium crowns|
9677518|NCT04973475|Experimental|Experimental: Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic distal gastrectomy with lymph node dissection for gastric adenocarcinoma.
9677519|NCT04973579||Simultaneous cardiac surgery and carotid stenting|Patients with Heart Team and NeuroVascular Team recommendation to perform simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) including proximal or distal neuroembolic protection and cardiac surgery (CABG or surgical valve replacement / repair procedure)
9677520|NCT04973371|Experimental|Home-based GeneXpert TB test|Screening household contacts + home-based GeneXpert® MTB/RIF TB testing for those with TB symptoms + immediate referral for clinic-based treatment initiation.
10174959|NCT03847883|Active Comparator|0.9 mg/kg Ateplase|Low dose 0.9 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A and n= 330 in Cohort B)
9677521|NCT04973371|No Intervention|Standard home-based TB symptom screening with immediate referral|Screening household contacts + immediate referral for clinic-based TB testing
9677522|NCT04973358|Experimental|BuccoTherm|buccotherm mouthwash
9677523|NCT04973358|Placebo Comparator|Placebo|placebo mouthwash
9677524|NCT04973306|Experimental|Neoadjuvant chemoradiotherapy combined with anti-PD-1 antibody|Neoadjuvant chemoradiotherapy (NCRT) combined with tislelizumab is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
9695306|NCT04779697|Placebo Comparator|Placebo|Placebo pen administered weekly over 12 weeks
10174960|NCT03848013|Active Comparator|Treatment|Treatment of cases of melasma using Q switched Nd YAG laser and Fractional CO2 laser separately and in combination
10174961|NCT03848013|No Intervention|Follow -up period|follow up of the treated cases for 2 months
10174962|NCT03848026||Group 1|middle ear fluid viscosity <439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
9677525|NCT04973306|Active Comparator|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by Ivor-Lewis or Mckeown esophagectomy in enrolled patients.
9677526|NCT04973033|Experimental|Tofactitinib|Tofacitinib 5mg twice a day
9677527|NCT04973007|Active Comparator|Gadoxetate disodium exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
9677528|NCT04973007|Active Comparator|Gadobenate Dimeglumine exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
9677529|NCT04973319|Experimental|test group|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment. The subject who has a second primary malignant tumor in a non-breast area will continue to be followed up until a recurrent disease or death due to primary breast cancer. The subjects who are hormone receptor-positive will be advised to receive endocrinotherapy simultaneously. Within 28 days after the last administration of the test drug, the subjects in the test group must complete the safety follow-up and the end-of-treatment visit and continue to receive the follow-up visit.
9677530|NCT04973319|Other|control group|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
10174963|NCT03848026||Group 2|middle ear fluid viscosity >439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
10174964|NCT03847688||Treatment resistant Major Depressive Disorder|
10174965|NCT03847805|Experimental|Experimental|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
9677531|NCT04973111|Experimental|CT-868|SC dose of CT-868 Intervention: Drug: CT-868
9677532|NCT04973111|Placebo Comparator|Placebo|SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo
9677533|NCT04973111|Active Comparator|Active Comparator|SC dose of Active Comparator Intervention: Drug: Active Comparator
9677534|NCT04973215||work package 1|all participants in Norwegian introduction program and their family relations
9677535|NCT04973215||work package 2|strategic sample of refugees with health problems currently participating in the introduction program
10174966|NCT03847805|Active Comparator|Control|The control group followed a program of glenohumeral stabilization exercises,
9677536|NCT04973215||work package 3|3-6 families from which one or more participate in the introduction program and one or more have health problems
9677537|NCT04973176|Active Comparator|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Standard Bougie|Patients randomised to standard bougie will be intubated using standard bougie (Frova® airway intubation catheter )
9677538|NCT04973176|Active Comparator|Endotracheal intubation with C-MAC D Blade Videolaryngoscopy and Flexi-tip Bougie|Patients randomised to Flexi-tio bougie will be intubated using Flexi-tip bougie (P3 medical Ltd, Bristol, UK)
9677539|NCT04972877|Active Comparator|Treatment group|Treatment group protocol：participants will receive electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
10174967|NCT03847818|Experimental|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|
10174968|NCT03847727||Experimental: 6 cycles BR -> 4 x BR|Induction plus BR as maintenance (N=56)
9677540|NCT04972877|Sham Comparator|Control group|Control group protocol：participants will receive sham electro-acupuncture twice or three times a week with a maximum of 24 times in 2-3 months. Each treatment session lasts for 30 minutes.
9677541|NCT04973241||OPG|
9677542|NCT04973241||CBCT|
9677543|NCT04973280||Healthcare Professionals (HCPs)|The PASS will be conducted among HCPs in a representative sample of EEA countries where REBLOZYL is commercially available. A sample of HCPs from EEA countries who manage care for patients with certain haematologic conditions and who may/do prescribe REBLOZYL will be recruited from the target population of HCPs who were sent the REBLOZYL aRMMs in these countries. The final list of countries to be included may include 1) only countries where reimbursement has been sought and gained, 2) a geographically representative sample (e.g., northern, southern, eastern, and western EU Members States to the degree possible based on the first criteria), 3) a mixture of countries with higher and lower REBLOZYL usage, and 4) other feasibility considerations such as the ability to conduct direct-to-HCP non-market research studies.
9695307|NCT04779788|Experimental|I-125 seeds loaded stent group|Patients who receive the I-125 seeds loaded stent insertion
10174969|NCT03847727||Proper historical control: 6 cycles BR|Induction only (N=56)
10174970|NCT03847792|Active Comparator|Group DB/Dexamethasone-Bupivacaine|Patients were received an intra-articular injection of 8mg dexamethasone added to18mL of 0.25% bupivacaine
10174971|NCT03847792|Active Comparator|Group FB /Fentanyl-Bupivacaine|Patients were received an intra-articular injection of 1 ug/kg fentanyl added to 18 mL of 0.25% bupivacaine
10174972|NCT03847792|Placebo Comparator|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2 mL isotonic saline added to 18 mL of 0.25% bupivacaine
10174973|NCT03847714|Active Comparator|Probiotic|Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water
10174974|NCT03847714|Placebo Comparator|Placebo|3g of a similar looking and tasting powder, twice daily
10174975|NCT03847636|Active Comparator|Familial Adenomatous Polyposis (FAP)|Individuals with duodenal adenomas (DAs) and FAP with Spigelman class 2,3 or 4, treated with cryoballoon ablation (intervention)
10174976|NCT03847636|Active Comparator|Sporadic duodenal adenomas|Individuals with at least 1 sporadic duodenal adenoma (DA) between 1-5 cm in maximum diameter, treated with cryoballoon ablation (intervention)
9677544|NCT04973267|Experimental|Game Plan for PrEP|Participants will be asked to use Game Plan for PrEP for however long they wish. Game Plan for PrEP is a web-based intervention that provides users with feedback about how much their risk for HIV is reduced on PrEP, their risk for bacterial STIs, and helps them make a plan to take their medication regularly and reduce their risk for STIs. Game Plan for PrEP also providers users with feedback about their alcohol use compared to others in their age group and encourages them to make a plan to reduce it.
9677545|NCT04973267|Sham Comparator|Lifestyle Habits Videos|Participants in this condition will view several videos that encourage them to adopt sleep hygiene and healthy diet behaviors. The videos were selected to last as long as the average time users engage with Game Plan for PrEP in its initial modules.
9677546|NCT04972994|Active Comparator|laparoscopic intracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic intracorporeal versus for right and left hemicolectomies in management of colonic cancers
9677547|NCT04972994|Active Comparator|laparoscopic extracorporeal anastomosis for right and left hemicolectomies|Surgical outcomes after laparoscopic extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
9677548|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in healthy young adults.|
9677549|NCT04973189|Placebo Comparator|placebo in healthy young adults.|
9677550|NCT04973189|Experimental|A single dose of SHR-1707 by intravenous infusion in elderly subjects.|
10174977|NCT03847909|Experimental|DCR-PHXC|Intervention, drug, DCR-PHXC
9677551|NCT04973189|Placebo Comparator|placebo in elderly subject|
10174978|NCT03847909|Placebo Comparator|Placebo - Sterile Normal Saline (0.9% NaCl)|Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection
10187168|NCT03728894|Active Comparator|A: Midazolam-hydroxyzine with 100% O2|Midazolam-hydroxyzine with 100% O2 was administrated to 30 children. Drug: Oral Medication (midazolam 7.5 mg and hydroxyzine 10 mg) and Inhalation Gas 100% O2 Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
9677552|NCT04972955||Pregnant women diagnosed with gestational diabetes|Pregnant women who have been diagnosed with gestational diabetes during the current pregnancy
9677553|NCT04972942|Other|Interventional|"Daratumumab (DARA) treatment post-HCT 8 mg/kg/dose~Induction: DARA 16 mg/kg IV weekly x 8 doses (Weeks 1-8)~Consolidation: DARA 16 mg/kg IV every 2 weeks x 8 doses (Weeks 9-24)~Maintenance: DARA 16 mg/kg IV every 4 weeks x 5 doses following start of treatment (Weeks 25-44)"
9677554|NCT04973293|Experimental|Neoadjuvant treatment|"Participants will receive 4 doses of sintilimab (200 mg, IV) and bevacizumab (15 mg/kg, IV) every 3 weeks (Q3W). Participants will also receive 4 doses of carboplatin (AUC=5, IV) and pemetrexed (500 mg/m2, IV) Q3W.~Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.~After the second dose of sintilimab, bevacizumab and chemotherapy, contrast-enhanced chest CT will be performed. Patients with progression disease will receive surgery without the last 2 doses of treatment."
9677555|NCT04972903||Group 1.HIV+/SAM+|Group 1. HIV-infected with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV+/SAM+)
9677556|NCT04972903||Group 2. HIV+/SAM-|Group 2. HIV-infected without SAM (none of the 3 criteria above) (HIV+/SAM-)
9677557|NCT04972903||Group 3. HIV-/SAM+|Group 3. HIV-negative with SAM (WHZ<-3SD or edematous malnutrition or MUAC <115) (HIV-/SAM+)
9677558|NCT04972903||Group 4. HIV-/SAM-|Group 4. HIV-negative without SAM (none of the 3 criteria above) (HIV-/SAM-)
9677559|NCT04972734|Experimental|NEC|premature newborns developing a NEC
9677560|NCT04972734|Active Comparator|Healthy control|premature newborns without NEC
9677561|NCT04972656|Experimental|Ambrisentan|Monotherapy using ambrisentan will start at a dose of 5 mg (once daily) and will be up-titrated to 10 mg (once daily) after 4 weeks apart if patients are tolerable.
10187169|NCT03728894|Experimental|Midazolam-hydroxyzine with 50% N2O/ O2|children received Midazolam-hydroxyzine with 50% N2O/O2, one tablet of oral midazolam 7.5 mg and one tablet of hydroxyzine 10 mg with 50% N2O/O2. Drug: Oral Medication and Inhalation Gas Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
10187170|NCT03728868|Placebo Comparator|Placebo|One capsule containing placebo (identical to the capsule with active product (F. prausnitzii and D. piger) in taste and appearance but without the active component) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
10187171|NCT03728868|Active Comparator|High dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E9-5x1E9 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
10187172|NCT03728868|Active Comparator|Low dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E8-5x1E8 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
9677562|NCT04972656|Placebo Comparator|Placebo|Placebo tablet
9677563|NCT04972773|Experimental|MM + standard-therapy intervention group|In addition to receiving standard-therapy, participants will be asked to practice MM using a MM app for at least 10 minutes per day from weeks 0 to 8.
9677564|NCT04972773|No Intervention|Standard-therapy control group|Participants randomized to the standard-therapy control group will receive their typical in- or out-patient therapy. This is expected to include small doses of MM.
9677565|NCT04972851|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
9677566|NCT04972851|Active Comparator|Implementation as Usual (IAU)|The organizations will implement SDLMI as usual. The research team will be available to provide support on the SDLMI intervention as needed.
9677567|NCT04972669|Sham Comparator|control group|sham electroaupuncture
9677568|NCT04972669|Experimental|experimental group|Electroaupuncture
9677569|NCT04972838|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
9677570|NCT04972838|Active Comparator|Implementation as Usual (IAU)|The organizations will implement RR as usual. The research team will be available to provide support on the RR intervention as needed.
9677571|NCT04972864|Active Comparator|Exercise training group|Individuals in the treatment group were given respiratory exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) and inspiratory muscle training with the Threshold IMT (T-IMT) device. Inspiratory muscle training was applied for 30 minutes, 3 times a day, 7 days a week for 6 weeks.
9677572|NCT04972864|Placebo Comparator|Control training group|Breathing exercises (diaphragmatic breathing, thoracic expansion, exercises to increase chest compliance with respiratory control with exercise band and leg strengthening exercises) were taught in the control group and only the exercise link containing these exercises was sent.
9677573|NCT04972370||Patients with Unilateral Cleft Lip with or without Cleft Palate|
9677574|NCT04972383|Experimental|Platelet Rich Plasma group|single injection platelet rich plasma
9677575|NCT04972383|Experimental|Hyaluronic Acid group|single injection of hyaluronic acid
9677576|NCT04972422|Experimental|Single Agent Dose Escalation|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
9677577|NCT04972448||Group1|Chemotherapy+endocrine therapy+radiotherapy
9677578|NCT04972448||Group2|Chemotherapy+endocrine therapy
9677579|NCT04972448||Group3|endocrine therapy+radiotherapy
9677580|NCT04972448||Group4|endocrine therapy
9677581|NCT04972526||Out-of-hospital Cardiac Arrest|Patients receiving TEE as part of their clinical evaluation during cardiac arrest that occurred outside the hospital (e.g. in/at a home or residence, in a public area, during transport to the emergency department, etc.)
9677582|NCT04972526||In-hospital Cardiac Arrest|Patients receiving TEE as part of the clinical evaluation during cardiac arrest that occurred within a hospital (e.g in the emergency department, an Intensive Care Unit, a hospital ward, the operating room, etc.)
10174979|NCT03847831|Experimental|PPASF Group|"Schools enrolled in the postprimary active school flag program. All 17 elements are included. Feasibility is measured of the 17 elements.~Student representatives are selected to have accelerometer, physical health measures and perceived health collected for feasibility purposes."
9677583|NCT04972526||Undifferentiated Shock or Acute Hemodynamic Decompensation|Patients receiving TEE as part of the initial evaluation of undifferentiated shock or acute hemodynamic decompensation
9677584|NCT04972526||Hemodynamic Monitoring in a Critically Ill Patient|Critically ill patients receiving TEE as part of hemodynamic monitoring
9677585|NCT04972526||Procedural Guidance|Patients receiving TEE as a means to assist providers performing procedures (e.g. intravenous pacemaker placement, veno-arterial or veno-venous extracorporeal membrane oxygenation [ECMO], impella heart pump placement, intra-aortic balloon pump placement, etc.)
9677586|NCT04972539|Experimental|Sequence A|Period 1: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose Period 2: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose
9677587|NCT04972539|Experimental|Sequence B|Period 1: AJU-A51(FDC tablet, Linagliptin/Dapagliflozin), single dose Period 2: AJU-A51R1 tablet(Dapagliflozin) and AJU-A51R2 tablet(Linagliptin), single dose
9677588|NCT04972591||CHB Group|Patients with CHB
9677589|NCT04972591||Compared Group|Healthy people
9677590|NCT04972799|Experimental|Treatment/Placebo|treatment sequence at day 0 and placebo sequence at 6 months
9677591|NCT04972799|Experimental|Placebo/Treatment|placebo sequence at day 0 and treatment sequence at 6 months
9677592|NCT04972617||observational group|"In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient.~The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.~In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined."
9677593|NCT04972708||Bipolar Disorder|100 patients after COVID-19 infection 100 patients without COVID-19 infection
9677594|NCT04972708||Healthy controls|100 controls after COVID-19 infection 100 controls without COVID-19 infection
9677595|NCT04972435|Experimental|Multifocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with multifocal intraocular lens implantation.
9677596|NCT04972435|Sham Comparator|Monofocal intraocular lens group|Cataract patients with PAC or PACG who underwent phacoemulsification with monofocal intraocular lens implantation which are the standard IOL.
9695308|NCT04779788|Active Comparator|Normal stent group|Patients who receive the normal stent insertion
9695309|NCT04779723|Active Comparator|LRYGB Procedure|LRYGB technique was performed by placing 4 to 6 trocars, a 150 cm ante-colic Roux-limb gastric pouch (30 to 50 ml) was created with linear stapled or circular stapled gastro-jejunostomy, a 50-cm long biliopancreatic limb was chosen. A passive drainage was kept near to the gastro-jejunostomy.
10174980|NCT03847584||Adults-low socioeconomic status|Survey completed by adults with low socioeconomic status
10174981|NCT03847584||Adults-middle/high socioeconomic status|Survey completed by adults with middle/high socioeconomic status
9695310|NCT04779723|Active Comparator|LSG Procedure|35 Fr bougie was used for the calibration of a gastric tube. 3 to 6 cm of longitudinal incision of the stomach was done at pylorus to the angle of His. Using of absorbable suture, the staple line was sewn.
9677597|NCT04972643|Experimental|EPA and DHA intervention|EPA 1000mg and DHA 1000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
10174982|NCT03847935||Surgery|Patients who underwent surgical release of A1 pulley
10174983|NCT03847935||corticosteroid injections only|Patients who underwent local corticosteroid injections only, and no other treatment
9677598|NCT04972643|Experimental|EPA intervention|EPA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
9677599|NCT04972643|Experimental|DHA intervention|DHA 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
9677600|NCT04972643|Placebo Comparator|Placebo|Placebo 2000mg capsule twice a day, the total exposure to the intervention for each subject is 24 months.
9677601|NCT04972279|Experimental|Aggressive adaptation strategy|Participants receive up to 6 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
9677602|NCT04972279|Experimental|Moderate adaptation strategy|Participants receive up to 3 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected randomly from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
9677603|NCT04972474|No Intervention|RADAR-MDD Questionnaire App as Usual|The RADAR-MDD questionnaire app as usual asks participants to complete 3x active tasks per week, with one reminder notification at 9am on a day that a questionnaire is due. The notification reads 'Questionnaire Time. Won't usually take longer than 3 minutes'. The participant is not able to view any data progress, aside from through the Fitbit app, which was present in the original RADAR-MDD study.
9677604|NCT04972474|Experimental|RADAR-MDD Adapted Questionnaire App|"The following components are also present:~Notifications: The notification will alternate between the phrases 'Questionnaire Time. Symptom tracking might increase self-awareness of your emotions (Bakker & Rickard, 2018)', 'Questionnaire Time. Symptom tracking is a technique often used in treatment to increase insight into your symptoms (Kramer et al., 2014)', and 'Questionnaire Time. Tracking your symptoms through a smartphone and Fitbit might help research to better understand health conditions'.~Progress visualisation: Participants will be able to view their questionnaire completion progress as a visualisation through the app, in the form of a graph.~Additional components: An additional text on the home screen of the active app will read 'You can contact your research team between 9am-5pm Mon-Fri if you have questions, onradar-engage@kcl.ac.uk'."
10174984|NCT03847935||hand therapy only occupational/physical|1 visit: orthosis fabrication, range of motion, nodule and ice massage.
10174985|NCT03847935||Injection and Hand therapy|This group of participants received a combination of corticosteroid injection in the affected finger and one visit of hand therapy.
10174986|NCT03847935||Modality Hand Therapy|Ongoing hand therapy treatment, which included the above plus modalities such as ultrasound or iontophoresis.
9677605|NCT04972357||Standard RYGB|
9677606|NCT04972357||Banded RYGB|
9677607|NCT04972357||Extended pouch RYGB|
9677608|NCT04972305|Experimental|Exercise group|12 weeks exercise programme, 3 days a week Bicycle ergonomics will be applied.
9677609|NCT04972305|Experimental|Ergonomics group|Bicycle ergonomics will be applied.
9677610|NCT04972305|No Intervention|Control group|No Intervention
9677611|NCT04972318|Active Comparator|ARDSNet strategy|"Patients will receive a mechanical ventilation strategy based on fixed values of positive end-expiratory pressure according to inspired fraction of oxygen.~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before.~This arm is similar to the ARMA (Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome) trial."
9677612|NCT04972318|Experimental|STAMINA strategy|"Patients will receive a mechanical ventilation strategy based on positive end-expiratory pressure tailored to achieve the optimal respiratory system compliance and to have driving pressure limited to 14 cmH2O.~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before."
9975720|NCT01344122|Experimental|KPI plus OLI|Study sites randomized to this arm will receive the KPI training plus a Organizational Linkage Intervention (OLI) that will: (a) establish a local Pharmacotherapy Exchange Council (PEC) among agencies important for the implementation of MAT in community corrections; (b) facilitate a strategic planning process within the PEC to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole; and (c) identify a community corrections coordinator in one of the local agencies to operationalize and implement the strategic plan.
10174987|NCT03847935||Injection and Modality Hand Therapy|Ccombination of local cortiscosteroid injection to the affected digit and ongoing hand therapy with modalities.
10174988|NCT03847571||Acetazolamide|Oral administration of acetazolamide 5 mg/kg/day for 4 weeks
9677613|NCT04972292|Experimental|Group 1: FDC of codeine 30 mg/dipyrone 500 mg from Eurofarma Laboratórios SA|Subjects randomized to this group will receive one (1) experimental drug tablet + one (1) Tylex® placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
9695311|NCT04779801|Experimental|ABFT|Adolescents and one or both parents will complete 16 weeks of Attachment-Based Family Therapy treatment.
10174989|NCT03847922|Placebo Comparator|Control group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection plus self-administered room air
9677614|NCT04972292|Active Comparator|Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg)|Subjects randomized to this group will receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
9677615|NCT04972123|Experimental|CPC Adminstration|Single dose of CPC will be given during tilt table test
9677616|NCT04972123|Placebo Comparator|Placebo Adminstration|Single dose of Placebo will be given during tilt table test
9677617|NCT04972084|Experimental|Powerscope group|Class II patients which will receive treatment using Powerscope appliance
9677618|NCT04972149||LC|laparoscopic surgery using conventional laparoscopic instruments
9677619|NCT04972149||LW|Using wristed laparoscopic instruments (Artisential Maryland dissector, Artisential Fenestrated grasper)
9677620|NCT04972149||RC|Conventional robotic surgery
9677621|NCT04972149||RSS|Use of single site system for reduced port robotic surgery
9677622|NCT04972149||RSP|Use of da Vinci SP system for reduced port robotic surgery
9975721|NCT01344135|Placebo Comparator|Group 1 (placebo control)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
9975722|NCT01344135|Experimental|Group 2 (nutritional intervention)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
9677623|NCT04972149||RRI|A new surgical robot Revo-i developed by Meerae company in Korea
9677624|NCT04972214||Very Preterm Infants|preterm infants were born at gestational age of less than 32 weeks
9677625|NCT04972136|Active Comparator|Active bilateral theta burst stimulation|An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). BL-TBS will be delivered at 90% RMT, corrected for scalp to cortex distance, to targeted left and right DLPFC sites, differing only in stimulation pattern and total number of pulses (triplet 50 Hz bursts, repeated at 200 msec (i.e., 5 Hz); right DLPFC (continuous TBS, cTBS): 120 seconds uninterrupted bursts (total of 600 pulses); left DLPFC (intermittent TBS, iTBS: 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds/hemisphere).
9677626|NCT04972136|Sham Comparator|Sham bilateral theta burst stimulation|"An X100 stimulator with a B65 A/P type coil (Magventure Inc.) will be used with the active coil facing away from the scalp, for sham stimulation. The coil is positioned under MRI guidance using real-time neuronavigation using Brainsight [x,y,z= -38, 44, 26(left), +38, 44, 26 (right). To reproduce the nociceptive qualities of the stimulation, the B65-type stimulation coil - sham side - includes a built in electrical stimulator in the coil connector which fires a synchronous electrical pulse along with the TMS stimulus through electrodes mounted on the forehead or near the area of stimulation, to generate auditory and somatosensory (vibration) stimuli."
9677627|NCT04972513||Prevention (survey, breathe tests, biospecimen collection)|Participants undergo computer-based spirometry testing, nitric oxide breath testing, airwave oscillometry, and an assessment of endothelial function. Participants will undergo collection of blood. Current e-cigarette users also vape their own e-cigarette device for 30 minutes.
9677628|NCT04972825|Experimental|UNITED|UNITED is premised on the idea that successful implementation in organizations like schools and early intervention systems requires a team-based approach, in which the team is thoughtfully assembled, develops a plan for implementation, assigns roles and responsibilities, and carefully tracks and supports implementation and sustainment in all its stages within a few meetings and ongoing coaching from the research staff.
9677629|NCT04972825|Active Comparator|Implementation as Usual (IAU)|The organizations will implement Mind the Gap as usual. The research team will be available to provide support on the Mind the Gap intervention as needed.
9677630|NCT04972006|Experimental|One week baseline|Participants randomized to baseline one will go through a one-week baseline period before beginning the treatment.
9677631|NCT04972006|Experimental|Two week baseline|Participants randomized to baseline two will go through a two-week baseline period before beginning the treatment.
9975723|NCT01344148|Experimental|Anti- TB therapy HAART|
9677632|NCT04972006|Experimental|Three week baseline|Participants randomized to baseline three will go through a three-week baseline period before beginning the treatment.
9677633|NCT04971798|Experimental|Cell-free Stem cell-derived Extract Formulation (CCM)|Intraarticular administration of CCM
9677634|NCT04972032|Experimental|Estrogen Intrauterine Stent System|An Intrauterine Stent System with estrogen will be introduced into the uterine cavity after TCRA(transcervical resection of adheison).
9677635|NCT04972032|Other|Foley balloon combined with self-cross-link sodium hyaluronate gel|Subjects will be given Foley balloon (manufacturer: Zhanjiang Star Enterprise Co., Ltd.) combined with self-cross-linked sodium hyaluronate gel (manufacturer: BioRegen Biomedical (Changzhou) Co., Ltd.) after TCRA surgery.
9677636|NCT04971915|Experimental|minimalist footwear|The participants in the experimental group will receive one pair of minimalist footwear and will be asked to use them for the interventional period.
9677637|NCT04971915|No Intervention|control|The participants in the control group will be asked to wear their standard footwear as before participating in the study.
9677638|NCT04971941|Active Comparator|active|Use of Dental Vibe with inferior alveolar nerve block
9677639|NCT04971941|Active Comparator|active long buccal|Dental Vibe with long buccal injection
9677640|NCT04971941|Experimental|Time for complete anesthesia|did dental vibe shorten time for complete anesthesia
9677641|NCT04971876|Experimental|Group 1 - Lips Enhancement|Participants treated with HLR-1 for lip enhancement, with optional Touch-Up (TU) 4 weeks afterwards
9677642|NCT04971876|Experimental|Group 2 - Nasolabial Fold Correction|Participants treated with HLR-2 for nasolabial folds (NLFs) correction, with optional Touch-Up (TU) 4 weeks afterwards
9677643|NCT04971876|Experimental|Group 3 - Treatment of Midface Volume Deficit|Participants treated with HLR-3 for treatment of midface volume deficit, with optional Touch-Up (TU) 4 weeks afterwards
9677644|NCT04972227|Experimental|CY6463|CY6463 once-daily (QD) for 14 days
9975724|NCT01344174|Other|glucocorticoids treatment|
9677645|NCT04972227|Placebo Comparator|Placebo|placebo QD for 14 days
9677646|NCT04972201||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected.
9677647|NCT04972201||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected.
9677648|NCT04971967|Experimental|Intervention Group|Participants in the intervention group will receive crowdsourced partner services intervention, including postcards from the crowdsourcing contest that promote PS, provider referral and dual referral services, and take-home HIV self testing kits.
9677649|NCT04971967|No Intervention|Control Group|Participants in the control group will receive traditional partner services intervention, including referral cards that encourage the index patient to notify their partners by themselves.
10174990|NCT03847922|Experimental|Study group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection + self-administered Pro-Nox 50% nitrous oxide/50% oxygen.
10174991|NCT03847844|Experimental|Group A|Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment
9677650|NCT04972045|Experimental|CuminUP60®,then Curcumin capsules|Participants first received CuminUP60® 1600mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 1600mg on the eighth day in a fasting state.
9677651|NCT04972045|Experimental|Curcumin capsules,then CuminUP60®|Participants first received curcumin capsules 1600mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP60® 1600mg on the eighth day in a fasting state.
9677652|NCT04972240|Active Comparator|Customized PEEK abutment/ crown on a Ti base.|
9677653|NCT04972240|No Intervention|Prefabricated titanium abutment, supporting ceramometal separate crown.|
9677654|NCT04972071|Other|CSRS practice recommendation|Knowledge translation of the Canadian Syncope Risk Score (CSRS) based practice recommendations
9677655|NCT04971759|Experimental|Group L|30 Patients will receive Levobupivacaine 5%
9677656|NCT04971759|Experimental|LD group|30 patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
9677657|NCT04971759|Experimental|LF group|30 patients will receive Levobupivacaine 5% + 1µg/kg fentanyl
9677658|NCT04971824|Experimental|Physiotherapeutic arm|"There will be the physiotherapeutic intervention, total duration for each participant is three months.~The participants will be asked to fill three validated questionnaires in the beginning and in the end of study and keep records of their exercises, period and ovulation in their diaries."
9677659|NCT04971889|Active Comparator|Diabetes MNT plus MI|--Group-based dietary/dietary motivation intervention
9677660|NCT04971889|Active Comparator|Diabetes MNT|-Group-based dietary intervention
9677661|NCT04971850|Experimental|Sleep-disordered breathing (SDB)|Patients aged 1 to 20 years old with a suspicion of SDB or a high-risk of SDB due to their pathology and hospitalized at Necker Hospital for a sleep study for their clinical care.
9677662|NCT04971343||Unselected blood donors|
9677663|NCT04971343||Hospitalized patients|
9677664|NCT04971343||Known HIV-1 Ab positive|
9677665|NCT04971343||Known HIV-2 Ab positive|
9677666|NCT04971343||Known Acute HIV-1 p24 Ag positive|
9677667|NCT04971551|Experimental|Jaktinib treatment|Participants began oral administration of Jaktinib at 75mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 100mg BID Or continue 75mg BID treatment .
9677668|NCT04971616||Group 1: Patients with shoulder, neck and lower back discomfort|Patients with shoulder, neck and lower back discomfort.
10174992|NCT03847844|Placebo Comparator|Group B|Placebo (normal saline) and standard treatment
9677670|NCT04971356|Experimental|Experimental arm|1-month of Aspirin + Ticagrelor, followed by 5-month of Ticagrelor monotherapy; Afterward, Aspirin monotherapy for 6 months
9677671|NCT04971356|Active Comparator|Reference arm|12-month Aspirin plus Ticagrelor
10174993|NCT03847961|No Intervention|Control Group|The control group receive routine treatment of sepsis only. All sites agree, when feasible, to follow the tenets of the Surviving Sepsis Campaign clinical practice guidelines for management of sepsis.
9677672|NCT04971629||Cohort 1|Patients with knee osteoarthritis who use medical cannabis to manage MSK symptoms.
9677673|NCT04971629||Cohort 2|Patients with knee osteoarthritis who do not use medical cannabis.
9677674|NCT04971460||Mother and Baby Unit|Fathers and partners of women admitted to a Mother and Baby Unit
9677675|NCT04971460||Peri-natal Community Mental Health Services|Fathers and partners of women accessing community perinatal mental health services
9677676|NCT04971460||Control group|Fathers and partners of women who are not accessing mental health services in the perinatal period
9677677|NCT04971382|Experimental|curcumin combined with particulate xenograft.|"Curcumin will be used in combination with xenograft after ridge splitting surgery~Curcumin is widely used in medicine due to medicinal properties, cost-effectiveness, and simple extraction from a turmeric plant that grows in different regions in the world. Recent evidences have shown that curcumin possesses multiple biological activities and pharmacological properties including anti-inflammation , antioxidation , anticancer , antimicrobial , and free radical scavenger effects"
9677678|NCT04971382|Active Comparator|alveolar ridge splitting with use of particulate xenograft alone.|xenograft will be used alone after ridge splitting
9677679|NCT04971317|Experimental|Sugar-Sweetened Beverage (SSB) Video|
9677680|NCT04971317|Experimental|Water Video|
9677681|NCT04971317|Active Comparator|Control|
9677682|NCT04971707|Active Comparator|standard exercise training|The physical exercises intervention will include a standardized aerobic exercises training, three sessions per week for 3 months.
9677683|NCT04971707|Experimental|HRV-guided exercise training|The physical exercises intervention will include an individualized aerobic exercises training, three sessions per week for 3 months.
10174994|NCT03847961|Experimental|Experimental Group|The experimental group receive routine treatment of sepsis combined with hemoperfusion with cytokine adsorption column (CA330).
10174995|NCT03847896|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
10174996|NCT03847896|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
10174997|NCT03847896|Active Comparator|BD MDI (PT008) 160 µg|
10174998|NCT03847896|Active Comparator|AS MDI (PT007) 180 µg|
10174999|NCT03847896|Placebo Comparator|Placebo MDI|
10175000|NCT03847506|Experimental|EZE/ROS+CAN/AML|Ezetimibe/Rosuvastatin 10 mg/10 mg and Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
9677684|NCT04971330||Known HCV Ab Positive Patients|leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for positive samples.
9677685|NCT04971330||Hospitalized Patients|"leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for hospitalized patient.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
9677686|NCT04971330||Unselected Blood Donors|"Leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. les. For blood donors, Abbott PRISM HCV will be used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status."
9677687|NCT04971603|Experimental|Acupuncture treatment group|The patients will receive 24-week acupuncture treatment and 12-week follow up. Seven visits will be arranged within the 24-wk treatment period and at the end of study at wk 6, 10, 14, 18, 22, 26 and 38 for medical consultation and investigation.
9677688|NCT04971525||Darvadstrocel Cohort|Participants diagnosed with CD and CPAF, who administered at least one dose of darvadstrocel in fistula tract tissue under surgical environment will be observed.
9677689|NCT04971525||Matched Control Cohort: Standard of Care (SoC)|Participants diagnosed with CD and PAF with no history of administration of darvadstrocel, matched age at index date (within 3 years), time from CD diagnosis (within 1 year), and sex to individuals in the darvadstrocel cohort who received the alternative Standard of Care (SoC), which varies from country to country and according to local centre expertise will be observed.
9677690|NCT04971421||Benign ovarian tumors|All histological proven benign ovarian tumors
9677691|NCT04971421||Malignant ovarian tumors|All histological proven malignant ovarian tumors
10175001|NCT03847506|Active Comparator|CAN/AML|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
9677692|NCT04971421||Borderline ovarian tumors|All histological proven borderline ovarian tumors
9677693|NCT04971577|Placebo Comparator|Control arm|
9677694|NCT04971577|Experimental|Treatment arm|
9677695|NCT04971304||G-CSF originator receipt|Patients receiving filgrastim (Neupogen) or pegfilgrastim (Neulasta) per Health Care Procedural Coding System (HCPCS) J-codes.
9677696|NCT04971304||G-CSF biosimilar receipt|Patients receiving filgrastim biosimilars (filgrastim-aafi, filgrastim-sndz, tbo-filgrastim) or pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-bmez, pegfilgrastim-cbqv) per Health Care Procedural Coding System (HCPCS) J-codes.
9677697|NCT04971369|Experimental|89Zr-NY001 injection|Patients will receive a tracer (5 mg, IV) dose of Zr-89 (1.5-2 mCi) labeled NY001 (89Zr-NY001)
9677698|NCT04971694||Inclusion Group|Infants born at <30 weeks and/or <1500g that were admitted to BUMCP between January 1, 2019 and December 31, 2020
10175002|NCT03847506|Active Comparator|EZE/ROS+CAN|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg, once a day for 6 weeks
9677699|NCT04971434|Experimental|laser|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
10175003|NCT03847493||Patients with suspected sepsis|Patients admitted in the ICU with the clinical suspicion of infection/sepsis.
9677700|NCT04971434|Experimental|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
9677701|NCT04971291|Experimental|AXS-05|45 mg dextromethorphan-105 mg bupropion
9677702|NCT04971291|Active Comparator|Bupropion SR|150 mg bupropion
9677703|NCT04971265|Experimental|Low SES/High Supports|"Participants assigned to the Low SES/High Supports arm will see the Low SES/High Supports intervention"
9975725|NCT01344200|Active Comparator|Phase I: Study drug Group 1 (Celecoxib 7 mg/kg)|Study participants randomized to this group will receive a single 7 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
9975726|NCT01344200|Active Comparator|Phase I: Study drug Group 2 (Celecoxib 14 mg/kg)|Study participants randomized to this group will receive a single 14 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
9977534|NCT01362582|Experimental|PN, Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Patients receive also Best Supportive Nutritional Care defined as nutritional consultation and recommendation by experienced ecotrophologists.~Intervention: Supportive Parenteral Nutrition"
9977535|NCT01362595|Other|Leucine|No alternative treatment arm
10175004|NCT03847493||Non-sepsis Patients (control group)|Patients admitted in the ICU with other conditions apart from infection/sepsis.
10175005|NCT03847532|Other|Patients with mutations in the MutYH-gene|Patients with established diagnosis of MutYH-associated polyposis with monoallelic and biallelic mutations in the MutYH-gene
10175006|NCT03847532|Other|Patients with multiple colon polyps|Number of polyps from 4+
10175007|NCT03847532|Other|Control sample|Patients who did not have colon polyps
10175008|NCT03847623|Experimental|Curcumin|Capsules, taken orally, 8g per day (Bi-daily dosing)
10175009|NCT03847623|Placebo Comparator|Placebo|Capsules, taken orally, bi-daily dosing
9677704|NCT04971265|Experimental|Low SES/Low Supports|"Participants assigned to the Low SES/Low Supports arm will see the Low SES/Low Supports intervention"
9677705|NCT04971265|Experimental|High SES/High Supports|"Participants assigned to the High SES/High Supports arm will see the High SES/High Supports intervention"
9677706|NCT04971265|Experimental|High SES/Low Supports|"Participants assigned to the Low SES/High Supports arm will see the High SES/Low Supports intervention"
9677707|NCT04971057|No Intervention|Control Group|The control group received routine care
9677708|NCT04971057|Experimental|Multimedia information Group|The experimental group received a multimedia information
9677709|NCT04971252||Co existance of diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with combined diabetes mellitus and chronic kidney disease
9677710|NCT04971252||Diabetes mellitus without chronic kidney disease|Study basic coagulation profile and platelet indices among those patients with diabetes mellitus only
9677711|NCT04971252||Chronic kidney disease without diabetes mellitus|Study basic coagulation profile and platelet indices among those patients with chronic kidney disease without diabetes mellitus
9677712|NCT04970940|Experimental|Sequence 1|"Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days)~Wash-out for 7 days~Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days)~Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)"
9677713|NCT04971018|Experimental|Active ta-VNS|
9677714|NCT04971018|Placebo Comparator|Sham ta-VNS|
9677715|NCT04971083|No Intervention|Usual Care|"Control (CG): receives Usual Care. Observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
9677716|NCT04971083|Active Comparator|Intervention Group|"Intervention Group (IG): The intervention consists of a built-in automated analysis that provide patient-tailored nutrition recommendations and behavioural tipps. Described in detail this means that dependent on the severity of the nutrition related symptom burden (NRSB) recorded, the patients in the intervention group only are, for example provided with detailed written nutrition information and cooking recipes and/or asked to discuss the symptoms with their health care provider, dietitian, and/or physician, or even asked to seek immediate medical care.~Analog to the control group, observational data regarding energy and fluid intake, weight, quality of life, symptoms, and distress status will be recorded in the Electronic Health Platform. They will have to ability to print and share this documentation with their HCP at their own discretion.~Inflammation status will be recorded when data from routine blood draws is available"
9677717|NCT04970888|Experimental|Combined|Combined physical exercise and cognitive training. The combined intervention will include a cognitive training with aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
10175010|NCT03847558||sexual maturation in patient receiving iron chelation|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
9677718|NCT04970888|Experimental|Exercise|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform exercise training sessions either home-based or centre-based.
9677719|NCT04970888|Active Comparator|Usual care|Usual medical care with no interventions
9677720|NCT04971135|Experimental|SAN711 (SAD)|6 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of SAN711
9677721|NCT04971135|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 7 cohorts) will be randomized to receive a single dose of Placebo
9677722|NCT04971135|Experimental|SAN711 (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of SAN711
9677723|NCT04971135|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 14 daily doses of Placebo
9677724|NCT04971239|Active Comparator|topical methotrexate microemulsion|Group(A): topical methotrexate micro emulsion formulation, each patient will be instructed to apply a very thin film of 0.5 ml of it over the three psoriatic plaques three times weekly .
9677725|NCT04971239|Experimental|combination of topical methotrexate microemulsion and excimer light|Group(B) : excimer laser will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks.
10175011|NCT03847363||general anesthesia|patients underwent general anesthesia
9677726|NCT04971239|Experimental|combination of topical methotrexate microemulsion and narrow band-ultraviolet B|Group(C) : Narrow band ultraviolet B will be done twice weekly on a different psoriatic plaques in combination with topical methotrexate micro emulsion for a total treatment course of 12 weeks
10175012|NCT03847363||general and epidural anesthesia|patients underwent general and epidural anesthesia
10175013|NCT03847363||general anesthesia combined with nerve block|patients underwent general anesthesia combined with nerve block
10175014|NCT03847454|Experimental|Intervention REACH group|The intervention REACH consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity. The participants will receive 30 min training every day during 3 weeks. 3 times a week the standard training will be replaced with the intervention. The training is conducted/ supervised by a physiotherapist.
9677727|NCT04971213|Active Comparator|Non Invasive Ventilation|Bilevel non-invasive ventilation. Support pressure will be set to obtain a 6-8 mL/kg of predicted body weight PEEP will be set within 5-10 cmH2O and FiO2 for a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure) All settings will be adjusted according tolerance of the patient.
9677728|NCT04971213|Experimental|High-flow nasal cannula heated and humidified oxygen|"Flow will be set at 60 L/min and ajusted according the tolerance of the patient.~FiO2 will be set according a SpO2 equal or over 94% target. (92% in patients with chronic respiratory failure)"
9677729|NCT04971070||Hypoglycemic disturbance group|
9677730|NCT04971070||Hypoglycemia was not a disorder of consciousness group|
10175015|NCT03847454|Active Comparator|Control group (Standard of care)|The participants will receive the standard of care as intervention which consists of 30 min training every day during 3 weeks. The training is conducted by a physiotherapist.
10175016|NCT03847298||Pacemaker|
10175017|NCT03847298||Control|
9677731|NCT04970979||patients with coronary artery disease|patients with coronary artery disease
9677732|NCT04970953||Patients with intermediate risk for HFpEF at rest|Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.
9677733|NCT04970836|Experimental|Low titer with two doses of HB Vaccines|anti-HBs titer 2.5-10 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
9677734|NCT04970836|Active Comparator|Low titer with one dose of HB Vaccine|anti-HBs titer 2.5-10 mIU/mL with one dose of HB Vaccine at Day 0
9677735|NCT04970836|Active Comparator|Extremely low titer with two doses of HB Vaccines|anti-HBs titer lower than 2.5 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
9677736|NCT04970836|Active Comparator|Extremely low titer with one dose of HB Vaccine|anti-HBs titer lower than 2.5 mIU/mL with one dose of HB Vaccine at Day 0
9677737|NCT04970849||one group that is IBD endoscopist who perform the endoscopy for IBD patients|Complete the questionnaire online
9677738|NCT04970823|Experimental|The somatosensory interactive game|The somatosensory interactive game, an independent nursing intervention, promotes pain relief on the experimental group.
10175018|NCT03847207|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 8 cohorts will be dosed. A single subcutaneous injection of HTL0030310 or placebo will be administered. In each cohort, 6 subjects will receive HTL0030310 and 2 subjects will receive placebo.
10175019|NCT03847207|Experimental|Part 2 Pasireotide PD Assessment|Sixteen subjects in 2 cohorts (8 subjects per cohort) will be dosed on 4 occasions. Within each cohort, 4 subjects will be randomised to active dosing with CRH with desmopressin, GHRH and OGTT challenge and 4 subjects will be randomised to placebo dosing with CRH with desmopressin, GHRH and OGTT challenge.
10175020|NCT03847207|Experimental|Part 3 Proof of Pharmacological Effect|Up to 80 subjects in 4 cohorts (up to 20 subjects per cohort) will be dosed in up to 3 study periods. In each period, subjects will receive active drug or placebo with GHRH, OGTT and CRH with desmopressin (optional).
10175021|NCT03847246|Active Comparator|Baraclude® tablets，1.0 mg|
10175022|NCT03847246|Experimental|Entecavir tablets，1.0 mg|
10175023|NCT03847259||A(public school)|"it will be consists of 200 adolescent female from public schools, their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire.~pain will be evaluated by VISUAL ANALOG SCALE(VAS) .stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21)."
10175024|NCT03847259||B(international school)|it will be consists of 200 adolescent female from international schools their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire .pain will be evaluated by VISUAL ANALOG SCALE (VAS).stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21).
10175025|NCT03847155|Experimental|Nicotine|The patients randomized into this study arm will receive a medical intervention - nicotine patch for the period of a maximum of 7 days.
10175026|NCT03847155|Placebo Comparator|Placebo|The patients randomized into this study arm will receive a placebo patch for the period of a maximum of 7 days.
10175027|NCT03847272|Experimental|Patients|
10175028|NCT03847480|Experimental|Dose painting|Dose painting
10175029|NCT03847441|Active Comparator|Group I|
10175030|NCT03847441|Active Comparator|Group II|
10175031|NCT03847441|Active Comparator|Group III|
10175032|NCT03847441|Placebo Comparator|Group IV|
10175033|NCT03847129|Experimental|Biofeedback training group|The participants in the biofeedback training group attend a 30 minute biofeedback protocol per session, two times a week for six to eight weeks that is also combined with the regular diabetic care treatment in the Occupational Therapy Room.
10175034|NCT03847129|Active Comparator|Home-based training group|The participants in this group receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment.
10175035|NCT03847129|No Intervention|Control group|The participants in the control group receive only diabetes disease prevention consultation once and outcome assessments twice.
10175036|NCT03847324|Active Comparator|Usual Care|Group-based preoperative biomedical education, postoperative hospital and home rehabilitation.
10175037|NCT03847324|Experimental|PNE|Usual care + Preoperative Pain Neuroscience Education
10175038|NCT03847324|Experimental|Multimodal Physiotherapy|Usual care + Preoperative Multimodal physiotherapy
10175039|NCT03847077|Experimental|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application
10175040|NCT03847077|Active Comparator|Standard counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
10175041|NCT03847103|Experimental|Robotic-aided rehabilitation with bilateral practice|In addition to a 10-minutes sensorimotor stimulation programs, the experimental group received 40-minutes Robotic-assisted Therapy with Bilateral Practice programs.
9677739|NCT04970823|Experimental|A VR (virtual reality) game|A VR (virtual reality) game promotes pain relief on the experimental group.
9677740|NCT04970732|Experimental|Experimental group|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
9677741|NCT04970732|No Intervention|Control group|The control group received routine nursing after surgery.
9677742|NCT04970745||high-risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of both tests are considered very high-risk patients,
9677743|NCT04970745||risk|After performing midbrain ultrasound and tremor analysis, patients with positive results of 1 out of 2 tests are considered risk patients
10175042|NCT03847103|Active Comparator|Unilateral task-specific training|In addition to a 10-minutes sensorimotor stimulation programs, the control subjects received 40-minute unilateral task-specific training.
9677744|NCT04970745||low-risk|After performing midbrain ultrasound and tremor analysis, patients with negative results of both tests are considered risk patients
9677745|NCT04970706||Healthy Volunteers|Volunteers were healthy people without ACL rupture
9677746|NCT04970706||Patients with ACL Rupture|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
9677747|NCT04970719|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
9677748|NCT04970719|Active Comparator|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5 -day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
9677749|NCT04970576|Experimental|Treatment group|Patients in the intervention group will receive Rivaroxaban 20 mg once a day (OD) for three months
10175043|NCT03846986|Active Comparator|Apple Juice1|100% Apple Juice
9677750|NCT04970576|Active Comparator|Control group|Patients in the control group will receive usual warfarin therapy dose adjusted as per the target INR of 2 to 3
9677751|NCT04970589|Placebo Comparator|Lean/Placebo Capsule|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
9677752|NCT04970589|Experimental|Lean/Probiotics|Participants (Lean:BMI 18-23) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
9677753|NCT04970589|Experimental|Obese/Placebo Capsule|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a placebo capsule every day for 8 weeks
9677754|NCT04970589|Experimental|Obese/Probiotics|Participants (Obese:BMI 27-35) will be asked to take 400g of mango and a probiotic capsule every day for 8 weeks
9677755|NCT04970797||Conventional treatment group|Western medicine treatment
10175044|NCT03846986|Experimental|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
10175045|NCT03846986|Placebo Comparator|Raw Apple|Raw Apple
9677756|NCT04970797||Combination treatment group|Xinglouchengqi decoction combined with western medicine treatment
9677757|NCT04970498||acute myelosuppression group|WBC <4.0×10^9 14 days after radiotherapy
9677758|NCT04970498||chronic myelosuppression group|WBC <4.0×10^9 90 days after radiotherapy
9677759|NCT04970498||no myelosuppression group|WBC >4.0×10^9 during radiotherapy
9677760|NCT04970615||Two-dimensional images|Patients who receive pre-operativeinformation while the two-dimensional MR images are being shown to them by the neurosurgeon.
9677761|NCT04970615||Three-dimensional printed model|Patients who receive pre-operative information while the three-dimensional printed models are being shown to them by the neurosurgeon.
9677762|NCT04970511|Experimental|The group I: BBAT Face-to-Face Training group|"Exercises consist of supine, sitting, standing position awareness exercises and walking exercises.~Considering eight weeks, the training is designed to progress gradually each week."
9677763|NCT04970511|Experimental|The group II: Online BBAT training group|"Patients in the Internet-based BFT group will conduct their training with a physiotherapist to be connected via an online video conference system.~This group will be given the same training as the face-to-face BFT group."
9677764|NCT04970511|No Intervention|The group III: Control group|No training will be applied to the control group patients.
10187173|NCT03728855|No Intervention|Standard care|Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
9677765|NCT04970524|Experimental|control group(conventional free gingival graft)|Conventional free gingival grafts are applied to the areas of the patients determined by randomization as suggested by Sullivan and Atkins.
9677766|NCT04970524|Experimental|test group(Partially de-epithelialized free gingival graft)|Partial free gingival graft is applied to the areas of the patients determined by randomization. Unlike the control group, the epithelium on the graft was partially epithelialized.
9677767|NCT04970667|Experimental|Flupentixol melitracen tablets|The patients were treated with Flupentixol melitracen tablets according to their own conditions
9677768|NCT04970810|No Intervention|Attention Control|Subjects monthly calls similar in structure to the intervention arms, but without support. (attention placebo control)
9677769|NCT04970810|Active Comparator|My Diabetes Goal|My Diabetes Goal protocol
9677770|NCT04970810|Active Comparator|My Diabetes Goal + Community Rx|My Diabetes Goal protocol + Community Rx protocol
9677771|NCT04970420|Experimental|HeRFAPIW|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).
9677772|NCT04970420|Active Comparator|Control group|
9677773|NCT04970784||Patients cared for by the adult sector|Patients admitted to emergencies, non-hospitalized and cared for by the adult sector of emergencies (classical emergencies)
9677774|NCT04970784||Patients cared for by the geriatric sector|Patients admitted to emergencies, non-hospitalized and cared for by the geriatric sector of emergencies
9677775|NCT04970758||study group|Athletes /strength exercise
9677776|NCT04970758||control group|
9827779|NCT02467842|Active Comparator|NBP607-Y|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
9977536|NCT01362621||Children 6 to less than 12 years of age|
9677777|NCT04970485|Experimental|Talking Matters intervention|Talking Matters is a group-level, two-pronged intervention for Black and African American 14 to 19 year old adolescents recruited from school- and community-based settings in Philadelphia, PA. Goals are to reduce teens' risk for unplanned pregnancy, sexually transmitted infections, and HIV, and to strengthen protective factors to improve health. The two prongs include (1) an adolescent-focused five-session, group-level intervention called We Get to Choose (WGTC) covering sexual and reproductive health (SRH) knowledge and skills, decision making and self-worth, healthy relationships, substance use and mental health; and (2) an adult-focused three-session, group-level training called Let's Talk Real Talk (LTRT) to build SRH knowledge and skills to communicate with teens about SRH. An opportunity to connect WGTC participants to trusted adults who completed LTRT is provided during one facilitated session conducted each quarter. LTRT participants are not human subjects of the study.
9677778|NCT04970485|No Intervention|Control Group|Business as usual
9677779|NCT04970602|Experimental|MB group|This group will be given 2mg/kg methylene blue infusion within 20 minutes, 2 hours later followed by 0.5mg/kg/h for 4 hours.
9677780|NCT04970602|No Intervention|control group|This group will be given conventional vasopressors, except methylene blue, based on the attending doctor's decision.
9677781|NCT04970446|Active Comparator|FMT arm|Anaerobically prepared, freeze-thawed faecal microbiota transplantation
9677782|NCT04970446|Placebo Comparator|Placebo arm|Placebo liquid formulation (normal saline, glycerol, food colorant)
9677783|NCT04970680|Active Comparator|blind glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block with the blind technique
10175046|NCT03846817|Experimental|FAIS with intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
10175047|NCT03846817|Experimental|FAIS without intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
10175048|NCT03846739|Active Comparator|Oxytocin & Placebo, 6 IU|Intranasal administration, 6 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
9677784|NCT04970680|Active Comparator|ultrasonic glossopharyngeal nerve block|patients will have the glossopharyngeal nerve block using the ultrasonic technique
9677785|NCT04970628||Study group|Patients performed airway obstruction after anterior cervical operation
9677786|NCT04970628||Control group|Patients did not perform airway obstruction after anterior cervical operation
9677787|NCT04970693|Experimental|Furmonertinib 80mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after first/second generation EGFR-TKI therapy. These patients will receive furmonertinib 80mg combined with radiotherapy as following therapy.
9677788|NCT04970693|Experimental|Furmonertinib 160mg combined with radiotherapy|This group will enroll NSCLC patients who are oligoprogressive after third generation EGFR-TKI therapy. These patients will receive furmonertinib 160mg combined with radiotherapy as following therapy.
9677789|NCT04970082|Experimental|FFR followed by FFR-DWP (investigation)|The FFR measurement is performed with the standard method first followed by the FFR measurement with the DWP method.
9677790|NCT04970082|Experimental|FFR-DWP (investigation) followed by FFR|The FFR measurement is performed with the DWP method first followed by the FFR measurement with the standard method.
9677791|NCT04970225|Experimental|Stable state|"45 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~With severe cftr mutations~With or without PA chronic infection~Treated or not with Ivacaftor-Lumacaftor"
9677792|NCT04970225|Experimental|Starting Ivacaftor-Tezacaftor-Elexacaftor|"40 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~With at least one severe cftr mutation~With or without PA chronic infection~Initiating Ivacaftor-Tezacaftor-Elexacaftor"
9677793|NCT04970225|Experimental|Exacerbation|15 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France and hospitalized for respiratory exacerbation
9677794|NCT04970069|Active Comparator|Analgesic education|
9677795|NCT04970069|Placebo Comparator|General perioperative education|
9695312|NCT04779411||Food Frequency Questionnaire Validation Group|"The validation procedure will span over four weeks, consisting of administering the Lutein and Zeaxanthin Food Frequency Questionnaire (FFQ L/Z) and 24-hour diet recalls at multiple timepoints. Timepoints for the eight 24-hour diet recalls will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on week days.~The weekly L/Z FFQ will be completed at the conclusion of each of the four weeks.~The monthly L/Z FFQ will be completed at baseline and at the conclusion of week four."
9695313|NCT04779411||Electronic Device Use Questionnaire Validation Group|The validation procedure will occur over eight weeks consisting of administering eight 24-hour diary of electronic device use (24-hour ED use diary) and the Electronic Device Use Questionnaire (EDUQ) at three time points. The time points for the eight 24-hour ED use diaries will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on weekdays. The EDUQ will be completed at baseline and at the conclusion of weeks four and eight.
9695314|NCT04779632|Other|Crossover study: Fish Oil --> Safflower Oil|4 weeks of fish oil supplementation followed by 4 weeks of safflower oil supplementation
9977537|NCT01362634|Experimental|CAPI Intervention|an interviewer-administered comprehensive health and social risk assessment intervention
9677796|NCT04970303||Case group|investigator will recruit 60 patients with ADHD (aged between 6 and 16). Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed. Patients with ADHD will receive treatment in a clinical practice and then will be followed up for 12 months. At the 12th month, the same procedures as those performed at the baseline will be replicated for patients with ADHD.
9677797|NCT04970303||Control group|investigator will recruit 60 age- and gender-matched control subjects. Blood (10 ml) and urine (10 ml) will be obtained from each participant to analyze the levels of EDCs (Phthalates, Phenols and Parabens), growth hormone and thyroid function (TSH, T3, Free T4, T4, growth hormone, IGF-1and IGF-BP3). Behavior symptoms (ADHD-RS and SNAP-IV) and neuropsychological function (WISC, CPT and CATA) of each participant will be assessed.
9677798|NCT04970004||Patients Diagnosed with HSCT-TMA|
9677799|NCT04970108|Experimental|Egito|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Egito, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan placebo, oral."
9677800|NCT04970108|Active Comparator|Empagliflozin + telmisartan|"The patient must take 3 tablets once a day, as follows:~1 tablet Egito placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan, oral."
10175049|NCT03846739|Active Comparator|Oxytocin & Placebo, 12 IU|Intranasal administration,12 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
10175050|NCT03846739|Active Comparator|Oxytocin & Placebo, 24 IU|Intranasal administration, 24 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
10175051|NCT03847012|Experimental|patients with coronary artery diseases|The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
10175052|NCT03846661|Active Comparator|Physiomesh|Patients undergoing laparoscopic incisional hernia repair reinforced with a Physiomesh.
9677801|NCT04970121|Experimental|Duloxetine arm|Chemotherapy regimens consisting of taxanes will be used according to treatment specifications. Subjects require therapeutic intervention for painful peripheral neuropathy will receive duloxetine 20 mg (orally, once daily) as the starting dose for 1 cycle of 7 days; the current dose will be maintained for effective pain control (NRS ≤ 3 points) and increased by 20 mg at the next cycle assessment for ineffective pain control (NRS > 3 points) up to a maximum dose of 60 mg (orally, once daily). Duloxetine administration will be maintained until the uncontrolled pain (under the condition of treatment with duloxetine at its maximum dose), intolerable toxicity, completed antineoplastic therapy or subject loss of visit, death, withdrawal of informed consent, or other conditions occur. The administration of duloxetine is up to a maximum of 12 weeks.
9677802|NCT04970329|Experimental|Systane|Instill one drop three times a day for one month.
10175053|NCT03846661|No Intervention|other mesh|Patients undergoing laparoscopic incisional hernia repair reinforced with other meshes than Physiomesh.
10175054|NCT03846726||observation group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and refused surgery but went on with the watch and wait approach.
9677803|NCT04970329|Experimental|Tears Naturale 2|Instill one drop three times a day for one month.
9677804|NCT04970329|Placebo Comparator|Placebo|Instill one drop three times a day for one month.
9677805|NCT04970095|Experimental|cleft lip and palate patient|Clefts patient with transverse maxillary constriction and anteroposterior deficiency
9677806|NCT04970238|Experimental|Levosimendan group|
9677807|NCT04970238|Placebo Comparator|placebo group|
10175055|NCT03846726||surgery group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and received radical resection.
9677808|NCT04970394||Intervention|"The principal investigator reviews the medical notes of all individuals they consult over a period of three years to check if they are non responders. If confirmed as non responder, they receive a three-step verbal intervention:~Your cervical cancer screening is now overdue.~The test is easy to perform and saves thousands of lives from cervical cancer every year.~Should we book an appointment for cervical screening now so that you make sure you have it done?~Those who are seen face-to-face receive a fourth intervention:~An appointment slip is given to the patient to hand to the receptionist. This includes the patient's name and the comment, book an appointment with practice nurse for cervical screening."
10175056|NCT03846973|Experimental|Tranexamic acid|group-I will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes followed by an intravenous infusion of 1 g TXA to be given and completed over 8 h in the hospital
9677809|NCT04970394||Control|The control group receives standard unstructured reminders regarding their overdue status from any of the 6 other clinicians during appointments and / or reminder letters from the administration team.
9677810|NCT04970342|Experimental|"Sober or Double Placebo"|Subject receives alprazolam capsule containing placebo (lactose). Subject receives placebo cannabis (0% THC / 0% CBD).
10175057|NCT03846973|Placebo Comparator|Placebo|group-II will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes but will receive placebo (normal saline) infusion to be given and completed over 8 h in the hospital
10175058|NCT03846843|Experimental|OCR-002 - Treatment A|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions
10175059|NCT03846843|Experimental|OCR-002 - Treatment B|A single 5 g oral dose of OCR-002 oral solution administered under fed conditions
10175060|NCT03846843|Experimental|OCR-002 - Treatment C|A single 5 g intravenous dose of OCR-002 solution infused over 1 hour under fasting conditions
9677811|NCT04970342|Experimental|Active Alprazolam (Xanax), Placebo Cannabis|Subject receives active 0.75 mg alprazolam capsule. Subject receives placebo cannabis (0% THC / 0% CBD).
9977538|NCT01362634|Experimental|ACASI Intervention|self-administered comprehensive health and social risk assessment intervention
9677812|NCT04970342|Experimental|Placebo Alprazolam (Xanax), Active Cannabis|Subject receives alprazolam capsule containing placebo (lactose). Subject receives active cannabis (6.18% THC / <0.025% CBD).
9677813|NCT04970160||TSARP|Is a surgical procedure
9677814|NCT04970160||ASARP classic|Surgical procedure
9677815|NCT04970160||PSARP|Surgical procedure
9677816|NCT04970160||Modified ASARP|Surgical procedure
10175061|NCT03846843|Experimental|OCR-002 - Treatment D|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions following discontinuation of lactulose
9677817|NCT04970030|Active Comparator|mechanical intracanal (ML) lithotripsy|TTS mechanical lithotripter
9677818|NCT04970030|Experimental|electrohydraulic intracolangioscopic (EHL) lithotripsy|electrohydraulic lithotripsy with Autolith probe
9677819|NCT04970381|Experimental|Rivaroxaban|
9677820|NCT04970316||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
9677821|NCT04970316||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
9677822|NCT04970043|Experimental|Camrelizumab+ pemetrexed + platinum|
9677823|NCT04969679|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Active group will receive E. coli Nissle 1917 (Mutaflor®).
9677824|NCT04969679|Placebo Comparator|Placebo|Placebo group will receive placebo drug.
10175062|NCT03846843|Experimental|OCR-002 - Treatment E|6 g OCR-002 per day (2 tablets TID for 6 g total daily dose)
10175063|NCT03846843|Experimental|OCR-002 - Treatment F|12 g OCR-002 per day (4 tablets TID for 12 g total daily dose)
10175064|NCT03846843|Experimental|OCR-002 - Treatment G|21 g OCR-002 per day (7 tablets TID for 21 g total daily dose)
10175065|NCT03846869|Experimental|major cations|bood sample
9677825|NCT04969692|No Intervention|non-warming group|
9677826|NCT04969692|Active Comparator|warming group|
9677827|NCT04969653||Cases|All adults with an episode of active atopic dermatitis at any point between 1st Jan 2010 to 1st Jan 2015 will be included for analysis.
9677828|NCT04969653||Controls|Adults without atopic dermatitis or other skin conditions matched to cases by age, gender, and duration of practice registration.
10175066|NCT03846908|Experimental|MCT|subjects start with MCT fat load
9677829|NCT04969640||infective keratitis|50 cases with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.
9677830|NCT04969809|Experimental|Patients on diet|We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment.
9677831|NCT04969809|Experimental|patients without diet|Half of the patients have abandoned the diet treatment and mostly no longer come for outpatient examinations.
9677832|NCT04969900|Placebo Comparator|Placebo - Jojoba Oil (100% organic golden expeller-pressed Simmondsia chinensis)|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
9677833|NCT04969900|Active Comparator|Investigational Product - A 10% dilute Lavandula angustifolia - jojoba oil essential oil blend|Study randomization to lavender aromatherapy or placebo will occur just prior to the initiation of the abortion procedure. A permutated block stratified randomization scheme will be utilized so that equal numbers of participants receiving no sedation and PO sedation will be randomized to lavender aromatherapy or placebo. 1cc of dilute lavender aromatherapy and placebo will be pre-filled in a 5/8 dram mini amber glass bottle provided to the patient. Immediately prior to procedure start (defined as after receiving antibiotic and emptying bladder), participants will be instructed to self-administer the study product. They will bring down their personal cloth mask to chin level and rub the study product within the amber glass bottle on their upper lip and nose (left and right ala, alarfacial grooves, and columella). Participants will be instructed to take 4 deep breaths and then replace their mask over their nose. The patient will then proceed to the procedure.
9677834|NCT04969705|Active Comparator|Group A (spinal Dexmedetomidine)|. Spinal needles (22 G) will be introduced in sitting position after skin disinfection with povidine iodine, iliac crest will be palpated and thumb extended to meet the midline, feeling the space between L4 and L5. spinal needle penetrates through the dura matter, a pop will be felt and then after the needle puncture into the subarachnoid space and the appearance of clear cerebrospinal fluid, the intrathecal local anesthetic will be injected. All patients will be receiving 2 ml heavy bupivacaine 0.5% plus 5 µg dexmedetomidine to total volume of 2.5 ml.
9695315|NCT04779632|Other|Crossover study: Safflower Oil --> Fish Oil|4 weeks of safflower oil supplementation followed by 4 weeks of fish oil supplementation
9695316|NCT04779463||Mechanical Ventilated patients|All patients are invasively mechanically ventilated at least 24 hours, and are clinically stable as ready to undergo a spontaneous breathing trial.
10175067|NCT03846908|Experimental|SFA|subjects start with SFA fat load
10175068|NCT03846908|Experimental|MUFA|subjects start with MUFA fat load
10175069|NCT03846921||Viral infection|Patients with proven viral infections will have laboratory blood test taken
10175070|NCT03846921||Bacterial Infection|Patients with proven bacterial infections will have laboratory blood test taken
10175071|NCT03846700|Experimental|aquablation|patients with prostatic volume included between 30 and 120 ml will be treated with water jet (aquablation). patients with prostatic volume > 65 ml will be compared with holep arm and patients with prostatic volume included between 30 and 65 ml will be compared with pvp arm.
9677835|NCT04969705|Active Comparator|Group B (spinal with transversus abdominus plane block)|Spinal needles (22 G) introduced in sitting position . patients receiving1.7 to 2.2 ml heavy bupivacaine 0.5%( according to weight and height ) + 1 ml normal saline = total volume of 2.5 ml then at surgery end under sonographic guide transducer placed in transverse plane above iliac crest.A 90 mm 22 G short beveled block needle inserted in-plane with transducer, in anterior-posterior direction. needle connected to syringe contains20 ml of bupivacaine 0.25%+10 µg dexmedetomidine to deposit local anesthetic deep into the fascial layer between internal oblique & transversus abdominis muscles on each side.
9677836|NCT04969705|Active Comparator|Group C ( controlled group ) Spinal Anesthesia only :|Patients will be anesthetized only with spinal anesthesia using Bupivacaine Hcl( 10 mg).
9677837|NCT04969822|No Intervention|Embryo selection by standard morphologic criteria|The embryo for transfer will be selected by the embryologist on the basis of the morphologic appearances on day 5, according to the Gardner criteria using the ranking guideline.
9677838|NCT04969822|Experimental|Embryo selection by iDA|Time-lapse videos will be analyzed by iDA and the embryo for fresh transfer on day 5 will be prioritized on the strict basis of the embryo with the highest iDA score. For a frozen cycle; the first embryo to be warmed will be the one with the highest iDA score.
9677839|NCT04969666|Experimental|IPED2015_dose 1|Active treatment
9677840|NCT04969666|Experimental|IPED2015_dose 2|Active treatment
9677841|NCT04969666|Placebo Comparator|Placebo|Placebo treatment
9677842|NCT04969874|Other|remote follow-up|patients with chronic disorders on sequelae of anti-cancer treatments after an intensive rehabilitation stay will undergo 5 months of remote follow-up with speech therapists including questionnaires and interview
9677843|NCT04969744|Experimental|Intermittent Cold Exposure (ICE)|Stage 1- healthy volunteers aged 16-26 years will receive ICE for one day. stage 2a - controls aged 8-16 will receive ICE for one day. Stage 2b- NAFLD patients aged 8-16 years will receive ICE for one day or choose to continue for 5 days.
9677844|NCT04969757|Experimental|Predigraft|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
10175072|NCT03846700|Active Comparator|holep|patients with prostatic volume > 65 ml will be treated with holmium laser technique (Holep)
10175073|NCT03846700|Active Comparator|pvp|patients with prostatic volume included between 30 and 65 ml will be treated with photoselective vaporization of prostate (pvp).
9677845|NCT04969796|Experimental|REACH Hope|Participants receive the REACH behavioral intervention coupled with the Department of Defense Hope Box app.
9677846|NCT04969796|No Intervention|Wait list control|No intervention.
10175074|NCT03846960|Experimental|preterm infants|A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. A feasibility study of 10 preterm infants 30-36 gestational age at birth, that requires surfactant administration for the indication of respiratory distress syndrome, and do not require immediate intubation
9677847|NCT04969614||kidney transplant recipients|kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine
9677848|NCT04969588||Children and adult|Participants aged 6-65 years old are recruited for the measurements of depth camera, bioelectrical impedance analysis and dual energy X-ray absorptiometry.
9677849|NCT04969952|Experimental|Group A|Group A had watching educational module plus ACP brochure
9677850|NCT04969952|Active Comparator|Group B|Group B ACP brochure only
9977539|NCT01362634|No Intervention|Control|waitlist control condition
9677852|NCT04969848||eMSGait|Record of IGP using IMU sensor (Metamotion R mbientlab) during T25FW.
9677853|NCT04969536|Experimental|Branched chain amino acid supplementation|Consumption of 8 ounces of water with addition of 2.5 g of leucine, 1.25 g of isoleucine, and 1.25 g of valine immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
9677854|NCT04969536|Placebo Comparator|Placebo|Consumption of 8 ounces of a flavor matched beverage sweetened with a sucralose-based drink mix immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
10175075|NCT03846713|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
10175076|NCT03846713|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
9677855|NCT04969523|Experimental|es-ketamine|es-ketamine 0.5mg/kg iv
9677856|NCT04969523|Placebo Comparator|saline|iv saline with the same volume of es-ketamine
9677857|NCT04969458||participants|The study included individuals whose native language is Turkish, who are over the age of 18 and under the age 70, diagnosed with chronic low back pain, without Psychiatric disorder, Cognitive impairment, Dementia, or Alzheimer's and who want to participate in the study.
9677858|NCT04969354|Experimental|CAR-T cell immunotherapy|The registered patients will received CAR-T cell immunotherapy for the new specific chimeric antigen receptor of CAIX antigen by infusion.
9677859|NCT04969263|Experimental|mRNA-1273 vaccine (Pfizer/BioNTech)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Pfizer/BioNTech will receive a third dose of the the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
9677860|NCT04969263|Experimental|mRNA-1273 vaccine (Moderna)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Moderna will receive a third dose of the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
9977540|NCT01362660||Infants with potential exposure in utero|
10175077|NCT03846856||Ovarian cancer patients|Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
10175078|NCT03846934||Ultrasonography thoracic|Ultrasonography thoracic
9677861|NCT04969146|Experimental|Modified Cognitive Behavioral Therapy Intervention Dyadic|The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up.
9677862|NCT04969146|Experimental|Modified Cognitive Behavioral Therapy Intervention Patient Only|The patient in the patient only intervention arm will receive 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up
9677863|NCT04969289|Experimental|Dr. Eric Digital Health Intervention|"Participants will interact with an ED-based iPad and the Dr. Eric app for a recorded period of time. After completion, an animated video will explain the ERIC texting program and live office hours. The participant enters his phone number and then receives a welcome text. Weekly texts are sent directly to the participant phone via short message service (SMS)."
9677864|NCT04969289|No Intervention|Standard of Care|Participants randomized to the SC arm will receive standard medical care as determined by the ED provider, which is typically referral to a primary care or adolescent provider. Mobile telephone numbers will be collected for follow up purposes.
9975727|NCT01344200|Placebo Comparator|Phase II: Group A: Placebo|"Study participants will receive a single dose of placebo. Placebo will be liquid. The study participant will drink it.~The timing of when the study participants in this group will take placebo will be determined in a second randomization:~Group A.1: will take placebo 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.2: will take placebo 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.3: will take the placebo 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group A.5: will take the study medication 0 to 60 minutes prior to having their LP±BMA. The study medication will be taken at the hospital."
9677866|NCT04969107|Active Comparator|transanal TME (taTME)|patients with rectal cancer receiving transanal TME
9677867|NCT04969107|Active Comparator|abdominal TME (abTME)|patients with rectal cancer receiving open, laparoscopic or robotic TME
9677868|NCT04969328|Active Comparator|ParTNer-STEPs|Parents and adolescents will receive the ParTNER-STEPs program and standard care.
9677869|NCT04969328|No Intervention|Standard care|The adolescent and their parents will receive standard care
9677870|NCT04969211|Experimental|Sequence A: VHX-896 then iloperidone|
9677871|NCT04969211|Experimental|Sequence B: Iloperidone then VHX-896|
9677872|NCT04969341||Screening (survey, medical record review)|Patients complete survey over 20 minutes consisting of validated and piloted items related to cost and convenience barriers in lung cancer screening, personal financial and lung cancer risk perception questions, and the Telehealth Satisfaction and Usefulness questionnaire. Patients also have their medical records reviewed retrospectively.
9677873|NCT04969484|Experimental|ImPAcTT intervention|Within 48-72 hours of enrollment in the study, the primary participant and family will receive an ImPAcTT Telehealth visit with the PC provider. The provider will conduct a comprehensive PC assessment aligned with the National Consensus Project for Quality Palliative Care guidelines. Visits, which may include remote physical assessment using a digital stethoscope, dermatoscope, etc., will be documented and transmitted to the NH. Advanced Care Planning (ACP) and goals of care discussions will be facilitated by the ability to virtually share and edit documents, such as the Physician Orders for Life Sustaining Treatment (POLST), in real time with primary participants and/or family. The PC provider will conduct follow-up visits 1 week following the initial visit, then on a case-by-case basis.
9677874|NCT04969484|No Intervention|Usual care|Participants will receive the standard of care established at the NH.
9677875|NCT04969406|Experimental|Imaging by BOSS System|Imaging by the BOSS System
9677876|NCT04969419||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
9677877|NCT04969419||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
9977541|NCT01362673|Experimental|Single dose|
9977542|NCT01362673|Experimental|Multiple dose|
9977543|NCT01362699|Experimental|JNJ-31001074|
9977544|NCT01362699|Placebo Comparator|Placebo|
9977545|NCT01362725|Experimental|Spinal cord stimulation|
9977546|NCT01362738|Active Comparator|Ablation of PV and extra-PV triggers|Conventional approach which includes pulmonary vein isolation (PVI) and ablation of extra-pulmonary triggers
10175079|NCT03846895|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following:~Power: 40 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 3~D-pulse mode."
9677878|NCT04969445||Vaccine group|Participants in this arm have received 3 doses of HPV 16/18 bivalent vaccine that contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant.
9677879|NCT04969445||Control group|Participants in this arm have received 3 doses of HEV vaccine that contains 30μg HEV virus-like particle antigen adsorbed in alum-adjuvant.
9677880|NCT04969432|Experimental|Telerehabilitation|
9677881|NCT04969432|Experimental|Face-to-face|
9677882|NCT04969393|Experimental|Group A (High Intensity Laser therapy + Conventional Physical Therapy)|Patients in group (A) received conventional physical therapy program along with HILT. Patients received pulsed Nd: YAG laser treatment, produced by EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2).
9677883|NCT04969393|Active Comparator|Group B (Conventional Physical Therapy)|Patients in this group received the conventional physical therapy program in the form of splinting, tendon and neural gliding exercises. Patients were instructed to wear a neutral custom volar splint at night and while performing strenuous activities during the day for 5 weeks.Also, the patients performed nerve-and tendon-gliding exercise under direct supervision of the therapist during the treatment sessions. Each exercise was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
9977547|NCT01362738|Active Comparator|LAA isolation along with the conventional ablation strategy|LAA isolation along with the conventional ablation strategy
9677884|NCT04969497|Experimental|Sequence ABC|Receives interventions in the sequence, A, B, C.
9677885|NCT04969497|Experimental|Sequence CAB|Receives interventions in the sequence, C, A, B.
10175080|NCT03846895|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following:~Power: 0.5 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 1,~Smart-pulse mode."
10175081|NCT03846752|Active Comparator|7 Fr. radial access|radial artery access for complex PCI
10175082|NCT03846752|Active Comparator|7 Fr. femoral access|femoral artery access for complex PCI
10175083|NCT03846765|Experimental|Phenylephrine continuous infusion|
10175084|NCT03846765|Experimental|Dobutamine continuous infusion|
9677886|NCT04969497|Experimental|Sequence BCA|Receives interventions in the sequence, B, C, A.
9677887|NCT04969497|Experimental|Sequence CBA|Receives interventions in the sequence, C, B, A.
9677888|NCT04969497|Experimental|Sequence BAC|Receives interventions in the sequence, B, A, C.
9677889|NCT04969497|Experimental|Sequence ACB|Receives interventions in the sequence, A, C, B.
9677890|NCT04969185||Group 1: Children eligible to receive SMC diagnosed with uncomplicated Plasmodium falciparum malaria|Children eligible to receive SMC (6-59 months of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility.
9677891|NCT04969185||Group 2: Children eligible to receive SMC presenting at health facility without malaria parasitemia|Group 2 will be defined as children eligible to receive SMC (6-59 months of age) who presented at the health facility and tested negative for malaria parasitemia.This group will serve as the control group to Group 1 Cases to compare the SP-AQ drug levels between children who did and did not get malaria.
9677892|NCT04969185||Group 3: Children 5-10 years of age diagnosed with uncomplicated Plasmodium falciparum malaria|Group 3 will be defined as children ineligible to receive SMC (5-10 years of age) who were diagnosed with uncomplicated P. falciparum malaria at the health facility. This group will serve as the control group to Group 1 Cases to compare the prevalence of SP and AQ resistance markers.
9677893|NCT04969172|Active Comparator|1010 Exosome|103 patients will receive either 1010 exosome particles.
9677894|NCT04969172|Placebo Comparator|Placebo|52 patients will receive placebo- saline.
9677895|NCT04969133|Active Comparator|TAP Block|"Transverse abdominal block is realisated at the beginning of the surgery with ultrasound guided technique with levobupivacaine 2.5mg/mL, 0.3mL/kg each side.~The patient receives usual analgesia protocol."
9977548|NCT01362751||Nursing home residents|In this study, patients from both the somatic and the psychogeriatric department are included. For the primary endpoint 'successful rehabilitation' only the patients from the somatic departments are included.
10175085|NCT03846648|Active Comparator|Cypep-1|"CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.~In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.~In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed."
9677896|NCT04969133|Active Comparator|local infiltration of the trocar wounds|"local infiltration of the trocar wounds is realisated at the end of the surgery by the surgeon with levobupivacaine 2.5mg/mL 0.6mL/kg distributed in each trocar opening.~The patient receives usual analgesia protocol."
9677897|NCT04969029|Experimental|immunotherapy|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
9677898|NCT04969029|No Intervention|chemotherapy|The chemotherapy regimen of the standard chemotherapy group was XELOX regimen, oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 21 days. The duration of treatment was determined according to the patient's postoperative pathological stage (3 months for T4N0/ T1-3N1 and 6 months for T4N+/ T1-3N2).
9677899|NCT04968756|Experimental|Treatment with the SPECTRALIS CENTAURUS device|"In Stage 1, two laser pattern will be applied in areas of the retina that require ablative laser photocoagulation.~In Stage 2, a laser pattern will be applied along and on the outside of the arcades. Furthermore, a treatment pattern will be applied to an area temporal to the fovea affected by intermediary age-related macular degeneration (AMD) and confluent soft drusen."
9677900|NCT04968795||Control|Participate in filling the questionnaire but NOT the meditation/wellness session (control).
9677901|NCT04968795||Wellness Group|Participate in filling the questionnaire and the meditation/wellness session
9677902|NCT04968977||UPLM-ISR|
9677903|NCT04968665||healthy volunteers|gait testing and MRI at baseline for healthy volunteers
9677904|NCT04968665||ACL-deficient patients|gait testing and MRI at pre-operation, 6 months post-operation, 1 year post-operation, 2 years post-operation
9677905|NCT04968691|Experimental|Telerehabilitation group|The group to which a structured exercise program supported by telerehabilitation will be treated.
9677906|NCT04968691|Active Comparator|Control group|The group to which the home exercise program will be treated.
9677907|NCT04968600|Experimental|Posterior-cruciate-ligament-retaining (CR)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
9677908|NCT04968600|Experimental|posterior-cruciate-ligament-stabilized (PS)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
9677909|NCT04968639||Axial pain positive group|Postoperative VAS score ≥ 3 points at 3-month follow-up
9677910|NCT04968639||Axial pain negative group|Postoperative VAS score ≤ 2 points at 3-month follow-up
9677911|NCT04968587|Other|Group 1: RACD - RCA|First period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED and second period of treatment with Regional Citrate Anticoagulation SLED
9677912|NCT04968587|Other|Group 2 : RCA - RACD|First period of treatment with Regional Citrate Anticoagulation SLED and second period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED
9977549|NCT01362764|Other|001|Abiraterone acetate tablets Type=exact unit=mg number= 250 form=tablet route=oral use as a single dose
10175086|NCT03846648|Placebo Comparator|Placebo|Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.
10175087|NCT03847025||Lead extraction|Patients undergoing clinically indicated lead extraction procedures.
10175088|NCT03846609|Experimental|double balloon platform|Device: double balloon interventional platform (DiLumen)
10175089|NCT03846609|Active Comparator|no double balloon platform|Device: no double balloon interventional platform (DiLumen)
10175090|NCT03846518|Active Comparator|Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
9677913|NCT04968704||patients undergoing facial reconstructive surgery|Patients with facial cancer or disfigurement who require reconstructive surgery will be offered participation in this study.
9677914|NCT04968769|Experimental|ischemic compression and exercise|"Individuals were positioned in a comfortable position in a chair with back support. By palpating the UT muscle, first the taut band and then the active TP on the muscle were determined. Before starting the treatment, , a statement was made to the individual that you will soon feel a high level of pain with pressure, and at the same time, you may feel pain, tingling, pricking in additional areas (head-neck-shoulder-arm), after a while the pain will decrease and disappear. In this process, try to stay as steady as possible and breathe regularly and calmly.'' The highest level of pressure that the patient could tolerate was applied to the determined TP with the thumb. Pressure time will be in the range of at least 10-20 seconds and at most 60 seconds; It was terminated after the therapist felt complete relaxation in the tissue under his thumb or after the patient received the return of pain completely disappeared"
9677915|NCT04968769|Experimental|kinesio taping and exercise|While performing KT, the individual was seated in a comfortable and upright position in a chair with back support. The subject was asked to bring his hand to his back in internal rotation of the shoulder of the taped side and to bring his head to the contralateral lateral flexion and contralateral rotation so that the UT muscle was in a tense position. KT was applied using 'muscle inhibition technique' to ensure correct contraction of the muscle with muscle length/tension optimization, to target the reduction of excessive muscle tension, and to increase circulation with the effects of the tape on the skin. In this technique, to inhibit the muscle, the tape direction is from the muscle insertion to the origin. KT was performed 5 cm below the acromion to the protuberantia occipitalis with 10% tension
9975728|NCT01344200|Active Comparator|Phase II: Group B: Study drug (Celecoxib 7 mg/kg)|"Study participants randomized to this group you will receive a single 7 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group B.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group B.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
10175091|NCT03846518|Experimental|mini Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the mini Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
10175092|NCT03846479|Experimental|Itacitinib|Itacitinib 200 mg administered orally daily
10175093|NCT03846466|Experimental|Part1 Dose 1A|Single administration
10175094|NCT03846466|Placebo Comparator|Part1 Dose 1P|Single administration
10175095|NCT03846466|Experimental|Part1 Dose 2A|Single administration
9677916|NCT04968769|Active Comparator|exercise|In order for all the exercises to be done correctly and not to cause any pain, the individuals were asked to perform the movements in front of the mirror. Posture exercises given the individuals for scapular retraction. During the posture exercises individual was positioned in a chair without back support. By counting 5 it was requested to do 10 repetitions of each exercise. For the UT muscle stretching, individuals were asked to hold their right ear with their left hand over their head while sitting on a back-supported chair with their hips and back fully resting on the chair, and to bring their left ear closer to their left shoulder with the help of their hand and count to 20 from the outside.
9677917|NCT04968860||Study group|Composed of children/adolescent individuals who have a definitive diagnosis of lymphoid leukemia or acute myeloid leukemia, who will be invited to participate in the research, regardless of race or gender.
10175096|NCT03846466|Placebo Comparator|Part1 Dose 2P|Single administration
10175097|NCT03846466|Experimental|Part1 Dose 3A|Single administration
10175098|NCT03846466|Placebo Comparator|Part1 Dose 3P|Single administration
10175099|NCT03846466|Experimental|Part1 Dose 4A|Single administration
10175100|NCT03846466|Placebo Comparator|Part1 Dose 4P|Single administration
10175101|NCT03846466|Experimental|Part1 Dose 5A|Single administration
10175102|NCT03846466|Placebo Comparator|Part1 Dose 5P|Single administration
10175103|NCT03846466|Experimental|Part1 Dose 6A|Single administration
10175104|NCT03846466|Placebo Comparator|Part1 Dose 6P|Single administration
10175105|NCT03846466|Experimental|Part1 Dose 7A|Single administration
10175106|NCT03846466|Placebo Comparator|Part1 Dose 7P|Single administration
10175107|NCT03846466|Experimental|Part2 Dose 1A|Multiple administration
10175108|NCT03846466|Placebo Comparator|Part2 Dose 1P|Multiple administration
10175109|NCT03846466|Experimental|Part2 Dose 2A|Multiple administration
10175110|NCT03846466|Placebo Comparator|Part2 Dose 2P|Multiple administration
10175111|NCT03846531|Active Comparator|Nano-Pulse Stimulation (NPS) Lesion|Three of four selected SK lesions receive Nano-Pulse Stimulation treatment.
10175112|NCT03846531|No Intervention|Non-Treated Lesion|One of four SK lesions is randomized to not receiving Nano-Pulse Stimulation treatment.
10175113|NCT03846440||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
10175114|NCT03846362|Experimental|intermediate risk MRD2>0,1%|MRD2>0,1% - FLA - MRD3 - HSCT
9677918|NCT04968860||Control group|The control group is going to consist of healthy children/adolescent individuals, non-syndromic, without history of cancer, matched by age and gender in relation to the study group, who have not used antibiotics 48 hours before or in the day of evaluation.
9677919|NCT04969042|Experimental|Stimulation|Participants will receive pre-implantation rehabilitation, implantation of the closed-loop spinal cord stimulator, and stimulation (according to the functional mapping) assisted rehabilitation post-implantation during the trial.
9677920|NCT04968990|Active Comparator|Favorable Histology Stage I & II and FH Stage III/IV|Favorable Histology Stage I & II and FH Stage III/IV Delayed Local Control with clear surgical margins and pathologically negative lymph nodes. Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
9677921|NCT04968990|Active Comparator|Stage III & IV Adjuvant RT and Stage V|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT.
9975729|NCT01344200|Active Comparator|Phase II: Group C: Study drug (Celecoxib 14 mg/kg)|"Study participants randomized to this group you will receive a single 14 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group C.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.4: will take the study medication 1 to 2 hours prior to having your LP±BMA. The study medication will be taken at the hospital.~Group C.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
9677922|NCT04968990|Active Comparator|Stage V Adjuvant RT:|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy. Those with evidence of LN involvement, surgical margin involvement, local or diffuse spill, gross disease in the renal bed or peritoneal implants, will receive adjuvant PBRT
9677923|NCT04968873|Experimental|Patients with Choledocholithiasis|Patients were managed by elective open cholecystectomy and operative exploration of the common bile duct.
9677924|NCT04968613|Experimental|Madopar monotherapy group|Patients in this group received Madopar monotherapy
9677925|NCT04968613|Active Comparator|senfrol monotherapy group|Patients in this group were treated with senfrol (D2 receptor agonist) alone
9677926|NCT04968613|Placebo Comparator|placebo group|Patients in this group were treated with selegiline alone
9677927|NCT04968626|Experimental|IS GROUP|Patients who received an operation to treat their isthmic spondylolisthesis (IS, Meyerding grade I-II)
9677928|NCT04968626|No Intervention|AS GROUP|The asymptomatic adults had no history of severe back pain or spinal trauma
9677929|NCT04969016|Experimental|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
9677930|NCT04969016|Active Comparator|Stapler|surgical wound closure with stapler
9677931|NCT04968730|Placebo Comparator|control group A|routine nursing after operation
9677932|NCT04968730|Experimental|intervention group B|Nursing care after operation with stage intervention
9677933|NCT04968561||cohort 1|"Adult patients~Admitted in the ENT and Cervico-Facial Surgery department of the Gabriel Montpied University Hospital in Clermont-Ferrand.~From November 2020 to October 2021,~Requiring endoscopic sinus surgery~With good quality imaging (CT scan and/or MRI)"
9677934|NCT04968535|Experimental|Therapy|Patients receiving suprathreshold electrotherapy in weekly intervals for a Duration of 30 min each. Device calibration with determination of the individual threshold was performed prior to the application of electrical current.
9677935|NCT04968535|Sham Comparator|Control|Patients receiving device calibration without consequent electrotherapy.
9677936|NCT04968535|No Intervention|Control of control|Patients lay on the mat without receiving device calibration nor electrotherapy.
9677937|NCT04968327|Experimental|Micro-osteoperforations|
9677938|NCT04968327|Active Comparator|Canine retraction|
9975730|NCT01344213|Active Comparator|Pregabalin|Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
9975731|NCT01344213|Active Comparator|Celecoxib|Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
9975732|NCT01344213|Active Comparator|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
9975733|NCT01344213|Placebo Comparator|Placebo|Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
9975734|NCT01344239|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
9975735|NCT01344239|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia
9975736|NCT01344252|Experimental|Topical|
9975737|NCT01344252|Active Comparator|subtenon|
10175115|NCT03846271|Experimental|Oxytocin then placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
10175116|NCT03846271|Experimental|Placebo then oxytocin|Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
9677939|NCT04968353|Active Comparator|Incisally-beveled|Use of incisally-beveled attachment to extrude lateral incisor
9677940|NCT04968353|Active Comparator|Gingivally-beveled|Use of gingivally-beveled attachment to extrude lateral incisor
9677941|NCT04968353|Active Comparator|Optimized|Use of optimized attachment to extrude lateral incisor
9677942|NCT04968353|Active Comparator|Horizontal|Use of horizontal (unbeveled) attachment to extrude lateral incisor
9677943|NCT04968275|Experimental|CHAMPS and EIS|The Cannabis Harm-reducing App for Managing Practices Safely (CHAMPS) is a brief harm reduction e-intervention based on the principles of motivational interviewing and harm reduction approaches. This e-intervention will be completed by the participant using a smart phone. There will be a total of six individual sessions each lasting 15-20 min. There will be one booster session offered at 4 weeks post-intervention to review goal setting, evaluate motivation around changing cannabis use practices. This e-intervention will be administered adjunctively to psychosis early intervention services (EIS).
9677944|NCT04968275|No Intervention|EIS alone|Early intervention services (EIS) for psychosis will be offered as per standard of care at participating clinical sites. Theses services vary but typically include pharmacotherapy and individual and/or group psychotherapy. Any visits and services offered in the EIS arm will be considered 'usual care' and administered either through in-person clinic visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
9677945|NCT04968314||ChiPP Groups|Parents enroll in Chicago Parent Program groups offered at their child's school
9677946|NCT04968392|Experimental|L group|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
9677947|NCT04968392|Experimental|LD group|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
9677948|NCT04968171||People with newly diagnosed diabetes mellitus type 1|"People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology.~Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years."
9677949|NCT04968431||Mitral Stenosis patient|
9677950|NCT04968301||hip developmental dysplasia group|patients with developmental dysplasia of hip
9677951|NCT04968301||femoroacetabular impingement group|patients with femoroacetabular impingement
9677952|NCT04968301||control group|healthy volunteers
9677953|NCT04968262||Sepsis|Patients receive sepsis therapy.
9677954|NCT04968262||Sepsis-related acute kidney injury|Patients receive sepsis and sepsis-related acute kidney injury therapy.
9677955|NCT04968496|No Intervention|Food Insecure Group|Children randomized to the naturally-occurring Food Insecure group will receive a weekly newsletter with information on available area-specific food programs. The weekly newsletter will be sent in two ways: 1) a paper copy will be mailed and 2) a link to an electronic version will be sent via Ilumivu to families to remove any barriers to engagement with the information. In the absence of school meal programs, children from low-income households are at increased risk for food insecurity during the summer.37-39 Given low engagement in summer food programs, it is not expected that this newsletter will impact food security in this group.
9677956|NCT04968496|Experimental|Food Secure Group|Children randomized to the Food Secure group will receive breakfast and lunch meals for eight weeks throughout the summer. Weekly meals will be delivered to each participant's home by Yumble, a company that prepares meals for children ages 3 to 12 years and ships them fresh in insulated, food safe packaging to the home. The meals have similar nutrition standards to those offered via the National School Lunch Program and include fruits, vegetables, whole grains, and lean/ vegetarian proteins. To accommodate cultural preferences or dietary constraints, Yumble offers 20 different breakfast, lunch and dinner meals each week. Families will choose their weekly menus to improve adherence. Participants who have siblings in their home will be provided a family meal kit, which provides 24 meals each week. Additional meals will help to prevent household food insecurity and ensure that the child enrolled in the study consumes the meals each week.
9677957|NCT04968223||Patient Group|Patients with Schizophrenia
9677958|NCT04968223||Relatives Group|Healthy first-degree relatives of persons with schizophrenia
9677959|NCT04968223||Control Group|Healthy subjects without family history of psychotic illness
9677960|NCT04968509|Experimental|treatment with PCSK9 inhibitor and statin|Patients in experimental group were treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab subcutaneously every two weeks ) and conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
9677961|NCT04968509|Other|statin-only treatment|Patients in control group were only treated with conventional intensive lipid-lowering therapy(Atorvastatin 40-80mg or Rosuvastatin 20-40mg or Atorvastatin 20mg+ Ezetimibe 10mg or Rosuvastatin 10mg+ Ezetimibe 10mg).
9677962|NCT04968132|Active Comparator|Standard care group|This group will receive standard perioperative care, surgical treatment, and pain medications.
9677963|NCT04968132|Experimental|Opioid reduction group|Patients will participate in a multicomponent pathway coordinated by a trained coordinator who will facilitate patient participation and engagement with each interventional component.
9677964|NCT04968145|No Intervention|Control Group|Participants in the control group receive routine follow up care which consists of (i) written instructions regarding potential complications and the contact information of their treating surgeon, (ii) a follow up telephone call 4 weeks following discharge by a member of the health care team and (iii) an in-person follow up visit in clinic with the treating surgeon 4-6 weeks following discharge.
9677965|NCT04968145|Experimental|Intervention Group|The participants in the intrevention group receive the same routine care as the control group in addition to post discharge monitoring with the Home to Stay app
9677966|NCT04968444|Active Comparator|one to one traditional physiotherapy|For clarity, 1-1 physiotherapy takes the form of a private consultation between patient and therapist. A discussion of symptoms is had and an individual physical examination is undertaken to explore what is mechanically causing their pain and what can be offered to help. This is also when the initial outcome scores are taken. Treatments are then offered which can take the form of exercise therapy, massage, and manual therapy. Symptoms are regularly monitored for effectiveness of treatment and adjusted accordingly. The number of sessions that forms their treatment is variable depending on response to treatment and how they are coping. At the final session the end outcome scores will be taken.
9975738|NCT01344265||consecutive patients|there is only one group in our study
9977550|NCT01362764|Other|002|Abiraterone acetate suspension Formulation 1 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
10175117|NCT03846596||Evaluated|An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
10175118|NCT03846375|Experimental|Participants in DBT|Psychotherapy: The participants will be given standard DBT treatment.
9677967|NCT04968444|Active Comparator|BOOST workshop group|The BOOST workshop is a novel approach whereby participants are invited to a 2.5 hour interactive session. Subjective discussion at the start is had about how people are affected and impacted by their back pain, and outcome scores are completed. Then during the 2.5 hours there is a delivery of information and a practical exercise component to better inform the participants on how to manage their back pain and understand it better. Following this on 3 separate occasions, 1 month apart further top up information is sent to ensure they remember exercises and advice on practical management if a flare up occurs or they are struggling to fit activity in to day to day routines. Finally, at 3 months, there participants are invited back to complete the outcomes scores but also to discuss any concerns they are having and be given any advice to support them continuing with managing with any ongoing symptoms.
9677968|NCT04968483||Study group|Patients with spine deformity undergoing surgical treatment
9677969|NCT04968002|Experimental|Preoperative neoadjuvant therapy for patients with stage IIa-IIIa non-small cell lung cancer.|No EGFR mutation or ALK gene translocation was found in the untreated patients with NSCLC stage IIa-IIIb diagnosed by imaging, histopathology or cytology. After informed consent is signed by the patients. The patients were treated according to the protocols.
9677970|NCT04967859|Placebo Comparator|Group 1 (control):|Patients using placebo ointment at the exit site of the hemodialysis catheter
9677971|NCT04967859|Experimental|Group 2 (intervention)|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
9695317|NCT04779619||Non-clinical Control|people who score below clinical cut off on measures of anxiety and depression (scoring <10 on PHQ-9 and <8 on GAD-7) and emotionally unstable personality traits (BSL-23) and are not currently using mental health services
9695318|NCT04779619||Clinical Group A|people who are accessing treatment through IAPT services and score above clinical cut off on measures of anxiety and/or depression (>9 on PHQ-9 and/or >7 on GAD-7) but below clinical cut off on a measure of emotionally unstable personality traits (BSL-23)
9695319|NCT04779619||Clinical Group B|people who are accessing treatment through IAPT services and score above clinical cut off on (BSL-23) a measure of emotionally unstable personality traits (irrespective of their scores on the PHQ-9 and GAD-7)
9695320|NCT04779255|Experimental|Tumescent anesthesia|Patient who will receive tumescent anesthesia as analgesic treatment
9695321|NCT04779255|Active Comparator|Painkillers and cold water|Patient who will receive painkillers 1 hour before photodynamic therapy and cold water during session as analgesic treatment
9695322|NCT04779346||Outpatient cancer patients|Cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)
10175119|NCT03846375|Other|Control Group|Control Group at preintervention.
10175120|NCT03846388|Other|Patients with unexplained infertility|
9695323|NCT04779606|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel (30 mg/mL), 3 drops instilled at a 1 min ± 15 sec interval.
9695324|NCT04779606|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel, 3 drops instilled at a 1 min ± 15 sec interval.
10175121|NCT03846388|Other|patients with tubal, male factor or polycystic ovary syndrome|
9695325|NCT04779593|Experimental|experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin."
9695326|NCT04779593|Active Comparator|control group|"Patients treated with bloodletting according to current guidelines ferritin alone"
10175122|NCT03846258|Active Comparator|Low bicarbonate arm (22 mmol/L)|PHOXILLUM solutions are used as a replacement solution in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 22 mmol/L.
9695327|NCT04779567|Experimental|Acetaminophen|Acetaminophen 1 gr in 100 ml saline 0,9% iv 4 times a day
10175123|NCT03846258|Active Comparator|High Bicarbonate (32 mmol/L)|PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
10175124|NCT03846557||Treatment|Transcatheter Aortic Valve Implantation (TAVI)
10175125|NCT03846583|Experimental|Dose Escalation|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
9695328|NCT04779567|Placebo Comparator|Placebo|100 ml saline 0.9% iv 4 times a day
9695329|NCT04779515|Experimental|Low-pressure|Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg
9695330|NCT04779515|Active Comparator|Standard-pressure|Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg
9975739|NCT01344278|Experimental|Lifestyle Counseling|
9975740|NCT01344278|No Intervention|Control|
9975741|NCT01344304|No Intervention|Standard therapy|The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone
9975742|NCT01344304|Experimental|Aprepitant / Fosaprepitant therapy|The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.
10175126|NCT03846583|Experimental|Arm A: Active Brain Metastases|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
9695331|NCT04779502|Experimental|oregano|oregawash mouthwash was used twice times daily for 7 days
9695332|NCT04779502|Placebo Comparator|placebo|distilled water was used twice times daily for 7 days
9695333|NCT04779502|Active Comparator|chlorhexidine|Corsodyl with 0.2%CHX mouthwash was used twice times daily for 7 days
9695334|NCT04779450|Experimental|Synchronous Telemonitoring|The sessions will be supervised by a therapist and conducted via video call using the WhatsApp® application, lasting 50 minutes, 3 times a week, for 6 consecutive weeks, the exercises will basically consist of active stretching, mobilization and scapular stabilization, and active shoulder exercises with gradual range of motion.
9975743|NCT01344317||Caffeine group|Premature infants below 30 weeks of gestation who receive Caffeine treatment
9975744|NCT01344317||Caffeine and Doxapram group|Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
9677972|NCT04968093|Other|Group sessions of mindfulness-based therapy|Education of patients followed by seven group sessions of mindfulness-based therapy
9677973|NCT04968067|Experimental|App group|In addition to the usual care, the participant will receive a health talk , a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
10175127|NCT03846583|Experimental|Arm B: Surgical Resection Needed|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
10175128|NCT03846583|Experimental|Arm C: Progressive Extracranial Disease|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
9677974|NCT04968067|Active Comparator|Nursing telephone advice (NTA) group|In addition to the above usual care, the participant will receive a health talk , three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages.
9677975|NCT04967989|Experimental|First Randomization: Low Energy SLT|"Low energy SLT will consist of 100 treatment spots delivered at 0.4mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ is no bubbles are seen with 5 consecutive spots.~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
10175129|NCT03846245||Young adults group|Cognitively unimpaired 18-25 years old
9677976|NCT04967989|Active Comparator|First Randomization: Standard Energy SLT|"Standard SLT will be performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.~Regardless of energy level randomization, energy may be adjusted downward in 0.1mJ increments throughout the procedure in response to factors such as heavy focal pigmentation or patient discomfort."
9677977|NCT04967989|Experimental|Second Randomization: Annual Low Energy Repeat SLT|At month 12, subjects remaining medication-free will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
9677978|NCT04967989|Active Comparator|Second Randomization: As-Needed Repeat SLT at Initial Energy|At month 12, subjects remaining medication-free will be re-randomized to undergo repeat SLT either annually at low energy or as needed at initially assigned energy (from first randomization). The method of SLT delivery is as described in the sections above.
9677979|NCT04967898|Experimental|bowen technique|group 1 will be treated with the Bowen technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up.
9677980|NCT04967898|Active Comparator|sustained stretching|group 1 will be treated with the sustained stretching technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up
9677981|NCT04967976|Experimental|Breast Reconstruction with breast mesh|The tissue expander-implant reconstruction with TiLoop Bra mesh.
9677982|NCT04967976|Active Comparator|Breast Reconstruction without breast mesh|The tissue expander-implant reconstruction without TiLoop Bra mesh. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
9677983|NCT04968054|Active Comparator|Propofol group|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively
9677984|NCT04968054|Experimental|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
9677985|NCT04968119|Experimental|Arm A (telehealth intervention)|Patients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
9677986|NCT04968119|Active Comparator|Arm B (delayed exercise intervention)|Patients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
9677987|NCT04968041|Experimental|MI-CBT KNA Program|6-week group intervention using MI and CBT strategies to promote adherence to a ketogenic nutrition program.
9677988|NCT04967911|Experimental|Rhythmic stabilization exercises|baseline physical therapy conventional treatment along Rhythmic stabilization exercises
9677989|NCT04967911|Other|Conventional treatment|Baseline physical therapy conventional treatment
9677990|NCT04967924|Experimental|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
9677991|NCT04967924|Active Comparator|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
10175130|NCT03846245||Old adults group|Cognitively unimpaired >= 70 years old
9677992|NCT04968080||Full Analysis Set|Participants will have their temperature collected by infrared thermal camera (IRT), oral, forehead, and ear thermometers.
10175131|NCT03846323|Experimental|Visiting policies: open 24h/24|Visiting policies: 24 hours a day, 7 days a week
10175132|NCT03846323|Other|Restriction of visiting policies|Restriction of visiting policies < 6 hours
10175133|NCT03846336|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
9677993|NCT04967625|Experimental|Sintilimab + Anlotinib|sintilimab 200mg, IV, d1, Q3W and anlotinib 12mg, PO, QD，d1-14, Q3W; treatment until disease progression, unacceptable toxicity, or death
9677994|NCT04967794|Active Comparator|Group Whatsapp|Will receive standardized brushing Teleorientation consultation through the Whatsapp communication platform
9677995|NCT04967794|Active Comparator|Group Vídeo for Health|You will receive a standardized brushing Teleorientation consultation through the V4H Platform, created specifically for Teleconsultations
9677996|NCT04967794|Active Comparator|Group de Orientação presencial|You will receive a standardized face-to-face brushing orientation consultation.
9677997|NCT04967937|Experimental|Single-Group|The neuromuscular training program will consist of three 90-minute training sessions per week for 6 weeks. The 3 components of the dynamic neuromuscular training protocol utilized in this study include: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training. Following the completion of the training program, each subject will be re-evaluated to determine change in total, anterior-posterior, and medial-lateral single-limb stability. Two-way analysis of variance models will be used to determine differences between pre-training and post-training and between limbs.
9677998|NCT04967781||"Group Severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), severe and critical types were grouped into case group as Severe."
9677999|NCT04967781||"Group Non-severe"|"Each enrolled patient was allocated into control group Non-severe or case group Severe as per the disease severity which was defined according to the Chinese novel coronavirus pneumonia prevention and control guideline (version 6.0), mild and moderate types were grouped into control group as Non-severe."
9975745|NCT01344317||Group with no treatment|Premature infants below 30 weeks of gestation with no stimulating treatment
10175134|NCT03846336|Other|Healthy individuals|20 healthy volunteers with matching ages and genders.
9975746|NCT01344330||Screening colonoscopy patients|Men and women age 50 to 75 scheduled for screening colonoscopy
9975747|NCT01344343|Experimental|Accelerated hip fracture surgery|Arrival in the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair
9678003|NCT04967729|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
9678004|NCT04967755|Experimental|Jing-Si-Herbal-Tea(JSHT)|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians.
9678005|NCT04967807|Other|Cohort A - Symptomatic|Those with clinical findings suggestive of myocarditis/myocardial injury after COVID-19 vaccination
9678006|NCT04967807|Other|Cohort B - Asymptomatic|Those without signs or symptoms suggestive of myocarditis after COVID-19 vaccination and have had prior cardiac MRI at UHN
9678007|NCT04967716||Peroneal muscular atrophy|Peroneal muscular atrophy (Charcot-Marie-Tooth, CMT) is a group of genetic diseases that invade the peripheral nervous system with very high genetic heterogeneity. It was proposed by Charcot, Marie of France and Tooth of the United Kingdom in 1886. The prevalence is about 1/2500-4000. It is the most common hereditary peripheral neuropathy. Inheritance includes all forms of Mendelian inheritance. The typical clinical manifestations are progressive, length-dependent limb weakness and atrophy, accompanied by hypoesthesia and weakened tendon reflexes.
9678008|NCT04967547|Experimental|Intervention group|be evaluated by using the self-care PD feasibility assessment in addition to education on renal replacement therapy and dialysis
9678009|NCT04967547|Active Comparator|Control group|education on renal replacement therapy and dialysis
9678010|NCT04967469|Experimental|take calcitriol|End-stage renal failure patients who is Hyperparathyroid with ESRD take calcitriol
9678011|NCT04967469|Experimental|take alphacalcidol|End-stage renal failure patients who is Hyperparathyroid with ESRD take 1-hydroxycholecalciferol (alfacalcidol)
9678012|NCT04967469|No Intervention|control|End-stage renal failure patients who is Hyperparathyroid with ESRD take standard treatment
9678013|NCT04967404|Experimental|Phosphatidylserine, 800 mg per day, 10 days|
10175135|NCT03846349|Experimental|Study Group|Participants from the study group will follow an upper airway reinforcement regimen using the IOPI device over 6 weeks. The reinforcement protocol will be adapted each week to improve Percentage of initial strength Exercises will be adapted each week
10175136|NCT03846349|Sham Comparator|Control group|"Participants from the control group will perform a sham reeducation protocol using an EMT threshold at minimal resistance. The expiratory pressure will remain unchanged over the weeks."
10175137|NCT03846180||Terlipressin group|Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
9678014|NCT04967404|Placebo Comparator|Maltodextrin, 800 mg per day, 10 days|
9678015|NCT04967456|Active Comparator|Measurement of pulpal blood flow of traumatised tooth|In the split-mouth design, the traumatised maxillary incisor will be investigated using Laser Doppler flowmetry.
9678016|NCT04967456|Other|Measurement of pulpal blood flow of non-traumatised tooth|In the split-mouth design, this arm - the non-traumatised maxillary incisor, contralateral tooth, will be investigated using Laser Doppler flowmetry as a control tooth.
9678017|NCT04967950|Experimental|Secukinumab 300mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
9678018|NCT04967950|Experimental|Secukinumab 150mg|Randomized in a 1:1:1 ratio to secukinumab 300mg or secukinumab 150mg or MTX 15mg qw
9678019|NCT04967950|Active Comparator|methotrexate|methotrexate
9975748|NCT01344343|No Intervention|Standard care|Surgical hip fracture repair according to the standard timing
9977551|NCT01362764|Other|003|Abiraterone acetate suspension Formulation 2 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
9678020|NCT04967326|Experimental|Patients with epilepsy|The therapies of patients with epilepsy were optimized using pharmacists' interventions, including medication consultation, dosage adjustment, medication switching/discontinuation, or combination therapy.
9678021|NCT04967586||Preclinical medical students|
9678022|NCT04967586||Clinical medical students|
9678023|NCT04967339|Experimental|Foot deformity correcting insole arm|"Patients allocated to the foot deformity correcting insole arm will receive insoles to correct their foot deformities (plano-valgus foot deformity)."
9678024|NCT04967339|Active Comparator|Lateral wedge insole arm|"Patient allocated to the Lateral wedge insole arm will receive conventional lateral wedge insole."
9527636|NCT03218371||control group (Non-indentation)|eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed without scleral indentation.
9678025|NCT04967300||First Visit|Children who visit dentist at first time
9678026|NCT04967300||Second Visit|Children who visit dentist at second time
9678027|NCT04967417|Experimental|Non-squamous cell carcinoma|"4 cycles of pemetrexed 500mg/m2 + carboplatin AUC 5.0 + pembrolizumab 200mg every 3 weeks~Followed by pemetrexed 500mg/m2 + pembrolizumab 200mg every 3 weeks up to 35 cycles"
9678028|NCT04967417|Experimental|Squamous cell carcinoma|"4 cycles of paclitaxel 200mg/m2 + carboplatin AUC 6.0 + pembrolizumab 200mg every 3 weeks~Followed by pembrolizumab 200mg every 3 weeks up to 35 cycles"
9678029|NCT04967482|Experimental|DEB-TACE|DEB-TACE will be performed for the patients who choose DEB-TACE as the primary treatment.
9678030|NCT04967482|Active Comparator|cTACE|cTACE will be performed for the patients who choose cTACE as the primary treatment.
9678031|NCT04967131||PNF group|Proprioceptive Neuromuscular Fascilitation exercises were given this group
9678032|NCT04967066||children with febrile convulsions|"Inclusion criteria~Age from 6 months to 6 years.~Seizures.~Fever (≥38°C).~Exclusion criteria~Central nervous system infection.~Epilepsy.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea)."
9678033|NCT04967066||Febrile children without convulsions|"Inclusion criteria~Age from 6 months to 6 years.~Fever (≥38°C) due to acute infection.~Exclusion criteria~Seizures.~Central nervous system infection.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea)."
9678034|NCT04967066||Healthy control children|"Inclusion criteria~Age from 6 months to 6 years.~Presented for routine check-up.~Exclusion criteria~Fever.~Seizures.~Central nervous system infection.~Previous neurological abnormalities.~Inborn errors of metabolism.~Immunological diseases.~Endocrinal diseases (e.g., diabetes mellitus).~Obesity.~Eating disorders.~Gastrointestinal disorders (e.g., diarrhea).~Any illness in the last month."
9678035|NCT04967118|Experimental|Skin-to-skin contact|Neonates will be placed ventral skin-to-skin position with their mother at least thirty minutes prior the heel lance to give time to calm down following transfer. Skin-to-skin positioning will be taken account comfortable position as possible for mother and the baby, easy to access heel for blood sample and interference minimizing during video recording and continuous NIRS, ECG, EMG and oxygen saturation measurement. Skin-to-skin contact will be continued for approximately thirty minutes after completion of blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
9678036|NCT04967118|Experimental|Mother's heartbeats as sound and vibration|Neonates will be placed in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The platform on which the mother's heartbeat will be played will be placed under mattress of the incubator or crib. The playing of the mother's recorded heartbeats will be started thirty minutes prior the heel lance and will be continued during and thirty minutes after the blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
9678037|NCT04967118|Active Comparator|30% oral glucose|Neonates will be placed on in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The neonates will be given a 30% oral glucose solution two minutes prior the heel lance
9678038|NCT04967183|Experimental|Group I|Annual FIT surveillance
9678039|NCT04967183|Active Comparator|Group II|Endoscopic surveillance
9678040|NCT04967196|Experimental|Treatment (ipilimumab, nivolumab)|Patients receive ipilimumab via DoseConnect on day 1 of cycle 1 and via IV over 30 minutes on day 1 of cycles 2-4. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9678041|NCT04967040|Active Comparator|group 1 : medial plantar artery flap|
9678042|NCT04967040|Active Comparator|group 2 : distally based sural artery flap|
9678043|NCT04967378|Experimental|HEPPI program|
9678044|NCT04967378|No Intervention|Waiting-list control group|Receives access to HEPPI program at the end of the study.
9977552|NCT01362777|Experimental|In-Patient Rehabilitation|"Sessions of rehabilitation contains :~Individualized exercise training~Educational activities~Dietary advices"
9678045|NCT04966988||CAV 0(Not significant)|No detectable angiographic lesion
9678046|NCT04966988||CAV 1 (Mild)|Angiographic left main (LM) <50%, or primary vessel with maximum lesion of <70%, or any branch stenosis <70% (including diffuse narrowing) without allograft dysfunction
9527637|NCT03218254|Other|Methylphenidate - Placebo|Methylphenidate before placebo
9678047|NCT04966988||CAV 2 (Moderate)|Angiographic LM <50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches
9678048|NCT04966988||CAV 3 (Severe)|Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology
9678049|NCT04967157|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
9678050|NCT04967157|Experimental|Cognizin®|Intervention: Dietary Supplement: Citicoline supplement
9678051|NCT04967001|Experimental|PSMAPET-MRI|
9678052|NCT04967001|Experimental|MRI-PSMAPET|
9678053|NCT04966949|Experimental|lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
9678054|NCT04966949|Active Comparator|nerve sparing group|Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.
9678055|NCT04967235|Active Comparator|Conventional Exercise-based Cardiac Rehabilitation|This interventional arm consists of a conventional exercise-based cardiac rehabilitation, composed of initial rest, warm-up, treadmill aerobic exercise, orthostatic passive recovery, and supine passive recovery.
9678056|NCT04967235|Experimental|Dance-Based Cardiac Rehabilitation|This interventional arm consists of a new dance-based cardiac rehabilitation, composed of initial rest, warm-up, dance therapy, orthostatic passive recovery and supine passive recovery.
10175138|NCT03846180||Somatostatin/Octreotide group|Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
10175139|NCT03846414||PEG-rhG-CSF group|This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
10175140|NCT03846414||rhG-CSF group|This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
10175141|NCT03846544|No Intervention|control group|
10175142|NCT03846544|Experimental|double pick up group|
10175143|NCT03846284|Placebo Comparator|Bupivacaine (B group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion 50 cm saline with rate 10-20 ml/h according to child weight."
9678057|NCT04967014|Experimental|Sequence A|Period I : RLD2104 Period II : HIP2104
9678058|NCT04967014|Experimental|Sequence B|Period I : HIP2104 Period II : RLD2104
10175144|NCT03846284|Experimental|Magnesium sulfate caudal (MC group)|"caudal block with bupivacaine 0.25% 1mg/kg + Magnesium sulfate 50 mg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion of 50 cm saline with rate 10-20 ml/h according to child weight."
10175145|NCT03846284|Experimental|Magnesium sulfate I.V (M V group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
10175146|NCT03846206|Experimental|mediterranean diet|Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
10175147|NCT03846206|No Intervention|Usual diet|Patients do usual diet for three months
9678059|NCT04966975||Histologically confirmed bladder cancer treated with NAC|
10175148|NCT03846141|Placebo Comparator|Placebo|Room air for inhalation
9678060|NCT04967365||Case patients|500 patients who experience greater than or equal to 3 nights in a pediatric ICU with intensive care instrumentation.
10175149|NCT03846141|Experimental|Hydrogen|Hydrogen (4%) for inhalation
10175150|NCT03846037|Placebo Comparator|Ground|Participants in this group perform protocol exercises on a stable surface.
10175151|NCT03846037|Experimental|vibrating platform|Participants in this group perform protocol exercises on a vibrating platform.
9678061|NCT04967365||Control patients|250 patients who experience an overnight stay in a pediatric ICU without intensive care instrumentation.
9678062|NCT04967495|Experimental|TACE-MKI-I|TACE combined with sorafenib/lenvatinib and iodion-125 seeds brachytherapy
9678063|NCT04967495|Active Comparator|TACE-MKI|TACE combined with sorafenib/lenvatinib
9678064|NCT04966650|Experimental|Intervention group|For the intervention group, participants will receive a 5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT). The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms. At the 2nd month, participants will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given a booster intervention. At 6th months, subjects will be assessed their depression symptoms and the level of physical activity changes via questionnaire.
9678065|NCT04966650|No Intervention|Control Group|A wellbeing leaflet from CHP will be provided to each participant. At the 2nd month, subjects will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given another wellbeing leaflets. At 6th months, subjects will be assessed their depression symptoms the level of physical activity changes via questionnaire.
9678066|NCT04966715|Experimental|Patients planned for complete cytoreductive surgery|Only one arm in the study. All patients operated for complete cytoreductive surgery and who signed informed consent form
9678067|NCT04966962||Bladder cancer|Patients who diagnosis with incident or recurrent bladder cancer
9678068|NCT04966962||benign disease of urinary system|Patients who clinically diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia.
9678069|NCT04966728||suspected tear of the anterior superior labrum of the hip|One group consisted of patients with suspected tear of the anterior superior labrum of the hip.
10175152|NCT03846115|Experimental|Peer-Led Seeking Safety app|This app is designed for Peer-Led Seeking Safety and includes enhanced app features.
10175153|NCT03846115|Active Comparator|Control app|This is a basic app that controls for time and attention. The basic app serves as the intervention in this trial.
10175154|NCT03846011||Experiment group|All eligible patients administered for active stone removal.
10175155|NCT03846102|Experimental|Levobupivacaïne|"Fascia Iliaca Compartment Block with Levobupivacaine Hydrochloride (weight based dosage and volume)~Ideal Body Weight : Levobupivacaïne dose (mg) : Dose/kilogram (mg/kg) : Total volume (ml)~[<64 kg : 100 mg : 2.0 mg/kg : 40 ml]~[65-74 kg : 125 mg : 1.9 mg/kg : 45 ml]~[≥ 75 kg : 150 mg : 2.0 mg/kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
9678070|NCT04966728||non-hip joint diseases|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
9678071|NCT04966702|Active Comparator|Albendazole|"The albendazole group will receive a single dose of 400 mg, given once a month for three months.~Generic products will be used in both countries. Bendex in Mozambique and Alben in Tanzania"
9678072|NCT04966702|Experimental|Ivermectin human|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol
9678073|NCT04966702|Experimental|Ivermectin human and livestock|The ivermectin group will receive a single dose of 400 mcg/kg, given once a month for three months. Product to be used is Stromectol. For livestock, locally registered veterinary injectable ivermectin at 1% will be used
9678074|NCT04966676|Experimental|Non-Small cell Lung Cancer|"Nivolumab, intravenously (given by vein), once every 3 weeks Ipilimumab, intravenously (given by vein), once every 6 weeks~Participants will have blood samples taken for cell free deoxyribonucleic acid (cfDNA) testing.~If there is an increasing or stable tumor cfDNA, platinum-doublet chemotherapy will be given."
9678075|NCT04966845||Smokers|Exclusive smokers of convnetional cigarettes
9678076|NCT04966845||HNBC|Exclusive smokers of Heat-Not-Burn Cigarettes (HNBC)
9678077|NCT04966845||Nonsmokers|Subjects that abstain from smoking for at least one year
9678078|NCT04966897|Experimental|GBNS + PERT placebo|GBNS + PERT placebo (drink volume sufficient to supply 0.5 g of MAG per kg of body weight plus PERT placebo capsules according to patient body weight.
9678079|NCT04966897|Active Comparator|Standard Nutritional Supplement + PERT|Standard nutritional supplement + PERT (drink volume sufficient to supply 0.5 g of TAG per kg of body weight plus PERT capsules according to body weight).
9678080|NCT04966793||Bronchiectasis patients group|Bronchiectasis patients group: Sputum specimens from bronchiectasis patients aged 18 to 79 years old .
9678081|NCT04966793||Healthy control group|Healthy control group: Sputum specimens from healthy people.
9678082|NCT04966572|Experimental|Presurgical vacuum formed nasoalveolar molding aligners group|In this group, all patients will receive 1-2 VF-NAM aligners incorporated with palatal screw in addition to taping from day 1 for 4-6 Months with follow-up every 3 weeks
9678083|NCT04966572|Experimental|conventional Grayson acrylic formed nasoalveolar molding appliances group|This group will receive conventional Grayson acrylic formed nasoalveolar molding appliances without taping except some cases, with follow up every week for activation.
10175156|NCT03846102|Placebo Comparator|Placebo|"Fascia Iliaca Compartment Block with placebo (Sodium Chloride 0.9%), similar volume to experimental arm.~Ideal Body Weight : Total volume (ml)~[<64 kg : 40 ml]~[65-74 kg : 45 ml]~[≥ 75 kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
10175157|NCT03845907|Active Comparator|Imagio Gen 1B|Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe
9678084|NCT04966832|Experimental|XW10508|XW10508 capsules or tablets
9678085|NCT04966832|Placebo Comparator|Placebo|Placebo capsules or tablets
9678086|NCT04966884|Experimental|A single-arm open-label pilot observational study|Patients were received a glucocorticoids (0.8mg-1mg/kg/day) and a combination with tofacitinib (at a dose of 5 mg twice daily).
9678087|NCT04966819|Experimental|Survivorship Care|"Survivorship care will consist of:~Regular meetings with the rectal cancer oncology pivot nurse~Identification of a primary care physician~Development of an individualized survivorship plan~Educational resources for patients"
9678088|NCT04966819|No Intervention|Standard Care|The control arm will consist of patients treated at the same institution who are receiving standard of care. Standard of care consists of meeting with colorectal oncology pivot nurse as needed (i.e. by referral from specialist based on patient needs).
9678089|NCT04966806|Other|Percentage of Coma and SA to Total ocular HOA|
9678090|NCT04966936||Unilateral traumatic transfemoral amputee patients using C-Leg prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
9678091|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
9678092|NCT04966936||Unilateral traumatic transfemoral amputee patients using Genium-X3 prosthesis|The activity levels of the patients will be evaluated by the Amputee Mobility Predictor, the mobility of the patients by the Locomotor Capacity Index, the prosthesis satisfaction in general with the visual analog scale (VAS), the walking ability and capacity with the prosthesis will be evaluated by the 2 min walking test, and the gait analysis will be evaluated in the motion analysis laboratory.
9977553|NCT01362777|Active Comparator|Educational activities alone|"Out-patient control arm contains only :~-Educational activities"
9678093|NCT04966520|Experimental|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or sham|"Patients will participate in the prospective longitudinal research protocol over a period of 1.5 months.~Treatment will include 8 visits of either accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or iTBS sham stimulation. Patients will be informed that iTBS sham stimulations will be part of the protocol (but will be blind to when treatment/sham will be administered)."
9678094|NCT04966507|Active Comparator|Listerine Cool Mint Antiseptic Mouthwash|Daily use of an antibacterial mouthwash (Listerine Cool Mint Antiseptic Mouthwash) during the 12-week follow-up period.
9678095|NCT04966507|Placebo Comparator|Biotene Oral Rinse|Daily use of a placebo mouthwash with no known antibacterial qualities (Biotene Oral Rinse) during the 12-week follow-up period.
10175158|NCT03845907|Active Comparator|Imagio Gen 1|Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System
10175159|NCT03845972|No Intervention|before SSFTB|
9678096|NCT04966260|Experimental|Standardized Virtual Reality|Participants in the standard virtual reality (VR) group will choose from the general library of VR experiences. Participants will be asked to select an experience they desire but have never experienced in person. The session will be facilitated by the therapeutic recreation staff on the unit.
9678097|NCT04966260|Experimental|Personalized Virtual Reality|There are two types of personalized VR: 1) Family/friends provide personalized content (e.g., life stories, photos, videos) that will be used during the VR session. Family/friends of participants in the personalized VR group will have the opportunity to upload custom photos, videos, life stories or capture their own 360° footage of family events using a GoPro camera that will be loaned to them for the study. This content will be uploaded to a cloud-based portal. 2) If the family/friends of those in the personalized VR arm are unavailable/unable/unwilling to provide personalized content the participant will select a video from the VR library of an experience that is personally memorable to them, such as their childhood hometown, a favourite vacation destination. The session will be facilitated by the therapeutic recreation staff on the unit.
9678098|NCT04966260|Active Comparator|Two-Dimensional Video|Participants in the active comparator group will choose a two-dimensional video such as a mountain view, ocean view or safari. Participants will view the two-dimensional video on an iPad and the session will be facilitated by the therapeutic recreation staff on the unit.
9678099|NCT04966338|Experimental|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
9678100|NCT04966338|Active Comparator|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
9678101|NCT04966286|Placebo Comparator|conventional education service program|received only standard enterostomy care brochure
9678102|NCT04966286|Experimental|multimedia education service program|received multimedia education service program introduction
9678103|NCT04966364|Active Comparator|patients with hypotension prediction index guided|Patients receiving hypotension prediction index guided. In this group, they will be alerted when the index exceeded 85 (range 0 to 100) indicating the later occurrence of MAP< 65mmHg for at least minutes and a treatment protocol based on advanced hemodynamic parameters recommended vasopressor or inotrope, fluid administration, or observation.
9678104|NCT04966364|Other|patients without hypotension prediction index gudied|Patients will receive usual care during the operation without hypotension prediction index alerted.
9678105|NCT04966351|Experimental|Circadian misalignment (Condition A)|Participants will eat meals during the biological nighttime while remaining awake to mimic overnight work shifts.
9678106|NCT04966351|Experimental|Circadian misalignment with time-restricted feeding (Condition B)|Participants will fast during the biological nighttime while remaining awake to mimic overnight work shifts.
9678107|NCT04966221||Adult healthy volunteers|Adult healthy volunteers, age matched to patient volunteers. Will undergo a combination of functional and structural lung MRI scans.
9678108|NCT04966221||Adults with Chronic Obstructive Pulmonary Disease|Will undergo a combination of functional and structural lung MRI scans. Some participants in this cohort will have lung volume reduction (LVR) as part of their normal clinical care. These participants will be given the option to attend two study visits - one before and one after LVR.
9678109|NCT04966221||Adults with alpha-1-antitrypsin deficiency|Will undergo a combination of functional and structural lung MRI scans.
9678110|NCT04966312|Other|study group|mothers receiving routine education plus digital video disk before surgery
9678111|NCT04966312|Other|control group|mothers receiving routine education
9678112|NCT04966442|Experimental|GrandAides|Patients randomized to this arm of the trial received access to a specially trained GrandAide to work as a credible messenger community health worker. This GrandAide received 6 weeks of education around congestive heart failure to support the patient in the outpatient setting.
9678113|NCT04966442|No Intervention|Standard of Care|This arm served as the control and included standard of care outpatient support for patients with heart failure.This support was done telephonically.
9678114|NCT04966299|Active Comparator|Sucrose|15 participants receive 25g sucrose per day during 5 weeks
9678115|NCT04966299|Experimental|Erythritol|15 participants receive 36g eryhtritol per day during 5 weeks
10175160|NCT03845972|Experimental|after SSFTB|
10175161|NCT03846154|Experimental|Intervention group|"Children and adolescents in the intervention group received:~A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~Access to schools and school material~Family visits~Their parents received training regarding agriculture and microcredit projects, and financial assistance~FORNET if affected by trauma-related symptoms, and/or acting aggressive~If needed medical assistance is provided~If needed legal assistance is provided"
9678116|NCT04966234|Experimental|Posaconazole arm|"90 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will receive posaconazole for 12 weeks. Patients in the posaconazole arm will be stratified for body weight and positive sputum cultures for Aspergillus species.~Patients will be followed-up for a total of 12 months post-randomization."
9678117|NCT04966234|No Intervention|Control arm|"45 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will not receive the active treatment.~Patients will be followed-up for a total of 12 months post-randomization. If participants in the control arm are deteriorating during the first 3 months after randomization, it is up to the treating physician to consider treatment for the initial asymptomatic Aspergillus infection"
9678118|NCT04966429|Active Comparator|Maraviroc 150 mg per day|
9678119|NCT04966429|Active Comparator|Maraviroc 600 mg per day|
9678120|NCT04966429|Placebo Comparator|Placebo|
9678121|NCT04966195|Other|radiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
10175162|NCT03846154|No Intervention|Control group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
9678122|NCT04966208|Active Comparator|root coverage surgeries using autologous connective tissue for treatment of gingival recession|root coverage surgeries using tunneling technique of autologous connective tissue as a treatment of Miller class two gingival recession
9678123|NCT04966208|Experimental|root coverage surgeries using xenogenic collagen matrix for treatment of gingival recession|root coverage surgeries using tunneling technique of mucodrm membrane ; xenogeneic collagen matrix as a treatment of Miller class two gingival recession
9678124|NCT04966468|Experimental|VR Group|Patients will be given the VR headset with non-interactive and interactive contents at home for four days
9678125|NCT04966468|Active Comparator|CTR group|Patients will be given a tablet at home for four days with relaxing non-interactive 2D videos with natural and artistic scenarios
9678126|NCT04966455|No Intervention|Control group|No intervention
9678127|NCT04966455|Experimental|Experimental group|Supplementation of 50 g daily of rainsins for 3 months
9678128|NCT04966416|Experimental|Pyrophosphate|
9678129|NCT04966416|Placebo Comparator|Placebo|
9678130|NCT04966026||COPD combined with CAP inpatients|(1) CAP meets the diagnostic criteria published in our 2016 CAP diagnosis and treatment guidelines; CPOPD and AECOPD meet the diagnostic criteria published in our 2013 COPD diagnosis and treatment guidelines; (2) age ≧ 18 years. Exclusion criteria: (1) age <18 years; (2) pregnancy; (3) positive human immunodeficiency virus (HIV) antibody; (4) suspected or confirmed tuberculosis or fungal infection of the lung.
9678131|NCT04966494|Experimental|BOSB Group|This group consumed a common beans and oats snack bar (BOSB) for 8 weeks.
9678132|NCT04966494|No Intervention|Control Group|This group corresponded to hypertriglyceridemic women who does not consume BOSB
9678133|NCT04965883|Experimental|Early Excision and Grafting|"The early excision will be done surgically within 4-10 days post burn by whatson knife by tangential excision of burned tissue until capillary bleeding appears to make a good bed to be covered with grafts split thickness grafts STG at the same time.~The first dressing will be in the fifth day post operative."
9678134|NCT04965883|Experimental|Dressing and Delayed Grafting|• Dressing will be done for the second group every other day until spontanous eschar seperation or after surgiacl debridrment of adherent eschar then for delayed grafting more than 10 days post burn.
9678135|NCT04965818|Experimental|Futibitanib in combination with binimetinib|"Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease.~Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC"
9678136|NCT04966000|Experimental|Prism Adaptation Therapy|10 sessions (60 trials each) 1x/day of Prism Adaptation Therapy
9678137|NCT04966143|Experimental|Treatment group|
9678138|NCT04965961|Experimental|Recombinant human erythropoietin treatment|Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.
9678139|NCT04965961|Placebo Comparator|Control group|Participants receive intravenous injections of ~0,5 mL saline (NaCl 0,9%) three times per week for four weeks on non-consecutive days.
9695335|NCT04779450|Experimental|Asynchronous Telemonitoring|An explicative schedule with the exercises to be performed asynchronously during the week will be delivered weekly via e-mail and WhatsApp®. The exercises will be the same as those performed by the synchronous telemonitoring group, and the participant will be free to ask any questions about the protocol to the therapist at any time via text message or e-mail.
9975749|NCT01344382|Experimental|CRAFT|All parents will be scheduled for 12 individual Community Reinforcement and Family Training for parents (CRAFT-P) training sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
10175163|NCT03845959|Experimental|TD0019.6cap|estimated dose, 2 oral capsules/time x 3 times/day
10175164|NCT03845959|Experimental|TD0019.9cap|1.5 times of estimated dose 2 oral capsules/time x 3 times/day
9695336|NCT04779450|Active Comparator|Control Group|Will receive only a booklet of usual guidelines for women after breast cancer, such as skin care, return to activities, upper limb functionality, self-care, lymphedema and physical activity practice.
9695337|NCT04779294||Fetus in labour at risk of acedimia|The Group of patients studied are fetuses in labour at risk of hypoxia with internal fetal monitoring and scalp lactate bloodsamples ( standard monitoring).
9695338|NCT04779294||Fetus in labour at risk of acedemia with STAN analysis|Same group of fetuses in labour at risk of hypoxia with internal fetal monitoring and STAN analysis(ST waveform analysis of the fetal electrocardiogram, opened after study inclusion finished)
9695339|NCT04779281|Experimental|Oral Rehydration Salts supplemented with L. Rhamnosus GG|a supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
9695340|NCT04779281|Experimental|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
9696465|NCT04766619||Staff and stakeholders|For the longitudinal process evaluation - staff and stakeholders who have had direct contact or involvement with and have an understanding of OptmiseRx and/or PINCER will be invited to take part in an interview or focus group, an observation and/or complete a questionnaire. For the consolidated learning exercise - those who are in a position to influence the wider adoption of these interventions will be invited to take part in an interview or development workshop.
9977554|NCT01362816||Palliative care cancer patients|"Inclusion criteria are:~Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence), local, loco-regional or metastatic disease, defined as a palliative care patient; enrolled in a palliative care programme, age 18 years or older, able to provide written informed consent, able to complete the data collection tool, preferably without help, available for follow up registration"
9827780|NCT02467842|Active Comparator|NBP607-V|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0
9678140|NCT04965948|Experimental|Active group|Snack enriched with camelina sativa oil
9678141|NCT04965948|Placebo Comparator|Placebo group|Snack no enriched with camelina sativa oil
9678142|NCT04965974|Experimental|1 blue light blocking filter group|digital blue light blocking filter is installed laptops and mobile phones of 80 individual using digital devices more than 4 hours. asked them to use the filter continuously while using digital devices.
9678143|NCT04965974|Experimental|2 non filter users|Effect of time duration of digital screen on the dry eyes is checked.
9678144|NCT04965987|Active Comparator|Oxaloacetate|"Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase.~Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to."
9678145|NCT04965987|Placebo Comparator|Placebo|Subjects will take either 500mg BID, 1000mg BID, or 2000mg BID each day for 4 weeks, depending on which cohort they are assigned to.
9678146|NCT04966169|Experimental|Sonendo GentleWave|Every participant will receive the same experimental treatment, which is root canal therapy using the Sonendo GentleWave System.
9678147|NCT04965922|Experimental|Multimodal intervention at inclusion|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
9678148|NCT04965922|Other|Multimodal intervention at 6 month|Multimodal intervention will be proposed to Multiple system atrophy patients and their caregivers.
9678149|NCT04966156|No Intervention|Usual care group|No change to patient's usual care at Princess Margaret Cancer Centre.
9678150|NCT04966156|Experimental|CaRE-4-allBMT plus usual care|a longitudinal 6-month rehabilitation program that uses a person- centred strategy and a multidimensional approach targeting physical activity, nutrition, psychosocial distress and promoting self-management skills.
9678151|NCT04966052||COPD combined with TB group|COPD combined with pulmonary TB infection
9678152|NCT04966052||COPD non-TB control group|COPD combined without pulmonary TB infection
9678153|NCT04966052||TB non-COPD control group|pulmonary TB infection without COPD
9678154|NCT04966052||Non-smoking non-TB control group|Non-smoking without pulmonary TB infection
9678155|NCT04965896|Placebo Comparator|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
9678156|NCT04965896|Experimental|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
9678157|NCT04965831|Experimental|Furmonertinib|Furmonertinib as perioperation therapy
9678158|NCT04966039||monochorionic twin pregnancies with demise of one fetus|Twin pregnancy was diagnosed and one fetus died in utero, 20 pregnant women
9678159|NCT04966039||Twin control group|Twin pregnancy with one abnormal fetus, 20 pregnant women
10175165|NCT03845959|Placebo Comparator|Placebo|Placebo 2 placebo oral capsules /time x 3 times/day
10175166|NCT03845868||Egang hospital physical examination center|
10175167|NCT03845868||Ezhou CDC physical examination center|
10175168|NCT03845855|Experimental|Virtual reality with robotic gait|virtual reality treatment with robotic gait therapy 2 times for week by 6 weeks.
10175169|NCT03845855|Active Comparator|Robotic gait therapy only|only robotic gait therapy 2 times for week by 6 weeks
10175170|NCT03845998|Experimental|three-finger method|"The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers. That is what we call the three-finger method.~The intervention is to use the three-finger method."
9678160|NCT04966039||Singleton control group|Singleton pregnancy with abnormalities outside the fetal brain, 20 pregnant women
9678161|NCT04966403|Experimental|standard physical therapy|Participants in the standard physical therapy received the standard physical therapy (sPT) program, which was conducted according to the needs of each participant and was generally concerned with building strength, enhancing developmental skills, boosting balance, coordination, and postural control, improving physical fitness, and minimizing the development of the compensatory movement patterns that children with DS are likely to develop.
9678162|NCT04966403|Experimental|trampoline-based stretch-shortening cycle exercises|In addition to the sPT, the SSC group received 15-minute SSC exercise sessions, twice weekly, with a total of 24 sessions over 12 successive weeks.
9678163|NCT04965792||HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) Patients|Newly diagnosed HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC) patients will undergo blood testing for circulating tumor HPV DNA.
9678164|NCT04965779|Experimental|Intervention group (Abdominal binder)|The abdominal binder is applied after the women come to the clinic (postpartum 1st hour) following cesarean delivery and removed after the postpartum 48th hour. Postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided together with the application of the abdominal binder.
9678165|NCT04965779|Active Comparator|Control group (No abdominal binder)|Only postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided with no abdominal binder or similar application.
10175171|NCT03845998|Active Comparator|weight-related method|"The size of the laryngeal mask airway for each patient was determined by the manufacturer's weight-related guidelines. That is what we call the weight-related method.~The intervention is to use the weight-related method."
10175172|NCT03845751|Experimental|ADT protocol|ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone [LHRH] agonist). Additionally, oral antiandrogen bicalutamide 50 mg once per day is given for 3 months, starting the same day of LHRH agonist injection. ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
9678166|NCT04966078|Active Comparator|liposuction|group A will be treated with liposuction
9678167|NCT04966078|Active Comparator|periareolar surgical excision|Group B will be treated with periareolar surgical excision
9678168|NCT04965428|Experimental|Fear-focused Self-Compassion Therapy|Experimental group receives group face-to-face Fear-focused Self-Compassion Therapy for eight weeks.
9678169|NCT04965428|No Intervention|Usual care|The no intervention group receives usual care supported by hospital or coming from elsewhere for eight weeks.
9678170|NCT04965415|Active Comparator|Lagged|Businesses in the lagged arm participated in Health Links for one year from their baseline assessment to their first follow-up assessment one year later. They were eligible to participate in the Leadership Training after both assessments were completed.
9678171|NCT04965415|Experimental|Early|Businesses in this arm participated in Health Links + Leadership Training for one year from their baseline assessment to their first follow-up assessment one year later.
9678172|NCT04965740||North American First Responders|Spread directly to union representatives for email and messaging to those interested in taking the survey
9678173|NCT04965740||Oceana and European first responders|First responder unions and groups that are located outside of North America - particularly Australia, New Zealand, United Kingdom, other commonwealth nations.
9678174|NCT04965545||Wilson's disease cohort|Patients were clinically diagnosed according to the Leipzig Score and included in the study when they were confirmed to carry ATP7B pathogenic variants in 2 different alleles.
9678175|NCT04965532|Experimental|chemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
9678176|NCT04965532|Active Comparator|chemotherapy patients using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
9678177|NCT04965532|Active Comparator|nonchemotherapy patients using sevoflurane anesthesia|Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.
9678178|NCT04965532|Active Comparator|nonchemotherapy patient using total intravenous anesthesia|Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.
9678179|NCT04965467||Screening population|Screening for Fabry disease with early symptoms
9678180|NCT04965441||Computer-assisted surgery (CAS) group|
9678181|NCT04965441||Non-CAS group|
9975750|NCT01344382|Active Comparator|Al-Anon Facilitation|All parents will be scheduled for 12 individual Alanon/Naranon Facilitation Training (ANF) sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
9975751|NCT01344395|Experimental|RK-group|
9975752|NCT01344395|Active Comparator|K-group|
9975753|NCT01344408|Experimental|Computer-training|The computer-training program, Move it to improve it was installed in the participants homes using an internet-connected computer with a web camera connected to a cloud-based specifically adapted interactive training program.
9975754|NCT01344408|Experimental|Printed instructions|A training program delivered as printed instructions
9975755|NCT01344421||hip dysplasia|Patients with hip dysplasia
9975756|NCT01344421||Healthy people|Enrolled from the patients acquaintance circle
9975757|NCT01344473|Experimental|Casein phosphopeptide in the form of TM|Experimental group will be given TM to use daily for 12 weeks
9975758|NCT01344473|No Intervention|No intervention|Standard oral care
9975759|NCT01344486|Experimental|Full conditioing|Intervention by alteration of laparoscopic gas with addition of oxygen and nitrous oxide, regulation of humidification and temperature (32°C), injection of 5mg Dexamethasone and application of Hyalobarrier Gel Endo (Nordic Pharma) at the surgical wound
9975760|NCT01344486|Active Comparator|carbon dioxide|induction pneumoperitoneum with carbon dioxide 100%
9975761|NCT01344499|Experimental|Adept|1000ml Adept will be left in the abdomen and measured over time
9975762|NCT01344499|Active Comparator|Ringer-lactate|1000 ml of Ringer lactate left in the abdomen and measured over time
9975763|NCT01344512|Experimental|Patients treated with Ceftazidime|
9975764|NCT01344512|Experimental|Patients treated with Ciprofloxacin|
9975765|NCT01344512|Experimental|Patients treated with Voriconazole|
9975766|NCT01344525|No Intervention|Control group|Nutritional counselings every 6 months, no further intervention
9975767|NCT01344525|Experimental|"low-calorie-diet (LCD)-based lifestyle intervention"|12 months multidisciplinary weight loss program including three months low-calorie formula diet (800 kcal) (OPTIFAST®52 program)
9975768|NCT01344525|Experimental|Laparoscopic gastric sleeve intervention|
9975769|NCT01344525|Experimental|Conventional bariatric surgery|Gastric Banding and Gastric Bypass
9975770|NCT01344551|Active Comparator|High Flavanol|High Flavanol cocoa drink containing 495mg cocoa
9975771|NCT01344551|Placebo Comparator|Low Flavanol|Low Flavanol cocoa drink (23mg)
9975772|NCT01344564|Other|ADT|All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot.
9975773|NCT01344577||Group1#|bone graft material used: Apatos Cortical® (porcine cortical bone 600-1000 µm)
9975774|NCT01344577||Group2#|bone graft material used: MP3® (porcine cortic-cancellous collagenated bone mix 600-1000 µm)
9975775|NCT01344577||Group3#|control group
9975776|NCT01344590|Active Comparator|saline lock maintenance|Standard saline lock maintenance
9527638|NCT03218254|Other|Placebo - Methylphenidate|Methylphenidate after placebo
9977555|NCT01362829||Patients with severe sepsis|Patients who are admitted to medical ICU with severe sepsis
9678182|NCT04965649||Chronic Myeloid Leukemia|There will be approximately 10 patients with Chronic Myeloid Leukemia in this group
9678183|NCT04965649||Philadelphia+ Acute Lymphoblastic Leukemia|There will be approximately 20 patients with Philadelphia chromosome-positive Acute lymphocytic leukemia in this group
9678184|NCT04965610|Experimental|Preoxygenation via THRIVE/High Flow Nasal Cannula|Patients receive preoxygenation for induction of general anaesthesia via High Flow Nasal Cannula for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
9678185|NCT04965610|Active Comparator|Preoxygenation via face mask (PROX)|Patients receive preoxygenation for induction of general anaesthesia via tight fitting face mask for the duration of 5 minutes. After that the induction agents will be given. Now arterial blood gases will be drawn every 2 minutes and the SpO2 will be measured until the 6th apnoeic ABG or if the SpO2 decreases to 92%. After that normal intubation follows.
9678186|NCT04965571||WD-seizures|Chinese WD patients with generalized epilepsy
9678187|NCT04965766|Experimental|U3-1402|All participants included in the study will receive a starting dose of 5.6 mg/kg of U3-1402 every 3 weeks until progression or until unacceptable toxicity
10175173|NCT03846063|Experimental|Intervention: Home-based rehabilitation program|"A twelve-week home-based exercise strategy will be offered to patients after their discharge from the hospital. This home-based exercise strategy will be delivered by means of videos on a tablet-pc and consist of specified exercise instructions for improving muscle strength, balance and functional movements.~The intervention group will be compared with existing patientdata who received usual care in the Netherlands"
9678188|NCT04965701||Untreated EGFR-mutant advanced non-small-cell lung cancer patients|
9678189|NCT04965584||Active Crohn's disease group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological manifestations and histological features were recruited, and patients with CDAI score ≥ 150 were included in this group.
10175174|NCT03845777||Surgical Staff|The surgical staff group is the only group of the study. Blood samples of the surgical staff before and after the using antiseptics solution that include iodine were analyzed.
9678190|NCT04965584||Crohn's disease remission group|Patients diagnosed with Crohn's disease after comprehensive evaluation of clinical symptoms, endoscopic features, radiological features and histological features were recruited, and patients with CDAI score < 150 were included in this group.
9678191|NCT04965584||Healthy control group|Normal healthy people were randomly recruited as the control group
9678192|NCT04965662|Experimental|Arm A: Home PEPSE (Immediate)|Patients randomised to the immediate arm (ARM A) will receive a 5 day PEPSE 'Home pack' containing Truvada® (tenofovir disoproxil -as fumarate- 245 mg, emtricitabine 200 mg), ONE tablet OD and Maraviroc 300 mg, TWO tablets OD.
9678193|NCT04965662|No Intervention|Arm B: Standard of Care (Deferred)|Standard of care antiretroviral therapy for PEPSE as per the British Association for Sexual Health and HIV (BASHH) guidelines.
9678194|NCT04965350|Experimental|2vHPV Consistency Lot 1|
9678195|NCT04965350|Experimental|2vHPV Consistency Lot 2|
9678196|NCT04965350|Experimental|2vHPV Consistency Lot 3|
10175175|NCT03845881|Active Comparator|Opioid|Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty
10175176|NCT03845881|Placebo Comparator|Non Opioid|Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty
10175177|NCT03845608|Experimental|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity
10175178|NCT03845608|Other|Intraperitoneal Hydrocortisone|Drug Injection: 100mg of Hydrocortisone will be injected In the peritoneum
9678197|NCT04965350|Active Comparator|2vHPV Pilot Scale Lot|
9678198|NCT04965129|Placebo Comparator|Placebo Comparator: Placebo|Placebo Comparator: Placebo All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given four tablet/day for four mounths.
9678199|NCT04965129|Experimental|Experimental: Fish oil|All subjects will be given fish oil with a dose of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
9678200|NCT04965025|Experimental|Multi-stage urethroplasty with graft inlay in first stage|
9678201|NCT04965025|Active Comparator|Multi-stage urethroplasty with graft inlay in second stage|
9678202|NCT04965233||Participants recruited in Denmark|Participants recruited in Denmark will consist of 63 healthy individuals and 187 individuals with atopic dermatitis
9678203|NCT04965233||Participant recruited in the United States of America|Participants recruited in the US will consist of 125 healthy individuals, 3000 individuals with atopic dermatitis
9678204|NCT04964999|Experimental|Exercise|Participants will perform aerobic and strength exercises for 2 weeks.
10175179|NCT03845608|No Intervention|control group|In the controls, carbon dioxide will be removed by the traditional passive deflation of abdominal cavity.
10175180|NCT03845764||Rapid on-site evaluation (ROSE)|Evaluation, made by a pulmonologist, a pathologist and a molecular pathologist, of the tumor burden in ROSE slides produced from endoscopic procedures aimed at sampling intrathoracic lymphadenopathy and pulmonary nodules
10175181|NCT03845621|Active Comparator|CM-OA-OA-CM Sequence|Use of a conventional custom-made mouthguard (CM) while playing water polo for first and fourth weeks and the occlusal-adjusted custom-made mouthguard (OA) for the second and third weeks.
9678205|NCT04964999|No Intervention|No exercise|Participants will not perform any exercises.
10175182|NCT03845621|Active Comparator|OA-CM-CM-OA Sequence|Use of an occlusal-adjusted custom-made mouthguard (OA) for the first and fourth weeks and a conventional custom-made mouthguard (CM) while playing water polo for the second and third weeks.
9678206|NCT04965194|Experimental|Erector spinae plane block (ESPB)|20 ml of 0.25% bupivacaine will be administered to perform ESP block on each side
9678207|NCT04965194|Experimental|Quadratus lumborum plane block (QLPB)|The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1.
9678208|NCT04965194|Placebo Comparator|Control group|patients received no regional block
9678209|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol, iQuit Mindfully text messages, and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
9678210|NCT04965181|Experimental|iQuit Mindfully|"Participants will receive iQuit Mindfully text messages and nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
9678211|NCT04965181|Experimental|Mindfulness-based Addiction Treatment (MBAT)|"Participants will receive virtual group counseling based on the Mindfulness-Based Addiction Treatment (MBAT) group protocol and nicotine replacement therapy (NRT). MBAT consists of 8 weekly 2-hour sessions. NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
9678212|NCT04965181|Active Comparator|Usual Care|"Participants in the usual care condition are provided with nicotine replacement therapy (NRT). NRT consists of 8 weeks of generic nicotine patches and nicotine lozenges. Participants who smoke >10 cigarettes/day will receive 4 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Those who smoke less than 10 cigarettes/day will receive 4 weeks of 14 mg patches and 4 weeks of 7 mg patches. Participants who smoke their first cigarette within 30 minutes of waking will receive 8 weeks of 4mg mini lozenges (6-9 4mg mini lozenges per day). Those who smoke their first cigarette over 30 minutes of waking will receive 8 weeks of 2mg mini lozenges (6-9 2mg mini lozenges per day). Participants will also be given the National Cancer Institute Clearing the Air booklet and a referral to the Tobacco Cessation Quitline."
9678213|NCT04965142|Experimental|Home Exercise Group|The home-based exercise group will be asked to exercise 3 to 5 times per week (≥ 150 minutes of aerobic exercises (i.e. walking, cycling, or treadmill) of at least moderate intensity) and to also complete resistance training (resistance bands or free weights) at least twice weekly over a 12-week period supervised by an exercise professional. The resistance training will be personalized, aiming for 6 to 10 exercises targeting the major muscle groups, progressing to 3 sets of 8 to 12 repetitions. Participants will receive one counselling session on healthy eating and physical activity at the start of the study along with an exercise manual.
9678214|NCT04965142|No Intervention|Control Group|Participants will receive one counselling session on healthy eating and physical activity at the start of the study.
9678215|NCT04965116|Experimental|Early Initiation d-POPs|Initiation of d-POPs 120-160 hours after delivery. Dosing is 4mg daily for 24 days followed by 4 daily inactive tablets for 2 months.
9678216|NCT04965116|Experimental|Early Initiation n-POPs|Initiation of n-POPs 120-160 hours after delivery. Dosing is 0.35mg daily for 28 days for 2 months.
9678217|NCT04965116|Placebo Comparator|Interval Initiation of d-POPs|Placebo starting 120-160 hours after delivery, continuing for 28 days. Followed by 24 days of 4mg daily of d-POPs and 4 daily inactive tablets.
9678218|NCT04965012|Experimental|CBT with MET treatment group|Participants in this arm will be provided with an MET-therapist guided introduction, in addition to the online CBT treatment.
9678219|NCT04965012|Experimental|CBT without MET treatment group|Participants in this arm will be provided with a brief non-MET research assistant-led welcome to the program, in addition to the online CBT treatment.
9678220|NCT04965012|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about cannabis and wellbeing.
9678221|NCT04965298|Experimental|Active treatment arm|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
9975777|NCT01344590|Experimental|ethanol maintenance|Instillation of 70% pharmaceutical grade ethanol solution into the central line in a volume calculated to fill the catheter lumen and hub.
9975778|NCT01344603||epidural|
9975779|NCT01344603||standard|
9975780|NCT01344655|Experimental|Formoterol 12 μg pMDI (Atimos®)|
9975781|NCT01344655|Active Comparator|Salmeterol 25 µg pMDI HFA (Serevent™)|
9975782|NCT01344655|Placebo Comparator|Matched Placebo|
9975783|NCT01344668|Other|Standard Diabetes Education|Standard Diabetes Education
9975784|NCT01344668|Other|Enhanced Diabetes Education|Enhanced Diabetes Education
9975785|NCT01344681|Experimental|Arm A|Micafungin sodium
9975786|NCT01344681|Active Comparator|Arm B|Itraconazole
10175183|NCT03845673|Experimental|Psyllium|This group of patients was given psyllium for 6 weeks
10175184|NCT03845673|Experimental|Bowel recipe|This group was administered a specialized bowel recipe for 6 weeks
10175185|NCT03845530|Active Comparator|Hemodialysis group|Blood sample taken and sent to laboratory for analysis
10175186|NCT03845530|Active Comparator|Peritoneal dialysis|Blood sample taken and sent to laboratory for analysis
9678222|NCT04965298|Placebo Comparator|Matched-Placebo arm|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
9678223|NCT04965324||Anaesthesia Depth BIS 35|BIS 35
9678224|NCT04965324||Anaesthesia Depth BIS 50|BIS 50
9678225|NCT04965051|Experimental|IDegAsp group|IDegAsp twice daily
9678226|NCT04965051|Active Comparator|basal insulin plus pre-prandial insulin group|basal insulin once or twice daily plus pre-prandial insulin
9678227|NCT04965103|Active Comparator|Bridging|Tendon repair with graft interposition
9678228|NCT04965103|Experimental|SCR|Superior Capsule reconstruction
9678229|NCT04964882|Experimental|C-E Mask ventilation under PIP 10 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
9678230|NCT04964882|Experimental|C-E Mask ventilation under PIP 15 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
9678231|NCT04964882|Experimental|C-E Mask ventilation under PIP 20 cmH2O|Two-handed C-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
9678232|NCT04964882|Experimental|V-E Mask ventilation under PIP 10 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 10 cmH2O.
9678233|NCT04964882|Experimental|V-E Mask ventilation under PIP 15 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 15 cmH2O.
9678234|NCT04964882|Experimental|V-E Mask ventilation under PIP 20 cmH2O|Two-handed V-E technique is performed during face mask ventilation using a mechanical ventilator with a peak inspiratory pressure of 20 cmH2O.
9678235|NCT04964869|Experimental|Epinephrine solution injection group|In injected group, The saline epinephrine solution (1mg in 10ml N/S) is injected to 2 sites of cutted papilla (1 o'clock and 11 o'clock) by injected needle, at least 0.5ml per injected site, and must be protruded from submucosal layer.
9678236|NCT04964869|No Intervention|non-injection group|In non injection group, the saline epinephrine solution is not given
9678237|NCT04964856|Experimental|ERAS exercise in perioperative period.|The patients take ERAS exercise from hospitalization to 30 days after operation.
9678238|NCT04964856|Sham Comparator|No ERAS exercise in perioperative period.|The patients do not take ERAS exercise in perioperative period.
9678239|NCT04964830|Active Comparator|Children with large overjet|Overjet ≥6 mm, planned orthodontic treatment with functional appliance
9678240|NCT04964830|No Intervention|Control group|Neutral occlusion, no indication for orthodontic treatment, no prior orthodontic treatment
9678241|NCT04965805|Experimental|Cold plasma jet|The treatment scheme of the cold plasma jet will be applied in the following manner, quantity and frequency: Cold plasma is always applicated for 30 seconds/ cm^2 wound size. Wounds will be treated three times in the first week, twice in the second week and once per week in the following observation period. In case of locally infected ulcers, treatment will be performed 1x per day during the first week and afterwards in the same manner as in non-infected ulcers. After application of cold plasma, the wound will be covered with Adaptic perforated gauze and a non-active dressing.
9678242|NCT04965805|Active Comparator|Best Practice wound dressings|Immediately after dressing removal, the wound will be cleaned with a physiological saline solution soaked swab. In case of locally infected wounds, an antiseptic will be used instead of the physiological saline solution. Subsequently, a wound phase-adapted primary dressing will be applied according to the experience of the practitioner and, if necessary, the wound will be covered with a secondary dressing according to the experience of the practitioner as well. In case of locally infected wounds, silver dressings can be applied. The dressing will be changed at least every 2nd day and on weekends every 3rd day; in case of locally infected wounds, dressings will be changed daily. Dressing changes beyond visits can also be performed by the general practitioner, a nursing service, or by the participant him- or herself.
9678243|NCT04965376|Active Comparator|Glenohumeral joint injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
9678244|NCT04965376|Active Comparator|Suprascapular nerve block|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
9678245|NCT04964661||SpA women MRI|Women affected by spondyloarthritis and performed a sacroiliac MRI
9678246|NCT04964583|Experimental|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
9678247|NCT04964583|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg, one tablet every 12 hours for ten days.
9678248|NCT04964583|Placebo Comparator|Placebo|Placebo one tablet every 12 hours for ten days.
9678249|NCT04964973|Active Comparator|Control Group|1. Control group. Patients have performed the conventional postsurgical program without adding TENS.
9678250|NCT04964973|Experimental|Experimental Group|Experimental group. The application of TENS has been added to the physiotherapy program. It had a frequency of 100 Hz and a phase duration of 100 µsec for a period of 30 minutes (through channel 1 of the TENS equipment), receiving and feeling the patient the physical sensation of the current.
9678251|NCT04964973|Placebo Comparator|Placebo Group|Placebo group. In this group, the same program as group 2 was proposed, using, in this case, channel 2, which did not activate the electric current, and the patient did not receive any physical sensation
9678252|NCT04964531||Adults|group of adults includes all patients aging 19 years or more
9678253|NCT04964531||children|group of children includes all patients aging less than 19 years
9678254|NCT04964687||Transplanted patients seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
9827781|NCT02468154|Experimental|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
9678255|NCT04964687||Transplanted patients not seen by an addictionology team|Adult patients with alcohol-related liver disease, possibly complicated by hepatocellular carcinoma, that required liver transplantation in participating centers from January 2000 to December 2015, and seen by an addictology team before and after the transplantation.
9678256|NCT04964804|Experimental|real-time ultrasound-CT fusion imaging|The experimental group of patients underwent selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging by sonographers
10175187|NCT03845712|Experimental|MT1621, dC/dT|This is an open label study with all participants in a single arm. Patients will take MT1621 up to a maximum of 400 mg/kg/day. MT1621 is deoxycytidine (dC) and deoxythymidine (dT) powders for solution for reconstitution in water. Study drug will be supplied as powder in packets containing 0.5 or 2.0 g or 4.0 g of dC or dT, and is typically dosed three times/day. MT1621 should be administered with food.
9678257|NCT04964804|Active Comparator|ultrasound alone|The control group underwent puncture under the guidance of ultrasound alone by sonographers
9678258|NCT04964479|Experimental|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 3 weeks, 1200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
9678259|NCT04964479|Active Comparator|Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules|"Pembrolizumab injection: once every 3 weeks, 200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Placebo of Anlotinib hydrochloride capsules:once a day, 0mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
9678260|NCT04964752|Other|the upper arm group on Day 2|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 2.
9678261|NCT04964752|Other|the upper arm group on Day 15±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 15±1 day.
9678262|NCT04964752|Other|the upper arm group on Day 29±1 day|The upper arm group to perform Visit 3 venous blood glucose measurement on Day 29±1 day.
9678263|NCT04964752|Other|the abdomen group on Day 2|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 2.
9678264|NCT04964752|Other|the abdomen group on Day 15±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 15±1.
9678265|NCT04964752|Other|the abdomen group on Day 29±1|The abdomen group to perform Visit 3 venous blood glucose measurement on Day 29±1.
9678266|NCT04964726|Experimental|Real-time fMRI dyadic neurofeedback|
9678267|NCT04964505|Experimental|Treatment (uproleselan, azacitidine, venetoclax)|Patients receive uproleselan IV over 1 hour Q12H on days 1-7, azacitidine IV or SC QD on days 1-7, and venetoclax PO QD on days 1-28. Beginning cycle 5, patients achieving MLFS or better response, may receive azacitidine IV or SC QD and uproleselan IV over 1 hour QD on days 1-6 and 8 or days 1-5 and 8-9 or days 1-5. Treatment with uproleselan repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Cycles with azacitidine and venetoclax repeat every 28 days in the absence of disease progression and unacceptable toxicity.
9678268|NCT04964518|Experimental|APG2575 + Azacitidine|200 mg APG2575 dose ramp up +AZA
9678269|NCT04964648||Inflammatory pancreatic lesions|older than 18 years with a diagnosis of acute or chronic pancreatitis
9678270|NCT04964648||Malignant pancreatic lesions|older than 18 years with a diagnosis of pancreatic neoplasm
9678271|NCT04964648||Control group|Healthy adult subjects
9678272|NCT04964492||responders to treatment|A patient will be defined as a responder to hydroxocobolamin infusion if there is an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
9678273|NCT04964492||non-responders to treatment|A patient will be defined as a non-responder to hydroxocobolamin infusion if there is not an increase of more than 20% in Average blood pressure, relative to the pre-treatment value, for at least 15 minutes within one hour of treatment administration.
9678274|NCT04964349|Experimental|Intralesional cortisosteroid injection|Intralesional corticosteroid injection
9678275|NCT04964349|Experimental|jessener solution|topical jessener solution
9678276|NCT04964401|Active Comparator|Thoracic Paravertebral Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the thoracic 5 spinous process, the US-compatible needle will be advanced to the paravertebral area with in-plane technique, and 20 ml of 0.25% bupivacaine hydrochloride will be injected into this area.
10175188|NCT03845595|Experimental|(LF-rTMS) group|Patients in the study group were treated with the contralesional (LF-rTMS) once per day for 20 minutes, Daily, 5 sessions per week (Sunday to Thursday), for 2 consecutive weeks in addition to the conventional upper limb physical therapy interventions.
10175189|NCT03845595|Active Comparator|Control group|Patients in the control group were treated with the conventional upper limb physical therapy interventions (40 minutes to 1 hour, daily, 5 times per week for two consecutive weeks )
9678277|NCT04964401|Active Comparator|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
10175190|NCT03845920|Other|tDCS sham + placebo|tDCS= transcranial direct current stimulation drugs= placebo (cellulose [2 grams])
10175191|NCT03845920|Experimental|tDCS sham + tyrosine|tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)
9678278|NCT04964180|Active Comparator|indomethacin group|group indomethacin (40 patients) recived two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
9678279|NCT04964180|Active Comparator|intraperitoneal lidocaine|200 ml saline containing 200 mg 2%lidocaine immediately after abdominal cO2 insufflation( pneumoperitoneum) the surgeon sprayed the total solution on the upper surface of the liver under the right subdiaphragmatic space, left subdiaphragmatic space and around the cholecystectomy site , all patients were maintained in trendelenberg position
9678280|NCT04964102|Experimental|Workshop|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
10175192|NCT03845920|Experimental|tDCS anodal + placebo|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose [2 grams])
9678281|NCT04964154|No Intervention|BRAVE Non-Intervention|Survey participants in the BRAVE non-intervention arm will not have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
9678282|NCT04964154|Active Comparator|BRAVE Intervention|Survey participants in the BRAVE intervention arm will have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
9678283|NCT04964232|Experimental|Temperature monitoring group|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
9678284|NCT04964427|Experimental|anodal tDCS- sham tDCS- MPH|(A) anodal tDCS at t1 (B) sham tDCS at t2 (C) MPH at t3
9678285|NCT04964427|Experimental|anodal tDCS- MPH- sham tDCS|(A) anodal tDCS at t1 (C) MPH at t2 (B) sham tDCS at t3
9678286|NCT04964427|Experimental|sham tDCS- anodal tDCS- MPH|(B) sham tDCS at t1 (A) anodal tDCS at t2 (C) MPH at t3
9678287|NCT04964427|Experimental|sham tDCS- MPH- anodal tDCS|(B) sham tDCS at t1 (C) MPH at t2 (A) anodal tDCS at t3
9678288|NCT04964427|Experimental|MPH- anodal tDCS- sham tDCS|(C) MPH at t1 (A) anodal tDCS at t2 (B) sham tDCS at t3
9678289|NCT04964427|Experimental|MPH- sham tDCS- anodal tDCS|(C) MPH at t1 (B) sham tDCS at t2 (A) anodal tDCS at t3
10175193|NCT03845920|Experimental|tDCS anodal +tyrosine|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)
10175194|NCT03845569|Other|Habitual Protein phase|A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
9678290|NCT04964414|Active Comparator|Smell Retraining Only|Participants will undergo smell retraining for 8 weeks. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose once a day.
9678291|NCT04964414|Experimental|Smell Retraining + Budesonide|Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.
9678292|NCT04964271||Low risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely low risk (PSA (prostate-specific antigen) <10 ng/ml, and stage T1/T2a and Gleason score 3+3).
10175195|NCT03845569|Experimental|Moderate Protein Phase|A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
10175196|NCT03845647|Experimental|Tumor diameter<=2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0 differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
9678293|NCT04964271||High risk prostate cancer patients|Prostate cancer risk category is based on the definition of the European Association of Urology, namely high risk (PSA (prostate-specific antigen) >20 ng/ml or stage T3 or higher or biopsy Gleason score 8-10).
10175197|NCT03845647|Experimental|Tumor diameter>2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0(Clinically N0) differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
10175198|NCT03845387|Experimental|KDT-3594|
10175199|NCT03845387|Other|Pramipexole|Reference drug
10175200|NCT03845478|Active Comparator|Control Group (CG)|Education, modifying diet and physical activity
10175201|NCT03845478|Experimental|Intervention Group (IG)|Education and modifying diet and physical activity with prescription and goal setting
10175202|NCT03845413|Active Comparator|Intervention|The intervention arm consisted of 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
9678294|NCT04964271||Healthy donor|Participants who are in good health and without history of cancer disease.
9678295|NCT04964297|Other|Cohort 1: Predetermined points measurement|"Cohort 1: Predetermined points measurement: 10 subjects with measurement of bowel gas at 8 predetermined time points during right laparoscopic colectomy as follow:~Initiation of surgery/laparoscopy start Insufflation~Abdominal exploration~Completion of colon mobilization~Colon transection~At Colotomy~At Enterotomy~Anastomosis completion~End of surgery- after re-insufflation before closure"
9678296|NCT04964297|Other|Cohort 2: Continuous monitoring|Cohort 2: Continuous monitoring: 10 subjects with continuous monitoring of bowel gases through the surgery. The level of H2 and CH4 gases will be noted at the 8 predetermined time points during the continuous monitoring as well.
10175203|NCT03845413|Active Comparator|Control|The control arm consisted of a home visit by the Community Health Worker scheduling an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
10175204|NCT03845361|Experimental|C. hand|Radial artery cannulation
10175205|NCT03845361|No Intervention|N.C. hand|No cannulation of the radial artery
10175206|NCT03845686||Subacute Stroke Sample|Participants with first-ever left-brain stroke, < 4 weeks post stroke, age >18 years, right-handed, fluent and literate in English prior to stroke, no prior neurological disorders or clinical stroke event, <4 weeks post-stroke; able to undergo an MRI and complete study tasks, and presence of reading deficits.
10175207|NCT03845686||Chronic Stroke Sample|The same group of participants examined in the chronic post-stroke period (>3 months post-stroke)
10175208|NCT03845335|Experimental|HA-coated hybrid implant|Patient allocated to this group will receive an iMAX® Hyaluronic Acid-coated hybrid dental implant for their dental implant-supported restoration.
9678297|NCT04964245|Experimental|Respiration monitoring group|The respiration is simultaneously measured by accelerometer, thermographic camera, Impedance Tomography, and mattress sensor.
9678298|NCT04964258|Experimental|Part 1: TAK-105|TAK-105 at starting dose of 30 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part 1 (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12) may be used. After the pre-specified first dose, subsequent doses will be determined by dose escalation committee based on emerging safety, tolerability, and PK data from the study.
9678299|NCT04964258|Experimental|Part 2: TAK-105|TAK-105 dose to be decided (TBD) or TAK-105 matching-placebo, subcutaneously, once weekly for 4 weeks. Dose of multiple rising dose (MRD) Cohorts (Cohorts 13-17) of Part 2 will be determined based on emerging safety, immunogenicity, tolerability, and PK data from Part 1 (SRD) determined by dose escalation committee.
9678300|NCT04964258|Experimental|Part 3: TAK-105|TAK-105 dose TBD or placebo-matching solution, subcutaneously, once weekly for 2-4 weeks. Dose for the first 2 Cohorts (Cohorts 18-19) of Part 3 will be based on emerging safety, tolerability, and available PK data from Part 1 single rising dose (SRD) and Part 2 (MRD) as determined by dose escalation committee. The data from Cohorts 18-19 will further determine additional enrollment of Cohorts 20, 21, 22 and 23. Part 3 will evaluate whether dose titration result in different tolerability in relation with CV observations.
9678301|NCT04964258|Experimental|Part 4: TAK-105|TAK-105 dose TBD or placebo-matching solution, subcutaneously, once a week for 2 weeks, followed by a period of withholding drug and then redosing with a third dose. Part 4 (Cohorts 24 to 27) will provide an exploratory evaluation to assess the safety and CV tolerability profile of redosing with TAK 105.
9678302|NCT04964167|Placebo Comparator|Group I (Standard Root Planning)|
9678303|NCT04964167|Active Comparator|Group II (Standard Root Planning + Photodynamic Therapy)|
9678304|NCT04964167|Experimental|Group III (Standard Root Planning + Aloe Vera)|
9678305|NCT04964219|Experimental|S-ketamine group|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
9678306|NCT04964219|Placebo Comparator|Control group|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
9678307|NCT04964336||Multiple sclerosis|Patients with relapsing-remitting multiple sclerosis
9678308|NCT04964310||APAP_DILI|"（①/②）+③+④：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU/L ④ liver impairment is caused by acetaminophen：Russel U-Calf Causality Assessment Method(RUCAM) causality score>6"
10175209|NCT03845335|Active Comparator|Moderately rough implant|Patient allocated in this group will receive an iMAX® non-coated moderately rough dental implant with a machined neck their dental implant-supported restoration.
9678309|NCT04964310||APAP_NO-DILI（NDILI）|"（①/②）not（③/④）：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：ALT or AST ≥ 1000 IU/L④ liver impairment is caused by acetaminophen：RUCAM causality score>6"
9678310|NCT04964388||GLP-1 cohort|Participants on GLP-1 receptor agonists
9678311|NCT04964388||Non GLP-1 cohort|Participants not on GLP-1 receptor agonists
10175210|NCT03845283|Experimental|Physical Activity|Participants will receive the core 6-month weight loss program and the tailored intervention to promote structured physical activity.
10175211|NCT03845283|Experimental|Core Program|Participants will receive the core 6-month weight loss program alone. This program includes weekly lessons for the first 12 weeks and monthly lessons for the remaining 12 weeks. Participants will track their intake, physical activity, and weight, input these data into the system, and received tailored feedback.
9975787|NCT01344694||patient with liver fat|30 patients with liver fat
9678313|NCT04964089|Experimental|KSI-301 (Treatment Group A)|Intravitreal injection of KSI-301 (5 mg) at Day 1 once every 4 weeks via intravitreal injection through Week 36.
9678314|NCT04964089|Active Comparator|Aflibercept (Treatment Group B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 3 monthly doses followed by intravitreal injection of aflibercept (2 mg) once every 8 weeks from Week 16 to Week 36. Sham injections will be administered at each monthly visit where an active treatment is not administered.
9678315|NCT04964037||Treatment success group|No intervention
9678316|NCT04964037||Treatment failure group|No intervention
9678317|NCT04964076||COPD patients in the plateau|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to December 2021.
9975788|NCT01344694||excess of visceral fat|50 pts. with excess of visceral fat
9975789|NCT01344694||control|30 control subjects
9975790|NCT01344720|Active Comparator|etoricoxib|etoricoxib up to 60mg/day as monotherapy
9975791|NCT01344720|Active Comparator|etoricoxib plus controlled-release oxycodone|combination treatment of etoricoxib (30 mg/day) plus controlled-release oxycodone (10 mg/day)
9975792|NCT01344733||MDD|Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance.
10175212|NCT03845283|Experimental|Physical Activity & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the virtual meetings to support weight loss.
10175213|NCT03845283|Experimental|Virtual Meetings|Participants will receive the core 6-month weight loss program and the virtual meetings to support weight loss.
10175214|NCT03845283|Experimental|Physical Activity & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and access to the virtual reality platform for behavioral weight loss skills training.
9678318|NCT04964076||COPD patients in the plain|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Peking University Third Hospital from January 2018 to December 2021.
9678319|NCT04964024||Residents in Nursing homes|
9678320|NCT04964024||Health professionals in Nursing homes|
10175215|NCT03845283|Experimental|Virtual Reality|Participants will receive the core 6-month weight loss program and access to the virtual reality platform for behavioral weight loss skills training.
9678321|NCT04963998|Experimental|Copper oxide dressings|Treatment of diabetic ulcers that were in a stagnated stage with copper oxide containing wound dressings
9678322|NCT04964011|Experimental|Board game group|The Board game group was led by an occupational therapist who has been working for six years. The intervention comprised 1 week of board game instruction and 11 weeks of board game tasks (combined with daily tasks), for a total of 12 weeks, once a week for 2 hours, for a total of 24 hours of intervention.
9678323|NCT04964011|Active Comparator|Health promotion group|MCI seniors in the health promotion group received general health promotion and were led by instructors from the long-term care facility for 12 weeks, including 4 weeks of physical activities, 4 weeks of singing activities, and 4 weeks of art activities, once a week for 2 hours, for a total of 24 hours.
9678324|NCT04963621|Experimental|Intervention|Child-Adolescent Emotion and Stress Intervention Program
9678325|NCT04963621|Active Comparator|waiting|treat as usual
9678326|NCT04963582|Experimental|Acupuncture Group|Bilateral LI4 acupuncture is administered before IUD insertion. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
9678327|NCT04963582|No Intervention|Control Group|IUD insertion is proceeded without any intervention. Pain perception is evaluated by 10 points rated VAS after completion of the procedure.
9678328|NCT04963868|Experimental|The novel strategy group|The stents were removed during the last necrosectomy when the endpoint of necrosectomy was achieved
9678329|NCT04963868|Active Comparator|The conventional strategy group|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image
9678330|NCT04963842|No Intervention|Conventional phase (use of conventional food packaging material)|During the conventional phase, participants are asked to maintain their usual habits for 5 days.
9678331|NCT04963842|Experimental|Intervention phase (use of bio-plastic and no plastic food packaging material)|During the 5-day long intervention period, all participants will be asked to: i) refrain from packaged (cans, plastic, paper) ready to consume foods, and foods from take away/delivery/fast food and ii) use the bio-based food packaging material to package their food.
10175216|NCT03845283|Experimental|Physical Activity, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the virtual meetings to support weight loss, and access to the virtual reality platform for behavioral weight loss skills training.
10175217|NCT03845283|Experimental|Virtual Reality & Virtual Meetings|Participants will receive the core 6-month weight loss program, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
9695341|NCT04779580|Experimental|Intervention Group (Only Group)|"Only one group in this study. 10 participants to have intervention.~Lateral femoral cutaneous nerve block and evaluation:~Routine ECG, pulse oximetry and blood pressure monitoring will be available. Using a sterile technique, the lateral femoral nerve will be approached using an in-plane ultrasound-guided technique, using a Stimuplex Ultra 360 50mm needle (B Braun, UK). Following negative aspiration, a one off STAT injection of 5mls lidocaine 1% will be administered subcutaneously.~After 10 minutes, any altered sensation will be assessed using ice to differentiate normal and altered sensation. This area will be marked on the skin using a black marker pen. Photographs will be taken and images of the procedure will be recorded.~The above will then be repeated for the subcostal nerve block.~The total area of anaesthesia will then be compared to the standard surgical incision for hip surgery to assess whether the subcostal nerve block will offer any further analgesia."
9695342|NCT04779528|Experimental|Group S|Patients will undergo fiberoptic intubation in supine position.
9695343|NCT04779528|Experimental|Group L|Patients will undergo fiberoptic intubation in lateral position.
9695344|NCT04779333|Experimental|LEAP Group|In addition to the components of the BMT group, the LEAP program includes an emphasis on supporting optimal physical activity, limiting screen time, and encouraging adequate sleep. The child and caregiver are also given a wrist-worn activity tracker and caregivers participate in a motivational Facebook group.
9695345|NCT04779333|Active Comparator|BMT Group|The BMT Group will take part in a family-based intervention within the context of evidence-based behavioral management training (BMT) for caregivers. Standard BMT represents the current standard of care for childhood ADHD.
9695346|NCT04779086||1. group|Scale score results of first year physiotherapy and rehabilitation department students
9695347|NCT04779086||2. group|Scale score results of 2nd year physiotherapy and rehabilitation department students
9695348|NCT04779086||3. group|Scale score results of 3rd year physiotherapy and rehabilitation department students
9695349|NCT04779086||4. group|Scale score results of 4th year physiotherapy and rehabilitation department students
9977556|NCT01362920||Sepsis or Septic shock cohort|
9977557|NCT01362920||Non-sepsis or non-Septic shock cohort|
10175218|NCT03845283|Experimental|Physical Activity & Bite Counter|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the Bite Counter device to reduce dietary intake.
10175219|NCT03845283|Experimental|Bite Counter|Participants will receive the core 6-month weight loss program and the Bite Counter device to reduce dietary intake.
10175220|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
10175221|NCT03845283|Experimental|Bite Counter & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
10175222|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
10175223|NCT03845283|Experimental|Bite Counter & Virtual Reality|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
9678332|NCT04963673||DFG> 40 ml / min|Kidney transplant population followed at CHU Amiens (group 1 ⇾ DFG> 40 ml / min).
9678333|NCT04963673||DFG < 40 ml / min|Kidney transplant population followed at CHU Amiens (group 2 ⇾ DFG < 40 ml / min).
9678334|NCT04963829|Active Comparator|Study Group (SG)|Participants who used the abovementioned gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration.
9678335|NCT04963829|Active Comparator|Control Group 1 (CG1)|Participants who were subjected to a standardized treatment (collagenase ointment was selected for this treatment),
9678336|NCT04963829|Active Comparator|Control Group 2 (CG2)|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum)
9678337|NCT04963764|Placebo Comparator|Placebo|Randomization to receive either oral placebo or amoxicillin for a standard course (10 days)
9678338|NCT04963764|Active Comparator|Amoxicillin|Randomization to receive either oral amoxicillin or placebo for a standard course (10 days)
9678339|NCT04963712|Experimental|Zadaxin-HIV(n=20)|Study participants will be given Zadaxin (1.6 mg subcutaneous injection, once a day) in the first 2 weeks, and changed frequency (1.6 mg subcutaneous injection, twice a week) in the second 22 weeks.
9678340|NCT04963556|Experimental|Red Bull|Drinking of 355 ml Red Bull
9678341|NCT04963556|Placebo Comparator|Placebo|Drinking of 355 ml sweetened water
9678342|NCT04963985|Experimental|Tafamidis group|During the treatment period, each participant will receive 20 mg tafamidis meglumine once daily for 24 weeks.
9678343|NCT04963530|Experimental|Wear of antagonist teeth to monolithic zirconia restorations|Evaluate enamel wear antagonist to monolithic zirconia restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
9678344|NCT04963530|Experimental|Wear of antagonist teeth to lithium disilicate restorations|Evaluate enamel wear antagonist to lithium disilicate restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
9678345|NCT04963530|Experimental|Wear of antagonist teeth to metalceramic restorations|Evaluate enamel wear antagonist to metal ceramic restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
10175224|NCT03845283|Experimental|Physical Activity, Bite Counter, Virtual Reality & Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
10175225|NCT03845283|Experimental|Bite Counter, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
10175226|NCT03845348|Experimental|TD3|TD3, bi-daily x 4 weeks
10175227|NCT03845348|Experimental|TD7|TD7, bi-daily x 4 weeks
9678346|NCT04963530|Experimental|Wear of natural enamel|Evaluate physiological enamel wear (control group) monitoring the short short and medium-term volume loss and assessing the factors that may influence this wear.
10175228|NCT03845348|Active Comparator|Ketoconazole 2%|Ketoconazole 2% shampoo bi-daily x 4 weeks
10175229|NCT03845322|Experimental|Curcumin pills group|24 Patient will receive Curcumin (CC) pills, within 24 hours post-operatively (as long as they are able to take oral medication). It will then be continued TID
10175230|NCT03845322|Placebo Comparator|Placebo group|24 Patient will receive Placebo pills, within 24 hours post-operatively (as long as they are able to take oral medication. It will then be continued TID.
10175231|NCT03845309|Experimental|Nutritional intervention for CHF|
10175232|NCT03845192|Other|ORI measurement by Radical-97|"In this arm ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®"
10175233|NCT03845205|Experimental|Integrated AUD Treatment (IAT)|IAT will include computer-delivered CBI in the hospital, nurse-delivered clinical monitoring and treatment adherence counseling, and at-home participation in web-based, 7-session computerized cognitive-behavioral therapy (CBT4CBT), supplemented by tailored text messages. Alcohol pharmacotherapy will be added to behavioral treatments as needed.
9678347|NCT04963608||non-interventional study|Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
9678348|NCT04963595|Experimental|Pyrotinib and Vinorelbine with Inetetamab|
9678349|NCT04963595|Experimental|Pyrotinib and Vinorelbine without Inetetamab|
9678350|NCT04963907|Active Comparator|Active CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Active devices are programmed to emit a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes. Participants will not be able to adjust the settings on the devices.
9678351|NCT04963907|Sham Comparator|Sham CES Therapy|Participants will be asked to use Alpha-Stim 60 minutes daily for 8 weeks. Sham devices are programmed to display a current intensity of 100 uA at 0.5 Hz and will be programmed to run for 60 minutes, but no current will be emitted from the device. Participants will not be able to adjust the settings on the devices.
9678352|NCT04963855|Active Comparator|CT300|GT300 capsule given once daily
10175234|NCT03845205|No Intervention|Treatment As Usual|All LT patients receive physician instructions to not drink alcohol. Consistent with current discharge procedures, AH patients are encouraged to engage in alcohol treatment services. Patients receive regular blood draws for monitoring of liver function, and regular phone calls for post-operative monitoring.
9678353|NCT04963855|Placebo Comparator|Placebo|Microcrystalline cellulose capsule given once daily
10175235|NCT03845231|Other|unvaccinated|will receive no Flucelvax vaccination and will receive human challenge virus
9678354|NCT04963803|Experimental|Active transcranial direct current stimulation (tDCS) paired with speech-language therapy|Active transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
9678355|NCT04963803|Sham Comparator|Sham transcranial direct current stimulation (tDCS) paired with speech-language therapy|Sham transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
9678356|NCT04963335|Experimental|Intervention|Participants perform 16 exergame training (video game-based physical exercise) sessions over a period of 4 to 8 weeks (depending on in-patient or out-patient). Each training lasts between 15 to 25 minutes. Exergames automatically adjust the game difficulty to the abilities of the respective participant.
9678357|NCT04963335|No Intervention|Control|Participants of the control group are instructed to continue their normal daily routine for eight weeks and to record their physical activities.
9678358|NCT04963244||AECOPD|
9678359|NCT04963244||Stable COPD|
9678360|NCT04963244||Control|
9678361|NCT04963257|Experimental|sertraline combined with fluvoxamine|Sertraline combined with fluvoxamine treatment group: Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
9678362|NCT04963257|Active Comparator|sertraline combined with aripiprazole|sertraline combined with aripiprazole treatment group:Gradually add the drug to the treatment dose, and monitor the symptom change, scale score, blood drug concentration and other indicators
9678363|NCT04963231|Active Comparator|Setmelanotide|"Dosage:~Patients 12 years of age and older: Setmelanotide 2 mg once daily (QD) for approximately 14 days, then increased to setmelanotide 3 mg QD for the remainder of the study.~Patients 6 to <12 years of age: Setmelanotide 1 mg QD for approximately 7 days, then increased to setmelanotide 2 mg QD for approximately 7 days, then increased to setmelanotide 3 mg QD for the remainder of the study.~Mode of administration:~-Subcutaneous (SC) injection"
9678364|NCT04963231|Placebo Comparator|Placebo|Placebo (vehicle) in a sterile solution for injection
9678365|NCT04963192|Experimental|OSA or COPD patients having an integrated management at home|OSA or COPD patients having an integrated management at home using connected devices, during 6 months
9678366|NCT04963127||Prospective Cohort|400 patients who are scheduled to undergo a clinically requested CT scan of parts of the skeleton using a Dual-Energy/Multi-Energy/Spectral acquisition mode to exclude or further define bone fractures.
9678367|NCT04963127||Retrospective Cohort|400 patients who had undergone a clinically requested CT scan of the skeleton in standard acquisition mode in the past to exclude or further define bone fractures.
9827782|NCT02468154|Active Comparator|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
9827783|NCT02468193|Experimental|Osilodrostat|Patients in this arm took the study drug, osilodrostat.
10175236|NCT03845231|Experimental|Vaccinated|will receive Flucelvax vaccination and human challenge virus
10175237|NCT03845244|Active Comparator|Flow reduction first group|Flow reduction first -> FiO2 reduction -> conventional oxygen therapy
10175238|NCT03845244|Active Comparator|FiO2 reduction first group|FiO2 reduction first -> flow reduction -> conventional oxygen therapy
10175239|NCT03845244|Active Comparator|Simultaneous reduction group|Simultaneous (Flow and FiO2) reduction -> conventional oxygen therapy
10175240|NCT03845257||Patients with COPD|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
10175241|NCT03845257||Patients with asthma|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
10175242|NCT03845179|Placebo Comparator|Placebo|Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
10175243|NCT03845179|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
10175244|NCT03845153|Active Comparator|Metformin|20 post-menopausal women with a bone fracture treated with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily for three months.
10175245|NCT03845153|Placebo Comparator|Placebo|20 post-menopausal women with a bone fracture treated with placebo once daily for two weeks then twice daily for three months.
10175246|NCT03845010|Active Comparator|Sotalol|
10175247|NCT03845010|Active Comparator|Flecainide and verapamil|
10175248|NCT03845010|Active Comparator|Catheter ablation|
10175249|NCT03844958|Experimental|Red Furu|Volunteer was randomized into group red furu
10175250|NCT03844958|Experimental|Fresh Tofu|Volunteer was randomized into group tofu
10175251|NCT03845049|Experimental|group aflibercept|
9975793|NCT01344746||Snoring group|"Subjects with snoring and AHI ≥ 20 episodes/h (severe SDB).~Snorers with AHI < 20 episodes/h and ≥ 5 episodes/h (moderate SDB)~Snorers with AHI < 5 episodes/h and ≥ 1 episodes/h (mild SDB)"
9975794|NCT01344746||Non-snoring group|"When testing serum and urinal samples, healthy children without snoring will be chosen as controls.~When testing lymphoid tissue samples, patients with recurrent infectious tonsillitis (at least five tonsillar infections in less than 6 months) but without snoring will be selected as controls before surgery and recruited to the study, because adenotonsillar tissue can't be obtained from normal children for obvious ethical reasons."
10175252|NCT03845049|Placebo Comparator|control group|
10175253|NCT03845075|Experimental|active arm|The active medication arm will be given co-administration of 0.5 mg tesofensine/50 mg metoprolol daily for 24 weeks.
10175254|NCT03845075|Placebo Comparator|placebo arm|The placebo arm will receive matching placebo tablets.
9678370|NCT04963361||fear of movement group|The score of fear of movement scale was more than 37
9678371|NCT04963361||non-fear of movement group|The score of fear of movement scale was no more than 37
9678372|NCT04963374||respiratory inpatient|respiratory inpatient with VTE
9678373|NCT04963426|Experimental|Intervention arm|"The intervention consists of interactive workshops that will be facilitated by WHO and trained local personnel and involve students, teachers and local authorities. In the workshops, the Global Accelerated Action for the Health of Adolescents (Global AA-HA!) approach will be used to:~identify adolescent health needs through exploring the collected baseline data;~assess policies and practices already in place;~identify gaps and needs for action to improve health. A menu of actions will be identified, prioritized, implemented and monitored."
9678374|NCT04963426|No Intervention|Control arm|The schools in the control arm will not participate in any intervention and continue 'as usual' after the baseline surveys.
10175255|NCT03844841|Active Comparator|Propofol|Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous
10175256|NCT03844841|Active Comparator|Dexmedetomidine|Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous
9678375|NCT04963114|Experimental|Art therapy|art therapy in the form of a one-hour guided tour of art works followed by a two-hour guided creative painting workshop on specific themes such as beauty and wonder and colors and emotions
9678376|NCT04963088|Experimental|TISLELIZUMAB、Anlotinib plus XELOX|
9678377|NCT04963465||Before rupture of membranes|Vaginal swab collection prior to iatrogenic rupture of membranes
9678378|NCT04963465||After rupture of membranes|Vaginal swab collection after iatrogenic rupture of membranes
9678379|NCT04963348||convolutional neural network (CNN)|a classical deep convolutional neural network (CNN) called Inception-V3 was applied to the image sets and validated the classification performance of the trained models
9678380|NCT04963309||OR-EX|the group with endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
9678381|NCT04963309||NOR-EX|the group without endotracheal tube extubation in the operating room in patients who underwent living-donor liver transplantation for end-stage liver failure
9678382|NCT04963400||Patients with low disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of low severity (e.g. patients with retinal detachment)
9678383|NCT04963400||Patients with medium disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of medium severity (e.g. patients with an uncomplicated acute pancreatitis oder an acute exacerbation of a chronic inflammatory bowel disease)
9975795|NCT01344772|Active Comparator|Internal fixation|Displaced femoral neck fracture treated with internal fixation using two parallel cannulated screws.
10175257|NCT03844984|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
10175258|NCT03844984|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
10175259|NCT03844932|Experimental|ST-0529 18.75 mg*|"ST-0529: 18.75 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
10175260|NCT03844932|Experimental|ST-0529 37.5 mg*|"ST-0529: 37.5 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
10175261|NCT03844932|Experimental|ST-0529 75 mg|ST-0529: 75 mg orally twice daily (BID)
10175262|NCT03844932|Placebo Comparator|Matching Placebo|Placebo: matching placebo orally twice daily (BID)
10175263|NCT03845088||Children TMJA or condyle absence with Jaw Deformity|inclusion criteria: <12 years old; Unilateral temporomandibular joint ankylosis or condyle absence； Temporomandibular joint reconstructed with costochondral graft；
10175264|NCT03845127|Experimental|Revivent TC Ventricular Enhancement System plus GDMT|Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
10175265|NCT03845127|Active Comparator|GDMT Only|Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
10175266|NCT03844867|Experimental|Filippo Cea and Carmel|Subjects <65 years.
10175267|NCT03844854|No Intervention|Control Group|Without intervention.
10175268|NCT03844854|Experimental|Research Group|With providing stabilization occlusal splint and manual therapy.
10175269|NCT03844880|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
10175270|NCT03844880|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
9678384|NCT04963400||Patients with high disease severity|Hospitalized patients without a diagnosed or suspected cardiac disease and with an acute medical condition of high severity (e.g. patients with a proximal femoral fracture)
9678385|NCT04963387|Experimental|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps vibration exposure was given in 1-minute bouts, with rest period of one to two minutes between bouts, with the exposure whole body vibration for about four minutes on every session. The duration of vibration exposure was preset with the automatic set time intervals in the vibration machine Prior to each vibration bout. When the predefined time was reached the machine automatically turned off . Based on previous researches the total exposure of four minutes per session interval was selected. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
9678386|NCT04963387|Active Comparator|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
9678387|NCT04963491|Experimental|3D printed personalized TKA prosthesis|Design：Personalized TKA prosthesis Manufacture：3D
9678388|NCT04963491|Active Comparator|Zimmer NexGen TKA prostheses|Prosthesis has been widely used in clinic
9678389|NCT04963075|Experimental|Unilaterally blind Subjects will be exposed to visual-auditory stimulation|The over-arching objective is to evaluate the functional recovery of vision in hemianopic patients engaged with a multisensory training paradigm. Unilaterally blind participants will participate in weekly training sessions in which they are exposed to high-density spatiotemporally congruent and consistent visual-auditory stimulation. The participants will be tested on a battery of visual tasks probing different levels of function in different environments in a longitudinal study to track recovery.
9975796|NCT01344772|Active Comparator|Total hip replacement|Displaced femoral neck fracture treated with total hip replacement through a posterior approach.
9975797|NCT01344785||Patients with a intertrochanteric fracture|Patients with a intertrochanteric fracture, n=100
9975798|NCT01344798|Experimental|Dose level 1|AAV1-gamma-sarcoglycan vector dose level: 3x10e9 vg/100µl
9975799|NCT01344798|Experimental|Dose level 2|AAV1-gamma-sarcoglycan vector dose level: 1.5x10e10 vg/100µl
9975800|NCT01344798|Experimental|Dose level 3|AAV1-gamma-sarcoglycan vector dose level: 4.5x10e10 vg/300µl
9975801|NCT01344811|Experimental|Telemonitoring group|"A Smartphone, body composition analyzer and Pedometer will be provided~transmitting the results to the Smart Care Server via Smartphone~At Smart care Center,care manager will provide remote body weight and activity monitoring and individual obesity case management"
9975802|NCT01344811|Other|Control group|"A weighing scale and Pedometer will be provided~recording in a self diary of body weight and the number of steps"
9975803|NCT01344837||Observational|Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).
9975804|NCT01344863|Experimental|1|
9975805|NCT01344863|Active Comparator|2|
9975806|NCT01344889||Cohort|
9975807|NCT01344902|Experimental|Hexaminolevulinate|
9975808|NCT01344915|Active Comparator|Knee brace|
9678390|NCT04963049|Experimental|With Mask|
9678391|NCT04962763||Heart Failure|
9678392|NCT04962763||Control|
9678393|NCT04962906|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
9678394|NCT04962906|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
9678395|NCT04962906|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
9678396|NCT04962789||with compaction|those whose endometrial thickness is calculated to decrease by the time of embryo transfer compared with the thickness at the day of ovulation trigger, analyzed according to the degree of compaction, i.e., 5%, 10%, 15%, or 20% decrease thickness
9678397|NCT04962789||without compaction|those who had an increase in their endometrial thickness or whose thickness decreased less than 5%
9975809|NCT01344915|Active Comparator|Locked knee brace|
9975810|NCT01344928|Experimental|HIT training|
9975811|NCT01344928|Active Comparator|Aerobic exercise training|
9975812|NCT01344941||Group 1|The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses
9975813|NCT01344941||Group 2|Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
9975814|NCT01344941||Group 3|Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
9975815|NCT01344954|Experimental|25mg TB-402|
9975816|NCT01344954|Experimental|50mg TB-402|
9975817|NCT01344954|Active Comparator|10mg QD Rivaroxaban|
9975818|NCT01344967|Experimental|Zometa, Bone Suppression, Active Ingredient|
9975819|NCT01344980|Experimental|Stainless steel MGH|Patients in this study arm will have their flexor tendon laceration repaired using stainless steel suture (size 3-0) in an MGH repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
9975820|NCT01344980|Active Comparator|Polypropylene DOLL|Patients in this study arm will have their flexor tendon laceration repaired using polypropylene suture (size 3-0) in a double-locking loop repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
9975821|NCT01345032|Experimental|Home visits|Nutritional follow-up after discharge, conducted as nutritional counselling performed as in-person counselling in the participants homes
9975822|NCT01345032|Experimental|Telephone consultation|Nutritional follow-up after discharge, conducted as nutritional counselling performed as telephone consultation
9975823|NCT01345032|No Intervention|Control|No follow-up after discharge
10175271|NCT03844971|Experimental|Computer assisted surgery|Intervention will be fabrication of patient specific surgical guide for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction using patient computed tomography with the aid of computer aided surgical simulation software
10175272|NCT03844815|Experimental|Treatment|"Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21~Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21~During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21"
10175273|NCT03844646|Experimental|CGM plus dietitian|Intermittent use of a continuous glucose monitor (CGM) plus dietitian support
10175274|NCT03844646|Other|Dietitian only|Dietitian support only
10175275|NCT03844555|Experimental|End Stage Renal Disease|Single oral dose of elafibranor 120mg
10175276|NCT03844555|Experimental|Healthy|Single oral dose of elafibranor 120mg
9678398|NCT04962828|Experimental|Collaboration group|This group of children will have targets and vocabulary that has been designed collaboratively and then the therapist and teacher both reinforce the vocabulary during the week
9678399|NCT04962828|Active Comparator|Non-collaborative group|This group of children will have targets and vocabulary that has been designed collaboratively but they will only be practiced with the therapist during the week
9678400|NCT04962984|Experimental|THAL +|patients with beta thalassemia major, requiring blood transfusion regimen. Additional blood sampling will be performed before and immediately after transfusion (21 millilters and 24 millilters respectively), on the occasion of 3 programed transfusions (consecutive or not).
10175277|NCT03844581|Active Comparator|interferential current|interferential current with a constant frequency of 100Hz for pain relief, then using rhythmic frequency of 1-100 Hz that help to disperse infiltration and adhesions for 8 successive weeks
9678401|NCT04962984|Sham Comparator|THAL -|Patients with beta thalassemia trait, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
9678402|NCT04962984|Sham Comparator|Healthy volunteers|healthy subjects, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
9678403|NCT04962672|Experimental|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide.
9678404|NCT04962672|Active Comparator|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group will received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide.
9678405|NCT04962893|Experimental|VLP-Wuhan group (Group V1)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
9678406|NCT04962893|Experimental|VLP-Alpha (British) variant group (Group V2)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
10175278|NCT03844581|Active Comparator|anticholinergics|anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks
10175279|NCT03844503|Placebo Comparator|Cereal Bar no fiber|Cereal bar without fiber
9678407|NCT04962893|Experimental|VLP-Wuhan+Alpha group (Group V3)|"110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan and Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.~Initial vaccination with Wuhan followed by a booster of Alpha variant."
9678408|NCT04962945|Active Comparator|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
9975824|NCT01345071||RA patients|RA patients with active disease or current use of anti-TNF. Treatment is according to treat to target principles.
10175280|NCT03844503|Active Comparator|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
10175281|NCT03844503|Active Comparator|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
10175282|NCT03844438|Experimental|LPM3480226|LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.
10175283|NCT03844607|Experimental|Active tDCS|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
10175284|NCT03844607|Sham Comparator|Sham tDCS|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
10175285|NCT03844568|Experimental|nasal CPAP group|Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment
10175286|NCT03844568|No Intervention|Control group|Usual pneumonia treatment
10175287|NCT03844633|Experimental|Intervention arm|Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
10175288|NCT03844633|Placebo Comparator|Placebo arm|0.9% sodium chloride injection provided within 48 hours of childbirth
10175289|NCT03844633|No Intervention|Open arm|No intervention provided
10175290|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)
9678409|NCT04962945|Active Comparator|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
9678410|NCT04962750|Experimental|laser therapy|
9678411|NCT04962750|Sham Comparator|Control|
9678412|NCT04963010|No Intervention|standard withdrawal colonoscopy|Observation of conventional colonoscopy
9678413|NCT04963010|Experimental|second forward view|second forward view examination of the proximal colon
9678414|NCT04962932|Experimental|Internet-delivered exposure-focused CBT|Internet-delivered CBT over 10 weeks The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
9678415|NCT04962932|Active Comparator|Internet-delivered stress management treatment|Stress management treatment for 10 weeks Participants randomized to The Stress Management Treatment will receive 10 weeks of stress managemen including relaxation technics, standard life style advice regarding physical activity, sleep and and standardized AF-information in line with current guidelines for AF. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
9678416|NCT04962802|Experimental|Manhood 2.0|Manhood 2.0 is a group-level intervention, delivered in 7 sessions over 13 hours, and is based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Sessions were delivered twice a week, for approximately 3.5 weeks. For the final session, participants received one hour of content and were administered the immediate post-intervention survey. The intervention takes a holistic, gender-transformative approach, includes reproductive health knowledge, healthy relationships, altering gender norms and stereotypes which drive reproductive health behavior, and explicit and proactive support of female partner contraceptive use. Activities are designed to engage young men in critical reflection and dialogue about gender norms, and then apply these discussions to a range of key issues including intimate relationships, gender-based violence, substance abuse, STIs, and early pregnancy.
9678417|NCT04962802|Placebo Comparator|Post-High School Readiness|The Post-High School Readiness Program helped youth build skills around identifying colleges or programs of interest, completing applications for programs, writing resumes and increasing financial literacy. The post-high school readiness curriculum was delivered by LAYC staff members and the content was delivered twice a week, for approximately 3.5 weeks (as with the intervention). For the final session, participants did not receive content and were administered the immediate post-intervention survey.
9678418|NCT04962997||Transgender women|Major person identifying as a transgender women consulting at Cayenne Hospital (French Guiana) or Bichat Hospital (Paris) between 06/2021 and 10/2022
9678419|NCT04963062|Experimental|Participants treated with Holmium laser with the Moses laser|
9678420|NCT04963062|Experimental|Participants treated with Holmium laser with the thulium laser|
9678421|NCT04963023||frequent exacerbation patients|
9678422|NCT04963023||non frequent exacerbation patients|
9678423|NCT04963023||Asthma-and-COPD overlap syndrome|
9678424|NCT04963023||Asthmatic patients (without COPD)|
9678425|NCT04962854||Monoblock Cup|53 patients received a monoblock cup (RM Pressfit vitamys®)
9678426|NCT04962854||Modular Cup|64 patients received a modular cup (ANA.NOVA® Implantec)
9678427|NCT04962958|Experimental|HAIC+Donafenib|Donafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
9678428|NCT04962841||Frail older adults treated with nutraceuticals and drugs|
9678429|NCT04962841||Frail older adults not treated with nutraceuticals and drugs|
9678430|NCT04962659|Experimental|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (~1 hour) delivered via telehealth.
9678431|NCT04962659|No Intervention|Business as Usual Control|No treatment control.
9678432|NCT04962425||The case group|Trastuzumab for the treatment of breast cancer patients with cardiotoxicity.
9678433|NCT04962425||The control group|Trastuzumab is used to treat patients with breast cancer who do not present with cardiotoxicity
9678434|NCT04962269||prostate cancer|The patient was pathologically diagnosed with prostate cancer
9975825|NCT01345084|Experimental|Radiation therapy, cisplatin and nimotuzumab|"Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.~Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week~Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)"
9975826|NCT01345084|Active Comparator|Radiation therapy and cisplatin|"Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week~Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)"
9975827|NCT01345097|Experimental|Younger Group|
9975828|NCT01345097|Experimental|Elderly Group|
9678435|NCT04962269||benign prostatic hyperplasia|The patient was pathologically diagnosed with benign prostatic hyperplasia
9678436|NCT04962282||group 1|Follow-up by telephone for researching compliance of patients receiving exercise prescriptions
9678437|NCT04962451|Experimental|Intervention group|
9678438|NCT04962451|Placebo Comparator|Placebo group|
9827784|NCT02468557|Experimental|Idelalisib 150 mg|Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.
9975829|NCT01345149|Experimental|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
9975830|NCT01345149|Experimental|Exercise|Exercise: Individual counselling
9975831|NCT01345149|No Intervention|Control|Standard treatment without intervention.
9678439|NCT04962529||Metastatic Breast Cancer patients|Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
9678440|NCT04962386||Perimenopausal women who did not undergo HRT|Perimenopausal women who did not undergo HRT at baseline. And they did not receive any other drugs
10175291|NCT03844490|Experimental|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops.~At this time, cord clamping will be made."
10175292|NCT03844451|Experimental|Liposomal bupivicaine with nerve block|The treatment group will receive an intraoperative V2 trigeminal nerve block using liposomal bupivacaine in addition to a standard bupivacaine nerve block.
10175293|NCT03844451|Placebo Comparator|Nerve block only|The control group will undergo conventional perioperative management without an ERAS protocol and standard bupivacaine intraoperative nerve block.
10175294|NCT03844542|Experimental|Therapeutic plasma exchange|Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
9678441|NCT04962386||Perimenopausal women who did undergo HRT|Perimenopausal women who did undergo HRT received estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV. Weesp, The Netherlands).Take this medicine once a day. A course of treatment was defined as 28 days of continuous treatment.
9678442|NCT04962256||Study group|Patients with degenerative CSM or OPLL undergoing C3-7 open-door laminoplasty
9678443|NCT04962464|Experimental|Fasting Mimicking Diet + Supplement / Usual Routine|Participants in will be asked to begin the Peak Human Labs calorie mimetic supplement. They will also begin on day 1 the 5 day Fasting Mimicking Diet Program. Participants will continue the supplementation for the 90 days and repeat the 5 day Fasting Mimicking Diet Program on days 1, 29 and 57. Starting at day 91, they will return to their usual daily routine.
9678444|NCT04962464|Experimental|Supplement / Usual Routine|Participants will be asked to begin the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days. Starting at day 91, they will return to their usual daily routine.
9678445|NCT04962464|Experimental|Usual Routine / Fasting Mimicking Diet + Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91, they will begin the 5-day Fasting Mimicking Diet Program and start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days and repeat the 5-day Fasting Mimicking Diet Program on days 91, 120, and 148.
9678446|NCT04962464|Experimental|Usual Routine / Supplement|Participants will have no intervention for the first 90 days, during which they will be asked not to start a new fasting program supplement. At day 91,start the Peak Human Labs calorie mimetic supplement. Participants will continue the supplementation for 90 days.
9678447|NCT04962555||Meniscus Suture|The patient underwent meniscus suture surgery
9678448|NCT04962555||Partial meniscus resection|The patient underwent partial meniscus resection
9678449|NCT04962555||Subtotal meniscus resection|The patient underwent Subtotal meniscus resection
10175295|NCT03844542|No Intervention|Standard care alone for sepsis|Standard care for patients with sepsis induced multi-organ failure
10175296|NCT03844789|Experimental|Closed Loop Control (CLC)|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem Control-IQ Technology & Dexcom G6 CGM vs Control Group for 16 weeks. Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 16 weeks. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
10175297|NCT03844789|Active Comparator|Control Group|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Control Group for 16 weeks. All participants will be provided the option of using t:slim X2 with Control-IQ system in a 12 week Extension Phase.
10175298|NCT03844776|Active Comparator|Co-Amoxiclav postoperatively alone|• Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Co-Amoxiclav 625 mg 0.2% chlorhexidine mouthwash following the surgery for 5 days (control group)
10175299|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with Metronidazole postoperatively|• Treatment 2: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of Metronidazole 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
10175300|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with amoxicillin postoperatively|• Treatment 3: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of amoxicillin 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
10175301|NCT03844477|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
10175302|NCT03844477|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
9678450|NCT04962555||Complete meniscectomy|The patient underwent complete meniscectomy
9678451|NCT04962373||Adolescents|Adolescents with a contract for Brief admission by self-referral
9678452|NCT04962373||Parents|Parents to adolescents with a contract for Brief admission by self-referral
9678453|NCT04962373||Staff|Health care providers who work with adolescents with a contract for Brief admission by self-referral
9678454|NCT04962308|Experimental|Experimental Group|200 subjects in group A1 will receive one dose of booster immunization 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
10175303|NCT03844620|Experimental|Arm I (ctDNA testing, regorafenib, TAS-102)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle. Patients in this arm will get ctDNA testing and will continue treatment beyond 1st cycle depending on ctDNA results. Beyond that patients will continue treatment in the absence of disease progression or unacceptable toxicity.
10175304|NCT03844620|Active Comparator|Arm II (SOC)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle as per standard of care. Patients in this arm will continue treatment in the absence of disease progression or unacceptable toxicity.
9678455|NCT04962308|Experimental|Control Group|200 subjects in group A2 will receive one dose of booster immunization 5 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine.
10175305|NCT03844529|Experimental|Sunmax FULLSGEN with Lidocaine|A subject would only receive single injection treatment(day 1) using Sunmax FULLSGEN , and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
10175306|NCT03844529|Active Comparator|Sumax FACIALGAIN collagen Implant with Lidocaine|A subject would only receive single injection treatment(day 1) using Sumax FACIALGAIN collagen Implant with Lidocaine, and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
9678456|NCT04962308|Experimental|Safety group|1000 subjects in group B will be enrolled and receive 1 dose of booster immunization more than 3 months after the completion of the second dose of primary immunization of the SARS-CoV-2 Inactivated vaccine
9678457|NCT04962620||Longidaze|75 patients receiving combination therapy: Longidaze + dienogest
9678458|NCT04962620||Control|74 patients receiving only Dienogest.
9678459|NCT04962295||Cerebral Small Vessel Diseases group|CSVD patients
9678460|NCT04962516||Test group|
9678461|NCT04962516||Control group|
9678462|NCT04962438||Tumor patients using anti-VEGF drugs|
9678463|NCT04962399||DKD group|Patients with type 2 diabetes mellitus complicated with diabetic nephropathy diagnosed by the second hospital of Shanxi Medical University
10175307|NCT03844724|Experimental|Group A|subjects using the drug-eluting PTA balloon dilatation catheter
10175308|NCT03844724|Active Comparator|Group B|subjects using the peripheral balloon dilatation catheter
10175309|NCT03844737|Experimental|VisuXL® Treatment|
10175310|NCT03844698||Patients with Sarcoidosis and Cancer|These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
10175311|NCT03844594|Experimental|Eptifibatide Drug: Eptifibatide Injection|
10175312|NCT03844685|Experimental|Treatment group|1 tablet /day of MCE-11 (Promensil) taken orally for 24 months
10175313|NCT03844685|Placebo Comparator|Placebo group|Placebo tablet (without active principle) given once a day for 24 months
10175314|NCT03844711|Experimental|Transcutaneous electrical diaphragmatic stimulation (TEDS)|For transcutaneous electrical diaphragmatic stimulation, surface electrodes will be used that will be positioned at the transcutaneous motor points of the diaphragm.
10175315|NCT03844711|Experimental|Inspiratory Muscle training (IMT)|The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax.
10175316|NCT03844711|Active Comparator|Conventional physiotherapy|The protocol of physiotherapy by the physiotherapists of HCPA will be twice a day and consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
9678464|NCT04962399||TDM group|Type 2 diabetes mellitus without diabetic nephropathy
9678465|NCT04962399||control group|Health examination population in the same period
9678466|NCT04962243||Patients undergoing repair of Achilles tendon rupture|Patients undergoing repair of Achilles tendon rupture
9678467|NCT04962243||Subjects who underwent physical examination during the same period|Subjects who underwent physical examination in the Physical Examination Center of Peking University Third Hospital during the same period
9678468|NCT04962581||Group 1 : Covidien|This cohort will be monitored with the Covidien capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
9678469|NCT04962581||Group 2: General Électrique|This cohort will be monitored with the General Electrique capnography, which will be connected to the isolated non-ventilated lung during the whole procedure.
9678470|NCT04962191||Lung Cancer|The Idylla EGFR Mutation Test, performed on the BioCartis Idylla System, is an in vitro diagnostic test for the qualitative detection of exon mutations. One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. This study can help test the BioCartis Idylla System against standard of care (SoC) pathology results from tissue biopsies in the same setting, ultimately being able to diagnose with a fraction of the tissue previously needed.
9678471|NCT04962100|Experimental|Study population|Male patients and donors who provide a sample of fresh ejaculated semen will be the population of this study, as well as female patients undergoing artificial insemination with their partner's semen or frozen donor semen.
9678472|NCT04962048|Experimental|pulse-synchronized negative pressure (PSNP) device|One leg will be treated with the pulse-synchronized negative pressure (PSNP). The other leg serves as non-treated control.
9678473|NCT04962165|Experimental|Experimental group|The group of SCI people will use a mandibular advancement device for treatment of obstructive sleep apnea.
9678474|NCT04961736||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
9678475|NCT04961736||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
9678476|NCT04962152|Experimental|Group Naldebain|ultrasound-guided intramuscular injection of Naldebain 150mg after the induction anesthesia immediately
9678477|NCT04962152|Placebo Comparator|Group Placebo|ultrasound-guided intramuscular injection of sesame oil (placebo) 2mL after the induction anesthesia immediately
9678478|NCT04961892||surgical treatment|Patients with CAI undergoing surgical treatment
9678479|NCT04961892||conservative treatment|Patients with CAI undergoing conservative treatment
9678480|NCT04961970|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin
9678481|NCT04961970|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and cisplatin
10175317|NCT03844763|Experimental|Phase I - II trial of CTX, RT, Avelumab|CTX: 50 mg Daily untill PD or major toxicity; Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity; RT: 8 Gy single shot day 8.
9678482|NCT04961684|Experimental|Solver Pen|
9678483|NCT04961684|Active Comparator|Loceryl 5%|
9678484|NCT04962074|Experimental|Density gradient method|Sperm prepared by density gradient method
9678485|NCT04962074|Experimental|Microfluidic chip|Sperm prepared by microfluidic chip method
9678486|NCT04961918|Experimental|Treatment Group|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
10175318|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with pacing
10175319|NCT03844516|Sham Comparator|Peak oxygen uptake test without pacing|Peak VO2 test without pacing
10175320|NCT03844425|Active Comparator|Conventional Vacuum-Formed Retainers|Vacuum-formed retainers constructed on conventional stone models.
10175321|NCT03844425|Experimental|Vacuum-Formed Retainers From SLA|Vacuum-formed retainers constructed on 3D reconstructed models using stereolitography (SLA) technique.
10175322|NCT03844425|Experimental|Vacuum-Formed Retainers From FDM|Vacuum-formed retainers constructed on 3D reconstructed models using fused deposition modeling technique (FDM).
10175323|NCT03844126|Experimental|Patients attending the classes|The patients attending the transition classes will receive a survey to assess transition preparedness before and after attending the class.
10175324|NCT03844295|Experimental|Activated Inspire® Upper Airway Stimulation System|INSPIRE® device will be active a month
10175325|NCT03844295|Placebo Comparator|Inactivated Inspire® Upper Airway Stimulation System|"After a period 15 days of wash-out the INSPIRE® device will be inactivated for a second period of one month."
10175326|NCT03844230|Other|Inhibition Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
10175327|NCT03844230|Other|Stimulation Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Stimulation, Experimental I- Stimulation, Experimental II -Stimulation). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
10175328|NCT03844204|Experimental|Servo-controlled system|The temperature probe of the servo-controlled system will be positioned on the patient's abdomen with an adhesive tape. The body temperature will be set at 37°C.
10175329|NCT03844204|Active Comparator|No servo-controlled system|The temperature of the infant warmer will be manually set at maximum of power output.
10175330|NCT03844191|Experimental|Part 1 Cohort 1|Cohort 1: 0.05 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
10175331|NCT03844191|Experimental|Part 1 Cohort 2|Cohort 2: 0.075 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
10175332|NCT03844191|Experimental|Part 2 Cohort 1|Cohort 1: initial dose to be selected by the Safety Review Committee (SRC) after completion of Part 1 (the same initial dose used in Part 1 or one of the previously studied higher doses that is lower than the overall RUC-4 BED) 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
10175333|NCT03844191|Experimental|Part 2 Cohorts 2-3|7 subjects (6 receiving RUC-4, 1 receiving placebo) will be enrolled in each dose cohort, with a safety evaluation performed after 2 subjects in a dose cohort receive RUC 4 and at the completion of dosing for all subjects in the dose cohort. Dose escalation to be determined by the SRC charter and will continue until identification of the overall RUC-4 BED or MTD
9678487|NCT04962113|Experimental|Tunnel group Tube bath during the phototherapy|
9678488|NCT04962113|No Intervention|Tunnel group rutin care|
9678489|NCT04962113|Experimental|LED group Tube bath during the phototherapy|
9678490|NCT04962113|No Intervention|LED group rutine care|
9678491|NCT04962061|Experimental|Multidomain intervention|The multidomain intervention will combine a cognitive training with aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
9678492|NCT04962061|Experimental|Physical exercise intervention|The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
9678493|NCT04962061|Active Comparator|Active control intervention|The active control intervention will include stretching and toning exercises, three sessions per week for 46 weeks. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.
9678494|NCT04961853|Experimental|Cases|
9678495|NCT04961931|Other|diabetes group|After qualifying for the study subjects with diabetes and chornic kidney disease received oral empagliflozin 10 mg once daily for 7 days.
9678496|NCT04961931|Other|non-diabetes group|After qualifying for the study subjects with chronic kidney disease without diabetes received oral empagliflozin 10 mg once daily for 7 days.
9678497|NCT04961931|Other|control|After qualifying for the study healthy subjects received oral empagliflozin 10 mg once daily for 7 days.
9678498|NCT04961983|Experimental|Intervention group|Tour guides who will receive a comprehensive travel health education model.
9678499|NCT04961983|No Intervention|Control group|Tour guides who will receive no intervention.
9678500|NCT04961788|Experimental|Gemox combined PD1 antibody|"Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
9678501|NCT04961710|Experimental|Hetrombopag Olamine|
9678502|NCT04961710|Placebo Comparator|Placebo|
9678503|NCT04961749|Experimental|Vibration group|This group will receive vibration stimulation while standing on a side-alternating vibration platform. Vibration sessions will occur three times per week over four-weeks. Each session will include three-minutes of vibration followed by three-minutes rest, completing this sequence three times per session
9678504|NCT04961749|No Intervention|Control group|This group will not receive vibration, but will rather hear a recording of the vibration, while still standing on the vibration platform. Still, this group will receive this training three times per week over four-weeks with a similar three-minute rotation as the vibration group.
9678505|NCT04961658|Experimental|Treatment Arm - Low Dose|Cohort of 3 subjects who receive a single dose of GEM00220 at 15 million cells
9678506|NCT04961658|Experimental|Treatment arm - Mid dose|Cohort of 3 subjects who receive a single dose of GEM00220 at 60 million cells
10175334|NCT03844191|Experimental|Part 2 Dose Expansion Cohort 1|"14 subjects will receive a selected dose of RUC-4 based on SRC review of dose escalation data.~In the expansion cohort, 7 subjects weighing 55 to 65 kg and 7 subjects weighing 100 to 120 kg will be enrolled; 12 subjects will receive a single subcutaneous dose of RUC-4 and 2 will receive matched placebo"
10175335|NCT03844152|Experimental|Fermented whey concentrate|Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume. Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
9678507|NCT04961658|Experimental|Treatment arm - High dose|Cohort of 3 subjects who receive a single dose of GEM00220 at 150 million cells
9678508|NCT04961463|Experimental|İnterventions group|İnterventions group:The 7-session psychoeducation program prepared on the basis of the Roy Adaptation Model was applied to the intervention group once a week for 90-120 minutes
10175336|NCT03844139||Feeding pump group(continous)|Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours
9678509|NCT04961463|No Intervention|Control group|Except for the routine hospital controls, no intervention was made to the control group
9695350|NCT04778930|Experimental|Group A_Intervention Group|It will consist of 18 sessions, 3 times a week, for 6 consecutive weeks; on the one hand, 12 face-to-face sessions of approximately 90 minutes duration, in which the Physical Therapy treatment will be carried out based on training of specific tasks directed to objectives and training of gait with a treadmill; In addition, a therapeutic education program will be carried out, with 6 telehealth sessions lasting approximately 60 minutes, which will include action observation activities. The face-to-face sessions will be held at the Physical Therapy Teaching Unit at University of Alcalá, and the telehealth sessions of the Therapeutic Education program will be carried out by remote assistance through a digital platform. All will be carried out by specialist Physical Therapists, members of the research team.
9695351|NCT04778930|Experimental|Group B_Control Group|The subjects in this group will receive their usual Physical Therapy intervention regimen for 6 weeks at their referral center and the same telehealth Therapeutic Education program of the intervention group.
9695352|NCT04779125|Experimental|Gluteus plasty enhanced with Progrip self gripping mesh|All study patietns will have a gluteus enhanced plasty after abdominoperineal reconstruction.
10175337|NCT03844139||Glycerin syringe group(intermittent)|Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times
9695353|NCT04778982||dose-escalation Phase|KN026 20 mg/kg + palbociclib 100 /125 mg/day (Patients with HR-/HER2-positive MBC) or KN026 20 mg/kg + palbociclib 100 /125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )
9695354|NCT04778982||parallel-group expansion Phase|KN026 20 mg/kg + palbociclib RP2D(Patients with HR-/HER2-positive MBC ) or KN026 20 mg/kg + palbociclib RP2D+Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )
9695355|NCT04779034|Experimental|Group 1|Basketball players
9695356|NCT04778891|Experimental|Intervention group|In addition to usual care provided by general practitioner (GP) and other health care providers, a pharmacist-practitioner in collaboration with GPs from the study setting provided CMM services to patients in the intervention group. Based on the pre-defined inclusion criteria, GPs were selecting patients and referring them to the pharmacist. The individual consultation with the patient was held at the private counselling area where pharmacist and patient were able to talk face-to-face apart from the other patients. The initial assessment lasted 60-90 minutes and the follow-up evaluations 30-60 minutes. Alternatively, patients were followed-up by telephone. Communication with GPs took place in a written (electronic consultation system Health net. PRO; e-mail) and, if needed by face-to-face conversation. Each patient in the intervention group needed to agree to participate in the study by signing an Informed consent form.
9695357|NCT04778891|No Intervention|Control group|Patients in the control group received the usual care which includes GP and other health care provider visits. Data for the patients pertaining to the control group were provided by the 'control' GP and collected parallel with the intervention group. 'Control' GP profile corresponded to the profile of GPs included in the intervention group - the number of years of professional experience in the primary health care less than ten.
9695358|NCT04778956|Experimental|Toripalimab plus salvage surgery|"Toripalimab: Toripalimab treatment before and after salvage surgery.~Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node."
9695359|NCT04778956|Active Comparator|Salvage surgery alone|1. Salvage surgery: endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor, and selective neck dissection for recurrent regional lymph node.
9695360|NCT04778800|Experimental|almonertinib 110mg PO once daily|
9977558|NCT01362933||VTE treatment in cancer patient|All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
10175338|NCT03844113|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
10175339|NCT03844113|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo for 6 months
9678510|NCT04961866|Active Comparator|Group A|patients received 1 g/ kg of protein
9678511|NCT04961866|Active Comparator|Group B|patients received 2 g/ kg of protein
10175340|NCT03844282||CArBON (baseline)|The RESCUE-RACER programme is formed of two studies; baseline (CArBON) and one post-injury (CARS). At baseline the larger CArBON study involves completion of a thorough single baseline neuroscientific assessment of healthy motorsport competitors including clinical, neuropsychological, neurocognitive, biomarker and vestibulo-ocular assessments, in addition to MRI of the brain.
10175341|NCT03844282||CARS (exposure to a potentially concussive event)|The RESCUE-RACER programme has a single post-injury study; after involvement in a potentially concussive event sustained during motorsport, CARS serially repeats the CArBON assessment battery in the immediate post-concussion recovery period. CARS participants will under-go post-exposure neuroscientific assessments immediately after injury and then at one, two and three weeks post-injury. If symptoms persist beyond this time, a further two assessments at monthly intervals will be offered.
9678512|NCT04961294|Experimental|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
9678513|NCT04961294|No Intervention|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
9678514|NCT04961385||ChAd0x1 nCoV-19 vaccinees|Participants who received first dose of ChAdox-1 n COV-19 were recruited. Participants were eligible if they were more than 18 years old
9678515|NCT04961632|Experimental|Dose-determination|
9678516|NCT04961632|Experimental|Dose-confirmation|
10175342|NCT03844269|Experimental|AKL-T01|
9678517|NCT04961359|Experimental|Population Ⅰ|Population Ⅰ has 20 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅠis intramuscular injection of deltoid muscle of upper arm with vaccine.
9678518|NCT04961359|Placebo Comparator|Population Ⅱ|Population Ⅱ has 5 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅱ is a placebo intramuscular injection of deltoid muscle of the upper arm.
9678519|NCT04961359|Experimental|Population Ⅲ|Population Ⅲ has 20 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is intramuscular injection of deltoid muscle of upper arm with vaccine.
9678520|NCT04961359|Placebo Comparator|Population Ⅳ|Population Ⅳ has 5 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅳ is a placebo intramuscular injection of deltoid muscle of the upper arm.
9678521|NCT04961359|Experimental|Population Ⅴ|Population Ⅴ has 20 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅤ is intramuscular injection of deltoid muscle of upper arm with vaccine.
9678522|NCT04961359|Placebo Comparator|Population Ⅵ|Population Ⅵ has 5 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅵ is a placebo intramuscular injection of deltoid muscle of the upper arm.
10175343|NCT03844308|Experimental|Group 1|Participants will be asked to complete Isha Kriya meditation twice daily for a total of six weeks in phase 1.
9678523|NCT04961424||Symptomatic spinal epidural hematoma Group|Patients who performed thoracic decompression surgery and developed neurological deficit after surgery due to the symptomatic spinal epidural hematoma were enrolled into case group.
10175344|NCT03844308|Active Comparator|Group 2|Participants will be asked to refrain from meditating for the first 6 weeks (phase 1) and then asked to complete Isha Kriya meditation for another 6 weeks (phase 2)
10175345|NCT03844256|Experimental|Regimen A|"Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
10175346|NCT03844256|Experimental|Regimen B|"Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
9678524|NCT04961424||Control group|hose who did not develop the symptomatic spinal epidural hematoma, underwent the same procedures of similar complexity at the same section of thoracic spine in the same period (the same year or the following year) were randomly selected from the pool of patients.
10175347|NCT03844256|Experimental|Regimen C|"Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
9678525|NCT04961411||published cases of patients with gallstone ileus|We will observe clinical signs, diagnostic procedures and therapeutic procedures and options
9678526|NCT04961333|Experimental|Rehabilitation group|Rehabilitation group will be provided multidisciplinary interventions online and individually by ExorLive app. The screening with self-scored questionnaires and physical tests will be performed before and after 8 weeks rehabilitation.
9678527|NCT04961333|No Intervention|Waiting list controls|Passive waiting list or control group, which will be offered to participate in rehabilitation after at least 8 weeks of waiting time. The group will fulfil screening twice, following the time schedule of intervention group. When invited to rehabilitation a new screening will be asked to be completed if the waiting time after the last screening will be longer than 2 weeks.
9678528|NCT04961268|Active Comparator|Tramadol 50|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 50 mg in opaque yellow size 000 capsules."
9678529|NCT04961268|Active Comparator|Tramadol 100|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 100 mg in opaque yellow size 000 capsules."
9678530|NCT04961268|Active Comparator|Ibuprofen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg in opaque yellow size 000 capsules."
9695361|NCT04778800|Experimental|almonertinib 160mg PO once daily|
9678531|NCT04961268|Active Comparator|Ibuprofen/acetaminophen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg/acetaminophen 1000 mg in opaque yellow size 000 capsules."
9678532|NCT04961268|Placebo Comparator|Placebo|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received Placebo in opaque yellow size 000 capsules."
10175348|NCT03844217|Experimental|Macimorelin 0.5mg/kg body weight|"Visit 1: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin.~Visit 2: After a washout-phase of 1 week, participants will undergo the oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight. Study procedures are equal compared to visit 1.~Macimorelin 0.75mg/kg body weight"
9678533|NCT04961346|Experimental|Ultrapro®|Participants received incisional hernia repair with an Ultrapro mesh in a sublay technique.
10175349|NCT03844360|Experimental|Antineoplastic Drugs and Anti-infective Drugs|Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
9678534|NCT04961346|Experimental|Premilene®|Participants received incisional hernia repair with a Premilene mesh in a sublay technique.
9678535|NCT04961554||Adult patients presenting with limited mouth opening|Adult patients presenting with limited mouth opening not allowing intubation by videolaryngoscopy, on mandibular surgical pathology requiring general anesthesia.
9678536|NCT04961606||patients with coronary artery disease|
9678537|NCT04961606||medical professionals|
9678538|NCT04961502|Experimental|Elderly person|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
9678539|NCT04961502|Active Comparator|Younger adults (priority caregivers)|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
9678540|NCT04961307||Women with breast cancer using trastuzumab|
9678541|NCT04961450||Patients|"Inclusion Criteria:~Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020.~Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines~Informed consent signed~Exclusion Criteria~Patients who receive alternative diagnoses during the follow-up.~Patients who refuse to sign informed consent."
9678542|NCT04961450||Control|"Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses.~Exclusion criteria:~Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on.~Individuals who refuse to sign informed consent."
9678543|NCT04961528|Experimental|Terlipressin|"Dosage: 1 mg /5 ml Pharmaceutical form: solution for infusion Posology: 1 mg /8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers"
9678544|NCT04961528|Experimental|Tranexamic Acid|"Dosage : 500 mg /5 ml Pharmaceutical form: solution for infusion Posology (and adjustments based on toxicity) : 500 mg/ 8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
9678545|NCT04961528|Placebo Comparator|Normal Saline Placebo|"Dose : normal saline solution (NaCl 0.9%) Pharmaceutical form : solution for infusion Posology : 5ml / 8 hours Treatment duration: 5 days~Method and route of administration: inhalation using the same jet nebulizers (INT'AIR Medical RN 300) in all Investigating centers."
9678546|NCT04961255||Control group|Healthy individuals will be evaluated only once throughout the study. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated.
9678547|NCT04961255||COVID-19 positive participants who had moderate symptoms group|"These participants will be evaluated 4 times throughout the study.~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
10175350|NCT03844373|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of STOCKHOLM for a period of 9 days.
10175351|NCT03844399||Patients|Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
10175352|NCT03844035|Experimental|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator(oxytet oral irrigatör).All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual).PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites.Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
9695362|NCT04778800|Experimental|almonertinib 220mg PO once daily|
9695363|NCT04778943||oblique lateral interbody fusion (OLIF)|Patients with lumbar spinal stenosis undergoing oblique lateral interbody fusion (OLIF)
9678548|NCT04961255||COVID-19 positive participants who had severe symptoms group|"These participants will be evaluated 4 times throughout the study.~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
9678549|NCT04961229|Experimental|Third dose of BNT162b2 vaccine with Immunosuppression reduction|Third dose of BNT162b2 vaccine with reduction of mycophenolic acid dose
9678550|NCT04961229|Experimental|Third dose of BNT162b2 vaccine without immunosuppression reduction|Third dose of BNT162b2 vaccine without reduction of mycophenolic acid dose
9975832|NCT01345175|Experimental|Pts receiving Rifaximin|This group will receive rifaximin 400mg bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
9678551|NCT04961229|Experimental|Third dose of BNT162b2 vaccine|Third dose of BNT162b2 vaccine with no change in immunosuppression for patients that are excluded from the randomised trial
9678552|NCT04961476||GrM0|GrM0 - without supplementation
9678553|NCT04961476||GrM1|GrM1 - with 1-MNA supplementation
9678554|NCT04961216|Experimental|OPTIMISE intervention|"After a baseline week of self-monitoring their meat consumption, participants will receive health and environmental feedback on their consumption and will be prompted to think about how they could reduce their intake. They will be asked to pre-select strategies from a list of meat consumption reduction actions and set themselves a meat reduction goal.~During the following four weeks (weeks 2-5), participants will be asked every morning to log their meat consumption of the previous day, plan one of their chosen actions and formulate an if-then plan. Participants will receive weekly feedback on their achieved meat reduction in comparison to week 1.~After the completion of the fifth week (follow-up 1), participants will be asked to continue performing the actions they found useful for the next four weeks (weeks 6-9). During the ninth week (follow-up 2) participants will be invited back to log their meat intake."
9678555|NCT04961216|No Intervention|Control|After a baseline week of self-monitoring their meat consumption participants will be asked to try and reduce their meat consumption over the next eight weeks, with no further guidance. They will be invited back to complete log their meat consumption of the previous day during weeks five and nine (follow-up 1 and 2).
9678556|NCT04961515|Experimental|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 250mg qd will be used for phase II trial.~Orelabrutinib: orally daily Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks (maximum 12 total dose)"
9975833|NCT01345175|Placebo Comparator|Pts receiving placebo|This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
9975834|NCT01345214|Experimental|E|
9975835|NCT01345227|Experimental|Intra BM islet infusion|single intra BM islet infusion at the level of the iliac crest will be performed in patients having contraindications for intraportal infusion
9975836|NCT01345240|Experimental|RTS,S Regimen A Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975837|NCT01345240|Experimental|RTS,S Regimen A Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9977559|NCT01362972||plerixafor + granulocyte colony stimulating factor (G-CSF)|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF) for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
9678557|NCT04961515|Experimental|Phase II|"Participants will receive orelabrutinib and sintilimab at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.~Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg) Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks"
9678558|NCT04961099|Experimental|low-dose group|low-dose group: HY01 10mg（20mg/ml）
9678559|NCT04961099|Experimental|high-dose group|high-dose group: HY01 20mg（40mg/ml）
9678560|NCT04961138|Experimental|Neoadjuvant group|
9678561|NCT04961138|Active Comparator|Surgery group|
9678562|NCT04960839|No Intervention|Standard group|Standard loco-regional treatment without prophylactic contralateral breast irradiation
9678563|NCT04960839|Experimental|Prophylactic irradiation group|Standard loco-regional treatment with prophylactic contralateral breast irradiation
9678564|NCT04960800|Experimental|Intervention group|The participants in the intervention group will participate in a 12- week specific exercise programme led by an experienced women's health physiotherapist. These groups will take place at a private physiotherapy clinic twice a week. In addition, the participants will carry out a self-managed exercise program twice weekly for the same 12-week period. They will be provided with an exercise diary so that adherence to the intervention can be registered and monitored. This exercise diary will be sent to the participants once a week as an electronic questionnaire; this will ensure that the information recorded is standardized and that the research assistant can aid the participants to register their activity and encourage the participants to adhere to the intervention.
9678565|NCT04960800|No Intervention|Control group|The control group will not participate in any exercise intervention. The participants in the control group will be explained the importance of a control group in RCTs and will be recommended to continue with their normal activity levels. They will however, be recommended to follow national guidelines for general exercise during pregnancy and will receive information about these guidelines (15).
9678566|NCT04960852|Experimental|a single shade structurally colored universal resin composite|Cavities will be prepared. one shade universal composite (Omnichroma) a will be applied according to the manufacturer.
9678567|NCT04960865|Experimental|Experimental Group|Participants will be applied Kinesio tape with 50% tension.
9678568|NCT04960865|Sham Comparator|Sham Group|Participants will be applied Kinesio tape without any tension.
9678569|NCT04960865|Placebo Comparator|Placebo Group|Participants will be applied rigid tape without any tension
9678570|NCT04960878|Placebo Comparator|Placebo|1.5 g maltodextrin in a sachet once daily for 8 weeks.
9678571|NCT04960878|Experimental|Synbiotic|1.5 g synbiotics supplement of Lactobacillus rhamnosus HN001 (1.5×10^11 CFU) , Bifidobacterium lactis HN019 (7.5×10^10 CFU), and 500mg fructooligosaccharides in a sachet once daily for 8 weeks.
9678572|NCT04960943|Experimental|Pyrotinib|Pyrotinib with or without paclitaxel/trastuzumab treatment
9678573|NCT04960969|Experimental|Time-restricted Feeding Group|Participants will apply time-restricted feeding (8 hours/day) for 28 days.
9678574|NCT04960969|No Intervention|Control Group|No intervention will be applied.
9678575|NCT04960982||PCOS-RM|PCOS women with history of RM
9678576|NCT04960982||Non PCOS RM|Non PCOS women with history of RM
9678577|NCT04960982||Control|women with no history of RM
9678578|NCT04960774||Control group|Patients with non-severe periodontitis or healthy people who were treated in our department in the same period were included as the control group.
9678579|NCT04960774||Severe periodontitis group|Severe periodontitis patients who meet the inclusion and exclusion criteria in the Department of Stomatology, the second affiliated Hospital of Medical College of Zhejiang University
9977560|NCT01362972||plerixafor + G-CSF + chemotherapy|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF)+chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
9977561|NCT01362972||granulocyte colony stimulating factor (G-CSF) + chemotherapy|Patients who receive granulocyte colony stimulating factor (G-CSF) + chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
9678580|NCT04960917|Experimental|eHealth literacy workshop|Community members from pre-existing municipality groups will participate in a workshop aimed to raise their ehealth literacy level.
9678581|NCT04961047|Experimental|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
9678582|NCT04961047|Active Comparator|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
9678583|NCT04960904||In-Kone® UNIVERSAL|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® UNIVERSAL
9678584|NCT04960904||In-Kone® PRIMO|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® PRIMO
9678585|NCT04960904||twinKon® UNIVERSAL|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges twinKon® UNIVERSAL
9678586|NCT04960904||EVL® S|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® S
9678587|NCT04960904||EVL® K|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® K
9678588|NCT04960904||EVL® C|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® C
9678589|NCT04960904||3.0|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges 3.0
9695364|NCT04778943||minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)|Patients with lumbar spinal stenosis undergoing minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
9695365|NCT04778995|Experimental|Manager nurses (Experimental group)|Manager nurses who participated in the structured training program based on qualitative data. Web based training program was the intervention for this group.
9678590|NCT04960735|Experimental|Patients with cancer (patients with breast cancer and patients with lung cancer)|"Health-related Quality of Life evidence was collected from patients with cancer (patients with breast cancer and patients with lung cancer) for six months. The evidence was collected by means of health related and patient reported questionnaires (ICHOM standard sets for breast cancer and lung cancer).~Patients were monitored for six months. Intervention outcomes were monitored at different times: for patients with breast cancer, at the start (on recruitment which coincided with diagnosis) and at six months; for patients with lung cancer, at the start (on recruitment which coincided with diagnosis), at three and at six months."
9678591|NCT04961060||Eosinophilic exacerbation|COPD exacerbation associated with eosinophilia.
9678592|NCT04961060||Viral exacerbation|COPD exacerbation associated with viral infection.
9678593|NCT04961060||Bacterial exacerbation|COPD exacerbation associated bacterial infection.
9678594|NCT04961060||Pauci-inflammatory exacerbation|Pauci-inflammatory COPD exacerbation
10175353|NCT03844035|Experimental|Interdental brush group|Fifteen patients using toothbrush and interdental brush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
10175354|NCT03844035|Active Comparator|Control group|Fifteen patients using only toothbrush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
10175355|NCT03844009|Experimental|Debriefing|Participant's of the debriefing group had a computer integrated debriefing at the end of each scenario of the computer-based simulator
10175356|NCT03844009|No Intervention|No debriefing|Participant's of the debriefing group had no computer integrated debriefing at the end of each scenario of the computer-based simulator
10175357|NCT03843983|Other|Lipiflow treatment|Lipiflow® application: Treated with Lipiflow. All patients in this study are treated with Lipiflow once.
10175358|NCT03844022||McArdle disease|Glycogen storage disease
9678595|NCT04960696||primary school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
9678596|NCT04960696||middle school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
10175359|NCT03844022||Healty controls|Age and gender matched
10175360|NCT03844243|Experimental|NGF condition + Control condition|"All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
10175361|NCT03844243|Experimental|Control condition + NGF condition|"All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
10175362|NCT03843827|Active Comparator|Group A (LMA Group)|Active Comparator: Group A (LMA Group) LMA-Classic™ laryngeal mask airway (Classic™LMA) by Dr. Archie Brain into clinical practice in 1988 brought about a revolution in anesthesia. In the literature, there are over 2,500 studies supporting Classic™ LMA usage. Following the success and popularity of Classic™ LMA, many different variants of this device have been designed and marketed,trying to offer a simple and effective alternative to the endotracheal intubation.
9678597|NCT04960696||high school/78 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
9678598|NCT04960696||university/81 subjects|Determining the negative effects of distance education on eye symptoms during the pandemic period.
9678599|NCT04961086|Experimental|energy drink arm|an open label branded energy drink which contains any one or more of the following ingredients: caffeine, ginseng, taurine
9678600|NCT04961086|Active Comparator|tea 5gm sugar arm|the usual easily available black tea with sugar 5 grams, and milk
9678601|NCT04961008|Experimental|Bottle-PEP|Bottle-PEP
9678602|NCT04961008|Active Comparator|Routine physiotherapy|v
9678603|NCT04961125||colorectal polyposis|
9678604|NCT04960826||Crohn's disease patients|
9678605|NCT04960826||Non IBD patients|
9678606|NCT04960566|Experimental|eCBT+|eCBT+ participants will be enrolled in 6, 45-minute sessions delivered via a secure video platform with a GI psychologist. To reinforce concepts reviewed in the sessions, participants will complete weekly home practice exercises. The targets are 1) improved maladaptive cognitive-affective processes associated with increased hypervigilance and symptom anxiety, 2) reduced behaviors associated with EHA including avoidance, increased medication/healthcare utilization and 3) reduced autonomic nervous system (ANS) arousal by increased HRV. Participants will learn to identify, question, and modify maladaptive thoughts, beliefs, and assumptions related to their symptoms (symptom anxiety). Systematic exposure to feared events are used to reduce maladaptive coping strategies (hypervigilance, PPI overuse, HCU). Specific, paced diaphragmatic breathing exercises (Resonance Frequency Breathing) designed to increase HRV are the last component (visceral hypersensitivity, reflux physiology).
9827785|NCT02468557|Experimental|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.
9678607|NCT04960566|Sham Comparator|Sham-SOC Lifestyle Coaching|Patients randomized to the SOC condition will receive lifestyle guidance recommended for patients with GERD over a period of 6, 45-minute sessions with the GI psychologist to maintain consistency of delivery between the two intervention arms. Topics include maintaining a healthy weight, identifying triggering food and drink, making healthy food choices, eating behaviors, smoking and/or alcohol use, and timing of meals. The SOC condition will be carefully designed to not include any principles of the eCBT+ condition rather be based solely on patient education and encouragement to practice lifestyle changes on their own.
9678608|NCT04961151|Experimental|Conductive Wrap Warming|Esophageal warming will be discontinued first
9678609|NCT04961151|Experimental|Esophageal Warming|Conductive wraps will be discontinued first
9678610|NCT04960761|Experimental|Intervention Group|Pre-operative training will be given by the clinic nurse with audio and picture book. Training content with audio and picture book; Before the operation, the procedures performed during the admission of the patient to the service (introducing the clinic and staff to the patient), what are the preoperative preparations (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown), wearing a patient tag on the wrist, taking him to the operating room on a stretcher), which will be used during the operation anesthesia techniques and how to provide sedation (the anesthetic agent can be given by mask or IV catheter, the reasons are the clothes worn by doctors and nurses in the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.).
9678611|NCT04960761|No Intervention|Control Group|Routine training will be given by a nurse working in the clinic during the preoperative period. The content of the routine training: What are the procedures performed during the admission of the patient to the service before the operation (introducing the clinic and the staff to the patient), what the preoperative preparation is (checking vital signs, intravenous (IV) catheter application, wearing a surgical gown, wearing a patient tag on the wrist, with a stretcher. being taken to the operating room), what are the procedures that can be applied after the surgery (vital signs control, monitoring, oxygen administration, serum insertion, etc.), there may be some medical materials that were applied to the patient during the surgery (nasogastric tube, IV catheter, types of drains placed in the wound site) includes information such as
9678612|NCT04960631||Clinical diagnosis of suspected malignant tumor by dual site CT guided needle biopsy|
9678613|NCT04960618|Experimental|Participants with confirmed mycosis fungoides/Sezary syndrome|Participants will have confirmed mycosis fungoides/Sezary syndrome, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher.
9678614|NCT04960605|Other|Test group|Patients with Primary Sjögren Syndrom
9678615|NCT04960605|Other|Control group|Patients with Primary Sjögren Syndrom, matched to the test group
9678616|NCT04960657|Active Comparator|PACAP38 and glibenclamide|Participants will receive glibenclamide after PACAP38 infusion
9678617|NCT04960657|Active Comparator|PACAP38 and placebo|Participants will receive placebo after PACAP38 infusion
9678618|NCT04960592||SCS Responders|Patients who receive Spinal Cord Stimulation treatment and experience greater than 50% reduction in pain score following treatment.
9678619|NCT04960592||SCS Non Responders|Patients who receive Spinal Cord Stimulation treatment and do not experience greater than 50% reduction in pain score following treatment.
9678620|NCT04961177|Other|EITC & ACEs Training|Trainings for frontline health workers about EITC and ACEs.
9678621|NCT04961177|Other|EITC Outreach and Screening|Our partners will implement EITC outreach events and EITC screening with clients.
10175363|NCT03843827|Active Comparator|Group B (I gel Group)|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature,thus minimising air leakage
10175364|NCT03843866|Active Comparator|Suture & steri-strips|
10175365|NCT03843866|Active Comparator|Adhesive Glue|
10175366|NCT03844165|Experimental|Diet change (red rice) with yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. Food for the diet (red rice and lentils) will be provided for those randomised to the diet arm. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
10175367|NCT03844165|Active Comparator|Yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
10175368|NCT03843801|Active Comparator|Volume reduction|Intragastric sutures are done to reduce the volume of the stomach
10175369|NCT03843801|Active Comparator|Gastric emptying reduction|Intragastric sutures are done to slower the gastric emptying
10175370|NCT03843801|Active Comparator|Increasing distension|Intragastric sutures are done to maximalize the gastric distension
10175371|NCT03843775|Experimental|Binimetinib and Encorafenib|Patients will be initially enrolled to the approved dose of encorafenib 450 mg oral QD and binimetinib 45 mg PO BID, dose level 1. If confirmed this dose level is safely tolerated in the study population, we will then escalate treatment to dose level 2 with the novel dosing regimen of encorafenib 450 mg oral QD continuous and binimetinib 60 mg oral BID 21 days on/7 days off.
10175372|NCT03843957|Experimental|"Clinic Patients on high touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
10175373|NCT03843957|Experimental|"Clinic Patients on low touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
9678622|NCT04961177|Other|EITC Assistance|Our partners will screen clients for EITC and refer those who qualify for free tax preparation assistance and assistance submitting their tax returns.
10175374|NCT03843957|Experimental|"Clinic personnel on high touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
10175375|NCT03843957|Experimental|"Clinic personnel on low touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
10175376|NCT03843749|Experimental|HER2-positive Metastatic Colorectal Cancar|
10175377|NCT03843996|Experimental|Treatment left|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
10175378|NCT03843996|Experimental|Treatment right|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
10175379|NCT03844178|Active Comparator|The right eyes with compensation for Pupil centroid shift|
10175380|NCT03844178|Active Comparator|The left eyes without compensation for Pupil centroid shift|
9678623|NCT04960501||New tension band system|
9678624|NCT04960501||Patella reduction band system|
9678625|NCT04960436|Experimental|Meniscus Allograft Transplantation|The patient underwent Meniscus Allograft Transplantation
9678626|NCT04960436|Active Comparator|Meniscectomy|The patient underwent Meniscectomy
9678627|NCT04960670||Dyads|Mother/infant pairs will be evaluated for anthropometric parameters, prenatal (dietary/lifestyle maternal factors)/postnatal determinants (type of feeding, sleep patterns, speed of growth) before discharge and after different follow-up after birth. Infant urinary and stool samples will be collected and stored. The infant adiposity rebound will be monitored.
9678628|NCT04960488|Experimental|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
9678629|NCT04960488|Active Comparator|carotid endarterectomy|carotid endarterectomy
9678630|NCT04960449||patients with partial-thickness rotator cuff tendon tears|Partial rotator cuff tears can be divided into three categories, bursa side tears, tendon tears and joint side tears. Studies have found that rotator cuff tendon tears account for 55% of partial tears, compared to the other two types of partial tears, there has been very little research on partial-thickness rotator cuff tendon tears, which has no consensus on diagnosis and treatment.
9678631|NCT04960384|Placebo Comparator|Placebo|
9678632|NCT04960384|Experimental|Human Fibroblast Growth Factor-2 (FGF-2)|
9678633|NCT04960553|Experimental|Device : Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up investigation : Up to 102 subjects with exuding chronic wounds deemed adequate by the Principle Investigator and Clinical Team for assigned treatment
9678634|NCT04960462||the treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement|The clinical data of patients with sacral cysts treated with nerve root sleeve reinforcement and reconstruction of the sacral canal cyst were summarized and followed up from 3 to 6 months after the operation to form a case summary and report.
9678635|NCT04960345||The traditional group|The traditional group underwent prosthesis placement using traditional intramedullary positioning method.
9678636|NCT04960345||The navigation group|The navigation group performed surgery using the Brainlab Knee 3 navigation system.Informed consent was signed after grouping.
9678637|NCT04960540||impaired speech comprehension processing in ALS|Brain functional network mechanism of impaired speech comprehension processing in ALS
9678638|NCT04960540||language use processing injury in ALS|Brain functional network mechanism of language use processing injury in ALS
9678639|NCT04960540||motor executive processing injury in ALS|Brain functional network mechanism of motor executive processing injury in ALS
9678640|NCT04960540||anguage cognitive impairment in ALS|Brain structural network mechanism of language cognitive impairment in ALS
9678641|NCT04960527|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK, 100% Montmorency) diluted with 220 mL water (totalling 250 mL). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries.
9678642|NCT04960527|Other|Water|250 mL water (neutral control)
9678643|NCT04960241|Active Comparator|Homebased telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
9695366|NCT04778995|No Intervention|Manager nurses (Control group)|Manager nurses who were not included to the structured training program based on qualitative data. No intervention was performed for this group.
9827786|NCT02468557|Experimental|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.
10175381|NCT03843853|Experimental|Pemetrexed + S-1 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
10175382|NCT03843931|Active Comparator|GLA:D|8 weeks of education (1 session/week for 2 weeks) and exercise therapy (2 sessions/week for 6 week)
10175383|NCT03843931|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injection (5 ml of 0.9% sodium chloride) every 2 weeks over an 8-week period
10175384|NCT03843879|Active Comparator|TAP Block|Single-injection transversus abdominis plane block
10175385|NCT03843879|Active Comparator|IV Lidocaine|Continuous intravenous lidocaine infusion
10175386|NCT03843918|Experimental|Group A (Phase II only)|LAE001+ADT
10175387|NCT03843918|Placebo Comparator|Group B (Phase II only)|Placebo+ADT
9678644|NCT04960241|Active Comparator|Homebased rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
10175388|NCT03843788|Experimental|Post-CS TENS|The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site. Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
10175389|NCT03843788|Experimental|Opioid Addicted Post-CS TENS|Subjects will be targeted on the basis of opioid addiction and usage of methadone maintenance. The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site). Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
10175390|NCT03843788|No Intervention|Post-CS Routine Care|Routine pharmacologic care will be provided.
9678645|NCT04960241|Active Comparator|No physical rehabilitation|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
9678646|NCT04960189|Experimental|Acupuncture|GB34 acupuncture will be applied every day. Patients will receive standard medical treatment
9678647|NCT04960189|No Intervention|Controls|Patients will only receive standard medical treatment
9678648|NCT04960267|Experimental|Use of pre-peritoneal drainage after rTAPP|"Use of pre-peritoneal drainage after rTAPP~Outcomes will be compared with retrospective cohort from our previous experiments"
10175391|NCT03843788|No Intervention|Opioid Addicted Post-CS Routine Care|Routine pharmacologic care will be provided.
10175392|NCT03843658||Rheumatoid Arthritis|Clinician diagnosed rheumatoid arthritis
10175393|NCT03843658||Spondyloarthropathy|Ankylosing spondylitis and psoriatic arthritis
10175394|NCT03843658||Crystalline arthritis|Gout and Pseudo gout
9678649|NCT04960033||Osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
9678650|NCT04960033||women without osteoporosis fracture|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was <20% or the 10-year probability of HF was <3%.
9678651|NCT04960293|Experimental|Spherical gelfoam|Patients who receive uterine artery embolization for symptomatic fibroids
10175395|NCT03843658||Connective Tissue Disease|Lupus, myositis, scleroderma, and sjogren's
10175396|NCT03843658||Non-Inflammatory arthritis|E.g. Osteoarthritis and Fibromyalgia
10175397|NCT03843814|Experimental|APT MRI|"Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.~Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.~An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.~Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment."
10175398|NCT03843944|Experimental|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
10187174|NCT03728855|Experimental|Self-administration of medication (SAM)|During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.
10187175|NCT03728829||Trastuzumab+TP neoadjuvant chemotherapy|100 cases of patients with stage II-III HER2+ breast cancer will be assigned participants to neoadjuvant treatment regimen, including Trastuzumab combined with Docetaxel and Carboplatin. 5-10 ml peripheral blood will be collected from each patient and formalin fixed paraffin embedded (FFPE) blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals before and after neoadjuvant therapy. The genomic characteristics between patients achieved pCR and non-pCR will be analyzed. The clinically actionable mutations for future therapy instructions will be identified.
10187176|NCT03728816||SCAP groups|all the SCAP patients who meet the inclusion criteria
9678652|NCT04960293|Active Comparator|Microsphere|Patients who receive uterine artery embolization for symptomatic fibroids
9678653|NCT04960410||Low air pollution|
9678654|NCT04960410||High air pollution|
9678655|NCT04960098||patient underwent hip and knee arthroplasty|Patients with hip and knee osteoarthritis underwent hip and knee arthroplasty included in inclusion criteria.
10187177|NCT03728803|Sham Comparator|Sham inspiratory muscle training|"Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance.~The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks."
9678656|NCT04960319|Experimental|Intravascular Lithotripsy|Study Device Treatment: IVL balloon catheter size is chosen in a 1:1 ratio to the distal reference vessel diameter. If the IVL balloon cannot be delivered into the target lesion a Guide catheter extension is recommended. The balloon catheter is then inflated to 4 ATM and 10 impulses are delivered. The balloon is then inflated to 6 ATM and deflated to reestablish blood flow. Up to 80 impulses can subsequently be delivered and the balloon can be repositioned within the lesion. In multiple lesions with different reference vessel diameters different sizes of IVL balloon can be used.
9678657|NCT04960319|Active Comparator|Rotational Atherectomy|Control group treatment: Rotablation should be performed as described in the ESC-Consensus document. Burr/vessel-ratio is 0.5 - 0.75. The use of different burr sizes as well as the use of a temporary pacemaker is left to the operator's discretion.
9678658|NCT04960358||Chronic LBP|Will be applied Surface Electromyography
9678659|NCT04960332|No Intervention|Standard treatment|Group A: Standard wound closure with staples and conventional wound dressing.
9678660|NCT04960332|Experimental|Prevena|Group B: Wound closure with staples and Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System).
9678661|NCT04960306|Active Comparator|Fecal filtrate transplantation|Patients randomized to the fecal filtrate transplantation group
9678662|NCT04960306|Active Comparator|Conventional fecal microbiota transplantation|Patients randomized to the conventional fecal microbiota transplantation group
10175399|NCT03843697|Experimental|Patients with IBD who develop resistance to anti TNF|Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs
10175400|NCT03843736|No Intervention|Health control group|Participants are healthy women and there are no interventions.
9678663|NCT04960111|Experimental|knee arthroplasty with radiostereometry tecnique|patient underwent total knee arthroplasty with insertion of microsphere in tantallium for radiostereometry tecnique.
10175401|NCT03843736|Experimental|Lifestyle interventions group|Participants are PCOS patients and only will be given lifestyle interventions.
9678664|NCT04960137|Experimental|Button Plates fixation system|Patients receiving surgery fixed with Button Plates fixation system
10175402|NCT03843736|Experimental|Probiotic Agent group|Participants are PCOS patients and will be given lifestyle interventions + Probiotic Agent interventions.
10175403|NCT03843736|Experimental|Oral contraceptive group|Participants are PCOS patients and will be given lifestyle intervention + Oral contraceptive interventions.
10175404|NCT03843671|Experimental|Group 1|Hyperbaric oxygen Hyperbaric chamber
10175405|NCT03843671|Sham Comparator|Group 2|Sham for hyperbaric oxygen Hyperbaric chamber
10175406|NCT03843684|Experimental|Knee osteoarthritis patients|
10175407|NCT03843606|Experimental|diet 1|60% fat, 15% protein, 25% carbohydrates
10175408|NCT03843606|Experimental|diet 2|70% fat, 15% protein, 15% carbohydrates
10175409|NCT03843606|Experimental|diet 3|80% fat, 15% protein, 5% carbohydrates
10175410|NCT03843437|Experimental|Tencel Therapeutic Garments|Children in this group will wear Tencel Therapeutic Garments
9678665|NCT04960137|Active Comparator|Non-absorbable Suture Anchor|Patients receiving surgery fixed with Non-absorbable suture anchor
9678666|NCT04960371||anxiety group|the score of Self-rating Anxiety Scale greater than 50
9678667|NCT04960371||non-anxiety group|the score of Self-rating Anxiety Scale less than 50
9678668|NCT04960020||ACL injuries with e-scooter trauma|
9678669|NCT04960007||Group A|Sarcopenia patients.
10175411|NCT03843437|Placebo Comparator|Cotton Therapeutic Garments|Children in this group will wear Cotton Therapeutic Garments
9678670|NCT04960007||Group B|Dynapenia patients.
9678671|NCT04960007||Group C|Age and gender matched non-sarcopenia and non-dynapenia patients.
9678672|NCT04959968|Experimental|Intervention group|An eye patch and earplug will be applied to the intervention group in the intensive care unit on the day of craniotomy and on the post-operative 1st day between 22:00 and 06:00
9678673|NCT04959968|No Intervention|Control group|Standard care procedure will be applied to the control group
9678674|NCT04959682|Experimental|Intervention group|Patients in the intervention group will receive 30 minutes of patient-tailored instrumental music in the beginning of one weekly hemodialysis treatment for a period of six weeks
9678675|NCT04959682|No Intervention|Control group|The procedure in the control group is the same as in the intervention group, except that they don't listen to music
9977562|NCT01362972||granulocyte colony stimulating factor (G-CSF) alone|Patients who receive granulocyte colony stimulating factor (G-CSF) alone for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
9678676|NCT04959955||AECOPD group|
9678677|NCT04959955||CAP group|
9827787|NCT02468648|Experimental|Combination of sofosbuvir and GS-5816|Combination of sofosbuvir and GS-5816 agent into a single pill will be used.
10175412|NCT03843398|Experimental|Minilaparotomy Group|Participants in this arm undergo colorectal cancer resection via minilaparotomy.
10175413|NCT03843398|Active Comparator|Laparoscopy Group|Participants in this arm undergo laparoscopic colorectal cancer resection.
10175414|NCT03843320||SAVR|"Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~INSPIRIS RESILIA;~EDWARDS INTUITY;~Carpentier-Edwards PERIMOUNT Magna-Ease."
10175415|NCT03843320||TAVR|"Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~SAPIEN 3;~SAPIEN XT."
10175416|NCT03843333|Experimental|CHW Intervention|CHWs will deliver three intervention components (Tai Ji Quan: Moving for Better Balance, Behavioral Activation, and Resource Navigation) to all participants at intervention sites over a 6-month period.
10175417|NCT03843333|Active Comparator|Enhanced Usual Care|Comparison participants will receive a guide on community resources for older adults, and assistance from the research team in making initial connections to resources if desired.
10175418|NCT03843476||Surgical with Rod|The patient is being treated with the patient specific rod with a surgery date planned
10175419|NCT03843541|Experimental|Active test treatment-NAC|NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
9678678|NCT04959942|Experimental|scapular stabilization exercise|the subjects will receive scapular stabilization exercise + postural correction exercise and advice three times per week for 10 weeks
9678679|NCT04959942|Experimental|postural correction exercise|the subjects will receive postural correction exercise and advice three times per week for 10 weeks
9678680|NCT04959942|Active Comparator|advice|the subjects will receive advice three times per week for 10 weeks
9678681|NCT04959734||Bronchiolitis|Infants less than 2 years who the clinician has diagnosed Bronchiolitis
9678682|NCT04959734||LRTI|Infants less than 2 years who the clinician has diagnosed a viral or bacterial lower respiratory tract infection
9678683|NCT04959734||Wheeze|Infants less than 2 years who the clinician has diagnosed the first presentation of a viral wheeze
10175420|NCT03843541|Active Comparator|Active control treatment-Ambroxol hydrochloride|Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
10175421|NCT03843541|Placebo Comparator|Placebo|Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
9678684|NCT04959747|Experimental|acupuncture group|"Subject will be scheduled for a total of 8 sessions of acupuncture treatment, to be done by the 30 minutes for each session, twice per week over a 4-week period.~Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
9678685|NCT04959747|Placebo Comparator|sham-acupuncture group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion. Its validity and credibility have been well demonstrated."
9678686|NCT04959604|Experimental|ICG-marked Colon Carcinoma|The participants will receive an endoscopic marking via ICG preoperatively
9678687|NCT04959721|Experimental|Injection group|Patients in the injection group will be injected 10 mg (0.25 mL) of triamcinolone acetonide, mixed with 0.25 mL of 0.125% bupivacaine and 0.5 mL of normal saline.
9678688|NCT04959656||X-ray|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
9678689|NCT04959656||CT|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
10175422|NCT03843385|Experimental|faecal microbiota filtrate|Encapsulated faecal microbiota filtrate . 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
9678690|NCT04959656||MRI|This study completed the manual labeling of preoperative multi-modal images of cervical spine structures and tumor lesions. On the normal cervical spine, six target areas were labeled: cervical spinal cord (MRI), cervical spine alignment (MRI), cervical intervertebral discs ( MRI), cervical spinal canal area (MRI), cervical cobb angle (X-ray) and cervical posterior longitudinal ligament ossification (CT). For cervical tumor lesions, complete MR and CT as well as orthopedic, axial and coronal positions. The label on the lateral X-ray image.
9678691|NCT04959786|Experimental|INTERVENTION ARM|
9678692|NCT04959786|No Intervention|standard of care|
9678693|NCT04959669|No Intervention|Control group|Usual care
9678694|NCT04959669|Experimental|Intervention group|DeSSBack (Decision Support System for Low Back Pain)
9678695|NCT04959773||COVID+ with exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who suffer from muscle weakness after more than two months from infection.~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.~general conditions."
9678696|NCT04959773||COVID+ without exercise intolerance|"Patients of both sexes who have contracted SARS-COV-2 infection (swab positive and positive serological test (IgG)) and who recovered and came to their normal life.~The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion."
9678697|NCT04959773||Control healthy subjects (CTRL)|Subjects of both sexes who do not have contracted SARS-COV-2 infection (swab negative and negative serological test (IgG)). The presence of cardiovascular or internal pathologies or in any case of serious disease will be considered an exclusion criterion.
9678698|NCT04959864|Experimental|Isitol® (Food supplement treated group)|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of Isitol® per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.~1 sachet of Isitol® (2,1g) contains 1000 mg of myo-inositol, 300 mg of N-acetyl-cysteine, 150 % of the Nutritional Reference Values (NRV) in zinc and 100 % of the NRV: in vitamins B2, B3, B6, B9 and E."
9695367|NCT04779164|Experimental|Patients with type 2 diabetes|Patients with diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
9977563|NCT01363024|Experimental|A|
9977564|NCT01363037|Experimental|Dapivirine-Maraviroc Vaginal Ring|
10175423|NCT03843385|Active Comparator|faecal microbiota|Encapsulated faecal microbiota. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
10175424|NCT03843385|Sham Comparator|Placebo|Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
10175425|NCT03843424|Active Comparator|Enhanced Standard of Care (eSOC)|This group will receive the eSOC program. A minimum of 6 visits to the primary care provider (PCP) and includes assessment of weight status, patient/family motivation and readiness to change, promotion of healthy eating and activity habits, and use of health behavior change strategies.
10175426|NCT03843424|Active Comparator|Family-Based Behavioral Treatment (FBT + eSOC)|This group will receive eSOC plus the FBT program. Family-based behavioral treatment (FBT), an effective treatment that targets both child and parents meeting regularly with a health coach for healthy eating, activity, positive parenting strategies, and managing environmental cues.
9678699|NCT04959864|Placebo Comparator|Placebo treated group|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of placebo per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.~1 sachet of placebo (2,1g) contains only excipients used in Isitol® and excipients to get similar organoleptic aspect (maltodextrin, sucralose, silicon dioxide, magnesium carbonate, citric acid and beta-carotene)."
10175427|NCT03843528|Experimental|Combined therapy|"Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design.~Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle."
10175428|NCT03843502|Experimental|Kava Pharmacokinetics Group|Each subject will take three 75 mg kava dietary supplement capsules in a single dose/timepoint and nine blood draws will be collected over an eight hour period following adminstration of kava.
9695368|NCT04779164|Other|Patients without type 2 diabetes|Patients without diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
9695369|NCT04779099|Experimental|4-session intervention|
10175429|NCT03843268|Active Comparator|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS)
9695370|NCT04779099|Active Comparator|Treatment as usual|
10175430|NCT03843268|Placebo Comparator|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger.
9695371|NCT04779190|Experimental|Low-level laser therapy|In the low-level laser therapy group, each patient are going to receive low-level laser therapy and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
9695372|NCT04779190|Experimental|Therapeutic ultrasound|In the therapeutic ultrasound group, each patient are going to receive therapeutic ultrasound and cold-pack therapy and perform a home-based exercise program 5 times a week, once a day for 15 sessions.
9695373|NCT04779190|Active Comparator|Control|Participants are going to perform a home-based exercise program and receive cold-pack therapy 5 times a week, once a day for 15 sessions.
9695374|NCT04779151|Experimental|1.A - Urothelial Bladder Cancer|
9695375|NCT04779151|Experimental|1.B - Gastric or gastro-esophageal junction adenocarcinoma|
9695376|NCT04779151|Experimental|1.C - Head and Neck Cancer|
10175431|NCT03843281|Experimental|Paracetamol|Paracetamol 1 g (100 mL) IV + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
10175432|NCT03843281|Placebo Comparator|Placebo|Placebo (NaCl 0.9% 100 mL IV) + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
9695377|NCT04779151|Experimental|1.D - Biliary Tract Cancer|
9695378|NCT04779151|Experimental|1.E - Others: any histology, excepted breast cancer, prostate cancer or serous ovarian cancer|
9695379|NCT04779151|Experimental|Cohort 2 - Platinum-sensitive urothelial bladder cancer|
9695380|NCT04779151|Experimental|Cohort 3 - Clear Cell Renal Cell Carcinoma|
9695381|NCT04779060|Active Comparator|fentanyle group|
9695382|NCT04779060|Active Comparator|dexamethasone group|
9695383|NCT04779060|Placebo Comparator|control group|
9696466|NCT04766619||Patients|Patients registered with a practice who have attended a consultation (or other related activity) for the PINCER intervention OR selected by their clinical care team OR attached to a patient group within a Clinical Commissioning Group (CCG) or practice OR patients identified through social media who have a long-term health condition and/or are taking any medication that requires them to have regular blood tests and have had a medication review in the past six month will be invited to take part in an interview or focus group.
9696467|NCT04766619||Public and patient representatives|For the consolidated learning exercise - patient and public representatives who have an understanding of the related medicines management issues in primary care will be invited to take part in an interview or workshop.
9696468|NCT04766593|Experimental|Oncological functional reeducation program|"It will consist of the following actions:~Prescription of multimodal physical exercise: This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).~Retraining in activities of daily living: Gradation and simplification of activities and training in energy saving techniques (EAT).~Finally, an exhaustive daily record of the activity carried out by the patient will be carried out, from which it will be modified, adapting it to the clinical situation of the patient."
9827788|NCT02468674|Other|Follow-up (arm 1)|Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.
9977565|NCT01363037|Placebo Comparator|Placebo Vaginal Ring|
9678700|NCT04959838|Experimental|Ophthalmology physicians and residents|"Ophthalmology physicians and residents will be followed during 34h, from 8 am to 6 pm the following day,in five different conditions:~Control day (no work)~Typical working day~Working day + one night shift~Emergency working day + two consecutive night shifts~Night shift."
9678701|NCT04959630|Other|Group A|Group A received first five patient cases and 3D models via DI and another five cases in the VR environment
9678702|NCT04959630|Other|Group B|Group B received first five patient cases and 3D models via VR and another five cases in the DI.
9678703|NCT04959578|Active Comparator|Erythropoietin|Recombinant Human Erythropoietin
10175433|NCT03843294|Experimental|Nivolumab with TAA-T cell|Patients will receive doses of Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.If patient meets eligibility criteria for TAA-T cell infusion, the patient will receive two TAA-T cell infusions given 2 weeks apart
10175434|NCT03843229|Experimental|treatment group|The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
9678704|NCT04959578|Experimental|Darbepoetin alfa|Darbepoetin Alpha
10175435|NCT03843229|Other|control group|The control group only receives Transarterial Chemoembolization (TACE).
9678705|NCT04959565|Experimental|16 online lectures in sports nutrition + 8 individual consultations for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
9678706|NCT04959565|No Intervention|Control|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing).~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation."
9678707|NCT04959565|Experimental|16 online lectures in sports nutrition for 16 weeks|"Non-smoking, non-contraceptive using, competitive female endurance athletes, 18-35 years of age, training a minimum of five times per week will be recruited through social media and endurance sports clubs (running, cycling, orienteering, triathlon, biathlon, and cross-country skiing) in Norway, Sweden, Germany, and Ireland.~Athletes with a LEAF-Q score ≥8 + EDE-Q score < 2.5 who meets the other inclusion criteria will be invited for further participation.~The lectures are designed for female endurance athletes at risk of RED-S. The participants will get access to a new lecture every week during the intervention."
9678708|NCT04959539|Active Comparator|endoscopic transcanal tympanoplasty with attico-antrostomy|
10175436|NCT03843515|Experimental|Neoadjuvant nivolumab|All subject will receive 400mg flat dose nivolumab in the neoadjuvant setting
9678709|NCT04959539|Active Comparator|endoscopic assisted canal wall up mastoidectomy|
9678710|NCT04959591|Experimental|Experimental (Pre): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg after anesthetic induction/before surgical incision and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given at the end of surgery before skin closure.
9678711|NCT04959591|Experimental|Experimental(post): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg at the end of surgery before skin closure and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given after anesthetic induction/before surgical incision.
9678712|NCT04959591|Placebo Comparator|Placebo comparator : placebo|Participants will receive 1.5ml/kg placebo (0.9% saline) before and after surgery and the same dose will be given postoperatively at 8hour intervals for 24hours.
10175437|NCT03843307|Experimental|Electrical stimulation|
9678713|NCT04959526|Experimental|Respiratory Function Testing|All subjects will receive standard respiratory function testing and ultrasound-based elastography measurements across various behaviors and conditions
9678714|NCT04959279|Experimental|ED-TREAT|EHR-embedded clinical decision support (CDS) tool designed to overcome the challenges to risk assessment and suggest pre-emptive use of behavioral techniques in the emergency setting.
9678715|NCT04959279|No Intervention|Usual Care|
9678716|NCT04959227||whirling dervish group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
9678717|NCT04959227||control group|Beck Anxiety Inventory Beck Depression Inventory International Physical Activity Questionnaire
9678718|NCT04959123|Active Comparator|Ropivacaine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mL in each syringe) In the Ropivacaine only group, there is no adrenaline, the syringe loaded with ropivacaine is supplemented to 20 mL with a 0.9% sodium chloride solution"
9678719|NCT04959123|Experimental|Ropivacaine + Epinephrine|"Patients receive 0.5 mg/kg of actual weight of ropivacaine; the appropriate dose of ropivacaine is drawn from an ampoule of 0.5% ropivacaine, i.e., 5 mg/mL (example for a 75 kg individual: 7.5 mLn each syringe) In the ropivacaine + epinephrine group, 0.1 mL of a 1 mg/mL ampoule of epinephrine is added to each syringe before making up to 20 mL (i.e., 100 µg of epinephrine for 20 mL of final solution, i.e., 5 µg/mL, i.e., 1 : 200000)."
9678720|NCT04959331|Active Comparator|Short-course fosfomycin|3 g of fosfomycin once daily for two days (sachets)
9678721|NCT04959331|Active Comparator|Short-course nitrofurantoin|Five-day nitrofurantoin 100 mg t.i.d. (pills)
9678722|NCT04959331|Active Comparator|Short-course pivmecillinam|Three-day pivmecillinam 400 mg. t.i.d. (pills)
9678723|NCT04959331|Active Comparator|Single-dose fosfomycin|Single 3 g dose of fosfomycin (sachet)
10175438|NCT03843567|Placebo Comparator|Didactic Training|Training will be conducted in a classroom for those participants randomised to receive didactic training, with training provided via a PowerPoint (Microsoft Inc., Redmond, Washington, USA) presentation by an expert endoscopist. An endoscopist with extensive experience in optical characterisation using virtual chromoendoscopy reviewed all teaching material.
10175439|NCT03843567|Active Comparator|Computer-based self-training|Participants randomised to the computer-based self-learning group will be given the same PowerPoint presentation as the didactic group and completed the training in a separate room. Participants completed training without feedback interaction.
9678724|NCT04959461|Experimental|webCHAT|Single session 20-40minute self-guided web program that discusses promotes healthy decision making around driving and discusses the risks of alcohol and cannabis-influenced driving.
9678725|NCT04959461|Active Comparator|Usual Care|Existing driving school education
9678726|NCT04959253|Experimental|Psilocybin 25mg PO|
9678727|NCT04959253|Placebo Comparator|Placebo PO|
9678728|NCT04959513|Experimental|GBR with L-PRF bone block|Guided bone regeneration using Leukocyte and platelet-rich fibrin
9678729|NCT04959500|Experimental|Experimental group|Experimental: Radiation therapy, Temozolomide and anlotinib Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 10 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
9678730|NCT04959500|Placebo Comparator|control group|Experimental: Radiation therapy, Temozolomide and Placebo Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Placebo will be given with a daily dose of 0 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
9678731|NCT04959396|Experimental|Treatment|IUB SEAD procedure
10175440|NCT03843060|Experimental|Single AZD9977|During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
10175441|NCT03843060|Experimental|Itraconazole + AZD9977|During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
9678732|NCT04959344|Experimental|Kleb4V target dose|Study participants receive 2 target doses of the non-adjuvanted investigational product 2 months apart.
10175442|NCT03843034||Study group|Infertile women with autoimmune disease
10175443|NCT03843034||Control group|Women from couples with severe male infertility
10175444|NCT03843086|Active Comparator|720 Low Intensity shockwave therapy|Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
10175445|NCT03843086|Active Comparator|600 Low Intensity shockwaves therapy|"Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration."
10175446|NCT03843203|Sham Comparator|s-tDCS|- Intervention: 'Transcranial Direct Current Stimulation - tDCS The patients will receive tDCS sham treatment. The patients will receive sham tDCS treatment over primary motor cortex. According to 10-20 EEG system, anode will be placed at left C3 and cathode at o contralateral F3. In sham stimulation the device only release flow current, in the first 30 s of session and in the remaining 30s in the end of the session, during 20 minutes.
10175447|NCT03843203|Active Comparator|M1 a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS active treatment over primary motor cortex.~According to 10-20 EEG system, anode will be placed at left C3 and cathode at contralateral supraorbital Fp2.~Active stimulation uses a 2 milliamperes current during 20 minutes."
10175448|NCT03843203|Active Comparator|DLPFC a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS active treatment over dorsolateral prefrontal cortex.~According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~Active stimulation uses a 2 milliamperes current during 20 minutes."
10175449|NCT03842956|Active Comparator|Primary wound healing|Primary woundclosure in Allgöwer suture technique
10175450|NCT03842956|No Intervention|Secondary wound healing|no closure, open wound healing
10175451|NCT03843099|Active Comparator|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
10175452|NCT03843099|Experimental|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
9678733|NCT04959344|Experimental|Kleb4V target dose + AS03|Study participants receive 2 target doses of the adjuvanted investigational product 2 months apart.
10175453|NCT03843177||Ingrown toenails|
10175454|NCT03843177||Control|
9678734|NCT04959344|Experimental|Kleb4V low dose|Study participants receive 2 low doses of the non-adjuvanted investigational product 2 months apart.
9678735|NCT04959344|Experimental|Kleb4V low dose + AS03|Study participants receive 2 low doses of the adjuvanted investigational product 2 months apart.
9678736|NCT04959344|Placebo Comparator|Placebo (Diluent)|Study participants receive 2 doses of the Placebo 2 months apart.
9678737|NCT04959357||coronary microvascular dysfunction group|
9678738|NCT04959357||obstructive coronary artery disease|
9678739|NCT04959357||control group|
9678740|NCT04959136|Experimental|Ambulatory Monitoring Solution|The evaluable device (Ambulatory Monitoring Solution and its parts) is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
9678741|NCT04959305|Experimental|Experimental 1|HCP1803-3
9678742|NCT04959305|Active Comparator|Active Comparator 1|RLD2003
9678743|NCT04959305|Active Comparator|Active Comparator 2|RLD2004
10175455|NCT03842943|Experimental|Combination T-VEC/Pembrolizumab|"Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab~T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors.~Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection."
10175456|NCT03843112|Active Comparator|Vivag Plus|Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.
10175457|NCT03843112|Placebo Comparator|Placebo|Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.
10175458|NCT03843047|Other|Dual cigarette smokers/e-cigarette users|Dual cigarette smokers/e-cigarette users will be recruited.
10175459|NCT03843047|Other|Exclusive cigarette smokers|Exclusive cigarette smokers with minimal prior e-cigarette experience will be recruited.
10175460|NCT03842904|Experimental|Trimbow pMDI|Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation solution.
10175461|NCT03842904|Active Comparator|Fostair pMDI|Fostair 100/6 micrograms per actuation pressurised inhalation solution.
10175462|NCT03842852||LTEPR|Patients who underwent inguinal hernia repair laparoscopic extra-peritoneal repair under general anesthesia.
10175463|NCT03842852||OPHSR|Patients that underwent inguinal hernia repair open using prolene hernia system mesh under general or regional anesthesia.
10175464|NCT03843021||VAD Healthcare Providers|Adult healthcare providers of VAD therapy recipients.
10175465|NCT03842761|Experimental|Dose group 1|Low Dose
9678744|NCT04959305|Active Comparator|Active Comparator 3|RLD2005
9678745|NCT04959214|Experimental|intervention: progressive relaxation exercise practice group|intervention: progressive relaxation exercise practice group: A group of 30 intensive care nurses who will practice the progressive relaxation exercise at home 3 days a week for 1 month.
9678746|NCT04959214|No Intervention|control: uninterrupted group|control: A group of 30 intensive care nurses who did not intervene for 1 month
9678747|NCT04959370|Experimental|Dynamic hip screw (DHS)|
9678748|NCT04959370|Active Comparator|Cannulated compression screw (CCS)|
9678749|NCT04959409||Exposed Cohort|Children receiving topical analgesia
10175466|NCT03842761|Experimental|Dose group 2|Medium Dose
10175467|NCT03842761|Experimental|Dose group 3|High Dose
10175468|NCT03842761|Experimental|Dose Group 4|Dose for healthy volunteers dependent on results from prior dose groups with patients
10175469|NCT03842553||Police officers|Police officers from the cantonal police forces in Bern, Switzerland
10175470|NCT03842553||Firefighters|Firefighters from the professional fire service of the Canton Bern, Switzerland
10175471|NCT03842553||Ambulance personnel|Ambulance personnel of the Canton Bern, Switzerland
10175472|NCT03842553||Emergency nurses|Emergency nurses of the Emergency Unit of the University Hospital of Bern, Switzerland
10175473|NCT03842553||Psychiatric nurses|Psychiatric nurses of the University Hospital of Psychiatry, University of Bern, Switzerland
9678750|NCT04959409||Control / Unexposed Cohort|Children who do not receive topical analgesia
9678751|NCT04959318|Experimental|Treatment group or counseling group|The treatment group will receive a counseling intervention addressing metabolic syndrome (comprised of abdominal adiposity, high blood pressure, high cholesterol, elevated fasting glucose, and elevated triglyceride level) and low vitamin D. This group will undergo baseline body composition measurements, phlebotomy, and an introduction to the digital app for recording diet and activity.
9678752|NCT04959318|Active Comparator|Control group or comparison group|Subjects randomized to the control group will undergo baseline body composition measurements, phlebotomy, and an introduction to the app for recording diet and activity. They will receive a packet of evidence-based pamphlets addressing Service-specific approaches to healthy eating and physical activity (e.g. Performance Triad). There will be no formal recurring interaction with an RD for those randomized to this control group.
9678753|NCT04959292||Meniscus regeneration|Reconstruction of the anterior cruciate ligament, total or partial meniscus resection was performed in our hospital, and two years after the operation, the meniscus regeneration was found under secondary arthroscopy.
9678754|NCT04959292||Meniscus without regeneration|Anterior cruciate ligament reconstruction, total or partial meniscus resection was performed in our hospital, and two years after the operation, no meniscus regeneration was found under secondary arthroscopy.
9678755|NCT04959071|Experimental|Group A|Group A included participants who underwent VAC therapy for diabetic Foot ulcers
9678756|NCT04959071|Active Comparator|Group B|Group B included participants who underwent conventional dressings for diabetic foot ulcers
10175474|NCT03842748||Retrospective study group|200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
10187178|NCT03728803|Active Comparator|Active inspiratory muscle training|Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.
10187179|NCT03728777|Placebo Comparator|Placebo|
10187180|NCT03728777|Experimental|Resveratrol|Over the counter supplement
10187181|NCT03728764|Other|single arm|
9678757|NCT04959084|Experimental|Acupuncture|Acupuncture group A , consisting of 20 women will be received laser acupuncture therapy and pelvic floor training every other day for 30 min , 3 times per week for 12 sessions
9678758|NCT04959084|No Intervention|Medical|Medical group B, consisting of 20 women will be maintained their ordinary medical treatment
9678759|NCT04958980|No Intervention|Placebo|The control group will be evaluated in 2 stages: at the beginning and at the end of the study and will be accompanied only with scheduled medical consultations (also simulating the reality of basic health units with a traditional model of care) and the intervention group will undergo evaluations with the multiprofessional team on two occasions (at the beginning and at the end of the study)
10175475|NCT03842748||Prospective observational study group|100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
9678760|NCT04958980|Active Comparator|Specific and educational guidelines on pathology care (diabetes mellitus)|"Multiprofessional educational guidelines and analysis of the following exams:~Periodontal record, bleeding rate on and visible plaque;~Body mass index (BMI): weight (kg) divided by height squared (m²);~Serum glucose values;~Glycated hemoglobin;~Blood count: hemoglobin;~Urea: male:~Creatinine male;~Uric acid;~Oxalacetic glutamic transaminase;~Glutamic pyruvic transaminase;~Total cholesterol and fractions: Cholesterol, Non HDL, LDL, VLDL;~Triglycerides;~Type I urine;~Vitamin D3 25OH;~Microalbuminuria;~Blood pressure: systolic;~Abdominal circumference."
10175476|NCT03842722||Critically ill septic patients|Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.
10175477|NCT03842917||Patient starting bevacizumab treatment for cancer|Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
9678761|NCT04959201|Experimental|NMDAE plus Antioxidant agent (AO)|An NMDA enhancer plus a drug with antioxidant property
9678762|NCT04959201|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
10175478|NCT03842800|Other|ASD Patients|This arm consists of patients diagnosed with Autism Spectrum Disorder (ASD) that will receive an MRI.
10175479|NCT03842800|Other|Schizophrenic Patients|This arm consists of patients diagnosed with Schizophrenia that will receive an MRI.
10175480|NCT03842800|Other|Healthy Controls|This arm consists of healthy control volunteer participants that will receive an MRI.
10175481|NCT03842800|Experimental|Healthy Controls with Ketamine|This arm consists of healthy control volunteer participants that elect to receive ketamine prior to receiving an MRI.
10175482|NCT03842735|Experimental|exercise and rehabilitation counselling|Subjects enrolled in exercise group make physical exercises and receive rehabilitative counselling indications
10175483|NCT03842735|Other|rehabilitation counselling|Subjects enrolled in exercise group only receive rehabilitative counseling indications.
10175484|NCT03842839|Experimental|COPD in Grade A|Patient with Grade A COPD (according to GOLD 2019), will start to use Tiotropium once daily.
10175485|NCT03842839|Active Comparator|COPD in Grade C|Patient with Grade C COPD (according to GOLD 2019), will start to use Olodaterol + Tiotropium once daily.
10175486|NCT03842774|Experimental|Test group|taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks
10175487|NCT03842774|Placebo Comparator|Control group|taken 3 tablets of placebo once a day for 12 weeks
10175488|NCT03842579|Experimental|Exercise and Protein (EXEPROT)|Participants in EXEPROT receive: a high-protein diet combined with Resistance training. The high-protein diet is based on milk-based protein-rich products to supplement the habitual diet (corresponding to a protein intake of 1.5 g/kg/day). 4-day food records are used to estimate the needed protein. Of the shelf-products (e.g. milk, cheese) are used considering the individually preferences. Products are delivered once a week. The training intervention includes progressive explosive type heavy-resistance training two times per week. The intervention runs for 16 weeks. Adherence to the training protocol is monitored at each session. Adherence with the nutrition protocol is monitored daily plus at phone follow-ups where participants are asked about e.g. appetite, weight, habitual intake.
10175489|NCT03842579|Active Comparator|Protein-only (PROT)|"Participants in PROT-group receive the nutritional intervention: The high-protein diet.~The diet is based on daily milk-based protein-rich products to supplement the habitual diet (corresponding to a total protein intake of 1.5 g/kg/day). The needed amount of protein supplementation is estimated from 4-day food records. Of the shelf-products (e.g. milk, skyr, cheeses) are used considering the individually preferences. Products will be delivered once a week at the home of the participant. The intervention runs for 16 weeks.~Adherence with the nutrition protocol is monitored daily (registration of compliance with the dietary plan) as well as at phone follow-ups where participants are asked about e.g. changes in appetite, weight, and habitual intake."
10175490|NCT03842579|Active Comparator|Recommendations (REC)|"Participants in the REC-Group receive the comparative intervention: Recommendations.~The official national dietary recommendations for adults >65 years, developed by the Ministry of Environment and Food of Denmark, and related materials is given to the participants and they are encouraged to follow the guidelines (recommending a protein intake of 1.0-1.3 g/kg/day). The intervention runs for 16 weeks.~During the intervention all groups will receive two seminars on specific topics related to healthy ageing (e.g. talks on physical activity, sedentary behaviour, and nutrition)."
9678763|NCT04959149|Experimental|face-to-face intubation|intubation approach from front of the patient
9678764|NCT04959149|Active Comparator|standard position intubation|intubation approach from behind the head of the patient
10175491|NCT03842605|Experimental|Strength training|
10175492|NCT03842644|Experimental|Tension Reduction|Tension reduction device for 3 months post surgery
9678765|NCT04958993|Experimental|Anlotinib combined with concurrent chemoradiotherapy|"Radiotherapy: 1.8-2.0Gy, qd, 54-66Gy, 5 days a week Chemotherapy: squamous cell cancer: paclitaxel + platinum;Adenocarcinoma: pemetrexed + platinum;A cycle of 3W was used, and the appropriate chemotherapy dose was selected by the researcher according to the patient's situation without any restriction on the chemotherapy dose.Pre-induction chemotherapy is allowed.~Anlotinib: QD, take 2 weeks and stop for 1 week (radiotherapy 1, 2, 4, 5 weeks)"
9678766|NCT04958889||HIV+ adults with recent COVID-19 diagnosis|"Required study visits:~Baseline questionnaire at enrollment or month 1.~Follow up questionnaire at month 1 and month 4~Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
10175493|NCT03842644|No Intervention|Control|No tension reduction
10175494|NCT03842631||Superficial Group|Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
10175495|NCT03842631||Deep Group|Hemangioma depth evaluated by B-ultrasonoscope is more than 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
10175496|NCT03842527|Active Comparator|Standard Fasting Group|Ultrasound scan of gastric antrum 1 hour prior to procedure. Patients assigned to this group will follow standard fasting procedures of no eating or drinking 8 hours prior to C-section.
10175497|NCT03842527|Experimental|Carbohydrate Loading Group|"Ultrasound scan of gastric antrum 1 hour prior to procedure.~Patients assigned to this group must stop eating 8 hours prior to their scheduled C-section time.~The night before their C-section they must drink 800mL of 100% apple juice (not from concentrate) OR 800mL of cranberry juice cocktail, not both~The day of their C-section, starting 3 hours before surgery and to be finished 2 hours before surgery time, patients must drink 400mL of 100% apple juice OR 400mL of cranberry juice cocktail, not both~Please note:~The apple juice must be 100% juice, not from concentrate~The cranberry juice cocktail must not be plain cranberry juice"
10175498|NCT03842787||SLE patients with lupus Nephritis|"14 SLE patients with lupus Nephritis~Biological analysis and biopsy were (routinely) performed~Ethics The protocol will be submitted to a randomly chosen Institutional Review Board (Comité de Protection des Personnes), in compliance to French regulation.~Investigators will include patients followed for routine care. Patients will be informed that samples (serum and kidney biopsy) that are performed for routine patient care will subsequently be used for research purposes, with no additional blood draw/biopsy. They will sign informed consent."
10175499|NCT03842540|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
10175500|NCT03842540|Active Comparator|PartyWise Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
10175501|NCT03842514|Experimental|High-emulsifier to Low-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days high-emulsifier (soya lecithin) low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate"
10175502|NCT03842514|Experimental|Low-emulsifier to High-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days high-emulsifier( soya lecithin) low-calorie diet at 100% resting metabolic rate"
10175503|NCT03842501|Placebo Comparator|Placebo|
10175504|NCT03842501|Experimental|Release supplement|
10175505|NCT03842449|Experimental|Smoking pregnant woman withCO measurement|
9678767|NCT04958889||HIV- adults with recent COVID-19 diagnosis|"Required study visits:~Baseline questionnaire at enrollment or month 1.~Follow up questionnaire at month 1 and month 4~Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
9678768|NCT04958889||HIV+ adults with no history of COVID-19|"Required study visits:~Baseline questionnaire at enrollment.~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~Height, weight, vital signs, and blood sampling at enrollment.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
10175506|NCT03842449|Other|Smoking pregnant woman without CO measurement|
10175507|NCT03842449|Other|Non Smoking pregnant woman|
10175508|NCT03842397|Experimental|Implanted Patients|Implantation of Kephalios Device 1
10175509|NCT03842462|Active Comparator|nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%
10187182|NCT03728751|Experimental|study group|Study group receiving dry needling and pupil diameter will be studied up to 23 minutes after needle placement.
10187183|NCT03728738|Experimental|Zero Degree HOB|Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy
9977566|NCT01363037|Active Comparator|Maraviroc Vaginal Ring|
9977567|NCT01363037|Active Comparator|Dapivirine Vaginal Ring|
9678769|NCT04958889||HIV- adults with no history of COVID-19|"Required study visits:~Baseline questionnaire at enrollment.~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
9678770|NCT04958928||Persistent AF Group|
10175510|NCT03842462|Active Comparator|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
10175511|NCT03842462|Experimental|NHFOV|"- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2."
10175512|NCT03842488|Experimental|RAL 1200 QD|Start treatment with Raltegravir (RAL) 1200mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
10175513|NCT03842488|Active Comparator|DRV/cb|Start treatment with Darunavir/Cobicistat (DRV/cb) 800-150mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
10175514|NCT03842475||Surgical cohort|Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
10175515|NCT03842475||Control|Healthy volunteers with normal body mass index
10175516|NCT03842319|Experimental|Control|In patients allocated to the control group, the currently used Spanish Mediterranean diet will be recommended as part of a standard high-quality secondary prevention program, where the patient is invited to participate in a single 45 minute nutritional educational group session. Interventions: Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation
10175517|NCT03842319|Experimental|High-intensity MedDiet|Patients allocated to the interventional group will be individually evaluated by a dietitian and will participate in dedicated individual and group sessions at baseline, and at 3, 6, 9 and 12 months. In the interventional group, a personalized MedDiet will assess chemical and nutritional composition and total energy intake will be adapted to participant's weight, age, and requirements, and the dietitian's tailored advice to his/her individual needs. A 14-item dietary screen for adherence to the Mediterranean diet will be used to personalize the intervention and negotiate dietary changes. Furthermore, free virgin olive oil, recipes, shopping list and designed weekly menus will be provided to maximize the differences between groups. Interventions: MedDiet, Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation, Diet evaluation
10175518|NCT03842241||WIth foot orthoses|Device: Non-custom made foot orthoses
10175519|NCT03842241||Without foot orthoses|Other: without foot orthoses
10175520|NCT03842423||Study Group|All patients under the age of 18 who were treated for upper extremity injuries between 2002 and 2018 and receiving brachial plexus anaesthesia.
10175521|NCT03842254|Experimental|Single arm|Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.
10175522|NCT03842150||derivation cohort|
10175523|NCT03842150||validation cohort|
9678771|NCT04959487|No Intervention|Standard of care|Control participants will receive standard of care as offered by clinical partners to all T2DM patients, including referral to nutritional counseling, T2DM support groups, and participation in local diabetes self-management programs. Control participants are also often provided referral information for locally available food support services in the region that provide diabetes-appropriate foods. At the end of follow up, the control arm will receive similar services from POH to what the intervention arm received during the intervention, regardless POH eligibility criteria (6 months of DM-tailored food support to meet 67% of their daily requirements, video recording of the 4 CHEFS-DM education classes, and access to a POH dietitian at their request).
9678772|NCT04959487|Experimental|Food support and nutrition education|The intervention entails two components: 1) food support that consists of weekly medically tailored meals and healthy groceries that on average covers 75% of daily energy requirements from baseline to six months and 2) diabetes-tailored nutritional education that consists of two individual counseling sessions with a Registered dietitian and four group education sessions.
10175524|NCT03842410|Other|Single-Incision Sling|Intervention with in office solyx suburethral sling DISST
10175525|NCT03842280||Prolonged mechanical ventilation|Prolonged mechanical ventilation with tracheostomy
9678773|NCT04959383|Experimental|Low complexity Exergame balance training group|Wobble board based exergame balance training, the game complexity will be low for this group.
9678774|NCT04959383|Experimental|Moderate complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be moderate for this group.
10175526|NCT03842202|Experimental|Semaglutide|Participants will receive increasing doses of semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
9678775|NCT04959383|Experimental|High complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be high for this group.
9678776|NCT04959383|Active Comparator|Control group|Wii fit based Exergame training on a stable surface
9678777|NCT04959058|Other|Volunteer|This study has only one arm for the brachial plexus evaluation with ultrasound
9678778|NCT04958603||Traditional surgery group|Traditionally loosen the lateral support belt proximally
9678779|NCT04958603||New surgery group|"Laterally loosen the outer support belt, that is, L-shaped loosen"
9678780|NCT04959045|Experimental|intervention group (Flipped Teaching Method Group)|Intervention group students will be given skill training with the Flipped Teaching method.
9977568|NCT01363063|Experimental|Ketorolac tromethamine (Part A)|
9678781|NCT04959045|No Intervention|Control group (Traditional Method Group)|Control group students will receive skill training with the traditional method. No intervention will be made.
9678782|NCT04958655|Other|Tetris, Positive Image|Participants randomised to order of intervention: this arm has; Tetris (Active Comparator) then Positive Future Image (Intervention).
9678783|NCT04958655|Other|Positive Image, Tetris|Participants randomised to order of intervention: this arm has; Positive Future Image (Intervention) then Tetris (Active Comparator).
10175527|NCT03842202|Placebo Comparator|Placebo (Semaglutide)|Participants will receive placebo (semaglutide). The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
9678784|NCT04958590||1 （asymptomatic）|the middle-aged and elderly Chinese asymptomatic population who underwent the whole spine X-ray in standing and sitting positions.
10175528|NCT03842215||silver hair people|Exam subject's physical function by a smart physical exam
10175529|NCT03842332|Experimental|Resilience Training|This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
10175530|NCT03842332|No Intervention|Standard Care|This group will receive case management referral to community training programs when requested by family, or need (as identified by case worker). Standard case management includes intake includes housing counseling, case management with mental health and behavioral services, and referral to day programs as needed and identified by case management
10175531|NCT03842371||Sepsis with type 2 diabetes|Sepsis patients with type 2 diabetes
10175532|NCT03842371||Sepsis without type 2 diabetes|Sepsis patients without type 2 diabetes
10175533|NCT03842371||Volunteers|Healthy volunteers
10175534|NCT03842124|Active Comparator|Intervention|Use of bidirectional rail (superior and inferior approaches) and force sensing using a force gauge to optimize Force application to less than 8 lbs during the extraction procedure.
10175535|NCT03842124|No Intervention|Control|Conventional lead extraction procedures using a superior approach is performed by experienced operators. Although force information is available the operators are blinded to the information. Inferior rail is left to the discretion of the operator.
10175536|NCT03842267|Active Comparator|Gemigliptin 50mg|
10175537|NCT03842267|Placebo Comparator|Gemigliptin Placebo|
10175538|NCT03842176||Neoadjuvant chemotherapy|CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
9678785|NCT04958590||2 （patients）|the patients who underwent posterior lumbar fusion surgery for lumbar degenerative disease has been followed up for three months.
9678786|NCT04958694|Experimental|CEDARS|Using an adapted stress-reduction intervention called the CEDARS, we will pilot the intervention in adolescents (N=50) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction.
10175539|NCT03842176||Surgery|CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
10175540|NCT03842072|No Intervention|No post-operative bracing|patients in this arm will not be prescribed a cervical collar following anterior cervical discectomy and fusion surgery
10175541|NCT03842072|Active Comparator|Post-operative bracing|Patients in this arm will be prescribed a cervical collar following anterior cervical discectomy and fusion surgery.
10175542|NCT03842059|Experimental|Computer-aided detection|
10175543|NCT03842059|Placebo Comparator|Standard colonoscopy|
10175544|NCT03841955|Experimental|Experimental group|Peripheral implantation of central venous catheters and accessories with high pressure tolerance
10175545|NCT03841955|Experimental|Control group|Peripheral intubation of central venous catheter
10175546|NCT03842046|Active Comparator|phenylephrine infusion|phenylephrine infusion (30 mL/h corresponding to 50 μg/min)
10175547|NCT03842046|Active Comparator|norepinephrine infusion|norepinephrine infusion (30 mL/h corresponding to 4 μg/min)
10175548|NCT03841903||relapsing-remitting MS undergoing spinal cord MRI|
10175549|NCT03841903||secondary progressive MS undergoing spinal cord MRI|
9678787|NCT04958720||Cohort 1|Resectable non-advanced cancer
9678788|NCT04958720||Cohort 2|Unresectable advanced cancer
9695384|NCT04778917|Experimental|Small dose low molecular weight heparin|Low molecular weight heparin calcium 100 units / kg/day, subcutaneous injection, 5-10 days of treatment or D-dimer recovery normal.
9977569|NCT01363063|Experimental|Ketorolac tromethamine (Part B)|
10175550|NCT03841903||primary progressive MS undergoing spinal cord MRI|
10175551|NCT03841903||healthy control (HC) undergoing spinal cord MRI|
10175552|NCT03842007|Active Comparator|Healthy Individuals|Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
10175553|NCT03842007|Active Comparator|Constipated Individuals|60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
10175554|NCT03842020|Experimental|Amiodarone dosage|Blood pharmacokinetics samples
10175555|NCT03841864|Other|Grade 1 Vein Visualization|Visual vein classification grade described as excellent Visualization. Objective vein criteria to be included in this group are vein raised above skin and wider than 1mm. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
10175556|NCT03841864|Other|Grade 2A Vein Visualization|Veins that don't fit grade 1 or 2b classification (see respective group descriptions). This groups visual vein classification is described as fair visualization. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
10175557|NCT03841864|Other|Grade 2b Vein Visualization|Only faint vein shadow appearance described as poor visualization. Initial IV placement attempt will be ultrasound guided
10175558|NCT03841864|Other|Grade 3 Vein Visualization|No vein visualization. Initial IV placement attempt will be ultrasound guided
9678789|NCT04958616||Patients sensitive to HDM|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled.Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
9678790|NCT04958616||Patients not sensitive to HDM allergy.|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled .Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation).
9678791|NCT04958746|Experimental|Ciprofol|Ciprofol group：0.4/0.2mg/kg
9678792|NCT04958746|Placebo Comparator|Propofol|Propofol group：2.0/1.0mg/kg
9678793|NCT04958629||non-FH Group|
10175559|NCT03841734|Experimental|Treatment bosentan|
10175560|NCT03841630|Experimental|LY3437943|Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
10175561|NCT03841630|Placebo Comparator|Placebo|Matching placebo administered as an injection under the skin in healthy participants
10175562|NCT03841981||I- Hypothalamic amenorrhea|10 women with exercise-associated hypothalamic amenorrhea
10175563|NCT03841981||II- Hyperandrogenic polycystic ovary syndrome|5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.
10175564|NCT03841981||III- Non-hyperandrogenic polycystic ovary syndrome|5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome
10175565|NCT03841981||IV- Trained women without ovulatory dysfunction|10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.
10175566|NCT03841981||V- Non-hyperandrogenic healthy women|10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis
10175567|NCT03841968|Active Comparator|Dynamic needle tip positioning|Dynamic needle tip positioning
10175568|NCT03841968|Active Comparator|Conventional long-axis|Conventional long-axis
9678794|NCT04958629||FH Group|
9678795|NCT04958863|No Intervention|No Mask|Runners do not use mask while running
9678796|NCT04958863|Experimental|Surgical Mask|Runners use surgical mask while running
9678797|NCT04958863|Experimental|Polyester Reusable Mask|Runners use polyester reusable mask while running
9678798|NCT04958759|Experimental|Functional Inspiratory Muscle Training Group|Functional inspiratory muscle training in patients with chronic kidney disease
9678799|NCT04958759|Experimental|Inspiratory Muscle Training Group|Inspiratory muscle training in patients with chronic kidney disease
10175569|NCT03841942|Other|clinically-based spacing|All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
10175570|NCT03841942|Other|Trough level-based spacing|Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
10175571|NCT03841604|Experimental|Experimental|Safinamide methanesulfonate film coated tablets once daily
10175572|NCT03841604|Placebo Comparator|Placebo|Safinamide methanesulfonate matching placebo film coated tablets once daily
10175573|NCT03841994||Preterm infant cohort|Preterm infants who were born <28 weeks of gestational age
10175574|NCT03841695|Experimental|Treatment Group|Experimental group received Robot Assisted Training (RMTC finger-hand robot (Mirror Hand)) and traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
10175575|NCT03841695|Active Comparator|Control Group|Control group received traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
10175576|NCT03841838|Experimental|Energy drink|Two 12 oz bottles of energy drink
10175577|NCT03841838|Placebo Comparator|Placebo|Two 12 oz bottles of placebo drink
10175578|NCT03841773|Experimental|TNX-102 SL Tablet 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
10175579|NCT03841773|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.
10175580|NCT03841851|No Intervention|temporization without soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.~Atraumatic extraction of badley decayed teeth in the aesthetic area~traditional drilling for immediate implant placement .~immediate temporization ."
10175581|NCT03841851|Active Comparator|temporization with soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.~Atraumatic extraction of badley decayed teeth in the aesthetic area~traditional drilling for immediate implant placement .~immediate temporization .~subepithelial connective tissue graft from the palate ."
10175582|NCT03841890|Experimental|Intubation with the Clarus Video System as a video stylet|
10175583|NCT03841890|Experimental|Intubation with the Clarus Video System as a lightwand|
10175584|NCT03841890|Active Comparator|Intubation with direct laryngoscope|
10175585|NCT03841721|Experimental|linezolid 300 mg|
9678800|NCT04958759|Experimental|Control Group|Breathing exercises in patients with chronic kidney disease
10175586|NCT03841643|Active Comparator|C group|In the C group, the cranial bone defect will be reconstructed with HydrosetTM (Stryker, New Jersey, USA), calcium phosphate cement, according to the current standard practice at the department.
9678801|NCT04958824|Experimental|Immediate return of results|The intervention for this study is the delivery of genetic test results that reflect pharmacokinetic and pharmacodynamic effects of specified genetic markers. We will use the Sanford panel being promoted by the VA through a clinical project entitled PHASER. The results are returned to the patient and provider approximately 1 week from randomization.
9678802|NCT04958824|No Intervention|Delayed return of results|In the control arm the genetic test results are not returned until 12 weeks when the main outcome is assessed.
10175587|NCT03841643|Experimental|P group|In the P group, the cranial bone defect will be reconstructed with a patient-specific implant (KLS Martin, Tuttlingen, Germany).
9678803|NCT04958707|Experimental|Informational support group|The participants in the intervention group will be added to a chat group in the Zalo app, created and managed by one investigator, which is named The Dementia Caregiver Support group. Weekly, the investigator will post one of the eight topics identified in Phase 1. Before posting the information, the investigator will ask the participants what topic they would like to read and discuss the week after by voting the answer. The posted information will be based on evidence-based resources and consulted by geriatricians, the neurologist, and the psychologist who specialize in dementia. Immediately after posting the topic, one investigator will call the participants to ensure they read and understand the post. The chat group monitor will also collect the questions or comments from the carers who are encouraged to share their feelings or experiences with relevant questions. Then the monitor will post the answers after consulting with the experts.
9678804|NCT04958707|Active Comparator|Controlled group|The participants will receive usual care, introduced to the website Alzheimer.org to search for eligible information. They will be interview by a questionnaire at baseline, post-intervention and 3 month post-intervention
9678805|NCT04958915||30 ° flexion position|Scan the knee at 30° flexion
10175588|NCT03841825|No Intervention|Control|No messages or oral hygiene instructions
10175589|NCT03841825|Experimental|Text message reminders|Standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays
10175590|NCT03841825|Active Comparator|In-person oral hygiene instructions|Oral hygiene instructions and motivation during visit
10175591|NCT03841825|Experimental|Text messages and in-person instructions|standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays and oral hygiene instructions and motivation during visit
10187184|NCT03728738|Active Comparator|Thirty Degree HOB|Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy
10187185|NCT03728725||TB case detection Group|Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.
10187186|NCT03728725||RIF-resistance MTB Group|"An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.~/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations."
10187187|NCT03728712||Never smokers|Participants with no history of cigarette smoking
10187188|NCT03728712||Active smokers|Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
10187189|NCT03728686|Experimental|3mins|Different given time: Fentanyl 2mcg/kg was given at either time 3 minutes before intubation
10187190|NCT03728686|Active Comparator|2mins|Different given time: Fentanyl 2mcg/kg was given at either time 2 minutes before intubation
10187191|NCT03728686|No Intervention|control|Different given time: Fentanyl 2mcg/kg was given at either time 1 minute before intubation
10187192|NCT03728673|Experimental|escitalopram|
10187193|NCT03728660|Experimental|LVES 2 first LEGACY second|Virtual bioptic magnification with large field of view (LVES 2) followed by 22-week washout period and then Full field magnification with small field of view (LEGACY)
10187194|NCT03728660|Active Comparator|LEGACY first LVES 2 second|Full field magnification with small field of view (LEGACY) followed by 22-week washout period and then Virtual bioptic magnification with large field of view (LVES 2)
10187195|NCT03728647|Experimental|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
10187196|NCT03728647|Active Comparator|regular health education|The regular (traditional) education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
10187197|NCT03728634|Experimental|AKCEA-TTR-LRx|Single and multiple doses of AKCEA-TTR-LRx administered subcutaneously
10187198|NCT03728634|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator administered subcutaneously
10187199|NCT03728621|Experimental|Individual-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
10187200|NCT03728621|Experimental|Group-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
9678806|NCT04958915||conventional flexion position|Routine body scan of the knee joint
9977570|NCT01363089|Experimental|Ketorolac tromethamine|
9678807|NCT04958837|Experimental|FIFA 11+ with dynamic core stability training|Participants in this group will undergo FIFA 11+ protocol along with additional Core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge will be given. Each exercise plan will be progressively increased.
9678808|NCT04958837|Active Comparator|FIFA 11+ protocol|Participants in this group will undergo traditional FIFA 11+ protocol which consists of slow paced running exercises, strength, plyometric & Balance exercises and high speed running with planting/cutting
9678809|NCT04958681||Covid-19 history positive|
9678810|NCT04958681||Covid-19 history negative|
9678811|NCT04958564|Active Comparator|group interlock|Intra medullary device used to treat tibial shaft fractures
9678812|NCT04958564|Active Comparator|group DCP (dynamic compression plate)|dynamic compression plate used to treat tibial shaft fractures
9678813|NCT04958525||Endoscopic Surgery Group|After a full evaluation of the patient's condition, the informed consent was signed to perform keyhole neuroendoscopic ultrasound-guided hematoma removal for the patient.
9678814|NCT04958525||Microsurgery group|After a full evaluation of the patient's condition, the informed consent was signed to perform small bone window craniotomy for hematoma removal under microscope for the patient.
9678815|NCT04958395||Myocardial bridge|Measure FFR and d-FFR
9678816|NCT04958343||reconstruction group|Patients will receive pelvic reconstruction following radical cystectomy during the operation.
9678817|NCT04958343||non-reconstruction group|Patients will not receive pelvic reconstruction following radical cystectomy during the operation.
9678818|NCT04958486|Experimental|Treatment|
9678819|NCT04958356||Children with increased risk for T1D and/or CeD|The participants carrying HLA-conferred susceptibility to type 1 diabetes will be screened annually for four diabetes predictive autoantibodies and followed up to 1-3 years of age. The participants carrying HLA-conferred susceptibility to celiac disease are screened for tissue transglutaminase antibodies (tTGA) at the age of 1 and 3 years. If a child tests positive for such autoantibodies, endomysial antibodies will be analyzed.
9678820|NCT04958200|Experimental|mhealth-pc for alcohol and chronic pain|Smartphone-based intervention
9678821|NCT04958200|Active Comparator|Treatment As Usual|In person session that provides enhanced treatment as usual
9678822|NCT04958512|Other|blank control group|
9678823|NCT04958512|Experimental|treatment group(Yangxue Qingnao pill)|
9678824|NCT04958512|Active Comparator|control group(hidezhen)|
9678825|NCT04958369|Active Comparator|Ultrasound-guided axillary venous access|Cardiac device implantation will be performed with ultrasound-guided axillary venous access.
9678826|NCT04958369|Active Comparator|Cephalic venous access|Cardiac device implantation will be performed with conventional cephalic venous access (cut-down technique).
9678827|NCT04958499|Experimental|Bio-Healthy Park|This group is the experimental group. The intervention program consisted in the realization of the program on bio-healthy machinery.
9678828|NCT04958499|No Intervention|Control|Adults and older assigned to the control group will not received any structured exercise programme. They will maintain their usual physical activities.
9678829|NCT04958317|Placebo Comparator|Early exercise|Participants will exercise for 30 minutes prior to an evening meal
9678830|NCT04958317|Experimental|Late exercise|Participants will exercise for 30 minutes after an evening meal
10175592|NCT03841929|Experimental|Study Arm|ELGANs recruited to the study group in addition to standard of care will have continuous cerebral NIRS monitoring for the initial 72 hours and TNE studies at definitive time frames and a hemodynamic report will be provided to the clinical team using the results of the multimodal monitoring and clinical data. The report will be a description of the hemodynamic status without any suggestions for management.
9678831|NCT04958460|Experimental|Probiotics group|"Probiotics~Candidates conditions excluded:~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~Participated in other clinical research in the past month.~Vegetarians or those currently undergoing special diet therapy.~Evaluation by the host is not suitable for entering the test."
9678832|NCT04958460|Placebo Comparator|Control group|"Placebo~Candidates conditions excluded:~Patients with major mental or neurological diseases such as intellectual disability, autism group disorders, schizophrenia, severe depression, bipolar disorder, epilepsy, brain injury, etc.~Those who have serious gastrointestinal diseases, physiological diseases or genetic diseases that will affect the results of intestinal microflora assessment~Have received ADHD-related drug treatment (containing Methylphenidate or Atomoxetine) in the past month.~Have used antibiotics or edible probiotic-related products (including drops, tablets, capsules, bacterial powder) in the past month.~Participated in other clinical research in the past month.~Vegetarians or those currently undergoing special diet therapy.~Evaluation by the host is not suitable for entering the test."
9678833|NCT04958330||lateral prostate capsule sparing group|Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.
9678834|NCT04958330||non nerve sparing group|Patients will receive standard radical cystectomy (not preserve the neurovascular bundles or lateral prostate capsule) during the operation.
9678835|NCT04958213|Other|Conventional physical therapy|Conventional physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises) will be applied to this group for 4 weeks (20 sessions).
9678836|NCT04958213|Active Comparator|Dextrose prolotherapy treatment|This group will be treated with 15% dextrose prolotherapy around and inside the knee, 2 times with a two-week interval, and home exercise program (isometric and isotonic exercises).
9678837|NCT04958135|Experimental|Sequence 1: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fasted conditions.~Period 2: Acoramidis as an immediate-release tablet under fed conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
9977571|NCT01363089|Experimental|Oxymetazoline hydrochloride|
9678838|NCT04958135|Experimental|Sequence 2: Acoramidis|"Participants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows:~Period 1: Acoramidis as an immediate-release tablet under fed conditions.~Period 2: Acoramidis as an immediate-release tablet under fasted conditions.~There will be a washout period of at least 14 days between acoramidis dosing."
9678839|NCT04958083|Experimental|aortopathy patient|Patients who have proximal aortic conditions and are referred to the aortic team in Royal Brompton and Harefield Hospitals will be screened for eligibility. For this pilot study and in view of the volume of aortic surgery in the Trust (approx. 100 cases per year), 30 patients will be recruited in the first year of this project to be followed for at least one year for clinical outcomes.
10175593|NCT03841929|No Intervention|Standard Arm|ELGANs recruited into Standard arm will have the standard monitoring including cardiorespiratory monitoring. The invasive blood pressure monitoring, NIRS and TNE monitoring as per the clinical team's discretion - consistent with the current standard of care. No hemodynamic report will be provided routinely.
10175594|NCT03841552|Experimental|Augmented Feedback|The exercises were conducted with the aim of improving postural- and movement control and awareness of the lumbar spine in both treatment groups. Both groups received nine 30-minute therapy sessions, during which they performed a series of exercises from an exercise catalogue. The exercises were selected based on their compatibility with the AF-system. Each patient performed impairment-specific exercises. The AF group received additional AF feedback during both the therapy sessions and the home exercise program, by combining the exercises with games designed to target movement control, body awareness, and stabilisation exercises.
10175595|NCT03841552|Active Comparator|Control Group|The control group performed the impairment-specific exercises without AF. The control group was able to receive conventional visual feedback, such as use of mirrors, as deemed appropriate by the therapists but no AF.
10175596|NCT03841747|Experimental|Pembrolizumab + Paclitaxel|200 mg Pembrolizumab intravenously (IV) every 3 weeks (Q3W) plus 80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
10175597|NCT03841747|Active Comparator|Paclitaxel|80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
10175598|NCT03841526|Experimental|Glucagon RTU, 50% insulin pump reduction|
10175599|NCT03841526|Placebo Comparator|Placebo, 50% insulin pump reduction|
10175600|NCT03841526|Experimental|Glucagon RTU, no basal rate reduction|
10175601|NCT03841539|Experimental|Mediterranean Diet|Follow a Mediterranean eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
10175602|NCT03841539|Active Comparator|Low-fat Diet|Follow a low-fat eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
10175603|NCT03841578|Experimental|Healthy|10 participants (matched per gender), aged 25-35 years old who accepts the consumption of dark chocolate plus a 'NutriDrink' previous to signing an informed consent and providing authorization to the handling of their personal data
10175604|NCT03841812|Experimental|Propofol|5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.
10175605|NCT03841812|Experimental|Propofol & Sevoflurane|2mg/kg/h Propofol & 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia
10175606|NCT03841591|Active Comparator|Insulin Group|This includes women with GDM allocated to receive insulin treatment. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
10175607|NCT03841591|Active Comparator|Metformin Group|This includes women with GDM allocated to receive metformin treatment. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
10175608|NCT03841877|Experimental|AH Plus-Cervical|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
10175609|NCT03841877|Experimental|MTA Fillapex-Cervical|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
10175610|NCT03841877|Experimental|AH Plus-2mm|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
10175611|NCT03841877|Experimental|MTA Fillapex-2mm|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
10175612|NCT03841370||endodontic|"The color of anterior (incisors and canines) and posterior (premolar) teeth treated at a private clinic in the city of Pelotas will be evaluated. Data will be collected regardless of technique, treatment time and sealer used.~The ΔE00 will be evaluated using the measurements obtained in the homologous tooth (without endodontic treatment) versus the measurement obtained from the tooth treated endodontically.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
9975838|NCT01345240|Experimental|RTS,S Regimen A Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975839|NCT01345240|Experimental|RTS,S Regimen B Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975840|NCT01345240|Experimental|RTS,S Regimen B Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975841|NCT01345240|Experimental|RTS,S Regimen B Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975842|NCT01345240|Experimental|RTS,S Regimen C Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975843|NCT01345240|Experimental|RTS,S Regimen C Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975844|NCT01345240|Experimental|RTS,S Regimen C Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9977572|NCT01363102|No Intervention|Control group|Group will undergo usual mobilization per standard SICU care
10175613|NCT03841409||Bupivacaine dosage in ESP block|The pharmacokinetics of bupivacaine 0.5% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following an ESP block will be determined by the collection of blood samples at predetermined time points.
9678840|NCT04958187|Experimental|ANG-3777|Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).
10175614|NCT03841435|Experimental|Hypofractionated Radiotherapy|15 Gy given in 3 fractions over 2 weeks
10175615|NCT03841383||Healthy controls|
10175616|NCT03841383||Hypertensive patients|
10175617|NCT03841305|Active Comparator|portal vein embolization|Liver preparation before major hepatectomy : portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.
10175618|NCT03841305|Experimental|liver venous deprivation|Liver preparation before major hepatectomy : Patients with the liver venous deprivation (LVD) technique that combines both PVE and hepatic vein embolization (HVE) during the same procedure.
10175619|NCT03841396|Active Comparator|Fraxiparine|Nadroparine, Pre-filled syringe, 3800IU, single dose
10175620|NCT03841396|Active Comparator|Clexane|Enoxaparin, Pre-filled syringe, 40 mg, single dose
10175621|NCT03841487||Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI).
10175622|NCT03841487||PCI alone|In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
10175623|NCT03841344|Active Comparator|Healthy volunteers|MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
10175624|NCT03841344|Active Comparator|Treatment naive patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH initiating PAH therapy for the first time"
10175625|NCT03841344|Active Comparator|Treatment change patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH, currently on PAH therapy who are undergoing an escalation of PAH therapy"
10175626|NCT03841344|Active Comparator|Stable patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients with PAH who are NOT undergoing changes in their treatment regime"
10175627|NCT03841500|Active Comparator|Aperture (biocomposite screw) fixation|"16 patients in this arm underwent ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw (BioComposite Screw, Arthrex, North Naples, FL; or MILAGRO screw, DePuy Mitek, Raynham, MA, USA).~Intervention: ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw."
10175628|NCT03841500|Active Comparator|Suspensory (endobutton) fixation|"17 patients in this arm underwent ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button (TightRope, Arthrex, North Naples, FL, USA).~Intervention: ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button."
10175629|NCT03841357|Experimental|Abatacept and Usual Care|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
10175630|NCT03841357|Active Comparator|Usual Care|Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
10175631|NCT03841474|Experimental|Intervention I|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
10175632|NCT03841474|No Intervention|Control|Cardiovascular patients after PCI without depressive symptoms and without the need for psychiatric intervention
10175633|NCT03841474|Experimental|Intervention II|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
10175634|NCT03841136|Experimental|anlotinib combined with EP|anlotinib combined with etoposide and platinum
10175635|NCT03841227|Active Comparator|Active-tDCS|10 patients will receive Active-tDCS intervention (2mA, 20 min) at home.
10175636|NCT03841227|Sham Comparator|Sham-tDCS|10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home.
10175637|NCT03841123|Experimental|Intervention|At the maternity wards mothers will receive dietary counseling and leaflets as a reminder to prevent the early introduction of added sugar and ultra-processed foods.
9977573|NCT01363102|Experimental|Study Group|Patient mobilization discussed on rounds, SOMS score goal created, specific attempt to mobilize patient and achieve goal throughout day.
10175638|NCT03841123|No Intervention|Control|At the maternity wards mothers assigned to control groups will have all the health assistance related to the maternity routine without any interference from the study protocol.
10175639|NCT03841071||ROM/CFS intervention|The ROM/CFS group (N>100), consists of patients who have undergone urostomy, colostomy, or ileostomy operations, and who are included in the routine follow-up program of the outpatient ostomy clinic at the Department of Surgery, Førde Central Hospital from April 2018 to June 2021.
10175640|NCT03841084|Active Comparator|Conservative Oxygen Management Strategy|Patients allocated to the conservative strategy will have the ECMO blender oxygen fraction (FbO2) will be titrated to achieve a post-oxygenator saturations of 92-96% (the FbO2 cannot be reduced to lower than 0.5). Post-oxygenator arterial blood gases (ABG's) will be taken to ensure safety and to allow for adjustments to be made. The ventilator FiO2 will be titrated to patient oxygen saturations (SpO2) of 92-96%.
9678841|NCT04958473|Experimental|Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic, previously treated or untreated)
10175641|NCT03841084|Active Comparator|Liberal Oxygen Management Strategy|Patients allocated to the liberal strategy will have the FbO2 set at 1.0 at all times. The ventilator FiO2 will be titrated to achieve a patient oxygen saturations (SpO2) of 97-100% (but not lower than 0.5).
10175642|NCT03841045||ulcerative colitis patient|people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.
10175643|NCT03841045||CD patient|people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.
10175644|NCT03841045||Health people|control group. no IBD patients can be included. patients with other diseases can be included.
10175645|NCT03841006||patient group|symptomatic patient and suspicious to have ODS by history and clinical examination those patient will have MRI defecography
10175646|NCT03841006||asymptomatic group|Asymptomatic group not suspicious to have ODS by history or clinical examination they will undergone MRI defecography
10175647|NCT03840954|Experimental|Neuromuscular Electrical Stimulation|The experimental group will receive the application of NMES associated with conventional physiotherapy. After the NMES application, conventional physiotherapy will be performed. The exercises performed will be according to the patient's physical condition, and the conducts will always be performed seeking the maximum possible functional performance for the patient. The conducts adopted according to the standard routine of the HCPA stroke unit are: passive, active, assisted and / or active exercises; muscle stretching; selective hip extension; trunk stabilization training in sedestation; orthostasis training and walking training.
9678842|NCT04958148|Experimental|High sodium|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 4,300 mg/d sodium for 4 weeks.
10175648|NCT03840954|No Intervention|Group Control|The control group will only receive conventional physiotherapy, composed of the same exercises performed in the experimental group.
10175649|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
10175650|NCT03840694|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
10175651|NCT03841188|Other|Nutritional Orientation|The patients received a nutritional orientation with emphasis in food rich in calcium
10175652|NCT03841461||Academicians|The academicians working in any program of any higher education institution
10175653|NCT03840655||palmar hyperhidrosis|VATS R4 Sympathicotomy performed on all patients. Fluorescent thoracoscopy was used to identify the shifting mode of sympathetic ganglions.
10175654|NCT03841019|Experimental|magnetic seizure therapy|12 treatment sessions of MST, three times per week.
10175655|NCT03841019|Active Comparator|electroconvulsive therapy|12 treatment sessions of ECT, three times per week.
10175656|NCT03841032|Experimental|Sunscreen Lotion|Subjects with rosacea will apply the test sunscreen lotion to the face for 4 weeks
10175657|NCT03840746|No Intervention|Habitual diet|participants remain on their habitual diet
10175658|NCT03840746|Experimental|Tomato, onion and lovage soup (TOL)|One tin of soup containing Tomato onion and lovage daily for 6 weeks
10175659|NCT03840746|Experimental|TOL soup with inulin|One tin of Tomato, onion and lovage soup with added inulin for 6 weeks
9678843|NCT04958148|Placebo Comparator|Placebo|Subjects will be counseled to consume a diet with 2,300 mg/d sodium and will supplement with taking placebo pills for 4 weeks.
10175660|NCT03840889||Women with a severe late PPH|Women with a severe late PPH will be recruited prospectively after verification of the inclusion criteria by a gynecologist-obstetrician or the investigating midwives, who will provide the patients information about the study and include them unless they object
10175661|NCT03840681|Experimental|Ridge augmentation by collagen membrane|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at defected area then covered at the defected area by a collagen membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
10175662|NCT03840681|Active Comparator|augmentation by titanium reinforced PTFE|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
9678844|NCT04957940|Experimental|SMOF lipid 20% IV infusion|Intravenous fish-oil-based lipid (SMOF lipid 20%) emulsion supplementation to standard enteral nutrition.
9678845|NCT04957940|Placebo Comparator|Saline placebo IV infusion|Intravenous 0.9% saline supplementation to standard enteral nutrition.
9678846|NCT04957979||Nursing/Medical Model of Care Coordination|Someone with medical/nursing training coordinates involvement of various medical resources and provides patients with education, self-management support, and referrals to community resources.
9695385|NCT04778917|Experimental|High dose of low molecular weight heparin|low molecular weight heparin calcium 200 units /kg/day, subcutaneous injection, treatment for 7 days or D-dimer return to normal.
10175663|NCT03840759|Experimental|usual care|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant and inpatient geriatric consultation team after a complete geriatric assessment (CGA). The CGA includes the assessment of depression, dementia, physical performance of Activity of Daily Living (ADL) and nutrition using Geriatric Depression Scale (GDC-15), Mini-Mental State Examination (MMSE), Barthel Index (BI), and Mini Nutritional Assessment-Short Form (MNA®-SF) respectively. Besides the geriatric physician, our multidisciplinary team included a social worker, nutritionist and physical therapist. In the control group, the participants only received routine hospital care and no geriatric physician was consulted.
10175664|NCT03840798||Pretest/Baseline period|
10175665|NCT03840798||Posttest/go-live period|
10175666|NCT03840941||Frail patients with COPD|No intervention
10175667|NCT03840941||Non-frail patients with COPD|No intervention
10175668|NCT03840876|Experimental|Group J|Jet ventilation was achieved via supraglottic jet oxygenation and ventilation with WEI NASAL JET (WNJ).
10175669|NCT03840876|No Intervention|Group I|Patients were ventilated with a small size endotracheal tube.
10175670|NCT03840785|Experimental|interventional group A|2 tango session per week during 6 month (M0 to M6)
9678847|NCT04957979||Medical/Social Model of Care Coordination|In addition to the services provided in the Medical/Nursing Model, a social worker by education has dedicated FTE as a member of the care team at the clinic, providing some direct services for care coordination patients and either spending some time on-site or in regular communication with its clinicians in addition to providing social work services.
10175671|NCT03840785|Placebo Comparator|Control group B|2 tango session per week during 3 month (M3 to M6)
10175672|NCT03840629||Hypotonic fluid maintenance|exclusive administration of 0.33% saline mixed with potassium and dextrose 5%
10175673|NCT03840629||Isotonic fluid maintenance|exclusive administration of 0.9% saline
9678848|NCT04958122|Experimental|Cefixime|Oral cefixime 400mg, taken twice a day for 10 days
9678849|NCT04958122|Active Comparator|Benzathine Penicillin G|Single intramuscular injection of 2.4 million units of benzathine penicillin G
10175674|NCT03840863|Experimental|Commercially-Available Energy drink|Healthy volunteers willing to consume two cans of energy drinks (16 oz./can) daily for 4 weeks
10175675|NCT03840850|Experimental|Intervention and usual care|Risk communication intervention and usual care including personalized lifestyle advice
10175676|NCT03840850|No Intervention|Usual care only|Usual care including personalized lifestyle advice
10175677|NCT03840460||Pancreatic Cancer|Patients who are investigated for and subsequently diagnosed with early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour.
10175678|NCT03840369|Experimental|rTMS to the Right Dorsolateral Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsolateral Prefrontal Cortex (DLPFC). The right DLPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
10175679|NCT03840369|Experimental|rTMS to the Right Dorsomedial Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsomedial Prefrontal Cortex (DMPFC). The right DMPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
10175680|NCT03840473|Experimental|MET+ICT+Conventional intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by ICT (90-second hold-time) and MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
10175681|NCT03840473|Experimental|MET+Conventional Intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
10175682|NCT03840473|Active Comparator|Conventional Intervention|Received hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) only.
10175683|NCT03840304|Experimental|Yoga Group|Participants in the intervention group engaged in a 8-week yoga program delivered at their place of work (IT companies). Sessions were group-based, prescribed three sessions per week during break time (30-mins).
10175684|NCT03840304|No Intervention|Wait-list Group|Participants in Wait-List control were not given any intervention. 8-weeks, group followed usual break time.
10175685|NCT03840577|Placebo Comparator|Clinical monitoring group|In the clinical monitoring group, the doses of sedative drugs will be regulated according to the patient's RASS. The RASS of the patient will be evaluated twice per nursing shift (every 4 hours). The BIS monitor will be placed on the patient, but blind to the nursing team, with the objective to measure the BIS values.
10175686|NCT03840577|Experimental|BIS group|"In the group Sedation guided by BIS, the sedation will be guided by the value of BIS. The BIS value of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The objective of BIS will be between 40 and 60.~According to the BIS value of the patient at the time of the evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target BIS, with 20% modifications of the current dose at the time of evaluation."
10175687|NCT03840538|Experimental|Probiotic group|Probiotic complex capsule taken twice daily for 5weeks
10175688|NCT03840538|Placebo Comparator|Placebo group|Placebo capsule taken twice daily for 5 weeks
9678850|NCT04957875||urgent endoscopy group|endoscopy <6h after admission
9678851|NCT04957875||early endoscopy group|endoscopy 6-24h after admission
9678852|NCT04957888||training group|the observational group to find out the potential biomarker
10175689|NCT03840330|Experimental|High-intensity interval training group|Frequency: 2 days/weeks; Intensity: 16-18 Börg/85-100%VO2max; Recovery: Active; Duration: 1 hour.
10175690|NCT03840330|Experimental|Moderate-intensity interval training group|Frequency: 2 days/weeks; Intensity: 12-14 Börg/60-70% VO2max; Recovery: Active; Duration: 1 hour.
10175691|NCT03840330|No Intervention|Control group|Maintain their normal daily activities throughout the sixteen-week experimental period.
10175692|NCT03840603|No Intervention|Control|Usual care of patients with suspected Low RespiratoryTract Infection at the discretion of the attending physician. Care may entail a CRP and/or a PCT measurement, but no nasopharyngeal swab sampling.
10175693|NCT03840603|Experimental|Film Array RP2 Assay guided|In the emergency room a nasopharyngeal swab sample will be collected from subjects with a suspected Low RespiratoryTract Infection for the Film Array RP2 Assay guided plus a blood sample for the PCT assay if the PCT measurement has not been already prescribed.
10175694|NCT03840512|Experimental|Oral CBD 75 BID|
10175695|NCT03840512|Experimental|Oral CBD 150 BID|
10175696|NCT03840512|Experimental|Oral CBD 300 BID|
10175697|NCT03840421|Experimental|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
10175698|NCT03840421|Active Comparator|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
10175699|NCT03840590|Experimental|AI-assisted Colonoscopy|Participants in this arm undergo AI-assisted colonoscopy using CSK AI system.
10175700|NCT03840590|Active Comparator|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy.
10175701|NCT03840395|Active Comparator|Active PES|Patients randomized to receive active Pharyngeal Electrical Stimulation (PES) via a Phagenyx Catheter.
10175702|NCT03840395|Sham Comparator|Sham PES|Patients randomized to sham will not receive any Pharyngeal Electrical Stimulation (PES) but will still have the Phagenyx Catheter inserted.
10175703|NCT03840564||Group point of care (POC)|All the analyzes will be done in delocalized
10175704|NCT03840564||control group|the analyzes will be done at the central laboratory
10175705|NCT03840356||Postoperative|The study will evaluate orthopedic postoperative patients during the hospitalization.
10175706|NCT03840434|Other|CCS group|Measurements by intramuscular punction and non invasive tool
10175707|NCT03840317|Experimental|Senl_1904A CD19 CAR-T|Autologous CD19-targeting CAR T cells, dosage 3*10^5/kg, intravenous injection once
10175708|NCT03840317|Experimental|Senl_1904B CD19 CAR-T|Autologous CD19-targeting CAR T cells,dosage 3*10^5/kg, intravenous injection once
10175709|NCT03840551|Other|Subjects|Subjects involved are required to do some specific motor tasks, commonly found in all main sports. Evaluated with inertial sensors (XSENS) and marker-based motion capture (BTS)
10175710|NCT03840499||Willing to participate in clinical study|
10175711|NCT03840499||Not-willing to participate in clinical study|
10175712|NCT03840408|Experimental|Mitochondrial therapy with radiofrequency ablation|
10175713|NCT03840408|Active Comparator|Surgery|
10175714|NCT03840265|Other|Carotid endarterectomy|All patients in this study will undergo carotid endarterectomy procedure
10175715|NCT03840109||All Participants|All participants will take an online questionnaire which includes their evaluation of one of 18 different emotional support messages randomly assigned through the Qualtrics survey system. The participants answer a series of closed ended scales regarding quality of the support message, supporter's competence, amount of emotional improvement they experienced after reading the message, and likelihood to seek support from the person writing the message.
10175716|NCT03839927||Evaluation Group|Survey Application
10175717|NCT03840031|Experimental|Orange Fleshed Sweet Potato High Iron|Meal sequence B, OFSP High Fe
10175718|NCT03840031|Active Comparator|Orange Fleshed Sweet Potato Control|Meal sequence A, OFSP control
10175719|NCT03839875|Experimental|Active Treatment|
10175720|NCT03840018|No Intervention|Control|Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
10175721|NCT03840018|Other|Letter by post to patients|Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
9678853|NCT04957888||validation group|the validation group to validate the parameters used for early diagnosis
10175722|NCT03840122|Experimental|A - ACB + IPACK with injection|50 arms: ACB + IPACK block with injection of local anesthetic of Ropivacaine, Epinephrine, Ketorolac, Clonidine and saline
10175723|NCT03840122|Active Comparator|B - ACB + IPACK without injection|50 arms: ACB + IPACK block without injection of local anesthetic
10175724|NCT03839888|Experimental|0.125% atropine group|patients used the 0.125 % atropine eyedrop every night before sleep for 7 days
10175725|NCT03840226|Active Comparator|Magnesium|oral magnesium oxide tablets [Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel]
10175726|NCT03840226|Placebo Comparator|Placebo|Placebo tablets
10175727|NCT03839953|Active Comparator|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
10175728|NCT03839953|Experimental|Supervised Exercise Program|Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
10175729|NCT03840057|Experimental|Azithromycin|Participants randomized to the azithromycin arm would receive 250mL of reconstituted solution containing 500mg of generic azithromycin to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic or renal impairment. No dose adjustment is made for geriatric population.
10175730|NCT03840057|Experimental|Metoclopramide|Participants randomized to the metoclopramide arm would receive 2mL of solution containing 10mg of generic metoclopramide to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic impairment. A 50% dose reduction is made for those with creatinine clearance of less than 40mL/minute. No dose adjustment is made for geriatric population.
9678854|NCT04957862|Active Comparator|Surgery Group|For patients who choose early conservative treatment, after the hematoma enters the subacute stage, complete the relevant imaging examinations and perform robotic minimally invasive aspiration.
9678855|NCT04957862|No Intervention|Conservative treatment Group|Patients who are unwilling to undergo surgery and have hemorrhage in the deep functional area of the brain within 30ml.
10175731|NCT03840057|Placebo Comparator|Placebo|Participants randomized to the placebo arm during Part 1 (azithromycin) of the study would receive 250mL of 0.9% sodium chloride solution to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. Participants randomized to the placebo arm during Part 2 (metoclopramide) of the current study would receive 2mL of 0.9% sodium chloride solution to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy.
10175732|NCT03840044|Other|Healthy volunteers|Healthy volunteers will perform the same protocol as foreseen for asthmatic patients. Both will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
9678856|NCT04957927|Experimental|Intranasal Fluticasone Propionate Group|Intranasal Fluticasone Propionate 50mcg/actuation in each nostril 24 hourly
9678857|NCT04957927|Experimental|Montelukast Group|Montelukast 4mg oral granule formulation 24 hourly
9678858|NCT04957849|Active Comparator|Trans-frontal keyhole approach|After general anesthesia, the patient was placed in supine position with head frame fixed. A straight or arc incision was made in the hairline of the affected side. The incision was 3cm beside the midline. The length of the incision was about 4cm and the diameter of the bone window was about 2.5cm. According to the preoperative thin-layer CT scan, the dura mater and part of the cerebral cortex were cut, and the endoport and other hard channels were inserted. The incision reached 2 / 3 of the length of the hematoma along the direction parallel to the long axis of the hematoma, During the operation, mini aneurysms were clipped to close the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity. The external drainage tube led out the skin through the subcutaneous tunnel, and the dura was sutured.
9678859|NCT04957849|Active Comparator|Trans-occipital keyhole approach|After general anesthesia, the patient was placed in prone position with head frame fixed. According to the preoperative thin-layer CT scan, the long axis of hematoma was perpendicular to the ground, and the occipital puncture point was found along the extension line of the long axis of hematoma. Taking the puncture point as the center, a straight or arc incision parallel to the sagittal sinus was taken. The length of the incision was about 4cm, and the diameter of the bone window was about 2.5cm, Endoport and other hard channels were inserted to reach 2 / 3 of the long diameter of the hematoma along the direction parallel to the long axis of the hematoma. Under the neuroendoscope, the hematoma was aspirated or resected in blocks. During the operation, mini aneurysm clamp was used to clamp the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity.
9678860|NCT04957576|Sham Comparator|Asynchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in an asynchronous way, i.e. with a time-delay between one hand-touch and the other
9678861|NCT04957576|Experimental|Synchronous Stimulation|The right and the left disown hands will be stimulated with a tactile stimulation (paintbrush) in synchronously, i.e. without a time-delay between one hand-touch and the other
9678862|NCT04957446|Experimental|Group 1|Subjects will receive 3 treatments of 1mL Poly-L-Lactic Acid (Sculptra Aesthetic)
9678863|NCT04957446|Placebo Comparator|Group 2|Subjects will receive 3 treatments of 1mL Saline solution.
9678864|NCT04957771|Experimental|Regular exercise group|
9678865|NCT04957771|No Intervention|non-regurlar exercise group|
9678866|NCT04957810|No Intervention|Patients who are given regular home functional exercises and discharged from the hospital|Discharge guidance using regular home function exercises, that is, existing regular missions and paper-based brochures
9678867|NCT04957810|Active Comparator|Patients who are guided by conventional discharge guidance and the optimized WeChat official account|Use regular discharge guidance and optimized WeChat public account guidance
9678868|NCT04957589|Experimental|VLCD & HIIT & protein supplementation|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, no free expenditure) High intensity interval training (3x sessions per week following intensity estimation using cardiorespiratory testing (VO2max), using an established training protocol within our department) 200kcal/day whey protein supplementation
9975845|NCT01345240|Active Comparator|Engerix B Regimen A Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975846|NCT01345240|Active Comparator|Engerix B Regimen B Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
9975847|NCT01345266|Other|Inhalation Profiling|All subjects have Inhaltion profiling, there are no other arms.
9975848|NCT01345279||cisplatin|
9975849|NCT01345279||cisplatin + topotecan|
9975850|NCT01345279||cisplatin + paclitaxel|
9975851|NCT01345331|Experimental|Real Stimulation|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain.
9975852|NCT01345331|Sham Comparator|Sham|The sham treatment will use the same equipment as the real treatment, but the participant will not receive any real stimulation to the ear.
9975853|NCT01345344|Experimental|Cognitive-Behavioral Therapy|8 individual weekly visits with a psychologist for pain-related CBT.
9695386|NCT04778917|Placebo Comparator|Vacuity contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
9695387|NCT04778917|No Intervention|contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
9678869|NCT04957589|Experimental|VLCD & HIIT|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) High intensity interval training (3x sessions per week following intensity estimation using cardiorespiratory testing (VO2max), using an established training protocol within our department) No additional protein supplementation
9975854|NCT01345344|Active Comparator|Disease Education|8 individual weekly visits with a psychologist for fibromyalgia education (this is an active comparator arm, matched for provider contact).
9678870|NCT04957589|Active Comparator|VLCD only|Very low calorie diet (standardised LighterLife meal replacement packages consisting of approximately 150kcal each, amounting to 600kcal/day, with 200kcal of a pre-determined free expenditure consisting of nuts and/or vegetables) No additional exercise or protein supplementation
9678871|NCT04957693|Experimental|treatment arm|vegan diet and lifestyle change
9678872|NCT04957680|Experimental|computer-based cognitive behavioral therapy|
9678873|NCT04957680|Active Comparator|online stress management program|
9678874|NCT04957680|No Intervention|waitlist|
9678875|NCT04957654|Experimental|VST with collagen plug soaked in blood|
9678876|NCT04957654|Active Comparator|VST with Allograft Demineralized bone matrix Grafton|
9678877|NCT04957654|Active Comparator|VST with autogenous cortical chips and bovine deprotinzed particles|
9678878|NCT04957797|Other|ROT-Group|reamed with round tunnel
9678879|NCT04957797|Experimental|FLT-Group|reamed with flat tunnel
9695388|NCT04778670|Active Comparator|Standard of Care|Standard of Care means all examinations will receive a flagging decision by: first reader and second reader radiologist as usual. However, in this paired design all participants will belong to both arms.
9695389|NCT04778670|Experimental|AI CAD combination|AI CAD combination in the primary end-point means the combination of the flagging decision of the first reader and AI CAD; in the secondary end-points it means any combination of AI alone, or AI in combination with first, second and both readers.
9975855|NCT01345344|No Intervention|Healthy Controls|No intervention.
9975856|NCT01345357|Experimental|CEP-9722 in combination with Gemcitabine and Cisplatin|Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
9975857|NCT01345370||Stupp protocole|All subjects enrolled must be treated according to the Stupp schedule : surgical resection followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles of adjuvant Temzolomide.
9975858|NCT01345383||Current smokers|
9975859|NCT01345396|Experimental|Education|
9975860|NCT01345396|No Intervention|No education|
9975861|NCT01345422|Experimental|Wii Balance Board|Wii Balance Board Training
9975862|NCT01345435|Experimental|Telemonitoring group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management"
9975863|NCT01345435|Experimental|Telemonitoring & Telemedicine group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management~taking telemedicine through video telephone instead of visiting hospital"
9695390|NCT04778865|Experimental|Vitamin D-correction|Subjects will receive one capsule with 50.000 IU cholecalciferol weekly for 3 months.
9695391|NCT04778865|Active Comparator|Vitamin D-RDA|Subjects will receive one capsule with 4.200 IU cholecalciferol weekly for 3 months.
9695392|NCT04778852|Experimental|EksoGT|Device: EksoGT. EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
9695393|NCT04778852|Active Comparator|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
9695394|NCT04778826|Active Comparator|Lung Lobectomy with standard ipsilateral lymphadenectomy|Lung lobectomy with ipsilateral lymphadenectomy
9695395|NCT04778826|Active Comparator|Lung Lobectomy with VAMLA|Lung lobectomy combined with video-assisted mediastinal lymphadenectomy through the neck (VAMLA). The approach is similar to transcervical mediastinoscopy and allows for a radical bloc dissection of all mediastinal lymph node stations. Besides the benefit of bilateral lung ventilation during this phase of the operation a bilateral mediastinal lymphadenectomy offers improved surgical radicality.
9695396|NCT04778735|Other|Pediatric Patients with Liver Transplantation|
9695397|NCT04778839|Experimental|Paclitaxel Micelles for Injection|In the First Period, Only three Participants in the first dose group were randomly assigned to 175 mg/m2 paclitaxel micelle for injection at a 1:1 rate.175 mg/m2, 260 mg/m2, 320 mg/m2, and 390 mg/m2 of paclitaxel micelle for Injection was intravenously administrated for three hours,three weeks constituted one course of treatment.
9695398|NCT04778839|Active Comparator|Paclitaxel Injection|three Participants were randomly assigned to 175 mg/m2 paclitaxel Injection,175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
9975864|NCT01345435|Other|Control group|"Blood glucose meter and body composition analyzer will be provided~Self-monitoring Blood Glucose (SMBG)"
9975865|NCT01345461||Healthy adult volunteers|Twelve healthy adult volunteers (6 men, 6 women)
9975866|NCT01345487|Other|Low Vegetable Protein|Meal with 10 E% protein from fava beans/split peas
9975867|NCT01345487|Experimental|High Vegetable protein|Meal with 20 E% protein from fava beans/split peas
9975868|NCT01345487|Experimental|High Animal Protein|Meal with 20 E% protein from pork/beef
9975869|NCT01345500|Experimental|Higher Carbohydrate/Lower Fat Diet|
9975870|NCT01345500|Experimental|Lower Carbohydrate/Higher Fat Diet|
9975871|NCT01345500|Active Comparator|Individualized Counseling|
9975872|NCT01345526|Experimental|Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream|
9975873|NCT01345526|Placebo Comparator|Metastatic colorectal cancer, Doxycycline, Cream|
9975874|NCT01345539|Other|SBRT|
9975875|NCT01345552|Other|SBRT|
9678880|NCT04957563|Experimental|experimental rehabilitation|recived olfactory rehabilitation
9678881|NCT04957563|No Intervention|control|withouth olfactory rehabilitation
9678882|NCT04957407||non-atrophic gastritis|OLGA-0 group；OLGA (Operative Link on Gastritis Assessment)
9678883|NCT04957407||mild-moderate atrophic gastritis|OLGA I-II group；OLGA (Operative Link on Gastritis Assessment)
9678884|NCT04957407||severe atrophic gastritis|OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment)
9678885|NCT04957407||gastric cancer|gastric cancer
10175733|NCT03840044|Other|Asthmatic subjects|Asthmatic patients will perform the same protocol as foreseen for healthy volunteers. They will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
10175734|NCT03839901|Experimental|isometric training programme|'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
10175735|NCT03839901|Experimental|isotonic training programme|'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.
9678886|NCT04957615|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9678887|NCT04957420||Neupro gruop|Patients using Neupro according to the standard clinical practice of therapists
9678888|NCT04957706||Acute injury|injury ≤ 2 months
10175736|NCT03840083|Experimental|Sleep|Individuals will either nap (Exps 1, 4) or have overnight sleep (Exps 2, 3, 5, 6)
10175737|NCT03840083|No Intervention|Wake|Individuals will stay awake for the same amount of time as they slept in the sleep condition
10175738|NCT03839914|Active Comparator|Intervention - Vancomycin|Intervention: 1g vancomycin powder locally applied to the deep wound and subcutaneous layer prior to closure.
10175739|NCT03839914|No Intervention|Control - No vancomycin application|No intervention, control group All other wound closure procedure and wound care and monitoring are the same
10175740|NCT03839862||Responder|Patient responding to TNF-inhibition
10175741|NCT03839862||non-Responder|Patient not responding to TNF-inhibition
10175742|NCT03840096|Experimental|Quadriceps NMES using Breg Flex|
10175743|NCT03840096|No Intervention|Control|
10175744|NCT03840252|Active Comparator|PD patients: Parkinson's disease group|"Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
10175745|NCT03840252|Active Comparator|PSP patients|"Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of probable PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
10175746|NCT03840252|Active Comparator|HC: healthy control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
10175747|NCT03839966|Experimental|Active Treatment|Interpretation Bias Modification for Loneliness
10175748|NCT03839966|Active Comparator|Control Treatment|Healthy Habits Psychoeducation and Relaxation.
10175749|NCT03839797|Experimental|Cadet Healthy Personal Skills|Cadet Healthy Personal Skills
9678889|NCT04957706||Chronic injury|injury > 2 months
9678890|NCT04957121||on-hours|"Hip surgeries with the start time of anesthesia between 8:00 and 17:59 were coded as on-hours."
9678891|NCT04957121||off-hours|"Hip surgeries with anesthesia beginning between 18:00 and 7:59 were coded as off-hours. Besides, taking the long duration of hip surgery into account, if the anesthesia began before 18:00 but ended after 20:00, it was also defined as off-hours."
9678892|NCT04957316|No Intervention|Control group|Conventional treatment of severe septic shock.
9678893|NCT04957316|Experimental|Blood purification group|Conventional treatment of severe septic shock and blood purification.
9678894|NCT04957277|Experimental|load modulation|Participants will experience different body weight loading conditions - with body weight added by a weighted vest or removed using the ZeroG overhead harness.
9678895|NCT04957108||All cardiac implantable devices|Assessed separately by Pacemaker ID app and cardia-x algorithm
9678896|NCT04957433||Cohort A|Patients new to The Lung Health Check (TLHC) pilot who are attending their first lung health check
9678897|NCT04957433||Cohort B (Nodule Suveillance)|Patients who have already undergone one lung health check as part of the TLHC programme, and are now being followed up at 3 months (B1), 12 months (B2) or other (BX) due to an indeterminate finding (e.g. lung nodule)
9678898|NCT04957433||Cohort C (Incident Scan)|Patients who are already part of TLHC attending for routine 'incident' round follow-up scanning (usually at approximately 24 months)
9678899|NCT04957433||Cohort D|Participants with interstitial lung abnormalities (ILAs) identified as part of TLHC, who are referred to the interstitial lung disease (ILD) unit at Royal Brompton Hospital.
9678900|NCT04957381||low to moderate CRF with low MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and low muscular fitness (MF).
9678901|NCT04957381||low to moderate CRF with moderate MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and moderate muscular fitness (MF).
9975876|NCT01345565|Experimental|Hepatocyte Transplantation|See Below
10175750|NCT03839797|Active Comparator|Standard Health Education|Standard Health Education
10175751|NCT03839836|No Intervention|Baseline|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack without the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
9678902|NCT04957381||low to moderate CRF with high MF|According to the senior fitness test norms in Taiwan, participants with low to moderate cardiorespiratory fitness (CRF) and high muscular fitness (MF).
9678903|NCT04957381||high CRF with low to moderate MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and low to moderate muscular fitness (MF).
9678904|NCT04957381||high CRF and high MF|According to the senior fitness test norms in Taiwan, participants with high cardiorespiratory fitness (CRF) and high muscular fitness (MF).
9678905|NCT04957355|Experimental|Experimental|"All individuals will be assigned to the experimental group and will undergo the testing and training procedure across two separate sessions. During the first session, the participants will go through the complete initial screening process. If eligible for the study, the participants will perform the experimental training protocols during the second session.~Experimental Protocol The quadriceps, hamstrings, tibialis anterior, gastrocnemius, and the trunk muscle group on the stroke-affected side (weaker side) will be stimulated according to the participant's comfort and tolerance. The range of the intensity allowed by the device is 0-50milliamperes (mA). The frequency of the electrical stimulation device ranges from 1-60Hz."
9678906|NCT04957199||Community|Individuals with or without COVID-19 in society
9678907|NCT04957329|Active Comparator|BAK-preserved|Xalatan eye drop
9678908|NCT04957329|Active Comparator|Preservative-free|Monoprost eye drop
9678909|NCT04957147||Group A: patients with dilated cardiomyopathy|Patients with recent-onset dilated cardiomyopathy
9678910|NCT04957147||Group B: healthy volunteers|Healthy volunteers with no known heart disease
9678911|NCT04957225|Experimental|Direct intervention|Goal level 60 hours of intensive treatment during 6 weeks. Intensive treatment of aphasia and AOS in ICAP-format (MIRAA).
9678912|NCT04957225|No Intervention|Waiting group|No intervention during 6 weeks, testing directly before and after the waiting period. After the waiting period the participants receives the same intervention as the direct intervention arm.
9678913|NCT04957212|Experimental|TCHP regimen (trastuzumab, pertuzumab® (CinnaGen Co.), carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; pertuzumab® (CinnaGen Co.) is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
9678914|NCT04957212|Active Comparator|TCHP regimen (trastuzumab, Perjeta®, carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; Perjeta® is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
9678915|NCT04957069||Avulsion fracture|avulsion fracture of the Achilles tendon
9678916|NCT04957069||Rupture|Achilles tendon rupture
9678917|NCT04957056||Study object|A young patient hospitalized in the Department of Neurosurgery of the Third Hospital of Beijing University of Medicine underwent CT examination of cervical vertebrae. The patient had no cervical bony deformity, no cervical degeneration, and no history of trauma
9678918|NCT04957030|Experimental|ULDCT group|underwent ultralow-dose chest CT(ULDCT)
9678919|NCT04957030|No Intervention|LDCT group|underwent conventional chest CT(LDCT)
9678920|NCT04957173|Other|Intensive lifestyle intervention|Participants will undergo an intensive lifestyle intervention, implemented virtually by a medical team with expertise in the management of T2DM. This team will be made up of an endocrinologist, a nutritionist and a nurse.
9678921|NCT04957186|Active Comparator|Patient Focus Group|Group consisting of 10 patients who have undergone breast cancer surgery (tumorectomy, mastectomy, lymph node dissection).
9678922|NCT04957186|Active Comparator|Caregiver Focus Group|Group consisting of 10 caregivers composed of 3 surgeons, 3 algologists, 3 oncologists and one study coordinator.
9678923|NCT04957251|Experimental|Anterior approach|Patient's undergoing an anterior approach to the hip
9678924|NCT04957251|Active Comparator|Posterior Approach|Patient's undergoing an posterior approach to the hip
9695399|NCT04778813|Experimental|Artemether-lumefantrin (AL)|"The tablets will be given orally according to patients' age and under supervision of study team as follows:~Day 0: H0 and H8~Day 1: H24 and H36~Day 2: H48 and H60"
9695400|NCT04778813|Experimental|Dihydro-artemisinin-piperaquin (DHA-PPQ)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
9975877|NCT01345604|Placebo Comparator|Saline|
9975878|NCT01345604|Active Comparator|Ropivicaine|
9975879|NCT01345617||cystic fibrosis patients|cystic fibrosis patients
9975880|NCT01345617||non-cystic fibrosis patients|non-cystic fibrosis patients
9975881|NCT01345643|Experimental|Hemoglobin level based on WCPT Score|According to WCPTS, the patient's hemoglobin level will be maintained not less than 7,8,9,or 10g/dL. Determination of whether a patient need red blood cells transfusion is based on WCPT Score.
9975882|NCT01345643|Active Comparator|Hemoglobin level 100g/L|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
9975883|NCT01345695||Treatment|Data collected on persons living in the catchment area for a WHP telemedicine center
9975884|NCT01345695||Control|Data collected on persons living in the catchment area where there is not a WHP telemedicine center
9975885|NCT01345734||Liraglutide|
9975886|NCT01345747|Experimental|laryngeal tube|laryngeal tube suction has suction port
9975887|NCT01345747|Experimental|endotracheal tube|
9975888|NCT01345760||Basal Cell Carcinoma|
9975889|NCT01345760||Squamous Cell Carcinoma|
9975890|NCT01345760||Actinic Keratosis|
9975891|NCT01345760||healthy non-lesional skin|
9975892|NCT01345773||Patients receiving gastric cancer surgery|
9975893|NCT01345799|Experimental|TRK-170 Low Dose|
9975894|NCT01345799|Experimental|TRK-170 Middle Dose|
9975895|NCT01345799|Experimental|TRK-170 High Dose|
9975896|NCT01345799|Placebo Comparator|Placebo|
9678925|NCT04957017|Active Comparator|Intervention group|"The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled with the volunteer ones face-to-face at their homes, complying with the social distance rules before the training. After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training. The data collection forms were re-filled three months after the training."
9678926|NCT04957017|No Intervention|Control group|The women with chronic disease were met, and the Descriptive Information Form, Social Hand-Washing Knowledge Form and the Nutritional Knowledge Level Scale for Adults were filled face-to-face at their homes with the ones volunteering to participate in the study, complying with the social distance rules. The same survey was re-filled after three months. No training was given to the women with chronic disease during the three-month period. After the research was completed, a 45 minute-training which is the same with the one provided to the intervention group was given individually to the control group, complying the social distance rules.
9678927|NCT04956731|Experimental|Pharmacist provision of medication abortion|This is a single arm study with 10 participants undergoing start to finish medication abortion provided by a pharmacist.
9678928|NCT04956666|Experimental|Lyophilized S95014|"Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL.~The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water For Injection to obtain a 750 U/mL solution for single use."
9678929|NCT04957004||OSA patients|Patients with OSA who have not been treated with CPAP
9678930|NCT04957004||control group|health control except OSA by using sleep monitorin
9678931|NCT04956874|Experimental|Experimental Group|Participants will complete the FL-REACH annualized caregiver intervention.
10175752|NCT03839836|Experimental|5% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 5%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
10175753|NCT03839836|Experimental|10% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 10%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
9678932|NCT04956874|No Intervention|Control Group|No-intervention control group
9678933|NCT04956913||Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
10175754|NCT03839836|Experimental|15% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 15%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
10175755|NCT03839836|Experimental|20% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 20%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
9678934|NCT04956913||Machintosh|Patients of this group were intubated using the classic Macintosh laryngscoscope
10175756|NCT03839849|Experimental|i-PRF (Test)|injected subgingivally i-PRF after scaling and root planing
9678935|NCT04956770|Experimental|Rehabilitation supported by TESS|"Patient will be asked to come to the hospital for three types of patient sessions:~Stimulation configuration sessions: TESS protocols will be setup and optimized during this phase.~Duration: minimum 4 sessions over 2 weeks, maximum 20 sessions over a month. In addition, some sessions at a free frequency as needed during rehabilitation will be programed (maximum once a week).~TESS-supported rehabilitation sessions: Patients will undergo an in-clinic rehabilitation training regime supported by TESS.~Duration: 24 sessions spread over minimum three months and maximum five months~Pre- and post-rehabilitation evaluation sessions: four clinical evaluation sessions will take place focusing on assessment of locomotion, balance and PD related deficits."
9678936|NCT04956614|Experimental|suture of Achilles tendon without immobilisation|
9678937|NCT04956614|Experimental|suture of Achilles tendon with immobilisation|
9678938|NCT04956861|No Intervention|Phase 1|Phase 1 is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 7 hours/night (short sleep).
9678939|NCT04956861|Experimental|Phase 2|Phase 2 is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in ART-treated HIV-1-seropositive adults who habitually sleep less than 7 hours/night.
9678940|NCT04956939||Group 1|PD patients receiving low frequency dose of levodopa.
9678941|NCT04956939||Group 2|PD patients receiving high frequency dose of levodopa.
9678942|NCT04956939||Control Group|Spouses of PD patients without PD diagnosis
9678943|NCT04956848|No Intervention|Embryo selection supported by KIDScore™ D5|Each embryo reaching at least developmental stage of 3BB will annotated by an embryologist using the parameters required by the KIDScore™ D5. The embryo with the highest KIDScore™ will be selected proposed for transfer.
9678944|NCT04956848|Experimental|Embryo selection supported by iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed selected for transfer.
9678945|NCT04956822||ALS|Amyotrophic lateral sclerosis group
9678946|NCT04956822||CMT|peroneal muscular dystrophy group
9678947|NCT04956822||KD|Kennedy's disease group
9678948|NCT04956822||Control|Healthy control group
9678949|NCT04956978|Experimental|Patient Decision Support Tool|Patient decision support tool to be used in conjunction with physician counseling to discuss the risk and benefits of systemic oral anticoagulation.
9678950|NCT04956978|No Intervention|Usual Healthcare Counseling|Traditional physician counseling regarding the risk and benefits of systemic oral anticoagulation
9678951|NCT04956562||Vaccinated with sinovac|Vaccinated COVID-19 patients over 65 years consisted the study group
9678952|NCT04956562||Unvaccinated|Unvaccinated patients over 65 years composed the control group
9678953|NCT04956432|Experimental|Treatment group A|SHR4640+Allopurinol Placebo；once a day, orally, for 16 weeks
9678954|NCT04956432|Active Comparator|Treatment group B|Allopurinol+ SHR4640 Placebo；once a day, orally, for 16 weeks.
10175757|NCT03839849|Active Comparator|saline (Control)|injected subgingivally saline after scaling and root planing
10175758|NCT03839706|Experimental|PET MRI Arm|Patient enrolled in the study will have a PET MRI exam scheduled before transplant
10175759|NCT03840070|Experimental|Potenfill|
10175760|NCT03839654|Experimental|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
10175761|NCT03839654|No Intervention|non-continuous positive airway pressure|The non-CPAP treatment group received baseline medicine treatment without CPAP treatment.
9678955|NCT04956419|Experimental|Treatment group A|SHR8008 capsule
10175762|NCT03839719|Experimental|Group OC|"Ocimum sanctum (OC) is a natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is also listed by the U.S. FDA as an herb Generally Recognized As Safe (GRAS) for its intended use as a therapeutic herb. Pharmacological constitutes present in the extract are eugenol, Urosolic acid, Carvacrol, linalool , limatrol, caryophyllene, and methyl carvicol. The literature showed that Ocimum sanctum extract has significant anti-gingivitis and anti-inflammatory effect as mouthrinse.~Other Names:~Tulsi Holy Basil"
10175763|NCT03839719|Active Comparator|Group CHX|"Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in a variety of oral disorders in various formulations.~As an antimicrobial agent, chlorhexidine is effective in vitro against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes and yeasts and fungi. The digluconate of chlorhexidine (1:6Di 4' chlorophenyl-diguani-dohexane) is a synthetic antimicrobial drug which has been widely used as a broad spectrum antiseptic.~Other Names:~Chlorhexidine"
9678956|NCT04956419|Active Comparator|Treatment group B|Fluconazole capsule
9678957|NCT04956744|Experimental|Low Dose|Low dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
9678958|NCT04956744|Experimental|High Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1.
9678959|NCT04956744|Experimental|Optional Dose|High dose of cells/kg of intravenous (IV) IMS001 as a single dose infusion on Day 1 and at Month 6.
10175764|NCT03839719|Placebo Comparator|Group PI|"Group PI: Placebo (Distilled water) as the mouthrinse.~Placebo (Distilled water) 10 ml is used as mouthrinse. Distilled water is commonly used as an excipient in a variety of drugs and it is also widely used as a placebo.~Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.~Treatment was carried out by placing 03 sterile agar plates uncovered at pre-designated sites to collect samples of aerosolized bacteria."
10175765|NCT03839615|Active Comparator|guided bone regeneration using ptfe|"Augmented anterior maxillary bone ridge using ptfe with 1:1 autogenous bone and xenograft mixture~Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~intervention:~Flap will be done.~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a ptfe membrane which will be stabilized by tacks."
9678960|NCT04956991||CDAI≤220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group A (CDAI≤220)
9678961|NCT04956991||CDAI>220|According to the Crohn's disease activity index (CDAI) scores, all the patients included in the study were divided into group B (CDAI>220)
9678962|NCT04956653||Patients diagnosed with Cervical Degenerative Disease|Patients who suffered from Cervical Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to CDD group.
9678963|NCT04956653||Patients diagnosed with Thoracic Degenerative Disease|Patients who suffered from Thoracic Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to TDD group.
9678964|NCT04956653||Patients diagnosed with Lumbar Degenerative Disease|Patients who suffered from Lumbar Degenerative Disease, treated by operation for the first time and aged 18 years old or over were assigned to LDD group.
9678965|NCT04956965|Active Comparator|Patient free cardiac amyloidosis|Patient with heart disease (related with rhythm disorders or conduction disorders) but free cardiac amyloidosis.
9678966|NCT04956965|Experimental|Patient with Transthyretin cardiac amyloidosis|Patient with transthyretin cardiac amyloidosis plus heart disease (related with rhythm disorders or conduction disorders).
9678967|NCT04956536||Group 1|Anterior cruciate ligament-injured patients
9678968|NCT04956705|Experimental|The Model for Improvement|Together with the health care staff at the nursing homes, the project group will identify which strategies to implement in order to increase the number of residents receiving the recommended daily supplements of 20 µg of vitamin D and 800-1000 mg of calcium. The Model for Improvement will be the methodological framework for defining, implementing, and evaluating strategies.
9678969|NCT04956367|Experimental|CO2 laser with PRP|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, PRP will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
9678970|NCT04956367|Placebo Comparator|CO2 laser with placebo|After anesthetizing the area and undergo one pass of ablative fractional CO2 laser (Smaxel, iDS, Korea) using the following settings: energy = 50 mJ; pulse duration = 2 ms; and density level = 15, pNSS will be injected through nappage technique at 1 cm intervals for three treatment sessions at four-week intervals.
9678971|NCT04956315||Examiner effect group|Two examiners performed the test on one healthy subject with both devices for ten consecutive days. We measured the AD of both knees and calculated the ADD of every test. We evaluated the contralateral-side effect by comparing the AD standard deviations of each knee with both devices, and compared the average ADD tested by different examiners with the same device, to estimate examiner effect.
9678972|NCT04956315||Method effect group|The experienced examiner performed tests on 20 healthy subjects using both devices. The means and standard deviations of both knees were calculated. We examined the difference in measurements using each device to determine the method effect.
9678973|NCT04956315||Equipment effectiveness group|The experienced examiner performed tests on 200 ACL ruptureand 200 healthy subjects using each device. Effectiveness was analyzed using 1.5 mm and 3 mm threshold values in ACL tears.
9678974|NCT04956601|Experimental|VBT|CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.
9678975|NCT04956601|Active Comparator|EBRT|Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.
9678976|NCT04956588|Experimental|experimental group|
10175766|NCT03839615|Experimental|collagen membrane|"Local anesthesia will be given to the patient. intervention:~Flap will be done.~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks."
9678977|NCT04956588|Active Comparator|control group|
9678978|NCT04956380|Experimental|Joint Count + Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered tender joint count (out of 68 joints on a homunculus) and self-administered Early Inflammatory Arthritis Detection Tool that were completed by the patient. Rheumatologist then uses the information provided in these tools by the patient to determine whether they should advance the urgency rating of the case.
10175767|NCT03839628|Experimental|Reduced Physical Activity|Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
9678979|NCT04956380|Experimental|Early Inflammatory Arthritis Detection Tool|Rheumatologist reviews both the self-administered Early Inflammatory Arthritis Detection Tool that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
9678980|NCT04956380|Experimental|Joint Count|Rheumatologist reviews both the self-administered Patient Tender Joint Count that was completed by the patient. Rheumatologist then uses the information provided in this tool by the patient to determine whether they should advance the urgency rating of the case.
9678981|NCT04956380|No Intervention|Control|Rheumatologist does not review any of the self-administered tools completed by the patient.
9678982|NCT04956484|Experimental|Belimumab 10 mg/kg plus standard of care|Standard of care and Belimumab: 10 mg per kilogram of body weight，days 1 (baseline), 15, and 29 and every 28 days thereafter to week 52
9678983|NCT04956484|Other|Standard of care|Standard of care: Steroid(≤1mg/kg/d) with or without proper immunosuppressants which doctors prescribed，including CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
9678984|NCT04956445||Population 1|Once a positive diagnosis of COVID-19 has been made in the clinical setting, the clinical team caring for the patient will ask the patient / family whether they would be willing to be contacted by the study team about the study. If so, a trained member of the study team will describe the study in person or by telephone. Community members who see the study flyer will also be able to reach out to the study team to learn more about the study and to find out if they meet eligibility criteria. If the eligible patient / legally authorized representative / legal guardian would like to participate. The verbal informed consent / verbal HIPAA, assent, and/or parental permission (as appropriate) will then be obtained in person.
9678985|NCT04956445||Population 2|Persons with a history of past (>14 days ago) diagnosis of COVID-19 infection will be invited to participate in this study. In addition, persons who have had significant exposure to a patient with COVID-19 (contact at a distance of less than 6 feet without personal protective equipment) and have remained asymptomatic for 14 days following exposure will be recruited. Candidates will be identified through initial enrollment in Population 1, or by clinicians who have been informed of the study but are not part of the study team. Then, the clinical care team will ask the patient if he/she is willing to be contacted by the study team. Community members who see the study flyer or are otherwise informed of the study will also be able to reach out to the study team. Additionally, individuals with no defined past COVID-19 infection, but the potential to have been exposed to, and mounted antibodies against, COVID-19 will also be enrolled in Population 2 for this study.
9678986|NCT04956328|Experimental|OCA Tablets 5-10 mg|OCA 5 mg once daily in combination with UDCA for 24 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
9678987|NCT04956328|Placebo Comparator|Placebo|Placebo once daily in combination with UDCA for 48 weeks.
9678988|NCT04956471||hospitalized patients with swallowing disorder after stroke,.|
9678989|NCT04956393|Experimental|Immediate SOAR Program|Participants with a past sport-related knee injury randomized to the 'immediate intervention' group will complete an 8-week (weeks 1-8) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) followed by an additional 8 weeks (weeks 10-17) of home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and optional weekly group-based exercise classes. Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more immediate SOAR group knee injury participants.
10175768|NCT03839576|Experimental|Computerized cognitive training|The computerized cognitive training will take place at each participant's residence. Participants will be asked to practice at least 1 session a day for 6 months, and a session lasts for 60 minutes.
10175769|NCT03839576|Experimental|Lower extremity strengthening|"This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months.~Each session will last 60 min."
10175770|NCT03839576|Experimental|Tai chi chuan|The 8-form Yang-style tai chi intervention will take place at a subject's residence or the neighborhood once a week for 6 months, and each session will last for 60 minutes.
9678990|NCT04956393|Other|Delayed SOAR Program|Participants with a past sport-related knee injury randomized to the 'delayed intervention' group will have a 9-week unstandardized delay before completing an 8-week SOAR program (weeks 10-17). During the delay (weeks 1-9) the delay comparison intervention will be unstandardized to reflect usual care in Canada. After the 9-week delay, these participants will complete an 8-week (weeks 10-17) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and an optional weekly group-based exercise classes). Consented trained physiotherapists will deliver the SOAR program from week 10 to week 17 to one or more delayed SOAR group knee injury participants.
9678991|NCT04956055|Experimental|Experiment group|Experimental group to be applied hand reflexology
9678992|NCT04956055|No Intervention|Control group|experimental group for which hand reflexology will not be applied
9678993|NCT04955912|Experimental|Experimental group|Music medicine
9678994|NCT04955912|No Intervention|Control group|not routinely do anything to reduce premenstrual symptoms
9678995|NCT04956094||First Trimester Prenatal Visit|Women attending an initial first trimester prenatal visit who will be undergoing a standard blood draw.
9678996|NCT04956250|Experimental|Traffic Calming Curb Group|
9678997|NCT04956250|Experimental|In-Street Sign Group|
9678998|NCT04955964||All Participants|Participants with diagnosis of HAE who have received at least one dose of lanadelumab according to currently approved indications in routine clinical practice settings in Argentina will be observed in this study.
9678999|NCT04956107||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
9679000|NCT04956107||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
9679001|NCT04956198||Patients with newly diagnosed as well as relapsed/refractory sarcomas.|The investigators intend to enroll newly diagnosed or refractory/relapsed pediatric patients with all types of sarcomas where tumor tissue would be available for ex vivo drug screening and genomic profiling. This observational study will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas
9679002|NCT04955977|Experimental|G1: People with a diagnosis of COPD stratified in GOLD 1-2.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~People with a diagnosis of COPD categorized in GOLD 1-2, with no record of respiratory crises in the last 3 months.~People with a diagnosis of COPD categorized by lung function in GOLD 1,2,3 and 4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~People who have read and signed informed consent and who have membership in a mandatory health plan."
9679003|NCT04955977|Experimental|G2: People with a diagnosis of COPD stratified in GOLD 3-4.|"Adult person, over 40 years of age, both sexes, resident in medium altitudes or 2,600 meters above sea level in the last 2 years.~People with a diagnosis of COPD categorized in GOLD 1,2,3 and 4, with no record of respiratory crises in the last 3 months.~People with a diagnosis of COPD categorized by lung function in GOLD 3-4 and by severity of symptoms in A, B and C, without the need for supplemental oxygen.~People with a diagnosis of COPD settled and domiciled for a minimum time of 14 months at moderate altitudes or 2600 m.a.s.l.~People who have read and signed informed consent and who have membership in a mandatory health plan."
9679004|NCT04955977|Active Comparator|G3: Control - People without a COPD diagnosis.|Healthy people, over 40 years old. No history of cigarette smoking or exposure to wood smoke. Who do not present diagnoses of musculoskeletal injuries and who are residents at 2600 meters above sea level for more than 14 months. With affiliation to a mandatory health plan and signature of informed consent.
9975897|NCT01345812|Active Comparator|urine-derived FSH|Follicle stimulating hormone
9975898|NCT01345812|Active Comparator|recombinant FSH|Follicle stimulation hormone
9975899|NCT01345825|Experimental|resistance training|
9679005|NCT04956120|Experimental|Citrate Dialysate then Standard Dialysate|Participants receiving hemodialysis using a citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a non-citrate acid concentrate dialysate (standard dialysate) for the second year of the study.
9679006|NCT04956120|Active Comparator|Standard Dialysate|Participants receiving hemodialysis using a non-citrate acid concentrate dialysate for the first year of the study, then receiving hemodialysis using a citrate acid concentrate dialysate for the second year of the study.
9679007|NCT04956211|Experimental|Non-surgical periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments .
9975900|NCT01345838||Dysplasia|Patients with developmental dysplasia of the hip undergoing PAO
9975901|NCT01345851|Experimental|Treatment (dose-escalation of RT)|Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.
9975902|NCT01345864|Other|Cohort A|Parallel design with 5 unique treatment groups Donepezil tablets and matching placebo tablets may be overencapsulated as needed.
9975903|NCT01345877|Other|gender|
9975904|NCT01345890|Experimental|electrical stimulation|stroke patients
9975905|NCT01345903|Experimental|Treatment (surgery)|Patients undergo robotic-assisted surgery using the da Vinci robot
9975906|NCT01345916|Experimental|CHF 1535 100/6 NEXT Dry Powder Inhaler®|CHF1535 100/6 NEXT DPI® 1 inhalation bis in day (b.i.d) (daily dose BDP 200/FF 12 µg)
9975907|NCT01345916|Active Comparator|CHF1535 100/6 pMDI|CHF1535 100/6 pressurisedMeterDoseInhaler 1 inhalation b.i.d (total daily dose BDP 200/FF 12 µg)
9679008|NCT04956211|Active Comparator|Conventional periodontal therapy|Oral hygiene instructions will be given to all individuals. Any hopeless tooth or categorised as irrational to treat at baseline visit will be extracted at the treatment visit(s). Supragingival cleaning and polishing of all dentition will be delivered to individuals in this group.
9679009|NCT04955925||Sevoflurane group|Anesthesia is maintained with sevoflurane during the surgery.
9679010|NCT04955925||Propofol group|Anesthesia is maintained with total venous anesthesia using propofol during the surgery.
9679011|NCT04956237||Tenonian surgery|Hospital recruitment with outpatient surgery without the presence of an anesthesiologist, without loco-regional anesthesia and without intravenous route
9679012|NCT04956237||Peribulbar surgery|Gold standard: City recruitment with outpatient surgery with the presence of an anesthesiologist and with loco-regional anesthesia
9679013|NCT04955782||62-84 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
9679014|NCT04955782||1-3 hours of abstinence|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability
9679015|NCT04955717|Experimental|Testing and treatment|Participants will receive CT and NG testing and treatment (if necessary) at their first antenatal care visit and a visit during their third trimester. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
9679016|NCT04955717|No Intervention|Standard of care|Participants will receive the standard of care for STI management, which is treatment based on signs and symptoms. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
9679017|NCT04955522||metastases|patients with spinal metastases
9679018|NCT04955522||multiple myeloma|patients with spinal multiple myeloma
9679019|NCT04955756|Experimental|mNGS group|
9679020|NCT04955756|Experimental|PCR group|
10175771|NCT03839576|No Intervention|Social interaction|Immediately after the baseline assessment, the care manager will visit the subject in this group once for comparability with the other two intervention groups.
10175772|NCT03839979||HCV positive patients|Patients tested positive for the hepatitis c virus antibodies by BIOLINE HCV kits.
9679021|NCT04955561|Experimental|Randomised to begin with oxygen-supplementation at 10L/min during ESWT|Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
9679022|NCT04955561|Experimental|Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
9679023|NCT04955561|Experimental|Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT|Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
9679024|NCT04955678|Experimental|ZG-801|
9679025|NCT04955678|Placebo Comparator|Placebo|
9679026|NCT04955665||Bone block procedure|patients with recurrent peroneal tendon dislocation underwent the bone block procedure
9679027|NCT04955665||Reattachment of the superior peroneal retinaculum|patients with recurrent peroneal tendon dislocation underwent reattachment of the superior peroneal retinaculum
9679028|NCT04955639|Active Comparator|Control|A commercially available mobile phone app and program
9679029|NCT04955639|Active Comparator|Pivot|Pivot mobile phone app and program
9679030|NCT04955548|Experimental|arthroscopic microfracture with autologous adipose gel|The experimental group will be treated with arthroscopic microfracture with autologous adipose gel.
9679031|NCT04955548|Active Comparator|arthroscopic microfracture|The control group will be treated with arthroscopic microfracture.
9679032|NCT04955574|Experimental|Probiotic + Antibiotic Placebo|
9679033|NCT04955574|Experimental|Probiotic + Antibiotic|
9679034|NCT04955574|Placebo Comparator|Probiotic Placebo + Antibiotic Placebo|
9679035|NCT04955834|Experimental|Insulin degludec injection|Insulin degludec injection subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
9679036|NCT04955834|Active Comparator|Tresiba®|Insulin degludec injection（Tresiba®）subcutaneous administration once daily for 26 weeks in combination with Oral antidiabetic drugs (OADs) used before.
9679037|NCT04955613|Active Comparator|Standard care|"12 sessions in total: sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:Mirror therapy (standard care) for a total of 10 sessions over a period of 5 weeks (15-20 minutes per session).~sessions 12: Meeting with a doctor and physical therapist."
9679038|NCT04955613|Active Comparator|MyMove/VR system|"sessions 1: Meeting with a doctor and physical therapist. sessions 2-11:MyMove devices and VR gear for a total of 10 sessions over a period of 5 weeks 15-20 minutes per session.~sessions 12: Meeting with a doctor and physical therapist."
9679039|NCT04955600||elderly patients with multimorbidity, relatives, health care personal|The care team consists of four nurses, two of whom are employed by the region and two by the municipality, 20 municipally employed assistant nurses and one physician. Other professions associated with the team are psychologist, dietitian, pharmacist, counsellor, physiotherapist, occupational therapist, and family consultants. All participants in the team will be invited to participate in the study. The technology will be place in 20-25 patients' home and patients and family members will be invited to participate in the study. Self-care education will be given to the patients and family members according to the middle-range theory of self-care of chronic illness.
9679040|NCT04955886|Experimental|Recurrent or Metastatic Nasopharyngeal Carcinoma.|Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma were given Surufatinib Combined With Toripalimab.
9679041|NCT04955873|Experimental|Test - Group A - Dentsply biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Dentsply Sirona Symbios Xenograft Granules and the resorbable collagen membrane Dentsply Sirona Symbios Collagen Membrane SR."
10175773|NCT03839979||HCV negative patients|Patients tested negative for the hepatitis c virus antibodies by BIOLINE HCV kits.
9679042|NCT04955873|Active Comparator|Active comparator - Group B - Geistlich biomaterials|"Dental extraction socket treated with the combined use of the xenogenic bone granules Geistlich Bio-oss Collagen and the resorbable collagen membrane Geistlich BioGide."
9679043|NCT04955873|No Intervention|Control - Group C - Spontaneous healing|Spontaneous postextraction alveolar healing
9679044|NCT04955795|Active Comparator|Alcohol Brief Intervention (BI)|At the time of trial enrollment, participants will receive a session of alcohol brief intervention (BI) via telephone.
9679045|NCT04955795|Experimental|Common Elements Treatment Approach (CETA) via Telemedicine|Participants will be provided with 6 to 12 weekly CETA sessions via telephone.
9679046|NCT04955509||Training|random splitting based on random sequences generated by engineers to train and optimize a machine learning model
9679047|NCT04955509||Testing|random splitting based on random sequences generated by engineers to evaluate the performance of the model
9679048|NCT04955860||Study Group|Individuals with bilateral posterior crossbite will be included.
9679049|NCT04955860||Control Group|Individuals with no anterior and/or posterior crossbite and transversal malocclusion will be included.
9679050|NCT04955483||Virtual single-energy imaging reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev)
9679051|NCT04955483||Virtual single energy (70-140Kev, interval 10Kev) combined with MAR reconstruction group|Rebuild a virtual single energy map (70-140Kev, interval 10Kev) combined with MAR reconstruction group
9679052|NCT04955847||PGE2|In period 1, the service protocol for induction at term on an unfavorable cervix indicated the use of a PGE2. In nulliparous women, Propess® was introduced intra-vaginally for 24 hours or until regular painful uterine contractions occurred. In the case of a multiparous woman, Prostine® gel, one or two mg depending on the cervical conditions at the time of induction, was introduced intravaginally and the cervix was reassessed after six hours. If the cervix remained unfavorable and the kinetics of the contractions were not optimal, a new dose of Prostine® one or two mg was administered to the patient.
9679053|NCT04955847||misoprostol|In period 2, patients who were induced with an unfavorable cervix at term were induced with misoprostol. Regardless of parity, the patient received oral misoprostol 25 μg, one tablet orally every two hours until a maximum of eight tablets per day, or 200 µg, was reached, with cessation of the tablets when painful, regular contractions were obtained.
9679054|NCT04955496||ERAS Group|Patients were treated by enhanced recovery after surgery
9679055|NCT04955496||Control Group|Patients were not treated by enhanced recovery after surgery
9679056|NCT04955470|Experimental|Intravenous ketamine|Infusion of 0.5 mg/kg of ketamine, at maximum dose of 40 mg, over 40 minutes.
9679057|NCT04955470|Active Comparator|Intravenous midazolam|Infusion of 0.03 mg/kg of midazolam, at maximum dose of 2 mg, over 40 minutes.
9679058|NCT04955470|Placebo Comparator|Intravenous saline|Infusion of 0.9% saline over 40 minutes.
9975908|NCT01345916|Active Comparator|beclomethasone dipropionate DPI|beclomethasone dipropionate 100 µg DPI, 1 inhalation b.i.d (total daily dose BDP 200 µg)
9975909|NCT01345942|Experimental|A food|
9975910|NCT01345942|Experimental|B without food|
9975911|NCT01345968|Placebo Comparator|NaCl 0.9%|
9975912|NCT01345968|Experimental|Ferinject|
9975913|NCT01345981|Experimental|lidocaine 20 mg|intravenous lidocaine
9975914|NCT01345981|Experimental|lidocaine 40 mg|intravenous lidocaine 40 mg
9695401|NCT04778813|Experimental|Artesunate-Pyronaridin (As-Pyr)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
9695402|NCT04778709|Experimental|Bone Graft A|Bone Graft A: Mixture of 25% small-particle cortical, 25% large particle cortical, 25% small particle cancellous, 25% large particle cancellous allograft
9695403|NCT04778709|Active Comparator|Bone Graft B|Bone Graft B: 100% large particle cancellous allograft
9695404|NCT04779047|Active Comparator|group 1|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days plus tocilizumab 800 mg once
9695405|NCT04779047|Active Comparator|group 2|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days and Ivermectin 36 mg at day 1,3 and 6 plus tocilizumab 800 mg once.
9695406|NCT04779203||Osseodensification|Osseodensification is a novel, biomechanical osteotomy preparation technique that preserves bone through a non-excavating drilling process utilizing specially designed burs with a tapered geometry and specially designed flutes progressively expand the osteotomy whilst compacting bone into its walls and apex.
9695407|NCT04779203||Standard Drilling|Utilizing conventional drilling technique with standard bone drilling techniques.
9975915|NCT01345981|Placebo Comparator|normal saline|2 ml
9975916|NCT01345994|Experimental|Acupuncture - local|acupuncture on forearm only
9975917|NCT01345994|Experimental|acupuncture - distal|acupuncture on both arm and leg
9975918|NCT01346007|Active Comparator|patients|Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A
9975919|NCT01346007|Active Comparator|controls|
9975920|NCT01346020||CLL|
9977574|NCT01363115|Experimental|OJ fortified with Ca and VitD|Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment) in combination with nutritional counseling
9977575|NCT01363115|Active Comparator|OJ without VitD and Ca|Regular OJ without Calcium or Vitamin D3: one 8 fluid oz serving three times/day (control)
9977576|NCT01363141|Active Comparator|Regular AGE Diet|Regular AGE Diet
9977577|NCT01363141|Active Comparator|Low AGE Diet|One year reduction in dietary AGE intake
9977578|NCT01363154|Active Comparator|Mozart K448|Treatment: music exposure to Mozart K448
9977579|NCT01363154|Placebo Comparator|Beethoven's Für Elise|Placebo: music exposure to Beethoven's Für Elise for piano
9977580|NCT01363154|No Intervention|No music exposure|Control: no music exposure
9977581|NCT01363167|Active Comparator|400 IU Cholecalciferol - Vitamin D|
9977582|NCT01363167|Placebo Comparator|Placebo|Placebo contains Fractionated Coconut Oil
9977583|NCT01363180||Control|
9977584|NCT01363180||Trauma-exposed without PTSD|
9679059|NCT04955106|Other|Sample for reliability|Reliability and validity of SEM Scanner : intra rater, inter rater and inter novice/trained 8(2 trained rater, 2 novice rater, each one performed twice)measured will be performed on each patient.
9679060|NCT04955223|Experimental|Yinhu Qingwen Granule|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day. All treatment should be used for 10 days unless all the symtopms of patient with the viral pneumonia are relieved.
9679061|NCT04955145|Active Comparator|Ruta C 60 group|Ascorbic Acid/Rutoside 60 tablet , each tablet contains: Rutin 60mg and Ascorbic acid 160mg Dosage:2 tablets three times daily for 4 months
9679062|NCT04955145|Active Comparator|C- Retard group|Ascorbic acid 500mg capsule dosage: 1 capsule two times daily for 4 months
9679063|NCT04955145|No Intervention|Control group|No intervention
9679064|NCT04955288|Experimental|Aortic balloon Assisted resuscitation group|The aortic balloon-assisted resuscitation group uses aortic balloon occlusion technology on the basis of the traditional resuscitation mode, that is, when the cardiopulmonary resuscitation begins, the aortic balloon catheter is quickly punctured and inserted to the distal end of the aortic area I via ultrasound. (Septum level), then continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
9679065|NCT04955288|Active Comparator|Traditional cardiopulmonary resuscitation group|The traditional cardiopulmonary resuscitation group uses the traditional manual chest compression mode, that is, referring to the latest version of the cardiopulmonary resuscitation guidelines, manual chest compressions are performed under the monitoring of the compression quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, Conditions such as a fixed compression position and sufficient chest wall rebound.
9679066|NCT04955288|Experimental|Esophageal cooling group|The esophageal cooling group adopts a new transesophageal cooling method, that is, an esophageal cooling catheter is placed after resuscitation in patients with cardiac arrest, and then a small temperature-controlled water circulation system is continuously perfused with 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature is adjusted Control the water circulation system to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
9695408|NCT04778683|Experimental|VR Group|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing.
9975921|NCT01346033||Those with Type 2 diabetes|All subjects have been diagnosed with type 2 diabetes.
9975922|NCT01346046||Those with Type 2 diabetes|270 subjects with Type 2 diabetes
9975923|NCT01346046||Non diabetic|30 healthy subjects
9975924|NCT01346098|Experimental|GROUP B|At the time of surgery the surgeon will directly assess pancreatic consistency and the pancreatic duct size. In the presence of a soft pancreas and a small duct (diameter <3 mm), the patient will be randomly assigned to receive either a pancreaticoduodenectomy with pancreatic anastomosis (group A) or a total pancreatectomy with IAT (group B).
9975925|NCT01346098|Active Comparator|GROUP A|
9975926|NCT01346111||generation cohort|Included 5 hospitals from Buenos Aires, Argentina
9975927|NCT01346124|Experimental|IMPT|High dose IMPT
9975928|NCT01346137|Experimental|meloxicam|15 mg versus 30 mg per day P.O for 15 days, during 3 menstrual cycles
9975929|NCT01346150||Stratum A -Typical SCID|Typical Severe Combined Immunodeficiency (SCID), Adenosine Deaminase-Deficient ADA SCID, and X-linked SCID (XSCID) who received a transplant
9975930|NCT01346150||Stratum B - Atypical SCID|Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant
9975931|NCT01346150||Stratum C - SCID w/Non-HCT Treatments|SCID who received Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) or gene therapy
9975932|NCT01346163|Active Comparator|PF-03654746|H3 receptor antagonist currently being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS) as well as with Alzheimer's disease.
9975933|NCT01346163|Placebo Comparator|Placebo|
9975934|NCT01346202||chronic pain|260 consecutive patients with verified chronic pain syndromes
9975935|NCT01346215|Experimental|Actparin® - Laboratorio Bergamo|
9975936|NCT01346215|Active Comparator|Heparin sodium - APP Pharmaceuticals|
9975937|NCT01346254|Experimental|Vildagliptin|16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily
9975938|NCT01346254|Experimental|Pioglitazone|16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily
9975939|NCT01346254|Placebo Comparator|Placebo|16 patients randomized into this arm will receive placebo medication orally once daily
9975940|NCT01346306|Experimental|DCS 1|
9975941|NCT01346306|Experimental|DCS 2|
9975942|NCT01346319|Active Comparator|Testosterone undecanoate|
9975943|NCT01346319|Placebo Comparator|Placebo|
9975944|NCT01346332||Anesthetization|
9975945|NCT01346358|Experimental|IMC-CS4 Weight Based Dosing|Participants receiving IMC-CS4 intravenously (weight based dosing)
9975946|NCT01346358|Experimental|IMC-CS4 Non-Weight Based Dosing|Participants receiving IMC-CS4 intravenously (non-weight based dosing)
9975947|NCT01346384||intracuff pressure N2O|measured intracuff pressure of LT with N2o during operative period
9975948|NCT01346423|Experimental|Intervention group|Treatment team with a physician, a physiotherapist, a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The patient meets at the outpatient clinic three times; at baseline, after 2 weeks and after 3 months. One year after baseline the patient has a telephone-follow-up. At baseline, the patient and the team works out a rehabilitation plan and in this process a new visual, educational tool is central.
9977585|NCT01363180||Trauma-exposed with PTSD|
9977586|NCT01363206|Experimental|Single arm open label|GM-CSF and Ipilimumab
9977587|NCT01363232|Experimental|BKM120 + MEK162|
9679067|NCT04955288|Active Comparator|Traditional cooling group|The traditional cooling group uses the traditional body surface ice blanket cooling method, that is, the patients with cardiac arrest lie on the temperature control blanket after resuscitation, and then use the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃ After that, adjust the ice blanket host to control the circulating water temperature to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
9679068|NCT04955353|Experimental|AVC-H2|Participants received Avicenna Hydrolyzed Chicken Collagen Type II (AVC-H2), 2.5g daily, for 8 weeks.
9679069|NCT04955353|Placebo Comparator|Placebo|Participants received placebo of matching amount to that of AVC-H2 daily for 8 weeks.
9679070|NCT04955093|Experimental|Intervention|
9679071|NCT04955093|No Intervention|Control|
9679072|NCT04955262|Experimental|Part 1 Initial Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214, 3 injections of 89Zr-Df-IAB22M2C, and 6 PET/CT scans. Starting with Cycle 2, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. Once the PET/CT imaging data from Part 1 have been reviewed, Part 2 will open for enrollment.
9679073|NCT04955262|Experimental|Part 2 Expansion Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214 or nivolumab, 2 injections of 89Zr-Df-IAB22M2C, and 3 PET/CT scans. In Cycle 2 and beyond, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. During Cycle 2, patients will receive 1 injection of 89Zr-Df-IAB22M2C and 1 PET/CT scan.
9679074|NCT04955301|No Intervention|Control message group|Participants will not receive the priming manipulation.
9679075|NCT04955301|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
9679076|NCT04955301|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
9679077|NCT04955301|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
9679078|NCT04955366|Active Comparator|Belatacept group (Control Group)|"Participants will receive the following:~Belatacept: 5 mg/kg i.v. monthly~Blood draws for PD studies at baseline/Month 0 and Month 6 fora total of two timepoints.~HLA labs at 6, 12 and 24 months~Basic chemistry panel (CP Basic) every 3 months per clinical protocol for efficacy analysis~Hemoglobin A1c at Screening visit~Urine pregnancy test via test kit for WOCP at Screening visit"
9679079|NCT04955366|Experimental|Abatacept Group (Conversion Group)|"Participants will receive the following:~Abatacept 125 mg s.c. weekly~Safety labs every 2 weeks (months 0-3) then monthly (months 4-12)~Blood draws forPK atMonth 6, Month 12, and two random time points in between Month 6 and Month 12 for a total of four time points.~Blood draws for PD studies at baseline/Month0 and Month 6 fora total of two timepoints.~HLA labs at 6, 12 and 24 months~Basic chemistry panel (CP Basic) at each study visit per clinical protocol for efficacy analysis~Hemoglobin A1c at Screening visit~Urine pregnancy test via test kit for WOCP at screening"
9679080|NCT04955197||the histo-pathological picture|"In the present study, the exfoliated cytology of group II and III will be compared to the histo-pathological picture of the lesion reference standard. That is because the histopathology analysis is the definitive diagnosis of oral mucosal lesions"
9679081|NCT04955119|Experimental|Fusion imaging contrast-enhanced ultrasound LI-RADS|"Fusion imaging contrast-enhanced ultrasound will be performed in patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
9975949|NCT01346423|Active Comparator|Controll group|The brief intervention is a standardized intervention based on the studies by Indahl and Hagen. Therapist treatment manuals will be written for the intervention. The essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. Unless symptoms and clinical findings indicate some serious disease, the patients will be informed about the good prognosis, and the importance of staying active to avoid development of muscle dysfunction.
9975950|NCT01346436|Active Comparator|Robotic|Use of daVinci surgical system (Intuitive Surgical Inc, Sunnyvale, CA) for the treatment of complex pelvic floor dysfunction
9975951|NCT01346436|Active Comparator|Laparoscopy|Use of standard laparoscopy for the treatment of complex pelvic floor dysfunction
9975952|NCT01346449|Active Comparator|Visual cue absent|
10175774|NCT03839667|Experimental|intensive diet intervention group|The participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
9679082|NCT04955067||Normal control group-Grade 0|Arthroscopic examination of the ankle joint was normal, and the ligament was intact without injury or tear.
9679083|NCT04955067||Ligament injury -Grade 1|Arthroscopic examination of the ankle joint showed ligament degeneration or injury, but no local or complete tear.
9679084|NCT04955067||Ligament tear-Grade 2|Arthroscopy of the ankle joint revealed partial or complete loss of ligaments.
9679085|NCT04955379|Other|Measurements|Subjects will be tested with the Autorefractor and the EQ103 device
9695409|NCT04778683|No Intervention|Control Group|The same evaluations were performed in children in the control group who received routine clinical care.
9695410|NCT04778605||Patients with septic shock stabilized between H6 and H24 of treatment under noradrenaline.|
9975953|NCT01346449|Experimental|Calorie information present|
9975954|NCT01346449|Active Comparator|Calorie information absent|
9975955|NCT01346449|Experimental|Visual cue present|
9679086|NCT04955418|Active Comparator|Epi-no Group|The study group was evaluated before the intervention (between 30 and 32 weeks) and 6 months after delivery.From the 34th week onwards, they performed 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device. The pregnant woman was placed in the supine position and EPI-NO® was inserted into vaginal canal. After the introduction of the deflated tube, it was minimally inflated until the perception in the vaginal canal. The first 5 minutes were for perception of the pelvic floor with 10 contractions and relaxation of the perineum in order to maintain muscle strength. After 15 minutes for stretching the perineum, the device was gradually inflated and always respecting the pregnant woman's tolerance. After a total of 20 minutes, the pregnant woman was asked to relax the pelvic floor in order for the inflated device to gently exit her vaginal cavity. The perimeter was measured using a tape measure in its largest diameter.
9679087|NCT04955418|Placebo Comparator|Control Group|The control group was evaluated only once, six month after delivery.
9679088|NCT04955392|Experimental|Intervention group|Group of patients that will receive the 4 techniques proposed to evaluate the changes on sleep quality
9679089|NCT04955392|Sham Comparator|Control group|Group of patients that will receive a sham technique
9679090|NCT04955171|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections( monthly) then under treat and extent regimen
9679091|NCT04955171|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections( monthly) then under treat and extent regimen
9679092|NCT04955002||Healthy UK adults|Healthy UK adults
9679093|NCT04954963||conventional examination|patients undergo conventional examination
9679094|NCT04954963||Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
9679095|NCT04954950||sports injuries|Patients were classified according to self-reported years of participation in skiing and snowboarding: beginner (first season), medium (1-5 years), advanced (5-10 years) and expert (≥10 years). Date of injury was divided into weekdays and weekends/ holidays according to the Chinese government holiday arrangement.
9679096|NCT04955054||control|patients without coronary artery disease
9679097|NCT04955054||UAP|patients without unstable angina pectoris
9679098|NCT04955054||AMI|patients with acute myocardial infarction
9679099|NCT04954781|Experimental|TACE in combination with Tislelizumab|
9679100|NCT04954664|Experimental|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
9679101|NCT04954664|Active Comparator|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
9679102|NCT04955041||mild CSM|preoperative modified Japanese Orthopedic Association (mJOA) score ≥15
9977588|NCT01363245|Experimental|Hospital phone counseling|multisession telephone counseling by hospital/study's smoking cessation staff
10175775|NCT03839667|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
9679103|NCT04955041||moderate CSM|preoperative mJOA score 13~14
9679104|NCT04955041||severe CSM|preoperative mJOA score ≤12
9679105|NCT04954703|Experimental|Muscle energy technique of gluteus maximus and tensor fascia lata|INTERVENTIONAL GROUP (muscle energy technique of gluteus maximus and tensor fascia lata)
9679106|NCT04954703|Active Comparator|Myofascial release of iliotibial band|CONTROL GROUP(Myofascial release of iliotibial band)
9679107|NCT04954625|Experimental|Autologous Blood Patch|
9679108|NCT04954625|Active Comparator|Standard of Care (Per physician)|
9679109|NCT04955028||intraoperative massive hemorrhage|blood loss of ≥200 mL with or without artery embolization (UAE) or local CSP resection by laparoscopy or laparotomy as additional interventions.
9679110|NCT04955028||the non-massive hemorrhage group|blood loss of <200 mL
9679111|NCT04954885||Ancillary-correlative (biospecimen, questionnaire, testing)|Patients receive treatment by their treating physician as described in the INSIGNA protocol based on their designated treatment arm. Patients then undergo stool sample collection, complete questionnaires and functional status assessments, such as short physical performance battery over 10 minutes and 6 minute walk test, at baseline, days 40 (cycle 3), day 80 (cycle 5), day 180 (cycle 10) and end of treatment (up to 2 years).
9679112|NCT04954534|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood-derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
9679113|NCT04954573|Other|Morphea|
9679114|NCT04954573|Other|Sclerotic graft-versus-host disease (GVHD)|
9679115|NCT04954716|Experimental|Deep Neck Flexor Massage|INTERVENTIONAL GROUP(DEEP Neck FLEXOR MASSAGE)
9679116|NCT04954716|Active Comparator|Post-Isometric Relaxation Technique|CONTROL GROUP (POST-ISOMETRIC RELAXATION TECHNIQUE)
9679117|NCT04954729||Experimental Group|The experimental group underwent neuropsychological testing, 18F-FDG PET/CT, 3T resting state fMRI examinations.
9679118|NCT04954729||MRI Control Group|The MRI control group underwent neuropsychological testing and 3T resting state fMRI examinations
9679119|NCT04954729||PET Control Group|The PET control group underwent 18F-FDG PET/CT examination
9679120|NCT04954560|Active Comparator|losartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
9695411|NCT04778488|Other|NIRS diagnostics|NIRS measurement
9695412|NCT04778696|Active Comparator|conventional pace mapping|Conventional PVC pace mapping without visual guidance of PASO
9977589|NCT01363245|Active Comparator|Fax-to-quit|Faxed referral to the state Quitline, which will then perform phone outreach as per Quitline protocol
9977590|NCT01363271||complicated skin and skin structure infections (cSSSI)|Identified through a pre-specified list of ICD-9 codes in study protocol.
10175776|NCT03839667|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
10187201|NCT03728608|Active Comparator|Group 1--Short Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 0-48 hours for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
9695413|NCT04778696|Experimental|PASO pace mapping|PASO pace mapping with visualisation in CARTO3
9975956|NCT01346527||Type 2 diabetes|"Women will be diagnosed with type 2 DM (pre-gestational, White classification B or C class). Since the majority of women with B or C class DM are on insulin therapy in our clinic, we will recruit only women on insulin therapy (i.e. no oral diabetes medications).~HbA1C ≤ 8 for greater than 3 months32, 33.~All women will have confirmed singleton pregnancies.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Pre-pregnancy BMI is anticipated to be >30 (i.e. obese) from the data regarding the patient population of our clinic. Women with pre-pregnancy BMI between 23-40 will be included."
9975957|NCT01346527||Healthy, obese pregnant controls|"No diagnosis of type 1 or 2 diabetes or previous gestational DM.~Women with pre-pregnancy BMI between 30-45: control participants will be BMI matched to women with DM.~A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Patients will have a singleton pregnancy with no fetal abnormalities (as determined by routine standard of care ultrasonography)."
9977591|NCT01363271||Pneumonia|Identified through a pre-specified list of ICD-9 codes in study protocol.
10187202|NCT03728608|Active Comparator|Group 2--Long Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 7 days for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
10187203|NCT03728569|Other|Subjects over the age of 70 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
10187204|NCT03728569|Other|Subjects between 18 and 30 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
10187205|NCT03728543|Experimental|Children 0-2yo|Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
10187206|NCT03728543|Active Comparator|Children 2-18yo|Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
10187207|NCT03728530|Experimental|Experimental Group|Deep /breathing exercises including Purse lip, diaphragmatic breathing and powered breathing
10187208|NCT03728530|No Intervention|Control Group|The participants from control group did not perform any exercise.
10187209|NCT03728504|Experimental|ASN002 40 mg|40 mg ASN002
10187210|NCT03728504|Experimental|ASN002 80 mg|80 mg ASN002
10187211|NCT03728504|Placebo Comparator|Placebo oral tablet|Matching placebo for ASN002 doses
10187212|NCT03728491|Experimental|Healthy Figurant|Hands-on training on healthy figurants for gaining competence in TUS
10187213|NCT03728491|Experimental|Simulator|Hands-on training on US Mentor simulator for gaining competence in TUS
10187214|NCT03728491|No Intervention|Controls|Controls with no hands-on training
10187215|NCT03728478|No Intervention|Treatment arm 1: Step-up|JIA patients managed with a Treat-To-Target strategy (T2T)
10187216|NCT03728478|Experimental|Treatment arm 2: Step-down|JIA patients treated with an early combined therapy
10187217|NCT03728465|Experimental|Treatment Phase|"Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only ."
10187218|NCT03728439|Experimental|Before|LED applications at the beginning, with a dose of 8 J/cm2, will be performed shortly after the blood collections, with a maximum period of 10 minutes, in which the participants of the other groups should remain in rest passive. At the end of these 10 minutes, a 5 minute warm up will be performed and then the tests will be started.
10187219|NCT03728439|Experimental|Interval|The LED therapy applied in the tests interval will be performed after the first block of tests, with a maximum duration of 10 minutes and dose of 8 J/cm2. Then the second block of maximum tests will be performed.
10187220|NCT03728439|Experimental|After|LED applications at the end will be performed 10 minutes after the second battery of tests, also with 8 J/cm2 and in the same muscles irradiated in the other moments of application.
10187221|NCT03728439|No Intervention|Baseline|On that day, participants will not receive any intervention.
10187222|NCT03728413|Other|Elderly Non-smoking|RSV A Memphis 37 will be given as intra-nasal drops.
10187223|NCT03728413|Other|Elderly ex and current smokers|RSV A Memphis 37 will be given as intra-nasal drops.
10187224|NCT03728413|Other|Young non-smokers|RSV A Memphis 37 will be given as intra-nasal drops.
10187225|NCT03728387|Experimental|osteoarthritis and clinical pilates exercise|34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section.
10187226|NCT03728374|Experimental|Anlotinib|
10187227|NCT03728335|Experimental|Treatment (enasidenib mesylate)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
10187228|NCT03728322|Experimental|iHSCs treatment group|
10187229|NCT03728296|Experimental|islet body treatment group|
9679121|NCT04954560|Active Comparator|eprosartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
9679122|NCT04954872|Active Comparator|Training as usual|Standard Problem Management Plus training.
9679123|NCT04954872|Experimental|Equip-based training|Training that uses the Equip platform to assess competencies and incorporate this information into trainers and supervisors activities.
9679124|NCT04954651||VAC|Vaccinated subject against Sars-Cov2
9679125|NCT04954794|Experimental|TACE in combination with Sintilimab plus a bevacizumab biosimilar|
9679126|NCT04954599|Experimental|Module 1A Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 monotherapy in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
10175777|NCT03839758|Active Comparator|TSA Standard|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
10175778|NCT03839758|Active Comparator|RTSA standard|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
10175779|NCT03839758|Experimental|TSA blueprint|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
10175780|NCT03839758|Experimental|RTSA blueprint|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
10175781|NCT03839771|Placebo Comparator|Arm A: Placebo|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |~The dosage for Placebo for AG-120 (IDH1): 500 mg dose/day~The dosage for Placebo for AG-221 (IDH2): 100mg dose/day"
9679127|NCT04954599|Experimental|Module 1B Monotherapy Dose Expansion Cohort|Expansion cohort dosing CP-506 monotherapy in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
9679128|NCT04954599|Experimental|Module 2A Combination with carboplatin Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with carboplatin in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
9679129|NCT04954599|Experimental|Module 2B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with carboplatin in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
10175782|NCT03839771|Experimental|Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |~The dosage for AG-120 (IDH1): 500 mg dose/day~The dosage for AG-221 (IDH2): 100mg dose/day"
10175783|NCT03839589|Experimental|MBSR-A|Intervention Mindfulness Condition: MBSR is a structured intervention delivered through an 8-week course. Mindful breathing, awareness, walking, and attention are core activities taught and practiced during and outside of the course.
10175784|NCT03839589|Placebo Comparator|Wait-listed MBSR-A|The MBSR-A Wait-listed group: This wait-listed group will be followed with the same outcome assessments as the MBSR- A immediate group but will receive no intervention until after outcomes from group 1 are collected at 3 months, when they will also receive the MBSR-A
9679130|NCT04954599|Experimental|Module 3A Combination with Immune Checkpoint Inhibitor Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with Immune Checkpoint Inhibitor in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
9679131|NCT04954599|Experimental|Module 3B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with Immune Checkpoint Inhibitor in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
10175785|NCT03839732||Vascular Calcification Group|Patients with prevalent vascular calcifications will be analysed to verify the intra- and inter-observer reliability of the score of abdominal aorta calcifications
10175786|NCT03840213||Patients undergoing chemotherapy treatment|Patients over 18 years of age, followed at the ICLN day hospital or hospitalized and undergoing chemotherapy treatment
10175787|NCT03839784||Neurocognitive Assessment Arm|
9679132|NCT04954755||RFS|
9679133|NCT04954755||non-RFS|
9679134|NCT04954846|Experimental|OMNi-BiOTiC SR-9|Treatment is taken twice a day for 3 months
9679135|NCT04954846|Placebo Comparator|Control|Placebo is taken twice a day for 3 months
9679136|NCT04955015||patients|patients with caotid atherosclerosis refering to carotid endarterectomy
9679137|NCT04954924|No Intervention|Control group - standardized physiotherapy program|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes.
9679138|NCT04954924|Experimental|Experimental group - standardized physiotherapy program and Kinesio tape|The standardized physiotherapy program was designed on the basis of S. van Grinsven et al.'s (2010) rehabilitation protocol - was applied 4 weeks, 3 times per week, the duration of the procedure was 60 minutes. The Kinesio tape (KT) technique was chosen on the basis of K. Kase et al.'s (2003) recommendations. KT (Japan) was applied to the injured leg using muscular and functional-corrective techniques on the quadriceps femoris and the hamstring muscle. There were 6 KT procedures per participant in the experimental group. The CON group received KT only during the baseline and final assessment to assess short-term effect of KT.
9679139|NCT04954638||sodium hypochlorite|group 1: control group with sodium hypochlorite desinfection
9679140|NCT04954638||hyperpure chlorine dioxide|group 2: study group with hyperpure chlorine dioxide desinfection
9679141|NCT04954378||Positive lymph node metastasis|pathological diagnosis :Positive lymph node metastasis
9679142|NCT04954378||Negative lymph node metastasis|pathological diagnosis :Negative lymph node metastasis
9679143|NCT04954508||P|patients suffering form shoulder pain and/or weakness or dislication
9679144|NCT04954482||The experimental group|The included specimens were used to establish a new posterior fork reconstruction procedure.
9679145|NCT04954482||The validation group|The included specimens were used to validate the new posterior fork reconstruction procedure.
10175788|NCT03839940|Experimental|Group I (dexamethasone)|Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
10175789|NCT03839940|Placebo Comparator|Group II (placebo)|Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
9679146|NCT04954209||Hospital program of resumption|Program of resumption with physical activities in the hospital
9679147|NCT04954209||Non hospital program of resumption|Program of resumption outside hospital with discovery sessions
9679148|NCT04954456|Experimental|QLS31901|"Part 1 (Dose escalation): QLS31901will be administered in sequential cohorts each receiving 1 of 6 doses of QLS31901 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The PK parameters of QLS31901 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
9975958|NCT01346527||Healthy, Lean Controls|No diagnosis of type 1 or 2 diabetes or previous gestational DM. 2) Women with pre-pregnancy BMI between 21-25.9 3) A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
9975959|NCT01346553|Experimental|ESVV treatment|using ESVV device
9679151|NCT04954417||MSCT image|Scanning of the vertebral body using MSCT
9679152|NCT04954417||micro-CT image|Scanning of the vertebral body using micro-CT
9679153|NCT04954170||RCT patients|Patients suffering from rotator cuff injury
9679154|NCT04954300||open|open: open ICU
9679155|NCT04954300||negative|negative: negative-pressure laminar flow ward
9679156|NCT04954300||positive|positive: laminar flow ward
9679157|NCT04954391|Active Comparator|PRF one nerve|Ultrasound guided PRF neuromodulation of suprascapular nerve and block axillary nerve, and articular branch of the lateral pectoral nerve with ropivacaine and dexamethasone
9679158|NCT04954391|Active Comparator|PRF three nerves|Ultrasound guided PRF neuromodulation of suprascapular, axillary nerves, and articular branch of the lateral pectoral nerve
9679159|NCT04954144|Experimental|Leap Motion Sensor|The Leap Motion Sensor is an optical hand tracking module that captures the movements of hands with unparalleled accuracy.
9679160|NCT04954144|Experimental|Neurodevelopmental Treatment Approach|Neurodevelopment treatment approach is used to influence the quality of the motor response and is carefully matched to the patient's abilities to use sensory information and adapt movements.
9679161|NCT04954235||Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia who received treatment with 2 infusions of 4 mg / Kg each of hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) separated by 48 hours
9679162|NCT04954235||Not Exposed to Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments|Group of patients with severe pneumonia not exposed to hyperimmune anti-SARS-CoV-2 serum (INM005, CoviFab®) during hospitalization corresponding to the period prior to the approval of the hyperimmune anti-SARS-CoV-2 serum for its use.
9679163|NCT04954118|Active Comparator|Group P|The clinicians performed an internal jugular vein cannulation using only personal protective equipment.
9679164|NCT04954118|Active Comparator|Group P&A|The clinicians performed an internal jugular vein cannulation using personal protective equipment and aerosol box.
9679165|NCT04954404|Experimental|Transcatheter mitral valve repair/replacement|
9679166|NCT04954443|Experimental|Removing urinary catheter at 24 hours after surgery|The participants will removing urinary catheters at 24 hour after vaginal surgery of pelvic organ prolapse.
9679167|NCT04954443|Placebo Comparator|Removing urinary catheter at 48 hours after surgery|The participants will removing urinary catheters at 48 hour after vaginal surgery of pelvic organ prolapse.
9679168|NCT04954430||fatigue|After enrollments, subjects were assigned to perform mental fatigue-inducing experiment-a 90 min of monotonous simulated driving task. They underwent repeated measurements of quantitative pupillary light reflex (PLR) using an automated quantitative pupillometer at baseline and at an interval of 30 min during the task. Subjective ratings, heart rate variability (HRV), and electroencephalography (EEG) were performed simultaneously.
9679169|NCT04954092|Experimental|1/10 of full adult dose|
10175790|NCT03839602|Experimental|reducing CTV|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC. The prescribe doses of GTVnx, GTVnd, CTV1 and CTV2 were 68Gy, 60-66Gy, 60Gy and 50-54Gy in 30 fractions, respectively.
10175791|NCT03839810|Experimental|stochastic resonance|stochastic resonance electrical stimulation is applied to the upper extremity during the subjects perform upper extremity motor function.
10187230|NCT03728283|Active Comparator|Conventional Implant placement|conventional implant placement following the manufacturer's instructions
9679170|NCT04954092|Experimental|1/5 of full adult dose|
9679171|NCT04954092|Experimental|Selected dose for second stage of the trial|
9679172|NCT04954092|Placebo Comparator|Placebo for second stage of the trial|
9679173|NCT04954274|Experimental|Fertiline group|Treated by supplementation of the culture medium with the molecule.
9679174|NCT04954274|No Intervention|Control group|No supplementation
9679175|NCT04953728|Experimental|Subjects with IBS-C|All participants will receive all treatment options. Each participant will receive all of the following treatments; 100 Hz ST36, 100 Hz PC6, 25 Hz ST36, 25 Hz PC6, as well as the sham comparator. Each administration will be performed on different dates, between 1 and 3 weeks apart.
9679176|NCT04953819||Revascularization group|This group includes patients with dialysis who have received revascularization by percutaneous coronary intervention or coronary artery bypass grafting for coronary artery disease.
9679177|NCT04953819||Medical treatment group|This group includes patients who have received medical therapy for coronary artery disease, not percutaneous coronary intervention or coronary artery bypass grafting.
9679178|NCT04953858|Other|Social Network Strategy|All study participants will receive social network strategy intervention as linkage method to receive HIV testing and care
9679179|NCT04953676|Other|Control Group|round tunnel
9679180|NCT04953676|Experimental|Experimental group|flat tunnel
9679181|NCT04953936|Experimental|HMB|The participants will receive oral HMB-enriched nutritional supplements (65 g once daily)
9679182|NCT04953936|Placebo Comparator|Placebo|The participants will receive a placebo (maltodextrin 65 g once daily) with the same package as the intervention.
9679183|NCT04953767|Experimental|Blue light therapy|The participants receive blue light therapy for 2hours, between 8am to 12pm in the morning.
9679184|NCT04953767|Sham Comparator|White light|The participants receive white light for 0.5 hour, between 8am to 12pm in the morning.
9679185|NCT04953754|Experimental|Melatonin Group|This group will get melatonin 5mg nightly
9679186|NCT04953754|Active Comparator|Control Group|This group will not get any treatment (melatonin)
9679187|NCT04953923|Experimental|Treatment A|Cedazuridine at a therapeutic dose
9679188|NCT04953923|Experimental|Treatment B|Cedazuridine at a supratherapeutic dose
9679189|NCT04953923|Placebo Comparator|Treatment C|Placebo control
9679190|NCT04953923|Active Comparator|Treatment D|Moxifloxacin positive control
10175792|NCT03839810|Sham Comparator|sham stimulation|sham electrical stimulation (same electrode location, but no electrical current is applied) is applied to the upper extremity during the subjects perform upper extremity motor function.
9679191|NCT04953715||1 - This is a multicenter microbiome and pharmacokinetic study.|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied. To assess the relationship between kidney graft outcomes and stool, oral, nasal and urine microbiome diversity. To assess the relationship between transplant graft outcomes and urinary transcriptome.
9679192|NCT04953793|Experimental|TAY SUCCESS intervention|This intervention group received the TAY SUCCESS intervention over the course of 1 school year approximately 30 sessions.
10175793|NCT03839563|Experimental|Conventional exercise|This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months. Each session will last 60 min.
10175794|NCT03839563|Experimental|Tai chi chuan|The 8-form Yang-style tai chi chuan intervention will take place at a subject's residence or in the neighborhood once a week for 6 months, and each session will last 60 min.
9679193|NCT04953793|Active Comparator|Usual Care|This usual care group received typical High school or transition program curriculum over the course of 1 school year.
9679194|NCT04953871|Experimental|Spondyloarthritis|Spondyloarthritis patients who was initiated TNF alfa blocker
10175795|NCT03839563|No Intervention|Health education/usual physical activity|After the baseline, the case manager will visit subjects in this group once for comparability with the other two intervention groups and instruct them to maintain their usual physical activity.
10175796|NCT03839550|Experimental|Apatinib Mesylate +SHR-1210|Experimental arm: Apatinib mesylate +PD-1 antibody SHR-1210 for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
10175797|NCT03839550|Active Comparator|Hepatic Arterial Infusion(HAI)|Active Comparator arm: HAI for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
9679195|NCT04953741|Active Comparator|Stop Fluticasone propionate Inhaled Aerosol Firstly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day
9679196|NCT04953741|Active Comparator|Stop Montelukast Secondly|Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day
9679197|NCT04953741|Active Comparator|Stop Montelukast Firstly|stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day
9679198|NCT04954014|Experimental|BEVACIZUMAB|Patients will receive best available treatment (BAT) for COVID-19 plus single dose bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
9679199|NCT04954014|Active Comparator|BEST AVAILABLE TREATMENT|Patients will receive best available treatment for COVID-19.
9679200|NCT04953663|Experimental|Low dose group|0.5 × 10 ^ 6 / kg (body weight) of it-hMSC per person
9679201|NCT04953663|Experimental|Middle dose group|1 × 10 ^ 6 / kg (body weight) of it-hMSC per person
9679202|NCT04953663|Experimental|High dose group|2 × 10 ^ 6 / kg (body weight) of it-hMSC per person
9679203|NCT04953663|Experimental|Highest dose cell group|Highest dose of it-hMSC
9679204|NCT04953663|Experimental|Sub high dose cell group|Sub high dose of it-hMSC
9679205|NCT04953663|Placebo Comparator|placebo group|placebo
9679206|NCT04954040|Experimental|Hydroxychloroquine + Azithromycin|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin. 1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0~Oral intake in all cases. Pills will be taken simultaneously."
9679207|NCT04954040|Active Comparator|SOC (Standard of Care)|"SOC for symptoms treatment~Acetaminophen or Metamizole, 1-1-1 Antitussives if needed"
9679208|NCT04953585||Normal D-dimer group|preoperative plasma D-dimer levels less than or equal to 1mg/L
9679209|NCT04953585||Elevated D-dimer group|preoperative plasma D-dimer levels greater than 1mg/L
9679210|NCT04953533||patients with gout|"age:year of 25~60;~consistent with the 2015 ACR gout diagnostic criteria ,and serum uric acid >420umol/L;~The patient are willing to take part in our study."
9679211|NCT04953533||patients with hyperuricemia|"age:year of 25~60;~A medical record in our hospital showed that the person is healthy, without key disease;~serum uric acid >420umol/L without gout flares."
9679212|NCT04953533||healthy controls|"age:year of 25~60;~A medical record in our hospital showed that the person is healthy, without key disease;~serum uric acid ≤420umol/L."
9679213|NCT04953572|Experimental|test group|Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy
9679214|NCT04953572|Active Comparator|control group 1|Patients in the control group 1 received microfracture surgical treatment
9679215|NCT04953572|Active Comparator|control group 2|Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane
9679216|NCT04953572|Active Comparator|control group 3|Patients in the control group 3 received autologous osteochondral transplantation
9679217|NCT04953637|Experimental|Physiotherapy group|Participants assigned to the physiotherapy group will receive physiotherapy treatment at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks. They will begin to receive the physiotherapy treatment at 4 months following their surgery and once their DBS settings are optimized.
9679218|NCT04953637|No Intervention|Control group|Participants assigned to the control group will not receive any additional intervention and will be precluded from starting formal physiotherapy for the duration of the study. However, they will be encouraged to keep an active lifestyle. In order to stay active, they will be recommended to do simple home exercises following a home exercise video that will be presented to them. They will be asked to do it 3 times/week for 8 weeks and keep an exercise log to help them stay on track.
9679219|NCT04953429||nurses|nurses in a third-grade hospital in Beijing
9679220|NCT04953416|Experimental|Scalp treatment with ResurFX|
9679221|NCT04953351|Experimental|cognitive registration targeted biopsy|
9679222|NCT04953351|Active Comparator|MRI-ultrasound fusion targeted biopsy|
9679223|NCT04953481||Amyotrophic lateral sclerosis group|Patients with amyotrophic lateral sclerosis undergoing home care.
9679224|NCT04953481||Caregiver group|Caregivers
9679225|NCT04953832|Experimental|Cognitive Training + exposure|Participants will complete adaptive computerized cognitive training plus a series of speech tasks
9679226|NCT04953832|Active Comparator|No training + exposure|Participants will complete a low-dose computerized cognitive program plus a series of speech tasks
9679227|NCT04953949|Experimental|NU-MAX®|Topical Hemostat
10175798|NCT03839498|Experimental|Axitinib (AG-013736)|Subjects with Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma will receive 16 weeks of therapy (Axitinib), and be seen in clinic every 4 weeks to monitor therapy.
10175799|NCT03839524|Experimental|TG4050 arm|Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.
9695414|NCT04778527|Experimental|Over-encapsulated DPP|A single, over-encapsulated DPP taken once daily for three 28-day cycles (Regimen A) followed by two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles (Regimen B)
10175800|NCT03839485|Active Comparator|Pasta Guedes-Pinto|Endodontic treatment using Guedes-Pinto Paste
10175801|NCT03839485|Experimental|Pasta Guedes-Pinto without antibiotic|Endodontic using Guedes-Pinto paste without antibiotic
10175802|NCT03839420|Experimental|CZM IOL|
10175803|NCT03839420|Active Comparator|Competitor IOL|
10175804|NCT03839251|Other|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
10175805|NCT03839342|Experimental|Binimetinib + Encorafenib|Binimetinib and encorafenib are administered orally on a twice daily or once daily schedule, respectively in 28-day cycles. Treatment will continue until it is discontinued due to unacceptable toxicity, clinical or radiological disease progression as per RECIST 1.1, investigator decision, and/or withdrawal of consent.
9695415|NCT04778527|Experimental|Two Separate Tablets|Two separate tablets (oral PrEP and COC) taken once daily for three 28-day cycles followed by a single, over-encapsulated DPP taken once daily for three 28-day cycles
9695416|NCT04778761|No Intervention|Usual Care|Usual care entails receiving usual medical care by the home-based care team.
9695417|NCT04778761|Experimental|Video intervention|In addition to usual care, the intervention will entail having a visit by a trained study clinician to provide access to the ACP video. The study clinician will discuss the content of the video and answer any questions.
9695418|NCT04778514|Experimental|Over-encapsulated DPP|This arm is a single, over-encapsulated DPP containing PrEP and a COC taken once daily for three 28-day cycles.
9695419|NCT04778514|Experimental|Two Separate Tablets|This arm is two separate tablets (PrEP and COC) taken once daily for three 28-day cycles.
9695420|NCT04778358|Experimental|OOCYTE DONORS|Administration of a higher dose of Rekovelle (follitropin delta) to increase the ovarian response to 17 oocytes (the optimal range being 15 to 25 oocytes) in an oocyte donor population without compromising safety and efficacy.
9695421|NCT04778475|Experimental|Group A|The treatment group will receive increased frequency of PT services within the first 3-5 days of admission, followed by daily PT services for the duration of their inpatient stay.
9695422|NCT04778475|Active Comparator|Group B|The control group will receive standard care of PT services 3-5 times per week during their hospitalization.
10175806|NCT03839459|Experimental|Denosumab|
10175807|NCT03839329|Experimental|ACT Group Condition|The ACT group condition will receive two 90-minute group Acceptance and Commitment Training (ACT) workshops (scheduled approximately one week apart) and will complete assessments.
10175808|NCT03839329|No Intervention|Assessment-Only Condition|The Assessment-only condition will not receive any intervention and will only complete assessments.
10175809|NCT03839407|Experimental|MUSE device Class 21|Participants will utilize the MUSE device for 12 weeks during the intervention period.
10175810|NCT03839407|No Intervention|No MUSE device Class 21|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
10175811|NCT03839407|Experimental|MUSE device Class 22|Participants will utilize the MUSE device for 12 weeks during the intervention period.
10175812|NCT03839407|No Intervention|No MUSE device Class 22|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
10175813|NCT03839264||Graft stenosis and thrombosis|Diagnostic performance for stenosis at angiography of non invasive screening tools (duplex ultrasound, access blood flow (Qa), dynamic and static dialysis machine venous pressures, dynamic dialysis machine arterial pressure, and monitoring) and incipient thrombosis (within 4-month period) of the presence and degree of stenosis at angiography, non invasive screening techniques and acute hypotensive episode/s during the follow-up
9679228|NCT04953494||Amyotrophic lateral sclerosis patients group|
9679229|NCT04953611||Group A in GOLD|CAT<10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year<2；
9679230|NCT04953611||Group B in GOLD|CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year<2
9679231|NCT04953611||Group C in GOLD|CAT<10、mMRC 0-1、 FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
10175814|NCT03839108|Active Comparator|Paraffin wax group|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
10175815|NCT03839108|Experimental|Prolotherapy group|"Drug = prolotherapy (%15 dextrose solution) into hand joints~%15 dextrose solution will be injected into medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period."
10175816|NCT03839147|Experimental|Education and Counseling|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. This education consisted of the definition and the purpose of hysterosalpingography, when and how it was applied, in what cases it was applied, whether it was a painful procedure, possible side effects and additional benefits of infertility treatment
9679232|NCT04953611||Group D in GOLD|CAT≥10、mMRC≥2、FEV1%<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1
9679233|NCT04953611||Control Group|not COPD
9679234|NCT04953520|Experimental|Ultrasound-CT fusion imaging guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
9679235|NCT04953520|Active Comparator|Pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
9679236|NCT04953559|Experimental|Active cTBS first, then sham cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
10175817|NCT03839147|No Intervention|Control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography. Within 5 minutes of completing the hysterosalpingography procedure, participants were asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale .
10175818|NCT03839225|Other|Children, Adolescents and Adults|children, adolescents and adults who have been victims of the armed conflict in the municipalities of Soacha-Cundimanarca (Colombia)
10175819|NCT03839173|No Intervention|Retrospective Chart Review|Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier
10175820|NCT03839173|Experimental|Prospective|"All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent.~Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data."
9679237|NCT04953559|Experimental|Sham cTBS first, then active cTBS|Participants complete an Enrollment Visit followed by one week of at-home actigraphy. Participants return to the lab for Overnight Visit 1 and undergo a MRI scan followed by sham cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep. Participants return home and complete another week of at-home actigraphy. Participants then return to the lab for Overnight Visit 2 where they undergo a MRI scan followed by active cTBS and then another MRI scan followed by a night of polysomnographic monitored in-lab sleep.
9679238|NCT04953507|Experimental|Thermal Radiofrequency|T2, T3 block by thermal radiofrequency lesioning at 80°c for 60-90 seconds
9679239|NCT04953507|Active Comparator|Chemical Neurolysis|T2, T3 block by chemical neurolysis using 2-3 ml of phenol in glycerin 6%
9679240|NCT04953377|Experimental|Intervention|PFMT educational intervention including a 120 min workshop and 8 weeks of self training
9679241|NCT04953624||CNAQ≤28|ALS patients with CNAQ ≤ 28
9679242|NCT04953624||CNAQ>28|ALS patients with CNAQ > 28
9679243|NCT04954001|Experimental|Single Arm|
9679244|NCT04953442|Experimental|Intervention|Fitbit Device Self-Determination Theory Text Messages
9679245|NCT04953442|No Intervention|Wait List Control|Informational flyer of evidence-based strategies on engaging in healthy physical activity and sleep lifestyle habits.
9679246|NCT04953455||pre-operation|Within one month before operation of diagnoses with a ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
9679247|NCT04953455||early after operation|Within three months after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement surgery
9679248|NCT04953455||lately after operation|within three months to one year after operation of ligament rupture, patella dislocation, meniscus injury, or total knee replacement
9679249|NCT04953455||healthy volunteers|Healthy people without abnormalities
9679250|NCT04953546||ACL group|According to the previous clinical diagnosis, volunteers who has suffered the ACL injury.
9695423|NCT04778241|Experimental|Micro-Osteoperforation group|All the participants bonded by the care provider with 0.022 inch MBT prescription appliance (Ortho TechanologyTM,USA). Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
10175821|NCT03839160|Active Comparator|SAPB group. Group S|In this group, serratus anterior plane block (SAPB) was performed before extubation with injection of 30 ml of 0.25% bupivacaine hydrochloride followed by 0.1ml/kg/hr of 0.12% bupivacaine hydrochloride. In addition to SAPB, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
10175822|NCT03839160|Placebo Comparator|Control group. Group C|In this group, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
10175823|NCT03839134|Experimental|Pain of buccal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) buccal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
10175824|NCT03839134|Active Comparator|Pain of buccal injection without DentalVibe®|Local anesthesia (LA) for buccal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
10175825|NCT03839134|Experimental|Pain of palatal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) palatal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
10175826|NCT03839134|Active Comparator|Pain of palatal injection without DentalVibe®|Local anesthesia (LA) for palatal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
10175827|NCT03839134|Experimental|Pain of block injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
10175828|NCT03839134|Active Comparator|Pain of block injection without DentalVibe®|Local anesthesia (LA) injection for inferior alveolar nerve (IAN) block using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
9679251|NCT04953468||ANXA2 high expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level ≥6 points were identified as the ANXA2 high expression group
10175829|NCT03839316|Active Comparator|tDCS group|"Sixteen stroke patient receiving bihemispheric tDCS in addition to a conventional physiotherapy (PT) and occupational therapy (OT) program for five consecutive days per week for a three week period (a total of fifteen sessions).~The one hour long conventional PT sessions will include an upper extremity range of motion, strengthening and neurofacilitation exercise program. The one hour long OT sessions will include task specific exercises chosen according to the patient's functional status, including activities aimed at improving gross and fine motor function of the upper extremities.~The tDCS application will be applied at the beginning of each OT session and will be continued for a total of thirty minutes at 2 mA."
9679252|NCT04953468||ANXA2 low expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level <6 points were identified as the ANXA2 low expression group
9695424|NCT04778241|No Intervention|Control group|All the participants in this group bonded by the principal investigator with 0.022-inch slot MBT prescription appliance (Ortho TechanologyTM,USA). No micro-osteoperforation was used in this group.
10187231|NCT03728283|Experimental|Implant and Connective tissue grafting|implant placement in combination with connective tissue grafting
10187232|NCT03728270|Experimental|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~A multilayer closure of the incisions will be accomplished using Vicryl sutures."
10187233|NCT03728270|Active Comparator|Inlay Autogenous Bone Graft|"A safety distance of 5 mm will be maintained from the apex of the mandibular incisor and inferior mandibular border, the mental foramen, and permanent canine follicle.~One corticocancellous bone block with a maximum depth of 4 mm will be removed by mallet and chisel based on the recommendation that bone from the chin should be harvested at this maximum depth, compatible with the course of the mandibular incisive nerve canal on CT scans.~After removal of bone from the chin, the intervening bone struts will be removed using rongeur forceps and used as an additional bone graft.~The bone removed will be trimmed and contoured in a wedge form to be used as an inter-positional graft in the previously down fractured articular eminence to act as an obstacle in front of the mandibular condyle to prevent its hyper movement."
10187234|NCT03728244|Experimental|test group Hyaluronic acid|Patients scheduled for free gingival graft harvesting will receive Hyaluronic acid gel 0.2%
10187235|NCT03728244|Experimental|test group MEBO ointment|Patients scheduled for free gingival graft harvesting will receive MEBO ointment
10187236|NCT03728244|No Intervention|negative control group|Patients scheduled for free gingival graft harvesting
9679253|NCT04953468||ANXA2 high expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level ≥2 were regarded as the ANXA2 high expression group
9679254|NCT04953468||ANXA2 low expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level <2 were regarded as the ANXA2 low expression group
9679255|NCT04953988|Experimental|Robotic surgery group|
10175830|NCT03839316|Sham Comparator|Sham group|Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
10175831|NCT03839290||Bilateral cleft lip and palate patients|Newborns with complete bilateral cleft lip and palate (cBCLP) and bilateral cleft lip and palate with tissue bridges (BCLP + B) analyzed one year after neonatal cheiloplasty
10175832|NCT03839290||Unilateral cleft lip and palate patients|Newborns with complete unilateral cleft lip and palate (cUCLP) and unilateral cleft lip and palate with tissue bridges (UCLP + B) analyzed one year after neonatal cheiloplasty
9679256|NCT04953988|Active Comparator|Manual operation group|
9679257|NCT04953598||acetabular labrum tears|Patients with clinically diagnosed acetabular labrum tears
9679258|NCT04953598||Patients with non-hip injuries|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
9679259|NCT04953247||Methylprednisolone|"As there was no consensus on the use of steroids in the early stage of the COVID-19 pandemic, all steroid therapies were initiated at the time of admission at the discretion of attending physicians on the basis of clinical symptoms and CT images. According to our previous experience, intravenous methylprednisolone at a dose of 1.0-1.5 mg/kg every 12 h was initiated for 5 days or until oxygen saturation improved, followed by gradual tapering by 0.5 mg/kg every 3-5 days.~Standard care such as the use of antibiotics, ventilation, laboratory testing, and hemodynamic management were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China."
9679260|NCT04953247||Standard care|Standard care were performed following the sixth edition of the Guidelines on the Diagnosis and Treatment of COVID-19 published by the National Health Commission of China.
9679261|NCT04953299|Experimental|Functional Imagery training|The FIT sessions will occur weekly for four weeks and last an hour per session. The sessions will be conducted over Zoom. Sessions will be facilitated by the PI who is trained in FIT, and attended by 4 participants.
9679262|NCT04953299|Active Comparator|Control|The control condition will ask participants to complete the 12 week NHS weight loss plan.
9679263|NCT04953260|No Intervention|GTR group|only conventional GTR technique was used to treat periodontal bone defect,
9679264|NCT04953260|Active Comparator|APRF+GTR group|GTR technique combined with APRF was used to treat periodontal bone defect
9679265|NCT04953260|Active Comparator|CGF+GTR group|GTR technique combined with CGF was used to treat periodontal bone defect
9679266|NCT04953117|Experimental|small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter≥2.00 mm) in small vessel cohort
9679267|NCT04953117|Active Comparator|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB in small vessel cohort
10175833|NCT03839368|Experimental|K plate|fixation of angle fracture using K plate versus two miniplates
9679268|NCT04953117|Other|very small vessel cohort: DCB of Lepu Medical|receiving the treatment with DCB of Lepu Medical(dimeter<2.00 mm) in very small vessel cohort
9679269|NCT04953013||sodium bicarbonate group|Sodium bicarbonate was initiated within 48 hours after ICU admission.
9679270|NCT04953013||non-sodium bicarbonate group|Patients were not infused with sodium bicarbonate.
9679271|NCT04953000||All Participants|Male participants with severe or moderate hemophilia A who have been treated with FVIII concentrate octocog alfa (Advate) during at least 12 months prior to the study enrollment, who started octocog alfa treatment in 2021 or currently being treated with octocog alfa will be observed in this study.
9679272|NCT04953130|Experimental|Male vaccination + national HPV vaccination programme|Single dose of the 4-valent HPV vaccine (Gardasil®; Merck & Co.) offered to all eligible boys aged 14 to 18 years in the 13 intervention communities. Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
9679273|NCT04953130|Active Comparator|National HPV vaccination programme only|Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
10175834|NCT03839368|Active Comparator|Conventional two miniplates|fixation of angle fracture using K plate versus two miniplates
9695425|NCT04778371|Experimental|Almond supplement|Participants will consume 32 g dry roasted, unsalted almonds twice a day for 12 weeks
10175835|NCT03839303|Experimental|Mini Implant Supported Appliance|this group will receive an Infra-zygomatic Mini Implant Supported Appliance after leveling and alignment of the four upper incisors for 8 months or till class I canine or incisors realation is reached with follow up every month
9679274|NCT04953104|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeats every 28 days (4 weeks) for up to 2 years in the absence of disease or unacceptable toxicity.
9679275|NCT04953169|Other|Video|The video is information regarding biobanking
9679276|NCT04953169|Other|Non-Video|The non-video group will receive a written informed consent
10175836|NCT03839303|Active Comparator|Headgear|this group will receive a high pull headgear appliance attached to a removable acrylic maxillary splint for 8 months or till class I canine or incisors realation is reached with follow up every month
10175837|NCT03839433|Active Comparator|ciclesonide positive|"Half of the Mannitol positive patients were given ciclesonide. Half of the Mannitol negative patients were given ciclesonide. All patients in the ciclesonide positive arm received ciclesonide."
9679277|NCT04952896||Group of patients with good prognosis|Western Ontario and McMaster University Osteoarthritis Index (WOMAC) self-assessment questionnaire scale assesses the frequency of osteoarthritis pain, the severity of pain, body stiffness, and physical dysfunction. The visual analog scale (VAS) is used to evaluate the pain The degree is represented by a total of 11 numbers from 0 to 10 (0 means no pain, 10 means the most painful), and patients are scored according to their own pain levels.
9679278|NCT04952896||Group of patients with poor prognosis|Western Ontario and McMaster University Osteoarthritis Index (WOMAC) self-assessment questionnaire scale assesses the frequency of osteoarthritis pain, the severity of pain, body stiffness, and physical dysfunction. The visual analog scale (VAS) is used to evaluate the pain The degree is represented by a total of 11 numbers from 0 to 10 (0 means no pain, 10 means the most painful), and patients are scored according to their own pain levels.
10175838|NCT03839433|Placebo Comparator|Placebo|"Half of the Mannitol positive patients were given a placebo. Half of the Mannitol negative patients were given a placebo. All patients in the placebo arm received placebo."
10175839|NCT03839277|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
10175840|NCT03839277|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
9679279|NCT04953026||Normal control group-Grade 0|Arthroscopic examination of the labrum was normal, and the labrum was intact without injury or tear.
9679280|NCT04953026||Ligament injury -Grade 1|Arthroscopic examination of the shoulder showed labrum degeneration or injury, but no local or complete tear.
10175841|NCT03839082|Active Comparator|Usual Care then FitBit|This is the waitlist control arm.
10175842|NCT03839082|Experimental|FitBit then Usual Care|Intervention includes education, physical activity, and a nutrition assessment.
9679281|NCT04953026||Ligament tear-Grade 2|Arthroscopy of the shoulder revealed partial or complete loss of labrum.
9679282|NCT04953221||M1 Test group|YJ001 for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
9679283|NCT04953221||M1 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 100mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
9679284|NCT04953221||M2 Test group:|YJ001 for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
9679285|NCT04953221||M2 control group:|YJ001 simulant for spray, topical application on the skin, drug concentration 150mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
9679286|NCT04953221||M3 Test group|YJ001 for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
10175843|NCT03838965|Experimental|biobeat sensor|
9679287|NCT04953221||M3 control group|YJ001 simulant for spray, topical application on the skin, drug concentration 200mg/mL, 2 times/day (interval 11-13h), 8 sprays each time, a total of 12 weeks.
9679288|NCT04953182||Around the clock analgetic treatment|Patients that underwent hemorrhoidectomy and pain killers are prescribed every specific hour independent of pain degree, if necessary drugs can be administered on demand.
9679289|NCT04953182||On demand analgetic treatment|A pain killers list is prescribed by the physician and the nurse decides which drug to administer depending on a protocol of treatment based on the visual analog scale.
9679290|NCT04952818||RANK/RANKL low expression|
9679291|NCT04952818||RANK/RANKL high expression|
9679292|NCT04952948|Experimental|PILATES Method Training Group|The PILATES program at moderate intensity lasted 12 weeks, at a frequency of 3 times a week, and with duration of 60 minutes for each exercise session.
9679293|NCT04952948|Sham Comparator|CONTROL Group|While the PILATES Group participated in the intervention with physical exercises, the CONTROL group only participated in the functional capacity and blood pressure assessments. However, at the end of the intervention in the PILATES Group, the CONTROL Group was invited to participate in a similar training program.
10175844|NCT03838900||Cohort A|Individuals who have not started Loop or who have been on Loop fewer than 7 days at the time of enrollment.
9679294|NCT04952688|Experimental|Experimental|"Inclusion~Before Anti-VEGF treatment: opht"
9679295|NCT04952649||pacemaker dependent patients after cardiac surgery|Pacemakers are widely used in cardiotomy patients, while it's common that the patients happen to be pacemaker dependent. When the doctor decides to set the heart rate of the pacemaker, we record the hemodynamic parameters and peripheral perfusion index from 70-80-90-100-110 bpm.
9695426|NCT04778371|Placebo Comparator|Placebo matched supplement|Participants will consume 100 g granola bar, calorie matched to Almond, twice a day for 12 weeks
10175845|NCT03838900||Cohort B|Participants who have been using Loop 7 or more days at the time of enrollment.
10175846|NCT03839017|Experimental|Digital cognitive aid|The leader uses a digital cognitive aid designed as a smartphone app during advanced combat casualty care. Intervention: Device: SIMMAXMARCHERYAN2 Digital cognitive aid during the management of simulated war wounded.
10175847|NCT03839017|Experimental|Without digital cognitive aid|The leader practices advanced combat casualty care without the digital cognitive aid designed as a smartphone app. Intervention: Device: SIMMAXMARCHERYAN2 Without digital cognitive aid during the management of simulated war wounded.
10175848|NCT03838848|Experimental|Safety cohort KN046 3mg|Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)
9679296|NCT04952584|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~Dose Level 1: 1 × 10^8 CD30.CAR-EBVST cells~Dose Level 2: 4 × 10^8 CD30.CAR-EBVST cells~Dose Level 3: 1 × 10^9 CD30.CAR-EBVST cells"
9679297|NCT04952831||Patients with mild CSM|mJOA score ≥15
10175849|NCT03838848|Experimental|Safety cohort KN046 5mg|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W
10175850|NCT03838848|Experimental|Efficacy cohort KN046|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046
10175851|NCT03839238|Experimental|Meniscus Injured patients|hESC Derived MSC Like Cell
9679298|NCT04952831||Patients with moderate CSM|mJOA score 13~14
9679299|NCT04952831||Patients with severe CSM|mJOA score ≤ 12
9679300|NCT04952831||Controls|health volunteers
9679301|NCT04952675||low-risk group|Risk Index∈[0,0.5)
9679302|NCT04952675||high-risk group|Risk Index∈[0.5,1)
9679303|NCT04952792|Experimental|Apixaban|Apixaban treatment, oral, 2.5 mg/12h, 28 days
9679304|NCT04952870||COVID-19 group|Perinatal COVID-19 infection group, including newborns born from COVID-19 infected mothers and newborns with postnatal COVID-19 infections;
9679305|NCT04952870||NO group|Newborns admitted in NICU and receiving inhaled NO for respiratory failure
9679306|NCT04952870||Control group|Newborns admitted in NICU for respiratory failure not receiving iNO and not infected with COVID-19;
9679307|NCT04952766|Other|immunocompromised and healthy subjects|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~Nasopharyngeal samples (not mandatory)~Associated data :~Demographic data~Description of clinical manifestations related to vaccination~Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
9679308|NCT04953208|Active Comparator|Active treatment|active tDCS (using the Neuroelectrics Starstim tCS 5G kit) and cognitive and emotional control video game
9679309|NCT04953208|Sham Comparator|Sham treatment|sham tDCS (using the Neuroelectrics Starstim tCS 5G kit) and non-active videogame
9679310|NCT04952740|Experimental|Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
9679311|NCT04952740|Active Comparator|No Ischemic postconditioning|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.)
10175852|NCT03838822|Experimental|Intervention|Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
9679312|NCT04953234|Experimental|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with COVID-19 best standard of care
9679313|NCT04952935|Experimental|True Acupuncture|
9679314|NCT04952935|Sham Comparator|Sham Acupuncture|
10175853|NCT03838913||IPNB|intraductal papillary neoplasm of the bile duct
10175854|NCT03838926|Experimental|Trichostatin A|
9679315|NCT04952961|Experimental|Single Arm Intervention|Participants will be shown how to perform vulval self-examination in a face-to-face intervention and provided with an information leaflet. They will be sent reminders to self-examine each month.
9679316|NCT04952714||Dynamic Cohort|"Initially, participants who meet the inclusion criteria will be recruited to assemble a cohort of patients with sepsis and those who develop sepsis-induced acute kidney injury will be observed.~Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device (Baxter), at a dose of 25 mL / Kg of PrismaSate dialysis solution (Baxter) and the removal filter oXiris® cytokines (Baxter) vs. the standard filter, for patients who require it, in the presence of a confirmed diagnosis of acute renal failure.~Hemodynamic and ventilatory parameters will be monitored every 24 hours, and inflammatory parameters every 48 hours. A follow-up will be done at 28 days to establish mortality."
10175855|NCT03838991|Experimental|Monostotic fibrous dysplasia|Patients with monostotic Fibrous dysplasia.
9679318|NCT04953195|Experimental|levothyroxine sodium|levothyroxine sodium
9679319|NCT04952883||COPD patients|The COPD questionnaire was conducted to collect the data of lung function, echocardiography and blood gas analysis, and the pulmonary vessels of HRCT were determined. Blood samples were collected for H2S-related indicators detection.
10175856|NCT03838991|Experimental|Polyostotic fibrous dysplasia|Patients with polyostotic Fibrous dysplasia.
9679320|NCT04952454|Active Comparator|External DCR|Patients treated with External DCR for functional epiphora
10175857|NCT03838991|Active Comparator|Controls|Control patients having a scheduled surgery for osteoarthritis.
10175858|NCT03838783|No Intervention|Usual CSII|Continue to use the established CSII insulin therapy
10175859|NCT03838783|Experimental|Untethered CSII|Basal dosing - total CSII basal dose will be delivered by 50% through continuing CSII therapy used prior to study enrollment and 50% through the addition of once daily insulin degludec injected in the morning; Bolus dosing - continue the established bolus insulin dose
10175860|NCT03838809|Experimental|INTERVENTION|A group that underwent a neurological physiotherapy program with electromyography-biofeedback on the hand and the foot
10175861|NCT03838809|Active Comparator|CONTROL|A group that underwent a conventional physiotheraphy intervention
9679321|NCT04952454|Active Comparator|Endonasal DCR|Patients treated with Endonasal DCR for functional epiphora
9679322|NCT04952454|Active Comparator|Transcanalicular DCR|Patients treated with Transcanalicular DCR for functional epiphora
9679323|NCT04952441|Experimental|Intervention Group|Intervention group will attend the RISE program which consists of eight 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor
9679324|NCT04952441|Active Comparator|Wait-list Control Group|The control group will attend the RISE program after the 3 month wait-list period (study months 6-7)
9679325|NCT04952506|Experimental|R-T1-T2|"Period 1: Reference~Period 2: Test 1~Period 3: Test 2"
9679326|NCT04952506|Experimental|T2-R-T1|"Period 1: Test 2~Period 2: Reference~Period 3: Test 1"
9679327|NCT04952506|Experimental|T1-T2-R|"Period 1: Test 1~Period 2: Test 2~Period 3: Reference"
9679328|NCT04952506|Experimental|T2-T1-R|"Period 1: Test 2~Period 2: Test 1~Period 3: Reference"
9679329|NCT04952506|Experimental|T1-R-T2|"Period 1: Test 1~Period 2: Reference~Period 3: Test 2"
9679330|NCT04952506|Experimental|R-T2-T1|"Period 1: Reference~Period 2: Test 2~Period 3: Test 1"
9679331|NCT04952571|Experimental|GBM at first relapse|
9679332|NCT04952571|Experimental|GBM at second relapse|
9679333|NCT04952519|Experimental|Amantadine|
9679334|NCT04952519|Placebo Comparator|Placebo|
9679335|NCT04952558||Cross sectional observational study|"Cross sectional observational study will be conducted among 700 patients of Egyptian inflammatory bowel diseased patients for different regions~Detailed history will be taken from all included patients focus on~age ,sex , special habit ,residence .~education level -socioeconomic status~type of the inflammatory bowel disease~lag time for reaching the proper diagnosis of inflammatory bowel disease which definite as time from the first symptoms presentation to reaching definite diagnosis~symptoms that causing patients seeking medical advice~number of Inflammatory bowel diseased patients referred for first time from surgeons~number of patients have perianal symptoms~number of patients have previous history of appendicectomy"
9679336|NCT04952428||Peri-implant group|It is based on clinical and radiographic bone loss. Implants should have clinical inflammation in combination with bleeding on probing and/or suppuration, also progressive bone loss when compared with baseline radiograph shall be demonstrable, as well as an increase in probing pocket depth (PPD) from the baseline examination (Baseline record are referred to those obtained after definitive prosthesis delivery). In those cases where no baseline records were available, marginal bone loss > 3mm and probing > 6mm were stated as requirements (2).
9679337|NCT04952428||Peri-implant mucositis group|The case definition of peri-implant mucositis it is based on clinical inflammation in combination with profuse bleeding on probing and/or suppuration with increasing of probing pocket depths and absence of bone loss beyond crestal bone level (initial remodelling) (2).
9679338|NCT04952428||Healthy patients group|The case definition of peri-implant health was based on absence of clinical inflammation, lack of bleeding on probing and absence of bone loss following initial healing (< 2mm) (2).
9679339|NCT04952363|Experimental|HFCWO+WBVT|Subjects received HFCWO+WBVT intervention twice a week for a period of 8 weeks
10175862|NCT03838796|Active Comparator|lenvatinib|use lenvatinib after liver resection in HCC patients
9679340|NCT04952363|Active Comparator|HFCWO only|Subjects received HFCWO intervention twice a week for a period of 8 weeks
9679341|NCT04952246||multiple sclerosis group|
10175863|NCT03838796|Active Comparator|lenvatinib and TACE|use lenvatinib and TACE after liver resection in HCC patients
9975960|NCT01346605||CCTA patients|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac catheterization laboratory for an invasive coronary angiogram or patients presenting with chest pain and clinical indication of Coronary CT Angiography and an initial calcium score above 300
9975961|NCT01346618||children ages 4-17 years|Participants are children and youth ages 4-17 years (inclusive) who performed or will perform a X-ray of the left hand for bone age assessment as part of any clinical work up, within 2 months of enrollment in this study.
9975962|NCT01346631|Experimental|paleolithic diet|Subjects will adhere to a paleolithic diet for the duration of three months
9975963|NCT01346644|Active Comparator|No probiotics|Infant formula with no probiotics
9975964|NCT01346644|Experimental|Probiotic|Infant formula supplemented with probiotic
10175864|NCT03838952|Experimental|Chinese herbal medicine group|drug for the subjects
10175865|NCT03838835|Experimental|Equine-facilitated group therapy|
10175866|NCT03838835|Experimental|Augmented equine-facilitated CBT group program|
10175867|NCT03838835|Other|Wait List Control (WLC)|
9679342|NCT04952246||non-prognosis group|
9679343|NCT04952259|Experimental|Intervention group|Shexiang Tongxin dripping pills + routine treatment
9679344|NCT04952259|Active Comparator|Control group|routine treatment
9679345|NCT04952194|Experimental|Stalevo group|Stalevo is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
9679346|NCT04952194|Active Comparator|Control group|Carbidopa and Levodopa Sustained-release Tablets is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
9679347|NCT04952207||DAA Group|Chronic hepatitis C patients treated with DAA
9679348|NCT04952285||Normal saline（I）|Intravenous infusion of 0.9% saline when start to cut the skin，do not intravenous tranexamic acid during the surgery
9679349|NCT04952285||Tranexamic acid（II）|Intravenous infusion of tranexamic acid 1g when start to cut the skin in 1 hour
9679350|NCT04952064|Experimental|200 mg group|Monosialoganglioside GM1, 200 mg/day, for 12-14 days
9679351|NCT04952064|Experimental|400 mg group|Monosialoganglioside GM1, 400 mg/day, for 12-14 days
9679352|NCT04952220||native septic arthritis of the knee|"Describe the ultrasound abnormalities observed at D0, D10 or before surgery, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee:~thickness and vascularity of the synovial membrane, existence and measurement of joint effusion existence of articular partitioning, erosions and adjacent soft tissue involvement (muscle abscess, cellulitis)"
10175868|NCT03839004|Experimental|Intervention group|200 woman with single spontaneous pregnancies who recieve, as well as traditional obstetrical care, yoga classes, myndfulness classes, coaching, nutrition counselling and osteopathic treatment
10175869|NCT03839004|No Intervention|Controls|200 woman with single spontaneous pregnancies recieving traditional obstetrical care
10175870|NCT03839069|Experimental|Minor Salivary Gland Transplantation|Cicatrizing conjunctivitis patients that received minor salivary gland transplantation for dry eye treatment.
9679353|NCT04952116|Other|Eyelid reconstruction|Direct eyelid closure will be done in small defects after periocular defects with or without canthyolysis , Larger defects will be reconstructed with anterior and posterior lamella reconstruction using grafts and flaps
9679354|NCT04951960|Other|A group from higher PEEP to lower PEEP|Patient allocated for this arm are received from higher to lower PEEP setting.
10175871|NCT03839043|Experimental|"Quit for a bit"|"Brief behavioral intervention (~5 min) that focus on quitting smoking from the morning of surgery until one week after surgery + Quit for a bit SMS program."
10175872|NCT03839043|Active Comparator|"Quit for good"|"Brief behavioral intervention (~5 min) that focus on quitting smoking permanently for as long as possible + Quit for good SMS program."
9679355|NCT04951960|Other|A group from lower PEEP to higher PEEP|Patient allocated for this arm are received from lower to higher PEEP setting.
9679356|NCT04951869|Experimental|Protescal group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, 1 mL Protescal gel was applied at the uterine suture site in Protescal group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). Protescal gel (0.5 mL) was applied over the subcutaneous tissue prior to skin closure in Protescal group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
9679357|NCT04951869|No Intervention|Control group|Caesarean-section was done in the usual manner. The transverse suprapubic skin incision was made and abdominal layers opened as usual. After delivering the baby, uterine muscle is closed in two layers with braided absorbable suture, polyglactin 910 (Vicryl no 1). After hemostasis secure, No Protescal gel was applied at the uterine suture site in this Control group. Peritoneal layer closed using braided absorbable suture, polyglactin 910 (Vicryl no 1). Rectus sheath was sutured using braided absorbable suture, polyglactin 910 (Vicryl no 1). Subcutaneous tissue closed interruptedly using braided absorbable suture, polyglactin 910 (Vicryl no 1). No application of Protescal gel (0.5 mL) over the subcutaneous tissue prior to skin closure in this Control group. The skin was then closed with the subcuticular method using braided absorbable suture, polyglactin 910 (Vicryl 3-0).
10175873|NCT03839030|Experimental|MBHP-Educa|Experimental: Intervention Group A novel Mindfulness-based Health Promotion program for Educators for active teachers will be employed. The intervention will be held once a week for 8-weeks, two-hour meetings (16.0-h total). Participants will be encouraged to meditate for 10-30 min/day via audio recording.
10175874|NCT03839030|No Intervention|Control Group|Control Group Teacher education as usual. These participants will participate in teacher training (Neuroscience for Education - Neuro Educa). The Neuro-Educa will be held once a week for 8-weeks, two-hour meetings (16.0-h total).
10175875|NCT03838887||control group|"Pregnant women:~Age between 18-35 years~Parity: primigravidas and multiparas.~Have no history of preeclampsia or eclampsia.~Have no history of chronic hypertension.~Not diabetic.~Not have antiphospholipid syndrome.~Not have autoimmune disease such as SLE"
9679358|NCT04952168|Experimental|Almonertinib group|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
9679359|NCT04951882|Placebo Comparator|hUC-MSCs treatment|Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.
9679360|NCT04951882|No Intervention|non-cell therapy|Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies.
9679361|NCT04951843|Experimental|Black soybean koji product|Oral supplement 2 servings of black soybean koji product per day, for 10 weeks.
9679362|NCT04951856|Experimental|Evolocumab + SOC|Investigational Product is open label Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
9679363|NCT04951856|Active Comparator|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
9679364|NCT04952129|Experimental|Selenomethionine|50 micrograms of selenium as Selenomethionine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
9679365|NCT04952129|Experimental|Methylselenocysteine|50 micrograms of selenium as Methylselenocysteine per oral capsule. Dosage: One capsule a day for 6 weeks, followed by two capsules per day for 6 weeks.
9679366|NCT04951830||control group|NORMAL TMJ
9679367|NCT04951830||Study group|patients with TMJ internal derangement
9679368|NCT04951921|Experimental|Hyperpolarized 13C pyruvate DNP-MRI scan|Patients receive hyperpolarized 13C pyruvate through IV injection less than 1-2 minute then undergo MRI over 3-5 minutes at baseline and 2 weeks after CCRT treatment. Total 2 times of MRI scan.
9679369|NCT04952051|Experimental|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
9975965|NCT01346657|Experimental|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects
10175876|NCT03838887||High risk group|"Pregnant women with:~History of preeclampsia -Eclapmsia~Chronic hypertension~Diabetic~Antiphospholipid syndrome.~Autoimmune syndrome such as SLE."
10175877|NCT03839056||IC+PIEB+PCEA high flow|Continuous Epidural Infusion to 3ml/h more Programed Intermittent Epidural Boluses of 7ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
10175878|NCT03839056||PIEB+PCEA high flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
10175879|NCT03839056||PIEB+PCEA standar flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of standar flow as clinical practice routine
9679370|NCT04952051|Active Comparator|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
9679371|NCT04952155|Experimental|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment.
9679372|NCT04952181|Experimental|optical biometry|
10175880|NCT03838705|Other|bariatric surgery patients|patients aged 18-65 years with ASA status II-III, BMI>40 who were undergoing bariatric surgery operation
10175881|NCT03838679||Cohort 1|80 participants with neovascular AMD and a minimum history of 12 months of anti- VEGF therapy will be included in cohort 1 and examined only once (1 study visit).
9679373|NCT04952181|Experimental|ultrasonic biometry|
9679374|NCT04952012||ATA-positive|
9679375|NCT04952012||ATA-negative|
9679376|NCT04951908||control group|NORMAL TMJ
9679377|NCT04951908||Study group|Patients with TMJ internal derangement
9679378|NCT04952025||ALS patients|
9679379|NCT04952025||normal controls|
9679380|NCT04951791|Experimental|treatment|patients will receive intravenous infusion of SMOFlipid 20%
9679381|NCT04951791|Placebo Comparator|control|patients will receive intravenous infusion of normal saline 0.9%
9679382|NCT04952038||ALS patients with sleep disorder|
9679383|NCT04952038||ALS patients without sleep disorder|
9679384|NCT04951895||control group|patients with normal TMJ
9679385|NCT04951895||Study group|Patients with TMJ internal deragement
9679386|NCT04951700||Schizophrenia|Women and men, all races and ethnicities, aged 18-65 years, meeting diagnostic DSM-5 criteria for schizophrenia or schizoaffective disorder.
9679387|NCT04951700||Healthy Controls|Women and men, all races and ethnicities, aged 18-75 years, without personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st- or 2nd-degree relatives.
9679388|NCT04951713|Experimental|XZP-3287 combined with clarithromycin|XZP-3287 combined with clarithromycin
9679389|NCT04951713|Experimental|XZP-3287 combined with rifampicin|XZP-3287 combined with rifampicin
9679390|NCT04951687|Experimental|Active: Ecologic Barrier©|"Dietary supplement: Ecologic Barrier©~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate, and probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58).~Subjects will consume 2g (5 billion CFU)/day of Ecologic Barrier©. The intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
9679391|NCT04951687|Placebo Comparator|Placebo|"Dietary supplement: placebo powder~Ingredients: maize starch, maltodextrin, vegetable protein, potassium chloride, magnesium sulphate, manganese sulphate.~As with the active treatment, the intervention is a powder which is sealed in sachets and an be stored at room temperature by participants. Subjects are to mix into warm water and drinking alongside a meal."
9679392|NCT04951674|Experimental|DIET|Participants will receive four individual, approximately 30-minute long dietary education sessions. The participants will receive detailed instructions (including meal plans, information on high fiber foods and serving sizes) on how to consume at least 30 grams of fiber per day.
9679393|NCT04951674|Placebo Comparator|CONTROL|No diet education. Group will spend same amount of time with study dietitian, but discussion is limited to review of current eating habits and minimal input on eating habits with referencing the standard food pyramid.
10175882|NCT03838679||Cohort 2|40 participants with treatment-naive neovascular AMD receiving standardized anti- VEGF therapy will be included in cohort 2 and followed for 12 months (6 study visits).
10175883|NCT03838666|Experimental|Suspension of human autologous MSC 3P|Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.
10175884|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts <350 cells/µL|Intervention to be administered: Prevenar13
10175885|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL|Intervention to be administered: Prevenar13
9695427|NCT04778306|Active Comparator|Trans Oral Laser Surgery (Group 1)|In TOLS, the tumor tissue was removed en bloc and in one piece. The removed specimen was marked on a card with the help of pins. Permanent surgical margins were taken from the anterior, posterior, superior, inferior and deep areas of the tumor area.
9695428|NCT04778306|Active Comparator|Radiotherapy (Group 2).|. In RT; the head was routinely stabilized with the help of a thermoplastic mask and subsequently covered the primary area with a size varying from 4x4 cm to 6x6 cm. Total 63-70 Gy radiotherapy was applied 2.0-2.3 Gy/ day,5 days a week, for 6-7 weeks.
9695429|NCT04778176|Experimental|DopaFuse Delivery System 50mg LD/hr or 68mg LD/hr flow rate|Either 50mg/13mg LD/CD per hour or 68mg/17mg LD/CD per hour flow rate based upon Subject's standard levodopa (LD) dose. Subjects will routinely wear each container for approximately 5 hours (3 containers per day).
9695430|NCT04778072|Experimental|Group 1|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
9695431|NCT04778072|Experimental|Group 2|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
9695432|NCT04778072|Experimental|Group 3|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily with matching placebo
9695433|NCT04778189|Placebo Comparator|normal saline group (NS)|patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes after spinal anesthesia
9695434|NCT04778189|Active Comparator|dexamethasone group (SD)|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline in 5-10 minutes after spinal anesthesia
9827789|NCT02468674|No Intervention|Follow-up (arm 2)|Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.
9827790|NCT02468700|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
10175886|NCT03838315|Experimental|Neural Mobilization with Soft Tissue Mobilization|"Neural Mobilization with Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization and Post Isometric Relaxation Techniques.~Frequency for Neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 40mints each session)"
10175887|NCT03838315|Active Comparator|Neural mobilization without Soft Tissue Mobilization|Neural Mobilization without Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural Mobilization Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 30mints each session)
10175888|NCT03838588||T-MENC Study Group|"In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including:~st: 10 Days after patients received radical resection.~nd: When patients finished the chemotherapy or target drug delivery two cycles.~rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles.~th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA)."
10175889|NCT03838640|Experimental|Study group|Consecutive eligible patients requiring endoscopic surgery for sinonasal pathology Transnasal localization of internal carotid artery with TEE ECHO device will be performed
10175890|NCT03838328|Experimental|Dose group 1|The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.
10175891|NCT03838328|Experimental|Dose group 2|The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.
10175892|NCT03838328|Active Comparator|Dose group 3|The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.
10175893|NCT03838523|Experimental|OLP group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women allocated to this group receive an 4-week Open Label Placebo treatment. After 4 weeks, they are randomized again to either continue or discontinue the OLP treatment for another 4 weeks."
10175894|NCT03838523|No Intervention|No-treatment group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women assigned to the no-treatment group do not receive any treatment as part of the study."
10175895|NCT03838432|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
10175896|NCT03838406|Experimental|BRCA1 positive|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
10175897|NCT03838406|Active Comparator|BRCA1 negative|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
10175898|NCT03838341||Included|The consecutive patients with atrial fibrillation assigned to totally thoracoscopic stand-alone left atrial appendage occlusion using AtriClip® for stroke prevention.
10175899|NCT03838445|Experimental|Therapy: V-Wave Shunt|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation.
10175900|NCT03838575|Active Comparator|A - NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
10175901|NCT03838575|Active Comparator|B - SKIN PREP|"Mechanism: A broad-spectrum antiseptic to clean and prepare the skin prior to surgery.~Supplier: BD"
10175902|NCT03838575|Active Comparator|C - DRAPE|"Mechanism: A thin impregnated plastic sheet applied to the prepared skin prior to incision to maintain sterility.~Supplier: 3M Infection Prevention"
10175903|NCT03838575|Active Comparator|D - SPONGE|"Mechanism: Small absorbable sponges placed into the wound at the time of closure which deliver high concentrations of antibiotic locally to kill pathogens present that may go on to cause SSI.~Supplier: SERB"
10175904|NCT03838575|Active Comparator|E - SKIN PREP and DRAPE|See descriptions in single arms (B & C)
10175905|NCT03838575|Active Comparator|F - SKIN PREP and SPONGE|See descriptions in single arms (B & D)
10175906|NCT03838575|Active Comparator|G - DRAPE and SPONGE|See descriptions in single arms (C & D)
10175907|NCT03838575|Active Comparator|H - SKIN PREP and DRAPE and SPONGE|See descriptions in single arms (B, C & D)
10175908|NCT03838354|Experimental|A|Chidamide 2.5 mg po tiw
10175909|NCT03838354|Experimental|B|Chidamide 5 mg po tiw
10175910|NCT03838380|No Intervention|conventional management group|The conventional management group received standard GDM management and could freely use the smartphone healthcare application.
10175911|NCT03838380|Experimental|mobile management group|The mobile management group received mobile healthcare services through smartphone application specifically developed for this trial including tailored mobile coaching.
10175912|NCT03838614|Experimental|RAS-MPT group|Rhythmical auditory stimulation gait training and muscle power training group
10175913|NCT03838614|Experimental|RAS group|Rhythmical auditory stimulation gait training group
10175914|NCT03838614|Experimental|MPT group|Muscle power training group
10175915|NCT03838614|Other|Control group|Usual care group
10175916|NCT03838419|Active Comparator|BCS + WBI|breast conserving surgery followed by whole breast irradiation
10175917|NCT03838419|Experimental|BCS + IORT|Breast conserving surgery incl intraoperative radiotherapy
9679394|NCT04951440|Experimental|Intervention group|"Intervention group: 30min intravenous point. Infusion of 1400 mg of tetranitrone was given to bed I with a dose of 100ml, twice a day, with an interval of 12 hours, and continued administration for 7 days, that is, a total of about 14 times.~version"
9679395|NCT04951440|Placebo Comparator|Placebo group|Placebo group: 30 minutes to earn pulse, I, 1, and dripping Yunmi gave 100mL placebo (sodium chloride injection). It is administered twice a day for 1 to 2 hours, and the pattern is transferred to about 7 people, that is, about 14 times in total.
9679396|NCT04951752||Hemicolectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
9679397|NCT04951752||Hemicolectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
9679398|NCT04951752||Nephrectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
9679399|NCT04951752||Nephrectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
9679400|NCT04951752||Percutaneous nephrolithotomy, Active treatment|1x30mL 0.75% Ropivacaine administered by way of transmuscular quadratus lumborum block
9679401|NCT04951752||Percutaneous nephrolithotomy, Placebo treatment|1x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
9679402|NCT04951752||Hysterectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
9679403|NCT04951752||Hysterectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
9679404|NCT04951752||Elective Caesarean section, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
9679405|NCT04951752||Elective Caesarean section, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
9679406|NCT04951505|Experimental|cefepime-taniborbactam|
9679407|NCT04951531|Experimental|BPTB double-bundle allograft group|The patient underwent arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
9679408|NCT04951531|Active Comparator|BPTB single-bundle allograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
9679409|NCT04951531|Active Comparator|BPTB single-bundle autograft group|The patient underwent arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
9679410|NCT04951765|Experimental|Arm A|Cycle1 Day 1：fasting；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：low-fat meal
9679411|NCT04951765|Experimental|Arm B|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：fasting
9679412|NCT04951765|Experimental|Arm C|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：high-fat meal
9679413|NCT04951765|Experimental|Arm D|Cycle1 Day 1：fasting；Cycle2 Day 1：low-fat meal；Cycle3 Day 1：high-fat meal
9679414|NCT04951765|Experimental|Arm E|Cycle1 Day 1：high-fat meal；Cycle2 Day 1：fasting；Cycle3 Day 1：low-fat meal
9679415|NCT04951765|Experimental|Arm F|Cycle1 Day 1：low-fat meal；Cycle2 Day 1：high-fat meal；Cycle3 Day 1：fasting
9975966|NCT01346670|Experimental|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor Tablet after single oral administration in healthy subjects using a 2x2 crossover design
9975967|NCT01346722|Other|Group A|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with conventional rice-based diet (Diet- CR)
10175918|NCT03838250|Experimental|Cellgram™ (Bone marrow-derived MSCs)|Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
9679416|NCT04951414||ICF|
9679417|NCT04951414||Control|
9679418|NCT04951635|Experimental|Almonertinib|
9679419|NCT04951635|Placebo Comparator|Placebo Almonertinib|
9679420|NCT04951739||Achalasia cardia patients - post peroral endoscopic myotomy|All the patients who will undergo peroral endoscopic myotomy for the treatment of achalasia cardia patients.
9679423|NCT04951648|Experimental|Almonertinib|
9679424|NCT04951648|Active Comparator|Platinum-based doublet chemotherapy|
9679425|NCT04951284||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9679426|NCT04951284||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9679427|NCT04951284||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9679428|NCT04951284||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9679429|NCT04951726|Active Comparator|IV push|2 mg slow intravenous injection over five minutes repeated q6hr until resolution for up to 24 hours. (8 mg total in 24 hours)
9679430|NCT04951726|Experimental|IV continuous infusion|5 mg/50cc intravenous infusion at 4cc/hr or 0.4 mg/hr over 12 hours. If no clinical response, then increase rate to 8 cc/hr or 0.8 mg/hr until 24 hours. (16 mg total in 24 hours)
9679431|NCT04951726|Experimental|subcutaneous|1.0 mg subcutaneous repeated q8hr until resolution for up to 24 hours (3.0 mg total in 24 hours)
9679432|NCT04951258|Experimental|Multicomponent exercise group|
9679433|NCT04951258|Active Comparator|Video home exercise group|
9679434|NCT04951349|Experimental|Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using GX-03 administered intranasally TID for 5 days.
9679435|NCT04951349|Placebo Comparator|Placebo Treatment of hospitalized patients with laboratory-confirmed COVID-19|Hospitalized patients with laboratory-confirmed COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 5 days.
9679436|NCT04951349|Experimental|Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using GX-03 administered intranasally TID for 10 days.
9679437|NCT04951349|Placebo Comparator|Placebo Prevention of SARS-COV-2 in Health Care Providers|Health care providers with laboratory-confirmed negative COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 10 days.
10175919|NCT03838276|Active Comparator|AL150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
10175920|NCT03838276|Experimental|AL100 BPL150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
10175921|NCT03838237||Fabry Disease patients|Patients with genetic diagnosis of Fabry Disease, clinical indication to Migalastat and signs of cardiac involvement (early or advanced) will undergo cardiological evaluation before and 18 months after therapy with Migalastat (123 mg every other day)
10175922|NCT03838211|Experimental|stimulation group|Anodal tDCS + intensive cognitive Training
10175923|NCT03838211|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
10175924|NCT03838224|Experimental|Dry needling|Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves.
10175925|NCT03838224|Sham Comparator|sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
10175926|NCT03838289||Individuals with absent filling of CVs|Individuals with absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
10175927|NCT03838289||individuals without any absent filling of CVs|Individuals without any absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
10175928|NCT03838510|Experimental|Brief Counseling Intervention|
10175929|NCT03838510|No Intervention|Control Group|
10175930|NCT03838302||Transvaginal retrieval|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
10175931|NCT03838302||Transabdominal retrieval|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
10175932|NCT03838107||Inpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the inpatient FIRST clinic at CCHMC and one of their parents or legal guardian.
10175933|NCT03838107||Outpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the outpatient Pain Management Center at CCHMC and one of their parents or legal guardian.
10175934|NCT03838107||Healthy Controls|For comparison purposes, healthy controls and one of their parents or legal guardian will be enrolled in this study as well.
10175935|NCT03838081|Experimental|Group 1|Group 1: Patients who were given only basic information verbally
10175936|NCT03838081|Experimental|Group 2|Group 2: Patients with detailed written information about preoperative, intraoperative, and postoperative periods
9679438|NCT04951167|Active Comparator|PB: prophylactic bolus|an IV bolus of 4 mcg Norepinephrine will be administered immediately after spinal anesthesia, and then SF infusion will be started at 1 ml/min.
9679439|NCT04951167|Active Comparator|PI:prophylactic infusion|1ml of saline is administered immediately after spinal anesthesia, and then infusion will be started with the study drug at 1 ml/min.(4mcg/min)
9679440|NCT04951167|Active Comparator|TB:therapeutic bolus|immediately after spinal anesthesia, 1 ml of saline, followed by 1 ml/min infusion of SF, and when the blood pressure decreases by 20%, 1 ml of working solution and then 1 ml/min of saline infusion will be started.
9679441|NCT04951167|Active Comparator|TBI:therapeutic bolus-infusion|1 ml of study drug and 1 ml/min of study drug infusion will be started immediately after spinal anesthesia, after 1 ml of saline followed by 1 ml/min of SF infusion when blood pressure decreases by 20% of the entry
9679442|NCT04951271|Experimental|Intervention (SFA) group|solution-focused approach intervention was applied for 7 weeks
9679443|NCT04951271|No Intervention|Control (no intervention) group|No intervention was made.
9679444|NCT04951193|Experimental|Goal2QuitVaping|Participants in the Goal2QuitVaping group will be asked to download the Goal2QuitVaping app to their smartphone. Goal2QuitVaping focuses on mood management as well as on quitting vaping nicotine. Participants will be asked to use Goal2QuitVaping regularly, at least once per day, for the study duration. Participants will also be asked to complete questionnaires weekly for 4 weeks.
9679445|NCT04951193|Other|Treatment as Usual|Participants in the treatment as usual group will be provided with educational material about quitting vaping nicotine and it will be suggested that they discuss any questions about mood management and about quitting vaping with their primary care provider. The educational material is from the National Cancer Institute's SmokeFree Teen website and includes information on recognizing reasons for quitting vaping, avoiding dual use of e-cigarettes and other tobacco products, setting a quit date, understanding triggers, and accessing social support.
9679446|NCT04950933|Experimental|Test group|
9679447|NCT04950933|Placebo Comparator|Control group|
9679448|NCT04950985||Participants|Adults undergoing a CT scan to investigate possible NOE.
9679449|NCT04951141|Experimental|anti-GPC3 CAR-T|
9695435|NCT04778293|Experimental|Experimental Group|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized (random.org), in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
9695436|NCT04778293|No Intervention|Control Group|No intervention
9695437|NCT04778202||first group (control group)|25 normal health control women apparently healthy. blood samples will be obtained after getting informed consent
9827791|NCT02468700|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
9679450|NCT04951063|Experimental|Concurrent radiotherapy and chemotherapy|"All patients will receive segmented adaptive intensity-modulated radiotherapy once a day, 5 days a week. Three weeks after the end of the first course of radiotherapy, the therapy efficacy will be evaluated. Lung function and lung perfusion imaging will be also evaluated. For patients whose tumors reached partial response and lung function can tolerate radiotherapy supplements, The second course of radiotherapy will be performed.~Under the premise of keeping the bioequivalent dose unchanged (BED=90GY), a single radiation dose climbing is carried out:~Level 1: The first course: total dose (DT) 5100cGy/17f/300cGy, the second course: DT 1800cGy/6f/300cGy.~Level 2: Thefirst course: DT 4000cGy/10f/400cGy, the second course DT 2400cGy/6f/400cGy.~Level 3: The first course: DT 3000cGy/6f/500cGy, the second course DT 3000cGy/6f/500cGy."
9679451|NCT04950829|Active Comparator|Conventional brackets|Patients will receive an orthodontic treatment using conventional brackets until achieving appropriate alignment of the upper anterior teeth.
9679452|NCT04950829|Experimental|Self-ligating brackets|Patients will receive an orthodontic treatment using self-ligating brackets until achieving appropriate alignment of the upper anterior teeth.
9679453|NCT04950829|Experimental|3- Self-Ligating brackets with fapless corticotomy|Patients will receive an orthodontic treatment using self-ligating brackets with corticotomy until achieving appropriate alignment of the upper anterior teeth.
9679454|NCT04950920||Y-2 sublingual test group|Y-2 sublingual tablets: Edaravone 30mg and d-borneol 6mg.
9679455|NCT04950920||placebo group|60 μg d-borneol
10175937|NCT03838081|Experimental|Group 3|Group 3: Patients with previous experience and knowledge about third molar extraction
9679456|NCT04951128|Experimental|Tranexamic acid arm|Eyelid(s) that received tranexamic acid in the local anesthetic
9679457|NCT04951128|Active Comparator|Control|Eyelid(s) that receive local anesthetic without tranexamic acid
9679458|NCT04951219|Experimental|Single-blind 80 mg Daily|Single-blind resmetirom 80 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
9679459|NCT04951219|Experimental|Single-blind 100 mg Daily|Single-blind resmetirom 100 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52
10175938|NCT03838055|Experimental|SLN only|Pelvic SLN's defined by ICG injected cervically
10175939|NCT03838185|Experimental|Study Drug|Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
9679460|NCT04951219|Experimental|Open-label 100 mg Daily|Open-label resmetirom 100 mg for an additional 52 weeks
10175940|NCT03838185|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.
9679461|NCT04950907|Experimental|treatment|Uniportal VATS biopsy
9679462|NCT04950907|Active Comparator|control|CT-guided fine needle biopsy
9679463|NCT04951232|Experimental|Test group (cinnarizide maleate injection group)|
10175941|NCT03838172||Parents|Parents who have a burned child
9679464|NCT04951232|Placebo Comparator|control group (placebo group)|
10175942|NCT03838068|Active Comparator|Mineral trioxide aggegate|white mineral trioxide aggregate (MTA) calcium silicate-based cement
10175943|NCT03838068|Experimental|Biodentine|calcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
9679465|NCT04951024|Experimental|Thoracolumbar interfacial plane (TLIP) Block|Thoracolumbar interfacial plane (TLIP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
9975968|NCT01346722|Other|Group B|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with a rice-based diet plus zinc fortificant (Diet-CR+Z)
10175944|NCT03837886|Experimental|Alkalosis group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of sodium bicarbonate
9679466|NCT04951024|Active Comparator|Erector Spinae Plane (ESP) Block|Erector Spinae Plane (ESP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance
9679467|NCT04950790|Experimental|Test group|Shuxuening injection + basic treatment
9679468|NCT04950790|Placebo Comparator|Control group|placebo (sterilized water for injection) + basic treatment
9679469|NCT04951115|Experimental|Radiation + Chemo-Immunotherapy|
9679470|NCT04950842|Experimental|JB-101|induced T cell with suppressive function
9679471|NCT04951180||Group 1|Femoral acetabular impingement syndrome (FAIS) patients with gluteus medius lesions
9679472|NCT04950816|Experimental|tailored MBI (.b)|
9975969|NCT01346735||ICU infections|Infections acquired during the ICU stay
9975970|NCT01346748|Experimental|Statin|
9977592|NCT01363284|Experimental|Duloxetine|The first week of the treatment is the placebo treatment. The effect of placebo will be taken into consideration for further evaluation the duloxetine effect on clinical pain and descending pain inhibition capabilities.
10175945|NCT03837886|Placebo Comparator|Placebo group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
10175946|NCT03837847|Experimental|Intervention|Participants in this group will receive 12 weekly health coaching calls followed by 12 weeks of living a normal life.
10175947|NCT03837847|Active Comparator|Attention Control|Participants in this group will receive 6 educational guides and 6 calls to remind them to read the educational guides (over a 12 week period). The participants will then move to 12 weeks of weekly health coaching calls.
9679473|NCT04950816|Active Comparator|attention control condition|
9679474|NCT04950894|Active Comparator|Active|HGN therapy activation at Month 1 - compared at Month 7 to Control group, continued stimulation through Month 13
9679475|NCT04950894|Other|Control|HGN therapy NOT activated at Month 1 - compared at Month 7 to Active group, stimulation will start at Month 7 + 1 Day and continue through Month 13
9977593|NCT01363310|Active Comparator|Quetiapine XR|
9679476|NCT04950478|Experimental|Virtual Reality|The children wore the virtual reality headset and game was started one minute before the venipuncture. The children took off the virtual reality headset after the venipuncture ended.
9679477|NCT04950478|No Intervention|Control Group|No intervention was performed to reduce pain in the control group
9679478|NCT04950673||Subjects who had COVID-19 infection and recovered at 3 months|500 subjects who have had a history of COVID19 infection and recovered 3 months prior to the enrollment
9679479|NCT04950673||Subjects who never had COVID-19 infection|500 subjects who never had a history of COVID19 infection prior to the enrollment
9679480|NCT04950569|Experimental|Levosimendan|Receive standard heart failure treatment, plus levosimendan treatment.
9679481|NCT04950569|No Intervention|Control|Receive standard heart failure treatment, without levosimendan treatment.
9679482|NCT04950738|Experimental|Acupuncture with press tack needle group (Acu)|Patients in acupuncture group will receive traditional Chinese acupuncture using Press Tack Needle (PYONEX 0.20 x l.5mm made by Seirin Corporation). The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), LI 4 (He Gu), SP 3 (Tai Bai,) ST 44 (Nei ting), LIV 3 (Tai Chong). The treatment will use bilateral acupuncture Interventions will be given on day 1, 3, and 5 after patient's enrolment.
9679483|NCT04950738|Placebo Comparator|Placebo group press tack placebo (Con)|Patients randomized to the control group will receive a press lack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to the acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), L1 4 (He Gu), SP 3; (Tat Bai), ST 44 (Ne1 tmg), LIV 3 (Tat Chong). Interventions will be given on days 1, 3, and 5 after the patient's enrolment.
9679484|NCT04950595|Experimental|Beef mince group|The test meal provided at lunch will be made up of 45% beef mince, with all remaining ingredients the same as the other arm.
9679485|NCT04950595|Experimental|Plant-based mince group|The test meal provided at lunch will be made up of 45% plant-based mince, with all remaining ingredients the same as the other arm.
9679486|NCT04950491|Experimental|Test group (s-CAIS)|The test group workflow used a fully computer-guided implant surgical protocol.
9679487|NCT04950491|Other|Control group (CIS)|The control group workflow used a conventional implant surgical protocol.
10175948|NCT03838094|Active Comparator|MTA Group|pulpotomy technique using fast-setting mineral trioxide aggregate (MTA) to be considered the control group for vital pulp therapy and was placed over the amputated pulps for 18 months. This group will be compared with the Biodentine group as the intervention group
9679488|NCT04950621|Experimental|Remimazolam|In remimazolam group, a 0.1 mg/kg dose of intravenous remimazolam was administered for induction, and 0.3-0.7 mg/kg/h infusion for maintenance after intubation.
9679489|NCT04950621|Active Comparator|Propofol|In propofol group, a 2 mg/kg dose of intravenous propofol was administered for induction, and 4-12 mg/kg/h infusion for maintenance after intubation.
9679490|NCT04950751|Experimental|SCB-2020S Standard Dose|Day 1 and 22: standard dose SCB-2020S with CpG 1018/alum adjuvant
9679491|NCT04950751|Experimental|SCB-2020S Low Antigen Dose|Day 1 and 22: low dose SCB-2020S with CpG 1018/alum adjuvant
9679492|NCT04950751|Experimental|SCB-2020S Low Adjuvant Dose|Day 1 and 22: standard dose SCB-2020S with low dose CpG 1018/alum adjuvant
9679493|NCT04950751|Experimental|SCB-2020S Mixed Series|Day 1 (Dose 1) standard dose SCB-2020S with CpG 1018/alum adjuvant and Day 22 Dose 2) standard dose SCB-2020S with alum adjuvant
10175949|NCT03838094|Experimental|Biodentine group|3 mm- thick Biodentine covered radicular pulp to allow pulp regeneration
10175950|NCT03838133|Experimental|TLC590 dose 1 (152 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
10175951|NCT03838133|Experimental|TLC590 dose 2 (190 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
10175952|NCT03838133|Experimental|TLC590 dose 3 (228 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
10175953|NCT03838133|Active Comparator|Naropin®|Naronpin injection contains ropivacaine HCl 50 mg (0.5%, 10 mL)
10175954|NCT03838133|Placebo Comparator|Placebo|Normal Saline (0.9% sodium chloride, 10 mL)
10175955|NCT03838133|Active Comparator|Bupivacaine|Bupivacaine HCl 50 mg (0.5%, 10 mL)
10175956|NCT03837821|Experimental|All Subjects|Abemaciclib 200 mg oral, every 12 hours
9679494|NCT04950751|Active Comparator|SCB-2019|Day 1 and 22: standard dose SCB-2019 with CpG 1018/alum adjuvant
9679495|NCT04950699||Control|Patients without typical symptoms of coronary heart disease, and coronary angiography or coronary CT showed no significant stenosis (coronary stenosis less than 30%), they were non coronary heart disease group, namely control group.
9679496|NCT04950699||myocardial infarction|This group includes acute myocardial infarction (ST segment elevation and non ST segment elevation) and old myocardial infarction. The diagnostic basis of acute myocardial infarction: cardiac biomarkers (cardiac troponin and / or myocardial enzymes) increased or decreased, at least once the value exceeded the upper limit of normal, and there was the following evidence of myocardial ischemia: (1) clinical symptoms of myocardial ischemia（ 2) New changes of myocardial ischemia appeared in ECG, i.e. new ST segment changes or left bundle branch block（ 3) Pathological Q wave appeared in ECG（ 4) Imaging evidence showed new loss of myocardial viability or regional wall motion abnormalities. Diagnosis of old myocardial infarction: the patient provided a history of previous myocardial infarction and confirmed as old myocardial infarction by the third or First Hospital of Peking University.
9977594|NCT01363310|Active Comparator|Escitalopram|
9977595|NCT01363323|Experimental|Arm 1|
9977596|NCT01363323|Experimental|Arm 2|
10175957|NCT03837769|Experimental|Aktiia SA PulseWatch|Aktiia OBPM PulseWatch wrist device
10175958|NCT03837951||Uninjured hands|healthy participants without injuries to hands or wrists
10175959|NCT03837951||Injured hands|participants undergoing medical treatment for recent hand or wrist injury
10175960|NCT03837795|Experimental|Neurofeedback therapy group|
10175961|NCT03837691|Experimental|g-Cath EZ|Placement of Snowshoe suture anchors from g-Cath EZ Delivery Catheters, in a defined pattern in the mid and distal portions of the stomach, along with a moderate intensity diet & exercise program, to treat primary obesity.
10175962|NCT03837691|No Intervention|Diet and Exercise|A moderate intensity diet & exercise program to treat primary obesity
10175963|NCT03837912|Experimental|Patient reported safety experiences fed back to PC providers|The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
10175964|NCT03837912|No Intervention|Patient reported safety experiences not fed back to providers|Waiting list: the practices allocated to the control group will receive the intervention (feedback report) after the trial finished (i.e., after post-intervention data collection has been completed).
10187237|NCT03728231||Fifty patients with RA.|"-CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* Disease activity Score(DAS)(17)"
10187238|NCT03728231||Fifty patients with SLE.|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* SLE Disease activity Index(SLEDAI)(18)"
10187239|NCT03728231||Fifty apparently healthy controls|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16)."
10187240|NCT03728218|Experimental|Orthokeratology Contact lenses|
10187241|NCT03728218|Experimental|Soft Multifocal Contact lenses|
10187242|NCT03728205|Experimental|Observational|All 10 pilot subjects will be taking yoga
9679497|NCT04950556|Experimental|Exercise group|Fast and slow contractions will be taught in PFMT. For fast contractions, they will be asked to contract and relax the pelvic floor muscles quickly. For slow contractions, they will be asked to contract the pelvic floor muscles slowly, keep them at maximum contraction and relax slowly. Ten slow contractions in addition to 10 fast contractions will be considered as 1 set of exercises. For the first week, they will be asked to do 5 sets of exercises per day, every day. Then, the number of sets will be increased by 5 each week and the number of sets will reach 30 in the 6th week. PFMT will be applied by the patients as a home program every day of the week for 6 weeks.
9679498|NCT04950556|Other|Control group|Waiting list will included in control group.
9679499|NCT04950725|Experimental|Low respiratory muscle training|Low dose of RMT and fewer repetitions and use of RMT device per week
9679500|NCT04950725|Experimental|Respiratory muscle training for strengthening|Higher number of sets with a slightly lower number of repetitions per set
9679501|NCT04950725|Experimental|Respiratory muscle training for strengthening and nasal breathing|Higher number of sets with a slightly lower number of repetitions per set RMT accompanied with sets of nasal breathing
9679502|NCT04950725|Experimental|Respiratory muscle training for endurance|One set of RMT with a higher number of repetitions
9679503|NCT04950725|Experimental|Respiratory muscle training for endurance and nasal breathing|One set of RMT with a higher number of repetitions accompanied with sets of nasal breathing
9679504|NCT04950335||AOPT|patients underwent AOPT to treat large cystic OLTs (>10mm)
9679505|NCT04950335||AOCT|patients underwent AOCT to treat large cystic OLTs (>10mm)
9679506|NCT04950517||Wave 1 participants|The study consists of three work packages. Wave 1 participants will be included in all work packages.
9679507|NCT04950517||Wave 2 participants|The study consists of three work packages. Wave 2 participants will only be recruited for work package 2.
9679508|NCT04950387|Experimental|Experimental group|Participants took part in breathing exercises
9679509|NCT04950387|No Intervention|Control group|Participant did not take part in intervention
9679510|NCT04950543||Meditation|
9679511|NCT04950140|Experimental|Robot Assisted Laparoscopic|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
9977597|NCT01363323|Experimental|Arm 3|
9679512|NCT04950140|Active Comparator|Conventional Laparoscopic Surgery|Conventional Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
9679513|NCT04950348|Experimental|3D printed personalized TKA prosthesis|Patients in the experimental group received 3D printed personalized TKA prosthesis treatment
9679514|NCT04950348|Active Comparator|Zimmer NexGen TKA prostheses|Patients in the active comparator group received Zimmer NexGen TKA prostheses treatment
9679515|NCT04950647|Experimental|Test group 1|Nitroketazine tablet 600 mg group
9679516|NCT04950647|Experimental|Test group 2|Nitroketazine tablets 1200 mg group
9679517|NCT04950647|Placebo Comparator|Control group|placebo group
9679518|NCT04950413|Active Comparator|Traditional Treatment Arm|conventional physical therapy program (infrared, stretching exercise, isometric strengthening exercise)
9679519|NCT04950413|Experimental|IASTM treatment arm|Instrument-assisted soft tissue mobilization (IASTM) is a therapeutic technique that is based on the soft tissue mobilization rationale introduced by James Cyriax.
9679520|NCT04950413|Experimental|Phonophoresis treatment arm|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2.
9679521|NCT04950413|Experimental|Combined IASTM and phonophoresis treatment arm|Combined phonophoresis and M2t Blade
9977598|NCT01363323|Placebo Comparator|Arm 4|
9977599|NCT01363323|Active Comparator|Arm 5|
9977600|NCT01363336||Group 1|
9977601|NCT01363362|Experimental|glaucoma patients|Glaucoma patients undergoing selective laser trabeculoplasty for further IOP reduction
10175965|NCT03838003|Experimental|Experimental: Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
10175966|NCT03838003|No Intervention|No Intervention: Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
9679522|NCT04950205|Experimental|Sevoflurane post conditioning group（S1）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery ,1% sevoflurane plus after open Carotid artery until the end of surgery
9679523|NCT04950205|No Intervention|The control group（P）|propofol：0.05～0.1mg/(kg.min) maintain throughout the whole surgery without sevoflurane
9679524|NCT04950153|Other|HIV Testing Intervention|Combination HIV testing and linkage to care intervention includes social media engagement and peer navigation
9679525|NCT04950153|Other|HIV Treatment Intervention|Combination HIV treatment outcomes (retention, ART adherence and viral suppression) intervention includes SMS text messaging and peer navigation
9679526|NCT04950101|Active Comparator|HAS-N|In this arm the patient without HIV using PrEP will be included
9679527|NCT04950101|Active Comparator|HAS-P|In this arm the patient with HIV will be included
9679528|NCT04950439|Other|Myocardial CT|The investigator will collect the usual clinical history and data. Risk factors and cardiovascular events are identified. A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
9679529|NCT04950452|Experimental|CLL-EX|Subjects will undergo supervised exercise training 3 x per week for 12 weeks. Three/sessions per week will consist of intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes. Following this, on 2 occasions/week subjects will complete muscular endurance resistance training on machine weights.
9679530|NCT04950452|No Intervention|CLL-CON|Subjects will not receive supervised exercise training and will be asked to maintain their daily lifestyle behaviors.
9679531|NCT04950088|Active Comparator|Game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
9679532|NCT04950088|Active Comparator|no game|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."
9679533|NCT04950049|Active Comparator|2 ml dexamethasone (5 mg/ml)|50 patients receive 2 ml dexamethasone (5 mg/ml) , the injection time of dexamethasone was less than 2s.
9679534|NCT04950049|Experimental|5 ml dexamethasone (2mg/ml)|50 patients receive 5 ml dexamethasone (2mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
9679535|NCT04950049|Experimental|10 ml dexamethasone (1mg/ml)|50 patients receive 10 ml dexamethasone (1mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
9679536|NCT04950049|Experimental|20 ml dexamethasone (0.5mg/ml)|50 patients receive 20 ml dexamethasone (0.5mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.
9679537|NCT04950400|Experimental|Carrelizumab + chemotherapy + apatinib|
9679538|NCT04949984|Experimental|Bright light therapy|The devices used for the intervention were bright white light lamps providing an intensity of 10,000 lux. Four users participated in each session, placing two users per lamp, seated in a comfortable chair with armrests 70 cm from the lamp. The sessions were 30 minutes/day in the time slot between 10:30 and 12:00 in the morning, 5 days a week (Monday to Friday) for 4 weeks (total 20 sessions). Two groups of participants per day were established, the first shift being from 10:30 to 11:00, and the second from 11:15 to 11:45 a.m., which means the stimulation of 8 people per day (month). During the sessions, while exposed to light, participants were watching documentaries on neutral topics (nature, Spanish and Galician culture, etc.).
9679539|NCT04949984|No Intervention|Control group|Participants were evaluated before and after the experimental group finishes the intervention program (pre- vs. postintervention) to facilitate an examination of the changes in the outcome measures.
9695438|NCT04778202||Second group (breast cancer patient group)|25 female patients referred to radiology departement at South Egypt Cancer Institute or Assiut University Hospital diagnosed as breast cancer patients as evidenced by clinical examination , mammography and histopathology
9695439|NCT04778137|Experimental|CMAB007|75mg×2
9977602|NCT01363375||normal foot|Subjects with normal foot structure
10175967|NCT03838029|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 35 days as follows. Etodolac:400mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery and the following morning, 40 mg PO bid for following 6.5 days, and 20 mg PO bid for next 22 days.
10175968|NCT03838029|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
10175969|NCT03837834|Experimental|4 MIN X 4 MIN HIIT of FES-LCE|4 min of high-intensity phase intersperses with 4 min of low-intensity phase for a total of 5 bouts.
10175970|NCT03837834|Experimental|2 MIN X 2 MIN HIIT of FES-LCE|2 min of high-intensity phase intersperses with 2 min of low-intensity phase for a total of 10 bouts.
10175971|NCT03837782|Experimental|minimally invasive surgery|"Patients were randomized to undergo minimally invasive radical resection (endoscopic surgery or robotic assisted surgery). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability)."
9695440|NCT04778137|Active Comparator|Xolair|150mg
9977603|NCT01363375||flat foot|Subjects with flat foot structure.
10175972|NCT03837782|No Intervention|open surgery|"Patients were randomized to undergo open radical resection (laparotomy). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability).~Exclusion criteria included a history of abdominal or pelvic radiotherapy, or evidence of metastatic disease on positron-emission tomography-computed tomography, magnetic resonance imaging, or computed tomography."
10175973|NCT03837938|Experimental|Levopront® syrup 30 mg/5 ml|Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml t.i.d. for 7 days The study drugs will be taken t.i.d. (with the interval of not less than 6 hours, between meals) during 7 days.
10175974|NCT03837938|Active Comparator|Libexin® 100 mg tablets|"Libexin® (prenoxdiazine) 100 mg tablets~1 tablet t.i.d. for 7 days."
9679540|NCT04950218||Psoriasis patients|Eligible psoriasis patients will be identified from the daily outpatient program, at the Department of Dermato-Allergology, that is the department will provide the patient's contact information to the project group. As most outpatient clinic psoriasis is classified as moderate to severe, in order to approximate a random sample as accurate as possible including patients with mild psoriasis, all people with a diagnosis of psoriasis will a general invitation to participate in the study through appropriate channels such as the Danish Psoriasis Foundation's newsletter.
9679541|NCT04950218||Control group|The control group will consist of a retrospective random sample of around 1.000 patients from the general population examined in the 4th and 5th Copenhagen City Heart Study, 2001-2003 and 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
9679542|NCT04949958|Experimental|Experimental: Exercise Based Manual (Supervised)|Supervised Exercises with exercise based Manual (exercise & Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of different type of exercises including warm up and rest interval
9679543|NCT04949958|Experimental|Experimental: Exercise Based Manual (Home Based)|Experimental: Exercise Based Manual (Home Based) Home Based- Exercise Manual (Exercise & Educational Component) for 16 weeks. Subject will be asked to maintain a regular exercise.
9679544|NCT04949958|Placebo Comparator|Placebo Comparator: Control|Age matched Control Group followed for 16 weeks with General Advise to active
9679545|NCT04950023||early COPD|1) <60 years old; 2) smoking ≥ 10 pack years. 3) with any of the following anomalies: a. Post-bronchodilator FEV1/FVC< 0.7. b. CT image abnormalities: emphysema, air trapping or bronchial wall thickening; c.Rapid decrease of FEV1 (>60 ml/yr).
9679546|NCT04950023||Control|1) <60 years old; 2) Pre-bronchodilator FEV1/FVC≥70% and FEV1 ≥ 80% predicted; 3) no exposure to harmful factors such as cigarettes and dust pollution.
9679547|NCT04950036||Normal control group-Grade 0|Arthroscopic examination of the hip was normal, and the labrum was intact without injury or tear.
9679548|NCT04950036||Ligament injury -Grade 1|Arthroscopic examination of the hip showed labrum degeneration or injury, but no local or complete tear.
9679549|NCT04950036||Ligament tear-Grade 2|Arthroscopy of the hip revealed partial or complete loss of labrum.
9679550|NCT04949997||control|patients without heart failure
9679551|NCT04949997||HF|patients with heart failure
9679552|NCT04950530|Experimental|Arm 1|"Biktarvy - one tablet once daily, orally administered for the first 28 days of the study.~No treatment for the last 44 days of the study."
9679553|NCT04950530|Experimental|Arm 2|No treatment for the first 28 days of the study. Biktarvy - one tablet once daily, orally administered for the last 28 days of the study (day 44-72).
9679554|NCT04950283||Magnetic resonance examination and anthropometric, metabolic characterization|
9679555|NCT04949919|Experimental|ESRD patients with supervised training|The participants will receive in-hospital supervised exercise training prior to HD
9679556|NCT04950270||Group|Critically ill adult patients meeting all eligibility criteria with MRI-based PRES diagnosis within the last 48 hours
9679557|NCT04950374|Experimental|Moisturizer Body Lotion and Lip Moisturizer Regimen|All participants will receive and use both products.
9679558|NCT04949945|Experimental|CHF patients who will receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients)(experimental group) will receive guided self help culturally adapted cognitive behavioral therapy.
9695441|NCT04778280||Group A|1-Group A(Healty group with negative Giardia lamblia or control group) 96 samples
9977604|NCT01363375||high arch foot|Subjects with high arch foot structure.
10175975|NCT03837808|Experimental|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT
10175976|NCT03837808|Active Comparator|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT
10175977|NCT03837665|Experimental|PRP Treatment|Participants receive platelet rich plasma treatment. Participants will be asked to make up to 5 trips to the clinic (one for eligibility, one for the PRP, three follow-up visits). Participation is expected to last up to about 6 weeks. After the second visit and application of PRP, patients will be monitored closely for any complications or concerns. This will include a follow up phone call 3-5 days after the initial application of PRP. Patients will also be followed closely in 2 week intervals or sooner should any problems or concerns arise.
10175978|NCT03837535||Patients undergoing surgery|Swedish patients, >18 years undergoing surgery 2007-2014
10175979|NCT03837704|Active Comparator|IQOS Arm|Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
10175980|NCT03837704|Active Comparator|CC Arm|Patients diagnosed with AAA, continuing to smoke cigarettes
9977605|NCT01363414|Experimental|Artificial tear|One drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
9679559|NCT04949945|No Intervention|CHF patients will not receive guided self help culturally adapted cognitive behavioral therapy|CHF(Chronic heart failure patients) (control group) will not receive Self Help Culturally Cognitive Behavior Therapy.
9679560|NCT04949867|Active Comparator|Dual-hormone Closed-loop|FiAsp® and GlucaGen®.
9679561|NCT04949867|Placebo Comparator|Single-Hormone Closed-loop|FiAsp® and isotonic saline.
9679562|NCT04949880|Experimental|Group A|Drug-Eluting Balloon Dilatation Catheter
9679563|NCT04949906||The experimental group|The application of raising serum brain granules
9679564|NCT04949906||The control group|No nourishing serum brain granules are used
9679565|NCT04949932|Experimental|Intervention Arm|Poly herbal powder (PHP)
9679566|NCT04949932|Placebo Comparator|Placebo Arm|Powder of Cicer arietinum
9679567|NCT04950062|Experimental|High intensity interval training|Group A included 30 subjects who will participate in high intensity interval training on a treadmill for 12 weeks, 3 times/week.
9679568|NCT04950062|Active Comparator|Intermittent fasting|Group B that included 30 subjects will participate in intermittent fasting for 12 weeks, 3 times/week.
9679569|NCT04949646|Experimental|pIONM|"In the experimental group pIONM will be performed intraoperatively. For the implementation of pIONM, a special device, that allows simultaneous monitoring of sphincter signals and bladder manometry, will be introduced. This device will employ the placement of a bipolar electrode in the internal and external anal sphincter. Moreover, another electrode will be placed on the surrounding tissues. For bladder manometry, the catheter will be connected to the pressure sensor, and subsequently to the pIONM monitor. Intraoperatively, depending on the approach (open or laparoscopic), the respective bipolar stimulator will be used.~Prior to the initiation of pIONM, urinary bladder will be drained and filled with 200 ml R/L. The pIONM parameters will be the following: 1-25 milliampere current, 30 Hz frequency and 200 μs monophasic pulses."
9679570|NCT04949646|No Intervention|Control|In the control group pIONM will not be performed intraoperatively
10175981|NCT03837704|Active Comparator|Smoking Cessation Arm|Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
9679571|NCT04949776|Experimental|Double reading of all cases with and without Transpara software|Double reading of all cases with and without Transpara software
9679572|NCT04949464|Experimental|Prevention (smoking cessation, nicotine replacement, LDCT)|Patients use the smartphone application, Positively Smoke Free - Mobile, for 42 days. Patients also receive nicotine replacement therapy for 12 weeks. Within 60 days of study registration, patients undergo LDCT.
9679573|NCT04949672||Open TME|Total Mesorectal Excision (TME) is the gold standard surgical treatment of rectal cancer. According to the technique first described by Bill Heald, TME entails the resection of the rectum including the whole mesorectal fat and an intact mesorectal fascia. Open TME is accomplished through a midline xifo-umbilical laparotomy and requires a complete mobilization of the left colon and central ligature of inferior mesenteric artery and vein.
9679574|NCT04949672||Laparoscopic TME|Laparoscopic TME mirrors the procedure performed through laparotomy with the same operative steps and performing rectal resection including the excision of the surrounding mesorectal fat and fascia.
9679575|NCT04949672||Robotic TME|Robotic TME mirrors the procedure described by Bill Heald for open surgery but the operation is performed by the master-slave DaVinci System under 3D laparoscopic guidance. The rectal resection is performed including mesorectal fat and fascia.
9679576|NCT04949672||TransAnal TME|TaTME has first described by Antonio Lacy in 2012. This procedure has two steps: abdominal and perineal. The abdominal step is performed through a laparoscopic approach as described for laparoscopic TME but the caudal dissection is stopped right below the level of the peritoneal rectal reflection (Douglas pouch). The perineal step is accomplished transanally inserting a specially designed platform into the anal canal and performing the total mesorectal excision under endoscopic guidance.
9679577|NCT04949659|Experimental|Low pressure pneumoperitoneum|Use of low pressure pneumoperitoneum during laparoscopic appendectomy
9679578|NCT04949659|Experimental|Medium pressure pneumoperitoneum|Use of medium pressure pneumoperitoneum during laparoscopic appendectomy
9679579|NCT04949516|Experimental|Mono Antiplatelet and Colchicine Therapy|Aspirin-free, single P2Y12 inhibitor (prasugrel or ticagrelor) and colchicine treatment
9679580|NCT04949802|Experimental|laser|treated with Vialase laser
10175982|NCT03837509|Experimental|INCB001158 + daratumumab SC|INCB001158 + daratumumab
10175983|NCT03837509|Active Comparator|Daratumumab monotherapy and crossover to INC001158+ daratumumab SC|Daratumumab will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
10175984|NCT03837509|Experimental|INCB001158 monotherapy and crossover to INC001158+ daratumumab SC|INCB001158 will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
9695442|NCT04778280||Group B|2- Group B(Cases group with positive Giardia lamblia )96 sample
9695443|NCT04778462|Experimental|Extracorporeal shock wave|Extracorporeal shock wave group A consist of 15 subject will receive extracorporeal shock wave and conventional treatment for trigger points for two weeks four treatment sessions
9695444|NCT04778462|Experimental|High-power pain thershold ultrasound|High -power pain thershold group b consist of 15 subject will receive high power pain threshold ultrasound and conventional treatment for upper trapezius trigger points for two weeks four treatment session
9695445|NCT04778462|Other|Controlled group|controlled group consist of 15 subjects will receive conventional treatment for trigger point for two weeks
9695446|NCT04777942|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
9695447|NCT04777942|Active Comparator|surgery alone|hepatic resection remove the liver tumors
9695448|NCT04777955|Experimental|Group 1, core stabilization exercises group|core stabilization exercises will be performed using swissball. Program: Sitting on the ball will include (weight shifts, forward, backward and lateral sides), (pelvic bridge), (curl-up), (curlsup with diagonal reaching), (bird-dog exercise), (push-up) exercises. The application will be carried out for 6 weeks, 3 days a week for 30-45 minutes daily.
9977606|NCT01363414|Placebo Comparator|Control|one drop of sterile 0.9% sodium chloride solution in the other eye
9679581|NCT04949581|Experimental|bioelectric therapy|patients will receive micro-current electrical stimulation three times/week for four weeks
9679582|NCT04949581|Active Comparator|cardiac rehabilitation programe|patients will receive a cardiac rehabilitation program three times/week for four weeks
9679583|NCT04949451|Placebo Comparator|TRF-C|Follows time restricted feeding protocol.
9679584|NCT04949451|Experimental|TRF-P|Follows time restricted feeding protocol, consumes protein supplement
9679585|NCT04949451|Experimental|TRF-S|Follows time restricted feeding protocol, consumes ketogenic supplement
9679586|NCT04949971||High volume group|The tidal volume of the exposed group was 10ml/kg ideal body weight.
9679587|NCT04949971||Low volume group|The tidal volume of the non-exposed group was 6ml/kg ideal body weight
9679588|NCT04949698||No TMA|parturients without thrombotic microangiopathies
9679589|NCT04949698||TMA with plasma exchange|parturients with thrombotic microangiopathies, and treated with plasma exchange
9679590|NCT04949698||TMA without plasma exchange|parturients with thrombotic microangiopathies, but not treated with plasma exchange
9679591|NCT04949542|Experimental|Bolster|Participants in the experimental arm will be provided access to the Bolster smartphone application designed to support caregivers of young adults with early psychosis. They will also have access to the research team by phone for technical troubleshooting and support as necessary.
9679592|NCT04949542|Other|Control|Participants in the control condition will be provided support resources from mental health advocacy organizations representing currently available resources for caregivers (including a selection from the National Alliance on Mental Illness and Mental Health America). They will also have access to the research team by phone for technical troubleshooting and support as necessary.
9679593|NCT04949607|Experimental|Chronic Traumatic Brain Injury|Subjects aged 18-70 years with chronic traumatic brain injury receiving Inulin treatment.
9679594|NCT04949607|Experimental|Healthy Controls|Healthy subjects aged 18-70 years receiving Inulin treatment.
10175985|NCT03837561|Experimental|Cunox|Cunox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
9679595|NCT04949282||Lutathera|
9679596|NCT04949113|Experimental|A: Neoadjuvant|"2 cycles of neoadjuvant ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by a total lymph node dissection (TLND) and if applicable, resection of in-transit metastases.~Patients not achieving a pathologic response in arm A will also receive adjuvant nivolumab 480 mg every 4 weeks 11 cycles. In case of BRAF V600E/K mutation-positivity, patients will be treated with adjuvant dabrafenib plus trametinib for 46 weeks instead."
9679597|NCT04949113|Active Comparator|B: Adjuvant|Standard upfront total lymph node dissection (TLND) and if applicable, resection of in-transit metastases followed by 12 cycles adjuvant nivolumab 480 mg every 4 weeks
9679598|NCT04949334|Experimental|Dofin Breathing Strength Builder|Usual post stroke care and respiratory muscle training
10175986|NCT03837561|Active Comparator|Botox|Botox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
10175987|NCT03837548|Experimental|Training with Neurofeedback|
9679599|NCT04949334|No Intervention|Usual post stroke care|Usual post stroke care
9679600|NCT04949217|Experimental|Inlay Bristow Group|Inlay Bristow procedure
9679601|NCT04949217|Active Comparator|Onlay Bristow Group|Onlay Bristow procedure
9679602|NCT04949178||Critically ill cirrhotics with septic shock and AKI undergoing CRRT|Consecutive critically ill cirrhotics with septic shock and AKI who give written informed consent will be included in this prospective study
9679603|NCT04949308||Genetic diagnosis|Genetic: Genetic diagnosis No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
9679604|NCT04949360|Active Comparator|Standard CBTi (CBTi-S):|This is a positive control group/active comparator, in which standard CBTi (the golden standard behavioral treatment for insomnia) will be made available. This treatment consists of an eight-week treatment composed by weekly and structured appointments with a board-certified sleep psychologist. The professionals performing the CBTi sessions will not be part of the research team. Due to the restriction imposed by the COVID-19 pandemic, the appointments will be made remotely (video calls with psychologists), which have already been proven to be equivalent to the in-person CBTi.
9679605|NCT04949360|Placebo Comparator|Minimal intervention - Sleep hygiene (MI-SH):|This group corresponds to a negative control group/placebo comparator, subjected to minimal intervention. It is based on the delivery of informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no-treatment or waiting list controls, due to the behavioral nature of insomnia.
9679606|NCT04949360|Experimental|Online CBTI (CBTI-O)|This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
9679607|NCT04949360|Experimental|Online CBTi + additional features (CBTi-O+)|This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.
9679608|NCT04949204||Migraine patients|Wearable wrist sensor + headache application on smartphone
9679609|NCT04949204||Cluster Headache Patients|Wearable wrist sensor + headache application on smartphone
9679610|NCT04949230||COVID-19 Patients|Subjects who have recovered from COVID-19
9679611|NCT04949048|Experimental|Magneto PE Kit|Treatment with Magneto PE Kit
10175988|NCT03837548|Experimental|The other Training with Neurofeedback|
10175989|NCT03837210|Experimental|Test Drug|This group is treated with Herbal formulation.
10175990|NCT03837210|Active Comparator|Control Drug|This group is treated with Quintuple therapy
10175991|NCT03837301|Experimental|NESS-EFTR|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation (basin dissection)
10175992|NCT03837288|No Intervention|Vaginal progesterone only|continue on vaginal progesterone only
9679612|NCT04949126||acute pain of pulpal origin|no intervention
9679613|NCT04949126||anxious group|no intervention
9679614|NCT04949347||Glycerin-preserved, human-donor, cornescleral patch grafts|Consecutive glaucoma patients who had undergone glaucoma drainage device implantation using glycerin-preserved, human-donor, cornescleral patch grafts
9679615|NCT04949477|Active Comparator|Group (D)|The patient will receive intranasal dexmedetomidine.
9679616|NCT04949477|Active Comparator|Group (P)|The patient will receive paracetamol orally.
9679617|NCT04949321|Experimental|Gadovist (gadobutrol) / two MRI|60 Meniere's Disease patients and 20 healthy volunteers (sample of 5 volunteers per MRI machine)
9679618|NCT04949087|Experimental|Corticosteroid Injection Group|80mg Depo-Medrol and 8cc Lidocaine ultrasound-guided intra-articular injection
9679619|NCT04949087|Active Comparator|Platelet-Rich Plasma Injection Group|15cc blood draw in Arthrex Autologous Conditioned Plasma (ACP) kit and processed per manufacturer instructions Ultrasound-guided intra-articular injection of isolated PRP
9679620|NCT04949386|Experimental|Treatment with S-1226 (8%)|Subjects randomized to this treatment arm will receive S-1226(8%) twice daily for 7 consecutive days. S-1226 will be administered by inhalation for 3-4 minutes.
9679621|NCT04949386|Placebo Comparator|Placebo|Subjects randomized to receive placebo will be administered with medical grade air with 3ml saline (0.9% NaCl) using the Circulaire II hybrid system. Placebo will be administered by inhalation for 3-4 minutes.
9679622|NCT04948944|Experimental|active transcranial direct current stimulation|The investigators use Soterix mini-CT Stimulator to deliver 30 minutes 2mAmp tDCS to the bilateral DLPFC (optimized lateral electrode placement montage), with the the anode on the left hemisphere and the cathode on the right hemisphere. The electrodes are rubber and are placed in an MRI compatible holder and affixed with conductive paste. The investigators will use a bespoke headstrap to place the electrodes, which are held in place by the conductive paste.
9679623|NCT04948944|Sham Comparator|sham transcranial direct current stimulation|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
9679624|NCT04949009||Patients with primary immune thrombocytopenia (ITP)|"Ever been diagnosed as ITP patients. The diagnostic criteria comply with the Chinese Guidelines for the Diagnosis and Treatment of Adult Primary Immune Thrombocytopenia (2020 Edition)"
10175993|NCT03837288|Experimental|Cervical cerclage plus vaginal progesterone|cerclage with vaginal progesterone.
9679625|NCT04948814|Experimental|ASD children|50 ASD children who meet the eligibility requirements will receive a fecal microbiota transplantation following a 2-week treatment with Vancomycin (40mg/kg/day). Fresh stool sample will be obtained from the donor. Fecal bacteria transplantation will be achieved via endoscopy, nasogastric/nasointestinal tubes, the proximal colon by colonoscopy, or the distal colon by enema, rectal tube, or sigmoidoscopy or a combined approach. The amount of fecal bacterial liquid transplantation for children is 5ml/kg each time. Fecal microbiota transplantation will be conducted at week 3-4, week 6-7, week 9, week 11 and week 13 for total 5 round.
9679626|NCT04948814|No Intervention|healthy children|stool donor
9679627|NCT04948866|Experimental|Intervention Condition: ADRD-PC Program|"Dementia-specific palliative care delivered by hospital-based specialty interdisciplinary palliative care teams.~Standardized caregiver education will be provided by the palliative care team. Clinicians will share and discuss the booklet Advanced Dementia: A Guide for Families, which addresses common concerns and treatment decisions.~Transitional care will be provided by the palliative care team, including facilitation of community-based services and two post-discharge telephone calls."
9679628|NCT04948866|Active Comparator|Control Condition|Patient-family caregiver dyads randomized to the control arm will receive educational materials from the Alzheimer's Association, specifically designed for late-stage ADRD caregivers. The patient will receive usual hospital and post-acute care.
9679629|NCT04948827|Experimental|Part A - Single-Dose (Active)|Each Part A cohort will be randomized to either active SBP-9330 or matching placebo in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
9679630|NCT04948827|Placebo Comparator|Part A - Single-Dose (Placebo)|Each Part A cohort will be randomized to either active SBP-9330 or matching placebo in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
9679631|NCT04948827|Experimental|Part A - Single-Dose Food-Effect (Active)|In this two-period food-effect cohort, each subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
9679632|NCT04948827|Placebo Comparator|Part A - Single-Dose Food-Effect (Placebo)|In this two-period food-effect cohort, each subject will receive the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects will receive the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort.
10175994|NCT03837249|Placebo Comparator|Passive Personal Sleep Monitoring|Wears personal sleep monitor but does not actively self-monitor (will have access to the sleep data and self-monitoring after 4 weeks).
10175995|NCT03837249|Active Comparator|Individual Personal Sleep Monitoring|Wears personal sleep monitor and actively self-monitoring sleep and using data to self-manage sleep.
10175996|NCT03837249|Active Comparator|Socially Supported Sleep Monitoring|Wears a personal sleep monitor, actively self-monitoring using sleep data to self-manage sleep and shares data for supportive self-management.
10175997|NCT03837275|Experimental|humsfe|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique)
10175998|NCT03837275|Active Comparator|closed sinus lift|transcrestal maxilllary sinus floor elevation
9679633|NCT04948827|Experimental|SBP-9330 - Multiple-Dose (Active)|Each Part B cohort will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
10175999|NCT03837197|Experimental|Kidney-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.
9679634|NCT04948827|Placebo Comparator|Placebo - Multiple-Dose (Placebo)|Each Part B cohort will be randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.
9679635|NCT04948840|Other|Group A|Patients with early grade ≥2 radio-induced epidermis Intervention : blood sample
9679636|NCT04948840|Other|Group B|Patients with early grade 0-1 radiation-induced epidermis Intervention : blood sample
9679637|NCT04948840|No Intervention|Group C|Patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
9679638|NCT04948840|No Intervention|Group D|Patients without late pathologic radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years) No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
9679639|NCT04948840|No Intervention|Group E|Control group : patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
9679640|NCT04948749|Experimental|DES with aggressive medical treatment group|"Device: drug eluting stent The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.~Aggressive Medical treatment The medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment), intensive management of the primary risk (systolic blood pressure and low density lipoprotein [LDL]), and management of secondary risk factors (diabetes, non-high-density lipo- protein [non-HDL], smoking, weight, and exercise)."
9679641|NCT04948749|Active Comparator|Standard medical treatment group|The standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment), intensive management of the primary risk factors (systolic blood pressure and low density lipoprotein [LDL]), and management of secondary risk factors (diabetes, non-high-density lipo- protein [non-HDL], smoking, weight, and exercise).
9679642|NCT04948918|Experimental|Distal renal denervation|The arm comprises patients undergoing distal bilateral radiofrequency renal denervation performed using Symplicity Spyral renal denervation system.
9679643|NCT04948775|Experimental|Intervention Group|"A progressive home-based cervical stabilization exercise program is going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.~Home exercises are going to be prescribed three times in a week for six weeks. Repeats and durations of the exercises are going to be increased every week to provide progression."
9679644|NCT04948775|No Intervention|Control Group|Patients in control group are not going to receive any exercise intervention.
9679645|NCT04948853|No Intervention|Treatment as usual|Treatment as usual, with respect to employment, for individuals on probation typically entails the probation officer informing the probationer that probationer is responsible for obtaining employment or could entail a referral from a probation officer to an employment or job assistance service, such as vocational rehabilitation. The probationer is responsible for follow up with that service.
9679646|NCT04948853|Experimental|Intervention - Individual Placement Support-Supported Employment|Subjects in this condition will receive services from a 1.5 FTE IPS-SE team that will work to provide one-on-one person-centered services to help obtain employment, including but not limited to career profiling, resume assistance, job placement, training and other activities.
9679647|NCT04949035||COVID-19 survivors|
9679648|NCT04948684||Patients with dystonia secondary to atypical Parkinsonism or Parkinson's disease|Patients with dystonia secondary to idiopathic Parkinson's disease or atypical parkinsonism and treated with BoNT
9679649|NCT04948684||Patients with atypical Parkinsonism or Parkinson's disease and no dystonia|Patients with idiopathic Parkinson's disease or atypical parkinsonism and without reported dystonia
9679650|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 1)|
9679651|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 2)|
9679652|NCT04948788|Experimental|GemOx (Stage 2)|
9679653|NCT04948879||Vascular reconstruction|Patients who have undergone resection with or without reconstruction of a major blood vessel in the context of surgery for a locally advanced pelvic malignancy. This will mostly refer to patients who have had resection/reconstruction of their internal iliac vessels, or less likely common iliacs.
9679654|NCT04948996|Experimental|El Buen Consejo Móvil- Group (EBCM-G)|Participants in the group condition will be placed in groups of five participants within the app. Their version of EBCM will have the functionality to connect individuals to one another via a facilitator-guided chat room (EBCM-G), where they can respond to suggested strategies within the app and communicate with each other or their facilitator guide using voice or text.
9679655|NCT04948996|Active Comparator|El Buen Consejo Móvil- Individual (EBCM-I)|Participants randomized to EBCM-I will receive the same program contents without the group functionality.
9827792|NCT02468804|Experimental|Parkinson's Disease Subjects, (rTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
9977607|NCT01363427||Crohn's disease|Patients with initially diagnosed Crohn's disease
9977608|NCT01363453||Patients with Ulcerative Colitis|
10176000|NCT03837197|No Intervention|Kidney-Static Cold Storage|Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
9679656|NCT04948983|Active Comparator|Intervention group|"The intervention group will access a web page, answer a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The intervention group will complete the same questionnaires two weeks later. Six months later we will confirm if the screening was undertaken by checking medical records.~The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?"
9679657|NCT04948983|Placebo Comparator|Control group|"The Control group will access a webpage, answer a set of questionnaires at baseline, and then receive standardised information given by the healthcare system.~The control group will complete the same questionnaires two weeks later, afterwards they will access the DA. Six months later we will confirm if the screening was undertaken by checking medical records."
9679658|NCT04948697|Experimental|Arm A: ociperlimab + tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks
9679659|NCT04948697|Experimental|Arm B: tislelizumab + BAT1706|tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks
9679660|NCT04948957||esmolol (Group E)|
9679661|NCT04948957||nitroglycerin (Group N)|
9679662|NCT04948801||genotype 3a HCV|genotype 3a hepatitis C
10176001|NCT03837197|Experimental|Liver-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.
10176002|NCT03837197|No Intervention|Liver-Static Cold Storage|Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
10176003|NCT03837626|Placebo Comparator|Placebo|6 months of daily placebo
9679663|NCT04948801||genotype 6 HCV|genotype 6 hepatitis C
9679664|NCT04948801||genotype 3b HCV|genotype 3b hepatitis C
9679665|NCT04948541|Experimental|treatment|
9679666|NCT04948541|Experimental|no treatment|
9679667|NCT04948502|Experimental|SaExten Vena Cava Filter System|Manufacturer: ShenZhen KYD BioTech Co., Ltd. SaExten IVCF system is a retrievable IVCF system consists of two parts: the vena cava filter and the transporting system.The vena cava filter is a mesh filtering device that prevents the formation of pulmonary embolism by filtering the thrombus. SaExten IVCF system can be inserted through jugular or femoral veins, and can be retrieved through femoral veins within 90 days or indwelled permanently.
9679668|NCT04948502|Active Comparator|Denali inferior vena cava filter|Manufacturer: C. R. BARD. Inc, US
9679669|NCT04948489|Experimental|LNG IUD+ Norethindrone Acetate|All eligible participants will have the LNG-IUD. Experimental participants will also receive norethindrone acetate 5 mg by mouth daily for 12 months.
9679670|NCT04948489|Placebo Comparator|LNG IUD+Placebo|All eligible participants will have the LNG-IUD. Participants in the placebo comparator group will also receive a placebo tablet, 1 tablet by mouth daily for 12 months.
9679671|NCT04948580|Experimental|ICC-T|5.5 days with 8 hours of training for teachers aiming at changing attitudes towards violence and equipping teachers with non-violent discipline strategies
9679672|NCT04948580|No Intervention|Monitoring condition|No intervention
9679673|NCT04948515||group 1 patients with severe covid 19 respiratory infections|Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17
9679674|NCT04948515||group 2 patients with non severe covid 19 respiratory infections|Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17
9679675|NCT04948450|Experimental|Intervention group|"Physical activity intervention:~Individual progressive resistance training with physiotherapists~Cognitive stimulation intervention:~Cognitive Stimulation Therapy with rehabilitation experts.~Metabolic and vascular risk factors:~Metabolic and vascular risk factors of the intervention group will be evaluated by cardiologists and endocrinologists. The study subjects will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologist and endocrinologists. The targets for blood pressure is less than 120/90 mmHg and the targets for HbA1c is less than 7 %"
9679676|NCT04948450|No Intervention|Control group|The control group will receive general health advice every 3 months based on their physical examination and blood findings. They will be provided information on the vascular risk factors for dementia and will be received instruction on exercise, lifestyle change.
9679677|NCT04948229||Control Group|This group will be included subjects who had no history or diagnosis of any disease, no infection history within last two weeks, no history of any particular medication, who were admitted to emergency department (ED) with complaints other than infectious issues, and who gave their written consent to participate in the study.
9679678|NCT04948229||Moderate Disease Group|This group will be consisted of the patients whose diagnoses of moderate COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
9679679|NCT04948229||Severe/Critical Disease Group|This group will be consisted of the patients whose diagnoses of severe/critical COVID-19 infection were confirmed by positive RT-PCR in ED according to WHO guidelines and who gave their written consent were included in the study.
9679680|NCT04948255||Healthcare Workers at the Gill Medical Centre|Clinical and non-clinical staff at the Gill Medical Centre will complete a validated stress questionnaire during the Covid-19 pandemic. A baseline was established in May, 2019.
10176004|NCT03837626|Experimental|Amiloride|6 months of amiloride (max dose 5 mg) treatment
10176005|NCT03837470|Experimental|Saline Loading and Diuretic Challenge|Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg
9679681|NCT04948567|Experimental|split-dose of Magnesium Sulfate solution|Those assigned to MSS group were instructed to take 30ml of 50% magnesium sulfate solution and then drink 600ml water on the evening before colonoscopy. 70ml of 50% MMS and then 1500ml water was taken at least 4 hours before procedure on the colonoscopy day.
9679682|NCT04948567|Placebo Comparator|split-dose of PEG|Patients in PEG group were instructed to take first dose of 1.5L PEG on the evening before colonoscopy and take the second dose of 1.5L PEG at least 4 hours before the colonoscopy procedure on the morning.
9679683|NCT04948242||Consecutive critically ill patients admitted to ICU with severe SARS-CoV-2 infection|Consecutive adult patients (> 16 years) with laboratory confirmed SARS-CoV-2 infection, detected by RT-PCR positive test of nasopharyngeal, oropharyngeal , swab or invasive respiratory samples according to the WHO recommendations. The follow-up of patients was to ICU discharge or death whichever occurred first. No interventions will be made. Only anonymized demographic data, clinical data, laboratory data and ventilatory support data will be collected. There is no standardized pharmacological treatment protocol. Only basic data are collected about the different treatments administered by the attending physician.
9679684|NCT04948190||SARS-CoV-2 Infected/ positive group|Has tested positive for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages). Aged 16 years or older, willing and able to provide informed consent.
9679685|NCT04948190||SARS-CoV-2 negative group|Has tested negative for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages, and in phase 2 part 1, 2 and 4 enrolment may be accepted using symptoms-based criteria). Aged 16 years or older, willing and able to provide informed consent.
9679686|NCT04948307|Other|SL BUP/NAL SOC background therapy|standard of care. Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
9679687|NCT04948307|Experimental|SL BUP/NAL + OXD01|standard of care + OXD01 (digital therapy). Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
9679688|NCT04948086||TT MTHFR genotype|
9679689|NCT04948086||Non-TT (i.e. CC/CT) MTHFR genotype|
9679690|NCT04948320||Temporomandibular Disorder Group|
9679691|NCT04948320||Control Group|
9679692|NCT04948203|Active Comparator|Sirolimus 0.5mg|Subject will take Sirolimus 0.5mg orally daily for 14 days.
9679693|NCT04948203|Active Comparator|Sirolimus 1mg|Subject will take Sirolimus 1mg orally daily for 14 days.
9679694|NCT04948203|Active Comparator|Sirolimus 2mg|Subject will take Sirolimus 2mg orally daily for 14 days.
9679695|NCT04948528||Case group:|All suspected upper tract urothelial carcinoma participants will be assigned to case group.
9679696|NCT04948528||Control group|All suspected upper tract urothelial benign participants such as ureteral/renal calculi, ureteral stricture, upper urinary tract polyps, pyelonephritis, urinary tuberculosis will be assigned to control group.
9679697|NCT04948177||Group A|Group A: Individuals who had normal pyloric orifice structure;
9679698|NCT04948177||Group B|Group B: Individuals who have abnormal pyloric orifice structure
9679699|NCT04948268|Experimental|Adaptive digital mental health intervention without coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and to prioritize psychological strategies to meet participant preferences.
9679700|NCT04948268|Experimental|Static digital Mental Health intervention without coaching|The static intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Messages and content will not be tailored based on participants profile or usage.
9679701|NCT04948268|Experimental|Adaptive digital mental health intervention with coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and to prioritize psychological strategies to meet participant preferences. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
9679702|NCT04948268|Experimental|Static digital Mental Health intervention with coaching|The static intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Message content, timing, and number, as well as the ordering of psychological content, will not be tailored based on participants profile or usage. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
9679703|NCT04948268|Active Comparator|Active control|The active control condition will provide a brief text message that includes a URL link to psychoeducational content, but will not include the messaging component described in experimental arms.
9679704|NCT04948294|Experimental|Channeled group|Group of patients using a channeled blade for videolaryngoscopy
9679705|NCT04948294|Active Comparator|Non-channeled group|Group of patients using a non-channeled blade (standard type) for videolaryngoscopy
9679706|NCT04948125|Experimental|treatment group|camrelizumab combined with apatinib
9679707|NCT04948385|Active Comparator|Patients|Deep sedation for digestive endoscopy.
9679708|NCT04948385|Other|Escorts|Accompanying persons are the adults who accompany the patients home. They do not receive any medication or intervention.
9679709|NCT04948008|Experimental|Treatment group 1|The subjects received IBI306 150 mg Q2W subcutaneously injected into the abdomen each time for 12 weeks;
9679710|NCT04948008|Experimental|Treatment group 2|The subjects received IBI306 300 mg Q4W subcutaneously injected into the abdomen each time for 12 weeks;
9679711|NCT04948372|Experimental|The terlipressin group|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
9679712|NCT04948372|Placebo Comparator|The usual care group|Patients in the usual care group were treated with standard care.
9679713|NCT04948281||Infection Group|A group of joint infection patients after arthroscopic ACL reconstruction surgery , diagnose was made according to American CDC criteria of joint infection
9679714|NCT04948281||Control Group|A group of patients which were matched to infections group retrospectively one-to-three who did not sustain any kind of infection after ACL reconstruction.
9679715|NCT04947904|Experimental|Optimised Restrictive Strategy|The volume of non-resuscitative fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in ICU according to a special protocol.
9679716|NCT04947904|No Intervention|Control|Resuscitation fluids, maintenance fluids, nutrition and drugs will be administered as usually performed and following most recent guidelines.
10176006|NCT03837405|Active Comparator|Diet Education|All participants will receive instruction in the Carbohydrate-Restricted (CR) diet and basic behavioral strategies in weekly, in-person, group sessions for 3 months. The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat.
9679717|NCT04947761|Experimental|modified Cheonwangbosimdan Hydrogel patch|Group receiving modified Cheonwangbosimdan Hydrogel patch
9679718|NCT04947761|Placebo Comparator|Placebo patch|Group receiving placebo patch
9679719|NCT04947748|Active Comparator|24 hour intravenous antibacterial therapy|S.Augmentin 1,2g x 3 i/v
9679720|NCT04947748|Experimental|24 hour oral antibacterial therapy|T.Augmentin 1g x 3 p/o
9679721|NCT04947878|No Intervention|Standard care|will not review a prompt list before their visit.
9679722|NCT04947878|Experimental|Prompt list|The patients in the intervention group will review a prompt list before their visit.
9679723|NCT04948034|Experimental|Treatment Arm|"A total of 68 metastatic colorectal cancer patients who have failed the first-line standard treatment will receive multisite SABR followed by Fruquintinib and Tislelizumab within two weeks from completion.~The dosing of Tislelizumab will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
9679724|NCT04947774||prophylactic cranial irradiation group|The extensive-stage SCLC patients will receive prophylactic cranial irradiation after standard first-line chemotherapy combined with immunotherapy, until disease progression or death.
9679725|NCT04947774||Observation group|Patients with extensive-stage SCLC do not receive preventive craniocerebral irradiation after standard first-line chemotherapy combined with immunotherapy until the disease progresses or death.
9679726|NCT04948164|Experimental|Test group|
9679727|NCT04948164|Placebo Comparator|Control group|
9679728|NCT04947891||Study group|Patients will be treated with intensive recovery method after surgery.
9679729|NCT04947891||Control group|Patients will be treated with regular recovery method after surgery.
9679730|NCT04948151|Experimental|Sildenafil Cream, 3.6%|
9679731|NCT04948151|Placebo Comparator|Placebo Cream|
9679732|NCT04947969|Experimental|Rear laser acupuncture group|Patients in the Real laser acupuncture group will receive real laser pen irradiation.
9679733|NCT04947969|Sham Comparator|Shame laser acupuncture group|Patients in the Shame laser acupuncture group will receive shame laser pen irradiation.
9679734|NCT04947735|Experimental|CYPRESS Extension Test Arm|Single vision, impact resistant spectacle lenses; CYPRESS Test Arm 1 and CYPRESS Test Arm 2 will move into CYPRESS Extension Test Arm
9679735|NCT04947735|Placebo Comparator|CYPRESS Extension Control Arm|Single vision, impact resistant spectacle lenses; CYPRESS Control Arm remains in control lenses as the CYPRESS Extension Control Arm
9679736|NCT04947722|Experimental|PREVENT Program|
9679737|NCT04947722|No Intervention|Control Group|Residents in homes allocated to the control group will receive usual care as provided within their home.
9679738|NCT04947696||1|Patients undergoing a Whipples procedure for pancreatic cancer
9679739|NCT04947501|Experimental|Participants with newly-diagnosed HR-Neuroblastoma|This pilot study of N9 as induction chemotherapy will enroll 15 patients with newly-diagnosed HR-NB.
9679740|NCT04947670|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
9679741|NCT04947670|Sham Comparator|Control Group|Sham intervention, maintenance of heart failure medications with option for cross-over renal denervation treatment after 12 months
9679742|NCT04947826|Experimental|HAIC + HLX10 + HLX04|HAIC: FOLFOX, q3w, up to 8 times; HLX10: 4.5mg/kg, iv, q3w, up to 2 years; HLX04: 15.0mg/kg, iv, q3w, up to 2 years.
9679743|NCT04947826|Placebo Comparator|HAIC + Placebo|HAIC: FOLFOX, q3w, up to 8 times; Placebo1: saline, iv, q3w, up to 2 years; Placebo2: saline, iv, q3w, up to 2 years.
9679744|NCT04947566|Experimental|Naproxen|in this group patients were given Naproxen
9679745|NCT04947566|Experimental|Ibuprofen|in this group patients were given ibuprofen
9679746|NCT04947488|Active Comparator|Bioarginina C|vials based on L-arginine and liposomal vitamin C
9679747|NCT04947488|Placebo Comparator|Placebo|vials without L-arginine and liposomal vitamin C
9679748|NCT04947423|Experimental|DPI-386 Nasal Gel|Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
9679749|NCT04947423|Placebo Comparator|Placebo|Placebo Nasal Gel (0.12 g)
9679750|NCT04948346||patient with ALS|
9679751|NCT04948346||patient'spouse(without ALS)|
9679752|NCT04947410|Active Comparator|OSAS Patients treated with CPAP|"Patients with OSAS will have 1 in 2 chance of being randomized into CPAP group"
9679753|NCT04947410|Sham Comparator|OSAS Patients treated with nasal dilators|"Patients with OSAS will have 1 in 2 chance of being randomized into nasal dilators group"
9679754|NCT04947410|No Intervention|Non OSAS Patients|Non OSAS Patients will be the parallel control group
9679755|NCT04947995||Gastric cancer group|
9679756|NCT04947995||Precancerous lesion group|
9679757|NCT04947995||Healthy group|
9827793|NCT02468804|Experimental|Control Subjects (rTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
10176007|NCT03837405|Experimental|Diet Education + Mindfulness|In addition to the diet components described above, participants randomized to the Education + Mindfulness (Ed+MBI) group will receive MBI components using the Eat Right Now (ERN) platform. This will consist of two integrated components: 1) use of the ERN app at home, during the week, to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based discussions of how the mindful eating practices are going, trouble-shooting obstacles/pain points, and doing group exercises and reflecting on them.
10176008|NCT03837327||Adnexal Mass|Women with an adnexal mass (pelvic mass) as confirmed by imaging
10176009|NCT03837457|Experimental|Cobomarsen|
10176010|NCT03837379|Other|Treatment As Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
9679758|NCT04947397|No Intervention|Group 1|Traditional deep extubation at 1.5 minimum alveolar concentration (MAC)
9679759|NCT04947397|Experimental|Group 2|Deep extubation guided by pupillometry -- at < 0.5 MAC of vapor + propofol and fentanyl
9679760|NCT04947371|Experimental|Anlotinib Hydrochloride|Oral anlotinib 12 mg/d
9679761|NCT04947865|Experimental|Post-stroke Stiff-Knee Gait Participants|Individuals with post-stroke Stiff-Knee gait
9679762|NCT04947865|Experimental|Healthy Individuals|Healthy Individuals
9679763|NCT04947982|No Intervention|Control|All laparoscopic surgical procedures were performed at 12 mmHg CO2 pressure throughout the surgery
9679764|NCT04947982|Experimental|Study|All laparoscopic surgical procedures were performed at 8 mmHg CO2 pressure throughout the surgery
9679765|NCT04947280|Experimental|Fractionated Stereotatic Radiation Therapy|
9679766|NCT04947228|Experimental|intervention group|in addition to the usual therapy, the patients were given access to the trackPAD app
9679767|NCT04947228|No Intervention|control group|patients in this group were treated as usual in the clinic without additional interventions.
9679768|NCT04947267|Experimental|3% mepivacaine|3% mepivacaine was administered via inferior alveolar nerve block.
9679769|NCT04947267|Active Comparator|2% mepivacaine with 1:100,000 epinephrine|2% mepivacaine with 1:100,000 epinephrine was administered via inferior alveolar nerve block.
9679770|NCT04947111|Other|Serological survey|A blood sample will be taken to estimate the specific serotype prevalence for dengue virus in groups of 5 to 35 years in areas of low and high dengue endemicity.
9679771|NCT04946929|Experimental|Ticagrelor, 2-3mg/kg, 12h|2-3mg/kg, q12h, p.o. for 2w
9679772|NCT04946929|Active Comparator|low molecular weight heparin|half amount low molecular weight heparin
9679773|NCT04946890|Experimental|MRX2843 orally 80 mg/d|"Participants received 80 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
9679774|NCT04946890|Experimental|MRX2843 orally 120 mg/d|"Participants received 120 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
9679775|NCT04946890|Experimental|MRX2843 orally 180 mg/d|"Participants received 180 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days~1 to 21 of a 21-day cycle."
9679776|NCT04947345|Experimental|Experimental group: Remimazolam Besylate|Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of Remimazolam is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.2-1 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and Remimazolam, no analgesic or sedative could be used during the experimental time period.
9679777|NCT04947345|Active Comparator|Positive control group: Propofol|"Patients should be given study drugs as soon as possible after entering the ICU. Syringe pump is used to administer medication. Loading dose of propofol is 0.2 mg/kg, which is administered for less than 1 min initially. Maintaining dose is 0.3-4.0 mg/kg/h. Sedative target is RASS between 0 and -2 points. Excepts for fentanyl and propofol, no analgesic or sedative could be used during the experimental time period.~Rescue therapy for experimental group During the treatment of the experimental group, if the RASS cannot be maintained at 0 to -2 points at the maximum Remimazolam maintenance dose of 1 mg/kg/h, a loading dose of propofol (0.2 mg/kg) can be given intravenously. If RASS fails to satisfied after three loading doses of propofol, Remimazolam is discarded and 0.3-4.0 mg/kg/h of propofol are used as rescue therapy for experimental group."
9679778|NCT04947189|Experimental|Seviteronel, dexamethasone and docetaxel|"Part 1: Seviteronel will be administered orally beginning with 450 mg (3 x 150 mg tablets) once daily along with 0.5 mg dexamethasone, continuously in 28-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly.~Part 2: The recommended phase 2 dose for seviteronel (established in Part 1) once daily along with 0.5 mg dexamethasone, continuously in 21-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly."
9679779|NCT04947306||All subjects|"Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia at our Institution in which the administration of rocuronium for neuromuscular blockade is anticipated.~All participants will be monitored with both TOF Watch and Tetragraph neuromuscular monitors."
9679780|NCT04947254|Active Comparator|Group A (Apa, ADT, XRT)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9827554|NCT02460822|Experimental|MyChemoCare|Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
9977609|NCT01363466|Experimental|with hysterectomy|
9679781|NCT04947254|Experimental|Group B (Apa, ADT, XRT, AAP, niraparib)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive abiraterone acetate PO QD, prednisone PO BID, physician's choice ADT, and niraparib PO QD. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
10176011|NCT03837379|Experimental|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
10176012|NCT03837366|Experimental|Activity Tracker with Health Coaching|Participants assigned to this condition will receive a Fitbit activity tracker to use for 3 months. Also, they will be asked to come in for a visit approximately one week following baseline assessments. Using the principles of Motivational Interviewing and Habit Formation, participants will discuss their perceived benefits and barriers of becoming more physically active with a member of the research team. They will also be encouraged to set a goal related to using their Fitbit to increase their physical activity. Lastly, they will be given information regarding habit formation and encouraged to identify one or more cues that regularly occur in their daily life to check their Fitbit data as a prompt to engage in physical activity.
9679782|NCT04947215||Cases group|It includes 100 neonates who are admitted in the neonatal intensive care unit in Assiut University children hospital suffering from RDS. The cases will be subdivided into subgroups according to1. Full term or preterm, 2. Type of pregnancy (normal or complicated), 3. Mode of delivery, and 4. LPCAT1 genetic polymorphism.
9679783|NCT04947215||control group|include 60 neonates without RDS.
9679784|NCT04947241|Experimental|Neoadjuvant therapy|Patients included are going to receive neoadjuvant therapy, surgery and adjuvamt therapy post surgery. Before surgery, patients will receive therapy as follows: PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles
9679785|NCT04947176|Active Comparator|Active|200mg of pentadecanoic acid (C15:0) supplementation in capsules form
9679786|NCT04947176|Placebo Comparator|Placebo|Matching placebo in capsules form
9679787|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with nicotine replacement therapy and text support|Participants in this arm will be instructed to quit tobacco cigarettes with nicotine replacement therapy (patches and lozenges) and text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
9679788|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with nicotine replacement therapy and text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with nicotine replacement therapy (patches and lozenges) and text message support.
9679789|NCT04946825|Experimental|Quit cigarettes, but continue using e-cigarettes, with text support.|Participants in this arm will be instructed to quit tobacco cigarettes with text message support. In addition, these participants will be encouraged to continue using electronic cigarettes to help them quit smoking tobacco cigarettes.
9679790|NCT04946825|Experimental|Quit cigarettes and quit e-cigarettes with text support.|Participants in this arm will be instructed to quit tobacco cigarettes and quit electronic cigarettes with text message support.
9679791|NCT04946981|Other|Randomized Crossover_Sequence 1|Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
9679792|NCT04946981|Other|Randomized Crossover_Sequence 2|Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase. Both study phases are separated by a washout period of minimum 14 days.
9679793|NCT04946864|Experimental|single arm|APG2575
9679794|NCT04946864|Experimental|combination arm|APG2575+palbociclib i
9679795|NCT04946903|Experimental|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008,~Period 2: Fasted state + HCP1902"
9679796|NCT04946903|Experimental|Sequence 2|"Period 1: Fasted state + HCP1902,~Period 2: Fasted state + RLD2007 + RLD2008"
9679797|NCT04946734|Experimental|Test Arm|Device PFO closure
9679798|NCT04946734|Other|Control Arm|Drugs only
9679799|NCT04946799|Experimental|Low-intensity training combined with blood flow restriction group (LI-BFR)|
9679800|NCT04946799|Active Comparator|High-intensity aerobic exercise group (HI)|
9679801|NCT04946799|Placebo Comparator|Low intensity group (LI)|
9679802|NCT04946513||Group 1|Patients with femoroacetabular impingement syndrome and underwent hip arthroscopy。
9679803|NCT04946539||Spondyloarthritis|
9679804|NCT04946474|Experimental|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
9679805|NCT04946474|Placebo Comparator|Placebo group|Xingnaojing injection simulation agent + Naoxueshu oral liquid simulation agent treatment was given.
9679806|NCT04946838|Experimental|TENS|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
9679807|NCT04946838|Sham Comparator|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
9679808|NCT04946812|Experimental|Intervention group|The velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%. While the speed of the treadmill will not change throughout the study, the duration of the training will increase each week. In the first week, the SBTM training will take place for 10 minutes. There will be a 5-minute rest period, and the split-belt conditions will continue for another 10 minutes of training (total training time= 20 minutes).
9679809|NCT04946812|Active Comparator|Control group|"The subject will continue to walk under tied-belt conditions adjusted to the over-ground walking speed. In the first week, the treadmill training will be for 10 minutes. They will get a 5-minute break, similar to the intervention group, and continue for another 10 minutes under tied-belt conditions.~The duration of each session will increase by 8 minutes every week. For example, in week 1, the treadmill training will be for a total of 20 minutes; in week 2, for 28 minutes; in week 3, for 36 minutes, and so forth, until it gets to 60 minutes by week 6. The rest period will remain at 5 minutes each session, and will always take place at the halfway mark. All 3 sessions in the week will have the same duration of training.~If the subject cannot tolerate the velocity or duration of the session, the protocol will be adjusted to most recently tolerated session (and will be recorded for further interpretation and analysis)."
9679810|NCT04946682|Experimental|Group of mNGS|
9679811|NCT04946682|Experimental|Group of PCR|
10176013|NCT03837366|Active Comparator|Activity Tracker alone|Participants assigned to this condition will use their Fitbit on their own for the duration of 3- month intervention, similar to the experience of participants buying the device off-the-shelf.
9679812|NCT04946461||group 1; lisdex - dex|subjects are assigned to group 1 based on the type of medication prescribed by the practitioner. Subjects which started with lisdexamphetamine are assigned to group 1.
9679813|NCT04946461||group 2; dex - lisdex|subjects are assigned to group 2 based on the type of medication prescribed by the practitioner. Subjects which started with dexamphetamine are assigned to group 1.
9679814|NCT04946500||Clindamycin and Rifampicin|Patients treated with Clindamycin and Rifampicin
9679815|NCT04946500||Clindamycin and Fluoroquinolone|Patients treated with Clindamycin and Fluoroquinolone
9679816|NCT04946695|Experimental|Telefisio India|Feasibility and efficacy of the use of Telephysiotherapy for improving functional independence and quality of life in children and young people with lower limb fracture in a low resource setting in Anantapur (India).
9679817|NCT04946448|Experimental|FIT group|Patients treated with biological treatment and the FIT diet
9679818|NCT04946448|No Intervention|Control group|Patients treated with biological treatment and the standard diet
9679819|NCT04946565||Sinopharm vaccine group|Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
9679820|NCT04946604|Other|Ashtangayoga|Participants attanded eight yoga sessions, one hour long.
9679821|NCT04946760|Sham Comparator|Sham Protocol|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention. To provide a sham for the OMT-WB protocol, subjects will lie supine with the physician's hands under the occiput, palms toward the table, so that the subject's head rests on the dorsal aspect of the physician's hands. The time used in the sham procedures will be approximately 20-25 minutes.
9679822|NCT04946760|Experimental|Whole-Body Protocol|"The whole-body protocol will include all the techniques in the OMT-ND protocol, but will also include techniques focused on the expected cranial dysfunctions [Rivera-Martinez 2002]. The OMT-WB protocol will last approximately 25-30 minutes.~The techniques will include:~Evaluation for strain pattern(s)~Occipitolatlantal decompression~Sphenobasilar synchondrosis decompression~Occipitomastoid suture V-spread~Temporal bone balancing~Venous sinus drainage technique"
9679823|NCT04946760|Experimental|Neck-down protocol|"The neck-down protocol takes into consideration previous relevant studies [Lopez 2011, Wells 1999]. OMT will be used bilaterally on the following areas with one or more techniques, including myofascial release, articulatory, muscle energy, and balanced ligamentous tension. The OMT-ND protocol will last approximately 15-20 minutes.~Cervical spine~Thoracic spine~Lumbar spine~Shoulder girdle~Sacroiliac joint~Innominates~Leg muscles (including psoas, piriformis, hamstring, adductors)~Ankles"
9679824|NCT04946578|Experimental|Prebiotic intervention group|Prebiotic supplementation
9679825|NCT04946578|Placebo Comparator|Placebo control group|Maltodextrin
9679826|NCT04946747|Active Comparator|Trained|"Both groups will be shown how to use the Virtual Reality goggles. The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.~Both groups will also wear our smart head-impact sensor system to measure their response to training."
9679827|NCT04946747|Active Comparator|Control|Both groups will be shown how to use the Virtual Reality goggles. The Control group will also receive the same CS and the same US, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge. Both groups will also wear our smart head-impact sensor system to measure their response to training.
9975971|NCT01346761|Experimental|Telephone genetic counseling|Participants randomly assigned to telephone counseling are mailed packets that included a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer (HBOC) genetic counseling with visual aids. At the time of their session, participants open their envelope and counselors use the visual aids to explain breast-ovarian cancer genetics and administer BRCA1/BRCA2 genetic counseling. Women receiving in-person counseling are given these same materials during their session at the community clinic. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
9977610|NCT01363466|No Intervention|without hysterectomy|
9977611|NCT01363505||Acute CHF patients|Acute CHF patients with BARD Intra-abdominal pressure monitors in ICU
9977612|NCT01363518||Operative|Operative group would have had surgery to treat their broken humerus.
9679828|NCT04946669|Experimental|Refractory Dermatomyositis|Patients who have been receiving glucocorticoids in combination with at least one immunosuppressive therapy for at least 3 months and who have failed therapy or are intolerant to therapy
9679829|NCT04946773||Malignancy Cohort|Patients with hepatic or hepatobiliary malignancy at enrolment
9679830|NCT04946773||Control Cohort|Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment
9679831|NCT04946487||group 1|patients in this group destructed the posterior ligamentous complex of the adjacent segment
9679832|NCT04946487||group 2|patients in this group did not destruct the of the posterior ligamentous complex of the adjacent segment
9679833|NCT04946617||H group|healthy periodontium, BOP at \20 % of the sites and no sites with probing depth (PD) [3 mm and clinical attachment level (CAL) [2 mm or alveolar bone loss (N = 20, 12 males, 8 females, mean age: 33.38
9679834|NCT04946617||G group|gingivitis, BOP at ≥20 % of the sites and no sites with PD and CAL [3 mm or bone loss (N = 20, 6 males, 14 females, mean age: 32.35);
9679835|NCT04946617||CP group|chronic periodontitis, ≥4 teeth in each jaw with PD of ≥5 mm, CAL of C4 mm, BOP at [≥80 % of the proximal sites and radiographic evidence of interproximal bone loss
9679836|NCT04946422||sports injury-related injuries|"Patients who are discharged from the hospital and diagnosed in accordance with sports injury-related injuries, and those whose service item names in the detailed database contain the keyword arthroscope. Any one of the above will be included in this topic."
9679837|NCT04946331|Experimental|Control|participants receive no surgical treatment
9975972|NCT01346761|Active Comparator|In-person genetic counseling|In-person BRCA1/BRCA2 genetic counseling is delivered by board-certified genetic counselors using a guide-line-concordant semistructured protocol that allows for personalization of counseling and is similar to that used by others. All sessions are audiotaped for treatment fidelity assessments. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
9679838|NCT04946331|Experimental|Rib Fixation Surgery|participants receive surgical treatment
9975973|NCT01346800|Experimental|Prasugrel 10mg po|
9975974|NCT01346800|Experimental|Prasugrel 10mg po + ritonavir 100mg po|
9975975|NCT01346826|Active Comparator|2 hours-infusion group|Number of patients: 57 (Standard 2 hours-infusion group)
9975976|NCT01346826|Experimental|1 hour-infusion group|Number of patients: 59 (1 hour-infusion group)
9975977|NCT01346826|Experimental|30 minutes-infusion group|Number of patients: 59 (30 minutes-infusion group)
9975978|NCT01346865|Experimental|cilostazol|cilostazol 100mg
9975979|NCT01346865|Placebo Comparator|dual therapy group|Placebo
9975980|NCT01346891||Hyponatremia Group (Cases)|Patients over 21 years old, with confirmed antecedent of thiazide-induced hyponatremia who required hospitalization with a serum sodium concentration lower than 125 meq/L.
9975981|NCT01346891||Good Thiazide Tolerance (Controls)|Patients over 21 years old, who have consumed thiazide diuretics for more than 2 years, with a serum sodium concentration persistently over 135 meq/L.
9975982|NCT01346917|Experimental|Lidocaine|
9975983|NCT01346917|Placebo Comparator|Placebo|
9975984|NCT01346930|Experimental|Macitentan|Macitentan tablet, 10 mg, once daily
9679839|NCT04946383|Experimental|Quercetin and Dasatinib supplements|500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.
9679840|NCT04946370|Experimental|Pembrolizumab + 225Ac-J591 + ARPI|Patients will receive one dose of 225Ac-J591 (single dose, either 65 or 90 Kbq/kg) in combination with pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule, examples of ARPI include enzalutamide and apalutamide).
9679841|NCT04946370|Experimental|Pembrolizumab + ARPI|Patients will receive pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule) without 225Ac-J591.
9679842|NCT04945980|Experimental|Low-MUFA ground beef|Participants consumed ground beef low in monounsaturated fatty acids.
9679843|NCT04945980|Experimental|High-MUFA ground beef|Participants consumed ground beef high in monounsaturated fatty acids.
9679844|NCT04946214|Other|Smart Water Bottle Intervention Arm|Patients will receive a smart water bottle, then instructed on bowel and bladder preparation for daily standard of care radiotherapy treatments for up to 10 weeks.
9679845|NCT04945954|Experimental|Cyclophosphamide|
9679846|NCT04946357|Experimental|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))
9679847|NCT04946357|Experimental|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))
9827555|NCT02460978|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
9975985|NCT01346943|Experimental|AAA Stent Graft System|Altura Medical AAA Stent Graft System
9975986|NCT01346982|Experimental|Silimarine|darunavir + ritonavir + silimarine
9975987|NCT01346995|Experimental|Experimental Knee Pain|Experimental knee pain induced by injections of 1 ml hypertonic saline in to the infrapatellar fat pad
9975988|NCT01346995|Active Comparator|Control|non-painful injections of isotonic saline into the infrapatellar fatpad.
9975989|NCT01347021|Active Comparator|sacrospinous, pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
9975990|NCT01347021|Active Comparator|uterosacral , pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
9975991|NCT01347099|Experimental|Internet CBT|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks.
9975992|NCT01347099|Placebo Comparator|Support therapy|10 weeks. Therapist support contact through e-mail.
9975993|NCT01347125|Experimental|ImCardia|Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
9975994|NCT01347125|No Intervention|AVR control group|Aortic stenosis patients candidates for aortic valve replacement
9975995|NCT01347138|Experimental|case management|case management regulary
9975996|NCT01347138|No Intervention|Control|usual care
9975997|NCT01347151|Experimental|Glide scope|
9975998|NCT01347151|Experimental|Pentax airway scope|
10176014|NCT03837613||Group 1 (TT<4mm)|Patients with a preoperative tumor thickness less than 4 mm. Intervention: tumor resection and neck dissection
10176015|NCT03837613||Group 2 (TT >= 4mm)|Patients with a preoperative tumor thickness equal to or more than 4 mm Intervention: tumor resection and neck dissection
10176016|NCT03837145||Liver transplant recipients|Adult patients requiring elective post-operative ventilation after a living donor liver transplant receiving intravenous propofol infusion for sedation titrated to Bi-Spectral Index (BIS) score of 60-80,as per our institutional protocol.
9679848|NCT04946084|Other|Healthy Children|Samples taken from nasal swabs, nasal wash, blood draws and in the case of acute otitis media, tympanocentesis
9679849|NCT04946162|Experimental|Tadalafil Group|Each patient will be given tadalafil 40 mg one time
9679850|NCT04946188|Experimental|Opuz NICGM|Participants will be provided with one non-invasive, custom-built prototype device (study device), which they will use throughout their day-to-day life/activities over the study period.
9679851|NCT04945876|No Intervention|Control group|"Participants is encouraged to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. No further follow up except for testing at 12 weeks and six months.~After the completion of the study the control group will be offered a session of individual exercise and diet guidance as well as a period of digital follow-up as needed."
9679852|NCT04945876|Experimental|Intervention group|Participants will receive a session of individual exercise and diet guidance with focus on goals and motivation for diet and exercise and help to overcome any barriers for self-efficacy. They will also receive an activity tracker and an introduction on how to use it. Further they will receive a monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise. The participants can also send sms if they have questions during the follow-up period. They will be encouraged to continue to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. If needed they can get help to find suitable exercise groups in their own municipality. The Garmin wristband will be used to facilitate daily activity and continuing exercise at recommended intensity level at home. Participants who are malnourished, or at risk of malnutrition, will receive specific guidance session on nutrition.
9679853|NCT04946240|Experimental|Supervised (BRACE) Group|the self-developed protocol (BRACE) is used in the experiment with a combination of balance, resistance, aerobic and cognitive exercises for 12 weeks with repetition of different tasks
9679854|NCT04946240|Active Comparator|Conventional Balance Exercises Group|The unsupervised home plan included balance and resistance exercise was guided to conventional group
10176017|NCT03837340|Experimental|FACT|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
10176018|NCT03837340|Active Comparator|CAU (Care as usual)|Patients with SMI receiving usual care, meaning mostly medical treatment
9679855|NCT04946136|Experimental|Gait modification|In this pilot study, participants modify their gait patterns guided by real-time visual feedback on their medial knee load while walking on an instrumented treadmill.
9679856|NCT04945902|Active Comparator|Asynchronous Group|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
9679857|NCT04945902|Experimental|Synchronous Group|If you are assigned to the synchronous intervention group, you will be required to complete the asynchronous interventions on Brightspace AND attend a weekly one-hour support group. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connections and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
9679858|NCT04945902|No Intervention|Waitlist|If you are assigned to the wait-list group, you will not have access to the asynchronous or synchronous interventions during the course of this study. After this study is completed, you will have access to the asynchronous intervention on Brightspace.
9679859|NCT04946019|Experimental|MR-Linac Guided Adaptive FSRT|Patients will receive FSRT (30Gy in 5 fractions) on the MR-Linac treatment machine.
10176019|NCT03837223||"patients underwent rescue protocols and fresh embryotransfer"|they were patients with good prognosis with a mean age of 34.13 ± 4.42 years, with a good ovarian reserve
9679860|NCT04946279|Experimental|Arm I (conversation tool)|Patients receive the conversation tool.
10176020|NCT03837106|Experimental|Rehabilitation program|Home and supervised exercise program specific to musicians. Injury prevention and management education program specific to musicians.
10176021|NCT03837106|No Intervention|No intervention|Control group, no intervention
9679861|NCT04946279|Active Comparator|Arm II (usual care)|Patients receive usual care.
9679862|NCT04946227|Experimental|Single Arm|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor.
9827556|NCT02460978|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
9975999|NCT01347164|Experimental|Life coaching sessions|6 2-hour counseling session with trained therapist/counselor. The sessions deal with coping and stress reduction as well as sexual health.
9976000|NCT01347164|Active Comparator|HIV counseling session|One 60-minute counseling session, based on standard HIV counseling content.
10187243|NCT03728192|Experimental|Mangosteen treated group|"HeLa and H357 cell lines were procured and were further subdivided into 2 subdivisions and were assigned interventions:~Mangosteen group- cells treated with mangosteen extract and Camptothecin group - cells treated with standard anticancer drug camptothecin(25 micro mole)"
10187244|NCT03728192|No Intervention|Untreated group|H357 and HeLa cell line without any drug intervention.
9679863|NCT04946045|Experimental|İntervention (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking) Group|"Tactile/Kinesthetic Stimulation (15 min): It was applied 3 times a day, once every 3 hours for 10 days.~Nonnutritive Sucking: It was applied 8 times a day for 10 days with Orogastric (OG) feeding throughout the feeding."
9679864|NCT04946045|No Intervention|Control (Nonnutritive Sucking) Group|1) Nonnutritive Sucking: Administered during feeding with Orogastric (OG) 8 times a day for 10 days.
9679865|NCT04946123|No Intervention|methimazole (control)|Patients with hyperthyroidism under methimazole treatment
9679866|NCT04946123|Experimental|methimazole+L-carnitine+selenium (intervention)|Patients with hyperthyroidism under methimazole treatment + supplementation with L-carnitine and Selenium
10176022|NCT03837236|Experimental|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
9679867|NCT04946201||With Extractions|Patients in this group will undergo dental extractions.
9679868|NCT04946201||Without Extractions|Patients in this group will not undergo dental extractions.
9679869|NCT04946071|No Intervention|Control|Period in which each group will not receive the arts-based HIV stigma intervention.
9679870|NCT04946071|Experimental|Group 1|"Arts-based HIV stigma intervention for three 8-week periods (24 weeks). The intervention will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
9679871|NCT04946071|Experimental|Group 2|"Arts-based HIV stigma intervention for two 8-week periods (16 weeks). Each intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
9679872|NCT04946071|Experimental|Group 3|"Arts-based HIV stigma intervention for one 8-week period. The intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
9679873|NCT04945889||Geriatric inpatients at risk for sepsis|"Consecutive patients admitted to an Acute Geriatric Unit for any reason presenting at least one National Institute for Health and Care Excellence (NICE) risk factor for sepsis (age ≥75 years, impaired immune function, long-term corticosteroid therapy, immunosuppressive or antineoplastic drug treatment, surgery or other invasive procedures within 6 weeks, any breach of skin integrity, intravenous drug misuse, indwelling lines or catheters).~In those with suspected infection (i.e. antibiotic prescription and a culture test within 24 hours before-72 hours after), clinical parameters (respiratory rate, blood pressure, heart rate, body temperature, peripheral oxygen saturation, mental status) were assessed at least twice daily throughout hospital stay and used by study investigators to determine the qSOFA, NEWS and MEWS."
9679874|NCT04945928|Experimental|Surgery after conversion therapy|Participants with locally advanced or advanced NSCLC who received first-line treatment have been evaluated as resectable after multidisciplinary discussion involving the department of thoracic surgery, respiratory medicine, radiology and oncology.
9679875|NCT04946097|Experimental|study group|received the conventional selected exercise program in addition to gross Myofascial Release
9976001|NCT01347177|Experimental|Zirconia-based adhesive bridges|Patients in this group will be treated with the employment of zirconia-based adhesive bridges to replace the missing tooth/teeth.
10176023|NCT03836911|Active Comparator|serious game|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a serious game
9679876|NCT04946097|Experimental|control group|the control group which received the conventional selected exercise program
9679877|NCT04945668|Other|Pericapsular nerve group block|combined ultrasound and fluoroscopy-guided technique for pericapsular nerve group block
9679878|NCT04945811|Experimental|Interlukein 6 and procalcitonin|Interlukein 6 and procalcitonin levels in COVID 19 patients
9827557|NCT02460978|Placebo Comparator|Placebo|Placebo tablet orally, once daily for 52 weeks
9827558|NCT02460991|Experimental|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
9976002|NCT01347177|Experimental|Metal-based adhesive bridges|Patients in this group will be treated with the employment of metal-based adhesive bridges.
9976003|NCT01347190|Experimental|Liquid API|
9976004|NCT01347190|Placebo Comparator|Placebo|
10176024|NCT03836911|Other|Classic program|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a classical exercise program in older subjects living in a nursing home
10187245|NCT03728153|Experimental|20mg dose|Fluoxetine 20 MG Oral Tablet
9679879|NCT04945525|Experimental|Care Continuity Program + Education|Participating clinics (and their prescribers and patients) will be randomly selected to implement the Care Continuity Program (CCP) intervention, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients will receive welcome letters and be required to complete CCP self-assessments before each appointment. Prescribers will begin using the generated CCP summary page at each appointment to help make decisions about initiating or maintaining an opioid prescription for an individual patient.
10176025|NCT03836872|Experimental|True Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
10176026|NCT03836872|Sham Comparator|Sham Acupuncture|In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
9679880|NCT04945525|No Intervention|Education Alone|Participating clinics (and their prescribers and patients) will be randomly selected to the control group, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients and prescribers will continue treatment as usual in their clinic.
9679881|NCT04945785||control|Before switch Advagraf to Envarsus
9679882|NCT04945785||case|After switch Advagraf to Envarsus
9679883|NCT04945603||Poor Grade Subarachnoid Hemorrhage|"All patients (prospective and retrospective) included will have to present a subarachnoid hemorrhage defined poor grade according to the WFNS scale due to the rupture of an intracranial aneurysm.~The patients are managed according to both most recent international guidelines on the specific disease (Stroke, May 2012) and according to national and institutional guidelines/protocols."
10176027|NCT03836872|No Intervention|Standard Control Group|The third arm will be a standard care control arm.
10176028|NCT03837054|Other|Breast cancer patients with external polychemotherapy|
10176029|NCT03837171|Active Comparator|Liberal strategy|Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock
10176030|NCT03837171|Experimental|Restrictive strategy|Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock
9679886|NCT04945629|Active Comparator|Simple suture|Atraumatic exodontia followed by simple suture
9679887|NCT04945629|Experimental|PRGF-Endoret|Atraumatic exodontia followed by simple suture
9679888|NCT04945824|Experimental|Novel Intracanalicular Insertion Device|
9679889|NCT04945837|Other|unique study arm|Initial socio-demographic questionnaire 5 timepoints psychologic and self-administered questionnaires
9679890|NCT04945681|Experimental|Mass vaccination|Mass vaccination of children aged 6 weeks to 14 years old with pneumococcal conjugate vaccine. Children 6 weeks to 11 months old receive two doses, spaced 4 weeks apart. All other children receive a single dose. Vaccination is simultaneous, as per a campaign delivery strategy.
9679891|NCT04945759|Experimental|Isokinetic Exercise (İE) Group:|"Isokinetic Exercise (IE) Group:~(Knee Joint Flexion / Extension, Hip Joint Internal / External Rotation and Abduction / Adduction Strengthening Program)~Patients will be seated on the isokinetic Cybex-Humac Norm device in a 90° upright sitting position. It will be fixed to the seat with torso, pelvis and thigh straps. During this training, patients will be told that the dynamometer arm will bring the knee from extension to flexion. During this exercise, the patient will be advised to resist the dynamometer as much as possible while moving the knee in flexion/extension, internal/external rotation, and abduction/adduction with the dynamometer."
9679892|NCT04945759|Active Comparator|Isokinetic Exercise + Aussie Current (IE+AC)Group:|Aussie Current and Isokinetic Exercise program will be applied to the patients. The distal electrode is placed on the anterior part of the thigh and superior to the patella. The proximal electrode will be placed on the thigh. One electrode will be placed between the anterior superior and posterior superior iliac spine of the PFPS(Patellofemoral Pain Syndrome) side and the other electrode will be placed in a triangle on the greater trochanter of the femur in the gluteus medius muscle. By contacting the Turkish authorities of the BTL 4825SPREMIUM device, the current was adjusted in the Aussie Current 1 kHz frequency, 400 ms phase time, 50 hz burst frequency, 4 ms duration device. This new burst modality medium frequency alternating current will be applied to the patient for 20 minutes.
9679893|NCT04945759|Active Comparator|Isokinetic Exercise + Russian Current (IE+RC) Group:|"Isokinetic Exercise program will be applied to the patients. Similarly, as with the Aussie Current, the Russian current will be applied to the vastus lateralis-medialis and gluteus medius muscles.~Russian current will be set as 2500 Hz sinusoidal current, 200 ms phase time, 50 hz burst frequency, 50% duty cycle, 10 ms duration.~The patient will be treated for 20 minutes."
9679894|NCT04945759|Placebo Comparator|Isokinetic Exercise + placebo Electrical Stimulation (IE+PES) Group:|Isokinetic Exercise program will be applied to the patients. The appropriate modalities will be set on the electrical stimulation device, but the device will not operate. It will be applied for 20 minutes.
9679895|NCT04945694|Experimental|Ultrasound-guided bilateral pecto-intercostal fascial block|Patients will receive bilateral ultrasound-guided pecto-intercostal fascial block
9679896|NCT04945694|Placebo Comparator|Intravenous fentanyl|Patients will receive only incremental doses of intravenous fentanyl
9679897|NCT04945265||Women aged <30|
9679898|NCT04945265||Women aged 30-36|
9679899|NCT04945265||Women aged 37-40|
9679900|NCT04945265||Women aged >40|
9679901|NCT04945265||Women undergoing egg freezing/male factor infertility/genetic testing|
9679902|NCT04945265||unidentified cause of infertility|
9679903|NCT04945265||PCOS|
9977613|NCT01363518||Nonoperative|Nonoperative group would have been treated with a brace, no surgery.
9679904|NCT04945265||endometriosis|
9679905|NCT04945265||tubal disorders|
9679906|NCT04945265||ovulatory disorders|
9679907|NCT04945265||other causes of infertility e.g., fibroids.|
9679908|NCT04945551|Experimental|Diabetes|Aerobic exercise training
9679909|NCT04945551|Experimental|Healthy|Aerobic exercise training
10176031|NCT03837041|Active Comparator|Reconditioning Proprioception group|Training Proprioception 1 hour for 2 day a week
10176032|NCT03837041|No Intervention|Control group|
9976005|NCT01347203|Experimental|Treatment A|DPOC-4088 prolonged release tablet 100 mg (Formulation A= 16 hr release formulation)
9679911|NCT04945577||Experimental: Mild Clinical Group|patients showing mild clinical symptoms without pneumonia.
9679912|NCT04945577||Experimental: Moderate Clinical Group|patients with fever, other respiratory symptoms, and pneumonia findings based on radiological imaging
9679913|NCT04945577||Experimental: severe/critical clinical group|severe one of these as follows; patients with hypoxia (≤93% oxygen saturation), respiratory distress (RR >30 times per minute), partial pressure of arterial blood oxygen (PaO 2 )/the fraction of inspired oxygen (FiO 2 ) ≤ 300 mmHg, patients whose chest imaging shows that lung damage develops significantly within 24 to 48 hours, or critical one of these as follows; respiratory failure requiring mechanical ventilation, signs of septic shock with multiple organ failure requiring intensive care unit admission.
9679914|NCT04945278|Other|Patients|"Both patients and healthy volunteers arms will undergo the double mirror test within a day.~But the patients arm will additionally respond to the EASE test."
10176033|NCT03836807|Experimental|Ketoprofen|Single oral administration of Ketoprofen lysine salt 40 mg granules
10176034|NCT03836807|Placebo Comparator|Placebo|Single oral administration of placebo granules
9679915|NCT04945278|Other|Healthy volunteers|Both patients and healthy volunteers arms will undergo the double mirror test within a day.
9679916|NCT04945447|Experimental|Intervention group - Medical clinics|Medical clinics receiving the pharmacist intervention described in the intervention group for patient level
10176035|NCT03836937|Experimental|Obeticholic acid|Patients diagnosed as NAFLD with raised ALT will be treated with both life style modification and Obeticholic acid. Obeticholic acid will be given as 10 mg twice daily. Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
9679917|NCT04945447|No Intervention|Control group - medical clinics|All medical clinics that are enrolled in the trial will eventually receive the intervention at some point. As some medical clinics act as the control group to being with.
10176036|NCT03836937|No Intervention|Lifestyle modification|Patients diagnosed as NAFLD with raised ALT will be given only life style modification.Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
10176037|NCT03836742||HF RCA|Cardiovascular surgery patients treated with hemofiltration with regional citrate anticoagulation
10176038|NCT03836703|Active Comparator|Single Dose Daily Iron|single dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
10176039|NCT03836703|Experimental|Double dose Daily iron|Double dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
10176040|NCT03836690|Experimental|Donor T cells depleted of CD62L+ cells (CD62L- Tem)|Donors will undergo a steady state apheresis for the collection of T cells. Selection of CD62L- Tem at the required dose will be performed at UCL Centre for Cell, Gene and Tissue Therapeutics (CCGTT). Donor Tem will be infused into patients on day 24-32 following allo-Stem Cell Transplant.
10176041|NCT03837158|Experimental|Control-group|Two Tissue Level TiZr Sand blasted long grit acid-etched (SLA) implants placed in positions 33 and 43 (diameter 3.3mm, length ≥10mm), early loading
9679918|NCT04945447|Experimental|Intervention group - patient level|"The intervention consists of two subgroups: Intervention pharmacist and intervention proposals. As the pharmacist conducts medication reviews of the polypharmacy patients in the medical clinic they can make a note to the physician about fx a specific medication the physician needs to pay attention to. These polypharmacy patients are enrolled in the group intervention proposals and are asked to complete questionaries at baseline and follow-up. Ultimately, it is up to the physician to react to the note in the polypharmacy patients medical record. Therefore the pharmacist only makes a note in the journal of the patient and does nothing else.~The group intervention pharmacist is polypharmacy patients where the pharmacist conducts a medication review and develops suggested interventions proposals for each participant"
9679919|NCT04945447|No Intervention|Control group - patient level|The control group will have access to usual care and other health services within the healthcare systems. Participants randomised to the control group are invited to participate in the evaluation of the current treatment in the primary health care sector
9695449|NCT04777955|Experimental|Group 2, electrical stimulation|"An adaptation of a pre-designed protocol will be used for the application of the Normocular Electrical Stimulation in the diaphragm. Current to be applied; Synchronous impulse at 30 Hz frequency, 1 sec beat increase time, 1 sec on (muscle contraction), 1 sec beat reduction time and 20 sec off (no warning) time. Two channels, each with two electrodes, will be placed in the seventh and eighth anterior intercostal space above and below the right and left sides of the xiphoid protrusion. The other two channels, each with two electrodes, will be placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
9695450|NCT04777955|Experimental|group 3, kinesiotape|"For anterior diaphragm banding, the patient will stand with arms raised. Next, the central part of the tape will be applied to the xiphoid protrusion with a tension of 50% to 70% after the maximum inhalation. While the patient is breathing, the ends of the tape will be pulled with 10 to 15% tension towards the lower ribs. To tape the rear diaphragm, the patient's body will bend forward, and the arms will be joined crosswise over the chest. After the maximum inhalation, the central part of the tape will be applied over the T10 with a tension of 50% to 70%. As the patient exhales and stretches the trunk, the ends of the tape will be attached to the lower ribs with a tension of 10 to 15%.~The supine position will be used in the Kinesiological taping of the right and left external oblique and internal oblique muscles. The application will be carried out for 6 weeks, 3 days a week, for 30 minutes daily."
9679920|NCT04945291|Experimental|research built JA Method mobile application + Counting method using the hands|The participant will watch a video that explains a new counting method using the hands and use the research built mobile application to log and track the calories
9679921|NCT04945291|Active Comparator|FitnessPal mobile application (or Arabic alternative) + Counting method using the hands|the participants will watch a video that explains a new counting method using the hands and they will be asked to use a commercial mobile app to log and track the calories
9679922|NCT04945291|Active Comparator|Fitness Pal Mobile Application (or Arabi alternative)|The participants will watch a generic video about the mobile app and they will be asked to use a commercial mobile app to log and track the calories
9679923|NCT04945304||Magnetic bariatric surgery|Bariatric procedure performed in a human using magnetic assistance in the steps of the surgery
9679924|NCT04945226|Active Comparator|Propecia|Propecia Tablet, QD, PO
9679925|NCT04945226|Experimental|IVL3001 (A mg)|S.C, Single Dose.
9679926|NCT04945226|Experimental|IVL3001 (B mg)|S.C, Single Dose.
9679927|NCT04945226|Experimental|IVL3001 (C mg)|S.C, Single Dose.
9679928|NCT04945564|Experimental|Oxygen therapy and physical therapy|
9679929|NCT04945564|Active Comparator|Oxygen therapy|
9679930|NCT04945642|Experimental|Treatment (HDR-BT, SBRT)|Patients undergo HDR-BT for up to 24 hours and undergo SBRT every other day or consecutive days for up to 14 consecutive chronologic days in the absence of disease progression or unacceptable toxicity.
10176042|NCT03837158|Experimental|Experimental-group|Four narrow-diameter implants (NDI) TiZr SLA implants in positions 34, 32, 42, and 44 (diameter 2.4mm, length ≥10mm), immediate loading
10176043|NCT03836924||Perampanel|Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.
9679931|NCT04945434|Experimental|S53P4 BAG intervention group|Patients recruited and enrolled in study for treatment with S53P4 BAG
10176044|NCT03836716|Experimental|Arimoclomol|Arimoclomol, capsule
10176045|NCT03836898|Experimental|Implantation phakic intraocular lens|Presbyopic posterior chamber phakic intraocular lens IPCL implanted to the participants eye
10176046|NCT03836885|Experimental|Apremilast|Oral tablet
9679932|NCT04945239|Experimental|Amplification of Positivity Training (6 Sessions)|
9679933|NCT04945239|Active Comparator|Stress Management Training (6 Sessions)|
9679934|NCT04945343|Other|Children who had growing rods instrumentation for correction of Early Onset Scoliosis|Growing spine profiler instrumentation
10176047|NCT03836885|Placebo Comparator|Placebo|Oral tablet
9679935|NCT04945317|Other|ROSE arm|Presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist
9679936|NCT04945317|Other|NO-ROSE arm|Absence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist
9679937|NCT04945252|Experimental|Care Navigation group|The teachers will signpost dental caries based on ICCMS visual criteria and refer to the nearest service. Annual monitoring of caries
9679938|NCT04945252|No Intervention|No internvention|Caries experience (dmft) activity monitored annually
9679939|NCT04945499|Other|D-glucose|During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.
9679940|NCT04945421|Experimental|Sintilimab and IBI310 (single arm)|The test group will be treated with either (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
9679941|NCT04945473|Experimental|Revision|"BMI≥30 or total weight loss (TBWL) < 10% and relaxation of gastric tubulisation at 6 months after ESG.~Additional stitches will be placed during the follow-up gastroscopy at 6 months."
9679942|NCT04945473|No Intervention|Without revision|The control gastroscopy will be performed without any additional procedure (no additional stitches).
9679943|NCT04945382|Experimental|Scotchbond universal 3M|Application of dental sealant with Scotchbond universal 3M adhesive.
9679944|NCT04945382|Active Comparator|Control (Single bond 3M)|Application of dental sealant with Single Bond 3M adhesive
9679945|NCT04945135||liver donors|
9679946|NCT04945122|Experimental|Pitavastatin|Patients diagnosed AMI with abnormal glucose metabolism use pitavastatin (4mg po Qn) to control cholesterol for 6 months.
9679947|NCT04945122|Active Comparator|Atorvastatin|Patients diagnosed AMI with abnormal glucose metabolism use atorvastatin (20mg po Qn) to control cholesterol for 6 months.
9679948|NCT04945070|Experimental|iGlarLixi|Subjects switched from MDI to iGlarLixi
9679949|NCT04945070|Active Comparator|Control|Patients continuing with previous MDI
9679950|NCT04945057|Experimental|Intervention group|All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns
9679951|NCT04945096|Experimental|Acetylcysteine + decitabine|Acetylcysteine (1.2g twice a day, oral administration, from day -10 to day 365 after HSCT). Conditional regimen: decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen); semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
9695451|NCT04777968|No Intervention|Control Group (A) : RMGI restoration without SDF and KI.|• RMGI restoration without SDF and KI.
9695452|NCT04777968|Experimental|Intervention Group (B): Pretreatment with SDF and KI prior to RMGI restoration.|• Pretreatment with SDF and KI prior to RMGI restoration.
9679952|NCT04945096|Active Comparator|Standard Treatment|Conditional regimen: semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.
9679953|NCT04944914|Experimental|Camrelizumab Plus Stereotactic Body Radiotherapy|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy, and then receive stereotactic body radiotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
10176048|NCT03836820|Experimental|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
10176049|NCT03836820|Experimental|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
9679954|NCT04944914|Active Comparator|Camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision or the upper limit of treatment duration of 1 year.
9679955|NCT04944875|Active Comparator|Group I; group headphone|In the first group of the patients in the isolation group wear the headphones but do not listen to music during the procedure. Then patients were sedated by midazolam and propofol.
9679956|NCT04944875|Active Comparator|Group II; group music|"In the second group of the patients wear the headphones and listen to Vivaldi's The Four Seasons violin concertos by sound isolating headphones during the procedure.~Then patients were sedated by midazolam and propofol."
10176050|NCT03836820|Experimental|Clinical pilates and Aerobic exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
10176051|NCT03837002|Experimental|foot care protocol|foot examination at the first interview, foot care and training once a month and weekly follow-up for 3 months, foot examination at the last interview (six month)
10176052|NCT03837002|No Intervention|Control|foot examination at the first interview, foot examination at the last interview (six month)
9679957|NCT04944875|Active Comparator|Group III; group maternal voice|In the third group of the patients wear the headphones and listen the maternal voice during the procedure.Then patients were sedated by midazolam and propofol.
9679958|NCT04944979|Experimental|Experimental: Kedrion IVIG 10%|Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
9679959|NCT04945005||Lead implantation with transesophageal echocardiography|All patients undergoing pacemaker/CRT implantation with concomitant transesophageal echocardiography in addition to fluoroscopic guidance
9679960|NCT04945005||Lead implantation without transesophageal echocardiography (retrospective)|All patients undergoing standard pacemaker/CRT implantation guided by fluoroscopy only (retrospective historical control group)
9679961|NCT04945031||cannabis-induced psychosis|
9679962|NCT04944836|Placebo Comparator|Control|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the control group, these will be placebo. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
9679963|NCT04944836|Experimental|Clomiphene|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. These will be taken every other day for seven months beginning four week prior to surgery and extending for six months after surgery.
10176053|NCT03836755|Other|METACOS|Required to do some motor tasks during static and dynamic RSA
10176054|NCT03836976|Experimental|All participants|All participants receive auditory gamma sensory stimulation.
9679964|NCT04944927||Patients with Alternating Hemiplegia of Childhood|"Patients that meet the clinical diagnostic criteria (Aicardi et al, 1995) for typical alternating hemiplegia with or without identified mutations in ATP1A3.~At least one prolonged ECG study available is required."
9679965|NCT04944966|Experimental|Group 1|"• Experimental: Group 1a: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 400mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1b: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 600mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1c: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1d: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis"
9679966|NCT04944966|Experimental|Group 2a|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Maytenus senegalensis.~Patients will be treated with Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Maytenus senegalensis"
9695453|NCT04777929||healthy pregnant woman|pregnant woman without any disease of pregnancy
9695454|NCT04777929||pregnant woman with preeclampia|pregnant woman with preeclampia but without any other disease of pregnancy
10176055|NCT03836833|Experimental|4in1 granules|Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks, Followed by Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
9679967|NCT04944966|Active Comparator|Group 2b|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Artemether-lumefantrine Patients will be treated with Artemether 20mg/lumefantrine 120mg administered orally by a six-dose regimen over 3 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Artemether 20mg/lumefantrine 120mg"
9679968|NCT04945187|No Intervention|Standard care|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management before each cycle of chemotherapy conducted by physicians.
9679969|NCT04945187|Experimental|Intervention group|Intervention: This arm will be assigned to the intervention which will be nurse-led consultations based on electronic patient-reported outcomes. The patients will report ePRO weekly during chemotherapy and the answers will be used proactively in the nurse-led consultations. Nurses will conduct the clinical assessment regarding side effects and management before each cycle of chemotherapy.
10176056|NCT03836833|Experimental|LPV/r Pellets Plus ABC/3TC|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.~Followed by Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks"
9679970|NCT04944693||Cohort 1|Anterior cruciate ligament-injured patients with excessive ATS
9679971|NCT04944693||Cohort 2|Anterior cruciate ligament-injured patients with minimal ATS
9679972|NCT04944810||Magnetic bariatric surgery|Perform a bariatric surgery using the magnetic device like a second assitant in the steps of the surgery in order to perform the surgery with less incisions and with the same safety
9679973|NCT04944823||Patients with COVID 19 infection who develop bacterial coinfection.|Follow-up for 24 months
9679974|NCT04944823||Patients with COVID 19 infection who do not develop bacterial coinfection.|Follow-up for 24 months
9679975|NCT04944719||chronically ill adult patients colonized by streptococcus pneumoniae|At baseline, adult patients with chronic disease who are colonized with Streptococcus pneumoniae will be identified. Then, after determining the colonized subjects, monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be taken to determine colonization by other serotypes or resolution of colonization status in these patients.
9679976|NCT04944719||chronically ill adult patients not colonized by streptococcus pneumoniae|Subjects who are not colonized with S. pneumoniae will be followed by monthly telephone follow-up and clinical outcome will be determined to identify patients who develop CAP or IPD. Additionally, follow-up samples similar to baseline will be collected every six months to determine colonization during the follow-up time in the study.
9679977|NCT04944758|Other|Light therapy|Daily exposure on weekdays to a standard light device (e.g., fluorescent light box such as the Carex Day-Light Classic, emitting 4000 Kelvin white light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter) for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am. Participants will also taper and discontinue their antidepressant medication.
9679978|NCT04944732||Patients with Creutzfeldt Jakob disease|Patients with Creutzfeldt Jakob disease
9679979|NCT04944680|No Intervention|Control group|Stroke patients accept the traditional rehabilitation alone.
9679980|NCT04944680|Active Comparator|Transcranial Direct Current Stimulation group|Stroke patients accept the Transcranial Direct Current Stimulation alone.
9679981|NCT04944680|Active Comparator|Motor imagery group|Stroke patients do the motor imagery alone.
9679982|NCT04944680|Experimental|Transcranial Direct Current Stimulation and motor imagery group|Stroke patients accept the Transcranial Direct Current Stimulation and do the motor imagery at the same time.
9679983|NCT04944498|Experimental|Intervention Group|Patients who received surgery with modified tarsorrhaphy technique
9679984|NCT04944498|Active Comparator|Control group|Patients who received surgery with gold weight implant technique
9679985|NCT04944446|Experimental|Group myofascial treatment|"The trial group will also be referred by the rehabilitating doctor to the physiotherapy room, these patients will be treated by two physiotherapists with training in myofascial release therapy with which they will carry out a treatment protocol that will consist of myofascial release of the shoulder blade angle, subscapularis and global pectoral technique as well as superficial myofascial release of said musculature with a during 12-15 minutes, in addition to a 30-minute session of active kinesitherapy with exercises and mechanotherapy. Same as the control group.~These mobilizations are carried out in the absence of pain, although the difference between joint tension or stretching and pain is explained to the patient."
9679986|NCT04944446|Active Comparator|Group Kinesitherapy treatment|"This group will be treated in a protocolized way with techniques such as passive kinesitherapy, active-assisted and active kinesitherapy to win mobility.~They consist of mobilizing the affected arm in the movements of flexion (upward), separation (towards the outer side) and rotation, these lateral decubitus (bring the hand to the nape of the neck) and internal (bring the hand to the lower back) trying to win joint amplitude.~These mobilizations are performed in the absence of pain, although the difference between joint tension or stretching and pain will be explained to the patient. The treatment will be carried out as usual with a duration of about 12-15 minutes of mobilization and about 30 minutes of active kinesitherapy with exercises and mechanotherapy, these consist of active shoulder mobility exercises. Emphasis will be placed on working with the pain threshold so as not to cause damage or negative nociceptive reactions."
9679987|NCT04944381|Experimental|SARS-Cov-2 mRNA vaccine immunization group|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd.
9679988|NCT04944381|Experimental|Inactivated SARS-Cov-2 vaccine immunization group|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
9679989|NCT04944537||ICU management for patients with severe trauma|Group to investigate the current status of ICU management for patients with severe trauma
9679990|NCT04944394||hospital professionals|all professionals working in hospitals in France
9679991|NCT04944602|Experimental|SYN008|patients received a dose of SYN008 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
9679992|NCT04944602|Active Comparator|Omalizumab|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
10176057|NCT03837080|Experimental|Nutrition Education|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care will go through a series of individual and group nutrition educations. Educations are specifically tailored for chronic pain patients, based on our preliminary findings on this group of patients.
9679993|NCT04944589|Experimental|single visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in single visit including access cavity, chemo-mechanical preparation and obturation, all were done in one visit
9679994|NCT04944589|Experimental|Multiple visit root canal treatment(RCT)|RCT(ROOT CANAL TREATMENT) of this group was performed in multiple visit including access cavity, chemo-mechanical preparation and obturation, all were done in two or three visits
9679995|NCT04944485|Active Comparator|class V cavities treated with putty nanohybrid resin composite|Selective enamel etching will be done and a universal adhesive (Prime&Bond universal™ ,Dentsply)will be applied to both enamel and dentin. After gentle dryness and solvent evaporation the bonding agent will be cured for 20 seconds. Composite (Neo Spectra™ST, Dentsply, Sirona, USA) will be placed incrementally and light cured for 20 seconds
9679996|NCT04944485|Experimental|class V cavities treated with Self adhesive giomer containing nanohybrid flowable composite|Cleaning and gentle air blowing of the preparation. Then applying FIT SA F03 (Low Flow), SHOFU, USA. Spread in a thin layer (≤0.5mm) on the prepared surface with needle tip, microbrush and gently air-blow leave for 20 seconds then light cure for 5 seconds. Then,apply additional increments (≤2mm) of FIT SA and light cure each increment for 10 seconds then finish and polish
9679997|NCT04944407|Experimental|LHP GROUP|patients recieved minimal invasive LHP procedure with diode laser
9679998|NCT04944407|Active Comparator|MM GROUP|patients received conventional MM hemorroidectomy
9679999|NCT04944238||Patients implanted with Ankoris IOL|To assess the IOL stability, slitlamp photos of the consecutive 30 patients with respect to time will then be analysed with a 5% confidence interval.
9680000|NCT04944511|Experimental|PD-1 antibody for mixed chimerism|PD-1 antibody (Toripalimab Injection) used for mixed chimerism in HLH patients after allo-HCT
9680001|NCT04944524|Experimental|Tofactitinib|partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
9680002|NCT04944524|Active Comparator|Methotrexate|partcipants would be given tablets of methotrexate (2.5mg per tablet) from the initial dose of 15mg (6 tablets) and add to the maximal and optimal dose of 20mg (8 tablets), once per week, the treatment duration will last 12 months during the whole follow-up period.
9680003|NCT04944459|Experimental|Muse-S|multi-sensor neurofeedback-assisted mindfulness training device (Muse-S)
9680004|NCT04944264|Active Comparator|Immediate start|Behavioral: Stress Management and Resiliency Training (SMART) program
9680005|NCT04944264|Active Comparator|Delayed start|Wait time control
9680006|NCT04944342||Individuals who have had COVID-19.|Individuals who have had COVID-19 and who treated by a standart medical treatment at home.
9680007|NCT04944342||Individuals who have not a COVID-19 illness history.|Individuals who have not a COVID-19 illness history.
9680008|NCT04944225|No Intervention|Control group: Pain management during the standard of care phase|In the standard of care phase, anesthetic and surgical care will be as per standard practice (according to local hospital protocol) for both the control and the intervention group. Generally, this means patients will be maintained on a more liberal opioid regime than in the opioid reduction strategy phase and will receive opioid and other medications for the acute postoperative pain. The choice of opioids will be at the discretion of the managing team. There will be a minimum 2-month baseline period before entry of the first randomized cluster to the intervention arm.
9680009|NCT04944225|Experimental|Intervention group: Pain management in the opioid reduction strategy phase|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
9680010|NCT04944329||COLCOVID|adults undergoing hip fracture surgery
9680011|NCT04944043|Experimental|TQ05105 Tablet|TQ05105 tablet 10mg given orally, twice daily in 28-cycle.
9680012|NCT04944615|Experimental|Intravascular ultrasound guidance|"All targeted CTO lesions will be examined and documented using a commercially available IVUS catheter (Opticross HD) according to its instructions (if not contraindicated, preoperative vasodilation with nitroglycerin to prevent spasm).~IVUS examination must be performed at least once before and after stent implantation."
9680013|NCT04944615|Active Comparator|Angiographic guidance|The patient will choose the appropriate length and diameter of the stent to be implanted by visual estimation. All commercially available drug-eluting stents (except first-generation DES, such as Taxus, Excel, Partner, Firebird, etc.) can be used. DES with high quality clinical evidence is strongly recommended. The type, diameter, and length of the stent are determined by the surgeon. The stent length should be selected to ensure complete coverage of the CTO lesion. If dissection is present, additional stents are implanted. Repeat angiograms were performed immediately after surgery in the same view as before surgery.
9680014|NCT04944160||Pre Covid-19 cohort|Children hospitalized in the Pediatric Department of the Hôpital Femme Mère Enfant, Lyon, France with a RT-PCR positive for RSV during the 2019-2020 winter epidemic
9680015|NCT04944160||Post Covid-19 cohort|Children hospitalized in the Pediatric Department of the Hôpital Femme Mère Enfant, Lyon, France with a RT-PCR positive for RSV during the 2020-2021 winter epidemic
10176058|NCT03837080|No Intervention|Control|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care. Patients will receive all treatments (e.g. physical therapy) except the nutrition education.
10176059|NCT03836768|Experimental|Experimental Treatment|DTRMWXHS-12, oral capsule, daily, 28 days as a cycle
10176060|NCT03836781|Active Comparator|ketorolac 3%|ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
9680016|NCT04944251|Experimental|aerobic exercise group|the patients in the aerobic group started to exercise at a heart rate corresponding to 60% of the maximal VO2, by adjusting the pedal resistance of the exercise bike, consistent with the Karvonen formula. This was followed by exercise cycling at a heart rate corresponding to 70% of maximal VO2 in the second month, and 80% of maximal VO2 in the third month, for 30 minutes, 3 days a week
9680017|NCT04944251|Experimental|strength exercise group|The patients included in the strength exercise group performed weight training exercises involving 10 large muscle groups (leg press, chest press, leg curl, lateral pull down, leg extension, dumbbell lateral raise, calf press, upright row, sit up, quadruped arm opposite leg raise), 3 days a week; including 1 set of 12-15 repetitions in the first month, 2 sets of 12-15 repetitions in the second month, and 3 sets of 12-15 repetitions in the third month (Figure 1). Participants' working weights were set as 60% of the maximum weight they could lift.
10176061|NCT03836781|Other|chlorhexidine 2%|chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
10176062|NCT03837119||Heterozygous Hemoglobinopathy|pregnancy outcome in women with heterozygous hemoglobinopathy
10176063|NCT03837119||No Heterozygous Hemoglobinopathy|pregnancy outcome in women without heterozygous hemoglobinopathy
10176064|NCT03836638|Experimental|Low dose young subjects|Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face
10176065|NCT03836638|Experimental|Low dose older subjects|Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face
10176066|NCT03836638|Active Comparator|high dose older subjects|Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)
10176067|NCT03836443|Active Comparator|NAFL patients (group 1)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
10176068|NCT03836443|Active Comparator|NASH patients (group 2)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
10176069|NCT03836495|Experimental|White bread unfortified (WB)|bread with no lysine no phosphorus
9680018|NCT04944251|No Intervention|control group|The patients who didn't want to exercise were included in the control group.
9680019|NCT04944303|Active Comparator|Sugammadex|In the early group, the injection of muscle relaxant was stopped 2min the operation finish, and 4mg kg-1 of sugammadex was injected .
10176070|NCT03836495|Experimental|White bread fortified with lysine (WB-L)|Bread with lysine
10176071|NCT03836495|Experimental|White bread fortified with phosphorus (WB-P)|bread with phosphorus
10176072|NCT03836495|Experimental|White bread fortified with lysine and phosphorus (WB-LP)|Bread with phosphorus and lysine
10176073|NCT03836391|Experimental|Nudge Intervention|"Each of 7 intervention message options has specific decision rules (including weighed/not weighed and progress toward daily dietary and activity goals) that make a participant eligible to receive a specific intervention type at a specific time (decision points).~At each decision point (early morning, morning, midday, and evening), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability)."
10176074|NCT03836482|Experimental|Selective Cytopheretic Device|
10176075|NCT03836365|Active Comparator|Preoperative counseling office visit|Participants will present for an in-person preoperative counseling office visit (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
10176076|NCT03836365|Active Comparator|Preoperative counseling phone call|Participants will receive a preoperative counseling phone call (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
10176077|NCT03836612||People with inflammatory bowel disease|Adults (18+) with inflammatory bowel disease registered with a contributing GP practice during the study period
10176078|NCT03836612||Controls|Adults (18+) without inflammatory bowel disease registered with a contributing GP practice during the study period
9680020|NCT04944303|Placebo Comparator|Normal Saline|the injection of muscle relaxant was stopped 2min the operation finish, and equal normal saline was injected .
9680021|NCT04944472||group I|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group I, project participants will only be presented with video publications on each of the declared topics (8 in total)."
9680022|NCT04944472||group II|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group II - only text publications (total 8)."
9680023|NCT04944472||group III|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group III - first text publications, and then video publications (16 in total)."
9680024|NCT04944472||group IV|"All participants will be divided into 4 groups (4 separate accounts), similar in gender, age and social status:~in group IV - first video publications, and then text publications (16 in total)."
9680025|NCT04944069|Experimental|Almonertinib With Bevacizumab|Almonertinib 110 mg oral once daily with Bevacizumab 15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
9680026|NCT04943978||Liver disease|Patients with either acute or chronic liver disease
9680027|NCT04944641|Experimental|A: Routine AED group|Routine and proper antiepileptic drugs group
9680028|NCT04944641|Experimental|B: AED and education group|Routine, proper antiepileptic drugs and education group
9680029|NCT04943991|Other|Patients with HCM/LVH at University Hospital Wuerzburg|
9680030|NCT04944082|No Intervention|Remdesivir only|(Dose 200 mg day one, 100 mg daily days 2-5), duration may extend to 10 days of remdesivir (200 mg day one, 100 mg daily days 2-10)
9680031|NCT04944082|Experimental|Combination remdesivir plus ivermectin group|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
9680032|NCT04944095||SARS-CoV-2 Antibody Levels|This is a single arm study by Southlake Diagnostics Inc. whereby changes in plasma antibody levels (IgG and total) are determined over 12 months on individuals residing in over 300 associated nursing homes, extended care facilities and over-55 residences following vaccination with one of the authorized SARS-CoV-2 vaccines (Pfizer, Moderna or J &J). No interventions are involved. The investigators are not responsible for administering the vaccines or determining subject eligibility or willingness to receive the vaccine. Blood samples will be drawn and plasma IgG and total antibodies will be determined at baseline, 3, 6, 9 and 12 months post-vaccination.
9680033|NCT04944147|Experimental|Anodal tDCS + cognitive training|
10176079|NCT03836508|Active Comparator|Medium cut-off|Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.
9680034|NCT04944147|Placebo Comparator|Sham tDCS + cognitive training|
9680035|NCT04944147|Active Comparator|Sham tDCS + Progressive Muscle Relaxation training|
9680036|NCT04944004|Experimental|Experimental CBCT Group|Participants of CBCT group will attend individual computer-based cognitive training sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
9680037|NCT04944004|Active Comparator|Training As Usual (TAU) Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CBCT training.
10176080|NCT03836508|Active Comparator|High-flux|High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.
10176081|NCT03836586|Experimental|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
10176082|NCT03836586|Active Comparator|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
9680038|NCT04944056|Active Comparator|Control Group|It includes ultrasound therapy, glides, exercises and home plan.
9680039|NCT04944056|Experimental|Experimental Group|It includes ultrasound therapy, glides, exercises, compression mobilization and home plan.
9680040|NCT04943965||Patient undergoing a cardiac surgery|Patients undergoing cardiac surgeries listed in inclusion criteria will be in this group.
9680041|NCT04943965||Clinicians|Clinicians defined as physicians (e.g. attendings, fellows, residents) or advanced practice providers (e.g. nurse practitioners and physician assistants) will be in this group.
9680042|NCT04943809||POD 26P AY FT|26 patients with corneal astigmatism higher than 1.0D in both eyes and lower than 2.5D and will be implanted with the POD 26P AY FT
9680043|NCT04943809||POD 26P AY F|26 patients with corneal astigmatism lower than 1.0D in both eyes will be implanted with the POD 26P AY F
9680044|NCT04943705|Experimental|Yin and Yang Regulating Moxibustion|1.The acupoints will be selected as Shenque and Mingmen.The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Each treatment was 60min, once a week, Wenyang Yishen moxibustion and Peiyuan Guben moxibustion were performed alternately. Each patient received WenYang Yishen moxibustion and then Peiyuan Guben moxibustion for a total of 12 weeks of treatment and 12 weeks of follow-up at the end of the treatment. 2.The diet and exercise control implementation plan is as follows:Participants weighed ≤113.6 kg (250 lbs) and had a prescription diet of 1200-1499 kcal/day, including traditional foods, of which protein was about 15-20 kcal, fat was about 20-35%, and the rest came from carbohydrates. People weighing ≥113.6 kg are prescribed 1500-1800 kcal per day. They were also instructed to continue moderate-intensity physical activities (such as jogging, brisk walking) at least 5 days a week, at least 210 minutes a week, preferably ≥270 minutes a week。
9680045|NCT04943705|Active Comparator|Mild Moxibustion|1.The acupoints will be selected as Zhongwan, Guanyuan, Sanyinjiao (double).The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.Light one end of the moxa stick and hang it about 2-3cm above the skin, taking the patient's local skin redness and conscious warmth as the degree. Moxa-box moxibustion will be used for 20 minutes each treatment, once every other day, 3 times a week, for a total of 12 weeks of treatment, and 12 weeks of follow-up after the treatment. 2.Lifestyle modification:It will be performed as the same as the Yin and Yang Regulating Moxibustion group.
10176083|NCT03836573|Experimental|E-cigarette only decision aid|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of information on e-cigarettes only. Patients will only be enrolled in this group in phase II if they self-identify as 'uninterested in quitting cigarettes'. During the physician encounter will be given harm-reduction guidance.
9680046|NCT04943692|Experimental|Group A: Metformin glycinate 1050 mg|Metformin glycinate 1050 mg Orally twice a day.
9680047|NCT04943692|Active Comparator|Group B: Metformin hydrochloride 850 mg|Metformin hydrochloride 850mg Orally twice a day.
9680048|NCT04944173|Experimental|MRD Negative|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have no detectable ctDNA at MRD landmark and will receive no further therapy.
9680049|NCT04944173|Experimental|MRD Positive, no further therapy|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to no further therapy.
9680050|NCT04944173|Experimental|MRD Positive, consolidation durvalumab|All subjects will receive four cycles of durvalumab with SABR concurrent at cycle 2, then will be evaluated for MRD. Subjects in this arm have detectable ctDNA at MRD landmark and are randomized to eight additional cycles of durvalumab
9680051|NCT04943562||Healthy participants|Participants from 20 to 40 years old, from both genders and with no sleep disorders
9680052|NCT04943562||Participants with sleep disorders|one sleep disorder or complaint. Among these, at least 30% of the sample should have moderate to severe insomnia (as measured by the insomnia severity index), 30% should have high risk to sleep apnea (as measured by the STOP-BANG questionnaire) and 70% should have excessive sleepiness scale (as measured by the Epworth sleepiness scale).
9680053|NCT04943588||HCV Negative|"At initial screen, this population will be HCV negative via the diagnostic testing. They will be eligible if they fulfil the following:~over 18 yrs old.~willing to participate~no previous history of therapy with oral medication for chronic HCV infection"
9680054|NCT04943588||HCV Positive with first-line treatment success|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir plus daclatasvir. After treatment, their blood sample will show that they have achieved a sustained virological response (SVR) defined as HCV RNA undetectable.
9680055|NCT04943588||HCV positive with first-line treatment failure|At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12/24 week treatment of sofosbuvir/daclatasvir. After treatment, this proportion of people will NOT achieve an (SVR - defined as HCV RNA undetectable).
9680056|NCT04943588||Cirrhotic Patients|Hepatitis C RNA positive that have cirrhosis
9680057|NCT04943718|Experimental|personalized vaccine|patients with recurrent malignant gliomas enrolled into this arm will receive the personalized vaccine through sub-cutaneous.
10176084|NCT03836573|Experimental|E-cigarette and Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. Patients will only be enrolled in this group in phase II if they self identify as 'interested in quitting and using e-cigarettes'. During the physician encounter will be given e-cigarette cessation guidance.
10176085|NCT03836573|Experimental|Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. All patients in phase I will be enrolled in this group. In addition, patients in phase II who self-identify as 'interested in quitting but do not use e-cigarettes' will also be enrolled in this group. During the physician encounter will be given standard smoking cessation guidance.
10176086|NCT03837262|Experimental|Flash glucose monitoring|Flash glucose monitoring continuously for 6 weeks then once a month up to 24 weeks, with structured education
10176087|NCT03836430|Experimental|Newborn Behavioral Observation|The Newborn Behavioral Observation-Family Wellness (NBO-FW) intervention is the experimental arm of this RCT. It consists of 3 NBOs - 2 during the birth hospitalization and the third at 6 weeks post-discharge as well as a journal with prompts for mothers to reflect on their infant's behavior and their own transition to motherhood. NBOs are clinical relationship-building tools used by trained clinicians/therapists to help parents understand their babies' unique language.
10176088|NCT03836430|No Intervention|Usual care|This arm is the usual care arm. Of note, both arms receive 2 parenting books, one at hospital discharge and one at 6 weeks post-discharge.
9680058|NCT04943744||String Test|Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.
9680059|NCT04943653|Experimental|Intraperitoneal paclitaxel + XELOX|"Intraperitoneal paclitaxel Day1, Day8 + *XELOX~*XELOX ; Capecitabine 2000mg/m2/day(Day1-14) Oxaliplatin 100mg/m2 IV Day1 q 3 weeks"
9680060|NCT04943536|Experimental|Biolen+Radiation Therapy|Localized single delivery of the Biolen implant (polymer + bicalutamide) with radiation therapy
9680061|NCT04943640|Experimental|kinesio taping|"The patient was advised to clean the skin with alcohol and shave the hairy areas. The standing patient was asked to take off high heels if he/she was wearing them.~The paravertebral technique was used with 5 cm x 5 m kinesio tape material. While the patient was standing in an upright position, two longitudinal pieces were cut by taking the tape and slightly rolling its corners. The patient was asked to lean forward. The lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. The patient was asked to do a slight rotation to the left, and while in this position, the tape was attached to T11-T12 without stretching at all. Kinesio tape was attached to the opposite side of the vertebrae with the same procedure."
9680062|NCT04943640|Experimental|rigid taping|The patient was asked to lean forward, and 5 cm x 5 m rigid tape material was used in the right paravertebral region. When bonding the tape, first, the lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. Then, the patient was asked to do a slight rotation to the left, and while in this position, the hypoallergenic tape (beta fix) was applied with no tension [23]. Then, rigid tape was applied upward onto the paravertebral muscles. The left paravertebral region was taped with the same procedure as the right paravertebral region .
9680063|NCT04943640|Placebo Comparator|placebo taping groups|"Placebo taping was applied to patients in this group using betafix, an elastic stabilization tape, as material. A straight line of betafix was applied to the non-painful scapular inferior alignment of the spine, right and left, while the patient was standing upright.~Treatment with taping was administered to all groups every 2 days by the same physiotherapist ."
9976006|NCT01347203|Experimental|Treatment B|DPOC-4088 prolonged release tablet 200 mg (Formulation A= 16 hr release formulation)
9680065|NCT04943419||Colorectal cancer|Patients with colorectal cancer qualified for elective operations.
9695455|NCT04778215|Experimental|Intervention group|progressive, 8 week lumbar stabilizing program
9695456|NCT04778215|No Intervention|Control group|Continue as usual
9695457|NCT04778163|Experimental|Humor group 1|"Group 1 - experimental - will participate in a humor group with a one-hour group session per week for 6 weeks."
9976007|NCT01347203|Experimental|Treatment C|DPOC-4088 prolonged release tablet 100 mg (Formulation B= 20 hr release formulation)
9976008|NCT01347203|Experimental|Treatment D|DPOC-4088 prolonged release tablet 200 mg (Formulation B= 20 hr release formulation)
10176089|NCT03836170|Experimental|Laparoscopic cholecystectomy|A laparoscopic cholecystectomy was performed to remove the gallbladder
10176090|NCT03836599|Experimental|24 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.
9680066|NCT04943380|Other|patients with hematuria undergoing investigation for UC|Patients will be recruited from those presenting with hematuria and undergoing investigative cystoscopy for the determination of possible urothelial carcinoma. This includes patients referred via imaging or from other departments for assessment of hematuria. Microscopic hematuria is defined as > 3 red blood cells per high-powered microscopy field for a properly collected urine sample.
9680067|NCT04943211|Other|R1|
9680068|NCT04942977|Experimental|Cardiac tele-rehabilitation|Patients in the Intervention Group will come to the hospital 4 times during two consecutive weeks, undergoing physical exercise sessions and the same educational talks as in the control group. Subsequently, they will follow the scheduled physical activities and adherence to the risk factor management according to individualised guidelines in their App, until the end of the study period. All data generated are recorded on the professional website. The degree of compliance with the objectives set is monitored by means of 7 coloured icons, which vary according to the target achievement.
9680069|NCT04942977|Active Comparator|Centre-based cardiac rehabilitation|Patients in the control group will come to the hospital 16 times during eight weeks for cycling and muscle strengthening exercises. Educational talks will be given. At the end of the hospital phase, a conventional outpatient follow-up by primary care and the corresponding specialist will be carried out.
9680070|NCT04942925|Other|Precision1, then Infuse|Verofilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9680071|NCT04942925|Other|Infuse, then Precision1|Kalifilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9680072|NCT04942951||Pregnant women with the diagnosis of urinary incontinence (Study group)|The pregnant women who were diagnosed with the urinary incontinence (n=80) with category 0 or category 1 Pelvic Organ Prolapse Quantification (POP-Q) score in physical examination.
9680073|NCT04942951||Healthy pregnant women (Control group)|Control group consisted of healthy women with uncomplicated pregnancies (n=80). They had no complaint of urinary incontinence and their gynecological examination did not reveal any finding of pelvic organ prolapse.
9680074|NCT04943068|Experimental|Bremelanotide|Bremelanotide (BMT) subcutaneously (SC) via auto-injector for 8-weeks double-Blind period
9680075|NCT04943068|Placebo Comparator|Placebo|Placebo subcutaneously (SC) via auto-injector for 4-weeks single-Blind period and for 8-weeks double-Blind period
9680076|NCT04942990|Experimental|exercise training group|The duration of the study was targeted as 8 weeks. Our trainings consist of 3 sessions per week, with an average of 45 minutes of calisthenic exercises per session. Exercises initially started with an average of 30 minutes, 10 repetitions, gradually increased difficulty once every two weeks, time increased to 45 minutes movements were modified for those who were forced to perform the exercise program. The program was completed with 5 minutes of warm-up and 5 minutes of cooling exercises before exercise training. All exercises were conducted on a video chat platform supervised by an experienced physiotherapist.
9680077|NCT04942990|No Intervention|control group|no exercise was given
10176091|NCT03836599|Experimental|12 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol once daily from Day -7 to Day -1. During Treatment Period, participants will receive a single dose of 12 mg verinurad and 300 mg allopurinol on Day 1. No dosing will be done on Day 2. Participants will continue dosing on Day 3 and will be dosed once daily until Day 9.
10176092|NCT03836599|Placebo Comparator|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
10176093|NCT03836196|Experimental|Combined radiation treatment|Combined low-dose-rate brachytherapy and external beam radiation therapy
10176094|NCT03836248|Other|1-Current practice Medication treatment|Medication treatment according to current practice.
10176095|NCT03836248|Sham Comparator|2- Sham osteopathic treatment|Medication treatment according to current practice + sham osteopathic treatment.
9680078|NCT04943055|Experimental|Low temperature plasma ablation with lacrimal duct catheterization|The experimental group received low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization
9680079|NCT04943055|Placebo Comparator|YAG lacrimal duct laser combined with lacrimal duct catheter|Control group received YAG lacrimal duct laser combined with lacrimal duct catheterization
9695458|NCT04778163|No Intervention|Control group 2|"Group 2 - the control group - will follow an usual treatment regimen for 6 weeks. At the end of the Humor Group of group 1, the 2 groups of patients will undergo a second series of tests identical to those of the pregroup. The paired patients should be randomly assigned. The control group will do the Humor Group after 6 weeks."
9695459|NCT04778319|Active Comparator|tubal occlusion|occlusion of tubes
10176096|NCT03836248|Experimental|3- Osteopathic treatment|Medication treatment according to current practice + osteopathic treatment.
10176097|NCT03836560|Active Comparator|Usual group|"Usual group with nicotine patch only:~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches."
9680080|NCT04943133|Active Comparator|3rd-term group: Pregnant women included in the last 3 months of pregnancy|Comparison of the profile of the curve according to whether there is presence or absence of blood pressure disorders.
10176098|NCT03836560|Active Comparator|Intervention group|"Nicotine patch and nicotine gum:~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required."
10176099|NCT03836118||IUI|all the IUI with controlled ovarian stimulation cycles in an academic tertiary ART center between January 1997 and December 2017
9680081|NCT04943133|Active Comparator|Before 20 weeks group. Pregnant women (normal blood pressure) included before 20 weeks of pregnancy.|Comparison of the profile of the curve according to the presence or absence of risk factors for pre-eclampsia
9680082|NCT04943029|Experimental|PD-1+Chemo+surgery+PD-1|Participants will receive neoadjuvant Carrelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection and adjuvant Carrelizumab for 16 cycles.
9680083|NCT04943107||healthy control|adults without glaucoma history or hypertension history
9680084|NCT04943107||glaucoma patients|adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history
10176100|NCT03836456|Experimental|Experimental Intervention|Mindfulness Based Stress Resilience Training: This approach will be conducted with study participants for 4 weeks. One evening per week.
9680085|NCT04943107||hypertension patients|adults with primary hypertension history; without glaucoma history
9680086|NCT04943107||glaucoma+hypertension|adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history
9680087|NCT04943315|Experimental|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia crowns
9680088|NCT04943315|Active Comparator|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic crowns
9680089|NCT04943003|Experimental|Active tDCS|"SimNIBS will be used for modeling. It is a free and open source software package for the simulation of electric field induced by tDCS in the individual brain.~Modeling will be done using T1-weighted anatomical images of each subject to reconstruct a high-resolution head model of each individual. For electrode placement, we will simulate areas F5 and F6, according to the EEG 10-20 system, for the anode and cathode, respectively, targeting the left and right Dorsolateral Prefrontal Cortex (DLPFC). This group will receive active tDCS, for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area."
9680090|NCT04943003|Sham Comparator|Sham tDCS|The electrodes will be placed in the same way as in the Active tDCS group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Afterwards, the device will be turned off, no longer emitting current.
9680091|NCT04943094||TURBT alone|Patients treated with TURBT without adjuvant instillation therapy
9680092|NCT04943094||TURBT and mitomycin C|Patients treated with TURBT followed by six adjuvant instillations with mitomycin C
9680093|NCT04943094||TURBT and bacillus Calmette-Guerin|Patients treated with TURBT followed by six adjuvant instillations with BCG
9680094|NCT04943198|Experimental|R1 time of vemurafenib treatment|vemurafenib will be given to 6 months after BRAF negativization
9680095|NCT04943198|Experimental|R2 time of vemurafenib treatment|vemurafenib will be given to 12 months after BRAF negativization
9680096|NCT04943016|Experimental|CD19 Chimeric Antigen Receptor (CAR) T Cells|The dose is escalated in standard 3 +3 design with a starting dose of 1x10^6 cell/kilogram and maximum treatment dose of 5 x 10^6 cell/kilogram. The minimum number of 9 subjects would occur if no dose-limiting toxicities are observed in the 3 dose escalation cohorts. The maximum sample size of 18 subjects would be enrolled in 3 dose escalation cohorts (six in each cohort) for meeting dose-limiting toxicities request. In addition, we hypothesize that we will be able to successfully manufacture CAR T cells to meet the established release criteria at a minimum target dose of 1 X 106 +-30% cells/kilogram in this patient population using the Miltenyi CliniMACS Prodigy® closed transduction system.
9680097|NCT04943276|Experimental|Embr Watch|Participants will receive the device and a technical onboarding video 3 days prior to study start to allow time for familiarization with the device and troubleshooting any technical questions or problems prior to study start. The study will consist of baseline measurements prior to using the Embr device and weekly outcome assessments at Week 1, 2, 3, and 4
10176101|NCT03836456|Active Comparator|Active Control Intervention|Health Enhancement Program: This is a validated active comparator used in Mindfulness-based training studies. It will be conducted with the participants one evening per week for 4 weeks.
10176102|NCT03836326|Experimental|Sensorimotor intervention|Is a 15-minute intervention consisting of tactile (i.e., stroking the whole body) and oral input (i.e., stroking the oral structures) for 15 minutes duration. The program will start 24 hours after nasal continuous positive airway pressure (NCPAP) is discontinued and 24 hours after 80 ml/kg/day of enteral feeds are tolerated. The program will be administered once a day for 10 days, within a 14-day period. The parents will perform all the interventions in the NICU. The infants will remain in the isolette for the duration of the program. This intervention does not involve any drugs or medical procedures. It is an intervention commonly used by occupational and physical therapists in the neonatal intensive care unit.
9680098|NCT04943263|Experimental|Tracheal Temperature|Intubation done with a temperature sensor located on the cuff surface of the endotracheal tube
10176103|NCT03836326|Other|Control|Infants in the control group will receive standard care only.
10176104|NCT03836274|Experimental|Experimental|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.
10176105|NCT03836313|Experimental|cryoneurolysis treatment|TKA patients randomized to receive preoperative rehabilitation and cryoneurolysis treatment with the iovera° device (n=70)
10176106|NCT03836313|No Intervention|no cryoneurolysis treatment (standard of care)|TKA patients randomized to receive preoperative rehabilitation only (no cryoneurolysis treatment) (n=70)
10176107|NCT03836534||patient coming to the emergency department|the group studied only concern adult adults consulting in the emergency departments and leaving after their consultations, during the permanence of care
9680099|NCT04943185|Other|Ab interno technique|Ab Interno is traditional method of stent XEN implantation, where the device will injected through a small corneal incision that closes with the preloaded XEN injector.
9680100|NCT04943185|Other|Ab externo technique|The ab externo approach does this without any incision, less invasive, and the implant is directly injected through the conjunctiva into the anterior chamber of the eye. Both methods create a new way out through the subconjunctival space, which is the traditional target of trabeculectomy.
9680101|NCT04943120|Experimental|"Snow-Plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
9680102|NCT04943120|Active Comparator|Bulk Fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
9680103|NCT04943081|Experimental|Case group|Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.
9680104|NCT04943146||control group|
9680105|NCT04943146||P+A group|aspirin: tablet 100mg qd 2-5weeks prednisone: tablet 10mg qd 2-5weeks
9680106|NCT04942912||French patients with juvenile Pompe disease|We aim to include all French patients with juvenile Pompe disease (maltase acid deficiency without cardiomyopathy)
9680107|NCT04943224|Experimental|R1 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 DAS score in three consecutive tests in three month intervals.
9680108|NCT04943224|Experimental|R2 time of trametinib treatment|Patients with negative status of any mutation in ctDNA or 0-1 DAS score in in five consecutive tests in three month intervals.
9680109|NCT04942886|Experimental|Treatment group|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation. The intervention group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months.
9680110|NCT04942886|No Intervention|delayed treatment group|The delayed treatment group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months. If the patient in the delayed treatment group shows HBV reactivation (positive HBsAg or HBV DNA ≥10 IU/mL), entecavir treatment is started.
10176108|NCT03836222|Experimental|PCS499 MR Tablet Prototype 2|600 mg single dose
9680111|NCT04942821|Experimental|Platelet rich fibrin and coronally advanced flap|Coronally advanced flap and platelet rich fibrin were used in treatment arms.
10176109|NCT03836222|Active Comparator|Trental MR tablet 400mg|single dose
10176110|NCT03836222|Experimental|PCS499 MR Tablet Prototype 4|600mg single dose
10176111|NCT03836222|Experimental|PCS499 MR Tablet Prototype 1|600mg single dose
10176112|NCT03836222|Active Comparator|Trental MR Tablet|400 mg multiple dose
10176113|NCT03836222|Experimental|PCS499 MR Tablet 900mg|multiple dose
10176114|NCT03836222|Experimental|PCS499 MR Tablet 600mg|multiple dose
10176115|NCT03836157|Experimental|Mirvetuximab and Bevacizumab|"Mirvetuximab Soravtansine 6mg/kg IV (adjusted ideal body weight), on day 1 of each 21 day cycle.~Bevacizumab 15 mg/kg, IV, on day 1 of each 21-day cycle."
10176116|NCT03835988|Experimental|Geniculate Artery Embolization|Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
10176117|NCT03836404|Experimental|Iliac Crest reconstruction surgery|The patients in the study group will be surgically treated and the GreenBone bone substitute will be implanted
10176118|NCT03836183|Other|ultrasound|"ultrasound is the only study group for all the patients~pleuropulmonary ultrasound~clinical examination~fibroscopy."
9680112|NCT04942821|Active Comparator|Connective tissue graft and coronally advanced flap|Coronally advanced flap and connective tissue graft were used in treatment arms.
9680113|NCT04942639|Experimental|Standard + JOE|Standard Maintenance Treatment plus JOE robot
9680114|NCT04942639|No Intervention|Standard|Standard maintenance Treatment
9680115|NCT04942626|Other|Chemoradiotherapy with Anakinra followed by either TME surgery or Watch and Wait|Capecitabine 500 mg/m2 bid or Capecitabine 650 mg/m2 bid or Capecitabine 825 mg/m2 bid combined with Radiotherapy and Kineret
9680116|NCT04942873||dabigatran group|NVAF patients who taking dabigatran capsule 110mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran.
9680117|NCT04942873||Rivaroxaban group|NVAF patients who taking rivaroxaban tablet 15mg，bid during 2016.2-2021.1，the duration of continuous medication was more than 3 months.PDC value and mmas-8 scale were used to evaluate the compliance of patients with dabigatran. PDC value and mmas-8 scale were used to evaluate the compliance of patients with rivaroxaban.
9680118|NCT04942873||wafarin group|NVAF patients who taking wafarin tablet during 2016.2-2021.1，the duration of continuous medication was more than 3 months， the dosage is adjusted according to INR. MMAS-8 scale was used to evaluate the compliance of patients with rivaroxaban.evaluate the compliance of patients with wafarin.
9680119|NCT04942548|Experimental|HFpEF|Patients diagnosed with obesity related heart failure with preserved ejection fraction(HFpEF)
9680120|NCT04942548|Experimental|PH-HFpEF|Patients diagnosed with obesity related pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF)
9680121|NCT04942860|Active Comparator|Methotrexate 1% gel|1% methotrexate gel applied onto a predefined limb
9680122|NCT04942860|Active Comparator|Methotrexate 0.5% gel|0.5% methotrexate gel applied onto a predefined limb
9680123|NCT04942860|Placebo Comparator|Vehicle gel|Vehicle gel applied onto a predefined limb
9680124|NCT04942691|No Intervention|non-exercise group (control group)|The control group not performed physical activity for a total of 20-weeks.
10176119|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
9680125|NCT04942691|Experimental|exercise group|The exercise group performed SuperJump® training that will be performed for three times a week, each session lasting 60 minutes for a total of 20-weeks.
9680126|NCT04942847|No Intervention|The control group|The control group received routine nursing, including diet nursing, life nursing, direct and indirect training, health education and so on. Patients were followed up regularly by telephone after discharge
9680127|NCT04942847|Experimental|Dual task training group|On the basis of routine swallowing function training, the use of sucking training rehabilitation device is mainly used for tongue muscle training and lip muscle training to improve the control and delivery ability of tongue muscle to food.At the same time,adopt Troup's playing and comprehensive analysis ability training.Disrupt the three sets of cards, instruct the patient to read words or say colors, and measure the patient's reaction time with an electronic timer.Comprehensive analysis ability training: including digital training or item classification training.
9680128|NCT04942600|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|1 session (3,000 pulses) of high-frequency (10Hz) repetitive stimulation applied over the right temporal parietal junction (TPJ) gyrus in individuals with Functional Neurological Disorder using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
9680129|NCT04942444|No Intervention|Control Group|Patients from the control group kept on taking the same medical treatment that they received before randomization
9680130|NCT04942444|Experimental|Dry needling group|Besides maintaining their current medical treatment, patients from the experimental group received an additional weekly one-hour session of dry needling over the 18 tender points for a 6-week-period.
9680131|NCT04942834|Active Comparator|Drug treatment group|receive class I or class III AAD to restore or maintain sinus rhythm.
9680132|NCT04942834|Experimental|cryoballoon ablation group|receive cryoballoon ablation to restore sinus rhythm.
9680133|NCT04942652|Experimental|Itraconazole 200 mg under fasted condition|A single oral administration of itraconazole 200 mg under fasted condition
9680134|NCT04942652|Experimental|Itraconazole 200 mg under fed condition|A single oral administration of itraconazole 200 mg under fed condition
9680135|NCT04942652|Experimental|Esomeprazole 40 mg + Itraconazole 200 mg under fasted condition|Oral administration of esomeprazole 40 mg once daily for 6 days and then a single oral administration of itraconazole 200 mg under fasted condition
9680136|NCT04942756|Experimental|Continuous Glucose Monitoring|"The FreeStyle Libre 2 Flash Glucose Monitoring System (FSL2) is a CGM device with real time alarms capability indicated for the management of diabetes in persons aged 4 and older. The Sensor holds eight (8) hours of data at a time. In order to have a daily diary of the Glucose level the patients or family or HCP must read the sensor (with reader or app) at least every height (8) hours. Every day at least three (3) scans of the sensor should be performed using the reader or the Smartphone App, generally at wake up in the morning, in the afternoon and at the time to go to sleep.~The alarm system will be activated, so that the Glucose level is over the cut off limit of 180 mmol/L or when it is lower than the cut-off limit of 80 mmol/L, the patient and/or the family members and/or the caregiver will check the Glucose level by scanning the reader/smartphone over the sensor."
9680137|NCT04942756|Active Comparator|Standard Care|"This arm will perform the usual standard routine for blood glucose monitoring in patients with insulin therapy, that is represented by at least three finger pricks/die according to the usual standards routine of each center.~Different frequency of finger pricks glucose measurements could be performed on the basis of health care professional patient assessment of each patient's needs."
9680138|NCT04942743||control group|patients with normal TMJ
9680139|NCT04942743||Study group|patients with TMJ internal derangement
9976009|NCT01347242|Experimental|study treatment|autologous CD34 positive cells transduced with a lentiviral vector containing the human WAS gene
10176120|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
10176121|NCT03835910|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
10176122|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
9976010|NCT01347268|Experimental|withdrawing GnRH agonists|
9976011|NCT01347268|Experimental|GnRH antagonist administration|
9976012|NCT01347281|Experimental|[18F]HX4 PET|Injection of [18F]HX4
10176123|NCT03835910|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
10176124|NCT03835780||People with inflammatory bowel disease|All individuals with an existing or incident diagnosis of IBD during the study period
10176125|NCT03835780||People with rheumatoid arthritis|All individuals with an existing or incident diagnosis of RA during the study period
10176126|NCT03835780||People with psoriatic arthritis|All individuals with an existing or incident diagnosis of IBD during the study period
10176127|NCT03835780||Controls|Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period
10176128|NCT03835962|Experimental|Intervention Arm|All participants will be asked to attend one experimental session. During the session, participants will listen one auditory stimulus sequence including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
9976013|NCT01347294|Experimental|Bleomycin + Fibrovein|
9976014|NCT01347294|Active Comparator|Bleomycin|
9976015|NCT01347294|Experimental|Natrium Tetradecyl Sulphate (Fibrovein )|
10176129|NCT03836001|Placebo Comparator|Placebo Oral Tablet|We aim to recruit at least 20 patients who will undergo two months of dosing with placebo (inactive drug or sugar pill), followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant at 5 mg (taken by mouth) daily for continued safety monitoring.
10176130|NCT03836001|Active Comparator|Serlopitant Tablet|We aim to recruit at least 20 patients who will undergo two months of Serlopitant dosing, followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant 5 mg (taken by mouth) daily for continued safety monitoring.
10176131|NCT03835806|Active Comparator|Elastikon - traditional|The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.
9680140|NCT04942353|Experimental|Home-based Exercise Rehabilitation|
9680141|NCT04942353|Active Comparator|Usual Care|
9680142|NCT04942769|Experimental|selenium|selenium was administered to patients with autoimmune thyroiditis
9680143|NCT04942782|Experimental|lumbopelvic stabilization exercises|the patients will receive trunk stabilization exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
9680144|NCT04942782|Experimental|Pilates exercises|the patients will receive trunk pilates exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
10176132|NCT03835806|Experimental|Rocktape - novel|The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape
10176133|NCT03835832||HIV-infected participants who receive TST test|0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants. They will learn how to interpret the results of the TST test. When they return to the clinic, the nurse will also interpret the results of the TST test. The results from the participants will be compared to the nurses' interpretation. We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
9680145|NCT04942782|Active Comparator|conventional therapy|the patients will receive trunk stabilization exercise three times/ week for three months
10176134|NCT03835845|Experimental|PICO7Y|PICO 7Y is a single-use NPWT System consisting of a small portable pump & pump clip, 2 AA batteries, 2 large multisite dressings, 2 extension tubes and secondary fixation strips.
10176135|NCT03835741|Experimental|Automated Oxygen titration|In this arm, an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
10176136|NCT03835741|Other|Manual Oxygen titration|In this arm, a manual adjustment of oxygen during patient hospitalisation by hospital staff
10176137|NCT03835793||Early-RRSO|"RRSO before the age of 45 years~RRSO was done 10 or more years ago"
10176138|NCT03835793||Late-/non-RRSO group|"Natural menopause ≥ 50 years of age~No RRSO ≤ age of 55~No treatment-induced menopause ≤ 50 years of age"
10176139|NCT03836014|Experimental|Fixed duration therapy for 24 months.|Daratumumab, Lenalidomide, Dexamethasone
10176140|NCT03836014|Active Comparator|Continuous therapy|Daratumumab, Lenalidomide, Dexamethasone
10176141|NCT03835663||Patients with non erosive reflux|Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
10176142|NCT03835663||Patients with erosive reflux|Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
9680146|NCT04942795||Mechanical thrombectomy|Patients who underwent mechanical thrombectomy for large vessel occlusion of the anterior circulation
9680147|NCT04942730|Experimental|FluBuBe|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
10176143|NCT03835663||Patients with no reflux|Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
9680148|NCT04942522|Experimental|ASD children A|Participants received probiotics PS128 [6×10^10 CFU(colony forming unit)/capsule} one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
9680149|NCT04942522|Experimental|ASD children B|Participants received placebo(450mg/capsule) one capsule orally twice daily for 8 weeks. After a washout period (4 weeks), they then received probiotics PS128(6×10^10 CFU/capsule) one capsule orally twice daily for 8 weeks. Stool, urine and blood specimen will be collected at baseline, week 8, week 12 and week 20.
9680150|NCT04942418|Active Comparator|Multicolor feldspathic ceramic laminate veneers|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
9680151|NCT04942418|Experimental|Multicolor hybrid ceramic laminate veneers.|Multi-shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
9680152|NCT04942509|Experimental|Coloring|This group did mindful coloring for at least 5 days or at least 100 minutes in total during a 10-day period
9680153|NCT04942509|No Intervention|Wait-list control|This group did not do mindful coloring at all during a 10-day period.
9680154|NCT04942392|Experimental|digital dance for PD|
9695460|NCT04778319|Sham Comparator|non occlusion of tube|non occlusion of tubes
9680155|NCT04942340|Active Comparator|Phase 1: Atipamezole & caffeine's in a 1:1 ratio|Is this arm, subjects will be randomized to IV administration of Atipamezole & caffeine's in a 1:1 ratio
10176144|NCT03835611|Experimental|Intervention group|"Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free."
10176145|NCT03835611|Active Comparator|Control Group|Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:
9680156|NCT04942340|Placebo Comparator|Phase 1: Precedex & Saline in a 1:1 ratio|Is this arm, subjects will be randomized to receive IV administration of Precedex & Saline in a 1:1 ratio
9680157|NCT04942587|Experimental|mother's voices|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of mother's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
10176146|NCT03835676|Experimental|Pulmonary hypertension treated with Treprostinil|Thirty patients who will be treated with Treprostinil.
10176147|NCT03835715|Experimental|Vortioxetine|
10176148|NCT03835520|Experimental|MOLECULAR TARGETED THERAPIES|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
10176149|NCT03835520|Experimental|IMMUNOTHERAPY|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
9680158|NCT04942587|Experimental|father's voices group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes. The baby was made listen to the lullaby recorded in the voice of father's starting with, during and after the care for 10 minutes. Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
9680159|NCT04942587|No Intervention|control group|Standard nursing care including, eye, mouth, nose, diaper change, skin care with baby oil and nurturing was applied respectively to the study groups for approximately 20 minutes.Heart rate, saturation, respiration rate and comfort behiavour scores of the newborn was measured 1 minutes before, during and 15 minutes after the care.
9680160|NCT04942431|Experimental|Interventiongroup|60 min per day school based Physical activity program (for one year)
9680161|NCT04942431|No Intervention|Waitinggroup|Intervention starts after one year.
9680162|NCT04942561|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for PIVC placement (i.e., a topical numbing spray and Buzzy® Bee, a vibrating device placed near the PIVC site for pain distraction).
9680163|NCT04942561|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction. Patients began gameplay <5 minutes before their PIVC placement and concluded after successful vascular access.
10176150|NCT03835637|Experimental|Regimen A|
9680164|NCT04942496|Active Comparator|Test Product 1 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
9680165|NCT04942496|Active Comparator|Test Product 2 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
9680166|NCT04942496|Active Comparator|Test Product 3 (2% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
9680167|NCT04942496|Active Comparator|Test Product 4 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
10176151|NCT03835637|Experimental|Regimen B|
10176152|NCT03835637|Experimental|Regimen C|
9680168|NCT04942496|Active Comparator|Test Product 5 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
9680169|NCT04942496|Active Comparator|Test Product 6 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
10176153|NCT03835637|Experimental|Regimen D|
10176154|NCT03835637|Experimental|Regimen F|
9680170|NCT04942496|Active Comparator|Test Product 7 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
9680171|NCT04942496|Active Comparator|Test Product 8 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
9680172|NCT04942496|Active Comparator|Test Product 9 (4% CHG)|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back
9680173|NCT04942496|Placebo Comparator|0.1% Sodium Lauryl Sulfate|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product with known irritancy potential.
9695461|NCT04777890|Active Comparator|suboccipital inhibition technique group|
10176155|NCT03835637|Experimental|Regimen H|
10176156|NCT03835637|Experimental|Regimen I|
10176157|NCT03835468|Experimental|Galacto-oligosaccharides (GOS) Group|Participants in this group will receive the daily dosage of galacto-oligosaccharides (GOS) prebiotic for 4 weeks
10176158|NCT03835468|Placebo Comparator|Maltodextrin Group|Participants in this group will receive the daily dosage of Maltodextrin placebo for 4 weeks
10176159|NCT03835429|Experimental|MyTAP oral appliance plus mouth shield|MyTAP plus mouth shield
10176160|NCT03835442|Active Comparator|baclofen arm|baclofen 10mg tid for 4 weeks
10176161|NCT03835442|Placebo Comparator|placebos arm|placebo tid for 4 weeks
10176162|NCT03835936|Active Comparator|Manual maneuvers physiotherapy|The protocol of physiotherapy treatment techniques consists of 20 minutes of FR based on prolonged slow expiration and cough provoked.
10176163|NCT03835936|Experimental|High frequency compression chest wall|The protocol consists in the application of the Smart Vest® device for high frequency compression of the chest wall, with a fixed frequency of 13 Hz and a time of 15 minutes. Then during 20 minutes will apply the same protocol as in the manual maneuvers group.
10176164|NCT03835624||juvenile idiopathic arthritis|about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
10176165|NCT03835624||control group|"about 60 apparently healthy children with comparable age and sex to the patients.~serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples."
10176166|NCT03835572|Experimental|CircaHealth|The CircaHealth group will receive access to an online educational module on circadian rhythms and health as their intervention. Every week for six weeks, these participants will receive a new module that contains videos, quizzes, behavioral modification checklists, and journal prompts.
10176167|NCT03835572|Active Comparator|Sleep hygiene materials|The control group will receive publicly available materials about sleep hygiene from the National Sleep Foundation and/or the American Academy of Sleep Medicine every week for six weeks as their intervention.
10176168|NCT03835871|Experimental|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 12 weeks
10176169|NCT03835871|Experimental|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg per day Daily dose of Beclomethasone 200 µg 1 inhalation 100 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
10176170|NCT03835871|Experimental|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg per day Daily dose of Beclomethasone 100 µg 1 inhalation 50 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
10176171|NCT03835871|Placebo Comparator|placebo|Intervention: Drug: placebo 2 inhalations 2 times a day for 12 weeks
10176172|NCT03835559|Active Comparator|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure for treatment of incompetent Saphenous Veins is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
10176173|NCT03835559|Active Comparator|Surgical stripping|For treatment of incompetent Saphenous Veins, surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries under all types of anesthesia (general, spinal, regional block, or local anesthesia). The saphenous vein is then removed using a stripper. Compression stocking is apply.
10176174|NCT03835507|Placebo Comparator|Control group|Inject Normal saline 100ml * 12 times (1month apart)
10176175|NCT03835507|Experimental|Low dose group|Inject 500IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
10176176|NCT03835507|Experimental|High dose group|Inject 750IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
10176177|NCT03835494|Experimental|Fallot patients|Fallot patients
10176178|NCT03835494|Experimental|healthy controls|healthy volunteers
10176179|NCT03835390|Experimental|Intervention|Participants who agree to participate in the SIMDiscovery program will be asked if they would like to participate in the research. If they consent, they will fill out pre- and post-questionnaires concerning quality of life, anxiety levels concerning the surgery, and a knowledge assessment.
10176180|NCT03835533|Experimental|Cohort A: NKTR-214 + Nivolumab|
10176181|NCT03835533|Experimental|Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab|
10176182|NCT03835533|Experimental|Cohort C: CDX-301 + INO-5151 + Nivolumab|
10176183|NCT03835260|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 2 or more cigarettes per day
10176184|NCT03835481|Placebo Comparator|Placebo|Blinded period of Placebo until Week 12
10176185|NCT03835481|Experimental|BI 730357 Fasted Condition|Blinded period of BI 730357 until Week 12 (4 dose levels or placebo as continued from trial 1407-0030). Open label period of BI30357 from Week 12 to end of trial (2 dose levels).
10176186|NCT03835481|Experimental|BI 730357 Fed Condition|Patients entering extension trial from Part 2 of trial 1407-0030
10176187|NCT03835286|Experimental|Vitamin C|Vitamin C experimental group
10176188|NCT03835286|Placebo Comparator|Control|Placebos Controlled group
10176189|NCT03835403|No Intervention|Usual Care (control arm)|These cardiac arrests will receive standard EMS response.
10176190|NCT03835403|Experimental|HeartRunner Activation|For these cardiac arrests, HeartRunners will be activated in addition to standard EMS response.
10176191|NCT03835351|Other|Intraoperative urinary catheter|After induction of general anesthesia, a standard catheterization kit available at the institution where the surgery is being performed will be used to place the urinary catheter using standard sterile technique.
10176192|NCT03835351|No Intervention|No intraoperative urinary catheter|No intraoperative urinary catheter will be used during the case
10176193|NCT03835325|Experimental|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
10176194|NCT03835312|Experimental|Interventional|Sequential transplantation of umbilical cord blood stem cells and islet cells
10176195|NCT03835299|No Intervention|Fear Control|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions then proceed through the normal blood donation process.
9680174|NCT04942496|Placebo Comparator|Distilled Water|Product applied to patch and randomly assigned application site on right and left parascapular regions of upper back. Product known not to cause irritancy
9680175|NCT04942366|Experimental|HIIT Group|High intensity interval training will be performed thrice a week using a treadmill.
10176196|NCT03835299|Experimental|Fear Intervention|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions and view a brief presentation of coping strategies presented via a computer tablet. They will then proceed through the normal blood donation process.
10176197|NCT03835299|No Intervention|No Fear Control|Participants who report no blood donation-related fear will proceed through the normal blood donation process.
9680176|NCT04942366|Active Comparator|ST Group|Strength training will be performed thrice a week, each session will consist of eight dynamic drills (with resistance of 60 - 70 % of 1 repetition maximum).
9680177|NCT04942314||Complete remission off therapy|"no clinical activity and serological activity~stop taking corticosteroid and immunosuppressive drugs~antimalarials allowed"
9680178|NCT04942314||Complete remission on therapy|"no clinical activity and serological activity~corticosteroid≤5 mg/day and immunosuppressive drugs allowed~antimalarials allowed"
9680179|NCT04942314||Clinical remission off therapy|"no clinical activity but serological activity allowed~stop taking corticosteroid and immunosuppressive drugs~antimalarials allowed"
9680180|NCT04942314||Clinical remission on therapy|"no clinical activity but serological activity allowed~corticosteroid≤5 mg/day and immunosuppressive drugs allowed~antimalarials allowed"
9680181|NCT04942314||Low disease activity state|(1) SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever), and no haemolytic anaemia or gastrointestinal active involvement; (2) no new lupus disease activity compared with the previous assessment; (3) a PGA ≤1; (4) a current predni- sone (or equivalent) dose ≤7.5mg/day; and (5) well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
9680182|NCT04942314||Not in LDAS or Remission|At the end of follow-up, the disease state of SLE children was not in LDAS or any remissions defined above.
9680183|NCT04942314||Never in LDAS|During the follow-up, the disease state was never get LDAS.
9680184|NCT04942301|Experimental|Endostar pump for three days|Group A: The first cycle, Endostar 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump for 72 hours;
9680185|NCT04942301|Experimental|Endostar pump for seven days|Group B: Cycle 1, Endo 7.5mg/m2/day, intravenous infusion for 4 hours, D1-14 First 2-4 cycles, Endo 105mg/m2/cycle D1 starts intravenous pump injection for 168 hours;
9680186|NCT04942171|Experimental|Atrial fibrillation catheter ablation group|catheter ablation
9680187|NCT04942171|Active Comparator|Medical therapy group|standard treatment include anti-arrhythmic drug
9680188|NCT04942119|No Intervention|Routine standard care group|This group will continue to receive the usual recommended care provided in the clinic and usual follow-up appointment as well as clinical assessment. Any required nutrition education by the dietitian or medication counseling will be provided at any visit or when requested.
9680189|NCT04942119|Experimental|Multifactorial intervention group|"Correction of magnesium and/or potassium levels, and correction of the underlying disease, if possible by a endocrinologist.~Education at each follow-up visit by a specialized dietitian, reinforcing optimal diet and exercise, with pre-& post-nutrition and physical activity assessment using the validated revised summary of diabetes self-care activities (SDSCA) scale.~Medication reconciliation and counseling, online post adherence questionnaire and confirm adherence by fixed medication possession ratio (FMPR) approach."
9680190|NCT04942145|Active Comparator|Virtual Reality Group|With virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
9680191|NCT04942145|Experimental|Control Grooup|Without virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
9680192|NCT04942132|Experimental|Treatment|A Smartphone self-administered cognitive-behavioral based intervention
9680193|NCT04942080|Experimental|CALRSUIVI cohort|
9680194|NCT04941976|Experimental|0.3% benzydamine hydrochloride spray oromucosal solution|A single application of 0.3% benzydamine hydrochloride spray oromucosal solution, corresponding to 2.04 mg of benzydamine (4 nebulizations)
9680195|NCT04941976|Active Comparator|3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine|A single 3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine.
9680196|NCT04942002|Placebo Comparator|Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution
10176198|NCT03835195|Experimental|Diabetes Disease Management Program|Diabetes Disease Management Program
10176199|NCT03835195|Active Comparator|Usual Care Process|Usual care process
10176200|NCT03835377|Experimental|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
10176201|NCT03835377|Active Comparator|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety)
10176202|NCT03834896|Experimental|Experimental|Patients with dysphagia requiring Stage 1, 2 or 3 thickened fluids as determined by Speech and Language Therapist and who are expected to require provision of Stage 1, 2 or 3 thickened fluids for at least 2 further weeks.
9976016|NCT01347320|No Intervention|No preoperative MRI|control arm of the study
10176203|NCT03834818|Experimental|COMPAS Participants|Patents between the ages of 18 and 90 who are undergoing orthopedic surgery at Duke Health will be eligible for enrollment.
10176204|NCT03834766|Active Comparator|AMPH ER Tab|Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
10176205|NCT03834766|Placebo Comparator|Matching Placebo|Matching Placebo Tablets 5, 10, 15 and 20 mg
10176206|NCT03834857|Other|single|Implantation of Stentrode TM device
10176207|NCT03834831|Active Comparator|Coenzyme Q10|Coenzyme Q10 200mg/day for 3 months
10176208|NCT03834831|Active Comparator|Selenium|Selenium mcg/day for 3 months
9680197|NCT04942002|Experimental|Standard treatment + intervention|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + retrobulbar injection of 2 cc (40 mg/mL) to methylprednisolone acetate
9680198|NCT04942262|Experimental|denture adhesive use|Participants were instructed to use a cream-type denture adhesive (Polident®, GlaxoSmithKline, Ireland) once a day in the morning and use it throughout the day. They applied denture adhesive onto the tissue surface of their maxillary and mandibular dentures using a spot method. The participants had to remove the DA and clean the denture every day after the last meal by soaking and brushing the CD with liquid soap and a soft toothbrush under running tap water. Two gauze pads were used to remove DA from the denture and oral mucosa. After the 1-month trial period of DA use. The outcomes were evaluated with all participants using DA, and they had to choose whether they wanted to continue or discontinue using DA for another 1 month. At 1-month after continuing or discontinuing DA use. At this time, some participants used DA during the outcome evaluations, while some did not, depending on the patient's decision on DA use.
9680199|NCT04941872|Experimental|68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of and 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
9680200|NCT04942275|Experimental|Intervention : Lung perfusion PET/CT using Ga68-MAA and SBRT planification|"All patients included for treatment with stereotactic radiotherapy for non-small cell lung cancer or lung metastasis will benefit from a pre-therapeutic functional assessment including:~The standard functional assessment recommended before performing an SBRT.~A perfusion PET/CT scan~The treatment planning will be carried out in 2 stages:~First, an anatomical planning will be carried out, blinded to the PET results.~Then, a functional planning, respecting the standard constraints applied during anatomical planning, but also incorporating a new functional lung volume constraint defined by pulmonary PET, will then be carried out.~A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months"
9680201|NCT04942288|Experimental|Acupressure + Massage Group|"Acupressure + Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention. On the second day, VAS will be applied before and after the intervention. On the third day, VAS before and after the intervention VAS, GMSSS will be applied.~Second menstrual cycle~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
9680202|NCT04942288|Experimental|Massage Group|"Massage Group First menstrual cycle - On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF- 12 will be applied. On the first day, intervention will be made and VAS will be applied after the intervention (1st hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied.~Second menstrual cycle~- On the first day, VAS will be applied before the intervention, and VAS will be applied after (1 hour). On the second day, VAS will be applied before and after the intervention (1st hour). On the third day, VAS before and after the intervention (1st hour) VAS, GMSSS will be applied."
9680203|NCT04942288|No Intervention|Control Group|"Control Group First menstrual cycle~- On the first day, Personal Information Form, VAS, GMSSS and Quality of Life Scale Short Form SF-36 will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.~Second menstrual cycle - On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS will be applied.~Third menstrual cycle~- On the first day, VAS, GMSSS will be applied. On the second day, VAS will be applied. On the third day, VAS, GMSSS and Quality of Life Scale Short Form SF-12 will be applied."
9680204|NCT04942197|Experimental|Arm 1|Participants who received three dimensional ultrasound with pregnancy application
10176209|NCT03834974|Experimental|Sun Safety Social Media Challenge|During this 4-week intervention, participants will be incentivized to create sun safety social media messages that will be distributed on our sun safety Twitter and Facebook feeds.
10176210|NCT03834974|Active Comparator|Digital Health Social Media Challenge|During this 4-week intervention, participants will be incentivized to create posts that promote the use of technology to engage in healthy lifestyle behaviors (diet, exercise) on our digital health Twitter and Facebook feeds.
10176211|NCT03835208|Experimental|Low-morning-carbohydrate|"Low morning intake and high evening intake of carbohydrates. This means a distribution of carbohydrate as follows:~10% morning, 40% lunch, 50% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
9680205|NCT04942197|Placebo Comparator|Arm 2|Participants who received three dimensional ultrasound without pregnancy management application
9680206|NCT04941898||TAK-660 15-50 international units per kilograms (IU/kg)|Participants will receive TAK-660 15-50 IU/kg slow intravenous injection every 8- 24 hours until the bleeding is resolved or wound healing.
9680207|NCT04942015|Experimental|Honghuaruyi Wan|Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
10176212|NCT03835208|Experimental|High-morning-carbohydrate|"High morning intake and low evening intake of carbohydrates.~This means a distribution of carbohydrate as follows:~50% morning, 40% lunch, 10% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
10176213|NCT03834844|No Intervention|Usual Care|patient receives same care as patients not enrolled in study intervention
10176214|NCT03834844|Experimental|AF education|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week.
10176215|NCT03834844|Experimental|Mindfulness Meditation Practice|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
9680208|NCT04942015|Placebo Comparator|Placebo|Placebo of Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
9680209|NCT04942223|Other|Subjects undergoing virtually planned GBR for extended and complex alveolar defects.|"Subjects undergoing virtually planned GBR for extended and complex alveolar defects.~The subjects were selected from the population of patients referring to the Oral & Maxillofacial Surgery Unit of S.Orsola-Malpighi University Hospital for oral function rehabilitation. Eligibility criteria were: the presence of horizontal and vertical alveolar defects in both jaws, inadequate for the placement of at least two fixtures, even ≤6 mm long ones; ≥ 18 years; informed consent signed."
9680210|NCT04942093|Experimental|With diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
9680211|NCT04942093|Other|Without diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
9680212|NCT04941924|Experimental|Intervention|Biliary stenting plus radio-frequency ablation of the bile duct
9680213|NCT04941924|Active Comparator|Control|Biliary stenting alone
9680214|NCT04941612|Experimental|Activa IM-Nail|Activa IM-Nail
9680215|NCT04941859|Experimental|experimental group|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
10176216|NCT03834844|Experimental|Weekly Phone Calls|Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
10176217|NCT03834844|Experimental|AF Education and Mindfulness Meditation|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
10176218|NCT03834844|Experimental|AF Education and Weekly Phone Calls|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
10176219|NCT03834844|Experimental|Mindfulness Meditation and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
9680216|NCT04941859|No Intervention|control group|The treatment plan of control group was carried out according to the diagnosis and treatment standard of acute poisoning.
9680217|NCT04941833|Experimental|Desogestrel group|Desogestrel group
9680218|NCT04941833|Placebo Comparator|Control group|Placebo
9680219|NCT04942249||Symptomatic|167 symptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
9680220|NCT04942249||Asymptomatic|167 asymptomatic Swiss army recruits who tested positive for SARS-CoV-2 in 2020
9680221|NCT04942249||No evidence of infection|167 Swiss army recruits with no evidence of infection (who also were tested for SARS-CoV-2 in 2020)
9680222|NCT04941586|Experimental|Education in pain, Manual Therapy and Exercises|The therapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 60 minutes, for one month. Each therapy will last 20 minutes.
9680223|NCT04941586|Active Comparator|Manual Therapy and Exercises|The terapies will be performed by one a physical therapist with experience in rehabilitation, twice a week, lasting 40 minutes, for one month. Each therapy will last 20 minutes.
9680224|NCT04941911|Active Comparator|Intervention group|Octreotide intravenous infusion, 100mcg bolus with a subsequent infusion of 100mcg per hour during surgery.
9680225|NCT04941911|Placebo Comparator|Placebo group|Sodium chloride 0.9% w/v
9680226|NCT04941599|Active Comparator|2-Hydroxybenzylamine (2-HOBA)|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
9680227|NCT04941599|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for 6 weeks.
9680228|NCT04941885|Experimental|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab(8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days) plus cyclophosphamide metronomic chemotherapy(50mg once a day orally) plus aromatase(once a day orally).
9680229|NCT04941820|Experimental|Clinical pharmacist intervention + usual care arm|Patients in the clinical pharmacist intervention + usual care arm received the clinical pharmacist intervention as well as usual care provided by the surgical team
9680230|NCT04941820|No Intervention|Usual care arm (Control arm)|Patients in the control arm received usual care by the surgical team without a coordinated contribution from the clinical pharmacist
9695462|NCT04777890|Experimental|INYBI group|Participants in this group will be treated with the INYBI, an instrument designed for treating the suboccipital area, in a more precise way than the manual technique.
9695463|NCT04777890|Experimental|combined treatment group|Participants in this group will be first treated with the INYBI and then receive an upper cervical manipulation
9827559|NCT02460991|Active Comparator|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
9680231|NCT04941482|Experimental|Multi-intervention program|A multi-intervention program will design for stroke patients including [1] periodic health examination for assessment of physical and mental health, recurrence risks, and harmful behaviors; [2] guiding the appropriate rehabilitation exercises for improving the physical status and monitoring through daily online report; [3] using the motivational interviewing methods to improve and prevent mental disorder; [4] applicating the technique of functional near-infrared spectroscopy (fNIRS) for measurement of oxy-hemoglobin on cortex prefrontal to early detect mental disorder and stroke recurrence risks.
9680232|NCT04941482|Active Comparator|Standard care|Standard health check and fNIRS measure
9680233|NCT04941495|Active Comparator|Control Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education
9680234|NCT04941495|Experimental|Experimental Group|It Includes the TENS, Infrared, Isometric and stretching exercises along with the home plan and postural education. It also include the cervical proprioceptive training
10176220|NCT03834844|Experimental|Meditation and Education and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
10176221|NCT03834805|Experimental|Pregnant women with a normal pregnancy|Assesment of fetal lung and liver stiffness with 2D Ultrasounds Shear Wave Elastography
10176222|NCT03835000||Pre operative patient|Patients who will require orthopedic surgery for corrective, replacement or repair
9680235|NCT04941807|Experimental|Platelet-rich plasma|The proximal nail fold is cleansed with alcohol and platelet-rich plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
9680236|NCT04941807|Placebo Comparator|Platelet-poor plasma|The proximal nail fold is cleansed with alcohol and platelet-poor plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
9680237|NCT04941625||non-AKI|patients do not have post-HIPEC AKI
9680238|NCT04941625||AKI|patients have post-HIPEC AKI
9680239|NCT04941690||Men seen for preconception physicals|Ready to conceive, i.e. not having contraception and not having children for less than 1 year
9680240|NCT04941690||Men seen for infertility|Couples who have not used contraception and have not had children for more than 1 year
9680241|NCT04941690||Men who visited the clinic for their wives' miscarriage|Couples whose wives were previously pregnant but terminated the pregnancy due to fetal abortion, spontaneous abortion, biochemical pregnancy, fetal malformation or ectopic pregnancy
9680242|NCT04941677||schizophrenia group|No intervention age between 20-65, diagnosed schizophrenia by DSM-5.
10176223|NCT03835091||Patient with mechanical ventilation and sedation|All patient hospitalized in intensive care under sedation and mechanical ventilation without neurologic disorder
10176224|NCT03834935|Experimental|Pim|20 patients receiving topical Elidel (pimecrolimus 1%) bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
10176225|NCT03834935|Placebo Comparator|Pl|20 patients receiving placebo (control group), cold cream bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
10176226|NCT03835104|Active Comparator|CRP in all|"All children will undergo a CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
10176227|NCT03835104|Experimental|CRP in high risk children only|"Children who are positive on a clinical prediction rule for serious infections in children will undergo CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
10176228|NCT03834883|Experimental|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
10176229|NCT03834883|Placebo Comparator|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
10176230|NCT03834883|Experimental|Premenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
10176231|NCT03834883|Placebo Comparator|Premenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
9680243|NCT04941573|Experimental|Hyperpolarized Xenon MRI for lung transplant diagnosis|"All post lung transplant patients will undergo hyperpolarized 129-Xenon MRI and conventional proton MR imaging of the lung. Recent HRCT and spirometry measurements as part of clinical care will be available in the medical history for comparison. There will be multiple administered inhalation of HP Xenon during an imaging session. Maps of xenon ventilation (distribution) will be used for analyzing function of the lungs. These maps will be compared against 3D high-resolution CT images for regional correlations, and against spirometry as global measurements of lung health status. Additionally, xenon dissolved in lung parenchyma and blood, allows for measurement of gas exchange properties.~Each subject will have a secondary imaging session after six-months for evaluating potential changes in the lung function and early detection of lung transplant complications such as CLAD."
9680244|NCT04941729|Experimental|Study Arm (dual mobility)|OR3O™ Dual Mobility in subjects who undergo Primary THA.
9680245|NCT04941729|Active Comparator|Controlled Arm (conventional)|A conventional, single-bearing design Total Hip System in subjects who undergo Primary THA.
9680246|NCT04941352|Experimental|Experimental: Study group|Study group intervention consists 6-session Interpersonal Relations Theory-Based Motivational Interviews and 3-month follow-up.
9976017|NCT01347320|Active Comparator|MRI group|preoperative MRI
9680247|NCT04941352|No Intervention|No Intervention: Control group|Control group receives general care and the training booklet at the end of the study. Also includes 3-month follow-up.
9680248|NCT04941417|Experimental|neoadjuvant PD-(L)1 inhibitor with chemotherapy followed by PD-(L)1 inhibitor for up to 1 year|
9680249|NCT04941131|Experimental|chlorhexidine digluconate mouthwash|
9680250|NCT04941131|Experimental|chlorhexidine digluconate lozenges|
10176232|NCT03835065|Active Comparator|Long Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
9680251|NCT04941131|Experimental|povidone iodine mouthwash|
9680252|NCT04941131|No Intervention|tap water|
9680253|NCT04941053||group 1 chronic haemodialysis patients|seroprevalnce of COVID 19
9680254|NCT04941053||healthy control|seroprevalnce of COVID 19
9680255|NCT04941105|Experimental|PCSK9 inhibitor (evolocumab)|140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations
9680256|NCT04941105|Placebo Comparator|Usual Care|1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2.
9680257|NCT04941014|Active Comparator|Light Physical Activity (LPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
9680258|NCT04941014|Active Comparator|Moderate Physical Activity (MPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
9680259|NCT04941014|Active Comparator|Vigorous Physical activity (VPA)|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
9680260|NCT04941170|Active Comparator|Group (T)|receive preoperative bilateral ultrasound-guided oblique subcostal transversus abdominis plane block.
9680261|NCT04941170|Active Comparator|Group (E)|receive preoperative bilateral ultrasound-guided erector spinae plane block.
9680262|NCT04941235|Active Comparator|NU group|Bth nerve stimulator and ultrasound guided interscalene brachial plexus block
9680263|NCT04941235|Active Comparator|U group|Ultrasound guided interscalene brachial plexus block
9680264|NCT04941235|Active Comparator|N group|Nerve stimulator guided interscalene brachial plexus block
9680265|NCT04941235|No Intervention|C group|No block only IV analgesics
9680266|NCT04941118|Sham Comparator|Control group|Only saline and local anesthetic (lidocaine)
9680267|NCT04941118|Active Comparator|Dextrose prolotherapy group|Dextrose, saline and local anesthetic (lidocaine)
9680268|NCT04941079||Immune-related Myopathy Patient (myasthenia gravis and inflammatory myopathy)|
9680269|NCT04941079||Health Control|
9680270|NCT04941092||patients with ARDS induced by SARS CoV 2|
9680271|NCT04941092||patients with ARDS induced by influenza|
9695464|NCT04778124|Other|Patients with hemorrhoidal disease undergoing HAL-RAR|This is a single-arm trial, in which all patients with grade II hemorrhoidal disease resistant to conservative treatment, grade III and IV hemorrhoidal disease underwent HAL RAR surgery.
9695465|NCT04778059|Experimental|USB002|
9695466|NCT04778059|Placebo Comparator|Placebo|
9695467|NCT04778098|Experimental|SMS group|"After postoperative standard discharge education was provided to the patients in the SMS group, they were given an individualized written Postoperative Medication Reference Chart. The patient/relative, whose contact information was received, was informed that they would be reminded via text message (SMS). SMS reminders which were individualized according to the patient based on the doctor's directive, were sent to the patients in the SMS group by the researcher clinical nurse (A. Ş). SMS sending started on postoperative day 1 and ended on day seven.~SAI was applied again to all patients who came to the outpatient clinic for control on postoperative day seven. Unlike the control group, the Patient Satisfaction Form, which was prepared for the use of SMS reminders, was applied to the patients in the SMS group. Confirmation was obtained from the patients and their relatives that SMS reminders were received every day."
9695468|NCT04778098|No Intervention|Control group|the Patient Identification Form and SAI were applied to patients in the control on the day of surgery (postoperative day 0). Routine discharge education was provided to all patients by clinical nurses. During the discharge of the patients in the control group, they were informed about the change of dressing on the next day (postoperative day one) and control in the outpatient clinic on postoperative day seven. The patients were given an individualized written Postoperative Medication Reference Chart indicating the dosage and application time of eye drops they must follow for seven days at home.
9695469|NCT04777747||viral infection|a child is infected by virus only
9695470|NCT04777747||viral and bacterial infection|a child is infected by virus and progress to bacterial infection
9695471|NCT04778007||Globus pharyngeus patients|The first group consists of 80 globus pharyngeus patients who have at least a year of globus sensation complaints. The participants will given the Turkish Version of the Laryngopharyngeal Measure of Perceived Sensation Questionnaire (T-LUMP), consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale. After the two weeks, 80 participants will given the T-LUMP and Visual analog scale for sampling.
9695472|NCT04778007||Healty subjects|The second group consists of 80 healty participants will given the T-LUMP consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale
9695473|NCT04778033||Vaccinated Men|Fertile men who were vaccinated with the BNT162b2 COVID-19 Vaccine
10176233|NCT03835065|Experimental|Short Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
10176234|NCT03834922||Total knee arthroplasty|Patients undergoing total knee arthroplasty
10176235|NCT03834922||Sternotomy|Patients undergoing sternotomy
10176236|NCT03834922||Breast|Patients undergoing breast surgery
10176237|NCT03834922||Endometriosis|Patients undergoing endometriosis-related surgery
10176238|NCT03834610|Active Comparator|Group A|receive L-arginine 5 g oral caps daily for 8 weeks serum testosterone level measurement penile doppler
10176239|NCT03834610|Active Comparator|Group B|receive tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
10176240|NCT03834610|Active Comparator|Group C|receive L-arginine 5 g oral caps plus tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
10176241|NCT03834610|Placebo Comparator|Group D|receive oral methyl cellulose daily for 8 weeks serum testosterone level measurement penile doppler
10176242|NCT03834623|Experimental|CC-122 Plus Nivolumab|Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.
9680272|NCT04941404|Experimental|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
9680273|NCT04941248||Healthy controls|All healthy subjects will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
9680274|NCT04941248||Patients with decreased EF value or aortic stenosis|All patients will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
9680275|NCT04940988||See alert|The intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly assigned to receive the intervention, which is implementation of the RTPB tool.
9680276|NCT04940988||Do not see alert|The non intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly selected to not receive the intervention.
9680277|NCT04941209||Case|Inpatients/Outpatients with confirmed COVID-19 with and without pulmonary symptoms.
9680278|NCT04941209||Matched-Control|Outpatients without COVID-19 without known non-pulmonary diagnoses or symptoms.
9680279|NCT04940975|Experimental|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
9680280|NCT04940975|Active Comparator|Insomnia educational program (Treatment as Usual Group)|A program composed of four educational talks on sleep hygiene and relaxation training, plus two individual sessions for the reviewing of sleep patterns.
9680281|NCT04940741|Experimental|VER-01|VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The optimal dose is titrated on a patient-by-patient basis. The maximum daily dose should not exceed 13 dose units (32.5 mg THC).
9680282|NCT04940741|Placebo Comparator|Placebo|The Placebo is administered orally (b.i.d.) using a dosing syringe. The optimal dose is titrated on a patient-by-patient basis, analogous to VER-01.
9680283|NCT04940884|Experimental|Supervised exercise training|Pre- and Post- exercise training effects. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised exercise training (SET) and the remaining participants follow the above instruction without additional supervised exercise training. After the 24 sessions of SET, they were then followed a 16-week of follow-up of their daily activities without additional exercise training.
9680284|NCT04940884|Active Comparator|home exercise training|All included subjects were instructed to walk>=8000 steps per day (stp/d), which was recorded by wrist-worm smart watches
9680285|NCT04940806||120 patients with narcolepsy|
9680286|NCT04940923||Patients|Patients within 4 weeks of a whiplash injury.
9680287|NCT04940923||Healthy controls|Age and gender matched healthy controls
9680288|NCT04940962|Experimental|Non-diabetic obese|
9680289|NCT04940962|Experimental|Diabetic obese|
9680290|NCT04940962|Active Comparator|Witnesses|
9680291|NCT04940793||Group 1|Patients indicated for cataract surgery who are candidates for a trifocal IOL implantation and have corneal astigmatism over 1.00 D will be selected for inclusion by the investigators
10176243|NCT03834662|Experimental|Dose Level 1: 180 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
10176244|NCT03834662|Experimental|Dose Level 2: 550 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks.
10176245|NCT03834662|Experimental|Dose Level 3: 1100 mg/m2|Intravenous infusion of AVID200 over 1.5 hours administered every three weeks.
10176246|NCT03834636|Active Comparator|Nanoparticulated composite - self-etch|
10176247|NCT03834636|Active Comparator|Nanoparticulated composite - total-etch|
10176248|NCT03834636|Active Comparator|Nanohybrid composite - self-etch|
10176249|NCT03834636|Active Comparator|Nanohybrid composite - total-etch|
10176250|NCT03834441|Other|Oral screening|
10176251|NCT03834441|Other|Written screening|
10176252|NCT03834454|Active Comparator|Bupivacaine 5 mg|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
10176253|NCT03834454|Active Comparator|Bupivacaine 7.5 mg|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
10176254|NCT03834415|Experimental|Lactobacillus reuteri DSM17038|Lactobacillus reuteri DSM17038, 1x108 CFU once a day for 30 days
10176255|NCT03834415|Placebo Comparator|Placebo probiotics|Placebo for probiotics, pols drops similar in consistency and flavor as experimental product
9680292|NCT04940689|Active Comparator|Standard arm|"General anesthesia strategy with morphine:~Within 10 minutes before the induction of general anesthesia: administration of a placebo of 50 mL of 0.9% NaCl by slow IV~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with IV curare and remifentanil (morphine derivative) IV for a concentration target of 3-6 ng / mL.~Maintenance of anesthesia will be carried out with propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qs bispectral index 40-60) and remifentanil (target concentration 1-10 ng / mL). The administration of curare will be carried out as needed. In order to anticipate the sudden end of the analgesia, an administration of morphine 0.15 mg / kg IV will be carried out 30 minutes before the end of the intervention as recommended"
9680293|NCT04940689|Experimental|OFA arm|"General anesthesia strategy without morphine~Within 10 minutes before the induction of general anesthesia: pre-induction dose of dexmedetomidine 0.5 g / kg and lidocaine 1.5 mg / kg by slow IV.~The anesthetic induction will be carried out by an intravenous hypnotic (propofol or etomidate) combined with an IV curare~The maintenance of the anesthesia will be carried out by propofol or a halogenated gas (sevoflurane or desflurane) in continuous administration (qsp bispectral index 40-60), dexmedetomidine 0.5-1.0 g / kg / h, lidocaine 2 mg / kg / h. The administration of curare will be carried out as needed."
10176256|NCT03834480|Experimental|• Steroid Group (S)|
9680294|NCT04940663|Other|Ecological Momentary Assessment (EMA)|
9680295|NCT04940949|Experimental|Single Intravenous (IV) Dose of Lu AF90103|Participants will receive a single IV dose of Lu AF90103.
9680296|NCT04940949|Placebo Comparator|Single IV Dose of Placebo|Participants will receive a single IV dose of placebo matching to Lu AF90103.
10176257|NCT03834480|Experimental|• Platelet rich plasma Group (PRP)|
9680297|NCT04940949|Experimental|2 Single IV Doses of Lu AF90103|Participants will receive 2 single IV doses of Lu AF90103 separated by at least 5 days.
9680298|NCT04940754|Other|Stabilzation of Fracture|Arthrodesis nail used for stabilzation of a fracture, single patient
9680299|NCT04940650|Other|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
9680300|NCT04940702|Experimental|Focal Vibration Group|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~the training is the same as the contol group with the difference of FV addiction."
9680301|NCT04940702|Active Comparator|Blood Flow Restriction Group|"Training with Blood Flow Restriction a pressure cuff occludes in the proximal part of the lower limb. Time of training 20-25 min.~the training is the same as the contol group with the difference of BFR addiction."
9680302|NCT04940702|Active Comparator|Training Group|"Traditional training. 3 times a week~Warm-up:~Main work:~Aerobic training~Strength training~Balance and coordination training~Return to calm"
9680303|NCT04940910|Experimental|Black rice bran extract group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 1 g/day)
9680304|NCT04940910|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 0 g/day)
9680305|NCT04940845|Experimental|HS-20090-2|
9680306|NCT04940845|Active Comparator|Prolia®|
9680307|NCT04940871|Experimental|Favipiravir HU + SOC|Favipiravir HU + SOC
9680308|NCT04940871|Placebo Comparator|Placebo HU + SOC|Placebo HU + SOC
9680309|NCT04940520|Active Comparator|Control group|Group A: control group, drug recommended by the Brazilian Society of Dermatology
9680310|NCT04940520|Active Comparator|Alpha-bisabolol and laser|Group B: alpha bisabolol-based product associated with low-level laser therapy
9680311|NCT04940520|Active Comparator|Alpha bisabolol|Group C: alpha bisabolol based product
9680312|NCT04940416||Cirrhosis|These will include patients with cirrhosis. They will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
9680313|NCT04940416||Non-cirrhosis|These will include patients without cirrhosis seen in the general gastroenterology clinic. Participants will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes.
9680314|NCT04940832|Active Comparator|radiofrequency with corticosteroids|corticosteroids- 80mg depo-medrol Pulsed radiofrequency to 42 derees celsius for 6 minutes
10176258|NCT03834389|Experimental|Experimental Group|Experimental group: case-based teaching method applied
10176259|NCT03834389|No Intervention|Control Group|Control group: classical teaching method applied
9680315|NCT04940832|Active Comparator|radiofrequency without corticosteroids|Pulsed radiofrequency to 42 derees celsius for 6 minutes
9680316|NCT04940819|Experimental|Mobile Application Intervention|Participants in this arm will receive mobile application dietary intervention as well as usual CKD dietary care.
9680317|NCT04940819|No Intervention|Care as Usual|Participants in this arm will receive usual CKD dietary care.
9680318|NCT04940715|Experimental|Passive joint mobilization|Patients lay down on a prone position, with their hands around the body and neck placed comfortable. The therapist performed a postero-anterior joint mobilization using Maitland's technique, applying pressure to spinous process of targeted vertebra (the one who reproduces patient's symptoms).
9827560|NCT02461134|Experimental|Ponesimod|Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.
10176260|NCT03834649|Active Comparator|Mucograft|Soft tissue augmentation of the defective alveolar ridge using Mucograft inside the prepared vestibular pouch leaving part of the mucograft exposed at the crestal area and will be sutured using 5/0 suture material around the defect margin and secured in the vestibular pouch.
9680319|NCT04940715|Experimental|Mobilization with movement|Patients perform their painful movement (flexion, extension…). If pain wasn't reproduced, a combination of movements will be performed (flexion + rotation…). The most painful vertebral level was assessed too with passive accessory vertebral movements. Afterwards, with the patient on a seated position on a stretcher with feet supported and a belt around the waist, the therapist performed a sustained glide on the targeted vertebra (spinous process) with the force and direction that relieved pain to the lowest level.
9680320|NCT04940715|No Intervention|Control group|"Patients were measured at baseline and then were placed on wait list until the end of the study. At this time, they were measured again."
10176261|NCT03834649|Experimental|Partially de-epithelialized connective tissue graft|Soft tissue augmentation of the defective alveolar ridge using Partially de-epithelialized connective tissue graft by preparing vestibular pouch at the defect site and place the de-epithelialized part inside the pouch leaving the epithelialized part sutured and exposed at the crestal area
10176262|NCT03834428|Active Comparator|No Text Message Control|Participants randomized to this arm will receive education about the ICOUGH protocol which includes the importance of ambulation.
10176263|NCT03834428|Experimental|Text Message Intervention|Participants randomized to this arm will receive daily text message reminders to ambulate in the hospital in addition to education about the ICOUGH protocol which includes the importance of ambulation.
10176264|NCT03834558|No Intervention|Control Group|They will follow their daily routine without added exercise
10176265|NCT03834558|Experimental|Intervention Group|They will perform the mixed exercise program
10176266|NCT03834506|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
10176267|NCT03834506|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
10176268|NCT03834584|Experimental|AG-636|AG-636 dosed orally.
10176269|NCT03834571|Experimental|Arm I (standard care, carboplatin, paclitaxel)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
10176270|NCT03834571|Active Comparator|Arm II (standard care, active monitoring)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months."
10176271|NCT03834467|Experimental|Arm 1 - Elevation Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 1 then presents the Moral Elevation stimulus video after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
9680321|NCT04940559|Experimental|Group 1: Sequence 1|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 3: Danicopan as a tablet under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
10176272|NCT03834467|Sham Comparator|Arm 2 - Control Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 2 then presents the control stimulus (nature video) after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
10176273|NCT03834259|Active Comparator|Group 1|12.5 mg 0.5% hyperbaric bupivacaine
9680322|NCT04940559|Experimental|Group 1: Sequence 2|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fed (medium-fat meal) conditions. Period 2: Danicopan as a tablet under fasted conditions. Period 3: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
9680323|NCT04940559|Experimental|Group 1: Sequence 3|"Participants received danicopan once each period as a single dose under fasted or fed (medium-fat meal) conditions as follows:~Period 1: Danicopan as a tablet under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. Period 3: Danicopan as a tablet under fed (medium-fat meal) conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
9680324|NCT04940559|Experimental|Group 2: Sequence 1|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as an LFC under fasted conditions. Period 2: Danicopan as a softgel capsule under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
9680325|NCT04940559|Experimental|Group 2: Sequence 2|"Participants received danicopan once each period as a single dose under fasted conditions as follows:~Period 1: Danicopan as a softgel capsule under fasted conditions. Period 2: Danicopan as an LFC under fasted conditions. There was a washout period of at least 4 days (96 hours) between each danicopan dosing."
9827561|NCT02461160|Placebo Comparator|SRD Cohorts 1-3: Placebo|TAK-915 placebo-matching suspension, orally, once on Day 1.
10176274|NCT03834259|Active Comparator|Group 2|10 mg 0.5% hyperbaric bupivacaine
10176275|NCT03834259|Active Comparator|Group 3|12.5 mg 0.5% hyperbaric bupivacaine
10176276|NCT03834207|Experimental|Intervention Group|Use of the C3-Cloud IT system
10176277|NCT03834233|Experimental|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
10176278|NCT03834272|Experimental|1st Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
10176279|NCT03834272|Experimental|2nd Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.5 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
10176280|NCT03834272|Experimental|3rd Tier Dose Level- LUM Imaging System|12 patients will receive LUM015 at the dose and timepoint selected based on the analysis of the data
10176281|NCT03834298|Experimental|Four Food Elimination Diet (FFED)|There is one arm to the study. All participants meeting eligibility will be assigned to intervention / treatment with a previously defined four food elimination diet (FFED) (Aim 1). This is a longitudinal study in which outcome measures including symptoms, QOL and inflammation at baseline and at 2, 4 and 6 weeks after starting stand of care (SOC) FFED will be measured. Participants meeting eligibility for Aim 2 will have foods added back to the diet using a specified protocol.
9680326|NCT04940429||Roux n Y Gastric Bypass (RYGB)|"Participants in this arm will include patients who will be having a RYGB after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit.~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
9680327|NCT04940429||Sleeve gastrectomy (SG)|"Participants in this arm will include patients who will be having a SG after their assessment by their bariatric surgeon. After reviewing and signing the consent form, participants will perform the paper-based standard psychometric tests (number connection test A and B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes) at their preoperative visit.~After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes at their preoperative visit:~These will also be performed at their post operative visits 2 weeks, 3, 6 and 12 months."
10176282|NCT03834324|Experimental|intervention|FES
9680328|NCT04940611||Participants With CPF-CD|Participants diagnosed with CPF-CD will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
9680329|NCT04940611||Participants With CD-RVF|Participants diagnosed with CD-RVF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
9680330|NCT04940611||Participants With CCF|Participants diagnosed with CCF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.
9680331|NCT04940312||Usual Care Group|Individuals with heart failure receiving standard medical care
9680332|NCT04940312||Intervention Group 1 (pedometer-monitoring only)|Individuals with heart failure receiving a pedometer for measurement of daily step count
9680333|NCT04940312||Intervention Group 2 (app-based coaching)|Individuals with heart failure receiving an individualized, app-based physical activity coaching on the basis of pedometer-based assessment of daily step count
9680334|NCT04940585|Experimental|Rose Program Group|ROSE is a 7-session intervention. Participants will attend 6 weekly group sessions virtually, through a program on the computer called WebEx or at the clinic, and then one individual session after delivery. Participants will complete a few questionnaires at three different timepoints, including demographics, stress, social support, physical and mental health, and trauma.
9680335|NCT04940585|No Intervention|Comparison Group|Participants will complete three sets of questionnaires including demographics, stress, social support, physical and mental health, and trauma.
9827562|NCT02461160|Experimental|SRD Cohort 1 TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1.
10176283|NCT03834181|Experimental|Monitoring evaluation|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"
10176284|NCT03834311|Experimental|isokinetic|
10176285|NCT03834311|Active Comparator|exercise band|
10176286|NCT03834285||Cirrhosis in pregnancy|Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.
10176287|NCT03834285||Pregnancy-associated liver diseases|Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.
10176288|NCT03834038|Experimental|Open Label Lyophilized Fecal Microbiota Transplantation|Eligible participants with history of recurrent or refractory CDI
10176289|NCT03833973||Runners|Long-distance runners, marathon runners, 5 km and 10 km runners, both female and male aged 20 - 40 years, participating in regular training and competitions.
10176290|NCT03833973||Soccer Players|High Level soccer players, both female and male aged 15-30, participating in all games
10176291|NCT03834051|Experimental|Open Label|Fecal Microbiota Transplantation
10176292|NCT03833999|Experimental|Ondansetron and lactulose|Ondansetron 8mg three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
10176293|NCT03833999|Placebo Comparator|Placebo and lactulose|placebo oral capsule, one three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
10176294|NCT03834142|Experimental|Intervention|NSS-2-Bridge auricular therapy will be given in addition to standard of care.
10176295|NCT03834142|No Intervention|Control|No intervention, subject receives standard of care
10176296|NCT03834103|Other|Arm 1: Self-rehabilitation arm|Self-rehabilitation arm
10176297|NCT03834012|Experimental|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 ug per day Daily dose of Beclomethasone 800 ug 4 inhalations 100 μg ex-valve 2 times a day for 6 weeks
9680336|NCT04940455|Experimental|Educational digital platforms|"Nursing students from the Experimental Group (GE), will participate in educational activities made available on digital platforms on nursing care for patients with signs and symptoms of sepsis"
9680337|NCT04940455|Active Comparator|High-Fidelity Simulation|Nursing students in the Control Group (GC) will be exposed to high-fidelity simulation in the intensive care setting, where they must solve situations and procedures related to the nurse's performance in recognizing the signs and symptoms of sepsis.
9680338|NCT04940728|Experimental|Creative Thinking Group|"Nursing students who took the Self-Knowledge and Communication Techniques course for the first time in March and agreed to participate in the study were divided into experimental (30) and control (30) groups using a simple randomization method.~Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were administered to the participants who volunteered to participate in the research using the Online Questionnaire System.~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups.~An intervention program based on creative thinking techniques was applied to the experimental group and post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
9680339|NCT04940728|No Intervention|Standart Group|"Pre-tests (Descriptive Information Form, Communication Skills Scale, and Problem Solving Scale) were applied to the participants who volunteered to participate in the study by using the Online Questionnaire System.~Considering the effect on the research data, after completing the routine courses of self-knowledge, communication skills, listening skills and problem solving skills of the 4 main topics in the course; Intermediate tests (Communication Skills Scale, and Problem Solving Scale) were applied to the experimental and control groups by using the Online Questionnaire System.~After the interim tests were applied, no intervention was made to the control group until the end of the period. At the end of the semester, post-tests (Communication Skills Scale, and Problem Solving Scale) were applied."
9680340|NCT04940507|Experimental|Tumor cohort|"Intervention 1:~Participants will undergo a partial tumor ablation with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel). Blood and CSF samples will be drawn on several timepoints before and after the procedure.~Intervention 2:~Participants will undergo a standard of care tumor biopsy/excision one day after the Intervention 1. Blood samples will be drawn on several timepoints before and after the procedure."
9680341|NCT04940507|Other|Essential tremor cohort|To identify the levels of circulating free DNA release after MRgFUS procedure in non-tumoral patients and to check whether the MRgFUS procedure induce tumoral mutations itself, we will draw blood samples from essential tremor patients before and after standard of care MRgFUS thalamotomy procedure.
9680342|NCT04940546|Experimental|Sintilimab + XELOX + Bevacizumab|"Patients receive Sintilimab + XELOX regimen every 3 weeks for 4 cycles and Bevacizumab every 3 weeks for 2 cycles.~Details are as follows:~Sintilimab: 200mg intravenously, d1 Oxaliplatin: 135mg/m2 intravenously, d1 Capecitabine: 2g/m2 orally, d1-14 for Bevacizumab: 7.5mg/kg intravenously, d1~After neoadjuvant treatment, if there are no new lesions upon radiological and Multidisciplinary Team (MDT) assessment, radical surgery is performed within 6 weeks. If there are new lesions the surgical team will assess the optimal time for surgery.~After surgery 4 cycles of XELOX regimen is advised for adjuvant therapy."
9680343|NCT04940598|Experimental|High intensity interval exercise|High intensity interval arm crank exercise
9680344|NCT04940598|Other|No-Exercise Control|No-exercise control group
9680345|NCT04940273|Experimental|remifentanil|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
9680346|NCT04940299|Experimental|Cohort 1 (ipilimumab, nivolumab, tocilizumab)|Patients with melanoma will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.
9680347|NCT04940299|Experimental|Cohort 2 (ipilimumab, nivolumab, tocilizumab)|Patients with urothelial cancer will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.
9680348|NCT04940299|Experimental|Cohort 3 (ipilimumab,, nivolumab, tocilizumab)|Patients with NSCLC receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 2 weeks for up to 2 years. Patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses). Treatment continues in the absence of disease progression or unacceptable toxicity.
9680349|NCT04940442|Experimental|Active choice|FIT or colonoscopy
9680350|NCT04940442|Experimental|Sequential choice|FIT offered first, then colonoscopy offered to those still unscreened
9680351|NCT04940325|Experimental|DS-1062a|All participants included in the study will receive a starting dose of 6 mg/kg of DS-1062a every 3 weeks until progression or until unacceptable toxicity
10176298|NCT03834012|Active Comparator|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day 4 inhalations 80 μg ex-actuator 2 times a day for 6 weeks
10176299|NCT03834012|Placebo Comparator|Placebo|Intervention: Drug: placebo 4 inhalations 2 times a day for 6 weeks
10176300|NCT03834012|Experimental|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 6 weeks Intervention: Drug: Placebo 2 inhalations 2 times a day for 6 weeks
10176301|NCT03833921|Other|Abiraterone acetate + prednisone|All subjects will receive abiraterone acetate and prednisone, as per standard of care. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone twice per day. Subjects will continue to take abiraterone acetate and prednisone until confirmed disease progression.
10176302|NCT03833882|Experimental|MAF1217/Cationorm|
9680352|NCT04940143|Experimental|Botulinum toxin-A|Botulinum toxin-A (Onabotulinum toxin type-A) injection with electrical stimulation guidance will be administered to spastic ankle plantar flexor muscles. After the injection, the patients will be included in the comprehensive physiotherapy program.
9680353|NCT04940221|Experimental|Phone-delivered decision-counseling program for shared decision making in lung cancer screening|All individuals who are eligible for lung cancer screening according to USPSTF criteria were invited to participate in the study and all patients who accepted the invitation and consented were slated to receive the intervention which was a phone-delivered on line decision-counseling program (DCP) and there was no one randomized or enrolled into a control group, nor was anyone randomized or enrolled into a usual care group.
9680354|NCT04939896||Compliance with rehabilitation|The patients' compliance with rehabilitation was followed up at 2, 6, 8, 12 and 24 weeks after onset, respectively
9680355|NCT04940104|Experimental|Botox|
10176303|NCT03833882|Experimental|Cationorm/MAF1217|
10176304|NCT03834129|Experimental|(Dex group) intravenous infusion of dexmedetomidine|Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%
9680356|NCT04940104|No Intervention|Control No Botox|
10176305|NCT03834129|Placebo Comparator|(Control group) intravenous infusion of physiological serum|Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%
10176306|NCT03833895|Experimental|Group 1 Elements|Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
10176307|NCT03833895|Experimental|Group 2 Elements|Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
10176308|NCT03833895|Placebo Comparator|Group 3 Elements|In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.
9680357|NCT04940091||Epidural labor analgesia|All participants will receive epidural analgesia during labor.
9680358|NCT04939922||Migraine|Patients with migraine (including vestibular migraine), including all types of migraine as defined by ICHD-3
9680359|NCT04939922||Other Primary Headache Disorders|Patients with other primary headache disorders (excluding migraine), including all types of other primary headache disorders (such as Tension-Type Headache, Cluster Headache) as defined by ICHD-3.
9680360|NCT04939922||Vertigo|Patients with other vertigo disorders (excluding vestibular migraine).
9680361|NCT04939922||Secondary Headache Disorders|Patients with secondary headache disorders as defined by ICHD-3.
9680362|NCT04939922||Normal control|Normal people do not have headache and vertigo.
9680363|NCT04939909|Other|Patients treated with Botulinum toxin type A|Patients were treated with Botulinum toxin type A
9680364|NCT04940000|Experimental|Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.|
9680365|NCT04939883|Experimental|Intervention Group|Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy.
10176309|NCT03834116|Experimental|Inspiratory muscle training group|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
10176310|NCT03834116|No Intervention|Control group|The control group will receive standard treatment in a fast-track design.
10176311|NCT03833908|Experimental|patients receiving MAF-1217|patients receiving MAF-1217 from week -2 to week 2 (preand post-surgery, total 4 weeks), standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin for 7 days) from day 0 (post-surgery.
10176312|NCT03833908|No Intervention|patients receiving just standard antibiotic therapy|patients receiving just standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin 7 days) from day 0 (postsurgery).
10176313|NCT03833986|Experimental|Stress management program|The stress program will be delivered to experimental group in a six-sessions for two weeks, each session will take 2 hours (2 hours/six sessions /two weeks).
10176314|NCT03833986|No Intervention|Control|There is no intervention for controlled group during workshop but they are put on a waiting-list to receive the intervention after the active treatment group does.
9680366|NCT04939883|Placebo Comparator|Control Group|Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
9680367|NCT04940117|Experimental|blood test data before and after taking|Checking eGRF value before and after taking Eefooton oral solution
9680368|NCT04940182|Experimental|XC221|XC221 100 mg orally. 1 tablet of XC221 100 mg 2 times a day during 14 full days of treatment period
9680369|NCT04940182|Placebo Comparator|Placebo|Placebo orally. 1 tablet of Placebo 2 times a day during 14 full days of treatment period
9680370|NCT04939623|Active Comparator|Probenecid 500 mg PO BID|Probenecid 500 mg X 1 PO BID and Placebo X 1 PO BID
9680371|NCT04939623|Active Comparator|Probenecid 1000 mg PO BID|Probenecid 500mg X 2 PO BID
9680372|NCT04939623|Placebo Comparator|Placebo PO BID|Placebo X 2 PO BID
9680373|NCT04939662|Experimental|Olaparib+Bevacizumab to SCLC patients|"Regimen and administration:~Administration of olaparib Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Administration of bevacizumab Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
9680374|NCT04939688|Experimental|Patients requiring a CT scan in the search for cranial lesions following head trauma|All patients will undergo both conventional dose AND ultra low-dose CT scans in the search for cranial lesions following head trauma.
10176315|NCT03834090|Experimental|rESWT|the group receiving rESWT
10176316|NCT03834090|Active Comparator|supervised exercises|the group receiving supervised exercises
9680375|NCT04939571||Preterm born infants treated for ROP|
9680376|NCT04939974|Active Comparator|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
9680377|NCT04939974|Placebo Comparator|placebo|Placebo packet same in colour, smell and constituent to that of placebo one packet daily for 24 weeks
9680378|NCT04939857|Experimental|experimental group|Trimetazidine was given 2 weeks before radiotherapy, 20 mg each time, three times a day for 3 months.
9680379|NCT04939857|No Intervention|control group|No intervention
9680380|NCT04939779|Experimental|Group A|Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
9680381|NCT04939779|Experimental|Group B|Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
9680382|NCT04939727|Experimental|OUD-CDS + Suicide Risk Model associated CDS (Intervention arm)|Providers that practice in the clinics in this intervention arm will receive access to the OUD-CDS + Suicide Risk Model associated CDS, for all eligible encounters.
9680383|NCT04939727|No Intervention|Control|"Providers that practice in the clinics in this control arm will not receive any access to the OUD-CDS + Suicide Risk Model associated CDS, however these clinical decision-support tools will run silently in the background, collecting data on eligible encounters."
9680384|NCT04940169|Experimental|quadriceps tendon autograft|Ramdomized half of the patient underwent quadriceps graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
9680385|NCT04940169|Experimental|hamstring tendon autograft|Ramdomized half of the patient underwent hamstring graft harvesting. Arthroscopic technique fixation methods rehabilitation style follow periods kept same as hamstring group except graft type.
9680386|NCT04939805|Experimental|Selective CRP apheresis as an adjunct to standard of care|Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
9680387|NCT04939805|No Intervention|Standard of care according to current guideline recommendations|
9680388|NCT04939675|Experimental|Anti-seizure medication|The intervention group will receive anti-epileptic drug treatment according to the guideline of American Epilepsy Society 15 for 12 weeks. The recommended regimens include zonisamide, lamotrigine, or levetiracetam at the minimal therapeutic doses (zonisamide 100mg twice daily, levetiracetam 500mg twice daily, lamotrigine 50mg twice daily), and the choices depend on tolerability of the participants and contraindications (allergy to any drugs, or allergy to sulphonamides in zonisamide users). The participants will be followed every 4 weeks.
9680389|NCT04939675|No Intervention|Observation|The participants will be followed every 4 weeks without anti-seizure medication.
9680390|NCT04939766|Other|Type 1 diabetic patients under CSII eligible for closed loop use|Diabetic patients age 13 or above under CSII with continuous glucose monitoring matching eligibility criteria for the use of a closed loop during a 6 months period. During the study, 4 physical appointments with a diabetologist and 3 phone contacts are anticipated.
9680391|NCT04939649|Experimental|Ketamine|Participants will receive up to a four-week course of twice-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
9680392|NCT04939649|Active Comparator|Midazolam|Participants will receive up to a four-week course of twice-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
9680393|NCT04939376||Group A|Women with hysteroscopically or ultrasonographic detected uterine anomalies(adenomyosis,fibroid) intracavitary lesions ( like polyp, adhesion or septum) and those with detected endometrial abnormalities (like hypervascularization,pale endometrium) ,cervical lesion and cervical canal lesion or pelvic lesion
9680394|NCT04939376||Group B|Matched women (eg. Age,parity, BMI, ovarian reserve….) with no uterine or ovarian abnormalities assessed by hysteroscopy or ultrasonography.
9680395|NCT04939454|Experimental|sarcopenic COPD patient|
9680396|NCT04939454|Other|non-sarcopenic COPD patient|
9680397|NCT04939558||Chronic Obstructive Pulmonary Disease|245 participants - GOLD 1, 2, 3 / A, B, C
9680398|NCT04939558||Asthma|55 participants - Mild to moderate, not labelled as severe.
9680399|NCT04939558||Congestive cardiac failure|55 participants
9680400|NCT04939558||Anaemia|55 participants - with at least 50% of participants recruited having no history of chronic cardiorespiratory conditions
9680401|NCT04939558||Bronchiectasis|55 participants - Acquired or genetic, e.g. cystic fibrosis or other primary ciliary dyskinesias
9680402|NCT04939558||Lung cancer|55 participants - including rare types e.g. mesothelioma
9680403|NCT04939558||Interstitial Lung Disease|55 participants - including pulmonary fibrosis pneumoconiosis, asbestosis, sarcoidosis, amyloidosis
9680404|NCT04939558||Long COVID|55 participants
9680405|NCT04939558||Upper airway obstruction disorder|55 participants
9680406|NCT04939558||Healthy|55 participants - with no previous or current chronic cardiorespiratory diagnoses
9680407|NCT04939506|Experimental|Participants Which Receive COVID-19 Vaccine Education at the Point of COVID-19 Testing|Vaccine education will be focused on addressing misinformation and concerns in a culturally competent manner with referral to resources. The vaccine education model will be translated to reach minority groups including African Americans, Vietnamese Americans and Hispanic Americans.
9680408|NCT04939311|Experimental|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
9680409|NCT04939311|Placebo Comparator|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
9680410|NCT04939493|Experimental|Rhythmic Auditory Cueing|Group (B): Patients in this group will receive the same designed physical therapy program given to the control group in addition to auditory cueing during bilateral arm training using the metronome.
9680411|NCT04939493|Active Comparator|Bilateral arm training|Patients in this group will receive a standard physical therapy program in addition to Bilateral arm training.
9680412|NCT04939298|Experimental|Patients under mechanical ventilation|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation
10176317|NCT03833947|Experimental|lignocaine with bicarbonate|Endotracheal tube cuff was filled with mixture of 7.5% sodium bicarbonate with 2% lignocaine in a ratio of 0.5:9.5 ml
10176318|NCT03833947|Active Comparator|lignocaine with dexamethasone|Endotracheal tube cuff was filled with mixture of dexamethasone with 2% lignocaine in a ratio of 0.5:9.5 ml
9680413|NCT04939155||Patients infected with SARS-CoV-2|The first part of this study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after they contracted SARS-CoV-2
10176319|NCT03834194|Experimental|Lottery + Monthly Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
10176320|NCT03834194|Experimental|Lottery + Overall Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
10176321|NCT03834194|Experimental|Lottery + Overall Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
10176322|NCT03834194|Experimental|Lottery + Monthly Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
10176323|NCT03834194|Experimental|Loss + Monthly Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
9680414|NCT04939155||Patients who have received an mRNA vaccination|The second part of the study looks at the methylation patterns in individuals who have a baseline test taken of their DNA methylation patterns in their epigenome and then a follow-up test after SARS CoV-2 mRNA vaccine injection.
9680415|NCT04939194|Experimental|Fast Track Protocol|the 22 items of ERAS (Early Recovery After Surgery) society
10176324|NCT03834194|Experimental|Loss + Overall Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
10176325|NCT03834194|Experimental|Loss + Overall Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
10187246|NCT03728114|Experimental|High Altitude RIC group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
9680416|NCT04939194|No Intervention|Conventional perioperative care program|standard perioperative care
9680417|NCT04939337|Experimental|TH-SC01|TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.
9827563|NCT02461160|Experimental|SRD Cohort 2: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1.
9680418|NCT04939480|Experimental|Atezolizumab|Pre-operative administration of atezolizumab 1200 mg followed by definitive resection of the tumor, followed by standard of care radiotherapy or radio-chemotherapy.
9680419|NCT04939402|Other|General|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
9680420|NCT04939025|No Intervention|Historic cohort|
9680421|NCT04939025|Other|Multi-interventional program cohort|
9680422|NCT04939285|Experimental|PEEP=5cmH2O|In PSV mode,PS = 8 cmH2O,PEEP= 5 cmH2O, and FiO2 level was consistent with that before SBT
10176326|NCT03834194|Experimental|Loss + Monthly Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
10176327|NCT03833869|Experimental|Assisted hatching|Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
9680423|NCT04939285|Experimental|PEEP=0cmH2O|In PSV mode,PS = 8 cmH2O,PEEP=0 cmH2O, and FiO2 level was consistent with that before SBT
9680424|NCT04939077|Experimental|CABG with hUC-MSC treatment group|In the CABG with hUC-MSC treatment group, 1×10^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.
10176328|NCT03833869|No Intervention|Control|Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer
9680425|NCT04939077|No Intervention|CABG group|CABG was performed under general anesthesia.
9680426|NCT04939207|Experimental|CT-derived FFR|In this study arm, the need for coronary revascularization will be determined by CT-derived Fractional Flow Reserve (FFR) calculations
9680427|NCT04939207|Experimental|Angiography-derived FFR|In this study arm, the need for coronary revascularization will be determined by FFR-calculations derived from angiographic images
10176329|NCT03834077|Experimental|Tissue flossing|Conventional physiotherapy consisted in electrotherapy and stretching in addition to tissue flossing.
10176330|NCT03834077|Placebo Comparator|Placebo comparator|Conventional physiotherapy consisted in electrotherapy and stretching in addition with tissue flossing without tension.
9680428|NCT04939207|Active Comparator|Routine Care|In this study arm, the need for coronary revascularization will be determined by angiography and invasive FFR-measurements
9680429|NCT04938947|Experimental|High-Intensity Resistance Training Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each resistance training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure (likely 8-12 repetitions) using 80% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2).
9680430|NCT04938947|Experimental|Low-Intensity Resistance Training with Blood Flow Restriction Group|Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure using 30% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2). Participants in this group will perform all leg extensions with blood flow restriction cuffs applied to the proximal thigh of both legs. The pressure that the cuffs are inflated to will be calculated based on estimates of each subject's arterial occlusion pressure from their thigh circumference. Once the target pressure is reached, the cuffs will not be deflated until after the final set of the training session.
9680431|NCT04939142|Experimental|SVd (Selinexor+Bortezomib+dexamethasone)|Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.
10176331|NCT03833843||TGA|
10176332|NCT03834155|Experimental|Hospital-based CR + Mobile Application|Traditional hospital-based cardiac rehabilitation with mobile application.
10176333|NCT03834155|Experimental|Choice CR + Mobile Application|Choice of hospital or home-based cardiac rehabilitation with mobile application.
10176334|NCT03834155|Experimental|Hospital-based CR + Mobile Application + Nudge|Hospital-based cardiac rehabilitation with mobile application and nudges.
9680432|NCT04939142|Experimental|Vd(Bortezomib+dexamethasone)|Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.
9680433|NCT04939441|Experimental|TAF group|TAF [Vemlidy® 25mg QD] monotherapy
9680434|NCT04939103||1|those with the examination of EUS-FNA ,CT,MR,enteroscope
9680435|NCT04938934|Experimental|Aversive conditioning|
10176335|NCT03834155|Experimental|Choice CR + Mobile Application + Nudges|Choice of Hospital or home-based cardiac rehabilitation with mobile application and nudges.
10176336|NCT03833830||longterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) >20 injections
10176337|NCT03833830||shortterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) < 5 injections
10176338|NCT03833518|Experimental|Hand impairment due to stroke or spinal cord injury|Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.
10176339|NCT03833505||Group 1,|E. vermicularis-positive
9680436|NCT04938934|Sham Comparator|Sham conditioning|
10176340|NCT03833505||Group 2|E. vermicularis-negative
10176341|NCT03833778|Other|Intervention group|Answering disease related questions during playing a tablet game
10176342|NCT03833778|No Intervention|control group|
9680437|NCT04938778|Experimental|Intervention Arm|8 week 14 hour prolonged nightly fasting intervention.
9827564|NCT02461160|Experimental|SRD Cohort 3: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1.
9680438|NCT04938869|Experimental|Supportive care (CGM)|Prior to hospital discharge, patients receive CGM application and education on how to apply the CGM, and how to use the sensor and its associated smart phone app. Patients also receive basic diabetes mellitus education. After hospital discharge, patients use CGM for up to 28 days.
9680439|NCT04938752|Experimental|Sequence I|
9680440|NCT04938752|Experimental|Sequence II|
9680441|NCT04938700|Experimental|Probiotics intervention group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of probiotic intervention and conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
9680442|NCT04938700|Active Comparator|Contrast group|children with definitive diagnosis of allergic rhinitis, asthma，atopic dermatitis and chronic urticaria were enrolled, each with 25 cases. 2) collect manure application of 16s rDNA probe hybridization technique to analyze the fecal flora, and compared with clinical symptoms rating scale and serum sIgE, IgG4 correlation analysis (3) application of conventional drugs, again in 3 months, 6 months after collecting dung is used to detect the intestinal flora in children with its correlation with clinical symptoms change were observed.
9680443|NCT04938583|Experimental|oregovomab, bevacizumab, paclitaxel and carboplatin|Combination of anti-angiogenesis and Chemo-immunotherapy
9680444|NCT04938596|Experimental|Respiratory Bundle Group|The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.
10176343|NCT03833648|No Intervention|Arm 1 - Usual Care|No intervention, patients will receive treatment as usual. Patients will download the UControl Pain app on their personal cell phones and will complete the four study surveys via the app or via REDCap.
10176344|NCT03833648|Experimental|Arm 2 - UControl Pain App with Education|Patients will install the UControl Pain app on their personal cell phones. The app will include educational information about pain management, e.g., using acetaminophen and NSAIDs for pain, as well as information on addiction and safe storage of medications. Subjects will also complete the four study surveys via the app or via REDCap.
9680445|NCT04938596|No Intervention|Standard of care|Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.
9680446|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab (CON)|Participants will be prescribed 36 sessions of center-based CR. This includes supervised exercise sessions, cooking demonstrations, didactic lectures, video presentations, group support, and stress management education. During sessions, participants have direct access to the medical director, case manager, registered nurse, exercise physiologist, and stress management specialists.
9680447|NCT04938661|Active Comparator|Conventional Center-Based Cardiac Rehab + mHealth (CON+)|"Participants will be prescribed 36 sessions of center-based CR as noted above. In addition, participants will be provided access to the mHealth platform which provides e-Learning modules with factsheets, videos, quizzes, and questionnaires (coinciding with activities being conducted during the CON program), a Social Network Module will allow patients to communicate via secure network with other patients who are part of their invited network. The Social Network Module also allows for secure two-way interaction with healthcare providers in the event that patients are experiencing signs or symptoms suggestive of worsening condition. This platform also contains a Personal Health Record Module allowing patients to upload, archive, and retrieve personal health data (e.g. fitness tracker data, heart rate monitor data, blood pressure recordings, etc.) and record vital signs, symptoms, treatments, and medical history."
9680448|NCT04938661|Active Comparator|Home-Based Cardiac Rehab + mHealth (HOM+)|Participants will be provided paper copies of educational content at the time of event/discharge. In addition, these participants will be provided access to the same mHealth platform as the CON+ group. Participants in this group will be encouraged to exercise three days per week while also completing the additional questionnaires and educational content provided by the mHealth platform in accordance with the CR program. Participation will be tracked using web/internet analytics.
9680449|NCT04938531|Experimental|Exercise|Exercise, passive
10176345|NCT03833752|Experimental|Flexible Cystoscopy|Diagnostic flexible cystoscopy for the patients in this arm
10176346|NCT03833752|Active Comparator|Rigid Cystoscopy|Diagnostic rigid cystoscopy is done for the patients in this arm
10176347|NCT03833739|Experimental|Upper Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the upper and lower arches.~starting treatment in the upper arch The upper ach was bonded for 28 patients and teeth alignment was started using round 0.014NiTi arch wire. The 0.014NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. Orthodontic treatment was continued in the upper arch with arch wire sequence of 0.014NiTi, 0.018NiTi, 0.016X0.022NiTi, 0.019X0.025NiTi, and 0.019X0.025stainless steel arch wires. The patients were followed up on a monthly basis until sufficient proclination of the upper incisors achieved to establish an overjet of at least 4 mm. After reaching the full working arch wire in lower arch (0.019 X 0.025stainless steel wire), lateral cephalogram and study models were taken."
10176348|NCT03833739|Experimental|Lower Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the lower arch and anterior bite plate in the upper arch.~The lower arch was bonded after taking the pretreatment records. At the same appointment an anterior bite plate in the upper arch was delivered to prevent shearing off the mandibular incisor brackets and help in correction of anterior deep bite .After lower arch alignment and leveling in the same arch wire sequence as the other group and 0.019 X 0.025stainless steel arch wire was reached, the anterior bite plate was removed and the upper arch was bonded. The same arch wire sequence was used in the upper arch as was used in the lower arch. When the full working arch wire (0.019 X 0.025stainless steel arch wire) was reached in the upper arch, study models and lateral cephalogram were taken."
10187247|NCT03728114|Sham Comparator|High Altitude Sham group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
9680450|NCT04938999|Experimental|MVgPA group|"The MVgPA group consists of 24 sessions conducted over 12 weeks for the study participants by the staff of residential care facilities.~The structured MVgPA group session (10 - 12 participants) will be conducted twice per week. The 75-min music-paced physical activities will be presented in the PowerPoint slideshow. The instructions for an upper limb exercise will be presented in a large number pad in the slideshow, and the participants will then be asked to follow the actions and directions presented on the slide."
9680451|NCT04938999|Other|Control group|residential care facilities will conduct their usual activities during the study period. A trained RA2 will record the activities conducted by the residential care facilities during the study period.
9976018|NCT01347359|Experimental|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, either face-to-face or by telephone.
10176349|NCT03833791|Active Comparator|Control Group (CON)|education and modifying diet
9680454|NCT04938739|Experimental|Cognitive Behavioral therapy|to modify any erroneous beliefs about pain and disability and to promote coping strategies and self-efficacy through a graded activity.
9680455|NCT04938739|Active Comparator|Home program exercises|Patients in both groups carried out exercise therapy for six weeks. There will be an educational session for each patient to make sure the exercises will be done successfully and supervision once per week.
9680456|NCT04938713|Active Comparator|AB group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The AB sequence consists of patients starting with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Ketamine and two infusions of Esketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
9680457|NCT04938713|Other|BA group|"If A = Ketamine and B = Esketamine, each patient included in the study will be randomized in a sequence of administration of the two products. The BA sequence consists of patients starting with intravenous Esketamine 0,15 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 1) and continuing with intravenous Ketamine 0,3 mg/kg in 1 hour (2 infusions separated by 6 weeks; Period 2). Each patient will be monitored during the IV perfusion, and then, the next hour.~The patient will receive a total of two infusions of Esketamine and then two infusions of Ketamine. Each patient will be his own witness because having received the two products without knowing which he started with. A wash-out period of one week will be observed between the two administration periods to avoid so-called carry-over effects according to which the administration of the first drug could influence the effect of the second drug administered."
9680458|NCT04938674||Standard process for blood collection using Ultrasonic Guided puncture|
9680459|NCT04938843|Experimental|F. prausnitzii and D. piger|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
9680460|NCT04938843|Placebo Comparator|Placebo|1 capsule administered once daily 45 minutes before breakfast for 12 weeks
9680461|NCT04938622|Experimental|Sedentary Control|Participants did not exercise but consumed a diet that has an appropriate number of calories to maintain body weight throughout the intervention (3 menstrual cycles).
9680462|NCT04938622|Experimental|Exercising control|Participants exercised but were given extra calories to remain in energy balance throughout the intervention (3 menstrual cycles).
10176350|NCT03833791|Experimental|Moderate physical activity Group (PAM)|education, modifying diet and physical activity prescription
10176351|NCT03833791|Experimental|Intensity physical activity Group (PAI)|education, modifying diet and physical activity prescription
9680463|NCT04938622|Experimental|15 percent energy deficit (ED1)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles.
9680464|NCT04938622|Experimental|30 percent energy deficit (ED2)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles.
9680465|NCT04938622|Experimental|30 percent energy deficit 15/15 (ED2)|Participants exercised for the equivalent of 15 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 15 percent to total a 30 percent energy deficit.
9680466|NCT04938622|Experimental|60 percent energy deficit (ED3)|Participants exercised for the equivalent of 30 percent of their daily caloric intake needs throughout the intervention cycles, and their dietary intake was decreased by 30 percent to total a 60 percent energy deficit.
9680467|NCT04938453|Experimental|Treatment sequence 1 (T-R)|first test (T), then reference (R) treatment
9680468|NCT04938453|Experimental|Treatment sequence 2 (R-T)|first reference (R), then test (T) treatment
9680469|NCT04938349|Experimental|Single session dual task perturbation training-OAwMCI|Participants will receive single session training of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
9827565|NCT02461160|Placebo Comparator|MRD Cohorts 4-6|TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.
10176352|NCT03833401|Sham Comparator|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation. This will serve as control group.
10176353|NCT03833401|Experimental|Autologous tissue transplantation|Root canal disinfection will be performed and revascularization will be induced with autologous tissue transplantation.
10176354|NCT03833635|Experimental|OMT|
10176355|NCT03833635|Placebo Comparator|Control|
9680470|NCT04938349|Experimental|Multiple session dual task perturbation training-OAwMCI|All participants will undergo stance and walking perturbation training for 4 weeks. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
9680471|NCT04938349|Active Comparator|Single session dual task perturbation training-CIOA|All participants will receive only one training session of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
10176356|NCT03833687|Experimental|Profhilo®|"The 1st treatment was performed during the basal visit and repeated after 1 month.~3 mL of Profhilo® for each brachial zone, 1.5 mL for hemiabdomen was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 horizontal-levels for each tested areas (3-4-3 injection points respectively for the 1st, the 2nd and the 3rd horizontal-level). The amount of product to be injected was of 0.3 ml for each point."
10176357|NCT03833544|Experimental|Treatment Arm|Exercise training: Progressive resistance training of hip, knee, and ankle flexors.
10176358|NCT03833726|Experimental|LED group|Participants who will submitted to active procedure with LED. Both groups will be submitted to kinesiotherapy.
9680472|NCT04938362||Brain abscess patients with cognitive dysfunction and/or fatigue|This group of patients experience cognitive dysfunction and/or fatigue after brain abscess.
9680473|NCT04938362||Brain abscess patients without cognitive dysfunction and/or fatigue|This group of patients does not experience cognitive dysfunction and/or fatigue after brain abscess.
9680474|NCT04938401||epistaxis|Postoperative pituitary tumor group with epistaxis
9680475|NCT04938401||no epistaxis|Postoperative pituitary tumor group without epistaxis
10176359|NCT03833726|Sham Comparator|Control group|Participants who will submitted to sham procedure with heated gel. Both groups will be submitted to kinesiotherapy.
10176360|NCT03833375|No Intervention|Usual Care (n=20)|Control: general information about TBI from Center for Disease Control (CDC)/about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
10176361|NCT03833375|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
10176362|NCT03833531|Active Comparator|PTSD-ImRS|PTSD treatment
10176363|NCT03833531|Experimental|Integrated SFT-ImRS|Integrated PTSD-PD treatment
10176364|NCT03833492|Experimental|Underwater EMR|"The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
10176365|NCT03833492|No Intervention|Traditional EMR|"The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
10176366|NCT03833349|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
10176367|NCT03833349|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
10176368|NCT03833349|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
10176369|NCT03833609|Experimental|Online yoga training (Group A)|Participants will receive an e-pamphlet on physical exercise developed by The Arthritis Society, and will be invited to complete a yoga training program. The yoga training program is a structured low-intensity Vishwas-Raj. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
10176370|NCT03833609|Experimental|Online aerobic dance training (Group B)|Participants will receive the e-pamphlet on physical exercise and will be invited to complete an aerobic dance program. The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
9680476|NCT04938128|Experimental|CPAP treatment|This group will receive CPAP treatment
9680477|NCT04938128|No Intervention|Control|This group will receive Diet and Lifestyle advice only
9680478|NCT04938466||Transition to long-acting growth hormone (LAGH)|Participants in this arm will transition between daily growth hormone treatment and long-acting growth hormone treatment.
9680479|NCT04938466||Consistent daily growth hormone (DGH)|Participants in this group will continue with daily growth hormone treatment.
9680480|NCT04938310|Active Comparator|Control Group|Sleeve gastrectomy
9680481|NCT04938310|Experimental|Support garment group|Sleeve gastrectomy followed by a period of 12-month with a support garment
9680482|NCT04938492|Experimental|Cognitive Behavioral Therapy (CBT)|CBT delivered over the course of 6, ~45 minute sessions delivered via telehealth.
9680483|NCT04938492|Active Comparator|Health Education|Health education sessions delivered over the course of 6, ~45 minute sessions delivered via telehealth.
9680484|NCT04938115|Experimental|CD7 CAR-T|
9680485|NCT04938193|Experimental|68Ga-citrate PET/CT|
9680486|NCT04938336||expert healthcare professionals|Delphi Procedure
9680487|NCT04938336||healthcare professionals, patients and informal carers|interviews
9680488|NCT04938297|Experimental|Primary CNS Lymphoma，age>65|8 cycles of induction ZR2 , followed by Zanubrutinib or Lenalidomide maintenance for CR/PR fit patients through randomization by 1:1 ration
9680489|NCT04938297|Experimental|Recurrent/refractory primary CNS lymphoma|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
9680490|NCT04938297|Experimental|Recurrent/refractory diffuse large B-cell lymphoma with CNS invasion|8 cycles of induction ZR2, followed by Lenalidomide maintenance for CR/PR fit patients.
10176371|NCT03833609|No Intervention|Wait list control (Group C)|Participants will receive the e-pamphlet on physical exercise and will be instructed to continue with their current medical care while they are on the wait list (12 weeks). After the completion of the study, the yoga and aerobic dance training videos will be available to all participants including those in the control group. In recruitment documents, this group will be termed the e-pamphlet group.
10176372|NCT03833596|Active Comparator|Standard course CS with Regular Food|40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
10176373|NCT03833596|Experimental|Standard course CS with EEN|40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
10176374|NCT03833596|Experimental|Short course CS with EEN|40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.
10176375|NCT03833557|Active Comparator|Nanohydroxyapatite Pulpotomy|"Biphasic calcium phosphate. Straumann BoneCeramic Regenerative Pulpotomy of 24 mandibular second primary molars using Nanohydroxyapatite~In Group 1: 24 mandibular second primary molars Caries removal and deroofing of pulp chamber Following the manufacturer's instructions, Nanohydroxyapatite was mixed with distilled water to homogeneous consistency then introduced into the pulp chamber and condensed properly against the pulp orifices.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy"
10176376|NCT03833557|Active Comparator|MTA Pulpotomy|"Angelus Grey MTA , Regenerative Pulpotomy Pulpotomy of 24 mandibular second primary molars using MTA Caries removal and deroofing of pulp chamber The MTA powder was mixed with sterile water in a 3:1 powder/water ratio according to the manufacturer's instructions to obtain a thick creamy paste, then placed on the floor of the pulp chamber using a messing gun and compacted against the pulp orifices with a condenser over a moist cotton pellet.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation at one, three ,six & 12 months after pulpotomy."
10176377|NCT03833557|Active Comparator|Formocresl Pulpotomy|"Buckley' s Formocresol , Fixation pulpotomy Pulpotomy of 24 mandibular second primary molars using Formocresol Caries removal and deroofing of pulp chamber~A cotton pellet with formocresol was placed on the pulp stumps then removed and ZO/E dressing was condensed against the pulp stumps.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy for clinical and radiographic evaluation. Independently, two examiners evaluated the teeth clinically and radiographically."
10176378|NCT03833336|Placebo Comparator|Placebo|normal saline solution plus oral lactose capsules
9680491|NCT04938011|Experimental|Progesterone + 7|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
9680492|NCT04938011|Active Comparator|Progesterone + 6|the transfer of day 6 blastocysts on the 6th day of progesterone supplementation
9680493|NCT04938037|Experimental|SSNB through the spinoglenoid notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
9680494|NCT04938037|Active Comparator|SSNB through the suprascapular notch|US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
9680495|NCT04937946|Experimental|Fentanyl|Fentanyl will be given within 24 hours from the initiation of mechanical ventilation at an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
9680496|NCT04937946|No Intervention|Placebo|Will receive continuous infusion of IV fluid up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
9976019|NCT01347359|Active Comparator|Control - Standard of care|"Standard of care is at the discretion of the treating rheumatologist."
9976020|NCT01347385|Experimental|Barbed suture|
9976021|NCT01347385|Active Comparator|Traditional suture material|
9976022|NCT01347398|Experimental|MicroMESAM|Sleep study made by MicroMESAM system
9680501|NCT04938102|No Intervention|Abnormal DI - Control|Patients' whose distensibility index is measured <2.8 will receive no intervention.
9680502|NCT04938102|Active Comparator|Abnormal DI - Botox|Patients' whose distensibility index is measured <2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
9680503|NCT04938102|No Intervention|Normal DI - Control|Patients' whose distensibility index is measured >2.8 will receive no intervention.
9680504|NCT04938102|Active Comparator|Normal DI - Botox|Patients' whose distensibility index is measured >2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
9680505|NCT04938154|Experimental|DBS On|
9680506|NCT04938154|Sham Comparator|DBS Off|
10176379|NCT03833336|Active Comparator|Intravenous ferric carboxymaltose|Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)
10176380|NCT03833336|Active Comparator|Oral iron A: ferroglycine sulfate|oral capsules of ferroglycine sulfate iron until week 24
10176381|NCT03833336|Active Comparator|Oral iron B: sucrosomial iron|oral capsules of sucrosomial iron until week 24
9680507|NCT04937907|Experimental|Hydroxychloroquine Cohort|Patients in the cohort will receive Hydroxychloroquine(HCQ) throughout the study.Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day for 6 months. During treatment with HCQ, patients also received enalapril(5-10mg qd).
9680508|NCT04937907|Sham Comparator|Comparator Cohort|During treatment with HCQ, Patients randomized to Comparator Cohort only received enalapril(5-10mg qd).
9680509|NCT04938219|Experimental|Shivering Treatment Group|Participants will be observed, and intervention will begin when a shivering score of 2 or higher is reached. The participants in the treatment group will receive one glove filled with warm water into each hand.
9680510|NCT04938219|No Intervention|Control Group|Participants in the control group will only be observed, and not given additional treatment for the shivering.
9680511|NCT04937985||UULEX Test Group|Patients with chronic neck pain
9680512|NCT04938063||Cerebral palsy children|Sample size estimation was carried out to determine the recruited number of the diplegic CP children from the outpatient clinic at the Faculty of Physical Therapy, Cairo University, Physical Therapy Department at the National Institute of Neuromotor Disorder, Abu El-Reesh Hospital, and private physiotherapy clinics. The age of patients will range from 18 months to 5 years old. Both sexes will participate in this study
9680513|NCT04937868||Blunt trauma patients undergoing abdominopelvic computed tomographic imaging|"The study will be observational and not alter the care or management of blunt injury victims. Medical decisions will be made by treating physicians using current standards of care. Thus, to reduce the potential for bias, the study will seek to enroll all blunt injury victims who undergo A/P imaging as part of their ED trauma evaluation. This may include children, the elderly, all races, both sexes, and any other demographic or social groups that may present among blunt injury patients. An individual will become eligible for the study when the treating physician determines that A/P CT imaging is needed for their trauma evaluation. Inclusion or exclusion will not be based on age, gender, pregnancy or child-bearing potential, or racial/ethnic origin.~There will be no exclusion criteria."
9680514|NCT04938076|Experimental|tDCS group|"tDCS stimulation~affected side :~primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)~2mA anode (+) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)~contralateral unaffected side~primary motor cortex (M1 cortex by using the C3 or C4 position of the 10-20 EEG system)~2mA cathode (-) for 30 minutes total 10 times for 7 days (ex) twice a day for 5 days)"
9680515|NCT04938076|Sham Comparator|Sham group|". Sham stimulation~1) the current ramps up to 2mA and slowly decreased over 30 s to ensure the typical initial tingling sensation"
9680516|NCT04937842|Experimental|MST|standard chemotherapy with microtransplantation
9680517|NCT04937842|No Intervention|CT|standard chemotherapy only, without microtransplantation
9680518|NCT04937699|Active Comparator|Standard-Does Ticagrelor plus aspirin (SD.T+A)|"Patients will be randomized after PCI, and receive standard-does ticagrelor plus aspirin in this arm as followed:~Ticagrelor 90mg bid+Aspirin 100mg qd for 12months"
10176382|NCT03833466|Experimental|metformin and chemotherapy|
10176383|NCT03833570|Experimental|Melatonin therapy|"Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks~Symptomatic treatment dose: Three times a day for six weeks"
10176384|NCT03833570|Active Comparator|Conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Dose: Three times a day for six weeks"
10176385|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Naive)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
10176386|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Naive)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
10176387|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Failure)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
9680519|NCT04937699|Experimental|Low-Does Ticagrelor monotherapy (LD.T)|"Patients will be randomized after PCI, and receive low-does ticagrelor plus aspirin for the first month and switch to low-does ticagrelor monotherapy in the following 5 months, and then further de-escalated to clopidogrel monotherapy till 1 year in this arm as followed:~Ticagrelor 60mg bid+Aspirin 100mg qd for 1 month; Ticagrelor 60mg bid, for 5 months; clopidogrel 75mg qd, for 6 months."
9680520|NCT04937673|Experimental|Camrelizumab+ Paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
10176388|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Failure)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
10176389|NCT03833583|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
10176390|NCT03833583|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
9680521|NCT04937673|Experimental|Camrelizumab+ Albumin bound paclitaxel+ Cisplatin|The subjects were randomly divided into the group of camrelizumab combined with paclitaxel and cisplatin or the group of camrelizumab combined with albumin bound paclitaxel and cisplatin according to the ratio of 1:1. Esophageal cancer resection was performed after 3 cycles of medication (the researchers decided the follow-up treatment according to the postoperative pathological situation). At the end of the treatment, the patients were followed up for safety and effectiveness.
9680522|NCT04937777||Group pre-2010|Patients who initiated first-line treatment between 2004 and 2010 (pre-2010).
9680523|NCT04937777||Group post-2010|Patients who initiated first-line treatment between 2011 and 2018 (post-2010).
9680524|NCT04937621||SARS-CoV-2 infection|This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
9680525|NCT04937855||Control group|25 gender and age matching healthy controls
9680526|NCT04937855||ARDS group 1|100 ARDS patients at the time of check in hospital
9680527|NCT04937855||ARDS group 2|100 ARDS patients at the time of 24h after check in hospital
9680528|NCT04937855||ARDS group 3|100 ARDS patients at the time of 48h after check in hospital
9680529|NCT04937855||ARDS group 4|100 ARDS patients at the time of 72h after check in hospital
9680530|NCT04937764||Study population|Population who underwent a surgical arthrodesis procedure for arthritic or inflammatory involvement of the Lisfranc tarsometatarsal joint
9680531|NCT04937569|Active Comparator|Group 1: Ivermectin + standard treatment|Patients will receive 4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard treatment (Azithromycin 500mg once daily for 5 days, Paracetamol 500mg every 8 hours, vitamin C 1gm once daily, Zinc 50 mg once daily, Lactoferrin 100mg sachets twice daily and prophylactic or therapeutic anticoagulation if D-dimer is elevated.
9680532|NCT04937569|Other|Group-2: Standard treatment only|This group will receive the standard treatment protocol as outlined above according to the Egyptian Ministry of Health protocol of treating cases with mild COVID-19.
9680533|NCT04937634|Experimental|Melphalan|
9680534|NCT04937530|Experimental|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
9680535|NCT04937530|Placebo Comparator|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
9680536|NCT04937504|Active Comparator|STAIR-PC Group|Participants in the Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) group will complete five (30 minute each) therapist-led sessions in-person or via Telehealth for up to 12 weeks.
9680537|NCT04937504|Experimental|WebSTAIR Group|Participants in the WebSTAIR group will complete 10 self-guided, web-based modules for up to 12 weeks.
9680538|NCT04937543|No Intervention|No intervation|patients receiving standart of care
9680539|NCT04937543|Active Comparator|Experimental intervation one|patients receiving standart of care + inhaled beclometasone
10176391|NCT03833765|Experimental|CAF+XCM|An envelope split-full-split thickness flap without vertical incisions will be carried out in the gingival recession area. Afterwards, a xenogenic collagen matrix (XCM) will be applied to all teeth with recession defect. The XCM will be cut into the right dimensions, measured with the probe, and its measurements recorded; then it will be placed from the CEJ to the bone crest on the recipient bed using single sutures, 7/0 PGA sutures. The matrix will be rehydrated with blood, in order to reconstitute and maintain the maximal thickness possible. The flap will be closed slightly coronal to the CEJ with a sling suture using resorbable PGA 6/0 sutures and avoiding any compression of the matrix.
10187248|NCT03728114|Experimental|Low Altitude RIC group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
9680540|NCT04937543|Active Comparator|Experimental intervation two|patients receiving standart of care + inhaled beclometasone/ formoterol / glycopyrronium
9827566|NCT02461160|Experimental|MRD Cohort 4: TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.
9976023|NCT01347398|Active Comparator|PSG|Sleep study made by PSG (polysomnography)
9680541|NCT04937933|Active Comparator|Coolant spray group|Coolant spray (Cryos ®Spray, Phyto Performance, Italy) was applied as suggested by the manufacturer (at a distance of 20 cm from the injured area for 5-10 s). Saline solution was sprayed for the same duration and at the same distance from the injured area as well. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
10176392|NCT03833765|Active Comparator|CAF alone|An envelope split-full-split thickness flap without vertical incisions will be carried out. The root surfaces will be mechanically treated with the use of curettes. A sharp dissection into the vestibular lining mucosa will be then carried out to eliminate muscle tension. Sling sutures will be performed to accomplish a precise adaptation of the buccal flap on the exposed root surfaces and to stabilize every single surgical papilla over the de-epithelialized anatomic papillae.
9680542|NCT04937933|Placebo Comparator|Placebo group|A standard saline solution in a bottle covered with opaque white paper and refrigerated at 4°C was prepared. Saline solution was sprayed for the same duration and at the same distance from the injured area as well like coolant spray application. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
9680543|NCT04937608||COVID-19 group|men aged 18 to 45 who have been infected with SARS-CoV-2 in the past 6 months
9680544|NCT04937608||Control group|healthy men aged 18 to 45 with normal sperm parameters (WHO 2010 criteria) and who have never contracted COVID-19
9680545|NCT04937881|Experimental|TAF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
9680546|NCT04937881|Active Comparator|TDF arm|Fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) delivered under direct observation for 8 weeks during pregnancy and 8 weeks in postpartum period
9680547|NCT04937439|Experimental|Segmental trunk training A|Children in this group will receive specially designed physical therapy program while wearing a segmental trunk support from the level of pelvis to a level just below the rib cage.
9680548|NCT04937439|Active Comparator|Segmental trunk training B|Children in this group will receive the same program given to (group A) while wearing a segmental trunk support from the level of pelvis to a level just below the inferior angle of scapula.
9680549|NCT04937439|Active Comparator|Segmental trunk training C|will receive the same program given to (group A and B) while wearing a segmental trunk support from the level of last rib to the level of the inferior angle of scapula.
9680550|NCT04937452|Experimental|Rotigotine 4 mg|Rotigotine 4 mg/24 hours transdermal patch administration
9680551|NCT04937452|Experimental|Rotigotine 6 mg|Rotigotine 6 mg/24 hours transdermal patch administration
9680552|NCT04937452|Placebo Comparator|Placebo|Placebo transdermal patch administration
9680553|NCT04937257|Active Comparator|Virtual Reality|"Participants randomized to the immersive virtual reality study arm, considered the intervention group received training on donning and doffing PPE using a program developed by Axon Park Inc. (California, USA)"
9680554|NCT04937257|Placebo Comparator|E-module|"Participants randomized to the e-module study arm, considered the control group received training on donning and doffing PPE using an e-module containing a video and slide show."
10176393|NCT03833414||(Group1)|Triceps lifting approach .
10176394|NCT03833414||(Group 2)|olecranon osteotomy approach
9680555|NCT04937192||Kidney stone former|
9827567|NCT02461160|Experimental|MRD Cohort 5: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.
10176395|NCT03833453|Active Comparator|PTSD-EMDR|PTSD treatment
10176396|NCT03833453|Experimental|Integrated DBT-EMDR|Integrated PTSD-PD-treatment
10176397|NCT03833440|Experimental|Durvalumab + Monalizumab|
10176398|NCT03833440|Experimental|Durvalumab + MEDI9447|
10176399|NCT03833440|Experimental|Durvalumab + AZD6738|
10176400|NCT03833440|Active Comparator|Docetaxel|
10176401|NCT03833388|Experimental|TOP1630 Ophthalmic Solution|
10176402|NCT03833388|Placebo Comparator|Placebo to TOP1630 Ophthalmic Solution|
10176403|NCT03833102||Colonized patients' group (CPG)|all adult patients hospitalized in or consulting the Rennes University Hospital, known as S. aureus colonized could be included. In our institution, S. aureus colonization in the nostrils is screened in all patients supposed to undergo neurosurgical or orthopedic surgery.
10176404|NCT03833102||SAB patients' group (SAB)|"all adult patients with SAB could be included. S. aureus colonization in the nostrils will be systematically screened immediately after the first result of positive S. aureus blood culture. Two subgroups will be individualized depending on the SOFA Score:~Severe patients~Non-severe patients"
10176405|NCT03833297||Hepatological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hepatological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
10176406|NCT03833024|Active Comparator|Venixxa|Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months
10176407|NCT03833024|Placebo Comparator|Placebo|"Placebo for 6 months~1 Tablet, BID (morning and evening) for 6 months"
10176408|NCT03833115|Experimental|vaginal gel containing sodium lauryl sulfate|
10176409|NCT03833011|No Intervention|no intervention|
10176410|NCT03833011|Experimental|Osteopathic manipulation|
10176411|NCT03833193|Experimental|Hypofractionated radiotherapy|The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
9680556|NCT04937218|Experimental|Egg demand creation campaign|Egg demand creation campaign using Above-the-line and Below-the-line methods for 14 months. Above-the-line interventions include television, radio, celebrity ambassadors and out-of-home advertising (e.g., billboards). Below-the-line interventions include interpersonal communication activation, trade promotions, point-of-sale materials, food demonstrations and giveaways and door-to-door activation.
9680557|NCT04937218|No Intervention|Comparison|Comparison arm with no campaign
9680558|NCT04937283|Experimental|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed after a comprehensive evaluation. As with lobectomy, systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated in the same manner as with lobectomy. When lymph node metastasis is present or resection margin is not cancer-free, the surgical procedure must be converted to a lobectomy.
9680559|NCT04937283|Active Comparator|Lobectomy with systemic lymph node dissection|"lobectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively.~The distance from the dissection margin to the tumor edge must be evaluated intraoperatively. If the distance is either less than the maximum tumor diameter or ,20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery."
9680560|NCT04937335||Non-hemorrhage group|Patients recognized as craniopharyngioma pathologically without tumoral hemorrhage observed during the operation
10176412|NCT03832972||Women using birth control|
10176413|NCT03832972||Women not using birthcontrol|
10176414|NCT03833232|Experimental|omentopexy and cyanoacrilate glue|Apposition of omentum with cyanoacrilate glue after gastric section
9680561|NCT04937335||Hemorrhage group|Patients recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation
9680562|NCT04937426|Experimental|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|During gastroscopy additional biopsies are taken in cases where infection with helicobacter pylori is suspected. It will then undergo laboratory analysis with fluorescent-labeled urease inhibitor marker. Results will be compared to standard analysis to determine efficacy.
9680563|NCT04937400||Pediatric Stem Cell Transplant Patients|A consecutive cohort of children admitted to the hospital for stem cell transplantation
9680564|NCT04937140||rheumatoid arthritis patients|90 RA patients diagnosed according to the American college of rheumatology (ACR) -EULAR RA classification criteria 2010
9680565|NCT04937140||control group|50 age and sex matched healthy controls. All
10176415|NCT03833232|No Intervention|gastrectomy without omentopexy|Gastric section without omentopexy
10176416|NCT03833076|Experimental|GROUP A: Medical Device Procto|"Medical device Procto presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
10176417|NCT03833076|Placebo Comparator|GROUP B: Matching placebo|"Investigational Product (IP) placebo presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
10176418|NCT03833219|No Intervention|Control (monitor only)|Continue in monitoring only mode
9680566|NCT04937049|Experimental|EMAeHealth digital tool|This team has designed a digital tool called EMAeHealth involving healthcare professionals. It is organized into 4 areas: 1) an Information area, 2) a Communication area, 3) a Health Self-management area, 4) a Clinical data area, The tool is conceived as a complement that can reinforce maternal health education with resources that facilitate its accessibility, and rapid remote response, which will also improve its results. It will be incorporated into the Osakidetza-Basque Health Service corporate Website.
9680567|NCT04937049|No Intervention|No EMAeHealth digital tool|Usual care. This group, like experimental group, receives the usual care, which includes traditional maternal education, but does not receive the EMAeHealth intervention
9680568|NCT04937114|Experimental|Flap will be approximated using conventional, simple continuous suturing with barbed sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with unidirectional barbed sutures.
9680569|NCT04937114|Active Comparator|Flap will be approximated using conventional, simple continuous suturing with conventional sutures|After administration of adequate amount of local anesthesia, planned muco-gingival surgery will be performed and flap will be approximated using conventional, simple continuous suturing with conventional sutures.
9680570|NCT04937101|Experimental|Antihistamine treatment group|Chlorpheniramine, the concentration is 10mg/ml per unit point, the highest dose is 1ml
9680571|NCT04937101|No Intervention|Control group|
9680572|NCT04937348||GDM G1|Mothers diagnosed with gestational diabetes mellitus, treated with diet; and their newborns
9680573|NCT04937348||GDM G2|Mothers diagnosed with gestational diabetes mellitus, treated with insulin; and their newborns
10176419|NCT03833219|Experimental|Social comparison feedback|Report user's handheld phone use/ hour of driving for week. Compare this week's performance to distribution for driver cohort.
10176420|NCT03833219|Experimental|End of rating period incentive|Monitor throughout intervention period and compare overall use to distribution for cohort. Notify participant at end of intervention period regarding the amount they have earned.
10176421|NCT03833219|Experimental|End of rating period incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant at end of intervention period regarding the amount they have earned.
9680574|NCT04937348||non-GDM / control group|"Healthy, non-diabetic mothers, without disturbances in glucose metabolism; and their newborns.~Control group."
9680575|NCT04937205||Cohort 2|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on February 13, 2019.
10176422|NCT03833219|Experimental|Weekly loss-framed incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned.
10176423|NCT03833219|Experimental|Larger weekly loss-framed incentive+social comparison feedback|"Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned. Incentive amount is higher than Weekly loss-framed incentive + social comparison feedback Arm."
9680576|NCT04937205||Cohort 3|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on November 5, 2019.
9680577|NCT04937205||Cohort 4|This group of study participants started the 52-week parent randomized controlled trial (NCT03411356) on October 22, 2020.
10176424|NCT03833258|No Intervention|Rehabilitation with precautions|Patients in this arm will continue with rehabilitation following routine care recommendations after total hip replacement; therefore following precautions.
10176425|NCT03833258|Experimental|Rehabilitation with no precautions|Patients in this arm will continue with rehabilitation after total hip replacement without precautions, being permitted to move within limits of their own pain only.
9976024|NCT01347411|No Intervention|Control|Usual treatment
10176426|NCT03833271|Active Comparator|TNF-alpha inhibitor|
9680578|NCT04937244|Experimental|Patients with new or recurrent malignant gliomas|
10176427|NCT03833271|Active Comparator|Methotrexate|
9680579|NCT04937023|Experimental|UDCA gel will be injected using a syringe with blunt cannula into the defect site|In the test group, the prepared UDCA gel will be injected using a syringe with blunt cannula into the two or three wall intra-bony defects with probing pocket depth ≥3mm after performing SRP.
10176428|NCT03833271|Active Comparator|Healthy|
10176429|NCT03833063|Placebo Comparator|placebo|injections with sodium chloride
9680580|NCT04937023|Placebo Comparator|placebo gel will be injected in to the defect site using a syringe with blunt cannula.|In patients allocated to control group, placebo gel will be injected in to the defect site using a syringe with blunt cannula after scaling and root planing.
9680581|NCT04937036||COMISA group|Patients with diagnosed COMISA.
9680582|NCT04937036||Healthy controlls|Healthy indyviduals.
9680583|NCT04937179|Sham Comparator|Ischemic Conditioning Low|Blood flow restriction with low compression
9680584|NCT04937179|Active Comparator|Ischemic Conditioning High|Blood flow restriction with high compression
9680585|NCT04936802|Experimental|Transcatheter tricuspid valve repair system (Trialign)|Subjects who received transcatheter tricuspid valve repair with Trialign will be included in this arm.
10176430|NCT03833063|Active Comparator|botulinum toxin A|injections with botulinum toxin A
10176431|NCT03832933|Experimental|High Protein Diet|
10176432|NCT03832933|Active Comparator|Standard Protein Diet|
10176433|NCT03832959|No Intervention|Non esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.
10176434|NCT03832959|Experimental|Esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM
10187249|NCT03728114|Sham Comparator|Low Altitude Sham group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
9680586|NCT04936633|No Intervention|No intervention by medical staff|The patients who start FSGM and receive general education on FSGM only.
9680587|NCT04936633|Experimental|Intervention by medical staff based on a cloud system|The patients who start FSGM and receive general education on FSGM and remote intervention based on a cloud system.
9680588|NCT04936893|Experimental|HeadSpace Mobile App|Mindfulness practice
9680589|NCT04936893|Active Comparator|Lumosity Mobile App|Cognitive games
9680590|NCT04936763|Experimental|Janesse 20|
9680591|NCT04936711|Experimental|Back Massager Device + Standard Pain Treatment|"Resteck Shiatsu Neck and Back Massager (brand name), with recommended use for at least every 2 hours for at least 15 minutes on the first post-operative day and then every 4 hours for 2 days and then as needed.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
9680592|NCT04936711|Active Comparator|Marcaine spray + Standard Pain Treatment|"30cc of 0.25% Marcaine spray on the diaphragm at the end of surgery.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
9827568|NCT02461160|Experimental|MRD Cohort 6: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.
9976025|NCT01347411|Experimental|CPAP|Treatment with CPAP
9976026|NCT01347424|Experimental|Test group|
9976027|NCT01347424|Active Comparator|control group|
9976028|NCT01347437|No Intervention|Condition|In the comparison condition, participants will receive MEMS only.
9977614|NCT01363531|Active Comparator|Direct antibiotic treatment|The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.
9977615|NCT01363531|No Intervention|No antibiotic treatment|The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.
9680593|NCT04936711|No Intervention|Standard Pain Treatment|"will receive standard pain treatment include local anesthetic agent at the incision sites + oral Tylenol and oral or IV opioid as breakthrough pain treatment postoperatively as needed.~Standard pain treatment:~Local anesthetic agent at the incision sites include: 0.5% Marcaine (10 cc) + 0.5% lidocaine and epinephrine (10 cc) (total volume: 20 cc)~Morphine 2 mg: Intravenous administration every 2 hours or as needed, if unable to take pills by mouth~Oxycodone 5 - 10 mg elixir: oral administration every 6 hours or as needed~Tylenol 650 mg Tab: oral administration every 6 hours"
9680594|NCT04936828|Experimental|Intervention group|Receive iCBT based EMI with message content, delivery frequency and timing personalised to participants' preferences.
9680595|NCT04936828|No Intervention|Control group|Receive general mental health information through instant message.
9680596|NCT04936672|Experimental|Brisk walking group|"Type of exercise is brisk walking. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time."
10176435|NCT03832894|Active Comparator|Group receiving oestradiol tablets in addition to progesterone|"Group A :Will receive 400mg progesterone in the form of vaginal or rectal suppositories in addition to estradiol valerate oral tablets in a dose of 4mg/day(2x2), for luteal phase support. Starting from the day of ovum pickup and for 14 days after embryo transfer.~Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer."
10176436|NCT03832894|Placebo Comparator|Group not receiving oestradiol tablets.|Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer
10176437|NCT03832777|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.
10176438|NCT03832777|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
10176439|NCT03832803|Experimental|Empty Bladder|Empty bladder prior to treatment.
10176440|NCT03832803|Other|Full Bladder|Conventional drinking protocol - 200ml water prior to treatment.
10176441|NCT03832582|Experimental|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
10176442|NCT03832660|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
10176443|NCT03832660|Active Comparator|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
10176444|NCT03832660|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
10176445|NCT03832504|Experimental|38°C and 60% RH + No intervention|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
10176446|NCT03832504|Experimental|38°C and 60% RH + Fan|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
10176447|NCT03832504|Experimental|38°C and 60% RH + Skin wetting|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
10176448|NCT03832504|Experimental|38°C and 60% RH + Fan + Skin wetting|Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
9680597|NCT04936672|Experimental|Tai Chi Chuan|"Type of exercise is Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity is 50%-70% of the individual's maximum heart rate."
9680598|NCT04936672|Experimental|Brisk walking combined with Tai Chi Chuan|"Type of exercise is brisk walking combine with Tai Chi Chuan. The duration of each exercise is from 35 minutes to 60 minutes, with 5 minutes of training time added every two weeks.~The frequency of each exercise is 3 times a week. Total exercise time is 12 weeks. The intensity of brisk walking is 50%-70% of the individual's maximum heart rate, gradually increasing the intensity over time.~The intensity of Tai Chi Chuan is 50%-70% of the individual's maximum heart rate."
9680599|NCT04936672|No Intervention|Control Group|Keeping their daily life.
9680600|NCT04936945|Active Comparator|arthroscopy plus platelet rich plasma.|Group A: will be treated with operative arthroscopy plus intra-articular injection of platelet rich plasma
9680601|NCT04936945|Active Comparator|arthroscopy plus hyaluronic acid.|Group B: will be treated with operative arthroscopy plus intra-articular injection of hyaluronic acid
9680602|NCT04936789|Experimental|Single arm|Single arm. All subjects will receive the intervention. Comparator device will be subjects' own prosthesis at baseline.
9680603|NCT04936594|Experimental|Intermittent Theta Burst Stimulation (iTBS)|Subjects randomized to the experimental arm will receive 1800 pulses of intermittent TBS using MagVenture B65 A/P coil
9680604|NCT04936594|Sham Comparator|Sham TMS|Sham TMS will be delivered using MagVenture B65 A/P coil
9680605|NCT04936906|Experimental|Extra Care (EC) Treatment Group|Participants in this group will receive the EC intervention pre and post standard of care (SoC) scheduled Mohs Surgery.
10176449|NCT03832504|Experimental|46°C and 10% RH + No intervention|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.
9680606|NCT04936906|Active Comparator|Usual Care (UC) Group|Participants in this group will receive the usual care provided to patients undergoing standard of care (SoC) scheduled Mohs Surgery.
9680607|NCT04936555|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
9680608|NCT04936555|No Intervention|No Intervention|Control group Routine maintenance will be applied
9680609|NCT04936620|Active Comparator|Duroplasty|Duroplasty (includes Surgery with Laminectomy)
9680610|NCT04936620|Active Comparator|No duroplasty|No duroplasty (but includes surgery with Laminectomy)
9680611|NCT04936503|Experimental|High-level athletes|"High level athletes are rugby players, intervention unit agents of the National Police, sports students.~Definition of a COVID-19 positive subject : Any subject whose serology is positive (IgM and/or IgG) and/or the Reverse Transcription Polymerase Chain Reaction (RT-PCR) result is positive and/or the questionnaire is positive and/or a new electrocardiogram (ECG) abnormality.~The COVID-19 negative subjects do not meet the definition of COVID-19 positive subjects."
9680612|NCT04936646|Experimental|Classic rTMS Stimulation using the B65 Coil|
9680613|NCT04936646|Experimental|Deeper rTMS Stimulation using the B70 Coil|
10176450|NCT03832504|Experimental|46°C and 10% RH + Skin wetting|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
9680614|NCT04936646|Sham Comparator|control group with a sham stimulation using a sham coil|
10176451|NCT03832816|Placebo Comparator|Placebo|Distilled Water
9680615|NCT04936698||Hyperthyroidism|Elevated fT4, low TSH
9680616|NCT04936698||Hypothyroidism|Elevated TSH, low fT4
9680617|NCT04936698||Euthyroid|Normal TSH/fT4 level
9680618|NCT04936841|Experimental|NKTR-214, anti-PD therapy plus Palliative Radiation|"Cycle 1 consists of anti-PD-1 therapy (200mg) and NKTR-214 (0.006 mg/kg3 administered intravenously), followed by palliative radiation (8 Gy x 3 or 4 Gy x 5 fractions) combined with anti-PD-1 therapy and NKTR-214 in cycle 2.~In subsequent cycles participants will receive NKTR-214 and anti-PD-1."
9680619|NCT04936412|Experimental|Personalized brace group|Personalized brace for patients
9680620|NCT04936412|Active Comparator|Conventional brace group|Conventional brace for patients
9680621|NCT04936659|Experimental|Treatment group|
9680622|NCT04936568|No Intervention|control|standard oncology care
9680623|NCT04936568|Experimental|intervention|standardized referral to outpatient palliative care by oncologists
9680624|NCT04936347|Experimental|Cold knife|The interference of the experimental group is to perform intrauterine adhesiolysis with scissors
9680625|NCT04936347|Other|Hot knife|The interference of the control group is to perform intrauterine adhesiolysis with bipolar electric needle electrode, part of the scar tissue removed by electronic loop when it is necessary.
9680626|NCT04936425|Experimental|OTSC Stentfix|
9680627|NCT04936425|No Intervention|Stent Suturing|
9695474|NCT04777786|Experimental|Physical Therapy Intervention|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning ~4 weeks after surgery (x̄=10 visits).
9695475|NCT04777786|No Intervention|Usual Care|The usual care group will be instructed to continue with their typical daily activities.
9695476|NCT04777760||one dose of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
9695477|NCT04777760||two and more doses of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
9695478|NCT04777916||Standard intensive 3+7 YOUNG OR ELDERLY|Standard intensive 3+7 (anthracycline + cytarabine) chemotherapy ± an approved FLT3 inhibitor (midostaurine, Rydapt®), according to different dose schedules in older versus younger patients
9695479|NCT04777916||GO, Mylotarg®) with 3+7|Combination of sequential gemtuzumab ozogamicin (GO, Mylotarg®) with 3+7
9695480|NCT04777916||CPX-351, Vyxeos®)|Liposomal formulation of daunorubicin + cytarabine (CPX-351, Vyxeos®)
9695481|NCT04777916||Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC)|Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC) in patients considered as not eligible for the more intensive options above
9695482|NCT04777916||Refractory or relapsed AML|"Secondly, no specific salvage regimen has emerged as a standard in patients with primary refractory or relapsed AML (R/R AML). R/R AML is thus an important field for investigational new drugs (INDs) and precision medicine development. To date, the only IND approved to treat R/R AML is gilteritinib for FLT3-mutated AML patients. The French agency ANSM also allow to use GO for treating R/R AML patients in the frame of a RTU (Recommendation Temporaire d'Utilisation).~In the real life, because of the multiplicity of treatments used in these patients, some of them being now quite efficient, it has become difficult to accurately describe the general outcome of R/R AML patients."
9695483|NCT04777903||underweight woman with twin pregnancy|underweight (BMI < 18.5 kg/m2)
10176452|NCT03832816|Experimental|Vaporized THC alone|5mg pure THC
10176453|NCT03832816|Experimental|Vaporized low CBD alone|50mg pure CBD
10176454|NCT03832816|Experimental|Vaporized medium CBD alone|100mg pure CBD
10176455|NCT03832816|Experimental|Vaporized high CBD alone|200mg pure CBD
10176456|NCT03832816|Experimental|Vaporized low CBD with THC|50mg pure CBD paired with 5mg THC
10176457|NCT03832816|Experimental|Vaporized medium CBD with THC|100mg pure CBD paired with 5mg THC
10176458|NCT03832816|Experimental|Vaporized high CBD with THC|200mg pure CBD paired with 5mg THC
10176459|NCT03832608||Older adults and Sarcopenia|Older adults with and without Sarcopenia living in Valencia Province.
9680628|NCT04936334|Experimental|Men diagnosed with clinically significant prostate cancer who are scheduled for prostatectomy|1. Men diagnosed with clinically significant prostate cancer who are scheduled or for prostatectomy will undergo injection of 68Ga-PSMA-11 at the time of their pre-treatment PSMA PET. Followed until 12 mo post surgery
9680629|NCT04936269||Group 1|Children under five years old
9680630|NCT04936971|Experimental|Everolimus|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Everolimus (EVL) to achieve 3-8 ng/mL trough levels and Corticosteroids (CS) as per local practice."
9680631|NCT04936971|Active Comparator|Mycophenolate Mofetil|"Kidney transplant induction with Rabbit Anti-Thymocyte globulin (rATG) as per local practice.~Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Mycofenolate Mofetil (MMF) 500mg/bid and Corticosteroids (CS) as per local practice."
9680632|NCT04936243|Experimental|FOLLOW UP VISIT-TELEMEDICINE|After initial in-person routine followup care, participants will be randomly assigned to receive telemedicine care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
9680633|NCT04936243|Experimental|FOLLOW UP VISIT-FACE TO FACE|After initial in-person routine followup care, participants will be randomly assigned to receive face-to-face care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
9680634|NCT04936282|Experimental|Steroids, tacrolimus, mycophenolate and Grafalon|Normal treatment for first 90 days, then add Grafalon single-dose if borderline lesions are present in protocol biopsy (performed at third month post-transplantation)
9680635|NCT04936282|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
9680636|NCT04936399||Cohort 1|Participants with Squamous Cell Oesophageal Carcinoma Receiving Nivolumab
9680637|NCT04936295|Experimental|Fulvestrant plus Anlotinib|Each participant receives fulvestrant combined with anlotinib.
9680638|NCT04936737|Experimental|Beta-alanine supplementation and high intensity exercise|Individuals will participate in a high-intensity exercise and will be supplemented with beta-alanine. This protocol will be conducted for six non-consecutive days.
9680639|NCT04936737|Experimental|Beta-alanine supplementation only|In this protocol, the individuals will be supplemented with beta-alanine without the exercise protocol for six non-consecutive days.
9680640|NCT04936152|Active Comparator|mime therapy using tablet PC mirror application|these individuals will receive mime therapy using tablet PC mirror application
9680641|NCT04936152|Experimental|the control intervention including the mime therapy|these individuals will receive the control intervention including the mime therapy).
9680642|NCT04936100|Experimental|"Visual acuity assessment using Vision Screening module of Easy Vision application"|
9680643|NCT04936100|Experimental|"Visual acuity assessment using Test Yourself module of Easy Vision application"|
9680644|NCT04936100|Experimental|"Visual acuity assessment using Peek Acuity application"|
9680645|NCT04936100|Other|Visual acuity assessment using the conventional methods|
9680646|NCT04936191|Experimental|DynamX Bioadaptor Drug-eluting Stent|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor DES and DESyne DES groups.
10176460|NCT03832556|Experimental|Preoperative evaluation: CT + MRI|"Preoperative evaluation by 2 examinations: CT scan and MRI.~CT scan with biphasic injection of contrast product;~MRI with injection of contrast."
9680647|NCT04936191|Active Comparator|DESyne Drug-eluting Stent|Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor DES and DESyne DES groups.
9680648|NCT04936204|Experimental|Group 1 ConnettivinaBio Plus cream|ConnettivinaBio Plus cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% Other components: Silver Sulfadiazine 1%, The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
9680649|NCT04936204|Active Comparator|Group 2 ConnettivinaBio cream|ConnettivinaBio Cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
10187250|NCT03728101|Experimental|Single arm|"Dabigatran etexilate~Simvastatin + Dabigatran etexilate"
9680650|NCT04936087|Other|WHO 8-steps|Single group intervention and described in the Intervention section.
9680651|NCT04936217||Patients operated for Continent Cutaneous Urinary Diversion, April 2004 - October 2017|The study focuses of a population of 70 patients operated between April 2004 and October 2017 au Nîmes University Hospital for Cutaneous Urinary Diversion.
9680652|NCT04936165|Experimental|Healthy experimental participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min intervention, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
9680653|NCT04936165|No Intervention|Healthy controlled participants|"The participants sat in a a quiet and darkened room with the upper arm at heart level and the forearm in an upward angle of 30°, 15-20 min prior to the experiment.~The experiments consists of 5-min rest, 90s inflated wrist cuff (240 mmHg) with 30s VO(one minute later), 3-min rest, 10-min rest, the same 4.5-min process of the wrist cuff, VO and rest.~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy probes of tow wavelengths were attached on the participants' forearm and brain to detect the changes of hemodynamic parameters."
9680654|NCT04936139|Experimental|Art Therapy|Patients assigned to the intervention group will participate in 12 weekly group therapy workshop sessions.
9695484|NCT04777903||normal weight woman with twin pregnancy|normal (BMI: 18.5-23.9 kg/m2)
9695485|NCT04777903||overweight and obese woman with twin pregnancy|overweight and obese (BMI ≥24 kg/m2)
10187251|NCT03728075|No Intervention|Control group|standard protocol for cardiac rehabilitation
9680655|NCT04936139|No Intervention|Control group|"Patients assigned to the control group will receive the usual follow-up care of each center provided for the cancer patient and will not perform art therapy workshops.~They will be offered the opportunity to participate in the workshops once they have completed their participation in the study, putting them on a waiting list."
9680656|NCT04935827||Patients initiating dialysis for end-stage kidney disease|"Patients whose start of dialysis is from 12/1/2007-11/30/2017. We use the following inclusion criteria:~Adult (>= 18 years old)~Did not die or have a transplant prior to the 90th day of dialysis~Valid medical evidence form~Medicare Part A/B as primary payer in the 30 days prior to initiating dialysis~Initiating dialysis in the USA"
9680657|NCT04936022|Other|Control|To receive standard care lifestyle advice only
9680658|NCT04936022|Experimental|Isometric Exercise|To receive standard care lifestyle advice plus 3 sessions of isometric exercise per week
9680659|NCT04935892|Experimental|Slippers|Patients wear slippers any time they are out of bed with a goal of avoiding any contact between socks/feet and the floor
9680660|NCT04935892|No Intervention|Control|Patients receive standard care with no intervention
9680661|NCT04936126|Active Comparator|Quetiapine group|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment.
9680662|NCT04936126|Experimental|Amantadine group|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment
9680663|NCT04936126|Experimental|Pramipexole group|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment
9680664|NCT04936048|Active Comparator|Music therapy/Play therapy|"This sequence of interventions begins with 12 weeks of music therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of play therapy intervention.~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, and interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
9680665|NCT04936048|Active Comparator|Play therapy/Music therapy|"This sequence of interventions begins with 12 weeks of play therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of music therapy intervention.~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
9680666|NCT04935814|Experimental|Continuous vasopressin infusion|After general anesthesia, patients will receive a continuous infusion of vasopressin in order to improve mean arterial pressure by 20 mmHg.
9680667|NCT04935840|Experimental|FertyBiotic Pregnancy|Participants received FertyBiotic Pregnancy one capsule a day
9680668|NCT04935840|Placebo Comparator|Control|Participants received 400 mcg of folic acid once a day
9680669|NCT04935996|Experimental|Pleuropulmonary echography|
9680670|NCT04935957||Single-group|Male and female adult subjects with controlled diabetes 1 and 2.
9680671|NCT04935970||patients with peripherial vestibular disorder|Forty patients with BPPV, vestibular neuritis or another peripherial vestibular disorder
9680672|NCT04935970||patients with central vestibular disorder|Forty patients vestibular disorder of central origin
9680673|NCT04935970||healthy controls|twenty healthy control without balance problems
9680674|NCT04935983|Active Comparator|High CHO|High CHO diet for 36 h
9680675|NCT04935983|Experimental|Low CHO|Low CHO diet for 36 h
10176461|NCT03832621|Experimental|temozolomide + nivolumab + ipilimumab|Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule
10176462|NCT03832634|Other|Fetal Genome Profiling|Trophoblast cells will be collected from the cervix approximately 5-6 weeks once pregnancy is achieved.
9680676|NCT04935931|Experimental|Pilot|Pre/post fMRI
9680677|NCT04935918|Experimental|Study Arm 1|Children with bladder exstrophy or isolated epispadias
9680678|NCT04935788|Experimental|milk protein|milk protein supplement
9680679|NCT04935788|Experimental|micellar casein|casein supplement
9680680|NCT04935788|Experimental|pea protein|pea protein supplement
9680681|NCT04935788|Experimental|milk/pea protein|a blend of milk and pea protein
9680682|NCT04935671|Active Comparator|Arm A|"20mg of chamomile and 1 mg saffron in form of teabag for preparation of herbal decoction in dose of two teabags per day for a month as an ADJUVANT THERAPY with standard allopathic treatment for depression."
9680683|NCT04935671|No Intervention|Arm B|Only allopathic medication for depression.
9680684|NCT04935684|Experimental|Group 1: Fecal Microbiota Transplantation (FMT)|"Patients randomized in the FMT group will received FMT. FMT product will be made by the the pharmacy of the Clermont-Ferrand University Hospital from stools of healthy volunteer donors within 6 hours after defecation in order to preserve the viability of the bacteria. The preparation will be standardized: 50g aliquots will be prepared and diluted in 250mL of 0.9% NaCl containing 10% glycerol, until a homogeneous suspension is obtained. The preparation will be rapidly frozen at -80°C until use, with a maximum shelf life of 18 months."
9680685|NCT04935684|No Intervention|Group 2: no intervention|"The comparator group will be constituted by patients randomized in the no FMT group. For ethical reasons, these patients will not receive any FMT and therefore no enema or colic preparation. No placebo will be administered. Prophylactic anti-infective treatments can be introduced at any time."
10176463|NCT03832673|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles) Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
9680686|NCT04935658|Experimental|Virtual Reality Group|in this group, patients will use virtual reality during the oocyte retrieval plus the standard anesthesic procedure (local anesthesia)
9680687|NCT04935658|Sham Comparator|Standard Group|in this group, patients will receive the standard anesthesic procedure during the oocyte retrieval wich is local anesthesia
10176464|NCT03832530|Experimental|HIV-uninfected women|"A sample of 150 women, aged 18-35, likely to be fertile based on reproductive health history, with reported personal or partner desire to have a child in the next year and who self-reports having a relationship with a partner she reports as HIV-infected or likely to be HIV-infected (e.g. taking medicine daily, goes to clinic routinely, has HIV-infected partners, he has implied that he is sick but has not disclosed). All women are offered comprehensive safe conception counseling -- this is the intervention -- inclusive of daily oral TDF/FTC as PrEP."
9680688|NCT04935411||nAMD patients|patients diagnosed with Neovascular Age-Related Macular Degeneration
9680689|NCT04935385||Study Cohort|Patients aged 18 and above undergoing elective surgeries (including general surgery, neurosurgery, ear nose and throat surgeries, cardiac surgery, orthopedic surgeries, vascular surgeries and urological surgeries) at Rabin Medical Center under general anesthesia
10176465|NCT03832712|Active Comparator|Surgical|Participants randomized to surgery
10176466|NCT03832712|Active Comparator|Medical|Participants randomized to best medical treatment
10176467|NCT03832868|Experimental|Pre-visit decision aid|Patients receiving the decision aid pre-visit will be given a paper copy of the decision aid in the waiting room and will have a minimum of 15 minutes to review it - either in the waiting room or in the exam room while waiting for the electrophysiologist.
9680690|NCT04935372||Subjective cognitive decline|Male and female, aged 55 to 80 years with subjective cognitive decline, either cognitively unimpaired or with mild cognitive impairment
9680691|NCT04935333||Leiomyoma samples|Leiomyoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
9680692|NCT04935333||Leiomyosarcoma samples|Leiomyosarcoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour
9680693|NCT04935333||Control samples|Peripheral blood samples obtained from women between 18 and 80 years without suspected myometrial tumour
9680694|NCT04935281||percutaneous repair with an intraoperative assissted ultrasound|a radiologist did an intraoperative ultrasound before the repair for identification the course of sural nerve and outline the medial and lateral edges of torn tendon.
9680695|NCT04935281||percutaneous repair without an intraoperative assissted ultrasound|the course of the sural nerve was determined according to the technique described by Blackmon et al .This technique depends on the leg length for location the point where the nerve crosses the lateral edge of the tendon
9680696|NCT04935424||Experimental：Leukoderma|Device: ApolloVue® S100 image system
9680697|NCT04935645|Experimental|Experimental Group|The experimental group was informed about progressive muscle relaxation (PMR) before colonoscopy. PMR audio recordings were given to the patients. Abdominal pain and distention scores were determined after colonoscopy. PMR was applied to the patients for 30 minutes. These scores were determined again after exercise and at the 2nd, 4th, 8th, 12th, 16th, and 24th hours.
9680698|NCT04935645|No Intervention|Control Group|VAS pain and VAS distension scores of the control group were determined after colonoscopy and 30 minutes later. VAS form was given to all patients to determine VAS abdominal pain and VAS distension scores at the 2nd, 4th, 8th, 12th, 16th and 24th hours after the procedure. The day after the colonoscopy, post test data were collected.
9680699|NCT04935515|Experimental|Mild|Patients with mild symptoms and normal CRP.
9680700|NCT04935515|Experimental|Moderate|Patients with mild symptoms and less than 10 fold increase in CRP.
10176468|NCT03832868|Experimental|Post-visit decision aid|Patients receiving the decision aid after the encounter will meet with the electrophysiologist first and receive the aid afterward.
10176469|NCT03832764||ANSPEC-PRO|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via prototype ANSPEC-PRO - correlated to a NRS number given by the awake patient in PACU/ICU.
10176470|NCT03832764||MEDSTORM|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via MEDSTORM - correlated to a NRS number given by the awake patient in PACU/ICU.
10176471|NCT03832751|Experimental|vitiligo patients|Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
10176472|NCT03832751|Active Comparator|Healthy controls|Tissue levels of human beta-defensin 1 in healthy controls
9680701|NCT04935515|Experimental|Severe|Patients with high grade fever persisting even on the third or fourth day after onset of symptoms or 10 fold or more increase in CRP.
9680702|NCT04935307|Experimental|Patients with multiple chemical sensitivity (MCS)|MCS is characterized by odour intolerance and various somatic symptoms attributed to the influence of toxic environmental chemicals in low usually harmless doses.
10176473|NCT03832699|Experimental|Oral progesterone|
10176474|NCT03832699|Active Comparator|Vaginal progesterone|
10176475|NCT03832725|Active Comparator|High protein (HP) weight loss diet|A weight loss high protein (HP) (30% Kcal protein, 40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
9680703|NCT04935307|Experimental|Patients with multi-systemic functional somatic disorders (FSD)|Based on empirical research, a phenotype of multi-systemic FSD or multi-organ bodily distress syndrome (multi-organ BDS) has been identified in the most severely affected patients who have symptoms from multiple organ systems, thus fulfilling the criteria for multiple FSS. Multi-organ BDS is a research diagnosis, and the terms FSD and BDS are used as synonyms. This diagnosis is defined by an identifiable physical symptom pattern with symptoms from four groups (a cardiopulmonary, a gastrointestinal, a musculoskeletal, and a general symptom group).
9680704|NCT04935307|Experimental|Healthy controls|Healthy participants
9680705|NCT04935567|Experimental|Predicted responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (≥50% seizure reduction).
10187252|NCT03728075|Experimental|Intervention group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
10176476|NCT03832725|Active Comparator|High carbohydrate (HC) weight loss diet|"A weight loss high carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.~Intervention with the HC diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
9680706|NCT04935567|Active Comparator|Predicted non-responders|Patients indicated VNS therapy as their standard for clinical care and are concerned about the prediction of VNS efficacy based on pre-implantation EEG, (<50% seizure reduction).
9680707|NCT04935203|No Intervention|Control message group|Participants will not receive the priming manipulation.
9680708|NCT04935203|Experimental|Health benefits priming group|"Participants will be cueing with health benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have health benefits, such as..."
9680709|NCT04935203|Experimental|Environmental benefits priming group|"Participants will be cueing with environmental benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have environmental benefits, such as..."
9680710|NCT04935203|Experimental|Environmental and health co-benefits priming group|"Participants will be cueing with environmental and health co-benefits by asking to do a word-search exercise beginning with: In the following, please choose words/statements that can indicate that having a healthy and sustainable diet can have both benefits for health and the environment, such as..."
9680711|NCT04935554|Active Comparator|Intervention|"Baseline testing with blood samples, blood pressure and 6 minute walking test. After answering a comprehensive screening tool questionnaire and a conversation with a resource person about What is important to you, the study participant will chose one or several of the following interventions: physical activity, nutrition, motivation, health competence, psychosocial."
9680712|NCT04935554|No Intervention|Control|Baseline testing with blood samples, blood pressure, 6 minute walking test and screening tool questionnaire.
9680713|NCT04935437|Active Comparator|Intervention|The patients in this arm will be enrolled in a 2 months supervised rehabilitation program. Evaluation will take place at recruitment time and at the end of the program (2 months).
9680714|NCT04935437|No Intervention|Control|The patients in this arm will not be enrolled in a supervised rehabilitation program. Evaluation will take place at recruitment and at 2 months.
9680715|NCT04935502|Experimental|Home based exercises with postural and ergonomic training|Home based exercises which consist of stretching, strengthening exercises along with postural and ergonomic training will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education
9680716|NCT04935502|Experimental|Home based exercises|Home based exercises which consist of stretching and strengthening exercises will be given to participants for a period of one month by a physiotherapist for 60 minutes via distance education.
9680717|NCT04935398|Experimental|Manual therapy|Football players with adductor tendinopathy undergoing treatment consisting of manual therapy and therapeutic exercise.
9680718|NCT04935398|Experimental|Electrotherapy|Footballers with adductor tendinopathy undergoing electrotherapy treatment
9680719|NCT04935294|Experimental|Group 1: Matched Control Group Of Healthy Participants|Participants received a single 200-milligram (mg) treatment on Day 1.
9680720|NCT04935294|Experimental|Group 2: Severe RI And Not On Dialysis|Participants received a single 200-mg treatment on Day 1.
9680721|NCT04935541|Active Comparator|Dexmedetomidine infusion|Dexmedetomidine (Precedex, Meditera, USA) was administered at a loading dose of 1 µg/kg for 10 minutes before local anesthesia to be applied to the eye by the surgeon. During the surgical procedure, it was administered at a dose of 0.4 µg/kg/h-1 infusion.
9680722|NCT04935541|Active Comparator|Remifentanil infusion|Remifentanil (Ultiva, Glaxo SmithKline, Turkey) infusion was started at a dose of 0.05 µg/kg/min-1, 10 minutes before the start of the surgery as baseline infusion and continued at the same infusion dose throughout the surgical procedure.
9680723|NCT04935255||Single Arm|The participating patients are treated according to local standard treatment (consisting of etoposide 100mg/m2 and cisplatin 20 mg/m2 during 5 consecutive days). Anti-emetic treatment with aprepitant will be given during days 3 to 7.
9680724|NCT04935190||Group 1|Subjects that have a diagnosis of a cardiac, pulmonary, or cardio-pulmonary condition (e.g., Congestive Heart Failure, COPD, Asthma) will be assigned to Group 1.
9680725|NCT04935190||Group 2|Subjects who are not known to have a cardiac, pulmonary, or cardio-pulmonary condition will be assigned to Group 2.
9680726|NCT04935151|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
9680727|NCT04935151|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
9680728|NCT04935021|Experimental|ATTR-CM|Patients or Gene carrier
9680729|NCT04935034|Experimental|Vitamin D enriched mixed micelles dairy drink|20ug vitamin D in pre-formed mixed micelle dairy drink
9680730|NCT04935034|Active Comparator|Vitamin D enriched olive oil dairy drink|20ug vitamin D in olive oil dairy drink
9680731|NCT04935034|Active Comparator|Vitamin D enriched fish oil dairy drink|20ug vitamin D in fish oil dairy drink
9680732|NCT04935034|Active Comparator|Vitamin D enriched fat-free dairy drink|20ug vitamin D in fat-free dairy drink
9680733|NCT04935086||MACE Group|MACE Group includes the patients suffered from any component of MACE after RA-CABG until the latest follow-up.
9680734|NCT04935086||Non-MACE Group|Non-MACE Group includes the patients freed from any component of MACE after RA-CABG until the latest follow-up.
9680735|NCT04934930|Experimental|Reduced number of bendamustine cycles in patients with mid-induction MRD negativity|Patients with follicular lymphoma treated with obinutuzumab bendamustine & achieving MRD negativity as well as complete metabolic response on PET-CT at mid-induction would continue obinutuzumab treatment while omitting bendamustin after 4 cycles.
9680736|NCT04935099|Experimental|Blueberry/Placebo|In this arm, participants will receive the blueberry intervention first, followed by the placebo one week later.
9680737|NCT04935099|Experimental|Placebo/Blueberry|In this arm, participants will receive the placebo first, followed by the blueberry intervention one week later.
9680738|NCT04934995||Study Population|Adult women undergoing cesarean delivery at The Ohio State University Wexner Medical Center under spinal anesthesia, ASA physical status I-III with a BMI during pregnancy ≥ 35 kg/m2 and singleton pregnancy.
9680739|NCT04935073|Experimental|Traditional Chinese Medicine herbs treatment group|the treatment group will receive treatment with the Chinese herbal formula on the 5th day of the menstrual cycle and lasts to 14 days after IVF-ET.
9680740|NCT04935073|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
9680741|NCT04935125|Active Comparator|Standard Program|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks.
9680742|NCT04935125|Experimental|Strength training|twelve 30-minute daily sessions of supervised incremental exercise training over a period of 3 weeks twelve 30-minute daily sessions of supervised peripheral limb muscle training, 2 set of 6-12 repetitions
9680743|NCT04934826|Experimental|Hydrolized proteins|Group receiving hydrolyzed proteins in the postprandial metabolic test
9680744|NCT04934826|Active Comparator|Intact proteins|Group receiving intact proteins in the postprandial metabolic test
9680745|NCT04934683|Active Comparator|Routine Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
9680746|NCT04934683|Active Comparator|Routine Pressure Management with propofol induction|Propofol will be used as an induction agent.
9680747|NCT04934683|Active Comparator|Tight Pressure Management with etomidate induction|Etomidate will be used as an induction agent.
9680748|NCT04934683|Active Comparator|Tight Pressure Management with propofol induction|Propofol will be used as an induction agent.
9680749|NCT04935164||Male patients with gender dysphoria|"male patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~patients without psychotropic treatments~patients who do not benefit of hormone therapy~patients who have not yet received gender reassignment surgery~patients aged 18 to 60 years~patients with normal or corrected vision~patients without mental defect~patients without neurological impairment"
10176477|NCT03832491|Other|Control Group|"Home Based Therapy: 16 patients with PCD~Airway clearence techniques, everday of the week, during eight weeks"
10176478|NCT03832491|Experimental|Game and home based therapy group|"Game based approach programme: 16 patients with PCD~Game based approach programme will be done using the exergame with the game console, fourty minutes three times per week for eight weeks.~Exergame includes five games selected from two kinects games CD. Each game will be played for five games set.~Airway clearence techniques, everday of the week, during eight weeks"
9680750|NCT04935164||Female patients with gender dysphoria|"female patients with gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~patients without psychotropic treatments~patients who do not benefit of hormone therapy~patients who have not yet received gender reassignment surgery~patients aged 18 to 60 years~patients with normal or corrected vision~patients without mental defect~patients without neurological impairment"
9680751|NCT04935164||Male volunteers without gender dysphoria|"male volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~volunteer aged 18 to 60 years~volunteer with normal or corrected vision~volunteer without mental defect~volunteer without neurological impairment"
9680752|NCT04935164||Female volunteers without gender dysphoria|"female volunteer without gender dysphoria according to DSM-V criteria (axis I), confirmed by MINI evaluation~volunteer aged 18 to 60 years~volunteer with normal or corrected vision~volunteer without mental defect~volunteer without neurological impairment"
10176479|NCT03832478|Experimental|Virtual Reality Headset Given|Virtual Reality headset (Samsung Gear VR) with mindfulness meditation app is given for patient use prior to surgery date and for duration of postoperative stay.
9680753|NCT04934709|Experimental|PBMT-sMF|Volunteers underwent intervention (active PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
9680754|NCT04934709|Placebo Comparator|Placebo|Volunteers underwent intervention (placebo PBMT-sMF) in the non-dominant lower limb. A single application was performed at each phase of the trial, between the first and second set of the exercise protocol.
10176480|NCT03832465|Experimental|Intraluminal Levofloxacin powder therapy|Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
10176481|NCT03832465|Active Comparator|Intraluminal Levofloxacin solution therapy|Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
10176482|NCT03832517|Active Comparator|Single intravenous doses of RC-01|Single escalating doses of RC-01 from 200 mg to 1600 mg
10176483|NCT03832517|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match RC-01
10176484|NCT03832517|Active Comparator|Multiple intravenous doses of RC-01|Two or three times daily escalating intravenous doses of RC-01 for 10 days. Doses to be determined
10176485|NCT03832517|Placebo Comparator|Multiple intravenous doses of placebo|Two or three times daily intravenous doses of placebo to match RC-01
10176486|NCT03832348|Experimental|PET scan imaging|PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
10176487|NCT03832335||Phakic group|21 eyehealthy individuals examined for baseline stereopsis and impact of aniseikonia on stereopsis. An non-invasive measurement.
10176488|NCT03832335||Cataract group|11 patients awaiting cataract surgery on both eyes. Measurement of baseline stereopsis and impact of artificial induced aniseikonia on stereopsis. A non invasive measurement that are repeated after dilatation of the eyes and again six weeks after surgery.
10176489|NCT03832088|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated for sarcopenia and balance disorders
10176490|NCT03832231|Experimental|Ventilator liberating trial|The diaphragmatic function of patients undergoing a ventilator liberating trial will be determined with transient shear wave elastography.
10176491|NCT03832244||Simple snoring|Patients undergoing to Sub-mental ultrasonography with Normal sleep: Fewer than 5 events per hour measured in over-night polysomnography
10176492|NCT03832244||Mild OSA|Patients undergoing to Sub-mental ultrasonography with Mild sleep apnea: 5 to 14 events per hour measured in over-night polysomnography
9680755|NCT04934644|Experimental|Hyperbaric oxygen treatment|30 HBO treatments and standard care. If surgery is needed an additional 10 HBO treatments postoperative.
9680756|NCT04934644|No Intervention|Control|Standard care. Surgery if needed.
9680757|NCT04934917||Patients with disc degenerative disease (DDD)|Patients suffering from disc degenerative disease, age 30-60 years that are on the waiting list for surgery (fusion/disc implants) at Stockholm Spine Center, Stockholm, Sweden.
9680758|NCT04934917||Healthy controls (HC)|Healthy controls matched according to age and sex, no chronic pain conditions.
9680759|NCT04934839|Experimental|Patients with osseointegrated prostheses|Patients with an osseointegrated prosthesis following a lower limb amputation
9680760|NCT04934839|Experimental|Patients with socket prostheses|Patients with a socket-mounted prosthesis following a lower limb amputation
9680761|NCT04934774|Experimental|anti-CD7 CAR T cells|anti-CD7 CAR T cells Dose escalation phase: anti-CD7 CAR T cells transduced with a lentiviral vector to express CD7 chimeric receptor domain on T cells with an escalation approach, 1 e6 to 5 e6 CAR-T cells/kg.
9680762|NCT04934735|Active Comparator|The intervention group: received a complex case-management rehabilitation program|The intervention group was followed at 6, 12, 18, 24 months after entering the study. The follow-up was conducted by the case manager for patients in the intervention group, and by a research assistant for patients in the control group. Medical data were retrieved from the computerized medical records in the relevant hospitals.
9680763|NCT04934735|No Intervention|The control: group received the standard care|The control group received regular care.
9680764|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with collagen sponge.|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with collagen sponge (CS).
9680765|NCT04934813|Experimental|Alveolar ridge preservation with particulated allograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Freeze-dried bone allograft (FDBA) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
9680766|NCT04934813|Experimental|Alveolar ridge preservation with particulated xenograft covered with autogenous soft tissue punch|Alveolar ridge preservation after tooth extraction. Demineralized bovine bone mineral xenograft (DBBM) was applied in the socket immediatelly after tooth extraction and it was covered with free gingival graft (FGG).
9680767|NCT04934813|Experimental|Alveolar ridge preservation without bone grafting covered with socket sealing mean|Alveolar ridge preservation after tooth extraction. No bone graft was applied and the socket was covered with free gingival graft (FGG).
9680768|NCT04934878||Referral information|first visit to our hospital/transfer from another hospital
9680769|NCT04934865|Other|Patients treated for their lung cancer and Moovcare® Lung follow-up.|
9680770|NCT04934761|Experimental|capacity shock|2ml/kg succinylateol gelatin
9680771|NCT04934761|Other|routine management|conventional strategy
9680772|NCT04934787|Experimental|ENMS-BSF assisted gait training|The participants will receive the full assistance of the ENMS-BSF during a 20-session gait rehabilitation.
10176493|NCT03832244||Moderate OSA|Patients undergoing to Sub-mental ultrasonography with Moderate sleep apnea: 15 to 29 events per hour measured in over-night polysomnography
9680773|NCT04934787|Active Comparator|Partial ENMS-BSF assisted gait training|The participants will receive a partial assistance of the ENMS-BSF during a 20-session gait rehabilitation.
9680774|NCT04934787|Sham Comparator|Sham ENMS-BSF assisted gait training|The participants will only wear the device without assistance during a 20-session gait rehabilitation.
9680775|NCT04934423|Experimental|active tDCS|tDCS active, for 30 minutes for 5 consecutive days, with an anode positioned in the left dorsolateral prefrontal cortex and cathode electrode placed over the right supraorbital area. The EEG International 10-20 system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (MRI) to estimate and individualize a dose to be administered.
9680776|NCT04934423|Sham Comparator|Sham tDCS|The electrodes will be positioned in the same way as in the intervention group. However, individuals in this group will receive a stimulation that will last only 20-30 seconds. Subsequently, the device is switched off, no longer emitting current.
9680777|NCT04934579|Experimental|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
9680778|NCT04934852|Experimental|ephedrine (4mg)|
9680779|NCT04934852|Experimental|ephedrine (8mg)|
9680780|NCT04934852|Experimental|ephedrine (12mg)|
9680781|NCT04934566|Experimental|patients|patients receiving temporary veno-arterial assistance whose weaning, or transfer to a heart transplant, or to long-term assistance or discontinuation is envisaged.
9680782|NCT04934436|Experimental|Intervention Group|According to their chronotype, the intervention group will then be given sleeping glasses and earplugs at night for those who are in the morning type, and till afternoon during the day for those who are in the evening type. Moreover, patients in the intervention group will be given 5000 Lux daylight during the time they are awake depending on their circadian rhythms. An Android smartwatch will be used to determine patients' sleeping and waking up times, sleep quality and sleep depth. Nursing care will also be provided when patients are awake per their chronotype. Before the study, intensive care nurses will be trained to provide appropriate care according to the circadian rhythm and chronotype to have consistency in the care. Patients will be observed for three days and during this time cortisone and melatonin levels will be checked in both control and intervention groups. At the end of the third day, surveys will be conducted once again with both groups.
9680783|NCT04934436|No Intervention|Control Group|All surveys that will be used in the study will be applied to both groups during the first and last interviews. The control group will not have any interventions, only the standard ICU care to be provided.
9680784|NCT04934618|Experimental|Carelizumab Combined With Irinotecan and Apatinib|Second-line treatment of advanced gastric cancer with three-drug regimen（Carelizumab Combined With Irinotecan and Apatinib ）
9680785|NCT04934631||CBT-ED trainees and therapists.|Qualified clinicians delivering CBT-ED throughout a variety of treatment settings, working with adult eating disorder patients. Clinicians will audio-record CBT-ED therapy sessions with their eating disorder patients.
9680786|NCT04934631||Eating Disorder patients.|Adult (18+ years) eating disorder patients currently accessing CBT-ED from one of the CBT-ED therapists/trainees stated above. Patients will have one of their therapy sessions audio-recorded.
9680787|NCT04934631||Raters/Judges.|Either experts or non-experts in the field of CBT-ED. Raters will use the CBTS-ED to assess clinician competence when listening to the therapy session audio-recordings.
9680788|NCT04934501||PAD patients|The entire cohort exists of patients recently treated with an endovascular stent placement in the superficial femoral artery (SFA).
10176494|NCT03832244||Severe OSA|Patients undergoing to Sub-mental ultrasonography with Severe sleep apnea: 30 or more events per hour measured in over-night polysomnography
10176495|NCT03832361|Experimental|IMGN853|IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
10176496|NCT03832114|Experimental|Cohort A - no kidney transplant|C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
10176497|NCT03832114|Experimental|Cohort B - kidney transplant|C3G patients who have received a kidney transplant and have C3G recurrence.
10176498|NCT03832452|Experimental|Part A: Treatment 1|A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
10176499|NCT03832452|Placebo Comparator|Part A: Treatment 2|A single oral dose of placebo on Day 1 and 3
10176500|NCT03832452|Active Comparator|Part B: Treatment A|A single oral dose of 400 mg moxifloxacin
10176501|NCT03832452|Experimental|Part B: Treatment B|A single oral dose of 1000 mg lucerastat
10176502|NCT03832452|Experimental|Part B: Treatment C|A single oral dose of 4000 mg lucerastat
10176503|NCT03832452|Placebo Comparator|Part B: Treatment D|A single oral dose of placebo
9680789|NCT04934371|Active Comparator|active TDCS and listening therapy|TDCS will be administered with NeurConn1 Channel DC-Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes at 2mA with a 15-s ramp-up and ramp-down period. Excitatory/anodal tDCS or sham will be administered alongside active listening therapy 5 times a week for 2 weeks.
9680790|NCT04934371|Sham Comparator|sham TDCS and listening therapy|The sham stimulation will also last for 20 min with 15 sec ramp-up and ramp-down, except the current will be turned down gradually to 0 milliamperes (mA) after 30 seconds. The sham procedure provides the same tingling and itching sensation felt during active tDCS. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
9680791|NCT04934488|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1). The experimental group will also receive care as usual from their healthcare providers.
9680792|NCT04934488|Other|Waitlist Control|The waitlist control group will receive care from usual healthcare providers and will receive the intervention at the conclusion of the study period (T2, 12 weeks after enrollment).
9680793|NCT04934514|Experimental|Ia stage-Dose escalation|"Using the 3+3 model, 1 subject was included in the 6 mg/kg dose group, and then 3 to 6 patients with HER2-positive advanced solid tumors that failed standard treatment were included in the fixed 3 dose groups (10 mg/kg, 15 mg/kg, and 20 mg/kg) ."
9680794|NCT04934514|Experimental|Ib stage-Dose extension|In the three fixed dose groups (10 mg/kg, 15 mg/kg and 20 mg/kg), when a certain dose group meets the condition of increasing the dose to the higher dose (after the DLT observation period for the last subject in the dose group), the second phase of the dose expansion study for this dose group can be carried out. Each dose group includes 6 patients with HER2-positive advanced solid tumors who have failed the standard treatment, and the interval between enrollment is determined by the investigator.
9680795|NCT04934514|Experimental|IIa stage-Single-agent study (cohort 1)|After the completion of the dose escalation in the 20 mg/kg dose group (Phase Ia), a total of 30 patients with HER2-positive advanced biliary system tumors who have failed standard treatment will be enrolled in the 20 mg/kg dose group. Every 3 weeks is a cycle, and the drug is administered once on the first day of each cycle, and the treatment is continued until any end-point event occurs.
9680796|NCT04934514|Experimental|IIa stage - IAH0968 combined GP regimen study (cohort 2)|After the completion of the dose escalation in the 20 mg/kg dose group (phase Ia), a total of 30 patients with newly treated HER2-positive advanced biliary system tumors will be enrolled in the 20 mg/kg dose group combined with the GP regimen (gemcitabine + cisplatin) . Every 3 weeks is a cycle, treatment until any end-point event occurs.
9680797|NCT04934384||Positive prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
9680798|NCT04934384||Negative or not performed prehospital eFAST|Patients with a positive prehospital eFAST, independently from their hemodynamic status or other vital signs
9680799|NCT04934176||Group 1|Group 1 will have had a muscle transfer driven by the trigeminal nerve (nV).
9680800|NCT04934176||Group 2|Group 2 will have had a muscle transfer driven by a cross-face nerve graft (nVII).
10176504|NCT03832400|Experimental|MET-2 20 g|Subjects will be given a once-daily loading dose of 5 grams (g) of MET-2 in the form of 10 MET-2 capsules orally for the first 4 days. For the following 10 days, patients will take 1.5 g MET-2 in the form of three MET-2 capsules taken once-daily
10176505|NCT03832400|Experimental|MET-2 40 g|Subjects will be given a once-daily loading dose of 10 g of MET-2 in the form of 20 MET-2 capsules orally for the first 4 days. For the following 10 days, subjects will take 1.5 g MET-2 in the form of three MET-2 capsules taken once daily
10176506|NCT03832400|Placebo Comparator|Placebo oral capsule|Subjects receive 10 placebo capsules that are identical in appearance to the MET-2 capsules
10176507|NCT03832075|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated with Berg Balance Scale, Timed Up and Go test and Korebalance balance system for balance disorder.
10176508|NCT03832218|Other|Mitochondrial disease|Psychiatric assessment
10187253|NCT03728062|Experimental|Mindfulness meditation during lunch break|"Participants performed mindfulness meditation during lunch break at work place for a month, beginning with 15 minutes and ending with 30 minutes. They had available a quiet room and mp3 audios with guided meditations based on the MBSR program."
9680801|NCT04934176||Group 3|Group 3 will have had a muscle transfer driven by dual innervation using both the trigeminal and cross-face nerve graft.
10176509|NCT03832283|Other|Usual Care Depression Screening|Patients randomized to this intervention arm will receive usual care annual depression screening when they come in for a clinic visit and are due for screening. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression screening. The CAD-MDD/CAT-DI screening during clinic visit will occur in a patient room, prior to their appointment with a primary care provider.
10176510|NCT03832283|Experimental|Population MyChart Depression Screening|Patients randomized to this intervention arm will continue to receive usual care annual depression screening when they come in for a clinic visit and are due for screening. In addition, they will receive email invitations to complete the CAD-MDD/CAT-DI screening via MyChart. Email invitations will be sent at preset intervals until depression screening is completed, or the end of the 1-year follow-up period, whichever comes first.
9680802|NCT04934176||Group 4|Group 4 will have had manipulations that involve performing direct coaptation between the trigeminal nerve and a branch to the native zygomaticus major muscle (5-7 transfer) and selective neurolysis in which several facial nerve branches that innervate muscles antagonistic to the smile animation.
9695486|NCT04777682|Other|single arm|A single-arm, open, single-center (hospital-based) prospective interventional study to compare intestinal ultrasound versus double balloon enteroscopy in diagnosis of malabsorption syndrome
9695487|NCT04777864|No Intervention|Usual Care|
9695488|NCT04777864|Experimental|Decision Aid|Usual care, plus introduction of a decision aid
9695489|NCT04777695||CICU Inpatients|This is a prospective observational study of all children admitted to the pediatric CICU during a one month period of time for patients aged 0 to less than or equal to 22 years of age, as per the World Health Organization definition of a pediatric patient.
9695490|NCT04778345|Experimental|18F-FDG PET/CT and 68Ga-FAPI PET/CT scan after abdominal enhanced CT|After the patient received abdominal enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT were further performed. The interval between 18F-FDG PET/CT and 68Ga-FAPI PET/CT was 2 days to 1 week.
9695491|NCT04778254|Active Comparator|conventional obturator|conventional group received conventional clasp-retained obturators with metallic framework (Control group).
9695492|NCT04778254|Experimental|metallic attachment retained obturator|metal group received an attachment-retained obturator with metallic framework
9695493|NCT04778254|Experimental|PEEk attachment retained obturator|PEEK group received attachment-retained obturators with milled PEEK framework,
9695494|NCT04777773|Other|control group|classical physical therapy+ classical physical therapy
9695495|NCT04777773|Other|study group|classical physical therapy+ dual-task training
9695496|NCT04777383|Experimental|Vascular effects of iontophoresed vasoactive substances|"Iontophoretically administered vasoactive substances in five concentrations (1%,0.1%,0.01%,0.001%, 0.0001%) dissolved in sterile water. Each concentration of the drug is separately administered using a electrical charge of 12 millicoulomb (mC) (600 seconds x 0.02 milliampere) for 3 repeated pulses (total electrical charge 36 mC). Each iontophoresis pulse is separated by a 30 minute wash-out period.~Vasoactive substances:~Miochol-E (Acetylcholine),10 mg/ml, Bausch & Lomb~Methacholine chloride, 100 mg/ml, APL~Norepinephrine, 1 mg/ml, Pfizer~Phenylephrine, 10 mg/ml, Unimedic~Atropine, 10 mg/ml, Bausch & Lomb~Neostigmine, 2.5 mg/ml, Unimedic Pharma~Sterile water, 100 ml, Braun"
9695497|NCT04777344|Experimental|Intervention group|The intervention group will receive the multi-component intervention (counseling with intake assessment, follow-up, help obtaining nicotine replacement therapy, and CF-specific smoke exposure education)
9695498|NCT04777344|No Intervention|Control group|The control group will receive usual care plus CF-specific smoke exposure education.
9695499|NCT04777578|Experimental|DN|
9695500|NCT04777578|No Intervention|Control|
9695501|NCT04777526|Active Comparator|Control group|"Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active~- resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle."
9695502|NCT04777526|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
9695503|NCT04777604||Patients with resectable pancreatic cancer after neoadjuvant chemotherapy|
9695504|NCT04777838|Active Comparator|Citalopram|Citalopram 10mg
9695505|NCT04777838|Active Comparator|Amitriptyline|Amitritptyline 25 mg
9695506|NCT04777838|Active Comparator|Bite Splint|Michigan Splint, nocturnal use
9695507|NCT04777552||Fixed-schedule|Untill mid 2013 patients with individually determined fixed-schedule dosage of benzodiazepines in the case of alcoholdependence.
9695508|NCT04777552||CIWA-Ar|Halfway through the year 2013 the department of psychiatry changed the protocol in alcohol withdrawal treatment and changed it to a symptom-triggered therapy with the use of CIWA-Ar to assess the severity of the alcohol withdrawal syndrome.
9695509|NCT04777669|Experimental|Experiment|Subjects will be tested for their ability to understand speech with and without noise reduction
9695510|NCT04777487|Experimental|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and GCF obtained.
9695511|NCT04777487|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
9695512|NCT04777487|Experimental|Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
9695513|NCT04778085||IMR patients|Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
9695514|NCT04778085||IMR therapists and other staff|Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
9695515|NCT04777500|Experimental|taVNS Group1|This group will receive taVNS for 4 weeks.
9695516|NCT04777500|Experimental|taVNS Group 2|This group will receive taVNS for 4 weeks.
9695517|NCT04777318|Experimental|Conventional physiotherapy|The individuals in the control group will be included in a total of 12 sessions of conventional physiotherapy program for 4 weeks, 3 days a week.
9680803|NCT04934059|Experimental|Yuxuebi tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
9680804|NCT04934059|Placebo Comparator|Placebo tablet|take 5 tablets once, 3 times a day, for 42（±3）days.
9680805|NCT04934085||Study group|subjects who had tested positive and recovered from COVID-19
9680806|NCT04934085||Control group|healthy subjects who did not have COVID-19, the controls will be matched to the study group for gender and age
9680807|NCT04934163|Experimental|60 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 60 L/min after extubation.
9680808|NCT04934163|Experimental|40 L/min arm|The flow rate of HFNC(high-flow nasal cannula) is set as 40 L/min after extubation.
9680809|NCT04934748|Active Comparator|Tight Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
9680810|NCT04934748|Active Comparator|Tight Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
9680811|NCT04934748|Active Comparator|Routine Pressure Management with phenylephrine|Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial
9680812|NCT04934748|Active Comparator|Routine Pressure Management with norepinephrine|Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
10176511|NCT03832283|Other|Usual Care Depression Monitoring|Patients who have depression and are randomized to this intervention arm will receive usual care PHQ-9 monitoring during clinic visits. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression assessment.
9680813|NCT04934397|Experimental|Study Infant Formula|Feed ad libitum during study period
9680814|NCT04934306||Patients without cleft|Patients without developmental speech disorder (including articulation disorder) or hearing impairment
9680815|NCT04934306||Patients with a cleft|Patients with a hard and/or soft palate cleft and for whom the perceptual speech-language pathology evaluation revealed a velopharyngeal insufficiency
9680816|NCT04934319|Experimental|Balance training|A single training group
9680817|NCT04934228|Placebo Comparator|Placebo|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of placebo to the research coordinator to give to the research participant.~The placebo is an inert substance with no intended medical value and is used as a negative control for comparison with the study drug.~Participants will receive a Placebo Pill; has no active ingredients but is made to look like the study drug."
9680818|NCT04934228|Experimental|Clonidine|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of clonidine to the research coordinator to give to the research participant.~Planned use in this study~Condition/disease indication(s): Vascular function and blood flow~Subject population: Hypertension~Dose(s): 0.1 mg (oral)~Administration: Oral~Dosing regimen: 0.1 mg twice daily by mouth"
9680819|NCT04934228|Experimental|Hydrochlorothiazide (HCTZ)|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of Hydrochlorothiazide to the research coordinator to give to the research participant.~Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Hypertension~Dose(s): 25 mg/day~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
9680820|NCT04934202||Patients from the 1st epidemic wave|"One year after their discharge from the initial hospitalization, patients who presented symptoms during the evaluation in COMEBAC 1st wave in summer 2020 will benefit from a telephone assessment on the same schedule as that detailed above. If symptoms persist, they will be called to the day hospital for an assessment similar to the one detailed above."
9680821|NCT04934202||Patients from the 2nd epidemic wave|"As during the evaluation carried out during the 1st wave, the detection of persistent symptoms will be done in two stages:~During a teleconsultation, to which all eligible patients will be invited, systematically looking for general, neurological, cognitive and respiratory symptoms~During a hospitalization in an outpatient clinic to which all survivors who have stayed in an intensive care unit (ICU) will be invited and, among patients who have not stayed in an ICU, those who have residual symptoms detected during the teleconsultation."
9680822|NCT04934345||FC administration|"All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice.~After the first episode of hypotension (MAP < 65 mmHg) the PPV is checked.~PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10')~PPV < 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion."
9680823|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A|"Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12) 6 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12)~Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12)~Lenalidomide: 25 mg per day orally from days 1 to 21~Dexamethasone: 40 mg orally on day 1, 8, 15, 22"
9680824|NCT04934475|Experimental|MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B|"Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2) 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8)~Lenalidomide: 25 mg per day orally from days 1 to 21~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
9680825|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C|"Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8) Melphalan 200 mg/m2 followed by autologous stem cell transplantation. 2 cycles of Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isa-KRD) (28-day cycle):~Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8)~Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8)~Lenalidomide: 25 mg per day orally from day 1 to day 21~Dexamethasone: 40 mg orally on days 1, 8, 15, 22"
9680826|NCT04934475|Experimental|MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D|tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.
9680827|NCT04934280|Other|2D transvaginal ultrasonography|
9680828|NCT04934150|Active Comparator|M1 stimulation|10 Hz stimulation of left motor area
9680829|NCT04934150|Active Comparator|DLPFC stimulation|5 Hz stimulation of left dorsolateral prefrontal cortex
9680830|NCT04934150|Sham Comparator|Sham TMS|Sham TMS over the left M1 area
9680831|NCT04934241|Experimental|Self-Acupressure|Self-Acupressure Each application to the acupressure points (HT 7, CV17,PC 6, LI4,SP 6) will be done in 2 minutes and right and left)
9680832|NCT04934241|No Intervention|Control group|Routine maintenance will be applied
9680833|NCT04934098|Experimental|Adjustable compression wrap|Daily use of the Adjustable Compression Wrap on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
9680834|NCT04934098|Active Comparator|Compression Bandage|Daily use of compression bandage on the upper limb with breast cancer-related lymphedema during phase 1 compression therapy.
9680835|NCT04933825|Experimental|"Four escalating dose-levels of ET-02 will be evaluated using a 3+3 design."|
9680836|NCT04933877|Active Comparator|Serratus Anterior Plan block|The SAPB was performed in the operative room (OR) after anesthesia induction using the same ultrasound machine (SonoSite) and linear ultrasound transducer 8- 12 Hz. The patient was positioned in a lateral position with the operative side up and arm flexed forward; then, a linear ultrasound transducer was placed in a sagittal plane over the mid-clavicular line of the thoracic cage. Then, moving inferior-lateral direction till the fifth rib was identified in the mid-axillary line. The following structures were recognized: the rib, pleura, teres major muscle (superior), latissimus dorsi muscle (superficial and posterior), and serratus muscles muscle (deep and inferior). Under complete sterile conditions, a 22-gauge echogenic needle was introduced in-plane with respect to the ultrasound probe targeting the plane deep to the serratus anterior muscle. Then, 0.4 ml/kg of 0.25% bupivacaine was injected with continuous ultrasound guidance.
10176512|NCT03832283|Experimental|Population MyChart Depression Monitoring|Patients who have depression and are randomized to this intervention arm will continue to receive usual care depression monitoring when they come for clinic visits. In addition, they will receive email invitations at preset intervals to complete the CAT-DI monitoring via MyChart. Invitations will be sent until major depressive disorder (MDD) remission is achieved, or the 1-year follow-up period ends, whichever comes first.
10176513|NCT03832270|Experimental|Parents InC|Group parenting support intervention based around four pillars: 1) empowerment/ownership; 2) education on ADHD and its effect on family identity/ values; 3) positive parenting in the context of ADHD; 4) making sense of ADHD in a developmental context. It is delivered over 5 weekly 2-hour sessions, a 6 week break, and a follow-up session.
9680837|NCT04933877|Active Comparator|Erector spinae plane block|Patients in Group ESPB receive US erector spinae plane block by injecting 0.4ml/kg (bupivacaine 0.25%). Under strict aseptic precautions, The T3 spinous process is located by palpating and counting down from the C7 spinous process. A high-frequency 12 MHz linear ultrasound transducer is placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Using an in-plane approach a 22 G needle is inserted in caudal-cephalad direction until the tip is deep to erector spinae muscle. Correct needle tip location is confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, bupivacaine is injected, and visualizing the fascial plane.
9680838|NCT04934046|Experimental|DaTSCAN brain scan images from the new CZT SPECT system|All patients will undergo additional SPECT acquisition (30min added time approximately), with no added radiation, with both new multipurpose CZT camera (StarGuide system, GE Healthcare, Haïfa, Israel) and conventional SPECT camera (Discovery 670, GE Healthcare, Haïfa, Israel)
9680839|NCT04933786|Experimental|Digital Health Nudging|During 12-week intervention period participants receive daily text messages via WhatsApp on their smartphone to encourage them to be physically active in their daily lives.
9680840|NCT04933786|No Intervention|Control|During 12-week control period participants receive no text messages.
9680841|NCT04933838|Placebo Comparator|Control Group|1% licocaine 3 mL + Normal saline 3 mL mixture
9680842|NCT04933838|Experimental|Atelocollagen group|1% lidocaine 3 mL + atelocollagen 3 mL mixture
9680843|NCT04933916|Experimental|EMB-001 Active|720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam
9680844|NCT04933994||Coronavirus disease; Influenza A(H1N1)|two independent cohorts of COVID-19 pneumonia (n=405) and H1N1 influenza pneumonia (n=78) retrospectively, all patients were confirmed by RT-PCR. Four hundred and five cases of COVID-19 pneumonia were confirmed in nine hospitals of Zhejiang province, China from January 21 to February 20, 2020. Seventy-eight cases of H1N1 influenza pneumonia were confirmed in our hospital from January 1, 2017 to February 29, 2020.
9680845|NCT04933981||interventional nursing home (INH).|regular, twice to three times weekly, and voluntary, i.e. non-mandatory, on-site testing for SARS-CoV-2 of HCW and visitors (INH)
9680846|NCT04933981||control nursing home (CNH)|routine setting without frequent regular testing for SARS-CoV-2 (control nursing homes; CNH). Testing only performed by local health authorities upon medical indication, i.e. non-surveillance testing
9680847|NCT04933604||LPN group|39 patients with high complexity renal tumors who underwent laparoscopic partial nephrectomy
9680848|NCT04933604||LRN group|39 patients with high complexity renal tumors who underwent laparoscopic radical nephrectomy
9695518|NCT04777318|Experimental|Muscle Energy Technique (MET)|In addition to the conventional physiotherapy program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the second group.
9695519|NCT04777318|Experimental|Cervical Mobilization Techniques (CMT)|In the third group, cervical mobilization techniques will be applied in addition to the conventional physiotherapy program for a total of 12 sessions for 4 weeks, 3 days a month.
9680849|NCT04933799|Active Comparator|PF-06650833 + Standard of Care treatment|Subjects randomized to the PF-06650833 arm of the study will receive 400 mg PF-06650833 (2 x 200 mg tablets) of the MR formulation orally QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). Subjects who cannot take tablets PO will receive PF-06650833 200 mg IR suspension formulation every 6 hours (NG tube or OG tube, or equivalent). Subjects for whom concomitant administration of a strong inhibitor of CYP3A4 (eg, ritonavir) will have the dose reduced to either 200 mg MR or IR QD. All dosing of study drug will be in addition to current hospital SOC treatment that must include treatment targeting SARS-CoV-2.
9680850|NCT04933799|Placebo Comparator|Placebo + Standard of Care treatment|Placebo will match the Active comparator in dosage form, dosage, frequency and duration.
9680851|NCT04933929|Experimental|"Coronavirus disease Positive group Covid (+)"|Positive PCR test.
9680852|NCT04933929|Active Comparator|"Coronavirus disease Negative group Covid (-)"|Negative PCR test.
9680853|NCT04933812|Other|Group Social Support Meetings and Facebook Group|Facebook group where community doulas will be providing information on various pregnancy and support topics in addition to 8 possible group Zoom meetings that will include pregnancy-related/reflection topics.
9680854|NCT04933578||Children|"The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children.~The children's preferences for the appearance of dentists were determined in the second part.~Routine dental examinations of children with a dental mirror and artificial light were completed by an experienced pediatric dentist according to the World Health Organization (WHO) guidelines and criteria."
9680855|NCT04933578||Parents|"The questionnaire including demographic information (age, sex, and medical and dental history) was applied to the parents.~In the second section, the MDAS was administered to parents, differently from children.~The parents' preferences for the appearance of dentists were determined in the second part."
9680856|NCT04933864|Experimental|Methylene Blue and Photodynamic Therapy|Methylene Blue 1 mg/kg water solution. Participants have orally received Methylene Blue solution of 1 mg/kg concentration one time in addition to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm^2 energy dose was performed.
10176514|NCT03832270|Active Comparator|Incredible Years|A group parenting support intervention aimed at strengthening parent-child interactions and attachment, reducing harsh discipline and fostering parents' ability to promote children's social, emotional, and academic development. The IY programme is delivered over 14 weekly 2-hour sessions. IY facilitators are videotaped during sessions to maintain intervention fidelity. IY also includes 1-4 pre-intervention preparation sessions which may involve home visits and telephone support and reminders.
9680857|NCT04933864|No Intervention|Control group|COVID-19 positive participants treated with standard medical supportive therapy (e.g. azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.).
9680858|NCT04933643||well prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that the stomach is well prepared when GCS ≥ 18
9680859|NCT04933643||inadequate prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that GCS < 18 is inadequate.
9680860|NCT04933409|Experimental|3D printed replica of Donor tooth|3D printed replica of Donor tooth
10176515|NCT03832023|No Intervention|Facility-based model|Standard of care of each country
10176516|NCT03832023|Experimental|Community-based model|Screening and initiating preventive therapy in communities
10176517|NCT03832166|Experimental|Fruits and Vegetables Only|This group will receive a prescribed amount of free fruits and vegetables (F & V) for 6 weeks through pick-up at a farm stand, or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 18 weeks with minimal contact
10176518|NCT03832166|Experimental|Fruits and Vegetables and Cook|"In addition to the prescribed amount of free F&V, participants will receive 6 weekly, group nutrition and cooking education classes based on The Happy Kitchen curriculum. Participants will also receive free ingredients to complete the recipe from each weekly session at home."
10176519|NCT03832101|Experimental|Difficult face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
10176520|NCT03832101|Experimental|Easy face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Easy group will discriminate between dissimilar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
10176521|NCT03832101|Active Comparator|Control|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Control group will perform a simple face-matching exercise. This training will last for approximately 30 minutes. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
10176522|NCT03832205||Capaciflector monitoring group|Patients undergoing their pre-planned, routine cardiopulmonary exercise test (CPET). Additional, non-invasive capaciflector monitoring only - no therapeutic intervention.
10176523|NCT03832296|Experimental|Weight-Loss Maintenance|Weight Loss Maintenance Intervention
9680861|NCT04933409|Active Comparator|Conventional|Conventional method of autotransplantation.
9680862|NCT04933422|Experimental|CM93 pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), pre-treatment with CM93 prior to surgical resection of recurrent glioblastoma
9680863|NCT04933422|No Intervention|No pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), no pre-treatment prior to surgical resection of recurrent glioblastoma
10176524|NCT03832296|Active Comparator|Health Education (Attention Control)|Health Education Intervention
10176525|NCT03832426|Experimental|Narlaprevir single - Healthy|2 tablets of 100 mg Narlaprevir once a day
9680864|NCT04933461|Other|Simulation of skin pricking by using Medlance Plus|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
9680865|NCT04933461|Other|Simulation of skin pricking by using myLance|Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.
9680866|NCT04933500||Conventional epidural|epidural needle: Tuhoy needle 1.3mm (18 G) with 20G multi-orifice epidural catheter
9680867|NCT04933500||Dural puncture epidural|epidural needle;Tuhoy needle 1.3mm (18G)with 20G multi-orifice epidural catheter and 25G Whitacre spinal needle
9680868|NCT04933487|Experimental|Ankoris IOL Implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris
9977616|NCT01363531|Experimental|Delayed antibiotic prescription 1|The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.
10176526|NCT03832426|Experimental|Narlaprevir single - Hepatic Impairment|2 tablets of 100 mg Narlaprevir once a day
9680871|NCT04933357|Experimental|Dose escalation|
9680872|NCT04933357|Active Comparator|Standard dose|
9680873|NCT04933955|Active Comparator|biodentine|pulptomy with biodentine
9680874|NCT04933955|Active Comparator|Theracal PT|pulpotomy with Theracal PT
9680875|NCT04933955|Active Comparator|Neo Putty|pulpotomy with Neo putty
9680876|NCT04933201|Experimental|Music group|Perioperative music intervention
9680877|NCT04933201|Active Comparator|Control group|No perioperative music
9680878|NCT04933097|Experimental|Sarcopenia|Only one arm with the sarcopenia assessment.
9680879|NCT04933175|Experimental|fluzopali combined with anlotinib|Patients 18 years of age or older, 75 years of age or younger with histologically proven small cell carcinoma of the lung were assessed by radiography as having an extensive stage (according to the American Veteran Lung Cancer Association). Patients received first-line two-drug chemotherapy with standard cisplatin, carboplatin, or lobaplatin, combined with or without immunotherapy, and developed radiologically evaluated disease progression during treatment or within 6 months of completion of treatment.
9680880|NCT04933318|Active Comparator|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)- analgesic current therapy
9680881|NCT04933318|Sham Comparator|shamTENS|shamTranscutaneous electrical nerve stimulation (TENS)- analgesic current therapy
9680882|NCT04933318|Active Comparator|Interferential current therapy (IFC)|Interferential current therapy (IFC)- analgesic current therapy
9680883|NCT04933318|Sham Comparator|shamIFC|shamInterferential current therapy (IFC)- analgesic current therapy
9680884|NCT04933305||RYGB patients|Patients that already received RYGB one year prior commencement of their participation in the study
9680885|NCT04933019|Other|Clindamycin Resistance Genes among Staphylococcus Isolates by Using Real Time PCR|
9680886|NCT04933019|Other|Clindamycin sensetive Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|
9680887|NCT04933292|Experimental|Methylprednisolone and Mycophenolate mofetil|
9680888|NCT04933292|Active Comparator|Methylprednisolone and Azathioprine|
9680889|NCT04933656|Experimental|50g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
9680890|NCT04933656|Experimental|90g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
9680891|NCT04933656|Experimental|130g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
9680892|NCT04933656|Experimental|170g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
9680893|NCT04933084|No Intervention|Usual Care|During their pre-operative visit, the usual care group will undergo usual pre-surgery patient education care dependent on their provider.
9680894|NCT04933084|Experimental|Text Handout|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout.
9680895|NCT04933084|Experimental|Text handout and Pre-recorded Video|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout AND pre-recorded video.
9680896|NCT04933266|Active Comparator|Low dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 5ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 5ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 10ml will be given).
9680897|NCT04933266|Active Comparator|High dose|After three injections of thoracic paravertebral block at T2, T4, T6 (a total of 21ml of 0.5% levobupivacaine with 1:200,000 adrenaline) under ultrasound guidance, patients will be put in supine position with ipsilateral arm and elbow flexed. Ultrasound scan will be performed below collarbone region, 10ml of 0.25% levobupivacaine will be injected in the first plane between pectoralis major and minor. Then under direct ultrasound visualization, the remaining 10ml of 0.25% levobupivacaine will be injected between the second plane of pectoralis minor and serratus anterior muscle (a total of 20ml will be given).
9680898|NCT04932993|No Intervention|Standard care|Will not write down goals their goals for their medical care (usual care).
10176527|NCT03832426|Experimental|Narlaprevir+Ritonavir - Healthy|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
10176528|NCT03832426|Experimental|Narlaprevir+Ritonavir - Hepatic Impairment|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
10176529|NCT03832036|Experimental|Patients with lumbar disc herniation|
9680899|NCT04932993|Experimental|Writing down goals|Will write down goals their goals for their medical care.
9680900|NCT04933045||Syndesmotic Fixation Group|Cohort of patients treated with anatomic ATFL reconstruction for syndesmotic ankle injury.
9680901|NCT04933162|Experimental|High Protein and Low Fiber Group|Subjects will consume a high protein and low fiber diet for 8 weeks
9680902|NCT04933162|Experimental|Low Protein and High Fiber Group|Subjects will consume a low protein and high fiber diet for 8 weeks
9680903|NCT04933110||Multiple Sclerosis|Individuals with early-stage multiple sclerosis
9680904|NCT04933110||Healthy Volunteers|Healthy volunteers of similar age and sex as individuals with multiple sclerosis
9680905|NCT04933071|Experimental|Podcast Education|Residents will be given access to podcasts during their rotation They will complete a survey after each obstetrics rotation
9680906|NCT04933071|No Intervention|Usual Teaching|Residents will have usual teaching They will complete a survey after each obstetrics rotation
9680907|NCT04933279|Experimental|Potassium iodide group|administrated the subjects with 150 ml - 200 ml iodine-containing spareribs soup delivering ≈ 600 µg or 1200 µg iodine
9680908|NCT04933279|Experimental|Natural kelp group|administrated the subjects with a bowl of 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine in natural kelp).
9976029|NCT01347437|Experimental|Positive STEPS|"Participants will receive one on one Positive STEPS counseling sessions (~1 hour sessions per week for 5 weeks).~Participants will receive motivational reminders to take medications sent via text message to their cell phones.~Participants will receive the Medication Event Monitoring Systems (MEMS) pill cap monitoring device to measure antiretroviral medication adherence."
9976030|NCT01347450|Experimental|Cocoa, Placebo|
9680911|NCT04932668|Experimental|Home-based Electrical Stimulation Program for lower limb spasticity|Single arm prospective intervention study to assess the feasibility and impact of a home-based program. Patient will apply home-based NMES on their leg for 20 minutes, 5 days a week for 4 weeks. At the end of the study, an outcome measures will be assessed and patient will be required to answer a questionnaires on their experience.
9680912|NCT04932655|Other|Fasted|Phase 3 simufilam 100 mg tablet dosed under fasted conditions.
9680913|NCT04932655|Other|High Fat|Phase 3 simufilam 100 mg tablet dosed 30 min after start of a high-fat meal.
9680914|NCT04932655|Other|Low Fat|Phase 3 simufilam 100 mg tablet dosed 30 min after start of a low-fat meal.
9680915|NCT04932655|Other|Phase 2 tablet|Phase 2 simufilam 100 mg tablet dosed under fasted conditions.
9680916|NCT04932642|Experimental|High-intensity interval training plus resistance training (HIIT+RT)|The HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points. Second, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of as many repetitions as possible in 60 seconds, followed by 60 to 120 seconds of passive recovery.
10176530|NCT03831997||Historical Controls|The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.
10176531|NCT03831997||Prospective Arm|The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.
9527639|NCT03218267|Experimental|Individuals after total hip replacement|Individuals after total hip replacement. Patients treated at the Out-Patient Ward of W. Dega Orthopaedic-Rehabilitation Clinical Hospital of Karol Marcinkowski University of Medical Sciences in Poznań. The examination of participants included the static posturography and one-leg standing test.
9680917|NCT04932642|Experimental|Resistance training plus High-intensity interval training (RT+HIIT)|Firstly, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of 60 seconds, followed by 60 to 120 seconds of passive recovery, as previously reported. Secondly, in the HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points.
9680918|NCT04932837||migrant worker residents|The target population will be the 124 residents in the 2 migrant worker residences who were included in the previous seroprevalence study and those who arrived at the 2 residences since September 1st, 2020
9680919|NCT04932928|Experimental|FreeStyle Libre (CGM) Group|Device: FreeStyle Libre (ver 1.0) Education on lifestyle modification
9680920|NCT04932928|Active Comparator|Self Monitoring of Blood Glucose (SMBG) Group|Device: Blood glucose meter Education on lifestyle modification
9680921|NCT04932551||Physician|
9680922|NCT04932616||Face To Face (Clinic) Group Functional Gait Assessment|"Evaluations to be applied for the cultural adaptation and reliability study of the scale:~Functional Gait Assessment, Timed Up and Go Test, Four-Step Square Test, Timed 25-Foot Walk Test, 12-Item Multiple Sclerosis Walking Scale Berg Balance Scale"
9680923|NCT04932616||Tele- Assessment Group Functional Gait Assessment|"The evaluation to be applied for the tele-evaluation reliability study of the scale:~Functional Gait Assessment"
9680924|NCT04932798||High-Risk group|: Montreal Heart Institute biobank participants with a high specific genome-wide polygenic risk scores for atrial fibrillation G
9680925|NCT04932798||Low-Risk group|Montreal Heart Institute biobank participants with a low specific genome-wide polygenic risk scores for atrial fibrillation G
9976031|NCT01347463||Traditional|
10176532|NCT03831984|Active Comparator|0,09% Bromfenac|Topical 0,09% Bromfenac twice daily 3 days before surgery
9680926|NCT04932629|Experimental|Experimental Group|The eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x106 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma.
10176533|NCT03831984|Placebo Comparator|0,1% sodium hyaluronate|Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
10176534|NCT03831867|Experimental|Pilates|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
9680927|NCT04932863||Subjects with cancer of any type and stage under active or prior medical treatment|BNT162b2 mRNA Covid-19 Vaccine as two injections, 21 days apart, of 30 μg per dose in the deltoid muscle.
9680928|NCT04932889||Change|the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19 (n=240)
9680929|NCT04932889||No change|the patients whose musculoskeletal symptoms did not change with Covid-19 (n=40)
9680930|NCT04932876||ESKD - HD|End Stage Kidney Disease on Long Term Dialysis
9680931|NCT04932876||KTR|Kidney Transplant Recipient
9680932|NCT04932564|Experimental|Leflunomide Arm|Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
9680933|NCT04932603||experimental|Patients with AF, hospitalized in one of the 6 geriatrics units participating in the study, aged 75 years or over, without evaluation of their antithrombotic treatment by the multidisciplinary team. The lack of review of patient's file by the multidisciplinary team is based on physician decision.
9680934|NCT04932603||Standard of care|
9680935|NCT04932746|Experimental|The dexmedetomidine group:|"An initial dose of 1 mcg / kg 1 dexmedetomidine will be given 10 minutes after the start of anesthesia infusion within 10 minutes, after which the dexmedetomidine infusion is maintained at a dose of 0.4 mcg / kg / hour.~The injection will be stopped before the skin is closed."
9680936|NCT04932746|Experimental|The Placebo group (the control group):|After the same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol.
9680937|NCT04932486|Active Comparator|Transcutaneous electrical stimulation|
9680938|NCT04932486|Sham Comparator|Inactive transcutaneous electrical stimulation|
9680939|NCT04932499|Active Comparator|Control group|Standard of care
9680940|NCT04932499|Experimental|Mindfulness Meditation|Mindfulness meditation in addition to standard of care
9680941|NCT04932772|Experimental|Group A (kinesiotaping group)|include 24 women will receive kinesiotaping combined with abdominal exercise (2sessions /week for eight weeks).
9680942|NCT04932772|Active Comparator|Group B (abdominal exercise group)|include 24 women will receive abdominal exercise only.
9680943|NCT04932720|Experimental|experimental group|Experimental group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
9680944|NCT04932720|No Intervention|control group|Also the control group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
9680945|NCT04932434|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately two weeks apart, with preparation sessions before and integration sessions after.
9680946|NCT04932304|Active Comparator|Active stimulation|Participants recieving active trancranial direct current stimulation (tDCS) Parameters: 20 minutes anodal tDCS 1mA. Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
10176535|NCT03831867|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
9527640|NCT03218267|Active Comparator|control group|The group with healthy individuals; without total hip replacement. The examination of participants included the static posturography and one-leg standing test.
9680947|NCT04932304|Placebo Comparator|Sham stimulation|Participants recieving passive / sham trancranial direct current stimulation (tDCS) Two times a week, for three weeks. Anode placed at F3, cathode placed at right cerebellum.
9680948|NCT04932330||ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score < 48 out of a maximal score of 60 when discharged.
9680949|NCT04932330||no ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score ≥ 48 out of a maximal score of 60 when discharged.
9680950|NCT04932538|No Intervention|Control Group|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy.
9680951|NCT04932538|Experimental|Kinesio Taping|Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy. Sessions were 40 minutes. The children in the taping group were taped 6 days per week for 4 weeks. The children were checked for allergies before applying the tape. A 5-cm tape was applied and kept in position for 3 days, and the region was then left to rest for 24 hours.
9976032|NCT01347476||patients older than 70 years|
10176536|NCT03831763|Active Comparator|ColdZyme|
10176537|NCT03831763|No Intervention|Optional care only|
10176538|NCT03831633|Experimental|AKYNZEO|
10176539|NCT03831633|Active Comparator|Standard of Care|
10176540|NCT03831737|Experimental|Group 1: In-Person|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will participate in in-person physical therapist-led instructional sessions three times per week. Each stretch will be performed twice, one on the left and one on the right. The therapist will describe what to do and briefly demonstrate each stretch. Stretches will be held for 45-60 seconds with therapist instructions and modification as needed based on subject technique."
10176541|NCT03831737|Experimental|Group 2: Video|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will complete sessions three times per week, led by a physical therapist and viewed remotely via pre-recorded video using a smartphone application."
9680952|NCT04932135||Group Treatment|Patients with newly diagnosed hyperthyroidism due to Graves' disease, if anti thyroid drug treatment is planned.
9680953|NCT04932135||Group Surveillance|Patients suffering from Graves' disease in whom discontinuation of the anti-thyroid therapy is planned.
9680954|NCT04932356|Other|Therapeutic Education by phone|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit and then reinforcement each 15 days over the weak points of this visit.
9680955|NCT04932356|Other|Traditional Therapeutic Education|Therapeutic education in diabetes mellitus (pharmacological, nutritional, physical exercise, social adherence ... etc) on face-to-face visit.
9680956|NCT04932252|Experimental|A4368 - Dose 1|Single dose of A4368 or placebo tablet, orally administered
9680957|NCT04932252|Experimental|A4368 - Dose 2|Single dose of A4368 or placebo tablet, orally administered
10176542|NCT03831542||direct aspiration group|Transvaginal ultrasound-guided oocyte retrieval was performed 36 hours after ovulation trigger. A 17-gauge double lumen needle will be used to aspirate a single follicle without flushing. If an oocyte is obtained, the subject will be assigned to group 1. If not, operator will proceed with follicular flushing.
10176543|NCT03831542||flushing group|If an oocyte is not obtained with direct aspiration, operator will proceed to follicular flushing and the subject will be assigned to group 2 if an oocyte is obtained following follicular flushing.
10176544|NCT03831828||Lymph node metastasis Positive|good prognosis; without Lymph node metastasis.
9680958|NCT04932252|Experimental|A4368 - Dose 3|Single dose of A4368 or placebo tablet, orally administered
9680959|NCT04932252|Experimental|A4368 - Dose 4|Single dose of A4368 or placebo tablet, orally administered
10176545|NCT03831828||Lymph node metastasis Negative|poor prognosis; with Lymph node metastasis.
10176546|NCT03831724|Experimental|EndoFLIP™ System|Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
10176547|NCT03831698|Experimental|Omega-3, 2 grams|Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months
9680960|NCT04932252|Experimental|A4368 - Dose 5|Single dose of A4368 or placebo tablet, orally administered
10176548|NCT03831802|Experimental|experimental group|The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary
10176549|NCT03831802|Active Comparator|Control group|The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance
10176550|NCT03831815||Grupo C: cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
10176551|NCT03831815||Grupo R: rocuronium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
10176552|NCT03831919|Experimental|SYNC III accommodative support lenses|Wear spectacles with SYNC III accommodative support lenses (add +0.75)
10176553|NCT03831919|Placebo Comparator|control|Wear single vision spectacles (no add)
9680961|NCT04932252|Experimental|A4368 - Dose 6|Single dose of A4368 or placebo tablet, orally administered
10176554|NCT03831607|Experimental|KHK7791|Patients start at KHK7791 30 mg BID and can down titrate weekly to 20, 15, 10, and 5 mg BID, sequentially based on a GI tolerability question.
9680962|NCT04932252|Experimental|A4368 - Dose 1 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
9680963|NCT04932252|Experimental|A4368 - Dose 2 repeated|Multiple dose of A4368 or placebo tablet, orally administered daily for 14 consecutive days
9680964|NCT04932369|Experimental|ER GROUP|The training sessions were based on the Dialectical Behavior Therapy Skills (Linehan, 2015). The students in the experimental conditions were divided into 10 groups, there were 10 students in each group. Each group received eight 90-min sessions of the emotion regulation training (one session per week) carried out by qualified clinical psychologists in online settings using Microsoft Teams. The training includes online group gathering, homework and telephone consultation as needed.
9680965|NCT04932369|No Intervention|Control group|they completed two assessments, 2-months apart
9680966|NCT04932096|Experimental|Melatonin and sleep plan|(melatonin doses of 1mg, 3mg, or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days) and sleep management plan based on patient age
9680967|NCT04932096|Placebo Comparator|Placebo|Placebo and standard care
9680968|NCT04932421|Experimental|Experimental group (UP-C intervention)|UP-C intervention 15 weekly sessions, for children and parents
9680969|NCT04932421|Active Comparator|Control group (ABC of emotions intervention)|ABC of emotions - a psychoeducational intervention 5 sessions every 3 weeks for children
9680970|NCT04932382|Other|Misoprostol group|400 µg misoprostol vaginally ; these tablets will be introduced by the principal investigator, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position
9680971|NCT04932382|Other|No misoprostol group|will not receive any pre-insertion medications.
9680972|NCT04932148|Experimental|Incremental HD|Participants randomised to incremental HD will commence HD twice weekly and continue until an indication for an increase to three sessions/week (trigger point) is reached.
9680973|NCT04932148|Other|Conventional HD|Participants randomised to conventional HD will commence HD thrice weekly from the first HD session.
9680974|NCT04932200||urgent-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy < 6 hours
10176555|NCT03831594|Experimental|Standard Physiotherapy and Galvanic Vestibular Stimulation|Standard physiotherapy concurrently with Galvanic Vestibular Stimulation for 45 minutes a day for two weeks (five days per week)
10176556|NCT03831594|Active Comparator|Standard Physiotherapy|Standard Physiotherapy for 45 minutes a day for two weeks (five days per week)
10187254|NCT03728062|Experimental|Physical exercise during lunch break|Participants performed physical exercises during lunch break at a gym for a month, beginning with 15 minutes and ending with 30 minutes. They were instructed to do cardio exercise such as running through a park or going to the gym for running, rowing, cycling or elliptical exercise. 20-140 beats per minute must be reach.
10187255|NCT03728062|No Intervention|Control group|Participants continue their normal lunch routine.
10187256|NCT03728049|Experimental|CT-ADP group|PVR assessment with the standard methods and with the CT-ADP that will be provided to the operator in real-time during TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator and based on the results of the CT-ADP on top of the standard methods of PVR assessment.
10187257|NCT03728049|Other|Control group|PVR assessment with standard methods only (at discretion of the operator excluding CT-ADP and transesophageal echocardiography). CT-ADP will not be provided to the operator at the time of TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator according to the results of the standard methods of PVR assessment.
10187258|NCT03728023|Experimental|AZD4205|Single ascending dose: 5mg, 20mg, 50mg, 100mg, 150mg Multiple ascending dose: low, medium and high dose once daily X 14 days
10187259|NCT03728023|Placebo Comparator|Placebo|placebo single dose in SAD and once daily for 14 days
10187260|NCT03728010||One-Lung Ventilarion|Thoracic surgery cases with one-lung ventilation strategy.
10187261|NCT03727958|Active Comparator|Lung and coronary CT assessment|Subjects will undergo simultaneous CT assessment of both coronary arteries and thoracic area
10187262|NCT03727958|Active Comparator|Coronary CT assessment|Subjects will undergo CT assessment of coronary arteries only
9680975|NCT04932200||early-endoscopy group|the time interval from gastroenterologic consultation to the start of emergency endoscopy between 6 and 24 hours
9695520|NCT04777825|Experimental|HRV biofeedback training|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist. This group of patients will also benefit from the HRV biofeedback training.
9695521|NCT04777825|Other|control|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist.
10187263|NCT03727945|Experimental|abdominopelvic exercise and posture|N=21 received supervised physiotherapy abdominopelvic exercise previous postural correction.
9695522|NCT04777474|Experimental|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy
9695523|NCT04777630||Patients with low vision who experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
10187264|NCT03727945|Experimental|abdominopelvic exercise|N=21 received supervised physiotherapy abdominopelvic exercise.
10187265|NCT03727932|Other|VioOne HIV Profile|HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
10187266|NCT03727906|Other|Non-insomnia Group|"Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
10187267|NCT03727906|Other|Insomnia Group|"Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
10187268|NCT03727867|Placebo Comparator|Drug group|Participants were under prescription of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) at the beginning and continued until disease progressed.
10187269|NCT03727867|Experimental|Drug plus SBRT group|After the first month of EGFR TKI orally, participants were given Stereotactic Body Radiation Therapy (SBRT) in dose of 50 Gy/5 F or 60 Gy/8 F for peripheral and central primary tumor, respectively, combined with oral EGFR TKI continually until the primary end point.
10187976|NCT03720743|Experimental|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
10187977|NCT03720743|No Intervention|Control Group|The study allowed control group subjects to participate in Biodanza sessions after the follow-up period.
10187978|NCT03720717|Experimental|Opioid Tolerant - baclofen|
9695524|NCT04777630||Patients with low vision who do not experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
9695525|NCT04777591|Active Comparator|Control - plain bupivacaine|Receives plain bupivacaine TAP block as part of multi-modal pain control intraoperatively
9695526|NCT04777591|Experimental|Experimental - Liposomal bupivacaine|Receives plain bupivacaine + liposomal bupivacaine TAP block as part of multi-modal pain control intraoperatively
9695527|NCT04777448|No Intervention|Control|Simple physical activity advices will be given to the 27 patients of the control arm
9695528|NCT04777448|Experimental|telerehabilitation|Patients in the tele rehabilitation arm will perform 24 1h-telerehabilition sessions (dance, gym, cardio training, yoga, ...)
9695529|NCT04777370|Experimental|sleeper stretch + thoracic manipulation|The group will receive the sleeper stretch at session #1, and a thoracic manipulation followed by the sleeper stretch at session #2.
10187979|NCT03720717|Placebo Comparator|Opioid Tolerant - placebo|
10187980|NCT03720717|Experimental|Opioid Naive - baclofen|
10187981|NCT03720717|Placebo Comparator|Opioid Naive - placebo|
10187982|NCT03720691|Active Comparator|Real rTMS Supplementary motor area|Real rTMS will be applied over the supplementary motor area
10187983|NCT03720691|Sham Comparator|Sham rTMS Supplementary motor area|Sham rTMS will be applied over the supplementary motor area
9680976|NCT04932174|Experimental|High-intensity Interval Training|Group 2: the included 15 subjects will participate in High intensity Interval training exercise running on treadmill for 12 weeks, 3 times / week.
9680977|NCT04932174|Active Comparator|Low-intensity Continuous Training|Group 1: the included 15 subjects will participate in low intensity continuous exercise on treadmill for 12 weeks, 3 times / week
10176557|NCT03831893|Sham Comparator|Control|A food product similar to the test products but without nopal
10176558|NCT03831893|Experimental|Nopal food product 1|Food product with Nopal
10176559|NCT03831893|Experimental|Nopal food product 2|Food product with Nopal
10176560|NCT03831789|Active Comparator|Unilateral cerebellar rTMS|
9680978|NCT04932525|Experimental|solid tumor or hematological malignancy|
9680979|NCT04932031||Study group|Adult females with newly diagnosed early-stage (stages I III) non-metastatic breast cancer receiving neoadjuvant or adjuvant chemotherapy that includes paclitaxel or docetaxel
9680980|NCT04932187|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
9680981|NCT04932278|Active Comparator|Usual Care Group|Participants in this group will receive routine care for the management and treatment of concussions
9680982|NCT04932278|Experimental|OMT Group|Participants who are randomized into OMT group will receive OMT in addition to their usual care.
9680983|NCT04932239|Experimental|Road traffic crashes first aid education module|It is an education module aiming to address the topics related to first aid: Recognizing emergency, Call for help, Scene safety, Airway and breathing, Haemorrhage control, First aid kit, Immobilization of fractures and transport of injured people.
9680984|NCT04932239|Placebo Comparator|Tuberculosis prevention education module|This education module covers the definition of the disease, types ways of prevention in working place, and its management
9680985|NCT04932226|Other|All participants|Each participant is his/her own control. Each will have all four interventions in random order.
9680986|NCT04932460|Experimental|CEUS+blue dye|The included patients will accept essential tests and CEUS before and after neoadjuvant chemotherapy to evaluate axillary lymph nodes status. When patients finish neoadjuvant therapy, SLNB with or without axillary lymph node dissection will be performed using CEUS lymphatic mapping to mark SLN on the skin combined with blue dye.
9680987|NCT04932408|Experimental|Hip Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed around the hip region.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
9680988|NCT04932408|Experimental|Chest Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
9680989|NCT04932109||Healthy Group|
9680990|NCT04932109||Hand Injuries Group|
9680991|NCT04932122|Active Comparator|Dorsal wrist ganglion alone (DWG)|Dorsal wrist ganglion excision alone
9680992|NCT04932122|Active Comparator|DWG with PIN|Dorsal wrist ganglion excision with posterior interosseus neurectomy (PIN)
9680993|NCT04932070|Experimental|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
9680994|NCT04932044|Experimental|Early Sleep Facilitation Program|Perform sleep circadian rhythm training during hospitalization, and provide caregivers with nursing guidance to promote sleep of premature infants before discharge
9680995|NCT04932044|Active Comparator|routine care and provide general discharge care and nursing guidance|Routine care and provide general discharge care and nursing guidance.
9680996|NCT04932161|Experimental|Titanium Granules as a bone graft in intrabony defects|In test group, after reflection of flap and degranulation, bone graft i.e., titanium particles will be placed in the void created by the defect and sutures will be placed.
9680997|NCT04932161|Active Comparator|Hydroxyapatite as a bone graft in intrabony defects|In control group, after reflection of flap and degranulation, bone graft i.e., hydroxyapatite will be placed in the defect and sutures will be placed.
9680998|NCT04932395|Experimental|Anshen Buxin Liuwei Pills|15 pills/time, 2 times/day, orally，for 8 weeks
9680999|NCT04932395|Placebo Comparator|Placebo|15 pills/time, 2 times/day, orally. for 8 weeks
9681000|NCT04931940|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
9681001|NCT04931940|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
9681002|NCT04931953|Active Comparator|Group 1|iTBS intervention lasting 30 minutes, given 4 days a week, for 1 week
9681003|NCT04931953|Active Comparator|Group 2|iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks
9681004|NCT04931953|Active Comparator|Group 3|iTBS intervention lasting 30 minutes, given 4 days a week, for 4 weeks
9681005|NCT04931953|Sham Comparator|Group 4|Sham iTBS intervention lasting 30 minutes, given 4 days a week, for 2 weeks.
9681006|NCT04931914||Group c|Patients admitted from June 9, 2020 to june 31, 2021.
9681007|NCT04931810|Experimental|All Nations Breath of Life|ANBL is a culturally tailored smoking cessation program that incorporates group-based and individual counseling. Participants may elect to take pharmacotherapy, but are not required to do so.
9681008|NCT04931784|Active Comparator|Nitrate Group|with administration of intra-coronary nitrate before percutaneous coronary intervention
9976033|NCT01347476||patients 70 years or younger|
10176561|NCT03831789|Experimental|Bilateral cerebellar rTMS|
10176562|NCT03831841|Experimental|Intervention|Multicomponent exercise programe involving all physical fitness paramenters and consisting on sesions of 1 hour, 3 days a week.
10176563|NCT03831841|No Intervention|Control|Control group with no intervention programe
10176564|NCT03831555|Active Comparator|PREP-C|The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.
10176565|NCT03831555|No Intervention|Standard of care|Participants will receive the standard of care (usual care) for chronic HCV infection.
9681009|NCT04931784|Placebo Comparator|Control Group|without administration of intra-coronary nitrate before percutaneous coronary intervention
10176566|NCT03831750|Experimental|Stress Reduction Intervention|Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.
10176567|NCT03831750|No Intervention|Control|Participants will receive the standard of care for IBD.
10176568|NCT03831581|Experimental|Erector Spinae Plane Block|Patients with chest pain or upper abdomen underwent Erector Spinae Plane Block guided by ultrasound, bupivacaine 0.5% 20 ml was administered in the interfascial plane between the transverse process of T5 and the erector muscles of the spine, 60 minutes after dermatomes distribution was evaluated with pinprick and cold.
9681010|NCT04931628|Active Comparator|salvianolic acid group|salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days
9681011|NCT04931628|Placebo Comparator|0.9% NaCl|0.9%NaCl 250ml, injection, 14 days
9681012|NCT04931797|Experimental|Video|Video decision aid and advance care planning discussion
9681013|NCT04931797|Active Comparator|Control arm|A standardized written form that details advance care planning options.
9681014|NCT04931732||Diagnosis|
9681015|NCT04931732||Relapse|
9681016|NCT04931706||N-Sleve patients|Patient that were selected for surgery
9681017|NCT04931576|No Intervention|Routine application of drainage tube|After TOETVA, patients will receive one drainage tube through anterior cervical area.
9681018|NCT04931576|Experimental|Omission of drainage tube|After TOETVA, patients will receive complete omission of drianage tube and directly close the incision.
9681019|NCT04931680||Patients with treatment success|"Patients with diagnosis of confirmed or clinical scabies and treatment success"
10176569|NCT03831399|Placebo Comparator|Control Group|"Subjects in control group will receive placebo (lactose) 6g/day in two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
10176570|NCT03831399|Active Comparator|Intervention Group|"Subjects in intervention group will receive leucine 6g/day, in tin two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
9681020|NCT04931680||Patients with treatment failure|"Patients with diagnosis of confirmed or clinical scabies and treatment failure"
9681021|NCT04931992||Molecular relapse|Confirmed molecular relapse, without overt cytological relapse
9681022|NCT04931992||Cytological relapse|Overt cytological relapse, without prior molecular relapse
9681023|NCT04931992||Persistent responders|No molecular or cytological relapse during follow-up
9681024|NCT04931693|Active Comparator|control|conventional control group(C) (n=20) where20 children will receive IV paracetamol 20 mg / kg and atracurium top ups at a dose of 0.1mg/kg. every 30 minutes.
10176571|NCT03831334|Experimental|Minoxidil Treatment|Low dose oral minoxidil
9681025|NCT04931693|Active Comparator|PECs|Pectoral nerves blocks group (P) (n=20) where 20 children will have PECs Block and atracurium top ups upon request.
9681026|NCT04931966|Active Comparator|Group A|Adductor canal block
9681027|NCT04931966|Active Comparator|Group B|Adductor canal block plus IPACK
9681028|NCT04931966|Active Comparator|Group C|Adductor canal block plus PAI
9681029|NCT04931719|Active Comparator|the PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
9681030|NCT04931719|Experimental|the PRP+HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
9681031|NCT04931433|Experimental|Lignocaine|This arm will receive intravenous Lignocaine bolus and infusion
9681032|NCT04931433|Placebo Comparator|Placebo|This arm will receive Normal saline 0.9% bolus and infusion
9681033|NCT04931394|Experimental|Organoid-Guided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
9681034|NCT04931394|No Intervention|Physician-decided Adjuvant Chemotherapy|The pancreatic cancer specimens are obtained from surgery to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Adjuvant chemotherapy should start within 2 months after surgery, and last at least 6 months.
9681035|NCT04931381|Experimental|Organoid-Guided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Patients will receive relatively sensitive chemotherapy regimen based on the test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
9681036|NCT04931381|No Intervention|Physician-decided Chemotherapy|The pancreatic cancer specimens are obtained from biopsy to be cultured for organoids. Then drug sensitivity is tested using organoid to obtain the sensitivity to the first-line drugs for pancreatic cancer (Gemcitabine, 5-fluorouracil, Paclitaxel, Oxaliplatin, Irinotecan). Physician will decide the the adjuvant chemotherapy regimen, according to National Comprehensive Cancer Network (NCCN) guideline for pancreatic ductal adenocarcinoma. And they don't know the drug sensitivity test results. Chemotherapy should start within 1 months after biopsy, and be given at least 1 cycle.
10176572|NCT03831386|Active Comparator|Vacuum|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.
9976034|NCT01347502||HCPs with smartphone|healthcare providers in MICU who have smart cellular phones
9681037|NCT04931498||GMPR sub-study|Study population will be split into five haplotypes based on a combination of rare and common variants at the GMPR locus. A total of 26 volunteers per genotypic group in a comparison between heterozygous and homozygous individuals will be tested.
9681038|NCT04931498||SWAP70 sub-study|To assess genotype-specific effects on SWAP70 protein levels as well as coronary artery disease-related immune processes, we will recruit 50 volunteers stratified by variant genotype, i.e. major and minor homozygotes only (25 participants will be recruited to each group).
9681039|NCT04931524|Experimental|carbon-14-[14C]-ANG-3777|Administered IV as a single dose over 30 minutes on the morning of Day 1 following an 8 hour overnight fast and remain in the clinical unit until up to 168 hours after dosing (to Day 8). If mass balance criteria have not been met on Day 8, the clinical unit residency may be extended up to an additional 96 hours (to Day 12).
9681040|NCT04931355|Experimental|Acupuncture treatment group|Method: Acupuncture at Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi. The acupuncture treatment starts on the 5th day of the menstrual cycle and lasts to the days before IVF-ET
9681041|NCT04931355|Active Comparator|Western medicine group|The western medicine group will be treated with conventional western medicine
9681042|NCT04931186||all patients|
9681043|NCT04931446||Gastroenteropancreatic neuroendocrine neoplasms|
9681044|NCT04931147|Experimental|Part A SAD - Cohort 1|This is the first treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive 2 mg of RXC007 on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
9681045|NCT04931147|Experimental|Part A SAD - Cohort 2|This is the second treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Cohort 1 Dose Escalation Data Review) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
9681046|NCT04931147|Experimental|Part A SAD - Cohort 3|This is the third treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
9681047|NCT04931147|Experimental|Part A SAD - Cohort 4|This is the fourth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
9681048|NCT04931147|Experimental|Part A SAD - Cohort 5|This is the fifth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
9681049|NCT04931147|Experimental|Part A SAD - Cohort 6|This is the sixth treatment arm in Part A (Single Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
9681050|NCT04931147|Experimental|Part A SAD - Optional Cohort 7|This is an optional seventh treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
9681051|NCT04931147|Experimental|Part A SAD - Optional Cohort 8|This is an optional eighth treatment arm in Part A (Single Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) on one occasion on Day 1. The remaining 2 participants will receive matching placebo.
10176573|NCT03831386|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.
10176574|NCT03831321|Active Comparator|Diclofenac group|The group who are 50 mg Diclofenac Sodium and lubricant gel administered one hour before cystoscopy and local
10176575|NCT03831321|Placebo Comparator|Placebo|The group who are not administered 50 mg Diclofenac Sodium before cystoscopy and administered lubricant gel just before local cystoscopy
9681052|NCT04931147|Experimental|Part B MAD - Cohort 1|This is the first treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
10176576|NCT03831477|Experimental|80 pin applicator|
10176577|NCT03831477|Active Comparator|160 pin applicator|
10176578|NCT03831464|Experimental|Metformin treatment group|
10176579|NCT03831464|Placebo Comparator|Placebo control group|
10176580|NCT03831438|Other|Dose escalation|"Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc).~Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period)."
10176581|NCT03831412|Active Comparator|CBT-I|5 sessions of treating insomnia
10176582|NCT03831412|Active Comparator|ERRT|5 sessions of treating post-trauma nightmares
9681053|NCT04931147|Experimental|Part B MAD - Cohort 2|This is the second treatment arm in Part B (Multiple Ascending Dose) of the study. 4 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of SAD and previous MAD cohort data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
10176583|NCT03831269|Active Comparator|Azithromycin|The dose of azithromycin will be 10mg/kg/day oral suspension for 3 consecutive days for pediatric patients (<12 years old) and 500mg/day in three consecutive days for adults. The cycle will be repeated every seven days (3 cycles/month) and will be repeated if required according to patient's response up to 6 cycles. Side effects of therapy will be recorded. This protocol is based on previous case reports.
9681054|NCT04931147|Experimental|Part B MAD - Optional Cohort 3|This is an optional third treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
9681055|NCT04931147|Experimental|Part B MAD - Optional Cohort 4|This is an optional fourth treatment arm in Part B (Multiple Ascending Dose) of the study. If deemed as necessary following Dose Escalation Data Review of previous cohorts data, up to 8 participants may be enrolled into this optional cohort. If enrolled, up to 6 participants will be randomised to receive a selected dose of RXC007 (following Dose Escalation Data Review of previous cohorts data) once daily for 14 days. The remaining 2 participants will receive matching placebo.
9681056|NCT04931004|Experimental|0.075% Cetylpyridinium Chloride|
9681057|NCT04931004|Experimental|1.5% Hydrogen peroxide|
9681058|NCT04931004|Experimental|Chlorhexidine gluconate|
9681059|NCT04931004|Placebo Comparator|Water rinse|Control for impact on viral load changes from mechanical rinsing
9681060|NCT04931303||Study Group|Enrolled patients receive a medical device which monitors gait quality and collects information about the patients health status. Possible changes of intervention (drug or physical therapy) within the observational phase (8 weeks) are initiated and prescribed by physicians as a result of routine care process or patient contact based on their (deteriorated) health status. With the chosen endpoints, changes of patients empowerment, gait quality and system usability by using a monitoring device are monitored.
10176584|NCT03831269|Active Comparator|Nb UVB|Patients recruited for nbUVB phototherapy will have an initial dose of 0.3J-0.5J according to Fitzpatrick's skin type. The dosage will be increased by 0.3J in every other treatment session. The sessions will be given 3 times weekly until improvement is noted or reaching 8 weeks at the EOS. We arrived at this initial dose based on our previous experience with Egyptian patients in Kasr Alainy phototherapy unit in Dermatology Department, Cairo University.
10176585|NCT03831243|Active Comparator|Single fraction of 8 Gy|The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
10176586|NCT03831243|Experimental|Single fraction of 20 Gy|Within the framework of stereotactic body radiotherapy, a single fraction dose of 20.0 Gy will be delivered to the metastasis using a PTV margin of 3-5 mm based on high-precision image-guided radiotherapy (IGRT). Therefore, only linear accelerators with the European Organization for Radiotherapy & Oncology advisory committee on radiation oncology practice (ESTRO-ACROP) specifications for SBRT can be accepted. A risk-adapted approach will be applied, aiming for the highest possible dose no less than 16 Gy, while respecting the tolerances of critical organs at risk (e.g. spinal cord, cauda equina, brainstem etc.).
10176587|NCT03831035||15 patients and both parents.|The patients are aged 12 months or under hospitalized in the ICU suffering from multiple congenital malformations and/or neurologic symptoms.
10176588|NCT03831178|Experimental|DHA|Participants will take 11 capsules per day containing DHA-enriched triglyceride oil (1 g capsules containing at least 400 mg DHA) for a total of 5 g DHA/day divided into three times daily with meals or as tolerated.
10176589|NCT03831178|Placebo Comparator|Placebo|Participants will take 11 capsules per day containing corn/soy oil blend capsules divided into three times daily with meals or as tolerated.
10176590|NCT03831139|Experimental|Prevention|TIM&SARA has a duration of 16 fifty-minute sessions and is organized in five modules. The first module (2 sessions) outlines the rationale for the program and establishes connections between group leaders and adolescents. The next module (2 sessions) focuses on helping adolescents to consider already existing goals, set new ones, and learn how to achieve goals to build up the motivation of the youth to learn and apply the material of the following modules. The third module (6 sessions) focuses on understanding the relations among cognitions, emotions, and behaviors, and teaching the participating youths how to identify and challenge negative cognitions. The forth module (5 sessions) trains the youth in assertive and social competent social behavior. Finally, the last session is a review session and includes a celebration. All parts of the program use illustrative, culturally relevant situations introduced by the participating adolescents.
10176591|NCT03831139|No Intervention|Control|The youth participate in school as usual.
10176592|NCT03831152|Experimental|Experimental ADV7103|All patients receive ADV7103 at their individualized dose
9681061|NCT04931160|Active Comparator|Sjögren patients|patients diagnosed Sjögren
9681062|NCT04931160|Other|Non-Sjögren witnesses|patients diagnosed no Sjögren
9681064|NCT04931173|Active Comparator|Group A: IV and Oral antibiotics (IVA+OA)|Patients will receive cefazolin 2g IV and metronidazole 500 mg IV administered by the anesthesiologist within 60 minutes prior to the skin incision on the day of surgery. Standardized re-dosing of cefazolin 2g IV will occur every 4 hours and metronidazole 500 mg IV will occur every 8 hours during the surgical procedure. Following surgery, no further IVA will be given for SSI prophylaxis. In addition, patients will self-administer 1g neomycin and 1g metronidazole orally at 1500, 1700 and 2300 hours the day before surgery. Following this, they will not receive any further OAs for SSI prophylaxis.
9681065|NCT04931173|Active Comparator|Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA)|Patients will receive IVA and OA per Group A. In addition, patients will stay on clear fluids and self-administer a 2L polyethylene glycol MBP orally, between 1500 and 2300 hours on the day before surgery.
9681066|NCT04931225|Experimental|Landiolol injection|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
9681067|NCT04931225|No Intervention|Usual tachycardia management|No treatment, usual tachycardia management.
9681068|NCT04931199|Active Comparator|CBT|
9681069|NCT04931199|Experimental|CBT+App|
9681070|NCT04931108|Experimental|Sequence 1|One pill of nitrendipine/atenolol combination (5/10mg) once daily for 6 weeks first, and followed by monotherapy for another 6 weeks, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily.
9681071|NCT04931108|Experimental|Sequence 2|Monotherapy for 6 weeks first, when patients will evenly assigned to one pill of nitrendipine (10mg) or one pill of atenolol (25mg) once daily, followed by one pill of nitrendipine/atenolol combination (5/10mg) once daily for another 6 weeks.
9681072|NCT04931121||Osteoarthritic patients|Subjects are patients referred for knee osteoarthritis and treated with an hyaluronic acid injection (viscosupplementation)
10176593|NCT03831113|Experimental|Buprenorphine Magnitude Group|Subjects will receive alternating reductions of 1 mg and then 2 mg weekly. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
9681073|NCT04930978||TB patients with SARS-CoV-2 PCR+|50 TB patients with SARS-CoV-2 PCR+ will be recruited in group 1
9681074|NCT04930978||TB patients with SARS-CoV-2 Ab+|100 TB patients with SARS-CoV-2 Ab+ will be recruited in group 2
9681075|NCT04930978||TB patients negative for SARS-CoV-2 PCR and Ab|100 TB patients with SARS-CoV-2 PCR and Ab negative will be recruited in group 3
9681076|NCT04931277|Other|stepped cataract surgery|
9681077|NCT04930939|Experimental|Heart rate variability-guided training group|Patients allocated to heart rate variability-guided training group trained 3 days a week for 6 weeks. These patients carried out moderate continuous traininig sessions or high intensity interval training sessions based on their daily heart rate variability assessments follwing a decision schema.
9681078|NCT04930939|Active Comparator|Predefined training group|Patients allocated to predefined training group also trained 3 days a week for 6 weeks. Nonetheless, these patients performed a predefined training program regarless of their parasympathetic modulation status.
9681079|NCT04930835|Active Comparator|Conventional Loading|implants are loaded at least after two months of healing
9681080|NCT04930835|Experimental|Immediate Loading|implants are loaded the same day of surgery
10176594|NCT03831113|Experimental|Buprenorphine Frequency Group|Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
9681081|NCT04930757||Patients with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.|Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab.
9681082|NCT04930926||INFECTION DISEASE PATIENTS WITH PNEUMONIA OR SARHS COVID19|NO SPECIFIC INTERVENTION
9681083|NCT04930744|Active Comparator|Standard Tuberculosis Medicine|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months.
9681084|NCT04930744|Experimental|Standard TB Medicines and Metformin|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months. For this arm, they will also take Metformin hydrochloride one 500 mg tablet daily starting one week after the initiation of tuberculosis medicines, then increasing to one 500 mg table twice daily through study week-12 for a total 11 weeks of metformin exposure.
9681085|NCT04930562|Experimental|200mg qd|200mg qd po.
9681086|NCT04930718|Active Comparator|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life;
9681087|NCT04930718|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise home program with a laptop.
10176595|NCT03831113|Experimental|Buprenorphine Dosing Group|Subjects will receive dose reductions identical to either the Magnitude (alternating 1 and 2 mg reductions) or Frequency (2 mg reductions on alternating 1 and 2 week intervals) groups. Subjects on BID dosing, as prescribed by their MAT provider, will be assigned to the Dosing group (n=10).
10176596|NCT03831373|Experimental|Upper-limb-focused resistance training|
9681088|NCT04930692|Experimental|Preoperative SLNs mapping provided by CT-lymphography method|Sentinel lymph nodes will be mapped by contrast-enhanced CT lymphography in breast cancer patients. A mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride will be used as a contrast agent provided by periaoreolar injection. No later than 10 days after the CT lymphography patients will receive surgical treatment with sentinel lymph node biopsy using the ICG-fluorescence method.
9681089|NCT04931030|Experimental|Low carbohydrate diet (LCBD)|Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.
9681090|NCT04931030|No Intervention|Low protein diet only (LPD)|Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.
10176597|NCT03831373|Experimental|Lower-limb-focused resistance training|Lower-limb-focused resistance training with elastic bands.
10176598|NCT03831373|Active Comparator|Stretching exercise|Stretching exercise program in a sitting position.
9681091|NCT04930575|Experimental|Muscle Energy Technique group|"Patients in the group (B) will receive muscle energy technique on tonic muscles in the neck (sternocleidomastoid, scalenes, levator scapulae, and upper trapezius) in addition to strengthening exercise for deep cervical flexors and advice to correct positions three times per week for 4 weeks.~The aim of the Muscle Energy Technique in the context of NP is to decrease pain, improve movement, motor control, and function and thereby reduce disability.~A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body thus alleviating the patient's signs and symptoms."
9976035|NCT01347502||HCP with non-smart phones|healthcare providers in MICU who have non-smart cellular phones
10176599|NCT03831126||betamethasone treatment|
10176600|NCT03831204||AHF/HFpEF|AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
10176601|NCT03831204||AHF/HFrEF|AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
10187270|NCT03727828||Patients with heart failure|Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
9681092|NCT04930575|Experimental|Mulligan Technique group|Patient in group A will receive specialized SNAGs technique adapted from Mulligan (2005), in addition to strengthening exercise for DNF muscles and advice to correct position three times per week for 4 weeks.
9681093|NCT04930510||Group 1 : Elderly 80 years or over patients referred for TAVI with CAD|Elderly 80 years or over patients referred for TAVI with CAD Group 1: Coronary lesion defined as significant (>50% narrowing) on the coronary angiography performed before TAVI, with or without PCI (decision of the heart team) Description of the coronary lesions included: proximal/non proximal, number of lesions, location of lesion
9681094|NCT04930510||Group 2 : No significant coronary disease group|No significant coronary disease group in the cohort of elderly 80 years or over referred for TAVI
9681095|NCT04930627|Experimental|oral administration of Empagliflozin|
10176602|NCT03831087|Other|TAVR-CMR|"All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D whole-heart coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA."
10176603|NCT03831087|Other|TAVR-CT|All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
10176604|NCT03831061|Experimental|Cognitive stimulation|"10 sessions of 45 minutes/week during 10 weeks. Each session included : (a) temporo-spatial orientation , (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~There are 54 participants subdivided into two groups of 27 participants that perform the same intervention in different days of the week."
10176605|NCT03831061|No Intervention|Control group (No intervention)|There are 68 participants in total. These participants did not receive intervention.
10176606|NCT03831009|Active Comparator|Weight-bearing stable/Gravity stable|Ankles that are considered stable using weight-bearing radiographs AND gravity stress test will be assigned to conservative treatment
10176607|NCT03831009|Active Comparator|Weight-bearing stable/Gravity unstable|Ankles that are considered stable using weight-bearing radiographs but unstable using gravity stress test will be assigned to conservative treatment
10176608|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity unstable|Ankles that are considered unstable using weight-bearing radiographs AND gravity stress test will be assigned to open reduction internal fixation (ORIF)
9681096|NCT04930848|Experimental|Intervention Arm|Euphorbia hirta
9681097|NCT04930848|Placebo Comparator|Placebo Arm|Terminalia arjuna and Terminalia bellerica
9681098|NCT04930523|Active Comparator|Decompression|It include the pre- Physiotherapy treatment than decompression and post physiotherapy treatment.
9681099|NCT04930523|Experimental|Experimental|It includes the Pre physiotherapy treatment than ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precaution and Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) then Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes and at last Post physiotherapy treatment
9681100|NCT04930497|Experimental|vestibular socket technique with bone grafting|
9681101|NCT04930497|Active Comparator|vestibular socket technique without bone grafting|
10176609|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity stable|Ankles that are considered unstable using weight-bearing radiographs but stable using gravity stress test will be assigned to open reduction internal fixation (ORIF)
10176610|NCT03831425|Experimental|Coenzyme Q|Each patient will be asked to take part in a 6 wk trial of pharmaceutical grade CoQ10 and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk CoQ10 trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
10187271|NCT03727828||healthy control|
10187272|NCT03727815|Experimental|Mindfulness Pain Management Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target pain management through mindfulness.
9681102|NCT04930887|Experimental|Exparel, Then Saline|Participants first received an endoscopically guided injection of Exparel (Bupivacaine). After 3 weeks they then received Placebo treatment (Saline).
9681103|NCT04930887|Experimental|Saline, Then Exparel|Participants first received Placebo treatment (Saline). After 3 weeks they then received an endoscopically guided injection of Exparel (Bupivacaine).
9681104|NCT04930679|Experimental|Group I|1 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
9681105|NCT04930679|Experimental|Group II|2 capsule of Andiabet x 3 times/ day . Taken 30 minutes before meals in 28 days
9681106|NCT04930640|Experimental|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 1x10^9 CFU/day, GF101 200 U/day)]
9681107|NCT04930640|Placebo Comparator|placebo group|1 times a day, 1 capsule for 1 time, before breakfast meal[350 mg/day (Bacillus amyloliquefaciens spore 0 CFU/day, GF101 0 U/day)]
9681108|NCT04930770|Experimental|Renal/renopancreatic transplant's patients with a verified seronegativity|
9976036|NCT01347515|Placebo Comparator|FOO250|FOO250 ppm, the standard virgin olive oil
9976037|NCT01347515|Active Comparator|FOO500|Olive oil enriched with its own broad-spectrum phenolic compounds; FOO500 ppm
9681109|NCT04930367|Active Comparator|Enhanced Standard of Care|To be implemented at all 12 clinic sites, includes a set of interventions aimed at optimizing the national standard of care (billboards/posters and radio shows, healthcare worker training, one-stop adolescent and youth friendly services, information/motivation walls, pill containers and tools to be used by clinic staff during clinical visits)
9681110|NCT04930367|Experimental|CombinADO Strategy|"To be implemented at 6 randomly selected clinic sites, includes all interventions in the Enhanced Standard of Care arm plus five additional intervention components, including 1) Mental health screening and linkage to adolescent-focused mental health support, 2) peer navigation support, 3) an informational video, 4) peer support groups for AYAHIV and 5) support groups for caregivers of AYAHIV"
9681111|NCT04930419|Other|Videolaryngoscopy group|
9681112|NCT04930419|Other|Direct laryngoscopy group|
10176611|NCT03831425|Placebo Comparator|Placebo|Each patient will be asked to take part in a 6 wk trial of placebo and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk placebo trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
10176612|NCT03831295|Experimental|Treatment (SD-101, BMS-986178)|"SAFETY COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and IV over 30 minutes on days 8, 29 and 58.~EXPANSION COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58."
9681113|NCT04930354|Experimental|Single arm|Single arm dose escalation study; ECP1014 oral capsule of10mg, 20mg, 40mg, 80mg and 160mg given once daily for 28 days
9681114|NCT04930458|Experimental|Nanosilver fluoride group|Nanosilver fluoride will be applied on carious lesion
9681115|NCT04930458|Active Comparator|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate group|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate will be applied on carios lesion
9681116|NCT04930458|Active Comparator|Sodium fluoride varnish group|Sodium fluoride varnish will be applied on carios lesion
9681117|NCT04930120||Transferred group|The transferred group includes all severe COVID patients admitted in a French ICU ward and then transferred between the 03/13/2020 and 04/10/2020 to another ICU located outside the region of the initial ICU stay.
9681118|NCT04930120||Control group|The control group includes patients selected out of those whose entire ICU care has taken place in one of the hospitals which transferred patients. Up to 4 control patients will be selected for each transferred patient.
9681119|NCT04930471||Metformin (all participants)|Patients with a new indication for Metformin (standard dosage as assigned by the treating physician) therapy. Samples will be collected before and after 12 weeks of Metformin treatment.
9681120|NCT04930393|Active Comparator|PECS II Block|This group will receive an interscalene block in addition to a pectoral nerve block under ultrasound guidance with local anesthetic injected in the plane between the pectoralis minor and serratus anterior muscles
9681121|NCT04930393|Active Comparator|Axillary Ring Block|This group will receive an interscalene block in addition to a ring block with local anesthetic injected subcutaneously along the axilla from anterior to posterior direction.
9681122|NCT04930289||LungGuard patients|Patients whose donor lung(s) was transported with the LungGuard device.
9681123|NCT04930289||Standard Transport Patients|Patients whose donor lung(s) was transported with a method other than the LungGuard
9681124|NCT04930224||Proliferative Diabetic retinopathy|40 patients with proliferative diabetic retinopathy
9681125|NCT04930224||Non-Proliferative Diabetic retinopathy|40 patients with non-proliferative diabetic retinopathy
9681126|NCT04930224||Healthy individuals|40 healthy persons
9681127|NCT04930211|Active Comparator|Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
9681128|NCT04930211|Active Comparator|Degenerative disc disease without Modic Type-1 changes|Transforaminal Epidural Steroid Injection will be performed on patients at the pathology detected level bilaterally. The Kambin approach will be preferred in order to reach the intervertebral disc.
9681129|NCT04930276|Experimental|GDM group|After participants are enrolled, they would be given medical nutrient treatment. Besides, they need have a follow-up visit every two weeks. Blood glucose, body weight, lifestyle and clinical information are collected. Blood samples and stool samples are collected in 28 and 32 pregnant weeks, respectively.
9681130|NCT04930276|Other|non-GDM group|After participants enrollment, they also would be given medical nutrient treatment. And the other conditions are same as the group of GDM.
9681131|NCT04930185|Experimental|Pamphlet|Participants will received pamphlet about COVID-19 vaccination
9681132|NCT04930185|Experimental|Webinar|Participants will received webinar about COVID-19 vaccination
9681133|NCT04930185|Experimental|SMS|Participants will received SMS about COVID-19 vaccination
9681134|NCT04930341|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
9681135|NCT04930341|No Intervention|Control group|Routine maintenance will be applied
9681136|NCT04929977|Other|Wearable device with smart mobile phone|20 mother/care provider-infant pairs practicing Kangaroo Mother Care, from a tertiary super-specialty hospital selected to wear the device ( few days in the hospital and for a week at home when discharged)
9681137|NCT04930380||Cases|"male and female aged 25 years or more~diagnosis of defined MS~written informed consent must be obtained before the enrolment."
9681138|NCT04930380||Controls|"male and female aged 25 years or more~written informed consent must be obtained before the enrolment no history of MS"
9681139|NCT04930055||Group 1|Patients with solid tumors receiving courses of cytotoxic therapy.
10176613|NCT03831308||Breast cancer new diagnosis|group will include volunteer women, diagnosed with breast cancer, in any stage, aged 18y or more; at least 100 patients will be recruited in medical oncology appointments; all subjects should be periodically submitted to non-invasive evaluation tests - that is, clinical test/clinical and physical assessment to collect information on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
10176614|NCT03830814||Cases|Patients with heart failure with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines
10176615|NCT03830827|Experimental|MBRP+vortioxetine intervention|"Participants who allocate to the experimental group will receive 8-week 10-20mg/day vortioxetine combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~10-20mg/day vortioxetine will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
10176616|NCT03830827|Experimental|MBRP intervention|"Participants who allocate to the control group will receive 8-week 1-2#/day placebo combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~1-2#/day placebo will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
10176617|NCT03830905|Experimental|XC221|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
10176618|NCT03830905|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
9681140|NCT04930055||Group 2|Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
9681141|NCT04930055||Group 3|Patients with solid tumors receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
9681142|NCT04930055||Group 4|Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
9681143|NCT04930055||Group 5|Patients receiving immune checkpoint inhibitors.
9681144|NCT04930055||Group 6|Patients who underwent allogeneic stem cell transplant within 12 months.
10176619|NCT03830762|Experimental|Cohort 1 / Cohort 2 (Active)|20mg or 30mg capsules of Xanamem respectively, to be administered PO once daily.
10176620|NCT03830762|Placebo Comparator|Cohort 1 / Cohort 2 (Placebo)|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
10176621|NCT03830957|Active Comparator|Ivabradine|
10176622|NCT03830957|Active Comparator|metoprolol|
10176623|NCT03830736|Placebo Comparator|Control product|A glucose solution (glucose and water) based on 42 gram carbohydrates.
10176624|NCT03830736|Experimental|Oat Beverage 1|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
10176625|NCT03830736|Experimental|Oat Beverage 2|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
10176626|NCT03830736|Experimental|Oat Beverage 3|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
10176627|NCT03830736|Experimental|Oat Beverage 4|The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
10176628|NCT03830801|Experimental|IVLCM tethered capsule for biopsies|IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.
9681145|NCT04930055||Group 7|Patients who underwent cellular therapy, including CAR-T cells or T cells with engineered TCRs within 12 months.
9681146|NCT04930055||Group 8|Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches
9681147|NCT04930055||Group 9|Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
9681148|NCT04930055||Group 10|Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
9681149|NCT04930055||Group 11|Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
9681150|NCT04930055||Group 12|Patients who have a cancer diagnosis but do not fall into group 1-11
9695530|NCT04777370|Experimental|posterior glenohumeral (PG) mobilization + thoracic manipulation|The group will receive a posterior glide mobilization at session #1, and a thoracic manipulation followed by posterior glide mobilization at session #2.
9695531|NCT04777305|Experimental|Aerobic exercise training|"The aerobic exercise training group, weeks 5-8 after surgery: this training will consist of 30 min. of walking, 3 times per week at an intensity of 60-70% of peak VO2 or RPE 6-7 on the Borg scale.~Weeks 9-26 after surgery: this training will consist of 60 minutes of exercise, 3 times per week at an intensity of 65-80% of peak VO2 or RPE 6-8 on the Borg scale. The aerobic exercises will consist of a treadmill or outside walking or running, stationary cycling or elliptical trainer in continuous and interval training."
9695532|NCT04777305|Experimental|Resistance exercise training|Resistance exercise training group, weeks 5-8 after surgery: this training will consist of 5-10 minutes of warmup, followed by 6-8 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. The intensity will increase on weeks 9-26 after surgery to 8-10 multi-joint exercises of 3-4 sets of 10 to 25 repetitions. For this training participants will use free-weights and body weight exercises.
9681151|NCT04930198|Other|Social Incentive|"For the social incentive, the mHealth application will track the participant's individual adherence score (% of doses taken), track the top scorers (leaderboard), and provide a figure highlighting the proportion of their peers with poor (<80%), medium (80-94%), or high (>94%) adherence scores. The display of the individual's adherence score relative to peer scores is considered a descriptive norm and is meant to portray what most people are doing, as young people often inaccurately estimate behaviors for their peer groups. Participants will also receive an injunctive norm, or an indication of what they ought to be doing. This will come in the form of an emoji or congratulatory vs. motivating text for those with high or low adherence scores, respectively. When coupled with descriptive norms, injunctive norms have counteracted regression to the mean for individuals who demonstrate desirable behaviors relative to their peers."
9681152|NCT04930198|Other|Social Plus Financial Incentive|"For the financial incentive, the top 5 scorers in the PEER+ arm will be eligible win a lottery prize each month of the 24 week pilot of 1000 Nigerian Naira (NGN) of data that can be directly loaded onto the winner's phone. Behavioral economics theory tells us that individuals are more averse to losses than rewarded by gains, so that even incentives/prizes should be framed in terms of losses. Accordingly, participants in the financial incentive arm will receive weekly motivating messages such as take your dose today or you lose the chance of winning the lottery."
9681153|NCT04930250|Experimental|Oat bran fibre processed with method A|Beverage powder with 12% oat bran processed with method A
9681154|NCT04930250|Experimental|Oat bran fibre processed with method B|Beverage powder with 12% oat bran processed with method B
9681155|NCT04930250|Experimental|Oat bran fibre processed with method C|Beverage powder with 12% oat bran processed with method C
9681156|NCT04930250|Active Comparator|Minimally-processed oat bran (positive control)|Beverage powder with minimally-processed oat bran (Positive Control)
9681157|NCT04930250|Placebo Comparator|Readily-digestible carbohydrate (negative control)|Beverage powder with readily digestible carbohydrate (Negative Control)
9681158|NCT04930146|Experimental|Intervention group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~Evaluating the meridian energy by M.E.A.D"
9681159|NCT04930146|No Intervention|Control group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~Conventional treatment.~Evaluating the meridian energy by M.E.A.D"
9681160|NCT04930146|Experimental|Intervention group (Moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~Evaluating the meridian energy by M.E.A.D"
9681161|NCT04930146|No Intervention|Control group (moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~Conventional treatment.~Evaluating the meridian energy by M.E.A.D"
9681162|NCT04930133||Cohort A|T790M+ patients sequentially treated with osimertinib in cohort A
9681163|NCT04930133||Cohort B|T790M- patients treated with chemotherapy or other treatments in cohort B
9681164|NCT04930133||Cohort C|patients with unknown mutation status in cohort C
9681165|NCT04930133||Cohort D|Cohort D included patients who were still ongoing with afatinib.
10176629|NCT03830970|Experimental|1 cup of canned beans of multiple varieties|Consumption of 1 cup of canned beans of multiple varieties each day for 4 weeks
10176630|NCT03830970|Experimental|1/2 cup of canned beans of multiple varieties|Consumption of 1/2 cup of canned beans of multiple varieties each day for 4 weeks
9681166|NCT04929951|Experimental|MFAT (Micro Fragmented Adipose Tissue)|Intra-articular shoulder injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's shoulder.
9681167|NCT04929951|Active Comparator|Conventional Therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg)
9681168|NCT04929964||Breast cancer|
9681169|NCT04930068|Experimental|ultra-sound|ultrasonic cavitation applied on abdominal region for 30 minutes, 2 times per week for 6 weeks.
9681170|NCT04930068|Experimental|aerobic exercise|aerobic exercises through treadmill (60-70% of VO2 max.) for 30 minutes, 2 times per week for 6 weeks
9681171|NCT04929743|Experimental|4.5 implants|
9681172|NCT04929743|Active Comparator|6.5 implants|
9681173|NCT04929756||Fixation PRL|Visual feedback will be provided at the the preferred retinal locus (PRL) to train subjects to attend to a fixation location. Feedback consists of a gaze-contingent ring whose size varies depending on task performance. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Gaze behavior will be measured with an eye tracker.
10176631|NCT03830970|Other|1 cup of White rice|Consumption of 1 cup of white rice each day for 4 weeks
10176632|NCT03830775|Experimental|Experimental - PRP injection|2cc of PRP is injected into the ulnocarpal joint
10176633|NCT03830775|Placebo Comparator|control - Saline injection|2cc of 0.9% sterile saline is injected into the ulnocarpal joint
10176634|NCT03830944||G1|"Study subjects with STEMI and increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
10176635|NCT03830944||G2|"Study subjects with STEMI and no increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
9681174|NCT04929756||Smooth Pursuit PRL|Visual feedback will be provided to train subjects to attend to a PRL for smooth pursuit eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on a drifting target. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Smooth pursuit tracking behavior will be measured with an eye tracker.
9976038|NCT01347515|Active Comparator|FOO750|Olive oil enriched with its own broad-spectra phenolic compounds; FOO750 ppm
9976039|NCT01347528|Experimental|TELEmonitoring intervention|
9976040|NCT01347528|No Intervention|Usual care|
10176636|NCT03830502||Salpingectomy|Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
10176637|NCT03830502||Tubal ligation|Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
9681175|NCT04929756||Saccade PRL|Visual feedback will be provided to train subjects to attend to a PRL for saccadic eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on an abruptly shifting dot. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Saccadic eye movement behavior will be measured with an eye tracker.
10176638|NCT03830489|Experimental|Large volume based preparation|This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.
10176639|NCT03830489|Active Comparator|Low volume based preparation|This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet
10176640|NCT03830632|Experimental|Plyometric Training Program|The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
10176641|NCT03830632|Active Comparator|Traditional Training|"AEROBIC TRAINING - A minimum of two low-intensity sessions a week consisting of 1 hour running. .~SHUTTLE SPRINTS - Placed two cones roughly 25 yards apart. Ask cricketer to sprint as fast as back and forth between the cones 12 times, for a total of six round-trips. ask them to finish in one minute. give rest for up to five minutes, then repeat once or twice."
10176642|NCT03830671|Experimental|investigational arm|the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months.
9681176|NCT04929756||Scotoma Awareness PRL|Subjects are often unaware of their scotomas because they are filled in with the surrounding background texture. The investigators will exploit this filling in to increase awareness of the scotoma by surrounding the scotoma with a visible disk that will be perceptually completed across the scotoma, rendering the scotoma visible. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Scotoma Awareness Disk at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
10176643|NCT03830515|Experimental|Closure of lacerations with microMend|Laceration closure with microMend
10176644|NCT03830463|Experimental|CTP-692|
10176645|NCT03830463|Placebo Comparator|Placebo|
10176646|NCT03830528|Experimental|Part A-1|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
10176647|NCT03830528|Experimental|Part A-2|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
10176648|NCT03830528|Experimental|Part A-3|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
10176649|NCT03830528|Experimental|Part B|There will be one cohort of Japanese healthy men dosed with multiple doses of KW-6356 or placebo and one potential additional cohort (KW-6356 dose as determined in Part A or placebo)
9681177|NCT04929756||Meta-Guidance PRL|Oculomotor control can be promoted in the location around our hands. The investigators will exploit this meta-guidance advantage by asking subjects to move their hand and their PRL to an on-screen target. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Hand Movement at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
9681178|NCT04929821|Other|Study Device Treated Group|Treated with the study device, UNITY-B Biodegradable Balloon-Expandable Biliary Stent System.
10176650|NCT03830528|Experimental|Part C-1|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
10176651|NCT03830528|Experimental|Part C-2|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
10176652|NCT03830528|Placebo Comparator|Placebo|
10176653|NCT03830684|Experimental|low-dose group|Baicalein Tablets group
10176654|NCT03830684|Experimental|high-dose group|Baicalein Tablets group
10176655|NCT03830684|Placebo Comparator|placebo group|control group
10176656|NCT03830593||Group 1|laparoscopic adrenalectomy group 1: tumor size as < 6 (group1)
10176657|NCT03830593||Group 2|Laparoscopic adrenalectomy group2: tumor size ≥ 6 cm (group2)
10176658|NCT03830593||Learning Curve|The patients, underwent laparoscopic adrenalectomy, were also classified into group A (1-25), B (26-50), C (51-75), and D (76-102) according to the chronological order of their surgery in order to evaluate the learning curve.
10176659|NCT03830606|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
10176660|NCT03830645|Experimental|Platelet rich plasma group|
9681179|NCT04930003|Experimental|Experimental: Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
10176661|NCT03830879||No treatment|This cohort study have any no treatment.
10187273|NCT03727815|Experimental|Mindfulness Self Esteem Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target self esteem through mindfulness.
10176662|NCT03830658|Experimental|Structured Intervention on Self-care with AVF|The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.
10176663|NCT03830658|Active Comparator|Usual-Care Control|Educational training was given during HD sessions. The dialysis nurse provided information about arteriovenous fistula care and trained the patient when he/she felt it was required. The dialysis units had no documentation concerning the educational training given to patients and the moment to provide such information was not defined, either.
10176664|NCT03830697|Experimental|Menstruation situation TCM symptom score standard|
10176665|NCT03830697|Placebo Comparator|Sham intervention|
10176666|NCT03830554|Experimental|intervention group|product name: organic Atlas cedar wood essential oil (Cedrus Atlantica): the intervention group smell 2 drops of organic Atlas cedar wood essential oil (applied on cotton ball) for a period of five consecutive nights (at least 8 hours each night).
10176667|NCT03830554|No Intervention|control group|participants of this group received no intervention.
9681180|NCT04930003|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9681181|NCT04930003|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9681182|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9681183|NCT04930003|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers aged 18-50 years who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
9681184|NCT04930003|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 volunteers from 50 years old and elder who will be the QazCoVac-P - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
9681185|NCT04929873|Placebo Comparator|routine treatment|routine nursing
9681186|NCT04929873|Experimental|Experimental group|Immediately after the establishment of the side branch cycle, the closed transdone is connected for real-time monitoring of pressure, and clinical nursing practice is guided by transdictor pressure.
10176668|NCT03830580|Experimental|Sung voice|
10176669|NCT03830580|No Intervention|Control|
10176670|NCT03830424||Control group|Healthy term newborns without pain relief during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
10176671|NCT03830424||Sucrose group|Healthy term newborns with oral application of sucrose during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
9681187|NCT04929665|Active Comparator|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
9681188|NCT04929665|Active Comparator|Erector spinae block|Patients who are planned to have an erector spina block will be advanced to the interfacial area under the erector spinae muscle by ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
9681189|NCT04929665|Active Comparator|Thoracic Paravertebral block and Erector spinae Block|In patients who are planned to have combined erector spinae block and thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 10 ml of 0.25% bupivacaine will be given to this area. Then, with the same needle, return 1-2 cm from the paravertebral area and inject 10 ml of 0.25% bupivacaine into the interfacial area under the erector spinae muscle.
9681190|NCT04929990|Experimental|Inpiratory and expiratory muscle training|The initial intensity of training was set on 30% of the MIP and MEP for inspiratory and expiratory muscle training, respectively. The intensity was adjusted to add 5% of resistance each week
9681191|NCT04929990|Active Comparator|Inspiratory muscle training|The initial resistance of the breathing trainer was also set on 30% of MIP, and the following adjustments were also in accordance to the protocol of the experimental group
9681192|NCT04929613|Experimental|Mindfulness-Based Resilience Training|Designed to train participants in a number of experiential exercises evoking qualities of mindfulness: mental focus, sustained attention and personal and situational awareness. These exercises include versions of the body scan (body awareness exercise), sitting meditation, mindful movement, walking meditation, eating meditation, mindful martial arts exercises and other elements of mindfulness.
9681193|NCT04929652|Experimental|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combine With Immunotherapy and Chemotherapy.
9681194|NCT04929717|Experimental|Intervention|The personal information form and BSES-SF were administered to women in the hospital before the intervention. Breastfeeding education and counseling were provided via social media (WhatsApp) to support women for breastfeeding and to ensure the continuity of breastfeeding in the postpartum period. Breastfeeding education was given to women in the first four weeks after discharge from the hospital. After the breastfeeding education was completed via social media, the counseling process started. Counseling was conducted via social media with a question-answer method between the first and 6th months of postpartum.
9681195|NCT04929717|Other|Control|The women in the control group were pre-tested at the hospital before discharge. The BSES-SF was re-administered by phone at the 3rd and 6th postpartum months. The control group received the routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures. Except for routine breastfeeding training, no intervention was applied to the control group.
9681196|NCT04929626|Active Comparator|Nebulized Ventolin|Nebulized Ventolin will given to 1st group after every 20 min for 1 hour
9681197|NCT04929626|Experimental|Nebulized Magnesium Sulphate + Ventolin|Dose of Nebulized Magnesium sulphate will vary in 3 subgroups.
9681198|NCT04929782|Active Comparator|Resin-based sealant|A dental isolation device was used (Mr. Thisty One Step, Zirc Dental, Buffalo, MN, USA) and the treatments were conducted by one operator according to following steps; Group 1: Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
9681199|NCT04929782|Active Comparator|Giomer sealant|Group 2: Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
9681200|NCT04929795|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of music beat serving as a type of rhythmic auditory stimulation (RAS).
9681201|NCT04929795|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
9681202|NCT04929795|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of RAS.
9681203|NCT04929795|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
9681204|NCT04929444|Active Comparator|Training group|The professionals of the primary care teams that are in Intervention group would receive the training at the beginning of the study
10176672|NCT03830424||Mother milk group|Healthy term newborns with oral application of mother milk during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
10176673|NCT03830437||Case group|The group will be subjected to double weighing, before and after the next 6 breastfeeding. Breastfeeding will be carried out each 4 hr.
10176674|NCT03830437||Control group|The group will be subjected to monitoring of body weight only at 24, 36 hr and 48 hr of life.
9681205|NCT04929444|No Intervention|Common Practice|The professionals of the primary care teams that are in Control group will be offered the training after the conclusion of the study
9681206|NCT04929314|Experimental|Intervention|Participants in the intervention group receive specialised nursing care that focuses on the interactive communication model. The nurses who deliver care to participants in the intervention group receive specific education and training in order to be able to provide nursing based on the interactive communication model and more individualised nursing based on health literacy level.
9681207|NCT04929314|No Intervention|Control|The participants in the control group receive usual care. The 98 municipalities in Denmark have a specialised role in community care and rehabilitation where nursing and practical help is carried out in the patients' own homes. Community care is usually provided at regular intervals based on a clinical evaluation of the patients' needs.
9681208|NCT04929691|Experimental|CPAP- Helmet Users|Patients admitted to a study site with suspected or confirmed COVID-19 and who consented to using the CPAP helmet
9681209|NCT04929691|Active Comparator|Non-CPAP helmet users|Patients admitted to a study site with suspected or confirmed COVID-19 but who did not use a CPAP helmet
9681210|NCT04929561|Experimental|Video-conferencing group|The mothers in the video-conferencing group were counseled via video-conferencing a total of six times (three times a week, at equal intervals) during the first 2 weeks after birth. Each interview was approximately 15-20 minutes. In video-conferencing sessions, the breastfeeding position, the mother's grasping the breast, the baby's latch-on, and sucking duration were observed. Mothers' questions were answered and solutions were offered for breastfeeding problems (sore nipple, engorgement, etc.).
9681211|NCT04929561|No Intervention|Control group|The mothers in the control group were given usual care before discharge and no intervention was made after discharge.
9681212|NCT04929574||beta thalassemia patients|
9681213|NCT04929860|Active Comparator|handwashing|This arm receives a scalable social marketing campaign using innovative behaviour change approaches to improve handwashing. The intervention is delivered by a commercial social marketing business unrelated to the investigating organisations
10176675|NCT03830398|Active Comparator|Paracetamol|Parol group: intravenous infusion in 30 min Generic name: Parol Dosage form: intravenous Dosage: 1 gr Frequency: preop one dose only Duration: For one week
10176676|NCT03830398|Active Comparator|Deksketoprofen trometamol|Sertofen group: intravenous infusion in 30 min Generic name: Sertofen Dosage form: intravenous Dosage: 50 mg Frequency: preop one dose only Duration: For one week
9681214|NCT04929860|No Intervention|control|
9681215|NCT04929457||Individuals screened for Familial Hypercholesterolemia|Individuals participating in diagnostic activities in the digiphysical health care screening program for Familial Hypercholesterolemia and have provided informed consent are included in the cohort.
10176677|NCT03830398|Placebo Comparator|Placebo|Placebo group: intravenous infusion in 30 min Generic name: Serum physiologic Dosage form: intravenous Dosage: 100 ml Frequency: preop one dose only Duration: For one week
10176678|NCT03830242|Experimental|<Sup>18<Sup>F-FDG PET/CT study group|<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
10187274|NCT03727815|No Intervention|Non-intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
10187275|NCT03727763|Experimental|FIVC group|Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)
10176679|NCT03830242|Other|B-ultrasonography group|B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
9681216|NCT04929535|Experimental|30% hydrogen peroxide|30% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
9681217|NCT04929535|Placebo Comparator|3% hydrogen peroxide|3% hydrogen peroxide liquid topical application. 2 drops (0.10 ml) of hydrogen peroxide solution per centimeter of lesion. Once every week for continuous 4 weeks. If there is complete clinical response, further hydrogen peroxide will not be done.
9681218|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 1|
10176680|NCT03830268|Experimental|MCT intake in young participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
10176681|NCT03830268|Experimental|MCT intake in older participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
9681219|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 2|
9681220|NCT04929288|Experimental|Males|Participants in this group will be adult male drinkers.
9681221|NCT04929288|Experimental|Females|Participants in this group will be adult female drinkers. Data will be segregated by menstrual cycle phase.
9681222|NCT04929275|Other|Enhanced recovery program|
10176682|NCT03830138||Acute coronary syndrome patients:|One hundred patients with acute coronary syndrome.
10176683|NCT03830138||Controls:|Fifty healthy control
10176684|NCT03830346|Experimental|Experimental|In the experimental group, instrument-assisted soft tissue mobilization techniques and post-isometric horizontal adduction stretches were performed. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment.
9681223|NCT04929522|Active Comparator|IANB/inferior alveolar nerve block|patients will be given standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
9681224|NCT04929522|Active Comparator|IANB+IO|patients will be given standard IANB plus an intra-osseous with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
9681225|NCT04929522|Active Comparator|IANB+PDL|patients will be given standard IANB plus a PDL injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
9681226|NCT04929522|Active Comparator|IANB+BI|patients will be given standard IANB plus a BI injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
9681227|NCT04929093|Experimental|Novel dose adjustment schedule|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with novel dose adjustment schedule.
10176685|NCT03830346|Experimental|Control|Control group only underwent soft tissue mobilization. With the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times.
10176686|NCT03830164|Experimental|Treatment (atorvastatin, vitamin E, pentoxifylline)|Patients receive atorvastatin PO QD for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning week 7, patients receive atorvastatin PO QD, vitamin E PO QD, and pentoxifylline PO TID for up to 12 months in the absence of disease progression or unacceptable toxicity.
10176687|NCT03830073||Group I:|Seventy patients with pancreatitis
10176688|NCT03830073||Group II:|Thirty healthy controls
10187276|NCT03727737|No Intervention|Sham|Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment
10187277|NCT03727737|Active Comparator|ACTIVE|Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment
9681228|NCT04929093|Active Comparator|Conventional dose adjustment|The patients in this group had late injections of more than 16 weeks in maintenance period, and restarted SCIT with conventional dose adjustment schedule.
9681229|NCT04929093|Active Comparator|Continuous cluster SCIT schedule|The subjects had a routine cluster SCIT schedule without interrupted period.
9681230|NCT04929145||MICROMS|No intervention will be administered. Stool, hair, and blood samples will be collected at baseline and three months post baseline. Clinical follow-up will occur at year 1, 2, and 4.5 (neurological consultation) and in-between visits (regular follow-up).
9681231|NCT04929353|Other|ARM A|Self-Reporting by electronic survey consisting of 14 items selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0)
9681232|NCT04929353|Other|Arm B|Standard symptom reporting following the conventional modalities of clinical oncology practice
9681233|NCT04929509|Experimental|self-assembling peptide (P11-4)|"Curodont Repair; Credentis will be applied to the~white spot lesion at baseline."
9681234|NCT04929509|Active Comparator|nanosilver fluoride varnish|"(Study group) Nano-silver fluoride varnish will be applied to the~white spot lesion at baseline."
9681235|NCT04929509|Placebo Comparator|sodium fluoride varnish|"(Control group) Fluoride varnish (Duraflor) will be applied to the~white spot lesion at baseline and 6 months follow up."
9681236|NCT04929327|Active Comparator|Self-etch resin based sealant|Self-etch resin based sealant (prevent seal) without prior sandblasting.
10176689|NCT03830112|Experimental|Pilates exercise with Theraband|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based exercises with Theraband® (blue color) from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based exercises with Theraband® (blue color) from week five to eight.~(saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
10176690|NCT03830112|Active Comparator|Pilates exercise|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based mat exercises from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based mat exercises from week five to eight. (saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
10176691|NCT03830385|Experimental|Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or|
10176692|NCT03830372|Experimental|VR Tier One|"Patients will receive:~10 sessions of 20 minutes of VR Tire One therapeutic game,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
10176693|NCT03830372|Active Comparator|Control|"Patients will receive:~10 sessions of 20 minutes of Schultz Autogenic Training,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
10176694|NCT03830086|Other|Group A: general anesthesia|Patients undergoing gynecological laparoscopic surgery under general anesthesia, using the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium, Sevoflurane
9681237|NCT04929327|Active Comparator|Prior Sandblasting|Self-etch resin based sealant prevent seal) with prior sandblasting.
9681238|NCT04929327|Active Comparator|Total-etch resin based sealant|Total-etch resin based sealant (ultraseal XT) (Ultradent Pro. Inc., USA)
9681239|NCT04929418|Other|10 km continuous running|Participants will perform a test of 10 km coninuous running.
9527641|NCT03218228|Placebo Comparator|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
9681240|NCT04929418|Other|1.5 km swimming|Participants will perform a test of 1.5 km coninuous swimming.
9681241|NCT04929301|Experimental|AME Hand-Expression|Participants in the antenatal milk expression (AME) group will learn hand-expression from a certified lactation consultant beginning at 37 weeks of pregnancy. At the same visit, the PI or RA will also provide oral and written instructions for AME at home, specifically instructing participants to do AME 1-2 times per day for no longer than 10 minutes.
9681242|NCT04929301|Active Comparator|Education|Participants in the education group will receive a weekly educational hand-out on varying breastfeeding topics (e.g., latch).
9681243|NCT04929340|Experimental|experimental|5 drops each day before bedtime but after toothbrushing. L. reuteri DSM 17938, L. reuteri ATCC PTA 5289, with a minimum of 100 million live bacteria of each strain.
9681244|NCT04929340|Placebo Comparator|placebo|5 drops each day before bedtime but after toothbrushing. The placebo drops had identical composition color and taste but no probiotic bacteria.
9681245|NCT04929171||Patients with myofascial pain having centralized pain features|Adult patients with myofascial pain having centralized pain features who will be undergoing physical therapy
9681246|NCT04929158|Experimental|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Intravascular ultrasound guided surgery
9681247|NCT04929158|No Intervention|Angiography-Guided Primary Percutaneous Intervention (PCI)|Angiography-Guided guided surgery
9681248|NCT04929015|Experimental|Diagnostic (biospecimen collection)|"Patients will receive standard treatment with surgery, HIPEC, and chemotherapy as appropriate to the patient situation, extent of disease and multi-disciplinary evaluation.~Patients undergo blood sample collection for ctDNA analysis at baseline, pre-surgery, post-surgery and every 3 months up to 2 years.~Patients undergo tissue collection before or during surgery and their medical records are reviewed."
9681249|NCT04929197|Experimental|Wear Personalized breast holder system (PERSBRA) to receiving radiotherapy|Wear PERSBRA to the end of radiotherapy.
9681250|NCT04928911||Adults receiving COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
9681251|NCT04928937||bariatric surgery|consisting of gastric bypass surgery: Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG)
9681252|NCT04928937||conservative therapy|consisting of medical visits, nutritional counseling, physiotherapy, anti-obesogenic medication and psychological coaching
9681253|NCT04929262|Active Comparator|Researcher-Only|The researcher-facilitated presentation, led by two clinical psychology graduate students, will be the same for all schools.
9681254|NCT04929262|Experimental|Key Opinion Leader|The key opinion leader (KOL) co-facilitated presentations will include the same core principles as the researcher-facilitated presentation but may vary by school in terms of specific examples and content emphasized based on KOL feedback. A caregiver KOL from the local community (selected by the parent teacher association or a similar group) will co-facilitate the presentation with a clinical psychology graduate researcher.
9681255|NCT04929067|Experimental|Immunotherapy combined with neoadjuvant chemotherapy forlocally advanced HNSCC|
9681256|NCT04929106|Experimental|MHealth intervention|Tailored physical activity program with motivational mobile health support on everyday levels of physical activity
9681257|NCT04929119||Before wearing the Orthokeratology|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
10176695|NCT03830086|Other|Group B: regional anesthesia|Patients undergoing gynecological laparoscopic surgery under regional anesthesia, using the following drugs: Sufentanil, Bupivacaine
9681258|NCT04929119||Wear Orthokeratology for a week|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
9681259|NCT04929119||Wear Orthokeratology for a month|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
9681260|NCT04929119||Wear Orthokeratology for three months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
9681261|NCT04929119||Wear Orthokeratology for six months|OPD-Scan was performed and the following data were recorded: 4 mm high order strehl ratio (SR) , 4 mm high order corneal aberrations (Hoa ) , Spherical Aberrations (SA) , Coma Aberrations (Coma) , Trefoil Aberrations (RMS) , corneal aspheric index (Q, e) , corneal surface regularity index (SRI) , corneal surface asymmetry index (Sai)
9681262|NCT04929002||McArdle Disease|
10176696|NCT03830216|Experimental|Treatment Arm|Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
10176697|NCT03830216|Sham Comparator|Control Arm|Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.
10176698|NCT03830177|Experimental|Adults|All adults in the study will receive the treatment for dry scalp.
10176699|NCT03830177|Experimental|Children|All children in the study will receive the treatment for dry scalp.
10176700|NCT03830294|Experimental|Self-adhesive Group|The participants used the adhesive breast prosthesis that adheres to the skin.
10176701|NCT03830294|Active Comparator|Conventional Group|The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
9681263|NCT04929002||Pompe disease|
9681264|NCT04929002||Controls|
9681265|NCT04928976||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9681266|NCT04928976||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9681267|NCT04928976||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
10176702|NCT03830190|Experimental|Intervention group|Parkinson's disease nurse specialist care
9681268|NCT04928976||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9681269|NCT04928469||P.1|Patients infected with the P.1 SARS-CoV-2 variant
9681270|NCT04928469||Other variants|Patients infected with SARS-CoV-2 variants other than P.1
10176703|NCT03830190|No Intervention|Control group|No intervention
10176704|NCT03830125|Experimental|Single Ascending Doses|
9681271|NCT04928443||Scar dressing group|Patients planning to treat surgical scar with scar dressing
9681272|NCT04928443||Regular care group|Patients treated with adhesive tapes or strips or did not take care of surgical scar.
9681273|NCT04928404|Other|obstructive sleep apnea patients|
9681274|NCT04928365|Other|Advanced melanoma patients|
9681275|NCT04928365|Other|Stage III and IV melanoma patients after radical surgery|
9681276|NCT04928495|Placebo Comparator|Treatment group 1|Control placebo (Vitamin C - 500mg / day, for 10 days)
9681277|NCT04928495|Active Comparator|Treatment group 2|N-acetylcysteine (NAC; 1800 mg / day, for 10 days)
9681278|NCT04928495|Active Comparator|Treatment group 3|NAC (1800 mg / day) + bromhexine-BMX (32 mg / day for 10 days)
9681279|NCT04928456|Experimental|OMT Intervention Arm|"OMT will include:~Myofascial release of the thoracic inlet: gentle pressure applied to shoulders and neck to move the tissue in different directions with a gentle motion.~Pectoral traction: The armpit will be contacted with the finger pads of the doctor and each side will be gently grasped and have a slow pulling force applied towards the shoulders.~Diaphragm release with MFR: The doctor will touch below the ribs on each side and will apply gentle pressure and move the tissue from side to side.~Splenic pump: below the ribs on the left hand-side, the doctor will apply pressure and release pressure several times to create a vibration over the area just below the ribs.~Thoracic pump: The doctor will place their hands over the chest wall on each side and will apply pressure and release pressure several times to generate a pumping action of about 100 times in one minute.~Treatment will last 5 minutes with each technique lasting 1 minute."
9681280|NCT04928456|No Intervention|Control|Participants in the control group will undergo the same assessments as the OMT intervention arm and will receive their vaccinations, but will not receive any OMT.
9681281|NCT04928885|Experimental|WW Treatment Group|Individuals will receive the 12-week Wits Workout Program. Individuals will take the baseline, 3 mos and 6 mos follow-up surveys. They will also take the Wits Workout satisfaction survey and participate in the 6 mos focus-groups.
9681282|NCT04928885|Other|WW Control Group|Individuals will be on a waitlist and will take the baseline, 3 mos and 6 mos. assessments. They will receive the Wits Workout workshop after the 6 month study period is completed.
10176705|NCT03830125|Experimental|Multiple Ascending Doses|
10176706|NCT03829878|Experimental|CP101|CP101 (Full Spectrum Microbiota) Capsule
10176707|NCT03829878|Placebo Comparator|Placebo|Placebo for CP101
10176708|NCT03830047|Active Comparator|nd yag laser|Applying nd yag laser to vulva
10176709|NCT03830047|Sham Comparator|Co2 laser|Applying CO2 laser to vulva
10176710|NCT03829995|No Intervention|Control group|Participants in the control group received the normal care following the Danish standard procedure.
9681283|NCT04928859||the albumin group|The albumin group, the patients who used albumin for resuscitation during their hospitalization in the burn ward constituted the albumin group.
9681284|NCT04928859||the control group|The control group, the patients who did not use albumin during their hospitalization in the burn ward constituted the control group.
9681285|NCT04928209|No Intervention|Usual Care (High-Income)|This group will receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments. They will not be randomized to receive supplemental teletherapy (intervention) and usual care.
9681286|NCT04928209|No Intervention|Usual Care (Low-Income)|"This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy but are not randomized to receive the intervention after allocation. Like the Usual Care (High-Income) arm, they will only receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments and usual care."
9681287|NCT04928209|Experimental|Usual Care + Teletherapy (Low-Income)|This group includes the low-income families who satisfy the criteria to receive supplemental speech-language teletherapy and are randomized to receive the intervention. They will receive both 3x comprehensive assessments every 9 months AND access to supplemental speech-language teletherapy for the 18-month study period.
9681288|NCT04928183|Sham Comparator|Room Air Rebreathe|Rebreathe protocol will be completed with a room air syringe rather than CO
9681289|NCT04928183|Experimental|CO Rebreathe|Rebreathe protocol will be completed with Carbon Monoxide
10176711|NCT03829995|Active Comparator|Intervention group|Participants in the intervention group received the normal care following the Danish stadard procedure. Additionally the participants was also offered the possibility to contact a hospital pharmacy department by phone or mail for drug counseling.
10176712|NCT03829865||Water-perfused HREM|Healthy volunteers examined with water-perfused high resolution esophageal manometry
10176713|NCT03829865||Solid-state HREM|Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter
10176714|NCT03830034|Experimental|Amino Acid chelated iron tab 15 mg group|Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
9681290|NCT04928170||HALLOA|306 individuals with knee pain in the age between 30 and 65 years, without cruciate ligament injury
9681291|NCT04928105|Experimental|CD7 CAR-T|
9681292|NCT04928066|Experimental|Tofacitinib (TF)+Iguratimod (IGU)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
9681293|NCT04928066|Other|Tofacitinib (TF)|"Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
9681294|NCT04928053|Experimental|phenotypic data and a blood prelevment|
9681295|NCT04928001|Other|Youth Thrive iCBT program|Youth Thrive iCBT online program
9681296|NCT04928027||Persons with PD|Adults with PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Self-Assessment
9681297|NCT04928027||Significant Others of those with PD|Adults whose significant other has a diagnosis of PD will be provided with email link to complete the Comprehensive Executive Function Inventory-Observer report
9681298|NCT04927936|Active Comparator|Janssen vaccine only|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination, blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
9681299|NCT04927936|Experimental|Janssen vaccine - Janssen vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Janssen vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
9681300|NCT04927936|Experimental|Janssen vaccine - Moderna vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Moderna vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
9681301|NCT04927936|Experimental|Janssen vaccine - Pfizer vaccine|"HCW already vaccinated with Janssen vaccine once. 84 days after the first vaccination a boost will be given with Pfizer vaccine and blood samples will be drawn (day =0, baseline) This will be repeated at day 28 (primary endpoint), day 180 and day 365. This arm will have 87 +25% seropositive for SARS-CoV-2 IgG at baseline or loss to follow-up = 108 participants.~In this arm half of the participants will undergo a detailed immunological assessment (n=54 per arm)."
9681302|NCT04927949|Sham Comparator|patients without HPR|standard primary PCI
9681303|NCT04927949|Experimental|patients with HPR randomized to cangrelor|Cangrelor perfusion started before PCI
9681304|NCT04927949|Placebo Comparator|patients with HPR randomized to standard of care|standard primary PCI
10176715|NCT03830034|Active Comparator|Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group|Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.
10176716|NCT03829956|Other|Snoring and mild OSA|This cohort of participants has been diagnosed with primary snoring or mild obstruction sleep apnoea. A medical device (intra-oral tongue stimulation device) will be introduced for 6 weeks and the effects will be assessed by comparing the outcome measures before and after the intervention.
9681305|NCT04928807|Experimental|Short course radiotherapy sequential camrelizumab and chemotherapy|"Radiotherapy will employ conformal or intensity-modulated radiation therapy, with a pelvic irradiation dose of 25 Gy/5 Fractions/1 week. Then rest for 1 week after radiotherapy and begin to receive neoadjuvant chemotherapy CAPOX and camrelizumab, for 2 cycles.~The patients were operated within 10 weeks after the last radiotherapy, and the surgical method is total mesorectal excision.~Postoperative adjuvant therapy will be started 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX + camrelizumab) for 6 cycles"
9681306|NCT04928807|Active Comparator|Long term concurrent chemoradiotherapy and sequential chemotherapy|"The patients received neoadjuvant therapy of CAPOX 2 weeks after long-term concurrent chemoradiotherapy (28*1.8Gy, during the same period, capecitabine was 825 mg / m2, twice a day, 5 days a week).~The patients were operated within 10 weeks after the last radiotherapy. Adjuvant therapy should begin within 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX) for 6 cycles"
9681307|NCT04928586|Experimental|Pirfenidone group|CTD-ILD patients treated with DMARDs and pirfenidone
9681308|NCT04928586|Active Comparator|No-Pirfenidone group|CTD-ILD patients treated with DMARDs, without pirfenidone
10176717|NCT03829696|Experimental|Non-pregnant women|"Participants will be provided Mifeprex® (oral mifepristone 200 mg) and misoprostol 800 mcg to be administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone) if unintended pregnancy occurs during the study period and the participant would like to end of the pregnancy. Participants who test positive for pregnancy will consult with a study clinician over the phone prior to administering mifepristone and misoprostol, and will then attend an in-person follow-up visit.~All participants will be provided with a single dose of ella® (ulipristal acetate emergency contraception 30 mg) by a clinician at the beginning of the study, as well as 6 AccuHome® midstream urine pregnancy tests."
10176718|NCT03829839|Active Comparator|Oxytocin or PLC|Single dose of intranasal oxytocin (24 international units) or PLC.
9681309|NCT04928651||Clonidine|Preterm infants (< gw 37+0) who are in need for analgesic or sedative medication will receive treatment with clonidine according to an algorithm based on pain and sedative scoring results
9681310|NCT04928833|Experimental|Pilates Group|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks.
9681311|NCT04928833|Active Comparator|Control Group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
9681312|NCT04928833|No Intervention|Evaluation of 'Core' Stability|"Core stability was evaluated with two important dimensions, core strength and endurance tests."
9681313|NCT04928833|No Intervention|Ultrasound Examination of M. Transversus Abdominus and M. Multifidus|M. transversus abdominus (TrA) and m. multifidus (MF) muscles were visualized by ultrasonography and the evaluations were performed by an experienced radiologist who was blind to the case groups.
9681314|NCT04928833|No Intervention|Evaluation of Lower Extremity Functional Strength|Lower extremity functional strength was evaluated with the 5-Times Sit-and-Stand Test.
9681315|NCT04928833|No Intervention|Evaluation of Balance|Balance was evaluated using the Berg Balance Scale (BBS).
9681316|NCT04928833|No Intervention|Evaluation of Functional Mobility|Functional mobility was evaluated using the Timed Up and Go Test (TUG).
10176719|NCT03829839|Active Comparator|Lorazepam or PLC|Single dose of lorazepam (1mg) or PLC
10176720|NCT03830021|Experimental|Salt reduction program|Salt reduction program.
10176721|NCT03830021|Active Comparator|Healthy lifestyle program|Healthy lifestyle program.
10176722|NCT03829748|Experimental|Intermittent aspiration|Empty syringe of 10cc and intermittent aspiration during puncture
10176723|NCT03829748|No Intervention|Continous/standard aspiration|Empty syringe of 10cc and continous aspiration during puncture
10176724|NCT03829761|Experimental|Cerebellar rTMS|Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
10176725|NCT03829761|Sham Comparator|Sham TMS|Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
10176726|NCT03829943||Vitamin D deficiency|The study group will be males discovered to have Vitamin D deficiency.
10176727|NCT03829943||Control group|The control group will be males with normal Vitamin D status
9681317|NCT04928833|No Intervention|Evaluation of Functional Exercise Capacity|Functional exercise capacity was evaluated using the 6 Minute Walking Test (6-MWT).
9681318|NCT04928833|No Intervention|Activities of Daily Living and Evaluation of Motor Impairment|Activities of daily living and motor impairment were evaluated with activities of daily living (II) and motor impairment (III) sub-dimensions of the Unified Parkinson's Disease Rating Scale (UPDRS).
10176728|NCT03829969|Experimental|Toripalimab|Toripalimab combine with paclitaxel and cisplatin
10176729|NCT03829969|Placebo Comparator|placebo|Placebo combine with paclitaxel and cisplatin
10176730|NCT03829774|Experimental|Primary Relief v 2.0 Device|The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
10176731|NCT03829774|Placebo Comparator|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
10176732|NCT03830008|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over the list with the general practitioners (GP) in the neighborhood of the participant and the written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by this physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
9681319|NCT04928833|No Intervention|Evaluation of Freezing|The Freezing of Gait Questionnaire (FOGQ) was used to identify and evaluate the subjective perception of Parkinson's patients regarding the severity and effect of freezing on gait performance.
9681320|NCT04928833|No Intervention|Evaluation of Fatigue|Fatigue, one of the non-motor findings associated with Parkinson's, was evaluated with the Parkinson's Fatigue Scale-16 (PFS-16).
10176733|NCT03830008|Experimental|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
10176734|NCT03830060||Group I:|Fifty AP patients on admission
9681321|NCT04928833|No Intervention|Evaluation of Quality of Life|Quality of Life was evaluated with Parkinson's Disease Questionnaire-39 (PDQ-39).
9681322|NCT04928820|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.
9681323|NCT04928547||U.S.|
9681324|NCT04928547||MRI|
9681325|NCT04928248|Experimental|Diabetes Dashboard integrated with Disease Manager App|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated Diabetes Dashboard that is integrated with the diabetes module of the Disease Manager App).
10176735|NCT03830060||Group II:|The previous AP patients after 72 hours
9681326|NCT04927897||Observational|In addition to standard workup and treatment, patients will undergo pre-operatively, after induction of general anaesthesia, an endorectal ultrasound and rigid rectoscopy as study procedures.
9681327|NCT04928638|Experimental|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
10176736|NCT03829670||Delirium Group|"UBACC: University of California, San Diego Brief Assessment of Capacity to Consent.~The participant may decline participation after this UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) assessment and will be removed from the study.~The Short IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) is administered to the legally authorized representative or caregiver by Dr. Schmidt. If the potential participant scores 3.3 or lower, the participant will continue in the delirium group. If higher, patient likely with pre-existing dementia. These patients are not eligible for study participation.~Delirium Rating Scale 98 will be performed on the ALGH (Advocate Lutheran General Hospital) rehabilitation unit~Cytochrome P450 testing~Delirium Status: Admission, Hospital Discharge, Outpatient Visit~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
10176737|NCT03829670||Patients without delirium|"Cytochrome P450 testing~Delirium Status: Admission, Hospital Discharge, Outpatient Visit~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
10176738|NCT03829709|Experimental|Intervention Group|The inspiratory muscle training (IMT) will be performed in the morning shift for 30 minutes, 3 times a week for 5 weeks. The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
9527642|NCT03218228|Experimental|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
9681328|NCT04928638|Experimental|Written educational intervention|Educacional intervention about the disease, the use of medication and the context of pandemic
9681329|NCT04928638|No Intervention|Control intervention|Control intervention
9681330|NCT04928690||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9681331|NCT04928690||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9681332|NCT04928690||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9681333|NCT04928690||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9681334|NCT04928625|Experimental|SHR-A1904|
9681335|NCT04928560||disease free survival|disease free survival
9681336|NCT04928560||non-disease free survival|non-disease free survival
9681337|NCT04928612|Experimental|Part A -CBP-1018 Dose escalation/Part B- CBP-1018 monotherapy|"Part A: CBP-1018 administrated iv Q 2 W (4 weeks/cycle), utilizing accelerated titration at lower doses (0.03 mg/kg and 0.06 mg/kg) and an i 3+3 design at following doses (0.08 mg/kg,0.10 mg/kg,0.12 mg/kg and 0.14 mg/kg, etc.), respectively.~Part B：Further evaluate the efficacy and safety profile of CBP-1018 in 4 tumor-specific cohorts.Cohort 1 (Metastatic castration resistant prostate cancer, mCRPC)；(Advanced renal cell cancer, RCC); Cohort 3 (Advanced lung squamous cell cancer, LSCC); Cohort 4 (Other advanced solid tumors)."
9695533|NCT04777305|Experimental|Combination exercise training|"The combination exercise training will consist of a combined aerobic and resistance exercise training sessions three times weekly. At weeks 5-8 after surgery the sessions will include 5-10 minutes of warmup, followed by 3-4 multi-joint exercises for major muscle groups, comprising 2 sets of 10 to 25 repetitions at 40% of the one-repetition maximum (1-RM) for each exercise. Afterwards the aerobic part of the training will consist of 10-15 minutes of aerobic exercises (treadmill or outside walking or running, stationary cycling or outdoors or elliptical trainer) at 60-70% of peak VO2 or RPE 6-7 at Borg scale.~The intensity will increase on weeks 9-26 after surgery to 4-5 multi-joint exercises of 3-4 sets of 10 to 25 repetitions and 30 minutes of aerobic exercises at 65-80% of peak VO2 or RPE 6-8 at Borg scale."
9681338|NCT04928573||Group I|"All participants previously randomized in Brazil for the phase III study RTXM83-AC-01-11 already completed, which was conducted to support the registration of the new biosimilar of rituximab (Vivaxxia) in different countries.~The RTXM83-AC-01-11 study compared the efficacy and safety between biosimilar rituximab (RTXM83) and the reference rituximab (Mabthera®), both associated with CHOP chemotherapy (RTXM83-CHOP and R-CHOP, respectively) and included participants of the research with a diagnosis of lymphoma other than large B cell (LDGCB) CD20 positive."
9681339|NCT04928235||All Participants|All participants will have thermal imaging of their lower extremities. The temperature values will be shared with the attending physician. The physician will be asked questions about their diagnostic confidence before and after seeing the temperature values.
9681340|NCT04928781|Experimental|Smoking Cessation Counseling - Intervention Arm|Intervention arm. All patients enrolled in the study will be provided with smoking cessation counseling.
9681341|NCT04928781|No Intervention|Retrospective Chart Review - Control Arm|Control arm. A retrospective chart review will be conducted to create a randomly selected cohort of patients that meet inclusion and exclusion criteria and did not receive smoking cessation counseling to serve as the control arm.
9681342|NCT04928274|Other|ball retained mandibular over denture|each patient in this group received 3 implant installed in mandible and 3 ball attachments for retention of over denture
10176739|NCT03829826||Patients receiving IVIg|Patients are currently receiving IVIg regularly for at least every 6 weeks and exhibit a favorable response will be recruited into the study (11 patients). They will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their impairment using the previously validated Stiffness and Sensitivity scales and quality of life questionnaire (QoL) at weeks 0, 4, 8, 12. At week 12, prior to the first SCIg infusion, blood will be drawn for humoral (immunological) studies. One week following the last dose of IVIg (at week 13), the participants will be started on SCIg at a total dose equivalent to the monthly dose of IVIg they have been receiving.
10176740|NCT03829826||de novo SCIg patients/IVIg-Naive Group|This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.
10176741|NCT03829800|Experimental|Ensure® Abbott Nutrition|A standard nutritional formula not specific for diabetics
10176742|NCT03829800|Experimental|Glucerna® Abbott Nutrition|A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
10176743|NCT03829800|Experimental|Diasip® Nutricia Advanced|A formula whose composition has isomaltulose and resistant starch
9681343|NCT04928274|Other|locator retained mandibular over denture|
9681344|NCT04928274|Other|telescopic retained mandibular over denture|
9681345|NCT04927910|Experimental|True self-acupressure|1) two individual/group acupressure training sessions over 2 weeks and (2) self-acupressure for 6 weeks.
9681346|NCT04927910|Sham Comparator|Sham self-acupressure|Same protocol to the true self-acupressure group but on the sham acupoints
9681347|NCT04927910|Other|Usual care|General advise on managing symptoms provided by healthcare providers
9681348|NCT04927819||short-length implant (<6.5 mm)|
9681349|NCT04927819||non-short length implant (≥6.5 mm)|
9681350|NCT04927754|Experimental|Group 1 (cartoon movie, then tell-show-do technique)|Group 1: Dental treatment was carried out with showing cartoon movie as a visual/auditory distraction during the treatment in the second visit. The third visit did not consist any visual/auditory distractions, tell-show-do technique was used as a behavioural guidance technique.
9681351|NCT04927754|Experimental|Group 2 (tell-show-do technique, then cartoon movie)|Group 2: Dental treatment was carried out using tell-show-do technique without any visual/auditory distraction in the second visit. The third visit consisted cartoon movie as a visual/auditory distraction.
10176744|NCT03829800|Active Comparator|Glicolab®|Glucose solution
10187278|NCT03727711|Experimental|Home Treatment|Participants will be taught home treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
10187279|NCT03727711|Active Comparator|Hospital Treatment|Participants will receive hospital treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
9527643|NCT03218280|Active Comparator|Antioxidant Therapy|
9681352|NCT04927741|Experimental|Method 1: Sweet Marjoram Essential Oil + Grapeseed Oil with Massage|Subjects randomized will receive dilution of sweet marjoram essential oil (mixed with grapeseed oil), which will be applied topically with massage after IUD insertion.
9681353|NCT04927741|Active Comparator|Method 2: Grapeseed Oil with Massage|Subjects randomized will grapeseed oil applied topically with massage after IUD insertion.
9681354|NCT04927741|No Intervention|Method 3: Control Group (no oil or massage)|Subjects will serve as control and no essential oils or massage will be applied.
9681355|NCT04927728|Experimental|Audio MP|Participants of the audio mental practice (MP) group will complete MP via audio-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
9695534|NCT04777305|No Intervention|The control group|The control group will receive routine health care without exercise supervision (clinical and nutritional follow up).
10187280|NCT03727698|Experimental|Radiotherapy delivered on the MR Linac|MR Guided radiotherapy treatment
10187281|NCT03727659|Experimental|SHADE therapy + CONNECT FaceBook support|SHADE is a 10-week, 10-session, computerized CBT/MET intervention for Cannabis Use Disorder and depression. At each visit, a study clinician meets with participants for a 'check-in' session, which includes: review of homework; plans for completing homework; suicide risk and mood assessment. The CONNECT FB intervention component will facilitate social support for between-session homework and CBT skills practice for managing depression and preventing relapse, and bolstering motivation to change. Daily posts will be delivered. Only those participating in the study will know about the existence of this group and will be able to access it. A weekly real-time, Facebook chat session will be held to provide feedback concerning homework practice or answer questions.
9681356|NCT04927728|Experimental|Video MP|Participants of the video mental practice (MP) group will complete MP via video-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
10176745|NCT03829787||Bipolar without Anxiety or Substance Use Disorder|Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
10176746|NCT03829787||Bipolar disorder with a current anxiety disorder only|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
10176747|NCT03829787||Bipolar disorder with a current anxiety disorder and a current|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
10176748|NCT03829787||Bipolar disorder with a current substance use disorder only|Subjects who are diagnosed with bipolar disorder & a substance use disorders but not a current anxiety disorder
10176749|NCT03829787||Healthy Volunteers|
10176750|NCT03829813|Experimental|Patients|Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
10176751|NCT03829813|Experimental|Family|Family participation in music therapy treatment sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour.
10176752|NCT03829813|Experimental|Administration and Staff|Staff/Administration are not participants in music therapy, but rather have observed sessions, or worked as co-treating clinicians with music therapists for patient participants.
10176753|NCT03829904|Experimental|VGH-BPH1 group|VGH-BPH1 includes Ji Sheng Shen Qi Wan 2.5g, Sangpiaoxiao powder 1.0g, Wuyao 0.3g, Yizhiren 0.3g, Danshen 0.3g, Yinyanghuo 0.3g, Fupenzi 0.1g, Huangbo 0.25g and Zhimu 0.25g, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
10176754|NCT03829904|Placebo Comparator|Control group|Placebo includes corn starch plus caramel coloring, and added 1/100 VGH-BHP1 compound, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
10176755|NCT03829917|Experimental|Paromomycin and Miltefosine|Paromomycin-Aquaphilic cream applied topically once daily for 28 days plus oral miltefosine pills 2.5 mg/day [50 mg tid] for 28 days.
9681357|NCT04927728|Experimental|Repetitive-Task Practice|Participants of the repetitive-task practice group will complete repetitive practice of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each participant completed at least 20 repetitions of the task.
9681358|NCT04927728|Active Comparator|Traditional Therapy|The control group received traditional occupational therapy stroke rehabilitation.
9681359|NCT04927767|Experimental|Denture adhesives|Participants will be shown to apply the adhesive following the manufacturer's instructions. The denture is pressed firmly into place, then held firmly as the participant bites down to secure it. Participants will be instructed to apply the adhesive twice daily with an 8-hour interval.
10176756|NCT03829917|Active Comparator|Miltefosine|Miltefosine pills alone [2.5 mg/day [50 mg tid] for 28 days. This group will also receive Aquaphilic-vehicle cream for 28 days
10176757|NCT03829917|Active Comparator|Paromomycin|Paromomycin-Aquaphilic cream applied topically once daily for 28 days.
9681360|NCT04927845|Experimental|Immediate Intervention Condition|Participants in this condition will receive 7-8 weeks of online intervention modules. Specific modules will be selected based on a campus-wide needs assessment conducted in May 2021.
9681361|NCT04927845|No Intervention|Waitlist Condition|Participants in this condition will wait to receive StriveWeekly until after the Immediate Intervention condition is complete and participants from both conditions have completed the posttest survey.
10176758|NCT03829982|Experimental|bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
10176759|NCT03829982|Experimental|dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
10176760|NCT03829930|Experimental|Entinostat and Enzalutamide|Entinostat and Enzalutamide
9681362|NCT04927858||Population 1|Patients ≥ 18 years old on 31st of December 2017 with Type 2 Diabetes Mellitus (T2DM) who were alive on 31st of December 2017 and had at least one registration in the Swedish National Diabetes Registry (NDR) between 1996 - 2017.
10176761|NCT03829384|Experimental|mRNA-1944|Escalating dose levels
10176762|NCT03829384|Placebo Comparator|Placebo|Saline
10176763|NCT03829449|Experimental|rVA576 Coversin|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
10176764|NCT03829553|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will received 2.67 Gy for 16 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67 Gy for 4 fractions following breast conserving surgery
10176765|NCT03829553|Active Comparator|Conventional radiotherapy|Patients with an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
10187984|NCT03720665|Active Comparator|Caffeine group|"200mg caffeine tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
9681363|NCT04927858||Population 2|Population 2 is a sub-population of population 1. Patients with Type 2 Diabetes Mellitus (T2DM) who were initiated on Empagliflozin between 1st of January 2015 and 31st of December 2017, who had at least one registration in the Swedish National Diabetes Register (NDR).
9681364|NCT04927663|Experimental|Cohort A: 11C-YJH08 with PET/MRI or PET/CT|Patients receive approximately 20 millicurie (mCi) of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline.
9681365|NCT04927663|Experimental|Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression|Patients receive approximately 20 mCi of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline and at time of disease progression.
9681366|NCT04927624|Active Comparator|transversus abdominis plane|In the group in which Transversus Abdominis Plan Block was applied, the patient was placed in the supine position. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and the anterolateral abdominal wall. After visualizing the external-internal obliq and transversus abdominis muscles, 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration by advancing the needle into the fascia between the internal obliq muscle and the transversus abdominis muscle with the in-plane technique.
9681367|NCT04927624|Active Comparator|quoadratus lumborum block|In the Quadratus Lumborum Block (Lateral approach) group, the patient was placed in the lateral position with the side to be blocked on top. After skin antisepsis was achieved with 10% povidone iodine, the USG probe was placed transversely between the iliac crest and costa edge. After visualizing the extarnal-internal obliq and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum muscle and thoracolumbar fascia were visualized. The needle was advanced to the anterolateral border of the quadratus lumborum muscle with the in-plane technique and 0.5 ml/kg of 0.25% bupivacaine was injected after negative aspiration.
9681368|NCT04927611||Gastroenteropancreatic neuroendocrine neoplasms|Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.
9681369|NCT04927611||Pancreatic ductal adenocarcinoma|Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.
9976041|NCT01347567|Experimental|BNP + Health Management|Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
9681371|NCT04927559||Observational (survey)|Patients complete a survey over 5-10 minutes about their understanding of radiation therapy.
9681372|NCT04927507|No Intervention|Control group|The control group was given routine nursing.
9681373|NCT04927507|Experimental|Observation group|The observation group was given the Internet plus nursing home rehabilitation mode.
9681374|NCT04927533|Experimental|Older adults with psychiatric problems|The target group is a group of older adults with psychiatric problems (≥60 years old) admitted to a residential psychogeriatric department of the Psychiatric Clinic of the Alexians Care Group Tienen. The following exclusion criteria apply: a score of less than 21 on the MMSE (excluding dementia or other moderate to severe cognitive disorders), a mother tongue other than Dutch and having undergone surgery and/or chemotherapy in the last 3 months.
9681375|NCT04927520||Endovascular therapy group|Unruptured middle cerebral artery aneurysms treated with coil embolization
9681376|NCT04927520||Clipping surgery group|Unruptured middle cerebral artery aneurysms treated with clipping surgery
9681377|NCT04927494|Experimental|Black women cervical cancer screening|Participants in this group with receive the Health is Wealth intervention.
9681378|NCT04927585|Experimental|Group 1 (Treatment): DNA Vaccine + Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0, and Months 3, 6, and 12.
9681379|NCT04927585|Placebo Comparator|Group 1 (Control)|"Participants will receive placebo at Day 0, Months 3, 6, and 12.~Interventions:"
9681380|NCT04927585|Experimental|Group 2 (Treatment): Admixture of DNA Vaccine and Protein Vaccine|Participants will receive admixture of 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine (no adjuvant) at Day 0, and Months 1, 3, 6, and 8.
9681381|NCT04927585|Placebo Comparator|Group 2 (Control)|"Participants will receive placebo at Day 0, and Months 1, 3, 6, and 8.~Interventions:"
9681382|NCT04927546|Experimental|IL-6 blockade|RA patients under pharmacological treatment with interleukin-6 blockade.
9681383|NCT04927546|Experimental|Anti-TNF-alpha|RA patients under pharmacological treatment with anti-TNF-alpha.
9681384|NCT04927546|Experimental|Healthy controls|Healthy participants.
9681385|NCT04927481|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Patients with advanced HER2 negative breast cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for about 6 cycles.
9681386|NCT04927338|Experimental|Bacopa|Eligible participants will be randomized to receive 12 weeks of BacoMind® (300 mg/day)
9681387|NCT04927338|Placebo Comparator|Placebo|Eligible participants will be randomized to receive 12 weeks of matching placebo
10176766|NCT03829371|Experimental|ARM A|"ARM A~Velcade (V):~1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;~1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 from cycle 5.~Melphalan (M):~- 9 mg/m2 orally on days 1, 2 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is a 42-day cycle. Duration: Maximum 9 cycles can be performed."
9681388|NCT04927117||high myopic group (group1:AL≥26.0 mm)|axial length≥26.0 mm)
9681389|NCT04927117||age-matched control group|axial length<26.0mm
9681390|NCT04927468|Experimental|supramaximal rectus recession|supramaximal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
9681391|NCT04927468|Active Comparator|normal rectus recession|normal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy
10176767|NCT03829371|Experimental|ARM B|"ARM B:~Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle. Duration: until PD or intolerance."
10176768|NCT03829566|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
9681392|NCT04927364|Experimental|Active rTMS and DBT skills training|"Participants will receive 20 rTMS treatments over 2 weeks, delivered 4-5 days/week. Each treatment visit will last 20-30 minutes in total.~Participants will also attend 6 hour-long dialectical behavioral therapy (DBT) sessions with a licensed clinical psychologist over the course of 2-3 weeks."
9681393|NCT04927364|Experimental|DBT skills training|Participants will also attend 6 hour-long dialectical behavioral therapy (DBT) sessions with a licensed clinical psychologist over the course of 2-3 weeks.
10176769|NCT03829592|Placebo Comparator|misoprostol in neutral media|Intervention : misoprostol in a neutral media will be given to women to induce labour
9681394|NCT04927286|Experimental|Mentoring+Mindfulness|
9681395|NCT04927286|Active Comparator|Mentoring as usual|
9681396|NCT04927299|Experimental|Group A: Losartan + chlorthalidone|Administered orally, one tablet a day, for 2 months.
9681397|NCT04927299|Active Comparator|Group B: Losartan + hydrochlorothiazide|Administered orally, one tablet a day, for 2 months.
9681398|NCT04927156||BALT medical devices|
10176770|NCT03829592|Active Comparator|Misoprostol in acidic media|Intervention : misoprostol in acidic media will be given to induce labour
10176771|NCT03829592|Sham Comparator|Misoprostol in alkaline media|Intervention : misoprostol in alkaline media will be given to induce labour
10176772|NCT03829527|Experimental|Psychotherapy|
10176773|NCT03829267|Experimental|eFIT Behavioral Intervention|Intervention: Participants randomized to the eFIT condition will join a 1-hour peer group meeting online each week, called eFIT intervention. They will learn about accountability partners, and use the group as an accountability partner to state and attain physical fitness goals.
9681399|NCT04927234|Experimental|Standard of care + geko™ Therapy|In addition to their standard of care, for patients randomised to the intervention arm, geko™ therapy will be applied immediately post-surgery on the operated leg and administered for 24 hours / day whilst the patient remains in hospital, after which geko™ therapy will then be applied for 12hrs / day until the patient returns for their first post-operative follow-up visit (Day 14 ± 2 days post-surgery)
9681400|NCT04927234|No Intervention|Standard of care|Patients will receive their standard of care as per hospital practice.
9681401|NCT04927091|No Intervention|Specialty Addiction Clinic|
9681402|NCT04927091|Experimental|ECHO-IC/QI-enhanced primary care clinic|
10176774|NCT03829267|Active Comparator|eJournal Behavioral Intervention|Intervention: Participants in the eJournal condition will spend 1-hour online each week engaged in an active journaling activity, called eJournal Intervention. They will also receive the same psychoeducational materials online as the eFIT participants are presented in group.
10176775|NCT03829475|Experimental|FMT + Bezlo|Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
9681403|NCT04927091|Active Comparator|ECHO-IC/QI-enhanced primary care clinic with Pay for Performance|
9681404|NCT04927104|Experimental|PEEK Knee Prosthesis|In this study, 10 subjects will be underwent total knee arthroplasty with PEEK knee prosthesis.
9681405|NCT04927130||Women in age 35 to 65 with confirmed breast cancer|
9681406|NCT04927130||Healthy Volunteers|
10176776|NCT03829475|Placebo Comparator|FMT + Placebo|Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
10176777|NCT03829358|Experimental|Probiotic|Lactobacillus plantarum IS-10506
10176778|NCT03829358|Placebo Comparator|Placebo|Placebo
10176779|NCT03829280|Experimental|Cognitive Adaptation Training|Psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology and the organization of belongings established in a person's home or work environment to bypass the cognitive and motivational difficulties associated with schizophrenia, and support habits for functional behavior to promote recovery.
9681407|NCT04927026|Experimental|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|Solution-focused brief therapy (SFBT) involving psychoeducation and structured life review therapy, as well as mindfulness-based training
9681408|NCT04927026|No Intervention|Control|No intervention
9681409|NCT04926844|Experimental|Study group|Children receiving levetiracetam + midazolam
9681410|NCT04926844|Placebo Comparator|Control group|Children receiving placebo + midazolam
9681411|NCT04927000|No Intervention|control group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)].~All subjects were treated with Glucocorticoid (10-15mg)/Days)."
9681412|NCT04927000|Experimental|Tofacitinib treatment group|"All subjects used one or two the basic DMARDs: Methotrexate (10mg) combined with sulfasalazine (2G / day), Iguratimod (50 mg / day), leflunomide (20 mg / day)].~All subjects were treated with Glucocorticoid (10-15mg)/Days). All subjects were treated with Tofacitinib 5mg/BID."
9681413|NCT04926883|Active Comparator|Sonic fill|
9681414|NCT04926883|Active Comparator|X-tra fill|
9681415|NCT04926805|Experimental|Mask A|Overnight CPAP using the participant's usual pressure settings and using Mask A. One night only.
10176780|NCT03829280|Active Comparator|Community Treatment|Medication follow-up and case management as provided by the community mental health center according to usual care.
10176781|NCT03829345|Experimental|Olaparaib|Olaparib will be given 300mg bd for a 28 day cycle.
10176782|NCT03829605||Group I:|Fifty AMI patients on admission
10176783|NCT03829605||Group II:|The previous AMI patients after 12 hours
10176784|NCT03829176|No Intervention|Standard-of-Care|Participants who are randomized to not have whole genome sequencing performed on their sample. These participants will have standard-of-care genetic testing only (ordered by their clinical provider) and will not receive genetic results as part of this study.
10176785|NCT03829176|Experimental|Whole Genome Sequencing|Participants who are randomized to have their genome sequenced and receive a whole genome sequencing report. Results disclosure sessions will include a discussion of the whole genome sequencing report, how the results compare to their standard-of-care genetic testing report, and any potential relevant recommendations. Participants in this arm will receive a copy of their whole genome sequencing report accompanied by a summary letter written by a study genetic counselor.
10176786|NCT03829319|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
10176787|NCT03829319|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
9681416|NCT04926805|Active Comparator|Mask B|Overnight CPAP using the participant's usual pressure settings and using Mask B. One night only.
9681417|NCT04927052|Active Comparator|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine is a clear, colorless gel in 1.2 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
9681418|NCT04927052|Active Comparator|Juvederm Voluma with Lidocaine|Juvederm Voluma with Lidocaine is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine.
9681419|NCT04927013|Experimental|Message-based Outreach Intervention (MBI) for Survivors|Cancer survivors randomized to receive a targeted letter with a unique website log in, access to the expanded website, free genetic counseling, and short message service (SMS) reminders.
10176788|NCT03829189|Active Comparator|inulin|
10176789|NCT03829189|Placebo Comparator|maltodextrin|
9681420|NCT04927013|Active Comparator|Standard Outreach for Survivors|Cancer survivors randomized to receive the standard outreach consisting of a standard letter with website access, access to a condensed version of the study website, and free genetic counseling.
9681421|NCT04927013|Experimental|Message-based Outreach Intervention for Close Relatives|Close relatives of cancer survivors who were randomized to receive the message-based outreach. Close relatives will have access to the expanded version of the study website and free genetic counseling.
9681422|NCT04927013|Active Comparator|Standard Outreach for Close Relatives|Close relatives of cancer survivors who were randomized to receive the standard outreach. Close relatives will have access to a condensed version of the study website and free genetic counseling.
9681423|NCT04926896|Experimental|Minimally invasive bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~Use the cortical bone opening device to open two bone holes with a diameter of 7.5 mm side by side in the iliac bone cortex ,place disposable battery-powered bone harvesting device for iliac crest bone harvesting operations.~The direction of the tool bit should be parallel to the outer iliac plate, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~.Scrap and collect the cancellous bone by tool bit during operation.~. After collecting sufficient amount of cancellous bone, turn off the power, screw out the cabin, and pour out the cancellous bone.~. Suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage."
9681424|NCT04926896|Placebo Comparator|Traditional iliac crest bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~Use a bone chisel to open a lid on the iliac crest ridge cortex ,open the cover length at 3cm.~Lift the iliac crest ridge cortex plate cover, use bone knife and scraper to harvest bone in the iliac bone marrow cavity.~Avoid violence when using bone knives and scrapers, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~After collecting sufficient amount of cancellous bone, suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage"
9681425|NCT04926753|Experimental|Experimental|5-Fluorouracil(750 mg/m2/d, CIV d1-5) Cisplatin(75mg/m2,d1)/Carboplatin(AUC5, d1) Toripalimab 240mg d1
9681426|NCT04927078||Participants with COVID 19 diagnosis|We will measure the breathing rate (BR) before and after the clinical diagnosis of COVID 19.
9681427|NCT04927078||Participants without COVID 19 diagnosis|Breathing rates will be measured for the same time duration as the cases.
9681428|NCT04926974|Experimental|Seeing AI Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
9681429|NCT04926974|Experimental|Supervision+ Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
10176790|NCT03829137|Experimental|Verum laser acupuncture|Verum laser acupuncture：Low level laser therapy stimulates 7 acupuncture points on both sides of the body .
10176791|NCT03829137|Sham Comparator|Sham laser acupuncture|sham laser acupuncture (no laser output)
9681430|NCT04926974|Experimental|Aira Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
9681431|NCT04926727||Pregnant women|"600 Pregnant women between the 18th and 22nd week.~200 from Northern Italy;~200 from Central Italy;~200 from Southern Italy and the Islands."
9681432|NCT04926480|Experimental|low flow Anesthesia group|Antioxidant parameters are measured in the low flow anesthesia group.
10187282|NCT03727646|Experimental|Open-label nicotinamide riboside|"Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg)~Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily~Washout Day of LVAD Surgery and/or Day 15: None"
10176792|NCT03829215|Experimental|CAERVest cooling device|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, the CAERvest device will be filled and placed on the supine patient's chest. A recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an additional endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device. The CAERvest device will be removed, when a temperature below 34°C is reached.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
10176793|NCT03829215|No Intervention|Control|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, a recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
9681433|NCT04926480|Active Comparator|high flow Anesthesia gruop|Antioxidant parameters are measured in the high flow anesthesia group.
9681434|NCT04926467|Experimental|Anakinra plus Chemotherapy|Patients will receive Anakinra during both pre-operative chemotherapy with Nab-paclitaxel, gemcitabine and cisplatin, followed by surgery and post-operative chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan.
9681435|NCT04926662||Aim 1: Focus Groups|Focus groups will be conducted in 2 New Hampshire and 2 Vermont towns to better understand patient knowledge, attitudes, and preferences regarding access to lung cancer screening.
9681436|NCT04926662||Aim 2: Cross Sectional Survey|Based on focus group feedback, the investigators will visit each proposed site to survey on 2 separate dates to confirm days and times of high traffic. The investigators will also survey patrons at the proposed locations to further determine prospective patient mobile screening preferences and evaluate willingness to participate in screening.
9681437|NCT04926662||Aim 3: Survey with follow up data|The investigators will pilot mobile lung cancer screening clinics at each chosen location using the knowledge acquired from focus group experience and local patient survey. Surveys will be conducted at these clinics, and patients will be followed for up to 5 years.
9681438|NCT04927039|Placebo Comparator|Control group|
9681439|NCT04927039|Experimental|Iloprost group|
9681440|NCT04926506|Experimental|Xiyanping injection combined with routine treatment|
9681441|NCT04926506|No Intervention|routine treatment|
9681442|NCT04926545|Experimental|Irinotecan naive cohort|"This cohort will enroll 6 postmenopausal female patients who have never received irinotecan treatment before. Patients in irinotecan naive cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 4 rounds of pharmacokinetic studies will be conducted.~Round 0 (before chemotherapy): pharmacokinetic testing (raloxifene 60mg as probe) before XCHT administration, then XCHT for 4 days with pharmacokinetic testing (raloxifene 60mg as probe) on the 4th day of XCHT administration.~Round 1(1st cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (without raloxifene) on day 4.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
9681443|NCT04926545|Experimental|Irinotecan used cohort|"This cohort will recruit 18 patients who were treated with irinotecan previously and have at least one diarrhea episode with a severity of more than grade 2. Patients in irinotecan used cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 3 rounds of pharmacokinetic studies will be conducted.~Round 1(1st cycle of chemotherapy): FOLFIRI, with pharmacokinetic testing (raloxifene 60mg as probe) on the first day of chemotherapy.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 4.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
9681444|NCT04926493||BIOPAVIR Cohort|Critically ill patient > 18 years of age with mechanical ventilation for >2 calendar days, at increased risk for the development of Ventilator-Associated Pneumonia in the Intensive Care Unit during COVID-19 pandemic.
9681445|NCT04926935||Patients hospitalized in the ICU during the study period.|Patients hospitalized in the ICU during the study period with clinically suspected infection.
9681446|NCT04926532|Experimental|Toripalimab + Sorafenib|Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Sorafenib was taken orally after meals, twice a day.
9681447|NCT04926870|Experimental|PACS group|PACS administration during teaching
9681448|NCT04926870|Active Comparator|Traditional group|Traditional teaching without PACS
9681449|NCT04926610|Experimental|proactive clinical ethics consultation group|
9681450|NCT04926610|No Intervention|routine care group|
9681451|NCT04926428|Experimental|experimental arm|In situ thrombolysis with tPA
9681452|NCT04926441||Students from 8 European Universities, regardless of field of study and academic year|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
9681453|NCT04926311||Developmental Language Disorder patients|
9681454|NCT04926766|Experimental|SHF-WBI|Patients with an indication for whole breast irradiation will receive 5.2 Gy in 5 fractions to whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
9681455|NCT04926389|Experimental|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|
9681456|NCT04926389|Active Comparator|low-level laser therapy applied every 3 weeks|
9681457|NCT04926402|No Intervention|Standard of care|The control group received standard routine care
9681458|NCT04926402|Experimental|Kangaroo care education program|The experimental group received a maternal kangaroo care education program
9681459|NCT04926350|No Intervention|Control|Tracking of outcomes during a normal week
9681460|NCT04926350|Experimental|Resistance Exercise|Tracking of outcomes during a normal week with the addition of daily resistance exercise breaks (8 breaks per day)
9681461|NCT04926649|Sham Comparator|Conventional ventilation group|Conventional SLV and complementary with DLV when necessary. When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. The right lung was totally collapsed. If the SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted.
9681462|NCT04926649|Active Comparator|CPAP group|"SLV of left lung and CPAP of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, CPAP was started with the pressure less than 8 cmH2O. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
9681463|NCT04926649|Experimental|HFLVV group|"SLV of left lung and HFLVV of right lung, and complementary with DLV when necessary.~When SLV was initiated, the patient was ventilated with left lung. FiO2 of 1.0, tidal volume of 6ml/kg, respiratory rate of 16-24 bpm, PEEP of 5-10 cmH2O. After the right lung was totally collapsed, HFLVV was started with tidal volume of 2ml/kg, respiratory rate of 60 bpm. If SpO2 decreased lower than 90%, DLV was started and the operation was paused until the SpO2 increased to 100%. Then the operation was restarted."
9976042|NCT01347567|Active Comparator|Health Management|Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
9681465|NCT04925973|Experimental|Treatment arm|Tofacitinib 10mg PO BID
9681466|NCT04926155|Experimental|Metformin+ADT+abiraterone|Patients in this arm will be treatet with metformin plus ADT and abiraterone
9681467|NCT04926155|No Intervention|ADT+abiraterone|Patients in this arm will be treatet with ADT and abiraterone, Abiraterone 1000mg once daily until disease progression.
9681468|NCT04926519||Aggressive periodontitis|Patients that got the diagnosis aggressive periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
9681469|NCT04926519||Chronic periodontitis|Patients that got the diagnosis chronic periodontitis at baseline. Since 2018 we have the classification system with stage and grade why patients get this classification at the clinical examination.
9681470|NCT04926207|Experimental|Physical Activity Breaks Intervention|Participants will sit continuously for 3 hours and interrupt their sitting by walking on a treadmill at a moderate intensity for 3 min.
9681471|NCT04926207|Active Comparator|Talking Breaks Control|Participants will sit continuously for 3 hours. They will interrupt solitary sitting activities (while remaining seated) by talking to a researcher for 3 min on pre-selected topics of general interest.
9681472|NCT04926142||Patients planned for percutaneous PFO closure|Patients will undergo implantation of a Holter device (Reveal Linq Medtronic) 2 months prior to percutaneous PFO closure. Devices will be monitored by telemonitoring until the PFO closure procedure, and at 2, 12 and 24 months after the procedure.
9681473|NCT04925921|Experimental|Treatment|Treatment with the SR-1 Laser
9681474|NCT04925908||Control Group|Infants of mothers with suspected but negative for COVID-19
9681475|NCT04925908||Case Group|Infants Born to COVID-19 positive mothers
9681476|NCT04925791|Experimental|The IPC group|subjects will get a standardized pre-conditioning treatment 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of occlusion alternating with 5 minutes of reperfusion while seated.
9681477|NCT04925791|Other|The CON group|subjects will get a controlled treatment of 20% of limb occlusion pressure 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of minimal occlusion alternating with 5 minutes of reperfusion while seated.
9681478|NCT04925817|Experimental|Diagnostic (ultrasound microvessel imaging)|Patients undergo 3 D ultrasound microvessel imaging over 45 minutes. Patients' medical records are reviewed.
9681479|NCT04925869||The hospitals of Besançon|Adult patients with MRI-confirmed CVA admitted to the hospitals of Besançon
9681480|NCT04925869||the hospitals of Cayenne|Adult patients with MRI-confirmed CVA admitted to the hospitals of Cayenne.
9681481|NCT04925869||the hospitals of Tours|Adult patients with MRI-confirmed CVA admitted to the hospitals of Tours.
9681482|NCT04925583|Experimental|Level 0|Total dose 50 Gy, (10 x 5 Gy single dose)
9681483|NCT04925583|Experimental|Level 1|Total dose 55 Gy, (10 x 5.5 Gy single dose)
9681484|NCT04925583|Experimental|Level 2|Total dose 60 Gy, (10 x 6 Gy single dose)
9681485|NCT04925583|Experimental|Level 3|Total dose 65 Gy, (10 x 6.5 Gy single dose)
9681486|NCT04925531||Antibiotic use for <3 days|a retrospective chart review to examine if either the utility of antibiotics administered for 3 days make a difference in the clinical outcomes after facial fractures
9681487|NCT04925531||Antibiotic use for 5 days|a retrospective chart review to examine if either the utility of antibiotics administered for 5 days make a difference in the clinical outcomes after facial fractures
9681488|NCT04925674|Experimental|HEC53856|HEC53856 Oral TIW There will be a total of 3 dose cohorts in the hemodialysis: 100mg，150mg，200mg； There will be only one dose cohort in the peritoneal dialysisp:100mg.
9695535|NCT04777188|Experimental|Hypertrophic Obstructive Cardiomyopathy|Left ventricular systolic function by speckle tracking echocardiography before and after percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy.
9695536|NCT04777136|Experimental|Geriatric home visit|Home-visit where a comprehensive geriatric assessment will be performed
9695537|NCT04777136|Active Comparator|Standard care|No follow-up.
9695538|NCT04777045|Experimental|Diltiazem|When signs of vascular dysfunction with the coronary function test.
9695539|NCT04777045|Placebo Comparator|Placebo|When signs of vascular dysfunction with the coronary function test.
10187283|NCT03727646|No Intervention|Baseline controls|Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.
9695540|NCT04777149|Experimental|transcranial Random Noise Stimulation (tRNS)|Participants in this group will receive a combined intervention (3 days of tRNS during functional task practice and 3 days of sham-stimulation during functional task practice).
9681489|NCT04925505||BPB success|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the SUCCESS (or failure) of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
9681490|NCT04925505||BPB failure|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the (success or) FAILURE of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
10176794|NCT03829293|Experimental|High-flow nasal cannula oxygenation group|Participants in the experimental group will receive high-flow nasal oxygen therapy (HFNO) during gastrointestinal endoscopy under sedation (with a flow at 70L/min and oxygen inspired fraction (FiO2) 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
10176795|NCT03829293|No Intervention|Standard Oxygenation|Participants in the current standard of care will receive standard oxygenation by nasal prongs (with a flow at 6L/min) or naropharyngeal catheter (with a flow at 5L/min) or standard face mask (with a flow at 6L/min)
9681491|NCT04925557|Active Comparator|Ocrevus|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Ocrevus by their neurologist.
9681492|NCT04925557|Active Comparator|Mayzent|Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Mayzent by their neurologist.
9527644|NCT03218280|No Intervention|Antioxidant Free|
9681493|NCT04925570|Experimental|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
9681494|NCT04925570|Sham Comparator|Education Only|"Education Only delivers weekly fact sheets that include information on:~Alcohol-specific topics;~Drug-specific topics;~General addiction topics;~Statistics relating to alcohol and substance use."
9681495|NCT04925596|Experimental|Intervention|general practitioners randomized to intervention group will be given access to ePrimaPrescribe online program
9681496|NCT04925596|Active Comparator|Control|general practitioners randomized to control group will be given access to an online program concerning doctor-patient communication
9681497|NCT04925739||OSA patients treated with CPAP|"OSA patient, not previously treated with CPAP, are treated with a ResMed Airsense 10 CPAP and an Air Liquide Medical Systems NINA mask during 30 days, monitored by the home care provider AGIRADOM.~After 30 days of CPAP treatment, 4 self-questionnaires are completed by the patient and parameters of the CPAP treatment (compliance, estimated unintentional leakage and therapeutic pressures) are collected."
9681498|NCT04925726|Active Comparator|Land based exercise|Land based exercise
9681499|NCT04925726|Active Comparator|Water based exercise|Water based exercise
9681500|NCT04925635||experimental group|The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group.
9681501|NCT04925635||control group|Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given.
9681502|NCT04925661|Experimental|HEC53856|Drug: HEC53856 TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
9681503|NCT04925661|Active Comparator|Roxadustat|Drug: roxadustat TIW dosing There will be only one cohort: 70mg
9681504|NCT04925661|Placebo Comparator|Placebo|Drug: placebo TIW dosing, capsule There will be a total of 3 dose cohorts: 100mg, 150mg, 200 mg
9681505|NCT04925440|Experimental|Probiotic|Probiotic capsules. Participants will consume 2 capsules once a day for 8 weeks.
9681506|NCT04925440|Placebo Comparator|Placebo|Placebo capsules. Participants will consume 2 capsules once a day for 8 weeks
9681507|NCT04925687|Experimental|Intravitreal autologous CD34+ cells|Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions
9681508|NCT04925518|Active Comparator|Conventional Ventilation Mode|Patients mechanically ventilated with a conventional mechanical ventilation mode until steady state is achieved for several hours.
9681509|NCT04925518|Experimental|Closed Loop Ventilation Mode|Once steady state on the conventional mechanical ventilation mode is achieved for several hours, switch to closed loop ventilation mode for the remainder of the study period.
9681510|NCT04925414|Experimental|oxygenotherapy|
9681511|NCT04925414|Placebo Comparator|placebo air aerosol|
9681512|NCT04925219|Experimental|Remotely supervised exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Intervention = electronic walking log and fortnightly video/telephone call with physiotherapist for 3 months."
10176796|NCT03829436|Experimental|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
10176797|NCT03829436|Experimental|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression.
10176798|NCT03829436|Experimental|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
10176799|NCT03829436|Experimental|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
10176800|NCT03829163|Active Comparator|Conventional Walker Group|
10176801|NCT03829163|Experimental|HAW Group|
10176802|NCT03829085|Active Comparator|Early oral refeeding|"The patients will be started the oral refeeding from the first day of admission in the hospital.~Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day"
10176803|NCT03829085|No Intervention|FASTING|The oral diet will be reintroduced in a traditional stepwise manner until the symptoms, signs, inflammatory parameters of AP have resolved
10176804|NCT03829124|Experimental|ketamine + propofol group|use ketamine + propofol for ECT induction
10176805|NCT03829124|Active Comparator|propofol group|use propofol only for ECT induction
9681513|NCT04925219|Active Comparator|Self-directed exercise|"Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD.~Control = electronic walking log and instructions to exercise 4 times per week for 3 months"
9681514|NCT04925453|Experimental|Active tDCS|"Based on previous studies targeting working memory, focality of current delivery, and comfort and tolerance levels, (Paulo S. Boggio et al., 2006; Hill et al., 2016; Hoy et al., 2013; Teo, Hoy, Daskalakis, & Fitzgerald, 2011), we will use a 2 mA current administered via two circular carbon rubber core electrodes in saline-soaked surface sponges (25 cm2), placed in a neoprene headcap with marked locations based on the 10-10 EEG system. The anodal stimulating electrode will be at location F3, over left dorsolateral prefrontal cortex (DLPFC) and the cathodal electrode at location F4, over right DLPFC. Two reference electrodes, CMS and DRL, will be attached to the EarClip and applied to the earlobe with conductive gel.~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
9681515|NCT04925453|Sham Comparator|Sham tDCS|"For sham stimulation, the electrodes will be placed at the same positions as for active stimulation (F3 and F4). After an initial ramp-up period of 30 seconds, stimulation fades out over a period of 30 seconds. Additionally, at the end of the sham stimulation period, stimulation will fade in over a period of 30 seconds and then end with a final 30 second ramp-down period. Participants will feel the initial itching sensation associated with tDCS and experience the ramp-down period at the end of the sham stimulation period but will receive no active current during the rest of the sham stimulation period. This method of sham stimulation has been shown to be reliable (Gandiga et al., 2006).~Before each training session, the impedance of the electrodes will be checked and verified to be ≤15 KOhm. Additionally, the stimulation will be terminated if the impedance of the electrodes is > 20 KOhm. The current and impedance will be recorded for every session."
9681516|NCT04925128|Experimental|Interventional Group|Hot pack for 10 min OR Infrared rays for 10 min Tens for 10 min Grade 2 mobilizations through maitland technique Treadmill walk for 30 to 150 minutes
9681517|NCT04925128|No Intervention|Control Group|Hot pack or Infrared rays for 10 min Tens for 10 min Grade 2 mobilizations through maitland technique
9681518|NCT04925258|No Intervention|Services-as-usual|Services-as-usual (referral list for online and telehealth parenting and family mental health services).
9681519|NCT04925258|Experimental|SPACE Parenting Program|"The experimental groups of Manitoba-based parent-child dyads (children ages 3-4 years old) include:~1. Weekly parenting materials, including online videos and mailed out parenting activities, that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program. Also included are weekly drop-in group sessions with other parents facilitated by trained MA-level or higher psychology students or psychologists."
9681520|NCT04925375|Experimental|Abatacept|"Pediatric subjects weighing <50 kg will be placed in an single arm with abatacept with dosing based on weight. Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26.~Pediatric dosing:~Abatacept subcutaneous every week:~10-25 kg: 50 mg; 25-50 kg: 87.5 mg; >50 kg: 125 mg~Adult dosing:~Abatacept: 125 mg subcutaneous every week"
9681521|NCT04925375|Placebo Comparator|Placebo|Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26. The composition of the placebo is the same as the active study drug without the abatacept. To maintain the blind, injection volumes will be the same as the active treatment.
9681522|NCT04925349||affected subjects|"adult patients with adrenomyeloneuropathy/adrenoleukodystrophy~children with adrenoleukodystrophy~children with metachromatic leukodystrophy"
9681523|NCT04925349||control subjects|-healthy children
9681524|NCT04925362|Other|Patients|Patients with histologically confirmed NAFLD
9681525|NCT04925141|Experimental|Dasatinib tablets|Dasatinib tablets 100 mg orally once daily
9681526|NCT04925232|Experimental|One group|All participants will undergo 2 weeks (5 times each week) of repetitive TMS
9681527|NCT04925206|Experimental|ET-01|
9681528|NCT04925063|Experimental|Metformin+ADT+abiraterone|Drug: Metformin The starting daily dose of metformin is 500mg once daily, to be increased to 2000mg once daily if tolerated until disease progression Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
9681529|NCT04925063|No Intervention|ADT+abiraterone|Drug: Abiraterone Abiraterone 1000mg once daily until disease progression
10176806|NCT03828877|No Intervention|Group C|Arm: Group C control group. Non-acupuncture group. Gruop C will be Control group.
10176807|NCT03828877|Active Comparator|Group A|Arm: Group A, group of acupuncture Akupunktur will be done with Pres Needle (0.22x1.5 mm) Blood will be taken for the measurement of IL 17 and IL 23 from Group A (Acupuncture) patients 24 hours prior to endovenous ablation procedure. Then, with press needle (0.22x1.5) LU 9 (Taiyuan), LU7 (Lieque), SP 6 (Sanyinjiao) , ST 36 (Zusanli), LI 4 (Hegu) and LIV 3 (Taichong) points will be applied acupuncture.On the 3rd day, patients will be called for control. Blood will also be taken from the blood to measure IL 17, IL 23 values.
10176808|NCT03829072|Experimental|cooking Education and adapted physical activity|
10176809|NCT03828890|Other|Single Arm Trial|Intervention includes screening eye exam using Optos technology
10176810|NCT03829150|Experimental|Dexlansoprazole MR group|Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
9681530|NCT04925115|Experimental|Interventional group|"Interventional group:~Warm up and cool down (10 minutes before physical activity)~Brisk walking ( 30 minutes each session for 5 days in a week)~Week 1 to week 6 same protocol"
9681531|NCT04925115|No Intervention|Control group|Routine activity of daily life
9681532|NCT04925310||RSV Bronchiolitis Group|hospitalized children with confirmed RSV infection between the first month of life and second year of life
9681533|NCT04925076|Experimental|Family History Positive|People reporting at least one parent with a history of alcohol problems.
9681534|NCT04925076|Experimental|Family History Negative|People who do not report having a parent with a history of alcohol problems.
9681535|NCT04925167|Experimental|argatroban group|Patients received argatroban for anticoagulation during V-V ECMO.
9681536|NCT04925167|Active Comparator|UFH group|Patients received UFH for anticoagulation during V-V ECMO.
9681537|NCT04924985|Experimental|Physiological Feedback CPR|
10176811|NCT03829150|Experimental|lansoprazole group|Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
10176812|NCT03828916|Other|NuShield|
9681538|NCT04924985|Active Comparator|Non-Physiological (Audiovisual) Feedback CPR|
9681539|NCT04925245|Experimental|Clinical Reminder|
9681540|NCT04925245|No Intervention|No Reminder|
9681541|NCT04925323|Experimental|a plastic or repair surgery indication generating surgical waste|
9681542|NCT04924972||Intracutaneous Suture|
10176813|NCT03829033|Active Comparator|Radiotherapy delivered with photons|
10176814|NCT03829033|Experimental|Radiotherapy delivered with protons|
9681543|NCT04924972||running Suture|
9681544|NCT04924998||AL-CM|
9681545|NCT04925011|Other|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
9976043|NCT01347567|Placebo Comparator|Control|Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
9976044|NCT01347593|Experimental|ceftizoxime (cefizox) injection|ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
9681548|NCT04925297||Non-NS ( Non-neurological sequelae) group|Patients who do not develop neurological dysfunction after acute carbon monoxide poisoning
9681549|NCT04925297||NS (Neurological sequelae) group|Patients who develop neurological dysfunction after acute carbon monoxide poisoning
9681550|NCT04924829||Tocilizumab|Group that received tocilizumab (8mg/kg, maximum dose 800 mg, only once) while being admitted with severe COVID-19 pneumonia.
9681551|NCT04924829||Non-tocilizumab|Group that did not receive tocilizumab but share the same indication according to the elegibility criteria for it as the tocilizumab group while admitted with severe COVID-19 pneumonia.
9681552|NCT04924686||Crohn's disease|The fecal and plasma were collected
9681553|NCT04924686||Ulcerative colitis|The fecal and plasma were collected
9681554|NCT04924686||Diabetes mellitus, type 2|The fecal and plasma were collected
9681555|NCT04924686||Atherosclerotic cardiovascular disease|The fecal and plasma were collected
9681556|NCT04924686||Colorectal cancer|The fecal and plasma were collected
9681557|NCT04924868|Active Comparator|UDCA (Ursodeoxycholic Acid) group|"Patients receiving Ursodeoxycholic Acid, capsules containing 300 mg, 10 mg/Kg per day:~Patients 40 to 70 kg: 2 capsules/day >70 to 100 Kg: 3 capsules/day >100 kg: 4 capsules/day"
9681558|NCT04924868|Placebo Comparator|Placebo group|Capsules containing placebo, indistinguishable from active treatment.
9681559|NCT04924530|Sham Comparator|Maltodextrin|Glucose polymer; a common sugar substitute
9681560|NCT04924530|Active Comparator|Sucrose|Fructose-glucose disaccharide
9681561|NCT04924530|Experimental|Lactose|Galactose-glucose disaccharide
9681562|NCT04924751|Experimental|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area was performed. After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
9681563|NCT04924751|Active Comparator|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
9681564|NCT04924582|Experimental|Capacity Coaching|Participants randomized to the Capacity Coaching arm will receive three months of coaching with a Health and Wellness coach. They will receive one one-hour session and five half-hour sessions approximately two weeks apart.
9681565|NCT04924582|No Intervention|No Capacity Coaching|Participants randomized to the No Capacity Coaching arm will receive usual care.
9681566|NCT04924595|No Intervention|Regular treatment|
9681567|NCT04924595|Experimental|Exercise Intervention|
10176815|NCT03829020|Experimental|Treatment (metformin, nelfinavir)|Patients receive metformin hydrochloride PO on days 1-14, nelfinavir mesylate PO BID on days 1-14, and bortezomib SC on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9681568|NCT04924647|Experimental|RD|lenalidomide and dexamethasone
9681569|NCT04924959||Modeling Group|
9681570|NCT04924959||Validation Group|
9681571|NCT04924504||Type A|Healthy pregnant women without pregestational or gestational diabetes
9681572|NCT04924504||Type B|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose <= 75 units/day
9681573|NCT04924504||Type C|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose >= 100 units/day
10176816|NCT03828968|Other|Bladder scan|Bladder scan performed on resident in homes for aged
10176817|NCT03829202|Experimental|A-B-A Group|Daily use of own mechanical knee for 4 weeks (A), followed by RheoKnee microprocessor prosthetic knee for 4 weeks (B), and concluding with own mechanical knee for 4 weeks (A).
9681574|NCT04924543|Active Comparator|Received short refresher training on optical diagnosis|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 Half of participants randomized 1:1 will also receive access to brief refresher training by week 8
9681575|NCT04924543|Active Comparator|No refresher training|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 This arm does not also receive access to brief refresher training
10176818|NCT03829202|Experimental|B-A-B Group|Daily use of RheoKnee microprocessor prosthetic knee for 4 weeks (B), followed by own mechanical knee for 4 weeks (A), and concluding with RheoKnee microprocessor prosthetic knee for 4 weeks (B).
10176819|NCT03829111|Active Comparator|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9681576|NCT04924569||Standard of Care|Individuals using an intermittent catheter to void urine through the urethra. Participants use their currently prescribed intermittent catheter per their clinician's standard of care.
9681577|NCT04924803|Experimental|No video condition|Participants in the no video condition will receive weekly text messages designed to increase vaccination among our sample.
9681578|NCT04924803|Experimental|Video text condition|Participants in the video text condition will receive the text messages designed to increase vaccination among our sample, along with links to iteratively developed intervention videos
9681579|NCT04924478||Severe Asthma Patients Treated with Mepolizumab|Following treatment, patients will be stratified into responders or non-responders
9681580|NCT04924634||Students|Students from 4 universities, regardless of field of study and academic year
9681581|NCT04924738||MOZART_SG|Women treated for hyperglycemia in pregnancy. Observational data are to be collected at follow-up visits during pregnancy, at delivery and postpartum.
10176820|NCT03829111|Experimental|Arm II (CBM588, nivolumab, ipilimumab)|Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
10176821|NCT03828942||Hematological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
10187284|NCT03727620|Experimental|doxycycline group|Drug Longamycine 200 mg the first day , then 100 mg per day for 14 days
9681582|NCT04924725|Experimental|CEH-EUS-guided FNB group|In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area under CEH mode was performed.
9681583|NCT04924725|Active Comparator|Conventional-EUS-guided FNB with fanning technique group|In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4).
9681584|NCT04924465||Anti-Jo1|Patients with anti-Jo1 antibodies
9681585|NCT04924465||Anti-PL7|Patients with anti-PL7 antibodies
9681586|NCT04924465||Anti-PL12|Patients with anti-PL12 antibodies
9681587|NCT04924465||Anti-EJ|Patients with anti-EJ antibodies
9681588|NCT04924465||Anti-OJ|Patients with anti-OJ antibodies
9681589|NCT04924491|Experimental|10.000.000 thyTreg /kg|Autologous thyTreg 10.000.000
9681590|NCT04924491|Experimental|20.000.000 thyTreg /kg|Autologous thyTreg 20.000.000
9681591|NCT04924192|Experimental|TQB3616 capsules+Anlotinib hydrochloride capsules|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 21 consective days as a treatment cycle;Anlotinib hydrochloride capsules 12mg, once a day for 2 consecutive weeks and stop for 1 week.
9681592|NCT04924192|Experimental|TQB3616 capsules +Irinotecan Hydrochloride for Injection|TQB3616 capsules 120/150/180mg orally on an empty stomach, once a day for 28 consecutive days as a treatment cycle. Irinotecan Hydrochloride Injection 100 mg/m2 intravenous infusion on D1、D8 and D15, a total of 4-6 cycles.
9681593|NCT04924049|Experimental|Experimental|The video-assisted education group also received routine treatment and care per protocol. Additionally, this patient group watched patient education through video in the patient room before TKR. The contents of the VE were developed by the researchers and included early postoperative care for TKR (knee positioning, early mobilization, pain control, and cold application), ADLs at home (bathing and toileting, eating, sleeping, vehicle driving, housekeeping, sexual life, praying, and maintaining home safety), and gradual exercise at home (for the first 90 days after discharge).
9681594|NCT04924049|No Intervention|Control|The control group received routine treatment and care per protocol.
9681595|NCT04924439|Experimental|experimental group (foot reflexology group)|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other.~Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks."
9681596|NCT04924439|No Intervention|control group|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
9681597|NCT04924361||Early onset dementia|Dementia patients with onset age lower than 65y/o
9681598|NCT04924361||Late onset dementia|Dementia patients with onset age between 65y/o and 85y/o
9681599|NCT04924361||Oldest old dementia|Dementia patients with onset age older than 85y/o
9681600|NCT04924361||Cognitive normal control|cognitive normal control
9681601|NCT04924270|Experimental|cFMT|
9681602|NCT04924270|Placebo Comparator|Placebo|
9681603|NCT04924218|Active Comparator|rigid cystoscopy|Group undergoing endoscopic urethral procedure with rigid cystoscopy after radical prostatectomy
9681604|NCT04924218|Active Comparator|flexible cystoscopy|Group undergoing endoscopic urethral procedure with flexible cystoscopy after radical prostatectomy
9681605|NCT04924218|Active Comparator|semi-rigid ureterorenoscopy|Group undergoing endoscopic urethral procedure with semi-rigid ureterorenoscopy after radical prostatectomy
9681606|NCT04924296|Experimental|Treatment group A|
9681607|NCT04924296|Placebo Comparator|Treatment group B|
9681608|NCT04924335|Active Comparator|ESP group|ESP group patients will be performed ultrasound-guided erector spinae plane block with 20 ml 0.025% Bupivacaine, preoperatively and will receive ERAS cardiac anesthesia protocol
9681609|NCT04924335|No Intervention|Conventional group|The conventional group will receive ERAS cardiac anesthesia protocol
9681610|NCT04924426||Patients with AMI|Patients with AMI
9681611|NCT04924426||Patients with no AMI|Patients with no AMI
9681612|NCT04924452|Experimental|Er:YAG laser therapy|Er:YAG laser will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment.
10176822|NCT03828981|Active Comparator|fast-track recovery program|"Pre-operative Verbal and video information Tobacco cessation Daily physical activity Light meal 6 hours and clear liquids up to 2 hours before surgery No bowel preparation A warm blanket Premedication paracetamol 1g and tematsepam 20mg~Intraoperatively For nausea and voimiting dexamethasone 10mg, dehydrobensperidol 1mg and ondancetron 4mg before emergence Analgesia: ropivacain at port sites before incision and at vaginal vault Opioids intravenously at discretion of anesthesiologist supplemented with Dexketoprofen 50mg Urinary catheter early removal Postoperative Pain: tramadol 50mg and ketoprofen100mg i.v., oral opioid if needed; patients with normal pain control receive oral pregabalin 25mg every 8 hours, paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours until discharge Out of bed after 2 hours from the end of surgery A liquid diet, if tolerated regular normal diet. For emesis ondansetron 4mg"
10176823|NCT03828981|No Intervention|conventional recovery program|"Preoperative preparation Verbal and written information Cessation of oral intake after previous midnight. Premedication paracetamol 1g+ diatsepam 5mg.~Intraoperative A warm blanket at the start of procedure. Prophylaxis for nausea and vomiting: Dexamethasone 5mg at induction, and Dehydrobenzperidol 1mg, ondancetron 4mg before emergence. Analgesia: injection of ropivacain 5% 20ml at port sites at the end of surgery, Opioids i.v. (oxycodone)~Postoperative Pain medication:Opioids i.v. (oxycodone), paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours Urinary catheter removal on next morning. Prolonged bowel and bed rest and gradual reintroduction of feeding."
9681613|NCT04924452|Active Comparator|Conventional therapy|Conventional rotary instruments will be used for caries treatment.
9681614|NCT04924205|No Intervention|Outpatient Physical Therapy|
10176824|NCT03828955|Experimental|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage.
9681615|NCT04924205|Experimental|Smart Orthotic Device (FM2 Knee Brace)|
9681616|NCT04924309||Patients undergoing assisted reproductive technology with donor sperm|
9681617|NCT04924309||Patients undergoing assisted reproductive technology with husband's semen due to male factor|
9681618|NCT04924413|Experimental|L-TIL and Tislelizumab|L-TIL（3-10）x10*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year
9681619|NCT04924283|Experimental|Cognitive Interference Task|Participants in this arm will complete random assessments of alcohol use and cravings on their phone, and be prompted to play Tetris on their phone after reporting cravings for alcohol.
9681620|NCT04924283|Active Comparator|Assessment Only|Participants in this arm will complete random assessments of alcohol use and cravings on their phone.
9681621|NCT04923789||ASCT Without CART|Patients who undergone ASCT successfully and did not receive CART cell infusion.
9681622|NCT04923789||ASCT Bridging CART|Patients who undergone ASCT and received CART cell infusion sequently within 1 month. Patients with disease recurrence or progression prior to the infusion of CART cells will be excluded.
9681623|NCT04923685||MDD with elevated CM and suicidality scores|Major Depressive Disorder with elevator childhood maltreatment and suicidality scores.
9681624|NCT04923685||MDD with CM history but lower suicidality|Major Depressive disorder with childhood maltreatment history but lower suicidality scores.
9681625|NCT04923685||MDD without CM but with elevated suicidality|Major Depressive Disorder without childhood maltreatment, but with elevated suicidality scores.
9681626|NCT04923685||MDD without CM but with lower suicidality|Major Depressive Disorder without childhood maltreatment but with lower suicidality scores.
9681627|NCT04923685||Healthy controls with CM history|Healthy controls with childhood maltreatment history,
9681628|NCT04923685||Healthy controls without CM history|Healthy controls without childhood maltreatment history.
9681629|NCT04923659|Experimental|LIFUS|Low Intensity Focussed ultrasound.
9681630|NCT04923932|Experimental|Savolitinib|GC
9681631|NCT04923698|Active Comparator|yoga|The yoga program consisted of 12 exercises, , 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
9681632|NCT04923698|Active Comparator|antidepressant|All women in group A were treated by antidepressant only for 12 weeks
9681633|NCT04923737|Active Comparator|Dexmedetomidine group|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
9681634|NCT04923737|Placebo Comparator|Control group|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
9681635|NCT04923724|Active Comparator|Tourniquet during surgery|Patients in this group get a tourniquet during surgery.
9681636|NCT04923724|Active Comparator|No Tourniquet during surgery|Patients in this group do not get a tourniquet during surgery.
9681637|NCT04923919|Experimental|Single arm|CLL-1 targeting CAR-T treatment
10176825|NCT03828955|Placebo Comparator|Placebo|Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage.
10176826|NCT03828721|Active Comparator|Control - screen time reduction|Families assigned to the control arm in each age category will receive customary ROR, including the provision of an age-appropriate children's book, and reading-related developmental surveillance and anticipatory guidance. In addition, control families will receive a new children's book reinforcing AAP screen-based media recommendations.
9681638|NCT04923711|Experimental|Moderate Intensity Group|Group received a moderate exercise prescription of moderate intensity
9681639|NCT04923711|Experimental|High Intensity Group|Group received a moderate exercise prescription of high intensity
9681640|NCT04923906|Experimental|Aumolertinib and platinum-based chemotherapy|
9681641|NCT04923906|Active Comparator|Aumolertinib|
9681642|NCT04923945|Experimental|Savolitinib|NSCLC
9681643|NCT04923984|Experimental|Embolization of Middle Meningeal Artery for Subdural Hematoma|All patients with CSDH will undergo embolization of Middle Meningeal artery
9681644|NCT04923997|Experimental|HealthScore Health Coaching|Participants on this arm of the study receive a physical activity tracker, weekly surveys and weekly health coaching for 6 months.
9681645|NCT04923646|Experimental|Active|Primer
9681646|NCT04923646|No Intervention|Control|No Primer
9681647|NCT04923633||Phase I Instrument-Assisted Soft Tissue Manipulation (IASTM) Stroke Pattern Analysis|Fifteen (n=15) experienced clinicians, each with 8 or more years experiences in instrument-assisted soft tissue manipulation (IASTM), will participate in an observational studying analyzing their application of basic stroke patterns (linear, curved) to a consistent research assistant/model. IASTM is a type of massage that uses rigid devices. A Quantifiable Soft Tissue Manipulation (QSTM) device system will be used for determining objective metrics of stroke parameters (e.g. stroke force, rate, angle) and results will be compared between participants to determine characteristic stroke profile patterns for use in training and research.
10176827|NCT03828721|Experimental|Rx for Success Smartphone Application|"Families in the intervention arm in both age categories will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively). No additional intervention will take place, other than push notifications and other content such as demonstration videos built into the RS application."
9681648|NCT04923633||Phase II Consistency of IASTM Force Application|"The reproducibility of applying a targeted STM stroke force will be determined within and between therapists, both with and without visual monitoring of the QSTM metrics and graphic display. Two novice and two experienced therapists will be trained using QSTM. A novice is defined as a clinician with <1 year and an experienced with >8 years of practice. Fifty (n=50) healthy, non-obese subjects will be enrolled that meet the inclusion/exclusion criteria. First, the clinicians will apply a self-perceived moderate force for 15sec (non-therapeutic dose), within subject tolerance, without using QSTM feedback. Then, the clinician will apply a targeted force of 10N with visual monitoring of QSTM feedback. This process will be repeated 5-7 days later to determine repeatability. After testing, subjects will participate in simple back and/or leg stretches and an ice pack applied."
9681649|NCT04923633||Phase III Reliability of Dynamic Pressure Pain Threshold Assessment|"The reliability of dynamic pressure pain threshold (DPPT) assessment over a specified area will be determined. Two novice and two experienced clinicians will be trained using QSTM. Subjects (n=50) will be recruited that meet the inclusion/exclusion criteria of healthy, non-obese, younger (≥18 but ≤30yo) and older individuals (≥50 but ≤75yo) (males and females). The clinicians will apply force to standardized areas of the back and thigh regions for 1 min, using the Quantifiable Soft Tissue Manipulation (QSTM) device system. The force applied will be applied up to but below the threshold of when a subject says to stop when they feel the pressure change into any sort of irritating discomfort/pain. Secondary clinical outcomes will be assessed before and after testing since testing could have effects on the soft tissue, pain, and physical performance measures. After testing, the subject will be instructed in simple back and/or leg stretches and an ice pack applied."
9681650|NCT04923971|Active Comparator|0C Trial|Participants will be sitting in a chair performing hand dexterity tasks in 0C (32F) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
10176828|NCT03828929|Experimental|Vitamin C and Thiamine|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
10176829|NCT03828929|Placebo Comparator|Placebo|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
10176830|NCT03829046|Placebo Comparator|Placebo|Placebo SC QM
10176831|NCT03829046|Active Comparator|Evolocumab|Evolocumab SC 420mg/dL QM
9681651|NCT04923971|Active Comparator|-10C Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C (14F) conditions.Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
9681652|NCT04923971|Active Comparator|-20C Surrogate Trial|Participants will be sitting in a chair performing hand dexterity tasks in -10C + 3m/s wind (14F+6 mph wind) conditions. Total rest period is 2 hours. After 2 hours, participants will perform athletic performance related tasks consisting of agility, power, muscular strength, and aerobic fitness.
9681653|NCT04923477|Experimental|Exercise Group|Therapeutic exercise of resistance and mobility training delivered by a trained health professional x 4 weeks.
9681654|NCT04923412|Experimental|Pulmonary branch of vagus nerve preserved|Pulmonary branch of vagus nerve is preserved during the mediastinal lymph node dissection using minimally invasive surgery
9681655|NCT04923412|Experimental|Pulmonary branch of vagus nerve not-preserved|Pulmonary branch of vagus nerve is not preserved during the mediastinal lymph node dissection using minimally invasive surgery
9681656|NCT04923373|Experimental|telerehabilitation|physiotherapeutic programme brochure exercises 7/week controlled by phone every week (5x in total)
9681657|NCT04923373|Active Comparator|standard physiotherapy|"Supervised physical therapy 3/ week,~+ physiotherapeutic programme brochure 4/week"
10176832|NCT03828864|Active Comparator|Active Pulsed Shortwave therapy|Application of the medical device emitting pulsed shortwave therapy. The medical device is used over the site of pain.
9681658|NCT04923243||Delirium group|Group of patients with postoperative delirium
9681659|NCT04923243||Non delirium group|Group of patients without postoperative delirium
9695541|NCT04777149|Active Comparator|transcranial Direct Current Stimulation (tDCS)|Participants in this group will receive a combined intervention (3 days of tDCS during functional task practice and 3 days of sham-stimulation during functional task practice).
9695542|NCT04777266|Experimental|Experimental Musictherapy Group|experimental group receiving the MT programme in addition to their usual treatment (pharmacological and psychosocial) (TAU + MT)
10176833|NCT03828864|Placebo Comparator|Placebo Pulsed Shortwave therapy|Application of the medical device that does not emit pulsed shortwave therapy. The medical device is used over the site of pain.
10176834|NCT03828565|Active Comparator|ScvO2 group|ScvO2 and Pulse Pressure Variation (PPV) : every 30 min (%) ScvO2 Evolution in case of corrective maneuver (%) PPV evolution in case of filling test (%)
10176835|NCT03828565|No Intervention|Control group|End-systolic Volume (ESV) : every 30 min (mL) ESV evolution in case of filling test (%)
10176836|NCT03828695|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
10176837|NCT03828578|Experimental|High flow oxygen therapy|"Patients allocated to the intervention group will receive high flow oxygen therapy via the tracheostomy tube from cessation of mechanical ventilation. The HFOT will provide oxygen therapy at a flow rate of 50-60 litres per minute at a FiO2 titrated by the bedside clinician to maintain a peripheral oxygen saturation of 95% of more (unless otherwise clinically indicated and documented by an appropriate consultant).~Once transferred to the ward patients will continue to receive HFOT 24 hours per day at a rate of 50-60 litres per minute at a maximum oxygen concentration of 40% to achieve oxygen saturations 95% and above (unless otherwise documented).~Patients may be disconnected from the HFOT for short periods for toileting, mobilising etc. Tracheostomy weaning will continue as per standard practice with an aim of cuff deflation followed by decannulation once clinically appropriate. systems. Following decannulation patients will resort to standard oxygen therapy as needed."
10176838|NCT03828578|No Intervention|Standard Care|Patients randomised to the standard care study arm will receive routine post-operative care as currently performed within the host organisation. Following cessation of mechanical ventilation, oxygen therapy will be delivered using equipment and rates appropriate to the clinical picture. On transfer to the ward patients will continue with existing methods of oxygen therapy and will be weaned from these accordingly. Patients will continue to use heat moisture exchanges (e.g. Swedish nose or Buchannan protectors) as clinically indicated, as well as having saline nebulisers prescribed and administered as per standard. Tracheostomy weaning will continue in accordance with current practice. Data on all of the applied procedures will be recorded.
9695543|NCT04777266|Active Comparator|Control Non Musictherapy Group|Group with usual treatment only (TAU).
9695544|NCT04777162|Experimental|tislelizumab+anlotinib|patients will be administrate with dual drugs, tislelizumab plus anlotinib.
9695545|NCT04777227|Active Comparator|Debridement|A debridement (procedure involving cleaning and removing all hyperkeratotic tissue) was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr
9695546|NCT04777227|Sham Comparator|Debridement with needle insertion|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
9695547|NCT04777227|Placebo Comparator|Debridement with physiological water injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 0.9% sterile sodium chloride water. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
9695548|NCT04777227|Experimental|Debridement with lidocaine injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 2% lidocaine solution. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
9695549|NCT04777097||healthy pregnant women|Healthy patients who receive a cesarean operation
9695550|NCT04777097||Pre-eclampsia|Patients with pre-eclampsia who receive a caesarean operation
9695551|NCT04777110|Experimental|Esketamine injection group (0.25mg/kg)|The main anesthesiologist standing on the right side of the patient gave successive injections of esketamine (0.25 mg/kg), and 1 minute later, injected propofol (1.5 mg/kg) for 30 s
9695552|NCT04777110|Sham Comparator|Saline injection group(0.05ml/kg)|The main anesthesiologist standing on the right side of the patient sequentially injects normal saline (0.05ml/kg), and 1 minute later injects propofol (1.5 mg/kg), the injection time is 30 seconds
9695553|NCT04776889|Active Comparator|Control/statin non-users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy.
9695554|NCT04776889|Experimental|Interventional/statin users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy and administered rosuvastatin 20 mg/day for 6 months
9695555|NCT04777123|Active Comparator|sitting position|patients will be left in the sitting position
9695556|NCT04777123|No Intervention|supine position|patients will lie down immediately after injection
9695557|NCT04776837||Main Cohort|"Patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival)~Prior to starting anti-cancer therapy and at subsequent designated visits (every one month)~Collections include:~Blood sample~Questionnaires quality of life, mood, and symptoms~Tissue may be obtained for next-generation sequencing."
9695558|NCT04776967|Active Comparator|Compression Profile 4|Compression Profile/Schedule 4 = 10 minute linear, Total Time Interval of Compression to treatment depth = 10 minutes, Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at treatment depth 45 fsw
9681660|NCT04923386||Diabetics who receive mRNA COVID-19 vaccine|Patients that have a history of Diabetes Mellitus Type I or Type II who received Pfizer-N-Biotech or Moderna mRNA COVID-19 vaccines
9681661|NCT04923204||Bipolar depression pharmacogenetics|Patients 18 years and older, with a diagnosis of bipolar disorder with an index episode of depression with or without associated psychotic symptoms (according to the Diagnostic Manual of Mental Disorder 4th Edition Text Revision, DSM-IV-TR), who attended the Bipolar Disorder Program of the Psychiatry Service of the Hospital Clínic de Barcelona (Spain).
9681662|NCT04923503|Experimental|lean ramadan fasting|conduct ramadan fasting for 30 days
9681663|NCT04923503|Experimental|obese ramadan fasting|conduct ramadan fasting for 30 days
9681664|NCT04923503|Experimental|diabetics ramadan fasting|conduct ramadan fasting for 30 days
10176839|NCT03828838|Experimental|Lu-177 PSMA-617|Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)
10176840|NCT03828643||Cases|Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
10176841|NCT03828643||Controls|Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
9681665|NCT04923399||TN (Trigeminal Neuralgia) group|Trigeminal neuralgia patients undergoing trigeminal nerve microvascular decompression
10176842|NCT03828708|Experimental|Standard iron arm|Participants randomized to this arm will consume infant formula containing 12 mg/L of iron, equivalent to the standard iron content in U.S. infant formula
10176843|NCT03828708|Experimental|Low iron arm|Participants randomized to this arm will consume infant formula containing 5 mg/L of iron, equivalent to the standard iron content in European infant formula
10176844|NCT03828409|Active Comparator|Short stitch|short stitch used as one arm
10176845|NCT03828409|Active Comparator|Long stitch|Long stitch as conventional mass-closure technique
10176846|NCT03828656|Experimental|Open Label Treatment Arm|Open-label Intervention with the NightWare Therapeutic System every night.
9681666|NCT04923399||Non-TN group|patients without chronic pain or history of chronic pain
9681667|NCT04923438|Experimental|telerehabilitation|The exercises will be applied twice a week for a total of 12 weeks, and each program will last roughly 30 minutes.
10176847|NCT03828435|Experimental|healthy control|This group does not undergo any treatment . Intervention : rTMS
9681668|NCT04923438|Active Comparator|control|The same exercise program will be prepared and given as a printout and they will be asked to do their exercises at home. This group will also be included in the study as a control group.
9681669|NCT04923308||Intervention group|
10176848|NCT03828435|Experimental|stroke patient|"this group undergoes rehabilitative therapy. It is a 24-week program and stroke patients practice the physical exercise for 1 hour each time. The intensity is three times a week.~Intervention : rTMS"
10176849|NCT03828604|Experimental|Stress; Trier Social Stress Task|5 min challenging speech task, 5 min challenging math task; performed in front of evaluators
10176850|NCT03828604|Active Comparator|Placebo Trier Social Stress Task|5 min speech task, 5 min math task; performed alone
10176851|NCT03828682|Experimental|Prospective Arm|"De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
10176852|NCT03828682|Active Comparator|Comparator arm|"Historical control arm consisting of the following~De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
10176853|NCT03828591|Other|Group A (intensive support)|Patients that receive standard and intensive psychological support during hospitalization
10176854|NCT03828591|Other|Group B (standard support)|Patients that receive only standard psychological support during hospitalization
10187285|NCT03727620|Active Comparator|amoxicillin plus metronidazole group|Drug Dispamox 500 mg, 3 times a day for 7 days Flagyl 250 mg, 3 times a day for 7 days
10187286|NCT03727607|Active Comparator|Gass|DESFLURANE ANESTHESIA
9681670|NCT04923308||Control group|
9681671|NCT04923529|Experimental|TAS-102|Single group assignment of TAS-102 in Patients with Advanced, Refractory Pancreatic Adenocarcinoma
9681672|NCT04923607|Experimental|TQC2731 injection(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 ."
9681673|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in healthy subjects|"For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once.~For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg)."
9681674|NCT04923607|Experimental|TQC2731 injection(SAD,iv.)|Healthy subjects received 210mg TQC2731 intravenously (iv.) once.
9681675|NCT04923607|Placebo Comparator|Matching Placebo(SAD,iv.)|Healthy subjects received 210mg matching placebo intravenously (iv.) once.
9681676|NCT04923607|Experimental|TQC2731 injection(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of TQC2731(70mg、210mg、280mg) .
9681677|NCT04923607|Placebo Comparator|Matching Placebo(sc.) in asthma subjects|For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of matching placebo(70mg、210mg、280mg) .
10176855|NCT03828669||Usual Care|Prior to the roll-out of the Recovery Toolkit program, all post-surgical patients receiving current standard of care are given pain care surveys at hospital discharge. Survey questions ask about pain, and satisfaction with pain care. The investigators will conduct chart review for pain and opioid use.
10176856|NCT03828669||Recovery Toolkit|After launch of the Recovery Toolkit program on Jan 25, all post-surgical patients will be offered a Recovery Toolkit by a unit nurse. A pain survey will be administered at hospital discharge to assess about pain in the hospital, satisfaction with pain care, whether they received a Toolkit, use of the Toolkit, and likelihood to recommend the Toolkit. The investigators will conduct chart review for pain and opioid use.
9681678|NCT04923451|Active Comparator|Patient with sexual addiction - active stimulation|25 patients with sexual addiction will be stimulated by active tDCS during 5 consecutive days
9681679|NCT04923451|Sham Comparator|Patient with sexual addiction - sham stimulation (placebo)|25 patients with sexual addiction will be stimulated by sham tDCS stimulation (placebo) during 5 consecutive days
9681680|NCT04923230|Experimental|CAP Intervention|CAP is a parent-focused intervention being developed to help parents in states with legalized medical marijuana to address adolescent marijuana use. The proposed intervention will address the effects of marijuana on adolescent behavioral health, brain development, and social functioning and enhance parent motivation to use CAP concepts. Guided by formative research, CAP will build skills and provide strategies to: (1) restrict adolescent exposure to cannabis products and parent cannabis use in the home, (2) improve parent communication about their own cannabis use and expectations about youth marijuana use, (3) improve monitoring, (4) increase positive reinforcement for youth abstinence, and (5) address parent negative emotions. Parents will meet in groups with an interventionist for two 75-minute sessions. Presentations, discussion, and roleplay will be used to help parents gain mastery of preventive parenting behaviors and related strategies to reduce adolescent marijuana use.
9681681|NCT04923230|No Intervention|Wait List|Parents randomly assigned to Wait List Delayed CAP (WL) will receive no intervention for the baseline to 3-month follow-up period. Thus, the WL condition will serve as a comparison group from baseline to the 3-month assessment point. After the 3-month follow-up assessment, WL parents will be offered the CAP intervention. The final assessment for the WL participants will function as a 3-month follow-up assessment, allowing us to aggregate data all 60 parent-adolescent dyads to conduct within group analyses of pre- to post-intervention change on key variables of interest.
9681682|NCT04923152|Experimental|moderate dose statin|Patients 1 month post PCI, allocated to 5 mg rosuvastatin per day
9681683|NCT04923152|Active Comparator|high dose statin|patients 1 month post PCI, allocated to 40 mg rosuvastatin
9681684|NCT04923425||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
9681685|NCT04923425||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
9681686|NCT04923425||Non exposure|Non-pharmacological treatment (psychotherapy)
10176857|NCT03828773|Other|high-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): homozygous for rs230561 and/or rs381652
10176858|NCT03828773|Other|low-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): other than homozygous for rs230561 and/or rs381652
9681687|NCT04922827|Experimental|Infliximab + Standard of Care|
9681688|NCT04922827|Active Comparator|Standard of Care|
9681689|NCT04922931||Post-COVID-19 group|The Post-COVID-19 group or case group includes post-COVID patients (confirmed by PCR) >18 years undergoing scheduled surgery without pulmonary disease prior to SARS-CoV-2 infection that at the time of surgery present negative PCR and absence of clinic due to SARS-CoV-2.
9681690|NCT04922931||Control group|The control group includes patients over the age of 18 who did not have COVID-19 and without moderate-severe pulmonary pathology prior to surgery and in conditions of hemodynamic and respiratory stability at time of surgery.
9681691|NCT04923074||DTI group|the patient in this group will receive DTI evaluation
9681692|NCT04923074||routine group|the patient in this group will receive routine evaluation
10176859|NCT03828812|Active Comparator|Breakfast promotion|Receiving the recommendation of daily breakfast
10176860|NCT03828812|Active Comparator|Nighttime snack reduction|Receiving the recommendation of reducing nighttime snack frequency
10176861|NCT03828812|Experimental|Breakfast promotion + nighttime snack reduction|Receiving the recommendation of daily breakfast + reducing nighttime snack frequency
9681693|NCT04923126|Experimental|Phase I: Recurrent and/or progressive low-grade glioma without prior exposure to MEK inhibitors|Participants will receive mirdametinib at one of the dose levels twice daily days 1-28. For the first cycle of treatment, participants will take mirdametinib tablets dissolved in water. After the first cycle of treatment, participants may receive the medicine the same way (dissolved in water) or may receive capsules. Treatment repeats every 28 days for up to 26 cycles of treatment (24 months) in the absence of disease progression or unacceptable toxicity.
9681694|NCT04923126|Experimental|Phase 2, Cohort 1: Newly diagnosed and/or previously untreated (except surgery)|Participants will receive the RP2D of mirdametinib. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
9681695|NCT04923126|Experimental|Phase 2, Cohort 2: Recurrent and/or Progressive without prior exposure to MEK inhibitors|Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
9976045|NCT01347619|Active Comparator|Arm 1. Toolkit only with Web Access|NHs in this arm will receive the toolkit only and web access to the materials.
10176862|NCT03828851|Experimental|Experimental group|ADL training program.
10176863|NCT03828851|No Intervention|Control group|Receive rehabilitation program in the hospital.
10187287|NCT03727607|Active Comparator|TIVA|TOTAL INTRAVENOUS ANESTHESIA
10187288|NCT03727568|Experimental|Cryobiopsy: longer freezing time|Group nº1: A total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and a freezing time from ≥5 seconds for the following biopsies.
9681696|NCT04923126|Experimental|Phase 2, Cohort 3a:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants with previous exposure to mirdametinib may receive a starting dose lower than the RP2D, depending on the dose they tolerated during their previous exposure. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
9681697|NCT04923126|Experimental|Phase 2, Cohort 3b:|Participants with recurrent and/or progressive low-grade glioma who previously received ≥ 6 courses MEK inhibitor (including mirdametinib) and did not progress while on active MEKi therapy. Participants will receive the RP2D of mirdametinib. Participants may take mirdametinib tablets dissolved in water, or receive capsules. Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in absence of disease progression or unacceptable toxicity.
9681698|NCT04922996||Ongoing|Patients already on calcium dobesilate treatment
9681699|NCT04922996||New|Patients with approved indication for calcium dobesilate treatment but not already on treatment
9681700|NCT04923061|Experimental|Acupressure group|The experimental group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
9681701|NCT04923061|Sham Comparator|Sham acupressure group|The sham group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
9681702|NCT04922957|Placebo Comparator|Placebo|Ringer's lactate solution
10176864|NCT03828383|Experimental|In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
10187289|NCT03727568|Experimental|Cryobiopsy: shorter freezing time|Group nº 2: A total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and a freezing time from <5 seconds for the following biopsies.
10187290|NCT03727555|Experimental|Lentivirus-mediated delivery of ABCD1 to the CNS.|Intracerebral injection with lentiviral TYF-ABCD1 vector carrying the functional gene
9681703|NCT04922957|Experimental|ALLOCETRA-OTS|Single IV dose of Allocetra-OTS containing 10x10^9 cells
9681704|NCT04923581|Experimental|Condition 1|Participants will receive the constant component only.
9681705|NCT04923581|Experimental|Condition 2|Participants will receive the constant component and storytelling videos .
9681706|NCT04923581|Experimental|Condition 3|Participants will receive the constant component and oral health promotion messages.
9681707|NCT04923581|Experimental|Condition 4|Participants will receive the constant component and a motivational interview session.
9681708|NCT04923581|Experimental|Condition 5|Participants will receive the constant component, oral health promotion messages and storytelling videos.
9681709|NCT04923581|Experimental|Condition 6|Participants will receive the constant component, oral health promotion messages, storytelling videos, and a motivational interview session.
9681710|NCT04923581|Experimental|Condition 7|Participants will receive the constant component, oral health promotion messages and a motivational interview session.
9681711|NCT04923581|Experimental|Condition 8|Participants will receive the constant component, storytelling videos, and a motivational interview session.
9681712|NCT04923113|Experimental|patients who meet the inclusion criteria|5 different methods will be performed to detect H. pylori infection in patients who meet the inclusion criteria，and patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.
9681713|NCT04923022|Experimental|Vegan diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last for eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
9681714|NCT04923022|Experimental|Therapeutic exercise|"The participants in the therapeutic exercise group will perform the following therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.~The patient, sitting in the cervical spine neutral position, performs flexion, extension and rotation of the cervical spine, unloaded and in the maximum possible range of motion.~While the patient is in the supine position, she performs passive lateral mobilization to the neck with the help of a physiotherapist.~In the supine position, the patient performs isometric neck flexion, lateral flexion and rotation movements against the manual resistance given by the physiotherapist~The patient lying on his back does isometric neck extension movement against gravity~The patient performs isometric neck flexion, lateral flexion and rotation movements against the elastic band in the sitting position"
9681715|NCT04923022|No Intervention|Control group|Participants in this group will not receive any intervention.
9681716|NCT04922905|Other|NEURO +|"Patients neuro + are those with a CASE score ≥ 2, Neuro + patients will benefit from additional evaluations using paraclinical examinations"
9681717|NCT04922905|Other|NEURO -|"Patients neuro - are those with a CASE score < 2"
9681718|NCT04923009|Experimental|Simple-ICE group|Patients undergoing ablation using only ICE visualization and ablation catheter
9681719|NCT04923009|Active Comparator|Standard mapping catheter without ICE|Patients undergoing ablation using standard approach including diagnostic and mapping electrodes as well as ablation electrode
9681720|NCT04922892|Experimental|Total Parathyroidectomy Alone|Total Parathyroidectomy Alone , without autotransplantation
9681721|NCT04922892|Active Comparator|Total Parathyroidectomy With Autotransplantation|Total Parathyroidectomy With Autotransplantation
9681722|NCT04923087||Patient hospitalized in geriatrics or EHPAD|Subjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents
9681723|NCT04922970|Experimental|Strength training|"In this arm participants will go through the Strength training intervention."
9681724|NCT04922814|No Intervention|Control group(group A)|Only sedation for mechanically ventilated COVID patients
9681725|NCT04922814|Experimental|Muscle relaxant group(group B)|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
9681726|NCT04922788|Experimental|25 mcg Dose|Intramuscular injection, two doses given 28 days apart
9681727|NCT04922788|Placebo Comparator|Placebo|Intramuscular injection, two doses given 28 days apart
9681728|NCT04922775|Other|conventional taping-Chinese medicine technique taping|Participants will accept conventional taping before muscle fatigue exercise for the first course then accept Chinese medicine technique taping before muscle fatigue exercise for the second course.
9681729|NCT04922775|Other|Chinese medicine technique taping-conventional taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise for the first course then accept conventional technique taping before muscle fatigue exercise for the second course.
9681730|NCT04922879|Experimental|Individualized lung rehabilitation programme|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
9681731|NCT04922918|Experimental|Probiotic arm|Administration of Ligilactobacillus salivarius MP101 (>9 log10cfu, daily) for 4 months
10176865|NCT03828383|Sham Comparator|Limited In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
10176866|NCT03828526|Experimental|High Fidelity Simulation|"Students will be exposed to the intensive care setting where they will have to solve issues related to general nursing care, including the stages of the medication process that involve the nurses' performance and their complexity.~During the experience of the scenario will be provoked external factors, such as telephone ringing, visit of the professional of the infection commission, to evaluate the reactions of the student and the strategies adopted to minimize the occurrence of adverse events against such external factors.~Subsequently, they will participate in the debriefing, where they will be reflected on the positives and those that should be adjusted to promote safer nursing care related to drug administration."
9681732|NCT04922359|Experimental|Experimental: Lidocaine group|
9681733|NCT04922359|Placebo Comparator|Placebo Comparator: comparator group|
9681734|NCT04922567|Experimental|lenalidomide + CHOP regimen|
9681735|NCT04922567|Active Comparator|CHOP regimen|
9681736|NCT04922476|Experimental|Probiotic|Alflorex® The participants consume one probiotic capsule a day for 12 weeks.
9681737|NCT04922606|Other|US of GSV|Ultrasound of the Great Saphenous Vein
9681738|NCT04922450|Experimental|Camrelizumab，albumin paclitaxel and cisplatin.|Participants will be given intravenous administration of Camrelizumab (200mg)，Albumin Paclitaxel(260mg/m²) and Cisplatin（80mg/m²）,After completing three times every three weeks of neoadjuvant therapy, The Participants will undergo surgery and Postoperative intensity modulated chemotherapy. The duration of treatment will till death, or unacceptable toxicity show up.
9681739|NCT04922372|Experimental|intervention arm copping veneered with composite resin|
9681740|NCT04922372|Active Comparator|control arm copping veneered with manual layering|
9681741|NCT04922658|Experimental|Surufatinib|
9681742|NCT04922658|Experimental|Surufatinib plus Vinorelbine|
9681743|NCT04922684|Active Comparator|Lower austic sub-group|16 times of mimicking emotional expressions
9681744|NCT04922684|Experimental|Higher austic sub-group|16 times of mimicking emotional expressions
9681745|NCT04922528|Experimental|Near-Infrared Fluorescence Cholangiography|Standard laparoscopic cholecystectomy completed with a combination of white light imaging and near-Infrared fluorescence cholangiography after administering 5 mg of a 25 mg/10 mL solution of indocyanine green (ICG) intravenously prior to the operation
9681746|NCT04922528|Active Comparator|White Light Imaging|Standard laparoscopic cholecystectomy completed with only standard white light imaging only
9681747|NCT04922411||Pilot Group|Participants (ages 20-75 years) who enroll as part of the Pilot Group of up to10, will follow the same inclusion criteria as the Control group with the exception of matching the age and sex distribution of the DBS group. The purpose of this group is to test the fluidity of the testing day as well as all of the measures, assessments, and scans (DOT and MRI).
9681748|NCT04922411||Control Group|Controls will match the age and sex distributions of the pre and post-surgical DBS groups. Participants will be males or females between 50 and 75 years of age who do not meet criteria for clinically definite PD. This group must be able to complete the testing day as well as all of the measures, assessments, and scans (DOT and MRI).
9681749|NCT04922411||Pre-Surgical Group|Subjects with PD who have been clinically consented for bilateral STN DBS surgery will be recruited from the DBS program within the Movement Disorders Clinic at WUSM. Pre-surgical STN DBS patients will be males or females between 50 and 75 years of age who meet criteria for clinically definite PD. This group must be able to complete the testing day as well as all of the measures, assessments, and scans (DOT and MRI).
9681750|NCT04922411||Post-Surgical Group|STN DBS: Subjects with PD who have been clinically consented for bilateral STN DBS surgery will be recruited from the DBS program within the Movement Disorders Clinic at WUSM (directed by Dr. Ushe, co-I). STN DBS patients will be males or females between 50 and 75 years of age who meet criteria for clinically definite PD. This group must be able to complete the testing day as well as all of the measures, assessments, and scan (DOT).
9681751|NCT04922398|Active Comparator|Group A: PRP group|Preparation of PRP sample fro the patient own blood then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period less than 2 min, approximately 4 ml of the PRP will be injected into each ovary by TVUS.
9681752|NCT04922398|Placebo Comparator|Group B: saline group|consists of 30 patients, who will receive 4 ml of a normal saline inj. 0.9% Nacl. then injected into each ovary by TVUS.
9681753|NCT04922723|Experimental|Daratumumab|"Daratumumab, IV, 16 mg/KG -~1 dose prior to surgery or biopsy; Weeks 1 - 8 = 1 dose weekly; Weeks 9 - 24 = 1 dose every other week; Weeks 25 onward (determined by disease progression) = 1 dose every 4 weeks"
10176867|NCT03828526|Active Comparator|Traditional teaching strategy|Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
10176868|NCT03828357||Ellipse VR with Durata|Ellipse VR single-chamber ICD with a Durata defibrillation lead
9681754|NCT04922437||Enterocystoplasty (EC)|Patients who had an implantation of the catheterizable continent channel by seromuscular plicature on the anterior wall of the bladder augmentation.
9681755|NCT04922437||Detrusor (D)|Patients who had an implantation of the catheterizable continent channel in the detruosr of their native bladder (Lich-Gregoir or Cohen).
9681756|NCT04922346||Healthy Pregnant|All volunteer pregnant women who were in the 2nd and 3rd trimesters (between 14-40 weeks) and who met the inclusion criteria in the study
9681757|NCT04922138|Experimental|Aumolertinib group|Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day .
9681758|NCT04922125|Experimental|Pulse flour|Puree produced from pulse flours and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
9681759|NCT04922125|Experimental|Pre-processed pulse flour|Puree produced from pre-processed pulse flour with different structural aspects and with added oil and herbs/spices. To standardize test products on textural aspects, different levels of thickener will be added. All test products will be produced in the Future Consumer Lab at the Department of Food Science at the University of Copenhagen prior to the appetite test days. Pulse flour will be produced in the food-grade laboratory environment at the Department of Food Design and Consumer behavior and dried prior to use.
10176869|NCT03828357||Ellipse DR with Durata & Tendril STS|Ellipse DR dual-chamber ICD with a Durata lead in the right ventricle (RV) and a Tendril STS lead in the right atrium (RA).
9681760|NCT04922177|Experimental|CAD/CAM Group|For the CAD/CAM group, an indirect ceramic restoration will be made using an optical impression.
9681761|NCT04922177|Active Comparator|Direct method Group|For the direct method group, a restoration using a Glass Ionomer Cement will be performed.
9681762|NCT04922242|Experimental|Population 1: NICU Study Staff|Interdisciplinary Professional Clinical Staff who are employed to work as a nurse, therapist, social worker or physician in the NICU.
9681763|NCT04922242|Experimental|Population 2: Mother-infant dyads in NICU|Parent and infant dyads admitted to a NICU for over 72 hours.
9681764|NCT04922268|Active Comparator|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
9681765|NCT04922268|Experimental|External focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
10176870|NCT03828357||Ellipse DR with Optisure and Isoflex|Ellipse DR dual-chamber ICD with an Optisure defibrillation lead in the right ventricle (RV) and an Isoflex lead in the right atrium (RA).
10176871|NCT03828357||Quadra Assura MP CRT-D|Quadra Assura MP CRT-D with an Optisure or Durata defibrillation lead in the RV, an Isoflex or Tendril STS lead in the RA, and a Quartet lead in the LV
10176872|NCT03828474|Experimental|Acetazolamide 125mg twice daily|Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
10176873|NCT03828474|Experimental|Acetazolamide 62.5mg twice daily|Acetazolamide pill 62.5mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
9681766|NCT04922086|Experimental|Test group|Patients will be submitted to ACL planned using cone beam computed tomography (CBCT), digital planning and guided dual technique.
9681767|NCT04922086|Active Comparator|Control group|Patients will be submitted to the conventional ACL planned using clinical examination.
9976046|NCT01347619|Active Comparator|Arm 2.Toolkit, Audit/Feedback, Education|NHs in the second arm will receive the toolkit, web access, periodic audit and feedback reports of antipsychotic prescribing to NH leadership, and faxed educational messages adapted from the AHRQ atypical antipsychotic CERSG to prescribers.
9976047|NCT01347619|Active Comparator|Arm 3. All above plus academic detailing|NHs in the third arm will receive the previous items plus face-to-face academic detailing.
9976048|NCT01347645|Active Comparator|1|Experimental Irinotecan plus E7820
9976049|NCT01347645|Active Comparator|2|FOLFIRI alone
10176874|NCT03828318|Experimental|Patient Activation Arm|
10176875|NCT03828318|No Intervention|Standard Care Arm|
10176876|NCT03828370|Active Comparator|Usual & Customary Information Group|"Study Cohort Assessment:~Baseline 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
10176877|NCT03828370|Experimental|B-SMART Intervention Group|"Study Cohort Assessment:~Baseline Web App Intervention 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
10176878|NCT03828279||hereditary angioedema type I|Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
10176879|NCT03828279||hereditary angioedema type II|Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was >50% of normal
10176880|NCT03828344|Experimental|hUC-MSC treatment|BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5×10^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.
9681768|NCT04922203|No Intervention|Control group|Anesthesiology residents do not receive any in situ simulation sessions during the observation period
9681769|NCT04922203|Experimental|Simulation group|Anesthesiology residents receive in situ simulations sessions during the observation period
9681770|NCT04922164|No Intervention|Control group|Receive education-based messages about the health benefit of breastfeeding
9681771|NCT04922164|Other|Social normative cues|Receive social normative cues related to breastfeeding
9681772|NCT04922164|Other|Goal-related cues|Receive goal-related cues related to breastfeeding
9681773|NCT04922047|Experimental|Experimental: Intravenous tislelizumab / Intravesical BCG|"Drug: tislelizumab / BCG~Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).~Other Name: BGB-A317"
9681774|NCT04922008|Experimental|IRIS-C|
9681775|NCT04922008|Experimental|IRIS-D|
9681776|NCT04922580||Hospitalization group|Newborns of ICP mothers require hospitalization after birth
9681777|NCT04922580||without Hospitalization group|Newborns of ICP mothers don't require hospitalization after birth
10176881|NCT03828344|Placebo Comparator|Placebo control|The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit.
10176882|NCT03828500|Experimental|Experimental Arm|encouraged by Research Assistant to drink clear fluids up to 2 hour limit. Arm 2 - standard of care
10176883|NCT03828500|No Intervention|Control Arm|
10176884|NCT03828305|Experimental|Training and creation of the Network-CPR|Training in CPR
10176885|NCT03828305|Active Comparator|Control Group|Primary Care Center Emergency Personnel
10176886|NCT03828175|Other|cop variables|non invasive cop vsriables correlation to basic monitoring variables during prone position spinal anesthesia intervention pcnl operation at basic ,1hour and 2hours .
10176887|NCT03828123|Experimental|Autologous Multipotent MSC|Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
9681778|NCT04922151|Experimental|group I|601 1.25mg
9681779|NCT04922151|Active Comparator|group II|Ranibizuman 0.5 mg
9681780|NCT04922385|Experimental|CBT|Individual 4-week CBT protocol
9681781|NCT04921930|Experimental|Artesunate|"Dose escalation of oral artesunate:~Step 1: 25 mg daily (1 tablet) during one week Step 2: 50 mg daily (2 tablets) during one week (if no effect on biomarker and no adverse reaction at step 1) Step 3: 75 mg daily (3 tablets) during one week (if no effect on biomarker and no adverse reaction at step 2) Step 4: 100 mg daily (4 tablets) duing one week (if no efficacy and no adverse reaction at step 3)"
9681782|NCT04922190|Experimental|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
9681783|NCT04922489||Patients with Astra Tech EV|Patients who has receive Astra Tech dental implant system placement.
9681784|NCT04921891|Active Comparator|Blocked arm|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
9681785|NCT04921891|Active Comparator|Unblocked arm|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
9681786|NCT04922307|Experimental|Blood Sparing Protocol|The intervention group (120 patients) will undergo radical nephrectomy with blood-sparing techniques. Acute Normovolemic Hemodilution (ANH) collects patients own blood prior to the start of surgical procedure; Cell saver is the collection of blood lost during surgery with subsequent auto-transfusion of the patients own cells; Veno-venous bypass will be used for patients with anticipated large loss of blood during surgery (>1L). The patients in the interventional group will be blinded to which blood sparing techniques utilized.
9681787|NCT04922307|Active Comparator|Standard Blood Replacement|The control group of one hundred and twenty (120) patients will undergo radical nephrectomy without blood sparing techniques (ie. Standard of care). Patients who need blood transfusion will receive cross-matched allogenic blood products.
9681788|NCT04921748||PD+FOG group|Patients affected by Parkinson's Disease with freezing of gait (PD+FOG group)
9681789|NCT04921748||PD-FOG group|Patients affected by Parkinson's Disease without freezing of gait (PD+FOG group)
9681790|NCT04921878|Experimental|Mitoxantrone Hydrochloride Liposome Injection|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 24 mg/m2, and then the dose is sequentially escalated to 30 mg/m2, 36 mg/m2 and 40 mg/m2.~Dose-expansion phase: After DLT observation, two to four dose cohorts will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection."
10176888|NCT03828227|Active Comparator|"Candidate group OPTIMOX plus bevacizumab (Arm A)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)"
10176889|NCT03828227|Active Comparator|"Candidate group - Capecitabine-bevacizumab (Arm B)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
10176890|NCT03828227|Active Comparator|"Non candidate group - Capecitabine-bevacizumab"|"Patients with:~Serum albumin level < 30g/L.~And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
10176891|NCT03828006|Experimental|Active Group|One tablet per day through oral administration of a dietary supplement containing red rice yeast as the main active ingredient
9681791|NCT04921579|Experimental|En masse retraction|six anterior teeth are retracted by en masse technique using a crimpable hook distal to upper lateral incisor and a power chain.
9681792|NCT04921579|Experimental|two step retraction|six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to upper lateral incisor and a power chain.
9681793|NCT04921592|Experimental|transcutaneous stimulation|"transcutaneous stimulation 60 sessions~Transcutaneous stimulation 40sessions~Transcutaneous stimulation 20 sessions"
9681794|NCT04921657||Patients treated with statin.|Patients with hypercholesterolemia treated with rosuvastatin 10 mg daily or simvastatin 40 mg daily.
9681795|NCT04921618||Index patients|"People aged 18 or more diagnosed with >= 1 STI in testing centers.~[STI = bacterial STIs and/or HIV and/or acute hepatitis C virus (HCV)]"
9681796|NCT04921618||Notified partners|"People aged 18 or more getting STI testing in testing centers after being notified by a sexual partner.~[STI = bacterial STIs and/or HIV and/or acute HCV]"
9681797|NCT04921670||Group A-Standard monitoring group (Reactive drug monitoring)|Participants assigned to this group will be managed the same as normally done per routine care, which involves adjusting their infliximab dose and/or dosing interval based on Inflammatory Bowel Disease (IBD) symptoms and routine care laboratory test results. The primary gastroenterologist will not be given the results of the infliximab and infliximab antibody level results of participants in this group unless their routine laboratory test results or IBD symptoms suggest their IBD may be worsening.
9681798|NCT04921670||• Group B- Infliximab level and infliximab antibody monitoring group (Proactive drug monitoring)|Participants assigned to the infliximab level and infliximab antibody level monitoring group will be managed based on the infliximab level and infliximab antibody level results as well as their IBD symptoms and the results of routine care laboratory tests. The goal is to keep infliximab levels in the optimal range with little to no antibodies. The primary gastroenterologist will remain blinded to the results of the infliximab level/infliximab antibody level test results and the participants' dose will be adjusted by one of the other study doctors who is not blinded to the results.
9681799|NCT04921852|Active Comparator|costoclavicular group|
9681800|NCT04921852|Active Comparator|lateral sagittal group|
9681801|NCT04921904|Experimental|Abemaciclib plus Ramucirumab|Abemaciclib 150mg dose administered orally twice daily every day plus Ramucirumab dose 8mg/kg iv every 2 weeks until evidence of disease
9681802|NCT04921813|Experimental|Schroth method + brace|3-dimensional scoliosis exercise program according to Schroth method + brace.
9681803|NCT04921813|Experimental|Schroth + balance-coordination exercises + brace.|3-dimensional scoliosis exercise program according to Schroth + balance-coordination exercises + brace.
10176892|NCT03828006|Placebo Comparator|Placebo Group|One tablet per day of placebo.
9681804|NCT04921813|Experimental|Brace|Only brace treatment.
9681805|NCT04921813|No Intervention|healthy individuals|Age-matched control group
9681806|NCT04921631|Experimental|Intervention|The intervention arm will receive early specialty palliative care integrated with standard critical care.
9681807|NCT04921631|No Intervention|No intervention|Usual ICU care; each study ICU has a policy for family meetings within 72 hours of admission and at least weekly thereafter.
9681808|NCT04921709||IBD Patients with Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have renal problems .~Age (18-65 years)~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
9681809|NCT04921709||IBD Patients without Renal Involvement|"Inclusion criteria: - patients with IBD diagnosed by colonoscopy and histopathology will classify the activity of the case to mild ,moderate and severe according to Mayo classification and have no renal problems .~Age (18-65 years)~Exclusion criteria: 1-patients underage of 18 2-HCV or HBV patients 3- renal patients diagnosed before diagnosis of IBD 4- diabetic or hypertensive patients 5- other autoimmune diseases such as Rheumatoid Arthritis, SLE. 6- Malignancy"
10176893|NCT03828032|Experimental|Mannitol injection|The participant receive mannitol injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
9681810|NCT04921696||RBC transfusion|RBC was transfused to the infants.
9681811|NCT04921696||no-RBC transfusion|RBC was not transfused to the infants.
9681812|NCT04921982|Experimental|Propranolol|
9681813|NCT04921982|Placebo Comparator|Placebo|
9681814|NCT04921566|Other|Sequence TR|13 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9681815|NCT04921566|Other|Sequence RT|13 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9681816|NCT04921514|Experimental|Patient and relatives|
9681817|NCT04921501|Experimental|Proven or suspected arrhythmias group|
9976050|NCT01347658|Experimental|Etravirine + echinacea|etravirine + root of Echinacea purpurea
10176894|NCT03828032|Experimental|Hypertonic saline injection|The participant receive hypertonic saline of specific concentration injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
10187291|NCT03727542|Experimental|Short AV-delay pacing|Participants will be their own control. Serum samples will be collected at baseline while the participants were in sinus rhythm and after 3 weeks of short AV-delay pacing serum samples will be recollected to measure matrix metalloproteinase levels .
10176895|NCT03828019|Active Comparator|Adalimumab (ADA)|"Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.~Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents <30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks."
9681818|NCT04921410|Experimental|Biofeedback Sleeve Effects on Preventive Biomechanics|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive an 'active' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide haptic feedback directly associated with potentially injurious events as determined by previously established cut-off values and artificially-intelligent algorithms.
10176896|NCT03828019|Active Comparator|Conventional immunosuppression (CON)|"Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.~Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID."
10176897|NCT03827941|Active Comparator|1 Hz group|1 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
9681819|NCT04921410|Sham Comparator|Sham Biofeedback|Biofeedback wearable sleeve will be utilized in at least 2 groups of athletes. This randomized group will receive a 'sham' wearable device. The device will be worn during regular sport practice sessions for 8-16 weeks. The device will provide random feedback at random intervals not directly associated with potentially injurious events.
9681820|NCT04921540|Experimental|Dermatologic intervention|Surgery with chemical cauterisation TCA
9681821|NCT04921540|Active Comparator|Orthopedic intervention|Only surgery
9695559|NCT04776967|Active Comparator|Compression Profile 3|Compression Profile/Schedule 3 = 10 minute non-linear, Total Time Interval of Compression to treatment depth = 10 minutes Rate (slope) of compression = Non-Linear rate of compression = 3 fsw/min to a depth of 17 fsw, then 5 fsw/min up to a depth of 38.5 fsw, then 6.5 fsw/min to arrival at the treatment depth of 45 fsw
9695560|NCT04776967|Active Comparator|Compression Profile 2|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
9695561|NCT04776967|Active Comparator|Compression Profile 1|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
9695562|NCT04776902|Other|Study Group|All patients will be enrolled in one arm
9695563|NCT04776954|Active Comparator|Forced Air Warming System|Participants in this arm will receive warming using a forced air warming system.
10176898|NCT03827941|Active Comparator|20 Hz group|20 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 20 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
10176899|NCT03827876|Experimental|Open Label Enstilar|once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
10176900|NCT03828240|Other|Enhanced rehabilitation|
9695564|NCT04776954|Active Comparator|Resistive Blanket Warming System|Participants in this arm will receive warming using a resistive blanket warming system.
10176901|NCT03827928|Experimental|Yoga/meditation|A 6-week yoga/meditation intervention.
9695565|NCT04776915||Study Group|Infertile patients due to polycystic ovarian syndrome
9695566|NCT04776915||Control Group|Infertile patients due to unexplained infertility
9695567|NCT04777032||Liver transplant recipients|All liver transplant recipient in Denmark aged 18-100 years will be eligible for inclusion in the DACOLT study. Inclusion requires the individual to be able to understand the study information in either Danish or English and to be able to provide an informed consent.
9695568|NCT04777032||Control group 1_CGPS|The Copenhagen General Population Study (CGPS) is an ongoing observational population study with more than 110.000 participants from the greater Copenhagen area. All residents in the greater Copenhagen area > 40 years and 25% of 20-40 years old are invited to participate in the study and in follow-up examinations every decade. A random sample of 10.000 participants aged ≥ 40 years had a contrast enhanced CT of the chest including CT angiography of the heart performed. Of these, 6500 had a contrast enhanced CT of the abdomen.
9695569|NCT04777032||Control group 1_CCHS|The Copenhagen City Heart Study (CCHS) includes a random population sample included from the greater Copenhagen area. Health surveys have been repeated 5 times between 1976 and 2015. Almost 4000 participants were randomly selected for echocardiography.
9695570|NCT04776850|Experimental|Treatment (PTIS, HCT)|See Detailed Description.
9696469|NCT04766593|Active Comparator|Prescription of multimodal physical exercise|This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The guideline will be to maintain a multimodal exercise to perform exercises of different characteristics, including aerobic exercises, balance exercises and low-load strength exercises for muscle groups, both in the upper quadrant and the lower quadrant. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).
9696470|NCT04766580|Experimental|Children with ADHD group|The same protocol is used for both groups
9696471|NCT04766580|Active Comparator|Children with no ADHD group|The same protocol is used for both groups
9696472|NCT04766567|Experimental|Serosal myomectomy|Patients with singleton pregnancy, who had serosal myomectomy during cesarean section
10176902|NCT03827928|No Intervention|Wait list|A wait list control period.
10187292|NCT03727529|Experimental|Intervention group|
10187293|NCT03727529|Active Comparator|Control group|
9681822|NCT04921306|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 28 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
10176903|NCT03827863||ARDS WITH ACP|"Diagnostic criteria for ARDS ARDS defined as within 1 week of a known clinical insult or new or worsening respiratory symptoms. ARDS was classified as mild (200 mmHg < PaO2/FIO2≤300 mmHg), moderate (100 mmHg < PaO2/FIO2≤200 mmHg) and severe (PaO2/FIO2≤100 mmHg) according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.~Ultrasound diagnostic criteria for ACP The specific diagnostic parameters are as follows: TR>2.8m/s; RVEDA/LVEDA>0.6 or Right ventricle/left ventricle basal diameter ratio>1.0 or systolic D sign; IVC >2cm with decreased inspiratory collapse; Pulmonary Regurgitation Velocity >2.2m/s."
10176904|NCT03827863||ARDS WITHOUT ACP|Diagnosis as ARDS but no ultrasound evidence of ACP.
9681823|NCT04921306|Placebo Comparator|Placebo|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 28 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
9681824|NCT04921462|Active Comparator|Silastic group|included patients who underwent nasal septoplasty followed by insertion of silastic intranasal splint
9681825|NCT04921462|Active Comparator|Quilting group|included patients who underwent septoplasty followed by quilting suture (Septal through and through suture)
9681826|NCT04921202||without metabolic syndrome and BMI<24|100 volunteers aged between 35-70 years old with body mass index(BMI)<24 without Metabolic syndrome
9681827|NCT04921202||Metabolic Syndrome with BMI>27|80 Metabolic syndrome patients with BMI>27 were included in the study
9681828|NCT04921280||Treatment group|Patients who have received treatment for severe health anxiety at the Internet Psychiatry Clinic, Psychiatry Southwest, Karolinska University Hospital Huddinge between April 2018 to April 2021.
10176905|NCT03828110||Children with neurological impairment|
10176906|NCT03827954|Experimental|Experimental Treatment|HeartMapp+CT
9681829|NCT04921267|Experimental|trained group|group receives training with sounds that correspond to simulated hearing protection
10176907|NCT03828084|Experimental|Formulation A|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
9681830|NCT04921267|No Intervention|Control|group receives no training
9681831|NCT04921241||SARS-CoV-2 Exposed Dyads|Mothers who had SARS-CoV-2 during pregnancy and their offspring
9681832|NCT04921241||SARS-CoV-2 Unexposed Dyads|Mothers who were not known to have SARS-CoV-2 during pregnancy and their offspring
10176908|NCT03828084|Experimental|Formulation B|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
10176909|NCT03828084|Experimental|Formulation C|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
9681833|NCT04921111|Experimental|Healthy Women Aged 18 to 26 Years|120 healthy women aged18 to 26 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil®9 : placebo =3:1:1.
9681834|NCT04921111|Experimental|Healthy Women Aged 27 to 45 Years|120 healthy women aged 27 to 45 years are in this arm. The first group was 40 subjects to be inoculated with low dose vaccine; After the first low dose group was completed, the safety observation was conducted 7 days after the first dose was completed. If there was no need to suspend / terminate the study, 40 subjects in the group were continued to receive the medium dose vaccine; After the first dose group was completed, the safety observation was 7 days after the first dose was completed. If there was no need to suspend / terminate the test, 40 subjects in the group were inoculated with high dose group. In each dose group SCT1000 : Gardasil® : placebo =3:1:1.
9681835|NCT04921436|Experimental|cardiac surgery patients with preventive treatment|"In addition to standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery), the following antibiotic regimens will be used perioperatively:~Doxycycline (the day before surgery 200 mg and 100 mg on days 1 and 2 after surgery) or Rimfampicin (150 mg 2 times a day before and after surgery) + Gentamicin (240 mg 3 times a day before and 2 days after surgery) or Clarithromycin (500 mg once daily for up to 2 days after surgery).~The route of administration (oral / intravenous) will depend on the condition of the patient."
9681836|NCT04921436|No Intervention|cardiac surgery patients without preventive treatment|standard antibiotic prophylaxis (cefazolin 2 g 60 minutes before skin incision and 2 g 3 times a day after surgery)
9681837|NCT04921163|Active Comparator|aluminium|4-day test periode with intake of aluminium pancakes
9681838|NCT04921163|Placebo Comparator|placebo|4-day test periode with aluminium-free pancakes
9681839|NCT04921163|Placebo Comparator|second placebo|Again a 4-day test periode with aluminium-free pancakes
10176910|NCT03828084|Active Comparator|Reference Formulation|3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
10176911|NCT03828097|Experimental|Experimental supplement|Participants in this arm will receive two capsules per day containing a total of 1 mg boron, 600 mcg folate, 8 mg iron, 50 mg magnesium, 320 mg omega-3 (DHA+EPA), 8 mcg vitamin B12, 50 mcg vitamin D3, and 7 mg vitamin E
10176912|NCT03828097|Placebo Comparator|Placebo|Participants in this arm will receive two capsules per day containing safflower oil
9681840|NCT04921254|Experimental|BSG005|Active antifungal drug
9681841|NCT04921254|Placebo Comparator|PÅlacebo|Will be a 5% glucose infusion
9681842|NCT04921345|Experimental|Cohort 1: Participants aged 7-11 years|Participants aged 7-11 years will receive nemolizumab for 52 weeks.
9681843|NCT04921345|Experimental|Cohort 2: Participants aged 2-6 years|Participants aged 2-6 years will receive nemolizumab for 52 weeks.
9681844|NCT04921137|Experimental|Omission of endocrine therapy|Omission of endocrine therapy
10176913|NCT03827902||Intervention Group|A Telcare 2.0 BGM, which is FDA cleared, will be used to upload blood glucose measurements to a cloud server accessible by providers. Intervention group will participate in an integrated care model where they will attend Diabetic Clinic and Foot Wound appointments on the same day.
9681845|NCT04921137|Active Comparator|Administration of endocrine therapy for at least 5 years|Administration of endocrine therapy for at least 5 years
10176914|NCT03827902||Control Group|Control Group will receive usual care (a non-integrated care model where Diabetes Clinic and Foot Wound appointments are on separate days.) These patients will not receive a blood monitoring glucose device.
10176915|NCT03827915|No Intervention|Third trial of DC cardioversion|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive a third trial of DC cardioversion (Standard of care)
10176916|NCT03827915|Experimental|Double sequential external defibrillation|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive DSED
10176917|NCT03828058|Experimental|Envarsus XR|Envarsus XR orally administered Daily
9681846|NCT04921423|Experimental|situational simulation teaching|Clinical case role play and empathy skill practice
9681847|NCT04921423|No Intervention|Clinical Case (Problem Based Learning)|Clinical Case discuss (Problem Based Learning)
10176918|NCT03828058|Active Comparator|Prograf|"Prograf PO administered twice daily Generic Name: tacrolimus~Dosage of prograf will be determined by trough levels and adjusted accordingly"
10176919|NCT03827889|Experimental|WMP of fluoride varnish|Whole mouth protocol group
10176920|NCT03827889|Experimental|TWLP of fluoride varnish|Tooth with lesion Protocol
10176921|NCT03827889|Active Comparator|DHP (educational intervention)|Diet and Hygiene guidance Protocol
10176922|NCT03828188|Experimental|group A|"Red Ginseng Concentrated Powder in 12 weeks → rest in 4 weeks → Placebo 12 weeks.~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
10176923|NCT03828188|Experimental|group B|"Placebo 12 weeks→ rest in 4 weeks → Red Ginseng Concentrated Powder in 12 weeks.~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
9681848|NCT04921371|Other|Healthy Reference Group|Participants who are identified as healthy will be a comparison group for the microbiome analysis. This group will participate in the examinations and plaque sampling only and will not receive a prophylaxis or product.
10176924|NCT03828071|Other|stem cell transplantation|patients enrolled in this study will received autologous hematopoietic stem cell transplantation as the initial treatment.
9681849|NCT04921371|Experimental|5% Hydroalcohol Mouthrinse (Negative control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 milliliter (mL) of 5 percent (%) Hydroalcohol Mouthrinse twice daily (morning and evening) up to 6 weeks.
9681850|NCT04921371|Experimental|Listerine® Cool Mint® (Positive control)|Participants after brushing with Colgate® Cavity protection toothpaste and Concept curve winter series Toothbrush will rinse mouth for 30 seconds with 20 mL of Listerine® Cool Mint® twice daily (morning and evening) up to 6 weeks.
9681851|NCT04921371|Experimental|Mouthrinse Prototype 1|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 1 twice daily (morning and evening) up to 6 weeks.
10176925|NCT03827785|Experimental|rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
10176926|NCT03827785|Sham Comparator|sham rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
9681852|NCT04921371|Experimental|Mouthrinse Prototype 2|Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 2 twice daily (morning and evening) up to 6 weeks.
9681853|NCT04921293|Active Comparator|Standard Diet|Standard diet incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with bitter taste placebo.
10176927|NCT03827772|Experimental|Intervention Arm: Fecal microbiota transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
10176928|NCT03827772|Other|Control Arm|Nutritional supplementation, supportive management
10176929|NCT03827707|Experimental|Noise|
10176930|NCT03827707|Sham Comparator|Silence|
10176931|NCT03827837|Experimental|SHR-1210 combined with Famitinb|SHR-1210 + Famitinib
10176932|NCT03827824|Experimental|Hysteroscopy & Virtual reality glasses|Hysteroscopy with use of virtual reality glasses
10176933|NCT03827824|Active Comparator|Hysteroscopy|Hysteroscopy without use of virtual reality glasses
10187294|NCT03727503|Other|group/cohort|operated patients from cardiac surgery. Once they arrived in the ICU, we will measure PPV with the capstesia and the PICCO device at baseline, and after a volume expansion of 500 ml of crystalloid.
9681854|NCT04921293|Experimental|Endogenous Ketosis|Ketogenic diet incorporating current recommendations for heart failure (<50gr of carbohydrates, low sodium, and liquids) for 10 days.
9681855|NCT04921293|Experimental|Exogenous ketosis|Standard incorporating current recommendations for heart failure (low sodium and liquids) and supplementation with exogenous ketones (ketone monoester) for 10 days.
9681856|NCT04921124|Experimental|Treatment|"Teriparatide, 20 µg Subcutaneous (S/C) per day.~Two doses in total."
9681857|NCT04921319|Experimental|VExUS-Guided Arm|Will receive 24 hour fluid balance target based on daily VExUS score.
9695571|NCT04776863||Smokeless tobacco|Individuals using smokeless tobacco
9681858|NCT04921319|No Intervention|Usual Care Control Arm|Treating team will be blinded to results of daily VExUS score and will set 24 hour fluid balance target based on usual care.
10176934|NCT03827850|Active Comparator|Cohort 1 FGFR trans|Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients) under daily Erdaifitinib treatment
9681859|NCT04921085||adult inpatients|adult inpatients with 7 categories of diseases (including digestive system, respiratory system, cardiovascular and endocrine system, tumor, nervous system, and urinary system)
9681860|NCT04921488|Experimental|Patients with indication for colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
9681861|NCT04921046|Active Comparator|Group Lignocaine|Group of 112 patients ASA-I and II (American Society of Anesthesiology)ages from 25-44 undergoing elective surgical procedure.
9681862|NCT04921046|Active Comparator|Group Midazolam|Group of 112 patients ASA-I and II ages from 25-44 undergoing elective surgical procedure.
10176935|NCT03827850|Active Comparator|Cohort 2 FGFR mut|Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients) under daily Erdafitinib treatment
10176936|NCT03827850|Active Comparator|Cohort 3 FGFR other|Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)
10176937|NCT03827811||PandrTB cohort|endTB participants on experimental regimen
10176938|NCT03827603|Experimental|patients with AIHA and CLL|patients with CLL and in Steroid Refractory AIHA receive ibrutinib 420 mg per day till progression or intolerance
9681863|NCT04921475||Renal regional oxygen saturation|Renal regional oxygen saturation is measured by using near infrared spectroscopy during transcatheter aortic valve implantation
9681864|NCT04920968|Experimental|Obinutuzumab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
9681865|NCT04920968|Active Comparator|Rituximab|Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.
9681866|NCT04920877|Experimental|Central catheter-related bloodstream infection rates in intensive care units|
9681867|NCT04920812||Mitochondrial diseases|annalysing with methology of multi-OMICS integration we will determined which RNA-Seq data (from muscle or fibroblasts) are the most informative for the interpretation of VUS identified by WES for patients suspected of mitochondrial myopathy.
9681868|NCT04920955||G1, CRC Relapse|Patients with an actual relapse of CRC, within 5 years from primary surgery. A single blood sample is collected at relapse diagnosis.
9681869|NCT04920955||G2, CRC Disease-free|Patients previously diagnosed with CRC and declared disease-free for at least 36 months but less than 5 years. A single blood sample is collected at standard monitoring visit.
9681870|NCT04920955||G3, CRC Disease-free (longitudinal)|Patients declared disease-free for at least 3 months but less than 18 months. Longitudinal blood samples will be collected during standard monitoring visits up to relapse, or for a maximum of 4 time points.
9681871|NCT04920955||G4, Primary CRC (longitudinal)|Patients with an actual diagnosis of CRC who are eligible for a treatment with curative intent. Blood samples will be collected pre and post-surgery (~6 weeks) and, eventually, at relapse.
9681872|NCT04920838|Active Comparator|Paracetamol|Patients in this arm will receive paracetamol during 14 days
9681873|NCT04920838|Experimental|Nitazoxanide and Ciclésonide|Patients in this arm will receive the combination of ciclezonide (Alvesco® 160 µg ) / nitazoxanide (Netazox® 500 mg) during 14 days
9681874|NCT04920838|Experimental|Telmisartan|Patients in this arm will receive telmisartan (Micardis® 20 mg) during 10 days
9681875|NCT04920747||S group|platin-5FU + trastuzumab
9681876|NCT04920747||T group|taxanes + platin-5FU + trastuzumab
9681877|NCT04920773|Experimental|Ayurveda Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati
9681878|NCT04920773|Active Comparator|Usual Care Group|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
9681879|NCT04921020||Normal participants|
9681880|NCT04921020||Patients with blepharoptosis|
9681881|NCT04921020||Patients with blepharospasm|
9681882|NCT04921020||Patients with dry eye disease|
9681883|NCT04921020||Patients with Graves' disease|
9681884|NCT04920851||Covid with sepsis|Covid patient with sepsis
9681885|NCT04920851||covid without sepsis|Covid patient without sepsis
9681886|NCT04920760|No Intervention|Control|Participants receiving standard treatment alone.
9681887|NCT04920760|Experimental|Vitamin A|Participants receiving standard treatment with an additional vitamin A supplementation.
9681888|NCT04920825|Active Comparator|Sacha Inchi Oil softgel|Oral Sacha Inchi oil softgel supplement
9681889|NCT04920825|Placebo Comparator|Corn oil softgel|Oral corn oil softgel
9681890|NCT04920669|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
9681891|NCT04920669|Experimental|erector spinae block + dexmedetomidine|erector spinae block with 19 ml bupivacaine + dexmedetomidine
9681892|NCT04920669|No Intervention|control group|standard general anesthesia without any block
9695572|NCT04776863||No smokeless tobacco|Individuals who do not use smokeless tobacco
10176939|NCT03827590|Experimental|HLIM|HLIM+SA160021 Placebo+SA160022 Placebo
10176940|NCT03827590|Active Comparator|SA160021|HLIM Placebo+SA160021+SA160022 Placebo
10176941|NCT03827590|Active Comparator|SA160022|HLIM Placebo+SA160021 Placebo+SA160022
10176942|NCT03827590|Placebo Comparator|Placebo|HLIM Placebo+SA160021 Placebo+SA160022 Placebo
10176943|NCT03827577|Experimental|LAT arm|"Lung resection (if primary in place) + local ablative therapy of all metastatic sites + standard medical treatment.~patients may be enrolled either before any systemic therapy or after 3 months of treatment without progression according to local coordinator decision"
10176944|NCT03827577|Active Comparator|Control Arm|"Standard medical treatment~Local ablative therapy on the brain will be administered in any case to patients harboring cerebral oligometastases"
10176945|NCT03827525||Cognitive and Behavioral Therapy|There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome
10176946|NCT03827499|Experimental|Ex-HMB|HMB dietary supplementation and Multicomponent physical exercise program
9681893|NCT04920656||Breast cancer patients|All adult patients with a confirmed diagnosis of breast cancer, aged 18 or older at time of cancer diagnosis, will be invited to participate.
9681894|NCT04920604||Teleconsultation|
9681895|NCT04920604||Control group|
9681896|NCT04920786|Experimental|TB006 70 mg - 5000 mg IV|TB006 infused intravenously over 1 hour
9681897|NCT04920786|Placebo Comparator|Placebo|0.9% normal saline infused intravenously over 1 hour
9681898|NCT04920695|Placebo Comparator|Placebo Control|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquid Healthcare, Montreal, Quebec, Canada).
9681899|NCT04920695|Active Comparator|Inhaled Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX™ gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; Control # 198879, DIN 02451328).
9681900|NCT04920409|Experimental|FAWGT Diet|Composed of fruit, avocado, whole grains and trout
9681901|NCT04920409|Active Comparator|Usual diet (UD)|Based on the food which the participants usually consumed prior to the study in their normal lifestyle.
10176947|NCT03827499|Experimental|NoEx-HMB|HMB Dietary supplementation
10176948|NCT03827499|Placebo Comparator|Ex-Plac|Multicomponent physical exercise program
9681902|NCT04920721||Allergic|suspected of immediate hypersensitivity reaction to platinum salts with positiv skin tests
10176949|NCT03827499|No Intervention|Controls|No intervention
10176950|NCT03827642|Experimental|Cohort 1: Treatment Sequence A-D-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment D on Day 1 of Period 2, Treatment C on Day 1 of Period 3 and Treatment B on Day 1 of Period 4.
10176951|NCT03827642|Experimental|Cohort 2: Treatment Sequence B-C-D-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, Treatment D on Day 1 of Period 3 and Treatment A on Day 1 of Period 4.
10176952|NCT03827642|Experimental|Cohort 3: Treatment Sequence C-A-B-D|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, Treatment B on Day 1 of Period 3 and Treatment D on Day 1 of Period 4.
10176953|NCT03827642|Experimental|Cohort 4: Treatment Sequence D-B-A-C|Participants received Treatment D on Day 1 of Period 1, Treatment B on Day 1 of Period 2, Treatment A on Day 1 of Period 3 and Treatment C on Day 1 of Period 4.
10176954|NCT03827551|Experimental|Parkinson's Patients|
10176955|NCT03827616|Active Comparator|2,5 Gy|hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy - 50,4 Gy).
10176956|NCT03827616|Active Comparator|3 Gy|hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).
10176957|NCT03827668|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design with two periods
10176958|NCT03827720|Experimental|Control|Healthy volunteers monitored with Sense Device
9681903|NCT04920721||Non allergic|suspected of immediate hypersensitivity reaction to platinum salts with negativ skin tests
9681904|NCT04920461|Experimental|Additional MRI sequences|
9681905|NCT04920708|Experimental|Palbociclib + Fulvestrant + Ipatasertib (Interventional arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to interventional arm receive Palbociclib + Fulvestrant + Ipatasertib. n = 87.
9681906|NCT04920708|Active Comparator|Palbociclib + Fulvestrant (Comparison arm)|Where high ctDNA is detected in screening, patients to be randomised on a 1:1 basis to interventional arm or comparison arm. Patients randomised to Comparison arm receive Palbociclib + Fulvestrant. n = 87.
9681907|NCT04920708|Active Comparator|Standard of Care (No ctDNA observational arm)|Where no ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 50.
9681908|NCT04920708|Active Comparator|Standard of Care (Low ctDNA observational arm)|Where low ctDNA is detected in screening, patients to be allocated to the observational arm and receive standard of care (Abemaciclib / Ribociclib / Palbociclib + fulvestrant). n = 100.
9681909|NCT04920565|Experimental|cardiac surgery patients with multiple organ dysfunction|hemoperfusion procedure with polymyxin B will be performed for 12 hours
9681910|NCT04920565|No Intervention|cardiac surgery patients|without hemoperfusion with polymyxin B
9681911|NCT04920682|Active Comparator|Group M (reversion with moderate neuromuscular blockade)|Administration of neostigmine 60 mcg/kg and atropine 30 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4.
9681912|NCT04920682|Active Comparator|Group S (reversion with superficial moderate neuromuscular blockade)|Administration of 0.9% saline solution (SF) when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4.
9681913|NCT04920682|Active Comparator|Group N (two-step reversal of neuromuscular blockade)|Administration of neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4 .
9681914|NCT04920682|Placebo Comparator|Group P (placebo)|Administration of 0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)> 0.4.
9681915|NCT04921033|Experimental|Exclusive Enteral Nutrition|35kcal/kg/day EEN (Nestle Modulen®) - Subjects will take medicine and EEN solution orally themselves.
9695573|NCT04776876|Experimental|Treatment (retifanlimab, telotristat ethyl)|Patients receive retifanlimab IV over 30-60 minutes on day 1 and telotristat ethyl PO TID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10176959|NCT03827720|Experimental|Intracranial Hemorrhage|Intracranial hemorrhage patients monitored with Sense Device
10176960|NCT03827720|Experimental|Acute Ischemic Stroke with LOV|Acute Ischemic Stroke patients that have large vessel occlusion monitored with SENSE Device
10176961|NCT03827720|Experimental|AIS without LOV|Ischemic Stroke patients that do not have large vessel occlusion monitored with SENSE device
10176962|NCT03827629|Experimental|Cohort 1: Treatment Sequence A-B-C|Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
10176963|NCT03827629|Experimental|Cohort 2: Treatment Sequence B-C-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
10176964|NCT03827629|Experimental|Cohort 3: Treatment Sequence C-A-B|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
10176965|NCT03827629|Experimental|Cohort 4: Treatment Sequence A-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
9681916|NCT04921033|Active Comparator|Standard of care|"Budesonide 9mg/day for mild disease~Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~Patients with moderate-to-severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
9681917|NCT04920396|Experimental|IRPL|Three treatments with IRPL (manufacturer: E-Swin, France) on days 0, 15 and 45
9681918|NCT04920396|Active Comparator|Warm compress|Daily use of a warm compress (manufacturer: The Eye Doctor, UK) with Sterileyes® twice a day for 5 minutes
9681919|NCT04920526||QHPV Vaccine|all participants have received QHPV
9681920|NCT04920357||Post-COVID-19|Persons with a verified previous COVID-19 infection
9681921|NCT04920357||COVID-19 naive|Persons that have no history of COVID-19
10176966|NCT03827629|Experimental|Cohort 5: Treatment Sequence C-B-A|Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
10176967|NCT03827629|Experimental|Cohort 6: Treatment Sequence B-A-C|Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
10176968|NCT03827408|Active Comparator|Midazolam group (MDZ)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.5 mg/kg Midazolam.
10176969|NCT03827408|Experimental|Dexmedetomidine group (DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 5µg/kg Dexmedetomidine.
10176970|NCT03827408|Experimental|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.
9681922|NCT04920630|Experimental|CBT-I|5-weekly Cognitive Behavioral Therapy for Insomnia group therapy sessions conducted virtually.
9681923|NCT04920448|Experimental|N-Acetylcysteine 150 mg/kg|Single intravenous injection of N-Acetylcysteine (150 mg/kg in 15 minutes).
9681924|NCT04920903|Experimental|COR588|
10176971|NCT03827681|Experimental|TIPS + Vasoactive Drug|
9681925|NCT04920903|Placebo Comparator|Placebo|
9681926|NCT04920591|Experimental|doll therapy (DT)|doll therapy (emathy dolls)
9681927|NCT04920591|No Intervention|Standard treatment (ST)|standard clinical practice
9681928|NCT04920318|Experimental|active TDCS|During intervention excitatory/anodal tDCS will be administered alongside speech-language therapy 5 days a week for 2 weeks. The exact location of the stimulation and electrode configuration will be targeted individually based on the optimal site identified in fMRI. TDCS will be administered with NeurConn1 Channel DC- Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes using sponge electrodes with a 30-s ramp-up and ramp-down period
9681929|NCT04920318|Sham Comparator|sham TDCS|The sham will be administered alongside speech-language therapy 5 days a week for 2 weeks. For sham, stimulation will be ramped up and then down to 0 milliamperes (mA) in the first minute of stimulation. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS
9681930|NCT04920500|Experimental|Daunorubicin Cytarabine liposome for injection|Induction 1: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (>90 min) d1,3
9681931|NCT04920500|Active Comparator|Vyxeos + Daunorubicin Cytarabine liposome for injection|Induction 1: Vyxeos[100 U/m²] i.v. (120 min) d1; Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d3,5 Induction 2: Daunorubicin Cytarabine liposome for injection [100 U/m²] i.v. (120 min±10min) d1,3 Consolidation therapy: Daunorubicin Cytarabine liposome for injection [65 U/m²] i.v. (>90 min) d1,3
9681932|NCT04920305|Experimental|Phosphatidylserine group|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
9681933|NCT04920305|Placebo Comparator|Bean powder group|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.) for 6 months.
9681934|NCT04920552|Placebo Comparator|Placebo binder first|"Participants in this arm will wear the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
9695574|NCT04776824||Patients with confirmed amyloidosis|Confirmed diagnosis of amyloidosis w/wo cardiac involvement
10176972|NCT03827681|Active Comparator|SEMS + Vasoactive Drug|
10176973|NCT03827382|Active Comparator|Intervention|Patients with intensive Lifestyle intervention
10176974|NCT03827382|No Intervention|Control|Patients with Standard Diabetes care
10176975|NCT03827486|Active Comparator|Standard of care|
10176976|NCT03827486|Experimental|Domicilary exercise program|
10176977|NCT03827733||AD patients|Participants who are diagnosed with AD.
10176978|NCT03827733||Partners of the AD patients|Partners of AD patients who live together with the AD patients.
10176979|NCT03827733||Elderly participants with normal cognition|Community dwelling elderly with normal cognition and with AD.
10176980|NCT03827434|Active Comparator|Continuous glucose Monitoring and Clarity|Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
9681935|NCT04920552|Active Comparator|Elastic abdominal binder first|"Participants in this arm will wear the active comparator (ABDO-SYNCRO 3-BAHNIG elastic abdominal binder, SYNCRO-MED GmbH) for 2 hours on treatment day-1 (i.e. Visit 1), followed by the placebo comparator (Clima Care body warmer, Bort Medical GmbH) for 2 hours on treatment day-2 (i.e. Visit 2)."
10176981|NCT03827434|Placebo Comparator|Point of Care Fingerstick Glucose values|Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
9681936|NCT04920266|Experimental|Smart sweat patch for sweat rate and sweat chloride concentration|Epidermal microfluidic patch that is a flexible 27 cm2 platform with an adhesive backing that collects sweat through a skin-facing inlet port. Custom software uses the smartphone camera to capture and analyze the microfluidic patch.
9681937|NCT04920266|Placebo Comparator|Reference sweat patch for sweat rate and sweat electrolytes|Regional absorbent patch technique for sweat rate (gravimetry) and electrolytes (sodium, potassium, chloride) by ion chromatography
9681938|NCT04920266|Experimental|Smart Cap bottle fluid measurement|Fluid level sensor integrated into the squeeze bottle cap measures the amount of fluid remaining in the bottle via light reflection
9681939|NCT04920266|Other|Reference method bottle fluid measurement|Scale weight of bottle (gravimetry method) for Smart Cap bottles (running and fitness subjects) and non-Smart Cap bottles (cyclists)
9681940|NCT04920019|Experimental|Thoracic continuous epidural analgesia|"Thoracic continuous epidural analgesia at T7-8 or T8-9 combined with IV PCA fentanyl (bolus mode only 15 ug/bolus, 5 minutes lockout, 4 hours limit 200 ug).~Multimodal analgesia Intraoperative : thoracic epidural infusion with 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h, morphine 2 mg epidurally are given.~Postoperative: 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h is given combined with IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug, multimodal analgesia: paracetamol 1000 mg iv every 6 hours until patient can take orally, change to 1000 mg orally every 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (etoricoxib 90 mg orally x2 days)"
9681941|NCT04920019|Active Comparator|intravenous opioid|IV PCA fentanyl, IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug multimodal analgesia: paracetamol 1000 mg IV every 6 hours until patient can take orally, change to 1000 mg orally q 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (Etoricoxib 90 mg orally x2 days)
9681942|NCT04919928|Experimental|Bimodal solution with cochlear implant and hearing aid (CI+HA)|"This Arm will serve as the intervention group. Patients referred for evaluation of cochlear implant candidacy at Odense University Hospital will be screened for eligibility in this study and invited to participate. All patients receive new replacement HAs that can later be fitted with the CI in a bimodal solution. The patients will use the new replacement HAs for one month and are then randomized to either the intervention group with CI+HA or to the control group with continuous use of HA+HA (bilateral) for another two months. Patients randomized to the intervention group CI+HA will undergo surgery as soon as possible after randomization.~Patients with the bimodal solution CI+HA will undergo follow-up one, three, six and twelve months after CI fitting."
9681943|NCT04919928|Experimental|Bilateral new replacement Hearing Aids (HA+HA)|This Arm will serve as the control group. The patients in the control group will use the new replacement HAs for one month like the intervention group and then for another three months, if they complete the study. The control group using the new replacement HAs for three months after randomization, will be offered the bimodal solution with CI to the poorer hearing ear and have the same follow-up period as the intervention group after a total of four months with new replacement HAs.
9681944|NCT04919967|Experimental|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course an also receive support through the Virtual Implementation Protocol.
9681945|NCT04919967|Active Comparator|E-learning/toolkit alone|Participants assigned to the e-learning/toolkit alone group will only complete the e-learning course/receive the e-learning toolkit.
10176982|NCT03827174|Active Comparator|Comparison intervention|Return To Work Coordination: external and internal coordination regarding sick leave. Establishment of a common return to work plan between employer and employee.
9681946|NCT04919967|No Intervention|Treatment as usual|Participants assigned to this group will not be provided any additional training or implementation assistance. They will be able to take trainings outside of study protocol if they would otherwise plan or want to do so. They will be offered the study-specific training and implementation assistance after they have completed the final study assessments.
9681947|NCT04919915|Other|Intervention group|Households are randomly assigned to the intervention group with asthma education and received two HEPA air cleaners designed to reduce PM and NH3.
9681948|NCT04919915|No Intervention|Control group|Households are randomly assigned to the control group. They only received the asthma education during the study period. These households receive a HEPA air cleaner at the end of the study.
9681949|NCT04920045|Active Comparator|Liberal Transfusion Arm|Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb>9g/dL, and this will be maintained throughout their hospitalization.
9681950|NCT04920045|Active Comparator|Restrictive Transfusion Arm|Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.
9681951|NCT04920032|Experimental|TASIRI|"Patients randomized to the experimental arm (TASIRI) will be treated with TAS-102 25mg/m2 p.o. on days 1-5 and irinotecan 180mg/m2 i.v. on day 1 every 14 days. If ANC <1500/uL on day 1 of a cycle, then G-CSF will be added on day 6 for three days."
10176983|NCT03827174|Experimental|Experimental intervention|"Return To Work Coordination + Behaviour Change Ability Programme~Behaviour Change Ability Programme:~Return to work coordination~Education for employers and employees in pain neuroscience, validation, and problem-solving~Patient specific goal setting for return to work~Exercise and behavioural skills training related to return to work"
9681952|NCT04920032|Active Comparator|Standard Arm|Patients randomized to the standard arm (i.e. continuation of the original regimen) are managed per investigator's discretion. Based on tolerability, the goal in the standard arm should be to complete a total of six months of adjuvant treatment.
9681953|NCT04920175||NICU Cohort|Participants will undergo a standard polysomnogram
9681954|NCT04920201|Experimental|Over-ground walking without GEMS-H|
9681955|NCT04920201|Experimental|Over-ground walking with GEMS-H with resist mode|
9681956|NCT04920201|Experimental|Stair ascent with GEMS-H with assist mode|
9681957|NCT04920201|Experimental|Incline walking with GEMS-H with assist mode|
10176984|NCT03827369||ICU patient|Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time.
9681958|NCT04920214||Experimental group|"patients with hepatic focal lesions~patients with non-high risk factors for hepatocellular carcinoma"
9681959|NCT04920227|Experimental|CLASS+PHACO|CO2 Laser-Assisted Sclerectomy Surgery combined with phacoemulsification
9681960|NCT04920227|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery
9681961|NCT04920240|Placebo Comparator|routine group|"In accordance with the intensive care unit hospital infection prevention and control norms requirements"
9681962|NCT04920240|Experimental|Experimental group|Implement a multi-center unified ICU high-frequency contact surface standardized cleaning and disinfection mode
10176985|NCT03827109|Experimental|Mentoring program|The Mentoring Program consists of year-long, 1:1 mentee-mentor relationships with group educational activities, online educational information, and a parent support component. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month. Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. They also provide opportunities to socialize with other mentors and mentees: lunch and games are provided before or after the educational event. Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing. Parents join the mentees and mentors for the educational topics. Due to the COVID-19 pandemic, these activities can be conducted virtually.
10176986|NCT03827109|Active Comparator|Educational activity program|The Educational Activity comparison group consists of separate educational group events on the same topics (with no social time), educational information posted online, and monthly encouragement to engage in activities in the community. Due to the COVID-19 pandemic, participants are encouraged to interact socially in safe ways, e.g., outdoors or virtually.
10176987|NCT03827239|No Intervention|Control|No intervention. Study participants will be seated during the entire sedentary 3-hour time period and wheeled to phlebotomy (and exercise) stations when required. During the sedentary period, participants will eat the food according to the study protocol and be seated at desks and allowed to read and use computers.
9681963|NCT04919941|Experimental|Decision aid|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
9681964|NCT04919941|No Intervention|Control|Did not receive the decision aid.
10176988|NCT03827239|Experimental|Intervention|Will disrupt their sedentary time with 3 minute exercise sessions every 30 minutes
10176989|NCT03827070|Experimental|Talcum powder & Afatinib|Talcum powder 4 g + Afatinib 0,4 g. Is entered once
10187295|NCT03727490|Active Comparator|Control|This group will have the subscapularis left un-repaired, which is the standard of care for our institution for reverse shoulder arthroplasty.
10187296|NCT03727490|Experimental|Study|This group will have the subscapularis tendon repaired through a bone to bone repair that will add approximately 5 minutes to the surgical procedure.
10187297|NCT03727464|Experimental|Propofol Abstract Priming|Patients undergoing propofol general anesthesia and stimulation with a list of abstract words
9681965|NCT04919902||Electric cardioversion|Patients who underwent elective cardioversion for atrial arrhythmia
9681966|NCT04919876|Experimental|fruit/vegetable supplement (FVS)|The experimental product will be prepared by combing Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend, and Juice Plus+ Berry Blend in an equal proportion.
9681967|NCT04919876|Placebo Comparator|placebo|The placebo comprises microcrystalline cellulose and 0.5% magnesium stearate.
9681968|NCT04919850|Active Comparator|Intervention group|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
9681969|NCT04919850|Placebo Comparator|Placebo group|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
9681970|NCT04919603|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
9681971|NCT04919603|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)telephone. The education is mainly consisted of instructions on diabetes prevention according to < Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)>.
9681972|NCT04919694|Experimental|combination of orbital compression and strabismus surgery|orbital compression and strabismus surgery are performed at the same time
9681973|NCT04919694|Active Comparator|perform strabismus surgery after orbital compression|Firstly, perform orbital compression, after about 3 to 6 months ,strabismus surgery is done.
9681974|NCT04919616|Experimental|Single-arm|
9681975|NCT04919720|Other|Human Factors Interventions|A 'bundle' of human factors interventions designed to improve response to deteriorating patients.
9681976|NCT04919525|Experimental|TrainPain Intervention|Daily TrainPain protocol - gamified sensory perceptual training
9681977|NCT04919746|Experimental|Group Acupuncture 1 - GA1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
9681978|NCT04919746|Experimental|Group Acupuncture 2 - GA2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
9681979|NCT04919746|Experimental|Group Acupuncture 3 - GA3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
9681980|NCT04919746|No Intervention|Group Control 1 - GC1|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 0.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
9681981|NCT04919746|No Intervention|Group Control 2 - GC2|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 2.5 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
9681982|NCT04919746|No Intervention|Group Control 3 - GC3|Healthy individuals aged between 18 and 38 years. The dielectric constant will be evaluated with a depth measurement of 5.0 mm, elasticity and infrared thermography in the region of the systemic acupuncture points.
9681983|NCT04919785|Experimental|Deep brain stimulation|Deep brain stimulation in the bed nucleus of stria terminalis
9681984|NCT04919733|Experimental|Non fluoroscopy CIED implant|Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system
9681985|NCT04919759|Active Comparator|Rashakaty Basic (R-Basic)|Participants in the R-Basic intervention arm had access to a website that contained the study questionnaires and nutrition education materials
10176990|NCT03827148|Experimental|Intervention: Pharmacist-delivered pharmaceutical care|The intervention consist of a pharmacist providing pharmaceutical care with aim to improve the treatment outcomes. It will be in the form of a single face-to-face session by pharmacist. Moreover, a specially designed rheumatoid arthritis disease education literature will be provided in both Urdu and English languages to patients for home use. The patients will be provided a contact number at which the pharmacist will be available at all times for the next three months (week 12). A specially designated counselling area in the pharmacy department of the hospitals served as venues for intervention.
9681986|NCT04919759|Experimental|Rashakaty Enhanced (R-Enhanced)|Participants in the R-Enhanced intervention were given access to smart phones applications for monitoring diet and physical activity levels as well as an online access to a nutritionist
9681987|NCT04919538||Relapsing Polychondritis Cohort|
10176991|NCT03827148|No Intervention|Control: Usual Care|The patient in control group will have usual care without pharmacist intervention.
10176992|NCT03827122|Experimental|Group one|Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks
10176993|NCT03827096|Experimental|Human AMSC (passage 3) 3P in 1.5 mL|Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL
10187298|NCT03727464|Experimental|Propofol Concrete Priming|Patients undergoing propofol general anesthesia and stimulation with a list of concrete words
10187299|NCT03727464|Active Comparator|Propofol Controls|Patients undergoing propofol anesthesia without any intraoperative priming
10187300|NCT03727464|Experimental|Sevoflurane Abstract Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of abstract words
10187301|NCT03727464|Experimental|Sevoflurane Concrete Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of concrete words
9681988|NCT04919772||Stroke survivors|Chronic stroke, generally speaking chronic stroke refers to the period of recovery that takes place at least six months after the initial stroke event
9681989|NCT04919837|Experimental|Algorithm assisted group|Patients receive assisting devices fitting services from human doctors assisted by the machine learning model
9681990|NCT04919837|Experimental|Human doctor group|Patients receive assisting devices fitting services from humanr doctors
9681991|NCT04919265||Mother and Infant|The cohort will be followed for 2 years with 8 follow-up measurement points of the infants until the age of 1 year.
9681992|NCT04919460|Other|clinical observation combined with pathological biopsy|Clinical observation (including inspection and palpation) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
9681993|NCT04919460|Experimental|Clinical observation, in vivo staining combined with pathological biopsy|Clinical observation (including inspection and palpation), in vivo staining (reagent: toluidine blue) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
9681994|NCT04919668|Sham Comparator|Low budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
9681995|NCT04919668|Active Comparator|High budget; no game|Participants will be asked to shop for 12 list items in the simulated grocery store without game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
9681996|NCT04919668|Active Comparator|Low budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a low budget of $30.
9681997|NCT04919668|Active Comparator|High budget; game|Participants will be asked to shop for 12 list items in the simulated grocery store with game elements (crowns and scoreboards) displayed. They will be given a high budget of $50.
9681998|NCT04919434|Other|Intervention|Women will be asked NOT to use their own personal care product during the intervention. They will only have to use the substitute one given by the research team
9681999|NCT04919577||RSS- Group|Patients without RSS after distal gastrectomy.
9682000|NCT04919577||RSS+ Group|Patients with RSS after distal gastrectomy.
9682001|NCT04919473|Experimental|vMCO-I High dose|Participants received 3.5E11vg/eye of vMCO-I
9682002|NCT04919473|Experimental|vMCO-I Low Dose|Participants received 1.75E11vg/eye of vMCO-I
10176994|NCT03827057|Experimental|Reconsolidation of Traumatic Memories (RTM)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
10176995|NCT03827057|Active Comparator|Prolonged Exposure (PE)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. PE will follow a manual written by the Foa and colleagues, and the therapists will be trained by expert trainers from the Center for Deployment Psychology. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
10176996|NCT03827005|Placebo Comparator|placebo|3 grams cornstarch once per day for one day.
10176997|NCT03827005|Experimental|L-arginine|3 g L-arginine once per day for one day.
10176998|NCT03827083||Spinal anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
10176999|NCT03827083||General anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
9695575|NCT04776785|Experimental|Group 1|"In Group 1, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications, Profluorid® Varnish application will be repeated for test 1 and control lesions."
9695576|NCT04776785|Experimental|Group 2|"In Group 2, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2).~At the 6th and 12th months after the clinical applications; Profluorid® Varnish application will be repeated for test 1 lesions, and MI Varnish™ application will be repeated for test 2 lesions."
9695577|NCT04776785|Active Comparator|Group 3|"In Group 3, one lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications; MI Varnish™ application will be repeated for test 2 lesions, and Profluorid® Varnish application will be repeated for control lesions."
9695578|NCT04776772|Placebo Comparator|Soccer player placebo|Soccer player consuming placebo sticks filled with 300 mg excipient of maltodextrin
10177000|NCT03827044|Experimental|Avelumab|6 months of 2 weekly Avelumab
10177001|NCT03827044|No Intervention|No intervention|After standard adjuvant 5FU based chemotherapy, patients will have no active intervention but will start standard follow up.
10177002|NCT03827356|Experimental|"High intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
10177003|NCT03827356|Active Comparator|"Low intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
10177004|NCT03827200|Experimental|Ambrisentan|Ambrisentan
10177005|NCT03827304|Experimental|Burns dressings patients|Virtual Reality pain distraction games scenarios
10177006|NCT03827278|Experimental|HIV Negative Host talaromyces using Voriconazole|Voriconazole On the first day, 6 mg/kg bid was given, and then 4 mg/kg bid was given intravenously for 6 days, and then oral voriconazole 200 mg bid was administered to maintain treatment for at least 6 months.
10177007|NCT03827278|Experimental|HIV Negative talaromyces AMB Sequential Itraconazole|Amphotericin B (AMB) sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until cluster of differentiation 4 (CD4+ T) cells are greater than 100 cells/L for at least 6 months
10177008|NCT03827031|No Intervention|Control group|
10177009|NCT03827031|Experimental|B1 interventional group|
10177010|NCT03827031|Experimental|B2 interventional group|
10177011|NCT03827317|Other|HER2 positive metastatic breast cancer|8 HER2 positive patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
10177012|NCT03827317|Other|HER2 negative metastatic breast cancer|8 HER2 negative patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
10177013|NCT03827135|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
10177014|NCT03827135|Experimental|Cyriax manipulation|Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle stretching.
10177015|NCT03827161|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
10177016|NCT03827161|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
10177017|NCT03826979|Experimental|Pilates treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
9682003|NCT04919278|Experimental|Intervention group|Participants will be evaluated for any health contraindication. Once reviewed they will received full spine chiropractic treatment for 4 weeks, at the rate of one adjustment per week. After three visits they will complete the outcome measures
10177018|NCT03826693|Experimental|Experimental: Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
10177019|NCT03826693|Placebo Comparator|Control: Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
10177020|NCT03826719|Experimental|NBP607QIV|1 dose of 0.5mL by Intramuscular injection
9682004|NCT04919278|No Intervention|Control group|Paticipants will be selected amongst thse attending predelivery sessions. They receive no chiropracti care. They will complete the outcomes at the same time as the Intervention group and then 4 weeks later.
10177021|NCT03826719|Active Comparator|Agrippal|1 dose of 0.5mL by Intramuscular injection
10177022|NCT03826732|Experimental|Guided self-help based on ACT|Participants follow a self-help program and receive weekly support by trained facilitators
10177023|NCT03826732|No Intervention|Wait-list control|Participants are informed that they will receive the intervention after the 6-month follow-up assessment
10177024|NCT03826940|Experimental|NF1 - experimental|
9682005|NCT04919486|Experimental|Experiment group|non-weight bearing visual feedback intervention under the of Labview software, and used rowing machine equipment for exercise training for 30 minutes,then eselastic band exercise training for 30 minutes.
10177025|NCT03826940|Placebo Comparator|NF1 - control|
9682006|NCT04919486|Active Comparator|elastic band exercise|elastic band exercise under the Physiotherapist, and used elastic band for exercise training for 60 minutes,include muscles flexion the hip joint, muscles extention the hip joint,etc.
9682007|NCT04919317|Placebo Comparator|Control|Control group patients received 29mL bupivacaine plus 1mL 0.9% saline. Like the experimental group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
9682008|NCT04919317|Experimental|Experimental|Experimental group patients received 29mL bupivacaine plus 1mL of 4mg/mL dexamethasone. Like the control group, 20mL of the mixture was injected into the fascial plane between the pectoralis minor and the serratus anterior muscles at the level of the third rib, while the remaining 10mL of the mixture was then injected into the fascial plane between the pectoralis major and pectoralis minor muscles during the same needlestick.
9682009|NCT04919070|Experimental|Connect for Caregivers|Connect for Caregivers is a single session behavioral intervention with three components: 1) psychoeducation on the importance of connectedness for health and well-being; a card sort-based discussion prioritization tool that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; 3) personalized resources to address the identified barriers and targets.
10177026|NCT03826940|Experimental|ASD - experimental|
10177027|NCT03826940|Placebo Comparator|ASD - control|
10177028|NCT03826953|Other|Nurse led allergy clinic|nurse led allergy clinic
10177029|NCT03826758|Other|E-DYNAMIC CDS|E-DYNAMIC clinical decision support (CDS) retrieves near-real time patient data from the electronic health record to help primary care providers identify patients with stage 3-5 CKD, present ASCVD risk, statin use and clinical recommendations for ASCVD risk reduction at point of care. E-DYNAMIC directs referrals to nurses for CKD education and to dietitians for MNT. Providers are also nudged to prescribe statin medications and address hypertension management.
10177030|NCT03826758|No Intervention|Standard care|No change in their clinical practice.
10177031|NCT03826537|Other|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin.
10177032|NCT03826862|Experimental|intervention group|All patients receive CT three-dimensional reconstruction before surgery.
10177033|NCT03826862|No Intervention|control group|All patients did not receive CT three-dimensional before surgery
10177034|NCT03826576|Experimental|Intervention Group|Intervention group will receive a Multicomponent Intervention.
10177035|NCT03826576|No Intervention|Control Group|Control group will not receive any kind of intervention, only it will receive information about AMED criteria and allergens of food.
10177036|NCT03826511|Active Comparator|Tiszasüly mud-pack|Patients in the Tiszasüly mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
10177037|NCT03826511|Active Comparator|Kolop mud-pack|Patients in the Kolop mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
10177038|NCT03826875|Experimental|Treatment|Patients randomized to the fluoxetine treatment group will be initially prescribed fluoxetine 20mg/day for a period of one year.
10177039|NCT03826875|Placebo Comparator|Placebo|Patients randomized to the placebo group will be initially prescribed placebo 20mg/day for a period of one year.
10177040|NCT03826680|Active Comparator|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by an ENT physician by flexible fiberoptic laryngoscopy before the surgery
10177041|NCT03826680|Active Comparator|Direct laryngoscopy|The same patients evaluated by flexible fiberoptic laryngoscopy will be evaluated by an anesthesiologist by direct laryngoscopy during surgery under general anesthesia
9682010|NCT04919005|Experimental|Healthy elderly people|Twelve healthy elderly people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
10177042|NCT03826784|Experimental|BHA|Subjects treated with BHA + standard of care
10177043|NCT03826784|No Intervention|Control|Subjects treated as per standard of care
10177044|NCT03826823|Experimental|infertile women|infertile women undergoing hysterosalpingography for evaluating fallopian tubes
9682011|NCT04919005|Experimental|Elderly people with Alzheimer's in the initial phase|Seven elderly people with Alzheimer's in the initial phase. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
10177045|NCT03826589|Experimental|Avelumab and Axitinib|"Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)~Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)"
10177046|NCT03826810|Experimental|aPDT + ART group|In this group, both aPDT and ART were performed.
9976051|NCT01347671|Active Comparator|25 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
10177047|NCT03826810|Experimental|ART group|In this group, only ART was performed.
10177048|NCT03826706|Active Comparator|C-MAC Videolaryngoscope D blade|Patients was intubated with C-MAC videolaryngoscope D blade.
10177049|NCT03826706|Active Comparator|McGrath MAC Videolaryngoscope X3 blade|Patients was intubated with McGrath MAC Videolaryngoscope X3 blade
10177050|NCT03826836|No Intervention|Control Group|Treatment as usual (i.e. best medical treatment).
10177051|NCT03826836|Experimental|Mindfulness-based stress reduction|Treatment as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based stress reduction programme.
10177052|NCT03826771|Experimental|POWER training|high velocity strength training
10177053|NCT03826771|Active Comparator|Stretching|Upper and lower body range of motion exercises
10177054|NCT03826498|Experimental|CP CB-MNC injection|CP CB-MNC injection from different donors and standard therapy.
10177055|NCT03826498|Other|Standard therapy|Patients with standard therapy as control group
10177056|NCT03826615|Experimental|Gabapentin|Gabapentin premedication group
10177057|NCT03826615|No Intervention|No medication|Control group
10177058|NCT03826641|Experimental|Sequence 1|Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801
10177059|NCT03826641|Experimental|Sequence 2|Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805
10177060|NCT03826641|Experimental|Sequence 3|Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801
10177061|NCT03826641|Experimental|Sequence 4|Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805
10177062|NCT03826602|Experimental|Tucatinib plus metformin|Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8
9682012|NCT04919005|Experimental|Healthy young people|Fifteen healthy young people. Each participant underwent a pre-test, the intervention with a Virtual Environment, and a post-test.
9682013|NCT04919135|Experimental|Treatment (UC-MSC trasnplatation)|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
9682014|NCT04919135|Other|control arm|standard frailty treatment and supplementary medication
9682015|NCT04919109|Placebo Comparator|Placebo comparator|Administered as nose drops
9682016|NCT04919109|Experimental|Experimental: CodaVax-RSV 10^6 PFU|Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops
9695579|NCT04776772|Experimental|Soccer player synbiotic|Soccer players consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
9976052|NCT01347671|Active Comparator|75 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
9976053|NCT01347671|Active Comparator|200 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
9976054|NCT01347671|Placebo Comparator|Matching Placebo|Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
10177063|NCT03826550|Experimental|Diclofenac Sodium Gel3%|Diclofenac Sodium Gel 3%, dosed twice daily for 60 days.
10177064|NCT03826550|Active Comparator|Solaraze|Solaraze Gel dosed twice daily for 60 days.
10177065|NCT03826550|Placebo Comparator|Placebo|Placebo Gel dosed twice daily for 60 days.
10177066|NCT03826654|Experimental|fortified oil|daily intake of fortified sunflower oil (700IU vitamin D/ 35g)
10177067|NCT03826654|Placebo Comparator|control|daily intake of plain oil
10177068|NCT03826485|Experimental|A group|Period 1: PRIC Period 2: Pranlukast hydrate
10177069|NCT03826485|Experimental|B group|Period 1: Pranlukast hydrate Period 2: PRIC
10177070|NCT03826524|Active Comparator|Low Dose Epinephrine|Epinephrine up to 2mg total
10177071|NCT03826524|Active Comparator|Standard Dose Epinephrine|Epinephrine up to 6mg total
10177072|NCT03826927||AF and cerebrovascular event|patients with AF and recent (< 3 month) stroke or transient ischaemic attack (TIA) or intracranial haemorrhage (ICH) with or without pre-existing oral anticoagulation, in whom treatment with NOACs or VKAs is initiated or continued for prevention of ischemic events
10177073|NCT03826446|Other|Open Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did open complete mesocolic excision procedures
10177074|NCT03826446|Other|Laparoscopic Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic complete mesocolic excision procedures
10177075|NCT03826368||TBI Controls|Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
10177076|NCT03826368||TBI HDS|Adult men and women between 18 and 55. History of traumatic brain injury. Experienced taking hemp-derived botanicals.
10177077|NCT03826472|Experimental|Almond Butter|Participants will consume one ounce per day (~32 g) of almond butter as an evening snack (i.e., after dinner and before sleep).
10177078|NCT03826472|No Intervention|No-snack Control|Participants will consume nothing besides water after dinner/bed sleep.
10177079|NCT03826329||Study Cohort|The observational study included all patients who had been admitted for their first ACDF surgery during the 16-year span, began on January 1st, 1998 till the end of 2013, recorded in the NHIRD. The admission for cervical disc herniation and spondylosis were identified using the ICD9-CM diagnostic codes of 722.0, 722.4 and 722.71, while the surgery of ACDF was confirmed with the procedure codes of 80.51, 81.00 and 81.02 during the same hospitalization.
10177080|NCT03826407||DOC patients|Patients in coma (GCS score of 3-8) or with other disorder of consciousness, primarily Minimally Conscious State (MCS) or Unresponsive Wakefulness Syndrome (UWS; also known as vegetative state)
9682017|NCT04919252|Experimental|Vedolizumab|"Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
9682018|NCT04919044|Experimental|Motor Imagery|The participants were instructed to imagine and visualize to straighten both knees with eyes closed. You have to see and feel only what you would see and feel if you had to perform the action to straighten both of your knees in sitting position. Imagine the movement using the most comfortable way for you, and make sure not to contract your muscles.
9682019|NCT04919044|No Intervention|Control|No intervention provided.
10177081|NCT03826407||Healthy Control|Matched healthy controls without current neurological diagnoses
10177082|NCT03826316|Experimental|Mutonpain Injection 10 mg/ml|
9682020|NCT04919200||modeling group|Of these 628 individuals, we set 407 patients enrolled from January 2018 to November 2019 as the modeling group
9682021|NCT04919200||verification cohort|221 patients enrolled from December 2019-December 2020 served as a prospective verification cohort
9682022|NCT04919213||Individuals with Intellectual Disabilities|Individuals will be invited to take part in an online survey (paper version will also be available). The participants will be recruited through advertisements on relevant platforms (e.g., Facebook, Twitter) and through relevant social care organisations. The study hopes to recruit 100 individuals from all over England (UK). A subgroup will be asked if they would like to take part in a one-to-one open-ended interview (n=20) and/or in direct observations (n=30).
9682023|NCT04919213||Family carers|Family carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of family carers (n=7) will be asked if they would like to take part in a focus group.
10177083|NCT03826394|Experimental|Exercise Intervention|Exercise intervention with the aim of incrementally increasing physical activity to meet the national recommendation of 150 minutes a week of moderate-vigorous physical activity, reducing BMI and improving overall health.
9682024|NCT04919213||Paid carers|Paid carers (n=50) of people with intellectual disabilities in England, who use the internet, will be invited to take part in an online survey. A subgroup of paid carers (n=7) will be asked if they would like to take part in a focus group.
9682025|NCT04919213||Professionals with safeguarding responsibilities|Professionals with safeguarding duties (e.g., social workers, learning disability nurses, police and safeguarding adults board members) supporting people with ID in England who use the internet will also be invited to take part in an online survey (n=50). A subgroup (n=7) from London and Kent (England, UK) will be asked if they would like to take part in a focus group.
10177084|NCT03826394|Experimental|Dietary Intervention|Staged dietary intervention with the aim of improving eating behaviours, reducing BMI and improving overall health.
9682026|NCT04919057|Experimental|Robotic perineal radical prostatectomy|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
9682027|NCT04919148|No Intervention|Participants receive control message|Participants only receive standard heat risk warning
9682028|NCT04919148|Experimental|Participants receive intervention message|Participants receive standard heat risk warning plus figures incorporating the health impacts of heat and pro-environment behaviors.
9682029|NCT04919421|Active Comparator|Virtual reality|Participants will wear a virtual reality headset during the dental injection in which a video is playing.
10177085|NCT03826381||Study 1: DM2 + normal kidney function|"Number of patients: 54~Patients in this group are diagnosed with Diabetes type 2. Kidney function: eGFR is > 60, absence of clinical proteinuria.~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions and the same as in the other group.~The patients are examined once."
10177086|NCT03826381||Study 1: DM2 + CKD stage 3-5|"Number of patients: 54~Patients in this group are all diagnosed with diabetes type 2. Furthermore, the patients have chronic kidney disease stage 3-5 (eGFR <60).~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions are the same as in the other group.~The patients are examined once."
10177087|NCT03826355|Active Comparator|Stripping technique|The endometrioma is removed according to standard surgery.
10177088|NCT03826355|Experimental|Laser technique|The endometrioma is drained, everted and then the inner wall of the endometrioma is vaporised with CO2 laser
9682030|NCT04919421|Active Comparator|Topical gel|Participants will receive application of topical anesthetic gel on the site of dental injection.
9682031|NCT04919330|Experimental|ACT Group|One four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP) and routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation.
9682032|NCT04919330|Other|Wait-list Control Group|Routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation
9682033|NCT04919161|Active Comparator|Body weight support system control group|In this arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system.
9682034|NCT04919161|Experimental|Body weight support system with balance perturbations|Similar to the control group arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system, with the inclusion of 8 total balance perturbations each session, including 2 in the posterior, anterior, left lateral, and right lateral directions.
10177089|NCT03826017|Experimental|Catechin high contain greentea extract|Catechin high contain greentea extract for 260 mg/day 12 weeks.
9682035|NCT04919161|No Intervention|Historical Standard of Care control|Retrospective anonymized Berg Balance Score data of stroke inpatients was collected from an institutional report for fiscal year 2018. 2018 was chosen as it preceded the implementation of the ZeroG body weight support system and reflects a no-intervention control baseline. This data was then filtered to show only patients with a Berg score of 21 or greater to match the study's inclusion criteria.
9682036|NCT04919174|Active Comparator|Control group|Patients receive dexmedetomidine for sedation
9682037|NCT04919174|Experimental|Test group|Patients receive remimazolam for sedation
9976055|NCT01347684|Active Comparator|Standard care using current drugs|Standard care with drug intervention
9682039|NCT04918940|Experimental|Post-vaccination immunity|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
9682040|NCT04918849||Community Sample|We plan to recruit a community sample of 1000 from the Indian Population.
9682041|NCT04919291|Active Comparator|Topoguided LASIK|Topoguided ablation profile on dominant eye
9682042|NCT04919291|Active Comparator|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
9682043|NCT04918914|Other|Intervention|
9682044|NCT04918589|Experimental|Tranexamic Acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
9682045|NCT04918589|Placebo Comparator|Normal Saline|40 mL topical of 0.9% normal saline
9682046|NCT04918498|Placebo Comparator|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
9682047|NCT04918498|Experimental|Experimental group|Implement early physiotherapy programs. The early physiotherapy program for VV-ECMO patients mainly includes the establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy.
10177090|NCT03826017|Placebo Comparator|Placebo|Placebo for 12 weeks.
9682048|NCT04918576|Experimental|Tranexamic Acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
9682049|NCT04918576|Placebo Comparator|Normal Saline|40 mL topical of 0.9% normal saline
9682050|NCT04918758|Experimental|Purastat Arm|Purastat 5ml once monthly for 3 months
9682051|NCT04918758|Other|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks
9682052|NCT04918537|Experimental|Intervention walnuts|During the 3 last weeks of the study, the participants will eat a 30g daily walnut serving
10177091|NCT03826290|Experimental|Intervention arm|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated diabetes dashboard).
10177092|NCT03826290|No Intervention|Control arm|When patients are seen in clinics in this arm, the clinical providers will not have access to the intervention (EHR-integrated diabetes dashboard). The providers will have access to the usual decision support tools and information sources.
9682053|NCT04918524||The Antiphospholipid syndrome (APS)|The cohort includes that patients who meet the proposed Sydney criteria.
9682054|NCT04918524||Undifferentiated connective tissue disease (UCTD)|The cohort includes the patients who are diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, aPL, and anti-cyclic citrullinated peptide (CCP) antibody, with or without at least one symptoms or signs suggesting CTD ,while not fulfilling any classification criteria of a defined CTD.
9682055|NCT04918719|Experimental|NAC arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine (NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.~The dosing of NAC will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours."
9682056|NCT04918719|Placebo Comparator|Placebo arm|"Both arms are subjects who present with neurological deficits consistent with stroke without hemorrhage less than 24 hours since symptom onset. Both arms will receive standard of care with the study intervention being considered an add-on therapy. Thirty minutes after enrollment, eligible subjects will be randomized into one of two arms: placebo or N-Acetylcysteine(NAC). Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion.~The placebo will consist of a 5% Dextrose in Water (D5W) instead of NAC (dosage and timings are the same as the NAC arm)."
9682057|NCT04918563|Active Comparator|nitroglycerin|"NO donor (Nitropohl) vs pgysiological saline~1mg/ml nitorhlycerin"
9682058|NCT04918563|Active Comparator|acethylcholine|10 mg/ml acetylcholine vs physiological saline
10177093|NCT03825952|Experimental|Participants using MERM device|Participants will use an electronic medication monitor to measure their adherence to ART in routine clinical care.
9682059|NCT04918745|Other|ABC|"A = Unmodulated~B = Angular modulation~C = Linear modulation"
9682060|NCT04918745|Other|ACB|"A = Unmodulated~C = Linear modulation~B = Angular modulation"
9682061|NCT04918745|Other|BAC|"B = Angular modulation~A = Unmodulated~C = Linear modulation"
9682062|NCT04918745|Other|BCA|"B = Angular modulation~C = Linear modulation~A = Unmodulated"
9682063|NCT04918745|Other|CAB|"C = Linear modulation~A = Unmodulated~B = Angular modulation"
9682064|NCT04918745|Other|CBA|"C = Linear modulation~B = Angular modulation~A = Unmodulated"
9682065|NCT04918680||EcoFit® Total Hip System with implacross® E Polyethylene|Subjects who meet the indications for use for the EcoFit® Total Hip System with implacross® E Polyethylene and are candidates for a primary hip replacement.
9682066|NCT04918615|Experimental|Sirolimus coated balloon catheter|Manufacturer: Shanghai MicroPort Medical Group Co, Ltd.
9682067|NCT04918615|Active Comparator|Paclitaxel coated balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd
9682068|NCT04918641||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral, and imaging measures.
9682069|NCT04918901||Severe COVID-19|Comparative Analysis of Clinical Parameters and Radiographic Changes
9682070|NCT04918862|Active Comparator|Granisetron 1 mg|Granisetron 1 mg: 105 patients received 1mg granisetron
9682071|NCT04918862|Active Comparator|Granisetron 3 mg|Granisetron 3 mg: 105 patients received 3mg granisetron
9682072|NCT04918953|Experimental|group 1|oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days
10177094|NCT03825965|Experimental|Cannabidiol (CBD)|Oral medicinal cannabis (125 mg cannabidiol daily suspended in oil)
9682073|NCT04918953|Experimental|group 2|oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days
9682074|NCT04918953|Experimental|group 3|budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks.
9682075|NCT04918706|Experimental|MSC week 4 and 3 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv
10177095|NCT03825965|Placebo Comparator|Placebo|Visually identical placebo (medium chain triglyceride oil)
10177096|NCT03825926||Gestational Diabetes Mellitus|The diagnosis of GDM is based on a 75-g oral glucose tolerance test (OGTT) performed between 24 and 28 gestational weeks, according to the American diabetes association (ADA) criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Recruited patients were accepted the standard of treatment of GDM according to the American college of obstetricians and gynecologists (ACOG) practice bulletin on gestational diabetes mellitus.
9682076|NCT04918706|Placebo Comparator|Placebo week 4 and 3 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
9682077|NCT04918706|Experimental|MSC week 12 and 11 before LVRS2|Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv
9682078|NCT04918706|Placebo Comparator|Placebo week 12 and 11 before LVRS2|Placebo: consisting of a 5% DMSO-solution in isotonic solution
9682079|NCT04918667|Experimental|Berberine MetX™ Ultra Absorption|16 healthy subjects will receive orally 500 mg of berberine in two capsules of Berberine MetX™ Ultra Absorption.
10177097|NCT03825926||Non-Gestational Diabetes Mellitus|normal group
9682080|NCT04918667|Active Comparator|Berberine MetX™|16 healthy subjects will receive orally 500 mg of berberine in one capsule of Berberine MetX™ (reference product).
9682081|NCT04918784|Experimental|Treatment with Synthetic Hybrid-Scale Fiber Matrix|Diabetic foot ulcers will be treated by application of the Synthetic Hybrid-Scale Fiber Matrix. The synthetic matrix will be applied weekly or as needed based on the clinician discretion and ongoing wound assessment.
9682082|NCT04918784|Active Comparator|Treatment with Standard of Care|Diabetic foot ulcers will be treated by application of an appropriate dressing (foam or alginate dressing) to maintain wound moisture balance in the wound and changed daily.
9682083|NCT04918797|Experimental|Study vaccine|SARS-COV2 vaccine
9682084|NCT04918628|Experimental|Arm A|Neoadjuvant Chemotherapy Combined With CCRT Followed by Adjuvant Chemotherapy and Anti-PD-1 Antibody(Sintilimab 200mg intravenous drip every three weeks until PD or 2 years).
9682085|NCT04918485|Experimental|the experimental group received psychological intervention|
9682086|NCT04918485|No Intervention|the control group receive normal process before surgery|
9682087|NCT04918199||Paris Transplant Group cohort|400 (10%) of the patients were randomly selected from 4,000 consecutive patients over 18 years of age prospectively enrolled at the time of kidney transplantation from a living or deceased donor at Necker Hospital, Saint-Louis Hospital, Foch Hospital, and Toulouse Hospital between January 1, 2005, and January 1, 2014, in France.
9682088|NCT04918355||Provider Group 1: no alert|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
9682089|NCT04918355||Provider Group 2: Mandated alert|Control group where providers will see a generic pop-up alert within the Electronic Health Record (EHR) whenever they initiate an opioid or benzodiazepine prescription without recording use of the PDMP. Patient risk factors are not assessed or presented in the alert. Providers in ambulatory clinics will not be assigned to this group. Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.
9682090|NCT04918355||Provider Group 3: PDMP alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on past/current prescriptions received. Patient risk factors are assessed and presented in the alert. Risk factors included are numbers of active or recent opioid and benzodiazepine prescriptions, overlapping prescriptions, co-prescribing of benzodiazepines and opioids, and use of long-acting opioids in opioid naïve patients.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
9695580|NCT04776772|Placebo Comparator|Sedentary individuals placebo|Sedentary individuals consuming placebo sticks filled with 300 mg excipient of maltodextrin
9695581|NCT04776772|Experimental|Sedentary individuals synbiotic|Sedentary individuals consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic
9696473|NCT04766567|Experimental|Endometrial myomectomy|Patients with singleton pregnancy, who had endometrial myomectomy during cesarean section
10177098|NCT03825887|Active Comparator|Group A-PCA Morphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
10187302|NCT03727464|Active Comparator|Sevoflurane Controls|Patients undergoing sevoflurane general anesthesia without any intraoperative priming
9682091|NCT04918355||Provider Group 4: PDMP + EHR alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on both prescriptions and other factors recorded in the patient's Electronic Health Record. Patient risk factors are assessed and presented in the alert. Risk factors included the risks described as in Group 3, along with a history of accidental opioid overdose, diagnosis of Opioid Use Disorder, multiple recent acute care incidents with opioid use, or high risk psychiatric diagnoses.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
9682092|NCT04918394||Asthma patients unexposed to mold / moisture|No mold / moisture exposure is defined by a negative response to all of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
9682093|NCT04918394||Asthma patients exposed to mold / moisture|Mold / moisture exposure is defined by a positive response to at least one of the 5 following questions, asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home.
9682094|NCT04918433|Active Comparator|TRANSEVERSUS THORACIS MUSCLE PLANE BLOCK (TTPB)|After induction of anaesthesia, ultrasound guided transverses thoracis muscle plane block will be done using 0.25% bupivacaine
9682095|NCT04918433|Active Comparator|PECTO-INTERCOSTAL FACIAL PLANE BLOCK (PIFB)|After induction of anaesthesia, ultrasound guided pectointercostal facial plane block will be done using 0.25% bupivacaine
9976056|NCT01347684|Experimental|Behavioral therapy, splint therapy and physical therapy|Using rehabilitation for comparing use of drug
9976057|NCT01347697|Experimental|Porcine collagen implant (biological mesh)|Reconstruction with an acellular porcine dermal collagen implant (biological mesh).
9682098|NCT04918238|Active Comparator|conventional treatment Arm|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
9682099|NCT04918238|Experimental|muscle energy technique arm|Group A received muscle energy technique with lateral recumbent positioning along with Conventional Physiotherapy Program
9682100|NCT04918446|Experimental|T-POSE|Technology based brief educational intervention for hospitalized patients that will be discharged with an opioid prescription.
9682101|NCT04918446|Other|Usual Care|Standard discharge instructions provided.
9682102|NCT04918251||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
9682103|NCT04918251||Amyotrophic lateral sclerosis patients|
10177099|NCT03825887|Experimental|Group B-PCA Nalbuphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
10177100|NCT03826251||systematic nasogastric tube|NGT was left systematically after surgery and removed after the first flattus
10177101|NCT03826251||Non systematic nasogastric tube|Nasogastric tube was removed immediately after surgery and was replaced in case of vomiting
10177102|NCT03826121|Experimental|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks
10177103|NCT03826121|Placebo Comparator|Placebo|placebo for 12 weeks
10177104|NCT03826147|Active Comparator|Nitrate-rich beetroot juice|Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
10177105|NCT03826147|Placebo Comparator|Nitrate-depleted beetroot juice|Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
10177106|NCT03826238||ARBD and depression|10 patients with ARBD and at least moderate depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale ≥ 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
10177107|NCT03826238||ARBD and no depression|10 patients with ARBD and no clinically relevant depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale < 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
10177108|NCT03826238||Healthy|10 healthy controls (no ARDB, no depression, no cognitive deficit). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
10187303|NCT03727412|Active Comparator|Naproxen Group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)
10187304|NCT03727412|Placebo Comparator|Control group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo
9682104|NCT04918251||Multiple sclerosis patients|
9682105|NCT04918251||Frontotemporal dementia patients|
9682106|NCT04918368||Pregnant women between 18-45 years old, being in second and third trimester of a singleton pregnancy|
9682107|NCT04918303|Experimental|SKNA group|
9682108|NCT04918264||Uracil concentration <16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage <16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot [Lyon], Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon].
9682109|NCT04918264||Uracil concentration ≥16 ng/mL|Patients were included in this arm if they have digestive cancer and an uracil dosage <16 ng/mL performed between February 2018 to January 2020, and if they received at least one cycle of fluoropyrimidine-based chemotherapy in one of the four oncology departments (Hopital Edouard Heriot [Lyon], Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon].
9976058|NCT01347697|Active Comparator|Gluteus maximus flap|Reconstruction with a gluteus maximus myocutaneous flap.
10177109|NCT03826069|Active Comparator|Conventional Simulation Curriculum|Four, one-hour small-group sessions on the theory of colonoscopy including pathology, anatomy, and therapeutic technique. Following each session, a multiple choice test on topics covered will be administered. In addition, this group will be given a total of six hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (5 hours). During the high-fidelity simulation, endoscopic procedures will be performed with instructor support. The difficulty of the therapeutic intervention (polypectomy) will rise after each successfully completed module. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
10177110|NCT03826069|Experimental|Augmented Reality Group|This group will receive the same 4 hours of small group teaching and 6-hours of hands-on simulator training. The intervention is the augmented reality-based curriculum: (1) a brief explanation of the principles of AR and how it will be used during the VR simulations and (2) performance of the therapeutic procedure (polypectomy) as demonstrated by the real-time AR platform. Specific videos corresponding to the therapeutic intervention and pathology (e.g pedunculated vs non-pedunculated polyp) will be available every time a polypectomy is required. Each new module will come with increased technical challenges and will require adjustment to previously used technique by the learner. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
9682110|NCT04918420|Experimental|Group A|Flow diverter(Ton-bridgeMT, China)
9682111|NCT04918381|Experimental|CellFX Procedure|Treatment of the BCC with CellFX System
10177111|NCT03825913|Active Comparator|Exercise Intervention|"Subjects in the exercise group will participate in a 3-month exercise program at the University of Miami UHealth Fitness and Wellness Center. Participants will complete two exercise sessions a week, each 45-60 minutes long and on a one-on-one basis.~In addition to two site visits, the participants will receive a tailored daily home-based walking plan. The participants will use physical activity trackers (Fitbit®), with an ultimate goal of achieving 10,000 steps by the end of the intervention.~Participants in the exercise intervention will complete 24 sessions."
10177112|NCT03825913|Sham Comparator|Wellness Intervention|For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
10177113|NCT03825900|Active Comparator|Active tDCS|Active transcranial direct current stimulation
10177114|NCT03825900|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
10177115|NCT03826134|Experimental|[11C]-PXT012253|
9682112|NCT04918095||Moderate-Severe COPD|COPD patients diagnosed GOLD 2- 3, C- D for moderate-severe, poorly controlled
9682113|NCT04918121|Experimental|Yutiq|A sustained-release steroid insert (Yutiq) will be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery.
9682114|NCT04918121|No Intervention|Control|Non-study eye will not receive the Yutiq insert
9682115|NCT04918056||beta thalassemia patients|
9682116|NCT04918043||HUCS, NKL|Newborns and their mothers at the Helsinki University Central Hospital maternity ward.
9682117|NCT04918030|Active Comparator|In-hospital staged PCI|Patients randomized to in-hospital staged PCI will have treated during the index procedure (7±3 days), after revascularization of the culprit lesion, all significant non-culprit coronary lesions.
9682118|NCT04918030|Experimental|Out-hospital staged PCI|Patients randomized to out-hospital staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized in 30±15 days for complete revascularization of all significant non-culprit coronary lesions.
9682119|NCT04917965||Healthy Term Neonates|Infants born at 37 weeks gestational age or greater born to mothers of any age with uncomplicated pregnancies. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
10177116|NCT03826160||Tesamorelin|Individuals who plan to initiate tesamorelin clinically
10177117|NCT03826160||No Treatment|Individuals who decline to initiate tesamorelin despite a clinical indication
10177118|NCT03826277|Experimental|Melanostop peel treatment group|"Adult women aged between 20-50 years old.~Melasma on the face~Fitzpatrick phototypes I-IV~Presenting facial melasma~In good health condition"
10177119|NCT03826004|Placebo Comparator|Placebo|Saline solution 2ml before anesthetic induction
10177120|NCT03826004|Experimental|Clemastine|Clemastine fumarate 2mg/2ml before anesthetic induction
10177121|NCT03825978|Active Comparator|Intervention|An individual and comprehensive prenatal genetic counseling was given to all pregnant women in the intervention group, including all screening tests and diagnostic tests for prenatal diagnosis and screening tests at the first antenatal visit.
10177122|NCT03825978|No Intervention|Control|There was no intervention from the first antenatal visit in the control group. Routine clinical information was given about prenatal screening and diagnostic tests.
9682120|NCT04917965||Term infants of diabetic mothers|Infants born at 37 weeks gestational age or greater to mothers of any age with gestational diabetes or Type 1 or Type 2 diabetes, managed with either diet or insulin. Following delivery, cord blood obtained from the placental portion of the umbilical cord will be used for analysis. To assure appropriate dilution, a hematocrit will be measured at the time of blood collection using a blood gas machine for prompt results. Sample blood will immediately be taken by the investigators from the delivery hospital to the children's hospital where the following clotting studies will be performed: PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s. Specimens will be transported utilizing Specimen Transport Guidelines.
10177123|NCT03825848|Experimental|Left Portal Vein Branch|Shunt left portal vein branch during the trans jugular intrahepatic portal systemic shunt
10177124|NCT03825848|Experimental|Right Portal Vein Branch|Shunt right portal vein branch during the trans jugular intrahepatic portal systemic shunt
10177125|NCT03825861|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
10187305|NCT03727386|Experimental|Coconut oil|A dietary intervention that relies on the administration of 30 ml of extra virgin coconut oil per day for six months will be utilized in this study. Coconut oil administered will replace the cooking/vegetable oil usually used by the participants. .
10187306|NCT03727386|Placebo Comparator|Sunflower oil|A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
10187307|NCT03727360|Experimental|Exercise Training|Group exercise and treadmill walking
10187308|NCT03727360|Active Comparator|Flexibility Control|Group exercise and flexibility exercise
10187309|NCT03727321|Placebo Comparator|Placebo|Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
10187310|NCT03727321|Experimental|Fecal Microbial Transplant and cellulose|"Fecal Microbial Transplant - Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.~Cellulose x 6weeks"
10187311|NCT03727321|Experimental|Fiber|Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
9682121|NCT04917653||Atrial fibrillation|"Patients with recent-onset atrial fibrillation treated by cardioversion intervention.~Intervention:~Device: Heart rhythm monitoring with portable device. Biomarkers: Biomarker kinetics based on blood samples."
9682122|NCT04917731|Experimental|Botox|
9682123|NCT04917731|Placebo Comparator|Placebo|
9682124|NCT04917679|Experimental|Combination group|Eltrombopag plus diacerein
9682125|NCT04917679|Placebo Comparator|Monotherapy group|Eltrombopag monotherapy
9682126|NCT04917822|Experimental|Emotion regulation arm|The emotion regulation arm aims at improving emotional regulation skills among parents and children.
9682127|NCT04917822|Active Comparator|Information provision arm|The information provision arm aims at providing information about Hong Kong, such as education, community resources, medical care, employment, housing, and job-seeking among parents and children.
9682128|NCT04917718|Experimental|Extended Release Tacrolimus|All participants who consent to the study will be in this group.
9682129|NCT04917952|Experimental|BFR group|The intervention group will receive resisted knee extension 30% of 1RM with blood flow restriction.
10187312|NCT03727321|Experimental|Fecal Microbial Transplant and Fiber|"Fecal Microbial Transplant~Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS)."
10187313|NCT03727308||Women recruited from pharmacies|"Investigators will enroll women seeking medical abortion pills without prescription from pharmacies.~- Medical abortion pills sourced from pharmacies"
10187314|NCT03727308||Women recruited from health clinics|"Investigators will enroll women seeking medical abortion pills from clinics.~- Medical abortion pills sourced from health clinics"
10187315|NCT03727295|Experimental|The control group 1|60 cases, idebenone 180mg/d, 3 times / day, oral
9682130|NCT04917952|Placebo Comparator|Sham BFR group|The control group will receive resisted knee extension 30% of 1RM with sham blood flow restriction.
9682131|NCT04917692|Experimental|empagliflozin|empagliflozin 2.5 mg daily
9682132|NCT04917926|Experimental|Financial and social intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, social incentives and weekly feedback on performance for 6 months.
9682133|NCT04917926|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
9682134|NCT04917926|Experimental|Financial intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, and weekly feedback on performance for 6 months.
9682135|NCT04917835|Experimental|treatment with argon- and nitrogen-NTAPP|PLADUO (argon- and nitrogen- non-thermal, atmospheric-pressure plasma) treatment
9682136|NCT04917627|Active Comparator|vancomycin group (intervention arm)|We will use one vial of vancomycin that contains 1000 mg of the drug in powder form on the surgical site before closing the wound
9682137|NCT04917627|No Intervention|control group|no vancomycin powder will be used
9682138|NCT04917744||Ancillary-correlative (blood collection, chart review)|Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.
9682139|NCT04917640||SBRT|Patients treated with Stereotactic Body Radiation Therapy (SBRT)
9682140|NCT04917640||IMRT|Patients treated with Intensity Modulated Radiation Therapy (IMRT)
9682141|NCT04917770|Experimental|Sintilimab in combination with Multimodality Radiotherapy group|The dose of sintilimab was 200mg per dose, intravenously, once every 3 weeks. Multimodal radiotherapy methods: ①SBRT: ≥1 independent lesion was selected, with a single dose of 8-10Gy and a total dose of 40-60Gy, divided into 5-6 times of radiotherapy. The final frequency and total dose of radiotherapy were determined by the radiologist.② Low-dose radiotherapy: ≥1 independent lesion was selected, and the single dose, the final frequency of radiotherapy and the total dose were determined by the radiologist.
9682142|NCT04917939||epilepsy with HS|
10187316|NCT03727295|Experimental|The control group 2|60 cases, idebenone 360mg/d, 3 times / day, oral
10187317|NCT03727295|Placebo Comparator|The placebo group|60 cases, placebo, 3 times / day, oral
10187318|NCT03727282|Other|Liberal strategy|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician
10187319|NCT03727282|Experimental|ejection volume index|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index
9682143|NCT04917939||epilepsy without HS|
9682144|NCT04917601|Experimental|Evira Care treatment|"The intervention arm will receive Evira Care in combination with Standard Lifestyle Care. If the standard treatment, after the first month of treatment, contains more frequent visits than every third month, the number of standard visits shall be reduced to a maximum of one visit every third month. During the first 2-4 weeks, participants will receive information about the system and how to utilize the daily weighings and communication system. The families will be informed about possible lifestyle changes that may be effective and that they are supposed to do lifestyle changes primarily regarding energy intake that they do consider feasible in their specific living situations.~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
9682145|NCT04917601|Active Comparator|Standard Lifestyle Care|"The control group will receive the standard care of treatment for childhood obesity, which addresses lifestyles without any restriction in visits or clinical support.~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
9682146|NCT04917900|Experimental|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
9682147|NCT04917991|Experimental|Extra Virgin Olive Oil Group|Subjects will consume 100 grams of Extra Virgin Olive Oil-enriched chocolate spread for 14 days.
9682148|NCT04917991|Active Comparator|Palm oil Group|Subjects will consume 100 grams of palm oil enriched chocolate spread for 14 days.
9682149|NCT04917978||beta thalassemia patients|
9682150|NCT04918004|Experimental|Case group|Patients in the case group were given one-to-one sleep hygiene training by researchers and, a brochure containing 10 lifestyle changes related to sleep hygiene as well as they assessed at the first interview and the last interview, received routine health care, and
9682151|NCT04918004|No Intervention|Control group|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
9682152|NCT04917666|Experimental|Treatment|Participants joined a 8-session horticultural therapy group program (60 minutes per session) over 8 weeks.
9682153|NCT04917666|Other|Comparison|Participants joined 4 sessions of individual, parallel, and table-top activities of their own interest, e.g. reading, drawing, coloring.
9682154|NCT04917497||Levosimendan Treated Group|All patients consecutively admitted to the medical ICU of the University Hospital Zurich aged over 18 years, with an underlying cardiogenic shock, receiving Levosimendan.
9682155|NCT04917458|Experimental|Cholecalciferol|-Vitamin D 25 (OH) 4000 IU capsules, tablet @ 1000 IU One capsule for once a day for 30 days of study period.
9682156|NCT04917458|Placebo Comparator|Control Group|Placebo will be administrated orally, One capsule once a day for 30 days of study period
9682157|NCT04917198|Experimental|median sternotomy|median sternotomy in penetrating cardiac trauma and hemodynamically unstable patients, does it affect morbidity and mortality.
9682158|NCT04917276||Training Group|The training cohort that used to built the response prediction model
9682159|NCT04917276||Validation Group|The validation cohort that used to validate the response prediction model
9682160|NCT04917484|Active Comparator|Standard|Patients in this arm receive our standard treatment. Four treatment with standard dose of 7.4 GBq Lu-177-DOTATOC
9682161|NCT04917484|Experimental|Dosimetry|Patients in this treatment arm receive individualized calcuted treatment depending on kidney function and kidney dose. The treatment activity can differ from one treatment to the next.
9695582|NCT04776551|Other|group (1)|group (1) who are complaining of acute scaphoid fractures,we will do percutaneous trans trapezial fixation of scaphoid by Herbert screw.Short arm circular cast including the thumb will be applied. After 3 weeks, cast will be removed and exercises will start.
10177126|NCT03826420|Experimental|Secure Confinement Group|Parolees assigned to this group will be assigned sanctions that include secure confinement.
10177127|NCT03826420|Experimental|Work Release Group|Parolees assigned to this group will be assigned sanctions that include work-release.
10177128|NCT03826420|Experimental|GPS Supervision Group|Parolees assigned to this group will be assigned sanctions that include GPS supervision.
10177129|NCT03826420|No Intervention|Control Group|
10177130|NCT03825744|Experimental|Hetrombopag Olamine+Standard Therapy|
10177131|NCT03825744|Placebo Comparator|Placebo+Standard Therapy|
10177132|NCT03826173|Experimental|Positive Psychology|On a weekly basis, participants will engage in group-based intervention sessions that focus on personal strengths and the value of positive emotions and cognitions. Participants will receive daily text-messages addressing the content introduced during group sessions.
10177133|NCT03826173|Active Comparator|Physical Activity Promotion|On a weekly basis, participants will engage in group-based intervention sessions that focus on the standard physical activity promotion components of the PPPA condition. Participants will receive daily text-messages addressing the content introduced during group sessions.
10177134|NCT03826212|Experimental|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
10177135|NCT03826212|Placebo Comparator|Placebo|Placebo 1,600 mg/day for 12 weeks.
10177136|NCT03825809|Experimental|Post-Operative Non Opioid Pain Protocol|"Patients will be administered a post-operative non-opioid pain protocol consisting of:~Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam"
10177137|NCT03825809|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
10187320|NCT03727269|Experimental|Wii Fit Training Experimental Group|receiving Wii fit based abdomino-pelvic training
10187321|NCT03727269|Active Comparator|Conventional Training Control Group|receiving conventional pelvic floor exercises.
10187322|NCT03727256|Active Comparator|Group 1 patients|Patients have grade 2 or 3 knee osteoarthritis ultrasound therapy
10177138|NCT03825627|Active Comparator|Antisaccade Task (active tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
10177139|NCT03825627|Sham Comparator|Antisaccade Task (sham tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm sham Transcranial Direct Current Stimulation will be used during the task.
10177140|NCT03825627|Active Comparator|Approach Avoidance Task (active tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
9682162|NCT04917406|Experimental|Use of iontophoresis|Lidocaine (local anesthetic) associated with dexamethasone (corticosteroid) will be administered by iontophoresis technique. Dose per session and iontophoresis: 10 minutes with an intensity of 4 mA.
9682163|NCT04917406|Active Comparator|Use of ultrasound|The treatment for the control group will be applied with a frequency of 3 times a week as usually performed in the ACP of the University of Seville. The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and 1MZ head.
9682164|NCT04917393|Experimental|Multi-organ denervation|Multi-organ (Hepatic and Renal) denervation with the Integrated Radio Frequency (iRF) Denervation System
9682165|NCT04917523|Experimental|Aged 3-6 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
9682166|NCT04917523|Experimental|Aged 7-12 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
9682167|NCT04917523|Experimental|Aged 13-17 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
9682168|NCT04917523|Active Comparator|Aged ≥18 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
9682169|NCT04917445|Experimental|SPIKES Protocol Compassionate Call|Nurses trained to contact IVF patients with negative pregnancy test results who were trained on the SPIKES-focused bad news delivery script.
9682170|NCT04917445|No Intervention|Control: Standard of Care Call|Nurses who will continue to deliver bad news as they have been in the past without a script.
9682171|NCT04917432|Active Comparator|IVUS guided CTO revascularization|To assess the effects of IVUS usage in CTO revascularization compared to conventional non-IVUS guided CTO-PCI as regard technical success and procedural success, MACE within 6 months.
9682172|NCT04917432|Active Comparator|Non-IVUS guided CTO revascularization|To compare this conventional non-IVUS guided CTO-PCI arm with the other IVUS guided arm as regard technical success and procedural success, MACE within 6 months.
9682173|NCT04917289|Experimental|Treatment Arm|Patients in this arm will receive treatment or change current adjuvant therapy immediately after detecting CTC.
9682174|NCT04917289|No Intervention|Control Arm|Patients in this arm will keep follow-up after detecting CTC until radiology evidence of recurrence appear.
9682175|NCT04917536|Active Comparator|rotator cuff approach|the nail is inserted through the supra-spinatus tendon, which is closed at the end of the surgery
9682176|NCT04917536|Experimental|rotator cuff split approach|the nail is inserted through the rotator cuff split, between the supra-spinatus tendon and the long part of the biceps
9682177|NCT04917510|Active Comparator|Control|Will not receive erector spinae block. Will be administered 30 mL of 0.5% Marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
9682178|NCT04917510|Experimental|Study|Will receive an erector spinae block prior to surgery using 30-45 mL of 0.25 bupivacaine w/ epinephrine and 5 mL of dexmedetomidine. Will be administered 30 mL of 0.5% marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
9682179|NCT04917380||Gram-negative bacteria group|Gram-negative bacteria intracranial infection after neurosurgery
9682180|NCT04917380||Gram-positive bacteria group|Gram-positive bacteria intracranial infection after neurosurgery
9682181|NCT04917211|Experimental|virtual reality mask|During the prior anesthesia consultation, the patient is informed of the possibility within the framework of the study of benefiting from analgesia with disconnection by a virtual reality mask, associated with local anesthesia. The patient will be explained that in the event of pain despite the virtual reality mask and local anesthesia, administration of remifentanil will be possible
9682182|NCT04917263||Retrospective|
9682183|NCT04917263||Prospective|
9682184|NCT04917354||hepatic lesion|
9682185|NCT04917575|Experimental|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing, risk assessment tool, and HIV and pre-exposure prophylaxis (PrEP) locators embedded within the game.
9682186|NCT04917575|Active Comparator|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
9682187|NCT04917172||Pancreaticoduodenectomy patients|Patients scheduled to receive elective Pancreaticoduodenectomy (PD) (according to Kausch-Whipple or Longmire-Traverso) for all kinds of pancreatic disease (benign, malignant or premalignant) will be enrolled, after having signed a proper informed consent. Each patient will undergo PD once checked the presence of a resectable mass as provided by the normal clinical practice through high-quality cross-sectional imaging. Pre-operative management will follow institutional standards, serum pancreatic amylase and lipase activity will be measured as a part of the standard pre-operative evaluation.
9682188|NCT04917159|Experimental|ACT Group|The ACT intervention was structured to take place over one month on a weekly basis. Each roughly 2-hour session will consist of a group-based ACT (1.5 hours) and a brief health education talk on CHF self-management (0.5 hours), the contents of which are the same as that offered to the control group. Each training session will serve about 7-8 dyads. In addition, each participant will receive one set of session handouts on CHF education, ACT skills, and a homework assignment at the beginning of each session.
9682189|NCT04917159|Placebo Comparator|HE group|The participants of the control group will receive four weekly 2-hour sessions of structured health education on CHF self-management over four consecutive weeks, delivered by a registered nurse working in the study hospital. Each session will include a brief health education talk (0.5 hours), a section in which participants share their experiences (0.5 hours), a discussion of the main topics (0.5 hours), and a Q&A section (0.5 hours) to evaluate the participant's understanding of the key concepts. Each session will be offered to 7-8 patient-caregiver dyads. In addition, each participant will receive session handouts on the main topic related to CHF self-management at the beginning of each session and will be invited to review them as homework assignments.
10177141|NCT03825627|Sham Comparator|Approach Avoidance Task (sham tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm sham Transcranial Direct Current Stimulation will be used during the task.
9682190|NCT04917913|Experimental|Intervention|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
9682191|NCT04917913|Placebo Comparator|Placebo|Subjects will be administered 3 daily doses (one per meal) of digestive enzymes (50mg), in a capsule, for 30 days
9682192|NCT04917094|Experimental|Below the knee compression stocking|
9682193|NCT04917341||preoperative endometrial sampling result (secondary hospital)/1|Endometrial biopsy samples taken at the stage 2 state hospital
10177142|NCT03826342|Experimental|Health Check-up for Expectant Moms|Theory-driven and derived from empirical support
10177143|NCT03826342|Active Comparator|Time, attention, and information-matched control|Well-validated
10177144|NCT03826108||Cases|Patient who underwent a primary hip (total or partial) or knee arthroplasty and developed a PJI that was culture-confirmed for SA during the first year after the procedure.
10177145|NCT03826108||Controls|Patient who underwent a primary hip or knee arthroplasty and did not develop any type of PJI during the first year after the procedure.
10177146|NCT03825601|Other|Patients with multiple sclerosis|The multiple sclerosis group (n=30) will be subdivided in two subgroups: 15 patients with a relapsing remmitting MS (RRMS), and 15 patients with a primary progressive MS (PPMS).
10177147|NCT03825601|Other|healthy subjects|15 healthy subjects will be included. Among them 7 to 8 subjects will be matched for age and gender with the RRMS subgroup, and 7 to 8 will be matched for age and gender with the PPMS subgroup.
10177148|NCT03825731|Experimental|GC022|The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.
10177149|NCT03825562|Experimental|research group|Research group is attending the ACT intervention first and from before and afte measurement are compared to the control group
10177150|NCT03825562|Active Comparator|control group|Control group is offered to attend the intervention afterwards
9682194|NCT04917341||preoperative endometrial sampling result (tertiary hospital)/2|Endometrial biopsy samples taken at the stage (tertiary hospital)
9682195|NCT04917341||final postoperative pathology/3|final postoperative pathology results with grade (endometrium cancer)
10177151|NCT03825471|Experimental|electrotherapy|Patients undergoing CES and general anesthesia in colon cancer surgery
9682196|NCT04917055|Active Comparator|Active Treatment|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus distal iPACK (between femoral condyles) single shot with long acting local anesthetic (ropivacaine) plus dexamethasone
9682197|NCT04917055|Placebo Comparator|Placebo|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus iPACK single shot with normal saline
9682198|NCT04917185|Experimental|Electro-Acupuncture group|The patients in this group will be treated with electro-acupuncture for 30 minutes twice a week in a month. We conduct Nei Guan (PC6), Shen Men (HT7), ZuSanli (ST36), SanYinjiao (SP6) as the major points. Each time treating, according to other symptoms, we will give no more than 2 additional points.
9682199|NCT04917185|No Intervention|Wait-list group|We give no intervention to the patients this group during the whole experiment. When finishing, the same ways of treatment will be given to these patients.
9682200|NCT04917016||Study group|Women undergoing hysteroscopy for removal of RPOC
9682201|NCT04917250|Experimental|treatment arm|Treated with gemcitabine, pegaspargase, etoposide and dexamethasone
9682202|NCT04916912||CABG-1|A group of non-obese patients (BMI less than 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
10177152|NCT03825471|Placebo Comparator|Opioid Anesthetics|Patients undergoing general anesthesia in colon cancer surgery
10177153|NCT03825705|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
10187323|NCT03727256|Active Comparator|Group 2 patients|Patients have grade 2 or 3 knee osteoarthritis neuromuscular electrical stimulation application
10177154|NCT03825614|Experimental|training gruop|The plates exercise program is concerned with the following main principles: efficient breathing, mental concentration, relaxation, correct spine elongation and posture, correct abdominal muscle control over spine stability and mobility, correct function of each upper and lower limb, precision, lowing integrated movement, and achieving muscle strength and stamina.
10177155|NCT03825614|Active Comparator|training group|Therapeutic exercise program was designed according to the American Collage of Sports Medicine's recommendations for healthy people. The exercise program was conducted using low- to moderate-intensity therapeutic exercises. These therapeutic exercises included a short educational talk that provided information on proper body mechanics, the benefits of exercise, realistic goal-setting, and overcoming common barriers (such as fear) when developing an exercise routine.
10177156|NCT03825614|No Intervention|Control group|Participants in the control group have no exercise in this study.
10177157|NCT03825770|Experimental|"The PEP Program"|"The PEP (Personal Energy Planning) Program"
10177158|NCT03825770|Active Comparator|General Education|General Education about Kidney Disease
10177159|NCT03825549|No Intervention|Control|No intervention
10177160|NCT03825549|Experimental|Individual Audit|Clinicians will receive individual audit feedback informing them of their performance.
10177161|NCT03825549|Experimental|Peer Comparison|Clinicians will receive peer comparison feedback informing them of how their performance compares to their peers.
10177162|NCT03825549|Experimental|Individual Audit and Peer Comparison|Clinicians will receive individual audit feedback informing them of their performance and peer comparison feedback informing them of how their performance compares to their peers.
10177163|NCT03825757|Experimental|Primaspan tablet 250 mg|Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
10177164|NCT03825757|Placebo Comparator|Placebo tablet|Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
10177165|NCT03825497|Experimental|Intervention|1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
10177166|NCT03825497|No Intervention|Usual care|All patients admitted to the control wards will receive usual care during and after hospitalization.
10177167|NCT03825666|Experimental|Active|Intervention with drink pre surgery and chewing gum post surgery. No subgroups, combined intervention will be assessed. ProvideXtra® Fresenius Kabi plus standard consumer xylitol chewing gum.
10177168|NCT03825666|No Intervention|Control|control group following standard guidelines
10177169|NCT03825380|Experimental|T4032|
10177170|NCT03825380|Active Comparator|Lumigan®|
10177171|NCT03825185|Experimental|Transcervical Thymectomy|50 patients were randomized to transcervical thymectomy for treatment of myasthenia gravis.
10177172|NCT03825185|Experimental|TranssternalThymectomy|50 patients were randomized to transternal thymectomy for treatment of myasthenia gravis.
10177173|NCT03825263|No Intervention|Control|Participants receive normal treatment
10177174|NCT03825263|Experimental|Intervention|Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment
10177175|NCT03825250|No Intervention|Group A: Control|Standard of care
10177176|NCT03825250|Experimental|Group B: Sodium Valproate Treatment|15 mg/kg for 1-2 weeks
10177177|NCT03825250|Experimental|Group C: Sodium Valproate Treatment|15 mg/kg for 4-6 weeks
10177178|NCT03825250|Experimental|Group D: Sodium Valproate Treatment|25 mg/kg for 4-6 weeks
10177179|NCT03825211|Experimental|Continuous suture|All parts of the perineal lesion (vaginal mucosa , perineal muscle and skin) be sutured with the same suture thread. A single suture for perineal lesion
9682203|NCT04916912||CABG-2|A group of obese patients (BMI over 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
10177180|NCT03825211|Active Comparator|Discontinuous suture|Interrupted suture technique: vaginal mucosa, perineal muscle and skin are sutured with separate and different threads, that is, the vaginal mucosa is sutured with a thread, then independently the perineal muscle is sutured with another type of thread and finally the skin is also sutured independently with another different thread. Three independent sutures for each of the parts that form a single perineal lesion
10177181|NCT03825159|Experimental|ES group|Using spinal orthosis with an integrated system of electric surface stimulation and heat sensing.
10177182|NCT03825159|Active Comparator|brace group|Using spinal orthosis BRACE
10177183|NCT03825445|Experimental|GnRHa trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial; Ferring Pharm Co, Switzerland) for ovulation trigger.
10177184|NCT03825445|Experimental|hCG trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive hCG (Pregnyl 5000IU; Organon Pharm Co, Nertheland) for ovulation trigger.
9695583|NCT04776512|Experimental|Epidural Analgesia|Patients of this group Will receive an epidural analgesia through a lumbar epidural catheter
10177185|NCT03825237||With sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
10177186|NCT03825237||Without sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
10177187|NCT03825198|Active Comparator|ESB group|"Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.~Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea."
10177188|NCT03825198|Sham Comparator|SHAM group|Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
10177189|NCT03825367|Other|Open label design|Nivolumab and 5-azacytidine,
10177190|NCT03825640|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
10177191|NCT03825146|Experimental|Treatment Arm (AMPC)|AMPC will be intravenously infused.
10177192|NCT03825276|Experimental|Mango consumption|
10177193|NCT03825328|Experimental|Chemotherapy|Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles
10177194|NCT03824821||IBS|
10177195|NCT03824951|Experimental|Anti-CD19 iCAR NK Cells|
10177196|NCT03825133|Experimental|Bone Marrow Aspirate Concentrate|Patients treated with single injection of BMAC in the knee
10177197|NCT03825133|Experimental|Leukocyte Rich Platelet Rich Plasma|Patients treated with single injection of LR-PRP in the knee
10177198|NCT03825133|Experimental|Hyaluronic Acid|Patients treated with 3 single injection of high molecular HA in the knee ( one injection weekly)
10177199|NCT03824769|Active Comparator|Behavioral Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
10177200|NCT03824769|Experimental|Behavioral Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
10177201|NCT03824847|Active Comparator|Intervention group|Intervention group: clarithromycin 1 tablet (250mg) twice daily for three days
10177202|NCT03824847|Placebo Comparator|Placebo group|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days.
10177203|NCT03824899|Experimental|CRT group|Patients With Advanced Rectal Cancer receiving CPT-11-based CRT and blood concentration check
9695584|NCT04776512|Experimental|ESP Block|Bilateral ESP block performed at the level of the 3 rd Lumbar transverse process.
10177204|NCT03824743||Lactate Ringer|Patients managed with Ringer Lactate
10177205|NCT03824743||Plasma-Lyte|Patients managed with Plasma-Lyte
10177206|NCT03824925|Placebo Comparator|Placebo oral zinc capsules|Group A: It was the control group. Participants were advised to start taking placebo capsule of Zinc in a look alike preparation on their first day of chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended
10177207|NCT03824925|Experimental|Zinc Sulfate 220 MG|Group B: Cap zinc 220 mg (equivalent to 50 mg of elemental zinc) on 1st day of their chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended.
10177208|NCT03824730||Endovascular occlusions group|Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed
10177209|NCT03824886|Experimental|Implementation of skin care algorithm|In the interventional nursing homes, a structured skin care prevention package based on a newly developed evidence-based skin care algorithm will be implemented at the nursing homes and delivered by nurses.
10177210|NCT03824886|No Intervention|Standard Care|In the control group, no additional intervention will be implemented. PU and IAD prevention and basic hygiene and skin care activities are routinely conducted in German nursing homes. This is considered as 'usual practice'.
10177211|NCT03824782|No Intervention|Standard of Care|Infants in the control arm received standard examinations to screen for retinopathy of prematurity.
9696474|NCT04766567|Placebo Comparator|Control group|Patients with singleton pregnancy, who did not have myomectomy during cesarean section
9682204|NCT04917003|Experimental|RIC group|"Patients who are allocated into RIC group will undergo the first EDAS surgery combined 3-month remote ischemic conditioning (RIC) treatment. The opposite operation will be performed at 3 months after the first operation.~RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm.~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used."
10177212|NCT03824782|Experimental|Standard of Care + Phototherapy Mask|Infants in the treatment arm will have a standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided. Infants will then receive standard examinations to screen for retinopathy of prematurity. The mask will be removed for the examination but reapplied promptly afterward.
10187324|NCT03727243||Septic/septic shock patients|Patients with underlying confirmed or probable cause of infection leading to sepsis or septic shock will form the active group of interest.
9682205|NCT04917003|Other|control group|"Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.~EDAS involves placement of an external carotid artery branch beneath the dura in the ischemic territories. The superficial temporal artery (STA) was commonly used. Under certain circumstances, depending on the territory at risk, the occipital artery was also used. The donor vessel with the strip of galea (the arterial bridge) was detached from the pericranium or the fascia below, and two burr holes are made beneath the proximal and distal ends of the arterial bridge. The burr holes, with an average size of 3.0 × 8.0 cm, were connected by mill to make an oval bone flap and the dura was exposed. The target artery was then sewn to the dura using 10-0 Prolene suture. The bone flap was closed after cutting out the entry and exit sites for the target artery."
9682206|NCT04916808||Ductal Carcinoma In Situ (DCIS)|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
9682207|NCT04916925|Experimental|pcos resistant to cc plus vit d|100 patients who are PCOS and resist CC will receive Vitamin D 10000 IU orally plus 150mg clomid orally for 3 months number and size of growing follicles will be monitored
9682208|NCT04917471|Active Comparator|Nitrate-rich beet root juice|Nitrate-rich Beet root juice 70 ml bid
9682209|NCT04917471|Placebo Comparator|Placebo|Nitrate-depleted beet root juice 70 ml bid
9682210|NCT04917302|Experimental|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
9682211|NCT04917302|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
9682212|NCT04916951|No Intervention|Amoxicillin - standard-of-care dose|Obtain amoxicillin plasma concentrations in patients already receiving amoxicillin
9682213|NCT04916951|No Intervention|Cephalexin - standard-of-care dose|Obtain cephalexin plasma concentrations in patients already receiving cephalexin
9682214|NCT04916951|Experimental|Amoxicillin - study dose|Obtain amoxicillin plasma concentrations after a study-administered dose of amoxicillin
9682215|NCT04916951|Experimental|Cephalexin - study dose|Obtain cephalexin plasma concentrations after a study-administered dose of cephalexin
9682216|NCT04916899||Group A: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Pharmaceutical Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Administration way: oral
9682217|NCT04916756|Experimental|baricitinib 2mg per day|
9682218|NCT04917133|Experimental|Adapted Physical workshops|The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective care : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests
9682219|NCT04917133|Other|Control|"Standard of care The control group will have the classic program performed in the standard of care with : kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, creation)."
9682220|NCT04917081|Experimental|Mindful Self-Compassion|
9682221|NCT04917081|Active Comparator|Progressive Muscle Relaxation|
9682222|NCT04916886|Experimental|50L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
9682223|NCT04916886|Experimental|500L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
9682224|NCT04916886|Experimental|800L Scale (Age 18-59)|Single dose of 0.5ml Ad5-nCoV containing 0.5E10 vp.
9682225|NCT04916886|Experimental|800L Scale Lot 1 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
9682226|NCT04916886|Experimental|800L Scale Lot 2 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
9682227|NCT04916886|Experimental|800L Scale Lot 3 (Age 13-17)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
9682228|NCT04916886|Experimental|800L Scale Lot 1 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
9682229|NCT04916886|Experimental|800L Scale Lot 2 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
9682230|NCT04916886|Experimental|800L Scale Lot 3 (Age 6-12)|Single dose of 0.3ml Ad5-nCoV containing 0.3E10 vp.
9682231|NCT04916782||Observational group|
9682232|NCT04916964|Experimental|Test & Exercise home-based program (T&E)|Eight home-based physiotherapy sessions will occur in two months, once a week
9682233|NCT04916821|Experimental|water extract of propolis|Patients given 2 ml of aqueous propolis extract (50mg / ml) orally 3 times a day for 1 week
9682234|NCT04916821|Experimental|olive oil extract of propolis including perga|Patients given 1 ml oily propolis extract (64 mg / ml) + 1 ml oily perga extract (120 mg / ml) orally 3 times a day for 1 week
9682235|NCT04916821|No Intervention|control|control group (patients not given any investigational product)
9682236|NCT04916860|Experimental|CD7 CAR-T|
9682237|NCT04916717|Other|Counseling|Quasi-experimental design. Face-to-face and telephone counseling were applied to individuals in the intervention group.
9682238|NCT04916522|Experimental|Colchicine|Colchicine 0.5 mg once daily
9682239|NCT04916522|Placebo Comparator|Placebo|Placebo once daily
10177213|NCT03825081|Experimental|Intervention|"Interventions will be the drugs:~pilocarpine - 0.5%~brimonidine - 0.2%~One drop of each of the study drugs will be placed in the non-dominant eye and patient will be evaluated for adverse events. At hour 1 and 3 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured and patient will be evaluated for adverse events. At hour 6 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured; patient will be evaluated for adverse events; and quality of life/satisfaction survey (NEI RQL-42) will be given to patient."
9682240|NCT04916535|Experimental|diagnostic flow|all patients with MAD as assessed during routine transthoracic echocardiography will undergo to the following further exams: i) 12-lead electrocardiogram (ECG), ii) 24-hour ECG monitoring, iii) cardiac magnetic resonance imaging (CMR), iv) cardiological visit
9682241|NCT04916444|Active Comparator|Active rTMS|Active rTMS will use a figure of eight TMS coil that will deliver real neurostimulation pulses to the patients.
9682242|NCT04916444|Sham Comparator|Sham rTMS|Sham rTMS will use a sham figure of eight TMS coil that sounds and looks like a real rTMS coil, except no neurostimulation is being delivered to the patient.
9682243|NCT04916457||group ND|control group without DM non-intervention
9682244|NCT04916457||group VD|"very low-risk group: diabetic patient with no loss of protective sensation(LOPS) and no peripheral artery disease(PAD).~non-intervention"
9682245|NCT04916457||group LD|low-risk group: diabetic patient with LOPS or PAD non-intervention
9682246|NCT04916457||group MD|moderate-risk group: diabetic patient with LOPS + PAD non-intervention
9682247|NCT04916457||group HD|"high-risk group: diabetic patient with LOPS or PAD, and one or more of the following:~history of a foot ulcer~a lower-extremity amputation (minor or major)~end-stage renal disease~non-intervention"
9682248|NCT04916639|Experimental|Active group|Physiomer®, undiluted seawater nasal spray
10177214|NCT03825068|Active Comparator|ESP block group|patients receive ESP Bock with local anaesthetics
10177215|NCT03825068|Placebo Comparator|control group|general anaestesia
10177216|NCT03825029|Experimental|Pillow Group|There will be a pillow placed between the patients legs during their operation.
10177217|NCT03825029|No Intervention|Control Group|They will receive a normal total hip arthroplasty.
10177218|NCT03824873|Active Comparator|internal iliac artery ligation + cesarean hysterectomy|
10177219|NCT03824873|Active Comparator|cesarean hysterectomy|
9682249|NCT04916639|No Intervention|control group|
9682250|NCT04916652||Infant Cohort|"aged from 1.5-6 months. Includes predominantly breastfed infants and formula-fed infants.~This is an observational trial so no intervention will be provided, with exception of study assessments, including MRI."
9682251|NCT04916652||Toddler Cohort|"aged from 9-15 months. Includes follow-up formula-fed / growing-up milk-fed infants & toddlers.~This is an observational trial so no intervention will be provided, with exception of study assessments, including MRI."
9976059|NCT01347723||Supportive care (pain therapy)|Patients undergo scrambler therapy for 30 minutes daily for up to 10 consecutive days. Treatment continues in the absence of unacceptable toxicity.
9682252|NCT04916496|Experimental|ACT-LCP Group|An Acceptance and Commitment Therapy-based healthy lifestyle counselling programme (ACT-LCP) and routine psychiatric outpatient/rehabilitation services of the study hospital.
9682253|NCT04916496|Placebo Comparator|Control Group|A healthy lifestyle talk and routine psychiatric outpatient/rehabilitation services of the study hospital.
9976060|NCT01347736|Experimental|Treatment (pain therapy)|Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
9976061|NCT01347749|Experimental|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
10177220|NCT03824665|Active Comparator|Nalbuphine Group|Nalbuphine Group (Nalbuphine) 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 4mg nalbuphine
10177221|NCT03824665|Active Comparator|Fentanyl Group|Fentanyl Group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 20 μg fentanyl
10177222|NCT03824665|Active Comparator|Control group|Control group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml normal saline
10177223|NCT03824678|Experimental|Administration of CC-220|All subjects will receive one 1-mg CC-220 capsule administered orally with approximately 240 mL of non-carbonated, room temperature water, and administered by trained clinical staff.
10177224|NCT03825016|Experimental|Lidocaine|Lidocaine Hydrochloride
10177225|NCT03825016|Experimental|Diclofenac|Oral Diclofenac
10177226|NCT03825055||Young patients with MS|young adults (i.e., 18-45 years) newly diagnosed with MS (Case-Only)
10177227|NCT03824717|Other|Ropivacaine dosage|Dose finding study - The volume of 0.5% ropivacaine used to achieve surgical anesthesia in infraclavicular brachial plexus block
10177228|NCT03824834|Experimental|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) with supervised exercise training.
10177229|NCT03824834|Placebo Comparator|Exercise training with placebo|Placebo treatment with supervised exercise training.
10177230|NCT03824795|Active Comparator|Group 1: 125mg b.i.d. for 10 days|Patients will be administered an oral dose of 125mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
10177231|NCT03824795|Active Comparator|Group 2: 250mg b.i.d. for 10 days|Patients will be administered an oral dose of 250mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
10177232|NCT03824795|Active Comparator|Group 3: 500mg b.i.d. for 10 days|Patients will be administered an oral dose of 500mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
10177233|NCT03824691|Experimental|Cabozantinib + Durvalumab|Subjects will receive 1500 mg durvalumab (MEDI4736) IV infusion every 28 days + Cabozantinib 40 mg orally once daily
10177234|NCT03824613||Endometrial cancer patients|
10177235|NCT03824613||Control group|Patients without cancer
10177236|NCT03824626||TEVAR patients|patients scheduled for thoracic endovascular aortic repair
10177237|NCT03824418||Chromoendoscopy follow-up|
10177238|NCT03824418||Autofluorescence follow-up|
10177239|NCT03824288|Active Comparator|The landmark technique|PTA a needle aspiration attempted according to the landmark technique is conducted. If the initial aspiration is unsuccessful, two additional attempts are made in the middle and lower pole of the tonsil.
9682254|NCT04916626|Experimental|OPUS YOUNG|OPUS YOUNG is a two years out-patients specialized early intervention services for children and adolescents with a first episode psychosis. OPUS YOUNG is characterized by a multidisciplinary team, assertive outreach, tailored cognitive behavioral case management, and low caseload and insensitive psychoeducational family involvement
9682255|NCT04916626|Active Comparator|Treatment as Usual, TAU|Treatment as Usual will be carried out by outpatient clinic in Child and Adolescent Mental Health Services (CAMHS). Patients will be offered treatment following national Danish guidelines and local guidelines, provided by a multidisciplinary team, case-management (no defined upper-case load), family support. In general, office visits take place in outpatient clinics.
9682256|NCT04916509||Palbociclib plus an aromatase inhibitor|"Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor.~Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
9682257|NCT04916509||palbociclib plus fulvestrant|"Adult metastatic breast cancer patients who initiated Palbociclib + fulvestrant. Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.~Aligned with Locally Approved Indication"
9682258|NCT04916548|Experimental|Intravenous Ketamine|Open-label ketamine infusion
9682259|NCT04916587|Active Comparator|Multifaceted Implementation Strategy|The core implementation strategy components are: 1) short video-trainings for clinic personnel (care team staff and providers) on the administration of caregiver-reported screening tools; 2) technical implementation support using an approach comprised of external academic consultants, and internal FQHC personnel to increase inner context capacity, 3) use of a validated clinical screening tool - Pediatric Symptoms Checklist (PSC-17), used in pediatric primary care settings to assess behavioral and social/emotional development. For this study, we will use the PSC tools that are tailored to children ages 0 to 5 years old with the Baby Pediatric Symptomatology Checklist (BPSC) for ages 0 to 18 months, and the Preschool Pediatric Symptom Checklist (PPSC) for ages 18 to 60 months. This screening tools is needed as the PEARLS only assesses ACEs exposure and not mental health symptomatology; and 4) use of a technology based tailored ACEs algorithm that incorporates multiple data sources.
9976062|NCT01347749|Active Comparator|Present Centered Therapy for PTSD|This is a more standard from of group psychotherapy (talk therapy) which focusses on current symptoms and stressors
10177240|NCT03824288|Experimental|Ultrasound-guided aspiration|An intraoral ultrasound is conducted with a Burr-Hole N11C5s transducer (BK Ultrasound) and if an abscess cavity is suspected, an ultrasound-guided aspiration is performed with an in-plane needle guide attached to guide the needle.
10177241|NCT03824431||patients with endoscopic microerosions|"==Patients with typical symptoms of Gastroesophageal Reflux Disease(GERD):~1- High resolution definition with NBI endoscopic findings of mucosal microerosions in distal esophagus .~."
10177242|NCT03824431||patients without microerosions|2- High resolution definition with NBI endoscopic without findings of mucosal microerosions in distal esophagus .
10177243|NCT03824444|Experimental|Treatment|Implant and followup
10177244|NCT03824275|Experimental|18F- DCFPyL PET/CT|Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
10177245|NCT03824262|Experimental|Group I|HICO-VARIOTHERM 550 and Mistral-Air Plus forced-air warming device
10177246|NCT03824262|Active Comparator|Group II|Mistral-Air Plus forced-air warming device
10177247|NCT03824379|Experimental|Magnesium arm|30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
10177248|NCT03824379|Active Comparator|Control|30 patients will receive the standard therapy (anti-diabetic)
10177249|NCT03824535|Experimental|Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)|Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
10177250|NCT03824327|Experimental|Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)|Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.
10177251|NCT03824171|Experimental|Raloxifene 60mg/Cholecalciferol 800IU to AD-102|Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
10177252|NCT03824171|Experimental|AD-102 to Raloxifene 60mg/Cholecalciferol 800IU|Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
10177253|NCT03824457|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours). The period of the treatment with the study drug lasts 3 days.
10177254|NCT03824457|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
10177255|NCT03824184|Active Comparator|manipulation of endometrium|Manipulation of endometrium with saline
10177256|NCT03824184|No Intervention|control group|Control group : No intervention
10177257|NCT03824314|Experimental|Group M|. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
10187325|NCT03727243||Non-septic/sterile inflammation patients|Patient with severe trauma, severe burns and patients admitted to ICU after major surgery or pancreatitis. Active comparator group.
10187326|NCT03727243||Healthy control patients|Active comparator group.
10177258|NCT03824314|Experimental|group F|"group F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally.~Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position"
10177259|NCT03824119|Active Comparator|Standard Postpartum Care|Subjects will receive NSAIDs (e.g. ibuprofen, ketorolac) for routine postpartum pain management.
10177260|NCT03824119|Active Comparator|Standard Postpartum Care without NSAIDs|Subjects will receive standard postpartum care without NSAID administration for pain management. Acetaminophen or narcotics will be substituted for ibuprofen as indicated by provider.
10177261|NCT03824301|Active Comparator|Volume-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with volume-controlled ventilation
10177262|NCT03824301|Active Comparator|Pressure-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with pressure-controlled ventilation
10177263|NCT03824301|No Intervention|No ventilation|During cardiopulmonary bypass period the patients were disconnected from ventilator
9682260|NCT04916587|Other|ACEs Screening|"Adverse Childhood Experiences (ACEs) are potentially traumatic events occurring before age 18, such as maltreatment, harsh migration experiences or exposure to violence. ACEs screening are increasingly recommended to prevent and address physical and mental health conditions associated with ACEs. To promote ACEs screening uptake, the state of California issued the ACEs Aware 2020 policy; a fee-for-service health policy that provides a financial incentive to Medicaid-serving clinics to promote yearly ACEs pediatric screenings in primary care settings. This study will focus on screening children ages 0-5, in line with the partnering FQHC's ACEs screening priorities."
10177264|NCT03824392|Experimental|Cohort 1|ATYR1923 1.0 mg/kg or placebo
10177265|NCT03824392|Experimental|Cohort 2|ATYR1923 3.0 mg/kg or placebo
9682261|NCT04916574|Active Comparator|BioBlock® concentration 0.2 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
9682262|NCT04916574|Active Comparator|BioBlock® concentration 0.1 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
9682263|NCT04916418|Placebo Comparator|G1, Placebo|Intravenous saline (NaCl 0,9%) will be administered. G1 group will be administered an initial dose of placebo (20ml) per catheter bilaterally (total volume 40ml) after TTP has been placed. This is followed by 20ml doses of placebo per catheter every 8 hours until 72 hours from the first dose has passed.
9682264|NCT04916418|Active Comparator|G2, Ropivacaine|Ropivacaine 0.5%. G2 group will be administered an initial dose of ropivacaine (20 ml) per catheter bilaterally (total volume 40ml) after the TTP has been placed. This is followed by 20 ml doses of ropivacain per catheter every 8 hours until 72 hours from the first dose has passed.
10177266|NCT03824392|Experimental|Cohort 3|ATYR1923 5.0 mg/kg or placebo
10177267|NCT03824509||Patients with an echocardiagram who suffered a stroke or TIA|"Medical record number~Sex~Age~BMI~Body surface area~Smoking status~Congestive heart failure~Hypertension~Diabetes,~Previous history of heart attack or vascular disease~Previous history of stroke~Date of stroke~Type of stroke~CHA2DS2-VASc scores~On an anticoagulant yes/no at time of stroke~Date of atrial fibrillation diagnosis~Date of echocardiogram~Echocardiographic features:~a. Left atrial volume, indexed to body surface area (BSA) b. Left ventricular hypertrophy 4. Stroke outcome:~Mortality~NIH Stroke Scale~Modified Rankin Scale~Discharge placement:~i. Home ii. Long term care iii. Skilled nursing facility e. 6-month survival"
9682265|NCT04916184|Active Comparator|aerobic exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
9682266|NCT04916184|Active Comparator|Combined exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
9682267|NCT04916171||Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome|"The diagnosis of endometriosis will be made by the presence of ovarian endometrioma and/or a deep infiltrating endometriosis nodule determined by transvaginal ultrasonography or by palpation of the endometriotic nodule on pelvic examination or surgical confirmation.~The diagnosis of adenomyosis will be made by transvaginal ultrasonography or surgical confirmation."
9682268|NCT04916171||Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis|For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used.
9682269|NCT04916223|Experimental|3 x 10-minute massage|Subject receives a 10-minute massage daily for three consecutive days
9682270|NCT04916223|Experimental|3 x 20-minute massage|Subject receives a 20-minute massage daily for three consecutive days
9682271|NCT04916223|Active Comparator|Single 20-minute massage|Subject receives one 20-minute massage
9682272|NCT04916392||liposomal bupivacaine|Nerve block will be preformed using 5ml of 1.33% liposomal bupivacaine with 5ml of 0.9% normal saline.
9682273|NCT04916392||standard bupivacaine|Nerve block will be preformed using 10ml of 0.5% standard bupivacaine.
9682274|NCT04916119|Experimental|IBI323|Phase Ia enrolls in patients with advanced malignancies. Phase Ib cohort A enrolls in NSCLC(IO-refractory), cohort B NSCLC(IO-naive), cohort C NSCLC(PD-L1 TPS≥1%), cohort D ES-SCLC or neuroendocrine tumors, cohort E MPM, cohort F UC, cohort G nccRCC, cohort H HCC, cohort I NPC, cohort J CC or HNSCC, cohort K GC or GEJC with HER2 negative, cohort L TNBC
9682275|NCT04916353|Experimental|20% hypertonic dextrose water injection group|echo guide 20% dextrose water 3ml was injection in lesion site
9682276|NCT04916353|Active Comparator|Steroid injection group|Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group
9682277|NCT04916691|Other|EPSB for rib fractures|EPSB for rib fractures
9682278|NCT04916483|Experimental|Exploring the effectiveness of GCST in people with schizophrenia.|The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.
9682279|NCT04916483|No Intervention|Control group|The control group maintains the usual care.
9695585|NCT04776590|Experimental|Tislelizumab arm|Radiotherapy: PTV 41.4Gy in 23 Fractions，5 days per week; Chemotherapy: Paclitaxel (Albumin bound) (100mg per square meter of body-surface area weekly) and Caboplatin (area under the curve of 2 mg per milliliter per minute weekly) for 5 weeks, concurrent with radiotherapy; Immunotherapy: Tislelizumab (200mg per 3 weeks)
9682280|NCT04916314|Experimental|Low Carbohydrate Diet|". The intervention, provided by Second Nature, involves diet, activity and behaviour change components. It comprises a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application. Each participant will also receive a hard copy of an instructional handbook and a recipe book."
9682281|NCT04916314|No Intervention|Standard NHS type 2 diabetes care|Participants randomised to the control group will receive no additional intervention, and will continue to receive their usual NHS diabetes care from their general practice.
9682282|NCT04916366|Experimental|Kinesio taping|In this arm, patients will be treated with blue Kinesio taping in a muscle relaxation position during 4 days.
9682283|NCT04916366|Placebo Comparator|Placebo|In this arm, patients will be treated with conventional bandage in a muscle relaxation position during 4 days.
9682284|NCT04916366|No Intervention|Control|In this arm, patients will be not treated but the outcomes will be measure after 4 days.
10177268|NCT03824509||Control Group - matched CHA2DS2-VASc score, age, and gender|"Controls from both PBMC and MMC will be obtained. Controls are patients from 2014-2017 with matched age (+/- 5 years), gender, and CHA2DS2-VASc score who had atrial fibrillation and had not had a documented stroke or TIA in EPIC or the Get with the Guidelines registry maintained at PBMC. Controls must have an echocardiogram on record and have a diagnosis of atrial fibrillation at the time of the echocardiogram."
10177269|NCT03824574|Experimental|Treatment arm|Subjects receiving the clear mandibular advancement appliance
10177270|NCT03824353|Experimental|Social Intelligence Training|The social intelligence training is delivered online to individuals in midlife (ages 40 and older). This is the sole active treatment condition within this RCT.
10177271|NCT03824353|Placebo Comparator|Attention Control|The attention control condition, known as The Healthy Living program provides information about different aspects of health.
10177272|NCT03824067|Active Comparator|Standard of Care Early Infant Diagnosis|Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
9682285|NCT04916275||Staff working in a nursing home in Occitanie|
9682286|NCT04916379|Experimental|Momordica charantia|Two 500 mg capsules of Momordica charantia twice daily before breakfast and dinner for 12 weeks
9682287|NCT04916379|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 12 weeks
9682288|NCT04916327|Experimental|Antioxidant then Placebo|Subjects will ingest an antioxidant cocktail prior to their second visit and a placebo prior to third second visit
9682289|NCT04916327|Experimental|Placebo then Antioxidant|Subjects will ingest a placebo prior to their second visit and an antioxidant cocktail prior to their third visit.
9682290|NCT04916145|No Intervention|No any treatment|Participants randomly assigned to this group will maintain a routine life without any treatments (no use of SAT-008).
9682291|NCT04916145|Experimental|Use of SAT-008|Participants randomly assigned to this group will be treated by SAT-008 during the study.
9682292|NCT04915898|Active Comparator|Oral Care Hygiene Intervention Group|Providing oral care kits designed to facilitate adherence to brushing teeth after meals and before sleep. Providing continuous education and feedback on performance to team members on the interventional units. Encouraging patients to brush their teeth and use the kits or own materials if desired.
9682293|NCT04915898|No Intervention|Control group - standard of care oral care on units|These units will perform their 'usual' or standard of care for oral hygiene practices without use of the oral care kits, no encouragement to perform outside of usual care
9682294|NCT04915872||Participant|Critically Ill Patients with Open Abdomen and Negative Pressure Wound Therapy
9682295|NCT04916093|Experimental|Sitagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received sitagliptin 100 mg therapy once daily before breakfast.
9682296|NCT04916093|Experimental|Vildagliptin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received vildagliptin 50 mg therapy twice daily before breakfast and supper.
9682297|NCT04916093|Active Comparator|Metformin Group|Included 20 recently diagnosed type 2 diabetic subjects. They all received control 1 gm twice daily
9682298|NCT04915846|Experimental|Drug: ApoTamox 10mg|Drug: Tamoxifen (tamoxifen citrate); ApoTamox 10 mg tablets orally twice daily for 6 months
9682299|NCT04915846|Placebo Comparator|Placebo|Placebo (no active ingredients) tablets orally twice daily for 6 months
9682300|NCT04916041||Vivity|Patients who have undergone bilateral implantation of Vivity intraocular lens
10177273|NCT03824067|Experimental|Point of Care Early Infant Diagnosis|The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
10177274|NCT03824496||Suspected acute stroke|"Any patient with suspected acute stroke triggering a stroke code and had a brain imaging angiogram"
10177275|NCT03824093|Active Comparator|AFIX Only|Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.
10177276|NCT03824093|Active Comparator|AFIX+ Provider Communication Training|Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.
10177277|NCT03824054||colorectal resection arm|Patients affected by symptomatic deep infiltrating endometriosis involving the bowel and submitted to colo-rectal resection
10177278|NCT03824197|Other|EVOO-phenol high|Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
10177279|NCT03824197|Other|OO-phenol low|Olive oil with low phenolic content that will be added to daily diet
10177280|NCT03824405|Active Comparator|BTX 1204|BTX 1204 twice daily
10177281|NCT03824405|Placebo Comparator|Vehicle|Vehicle twice daily
10177282|NCT03824340|Active Comparator|Doxycycline before ICSI|extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
10177283|NCT03824340|No Intervention|control group|control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
10177284|NCT03824002|Experimental|patients treated with dulaglutide|Diabetes therapy with dulaglutide and various combinations of aspart insulin, glargine, metformin, repaglinide
10177285|NCT03824002|Active Comparator|patients not treated with dulaglutide|Diabetes therapy with various combinations of aspart insulin, glargine, metformin, repaglinide but without dulaglutide
10177286|NCT03824210||Stage 1|School children age 11-18 (from two nominated schools) and young carers 11-18
10177287|NCT03824210||Stage 2|Young carers from Young Carers in Herts 11-18
9682301|NCT04916041||Eyhance|Patients who have received bilateral implantation of an Eyhance intraocular lens
9682302|NCT04916041||EMV|Patients who have undergone bilateral implantation of Vivity intraocular lens
9682303|NCT04916041||Panoptix|Patients who have undergone bilateral implantation of Panoptix intraocular lens
9682304|NCT04916041||Rayner Trifocal|Patients who have undergone bilateral implantation of Rayner trifocal intraocular lens
9682305|NCT04916262||TSH < 30uIU/mL group|Clinical information was collected from patients with TSH < 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
9682306|NCT04916262||TSH ≥ 30uIU/mL group|Clinical information was collected from patients with TSH ≥ 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
9682307|NCT04915885|Other|Control arm|routine contraceptive counseling and care and a range of family planning methods that are routinely available at field level
9682308|NCT04915885|Experimental|Intervention package|contraceptive counseling package but still with a range of family planning methods that are routinely available at field level
10177288|NCT03824028||Clareon IOL AutonoMe|Prior implantation with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system
10177289|NCT03824015|Experimental|KAPA intervention arm|KAPA participants who completed the 24-week commissioned Falls Management Exercise program received six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.
10177290|NCT03824015|Other|Usual care|The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package.
10177291|NCT03824041|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
9682309|NCT04915885|Experimental|Intervention package & expanded methods|contraceptive counseling package but with an expanded range of family planning methods that are recommended by national guidance
9682310|NCT04916080|Experimental|after treatment|chronic kidney disease patients after receiving NAC for 3 months
9682311|NCT04915963|Experimental|vitamin D group|170 patients receiving a single dose of 400,000 IU of VD3 (2 vials of 200,000 IU VD3; B.O.N., BOUCHARA RECORDATI) orally or through a nasogastric tube
9682312|NCT04915963|Sham Comparator|Placebo group|170 patients receiving distilled water (2 vials of 1 ml distilled water) orally or through a nasogastric tube
9682313|NCT04915807||Prospective population|The target group for the purpose of prospectively collecting the clinical data (RWD) of patients using ramucirumab/paclitaxel as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
9682314|NCT04915807||Historical retrospective population|The target group for the purpose of retrospectively collecting the clinical data (RWD) of patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018, when health insurance coverage for the ramucirumab/paclitaxel combination therapy started in South Korea.
9682315|NCT04915651|Experimental|Gallbladder Cryoablation|High-risk patients who undergo gallbladder cryoablation
9682316|NCT04915989|Experimental|GX-19N|Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29. (Optional administration on day 57)
9682317|NCT04915794|Experimental|Simulation based education|Simulation is a technique that creates a situation or environment that allows people to experience the representation of a real event, practice, learn, evaluate, test, or gain an understanding of systems or human actions
9682318|NCT04915794|No Intervention|Traditional education|Necessary procedures explained theoretically
9682319|NCT04915716||healthy pregnant woman|healthy pregnant woman
9682320|NCT04915716||pregnant women with GDM|pregnant women with gestational diabetes mellitus
9682321|NCT04916015||children (0-14 years)|
9682322|NCT04916015||AYAs (15-25 years)|
9682323|NCT04915638|Experimental|Intervention group|Schoolchildren received enriched cookies containing a multiple micronutrients formula. Enriched cookies (20g) with a daily dose of 0.33g of organic mix formula were given in the morning during 4-weeks. The formulation is an industrial secret of UNAM.
9682324|NCT04915911||adult patients with Crohn's disease|multi-center cross-sectional study
9682325|NCT04915924|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
9682326|NCT04915508|Experimental|Treatment (SBRT, hormone therapy)|Patients undergo SBRT every other day or on consecutive days for up to 14 days. Patients may receive hormonal therapy at the discretion of the treating physician.
10177292|NCT03824041|Experimental|Aronia full spectrum - half dose|Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
10177293|NCT03824041|Experimental|Aronia full spectrum - full dose|Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
10177294|NCT03823911|Active Comparator|HIV Mono-Infected|Patients infected with HIV only, and not currently or previously infected with hepatitis C.
9527645|NCT03218293|Experimental|RIPC|Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
9682327|NCT04915612|Experimental|Treatment (CPX-351, GO)|"INDUCTION 1 (28 days): Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.~INDUCTION 2: Patients who do not attain a defined clinical response after cycle Induction 1 receive CPX-351 IV on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Beginning 4 weeks after last induction, patients receive CPX-351 IV over 90 minutes on days 1 and 3 and GO IV over 2 hours on day 1 in the absence of disease progression or unacceptable toxicity."
9695586|NCT04776525|Experimental|Sequential ifosfamide and doxorubicin|Four cycles ifosfamide 9 g/m2 and four cycles doxorubicin 80 mg/m2. Each cycle has a duration of 14 days.
9695587|NCT04776577|Other|Study arm|"Group 1 and group 2 will be recruited and assessed in parallel at the discretion of the treating physician, based on the characteristics of the patient. Group 3 will be recruited from suitable patients in group 1 and 2.~Simultaneous measurements study (group 1) Regular study group (group 2) Echocardiography-CFR group (group 3)"
9695588|NCT04776655|Experimental|Bevacizumab in combination with FOLFIRI chemotherapy|"Bevacizumab will be administrered at a dose of 5 mg/kg iv every 2 weeks. The first dose of Bevacizumab will be administered over 90 minutes. Then, if the first infusion is well tolerated without infusion-related reaction, the second dose will be administered over 60 minutes. Then, if the second dose is also well tolerated without an infusion reaction, all subsequent doses will be administered over 30 minutes.~Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
9976063|NCT01347775|Sham Comparator|Sham inspiratory muscle training|Patients in the sham group used the threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), with the diaphragm removed.
9976064|NCT01347775|Experimental|Inspiratory muscle training|Inspiratory muscle training will be by a threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), a commercially available spring-loaded inspiratory muscle training device. It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
9976065|NCT01347801|Placebo Comparator|2C - 1|TNF and OGTT and saline
9976066|NCT01347801|Active Comparator|2C - 2|TNF and OGTT and GLP-1
9976067|NCT01347801|Placebo Comparator|2C - 3|TNF and IVGTT and saline
9976068|NCT01347801|Active Comparator|2C - 4|TNF and IVGTT and GLP-1
9976069|NCT01347801|Placebo Comparator|2A-1|Saline infusion and OGTT
9976070|NCT01347801|Placebo Comparator|2A-2|Saline and IVGTT
9976071|NCT01347801|Active Comparator|2A-3|TNF and OGTT
9976072|NCT01347801|Active Comparator|2A-4|TNF and IVGTT
9976073|NCT01347801|Experimental|1C|OGTT and corresponding IVGTT
9976074|NCT01347827||on pump|Coronary artery bypass grafting (CABG)with with cardiopulmonary bypass
9976075|NCT01347827||off pump|off-pump CABG surgery
9976076|NCT01347853|Experimental|Ketorolac tromethamine|
9976077|NCT01347853|Placebo Comparator|Placebo|
9976078|NCT01347892||DeNovo NT Subject|Subjects who have received or who are scheduled to receive a DeNovo NT Graft for repair of a cartilage lesion in the ankle.
9976079|NCT01347905||Obese women and men|Obese women and men undergoing restrictive bariatric surgery. Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
9977617|NCT01363531|Experimental|Delayed antibiotic prescription 2|The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
9977618|NCT01363544|Experimental|Neurofeedback|
9977619|NCT01363544|Experimental|Exercise|
9977620|NCT01363544|Active Comparator|methylphenidate|optimum dose of methylphenidate (assessed by a double blind placebo-controlled procedure)
9977621|NCT01363557|Experimental|Arm A : Gefitinib + WBRT|Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance
9977622|NCT01363557|Experimental|Arm B : Gefitinib|Arm B : Gefitinib alone
9977623|NCT01363570|Other|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
9977624|NCT01363583|Active Comparator|epoprostenol, Flolan®|Measurement on the effect of epoprostenol on lactate/pyruvate ratio measured by cerebral microdialysis
9977625|NCT01363583|Placebo Comparator|normal saline|Effect of saline on the lactate/pyruvate ratio measured by cerebral microdialysis
9977626|NCT01363609|Experimental|Liraglutide|12 week treatment with liraglutide in fixed dosage
9977627|NCT01363609|Active Comparator|Insulin glargine|12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
9977628|NCT01363609|Other|before start of treatment period|before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
9977629|NCT01363622||SGA|SGA (small for gestational age)
9977630|NCT01363622||LGA|LGA (large for gestational age)
9977631|NCT01363622||AGA|AGA (appropriate-for-gestational-age)
9977632|NCT01363648|Experimental|Choline alfoscerate|choline alfoscerate 400mg, 3 times a day, for 12 weeks.
9682328|NCT04915586|Experimental|Treatment Arm|"Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours~Intervention Drug: Combination Alteplase and pulmozyme (DNase)"
10177295|NCT03823911|Experimental|Hepatitis C Mono-Infected|Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
10177296|NCT03823911|Experimental|HIV and Hepatitis C Co-Infected|Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.
9682329|NCT04915703|Experimental|Intervention|flushing of internal external PTBD catheter 3 times a day
9682330|NCT04915703|No Intervention|Standard of Care|no flushing of PTBD catheter
10177297|NCT03823846|Experimental|Experimental Group|Patients in the experimental group were received doctor-nurse-patient cooperative analgesic linkage program.
10177298|NCT03823846|Active Comparator|control group|Patients in the control group were received routine analgesic and functional rehabilitation.
10177299|NCT03823677|No Intervention|control group 15|"Protein expression and emotional test~15 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
10177300|NCT03823677|No Intervention|control group 30|"30 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
10177301|NCT03823677|No Intervention|control group 60|"60 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
10177302|NCT03823677|Experimental|hypoxia 5000ft group 15|Intervention: 15 minutes hypoxia
10177303|NCT03823677|Experimental|hypoxia 5000ft group 30|Intervention: 30 minutes hypoxia
9682331|NCT04915560|Experimental|ORTEC Employee|ORTEC professional employees performing an industrial cleaning task.
9682332|NCT04915573||patients with Cirrhosis|Patient with clinical evidence of liver disease, portal hypertension, ultrasound or computed tomography results, laboratory data will be used to confirm liver disease
10177304|NCT03823677|Experimental|hypoxia 5000ft group 60|Intervention: 60 minutes hypoxia
10177305|NCT03823677|Experimental|hypoxia 8000ft group 15|Intervention: 15 minutes hypoxia
10177306|NCT03823677|Experimental|hypoxia 8000ft group 30|Intervention: 30 minutes hypoxia
10177307|NCT03823677|Experimental|hypoxia 8000ft group 60|Intervention: 60 minutes hypoxia
10177308|NCT03823677|Experimental|hypoxia 10000ft group 15|Intervention: 15 minutes hypoxia
10177309|NCT03823677|Experimental|hypoxia 10000ft group 30|Intervention: 30 minutes hypoxia
10177310|NCT03823677|Experimental|hypoxia 10000ft group 60|Intervention: 60 minutes hypoxia
10177311|NCT03823677|Experimental|hypoxia 15000ft group 15|Intervention: 15 minutes hypoxia
9682333|NCT04915547|Experimental|Group-Based Exercise|The group-based exercise (GBE) programme will be delivered by a physiotherapist. The GBE comprises three sessions per week of group-based exercise in a local community centre, for 8 weeks.
9682334|NCT04915547|No Intervention|Control Group|Participants randomly allocated to the control group will remain on a waiting list. In addition, weekly contact will be made to ensure that they do not start treatment during the study protocol. After the end of the study, participants randomly allocated to the control group will receive the same intervention as the Group-Based Exercise.
9682335|NCT04915625||Death group|Retrospective observational studies
9682336|NCT04915625||Survival group|Retrospective observational studies
9682337|NCT04915339|Experimental|Group 1: physical activity then cognitive training|Using an online-computerized application, physical activities will be prescribed for one month. After a 15 days break, cognitive training activities will be prescribed the same way. A feedback by the patient will be asked fallowing each activity to control the observance.
9682338|NCT04915339|Experimental|Group 2: Cognitive training then physical activity|Contrary to the first group, the second one starts with cognitive training intervention then engages in physical activity in same way as the first group. A feedback by the patient will also be asked fallowing each activity to control the observance
9682339|NCT04915339|Experimental|Group 3 : resonance frequency breathing then combined physical activity and cognitive training|The third group takes part in a 1 month breathing exercise program. After a 15 days break (as the groups 1 and 2), a combined physical activity and cognitive training program is administrated for 1 month. As the others arms, a feedback by the patient will be asked fallowing each activity to control the observance
9682340|NCT04915482|Experimental|Combined use of eltrombopag with low-dose rituximab|The starting dose of eltrombopag is 75mg daily. Before or within 4 weeks after the treatment, rituximab 375mg/m2 will be used once. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance. If the continuous application of 75 mg once a day of eltrombopag for 6 weeks is still ineffective, discontinue the use of eltrombopag.
9682341|NCT04915482|Active Comparator|The best available therapy other than combined use of eltrombopag with rituximab|The best available therapy except for combined use of eltrombopag with rituximab includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists other than eltrombopag, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
10177312|NCT03823677|Experimental|hypoxia 15000ft group 30|Intervention: 30 minutes hypoxia
10177313|NCT03823677|Experimental|hypoxia 15000ft group 60|Intervention: 60 minutes hypoxia
10177314|NCT03823703|Experimental|Miricorilant- 900 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 900 mg miricorilant once daily for 12 weeks.
10177315|NCT03823703|Experimental|Miricorilant- 600 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 600 mg miricorilant plus placebo once daily for 12 weeks.
9682342|NCT04915521|Active Comparator|erector spinae plane block group|ESPB group received ultrasound-guided bupivacaine and lidocaine injection at T9 vertebral level before anesthesia induction.
9682343|NCT04915521|No Intervention|non block control group|Control group received 5 ml 0.5% bupivacaine injection to each trocar site (total of 25 ml) at the beginning of the operation.
9682344|NCT04915469|No Intervention|Pre-standardization group|Pre intervention- patient level data are abstracted retrospectively from the charts of patients with VL >1000 copies/ml on demographic characteristics and clinical outcomes and facility level data from summary forms for up to 24 months prior to the implementation of the standardized EAC package.
9682345|NCT04915469|Other|Post-standardization group|This group of participants will receive the standardized enhanced adherence package. After implementation of the standardized EAC package, data will be prospectively collected from participants with high viral load (>1000 copies).
9682346|NCT04915391||Group of controls|Control group of 40 patients with ≥1 bare metal stent which in a posterior catheterization performed by clinical follow-up had no restenosis
10177316|NCT03823703|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive placebo once daily for 12 weeks.
9682347|NCT04915391||Group of cases|Group of cases with 20 patients with ≥1 bare metal stent and 20 patients with ≥1 drug eluting stent which had restenosis in a posterior catheterization performed by clinical follow-up.
9682348|NCT04915443|Experimental|Periotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using H.ZEPF 26.182.13 & 26.182.11 periotome instrument.
9682349|NCT04915443|Experimental|Piezotome Group|An Atraumatic simple extraction procedure is done to teeth or roots with sound form indicated for simple extraction using SOLO LED PIEZOTOME Kit with ESSENTIAL tips from SATELEC ACTEON.
9682350|NCT04915781||Tobacco users|Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers. For FinSote 2018 and 2020, we will also compare never users of (1) smokeless tobacco (snus), (2) electronic cigarettes with and without nicotine or (3) nicotine replacement therapy products with respective former, occasional and daily users.
10177317|NCT03823872|Experimental|Overweight|Participants with BMI 25-29.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
9682351|NCT04915365|Experimental|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
9682352|NCT04915365|Placebo Comparator|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
9682353|NCT04915820|Active Comparator|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
9682354|NCT04915820|No Intervention|No iron treatment|no intravenous iron carboxymaltose before vaccination
10177318|NCT03823872|Experimental|Obese|Participants with BMI 29.9-34.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
10177319|NCT03823807|Experimental|SH-1028|QD,Oral
9682355|NCT04915222|Experimental|Natural apophyseal glides|This group receives natural apophyseal glides along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
9682356|NCT04915222|Active Comparator|Cervical manual traction|This group receives cervical manual traction along with conventional physical therapy and manual techniques as treatment for 3 sessions per week on alternate days for 3 weeks
9682357|NCT04915092|Experimental|Intervention group|The app is explained and installed during the recruitment to the family in the intervention group. Some families in this group will be selected to take part to the qualitative research.
9682358|NCT04915092|No Intervention|Control group|Every months during the first year of study a newsletter is sent only to the members of the control group.
10177320|NCT03823820||Cesarean section|Women attending for elective CS.
10177321|NCT03823820||Induction of labour|Women admitted for induction of labour and expected to stayed in hospital for more than 24 hours.
10177322|NCT03823820||pregnancy complication group|"Maternal condition that could affect body fluid including:~Pre-eclampsia requiring hospital admission.~Hyperemesis gravidarum.~Major postpartum haemorrhage."
10177323|NCT03823820||control|Gestational age matched controls.
10187327|NCT03727230|Other|"Asia type DEL recipients"|"To identify Asia type DEL patients by phenotyping and gentoyping methods in the Chinese recipients and then blood transfusion of D+ blood rather than the rare D negative blood to the identified Aisa type DEL recipients."
10187328|NCT03727217|Experimental|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative.
10187329|NCT03727204||Aarhus University Hospital|100 patients undergoing on-pump cardiac surgery at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
10187330|NCT03727204||Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand|50 patients undergpoing on-pump cardiac surgery at at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
10187331|NCT03727191|Active Comparator|Control Group|Nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity.
10187332|NCT03727191|Experimental|Experimental Group|Nutritional education and guidelines for the consumption of a completed shreded diet including: 2 packets of 90 grams every day (One salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month.
9682359|NCT04915417|Experimental|Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|10 Resectable PDAC patients will receive a hybrid PET/MRI before SABR and DCE-CT before SABR, 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
9695589|NCT04776655|Active Comparator|Cetuximab in combination with FOLFIRI chemotherapy|Cetuximab will be administered at a dose of 500 mg/m² iv every 2 week (14 days/cycle) Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
10187333|NCT03727165|Active Comparator|Continuous infusion|Patients with continuous infusion enteral nutrition in the intensive care unit at San Ignacio University Hospital
10187334|NCT03727165|Experimental|Cyclic infusion|Patients formulated with cyclic enteral nutrition infusion, administrated at night hours, from 4pm until 7am.
10177324|NCT03823963|Other|Standard care|pressure ulcer prevention standard care
10177325|NCT03823963|Experimental|standard care + Mepilex® Border|pressure ulcer prevention standard care + Mepilex® Border applied on sacrum
10177326|NCT03823898|Experimental|Supervised exercise|"Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants were involved in two supervised exercise sessions per week plus healthy lifestyle interactive sessions.~The experimental intervention consisted of: a) monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study; b) The supervised exercise sessions were prescribed using an aerobic mode performed at a moderate-to-vigorous intensity during 45 minutes, twice a week, preferably during the weekends."
10177327|NCT03823898|Active Comparator|Control Group|Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants received no intervention
9682360|NCT04915417|Experimental|Borderline Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|20 Borderline Resectable PDAC patients will receive a DCE-CT scan prior to neoadjuvant chemotherapy, a PET/MRI and DCE-CT after neoadjuvant chemotherapy and before SABR, DCE-CT at 6 hours after the first SABR fraction, and 4 weeks after the last fraction of SABR (before surgery)
9682361|NCT04915209|Other|Narrative interviews|Narratives are stories that are based on the unfolding of events or actions from the perspective of a patient's life experience. Patients and care partners tell their stories of illness and how they live with illness over time . The researcher could focus on the care priorities, the support needed, the information needed and the challenges faced. The narrative interview will be used to get an overview of the patient's trajectory.
9682362|NCT04915430|Active Comparator|Supervised training regimen|"This training regimen consisted of 3 phases: the 1st focused on restoring motion, the 2nd on strengthening of the rotator cuff muscles, and the 3rd on strengthening of the scapular muscles. Stretching completed every training session.~Motion training consisted of 6 exercises.~Postural training: shoulder shrugs and shoulder retraction exercises.~Glenohumeral training: pendulum exercises, and active assisted flexion, abduction and external rotation.~Strengthening of the rotator cuff: side lying external rotation, internal rotation and scaption.~Strengthening of the scapular muscles: press-up, push-up with a plus, serratus anterior supine punch, standing rowing (low row), and seated rowing (high row).~Training sessions ended with 4 stretches: anterior shoulder stretch, posterior shoulder stretch, inferior capsular stretch, sleepers stretch.~Exercises were performed 3 times a week, with progression after the 1st week, and thereafter every 2nd week."
9682363|NCT04915430|Active Comparator|Home training regimen|"The program consisted of the following:~1 motion exercise: upper trapezius relaxation~3 strengthening exercises: serratus anterior strengthening exercise, humeral external rotation with the arm at the side of the body, and humeral external rotation with a rubber band and the arm at 90 degrees abduction.~2 stretching exercises: posterior shoulder and pectoralis minor stretching, Exercises were performed daily, with weekly progression."
9682364|NCT04915105|Experimental|Prescreen on psoriasis and psoriatic arthritis treatment|Prescreen markers from individual PBMCs and choose proper biologics before starting treatment on psoriasis and psoriatic arthritis patients.
9682365|NCT04915079|Experimental|PRISM|Patients in this arm will be recipients of the PRISM intervention
9682366|NCT04915079|No Intervention|Usual Care|Patients in this arm will not receive the PRISM intervention, but will continue to receive usual care the discretion of their treating clinicians.
10177328|NCT03823898|Experimental|Monthly behavioral sessions|"Participants in this group received a lifestyle intervention from baseline to 4 months and then from 4 to 16 months participants were involved in non-supervised exercise group sessions with monthly behavioral sessions.~The experimental intervention consisted of monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study"
10177329|NCT03823794||Prevalent case of atopic dermatitis|People with atopic dermatitis meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
10177330|NCT03823794||Controls|Age, gender and primary care practice-matched controls without a diagnosis of atopic dermatitis or another exclusion condition (psoriasis, photodermatitis, or ichthyosis) and registered with one of the study practices for one or more years during the study period.
9682367|NCT04915261|Active Comparator|Strict Arm|"The strict arm group will be given the following restrictions. These restrictions are the current institutional protocol at the study site and falls within common practice pattern across Canada:~No arm or shoulder movement x 24 hours~No movement of affected arm overhead x 8 weeks~No lifting anything heavier than 5 lbs (2.5kg) and avoid any kind of sports or other vigorous activities including golf, tennis, swimming or sweeping x 8 weeks~Avoid any kind of shovelling x 8 weeks"
10177331|NCT03823729|Experimental|Elosan Cabin|Treatment with Elosan cabin
10177332|NCT03823729|No Intervention|No Treatment|Continuation of taking pain medication as prescribed before study start.
10177333|NCT03823495|Experimental|Experimental group|12-week PAP (one 1-hour session per week). Each session includes 20-minute exercise, 30-minute interactive pain management education, practices on non-drug management techniques, and portfolio entry for activities of the day.
10177334|NCT03823495|No Intervention|Control group|The control group will receive the usual care and a pain management pamphlet distributed by nursing home staff
10177335|NCT03823664||Type 2 Diabetic|"Fasting Plasma Glucose ≥126 mg/dL (7.0 mmol/L). OR * A1C ≥6.5% (48 mmol/mol). OR * Patients with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).OR* 2-h Plasma Glucose ≥200 mg/dL (11.1 mmol/L) during oral glucose tolerance test*~* American Diabetes As. (ADA) type 2 diabetes diagnosis criteria"
9682368|NCT04915261|Active Comparator|Lenient Arm|"The lenient arm restriction group will be given the following restrictions. The justification for the selected lenient restriction is based on the current recommendations at a Canadian center as identified by the national survey:~No shoveling 7 days,~No golfing/swimming/tennis 14 days~No other restrictions (overhead activity and weight lifting no limitation)"
9695590|NCT04776603||Group 1|group 1 includes patients who axial length(AL)<26mm
9682369|NCT04915287|Experimental|Avatrombopag|Oral administration of Avatrombopag Maleate Tablets to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whose mean baseline platelet count is less than 50 × 10^9/L. RhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc., are prohibited during the trial.
9682370|NCT04915287|Experimental|Conventional treatment|Conventional treatment (platelet transfusion if needed or rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.) to the thrombocytopenic patients with chronic liver disease undergoing an elective procedure whoes mean baseline platelet count is less than 50 × 10^9/L.
9682371|NCT04915196||Ferrous Sulphate|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Ferrous Sulphate for iron replacement
10177336|NCT03823664||Prediabetic|"Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (Impaired Fasting Glucose)* OR A1C 5.7-6.4% (39-47 mmol/mol)* OR 2-h Plasma Glucose during 75-g Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (Impaired Glucose Tolerance)*~* ADA prediabetes criteria"
10177337|NCT03823664||Healthy|Healthy glucose metabolism and according to endocrinology visit no health problems related or affect cardiorespiratory fitness and other parameters examined in this study.
10177338|NCT03823508|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (left dorsolateral prefrontal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
10177339|NCT03823508|Placebo Comparator|sham tDCS|Patients will receive sham tDCS (15 secondes of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
10177340|NCT03823950|Experimental|Receive G-CSF 72 hours following chemotherapy|"Children will be enrolled during the first four rounds of chemotherapy. Upon enrollment, children will receive G-CSF at 24 hours following chemotherapy. G-CSF will be discontinued when absolute neutrophil count (ANC) has increased post nadir in accord with G-CSF administration guidelines. Parents and children will then complete questionnaires to determine rates of side effects and needle distress at the end of G-CSF during their next regular outpatient oncology clinic visit.~Following children's next course of chemotherapy, G-CSF will be started 72 hours after completion of chemotherapy."
10177341|NCT03823950|No Intervention|Historical Controls|Four matched historical controls who received G-CSF at 24 hours following chemotherapy for each patient enrolled will be selected as each enrolled patient completes G-CSF therapy.
10177342|NCT03823599|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
10177343|NCT03823599|Active Comparator|control group|Alcohol brief intervention
10177344|NCT03823612|Experimental|GC tooth mousse|Drug: GC tooth mousse it contains complex of Casein Phosphopeptide,Amorphous Calcium Phosphate ( CPP-ACP ) other name: Tooth Mousse (Bio-available calcium and phosphate, without fluoride)
10177345|NCT03823612|Active Comparator|clinpro tooth creme|"it contains 0.21% Sodium Fluoride, Anti-Cavity Paste is an advanced formula containing an innovative tri-calcium phosphate ingredient~other name:0.21% w/w Sodium Fluoride Anti-Cavity Paste with Tri-Calcium Phosphate"
10177346|NCT03823638|Experimental|D-Mannitol|Oral Supplement of the investigated substance: D-Mannitol powder (manufacturer Roquette)
10177347|NCT03823638|Placebo Comparator|Placebo|Oral Supplement of the placebo: Dextrose monohydrate powder (manufacturer Roquette)
10177348|NCT03823352|Experimental|Antroquinonol|Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
10177349|NCT03823586||Children|
10177350|NCT03823586||Adolescents|
10177351|NCT03823313|Experimental|Spiritual Care Assessment and Intervention|
10177352|NCT03823560|Experimental|GROUP A: medical device Celegyn®|"Medical device Celegyn® presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
10177353|NCT03823560|Placebo Comparator|GROUP B: matching placebo|"Investigational Product (IP) placebo presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
10177354|NCT03823924||Psoriatic arthritis|
10177355|NCT03823924||Healthy volunteers|
10177356|NCT03823625|Experimental|ARM A: Nivolumab plus Ipilimumab|Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months. Platinum-based chemotherapy will be given up to 6 cycles.
9682372|NCT04915196||Liposomally-bound Iron|Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Liposomally-bound Iron for iron replacement
9682373|NCT04914832|Experimental|All individuals who register on the National Vaccination Registry|This will be open-label, single-arm implementation study in Eswatini. All individuals who register on the National Vaccination Registry will be eligible for enrolment. Participants will receive appointments for vaccination using the registry.
9682374|NCT04915040|Experimental|Behavioral Activation for Depression|
9682375|NCT04915326||Retrospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The first step will be a retrospective and exploratory analysis of FFPE slides retrieved from the pathology archives testing a panel of molecular marker exploring the immune reaction to the cancer (i.e. antigen presenting cells and T lymphocytes activation).
9695591|NCT04776603||Group 2|group 2 includes patients who axial length（AL）≥26mm
10177357|NCT03823625|Experimental|ARM B: Platinum-based chemotherapy plus Nivolumab|Platinum-based chemotherapy will be given up to 6 cycles. Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months.
10177358|NCT03823781|Experimental|milrinone|milrinone milrinone will be administered intravenously at a rate of 0.75ug/kg/min for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
10177359|NCT03823781|Placebo Comparator|normal saline|placebo placebo (normal saline) will be administered intravenously for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
10177360|NCT03823859||Healthy volunteers|"Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
10177361|NCT03823859||Patients with thyroid dysfunction|"Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism~Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
10177362|NCT03823339||Patients with type 2 diabetes (T2DM)|Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
9682376|NCT04915326||Prospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The second step will be a prospective and validating analysis. Tissue samples will be obtained from normal rectal mucosa adjacent to the cancer at the time of the trans anal or trans abdominal resection. In patients with early rectal cancer, the combination of immunological markers on healthy rectal mucosa adjacent to the cancer obtained in the part 1a of the study will be validated to identify the patients that will have not any nodal metastasis.
10177363|NCT03823417|Placebo Comparator|Normal saline placebo|the participant will get saline 0.9% intravenous infusion for the duration of the surgery
10177364|NCT03823417|Experimental|Intravenous Tranexamic acid|Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
10177365|NCT03823573|Experimental|Rapid recovery protocol|They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
10177366|NCT03823573|Active Comparator|Classic protocol|They will start walking 3 days after surgery. Levobupivacain 5 mg/ml will be placed in the femoral nerve. Tranexamic acid inside the knee. A Redon drain will be used.
10177367|NCT03823456|Experimental|True self-acupressure group|"True self-acupressure group [Enhanced standard care + True self-acupressure intervention protocol]:~Participants in this group will practice the four-week acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers."
10177368|NCT03823456|Placebo Comparator|Sham self-acupressure group|Patients in this group will practice the four weeks sham self-acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice sham acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers
10177369|NCT03823456|No Intervention|Enhanced standard care group|The standard care for cancer patients undergoing chemotherapy includes health assessment, regular health advice regarding symptoms that patients report and nutrition advice during taking chemotherapy treatment. Apart from the standard care, we provide participants a leaflet with 10 recommendations which help participants manage insomnia, depression, and anxiety. By providing this leaflet, we slightly enhance the standard care but do not contaminate the effective of the intervention since these tips are basic and participants can easily read about them on the internet or newspaper. In addition, to minimize the bias caused by contacting between interventionist and participants, we also provide participants in the enhanced standard care group weekly follow up phone call in four weeks.
9682377|NCT04915053|Experimental|ABG Black Garlic Extract|Daily intake of a 550 mg tablet, containing 250 mg of Black Garlic Extract and 300 mg of excipients.
9682378|NCT04915053|Placebo Comparator|Placebo|Daily intake of a 550 mg tablet, containing 250 mg of microcrystalline cellulose and 300 mg of excipients
9682379|NCT04915456|Experimental|Systemic steroid (Prednisolone)|Prednisolone 50mg (tapered down until postoperative day (POD) 14, then 5mg for 14 days), tablets
9682380|NCT04915456|Placebo Comparator|Placebo|Lactose monohydrate, tablets
9682381|NCT04914962|Active Comparator|monolithic glazedcrowns|glazed Celtra due crowns
9682382|NCT04914962|Experimental|monolithic polished crowns|polished Celtra due crowns
9682383|NCT04914884||intraocular inflammation group|
9682384|NCT04914884||Cataract patients group|
9682385|NCT04914923|Experimental|Cognitive Behaviour Therapy|This study arm will receive 12 weeks of cognitive behaviour therapy as an intervention.
9682386|NCT04914923|Experimental|Mindfulness-based Cognitive Therapy|This study arm will receive 12 weeks of a mindfulness-based cognitive therapy intervention, along with open mindfulness sessions via an EEG headset.
9682387|NCT04914923|No Intervention|Waitlist|This study arm will not receive an intervention for 12 weeks.
9682388|NCT04915170|Experimental|High intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
9682389|NCT04915170|Experimental|Low intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
9695592|NCT04776642||MARK_AF|MARKers of ATrial Remodeling in Patietns with Atrial Fibrillation. Patients with paroxysmal and persistent atrial fibrillation undergoing thoracoscopic atrial fibrillation ablation surgery
9976080|NCT01347918||control|Healthy controls
9976081|NCT01347918||IBS|Patients that fulfil the Rome III criteria for irritable bowel syndrome (IBS)
10177370|NCT03823079|Experimental|rhTPO arm|"rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
10177371|NCT03823079|Active Comparator|rhIL-11 arm|"rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
10177372|NCT03823183|Experimental|Multi-domain training|Group that receives cognitive training and physical training
10177373|NCT03823183|Experimental|Cognitive training|Group that receives cognitive training and physical control activity
9682390|NCT04914715|Experimental|Non-invasive High Frequency Oscillatory Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirefment more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option."
9682391|NCT04914715|Active Comparator|Conventional Invasive Ventilation|"Preterm babies (26-28 weeks) born with respiratory distress will be initially started on nCPAP with setting of flow 6-8 liter, PEEP 5-6, FiO2 21-40%. If fio2 requirement more than 40%, surfactant will be given in first 2 hours of birth. If baby fails on CPAP then will be switched to nHFOV with below mentioned settings.~Preterm born babies 28-34 weeks gestation with RDS, respiratory support will be started on Heated Humidified High Flow Oxygen therapy or nCPAP, if that fails then baby will be switched to invasive ventilation through endotracheal tube, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40."
10177374|NCT03823183|Experimental|Physical activity|Group that receives control cognitive activity and physical training
10177375|NCT03823183|Active Comparator|Active control|Group that receives cognitive control activity and physical control activity
10177376|NCT03823222|Experimental|Duckweed protein|20 gram of isolated protein
10177377|NCT03823222|Experimental|Whey protein|20 gram of isolated protein
10177378|NCT03823066|Experimental|Coach Pepper|Pepper is a humanoid socially assistive robot
10177379|NCT03823170|Experimental|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW (Therapy EC, DMC) will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
9682392|NCT04914754||Long COVID with severe exercise impairment|"Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue or exercise intolerance.~An abnormal response on 6 minute walk test including any one of:~Peripheral oxygen desaturation~< 85% predicted walk distance~Lactate rise> 1.0 from baseline~Borg score > 5 for breathlessness or fatigue at end of test"
9682393|NCT04914754||Long COVID with preserved exercise capacity|Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue.
9682394|NCT04914624|Placebo Comparator|Regular ACBT training|Including quitting smoking, ACBT training, cough practicing.
10177380|NCT03823170|Active Comparator|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish (Duraphat), with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
9682395|NCT04914624|Experimental|Positive expiratory pressure therapy|Use acpella®PEP therapeutic system and regular nursing care.
10177381|NCT03823170|Experimental|Laser therapy and fluorotherapy|The teeth will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
9682396|NCT04914624|Experimental|External diaphragm pacemaker|Patients are trained to use external diaphragm pacemaker and receive regular nursing care.
10177382|NCT03823209|Experimental|Social Network Approach|"Participants will receive brief HIV counseling at baseline visit.~Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.~All social network members will be asked about intervention exposure at 6- and 15-month followups."
10177383|NCT03823209|Active Comparator|Comparison|Participants will receive brief HIV counseling at baseline visit.
9682397|NCT04914910|Experimental|780G-780G|Participants will use MiniMed 780G system for 14 weeks + 14 weeks
9682398|NCT04914910|Placebo Comparator|Usual Care - 780G|Participants will continue with their usual insulin pump for 14 weeks. After completion of the first 14-week periode, they switch to 780G for another 14 weeks.
9682399|NCT04914936|Experimental|Part 1: ACP-196 and Calcium carbonate|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and a single oral dose of calcium carbonate 1 g tablet coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 2.
9682400|NCT04914936|Experimental|Part 2: ACP-196 and Omeprazole|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of omeprazole 40 mg capsules once daily (QD) for 5 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 5 of Period 2.
9976082|NCT01347957|Experimental|Nitric Oxide (NO) Gel|
9976083|NCT01347957|Placebo Comparator|Placebo Gel|
10177384|NCT03823261|Experimental|CBT|
9682401|NCT04914936|Experimental|Part 3: ACP-196 and Rifampin|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of rifampin 600 mg capsule QD for 9 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 and Day 9 of Period 2.
9682402|NCT04914806||Cases|Infants treated with iNO (from birth to 1-3 weeks of life) or sequential treatment with iNO and sildenafil (for 1 to 3 months).
10177385|NCT03823235|Experimental|Culture of human embryo in non-humidified incubator|Embryo culture after in vitro fertilization in incubator with no humidity
9527646|NCT03218293|No Intervention|Blank control group(BC)|Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
9682403|NCT04914806||Controls|Infants matched to cases (gestational/postnatal age, gender, disease state) and no iNO treatment.
9682404|NCT04914390|Experimental|Tislelizumab + Anlotinib + Chemotherapy|Participants receive Tislelizumab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + AT regimen (Q3W) x 6 cycles as neoadjuvant therapy prior to surgery.
9682405|NCT04914871|Experimental|The experimental protocol UN Lifeguard Kids in the Tunja version|Group to which the experimental protocol will be offered.
9682406|NCT04914871|Placebo Comparator|Educational session, accident prevention and wound management.|The control group will be offered the Educational session.
9682407|NCT04914572|Experimental|Therapeutic rainforest & MIndful walking|The first arm uses mindful walking through a 2km forest trail in Singapore. All Interventional and Control arms will conduct their walk between 8 am to 11 am for five occasions weekly. At the T1, participants will attend a Zoom orientation session to familiarize themselves with the route. During this session, participants will need to answer the self-report questionnaire and provide the first saliva sample for the baseline measurement. In T2, a pre-intervention and post-intervention saliva sample will be taken before the walk. This will follow by T3 the following week. At T4, participants will attend a 60 mins reflection session and answer the self-report questionnaire. On T5 and T6, the participants will continue with the therapeutic rainforest mindfulness walk. On T7, a pre-intervention and post-intervention saliva sample will be taken. On T8, participants will attend a 60 mins reflection session and answer the self-report questionnaire.
9682408|NCT04914572|Experimental|Therapeutic rainforest walk|The second arm of the intervention includes walking through a guided forest trail suggested by NParks Board. The collection of samples and answering of the self-report questionnaire will follow the same sequence as the 1st arm of the 3-arm RCT.
9682409|NCT04914572|Active Comparator|Campus green walk|The control for this study includes guided casual walking around the campus green trial conducted at the same intervals as per the interventions. The collection of samples and answering of the self-report questionnaire will also follow the same sequence as the 1 arm of the 3-arm RCT.
9682410|NCT04914481||Classical Low-Flow, Low-Gradient Aortic Stenosis|Classical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction <50% and stroke volume index (SVi) ≤35 mL/m2 by resting transthoracic echocardiography. Dobutamine stress echocardiography is not mandatory for the definition of classical LFLG AS. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
9682411|NCT04914481||Paradoxical Low-Flow, Low-Gradient Aortic Stenosis|Paradoxical Low-Flow, Low-Gradient Aortic Stenosis is defined as valve area <1 cm2, mean gradient <40 mmHg, ejection fraction ≥50% and SVi ≤35 mL/m2 by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI and have available data on aortic valve calcification.
9682412|NCT04914481||High-Gradient Aortic Stenosis (Control group)|High-Gradient Aortic Stenosis is defined as valve area <1 cm2 and mean gradient >40 mmHg by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI. Data on aortic valve calcification is not mandatory for this control group.
9682413|NCT04914481||Conservative treatment (Control group)|The subgroup includes all patients with (severe or non-severe) aortic stenosis, who underwent conservative treatment. Data on aortic valve calcification is not mandatory for this control group.
9682414|NCT04914468||TMVR|Patients undergoing Transcatheter Mitral Valce Replacement (TMVR)
9682415|NCT04914468||TEER|Patients undergoing mitral Transcatheter Edge-to-Edge Repair (TEER) after screening for TMVR
9682416|NCT04914468||Surgery|Patients undergoing mitral valve surgery (repair or replacement) after screening for TMVR
9682417|NCT04914468||Medical therapy|Patients undergoing medical therapy after screening for TMVR
9682418|NCT04914455||Fluid responsiveness groups (responders and non-responders)|Fluid responsiveness is defined as an increase in stroke volume of 10% and more form baseline.
9682419|NCT04914325|Experimental|Intervention arm :copings veneered with CAD/CAM composite resin|
9682420|NCT04914325|Active Comparator|Control arm : copings veneered with manual layering|
9682421|NCT04914533|Experimental|Intervention Arm|Luminance Red Treatment Arm
9682422|NCT04914598|Active Comparator|ENDOSTAR combined with cisplatin|
9682423|NCT04914598|Placebo Comparator|Placebo combined with cisplatin|
9682424|NCT04914845|Active Comparator|De-escalation Cohort; 20mg|For the purposes of dose escalation decisions, a standard 3+3 dose escalation design will be used.The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg. If the MTD is exceeded at cohort 1, de-escalation to cohort 0 (20 mg) will occur. If the MTD is not exceeded in cohort 1, dose escalation will continue based on a standard 3+3 design at the dose levels.
9976084|NCT01347996|Experimental|histamine dihydrochloride and IL-2|histamine and IL-2 subcutaneous injections
9976085|NCT01348009|Experimental|Tesetaxel-capecitabine-cisplatin|
10177386|NCT03823235|No Intervention|Culture of human embryo in humidified incubator|Embryo culture after in vitro fertilization in incubator with humidity
10177387|NCT03823482|Experimental|Lidocaine group|Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.
10177388|NCT03823482|No Intervention|Control group|Participants in control group will have general anesthesia without lidocaine administration.
9682425|NCT04914845|Active Comparator|Cohort 1; 30 mg|The initial cohort, Cohort 1, will consist of 3 enrolled patients who will be treated at 30 mg.
9682426|NCT04914845|Active Comparator|Cohort 2; 40mg|Dose escalation to 40 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
10177389|NCT03823053|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 30 minutes. The content of the physiotherapy program; posture, interscapular muscle strengthening, stretching and lateral flexion exercises are formed.
10177390|NCT03823053|Experimental|Training Group|"In addition to home based traditional scoliosis exercise, the training group will also receive core stabilization exercise training for 8 weeks, 5 days a week, for 30 minutes. Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and latissimus dorsi."
10177391|NCT03823040|Active Comparator|Tinox® group|Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
10177392|NCT03823040|Experimental|Oxiconazole nitrate SLNs loaded gel group|13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
10177393|NCT03823105|Experimental|Nocturnal Recording|Recording of photoplethysmographic pulse wave and accelerometry with two devices (OHR Tracker, PulseWatch) in parallel to the standard polysomnography
10177394|NCT03823118|Experimental|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
10177395|NCT03823196|Experimental|Verum900|The arm will receive 900 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
10177396|NCT03823196|Experimental|Verum1800|The arm will receive 1800 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
10177397|NCT03823092||Normal|phakic participants with no evidence of eye disorders
10177398|NCT03823092||Cataract|participants with cataract
10177399|NCT03823092||AMD|participants with age related macular degeneration
10177400|NCT03823092||Pseudophakic|particpiants who have had cataract surgery with intraocular lens implant
10177401|NCT03823092||other macula|participants with macular ddisorders other than AMD
10177402|NCT03823092||DR|participants with diabetic retinopathy
10177403|NCT03823248|Experimental|MoLuoDan and Sanchi powder group|Experiment group: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day, + oral administration of Folic Acid Tablet simulation half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
10177404|NCT03823248|Active Comparator|Folic Acid Tablet group|Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
10177405|NCT03822988||patients accepting to answer to the survey|patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
10177406|NCT03822975|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during primary PCI
10177407|NCT03822975|Active Comparator|Heparin|Heparin alone during primary PCI
10177408|NCT03822910||Healthy Controls|Matched Healthy Controls
10177409|NCT03822910||Firt Episode Psychosis (FEP)|subjects before and after antipsychotic treatment
10177410|NCT03822923|Experimental|Experimental group|Neurodynamics (Dynamic Neural Mobilization) with conventional treatment (stretching, AROM) will be applied.
10177411|NCT03822923|Active Comparator|control group|Conventional treatment (stretching, AROM) will be applied
10177412|NCT03822936|Experimental|Preoperatory chemoradiation therapy with carbon ions|Chemoradiation followed by surgery
10177413|NCT03822819|Experimental|probiotic cocktail capsules uptake|Participants take two capsules of probiotic cocktail everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
10177414|NCT03822819|Placebo Comparator|placebo capsules uptake|Participants take two capsules of placebo everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
10177415|NCT03822702|No Intervention|1st part:System development of Adult|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
9682427|NCT04914845|Active Comparator|Cohort 3; 60mg|Dose escalation to 60 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
9682428|NCT04914845|Active Comparator|Cohort 4; 80mg|Dose escalation to 80 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
9682429|NCT04914845|Active Comparator|Cohort 5; 100mg|Dose escalation to 100 mg after initial cohort (Cohort 1) after a minimum of 1 cycle of treatment, defined as receiving ≥75% of KPT-9274 doses during Cycle 1 (e.g., ≥9 of 12 doses in the 3 doses/week schedule), or have a DLT within the first cycle of treatment to be evaluable for dose escalation decisions.
10177416|NCT03822702|No Intervention|1st part:System development of Child|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
10177417|NCT03822702|No Intervention|2nd part:Handwriting Difficulty|No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour with sensors on the hand. A handwriting screening questionnaire shall be filled.
10177418|NCT03822702|Experimental|3rd part: Biofeedback Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Biofeedback Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
10177419|NCT03822702|Experimental|3rd part: Motor Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Motor Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
10177420|NCT03822702|No Intervention|3rd part:Control Group|"No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~The same procedure will be ask to do again about one and a half month later."
10177421|NCT03823027|Experimental|Single-arm|The device will be taken before three daily main meals togteher with water. The dose will be escalated from 1g per main meal to the full dose of 3g per main meal. The device is provided in foil stick-packs packed in boxes with weekly supply. The treatment is for 12 weeks.
10177422|NCT03822962|Other|Standard Tylenol Regimen|"Patient will be given a standard regimen:~Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed."
9682430|NCT04914364||Patients who have tested positive for COVID-19|
10177423|NCT03822962|Active Comparator|Ibuprofen 600mg|Tylenol 1000 mg by mouth every 6 hours scheduled and ibuprofen 600 mg tablet by mouth every 8 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
10177424|NCT03822728|No Intervention|Without 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), the patients will undergo surgery without 3D-DESS MRI (currently routine practice).
9682431|NCT04914689|Active Comparator|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
9682432|NCT04914689|Experimental|Visual external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
9682433|NCT04914689|Experimental|Auditory external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving auditory feedback of their movement patterns.
9682434|NCT04914078||Mepolizumab treated patients|Severe eosinophil severe asthmatic patients treated with anti IL-5 monoclonal antibody Mepolizumab
9682435|NCT04914104|Experimental|Intervention|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
9682436|NCT04914104|No Intervention|Control|The control group will receive standard of care, which does not involve routine in-person or free access to mobile mindfulness therapy.
9682437|NCT04914143|Experimental|Experimental group|
10177425|NCT03822728|Experimental|With 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), preoperative 3D-DESS MRI will be additionally performed to delineate the intra-parotid facial nerve.
10177426|NCT03822624|Experimental|Probiotic group|
10177427|NCT03822624|Placebo Comparator|Placebo group|
9682438|NCT04914143|Placebo Comparator|placebo comparator group|
9682439|NCT04914559|Active Comparator|Oral Nutrition Supplement Control|The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
9682440|NCT04914559|Active Comparator|Oral Nutrition Supplement Test|The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
9682441|NCT04914156|Experimental|Personalised, genetic-based advice for sport performance|This group will receive personalised nutrition advice for sports performance based on their genetic test results and tailored to their current dietary intake.
9682442|NCT04914156|Active Comparator|Personalised nutrition advice for sport performance based on population-based evidence|This group will receive personalised nutrition advice on key nutrients relating to sports performance based on current best practice, population-based sport nutrition guidelines. These will be tailored to their current dietary intake
9682443|NCT04914039||CTA examination|CTA examination group for suspected brain death
9682444|NCT04914039||Confirmed|Confirmed group for brain death
9682445|NCT04913974||Uni-condylar knee arthroplasty|A cohort of patients who will undergo uni-condylar knee replacement surgery with the Univation X system and have biomechanical anaylsis
9682446|NCT04913987|Experimental|Total knee|Standard care
9682447|NCT04913987|Experimental|Partial knee|Intervention using relatively new partial knee.
9682448|NCT04914169||Indoor cycling training|8 subjects were asked to complete indoor cycling training, 3 times a week for 4 weeks. Each session of training consisted of 30-minute stationary biking (5 minutes of warm-up, 20 minutes of training and 5 minutes of cooldown).
9682449|NCT04914273|Experimental|Sequence A: 1. Ingestion 2. Inhalation|Group A is treated in the following sequence: 1. oral drug 2. inhalative drug
9682450|NCT04914273|Experimental|Sequence B: 1. Inhalation 2. Ingestion|Group B is treated in the following sequence: 1. inhalative drug 2. oral drug
9976086|NCT01348022||Xience V stent|unprotected Left Main Coronary Artery stenting treated with Xience V stent
9977633|NCT01363648|Placebo Comparator|placebo (for choline alfoscerate )|placebo tablet, 3 times a day, for 12 weeks.
10177428|NCT03822598|Experimental|Intervention group|Teaching Recovery Techniques implemented 1- 3 weeks after recruitment
9682451|NCT04914052||Study group|"Patients will be requested to sign an informed consent in which they will agree to have their face filmed in the post-anesthesia care unit.~The facial expressions will be filmed in 30 second segments. A pain assessment will be measured immediately following filming of each segment using two modalities:~Pain score assessed by an attending anesthesiologist assigned to the study team.~VAS assessment by the patient. Following data collection, the data will be forwarded in a coded manner, according to Clalit's data security regulations, to Third Eye systems a facial recognition software company.~Third Eye systems will analyze and process the data using AI and machine learning models and develop an algorithm that can predict pain level by watching facial expressions."
9682452|NCT04914299|Experimental|A novel mobile-App based intervention|"An App-based positive intelligence intervention consisting of 6 weeks of weekly videos and support group sessions, and 6 weeks of daily App-guided practices."
10177429|NCT03822598|Active Comparator|Wait-list control group|Delayed implementation of Teaching Recovery Techniques (after the experimental group has completed the program)
10177430|NCT03822754|Experimental|Experimental Group|sIPV-bOPV-bOPV vaccination schedule
10177431|NCT03822754|Active Comparator|Control Group|wIPV-bOPV-bOPV vaccination schedule
10177432|NCT03822715|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
10177433|NCT03822806|Experimental|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise (using the videogame JustDance) for the first 30 minutes of those 2 hours using the video game (continuing to wear the patch for 90 minutes after exercise).
10177434|NCT03822676|Experimental|Stent|Prophylactic pancreatic stent before segmental pancreatic surgery
10177435|NCT03822676|No Intervention|No stent|No prophylactic stent before surgery
10177436|NCT03822663|Experimental|Caffeine supplementation|Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
9682453|NCT04914299|Active Comparator|Standard of Care|Standard prenatal care and follow up
9682454|NCT04914338|Experimental|Supportive care (MDT-intervention)|Patients participate in the MDT-intervention including access to a HCT physician, a geriatrician, physical or occupational therapist, dietician, and a social worker for three months before HCT and up to 100 days after HCT.
9682455|NCT04914130||Older HIV-positive cohort (n=500)|"documented HIV infection~age >50 years at study entry~Korean ethnicity~likely route of HIV acquisition via sexual exposure by male to male exposure~able to comprehend study patient information leaflet.~Virologically suppressed subjects Subjects with primary HIV infection are eligible and investigators are encouraged to recruit such subjects. Our target population (those infected with HIV via sexual routes of men who have sex with men) has been chosen as this group represent the vast majority of older HIV-positive individuals attending for care in Korea; analyses of other groups (e.g. injection drug users, those infected through blood/blood products and transgender individuals), who may have very different needs and outcomes, would likely be under-powered."
9682456|NCT04914130||Younger HIV-positive cohort (n=250)|"documented HIV infection~age <50 at study entry*~Korean ethnicity~likely route of HIV acquisition via sexual exposure by male to male exposure~able to comprehend study patient information leaflet * this group will comprise of at least 70 subjects in each of the following age groups: 20-29, 30-39, 40-49 years. Recruitment will be monitored by the Study Monitoring Team"
9682457|NCT04914130||HIV-negative cohort (n=250)|"documented negative HIV test at screening~age >50 years at study entry~Korean ethnicity~self reported sexual preferences of men who have sex with men~To enroll matched control, we will try to match age, sexual orientation, and participating clinic."
9682458|NCT04913792||ZXR00|The ZXR00 group included 30 patients bilaterally implanted with the Tecnis Symfony IOL (Abbott Medical Optics, Inc.)
9695593|NCT04776642||INDICO AF|Atrial Fibrillation in Patients With an Implantable Cardioverter Defibrillator and Coronary Artery Disease. Investigate the incidence of new-onset AF in patients with coronairy artery disease and an impaired LVEF, who will receive a single chamber ICD as primary prevention for sudden cardiac death.
10177437|NCT03822663|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo.
10177438|NCT03822689|Active Comparator|Gas flow:2L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
10177439|NCT03822689|Active Comparator|Gas flow:5L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
10177440|NCT03822767|Experimental|Experimental Group|sIPV-sIPV-bOPV vaccination schedule
10177441|NCT03822767|Active Comparator|Control Group|wIPV-wIPV-bOPV vaccination schedule
10177442|NCT03822949|Experimental|Experimental: Exposed to Day light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.
10187335|NCT03727126|Experimental|Robotic esophagectomy|Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system
10187336|NCT03727126|Active Comparator|Thoracolaparoscopic esophagectomy|Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques
10187337|NCT03727113||Control cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
9976087|NCT01348035||Water Load Group|Water load group: 2.5 ~ 3 L water intake daily for 12 months (50ml/Kg body weight/day). When large amount water intake is not sustainable, patients can reduce the amount of water intake to the levels as much as large he or she can sustain.
9682459|NCT04913857|Experimental|24-week SUDOKU Training Programme|"The SUDOKU training program include a 12-week face-to-face training session and a 12-week facilitated self-practice. The 12-week (60-minute sessions) training program will be evenly divided into 3 modules of increasing difficulty for the suboptimal cognitive function of the participants with MCI. As the use of T-code in solving the SUDOKU allows communicating the way a number is assigned to a box, participants are grouped into a small team of 3, so that they will work together during the tutorial practice.~Facilitated self-practice will last for another 12 weeks immediately after the group training session. The instructor will give them a workbook with 12 SUDOKU puzzles of increasing level of difficulty for completion. The instructor will encourage and facilitate their accomplishment by giving them guidance on the taught method through regular phone call. Solutions of the assigned puzzle and the T-code will be provided in the following week."
9682460|NCT04913857|Active Comparator|wait-list|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
9682461|NCT04913844||Skiers group|"The skiers group was formed from licensed ski athletes (17 male, 17 female) who have been active in sports for at least the last 2 years.~There will be no interventions. Physical performance tests and observational assessments will be conducted."
9682462|NCT04913844||Control group|"The control group was composed of non-athletic and age-matched participants (17 male, 17 female) with no skiing experience.~There will be no interventions. Physical performance tests and observational assessments will be conducted as in the Skiers Group."
9682463|NCT04913818|Experimental|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40 minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements in order to achieve a feeling of 'somewhat hard' at the Borg RPE rating of 12-14. The training session will end with a 10-minute cool down exercise session.
9682464|NCT04913818|Active Comparator|Usual Care|Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
9682465|NCT04914221|Experimental|Group I|Period I- comparator / Period II- comparator / Period III-JLP-2002
9682466|NCT04914221|Experimental|Group II|Period I- comparator / Period II- -JLP-2002 / Period III- comparator
9682467|NCT04914221|Experimental|Group III|Period I- JLP-2002/ Period II- comparator / Period III- comparator
9682468|NCT04913740|No Intervention|Control group|health care workers who did not use any preventive measures on the basis of tertiary protection
9695594|NCT04776642||PREDICT AF|PREDICT AF, Tissue, Blood and biomarkers to predict future Atrial Fibrillation. Patients without a history of atrial fibrillation undergoing cardiothoracic surgery
9976088|NCT01348035||Non-Water Loaded Group|Non-water load group: The patients are free to access water intake, as they like.
9976089|NCT01348048|Experimental|Specialised palliative care (SPC) group|Patients continue with their standard treatment (typically they receive treatment in one or more hospitals departments and from their GP). In addition, they are offered a consultation in the SPC out-patient clinic (or at home if the patient cannot attend the hospital) as soon as possible and no more than one week after randomization. If possible, each patient will have at least two contacts to the SPC in the trial period.
10177443|NCT03822949|Sham Comparator|Sham Comparator: Exposed to Room light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.
10177444|NCT03822611|Experimental|Targeted Subsidy|In these communities, households identified as vulnerable receive a voucher for a free latrine sub-structure (slab + pit lining), redeemable with local sanitation suppliers.
10177445|NCT03822611|No Intervention|No subsidy|In these communities, no household receives a voucher.
10177446|NCT03822559|Experimental|DE-111A eye drops|
10177447|NCT03822559|Active Comparator|0.0015% tafluprost eye drops|
10177448|NCT03822845|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET/CT scan
10177449|NCT03822546|Experimental|Conventional cigarette|The subject's preferred brand of commercially available conventional cigarette
10177450|NCT03822546|Active Comparator|myblu 25 mg freebase|myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
10177451|NCT03822546|Active Comparator|myblu 16 mg nicotine salt|myblu pod-system containing 16 mg nicotine salt tobacco flavour
10177452|NCT03822546|Active Comparator|myblu 25 mg nicotine salt|myblu pod-system containing 25 mg nicotine salt tobacco flavour
10177453|NCT03822546|Active Comparator|myblu 40 mg nicotine salt|myblu pod-system containing 40 mg nicotine salt tobacco flavour
10177454|NCT03822546|Active Comparator|blu PRO 48 mg nicotine salt|blu PRO open-system containing 48 mg nicotine salt tobacco flavour
10177455|NCT03822585|Other|Close Relatives Of β-thalassemia|Laboratory diagnostic tests as (CBC, Iron Study, Serum Ferritin, HPLC, Genetic study) will be done to Brothers, Sisters & Cousins of β-thalassemia Children With Microcytic Hypochromic Anemia Attending Assiut University Child Hospital
10177456|NCT03822481|Experimental|Experimental|Participants in this arm were given the MCD. The MCD is a mindful eating intervention aimed at facilitating weight loss and cultivating a present centred awareness. The MCD consists of ten questions that an individual must consider while eating. Participants were required to consider the questions while eating (no writing required). Participants were asked to use the MCD at their three main meals (breakfast, lunch, dinner). The
9682469|NCT04913740|Experimental|Experimental group|"On the basis of three-level protection, skin correlation prevention is carried out:~pay attention to the protection of exposed skin, so that it is local dry.~Do a good job of facial moisturizing work before workuse moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~After work, avoid using irritantsto clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
9682470|NCT04913896||Single Group Assignment|Patients with AGC who underwent neoadjuvant immunotherapy and/or chemotherapy would recieve MRI and CT examination before and after 3 cycles treatment.
9682471|NCT04913909|Active Comparator|Dentoblis™ group|In Probiotic group; Dentoblis™, as a test lozenge, contains 4 billion CFU/g S. salivarius M18 strain probiotic isolated from a healthy oral microbiota, has been utilized one lozenge a day for 30 days.
9682472|NCT04913909|Placebo Comparator|Placebo group|The placebo was indistinguishable in form, size, color, smell and taste from the probiotic lozenge, but contained no bacteria and utilized one lozenge a day for 30 days . Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code.
9682473|NCT04913714|Active Comparator|Intervention|A district where the radio intervention will be broadcast.
9682474|NCT04913714|No Intervention|Control|A district where the radio intervention will not be broadcast.
9682475|NCT04913545||normal group|participants with out any systemic medical problemes or oral lesions. we will only take saliva sample.
9682476|NCT04913545||potientially malignant group|participants with suspicious oral lesions without any medical diseases. we will take saliva sample and take a biopsy sample .
9682477|NCT04913545||malignant group|participants with already diagnosed oral malignant lesions without receiving any treatment yett
9976090|NCT01348048|No Intervention|Standard care group|Patients continue with their standard treatment. They are instructed to contact either their GP or their hospital department if they feel that additional treatment or care is needed.
9976091|NCT01348061||Elderly Healthy Control (EHV)|No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.
9976092|NCT01348061||Progressive Supranuclear Palsy (PSP)|A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.
10177457|NCT03822481|No Intervention|Control|Participants in this arm were required to eat as normal and were not given the MCD until the study was complete.
9976093|NCT01348061||Alzheimer's Disease (AD)|A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.
9976094|NCT01348074|Experimental|Double dose|Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.
10177458|NCT03822429||women < 35 years old|
10177459|NCT03822429||women between 36 and 38 years old|
10177460|NCT03822429||women between 39 and 40 years|
10177461|NCT03822429||women > 41 years old|
10177462|NCT03822533|Other|Physiotherapist as primary assessor|"The healthcare process will be started with a physiotherapist assessment and treatment. Treatments could involve individual or group treatment including patient education and physical exercise.~Patients can seek a physician anytime after the first assessment with the physiotherapist."
9976095|NCT01348074|No Intervention|Usual maintenance dose|Usual maintenance dose from Day 1, i.e. no postoperative loading dose.
9976096|NCT01348113|Experimental|Brief Alcohol Intervention|
9976097|NCT01348113|No Intervention|No intervention|
9976098|NCT01348126|Active Comparator|Single agent docetaxel|
10177463|NCT03822533|Other|Physician as primary assessor|"The Healthcare process will be started with a physician assessment and treatment. Treatments could involve drug prescription, referral to x-ray, referral to other healthcare providers and sick-leave.~Patients can seek a physiotherapist anytime after the first assessment with the physician."
9682478|NCT04913558|Active Comparator|Traditional Treatment Arm|This group will consist of thirty employed lactating women suffering from stress and fatigue. This group will receive the same lifestyle modification advice that will be given to the aerobic exercise group during the six weeks of the program period.
9682479|NCT04913558|Experimental|Aerobic exercise group|This group will consist of thirty employed lactating women suffering from stress and fatigue. These women will perform aerobic exercise for 30 minutes for each session, 5 times per week, for 6 weeks in the form of treadmill training (60- 70% of HR max) and do some modifications of their routine by following lifestyle modification advice given to them during the 6 weeks of the program period.
9682480|NCT04913935||TMC OA|women who were diagnosed with TMC OA
9682481|NCT04913935||Control|healty volunteer women
9695595|NCT04776642||WEIGHTLOSS AF|The change of adipose tissue characteristics upon drastic weight loss: Implications for atrial fibrillation.
9976099|NCT01348126|Experimental|Combination of ganetespib and docetaxel|
9976100|NCT01346462|Experimental|PaCT|The Patient-Centered Transition Arm
9976101|NCT01346462|No Intervention|Control|Control group patients will receive routine care from the admitting hospital, including routine patient management, and discharge planning.
9976102|NCT01348178||developmental dysplasia of the hip, PAO|All patients who underwent periacetabular osteotomy from 1999-2007 at the University Hospital of Aarhus
9977634|NCT01363687|Experimental|Remote ischemic postconditioning group|Recipients receive remote ischemic postconditioning after declamping of renal artery during kidney transplantation
9682482|NCT04913779|Active Comparator|Anti-SARS-CoV-2|Administration of 10 ml of a concentrated equine hyperimmune serum solution with neutralizing activity of SARS-CoV-2 not less than1/5120, administered in slow intravenous infusion (10 ml diluted in100 ml of physiological solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
9682483|NCT04913779|Placebo Comparator|Placebo|Administration of 10 ml of a control-solution with no-neutralizing activity of SARS-CoV-2, administered in slow intravenous infusion (10ml diluted in 100 ml of physiological solution, administered over 50 to60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0when incorporated into the study -initial dose- and at 48 hours -second dose-).
10177464|NCT03822494|Experimental|Dose Escalated CyberKnife SBRT|
9682484|NCT04913662|Experimental|PIPAC Paclitaxel with FOLFOX|PIPAC (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
10177465|NCT03822273|Experimental|Traditional acupuncture (TA)|The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
9682485|NCT04913831|Experimental|Cerebrolysin|
9682486|NCT04913831|Placebo Comparator|Placebo|
9682487|NCT04913701||1 - Health workers|A total number of 200-300 healthcare workers, exposed to close contact with patients, will be asked to participate to the study and will be asked to sign the informed consent.
9682488|NCT04913701||2 - Patients|A total number of 100-200 patients admitted to the rehabilitation facility, referred from other healthcare facilities or from their own home, will be asked to participate to the study.
9682489|NCT04913701||3 - Real life participants|A total number of 100 real-life participants, will be represented by volunteers (other employees, staff not in contact with patients
10177466|NCT03822273|Active Comparator|Laser acupuncture (LA)|The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
10177467|NCT03822273|Placebo Comparator|Sham laser acupuncture (SLA)|The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
10177468|NCT03822403|Active Comparator|EQUIA|EQUIA Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
9682490|NCT04913727|Experimental|Treatment Arm|Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.
9682491|NCT04913610|Experimental|Part 1: Arm A|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
9682492|NCT04913610|Experimental|Part 1: Arm B|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by ABBV-4083 for 7 days.
9682493|NCT04913610|Experimental|Part 1: Arm C|Participants will receive ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
9682494|NCT04913610|Experimental|Part 1: Arm D|Participants will receive ABBV-4083 + albendazole for 3 days followed by ABBV-4083 + placebo for albendazole for 4 days followed by placebo for ABBV-4083 for 7 days.
9682495|NCT04913610|Experimental|Part 1: Arm E|Participants will receive placebo for ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
10177469|NCT03822403|Active Comparator|Gradia Direct Posterior|Gradia Direct Posterior The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
9682496|NCT04913610|Experimental|Part 2: Arm K|Participants will receive active regimen from Part 1 followed by ivermectin at Month 6.
9682497|NCT04913610|Experimental|Part 2: Arm L|Participants will receive active regimen from Part 1 followed by placebo for ivermectin at Month 6.
9682498|NCT04913610|Experimental|Part 2: Arm M|Participants will receive active regimen from Part 1 followed by placebo for ivermectin or matching placebo at Month 6.
9682499|NCT04913610|Experimental|Part 2: Arm N|"Scenario 1: Participants will receive placebo for ABBV-4083 + placebo for albendazole followed by ivermectin at Month 6.~Scenario 2: Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for appropriate duration followed by ivermectin or matching placebo at Month 6."
10177470|NCT03822572|Experimental|A - endurance exercise|All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan. The individual pulse-controlled endurance exercise should be performed 3 times a week. On the basis of age, weight, sex and body fat the normal weight will be calculated. The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight. The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise. Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
10177471|NCT03822572|Other|B - control arm|Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
9682500|NCT04913688||suspected DVT group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, the patients become eligible for study subjects.
9695596|NCT04776642||MAD AF|(123I-mIBG And Defibrillation for Atrial Fibrillation) Enhanced sympathetic activity as a mechanism of Atrial Fibrillation. Patients will undergo 123I-mIBG scintigraphy within 7 days before and six week after an elective cardioversion is performed.
9695597|NCT04776642||Adapt Biobank - AF surgery|Patients with Atrial Fibrillation who only donate blood and tissue for the biobank. Patients undergo thorascopic surgery, LAA will be amputated, blood will be collected.
9695598|NCT04776642||Adapt Biobank - blood|Patients with cardiac arrhythmias who only donate blood for the ADAPT biobank.
9695599|NCT04776486|Experimental|Critically ill patients with augmented renal clearance|ICU patients with estimated renal clearance over 130ml/min/1.73m2
9695600|NCT04776538|Experimental|Stem cell group|60 patients will be randomized to receive adipose-derived allogeneic stem cells
9682501|NCT04913506|Active Comparator|Group Mirror|Along with conventional rehabilitation techniques, patients will be given ROM exercises in all directions, in front of the real mirror, by the practitioner on the healthy upper extremity for 30 minutes.
10177472|NCT03822143|Experimental|Fetus anemia diagnosis|Diagnosis of anemia in the fetus through use of ultrasound data collection
10177473|NCT03822156||Cavitary Pulmonary Tuberculosis|The patients who are diagnosed with the cavitary pulmonary tuberculosis
10177474|NCT03822156||Endobronchial Tuberculosis|The patients who are diagnosed with the endobronchial tuberculosis
10177475|NCT03822286|Experimental|Intervention|E-training course programs, counseling mentoring supports and support group gatherings meeting.
10177476|NCT03822286|Active Comparator|Control|Traditional classroom teaching course programs.
10177477|NCT03822247|Experimental|Multidisciplinary Recovery Program|"Two cohorts of patients will randomly be placed in either experimental od no intervention group.~Patients undergoing Multidisciplinary Recovery After Surgery Program will gain better preparation for early mobilization after surgery, nutritional support, individually modified analgesia and psychological support during inpatient treatment. Program includes preoperative, intraoperative and postoperative multidisciplinary comprehensive interventions."
10177478|NCT03822247|No Intervention|Conventional Perioperative Care|Patients undergoing conventional care
10177479|NCT03822299|No Intervention|Placebo|Patients receive suspension of their own feces.
10177480|NCT03822299|Active Comparator|30 g donor dose|Patients receiving 30 g of a healthy donor feces.
10177481|NCT03822299|Active Comparator|60 g donor dose|Patients receiving 60 g of a healthy donor feces.
10177482|NCT03822234|Experimental|Modified ileal conduit|With our modified ileal conduit technique
10177483|NCT03822234|No Intervention|Conventional ileal conduit|Conventional ileal conduit
10177484|NCT03822208|Active Comparator|AL003 by intravenous (IV) infusion|Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort
10177485|NCT03822208|Placebo Comparator|Placebo by intravenous (IV) infusion|Matching saline solution will be administered for placebo subjects
9682502|NCT04913506|Active Comparator|Group NMES|Along with conventional rehabilitation techniques, NMES will be applied to the hemiplegic arm for 30 minutes by the practitioner while the patients are sitting in a chair.
9682503|NCT04913506|Active Comparator|Group Mirror+NMES|In addition to conventional rehabilitation techniques, patients will be given ROM exercises for 30 minutes in all directions in front of the real mirror to the healthy extremity, which the practitioner will synchronize with visual or auditory stimuli, and NMES treatment for 30 minutes to the paretic upper extremity.
10177486|NCT03822455|Active Comparator|OligoG DPI|Active DPI containing the oligosaccharide OligoG and excipients
9682504|NCT04913753|Experimental|No systematic CBEU|Patients will not have bacterial culture performed before double J removal.
9682505|NCT04913753|Active Comparator|Systematic CBEU|Patients will have a systematic urine culture performed before double J removal.
9682506|NCT04913480|Experimental|Durvalumab and stereotactic body radiation therapy|"Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles, starting 1 week before commencement of stereotactic body radiation therapy~Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days"
9682507|NCT04913766|Active Comparator|Services as usual|Persons screening positive for depression will be referred from community-based organizations. The referrals will be made to mental health specialists who will provide care based on their standard of care.
9682508|NCT04913766|Experimental|Problem Management Plus|Persons screening positive for depression will be offered Problem Management Plus delivered by community based organization staff.
9682509|NCT04913428|Experimental|Interdigital exercise group|"Interdigital exercises:~12 repetitions in 3 sets of 4 repetitions~Conventional Physical Therapy:~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
9682510|NCT04913428|Active Comparator|Blow-Bottle technique group|"Blow-Bottle technique:~12 repetitions in 3 sets of 4 repetitions~Conventional Physical Therapy:~Incentive spirometer 3 - 4 times a day, Percussion twice a day, Mobilization of the patient Total session given was for 20 -30 minutes"
9682511|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in cemented THA|
9682512|NCT04913623||Correlation of intramedullary pressure and systemic inflammatory parameters in non cemented THA|
9695601|NCT04776538|Placebo Comparator|Placebo group|60 patients will receive placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
10177487|NCT03822455|Placebo Comparator|Placebo DPI|Placebo DPI containing lactose and excipients
10177488|NCT03822195||asymptomatic|asymptomatic patients undergoing carotid endoarterectomy for stenosis >70% (velocimetric criteria at echodoppler)
10177489|NCT03822195||symptomatic|symptomatic (TIA, crescendo TIA, minor stroke) patients undergoing carotid endoarterectomy, independently from stenosis evaluated by echodoppler
10177490|NCT03822260||Sur1/ Trpm 4 acitivities at SAH|only after collecting sample,
9527647|NCT03218319|Experimental|All patients|
10177491|NCT03822520|Experimental|Celecoxib, Moxifloxacin, Water in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day"
10177492|NCT03822520|Experimental|Celecoxib, Water, Moxifloxacin in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day"
10177493|NCT03822520|Experimental|Moxifloxacin, Water, Celecoxib in order|"Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
10187338|NCT03727113||Optimization cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
10177494|NCT03822520|Experimental|Water, Moxifloxacin, Celecoxib in order|"Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
10177495|NCT03822364|Experimental|A-1 (009-1 -> active comparator)|Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)
10177496|NCT03822364|Experimental|A-2 (active comparator -> 009-1)|Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)
10177497|NCT03822364|Experimental|B-1a (009-2)|Part B, Arm 1 (Inhaled apomorphine, Dose 2)
9977635|NCT01363687|No Intervention|Control group|Patients who have a deflated cuff placed on the upper limb free of arteriovenous fistula during the surgery
10177498|NCT03822364|Placebo Comparator|B-1p (009-0)|Part B, Arm 1 (Inhaled placebo)
9682513|NCT04913649|Experimental|Intravenous iron (ferric derisomaltose)|The intervention consists of a single dose of ferric derisomaltose (Monofer®) 100 mg/mL solution for infusion (Monofer® is a registered product with a marketing authorization in the Netherlands (RVG number: 103070). Manufacturer: Pharmacosmos A/S, Denmark. Dutch marketing authorization holder: Cablon Medical B.V). The method of administration and dosage of the investigational medication are standard treatment. The ferric derisomaltose dose will calculated for each patient depending on body weight (20mg/kg) and diluted in 250 ml NaCl 0.9%. Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
10177499|NCT03822364|Active Comparator|B-2a (009-3)|Part B, Arm 2 (Inhaled apomorphine, Dose 3)
10177500|NCT03822364|Placebo Comparator|B-2p (009-0)|Part B, Arm 2 (Inhaled placebo)
9682514|NCT04913649|Placebo Comparator|Placebo|Single dose of sodium chloride 0.9% (250ml). Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
9682515|NCT04913454|Experimental|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks).
10177501|NCT03822364|Experimental|B-3a (009-4)|Part B, Arm 3 (Inhaled apomorphine, Dose 4)
9682516|NCT04913454|Active Comparator|Cognitive training only|Cognitive training only (1 hour per day, per 5 days/week, for a total of 8 weeks).
9682517|NCT04913571|Experimental|TMB High group|
10177502|NCT03822364|Placebo Comparator|B-3p (009-0)|Part B, Arm 3 (Inhaled placebo)
10177503|NCT03822364|Experimental|C-1a (009-3)|Part C, Arm 1 (Inhaled apomorphine, Dose 3)
9682518|NCT04913571|Experimental|PD-L1 positive group|
9682519|NCT04913571|Experimental|Immunomodulatory (IM) group|
9682520|NCT04913571|Experimental|NanoString superiority group|
9682521|NCT04913571|Experimental|other types|
9682522|NCT04913532|Experimental|Hypofractionation with SIB|Hypofractionation with SIB
10177504|NCT03822364|Placebo Comparator|C-1p (009-0)|Part C, Arm 1 (Inhaled placebo)
10177505|NCT03822364|Experimental|C-2a (009-4)|Part C, Arm 2 (Inhaled apomorphine, Dose 4)
10177506|NCT03822364|Placebo Comparator|C-2p (009-0)|Part C, Arm 2 (Inhaled placebo)
10177507|NCT03822364|Experimental|C-3a (009-5)|Part C, Arm 3 (Inhaled apomorphine, Dose 5)
10177508|NCT03822364|Placebo Comparator|C-3p (009-0)|Part C, Arm 3 (Inhaled placebo)
10177509|NCT03822221|Experimental|SK20º|MVIC and NMES with hip at 85º and knee at 20º
10177510|NCT03822221|Experimental|SK60º|MVIC and NMES with hip at 85º and knee at 60º
9682523|NCT04913597||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and avatrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 14 days as initial treatment. After initial treatment, maintenance therapy were performance. At initial therapy, rhTPO will be suspended when platelet counts ≥100×10^9 / L. During maintenance therapy, patients with platelet counts >150×10^9 / L will suspend treatment until platelet counts drop to ≤150×10^9 / L. Dosing interval will be prolonged when platelet count is ≥100×10^9 / L to ≤150×10^9 / L. Dose modification is not required when platelet count is ≥30×10^9 / L to <100×10^9 / L. The efficacy, safety, and patient/physician preference will be assessed.
9695602|NCT04776616|Sham Comparator|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
9695603|NCT04776616|Experimental|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
9977636|NCT01363726||2|Jewish and Bedouin children < 5 years of age in southern Israel
10177511|NCT03822221|Experimental|LK20º|MVIC and NMES with hip at 0º and knee at 20º
10177512|NCT03822221|Experimental|LK60º|MVIC and NMES with hip at 0º and knee at 60º
10177513|NCT03822052|Active Comparator|Primiparous Patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
10177514|NCT03822052|Active Comparator|Primiparous Patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
10177515|NCT03822052|Active Comparator|Multiparous patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
10177516|NCT03822052|Active Comparator|Multiparous patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
10177517|NCT03822130|Placebo Comparator|Group 1|Systemic Chemotherapy + Oral Chemotherapy Group
10177518|NCT03822130|Experimental|Group 2|Arterial catheter infusion chemotherapy plus oral chemotherapy group
10177519|NCT03822130|Experimental|Group 3|Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group
10177520|NCT03822091|Active Comparator|TERLIPRESSIN GROUP|
10177521|NCT03822091|Experimental|TERLIPRESSIN WITH NORADRENALINE GROUP|
10177522|NCT03822065|Experimental|Sequence 1: LY03005 Fed Crossover to Fasted|Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.
10177523|NCT03822065|Experimental|Sequence 2: LY03005 Fasted Crossover to Fed|Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.
10177524|NCT03822312|Experimental|DBT-TOBI|"Subjects will be imaged using DBT-TOBI at the time points indicated in the Study Calendar (Baseline, before cycle 2, and additional optional time points).~Both breasts will be measured in turn.~Each breast is symmetrically centered on the x-ray detector/optical illuminator and is first compressed according to standard mammography procedures to determine the amount of force needed for each given patient~An optional Magnetic Resonance Imaging TOBI (MRI-TOBI) scan will also be performed."
10177525|NCT03822338|Experimental|Pneumoperitoneum preconditioning group|Participant assigned to the this group will receive a treatment consisting of three cycles of 5 min insufflation (intra-abdominal pressure at 15 mmHg) and 5 min desufflation, after complete anesthesia and successfully implanting the veress.
10177526|NCT03822338|Sham Comparator|Control group|Participants in the control group will receive the same placement of the veress but without insufﬂation and subsequent desufﬂation.
9682524|NCT04913597||Avatrombopag group|Patients who fail previous steroids and rh-TPO and then switch to avatrombopag will be enrolled. The reason for switch will be recorded. Patients will be given avatrombopag 20mg once daily as initiate treatment, and adjust the dosage according to the count of platelets. The maximum dose of avatrombopag is 40mg daily.Avatrombopag will be terminated any time the platelet counts increased above 250×10^9/L. Dose adjustment of avatrombopag will be allowed to maintain platelet counts between 30×10^9/L and 150×10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
10177527|NCT03822026|Other|patients with severe TBI|Patients with severe TBI enrolled in the study undergo an hyperventilation test, in which the alveolar ventilation is increased by a stepwise increase in tidal volumes and respiratory rate until a reduction of etCO2 of 0.7 kPa is achieved.
10177528|NCT03822169|Experimental|Choline added as a phospholipid|A shake with phospholipid-bound choline (and bound DHA),
10177529|NCT03822169|Active Comparator|Choline added as a salt|control shake with choline added as a salt and added DHA.
10177530|NCT03822000||Elderly Patients with Femoral Fracture|Elderly patients with fall-induced femoral fracture. Patients were categorized into two groups: death (n = 42) and survival (n = 2,365).
10177531|NCT03821961|Experimental|Metabolic surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
10187339|NCT03727100|Active Comparator|Clonidine Micropellets|single dose injection into the lumbar epidural space
10187340|NCT03727100|Sham Comparator|Sham Control|non-epidural needle placement
10187341|NCT03727087||Melanoma|Subjects with clinically confirmed melanoma or high suspicion of a primary malignancy of melanoma based on skin exam or imaging and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
10187342|NCT03727074|Experimental|5-FU Cream|topical cream
9682525|NCT04913922|Experimental|Combination therapy|"5-azacitidine 75 mg/m2 body surface area s.c. for 7 days nivolumab 480mg i.v. day 1 relatlimab 80-160mg i.v. day 1~repeat day 28"
9682526|NCT04913389|Active Comparator|Acetazolamide|Acetazolamide (oral capsules)
9682527|NCT04913389|Placebo Comparator|Placebo|Placebo (oral capsules)
9682528|NCT04913298|Other|Cytosorb therapy|blood samples are taken before and after the cytokine adsorber at given times
9682529|NCT04913376|Experimental|Hilotherapy|
9682530|NCT04913376|No Intervention|Standard care|
9682531|NCT04913363|Experimental|Walking|This contemplative activity will see users taken to a local green space area near their center and encouraged to walk around the space. It is anticipated walks will last around 15-20 minutes.
10187343|NCT03727074|Active Comparator|Efudex®|topical cream
10187344|NCT03727074|Placebo Comparator|Vehicle|topical cream
10187345|NCT03727048|Active Comparator|Control|To the control group post ankle fracture surgery, per subject 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
10187346|NCT03727048|Experimental|Intervention|To the treatment group post ankle fracture surgery, per subject 30mg of IV ketorolac intraoperatively; 20 tablets of 10mg ketorolac with instructions to take every 6 hours, and 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
10187347|NCT03727035||Group I|Group I :40 Generalized chronic periodontitis subjects without type II diabetes mellitus
10187348|NCT03727035||Group II|Group II: 40 Generalized chronic periodontitis subjects diagnosed with type II diabetes mellitus
10187349|NCT03727009||Hematologic Malignancy|Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
10187350|NCT03726983|Experimental|eHMP experimental group|"The experimental group received health management support and counseling,including:~GDM health care knowledge~self-awareness of health~self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)~participation in discussions or browsing forums~healthy lifestyle guidance and counseling~reminder systems~a token system of earning points in exchange for prizes."
10187351|NCT03726983|No Intervention|Control group|only received usual care
10187352|NCT03726970|Experimental|Tube Potential difference|Different kVp values of the CBCT machine 70, 80 ,90 kVp
10187353|NCT03726970|Experimental|MAR tool|MAR option in the software off and on
10187354|NCT03726944|Other|Group 1 - Meditation1+Meditation2|8 weeks in total; 4 weeks of unnamed consumer-based meditation app + 4 weeks of Calm meditation app
10187355|NCT03726944|Other|Group 2 - Meditation2+Meditation1|8 weeks in total; 4 weeks of Calm meditation app + 4 weeks of unnamed consumer-based meditation app
10187356|NCT03726944|Other|Group 3 - Control+Meditation1|8 weeks in total; 4 weeks of educational control + 4 weeks of unnamed consumer-based meditation app
9527648|NCT03218306|Experimental|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
9682532|NCT04913363|Experimental|Citizen Science|This cerebral activity sees users engage with local green spaces, under the instruction of a citizen scientist, to learn about the intricacies of the space. This may include lichen counts (or similar) where the main outcome is learning based.
9682533|NCT04913363|Experimental|Planting|This physical activity will see users, lead by a local Master Gardener, engage with planting vegetables/fruit in raised beds. Not only will this allow users a chance to engage physically with nature, but it is anticipated that the grown produce will be used for center users.
9682534|NCT04913350|Experimental|Russian current and elbow support group|participants in the experimental group will apply elbow support and will receive Russian current on biceps and triceps muscles of the unaffected elbow three therapy sessions per week for 4 weeks.
9682535|NCT04913350|Active Comparator|elbow support group|Participants in this group will apply elbow support only.
9682536|NCT04913090|Experimental|Part A-experimental|Single Ascending Dose (SAD) phase
9682537|NCT04913090|Placebo Comparator|Part A-placebo|Single Ascending Dose (SAD) phase
9682538|NCT04913090|Experimental|Part B-experimental|multiple ascending dose (MAD) phase
9682539|NCT04913090|Placebo Comparator|Part B-placebo|multiple ascending dose (MAD) phase
9682540|NCT04913090|Experimental|Part C1-experimental|Food Effect (FE) phase
9682541|NCT04913090|Experimental|Part C2-experimental|Food Effect (FE) phase
9682542|NCT04913181||Sepsis prediction model|This group of people was used for the clinician's decision, and the sepsis prediction model was used simultaneously for the prediction, but the model was not involved in the decision, and was only used for verification
10177532|NCT03821987|Experimental|BFCA regimen|"Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."
10177533|NCT03821909||Pancreatic cancer|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology.
10177534|NCT03821909||Benign pancreatic diseases|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology, e.g. PCLs.
10177535|NCT03821974|Experimental|dry group|The sequence of the technique of the puncture is dry-wet-dry-wet.
10177536|NCT03821974|Experimental|wet group|The sequence of the technique of the puncture is wet-dry-wet-dry.
10177537|NCT03821831||Continuous Positive Airway Pressure|This group consists of consenting patients and their parents who choose Continuous Positive Airway Pressure (CPAP). The CPAP is a type of therapy that applies mild air pressure to a person's upper airway to keep their airway open so that they can breathe normally while they sleep.
10177538|NCT03821831||Orthodontic Intervention|This group consists of consenting patients and their parents who choose orthodontic intervention will be seen by participating orthodontists who will determine types of orthodontic intervention; mandibular advancement devices or rapid maxillary expansion devices. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
10177539|NCT03821831||Control|This group consists of consenting patients and their parents who choose to remain untreated. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
10177540|NCT03821792|Experimental|Treatment (abiraterone acetate, prednisone, apalutamide)|Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
10177541|NCT03821922||pregnancy-induced pregnancy|Those women (subjects) with pregnancy-induced pregnancy.
10177542|NCT03821922||Control|Those healthy pregnant women
10177543|NCT03821649|Experimental|SOONER Training and Naloxone Kit|Participants in this arm will be shown the SOONER overdose response training video at the time of recruitment and given the SOONER Naloxone kit to take home.
10177544|NCT03821649|Active Comparator|Community or Hospital-Based Training|Control arm - participants in this arm will be referred to the standard of care for Naloxone training. This standard of care includes community-based OEND programs and/or an existing hospital-based OEND program..
10187357|NCT03726944|Other|Group 4 - Control+Meditation2|8 weeks in total; 4 weeks of educational control + 4 weeks of Calm meditation app
10187358|NCT03726931|Experimental|[18F]FES|All patients will receive an additional PET/CT scan: [18F]FES PET/CT scan.
10187359|NCT03726918||Osteoarthritis|Surgery for implantation of a prosthesis in case of Osteoarthritis
10187360|NCT03726918||Non Osteoarthritis|Surgery for implantation of a prosthesis fon non Osteoarthritis cases
9527649|NCT03218306|Active Comparator|Clinical Guided Analgesia|No SPI guidance
9682543|NCT04913181||Daily clinical judgment of doctors|This group of people was used for the clinician's decision without sepsis prediction model.
9682544|NCT04913402||Consultation|Patient who were administered sufentanil in acute trauma by paramedics after phone call consultation with medical doctor.
9682545|NCT04913402||Competency|Patient who were administered sufentanil in acute trauma by paramedics with competence to administer sufentanil without any consultation with medical doctor.
9682546|NCT04912986|Placebo Comparator|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
9682547|NCT04912986|Experimental|Experimental group|The intervention was implemented in accordance with the Early Lung Rehabilitation Training Programme for Adult Double Lung Transplant Patients
9682548|NCT04913103|Experimental|single arm, open-label|combination of polatuzumab-vedotin, bendamustine and rituximab
9682549|NCT04913155|Other|Reporting group (coronary calcium score and emphysema score)|Coronary calcium score and emphysema score are reported to subjects
9682550|NCT04913155|Other|Reporting group (coronary calcium score only)|Only coronary calcium score is reported to subjects
9682551|NCT04913155|Other|Reporting group (emphysema score only)|Only emphysema score is reported to subjects
9682552|NCT04913155|Other|Non-reporting group|Coronary calcium score and emphysema score are not reported to subjects
9682553|NCT04913155|No Intervention|Low-risk group|No CT screening, collection of health data only
9682554|NCT04913142||control|patients not suffering from COVID-19 hospitalized in intensive care unit
9682555|NCT04913142||patients COVID-19|patients suffering from COVID-19 hospitalized in intensive care unit
9682556|NCT04913038||case group|children over 2 years of age and prepubescent ventilated and sedated in pediatric intensive care.
10177545|NCT03821662|Experimental|OT Diabetes Self-Management Intervention|The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
9682557|NCT04912934||MetS diagnosis|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The MetS group for the research included individuals with metabolic syndrome diagnosis according to IDF-2005 diagnostic criteria.
9682558|NCT04912934||non-MetS|The research included individuals aged 18 years and older, who were not pregnant or breastfeeding, without any psychological disorder diagnosed by psychiatry, without diagnosis of COVID-19 and not using any psychiatric medications. The non MetS group in the research included healthy individuals not using any psychiatric medications, without any chronic disorder, and with similar BMI to the individuals in the subject group.
9682559|NCT04913077|Other|Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
10177546|NCT03821701|Experimental|Newly diagnosed HFrEF ARNI|Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
10177547|NCT03821701|Active Comparator|Newly diagnosed HFrEF ACEI/ARB|Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
9682560|NCT04913168|Experimental|Control Group|Control Group; no intervention
10177548|NCT03821701|Experimental|Prior diagnosed HFrEF ARNI|Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
10177549|NCT03821701|Active Comparator|Prior diagnosed HFrEF ACEI/ARB|Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
10177550|NCT03821896|Experimental|Conversation Cards for Adolescents and Goal-Setting|Adolescents in the experimental arm will receive the tool 15 minutes prior to their appointment with their primary care provider. They will be instructed to familiarize themselves with the tool and to select the top 3 factors that resonate most with them in their attemps to change their lifestyle habits. They will then proceed to their clinical appointment to set one S.M.A.R.T. goal based on their selections and in collaboration with their primary care provider.
9682561|NCT04913168|Experimental|Intervention Group|Intervention Group; receives 13 month intervention
9682562|NCT04913207|Sham Comparator|Traditional echo-fluoroscopy guided group|LAA angiography is performed with a 6F pigtail catheter in LAA at the view of RAO 30°, CAU 20° and RAO 30°, CRA 20°. Next, the outline of the LAA will be drawn on the screen according to the LAA angiography. LAmbre device size selection is based on diameters of LAA ostium and landing zone measured on LAA angiography. The process of device implantation, assessment, releasing will be carried out at RAO 30°, CAU 20°. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
9682563|NCT04913207|Experimental|3D-CTA guided group|Patients in 3D-CTA based perimeter group will undergo CCTA examination before LAAO and a 3D model of the left atrium is reconstructed by a workstation. LAmbre device size selection is based on perimeters of LAA ostium and landing zone which are obtained by the measurement method shown previously in this protocol. After transseptal puncture, LAA angiography is performed with a 6F pigtail catheter in LAA at the tangent angle view which is obtained preoperatively by 3D-CCTA. Then, the outline of the LAA will be drawn on the screen according to the LAA angiography. The process of device implantation, assessment, releasing will be carried out at this tangent angle view. TEE is used to check whether the residual peri-device leaks is less than 5mm. The device will be released if it passes the 'COST' standard; otherwise readjusting the implantation position, change the device size and even re-puncturing transseptal to achieve a better axis will be proceeded.
9682564|NCT04913194|Experimental|Immediate Treatment|Participants in this arm will receive the intervention within 2 weeks of completing the intake session.
10177551|NCT03821896|Active Comparator|Goal-Setting|Adolescents in the control arm will not complete the tool activity, but will still set a S.M.A.R.T. goal with their primary care provider.
10177552|NCT03821623|Experimental|Nicotinamide riboside|Subjects will take 500 mg of the vitamin B3-precursor, nicotinamide riboside (NIAGEN) twice per day (1,000 mg per day total) for 3 months.
10177553|NCT03821623|Placebo Comparator|Placebo|Subjects will take placebo pills twice a day for 3 months.
9682565|NCT04913194|Other|Waitlist Control|Participants in this arm will not receive any intervention for two weeks. Participants will complete the treatment after 4-6 weeks of being on the waitlist after their intake session.
9682566|NCT04913324|Experimental|Virtual Care|
10177554|NCT03821753||Case|Patients with glycemic variability, defined by a coefficient of variation (CV)> 36%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)
9682567|NCT04913324|No Intervention|Standard of Care|
10177555|NCT03821753||Control|Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)
9682568|NCT04913259|Other|Remote monitoring for elderly patients with cancer|
9977637|NCT01363752|Active Comparator|Advagraf + MMF + Steroids|Without sirolimus
9682569|NCT04913311||Observational (biospecimen collection, standard treatment)|Patients undergo collection of blood, stool and saliva samples at baseline. Patients receive standard of care treatment consisting of concurrent chemoradiation from baseline up to week 62 and immune checkpoint inhibitors from week 10-62. Patients also undergo the collection of blood, stool, saliva and BAL samples at week 10. During the course of treatment, patients also complete routine tests and procedures to monitor for side effects per standard of care including CT within 4 weeks, lung function tests including home spirometry TIW from week 10-62, bronchoscopy and/or a nasal wash to check for viral infection. Patients also complete questionnaires about symptoms and quality of life QW for weeks 1-9, BIW during weeks 5-54, and once a month until week 62.
9682570|NCT04912622|Experimental|Control|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
10177556|NCT03821714|Experimental|Glucocorticoid combination therapy Group|Hydrocortisone 200mg continuous intravenous infusion(24h) combined with vitamin C1.5g intravenous infusion every 6 hours and vitamin B1 200mg intravenous infusion every 12 hours.
10177557|NCT03821714|Active Comparator|Glucocorticoid Group|Hydrocortisone 200mg continuous intravenous infusion(24h)
9682571|NCT04912622|Experimental|Patient|Device: Cellularis version 2.0 imaging Image acquisition of retinal pigment epithelium (RPE) cells of central retina with consecutive qualitative and quantitative description of these retinal cell layers.
10177558|NCT03821779|Experimental|Group 1: Go-no-go phase|"The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners.~Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery).~Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study."
10177559|NCT03821779|Experimental|Group 2.1|"In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~real exposure: oral presentation to a panel of examiners~virtual reality : oral presentation to virtual examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
9682572|NCT04912700||Unvaccinated|Unvaccinated individuals are defined as having positive laboratory COVID-19 testing with no record of immunization against COVID-19 or first-dose vaccination after symptom onset.
10177560|NCT03821779|Experimental|Group 2.2|"In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~virtual reality : oral presentation to virtual examiners~real exposure: oral presentation to a panel of examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
9682573|NCT04912700||Partially vaccinated|Partially vaccinated individuals are defined as having positive laboratory COVID-19 testing and symptom onset after a single dose of either mRNA (Pfizer, Moderna) vaccine, or < 14 days after the second dose of either mRNA vaccine (Pfizer, Moderna) or < 14 days after the administration of the single dose of viral vector vaccine (Johnson & Johnson).
9682574|NCT04912700||Fully vaccinated|Fully vaccinated individuals are defined as having positive laboratory testing for COVID-19 and symptom onset >14 days since administration of second dose of either mRNA vaccine, or >14 days since administration of viral vector vaccine (Johnson & Johnson).
9682575|NCT04912895|Experimental|SARS-CoV-2 Positive|Participants who test positive for SARS-CoV-2 with the Polymerase Chain Reaction (PCR) test.
10177561|NCT03821428|Experimental|Acupuncture|Needling of acupoints P6 and CV24 with indwelling permanent needles, withdrawn after TEE procedure
10177562|NCT03821428|Placebo Comparator|Control|Application of Placebo needles in the areas of P6 and CV24 acupoints
10177563|NCT03821805|Experimental|Foot reflexology massage group|The duration of intervention was 30 min (15 min massage duration for each leg)
10177564|NCT03821805|No Intervention|Control group|Rest for 30 min
10177565|NCT03821480|Experimental|Fluconazole 50 mg, Manufacturer: Amboise|Test drug
10177566|NCT03821480|Active Comparator|Fluconazole 50mg, Manufacturer:West Ryde|Reference drug
10177567|NCT03821441|Experimental|bOPV(Candy)|"bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
10177568|NCT03821441|Experimental|bOPV(Liquid)|"bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )"
10177569|NCT03821441|Experimental|bOPV（liquid）|bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50，type1 polio virus≥6.0 lgCCID50，type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)
9682576|NCT04912895|Active Comparator|Non-COVID-19 Acute Respiratory Illness|Participants who have an acute respiratory illness other than SARS-CoV-2 infection.
9682577|NCT04912895|Other|Healthy Controls|Participants without any acute respiratory illness.
9682578|NCT04912817|Experimental|Off the Shelf VR (PR-VR program + usual care)|"One session per week x 4 weeks; total 4 sessions over 1 month~PR-VR program (30 min) + Usual care (30 min SVPT)~Total intervention time = 4 hours~10 selected for post-study telephone interview"
9977638|NCT01363752|Experimental|Advagraf + MMF + Steroids + Sirolimus|With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28
10177570|NCT03821636|Sham Comparator|Standard Roux-en-Y|
9682579|NCT04912817|Experimental|Custom VR (Modified PR-VR program + usual care)|"One session per week x 4 weeks; total 4 sessions over 1 month~Mod PR-VR program (30 min) + Usual care (30 min SVPT)~Total intervention time = 4 hours~10 selected for post-study telephone interview"
9682580|NCT04912817|No Intervention|Standard Virtual Physiotherapy Treatment (control; usual care),|"One session per week x 4 weeks; total 4 sessions over 1 month~Usual care (60 min SVPT)~Total intervention time = 4 hours"
9682581|NCT04912778||Persons who had a covid-19 infection.|Male and female adults who were previously infected with covid-19.
9682582|NCT04912765|Experimental|Neoantigen Dendritic Cell Vaccine and Nivolumab|"NA DC vaccine every 2 weeks at a dose of 3-5 million cells.~Adjuvant nivolumab every 2 weeks at 240mg when given concurrently with the vaccine; every 4 weeks at 480mg after vaccine treatment is completed for a total duration of 1 year."
9682583|NCT04912752|Other|Case-Control|Copy number variation
9682584|NCT04912752|Experimental|Case-Control 1|Gene expression
9682585|NCT04912635|No Intervention|Control|
9682586|NCT04912635|Experimental|Intervention|
10177571|NCT03821636|Active Comparator|Long alimentary limb Roux-en-Y|
10177572|NCT03821324|Other|Intervention|Device: Venus Viva
10177573|NCT03821532|No Intervention|Control group|Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
10177574|NCT03821532|Experimental|Experimental group|Each family will receive a randomized packet containing educational information, rewards charts, an adult literacy test and a constipation action plan tool. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms, adherence to the treatment plan, and action plan utility.
10177575|NCT03821766||Heart failure|Patients suffering from heart failure regardless to the etiology will undergo cardiac catheterization according to their medical condition. the SCG and BCG signals will be recorded along with the intracavitary pressure profiles detected invasively with the cardiac catheterization.
10177576|NCT03821350|No Intervention|Control Group|The control group was given verbal information
10177577|NCT03821350|Experimental|Leaflet Group|The second group was given verbal information and a detailed information leaflet with written and visual content
10177578|NCT03821597|Experimental|Sequential compression devices|Sequential compression devices (SCDs) are applied during surgery.
10177579|NCT03821597|Active Comparator|No sequential compression devices|No sequential compression devices are applied.
9976103|NCT01348191||Elective caesarean section|"Population: ten pregnant women, scheduled for elective caesarean section with a term pregnancy ( > 37 weeks).~Inclusion criteria~Elective caesarean section~Term pregnancy > 37 weeks~Age > 18 years~Exclusion criteria~Previous caesarean scar~Gestational age < 37 weeks~Maternal temperature > 37.8 degrees Celsius~Meconium stained liquor~Foetal distress~Maternal diabetes~Seropositivity~Use of thyroid medication~Maternal thyroid disease~Age < 18 years"
9976104|NCT01348204|Experimental|quercetin|health food supplement
10177580|NCT03821415|Experimental|1 - RP101 0.05%|RP101 0.05% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
10177581|NCT03821415|Experimental|2 - RP101 0.1% / Placebo|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye in the morning (q.d.) followed by one drop of placebo each eye in the evening for 90 consecutive days
10177582|NCT03821415|Experimental|3 - RP101 0.1%|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
10177583|NCT03821415|Placebo Comparator|4 - Placebo|RP101 matching placebo, ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
10177584|NCT03821155|Active Comparator|Neuritis vestibularis (group 1)|"Corticosteroid (prednisolone)"
10177585|NCT03821155|Experimental|Neuritis vestibularis (group 2)|"Corticosteroid (prednisolone) + vestibular rehabilitation"
10177586|NCT03821454|Experimental|Capecitabine|The experimental group received oral capecitabine for eight cycles.
10177587|NCT03821454|Placebo Comparator|Placebo|The placebo group received oral placebo for eight cycles.
10177588|NCT03821181|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
10177589|NCT03821181|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
10177590|NCT03821142|Experimental|Calistar S|Single arm cohort trial
10187361|NCT03726905|Experimental|respiratory muscles training|4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
9682588|NCT04912726|Experimental|Intervention|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
9682589|NCT04912726|No Intervention|Placebo|The control group will receive placebo at the same loading dose and infusion with 0.9% saline solution plus standard management under the unit protocol immediately after the echocardiographic diagnosis.
10177591|NCT03821493|Experimental|PF-06651600 treatment arm|This arm includes two treatment periods. Period 1-Single oral dose of PF-06651600 30 mg as tablets on Day 1 followed by Period 2 in which itraconazole 200 mg (oral solution) is given for 5 days. On Day 4 of Period 2, a single oral dose of PF-06651600 30 mg is given with itraconazole
10177592|NCT03821168|Active Comparator|intravitreal injection of bevacizumab and erythropoietin|erythropoietin:
10177593|NCT03821168|Active Comparator|intravitreal injection of bevacizumab|bevacizumab:1.25 mg
10177594|NCT03821818||Control|Food Allergen Elimination only
10177595|NCT03821818||Allergen Elimination + Willis Exercise|Subjects will have food allergens eliminated and also perform Aerobic-surge, brief high intensity exercise > 75% max HR), five times/day.
10177596|NCT03820999|Experimental|Teaching arm|The Primary Health Care physicians getting oral and written information on tick-bites and Lyme disease with focus on Lyme neuroborreliosis.
10177597|NCT03820999|No Intervention|Passive arm|The Primary Health Care physicians that does not get contacted with an offer to receive oral and written information.
9682590|NCT04912713|Active Comparator|Arm 1|This group will be randomly immersed in ice water (2°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the arithmetic task of counting backwards from the number 2043 as quickly and accurately as they can. Each time they make a mistake in the mental task, they will be given negative feedback and must start again from the number 2043. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively.
9682591|NCT04912713|Active Comparator|Arm 2|This group will not be falsely recorded or evaluated. They will be randomly immersed in warm water (35-37°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the simple counting task, in which they will have to count consecutively from 1 to 25 at their own pace. If they reach 25 they must start again and will never be given negative feedback. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively
9682592|NCT04912596|Placebo Comparator|Placebo|Two different Reference Placebo inhalers and two different Test Placebo inhalers
9682593|NCT04912596|Active Comparator|Reference 1|One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers
9682594|NCT04912596|Active Comparator|Reference 2|Two different Reference inhalers and two different Test Placebo inhalers
9682595|NCT04912596|Experimental|Test|One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers
9682596|NCT04912661|Active Comparator|Immediate iron treatment|intravenous iron carboxymaltose before vaccination
9682597|NCT04912661|No Intervention|No iron treatment|no intravenous iron carboxymaltose before vaccination
9682598|NCT04912882||Training Group|Training group including about 500 patients that be using to building the prognosis model
9682599|NCT04912882||Validation Group|Validation group including about another 500 patients that be using to validating the prognosis model
9682600|NCT04912947|Active Comparator|Dietary supplement|One cp/day of the IMMUSYSTEM food supplement for 3 months
9682601|NCT04912947|Placebo Comparator|Placebo|One cp/day of Placebo for 3 months
9682602|NCT04912453|Experimental|Primary anastomosis group|
9682603|NCT04912453|Experimental|Enterostomy group|
9682604|NCT04912323|Experimental|MAGNITUDE® Scaffold|Subject with up to three study lesions treated by implanting a maximum of 3 R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffolds
9682605|NCT04912349|Experimental|Test Group|Patients received the transurethral split of the prostate(TUSP) treatment.
9682606|NCT04912349|Active Comparator|Control Group|Patients received the transurethral resection of the prostate(TURP) treatment.
10177598|NCT03821025|Active Comparator|Multiple Plastic Stents|Patients will receive two 8.5Fr Platic biliary stents placed side by side across the biliary stricture.
10177599|NCT03821025|Active Comparator|Self-expandable Metal Stents|Patients will receive a fully covered Self-expandable Metal Stents (10mm) across the biliary stricture
10177600|NCT03821116|Experimental|Milk|At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
10177601|NCT03821116|Experimental|Soured milk (filmjölk)|At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
10177602|NCT03820934|Other|Patients undergoing Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these test. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
10177603|NCT03820921||PATIENTS WITH PANCREATIC CANCER|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNB for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNB will be further verified during a clinical follow-up of at least 6 months.~Immunochemistry will be performed on the EUS-FNB specimens to determine PD-L1 expression and MMR status"
10177604|NCT03820843|Experimental|Art therapy|Art therapy and standard orthophonic rehabilitation
10177605|NCT03820843|No Intervention|Control group|Only standard orthophonic rehabilitation
10177606|NCT03820856|Experimental|acupuncture plus fire needle group|
10177607|NCT03820856|Active Comparator|acupuncture group|
10177608|NCT03820830|Experimental|Palbociclib plus standard endocrine therapy|Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.
10177609|NCT03820830|Active Comparator|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
10177610|NCT03820869|Active Comparator|Control|Children with ASD
10177611|NCT03820869|Experimental|Intervention|Children with ASD
10177612|NCT03820882|Experimental|stent retriever(Catfish)|Mechanical thrombectomy with Catfish flow restoration device
10177613|NCT03820882|Active Comparator|stent retriever(Solitaire FR)|Mechanical thrombectomy with Solitaire FR flow restoration device
9682607|NCT04912310|Experimental|Acute angle closure glaucoma|Argon laser peripheral iridoplasty
10177614|NCT03820713|Experimental|Investigational arm|Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
10177615|NCT03820713|Placebo Comparator|Control arm|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
10177616|NCT03820700|No Intervention|Control group|[Randomized] Patients in control group will receive regular nursing care but no behavioral therapy intervention.
10177617|NCT03820700|Experimental|Hypnosis (Hypn)|[Randomized] Patients will receive a hypnosis recorded audiotape.
10177618|NCT03820700|Experimental|Virtual reality (VR)|[Randomized] Patients will see a 3D movie with a beautiful landscape.
10177619|NCT03820700|Experimental|Virtual reality hypnosis (VRH)|[Randomized] Patients will see the same 3D film combined with a hypnotic voice.
10177620|NCT03820674|Experimental|Energy Conservation plus Problem Solving Therapy Intervention|Receiving experimental intervention
9682608|NCT04912440||MSE-ERCP|Group of patients, that received motorized spiral enteroscopy assisted ERCP in altered anatomy at the single study center
9682609|NCT04912206|Experimental|Intervention|Point-of-Care Ultrasound on top of diagnosis work-up
9682610|NCT04912206|No Intervention|Control|Usual diagnosis work-up without Point-of-Care Ultrasound
9682611|NCT04912167|Experimental|ARNI-Sacubitril-Valsartan|patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.
10177621|NCT03820674|Active Comparator|Health Education Intervention|Receiving control intervention
10177622|NCT03820648|Experimental|Alexis® device|In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
10177623|NCT03820648|Active Comparator|Standard 3M™ Steri-Drape 2|In this group, we will be used Standard 3M™ Steri-Drape 2
10177624|NCT03821194|Experimental|Gua sha group|do gua sha for the subjects
9682612|NCT04912167|Active Comparator|ACEI-Enalapril|patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril
9682613|NCT04912466|Experimental|IBI322|Singal arm
9682614|NCT04912375|Experimental|Low EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
9682615|NCT04912375|No Intervention|Low EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have low EF. They will play a similar puzzle task but the statements they searched are neutral.
9682616|NCT04912375|Experimental|High EF with priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a puzzle task that will ask participants to take 5 min to search Chinese words for meaningful statements. Each statement represents an implicit goal of healthy eating.
10177625|NCT03821194|Active Comparator|control group|give hot pack for the subjects
10177626|NCT03820609|Experimental|Digital Intervention|Make a Change is a universal sexual assault (SA) prevention program that aligns with best-practices in prevention, utilizes the theory and strategies of serious games for health, and addresses risk and protective factors for SA across the social ecology of individual, peer and community factors that foster SA. This novel digital application also leverages theories of behavior change within serious games for health, and integrates successful practices in videogame design to promote engagement, learning and skill-building.
10177627|NCT03820570|Experimental|lichtenstein|hernia repair
10177628|NCT03820635||Calcified|those with evidence of vascular calcification
10177629|NCT03820635||Non-calcified|those with no evidence of vascular calcification
10177630|NCT03820622|Experimental|DIOR group|in this group, patients will be treated with Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
10177631|NCT03820622|Active Comparator|Bingo group|in this group, patients will be treated with Paclitaxel-Eluting Balloon (Bingo)
10177632|NCT03820531|Experimental|Suspected mucinous pancreas cyst|In all pancreas cysts > 15mm and/or pancreas duct dilatation > 5mm in patients who are fit for surgery EUS-guided pancreas cyst fluid aspiration is conducted. In cyst fluid CEA and lipase examination, cytology and Next Generation Sequencing is performed. After that, the pancreas cyst will be resected and histopathologically analysed.
10177633|NCT03820518|Experimental|High-dose|Receiving 60 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
10177634|NCT03820518|Experimental|Low-dose|Receiving 20 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
10177635|NCT03820492|Other|Patient with left-main stenosis|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
10177636|NCT03820557|Experimental|Decision Counseling|Patients undergo participation in the DCP prior to an audio-recorded oncology appointment.
10177637|NCT03820453|Experimental|Active group|One tablet per day in the morning through oral administration of a dietary supplement containing Tribulus terrestris as the main active ingredient. During three months with the possibility to extend for another three months.
10177638|NCT03820453|Placebo Comparator|Control group|One tablet per day in the morning through oral administration of Placebo. During three months.
10177639|NCT03820440|Experimental|Treatment - hemodynamic tests|"Treatment - hemodynamic tests:~The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.~The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds"
10177640|NCT03820427||bronchial asthma|Patients with known or suspected asthma.
10177641|NCT03820427||pulmonary healthy controls|Patients without known or suspected pulmonary disease
10177642|NCT03820414|Experimental|CRV101 Group 1|Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
10177643|NCT03820414|Experimental|CRV 101 Group 2|Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
9682617|NCT04912375|No Intervention|High EF without priming|Participants will be first stratified by their Executive function (EF). In this arm, participants have high EF. They will play a similar puzzle task but the statements they searched are neutral.
9682618|NCT04912570|Experimental|Manual Thrombus Aspiration|Manual Thrombus aspiration in STEMI patients with Heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
10177644|NCT03820414|Experimental|CRV 101 Group 3|Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
10177645|NCT03820414|Experimental|CRV 101 Group 4|Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
10177646|NCT03820414|Placebo Comparator|Control Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
10177647|NCT03820401|Experimental|Solacea_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177648|NCT03820401|Experimental|Solacea_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177649|NCT03820401|Experimental|FX800_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177650|NCT03820401|Experimental|FX800_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
9682619|NCT04912570|Active Comparator|Standard PCI|Conventional PCI according to the most recent guidelines in STEMI patients with no heavy thrombus burden (TIMI 0-1 or TB classification 4-5)
9682620|NCT04912271|Experimental|Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone|Patients received granisetron transdermal patch plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Granisetron transdermal patch Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
9682621|NCT04912271|Active Comparator|Palonosetron, aprepitant or fosaprepitant, dexamethasone|Patients received intravenous palonosetron plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Palonosetron 0.25 mg IV D1 Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1
9682622|NCT04912362|Experimental|YAG iridotomy+CLASS|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
9682623|NCT04912362|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery only
9682624|NCT04912219|Experimental|Treatment|
9682625|NCT04912219|No Intervention|Control|
9682626|NCT04912388|Experimental|The stabilization group|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
9682627|NCT04912388|Experimental|The general exercise group|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
9682628|NCT04912388|No Intervention|The control group|Individuals in the control group will not be treated.
9682629|NCT04912284||General population|Questionnaire administered to adult population
9682630|NCT04912284||Health care workers|Questionnaire administered to adult health care workers
9682631|NCT04912193||antithrombin III < 50 %|preoperative antithrombin III levels <50%
9682632|NCT04912193||Antithrombin III ≥ 50 %|preoperative antithrombin III levels ≥ 50 %
9682633|NCT04912557||Patients|Open major abdominal surgery patient (predicted operative time ≥ 2 hours) with Peridural Analgesia accepted
9682634|NCT04912258|Experimental|Arm A|DEB-TACE before liver surgery
9682635|NCT04912258|No Intervention|Arm B|direct liver surgery
9682636|NCT04912297||PCV10 2+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 2+1 schedule (two vaccinations with minimum 8-week intervals followed by a booster dose at least 4 months after the last primary dose).
9682637|NCT04912297||PCV10 3+1 schedule|Ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) administered with a 3+1 schedule (three vaccinations with minimum 4-week intervals, followed by a booster dose at least 4 months after the last primary dose).
9682638|NCT04912336||VV-ECMO|Patients supported because of respiratory failure by Veno-Venous Extra Corporeal Membrane Oxygenator.
9682639|NCT04912336||VA-ECMO|Patients supported because of circulatory failure by Veno-Arterial Extra Corporeal Membrane Oxygenator.
9682640|NCT04912414|Experimental|Brief Family Therapy (BFT) for the treatment of psychosomatic symptoms in Rwanda|The participants from the control group were assigned to the Brief Family Therapy for reducing the medically unexplained symptoms. But the control group was not assigned to the intervention (BFT).
9682641|NCT04912154|Experimental|Traditional rehabilitation protocol|Traditional rehabilitation protocol after the surgery will be conducted
9682642|NCT04912154|Active Comparator|Accelerated rehabilitation protocol|Accelerated rehabilitation protocol under ultrasonic monitoring after the surgery will be conducted
9682643|NCT04911881|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
9682644|NCT04912128||Anlotinib group|Patients in Anlotinib group took Anlotinib 1 week before the MRI-based simulation，12mg/d QD，day1~14, 21d/cycle. All patients received SBRT for brain metastases.
9682645|NCT04912128||SBRT group|Patients in SBRT group took no anti-angiogenic drugs. All patients received SBRT for brain metastases.
9682646|NCT04911894|Experimental|Phase Ia Dose-Escalation Stage: IBI321|
10177651|NCT03820401|Experimental|Solacea_HD_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177652|NCT03820401|Experimental|Solacea_HD_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177653|NCT03820401|Experimental|FX800_HD_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
9682647|NCT04911985||ICU Patients with PAC|All patients admitted to the Medical ICU of the University Hospital Zürich, complying with the inclusion criteria and monitored by a pilmonary artery catheter
10177654|NCT03820401|Experimental|FX800_HD_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177655|NCT03820401|Experimental|FX800_HD_1/2anticoagulation_albuprime|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177656|NCT03820401|Experimental|Evodial_HD_no anticoagulation|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177657|NCT03820401|Experimental|Evodial_HD_no anticoagulation_albuprime|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
9682648|NCT04911920|Other|Patients with lateral epicondylitis|Patients with lateral epicondylitis who are treated with at least one ACP injection.
9682649|NCT04911959|Other|control group|
9682650|NCT04911959|Experimental|Intervention group|
9682651|NCT04912076|Experimental|BM41|9 treatment visits where subcutaneous injections with BM41 (adsorbed to aluminium hydroxide) will be given in a blinded fashion starting with 12.5 nanogram increasing to 20 microgram which is maintenance dose. Subsequently 3 maintenance doses will be given.
9682652|NCT04912076|Placebo Comparator|Placebo|Placebo consisting of only aluminium hydroxide will be administered blinded in amounts according to BM41.
9682653|NCT04912076|Active Comparator|Alutard|Alutard SQ (ALK) will serve as the comparator and administration is open. Up-dosing is performed according to the official cluster scheme, reaching maintenance of 100.000 SQ-E
9682654|NCT04912141|Placebo Comparator|Conestat alfa 50 U/kg - Placebo|50 U/kg conestat alfa pre-angiography and placebo 3 hours after the first dose
9682655|NCT04912141|Active Comparator|Conestat alfa 50 U/kg - Conestat alfa 50 U/kg|50 U/kg conestat alfa pre-angiography and 3 hours after the first dose
9682656|NCT04912141|Active Comparator|Conestat alfa 100 U/kg - Conestat alfa 50 U/kg|100 U/kg conestat alfa pre-angiography and 50 U/kg conestat alfa 3 hours after the first dose
9682657|NCT04912141|Placebo Comparator|Placebo - Placebo|Placebo pre-angiography and 3 hours after the first dose
9682658|NCT04911946||R1|Resident of the first year of orthopedics and traumatology at IOT-HC-FMUSP.
9682659|NCT04911946||R2|Resident of the second year of orthopedics and traumatology at IOT-HC-FMUSP.
9682660|NCT04911946||R3|Resident of the third year of orthopedics and traumatology at IOT-HC-FMUSP.
9682661|NCT04912037|Experimental|with AI-assisted system|The novice doctors are trained in colonoscopy with an artificial intelligence assisted system that can indicate abnormal lesions and the speed of withdrawal in real time, as well as feedback on the percentage of overspeed.
9682662|NCT04912037|No Intervention|without AI-assisted system|The novice doctors receive routine colonoscopy training without artificial intelligence assistance system and no special tips
9682663|NCT04911933|Experimental|Intervention|The form of treatment involve systemic family therapy sessions every two weeks about an hour each.
9682664|NCT04911933|No Intervention|Waitlist Control|Participants assigned to the control condition will be placed on a waitlist for future enrollment. After primary data collection has ceased, those assigned to the control arm will receive the identical intervention delivered in the experimental condition.
10177658|NCT03820401|Experimental|Solacea_preHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
9682665|NCT04911907|Experimental|Squamous cell carcinoma of head and neck: Utidelone Injection|Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy
9682666|NCT04911907|Experimental|Esophageal cancer: Utidelone injection|Cohort 2 Esophageal cancer. Participants will be treated with utidelone monotherapy.
9682667|NCT04911907|Experimental|Stomach cancer: Utidelone injection|Cohort 3 Stomach cancer. Participants will be treated with utidelone monotherapy.
9682668|NCT04911907|Experimental|Pancreatic cancer: Utidelone Injection|Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.
10177659|NCT03820401|Experimental|Solacea_postHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177660|NCT03820401|Experimental|Solacea_HD_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
9682669|NCT04911907|Experimental|Ovarian cancer: Utidelone Injection|Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.
10177661|NCT03820401|Experimental|Solacea_preHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177662|NCT03820401|Experimental|Solacea_postHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177663|NCT03820401|Experimental|Solacea_HD_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10177664|NCT03820466|Active Comparator|Aspirin|Aspirin 100 mg once daily and Placebo Atorvastatin once daily
10177665|NCT03820466|Active Comparator|Atorvastatin|Atorvastatin 20 mg once daily and Placebo Aspirin once daily
10177666|NCT03820466|Experimental|Aspirin-Atorvastatin|Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
10177667|NCT03820466|Placebo Comparator|Placebo|Placebo Aspirin once daily and Placebo Atorvastatin once daily
10177668|NCT03820336|Experimental|Extra Virgin Olive Oil|
10177669|NCT03820336|Placebo Comparator|Control Oil|
10177670|NCT03820297|Other|Anti-Stigma Group|Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.
10177671|NCT03820271|Other|SuperMELD|
10177672|NCT03820245|Experimental|Bixin|Consumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
10177673|NCT03820245|Experimental|Norbixin|Consumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
10177674|NCT03820245|Active Comparator|Lycopene|Consumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
10177675|NCT03820245|Placebo Comparator|Placebo|Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
10177676|NCT03820232||Surgical patients|Patients who were candidates for major or urological surgery under general anaesthesia will be observed. In particular, the core body temperature will be measured with both a single-use oesophageal probe and a SpotOn® heated controlled servo sensor.
9682670|NCT04911907|Experimental|Cholangiocarcinoma: Utidelone|Cohort 6 Cholangiocarcinoma. Participants will be treated with Utidelone monotherapy
10177677|NCT03820219|Placebo Comparator|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
10177678|NCT03820219|Active Comparator|Prevena™ system|The Prevena™ System is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment, until it is removed at Post-Operative Day 7.
10177679|NCT03820206|Active Comparator|Tranexamic acid group|1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
10177680|NCT03820206|Placebo Comparator|Control group|30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
9682671|NCT04911907|Experimental|Other solid tumors: Utidelone Injection|Cohort 7 Other solid tumors. Participants will be treated with Utidelone monotherapy
9682672|NCT04912102|Active Comparator|Group H|Oxygen will be delvered via HFNO canula at 20 L/min, Fio2 0.4 and temperature of 37o c using Vapotherm Precision Flow.
9682673|NCT04912102|Active Comparator|Group M|Mask group will be provided with nasal CPAP (10cmH2O) at an oxygen flow rate of 15 L/min.
9682674|NCT04912102|Active Comparator|Group C|In the Control group, oxygen via a nasal cannula at a flow rate of 5 L/min will be delivered
10177681|NCT03820193|Experimental|Post-Operative Non Opioid Pain Protocol|Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
10177682|NCT03820193|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
10177683|NCT03820141|Experimental|Durvalumab + Trastuzumab + Pertuzumab|Durvalumab, trastuzumab, and pertuzumab will be administered on Day 1 every 3 weeks for 6 cycles. Trastuzumab will be administered as 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg IV. Pertuzumab will be administered as 840 mg IV loading dose, followed by 420 mg. Durvalumab will be administered at a fixed dose of 1120 mg IV.
9682675|NCT04912011|Experimental|Canrenoate potassium|Administration of 200 mg of potassium Canrenoate potassium dissolved in 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
9682676|NCT04912011|Placebo Comparator|Placebo|Administration of 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.
9682677|NCT04911842||TPU|Thermoplastic polyurethane
9682678|NCT04911842||HBM|Hydrophilic BioMaterial
9682679|NCT04911712|Active Comparator|Randomly selected malnourished patients for normal protein liquid diet supplementation|Randomly selected malnourished patients for normal protein liquid diet supplementation
9682680|NCT04911712|Experimental|Randomly selected Malnourished patients with high protein liquid diet supplementation|Malnourished patients with high protein liquid diet supplementation
10177684|NCT03820154|Active Comparator|Skin Prick Test TAPE|"The Skin Prick Test Tape is an innovative sterile all-in drug carrying 8 allergens and 2 control solutions including prick needles in one Tape for easy use and standardization. Single use. Reading of wheal reactions after 15 minutes, facilitated by stripes with the allergen names."
9682681|NCT04911829|Active Comparator|Inpatient treatment|High intensity high dosage inpatient short-term psychodynamic psychotherapy
9682682|NCT04911829|Experimental|Outpatient treatment|Low dosage outpatient short-term psychodynamic psychotherapy
10177685|NCT03820154|Active Comparator|Skin Prick Test|The conventional SPT is the world-wide standard in allergy Type 1 diagnosis for inhalant and food allergens. Drops of allergens are applied to the forearm and, with the help of a lancet, brought into the skin. Reading of wheal reactions after 15 minutes.
10177686|NCT03820180|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
10177687|NCT03820180|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
10177688|NCT03820128|Active Comparator|Very early refeeding|"Very early diet intervention: refeeding within 24 hours from the hospital admission.~Participants will be encouraged to start eating immediately after the time of admission. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
10177689|NCT03820128|Active Comparator|Early refeeding|"Early diet intervention: refeeding after 24 hours from the hospital admission .~During the first 24 hours after admission participants will be on fluid only (orally and/or intravenously). Later on they will be encouraged to start eating. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
9682683|NCT04911764|Experimental|Three-min Step Test and Exercise desaturation detection in COPD|Each patient recruited will performed both field tests, being therefore his or her own witness.
9682684|NCT04911803|Experimental|Anxiety Group|Participants will download the anxiety application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the anxiety application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the anxiety group are asked to complete daily brief exercises. For example, they will practice noticing worry thoughts and journal them down.
9682685|NCT04911803|Active Comparator|Procrastination Group|Participants will download the procrastination application to their own handphones, and will complete the programme subsequently in their own time over the course of 2 weeks. The expected duration participants will spend on the procrastination application daily is estimated to be around 5 to 10 minutes, amounting to a total of around 140 minutes (2 hours and 10 minutes) during the 2 weeks intervention. Participants in the procrastination group are asked to complete daily brief exercises. For example, they will practice to reduce procrastination-related thoughts.
9695604|NCT04776733|Experimental|prepackaged group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
9695605|NCT04776733|Active Comparator|restricted diet group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
9695606|NCT04776395|Experimental|Arm A (iberdomide hydrochloride, dexamethasone)|Patients receive iberdomide hydrochloride PO QD on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10177690|NCT03820115|Experimental|Elastic abdominal binder|
10177691|NCT03820115|No Intervention|No binder|
10177692|NCT03820076|Experimental|dose 1|AZT-04
10177693|NCT03820076|Experimental|dose 2|AZT-04
10177694|NCT03820076|Experimental|dose 3|AZT-04
10177695|NCT03820063|Experimental|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~Carboplatin AUC 6mg•ml/min administered intravenously on day 1~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~Treatment cycles are repeated on day 22~Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1."
10177696|NCT03820037|Active Comparator|OPC, Ongentys|Single oral doses of 50 mg opicapone, administered using the reference (Ongentys ®) active pharmaceutical ingredient (API) source
10177697|NCT03820037|Experimental|BIA 9-1067|Single oral doses of 50 mg opicapone, administered using the test (BIA 9-1067)
10177698|NCT03820011|Experimental|PEM-Plus Group|For Aim 1, 6 parents of young children were recruited to perform tasks related to navigating the PEM+ interface. Data on completion rate and time, as well as user satisfaction, were analyzed to guide PEM+ improvements. For Aim 2, we recruited 26 participants to enroll in a feasibility trial of PEM+. Caregivers who completed the YC-PEM e-PRO to evaluate their child's participation clicked on a weblink to begin PEM+, whereby they built on their YC-PEM responses for the purpose of creating a participation-focused care plan to share with their child's rehabilitation team. Caregivers were instructed to complete the PEM+ over a two-week (14 day) period because it mimics what would be provided in routine care.
10177699|NCT03819985|Experimental|Treatment (hypofractionated RT)|Patients receive hypofractionated radiation therapy in 15 daily fractions over 3 weeks in the absence of disease progression or unacceptable toxicity.
10177700|NCT03819946|Experimental|Study Group- esophgeal cooling|In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.
9682686|NCT04911647|Active Comparator|The Plastic stent|Patient group with plastic stent inserted in biliary obstruction through endoscope
9682687|NCT04911647|Experimental|The metal stent|Patient group with metal stent inserted in biliary obstruction through endoscope
10177701|NCT03819946|Active Comparator|Control group- esophgeal temperature probe|In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.
10177702|NCT03819972|Placebo Comparator|Control|Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)
10177703|NCT03819972|Active Comparator|Dose 1|Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)
10177704|NCT03819972|Active Comparator|Dose 2|Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)
10177705|NCT03819972|Active Comparator|Dose 3|Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)
9682688|NCT04911478||Rollover subjects from Adicet Bio allogeneic T cell interventional studies.|"This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in any Adicet Bio allogeneic gamma delta T cell study.~Patients will be followed for up to 15 years after initial dosing of Adicet Bio allogeneic gamma delta T cell investigational products."
9682689|NCT04911530||elderly patients (aged ≥ 65 years)|elderly patients undergo surgeries
9682690|NCT04911738|Experimental|Plane A for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane A, which corresponds to the following order: verticality perception (Baseline, effect during the intervention, post-effect), then active vertical body orientation (Baseline, effect during the intervention). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
9682691|NCT04911738|Experimental|Plane B for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane B, which corresponds to the following order: active vertical body orientation (Baseline, effect during the intervention), then verticality perception (Baseline, effect during the intervention, post-effect). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
9682692|NCT04911452|No Intervention|Control|Standard Neonatal Intensive Care Unit (NICU) care
9682693|NCT04911452|Experimental|Calmer|Calmer placed and left in infant incubator for the 3-week study period. Calmer treatment provided for minimum total of 3 hours/day (can be discontinuous).
9682694|NCT04911621|Experimental|Stratum A (newly diagnosed)|Dendritic cell vaccination plus temozolomide-based chemoradiotherapy
10177706|NCT03819998||PCOS group|women who have PCOS
10177707|NCT03819998||control group|women who donnot have PCOS
10177708|NCT03819933|Other|Pregnant women and their partners|"For the qualitative arm of this mixed method study, using an exploratory sequential design, investigators will enroll ~ 30 adult pregnant women admitted estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners to participate in a post-counseling semi-structured interview to explore preferred language and approaches, and better inform questionnaire development. Sample size will be up to 30 families, or until thematic saturation is achieved (total up to 60 if all partners agree to participate).~For the quantitative arm of this study, investigators will enroll ~100 adult pregnant women admitted between estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners (up to total ~200 if all partners present and agree to participate)."
10187362|NCT03726905|Sham Comparator|sham respiratory muscles training|"4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with 0 pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)"
9682695|NCT04911621|Experimental|Stratum B (prior treatment)|Dendritic cell vaccination plus optional conventional anti-glioma treatment (in line with standard-of-care practice, at the investigator's discretion)
9682696|NCT04911569|Experimental|Cryoneurolysis|All 25 patients will receive cryoneurolysis
9682697|NCT04911608|Experimental|cervical manipulation|"The cervical spinal manipulation will consist of one session of a standard technique that will be performed by an experienced (>10 years) doctor of physical therapy practitioner. The technique is described by Gibbons and Tehan as a high-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restrcition. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation. This type of cervical manipulation procedure is described by Gibbons and Tehan as Minimal Leverage Thrust and it results in optimal patient comfort while receiving the treatment thus reducing post-treatment soreness/pain."
9682698|NCT04911608|Experimental|cervical mobilization|The cervical spinal mobilization treatment will also consist of one session of a standard technique that will be performed by an experienced (>10 years) doctor of physical therapy practitioner. For this procedure, the participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments. The magnitude of a mobilization-or how hard the therapist pushes on the spine-is usually reported as the magnitude of force. For an oscillatory posterior-anterior (PA) mobilization technique, the maximum magnitude of applied force is usually reported as the mean of the force peaks that occur during a specified period.34 The cervical mobilization will consist of oscillations of 1Hz and magnitude forces of 30 Newtons (N) for 30 seconds, 90N for 120 seconds and 30N for 30 seconds at the localized segment.
10177709|NCT03819933|Other|Counseling MFM and Neonatology providers|Investigators will enroll ~100 counseling Maternal-Fetal Medicine (MFM) specialists and 100 counseling Neonatologists (total ~200 providers), who provided counseling to the enrolled pregnant women between 22 0/7-25 6/7 weeks' estimated gestation for anticipated extremely preterm delivery. This assumes 1 counseling provider from MFM and 1 from Neonatology per pregnant woman, although there could be more if a consult is performed by both an attending physician and a training fellow or practitioner, or less, if a counseling provider declines to participate in the study. There will be anticipated repetition of counseling providers, accounted for in the statistical analysis. Providers will be asked to complete educational interventions to improve counseling at extreme prematurity.
10177710|NCT03819920|Placebo Comparator|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
10177711|NCT03819920|Active Comparator|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
10177712|NCT03819907|No Intervention|Control|"15 participants will be randomly assigned to the control group. They will receive no intervention other than the injection (which is not a part of the trial).~Pre-injection they will receive all baseline measures and questionnaires. Post injection they will receive the primary outcome measures: 1) Numeric Pain Rating Scale and 2) Anxiety thermometer"
10177713|NCT03819907|Active Comparator|Audiovisual (AV) Guided Relaxation|Combination Product: Audiovisual Guided Relaxation Five-minute guided relaxation delivered via a computer screen and speakers
10177714|NCT03819907|Experimental|Virtual Reality (VR) Guided Relaxation|"Combination Product: Virtual Reality Guided Relaxation Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.~Other Names:~• Samsung Galaxy 7s/Samsung adaptable VR headset"
10177715|NCT03819894|Experimental|Intervention|The intervention is the introduction of a lower female threshold. In cluster-randomized trials, the cluster (i.e., hospital) is the unit of randomization.
10177716|NCT03819894|No Intervention|Control|The control phase will be standard of care, with the use of an overall population hs-cTn T and I threshold, for both men and women, to identify those with myocardial injury/infarction.
10177717|NCT03819868|Active Comparator|High Cost|Restoration using a high-cost sealant
10177718|NCT03819868|Experimental|Low Cost|Restoration using a low-cost sealant
10177719|NCT03819881|Experimental|STMC-103H|"Oral administration of STMC-103H twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
10177720|NCT03819881|Placebo Comparator|Placebo|"Oral administration of placebo twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
10177721|NCT03819816|Experimental|DEA-App|The intervention (DEA) group will receive the newly developed app.
10177722|NCT03819816|Other|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
10177723|NCT03819790|Experimental|Insulin Glargine + GLP-1 RA|Insulin Soliqua (a titratable combination of insulin Glargine + GLP-1 RA) will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with or without metformin.
9682699|NCT04911608|No Intervention|postural correction education|Participants will be presented with a standardized educational short video regarding the importance of postural correction movements.
9682700|NCT04911699||breast adenocarcinoma|"The surgical pathological tissue report confirms the diagnosis of breast adenocarcinoma women with stage I~III~Those who are admitted to the hospital and receive adjuvant chemotherapy for the first time.~Age (inclusive) over 20 years old."
9682701|NCT04911699||Control|"The surgical pathological tissue report establishes women diagnosed as stage 0 to stage III breast cancer~Those who are admitted to the hospital to receive anti-hormonal drug treatment.~Age (inclusive) over 20 years old."
9682702|NCT04911556|Placebo Comparator|the placebo group|A placebo made of starch
9682703|NCT04911556|Experimental|Bifidobacterium longum group 1|Bifidobacterium longum 274
9682704|NCT04911556|Experimental|Bifidobacterium longum group 2|Bifidobacterium longum 4-1
10177724|NCT03819790|Active Comparator|Basaglar/Lantus + gliclazide MR|Basal insulin Basaglar/Lantus will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with gliclazide MR 60 mg OD, with or without metformin.
10177725|NCT03819777||Idiopathic PAH|
10177726|NCT03819777||CTD-PAH|
10177727|NCT03819777||CTD without PAH|
9682705|NCT04911556|Experimental|Bifidobacterium longum group 3|Bifidobacterium longum gs
10177728|NCT03819764|Active Comparator|Aerobic Exercise & Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling~45 minutes of upper extremity repetitive arm exercises"
10177729|NCT03819764|Active Comparator|Upper Extremity Repetitive Task Practice Only|"Participants will perform the following:~1. 90 minutes of upper extremity repetitive arm exercises"
10177730|NCT03819738|Experimental|fMRI intervention|
10177731|NCT03819725|Other|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla® ) and glucose measurements will be monitored during 2-5 days. Oral food intake will be recorded.
10177732|NCT03819751|Other|MRI-targeted prostate biopsy|Participants receive both type of MRI-targeted biopsy. Patients are randomized with one half having visual registration first and the other half having software registration first.
10187363|NCT03726892|Active Comparator|The SYNERGY stent|
10187364|NCT03726892|Active Comparator|Xience|
10187365|NCT03726866|Experimental|Sequence 1|Sequence 1
10187366|NCT03726866|Experimental|Sequence 2|Sequence 2
10187367|NCT03726866|Experimental|Sequence 3|Sequence 3
10187368|NCT03726866|Experimental|Sequence 4|Sequence 4
10187369|NCT03726866|Experimental|Sequence 5|Sequence 5
10187370|NCT03726866|Experimental|Sequence 6|Sequence 6
10187371|NCT03726853|Experimental|CKD-497 200mg|CKD-497 200mg
10187372|NCT03726853|Experimental|CKD-497 300mg|CKD-497 300mg
10187373|NCT03726853|Active Comparator|Active Comparator|compartor
10187374|NCT03726853|Placebo Comparator|Placebo|CKD-497 placebo and comparator placebo
10187375|NCT03726840|No Intervention|Driving performance no fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with no fragrance
10187376|NCT03726840|Experimental|Driving performance Fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with fragrance
9682706|NCT04911374|Other|Anti-Aging Face Moisturizer and Eye Cream|"Dual Regimen:~Multi-ingredient anti-aging face moisturizer~Multi-ingredient anti-aging eye cream"
9682707|NCT04911816|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate
9976105|NCT01348217|Active Comparator|ARM A|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)~Boost 10 Gy in 5 fr: PTV = +1cm.~Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)"
10187377|NCT03726827||population|self selected members of the general population who perceive a value in having a Fibroscan screening test of their liver
10187378|NCT03726814|Experimental|EPC treatment group|
10187379|NCT03726801|Experimental|Stratum C|"N 32 C~Women who are going to be mastectomized, conservate surgery and ostomy who attend the health education together with their immediate family member prior to surgery"
10187380|NCT03726801|Placebo Comparator|Stratum E|"N 32 E~Patients who are going to be subjected to a mastectomized, conservate surgery and ostomy who come alone to the health education prior to surgery"
10187381|NCT03726788|Experimental|Botulinum Toxin Type A 100U|one intra-articular injection in the painful knee 30 days after the inclusion visit
10187382|NCT03726788|Experimental|Botulinum Toxin Type A 200U|one intra-articular injection in the painful knee 30 days after the inclusion visit
10187383|NCT03726788|Active Comparator|Triamcinolone Hexacetonide 20 MG/ML|one intra-articular injection in the painful knee 30 days after the inclusion visit
10187384|NCT03726775|Experimental|RT-durvalumab|durvalumab at fixed dose of 1120 mg on Day1 of RT and every 3 weeks during the RT. Durvalumab with be continued at a fixed dose of 1500 mg every 4 weeks during 6 months following RT.
10187385|NCT03726762|Experimental|Diet Beverages|'Diet beverages' after the main meal
10187386|NCT03726762|Experimental|Water|'Water' after the main meal
10187387|NCT03726749|Experimental|Tocilizumab and prednisone|"TCZ 162 mg administered by subcutaneous injection weekly for 52 weeks.~Prednisone taper over 8 weeks with a starting dose between 20 and 60 mg."
10187388|NCT03726736|Experimental|Anlotinib combined Docetaxel|patients treated with anlotinib and Docetaxel (21 days for 1 cycle) until PD (progressive disease)
10187389|NCT03726736|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until PD (progressive disease)
10187390|NCT03726710|Experimental|Blood Pressure measurement and pharmacy|Blood Pressure measurement performed by barber and Blood pressure measurement and management visits with study pharmacist in person and through Telemedicine.
10187391|NCT03726697|Experimental|Tahneek|Infants receiving a single dose of soft date, prepacked by the pharmacy containing glucose equivalent to 200mg/kg at 1 hour after birth in the nursery.
10187392|NCT03726697|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
10187393|NCT03726684|Experimental|Coding strategy for cochlear implants|Measure neural responses of cochlear implant recipient Use measured values of refractoriness, spread of excitation and facilitation as parameters for a bioinspired coding strategy perform listening tests to compare new coding strategy with standard clinical coding strategy
10187394|NCT03726645|Active Comparator|Study group|Allogeneic fecal microbiota transplantation (from donor)
10187395|NCT03726645|Placebo Comparator|Control group|Autologous fecal microbiota transplantation (own stool)
10187396|NCT03726619|Experimental|e-CHEC-uP|Group 1 will receive the education study intervention after the first baseline questionnaire. Participants will be asked to take part in a one-time, 1 to 1.5-hour online education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker to help address any barriers in order to help receive a mammogram or a Pap test.
9682708|NCT04911504||Questionnaire survey group|All nurses were recruited from 3 tertiary hospitals in central China from 3rd October, 2019 to 15th December, 2019. A total of 992 clinical nurses from different nursing departments were recruited through convenience sampling. Data were collected using General information questionnaire, the Professional Quality of Life Scale, the Connor-Davidson Resilience Scale and General Perceived Self-Efficacy Scale.
9682709|NCT04911114|Experimental|Intervention Arm|This is a single arm pilot study of group base exercise
9682710|NCT04911127|Placebo Comparator|Placebo|Participants will receive capsules containing medium chain triglyceride (MCT) oil
9682711|NCT04911127|Experimental|200mg CBD twice daily|
9682712|NCT04911127|Experimental|400 mg CBD twice daily|
9682713|NCT04911426|No Intervention|Treatment as usual|Individuals in the treatment as usual condition will participate in substance use treatment as part of the standard police opioid diversion program model.
9682714|NCT04911426|Experimental|Treatment plus telehealth|Individuals in the treatment plus telehealth condition will receive telehealth support services, including seven brief motivational interviewing sessions, delivered by a licensed substance use counselor via live interactive video calls during the 12-week intervention.
9682715|NCT04911413|Experimental|low-dose group,|A bolus of 10 mg/kg Tranexamic Acid followed by a maintenance dose of 10 mg/kg/h Tranexamic Acid until the end of surgery
9682716|NCT04911413|Experimental|middle-dose group,|A bolus of 20 mg/kg Tranexamic Acid followed by a maintenance dose of 15 mg/kg/h Tranexamic Acid until the end of surgery
9682717|NCT04911413|Experimental|high-dose group|A bolus of 30 mg/kg Tranexamic Acid followed by a maintenance dose of 20 mg/kg/h Tranexamic Acid until the end of surgery
9682718|NCT04911725|Experimental|With device use|Volunteers included will use IMD during one of the two periods of the study.
9682719|NCT04911725|No Intervention|Without device use|Volunteers included will not use IMD during the other period of the study (reverse of experimental)
9682720|NCT04911400|Experimental|Upper-lower clear plastic retainers + Class III elastics|Upper-lower clear plastic retainers + Class III elastics
9682721|NCT04911400|Active Comparator|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
9682722|NCT04911205|Experimental|Intervention Group|Patients who were randomly allocated to intervention group (N=44) completed a 6-week preoperative training program, 5 days per week prior to surgery
9976106|NCT01348217|Experimental|ARM B|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)~Boost 26 Gy in 13 fr: PTV = +1cm.~Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43)."
9976107|NCT01348230||prior preterm delivery at 24-32 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
9976108|NCT01348230||prior preterm delivery at 32-34 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
9976109|NCT01348230||prior preterm delivery at 34-36 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
10177733|NCT03819712|Experimental|No recurrent UTI|Healthy female volunteer aged 18 to 28 years reporting a single cystitis since the age of 14 years
10177734|NCT03819712|Experimental|Recurrent UTI|
10177735|NCT03819673|Experimental|Intervention Group (IG)|Care based on the computerised decision-support tool
10177736|NCT03819673|No Intervention|Control Group (CG)|Usual care advice by primary care provider or dietitian of participating hospital
10177737|NCT03819699|Experimental|Cohort 1 - dose regimen 1|Cohort 1: encompasses patients enrolled prior to the PA1
10177738|NCT03819699|Experimental|Cohort 2 - dose regimen 2|Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
10177739|NCT03819699|Experimental|Cohort 2 - dose regimen 3|Cohort 2: 10 patients who will not receive a booster vaccine
10177740|NCT03819647|Experimental|stiripentol (Diacomit)|
10177741|NCT03819621|Experimental|OCULAR PROSTHESIS MOTILITY|All participants ocular prosthesis motility will be measured using the mediGrid app, Image J software in comparison to the ruler as a gold standard.
10177742|NCT03819608|Experimental|real APT+ real iTBS|real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
10177743|NCT03819608|Active Comparator|real APT + placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
10177744|NCT03819608|Active Comparator|placebo APT+ real iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
9682723|NCT04911205|No Intervention|Control Group|Patients who were randomly allocated to control group (N=44), they continued to live as usual, prior to surgery
9682724|NCT04910971||Group 1: Recipients of BNT162b2 mRNA Covid-19 Vaccine|
9682725|NCT04910971||Group 2: Recipients of mRNA-1273 SARS-CoV-2 Vaccine|
9682726|NCT04911283||MCs type 1 patients (study group; n=37)|
9682727|NCT04911283||MCs type 2 patients (comparator group; n=44)|
9682728|NCT04911283||healthy controls (n=37)|
9682729|NCT04911296|Other|Swallow Group|
9695607|NCT04776395|Active Comparator|Arm B (iberdomide hydrochloride)|Patients receive iberdomide hydrochloride PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9976110|NCT01348243|Experimental|Clodronate 200 mg|
9976111|NCT01348243|Active Comparator|Clodronate 100 mg|
10177745|NCT03819608|Active Comparator|placebo APT+ placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
10177746|NCT03819595|Experimental|Supervised arm|Supervised exercise. The intervention will be a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
10177747|NCT03819595|Active Comparator|Control arm|"Supervised exercise.The intervention will be a Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.~After 3 months, it become supervised arm"
10177748|NCT03819582|Experimental|Intraocular lens|Subjects implanted with the EyeCee One Intraocular lens
10177749|NCT03821311|Experimental|Computed tomography examination|Each patient will undergo a low-dose supine position chest CT scan including end-inspiratory and expiratory acquisitions, corresponding to the routine protocol for COPD patients, except that this end-inspiratory/end-expiratory CT is repeated 3 times for total of 6 CT acquisitions.
10177750|NCT03819543|Experimental|Transcranial Direct Current Stimulation|
10177751|NCT03819556|Active Comparator|Active immunotherapy with milk protein|Daily dose fresh milk protein increased in 11 steps
9682730|NCT04911010|Experimental|Experimental: Prolonged Exposure + Treatment as usual|"Participants in this arm will receive 16 weekly sessions with Prolonged Exposure Therapy (RT) over 4 months in addition to their treatment as usual.~Interventions:~Behavioral: Prolonged Exposure Therapy Other: Treatment as usual"
9682731|NCT04911010|No Intervention|Waiting-Controll-Group|"Treatment as usual Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally.~Intervention: Other: Treatment as usual"
9682732|NCT04911140|Active Comparator|Photobiomodulation twice a week|This group will receive the application of photobiomodulation (PBM) twice a week for 4 weeks.
10177752|NCT03819556|No Intervention|Control|Diet free from milk protein
10177753|NCT03821545|Active Comparator|Lidocaine Group|
9682733|NCT04911140|Active Comparator|Photobiomodulation three times a week|This group will receive the application of photobiomodulation (PBM) three times a week for 4 weeks.
9682734|NCT04911140|Placebo Comparator|Simulated Photobiomodulation|This group will receive the application of simulated photobiomodulation (PBM) twice a week for 4 weeks.
9682735|NCT04911101|Experimental|7G needle|7G needle dimension used
9682736|NCT04911101|Experimental|10G needle|10G needle dimension used
9682737|NCT04911179|Experimental|Combined multicomponent physical exercise and cognitive stimulation (Vivfrail-Cog)|"The supervised multicomponent exercise training program (resistance, endurance, balance and flexibility) will be comprised of upper and lower body exercises tailored to the individual's functional capacity. Subjects will be encouraged at performing strength and endurance exercise at a moderate intensity. Exercise will progress in terms of intensity and difficulty upon individual adaptation.~The cognitive intervention will include the performance of different exercises with pencil and paper in order to train different cognitive areas, especially the executive functions."
10177754|NCT03821545|Active Comparator|Ketamine Group|
10177755|NCT03821545|Active Comparator|Lidocaine and Ketamine Group|
10177756|NCT03821545|Placebo Comparator|Placebo (0.9% NaCl) Group|
10177757|NCT03821675|Active Comparator|Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
10177758|NCT03821675|Sham Comparator|Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
10177759|NCT03819530|Experimental|Supplementation Group|Receives baseline deworming medication. Intervention: receive daily micronutrient supplementation packets- 6 month supply, to be taken every day. Blood iron and anthropometric measurements taken at 0 and 6 months.
10177760|NCT03819530|No Intervention|Control Group|Receives baseline deworming medication. Blood iron and anthropometric measurements taken at 0 and 6 months.
10177761|NCT03821571|Experimental|Patient with primary aldosteronism|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
10177762|NCT03821571|Active Comparator|Patient with essential hypertension|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
10177763|NCT03819517|Active Comparator|Resveratrol|500 mg of time released micronized trans-Resveratrol
10177764|NCT03819517|Placebo Comparator|Placebo|Placebo will be used in the form of an empty white colored soft vegetarian capsule as resveratrol is presented
10177765|NCT03819504|Experimental|4-D navigated stereotactic radiosurgical ablation|Patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias will undergo 4-D navigated stereotactic radiosurgical ablation
9682738|NCT04911179|No Intervention|Usual care|The usual care group will receive normal outpatient care (including the evidence-based Otago exercise program).
10177766|NCT03821389|Experimental|NIOD Frequencer of 40Hz|40 Hz of NIOD will be applied and then 60Hz will be used 3 hours later. 60 Hz of NIOD will be applied and then 40Hz will be used 3 hours later for the rest of the patients. The investigators will analyze the difference in average effects between 40Hz and 60Hz.
10177767|NCT03821389|Active Comparator|NIOD Frequencer of 60Hz|
9682739|NCT04911192|No Intervention|systemic thrombolysis group|patients without any contraindications for systemic fibrinolytic therapy will be treated with traditional systemic thrombolysis (intravenous administration of streptokinase).
10177768|NCT03821285|Experimental|pulmonary rehabilitation|Pulmonary rehabilitation program
10177769|NCT03821506|Experimental|Dynamic light|The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
10177770|NCT03821506|Placebo Comparator|Usual care|The usual care is constant standard LED-light with two elements: two ceiling mounted lamps and a wall mounted lamp.
9682740|NCT04911192|Active Comparator|mechanical fragmentation group|patients will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy.
9682741|NCT04911192|Active Comparator|In Situ thrombolysis group|patients will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC(Swan-Ganz pulmonary artery catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
9682742|NCT04911244|Experimental|VAP group|patients confirmed diagnosis of VAP with bronchoalveolar lavage
9682743|NCT04911244|Experimental|Non VAP group|patients confirmed not VAP with bronchoalveolar lavage
9682744|NCT04910763|Experimental|Resistance Exercise|Resistance exercise will be training all major muscle groups 2x/week (2 days upper body, 2 days lower body) at 40-50% 1 repetition max (RM; estimated from 10 RM baseline testing) for 3 sets of 10-12 reps. This equals 4x/week for the 3 week intervention period.
9682745|NCT04910997|Experimental|HRV Group|Heart rate variability training group
9682746|NCT04910997|Active Comparator|Traditional Exercise Group|Traditional (e.g. standard) exercise training
9682747|NCT04910997|No Intervention|Control Group|Usual care
10177771|NCT03821207|Active Comparator|The exercise group|The group will be instructed to perform stretching exercises including the pelvic and lumbar regions 3 times a day for the first 3 days of the menstrual cycle
10177772|NCT03821207|Active Comparator|The abdominal massage group|The group will be instructed to massage the abdomen for 10 mins a day on the first 3 days of the menstrual cycle.The massage is to be applied as effleurage (light touch) clockwise over the abdomen
9682748|NCT04910984|Experimental|Chatbot group|
9682749|NCT04910984|Placebo Comparator|TAU group|
9682750|NCT04910802|Experimental|HPV-vaccination|Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.
9682751|NCT04910841|Experimental|Connect|
9682752|NCT04910620|Placebo Comparator|Placebo|Placebo without TCI378 and TCI507
9682753|NCT04910620|Experimental|TCI378|probiotics TCI378 (Lactobacillus plantarum TCI378)
9682754|NCT04910620|Experimental|TCI507|TCI507 (Lactobacillus plantarum TCI507)
9682755|NCT04911465||Pediatric Trauma Patients|All pediatric patients >31 days who meet criteria for highest level trauma activation (Level Red or Level 1) at the Children's Hospital Colorado.
9682756|NCT04910893|Experimental|Cytokine Adsorption Arm|Intervention with CytoSorb
9682757|NCT04910893|Other|Historical Comparison|Patients extracted from a septic shock population treated at the same institution between 2010 and 2018 and matched to the intervention group.
9682758|NCT04910659|Active Comparator|acupuncture|Group1, laser acupuncture was applied to each of the previously described P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds
10177773|NCT03821207|Placebo Comparator|The control group|The control group will perform no exercise or massage.
10177774|NCT03821376|Experimental|Renal malignancy|Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
10177775|NCT03821298|Experimental|Standard of Care|short thumb orthoses during ADL, joint reeducation for hand used, radial nerve gliding exercises and thumb proprioception exercises
10177776|NCT03821220|Active Comparator|Group A|Patients will receive an activity tracker and written information for pre-diabetic, on top of their usual care.
10177777|NCT03821220|Active Comparator|Group B|Patients will receive an activity tracker, written information for pre-diabetic, and personalized physical activity prescription, on top of their usual care.
10177778|NCT03821220|Active Comparator|Group C|Patients will receive an activity tracker, written information for pre-diabetic, personalized physical activity prescription, three sessions of motivational interview support from trained physician assistants, and two session of dietitian support, on top of their usual care.
10177779|NCT03821103|Experimental|Standard training arm|The standard training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period.
10177780|NCT03821103|Experimental|Behavioral economic enhanced arm|The behavioral economic enhanced training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period in addition to an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders
10177781|NCT03819335|Active Comparator|Standard care|Usual follow-up of diabetes type 1 with face-to-face visits
10177782|NCT03819335|Experimental|mySugr app|Telemedical assistance with mySugr app
10177783|NCT03819296|Experimental|Supportive Care (standard of care, sample collection, FMT)|"PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.~PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples.~PROJECT 3: Patients undergo FMT."
10177784|NCT03819270|Experimental|LY3372689|Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
10177785|NCT03819270|Placebo Comparator|Placebo|Matching placebo administered orally in healthy participants in one of three study periods
10177786|NCT03819309|Experimental|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
9682759|NCT04910659|Sham Comparator|false acupuncture|P6, LI4 and LI 11 points on both arms with laser acupuncture device (Sedatelec Premio 32) for 30 seconds while laser acupuncture closed
9682760|NCT04910789|Experimental|Thoracoabdominal approach|Radical surgery should be finished via Thoracoabdominal approach.
9682761|NCT04910789|Active Comparator|Transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach.
9682762|NCT04910477|Experimental|Dexmedetomidine|Group D (patients will receive ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
9682763|NCT04910477|Experimental|Neostigmine/atropine|Group N (patients will receive nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
9682764|NCT04910477|Placebo Comparator|Saline placebo|Group S (patients will receive nebulization of saline placebo in 4 ml)twice daily for three days.
9976112|NCT01348256|No Intervention|Observation|Observation after standard treatment
9682765|NCT04910347|Experimental|Single Arm|Nivolumab
9682766|NCT04910490||Patients received stereotaxic aspiration|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
9976113|NCT01348256|Experimental|Dendritic cells vaccine|Adjuvant treatment with dendritic cells vaccine after standard treatment
9976114|NCT01348269|Active Comparator|Aclasta|
9976115|NCT01348269|Placebo Comparator|NaCl Solution|
9976116|NCT01348282|Experimental|Lithium|Lithium group: Patients who will initiate therapy with lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
9976117|NCT01348282|Active Comparator|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
9976118|NCT01348282|No Intervention|Control group|Patients who will not initiate treatment
9976119|NCT01348295||Mechanically ventilated children|All children under 16 years of age who are needing mechanical ventilation for any reason.
9976120|NCT01348308|Active Comparator|Maraviroc|Maraviroc 300, 600 or 1200mg per day
9976121|NCT01348308|Placebo Comparator|Placebo|Placebo 300, 600 or 1200mg per day
9976122|NCT01348321|Experimental|Azithromicine plus levamisole|
9976123|NCT01348321|Experimental|Azithromicin|
9976124|NCT01348334|Active Comparator|Vypromesh®(Ethicon,USA)|Vypromesh®(semiabsorbable multiflament mesh;non-absorbable Polypropylene+absorbable Poliglactin)
9976125|NCT01348334|Active Comparator|Ultrapromesh®(Ethicon,USA)|Ultrapromesh®(semiabsorbable monofilament mesh;non-absorbable Polypropylene+absorbable polyglecaprone).
9976126|NCT01348334|Active Comparator|Prolene light mesh®(Johnson&Johnson,USA)|Prolene light mesh®(cpp-Condensed monofilament non absorbable polypropylene mesh)
9976127|NCT01348360||NOBORI stent|
9976128|NCT01348373||GENOUS EPC-coated stent|Patients treated with GENOUS EPC-coated stent
9976129|NCT01348386|Experimental|KOH 10%|Treatment consists of the application of topical 10% KOH in an aqueous solution.
9976130|NCT01348386|Experimental|KOH 15%|Treatment consists of the application of topical 15% KOH in an aqueous solution
9976131|NCT01348386|Placebo Comparator|PLACEBO|100 milliliters of saline solution
9976132|NCT01348399||XIENCE PRIME stents|
9976133|NCT01348412|Experimental|ARM A|Hepatic artery infusion through an implanted arterial catheter of the combination of raltitrexed (3 mg/m ²) and oxaliplatin (100 mg/m ²) every 21 days.
9682767|NCT04910490||Patients received conservative therapy|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
9682768|NCT04910308|Experimental|Dose painting|Dose painting
9682769|NCT04910386|Experimental|Envafolimb|"Envafolimab plus Gemcitabine&Cisplatin Envafolimab: 300 mg on Day 1 of each cycle, subcutaneous injection. Every 21 days is a treatment cycle.~Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
9682770|NCT04910386|Active Comparator|Gemcitabine&Cisplatin|"Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.~Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles."
9682771|NCT04910646|Experimental|orange peel fermentation|
9682772|NCT04910646|Placebo Comparator|placebo|
9976134|NCT01348412|Active Comparator|ARM B|Intravenous standard chemotherapy.
9976135|NCT01348438|Other|Single arm study|
9976136|NCT01348451|Experimental|surgery|A sequential design of five groups will be utilized to reduce risk to subjects. The first group (Group A) will include six subjects and the subsequent groups will include three subjects per group. Each group represents both different inclusion criteria and location of surgery.
9976137|NCT01348464||lifestyle, wound satisfaction|single site access three site access for appendectomy
9976138|NCT01348477|Experimental|Elliptical domed mesh technique|84 adult patients with primary uncomplicated inguinal hernia, treated with an open preperitoneal elliptical mesh technique
9976139|NCT01348477|Active Comparator|Lichtenstein technique|84 adult patients with primary uncomplicated inguinal hernia treated with the Lichtenstein technique (gold standard)
9976140|NCT01348503|Experimental|Open Label, Single Arm|Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
9976141|NCT01348516|Experimental|KM-023|
9976142|NCT01348516|Placebo Comparator|Placebo for KM-023|
9976143|NCT01348529|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
9976144|NCT01348555|Experimental|V0162|
9976145|NCT01348555|Placebo Comparator|Placebo|
9976146|NCT01348568|Experimental|Low glycemic index diet with canola oil bread|Subjects will be given whole wheat bread which includes canola oil, and advised to follow a diabetic diet using low glycemic index foods.
9976147|NCT01348568|Active Comparator|high fiber diet|Subjects will be given whole wheat bread, and advised to follow a healthy high fiber diabetic diet.
9976148|NCT01348581|Experimental|Marigen Wound Dressing|
9976149|NCT01348594||Vitamin D deficient|
9976150|NCT01348594||Vitamin D sufficient|
9976151|NCT01348620|Experimental|Single port laparoscopic device|
10177787|NCT03819309|Active Comparator|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
10177788|NCT03821012||CSCAP-1|STEMI with symptom onset within 12 h regardless of whether receiving reperfusion or symptom onset within 12-24 h of needing PPCI
9682773|NCT04910399|Experimental|Blue fish hydrolysate|The test product is a food supplement named BrainBooster in our project. It is presented as a capsule containing a blue fish hydrolysate, containing peptides and n-3 polyunsaturated fatty acids.
10177789|NCT03821012||CSCAP-2|STEMI patients with symptom onset within 30 days
10177790|NCT03821012||CSCAP-3|STEMI patients with symptom onset within 30 days
10177791|NCT03819348||TSM of HIV-negative Host|Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
10177792|NCT03819283|Other|Hepatic evaluation|
9682774|NCT04910399|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
9682775|NCT04910516|No Intervention|Control Group|The nurses in the control group were informed about the purpose of working in a quiet room. STAI-D, STAI-S, SUD, P19-S scales were filled face-to-face by the investigator after their informed consent was obtained. The scales were filled again by the researcher after a break of 7 (seven) days.
9682776|NCT04910516|Experimental|Experiment Group|In order to avoid bias in the intervention applied in our study, the experimental group was started after the control group was finished. The participants were informed about the purpose of working face-to-face in a quiet room so that EFT, which will be applied online for 7 (seven) days by the researcher, can be applied effectively and accurately. STAI-D, STAI-S, SUD, P19-S scales were completed after their consent was obtained. The researcher, who has the EFT certificate, first showed the application steps on himself with the guidance of the EFT guideline, and ensured that the application steps were applied again simultaneously on both himself and the participant. After this application, it was provided to make EFT online for 7 (seven) days. STAI-D, STAI-S, SUD, P19-S scales were filled in after the last EFT application.
10177793|NCT03819244|Experimental|Diode laser|Soft tissue incision with 940 nm Gallium Aluminum Arsenide diode laser, at implant recovery settings (2.5 W output power, average power: 1.25 W, pulse length : 1.00 ms, pulse interval: 1.00 ms) in second-stage implant surgery.
10177794|NCT03819244|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz, H mode, 10% water and 10% air) in second-stage implant surgery.
10177795|NCT03819426|Experimental|High Intensity Interval Training|Participants will be shown the appropriate techniques and intensity (high intensity; i.e., 70-90% of maximum heart rate (220-age) with a verified online youtube video. Participants will be provided with this video and other options that can be followed to complete 15 minute HIIT interventions at home. Interventionist will observe participant engaging in HIIT for 15 minutes. HIIT intervention (for 15 minutes) will also be observed during Session 4 and 8.
10177796|NCT03819426|Experimental|Walking|This intervention will be demonstrated during Session 1. Participants will be shown the appropriate walking intensity (low intensity; i.e., approximately 50% of maximum heart rate (220-age) or lower) by interventionist. Interventionist will observe participant engaging in walking at appropriate intensity level for 15 minutes. Walking intervention (for 15 minutes) will also be observed during Session 4 and 8.
10177797|NCT03821363|Experimental|Low dose group|SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
9682777|NCT04910555||women over 65 years old with OAB|Community-dwelling women over 65 years old, with non-neurogenic OAB, with or without UI
9682778|NCT04910633||Solid Tumor and COVID-19|Patients with a solid tumor followed by an oncologist of Lyon University Hospital Cancer Institute (LUHCI) who have been hospitalized at LUHCI for the COVID-19 between March and May 2020 and who didn't oppose the reuse of their medical file data for research purpose.
9682779|NCT04910412|Experimental|Anodal tDCS with gait training|Anodal tDCS will be applied over the primary motor cortex (M1) (anodal or active electrode on M1 area, cathodal or reference electrode on supraorbital area) for 20 mins with 2 mA intensity before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
9682780|NCT04910412|Active Comparator|Sham tDCS with gait training|Sham tDCS will be applied over the primary motor cortex for 20mins before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
9682781|NCT04910698||Short course treatment|Patients who received antibiotic for 7 or less days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
9682782|NCT04910698||Long course treatment|Patients who received antibiotic for more than 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.
10177798|NCT03821363|Experimental|Middle dose group|SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
9527650|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
9527651|NCT03218332||Healthy controls|Active Comparator
9682783|NCT04910828|Experimental|Common foods of varying glycemic indices|Common foods of varying glycemic indices
10177799|NCT03821363|Experimental|High dose group|SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
10177800|NCT03820986|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
10177801|NCT03820986|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
10177802|NCT03819231|Experimental|Mindfulness and intranasal oxytocin|Given oxytocin through intranasal administration and self-directed mindfulness training.
10177803|NCT03819231|Active Comparator|Mindfulness and placebo|Given sterile saline through intranasal adminstration and self-directed mindfulness training.
10177804|NCT03819231|Sham Comparator|Sham mindfulness and placebo|Given sterile saline through intranasal adminstration and sham self-directed mindfulness training.
10177805|NCT03819361||Suspected OSA|
10177806|NCT03819322|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
9682784|NCT04910672|Active Comparator|Control Group|The control group (n = 30) will only carry out a bilateral global pelvic manipulation
9682785|NCT04910672|Experimental|Experimental Group|The experimental group (n = 30) will be treated following an osteopathic treatment, through a bilateral global pelvic manipulation and a specific internal technique for mobility of the cervix
9682786|NCT04910282||Eye Disease Patients|Patients with eye diseases age 65 and above will be included. Patients from the Ivey Eye Institute, St. Joseph's Health Care London, ON will be recruited in-person, based on inclusion and exclusion criteria.
9682787|NCT04910191|Experimental|Open Label|"Up to 200 patients will participate in this open study. Before each examination with the study device, data from each patient (Current medical condition, medical history and demographic data) will be inserted to a computer and added to the database of the study for further processing in conjunction with the study device results.~The study device electronic stethoscope membrane will be put on the patient's chest area in predefined anterior and posterior points. At the end of each examination the data will be transferred to a computer and stored in the patient's file. Each patient will be requested to attend the examination once."
9682788|NCT04910126|Experimental|experiment group|adriamycin and Camrelizumab
10177807|NCT03819322|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
10177808|NCT03819166|Experimental|experimental group|The participants recruited in the group will receive the input of deep touch pressure during their procedures of dental treatment.
10177809|NCT03819166|Sham Comparator|control group|The participants recruited in the group will not receive the input of deep touch pressure during their procedures of dental treatment.
10177810|NCT03819192||neonates with signs of EONS|
10177811|NCT03819192||neonates without signs of EONS|
9682789|NCT04910126|Active Comparator|control group|adriamycin
9682790|NCT04909892|Experimental|COVI-MSC 1 vial|Subjects will receive intravenous infusions of COVI-MSC (one vial, ~18.5 million cells) on Day 0, Day 2, and Day 4.
9682791|NCT04909892|Experimental|COVI-MSC 2 vials|Subjects will receive intravenous infusions of COVI-MSC (two vials, ~37 million cells) on Day 0, Day 2, and Day 4.
10177812|NCT03819192||pregnant women with PPROM|
10177813|NCT03820908|Experimental|Bisantrene|patients will receive bisantrene 250mg/m2/d for 7 days
10177814|NCT03819205|Experimental|kinesiotaping group(before/after)|"Hemiplegic CP:Kinesiotaping on the affected side~Diplegic, tetraplegic CP: side of upper extremity which children have been used to but have obstacles in daily life~intervention Duration: For 1 week at least 2-3 hours a day, renewing if it's necessary.~Note:Patients will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day.~Evaluation: In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion"
10177815|NCT03819257||Patients with perianal Crohn's disease.|
10177816|NCT03819140|Active Comparator|Continuous OCP Therapy|Participants randomly assigned to this arm will receive 8 packs of a 21 day oral contraceptive pills (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which comes in a formulation of 21 days of active hormone and 7 days of sugar pills. In this arm, participants will only be expected to take active hormone pills (colored pills) for the 6 months straight without stopping or taking the sugar pills in each pack.
10177817|NCT03819140|Active Comparator|Cyclical OCP Therapy|Participants randomly assigned to this arm will receive 6 packs of a 21 day oral contraceptive pill (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which has 21 days of active hormone and 7 days of sugar pills. Participants will take one pill daily for 6 months and be expected to take the sugar pills at the end of each monthly pack prior to starting a new pack.
10177818|NCT03819036|Experimental|Patients|Questionnaires for patients requiring dental emergencies care
10177819|NCT03819179|Experimental|Serum|Burt's Bees Serum
10177820|NCT03819179|Experimental|Serum with Biulin|Burt's Bees Serum with Biulin
10177821|NCT03819179|Experimental|Serum with Berenew Complex|Burt's Bees Serum with Berenew Complex
10177822|NCT03819179|Experimental|Serum with Ecoskin|Burt's Bees Serum with Ecoskin
10177823|NCT03819179|Experimental|Serum with Bonicell|Burt's Bees Serum with Bonicell
10177824|NCT03819023|No Intervention|Normal subjects|
10177825|NCT03819023|Active Comparator|respiratory suppressing drugs|
10177826|NCT03819101|No Intervention|Arm A|Standard of Care (SOC) for CRPC
10177827|NCT03819101|Experimental|Arm B|SOC + acetylsalicylic acid 100 mg daily
10177828|NCT03819101|Experimental|Arm C|SOC + atorvastatin 80 mg daily
10177829|NCT03819101|Experimental|Arm D|SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8
10177830|NCT03820804||Diet-treated|Patients with Phenylketonuria under dietary treatment.
10177831|NCT03820804||Sapropterin-treated|Patients with Phenylketonuria under sapropterin treatment.
10177832|NCT03820791|Experimental|Poster|A poster with pictorial information about dysphagia-specific food procedures placed in patients' rooms for one month
9682792|NCT04910178|Experimental|Empa group|patients will be given Empagliflozin 25 mg once daily
9682793|NCT04910178|Experimental|PTX group|patients will be given PTX 400 mg twice daily or 3 times daily
9682794|NCT04910178|Experimental|UDCA group|patients will be given UDCA 500 mg twice daily
9682795|NCT04910178|Placebo Comparator|Placebo|patients will be given a placebo
10177833|NCT03820791|No Intervention|No poster|No poster is placed in patients' room.
10177834|NCT03819127|Active Comparator|Metformin|metformin 1 g twice a day for 24 weeks
9682796|NCT04910165|Experimental|Exparel|Liposomal Bupivacaine use as active ingredient in the block
9682797|NCT04910165|Active Comparator|Control|Ropivacaine use as active ingredient in the block
9682798|NCT04910217|Experimental|Lokomat intervention|Patients randomized into the Lokomat arm will undergo therapy with Lokomat Pro FreeD for 20-50 minutes 5-times a week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.
9682799|NCT04910217|Experimental|Leg/lower body exerciser|Patients in this arm will undergo therapy with leg/lower body exerciser for 20-50 minutes, 5 times per week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.
9682800|NCT04910256|Experimental|HuaTuo ZaiZao group|"In this arm, patients take 8g of HuatuoZaizao pill three times a day. Besides，participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
9682801|NCT04910256|Active Comparator|Control group|"participants will receive basic treatment in accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation.Treatment lasts for 12 weeks"
9682802|NCT04909788||Healthy adults with regular exercise|Subjects will be asked to wear a small monitoring equipment before,during and after a long distance running (over 3 km).
9682803|NCT04909710|Experimental|Autism Case Group|Autistic participants will receive mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
9682804|NCT04909710|Other|Neurotypical Sibling Control Group|Neurotypical control participants will receive the same mobile game system for 12 weeks and be asked to play a minimum of ten 90-second game sessions per week per child over 12 weeks. Research team will further require that at least three of these 10 weekly sessions with each child be with game decks displaying emotion.
9682805|NCT04909814||Vaccinated women with positive screening test|All women in one Swedish county taking their first screening test within the organized cervical screening program
9976152|NCT01348620|Active Comparator|Four-port laparoscopic device|
9682806|NCT04909736|Experimental|Music Exposure|Patient will listen to a specified duration of music.
9682807|NCT04910035|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
9976153|NCT01348633||Sub-study 1|The Quantitative, Doppler SD-OCT Blood Flow Technology will be validated and calibrated by manipulating end-tidal blood gases using the computer-controlled gas sequencer (Slessarev et al, 2005) in 15 healthy controls. Homeostatic inner retina blood flow values and the magnitude of vascular reactivity will be compared between Doppler SD-OCT blood flow technology and the Canon Laser Blood Flowmeter, an established standard, at specific locations within the retinal vascular tree.
10177835|NCT03819127|Experimental|Metformin plus vildagliptin|metformin 1 g plus vildagliptin 50 mg twice a day for 24 weeks
9682808|NCT04910035|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
9682809|NCT04910009|No Intervention|Theoretical training group|Students participating in only theoretical training of the privacy education for two 40-minute sessions.
9682810|NCT04910009|Experimental|Digital story and ethical case analysis group|Students participating in 2 sessions of 40-minute theoretical training and then participating in 4 sessions of 60-minute digital story and ethical case analysis preparation and presentation.
9682811|NCT04910009|Experimental|Only ethical case analysis group|Students participating in 2 sessions of 40 minutes of theoretical training and then participating in 4 sessions of 60-minute ethical case analysis preparation and presentation only.
9682812|NCT04909931|Experimental|vitamin D supplementation group|First arm ; add on vitamin D 40,000 IU/week for 12 weeks
9682813|NCT04909931|Experimental|second arm|add on placebo
9682814|NCT04909918|Experimental|(Group D )Dexamethasone|Intravenous dexamethasone 8 mg/day given for 7 days
9682815|NCT04909918|Experimental|(Group M) methylprednisolone|Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
9682816|NCT04910139|Experimental|Treatment|Treatment using acoustic energy
9682817|NCT04909944|Experimental|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation and ventilation
9682818|NCT04909944|Experimental|laryngeal tube suction disposable supraglottic insertion for oxygenation|laryngeal tube suction disposable insertion for oxygenation and ventilation
9682819|NCT04909879|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
10177836|NCT03820778|Experimental|Study Arm|Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
10177837|NCT03818867|Experimental|Cerclage arm|Pregnancies which had cervical cerclage inserted.
10177838|NCT03818867|No Intervention|No-cerclage arm|Pregnancies which did not have cervical cerclage inserted.
10177839|NCT03819010|Active Comparator|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
10177840|NCT03819010|Active Comparator|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
9682820|NCT04909879|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
9682821|NCT04909827|Experimental|group A|3D printed microfilled hybrid composite Endocrowns
10177841|NCT03818997|Experimental|BTC Cohort|Patient in BTC cohort will receive immune therapy and DKN-01 IV until PD
10177842|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab + paclitaxel (Arm 1)|Patient randomized in the EGC Arm 1 will receive immune therapy, DKN-01 and chemotherapy intravenously (IV) until PD.
10177843|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab without paclitaxel (Arm 2)|Patient randomized in the EGC Arm 2 will receive immune therapy and DKN-01 IV until PD
9682822|NCT04909827|Experimental|group B|prefabricated zirconia crowns
9682823|NCT04909840|Experimental|dental floss|Instructions of oral hygiene with toothbrush plus dental floss
9682824|NCT04909840|Active Comparator|without dental floss|Individuals who will use only toothbrush
9682825|NCT04909749|Experimental|PGx-guided antidepressant therapy|These individuals will be prescribed medication guided by the Oneome RightMed Test.
9682826|NCT04909749|No Intervention|Treat as usual based on Clinical Physician Recommendation|These individuals will receiving medication as usual based on the clinics internal guidelines and physician recommendations.
9682827|NCT04909684|No Intervention|Standard of care|100% pembrolizumab
9682828|NCT04909684|Experimental|Intervention|75% pembrolizumab
9682829|NCT04909762|Other|Early rehabilitation and mobilisation|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package, provided by health care professionals from multiple disciplines and parents/carers within intensive care settings to promote recovery, both physical (e.g. movement, functional activities, ambulation) and non-physical (e.g. speech, play, psychological, cognitive). In adult intensive care, ERM has been shown in clinical trials to improve long term physical functioning and return to independence. It can also shorten the length of ventilation and stay in intensive care and hospital with significant economic benefit.
10177844|NCT03819075|Experimental|Laser|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units.
10177845|NCT03819075|Active Comparator|Control|Standard periimplantitis treatment will be conducted in the control group.
10177846|NCT03818958||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
10177847|NCT03818958||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
10177848|NCT03818958||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
9682830|NCT04909619|Experimental|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|Patients randomized to this arm will receive an ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg of 0.2% ropivacaine per side, for a total of 0.3 ml/kg immediately after induction of general anesthesia and prior to incision. Participants will also receive local infiltration of the palate with an equivalent injection volume of 0.9% saline with 1:400,000 epinephrine at 2 ml/kg. Pediatric anesthesiologists with fellowship training in regional anesthesia will perform the nerve block. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
9695608|NCT04776629|Active Comparator|Active Treatment|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
9695609|NCT04776629|Placebo Comparator|Placebo|"Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes.~Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months."
10177849|NCT03818958||fibromyalgia|subjects with fibromyalgia
9827569|NCT02461160|Experimental|DDI Cohort 7: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).
10177850|NCT03818841|Experimental|High-flow nasal cannula group|Patients randomised in this group will receive oxygen therapy via a high-flow nasal cannula device with a 60 L/min flow and a 100% fraction of inspired oxygen
10177851|NCT03818841|Other|Non-rebreathing oxygen mask group|In this group patients will be treated with standard oxygen therapy delivered through a non-rebreathing face mask with a 15 L/min flow
10177852|NCT03818906|Active Comparator|Control Group|Patients with first or second molars where the extractions will be performed in a conventional way without any additional local treatment to be done in the alveolus. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
10177853|NCT03818906|Experimental|Test Group 1|Patients with first or second molars where the extractions will be performed in a conventional way and after extraction will be performed aPDT inside the alveolus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
10177854|NCT03818906|Experimental|Test Group 2|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia, the fresh socket will receive local application of infrared in the outer vestibular portion. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
10177855|NCT03818906|Experimental|Test Group 3|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia the approaches from the previous groups (Test Group 1 and 2 (aPDT + infrared) will be done. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
10177856|NCT03818945|Other|Sodium Fluoride Varnish|
10177857|NCT03818945|Active Comparator|PRG barrier Giomer|
9682831|NCT04909619|Active Comparator|Local anesthetic infiltration of the palate|Patients randomized to this arm will receive local infiltration of the palate using 0.125% bupivacaine + 1:400,000 epinephrine at a dose of 2 ml/kg intraoperatively. Local anesthetic infiltration will be performed by one of four board-certified pediatric plastic and craniofacial surgeons during repair of the palate. Patients, parents, surgeons, and the anesthesiologist will not be blinded to the specific intervention group due to the nature of the procedures involved. Nurses and the two key personnel responsible for data collection and analysis will be blinded throughout the entirety of the study.
10177858|NCT03818932|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
10177859|NCT03818932|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
10177860|NCT03818919|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
10177861|NCT03818919|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500
10177862|NCT03818568|Experimental|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
10177863|NCT03818568|Active Comparator|Control|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).
10177864|NCT03818724||CoolLoop® cryoablation system|Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system
10177865|NCT03818893|Experimental|New Combination Immunotherapy|"Patients will receive Pembrolizumab once every 3 weeks and a maximum of 35 doses over 105 weeks .~The patients should be inpatient during treatment with GEN0101 in each treatment cycle and may be outpatient during off-treatment period with GEN0101, observation period, follow-up period with Pembrolizumab.~GEN0101 in a vial will be reconstituted with 1 mL of sterile distilled water and then will be injected intracutaneously (including skin tumor site). Nonetheless, it will not be deemed as deviation if an injection has been given subcutaneously unintentionally, e.g., leakage around the peri-injection sites.~A dose will be 60,000 mNAU in total, and 1 mL per injection site should be administered to 6 injection sites in total. For a patient, the total dose in a treatment cycle will be 360,000 mNAU (360 NAU), and the total dose over 2 treatment cycles will be 720,000 mNAU (720 NAU)."
10177866|NCT03818685|Experimental|Nivolumab + Ipilimumab|Nivolumab (360 mg IV, every 3 weeks) for 8 doses and Ipilimumab (1 mg/kg, IV, every 6 weeks or every 2 doses of Nivolumab in case of dose delays) for 4 doses.
10177867|NCT03818685|Active Comparator|Capecitabine|Capecitabine (1000 mg/m2 twice a day, Bis In Die), 14 days on / 7 days off for 8 cycles.
10177868|NCT03818633|Experimental|Elastic abdominal binder|
10177869|NCT03818633|No Intervention|No binder|
10177870|NCT03818789|Experimental|Mindfulness|A mindfulness training is applied to see if it supports exercise endurance in-lab and during follow-up
10177871|NCT03818789|Placebo Comparator|Control|A study skills video is shown intended to have no effect on exercise but to match for time.
10177872|NCT03818581|Active Comparator|Treatment Group|
9682832|NCT04909411|Other|Exposed arm|child infected with chikungunya virus during childbirth
9682833|NCT04909411|Other|Non-exposed arm|child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified
9682834|NCT04909632|Experimental|To establish metabolite pattern and biomarkers of tongue fur in DM|
9682835|NCT04909866|Experimental|TACE+Lenvatinib+Camrelizumab|
10177873|NCT03818581|Placebo Comparator|Placebo Responders|
10177874|NCT03818581|Active Comparator|Placebo Non-responders Re-randomized to Treatment|
10177875|NCT03818581|Placebo Comparator|Placebo Non-responders Re-randomized to Placebo|
10177876|NCT03818854|Experimental|Human Mesenchymal Stromal Cells|A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.
10177877|NCT03818854|Experimental|Cell Reconstitution Media|A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes.
10177878|NCT03818672|Experimental|Rifaximin|Rifaximin 550 mg BID
10177879|NCT03818984|Experimental|Safer Conception Intervention|Men will participate in 3 counseling sessions with a lay counselor. In the first session, the counselor will share information on the various safer conception strategies and help the participant think about developing a healthy plan. In the following 2 sessions, the counselor and the participant will work together to develop a healthy baby plan using motivational interviewing and problem solving. In the 2 booster sessions, the counselor and the participant will check in to evaluate the success of the plan and make changes as necessary.
10177880|NCT03818711|Experimental|Communication & Coping Intervention|A cognitive behavioral intervention for mothers of adolescents with type 1 diabetes to improve coping and the quality of parental involvement.
10177881|NCT03818711|Active Comparator|Education & Check Ins|The comparison group receives educational materials on diabetes management and phone calls, as well as access to a secret Facebook group with daily posts on diabetes management.
10177882|NCT03818555|Other|Sebacia Microparticles Treatment|
9682836|NCT04909476||Severe COVID pneumonia with ET|Severe COVID 19 pneumonia undergoing endotracheal intubation
9695610|NCT04776564||Intensive courses|Participants on courses delivered within four days
9695611|NCT04776564||Long courses|Participants on courses delivered over minimum four weeks
9695612|NCT04776564||Clinical|Participants attending G7P courses delivered within the specialist health care setting
9695613|NCT04776564||Internett|Participants attending G7P courses delivered as an online course
10177883|NCT03818750|Experimental|Experimental arm|"Patients (60) will be selected from the Alcohol Use Disorders Identification Test (AUDIT-C) :~light drinkers (score between 1 to 3)~heavy drinkers (score between 4 to 7) Two clinical visits will be realized in less than 4 weeks"
10177884|NCT03818451|No Intervention|Control Group|"All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:~Surgical evacuation of hemorrhagic masses and brain contusion~Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Prevention of secondary complications of critical illness included: preventive treatment of venous thromboembolism (VTE) and seizures~Patient who undergo surgical treatment, will recieve also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage"
10177885|NCT03818451|Experimental|Study Group|Standard treatment plus specific treatment. The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).
10177886|NCT03818438||Case subjects adult patients with chronic ankle instability|"Male or female subjects aged 18-45, presenting :~at least one acute lateral ankle sprain (i.e. initial ankle sprain more than 12 months before inclusion),~at least one residual symptom (giving way OR sensation of instability OR recurrent ankle sprain), confirmed by a score < 24 on the Chronic Ankle Instability Tool (CAIT)~Impact on activities of daily living and sport, score < 90% on Foot and Ankle Ability Measure (FAAM) and < 80% on FAAM-sport Case subjects are free of any other lower extremity pathologies or pain Subjects presenting bilateral chronic ankle instability are excluded"
10177887|NCT03818438||Healthy subjects|Male or female subjects aged 18-45 (matched with case Healthy subjects), without any lower extremity pathologies
10177888|NCT03818503||OligoCare|Patients with oligometastatic disease treated with radical radiotherapy
10177889|NCT03818503||ParticleCare|Patients with cancer treated with particle therapy
10177890|NCT03818412|Experimental|Soft Tissue Sarcoma|"A sample of archival tumor tissue will be collected.~Blood samples (about 20-30 mL or 1-2 tablespoons each sample) will be taken:~Prior to planned radiation treatment~2-4 weeks after cancer surgery~Every 12 weeks after surgery for up to 2 years"
10177891|NCT03818490|Experimental|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit.
10177892|NCT03818490|No Intervention|Control|Patients in this group did not experience an intervention.
10177893|NCT03818542|Experimental|Arm 1: ABBV-181 IV|A single dose of ABBV-181 administered via intravenous (IV) infusion on Day 1.
10177894|NCT03818542|Experimental|Arm 2: ABBV-368 IV|A single dose of ABBV-368 administered via intravenous (IV) infusion on Day 1.
10177895|NCT03818542|Experimental|Arm 3: ABBV-927 IV|A single dose of ABBV-927 administered via intravenous (IV) infusion on Day 1.
10177896|NCT03818542|Experimental|Arm 4: ABBV-927 IT|A single dose of ABBV-927 administered via intratumoral (IT) injection on Day 1.
10177897|NCT03818282|Experimental|Paclitaxel for injection (albumin-bound)|
10177898|NCT03818191|Active Comparator|Acamprosate|"All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.~The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia."
10177899|NCT03818191|Placebo Comparator|Placebo|All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
10177900|NCT03818152|Other|study group|Reliability study isokinetic strength assessment of the lower limbs.
10177901|NCT03818126|Experimental|del Nido cardioplegia|
10177902|NCT03818126|Active Comparator|cold blood cardioplegia|
10177903|NCT03818347|Experimental|oxyhydrogen generator (AMS-H-03)|Model: AMS-H-03 Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively In this group, the patients will inhale hydrogen and oxygen with oxyhydrogen generator. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
10177904|NCT03818347|Placebo Comparator|Control|In this group, the patients will inhale normal air with analogue machine. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
10177905|NCT03818243|Experimental|RLS-|patients with Parkinson disease without RLS
10177906|NCT03818243|Experimental|RLS+|patients with Parkinson disease with RLS
10177907|NCT03818217|Experimental|Coach Pepper group|Pepper is a humanoid socially assistive robot.
10177908|NCT03818217|Other|Tablet group|Tablet training
10177909|NCT03818308|Experimental|Sofosbuvir and Velpatasvir|SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks
9682837|NCT04909580|Experimental|decision coaching|Decision coaching with a patient decision aid guided by the Ottawa Decision Support Framework
9682838|NCT04909489||PDR group|Phlegm-Dampness Retention syndrome group
10177910|NCT03818022|Experimental|Experimental|Patients receiving Cryoneurolysis (Iovera) prior to total knee arthroplasty
9527652|NCT03218345|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
9682839|NCT04909489||SKYD group|Spleen and Kidney Yang Deficiency syndrome group
9682840|NCT04909489||NC group|Normal Control group
9682841|NCT04909437|Experimental|Mycobiotic group|
9682842|NCT04909437|Placebo Comparator|Placebo group|
9682843|NCT04909658|Experimental|ACT matrix protocol|Parents of childrens with Autism Spectrum Disorders (ASD). The ACT protocol group received exercises to improve the psychological well-being of the parents.
9682844|NCT04909658|Active Comparator|PT protocol|Parents of childrens with Autism Spectrum Disorders (ASD).
9695614|NCT04776564||Professional|Participants attending G7P courses wihere professional health care personell are delivering the teaching
10177911|NCT03818022|No Intervention|Control|
10177912|NCT03818009||women undergoing elective CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
10177913|NCT03818009||women undergoing emergency CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
10177914|NCT03817918|Experimental|Determination of local pleural strain|The local pleural strain will be determined over three consecutive respiratory cycles using lung ultrasonography
10177915|NCT03817970|Experimental|Granisetron|Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
10177916|NCT03817970|Experimental|Ondansetron|Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
10177917|NCT03817970|Experimental|Palonosetron|Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
9977639|NCT01363778|Experimental|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
10177918|NCT03818295|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-praliciguat
10187397|NCT03726619|Active Comparator|CHEC-uP|Group 2 will receive a similar education intervention but the education is offered face-to-face instead. Participants will be asked to take part in a one-time, 1 to 1.5-hour face-to-face education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker.
10187398|NCT03726606|Experimental|Extended depth of focus intraocular lens|Bilateral implantation of extended depth of focus intraocular lenses.
10187399|NCT03726606|Active Comparator|Trifocal intraocular lens|Bilateral implantation of trifocal intraocular lenses.
10187400|NCT03726593|Experimental|ASPY|Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
10187401|NCT03726593|Experimental|AP+ASPY|Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking
10187402|NCT03726593|Experimental|AP+ASMQ|Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.
10187403|NCT03726580||control group|regional anesthesia
10187404|NCT03726580||general anesthesia(S)|general anesthesia with sevoflurane
10187405|NCT03726580||general anesthesia(I)|general anesthesia with isoflurane
10187406|NCT03726580||total intravenous anesthesia|total intravenous anesthesia with propofol.
10187407|NCT03726567|Active Comparator|Bariatric surgery group|Patients who are undergoing bariatric surgery for weight loss
10187408|NCT03726567|No Intervention|Non bariatric surgery group|Patients who are undergoing abdominal surgery for non-weight loss reasons
10187409|NCT03726541|Experimental|Early physiotherapy group|breathing exercise incentive spirometry training ambulation coughing
10187410|NCT03726515|Experimental|CART-EGFRvIII + Pembrolizumab|
10187411|NCT03726502|Active Comparator|ureteroscopy with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
10187412|NCT03726502|Placebo Comparator|ureteroscopy alone|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
10187413|NCT03726502|Active Comparator|with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
10187414|NCT03726502|Placebo Comparator|without safety guide-wire|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
10187415|NCT03726489|Other|Office Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
10187416|NCT03726489|Active Comparator|Home Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.
10187417|NCT03726463||polycystic kidney disease|patients with polycystic kidney disease who receive kidney transplantation at Asan Medical Center
10187418|NCT03726450|Experimental|Andrositol Plus|all the patients will be treated for three months with a dietary supplement containing Myo-inositol, NAC, Folic acid, selenium, vitamin E, L-Arginine and L-Carnitine
10187419|NCT03726437|Experimental|RealConsent|A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
10187420|NCT03726437|Placebo Comparator|Stress and Mood Management|A 3-hour general mental health web-based program.
10187421|NCT03726424||mutation|patients carrying one or more specific pathogenic mutations
10187422|NCT03726424||control|patients not carrying the pathogenic mutation(s)
10187423|NCT03726411|Experimental|periodontitis group|in this group, prolactin in GCF will be assessed at baseline and after 3 months of receiving non-surgical periodontal treatment
10187424|NCT03726411|No Intervention|control group|in this group of systemically and periodontally healthy participants, prolactin in GCF will be assessed at baseline only
10187425|NCT03726398|Experimental|Opsumit|Opsumit 10 mg tablet by mouth once daily
10187426|NCT03726372|Experimental|deep neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given by continuous infusion at a dose that reaction to train of four (TOF) stimulation is depressed to zero
10177919|NCT03817996||HFNC + hypoperfusion + Responders|"Patients treated with HFNC presenting with any sign of hypoperfusion, in whom volume expansion was planned by the attending physician.~Clinical signs of inadequate tissue perfusion were suspected at the bedside by observing hypotension (systolic blood pressure <90 mm Hg or the need for norepinephrine), oliguria (urine output <0.5 mL/kg/hr), and cool, mottled extremities.~Their CO increases >15% after passive leg raising."
10177920|NCT03817996||HFNC + hypoperfusion + Non-Responders|Same as previous but their CO do not increase >15% after passive leg raising maneuver.
10177921|NCT03818256|Experimental|CORT118335- 600 mg|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
10177922|NCT03818256|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
10177923|NCT03817866||BRAHMS CgA II KRYPTOR|Adult patients with well defined grade 1 and grade 2 GEP-NETs. Serial serum samples from all patients will be analyzed using the BRAHMS CgA II KRYPTOR Assay.
10177924|NCT03818113||HTK-Bretschneider cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with HTK-Bretschneider cardioplegic solution
10177925|NCT03818113||St. Thomas cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with St. Thomas cardioplegic solution
10177926|NCT03818269|Other|Septic shock|
10177927|NCT03818269|Other|Control|
10177928|NCT03817931|Placebo Comparator|Placebo|Placebo pill identical will be identical to tablets in the other 2 arms.
10177929|NCT03817931|Active Comparator|Anticholinergic|Solifenacin 5 mg tablet orally once daily for 30 days
10177930|NCT03817931|Active Comparator|Beta-3 agonists, adrenergic|Mirabegron 25 mg tablet orally once daily for 30 days
10177931|NCT03818061|Experimental|HPV +|Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
10177932|NCT03818061|Experimental|HPV -|Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.
10177933|NCT03818074|Experimental|Boston Wavewriter (1000Hz) spinal cord stimulation|To investigate the response to high frequency (1000Hz) in patients who are due to have spinal cord stimulation for neuropathic back pain.
10177934|NCT03818087||Elevate|Participants over the age of 70 years old with early-stage breast cancer will be recruited.
10177935|NCT03818048|Experimental|Group Propofol|propofol infusion
10177936|NCT03818048|Experimental|Group Sevoflurane|inhalation with sevoflurane
10177937|NCT03818334|Experimental|Post Cyclophosphamide|Cyclophosphamide 50 mg/Kg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35
10177938|NCT03818334|Active Comparator|Thymoglobulin (ATG)|Thymoglobulin (ATG) total dose 5 mg/Kg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11
10177939|NCT03817827|Experimental|Acupuncture|this group will receive Acupuncture therapy for 30 minutes three times per week
10177940|NCT03817827|Experimental|diet modification|this group will receive diet using soy products a
10177941|NCT03817827|Experimental|combined group|will receive both acupuncture therapy and soy products
10177942|NCT03817788|Active Comparator|polyethylene glycol group (group P)|For all patients of this group, polyethylene glycol solution should be taken orally for colonic cleansing of colonoscopy
10177943|NCT03817788|Experimental|sodium phosphate group (group S)|For all patients of this group, sodium phosphate solution should be taken orally for colonic cleansing of colonoscopy
10177944|NCT03818321|Experimental|Methenamine Hippurate with Cranberry|Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
10177945|NCT03818321|Placebo Comparator|Placebo with Cranberry|"Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016."
10177946|NCT03817749|Experimental|Experimental|"Participants will consume 20 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~All meals will be provided throughout the supplementation period~Participants will wear a continuous glucose monitor for 6 consecutive days during the supplementation period."
10177947|NCT03817749|Placebo Comparator|Placebo|Participants will consume a flavor matched placebo drink and undergo the same procedures described in the Experimental Arm
10177948|NCT03817541|Experimental|Bariatric surgery|Patients due for bariatric surgery, BMI > 30
10177949|NCT03817541|Experimental|Cholecystectomy|Normal weight patients due for cholecystectomies
10177950|NCT03817619|Active Comparator|Treatment R (reference)|Single-dose ELB/GZR as a whole tablet in a fasted state.
10177951|NCT03817619|Experimental|Treatment T (test)|Single-dose crushed ELB/GZR in a fasted state.
9977640|NCT01363804|Experimental|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
10177952|NCT03817567|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|6.0mg/kg QW for 6 weeks, then 8.0mg/kg Q2W
10177953|NCT03817411|Active Comparator|Telatinib+Capecitabine+Oxaliplatin|Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
10177954|NCT03817411|Placebo Comparator|Placebos+Capecitabine+Oxaliplatin|Patients receive placebo orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
10177955|NCT03817658|Experimental|SHR-1210|SHR-1210
10177956|NCT03817658|Placebo Comparator|placebo|placebo
10177957|NCT03817476|Experimental|T1-T2-R|
10177958|NCT03817476|Experimental|T1-R-T2|
10177959|NCT03817476|Experimental|T2-T1-R|
10177960|NCT03817476|Experimental|T2-R-T1|
10177961|NCT03817476|Experimental|R-T1-T2|
10177962|NCT03817476|Experimental|R-T2-T1|
10177963|NCT03817671|Other|Control arm (5% O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 5% O2, and 89.3% N2 till embryo transfer
10177964|NCT03817671|Experimental|Experimental arm (2%O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 2% O2, and 92.3% N2 till embryo transfer
10177965|NCT03817645|Experimental|Panaceo MED|Zeolite, Medicinal product, class IIa for oral intake, daily intake of 2 sachets (3 g), for 3 months.
10177966|NCT03817645|Placebo Comparator|Control|Micro crystalline cellulose daily intake of 2 sachets (3 g), for 3 months.
10177967|NCT03817450|Experimental|Daily Mouth Care|The intervention consists of training in Mouth Care Without a Battle (MCWB) techniques and support in established quality improvement techniques. MCWB is a system-level, evidence based, tested approach to person-centered daily mouth care, which includes tooth-brushing, flossing, care of the gums, and denture care. MCWB provides training to all certified nursing assistants (CNAs) and nursing supervisors, and also supports the designation and specialized training of a CNA to serve as a dedicated, full-time Oral Care Aide (OCA) to provide mouth care to the residents who are at greatest risk for pneumonia and require specialized support to achieve good oral hygiene.
10177968|NCT03817450|No Intervention|Standard Mouth Care|Nursing homes will continue to provide standard mouth care to all residents. Nursing home staff will not receive training or supplies in the control condition.
10177969|NCT03817723||Specialist surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy. C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
10177970|NCT03817723||Resident surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy.C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
10177971|NCT03817489|Experimental|Intervention: Baduanjin qigong|This arm of participants will be receiving the Baduajin qigong intervention.
10177972|NCT03817489|Experimental|Intervention: Mindfulness meditation|This arm of participants will be receiving the Mindfulness meditation intervention.
10177973|NCT03817489|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a Wait-list Control group.
10177974|NCT03817736|Experimental|START-FIT|"Single group assignment combining TACE and SBRT with immune checkpoint inhibitor as treatment in HCC patients.~Procedure of TACE will be standardized.~SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.~An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons."
10177975|NCT03817385|Experimental|repetitive TMS (Transcranial Magnetic Stimulation)|rTMS and physical / occupational therapy
10177976|NCT03817385|Experimental|robotic GT (Gait Training)|robotic gait training for 20 times and physical / occupational therapy
10177977|NCT03817385|No Intervention|traditional rehabilitation|patient only received traditional rehabilitation program
10177978|NCT03817684|Experimental|BPN14770 10mg bid|10 mg bid dose of the Drug BPN14770
10177979|NCT03817684|Experimental|BPN 14770 25mg bid|25mg bid dose of the Drug BPN14770
10177980|NCT03817684|Placebo Comparator|Placebo|
10177981|NCT03817424|Experimental|Cohort 1: VIB7734 Dose 1|Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
10177982|NCT03817424|Experimental|Cohort 2: VIB7734 Dose 2|Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
10177983|NCT03817424|Experimental|Cohort 3: VIB7734 Dose 3|Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
10177984|NCT03817424|Placebo Comparator|Placebo|Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
10177985|NCT03817697||Drug users|The cohort will be constituted of adult patients drug users, substituted/weaned or not, consulting at the Croix-Rousse CSAPA
10177986|NCT03817372|Active Comparator|Anterior-posterior electrode position|The anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
10177987|NCT03817372|Active Comparator|Anterior-lateral electrode position|The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
10177988|NCT03817307|Experimental|USPIO enhanced-MRI|The contrast agent ferumoxtran-10 will be administered intravenously under constant medical supervision 24-36 hours before performing a T2* weighted MRI scan (prior to surgery).
10177989|NCT03817359|Experimental|Mix infusion using single TCI pump|participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump infusion
10177990|NCT03817359|No Intervention|Separate infusion using two TCI pumps|participants receive total intravenous anesthesia with remifentanil and propofol separately by two TCI pumps infusion
10177991|NCT03817086|Experimental|Hand coordination and mental practice|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to mentally imagine doing the task with an action observation of perfect performance.
10177992|NCT03817086|Active Comparator|Hand coordination and action observation|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to observe a visual feedback of performance.
9977641|NCT01363817|Experimental|Escalation Phase: BMS-906024|BMS-906024 escalating doses starting at 0.3 mg solution for intravenous (IV) administration once weekly continuously until disease progression or unacceptable toxicity
10177993|NCT03817346|Active Comparator|Experimental GT-002 SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
10177994|NCT03817346|Placebo Comparator|Experimental Placebo oral capsule SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
10177995|NCT03817021|Experimental|All Factors On|Nutrition and Physical Activity Self-Assessment of Childcare (Core NAP SACC) will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned on
10177996|NCT03817021|Experimental|NAP SACC on/ECE on/Parent RF on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned off
10177997|NCT03817021|Experimental|NAP SACC on/ECE on/Child Regulation on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned on
10177998|NCT03817021|Experimental|NAP SACC on/ECE on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned off
10177999|NCT03817021|Experimental|NAP SACCon/Parent RF on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned on
10178000|NCT03817021|Experimental|NAP SACC on/Parent RF on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned off
10178001|NCT03817021|Experimental|NAP SACC on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned on
10178002|NCT03817021|Experimental|NAP SACC on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned off
10178003|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) post-EBRT|Prostatic Urethral Lift (PUL) following External Beam Radiotherapy (EBRT)
10178004|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) pre-BT|Prostatic Urethral Lift (PUL) preceding Brachytherapy (BT)
10178005|NCT03817216|Active Comparator|Prostatic Urethral Lift (PUL) post-BT|Prostatic Urethral Lift (PUL) following Brachytherapy (BT)
10178006|NCT03817034|Experimental|Multimodal Analgesia|
10178007|NCT03817294|Active Comparator|Eccentric cycling|
10178008|NCT03817294|Active Comparator|Concentric cycling|
10178009|NCT03817294|Active Comparator|Single leg cycling|
10178010|NCT03817294|Active Comparator|Lower limb resistance training|
10178011|NCT03817242|Active Comparator|tympanoplasty with tragal cartilage|Tympanoplasty was performed using tragal cartilage graft
10178012|NCT03817242|Active Comparator|tympanoplasty with temporalis fascia|Tympanoplasty was performed using temporalis fascia graft
10178013|NCT03817047|Experimental|Physical active learning (PAL)|"Three components:~Physical education (60 minutes)~Physical active learning (30 minutes)~Physical activity (30 minutes)"
10178014|NCT03817047|Experimental|Don't worry - be happy|"Two components:~Physical education (60 minutes) - don't worry class~Physical activity (60 minutes) - be happy class"
10178015|NCT03817047|No Intervention|Control group|Current practice
10178016|NCT03817099|Experimental|My Dia-RNP|In the My Dia-RNP group, participants will undergo the pre-RNP assessment 2 weeks before Ramadan. They will be given a nutrition education based on the Ramadan Nutrition Plan Guide published by IDF-DAR Practical Guidelines. They will also be asked to incorporate diabetes-specific nutrition formula (Nutren untuk Diabetik®) within the prescribed calories before Ramadan period to help them familiarise with a dietary change.
10178017|NCT03817099|Active Comparator|Usual Care|Participant in this group will continue in a usual care (UC) group. They will receive dietary advice based on the Practical Guide to Diabetes Management in Ramadan produced by Ministry of Health (2015).
10178018|NCT03817177|Placebo Comparator|nasal prong|conventional nasal prong application after the surgery in postanesthetic care unit (PACU)
10178019|NCT03817177|Experimental|high flow nasal cannula oxygenation|high flow nasal cannula application after the surgery in postanesthetic care unit (PACU)
10178020|NCT03817281||Accuryn Monitoring System|Observational only (no intervention). Study Cohort is patients using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
10178021|NCT03817190|Experimental|2g Oral DS107|2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks
10178022|NCT03817190|Placebo Comparator|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 16 weeks
10178023|NCT03817060|Active Comparator|Cleavage|Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development
10178024|NCT03817060|Active Comparator|Blastocyst|Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)
10178025|NCT03816969|Active Comparator|Self-pressurized air-Q with blocker|Self-pressurized air-Q with blocker has a greater seal pressure compared to Air-Q blocker, easier and faster in insertion and has less morbidity and complications while and after insertion
10178026|NCT03816969|Active Comparator|Air-Q ILA blocker|It has a drain tube through which a suction tube is passed
10178027|NCT03816982|Active Comparator|Bupivacaine HCl/Bupivacaine CISB|23 patients will be enrolled to receive a single-injection bupivacaine HCL interscalene block with bupivacaine CISB added.
10178028|NCT03816982|Experimental|Liposomal Bupivacaine Added to Interscalene Block|23 patients will be enrolled to receive a single-injection bupivacaine HCl interscalene block with liposomal bupivacaine added to same injection.
10178029|NCT03817320|Other|Open label design|Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin
10178030|NCT03817203|Experimental|Kinesio tape group|Kinesio tape application and pelvic floor exercise have been applied
10178031|NCT03817203|Sham Comparator|Control group|Sham kinesio tape application and pelvic floor exercise have been applied
10178032|NCT03817164|Active Comparator|Active Treatment|Active stimulation pulsed current delivered over 15 minutes.
10178033|NCT03817164|Sham Comparator|Control Treatment|Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
10178034|NCT03816943|No Intervention|Control|control group with no intervention
10178035|NCT03816943|Experimental|Whatsapp|intervention group receiving a Whatsapp instant text message with encouraging words after bond up of fixed appliances
10178036|NCT03816943|Experimental|Call|intervention group receiving a phone cal with encouraging words after bond up of fixed appliances
10178037|NCT03816930|Active Comparator|Mechanical cord usage|Mechanical retraction
10178038|NCT03816930|Active Comparator|Chemical contained retraction usage|Chemical retraction
10178039|NCT03816930|Active Comparator|MZ-6 laser tip used throughing|Laser retraction
10178040|NCT03816917||topical treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: only topical/UV therapy (no systemic therapy)
10178041|NCT03816917||systemic treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy, but no biologicals. Topical therapy is permitted.
10178042|NCT03816917||biologics|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy with biologics. Other systemic and topical therapy is permitted.
10178043|NCT03816904||Breast or prostate cancer|Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
10178044|NCT03817268|Experimental|Capecitabine monotherapy group|
10178045|NCT03817268|No Intervention|Control group|
10178046|NCT03817255|Experimental|Substance use|In this screening intervention, participants complete a substance use questionnaire (=intervention).
10178047|NCT03817255|Active Comparator|Physical activity|In this screening control condition, participants complete a physical activity questionnaire (=control).
10178048|NCT03817112|Active Comparator|Dexmedetomidine|Infusion of dexmedetomidine
10178049|NCT03817112|Active Comparator|Propofol|Propofol infusion
10178050|NCT03816722|Experimental|intervention|Patients starting the cross over with 6 weeks of high flow treatment with Airvo2 in addition to usual care
10178051|NCT03816722|Experimental|control|Patients starting the cross over in the usual care Group but after 6 weeks receiving High Flow treatment with Airvo2
10178052|NCT03816774|No Intervention|PEG split-dose|Group A: PEG split dose ending 3 hours before colonoscopy
10178053|NCT03816774|Active Comparator|PEG split-dose and simethicone|Group B: 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
10178054|NCT03816748|Experimental|intervention|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept HFNC treatment
10178055|NCT03816748|No Intervention|control|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept usual care
10178056|NCT03816644|Experimental|5-Cog|The 5-Cog coupled with a decision tree is a simple, 5-minute procedure that will identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. The 5-Cog includes the Picture Memory Impairment Screen (PMIS), Motoric Cognitive Risk syndrome (MCR), and the Symbol Match test. The 5-Cog will be given after randomization and before the patients sees the physician. The 5-Cog will sort patients with 'cognitive impairment' from those with 'no cognitive impairment'. After completing the 5-Cog, the non-physician tester will send a message through the Electronic medical record (EMR) system to provide the physician with the 5-Cog results and guide the them through the follow-up based on the results.
10178057|NCT03816644|Active Comparator|Health Literacy & Grip Assessment|The 5 minute assessment includes the Short Assessment of Health Literacy (SAHL) and a grip assessment measured using a handgrip dynamometer. After completing the SAHL and grip assessment, the non-physician tester will send a message through the EMR to provide the physician with the results from the assessments and guide the them through the follow-up based on the results.
10178058|NCT03817073|Experimental|Iowa Oral Performance Instrument (IOPI)|All MS patients will be included in this arm to compare with a historical control arm. Iowa Oral Performance Instrument (IOPI).
10178059|NCT03816579|Experimental|PRO-A|Beef protein
10178060|NCT03816579|Experimental|PRO-B|Complementary proteins at each meal
10178061|NCT03816579|Experimental|PRO-C|Complementary proteins over 24 hours
10178062|NCT03816579|No Intervention|CON|Low protein (<5 g) meal
10178063|NCT03816592||Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
10178064|NCT03816592||Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
10178065|NCT03816488|Experimental|Metformin|Self-administered metformin (patient's usual dose) taken 2 hours prior to surgery
9527653|NCT03218111|Other|Healthy Normal Subjects|Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period
10178066|NCT03816488|Experimental|Salsalate|Self-administered salsalate taken 2 hours prior to surgery
10178067|NCT03816488|No Intervention|Placebo|Self-administered placebo taken 2 hours prior to surgery
10178068|NCT03816540|Experimental|FXTAS-affected|FXTAS-affected participants will receive HRV and respiratory coherence biofeedback training for 20 sessions.
10178069|NCT03816540|Active Comparator|FXTAS-unaffected|FXTAS-unaffected participants will be assessed to compare the effects of biofeedback based on FXTAS status. This arm will receive HRV and respiratory coherence biofeedback training for 20 sessions.
10178070|NCT03816631|Experimental|Part A: Group 1: Severe hepatic function|Participants with severe hepatic function will receive single oral dose of pimodivir 600 milligram (mg) (2*300 mg tablet) under fasted condition on Day 1.
10178071|NCT03816631|Experimental|Part A and B: Group 2: Normal hepatic function|Participants with normal hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
10178072|NCT03816631|Experimental|Part B: Group 3: Moderate hepatic function|Participants with moderate hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
10178073|NCT03816631|Experimental|Part B: Group 4: Mild hepatic function|Participants with mild hepatic function will receive single oral dose of Pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
10178074|NCT03816553|Experimental|SHR-1210 + Apatinib|Participants receive SHR-1210 200mg (3mg/kg for underweight patients) intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
10178075|NCT03816566|Experimental|Wearable Device and PSG|The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.
10178076|NCT03816618|Experimental|CONTROL|CONTROL GROUP
10178077|NCT03816618|Experimental|TREATMENT1|TREATMENT GROUP 1
10178078|NCT03816618|Experimental|TREATMENT2|TREATMENT GROUP 2
10178079|NCT03816618|Experimental|TREATMENT3|TREATMENT GROUP 3
10178080|NCT03816826|Experimental|laser|athletes with acute soft tissue injuries will be recruited in the study , patients will be treated using the the laser therapy
10178081|NCT03816826|Experimental|strain/counter strain|athletes with acute soft tissue injuries will be treated with with strain counter strain technique
10178082|NCT03816826|Experimental|combination therapy|combination of laser therapy along with strain counter strain technique to visualize the effect the
10178083|NCT03816475|Experimental|Hypofractionated radiotherapy|5x5 Gy radiotherapy and delayed surgery (after 6-8 weeks)
10178084|NCT03816501|Other|music|The preference of the patients will be listened to preoperatively through the headphones.
10178085|NCT03816501|Other|no music|preoperative music will not be listened
10178086|NCT03816527||AUD patients|Individuals with alcohol use disorder
10178087|NCT03816527||Healthy controls|Healthy controls
10178088|NCT03816670|Experimental|poor responders day 2|"poor responders women stimulated with CF from day 2 of menstrual cycle"
10178089|NCT03816670|Experimental|poor responders day 4|"poor responders women stimulated with CF from day 4 of menstrual cycle"
10178090|NCT03816670|Experimental|normal responders day 2|"normal responders women stimulated with CF from day 2"
10178091|NCT03816670|Experimental|normal responders day 4|"normal responders women stimulated with CF from day 4"
10178092|NCT03816670|Experimental|high responders day 2|"high responders women stimulated with CF from day 2"
10178093|NCT03816670|Experimental|high responders day 4|"high responders women stimulated with CF from day 4"
10178094|NCT03816514|Experimental|SpHb monitoring group|In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.
10178095|NCT03816514|Active Comparator|Control group|In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.
10178096|NCT03816800|Placebo Comparator|Placebo-Allergic|Over the course of 6 months allergic participants receive twice daily a placebo tablets.
10178097|NCT03816800|Active Comparator|Active-Allergic|Over the course of 6 months allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
10178098|NCT03816410|Experimental|LAA amputation group|
10178099|NCT03816410|No Intervention|No LAA amputation group|
10178100|NCT03816449|Active Comparator|experimental group|Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
10178101|NCT03816449|Placebo Comparator|control group|Control group will include about postmenopausal women who will not practice exercise program (aerobic exercise, resistance training and balance exercise) .They will continue to carry out activities of daily living, which are conducted daily before inclusion in the study. These patients will be asked to not include in any other program of physical activity and exercise during the research period (12 weeks). After this period, patients will be offered to participate in the same exercise program that had patients from the experimental group.
10178102|NCT03816436||Follow- up (FU) assessment on clavicular non- union|clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting
10178103|NCT03816787|Experimental|dry cupping for patients of low back pain|Patients will receive four consecutive dry cupping therapy application in one month.
10178104|NCT03816787|Active Comparator|dry cupping for health people|Health people will receive four consecutive dry cupping therapy application in one month.
10178105|NCT03816423|No Intervention|Traditional counseling|Patients will undergo routine prenatal care visit with clinical practicioner only
10178106|NCT03816423|Experimental|video group|"Participants randomized to the intervention group (video education) will view the prenatal screening video How to Decide About Prenatal Genetic Testing, followed by a routine prenatal appointment."
9976154|NCT01348633||Sub-study 2|The Quantitative, Hyper-Spectral Imaging Derived Oxygen Saturation Maps of the major retinal vessels and capillary beds will be validated and calibrated in human volunteers using our novel and exact technique that allows the precise control of the partial pressure of oxygen (PO2) to induce controlled and safe levels of hypoxia. Oxygen saturation values will be compared to measured PO2 values (i.e. recognized standard) for various levels of hypoxia and will be used to provide in-sight into the properties of the data output e.g. effective operating range, linearity of response. At the end of the study, subjects will be returned to normoxic conditions to assess reproducibility of oxygen saturation maps.
10178107|NCT03816384|Active Comparator|Standard of Care|Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
10178108|NCT03816384|Experimental|Drain Line Clearance (DLC) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
9977642|NCT01363817|Experimental|Expansion Phase: BMS-906024 + Dexamethasone|BMS-906024 maximum tolerated dose (To be determined) solution for IV administration once weekly and Dexamethasone 20mg/day tablet by mouth (Oral) for 3-4 days every week for 3-4 weeks per cycle continuously until disease progression or unacceptable toxicity
10178109|NCT03816384|Experimental|Drain Line Clearance and Silver (DLCS) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
10178110|NCT03816371|Active Comparator|supine 0 degree head-of-bed elevation|0 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
10178111|NCT03816371|Experimental|30 degree head-of-bed elevation|30 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
10178112|NCT03816371|Experimental|45 degree head-of-bed elevation|45 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
10178113|NCT03816280||Group T2DM-alpha|Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management
10178114|NCT03816280||Group T2DM-pH|Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management
10178115|NCT03816280||Group Ctrl-alpha|Control patients undergoing CPB with alpha-stat acid-base management
10178116|NCT03816280||Group Ctrl-pH|Control patients undergoing CPB with pH-stat acid-base management
10178117|NCT03816267|Active Comparator|Nebulizer|Containing salbutamol
10178118|NCT03816267|Experimental|Metered Dose Inhaler and spacer|Containing Salbutamol
10178119|NCT03816241|No Intervention|Control|Vignette contains no extra information.
10178120|NCT03816241|Experimental|Frame|Vignette is framed in a particular manner
10178121|NCT03816241|Experimental|Norms|Vignette contains extra information about norms
10178122|NCT03816241|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
10178123|NCT03816215|Experimental|Adolescent Participants|Participants will be assigned to participate in community service (from a menu of options) for 30 hours.
10178124|NCT03816059||Hospitalized - ACS|Hospitalized patients with acute coronary syndrome
10178125|NCT03816059||Hospitalized - stroke|Hospitalized patients with stroke
10178126|NCT03816059||Hospitalized - chronic lung disease|Hospitalized patients with exacerbation of chronic lung disease
10178127|NCT03816059||Outpatient|Outpatients
10178128|NCT03816293|Active Comparator|Negative Pressure Wound Therapy|NPWT use on closed incision for 7 days after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
10178129|NCT03816293|No Intervention|Control Dressing|Standard dressing on closed incisions after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
10178130|NCT03816306||Single group study|
10178131|NCT03816137|Active Comparator|ConM SOSIP and Mosaic SOSIPs|"ConM SOSIP 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
10178132|NCT03816137|Active Comparator|EDC ConM SOSIP and Mosaic SOSIPs|"EDC ConM SOSIP 100G Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
10178133|NCT03816137|Active Comparator|ConS UFO and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
10178134|NCT03816137|Active Comparator|EDC ConS UFO and Mosaic SOSIPs|"EDC ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
10178135|NCT03816137|Active Comparator|ConS UFO and ConM SOSIPs and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0 and 3 months~ConM SOSIP Administered at 12 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
10178136|NCT03816085|Experimental|Shoe with 4 cm heel|Shoes with 4 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
10178137|NCT03816085|Experimental|Shoe with 10 cm heel|Shoes with 10 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
10178138|NCT03816085|No Intervention|Without shoes|Women will be included in the tests to measure balance, muscular endurance and function without shoes.
9682847|NCT04909398|Experimental|Dynamic pupillometry sessions|"It is planned to include 60 participants divided into different groups:~15 healthy subjects, called controls.~15 patients with retinitis pigmentosa.~15 patients with Leber's hereditary optic neuropathy.~15 patients with Stargardt's disease."
9695615|NCT04776564||Non-professional|Participants attending G7P courses wihere no professional health care personell are delivering the teaching
10178139|NCT03816033|Active Comparator|Cryotherapy|Cryotherapy ablation energy will be utilised in the catheter ablation procedure
10178140|NCT03816033|Active Comparator|Radiofrequency|Radiofrequency ablation energy will be utilised in the catheter ablation procedure
10178141|NCT03816020|Active Comparator|NR Group|Participants receiving Nicotinamide Riboside capsules, 500mg BI'D for 30 days
10178142|NCT03816020|Placebo Comparator|Placebo Group|Participant receiving Placebo BIDfor 30 days
10178143|NCT03816072|Active Comparator|Propofol|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with intravenous anaesthesia (propofol).
10178144|NCT03816072|Active Comparator|Sevoflurane|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with inhalational anaesthesia (sevoflurane).
10178145|NCT03816189||Diffuse SSc|Recruitment of 20 patients with diffuse SSc
10178146|NCT03816189||Limited SSc|Recruitment of 20 patients with limited SSc
10178147|NCT03816189||Healthy subjects|Recruitment of 20 healthy subjects (control)
10178148|NCT03816046|Experimental|Technique 1 The Quadrant technique|Intervention: 25 Botulinum Toxin injections. 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
10178149|NCT03816046|Experimental|Technique 2 the six injection technique|Intervention: 6 Botulinum Toxin injections. will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units
10178150|NCT03816124|Experimental|Genicular RF|Patients who will receive genicular radiofrequency ablation
10178151|NCT03815903|Active Comparator|A - induction chemotherapy|
10178152|NCT03815903|Experimental|B - chemoradiotherapy|
10178153|NCT03815864||D2SA+|Median fluoresce intensity > or = 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
10178154|NCT03815864||D2SA-|Median fluoresce intensity < 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
10178155|NCT03815942|Experimental|Intermediate risk prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
10178156|NCT03815942|Experimental|Advanced metastatic prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
10178157|NCT03815968|Experimental|low sodium diet|women diagnosed with oligohydramnios designated for conservative management applying a low-salt diet.
10178158|NCT03815968|No Intervention|regular diet|women diagnosed with oligohydramnios designated for conservative management applying a regular diet.
10178159|NCT03815877|Active Comparator|The intervention group (C group receiving caffeinated coffee)|100cc coffee at 3, 6 and 9 hours after the Cesarean section
10178160|NCT03815877|Placebo Comparator|The control group (N group receiving decaffeinated coffee)|100cc decaf coffee at 3, 6, 9 hours after the Cesarean section
10178161|NCT03815708||wheelchair rugby players|well-trained spinal cord injured wheelchair rugby players
10178162|NCT03815708||wheelchair basketball players|well-trained spinal cord injured wheelchair basketball players
10178163|NCT03815760|Experimental|Exercise with Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~The BFR cuff will be applied to the upper arm. Arterial occlusion will be set to 50%.~Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps. The occlusion will be maintained for the 8 min treatment period."
10178164|NCT03815760|Active Comparator|Exercise without Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~This group will not have BFR applied. Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps."
10178165|NCT03815747|Experimental|Treatment Group|Treatment with the investigational device - High- Intensity Focused Electromagnetic (HIFEM) Field Device
9682848|NCT04909775|Experimental|Arm 1|Patients will receive 4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before cystectomy discussion. The patients reach clinical complete remission will receive tislelizumab maintenance therapy for a year or 13 cycles.
9682849|NCT04909281||Long-term non-attenders in the cervical screening program|All women who had not attended tthe cervical screening program in Sweden for at least 10 years were eligeble.
9682850|NCT04909528|Experimental|Experimental Group|Low-level tragus stimulation
9682851|NCT04909528|Sham Comparator|Control Group|Sham stimulation
9682852|NCT04909268||Patients with positive pneumococcal antigenuria|
9682853|NCT04909385||Bronchoalveolar lavage (BAL) samples for pulmonary TB|
9682854|NCT04909385||(EBUS-TBNA) samples for mediastinal TB|
9682855|NCT04909333|Experimental|Group A (EHH Patients)|Group A will receive a placebo injection (0.9% saline solution) on Day 1 and 10μg Exenatide injection on Day 2.
10178166|NCT03815994|Experimental|Experimental: group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
10178167|NCT03815994|Sham Comparator|group 2|Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
10178168|NCT03815617|Active Comparator|Probiotic|The study design is a crossover randomized double-blind two-block placebo-controlled single center trial with an allocation ratio of 1:1 conducted between February 2017 and May 2018. Subjects are randomized at baseline visit to receive Block 1 (Zircombi 3 g, containing Bifidobacterium longum BB536 four billion CFU, Lactobacillus rhamnosus HN001 one billion CFU with B6 vitamin 1.4 mg) and Block 2 (placebo: maltodextrins, corn starch, silicon dioxide) depending on the randomization sequence. Subjects received one sachet pack daily containing placebo or probiotic. The active treatment was undistinguishable from placebo by physical and organoleptic characteristics. Participants in the study followed a free diet.
10178169|NCT03815617|Placebo Comparator|Placebo|Same appearance of probiotic.
10178170|NCT03815604|Experimental|RCT-IHS|Behavioral: At the Zurich site, the experimental intervention is called Independent Housing and Support
10178171|NCT03815604|Active Comparator|RCT-RCS/TAU|Behavioral: At the Zurich site, the comparator is usual residential care
10178172|NCT03815604|Experimental|OSD-IHS|Behavioral: At the Berne site, the experimental intervention is called Independent Housing and Support
10178173|NCT03815604|Active Comparator|OSD-RCS/TAU|Behavioral: At the Berne site, the comparator is usual residential care
9682856|NCT04909333|Experimental|Group B (EHH Patients)|Group B will receive a 10μg Exenatide injection on Day 1 and placebo injection (0.9% saline solution) on Day 2.
10178174|NCT03815630|Experimental|PD-1 and dc-cik treatment group|
10178175|NCT03815838|Experimental|PET imaging|18F-FDOPA and 18F-Fallypride PET imaging
10178176|NCT03815656|Experimental|Implanted RC+S|Implanted Medtronic RC+S IPG with dual DBS electrodes in STN and GPi. DBS stimulation will be administered to: 1) STN alone, 2) GPi alone, 3) cooperative STN + GPi, and 4) adaptive, closed-loop stimulation of STN and/or GPi.
10178177|NCT03815955|Experimental|Non-Sedentary Behaviour Group|Participants in this arm will model the primary care team as they engage in minimal sedentary behaviour and replace sitting with standing and light, incidental movements.
10178178|NCT03815955|No Intervention|Standard Care Control Group|Participants that are limited to standing, due to amputations, diabetic foot pain and ulcers, or sensory diabetic neuropathy, will follow standard care and attend the DIGMA in a seated position.
10178179|NCT03815786|Experimental|CKD patients|CKD patients stage 3b-4 will follow a 2-months supplementation of either symbiotic or placebo
10178180|NCT03815786|Other|Controls|Healthy volunteers will follow a 2-months supplementation of either symbiotic or placebo
10178181|NCT03815526|Experimental|Dynamic tape|
10178182|NCT03815526|Experimental|Kinesio tape|
10178183|NCT03815526|Experimental|Sport tape|
10178184|NCT03815721|Experimental|daily stimulation|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
10178185|NCT03815721|Experimental|stimulation every other day|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
10178186|NCT03815552|Experimental|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with type 1 Diabetes.The System will be set to provide realtime glucose information, including alarms and alerts in the home settings für 180 days.
10178187|NCT03815812|Experimental|IBI306|Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
10178188|NCT03815812|Placebo Comparator|placebo|Participants received matching placebo dose regimen by subcutaneous injection.
10178189|NCT03815513|Experimental|cases|Patient with spontaneous intracerebral hemorrhage
10178190|NCT03815513|Experimental|controls|Healthy control without history of symptomatic cerebrovascular diseases
10178191|NCT03815500|Experimental|Patients with open surgical wounds|Patients with open surgical wounds will undergo enhanced packing education with curriculum designed for learners with low literacy, dyslexia or associated learning disorders.
10178192|NCT03815565|Experimental|levobupivacaine 0.125%|continuous femoral block with levobupivacaine 0.125%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
10178193|NCT03815565|Active Comparator|ropivacaine 0.2%|continuous femoral block with ropivacaine 0.2%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
10178194|NCT03815539|Experimental|dry eye group|Part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
10178195|NCT03815487|Experimental|Therapy with Hybrid Closed Loop (HCL)|"The Intervention is the specific function of the Insulin Pump from Medtronic® with the name MiniMed® 670G (MMT-1780) to deliver Insulin as medication.~This Medtronic MiniMed 670G Insulin Pump in Auto Mode is an Hybrid closed loop (HCL) system including an Auto Mode function. It provides as intervention several additional effects concerning automatically insulin delivery by pump: e.g. in case of high values (or predicted) - more insulin will be administered automatically, in case of low values (or predicted) - the insulin infusion will be decreased a suspended and resumed again. The patients will wear the pump continuously."
9682857|NCT04908982|Experimental|Aspirin|Participants in this arm will be instructed to take 1 81mg aspirin daily beginning between weeks 12 and 16 of pregnancy and continuing until delivery.
9682858|NCT04908982|No Intervention|No Aspirin|Participants in this arm will receive no aspirin.
9682859|NCT04909294|Experimental|stereotaxic external radiation therapy|
9682860|NCT04908917|Experimental|PAC with HEPA|Intervention group (N=100) to use a portable air cleaner (with a HEPA filter in PAC)
9682861|NCT04908917|Sham Comparator|PAC without HEPA|control group (N=100) with a sham portable air cleaner (no HEPA filter in PAC)
9682862|NCT04909086|Active Comparator|Standard Physical Therapy|Control group for the study.
9682863|NCT04909086|Experimental|Open Kinetic Chain|Standard care in addition to open kinetic chain exercises for the knee joint muscles.
9682864|NCT04909086|Experimental|Closed Kinetic Chain|Standard care in addition to closed kinetic chain exercises for the knee joint muscles.
9682865|NCT04909008|Experimental|Exercise Training|Two sets of exercise testing (before and after) 10 weeks of supervised exercise training (3 sessions per week) at Mayo Clinic Florida.
9682866|NCT04909008|No Intervention|Control Groups|Two sets of exercise testing while continuing with standard medical care in between.
10178196|NCT03815487|Active Comparator|Sensor Augmented Pump (SAP) therapy|"The Intervention is the specific therapy of the Sensor Augmented Insulin Pump MiniMed® 670G (MMT-1780) without Auto Mode.~This Medtronic MiniMed 670G Insulin Pump without Auto Mode' is a Sensor Augmented Pump (SAP) therapy and means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. The patients will wear the pump also continuously, but have to respond manually after the alarm. There are no automatically steps from the pump."
10178197|NCT03815799|Experimental|Erector Spinae Plane Block Group|"Procedure:~In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve erector spinae block under ultrasound guidence after the strict aseptic precautions."
10178198|NCT03815799|Sham Comparator|Control|Routine standard perioperative and postoperative analgesic protocol will be given.
9682867|NCT04908943|Experimental|Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)|RENEW was created by researchers, doctors, and patients with scleroderma. It is a web-based peer-led program to help manage energy and symptoms in people who have scleroderma.
10178199|NCT03815474|Experimental|anlotinib & epirubicin& ifosfamide|interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
10178200|NCT03815461|Experimental|experiment group|Nab-paclitaxel+S-1
10178201|NCT03815448|Experimental|Methotrexate|Methotrexate 2.5mg/ tablet, oral, once a week, 2-6 tablets each time
9682868|NCT04908943|No Intervention|Waitlist|Participants will be asked about changes in health status, and use of any new treatments or services at 6 and 12 weeks.
9682869|NCT04908995|Experimental|EC5026|Single 8 mg oral dose of EC5026
9682870|NCT04908995|Placebo Comparator|Placebo|Single dose of matching oral placebo
9682871|NCT04909320|Experimental|Intervention group|
9682872|NCT04909320|Active Comparator|Control group|
9682873|NCT04909125|Active Comparator|Hypofractionation Arm|40Gy / 15 fractions, 2.67Gy per fraction, over 3.5 week (9 fractions per fortnight)
9682874|NCT04909125|Other|Standard /Conventional fractionation Arm|50Gy / 25 fractions, 2Gy per fraction, over 5.5 week (9 fractions per fortnight)
9682875|NCT04909255|Active Comparator|Antimuscarinic|oxybutynin, tolterodine, solifenacin
9682876|NCT04909255|Experimental|B3-agonist|mirabegron
9682877|NCT04909034|Experimental|MS-20 oral solution|Oral Solution 8 c.c per day divided twice daily (BID) for 48 weeks.
9682878|NCT04909034|Placebo Comparator|Placebo|Oral Solution 8 c.c per day divided twice daily (BID) for 48 weeks.
9682879|NCT04909164||Immunotherapy group|Patients receiving reimbursed immunotherapy as a second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy)
9682880|NCT04909164||Cytotoxic chemotherapy group|Patients receiving reimbursed cytotoxic chemotherapy as second-line therapy after failure of platinum-based chemotherapy
9682881|NCT04909359||Crohn's disease (CD)|People with CD recently receiving vedolizumab as standard of care will be followed up to 5 years.
9682882|NCT04909359||Ulcerative colitis (UC)|People with UC recently receiving vedolizumab as standard of care will be followed up to 5 years.
9682883|NCT04908878|Experimental|Group I (pectoral nerve (PECS) block -transversus thoracic plane (TTP) block group)|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
9682884|NCT04908878|Experimental|Group II (serratus anterior plane (SAP) block group)|Patients will receive US-guided SAP block after induction of general anesthesia.
9682885|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.5km/h|
9682886|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 0.8km/h|
9682887|NCT04909151|Experimental|Robot-assisted gait training with walking speed of 1.1km/h|
9682888|NCT04908865|Experimental|Pediatric participants receiving belimumab|
9682889|NCT04908891|Experimental|persons with Multiple Sclerosis|
9682890|NCT04908891|Active Comparator|Healthy controls|
9682891|NCT04908891|Active Comparator|Stroke Patients|
9682892|NCT04908488|Other|P1fA, then AMfA|Verofilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9682893|NCT04908488|Other|AMfA, then P1fA|Etafilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9682894|NCT04908709|Experimental|Diagnostic (sMRI)|Patients undergo sMRI over less than 1 hour within 7 days prior to start of standard of care radiation therapy and at 10 weeks.
9682895|NCT04908709|Active Comparator|Group 2|Patients will undergo 3-4 sMRI scans at baseline prior to RT, 1 month, 4 months, and 7 months after RT, and/or at any time of suspected tumor recurrence.
9682896|NCT04908527|Experimental|Walk group|Patients walked to operating room (OR)
9682897|NCT04908527|No Intervention|Bed group|Patients go to OR while in bed
9682898|NCT04908566|Experimental|PD-1 antibody combined with FOLFIRINOX regimen|
9682899|NCT04908566|Active Comparator|PD-1 antibody combined with SOX program|
9682900|NCT04908553|Other|low dose group|Remimazolam Tosilate for Injection 0.1mg/kg at induction
9682901|NCT04908553|Other|medium dose group|Remimazolam Tosilate for Injection 0.15mg/kg at induction
9682902|NCT04908553|Other|high dose group|Remimazolam Tosilate for Injection 0.2mg/kg at induction
9682903|NCT04908657|Experimental|Treatment group|treatment group will administrate oral sildenafil 20 mg three times per day for 3 years
9682904|NCT04908657|No Intervention|Control group|the control group will not receive any specific therapy for decreasing the pulmonary vascular resistance
9682905|NCT04908540|Active Comparator|MARPE/ Conventional (Control) (Group A)|patients will open the appliance in its conventional way; 2 quarter turn (0.2 mm) in the morning, and 2 quarter turn in the evening until overcorrection achieved.
9682906|NCT04908540|Experimental|MARPE/ ALT-RAMEC (Group B)|Patients will open 2 quarter turn (0.2mm) in the morning, and 2 in the evening in the first week, then alternate with closing 2 quarter turn in the morning and 2 in the evening in the second week. And then continuing opening and closing till end with opening in the 7th week and continue opening until overcorrection achieved.
9682907|NCT04908618|Active Comparator|digital impression with normal abutment for dental implant|digital impression using a ready-made abutment for dental implant
9682908|NCT04908618|Experimental|digital impression with scan abutment for dental implant|digital impression with scan body abutment for dental implant
9682909|NCT04908618|Experimental|open tray conventional dental implant impression|Digitized open tray dental implant impression
10178202|NCT03815448|Placebo Comparator|Placebo|Placebo 2.5mg/ tablet,oral,once a week,2-6 tablets each time
10178203|NCT03815344|Active Comparator|Standard|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy.
9682910|NCT04908618|Experimental|closed tray impression for dental implant|Digitized closed tray dental implant impression
9682911|NCT04908696||TLM treatment for LC and PHC patients with early stage|TLM group: Laryngeal carcinoma (LC) (supraglottic type and glottic type) and hypopharyngeal carcinoma (HPC) (pyriform sinus and posterior pharyngeal wall) patients with T1 and T2 stages can be treated with transoral laser microsurgery (CO2 laser resection) for proper indications (NCCN 2020).
10178204|NCT03815344|Experimental|Standard-Vaginal Misoprostol|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
10178205|NCT03815305|Active Comparator|Topical CA and Placebo Oral Drug|Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
9682912|NCT04908696||OPL treatment for LC and PHC patients with T1, T2, and T3 stages|OPL group: Open partial laryngectomy with laryngeal function preservation is performed for patients with laryngeal carcinoma (LC) (supraglottic type, glottic type, and subglottic type) and hypopharyngeal carcinoma (PHC) (pyriform sinus, postcricoid, and posterior pharyngeal wall) with proper indications (NCCN 2020).
9682913|NCT04908696||R treatment for LC and PHC patients with early stage|R group: radiotherapy is treated for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications (NCCN 2020).
9682914|NCT04908696||TORS treatment for LC and PHC patients with early stage|TORS group: transoral robotic surgery is performed for proper laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications.
9682915|NCT04908696||SPA treatment for LC and PHC patients with advanced stage|SPA group: surgical treatment (S) ± postoperative adjuvant (PA) therapy is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
9682916|NCT04908696||CCR treatment for LC and PHC patients with advanced stage|CCR group: concurrent chemoradiotherapy (CCR) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
10178206|NCT03815305|Placebo Comparator|Petroleum Jelly and placebo oral drug|Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
9682917|NCT04908696||ARC treatment for LC and PHC patients with advanced stage|ARC group: neoadjuvant therapy (A) + radiotherapy/chemoradiotherapy (RC) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
9682918|NCT04908696||ASRC treatment for LC and PHC patients with advanced stage|ASRC group: neoadjuvant therapy (A) + surgery (S) + radiotherapy (R) or chemoradiotherapy (C) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
9682919|NCT04908774|Experimental|Fasting Mimicking Diet Group|The intervention group follows a fasting mimicking diet for 5 days every 6-8 weeks (a total of 3 times in 5 months).
9682920|NCT04908774|No Intervention|Control Group|This group maintains their individual diet during the whole time of the study. After 6 months they are offered a fasting intervention.
9682921|NCT04908501||Intervention group|Services of the non-transversal clinical departments of the Bordeaux University Hospital willing to participate to the programme.
9682922|NCT04908501||Control group|Services of the non-transversal clinical departments of the Bordeaux University Hospital not willing to participate to the programme.
9682923|NCT04908644|Experimental|MS-20 oral solution|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
9682924|NCT04908644|Placebo Comparator|Placebo|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
9682925|NCT04908514|Experimental|ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.|
9682926|NCT04908813|Experimental|HLX22(25mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 25mg/kg HLX22 IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
9682927|NCT04908813|Experimental|HLX22(15mg/kg)+Trastuzumab + Chemotherapy (XELOX)|Participants receive 15mg/kg HLX22 IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
9682928|NCT04908813|Active Comparator|Placebo +Trastuzumab + Chemotherapy (XELOX)|Participants receive placebo IV Q3W plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with XELOX chemotherapy
9682929|NCT04908670|Active Comparator|PNE group|5 minute video :Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI.
10178207|NCT03815305|Experimental|Centella asiatica extract and Topical CA|Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
9682930|NCT04908670|Active Comparator|Manipulation group|PA grade I-II oscillation on C7, T4 and L4
9682931|NCT04908462|Experimental|Part A Healthy volunteers: Single ascending doses|
9682932|NCT04908462|Experimental|Part B Healthy Volunteers Multiple ascending doses|
9682933|NCT04908462|Experimental|Part C Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)|"The dose levels for Part C will be determined following completion of the MAD portion (Part B) of the study.~Adult participants with a confirmed diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are expected to be enrolled at each of two dose levels."
9682934|NCT04908384|Experimental|IMPACT Intervention|IMPACT health application and wearable device
9682935|NCT04908384|No Intervention|Usual care control|Usual care control.
9682936|NCT04908098|Experimental|Laser group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling. Laser application was then applied to the areas where root planning was applied. Laser was applied in continuous phase at 0.80W power, 940 nm wavelength and 0.80 J / s energy level.
9682937|NCT04908098|Active Comparator|Control group|Root-planning was performed using Gracey curettes in the areas where periodontal pockets were diagnosed after scaling.
9682938|NCT04907981||Novel coronavirus infection|All patients were diagnosed according to the diagnostic criteria of the National Health Commission of China and confirmed by RT-PCR detection of viral nucleic acids.
9682939|NCT04907981||Not infected by novel coronavirus|Healthy controls and patients with liver disease
9682940|NCT04907981||Recovered patients with nucleic acid negative after infection with novel coronavirus|Novel coronavirus nucleic acid changed from positive to negative.
10178208|NCT03815331|Experimental|PD treatment with Xiaflex® plus Aveed|Peyronie's Disease treatment with Xiaflex® and Aveed®. All 20 subjects will be treated with Xiaflex® and Aveed®. The data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD with Xiaflex® alone.
9682941|NCT04908033||myocardial pacing group|patients with the pacing lead placed into the right ventricle to obtain myocardial capture
9682942|NCT04908033||physiological pacing group|patients with the pacing lead placed into the His bundle or left bundle branch area
9682943|NCT04908332|Experimental|Kangaroo baby Massage|The mother will apply the massage. The baby kangaroo will be exposed to the KBM for 10 minutes once a day during the time that the infant need to stay in kangaroo position at home. If the baby wakes up and wants to eat the KBM will be interrupted immediately and the baby will be fed, The temperature will be measured before and after the intervention. The massage will begin 60 minutes after the feed.
9682944|NCT04908332|Active Comparator|Kangaroo position|The infant must be in Kangaroo position with the mother semi sitting on bed with elevation of at least 30 degrees during 10 minutes every day until the infant doesn´t need to stay in kangaroo position at home.The temperature will be measured 60 minutes after the feed and 10 minutes after KP. If the baby wakes up and wants to eat the KP will be interrupted immediately and the baby will be fed, then the KP will be completed of time ( 10 minutes) to measure the temperature.
9682945|NCT04908397|Experimental|Supplement|Form: 500 mg L-carnitine tablet Dosage: Subjects 50-90kg: 3g/day Subjects <50kg or >90kg: 50mg/kg/day Frequency: twice a day for 2 weeks
9682946|NCT04908085|Experimental|OPC|Occupational Performance Coaching delivered by telephone
9682947|NCT04908085|No Intervention|Waitlist control|Intervention provided after post intervention assessment
9682948|NCT04908124|Experimental|Lubricant A - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
9682949|NCT04908124|Experimental|Lubricant B - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
9682950|NCT04908124|Experimental|Lubricant C - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
9682951|NCT04908124|Experimental|Lubricant D - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
9682952|NCT04908124|Experimental|Lubricant E - Tolerance|"A 3-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment.~This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase."
9682953|NCT04908124|Experimental|Lubricant A - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
9682954|NCT04908124|Experimental|Lubricant B - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
9682955|NCT04908124|Experimental|Lubricant C - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
9682956|NCT04908124|Experimental|Lubricant D - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
9682957|NCT04908124|Experimental|Lubricant E - Treatment|"A 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment.~This includes a sub-set population who were also enrolled into the arm using the same IP for the tolerability phase."
9682958|NCT04908007||Professional qualitative group|Qualitative analysis of crisis management by interviewing professionals most involved during the crisis in each university hospital.
9682959|NCT04908007||Professional quantitative group|Quantitative analysis of crisis management using the WHO grid adapted sent to the target persons identified within the establishments
9682960|NCT04908007||Patient quantitative group|Quantitative analysis of crisis management using a questionnaire sent to patients hospitalized in the first wave asking them about their perception of crisis and post-crisis management.
9682961|NCT04908007||Tools development|Development of tools to prepare for situations of uncertainty
9682962|NCT04908046|Experimental|HMPL-295S1 open-label treatment arm|"During dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile. Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
9695616|NCT04776564||Control group|A sample of couples from the public that do not at the moment participate in couple therapy or any couple enhancement programs
9695617|NCT04776291|Experimental|Recruitment and image processing|
9695618|NCT04776369|Active Comparator|Lidocaine group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
9976155|NCT01348633||Sub-study 3|Subjects with symptoms of branch and central retinal artery and vein occlusion within the past 2 months will be used to validate the Doppler SD-OCT blood flow technology and the hyperspectral imaging derived oxygen saturation maps. In cases of central retinal vein and artery occlusion, imaging values (i.e. inner retinal and choroidal blood flow, oxygen saturation values of the major retinal vessels and the capillary beds of the retina and ONH) will be compared between the affected and unaffected eyes. In cases of branch occlusion, imaging values will be compared between the affected and unaffected quadrants of the affected eye and between the affected and unaffected eyes. The difference in inner retinal and choroidal blood flow for each eye will be calculated and compared between eyes.
9682963|NCT04907994||Older patients and/or with chronic diseases|Retrospective cohort study of exposed/unexposed individuals in the national health data system (SNDS). The study population is composed of individuals aged 70 years or older and patients with a chronic disease. Exposure to containment is defined as the period between 17 March 2020 (beginning of week 12, start of containment) and 10 May 2020 (end of week 19, end of containment). The end of monitoring is set at 12 months after the start of the containment, on 17 March 2021. The unexposed group consists of random samples of comparable individuals (aged 70 years or older and/or chronically ill) for the two years prior to the outbreak (2015 and 2016). The second study period (May 10, 2020 to March 17, 2021) may be subdivided depending on the evolution of the health crisis and the governmental measures adopted. Measurement of the outcome measures and comparison between exposed and unexposed will be carried out at the end of each of the two periods.
9682964|NCT04908020||Follow up|"The group is made up by children and adolescents, aged from 9 to 17, who received a cancer diagnosis, who completed oncological treatment and who are included in a clinical follow-up program since less than 3 years.~Furthermore, the study involves one parent for each patient to collect demographics and clinical data."
9682965|NCT04908345|Experimental|Methadone|Methadone 0,075mg/kg for induction and half of induction dose of boluses as needed during surgery
9682966|NCT04908345|Active Comparator|Fentanyl|Fentanyl 3 mcg/kg for induction and half of induction dose of boluses as needed during surgery
9682967|NCT04908072|Active Comparator|Virtual Reality Training|Will participate in an Intensive virtual reality (R) cataract simulation course that includes a five day instructor led VR course using the Orbis-FundamentalVR cataract surgical simulator, in addition to standard resident training at the training facility.
9682968|NCT04908072|No Intervention|Traditional Training|Will receive standard resident training at the training facility.
9682969|NCT04907708|No Intervention|Normal healthy controls|females in second trimester with normal glucose levels
9682970|NCT04907708|No Intervention|Diet controlled|females in second trimester with blood sugar levels below 129mg/dl
9682971|NCT04907708|Experimental|Metformin|females in second trimester with blood sugar levels above 130mg/dl treated with Metformin
9682972|NCT04907708|Experimental|Insulin|females in second trimester with blood sugar levels above 130mg/dl being treated with Insulin
9682973|NCT04908150|Experimental|Core Group|The Core Group carried out core stability exercises. Their training consisted of the following exercises: bridge, Klapp, front plank and lateral plank
9682974|NCT04908150|Active Comparator|Abdominal Group|The Abdominal Group performed traditional exercises: trunk flexion or abdominal crunch, trunk extensions, lower abdominals with hip lifts and crunch with crossed legs
9682975|NCT04908254|Experimental|Dayspring Active Wearable Compression Device|The Dayspring Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure full-arm compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
9682976|NCT04908254|Active Comparator|Advanced Pneumatic Compression Device|A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
9682977|NCT04907942|Active Comparator|EMA Alone|3 weeks of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey.
9682978|NCT04907942|Experimental|EMA + Automated Text Message Intervention|"1 week of EMA, consisting of 2 surveys per day delivered via text message and email during waking hours to prompt participants to complete the survey followed by~2 additional weeks of EMA in combination with 2 text messages per day with content related to stress management techniques."
9682979|NCT04907812|Experimental|Tranexamic Acid (TXA)|Patients in the TXA arm will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before their surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after the first dose on the day of their surgery
9682980|NCT04907812|Placebo Comparator|Standard of Care (SOC)|Patients in the (SOC) arm will receive 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) before their surgery and 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) 3-6 hours after the first dose on the day of their surgery
9682981|NCT04907864|Experimental|MIC|Multi-modal intervention
9682982|NCT04907864|No Intervention|CPC|Conventional Palliative Care
9682983|NCT04907721|Experimental|Measuring glucagon sensitivity in humans|Participants will be subjected to two experimental days.
9682984|NCT04907955|Active Comparator|panoptix PANFOCAL intraocular lens|panoptix PANFOCAL intraocular lensis a single-piece aspheric non-apodized diffractive panfocal IOL that distributes light energy to three focal points in both small and large pupil conditions
9682985|NCT04907955|Active Comparator|Trifocal Diffractive the AT LISA intraocular lens|Trifocal Diffractive the AT LISA is a preloaded single-piece aspheric diffractive trifocal IOL and made of hydrophilic acrylic with a hydrophobic surface with an ultraviolet absorber. This aspheric IOL is aberration -correcting in order to reduce and compensate for corneal spherical aberrations.
9682986|NCT04907955|Active Comparator|Symphony EDOF (extended depth of focus) intraocular lens|SYMPHONY EDOF intraocular lens is a single-piece aspheric biconvex hydrophobic acrylic IOL with a 6.0 mm optic and an 13.0 mm overall diameter. This IOL consists of a wavefront-designed anterior aspheric surface (negative spherical aberration of -0.27 mm to counterbalance the net positive spherical aberration from cornea) and a posterior achromatic diffractive surface with echelette design.
9682987|NCT04907786||Study population|All patients eligible for participation in this registry are aged 18-80 years old and undergoing invasive coronary angiography because of abnormalities found on CCTA in either the left or right coronary artery and no or minimal stenosis (CAD-RADS 0-1; 0-24% stenosis) in the contralateral coronary artery. Patients will be asked for written informed consent to register their clinical data in an anonymized database. The period between CCTA and ICA may not exceed 90 days, in order to prevent possible aggravation of coronary artery disease between both examinations.
10178209|NCT03815318|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
9682988|NCT04907929|Experimental|post-implantation care|
9682989|NCT04907682|Active Comparator|Intravenous ribavirin|"standard treatment: Irrua regimen~100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day)~25 mg/kg days 2-7~12.5 mg/kg days 8-10"
9682990|NCT04907682|Experimental|Oral favipiravir|"Oral favipiravir~Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16)~Day 2-10 1200mg twice daily (BD)"
9682991|NCT04907604|Other|First intervention group|Clusters 1 and 2 (group 1) will start the intervention at month 1, immediately after completing the baseline assessment. After 7 weeks of using the app and having access to the EMPOWER website (with material related to the anti-stigma campaign and recommendations for employees to deal with psychosocial risk factors), they will answer a post-treatment assessment protocol through the app.
9682992|NCT04907604|Other|Second intervention group|Clusters 3 and 4 (group 2) that serve as control group of cluster 1 and 2 (group 1), will also complete the assessment at T1. Clusters 3 and 4 (group 2) will start the intervention in step 2, after completing the second assessment.
9682993|NCT04907604|Other|Third intervention group|Clusters 5 and 6 (group 3), that serve as control group of group 1 and 2, will also complete the assessment at T2. Clusters 5 and 6 (group 3) will start the intervention in step 3. All clusters will answer a total of five assessments
9682994|NCT04907565||Obese patients|BMI >30kg/m2
9682995|NCT04907565||non obese patients|BMI between 18 to 29kg/m2
9682996|NCT04907526|Experimental|Treatment Arm|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 3 million cells per kilogram of body weight. This is a one time treatment at the time of Stage III Fontan surgery.
9682997|NCT04907526|No Intervention|Control Arm|Control cohort not receiving the cell product, which will be enrolled and followed using the same inclusion/exclusion criteria and follow-up requirements as the treatment arm.
9682998|NCT04907760|Experimental|With a personalized care program|The strategy implemented is a personalized care pathway that includes participant follow-up by a nurse for 5 years with contact every 4 months for the first year, then every 6 months
9682999|NCT04907760|No Intervention|Without a personalized care program|The comparison strategy does not include any specific management. The patient will not receive individualized management with the nurse coordinator.
9683000|NCT04907448|Experimental|IsoK-ST group|Participants in this group received the usual physical rehabilitation program in addition to an IsoK-ST program.
9683001|NCT04907448|Active Comparator|Control group|Participants in this group received the usual physical rehabilitation program only.
9683002|NCT04907435||patient with simultaneous laparoscopic operations|
9683003|NCT04907435||patient with simultaneous open operations|
10178210|NCT03815201|Placebo Comparator|Group 1|exercise training program: 2 non-consecutive days per week during 12 weeks plus placebo ingestion post-training
9683004|NCT04907838|Experimental|Type 2 diabetics|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
9683005|NCT04907838|Experimental|Healthy controls|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
10178211|NCT03815201|Active Comparator|Group 2|exercise training program: 2 non-consecutive days per week during 12 weeks plus leucine-enriched protein supplementation post-training
9683006|NCT04907474|Other|1 Mist|One mist of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
9683007|NCT04907474|Other|2 Mists|Two mists of tropicamide-phenylephrine fixed combination solution administered to each eye with the MAP Dispenser
9683008|NCT04907747|Experimental|Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 10days
9683009|NCT04907747|Experimental|Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days|Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
9683010|NCT04907747|Active Comparator|Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days|Esomeprazole 20 mg bid, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days
9683011|NCT04907591|Experimental|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band for 12 months.
9977643|NCT01363830|Experimental|Two-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for two-weeks following discectomy.
10178212|NCT03815435|Experimental|Balanced anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/ kg) + Propofol (2-3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: Desflurane 0.8-1.2 MAC + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60
10178213|NCT03815435|Experimental|Total intravenous anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/kg) + Propofol (2 -3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: continuous administration of Propofol 6-12 mg /kg/h + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60 Hypotensives: Nitro Pohl 1mg/ml 0-10 ml/h
9683012|NCT04907591|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
9695619|NCT04776369|Active Comparator|Magnesium group|30 patients will receive IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.
9977644|NCT01363830|Active Comparator|Six-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for six-weeks following discectomy.
10187427|NCT03726372|Experimental|moderate neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given at a dose by intermittent injection that reaction to train of four (TOF) stimulation is kept 1 to 2
9683013|NCT04907461|Experimental|Laparoscopic guided TAP block|"The surgeon uses a laparoscopic technique to visualise the peritoneum from the inside of the abdomen and guides the hypodermic needle through the abdominal wall from the outside. When the needle point is visible through the peritoneum and almost enters the abdominal cavity, the surgeon retracts the needle around 5 mm. Then by deploying a test dose of the local anaesthetics a so called Doyle's bulge sign can confirm the right position in the nervous plane. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin."
9683014|NCT04907461|Active Comparator|Ultrasound guided TAP block|The anaesthesiologist uses ultrasound to identify the nervous plane in-between the external and transverse abdominal muscles. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin.
9683015|NCT04907617|Experimental|G1|After the induction of anaesthesia, the first group will be heated with only forced-air warming device.
9683016|NCT04907617|Experimental|G2|After the induction of anaesthesia, the second group will receive only warmed IV and irrigation fluids.
9683017|NCT04907617|Experimental|G3|After the induction of anaesthesia, forced-air warming as well as warmed IV and irrigation fluids will be applied to the third group
9683018|NCT04907617|Experimental|G4|After the induction of anaesthesia, the fourth group will be the control group without any intervention.
9683019|NCT04907630|Experimental|intervention group-antenatal education of health literacy (HL-AE)|It is the group that is given antenatal education based on improving health literacy (HL-AE).
9683020|NCT04907630|Experimental|intervention group-Antenatal Education (AE)|It is the group that gives antenatal education (AE)
9683021|NCT04907630|Experimental|Control group|No Intervention
9683022|NCT04907578||postpartum full term neonates|immediate postpartum full term neonates with no intrauterine growth restricted
9683023|NCT04907578||intrauterine growth restricted neonates|preterm or full-term intrauterine growth restricted neonates
9683024|NCT04907500|Experimental|Multifocal IOL|Implantation of a multifocal intraocular lens
9683025|NCT04907136|Experimental|Preferred ENDS|All participants will complete a lab visit where they will use their preferred ENDS ad libitum for up to 60 minutes
9683026|NCT04907136|Experimental|Preferred ENDS with HWL|All participants will complete a lab visit where they will use their preferred ENDS with a HWL on the device ad libitum for up to 60 minutes
9683027|NCT04907422||CXPA group|carcinoma ex pleomorphic adenoma of major and minor salivary glands.
9683028|NCT04907422||PA group|Benign pleomorphic adenoma of major and minor salivary glands.
9683029|NCT04907422||Control group|normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.
9683030|NCT04907123|Experimental|UNa+ Driven Intensive Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 6 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: Spot Urinary Sodium > 70 mEq/L AND mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
9683031|NCT04907123|Active Comparator|Standard Therapy|"Ask patient to empty bladder. Start treatment (step 1). Re-evaluate patient every 12 hours; if therapeutic goal is not met, treat according to the following step.~Therapeutic goal: mean diuresis > 1,5 ml/kg/h Step 1 Furosemide i.v. continuous infusion (2 times oral daily dose; minimum dose: 240 mg die) Step 2 Double furosemide i.v. continuous infusion (maximal dose: 720 mg die) Step 3 Add oral metolazone 5 mg b.i.d. Step 4 Add oral acetazolamide 250 mg b.i.d."
9683032|NCT04907149|Experimental|Absolute Bioavailability - Period 1|Participants will receive GLPG3970 under fasted conditions followed by an intravenous (i.v.) microtracer microdose of [14C]GLPG3970 on Day 1.
9683033|NCT04907149|Experimental|Mass Balance - Period 2|Participants will receive [14C]GLPG397 under fasted conditions on Day 1.
9683034|NCT04907084|Experimental|Serine 200 mg/kg/day|Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
9683035|NCT04907084|Experimental|Serine 400 mg/kg/day|Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).
9683036|NCT04907084|Experimental|Fenofibrate 160 mg/day|Fenofibrate 160 mg per day. To be taken once per day for 6 weeks.
9683037|NCT04907084|Experimental|Serine 200 mg/kg/day and Fenofibrate 160 mg/day|"Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
9683038|NCT04907084|Experimental|Serine 400 mg/kg/day and Fenofibrate 160 mg/day|"Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)).~Fenofibrate 160 mg per day. To be taken once per day for 6 weeks."
9683039|NCT04907084|No Intervention|No treatment|Control group: no investigational product taken
9683040|NCT04907097|Other|MOF/placebo|During period 1 (4 weeks) participants will receive monomeric and oligomeric flavanols and during period 2 (4 weeks) placebo. Wash out period between two interventions will be 4 weeks. The daily dose of monomeric and oligomeric flavanols will be 200 mg (2 capsules once a day) and for placebo (2 capsules once a day).
9683041|NCT04907097|Other|Placebo/MOF|During period 1 (4 weeks) participants will receive placebo and during period 2 (4 weeks) monomeric and oligomeric flavanols. The wash out period between two interventions will be 4 weeks. The daily dose of placebo will be 2 capsules once a day and for monomeric and oligomeric flavanols 200 mg (2 capsules once a day).
9683042|NCT04907110|Experimental|Exercise + NR|Participants will be asked to take two pills of NR (250mg/pill) twice daily (a total of 4 pills/day; 1000mg/day), for 40 days. During days 17-38 of the NR intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of NR supplementation.
9695620|NCT04776369|Active Comparator|Combination group|30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV magnesium sulfate 30 mg/kg in 50 ml volume over 30 min. after induction of anesthesia.
9683043|NCT04907110|Placebo Comparator|Exercise + Placebo|Participants will be asked to take two pills of placebo, twice daily (a total of 4 pills/day), for 40 days. During days 17-38 of the intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of the placebo supplementation.
9683044|NCT04907383||Diverticular disease|"All consecutive patients admitted to a Surgical Unit with a diagnosis of left-side colinic diverticulitis will be enrolled in the registry. Patients will be identified through their medical record numbers. One investigator in each center will obtain written informed consent from each patient and keep the patients updated on data collection.~Inclusion criteria: 1) imaging-proven colonic diverticular disease 2) patient aged > 18 years old; 3) Written informed consent obtained. 4) A colonoscopy showing diverticular disease will be required during the follow-up or before surgical treatment if possible"
9695621|NCT04776369|Placebo Comparator|control group|30 patients will receive IV saline 50 ml plus IV saline 50 ml over 30 min. after induction of anesthesia.
9695622|NCT04776343|Experimental|Telemedecine follow-up|
9695623|NCT04776343|No Intervention|Hospital follow-up|
9695624|NCT04776304|Other|qEEG Art Therapy|Participants will receive art therapy while a noninvasive, mobile qEEG measures brain activity. There is no comparison as this is an exploratory pilot study.
10178214|NCT03815357||Children with IPD|Children with IPD will be referred for immunological evaluation. The protocol for immune work up will be the same but between centres there is variation in the age criteria for referral i.e. >2 years in some, >6 months in others.
9695625|NCT04776421||ileostomy group|
9695626|NCT04776200||Ballet Groups|It was invited the individuals, who were ongoing for at least 3 months in classical ballet dance activity in the dance studio, between December 2019 and March 2020.
9695627|NCT04776200||Control Groups|It was invited the individuals, who have just registered for classical ballet dance activity.
9695628|NCT04776083|Experimental|radiotherapy arm|after first line systemic therapy, patients will receive radiotherapy to the primary lesion, hypo-fractionated regimen 45gy will be given over 15 fractions
9695629|NCT04776083|Active Comparator|no intervention arm|after first line systemic therapy, patients will be kept under follow up
9695630|NCT04776330|Experimental|BCMA targeted prime CAR-T cells treat|Patients will be be treated with BCMA targeted prime CAR-T cells
9695631|NCT04776239|Experimental|Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group|Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).
9695632|NCT04776239|Experimental|Group 2: Placebo Group|Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.
9695633|NCT04776356||QuickFix Small Staple|The QuickFix Small Staple will be used for an Akin osteotomy to correct hallux valgus interphalangeus.
9695634|NCT04776109|Active Comparator|(Group of continous thoracic epidural bupivacaine infusion [CEI])|Group I : An epidural catheter will be inserted via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T8 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine (sunny-bupivacaine) infusion. Proper placement of the catheter will be verified through an aspiration test and a test dose (2 ml) of lidocaine 2% with adrenaline. At the end of surgery, a 0.2 ml/kg bolus of bupivacaine 0.25% will be administered through the catheter and then an infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h will be administered immediately postoperative and continued for 48 hours.
9695635|NCT04776109|Active Comparator|(Group of continous bilateral erector spinae bupivacaine infusions[CESI])|Group II : Bilateral erector spinae catheters will be placed at T8 level. Surface anatomy or ultrasound (counting up from the 12th rib) will be used to identify the level of T8 after skin sterilization with the patient on the lateral position. Then a high frequency linear-array ultrasound transducer (Sono Site MW, Bothell, WA, USA) covered in a sterile sleeve will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, and the transverse Processes with shimmering pleura in between. Next, 2-3 ml of 2% lidocaine will be infiltrated .
9977645|NCT01363856||First ever acute stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
9695637|NCT04776135|Experimental|MT-1186 orally|Subjects receive the edaravone oral suspension orally.
9695638|NCT04776135|Experimental|MT-1186 via a nasogastric tube|Subjects receive the edaravone oral suspension via a nasogastric tube
9695639|NCT04776226|No Intervention|Patients without depression|This group included patients without depression during enrollment of the cases.
9695640|NCT04776226|Experimental|Depressive patients with treatment|This group included patients wit depression but with treatment during enrollment of the cases.
9695641|NCT04776226|No Intervention|Depressive patients wihout treatment|This group included patients without depression but withou treatment during enrollment of the cases.
9695642|NCT04776122|Active Comparator|Control with no device|Breathing performed with no device
9695643|NCT04776122|Experimental|Therapy - device assisted breathing|Breathing performed with device
9695644|NCT04776187|Active Comparator|Gadodiamide|"Patients who have undergone contrast-enhanced MRI using Gadodiamide contrast agent for clinical purposes.~Generic name: Gadodiamide Injection; Product name: OMNISCAN; Sample specifications: 15ml: 4.305g (a sterile solution containing 287mg/ml gadodiamide)."
9977646|NCT01363869|Experimental|Green tea extracts 2 gm/day|Green tea extracts 2 gm/day for 14 days
9695645|NCT04776187|Experimental|Gadoteric Acid Meglumine Salt|"Patients who have undergone contrast-enhanced MRI using Gadoteric Acid Meglumine Salt contrast agent for clinical purposes.~Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid meglumine salt)."
9695646|NCT04776265||RR HL Who Receive Salvage Chemotherapy and ASCT|Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant
9683045|NCT04907318||ANKORIS|Cataract surgery performed with POD26PAYT
10187985|NCT03720665|Placebo Comparator|Placebo group|"Non-active tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
9683046|NCT04907318||FINEVISION TORIC|Cataract surgery performed with POD26PAYFT
9683047|NCT04907331|Active Comparator|Corminaty twice|The participants receive Comirnaty twice 3-7 weeks apart
9683048|NCT04907331|Active Comparator|Vaxzevria twice|The participants receive Vaxzevria twice 12 weeks apart.
9683049|NCT04907331|Experimental|Heterologous|The recipients receive Vaxzevria followed by Comirnaty 12 weeks apart
9683050|NCT04906954|Other|Neuromuscular electrical stimulation (NMES)|"30 NMES sessions will be performed by patients for 30 min, for a period of 8 weeks, according to a standardized protocol.~The number of sessions per week will be gradually increased to reach 5 sessions/week at week 4."
9683051|NCT04907344|Experimental|Part 1: Camrelizumab + Chemotherapy|
9683052|NCT04907344|Experimental|Part 2: Camrelizumab + Chemotherapy|
9683053|NCT04907344|Active Comparator|Part 2: Chemotherapy|
9683054|NCT04907019|Experimental|Group-drugs interaction|24 subjects were enrolled in this study. The effects of rifampicin single dose and steady-state on the pharmacokinetics of sy-004 will be analyzed.
9683055|NCT04906863||Mild Cognitive Impairment|Individuals with mild cognitive impairment that began before age 70
9683056|NCT04906863||Dementia/Alzheimer's Disease|Individuals with Alzheimer's Disease or other dementia that began before age 70
9683057|NCT04906863||Cognitively Healthy|Cognitively healthy individuals over the age of 30 years
9683058|NCT04906889|Experimental|dexmedetomidine-lidocaine|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
9683059|NCT04906889|Active Comparator|remifentanil|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy
9683060|NCT04906876|Experimental|Stratum A: Soft Tissue Sarcoma|Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9683061|NCT04906876|Experimental|Stratum B: Bone Sarcoma|Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9683062|NCT04906772|Experimental|Group KD|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
9683063|NCT04906772|Active Comparator|Group KP|participants received loading of ketamine 1 mg/kg and propofol 1 mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25 µg/kg/hr dexmedetomidine throughout the procedure.
9976156|NCT01348633||Sub-study 4|Calibration for retinal melanin, crystalline lens absorption, macular pigment, morphological variation and pre-retinal autofluorescence in healthy subjects (n=20 per decade, range 40 to 80yrs). Established reflectometric techniques to derive absorption values and autofluorescence techniques will be used to calculate correction values for each parameter that influences the hyper-spectral retinal and ON oxygen saturation imaging data (Keilhauer and Delori, 2006; Delori et al, 2007).
10187986|NCT03720639|Active Comparator|Abbott, Inc Confirm Rx™|Every other consenting subject will receive the Abbott Inc. Confirm Rx™ device.
9683064|NCT04906733||Cancer patient|RAS/RAF wild-type metastatic right colon cancer patients receiving chemotherapy or chemotherapy combined target therapy treatment.
9683065|NCT04907162||Neuromuscular disease (NMD) Patients|"The patient has one of the following neuromuscular diagnoses:~histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or~genetically confirmed late-onset Pompe disease (LOPD), or~genetically confirmed spinal muscular atrophy type 3 (SMA3), or~genetically confirmed myotonic dystrophy type 1, or~genetically confirmed myotonic dystrophy type 2, or~genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD)."
9683066|NCT04907162||Healthy control|no known neuromuscular disorder
9683067|NCT04906681|Experimental|Arthroplasty, hip or knee|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
9683068|NCT04906681|Experimental|Neurology: stroke or Parkinson disease|Minimum 5x/week (of which minimal 3x/week with therapists and 2x/week during weekend), 30-60 minutes training, for 4 weeks, with i-ACT system. i-ACT provides individualised exercises based on patients own goalsetting.
9683069|NCT04906629|Experimental|INO-4201|One intradermal injection of INO-4201 followed by electroporation
9683070|NCT04906629|Placebo Comparator|Placebo|One intradermal injection of normal saline followed by electroporation
9683071|NCT04906655|Experimental|Cohort A glycopyrronium 30 minutes cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time in cotton gloves~Complete daily diary.~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put cotton gloves on both hands.~Set timer for 30 minutes.~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
9695647|NCT04776057|Other|lying|after cataract lying for 1 hour
9695648|NCT04776057|Other|sitting, walkin|after cataract sitting or walking for 1 hour
9695649|NCT04775823|Experimental|Hybrid composite nano-ceramic|
9695650|NCT04775875|Experimental|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the caudate. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
9683072|NCT04906655|Experimental|Cohort B glycopyrronium 30 minutes under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~30 minutes residence time under occlusion~Complete daily diary.~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put gloves on both hands.~Set timer for 30 minutes.~After 30 minutes, remove gloves and throw them away. Immediately wash hands thoroughly with warm water and soap, and dry them."
9695651|NCT04775940|Experimental|Perforated collagen membrane|
9695652|NCT04775940|Active Comparator|Occlusive collagen membrane|
10178215|NCT03815266|Experimental|Patient with first ischemic or hemorrhagic stroke|"Patient with first ischemic or hemorrhagic stroke will be included. They will have the following program Computerized Mirror Therapy (CMT) associated at transcranial Direct Current Stimulation (tDCS). This program will consist of 5 sessions per week for 4 weeks (20 minutes).~In more, they will have the following tests: Tolerance Assessment Questionnaire, Ashworth's scale, Frenchay arm test, Abilhand questionnaire, Fugl-Meyer test, and Goal Attainment Scaling (GAS)."
10178216|NCT03815214|Experimental|Diet Intervention|The diet intervention is a partial meal replacement program using the commercially available OPTAVIA® Optimal Weight 4&2&1 Plan™. In the OPTAVIA program, subjects are asked to eat 6 times each day, once every 2 to 3 hours.
10178217|NCT03815214|Placebo Comparator|Enhanced Standard Care|The control group will receive instruction on a healthy diet as defined by the United States Department of Agriculture.
10178218|NCT03815383|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
10178219|NCT03815253|Experimental|Acupuncture group|"Body electro-acupuncture will be conducted for 2 sessions per week over 8 consecutive weeks.~Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
10178220|NCT03815253|Placebo Comparator|sham-acupuncture group|"As to the participants allocated to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to act as sham control at the same acupoints with same stimulation modality. However, the needles will be only adhered to the skin instead of insertion. The validity and credibility of this model has been well demonstrated."
10178221|NCT03815084|Experimental|PD-1 and DC-NK treatment group|
10178222|NCT03815045|Active Comparator|Landmark-based lumbar puncture|Landmark-based LP
10178223|NCT03815045|Active Comparator|Ultrasound-guided lumbar puncture|Ultrasound-guided LP
10178224|NCT03815409|Experimental|BWSTT group|The sessions were conducted on a treadmill with partial weight unload.
10178225|NCT03815409|Other|Control group|The traditional PT rehabilitation treatment included passive, active and active-assisted exercises, according to the methods commonly used (Kabat, Bobath).
10178226|NCT03815032|Experimental|Optowire Deux FFR assessment (1)|"A total of 45 consecutive patients will be recruited:~group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires"
10178227|NCT03815032|Experimental|Optowire Deux FFR assessment (2)|group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire
10178228|NCT03815227|Experimental|Outpatient birth|Maternity out the same date or the next day of the birth
10178229|NCT03814902|Experimental|Electronic Tracking Device|Participants will be given a wearable electronic tracking device (ETD) to use for their child with autism spectrum disorder (ASD) for 6 weeks.
10178230|NCT03814980|Experimental|Pilot Study|Participants will be shown how to use a mindful breathing software application. The software will be used for 1 week. At the end of the week, participants will evaluate the software.
10178231|NCT03815136|Active Comparator|Chewing Gum|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy. Subjects chewed one piece of gum for approximately 15 min every 30 min at the first hour of the examination.
10178232|NCT03815136|Placebo Comparator|Control|The control group will not chew chewing gum while undergoing capsule endoscopy.
10178233|NCT03815279|Experimental|High-risk SMM and MM|"Twelve cycles of Carfilzomib-Lenalidomide-Dexamethason. Each cycle is 28 days. Carfilzomib intravenous, days 1, 8 and 15 (starting dose, 20 mg/m2 on day 1 of cycle 1; target dose, 56 mg/m2 thereafter) during cycles 1 through 12.~Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks then 20 mg weekly for 16 weeks and thereafter 10 mg weekly for 16 weeks.~Maintenance (1 year):~Carfilzomib intravenous days 1 and 15 (56 mg/m2) during cycles 13 through 24. Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks Dexamethasone 10 mg weekly for 52 weeks."
10178234|NCT03815279|Experimental|Intermediate-risk SMM|"Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks, then 20 mg weekly for 16 weeks.~Maintenance (1 year):~Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks."
10178235|NCT03815071|Experimental|ips-nsc treatment group|
10178236|NCT03814954|Active Comparator|Salbutamol|Patients will receive salbutamol (2 units/kg) with 3 ml normal saline by nebulizer.
10178237|NCT03814954|Experimental|Epinephrine|Patients will receive epinephrine (0.5 mg/dose) with 3 ml normal saline by nebulizer.
9695653|NCT04775862|Experimental|RAS wild type; investigator choice re-challenge with anti EGFR Rx|
9695654|NCT04775862|Active Comparator|RAS mutant; investigator choice of SOC third line Rx|
9977647|NCT01363869|Experimental|Green tea extracts 4 gm/day|Green tea extracts 4 gm/day for 14 days
9977648|NCT01363869|Experimental|Green tea extracts 6 gm/day|Green tea extracts 6 gm/day for 14 days
10178238|NCT03814928|Experimental|Caregivers e-Learning Intervention|
10178239|NCT03815149||patients with intracranial aneurysm(s)|Standard of care elective, unscheduled or emergency procedures for the treatment of an unruptured or ruptured intracranial aneurysm(s) using a Pipeline™ Flex Embolization Device(s) with Shield Technology™
10178240|NCT03815097|Experimental|Intervention|Monitored anesthesia care with a mapleson circuit and nasal trumpet
10178241|NCT03815097|No Intervention|Standard of care|Standard monitored anesthesia care
10178242|NCT03814941||paper-based anesthesia record|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by paper-based documented anesthesia record."
9683073|NCT04906655|Experimental|Cohort C glycopyrronium overnight in cotton gloves|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight in cotton gloves~Complete daily diary~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put on the cotton gloves on both hands and go to bed.~In the morning, after at least 4 hours of wearing the gloves , remove the cotton gloves and throw them away.~Immediately wash hands thoroughly with warm water and soap, and dry them."
9683074|NCT04906655|Experimental|Cohort D glycopyrronium overnight under occlusion|"Study drug should be applied to clean, dry skin. A single cloth will be used to apply study drug to both hands once daily, at bedtime. The subject will be instructed to apply the study drug as follows:~Overnight under occlusion~Complete daily diary~Remove all jewelry.~Tear open the top of the pouch at the notch.~Wash hands thoroughly with warm water, and dry them.~Remove the wipe from the pouch and unfold the wipe.~Wipe both hands with the wipe continuously until the wipe is dry (up to 3 minutes).~Return the wipe to the pouch and put it back in the box.~Carefully put on the occlusive gloves and go to bed.~In the morning, after at least 4 hours of wearing the gloves, remove the occlusive gloves and throw them away.~Immediately wash hands thoroughly with warm water and soap, and dry them."
9683075|NCT04906915|Experimental|Ketamine|The experimental group was continuously pumped with remifentanil + ketamine for analgesia, and the control group was continuously pumped with remifentanil + placebo (normal saline) for analgesia. RASS and CPOT scores were performed to evaluate the pain degree of the patients.
9683076|NCT04906798|Experimental|Sequence1|"Period 1: Reference drug(D744)~Period 2: Test drug(CKD-385)"
9683077|NCT04906798|Experimental|Sequence2|"Period 1: Test drug(CKD-385)~Period 2: Reference drug(D744)"
9683078|NCT04907006|Experimental|Group-1|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
9683079|NCT04907006|Experimental|Group-2|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
9683080|NCT04906967|Active Comparator|modified sural flap|modified sural flap used to cover soft tissue defect around ankle
9683081|NCT04906967|Active Comparator|anterolateral thigh flap|anterolateral thigh flap used to cover soft tissue defect around ankle
9683082|NCT04906512|Experimental|Tegaderm CHG Dressing|Tegaderm CHG dressing is used to cover and protect insertion catheter sites and to secure devices to skin. It is available in a variety of shapes and sizes. Tegaderm CHG Dressing is intended to reduce skin colonization and catheter colonization and to suppress regrowth of microorganisms commonly related to bloodstream infections. Tegaderm CHG dressing is intended to reduce catheter-related bloodstream infections (CRBSI) in patients with central venous or arterial catheters.
9683083|NCT04906512|Active Comparator|Tegaderm Standard Dressing|Tegaderm Standard Dressing is used to cover and protect insertion catheter sites and to secure devices to skin.
9695655|NCT04776096|Experimental|Bepotastine besilate 1,5% preservative free|Bepotastine besilate 1,5% in preservative-free bottle, administered once a day during the morning.
10178243|NCT03814941||electronic documents|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by electric documented anesthesia record."
10178244|NCT03814876|Experimental|SCI intervention|Spinal cord injury intervention group
10178245|NCT03814876|Active Comparator|SCI control|Spinal cord injury control
10178246|NCT03814876|Experimental|TBI intervention|Traumatic brain injury intervention group
10178247|NCT03814876|Active Comparator|TBI control|Traumatic brain injury control group
10178248|NCT03814733|Experimental|Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
10178249|NCT03814733|Experimental|Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
10187987|NCT03720639|Active Comparator|Medtronic, Inc Reveal LINQTM|Every other consenting subject will receive the Medtronic, Inc. Reveal LINQTM.
9527654|NCT03218098|Experimental|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
9683084|NCT04906811|Active Comparator|Fat grafting with the AuraGen 1-2-3 with AuraClens System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.
9683085|NCT04906811|Active Comparator|Fat grafting with the Revolve System|Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.
10178250|NCT03814733|Active Comparator|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
9683086|NCT04906785|Experimental|Sequence1|"Period 1: Reference drug(D744)~Period 2: Test drug(CKD-385)"
9683087|NCT04906785|Experimental|Sequence2|"Period 1: Test drug(CKD-385)~Period 2: Reference drug(D744)"
9683088|NCT04906720|No Intervention|Standard of care|Usual standard of care post atrial fibrillation ablation.
9683089|NCT04906720|Experimental|Colchicine|0.6mg colchicine oral twice daily for 7 days.
9683090|NCT04906486||Observational: Patients with restless legs syndrome|A total of 70 patients who diagnosed with primary restless legs syndrome according to the five essential criteria as established by the International Restless Legs Syndrome Study Group.
9683091|NCT04906486||Observational: Healthy controls|The control group consisted of 85 age- and gender-matched healthy volunteers.
9683092|NCT04906408|Experimental|Prevena|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
9683093|NCT04906408|Experimental|Prineo|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
9683094|NCT04906408|Active Comparator|Standard Dressing|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
9683095|NCT04906538|Active Comparator|anterior cruciate ligament reconstruction with internal suture augmentation technique|This group will be operated by using all-inside ACLR technique with internal suture augmentation technique
9683096|NCT04906538|Active Comparator|anterior cruciate ligament reconstruction without internal suture augmentation technique|This group will be operated by using all-inside ACLR technique without internal suture augmentation technique
9683097|NCT04906642|Active Comparator|Standard of Care|"Each of the following procedures will be conducted according to general or local site Standard of Care (SoC):~Medication administration at surgery~Surgical irrigation and wound debridement~Surgical fracture preparation/fixation~Surgical closure"
9683098|NCT04906642|Experimental|Standard of Care plus Next Science|In addition to the SoC, the blinded product will be applied in place of saline irrigation as the wound is closed (after bone fracture preparation/fixation), depending on the randomization.
9683099|NCT04906460|Experimental|WVE-N531|
9683100|NCT04906291|Experimental|H.A.F. toothpaste (1000 ppm F-)|The children were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
9683101|NCT04906291|Active Comparator|Fluoridated toothpaste (1000 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
9683102|NCT04906291|Experimental|H.A.F. toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
9683103|NCT04906291|Active Comparator|Fluoridated toothpaste (1450 ppm F-)|The subjects were instructed to brush their teeth for at least two minutes after each main meal (three times/day).
9683104|NCT04906473|Experimental|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
9683105|NCT04906343|No Intervention|Group 1 (2 years)|Group 1, surveillance colonoscopy in two years after the last complete colonoscopy in SPS patient.
9683106|NCT04906343|Active Comparator|Group 2 (3 years)|Group 2, surveillance colonoscopy in three years after the last complete colonoscopy in SPS patient.
9683107|NCT04906499|Experimental|Physical Activity Promotion Group|Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day.
9683108|NCT04906590|Experimental|Study Drug|All participants will receive PI-2620.
9683109|NCT04906317|Active Comparator|Sedation and Analgesia|0.05 mg/kg midazolam and 5mg dezocine iv infusion
9683110|NCT04906317|Active Comparator|Anesthesia|continuous 1.5mg/kg propofol iv infusion
9683111|NCT04906525|Other|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
9683112|NCT04906525|Experimental|Resistance training|Participants will undergo 6 weeks of supervised resistance training
9683113|NCT04906356||Study group|Single group observational study
9683114|NCT04906434|Experimental|ABSK011 60mg cohort|60mg cohort：1 patient will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, the patient will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
9695656|NCT04776096|Active Comparator|Olopatadine hydrochloride 0,2% with BAK|Olopatadine hydrochloride 0,2% with BAK as preservative, administered once a day during the morning.
10178251|NCT03814733|Active Comparator|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
10178252|NCT03814733|Placebo Comparator|Placebo for Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
10178253|NCT03814733|Placebo Comparator|Placebo for Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
10178254|NCT03814733|Placebo Comparator|Placebo for Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
10178255|NCT03814759|Experimental|SP+CCRT|S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks
10178256|NCT03814824|Active Comparator|VLE without IRIS, followed by VLE with IRIS|VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.
10178257|NCT03814824|Active Comparator|VLE with IRIS, followed by VLE without IRIS|VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.
10178258|NCT03814655|Experimental|Full digital workflow|"Intraoral scan of the partially edentulous site, antagonists and occlusion registration. Radiopaque tray customization over the partially edentulous arch.~CBCT with customized radiopaque tray.~Merging files in R2 Gate software and implant planning.~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~Digital impression for final screw-retained crown/bridge.~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
10178259|NCT03814655|Active Comparator|Partially digital workflow|"Impression of the edentulous arch and antagonist, occlusion registration. Radiopaque tray customization over the edentulous arch.~CBCT with customized radiopaque tray.~Stone models alone, maximum intercuspal position and customized radiopaque tray will be scanned using a desktop scanner.~Merging files (CBCT and model stl) in R2 Gate software and implant planning.~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~Classic impression in customized tray with Impregum.~Functional models will be scanned using the same desktop scanner.~Final screw-retained crown/bridge manufacturing.~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
10178260|NCT03814564||Circulatory failure / NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
10178261|NCT03814564||Circulatory Failure / no NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
9683115|NCT04906434|Experimental|ABSK011 120mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
9683116|NCT04906434|Experimental|ABSK011 180mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
9683117|NCT04906434|Experimental|ABSK011 240mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
9683118|NCT04906434|Experimental|ABSK011 320mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
9683119|NCT04906434|Experimental|ABSK011 400mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
9683120|NCT04906187|Experimental|Arm A : Experimental group with intraoperative ANI monitoring of nociception|
9683121|NCT04906187|Other|Arm B : Control group without ANI intraoperative monitoring of nociception|
9683122|NCT04906031|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
9683123|NCT04906603|Experimental|TBS Headache|
9683124|NCT04906304|Experimental|Evrolimus|The treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral) low dose pluse cellcept
9683125|NCT04906304|Active Comparator|Control|0.75 mg/bid everolimus with everolimus C0 3-8 ng/mL plus Sandimmun (Neoral)standard dose plus cellcept
10178262|NCT03814564||Gut dysbiosis, delirium and long term cognition|"ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.~Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission."
10178263|NCT03814603||African Americans|
9683126|NCT04906096|Experimental|PAXALISIB|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.~Paxalisib (GDC-0084)~Each study treatment cycle lasts 28 days, up to 24 months."
9683127|NCT04906070|Experimental|HB-001 DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
9683128|NCT04906109|Experimental|Reference-Test|
9683129|NCT04906109|Experimental|Test-Reference|
9683130|NCT04906083|Experimental|Intervention group|Avatrombopag+Standard medical treatment
10178264|NCT03814603||Non-Hispanic Whites|
10178265|NCT03814668|Experimental|Probiotic powder|One sachet of Probiotic powderwill be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
9683131|NCT04906083|Other|Control group|Standard medical treatment
10178266|NCT03814668|Active Comparator|Lactase|One sachet of Lactase powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
9683132|NCT04906265|Active Comparator|High Intensity Functional Exercise|The intervention comprises the HIFE protocol as a rehabilitation method and, if necessary, other completing exercises. HIFE consists of five exercise categories depending on the capabilities of the patient.
9683133|NCT04906265|Experimental|High Intensity Functional Exercise and wearable sensor|The intervention comprises the HIFE protocol as a rehabilitation method and, if necessary, other completing exercises. HIFE consists of five exercise categories depending on the capabilities of the patient. In addition, follow-up and feedback during the rehabilitation period will be given via a wearable inertial measurement unit (IMU).
9683134|NCT04906265|Active Comparator|Standard rehabilitation|The intervention comprises the standard rehabilitation services: walking training and adaptions to the walking pattern of the patient prior to surgery together with func-tional exercises. The intervention is tailored to each patient, based on the type of fracture, type of surgery, and assessment by the PT as well as treatment goals.
9683135|NCT04906005|Experimental|gadopiclenol|"Dose per administration: dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.025; 0.05 or 0.1 mmol/kg BW (depending on each group).~6 volunteers will receive gadopiclenol per group"
9683136|NCT04906005|Placebo Comparator|Placebo|"Dose per administration: similar dose (Volume/weight) as the one used for Gadopiclenol in the considered group.~3 volunteers will receive gadopiclenol per group"
9683137|NCT04906252||Ventricular Fibrillation|Patients presenting to the Emergency Department after Ventricular Fibrillation (Vfib) Cardiac Arrest or Patients demonstrating Vfib during cardiac arrest
9683138|NCT04906252||PEA|Patients presenting to the Emergency Department after Pulseless Electrical Activity (PEA) Cardiac Arrest. Patients demonstrating PEA during cardiac arrest
9683139|NCT04906252||Asystole Cardiac Arrest|Patients presenting to the Emergency Department after Asystolic Cardiac Arrest. Patients demonstrating Asystole during cardiac arrest
9683140|NCT04906200|Experimental|Group A (YES portal)|Patients receive access to YES portal for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months.
9683141|NCT04906200|Active Comparator|Group B (usual care)|Patients receive usual care for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months. After 9 months, patients may also receive access to YES portal for 3 months.
9683142|NCT04906577|Experimental|VIZOLF|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to the body odour emitted by the child during the first 5 days of life
9683143|NCT04906577|Experimental|VIZ|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to a neutral odour during the first 5 days of life
9683144|NCT04906161||Successful dental implant|Patients showed a successful implant placement with no complications before loading
9683145|NCT04906161||Early dental implant failure|Early complications and failure of dental implant before loading
9683146|NCT04905966|Experimental|Nutrition education + Physical activity intervention|Physical Activity and Nutrition Education: An additional 45 minute weekly physical education class and 5 weekly active break sessions of 10 minutes each will be added to the provisions of the children's curriculum. In addition, schools will receive high intensity nutrition education, that is, 3 weekly nutrition education classes of one hour in each session over a period of 6 months.
9683147|NCT04905966|No Intervention|Control|Schools receiving a lower intensity nutrition education served as control. This group received 3 sessions of 1 hour with a total of 3 educational sessions over the 6 month period. The educational material was the same as the intervention group but the development of lessons was not as specific and deep as the intervention group.
9683148|NCT04906044|Experimental|Total Neoadjuvant Treatment combined with Tilelimumab|
10178267|NCT03814668|Placebo Comparator|Placebo|One sachet of placebo powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
10178268|NCT03814811||Bone metastasis(+) with low cOC|Patients who have bone metastasis with low number of circulating osteocalcin-positive (cOC) cells
10178269|NCT03814811||Bone metastasis(+) with high cOC|Patients who have bone metastasis with high number of circulating osteocalcin-positive (cOC) cells
10178270|NCT03814811||Bone metastasis(-) with low cOC|Patients who have metastasis only in extraskeletal sites with low number of circulating osteocalcin-positive (cOC) cells
10178271|NCT03814811||Bone metastasis(-) with high cOC|Patients who have metastasis only in extraskeletal sites with high number of circulating osteocalcin-positive (cOC) cells
9683149|NCT04906122|Experimental|Experimental group|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
9683150|NCT04906122|No Intervention|Control Group|Control Group: No additional attempt or routine call will be made to grandmother and mothers in the control group. The questionnaires will be given to the mothers at the same time for filling the surveys after birth, one month, 3 and 6 months follow up will be done with grandmothers and mothers.
9683151|NCT04905979|Experimental|AD113|Two oral capsules administered before bed
10178272|NCT03814525|Active Comparator|Photobiomodulation group|PBM will be applied after the surgeries with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
10178273|NCT03814525|Placebo Comparator|Control group|Participants will be attended in the same way as the PBM group. The person who is responsible for the application of the PMB will simulate the irradiations by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off.
10178274|NCT03814577|Active Comparator|Desflurane|Anesthesia will be maintained with Desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture.Total Intravenous Anesthesia will not be used in this group. While target desflurane minimum alveolar concentration (MAC) will be 1-1.5 and Bispectral Index values will be between 40-60, the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
9683152|NCT04905979|Experimental|Atomoxetine|Two oral capsules administered before bed
10178275|NCT03814577|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia: Anesthesia will be maintained with inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture. Desflurane will not be used in this group. Total Intravenous Anesthesia (propofol and remifentanyl infusion) will be performed to the patients while target Bispectral Index values were between 40-60. Also the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
9683153|NCT04906226|Experimental|Intervention group|Individuals participating in the study will be divided into intervention and control groups. The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
9683154|NCT04906226|No Intervention|Control group|There will be no additional application other than routine to the control group, data collection forms will be applied and recorded at the beginning of the study and at the end of four weeks.
9683155|NCT04906174||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
9683156|NCT04905992|Experimental|Single daily session (Hypertonic saline + airway clearance techniques)|The experimental group will perform a daily session at home including nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
9683157|NCT04905992|Active Comparator|Twice daily session (Hypertonic saline + airway clearance techniques)|The control group will perform two daily sessions at home involving nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.
10178276|NCT03814551||Comparison|Cohort of participants who regularly eat in cafeteria without health signage.
10178277|NCT03814551||Signage|Cohort of participants who regularly eat in cafeteria in which health signage is placed.
10178278|NCT03814486||patient transfused in platelet in the 6 last months of life|patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life
10178279|NCT03814395||Exposure group|Group with environmental, nutritional or lifestyle exposures
10178280|NCT03814395||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
10178281|NCT03814798|Experimental|Cohort 1|IGSC 20% daily push versus every 2 weeks pump or the reverse sequence
9683158|NCT04905732|Experimental|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
9683159|NCT04905732|Active Comparator|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
9695657|NCT04775901|Other|CT-guided lung biopsy|Participants in this arm received conventional CT-guided percutaneous transthoracic lung biopsy.
10178282|NCT03814798|Experimental|Cohort 2|IGSC 20% daily push versus once a week pump or the reverse sequence
10178283|NCT03814798|Experimental|Cohort 3|IGSC 20% daily push versus 2 times per week pump or the reverse sequence
10178284|NCT03814798|Experimental|Treatment-Naive IGSC 20% pump dosing|IGSC 20% 150 mg/kg
10178285|NCT03814408|Experimental|RP-L102|RP-L102 is a self-inactivating lentiviral vector carrying the therapeutic FANCA gene
10187988|NCT03720600|Experimental|MAB Intervention|Participants in this condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will watch a voice-guided PowerPoint on MAB strategies for coping with discrimination. For the following two weeks, they will be asked to complete multiple momentary assessments daily for two weeks. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires and complete a qualitative exit-interview.
9683160|NCT04905849|Experimental|Adaptive Cognitive Control Trainer (ACCT)|There are three modules within the game, each training a different aspect of cognitive control (attention, goal management, working memory): a visual search task for attention abilities, a spatial span task for working memory, and a task switching paradigm for goal management abilities. There are also 3 different levels of difficulty associated with each module; advancing to the next level delivers an advanced challenge that enhances the difficulty in performing the given cognitive task. Participants advance to the next level of difficulty following 6 training sessions occurring over 2 weeks, with the total training experience being 6 weeks of training (3 days/week), with each training session lasting 36 minutes (not including self-paced breaks).
9683161|NCT04905849|Active Comparator|Active Control Group|An active control application will be used for this arm. The total training experience here will also be for 6 weeks (3 days/week), with each training session lasting ~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.
10178286|NCT03814512|Experimental|Extended Sleep Intervention (ES)|Participants will receive a Standard Care Diet and Physical Activity Education Intervention (SC) and an Extended Sleep Intervention (ES). For the SC, participants will have their diet, physical activity, and screen time assessed by study interventionist. Prescribed goals will be determined collaboratively through discussion with participants and parents. For the ES, participants will subsequently be prescribed a sleep schedule that allows them to obtain 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively.
10178287|NCT03814473|Experimental|Dietary intervention|All participants will follow an ad libitum self-administered Paleo diet for 8-weeks
10178288|NCT03814694|Experimental|CRHP Diet|Hypo-energetic carbohydrate-reduced high-protein (CRHP) dietary intervention with a controlled 5-7% loss in body weight.
9683162|NCT04905914|Active Comparator|50mg Capsule|
9683163|NCT04905914|Active Comparator|100mg Capsule|
9683164|NCT04905914|Active Comparator|200mg Capsule|
9683165|NCT04905914|Active Comparator|400mg Capsule|
9683166|NCT04905914|Active Comparator|800mg Capsule|
9683167|NCT04906057|Experimental|Forced Aerobic Exercise (FE)|The FE group (N=10) will complete 45 minutes of FE on the custom-engineered cycle designed to augment pedaling rate to greater than 70 revolutions per minute (RPM's). The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer at their self-selected cadence without assistance.
9683168|NCT04906057|Active Comparator|Voluntary Aerobic Exercise (VE)|The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer for 45 minutes at their self-selected cadence without assistance.
9683169|NCT04905797||Deliberate self-harm|Individuals with psychiatric disorders and persistent DSH
9683170|NCT04905797||Clinical cases who ceased self-harm|Individuals with psychiatric disorders who have ceased DSH
9683171|NCT04905797||Clinical cases with no self-harm|Individuals with psychiatric disorders who never had DSH
9683172|NCT04905797||Healthy controls|Healthy controls who never had DSH
9683173|NCT04905667|Experimental|GB221 group|6 mg/kg, single dose, intravenous infusion, 90-100 min
9683174|NCT04905667|Active Comparator|Herceptin group|6 mg/kg, single dose, intravenous infusion, 90-100 min
9683175|NCT04905615|No Intervention|Baseline Measures|The first two-weeks within each school children's baseline physical activity data will be collected. Children will be blinded to the data, receiving no feedback. Teachers will be instructed not to change normal school practices or encourage children's physical activity.
9683176|NCT04905615|Experimental|Data-Driven Strategy Based Intervention|During the following 2-weeks teachers will be implementing strategies to improve their class' physical activity. These are individualised strategies which will be co-developed during semi-structured interviews where teachers will discuss data visualisations with the researcher which depicts their class' physical activity over the 2-week baseline period. Teachers will then implement these strategies over the subsequent 2-weeks. During this time teachers are able to share the physical activity data with their pupils if they wish.
9683177|NCT04905875||Critically ill patients with COVID-19|n centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing PP - that are homogeneous in terms of both clinical and treatment characteristics - will be prospectively observed.
9683178|NCT04905719||Patients with dyspnea|Patients who visit a general practitioner for dyspnea will undergo a Point-of-Care ultrasound examination of the lungs to identify the presence or the absence of A-profile, B-profile and pleural effusion.
9683179|NCT04905719||Patients with abdominal pain|Patients who visit a general practitioner for abdominal pain in the right upper quadrant will undergo abdominal Point-of-Care ultrasound examination to identify cholecystolithiasis.
9683180|NCT04905719||Patients with suspected deep vein thrombosis|Patients who visit a general practitioner for pain and / or swelling of the lower extremity will undergo compression ultrasound testing to identify proximal deep vein thrombosis.
10178289|NCT03814694|Active Comparator|CD Diet|Hypo-energetic conventional diabetes (CD) dietary intervention with a controlled 5-7% loss in body weight.
10178290|NCT03814629|Other|precancerous lesions of gastric cancer|120 cases of chronic atrophic gastritis with intestinal metaplasia or dysplasia,It was randomly divided into 60 cases of treatment group and 60 cases of control group,treatment group was given Weifuchun tablets,The control group was given vitamin tablets.
10178291|NCT03814434|Experimental|Smokers with Periimplantitis group|Heavy smokers patients with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
10178292|NCT03814434|Experimental|Type 2 Diabetes with Periimplantitis group|Patients diagnosed with Type 2 Diabetes with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
10178293|NCT03814434|Experimental|Chronic Periodontitis with Periimplantitis group|Patients diagnosed with Chronic Periodontitis and periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
10178294|NCT03814434|Experimental|Control with Periimplantitis group|Systemically healthy patients with periimplantitis will be included in this group. Patients will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
9683181|NCT04906148|Experimental|Smokers|Smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
9683182|NCT04906148|Experimental|Non-smokers|Non-smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
9683183|NCT04905823||Type 1 diabetes patients|Patients with type 1 diabetes
9683184|NCT04905823||Non-diabetic subjects|Subjects in whom diabetes has not been diagnosed
9683185|NCT04905823||Type 2 diabetes patients|Patients with type 2 diabetes
9683186|NCT04905498|Placebo Comparator|Control|Children were exposed to food commercials without narratives.
9683187|NCT04905498|Experimental|Intervention|Children were exposed to narrative statements that were shown and read aloud in between commercials played.
9683188|NCT04905537||Sick Neonates or Stillbirth|Infants and their parents enrolled through Neonatal Intensive Care Unit or stillbirths through Obstetrics Department of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/ physical exam, and the results of the genomic sequencing report.
9683189|NCT04905394|Experimental|Treatment with subchondroplasty for bone edema in the knee|Patients treated with subchondroplasty for bone edema of the knee
9683190|NCT04905576|Experimental|Relaxation training following daily radiation|All relaxation sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving relaxation will learn exercises to release tension through muscle relaxation, breathing, and imagery
10178295|NCT03814707|Active Comparator|Topical application 0.2%Hyaluronic Acid|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting and covered by periodontal pack
10178296|NCT03814707|Experimental|Platelet Rich Fibrin|Palatal donor site will receive a platelet rich fibrin and then will be sutured by criss cross suture then covered by periodontal pack.
9683191|NCT04905576|Experimental|Healing touch therapy following daily radiation|All Healing Touch sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving Healing Touch will receive a series of standardized therapeutic techniques designed to promote optimal flow of energy throughout the body.
9683192|NCT04905576|Active Comparator|No intervention|The no intervention group will receive no special intervention other than standard medical care, which includes the regular medical care given by the patient's physician and health care professionals.
9683193|NCT04905602|Experimental|Cohort 1|A single subcutaneous injection of SHR-1905/placebo dose 1 in healthy subjects
9683194|NCT04905602|Experimental|Cohort 2|A single subcutaneous injection of SHR-1905/placebo dose 2 in healthy subjects
9683195|NCT04905602|Experimental|Cohort 3|A single subcutaneous injection of SHR-1905/placebo dose 3 in healthy subjects
9683196|NCT04905602|Experimental|Cohort 4|A single subcutaneous injection of SHR-1905/placebo dose 4 in healthy subjects
9683197|NCT04905602|Experimental|Cohort 5|A single subcutaneous injection of SHR-1905/placebo dose 5 in healthy subjects
9683198|NCT04905602|Experimental|Cohort 6|A single subcutaneous injection of SHR-1905/placebo dose 6 in subjects with mild asthma
9683199|NCT04905459||Retinal Imaging and Mydriatic Agents|Subjects will undergo several types of retinal imaging before and after administration of mydriatic agent. Subjects will be administered mydriatic medication to dilate their pupils.
9683200|NCT04905680|No Intervention|Control group|The health screening before the study and at the end of study will collect anthropometric data (height, weight, waist and hip circumference), blood pressure data, and blood samples (for testing of HbA1c, fasting blood glucose, fasting insulin and lipid profile). Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications. For participants in the control arm, there is no health coaching or study activities until the end of the study, where individuals will attend a 20- to 30-minute session with a coach to have their baseline lifestyle tracking results explained to them and receive personalised suggestions on lifestyle modifications.
10178297|NCT03814447|Experimental|anti- MESO CAR-T cells|The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d d-4~-2. Then anti- MESO CAR-T cells will be injected by a dose of 5×106/kg once at d1(rang from d1-3).
9683201|NCT04905680|Experimental|Experimental group|The activities during health screening before the study and at the end of study is similar to the control. Individuals are provided with an educational brochure upon receiving their screening results. Participants will then go through a baseline lifestyle tracking session using a study-issued smartphone and smartwatch, pre-installed with certain study applications, which will be used for the lifestyle tracking sessions. The experimental arm will go through 4 additional lifestyle tracking sessions (i.e., total of 5 including baseline), of which 1 will include Continuous Glucose Monitoring (CGM) tracking. For this CGM tracking session, participants will receive real-time feedback through the study applications, which will display the CGM trace. The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans.
9683202|NCT04905706||3D laparoscopic adrenalectomy|Operations are done with an high definition 3D laparoscopic system (Olympus, Tokyo, Japan); all personnel wear polarized glasses to achieve stereoscopic imaging in the operating room. Dissection is realized using a hybrid energy system (Thunderbeat, Olympus Europe Se & Co, Hamburg, Germany).
9683203|NCT04905563|Other|Control|Standard of care- weight based dose of liquid acetaminophen-hydrocodone- 0.15 mg/kg/dose every six hours with a max dose of 10 mg/dose
9683204|NCT04905563|Experimental|Treatment|Weight based dose of liquid acetaminophen and ibuprofen- acetaminophen 15 mg/kg/dose and ibuprofen 10 mg/kg/dose every six hours with a max dose of 650 mg/dose of acetaminophen and 600 mg/dose of ibuprofen.
10178298|NCT03814772||Liver transplant|"18 years to 65~48h preoperative biochemical indicators, blood general indicators, coagulation test complete"
10178299|NCT03814616|Experimental|Arm Pyramax 3 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for three days (Arm A)
9683205|NCT04905511|Experimental|TRUE Vascular Graft|Patients will be implanted with the TRUE Vascular Graft in the upper arm or forearm
9683206|NCT04905485|Other|Intervention|All participants received the intervention in this trial. They received recommendations on their diets and supplements based on their results of microbiome expression.
9683207|NCT04905472|Experimental|Vestibular & Cochlear Implant Patients|"scheduled for CI surgery because of deafness~a minimum of five year history of documented absence of auditory and vestibular function, based on review of their audiograms and vestibular tests.~Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant < 3.0 sec and gain < 0.25; and reduced head impulse gain (<0.25) for all canal planes.~Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears"
9683208|NCT04905758|Experimental|Maxi-Z plus dental implant|platform switched dental implants
9683209|NCT04905758|Active Comparator|Maxi-Z dental implant|platform matched dental implants
9683210|NCT04905550|Experimental|Craniocerebral radiotherapy combined with Almonertinib 110mg p.o qd|"Almonertinib mesylate tablet, 110mg, qd; until the disease progresses or unacceptable toxicity.~The craniocerebral radiotherapy was acceptable from 1 week before to 6 weeks after treatment with Almonertinib.~Dose adjustment and delay of Almonertinib are allowed. Delay of Almonertinib is allowed for up to 9 weeks, calculated from the time of last administration, otherwise, treatment is terminated."
9683211|NCT04905277|Experimental|Atenolol|Study subjects will take Atenolol 50 mg daily over 2 years
9683212|NCT04905277|Placebo Comparator|Placebo|Study subjects will take a placebo daily over 2 years
9683213|NCT04905355|Active Comparator|Virtual Reality (VR)|Patient with VR experience during the ambulatory orthopedic surgery
9683214|NCT04905355|No Intervention|NO VR|Patient without any VR experience during the ambulatory orthopedic surgery
9683215|NCT04905329||"Patients with high and gray zone risk reccurrence early breast cancer"|
9683216|NCT04905329||Patients with gastointestinal cancers|
9683217|NCT04905329||Patients with gynecological malignancies|
9683218|NCT04905108|Active Comparator|Riboflavin drop every 2 minutes|Administration of one drop of Riboflavin every 2 minutes during UV exposure
9683219|NCT04905108|Active Comparator|Riboflavin drop every 10 minutes|Administration of one drop of Riboflavin every 10 minutes during UV exposure
9695658|NCT04775901|Experimental|Template-guided lung biopsy|Three-dimensionally printed navigational template was designed based on the CT scan images acquired before the biopsy. Under the guidance of navigational template, percutaneous transthoracic lung biopsy was conducted.
9695659|NCT04775914|Active Comparator|PCI standard|
9695660|NCT04775914|Experimental|PCI standard + ischemic conditioning|
9695661|NCT04775914|Experimental|Stent with ultrasound|
9695662|NCT04775914|Active Comparator|Stent without ultrasound|
9695663|NCT04775979|Experimental|Diphenylcyclopropenone (DPCP)|Applying DPCP topically
9695664|NCT04775927|Experimental|education group|marriage preparation training
9695665|NCT04775927|No Intervention|control group|No intervention
10178300|NCT03814616|Experimental|Arm Pyramax 2 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for two days (Arm B)
10178301|NCT03814616|Experimental|Arm Pyramax 1 day|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for one day (Arm C)
9695666|NCT04775992||preemptive group|patients in this group will receive preoperative gabapentoids
9695667|NCT04775992||control group|patients in this group will not receive gabapentoids
9695668|NCT04775797|Experimental|Part 1 (Healthy Subjects): Single Ascending Dose (SAD)|Two cohorts (Cohorts A and B) of healthy subjects will receive single doses of AB-836/placebo in an alternating cohort design under fasted conditions. One additional treatment will be administered under fed conditions.
9695669|NCT04775797|Experimental|Part 2 (Healthy Subjects): Multiple Ascending Dose (MAD)|Participants in Cohorts C, D and E will receive a once daily dose of AB-836/placebo for 10 days
9695670|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohorts F-H|Participants in Cohorts F, G, and H will receive multiple doses of AB-836/placebo once daily for 28 days.
9695671|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort I|Participants in Cohort I will receive multiple doses of AB-836/placebo once daily for 28 days in combination with ongoing nucleos(t)ide analog (NA) therapy.
9695672|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort J|Participants in Cohort J will receive AB-836/placebo and TDF in combination once daily for 28 days.
9695673|NCT04775849|Experimental|Intraoperative Berger Space Imaging|Intraoperative OCT imaging of the space between the posterior capsule and the anterior hyaloid
9695674|NCT04775758|Experimental|Atypical facial pain group|Patients with clinally diagnosed G50.1 - atypical pain condition after all necessary diagnostic measures are taken to exclude a clear organic pathology (multiple diagnostic tests including MRI, CT and consultations from other specialists). Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
9695675|NCT04775758|Active Comparator|Maxillofacial fracture pain group|Patients with maxillofacial fracture (S02.3, S02.4, S02.6.) will be subjected into control group. Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
9695676|NCT04775784||Adult neurosurgical patients|Adult, both sex, neurosurgical patients candidate for intracranial surgery, able to sign informed consent.
10178302|NCT03814642|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
10178303|NCT03814642|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
10178304|NCT03814642|Experimental|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
10178305|NCT03814421|Experimental|Low dose intermittent|Pantoprazole 40mg as a bolus injection daily for 72hours
10178306|NCT03814421|Active Comparator|High dose continous|Pantoprazole 40mg as a bolus injection followed by continuous infusion at 8mg/hr for 72hours
10178307|NCT03814291|Experimental|cohort 1 IBI302 treated with first dose level of IBI302|
10178308|NCT03814291|Experimental|cohort 2 IBI302 treated with second dose level of IBI302|
10178309|NCT03814291|Experimental|cohort 3 IBI302 treated with third dose level of IBI302|
9827794|NCT02468804|Sham Comparator|Parkinson's Disease Subjects, (sTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
10178310|NCT03814291|Experimental|cohort 4 IBI302 treated with fourth dose level of IBI302|
10178311|NCT03814291|Experimental|cohort 5 IBI302 treated with fifth dose level of IBI302|
10178312|NCT03814291|Experimental|cohort 6 IBI302 treated with sixth dose level of IBI302|
9683220|NCT04904978|Experimental|Trial Group|Use of Blanx Black Toothpaste + Mouthwash.
9683221|NCT04904978|Active Comparator|Control Group|Use of Blanx Nordic Toothpaste.
9683222|NCT04905186||healthy adults|This is a cross-over study with no intervention.
9683223|NCT04905030|Experimental|Immigrant mother stratum|The receiver is an immigrant mother born in Eritrea, Somalia, Syria, Afghanistan, Iran or Iraq.
10178313|NCT03814343|Active Comparator|Active comparator|10 patients with NDMs onychomycosis treated with amphotericin B in 30% DMSO.
10178314|NCT03814343|Placebo Comparator|control comparator|10 patients with NDMs onychomycosis treated with 30% DMSO.
10178315|NCT03814369|Experimental|AmplifEYE colonoscopy|Colonoscopy performed with AmplifEYE equipped
10178316|NCT03814369|No Intervention|Standard colonoscopy|Standard colonoscopy performed
10178317|NCT03814460||Control Group|A control group of healthy subjects with no previous history of neurological disorders or conditions. This group pf participants will be selected in a similar population based-cohort than the other two study groups.
9683224|NCT04905030|Experimental|Educ 1 stratum|The receiver is a mother born in Sweden whose education does not exceed 3 years of high school.
9683225|NCT04905030|Experimental|Educ 2 stratum|The receiver is a mother born in Sweden whose education is at least 3 years of high school but no more than high school diploma.
9683226|NCT04905030|Experimental|Educ 3 stratum|The receiver is a mother born in Sweden whose education is at least some college (undergrad) but does not exceed an undergraduate degree
9683227|NCT04905030|Experimental|Educ 4 stratum|The receiver is a mother born in Sweden whose education is an undergraduate degree plus at least some graduate education
9683228|NCT04905043|Experimental|SmartPill® + Acalabrutinib|Participants will receive 1 SmartPill® capsule followed immediately by a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2). There will be 72 hours of washout between acalabrutinib dosing of each period.
9683229|NCT04905056|Experimental|ablation therapy in the treatment of lung cancer presenting as ground-glass nodules|
9683230|NCT04905238|Active Comparator|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
9683231|NCT04905238|No Intervention|Conservative treatment|Diet and general life style recommendations.
9683232|NCT04905095|Experimental|EWS|Early Warning Score will be implemented in the computer system of the nursing station
9683233|NCT04905095|No Intervention|Control|Nursing supervision will be carried out in the usual way.
9683234|NCT04905147|Active Comparator|The mosapride group|The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
9683235|NCT04905147|Placebo Comparator|The control group|The control group received 15 mg of placebo drug with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
9683236|NCT04905004|Experimental|2-week reactivation interval|Replacement of elastomeric chain every 2 weeks and reestablishing a 150 g force
10178318|NCT03814460||Acute Stroke Group|In this group, participants who suffered a previous stroke within 3 months before data collection will be included.
10178319|NCT03814460||Chronic Stroke Group|In this group, only participants who have suffered a previous stroke of more than 3 months duration before data collection will be included.
10178320|NCT03814304|Experimental|Personalized tDCS|Personalized tDCS: This intervention is designed to facilitate the excitability of the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
10178321|NCT03814304|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
10178322|NCT03814330|Placebo Comparator|Sedation/Analgesia|Patients with applied sedation analgesia will perform State-Trait Anxiety Inventory and Quality of Recovery Score
10178323|NCT03814330|Active Comparator|Laryngeal Mask Airway|Patients with applied Laryngeal Mask Airway will perform State-Trait Anxiety Inventory and Quality of Recovery Score
10178324|NCT03814265|Experimental|Intervention|Laughter yoga group
10178325|NCT03814265|No Intervention|Control|No intervention
10178326|NCT03814278|Experimental|Complete bed rest|Participants on complete bed rest group kept antepartum confinement to bed with toileting restricted to bedpan use. Participants in this group received prophylactic subcutaneous enoxaparin (40mg/day).
10178327|NCT03814278|Experimental|Activity restriction group|Activity restriction group had motion limited to bathroom privileges and walks to the ward canteen four times per day.
9527655|NCT03218098|Active Comparator|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
10178328|NCT03814252|Experimental|Lesion-targeted ablation with MRI-TULSA|Intervention: Targeted lesion based thermoablation of MRI-visible biopsy proven clinically significant prostate cancer. Ablative effect is aimed to cover lesion with 5 mm MRI based healthy tissue overlap wherever possible but not compromising viability of critical tissues, mainly the wall of rectum.
10178329|NCT03814213||No-CGA|Patients were not initially offered CGA due to no booking for CGA
10178330|NCT03814213||CGA alone|Patients had CGA, but no tailored follow-up upon identified problems
9683237|NCT04905004|Active Comparator|4-week reactivation interval|Replacement of elastomeric chain every 4 weeks and reestablishing a 150 g force
9683238|NCT04905004|Experimental|6-week reactivation interval|Replacement of elastomeric chain every 6 weeks and reestablishing a 150 g force
9683239|NCT04905004|Experimental|8-week reactivation interval|Replacement of elastomeric chain every 8 weeks and reestablishing a 150 g force
9683240|NCT04904874|Other|flourescein staining, miboscore|
9683241|NCT04904991|Experimental|Qigong group|Participants in the Qigong group were given a structured program about Chan-Chung qigong for 3 months which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice . The movements should be repeated and maintained for 10 minutes per time, 3 time a day .
9683242|NCT04904991|No Intervention|Control group|those in the control group received usual care for cognitive impairment during the same study period.
9683243|NCT04904796|Experimental|Constraint-induced Movement Therapy With Home-based Hand-arm Bimanual Intensive Therapy|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours), and 2-hour home-based HABIT sessions, 3 days/week for 5 weeks (30 hours).
9683244|NCT04904796|Active Comparator|Constraint-induced Movement Therapy only|Children in experimental group will receive 2-hour clinic-based CIMT sessions, 5 days/week for 3 weeks (30 hours).
9683245|NCT04905160|Experimental|Subjects Hospitalized with a Primary Diagnosis of ADHF or Acute MI|Phase 1 subjects 18 years or above hospitalized with a primary diagnosis of ADHF or acute MI. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
9683246|NCT04905160|Experimental|Subjects Testing Positive Covid-19 Antigen Test|Phase 2 subjects 50 years or older with positive Covid-19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in this arm of the study. Subjects will be randomized within 48 hours of Covid-19 antigen positive status. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
9683247|NCT04904913|Experimental|IBI362 high dose|high dose IBI362 administered subcutaneously (SC) once a week.
9683248|NCT04904913|Experimental|IBI362 low dose|Low dose IBI362 administered subcutaneously (SC) once a week.
9683249|NCT04904913|Placebo Comparator|placebo|placebo administered subcutaneously (SC) once a week.
9683250|NCT04904913|Experimental|IBI362 moderate dose|moderate dose IBI362 administered subcutaneously (SC) once a week.
9683251|NCT04904861|Experimental|Videoconference Intervention group|Brief group videoconferencing attachment-based intervention (sessions once a week for 4 weeks)
9683252|NCT04904861|Active Comparator|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks)
9683253|NCT04905225||Ascending aortic replacement|Ascending aortic replacement in ascending aortic aneurysm in men and women
9683254|NCT04904666||Bleach baths with .0125%|
9683255|NCT04904666||Clorhexidine 2%|
9683256|NCT04904666||Soap and water|
10178331|NCT03814213||CGA with tailored care|CGA and a tailored follow-up and care for 90 days following the CGA
10178332|NCT03814226|Experimental|PACAP-38 infusion|According to main hypothesis PACAP-38 is expected to induce headache. PACAP-38 causes marked vasodilation visible to investigator. PACAP38 (10 pmol/kg/min) is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
9683257|NCT04904666||Bleach baths with .005%|
9683258|NCT04904627||Polyehtylene vs Poliìycarbonate|super rigid vs rigid material
9683259|NCT04904627||Free pelvis vs classic pelvis|fixed pelvis versus free pelvis, allowing adjustment in the sagittal plane.
9683260|NCT04904510|Experimental|Dual-Track Testing Algorithms A|In Approach A, a preliminary positive result from the INDICAID™ Rapid Test would expedite the corresponding patient VTM sample for laboratory-based RT-PCR. Expedited testing would obtain results typically within an additional 8 hours compared to the standard approach requiring 48-hour government mandated turnaround time.
9695677|NCT04775602|Experimental|18F-PSMA PET/CT|Patients with evidence of biochemical recurrence of prostate cancer radically treated, with negative results to traditional diagnostic methods or doubtful imaging of 18F- Fluoro Methyl Choline (18F-FMC) PET/CT will perform a 18F-PSMA PET/CT as a tool for searching and location of recurrence.
9695678|NCT04775732|Experimental|ultra proactive arm|
9695679|NCT04775732|Active Comparator|reactive arm|
9695680|NCT04775407||Screening|Serological SARS-CoV-2 test
9695681|NCT04775615|Experimental|Treatment group A|
9527656|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
9683261|NCT04904510|Experimental|Dual-Track Testing Algorithms B|In Approach B, a preliminary positive result from the INDICAID™ Rapid Test result would trigger the testing of the corresponding patient VTM sample with an onsite rapid nucleic acid amplification test (cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test on the cobas® Liat system, Roche Molecular Diagnostics). Results from the onsite rapid nucleic acid amplification test would typically be obtained within an additional hour. In addition to the onsite rapid RT-PCR test, the corresponding patient VTM sample was also sent for expedited laboratory-based RT-PCR testing. All samples testing negative with the INDICAID™ Rapid Test were sent for RT-PCR testing with the standard approach by the ONCO Medical Laboratory in batches.
9683262|NCT04904640||CLS stem|CLS Zimmer stem implantation (single wedge, tapered stem) using the 3D CT based software for surgical pre-operative planning
9683263|NCT04904640||Wagner cone stem|Wagner cone Zimmer stem implantation (conical tapered stem) using the 3D CT based software for surgical pre-operative planning
9683264|NCT04904640||Aptafix stem|Aptafix Ortho stem implantation (anatomical stem) using the 3D CT based software for surgical pre-operative planning
9683265|NCT04904757|Other|CESM Pre and Post Survey|"Subject will be asked to complete a questionnaire that will ask you about your general attitude toward Contrast-Enhanced Spectral Mammography (CESM). Questions will include:~Thoughts regarding risk of breast cancer~Concerns regarding contrast procedures such as the CESM~Past mammogram/breast imaging experience"
9683266|NCT04904783|Active Comparator|Study arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and give written informed consent would be in study arm. All patients, belong to both study and control groups would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease. Only low dose radiotherapy would be added to patients in the study arm.
9683267|NCT04904783|No Intervention|Control Arm|10 patients of confirmed diagnosis of moderate COVID-19 who fulfil the inclusion criteria and have not given written informed consent would be in study arm. These patients would receive the same treatment (oxygen support, steroids, anticoagulant therapy, remdesivir and other supportive therapy) as per the Institute guidelines for management of moderate COVID-19 disease except low dose radiotherapy.
9683268|NCT04904887|Other|Assessment of intermediate vision, defocus curve|"Standardized logarithm of the minimum angle of resolution (logMAR) charts were used for visual acuity measurement at 4 m, 80 cm, and 40 cm.~he binocular defocus curve: The binocular defocus curve was done to evaluate the functional range of vision. The curve was obtained while the patient wearing his distance correction to provide the best distance visual acuity in both eyes. The test was performed under photopic conditions (85 candelas/m2) using ETDRS charts at a distance of 4m with the introduction of defocusing lenses from +1.00 D to -4.00 D in 0.50 D steps."
9683269|NCT04904835||Unselected blood donors|leftover samples from unselected blood donors from at least 2 donation centers. Leftover samples to be tested by Access HBV serological marker assays and CE-marked (european compliance marked) predicate assays
9683270|NCT04904835||Hospitalized patients|Leftover samples to be tested by Access HBV serological marker assays and CE-marked predicate assays
9683271|NCT04904835||Presumed HBsAg positive patients|"Leftover samples from patients at different stages of HBV infection (acute and chronic, minimum 10 per stage of infection), HBsAg positive by a Confirmatory testing of a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling), and minimum 20 high positive samples (>26 IU/mL) and minimum 20 samples in the cut-off range. If not enough samples in the cut-off range are obtained during the clinical trial, additional HBsAg specimens in the cut-off range will be tested by Research &Development to fit with Common Technical Specification requirements.~Leftover samples to be tested by Access HBsAg assays and CE-marked predicate assays"
9683272|NCT04904835||Patients having recovered from natural HBV infection, presumed Anti-HBs positive|"Leftover samples from Patients positive for Anti-HBs and Anti-HBc Total by CE-marked assays. Target is to have at least ¾ of them recovered without HBV antiviral treatment.~Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays"
9683273|NCT04904835||Patients having received HBV vaccination, presumed Anti-HBs positive|Leftover samples Confirmed as vaccinated by testing at the time of enrollment (i.e. positive for Anti-HBs and negative for Anti-HBc by CE-marked assays).Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays
9683274|NCT04904835||Presumed Anti-HBc Total positive patients|"Leftover samples from Patients at different stage of infection (acute, chronic or recovered, minimum 10 per stage of infection) positive for Anti-HBc Total by a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling).~Leftover samples to be tested by Access anti-HBc Total and CE-marked predicate assays"
9683275|NCT04904835||Presumed Anti-HBc IgM positive patients|"left over samples from Patients with acute/recent HBV infection, positive for Anti-HBc IgM by a CE-marked assay.~Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assays"
9683276|NCT04904835||Presumed HBeAg positive patients|"Leftover samples from Patients at different stages of infection (acute and chronic, minimum 5 per stage of infection), positive for HBeAg by a CE-marked assay.~Leftover samples to be tested by Access HBeAg assay and CE-marked predicate assays"
9683277|NCT04904835||Presumed Anti-HBe positive patients7|"Leftover samples from Patients at different stages of infection (chronic and recovered, minimum 5 per stage of infection), positive for Anti-HBe by a CE-marked assay.~Leftover samples to be tested by Access anti-HBe assay and CE-marked predicate assays"
9683278|NCT04904835||Patients with chronic HBV infection|Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assay
9683279|NCT04904536|Experimental|Study Medication Arm|6-monthly supplies of atorvastatin 40mg on top of standard care for a period of 18 months.
9683280|NCT04904536|Active Comparator|Standard Care Arm|Standard care for a period of 18 months.
9683281|NCT04904653|Experimental|Hemopatch Group:|Hemopatch + suction drainage
9683282|NCT04904653|Other|Control group|No sealant (liquid, gel or patch) + suction drain
9683283|NCT04904328|Active Comparator|Lumishade® active lens|Treatment of photosensitive migraine with a Lumishade® active device.
9683284|NCT04904328|Sham Comparator|Lumishade® sham lens|Treatment of photosensitive migraine with a Lumishade® sham device.
10178333|NCT03814226|Active Comparator|VIP infusion|According to main hypothesis VIP is not expected to induce headache. VIP also causes marked vasodilation visible to investigator, which is why VIP is chosen as an active comparator. VIP (10 pmol/kg/min) is infused over 20 minutes. VIP is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
10178334|NCT03814239||no protocol|liberal fluid therapy
9683285|NCT04904289||Sepsis with MODS|Patients with sepsis occurred MODS.
10178335|NCT03814239||protocol|fluid therapy according to stroke volume variation (SVV) monitor, tranexamic acid administration, use of cell saver
9683286|NCT04904289||Sepsis without MODS|Patients with sepsis did not occur MODS.
9683287|NCT04904367|Active Comparator|Deep tissue massage|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation(TENS) to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 Megahertz(MHz) and at a dosage of 1 w / cm2. Also, administered DTM to the back and neck region for 20 min in 12 sessions in addition to the conventional physical therapy.
9683288|NCT04904367|Experimental|Conventional physiotherapy|For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
9683289|NCT04904341|Experimental|active|The first Cerebrolysin infusion (30 ml mixed with 250 mL of saline) is intended to be initiated as soon as possible after successful recanalization is achieved and within 8h of AIS stroke onset. Cerebrolysin treatment will be continued (30 ml/d) once daily until day 21 (first cycle). The patients will receive a second cycle of treatment (30 ml/d for 21 days given in the Outpatient Department or Neurorehabilitation Clinic) from day 69 to 90 (± 3 days).
9683290|NCT04904341|No Intervention|historical control|Historical data will be obtained by retrospective clinical chart reviews of patients hospitalized in the study center between 2017 and Dec.2020 and fulfilling the same clinical and radiological inclusion criteria in whom 12-month follow-up (including mRS, NIHSS, BI, EQ-5D-5L) could be obtained.
9683291|NCT04904523||Cases|"Cases:~1. Children and young people up to age 18 years, admitted to PCCU with probable or confirmed COVID-19, irrespective of severity of illness. This includes patients transferred from other hospitals as well as those admitted from Accident and Emergency department."
9683292|NCT04904523||Controls|"Controls:~Children proven to have a non COVID infectious illness on laboratory testing.~Children with sepsis or septic shock due to non-COVID infectious illness.~Children or young people admitted to PCCU following accidental trauma."
9683293|NCT04904302|Experimental|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9683294|NCT04904185|Other|Part A|Six patients will be included in Part A. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0.
9683295|NCT04904185|Other|Part B|Six patients will be includede in Part B. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v on day -4, -3) followed by i.v infusion of the MASE-T product on day 0. Pembrolizumab 2 mg/kg will be administered on day -1 and day +21.
9683296|NCT04904432|Other|young ACS patients|
9683297|NCT04904406|Experimental|dolutegravir/lamivudine|50 mg dolutegravir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
9683298|NCT04904406|No Intervention|dolutegravir/abacavir/lamivudine|50 mg dolutegravir, 600 mg abacavir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
9683299|NCT04904237|Experimental|aza-ven +MBF|treatment with aza-ven debulking therapy followed by allo-HSCT with MBF conditioning
9683300|NCT04904198|Experimental|Care Management Intervention for Non-cardiac chest pain|Multicomponent care management intervention.
9683301|NCT04904068||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease.
9683302|NCT04904068||Healthy|Healthy individuals with no known neurological disorders.
9683303|NCT04904094|Experimental|Intervention group|This group will receive casting of the lower limb for approximately 2 weeks combined with a passive stretching program of the knee flexors, followed by a homebased stretching exercise program for the plantar flexors and hamstrings for 4 weeks after casting.
9683304|NCT04904094|No Intervention|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic devices.
9683305|NCT04904081|Experimental|Treatment Arm (Indocyanine Green [ICG])|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
9683306|NCT04904081|No Intervention|Control Arm (Standard Care)|The Standard Care group will have no change to the medical and surgical care they receive while in the hospital. The surgeon will perform the surgery as they normally would outside of this study. This involves a laparoscopic-assisted transanal pullthrough surgery.
9683307|NCT04904224|Active Comparator|PICE|Participants receive a panintestinal video capsule endoscopy (PICE)
9683308|NCT04904224|Active Comparator|Colonoscopy|Participants receive an (Ileo-)Colonoscopy
9683309|NCT04904146||Patients with Mycosis fungoides and Sézary syndrome|
9683310|NCT04904146||Healthy volontaires|
9683311|NCT04904055||Value-based Formulary Beneficiaries|enrolled in the value-based formulary
9683312|NCT04904055||Standard Formulary Beneficiaries|enrolled in a standard (i.e., non-value-based formulary)
9683313|NCT04903990||Patients|"women 18-50 years~with previous history of a male birth~scheduled for malignant breast tumor surgery"
10178336|NCT03813875||TEE (transesophageal echocardiography)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~TEE group: the routine sedation medication for the procedure include midazolam (approximately 1~5mg per patient), alfentanil (200~1000mcg per patient) and propofol (small boluses of 10~20mg on demand, total dose usually below 100mg per patient depending on the overall examination timespan) all in intravenous boluses. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
9683314|NCT04903990||Controls|"women 18-50 years~with previous history of a male birth~scheduled for benign breast tumor surgery~or cancer free"
9683315|NCT04904276||Initiating treatment with fostamatinib as second-line therapy|
9683316|NCT04904276||Treated with fostamatinib for at least 12 weeks as second-line therapy|
9683317|NCT04903886||All patient colonized with ESBL-E in Brest Intensive Care unit|All patient colonized with ESBL-E in Brest Intensive Care unit, in a 5 years period (2015-2019)
9683318|NCT04904120|Active Comparator|[203Pb]VMT01 first|Participants randomized to this arm will receive imaging agent [203Pb]VMT01 and undergo SPECT/CT imaging first. Later, participants in this arm will receive [68Ga]VMT02 and undergo PET/CT imaging.
9683319|NCT04904120|Active Comparator|[68Ga]VMT02 first|Participants randomized to this arm will receive imaging agent [68Ga]VMT02 and undergo PET/CT imaging first. Later, participants in this arm will receive [203Pb]VMT01 and undergo SPECT/CT imaging.
9683320|NCT04903899|Experimental|177Lu-DOTATATE|A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.
9683321|NCT04904003|Experimental|Experienced LLA - intervention|Experienced lower-limb amputees that complete a 4-week semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
9683322|NCT04904003|Experimental|Experienced LLA - controls|Experienced lower-limb amputees that will be tested with a 4-week interval. No intervention. This group will be matched to the group of experienced lower-limb amputees.
9683323|NCT04904003|Experimental|New LLA learning to use prosthesis|New lower-limb amputees that complete a 8-11 weeks semi-structured individualized rehabilitation regime with extensive testing before and after the intervention.
9683324|NCT04903938||Criminal-Antisocial Personality Disorder|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
9683325|NCT04903938||Non-criminal group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
9683326|NCT04903938||Control group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
9683327|NCT04904497|Experimental|Early Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
9683328|NCT04904497|No Intervention|Standard|"The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.~Occupational Therapy interventions for control group will be allowed for this group only before 1 week after the first day on light sedation"
9683329|NCT04904159||Benign|Patients who have benign pathologies after thyroidectomy
9683330|NCT04904159||Malign|Patients who have malign pathologies after thyroidectomy
9683331|NCT04904016|Experimental|Intervention FlowOx treatment|Each participating subject will be provided with one FlowOx™ system, which will be used about 1 hour per day every day of the week for a 4-week period with the option to extend the treatment time to up to 6 months if the patients would like to continue.
9683332|NCT04904133|Active Comparator|Saccharine Group|140 mg saccharin (Hermesetas) dissolved in 330 mL water for 4 weeks.
9683333|NCT04904133|Active Comparator|Sucralose Group|66 mg sucralose (Splenda) dissolved in 330 mL water for 4 weeks.
9683334|NCT04904133|Active Comparator|Aspartame+Acesulfame-K Group|88 mg aspartame+88 mg acesulfame-K (Takita) dissolved in 330 mL water for 4 weeks.
9683335|NCT04904133|Placebo Comparator|Control Group|330 mL water for 4 weeks.
9683336|NCT04904380|Experimental|Intervention|HMS, HBS and peer learning in combination with AIR and PRISMS
9683337|NCT04904380|Active Comparator|Comparison arm|HMS, HBS and peer learning in combination with PRISMS but no AIR
9683338|NCT04903925|Experimental|Group 1|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a probiotic for 21 days (2 tablets/day).
9683339|NCT04903925|Placebo Comparator|Group 2|All patients will undergo an impacted tooth extraction; patients allocated to group 1 will receive an antibiotic therapy with amoxicillin for 6 days (2 g/day) and a placebo of the probiotic for 21 days (2 tablets/day).
9695682|NCT04775615|Experimental|Treatment group B|
9695683|NCT04775615|Experimental|Treatment group C|
9695684|NCT04775693|Experimental|RE|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as both an inpatient (2 days a week RE) and an outpatient (3 days a week RE).
9683340|NCT04903964|Experimental|oral nutrition only group that received nutrition education|This group consists of children who are fed orally according to their chronological age. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the hospitalized child after the operation will be determined and the measurements will be checked.
9683341|NCT04903964|Experimental|group that received nutrition education and fed with nutritional support|This group consists of children who receive nutritional support provided by oral food supplements, oral food supplements, enteral tube feeding and / or parenteral nutrition. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the child hospitalized after the operation will be determined and the measurements will be checked.
10178337|NCT03813875||LMA (laryngeal mask airway)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~LMA group: routine induction medications include propofol (50~200mg per patient), fentanyl (50~150mcg per patient) and sevoflurane (machine setting at 1.5% to 3% according to clinical needs). Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
9683342|NCT04903964|No Intervention|control group|While collecting research data on the specified dates; Comparison group (KG) will be selected as many as the number of volunteers who want to participate in the research. No nutritional attempt will be made to the child included in this group. The parameters used in the evaluation of growth (height, head and chest circumference measurement) and the Ankara Development Screening Inventory (AGTE) will be applied to children aged 0-3 who are followed up due to congenital heart disease.
9683343|NCT04903860|Active Comparator|Single use reamers|Total hip replacement with the use of disposable reamers
9683344|NCT04903860|Active Comparator|conventional ancillary|Total hip replacement with the use of conventional reamers
9683345|NCT04903847|No Intervention|Dolutegravir/tenofovir disproxil/lamivudine|Continue dolutegravir 50 mg, tenofovir disproxil 245 mg, ,and lamivudine 300 mg once daily for 48 weeks.
9683346|NCT04903847|Experimental|dolutegravir/lamivudine|dolutegravir 50 mg/lamivudine 300 mg once daily for 48 weeks
9683347|NCT04903847|Experimental|doravirine/tenofovir disproxil/lamivudine|100 mg doravirin, 245 mg tenofovirdisoproxil and 300 mg lamivudine once daily for 48 weeks.
9683348|NCT04904211|Experimental|Feasiblity and Safety|All eligible patients will be assigned to this arm
9683349|NCT04903808|Experimental|Allium sativum oil|The pulp stumps of the molars are dressed with a cotton pellet that is made damp with Allium Sativum oil for 1 min .
10178338|NCT03813810||Normal|People without any chronic pulmonary diseases.
10178339|NCT03813810||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease.
9683350|NCT04903808|Active Comparator|Mineral Trioxide Aggregate|The material will be prepared according to the manufacturer's instructions , applied to the pulp chamber and a moistened cotton pellet was placed over the MTA paste to allow the material to set.
9683351|NCT04903665||Cancer Arm|Participants with new diagnosis of gynecologic cancers, from whom blood samples will be collected.
9683352|NCT04903665||Benign Arm|Participants with new diagnosis of benign gynecologic diseases, from whom blood samples will be collected.
9683353|NCT04903769|Other|Parkinson's Patients and Caregivers|Will participate in the 8-session SMART-PD program as a participant with Parkinson's disease or as a caregiver of a participant with Parkinson's disease
10178340|NCT03813810||Asthma|Patients with asthma
9683354|NCT04903743|Placebo Comparator|group B|28ml of 0.25% bupivacaine and 2ml normal saline
9683355|NCT04903743|Active Comparator|group BM|received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
10178341|NCT03813810||Idiopathic pulmonary fibrosis|Patients with idiopathic pulmonary fibrosis
9683356|NCT04903782||Children and adolescents with newly diagnosed malignancy|
9683357|NCT04903834||COVID-19 - no hyperinflammation|Confirmed Sars-CoV-2 infection Hospitalised case
9683358|NCT04903834||COVID-19 - hyperinflammation|Sars-CoV-2 infection Hospitalised case
10178342|NCT03813784|Experimental|A|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 250 mg PO qd.
10178343|NCT03813784|Active Comparator|B|Capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus Oxaliplatin 130 mg/m^2, IV q3w
10178344|NCT03813784|Experimental|C|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210
9683359|NCT04903756||Patients|Adult patients where major lower limb amputation is being considered.
10178345|NCT03813901|Experimental|Samalochana Counselling group|Arsha Vidya advaita vedanta based counselling were given to the women
10178346|NCT03813901|Other|Wait-list control group|Wait list group were not given any supportive care during the period. After that, they were offered the similar program as Counselling group.
9683360|NCT04903756||Healthcare professionals|Surgeons, anaesthetists, and allied health professionals involved in decision making with patients where a major lower limb amputation is being considered.
9683361|NCT04903457|Experimental|Real stimulation before motor learning training|Patients receive five sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
9683362|NCT04903457|Active Comparator|Sham stimulation before motor learning training|Patients receive five sessions of sham stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system immediately before sequential finger tapping task.
9683363|NCT04903301|Experimental|Study Group|Contoura Vision LASIK using Phorcides Analytic Software
10178347|NCT03813979|Experimental|Hepatic impairment group|Dolutegravir in HIV-seronegative subjects with severe hepatic impairment (child-Pugh score 10 or greater)
10178348|NCT03813979|Active Comparator|Matched controls|Dolutegravir in control group matched for gender, age and BMI with subjects in hepatic impairment group
10178349|NCT03814070|Active Comparator|Non-reinforced full arch acrylic restorations|
10178350|NCT03814070|Experimental|full arch acrylic restorations with fiber-reinforced framework|
9683364|NCT04903561|Experimental|Intervention|In the experimental arms, the woman will be asked to collect a vaginal sample with the Evalyn® Brush or a urine sample with the Colli-PeeTM. Women shall receive this self-sampling device directly from the GP or shall pick it up at a close by pharmacist with a prescription of the GP. In four GP practices (1, 2, 5, 6) the patient has to collect the SS preferentially in the GP practice (at home if the GP practice is not well equipped) whereas in the other four GP practices (3, 4, 7, 8), the patient has to collect the SS at home and send it to the laboratory by using a prepaid envelope.
9683365|NCT04903561|No Intervention|control|Women in the control group will receive an oral recommendation given by the GP with a reminder of the current screening policy to have a cervical sample taken by a physician chosen by the woman. This clinician-taken cervical sample will be sent to a laboratory for processing with the usual screening test. Today the usual screening test still is cytology, but this will change in the future (date to be defined) to an HPV test.
9683366|NCT04903600|Experimental|Probiotics|32g probiotics fruit vegetable fiber powder product contained 1.12*10(11) CFU of probiotics for 12 weeks
9683367|NCT04903600|Placebo Comparator|Placebo|32g placebo contained only maltodextrin (100%) for 12 weeks
9683368|NCT04903535||Healthy Volunteers|Study will enroll 5 healthy volunteers to test the assay
9683369|NCT04903483|Other|target-controlled infusion (propofol) with depth of anesthesia monitoring|In this group, propofol dosing is adjusted with bispectral index monitoring.
9683370|NCT04903483|Other|target-controlled infusion (propofol) without depth of anesthesia monitoring|In this group, propofol dosing is adjusted without bispectral index monitoring.
9683371|NCT04903691|Experimental|Exercise training|130 patients who underwent open heart surgery and are cleared for exercise.These will include patients who enter supervised cardiac rehabilitation as well as patients who enter a supervised exercise program focusing strength training, endurance of functional training.
9683372|NCT04903691|No Intervention|Additional controls|5 patients who choose not to enter any organized exercise program.
9683373|NCT04903405||Sepsis|
9683374|NCT04903444|Experimental|with AI navigation system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
9683375|NCT04903444|No Intervention|without AI navigation system|The endoscopists in the contrpl group performs ERCP routinely without special prompts.All patients underwent MRCP in the prone position prior to ERCP. A round box with a diameter of 2mm filled with water was pasted next to the patient's spine at the level of angulus inferior scapulae during MRCP, and a sheet metal with a diameter of 2mm was pasted at the same area during ERCP.
9683376|NCT04903431|Active Comparator|Clinician-administered Crisis Response Plan|Clinicians will administer the Crisis Response Plan to 75 military veterans.
9683377|NCT04903431|Experimental|Self-administered Crisis Response Plan|Participants will complete a self-guided version of the Crisis Response plan online.
9683378|NCT04903470|Experimental|Effect of atropine on the defecation|Atropine is an anticholinergic drug and expected to inhibit rectal contractions and inhibit evacuation of the rectal balloon. Each subject will be studied twice once with and once without atropine.
9683379|NCT04903470|Experimental|Effect of bisacodyl on the defecation|Bisacodyl is a stimulant of rectal contraction and expected to facilitate evacuation of rectal balloon (fecobionics device). Each subject will be studied twice, once with and once without bisacodyl.
9683380|NCT04903678|Experimental|intrathecal chemotherapy in patients with central metastases|Systemic chemotherapy and intrathecal chemotherapy are performed every 3 weeks. After three treatment cycles, the treatment response is comprehensively evaluated including cerebrospinal fluid, intracranial and orbital tumors. If necessary, local radiotherapy and arterial interventional chemotherapy are performed for local solid tumors. Cerebrospinal fluid is detected in each treatment cycle. If RB tumor cells still exist in cerebrospinal fluid, chemotherapy and intrathecal chemotherapy are continued until the end event. If cerebrospinal fluid was negative, intrathecal chemotherapy is supplemented for another 2 cycles with a total of 6 cycles of systemic chemotherapy. The patients are followed up after treatment.
10178351|NCT03814135|Experimental|HIPNOS 3|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 3 and 1 placebo tablet, oral, once a day."
10178352|NCT03814135|Experimental|HIPNOS 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 5 and 1 placebo tablet, oral, once a day."
10178353|NCT03814135|Placebo Comparator|HIPNOS Placebo|The study is double-dummy. Thus, the patient will take 2 tablet of placebo, oral, once a day.
10178354|NCT03814096|Experimental|Syphilis POC-prenatal screening|Syphilis prenatal screening late in gestation at 24-28 weeks (at the time of the routine prenatal care clinic visit for the routine Glucose Tolerance Test [GTT]) using the Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
10178355|NCT03814148|Experimental|LENINGRADO 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Leningrado 5 association and 1 tablet Natrilix® SR placebo."
10178356|NCT03814148|Active Comparator|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado 5 association placebo."
10178357|NCT03814122|Experimental|ABCR Treatment Group|Group that is immediately administered action-based cognitive remediation intervention.
10178358|NCT03814122|Active Comparator|Waitlist Control Group|Group that is waitlisted (i.e., receives treatment-as-usual) and after approximately 8 weeks received action-based cognitive remediation intervention
10178359|NCT03814109|Experimental|LENINGRADO|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet Leningrado association,1 tablet indapamide placebo, 1 tablet levamlodipine placebo, oral, once a day."
9527657|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
9683381|NCT04903366||Chronic wound|Any chronic wound, for greater than 30 days with minimal improvement
9683382|NCT04903366||Glaucoma|Any diagnosis of glaucoma and active prescription of timolol drops
9683383|NCT04903379|Other|Pain science education and self management strategies|The intervention will be educational in the form of the provision of contemporary pain science education and supportive advice from people with a history of persistent pain. The duration of the webinar will be 90 minutes.
9683384|NCT04903639||obese COPD|COPD patient with BMI more than 30
9683385|NCT04903639||non obese COPD|COPD patient with BMI less than 30
9683386|NCT04903275|Experimental|Fluoride and Laser|In the split-mouth design, the left maxillary anterior teeth receive topical fluoride application and carbon dioxide (CO2) laser irradiation.
9683387|NCT04903275|Active Comparator|Fluoride|In the split-mouth design, this arm - the contralateral teeth (right maxillary incisors), will receive topical fluoride application.
9683388|NCT04903054|Experimental|Lulizumab + SOC|"N=27 participants will receive a loading dose of lulizumab on Day 0, the day of surgery. This will be followed by a maintenance dose administered on a weekly basis (weeks 1 through 26 post-transplant), followed by administration every two weeks (weeks 28 through 52 post-transplant). Method of administration: subcutaneously. Dose unit of measure: milligrams (mgs).~Plus (+) Standard of Care (SOC) Regimen, per protocol-~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:~Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.~Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.~Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.~Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
9683389|NCT04903054|Active Comparator|Tacrolimus + SOC|"N=27 participants will receive tacrolimus initiated according to local standard of care and adjusted over time (maintenance) to target optimal trough levels measured in ng/mL: 0 to 6 months, 7 to 12 months and, thereafter, until completion of study participation. Dose unit of measure: mg/kg.~Plus (+) Standard of Care (SOC) Regimen, per protocol-~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:~Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.~Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.~Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.~Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
9683390|NCT04902833||Cohort I|"Approximately 75 anemic (Hgb <11.0 g/dL) MDS Participants without overt clinical evidence of hemolysis.~- Single Blood Draw"
9683391|NCT04902833||Cohort 2|"25 Participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia~-Single Blood Draw"
9683392|NCT04902911|Experimental|Antigen testing in those who have history of COVID-19|Individuals must have had history of COVID-19. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
10178360|NCT03814109|Active Comparator|Indapamide|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet indapamide 1,5 mg, 1 tablet Leningrado association placebo, and 1 tablet levamlodipine placebo, oral, once a day."
10178361|NCT03814109|Active Comparator|Levamlodipine|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet levamlodipine 2.5/ 5 mg, 1 tablet indapamide placebo, and 1 tablet Leningrado association placebo, oral, once a day."
9527658|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
9527659|NCT03218072|Experimental|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
9683393|NCT04902911|Experimental|Antigen testing in those who do not have history of COVID-19 and COVID immunization|Individuals may not have history of COVID-19 and COVID immunizations in order to be eligible. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
9683394|NCT04902885|Active Comparator|Trilaciclib, carboplatin, etoposide|Trilaciclib plus Carboplatin combined with Etoposide (first line ES-SCLC patients)
9683395|NCT04902885|Placebo Comparator|Placebo, carboplatin, etoposide|Placebo plus Carboplatin combined with Etoposide (first line ES-SCLC patients)
9683396|NCT04902885|Active Comparator|Trilaciclib, Topotecan|plus Topotecan (second/third line ES-SCLC patients)
9683397|NCT04902885|Placebo Comparator|Placebo, Topotecan|Placebo plus Topotecan (second/third line ES-SCLC patients)
9695685|NCT04775693|Active Comparator|SOC|Participants receive standard of care gait training only as both an inpatient (at least 2 days a week) and an outpatient (at least 3 days a week).
9527660|NCT03218072|Experimental|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
9527661|NCT03218072|Experimental|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
9683398|NCT04902963|Experimental|Meeting indication for short term ventilation tube placement|Adult patients meeting standard criteria for short-term ventilation tube placement were offered placement of a bioabsorbable ear tube in place of a durable ear tube that would later be removed.
9683399|NCT04902950|Placebo Comparator|Group 1|The solution of saline will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 1 will undergo application of three normal saline soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
10178362|NCT03814031||EAD|Early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST > 2,000 IU/L within the first 7 days.
10178363|NCT03814031||Non EAD|No EAD
9683400|NCT04902950|Experimental|Group 2|The solution of Tranexamic Acid (TXA) will be placed into a sterile bowl in the operating area and three lap sponges will be placed in the solution at the beginning of the procedure. Group 2 will undergo application of three (TXA) soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.
10178364|NCT03814083|Experimental|Active-tDCS and Sham-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, for sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
10178365|NCT03814083|Active Comparator|Active-tDCS and wait-list|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, participants in the wait-list control group will not receive any intervention.
9695686|NCT04775693|Experimental|RE/SOC|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as an inpatient (2 days a week RE) and standard of care only as an outpatient (at least 3 days a week).
9695687|NCT04775563||Rheumatic diseases outpatients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences and General Hospital.
9695688|NCT04775589|Experimental|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps.
9695689|NCT04775498|Active Comparator|Face-to-face psychoeducation group|The group of face-to-face psychoeducation or standard intervention will consist of the participation by the patients include in all the sessions of a therapeutic education programme of the investigator center.
9695690|NCT04775498|Experimental|SIMPLe mobile application|The experimental intervention consists of the use of the SIMPLe application during 1 year: answers of 5 daily questions and to the weekly questions. Moreover, daily and personalized psychoeducation messages (adapted to the answers to the tests carried out) will be sent to user by notifications.
9695691|NCT04775277||cases|pregnant female with idiopathic pulmonary fibrosis
9695692|NCT04775277||control group|pregnant female with bronchial asthma
9695693|NCT04775355||Observational (biospecimen collection, questionnaire)|Patients undergo collection of stool and urine samples within 2 weeks before hormone therapy or radiation therapy, after hormone therapy but before start of radiation therapy, and after completion of radiation therapy. Patients also complete a series of questionnaires prior to starting radiation therapy, mid-way through radiation therapy, and after completion of radiation therapy (within 1-3 weeks, at 3 months, and then every 6 months until 3 years from radiation completion). Patients' medical records are also reviewed.
9695694|NCT04775303|Experimental|experimental group|Cyclosporine 0.1% (Ikervis®) eye drop - one drop once daily
9695695|NCT04775524|Experimental|Storytelling Through Music (STM)|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Storytelling Through Music (STM) group will participate in the study for a total of 19 weeks with 6 weeks of the STM program and 3 months follow up.~Storytelling Through Music (STM) utilizes multiple modalities including storytelling, reflective writing, self-care skills (i.e., breathing exercises, meditation, self-compassion, body scans), and songwriting.~Weeks 1-4: participants are led through weekly writing workshop over an online platform (i.e., Zoom or an equivalent) to develop their stories. Simultaneous with the writing sessions are 10-minute self-care lessons~Week 5: Participants will be paired with a professional songwriter who will put their story into a song.~Week 6: During the last week, participants will have one more writing workshop to debrief about the intervention."
9695696|NCT04775524|Experimental|Wait List / Storytelling Through Music-Hybrid|"Participants will be randomized into two (2) groups: Storytelling Through Music (STM) and Waitlist (Storytelling Through Music-Hybrid)~Waitlist control group (Storytelling Through Music-Hybrid) will participate in the study for a total of 13 weeks with 2 weeks of Storytelling Through Music-Hybrid program and 11 weeks of follow up .~Storytelling Through Music-Hybrid involves participants listening to songs created for other healthcare professionals for 2 weeks."
9695697|NCT04775251|Experimental|one group|The treatment program consisted of upward rotation exercises for 3 sessions/week, for 6 weeks.
9695698|NCT04775472|Experimental|Early left atrial septostomy group|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation.
10178366|NCT03814083|Sham Comparator|Sham-tDCS and wait-list|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode. On the other hand, participants in the wait-list control group will not receive any intervention.
10178367|NCT03813927|Experimental|Vitamin D|supplementation with tablet 170 μg Vitamin D each day.
9683401|NCT04902924|Experimental|Repeated cold-water immersion|In this arm, the participants undergo repeated cold water immersion at 10°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crest
9683402|NCT04902924|Active Comparator|Repeated warm-water immersion|In this arm, the participants undergo repeated warm water immersion at 40°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crestParticipants will be immersed up to the iliac crest.
9683403|NCT04902924|Other|Control|In this arm, the participants undergo the control intervention which comprises to remain seated for 12.5 min. The participants, that will perform the muscle damaging protocol under hypoxia will also be treated with the control condition.
9683404|NCT04902807||Patients|"based on the potential for inclusion of patient's cohort followed in Necker hospital with PIDs and poly-autoimmunity related to known genetic defects. Recruitments will be made at Pediatric Rheumatology Immuno Hematology department, and paediatric Gastroenterology department (n=250).~Collection of blood, urine and stools at inclusion and blood at 12 months consultation/ follow-up."
10178368|NCT03813927|Placebo Comparator|Placebo|Placebo, tablet with 20 μg Vitamin D each day.
10178369|NCT03813940|Experimental|HPV Vaccine,135μg/0.5ml|Participants in this arm would receive 135μg/0.5ml HPV vaccines
9683405|NCT04902807||Patients' relatives (control)|Brothers or sisters of the patients (n=125). Collection of blood, urine and stools at inclusion.
9683406|NCT04902807||Patients with unrelated diseases (control)|"Recruitments will be made at the Paediatric Gastroenterology Department, in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery at Necker's Hospital. Participants will be included if not diagnosed PIDs and poly-autoimmunity (n=125).~Collection of blood, urine and stools."
9683407|NCT04903236||Non-patient healthy volunteer|Undertake MR Imaging to enable development of sequences.
10178370|NCT03813940|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
10178371|NCT03813914|Experimental|Sineos|Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
9683408|NCT04903236||Patient|Provide weekly blood and urine samples during period of radiotherapy as well as additional MR images.
9683409|NCT04903002|Other|Crossover sequence 1: Oxytocin first|Patients receive 2-weeks courses of 24-IU oxytocin, placebo, 48-IU oxytocin.
9683410|NCT04903002|Other|Crossover sequence 2: placebo first|Patients receive 2-weeks courses of placebo, 24-IU oxytocin, 48-IU oxytocin.
10178372|NCT03813914|Placebo Comparator|Placebo comparator|placebo 2 pills/day for 3 months
10178373|NCT03814057||Elderly Medical Patients at hospital admission|
10178374|NCT03813953|Experimental|Local Anaesthetic Wound Infiltration|Wound catheter delivering local anaesthetic for 48 hours post-operatively following liver resection
10178375|NCT03813953|Active Comparator|Epidural|Conventional practice following liver resection
10178376|NCT03813888|Experimental|Arsha Vidya Group|After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
10178377|NCT03813888|Other|Usual Activity Group|After school, control group were asked to conitue their usual routine.
10178378|NCT03813823||Phobic|Adults aged 18-40 exhibiting high levels of self-reported phobic symptoms to spiders
10178379|NCT03813823||Nonphobic|Adults aged 18-40 exhibiting low levels of self-reported phobic symptoms to spiders
10178380|NCT03813797|Experimental|Arm A: Low Pressure (5-7 mmHg)|Laparoscopic colectomy surgery with low pressure (5-7mmHg)
9683411|NCT04903158|Experimental|Test group|Test formulation of SHR3680
9683412|NCT04903158|Other|Reference group|Reference formulation of SHR3680.
9976157|NCT01348633||Sub-study 5|Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
9976158|NCT01348646|Other|Lifestyle counseling|
9976159|NCT01348659|Active Comparator|7.2% NaCl/hydroxyethyl starch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)
9976160|NCT01348659|Active Comparator|0.9% NaCl|250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)
10178381|NCT03813797|Active Comparator|Arm B: Standard pressure (12-15 mmHg)|Laparoscopic colectomy surgery with standard pressure (12-15mmHg)
10178382|NCT03813667|No Intervention|Control|The control patients have standard care given through the WVU hospital and outpatient clinics, prescribed by the patient's pulmonologist and recorded in the medical record
10178383|NCT03813667|Experimental|Intervention|The FamPALcare intervention group receives all standard care plus 2 weeks of home EOLPC coaching by community nurses experienced in end-of-life palliative care.
10178384|NCT03813576|Other|All participants|Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab
10178385|NCT03813563||Mix group|Patients who used two balanced salt solutions during icu stay
10178386|NCT03813563||RL group|Patients who have only used lactated Ringer's during icu stay
10178387|NCT03813563||PLA group|Patients who have only used PlasmaLyte during icu stay
9683416|NCT04903171|No Intervention|GROUP ONE|The participants do not receive incentive to visit any gardens
9683417|NCT04903171|Placebo Comparator|GROUP TWO|The participants receive incentives by carers to visit regularly a conventional sensory garden
9683418|NCT04903171|Experimental|GROUP THREE|The participants receive incentives by carers to visit regularly an enriched garden
9683419|NCT04902872|Experimental|Phase 1 Dose Escalation (Daily Dosing x 5)|CBX-12 administered on a daily x 5 every 3 weeks schedule
9683420|NCT04902872|Experimental|Phase 1 Dose Escalation (Daily Dosing x 3)|CBX-12 administered on a daily x 5 every 3 weeks schedule
9683421|NCT04902872|Experimental|Phase 2 Ovarian Cancer Expansion Cohort|CBX-12 administered on a daily x 5 every 3 weeks or on a daily x 3 every 3 weeks schedule
9683422|NCT04902872|Experimental|Phase 2 Small Cell Lung Cancer Expansion Cohort|CBX-12 administered on a daily x 5 every 3 weeks or on a daily x 3 every 3 weeks schedule
9683423|NCT04902859|Experimental|Clonidine with eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
9683424|NCT04902859|Placebo Comparator|Placebo with eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
9683425|NCT04902859|Experimental|Clonidine without eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
9683426|NCT04902859|Placebo Comparator|Placebo without eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
9683427|NCT04902937||premenopausal patients|
9683428|NCT04902937||postmenopausal patients|
9683429|NCT04902846||Control (no kidney injury)|Patients who receive ICI but no develop kidney injury
9683430|NCT04902846||Case (kidney injury)|Patients who receive ICI and develop kidney injury
10178388|NCT03813771|Experimental|Abnormal T-cells: Benepali + T2T Care|"Treatment Arm C will receive Benepali and methotrexate combination therapy and followed as per T2T care over a total duration of 24 weeks. Sulfasalazine or Hydroxychloroquine may be added to therapy at follow up visits in-line with T2T care.~Benepali will be administered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).~Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks."
10178389|NCT03813771|Active Comparator|Abnormal T-cells: Methotrexate + T2T Care|"Treatment Arm B will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination synthetic DMARD (Including sulfasalazine and/or hydroxychloroquine).~therapy if not achieving low disease activity (LDA) at, or after, 8 weeks)."
10178390|NCT03813771|Other|Normal T-cells: Methotrexate + T2T Care|Treatment Arm A will receive standard T2T care as per Arm B.
10178391|NCT03813550|Other|PXE cohort 2019-2020|PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
10178392|NCT03813472||Atopic Dermatitis|Evaluate sensor performance for hydration sensing.
10178393|NCT03813472||Healthy aged matched controls|Evaluate sensor performance for hydration sensing.
10178394|NCT03813680|Active Comparator|PVM group|This group included 30 participants. Passive vertebral mobilization was given along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
10178395|NCT03813680|Active Comparator|PNF group|This group included 30 participants. PNF exercise in the form of diagonal pattern neck movements was along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
10178396|NCT03813680|Active Comparator|RPT(Routine Physiotherapy) group|This group included 30 participants.Routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care.
9683431|NCT04903184|Experimental|Group RUTI|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
9683432|NCT04903184|Placebo Comparator|Group Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
9683433|NCT04902664|Experimental|Intervention Arm|Intervention arm physicians will receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals, along with physician-facing education materials. This email will be sent before each patient visit for all ten patients in the study. Ten patients of intervention arm physicians with upcoming physicals will receive patient education materials one to two days before their visit.
9683434|NCT04902664|Placebo Comparator|Control Arm|Control arm physicians receive an email with information on the general visit preparation tips that their patients will receive. Ten patients of control arm physicians with upcoming physicals will receive general visit preparation tips one to two days before their visit.
9683435|NCT04902651|Experimental|HM242-Gel|
9683436|NCT04902651|Active Comparator|Intrasite Gel|
9683437|NCT04902547|Experimental|Multidisciplinary Tapering Program Only|Patients in this arm will take part in the clinical multidisciplinary opioid tapering program (MTP).
9683438|NCT04902547|Experimental|Patient Education Workshop & Multidisciplinary Tapering Program|As above, though patients in this group will also take part in an opioid education workshop
9683439|NCT04902573||Asthma patients|Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.
9683440|NCT04902599|Active Comparator|Vaser ulstrasound-assisted dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with the Vaser ultrasound-assisted dissection technique.
9683441|NCT04902599|Active Comparator|Blunt dissection technique|Patient's arm that undergoes treatment using Renuvion/j-Plasma for subdermal skin tightening and contouring with blunt dissection technique.
9683442|NCT04902716|Experimental|Precision Nursing, Frail women, Cognitive function, Sleep quality, Emotional state,|According to the characteristics of the elders in the community and making good use of health policies and local resources, a 12-week appropriate diversified curriculum is arranged as intervention measures.
9683443|NCT04902742|Active Comparator|Ganglion impar block group|Fluoroscopy-guided ganglion impar block is applied to patients in this group.
9683444|NCT04902742|Active Comparator|Caudal epidural steroid injection group|Fluoroscopy-guided caudal epidural steroid injection is applied to patients in this group.
9683445|NCT04902586|Experimental|E group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）and TTFields therapy during RT. The TTFields therapy started on the day the radiotherapy started.
9683446|NCT04902586|No Intervention|C group|All patients received chemoradiotherapy (CRT) ( PTV-GTV: 60Gy at 2.0Gy per fraction, 5 fractions per week for 6 weeks; PTV-CTV: 54Gy at 1.8Gy per fraction, 5 fractions per week for 6 weeks) with a Temozolomide (TMZ) regimen（75mg/m2 per day during RT）
9683447|NCT04902794|Experimental|Light Emitting Diode|Light Emitting Diode in the Treatment of Menopause Genitourinary Syndrome
9683448|NCT04902794|Sham Comparator|Light Emitting Diode Sham|Light Emitting Diode device turned off
9683449|NCT04902729|Active Comparator|Oxytocin 1IU|Oxytocin 1IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
10178397|NCT03813641|Experimental|RALOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Raltitrexed 3mg/m2, i.v.gtt 15min ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
9683450|NCT04902729|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
9683451|NCT04902638|Active Comparator|Diabetic patients with steroid|
9683452|NCT04902638|Placebo Comparator|Diabetic patients without steroid|Injection of normal saline
9683453|NCT04902638|Active Comparator|Pre-diabetic patients with steroid|
9683454|NCT04902638|Placebo Comparator|Pre-diabetic patients without steroid|Injection of normal saline
9683455|NCT04902638|Active Comparator|Non-diabetic patients with steroid|
9683456|NCT04902638|Placebo Comparator|Non-diabetic patients without steroid|Injection of normal saline
9683457|NCT04902534|Experimental|Naoqingzhiming Tablets|"Naoqingzhiming Tablets, specification:500mg(contains echinacoside 180mg) Single dose ascending. Qualified subjects will enter 6 dose groups in order from low to high: 180mg, 360mg, 720mg, 1080mg, 1620mg and 2160mg, with increasing dose design The first group (180mg) is a pre-experiment. Two subjects were selected and all received the test drug.~Groups 2 to 6 received the experimental drug in 8 patients per group. Multi-dose ascending was divided into two groups: 360mg and 720mg. 10 subjects in each group received the test drug 3 times a day for 14 consecutive days."
9683458|NCT04902534|Placebo Comparator|placebo (without active ingredients echinoside)|Placebo Tablets, specification: 500mg(without echinoside) Single dose. Groups 2 to 6 received the placebo in 2 patients per group. Multi-dose ascending. Two people in each group received placebo 3 times a day for 14 consecutive days.
9683459|NCT04902391|Experimental|Acute Mental Health Care Bundle|We developed an evidence-based bundle of care to address current gaps in care. The bundle: 1) brings together multiple evidence-based assessment tools (ASQ, HEADS-ED) to ensure efficient, high-value ED-based care; 2) removes barriers to assessment and builds connections to care: Assessments are conducted by a mental health care provider and families have access to urgent follow-up care; and 3) prioritizes family engagement: A shared decision-making framework (Choice and Partnership) is used to promote children and youth as stewards of their care and support partnership between EDs and follow-up services with the duration of care determined collaboratively by the patient and their provider.
9683460|NCT04902391|No Intervention|Usual ED-Based Mental Health Care|Local standards of ED-based mental health care will be delivered at control sites. Site leads have determined that this care does not involve the 3 specific core innovations in the bundle. Local care standards are similar across study sites and include use of CTAS score at triage (but no mental health risk assessment tool), ED physician medical clearance and assessment of consultation need, and no consistent mental health follow-up plan. Sites that are randomized to the control arm will not adopt core bundle elements.
9683461|NCT04902404|Experimental|First Pathways Group|Parents in the First Pathways Game group will be instructed to log into the First Pathways website daily and play First Pathways games with their child. They will receive daily reminders for the first month after randomization but will not receive reminders for the second month.
9683462|NCT04902404|No Intervention|Wait-list Control|Parents in the wait-list control group will receive access to the First Pathways game after completing their final two-month study assessment.
9976161|NCT01348672||1. ARMD Study arm|"The ARMD study arm (n=150) consists of 3 groups. The groups are organised according to established risk criteria for clinical progression (AREDS, 2003).~Group 1A (n=50); Early stage ARMD with low risk of progression; several small drusen, or a few medium-sized drusen, in one or both eyes. One eye will be randomly selected for the study.~Group 2A (n=50); Intermediate ARMD with high risk of progression to advanced ARMD; many medium-sized drusen, or one or more large drusen, in one or both eyes. More severely affected eyewill be selected for the study.~Group 3A (n=50); In one eye only, either a break-down of light-sensitive cells and supporting tissue in the central retinal area (i.e. geographic atrophy), or abnormal and fragile blood vessels under the retina (i.e. choroidal neovascular membrane formation). The fellow eye is at high risk of progression to advanced ARMD. The fellow eye will be selected for the study."
10178398|NCT03813641|Active Comparator|CAPOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Capecitabine 1000mg/m2, po. ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
9683465|NCT04902261|Experimental|Tislelizumab combined with Nab-paclitaxel and Gemcitabine|
9683466|NCT04902261|Active Comparator|Nab-paclitaxel and Gemcitabine|
10178399|NCT03813706|Active Comparator|LN-prRLN dissection|
10178400|NCT03813706|Experimental|no LN-prRLN dissection|
9683467|NCT04902352|Experimental|Periadventitial dissection|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process."
9683468|NCT04902352|Active Comparator|NO periadventitial dissection|For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
9683469|NCT04902495|Experimental|Pulp Dressing MTA Angelus|pulp therapy
9683470|NCT04902495|Experimental|Pulp Dressing MTA Pro Root|pulp therapy
9683471|NCT04902495|Experimental|Pulp Dressing Biodentine|pulp therapy
9683472|NCT04902183|Experimental|10^9 dose of exosomes overexpressing CD24|The patients will receive the dose of 10^9 exosomes overexpressing CD24
9683473|NCT04902183|Experimental|10^10 dose of exosomes overexpressing CD24|The patients will receive the dose of 10^10 exosomes overexpressing CD24
9683474|NCT04902521|Experimental|Transcranial magnetic stimulation with constraint induced movement therapy|CIMT/TMS: Five participants will receive a one-hour weekly occupational therapy session of CIMT with 2-hours of daily home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of TMS 1HZ.
9683475|NCT04902521|Sham Comparator|constraint induced movement therapy Sham transcrianial magnetic stimulation|(CIMT/sham TMS): Five participants will receive a one-hour weekly session of CIMT with 2-hours daily of home program for a total of 6 weeks; immediately prior to initiation of each CIMT session, participants will receive 20 minutes of sham TMS 1HZ.
9683476|NCT04902222||Patients undergoing primary hip or knee arthroplasty|Patients undergoing primary hip or knee arthroplasty
10178401|NCT03813693|Experimental|towels with chlorhexidine gluconate 2%|Composed of 25 patients, who received 2 towels with chlorhexidine gluconate 2% packages each containing six towels and detailed instructions on the form and sequence of application of the towels; the time of application, that is, the night before surgery, between 20 and 22h, and, on the morning of surgery, between 5 and 6h; besides other general orientations.
10178402|NCT03813693|Active Comparator|chlorhexidine gluconate 2% liquid|Composed of 23 patients, two 100 ml flasks of chlorhexidine gluconate 2% liquid were supplied, and detailed instruction manual for the product, containing form and application sequence; time of application (the night before surgery, between 20 and 22h, and on the morning of surgery, between 5 and 6h); and general guidelines.
10178403|NCT03813628|Experimental|polished celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
9683477|NCT04902456|Experimental|Power Chain and Crimpable hook for En-masse retraction|"Retraction will start on a 0.017x0.025 Stainless Steel wire using elastomeric chain ( force applied will be 212 g per side ) extending between the crimpable hooks and the miniscrew"
9683478|NCT04902456|Experimental|T-loop|"Closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine."
9683479|NCT04902209||1- study group- patients after surgical treatment of acetabular fracture|1- study group- patients after surgical treatment of hip acetabular fracture
9683480|NCT04902209||2- control group- healthy subjects|2- control group- healthy subjects age, BMI matched
9683481|NCT04902014|Active Comparator|Education|
9683482|NCT04902014|Experimental|Motivational Interviewing|
9683483|NCT04902014|Experimental|Wearable Fitness Tracker|
9683484|NCT04902014|Experimental|Wearable Fitness Tracker+|
9683485|NCT04902196|Experimental|Group 1|persons with chronic low back pain of an non-specific origin
9683486|NCT04902196|Active Comparator|Group 2 (Control group)|"healthy persons (pain-free)"
9683487|NCT04902430|Experimental|En-Masse Retraction using sliding mechanics (Friction)|6 anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
9683488|NCT04902430|Experimental|En-Masse Retraction using segmental mechanics (Frictionless)|6 anterior teeth (en-Masse) retracted using a T- loop
9683489|NCT04902326|Active Comparator|Enhanced Usual Care (EUC)|Receives one intervention: automated educational text messages
9683490|NCT04902326|Experimental|Financial Incentives|Receives two interventions: automated educational text messages and financial incentives.
9683491|NCT04902326|Experimental|Tailored Messages|Receives two interventions: autonomy-supportive automated educational text messages and tailored text messages.
9683492|NCT04902326|Experimental|Combo Arm-Financial Incentives Plus Tailored Messages Arm|Receives three interventions: autonomy-supportive automated educational text messages, tailored text messages, and financial incentives.
9683493|NCT04902313|Experimental|Cancer patients|Youths (10-18 y) with newly diagnosed cancer, as well as their family members.
9683494|NCT04902313|Active Comparator|Pediatric patients|Youths (10-18 y) with a chronic somatic disease receiving care at a pediatric outpatient facility.
9683495|NCT04902339|Experimental|MORE+NF|
9683496|NCT04902339|Active Comparator|MORE|
9683497|NCT04902339|Active Comparator|Supportive Psychotherapy|
9683498|NCT04902378|Experimental|Tandem t:slim X2 insulin pump with Control IQ technology plus CGM|Participants randomized to the intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology and Dexcom G6 Continuous Glucose Monitor.
9683499|NCT04902378|No Intervention|Standard insulin delivery (multiple daily injections (MDI) or pump) and CGM|Participants randomized to the control group will be fitted with the Dexcom G6 Continuous Glucose Monitor. They will continue to use standard insulin delivery (MDI or pump) and CGM.
9683500|NCT04902027|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Rrecurrent/metastatic Head and Neck Cancers will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles
9683501|NCT04902105|Other|Cohort A|"Ecopipam HCL - 2 doses of 200mg~Mefenamic acid 250mg Q6H for 7 days"
9683502|NCT04902105|Other|Cohort B|"Ecopipam HCL - 2 doses of 200mg~Divalproex acid 1250mg QD for 10 days"
9695699|NCT04775472|Active Comparator|Conventional approach group|Conventional approach group will receive left atrial septostomy in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
9695700|NCT04775576|Active Comparator|Group 1|This group will have fluid theraphy due to conventional methods. The participants in this group will have 8-10 ml/kg/hour cristalloid infusion. If the mean arterial pressure (MAP) is <65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
10178404|NCT03813628|Experimental|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
10178405|NCT03813628|Active Comparator|contralateral natural teeth|the poilshed and glazed all ceramic crowns will be compared by the contralateral natural teeth
10178406|NCT03813758||finger after digital nerve cut|
10178407|NCT03813758||healthy finger|
10178408|NCT03813394|Experimental|Treatment Arm A|Intravenous pembrolizumab alone,D8 of 21-day cycle.
10178409|NCT03813394|Experimental|Treatment Arm B|Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
10178410|NCT03813433|Experimental|Enosequence|3-4 mm of Endosequence will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
10178411|NCT03813433|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of Mineral Trioxide Aggregate will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
10178412|NCT03813745||early denudation|Cumulus-oocyte complexes will be denudated in 30 min after oocyte retrieval
10178413|NCT03813745||late denudation|Denudation will be done 2 hr after oocyte retrieval
10178414|NCT03813329|Placebo Comparator|Placebo|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of Calcium carbonate
10178415|NCT03813329|Active Comparator|Acute Sodium Bicarbonate|3 doses of calcium carbonate (110 mg·kg-1, 130 mg·kg-1, 160 mg·kg-1), followed by one acute does (300 mg·kg-1) of sodium bicarbonate.
10178416|NCT03813329|Experimental|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
10178417|NCT03813732|Other|orbital fracture|using the trans-conjunctival approach with lateral canthotomy
10178418|NCT03813277|Experimental|Dexmedetomidine|Dexmedetomidine 100microg/ml
10178419|NCT03813485|Active Comparator|Dry needling in upper trapezius|"Patients receive dry needling in latent myofascial trigger point in upper trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
10178420|NCT03813485|Experimental|Dry needling in lower trapezius|"Patients receive dry needling in latent myofascial trigger point in lower trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
10178421|NCT03813316|Experimental|Interventional Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin after receiving extra training on individualized care.
10178422|NCT03813316|Experimental|Control Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin as per standard care/Diabetes Canada guidelines.
10178423|NCT03813498|Experimental|intervention group|
10178424|NCT03813498|Other|control group|
10178425|NCT03813420||Physiotherapy students|"Pittsburgh Sleep Quality Index-PSQI:The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month~International Physical Activity Questionnaire-IPAQ: The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as the intensity of physical activity in the last seven days.~Short Form-36-SF-36: The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts."
10178426|NCT03813524|Experimental|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
10178427|NCT03813602|Experimental|Cannabis sativa|a 750 mg cannabis cigarette with 12.5% THC
10178428|NCT03813264|Experimental|preliminary arm|pairs of patients and their therapists
10178429|NCT03813303|Active Comparator|Midazolam group|Midazolam and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist . Complications and procedure and recovery times were recorded for comparison with the Fentanyl group.
10178430|NCT03813303|Active Comparator|Fentanyl group|Fentanyl and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist .Complications and procedure and recovery times have were recorded for comparison with the Midazolam group.
10178431|NCT03813381|Experimental|Intervention Arm (IA)|Patients randomized in the Intervention Arm (IA) will be given personalized diet based on calorie and protein restriction. Calorie restriction will be up to 600 kcal below patients' energy requirements and the amount of protein will be 0.8g of protein/Kg body weight mostly form plant-origin food.
10178432|NCT03813381|No Intervention|Control Arm (CA)|Participants in the CA will be given information about the importance of a healthy lifestyle in reducing the risk of cancer and will receive a leaflet based on WCRF/AICR recommendations.
10178433|NCT03813355|Experimental|Active stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with active stimulations
10178434|NCT03813355|Sham Comparator|Sham stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with inactive stimulations
10178435|NCT03813043|Other|Midazolam|Midazolam 2 mg as started dosage will be used for first patients and for the other patients will receive an predetermined dosage accordingly
10178436|NCT03813004|Experimental|Young healthy adults|
10178437|NCT03813251|Experimental|Assigned Interventions|ForConti Contix Fecal Incontinence Management System (FIMS)
10178438|NCT03813069|Other|Laboratory study|
10178439|NCT03813069|Other|Field study: IR3535|
10178440|NCT03813069|Other|Field study: Permethrin lower dose|
10178441|NCT03813069|Other|Field study: Permethrin higher dose|
10178442|NCT03813069|No Intervention|Field study: control arm|
10178443|NCT03813108|Experimental|1: 3: NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
10178444|NCT03813108|Experimental|2: 3: Low dose NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 5 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
10178445|NCT03813108|Experimental|3: NF135 CPS-immunization (A/L) challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes.
10178446|NCT03813108|Experimental|4: 3: NF135 CPS-immunization (A/L) challenged by NF54|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
10178447|NCT03813108|Other|5: Control group challenged by NF135.C10 Cohort A|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
10178448|NCT03813108|Other|6: Control group challenged by NF54 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
10178449|NCT03813108|Other|7: Control group challenged by NF135 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
10178450|NCT03813225|No Intervention|Conventional Analgesia|"These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation for handling an analgesic in cardiovascular surgery, this start in surgery with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.~and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus."
10178451|NCT03813225|Experimental|Serrato intercostal plane Block|These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.In this Arm the patient will give a bilateral serratus intercostal plane block, will be performed echo-guided puncture in the line anterior axillar with fifth costal arch, whit 21 ml of anesthetic mass, 20 ml of Levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone. and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus
10178452|NCT03813056|Experimental|Glanatec|Glanatec eye drops will be administered 6x per day for 2-4 weeks
10178453|NCT03813056|Placebo Comparator|Placebo Control|Optive artificial tears will be administered 6x per day for 2-4 weeks
10178454|NCT03813134|Active Comparator|Immediate PCI with medical therapy|"Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP >90mmHg).~No mechanical support device allowed."
10178455|NCT03813134|Experimental|Immediate PCI with early VA-ECMO|Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.
10178456|NCT03812965|Experimental|Group 1 - Botulinum Toxin type A (4 points of application)|4 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle and Levators labii superioris muscle (n=10 Patients)
10178457|NCT03812965|Experimental|Group 2 - - Botulinum Toxin type A (2 points of application)|2 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle (n=10 Patients)
10178458|NCT03813186|Experimental|ASTX727 + Day 2 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 2 of Cycle 1.
10178459|NCT03813186|Experimental|ASTX727 + Day 4 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 4 of Cycle 1.
10178460|NCT03813173|Active Comparator|central cervical dissection|
10178461|NCT03813173|Experimental|non central cervical dissection|
10178462|NCT03812978|No Intervention|Control|Standard treatment
10178463|NCT03812978|Experimental|Intervention|Standard treatment and intervention (Smart phone application)
10178464|NCT03813030|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 6 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
10178465|NCT03813030|Experimental|Pivotal Study|"Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 20 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.~Clearance Visit: Clearance of lidocaine will be evaluated after intravenous infusion of lidocaine."
10178466|NCT03813095|Experimental|APH-1501 400mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 400mg BID( twice daily) for 28 days.
10178467|NCT03813095|Experimental|APH-1501 600mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 600mg BID ( twice daily) for 28 days.
10178468|NCT03813095|Experimental|APH-1501 800mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 800mg BID ( twice daily) for 28 days.
10178469|NCT03813095|Placebo Comparator|Placebo Comparator: Placebo|Nano-encapsulated for oral delivery. The study is planned for patients to receive a placebo dose BID ( twice daily) for 28 days.
10178470|NCT03813082|Experimental|Sleep deprivation young men|Young study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
10178471|NCT03813082|Experimental|Sleep deprivation older men|Older study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
10178472|NCT03812900|Experimental|Formulation A|Echinacea purpurea alcoholic extract lozenges (novel formulation)
10178473|NCT03812900|Experimental|Formulation B|Echinacea purpurea alcoholic extract spray (novel formulation)
10178474|NCT03812900|Active Comparator|Formulation C|Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
10178475|NCT03812900|Active Comparator|Formulation D|Echinacea purpurea alcoholic extract, drops (basic formulation, reference)
10178476|NCT03812913||Turner Syndrome|"35 girls with Turner syndrome (except patients with part of a Y chromosome in their karyotype and r(X) cases).~age : 7 years -16 years and 11 months.~Psychological evaluation of cognition, social cognition and affective cognition"
10178477|NCT03812913||isolated GHD|"35 girls with isolated Growth Hormone Deficiency (GHD).~age : 7 years -16 years and 11 months.~Psychological evaluation of cognition, social cognition and affective cognition"
9683503|NCT04902040|Experimental|Arm A (radiation therapy, plinabulin, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients receive plinabulin IV over 30-60 minutes on days 1 and 4 of cycle 1, days 1 and 4 of cycle 2 (if receiving radiation therapy in cycle 2), and day 1 and or 15 (any day receiving immunotherapy) of subsequent cycles. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
9977649|NCT01363882|Active Comparator|Standard NIV|Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of <50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
10178478|NCT03812783|Experimental|HAIC of FOLFIRINOX plus sorafenib|
10178479|NCT03812783|Active Comparator|HAIC of FOLFOX plus sorafenib|
10178480|NCT03812796|Experimental|Domatinostat plus Avelumab|This is a multicentre open-label, phase II non-randomised clinical trial domatinostat plus avelumab (two separate cohorts in phase IIB part of trial).
10178481|NCT03812861|Experimental|CAMDS bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients with the help of a cognitive aid bundle
10178482|NCT03812861|No Intervention|No bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients without the help of a cognitive aid bundle
10178483|NCT03812809|Experimental|BPI-7711|BPI-7711: 180mg, QD, oral
10178484|NCT03812848|No Intervention|Pre program implementation|All hospitalized patients on therapeutic anticoagulant medication during the pre-implementation period of the anticoagulation stewardship program.
10178485|NCT03812848|Experimental|Post program implementation|All hospitalized patients on therapeutic anticoagulant medication during the post-implementation period of the anticoagulation stewardship program.
10178486|NCT03812822|Experimental|Insole Group|Gait and foot posture analysis with and without the insole.
10178487|NCT03812822|No Intervention|Control Group|Gait and foot posture analysis.
10178488|NCT03812757||Supraclavicular fossa US scanning|Following insertion of at least 20 cm of the guidewire into the right subclavian vein, the probe is shifted to the right supraclavicular fossa to scan the right internal jugular vein in order to exclude malposition of the guidewire. The probe is then tilted in a caudal direction to obtain a view of the guidewire within the superior vena cava. Misplaced guidewires will be corrected under real-time ultrasound guidance.
10178489|NCT03812406|Experimental|FAUCS|Patients undergoing a cesarean section using the FAUCS technique
10178490|NCT03812406|Active Comparator|Control|Patients undergoing a cesarean section using the traditional (Misgav-Ladach) technique
10178491|NCT03812731|Active Comparator|Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2 mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive CEB with 0.2 % ropivacaine 1-ml/kg for maintaining analgesia"
10178492|NCT03812731|Active Comparator|Non- Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2-mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive fentanyl citrate 1-mcg/kg/hr for maintaining analgesia"
10178493|NCT03812640|Experimental|Vicryl|Vicryl suture
10178494|NCT03812640|Active Comparator|Nylon|Nylon suture
9683504|NCT04902040|Active Comparator|Arm B (radiation therapy, immunotherapy)|Patients undergo radiation therapy on days 1-3, 1-4, or 1-5 of cycle 1. Patients may undergo additional radiation in cycle 2 at the discretion of treating physician. Patients also receive immunotherapy consisting of either: avelumab IV over 1 hour on days 1 and 15; atezolizumab over 30-60 minutes on day 1; durvalumab IV over 1 hour on days 1 and 15; nivolumab IV over 30-60 min on days 1 and 15; or pembrolizumab IV over 30 min on day 1. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
9683505|NCT04902092|Active Comparator|High Intensity Physical Training|12-week, 36 session, cardiorespiratory-focussed physical exercise program delivered by an accredited exercise physiologist
9683506|NCT04902092|Active Comparator|Low Intensity Physical Training|12- week, 36 session, strength-focussed physical exercise program delivered by an accredited exercise physiologist
9683507|NCT04901949||BMI Group 1|If BMI is less than 24,9 kg/m2
9683508|NCT04901949||BMI Group 2|If BMI is between 25 - 30 kg/m2
9683509|NCT04901949||BMI group 3|If BMI is more than 30,1 kg/m2
9683510|NCT04901897|Experimental|kalifilcon A|kalifilcon A daily disposable contact lens
9683511|NCT04901897|Active Comparator|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
10178495|NCT03812497|Experimental|Obese Children Group|To reduce the weight, every obese children will receive individualized education program about a way of dietary control and exercise in their usual life. This individualized education program, developed by investigators, specialized dietitian and exercise teacher, is scheduled once a month.
10178496|NCT03812497|No Intervention|Normal Weight Children Group|Normal weight children
10178497|NCT03812549|Experimental|Sintilimab Combined with SBRT and LDRT|"Part A-Dose escalation cohort. DOSE LEVEL: Stereotactic body radiation therapy (SBRT) dose at 30 Gy/3f + Low Dose Radiotherapy (LDRT) dose from 2 Gy to 10Gy + anti-PD-1 inhibitor 200mg.~Part-B - Expansion cohort. SBRT dose at 30 Gy/3f + LDRT + anti-PD-1 inhibitor 200mg, LDRT dose at MTD determined in Part A ."
10178498|NCT03812380|Experimental|EffCaMgCit|19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
9683512|NCT04901897|Active Comparator|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
9683513|NCT04901871|Active Comparator|1 (0.02 mg/kg, age<65)|Remimazolam of 0.02 mg/kg will be infused in patients aged<65.
9683514|NCT04901871|Active Comparator|2 (0.07 mg/kg, age<65)|Remimazolam of 0.07 mg/kg will be infused in patients aged<65.
9683515|NCT04901871|Active Comparator|3 (0.12 mg/kg, age<65)|Remimazolam of 0.12 mg/kg will be infused in patients aged<65.
9683516|NCT04901871|Active Comparator|4 (0.17 mg/kg, age<65)|Remimazolam of 0.17 mg/kg will be infused in patients aged<65.
9683517|NCT04901871|Active Comparator|5(0.22 mg/kg, age<65)|Remimazolam of 0.22 mg/kg will be infused in patients aged<65.
9683518|NCT04901871|Active Comparator|6(0.27 mg/kg, age<65)|Remimazolam of 0.27 mg/kg will be infused in patients aged<65.
9683519|NCT04901871|Active Comparator|7 (0.02 mg/kg, age≥65)|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
9683520|NCT04901871|Active Comparator|8 (0.07 mg/kg, age≥65)|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
9683521|NCT04901871|Active Comparator|9 (0.12 mg/kg, age≥65)|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65.
9683522|NCT04901871|Active Comparator|10 (0.17 mg/kg, age≥65)|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
9683523|NCT04901871|Active Comparator|11 (0.22 mg/kg, age≥65)|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
9683524|NCT04901871|Active Comparator|12 (0.27 mg/kg, age≥65)|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
9683525|NCT04901936|Experimental|Pegcetacoplan|
9683526|NCT04901923|Experimental|Part 1 Cohort 1|Participants will receive ACP-196 2.5 mg capsule orally BID on Day 1.
9683527|NCT04901923|Experimental|Part 1 Cohort 2|Participants will receive ACP-196 5 mg (2 x 2.5 mg capsules) orally BID on Day 1.
9683528|NCT04901923|Experimental|Part 1 Cohort 3|Participants will receive ACP-196 25 mg capsule orally BID on Day 1.
9683529|NCT04901923|Experimental|Part 1 Cohort 4|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally BID on Day 1.
9683530|NCT04901923|Experimental|Part 1 Cohort 5|Participants will receive ACP-196 100 mg (4 x 25 mg capsules) orally QD on Day 1.
9683531|NCT04901923|Experimental|Part 2 Cohort 6|Participants will receive ACP-196 75 mg (3 x 25 mg capsules) orally QD on Day 1 and Day 8.
9683532|NCT04901923|Experimental|Part 3 Cohort 7|Participants will receive ACP-196 50 mg (2 x 25 mg capsules) orally QD on Day 1, itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then ACP-196 50 mg (2 x 25 mg capsules) along with itraconazole 200 mg capsule QD on Day 9 under fasting state.
9683533|NCT04901767||Receiving drug coated balloon (DCB)|
9683534|NCT04901767||Receiving drug eluting stent (DES)|
9683535|NCT04901884|Experimental|One arm / exploratory study|Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours.
9683536|NCT04901611|Experimental|Parental touch (pre-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance will be administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just before the control procedure and clinical heel lance.
9683537|NCT04901611|Placebo Comparator|Parental touch (post-procedural)|Parents will stroke their baby on the posterior lower limb of the leg where the heel lance was administered, at a speed of 3cm/s for 10 seconds using the whole hand and in one direction down the limb towards the foot. This will happen just after the control procedure and clinical heel lance.
9683538|NCT04901624|Experimental|Personal Risk + Loss Protection|Personal Risk + Loss Protection
9683539|NCT04901624|Experimental|Personal Risk + Lottery Incentive|Personal Risk + Lottery Incentive
9683540|NCT04901624|Experimental|Family Risk + Loss Protection|Family Risk + Loss Protection
9683541|NCT04901624|Experimental|Family Risk + Lottery Incentive|Family Risk + Lottery Incentive
9683542|NCT04901793|Experimental|Virtual Reality Intervention Group|Patient is fitted with a Virtual Reality headset and handheld remote control. Subject is able to play an interactive game during the duration of the in-office procedure.
10178499|NCT03812380|Placebo Comparator|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
9683543|NCT04901793|No Intervention|Control Group|standard of care
9683544|NCT04901832|Experimental|Experimental Group|The intervention in this group is stretching exercises with the aim of prevention and reduction of leg muscle cramps among patients undergoing hemodialysis
9683545|NCT04901832|No Intervention|Control Group|The participants in this group used as reference group
9683546|NCT04901442|Active Comparator|Running with an Orthotic|Group A will receive an L700 Speed Orthotic (https://www.aetrex.com/running-orthotic/?lang=en_US) according to participants shoe size and will run with this Orthotic in the participants normal running shoes. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to run as normal over the 8-week trial period
9683547|NCT04901442|No Intervention|Running without an Orthotic|Group B will not be provided with the Orthotic and will run in the participants normal running shoes during the course of the study. The group will be asked to run as normal over the 8-week trial period. At the end of the study and following collection of data participants in Group B will also be provided with an L700 Speed Orthotic.
9683548|NCT04901728||Target Population|People living with HIV and following a DTG/3TC drug regimen
9683549|NCT04901728||Control Group on Dual Regimens|The first control population will include a group on dual regimens other than DTG/3TC and a group on triple therapy. In the control group of patients receiving dual therapies, we will include patients (i) on Juluca (DTG/rilpivirine[RPV]), (ii) on boosted darunavir plus lamivudine (DRV/r or DRV/c + 3TC), and (iii) on boosted darunavir plus raltegravir (DRV/r or DRV/c + RAL).
9683550|NCT04901728||Control Group on Triple Regimens|The second control population will include a group on triple regimens including: 2 NRTIs + 1 NNRTI; 2 NRTIs + 1 INSTI, and 2 NRTIs + 1 PI/b.
9683551|NCT04901572|Other|QART Imaging|"Cells will be individually selected with the system's micromanipulator under bright-field imaging. The cells will be representative of the cell population to be selected in ICSI procedures, covering the entire range of human sperm cell dimensions. Each selected cell will be simultaneously imaged by the QART system in two modalities:~Standard brightfield.~QART's imaging methodology."
9683552|NCT04901546|Experimental|Infants with Esophageal Atresia|Starting at 3 weeks, infants will be administered 1 mL of their own saliva via gastrostomy tube, with each feed (8x/day) for one week.
9683553|NCT04901546|No Intervention|Comparison Infants without Esophageal Atresia|Infants do not have EA and thus can swallow their own saliva.
9683554|NCT04901403|Other|Education intervention|Parents in the treatment group will receive information about Earned Income Tax Credit, including how to sign up for free. They will also receive help with budgeting and finances from their home visitor.
9683555|NCT04901403|Other|Control group|Control group families will receive home visiting services as usual.
9683556|NCT04901338||Veno-arterial ECMO patients|Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption.
9683557|NCT04901338||Veno-venous ECMO patients|Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption.
9683558|NCT04901650||Inpatient population|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
9683559|NCT04901494||SSRI for at least one year prior to the diagnosis of MCI|subjects with an initial diagnosis of MCI who were treated with an SSRI for at least one year prior to the diagnosis of MCI
9683560|NCT04901494||SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI|SSRI at the time of diagnosis and treated with it for at least 6 months after the diagnosis of MCI
9683561|NCT04901494||Subjects without SSRI use|Subjects without SSRI use
9683562|NCT04901533|Experimental|cervical manipulation|The objective of this technique is to restore joint mobility between the joints of the occipital, first (atlas) and second cervical vertebra (axis). It is a technique performed in rotation on a vertical axis that passes through the odontoid process of the axis, without placing flexion or extension, and with very slight sidebending; it is done bilaterally.
9683563|NCT04901533|Active Comparator|Cranial Listening|Cranial palpation maneuver
9683564|NCT04901585||Totally intracorporeal distal gastrectomy|All patients who underwent minimally invasive distal gastrectomy with intracorporeal anastomosis for gastric cancer
9683565|NCT04901520|Experimental|High Intensity Training (HIT)|Participants trained at 80-90% of 1RM for 12 weeks, twice per week.
9683566|NCT04901520|Experimental|Moderate Intensity Training (MIT)|Participants trained at 65-75% of 1RM for 12 weeks, twice per week.
9683567|NCT04901520|Experimental|Low Intensity Training (LIT)|Participants trained at 50-60% of 1RM for 12 weeks, twice per week.
9683568|NCT04901520|No Intervention|Control Group (CG)|Participants did not participate in any training and they advised to do their daily activity
9683569|NCT04901429|Experimental|Truncal Vagotomy|Truncal vagotomy will be performed during other routine procedure.
9683570|NCT04901429|No Intervention|No Truncal Vagotomy|No truncal vagotomy will be performed during other routine procedure.
9683571|NCT04901663|Active Comparator|Omeprazole Group|Omeprazole 20 mg BD Amoxicillin 1000 mg BD Clarithromycin 500 mg BD
9683572|NCT04901663|Experimental|Vonoprazan Group|Vonoprazan 20 mg BD Amoxicillin 1000 mg BD
9683573|NCT04901845||Patients applying to Primary Healthcare Consultation|Consequent patients applying to the Primary healthcare to consult for any reason during 2 week period
9683574|NCT04901845||Patients applying to Specialized Healthcare Consultation|Consequent patients applying to the Specialized healthcare to consult for any reason during 2 week period
9683575|NCT04901481|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower active treatment.
9683576|NCT04901481|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location twice daily for six weeks. Treatment adherence will be assessed and participants will complete surveys to evaluate the feasibility and acceptability Empower sham treatment.
9683577|NCT04901559||BQT|Patients treated with the Bone Quadriceps Tendon (BQT) autograft
9683578|NCT04901559||STG|Patients treated with the Semitendinosus-Gracilis (STG) autograft
9683579|NCT04901559||BPTB|Patients treated with the Bone-Patellar Tendon-Bone (BPTB) autograft
9683580|NCT04901390|Experimental|Yogurt with B. lactis and added cane sugar|Participants will consume yogurt with B. lactis and added cane sugar twice daily for 14 days.
9683581|NCT04901325|Experimental|Baricitinib for PG|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
9683582|NCT04901780|Experimental|PPCS|Novel intervention
10178500|NCT03812458|Experimental|Guidance|The intervention group will consist of the relatives who will receive a printed brochure and are encouraged to visit a website with detailed information and with simple language regarding the ICU environment (treatments, care, alarms, multidisciplinary team) and the characteristics of critically ill patients (organ dysfunction, prognosis, palliative care, organ dysfunction).
9683583|NCT04901780|Active Comparator|CBS|Cross arm stretch gave to individuals
9683584|NCT04901312|Experimental|Enhanced A-CRA (E-ACRA)|ACRA, T4 and MI
9683585|NCT04901312|Experimental|ACRA Lite|Only 4 weeks of ACRA, minus the caregiver component; plus ACC and MI
9683586|NCT04901312|Experimental|Education|Opioid Education Workbook
9683587|NCT04901286|No Intervention|Seated Rest|Behavioral: Seated Rest In the seated rest control condition, participants will sit on the bike for 30 minutes. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
9683588|NCT04901286|Active Comparator|Exercise Only|Behavioral: Exercise Only In the exercise-only condition, participants will complete a total of 30-minutes on the stationary bike. This will include a) 5-min warm-up at low resistance, b) 20 minutes of moderate-vigorous intensity cycling, and c) a 5-min cool-down at low resistance. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
9683589|NCT04901286|Experimental|Exercise + Non-Immersive Virtual Reality|"Behavioral: Exercise + Non-Immersive Virtual Reality In the exercise with non-immersive Virtual Reality condition, participants will complete a total of 30-minutes on the stationary bike while watching a video on an iPad. The cycling session will be identical to that in the Exercise Only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, a YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]) will play on an iPad placed on the front of the bike. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
9683590|NCT04901286|Experimental|Exercise + Immersive Virtual Reality|"Behavioral: Exercise + Immersive Virtual Reality In the exercise with immersive virtual reality condition, participants will complete a total of 30-minutes on the stationary bike while wearing Oculus Quest 2 goggles. The bout of cycling will be identical to the prescription given in the exercise only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, the Oculus YouTubeVR app will play a 360° version of the YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]). Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart Rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
9683591|NCT04901000||Carotid Endarterectomy under Local Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under local anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
9683592|NCT04901000||Carotid Endarterectomy under General Anaesthetic Pre-CABG|Patients that underwent carotid endarterectomy under general anaesthetic prior to coronary artery bypass operations in staged fashion within 6 months.
9683593|NCT04901026|Active Comparator|An in-house manikin|Participants use an in-house manikin
9683594|NCT04901026|Sham Comparator|A manikin in market|Participants use a manikin from market
9683595|NCT04901091||study group№ 1|patients who have left ventricular aneurysm without thrombosis
9683596|NCT04901091||study group№ 2|patients who have left ventricular aneurysm with thrombosis
9683597|NCT04901091||control group|patients who have not left ventricular aneurysm
9683598|NCT04900909||Aortic valve replacement with mechanical valves|
9683599|NCT04900909||Aortic valve replacement with bioprostheses|
9683600|NCT04901039||Decompensated heart failure|Previously diagnosed heart failure presenting with decompensation to the emergency department
9683601|NCT04901260||Quality Initiative|Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and GAA clinical staff.
9827570|NCT02461160|Experimental|BA/FE Cohort 8 Group 1: A,B,C|Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.
9683602|NCT04901117|Experimental|10-day treatment group|"Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
9683603|NCT04901117|Active Comparator|14-day treatment group|"Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.~The dosage of each drug is:~Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid"
9683604|NCT04901065|Experimental|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle.
9683605|NCT04901065|Sham Comparator|Control|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery.
9683606|NCT04900961|Active Comparator|Intervention|A personalised, resistance-based exercise intervention for patients during the convalescence phase in-hospital through to 3-months post-discharge, a duration reflecting chronic, maintenance treatment studies. To maximise enrolment of eligible patients, the intervention may be initiated in-hospital or in the community post-discharge. Resistance bands may be used according to the exercise guideline.
9683607|NCT04900961|No Intervention|Control|Standard of care treatment
9683608|NCT04901130|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through colonoscopy examination with the assitance of AQCS.
9683609|NCT04901130|No Intervention|Control group|Patients in control group will go through conventional standard colonoscopy examination without the assistance of the AQCS.
9695701|NCT04775576|Active Comparator|Group 2|Patients in the PVI group will be started on maintenance fluid therapy at 2-3 ml / kg / hour. In addition to standard monitoring, if PVI is <13% and OAB≥65mmHg in measurements made with PVI, current fluid therapy will continue. If PVI is <13% and MAP <65 mmHg, noradrenaline infusion will be started. If PVI is> 13% and OAB≥65 mmHg, 250 ml iv colloid bolus will be administered, and iv colloid bolus will be continued until the PVI is <13% in the 5-minute follow-ups. If PVI> 13% and MAP <65 mmHg, patients should receive 250 ml i.v. colloid infusion will be given, if MAP <65mmHg continues in 5 minutes follow-up, 250 ml i.v. Colloid and noradrenaline infusion will be started and repeated until the OAB≥65 mmHg and PVI <13%.
9695702|NCT04775511|Experimental|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
9695703|NCT04775511|Experimental|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
9695704|NCT04775511|Other|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
9695705|NCT04775342||1 group|1 group will be assessed then will be given smartphone to use and assessed
9695706|NCT04775420||Group 1|Ascetic patients without spontaneous bacterial peritonitis
9695707|NCT04775420||Group 2|Ascetic patients with spontaneous bacterial peritonitis
9695708|NCT04775290|Experimental|Arm Yoga (YG)|Patients assigned to the YG arm participate in yoga classes
9695709|NCT04775290|No Intervention|Arm control (CG)|Patients assigned to the CG arm will follow the normal course of radiotherapy.
9695710|NCT04775381|Experimental|Vitamin D|During preoperative visit (Month -2) patients will receive a cholecalciferol supplementation added to a fruit juice.
9695711|NCT04775381|No Intervention|Fruit juice|During preoperative visit (Month -2) patients will receive only fruit juice.
9695712|NCT04775459||Surfactant administration without using score LUS|"It is a retrospective cohort : preterm newborns from august 2019 to december 2019 needed a surfactant administration.~The surfactant was administrated only if the fraction of inspired oxygen (FiO2) >30% among the Guidelines of 2019"
9695713|NCT04775459||Surfactant administration using score LUS|"It is a prospective cohort : preterm newborns from january 2021 to juin 2020 needed a surfactant administration.~The surfactant is administrated if FiO2 >30% OR if score LUS >8/18 among the literature"
9695714|NCT04775264|Experimental|Pulsed Electric Field Energy Ablation|ablation of ganglionated plexi structures on the epicardial surface of the heart delivered as a concomitant procedure during open heart surgery to eliminate atrial fibrillation
9695715|NCT04775212|Active Comparator|desflurane|patients to be anesthetized with desflurane
9695716|NCT04775212|Active Comparator|sevoflurane|patients to be anesthetized with sevoflurane
9695717|NCT04775238|Active Comparator|Group 1 (Staphylococcus aureus)|Staphylococcus aureus is an example of gram positive bacteria which is a strong biofilm producer and highly resistant to antibiotics. Staphylococcus aureus will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
9683610|NCT04901156|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
9683611|NCT04901156|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
9683612|NCT04901208|Active Comparator|Users of Juul|Individuals who use Juul devices to vape nicotine
9683613|NCT04901208|No Intervention|Controls|Healthy non-smokers
9977650|NCT01363882|Experimental|Sleep study titrated NIV|ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) <50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.
9683616|NCT04900974|Experimental|Doravirine|100mg doravirine given by mouth once at each sampling visit.
9683617|NCT04901234|Active Comparator|Standard radiotherapy|Radiotherapy as planned at baseline, with replanning allowed only if significant weight loss or change in anatomy due to unforeseen circumstances (eg that would affect dosimetry and treatment delivery of baseline treatment plan). No adaptation to shrinking tumour is allowed.
9683618|NCT04901234|Experimental|Adaptive radiotherapy|Systematic radiation treatment plan adaptation according to the shrinking tumour on mid-treatment MRI.
9683619|NCT04901182|Active Comparator|White sesame soy milk smoothie (WS)|a formula developed from natural ingredients such as soybean and white sesame
9683620|NCT04901182|Active Comparator|Chicken shitake smoothie (CS)|a formula developed from natural ingredients such as chicken and shitake mushroom
9683621|NCT04901182|Placebo Comparator|Ensure|a conventional well-known commercial formula
9683622|NCT04901052|Experimental|n-3 supplementation group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus Omega 3 supplementation, the dosage was 2 capsules per day, containing 1.5 g of omega 3, of which 1000 mg were EPA and 500mg DHA. The omega 3 capsules were obtained from the same batch.
9683623|NCT04901052|Placebo Comparator|Placebo group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus placebo capsules (2 capsules per day made from sunflower oil)
9683624|NCT04901013|Active Comparator|Affinity plus SOC|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM). Affinity is human allograft tissue that is regulated as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) as defined by FDA 21 CFR Part 1271. Affinity may be applied as a wound covering to partial- and full-thickness acute and chronic wounds
9683625|NCT04901013|No Intervention|Standard of Care (SOC)|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
9683626|NCT04900948|Experimental|Experimental group №1|proactive therapy with local calcineurin inhibitors + emollients
9683627|NCT04900948|Active Comparator|Experimental group №2|proactive therapy with local glucocorticosteroids + emollients
9683628|NCT04901104||thymosin α1 group|The patient was treated with thymosin α1 in sepsis
9683629|NCT04901104||placebo group|The patient was treated without thymosin α1 in sepsis
9683630|NCT04900792|Experimental|Cohort 1 (starting)|"Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, then at radiation treatments 6, 25, and 31 (± 1 radiation treatment)~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks. T~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for 42 days or until radiation is completed (whichever comes first)."
9683631|NCT04900792|Experimental|Cohort 2 (-1 dose level)|"Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, then at radiation treatment 25 (± 1 radiation treatment)~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks. T~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for 42 days or until radiation is completed (whichever comes first)."
9683632|NCT04900636|Experimental|Telemedicine Arm|Use of a telemedicine platform combined with face-to-face visits according to protocol
9683633|NCT04900636|No Intervention|Control Arm|conventional follow-up according to routine clinical practice.
9683634|NCT04900649|Experimental|study group|the study group has conducted chest resisted exercise combined with chest expansion exercise in addition to a usual chest physiotherapy. For chest resistance exercise, the children in the study group underwent sequential 12-week chest resistance exercise and chest expansion exercise, three sessions a week. Chest resistance exercises have been consisted of manual resistance exercise and resistance exercise via POWER breath KH2.
9683635|NCT04900649|Experimental|control group|12-week usual chest physiotherapy in form of bilateral vibration and gentle percussion for 3-5 minutes with distal finger phalanges to the upper apical lobes in modified drainage positions, placing the patient in a side-lying position or a prone position to increase oxygenation, at least 2-3 times a week
9695718|NCT04775238|Active Comparator|Group 2 (Pseudomonas aeruginosa )|Pseudomonas aeruginosa is an example of gram negative bacteria which is a strong biofilm producer and highly resistant to antibiotics. Pseudomonas aeruginosa will be exposed to silver nanoparticles and copper nanoparticles separately to study their antibacterial and biofilm inhibiting properties and their synergistic effect in combination with antibiotics.
9683636|NCT04900857|Active Comparator|Dry needling treatment group|Dry needling treatment group will be treated with acupuncture needles (0.25x25 mm Hua Long Brand).In this group, one active trigger point area in the trapezius muscle was precisely determined and marked with a permanent pen, and dry needling treatment was applied to that area with disposable acupuncture needles in a single session. the trigger point was palpated. From the center, the needle tip was inserted perpendicular to the skin quickly into the subcutaneous tissue and inserted into the muscle with the needle tip until it found the trigger point in the muscle band. Local twitch responses (LTRs) were similar to Hong's rapid entry and exit technique. It was obtained by inserting a large number of rapid needles in and out of. The needle was not removed from that area for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
9683637|NCT04900857|Experimental|Localized vibration treatment group|The tight band in the muscle was determined by palpation, and the location of the most painful points (the middle of the most vertical fibers of the upper part of the trapezius muscle) in the muscle tension band was digitally determined. It was determined with a permanent marker. The skin was cleaned with a suitable antiseptic agent. Localized vibration therapy was applied for 20 minutes with a vibration frequency of 110 Hz and an amplitude of 5.57 mm using a vibrator device. Vibration therapy was applied to our patients by attaching an apparatus with a small area of 1 cm2 to the skin on the trigger point in the trapezius muscle and fixed with medium pressure. We applied a total of 3 sessions every other day in hospital conditions by a single practitioner to all patients.
9683638|NCT04900701|Experimental|Hypocaloric|Participants placed in energy restriction.
9683639|NCT04900701|Experimental|Energy Balance|Participants placed in energy balance.
10178501|NCT03812458|No Intervention|Control|The families who will not receive the brochure and are not encouraged to visit the website.
9683640|NCT04900701|Experimental|Hypercaloric|Participants placed in energy surplus.
9683641|NCT04900389||Case Group: Nurses with COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark the answer Yes to the question Have you been diagnosed with COVID-19? 5th question; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
9683642|NCT04900389||Kontrol Group: Nurses who have not had COVID-19|"The questionnaire form is included in the section on COVID-19. 2nd question; They will mark No to the question Have you been diagnosed with COVID-19? And move on to the 4th question in the same section.~The 5th question in Annex 2 of the questionnaire form; Individuals who answer No to the question Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process? Will move on to the 11th question in the same section."
9683643|NCT04900467|Active Comparator|Pfizer-Pfizer|Pfizer-Pfizer Length of use : 1 day
9683644|NCT04900467|Experimental|Pfizer-Moderna|Pfizer-Moderna Length of use : 1 day
9683645|NCT04900467|Active Comparator|Moderna- Moderna|Moderna- Moderna Length of use : 1 day
9683646|NCT04900467|Experimental|Moderna - Pfizer|Moderna - Pfizer Length of use : 1 day
9683647|NCT04900675|Experimental|bright white light intervention|exposure to 5,000 lux with polychromatic white light with 5,300 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
9683648|NCT04900675|Placebo Comparator|dim reddish light intervention|exposure to 50 lux with polychromatic reddish light with 2,200 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks
9683649|NCT04900532|Experimental|Effects of supplementation with tocotrienol on chronic kidney disease patients|Administration of tocotrienol-rich-fraction (TRF) capsules, containing 360mg of tocotrienol and 80mg of tocopherol twice a day for six months.
9683650|NCT04900532|Placebo Comparator|Effects of supplementation with tocotrienol on lipid profile of chronic kidney disease patients|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
9683651|NCT04900415|Experimental|Vitamin A and smell training|14-day course of daily oral vitamin A 7500µg RAE in combination with smell training three times per day for 4 weeks
9683652|NCT04900415|Active Comparator|Smell training|Smell training three times per day for 4 weeks
9683653|NCT04900415|No Intervention|Control|Observation
9683654|NCT04900571|Experimental|Nitrofurantoin|Measuring pain score using numerical pain scale post-operatively at different time intervals.
9683655|NCT04900571|Experimental|Calcium Hydroxide|Measuring pain score using numerical pain scale post-operatively at different time intervals.
9683656|NCT04900571|Experimental|Control|Measuring pain score using numerical pain scale post-operatively at different time intervals.
9683657|NCT04900610|Active Comparator|Vitamin K2|1mg/day per os
9683658|NCT04900610|Placebo Comparator|Placebo|matching placebo
9683659|NCT04900623|Experimental|LOW RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what radiation dose received . The specimens will be de-identified. The specimens will be banked for future use.~Radiation Therapy: Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
9827795|NCT02468804|Sham Comparator|Control Subjects (sTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
10178502|NCT03812523|Active Comparator|Control|Duloxetine 60 mg qd
10178503|NCT03812523|Experimental|Intervention|Lorcaserin 10 mg bid
10178504|NCT03812562|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
10178505|NCT03812393|Experimental|Treatment|TNBC patients with HER2 signal positive are treated with neratinib for 3 weeks followed by 12 weeks of neratinib in combination with weekly paclitaxel and carboplatin
10178506|NCT03812419|Active Comparator|group I|Esomeprazole 40 mg capsules once daily for 6 months
10178507|NCT03812419|Active Comparator|group II|Pantoprazole 40 mg tablets once daily for 6 months
10178508|NCT03812744|Experimental|WCCE|
10178509|NCT03812744|Placebo Comparator|Placebo|
10178510|NCT03812692||MATRx plus test|All participants will complete the MATRx plus test unattended in the home. Not all participants will be predicted responders to oral appliance therapy; both predicted responders and non-responders will undergo an outcome home sleep apnea test with a custom oral appliance in place to validate the prediction made by the test. Twenty participants will also complete an in-lab sleep study prior to the home study.
10178511|NCT03812705|Experimental|fecal microbiome transplantation|"Perform fecal microbiome transplantation to patient under colonoscopy or gastroscopy: injection of 200~300 ml fecal microbiome fluid as fecal microbiome transplantation to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;~If patient's condition is stable or improved within 1 week, second fecal microbiome transplantation may be performed 1 week later, up to 4 times will be performed if patient response;~If patient's condition is not improved after the second fecal microbiome transplantation, stop fecal microbiome transplantation."
10178512|NCT03812536|No Intervention|SOC Voiding Protocol|Patients in the control group will follow the standard of care protocol and are required to void post anorectal surgery before being discharged home.
10178513|NCT03812536|Experimental|No Void Intervention|Patients in the experimental group (No Void Intervention) will be discharged home without voiding spontaneously.
9683660|NCT04900623|Experimental|HIGH RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what dose of radiation received. The specimens will be de-identified. The specimens will be banked for future use.~Radiation Therapy: Higher risk participants will receive standard radiation dose for up to 7-8 weeks~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
9683661|NCT04900545||beta blocker navie patients with acute coronary syndrome|
9683662|NCT04900324|Experimental|MRI guidance|Injections of botulinum toxin performed using MRI guidance
9683663|NCT04900324|Experimental|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
9683664|NCT04900766|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with unresectable or metastatic bone and soft tissue sarcoma will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for a maximum of 6 cycles.
9683665|NCT04900584|Experimental|Intervention group|The intervention group is managed by applying all three types of intervention.
9683666|NCT04900584|No Intervention|non-Intervention group|Non-intervention group is managed by conventional heart failure treatment.
9683667|NCT04900740|Active Comparator|Standard care - catheter fixation with surgical stitch|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed in the standard way, using a surgical stitch.
9683668|NCT04900740|Experimental|Experimental - catheter fixation with glue|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed using the glue.
9683669|NCT04900558||Radical Cystectomy|Patients who underwent radical cystectomy for bladder cancer in our centre
9683670|NCT04900311|Experimental|pyrotinib + trastuzumab + nab-paclitaxel|
9683671|NCT04900311|Active Comparator|pertuzumab + trastuzumab + nab-paclitaxel|
9683672|NCT04900363|Experimental|AK112|Subjects receive AK112 monotherapy intravenously (IV) until no more benefits from treatment.
9683673|NCT04900350|Experimental|AK117+ azacitidine|"Phase 1: Subjects will receive escalating doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;~Phase 2: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle."
9683674|NCT04900337|Experimental|AMOR 18 Powder & Inhalation|"AMOR_inhaled Double Pack- Each kit contains two tubes that after mixing result with 1.14 % ACC in 10 ml suspension.~AMOR_powder- ACC in a dry powder (up to 2000mg Calcium/day sublingually)."
9683675|NCT04900337|Placebo Comparator|Placebo|"Placebo_Inhaled Double Pack - Each kit contains two tubes of saline at different volumes (similar to investigational product) after mixing the results remains saline at a final volume of 10ml.~Placebo_Powder: Each sachet contains powder at the same particle size and weight as the powder of the investigational product."
9827796|NCT02468830|Experimental|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
10178514|NCT03812185|No Intervention|TEE image before suctioning orogastric tube|for intraoperative TEE used cardiac or transplant cases, TEE images will be stored before and after suctioning orogastric tube which is attached to TEE probe cover. This Arm is TEE image BEFORE suctioning.
10178515|NCT03812185|Experimental|TEE image after suctioning orogastric tube|This Arm is TEE image AFTER suctioning
10178516|NCT03812445|No Intervention|No Intervention|the patients in this arm will not receive probiotics.
10178517|NCT03812445|Experimental|Experimental|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus for 3 months.
10178518|NCT03812432|Experimental|near-infrared cholecystocholangiography|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence. Once the fundus is grasped and retracted, a needle-tipped cholangiogram catheter is introduced through the skin, adjacent to gallbladder. The catheter, guided by a grasping or dissecting instrument, is used to puncture the infundibulum of the gallbladder. Nine milliliters of bile is aspirated from the gallbladder into a syringe and and a indocianine green solution is injected into the gallbladder. The catheter is removed and the puncture site pinched closed with a grasper. Dissection is then performed under either ambient light or near-infrared mode. The surgical view of the gallbladder dissection is toggled back and forth between the two viewing.
9683676|NCT04900285|Other|Dental Device Arm|Subjects in this single arm study serve as their own control by recording snoring on the SnoreLab device for five days and completing the Snore Outcomes survey. After five nights with now device, the lower dental device is used for five nights and snoring is recorded in the SnoreLab app. At the end of the five nights the subjects complete the Comfort and Difficulties Form and the bed partner completes the Snore Outcomes Survey. If the lower device was tolerated well, the process is repeated with the upper dental device used with the lower device.
9683677|NCT04900727||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
9683678|NCT04900727||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
9683679|NCT04900727||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
9977651|NCT01363895|Active Comparator|Percutaneous closure of LAA|Percutaneous closure of LAA
9977652|NCT01363895|Active Comparator|Catheter ablation of AF|Catheter ablation of AF
9683682|NCT04900272|Experimental|VIPA device and companion booklet|For Aim 2, we will recruit a total of 20-40 older adult homebound patients who are likely to be socially isolated, through the Geriatric and General Internal Medicine clinics at Northwestern (over 2,300 homebound older adults) to use the VIPA and accompanying instructional booklet focused on social-isolation. Either the study PI or Research Study Coordinator (RSC) will visit the participant's home, or assist the patient virtually, once consented, to set up the Google Home or Amazon Alexa device for them and review the companion VIPA booklet with them.
9683683|NCT04900142|Experimental|1500 mW|1500 mW of Power
9683684|NCT04900142|Active Comparator|1000 mW|Standard treatment, 1000 mW
9683685|NCT04900181|Experimental|the same-day discharge surgery|Patients in the the same-day discharge surgery group were admitted to hospital, operated and discharged within 24 hour
9683686|NCT04900181|No Intervention|inpatient surgery|Patients in inpatient surgery follow routine procedures and do not need to be discharged on the same day.
9683687|NCT04899921|Experimental|Safety Run-In|Up to three cohorts of patients will be treated in a 3+3 design with the triple drug combination of Ipilimumab + Nivolumab + Troriluzole to provide dosing information and an early assessment of safety.
9683688|NCT04899921|Experimental|Ipilimumab + Nivolumab + Troriluzole|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Troriluzole self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Troriluzole self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
9683689|NCT04899921|Experimental|Ipilimumab + Nivolumab + Placebo|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Placebo self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Placebo self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
9683690|NCT04899960|No Intervention|Observational Group|
9683691|NCT04899960|No Intervention|Control (Validation) Group|
9683692|NCT04899960|Experimental|İnterventional Group|
9683693|NCT04900064|Experimental|Diagnostic Assessment - Given self-help CBT|"The diagnostic assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview (MINI - International Neuropsychiatric Interview) and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).~In the primary analysis, only patients receiving treatment with self-help CBT are included."
9683694|NCT04900064|Active Comparator|Contextual Assessment - Suitable for self-help CBT but given brief interventions|"The contextual assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.~In the primary analysis, only patients suitable for self-help CBT are included. This is decided by an algorithm based on data from their screening, which takes into account symptom severity and type, patient preference and known variables that make self-help CBT a worse fit."
9683695|NCT04900064|Experimental|Diagnostic Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they receive treatment with self-help CBT or brief interventions."
9683696|NCT04900064|Active Comparator|Contextual Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they are deemed suitable for self-help CBT or not."
9683697|NCT04900155|Active Comparator|Atorvastatin 80 mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
9977653|NCT01363921|Experimental|Dialysis treatment with HCO1100|
9977654|NCT01363934|Experimental|Group A|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
9683698|NCT04900155|Active Comparator|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
9683699|NCT04900129|Experimental|Study Group|This group inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg. These drugs have no systemic and local side effects in these small doses, though it may cause slight eye irritation.
10178519|NCT03812770|Experimental|Sorafenib plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
10178520|NCT03812770|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
10178521|NCT03812484|Experimental|SCF Parole|Parolee supervised under the SCF Supervision model
9683700|NCT04900129|No Intervention|Control Group|This group inhaled plain aquatic vapor in addition to conventional treatment.
9683701|NCT04900194|Experimental|MBSC group|counseling group
9683702|NCT04900194|No Intervention|Control group|standard care group
9683703|NCT04900168||ICP monitoring group|patients received ICP monitoring
9683704|NCT04900168||conventional treatment group|patients without ICP monitoring and received conventional treatment
9683705|NCT04899765|Experimental|Measles vaccine|Measles vaccine in standard dose of 0.5 ml.
9683706|NCT04899765|Experimental|BCG vaccine|BCG vaccine in standard dose of 0.1 ml.
9683707|NCT04899765|Placebo Comparator|Placebo|Saline injection
9977655|NCT01363934|Experimental|Group B|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
9977656|NCT01363934|Experimental|Group C|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
9683710|NCT04900090|Experimental|Case group : gout patients|Epidemiological study
9683711|NCT04900090|Experimental|Control group|Epidemiological study
9683712|NCT04900233||Control group|
9683713|NCT04900233||Pandemic group|
9683714|NCT04899830|Experimental|Installation of a telepresence robot in the home of a disabled person hospitalized in a PRM center|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
9683715|NCT04900012||Distal pancreatectomy|All cases operated on performing distal pancreatectomy in involved Units
9683716|NCT04899882|No Intervention|Control group|
9683717|NCT04899882|Experimental|KinHémo group|
10178522|NCT03812484|Active Comparator|Parole-As-Usual|Parolees are supervised under standard parole supervision practice in New Jersey.
10178523|NCT03812250|Active Comparator|ERCP assisted trans-papillary drainage|ERCP assisted trans-papillary drainage for malignant biliary obstruction
9683718|NCT04899570|Experimental|Zanubrutinib combined with R-CHOP|"The experimental arm will be treated zanubrutinib combined with R-CHOP regimen for 8 cycles. The interim evaluation will be performed after 4 cycles, and the patients who can't achieve PR or CR will be withdrawn from this trial and receive salvage regimens.~After 8 cycles of ZR-CHOP, the patients will be followed for 2 years to evaluate the PFS."
9683719|NCT04899453|Experimental|Zanubrutinib/rituximab & intravitreal MTX|Experimental arm will be treated with rituximab plus zanubrutinib (ZR) regimen for 6 cycles and followed by zanubrutinib maintenance for 2 years, meanwhile, intravitreal methotrexate will be given as protocol during the 1st year of treatment.
9683720|NCT04899531||Longitudinal observation|No specific intervention, pre-post measurements only
9683721|NCT04899817|Active Comparator|Group G|will receive granisteron 1mg after induction of general anesthesia
9683722|NCT04899817|Placebo Comparator|Group C|Will receive metoclopramide 10 mg after induction of general anesthesia
9683723|NCT04899752|Experimental|Traditional OPCR|Those who are in the traditional group will discuss topics like medication adherence, physical activity questions, or eating habits without a clear from of autonomy or nonautonomy basis as is currently completed in OPCR. This will occur in a face to face format.
9683724|NCT04899752|Experimental|OPCR + MI|The MI group will be consistent with the spirit of MI and utilize a high autonomy communication style to provide support for behavior change across multiple behaviors. This will occur in a face to face format.
9683725|NCT04899752|Experimental|OPCR + Clinician centered|The OPCR + CC group will participate in low-autonomy face to face interviews. Meaning the communication style will be clinician centered, providing goals to the participants without valuing their input.
9683726|NCT04899674|Experimental|Bupropion (Reference, R) - BI 1358894 + Bupropion (Test, T)|
9683727|NCT04899713||Experimental group (neo-adjuvant chemotherapy combined with ZOMETA®) (zoledronic acid)|Patients treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : zoledronic acid 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with zoledronic acid 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
9683728|NCT04899713||Control group (neo-adjuvant chemotherapy alone)|Patients treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
9683729|NCT04899479|Experimental|SGLT-2 inhibitor|The SGLT-2 inhibitor group will receive SGLT-2 inhibitor once daily until the end of the study period.
9683730|NCT04899479|Placebo Comparator|Control|The control group will not receive any additional drugs.
9683731|NCT04899726|Experimental|Intervention|Oncology patients candidate for rectal surgery (tumors located up to 15 cm from the anal margin) and meet inclusion criteria. Rectoscope (P201630551) allows the identification of the distal section margin.
9683732|NCT04899648|Experimental|Behavioral Intervention|Receives nutrition and exercise intervention classes
9683733|NCT04899648|No Intervention|Control Group|Does not receive any intervention classes
10178524|NCT03812250|Active Comparator|EUS-guide biliary drainage|EUS-guide biliary drainage for malignant biliary obstruction
10178525|NCT03812354|Active Comparator|THRIVE 2L/kg/min using OptiFlow|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
9683734|NCT04899427|Experimental|orelabrutinib combined with PD-1 inhibitor|"The experimental arm will be treated orelabrutinib plus PD-1(programmed death）inhibitor every 21 days as one cycle. The responses will be evaluated every 2 cycles during the first 6 cycles and every 3 months until progression.~The investigators can choose Sintilimab Injection or Tislelizumab Injection at the beginning of treatment，but they can't exchange to another during the whole treatment."
9683735|NCT04899414|Experimental|Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma|4-6 cycles of induction DAPT followed by Auto HSCT as consolidation for CR/PR fit patients ,then by PD-1 as maintenance treatment (up to 16 cycles) for received Auto-HSCT
9683736|NCT04899778|Experimental|Oral Contraceptive Pill|Oral contraceptive, 1/day, for one year
9683737|NCT04899778|No Intervention|No Oral Contraceptive|No intervention
9683738|NCT04899258|Other|Pre-surgery and post-surgery|femtosecond assisted LASIK
9683739|NCT04899466|Experimental|ActiGraft|Whole blood clot (WBC) gel
9683740|NCT04899739|Experimental|Peripancreatic and distant lymph node assessment|All patients programmed for an endoscopic ultrasound in the context of a pancreatic cancer
9683741|NCT04900259||COVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the COVID-19 period
9683742|NCT04900259||PreCOVID-19 Bladder Cancer|Patients diagnosed with primary bladder cancer in the preCOVID-19 period
10178526|NCT03812354|Experimental|THRIVE 4L/kg/min using OptiFlow|"After apnea sets in and mask ventilation is successfully established, randomization envelopes are opened and according to group allocation, the following oxygen delivery system is applied.~High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand."
10178527|NCT03812315|Experimental|Propolis chewing gum|2 % pure raw propolis, 20-35% gum base, 2.5% flavors, 0.3% sorbitol and 0.3% coloring substance. Children will be instructed to chew the specially prepared propolis chewing gum for at least 20 minutes, twice daily, after breakfast and before bedtime.
10178528|NCT03812315|Active Comparator|Propolis mouthwash|The formulation includes 2% pure raw propolis, 40 ml flavors, 150 ml propylene glycol, 60 gm sorbitol, 0.1 g coloring substance and water. Children will be instructed to rinse using the prepared propolis mouthwash for 1 min, twice a day, after breakfast and before bedtime.
9683743|NCT04899323||Cohort|Perform a 250cc vascular filling over 10 minutes and then perform a cardiac ultrasound. Repeat the vascular filling followed by the ultrasound as long as the patient is responsive.
9683744|NCT04899518|Placebo Comparator|Vehicle Ophthalmic Solution|
9683745|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 1|
10178529|NCT03812068|Experimental|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
10178530|NCT03812068|Active Comparator|Developmental behavioral intervention|only parent-mediated developmental behavioral intervention
9683746|NCT04899518|Experimental|ALY688 Ophthalmic Solution Concentration 2|
9683747|NCT04899297||Quality of life|
9683748|NCT04899401|Experimental|Standard of care +PediaFlù®|
9683749|NCT04899401|Active Comparator|Standard of care|
9683750|NCT04899635||Diseased cardiac tissue|Heart muscle or cells (cardiomyocytes) will be obtained from patients undergoing cardiac surgery, namely coronary artery bypass grafting or for severe valvular heart disease.
9683751|NCT04899635||Healthy cardiac tissue|Healthy donor hearts from deceased individuals that are not transplantable due to technical reasons
9683752|NCT04899154|Experimental|Patients with spondyloarthritis (Spa)|
9683753|NCT04899154|Experimental|Healthy subjects|
9683754|NCT04899375|Experimental|One group taking part in 2 separate conditions|Subjects will be randomly assigned to either group A or B. Session 1 will serve to familiarize all participants with the battery of tests including the 100 mm VAS, Short-form Mcgill Pain Questionnaire (SF-MPQ), Likert perception scale adapted from Kiefer et al. (2017), algometry, manual muscle testing, assessed via hand-held dynamometer (HHD), and grip strength assessed via hydraulic hand dynamometer; subjects will also be instructed in the AROM protocol. Familiarization will be conducted a minimum of 24 hours prior to the first condition. There will be a minimum washout period of 1 week to reduce both order and carry-over effects. Only the principal investigator will be abreast to the order of intervention, sufficiently blinding the raters. Prior to each trial, participants will be instructed to refrain from resistance training for a minimum of 48 hours and to abstain from the use of stimulants or analgesic medication for a minimum of 6 hours prior to reporting to the lab.
9683755|NCT04899128||Observational Group|Patients receive pyrotinib-based therapy after lapatinib progression.
9683756|NCT04899115|Placebo Comparator|Placebo|
9683757|NCT04899115|Experimental|VE303|VE303 is a live biotherapeutic product comprising 8 nonpathogenic commensal strains of Clostridia.
10178531|NCT03812120|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
9683758|NCT04899037||Osseointegrated Device Uptake|The participants in this group will be in the 18-85 year age range who have a hearing loss configuration that would benefit from an OID and choose to uptake an OID.
9683759|NCT04899037||Osseointegrated Device Non Uptake|The participants in this group will be in the 18-85 year age range and who a hearing loss configuration that would benefit from an OID but choose to not uptake an OID.
9683760|NCT04898920|Placebo Comparator|Control Group|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
9683761|NCT04898920|Experimental|Dexamethasone Group|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
9683762|NCT04898972|Experimental|Mindfulness-based stress reduction intervention|Patient-family caregiver dyads will take part in 8-week Mindfulness-based stress reduction intervention (MBSR).
9683763|NCT04898972|Active Comparator|information booklet|Patient-informal caregiver dyads will receive an informative booklet on stress reduction strategies
9683764|NCT04898998|Experimental|TENS to alleviate the effect of thirsty after surgery|Transcutaneous electrical nerve stimulation (TENS) on experimental group 20 mins to treatment postoperative thirsty.
10178532|NCT03812120|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
9683765|NCT04898998|Placebo Comparator|Routine care to alleviate the effect of xerostomia (dry mouth) after surgery|routine care
10178533|NCT03812237|Experimental|(EWB) Early Weight Bearing (2 Weeks Post-op)|Subjects in the EWB group were allowed to begin bearing 50 pounds (lbs) through their hindfoot in either the boot or the short leg cast at the two-week visit. They were allowed to advance their weightbearing as tolerated by 25 lbs every four days until full weightbearing through the hindfoot was achieved.
10178534|NCT03812237|No Intervention|(SOC) Standard of Care Weight Bearing (6-8 Weeks Post-op)|Subjects in the SOC group were allowed to heel touch weightbear for balance only on the operative foot until the six to eight week visit. At this visit all subjects were placed into a short leg walking boot. Non-weightbearing patients were permitted to begin the progressive weightbearing protocol, without hindfoot restriction.
9683766|NCT04898777|Active Comparator|ERCP-BD|ERCP Biliary Drainage by papillary approach with stent placement.
9683767|NCT04898777|Active Comparator|EUS-BD|Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.
9683768|NCT04898946||BNT162b2|Subjects who receive mRNA vaccine BNT162b2.
9683769|NCT04898946||CoronaVac|Subjects who receive inactivated vaccine, CoronaVac.
9683770|NCT04898738|Active Comparator|Alcohol-based hand sanitizer|Half the study households with receive ABHS through the course of the study
9683771|NCT04898738|No Intervention|No Alcohol-based hand sanitizer|Half the study households with not receive ABHS through the course of the study
9695719|NCT04775160|No Intervention|Control group|The control group will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and will receive treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
9695720|NCT04775160|Experimental|Intervention group|The intervention group will receive an Ecological Momentary Intervention called SmartSafe, will be monitored using smartphone-based active and passive Ecological Momentary Assessment through the MEmind and eB2 mobile applications, and their treatment as usual, which will consist of psychiatric follow-up (scheduled appointments with their psychiatrist) in an outpatient Secondary Suicide Prevention Programme, with predetermined clinical reviews according to the Brief Intervention Contact recommendations (1, 2, 4, 7 and 11 weeks, and 4, 6, 9 and 12 months)
9695721|NCT04775134||Subjects with earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
9695722|NCT04775134||Subjects WITHOUT earlier PCR-proven COVID-19 and/or serum anti-SARS-CoV-2 antibodies|Patients that require a medically indicated pulmonary resection.
9695723|NCT04775108|Experimental|Implanted patients|Implantation of Epygon mitral valve prosthesis
9695724|NCT04775199|No Intervention|Control|Control: In all conditions, we will teach science using the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) a visual Journal/Reflection, and 4) a pre-recorded reading centered around a given theme such as sound. A research speech-language pathologist will provide two 30-minute interactive science lessons per week for six weeks to children with language learning challenges recruited nationwide. Children will participate in groups of three. Families will log on five additional times during each week to view the science book reading. In the control condition, children will receive these science lessons but no language intervention. Therefore, this intervention constitutes a nonintervention.
9695725|NCT04775199|Experimental|Science + Grammar Intervention|"Grammar: In the science + grammar condition, focused stimulation plus explicit instruction will be employed. Focused stimulation an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities.. The active ingredients are models (30) and recasts (5 per child) of the target structure (e.g., You measured how long the ramp is). Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Focused stimulation will be supplemented with explicit instruction using choral production and visual supports (3x per lesson) and a definition of the meaning of the structure (1 per lesson)."
9695726|NCT04775199|Experimental|Science + Vocabulary Intervention|Vocabulary: We will provide Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 12 words that pertain to scientific practices applicable to the FOSS lessons. The words are: compare, diagram, evidence, explanation, hypothesis, materials, model, multiple, pattern, problem, scientist, search. Two words will be targets in each session. We will ensure that for each target word per session there will be at least one definition model and 3 other models directed to the triad of participants and at least 2 elicitations per child. The recorded books also include 6 additional exposures to the words, for a cumulative exposure of 12.
9695727|NCT04775186|Experimental|Laparoscopic Burch colposuspension|
9695728|NCT04775186|Experimental|midurethral sling|
9695729|NCT04774900||Standardised|The procedures will be observed with standardized equipment placement.
10178535|NCT03812042||Screen population|The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
9695730|NCT04774900||Modified|The procedures will be observed with modified equipment placement - placement according to older methodology or custom.
9695731|NCT04775225|Active Comparator|Hip denervation group|This group will receive Lidocaine 2% block of the femoral and obturator genicular branches.
9695732|NCT04775225|Placebo Comparator|control group|this group will receive saline injection subcutaneously at the same places.
9695733|NCT04775069|Active Comparator|mRNA Group|The subjects will be vaccinated with the mRNA vaccine (Pfizer-Biontech).
9695734|NCT04775069|Active Comparator|Inactivated Virus Group|The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).
9695735|NCT04775069|Active Comparator|Adenovirus-vector Group|The subjects will be vaccinated with adenovirus-vector COVID-19 vaccine (Astrazeneca-Oxford).
9695736|NCT04774835|Active Comparator|Standard aPS|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor.
9977657|NCT01363934|Experimental|Group D|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
10178536|NCT03812055||LSD|Subjects diagnosed or suspected to have any of the following lysosomal storage diseases: Gaucher disease, Fabry disease, Pompe disease, Mucopolysaccharidoses.
10178537|NCT03812055||Control|Subjects with no known lysosomal storage disorder
9683772|NCT04898751||Cutaneous toxicity|Patients who reported a cutaneous immune related adverse event following ICI initiation with appropriate chronology that indicates drug toxicity.
9683773|NCT04898881|Active Comparator|Breast Milk|2 ml of Breast milk given one time, two minutes prior to the heel lance
9683774|NCT04898881|Other|24 %Sucrose|0.5 ml sucrose to be given once, two minutes prior to the heel lance
9683775|NCT04898842|Experimental|4 stage bowel obstruction diet|"All eligible participants will be assessed by a specialist dietitian and a diet history and symptoms will be recorded. Depending on the degree of sub-acute bowel obstruction, symptoms and type of diet being followed, patients will be given detailed instructions on which stage of the 4 stage diet to use. They will be followed up by telephone or face to face weekly for a 4 week period and shown how to alter their diet by moving up and down the stage of the diet if symptoms resolve or worsen. This is current standard of care.~Additional assessments will be carried out at the start and end of the study when participants will complete the Memorial Symptom Assessment Scale (MSAS) and EORTC QLQ-30 quality of life questionnaire. They will be asked to complete a daily diet diary, and an 'ease of use' questionnaire at the end of the 4 week period."
10178538|NCT03812198|Active Comparator|Group 1-1|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 modified release tablet; LEO 32731 blend, hard capsule; LEO 32731 API hard capsule (reference formulation).
9683776|NCT04898907|Experimental|ANG-3777 (Therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
9683777|NCT04898907|Placebo Comparator|Normal Saline|The placebo will be administered as a single dose on separate occasions intravenously as 30-minute infusions on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
9683778|NCT04898907|Active Comparator|Moxifloxacin Hydrochloride|The comparator will be administered as a single dose oral Moxifloxacin Hydrochloride tablet (open-label), with a total of 240 mL of water. There will be a minimum washout of 3 days between each study drug administration.
9683779|NCT04898907|Experimental|ANG-3777 (Supra-therapeutic Dose)|Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
9683780|NCT04898985||500 patients in the LLS COVID-19 Registry with no/limited antibody response|Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in this Research Study.
9683781|NCT04898985||500 patients also participating in the LLS COVID-19 Registry with antibody response|500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled in this Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).
9683782|NCT04898647|Experimental|Patients with confirmed HVS|presence of unexplained elsewhere fundoscopic abnormalities AND either IgM concentration above 30 g/L (densitometry) or cryoglobulin activity
9683783|NCT04898647|Active Comparator|Patients with confirmed absence of HVS|
9683784|NCT04898647|Experimental|Remaining patients|
9977658|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by IV|Darbepoetin alfa 30ug/kg once intravenously
9977659|NCT01363934|Experimental|Group H|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
9683787|NCT04898855|Experimental|SONO (internet-delivered cognitive-behavioral treatment for insomnia)|Participants assigned to the experimental group receive immediate access to the SONO program, a web-based self-guided cognitive-behavioral intervention for insomnia consisting of 6 weekly sessions. A certified psychologist will monitor the participant's progress and provide feedback.
9683788|NCT04898855|No Intervention|waitlist control|Participants assigned to the waitlist control group receive access to the SONO program after 7 weeks.
9683789|NCT04898868|Experimental|vaginal delivery with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
9683790|NCT04898868|Experimental|vaginal delivery with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
9977660|NCT01363934|Experimental|Group I|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
9977661|NCT01363934|Experimental|Group J|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
10178539|NCT03812198|Active Comparator|Group 1-2|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 soft capsule; LEO 32731 gastro-resistant capsule; LEO 32731 API hard capsule (reference formulation).
10178540|NCT03812198|Experimental|Group 2-1|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
10178541|NCT03812198|Experimental|Group 2-2|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
9683791|NCT04898868|Experimental|CS with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
9683792|NCT04898868|Experimental|CS with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
9683793|NCT04898699|Experimental|PrEP+|PrEP+ is an experimental pre-exposure prophylaxis (PrEP)-focused prevention strategy providing daily oral tenofovir/emtricitabine (TDF/FTC) in combination with two adherence self-management interventions: (1) real-time feedback from point-of-care urine drug-level assay, (2) HIV self-testing and (3) 2-way text message reminders in addition to standard of care HIV risk-reduction counseling among male clients (MC) of female sex workers in Kisumu, Kenya.
9683794|NCT04898582|Other|20 women 20-60 years old with sensitive skin and persistent centrofacial erythema of rosacea|"The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions. The subjects were allowed to use their habitual foundation and makeup products on the whole face.~The side of application of the product M89 Probiotic Fractions (right or left side of the face) was randomized among the subjects.~The assignment of subject number and subsequent placement on the randomization chart were made in order of appearance at the study centre on the first day."
9683795|NCT04898803||conventional gastroscopy training course|physicians receive the DGVS-recommended training, consisting of a 2-day course with 1 hour of simulator training
10178542|NCT03812198|Experimental|Group 2-3|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
9683796|NCT04898803||extended simulator course|physicians receive a two-day simulator course with a minimum of 6 hours of simulator training per trainee, structured in stages in the sense of progressive or mastery learning. The initial part of the training will be part-task training.
9683797|NCT04898608|Experimental|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
9683798|NCT04898608|No Intervention|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
10178543|NCT03812198|Placebo Comparator|Group 3-1|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
10178544|NCT03812198|Placebo Comparator|Group 3-2|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
9683799|NCT04898725|Experimental|Vit D Group (randomized)|Subjects will be randomly assigned to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks
9683800|NCT04898725|No Intervention|Control Group (randomized)|Subjects will be randomly assigned to receive a placebo for 8 weeks.
9683801|NCT04898725|Experimental|Preference Vit D Group (non-randomized)|Subjects with a strong preference to receive a daily vitamin D supplementation (4800IU daily) for 8 weeks.
9683802|NCT04898725|No Intervention|Preference no Vit D Group (non-randomized)|Subjects with a strong preference to receive usual care (not receiving vitamin D supplements) for 8 weeks.
9683803|NCT04899011||Middle ear surgery|
9683804|NCT04898816|Experimental|Group A|Application of cyanoacrylate tissue adhesive over the surgical wound
9683805|NCT04898816|Active Comparator|Group B|Suturing the surgical wound using braided black silk
9683806|NCT04898712|Experimental|Tranexamic Acid Arm|"Participants in the experimental arm will receive tranexamic acid (TXA) during surgery for CSDH evacuation with a single 1000mg intraoperative intravenous (IV) dose. Participants with a body weight 60-100kg will also receive a post-operative dose regimen of 500 mg TXA orally, 3 times a day (TID).~Weight deviations from this body weight range will be considered with a dose adjustment of 1000mg TXA two times a day (BID) for a body weight >100 kg, and 500 mg TXA BID for body weight <60kg."
9683807|NCT04898712|Placebo Comparator|Placebo Control Arm|Participants in the control arm will placebo according to the same administration regimen.
9683808|NCT04898387|Experimental|T4030 Group|
9683809|NCT04898387|Active Comparator|Ganfort Group|
9683810|NCT04898374|Experimental|Induction Arm|patients will receive three cycles of IC Gemcitabin/Cisplatin followed by radical CRT
9683811|NCT04898374|Active Comparator|Adjuvant Arm|Patients will receive radical CRT followed by three cycles of AC Gemcitabin/Cisplatin
10178545|NCT03812003|Experimental|remifentanil|After emergence and extubation of endotracheal tube, remifentanil 1mcg/kg were diluted with 0.9% saline to 50 ml, added in IV bag, and drip for 30 minutes.
10178546|NCT03812003|No Intervention|no intervention|After emergence and extubation of endotracheal tube, 0.9% saline 50ml were added in IV bag and drip for 30 minutes.
10178547|NCT03812211|Active Comparator|Active Supplement|Participants will be allocated in a randomized, double-masked manner to receive a multi-faceted supplement for the 12-week duration of the study
9683812|NCT04898400|Experimental|Subjects with Obesity|Subjects will be recruited to undergo endoscopic sleeve gastroplasty. The subjects will be studied at baseline, 30, 60, 90 days after procedure
9683813|NCT04898569|Experimental|Ferinject®|
9683814|NCT04898569|Placebo Comparator|Normal saline|
9695737|NCT04774835|Experimental|aPS + HIVST|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor as well as the option to do HIV self-testing (HIVST) instead of testing at the local HTS location.
9683815|NCT04898361|Active Comparator|PFO closure|Patients with embolic stroke of undetermined source (ESUS) with patent foramen ovale (PFO) eligible for interventional PFO occlusion receiving a structured electrophysiological study due to palpitations before the PFO closure. Extensive cardiac monitoring.
9683816|NCT04898361|No Intervention|NO PFO|Patients with embolic stroke of undetermined source (ESUS) with NO patent foramen ovale (PFO) receiving a structured electrophysiological study due to palpitations. Extensive cardiac monitoring.
10178548|NCT03812211|Placebo Comparator|Placebo|Participants will be allocated in a randomized, double-masked manner to receive a placebo supplement (the placebo will be made of microcrystalline cellulose, and will be matched in size, appearance, taste and caloric value) for the 12-week duration of the study
9683817|NCT04898348|Placebo Comparator|Placebo (after Vancomycin pre-treatment)|3 capsules twice a day dosing of Placebo (after Vancomycin pre-treatment)
9683818|NCT04898348|Experimental|KBL697 (after Vancomycin pre-treatment)|3 capsules twice a day dosing of KBL697 (after Vancomycin pre-treatment)
9683819|NCT04898465|Experimental|Social Paediatric Intervention|Multiprofessional social paediatric meeting with the family.
9683820|NCT04898465|No Intervention|Control group|Normal post-DGA dental programme.
9683821|NCT04898335||Tendyne|all patients treated with a Tendyne Mitral Valve System
9683822|NCT04898101|Experimental|Cohort 1|Participants will receive a single 100 mg oral capsule dose of acalabrutinib and at 58 minutes postdose, participants will receive a single microtracer (<10 μg; <=1 μCi) [14C]ACP-196 as a 5 mL IV push over 2 minutes.
9683823|NCT04898101|Experimental|Cohort 2|Participants will receive a single 100 mL oral solution of acalabrutinib, 1 mg/mL oral solution containing a microtracer dose (<10 μg; <=1 μCi) of [14C]ACP-196.
9683824|NCT04898556|Active Comparator|Active Treatment|Patients who will undergo treatment with Intrarosa (Prasterone 6.5mg) in ovules, will apply one ovule a day before going to bed for 12 weeks.
9683825|NCT04898556|Placebo Comparator|Control Group|Patients who will not undergo any treatment for vulvovaginal atrophy for 12 weeks.
9683826|NCT04898205|Experimental|Treadmill Exercise with Supplemental Oxygen|Participants will receive 24 sessions (2 x week for 12 weeks) of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
9683827|NCT04898205|Sham Comparator|Treadmill Exercise with Air|Participants will receive 8 sessions (2 x week for 4 weeks) of treadmill exercise combined with air delivered via nasal cannula during exercise and 5-minutes of recovery. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
9683828|NCT04898205|Sham Comparator|Supplemental Oxygen Only|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of 6 liters per minute of continuous oxygen via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
9683829|NCT04898205|Placebo Comparator|No Intervention|Participants will receive 8 treatment sessions (2 x week for 4 weeks) of air via nasal cannula for 30 minutes at rest. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three minutes. They will then cross-over to 16 sessions of treadmill exercise combined with 6 liters per minute of supplemental oxygen via nasal cannula during exercise and 5-minutes of recovery. The first treadmill session will last 25% longer than the exercise tolerance test, but at a lower intensity, such that 80-100% of peak exercise intensity calculated from the exercise tolerance test MET is achieved within three sessions, after which time and intensity will be increased by no more than 0.5 METS, as tolerated based on symptoms and vitals. Heart rate, rhythm, and oxygen saturation will be continuously monitored, and blood pressure readings will be obtained every three to five minutes.
9683830|NCT04898296||Patients over 55 Years with coronary heart disease|Questionnaire and semistructured Interview 45 -60 minutes
9683831|NCT04898296||physical therapists working with patients with coronary heart disease|Focus group 60 -90 minutes
9683832|NCT04898088|Experimental|Conventional Therapy|
9683833|NCT04898088|Experimental|Conventional Therapy with Add-On MSC therapy|
9683834|NCT04898283|Experimental|10,000 MG01 + 10,000 T521|10,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
9683835|NCT04898283|Experimental|30,000 MG01 + 10,000 T521|30,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
9683836|NCT04898283|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
9695738|NCT04774978|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE continuously with ProbeFix
9695739|NCT04774861||CCTA Group|This is an all-comers group, of all ages and ethnicities who have been evaluated with a CCTA from 2017-2020.
9977662|NCT01363934|Experimental|Group K|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
10178549|NCT03812029|Experimental|EYP001a 100 mg BID|Oral dose twice daily for 12 weeks (84 days)
10178550|NCT03812029|Experimental|EYP001a 200 mg QD|Oral dose once daily for 12 weeks (84 days)
9683837|NCT04898218|Active Comparator|Group A (Aerobic Exercise Group)|Warm-up exercises were performed by the participants on a cycle ergometer for a duration of 5-10 minutes. Group A was advised to start walking at a comfortable speed on a treadmill for the duration of 30-60 minutes; the intensity of the exercises was 55-75% of MHR, calculated by using a Karvonen method. Initially with the minimum intensity that was gradually raised up to the intensity of Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase for 5-10 min.
9683838|NCT04898218|Active Comparator|Group B (Resistance Exercise Group)|Group B was instructed for strengthening exercises of ten major muscle groups that include Biceps, Triceps, Pectoralis Major, Deltoid, Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight-bearing exercises was calculated using 1 Repetition Maximum (RM) method.
10178551|NCT03812029|Experimental|EYP001a 400 mg QD|Oral dose once daily for 12 weeks (84 days)
10178552|NCT03812029|Placebo Comparator|Placebo|Oral dose twice daily for 12 weeks (84 days)
10178553|NCT03812029|Experimental|EYP001a 100 mg QD|Oral dose once daily for 12 weeks (84 days)
10178554|NCT03811938|Active Comparator|Pulmonary Vein Isolation|Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.
9683839|NCT04898218|Experimental|Group C (Osteoanabolic Exercise Group)|"Group C was performed Osteoanabolic exercise divided into two different phases:~Aerobic Conditioning Phase Participants were instructed to walk on treadmill for 30-60 min. The intensity of the exercises was 55-75% MHR, calculated by Karvonen method. Intensity gradually raised up to the Targeted Heart Rate (THR). Once the THR is achieved the intensity was gradually decelerated and patient proceeded for the cool-down phase. The participants performed 3 days per week for 12 weeks on alternative days.~Anaerobic (Resistance) Conditioning Phase Resistance training was started on every alternative day of the aerobic conditioning (3 days per week) for 45 min. The intensity of the weight-bearing exercises was calculated using 1 RM method. Resistance training muscle and protocol was the same as for Group B. The participants performed warm-up and cool down similar to that of group A and group B."
9683840|NCT04898426|No Intervention|Standard Bowel Preparation Instruction|Patients receive the standard-of-care bowel preparation instruction.
9683841|NCT04898426|Experimental|Enhanced Bowel Preparation Instruction|Patients receive enhanced instructions (SMS, phone call, info website) in addition to the standard-of-care bowel preparation instruction.
9683842|NCT04898452||Patients needing antibiotics infusion|Patients needing antibiotics infusion A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
9683843|NCT04898452||Next of kin|Next of kin A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
9683844|NCT04898452||Health professionals|A new model of interaction across health services with use of welfare technology and telemedicine Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
9683845|NCT04898023|Experimental|zinc-green tea extract-ascorbic acid|Compounded capsules will be prepared containing each 50mg of zinc citrate, 400mg of green tea extract, and 100mg of ascorbic acid. Randomized patients will take two (2) capsules taken orally two (2) hours following a meal twice daily x5 days.
9683846|NCT04898023|Placebo Comparator|Placebo|"Compounded capsules will be prepared containing each 650mg of microcrystalline cellulose.~Randomized patients will take two (2) capsules taken orally two (2) hours following a meal twice daily x5 days"
9683847|NCT04898504|No Intervention|2nd line chemotherapy|2nd line chemotherapy is the current standard treatment for patients with CRLM and progression on 1st line chemotherapy. We will include 18 patients in this treatment arm thus empowering the study to show non-inferiority between HAI and 2nd line chemo.
10178555|NCT03811938|Experimental|Low voltage ablation|Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.
9683848|NCT04898504|Active Comparator|Liver transplant|Liver transplantation (LTX) has emerged as a possible solution for some patients with unresectable CRLM who otherwise have good prognosis based on available scorings systems. We will include 9 patients in this treatment arm. They will be given 2nd line chemotherapy followed by Liver-Tx. Including 9 patients will only empower the study to show non-inferiority between Liver-Tx and 2nd line chemo (where we expect a large difference in the primary end-point) but not between HAI and Liver-Tx.
9683849|NCT04898504|Active Comparator|Hepatic artery infusion (HAI) chemotherapy|The biological rationale for intra-arterial chemotherapy is that the hepatic artery rather than the portal vein is responsible for most of the blood supply to liver tumors. Floxuridine has for years been established as viable treatment option for similar patients at The Memorial Sloan Kettering Cancer Institute, New York, but has yet to gain foothold in Europe despite promising results. We will include 18 patients in this arm receiving 6 cycles of HAI-Floxuridine and a full course of 2nd line chemotherapy.
10178556|NCT03812081|Active Comparator|Group A Baska Mask|In which Baska Mask Airway (size 3,4,5) will used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
10178557|NCT03812081|Active Comparator|Group B Proseal Mask|In which Laryngeal Mask Airway- Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
10178558|NCT03811899|Experimental|18F-DCFPyL PET/CT imaging|We will use technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
9683850|NCT04898075|Experimental|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
9683851|NCT04898075|Placebo Comparator|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
9683852|NCT04898478|Experimental|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|This arm will consist of a behavioral intervention to increase treatment seeking among Pacific Islanders with opioid use disorders.
9683853|NCT04898114|Experimental|NebMag|Nebulized magnesium sulfate and oral sildenafil
9683854|NCT04898114|Placebo Comparator|Control|Nebulized placebo (isotonic saline) and oral sildenafil
9683855|NCT04898231|Active Comparator|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
9683856|NCT04898231|Active Comparator|Methylprednisilone (steroids)|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
9683857|NCT04898231|Active Comparator|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
9683858|NCT04898257|Other|Lactibiane Tolerance®|30 consecutive patients with IBS-D and an increased intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA will receive the multistrain probiotic Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day (30 minutes before breakfast and 30 minutes before dinner) for 30 days treatment. At the end of treatment, patients will repeat intestinal permeability assessment by 51Cr-EDTA or 99mTc-DTPA.
9683859|NCT04898270|Experimental|MARTAs combined with flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity.~Other Names:~Fute tables, Fluanxol~Multi-acting receptor-targeted antipsychotics (MARTAs): clozapine, olanzapine, quetiapine."
10178559|NCT03811860|Active Comparator|Once Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium once daily at bedtime. After 4-6 days, a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (twice daily dosing, if they have not already done so). Frequency of selected medication use is noted.
9683860|NCT04898270|Active Comparator|Multi-acting receptor-targeted antipsychotics (MARTAs)|clozapine, olanzapine, quetiapine
9683861|NCT04898140||Healthy volunteers|Individuals who were not infected and not having been demonstrated COVID-19 symptoms since December 2019.
9683862|NCT04898140||Recovered|Individuals who were recovered from COVID-19 with different severity.
9683863|NCT04898140||Vaccinated|"Individuals who were vaccinated against SARS-CoV-2 with Sputnik V vaccine."
9683864|NCT04898140||Special group|Individuals who recovered from COVID-19 concomitant with other immune-related comorbidities (tuberculosis, chronic obstructive pulmonary disease, HIV infection, hematological neoplasia).
9683865|NCT04898127|Experimental|Rapid test and concert|Participants in this arm will be offered access to a concert, after a negative rapid test.
9683866|NCT04898127|No Intervention|Control|Participants in this are will not be offered access to a concert during the study period.
9683867|NCT04897997||non smokers|never having smoked patients
9683868|NCT04897997||smokers|actively smoking patients
9683869|NCT04897997||acute coronary syndrome|patients with the coronary indication of ACS
9683870|NCT04897997||stable|patients with the coronary indication of stable or silent ischemia
9683871|NCT04897984|Experimental|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
9683872|NCT04897971||Spine implant associated infection cohort|Adult patients undergoing revision spine surgeries with suspected infection of previous instrumentation.
9683873|NCT04897828||Covered Stent Group|Patients with a dysfunctional hemodialysis vascular access undergoing treatment procedure using a covered stent (stent graft).
9683874|NCT04897724|Other|patients have carious lesions in one or more surface of molars and premolars|patients received direct composite restorations using a nanohybrid and a nonofil composite restorations
10178560|NCT03811860|Active Comparator|Twice Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium divided into two daily doses. After 4-6 days a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (once daily dosing, if they have not already done so).Frequency of selected medication use is noted.
9683875|NCT04897958||Degarelix|Reference group
9683876|NCT04897958||Leuprolide|Exposure group
9683877|NCT04897633|Experimental|Patients ON|Patients will performed Simon's task with tDCS active or sham when treatment is OFF (for standard care procedure)
9683878|NCT04897633|Experimental|Patients OFF|Patients will performed Simon's task with tDCS active or sham when treatment is ON (for standard care procedure)
9683879|NCT04897633|Experimental|Healthy volunteers|Healthy volunteers will performed Simon's task with tDCS active or sham
9683880|NCT04897685|Experimental|Nature-based treatment group|The participants in the treatment group were offered 12 nature-based group therapy sessions in addition to standard care.
9683881|NCT04897685|No Intervention|Control group|The participants in the control group continued treatment as usual in the health care services.
9683882|NCT04897789||children/pregnant women|children/pregnant women (2,310)
9683883|NCT04897789||parents|parents (2,310)
10178561|NCT03812172||Blacks/Hispanics with Heart Failure|Blacks/Hispanics with heart failure due to transthyretin cardiac amyloidosis will be identified by 99mTc-PYP scintigraphy. Those with transthyretin cardiac amyloidosis will be further subtyped into those with a genetic cause (ATTRm) and those with a non-genetic cause (ATTRwt - wild type transthyretin cardiac amyloidosis).
9977663|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by SC|Darbepoetin alfa 30ug/kg once subcutaneously
9683884|NCT04897789||classrooms/teachers|classrooms/teachers (840)
10178562|NCT03811964|Other|primary sleep-wake disorder|Subjects with primary sleep-wake disorder
10178563|NCT03811964|Other|neurological pathology|subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep
10178564|NCT03811964|Other|psychiatric pathology|subject presenting a psychiatric pathology with disorder of the controls of the wake and the sleep
10178565|NCT03811964|Other|ophthalmological pathology|subject presenting an ophthalmological pathology with possible alteration of the photoreception and / or phototransduction
9683885|NCT04897789||home visitors|home visitors (630)
10178566|NCT03811964|Other|photosensitivity|subjects with photosensitivity with regulation disorder of sleep and wake
9683886|NCT04897789||center directors|center directors (493)
9683887|NCT04897789||program directors|program directors (140)
9683888|NCT04897854|Active Comparator|Immediate treatment|The treatment schedule will be direct (start within 3 weeks of bate of diagnosis) FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.
9683889|NCT04897854|Active Comparator|Delayed treatment|"The treatment schedule will be delayed treatment (based on symptoms) with FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.~Chemotherapy will start as soon as one of the following criteria is met:~Decline in performance status to ECOG < 1 or Karnofsky < 80%~Weight loss more than 5% of the total body weight from the time of study entry~Persistent nausea requiring medication~Pain requiring regular narcotic analgesics~Development of clinically significant third-space fluid collections~Liver function deterioration in the presence of progressive liver metastases"
9683890|NCT04897880|Experimental|Osteosarcoma [arm closed]|
9683891|NCT04897880|Experimental|Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid Tumor|
9683892|NCT04897880|Experimental|Neuroblastoma [arm closed]|
9683893|NCT04897932|Active Comparator|Adult nocturia|Use of device over 28 days
9683894|NCT04897932|Active Comparator|Adult urge urinary incontinence|Use of device over 28 days
9683895|NCT04897932|Active Comparator|Adult frequency urinary incontinence|Use of device over 28 days
9683896|NCT04897932|Active Comparator|Adult functional incontinence|Use of device over 28 days
9683897|NCT04897737|Experimental|Intervention|HIV self-testing kits and counseling on use for participant and partner use + enhanced adherence counseling including urine tenofovir test to provide biofeedback in women using PrEP
9683898|NCT04897737|No Intervention|Control|Standard of care intervention including facility based HIV testing, referral for partner to attend facility for testing, and PrEP adherence counseling without biofeedback
9683899|NCT04897815||20 patients with type 2 diabetes mellitus|Fasting blood glucose and TCD will be measured in 20 patients with type 2 diabetes mellitus, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
9683900|NCT04897815||20 healthy volunteers whose sex and age and BMI matched with the experimental group|Fasting blood glucose and TCD will be measured in healthy control group, and the data of Vm, PI and cerebrovascular reactivity of cerebral artery will be obtained. One hour after drinking 300ml lukewarm water which has dissolved 75g glucose powder, the blood glucose will be detected again and TCD examination will be performed again.
9683901|NCT04897906|Experimental|Experimental group|Experimental group; It is the group that will be given mother and neonatal care education.
9683902|NCT04897906|No Intervention|Control Group|Control group; It is the group in which no intervention will be made other than data collection.
9683903|NCT04897893|Experimental|Experimental Treatment|All subjects enrolled in the study will receive an identical dose of 2g/day (4 capsules of MAG-EPA) which will be taken by the subject at home. The duration of treatment should not be prolonged in the event of missed doses, that is, treatment should end on the 84th day as planned. A deviation of ± 3 days is acceptable, which means that treatment can be stopped from day 81 to day 87 of subject's participation.
9683904|NCT04897555|Experimental|LLLT Active Treatment|LLLT Therapy will be administered to the treatment site.
10178567|NCT03811964|Other|group control|healthy subject
9683905|NCT04897555|No Intervention|No LLLT Comparator|No LLLT Therapy will be administered to the comparator site.
9683906|NCT04897516|Experimental|Short regimen of benznidazole|Participants will receive an investigational treatment of benznidazole for 2 weeks.
9683907|NCT04897516|Active Comparator|Standard treatment with benznidazole|Historical controls who received the standard treatment of benznidazole (8 weeks).
9683908|NCT04897568|No Intervention|Control|The control group will consist of each participant and clinic before the intervention (baseline, first 2 months).
9827797|NCT02468934|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
10178568|NCT03811977|Experimental|Test group|Test group will receive investigational product - lutein syrup (2 mg/mL; daily dose 20 mg). Participants in this group will test continuous administration of investigational product for 12 weeks.
10178569|NCT03811977|Placebo Comparator|Placebo group|Placebo group will receive placebo product - placebo syrup (lutein 0 mg/mL; daily dose 0 mg). Continuous administration of placebo product for 12 weeks.
10178570|NCT03811795|Other|Arm 1-Repeat Cryoballoon Ablation|Subjects will be randomized to repeat cryoballoon ablation.
10178571|NCT03811795|Other|Arm 2-Radiofrequency Ablation|Participants will have radiofrequency ablation guided by high-fidelity mapping (Rhythmia) following an initial cryoballoon ablation.
10178572|NCT03811990|No Intervention|Control|
10178573|NCT03811990|Active Comparator|Intervention|
10178574|NCT03811730|Experimental|TEE group|Eligible patients would be conducted TEE examination by researcher A,The examination results are judged by A and provided to the physician of this patient,
10178575|NCT03811730|Active Comparator|TTE group|Eligible patients would be conducted TTE examination by researcher B,The examination results are judged by B and provided to the physician of this patient,
10178576|NCT03811717|Experimental|FAST+EX - FAST|FAST+EX then FAST alone
10178577|NCT03811717|Experimental|FAST - FAST+EX|FAST alone then FAST+EX
10178578|NCT03811743|Experimental|Adolescents Participants|Adolescents will participate in the Dyad Plus program along with their caregivers. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
10178579|NCT03811743|Experimental|Caregivers of adolescents participants|Adult caregivers will participate in the Dyad Plus program along with their youth participants. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
9683909|NCT04897568|Active Comparator|Patient decision aid|The intervention group will consist of each participant and clinic once they move to the intervention phase (stepped-wedge design: practices will be randomized into step 1, 2 or 3; for step 1: the intervention will start at 2 months, for step 2: the intervention will start at 4 months, for step 3: the intervention will start at 6 months).
9683910|NCT04897542|Experimental|Patients will undergo a Gallium-68 NODAGA-JR11 PET/CT as well as a Gallium-68 DOTATATE PET/CT|"Each patient receive a single intravenous injection of Gallium-68 DOTATATE (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.~All patients have to do a Gallium-68 NODAGA-JR11 PET/CT scan (40ug/150-200MBq, 40-60 min post-injection) for comparison on the next day of DOTATATE scan."
9683911|NCT04897503|Active Comparator|CXL using Riboflavin/Dextran solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 20% dextran
10178580|NCT03811782|Experimental|Single-task Training Group|Single-task walking group
10178581|NCT03811782|Experimental|Dual-task Training Group|Dual-task walking group
9683912|NCT04897503|Active Comparator|CXL usinng Riboflavin/Methylcellulose solution|Corneal collagen crosslinking using 0.1% riboflavin mixed with 1.0% hydroxypropylmethylcellulose ( HPMC)
10178582|NCT03811782|Experimental|Analogy Training Group|Analogy walking group
10178583|NCT03811925|Other|DCB|
10178584|NCT03811925|Other|Stenting|
9683913|NCT04897386|Experimental|Duvalizumab Combined With Neoadjuvant Chemotherapy|
9683914|NCT04897334|Active Comparator|Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
10178585|NCT03811639|Active Comparator|RF ablation|Patients treated with point-by-point radio-frequency ablation
10178586|NCT03811639|Experimental|Cryoballoon ablation|Patients treated with cryoballoon ablation
9683915|NCT04897334|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of sham tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
9683916|NCT04897321|Other|Treatment Phase|During the treatment phase, the participant receives an infusion of the B7-H3-CAR T cells that were made in the Collection and Manufacturing Phase. Chemotherapy is given for several days prior to the cellular infusion. Patients are then monitored for possible side effects, as well as effects of the treatment on their cancer.
9683917|NCT04897126|Active Comparator|Experimental group|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
9683918|NCT04897126|Placebo Comparator|Placebo group|The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.
10178587|NCT03811613|Experimental|Photobiomodulation group|"17 Parkinson´s disease patients were randomly assigned to the photobiomodulation group (experimental group).~Intervention: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength in six 1-minute blocks alternating the LEDs between the right and left temples, with a 30-second rest between blocks."
10178588|NCT03811613|Sham Comparator|Sham group|"18 Parkinson´s disease patients were randomly assigned to the sham group.~Intervention: Procedures for the sham group were identical as the photobiomodulation one, except that patients received photobiomodulation during only 5 seconds followed by 55 seconds with no treatment (equalling 1/12th of the energy used for the intervention group)."
10178589|NCT03811704|Experimental|Experimental group|Hepatectomy procedures were performed under Laparoscopic surgical navigation system and Indocyanine Green guidance.
10178590|NCT03811652|Experimental|NSCLC-Sq/HNSCC|Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
9683919|NCT04897308|Active Comparator|Suprascapular nerve block|This group will include will under go suprascapularnerve block as following :10 ml of .5% bupivacaine and 2 ml of methylpradnisolon 40mg/ml
9683920|NCT04897308|Active Comparator|Hydrodilatation of shoulder capsule|This group will undergo intraarticular hydrodilatation by injection of :first lidocaine10ml%followed by 1ml of methylprednisolon 40mg/ml and finally 20ml of .9 % sodium chloride slowly in the gleno humeral joint
9683921|NCT04897308|Active Comparator|Hydrodilatation of shoulder interval|This group will undergo interval hydrodilatation by injection of :first mepivacaine 10ml folowed by 20ml of sterile water slowly in the shoulder interval
10178591|NCT03811652|Experimental|Small Cell Lung Cancer|Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
10187989|NCT03720600|Other|Waitlist-Control|"Participants in the waitlist-control condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will complete an initial set of questionnaires. For the following two weeks, they will be asked to complete multiple daily momentary assessments daily. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires, watch a voice-guided PowerPoint on MAB strategies for coping with discrimination, and complete a qualitative exit-interview."
10187990|NCT03720600|No Intervention|No-EMA Control|"Participants in the No-EMA Control condition will only complete questionnaires at T1 and T2."
10178592|NCT03811652|Experimental|Colorectal Cancer|Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
9683922|NCT04897191||Healthy|Healthy people age 20-70 years
9683923|NCT04897113|Experimental|plasmapheresis with albumin compensation|a course of hardware plasmapheresis procedures with replacement by colloidal (5% albumin solution) and crystalloid solutions (saline) in a ratio of 1: 3
9683924|NCT04897113|Experimental|plasmapheresis without albumin compensation|a course of hardware plasmapheresis procedures without replacement by albumin solution, only crystalloid solutions (saline).
9683925|NCT04897100|Experimental|Needle tenotomy|
9683926|NCT04897100|Active Comparator|Blade tenotomy|
10178593|NCT03811652|Experimental|Pancreatic Ductal Adenocarcinoma|Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
10178594|NCT03811652|Experimental|Metastatic Castration-Resistant Prostate Cancer|Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
9683927|NCT04897230|Active Comparator|Hatha Yoga Condition|An experienced yoga instructor led the 30 minutes yoga condition session which consisted of 5 minutes warm up, 5 minutes breathing exercises, and 20 minutes yoga poses practice. The yoga props were used according to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably.
9683928|NCT04897230|Placebo Comparator|Control Condition|Participants in the control condition were watching a neutral video on a television.
9683929|NCT04897477|Experimental|combination of Azacytidine, Bendamustine and Piamprizumab|combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma, every 28 days
9683930|NCT04897464|Experimental|Treatment|
10178595|NCT03811652|Experimental|Other advanced/metastatic target expressing solid tumors|Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
10178596|NCT03811691|Other|1.5 Tesla MRI Scan|Subjects will undergo 1.5T MRI exam
9683931|NCT04897360|Experimental|Normocapnic SRT, Hypocapnic SRT, Recovery SRT|Sharpened Romberg Test
9683932|NCT04897243||Multidisciplinary model of care|The Chronic Viral Illness Service at the Glen hospital of the MUHC will provide care with a multidisciplinary assessment, according to local current standard practice. Each newly-referred patient at the CVIS will be first received by a dedicated nurse, who then orients referral to a physician and/or a social worker and/or a pharmacist.
9683933|NCT04897243||Physician-only model of care|The Jewish General Hospital will provide care as per current local standard practice. Each newly-referred patient will be assessed by a clinician. Blood tests will be performed by central laboratory nurses who are not part of the HIV clinic.
10178597|NCT03811691|Other|3 Tesla MRI Scan|Subjects will undergo 3T MRI exam
10178598|NCT03811678|Experimental|50 mg single dose|It includes two groups, one group is a pilot study, 2 healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet . Another group is a formal study, healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
9683934|NCT04897178||Fetuses with normal anatomy|Fetuses with normal anatomy scan who demonstrate no structural abnormalities of different systems (CNS, chest and heart, abdomen, skeletal system)
9683935|NCT04897178||Fetuses with abnormal anatomy|Fetuses with abnormal anatomy scan who demonstrate any structural abnormalities that can be detected with ultrasound
9683936|NCT04897269|No Intervention|Control group|In the control group, the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg two times per day for 14 days, without any progesterone supplementation. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
9683937|NCT04897269|Experimental|Study group|In the interventional group,the patients will be indicated with standard protocol, micronized progesterone (Cyclogest pessary) 400mg x 2 per day for 14 days, supplemented with intramuscular progesterone (Progesterone 25mg/ml) 25 mg x 2 at one time per day for 14 days. If the beta-hcg test is positive, the patients will be treated with the same protocol and followed till 7 weeks of pregnancy when the fetal heart can be confirmed
9683938|NCT04896905||Isolation group with active Covid19|Patients assigned to rehab which had to be treated in isolation wards dur to active disease
9683939|NCT04896905||Post-Covid-group|Patients assigned to rehab after active disease, still having restrictions in activity and particiaption
9683940|NCT04896905||Control group|Pateints assigned to rehabilitation in the same time period without any signs of Sars-coV-2 infection
9683941|NCT04897139|Experimental|treatment arm|treatment arm
9683942|NCT04897204|Experimental|Left Atrial Appendage Electrical Isolation with One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion and additional left atrial appendage electrical isolation operation.
9683943|NCT04897204|Other|One-stop treatment of atrial fibrillation|The patients received routine catheter ablation of atrial fibrillation with left atrial appendage occlusion.
10178599|NCT03811678|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg Kangdaprevir Sodium Tablet (N=20) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
10178600|NCT03811678|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
10187991|NCT03720574|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
9683944|NCT04897048|Experimental|Oxygen|Supplemental oxygen will be applied via a mask during CPET
9683945|NCT04897048|Sham Comparator|Air|Sham ambient air will be applied via mask during CPET
9683946|NCT04897035|Experimental|Subjects with Lower Extremity Lymphedema and phlebolymphedema|Lower Extremity Lymphedema and phlebolymphedema
9683947|NCT04896996|Experimental|Whole eggs (WE)|consume 10 additional eggs per week
9683948|NCT04896996|Experimental|Egg substitute (ES)|consume the yolk-free egg substitute equivalent to 10 eggs per week
9683949|NCT04896996|No Intervention|Control group|Regular school meals
9683950|NCT04896892||Total Knee Arthroplasty|Patients in this group will be undergoing total knee arthroplasty.
9683951|NCT04896892||Total Hip Arthroplasty|Patients in this group will be undergoing total hip arthroplasty.
9695740|NCT04774744|Experimental|Group I (digital health coaching program)|Patients receive the PACK Health digital health coaching program over 3 months consisting of communication initiated by either the PACK Health coach or the patient through either text, e-mail, or phone call, to provide education and support related to a specific topic such as fatigue, nutrition, or exercise.
9695741|NCT04774744|Active Comparator|Group II (standard of care support services)|Patients receive standard of care support services consisting of a telephone triage line that patients may call when experiencing physical or psychological concerns, or with any other questions related to their disease or treatment.
9695742|NCT04774705|Experimental|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|
9695743|NCT04774705|Placebo Comparator|Control group|For the SNV placebo group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
9695744|NCT04774757|Experimental|Systemic therapy sequenced PALND|All received systemtic therapy (at most two lines).
9695745|NCT04775043||Control population|First part of the study for the HFRDIS Questionnaire French validation
9695746|NCT04775043||Patients on hormone therapy for breast cancer|Second par of the study for the HFRDIS questionnaire use on patients on hormone therapy for breast cancer
9695747|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to high frequency oscillating ventilator.
9695748|NCT04774848|Active Comparator|High Frequency Jet Ventilation (HFJV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFJV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to high frequency oscillating ventilator.
9695749|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) with intrathoracic liver|Babies known to have the presence of the liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies with intrathoracic liver and randomized to HFJV.
9695750|NCT04774848|Active Comparator|High Frequency Oscillatory Ventilation (HFOV) without intrathoracic liver|Babies who do not have any liver in the intrathoracic space will be placed on the HFOV at delivery or as soon as possible after consent. During analysis, these babies will be compared to babies without intrathoracic liver and randomized to HFJV.
9695751|NCT04774874|Experimental|FOL- 005 (0.1 %)|topical formulation
9695752|NCT04774874|Experimental|FOL -005 (0.5 %)|topical formulation
9695753|NCT04774874|Experimental|FOL -005 (1.5 %)|topical formulation
9695754|NCT04774874|Placebo Comparator|Vehicle|topical formulation
9695755|NCT04775004|Active Comparator|Bone marrow venting procedure (BMVP)|Subjects randomized in the OR to undergo BMVP surgical augmentation
9695756|NCT04775004|Active Comparator|Platelet rich plasma (PRP)|Subjects randomized in the OR to undergo PRP surgical augmentation
9695757|NCT04774822||Sequential Enrollment|Enrollment based on default inclusion criteria listed below
9695758|NCT04774822||Enrichment Enrollment|Enrollment based periodic statistician-activated inclusion criteria adjustment to attain statistically adequate distribution
9695759|NCT04774770|Experimental|HED-Start Intervention arm|Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.
9695760|NCT04774770|No Intervention|Standard care arm|Participants assigned to the standard care arm will proceed with routine standard care.
9695761|NCT04774939|Active Comparator|EVLA only|Only main trunk/trunks with venous reflux will be treated
9695762|NCT04774939|Active Comparator|EVLA and sclerotherapy of tributaries|Main trunk/trunks with venous reflux will be treated combined with foam sclerotherapy
9977664|NCT01363947|Experimental|Dose Escalation Cohort (DNIB0600A)|Participants will receive IV infusions of DNIB0600A at doses ranging from 0.2 milligrams/kilogram (mg/kg) to 2.8 mg/kg q3w until dose-limiting toxicity (DLT) is reached, or up to 28 cycles.
9695763|NCT04774783|Experimental|Low-Level Laser Therapy|Over the course of the study, participants within this group will receive 12 sessions of Low-Level Laser Therapy (LLLT) treatment over a duration of 4 weeks using the Richmar TheraTouch LX2 device. Treatment location will be determined through assessment of each qualifying participant. Treatment sessions will be limited to a single area of the body associated with the qualifying participant's primary pain complaint.
10178601|NCT03811678|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
9695764|NCT04775121|Experimental|Experimental|Oral administration of 20 g Deuterium Glucose on a 3-hour period followed by sequential blood sampling to sort monocytes on a 30-days period of time
9695765|NCT04774653||MIH Group in short stature from 6-8 years old|Molar Incisor Hypomineralization in stunted children aged from 6-8 years
9695766|NCT04774653||HSPM Group in short stature from 5-8 years old|Hypomineralization of Second Primary Molars in stunted children aged from 5-8 years
9695767|NCT04774653||Both MIH &HSPM Group in stunted (from 5-8) years old|When both primary molars and permanent teeth( First permanent molars & permanent incisors) are hypo-mineralized in children with short stature with age range from 5-8 years old
9695768|NCT04774731|Experimental|Whole Body Vibration|
9695769|NCT04774731|No Intervention|Control|
9683952|NCT04896944||ICU Centre Hospitalier de Saint Denis|
9683953|NCT04896944||ICU Hôpital Ambroise Paré Boulogne|
9683954|NCT04896710|Experimental|Self administration|The participant will self administer the SD Biosensor. Their rapid antigen test result will be compared to health care professional administered SD Biosensor
10178602|NCT03811678|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
9683955|NCT04896801|Experimental|MR-guided prostate stereotactic body radiotherapy|Patients will receive MR-guided RT in 5 fractions over 7 days (daily excluding weekend, i.e. start on Wednesday or Thursday, until Tuesday or Wednesday respectively the week after).
9683956|NCT04896853|Experimental|Treatment|Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells.
9683957|NCT04896684||Patient screened or followed-up for IBS or IBD or colorectal cancer|Blood and colon biopsy sampling
9683958|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|
10178603|NCT03811678|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
10178604|NCT03811678|Experimental|100 mg multiple dose|Healthy subjects, receiving 100 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
9683959|NCT04897165|Experimental|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|
9683960|NCT04897165|No Intervention|Waitlist controls|
9683961|NCT04897009||Observational (biospecimen collection)|Patients undergo blood sample collection at baseline (prior to first NAC treatment), after taxane and prior to first dose of A/C (for patients receiving a taxane), end of NAC, 1-4 weeks and 6 months post-surgery. Patients also undergo tissue collection at 1-4 weeks and 6 months post-surgery.
10178605|NCT03811678|Experimental|200 mg multiple dose|Healthy subjects, receiving 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
10178606|NCT03811678|Experimental|400 mg multiple dose|Healthy subjects, receiving 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
9683962|NCT04896671|Experimental|Intervention group|Each participant joins a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes.
9683963|NCT04896671|No Intervention|Waitlist control group|They receive no treatments.
9683964|NCT04896515||Standard Nutrition Arm|"In INTENT (the parent study) participants will be randomised to the i) Standard Nutrition or ii) Intensive Nutrition arm. A brief description of each is below.~In ICU:~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~Parenteral Nutrition (PN) will only be used if the above methods have been attempted, or an absolute contraindication to enteral nutrition (EN) develops.~After ICU:~1. Nutrition management will be as per usual site management at that hospital."
9683965|NCT04896515||Intensive Nutrition Arm|"In ICU:~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose will be determined by the amount of energy received in the 24 hours prior to randomisation~The need for the intervention will be based on the adequacy of nutrition provision and assessed daily until ICU discharge~If there is an interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~1. An intensive nutrition intervention will be provided on the ward.~The goal of nutrition care across the hospital stay will be to ensure 80-100% of participant's estimated energy requirements are met."
9683966|NCT04896723||Chronic liver disease|
9683967|NCT04896723||Healthy volunteers|
10178607|NCT03811457|Experimental|Welgenaleucel (UWC19)|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage: 100mL in total Frequency:the first day, the second day, the third day Duration:total three times
10178608|NCT03811418|Experimental|Kanjinti/Pertuzumab plus Vinorelbine|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus vinorelbine.
10178609|NCT03811418|Active Comparator|Kanjinti/Pertuzumab plus Docetaxel|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus docetaxel.
10178610|NCT03811496||GD-PD|Patients and carriers of Gaucher disease with confirmed mutations in GBA gene who have developed Parkinson's disease symptoms
10178611|NCT03811496||GD-nonPD|Patients with Gaucher disease but no known Parkinson's symptoms
9683968|NCT04896762||Extrapulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with extrapulmonary system affection
9683969|NCT04896762||pulmonary presentation for COVID-19|patients with confirmed covid 19 disease who primarily presented with pulmonary disease
9683970|NCT04896788|Other|Monitoring of the immune response|Immune response controlled with blood sample at 3, 6, 12, 18 and 24 months
9683971|NCT04896450|Experimental|Test group|Test subjects receive GTR and early initiation of OTM.
9683972|NCT04896450|Active Comparator|Control group|Control subjects receive only GTR.
9683973|NCT04896359|Experimental|Vitamin C|i.v. infusion of 12.5 g vitamin C 48 h before surgery, immediately before surgery, and 48 h after surgery
9977665|NCT01363947|Experimental|Expansion Cohort (DNIB0600A)|Participants will receive 2.4 mg/kg, by IV infusion, of DNIB0600A q3w for up to 26 cycles.
10178612|NCT03811496||nonGD-nonPD|Non-Gaucher disease/healthy controls
10178613|NCT03811431|Experimental|CEUS guidance|SonoVue 2, 4 ml
10178614|NCT03811431|Experimental|Conventional US guidance|No drugs
9683974|NCT04896359|Placebo Comparator|Control|i.v. infusion of placebo 48 h before surgery, immediately before surgery, and 48 h after surgery
9683975|NCT04896281|Experimental|phenylalanine-free diet|phenylalanine-free diet for patients with hyperphenylalaninemia
9683976|NCT04896879||Patients|Patients with major LARS
9683977|NCT04896879||Informal caregivers|Informal caregivers of patients with major LARS
9683978|NCT04896879||Healthcare professionals|Healthcare professionals taking care for patients with LARS
9683979|NCT04896424|Other|Cryoballoon-based pulmonary veins isolation cohort|Patients treated with a 28-mm second-generation cryoballoon (Arctic Front Advance, Medtronic) for paroxysmal atrial fibrillation and screened over a 2-year post-ablation period.
9683980|NCT04896554|Active Comparator|quit smoking|patients who have quit smoking
9683981|NCT04896554|Active Comparator|not quit smoking|patients who have not quit smoking
9683982|NCT04896528|Experimental|Avatrombopag|"Avartripopa is a new generation of oral TPO receptor agonist that simulates the biological effects of TPO in vitro and in vivo.~TPO stimulates megakaryocytes through binding and activation of TPO receptor, which is expressed in hematopoietic stem cells, megakaryotic cell lines and platelets.~By binding to the transmembrane region of the thrombopoietin receptor, Ava Tripopa activates the thrombopoietin receptor in humans, stimulates signal transduction and mimics the biological effects of thrombopoietin, leading to an increase in platelet count."
9683983|NCT04896190|Experimental|Experimental group|Before the evaluation of EMG amplitude on dynamic balance position, the Q angle was measured in supine and standing positions. The EMG signals collected by measuring the muscle activation of the Vastus Medialis and Vastus Lateralis during dynamic balance position on the ProKin device were recorded. Q angle evaluations, static and dynamic balance and functional status of all participants were evaluated.
9683984|NCT04896567|Experimental|Intervention|Patients will have kidney biopsy designated for cell isolation and culture.
9683985|NCT04896398|Experimental|ESWT Group|A total of 5 sessions of ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the patients in this group for 2 weeks. Median nerve and tendon shifting exercises will be taught to the patients and they will be asked to do it regularly.
9683986|NCT04896398|No Intervention|Control Group|Patients in the control group will be asked to do median nerve and tendon shifting exercises only for the wrist.
9683987|NCT04896489|Experimental|hydrocortisone|Participants receive hydrocortisone (20mg)
9683988|NCT04896489|Placebo Comparator|placebo|Participants receive placebo.
9683989|NCT04896047|Experimental|CKD patients|Patients with CKD, non-diabetic, without a history of renal transplantation, without digestive pathology, aged 18 to 70 and an estimate of the glomerular filtration rate (eGFR) <60 ml / min / 1.73m2 according to the formula of CKD-EPI.
9683990|NCT04896047|Active Comparator|Haemodialysis patients|Patients on hemodialysis, for more than 3 months, with no history of kidney transplantation, without digestive pathology, aged 18 to 70 with a BMI between 18 and 30 kg / m2
9683991|NCT04896047|Active Comparator|Healthy volunteers|Healthy volunteers (controls) recruited from the population of living kidney donors
9683992|NCT04896294|Active Comparator|Group 1 - HAP-containing toothpaste|"The use of HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
9683993|NCT04896294|Experimental|Group 2 - Zn Mg HAP-containing toothpaste|"The use of Zn Mg HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Zn-Mg-hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
9683994|NCT04896294|Experimental|Group 3 - FAP-containing toothpaste|"The use of FAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Fluorapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene."
9683995|NCT04896580|Experimental|Active|Participants will be asked to complete a 12 week exercise program
9683996|NCT04896203||Group 1|Ulcerative Colitis or Crohn's Disease patients, in remission according to inclusion criteria
9683997|NCT04896203||Group 2|Ulcerative Colitis or Crohn's Disease patients, with activity defined by the inclusion criteria
9683998|NCT04896151|Active Comparator|Standard MMPI|Participants will be instructed to complete the MMPI-2-RF-EX and other measures under standard conditions (e.g., to not simulate underreporting of suicide risk).
9683999|NCT04896151|Experimental|Simulation MMPI|Participants will be instructed to conceal current suicide risk when completing the MMPI-2-RF-EX and other measures.
9684000|NCT04896138||ILD Cohort|Patients with Interstitial Lung Disease seen at the UVA ILD or Pulmonary Clinic
9684001|NCT04896138||Control Cohort|Control group of patients and family members of those with an Interstitial Lung Disease
9684002|NCT04895891|Experimental|EOS imaging|For each patient, EOS images are compared with computed tomography [CT] images
9684003|NCT04896229|Experimental|Experimental: Intervention|Parent/student/dyads in the treatment condition will be sent program materials via mail and text or email, including smart-speaker hardware, wireless network bridges for wireless network connectivity, and web links to Talk STEM Familia, including set-up video tutorials, and graphic instructions. Intervention activities will take place in participants' homes over the 24-week intervention period and will include using the dual-language Talk STEM Familia technology to receive instruction, practice, and feedback on academic vocabulary.
9684004|NCT04896229|No Intervention|Treatment as usual|Parent/student dyads in this arm will receive treatment-as-usual (the vocabulary instruction regularly provided in their schools). They will receive the TSF technology after post-test data has been collected.
9684005|NCT04896177|Experimental|Sirolimus drug-eluting coronary balloon catheter|Manufacturer: Shenzhen Salubris Pharmaceuticals Co., Ltd. This product is a sirolimus drug eluting balloon catheter for coronary artery therapy. It is a rapidly exchangeable PTCA balloon catheter (RX), effective length is 140cm, and compatible with 0.014 in. (0.36mm) guide wire. The balloon at the distal end of the catheter was coated with sirolimus, an anti-proliferative and anti-inflammatory drug.
9684006|NCT04896177|Active Comparator|Drug-eluting balloon catheter|Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd Coated with paclitaxel.
9684007|NCT04896125||Lumigan PF|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.03% bimatoprost (preservative-free) (Lumigan PF, Allergan Inc., CA, USA).
9684008|NCT04896125||Xalatan|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.005% latanoprost (containing 0.02% BAK as a preservative) (Xalatan, Pfizer, NY, USA).
9684009|NCT04896125||Control|Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were not diagnosed with glaucoma.
9684010|NCT04896164|Experimental|Investigational arm|Patients in the investigational arm will receive curcumin lozenges (4 gm BD containing 400 mg curcumin BD) as prophylaxis from two days prior to receiving high dose chemotherapy .
9684011|NCT04896164|Placebo Comparator|Control arm|patients in the control arm will receive matching placebo lozenges from two days prior to receiving high dose chemotherapy
9684012|NCT04896112|Experimental|Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg|Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles
9684013|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg|LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles
9684014|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 45 mg|LNK01002 45 mg BID, followed by a 3-day observation period then 45 mg BID in 28-day treatment cycles
9684015|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg|LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles
9684016|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 80 mg|LNK01002 80 mg BID, followed by a 3-day observation period then 80 mg BID in 28-day treatment cycles
9684017|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg|LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles
9684018|NCT04896112|Experimental|Patients with Acute Myeloid Leukemia With Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
9684019|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
9684020|NCT04896112|Experimental|Patients with Primary or Secondary Myelofibrosis|LNK01002 at the RP2D dose in 28-day treatment cycles
9684021|NCT04895995|Experimental|Digital Cognitive Behavior Therapy (dCBT) for Generalized Anxiety Disorder|
9684022|NCT04895995|No Intervention|Waitlist Control|
9684023|NCT04895943||Group with adjustable IGB|
9684024|NCT04895943||Group with non-adjustable IGB|
9684025|NCT04896255||interferon cohort|Patients who are going to take peginterferon alpha based regimen
9684026|NCT04896255||nucleos(t)ide cohort|Patients who are going to take nucleos(t)ide alone
9684027|NCT04895917|Experimental|Pomalidomide and daratumumab|
9684028|NCT04896034|Placebo Comparator|" control 1  fake MILTA device"|Fake device (control 1) which emits 10% red light (and no infrared) so that the difference between the two machines cannot be seen with the naked eye. The magnets present in the real device are absent in the fake machine and replaced by inert materials of the same mass.
9684029|NCT04896034|Experimental|MILTA Device|The MILTA device used for the study is composed of a panel which gathers 18 emitters composed of red, green and blue LEDs, 3 nanopulsed infrared laser diodes (cold laser), 3 infrared diodes and a permanent magnet
9684030|NCT04896034|No Intervention|" control 2  standard pain management with medication"|In first intention: PARACETAMOL: max 1 g x 4 / 24 h Second intention: IBUPROFEN: max 100 mg x 2 for 48 h Third intention: ACUPAN 20 mg in sugar 3 times per 24 h Last intention: ACTISKENAN 10 mg x 4 / 24 h
9684031|NCT04895865|Experimental|Self-selected|"Participants in the self-selected arm will choose the initial resistance in view of their preferences, and complete as many repetitions as they wish in order to reach the target rating of perceived exertion RPE of 7/10"
9684032|NCT04895865|Active Comparator|Predetermined|"Participants in the predetermined arm will be instructed to complete ten repetitions per set and exercise, while aiming to reach a rating of perceived exertion (RPE) of 7/10 by the 10th repetition. This means that participants will need to select and adjust the resistance of each exercise (e.g., band's resistance) to achieve this goal."
9684033|NCT04895683|Active Comparator|Arm 1 - Control SMS|Control (current practice) text message invitation
9684034|NCT04895683|Experimental|Arm 2 - Behavioural Science informed SMS content|Experimental text message invitation
10178615|NCT03811301|Experimental|Interventional|Wireless Implantable Neurodevice Microsystem
10178616|NCT03811600||OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
9684035|NCT04895683|Experimental|Arm 3 - Pre-alert and behavioural science informed SMS content|Two text messages, including a pre-alert SMS and the text message intervention in trial arm 2.
9684036|NCT04895826||Back pain and no back pain|Participants with and without back pain will be included in the study and they will be asked to perform standard functional movements that would be used for a physiotherapy assessment for a back condition. The participants will also perform these movements in front of a camera for video recordings to be analysed by the CV system. The measurements by the CV system will be compared to the measurements by the physiotherapist. Additionally, participants will perform and record videos of the same set of movements at home to test the feasibility of the CV system in a home environment.
9684037|NCT04895462||Ischemic Stroke and COVID-19|Ischemic stroke patients with COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
9695770|NCT04774809|Active Comparator|SHR0302 Low Dose|Drug: SHR0302 SHR0302 Ointment BID Low Dose
10178617|NCT03811600||Non OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index <15 per hour
10178618|NCT03811444|Experimental|simulation of skin pricking type 420|The evaluator simulated the capillary blood sampling with the safety lancet type 420
9684038|NCT04895462||Control group: Ischemic Stroke without COVID-19|Ischemic stroke patients without COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
9684039|NCT04895657|Other|Piperacillin/Tazobactam Intermittent infusion|4.5 gm Piperacillin/Tazobactam I.V intermittent over 30 min. every 8 hours.
9977666|NCT01363960||neonates with retinopathy of prematurity|"all neonates meet the criteria:~a BW of less than 1501 gram (g)~born at a GA of 34 weeks (wk) or less and~selected infants with an unstable clinical course were included"
9684040|NCT04895657|Other|Piperacillin/Tazobactam Continuous infusion|4.5 gm Piperacillin/Tazobactam I.V extended infusion over 4 hours every 8 hours.
9684041|NCT04895423|Experimental|Group №1: Methotrexate therapy|
9684042|NCT04895423|Experimental|Group №2: Mycophenolate mofetil therapy|
9684043|NCT04895423|Experimental|Group №3: Cyclosporine therapy|
9684044|NCT04895423|Experimental|Group №4: Dupilumab therapy|
9684045|NCT04895540||Diagnosed ACM patients|
9684046|NCT04895540||First degree relatives of ACM patients|
9684047|NCT04895540||Relatives of ACM patients who have suffered an SCD|
9684048|NCT04895800|Experimental|Herbal Supplement|(Phytovive™); comprised of Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
9684049|NCT04895800|Active Comparator|Caffeine|Green tea caffeine extract (170 mg; to deliver 34 mg caffeine [20% natural caffeine]),
9684050|NCT04895800|Placebo Comparator|Placebo|Flavored placebo
10178619|NCT03811444|Experimental|simulation of skin pricking type 430|The evaluator simulated the capillary blood sampling with the safety lancet type 430
10178620|NCT03811444|Experimental|simulation of skin pricking type 520|The evaluator simulated the capillary blood sampling with the safety lancet type 520
9977667|NCT01363973|Experimental|Sensory stimulation|Transcutaneous electrical stimulation at 75% of motor threshold
10178621|NCT03811314|Experimental|Strength training|Muscle strength training programs
10178622|NCT03811314|Experimental|Aerobic training|Aerobic training programs
9684051|NCT04895306|Experimental|Testosterone|Weekly intramuscular administration at a dose of 3 mg
9684052|NCT04895306|Placebo Comparator|Placebo|Weekly intramuscular administration of placebo
9684053|NCT04895371|Experimental|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
9684054|NCT04895371|Active Comparator|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
9684055|NCT04895631|Experimental|Fluorocholine PET Imaging|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
9684056|NCT04895592|Experimental|Arm A (SRS, low dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive low dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
9684057|NCT04895592|Experimental|Arm B (SRS, high dose dexamethasone, surgery)|Patients undergo SRS to the brain metastasis for 1-3 fractions over 1-5 days. Patients also receive high dose dexamethasone PO or IV for 2-21 days until the day of surgical resection. Patients then undergo surgical resection.
9684058|NCT04895397|Active Comparator|Group A: (30 patients)|modified pectoral nerve block will be done.
9684059|NCT04895397|Active Comparator|Group B: (30 patients)|serratus plane block will be done.
9684060|NCT04895475||Lactating Mothers|Lactating mothers who plan to receive or have received the SARS-CoV-2 vaccine within 60 days.
10178623|NCT03811353||Children with cerebral palsy|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
9977668|NCT01363973|Experimental|Motor stimulation|Transcutaneous electrical stimulation at motor threshold
10178624|NCT03811353||Healthy children|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
10178625|NCT03811548|Experimental|Janagliflozin 25mg|Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
10178626|NCT03811548|Experimental|Janagliflozin 50mg|Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
10187992|NCT03720574|Placebo Comparator|Matching Placebo BID|Matching Placebo tablet each morning and evening
9684061|NCT04895345|Experimental|TQB2450+Intensity modulated radiotherapy|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day；The total dose of radiotherapy should meet PTVnx: 60Gy/27Fr/2.22Gy, PTVnd: 60-64Gy/27Fr/2.22-2.37Gy, PTV1: 54Gy/27Fr/2.00Gy, once a day, 5 times/week.
9684062|NCT04895566|Experimental|monoclonal antibody (Mab) sB24M|Therapy by injecting 200 mg of the monoclonal antibody (Mab) sB24M into the areas affected by pyoderma
9684063|NCT04895059|Experimental|Group A: Rosuvastatin / Ezetimibe fixed dose|In fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg / 10 mg Administration way: oral
9684064|NCT04895059|Active Comparator|Group B: Rosuvastatin (Crestor®)|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
9684065|NCT04895059|Active Comparator|Group C: Ezetimibe (Ezetrol®)|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration wat: Oral
9684066|NCT04895085|Experimental|Caregiver of Children with medical complexity (CMC)|
9684067|NCT04895124||Healthy volunteers|
9684068|NCT04895124||Healthy smokers|
9684069|NCT04895124||COPD GOLD I|
9684070|NCT04895124||COPD GOLD II|
9684071|NCT04895124||COPD GOLD III/IV|
10178627|NCT03811548|Experimental|Placebo/Janagliflozin|In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.
10178628|NCT03811626|Experimental|Intervention|Patient who underwent cognitive-behavioral rehabilitation
9684072|NCT04895163||Foreign workers|Foreign workers aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
9684073|NCT04895163||Local patients|Local patients aged 18-50 who were admitted to our institution between January 1st, 2013 and October 31st, 2018, with the diagnosis of acute appendicitis.
9684074|NCT04895007||Group, vaccinated with Inactive Vaccine (Sinovac Life Sciences, Beijing, China).|- Any person, male or female, over 18 years of age, were vaccinated with Inactive Vaccine.
9684075|NCT04895007||Group, vaccinated with recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V).|- Any person, male or female, over 18 years of age, were vaccinated with recombinant human adenovirus serotype number 26.
9684076|NCT04895007||Group, vaccinated with mRNA Vaccine (Pfizer/BionTEC).|- Any person, male or female, over 18 years of age, were vaccinated with mRNA Vaccine.
9684077|NCT04895137|Experimental|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colon and upper rectum cancer
9684078|NCT04895020|Experimental|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
10178629|NCT03811626|No Intervention|Comparator|Patient with no specific management
10178630|NCT03811483||Female gender|
10178631|NCT03811483||Male gender|
10178632|NCT03811379|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
10178633|NCT03811522||Carbon Dioxide Insufflation|Received CO2 insufflation during procedure
9684079|NCT04894877||Active Comparator: Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
9684080|NCT04894877||Active Comparator: Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
9684081|NCT04895033|Experimental|Responsibility vs No Responsibility|Within-subjects experimental manipulation of responsibility vs. no-responsibility condition
9684082|NCT04894994|Experimental|FLX475 and ipilimumab combination therapy|
9684083|NCT04895228|Active Comparator|SpA patients recieving local steroid injection|the active group will receive triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance.
9684084|NCT04895228|Placebo Comparator|placebo group|Group 2 will receive similar amount of saline injecteed subcutaneously
9684085|NCT04895254||Experimental: Motorized spiral Enteroscopy|Consecutive patients with difficult colonoscopies to be enrolled to achieve total colonoscopy using the motorized spiral enteroscope.
9684086|NCT04894851|Experimental|Contingency Management|Receives contingency payments each month based on decluttering scores
10178634|NCT03811522||Air Sufflation|Received ambient insufflation during procedure
9684087|NCT04894825|Experimental|Dose Escalation Cohort|"Monotherapy: Five dose levels of M108 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of M108 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (21 days)."
9684088|NCT04894825|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, 1~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.
9684089|NCT04894539|Experimental|TENS1|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
9684090|NCT04894539|Experimental|TENS2|TENS with 80/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
9684091|NCT04894539|Sham Comparator|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
10178635|NCT03811509|Active Comparator|AI with osteoporosis|Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
10178636|NCT03811509|No Intervention|AI without osteoporosis|All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
10178637|NCT03811327|Experimental|Treatment group|Zero-time Exercise group
10178638|NCT03811327|No Intervention|Waitlist group|
10178639|NCT03811288||Participants with type 2 diabetes mellitus (T2DM)|T2DM patients being managed in both primary and specialist care in 10 selected countries.
9684092|NCT04894604|Experimental|Subjects with a low to moderate exuding surgically closed incision|Up to 34 study Subjects with a low to moderate exuding surgically closed incision deemed adequate by the Principal Investigator and clinical team for NPWT treatment.
9684093|NCT04894565|Experimental|intervention|effect of rehabilitation program in the intervention arm
9695771|NCT04774809|Active Comparator|SHR0302 High Dose|Drug: SHR0302 SHR0302 Ointment BID High Dose
9695772|NCT04774809|Placebo Comparator|Placebo Comparator: Vehicle|Drug: vehicle Vehicle BID Placebo
10178640|NCT03811392|Active Comparator|Hernioraphy/Caudal block|patients will receive a caudal block after induction of general anaesthesia.
9827798|NCT02469038|Experimental|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
10178641|NCT03811392|Active Comparator|Hernioraphy/Quadratus Lumborum block|patients will receive ultrasound guided quadrates lumborum block (QL )
10178642|NCT03811262|Active Comparator|ESP BLOCK|Intervention:30 ml of 0.25% Levobupivacaine where: ESP block as described by Forero at T5 level (single injection between transversour process and erector spinae muscles)
10178643|NCT03811262|Active Comparator|PECS block|Intervention:30 ml of 0.25% Levobupivacaine where:PECS II block as described by Blanco.
9684094|NCT04894643|Other|Preoperative, proton- radiotherapy combined with chemotherapy|Patients treated with three cycles of chemotherapy with Nab-PACLitaxel (Abraxane®) (125 mg/m² on day 1, 8, 15; powder for making a infusion solution) and Gemcitabine (1000 mg/m² on day 1, 8, 15; powder for making a infusion solution), followed by concomitant chemotherapy with capecitabine (1.660ml/m² on 5 days per week during the radiation therapy) and proton-therapy (with simultaneous integrated boost (SIB) 50.4 Gy Relative Biological Effectiveness (RBE) and 60.2 Gy (RBE) in 28 fractions of 1.8 Gy (RBE) and 2.15 Gy (RBE) 5 days per week), followed by re-evaluation and surgery
9684095|NCT04894838|Experimental|Distal gastric bypass type I|Laparoscopic distalisation of RYGB type I. The RYGB is modified by dividing the Roux limb (AL) at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long biliopancreatic limb (BPL). In cases of initial AL lengths shorter than 100 cm, the CC lengths should be adjusted to create a TALL of at least 300 cm.
9684096|NCT04894838|Experimental|Distal gastric bypass type II|Laparoscopic distalisation of RYGB type II. The RYGB is modified by dividing the BPL at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long AL.
9684097|NCT04894630|Other|infective keratitis|150 patients with mean age 30 (range 12 to 85 years), 90 patients (60 %) were males and 60 (40%) were females, clinically diagnosed as infective corneal ulcer, attending the Ophthalmology Department - Faculty of Medicine. Minia University, Minia, Egypt. From 2018 to 2020.
9684098|NCT04894578|Active Comparator|Group A|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a reverse distal metatarsal minimal-invasive osteotomy
9684099|NCT04894578|Active Comparator|Group B|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a fusion of one or more midfoot (tarsometatarsal) joints
9684100|NCT04894617|Active Comparator|Amantadine|The intervention group will receive a dose at day 1 of amantadine 100 mg followed by 100 mg amantadine after 6 hours. The following 4 consecutive days, study participants will receive a daily dose of 200mg amantadine, 100 mg (1 capsule) morning and 100 mg (1 capsule) evening, yielding 5 days of treatment in total (10 capsules in total).
9684101|NCT04894617|Placebo Comparator|Placebo|The control group will receive placebo treatment with lactose monohydrate; 1 capsule, followed by 1 capsule after 6 hours on day 1. The following 4 consecutive days, study participants will receive 1 capsule morning and 1 capsule evening, yielding 5 days of treatment in total (10 capsules in total).
9684102|NCT04894552|Experimental|One arm clinical trial|Convenience sampling method in which the first twenty cases of endometrial carcinoma patients who will undergo laparoscopic hysterectomy will be included. All cases will undergo laparoscopic hysterectomy. Sentinel lymph node biopsy will be detected, dissected and isolated. Then standard lymphadenectomy will be done
9684103|NCT04894708|Other|AI colonoscopy|colonoscopy with artificial intelligence added
9684104|NCT04894708|Sham Comparator|conventional colonoscopy|conventional colonoscopy
9684105|NCT04894695||healthy control (HC)|healthy control
9684106|NCT04894695||Systemic Lupus Erythematosus (SLE)|Systemic Lupus Erythematosus
9684107|NCT04894695||lupus nephritis (LN)|lupus nephritis
9684108|NCT04894929|Experimental|A. Multi-conponente exercise|"A 6-week therapeutic multi-component physical exercise program will be carried out. The ministerial guide will be followed by carrying out 5 weekly sessions (from Monday to Friday), offering the application through a web link of the weekly programming of the exercises for the patient (type of exercise, video of its execution, number of repetitions and description) having a approximate duration of 40 minutes.~Said sessions will be carried out daily and from the center a call was made at the end of the week to mark the follow-up and resolve any questions related to symptoms"
10178644|NCT03811106|Active Comparator|NMES + PT|NMES will be applied to the back muscles with the chattanooga intelect advanced device. In addition, conventional physiotherapy and rehabilitation applications will be made.
10178645|NCT03811106|Other|PT|Conventional physiotherapy and rehabilitation practices will be carried out.
10178646|NCT03811119|Active Comparator|MANTA vascular closure device|Arteriotomy closure with a collagen-based vascular closure device (MANTA™)
10178647|NCT03811119|Active Comparator|Suture based vascular closure device|Arteriotomy closure with 2 or more suture-based vascular closure devices (ProGlide)
10178648|NCT03810885|Experimental|Salt reduced bread|Bread with reduced salt content
10178649|NCT03810885|Experimental|Dietary advice and Salt reduced bread|bread with reduced salt content, dietary advice
10178650|NCT03810885|Placebo Comparator|Normal bread|Bread with standard salt content
9684109|NCT04894929|Experimental|B. Vestibular exercise|"The vestibular exercises will be performed with the instructions of a physiotherapist, in sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec All participants will have a weekly follow-up from Monday to Friday to control attendance and compliance via telephone."
9684110|NCT04894526|Experimental|Alternating energy intake schedule|To alternate between caloric overconsumption and caloric underconsumption from day-to-day
9684111|NCT04894526|Active Comparator|Regular energy intake schedule|To consume the usual energy intake on a daily basis
9827799|NCT02469038|Active Comparator|Control|We will use ultrasound-guided conventional IV for patients in the control group.
10178651|NCT03810963|Experimental|FES Cycling and Nutrition Counseling|"Device:~HIIT-FES cycling will be performed 30 minutes per session, 3 times per week for 3 weeks combined with~Behavior:~Nutrition counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
10178652|NCT03810963|Other|Nutritional Counseling Only|"Behavior:~Nutritional counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
10178653|NCT03810898|Experimental|Phase 1 (a & b)|"Radioligand [¹¹C]CHDI-00485180-R and/or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 young (< 35) HCs/ Imaging- MRI and PET/~Both radioligands administered- 1x each/ Optional CSF collection for HDGECs"
10187993|NCT03720548|Experimental|LY3372993 (Part A)|LY3372993 administered intravenously (IV) to healthy participants.
10187994|NCT03720548|Placebo Comparator|Placebo (Part A)|Placebo administered IV to healthy participants.
9684112|NCT04894682||Vaccinated Case|Pulmonary nodules/lung cancer patients who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
9684113|NCT04894682||Vaccinated Healthy Control|Healthy people who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)
10178654|NCT03810898|Experimental|Phase 2a|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
10178655|NCT03810898|Experimental|Phase 2b|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x -HCs/"
10178656|NCT03810898|Experimental|Phase 2c|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
10178657|NCT03810872|Other|Open label|Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2
9684114|NCT04894682||Unvaccinated Case|Pulmonary nodules/lung cancer patients who are not vaccinated against the SARS-CoV-2
9684115|NCT04894487|No Intervention|Control Group|The babies have got sternum incision after the pediatric cardiac surgery. Experiment is about the dressing of the sternum incision. There is no extra intervention during sternum dressing at control group like routine of pediatric cardiovascular surgery intensive care clinic. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
9684116|NCT04894487|Experimental|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABIES GROUP|Baby mobile and Brahms Lullaby started before the 10 minutes of sternum dressing process and controlled permanence of the baby mobile and Brahms Lullaby during sternum dressing. Saved pain scores and physiological parameters and pain scores; just before the sternum dressing, just after sternum dressing and after the 15 minutes sternum dressing.
9684117|NCT04894461|Experimental|Moxibustion|Moxibustion treatment sessions eight weeks from the baseline.
9684118|NCT04894461|No Intervention|Waiting|A waiting period of eight weeks by moxibustion treatment sessions in the same way with moxibustion group.
10178658|NCT03811223|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
9695773|NCT04774796|Experimental|Cognitive Behavioural Therapy|Participants in this group will take part in a group CBT workshop for parents of children with food allergy. They will also have access to a self-help booklet in order to reinforce the learning that has taken place during the workshop.
9695774|NCT04774796|No Intervention|Treatment as usual|Participants in the control group will not take part in the group CBT workshop, but will have access to any treatment as usual relating to their child's food allergy. They will have access to the CBT self-help booklet after the all data collection has been finalised.
10178659|NCT03811223|Placebo Comparator|Placebo|Placebo injection once every 2 weeks for 12 weeks
10178660|NCT03811054|Experimental|Apatinib combined with EGFR-TKI|Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI
9695775|NCT04774679|Experimental|Biopsy Arm|All patients who underwent EUS Guided biopsy
9695776|NCT04774887|Experimental|HPV vaccination|Children receiving HPV vaccine will be studies for seroconversion to HPV types, and aflatoxin levels in blood will be measured and compared to seroconversion.
9695777|NCT04775030|Experimental|CBD occlusal appliance|CBD occlusal appliance
9695778|NCT04775030|Placebo Comparator|occlusal appliance|Traditional material occlusal appliance
9695779|NCT04775329|No Intervention|Control arm|Standard of care
9695780|NCT04775329|Active Comparator|Treatment arm|
9695781|NCT04774614|Experimental|VITA ENAMIC multiColor anterior laminate veneers|
9695782|NCT04774614|Active Comparator|IPS e.max CAD anterior laminate veneers|
9977669|NCT01364012|Experimental|Bevacizumab + Paclitaxel/Carboplatin|Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
9695784|NCT04774471||Women with breast lesions|Women with an identified breast lesion have a non-invasive non-contrast MRI scan prior to biopsy.
9695785|NCT04774432|Active Comparator|GM-CSF group|"Patients will be randomly allocated to intervention group with GM-CSF added to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
9695786|NCT04774432|Active Comparator|Control group|"Patients will be randomly allocated to control group without the addition of GM-CSF to CAPA and maturation medium.~Following the 24h CAPA period, the evaluation of maturation (MII, GVBD, GV) will be done after 30 hrs IVM step.~Mature eggs are fertilized using Intracytoplasmic sperm injection (ICSI). Fertilized oocytes will be placed in a time-lapse incubator (ASTEC) and their development until the Day 5/6 (blastocyst formation) will be followed."
10178661|NCT03810937|Active Comparator|Group sniffing (S)|intervention: Head position changes : we will start by performing first videolaryngoscopy to find best view in flat position then the anesthesiologist will remove the Glidescope and the patient will be positioned in sniffing position using the pillow and another videolaryngoscopy will be attempted in sniffing position to find best view in this position and the patient will be intubated in this position.
10178662|NCT03810937|Active Comparator|Group Flat (F)|intervention: Head position changes same procedure will be done but starting from sniffing position and the patient will be intubated in flat position.
9695787|NCT04774588|Other|Using VSI Streamer and Telemedicine Study|Using the real time streaming of input from video capture devices to a head mounted display during interventional radiology procedures
9695788|NCT04774588|Placebo Comparator|Not using VSI Streamer and Telemedicine Study|Not using real time streaming of input from video capture devices to a head mounted display and just using current standard imaging in the Interventional Suite.
9684119|NCT04894513|Experimental|study group|the study group received the conventional selected program in addition to Kabat motor control re-education
9684120|NCT04894513|Experimental|control group|the control group received the conventional selected program
9684121|NCT04894344|Experimental|Educational program|"Participants will be randomly assigned. Intervention Group: 57 participants Each participant will receive the same educational information throughout the study, each week a newsletter will be provided with recommendations and information that teaches them to choose low-sodium foods for 4 weeks.~Urine samples of 24 h before and after the Intervention will be analyzed."
9684122|NCT04894344|No Intervention|Control group|Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed.
9684123|NCT04894318|Other|Low-fat, low-cholesterol diet|Patients diagnosed with dyslipidemia by the endocrinologist were followed up for 12 weeks with a low-fat, low-cholesterol diet on a monthly basis, provided that they were suitable for each.
9684124|NCT04894149|Experimental|Physiotherapy|
9684125|NCT04894253||Single group of 30 patients with systemic lupus|
9684126|NCT04894422||No face mask|Volunteers who did not wear a face mask
9684127|NCT04894422||Cotton face mask|Voluntarily wearing a cotton face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
9684128|NCT04894422||Surgical face mask|Voluntarily wearing a surgical face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
9684129|NCT04894097|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
9684130|NCT04894097|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy
9684131|NCT04894383|Experimental|Prefabricated Orthotics in shoes & indoor comfort sandals with built-in arch support|Participants from Group A will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) and an Aetrex comfort sandal with built-in arch support (https://www.aetrex.com/aetrex-flips-black-L3000M.html?lang=en_US or https://www.aetrex.com/fiji-flips-women-watermelon-L7009W.html?lang=en_US) according to participants shoe size. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the orthotic/comfort sandal wherever possible.
9684132|NCT04894383|Active Comparator|Prefabricated Orthotics in shoes only|Group B will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) alone. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the Orthotic wherever possible.
9684133|NCT04894396|Experimental|Prefabricated Orthotics with metatarsal pad|Participants in Group A will receive the Orthotic with the metatarsal pad (L 2305) according to participants shoe size (https://www.aetrex.com/search?q=l2305&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities.
9684134|NCT04894396|Active Comparator|Prefabricated Orthotics without metatarsal pad.|Participants in Group B will receive the neutral Orthotic with a cupped heel (L 2300) according to participants shoe size (https://www.aetrex.com/search?q=l2300&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the Orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities
9684135|NCT04894409|Experimental|Experimental group|The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution.
9684136|NCT04894409|Active Comparator|Control group|"The control group was instructed to do mouthwashes and nose rinse in a conventional way."
9684137|NCT04894201||All patients with relevant dental findings|
9684138|NCT04894240|Experimental|Monepantel treatment arm|Monepantel tablets will be administered to participants in this arm daily for 28 days. Dose escalation will occur at the end of each 28 day period according to a modified Fibonacci sequence based upon recommendations from the safety management committee
9684139|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 1 according to 0,28-day immunization schedule.
9684140|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 2 according to 0,28-day immunization schedule.
9684141|NCT04894227|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3|Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 3 according to 0,28-day immunization schedule.
9684142|NCT04894084|Experimental|Test product|
9684143|NCT04893863|Active Comparator|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
9684144|NCT04893863|Experimental|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
9695789|NCT04774224|Active Comparator|Baricitinib|Baricitinib is an oral JAK1/JAK2-selective inhibitor. Dosage: The dose of baricitinib is 1 x 4mg tablet once daily Duration of administration: 48 weeks Mode of administration: Orally, with or without food
9695790|NCT04774224|Placebo Comparator|Placebo|One placebo tablet once daily for a duration of 48 weeks. Placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
9684145|NCT04894331||SNAS patients|Patients with (a) history of SNAS (coexistence of typical cutaneous and gastrointestinal symptoms); (b) positive Ni-patch test; (c) clinical improvement of at least 70% from baseline after 4 weeks of low-Ni diet; (d) positivity of a double-blind placebo-controlled oral Ni challenge (DBPCO). Exclusion criteria include (a) age < 18 years and >65 years; (b) other organic gastrointestinal diseases, such as peptic ulcer, inflammatory bowel diseases, celiac disease, gastrointestinal infections, and small intestinal bacterial overgrowth; (c) diabetes mellitus; (d) hepatic, renal or cardiac dysfunction; (e) thyroid disease or tumour; (f) concomitant treatment with steroids and/or antihistamines in the previous 4 weeks; (g) pregnancy and lactation; (h) smoking, abuse of alcohol, coffee, tea, and cola intake, and (i) inability to give written informed consent.
9684146|NCT04893889|Experimental|Fabry disease patients|Patients diagnosed with Fabry disease. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
9684147|NCT04893889|Active Comparator|Amyloidosis transthyretin with cardiac commitment|Patients diagnosed with amyloidosis who present cardiac commitment. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test and quality of life questionnaires.
10178663|NCT03810950|Experimental|Social Stress Test|Participants undergo the Trier Social Stress Test before Barlab-Exposure
9684148|NCT04893889|Placebo Comparator|Healthy subjects|Healthy patients. Interventions will be as follows: Shear wave myocardial elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity (EMD) in Fabry disease (DF) and cardiac amyloidosis (AC) in the ATTRh form and correlating with other complementary imaging tests and laboratory tests (electrocardiogram, 2D echocardiogram, troponin and BNP) and with a 6-minute walk test.
9684149|NCT04893993|Other|Thiamine-Placebo|"12 weeks: 4 weeks with Thiamine, 4 weeks wash-out, 4 weeks placebo~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
9684150|NCT04893993|Other|Placebo-Thiamine|"12 weeks: 4 weeks placebo, 4 weeks wash-out, 4 weeks with Thiamine~Both placebo and Thiamine are oral tablets of 300mg pr. tablet. The dosage depends on gender and weight of the participants, with a maximum of 1800mg intake pr. day."
9684151|NCT04894136||ICSI-TESE cycles for obstructive azoospermia|Couples who underwent ICSI-TESE cycles for obstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
9684152|NCT04894136||ICSI-TESE cycles for nonobstructive azoospermia|Couples who underwent ICSI-TESE cycles for nonobstructive azoospermia between January 2001 and December 2019 at Humanitas Fertility Center
9684153|NCT04893941|Experimental|CM310 75mg arm|75mg for 3 doses, every 2 weeks, SC
9684154|NCT04893941|Experimental|CM310 150mg arm|150mg for 3 doses, every 2 weeks, SC
9684155|NCT04893941|Experimental|CM310 300mg arm|300mg for 3 doses, every 2 weeks, SC
9684156|NCT04893941|Experimental|CM310 600(1st)+300mg(2nd,3rd) arm|600mg for 1st dose, and then 300 mg for 2nd and 3rd doses, every 2 weeks, SC
9684157|NCT04893941|Placebo Comparator|placebo arm|placebo for 3 doses, every 2 weeks, SC
9684158|NCT04893798|Experimental|Sayana Press, Upper Arm injection|Sayana Press, administered subcutaneously into upper arm
9684159|NCT04893798|Active Comparator|Sayana Press, anterior thigh|Sayana Press, administered subcutaneously into anterior thigh
10178664|NCT03810950|Active Comparator|Control Condition|Participants reads newspaper before Barlab-Exposure
10178665|NCT03811184||MemScreen|Each participants will undergo MemScreen : a screening tool on smartphone for detecting mild cognitive impairment.
9684160|NCT04893798|Active Comparator|Sayana Press, abdomen|Sayana Press, administered subcutaneously into abdomen
9684161|NCT04894045|Other|Personalized management group|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
9684162|NCT04894045|No Intervention|Control group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients in the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
9684163|NCT04893980|Experimental|Low-dose interleukin-2 treatment group|Use Interleukin-2 to treat CSU during day1-day28.
10178666|NCT03811067|No Intervention|Control group|
9684164|NCT04893980|Other|Control group|Use Interleukin-2 to treat CSU during day15-day28.
9684165|NCT04894058|Active Comparator|10 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 10 ° reverse Trendelenburg position
9684166|NCT04894058|Active Comparator|20 ° reverse Trendelenburg|Patients who underwent ureteroscopic lithotripsy in the 20 ° reverse Trendelenburg position
9684167|NCT04894058|Sham Comparator|Standard lithotomy|Patients who underwent ureteroscopic lithotripsy in standard lithotomy position
9684168|NCT04894292||Adenomyosis Group|
9684169|NCT04894292||Non-adenomyosis Group|
10178667|NCT03811067|Active Comparator|TAP group|Transversus abdominis plane block administered group
10178668|NCT03811067|Active Comparator|RS group|Rectus sheath block administered group
10178669|NCT03810989|Experimental|infra-red sauna|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
10187995|NCT03720548|Experimental|LY3372993 (Part B)|LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.
10178670|NCT03810989|Experimental|argometer and treadmill|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
9684170|NCT04893902|Active Comparator|conventional ear impression|
9684171|NCT04893902|Experimental|digital auricular impression without marker using intra oral scanner|
9684172|NCT04893902|Experimental|digital auricular impression with marker using intra oral scanner|
9684173|NCT04893850|Experimental|BRIDGE-KIDTHINK Condition|Caregivers in this group will participate in 16 sessions of online therapy delivered through a combination of asynchronous material and virtual support groups. These sessions will include Dialectical Behaviour Therapy (DBT) and parenting training. This group will be asked to evaluate the program with surveys completed pre-program, immediately post-program, and three months post-program. This group will also be invited to complete weekly surveys expected to take 5 minutes.
9684174|NCT04893850|Experimental|Services as Usual Condition|Caregivers in this group will not participate in Dialectical Behaviour Therapy (DBT) and parenting training. Rather, this group will be asked to refer to a list of community mental health and family support services as part of the BRIDGE therapy program. This group will be asked to complete weekly surveys expected to take 5 minutes.
9684175|NCT04893655|Experimental|Dobutamine|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
9684176|NCT04893434|Experimental|DCE-MR images with Gadobutrol (GBCA)|10 volunteers will undergo a single DCE-MRI of the normal cervix to fine-tune parameters and test the performance of reconstruction and quantification algorithms. Goldenangled radial LAVA data will be continuously acquired for 5 minutes and the contrast agent will be injected intravenously after 1 minute (same contrast agent and injection rate. 60 cervical cancer patients will be enrolled (inclusion criterion: newly diagnosed FIGO stage IB2-IVA cervical cancer scheduled for standard of care pelvic MRI for staging). Data from 30 of the patients will be used to assess repeatability; DCE-MRI will be acquired at baseline and repeated 48 hours (+/- 24 h) later (no therapy between the 2 scans). Data from the other 30 patients will be used to document treatment induced changes in DCE-MRI; patients in this group will undergo DCE-MRI at baseline and repeated after 2 weeks (+/- 3 days) of completion of chemoradiation treatment.
9684177|NCT04893447|Experimental|SPI+: Safety Planning Intervention plus structured phone-based follow-up|The Safety Planning Intervention (SPI+) includes safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus a structured telephone-based intervention from a suicide prevention hotline
9684178|NCT04893447|Experimental|Caring Contacts: Safety Planning Intervention plus Caring Contacts (SP+CC)|SP+CC will include safety planning (moderate or high risk for suicide) or connection & support planning (low risk for suicide) at the clinic or ED, plus caring text messages or emails from a suicide prevention hotline.
9684179|NCT04893473||Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
9684180|NCT04893473||Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for carbon dioxide."
9684181|NCT04893369|Experimental|The Low Back Pain and Disability Drivers Management model|Participating clinicians in the intervention arm will use the PDDM model to guide assessment and treatment of their patients and data will be collected over a 12-weeks period.
9684182|NCT04893369|Active Comparator|Low back pain clinical practice guidelines|Participating clinicians in the active comparator arm will perform assessment and treatment of their patients based on the recommendations from the most recent and high-quality clinical practice guidelines (CPGs) and data will be collected over a 12-weeks period.
9684183|NCT04893616|Experimental|Intervention Arm|These facilities will be those selected to have the intervention carried out.
9684184|NCT04893551|Experimental|Tilvestamab|Participants will receive tilvestamab at a low starting dose level (Cohort A) given via intravenous (IV) infusion every 2 weeks. Dose escalations to subsequent cohorts (Cohort B and Cohort C) will be decided by the Protocol Steering Committee (PSC) after review of all Cycle 1 (28 days cycle) safety and pharmacokinetics (PK) data up to Cycle 1 Day 22 for all participants in the ongoing cohort.
9684185|NCT04893746|Placebo Comparator|Placebo|
9684186|NCT04893746|Experimental|TWK10-L|Low dose
9684187|NCT04893746|Experimental|TWK10-H|High dose
9684188|NCT04893733|Experimental|Vitamin B complex|Randomized patients with AKI to this arm will received during 5 consecutive days IV Vitamin B complex each 12 hours. They will also received the Institution standard of care for AKI.
9684189|NCT04893733|Placebo Comparator|Placebo|Randomized patients with AKI to this arm will received during 5 consecutive days IV placebo each 12 hours. They will also received the Institution standard of care for AKI.
9684190|NCT04893629|Experimental|intervention group|children diagnosed with dilated cardiomyopathy , will undergo trans endocardium injection of mono nuclear cells
9684191|NCT04893629|Active Comparator|control group|children diagnosed with dilated cardiomyopathy ,will continue the classic medical treatment
9827800|NCT02469064|Experimental|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
9977670|NCT01364012|Active Comparator|Placebo + Paclitaxel/Carboplatin|Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
10178671|NCT03810989|Experimental|combination of sauna and hot bath|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
9684192|NCT04893421|No Intervention|Standard of Care WGS or RSL|Patients will undergo the institutional standard of care approach (WGS or RSL) for BCS. For WGL, a hooked wire will be implanted to mark the center or outer edges of the lesion under imaging guidance. For RSL, patients will be implanted with a radioactive seed using an impregnated needle under imaging guidance. A special handheld probe will be used to find the radioactive seed during the lumpectomy surgery.
9684193|NCT04893421|Experimental|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
10178672|NCT03810989|Experimental|combination of sauna and hot bath in CKD|During the ﬁrst month (control phase), S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be calculated. During the next two months (intervention phase) the patient will be subjected to three session of sauna of 15 minutes duration separated by ten minutes rest outside the sauna then the patients will be immersed up to neck for one hour in water at 37 -43 C .
9684194|NCT04893525|Active Comparator|Buprenorphine/naloxone Microdosing|"Participants with Opioid use disorder will receive a Buprenorphine/naloxone microdosing package from the ED. This will consist of a five-day take-home packages with gradually increasing doses of 2mg/0.5mg buprenorphine/naloxone tablet employing a four times daily dosing schedule over five days.~Day 1: Buprenorphine 0.5 mg-naloxone 0.125 mg SL* QID** (One quarter tablet),~Day 2: Buprenorphine 1 mg-naloxone 0.25 mg SL QID (One half tablet),~Day 3: Buprenorphine 2 mg-naloxone 0.5 mg SL QID (1 tablet),~Day 4: Buprenorphine 3 mg-naloxone 0.75 mg SL QID (1.5 tablets)~Day 5: Buprenorphine 16 mg-naloxone 4 mg SL once daily (8 tablets).~*SL: Sublingual~** QID: four times daily"
9684195|NCT04893525|Active Comparator|Buprenorphine/naloxone Standard Dosing|"The control intervention will be provision of a buprenorphine/naloxone standard dosing package from the ED. This will consist of a five day package with a commonly accepted standard dosing regimen aiming to achieve a therapeutic buprenorphine/naloxone dose within 24 hours of initiation. Standard dosing packages are currently available in EDs in BC and Alberta as standard of care.~Day 1: Buprenorphine 2 mg-naloxone 0.5 mg SL q1h prn to a maximum of 6 tablets in the first 24 hours (1 tablet),~Day 2: Buprenorphine 12 mg-naloxone 3 mg SL once daily (6 tablets),~Day 3: Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets),~Day 4:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets).~Day 5:Buprenorphine 16 mg-naloxone 3 mg SL once daily (8 tablets)."
9684196|NCT04893603|Experimental|Severe Aortic Valve Stenosis|Patients will be treated with Transcatheter Aortic Valve Systerm
10178673|NCT03811197|Experimental|individual MNT|Dietary counseling via face to face meeting
9684197|NCT04893330||patients|children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV
9684198|NCT04893356||Dacarbazine treated sarcoma patients|"Approximately 75 patients with histological diagnosis of Leiomyosarcoma (SCL) and Solitary Fibrous Tumor(SFT), previously treated with dacarbazine alone or associated with anthracyclines, will be enrolled, diagnosed from 2010 to 2020.~From formalin fixed tumor samples, DNA will be extracted and MGMT expression and MGMT promoter methylation analyzed."
9684199|NCT04893395|Experimental|Pharmacogenomic Screening|Eligible patients who verbally consent to participate will receive two pharmacogenomics telehealth visits.
9684200|NCT04893668||Exposed with COVID 19|The participant with confirmed RT-PCR Covid 19 at the beginning of the study
9684201|NCT04893668||Unexposed with COVID 19|The participant without confirmed RT-PCR Covid 19 at the beginning of the study until 6 month follow up period
9684202|NCT04893499|Experimental|Low-dose mastic group|This arm will consume 600 mL of a sparkling water enriched with Chios mastic per day for a 3-month period.
9684203|NCT04893499|Placebo Comparator|Low-dose control group|This arm will consume 600 mL of a standard sparkling water per day for a 3-month period.
9684204|NCT04893499|Experimental|High-dose mastic group|This arm will consume 600 mL of a sparkling fruit juice enriched with Chios mastic per day for a 3-month period.
9684205|NCT04893499|Placebo Comparator|High-dose control group|This arm will consume 600 mL of a standard sparkling fruit juice per day for a 3-month period.
9684206|NCT04893317|Experimental|Ablation in the ventricle with the Adagio VT cryoablation system|
9684207|NCT04893642|Active Comparator|Abdominal suture rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
10178674|NCT03811197|Experimental|Individual MNT and T|Dietary counseling via face to face meeting and Telemedicine
10178675|NCT03811197|Experimental|Individual MNT and HS|Dietary counseling via face to face meeting and Hypnotic Suggestions
10178676|NCT03810846|Experimental|Exercise|Walking football exercise program
9684208|NCT04893642|Active Comparator|Abdominal resection rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
9826765|NCT02431793|Experimental|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.~A single-page medication information sheet with content from a patients perspective and following health literacy best practices.~Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.~Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
10178677|NCT03810976|Experimental|eribulin+gemcitabine|The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
10178678|NCT03810924|Active Comparator|Control|Participants reads newspaper before Barlab-Exposure
10178679|NCT03810924|Experimental|Experimental 1 (Distress)|Participants undergo the Trier Social Stress Test before Barlab-Exposure
9684209|NCT04893642|Active Comparator|Perineal Delorme|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
9684210|NCT04893642|Active Comparator|Perineal Altemeier|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
9684211|NCT04893304|Other|1 group of 20 patients doing both types of lasers on 2 sites|comparing both types of laser
9684212|NCT04893174|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.
9684213|NCT04892953|Experimental|Cohort A (oligoprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10178680|NCT03810924|Experimental|Experimental 2 (Eustress)|Participants ride an ergometer before Barlab-Exposure
10178681|NCT03811080|Experimental|DWP14012 A mg|DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks
10178682|NCT03811080|Experimental|DWP14012 B mg|DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks
10178683|NCT03811080|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
10178684|NCT03811249|Experimental|Implantation-Non-randomized|Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively for an additional 36 month period to measure long term safety and effectiveness outcomes.
9684214|NCT04892953|Experimental|Cohort B (polyprogressive)|Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Patients also receive one of the following chemotherapy options: carboplatin and paclitaxel on day 1, carboplatin on day 1 and nab-paclitaxel on days 1, 8, 15, or carboplatin on day 1 and gemcitabine on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous histology receive pemetrexed on day 1 every 21 days for cycles 1-4, pemetrexed and durvalumab IV on day 1 every 28 days in the absence of disease progression or unacceptable toxicity.
9684215|NCT04892940|Experimental|Virtual Reality group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
9684216|NCT04892940|Active Comparator|Control group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
9684217|NCT04892979|Experimental|Centre-based|Centre-based exercise cardiopulmonary rehabilitation program for 6 weeks
9684218|NCT04892979|Experimental|Online-based|Online-based exercise cardiopulmonary rehabilitation program for 6 weeks
9684219|NCT04892979|Experimental|Combined|Combined centre- and online-based exercise cardiopulmonary rehabilitation program for 6 weeks
9684220|NCT04893252|Experimental|vactosertib in combination with durvalumab|single arm study
9684221|NCT04893070||COVID+|Questionnaires on COVID-19 symptomatology and quality of life
9684222|NCT04893070||COVID-|Questionnaires on quality of life
9684223|NCT04892966|Experimental|TXI (TXI group)|Arm undergoing normal colonoscopy with TXI light
9684224|NCT04892966|Active Comparator|WLI (White Light Imaging Group)|Arm undergoing normal colonoscopy with standard white light
9684225|NCT04892992|Experimental|Intervention group I|6 sessions of intervention DFG starting at once (baseline). After DFG treatment as usual at Helsinki University hospital. The change between before the intervention (baseline) and after the intervention (3 months later) is being assessed.
9684226|NCT04892992|Experimental|Intervention group II|6 sessions of intervention DFG starting 3 months after baseline (3 months on waiting list). Between baseline and 3 months waiting list families were getting treatment as usual at Helsinki University hospital. The change between baseline - after 3 months waiting list (3 months from baseline)/ before the intervention - and after intervention (6 months from baseline) is being assessed. Also the difference between Intervention group I and II is assessed.
9684227|NCT04893213|Active Comparator|Baseline availability|Baseline availability of lower energy meal options
9684228|NCT04893213|Experimental|Increased availability|Increased availability of lower energy meal options
9684229|NCT04893031||Tocilizumab treatment group|Symptoms of hypoxia and systemic inflammation (SpO2 <90% on room air with accompanying elevation of any two of the systemic inflammatory markers such as CRP, LDH and Ferritin) and / or acute bilateral infiltrations on chest radiography or rapid progression of existing infiltrations, but who did not need mechanical ventilation at admission and were given tocilizumab treatment.
9684230|NCT04893031||Standard treatment group|Patients who did not require mechanical ventilation in intensive care admission and did not receive tocilizumab treatment during any period of hospitalization.
10178685|NCT03810833|Experimental|Participants with Brilliance sensor placement|Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours
10178686|NCT03811145|Experimental|Tendoncel|Topically applied experimental gel - Tendoncel. 80ul applied once a day for 21 consecutive days.
10178687|NCT03811145|Placebo Comparator|Placebo control gel|Placebo control gel. Similar to Tendoncel but without platelet derived small molecules and growth factors. 80ul applied once a day for 21 consecutive days.
10178688|NCT03810820|Other|Outpatient TAVI|Consecutive patients scheduled for outpatient TAVI.
9684231|NCT04893057||Pregnant women|Women admitted to hospital for a live birth.
9684232|NCT04893057||Blood donors|Subjects qualified for whole blood donation
9684233|NCT04893200||Lung adenocarcinoma|Imaging from patients with surgically treated lung adenocarcinoma were collected and processed for the construction of the radiomics-based prediction model
9684234|NCT04892849||Trial cohort|"The study cohort consist of patients suffering from HNSCC (palliative), NSCLC (separately palliative and adjuvant) and other solid tumors (including in particular esophageal carcinomas, urothelial and renal carcinomas, small cell bronchial carcinomas and squamous cell carcinomas of the skin [depending on the current drug approval]) which will be treated with ICI (PD-1/PD-L1) and potential radiation of metastases at Department of Radiation Oncology of Universitätsklinikum Erlangen."
9684235|NCT04892810||RFA|Patient with HCC and decision of treatment with ablation
9684236|NCT04892810||MWA|Patient with HCC and decision of treatment with ablation
9684237|NCT04892836|Experimental|High Intensity Training (HIT)|They have trained at 80-90% of 1RM for 12 weeks, twice per week
9684238|NCT04892836|Experimental|Moderate Intensity Training|They have trained at 65-75% of 1RM for 12 weeks, twice per week
9684239|NCT04892836|Experimental|Low Intensity Training|They have trained at 50-60% of 1RM for 12 weeks, twice per week
10178689|NCT03810560|No Intervention|open flap debridement|surgical treatment of periodontal pocket without any intervention
9684240|NCT04892836|No Intervention|Control Group|This groups subjects did not participate in any training
10178690|NCT03810560|Active Comparator|laser device with open flap debridement|surgical intervention associated with application of Erbium chromium: YSGG laser therapy
9684241|NCT04892784|Experimental|Press tack needle acupuncture|
9684242|NCT04892784|No Intervention|Control|
9684243|NCT04892732||Budesonide|Reference Group
9684244|NCT04892732||Budesonide-formoterol|Exposure Group
9684245|NCT04892823||Supportive care (EAR, questionnaires, biospecimen collection)|Participants will complete comprehensive assessments of social processes at 100 days and 1 year after HCT that combine reports of social support, strain, and isolation with a naturalistic observation tool, the Electronically Activated Recorder (EAR), which captures ambient sound bites to assess social interactions in survivors' daily lives. At each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, DNA damage, SASP, and cellular stress using genome wide RNA sequencing. Relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.
9684246|NCT04892758||Formoterol fumarate 10 mcg|Reference Group
9684247|NCT04892758||Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Exposure Group
9684248|NCT04893044|Experimental|Exposure|These participants watched a 3 minute long video prior to a long weekend. The intent was to see if watching the video altered their alcohol consumption compared to a group that did not watch the video. Urine alcohol metabolites were measured before and after the weekend.
9684249|NCT04893044|No Intervention|Control|These participants did not watch a video, and their urine alcohol metabolites were measures at the same dates as the exposure group above.
9684250|NCT04892615||Cohort A|The drainage tube was removed on the 5th day after surgery.
10178691|NCT03810664|Experimental|Somatrogon pre-filled PEN|
10178692|NCT03810664|Active Comparator|Somatrogon frozen liquid formulation|
9684251|NCT04892615||Cohort B|The drainage tube was removed on the 7th day after surgery.
9684252|NCT04892485||CF patients|
9684253|NCT04892485||Controls|
9684254|NCT04892407|Experimental|Algeness DF 3.5%|This arm is with the Sponsor's product. The product is already CE Marked and sold for this indication for the majority of participating countries.
9684255|NCT04892407|Active Comparator|Juvéderm Voluma|This arm is with a Control product that is already CE Marked and sold for this indication.
9684256|NCT04892498|Experimental|RT+PD-1+GM-CSF+IL-2|
9684257|NCT04892589||Active Comparator: Control group|Thumb orthosis at night and day for 3 to 4 hours during Activities of Daily Living that included thumb metacarpophalangeal joint (MCP) for three months. In addition to a classic home exercise program.
9684258|NCT04892589||Experimental: Experimental group|The experimental group will receive thumb orthosis at night and daytime use for 3 to 4 hours during Activities of Daily Living that included the thumb MCP for three months. In addition to a classic home exercise program and a proprioceptive home exercises program divided in three phases.
9684259|NCT04892511|No Intervention|Standard treatment|"Post-thrombectomy patients will have their blood pressure measured every hour for the first 24 hours after thrombectomy, and every 6 hours from 24 to 72 hours. The target blood pressure is not predefined by the study, but in patients who have received previous treatment with rt-PA, it is advisable to keep it below 180/110 mmHg. If the patient has not received rt-PA, there is no limitation, although the guidelines recommend keeping the pressure below 200/120 mmHg.~The hypotensive or hypertensive treatments used will be noted."
9684260|NCT04892511|Experimental|Optimized hemodynamic treatment|"Post-thrombectomy patients will have their blood pressure measured every 30 minutes for the first 24 hours after thrombectomy, and every 1 hour from 24 to 72 hours. Blood pressure objectives will depend on the degree of recanalization achieved after thrombectomy (see intervention section).~The hypotensive or hypertensive treatments used will be noted."
9684261|NCT04892368|Active Comparator|Home supervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions. They will also receive 3-4 home visits by physiotherapists between recruitment and surgery, to conduct exercises in their homes.
9684262|NCT04892368|No Intervention|Home unsupervised exercise program|This group receives standard preoperative physiotherapy education as well a home-exercise instructions.
9684263|NCT04892550|Experimental|Traction group|"Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.~In addition, the participants in the intervention group will receive the Denneroll™ thoracic traction orthosis. All participants will begin at 3-minutes per session of DTTO application, each visit they will be encouraged to increase the duration by 2-3 minutes, until such time they will be able to reach the goal of 15-20 minutes per session."
9684264|NCT04892550|Active Comparator|Control group|Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises. The multimodal program will be delivered by the same physiotherapist, with 10 years of experience and training in the specific manual techniques in order to minimize inter-therapist variation and enhance fidelity.
9684265|NCT04892342|Experimental|ESG401 dose level 1|
9684266|NCT04892342|Experimental|ESG401 dose level 2|
10178693|NCT03810716|Experimental|Interactive Platform|Tha participants in this group will see the interactive platform and answer a survey before and after the intervention. Their clinical health records will be checked one month ago.
9684267|NCT04892342|Experimental|ESG401 dose level 3|
9684268|NCT04892342|Experimental|ESG401 dose level 4|
10178694|NCT03810716|No Intervention|Control|The participants in this group will answer the survey. Their clinical health records will be checked one month ago.
10178695|NCT03810586|Experimental|Comparing blood pressure measurement|In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
9684269|NCT04892342|Experimental|ESG401 dose level 5|
9684270|NCT04892342|Experimental|ESG401 dose level 6|
9684271|NCT04892381||Lichen Planus group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA in lesional and non lesional skin
9684272|NCT04892381||Control group|Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels using ELISA
9684273|NCT04892537|Active Comparator|CSR|Coronary Sinus Reducer implantation
9684274|NCT04892537|Placebo Comparator|Placebo|Placebo procedure
9684275|NCT04892394|Experimental|Video Group|Detailed visual video information was given to the video group patients before endodontic treatment by the clinician.
9684276|NCT04892394|Experimental|Control Group|Basic verbal information was given to the control group patients before endodontic treatment by the clinician.
9684277|NCT04892576|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program.
9684278|NCT04892576|Experimental|SSC group|Participants in this group received the standard physical rehabilitation program as the control group in addition to the SSC exercise program
9684279|NCT04892680|Experimental|Online Diabetes Self-Management Education and Support (DSMES) Program|Participants will receive access to a 6-month online DSMES program that includes several components that are standard to DSMES. Participants receive online curriculum, access to a live Certified Diabetes Care and Education Specialist (CDCES), interactive group message forums, and connected devices for monitoring food intake, weight, physical activity and glucose levels.
9684280|NCT04892680|No Intervention|Matched Control|A de-identified dataset of control subjects matched on baseline demographics and clinical characteristics will be cultivated for comparison to the active intervention arm.
9684281|NCT04892693|Experimental|Talazoparib|; Talazoparib should be taken orally once daily (ie, continuous daily dosing) at approximately the same time each day (preferably in the morning). Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the discretion of the treating physician.
9684282|NCT04892654|Experimental|Immediate Switch|Two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 96 weeks.
9684283|NCT04892654|Other|Delayed Switch|Participants will continue their current triple cART regimen for 48 weeks. Patients will then be switched to two-pill regimen, doravirine (100 mg) + dolutegravir (50 mg) tablets taken orally once daily for 48 weeks.
9684284|NCT04892329|Experimental|EUS AI navigation system augmentation|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
9684285|NCT04892329|No Intervention|without EUS AI navigation system augmentation|The endoscopists in the contrpl group performs the examination routinely without special prompts.
9684286|NCT04892563|Experimental|ESPB Block|Patients with rib fracture randomized to block group
9684287|NCT04892563|Active Comparator|Standard Care|Patients with rib fracture receiving IV analgesia/standard care
9684288|NCT04892316||Junior doctor group|Patients receive assisting devices fitting services from junior doctors
9684289|NCT04892316||Senior doctor group|Patients receive assisting devices fitting services from senior doctors
9684290|NCT04892316||Algorithm assisted group|Patients receive assisting devices fitting services from junior doctors assisted by the machine learning model
9695791|NCT04774562|Experimental|Video-Assisted Discharge Education (VADE) Group|VADE group received video-assisted discharge education in addition to the physiotherapy program given to the PT group on the same day by the same physiotherapist. The VADE program included information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities, home settings. VADE was prepared as a presentation of written information and videos which is shown this information by a professional model. Video shoots were done by a physiotherapist experienced in the field of physiotherapy and rehabilitation after THR surgery. The presentation was stopped when participants have questions or have points were not understood and the necessary explanations were shown verbally and practically. Along with the physiotherapy booklet, the participants were given an educational booklet containing written and visual information prepared in the same content as VADE.
9695792|NCT04774562|Experimental|Physiotherapy (PT) Group|The physiotherapy program given to the PT group after THR surgery. The physiotherapy program included breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation. The whole program was taught verbally and practically to participants and their relatives. Information was given about the exercises to be added at the end of the first week and in the 4th week. A physiotherapy booklet prepared with the same content was given to the participants. The booklet was examined by the patient and relatives, and the questions they asked were answered by the same physiotherapist. The participants were informed that they should continue the exercises for 12 weeks.
9695793|NCT04774185|Experimental|New hearing aid loudspeaker|The new hearing aid loudspeaker is a loudspeaker system with a modified acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
9695794|NCT04774185|Active Comparator|Standard hearing aid loudspeaker|The hearing aid loudspeaker is a loudspeaker system with the existing acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
9695795|NCT04774341||CDSS (MedicBK) Analysis|
9695796|NCT04774341||Core Laboratory Analysis|
10178696|NCT03810534|Experimental|Connect-Home|Connect-Home intervention at the skilled nursing facility and at the subject's home.
10178697|NCT03810534|No Intervention|Control|Standard discharge planning at the skilled nursing facility only.
9684291|NCT04892290||Group C|Postdural puncture headache patients treated with Conservative treatment
9684292|NCT04892290||Group SGB|Postdural puncture headache patients treated with Sphenopalatine Ganglion Block and conservative treatment
9976162|NCT01348672||2. POAG study arm|"Patient groups are organised according to established risk criteria for clinical progression (EMGT, 2003).~Group 1P (n=36); Stable, early to moderate, treated patients with POAG. Early to moderate POAG is defined as having an untreated IOP prior to treatment of >21mmHg and a repeatable visual field defect with a Mean Deviation of <12dB and/or documented but stable ONH appearance, consistent with a diagnosis of glaucoma.~Group 2P (n=36); Early to moderate, treated patients with normal tension glaucoma (NTG). Normal Tension Glaucoma is defined using the same criteria as POAG but with an untreated IOP of <21mmHg throughout the day. This group has NTG and is thought to be at increased risk of vascular dysfunction due to loss of ONH perfusion.~Group 3P (n=36); Early to moderate, treated patients with POAG or NTG with recurrent disc hemorrhage (indicative of progression)."
9684293|NCT04892303|Other|High-risk thyroid cancer patients|All study patients will have histologically confirmed recurrence of thyroid cancer that is incompletely responsive to initial surgery.
9684294|NCT04892212|Experimental|Sirolimus group|"The initial dose of sirolimus is 1mg/day. And the serum trough level of sirolimus is monitored at Week 2, Week 4, Week 8, and Week 12，respectively. The target serum trough level of sirolimus is 5-8 ng/mL. The dose of sirolimus is titrated according to therapeutic drug level monitoring.~The previous immunosuppressive medication is not allowed to be changed during the 3-month follow-up, unless premature discontinuation from study."
9684295|NCT04892199|Active Comparator|Semaglutide injection once-weekly|
9684296|NCT04892199|Placebo Comparator|Semaglutide-Placebo injection once-weekly|
9684297|NCT04892264|Experimental|Arm A (belantamab mafodotin, lenalidomide, daratumumab)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles (starting cycle 13), lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
9684298|NCT04892264|Experimental|Arm B (belantamab mafodotin, lenalidomide, daratumumab, Dxevo)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of cycles 2, 4, 6, 8, 10, and 12, lenalidomide PO QD on days 1-21, daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 3, and days 1 and 15 on cycles 5, 7, 9, and 11. Patients also receive dexamethasone PO on days 1, 8, 15 and 22. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of even numbered cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1 of odd numbered cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
9684299|NCT04892056|Experimental|Anterior Segment Retraction using Friction mechanics by elastomeric power chains|"Elastomeric power chains extending from 8mm crimpable hooks, distal to the lateral incisors, on 0.017x0.025 Stainless Steel WIres, to the mini-screws. The power chains delivered 160g of force per side."
9684300|NCT04892056|Experimental|Anterior Segment Retraction using Frictionless mechanics by T-loops|"T shaped closing loops were fabricated on 0.017x0.025 Titanium- Molybdenum wires (TMA) were used to deliver 160g of force per side by 4mm distal activations."
9684301|NCT04892069||Ryzodeg®|Participants are patients with Type 2 Diabetes (T2D) treated with Ryzodeg® (Insulin Degludec/Insulin Aspart) in a real-world adult population in Lebanon
9684302|NCT04892251|Experimental|MORE+KAP|8 weeks of Mindfulness-Oriented Recovery Enhancement plus two ketamine assisted psychotherapy sessions
10178698|NCT03810599|Other|Early cardiac rehabilitation|Single Group: 5 week cardiac rehabilitation programme. Pre-post comparison.
10178699|NCT03810625|Experimental|Sequence AB|D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.
9684303|NCT04892251|Active Comparator|MORE|8 weeks of Mindfulness-Oriented Recovery Enhancement
9684304|NCT04891939|Experimental|The intervention Arm|This arm will receive the novel intervention package for a period of three months to prevent smoking initiation and increase quit rate. The intervention will consist of 4 lessons which will be taught for about one hour each day. This will be segmented into two broad areas as knowledge and skill development. Under the knowledge-based program, participants will be taught, the global challenge of tobacco and tobacco products, correcting the erroneous impression about tobacco, the media and advertisement, and the harmful effects of smoking. The skill development program teaches about refusal skills (self-esteem, interpersonal relationship skills, and problem-solving skills). The participants will understand the tobacco advertising and marketing strategies; peer influence, and skills for resisting influences to smoke.
9684305|NCT04891939|Active Comparator|The Control Arm|The control arm will not receive novel intervention program but will continue with the usual School Health and Education program (SHEP) however, at the end of the intervention, all the materials will be sent to the control arm to also benefit from the lessons.
9684306|NCT04892017|Experimental|Dose Escalation (Part 1-A Monotherapy)|DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation will continue to the next planned dose cohort.
9684307|NCT04892017|Experimental|Dose Escalation (Part 1-B Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.
9977671|NCT01364025|Experimental|uterosacral ligament suspension|uterosacral ligament suspension colpopexy sutures will be placed bilaterally at the time of hysterectomy
10178700|NCT03810625|Experimental|Sequence BA|D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.
10178701|NCT03810677||Patients with varicose veins, eligible for EVLA|
10178702|NCT03810703|Placebo Comparator|placebo arm|Participant will receive placebo oral capsule during this four hour session.
10178703|NCT03810703|Experimental|amphetamine 10 mg arm|Participant will receive d-amphetamine 10 mg oral capsule during this four hour session.
10178704|NCT03810703|Experimental|amphetamine 20 mg arm|Participant will receive d-amphetamine 20 mg oral capsule during this four hour session.
9684308|NCT04892017|Experimental|Expansion Cohort 1 (Part 2)|DCC-3116 tablets BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with pancreatic ductal adenocarcinoma (PDAC).
9684309|NCT04892017|Experimental|Expansion Cohort 2 (Part 2)|DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with non-small cell lung cancer (NSCLC).
9684310|NCT04892017|Experimental|Expansion Cohort 3 (Part 2)|DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with colorectal cancer (CRC).
9684311|NCT04892017|Experimental|Expansion Cohort 4 (Part 2)|DCC-3116 tablets orally BID given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with melanoma.
9684312|NCT04892082|Experimental|Mindful Moment|Mothers who present parenting stress equal or above 41 score on PSS will receive a web-based intervention to reduce parenting stress (the Mindful Moment program).
9684313|NCT04892082|Active Comparator|Control|All mothers who present parenting stress will have access to Mindful Moment intervention. The control group only receive the intervention at the end of the intervention group.
9684314|NCT04892095||Study participants|Adult subjects (men and women) aged 18 years or more, living in 12 European countries
9684315|NCT04891848||migraine with aura|51 patients with MA
9684316|NCT04891848||migraine without aura|51 patients with migraine without aura
9684317|NCT04891848||tension type headache|48 patients with tension type headache
9684318|NCT04891848||healthy controls|80 healthy participants
9684319|NCT04892030|Experimental|Intervention|All participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies remotely, through an e-learning platform.
9684320|NCT04892160|Other|Guided Imagery First/Virtual Reality Second|Patients will be played a guided imagery experience first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the virtual reality intervention.
9684321|NCT04892160|Experimental|Virtual Reality First/Guided Imagery Second|Patients will have the VR interactive experience played first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the guided imagery intervention.
9684322|NCT04892108|Experimental|Group STARR|Patients undergoing transanal prolassectomy with mechanical stapler (STARR: Stapled Trans Anal Rectal Resection) randomly
9684323|NCT04892108|Experimental|Group LVR|Patients undergoing Laparoscopic suspensory correction of rectal prolapse by ventral rectopexy with biological prosthesis (LVR) randomly
9684324|NCT04892225|Experimental|Intervention group|Individuals in this group will be randomly assigned to text message in Urdu language on dietary sodium and fluid restriction daily for 8 weeks.
9684325|NCT04892225|No Intervention|Control group|Randomly assigned Control group will not receive any text message.
9684326|NCT04891861|Active Comparator|1 week restart|restart DOAC at 1 week post injury at label dose and frequency
9684327|NCT04891861|Active Comparator|4 week restart|restart DOAC at 4 weeks post injury at label dose and frequency
9684328|NCT04891744|Experimental|Selinexor in combination with thalidomide and Dexamethasone|Selinexor in combination with thalidomide and Dexamethasone. Thalidomide will be given at 100mg/d d1-28,and Dexamethasone 20 mg/d will be given on day 1, 2,8,9,15,16,22,23. Treatment will be administered in 28-day cycles,include a total of 12 cycles. Selinexor dose escalation: 60, 80, 100mg respectively on day 1,8,15,22 for 4-week cycles. Then Selinexor will be given at the recommended dose level on phase II.
9684329|NCT04891783||50 patients diagnosed as AS|50 patients diagnosed as AS according to 1984 modified New York criteria of AS .including radiographic and non-radiographic AS according to ASAS criteria these patients will undergo carotid ultrasound examination
9684330|NCT04891783||30 patients with psoriatic arthritis|30 patients with psoriatic arthritis who will be diagnosed according to the Classification Criteria of Psoriatic Arthritis (CASPAR) study these patients will undergo carotid ultrasound examination
9684331|NCT04891783||40 healthy controls|healthy controls will undergo carotid ultrasound examination
9684332|NCT04891874|Experimental|SBRT group|Participants in SBRT group will receive SBRT as adjuvant radiotherapy for hepatocellular carcinoma with microvascular invasion and narrow resection margin.
9684333|NCT04891874|No Intervention|Surgery alone group|Participants in surgery alone group will not receive any adjuvant therapy after surgery for hepatocellular carcinoma.
9977672|NCT01364025|No Intervention|hysterectomy alone|
9977673|NCT01364064|Active Comparator|Conventional adjuvant Temozolomide|TMZ d 1-5 of 28-d cycle 6 cycles
10178705|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 1|mRNA-3704
10178706|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 2|mRNA-3704
9684334|NCT04892004|No Intervention|Control group|Standard information defined as the standard care, unplanned, provided for Heart Failure patients and not personalized.
9684335|NCT04892004|Experimental|Interventional group|A nurse provides the intervention with expertise in Heart Failure and addresses reinforcements on: a) an explanation on signs and symptoms of Heart Failure and how to recognise them; b) importance on daily fluid management, by planning 1.5-2 litres of liquids per day (e.g., soup, milk, coffee, water, tea and yoghurts); and c) when doctors or nurses should be contacted (when symptoms escalation or a weight gain of 2 kg in three days or 5 kg in a week were detected).
10178707|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 3|mRNA-3704
10178708|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 4 (optional)|mRNA-3704
10178709|NCT03810690|Experimental|Dose Expansion Phase: mRNA-3704|
9684336|NCT04891926|Experimental|Hormonal therapy|Patients choosing to start hormoanl treatment using ural or transdermal estrogen.
10178710|NCT03810742|Experimental|Nanoliposomal Irinotecan + TAS-102|different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
10178711|NCT03810755|Other|Control group|Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
9684337|NCT04891900|Experimental|TQB2450 combined with anlotinib, oxaliplatin and capecitabine in the treatment of GC or AEG|In this study, all subjects were treated with TQB2450 (PD-L1 inhibitor) plus anlotinib combined with oxaliplatin and capecitabine, once every 3 weeks, six cycles of chemotherapy with oxaliplatin and capecitabine. Subsequently, TQB2450 (PD-L1 inhibitor) combined with anlotinib was maintained until disease progression, intolerable toxicity, withdrawal of informed consent, loss of follow-up or death, or other circumstances that the researcher judged should stop treatment, whichever occurred first.
9684338|NCT04891913|Experimental|15mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 15mg SY-007 or placebo twice a day for seven consecutive days.
9684339|NCT04891913|Experimental|30mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 30mg SY-007 or placebo twice a day for seven consecutive days.
9684340|NCT04891913|Experimental|60mg SY-007/ Placebo Repeat Dose|Intravenous infusion of 60mg SY-007 or placebo twice a day for seven consecutive days.
9684341|NCT04891887|Experimental|Intervention|Health education program
9684342|NCT04891653|Experimental|5-65mg QD|
9684343|NCT04891731||leuprorelin 3M plus AIs|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year AIs: anastrozole 1mg /letrozole 2.5mg/exemestane 25mg daily for 1 year
9684344|NCT04891731||leuprorelin 3M plus TAM|leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year TAM: daily for 1 year
9684345|NCT04891796||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
9684346|NCT04891796||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
9684347|NCT04891796||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
9684348|NCT04892238||Treatment-naïve|Subjects without previous experience of treatment provided for H.pylori infection
9684349|NCT04892238||treatment experienced|Subjects who were previously tested positive for H.pylori infection and who were treated for H.pylori infection with at least 2 antibiotics in combination with proton pump inhibitor not less than 6 weeks before the 13C-urea breath test
9684350|NCT04891601|Active Comparator|Group II MA Mesh alone repair|patient use mesh alone as treatment of inguinal hernia
9684351|NCT04891601|Active Comparator|Group I CMD Combined Mesh & darn|patients utilize both mesh and darn repair
9684352|NCT04891588|Experimental|Switching the preserved to preservative free prostaglandin analog-timolol FC|To switch preserved prostaglandin analog- timolol FC (Fixapost 50 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC in order to investigate whether that can result in alleviation or elimination of OSD and improvement of local tolerability.
9684353|NCT04891497|Experimental|Intraarterial Treatment plus Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
9684354|NCT04891497|Placebo Comparator|Intraarterial Treatment plus placebo|Placebo 240mg orally twice daily for 3 consecutive days
9684355|NCT04891510|Active Comparator|REVOLVE Advanced Adipose System|Participants will receive the REVOLVE Advanced Adipose System technique during breast reconstruction.
9684356|NCT04891510|Active Comparator|LipoGrafter|Participants will receive the LipoGrafter technique during breast reconstruction.
9684357|NCT04891510|Active Comparator|Standard Decantation|Participants will receive the Standard decantation technique during breast reconstruction.
9684358|NCT04891679|Active Comparator|Group A (Titrated OMS)|Titrated oral misoprostol solution
9684359|NCT04891679|Active Comparator|Group B (Static OMS)|Static oral misoprostol solution
9684360|NCT04891471|Experimental|SRS/SBRT arm|Patients with five or more brain metastasis assigned by randomization to Stereotactic RadioSurgery (SRS) or Stereotactic Body RadioTherapy (SBRT) will be treated with a highly-conformal metastasis-directed single dose between 15 and 24 Gy or fractionated dose (e.g. 27 Gy in 3 fractions), respectively, depending on lesion size, while sparing clinically negative brain. The treatment will be delivered using five non-coplanar arcs and a mono-isocentric technique.
9684361|NCT04891471|Active Comparator|WBI arm|Patients with five or more brain metastasis assigned by randomization to Whole Brain Irradiation (WBI) will be treated using a 3D-Conformal RadioTherapy technique for a uniform dose delivery of 30 Gy in 10 daily/fractions to the target, that is entire brain.
9684362|NCT04891367|Experimental|Group CBT|Group cognitive behavioral therapy for obsessive compulsive disorder in youth
9684363|NCT04891666|Experimental|Lactobacillus plantarum DSM 33464|1 sachet of Lactobacillus plantarum DSM 33464 (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks
9684364|NCT04891666|Placebo Comparator|placebo|1 sachet of placebo (2 g) and 1 sachet of supplement YingKangWei per day for 24 weeks
9684365|NCT04891458|Experimental|Patients received lighter sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 0-2.
9684366|NCT04891458|Experimental|Patients received heavier sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 3-5.
10178712|NCT03810755|Other|Supervision group|Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
10178713|NCT03810547|Active Comparator|Spinal anesthesia|Patients undergoing abdominoplasty under spinal anesthesia may need to drug administration like propofol or ketamine or change anesthesia to general anesthesia.
10178714|NCT03810547|No Intervention|General anesthesia|General anesthesia for abdominoplasty
9827801|NCT02469064|Active Comparator|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
9684367|NCT04891458|Experimental|Patients received lighter sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 0-2.
9684368|NCT04891458|Experimental|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 3-5.
9684369|NCT04891627||Healthy control groups|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
9684370|NCT04891627||Periodontitis group|Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4. Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.
9684371|NCT04891627||Periodontitis with diabetes group|"Inclusion criteria for T2DM patients were based on the American Diabetes association published in 2010. Individuals to the T2DM group; It was selected from individuals diagnosed with T2DM for more than 5 years by their own physicians according to daily plasma glucose (200 mg / dl) and hemoglobin A1c (HbA1c ≥6.5%).~Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4. Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C."
9684372|NCT04891406|Other|ZoneX#2 - ZoneX#3 - Skruf - Swave - Cigarette (sequence order ABCDE)|"Subjects use product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes on Day 1, then switch to use product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 min on Day 2, then product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 min on Day 3, then D (Swave Daquiri, nicotine pouch, 10.6 mg/pouch) on Day 4 and finally E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette), smoked in approximately 5 minutes with puffs taken at regular intervals approximately 30 seconds apart, on Day 5.~Subjects can use their assigned product ad libitum on each study day, after all study assessments are performed, until 10pm. A washout period of product abstinence is observed between products, overnight."
9684373|NCT04891406|Other|ZoneX#3 - Skruf - Swave - Cigarette - ZoneX#2 (sequence order BCDEA)|Same as previous arm but in a different randomization order.
9684374|NCT04891406|Other|Skruf - Swave - Cigarette - ZoneX#2 - ZoneX#3 (sequence order CDEAB)|Same as previous arm but in a different randomization order.
9684375|NCT04891406|Other|Swave - Cigarette - ZoneX#2 - ZoneX#3 - Skruf (sequence order DEABC)|Same as previous arm but in a different randomization order.
9684376|NCT04891406|Other|Cigarette - ZoneX#2 - ZoneX#3 - Skruf - Swave (sequence order EABCD)|Same as previous arm but in a different randomization order.
9684377|NCT04891575|Active Comparator|Active Control Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes who is randomized to this arm will attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The index participant will attend the sessions as an individual and will receive standard individual-focused lifestyle modification education.
9684378|NCT04891575|Experimental|Family Dyad Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes and a co-participating family member will together attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The dyadic intervention sessions also incorporate family-focused throughout each session to encourage dyadic support.
9684379|NCT04891562|Experimental|pDCD (hildren with (probably) Developmental Coordination Disorder)|children with (probably) Developmental Coordination Disorder (pDCD)
9684380|NCT04891562|Active Comparator|TDC (Typically Developing Children)|Typically Developing Children
9684381|NCT04891536|Experimental|Patients with histologically confirmed recurrent prostate cancer after primary radiation therapy|
9684382|NCT04891718|Experimental|MVC-101 and Nivolumab|Patients with HNSCC who are scheduled for surgical biopsy or tumour resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline and solution stabilizer), a pre-cleaved/pre-activated drug control (cMVC-101), MVC-101 (the prodrug), or nivolumab as single agents or as combinations. Each drug will be delivered in subtherapeutic microdoses, and each microdose is simultaneously injected in a columnar fashion through each of 3, 5, or 8 needles (in a device configuration determined by tumour dimensions) into a single solid tumour or effaced metastatic lymph node.
9684383|NCT04891237|Experimental|10,000 MG01 + 10,000 T517|10,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
9684384|NCT04891237|Experimental|30,000 MG01 + 10,000 T517|30,000 TU/mL of MG01 + 10,000 TU/mL of T517 of subcutaneous immunotherapy
9684385|NCT04891237|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
9684386|NCT04891263|Experimental|Suture-Septoplasty|Participants will receive suture-septoplasty technique, and will be followed for three months postoperatively.
9684387|NCT04891224|Other|Pathway Platform application use|Study participants will download the Pathway app to their mobile device. This app will gather patient health data, present standardized questionnaires and research data collection tools. Subject responses will be visible to their provider via interface with the electronic medical record.
9684388|NCT04891172|No Intervention|Control|The Control group will be receive Standard of care only
9684389|NCT04891172|Experimental|C-IVIG|The intervention group will receive the single dose of C-IVIG (0.15g/kg) with Standard of Care
9684390|NCT04891146||Inhalation anesthesia|Sevoflurane for opioid remifentanyl used
9684391|NCT04891146||Total Intravenous Anesthesia|Propofol for opioid remifentanyl used
9684392|NCT04891380|Other|Cardiac arrest patients|Cardiac arrest patients receiving cardiopulmonary resuscitation with LUCAS 2 Active Decompression 2.
9684393|NCT04891380|Other|Hypotension|Patients developed or may develope hypotension of non traumatic origin.
9684394|NCT04891380|Other|Intensive care patient transport|Patients who are transported from one intensive department to another.
9977674|NCT01364064|Experimental|Dose intensive Temozolomide|TMZ d 1-21 of 28-d cycle 6 cycles
9977675|NCT01364077|Active Comparator|Ivabradine|
9684395|NCT04891380|Other|LUCAS 2 Active Decompression|The hemodynamic measurements of the cardiac arrest patients in the present study will be compared with the hemodynamic measurements achieved in the previous study NCT02479152.
10178715|NCT03810521|Experimental|CLT low-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
9684396|NCT04891120|Experimental|With, then without a mask|Participants will first perform a treadmill test with a mask and 48 hours or more later will perform another similar treadmill test without a mask.
9684397|NCT04891120|Experimental|Without, then with a mask|Participants will first perform a treadmill test without a mask and 48 hours or more later will perform another similar treadmill test with a mask.
9684398|NCT04891159||Shared decision making|During the first consultation (V1), the doctor will present the patient on the therapeutic treatment information related to diabetes according to the shared decision making (options, benefits, risks) with the assistance of decision support tools. The decision-making visit will take place after a reflection period of 8 to 15 days after V1. A discussion based on the feedback from this period of reflection will take place between the two actors and either there is a common agreement on the decision taken (shared decision-making), or the decision is taken by the patient, or the decision is made by the physician at the request of the patient. A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing. After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires: SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire
9684399|NCT04891159||Control group|"Decision-making for insulin therapy is based on the usual practice defined in each Cystic Fibrosis Centers Competences with decision-making procedures specific to each center and doctor. The decision-making process is generally carried out in two consultations.~A social sciences and humanities methodologist will attend each consultation, onsite or in videoconferencing.~After the consultation, he realized a semi-structured interview with the patient. During this interview, the patient filled the self-administered questionnaires (SDM-Q-9, SURE, CollaboRATE, Spielberger test and the research team questionnaire)."
9684400|NCT04891302|Experimental|Clevudine|Clevudine 150 mg once a day for 10 days
9684401|NCT04891302|Placebo Comparator|Placebo|Matching Placebo once a day for 10 days
9684402|NCT04891211|Active Comparator|Pediatric endocrinologist|Patient selection by pediatric endocrinologist on the basis of vitamin D
9684403|NCT04891211|No Intervention|Ophthalmologist|"Evaluation of the results by 2 different retina specialists during the examination of patients~Interpretation of the results without knowing the vitamin D level of patients"
9684404|NCT04891042||Latent Phase of Labour|
9684405|NCT04891042||Active Phase of Labour|
9684406|NCT04891107|Experimental|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Will walk for 30 minutes at a time, 5 times a week, for 4 weeks using the wearable sensor system at home or in the community.
9684407|NCT04890990|Active Comparator|Black girl, control (BC)|~120-second video of a Black adolescent girl, without depression
9684408|NCT04890990|Active Comparator|Black girl, depressed (BD)|~120-second video of a Black adolescent girl, depressed
10178716|NCT03810521|Experimental|CLT medium-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
10178717|NCT03810521|Experimental|CLT high-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
10178718|NCT03810443|Experimental|pulmonary arterial hypertension|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
10178719|NCT03810300|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
10178720|NCT03810300|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
9977676|NCT01364077|Placebo Comparator|Control|
10178721|NCT03810300|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
10178722|NCT03810300|Experimental|Cash transfer + nutrition BCC|1500 taka ($18.75) per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
10178723|NCT03810300|Experimental|Food transfer + nutrition BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
10178724|NCT03810300|Experimental|Control|No transfer, no behavior change communication
10178725|NCT03810430|Active Comparator|intervention group|ten clusters (villages) were received health promotion activities during six months of interventions
10178726|NCT03810430|No Intervention|control group|10 clusters (villages) were not received intervention during the intervention period and by the end of study, it will be compared with the intervention group to measure the change in the primary and secondary outcomes.
10178727|NCT03810170|Active Comparator|control|control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
10178728|NCT03810170|Experimental|intervention|intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
10178729|NCT03810118|Experimental|Treatment|All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
10178730|NCT03810287|Experimental|Patients receiving Domperidone|Patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy.
10178731|NCT03810131|No Intervention|Waitlist control|This is a group who are waiting for treatment (the control group)
10178732|NCT03810131|Experimental|BOA online intervention|The is the group who are receiving the BOA online intervention.
10178733|NCT03810157|Experimental|Laser-assisted hatching system|Embryos were exposed to a dose of laser energy focused outside the zona pellucida by aser-assisted hatching system.
10178734|NCT03810157|No Intervention|Control group|Nothing is done.
10178735|NCT03810326|Experimental|Intervention|
10187428|NCT03726307|Experimental|DCreg: 0.5 million cells/kg+SOC|"N=3 participants will receive 0.5 (± 0.1) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
9684409|NCT04890990|Active Comparator|Black girl, depressed, adjusted (BDa)|~120-second video of a Black adolescent girl, depressed - adjusted for the specifics of being a Black girl (as informed by a focus group of Black girls and women)
9684410|NCT04890977|Experimental|Talking Story|Talking Story is a modular behavioral intervention intended to increase mental health treatment-seeking among Pacific Islanders through the use of narrative films and other culturally syntonic approaches.
9684411|NCT04890977|Placebo Comparator|Wait-list control|The wait-list control will be administered as a control arm to the active Talking Story arm.
9684412|NCT04891003||Patients Diagnosed with Endometriosis (or endometrioma alone)|Nulliparous patients who had diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
9684413|NCT04891003||Patients With No Gynecological Pathology|Nulliparous patients who had not diagnosed with endometriosis, no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies
9684414|NCT04890951||Uterine Preservation|
9684415|NCT04890951||Hysterectomy|
9684416|NCT04890925|No Intervention|Control group|Women who have experienced intimate partner violence but no sustained brain injury (Brain Injury Severity Assessment; BISA = 0)
9684417|NCT04890925|Experimental|Community Support Network (CSN) intervention group|The SOAR Community Support Network (CSN) intervention includes cognitive training, aerobic exercise, mindfulness meditation, counselling, quality of life tracking.
9684418|NCT04890925|Active Comparator|Usual care|Participants in this group will receive dose-equivalent usual care
9684419|NCT04890782||MMD group|Consecutive patients diagnosed with MMD during hospitalization in Beijing Tiantan Hospital, Capital Medical University will be recruited.
9684420|NCT04890782||Healthy control group|Age and sex matched subjects will be invited to join the study as the control.
9684421|NCT04890834|Active Comparator|Arm I (Standard of care)|Patients and caregivers receive standard care including education pertaining to symptom management, prophylactic dental hygiene and possible extraction, speech pathology for baseline swallowing assessment and prophylactic treatment, and dietary services for regular nutrition consults during CRT. Psychiatry, social work, interventional radiology and supportive care services are consulted as needed.
9684422|NCT04890834|Other|Arm II (exercise, yoga sessions)|Patients and caregivers receive standard care as in arm I. Patients and caregivers also participate in yoga sessions 3 times per week over 60 minutes each for a total of 15 sessions.
9684423|NCT04890730||Southern Medical University of Nanfang Hospital|Southern Medical University of Nanfang Hospital
9684424|NCT04890730||Tongji Hospital Affiliated to Tongji University|Tongji Hospital Affiliated to Tongji University
9684425|NCT04890730||The Second Affiliated Hospital Of Nanchang University|The Second Affiliated Hospital Of Nanchang University
9684426|NCT04890808|Experimental|Over-the-Counter Dietary Supplement Inosine|capsules containing 500 mg of inosine Two capsules Twice Daily Other Name: hypoxanthine 9-β-D-ribofuranoside 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl) oxolan-2-yl]-1H-purin-6-one
9684427|NCT04890808|Experimental|Over-the-Counter Dietary Supplement IP6|"capsules containing 500mg of IP6 Two capsules Twice Daily Other Name: Inositol hexaphosphate~(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexakis[dihydrogen (phosphate)]"
9684428|NCT04890639|Experimental|AIH group|Hypoxia will be administered by a specialized face mask which controls oxygen content in inhaled air while breathing into a gas mixing device (HYP123, Hypoxico Inc).The hypoxia administering unit will be manually adjusted to reach the targeted level (approximately 21%-normal oxygen, 17%, 13%, and 9%) for each of the four sessions. These hypoxia sessions consist of breathing in normal air followed by 15 cycles of hypoxia for up to 60 seconds combined with 90 second room air breaths between hypoxic sessions. An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered (MAX-250E, Maxtec Inc.).
9684429|NCT04890743|Experimental|Conventional TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
9684430|NCT04890743|Experimental|Pseudo-acupuncture TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
9684431|NCT04890743|Experimental|Trabert ultrastimulation group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
9684432|NCT04890743|Placebo Comparator|Placebo group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
9684433|NCT04891081||Patients with cyanotic Congenital Heart Disease|
9684434|NCT04891081||Patients with acyanotic Congenital Heart Disease|
9684435|NCT04890717||ASD and/or ADHD children (Case group)|Suspected or confirmed cases of ASD and/or ADHD children (Case group); no intervention(s) to be administered.
9684436|NCT04890717||Parent group|Parents of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
9684437|NCT04890717||Sibling group|Typically developed siblings of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
10187996|NCT03720548|Placebo Comparator|Placebo (Part B)|Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.
9684438|NCT04890717||Control group|Typically developed children not related to the case group ; no intervention(s) to be administered.
9684439|NCT04890626|Experimental|Main randomization.Arm: Emtricitabine / Tenofovir disoproxil fumarate|Emtricitabine / Tenofovir disoproxil fumarate
9684440|NCT04890626|No Intervention|Main randomization.Arm: No treatment|No treatment
9684441|NCT04890626|Other|Rescue randomization: Arm: Dexamethasone + Baricitinib|Rescue randomization: patients with oxygen requirements, O2 Sat <95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
9684442|NCT04890626|Other|Rescue randomization: Arm: Dexamethasone|Rescue randomization: patients with oxygen requirements, O2 Sat <95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: Dexamethasone + Baricitinib or Dexamethasone.
9684443|NCT04890704|Experimental|Curcumioids|The investogators prescribed curcuminoids 1,500 mg/day . The regimen was curcuminoids 500 mg three times a day from three days before the procedure until two days after. All patients also received standard prophylaxis protocol which included 0.9% sodium chloride 1 mL/kg/hour, given 12 hours before and 12 hours after CAG unless contraindicated.
9684444|NCT04890704|Placebo Comparator|Placebo|The placebo was identical capsule given three times daily and the remaining protocols were the same as the active group
9684445|NCT04890964|Active Comparator|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - DLPFC|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
9684446|NCT04890964|Sham Comparator|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - DLPFC|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
9684447|NCT04890964|Active Comparator|Transcranial Direct Current Stimulation (tDCS), Active Stimulation - M1|Participants received Active stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
9684448|NCT04890964|Placebo Comparator|Transcranial Direct Current Stimulation (tDCS), Sham Stimulation - M1|Participants received Sham stimulation 20 minutes daily for 20 days, and 4 times after continuous stimulation, every 15 days.
9684449|NCT04890860|Experimental|Adults patients undergoing mitral and / or tricuspid valve surgery with cardiopulmonary bypass.|
9684450|NCT04890535|Active Comparator|Part 1 Dose Level 1: 25 mg TBAJ-587|25 mg TBAJ-587
9684451|NCT04890535|Placebo Comparator|Part 1 Dose Level 1: placebo|placebo
9684452|NCT04890535|Active Comparator|Part 1 Dose Level 2: 50 mg TBAJ-587|50 mg TBAJ-587
9684453|NCT04890535|Placebo Comparator|Part 1 Dose Level 2: placebo|placebo
9684454|NCT04890535|Active Comparator|Part 1 Dose Level 3: 100 mg TBAJ-587|100 mg TBAJ-587
9684455|NCT04890535|Placebo Comparator|Part 1 Dose Level 3: placebo|placebo
9684456|NCT04890535|Active Comparator|Part 1 Dose Level 4: 200 mg TBAJ-587, Part one food effect cohort|200 mg TBAJ-587, Part one food effect cohort
9684457|NCT04890535|Placebo Comparator|Part 1 Dose Level 4: placebo|placebo
9684458|NCT04890535|Active Comparator|Part 1 Dose Level 5: 400 mg TBAJ-587|400 mg TBAJ-587
9684459|NCT04890535|Placebo Comparator|Part 1 Dose Level 5: placebo|placebo
9684460|NCT04890535|Active Comparator|Part 1 Dose Level 6: 800 mg TBAJ-587|800 mg TBAJ-587
9684461|NCT04890535|Placebo Comparator|Part 1 Dose Level 6: placebo|placebo
9684462|NCT04890535|Active Comparator|Part 2 Dose Level 1: XXX mg TBAJ-587|XXX mg TBAJ-587
9684463|NCT04890535|Placebo Comparator|Part 2 Dose Level 1: placebo|placebo
9684464|NCT04890535|Active Comparator|Part 2 Dose Level 2: XXX mg TBAJ-587|XXX mg TBAJ-587
9684465|NCT04890535|Placebo Comparator|Part 2 Dose Level 2: placebo|placebo
9684466|NCT04890535|Active Comparator|Dose Level 3: XXX mg TBAJ-587|XXX mg TBAJ-587
9684467|NCT04890535|Placebo Comparator|Dose Level 3: placebo|placebo
9684468|NCT04890886||Pre-existing Type 1 Diabetes and Type 2 Diabetes|Women with type 1 diabetes and type 2 diabetes diagnosed prior to pregnancy
9684469|NCT04890886||Gestational Diabetes|Women with gestational diabetes diagnosed in pregnancy by the oral glucose tolerance test
9684470|NCT04890886||Intrahepatic cholestasis of pregnancy|Women with intrahepatic cholestasis of pregnancy
9684471|NCT04890886||Control|Women without metabolic disease in pregnancy
9684472|NCT04890847||human-machine collaboration group|healthcare professionals and machine collaboration for annotation and AI model development
9684473|NCT04890847||pure mannual group|healthcare professionals for pure manual annotation and AI model development
9684474|NCT04890795|Experimental|AL8326|Subject will received AL8326 once daily for 28-days cycle until intolerable toxicity or disease progression or death or voluntary withdrawal the end of this study.During treatment, subjects will be evaluated for anti-tumor efficacy and corresponding safety examinations every 2 cycles, and tumor disease status will be according to RECIST 1.1.
9684475|NCT04890522|Experimental|Experimental group|5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days, and intravenous infusion of cisplatin 80 mg/m2 on day 1 and day 28, and intravenous infusion of JS001 240mg on day 1 and day 21, every 60 days.
9684476|NCT04890522|Active Comparator|Control group|gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1, and intravenous infusion of JS001 240mg on day 1, every 21 days.
9684477|NCT04890756||Reliability Group|100 Healthy Adults
9684478|NCT04890756||Validity Group|45 Healthy Adults
9684479|NCT04890678|Experimental|22 residentsat risk for PU development|"22 residents at risk for PU development, defined by a Braden score < 12 and/or a Braden subscale 'Mobility' score ≤ 2 and/or the presence of non-blanchable erythema in the sacral area.~aged 65 years or over"
9684480|NCT04890678|Experimental|18 residents at least one PU category III-IV in the sacral area|18 residents at least one PU category III-IV in the sacral area aged 65 years or over
9684481|NCT04890691|Experimental|BLT-1|Light therapy (wavelengths between 470nm and 525nm), 30 minutes/day for 4 weeks.
10178736|NCT03810391|Experimental|preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group A were >11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
9684482|NCT04890691|Placebo Comparator|BLT-2|Placebo light (wavelength between 620nm and 750 nm), 30 minutes/day for 4 weeks.
10178737|NCT03810391|Placebo Comparator|preoperative anxiety and saline|preoperative anxiety scores of patients in Group B were >11 and received an infusion of the same volume of physiological saline
10178738|NCT03810391|Experimental|non-preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group C were ≤ 11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
9684483|NCT04890587|Experimental|AL8326|"Part 1:(closed)Cohort 1 will initiate with AL8326 for single dose and multiple dose (28-Day cycles) . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, several additional cohorts will be sequentially for the same 28-day cycles.~Part 2 :(open)Each subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy.~Part 3:(open)Cohort 3 will initiate with AL8326(bid), for 28-Day cycles . After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at decreased dose of AL8326 for the same 28-day cycles."
9684484|NCT04890561|Experimental|Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1.
9684485|NCT04891055||patients treated with nivolumab|Patients candidates for II line therapy with Nivolumab from clinical practice
9684486|NCT04891055||patients treated with TKI|Patients candidates for II line therapy with TKI from clinical practice
9684487|NCT04890665|Experimental|Experimental: Self-applied psychological intervention for healthcare workers|Participants in this group will receive 9 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, stress, burnout, fatigue compassion, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life. The participants will have the option to do 3 extra modules that are complimentary for the intervention.
9684488|NCT04890665|Active Comparator|Control: Self-applied psychological intervention for healthcare workers|The participants in this group will receive exactly the same intervention but delivered through a therapist in a weekly session through an online video call. The participants will be informed also about the 3 extra modules and briefly what it is the contents of these modules so they can accept or not receive these extra contents.
9684489|NCT04890457|Experimental|Tragus then earlobe stimulation|
9684490|NCT04890457|Experimental|Earlobe then tragus stimulation|
9684491|NCT04890353|Experimental|standard management plus Dimethyl Fumarate|
9684492|NCT04890353|Placebo Comparator|standard management plus placebo|
9684493|NCT04890288|Experimental|Intervention group - High flow|High-flow nasal cannula oxygen 2L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0; enabling apneic oxygenation during laryngoscopy.
9684494|NCT04890288|Experimental|Intervention group - Low flow:|Low-flow oxygen (100%, 0.2 l/kg/min) via conventional neonatal nasal cannula (Intersurgical, Wokingham, Berkshire, United Kingdom) enabling apneic oxygenation during laryngoscopy.
9684495|NCT04890288|No Intervention|Conventional|Conventionally practiced standard of care with preoxygenation with facemask with an FiO2 of 1.0, followed by bag mask ventilation after induction before oral intubation without apneic oxygenation.
9684496|NCT04890301|Experimental|Puncture Template and CT group|Puncture Template assisted CT guided lung biopsy was performed.
9684497|NCT04890301|Active Comparator|CT group|Simple CT guided lung biopsy was performed.
9684498|NCT04890366|Experimental|Alteplase plus Dimethyl Fumarate|
9684499|NCT04890366|Placebo Comparator|Alteplase plus placebo|
9684500|NCT04890223|Experimental|Intervention group|The participants in the intervention group will be asked to identify an unfavourable behaviour that they wish to change when filling out the baseline questionnaire. The research nurse will conduct the individual face-to-face brief MI interviews for this purpose, which will last for approximately five to ten minutes. After the face-to-face brief MI interviews, the participants in the intervention group will receive brief MI messages individually by means of mobile instant messaging for six months from the baseline. After six months, the brief MI messages will cease to be delivered to the participants in the intervention group, with whom the research team will then maintain only minimal contact until the 12-month follow-up.
9684501|NCT04890223|Placebo Comparator|Control group|Participants in the control group will be asked to identify an unfavourable behaviour that they want to change at the baseline but, rather than brief MI interviews delivered face-to-face, received generic health advice consultations on the selected unfavourable behaviour that lasted approximately five to ten minutes. Each participant will receive a self-help smoking cessation booklet titled Be Smart, Quit Smoking! published by the Hong Kong Council on Smoking and Health with information about the negative health consequences of smoking, reasons to quit, strategies for quitting, and smoking cessation services available in Hong Kong along with a public quitline number (specifically, 1833183). Those who express the intention to quit at follow-ups will receive usual smoking cessation support.
9695797|NCT04774510|Other|Optimized C-ARM CBCT|An optimized C-arm CBCT evaluation with a different acquisition geometry and a novel software for the rapid, quality improved and less-artefacts assessment of brain parenchyma and angiogram.
9695798|NCT04774276||Group with occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They will have the cardiac rehabilitation protocol (4 weeks) with occupational therapist as usual practice. The inclusion in this group will be prospective, from January 2021.
9695799|NCT04774276||Group without occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They have done the cardiac rehabilitation protocol (4 weeks) without occupational therapist until december 2020. The inclusion in this group will be retrospective,
9684502|NCT04890275|Experimental|BFR|Participants will participate in a supervised low load lower body blood flow restriction resistance exercise program twice a week for 12 weeks
9684503|NCT04890275|Active Comparator|NON-BFR|Participants will participate in a supervised low load lower resistance exercise program twice a week for 12 weeks (matched training volume as experimental arm but without BFR)
9684504|NCT04890379|Experimental|standard management plus Dimethyl Fumarate|
9684505|NCT04890379|Placebo Comparator|standard management plus placebo|
9684506|NCT04890496||inpatients of ZOC|Patients have retrospective hopitalization record of ZOC from 1998 to 2020.
9684507|NCT04890405|Active Comparator|FMT group|Standardized FMT once.Extract all the flora from the feces provided by the donor to make fecal bacteria transplant capsules. The patient took orally on an empty stomach, each time using 3.2g of fecal bacteria.
9684508|NCT04890405|Experimental|JZ group|1.6g Po perday,for 28 days. probiotics that are effective against diarrhea were selected to make precise flora capsules, which are taken when the patient is on an empty stomach, once a day, using 1.6 g of bacteria per day, orally for 28 consecutive days.
9684509|NCT04890145|Experimental|Mild to severe hearing loss|
9684510|NCT04890418|Active Comparator|Study drug|0.3 mg/kg intravenous ketamine diluted into 10mL saline after the realization of peripheral nerve block (PNB), before tourniquet set up and beginning of surgery
9684511|NCT04890418|Placebo Comparator|Placebo|10 mL 0.9% saline after the realization of PNB, before tourniquet set up and beginning of surgery
9684512|NCT04890483|Experimental|Intervention|The ARD patients with post-acute COVID-19 will receive tDCS sessions for one week.
9684513|NCT04890392|Experimental|PD-1 with SOX|S-1: 40~60mg Bid，d1~14, q3w Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w
9684514|NCT04890184|Active Comparator|grape juice|100 g of grape juice daily
10178739|NCT03810391|Placebo Comparator|non-preoperative anxiety and saline|preoperative anxiety scores of patients in Group D were ≤11 and received an infusion of the same volume of physiological saline
9684515|NCT04890184|Placebo Comparator|control|no dietary intervention
9684516|NCT04890210|Experimental|Early Diet Group|"1st diet: 100 ml of clear fluid (1 hour after esophageal variceal ligation)~2nd diet: 100 ml of clear fluid (4 hours after the 1st diet)~3rd diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 4 hours after the 2nd diet~4th diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 3rd diet~5th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 4th diet~6th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 5th diet~7th diet: soft rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 6th diet~8th diet: regular rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 7th diet"
9684517|NCT04890210|Active Comparator|Late Diet Group|"1st diet : 100 ml of clear fluid (6 hours after esophageal variceal ligation)~After the 1st diet (Day 1): 6x100 ml of clear fluid for 24 hours~Day 2: soft porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 3: porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 4: soft rice (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 5: regular rice (the amount will be calculated according to patient's caloric needs) for 24 hours and beyond"
9684518|NCT04890171|Active Comparator|Endoscopic treatment arm|Endoscopic submucosal dissection
9684519|NCT04890171|Active Comparator|Surgical treatment group|Gastrectomy with lymph node dissection
9684520|NCT04890262||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) treatment in line with current Summary of Product Characteristics (SmPC) or local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.
9684521|NCT04890015|Experimental|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
9684522|NCT04890015|No Intervention|Non intraoperative transanal decompression tube placement|The usual postoperative care approved by the unit will be followed.
9684523|NCT04890197|Active Comparator|tahini|48 gr per day
9684524|NCT04890197|Placebo Comparator|control|no intervention
9684525|NCT04890314||Active Surveillance (AS)|Doctor will monitor the patient without directly treating the cancer.
9684526|NCT04890314||Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment of prostate cancer requiring less than 2 weeks of treatment.
9684527|NCT04890314||Intensity-Modulated Radiation Therapy (IMRT)|Radiation treatment of prostate cancer requiring more than 2 weeks of treatment.
9684528|NCT04890314||Partial Gland Ablation (PGA)|Prostate cancer treatment that involves only treating part of the prostate that has cancer. Examples include, but are not limited to, high intensity focused ultrasound (HIFU) and cryotherapy.
9684529|NCT04890314||Radical Prostatectomy (RP)|Prostate surgery that removes the whole prostate.
9684530|NCT04890470|Experimental|oxytocin group|subjects with oxytocin treatment
9684531|NCT04890470|Experimental|vasopressin group|subjects with vasopressin treatment
9684532|NCT04890470|Placebo Comparator|placebo group|subjects with placebo treatment
9684533|NCT04890080|Experimental|PR Group|Patients diagnosed with COPD according to GOLD and completed the 2-day / 8-week PR program
9684534|NCT04890041|Experimental|Treatment group|20 subjects will be enrolled with the indicated treatment dose of avatrombopag
9695800|NCT04774354||Abdominal surgery|POSSUM, the P-POSSUM and the Charlson comorbidity index will be calculated and compared to the outcomes obtained in our center.
9695801|NCT04774263||General population|general population
9695802|NCT04774263||emergency caregivers|emergency caregivers
10187997|NCT03720522||Group 1: Patients suffering from acute myocardial infarction|Patients with positive gadolinium late enhancement and positive intramyocardial oedema in the short CMR have an acute myocardial infarction and will be allocated to group 1.
10178740|NCT03810378|Experimental|Mediterranean Diet (Med-Plus)|Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
9684535|NCT04889768|Experimental|Experimental: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"surgical exploration, if PCI<20, then we perform this study.~HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
9684536|NCT04889963|Placebo Comparator|control group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)
9684537|NCT04889963|Active Comparator|conditioned medium group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium
9684538|NCT04889963|Active Comparator|stem cells group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition
9684539|NCT04889963|Experimental|composite group|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium
10178741|NCT03810378|Experimental|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.
10178742|NCT03810209|Active Comparator|magnesium sulphate group|The investigator injected 28.5 mL of bupivacaine 0.5% and 1.5 ml MgSo4 (150 mg), a total volume of 30 ml, it was confirmed visually by the ultrasound.
10178743|NCT03810209|Placebo Comparator|control group|The investigator injected 28.5 mL of Bupivacaine 0.5% and 1.5 mL of normal saline, a total volume of 30 ml, it was confirmed visually by the ultrasound.
9684540|NCT04890002|Experimental|Far-infrared emitting pyjamas (FIR pyjamas) group|Subjects in this group will be provided the Far-infrared emitting pyjamas. The FIR pyjamas was fabricated by using two textile materials, pure cotton fibres and the proposed man-made FIR fibres with the far-infrared emitting function.
9684541|NCT04890002|Sham Comparator|Sham-pyjamas Group|To control the placebo effect in the FIR pyjamas group, participants in this group will receive pyjamas with identical physical appearance which are produced using the same fabrication process as the pyjamas received in FIR pyjamas group. The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function. The participants will be asked to wear the sham-pyjamas daily at night for 6 consecutive weeks.
9684542|NCT04889911|Experimental|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a structured, 20-session group-based treatment called that combines psychoeducation, cognitive restructuring, and elements of narrative psychotherapy. NECT-YA will be modified to meet the needs of people who have experienced an FEP and may have fewer sessions or be provided in individual format or via telehealth for this study. NECT-YA will be offered to participants who are also receiving treatment within Coordinated Specialty Care programs for First Episode Psychosis.
10178744|NCT03810365|Experimental|Behavioral: Brief behavioral treatment for insomnia|Brief behavioral treatment for insomnia includes 45 minute individual intervention with two follow up phone calls.
10178745|NCT03810365|Active Comparator|Behavioral: Healthy eating control|Healthy eating control involves a 45 minute individual session with two follow up phone calls.
9684543|NCT04889911|Active Comparator|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based treatment for FEP that includes multiple treatment components. The FEP programs in at the recruiting site follow the Coordinated Specialty Care model.
9684544|NCT04889820|Active Comparator|The Control group|- The patients who are assigned into control group take a curative surgery within 2 weeks after successful SEMS placement. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during 6 months (total 12 cycles).
9695803|NCT04774458|Experimental|Fluoroscopic-guided cervical epidural access|Cervical epidural access with loss of resistance technique using CLO view at 50 degree under fluoroscopic guidance.
10178746|NCT03810274||3DV+TPS|This experiment included a total of 300 patients with nasopharyngeal carcinoma, using 3DV + TPS software and imported TPS, domestic TPS, these three sets of TPS delineate bilateral crystal, bilateral optic nerve, bilateral eyeball, bilateral parotid gland, oral cavity, spinal cord There are 12 organs in the brainstem and brain, and the accuracy and speed of the 3 sets of TPS sketches are compared.
10178747|NCT03810066|Experimental|Osimertinib|
10178748|NCT03809845|Active Comparator|Motor neuron disease|
10178749|NCT03809845|Active Comparator|Benign fasciculation syndrome|
10178750|NCT03809949|Active Comparator|Fentanyl Opioid Anesthesia|Fentanyl (1mg/kg i.v.) will be administered before general anaesthesia (GA). GA will be maintained with inhalation anaesthetics (isoflurane) at a minimum alveolar concentration of 0.7-1.3.
10178751|NCT03809949|Placebo Comparator|Saline Nonopioid Anesthesia|Opioid free anesthesia (syringe of saline is given instead of fentanyl) and the same general anesthesia is given as group A(muscle relaxant ,propofol, inhalation for maintance).
10178752|NCT03809975|Active Comparator|Control Arm|"Current model of care~Patients will undergo the current standard of care in the Orthopaedic Outpatient Clinic in Tan Tock Seng Hospital. Patients will undergo routine consultation with an orthopaedic surgeon and will be provided with standard treatment as necessitated based on the assessment of the orthopaedic surgeon. Subsequent follow up appointments will be scheduled at the discretion of the orthopaedic surgeon. Patients will be referred to the physiotherapists, dietitian and psychologists as necessary for regular or adhoc sessions at the discretion of the allied health professional."
9684545|NCT04889820|Experimental|The Experimental group|- The patients who are assigned into the experimental group take a neoadjuvant FOLFOX chemotherapy within 2 weeks after successful SEMS placement. After three cycles of FOLFOX, they will take a curative surgery. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during about 4 months (total 9 cycles). The perioperative FOLFOX chemotherapy in the experimetal group will be totally 12 cycles during 6months.
9684546|NCT04890132|Experimental|Normal Controls|normal control participants - no history of neurologic or inner ear disease
9684547|NCT04890132|Experimental|Peripheral Vestibular Dysfunction|"Patients with unilateral vestibular damage due to monophasic illness such as vestibular neuritis or vestibular schwannoma (VS).~For VS patients, the investigators will test them in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months)."
9684548|NCT04889612|Experimental|motor coordination and grip strength in dominant/non-dominant hand|Dominant and non-dominant hand motor coordination and grip strength were tested in the stable position of the trunk and the upper arm, in post-stroke patients (study group) and in healthy subjects (control group).
9684549|NCT04890340||Women in age 35 to 65 with suspected breast cancer|Women in age 35 to 65 with suspected breast cancer, previously untreated. Additionally, eligible patients should have appropriate mammography results, either breast ultrasound or breast MRI.
9684550|NCT04890340||Healthy Volunteers|Healthy woman in age 35 to 65.
9684551|NCT04889885|Experimental|High-intensity laser therapy (HILT)|The participants in the intervention group were treated by HILT which was applied to the knee joint (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
9684552|NCT04889885|Sham Comparator|Sham laser|The control group received a sham laser by the same laser machine (2-3 sessions a week for a total of 10 sessions) plus conservative treatment.
9684553|NCT04889586|Experimental|Experimental Group|The subjects were clinically assessed with a define clinical protocol. After that, the subjects executed the device test with EMG-biofeedback wearable armband.
9684554|NCT04889729||GENOMED4ALL - MDS patients|Information on targeted mutation screening (NGS including 60 genes related to MDS) from 8200 MDS patients
9684555|NCT04889742|Experimental|Hyperthermia|Patients will receive 6-8 treatments additional loco-regional hyperthermia concurrent to re-irradiation. Hyperthermia will start on the third day of fractionated radiotherapy and will be given twice per week. According to site of recurrent disease either deep-regional, capacitive or superficial hyperthermia devices may be used.
9684556|NCT04889781|Experimental|Rotatory Instruments without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy without Intramuscular Dexamethasone injection
9684557|NCT04889781|Experimental|Rotatory Instruments with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using conventional rotatory instruments to perform osteotomy with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
9684558|NCT04889781|Experimental|Piezosurgery technique without Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique without Intramuscular Dexamethasone injection
9684559|NCT04889781|Experimental|Piezosurgery technique with Dexamethasone injection|Surgical extraction of Impacted Mandibular Third Molar using the piezosurgery technique with 8 mg Intramuscular Dexamethasone injection 30 min before surgery
9684560|NCT04889833|Experimental|Hypnosis Therapy Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a pre-recorded video (~19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Before & after the video, they will rate pain/anxiety levels. On the day of surgery, they will watch the video again & answer questions about their average anxiety and pain level. After surgery, they will watch the video each day and report on pain/anxiety, medication use, satisfaction, and sleep disturbance until postoperative day 7. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication & study doctor will be the same as any shoulder arthroplasty patient regardless of study participation.
9684561|NCT04889833|No Intervention|Usual Care Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a daily questionnaire about their pain & anxiety over the last 24 hours. On the day of surgery, before they are given any anesthesia, they will answer questions about their average anxiety & pain levels. Starting the next morning on the day following surgery and every day for the subsequent week, they will be given questionnaires about their pain & anxiety levels, medication use, satisfaction, and sleep disturbance due to pain. Their postoperative course will be otherwise completely standard of care, including a first postoperative clinic visit at 10 days after surgery, where the patients will be given these same questionnaires. Finally, patients will answer them one more time on postoperative day 49 and this will constitute a study endpoint. The whole process each day should take approximately 10 minutes.
9684562|NCT04889651|Experimental|A(TRTR)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).~* Sequence A: T-R-T-R~T: BR9004, oral single-dose administration, 1 tablet per day~R: BR9004-1, oral single-dose administration, 1 tablet per day~Washout interval between periods: 7 days"
9695804|NCT04774549||Patients with inflammatory cardiomyopathy|Patients referred to CMR for suspected/known inflammatory cardiomyopathy and/or diagnosed inflammatory cardiomyopathy from CMR findings
9684563|NCT04889651|Experimental|B(RTRT)|"The selected subjects are randomized into two sequence group(Sequence A (TRTR) & Sequence B (RTRT)).~* Sequence B: R-T-R-T~T: BR9004, oral single-dose administration, 1 tablet per day~R: BR9004-1, oral single-dose administration, 1 tablet per day~Washout interval between periods: 7 days"
9684564|NCT04889456|No Intervention|Surgical variations laparoscopic right hemicolectomy|
9684565|NCT04889456|Active Comparator|Implementing standardised laparoscopic right hemicolectomy with proctoring|
9684566|NCT04889456|Active Comparator|Implementing standardised laparoscopic right hemicolectomy without proctoring|
9684567|NCT04889690|Experimental|Cohort 1: 200 mg|All participants under fasted conditions received 200 mg of danicopan or placebo twice daily (BID) over a 14-day period.
9684568|NCT04889690|Experimental|Cohort 2: 500 mg|All participants under fasted conditions received 500 mg of danicopan or placebo BID over a 14-day period.
9684569|NCT04889690|Experimental|Cohort 3: 800 mg|All participants under fasted conditions received 800 mg of danicopan or placebo BID over a 14-day period.
9684570|NCT04889690|Experimental|Cohort 4: 75 mg|All participants under fasted conditions received 75 mg of danicopan or placebo thrice daily (TID) over a 7-day period.
9684571|NCT04889664|Experimental|Ketamine and Written Exposure Therapy|Intravenous Ketamine 0.5 mg/kg and Written Exposure Therapy
9684572|NCT04889677|Experimental|Group 1: 200 mg|All participants (fasted) received either 200 mg of danicopan as a single oral dose or dose-matched placebo.
9684573|NCT04889677|Experimental|Group 2: 600 mg|All participants (fasted) received either 600 mg of danicopan as a single oral dose or dose-matched placebo.
9684574|NCT04889677|Experimental|Group 3: 1200 mg|All participants (fasted) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
9684575|NCT04889677|Experimental|Group 4: 2400 mg|All participants (fasted) received either 2400 mg of danicopan administered as 2 single doses of 1200 mg each, 12 hours apart, or dose-matched placebo.
9684576|NCT04889677|Experimental|Group 5: 1200 mg|All participants (fed) received either 1200 mg of danicopan as a single oral dose or dose-matched placebo.
9684577|NCT04889508|Experimental|Socio-emotional mental training|The socio-emotional intervention will consist of 10 weeks of daily Affect Dyad practice with a partner.
9684578|NCT04889508|Experimental|Mindfulness-based mental training|The intervention will consist of 10 weeks of daily individual Breathing Meditation practice.
9684579|NCT04889508|Other|Retest Control Group (Waitlist control)|"The retest control group, which is also a waitlist control group, will first not undergo an intervention, but will be tested prior to and after the 10-week period at Pre- and Post-test wherein other groups undergo the interventions.~In a second step, the waitlist control group will then also undergo a 10-week period of socio-emotional intervention.~During the first 10-week intervention period, this group will only be tested serving as a re-test control group. After Post-test, however, they will be given the chance to also enroll in a 10-week socio-emotional mental training with the exact same protocol as the socio-emotional intervention experimental group above.~Both the experimental intervention arm groups will be given the possibility to continue their daily assigned practices (respective socio-emotional and mindfulness-based training exercises) after post-test for the duration of the 10-weeks during which the waitlist control group undergoes the socio-emotional intervention."
9684580|NCT04889170||Biofeedback therapy + Voice training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
9684581|NCT04889170||Biofeedback therapy + Swallow training|The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and a speech and language therapist watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.
9684582|NCT04889391|Experimental|[14C]-Danicopan|Participants were administered a single oral dose of danicopan between 151 and 154 mg (nominal dose of 150 mg), providing approximately 100 μCi of [14C] radiolabel in the form of [14C]-danicopan.
9684583|NCT04889235||Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
9684584|NCT04889235||No Sarcopenia|Sarcopenia will be defined as either low estimated muscle mass measured by CT-muscle volumetry or reduced muscle function measured by handgrip strength, or reduced physical condition as defined by the European Working Group on Sarcopenia in Older People (EWGSOP)
9684585|NCT04889339|Experimental|Test group: Braces designed with growth modulation simulation|The braces will be designed using a growth modulation method.
9684586|NCT04889339|Active Comparator|Control group: Conventional method|The braces will be designed by an orthotist without growth modulation simulation.
9684587|NCT04889300|Experimental|Best Possible Self|Positive affect and optimism will be induced through the Best Possible Self (BPS) Intervention. In the optimism intervention, participants will be asked to imagine a future in which everything went well and in which all their wishes are fulfilled. This procedure is known to reliably generate positive affect and positive future expectations (Carrillo et al., 2019). Orientated at Flink et al. (2015) the BPS condition was adapted for a pain population.
9684588|NCT04889300|Active Comparator|Typical Day|In the control condition, participants are asked to describe and visualize a typical day (TD). We adapted the TD condition in order to take possible changes in participants´ TD due to the COVID-19 pandemic into account.
9684589|NCT04889378||Pre-habilitation|participants will join prehabilitation with very low calories diet (800-1000kcal/day) and moderate intensive aerobic exercise (1 hour per section; 3 sections per day) for 2 weeks before bariatric surgery.
9684590|NCT04889079||Adolescent females, aged 15-18|Adolescents females aged 15-18, who selected a contraceptive implant to prevent pregnancy.
9684591|NCT04889079||Adolescent females, aged 19-24|Adolescents females aged 19-24, who selected a contraceptive implant to prevent pregnancy.
10178753|NCT03809975|Experimental|Intervention Arm|"Multidisciplinary Community Program~Community based, personalized, structured, 12-week multidisciplinary program that includes Orthopaedics, Physiotherapy, Dietitics, Psychology interventions. This intervention involves the use of formal assessment such as BMI and psychological questionnaires to determine the need for dietetics or psychological intervention. In addition, there are educational sessions to improve patient's understanding of osteoarthritis and improve their activation level. An optional support group session will be arranged at approx. 3-4 months after completion of the 12-week intervention program to improve sustainability of treatment effect."
10178754|NCT03810001|No Intervention|standard ICSI procedure|a single spermatozoon was injected into the ooplasm
10178755|NCT03810001|Experimental|modified ICSI procedure|slight mechanical stimulation before standard ICSI procedure
9684592|NCT04889196|Active Comparator|control group|The group that have caries in primary molars and treat them with hall technique
9684593|NCT04889196|Experimental|experimental group|the group that have caries in primary molars and treat them with silver diamine fluoride (SDF) solution would exert a prevention result in managing early childhood caries ECC
10178756|NCT03810027||OAB with nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Precence of nocturnal polyuria will be classified in this group.
9684594|NCT04889365||COVID-19 positive, asymptomatic|COVID-19 positive, asymptomatic (i.e. no current symptoms of COVID-19, confirmed PCR positive for COVID-19)
9684595|NCT04889365||COVID-19 positive, symptomatic|COVID-19 positive, symptomatic (i.e. current symptoms of COVID-19, confirmed PCR positive for COVID-19)
9684596|NCT04889365||COVID-19 negative|COVID-19 negative (i.e. no current or previous symptoms of COVID-19, confirmed PCR negative for COVID-19)
9684597|NCT04889326||patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination|
9684598|NCT04889131|Experimental|Yoga Program|12-week yoga program begins immediately
10178757|NCT03810027||OAB without nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Absence of nocturnal polyuria will be classified in this group.
10178758|NCT03810040|Active Comparator|Odd-numbered days|Once odd-numbered days the zytoges of IVF cycle were collected. The 140 microns denuding pipette was used.
9684599|NCT04889131|Active Comparator|Wait-list Control|Wait-listed to take the Yoga Program in 12-weeks time
9684600|NCT04889053||D2M, Vascular calcification-free|Meet the inclusion criteria, there is no calcification detected by low dose prospectively triggered sequential dual-source CT coronary angiography
9684601|NCT04889053||D2M with vascular calcification|Meet the inclusion criteria, and have coronary artery calcification ( be confirmed by low dose prospectively triggered sequential dual-source CT coronary angiography)
9684602|NCT04889092|Experimental|blood flow restriction exercise|8 weeks (20 sessions) of blood flow restriction knee extension/flexion exercise
9684603|NCT04889092|Active Comparator|traditional resistance exercise|8 weeks (20 sessions) of traditional knee extension/flexion resistance exercise
9684604|NCT04888676|Experimental|Self- Adhesive Bulk fill Resin Composite ( Surefil one™ ,Dentsupply Sirona)|New Surefil one™ restorative Self-adhesive: no etching, bonding or cavity conditioning inserted in increments of up to 4 mm in thickness.
9684605|NCT04888676|Active Comparator|Bulkfill Resin Composite. (GrandioSO x-tra® bulk)|after selective etching of enamel and bonding, the bulk-fill composite resins are inserted in increments of up to 4 mm in thickness.
9684606|NCT04888949|Experimental|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
9684607|NCT04888949|Placebo Comparator|Placebo|Saline
9684608|NCT04888663|Experimental|Study treatment|(Phase Ib part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel 80 or 70 mg/m2 IV (according to dose level) (Phase II part) Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg IV, ramucirumab 8 mg/kg IV, and paclitaxel at RP2D (80 or 70 mg/m2 IV)
9684609|NCT04888975|Experimental|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery|Patients with Breast-cancer related lymphedema (BCRL) after lymphatic surgery
9684610|NCT04888806|Experimental|Camrelizumab+ablation +chemotherapy|The enrolled patients received ablation of liver metastases/pulmonary metastasis first, followed by chemotherapy (standard treatment plan for advanced colorectal cancer, determined by the investigator) and camrelizumab treatment (200mg, iv, q3w) one week later. If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times. Sequential chemotherapy and camrelizumab is administered one week after each ablation therapy. Treatment will continue until disease progression, unacceptable toxicity, or voluntary patient withdrawal.
9684611|NCT04888728|Experimental|DWN12088 and Nebivolol|Period 1 - Nebivolol A mg, Tablet, oral, once daily, Period 2 - DWN12088 X mg, Tablet, oral, twice daily, Period 3 - 1) Nebivolol A mg, Tablet, oral, once daily & DWN12088 X mg, Tablet, oral, twice daily, 2) DWN12088 X mg, Tablet, oral, once daily
9684612|NCT04888728|Experimental|DWN12088 and Paroxetine|Period 1 - DWN12088 X mg, Tablet, oral, once daily , Period 2 - Paroxetine B mg, Tablet, oral, once daily, Period 3 - 1) DWN12088 X mg, Tablet, oral, once daily & Paroxetine B mg, Tablet, oral, once daily, 2) Paroxetine B mg, Tablet, oral, once daily
10178759|NCT03810040|Experimental|Even-numbered days|Once even-numbered days the zytoges of IVF cycle were collected. The 150 microns denuding pipette was used.
10178760|NCT03809793|Active Comparator|Acipimox ingestion|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor), muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest 250 mg of Acipimox 1 hour before each exercise session of the 12 week intervention.
10178761|NCT03809793|Placebo Comparator|No drug|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor) with muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest nothing prior to their exercise sessions during the 12-week exercise programme.
10178762|NCT03809754|Experimental|OCT-guided PCI|
9684613|NCT04888962||Prospective cohort group|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
9684614|NCT04888962||Control group|This cohort will include pregnant patients without a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
9684615|NCT04888780|Experimental|Experiment adolescent group|The web-based Watson's Human Care Theory oriented training and support program are applied to the intervention group.
9684616|NCT04888780|No Intervention|Control adolescent group|No intervention is applied to the control group.
9684617|NCT04888910||asthma with nasal polyps|severe asthma with involvement of the upper airways (chronic rhinosinusitis with nasal polyps)
9684618|NCT04888910||severe asthma without nasal polyps|severe asthma without involvement of the upper airways
10178763|NCT03809754|Sham Comparator|Angiography-guided PCI|
10178764|NCT03809702|Active Comparator|Pregabalin group|Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg
9684619|NCT04888702|Experimental|SMA patients|Patients with type 2 or 3 spinal muscular atrophy undergoing Spinraza° or risdiplam treatment.
9684620|NCT04888689|Experimental|MS patients|Ambulant patients with multiple sclerosis
9684621|NCT04888650||angiodema hereditary patients|Patient with HAE with or without C1 inhibitor deficiency will respond to an electronic questionnaire
9684622|NCT04888845|Active Comparator|Structured interview and Safety Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
9684623|NCT04888845|Active Comparator|Structured interview and Crisis Response Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
9684624|NCT04888845|Active Comparator|Narrative assessment and Safety Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk."
9684625|NCT04888845|Active Comparator|Narrative assessment and Crisis Response Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation."
9684626|NCT04889001|Other|Before/After|Before and after comparison- one arm study
10178765|NCT03809702|Placebo Comparator|Placebo group|Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment
10178766|NCT03809871|Experimental|Biomarker group|These participants will receive information about cardiometabolic biomarkers pre and post weight management course
9684627|NCT04888741|Active Comparator|Control Arm Thymoglobulin + Cyclosporine + MMF|"Thymoglobulin is given as an intravenous infusion of 2.5 mg/kg/day over 2 days (days -2 and -1; total dose 5 mg/kg) via a central line through a 0.2 micron inline filter. Each dose will be infused over 6-8 hours. No test dose will be given. 30 minutes before Thymoglobulin, the patient should receive methylprednisolone 1mg/kg intravenously, 1g paracetamol PO and 10mg chlorphenamine IV. Patients should be monitored carefully and receive appropriate therapy for any infusion-related or anaphylactic reactions as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day -1 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of any active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day -1 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
10178767|NCT03809871|No Intervention|Control group|They will receive the same weight management programme as the experimental group, but they will not have biomarker information.
10178768|NCT03809858|Experimental|Klue App Use then Usual Care|Subjects will use the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
9684628|NCT04888741|Experimental|Experimental arm (PTCy + Cyclosporine + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Patients will receive IV/PO cyclosporine according to local policy to begin on day 5 maintaining a trough level of 100-200 µg/L until day 90 before a subsequent taper in the absence of active GvHD.~MMF will be given IV/PO according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
10178769|NCT03809858|Experimental|Usual Care then Klue App Use|Subjects will begin the study without using the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
10178770|NCT03809936|Active Comparator|real tDCS|real tDCS:anodal transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
10178771|NCT03809936|Sham Comparator|sham tDCS|sham tDCS:sham transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
10178772|NCT03810261|Experimental|Oil-based vitamin D group|Oil-based vitamin D, 1000 IU/day for 8 weeks
10178773|NCT03810261|Experimental|Water-based vitamin D group|Water-based vitamin D, 1000 IU/day for 8 weeks
10178774|NCT03810261|Experimental|Vitamin D capsules group|Vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks
9684629|NCT04888741|Experimental|Experimental arm (PTCy + Sirolimus + MMF)|"Cyclophosphamide is given as an IV infusion of 50 mg/kg/day over 2 days (days 3 and 4; total dose 100 mg/kg) together with IV hydration and Mesna, as per local policy.~Sirolimus will be initially given PO as a loading dose of 6 mg on day 5 followed by 2 mg daily; doses will be adjusted to maintain a trough level (in whole blood) of 8 to 14 ng/mL until day 60, thereafter 5-8 ng/mL until day 90. In the absence of active GvHD, the dose of sirolimus will be tapered from day 90. We recommend that the daily maintenance dose of sirolimus is reduced empirically to 0.5-1mg daily with concomitant treatment with a triazole anti-fungal agent.~MMF will be given IV/O according to local policy at a dose of 1g TDS to begin on day 5 and discontinued on day 35 without taper if there is no evidence of active GvHD. In adults weighing <55kg, MMF should be given at a lower dose of 0.75g IV/PO TDS."
9684630|NCT04888715|Experimental|DWN12088 and Pirfenidone|T1 - Pirfenidone A mg, Tablet, oral, once daily, T2 - 1) DWN12088 X mg, Tablet, oral, once daily, 2) DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Pirfenidone A mg, Tablet, oral, once daily
9684631|NCT04888715|Experimental|DWN12088 and Nintedanib|T1 - Nintedanib B mg, Tablet, oral, once daily, T2 - DWN12088 X mg, Tablet, oral, twice daily, T3 - DWN12088 X mg, Tablet, oral, once daily+ Nintedanib B mg, Tablet, oral, once daily
9684632|NCT04889014|Active Comparator|Personal genomic educational testing (PGET)|PGET group participants received their own pharmacogenomic testing results prior to the course modules covering material tested in the knowledge assessment
9684633|NCT04889014|Placebo Comparator|No personal genomic educational testing (NPGET)|No PGET (NPGET) group participants did not receive their own pharmacogenomic testing results until after study completion.
9684634|NCT04888819|Experimental|fed state group|just after a meal
9684635|NCT04888819|Experimental|fasted state group|before a meal
10178775|NCT03810261|No Intervention|Control group|This group will receive no intervention.
9684636|NCT04888871||Only Fundal Pressure (Kristeller Maneuver)|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Only Fundal Pressure (Kristeller Maneuver) and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
9684637|NCT04888871||Only Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying only vacuum extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
9684638|NCT04888871||Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction|prolonged second stage phase and not prolonged second phase in pregnant women to singletons at the weeks between 37-42, applying Both Fundal Pressure (Kristeller Maneuver) and Vacuum Extraction and the postpartum evaluation of maternal episiotomy needs presence of second and third degree perineal tears, presence of postpartum hemorrhage and need for blood transfusion , cesarean rates and fetal first and fifth minute Apgar score , fetal blood gas parameters, presence of fetal trauma, need for neonatal intensive care will
9684639|NCT04888559|Active Comparator|Whole grain breakfast product|
9684640|NCT04888559|Placebo Comparator|Reference|
9684641|NCT04888637||All Subjects|MEG baseline session Receptive Language Task Memory Task
9684642|NCT04888520|Experimental|Tensioning protocol of the elastic bandage (WT)|The group will have progressive tension throughout the week - based on the reduction of the tape in relation to the size of the applied area (which will always be the same), which generates a longitudinal tension of the tape in relation to the participant's skin. The Therapy Tex® brand has the elastic deformation capability of up to 40%. The tensioning protocol of the elastic bandage will work with 20% of the elastic deformation capacity of the bandage. The tension will be given from point A to point B in order to generate excitatory stimuli. The percentage of 20% reduction in tension will be distributed over the 7 weeks of intervention, and the first week of the protocol included application without tension. The tape reduction will be controlled by the formula: (size of the application area on the skin*20% /7 weeks= size of the tape to be cut in each of the 7 applications starting from the second week. Tape size and tape application area will be calculated in centimeters (cm).
9684643|NCT04888520|Placebo Comparator|Free tension|The group will have no tension in any of its tape applications; that way the size of the tape over the applied area will always be the same.
9684644|NCT04888442|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
9684645|NCT04888598||Type 1 diabetic patients|Recently diagnosed type 1 diabetes patients
9684646|NCT04888546|Other|Anlotinib hydrochloride capsules combined with TQB2450 injection|Anlotinib hydrochloride capsules (10mg po qd, Two weeks off for one week) combined with TQB2450 injection (1200mg ivgtt, q3W)
9684647|NCT04888533||All Patients evaluated by PESP during the trial period.|EHSSA tool applied to every patient in cohort.
9684648|NCT04888234|Experimental|Treatment group|The treatment group receive topical treatment of Ru-Yi-Jin-Huang Powder.
9684649|NCT04888234|No Intervention|Control group|The control group receive regular management for radiation-induced dermatitis.
10178776|NCT03809819||Patients with MRKHS|Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty
10178777|NCT03809819||Control group|A control group of 13 age-matched, childless, sexually active women
10178778|NCT03809741|Experimental|Preventing L&D Infections|Low-cost bundled L&D infection prevention interventions will be implemented, including education, visual reminders, feedback, and alcoholic hand rub supply. Infection control practices and child delivery outcomes will be assessed after implementation of these interventions.
10178779|NCT03809897|Experimental|Varenicline|Patients randomized to the experimental arm will receive 3 days of 0.5 mg of varenicline, followed by 4 days of 1 mg of varenicline (until day 7). Finally, until week 12, they will receive 2 mg of varenicline. Varenicline is supplied in capsules and taken orally.
10178780|NCT03809897|Active Comparator|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21 mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
9684650|NCT04888351||Mastectomies with IBR|Every women>18 years who underwent mastectomies followed by IBR (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) for breast cancer in Hôpital de la Croix-Rousse between January 2016 and January 2020
9684651|NCT04888351||Mastectomies without IBR|Every women>18 years who underwent mastectomies for breast cancer followed by delayed reconstructions (prothesis, latissimus dorsi flap, lipofeeling, isolated or combined) or no reconstructions between January 2016 and January 2020 in Hôpital de la Croix-Rousse
9684652|NCT04888260||Coronary Artery Disease Group|Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment were included in the patient group.
9684653|NCT04888260||Control Group|The control group consisted of healthy people with normal coronary arteries angiographically
9684654|NCT04888182|Active Comparator|intervention|Individual nutritional guidance of a protein intake of ≥25 E%.
9684655|NCT04888182|No Intervention|control|Free diet
9684656|NCT04888117||Laparoscopic cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a laparoscopic cholecystectomy.
9684657|NCT04888117||Robotic-assisted cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a robotic-assisted cholecystectomy.
9684658|NCT04888325|Experimental|Oral glucose|ORal glucose consumption 1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours
9684659|NCT04888325|Experimental|Intravenous glucose|0% intravenous glucose infusion at a rate of 3.6 ml/kg/h
9684660|NCT04888390|Experimental|Intervention group|The intervention group will receive multi-model exercise intervention 2-3 times per week for 3 months.
9684661|NCT04888390|Active Comparator|Usual care group|The Usual care group will receive heart failure disease and exercise-related education.
9684662|NCT04888429|Experimental|Camrelizumab + Famitinib|Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.
9684663|NCT04888273|Experimental|All adolescents and parents who meet the eligibility criteria|The adolescents and parents will be invited to participate in a 5-component intervention that will hopefully empower and prepare the pair for the transition to adult care.
9684664|NCT04888091|Active Comparator|Cervical mucus removal with cotton swab|Cervical mucus will be removed with cotton swab before embryo transfer
9684665|NCT04888091|Active Comparator|Cervical mucus removal with cannula|Cervical mucus will be removed with cannula before embryo transfer
9684666|NCT04888091|No Intervention|No cervical mucus removal|Cervical mucus will not be removed prior to embryo transfer
9684667|NCT04888130||Cases|This study comes following an outbreak signal that occurred in May 2020, after the detection of numerous cases of cutaneous leishmaniasis in military personnel probably contaminated during a training course (Training Center in the Equatorial Forest, CEFE) in the town of Regina. To date, around 40 cases have been detected.
9684668|NCT04888130||Controls|A case-control study can therefore be carried out using a questionnaire offered to all course participants over the 1st semester of 2020. The controls will then be participants who have not been infected. A comparison can also be made between the military personnel present in French Guiana during the first half of 2020 and having carried out missions in the forest, by opposing the participants and non-participants of the CEFE.
9684669|NCT04888221|Experimental|tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks|Tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks
9684670|NCT04888221|Placebo Comparator|placebo administered subcutaneously (SC) weekly during 24 weeks|Placebo administered subcutaneously (SC) weekly during 24 weeks
9684671|NCT04888208|Experimental|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
9684672|NCT04888208|No Intervention|Control Arm|The control group will be offered sources of conventional health information (government and institutional websites) on a terminal located in the virtual world.
9695805|NCT04774081||Study group|Participants will be recruited among those whose insulin sensitivity has been previously measured by a high-dose euglycemic-hyperinsulinemic clamp at Pennington Biomedical during the last 5 years and indicated their wiliness to be re-contacted for future research
9695806|NCT04774029|Experimental|BVN Block|Patients will receive temporary basivertebral nerve block using lidocaine during the vertebral augmentation procedure for osteoporotic compression fracture.
9695807|NCT04774042|Placebo Comparator|Placebo|Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
9695808|NCT04774042|Experimental|HAC|Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
9695809|NCT04774042|Experimental|Infloran|Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
9695810|NCT04773847|Experimental|MimetikOss 3D|
9695811|NCT04773860|Experimental|Experimental|The experimental group shall be receiving a 4 week programme of Muscle Energy Techniques on the following accessory muscles; Sternocleidomastoid, Pectoralis Minor, Trapezius, Scalene muscles and Latissimus Dorsi
9695812|NCT04773860|No Intervention|Control group|The control group will be taking their prescribed medication and continue with any conventional physiotherapy recommended for the individual.
9695813|NCT04773769|Experimental|Overall Statistical design|We will treat 9 patients of each tumor type with a tea made of Graviola Leaves. If no responses are observed then the trial will be closed for that particular histological type. Should a response occur, then the trial will continue to the second stage for that cell type until 24 patients are accrued. If 3 or more responses are observed out of 24 cases, then the result will be considered promising.
9695814|NCT04773756|Other|Sofosbuvir / Daclatsvir|A drug used in the treatment of HCV infection, given in the same dose 400mg and 60 mg respectively once daily for 14 days
9695815|NCT04773951|Experimental|Dose escalation and extension group|"JS004 dose escalation: 1mg/kg, IV Q3W; 3mg/kg, IV Q3W; 10mg/kg, IV Q3W;~JS004 dose extension: 3mg/kg, IV Q3W; 200mg, IV Q3W;~JS004+Toripalimab Injection dose escalation: JS004 100mg+Toripalimab Injection 240mg, IV Q3W; JS004 200mg+Toripalimab Injection 240mg, IV Q3W;~JS004+Toripalimab Injection dose extension: JS004 100mg+Toripalimab Injection 240mg, IV Q3W or JS004 200mg+Toripalimab Injection 240mg, IV Q3W，to be determined."
9684673|NCT04888286||patients who underwent mismatched allogeneic transplantation|Pediatric and adult patients who underwent mismatched allogeneic transplantation, from January 2014 to June 2017.
9684674|NCT04888013|Placebo Comparator|control group|Routine care for childbirth
9684675|NCT04888013|Experimental|experimental 2|Building childbirth environment
9684676|NCT04888013|Experimental|experimental 1|Building childbirth environment and labor delivery recovery room
9684677|NCT04888052|Experimental|Group 1|
9684678|NCT04888416|Experimental|Acute care|Acute care practitioners who will receive the I-STROM intervention
9684679|NCT04888416|Experimental|Inpatient|Inpatient practitioners who will receive the I-STROM intervention
9684680|NCT04888416|Experimental|Outpatient|Outpatient practitioners who will receive the I-STROM intervention
9684681|NCT04888000|Other|single|Educational intervention.
9684682|NCT04888455||Painful neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with probable or definite neuropathic pain according to the NeuPSIG algorithm.
9684683|NCT04888455||Painless neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with unlikely neuropathic pain according to the NeuPSIG algorithm.
9684684|NCT04888403|Experimental|Toripalimab combined with neoadjuvant radiotherapy and chemotherapy Single arm study|"Induction period:~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy."
9684685|NCT04887987|Experimental|Lumbar strengthening training combined with LED PBMT (TR+LED)|Each participant will be submitted to a 16-wk lumbar strengthening training program and will receive the LED PBMT 30 minutes before each training session.
9684686|NCT04887987|Placebo Comparator|Lumbar strengthening training combined with placebo PBMT (TR+PLA)|Each participant will be submitted to a 16-wk lumbar strengthening training program and will receive the placebo PBMT 30 minutes before each training session.
9684687|NCT04887818|Experimental|Topical diltiazem + lidocaine|
9684688|NCT04887818|Active Comparator|Topical nifedipine + lidocaine|
9684689|NCT04887961|Experimental|Single Arm|PLD 30 mg/mq 1 h iv + Trabectedin 1.1 mg/mq 3 h iv d1q21 up to 6 cycles or PD.
9684690|NCT04887883||Males|10 young healthy biological males aged 18 - 30 y
9684691|NCT04887883||Females|10 young healthy biological females aged 18 - 30 y
9684692|NCT04887649|Placebo Comparator|Placebo|Patients en treatment whit placebo, salIne solution in peridural cateter
9684693|NCT04887649|Active Comparator|Morphine|Epidural Catheter morphine 2mg
9684694|NCT04887649|Active Comparator|morphine|Epidurla cateter morphine 3 mg
9684695|NCT04887610|Sham Comparator|Ischemic preconditioning control|
9684696|NCT04887610|Active Comparator|Ischemic preconditioning|
9684697|NCT04887610|Active Comparator|High fat meal|
9684698|NCT04887610|Placebo Comparator|Low fat meal|
9684699|NCT04887532|Experimental|HR19042 capsule|
9684700|NCT04887636||Normal women group|I. Women of childbearing age who are physically and mentally healthy, have regular menstruation and are between 20-45 years old; II. Women who are evaluated as normal by vaginal microbiome morphological characterization; III. Women who agree to participate in this study and have signed an informed consent form; IV. Those who have full capacity for civil and legal conduct; V. The quality of vaginal samples meets the evaluation requirements of this program.
9684701|NCT04887753|Experimental|persons with cerebellar lesions|
9684702|NCT04887753|Active Comparator|Healthy controls|
9684703|NCT04887584|Experimental|Group 1|"Order of treatments:~A: Control diet B: Low pulse diet C: High pulse diet"
9684704|NCT04887584|Experimental|Group 2|"Order of treatments:~A: Control diet C: High pulse diet B: Low pulse diet"
9684705|NCT04887584|Experimental|Group 3|"Order of treatments:~B: Low pulse diet A: Control diet C: High pulse diet"
9684706|NCT04887584|Experimental|Group 4|"Order of treatments:~B: Low pulse diet C: High pulse diet A: Control diet"
9684707|NCT04887584|Experimental|Group 5|"Order of treatments:~C: High pulse diet A: Control diet B: Low pulse diet"
9684708|NCT04887584|Experimental|Group 6|"Order of treatments:~C: High pulse diet B: Low pulse diet A: Control diet"
9684709|NCT04887675|Active Comparator|Patients switched from PI/EFV based ART to INSTI based ART|60 patients on PI/EFV based ART, stable on treatment (undetectable viral load for at least 6 months). At the beginning of the study they are switched to INSTI based regimen. The reasons for the switch will be side effects or long-term toxicities like hyperlipidemia, diarrhea, (PI), insomnia, headache (EFV), high Framingham score (PI/EFV)
9684710|NCT04887675|Active Comparator|Patients initially treated with INSTI based regimens|60 patients initially started on INSTI based ART (raltegravir and dolutegravir), stable on treatment (undetectable viral load for at least 6 months).
9684711|NCT04887714|Experimental|Mask|cloth mask wearing
9684712|NCT04887714|No Intervention|control|control, without mask.
9684713|NCT04887805|Experimental|Treatment (pembrolizumab, lenvatinib mesylate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib mesylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9695816|NCT04773873|Active Comparator|Arm 1: Porcelain fused to metal (PFM)|Implant screw-retained PFM crown fabricated by a laboratory using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
9684714|NCT04887844|Active Comparator|Group I|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per American College of Rheumatology (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
9684715|NCT04887844|Active Comparator|Group II|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
9684716|NCT04887844|Other|Group III|34 patients who were diagnosed with concomitant knee osteoarthritis and pes anserine bursitis and met inclusion criteria were included in the study. Inclusion criteria were as follows: having stage II-IV knee osteoarthritis along with pes anserine bursitis, duration of symptoms for more than three months, and age between 20 and 70 years. Primary knee osteoarthritis was diagnosed as per (ACR) criteria and graded via Kellgren-Lawrence radiological classification included in this study.
9684717|NCT04887467|Experimental|Patients with Parkinson disease|Apomorphine 5mg/mL, solution for infusion, intraveinous use
9684718|NCT04887974|Experimental|Canine retraction|The canines will be retracted by extending short silver elastomeric chains between the power arms in the canine brackets and the TADs. The applied force will be checked and adjusted to 150 g.
9684719|NCT04887727|Experimental|Healthy, recreationally-active adult males - Muscle Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine and L-ring-[2H5]phenylalanine with a primed-constant infusion of L-[555-2H3]leucine to assess myofibrillar protein synthesis rates
9684720|NCT04887727|Experimental|Healthy, recreationally-active adult males - Whole Body Trial|Subjects receive 0.25g/kg crystalline amino acids modelled after egg protein, enriched with L-[1-13C]leucine with a primed-constant infusion of L-[555-2H3]leucine to whole-body protein turnover, amino acid oxidation, and net protein balance
10178781|NCT03809806|Other|patients after hysterectomy|modified anterior transvaginal mesh surgery
10178782|NCT03809637|Experimental|pemetrexed+cisplatin|Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.
10178783|NCT03809728|Other|IBD patients|All patients with an established Crohn's disease or ulcerative colitis
9684721|NCT04887545||Thoracentesis|Patients who need removal of excess pleural effusion and assessed for the possibility of lung cancer.
9684722|NCT04887571||Observational ACS Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an acute coronary syndrome will be recruited into the PERFUSION registry across the study duration.
9684723|NCT04887493|Experimental|Sublingual misoprostol|Sublingual misoprostol group will receive misoprostol 25µg by sublingual routes; the dose will be given repeatedly every 4 hours by sublingual route till there is labour pain or contraction or to a maximum of 6 dosages.
9684724|NCT04887493|Experimental|Vaginal misoprostol|Vaginal misoprostol group will receive misoprostol 25µg by per vaginal routes; the dose will be given repeatedly every 4 hours by per vaginal route till there is labour pain or contraction or to a maximum of 6 dosages.
9684725|NCT04887376|Active Comparator|Mirror Therapy|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors. In addition to this application, mirror therapy was applied simultaneously with NMES.
9684726|NCT04887376|Placebo Comparator|Control|Participants were asked to sit with their knee joints in full extension and both ankle joints in a neutral position. Five sessions of neuromuscular electrical stimulation (NMES) were applied to the non-affected side ankle dorsiflexors.
9684727|NCT04887259|Experimental|Single arm|"In part 1 (dose escalation) LAVA-051 will be administered via intravenous infusion with dose escalation until an estimated therapeutic dose level has been reached.~In part 2 (dose expansion) patients will receive LAVA-051 at the recommended phase 2 dose(s) established in part 1 of the study in disease specific cohorts for MM and/or CLL and/or AML"
10178784|NCT03809689|Other|acute infarction|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
10178785|NCT03809689|Other|acute infarction requiring reperfusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
10178786|NCT03809689|Other|chronic ischemic occlusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT before and 2 months after reperfusion treatment
10178787|NCT03809650|Experimental|Open-label treatment period|oral administration of macitentan 10 mg once daily
10178788|NCT03809676||heaart transplant recipients|
10178789|NCT03809676||healthy controls|
10178790|NCT03809832||Patients with COPD|Patients established on home non-invasive ventilation for COPD admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
10178791|NCT03809832||Patients with OHS|Patients established on home non-invasive ventilation for obesity hypoventilation syndrome admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
10178792|NCT03809546|Placebo Comparator|Placebo|
10178793|NCT03809546|Active Comparator|7.5 mg THC|
10178794|NCT03809546|Active Comparator|15 mg THC|
10178795|NCT03809559||Biliary Conditions|Participants who have a history of a biliary tree related condition
10178796|NCT03809559||Liver conditions|Participants who have a history of a non-biliary tree related liver condition
10178797|NCT03809559||Healthy Volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
9684728|NCT04887337|Active Comparator|Arthroscopic stabilization|Patients will have an initial evaluation with a diagnostic shoulder arthroscopy and examination under anesthesia will be performed to confirm the degree of anterior instability and assess range of motion of the affected shoulder. Diagnostic arthroscopy will commence with the use of 3 standard shoulder portals (posterior viewing and two anterior working portals for suture passing), and a detailed arthroscopic examination will be performed. Once the soft tissue tear (including the labrum, and capsule labrum ligaments) is identified, it will be mobilized using a rasp or elevator and a burr will then be used to create a surface for a bleeding bone bed. Capsulolabral repair will then commence with the labrum fixed to the glenoid using suture anchors (the Bankart repair). Following surgery, subjects in this group will follow the same rehabilitation protocol as the comparison group.
9684729|NCT04887337|Active Comparator|Rehabilitation including a period of immobilization followed by physical therapy|Subjects in this group will use an internal-rotation shoulder immobilizer, using a standard sling for 6 weeks from the day of enrollment. Subjects will be advised to maintain range of motion (ROM) in the elbow and wrist during this period of time. The immobilizer can be removed for passive pendulum exercises and elbow ROM during the period of immobilization up to 4 times per day. Formal physiotherapy commences at 4 weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
9684730|NCT04887272|Active Comparator|Exercise Training (EXT)|Research participants will complete six weeks of supervised progressive aerobic and resistance exercise training (EXT). Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post EXT.
9684731|NCT04887272|Experimental|Inspiratory Muscle and Exercise Training (IMET)|Research participants will complete six weeks of supervised aerobic and resistance exercise training in addition to supervised respiratory muscle training (IMET). IMET sessions will be performed similar to EXT, with the exception of having sessions of at-home IMT training. On these days, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle, and end of the session. Cardiopulmonary, cerebral and peripheral vascular function will be measured pre and post IMET.
9684732|NCT04887480|Active Comparator|Negative Wound Pressure Therapy|Negative Pressure Would Therapy
10178798|NCT03809286|Experimental|Active Stimulation|Participants will be receiving active rTMS.
9684733|NCT04887480|Active Comparator|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation
9684734|NCT04887103|Experimental|hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
10178799|NCT03809286|Sham Comparator|Sham Stimulation|Participants will be receiving sham stimulation with a smaller coil housed within the rTMS device.
10178800|NCT03809403||"No touch group:"|Patients with left sided colic adenocarcinoma who underwent left colectomy with an early ligation of mesenteric vessels
10178801|NCT03809403||"Mobilisation first group"|patients with right colic adenocarcinoma who underwent right colectomy with early mobilisation of the tumor followed by the ligation of the vessels.
10178802|NCT03809377||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
10178803|NCT03809494|Experimental|Treatment Arm|Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
10178804|NCT03809494|Placebo Comparator|Saline (Control Arm)|Patients assigned to the control arm will be injected with saline three times at six week intervals.
9684735|NCT04887103|No Intervention|Control group|There will be no intervention other than routine follow-up and maintenance.
9684736|NCT04887090|Experimental|Acupuncture and drug compound technology group|Routine perioperative management and transcutaneous electrical acupoints stimulation treatment
9684737|NCT04887090|Other|Control group|Routine perioperative management
9684738|NCT04887142||The discharged subjects|The COVID-19 inpatients treated with standard care who survived the disease and discharged from hospital.
9684739|NCT04887142||The deceased subjects|The COVID-19 inpatients treated with standard care who died from the disease.
9684740|NCT04887233|Experimental|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
9684741|NCT04887233|Placebo Comparator|Placebo nasal spray|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
9684742|NCT04887168|Experimental|Compressed|Treatment delivered at higher intensity - twice weekly
9684743|NCT04887168|Experimental|Spaced|Treatment delivered at lower intensity - once weekly
9684744|NCT04887025|Experimental|Dose Escalation|Subjects will be treated with RGV004 as a single injection, one time.
9684745|NCT04887246||UNISALUD population|Refers to all affiliated members or beneficiaries of the UNISALUD entity, who got any of tthe COVID-19 vaccines available in Colombia
9684746|NCT04887129|Experimental|Students and staff at Mary Cariola Center|All students enrolled at the Mary Cariola Center in Rochester, NY. All staff working at the Mary Cariola Center in Rochester, NY.
9684747|NCT04887363|Experimental|Core exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
9684748|NCT04887363|Experimental|Tai Chi exercise group|The healthy community-dwelling older adults (60-74 years old), who had not received any core stability or Tai Chi Chuan training within the previous 6 months, were recruited in this study. All the subjects were independent in basic daily living activities and able to move freely without any assistance.
9684749|NCT04887363|No Intervention|Young adults group|The healthy young adults who have not any neurological, musculoskeletal or rheumatic disease were recruited as a reference group. They would not receive any training program in the study.
9826766|NCT02431793|Experimental|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
10178805|NCT03809312|Active Comparator|Clavulin group with polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
9684750|NCT04887389|Experimental|Group of • Nano Silver Fluoride varnish ( NSF)|"Selected children will be divided randomly into three groups:~Group 1: Children receiving Nano Silver Fluoride varnish (NSF) (n =50)."
9684751|NCT04887389|Experimental|group of Nano hydroxyapatite varnish (n-HAP)|Group 2 Children receiving Nano-hydroxyapatite varnish (n = 50)
9684752|NCT04887389|Experimental|group of Sodium Fluoride Varnish (NaF)|Group 3: Children receiving Sodium Fluoride Varnish (n = 50)
9684753|NCT04887311|Experimental|Cohort 1|"Group 1 Patients ≥13 years old will receive a total daily dose of 1200 mg/day.~Group 2 - Group 4~Patients 4-12 years old will receive group weight-tiered doses at 17 mg/kg:~Group 2~Patients aged 4-12 years weighing 15kg to <25 kg will take 340 mg/day. Group 3~Patients aged 4-12 years weighing 25kg to <35 kg will take 510 mg/day. Group 4~Patients aged 4-12 years weighing ≥35 kg will take 850 mg/day."
9684754|NCT04887181|Active Comparator|Teethmate Desensitizer|Tetracalcium phosphate and dicalcium phosphate containing desensitizer
9684755|NCT04887181|Active Comparator|Gluma Desensitizer|%35 hydroxyethyl methacrylate and %5 glutaraldehyde containing desensitizer
9684756|NCT04887181|Active Comparator|Hybrid Bond|Self-etch adhesive resin
9684757|NCT04886921|Experimental|TRAM abdominal muscle training group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~All subjects will receive 1-hr training sessions consisting of core stability exercises for 12 weeks for the TRAM group."
9684758|NCT04886921|No Intervention|TRAM control group|"Patients were recruited at least 6 months after the muscle-sparing (MS) pedicled Transverse rectus abdominis musculocutaneous (TRAM) flap procedure and at least 1 month after the conclusion of the last chemotherapy course, if any.~The control group was not received any exercise program."
9684759|NCT04886921|No Intervention|Healthy women group|A control group comprising female volunteers who were apparently healthy and had comparable socioeconomic backgrounds and physical conditions was recruited by convenience sampling from communities.
9684760|NCT04886986|Experimental|All Subjects|Patients enrolled in the study will receive the study drugs 225Ac-J591 and 177Lu-PSMA-I&T, along with 68Ga-PSMA-11.
9684761|NCT04887012|Experimental|CAR-NK019|All subjects were intravenously administrated with CAR-NK019
9684762|NCT04886960|Experimental|Amniotic Fluid Injection|Amniotic Fluid Injection, 3ml, one time dose.
9684763|NCT04886960|Active Comparator|Standard of Care Steroid Injection|Corticosteroids, 3ml, one time dose.
9684764|NCT04886869|Experimental|Coffee|Oral consumption of 3 cups of coffee containing 240 mg caffeine
9684765|NCT04886869|Experimental|Energy drink|Oral consumption of 750 mL of a commercial energy drink containing 240 mg caffeine
9684766|NCT04886869|Placebo Comparator|Placebo|Oral consumption of 750 mL water
9684767|NCT04886947|Experimental|stem cell intervention|"Arm A patients who will have surgery with stem cell added.~Arm B only surgery with no stem cell added."
9684768|NCT04886882|Placebo Comparator|Group placebo|Isotonic solution will be administered daily to 6 female rats.
9684769|NCT04886882|Sham Comparator|Group sham|Base cream to be applied twice a day to 6 female rats.
9684770|NCT04886882|Experimental|Group %1 mgso4|Cream containing 1% MgSO4 will be applied twice a day to 6 female rats.
9684771|NCT04886882|Experimental|Group %10 MgSO4|Cream containing 10% MgSO4 will be applied twice a day to 6 female rats.
9684772|NCT04886882|Active Comparator|Group positive control|Cream containing centella asiatica will be applied twice a day to 6 female rats.
9684773|NCT04886661||PATIENTS WITH CHRONIC NECK PAIN|Patients between the ages of 18-65 who are eligible for the inclusion criteria will be included in the study who have cervical X-RAY and cervical MRIs taken in the last 3 months.
9684774|NCT04886843|Active Comparator|Cold Therapy|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week. In addition to this application, a cold pack was applied on the affected side dorsiflexor muscle skin. The cold pack was applied on a moist towel for five minutes. A five-minute break was given and a further 5-minute cold application was repeated. The cold application was done simultaneously with NMES.
9684775|NCT04886843|Placebo Comparator|Control|The patients have seated the knee joints in full extension and both ankle joints in a neutral position. Neuromuscular electrical stimulation (NMES) was applied to the non-affected side ankle dorsiflexors for five days, five sessions for a week.
9684776|NCT04886648|Experimental|Mother Voıce|Premature baby group with mother voıce application.
9684777|NCT04886648|Experimental|Lullably|Premature baby group with lullably application.
9684778|NCT04886648|No Intervention|Control|Premature baby group with no application
9684779|NCT04886765|Experimental|ALMB-0168|"Dose Escalation Cohort ：The accelerated titration and traditional 3+3 design will be used in the dose-escalation phase. Seven dose cohorts will be evaluated. ALMB-0168 will be administered intravenously once every 3 weeks until either the disease progresses or intolerable toxicity occurs.~Dose Expansion Cohort: Based on the results of Part I, 1-3 dose expansion cohorts will be started to further evaluate the safety and efficacy of ALMB-0168."
9684780|NCT04887051|Experimental|telerehabilitation|pre-post telerehabilltation
9684781|NCT04886674||Remuverol|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for < 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
9684782|NCT04886739|Experimental|CGB-400 Topical Gel|Topical administration twice daily for 12 weeks
9684783|NCT04886739|Placebo Comparator|Vehicle Gel|Topical administration twice daily for 12 weeks
9684784|NCT04886713||Obese HFpEF|Left ventricular-EF ≥ 50%, N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, Left ventricular-hypertrophy or Left atrial-dilatation) BMI ≥30 kg/m²
9684785|NCT04886713||Obese controls|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI ≥ 30kg/m²
9684786|NCT04886713||Lean control|No history of heart failure, Left ventricular-EF > 50% and NT-pro-BNP <125ng/l, BMI < 30kg/m²
9684787|NCT04886778|Experimental|Group A or Trial group|Group A was treated with a 12-week low-carbohydrate diet combined with probiotic compound preparations.
9684788|NCT04886778|Placebo Comparator|Group B or Placebo control group|Group B was treated as a control group with a 12-week low-carbohydrate diet combined with placebo treatment.
9684789|NCT04886752|Sham Comparator|vitamin C without liposome|vitamin C without liposome
9684790|NCT04886752|Placebo Comparator|liposomal process A vitamin C|liposomal process A vitamin C
9684791|NCT04886752|Experimental|liposomal process B vitamin C (Double Nutri™)|liposomal process B vitamin C (Double Nutri™)
9684792|NCT04886557||DDS fixation|Adult patients with degenerative spondylolisthesis over L4-L5 received DDS with a minimum of 2-year follow-up were reviewed. Surgical indications were patients who failed to respond to conservative treatment for at least 6 months. The exclusion criteria were: (1) presence of degenerative scoliosis or spinal deformity, (2) prior spine surgery, (3) lost to follow-up, or (4) failure to complete the questionnaires or radiographic examinations.
9684793|NCT04886375|Active Comparator|esp group|The investigators performed erector spina plane block to that patient group for postoperative analgesia
10178806|NCT03809312|Placebo Comparator|Placebo group with polyps|Group who will receive placebo after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
10178807|NCT03809312|Active Comparator|Clavulin group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
10178808|NCT03809312|Placebo Comparator|Placebo group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
10178809|NCT03809507||NC Clinicians|Qualtrics Survey of NC Clinicians with DEA registration
10178810|NCT03809468|No Intervention|control|Routine follow up of a clinic visit at 1-2 weeks postop, and 6-8 weeks postop.
10178811|NCT03809468|Experimental|study|phone call follow up instead of clinic visit follow up at 1-2 weeks, followed by 6-8 week clinic follow up
9684794|NCT04886375|Active Comparator|pecs group|The investigators performed modified pectoral nerve block to that patient group for postoperative analgesia
9684795|NCT04886830||Appendectomy performed with single endoloop to appendiceal stump|Appendectomy performed with single endoloop for closure of appendiceal stump
10178812|NCT03809520|Experimental|Experimental: pedCAT|Subjects in this group will undergo weight-bearing CT (pedCAT) imaging at 6 months, 12 months, and 18 months post-ankle injury.
10178813|NCT03809585||Iris Tumors|This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
10178814|NCT03809585||Healthy Controls|This group will consist of 50 adults age 18 and older who have healthy eyes.
10178815|NCT03809442|Experimental|Ropivacaine with Ketamine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that possesses both central and peripheral analgesic effects. Preincisional infiltration of ketamine prolongs the time to first analgesic requirement and also decreases the total amount of analgesics used postoperatively.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group)."
10178816|NCT03809442|Experimental|Ropivacaine with Tramadol|"Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak mu receptor agonist) and nonopioid receptors (inhibits reuptake of nor-adrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway.~It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.~In one study it was found that the addition of tramadol or midazolam to caudal epidural ropivacaine prolongs the duration of analgesia without causing significant side effects.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group)."
10178817|NCT03809442|Experimental|Ropivacaine with Midazolam|"The analgesic effect of extradurally administered midazolam is through γ-amino butyric acid (GABA)/benzodiazepine system of spinal cord.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group)."
9684796|NCT04886830||Appendectomy performed with two endoloops to appendiceal stump|Appendectomy performed with two endoloops for closure of appendiceal stump
9684797|NCT04886830||Appendectomy performed with a clip to appendiceal stump|Appendectomy performed with a clip for closure of appendiceal stump
9684798|NCT04886466|Experimental|The trunk movement coordinated and legs coordination during walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in post-stroke patients (study group).
9684799|NCT04886466|Experimental|The coordinated movement of the trunk and legs during fast walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in patients with back pain syndrome, but without neurological deficits (control group).
9684800|NCT04886245|Experimental|facial palsy|Patient with peripheral facial palsy, irrespective of grade, whether or not previously treated
9684801|NCT04886245|Sham Comparator|healthy volunteers|- Subject without major facial sequelae
9684802|NCT04886323|Experimental|cold atmospheric plasma treatment group|Patients are treated with a plasma device. Each treatment time was 5min/cm2 based on the skin lesion area.The frequency of treatment is once every two days. The duration of the treatment period is 1-4weeks.
9684803|NCT04886323|Active Comparator|2% ketoconazole cream treatment group|Patients are treated with 2% ketoconazole cream, twice a day.The duration of the treatment period is 1-4weeks.
9684804|NCT04886180|Experimental|Experimental|
9684805|NCT04886180|Active Comparator|Control|
9684806|NCT04886414|Experimental|Phone-based monitoring without blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer (ABHS).
9684807|NCT04886414|Experimental|Phone-based monitoring without blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
9684808|NCT04886414|Experimental|Phone-based monitoring with blood oxygenation monitoring with ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer.
9684809|NCT04886414|Experimental|Phone-based monitoring with blood oxygenation monitoring without ABHS|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a phone-based patient monitoring form. Oxygen saturation level will be assessed four times per day (morning, midday, evening, plus during the phone-based assessment) by the patient and/or family member and the lowest stable (i.e. without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Patient's will be provided monitoring sheets to record the times and dates of the oxygen saturation levels. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
9684810|NCT04886414|Experimental|In-person monitoring with blood oxygenation monitoring with ABHS|Study staff will perform daily in-person home-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a patient monitoring form. Oxygen saturation level will be assessed at the time of the in-person evaluation by a project study staff member. The lowest stable (ie without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Subjects will received a home-based care kit that contains alcohol-based hand sanitizer.
10178818|NCT03809442|Experimental|Ropivacaine with Dexamethasone|"The glucocorticoid dexamethasone appears to be effective in a small number of preclinical and clinical studies and found that dexamethasone prolongs analgesia from interscalene blocks using ropivacaine or bupivacaine, with the effect being stronger with ropivacaine.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group)."
10178819|NCT03809442|Experimental|Ropivacaine with Dexmedetomidine|"Dexmedetomidine is a new highly selective alpha2 (a2) agonist with known sedative, antihypertensive, anxiolytic, and analgesic properties.~In one study, it was found that wound infiltration with combined ropivacaine and dexmedetomidine found to be significantly superior for postoperative analgesia compared with either combined ropivacaine and tramadol or ropivacaine alone for lumbar discectomies.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kgdexmedetomidine (8mL per incision) (Dexmedetomidine group)."
10178820|NCT03809442|Placebo Comparator|Ropivacaine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg."
9684811|NCT04886414|Experimental|In-person monitoring with blood oxygenation monitoring without ABHS|Study staff will perform daily in-person home-based assessments using standardized electronic study tools (tablets). Clinical features and oxygen saturation levels will be documented on a patient monitoring form. Oxygen saturation level will be assessed at the time of the in-person evaluation by a project study staff member. The lowest stable (ie without substantial fluctuations) level recorded during a monitoring period of one minute will be recorded and registered. Subjects will received a home-based care kit that does not contain alcohol-based hand sanitizer.
9684812|NCT04886076||Participants with RBD|Participants with REM Sleep Behavior Disorder
9684813|NCT04886076||Participants without RBD|Age- and gender-matched controls, without REM Sleep Behavior Disorder
9684814|NCT04886492||NMO|Pts presenting to enrolling sites across the northern America are invited to enroll if eligible
9684815|NCT04886128||Aim 1/Outcome 1|Secondary analysis of frozen plasma samples from the existing STRATIFY cohort of patients with and without acute heart failure presenting to emergency departments. n= ~900
9684816|NCT04886128||Aim2/Outcome 2|Secondary analysis of frozen plasma samples from the existing EMROC cohort of patients with and without acute heart failure presenting to emergency departments. n= ~900
9684817|NCT04886128||Aim 3/Outcome 3|Prospective recruitment of approximately 1000 patients with and w/o acute heart failure presenting to emergency departments.
9684818|NCT04886297|Placebo Comparator|placebo|"The placebo capsules only contained pullulan and maltodextrin. During the trial period, the participants were instructed to consume two Mega Resveratrol® placebo capsules once daily (30 min after breakfast).~Intervention: Drug: Mega Resveratrol® capsules"
9684819|NCT04886297|Experimental|100mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (100 mg anthocyanins per capsule) will provid a total daily intake of 100 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
9695817|NCT04773873|Experimental|Arm 2: Hybrid abutment Lithium disilicate (e.max CAD)|Hybrid crown abutment: chairside-made perforated CAD-CAM Lithium disilicate crown (IPS e.max CAD LT A16) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
9684820|NCT04886297|Experimental|300mg/d resveratrol|"During the trial period, the participants will be instructed to consume one Mega Resveratrol® capsules and one Mega Resveratrol® placebo capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule) will provid a total daily intake of 300 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
10178821|NCT03809455|Experimental|FAR Arm|
10178822|NCT03809455|Placebo Comparator|Placebo Arm|
10178823|NCT03809325||Participants with Schizophrenia|No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
10178824|NCT03809351|Experimental|[F-18]AV-1451-PET/MRI|All participants in this study will undergo a tau-PET imaging using the tracer [F-18]AV-1451 with a simultaneous PET/MRI system. The [F-18]AV-1451 dosage is 740MBq (10 mCi) given intravenously, and the PET/MRI imaging will occur 75-105 min after tracer injection.
9684821|NCT04886297|Experimental|600mg/d resveratrol|"During the trial period, the participants will be instructed to consume two Mega Resveratrol® capsules 30 min after breakfast. The resveratrol capsules (300 mg anthocyanins per capsule, 2 per day) will provid a total daily intake of 600 mg resveratrol.~Intervention: Drug: Mega Resveratrol® capsules"
10178825|NCT03809260|Experimental|Part 1|Metformin/Vancomycin
10178826|NCT03809260|Experimental|Part 2|Metformin
9684822|NCT04886362|Experimental|Intervention Group|Ivermectin 600 mcg/kg every 12 hours for 5 days.
10178827|NCT03809416|No Intervention|Control|32 biopsy specimens from acne scars will be excised without any treatment.
9684823|NCT04886362|Placebo Comparator|Control Group|Same volume like ivermectin
9684824|NCT04886193|Experimental|FLOT combined with PD-1|"The enrolled patients will receive 4 cycles of FLOT regimen + teriprizumab treatment before surgery Q2W.~If the transformation is successful, the patient undergoes R0 surgical resection of D2 lymph node dissection, and will continue to receive 4 cycles of FLOT regimen + Teripril after surgery. Anti-treatment, the treatment plan is the same as before.~After completing the 4 cycles of treatment, oral Tiggio Capsule (S-1) and Teriprizumab were maintained for 1 year."
9684825|NCT04886167|Active Comparator|120U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 120 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.025mL (5 U).~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 18 injection sites, with each injection site receiving 0.025mL (5 U)."
9684826|NCT04886167|Active Comparator|180U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 180 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.0375mL (7.5 U).~At the 14 day visit, an optional touch-up using up to 90 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.0375mL (7.5 U)."
9684827|NCT04886167|Active Comparator|240U abobotulinumtoxinA|"Treatment of platysmal bands using a total of 240 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.05mL (10 U).~At the 14 day visit, an optional touch-up using up to 120 U of abobotulinumtoxinA can be performed. This will involve up to 12 injection sites, with each injection site receiving 0.05mL (10 U)."
9684828|NCT04886336||Tenofovir Disoproxil Fumarate(TDF) switch to TAF|The indications of TDF switching to TAF due to adverse events of TDF or physician's judgement according to clinical conditions.
9684829|NCT04886336||Entecavir(ETV)switch to Tenofovir Alafenamide(TAF)|In entecavir switch group, at least 30 patients should have baseline BW data before entecavir treatment. The indications of entecavir switching to TAF include suboptimal HBV suppression (defined as detectable HBV DNA after at least one year of entecavir treatment), adverse events due to entecavir, physician's judgement according to clinical conditions.
9684830|NCT04886336||observation groups with take either entecavir (25patients) or TDF (25 patients).|observation groups with total 50 patients who continuously take either entecavir (25patients) or TDF (25 patients) will be enrolled.Examination schedules for these two additional groups are the same as switching groups.
9977677|NCT01364129|Experimental|Telemedicine|Participants in this group have digital images of their retina captured with a non-mydriatic camera and are encouraged to see an eye care provider yearly.
9684832|NCT04885959|Placebo Comparator|Usual diet|Participants are subjected to received general dietary advice from attended nurses or physician during their antenatal visits.
9684833|NCT04885959|Experimental|PPBe Diet|Participants will receive dietary intervention which is tailored to the study objective to increase targeted bacteria of Prevotella sp and the short-chain fatty acids namely butyrate.
9684834|NCT04885933||COPD exacerbation|
9684835|NCT04885946|Experimental|Vancomycin 125 x 4 for 10 days + 2 Fecal Microbota Transplantation|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, FMT.
9684836|NCT04885946|Placebo Comparator|Vancomycin 125 x 4 for 10 days + 2 Placebo|Patients are required to undergo full treatment with vancomycin and are randomized following completion to, in this arm, placebo.
9684837|NCT04885946|Other|Open-label for screened, but not randomized patients with fulminant CDI|This arm exists for patients with fulminant CDI and for randomization to placebo may be considered unethical.
10178828|NCT03809416|Sham Comparator|Lasers plus Normal Saline Solution|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of normal saline solution.
10178829|NCT03809416|Active Comparator|Lasers plus Platelets Rich Plasma (PRP)|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of platelets Rich Plasma (PRP).
10178830|NCT03809338||flight attendant women|Assesment antral follicle count on day 3 5ml blood sample to be taken
10178831|NCT03809338||day working women|Assesment antral follicle count on day 3 5ml blood sample to be taken
10178832|NCT03809273|Experimental|Yangxinshi|
10178833|NCT03809273|Active Comparator|Trimetazidine|
10178834|NCT03809026||Study group|Couples where the men have Klinefelter's syndrome, maturation stop in the spermatogenesis or failed retrieval of testicular sperm by conventional techniques with needle or TruCut, and where testicular sperm could be obtained by micro-TESE.
10178835|NCT03809026||Control group|Couples as in the study group, but where testicular sperm could not be obtained by micro-TESE. The oocytes therefore must be fertilized using donor sperm.
9684838|NCT04885907|Active Comparator|Experimental group|Participants will receive a one dose of mRNA-1273 vaccine 0.5mL i.m. in deltoid muscle
9684839|NCT04885907|Placebo Comparator|Comparator Group|Participants will receive one dose of normal saline injection 0.5mL i.m. in deltoid muscle
9684840|NCT04885647|Experimental|Arm1|Low dose once every 2 weeks group
9684841|NCT04885647|Experimental|Arm2|Low dose once every 4 weeks group
9684842|NCT04885647|Experimental|Arm3|High dose once every 2 weeks group
9684843|NCT04885647|Experimental|Arm4|High dose once every 4 weeks group
9684844|NCT04886037||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
9684845|NCT04886037||control|It consists of healty women between the ages of 18-45
9684846|NCT04885842|Experimental|Study Group|injection I-PRF with brackets
9684847|NCT04885842|No Intervention|Control Group|applying brackets only
9684848|NCT04885738||Chronic Cough|cough as a sole presenting lasted more than 8 weeks; with an age of 18-70years; with a normal chest X-ray; without steroids treatment in the last 4 weeks.
9684849|NCT04885738||Asthma|classic asthma
9684850|NCT04885738||COPD|patients with COPD in stable stage or acute exacerbation
9684851|NCT04886024||women with endometriosis|It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
9684852|NCT04886024||control|It consists of healthy women between the ages of 18-45
9684853|NCT04885777|Active Comparator|Lidocaine group|One ml of a solution containing 20 mg/ml of lidocaine was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group.
9684854|NCT04885777|Placebo Comparator|Placebo group|The Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril).
9684855|NCT04885894||MS Zeposia|Individuals with MS who will begin taking Zeposia as part of standard care.
9684856|NCT04885894||MS High dose efficacy medication|Individuals with MS who will begin taking high dose efficacy oral medication as part of standard of care.
9684857|NCT04885894||Healthy Control|Healthy controls, all of whom will be matched on age, education and gender to the MS groups.
9684858|NCT04885595|Active Comparator|Forceps-Cryo 1.1 mm|Forceps biopsy following cryobiopsy with a 1.1mm cryoprobe are obtained within the same session
9684859|NCT04885595|Active Comparator|Forceps-Cryo 1.7 mm|Forceps biopsy following cryobiopsy with a 1.7mm cryoprobe are obtained within the same session
9684860|NCT04885673|Active Comparator|Group A (High flow nasal cannula group)|(Vapotherm) will be used during the bronchoscopy time flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
9684861|NCT04885673|Active Comparator|Group B (Apeieoc oxygenation group)|The standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
9684862|NCT04885660|Experimental|Compound lisinopril tablets|a single oral of Compound lisinopril tablets test formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
9684863|NCT04885660|Active Comparator|Compound lisinopril tablets(Lisonorm®)|a single oral of Compound lisinopril tablets reference formulation( Lisinopril 10mg/Levamlodipine besylate 5mg)
10178836|NCT03808935|Experimental|Medical cannabis|Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
9684864|NCT04885556|Experimental|Immediate Use|Subjects in this arm will be instructed to use the study device for 2 minutes and remove
9684865|NCT04885556|Experimental|1 hour use|Subjects in this arm will be instructed to use the product for one hour and then remove
9684866|NCT04885686|Experimental|Endomethasone N RCS|Endomethasone N RCS is used in combination with gutta percha points for the permanent obturation of root canals.
9684867|NCT04885686|Active Comparator|Endomethasone SP RCS|Endomethasone SP RCS is used in combination with gutta percha points for the permanent obturation of root canals.
9684868|NCT04885855|Experimental|8-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 8 weeks.
9684869|NCT04885855|Active Comparator|12-week|Patient will be receiving treatment of tablet Sofosbuvir 400mg and tablet Ravidasvir 200mg combination once daily for the duration of 12 weeks.
9684870|NCT04886011|Placebo Comparator|placebo gel|Methylcellulose gel was applied to the ulcer till complete healing
9684871|NCT04886011|Experimental|camel whey protein gel|camel whey protein dissolved in methycellulose gel was applied to the ulcer till complete healing
9684872|NCT04885478||Healthy health care workers|"≥ 18 years of age~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.~To be a health care professional worker infected or exposed to SARS-CoV-2~RT-PCR (SARS-CoV2), negative at baseline or follow up~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), negative positive at baseline or follow up"
9684873|NCT04885478||Infected health care workers|"≥ 18 years of age~Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki.~To be a health care professional worker infected or exposed to SARS-CoV-2~RT-PCR (SARS-CoV2), positive at baseline or follow up~Anti-SARS-CoV-2 IgG and IgM antibodies (Nucleopcapside), positive at baseline or follow up"
9684874|NCT04885621||underserved patients with diabetes mellitus|patients with type 2 diabetes mellitus living in underserved, financially challenged areas of Southwest Virginia who are poorly controlled
9684875|NCT04885582||Patients with biliary complications|patients with postoperative biliary fistula, biliary stenosis
9684876|NCT04885582||Patients without biliary complications|patients without postoperative biliary fistula and biliary stenosis
9684877|NCT04885751|Experimental|eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
9684878|NCT04885751|Active Comparator|rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
9684879|NCT04885465|Experimental|Intervention group|Study participants will receive a web-based support program
9684880|NCT04885465|No Intervention|Control group waiting list|Study participants in the control group waiting list will receive standard support from health care and municipalities. After study termination they will receive access to the same web-based program as the experimental group
9684881|NCT04885803|Experimental|Nano Liquid D3|Arm receiving Nano Liquid Vitamin D3
9684882|NCT04885803|Active Comparator|Softgel D3|Group receiving Softgel Vitamin D3
9684883|NCT04885803|Placebo Comparator|Placebo Control|Liquid mixture, identical in process, taste, smell, and appearance to Nano Liquid D3, but containing no active ingredient (no Vitamin D3)
9684884|NCT04885634|Active Comparator|Intervention group|Semaglutide 2.4 mg subcutaneously once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
9684885|NCT04885634|Placebo Comparator|Control group|Placebo treatment with volume-matched placebo s.c. once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
10178837|NCT03808935|Placebo Comparator|Placebo Control|"Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis."
10178838|NCT03808974|Experimental|Intervention|The intervention group will be shown an educational video
10178839|NCT03808974|Active Comparator|Control|The control group will be given an educational leaflet
9684886|NCT04885517|Experimental|Spontaneous breathing, Venturi Mask FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 0.5 (Venturi Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684887|NCT04885517|Experimental|Spontaneous breathing, Non Rebreathing Mask, seated decubitus|Patient will be evaluated after 20 minutes of spontaneous breathing, with FiO2 1 (Non Rebreathing Mask), during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684888|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684889|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, supine decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during supine decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684890|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 0.5, prone decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 0.5, during prone decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684891|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 7 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684892|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 0.5, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (12 cmH2O), with FiO2 0.5, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684893|NCT04885517|Experimental|Continuous Positive Airway Pressure (CPAP) 12 cmH2O, FiO2 1, seated decubitus|Patient will be evaluated after 20 minutes of CPAP (7 cmH2O), with FiO2 1.0, during seated decubitus. Respiratory, haemodynamics, and data on blood gas analysis will be obtained.
9684894|NCT04885348|Experimental|Dental Home Visits and Dental Home Education Leaflets|Two trained dental home visitors made 6-monthly Dental Home Visits (DHVs) to families in the Intervention Group. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion.
9684895|NCT04885348|Active Comparator|Dental Home Education Leaflets|Only Dental Home Education Leaflets were provided every six months for 2 years.
9684896|NCT04885270|Experimental|Arm i.p|paclitaxel i.v. and cisplatin i.p.
9684897|NCT04885361|Experimental|Arm 1 injection|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
9684898|NCT04885361|Experimental|Arm 2 injections separated by 21 days|The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
9684899|NCT04885387|Other|Standard protocol using chest CT|
9684900|NCT04885387|Experimental|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|
9684901|NCT04885140|Experimental|Feedback-based health education health education and Routine health education|"Feedback-based health education:(1) Implementation of the feedback method includes information transmission, patient feedback, clarification and correction, and confirmation of understanding.① One day before surgery: Health education team members provided bedside one-on-one education for patients, 15-20 min per session, twice a day.~② One week after surgery: One-on-one education on rehabilitation exercise was conducted for the patients by the health education team members, 15-20 min per session, twice a day.~③ Two to four weeks after surgery: The health education group members guided the patients through functional rehabilitation exercises via WeChat. Each intervention lasted 20-30 min. The patients interacted once through WeChatB1, and their questions were answered at any time.~④ Five to 12 weeks after surgery: The health education group members guided patients through the functional rehabilitation exercises via WeChat."
9684902|NCT04885140|Experimental|Routine health education|"Routine health education:~Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method."
10178840|NCT03809065|Experimental|group N|Patients in this group will receive Nitroglycerin infusion for deliberate hypotension at a rate of 0.5-2 μg /kg/min .
10178841|NCT03809065|Active Comparator|group L|Patients in this group will receive Labetalol infusion for deliberate hypotension at a rate of be 0.5-2 mg/kg/h .
10178842|NCT03809091||Bronchiectasis|The patient with bronchiectasis who has no apparent bronchiectasis-causing etiology will be enrolled. The patient's family who has no bronchiectasis will be also enrolled to identify the patient-specific variants.
10178843|NCT03808909|Experimental|Doula|Participants will be assigned a doula.
9684903|NCT04885309|Active Comparator|Obturator Nerve Block + Spinal Anaesthesia|Patients who underwent obturator nerve block with spinal anesthesia prior to TURBT
9684904|NCT04885309|Sham Comparator|Spinal Anaesthesia|Patients who underwent spinal anesthesia prior to TURBT
9684905|NCT04885374||Amyotrophic lateral sclerosis patients|Amyotrophic lateral sclerosis patients with traditional Chinese medicine
9684906|NCT04885439|Experimental|NextSteps Intervention|Patients and caregivers will each receive their own tailored manual and six weekly 45-minute telephone calls that correspond to the manual, delivered by a Masters level trained interventionist.
9684907|NCT04885439|No Intervention|Usual Medical Care|UMC consists of standard oncologic care for the patient from the point of diagnosis of advanced cancer.
10178844|NCT03808909|No Intervention|Control|Participants will not be assigned a doula.
9684908|NCT04885426|Experimental|low-dose metformin group|low-dose metformin, 250mg/day
9684909|NCT04885426|Experimental|high-dose metformin group|high-dose metformin, 500mg/day
9684910|NCT04885426|Placebo Comparator|control group|placebo
9684911|NCT04885413|Experimental|study arm|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
9684912|NCT04885010|Experimental|Probiotics|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
9684913|NCT04885010|Placebo Comparator|Placebo|participants will train for 15 days while consuming the dietary supplement. During the last 8 days the intensity of training will increase to induce overreaching.
9684914|NCT04885153|Experimental|Intervention Group|Subjects who were given simvastatin 10 mg and fenofibrate 200 mg.
9684915|NCT04885153|Placebo Comparator|Control Group|Subjects who were given simvastatin 10 mg and placebo (lactic acid) 200 mg.
10178845|NCT03809143|Experimental|Depot buprenorphine arm|All participants will receive monthly injections of depot buprenorphine (RBP-6000, Sublocade)
10178846|NCT03809195|Experimental|Hypnosis Intervention|The intervention is clinical hypnosis--a single in-person session followed by instructions to listen to audio recordings at home. The sessions consist of the provider's voice guiding the participant into a relaxed and focused state and providing therapeutic suggestions--for example, to replace discomfort with a more pleasant sensation, to ease anxiety, and to increase energy.
10178847|NCT03809195|No Intervention|Waitlist Control|This group will serve as a control comparison and be offered the intervention after control data collection is complete.
9684916|NCT04885205|Experimental|CBT-I Initial Group|The CBT-I Initial Group will start the CBT-I intervention immediately following baseline assessments. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
9684917|NCT04885205|Active Comparator|Wait List Group|The WL will wait 6 weeks before starting the CBT-I intervention. After re-assessment 1, participants in the CBT-I Initial Group will continue with typical activities while the WL group will receive the CBT-I intervention. After re-assessment 2, both groups continue typical activities. All participants will complete a third re-assessment 21 weeks after starting the study.
9684918|NCT04884997|Active Comparator|Arm A|toripalimab 3mg/kg, Q2w;
9684919|NCT04884997|Experimental|Arm B|toripalimab 3mg/kg, Q2w; Temozolomide 150mg/m2,d1-5,Q4w
9684920|NCT04884984|Experimental|CLL1 positive relapsed or refractory acute myeloid leukemia|
9684921|NCT04885231|Experimental|Opioid-Limiting Perioperative Pain Management Education and Counseling|"Patients will be instructed to take oxycodone only as a last resort if the pain becomes unbearable. The goal should be to take as little oxycodone as possible."
9684922|NCT04885231|Active Comparator|Traditional Perioperative Pain Management Education and Counseling|"Patients will be instructed to take opioids as needed for severe pain to manage and stay ahead of the postoperative pain"
9684923|NCT04884906|Experimental|Camrelizumab combined with radiotherapy and chemotherapy|
9684924|NCT04884880|Experimental|Luo-Fu-Shan Plaster 10g|10g，once daily，4 weeks
9684925|NCT04884880|Placebo Comparator|Placebo|10g，once daily，4 weeks
9684926|NCT04884867|Experimental|Supportive life skills coaching|CBT-based supportive like skills delivered by phone by lay coaches
9684927|NCT04884932|Experimental|30 kHz stimulation|"Percutaneous application of high frequency electrical current at 30 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
9684928|NCT04884932|Experimental|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
9684929|NCT04885075|Other|Intravenous Diazepam|Intravenous diazepam (0.2mg/kg/dose) single dose stat
9684930|NCT04885075|Other|Intranasal Midazolam|Intranasal midazolam (0.2mg/kg/dose) single dose stat
9684931|NCT04885179||Individuals with SPLIS|Individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
9684932|NCT04885179||Parents of individuals with SPLIS|Parents of individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1
9684933|NCT04885179||age and gender-matched controls|The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.
9684934|NCT04885062|Experimental|UH-Participant|Potential participants with suspected OSA will be identified from the schedule of the UH Beachwood and Bolwell sleep labs.Those subjects who satisfy the study inclusion and exclusion criteria will be approached and invited to participate in the study.
9684935|NCT04884945|Active Comparator|Robotic Surgery|Robotic-Assisted Laparoscopic Pyeloplasty (RALP), standard of care treatment option for UPJ obstruction
9684936|NCT04884945|Active Comparator|Open Surgery|Open Pyeloplasty (OP), standard of care treatment option for UPJ obstruction
10178848|NCT03809117|Experimental|Experimental|Gastrointestinal Polymerase Chain Reaction test performed and results communicated to treatment provider. Followed by usual care per treating physician.
10178849|NCT03809117|Active Comparator|Control|Gastrointestinal Polymerase Chain Reaction test performed at the conclusion of the study. Clinician will not be informed of results. Usual Care performed per treating physician.
9684937|NCT04884958||Index patient|Adults with confirmed clinical infection caused by Staphylococcus aureus, including skin and soft tissue infection or infection of a normally sterile site. These cases will be identified following admission to Anuradhapura General Hospital.
9684938|NCT04884958||Household contacts|This cohort are resident in the same household as the index patient (maximum of four).
10178850|NCT03808896|Active Comparator|bougie-assisted intubation|use bougie as guide, intubation with loading endotracheal tube under direct or video laryngoscopy
9684939|NCT04884919|Placebo Comparator|Regular Gauze Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a regular gauze made of traditional cotton yarn. The regular gauze is applied on the half side of the wound.
9684940|NCT04884919|Experimental|Chitosan Dressing Treatment|Participants who undergo a cesarean section are first dissected in about 5 cm length and 2 cm width and receive a chitosan dressing made of chitosan material. The chitosan dressing is applied on another half side of the wound.
9684941|NCT04885049|Experimental|Group A|Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration
9684942|NCT04885049|Experimental|Group B|Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration
9684943|NCT04885023|Experimental|Study group|Twenty six patients who received hippotherapy combined with Schroth exercises for ten weeks
10178851|NCT03808896|Active Comparator|intubation with epiglottic lifting|Lifting of epiglottis with stylet-equipped endotracheal tube to assist intubation under direct or video laryngoscopy
10178852|NCT03808896|No Intervention|Traditional intubation|intubation under direct or video laryngoscopy without epiglottis lifting nor bougie-assited
9684944|NCT04885023|Other|Control group|Twenty six patients who received only Schroth exercises for ten weeks
9684945|NCT04885114|Experimental|Cohort 1 Unilateral low dose|3.0 x 10^9 (vg/mL) rAAV1-miHHT
9684946|NCT04885114|Experimental|Cohort 2 Bilateral low dose|3.0 x 10^9 (vg/mL) rAAV1-miHHT
9684947|NCT04885114|Experimental|Cohort 3 Bilateral mid dose|1.7 x 10^10 (vg/mL) rAAV1-miHHT
9684948|NCT04885114|Experimental|Cohort 4 Bilateral high dose|9.9 x 10^10 (vg/mL) rAAV1-miHHT
9684949|NCT04884828||one group|patients from the Pulmonology Service of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) who met the following criteria: over 18 years of age, hospital admission for acute chronic respiratory failure, home NIV (single-limb system with intentional leakage) users for more than 6 months with adequate compliance (greater than or equal to 5 hours/night). Patients with underlying psychiatric disease were excluded. The study was conducted during the patient's predischarge phase (the same day or the day before)
9684950|NCT04884581|Experimental|GI Genius CADx device|
9684951|NCT04884607|Experimental|Study group|Study group will receive subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes.
9684952|NCT04884594|Experimental|AAV8-hCocH Low dose: 2e12 vg/kg|Cohort 1: Participant receives one-time IV administration of low dose 2e12 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
9684953|NCT04884594|Experimental|AAV8-hCocH Medium dose: 6e12vg/kg|Cohort 2: Participant receives one-time IV administration of medium dose 6e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
9684954|NCT04884594|Experimental|AAV8-hCocH High dose: 2e13 vg/kg|Cohort 3: Participant receives one-time IV administration of high dose 2e13 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
9684955|NCT04884724|Experimental|Adaptive Dance Exercise Group|"In addition to the routine physiotherapy programs received in the rehabilitation center for children and adolescents with cerebral palsy, an adaptive dance exercise program will be applied 2 days a week in the rehabilitation center for 5 weeks and online for 3 weeks in the presence of a physiotherapist. The duration of each session of the adaptive dance exercises to be applied is planned to be 45-60 minutes. It is planned that the adaptive dance exercises to be applied will be accompanied by the selected song.~Before and after the 8-week exercise program, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests."
9684956|NCT04884724|No Intervention|Control Group|Children and adolescents diagnosed with Cerebral Palsy will continue their routine physiotherapy and rehabilitation programs in the rehabilitation center. At the beginning of the study and after 8 weeks, the participants' trunk stabilization, balance, functional mobility and quality of life will be questioned with determined questionnaires and tests.
9684957|NCT04884802|Experimental|Tight pressure management|"In patients assigned to tight blood pressure control, angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg.~Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication.~The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days."
9684958|NCT04884802|Other|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
9977678|NCT01364129|No Intervention|Traditional Surveillance|Participants in this group are encouraged to see an eye care provider each year for a diabetic eye exam.
10178853|NCT03809221|Experimental|early follicular phase down-regulation|Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle. If complete pituitary down-regulation is achieved after 28-42 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours after pre-ovulatory hCG injection transvaginally under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
10178854|NCT03809221|Active Comparator|luteal phase down-regulation|Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle. If complete pituitary down-regulation is achieved after 14-21 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and the serum hormone level and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours later under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
10178855|NCT03809156|Experimental|Combo Riociguat and Ambrisentan Therapy|Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.
10178856|NCT03809169|Experimental|ROSE with guide sheath|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique and presence of ROSE
10178857|NCT03809169|Experimental|ROSE without guide sheath|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no guide sheath and the presence of ROSE.
10178858|NCT03809169|Experimental|Guide sheath without ROSE|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique but without ROSE.
10178859|NCT03809169|Experimental|No guide sheath without ROSE|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no the guide sheath an without the presence of ROSE.
10178860|NCT03808857|Experimental|GB226|Geptanolimab Injection,3mg/kg once per 2 weeks
10178861|NCT03808844|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
10178862|NCT03808844|Active Comparator|Propofol|2.0mg/kg/1.0mg/kg
9684959|NCT04884737|No Intervention|Pre-Intervention|Pre-Intervention Group participants will have 6 visits. During the pre-intervention baseline (3 months) participants will undergo visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, conducted by the research staff: 1.) consent and preoperative, 2.) immediately following surgery in the Post Anesthesia Recovery (PAR) Unit, 3.) on transfer to the floor unit, 4.) post-operative day 1, 5.) post-operative day 3 and 6.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 40 minutes.
9684960|NCT04884737|Experimental|Intervention|Intervention Group participants will have 7 visits. During intervention (3 months) research staff will conduct the visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, and place the MBF dressings to the face (chin, cheeks, forehead), chest and iliac crest: 1.consent and preoperative, 2. MBF dressing placement, 3.) immediately following surgery in the PAR unit with the MBF dressings removed , 4.) on transfer to the floor unit, 5.) post-operative day 1, 6.) post operative day 3 and 7.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 55 minutes.
9684961|NCT04884750|Experimental|High engagement mechanisms, tailed content|During this time the investigators will conduct a 2x2 factorial RCT (with the individual the unit of random assignment and measurement) to assess the impact of two app design features on engagement and outcomes: (1) the investigators will manipulate engagement mechanisms (ENGAGEMENT), including reminder notifications and trust-building dialogue by the ECA and, (2) independently manipulate cultural tailoring of vaccination promotion counseling language used by the agent (TAILORING) to either adaptive religiosity (tailored) or secular (non-tailored). The investigators' primary hypotheses are that participants with have significantly greater vaccination completion rates in the high engagement and tailored conditions at 6 months (H1) and 12 months (H2) compared to other conditions.
9684962|NCT04884750|Experimental|Low engagement mechanisms, tailed content|manipulate low engagement mechanisms while provide adaptive religiosity (tailored) content
9684963|NCT04884750|Experimental|High engagement mechanism, non-tailed content|manipulate high engagement mechanisms while provide secular (non-tailored) content
9684964|NCT04884750|Experimental|Low engagement mechanism, non-tailed content|manipulate low engagement mechanisms and provide secular (non-tailored) content
9684965|NCT04884646|Experimental|Virtual Reality with Routine Physical Therapy|The duration of the VR will be from 10 to 15 minutes during each session and Routine Physical Therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
9684966|NCT04884646|Experimental|Motor imagery technique with Routine Physical Therapy|Motor Imagery techniques will be given for 5 to 10 minutes along with routine physical therapy for 40 minutes which consists of warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
9684967|NCT04884646|Experimental|Routine Physical Therapy|Only routine physical therapy will be given (including warming-up, stretching, strengthening and active exercises for relaxation, coordination exercises for limbs, trunk, neck, and gait training)
9684968|NCT04884620||Cross-sectional cohort|Healthy children and adolescents from twenty-five selected schools in the metropolitan area
9684969|NCT04884620||Longitudinal cohort|Cases with first-time diagnoses of extremely early puberty within the period 1995-2019 in the National Patient Registry and five randomly selected references drawn from the general background population in the Danish Civil registry (CPR) matched on age and sex for each case
9684970|NCT04885088||Interventions|"Device: Wisdom bracelet~Other Names:~control group (routine medical)"
9684971|NCT04885088||control|routine medical Non-invasive Wearable Device
9684972|NCT04884776|Active Comparator|Active arm|Subject will be instructed to take microbiome immunity formula 2 sachets daily for a total of 12 weeks.
10178863|NCT03809130|Experimental|Arm I (Untire application)|Patients use Untire application intervention after baseline up to 6 months.
10178864|NCT03809130|Active Comparator|Arm II (Untire application)|Patients use Untire application intervention after 3 months up to 6 months.
9684973|NCT04884776|Placebo Comparator|Placebo arm|Subject will be instructed to take active placebo daily for a total of 12 weeks.
9684974|NCT04884685|Experimental|Experimental Group|Participant will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
10178865|NCT03809078|Experimental|68Ga RM2 first followed by 68Ga PSMA11|Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
10178866|NCT03809078|Experimental|68Ga PSMA11 first followed by 68Ga RM2|Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2
9684975|NCT04884685|Placebo Comparator|Control Group|Placebo will receive two doses of placebo. The placebo will given by intramuscular injection on day 0 and day 28.
9684976|NCT04884659|Experimental|Timed restricted feeding|"Time restricted feeding then usual feeding pattern Day 1, testing~Day 2-7 all meals will be consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm. Day 8 testing. Day 9-14 crossover to usual feeding pattern arm (meals consumed ad lib with 50% of calories consumed after 4 PM) for 6 days."
10178867|NCT03808701|Experimental|low dose group|Initially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
10178868|NCT03808701|Experimental|HIGH dose group|Initially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
9684977|NCT04884659|Experimental|Usual feeding pattern|"Usual feeding pattern, then time restricted feeding Day 1 testing~Day 2-7 all meals will be consumed as follows:~Meals consumed ad lib with 50% of calories consumed after 4 PM. Day 8 testing. Day 9-14 crossover to time restricted feeding arm with all meals consumed as follows:~80% of calories consumed before 2 PM with remaining 20% consumed by 4PM. Fasting except for water, non caloric drinks for 14-16 hours Same number of calories consumed as in usual feeding pattern arm for 6 days."
9684978|NCT04884711||Interviews: Older people living at the Leach Court (Brighton, UK).|Older adults who will be enrolled at the Leach Court (Brighton, UK) as a part of the INNOVATEDIGNITY project will be involved in 1:1 open ended interviews.
9684979|NCT04884711||Focus Group Discussions: Older People Living at the Leach Court (Brighton, UK)|10 older people who have previously participated in the interview stage will be involved in two focus group discussions in a group of 5 participants each to co-design digital health technologies that are 'dignity' sensitive and aims to resolve the barriers older people face in technology adoption.
9684980|NCT04884555||post-stroke patient|patients with subacute stroke who have a stroke for the first time and admitted to the hospital for the first rehabilitation treatments
9684981|NCT04884555||Control|healthy volunteers who have not got any known disease and any sign in physical examination
9684982|NCT04884841||Patients with postoperative complications|Patients with postoperative complications
9684983|NCT04884841||Patients without postoperative complications|Patients without postoperative complications
9684984|NCT04884529|Experimental|Chair Yoga Treatment Group|The chair-yoga session will occur for 8-weeks (60 minutes/week) on Zoom. The chair-yoga intervention will include gentle seated postures, relaxation using breathing techniques, and a mindfulness component.
9684985|NCT04884529|No Intervention|Waitlist Control Group|These participants will be on a waitlist to receive the chair yoga program after data collection has been completed (e.g., after 8-weeks).
9684986|NCT04884503|Experimental|Patients diagnosed with BMS traeting with Clonazepam|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
9684987|NCT04884503|Active Comparator|Patients diagnosed with BMS treating with tongue pads|patients wearing tongue pads 3 times a day for 20 minutes for 4 weeks to exclude parafunctions
9684988|NCT04884516|Other|Intervention arm|Participants take retinol gummy once a day
9684989|NCT04884490|Experimental|Intervention|"Eligible patients will be receiving either to oral co-trimoxazole + standard therapy.~Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.~The following treatments are recommended as standard therapy:~Antibiotics for secondary bacterial infection as per institutional guidelines~Supplemental oxygen (to keep saturations between 92% to 96%)~Intravenous hydration (to maintain euvolumia)~Thrombo-prophylaxis as per local guidelines~Paracetamol (oral or I/V 1gram QDS as required or regular)~To consider steroids in appropriate cases.~Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally."
9695818|NCT04773873|Experimental|Arm 3:Hybrid abutment ceramic polymer infiltrated (Enamic)|Hybrid crown abutment: chairside-made perforated CAD-CAM ceramic-polymer infiltrated crown (Enamic) adhesively cemented to a TiBase and screw-retained to a Straumann titanium implant (regular and wide neck)
9695819|NCT04773964|Experimental|MET642 high dose|
9695820|NCT04773964|Experimental|MET642 low dose|
10178869|NCT03808831|Experimental|Experimental groups|Subjects in the experimental group will wear the fall detection and prevention system on the lower back. The system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
10178870|NCT03808831|Sham Comparator|Sham group|In the sham group, subjects wear a sham system with record but no alert function.
10178871|NCT03808818|Active Comparator|Arm A (smoking assessment, quitting advice, Quitline referral)|Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.
9684990|NCT04884490|Placebo Comparator|Standard|"Standard therapy along with placebo.~Placebo thrice (8 hourly) for 7 days.~The following treatments are recommended as standard therapy:~Antibiotics for secondary bacterial infection as per institutional guidelines~Supplemental oxygen (to keep saturations between 92% to 96%)~Intravenous hydration (to maintain euvolumia)~Thrombo-prophylaxis as per local guidelines~Paracetamol (oral or I/V 1gram QDS as required or regular)~To consider steroids in appropriate cases.~Nasopharyngeal and throat swab to be sent for RT PCR to detect SARS-CoV-2 (if not already done) and blood culture"
10178872|NCT03808818|Experimental|Arm B (virtual counseling sessions, NRT)|Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).
10178873|NCT03808805|Experimental|studied group|Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days
10178874|NCT03808805|Active Comparator|comparative group|Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days
9684991|NCT04884425|Active Comparator|PEMF Device Group|This arm will consist of participant's who have been randomly assigned to use the PEMF device daily for 30 mins for an overall 3 months
10178875|NCT03808714|Active Comparator|Intervention|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session (delivered by a trained Community Health Worker) plus pharmacological consultation(s) via telemedicine, but this will be determined during pretesting.
10178876|NCT03808714|Active Comparator|Control|"Alabama Tobacco Quitline, which is considered the standard-of-care for smoking cessation in Alabama."
9684992|NCT04884425|No Intervention|Waiting List Control Group|These participants will be randomly selected to be on the waiting list group. All waiting list participants will be offered the use of the PEMF device after the study has completed
9684993|NCT04884373||Fasted adult patients for elective surgery|"Age ≥ 18 years~Fasted according to national guidelines~Elective surgery~ASA physical status I-II~Ability to assume both supine and right lateral decubitus position.~Able to understand and to sign informed consent"
9684994|NCT04884399|Experimental|CMAB818|0.5 mg by intravitreal injection once on the first day.
9684995|NCT04884399|Active Comparator|Lucentis®|0.5 mg by intravitreal injection once on the first day.
9684996|NCT04884204|Experimental|Symptom management with Lee Symptom Scale|Participants will receive disease specific questionnaires electronically, cGVHD-PRO (Lee Symtpom Scale), one week prior to their scheduled visit in the outpatient clinic. The participants will be asked to answer the questionnaire from home without any involvement from clinicians. Afterwards the PRO data will be used during the scheduled clinical consultations as an instrument to discover symptoms on chronic GVHD and systematically to monitoring symptoms developing over time.
9684997|NCT04884230||Group A|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
9684998|NCT04884230||Group B|We selected 225 patients (group A) from the period 2019-2020 where the stapling line of the gastric remnant was oversewn and another group of 225 patients (group B) from the period of 2017-2018 with stapling alone.
9684999|NCT04884217|Active Comparator|Pro-ocular™|Pro-ocular™ Topical Gel
9685000|NCT04884217|Placebo Comparator|Placebo|Placebo Topical Gel
9685001|NCT04884087|Experimental|EMA, 3x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
9685002|NCT04884087|Experimental|EMA, 6x/day, fixed incentive|Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
9685003|NCT04884087|Experimental|EMA, 3x/day, prize-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 3 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
9685004|NCT04884087|Experimental|EMA, 6x/day, prized-based incentive|"Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will be rewarded for high survey completion with increasing numbers of draws for prizes depending on their level of response each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws)."
10178877|NCT03808584|No Intervention|Control group|The patients in the control group will receive standard physiotherapy and will be instructed to limit core muscle activity and weight bearing according to their pain symptomatology. Standard physiotherapy for all hospitalised patients includes early mobilization and exercises to prevent thrombosis and pulmonary complications (atelectasis, pneumonia, diaphragmatic deconditioning), balance training and endurance and exercise training
10178878|NCT03808584|Experimental|Intervention group|The patients in the intervention group will be given exercises to perform postoperatively.They will be instructed by a physiotherapist in how to perform the four specific exercises targeting core muscles. The patient will perform these exercises daily during hospitalization under the supervision of the physiotherapist and then at home for two months after the operation. The intensity of the exercises will be adjusted daily to the physical capabilities of the patient. They will also benefit from standard physiotherapy as described above.
10178879|NCT03808753|Experimental|Treatment - hemodynamic tests: EEOT and mFC|Interventions: all the enrolled patients will be tested using the EEOT and the mFC.
10178880|NCT03808779|Experimental|Radiofrequency Ablation|Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
10178881|NCT03808779|Active Comparator|Conventional Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
9685008|NCT04884191|Experimental|Pacritinib 100 mg QD|
10178882|NCT03808766|Other|Tumor <=3cm|Embolization with particulate or liquid embolic agent
9685009|NCT04884191|Experimental|Pacritinib 100 mg BID|
9685010|NCT04884191|Experimental|Pacritinib 200 mg BID|
9685011|NCT04884139|Experimental|Dovato arm|DTG/3TC
9685012|NCT04884139|Active Comparator|Biktarvy arm|BIC/FTC/TAF
9685013|NCT04884074|Experimental|The study group|The procedure done to this group is Sleeve Gastrectomy with Anterior Crural Repair (ACR)
9685014|NCT04884074|Other|The control group|The procedure done to this group is the Standard Sleeve Gastrectomy (SSG)
9685015|NCT04884178|Experimental|Trifocal Preloaded IOL Delivery System|Bilateral trifocal IOLs implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
9685016|NCT04884282|Experimental|Arm A - tedopi + docetaxel|Tedopi every 3 weeks plus docetaxel every 3 weeks only for 6 cycles, then maintenance with Tedopi alone every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal.
9685017|NCT04884282|Experimental|Arm B - tedopi + nivolumab|Tedopi every 3 weeks plus nivolumab 360 mg every 3 weeks for 6 cycles, then maintenance nivolumab 360 mg every 3 weeks plus Tedopi every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal
9685018|NCT04884282|Other|Arm C - docetaxel|Docetaxel every 3 weeks until disease progression, unacceptable toxicity, patient refusal, or for a maximum of 6 cycles (whichever comes first).
9685019|NCT04884334||VAC-Stent® treatment|spontaneous, iatrogenic or postoperative leakage of the oesophagus or colon
9695821|NCT04773964|Placebo Comparator|MET642 Placebo|
9695822|NCT04774016|Experimental|Test formula C|
9695823|NCT04774016|Experimental|Test formula B|
9695824|NCT04774016|Placebo Comparator|Test formula A|
9695825|NCT04773795|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
9695826|NCT04773691|Experimental|test group|
9695827|NCT04773691|Placebo Comparator|control group|
9695828|NCT04773977|Experimental|IBI362 liquid formulation|Participants received single subcutaneous injection of IBI362 liquid formulation
9695829|NCT04773977|Experimental|IBI362 lyophilized powder|Participants received single subcutaneous injection of IBI362 lyophilized powder
9695830|NCT04773717|Experimental|Ascorbic acid|"Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours.~Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours."
9695831|NCT04773717|Placebo Comparator|Placebo|Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.
9695832|NCT04773743|Experimental|chronic nonspecific low back pain|Remotely delivered yoga intervention
9695833|NCT04773535||healthy Volunteers|Adult (>18y) healthy volunteers without previous injuries or pathologies of the hand and upper extremity
9695834|NCT04773509|Active Comparator|PVB group|Patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides
10178883|NCT03808766|Other|Tumor >3cm to 7cm|Embolization with particulate or liquid embolic agent
9695835|NCT04773509|No Intervention|Control group|PVB are not performed in the control group.
9695836|NCT04773678|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
9695837|NCT04773678|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
9695838|NCT04773678|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
9695839|NCT04773990|Other|Experimental Group|Group (A) twenty-five patients will receive biodex balance training
9695840|NCT04773990|Other|Controlled Group|twenty-five patients will receive a physical therapy exercise protocol
10178884|NCT03808766|Other|Tumor > 7cm|Embolization with particulate or liquid embolic agent
9695841|NCT04773561|Experimental|multifetal pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
9695842|NCT04773561|Active Comparator|singleton pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
9695843|NCT04773561|Active Comparator|age-stratified healthy non-pregnant women|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed.
9695844|NCT04773574|Experimental|Normal pregnant women with high myopia|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA) were performed in each trimesters and at 6 weeks after childbirth.
9695845|NCT04773665|Experimental|Phase 1a, Group G1|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Day 1 and placebo at Day 28
9695846|NCT04773665|Experimental|Phase 1a, Group G2|20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Days 1 and 28
9695847|NCT04773665|Placebo Comparator|Phase 1a, Group G3|20 participants age 18-54 will receive placebo at Days 1 and 28
9695848|NCT04773665|Experimental|Phase 1b, Group G4|27 participants age 18-54 will receive VBI-2905a at a dose of 5 μg of S protein at Day 1
9695849|NCT04773665|Placebo Comparator|Phase 1b, Group G5|27 participants age 18-54 will receive placebo at Day 1
9695850|NCT04773665|Experimental|Phase 1b, Group G6|27 previously unvaccinated participants age 18-54 will receive VBI-2905a at a dose of 5 µg of S protein at Day 1 and Day 28
9695851|NCT04773470|Experimental|Spinal Muscle Atrophy|All patients with Spinal Muscle Atrophy type 1 to 4
9695852|NCT04773496||Balance evaluation|patient's balance is evaluated with instrumental posturography
9977679|NCT01364142||thoracic surgery|Patients undergoing thoracic surgery in which one lung ventilation is needed.
10178885|NCT03808792||Ovarian cancer patients|Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
10178886|NCT03808649|Active Comparator|Individualized group|Participants are given different volume of a preparation of mannitol based on BMI as oral contrast agent over an hour prior to the examination.
9685020|NCT04884477||COVID-19 with previous anti-CD20 therapy and Convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy and who received Convalescent plasma in addition to standard treatment for COVID-19
9685021|NCT04884477||COVID-19 with previous anti-CD20 therapy and no convalescent plasma|Patients with COVID-19, treated in the past 3 years with anti-CD20 therapy treated with standard COVID-19 treatment and who did not receive Convalescent plasma treatment for COVID-19
9685022|NCT04883996|Active Comparator|EXP039|At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.
9685023|NCT04883996|Placebo Comparator|Saline control|At Visit 1, single dose 1 drop of saline is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop EXP039 1% at Visit 2.
9685024|NCT04884022|Experimental|Miniplates in mandibular symphysis & infrazygomatic|
9685025|NCT04884022|Active Comparator|Miniplates in external oblique ridge & anterior maxillary region|
10178887|NCT03808649|Experimental|conventional group|Participants are given 1500ml of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
9685026|NCT04884022|No Intervention|Growing skeletal Class II subjects|
10178888|NCT03808662|Experimental|Arm 1: Early Stereotactic Body Radiotherapy/SBRT|SBRT to all oligoprogressive sites
10178889|NCT03808662|Active Comparator|Arm 2:Standard of Care|
9685027|NCT04884451|Experimental|Intervention|Participants will receive nutritional counselling from the researcher based on Stage-Based, Nutrition Education Package for Childhood Obesity (ST-NEPCO). Nutritional advice and educational tools will be provided according to participants' stages of change.
9685028|NCT04884451|No Intervention|Control|Participants will receive counseling from dietitians based on the routine care for the management of childhood obesity.
10178890|NCT03808597|Experimental|Intervention group|The participants in this group will be exposed to digital health promotion. Please note that the participants are not randomly chosen, but stratified after the project villages. The participants in this group belong to the villages: Izazi and Migoli.
10178891|NCT03808597|No Intervention|Control group|"The participants in this group will be not be exposed to digital health promotion, but the villages will receive the intervention after one year. Please note that the participants are not randomly chosen, but stratified after the project villages.~The participants in this group belong to the villages: Kimande and Idodi."
10178892|NCT03808532|Experimental|High-Risk with Moisturizer|
10178893|NCT03808532|No Intervention|High-Risk without Moisturizer|
10178894|NCT03808675|Experimental|Aerobic|Participants randomized to aerobic exercise
10178895|NCT03808675|Other|Control|Participants randomized to usual care with PD specific health education
10178896|NCT03808571||Study group|Pregnancies complicated with intrauterine growth restricted fetuses
10178897|NCT03808571||Control group|Healthy pregnancies
10178898|NCT03808636||TB patients|Any patient with possible or diagnosed tuberculosis who is capable to give informed consent will be offered to be included in the trial
10178899|NCT03808545|Active Comparator|BIPAMS|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
10178900|NCT03808545|Experimental|BIPAMS + Diet|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.
10178901|NCT03808376|Experimental|Continuous Glucose Monitoring Device|The Eversense® 180 CGM System
9685029|NCT04884126||One stage dental implants placement|
9685030|NCT04884126||Second stage dental implants placement|
9685031|NCT04884464||Hyaluronic acid-based gel|The composition of the gel, ranked by weight is: xylitol, glycerin, Rosa damascena petal extract, xanthan gum, polycarbophil, hyaluronic acid sodium salt (0.24%), pectin, potassium sorbate, sodium benzoate, panthenol, Aloe barbadensis leaf extract, stevia.
9685032|NCT04884464||Chlorhexidine gluconate|Chlorhexidine gluconate at a concentration of 0.2%.
9685033|NCT04884061||Experimental|Patients hospitalized with SARS-CoV2 infection proven by RT-PCR test
9685034|NCT04884061||Comparator|Patients hospitalized with lower respiratory tract infections unrelated to SARS-CoV2 (RT-PCR negative for SARS-CoV2)
9685035|NCT04884061||Comparator 2|Patients who have had bronchoscopy performed as part of the assessment of a distal pulmonary nodule (RT-PCR negative for SARS-CoV2).
9685036|NCT04884048||Benign bone tumors|Patients with benign lesions confirmed either by histology or imaging follow-up showing lesion stability.
9685037|NCT04884048||Malignant bone tumors|Patients with malignant lesions confirmed by histology.
9685038|NCT04884009|Experimental|SHR-1701+ Famitinib|
9685039|NCT04884009|Experimental|SHR-1701|
9685040|NCT04883957|Experimental|Cohort A: R/R NHL|Participants with R/R NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or transformed NHL, will receive oral BGB-11417 until the MTD (or maximum ascending dose [MAD]) and the RP2D can be determined.
9685041|NCT04883957|Experimental|Cohort B: R/R CLL/SLL (low tumor burden)|Participants with low tumor burden R/R CLL/SLL will receive oral BGB-11417 until the MTD (or MAD) and the RP2D can be determined.
9685042|NCT04883957|Experimental|Cohort C: R/R CLL/SLL (high tumor burden)|Participants in this cohort will not be enrolled until the RP2D for Cohort B is established. Participants will be treated with the monotherapy ramp-up schedule and the RP2D established in Cohort B.
9826767|NCT02431806|Placebo Comparator|Placebo|Participants received 2 dose matched over-encapsulated placebo capsules, once daily, orally during the Double-blind Treatment Period up to 8 weeks followed by a 1 week Taper-down Period if applicable as determined by the investigator.
9977680|NCT01364155|Experimental|600 mg LIM-0705 BID for 28 days|
9685043|NCT04884347|Experimental|Alline proMEN|The qualitative and quantitative formula is as follows: 500 mg Keratin, 225 mg Inactive dried yeast rich in vitamin (containing 200 mg Saccharomyces cerevisiae 100% inactivated, 11.218.4 mg Vitamin B3, 6.8-7.2 mg Vitamin B5, 1.6-1.8 mg Vitamin B6, 1.6-1.8 mg Vitamin B2, 1.6 -1.8 mg Vitamin B1, 0.2-0.4 mg Vitamin B9, 0.2 mg Vitamin B8, 5.6 μg Vitamin B12), 150 mg Venus hair fern extract, 117.6 mg Iron gluconate (containing 14.7 mg Iron), 84.2 mg Sodium ascorbate coated, 76.8 mg Zinc gluconate (11 mg Zinc) 24 mg Beta carotene 20%, 14.8 mg Vitamin E, 256.3 mg Acacia gum, 100 mg Microcrystalline cellulose, 11.3 mg Magnesium stearate, 78 mg White coating (containing: 23.4-39 mg Hydroxypropylmethylcellulose (E464), 15.6-23.4 mg Calcium sulfate anhydrous (E516), 15.6-23.4 mg Magnesium carbonate, light (E504), 7.8-15.6 mg Hydroxypropylcellulose (E463), 3.9-11.7 mg Stearic acid (E570)).
9685044|NCT04884347|Placebo Comparator|Placebo|1095 mg Microcrystalline cellulose, 5 mg Magnesium stearate, 55 mg White coating (containing: 16.5-27.5 mg Hydroxypropylmethylcellulose (E464), 11.0-16.5 mg Calcium sulfate anhydrous (E516), 11.0-16.5 mg Magnesium carbonate, light (E504), 5.5-11.0 mg Hydroxypropylcellulose (E463), 2.8-8.2 mg Stearic acid (E570).
10178902|NCT03808428|Experimental|Ankle Group|Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm.
9685045|NCT04883840|Placebo Comparator|Placebo|
9685046|NCT04883840|Experimental|Rosuvastatin 10 mg|
9685047|NCT04883853|Experimental|Mild -Moderate Ptosis with good levator function (more than 8 mm)|The upper eyelid crease was marked for the incision site, up to 5-7 mm from the lid margin, guided by the fellow eyelid crease position. The skin incision was done and the orbicularis occuli muscle was dissected to the tarsus. The anterior surface of the tarsal plate was then identified with the aponeurosis at its insertion, the orbital septum was then opened with a resultant fat prolapse, and the levator aponeurosis exposed until Whitnall's ligament. Three double-armed 5/0 polyester white braided, non-absorbable sutures, with spatulated needle 1/4 circle (Astralen, Assut Medical Sàrl, Pully-Lausanne, Switzerland) were passed between the levator aponeurosis near Whitnall's ligament and the anterior surface of the tarsus in a mattress form
10178903|NCT03808415|Experimental|EMG-driven|The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand.
9685048|NCT04883723|Experimental|Experiment I (Shotblocker) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position. The determined injection site was cleaned with a cotton pad with alcohol, with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. The protruding surface of the Shotblocker was placed in the area just before the injection, so that the needle entry point would not be contaminated. It was lightly pressed into the shotblocker with fingertips and the injection was performed. ShotBlocker has been removed after removing the needle. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
9685049|NCT04883723|Experimental|Experiment II (Manual Pressure) Group|Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
10178904|NCT03808519|Experimental|n3 PUFA|n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
10178905|NCT03808519|Placebo Comparator|Placebo|Organic Sunflower Oil 5000mg per day
10178906|NCT03808441|No Intervention|Standard Arm|"Dabrafenib + Trametinib~Switch to N+I at first progression"
10178907|NCT03808441|Active Comparator|ctDNA Guided Switch|"Dabrafenib + Trametinib~Switch to N+I when ctDNA levels in the blood have dropped by ≥80%."
10178908|NCT03808506||Ulcerative colitis patients|Patients with documented ulcerative colitis who are initiating adalimumab therapy will have baseline bowel ultrasound and fecal calprotectin completed.
9695853|NCT04773613|Experimental|Experimental SLP|Infant placed in a SLP on the researcher's lap. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
9977681|NCT01364155|Placebo Comparator|Placebo LIM-0705 for 28 days|
10178909|NCT03808324|Experimental|Heart transplant recipients|
10178910|NCT03808285||mandibular osteomylitis|description of mandibular osteomylitis due to denosumab
10178911|NCT03808233||Spinal Muscular Atrophy Type 1|Non rolling infants or children with SMA
10178912|NCT03808233||Non Rolling Function matched control|Non rolling typically developing infant
10178913|NCT03808207|Experimental|Intervention group|Increase of the average intake of dietary DHA: dietary advices concerning the concentration of docosahexaenoic acid (DHA) in several foods; the recommended daily or weekly intake of different food options (animal, vegetal) in order to reach the average intake of 300-350 mg DHA/day
10178914|NCT03808207|No Intervention|Control group|No specific dietary advice; Only endorsement and promotion of breastfeeding.
10178915|NCT03808363|Experimental|High Intensity Interval Training Group|Approximately eight individuals with spinal cord injuries will participate in high intensity interval training for 6 weeks
10178916|NCT03808168|Active Comparator|Arm 1|Nivolumab, 3 mg/kg Iv, day 1
10178917|NCT03808168|Active Comparator|Arm 2|Nivolumab, 3 mg/kg IV, days 1, 15, 29
9685050|NCT04883723|No Intervention|Control Group|The patients in the Manual Pressure group were given detailed information about the procedure and the research, and the patients who agreed to participate in the study were signed by an informed consent form. Before the injection, the heart rate and blood pressure values of the patient were measured and recorded. The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Injection was given using the normal intramuscular injection procedure. Visual comparison scale and injection satisfaction evaluation scale were applied to the patient in the first minute after the intramuscular injection. The obtained scores were recorded in the patient identification form. Pulse and blood pressure values were measured and recorded again. Finally, the patient introduction form was filled.
10178918|NCT03808142||Treatment|During a 3-months period all patients with an active myBETAapp account were invited to participate in the study (3-month invitation period=enrollment period). Patients seek more information about the study were able to access a detailed informed consent form via their app providing step-by-step background information. Those patients were wishing to participate in the study were able to provide (electronic) informed consent (ICF).
10178919|NCT03808116|Experimental|SmartBx biopsy collection|"Biopsy cores will be collected from the breast during US guided biopsy procedure.~The number of cores taken will be decided per the physician discretion according to the clinical demand.~Additional two biopsy core will be taken the SmartBx cassette"
10178920|NCT03808259|Experimental|Part 1: OTF Sublingual and IV|Participants will receive (S)-ketamine oral thin film (OTF) at a dose of 7 milligram (mg) [cohort 1], 14 mg [cohort 2], and 28 mg [cohort 3] via sublingual route or 14 mg (S)-ketamine intravenous (IV) infusion for 40 minutes or matching placebo in 1 of 3 serial cohorts. Dose escalation decisions to further cohorts of Part 1 will be made based on safety and tolerability profile of the preceding lower dose level.
9685051|NCT04883866|Experimental|Intervention Group|"Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.and implementing a Telephone Breastfeeding Support Program."
9685052|NCT04883866|Experimental|Control Group|Sending breastfeeding guidelines for premature babies to phones after the discharge procedure is completed.
9685053|NCT04883684|Experimental|Patients(Care givers)|"400 patients(caregivers) are enrolled and use the personal health wallet service (Personal Health Records service).~They fill out questionnaire to evaluate the service~Some of them are invited for an in-depth interview."
9685054|NCT04883801||COVID-19 case group|Newborns born to pregnant women diagnosed with COVID-19 during hospitalization for delivery
9685055|NCT04883801||Control group|Newborns born to pregnant women who were not diagnosed with COVID-19 in their medical history and hospitalization for delivery
9685056|NCT04883827||RCC with clear cell component|
9685057|NCT04883827||Healthy Volunteer|
9685058|NCT04883736|Experimental|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9685059|NCT04883736|Active Comparator|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9685060|NCT04883736|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9685061|NCT04883944|Experimental|Intervention group|All the enrolled infants will receive the heel stick procedure with the maternal involvement after mother will be trained on the application of the non-pharmacological techniques during the performance of the procedure.
9685062|NCT04883944|Active Comparator|Standard care|All the enrolled infants will receive the heel stick procedure according to local protocol without the maternal involvement. The non-pharmacological techniques will be performed by a second nurse not involved in the heel stick procedure itself.
9685063|NCT04883892|Experimental|BMAC injection|Single injection of Bone Marrow Aspirate Concentrate (BMAC) into the ankle joint
9685064|NCT04883892|Active Comparator|HA injections|"two injections of Hyaluronic Acid (HA) into the ankle joint - one injection every 15 days.~After 12 months patients are allowed to cross-over in the BMAC arm."
9685065|NCT04883970|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 124I-18B10(10L) PET/CT scans
9685066|NCT04883528|Experimental|Sacubitril/valsartan|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.~Other Name: LCZ696"
9685067|NCT04883528|Placebo Comparator|Placebo|"Initial dose for patients randomized to sacubitril/valsartan matching placebo will be determined by the blood pressure at the time of randomization. Study treatment will be titrated to the next highest dose (dose level 2 or 3) based on blood pressure at the time of visit 2/titration visit. Dose adjustments are only allowed if indicated per protocol defined criteria and per investigator judgement of safety and tolerability.~Sacubitril/valsartan matching placebo with minimum dose matching the 24/26 mg dose, maximum dose matching the 97/103 mg dose, adminstered twice daily orally."
9685068|NCT04883450||Risk of pancreatic cancer|Subjects with an increased predicted 18-month risk of pancreatic cancer
9685069|NCT04883476||Chronic Low Back Pain and Neck Pain|
9685070|NCT04883515|Experimental|Oral glutamine supplementation|patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks
10178921|NCT03808259|Experimental|Part 2: IV Different Infusion Duration|Participants will receive single dose (S)-ketamine less than or equal to (<=)14 mg IV at a different infusion duration or matching placebo at a different infusion duration. The infusion duration and dose will be chosen after completion of Part 1.
9685071|NCT04883515|Active Comparator|Oral protein powder supplementation|patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks
10178922|NCT03808194|Active Comparator|Optimized ART linkage package|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART.
9685072|NCT04883411|Experimental|Treatment|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System.
9685073|NCT04883632|Experimental|Volume Lidocaine HQ|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma HQ Facility
9685074|NCT04883632|Active Comparator|Volume Lidocaine C1|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma C1 Facility
9685075|NCT04883541|Experimental|The Study Group|Pregnant women participated in the applications, which lasted two days a week, for ten weeks, and for 60 minutes a day.
9685076|NCT04883541|Placebo Comparator|Control Group|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
9685077|NCT04883658|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(2) - A single oral dose of 1 tablet under fasting condition"
10178923|NCT03808194|Experimental|Conditional lottery incentive|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART and will be entered into a lottery each time they meet the following conditions: visited the clinic by month 1, initiated treatment by month 3, and achieved viral suppression by month 6
10178924|NCT03808129|Active Comparator|ESP Group: Bupivacaine and lidocaine|ESP Group: Bupivacaine and lidocaine: Erector Spinae Plane Block : (1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine) was administered.
10178925|NCT03808129|No Intervention|control group|Control Group:
10178926|NCT03808103|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally twice a day for 15 days
9685078|NCT04883658|Experimental|Sequence 2|"Period 1: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(2) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
9685079|NCT04883593|Experimental|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
10178927|NCT03808103|Experimental|Phage|Dose is 1mL of bacteriophage preparation given orally twice a day for 15 days
9685080|NCT04883593|Placebo Comparator|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
9685081|NCT04883255|Experimental|HIV-positive subjects|Adult human subjects seropositive for HIV-1
9685082|NCT04883255|Active Comparator|Healthy Comparison Volunteers|Adult human subjects without HIV
9685083|NCT04883164||Healthy non-immunocompromized subjects|"Healthy individuals are those with no pre-existing conditions that cause immune deficiency, and who are not receiving drugs to suppress the immune system.~•"
9685084|NCT04883164||Immunocompromized|Immunocompromised subjects are those receiving immunosuppressive or immunomodulatory drugs such as those given for autoimmune disease, inflammatory bowel disease, malignancies and transplantation. Bone marrow transplant recipients and subjects with known immune deficiency diseases are also considered immunocompromised.
9685085|NCT04883190||1. after SARS-CoV-2 infection|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
9685086|NCT04883190||2. control group with negative antibody test|"All participants in the study and control group of the FSC19-KN study will be contacted either by email or by post.~We plan to write to around 200-250 patients after SARS-CoV-2 infection and 200-250 test subjects in the control group."
9685087|NCT04883151|Experimental|SOFUS pilot program|
9685088|NCT04883580|Experimental|experimental group|
9685089|NCT04883580|Active Comparator|control group|
9685090|NCT04883203|Active Comparator|VITD|A single vial of Cholecalciferol (1 ml) (200,000 IU / 1 m), Oral form,
10178928|NCT03808246|Experimental|naive/realistic environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
10178929|NCT03808246|Experimental|informed/realistic environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
10178930|NCT03808246|Experimental|informed/laboratory-like environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
10178931|NCT03808246|Experimental|naive/laboratory-like environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
10178932|NCT03808181|Other|Active treatment with ChloraSolv|Single arm
10178933|NCT03808454|Experimental|Platelet rich plasma (PRP)|PRP injection only
10178934|NCT03808454|Experimental|PRP+Rehabilitation|PRP injection combined with rehabilitation
10178935|NCT03808454|Active Comparator|Rehabilitation|Rehabilitation treatment only
9685091|NCT04883203|Placebo Comparator|Placebo|A single vial of physiological salin Oral form
9977682|NCT01364168||First ever acute ischemic stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
10178936|NCT03808155|Active Comparator|Tamsulosin|The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation.
10178937|NCT03808155|Placebo Comparator|Placebo Oral Tablet|The placebo is taken once a day per os five days prior to the operation and two days after the operation.
10178938|NCT03808220||post-surgical patients|post-surgical patients > 18 years
10178939|NCT03808220||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
10178940|NCT03807986|Experimental|Nanofat grafting and PRP injection|Striae diatensae will be treated by nanofat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
9685092|NCT04883034|Placebo Comparator|pain management post total knee arthroplasty with analgetic oral|Patients in control group were given analgesic (etoricoxibe) on a daily basis, with the option to increase the dose if pain persisted, up to a maximum of 120 mg per day.
10178941|NCT03807986|Experimental|Microfat grafting and PRP injection|Striae diatensae will be treated by microfat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
9685093|NCT04883034|Active Comparator|pain management post total knee arthroplasty with adductor canal block|On postoperative day 14 (POD 14), the ACB was performed for ACB group
10178942|NCT03807934|Experimental|Active High-Definition Stimulation|Active high-definition stimulation of targeted brain regions involved in perception and cognition.
10178943|NCT03807934|Sham Comparator|Sham High-Definition Stimulation|Sham high-definition stimulation of targeted brain regions involved in perception and cognition.
9685094|NCT04883268|Experimental|Intervention Group|Participants in the intervention group completed the Expand Your Horizon programme (Alleva et al., 2015).
10178944|NCT03808038||No Diary Group|Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
9685095|NCT04883268|No Intervention|Comparison Group|Participants in the comparison group did not complete any intervention (i.e., this was a waitlist comparison group).
9685096|NCT04883047|Experimental|experiment|"Women in the experimental group will be given care at the first stage of labor (will start in the latent phase) using Integrated Birth Support Strategies created in line with the Algorithm for Coping with Birth Pain.~Among the interventions made into a checklist, the interventions applied to the woman will be marked by the midwives and nurses working in the delivery room. The Scale for Coping with Birth Pain (DABS), which will be applied once in each phase (latent phase, active phase and transition phase), will guide the delivery of care; Care practices will differ depending on the woman's ability to cope with labor pain.At least 3 of each sub-heading of the physical comfort parameter, at least 1 of each sub-heading of the parameter of providing emotional comfort, at least 2 of each sub-heading of informative support and advocacy sub-parameters will be applied to pregnant women by midwives / nurses working in the delivery room."
9685097|NCT04883047|No Intervention|control|Pregnant women assigned to the control group will be followed up with the routine care applied in the delivery room.
9685098|NCT04883294||Disease Group|A disease group including patients older than 18 years old with any kind of histopathologically proven malignancy of the thyroid gland (including Papillary thyroid cancer (PTC), Follicular thyroid cancer (FTC), Medullary thyroid cancer (MTC), and Anaplastic thyroid cancer);
9685099|NCT04883294||Control|A control group including patients older than 18 years old with any kind of histopathologically proven benign thyroid gland disease (including adenoma, hyperplasia).
9685100|NCT04883320||participants with no asthma|Have no evidence of any long term lung condition or any other disabling condition and they must not have had a chest infection in the preceding 4 weeks.
9685101|NCT04883320||participants with mild/moderate asthma|
9685102|NCT04883320||participants with severe asthma|
9685103|NCT04883307|Experimental|Coaching Intervention|Paired with a coach outside of their specific area of interest; encouraged to meet 3 times over 9 months for a 1:1 coaching meeting
9685104|NCT04883307|Active Comparator|Wellness Resources|Emailed wellness resources
9685105|NCT04883567||AI arm|AI would be used to assist the trainee endoscopist
9685106|NCT04883567||Non-AI arm|Trainee endoscopist would perform OGD as usual.
10178945|NCT03808038||Diary Start Group|Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
10178946|NCT03808038||Daily Start Group|Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
10178947|NCT03807947|Experimental|Radial access|
10178948|NCT03807947|Active Comparator|Transfemoral Access|
9685107|NCT04882969|Experimental|Fractionated Thulium Laser and KeraFactor|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied KeraFactor every 2 weeks for 12 week period.
9685108|NCT04882839|Experimental|Active participants|Participants undertaking to full therapeutic protocol including psychotherapy sessions and Psilocybin sessions
9685109|NCT04882956|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
9685110|NCT04882956|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months
9685111|NCT04882787|Experimental|BTE hearing aid model|BTE or SP-BTE (super power) hearing aid fitting
9685112|NCT04883229|Experimental|tDCS +speech therapy followed by sham tDCS + speech therapy|
9685113|NCT04883229|Active Comparator|sham tDCS +speech therapy followed by tDCS + speech therapy|
10178949|NCT03807960|Experimental|visual|The video about patient controlled analgesia device (PCA) usage will shown to the patients via notebook.
10178950|NCT03807960|Experimental|written|The written form which include the same knowledge will give to the patient for reading.
10178951|NCT03807960|Other|control|The anesthesiologist will describe the PCA usage as in the routine care to the control group patients.
10178952|NCT03807999|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel 125 mg/m2 as 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) once weekly for 3 weeks followed by a week of rest. plus Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) once weekly for 3 weeks followed by a week of rest.
10178953|NCT03807999|Experimental|Gemcitabine|Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
10178954|NCT03807895|Experimental|REBT Career Intervention|High-school students in the experiment group attend to eight modules of career intervention with rational emotive behavioral therapy (REBT) techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive Restructuring, Exposure/behavior activation and problem solving, Planning, Goal Setting.
10178955|NCT03807895|Active Comparator|Regular Career Intervention|High-school students in the treatment as usual group attend to eight modules of career intervention with regular career intervention techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Problem solving, Planning, Goal Setting.
10178956|NCT03807908|Experimental|Intervention Tape|"The intervention includes 3 strips of tape; 2 (1 on each side) placed vertically along the lumbar erectors and 1 horizontally at the posterior superior iliac spine.~Subjects will wear the tape for as long as possible up to 5-7 days."
10178957|NCT03807908|Sham Comparator|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction.~Subjects will wear the tape for as long as possible up to 5-7 days."
10178958|NCT03807596|Active Comparator|SRP group|Chronic periodontitis patients with type 2 diabetes mellitus recieved Periodontal treatment in the form of scaling & root planing (SRP) alone.
10178959|NCT03807596|Experimental|Hyaluronic acid & SRP group|Chronic periodontitis & type 2 diabetes mellitus patients received Periodontal treatment in the form of scaling & root planing (SRP) with the adjunctive use of hyaluronic acid.
9685114|NCT04882800|Experimental|Study Device|Participants will be fit with study devices first for two weeks, and then fit with Comparator devices for two weeks
10178960|NCT03808012|Experimental|Braking after inguinal hernia surgery|Cohort testing of driving performance in a brake simulator in patients before and after scheduled inguinal hernia surgery
9685115|NCT04882800|Active Comparator|Comparator Device|Participants will be fit with Comparator devices first for two weeks, and then fit with Study devices for two weeks.
9685116|NCT04883073|Experimental|Endo App use|use of Endo App during trial
9685117|NCT04883073|No Intervention|control|no use of Endo App during trial
9685118|NCT04882826|Other|Sequence TR|22 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9685119|NCT04882826|Other|Sequence RT|22 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9685120|NCT04883008||Intervention|CorPath GRX with technIQ automated movements enabled (technIQ ON)
9685121|NCT04883008||Control|CorPath GRX with technIQ automated movements disabled (technIQ OFF).
10178961|NCT03807687||Patient with pancreatic disease|Patients diagnosed with pancreatic disease evaluated at this institution.
10178962|NCT03807726|Experimental|Intervention Group|Both standard usual care and the integrated breastfeeding education program (IBEP) will be provided to the participants in the intervention group. The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy. The details of each education components are presented at the following section.
10187998|NCT03720522||Group 2: Patients suffering from chronic myocardial infarction|Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
9685122|NCT04883008||CTO Registry|CorPath GRX with technIQ automated movements enabled (technIQ ON) in subjects undergoing robotic-assisted PCI for chronic total occlusions (CTOs)
9685123|NCT04883060|Experimental|Intervention|Patients undergoing ventriculoperitoneal surgery where the midline localizer was used
9685124|NCT04882865||"healthy volunteers as patients"|"use of the device (AMMP) and the process on 5 healthy volunteers undergoing proning, as well as general care (movement up or down the bed, rotated laterally). As well, repositioning sheets will be used for general care. Surveys of the impressions of team members of the value (ease of use, efficiency, safety, physical demands) of using the AMMP and the repositioning sheets with these patients will be completed.~The impressions of the volunteers as patients will be surveyed, with particular reference to comfort and security during movement"
9977683|NCT01364181|Experimental|Udenafil|Udenafil 50mg qd po
9977684|NCT01364194|Active Comparator|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
9977685|NCT01364194|Placebo Comparator|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
10178963|NCT03807726|No Intervention|Control Group|The mother and her partner in the control group will receive the standard usual care provided at the study site. The study site hospital where follows the 10 steps of the Baby Friendly Hospital Initiative will provide breastfeeding care during prenatal check-up and postpartum care. The standard care protocols encompass elements such as prenatal breastfeeding consultation using breastfeeding pamphlets, and postpartum care like skin to skin contact, rooming- in, and breastfeeding consultation using pamphlets. The pregnant women need to register for childbirth class which contains only one breastfeeding class by themselves if needed. After delivery, the mothers are taught on breastfeeding knowledge and skills by the nurses at the postpartum ward or nursey.
10178964|NCT03807804|Experimental|HLCM051 group【ARDS caused by pneumonia cohort】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
10178965|NCT03807804|No Intervention|Standard treatment group【ARDS caused by pneumonia cohort】|•Patients will receive the standard therapy
10178966|NCT03807804|Experimental|HLCM051 group【ARDS caused by COVID-19 cohort 】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
10178967|NCT03807791|Experimental|Patient living in the Unit of Long Term Care|Patient living in the Unit of Long Term Care without any limit time
9685125|NCT04882865||ICU patients severe respiratory failure|patients with severe respiratory failure eligible for prone ventilation will be recruited with surveys provided to team members to gauge their impressions of the value of using the AMMP with the proning process for these patients. Surveys for 40 proning processes will be obtained. Movement from back to stomach or from stomach to back is considered a single process. A single patient may undergo multiple proning processes as prone ventilation is delivered for several days, with multiple healthcare team members participating in their care. We anticipate this will involve 10 patients, and 3 team members to be involved with each proning process.
9685126|NCT04882865||Patients admitted to the ICU|40 patients will have the AMMP used for general care. An additional 40 will have repositioning sheets used for general care. Healthcare team members involved with the care of these patients will be surveyed re their impressions of the value of using the AMMP or the repositioning sheets. We cannot predict the number of healthcare team members involved with the care of each patient s because of clinical conditions and length of stay
9685127|NCT04882761|Active Comparator|Socket shield in direct contact with dental implant|eight partially extracted sockets where implant (Neobiotech) was placed in direct contact to socket shield
9685128|NCT04882761|Active Comparator|Socket shield with gap and xenograft with dental implant|eight partially extracted sockets where a gap was left between implant (Neobiotech) and socket shield
9685129|NCT04883021|Experimental|Dual Target Theta Burst Stimulation|The TMS intervention is open-label dual-target theta burst stimulation delivered in sequential fashion to the DLPFC and the MPFC.
9685130|NCT04883112|No Intervention|No Intervention: ankle dorsiflexion|ankle dorsiflexion pre measurement with bipedestation position, will be performed
9685131|NCT04883112|Experimental|Experimental: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
9685132|NCT04883112|Placebo Comparator|Placebo: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
9685133|NCT04882904|Experimental|Patient with ALS|Patient with amyotrophic lateral sclerosis
9685134|NCT04882943||patients with unexplained or refractory chronic cough|Patients with cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough)
9685135|NCT04882813||Dapagliflozin|Exposure group
9685136|NCT04882813||Sitagliptin|Reference group
9685137|NCT04882930|Experimental|Functional Near-Infrared Spectroscopy (fNIRS) acquisitions|The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
9685138|NCT04882891|Experimental|MS patients|Ambulant patients with multiple sclerosis
9685139|NCT04882670||hip fracture|
9685140|NCT04882618|Experimental|ICG group|ICG injection before LRRP via cystoscopy
9685141|NCT04882527|Experimental|anodal stimulation of the rIFL|Anodal stimulation over the right inferior frontal lobe
9685142|NCT04882527|Experimental|cathodal stimulation of the rIFL|Cathodal stimulation over the right inferior frontal lobe
9685143|NCT04882527|Experimental|anodal stimulation of the lIFL|Anodal stimulation over the left inferior frontal lobe
9685144|NCT04882527|Experimental|cathodal stimulation of the lIFL|Cathodal stimulation over the left inferior frontal lobe
9685145|NCT04882527|Experimental|anodal stimulation of the rSPL|Anodal stimulation over the right superior parietal lobe
9685146|NCT04882527|Experimental|cathodal stimulation of the rSPL|Cathodal stimulation over the right superior parietal lobe
9685147|NCT04882527|Sham Comparator|sham stimulation|Sham stimulation over either of the three real stimulation areas
9685148|NCT04882501|Active Comparator|Actual aromatherapy product|QUEASEEase quick tab Aromatherapy product 50 % chance of participant receiving based on randomization
9685149|NCT04882501|Placebo Comparator|Placebo product|Placebo product (normal saline) 50% chance of participant receiving based on randomization
9685150|NCT04882995|Experimental|Intervention - Received fiber|
9685151|NCT04882995|No Intervention|Control - Did not receive fiber|
9685152|NCT04883125|Active Comparator|Interventional no|Patients treated with both drugs ( imatinib and pioglitazone)
9685153|NCT04883125|No Intervention|Control|Historical control (treated with imatinib only)
9685154|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 1 default|Receiver-in-canal hearing aid with current default compression strategy
9685155|NCT04882709|Active Comparator|Receiver-in-canal hearing aid 2|Receiver-in-canal hearing aid from a different manufacturer with default compression strategy
9685156|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 1|Receiver-in-canal hearing aid with modified compression strategy 1
9685157|NCT04882709|Experimental|Receiver-in-canal hearing aid 1 strategy 2|Receiver-in-canal hearing aid with modified compression strategy 2
10178968|NCT03807843|Experimental|Treatment Arm|Subjects randomized to the treatment arm will receive two vaccinations with MV-CHIK, a recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. The vaccinations will be provided on days 0 and 28 after enrollment.
10178969|NCT03807843|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive two injections of sterile physiological saline. The injections will be provided on days 0 and 28 after enrollment.
10178970|NCT03807830|Other|One arm feasbility study|
10178971|NCT03807882|Experimental|Test group|Bilateral Maintenance ECT (B/L M-ECT)
10178972|NCT03807882|Active Comparator|Control group|Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
9685158|NCT04882709|No Intervention|No device|Stimuli recordings without hearing aid
9685159|NCT04882774|No Intervention|Fluid Management|Fluid management protocol only
9685160|NCT04882774|Experimental|Oral Treprostinil|Drug - oral treprostinil
9685161|NCT04882605||Donor/recipient couple with Matched Sibling Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation~+ its 10/10 HLA-matched donor recruited among his siblings"
9685162|NCT04882605||Donor/recipient couple with Haploidentical Donor|"Donor/recipient couple = Patient undergoing a hematopoietic stem cell transplantation~+ its 5/10 HLA-matched donor recruited among his relatives"
10178973|NCT03807557|Experimental|Robotic mCIMT group|1 hour unilateral robotic therapy, followed by 30 minutes of functional practice of affected UE using shaping technique, 3/week for 8 weeks and restraint of the unaffected limb at home for 2 hrs per day
10178974|NCT03807557|Active Comparator|Control group|conventional upper extremity rehabilitation training 1.5 hours per session, 3/week for 8 weeks and home exercise 2 hrs per day
10178975|NCT03807869|Experimental|coexisting glaucoma and cataract|Patients with coexisting glaucoma and cataract qualified to combined glaucoma surgery
10178976|NCT03807752|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
10178977|NCT03807752|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
10178978|NCT03807609|Experimental|CON .|The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
10178979|NCT03807609|Experimental|EX -30.|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
10178980|NCT03807609|Experimental|EX-180|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their appetite feelings will be assessed at regular intervals.
10178981|NCT03807583|No Intervention|Control group|
10178982|NCT03807583|Active Comparator|AMINOVEN® 10%|"The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.~The product is administered per os during the first hour of dialysis sessions for the duration of the study."
10178983|NCT03807583|Experimental|RENORAL®|"The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.~The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins."
10178984|NCT03807674|Other|Control group - Healthy teeth|Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
10178985|NCT03807674|Experimental|Test group - Teeth with pulpitis|Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
10178986|NCT03807635|Experimental|simulation of skin pricking type 450|The evaluator simulated the capillary blood sampling with the safety lancet type 450
10178987|NCT03807635|Experimental|simulation of skin pricking type 610|The evaluator simulated the capillary blood sampling with the safety lancet type 610
9685163|NCT04882540|Experimental|brivaracetam|This is a Single-Arm study with Single- and Multiple- Dose Periods. Study participants will receive a single dose of brivaracetam (BRV) on Day 1 and will then receive multiple doses of brivaracetam from Day 5-10.
9685164|NCT04882436||severe pneumonia|Patients with severe pneumonia
9685165|NCT04882423|Experimental|Test meal 1 - grilled hamburger (7 oz) with no vegetables|Randomly assigned participants are given grilled hamburger (7 oz) with no vegetables
9685166|NCT04882423|Experimental|Test meal 2 - grilled hamburger with steamed broccoli and Brussels sprouts|Randomly assigned participants are given grilled hamburger with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
9685167|NCT04882423|Experimental|Test meal 3 - grilled hamburger with steamed parsnips, fresh parsley, and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
10178988|NCT03807570|Experimental|Morus Alba L. extract|Morus Alba L. extract 30 ml/day for 12 weeks
9685168|NCT04882423|Experimental|Test meal 4- grilled hamburger with broccoli, Brussels sprouts, parsnips, parsley and celery sticks|Randomly assigned participants are given grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
9977686|NCT01364220|Experimental|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
9685169|NCT04882267|No Intervention|Determination of attitudes and perceived barriers to exercise|Adults with CF will take part in a quantitative modified Exercise Benefits/Barriers Scale (EB/BS) survey to identify universal and unique benefits and barriers to regular exercise activity. Subjects will be surveyed on potential ways to engage in exercise, including perceptions and prior use of smart device exercise technology. Qualitative input will be incorporated to better understand potential solutions to barriers, and develop more personalized plans for exercise engagement.
9685170|NCT04882267|No Intervention|Determination of baseline exercise activity (Baseline Period)|Adults with CF who identify as 'willing to use technology' and own compatible smart phones/tablets will undergo the Short General Health Questionnaires (GHQ 12) to establish baseline levels of general and mental health. Subjects will be fitted with wrist actigraphy and monitored for four weeks to establish baseline levels of exercise activity at home. Anticipated outcomes: Access to actigraphy will encourage personal accountability, and physical activity will increase during the first two weeks before reaching a plateau.
10178989|NCT03807570|Placebo Comparator|Placebo|Placebo 30 ml/day for 12 weeks
10178990|NCT03807206||Flashmob 2019|Patients from the following hospitals will receive a questionnaire/structured intereview: Erasmus MC, Franciscus Gasthuis & Vlietland, Ikazia, Haaglanden Medisch Centrum, Albert Schweitzer ziekenhuis, Jeroen Bosch ziekenhuis, Rijnstate ziekenhuis, Amphia ziekenhuis, Tergooi klinieken, Medisch Spectrum Twente, Reinier de Graaf gasthuis. Pending: Maasstad ziekenhuis
10178991|NCT03807297|Other|TIVA - total intravenous anaesthesia|only intravenous type of anaesthesia using Injection propofol, 10 mg and Injection dexmedetomidine drug infusion will be infused for maintenance of anaesthesia
10178992|NCT03807297|Other|Inhalational anaesthesia|In this group, both nitrous oxide and sevoflurane will be given for maintenance of anaesthesia
10178993|NCT03807219|Active Comparator|Magnox Comfort|80 subjects will be on the Magnox Comfort arm.
10178994|NCT03807219|Placebo Comparator|Placebo|80 subjects will be on the Placebo arm.
10178995|NCT03807284|Experimental|A group psycho-social course|The intervention group received a group psycho-social course, a 2 hour, weekly, eleven week intervention delivered by a health professional working in stroke and usual care.
10178996|NCT03807284|No Intervention|Control Group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
10178997|NCT03807531|Other|Treatment with TSS|This is a single-arm study. Participating subjects will be treated with the Temporary Spur Stent System (TSS)
10178998|NCT03807505|Active Comparator|Interscalene nerve block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot interscalene brachial plexus nerve block or an interscalene brachial plexus nerve catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
10178999|NCT03807505|Active Comparator|Erector Spinae Plane block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot erector spinae plane block or receive erector spinae plane catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
10179000|NCT03807375|Other|CPAP|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O. The process will continue until the end-tidal O2 concentration ≥ 90% is removed.
10179001|NCT03807375|No Intervention|standard preoxygenation|During the preoxygenation, the ventilator device will be put in spontaneous mode and the procedure will continue until the End-tidal O2 concentration ≥90% is removed without additional pressure.
10179002|NCT03807362|Experimental|CC-11050 treatment|200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
10179003|NCT03807492||EMPOWeR Study|This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
10179004|NCT03807388|Experimental|ReMindCare Intervention Group|"Patients from First Episode of Psychosis Unit who will use ReMindCare app.~ReMindCare is an user-friendly app which conducts daily evaluations of the health status of patients with psychosis by some quick questions that patients will have to answer."
10179005|NCT03807388|Other|Treatment as Usual|Patients from First Episode of Psychosis Unit who will follow psychiatric usual care.
10179006|NCT03807258|Experimental|COPD patients group|COPD patients undergoing transcranial magnetic stimulation (TMS) evaluations.
10179007|NCT03807258|Active Comparator|Controls group|Healthy matched controls undergoing transcranial magnetic stimulation (TMS) evaluations.
10179008|NCT03807518|Experimental|Structured Exercise Intervention|The exercise training program was designed to improve physical fitness while the patients are receiving neoadjuvant treatment prior to surgery and for a 6 week period after surgery once patients are deemed fit to return to training.
10179009|NCT03807518|No Intervention|Standard Oncological Care|This group will receive standard oncological care and will receive no formal education of exercise intervention.
10179010|NCT03807427|Experimental|READY-Nepal|Skills groups based on dialectical behavior therapy principles delivered over 10-12 weeks in a classroom format.
9977687|NCT01364220|Placebo Comparator|Placebo|Placebo tablet, once daily, for 14 days
9977688|NCT01364246|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Intervention group
10179011|NCT03807427|No Intervention|Waitlist Control|Adolescent participants assigned to the control condition will be placed on a waitlist for future enrollment in READY-Nepal. After primary data collection has ceased, those assigned to the control arm will receive the identical READY-Nepal intervention delivered in the experimental condition.
10179012|NCT03807466|Active Comparator|Dynamic/Interactive Report|LTC physician receives dynamic/interactive report only
10179013|NCT03807466|No Intervention|Static/Paginated Report|LTC physician receives static/paginated report only
10179014|NCT03807466|Active Comparator|LTC Physicians Enrolled in Reports|"All LTC physicians who receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
10179015|NCT03807466|No Intervention|LTC Physicians Not Enrolled in Reports|"All LTC physicians who do not receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
10179016|NCT03807323|Experimental|'Lifestyle counselling and exercise' .|The study is a single-arm study where all participants undergo the same intervention 'Lifestyle counselling and exercise' .
10179017|NCT03807349|Other|N-Force Screws|N-Force Screws augmented with N-Force Blue in Intracapsular Femur Fractures.
10179018|NCT03807271|Experimental|Smart Pilot(R) View|Anesthesia provided by standard procedure, additionally guided by Smart Pilot(R) View, a device with calculated and graphically produced depth of anesthesia.
9685171|NCT04882267|Experimental|Engagement in home self-directed exercise incorporating Team and Technology (Intervention Period)|"Subjects will take part in a live demonstration of three subscription-based AI-learning home exercise apps, and one self-directed exercise website designed by a CF patient partner. Subjects will be surveyed on willingness to use technology, and provide feedback on exercise options. They will be given free full access to the apps and website (Technology), and receive a phone call once a week from their CF specialty team offering encouragement and positive reinforcement (Team). App and website usage, actigraphy, EB/BS and GHQ 12 scores will be measured at the end of four weeks. Anticipated outcomes: Activity will increase significantly during the Team and Technology intervention period, barriers on the EB/BS score will decrease, and GHQ 12 scores will increase."
10179019|NCT03807271|No Intervention|Standard|Anesthesia provided by standard procedure.
10179020|NCT03807453||Psoriasis Vulgaris patients-Lesion|
10179021|NCT03807453||Psoriasis Vulgaris patients-Lesion free|
9685172|NCT04882267|Active Comparator|Determination of sustainability (Sustainability Period)|Phone calls will cease, but subjects will maintain access to apps, websites, and actigraphy. After four weeks, EB/BS and GHQ 12 scores, physical activity, app and website use will be reassessed. Anticipated outcomes: Activity will decrease during the sustainability period, but will remain significantly greater than the pre-intervention period. Overall GHQ 12 and EB/BS scores will improve.
9685173|NCT04882371||MRI RECIST|Radiological responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) and changes in contrast enhancement patterns on MRI
9685174|NCT04882371||PET-CT PERCIST|Radiological responses were evaluated according to the classification of PET Response Criteria in Solid Tumors (PERCIST) on PET-CT.
9685175|NCT04882462|Experimental|single arm|
9685176|NCT04882683|Experimental|control group|Prednisone+Azathioprine/Adalimumab
9685177|NCT04882683|Experimental|UCB-MNCs group|Prednisone+Azathioprine/Adalimumab+UCB-MNCs
9685178|NCT04882579|Experimental|PoCUS group|Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ
9685179|NCT04882579|No Intervention|Control group|Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation
10179022|NCT03807453||Seborrheic Dermatitis-Lesion|
10179023|NCT03807453||Seborrheic Dermatitis-Lesion free|
10179024|NCT03807453||Control Group|
10179025|NCT03807336|Experimental|Experiential Condition|This group will receive an experiential version of the program Emotion-Focused Skills Training for Parents, meaning they will engage in tasks that are supposed to activate the parents emotional system, providing them with a deeper sense of understanding towards their child.
10179026|NCT03807336|Active Comparator|Psychoeducational version|This group will receive a non-experiential, psychoeducational version of the program Emotion-Focused Skills Training for Parents, meaning they will not engage in tasks that are meant to activate the parents emotional system.
10179027|NCT03807479|Experimental|Ponatinib|Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
10179028|NCT03807180|Other|Group of Tai Chi|Group of Tai Chi intervention include 18 patients with AS. Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques, will be applied by an experienced physiotherapist who is trained with Tai Chi. The training will take 60 minutes, 2 days a week and 10 weeks in total.
10179029|NCT03807180|No Intervention|Group of control|Conventional exercises are stretching for the cervical, thoracic and lumbar flexibility, shoulder circumference, hamstring and erector spinal muscles, strengthening exercises for abdominal, back and proximal muscles. The exercises that will be taught in detail to each stage of the patient will be performed at home by the patient for 60 minutes, 2 days a week. The patients will be inspected and controlled by monthly controls.
10179030|NCT03807193|Experimental|Fixed treatment, weekly support|Receives a predetermined treatment program and have weekly support.
10179031|NCT03807193|Experimental|Fixed treatment, support on demand|Receives a predetermined treatment program and have access to support on demand.
10179032|NCT03807193|Experimental|Selected treatment, weekly support|Select their own treatment material and have weekly support.
10179033|NCT03807193|Experimental|Selected treatment, support on demand|Select their own treatment material and have access to support on demand.
10179034|NCT03807167|Experimental|Patients|
10179035|NCT03807167|Active Comparator|healthy controls|
10179036|NCT03807154|Experimental|Internet-based cognitive behavioral therapy (ICBT)|A nine-week long ICBT intervention with therapist support.
10179037|NCT03807154|Experimental|Internet-based Interpersonal Therapy (IIPT)|A nine-week long intervention based in interpersonal psychotherapy with therapist support.
9685180|NCT04882345|Experimental|Almonertinib group|Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
9685181|NCT04882228|Experimental|Entelon Tab.150mg|
9685182|NCT04882228|Active Comparator|Venitol tab.|
9685183|NCT04882254|Experimental|Normothermic machine perfusion|Additional 2 hours of normothermic machine perfusion of donor kidney with a red cell based perfusate.
10179038|NCT03807154|No Intervention|Wait-list|Wait-list control group
10179039|NCT03807141|Experimental|Diet arm|"Modified Atkins diet will be administered with carbohydrate restriction to 10 grams per day. Proteins will be allowed unrestricted and fats will be actively encouraged.~The ongoing antiepileptic medication will be continued unchanged"
10179040|NCT03807141|No Intervention|Control|The control group will continue their anti-epileptic medication unchanged with no additional dietary input
10179041|NCT03807050|Experimental|Astaxanthin|Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
10179042|NCT03806985|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
10179043|NCT03806985|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
10179044|NCT03806985|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
9685184|NCT04882254|No Intervention|Standard-of-care|Standard-of-care, which is hypothermic kidney machine perfusion in the Netherlands.
9685185|NCT04882137|No Intervention|Standard Education|Pediatric Providers in this arm will receive a continuing medical education on etonogestrel contractive implant but will not receive specialist coaching on how to manage side effects.
9685186|NCT04882137|Experimental|Standard Education plus Coaching|Pediatric Providers in this arm will receive a continuing medical education program on etonogestrel contraceptive implant. Providers in this arm will also receive a tip-sheet on how to manage side effects as well as a number to directly access a specialist who places them if needed.
9685187|NCT04882033|Experimental|Concurrent chemoradiotherapy plus anlotinib|Concurrent chemoradiotherapy plus anlotinib for 4-6 cycles This study will include a sequential evaluation of 3 subjects per dose group. Low-dose groups: anlotinib 8mg per day with concurrent chemoradiotherapy. Middle-dose groups: anlotinib 10mg per day with concurrent chemoradiotherapy. High-dose groups: anlotinib 12mg per day with concurrent chemoradiotherapy.
9685188|NCT04882306|Other|Main study group|
9685189|NCT04882215|Experimental|Adaptive Training (AT)|For AT participants, difficulty of the training tasks is progressively increased in response to task performance.
9685190|NCT04882215|Active Comparator|Non Adaptive Training (NA)|For NA participants, task difficulty is fixed at a relatively low level across all sessions.
9685191|NCT04882358|Experimental|GROUP 1 DIRECT SODIUM REMOVAL + SGLT-2 INHIBITOR|SUBJECTS TREATED WITH DSR + STANDARD DOSE OF APPROVED SGLT-2 INHIBITOR
9685192|NCT04882358|Experimental|GROUP 2 DIRECT SODIUM REMOVAL|SUBJECTS TREATED WITH DSR
9695854|NCT04773613|Other|Experimental SEP|Infant placed in a SEP on the researcher's lap. The head rests on the researcher's hand. Shoulder girdle higher than the pelvic girdle, head and back in a straight line at an angle of 30-45° to the ground - slight, natural body bend is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
9695855|NCT04774159|Active Comparator|Colchicine|Colchicine 0.5mg daily for the duration of the trial
9695856|NCT04774159|Placebo Comparator|Colchicine-Placebo|Colchicine-Placebo daily
9695857|NCT04774406||parp inhibitors|All patients treated at least with 1 PARPi
9695858|NCT04773431|Experimental|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
10179045|NCT03806985|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
10179046|NCT03806985|Experimental|High Dose Psilocybin/Low Dose Psilocybin|Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
9695859|NCT04773886|Sham Comparator|MTA GROUP|Vital Pulpotomy will be done using Mineral trioxide aggregate(MTA) as pulp capping agent.
9695860|NCT04773886|Sham Comparator|BIODENTINE GROUP|Vital Pulpotomy will be done using Biodentine as pulp capping agent.
9695861|NCT04773886|Active Comparator|PRF + MTA GROUP|Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent
9695862|NCT04773886|Active Comparator|PRF+ BIODENTINE GROUP|Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
9695863|NCT04773366|Experimental|Group 1|"Multisystem patients (≥2 organs/systems) with involvement of one or more Risk organs, i.e. hematopoietic system, liver or spleen.~All patients in this group receive an initial therapy (Week 1~6) followed by a consolidation continuation therapy (Week 7~22) and maintenance continuation therapy (Week 25~52)."
9695864|NCT04773366|Experimental|Group 2|"Multisystem patients, but without involvement of Risk organs.~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
10179047|NCT03806985|Experimental|Low Dose Psilocybin/High Dose Psilocybin|Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.
10179048|NCT03807102|Experimental|Tumor Vaccine|Injection of NeoAntigen Tumor Vaccine
10179049|NCT03806842|Experimental|Easytech group|patients who require a reverse total shoulder, meet the eligibility criteria and receive the Easytech Reversed Shoulder System
10179050|NCT03806920|Active Comparator|Intervention A|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
10179051|NCT03806920|Active Comparator|Intervention B|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g palatinose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
9685193|NCT04882176|Experimental|LM061 Dose Escalation Level 1, 2.5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 2.5mg QD, n=1;"
9685194|NCT04882176|Experimental|LM061 Dose Escalation Level 2, 5mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 5mg QD, n=3;"
9685195|NCT04882176|Experimental|LM061 Dose Escalation Level 3, 10mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 10mg QD, n=3;"
9685196|NCT04882176|Experimental|LM061 Dose Escalation Level 4, 20mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 20mg, n=3;"
10179052|NCT03806920|Active Comparator|Intervention C|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
10179053|NCT03806920|Active Comparator|Intervention D|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g isomaltulose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
10179054|NCT03806816|Experimental|HYPOTHERMIA / MELATONIN group|HIE infants who will receive melatonin in addition to the routine cooling treatment
10179055|NCT03806816|Experimental|HYPOTHERMIA / PLACEBO group|HIE infants who will not receive melatonin in addition to the routine cooling treatment
10179056|NCT03806959|Other|Pan Capsule and colonoscopy|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only
10179057|NCT03806881||Treatment group|Patients treated with a Glenius Glenoid Reconstruction System
10179058|NCT03807115|Other|Intervention|Arm: Intervention: Implementation of stroke mobility guidelines
9685197|NCT04882176|Experimental|LM061 Dose Escalation Level 5, 30mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 30mg, n=3;"
9685198|NCT04882176|Experimental|LM061 Dose Escalation Level 6, 40mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 40mg, n=9;"
9685199|NCT04882176|Experimental|LM061 Dose Escalation Level 7, 60mg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~seventh dose: 60mg, n=15;"
10179059|NCT03807115|No Intervention|Control|Arm: Control: Usual care
10179060|NCT03806998|Experimental|Ketoacid supplementation|Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight
10179061|NCT03806998|Placebo Comparator|Placebo|Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight
10179062|NCT03807076|Other|GIP-A|Infusion of GIP-A alone as a study tool.
9685200|NCT04882163|Experimental|CC-220 + Polatuzumab vedotin + rituximab- Cohort A|Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
9685201|NCT04882163|Experimental|CC-220 + Tafasitamab- Cohort B|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
9685202|NCT04882163|Experimental|CC-220 + Rituximab + Chemo (Cohort C)|Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
9685203|NCT04882163|Experimental|CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)|Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
9685204|NCT04882163|Experimental|CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E|Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
10179063|NCT03807076|Placebo Comparator|Placebo|Saline
10179064|NCT03806686|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
10179065|NCT03806686|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
10179066|NCT03806686|Placebo Comparator|Control group|Participants will receive 0.5 mL Placebo (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
10179067|NCT03806712||patient|patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient
10179068|NCT03806712||hematologist|medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist
10179069|NCT03806712||Nurses|nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse
10179070|NCT03806855||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
10179071|NCT03806855||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
10179072|NCT03807011|Active Comparator|fentanyl|A bolus dose of fentanyl 2 μg/kg was administered intravenously at anesthetic induction
10179073|NCT03807011|Active Comparator|remifentanil|Remifentanil was continuously infused at a rate of 0.2 μg/kg/min from anesthetic induction to the end of surgery
10179074|NCT03807024||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
10179075|NCT03807024||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
10179076|NCT03806829|Active Comparator|Water + Meal|250 ml Water and a high calorie, high fat meal (>900 kcal, 50g fat)
10179077|NCT03806829|Experimental|Red Wine + Meal|250 ml Red Wine and a high calorie, high fat meal (>900 kcal, 50g fat)
10179078|NCT03806829|Experimental|Green Tea + Meal|250 ml Green Tea and a high calorie, high fat meal (>900 kcal, 50g fat)
9685205|NCT04882163|Experimental|CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)|Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
9685206|NCT04882007|Experimental|OSE-127 High dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
10179079|NCT03806829|Experimental|Orange Juice + Meal|250 ml Orange Juice and a high calorie, high fat meal (>900 kcal, 50g fat)
10179080|NCT03806699|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
10179081|NCT03806699|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
9685207|NCT04882007|Experimental|OSE-127 Low dose induction phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6
10179082|NCT03806699|Placebo Comparator|Control group|Participants will receive 0.5 mL (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
9685208|NCT04882007|Placebo Comparator|Placebo induction phase|Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6
10179083|NCT03806673|Active Comparator|primipara|primipara subjected to their first epidural block
10179084|NCT03806673|Active Comparator|multipara|multipara subjected to their repeated epidural block.
10179085|NCT03807063|Experimental|Treatment (rivogenlecleucel)|Each subject may receive up to 3 IV infusions of rivogenlecleucel at intervals no less than 28 days apart. Subjects who meet protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia or encephalopathy will be treated with rimiducid infusion(s).
10179086|NCT03806946||group1|ADHD with normal EEG
10179087|NCT03806946||group 2|ADHD with abnormal EEG
10179088|NCT03806946||group 3|Epilepsy
9685209|NCT04882007|Experimental|OSE-127 High dose optional extension phase|OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34
9685210|NCT04881942|Experimental|e-Vapor Product A|Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion [2.5% nicotine by weight {NBW}])
9685211|NCT04881942|Experimental|e-Vapor Product B|Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic [4.0% NBW])
9685212|NCT04881942|Experimental|e-Vapor Product C|Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint [3.5% NBW])
9685213|NCT04881942|Experimental|e-Vapor Product D|Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol [4.0% NBW])
9685214|NCT04882020||AHI ≤ 5|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≤ 5 events / hour; prior blood collection between 7-9 am and questionnaires.
10179089|NCT03806946||group 4|Healthy control group
10179090|NCT03806946||group 5|ADHD and epilepsy
10179091|NCT03806725||Liver transplant (LTx) candidates with eGFR>=60|Liver transplant candidates with renal function defined by eGFR above or equal to 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement.
9685215|NCT04882020||AHI ≥ 30|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≥ 30 events / hour; prior blood collection between 7-9 am and questionnaires.
10179092|NCT03806725||LTx candidates with eGFR<60|"Liver transplant candidates with decreased renal function.~Defined by eGFR less than 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement."
10179093|NCT03806764|No Intervention|Retrospective study|Medical records of 250 allo-HSCT recipients will be evaluated retrospectively to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes.
10179094|NCT03806764|Other|Prospective study|"120 recipients of allo-HSCT will be recruited into the prospective part of the study. Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. clinical assessment will be made such as CMV viremia, transplant related complications and current medications.~Participants who are at high risk of CMV will have study blood sampling taken to assess immune functions"
10179095|NCT03806595|Experimental|Intranasal lidocaine|1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
10179096|NCT03806595|Placebo Comparator|Intranasal normal saline|1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
10179097|NCT03806777|Experimental|Intra-nasal dexmedetomidine|A single dose of dexmedetomidine, determined by a biased coin algorithm (min: 1 mcg/kg; max: 4 mcg/kg or 200mcg), will be delivered intranasally 45min before an MRI scan.
10179098|NCT03807037|Experimental|Treatment|Mixed tocotrienols 200mg, twice daily (400mg/day)
10179099|NCT03807037|Placebo Comparator|Control|Matching Placebo (Placebo oral capsule)
10179100|NCT03806868|Active Comparator|Intervention group|The Intervention group will receive a voucher for ordering foods (ONLY omega-3 rich foods) weekly (4 times).
9685216|NCT04881890|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
9685217|NCT04881929|Experimental|KN026 + Docetaxel|KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles
9685218|NCT04881981|Experimental|SCART Arm|Single Arm patients will be treated with SCART to different dose levels.
9685219|NCT04881838|Experimental|High risk group|"Stage I, unresected; Stage I with B syndrome~Stage II~Stage III~Stage IV without CNS involvement"
9685220|NCT04881994|Experimental|Mild hepatic impairment (Child Pugh A)|Participants with mild hepatic impairment (Child Pugh A) received single oral dose of finerenone.
9685221|NCT04881994|Experimental|Moderate hepatic impairment (Child Pugh B)|Participants with moderate hepatic impairment (Child Pugh B) received single oral dose of finerenone.
9685222|NCT04881994|Experimental|Healthy participants|Healthy age-, weight-, and gender- matched participants received single oral dose of finerenone.
10179101|NCT03806868|Sham Comparator|Control group|The Control group will receive a voucher for ordering foods in general (any type of foods) weekly (4 times). Participants will NOT be limited to purchasing foods rich in omega-3.
10179102|NCT03806582|Active Comparator|intervention|intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function
9685223|NCT04881513|Other|Structure /function of the taste buds and QoL|"The structure of the taste buds is measured by Narrow Band Imaging (NBI) technique prior to the operation, one month and six months after the surgery.~The tongue sensation is measured by two point discrimination before the operation, one month and six months after the operation.~The taste is tested by the taste strips prior to, on month and six month after the surgery.~The quality of life is measured by the SF36 questionnaire. The threshold change is measured by the stimulating electrode at the beginning and at the end of the surgery."
10179103|NCT03806582|No Intervention|control|control group; treatment according to current standards, observation of the effect on right ventricular function
10179104|NCT03806738|Experimental|Shared Decision Making Questionnaire|"Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.~One month or at the next visit following the decision, the patient will be asked to complete a research survey using REDCap."
10179105|NCT03806738|Other|Standard of Care Questionnaire|"Patients randomized to standard of care will receive the standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months for patients with MBC who have not made a treatment decision until a treatment decision is made.~One month or at the next visit following the decision, the patient will be asked to complete a post-treatment survey using REDCap."
10179106|NCT03806894||Jewish communities|Ashkenazi, Sephardi, Ethiopian
10179107|NCT03806894||Arab populations|Muslim, Christian, Druze
10179108|NCT03806621||Rotational Atherectomy|
9685224|NCT04881864|Experimental|Tele-EF|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
9685225|NCT04881734||the control group and the overtime group|Patients who started surgery between 8:00 and 16:59 were included in the control group.
9685226|NCT04881734||the overtime group|Patients who started surgery from 17:00 to 22:00 were included in the overtime group.
10179109|NCT03806569|Active Comparator|MAC-cbt group treatment for adult ADHD|"The patients will be treated with psychological group treatment for 8 sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process. This will be called Mindfulness, Acceptance and Commitment-Therapy for adult Patients with ADHD"
10179110|NCT03806569|Sham Comparator|Relaxation-group for adult ADHD|"The patients will be treated with a relaxation-treatment, long-time established as Jacobson muscle relaxing technique."
10179111|NCT03806413||Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
10179112|NCT03806426|Experimental|Treatment Group A|Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
10179113|NCT03806426|Placebo Comparator|Treatment Group B|Placebo 500mg
9685227|NCT04881747|Active Comparator|Lasmiditan (DOSE 1)|Participants will receive lasmiditan as immediate-release (IR) tablet formulation administered orally.
9685228|NCT04881747|Experimental|Lasmiditan (DOSE 2)|Participants will receive lasmiditan as oral-disintegrating (OD) tablet formulation administered orally without water.
9685229|NCT04881747|Experimental|Lasmiditan (DOSE 3)|Participants will receive lasmiditan as oral-disintegrating (OD) tablet formulation administered orally with water.
9685230|NCT04881591|Experimental|APP+Usual Treatment|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
9685231|NCT04881786|No Intervention|Untreated teeth control group|Premolars without orthodontic forces
9685232|NCT04881786|Experimental|Moderate force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 45º with a force of 56 g. Forces were measured with an orthodontic dynamometer. For 7 days
10179114|NCT03806439||Patients undergoing radical cystectomy.|After approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6, 9 and 12 months after surgery.
10179115|NCT03806478|Experimental|0.5 µg|Intranasal (IN) nanoparticles - 0.5 micrograms. The study is planned to include 1 dose of APH 1105 / 0.5 µg, administered twice a week for 12 weeks, for a total of 24 doses.
10179116|NCT03806478|Experimental|1.0 µg|Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
9685233|NCT04881786|Experimental|Severe force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 90º with a force of 224 g. Forces were measured with an orthodontic dynamometer. For 24 hours
10179117|NCT03806478|Experimental|2.0 µg|Intranasal (IN) nanoparticles - 2.0 micrograms. The study is planned to include 1 dose of APH 1105 / 2.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
10179118|NCT03806478|Placebo Comparator|Placebo|Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
10179119|NCT03806465||Feasibility survey|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age. For the midline household survey, this would be restricted to children aged 12-23 months of age.
10179120|NCT03806465||Sentinel hospital surveillance|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age who are hospitalized in the 18 sentinel hospitals.
10179121|NCT03806465||Community mortality surveillance|These will be children whose deaths are reported in the vaccinating and in non-vaccinating areas aged less than 5 years of age .
10179122|NCT03806530|Active Comparator|Gabapentin + Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
10179123|NCT03806530|Placebo Comparator|Gabapentin + Placebo Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
10179124|NCT03806530|Placebo Comparator|Ropinirole + Placebo Gabapentin|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
10179125|NCT03806530|Placebo Comparator|Placebo Gabapentin + Placebo Ropinirole|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
10179126|NCT03806114|Other|Anterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
10179127|NCT03806114|Other|Posterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
10179128|NCT03806114|Other|Anterior Approach No Precautions|This group receives does not precautions and have a total hip arthroplasty with an anterior approach.
10179129|NCT03806114|Other|Posterior Approach No Precautions|This group receives does not receive precautions and have a total hip arthroplasty with a posterior approach.
10179130|NCT03806322|Experimental|Cold-pack Group|One group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs
9685234|NCT04881565|Experimental|Reactive balance training plus functional electrical stimulation|
9685235|NCT04881565|Active Comparator|Reactive balance training|
10179131|NCT03806322|Experimental|Intermittent Pneumatic Compression|The second group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression
10187429|NCT03726307|Experimental|DCreg: 1.2 million cells/kg+SOC|"N=3 participants will receive 1.2 (± 0.2) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
10187430|NCT03726307|Experimental|DCreg:2.5 to 5.0 million cells/kg+SOC|"N=8 participants will receive 25 to 5.0 million cells /kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
10187431|NCT03726281|Experimental|single-arm trial of Nivolumab|Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.
9685236|NCT04881669|Experimental|low group|low thickness group
9685237|NCT04881669|Experimental|moderate group|moderate thickness group
9685238|NCT04881669|Experimental|high group|high thickness group
9685239|NCT04881695||Patients|Women aged 18-26 years with congenital (Turner syndrome or other determined or undetermined genetic cause) or acquired (post-therapeutic)
10187432|NCT03726268|Active Comparator|IV methadone|Intraoperative and post-operative IV methadone
10187433|NCT03726268|Active Comparator|IV fentanyl, sufentanil, morphine or hydromorphone|Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion
10187434|NCT03726255||Stromal Vascular fraction|31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)
10187435|NCT03726255||Autologous mesenchymal stem cells|9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)
9685240|NCT04881695||Controls|Women aged 18-26 years who do not have a condition that compromises their fertility
9685241|NCT04881643|Experimental|Blended treatment for PTSD|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
9685242|NCT04881552||Group 1|non-spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade 0-II)
10179132|NCT03806075|Experimental|Peutz-Jeghers patients|All Peutz-Jeghers patients meet the clinical criteria
10179133|NCT03806075|Placebo Comparator|Health persons|Those without Peutz-Jeghers syndrome
10179134|NCT03806218|Active Comparator|TICW-RFA|Bipolar RFA using twin internally cooled-wet electrodes
9685243|NCT04881552||Arm 2|spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade III)
10179135|NCT03806218|Active Comparator|SC-RFA|Switching monopolar RFA using separable clustered electrodes
10179136|NCT03806062|Active Comparator|control group|10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
10179137|NCT03806062|Active Comparator|Laser group|"The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)"
10179138|NCT03806062|Active Comparator|Electro acupuncture group|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes
10179139|NCT03806088||patients of chronic kidney disease|no interventions
10179140|NCT03806036|Active Comparator|Vitamin D group|50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
10179141|NCT03806036|Placebo Comparator|Control group|50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
10179142|NCT03806504|Active Comparator|high PEEP|35 cm/H2O PEEP, 2-3 ml/kg tidal volume,45 seconds, after cardiopulmonary bypass
9685244|NCT04881526|Active Comparator|Ketone ester drink|
10179143|NCT03806504|Active Comparator|control group|6 cm/H2O PEEP, 6-8 ml/kg tidal volume, continues, after cardiopulmonary bypass
10179144|NCT03805997|Experimental|Experimental Group|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
10179145|NCT03805997|Placebo Comparator|Control Group|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
10179146|NCT03805984|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
10179147|NCT03805984|Placebo Comparator|Placebo Comparator Group A|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
10179148|NCT03805984|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
10179149|NCT03805984|Placebo Comparator|Placebo Comparator Group B|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
10179150|NCT03805906||Primary group|Ultrasound-Guided L5 Dorsal ramus block
10179151|NCT03805828|Experimental|Expermental|In the intervention group, the educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism.
10179152|NCT03805828|Active Comparator|Control|In the control group, the educational about communicable disease among childhood deliver as a one-day event in four sessions: (1) introduction and background communicable disease of childhood,(2) communicable diseases of childhood (Chicken Pox, Diphtheria,and pertussis[a whooping cough]),(3) communicable diseases of childhood (Measles,Mumps,rubella[German Measles]and Poliomyelitis(,and (4) infection control.
10179153|NCT03805958|Experimental|Pre-procedure|Confirmed landmark by ultrasound scan before procedure
10179154|NCT03805958|Active Comparator|Real time|Confirmed landmark by ultrasound scan during procedure
10179155|NCT03806023|Experimental|All subjects|All subjects undergo same full protocol, including PNS and TMS at rest and active hand movements (signals from thumb muscle) triggered PNS and TMS.
10179156|NCT03805945|Experimental|dexmedetomidine group|After umbilical cord was cut, a loading dose of dexmedetomidine was pumped at 0.5ug/kg within 10min, followed by a further infusion of dexmedetomidine at 0.5ug /kg/h until the end of the surgery.Then connected with patient-controlled intravenous analgesia pump (dexmedetomidine 2ug/kg + sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
10179157|NCT03805945|Placebo Comparator|control group|Continuous infusion of saline after the umbilical cord was cut until the end of the operation.Then connected with patient-controlled intravenous analgesia pump (sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
10179158|NCT03805854|Experimental|Transcranial alternating current stimulation (tACS)|
10179159|NCT03805802|Experimental|active product|Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
9685245|NCT04881526|Placebo Comparator|Placebo drink|
9685246|NCT04881682|Experimental|Immunoadsorption|3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)
9685247|NCT04881682|Active Comparator|Immunoglobulins|5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.
9685248|NCT04881474|Active Comparator|ibuprofen and paracetamol|
10179160|NCT03805802|Placebo Comparator|reference product|Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
10179161|NCT03806010||Quantitative sensory testing|QST will be performed at baseline two weeks and 2 months
9685249|NCT04881474|Active Comparator|paracetamol only|
9685250|NCT04881435|Experimental|Hydrogen gas inhalation therapy accompanied with standard steroid treatment|
9685251|NCT04881435|Active Comparator|Standard steroid treatment|
9685252|NCT04881812|Experimental|Drug-coated balloon|Patients will receive stenting of the actual CTO body with additional DCB treatment of the residual disease of the coronary artery.
9685253|NCT04881812|Active Comparator|Drug-eluting stent|Patients will receive complete stenting of the CTO body and residual disease of the coronary artery.
9685254|NCT04881422|Experimental|Experimental group|A group of pwMS participate in a multidimensional integrate high-motivating rehabilitation program for the change of lifestyle and bad habits.
10179162|NCT03806140|Active Comparator|Intervention group|Receive daily text messages
10179163|NCT03806140|No Intervention|Control group|No text messages, only written educational materials
10179164|NCT03806348|Experimental|Resuturing|Early resuturing of perineal wound dehiscence. Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
10179165|NCT03806348|No Intervention|Conservative treatment|Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
10179166|NCT03805763|Experimental|Large extent of ILM Peeling|Extent of ILM peeling is 4DD and the ILM flap is inserted
10179167|NCT03805763|Experimental|Small extent of ILM Peeling|Extent of ILM peeling is 2DD and the ILM flap is inserted
10179168|NCT03806374|Active Comparator|Fentanyl|Administered propofol and fentanyl for induction.
10179169|NCT03806374|Active Comparator|Ketamine and lidocaine|Administered propofol, ketamine and lidocaine for induction.
10179170|NCT03805724||Periodontally healthy subjects|They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level & probing depth ≤ 3 mm. Plaque samples will be collected.
10179171|NCT03805724||Chronic Periodontitis|Chronic periodontitis patients having probing depth of ≥3 mm and clinical attachment level ≥ 1 mm. Plaque samples will be collected.
10179172|NCT03805724||Chronic Gingivitis|Gingivitis patients having signs of clinical inflammation with no clinical attachment loss. Plaque samples will be collected
10179173|NCT03805776|Experimental|Interventional|Will observe intermittent fasting
10179174|NCT03805776|No Intervention|Control|
10179175|NCT03806192|Experimental|Group A (psychoeducational counseling sessions via telephone)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via telephone.
10179176|NCT03806192|Experimental|Group B (psychoeducational counseling sessions in person)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via video teleconference.
10179177|NCT03806101|Experimental|Arm 1|Single dose of rosuvastatin on Day 1 of Period 1 and Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 2.
10179178|NCT03806101|Experimental|Arm 2|Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 1 and single dose of rosuvastatin on Day 1 of Period 2.
10179179|NCT03806153|Active Comparator|Conventional morphology arm (reference method)|
10179180|NCT03806153|Experimental|Morphokinetic arm|
10179181|NCT03806049|Experimental|A: triplet|chemotherapy-free combination of niraprib + bevacizumab + Dostarlimab
10179182|NCT03806049|Experimental|B: Doublet|chemotherapy-free combination of niraparib + bevacizumab
10179183|NCT03806049|Active Comparator|C: standard of care|Standard of care chemotherapy: Carboplatin + paclitaxel
10179184|NCT03805516|Experimental|Intervention|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly SCOPP-CW educational modules delivered via WeChat.~6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences"
9685255|NCT04881136|Experimental|Reveal LINQ|The Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present is implanted to the participants who are have experienced non accidental falls. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data.
9685256|NCT04881851|Experimental|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
9685257|NCT04881851|Experimental|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
9685258|NCT04881851|Placebo Comparator|Folic acid|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
9685259|NCT04881604|Experimental|Adjustable Compression Wrap|Daily use of the adjustable compression wrap on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy.
9685260|NCT04881604|Active Comparator|Compression Sleeve|Daily use of the compressive sleeve on the upper limb with breast cancer-related lymphedema during phase 2 of compressive therapy
10179185|NCT03805516|Active Comparator|Control|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly non-tailored educational modules on general health topics delivered via WeChat."
10179186|NCT03805607|Placebo Comparator|Placebo|1 ml of normal saline
10179187|NCT03805607|Experimental|Ketorolac|30 mg of ketorolac in 1 ml
10179188|NCT03805568|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
10179189|NCT03805568|Active Comparator|remifentanil infusion group|remifentanil of 4 ng/ml during induction, followed by remifentanil infusion (1.5~2.5 ng/ml) during the surgery
10179190|NCT03805633||Sarcoidosis Patients|Patients referred to UAB Pulmonology who are diagnosed with sarcoidosis.
10179191|NCT03805633||Diabetes Patients|Patients followed by UAB Endocrinology with diabetes mellitus.
10179192|NCT03805633||Sarcoidosis and Diabetes patients|Patients followed by UAB Pulmonary and/or UAB Endocrinology with both sarcoidosis and diabetes mellitus.
10179193|NCT03805620|Active Comparator|Phys Group|physical training group
9685261|NCT04881344|Experimental|The laser hemorrhoidoplasty (laser group, intervention group)|
10179194|NCT03805620|Active Comparator|Cog Group|cognitive training group
10179195|NCT03805620|Experimental|Phys-Cog Group|combined physical-cognitive training group
10179196|NCT03805620|No Intervention|Con Group|educational control group
10179197|NCT03805555|Active Comparator|Radiofrequency ablation|Best radiofrequency ablation
10179198|NCT03805555|Experimental|Cryoballoon ablation|Best cryoballoon ablation
9685262|NCT04881344|Active Comparator|The hemorrhoidopexy (mucopexy group, control group)|
10179199|NCT03805295|Experimental|Spring 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Winter-Spring 2018. They will serve as the control group in Fall 2018.
10179200|NCT03805295|Experimental|Fall 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Fall 2018.
10179201|NCT03805646|No Intervention|No Mobile Phone-administered Triage Tool|For each hospital site: Baseline data will be collected for six months.
10179202|NCT03805646|Experimental|Mobile Phone-administered Triage Tool|"For each hospital site: After the first six months of baseline data collection, the mobile phone-administered triage tool (or Mobile Phone-based Triage Tool) will be implemented for a year."
10179203|NCT03805282|Experimental|Female 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
10179204|NCT03805282|Active Comparator|Male 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
10179205|NCT03805282|Active Comparator|Male > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
10179206|NCT03805282|Active Comparator|Female > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
10179207|NCT03805542|No Intervention|Control group|I-stage nephrostomy（Double J stent placement under cystoscopy） and II-stage operation
10179208|NCT03805542|Experimental|I-stage operation group|Disinfection of pelvis with 0.5% iodophors
10179209|NCT03805477|Experimental|Nintedanib|Nintedanib 150 mg Kps bid (oral)
10179210|NCT03805360|Sham Comparator|ESP block with normal saline|An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
10179211|NCT03805360|Experimental|ESP block with local anesthetic|An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.
10179212|NCT03805503|Experimental|chloroprocaine 1% injectable solution|"Prospective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%.~An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study.~An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study."
10179213|NCT03805308|No Intervention|Medical Management|Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
10179214|NCT03805308|Experimental|Intra-arterial Therapy|For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
10179215|NCT03805178|Experimental|Rejection post-transplant|Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
10179216|NCT03805178|Experimental|Pre-transplant desensitization|Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
10179217|NCT03805425|Experimental|Photorefractive intrastromal corneal crosslinking (PiXL)|Patients undergo PiXL where the UVA light is delivered in customized patterns and corneal changes are achieved. For hyperopia, a ring shape irradiation is used to steepen the central cornea. An oxygen mask is used to enhance the crosslinking efficacy. A dedicated riboflavin formulation penetrates the corneal stroma. Pulsed UVA light with oxygen triggers the covalent bonds of collagen strands in riboflavin soaked cornea.
9977689|NCT01364324||Gastrectomy|Twenty gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
9685264|NCT04881279||Control|Trauma admissions in April-June 2016.
9685265|NCT04881279||Ransomware Group|Trauma admissions in April-June 2017.
9685266|NCT04881201|Other|Patients Charcot-Marie-Tooth|
9685267|NCT04881201|Other|Control subjects|
9685268|NCT04881227|Experimental|Chatbot condition|Participants randomly assigned to this arm will access to a Chatbot condition, in which they had the opportunity to interact with the chatbot on COVID-19 vaccine hesitancy.
9685269|NCT04881227|Active Comparator|Control condition|Participants randomly assigned to this arm will access to a brief text describing the way vaccines work.
9685270|NCT04881214|No Intervention|Control|Patients in this arm will receive standard of care
9685271|NCT04881214|Experimental|Pulmonary Rehabilitation|Patients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included.
9977690|NCT01364324||Non-gastrectomy|Twenty non-gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
9685272|NCT04881006|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
9685273|NCT04881006|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
9685274|NCT04881383||Patients from Primary Care Clinics|Participating Chinese adults aged 18-84 from Primary Care clinics to validate the risk prediction function. Each subject will complete an assessment on the relevant risk factors and have a blood test on OGTT and HbA1c on recruitment and at 12 months.
9685275|NCT04881266||Post Critical Illness due to COVID-19|
9685276|NCT04881266||Caregivers of Post critically ill COVID-19 patients|
10179218|NCT03805269|Experimental|TAP block|USG guided TAP block
10179219|NCT03805269|Active Comparator|wound infiltration|local anesthetics infiltration at surgical incision site
10179220|NCT03805126|Experimental|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
10179221|NCT03805126|Active Comparator|Usual Care|Usual care includes consultation with a social worker and a community health worker.
10179222|NCT03805347|Experimental|Medication|Extract of Helminthostachys zeylanica(L.)Hook in capsule, 1gm/time, 3 times daily
10179223|NCT03805347|Placebo Comparator|Starch|Starch in capsule，1gm/time, 3 times daily
10179224|NCT03805139|Experimental|Ajwa Dates group|55-65gms Ajwa dates 7 days a week for 6 weeks
10179225|NCT03805139|No Intervention|Control|No intervention
10179226|NCT03805113|Experimental|Intervention group|Treatment with magnetotherapy device 15 20-minute-sesions every consecutive working day.
10179227|NCT03805113|Placebo Comparator|Control group placebo|Treatment with misconnected magnetotherapy device 15 20-minute-sesions every consecutive working day.
10179228|NCT03805412|Active Comparator|DEXCOM G6 RT-CGM|These participants will wear blinded continuous glucose monitoring for 10 days at baseline and 14 weeks. They will also complete real-time continuous glucose monitoring (RT-CGM) for 10 days at 2 weeks and 6 weeks. They will receive Nutrition and exercise counseling at week 2 and 6. They will also receive additional training on continuous glucose monitoring.
10179229|NCT03805412|No Intervention|Blinded CGM|These participants will have blinded continuous glucose monitoring(CGM) at the baseline and last 14 weeks. They will not wear continuous glucose monitoring at the interim appointments. They will receive 2 session of nutrition and exercise counseling at week 2 and 6.
10179230|NCT03805334|Experimental|Touchpoints|Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn ~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
9685277|NCT04881188||Patients with chronic low back pain|Patients suffering from chronic low back pain (duration longer than 3 months) undergoing a multimodal pain therapy
9685278|NCT04881084|Experimental|Digital storytelling group (Group 1)|Participants will be randomly assigned to the digital storytelling group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six digital storytelling videos which will be assessed using a between-subjects design.
9685279|NCT04881084|Active Comparator|Social marketing/fundraising group (Group 2)|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
9685280|NCT04881019||Type 2 Diabetes|Individuals who have been diagnosed with Type 2 diabetes.
9685281|NCT04881019||Non type 2 diabetes|Individuals who have not been diagnosed with Type 2 diabetes.
9685282|NCT04881305||Cases|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, with cognitive/emotional complaints.
9685283|NCT04881305||Controls|Adults recovered from COVID-19 (diagnosed using RT-PCR), 3-8 months after the onset of the acute stage of the disease, reporting no cognitive/emotional complaints.
9685284|NCT04881071|Experimental|Scarf|
9685285|NCT04881071|No Intervention|Usual clinical practice|
9685286|NCT04881396||All haemodialysed patients with a medical prescription of BTN162b2 mRNA Cov-19 vaccine|Serological response is defined by a 4 fold increase of IgG anti-spike protein of SARS-Cov2 between Day 0 (before vaccination) and after complete vaccination (evaluated at Day 7 - 14 post-boost).
10179231|NCT03804957|Active Comparator|CT-guided core needle biopsy (CNB)|18 gauge ct-guided lung biopsy
10179232|NCT03804957|Experimental|CNB followed by ABPI.|17 gauge coaxial needle for a 18g ct-guided lung biopsy followed by autologous blood patch injection
10179233|NCT03804970|Experimental|Intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+ Having the Diabetic Club+Watching brief video and basic explanation for disease
10179234|NCT03804970|Experimental|Adjusted intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+Having the Diabetic Club+Watching brief video and basic explanation for disease( But the intensity of intervention based on the severity of diabetic disease)
10179235|NCT03804970|Active Comparator|Control group|Watching brief video and basic explanation for disease
10179236|NCT03805087|Experimental|Coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
10179237|NCT03805061|Active Comparator|Aerobic exercise group|Group 1 was 'aerobic exercise group'. Patients in this group were included in an aerobic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise.
9685287|NCT04881110|Experimental|Liraglutide group|Patients in this arm will receive liraglutide, according to the current clinical practice.
10179238|NCT03805061|Active Comparator|Isokinetic exercise group|Group 2 was 'isokinetic exercise group'. Patients in this group were included in an isokinetic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study.
10179239|NCT03804931|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation
10179240|NCT03804931|Sham Comparator|placebo fecal microbiota transplantation|Infusion of Saline
10179241|NCT03804931|Other|Traditional treatments|Drug:5-Aminosalicylic acid(5-ASA) and/or Prednisone
10179242|NCT03805152|Active Comparator|Neuronox(R) intramuscular injection|Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)
10179243|NCT03805152|Active Comparator|Dysport (R) intramuscular injection|Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)
10179244|NCT03805451|Experimental|Life Steps for PrEP for Youth|Life Steps for PrEP for Youth was derived from our prior PrEP work supported by the National Institute of Mental Health and will be tailored for YMSM/TWSM based on the findings from 20 qualitative interviews with YMSM and TWSM and 10 qualitative interviews with key informants. It will likely consist of four weekly sessions at the time of PrEP initiation and two booster sessions, which occur two and three months after PrEP initiation. Overall, the core components of the intervention will focus on medication adherence, sexual behavior, and problem solving barriers to adherence, using motivational interviewing when needed.
9685288|NCT04881110|Other|Control group|Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.
9685289|NCT04880915|Experimental|SMOKE PROTECTION|Pre- and post-operative blood and urine samples of the surgical team (surgeon, surgical resident, anaesthesiologist, scrub nurse, circulating nurse, support staff and researcher), who worked in the standard practice, and the use of four different preventive measures that may affect the surgical smoke exposure during total mastectomy surgery in the operating room of the General Surgery Department of a University HospitaL. The surgical resident, anaesthesiologist, anaesthesia technician and support staff included in the study did not consist of the same people due to the change in the work schedules. Blood and urine samples were collected from a team of seven people before and after surgery [7 volunteers × 2 (blood and urine before and after surgery) = 14 (14 blood analysis + 14 urine analysis) 14 × 5 surgery = 70 (70 blood analysis + 70 urine analysis)].
10179245|NCT03805451|No Intervention|Standard of Care|After being prescribed PrEP, participants will receive standard-of-care adherence support for PrEP. They will have blood collected for medication adherence measures and will complete computer assisted behavioral surveys during study visits. Participants in this arm will also be followed for 6 months.
10179246|NCT03805009|Experimental|Robotic Group (RG)|Robotic Group (RG) will perform, in addition to conventional therapy, gait training using an end-effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 20 sessions. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
10179247|NCT03805009|No Intervention|Conventional Group (CG)|Conventional Group (CG) will perform conventional gait rehabilitation program. The treatment will include: muscle strengthening exercises and stretching of the lower limb, and static and dynamic exercises for the recovery of balance in the supine and standing positions using assistive devices; training gait exercises with parallel bars or in open spaces performed both with and without assistive devices; training to climb up and down stairs; exercises to improve proprioception in the supine, sitting and standing positions, using a proprioceptive footboard; exercises to improve trunk control.
10179248|NCT03804944|Active Comparator|ARM 1|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
10179249|NCT03804944|Active Comparator|ARM 2|Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
9685290|NCT04880993|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
9685291|NCT04880993|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
9685292|NCT04880954|Experimental|Soft Tissue Mobilization|
9685293|NCT04880954|Experimental|Rehabilitation|
9685294|NCT04880954|Experimental|Soft Tissue Mobilization and Rehabiliation|
9685295|NCT04881357|Experimental|Experimental Group|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
9685296|NCT04881357|Placebo Comparator|Control Group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
9977691|NCT01364337|Active Comparator|DASH diet|
10179250|NCT03804944|Active Comparator|ARM 3|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days + Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, (every other day (M/W/F or W/F/M or F/M/W).
9685297|NCT04880798|Experimental|124I PET/CT|All eligible patients will be allocated to this arm (single-arm study).
9685298|NCT04880746|Active Comparator|BEAC|Patients in this arm will receive BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
9685299|NCT04880746|Experimental|Cladribine combined with BEAC|Patients in this arm will receive Cladribine combined with BEAC (Semustine, Etoposide, Cytarabine, Cyclophosphamide) as pretreatment regimen of ASCT
9685300|NCT04880941|Experimental|Progressive Relaxation Exercise|The Progressive Relaxation Exercise will be held 7 days for 4 weeks, a total of twenty eight sessions. Each session is set as fifty minutes
9685301|NCT04880941|No Intervention|Control group|Routine maintenance will be applied
9977692|NCT01364337|Active Comparator|lower carbohydrate DASH diet|
9685302|NCT04880811|Experimental|Afatinib plus toripalimab|
9685303|NCT04880759|Experimental|Bike desks in classroom|All participants receive the same intervention: the use of bike desks during school.
9685304|NCT04880785|Experimental|Dovato (Dolutegravir+lamivudine)|Treatment: Dolutegravir 50 mg/Lamivudine 300 mg, one film coated-tablet once daily during 96 weeks
9685305|NCT04880837|Experimental|Prevention (educational session, handout, survey)|Participants attend educational session about HPV-related cancers, screening, and HPV vaccination and guidelines and receive informational infographic handout on HPV vaccination. Participants also complete surveys pre and post education session over 5 minutes each to assess HPV vaccination status among children of participants, HPV knowledge, and intentions to get the HPV vaccination, and screening among participants. In addition, participants complete surveys over telephone or face-to-face at 3 and 6 months.
9685306|NCT04880902|Experimental|sleeve gastrectomy followed by volumetric assessment|
9685307|NCT04880889|Experimental|BL 3000|One capsule, once a day for 180 days.
9685308|NCT04880889|Active Comparator|Reference - Pantogar -|One capsule, three times a day for 180 days
10179251|NCT03804944|Active Comparator|ARM 4|Ftl-3 ligand, self administered subcutaneous injections at day 1 for 5 consecutive days+ Focal hypo-fractionated Radiation therapy starting day 8, - 8 Gy x 3 fractions, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), 200mg IV infused over 30 minutes then repeated every 3 weeks until disease progression or unacceptable toxicity.
10179252|NCT03805035|Sham Comparator|sham EA group|Minimal needling at ST36 and GB34 (n=10)
10179253|NCT03805035|Experimental|true EA group|EA at ST36 and GB34 (n=10)
10179254|NCT03805035|Active Comparator|EA+antihistamine(low dose) group|EA at ST36 and GB34 plus low-dose chlorpheniramine( Dexchlorpheniramine maleate 2mg/tab, 1 tab; n=10)
10179255|NCT03805035|Active Comparator|EA+antihistamine(high dose) group|EA at ST36 and GB34 plus high-dose chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 2 tabs; n=10)
10179256|NCT03805048|Other|Native Vessel PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
10179257|NCT03805048|Other|Graft PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the bypass graft will be performed following current standards and at the discretion of the operating interventional cardiologist. Only commercially available second generation DES will be used in the treatment of bypass grafts. The second generation DES used in this study will be the XIENCE Sierra stent. The use of a filter-wire during the procedure will be left at the discretion of the operator.
10179258|NCT03804983|Active Comparator|Hybrid Closed Loop (HCL)|Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ with Hybrid Closed Loop (HCL) or the Control-IQ with MyTDI. Participants randomized to Control-IQ, participants will continue using their home insulin parameters during the ski admission and then 5 additional days at home.
10179259|NCT03804983|Experimental|Control-IQ with MyTDI|"Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ or the Control-IQ with MyTDI. Participants randomized to Control-IQ with MyTDI, participants will be adjusted as noted below during the ski admission and will then continue these parameters for 5 additional days at home:~A single basal rate equal to total daily insulin (TDI)/48 will be implemented across the whole day~A single correction factor (CF) of 1650/TDI will be implemented across the whole day~Carbohydrate ratios (CR) will be set at:~00:00-04:00 CR=450/TDI~04:00-11:00 CR=360/TDI~11:00-00:00 CR=450/TDI TDI will be set at the internal Control-IQ estimation total daily dose; if not available, total daily dose over the last 5 days will be used."
10179260|NCT03804866|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
10179261|NCT03804866|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
10179262|NCT03804788|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for six (6) weeks.
9685309|NCT04880564|Experimental|A (CN1 0.5mg/kg and CN401 400mg)|"Patients were administered with CN1, 0.5mg/kg, once every three week in combination with 400mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm."
9977693|NCT01364350||TODAY cohort|The cohort of participants diagnosed with type 2 diabetes ages 10 to <18 and obese at time of diagnosis who participated in the TODAY clinical trial are recruited, consented and followed.
9977694|NCT01364363|Other|Total Body Irradiation/VP16|Acute Leukemias, Myelodysplastic syndromes
9977695|NCT01364363|Other|Cytoxan/Total Body Irradiation|Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease
9977696|NCT01364363|Other|Busulfan/Cytoxan|Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states
10179263|NCT03804788|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants.
10179264|NCT03804905|Experimental|Drug cards|Eligible patients of physicians allocated to the drug cards arm will receive drug cards from their physician.
10179265|NCT03804905|No Intervention|Usual care|Eligible patients of physicians allocated to the usual care arm will continue to access their medications through self-pay or other mechanisms.
9685310|NCT04880564|Experimental|B (CN1 1mg/kg and CN401 600mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 600mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
9685311|NCT04880564|Experimental|C (CN1 1mg/kg and CN401 800mg)|"Patients were administered with CN1, 1mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
10179266|NCT03804814|Active Comparator|Motivational Interviewing Training|Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
10179267|NCT03804814|No Intervention|Standard Clinical Encounter|Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.
10179268|NCT03804801|Experimental|Intervention Arm (or Group)|This arm will receive the intervention (Hibiscus Sabdariffa extract supplement)
10179269|NCT03804801|No Intervention|Control Arm (or Group)|This arm will receive no intervention whatsoever, not even placebo
10179270|NCT03804892|Experimental|Acipimox ingestion|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
10179271|NCT03804892|Other|No drug|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
10179272|NCT03804840|Placebo Comparator|Placebo|
10179273|NCT03804840|Active Comparator|7.5 mg THC|
10179274|NCT03804840|Active Comparator|15 mg THC|
10179275|NCT03804775||case group|patients presenting with gallstone disease
10179276|NCT03804775||control group|inpatients with no history of gallstones
10179277|NCT03804697|Experimental|selective anticoagulation group|"Selective anticoagulation group used anticoagulant when thromboelastogram（TEG） indicated hypercoagulability.~TEG was performed 1 day before the surgery, 1 day after the surgery, 3 days after the surgery, and 5 days after the surgery.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
10179278|NCT03804697|Active Comparator|conventional anticoagulation group|"The Intervention for conventional anticoagulation group was using anticoagulant until one month after surgery routinely.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
9685312|NCT04880564|Experimental|D (CN1 3mg/kg and CN401 800mg)|"Patients were administered with CN1, 3mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
10179279|NCT03804762|Experimental|patients received treatment of TS-RECS|
10179280|NCT03804749|Experimental|Group 1-1|The dose of suramin sodium is 10 mg/kg
10179281|NCT03804749|Placebo Comparator|Group 1-2|The placebo is 0.9% sodium chloride injection
10179282|NCT03804749|Experimental|Group 2-1|The dose of suramin sodium is 15mg/kg
10179283|NCT03804749|Placebo Comparator|Group 2-2|The placebo is 0.9% sodium chloride injection
9685313|NCT04880564|Experimental|E (CN1 10mg/kg and CN401 800mg)|"Patients were administered with CN1, 10mg/kg, once every three week in combination with 800mg CN401 twice a day, fasted.~Dosage/Route of admin: CN1- Intravenous Infusion(IV); CN401- Tablet, Oral~Three to six patients are expected to be enrolled in each arm"
9685314|NCT04880525|Experimental|Study Group|The study group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). In addition to pilates, the women in the SG followed a personalized weight loss diet. In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
10179284|NCT03804749|Experimental|Group 3-1|The dose of suramin sodium is 20mg/kg
10179285|NCT03804749|Placebo Comparator|Group 3-2|The placebo is 0.9% sodium chloride injection
10179286|NCT03804736|Active Comparator|FMT-c|Patients in this arm received FMT-c (15 capsules every 12 h for 2 days)
10179287|NCT03804736|Experimental|FMT-c lactobacillus|Patients in this arm received FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
10179288|NCT03804476|Experimental|AER-271|The experimental drug AER-271 will be administered in this Arm. In Part A single ascending doses will be administered by IV bolus infusion of AER-271 formulated in phosphate buffered normal saline over a 30-min period. In Part B multiple ascending doses of AER-271 will be administered by IV 30-min bolus infusion BID for 72 hours. AER-271 will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours.
10179289|NCT03804476|Placebo Comparator|Placebo|A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
9685315|NCT04880525|No Intervention|Control Group|The control group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). Individuals in the CG received no dietary or nutritional intervention. On any diet, the status of women in the CG was frequently questioned.
9685316|NCT04880486|Sham Comparator|Control group|usually care with extra health education on upper limb exercise
9685317|NCT04880486|Experimental|Exercise group|usually care with extra supervision upper limb exercise with VR
9685318|NCT04880603|Active Comparator|A - Standard of Care|
10179290|NCT03804398|Experimental|optimal PEEP group|The study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained
10179291|NCT03804398|Active Comparator|PEEP level of 5 cmH2O group|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
10179292|NCT03804515|Experimental|14C-labeled Poziotinib|
10179293|NCT03804489|Experimental|Decision aids group|Shared decision making using decision aids,
10179294|NCT03804489|No Intervention|Control group|Standard oral explanation with booklet.
10179295|NCT03804463|Experimental|radical surgery group|Endometrial cancer radical surgery to be administered in this arm.
10179296|NCT03804463|Experimental|fertility preservation group|Fertility-sparing surgery to be administered in this arm.
10179297|NCT03804463|Experimental|ovarian preservation group|Ovarian preservation surgery to be administered in this arm.
10179298|NCT03804450|Experimental|Test group|The root canals were instrumented using Pro-taper next rotary files till size X3. REPs via blood clot using calcium hydroxide were then applied
10179299|NCT03804450|Experimental|Control group|The root canals were instrumented using Pro-taper next rotary files till size X5. REPs via blood clot using calcium hydroxide were then applied.
10179300|NCT03804385|Other|intercostal tube|insertion of intercostal tube is surgical operation used in pneumothorax
10179301|NCT03804606|Experimental|High benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
10179302|NCT03804606|No Intervention|High benefit, no MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
10179303|NCT03804606|Active Comparator|Low benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
10179304|NCT03804372|Experimental|Study group|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
10179305|NCT03804541|Experimental|[14C]Ensartinib|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]Ensartinib to healthy Chinese male subjects。
10179306|NCT03804502|Experimental|TearCare|Subjects will receive one TearCare treatment at the baseline visit
10179307|NCT03804671|Experimental|All Subjects|Test treatment T followed by Reference treatment R
10179308|NCT03804619|Experimental|Left DLPFC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
10179309|NCT03804619|Experimental|ACC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
10179310|NCT03804528|Experimental|Exercise group|Each participant will engage in 60 minute daily sessions delivered 3 times/week for 8 consecutive weeks (a total of 24 sessions).
10179311|NCT03804684|Experimental|Healthy Controls|Healthy subjects between 21 and 80 years of age with no eye diseases. Eyes will have normal appearing optic nerve and retina, intraocular eye pressure less than 19 millimeters of mercury, normal, reliable standard automatic perimetry and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
10179312|NCT03804684|Experimental|Mild Glaucoma|Subjects between 21 and 80 years of age with Mild Glaucoma. Eyes will have reliable standard automatic perimetry with no more than -6 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
9685319|NCT04880603|Experimental|B - Restrata Graft|
9685320|NCT04880655|Experimental|Intervention|Dressed with WSD and petrolatum gauze
9685321|NCT04880655|Active Comparator|Control|Dressed with bacitracin and petrolatum gauze
9685322|NCT04880772|No Intervention|Standard care|Standard Care: Surgery school as per ELHT pre-operative guidelines (includes generic pre-operative information, advice and optimisation e.g correction of anaemia)
9685323|NCT04880772|Experimental|Prehabilitation|Surgery School plus Moderate intensity exercise & Forceval (multivitamin)
9685324|NCT04880551||COPD patients with a recent Spirometry|Patients that have a diagnosis of COPD and have completed a recent Pulmonary Function Test - Spirometry.
9685325|NCT04880499|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus other cofactors for hematopoiesis, other than the standard of care.
9685326|NCT04880499|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
9685327|NCT04880369|Experimental|Lignan capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
9685328|NCT04880369|Experimental|Isoflavones capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
9685329|NCT04880369|Placebo Comparator|Placebo capsule|1 capsule/day from baseline to end-of-follow-up (approx. 4 months)
9685330|NCT04880356||Retrospective study|collection of retrospective data from adult patients with ultra-rare inherited neurological diseases
10179313|NCT03804684|Experimental|Moderate Glaucoma|Subjects between 21 and 80 years of age with Moderate Glaucoma. Eyes will have reliable standard automatic perimetry with between -6 mean and -12 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
10179314|NCT03804567|Experimental|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
10179315|NCT03804567|Active Comparator|Routine low back pain management|Normal accepted physiotherapy treatment for persistent low back pain.
10179316|NCT03804645|Experimental|Cohort 1|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
10179317|NCT03804645|Experimental|Cohort 2|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
10179318|NCT03804645|Experimental|Cohort 3|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
10179319|NCT03804645|Experimental|Cohort 4|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
10179320|NCT03804645|Experimental|Cohort 5|In Part B, each subject will receive one formulation from Part A chosen for further development, dose under fed conditions, followed by dose under fasted condition.
10179321|NCT03804723|Experimental|GC withdrawal|
10179322|NCT03804723|Placebo Comparator|non GC withdrawal|
10179323|NCT03804411|Experimental|Treatment chosen by automated decision-making system|Group A: type 2 diabetic patients randomized to receive antidiabetic drugs according to predictors chosen with developed automated decision-making system: subgroup 1A- addition of vildagliptin 100 mg/day, subgroup 2A - addition of sitagliptin 100 mg/day, subgroup 3A- addition of dapagliflozin 10 mg/day, subgroup 4A- addition of empagliflozin 10 mg/day, subgroup 5A- addition of liraglutide 1,2-1,8 mg/day, subgroup 6A- addition of exenatide 20 μg/day, subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide.
10179324|NCT03804411|Experimental|Treatment based on standard recommendations|Group B: type 2 diabetic patients randomized to receive antidiabetic drugs according to standard recommendations : subgroup 1B- addition of vildagliptin 100 mg/day, subgroup 2B - addition of sitagliptin 100 mg/day, subgroup 3B- addition of dapagliflozin 10 mg/day, subgroup 4B- addition of empagliflozin 10 mg/day, subgroup 5B- addition of liraglutide 1,2-1,8 mg/day, subgroup 6B- addition of exenatide 20 μg/day, subgroup 7B - addition of glimepiride, subgroup 8B - addition of gliclazide.
10179325|NCT03804424|Experimental|Cohort 1: Pilot 64Cu-LLP2A Imaging|"16 adult individuals (6-8 patients with known MM; 6-10 healthy volunteers)~All subjects who enter the study in Cohort 1 will be injected with up to 11 mCi of 64Cu-LLP2A and will undergo body imaging at least twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry~6 subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A."
10179326|NCT03804424|Experimental|Cohort 2: Quantitative 64Cu-LLP2A Imaging|"20 patients with MM will be recruited~Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic imaging over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI or low dose CT scan for attenuation correction, subjects will be injected with a dose of up to11 mCi of 64Cu-LLP2A and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON or low dose CT scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed"
10179327|NCT03804359|No Intervention|GEMRITUX protocol|6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.
10179328|NCT03804359|Experimental|Personalized treatment|"restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)~restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;~Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6."
10179329|NCT03804333|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
10179330|NCT03804333|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
9685331|NCT04880356||Prospective study|prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years
9685332|NCT04880395|Experimental|Experimental : Dolutegravir plus Lamivudine|DOVATO: Dolutegravir 50mg/lamivudine 300 mg, FDC, 1 coformulated tablet QD
9685333|NCT04880395|Active Comparator|active comparator : TDF/XTC plus Dolutegravir (XTC stands for lamivudine OR emtricitabine)|"Unit Dose:~TDF/FTC 300/200 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD OR~TDF/3TC 300/300 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD"
9977697|NCT01364363|Other|BEAM (BCNU, etoposide, Ara-C, melphalan)|Lymphomas, Hodgkin's Disease
9685334|NCT04880382|Other|Standard Arm A: treatment by ICI will be continued|After achieving objective response between 6 and 12 months after treatment onset, for these patients ICI treament will continue as per market authorization
10179331|NCT03804086|Experimental|Test Group|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement (OFD).
10179332|NCT03804086|Active Comparator|Control Group|Open flap debridement alone.
10179333|NCT03804242|Experimental|Black Youth M.A.T.T.E.R.|The session topics are as follows: (1) Debunking the Stigma of Mental Health in the Black Community, (2) School to Prison Pipeline, (3) Achievement Gap, (4) Cultural Barrier that Black Students Experience with Teachers, (5) Trauma 101, (6) Trauma 102, (7) Actions of Today, Blueprints for Tomorrow: Youth Organizing to Transform Education film, (8) My Voice Will Be Heard (Part I), and (9) My Voice Will Be Heard (Part II). The intervention will be conducted in 2-hour weekly group sessions.
10179334|NCT03804242|No Intervention|Usual Care|All participants already participate in Youth Justice Coalition's Free LA High School. Those in control condition will participate in educational activities as usual.
10179335|NCT03804281|Experimental|Test group|esthetic crown lengthening with microsurgical approach
10179336|NCT03804281|Active Comparator|Control group|esthetic crown lengthening with conventional approach.
10179337|NCT03804307|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
10179338|NCT03804307|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
10179339|NCT03804034|Experimental|Occlusal trauma group|an occlusal interference was placed on the lower teeth as follows. Articulating paper was used to mark the contact area between the upper and lower premolars indicated for extraction. Once established, the marked area on the lower premolar was acid-etched with 37% phosphoric acid for 15 s, washed, and dried. A bonding agent was placed and light-cured for 15 s, and finally, a 1- to 2-mm block of resin was placed over the contact area and light-cured for 40 s. Articulating paper was used again to verify that only the premolars that were going to be extracted had contact during normal occlusion as well as in lateral movements. Patients were given chewing gum and indications to repeat 20 masticatory cycles for 30 s, followed by a 30-s rest interval, and repeat the sequence again for a period of 30 min. This chewing cycle was repeated three times every 8 h for the first 24 h
10179340|NCT03804034|Experimental|Moderate orthodontic force group|A convertible standard buccal tube was bonded over the buccal face of the first molar with resin and a McLaughlin, Bennett, and Trevisi slot size 0.022 bracket was bonded over the buccal face of the premolars. One 0.0017 × 0.025 in titanium molybdenum alloy wire cantilever was inserted into each first molar tube, and the wire was bent buccally to form a helix. The cantilever was clinched to the distal end of the tube, and a tipping and extrusive force was applied on the premolar. The activation angle was 45° with a force of 56 g, which was applied to the tooth for 24 h before it was extracted.
10179341|NCT03804034|Experimental|Occlusal trauma and moderate orthodontic force group|the combination of occlusal trauma and orthodontic force .
10179342|NCT03804034|No Intervention|Control Group|No experimental device to produce occlusal trauma or orthodontic forces
10179343|NCT03804151|Experimental|FitSpirit Intervention|FitSpirit physical activities and events are organized by participants' schools during the school year. Girl-only activities such as physical activity sessions, speaking engagements, turnkey running program and special events can be offered. The number, type and frequency of activities are decided by each school.
10179344|NCT03804320|Other|Patients with small renal masses|Active surveillance
10179345|NCT03804164|Experimental|Supportive Care (psycho-educational sessions)|Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
10179346|NCT03803982|Experimental|Deep Neuromuscular Blockade, Sugammadex|All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
10179347|NCT03803982|No Intervention|Standard Anesthetic|Patients in the standard anesthetic (or control group) will also receive anesthetic induction as per routine using a combination of propofol, opioids, dexamethasone, and rocuronium, with a lidocaine infusion. Patient monitoring will be similar to the experimental group, with electrocardiography, blood pressure, heart rate, and bispectral index monitoring. Patients in the control group will receive rocuronium 30 mg intravenous prior to intubation, followed by repeated 10 mg doses to reach a TOF of 1-2 twitches.
10179348|NCT03804177|Experimental|implant with hyaluronic melatonin vit c|implant placement with topical application of hyaluronic and melatonin and systemic administration of vitamin C
10179349|NCT03804177|Active Comparator|immediate implant|immediate implant placement alone without melatonin or hyauronic acid nor vitamin c
10179350|NCT03804229|Experimental|active group|Take two pills (100 mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
10179351|NCT03804229|Placebo Comparator|control group|Take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
10179352|NCT03804190||1-5years experience|1-5years of experience working as otorhinolaryngologist
10179353|NCT03804190||5-10 years experience|5-10years of experience working as otorhinolaryngologist
9685335|NCT04880382|Experimental|Experimental Arm B: treatment by ICI will be discontinued|After achieving objective response between 6 and 12 months after treatment onset, for these patients first-line or second line regimen should be discontinued. Patients will be followed as per standard management.
9685336|NCT04880512|Experimental|SYHX 1901 tablets for SAD|Two subjects will be enrolled in a single dose group which is recommended as the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of SYHX 1901 tablets in fasted state.
9685337|NCT04880512|Placebo Comparator|Placebo for SAD|2 out of 10 healthy subjects will be randomized to receive a single dose of placebo in fasted state
9685338|NCT04880512|Experimental|SYHX 1901 tablets for MAD|8 out of 10 healthy subjects will be randomized to receive multiple doses of SYHX 1901 tablets in fasted state
10179354|NCT03804190||10-15years experince|10-15years of experience working as otorhinolaryngologist
10179355|NCT03804190||15_20years experience|15-20years of experience working as otorhinolaryngologist
10179356|NCT03804073|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
10179357|NCT03804073|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
10179358|NCT03804255||Observational (survey)|Participants complete a self-administered web-based Biomarker Survey and may also complete an Outcome Validation Survey.
10179359|NCT03803930|Other|Arm 22G+SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
10179360|NCT03803930|Other|Arm 22G+MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
10179361|NCT03803930|Other|Arm 20G+SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
10179362|NCT03803930|Other|Arm 20G+MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
10179363|NCT03804203|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
10179364|NCT03804203|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
10179365|NCT03804047|Experimental|Kinesio Tape (KTG)|Participants allocated into the KTG will receive a single time application of the kinesio tape flexible tape (Kinesio® Tex, Albuquerque, NM, USA) in the upper-body (i.e., back part of the trunk) and in the lower-body (i.e., legs and ankle) according to standardized procedures (https://kinesiotaping.com/how-to/). The tape is latex-free and wearable for weeks without causing skin irritation (i.e., hypoallergenic); and safe for populations ranging from pediatric to geriatric. The tape will be applied by a Physical Therapist with experience in tape application. Tape application will be conducted in a private room with a complete structure for the procedure.
10179366|NCT03804047|Sham Comparator|Sham Tape (STG)|Participants allocated into the STG will receive a single time application of an inflexible tape (i.e., sham tape) in the same body segments as the intervention condition. Tape application will be conducted in a private room with a complete structure for the procedure.
10179367|NCT03803956|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) with a total dose of 850 Joules.
10179368|NCT03803956|Placebo Comparator|Placebo PBMT|Application of placebo PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
10179369|NCT03803917|Other|Treatment|Injection with freshly collected autologous adipose tissue
10179370|NCT03804294||vitamin D-ART|Infertile couples who undergo their ﬁrst IVF/ICSI and IUI cycle in Reproductive Medicin Center of Peking university Third Hosiptal.
10179371|NCT03803904|Experimental|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
10179372|NCT03803904|Active Comparator|Control|Participants in the control group will be equalized (frequency and duration) to the Spin group for contact and monitoring. As such they will report to the same facility and interact with the same experienced interventionist; however instead of progressive Spin exercise they will participate in sessions focused on balance and stretching. Similar to the aerobic intervention, these exercises will take place in a group setting and heart rate will be consistently monitored during each session to verify heart rate does not reach 50% HRR.
10179373|NCT03803891||Endoscopic full-thickness resection|Patients with neoplastic lesions less than 30mm unresectable en bloc by other less invasive endoscopic techniques, including lesions suggestive of T1 colorectal cancer, subepithelial tumors, lesions with diverticular involvement, lesions with no-lifting sign (recurrent, incomplete prior resection or untreated lesions).
9685339|NCT04880512|Placebo Comparator|Placebo for MAD|2 out of 10 healthy subjects will be randomized to receive multiple doses of placebo in fasted state
9685340|NCT04880343|No Intervention|Group (C)|Control
9685341|NCT04880343|Experimental|Group (A)|Treatment
9685342|NCT04880343|Experimental|Group (B)|Treatment
10179374|NCT03803878||Group 1|Group 1 is anticipated to consist of 300 women with MUI, and the categorization function of MESA questionnaire will be validated among those patients.
10179375|NCT03803878||Group 2|Group 2 is anticipated to consist of 282 women with urgency-predominant MUI.
10179376|NCT03803878||Group 3|Group 3 is anticipated to consist of 94 women with urgency-predominant MUI.
10179377|NCT03803865|Active Comparator|Headspace|30-day smartphone based mindfulness training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
9685343|NCT04880304|Experimental|ADHD diagnosis and subconcussive head impacts|"ADHD Group: Individuals clinically diagnosed with ADHD, currently taking his/her prescribed ADHD medication.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
9685344|NCT04880304|Experimental|No history or current diagnosis of ADHD and subconcussive head impacts|"Non-ADHD Group: Individuals with no current or prior diagnosis of ADHD.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
9685345|NCT04880590||Sex Intercourse|women with a heterosexual sexual relationship after embryo transfer
9685346|NCT04880590||Non sex intercourse|women without a heterosexual sexual relationship after embryo transfer
9685347|NCT04880265||Patients undergoing cardiac surgery|
9685348|NCT04880057|Active Comparator|Resistance+Aerobic training group|Resistance+Aerobic training group (RAeT) RAeT includes resistance training (RT) program and aerobic training (AeT) program.
9685349|NCT04880057|Experimental|Agility training group|Agility training
10179378|NCT03803865|Active Comparator|Recharge|30-day smartphone based reflection and problem solving training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
9685350|NCT04879901|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
9685351|NCT04880005|Experimental|The intervention group|The three core elements of the intervention are: 1) individualized data-driven recommendations to GPs on how to treat each individual T2D patient, as well as 2) individualized digital coaching of T2D patients, and 3) on-line presentation of patient registered outcomes (PRO) to GPs.
10179379|NCT03803553|Experimental|ctDNA-POSITIVE: FOLFIRI Protocol|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- ctDNA-POSITIVE: FOLFIRI Protocol~FOLFIRI chemotherapy via intravenous infusion on days 1-3 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drugs~5-Fluorouracil~Irinotecan~Leucovorin"
9685352|NCT04880005|No Intervention|Control group|Usual care
10179380|NCT03803553|Active Comparator|ctDNA-POSITIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~-- Active surveillance.~Observation and monitoring with imaging (every 3 months), tumor markers, and ctDNA draws every 1 month for the initial 6 months.~After 6 months, followed with ctDNA, tumor markers, and scans every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician. ."
9685353|NCT04880200|Experimental|POC NAT & Adherence Intervention|These participants will receive the POC NAT test during their study visit. The result will be conveyed to their provider, who will deliver the result and an adherence intervention.
9685354|NCT04880200|No Intervention|Standard of Care|These participants will receive the clinical standard of care during their visit.
10187436|NCT03726255||Allogenic mesenchymal stem cells|12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)
9685355|NCT04880226|Other|Healthy Volunteers|Imaging of healthy volunteers would performed to optimize image parameters (contrast, SNR) prior to clinical imaging of actual patients receiving treatment.
9685356|NCT04880226|Experimental|Patients receiving MRI-guided procedures|As described in the study protocol this imaging would be performed to evaluate a given sequence for potential benefit during MR-guided interventions.
9685357|NCT04880213|Experimental|Japanese: M5049 Dose A (low dose)|
9685358|NCT04880213|Experimental|Japanese: M5049 Dose B (medium dose)|
9685359|NCT04880213|Experimental|Japanese: M5049 Dose C (high dose)|
9685360|NCT04880213|Experimental|Caucasian: M5049 Dose A (low dose)|
9685361|NCT04880213|Experimental|Caucasian: M5049 Dose B (medium dose)|
9685362|NCT04880213|Experimental|Caucasian: M5049 Dose C (high dose)|
9685363|NCT04879953||PIPAC CHEM|PIPAC associated with systemic chemotherapy
9685364|NCT04879953||ONLY CHEM|systemic chemotherapy alone
9685365|NCT04879888|Experimental|Vacuna|Triple-negative breast cancer patients with specific tumor mutation, with six doses of peptide-pulsed autologous dendritic cells after surgery.
9685366|NCT04879927|Experimental|RESOURCE Matching|Participants randomized into the intervention arm will receive customized resource matching
9685367|NCT04879927|Active Comparator|Usual Care|Participants randomized into the control group will receive a pre-existing pamphlet detailing DFCI resources
9685368|NCT04880083|Experimental|Formula-Fed (FF) Group|Subjects will be fed commercial bovine milk-based, whey-predominant, α-lactalbumin-enriched term formula with high sn-2 palmitate fat blend, supplemented with oligofructose for 6 weeks.
9685369|NCT04880083|No Intervention|Breast-Fed (BF) Group|Subjects will continue exclusive/ predominant breastfeeding for 6 weeks. Breastmilk may be consumed directly from the breast or breast milk may be expressed and fed through infant feeding bottle.
9685370|NCT04880161|Experimental|Active|Ampion
9685371|NCT04880161|Placebo Comparator|Control|Placebo
9685372|NCT04879836||Teething Ring + Teething Gel|
9685373|NCT04879836||Teething Ring|
9685374|NCT04880096||chronic pain patients|All adult patients followed-up in participating pain clinics
9685375|NCT04879797|Other|Maternal Safety Bundles Implementation|The first intervention targets obstetric hemorrhage, severe hypertension and maternal health equity by implementing three relevant AIM bundles: Obstetric Hemorrhage, Severe Hypertension in Pregnancy, and Reduction of Peripartum Racial/Ethnic Disparities. The Perinatal Neonatal Quality Improvement Network (PNQIN) will facilitate this collaborative QI project and support participating hospitals by providing guidance, education, and technical assistance to hospitals to support implementation of bundles using the QI process. Implementation strategies are based on the Institute for Healthcare Improvement (IHI) improvement model and the AIM program implementation toolkit and have previously been used by PNQIN to implement the Obstetric Care for Women with Opioid Use Disorder AIM bundle in 22 hospitals, including the five hospitals for this study.
9685376|NCT04879797|Other|Doula Services|The second intervention that this study evaluates is doula services. Investigators are evaluating doula services that are offered by two doula organizations at three hospitals. Investigators will provide top-up training to these doulas in order to provide some standardization and quality assurance of the services delivered. The training is developed and delivered by an obstetrician (Meadows) and doula (Gebel) and will take place among providers (staff associated with three chosen hospitals), patient navigators, and two doula groups, Birth Sisters and Accompany Doula Care, on factors that comprise the risk profile and how to offer targeted doula services to women who fit the risk profile. All sites will use standardized data instruments to evaluate the number of factors in the risk profile being met as well as standardized language and recruitment materials for mothers.
10179381|NCT03803553|Active Comparator|ctDNA-NEGATIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- Observation and monitoring with imaging, tumor markers, and ctDNA collections every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician"
9685377|NCT04879784||Stored antenatal sera|Antenatal sera from women booking for antenatal care at six centres in England
10179382|NCT03803553|Experimental|ctDNA-POSITIVE MSI-H: NIVOLUMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and MSI-H, the participant will not be randomized and will be placed into the group: ctDNA positive, MSI-H: Nivolumab~-ctDNA-Positive, MSI-H: Nivolumab Protocol~Nivolumab treatment via intravenous infusion on day 1 of each cycle. Cycle is 28 days long. This will occur for up to 12 cycles (48 weeks).~infusions will consist of the drug Nivolumab"
9685378|NCT04880135|Experimental|Supervised stretching and strengthening exercise|Stretching and strengthening exercises will be performed under the supervision of Physical therapist for a period of one month
9685379|NCT04880135|Experimental|Home-based stretching and strengthening exercises|Stretching and strengthening exercises will be performed at home by individuals having musculoskeletal pain due to quarantine for a period of one month.
9685380|NCT04880122|Experimental|Nursing home residents/staff members|Matched venous blood/dried blood spots collection in a single arm.
9685381|NCT04879992|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
9685382|NCT04879992|Experimental|rifabutin triple therapy|Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid
9685383|NCT04879966||UC cohort|the patiente of Moderate to Severe Ulcerative Colitis who recieved infliximab(IFX) or corticosteroids(CS) as induction therapy would be enrolled in this cohort
9685384|NCT04879914|Experimental|Butyrate|Patients taking butyrate
9685385|NCT04879914|Experimental|Placebo|Patients taking placebo
9685386|NCT04880018|Experimental|Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd|Specification model: CTR1109、CTR1210、CTR1311、CTR1412、CTR1513 Manufacturer: Eyebright Medical Technology (Beijing) Co., Ltd.
9685387|NCT04880018|Active Comparator|Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd|Specification model: TENSIOBAG 10、TENSIOBAG 11、TENSIOBAG 12、TENSIOBAG 13、TENSIOBAG14 Manufacturer: Carl Zeiss Medical Technology Co., Ltd.
9685388|NCT04879771||Morning GIE|
9685389|NCT04879771||Afternoon GIE|
9685390|NCT04879758|No Intervention|Control Group|The control group will receive a Fitbit device and general lifestyle advice e-leaflet, which includes information about T2D, health impacts of T2D and lifestyle advice on 4 major risk markers of T2D (e.g., PA, diet, smoking, weight management) as recommended by the World Health Organization.
9685391|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk of T2D in addition to the Fitbit and e-leaflet.
9685392|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
9685393|NCT04879745|Experimental|Decision Aid Users|Patients with a rheumatic disease who are given access to the MyVoice:Rheum decision aid
9685394|NCT04879745|Active Comparator|Pamphlet Users|Patients with a rheumatic disease who are given access to a widely-accessible pamphlet about family planning
9685395|NCT04879745|Experimental|Rheumatologists|Rheumatologists who interact with patients who have used the MyVoice: Rheum decision aid
9685396|NCT04879693|Experimental|Hospitalized Patients|To assess performance of CGM compared to comparator measurement.
9685397|NCT04879667|No Intervention|group (1)|surgical management of gastrocutaneous fistula after laparoscopic sleeve gatrectomy by surgical exploration
9685398|NCT04879667|Active Comparator|group (2)|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral & I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral & I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
9685399|NCT04879446|Experimental|A-PRF Test Group|Advanced Platelet Rich Fibrin liquid applied into the implant cavity and implant surface. That is the only difference between A-PRF control group and A-PRF test group.
9685400|NCT04879446|Experimental|CGF Test Group|Concentrated growth factor liquid applied into the implant cavity and implant surface. That is the only difference between CGF control group and CGF test group.
10187437|NCT03726242|Active Comparator|Levcromakalim|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0."
9685401|NCT04879446|Experimental|A-PRF Control Group|Dental implant applications were made with traditional methods.
9685402|NCT04879446|Experimental|CGF Control Group|Dental implant applications were made with traditional methods.
9685403|NCT04879511|Active Comparator|Receiving metformin|Active group receiving metformin with basal /bolus insulin
9685404|NCT04879511|Placebo Comparator|Placebo|Control group receiving Placebo with basal/bolus insulin
9685405|NCT04879303|Experimental|Robot-assisted social skill intervention|Social robotics will be used by the instructor to conduct the social skill training activities.
9685406|NCT04879303|Active Comparator|Human-only instruction program on social skill training|The children will receive only the human-delivered social skill training.
9685407|NCT04879303|No Intervention|Control|There will be no intervention conducted during the tested period
9685408|NCT04879719|Experimental|Ego-depletion group|Participants in this condition are asked to suppress their emotion while watching an emotional video of a surgery. Suppressing the natural emotional reaction to such a video demands cognitive resources and thus can induce a state of ego-depletion.
9685409|NCT04879719|Active Comparator|Control group|Participants in the control group are asked to watch the same emotional video. However, they are required to simply watch the video without suppressing any emotions.
9685410|NCT04879381||Cystic Fibrosis patients|Sputum samples
9685411|NCT04879524||Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|100 units of Botulinum toxin type A (Botox, Allergan, Ireland) injection into the puborectalis muscle to each side of the midline, achieving a total of 200 units
9685412|NCT04879472||Age 50 years and below|"Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement~Surgical approach either posterior, lateral or anterolateral~Type of anaesthesia either general or spinal~Presence or absence of comorbidities~Sex"
9685413|NCT04879472||Age more than 50 years|"Type of surgery (modality of treatment) either osteosynthesis, Hemiarthroplasty or Total hip replacement~Surgical approach either posterior, lateral or anterolateral~Type of anaesthesia either general or spinal~Presence or absence of comorbidities~Sex"
9685414|NCT04879641|No Intervention|1_Waiting List control|Randomized participants will only get the full intervention after study completion period (6 months since the randomization)
9685415|NCT04879641|Experimental|2_Exposure only|Randomized participants will only get the Exposure component
9685416|NCT04879641|Experimental|3_Attention Training only|Randomized participants will only get the Attention Training component
9685417|NCT04879641|Experimental|4_Exposure + Attention Training|Randomized participants will get Exposure + Attention Training components
9685418|NCT04879641|Experimental|5_Cognitive Restructuring only|Randomized participants will only get the Cognitive Restructuring component
9685419|NCT04879641|Experimental|6_Cognitive Restructuring + Exposure|Randomized participants will get Cognitive Restructuring + Exposure components
9685420|NCT04879641|Experimental|7_Cognitive Restructuring + Attention Training|Randomized participants will get Cognitive Restructuring + Attention Training components
9685421|NCT04879641|Experimental|8_Cognitive Restructuring + Attention Training + Exposure|Randomized participants will get Cognitive Restructuring + Attention Training + Exposure components
9685422|NCT04879641|Experimental|9_Psychoeducation only|Randomized participants will only get the Psychoeducation component
10179383|NCT03803553|Experimental|ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and has a BRAF mutation, the participant will not be randomized and will be placed into the group: ctDNA positive, BRAF mutant: Encorafenib/Binimetinib/Cetuximab~-ctDNA-Positive, MSI-H: Encorafenib/Binimetinib/Cetuximab Protocol~Encorafenib/Binimetinib treatment is received orally every day and Cetuximab via intravenous infusion on day 1 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drug Cetuximab"
9685423|NCT04879641|Experimental|10_Psychoeducation + Exposure|Randomized participants will get the Psychoeducation + Exposure components
9685424|NCT04879641|Experimental|11_Psychoeducation + Attention Training|Randomized participants will get the Psychoeducation + Attention Training components
9685425|NCT04879641|Experimental|12_Psychoeducation + Attention Training + Exposure|Randomized participants will get the Psychoeducation + Attention Training + Exposure components
9685426|NCT04879641|Experimental|13_Psychoeducation + Cognitive Restructuring|Randomized participants will get the Psychoeducation + Cognitive Restructuring components
9685427|NCT04879641|Experimental|14_Psychoeducation + Cognitive Restructuring + Exposure|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Exposure components
9685428|NCT04879641|Experimental|15_Psychoeducation + Cognitive Restructuring + Attention Training|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training components
9685429|NCT04879641|Experimental|16_full version (Psychoeducation + Cognitive Restructuring + Attention Training + Exposure)|Randomized participants will get the Psychoeducation + Cognitive Restructuring + Attention Training + Exposure components
9977698|NCT01364363|Other|Total Lymphoid Irradiation|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
9977699|NCT01364363|Other|Cladribine/Melphalan|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
9685432|NCT04879316||adult patients with NSCLC initiating nivolumab or pembrolizumab|Patients underwent a multidisciplinary evaluation including consultation with an oncologist and a dietitian. Such an assessment includes subjective and objective parameters such as medical history, weight loss, current dietary intake (including energy and protein balance), physical examination and anthropometric measurements, functional and mental assessment, medications, Resting Energy Expenditure measurement using indirect calorimetry and laboratory values.
9685433|NCT04879342|Experimental|VIP Program Group|Participants in this group will receive a 26 week course on risk reduction strategies.
9685434|NCT04879420||Teriparatide|Reference Group
9685435|NCT04879420||Risedronate|Exposure Group
9685436|NCT04879615|Experimental|Alteplase with standard therapy|
9685437|NCT04879615|No Intervention|Standard therapy|
9685438|NCT04879537|No Intervention|Control|Participants in this group are routinely treated.
9685439|NCT04879537|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
9685440|NCT04879485|No Intervention|Standard transfusion|Includes standard transfusion with a mixture of red blood cells and plasma
9685441|NCT04879485|Active Comparator|Plasma|Transfusion with plasma
9685442|NCT04879485|Active Comparator|Red Blood cells|Transfusion with red blood cells
9685443|NCT04879576|Experimental|Treatment Group|
9685444|NCT04879576|No Intervention|Control Group|
9685445|NCT04879550||thrombotic event developing / not|Group I: Patients with no bleeding/thrombosis complications Group II: Patients with Thrombotic and/or thromboembolic complications Group III: Patients with bleeding complications
9685446|NCT04879602|Experimental|Bronchoscopy group|patients receive suction before extubation by bronchoscopy in PACU
9685447|NCT04879602|No Intervention|Control group|patients receive routine ordinary suction in PACU
9685448|NCT04879498|Experimental|Monolithic zirconia|Monolithic zirconia posterior 3-unit fixed partial dentures
9685449|NCT04879498|Active Comparator|Veneered zirconia|Veneered zirconia posterior 3-unit fixed partial dentures
9685450|NCT04879498|Active Comparator|Metal-ceramic|Metal-ceramic posterior 3-unit fixed partial dentures
9685451|NCT04879407||Warfarin|Reference group
9685452|NCT04879407||Rivaroxaban|Exposure group
9685453|NCT04879394|Experimental|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
9685454|NCT04879394|No Intervention|Control|Receives standard care as usual. Assessments will be made in the same time points as experimental group, but without undergoing intervention.
9685455|NCT04879563|Experimental|ASCAPE-based follow-up strategy|Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions.
9685456|NCT04879654|Experimental|endonasal endoscopic surgery with adjuvant therapy|endonasal endoscopic surgery followed by Toripalimab,radiotherapy and/or chemotherapy
9685457|NCT04879277|Other|Healthy subject|"The intervention, specific to the study, is to take blood samples on patients healthy volunteers.~Healthy subject will be paired to patient with phenylketonuria according to body mass index and sex."
9685458|NCT04879277|Other|Patient with phenylketonuria|The intervention, specific to the study, is to take blood samples on patients with phenylketonuria
9685459|NCT04878887|Other|IP-DRA|In plane distal radial artery catherterization
9685460|NCT04878887|Other|IP-PRA|In plane proximal radial artery catherterization
10179384|NCT03803852|Experimental|0°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 0°
9685461|NCT04879147||Syncope|Subjects admitted immediately after syncopation.
9685462|NCT04879147||Seizre|Subject admitted immediately after cerebarl seizure
9685463|NCT04878939|Experimental|Anterior segment retraction using sliding mechanics (friction)|Power chain
9685464|NCT04878939|Experimental|Anterior segment retraction using segmental mechanics (frictionless)|T-loop
10179385|NCT03803852|Experimental|45°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 45°
9685465|NCT04879108|Experimental|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation approaches after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~TENS therapy was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
9685466|NCT04879108|Active Comparator|Physiotherapy rehabilitation Group|"This group was enrolled only physiotherapy and rehabilitation program after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
9685467|NCT04879199|Experimental|Typically Developing (TD) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) who are typically developing, 3) able to stand and walk alone without using assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
9685468|NCT04879199|Experimental|Spastic Cerebral Palsy (sCP) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) with the diagnosis of spastic CP or CP similar (both unilateral and bilateral), functionally classified level I or II according to the Gross Motor Function Classification System (GMFCS) [98], 3) being able to stand and walk alone without assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
9685469|NCT04879004|Experimental|Ropivacaine Group|ESPB performed with infusion of Ropivacaine 0,375% (20 ml at ech side)
9685470|NCT04879004|Placebo Comparator|Control Group|ESPB performed with infusion of N/S 0,9% (20 ml at each side)
9685471|NCT04879134|Experimental|Apomorphine Injections|
9685472|NCT04879134|Placebo Comparator|Placebo Injections|
9685473|NCT04879056||intra-system|reviewing selected features on images from three iterations of the same scanner.
9685474|NCT04879056||inter-system|reviewing selected features on images from three different scanners.
9685475|NCT04879264|Experimental|Patients irradiated for breast cancer|Participants with breast cancer who receive adjuvant radiotherapy following breast-conserving surgery or mastectomy.
9685476|NCT04879173||Hyperthyroidism caused by Graves' disease|
9685477|NCT04879173||Hyperthyroidism caused by painless/subacute thyroiditis|
9685478|NCT04878861|Experimental|Training in blind field|All participants undergo this intervention. Internal control is comparing sighted and non-sighted parts of the field.
9827571|NCT02461160|Experimental|BA/FE Cohort 9 Group 1: B,C,A|Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.
10179386|NCT03803852|Experimental|90°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 90°
10179387|NCT03803852|Experimental|135°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 135°
10179388|NCT03803618||Confirmed dengue case|Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with <5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR
10179389|NCT03803618||Control|Age and sex matched neighborhood controls
10179390|NCT03803644|Experimental|Administration of CC-92480 - Part 1|dose escalation
10179391|NCT03803644|Experimental|Administration of CC-92480 under fasted conditions - Part 2|Food effect
10179392|NCT03803644|Experimental|Administration of CC-92480 under fed conditions - Part 2|food effect
10179393|NCT03803657||Neonates|Neonates 0-28 days
10179394|NCT03803657||Infant|29 days to 1 year
10179395|NCT03803657||Child|>1 year and <10 kg
10179396|NCT03803488|Experimental|simulation of injection|The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.
10179397|NCT03803722|Experimental|Arm A Eyestil Protection®|"No inferiority of Eyestil Protection® unidose versus Vismed® unidose The intervention consists of Eyestil Protection® : sterile preservative free, medical device, class IIa and CE marked. It contains 0.2% xanthan gum, presented in 0.3 ml unidose containers. It is not available yet on the French Market.~dosage: 6 drops a day for three months period."
10179398|NCT03803722|No Intervention|Arm B Vismed®|"Vismed®: sterile preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate, presented in 0.3 ml unidose containers. It is already on the French market.~dosage: 6 drops a day for three months period."
10179399|NCT03803670||acute lymphoblastic leukemia patients|We observed within adult patients with ALL three groups of patients: patients without central nervous system (CNS) involvement, patients with manifest CNS involvement and patients with occult CNS involvement.
10179400|NCT03803683|Experimental|mLab App Intervention|Youth randomized to the intervention arm (arm 1) will be provided with the mLab App, 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at their 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
9685479|NCT04878991||Treatment Group|"Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.~Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.~For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation."
9685480|NCT04879238|Experimental|Yoga-Mindfulness Intervention|Completing single session of yoga blended with mindfulness.
9685481|NCT04878978|Active Comparator|Routine care|Women who present with PPROM or threatened PTL and have routine care
9685482|NCT04878978|Experimental|Amniocentesis and biofire directed antibiotic use|Women who present with PPROM or threatened PTL and randomised to amniocentesis and biofire directed antibiotic treatment
9685483|NCT04878809|Experimental|Experimental group|People attending L'Horitzó School (students, teachers, administrative and service staff)
9685484|NCT04878809|Other|Control Group|Escola John Talabot, will provide the incidence rate of infections by SARS-CoV-2
9685485|NCT04878926|Active Comparator|Group A (n=30)|IV Sedation + TAP block
9685486|NCT04878926|Active Comparator|Group B (n=30)|IV Sedation + LA infiltration
9685487|NCT04878874|No Intervention|No Intervention:hip flexion|hip flexion pre measurement with extension knee will be performed
9685488|NCT04878874|Experimental|Experimental: hip flexion|hip flexion post experimental application measurement with Magnetic tape Application with extension knee will be performed
9685489|NCT04878874|Placebo Comparator|Placebo Comparator: hip flexion|hip flexion post placebo application measurement with kinesiology tape Application with extension knee will be performed
9685490|NCT04879082||ILD|Patients with ILD, whose file has been discussed in a multidisciplinary meeting since May 2020 at the Louis Pradel Pneumological Hospital, and who have benefited from a professional interview in the Occupational pathology consultation center of the Hospital Center Lyon Sud.
9685491|NCT04879186||Patients undergoing peripheral endovascular angioplasty|Patients undergoing peripheral endovascular angioplasty. No intervention other than what was already completed as part of routine clinical care, as this is a retrospective cohort.
9685492|NCT04879069||Intermediate-high risk PE|Confirmed PE causing right ventricle dysfunction confirmed by computed tomography pulmonary angiography or transthoracic echocardiography and elevated troponin level
9977700|NCT01364363|Other|FLAG (fludarabine, Ara-C, G-CSF)|For patients undergoing a second allogeneic transplant
9977701|NCT01364376|Active Comparator|FOLFOX|
9977702|NCT01364376|Experimental|SOX|
10179401|NCT03803683|Active Comparator|Standard of Care HIV Information Control Arm|Youth randomized to the Standard of Care HIV information control arm (arm 2) will receive standard-of-care HIV/STI testing-related risk reduction counseling, a box of condoms, PrEP assessment, and referral information for clinics that provide PrEP during their first visit. Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including pre-exposure prophylaxis (PrEP) and HIV testing information that is found on the CDC website.They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
10179402|NCT03803683|Active Comparator|HIV Home Tests|Youth randomized to the HIV home testing arm (arm 3) will be provided with the 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at the 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
10179403|NCT03803748|Experimental|Eyestil Plus®|"It's a clinical comparative performance study. Eyestil Plus® eyedrops multidose to be not inferior to Vismed multidose eye drops. Eyestil Plus is an ophthalmic aqueous formulation, multidose sterile preservative free, medical device, class IIB and CE marked. It contains 0.4% sodium hyaluronate. It is not available yet in the French Market.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period,"
10179404|NCT03803748|No Intervention|Vismed|"Vismed Multi® is also a sterile multidose preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period.~The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes."
9685493|NCT04879069||High-risk PE|"Confirmed PE causing hemodynamic instability:~Cardiac arrest (need for cardiopulmonary resuscitation) or,~Obstructive shock (systolic blood pressure < 90 mmHg or vasopressors required to achieve a systolic blood pressure ≥90 mmHg despite adequate filling status and end-organ hypoperfusion), or~Persistent hypotension (systolic blood pressure < 90 mmHg for at least 15 minutes)"
9685494|NCT04879030|Active Comparator|beta-lactam monotherapy|only beta-lactam antibiotics
9685495|NCT04879030|Experimental|beta-lactam and fluoroquinolone combination therapy|one beta-lactam antibiotic and one fluoroquinolone
9685496|NCT04878835|No Intervention|Control group|No intervention was given. No intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) was given at 2 weeks prior to pterygium excision surgery
9685497|NCT04878835|Experimental|Intervention group|The interventional group was given intralesional ranibizumab (Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL) 2 weeks prior to pterygium excision surgery
9685498|NCT04878848|Experimental|Proprioceptive Neuromuscular Facilitation Group|"Participants in the proprioceptive neuromuscular facilitation group will be given a treatment protocol consisting of rhythmic initiation, repeated stretch and hold-relax PNF techniques for upper extremity flexion-abduction-external rotation pattern and the scapular patterns of anterior elevation, posterior depression, anterior depression, posterior elevation for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks."
9685499|NCT04878848|Experimental|Conventional Rehabilitation Group|Participants in the conventional rehabilitation group will be given a treatment protocol consisting of stretching, strengthening exercises and joint mobilization techniques for a total of 4 weeks, 3 days a week for 45 minutes. Assessments will be applied in the baseline and at the end of 4 weeks.
9685500|NCT04879212|Experimental|PCIA +Acupuncture group|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, but no electricity. Acupuncture was given once a day. PCIA（patient controlled intravenous analgesia）.
9685501|NCT04879212|Experimental|PCIA +2 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 2Hz, continuous wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
9685502|NCT04879212|Experimental|PCIA +20/100 Hz Electroacupuncture group|Acupuncture bilateral Zusanli (ST36) and Sanyinjiao (SP6) to connect Huatuo brand electroacupuncture apparatus, and the ipsilateral Zusanli, Sanyinjiao were respectively connected as a loop. The parameters of electroacupuncture were set as 20 / 100Hz, density wave, 25min, and current intensity was 0.1-5.0mA. Acupuncture was given once a day.
9685503|NCT04878575||ASD group|120 ASD patients (aged 5-18 years)
9685504|NCT04878575||ADHD group|120 ADHD patients (aged 5-18 years)
9685505|NCT04878575||TDC group|120 age-, and sex-matched typically developing controls (TDC) will be recruited from the same geographic areas of the ASD/ADHD groups via referral by teachers or the invitation of participants without any psychiatric disorders
9685506|NCT04878601|Experimental|hbART|Home-Based ART initiation and continuation for 3-months with male-specific counseling and assisted facility navigation at 4-months.
9685507|NCT04878601|Active Comparator|fbART|Facility-Based ART initiation and continuation with male-specific counseling.
9685508|NCT04878757|Experimental|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
9685509|NCT04878757|No Intervention|Control - Business-As-Usual|Involves participation in the schools' typical math program
9685510|NCT04878770|Active Comparator|Topical corticosteroids (control)|This group will receive topical corticosteroids.
9685511|NCT04878770|Active Comparator|Systemic cyclosporine|This group will receive topical corticosteroids and systemic cyclosporin.
9685512|NCT04878770|Active Comparator|Systemic dupilumab|his group will receive topical corticosteroids and systemic dupilumab.
9685513|NCT04878692|Experimental|Onco-Rash arm|"In this arm label, patients will apply the Onco-Rash cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks."
9685514|NCT04878692|Placebo Comparator|Onco-Neutre arm|"In this arm label, patients will apply the Onco-Neutre cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.~Onco-Neutral cream will be used as an experimental comparator to Onco-Rash cream.~This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks."
9685515|NCT04878614|Active Comparator|Standard Levothyroxine Management|Participants will continue with the same regimen
9685516|NCT04878614|Experimental|Liquid Levothyroxine Management|Participants will be treated with dose equivalent regimen through enteral feeding tube
9685517|NCT04878705|Experimental|TWP-201|
9685518|NCT04878705|Placebo Comparator|placebo|
9685519|NCT04878731|Experimental|single arm|PF-06741086 300mg subcutaneous(SC)
9685520|NCT04878471|Experimental|ASP5354|Three participants in three dose levels will receive a single intravenous dose of ASP5354 on Day 1 under fasting conditions.
9977703|NCT01364402|Experimental|Erythropoietin|
9977704|NCT01364402|Placebo Comparator|Placebo|
10179405|NCT03803709|Placebo Comparator|placebo|"maltodextrin received at 4g/day on day 3 and 4~maltodextrin received at 8g/day from day 5 to 14~maltodextrin received at 16g/day from day 15 to 20"
10179406|NCT03803709|Experimental|inulin|"inulin received at 4g/day on day 3 and 4~inulin received at 8g/day from day 5 to 14~inulin received at 16g/day from day 15 to 20"
9685521|NCT04878471|Placebo Comparator|ASP5354 Matching Placebo|One participant in three dose levels will receive a single intravenous dose of matching placebo on Day 1 under fasting conditions.
9685522|NCT04878510|Experimental|Dexmedetomidine Intervention|Patients randomized to the experimental arm will receive dexmedetomidine. At initiation, a bolus will NOT be administered. In keeping with Health Canada. Guidelines, the infusion will start at a mid-range dose of 0.6mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (Richmond Agitation-Sedation Scale [RASS] = -2 to +1 or Riker Sedation-Agitation Scale [SAS] 3-4).
9685523|NCT04878510|Placebo Comparator|Control Intervention|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 50mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans.
9685524|NCT04878744|Experimental|Noticing the good things about green spaces|"The intervention condition will prompt participants once a day to notice the good things about green spaces, write notes about the 'good things in nature' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of species variety).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation.~Both the intervention and active control conditions are based on gratitude interventions. Practicing gratitude in controlled psychological intervention settings has been shown to have lasting effects on dispositional gratitude and psychological wellbeing (Seligman et al. 2005)."
9685525|NCT04878744|Active Comparator|Noticing the good things about built spaces|"In the control condition, participants will not be prompted to notice nature, rather they will be prompted to record the good things about the built environment, write notes about the 'good things in built spaces' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of the area being built-up).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation."
9685526|NCT04878523|Placebo Comparator|Placebo drink|
9685527|NCT04878523|Experimental|multi berries juice|
9685528|NCT04878588||patients receiving esophagectomy|the patients receiving esophagectomy during perioperative period. They receive barium examination and high resolution impedance manometry at the same time
9685529|NCT04878276||Dimet 5|"Dimet 5 is a certified medical device for the treatment of head lice infestation. It contains only (liquid) dimeticone oil and, when used correctly, enables physical killing of head lice and their eggs."
10179407|NCT03803592|Experimental|Dyadic MCS program|"Participants from the experimental group will receive a dyadic multisensory and cognitive stimulation (MCS) programme.~The MCS program is a 15- week program. In the first 4 weeks, participants will attend the center-based Face-to-face (FTF) session twice a week (8 sessions), while in the remaining week (5th-15th Week), home-based sessions will be delivered by the caregivers with the PWD at home and was suggested to deliver the intervention 3 times/week at home. The home-based sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions over the intervention period."
9685530|NCT04878276||Hedrin Once Liquid Gel|Hedrin Once Liquid Gel is a certified medical product for the removal of head lice and nits. The liquid gel contains 4% dimethicone and nerolidol (Penetrol®).
9685531|NCT04878341|Experimental|Erector Spinae plane Block|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and the transverse process of T5-T7 vertebrae and Erector Spinae (ES) fascia will be located with a linear ultrasound probe. A 19G or 20G epidural needle (according to age) will be positioned under the ES muscle and a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered; after hydrodissection, the catheter will be threaded, followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
9685532|NCT04878341|Active Comparator|Thoracic Epidural Anesthesia|After induction of general anesthesia, patients will be positioned in lateral decubitus with surgical site up and a 19G or 20G epidural needle (according to age) will be positioned at T5-T7 level with cathether placement; a bolus of of 0.3-0.5ml/kg of 0.2% ropivacaine will be administered and followed by an infusion of 0.2mg/kg/hr for the next 48 hours.
9685533|NCT04878497||Warfarin|New users of warfarin
9685534|NCT04878497||Dabigatran|New users of dabigatran
9685535|NCT04878497||Rivaroxaban|New users of rivaroxaban
9685536|NCT04878497||Apixaban|New users of apixaban
9685537|NCT04878497||Edoxaban|New users of edoxaban
9685538|NCT04878445||Cohort A: 10 participants with no COPD|"Control patients Have no physician diagnosis of COPD Have no other significant chronic lung disease (asthma, fibrotic diseases) or ongoing lung infection other than the suspected cancer for which they have been referred for surgery.~Lifelong never-smokers or ex-smokers (< 10 pack years). (1 pack year= 20 cigarettes/day for 1 year)."
9685539|NCT04878445||Cohort B: 10 participants with COPD - chronic bronchitis|Have a physician diagnosis of COPD with primarily a chronic bronchitis presentation (determined via CT, spirometry, histopathology, GOLD COPD classification).
9685540|NCT04878445||Cohort C: 10 participants with COPD emphysema|Have a physician diagnosis of COPD with primarily a emphysema presentation (determined via CT, spirometry, histopathology, GOLD COPD classification) .
10179408|NCT03803592|No Intervention|Control group|Participants from the control group will receive usual care and no intervention will be received.
9685541|NCT04878393||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment
9685542|NCT04878406|Experimental|1.7 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 1.7 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
9977705|NCT01364415|Experimental|Pasireotide LAR|
9685543|NCT04878406|Placebo Comparator|Placebo (1.7 mg NNC0480-03899) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
10179409|NCT03803800|Experimental|Classic training & beta-alanine|Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
10179410|NCT03803800|Placebo Comparator|Classic training & placebo|Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
9685544|NCT04878406|Experimental|8.6 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 8.6 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
9685545|NCT04878406|Placebo Comparator|Placebo (8.6 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
9685546|NCT04878406|Experimental|30 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 30 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
9685547|NCT04878406|Placebo Comparator|Placebo (30 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
9685548|NCT04878250|Experimental|Bintrafusp alfa|
10179411|NCT03803800|Experimental|Periodized training & beta-alanine|Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
10179412|NCT03803800|Placebo Comparator|Periodized training & placebo|Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
9685549|NCT04878198|Experimental|Jogging intervention|This intervention will be a 10-week jogging program consisting of 50 sessions (5 sessions per week, 30 min per session) in each participating school. The jogging program is confined to morning sessions based on the favourable sleep outcomes from previous study. To counteract the possible influence of natural sunlight exposure, all jogging sessions will be confined to indoor setting. Each session will be conducted in an identical format with 5 minutes of warm-up activities, followed by 20 minutes of jogging (intervention), and 5 minutes of cool-down activities. Participants are instructed to jog at a moderate intensity level. The intensity level of jogging will be measured by heart rate monitor (Polar H1). Meanwhile, questionnaire will be given to the research staff assisting the jogging intervention to assess the adherence of the intervention at T2.
10179413|NCT03803527|Experimental|EST|"All subjects enrolled into the study will:~Complete a clinical history~Have vitals obtained~Complete Patient-reported outcomes~Have Esophageal mucosal biopsies collected as part of standard of care at the time of the most recent endoscopy to report the peak eosinophilia per hpf.~Complete the Esophageal String test"
10179414|NCT03803787|Experimental|QT/RT + Budesonide|Patients are receiving chemotherapy (QT) and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
10179415|NCT03803787|No Intervention|QT/RT + No medication|Patients are receiving chemotherapy (QT) and radiotherapy (RT) without intervention therapy and followed during 12 months.
10179416|NCT03803787|Experimental|Target drug/RT + Budesonide|Patients are receiving target therapy and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
10179417|NCT03803787|No Intervention|Target drug/RT + No medication|Patients are receiving target treatment and radiotherapy (RT) without intervention therapy and followed during 12 months.
9685550|NCT04878198|Experimental|Melatonin supplement group|Participants in this intervention group will undergo a 10-week melatonin supplement intervention period, where melatonin supplement (Natrol®, Chatsworth CA) will be provided 30 minutes before bedtime. The prescription time (i.e. 30 minutes before bedtime) and the dosage of 3mg will be used because these are optimal for most of the participants as suggested by Malow and colleagues. 1 mg and 9 mg are not suggested to ensure the effectiveness of the intervention while preventing the potential daytime sleepiness. Similar to the aforementioned intervention, adherence of the intervention will be assessed at T2.
10179418|NCT03803514||Treated group (rEPO)|"Patients with ESRD in HD, and medical indication of recombinant EPO for management of anemia (Hb < 10 g/dL). Ambulatory hemodialysis 3 times per week.~Recombinant beta-epoetin (Recormon) will be used, according to current recommendations.~Clinical and laboratory data will be obtained before and during the study. The primary outcome (changes of plasma intact FGF23) will be measured during the follow-up, up to 12 weeks."
10179419|NCT03803514||Control group|"Patients with ESRD and HD, without medical indication of recombinant EPO (Hb > 10 g/dL). Ambulatory hemodialysis 3 times per week.~Follow-up for 3 months, similar than rEPO group. Clinical and laboratory data will be obtained before and during the study, similar periods than rEPO group.~The primary outcome (changes of plasma FGF23) will be measured every 2 week during the evaluation period."
10179420|NCT03803826|Experimental|CRT-D re-programming|"The ineffective previously implanted CRT-D is reprogrammed under supervision of transthoracic echocardiography to:~adjust the atrioventricular interval so that E and A waves do not overlap~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.~Transthoracic echocardiography is performed prior to optimization and 3 months after optimization (i.e., 3 and 6 months after the CRT implantation) and and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods re-programming of the interventricular interval"
10179421|NCT03803826|No Intervention|Control Group|Only trans-thoracic echocardiography is performed during follow-ups at 3 and 6 months from CRT implantations performed and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods
10179422|NCT03803449|Active Comparator|Control group|Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam
10179423|NCT03803449|Experimental|Fentanyl group|Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.
10179424|NCT03803436|Experimental|Study arm|Liver transplant
9977706|NCT01364441|Placebo Comparator|P|
9977707|NCT01364441|Experimental|E|
10179425|NCT03803436|Active Comparator|Parallel arm|Chemotherapy
10179426|NCT03803696|Active Comparator|Enhanced Standard Care|"Baseline data collection, registration and randomization~Inform primary transplant clinician of sexual dysfunction causing distress~Receive American Cancer Society sexual educational material"
9685551|NCT04878198|Experimental|Combination group|Participants will receive the jogging program and supplemental melatonin dose with identical format as that in the intervention A and B (e.g., identical duration, identical manpower, identical warm-up and cool-down, identical dose, identical acclimation procedure before the intervention adherence of the intervention for this group will also be assessed at T2.
9685552|NCT04878198|No Intervention|Control group|Participants in the placebo control group will receive no jogging and melatonin supplement dosing activity. However, they will be given a placebo flavored similar to the melatonin supplement (compounded by Pharmacare, Mt. Juliet, NT®). Meanwhile, they will also be required to wear an actigraph to control for their physical activity level at the assessment points (i.e. T1, T2, and T3). They will be expected for following their daily routine without participating in any additional formal physical exercise training program throughout the whole study period (T1-T3). After T3, they will be assisted with jogging program to recognize their contribution as controls.
9685553|NCT04878133|Experimental|Exsperimental Arm|
9685554|NCT04878133|No Intervention|Control Arm|
10179427|NCT03803696|Active Comparator|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~3 Monthly visits with trained study nurse practitioners~Referral to specialist if~Psychological etiology~Sexual Trauma~Relationship Discord~Concern for Malignancy or anatomic scarring requiring surgery"
10179428|NCT03803839|Active Comparator|Clodronate|1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
9685555|NCT04878185|Experimental|Exercise|"A high-intensity, home-based, exercise program consisting of inspiratory muscle training (IMT), endurance- and functional strength exercise. The sessions will supervised by a physiotherapist during six occasions and start 2-3 weeks before surgery. IMT will be conducted with an intensity starting from 50 % of maximal capacity, with a self-reported effort of 5-7 on the Borgs CR-10 scale. Endurance and functional strength exercises will be performed at a self-reported effort of 7-8. Interval training, chair stand- and step-up exercises will be key components of the exercise program. Furthermore, the program will include task-specific exercises based on the participants self-expressed needs.~On non-supervised days, participants will perform IMT twice a day as well as endurance and strength training, 2-3 days per week with 1-2 days per week of active recovery in the form of moderate intensity walks. This will be monitored with an activity journal and an accelerometer."
9685556|NCT04878185|No Intervention|Control group|Participants in the control group receive pre- and postoperative care as usual. In addition, they will be encouraged to follow the WHO guidelines of moderate intensity aerobic physical activity for at least 150 min per week. Their activity level will be monitored with an accelerometer.
10179429|NCT03803839|Placebo Comparator|Saline|1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
10187438|NCT03726242|Placebo Comparator|Saline|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0."
9685557|NCT04878237|Placebo Comparator|Non Allergic Patients|
9685558|NCT04878237|Active Comparator|Allergic Asthma Patients|Allergy to Grass Pollen
9685559|NCT04878237|Active Comparator|Allergic Rhinitis Patients|Allergy to Grass Pollen
9685560|NCT04878159||Emergency high-risk abdominal surgery|Patients undergoing emergency high-risk abdominal surgery, defined as immediate emergency laparoscopy or laparotomy, including intestinal obstruction, perforated viscus, intestinal ischemia and intraabdominal bleeding. Includes both primary surgery and re-operation after elective surgery.
9685561|NCT04878302|Experimental|Experimental: Taming Tics Together Protocol|"Families will participate in the 5-day telehealth-based intensive intervention and will receive three treatment formats which will provide CBIT and co-occurring diagnosis treatment:~Child/teen-only groups~Individual one-to-one sessions~Parent/caregiver-only groups"
9685562|NCT04878302|No Intervention|1-Month Waitlist Control|Families in the 1-month waitlist control group will participate in the initial intake assessment, then receive no treatment for a 1-month period. Following the 1-month period, families will participate in an assessment, then will be offered a place in a Taming Tics Together group
9685563|NCT04878146|Active Comparator|Sacrocolpopexy|Used as the standard intervention for prolapse
9685564|NCT04878146|Experimental|Sacro-spinous fixation|To be demonstrated as non inferior
9685565|NCT04878094|Active Comparator|Arm A|Randomized to standard technique and assessment of anastomosis without the use of NIR angiography
9685566|NCT04878094|Experimental|Arm B|Randomized to additional assessment of proximal colonic stump and anastomotic perfusion using NIR angiography
9695865|NCT04773366|Experimental|Group 3|"Includes patients with single system, multifocal or with single system, unifocal and special site (Isolated lesion of special site) or with single system, unifocal and CNS risk or with single system, unifocal i.e. thyroid, lung, thymus, hypothalamic-pituitary or with single system, unifocal and other functionally critical anatomical sites.~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
9695866|NCT04773366|Experimental|Group 4|"Patients with single system, unifocal i.e. bone, skin or lymph node (not the draining lymph node of another LCH lesion).~All patients in this group enter into observation after local therapy. Chemotherapy only apply to patients with disease reactivation during observation."
9695867|NCT04773327|Experimental|PEG-rhG-CSF prevention|Mecapegfilgrastim subcutaneous injection, 6mg, 24-48h after the end of antitumor drug administration in each chemotherapy cycle,
9695868|NCT04773327|No Intervention|non-prevention|Only close monitoring after chemotherapy
9695869|NCT04773301|Experimental|LEVOBUPIVACAINE|Patients treated with Levobupivacaine Altan 7.5 mg / ml solution for injection and infusion
9977708|NCT01364454|Experimental|Eligible patients' paper-based reminder|
9685567|NCT04877886|Experimental|Ultrasound with IV contrast|use ultrasound with IV contrast to perform in acute flank pain patient
10179430|NCT03803358|Experimental|cycle exercise with additional NIV|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
10179431|NCT03803358|Active Comparator|cycle exercise without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
10179432|NCT03803371|Experimental|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets by mouth on Day 1 of period 1 or 2
10179433|NCT03803371|Active Comparator|Ultracet tablet|Ultracet tablet (Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg) by mouth on Day 1 of period 1 or 2
9685568|NCT04877886|Active Comparator|CT with IV contrast|to compare with ultrasound with IV contrast in acute flank pain patient
9685569|NCT04877886|Active Comparator|Ultrasound without IV contrast|baseline for the Ultrasound with IV contrast
10179434|NCT03803254|Experimental|HAIC plus lenvatinib and PD-1 antibody|Hepatic arterial infusion chemotherapy plus lenvatinib and programmed cell death protein-1 antibody
10179435|NCT03803254|Active Comparator|HAIC plus lenvatinib|Hepatic arterial infusion chemotherapy plus lenvatinib
9685570|NCT04877886|Active Comparator|CT without IV contrast|baseline for the CT with IV contrast
9685571|NCT04878042|Experimental|Active|Mouth wash and nasal spray containing a diluted solution of hydrogen peroxide
9685572|NCT04878042|Placebo Comparator|Placebo|Mouth wash and nasal spray not containing a diluted solution of hydrogen peroxide
10179436|NCT03803124|Active Comparator|Tolvaptan|"Drug: Tolvaptan~1 tablet before renography"
10179437|NCT03803124|Placebo Comparator|Placebo|"Placebo~1 tablet before renography"
9685573|NCT04877912||Biopsy Group|We will scan 50 women who are scheduled for a breast biopsy. Subjects will receive an MRI exam that is research-only prior to the biopsy.
9685574|NCT04877912||MRI Unknown Cancer Status Group|We will scan 150 women with dense breasts and/or women who have intermediate risk of breast cancer for this study. Subjects will receive an MRI exam that is research-only.
9685575|NCT04877795||Cardiac Surgery|Adult Patients undergoing elective on-pump cardiac surgery (i.e. Coronary artery bypass graft surgery (CABG) and/or valvular surgery)
10179438|NCT03803267|Active Comparator|Erector spinae plane block|Patients will receive bilateral ultrasound-guided erector spinae plane block as an adjuvant analgesic technique
9685576|NCT04878029|Experimental|Treatment (cabozantinib, enfortumab vedotin)|Patients receive cabozantinib PO QD on days 1-28 and enfortumab vedotin IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9685577|NCT04877717|Experimental|SHR-A1904|
10179439|NCT03803267|Active Comparator|Quadratus lumborum block|Patients will receive bilateral ultrasound-guided quadratus lumborum block as an adjuvant analgesic technique
10179440|NCT03803319|Active Comparator|Fibre 1 (combined fibres)|Ingestion of 150mls water with 7.5g fibre (two times a day)
10179441|NCT03803319|Active Comparator|Fibre 2 (natural fibres)|Ingestion of 150mls water with 15g fibre (two times a day)
10179442|NCT03803319|Placebo Comparator|Dietary Supplement (placebo)|Ingestion of 150mls water with 7.5g (two times a day)
10179443|NCT03803384|Experimental|ESWT Order A and B|First Endurance Shuttle walk test (A) with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92% and second Endurance Shuttle walk (B) test with supplemental Oxygen therapy via constant oxygen flow rates
10179444|NCT03803384|Experimental|ESWT Order B and A|First Endurance Shuttle walk test (B) with supplemental Oxygen therapy via constant oxygen flow rates and second Endurance Shuttle walk (A) test with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92%
10187439|NCT03726229||Fontan patient|Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
9685578|NCT04877639|Active Comparator|Esmketamine group|Intravenous injection of 1.0mg/kg esmketamine was given, and nasal endoscopy was started 3 minutes later to maintain 1.0mg/kg/h esmketamine
9685579|NCT04877639|Active Comparator|Dexmedetomidine group|Dexmedetomidine 1 μg/ kg at least 10 min after intravenous injection + maintain 1 μ After intravenous injection of dexmedetomidine 1 ug / kg, sufentanil 0.05 mg / kg was given 5 minutes
9685580|NCT04878068||Rapid Antigen Saliva Test|Participants who have had a COVID-19 PCR test will self-administer the saliva test. The research team will conduct the processing of the test for the results of positive, negative or inconclusive
9685581|NCT04877938|Experimental|Echological Intervention|A starting point for this 'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV). Taking into consideration the guidance provided by ecologic models of health behavior evidences about specific constructs to guide EEI may be derived from behavioral research on physical activity.
9685582|NCT04877938|Active Comparator|Standard Physical Activity Intervention|People included in this group will be assigned to a standard physical activity program that will follow the guidelines of the American College of Sport and Medicine. The program will include moderate intensity aerobic and strength training, three times a week for a total amunt of 200 min of physical activity/week.
9685583|NCT04877938|No Intervention|Control group|Individuals included in this group will be asked to keep their life style,without taking part in any physical activity program.
9685584|NCT04877951|Other|Effect of LSVT BIG therapy on Postural Control and Gait Parameters|LSVT BIG is a commonly used protocol to manage functional movement for those with Parkinson's Disease. This study measured postural control and gait parameters following a 4-week course of LSVT BIG therapy.
9685585|NCT04877574|Experimental|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI index.
9977709|NCT01364454|No Intervention|Control group|
9685586|NCT04877574|Active Comparator|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
10179445|NCT03803293|Other|Primary cohort|All eligible Biobank participants that receive the majority of their care at Mayo Clinic based on EHR length and depth had pharmacogenomic testing done.
10179446|NCT03803176||Periodontally healthy subjects|Healthy subjects who attended the restorative dental clinic and have clinically healthy gingiva with zero plaque index (PI), gingival index (GI), and CAL (≤3 mm PD). Oral hygeine instructions will be given to these patients.
10179447|NCT03803176||Chronic Periodontitis|Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling & root planing.
9685587|NCT04877613|Experimental|Cohort 1: single dose of 5x10^7 CART-GFRa4 cells via intravenous infusion|
9685588|NCT04877613|Experimental|Cohort -1: single dose of 2x10^7 CART-GFRa4 cells via intravenous infusion|
9685589|NCT04877613|Experimental|Cohort 2: single dose of 1x10^8 CART-GFRa4 cells via intravenous infusion|
9685590|NCT04877613|Experimental|Cohort 3: single fixed dose of 3x10^8 CART-GFRa4 cells via intravenous infusion|
9685591|NCT04877964||pediatric patients with scoliosis|Patients aged 3-14 years with scoliosis and who request epidural analgesia
9685592|NCT04877769|Experimental|AT-527 Group A|n=8
9685593|NCT04877769|Experimental|AT-527 Group B|n=8
9685594|NCT04877769|Experimental|AT-527 Group C|n=8
10179448|NCT03803137|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection
9685595|NCT04877548|Experimental|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
9685596|NCT04877548|Experimental|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
9685597|NCT04877548|Placebo Comparator|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
9685598|NCT04878016|Experimental|ZKAB001＋carboplatin+etoposide|"The induction phase will consist of four cycles of ZKAB001 plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, patients will receive drug infusions in the following order:~ZKAB001 → carboplatin → etoposide"
9685599|NCT04878016|Placebo Comparator|placebo + carboplatin + etoposide|"The induction phase will consist of four cycles of placebo plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, all eligible patients will receive drug infusions in the following order:~placebo → carboplatin → etoposide"
9685600|NCT04877834|Experimental|DelanzoTMDR group|Subjects will take DelanzoTMDR 60 mg Capsule, manufactured by SAMI Pharmaceuticals (Pvt.) Ltd. after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
9685601|NCT04877834|Active Comparator|Dexilant® Group|Subjects will take Dexilant® 60 mg Capsule, manufactured by Takeda Pharmaceutical Company Limited after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
9685602|NCT05258006|Placebo Comparator|Open flap debridement + allograft bone (Maxgraft)|
9685603|NCT05258006|Active Comparator|Open flap debridement + Autogenous demineralized nanoparticles|
9685604|NCT05257993|Experimental|Arm A (mFOLFIRINOX)|JPI-547 and Combination Chemotherapy(mFOLFIRINOX) The study is conducted in a 3+3 dose escalation method.
9685605|NCT05257993|Experimental|Arm B (GemAbraxane)|JPI-547 and Combination Chemotherapy (Gemcitabine-nab-paclitaxel) The study is conducted in a 3+3 dose escalation method.
9685606|NCT05257980|Experimental|Dietary supplement (ONS)|All patients will receive standardised dietary advice in addition to the ONS prescribed daily for 28 days. The ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The ONS prescribed will be the same throughout the 28 days and will be taken orally.
9685607|NCT05257967|Experimental|Experimental arm|ddPCR and Canexia Follow It completed on cerebral spinal fluid and blood circulating tumor DNA
9685608|NCT05257941|Active Comparator|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
9685609|NCT05257941|Active Comparator|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back.
9685610|NCT05257928|Experimental|CARE-CITE GAIT Carepartner|This study arm consists of carepartners (CP) receiving the CARE-CITE Gait intervention. Over a period of one month, alongside the stroke survivor, the CP will receive 2 two-hour home-based therapy visits with a licensed physical therapist to develop therapy goals related to gait, mobility and balance and develop a home exercise plan to improve function. The CP will receive two additional phone calls to discuss the online CARE-CITE educational modules.
9685611|NCT05257928|Experimental|CARE-CITE GAIT Stroke Survivor|This study arm consists of stroke survivors (SS) of carepartners receiving the CARE-CITE Gait intervention. Over a period of one month, along with the CP, the SS will receive 2 two-hour home-based therapy visits with a licensed physical therapist to develop therapy goals related to gait, mobility and balance and develop a home exercise plan to improve function.
9685612|NCT05257915||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
9685613|NCT05257902|Active Comparator|Treatment group|Participants in the treatment group will take the choline alfoscerate as adjunctive therapy with their own antidepressants.
9685614|NCT05257902|Placebo Comparator|Control Group|Participants in the control group will take the placebo, which would not affect their medical condition, for the adjunctive therapy is the choice of agreement between clinician and participants. If there is the necessity of change in antidepressant or of adjustment of their dosage, investigator can stop the clinical trial and proceed to another treatment.
9685615|NCT05257889||neonatal seizures cases|Cases of neonatal seizures
9685616|NCT05257889||seizure-free neonates|cases that are seizure free
10179449|NCT03803033|Experimental|Intervention|The objective of the group was to introduce an experimental clinical pharmacy-based home medication review service in the outpatient clinic setting of the Jordan University Hospital in Amman, Jordan. The intervention under evaluation in the study is the pharmacy-based home medication review service.
9685617|NCT05257876|Experimental|Intervention group|Participants in the intervention group will receive breathing exercise training, pain information booklet, and usual care.
9685618|NCT05257876|No Intervention|Control group|Participants in the control group will receive pain information booklet and usual care.
9976163|NCT01348672||3. DR study arm|"DR patient groups are organised according to established risk factors for the clinical progression of DR (increasing from Groups 1 A to 3 A, ETDRS, 1991). We will recruit 41 patients per group (Klein et al, 1984).~Group 1D (n=41); Type 2 diabetic patients with no, or minimal, clinically visible DR. These patients are at low risk of developing sight-threatening DR.~Group 2D (n=41); Type 2 diabetic patients with microaneurysms and / or hard exudates within 2 disc diameters of the fovea and no clinical evidence of retinal thickening. These patients are at increased risk of developing DME.~Group 3D (n=41); Type 2 diabetic patients with the typical features of moderate-to-severe DR i.e. venous beading, intra-retinal microvascular abnormalities (IRMA) and dark blot intra-retinal haemorrhages. These patients are at a much increased risk of developing proliferative DR and/or ischemic maculopathy."
9976164|NCT01348724|Experimental|[14C] NKTR-118|
9685621|NCT05257837|Experimental|Gun safety vid x Movie clip - guns present|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
9685622|NCT05257837|Active Comparator|Gun safety vid x Movie clip - guns absent|Participants in this condition will view a gun safety video featuring The Ohio State University Chief of Police about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure with the guns edited out.
9685623|NCT05257837|Active Comparator|Seatbelt safety video x Movie clip - guns present|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
9685624|NCT05257837|Active Comparator|Seatbelt safety video x Movie clip - guns absent|Participants in this condition will view a seatbelt safety video about a week before coming into the lab. In the lab, they will watch a ~20 minute clip of either The Rocketeer or National Treasure featuring guns.
9685625|NCT05257824|Active Comparator|short-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU < 550 and PRU 85 ~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 6 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling
9685626|NCT05257824|Experimental|long-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU < 550 and PRU 85 ~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 12 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling.
9685627|NCT05257720||Remission|Patient with schizophrenia in remission
9685628|NCT05257720||treatment resistant|patient with treatment resistant schizophrenia
9685629|NCT05257720||controls|healthy controls
9685630|NCT05257707|Experimental|intervention|
9685631|NCT05257668|Active Comparator|Group 1|High intensity interval training
9685632|NCT05257668|Active Comparator|Group 2|Moderate intensity training
9685633|NCT05257668|No Intervention|Group 3|Control
9685634|NCT05257616|Other|Control Group|Questionnaires were given to the participants. Before the initiation of treatment, procedure and consent details were explained and verbally translated into the native languages of participants, followed by the written signed approval on the questionnaire. Cervical ranges were measured using inclinometer which included neck flexion, extension, left and right side bending. Succeeding it were vitals in which oxygen saturation, heart rate, blood pressure, ventilation rate were jotted along with pain measurement using NPRS scale.
9685635|NCT05257616|Active Comparator|Experimental Group|Questionnaires were given to the participants. Before the initiation of treatment, procedure and consent details were explained and verbally translated into the native languages of participants, followed by the written signed approval on the questionnaire. Cervical ranges were measured using inclinometer which included neck flexion, extension, left and right side bending. Succeeding it were vitals in which oxygen saturation, heart rate, blood pressure, ventilation rate were jotted along with pain measurement using NPRS scale.
9976165|NCT01348737|Experimental|AZD3839|Oral Treatment
9685637|NCT05257577||Study group|Breast conserving surgery
9685638|NCT05257564|Other|Diagnostic|Fingerstick collection and venous whole blood collection.
9685639|NCT05257538|Active Comparator|FMT enema|FMT enema 3-5 days after standard antibiotic treatment
9685640|NCT05257538|Placebo Comparator|plasebo enema|placebo
9685641|NCT05257525|Other|Univentricular physiology|Neonates with univentricular physiology
9685642|NCT05257525|Other|Biventricular physiology|Neonates with biventricular physiology
9695870|NCT04773301|Experimental|ROPIVACAINE|Patients treated with Ropivacaine Altan 2 mg / ml solution for infusion
9695871|NCT04773340||DBT intervention|Adaptation of Dialectical Behavior Therapy designed for repeat criminal offenders at high risk of reoffense.
9695872|NCT04773236|Active Comparator|Buffered Local anesthesia|Sodium bicarbonate with 2% lidocaine and 1:80.000 epinphrine
9976166|NCT01348737|Placebo Comparator|AZD3839 Placebo|Oral Treatment
9976167|NCT01348750|Other|Group A|This group receives 6 Healing Touch & Guided Imagery treatments in addition to standard medical care.
10179450|NCT03803033|No Intervention|Control|The objective of the control group was to identify changes in treatment and associated costs that take place in patients as part of the usual practice, as compared to the intervention arm, regardless of the clinical pharmacist service intervention.
9685643|NCT05257460|Active Comparator|Closed-loop using standard rapid-acting insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
10179451|NCT03803150|Experimental|PRA approach|PRA extends downward in curvilinear fashion in cervicomastoid skin crease
9685644|NCT05257460|Experimental|Closed-loop using ultra-rapid insulin lispro|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using ultra-rapid insulin lispro.~The CamAPS FX closed-loop system comprises Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), an Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system."
9685645|NCT05257408|Experimental|Nab-paclitaxel 80 mg/m^2 with Relacorilant 150 mg|Patients receive nab-paclitaxel 80 mg/m^2 administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.
9685646|NCT05257408|Active Comparator|Investigator's choice of standard chemotherapy|Patients receive investigator's choice of standard chemotherapy (liposomal doxorubicin, paclitaxel, topotecan, or nab-paclitaxel)
9685647|NCT05257395|Experimental|XZP-3287+ Letrozole/Anastrozole|
9685648|NCT05257395|Placebo Comparator|Placebo + Letrozole/Anastrozole|
9685649|NCT05257382|Active Comparator|Endoscopy suite|In this arm, ENB procedure will be performed in a classical endoscopy suite equipped by a fluoroscopy.
9685650|NCT05257382|Experimental|CBCT suite|In this arm, ENB procedure will be performed in a n hybrid room equipped by a cone beam CT (CBCT). This will allow to perform a real time visualisation of the lesion, enhanced fluoroscopy and to use the CrossCountry technique if required.
9685651|NCT05257369|Experimental|1.Blue-Green LED wide band phototherapy|"For experimental group was used Malysh phototherapeutic device (Luzar ltd, Belarus); it includes of eighteen blue- green super bright LEDs (12 blue (λmax 476 ) and 6 green (505 nm)."
9685652|NCT05257369|Active Comparator|2.Blue LED narrow band phototherapy|For control group was used blue LED BILI-THERAPY (Atom Medical Inc., Tokyo, Japan) in high-mode which have a 20 μW/cm2 with peak wavelength between (λmax 480 nm).
9685653|NCT05257343|Placebo Comparator|Placebo|Daily dose (10 mL) of a visually identical liquid placebo supplement to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
9685654|NCT05257343|Experimental|Blood Builder Treatment|Daily dose (10 mL) of liquid iron supplement (Blood Builder®) formulation to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
9685655|NCT05257317|Experimental|Intervention|It will consist of osteopathic manual therapy techniques applied to the occipital and temporal bones.
9685656|NCT05257317|Placebo Comparator|Placebo|It consists of a light contact applied to the cranial vault (frontal and parietal bones) where circular movements will be induced.
9685657|NCT05257291|No Intervention|Control group|Group of essential hypertensive patients who have received no additional therapies in addition to their established treatment plan (each patient was on specific antihypertensive therapy that has not been changed).
9685658|NCT05257291|Active Comparator|Melatonin treated group|Group of essential hypertensive patients who have received additional therapies consisting in 1 mg/day of melatonin for 1 year, in addition to their established treatment plan.
9685659|NCT05257265|Experimental|High Dose Centanafadine Hydrochloride|328.8 mg total daily dose
9685660|NCT05257265|Experimental|Low Dose Centanafadine Hydrochloride|164.4 mg total daily dose
9685661|NCT05257265|Placebo Comparator|Matching Placebo|
9685662|NCT05257187|Active Comparator|6 hour foley catheter retention|Patients will have the foley catheter in place for up to 6 hours starting from insertion time to removal. If the catheter falls out earlier than the 6 hour mark, the patient will still be included for analysis.
9685663|NCT05257187|Placebo Comparator|12 hour foley balloon retention|Patients will have the foley catheter in place for up to 12 hours starting from insertion time to removal. If the catheter falls out earlier than the 12 hour mark, the patient will still be included for analysis.
9685664|NCT05257161|Active Comparator|Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))|183 Carotid stenting (Emboshield NAV6™ Embolic Protection System + CGuard™ (The CGuardTM Embolic Prevention System (EPS))
9685665|NCT05257161|Experimental|MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS)|183 Carotid stenting (MO.MA Proximal Cerebral Protection Device+ CGuard™ (The CGuardTM Embolic Prevention System (EPS))
9685666|NCT05257122|Experimental|Arm A|Monotherapy of Fruquintinib
9685667|NCT05257096|Experimental|Medical clown EEG|50 Children performing the EEG at the days that the medical clown is available will be included in the study group.
9685668|NCT05257096|No Intervention|Regular EEG|50 Children performing the EEG at the days that the medical clown is unavailable will be included in the control group. The EEG will be performed in the traditional way without medical clowns.
9695873|NCT04773236|Placebo Comparator|Non Buffered Local anesthesia|2%lidocaine with 1:80.000 epinphrine.
9976168|NCT01348750|No Intervention|Group B|This group receives standard medical care but NO Healing Touch and Guided Imagery.
10179452|NCT03803150|Active Comparator|RT approach|RT begins 5mm below the ear lobe and continues 3 to 3.5cm inferiorly.
10179453|NCT03803241|Experimental|PVE + CD133|preop portal vein embolization + stem cells infusion
10179454|NCT03803241|Sham Comparator|PVE|only preop portal vein embolization
9685669|NCT05257083|Active Comparator|Arm A: DVRd + ASCT+DVRd (Standard Therapy)|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 4 induction cycles. Followed by ASCT and 2 cycles of DVRd consolidation, and lenalidomide maintenance therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6. Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6. Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
9685670|NCT05257083|Experimental|Arm B: DVRd followed by Ciltacabtagene Autoleucel|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) for 6 induction cycles.~Participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg), followed by lenalidomide post CAR-T cell therapy for 2 years~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6.~Bortezomib SC 1.3 mg/m^2 on days 1, 4, 8, and 11 of each cycle 1-6.~Lenalidomide orally, 25 mg on days 1 to 21 of each cycle 1-6.~Dexamethasone orally, 40 mg once a week on days 1, 8, 15 and 22 of each cycle 1-6.~Each cycle will consist of 28 days.~Lenalidomide maintenance orally 10 to 15 mg on days 1 to 28 (continuously) until confirmed progressive disease or unacceptable toxicity or for a maximum of 2 years"
9685671|NCT05257057||Endometrial hyperplasia|These are patients with a diagnosis of endometrial hyperplasia at WellSpan in the study time frame diagnosed via endometrial biopsy, dilation and curettage, or hysterectomy.
9685672|NCT05257044|Experimental|CBG|Participants will ingest 20 mg of CBG tincture in this arm
9685673|NCT05257044|Placebo Comparator|Placebo|Participants will ingest 20 mg of placebo tincture in this arm
9685674|NCT05257031|Experimental|SmofKabiven extra Nitrogen|"The investigational product will be administered in a volume that provides the target caloric intake of 15 kcal/kg BW on Study Day 1 and 20 kcal/kg BW/day on Study Days 2 to 5.~If calories are provided from other sources (e.g., enteral/oral nutrition/oral nutritional supplements or non-nutritional sources including glucose solution for drug dilution or propofol), the dose of the investigational product will be reduced accordingly to avoid calorie overload above the respective daily caloric targets."
9685675|NCT05257018|Experimental|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~Rituximab 375 mg / m^2，D1~Cyclophosphamide 750 mg / m^2，D2~Doxorubicin Hydrochloride Liposome Injection 35mg / m^2，D2~Vincristine 1.4mg/m^2 (dose capped at 2 mg)，D2~Prednisone 50 mg， bid D2-6~Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24h after chemotherapy）"
9685676|NCT05257005||Patient cohort|Non interventional study
10179455|NCT03803189|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports each time they complete a survey, and their PCP will receive supports in the EMR to facilitate postpartum mental healthcare.
10179456|NCT03803189|No Intervention|Usual care|The control arm will not receive intervention materials, unless they express suicidality, in which case they will receive a message with supports for suicidality including local emergency departments and crisis lines and an urgent message via EMR and fax will be sent to their PCP. Control arm participants will be asked to complete a baseline e-survey in their third trimester, and a follow-up e-survey 24-weeks after their baby is born.
9685677|NCT05256992|Experimental|Treatment-Ray of Hope|Treatment group participants receive standard and enhanced services. Standard services are delivered as primary services to participants in both study groups under a shared condition, and they are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Finally, only the treatment group receives 10 hours of the Ray of Hope curriculum as an enhanced service. Optional services are available to both study groups by selecting 1-3 hours of coursework from a menu of courses in the Mini-Clinic that address a variety of needs.
10179457|NCT03803007|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
10179458|NCT03803007|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
9685678|NCT05256992|Experimental|Control-No Ray of Hope Curriculum|Only standard services are delivered to participants in the control group under a shared condition with the treatment group, and they are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services are available to both study groups by selecting 1-3 hours of coursework from a menu of courses that address a variety of needs.
9685679|NCT05256966|Active Comparator|Sauna|Firefighters/participants based at the station with an existing sauna will be allocated to the intervention arm/sauna group. They will include a sauna session, as per study protocol, which is the intervention.
9685680|NCT05256966|No Intervention|Non Sauna|Firefighters/participants based at the stations without a sauna will be allocated to the control arm/Non sauna group. They will not sauna, as per study protocol, as to not receive the study intervention.
9685681|NCT05256953|Active Comparator|Group ESP|bilateral ESPB (total of 40 ml, %0.25 bupivacaine) + IV morphine PCA
9685682|NCT05256953|Active Comparator|Group GA|only IV morphine PCA
9685683|NCT05256901|Experimental|Sugammadex|The reversal agent, Sugammadex, will be administered at the start of closure.
9685684|NCT05256901|Active Comparator|Neostigmine/Glycopyrrolate|The reversal agent, Neostigmine, will be administered at the start of closure.
9685685|NCT05256836|Experimental|tablet group|A total of 36 sessions per week for 12 weeks of cognitive training program using a tablet computer are performed.
9685686|NCT05256836|No Intervention|control group|Subjects assigned to the control group did not receive any separate cognitive training for 12 weeks.
10179459|NCT03803306|Experimental|Vedic Medical Astrology Group (VMA)|
10179460|NCT03803306|Sham Comparator|Placebo vedic medical astrology (PMA)|
10179461|NCT03802942|Experimental|Glucerna|2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
10179462|NCT03802942|No Intervention|Control|Regular meal plan supplied by the hospital
9685687|NCT05256771|Active Comparator|Arm A: Full Treatment Arm (Laser + EMS + RF/PEMF)|Arm A: Three (3) diode laser treatments treatments at days 0, 28 and 56 (±2 days). Subjects will also receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
9685688|NCT05256771|Active Comparator|Arm B: EMS/RF Arm (EMS + RF/PEMF)|Arm B: Subjects will receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
9685689|NCT05256771|Active Comparator|Arm C: EMS Arm (EMS only)|Arm C: Subjects will receive weekly electrical muscle stimulation treatments at days 0, 7, 14, 21, 28 and 35 (±2 days).
9685690|NCT05256758|Experimental|OxFAST Fibrate group|49 patients randomised to receive fenofibrate 200mg capsules.
10179463|NCT03803020||single coronary chronic total occlusion|"symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI.~fractional flow reserve and SPECT detection before and after intervention."
10179464|NCT03802851|Experimental|Holmium Laser Enucleation of Prostate (HoLEP)|Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
9685691|NCT05256758|Placebo Comparator|OxFAST placebo group|13 patients randomised to receive placebo will act as controls.
9685692|NCT05256745|Experimental|Cohort 1: TTP488 (Azeliragon) co-administered with dose dense paclitaxel (ddAC/ddT)|Cohort 1: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2).
9685693|NCT05256745|Experimental|Cohort 2: TTP488 (Azeliragon) co-administered with TC|TC: docetaxel and cyclophosphamide Cohort 2: Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).
9685694|NCT05256745|Experimental|Cohort 3: TTP488 (Azeliragon) co-administered with TCHP|TCHP: docetaxel, carboplatin, trastuzumab, and pertuzumab Cohort 3: Cycle 5 Day 14 (C5D14), take twelve capsules of azeliragon daily for 6 days, then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 6 Day 2 (C6D2).
9685695|NCT05256745|Experimental|Cohort 4: TTP488 (Azeliragon) co-administered with chemotherapy regimen that includes ddAC|"given at the end of the chemotherapy plan [can include: (1)weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide]~Cohort 4: On day 7 of cycle 3, twelve capsules of azeliragon taken daily for 6 days, and then four capsules of Azeliragon each day continuously through the end of that cycle of chemotherapy, extending into Cycle 4 Day 2 (C4D2)."
9685696|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg single dose usage
9685697|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg single dose usage
9685698|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg single dose usage
9685699|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg single dose usage
9685700|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg single dose usage
9685701|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
9685702|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg, i.v. single dose usage.
9685703|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
9685704|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
9685705|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
9685706|NCT05256706|Experimental|SomaSignal Informed Medical Management SSCVD|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will be sent to the providers and participants approximately 2-4 weeks after testing.
9685707|NCT05256706|Active Comparator|Standard of Care (Uninformed Arm)|Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will not be provided to the provider or participant until the 6-month visit.
9685708|NCT05256693|Experimental|Vancomycine|Oral vancomycine 125 mg twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
9685709|NCT05256693|Placebo Comparator|Placebo|Vancomycine placebo, twice a day, from inclusion (at the time of hospitalization for allogeneic stem cell transplant) until hospital discharge or 5 weeks in hospital at most.
9685710|NCT05256680|Experimental|Gardening Activities|In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.
9685711|NCT05256680|Active Comparator|Control|No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home.
9685712|NCT05256667|Other|Root canal treatment in single visit - RCT-SV|Group 1- RCT-SV: Endodontic treatment in a single visit using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
9685713|NCT05256667|Other|Root canal treatment in two visits with intracanal dressing - RCT-TVWD|Group 2- RCT-TVWD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by intracanal dressing (calcium hydroxide powder, CPMC, glycerine) and temporary restoration (glass ionomer cement) for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
9685714|NCT05256667|Other|Root canal treatment in two visits without intracanal dressing - RCT-TVWOD|Group 3- RCT-TVWOD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by temporary restoration (glass ionomer cement) for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
9685715|NCT05256628|Other|Early Weightbearing|Patients randomized to early weightbearing will be permitted to begin immediate postoperative weightbearing as tolerated with crutches for additional stability.
9685716|NCT05256628|Other|Protected Weightbearing|Patients in the protected weightbearing group will be instructed to be touch weightbearing for a period of 6-weeks postoperatively before commencing to be weightbearing as tolerated.
9685717|NCT05256615|Experimental|Diabetes|Participants recruited to this arm have been clinically diagnosed with either gestational, pre- or type 2 diabetes.
9685718|NCT05256615|Experimental|Non-diabetes|Participants recruited to this arm of the study do not have gestational, pre- or type 2 diabetes.
9685719|NCT05256602||survey respondant|
9685720|NCT05256576|No Intervention|Control Group 1|Historic control group from both study sites: patients who took part in the FRAILTY study at Charité University hospital Berlin, as well as patients who were treated for OC at Evangelische Kliniken Essen Mitte during the same time period. Retrospective analysis looking at some of the main outcome variables will be conducted.
9685721|NCT05256576|No Intervention|Control Group 2|Prospective control group: patients who undergo treatment for OC at both sites. Main outcomes are determined while under standard hospital care before start of the change management and implementation of the new intervention.
9685722|NCT05256576|No Intervention|Control Group 3|Control group for health economical analysis to determine the cost-effectiveness of the new intervention.
9685723|NCT05256576|Experimental|Intervention Group|Intervention Group undergoing the new multi-modal perioperative care pathway, including the implementation of ERAS pathway, in combination with a tri-modal prehabilitation program following a comprehensive frailty assessment.
9685724|NCT05256563||Right brain stroke survivors|People with right brain stroke who are recruited to the study.
9685725|NCT05256524||Patients with critical COVID-19 responding to LMWH treatment|Responders are defined as patient who achieve aFXa-levels, peak or trough, within target-range as excepted from the given dose of LMWH.
9685726|NCT05256524||Patients with critical COVID-19 not responding to LMWH treatment|Non-responders are defined as patients who do not achieve aFXa-levels, peak or trough, within target-range as excepted from the given dose of LMWH.
9685727|NCT05256511||SARS-CoV-2 first wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the first wave of the pandemic, starting on 01-01-2020
9685728|NCT05256511||SARS-CoV-2 second wave|Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the second wave of the pandemic, starting on 10-01-2020
9685729|NCT05256498|Experimental|Amber UI Stimulation|Short-duration pudendal nerve stimulation
9685730|NCT05256485|Active Comparator|cognitive behavioral therapy|Standard CBT comprises an array of approaches directed toward modifying dysfunctional thinking and behavior. The two critical components are analysis of thoughts, feelings, and behaviors, as well as skills training for achieving active behavior and thought modification.
9685731|NCT05256485|Active Comparator|mindfulness based relapse prevention|"MBRP training is based on a two-component process:~Attention to present moment experience, even if it includes craving or negative emotion.~An accepting attitude towards this experience letting it be exactly as it is, without judging it or reacting to it."
10179465|NCT03802851|No Intervention|Control Arm|Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
10179466|NCT03803215||Theophylline group|Patients who have electrocardiographic documentation of asystolic syncope will be treated with oral theophylline at tailored dosage
9685732|NCT05256485|Active Comparator|twelve-step therapy|12-step therapy was based on strengthening conscious contact with God and awakening spirituality through prayer and meditation
9685733|NCT05256472|Experimental|combination treatment group|Subjects in this group will receive AK104 (RP2D, administered intravenously) plus Axitinib 5 mg bid, administered orally.
9685734|NCT05256459||HBV-DNA negative|HBV-DNA negative patients, no matter what antiviral drugs they take orally.
9685735|NCT05256459||HBV-DNA positive,ETV|HBV-DNA positive patients followed by entecavir.
9685736|NCT05256459||HBV-DNA positive,TEF|HBV-DNA positive and followed by tenofovir.
9685737|NCT05256459||HBV-DNA positive,TAF|HBV-DNA positive patients followed by propofol tenofovir.
9685738|NCT05256459||HBV-DNA positive, no TAF to TAF|Patients with HBV-DNA positive, who had previously taken non propofol tenofovir orally, and high-precision HBV-DNA quantification showed that they were positive, and those who changed to propofol tenofovir.
9685739|NCT05256459||liver nodules, no treat|Patients with liver nodules, regardless of their HBV-DNA value, were not treated and closely.
9685740|NCT05256459||liver nodules, treat|Patients with liver nodules, regardless of their HBV-DNA value, were treated with radiofrequency ablation and surgery
9695874|NCT04774393|Experimental|Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and ivosidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
9685741|NCT05256433|Experimental|IASTM|
9685742|NCT05256433|Active Comparator|Transverse friction massage|
9685743|NCT05256420|Experimental|Kinesiotape|Application of a kinesiotape bandage on the knee.
9685744|NCT05256420|Sham Comparator|Sham Bandage|Application of a sham bandage on the knee.
9685745|NCT05256407|Experimental|Intervention, digital support|Parents are offered participation in a digital channel consisting of video consultations, parental support gruops and parental education.
9685746|NCT05256407|No Intervention|Control, usual care|Usual child health care.
9685747|NCT05256394|Active Comparator|Pain Manager + tailored implementation support Pain Manager|Pain Manager is a decision support tool. All study clinics will begin the trial with Pain Manager integrated and available in their EHR. Consistent with the stepped-wedge design, intensive implementation support (e.g, administrative support, technical support)will be provided to two clinics at once by a multidisciplinary team.
9685748|NCT05256394|No Intervention|Pain Manager implementation in EHR|Pain Manager is a decision support tool. All study clinics will begin the trial with Pain Manager integrated and available in their EHR. The other 6 clinics will have no additional tailor support.
9685749|NCT05256368||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-80
9976169|NCT01348802|Experimental|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
9976170|NCT01348802|Placebo Comparator|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
9976171|NCT01348841|No Intervention|Control Arm|Usual care is care as currently delivered to clients with chronic wounds in the community.
9685753|NCT05256342|Active Comparator|Duloxetine|Eight weeks treatment, one pill a day. Week 1st - 30 mg a day. Weeks 2nd - 8th - 60 mg a day.
9685754|NCT05256342|Active Comparator|Etoricoxib|Eight weeks treatment. 60 mg daily pill ; from the second week adding omeprazol 20 mg daily
9685755|NCT05256329||Oncology patients|Patients suffering from specific solid cancers or hematological malignancies
9685756|NCT05256277|Experimental|CT101a|1 dose infusion
9685757|NCT05256264||Control group|Sevoflurane
9685758|NCT05256264||Low dose ketamine group|Sevoflurane + 3µg/kg/min ketamine infusion
9685759|NCT05256264||High dose ketamine group|Sevoflurane + 6µg/kg/min ketamine infusion
9685760|NCT05256238|Experimental|usual supportive care + comprehensive supervised exercise program (CSEP)|
9685761|NCT05256238|No Intervention|usual supportive care|
9685762|NCT05256212||firefighters|firefighters in active service
9685763|NCT05256199|Experimental|high-intensity group|The high intensity group receives a personalized, supervised intervention consisting of group meetings and individual sessions.
9685764|NCT05256199|No Intervention|low-intensity group|The low-intensity arm receives online access to general lifestyle-related health information.
9685765|NCT05256186|Experimental|Basketball pre-injury attack program|The intervention group carried out a program for 24 weeks. The participant had to perform the program 3 days per week for 12-15' each day (training days with the team, prior to group activation).
9685766|NCT05256186|No Intervention|Control|The control group performed only the initial, follow-up (12 weeks) and final (24 weeks) evaluations.
9685767|NCT05256173|Experimental|Melatonin Tablets|
9685768|NCT05256173|Placebo Comparator|Lactasin Tablets|
9685769|NCT05256173|Experimental|transcutaneous vagus nerve stimulation|
9685770|NCT05256173|Sham Comparator|sham transcutaneous vagus nerve stimulation|
9685771|NCT05256160|Experimental|CVS subjects|Subjects diagnosed with Cyclic Vomiting Syndrome (CVS)
9685772|NCT05256160|Active Comparator|healthy, non-CVS subjects|Subjects not diagnosed with CVS
9685773|NCT05256147|Experimental|Intervention group|There is one group in this study and they will receive ibuprofen 400 mg before their narrow band UVB phototherapy session which occurs two to three times weekly. The treatment dose of NBUVB will start off at 150 mJ/cm2 and will be increased 10% as tolerated til the patient reaches 700 mJ/cm2. They will receive ibuprofen before each phototherapy session.
9685774|NCT05256121|No Intervention|control|At 6 months and 12months the study team will communicate with the participants by phone to inquire about risk factors data, propose alternative activities, and provide positive reinforcement and feedback
9685775|NCT05256121|Experimental|intervention|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants' every 3-4 weeks by phone. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
9977710|NCT01364493|Experimental|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
9977711|NCT01364506|Experimental|Water exercise|
9977712|NCT01364506|No Intervention|Control|
9977713|NCT01364519|Experimental|Arm 1|
9685781|NCT05256095|Experimental|Immediate Assignment to Intervention Group|This group will begin to receive the intervention immediately upon entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
9695875|NCT04774393|Experimental|Arm B (decitabine/cedazuridine, venetoclax, enasidenib)|Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and enasidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
9685782|NCT05256095|Experimental|Waitlist Assignment to Intervention Group|The Waitlist group will begin to receive the intervention 10 weeks after entering the study. Thinking in Speech is a novel cognitive therapy that helps children with autism independently cope with everyday events that cause stress, by developing their ability to use inner speech. Participants will complete two sessions per week for eight week, for a total of sixteen sessions. Sessions will be conducted by speech-language pathologists who are trained in Thinking in Speech. Sessions will be conducted via a secure Zoom platform.
10179467|NCT03803215||Control untreated group|A propensity-score matched control group is generated from the large database of patients who had received an implantable loop recorder
10179468|NCT03803163|Experimental|TransCon Treprostinil|
10179469|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab Alone|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab.
10179470|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab + Tremelimumab|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab + Tremelimumab.
10179471|NCT03802838|Active Comparator|Acupuncture|Acupuncture+Amisulpride
10179472|NCT03802838|Other|Amisulpride|Amisulpride only.
9685783|NCT05256082|Active Comparator|with mask (FFP2 mask or surgical mask)|Patient is Walking with mouth/nose-mask for 6 Minutes.
9685784|NCT05256082|Placebo Comparator|without mask|Patient is Walking without mouth/nose-mask for 6 Minutes.
9685785|NCT05256069|Experimental|Hypoxia Exposure|Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
9685786|NCT05256043||Target Population|Adult patients age ≥ 18 admitted to the Stamford Hospital ICU between 9/14/11 and 11/30/19 with HbA1c available on admission and at least 4 blood glucose (BG) tests during ICU stay. Two groups were created; patients with previously undiagnosed diabetes (NDDM) compared to those with known diabetes (KDM) at the time of admission to the intensive care unit (ICU).
9685787|NCT05256030|Experimental|Control-Traditional Rehabilitation Group|"This group will receive a 6-week neurorehabilitation program that includes stretching for spasticity inhibition, strengthening of the antagonist muscle, autogenic inhibition methods, as well as conscious-unconscious balance training and gait training, which are routinely applied in physical therapy and rehabilitation units. The treatment will be applied 5 days a week.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
9685788|NCT05256030|Experimental|Study-Neurodevelopmental Therapy Group|Function-oriented Neurodevelopmental Therapy will be applied to the subjects included in the study and randomly assigned to the study group in different positions such as supine, prone, sitting, standing for 6 weeks, 5 sessions per week, and the goal will be to achieve the task at different speeds. Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
9685789|NCT05256017|Active Comparator|Acoziborole|Single dose administration of 3 tablets of 320 mg
9685790|NCT05256017|Placebo Comparator|Placebo|Single dose administration of 3 tablets of 320 mg
9685791|NCT05255991|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
9685792|NCT05255991|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
9685793|NCT05255939|Experimental|dTRA group|Investigators perform percutaneous coronary intervention by dTRA
10179473|NCT03802903|Experimental|Remo-Wax|Test product will be applied into ear canal for 20-60 minutes.
10179474|NCT03802669||caries free children aged between 3-6|
10179475|NCT03802669||caries active children aged between 3-6|
10179476|NCT03802669||caries free children aged between 6-12|
10179477|NCT03802669||caries active children aged between 6-12|
10179478|NCT03802669||caries free adult aged between 18-25|
10179479|NCT03802669||caries active adult aged between 18-25|
10179480|NCT03802682|Experimental|Treatment Sequence AB|Participants will receive a single dose of apalutamide 240 milligram (mg) (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A [reference]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B [test]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
10179481|NCT03802682|Experimental|Treatment Sequence BA|Participants will receive a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 1 (Treatment B [test]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 2 (Treatment A [reference]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
9685794|NCT05255939|Other|TRA group|Investigators perform percutaneous coronary intervention by conventional TRA
9685795|NCT05255926|Experimental|68Ga-pentixafor and 18F-FDG PET/CT|Investigators recruit patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies. Then patients undergo 68Ga-pentixafor and 18F-FDG PET/CT imaging in one week.
9685796|NCT05255913|Experimental|group 1|
9685797|NCT05255913|Active Comparator|group 2|
9695876|NCT04773171|Experimental|CACR Group|Participants of CACR group will attend individual computer-assisted cognitive remediation sessions. Researcher will give instruction in the use of the computerized training programs and assists participants during their training sessions.
9977714|NCT01364519|Placebo Comparator|Arm 2|
10179482|NCT03802708|Other|control|control
9685798|NCT05255874|Experimental|Aromatherapy Group|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
9685799|NCT05255874|No Intervention|Standard of care|Routine treatment and care interventions will be applied to the patients included in the control group during the procedure. Patients in the control group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level.
9685800|NCT05255848|Experimental|Intervention|Heparin sodium will be administered as a nebulised aerosol dose of 5000 IU heparin three times a day (TDS) via an ai compressor nebuliser plus standard of care treatment
9685801|NCT05255848|No Intervention|No Intervention|Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin
9685802|NCT05255835|Active Comparator|Semiconductor knee-sleeves|Knee-sleeves containing semiconductor elements within the fabric constitute the intervention arm.
9685803|NCT05255835|Placebo Comparator|Placebo knee-sleeves|Cotton knee-sleeves constitute the placebo arm.
9685804|NCT05255796|Experimental|one-piece|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
9685805|NCT05255796|Experimental|plate-haptic|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
9685806|NCT05255783|Other|Critically ill adults requiring insulin|Patients admitted to the intensive care unit requiring insulin infusion to maintain blood glucose within target range
9685807|NCT05255770|Experimental|Test condom A (NRL condom with 5% benzocaine paste)|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
9685808|NCT05255770|Experimental|Test condom B (NRL condom with 3% benzocaine paste)|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
9685809|NCT05255770|Active Comparator|Control NRL condom|Following randomisation each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
9685810|NCT05255757|No Intervention|Control Group|This group will only complete study survey and refer members of their family and social network for participation in a web survey.
9685811|NCT05255757|Experimental|Rhetorical Intervention|This group will complete the survey, refer members of their family and social network for participation in a web survey, and review a set of suggested talking points and an example script to guide discussion of potential living donation with members of their network.
9685812|NCT05255757|Experimental|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
9685813|NCT05240976|Experimental|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
9685814|NCT05240976|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
9685815|NCT05238831|Experimental|Treatment (SMMART-ACT)|"PRE-SCREENING: Patients undergo a screening biopsy and blood collection to assess their tumor. Clinical assays may be used to provide an individualized treatment which may or may not include a SMMART-ACT treatment regimen.~SMMART-ACT TREATMENT: Prior to enrollment, patients must receive a recommendation of one or more SMMART-ACT treatment regimens based on the SMMART-CAP clinical assays. Treatment may be administered alone or as part of a combination. For specific treatment recommendations, a monotherapy lead-in may be considered for up to 4 weeks which proceeds to a combination therapy. After about 2 weeks of single agent, participants undergo an on-study tumor biopsy. All other patients have the option to undergo a repeat biopsy during treatment. Treatment cycles repeat every 21 to 28 days in the absence of disease progression or unacceptable toxicity. Cycles are based on the study agent(s). At disease progression, patients have the option to undergo an additional biopsy."
9685816|NCT05232942||Studied group|The study population will consist of patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (galcanezumab, fremanezumab or eptinezumab) or else its receptor (erenumab), with positive response, and discontinue the treatment.
9685817|NCT05232669|Active Comparator|Cocoa extract + multivitamin|
9685818|NCT05232669|Active Comparator|Cocoa extract + multivitamin placebo|
9685819|NCT05232669|Active Comparator|Cocoa extract placebo + multivitamin|
9685820|NCT05232669|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
9685821|NCT05231941|Experimental|Lidocaine Group|After induction of anaesthesia, a bolus of 2mg/kg intravenous lidocaine will be given followed by Lidocaine infusion at the rate of 1.5 mg/kg/hour which will be stopped at the end of surgery.
9695877|NCT04773171|Active Comparator|TAU Group|Participants of TAU group will attend usual training sessions offered by the training centres with similar intensity and frequency as the CACR training.
9695878|NCT04773548|Experimental|VR-JIT|
10179483|NCT03802929||Derivation Cohort|"Derivation Cohort of Diagnostic Prediction Model:~Participants will be recruited from the emergency department of five general urban hospitals in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; from March 1, 2019. The investigators will randomly assign 70% participants to a derivation cohort.~Derivation Cohort of Prognostic Prediction Model:~Patients with VTE from 5 thrombosis centers in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; between January 2014 and December 2018."
10179484|NCT03802929||Validation Cohort|"Validation Cohort of Diagnostic Prediction Model:~The investigators plan to randomly assign 30% participants for developing the diagnostic prediction model to a Validation cohort.~Validation Cohort of Prognostic Prediction Model:~New individuals selected by the same inclusion and exclusion criteria as the derivation cohort of prognostic prediction model from the same institutions as a validation cohort of prognostic prediction model will be recruited from January 2019."
10179485|NCT03802617|Experimental|MR13A9 low dose|
10179486|NCT03802617|Experimental|MR13A9 medium dose|
9685822|NCT05231941|Experimental|TAP group|After completion of procedure and before extubation, bilateral ultrasound guided subcoastal transversus abdominis plane (TAP) block will be performed by the primary anaesthetist. After taking aseptic measures, with patient in supine position a high frequency (6-13 MHz) linear ultrasound probe will be placed obliquely just inferior to the costal margin over the anterior abdominal wall. With the help of a 21G or 22G, 100 mm needle, 20 ml of 0.375% Ropivacaine will be injected between rectus sheath and fascia of transversus abdominis muscle, bilaterally.
9685823|NCT05231941|No Intervention|Control group|No additional intervention will be given to this group
9685824|NCT05231590|Other|Children Aged 5 to <12 Years|
9685825|NCT05231590|Other|Children Aged 12 to <18 Years|
9685826|NCT05231590|Other|Adults Aged 18 to 40 Years|
9685827|NCT05231096|Experimental|Group A: SRD & Gingival massage with Aloe-vera gel.|Group A: Scaling and Root Debridement & Gingival massage with Aloe-vera gel.
9685828|NCT05231096|Experimental|Group B: SRD & Gingival massage with Sidr honey|Group B: Scaling and Root Debridement & Gingival massage with Sidr honey
9685829|NCT05231096|Other|Group C SRD only.|Group C Scaling and Root Debridement only.
9685830|NCT05231070|Experimental|TeleSPC|Patients will be offered regular multidisciplinary video consultations with the SPC team and these patients and their relatives will also be offered a dyadic psychological intervention.
9685831|NCT05231070|No Intervention|Control|Patients will follow the current practice in the healthcare system (standard care). Control patients will be offered information to clarify the options available in case of unmet palliative needs. Patients' relatives will be invited to participate in the study, but no intervention will be offered.
9685832|NCT05224739||Patients who underwent MILR from January 1, 2000 to December 31, 2020|Hospital of patients who underwent MILR from January 1, 2000 to December 31, 2020.
9685833|NCT05222984|Experimental|Treatment (navitoclax, venetoclax, decitabine)|Patients receive venetoclax PO QD and navitoclax PO QD on days 1-35, and decitabine IV over 1 hour on days 8-12 of cycle 1. Starting on cycle 2, patients receive venetoclax PO QD and navitoclax PO QD on days 1-28, and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9685834|NCT05219019||PD patients who have elected DBS|Ten individuals with moderate to advanced Parkinson's disease who have elected to undergo deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal globus pallidus (GPi) as standard of care for management of Parkinson's disease tremor and/or motor complications
10179487|NCT03802617|Experimental|MR13A9 high dose|
10179488|NCT03802617|Placebo Comparator|Placebo|
9685837|NCT05217745|Experimental|Treatment|MLCT oil (provided through ready to eat meals and snacks)
9685838|NCT05217745|Placebo Comparator|Control|Corn oil (provided through ready to eat meals and snacks)
9685839|NCT05216575||Almitrine treated patients|Administration of Almitrine in spontaneoulsy breathing COVID-19 patients with moderate to severe ARDS treated by high-flow nasal canula oxygen therapy as first-line ventilatory support with persitent severe hypoxemia after awake prone positioning.
9685840|NCT05214417|Experimental|KAP (Ketamine-assisted Psychotherapy) Recipients|Two separate IM ketamine injection sessions, with possible multiple doses administered at each session not to exceed 100 mg IM ketamine total for the session.
9685841|NCT05214417|Other|Naturalistic Comparator|Pre-existing conventional treatment will continue for this group during the study period.
9685842|NCT05213078|Experimental|Supportive Care (teaching intervention, questionnaire)|Participants attend 2 teaching sessions with a research nurse. Participants also complete questionnaires at baseline, 3, and 7 weeks.
10179489|NCT03802734|Experimental|Mindful Meditation App|Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.
10179490|NCT03802734|No Intervention|No Meditation App|Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.
10179491|NCT03802578|Experimental|EXERCISE GROUP|Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises (Hand exercise), of 30 minutes duration daily, for 12 weeks in addition to medical care.
9685843|NCT05208866|Experimental|Lixivaptan|Lixivaptan capsules 100 - 200mg twice daily
9685844|NCT05205252|Active Comparator|Arm 1-Tazmetostat plus CD19 Ab (tafasitamab-cxix) lenalidomide in subjects with R/R DLBCL|Tazemetostat- Orally, twice daily in continuous 28-day cycles CD-19 Ab (tafasitamab-cxix)/12 mg/kg- IV, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle. Lenalidomide -10 mg or 20 mg based on kidney function- Orally, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles
9977715|NCT01364532|Experimental|Transulnar arterial access|Transulnar arterial access for coronary angiography, ad-hoc or elective PCI
10179492|NCT03802578|No Intervention|CONTROL GROUP|Patients in the control group continued their usual medical care.
9685845|NCT05205252|Active Comparator|Arm 2 -Tazemetostat plus lenalidomide in subjects with R/R DLBCL|Tazemetostat- Orally, twice daily in continuous 28-day cycles Lenalidomide-10 mg or 20 mg based on kidney function- Orally, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles
9685846|NCT05205252|Active Comparator|Arm 3 -Tazemetostat plus Bruton tyrosine kinase inhibitor in subjects with R/R mantle cell lymphoma|Tazemetostat- Orally, twice daily in continuous 28-day cycles BTKi (acalabrutinib)- 100 mg- Orally, twice daily
9685847|NCT05205252|Active Comparator|Arm 4- Taz plus Daratumumab/ pomalidomide/ dexamethasone in subjects with R/R multiple myeloma.|"Tazemetostat- Orally, twice daily in continuous 28-day cycles Daratumumab (IV) or daratumumab and hyaluronidase-fihj (subcutaneous)~Daratumumab IV 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.~Daratumumab 1,800 mg and hyaluronidase-fihj 30,000 units subcutaneous once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.~Pomalidomide 4 mg Orally, once daily on Days 1-21 of continuous 28-day cycles~Dexamethasone 20 mg or 40 mg Orally, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles"
10179493|NCT03802656|Experimental|Anterior Vertebral Body Tethering|Subjects who will be undergoing the anterior vertebral body tethering surgery.
9685848|NCT05200104|Experimental|PXL065|PXL065 22.5 mg QD
10187440|NCT03726216||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in France
9685849|NCT05199506|Experimental|Each leg/buttock will be treated with the RAP device|Each leg will be treated with standard RAP treatment settings.One leg will receive treatments with 100Hz and the other with 50hz
9685850|NCT05199350||Population including people with NGT, IFG and IGT and diabetes.|"Normal Glucose Tolerance (NGT) is defined as a plasma glucose concentration i.e < 140 mg/dl.~IFG is defined by an elevated fasting plasma glucose (FPG) concentration i.e ≥ 100 and < 126 mg/dl.~IGT is defined by an elevated post-prandial plasma glucose concentration i.e ≥140 and < 200 mg/dl.~Presence of confirmed diabetes (HbA1c level > 6.4 %) without complications i.e no neuropathy, no retinopathy, no nephropathy etc.~Presence of confirmed diabetes (HbA1c level > 6.4 %) with at least one of the above complications."
9685851|NCT05198700|Experimental|Experimental Group|Participants in this group will be randomized to receive the probiotic formulation for 4 weeks.
9685852|NCT05198700|Placebo Comparator|Control Group|Participants in this group will be randomized to receive the placebo for 4 weeks.
9685853|NCT05197842|Experimental|Group A|BDB-001 injection low dose plus reduced dose glucocorticoids in combination with cyclophosphamide
9685854|NCT05197842|Experimental|Group B|BDB-001 injection high dose plus reduced dose glucocorticoids in combination with cyclophosphamide
9685855|NCT05197842|Active Comparator|Group C|Standard dose glucocorticoids in combination with cyclophosphamide
9685856|NCT05194267|Experimental|Active tDCS|Will be receiving active intensive tDCS treatment
9976172|NCT01348841|Experimental|Intervention Arm|"Systematic referral to MDWCT and comprehensive primary care:~Intervention consists of systematic referral to MDWCT in conjunction with comprehensive primary care.Systematic referral to, and follow up, by MDWCTs, co-ordinated by the CM, will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4."
9976173|NCT01348867|No Intervention|Usual Care|These 120 controls will undergo a comprehensive assessment at baseline then again at 12 months, which is similar to the intervention group. However, in between these 2 time points the 'control' patients will receive usual care and hence will not be monitored under the structured care protocol by a diabetes nurse consultant led team.
9685859|NCT05189730|Experimental|Total neoadjuvant therapy|The patients would receive neoadjuvant chemoradiotherapy treatment firstly. And then evaluated efficacy according to RECIST 1.1. If patients with cCR would receive surgery treatment after 4-6 weeks. After surgery, patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy alone treatment. If patients evaluated as PD, they would receive new treatment regimen after MDT discussed. Other patients with PR and SD would receive 2 cycles of neoadjuvant immunochemotherapy. And then, Efficacy of immunochemotherapy would be evaluated according to RECIST 1.1. For patients suitable for surgery, surgery should be performed after 4-6 weeks of immunotherapy. After surgery, the patients with R0 resection would divided into two groups, if patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy treatment. Other patients without R0 resection would receive new treatment regimen after MDT discussed.
9685860|NCT05184257||Study Drugs|The study drug is Zoladex® 10.8 mg. The maximum observation time window for effectiveness analysis is 28 (24+4) weeks.
9685861|NCT05184257||Comparison Drugs|The comparison drug is Zoladex® 3.6 mg. The maximum observation time window for effectiveness analysis is 28 (24+4) weeks.
9685862|NCT05183243|Experimental|Monotherapy Dose Escalation.|Treatment with GH21 alone, conducted until disease progression, intolerance or end of study.
9695879|NCT04773392|Active Comparator|Twice-daily Regimen|Twice-daily regimen of immediate release tacrolimus, mycophenolate mofetil (MMF)/mycophenolic acid (MPA) plus daily methylprednisolone or prednisone.
9695880|NCT04773392|Active Comparator|Once-daily Regimen|Once-daily regimen of Envarsus, azathioprine plus methylprednisolone or prednisone.
9695881|NCT04773132|Experimental|Low Protein Diet|All subjects will be given a low protein/protein-free diet in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
9977716|NCT01364532|Active Comparator|Transradial arterial access|Transradial arterial access for coronary angiography, ad-hoc or elective PCI
9977717|NCT01364545|Other|Ketone ester drink Vs placebo drink|Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
9977718|NCT01364571|Experimental|1|SA4Ag vaccine low dose
9977719|NCT01364571|Experimental|2|SA4Ag vaccine mid dose
10187441|NCT03726203|Experimental|trocars of type MiniLap|Patients benefiting from the use of trocars of type MiniLap of Teleflex during the realization of their coelioscopy scheduled in ambulatory
9977720|NCT01364571|Experimental|3|SA4Ag vaccine high dose
9685863|NCT05179369|No Intervention|Standard Care|Participants randomized to standard care will be offered prenatal and postpartum care in accordance with site-specific procedures based on AAP and ACOG Guidelines for Perinatal Care. The initial intake appointment, involving a comprehensive visit with physical exam, medical and psychosocial history, laboratory testing, and education would optimally occur in the 1st trimester. Subsequent prenatal visits, per ACOG, is monthly for the first 28 weeks, biweekly for weeks 28-36, and weekly after 36 weeks. More frequent visits may be offered to women at high risk. In addition, some sites may offer supports such as nutritional counseling, childbirth education, and case management. A comprehensive postpartum care visit would typically occur within the first 6 weeks of birth, involving a physical examination, lab tests, and immunizations.
9685864|NCT05179369|Experimental|Standard Care with Well-Mama Intervention|Participants will receive standard perinatal care plus the Well Mama intervention, including the Well Mama Checklist, assistance from a Community Doula Navigator, and virtual support groups.
9685865|NCT05179200|Experimental|"Group 1: Frequent plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis three times every 2 weeks for 16 weeks.
9685866|NCT05179200|Active Comparator|"Group 2: Regular plasma donors"|Donors will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis once every 14 days for 16 weeks.
9685867|NCT05179200|Placebo Comparator|"Group 3: Regular whole blood donors"|Donors will donate 450 ml (405-495 ml) whole blood every 3 months for 16 weeks.
9685868|NCT05178927|Sham Comparator|Standard of Care-Group 1|"During treatments 1-5, radiation therapists will position the participant for treatment using the standard of care method.~During treatments 6-10, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method."
9685869|NCT05178927|Experimental|Mixed-reality guided patient setup-Group 2|"During treatments 1-5, radiation therapists will use the hologram the investigators created to initially position the participant for treatment. The participant's final position will be obtained using a standard of care method.~During treatments 6-10, radiation therapists will position the participant for treatment using the standard of care method."
9685870|NCT05178706||non-operative conservative treatment|"9 individuals diagnosed with FSHD who have not undergone unilateral or bilateral surgery who meet the inclusion criteria.~application of determined outcome scales and rehabilitation program on patients"
9685871|NCT05178706||scapulothoracic arthrodesis|"9 individuals diagnosed with FSHD who have undergone bilateral surgery who meet the inclusion criteria.~application of determined outcome scales and rehabilitation program on patients"
9685872|NCT05178706||healthy control|18 participants for measuring the normative datas; application of determined outcome scales
9685873|NCT05170984|Experimental|CACIPLIQ20®|
9685874|NCT05168709|Experimental|Approved COVID-19 vaccination|The approved COVID-19 vaccination arm will receive the COMIRNATY™ (tozinameran - BNT162b2 [mRNA]) COVID-19 VACCINE. The dose, strength of the dose unit, dosing interval and dosing period of tozinameran used in this trial will be as approved by the Therapeutic Goods Administration (TGA) and recommended by the Australian Technical Advisory Group on Immunisation (ATAGI) for children aged 5 to <12 years of age. The recommended dose of tozinameran for this age group is 10 µg (0.2 mL) and the recommended schedule is 2 doses, 8 weeks apart. Therefore two tozinameran doses of 10µg (0.2 mL) will be administered intramuscularly 8-weeks apart as part of this arm of the trial.
9685875|NCT05165264||Cohort 1|Participants with previously untreated advanced or metastatic gastric cancer (GC), gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma (EAC)
9685876|NCT05163184||Laparotomy|Patients undergoing laparotomy
9685877|NCT05163106|Experimental|Ribociclib and Letrozole Arm|Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months. Premenopausal women will also receive treatment with goserelin 3.6 mg s.c. every 4 weeks.
9685878|NCT05158257|Active Comparator|Intervention: balloon and Stents|plain balloon and Stents group
9685879|NCT05158257|Experimental|Intervention: debulking and drug coated balloon|debulking and drug coated balloon group
9685880|NCT05155319|Active Comparator|Cohort 1, 1A|Low dose (Day 1) plus placebo (Day 22)
9685881|NCT05155319|Active Comparator|Cohort 1, 1B|Low dose (Day 1) plus low dose (Day 22)
9685882|NCT05155319|Placebo Comparator|Cohort 1, 1C|Placebo (Day 1) plus Placebo (Day 22)
9685883|NCT05155319|Active Comparator|Cohort 2, 2A|High dose (Day 1) plus placebo (Day 22)
9685884|NCT05155319|Active Comparator|Cohort 2, 2B|High dose (Day 1) plus high dose (Day 22)
9685885|NCT05155319|Placebo Comparator|Cohort 2, 2C|Placebo (Day 1) plus Placebo (Day 22)
9685886|NCT05154123|Experimental|AT-527 + rosuvastatin (simultaneous) n=14|
10179494|NCT03802448|Active Comparator|Control group|"composed of fifteen pregnant women who only wore a natural wrist splint during sleeping for 4 weeks.~A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping"
9685887|NCT05154123|Experimental|AT-527 + rosuvastatin (staggered) n=14|
9685888|NCT05151133|Experimental|Low dose UCMSCs|
9685889|NCT05151133|Experimental|Moderate dose UCMSCs|
9685890|NCT05151133|Experimental|High dose UCMSCs|
9685891|NCT05147506|Experimental|CBT DTx|Participants randomized to active intervention will access a structured, cognitive behavioral therapy (CBT) intervention.
9685892|NCT05147506|Active Comparator|Psychoeducations DTx|Participants randomized to the comparison group will access an unstructured educational DTx.
9685893|NCT05146284|Experimental|PXL770 500 mg QD|
9685894|NCT05146284|Experimental|PXL770 250 mg BID|
9685895|NCT05143255|Experimental|KNOW Intervention|
9685896|NCT05139251|Experimental|Recovering from Intimate partner violence through Strengths and Empowerment (RISE) +ePALS|
9685897|NCT05136092|Experimental|Cohort 1: HFCS (fructose-fed)|"Day Before Surgery between 09:00 pm and 10:00 pm~Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between 09:00 pm and 10:00 pm. Subjects will be reminded the day before the surgery to drink the solution."
9685898|NCT05136092|Experimental|Cohort 2: D-Xylose (xylose-fed)|"Day Before Surgery between 09:00 pm and 10:00 pm~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between 09:00 pm and 10:00 pm. Subjects will be reminded the day before the surgery to drink the solution."
10179495|NCT03802448|Experimental|Study group|"a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
10179496|NCT03802396|Experimental|CN-105|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
10179497|NCT03802396|Placebo Comparator|Placebo|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
9685899|NCT05119959|Experimental|Arm 1- CHEU + ECD intervention|Participants randomized to this arm will receive a bi-weekly community health worker-delivered ECD intervention for CHEUs
9685900|NCT05119959|Active Comparator|Arm 2- CHEU without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
10179498|NCT03802331|Experimental|Test Treatment|fed
9685901|NCT05119959|Active Comparator|Arm 3- HIV Unexposed (HUU) without ECD intervention|Participants randomized to this arm will receive the current Ministry of Health (MoH) standard of care with no formalized routine assessment of neurodevelopment.
10179499|NCT03802331|Experimental|Reference Treatment|fasted
10179500|NCT03802461|Active Comparator|Fecal Microbiota Transplantation (FMT)|Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.
10179501|NCT03802461|No Intervention|Standard of Care|Patients in this arm will not receive intervention and will be on standard of care .
10179502|NCT03802552|Experimental|Cefadroxil then Cephalexin|Receive cefadroxil first, then receive cephalexin after washout.
9685906|NCT05089656|Experimental|OAV101|Administered as a single, one-time intrathecal dose
9685907|NCT05089656|Sham Comparator|Sham control|A skin prick in the lumbar region without any medication.
9685908|NCT05085288|Active Comparator|Intermittent electrical stimulation system (IES) treatment Group|Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10 seconds every 10 minutes.
9685909|NCT05085288|Active Comparator|Standard of care Group|Turning the patient every two hours as per standard inpatient nursing practice and any other wound care or plastic surgery treatments deemed appropriate as per usual care.
9685910|NCT05076266||Women Who Decline TMIST|Women who decline TMIST will be asked to fill out a survey with questions about demographics, income and employment, attitudes and experiences about COVID-19, and emotional well-being.
9685911|NCT05074693|Experimental|EASE App|EASE is a intervention designed to address anxiety and depression symptoms in its users through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress.
9685912|NCT05074693|Other|INSIGHT (Control) APP|The Insight app provides users with educational videos on mindfulness and meditation techniques.
9685913|NCT05048264|Active Comparator|Kenalog 40 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Kenalog in the index shoulder.
9685914|NCT05048264|Active Comparator|Dexamethasone 4 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 4 mg corticosteroid injection of Dexamethasone in the index shoulder.
9685915|NCT05048264|Active Comparator|Celestone 6 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 6 mg corticosteroid injection of Celestone in the index shoulder.
9685916|NCT05048264|Active Comparator|Depo-medrol 40 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Depo-Medrol in the index shoulder.
9685917|NCT05028608|Experimental|Period 1|Fixed treatment sequence starting with 2 single oral doses of midazolam and a single dose of elinzanetant.
9685918|NCT05028608|Experimental|Period 2|Up titration of carbamazepine over 4 days (dose 1, 2, 3) continued by fixed dose 3 of carbamazepine prior to administration of midazolam / elinzanetant, followed by carbamazepine administration.
9695882|NCT04773223||Open surgery group|Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm
10179503|NCT03802552|Experimental|Cephalexin then Cefadroxil|Receive cephalexin first, then receive cefadroxil after washout.
10179504|NCT03802357|Experimental|High training intensity|Exercise Training with high intensities consists of a cycling Interval Training at 100% of the individual Peak work rate, resistance Training for 3 sets à 8 repetitions and squats on a Vibration plate.
10179505|NCT03802357|Active Comparator|moderate training intensity|Exercise Training with moderate intensities consists of a cycling endurance Training at 60% of the individual Peak work rate, resistance Training for 3 sets à 20 repetitions and squats on the floor.
10179506|NCT03802786|Experimental|Moderate hepatic impairment|Single dose of Imeglimin
10179507|NCT03802786|Experimental|Normal hepatic function|Single dose of Imeglimin
10179508|NCT03802526|Experimental|NVP-1805-R1|"Drug: NVP-1805-R1~1 tablet, oral dosing"
10179509|NCT03802526|Experimental|NVP-1805-R2|"Drug: NVP-1805-R2~1 tablet, oral dosing"
10179510|NCT03802526|Experimental|NVP-1805-R1 and NVP-1805-R2|Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)
10179511|NCT03802318|Experimental|HDDT group|high dose PPI induction (oral rabeprazole 20mg qid) for 3 days, then 14 days combined with amoxicillin (regular dose, daily 2 g, 500mg qid) for high frequency dual therapy.
9685919|NCT05024812|Experimental|Experimental|fruquintinib + toripalimab + SOX
9685920|NCT05022355||scapulothoracic arthrodesis|"Individuals diagnosed with FSHD who have undergone unilateral or bilateral surgery who meet the inclusion criteria.~application of determined outcome scales on patients"
9685921|NCT05022355||non-operative|"Participants diagnosed with FSHD who have not undergone any surgery, who meet the inclusion criteria.~application of determined outcome scales on patients"
9685922|NCT05020899|Experimental|Quit for Life group|Participants randomized to this arm will receive a 8 week quit smoking program delivered by trained counselors and messages to their cell phones. Participants will also be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
9685923|NCT05020899|Active Comparator|Control group|Participants randomized to this arm will be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
9685924|NCT05012163|Experimental|Pennsylvania (PA) Lottery Scratch-Off Financial Incentive|"Participants in this arm will receive a message stating that they will receive a PA lottery $1 scratch-off ticket if they get a flu shot at an upcoming appointment. The message will mention that they could win $5,000 (the top prize for the scratch-off game).~Note: $1 scratch-off products vary over time; at study implementation, an active game with top prize of $5,000 (or the next-highest top prize) will be selected and will define the prize in the raffle absent upfront odds"
9685925|NCT05012163|Experimental|Certain Cash Payout Financial Incentive|Participants in this arm will receive a message stating that they will receive $1 in cash if they get a flu shot at an upcoming appointment.
9685926|NCT05012163|Experimental|Reminder / Active Control (No Financial Incentive)|Participants in this arm will receive a message stating that they can get a flu shot at an upcoming appointment. These participants will not be offered a financial incentive for getting a flu shot.
9685927|NCT05012163|No Intervention|No Treatment Control|No additional contact beyond standard Geisinger flu shot communications
9685928|NCT04984317|Experimental|Botox Injection|One-time injection of 100U BOTOX (onabotulinumtoxin A) into the fundus of the bladder under direct visualization via cystoscopy.
9685929|NCT04982250|Experimental|"formal peer PrEP referral + HIVST delivery"|After a brief training, young female PrEP users are encouraged to refer 4 peers using PrEP educational materials and HIVST kits (2 kits/peer = 8 kits total).
9685930|NCT04982250|No Intervention|"informal peer PrEP referral"|After a brief training, young female PrEP users will be encouraged to refer 4 peers to PrEP using word-of-mouth, the current standard-of-care with PrEP delivery in Kenya.
9685931|NCT04981847|Experimental|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
9685932|NCT04981847|Experimental|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern. There is also less calcium and vitamin D because it includes fewer dairy foods.
10179512|NCT03802318|Placebo Comparator|CATT group|conventional triple therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
10179513|NCT03802318|Experimental|LHDT group|high dose PPI (oral rabeprazole 20mg qid) induction for 3 days, then Rabeprazole 20 mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 14 days.
9685933|NCT04981847|Experimental|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
9685934|NCT04962646|Experimental|Intervention|Once the thoracic cavity os opened during surgery, carbon dioxide flooding using a diffusor will be instigated with a flow of 5L/min. The flooding will be terminated once the aorta and the heart have no open contact with surrounding air.
9685935|NCT04962646|No Intervention|Control|No intervention. No sham will be used as the staff performing the surgery would have been able to detect the lack of carbon dioxide in the surgical wound.
9685936|NCT04936997|Experimental|3rd COVID-19 vaccine (2nd booster)|Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
9685937|NCT04881968|No Intervention|Control: Usual Care|The control arm occurs prior to receipt of the video game intervention and reflects usual care. Each hospitalist 'crosses over' from control to intervention at a single time point.
10179514|NCT03802318|Placebo Comparator|LATT group|levofloxacin base rescue therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, levofloxacin 500 mg qd)
10179515|NCT03802422|Experimental|Vitamin B12 hydrodissection|Ultrasound-guided hydrodissection with Vitamin B12 between carpal tunnel and median nerve.
10179516|NCT03802422|Placebo Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
10179517|NCT03802513|Other|Single arm|This study has 1 health-related intervention. Veterans with somatosensory tinnitus will receive individualized physiotherapy.
10179518|NCT03802370|Other|single am|single arm , superiority trial , tunneling technique in connective tissue graft around dental implants
9685938|NCT04881968|Experimental|Video Game Intervention|Each hospitalist 'crosses over' from control to intervention at a single time point by receiving a link to the Hopewell Hospitalist game via email and logging in to play the video game.
9695883|NCT04773223||Endovascular group|Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc.
9695884|NCT04774367|Other|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|
9695885|NCT04774367|Other|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|
10179519|NCT03802760||TAVI patients|Patients undergoing transfemoral TAVI
10179520|NCT03802760||MitraClip patients|Patients undergoing MitraClip implantation
10179521|NCT03802760||TricuspidalClip|Patients undergoing TricuspidalClip implantation
10179522|NCT03802292|Active Comparator|Single Ascending Dose YQ23|
10179523|NCT03802292|Placebo Comparator|Single Dose Placebo|
10179524|NCT03802539|Experimental|Glass Liner|Tooth restoration with a glass ionomer liner material under a nanohybrid composite resin
10179525|NCT03802539|No Intervention|No liner|Tooth restoration without a glass ionomer liner material under a nanohybrid composite resin
10179526|NCT03802253|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
10179527|NCT03802253|Active Comparator|RCD|Participants in this group will focus on standard care with daily reduced calorie diet (RCD)
10179528|NCT03802006||fasted patient with previous gastrectomy|The fasted patient with previous subtotal gastrectomy except exclusion criteria are included
10179529|NCT03802071|Experimental|Durvalumab+doxorubicin combination|
10179530|NCT03802136||high concentration of biomarkers|the patients with biomarkers level over the normal max value
10179531|NCT03802136||low concentration of biomarkers|the patients with biomarkers level below the normal max value
10179532|NCT03802149|Experimental|Ulipristal Acetate|Participants will be administered a one time dose of 90mg ulipristal acetate 18-24-hours prior to dilation and evacuation (surgical abortion) for cervical preparation.
10179533|NCT03802279||Rhabdomyolysis with myoblasts back up|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited from a diagnostically muscle biopsy and whose myoblasts are available.~Patients benefit from an effort test as part of their care."
10179534|NCT03802279||Rhabdomyolysis|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited or not from a diagnostically muscle biopsy but whose myoblasts are not available.~Patients benefit from an effort test as part of their care."
10179535|NCT03802279||Witness patients : effort test|10 patient-matched healthy controls for age and sex having performed an effort test and cardiac exploration as part of their care.
10179536|NCT03802279||Witness patients : myoblasts|6 healthy controls matched by age and sex having performed a muscle biopsy as part of their care and whose myoblasts are kept.
10179537|NCT03802032|Experimental|Study Group|15g of Topical Xylocaine gel
10179538|NCT03802032|Placebo Comparator|Control group|15g of KY Jelly
10179539|NCT03801954||RC Patients|Patients at the University of Kansas Medical Center who have not yet had their radical cystectomy, after their radical cystectomy, or between the completion of chemotherapy and the radical cystectomy.
10179540|NCT03801967|Experimental|AZD9977|Each participant will receive AZD9977 at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
10179541|NCT03801967|Placebo Comparator|Placebo|Each participant will receive placebo at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
10179542|NCT03802058|Experimental|Nab-paclitaxel|Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy
10179543|NCT03802214||vedolizumab-UC-naïve to TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy
10179544|NCT03802214||vedolizumab-UC- previous TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure
10179545|NCT03802266|Experimental|Electromagnetic Navigation group|Electromagnetic Navigation Guided Transthoracic Needle Aspiration
10179546|NCT03802266|Active Comparator|CT group|CT-guided Transthoracic Needle Aspiration
10179547|NCT03802084|Experimental|vactosertib/imatinib combination|
10179548|NCT03802162|Experimental|CKD-355A|
10179549|NCT03802162|Experimental|CKD-355B|
10179550|NCT03802162|Active Comparator|D797, D324|
10179551|NCT03801980|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
10179552|NCT03801980|Placebo Comparator|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
10179553|NCT03801889|Experimental|Cohort 1|SP-420 initially at 28 mg/kg
9977721|NCT01364571|Placebo Comparator|4|Placebo
10179554|NCT03801889|Experimental|Cohort 2|SP -20 initially at 56 mg/kg
10179555|NCT03801889|Experimental|Cohort 3|SP-420 initially at 84 mg/kg
10179556|NCT03802045|Experimental|Low frequency EA|"25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 2Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm)."
10179557|NCT03802045|Experimental|High frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
9685939|NCT04873596|Active Comparator|nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
9685940|NCT04873596|Active Comparator|nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam diluted in normal saline (0.9%) solution till total volume of nebulized solution will become 5 ml and will be nebulized by a standard hospital jet nebulizer via mouthpiece, with a continuous flow of 100% oxygen at 6 L/min. for 15 minutes, and the treatment will be stopped when the nebulizer will be began to sputter.
9685941|NCT04854434|Experimental|Arm A: Selinexor 80 mg|Participants will receive a single dose of 80 milligrams (mg) of selinexor once weekly (QW) (4 oral tablets of 20 mg each) on Day 1 of each week (days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) until progressive disease (PD), intolerable toxicity, or withdrawal from the study.
10179558|NCT03802045|Experimental|Alternating frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz and 2Hz for 3 seconds each; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
10187442|NCT03726203|Active Comparator|trocars classics|Patients benefiting from the use of trocats classics during the realization of their coelioscopy scheduled(programmed) in ambulatory.
10187443|NCT03726190||OLLIF|Patients who underwent Oblique Lateral Lumbar Interbody Fusion
9685942|NCT04854434|Experimental|Arm B: Selinexor 80 mg and Pembrolizumab 400 mg|Participants will receive a single dose of 80 mg of selinexor tablets QW (4 oral tablets of 20 mg each) of selinexor oral tablets QW on Day 1 of each week (days 1, 8, 15, 22, 29, and 36) in combination with pembrolizumab 400 mg intravenously (IV) once every 6 weeks of each 42-day cycle until PD, intolerable toxicity, or withdrawal from the study.
9685943|NCT04854434|Active Comparator|Arm C: Standard of care (SOC)|Participants will receive combination of trifluridine and tipiracil 35 milligrams per square meter (mg/m^2) per dose (15 mg tablet + 20 mg tablet) as oral tablets twice daily (BID) (maximum 80 mg allowed per dose) as SOC on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until PD, intolerable toxicity, or withdrawal from the study.
9685944|NCT04851899|Experimental|Low dose Phaeosol group|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 440mg/day look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant
9685945|NCT04851899|Experimental|High dose Phaeosol group|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant
9685946|NCT04851899|Placebo Comparator|Placebo group|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day containing Microcellulose (look like capsule of natural stimulant)
9685947|NCT04849520|Experimental|High flow|Application of high flow nasal cannula during apnea
9685948|NCT04849520|Active Comparator|Buccal|Application of buccal oxygenation during apnea
9685949|NCT04824183|Experimental|Music intervention|Music intervention that begins with patient education on WhatsApp will be delivered to participants 3 times within 48 hours before surgery followed by face-to-face monitoring of intervention usage.
9685950|NCT04824183|No Intervention|Usual care|Participants in the control group will receive preoperative pain education via a one-on-one WhatsApp chat. The pain education will focus mainly on the type of pain to expect after surgery, how to report pain and how to request pain medication. MI will not be introduced to the participants in this group neither will there be any phone call for psychological support. Other preoperative care and postoperative care will be provided according to the hospital and ward practices.
9685951|NCT04819334|Placebo Comparator|Commercially Available Sports Drink A|A commercially available flavored electrolyte solution, The Coca-Cola Company
9685952|NCT04819334|Experimental|Commercially Available Sports Drink B|A commercially available flavored electrolyte solution, PepsiCo
9685953|NCT04819334|Experimental|Commercially Available Sports Drink A with added Amino Acids|he same as sports drink A above (a commercially available flavored electrolyte solution, The Coca-Cola Company), but with the addition of a small amount of amino acids (~2.6 g/100 ml).
9685954|NCT04814108|Experimental|ZN-c3 Single Agent|
9685955|NCT04802096|Experimental|Inspiratory muscle training combined pulmonary rehabilitation|
9685956|NCT04802096|Sham Comparator|Sham inspiratory muscle training combined pulmonary rehabilitation|
9685957|NCT04799665||All Participants|
9685958|NCT04795336|Active Comparator|Knee cohort|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
9685959|NCT04795336|Placebo Comparator|Knee cohort control|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
9685960|NCT04795336|Active Comparator|Hip cohort|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
9685961|NCT04795336|Placebo Comparator|Hip cohort control|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
9695886|NCT04773444|Experimental|Eccentric cycling training|Moderate intensity cycling training in eccentric type
9685962|NCT04790968|Experimental|PSMA-PET/MRI and PET/CT for detection of lymph node metastases.|"Each patients will undergo an MRI-, PET/MRI- and PET/CT-examination (on the same day) prior to treatment.~Patients in the radiotherapy cohort will additionally undergo an MRI examination after hormonal treatment, before radiotherapy."
9685963|NCT04771351|Experimental|COVI-AMG 100 mg|A single injection of 100 mg of COVI-AMG will be administered.
9685964|NCT04771351|Experimental|COVI-AMG 200 mg|A single injection of 200 mg of COVI-AMG will be administered.
9685965|NCT04771351|Placebo Comparator|Placebo|A single injection of placebo will be administered.
9685966|NCT04768725|Active Comparator|Dietary intervention|Participants will consume a self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day).
9685967|NCT04768725|Active Comparator|Physical-cognitive intervention|Participants will perform home-based physical-cognitive training for 60 minutes per session, 3 session a week.
9685968|NCT04768725|Experimental|Physical-cognitive with dietary intervention|Participants will receive both dietary intervention and physical-cognitive training same as those in the dietary and physical-cognitive intervention groups.
9685969|NCT04768725|No Intervention|Control|Participants in the control group will be encouraged to continue their activities and calorie intakes as they usually would.
9685970|NCT04754022|Active Comparator|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <75 g/L (<7.5 g/dL; <4.7mmol/L) intraoperatively and/or postoperatively.
9685971|NCT04754022|Active Comparator|Liberal Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <95 g/L (<9.5 g/dL; <5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or <85 g/L (< 8.5 g/dL; <5.3mmol/L) on the ward.
9685972|NCT04743999|Experimental|Quality of life evaluation|This prospective arm will consist of evaluating quality of life outcomes in women in women with advanced endometrial cancer undergoing adjuvant concurrent chemotherapy with carbo/Taxol and radiation therapy. Assessments will occur following surgery (baseline), 3, 6, 12, and 24 months.
9685973|NCT04738175|Experimental|COVI-AMG|40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
9685974|NCT04738175|Placebo Comparator|Placebo|Placebo will be administered
9685975|NCT04734860|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be administered
9685976|NCT04734860|Placebo Comparator|Placebo|A single injection of placebo will be administered
9685977|NCT04731818|Experimental|ZB-06|All participants will receive a single ZB-06 film for intravaginal administration prior to intercourse.
9685978|NCT04729400|Experimental|Experimental group|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
9685979|NCT04729400|Experimental|CONTROL GROUP|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
9685980|NCT04717570|Experimental|TRIA Mitral Valve|Patients receiving the Foldax Mitral Valve
9685981|NCT04713202|Experimental|Telotristat Ethyl + PRRT|"Telotristat ethyl, 250 mg, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
9685982|NCT04713202|Placebo Comparator|Placebo + PRRT|"Placebo, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
9685983|NCT04711187|Experimental|AT-527 Formulation 1 Dose 1|
9685984|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1|
9685985|NCT04711187|Experimental|AT-527 Formulation 2 Dose 2|
9685986|NCT04711187|Experimental|AT-527 Formulation 1 Dose 3|
9685987|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3|
9685988|NCT04711187|Experimental|AT-527 Formulation 2 Dose 1 Fast/Fed|
9685989|NCT04711187|Experimental|AT-527 Formulation 2 Dose 3 Fast/Fed|
9685990|NCT04698330|Experimental|Group A|LADA patients are assigned to receive berberine and inulin for 3-month.
9685991|NCT04698330|Experimental|Group B|LADA patients are assigned to receive berberine and placebo(for inulin) for 3-month.
9685992|NCT04698330|Experimental|Group C|LADA patients are assigned to receive placebo(for berberine) and inulin for 3-month.
9685993|NCT04698330|Placebo Comparator|Group D|LADA patients are assigned to receive placebo(for berberine) and placebo(for inulin) for 3-month.
9685994|NCT04689256|Experimental|MR-010 walking therapy|Subjects will use the MR-010 three times a week for 30 minutes per session for 90 days. Subjects will undergo a 10-meter walk test bi-weekly and at 45 and 90 days.
9685995|NCT04689256|No Intervention|Standard of Care|Subjects will undergo a 10-meter walk test bi-weekly for 90 days and at 45 and 90 days
9685996|NCT04685876|Active Comparator|liposomal bupivacaine|40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block.
9685997|NCT04685876|Active Comparator|plain bupivacaine|50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block.
9685998|NCT04685876|Placebo Comparator|Normal Saline|patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites.
9685999|NCT04676399|Experimental|Hydrochlorothiazide Pill (12.5 mg twice a day)|"Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Chronic pain~Dose(s): 12.5 mg twice per day for 14 days.~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
9686000|NCT04676399|Placebo Comparator|Placebo|"Has no active ingredients but is made to look like the study drug.~2 pills/day for 14 days."
9686001|NCT04674189|Experimental|CVnCoV: Group 1, Lot 1|Participants in Group 1 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9686002|NCT04674189|Experimental|CVnCoV: Group 2, Lot 2|Participants in Group 2 will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9686003|NCT04674189|Placebo Comparator|Placebo|Participants will receive a placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9695887|NCT04773444|Experimental|Concentric cycling training|Moderate intensity cycling training in concentric type (intensity matched the eccentric training)
10179559|NCT03802045|Active Comparator|Control Group|"25 participants will follow exactly the same protocol as the experimental groups, however they will not undergo electrical stimulation, as the acupuncturist will activate channels that are not connected to the patient.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
10179560|NCT03802045|Placebo Comparator|Placebo Group|"25 participants will will follow exactly the same protocol as the experimental groups, however an adhesive moxa (Dong Yang®) will be placed on each acupoint and the needle will be inserted over it, so that the participant only feels the needle prick, but without perforation of the skin and the deQi sensation. In addition, as in the control group, the electrodes will be connected to the needles, however, no electrical current will be applied.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
9686004|NCT04664205|Experimental|High intensity interval training, then Moderate Intensity Continuous Training|Participants randomly assigned to this arm will first receive high intensity interval training followed by moderate intensity continuous training.
9686005|NCT04664205|Experimental|Moderate Intensity Continous Training, then High Intensity Training|Participants randomly assigned to this arm will first receive moderate intensity continuous training followed by high intensity interval training.
9686006|NCT04664205|No Intervention|Control: No exercise|Participants will complete the same pre- post measurements, with no exercise in between.
10179561|NCT03801850|Experimental|observational cohort|
10179562|NCT03801837|Active Comparator|Macadamia Nut Diet|This group will have their habitual diet supplemented with appropriate portion of Macadamia Nuts (15% of daily calories or 30-45 grams based on Kcal requirement of the individual)
10179563|NCT03801837|Placebo Comparator|Control Diet|This group will continue with their Habitual Diet
10179564|NCT03801824|Active Comparator|Standard Nutrition Therapy|Subjects in this group receive a standard nutrition therapy based on local guidelines that is usually high in fibre with moderate to high glycemic index food
10179565|NCT03801824|Experimental|Low Glycemic Index|Subjects in this group receive intervention on low glycemic index foods
9686007|NCT04659603|Experimental|Cohort A metastatic breast cancer (mBC)|tusamitamab ravtansine (SAR408701) dose administered via intravenous infusion (IV)
9686008|NCT04659603|Experimental|Cohort B metastatic pancreatic adenocarcinoma (mPAC)|tusamitamab ravtansine (SAR408701) dose administered via intravenous infusion (IV )
9686009|NCT04650399|Experimental|Active|VLA1553
9686010|NCT04650399|Placebo Comparator|Placebo|Placebo
9686011|NCT04643808|Experimental|taVNS once daily|taVNS paired with bottle feeding once daily for 2-3 weeks
9686012|NCT04643808|Experimental|taVNS twice daily|taVNS paired with bottle feeding twice daily for 2-3 weeks
10179566|NCT03801603|Experimental|HPV Vaccination Training and Education|Participants will be educated on the importance of HPV vaccination.
10179567|NCT03801577|Experimental|Hepaxa|Subjects will receive Hepaxa according to standard use (4 capsules daily over a 6 month period)
9686013|NCT04638998||Healthy Control|The healthy control group are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. This cohort do not experience any Gulf War Illness symptoms.
9686014|NCT04638998||Gulf War Illness|The GWI cohort are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. The men in this cohort will also meet the Kansas Inclusion Criteria for GWI.
9686015|NCT04638673|Experimental|Active-Active Stimulation Group|This group will be randomized into the active stimulation group for weeks 1&2 of stimulation and active stimulation during weeks 3&4 of stimulation of study participation.
9686016|NCT04638673|Sham Comparator|Sham-Active Stimulation Group|This group will be randomized into the sham stimulation group for weeks 1&2 of stimulation and active stimulation for weeks 3&4 of stimulation of study participation.
9686017|NCT04634331|Active Comparator|Traditional Multi-Modal Training|A physical therapist will provide 1:1 multi-modal training. Multi-modal training is the simultaneous performance of a motor and a cognitive task (i.e. marching while answering math questions)
9686018|NCT04634331|Experimental|Augmented Reality Multi-Modal Training|Multi-modal training will be administered via the Microsoft HoloLens 2 augmented reality head set. Augmented reality allows user to see the real world, and inserts holograms into the environment. For example, the user could see boxes on the ground that they need to step around when walking. The boxes are not real, but rather a hologram that only the user can see. The augmented reality device will instruct the participant on the motor and cognitive task that should be performed simultaneously in a similar manner to the physical therapist in the traditional multi-modal training group. The intervention will be overseen by a physical therapist.
10179568|NCT03801746|Experimental|Vadadustat, Cyclosporine|Part 1: Arm 1: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral cyclosporine 500 mg in a crossover design
10179569|NCT03801746|Experimental|Vadadustat; Probenecid|Part 1: Arm 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral Probenecid 500 mg Q12h in a fixed sequence design
10179570|NCT03801746|Experimental|Vadadustat and Rifampin|Part 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with IV rifampin 600 mg in a cross-over design
9695888|NCT04773444|No Intervention|Control group|without receiving any exercise training
9977722|NCT01364610|Active Comparator|Standard Care|Group 1 will have standard catheter based pH-metry. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour monitoring period.
10179571|NCT03801772|Active Comparator|Metronome|This arm will be using the metronome as a pacing device during aquatic exercises.
10187444|NCT03726177|Active Comparator|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
10187445|NCT03726177|Active Comparator|aspirin 81 mg plus placebo|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
10187446|NCT03726151|No Intervention|Usual Care|
10187447|NCT03726151|Experimental|Parent Reminders|
10187448|NCT03726151|Experimental|Multicomponent clinic-system strategies|
9686019|NCT04632888|Experimental|Study group/Telephone support for breastfeeding follow-up|"Study group: The women in the study group will be provided with a video call every day for the first week after discharge from the hospital, to provide consultancy to the mother on the matters she needs and to be recorded in the Baby Monitoring Form. The general appearance of the baby, observation during sucking, jaundice, drowsiness, reluctance to suck will be observed. The consultancy will be provided to the mother on these issues.~In the following weeks, the consultancy will continue to be given to the study group by making a video talk one week apart.~The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded."
10179572|NCT03801772|No Intervention|Control|The patients will be educated on proper performance of aquatic exercises following normal physical therapy procedures. Patients will start with 10-20 repetitions of the exercises depending on their physical ability and progressed as the patient's strength and endurance improve. Each session will last approximately 30 to 45 minutes. The BORG scale (a valid, subjective measure of perceived exertion) will be used as a monitoring device to ensure that a desired level of exercise intensity is reached. The desired level is a score between 12 and 16. The patients will be asked to rate their level of exertion at the end of each session. Intensity of the exercises will be adjusted the next session if the patient's reported level of exertion does not fall within the desired range. The pain rating and the BORG number will be recorded for both groups in the chart and flow
10179573|NCT03801616|Experimental|Virtual Reality|Every participant is provided with a VR headset
10179574|NCT03801733|Experimental|Rosuvastatin, Vadadustat|Part 1: Subjects will receive rosuvastatin 20 mg alone, vadadustat 600 mg alone, followed by rosuvastatin 20 mg in combination with vadadustat 600 mg in a fixed-sequence dosing design.
10187449|NCT03726151|Experimental|Combined Condition|
9686020|NCT04632888|No Intervention|Control Group|"Control Group: No additional attempt or routine call will be made to mothers in the control group. The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded.~The control group will be called to fill in the scales for monitoring purposes."
9686021|NCT04630847|Experimental|Autism Subjects|These subjects will be administered fecal microbiota transplant by colonoscopy
9686022|NCT04622085|Experimental|ANIMERS Chiara LA|
9686023|NCT04622085|Active Comparator|JUVÉDERM VOLUMA®|
9686024|NCT04621435|Experimental|Dosimetry population (Cohort 1)|PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection. Contrast may be administered if clinically indicated.
9686025|NCT04621435|Experimental|Participants with metastatic disease (Cohort 2)|Participants with metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if clinically indicated.
9686026|NCT04621435|Experimental|Participants without metastatic disease (Cohort 3)|Participants without metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if if clinically indicated.
9686027|NCT04605991|Experimental|LY900014|LY900014 given via subcutaneous (SC) injection
9686028|NCT04604236|Experimental|Mapping Enhanced Counseling (MEC)|MEC will target attitudes and norms. Attitudes include motivation for change, such as problem recognition and a belief that treatment will help. Subjective norms include normative beliefs about SU in adolescence (e.g., belief that it is ok to allow SU with parental supervision; experimentation is normal) and expectations about treatment.
9686029|NCT04604236|Experimental|Active Linkage (AL)|AL will target perceived control. Perceived control includes perceived logistical barriers and the degree to which individuals feel they can overcome them.
9686030|NCT04599335|Experimental|HA + Lidocaine|
9686031|NCT04599335|No Intervention|Negative|
9686032|NCT04599088|Experimental|Brain functional MRI with simplified urodynamics|Females with urgency urinary incontinence
9686033|NCT04590079|Experimental|First intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment and daily sessions with the medical device - 1 month of wash-out - 3 months of conventional pain treatment.
9686034|NCT04590079|Experimental|Second intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment - 1 month of wash-out - 3 months of conventional pain treatment and daily sessions with the medical device.
9686035|NCT04589533||EDUCATIONAL PROGRAM GROUP|This group will receive an educational program based . This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
9686036|NCT04589533||CONTROL GROUP|Control group will not receive educational program. This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
9686037|NCT04587271|Experimental|Lactating Mothers (Moringa)|Lactating mothers.
9686038|NCT04587271|Experimental|Breastfeeding Infants (Moringa)|Breastfeeding infants from lactating mothers
9686039|NCT04587271|Experimental|Children (Moringa)|Children from 6-59 months of age.
9686040|NCT04587271|Placebo Comparator|Lactating Mothers (placebo)|Lactating mothers.
9686041|NCT04587271|Placebo Comparator|Breastfeeding Infants (placebo)|Breastfeeding infants from lactating mothers
9686042|NCT04587271|Placebo Comparator|Children (placebo)|Children from 6-59 months of age.
9686043|NCT04582318|Experimental|Part 1 Dose Level 1 - Active|
9686044|NCT04582318|Placebo Comparator|Part 1 Dose Level 1 - Placebo|
9686045|NCT04582318|Experimental|Part 1 Dose Level 2 - Active|
9686046|NCT04582318|Placebo Comparator|Part 1 Dose Level 2 - Placebo|
9686047|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 1 - Active|
9686048|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 1 - Placebo|
9686049|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 2 - Active|
9686050|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 2 - Placebo|
9686051|NCT04581200|Experimental|Lift mobile mindfulness program|Will receive standard dose Lift mobile mindfulness program intervention content, app-based response to elevated symptoms, and no introductory call from a therapist. This program lasts 1 month and includes 4 unique weeks' worth of audio, video, and text content.
9686052|NCT04581200|No Intervention|Usual care control|Usual care.
9686053|NCT04576962||Children aged 14 years or younger|All children in Indiana aged 14 years and younger who received the first dose of HPV vaccine during the 2017 and 2018 calendar years. This is a non-interventional study, with data to be analyzed at the county level only.
9686054|NCT04569045|Experimental|HA + Lidocaine|Sodium Hyaluronate with Lidocaine Hydrochloride
10179575|NCT03801733|Experimental|Sulfasalazine. Pravastatin, Vadadustat|"Part 2, Arm 1: Subjects will receive sulfasalazine 500 mg alone followed by sulfasalazine 500 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 2, Arm 2: Subjects will receive pravastatin 40 mg alone followed by pravastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
9686055|NCT04569045|Active Comparator|HA|Sodium Hyaluronate
9686056|NCT04567979||Patients with solid tumors|Patients with solid tumors under chemotherapy and / or radiotherapy treatment at our center.
9686057|NCT04567979||Healthcare workers|Healthcare workers at the chemotherapy and radiotherapy unit in our center.
9686058|NCT04556123|Experimental|BIS-guided decongestion|
9686059|NCT04556123|Active Comparator|Decongestion based on clinical judgement|
9686060|NCT04551157|Experimental|Video Viewing|Participants will receive the intervention where they will view two patient information videos. The first video will be viewed within the first week of their inpatient stay and the second video will be viewed just before discharge.
9686061|NCT04551157|No Intervention|Treatment as usual|No change to routine care.
9686062|NCT04550195|Experimental|Part A Single Ascending Dose (SAD) Cohort A1|
9686063|NCT04550195|Experimental|Part A SAD Cohort A2|
9686064|NCT04550195|Experimental|Part A SAD Cohort A3|
9686065|NCT04550195|Experimental|Part A SAD Cohort A4|
9686066|NCT04550195|Experimental|Part A SAD Cohort A5|
9686067|NCT04550195|Experimental|Part A SAD Cohort A6|
9686068|NCT04550195|Experimental|Part B Multiple Ascending Dose (MAD) Cohort B1|
9686069|NCT04550195|Experimental|Part B MAD Cohort B2|
9686070|NCT04550195|Experimental|Part B MAD Cohort B3|
9686071|NCT04550195|Experimental|Part B MAD Cohort B4|
9686072|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C1|
9686073|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C2|
9686074|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C3|
9686075|NCT04537962|Placebo Comparator|Colgate Periogard and Peroxyl®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution
9686076|NCT04537962|Placebo Comparator|Colgate Periogard®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution;
9686077|NCT04537962|Placebo Comparator|Colgate Peroxyl®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution
9686078|NCT04537962|Placebo Comparator|Colgate Total 12®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate
9686079|NCT04537962|Active Comparator|Toothpaste with sodium monofluorophosphate|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing only 1.1% fluoride, water, glycerin, cellulose, sodium lauryl sulfate, and sodium bicarbonate
9686080|NCT04537962|Active Comparator|Toothpaste with sodium fluoride and zinc|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.32% fluoride, 0.96% zinc, arginine, poloxamer, glycerin, water, hydrated silica, sodium lauryl sulfate, and sodium saccharin
9686081|NCT04537962|Active Comparator|Toothpaste with tin fluoride|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.454% stannous fluoride, water, sorbitol, hydrated silica, glycerin, tetrasodium pyrophosphate, microcrystalline cellulose, and xanthan gum
9686082|NCT04525391|Experimental|Durvalumab+AZD2811 to SCLC patients|"Dosage and Schedule: AZD2811 500mg and durvalumab 1500mg via IV administered on Day 1 for every 3weeks (fixed dosing for subjects > 30 kg body weight for durvalumab). One cycle is consisted of 3 weeks.~The drug products must be dosed consecutively using different infusion lines. The sequence of infusions is as follows: durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. A waiting time interval of at least 30 minutes between the end of durvalumab infusion and start of AZD2811 infusion should be adhered to."
9686083|NCT04519086|Experimental|Low-dose CT for acute appendicitis in patients with BMI >30|Low-dose computed tomography (CT) vs. standard CT for diagnosing acute uncomplicated appendicitis in patients with BMI > 30 Laparoscopic appendectomy
9686084|NCT04486560|Experimental|Single Arm: Cryoprobe|Everyone who enrolls in this study will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe.
9686085|NCT04482179|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
9686086|NCT04482179|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz sham TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
10179576|NCT03801733|Experimental|Atorvastatin, Simvastatin, Vadadustat|"Part 3, Arm 1: Subjects will receive atorvastatin 40 mg alone followed by atorvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 3, Arm 2: 24 subjects will receive simvastatin 40 mg alone followed by simvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
10187450|NCT03726125|Experimental|LY3374849 - SC (Part A)|Single subcutaneous (SC) dose of LY3374849
9686087|NCT04481061|Other|Decision Making About Genetic Results|Adolescents between 13-21 and parent (if applicable) will make decisions about learning results using an electronic decision tool. Results that match their choices will be returned.
9686088|NCT04481048|Experimental|N-Acetylcysteine (NAC)|"Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3.~Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg~*Max dose not to exceed 2700mg/day (1350mg BID)"
9686089|NCT04481048|Placebo Comparator|Placebo|Each subject will be dosed with placebo for 8 weeks.
10179577|NCT03801707|Experimental|Intervention group|kidney transplant recipients who receive kidney allograft from hepatitis C viremic donors followed by treatment with direct acting antiviral therapies.
10179578|NCT03801668|Experimental|Nab-P/S-1|Patients in this arm receive chemotherapy with Albumin-bound Paclitaxel plus S-1.
10179579|NCT03801668|Active Comparator|SOX|Patients in this arm receive chemotherapy with Oxaliplatin plus S-1.
10179580|NCT03801629|Experimental|High Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.07 mg/kg).
10179581|NCT03801629|Experimental|Low Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.04 mg/kg).
10179582|NCT03801798|Experimental|NAs antivirals + GC1102 180,000 IU|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17 : IV bolus injection twice a week~V18 to V33 : IV bolus injection once a week"
10179583|NCT03801798|Placebo Comparator|NAs antivirals + GC1102 Placebo|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17: IV bolus injection twice a week~V18 to V33: IV bolus injection once a week"
10179584|NCT03801551|Experimental|Patient|
10179585|NCT03801564|Experimental|Platelet Rich Plasma Group (PRP)|Platelet Rich Plasma Treatment Group (PRP): The blood is drawn from the antecubital vein to the 10cc line of EasyPRP syringe consisted 1.5ml of anticoagulant. The syringe is centrifuged at a rate of 1200 g for 2 minutes. Then the syringe is rotated and the lower chamber filled with erythrocytes is discharged. The connector is inverted and the air gap is discharged. The injector is again centrifuged at 1200G for 10 minutes. Then the injector is rotated in the direction of the arrow, the lower stopper is removed. The application injector of 3cc with connector is placed in the EasyPRP injector. 1 ml of the PRP containing Buffycoat is separated for content analysis, the remaining 2 ml of the string is injected. Injection is repeated one month interval
10179586|NCT03801564|Experimental|Hyaluronic acid Group (HA)|Hyaluronic Acid Treatment Group (HA): 2 ml HA (32mg / ml) containing 1.6% sodium hyaluronate is injected intraarticular. The molecular weight is 800 - 1200 K Dalton. The viscosity is 20 pascal / s. The pH of the product is 7-7.5.Injection is repeated one month interval.
10179587|NCT03801460|No Intervention|SOC|Standard of Care
10179588|NCT03801460|Experimental|RAPR|Remotely administered physiological reconditioning program
10179589|NCT03801486||Experimental (SCF40)|At the experimental data collection visits participants consumed 255g of pasta made with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
10179590|NCT03801486||Control (SEM100)|At the control data collection visits participants consumed 255g of pasta made with 100% semolina flour (SEM100) with butter.
10179591|NCT03801421|Experimental|Continous suture group|The surgical incision will be treated by mass continous suture with PDS.
10179592|NCT03801421|Active Comparator|Control group|The surgical incision will be treated by interrupted suture with thread.
10179593|NCT03801343|Experimental|Nutrakos®|12 female subjects aged 35-70, have taken during a meal, for the 1 month ,2 stick packs/die of the food supplement
10179594|NCT03801720|No Intervention|Control Group|Utilize standard practice for obtaining a CCU in pre-continent children; this consists of cleaning the GU area with betadine and waiting 5 minutes for micturition to occur.
10179595|NCT03801720|Experimental|Experimental Group|Consists of cleaning the GU area with betadine followed by using an ultrasound probe to apply cool ultrasound gel and subprapubic pressure to the patient to induce micturition.
10179596|NCT03801655|Experimental|Bio-Kult|4 capsules/day
10179597|NCT03801655|Placebo Comparator|Placebo|4 capsules/day
10179598|NCT03801590|Experimental|CXL on patients with infectious keratitis|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .
10179599|NCT03801382|Other|Digital / Paper|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
10179600|NCT03801382|Other|Paper / Digital|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.
10179601|NCT03801382|Other|Digital / Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.
9686090|NCT04469530|Experimental|Maintenance Chemotherapy Regimen|"Participants with metastatic osteosarcoma, metastatic Ewing sarcoma, high-risk rhabdomyosarcoma, metastatic non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), desmoplastic small round cell tumor (DSRCT), and malignant rhabdoid tumor (MRT) in first complete remission (cohort 1) or participants with recurrent solid tumors (any histology) in second complete remission (cohort 2), receiving a maintenance chemotherapy regimen administered as a 12-month course of continuous sirolimus with celecoxib and low-dose oral etoposide alternating every 21 days with low-dose oral cyclophosphamide following the completion of standard therapy."
9686091|NCT04469530|No Intervention|Historical Control Cohort Receiving Standard Therapy|This study arm is a historical control cohort of patients matched with cohort 1 on diagnosis, age, metastatic site, and date of diagnosis. The matched historical controls will be obtained from the same treating institution as the corresponding case to account for institutional differences in treatment and supportive care. Patients in the historical control cohort received standard therapy.
10179602|NCT03801382|Other|Paper / Paper|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
10179603|NCT03801382|Other|Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A
10179604|NCT03801759|Experimental|Vadadustat, digoxin|Arm 1: Subjects will receive a single oral dose of digoxin 0.5 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of digoxin 0.5 mg.
10179605|NCT03801759|Experimental|Vadadustat, adefovir|Arm 2: Subjects will receive a single dose of oral adefovir 10 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of adefovir.
9686092|NCT04466761|Experimental|Experimental: Cohort 1-4|60% of subjects per cohort will consume 30-90 grams of dietary supplement daily for 4 weeks, with each successive cohort dosage increasing according to a Fibonacci dose escalation.
9686093|NCT04466761|Placebo Comparator|Placebo: Cohort 1-4|40% of subjects per cohort will consume 30-90 grams of daily placebo for 4 weeks with each successive cohort dosage increasing in parallel to the experimental arm.
9686094|NCT04464993|Experimental|CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app and a Fitbit watch to use throughout the 16-week intervention.The Fitbit will provide device-based behavioral feedback through the StandUPTV self-monitoring component. SST feedback will be Self-monitoring will provide passive and objective feedback regarding SST behaviors and MVPA drawn from Fitbit and SCREENTIME sources. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
9686095|NCT04464993|Experimental|CORE + text|CORE components + The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV app) that will provide simple adaptive content based upon length of most recent SST bout and time of day. These prompts will specifically target outcome expectations around SST and MVPA.
9686096|NCT04464993|Experimental|CORE + Lockout|CORE components + Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided with a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
9686097|NCT04464993|Active Comparator|CORE + Earn|CORE components + the investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
9686098|NCT04464993|Active Comparator|CORE + Text + Earn|"Intervention components will be delivered as described in simpler factorial conditions.~App shows progress toward SST goal or if goal is exceeded. Can earn additional SST through exercise based on 3:1 ratio , simple adaptive content (by SST bout, time of day). Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation."
9686099|NCT04464993|Active Comparator|CORE + Text + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Simple adaptive content (by SST bout, time of day)."
9686100|NCT04464993|Active Comparator|CORE + Earn + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio."
9686101|NCT04464993|Active Comparator|CORE + Earn + Lockout + Text|"Intervention components will be delivered as described in simpler factorial conditions, and...~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise based on 3:1 ratio). Simple adaptive content (by SST bout, time of day)."
9686102|NCT04462302|Experimental|Internet-based program + Pain Education|If you are in this group, in additional to your usual care, you will be provided access to the 8-session Internet-based pain program plus pain education. You will need to complete your sessions within 10 weeks of being provided your log-in code. You will be allowed to revisit sessions that you have completed during this 10 weeks. After completion of the study, you will still be provided access to the 8-session Internet-based pain program.
9686103|NCT04462302|No Intervention|Pain Education Only|If you are in this group, in addition to your usual care, you will be provided pain education at your initial clinic visit. After you have completed the 6-month follow up assessment, you will be provided a secure log-in code and invited to complete the 8 sessions of this Internet-based pain program on your own.
9977723|NCT01364610|Active Comparator|Bravo pH Monitoring System|Group 2 will undergo unsedated peroral placement of the Bravo capsule. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour pH monitoring period.
10179606|NCT03801759|Experimental|Vadadustat, Furosemide|Arm 3: Subjects will receive a single dose of oral furosemide 40 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone, and in combination with a single dose of furosemide 40 mg.
10179607|NCT03801512|Experimental|Steroid Injections|Inject steroid at neuritis nerve root.
10179608|NCT03801512|Experimental|Acupuncture|Acupuncture at acupoints BL23 to BL26.
10179609|NCT03801512|Experimental|Platelet Rich Plasma Injection|Inject Platelet Rich Plasma at neuritis nerve root.
10179610|NCT03801681||myocarditis|patients with clinically suspected myocarditis
10179611|NCT03801499|Experimental|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
9686107|NCT04436822|Experimental|Subjects with diabetes wearing DS5|Subjects wearing DS5 over 7 days and participating in FSTs.
9686108|NCT04425291|Experimental|4-valent HPV Vaccine|Participants in this arm would receive 4-valent Human Papillomavirus (Types 6, 11, 16 and18) Recombinant Vaccine (Hansenula Polymorpha)
9686109|NCT04425291|Experimental|9-valent HPV Vaccine|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
9686110|NCT04425291|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
9686111|NCT04423055|Experimental|COC users or new starts|Subjects will have an etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women using COC for less than 1 month will be considered new starts.
9686112|NCT04397432||Elemene plus TKIs|This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
9686113|NCT04397432||TKIs only|This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
9686114|NCT04389073|Experimental|Arm 1 (PD-1+NVB)|"The treatments received are:~Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])."
9686115|NCT04389073|Experimental|Arm 2 (PD-1+NVB+Bev)|"The treatments received are:~Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Bevacizumab (5 mg/kg every 3 weeks, intravenously [IV])."
9686116|NCT04389073|Experimental|Arm 3 (PD-1+NVB+DDP)|"Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Cisplatin (50mg/m2 every 3 weeks, intravenously [IV])."
9686117|NCT04389073|Experimental|Arm 4 (PD-1+VEX)|"Vinorelbine (40 mg/day, tiw, per os)~Toripalimab (240 mg every 3 weeks, intravenously [IV])~Cyclophosphamide (50 mg/day, qd, per os)~Capecitabine (500 mg, tid, per os)"
9686118|NCT04389073|Active Comparator|Arm 5 (NVB)|• Vinorelbine (40 mg/day, tiw, per os)
9686119|NCT04373265|Experimental|Relacorilant in Combination with Pembrolizumab|"Patients will treated with a lead-in of 300 mg relacorilant once daily from Day -3 to Cycle 1 Day 1 prior to the first dose of pembrolizumab. From Cycle 1 Day 1 until confirmed p or unacceptable toxicity with relacorilant and pembrolizumab. Pembrolizumab will be administered every 6 weeks (on Day 1 of each 42-day cycle) and relacorilant will be administered daily.~On Cycle 1 Day 2, the patient's dose increases to 100 mg relacorilant once daily for 2 weeks. The patient's relacorilant doses may then escalate by 100-mg increments every 2 weeks based on tolerability until they reach 400 mg relacorilant once daily.~For patients who tolerate the 400 mg relacorilant once daily, but their Cushing-syndrome symptoms persist, further dose escalation in 100-mg increments to a maximum of 600 mg relacorilant once daily may be considered after approval of the Medical Monitor and as long as the patient's AUC0-24 at their current dose does not exceed the maximum allowable exposure."
9686120|NCT04371445|Experimental|Intracanalicular dexamethasone insert group|This arm will receive the DEXTENZA® insert within minutes after the completion of the surgery.
9686121|NCT04371445|Active Comparator|Topical steroid drop group|This arm will receive the prescription for daily prednisolone acetate 1% eye drops 4 times a day for the first week following the procedure, starting on the day of surgery.
9686122|NCT04371055|Experimental|Risk-adapted ECG monitoring for atrial fibrillation|"Intervention Group with high Risk for AF:~Continuous Rhythm Monitoring using an implantable cardiac Monitor~Intervention group with low risk for AF:~7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation"
9686123|NCT04371055|Other|Standard of Care|Standard of care rhythm monitoring
9686124|NCT04369066|Other|Subjects who are not showing active SARS-Cov2 infection|
9686125|NCT04365387|Experimental|Nemolizumab|Participants will receive a loading dose of nemolizumab (60 milligram [mg]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) will then be administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.
9686126|NCT04365387|Placebo Comparator|Placebo|Participants will receive a placebo via 2 SC injections at baseline. Placebo will then be administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.
9686127|NCT04357782|Active Comparator|Mild hypoxemia|S/F ratio >250 prior to Vitamin C infusion
9686128|NCT04357782|Active Comparator|Severe Hypoxemia|S/F ratio ≤250 prior to Vitamin C infusion
9686129|NCT04354077|Experimental|NAc DBS|Subjects will receive bilateral DBS of the NAc
10187451|NCT03726125|Experimental|Insulin Degludec - SC (Part A)|Single SC dose of insulin degludec
10187452|NCT03726125|Experimental|LY3374849 - SC (Part B)|Single dose of LY3374849 administered SC in up to three of three study periods
10187453|NCT03726125|Experimental|LY3374849 - IV (Part B)|Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods
9686130|NCT04345068|Experimental|Calm Meditation|"The intervention will be 8-weeks in duration and will consist of a series of pre-approved meditation classes. Patients will be asked to participate in at least 10 min/day of meditation (i.e., ~70 min/week). Week 1-4 will consist of the 7 Days of Calm followed by the 21 Days of Calm, which are introductory courses offered by Calm and provide basic, introductory meditation classes for beginners. Weeks 5-8 will consist of patients participating in the Daily Calm that Calm provides, consisting of 10-12 min meditation classes that have a unique focus each day. Patients will be instructed to participate in at least 10 min/day of meditation, but will be encouraged to do more if they can."
9686131|NCT04345068|Active Comparator|Health Education Podcast|The control group will serve as an active control group and will be matched for time and attention to the intervention group. Participants assigned to the control group will be asked to listen to/view 10-min/day (i.e., ~70 min/week) of health education podcasts via a smartphone app. Topics covered in the health education control vary and will be aimed at providing useful and informative health-related information pertinent to cancer patients. The podcast app was developed by an independent app developer, and it was designed to mirror the type of functionality that the Calm app offers its users.
10187454|NCT03726125|Experimental|LY3374849 - IV (Part C)|Single IV dose of LY3374849 in one of two study periods
10179612|NCT03801538|Experimental|PEG-IFN group|"patients were treated with NAs once a day and PEG-IFN once a week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.~①If the decrease of HBsAg is more than 50%. NAs was stopped. PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.~②If the decrease of HBsAg is less than 50%.NAs and PEG-IFN was extended to week 24. Then, If the decrease of HBsAg is more than 50%. NAs was stopped, PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96. If the decrease of HBsAg is less than 50%. PEG-IFN was stopped, patients were treated with NAs once a day and then followed up for 48 weeks."
10179613|NCT03801538|Other|NAs group|CHB patients do not need to change their NAs treatment.
9686132|NCT04337073|Placebo Comparator|normal saline (N) group|Before anesthesia induction, N group received corresponding intravenous normal saline of the same volume.
9686133|NCT04337073|Active Comparator|propofol (P) group|Before anesthesia induction, P group received intravenous injection of 0.3mg/kg propofol
9686134|NCT04330248|Experimental|Erdafitinib and Carbamazepine|Participants will receive single oral dose of erdafitinib dose 1 on Day 1 30 minutes after the start of a standardized breakfast in Period 1 followed by repeated doses of carbamazepine orally every 12 hours from Days 15 to 35 (carbamazepine Dose 1 from Days 15 to 17, Dose 2 from Days 18 to 20, and then Dose 3 from Days 21 to 35) 30 minutes after the start of standardized meal (breakfast and dinner) in Period 2. After 8 Days of Dose 3 carbamazepine treatment, on Day 28, participants will receive a single oral dose of erdafitinib dose 1 with that day's carbamazepine dose.
9686135|NCT04328662||Cohort 1: Participants with RRMM|Participants diagnosed with relapsed or refractory multiple myeloma (RRMM) who have received at least one dose of ixazomib plus lenalidomide - low dose dexamethasone (IRd) treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
9686136|NCT04328662||Cohort 2: Participants with NDMM, RRMM, and Non-myeloma|Participants with NDMM, RRMM, and Non-myeloma Participants diagnosed with newly diagnosed multiple myeloma (NDMM) who have received at least one dose of ixazomib-based regimen treatment and diagnosed with RRMM who have received at least one dose non-IRd ixazomib-based regimens treatment, and diagnosed with non-myeloma who have received at least one dose of ixazomib-based regimens treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
9686137|NCT04316806|Experimental|Probiotic|Treatment with probiotic formula
9686138|NCT04316806|Other|Antibiotic|Treatment with antibiotic rifaximin
9686139|NCT04312945|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
9686140|NCT04312945|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
9686141|NCT04312945|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
9686142|NCT04312945|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
9686143|NCT04311606|Experimental|Saline and aflibercept|Group 1: Sub-tenon's injection of saline followed by sub-tenon injection of aflibercept
9686144|NCT04311606|Experimental|Hyaluronidase and aflibercept|Group 2: Sub-tenon's injection of hyaluronidase (HA) followed by sub-tenon injection of aflibercept
9686145|NCT04311606|Placebo Comparator|Hyaluronidase alone|Group 3: Sub-tenon injection of HA injection alone
9695889|NCT04773249|Experimental|Lateral Epicondylitis Bandage|A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
9695890|NCT04773249|Experimental|Wrist Extension Splint|A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
9695891|NCT04773249|No Intervention|Wait-and-see Policy|These patients will be monitored with a wait-and-see policy. No splint or band will be given to the patient.
9695892|NCT04773483|Active Comparator|Quorn Food products|
9695893|NCT04773483|Active Comparator|Meat/fish products|
9695894|NCT04773210|Experimental|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment.
9695895|NCT04773210|Active Comparator|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment.
9695896|NCT04773145||Femoral neck fracture|Patients over 80 years when suffering of femoral neck fracture with at least one year follow-up.
9695897|NCT04773119|Active Comparator|Pulmonary vein isolation (PVI) only|
9695898|NCT04773119|Active Comparator|PVI with substrate|
10187455|NCT03726125|Experimental|Insulin Degludec - IV (Part C)|Single IV dose of insulin degludec in one of two study periods
10187456|NCT03726112|Active Comparator|SpotOn Specs|Eyeglasses with Neuro-Balance Active (NBA) Spots
9695899|NCT04773080||esophageal cancer surgery|patients undergoing elective esophageal surgery for cancer
9695900|NCT04773093|Active Comparator|Continous Intravenous Lidocaine Infusion|Patient will recieve Continous Intravenous Lidocaine Infusion
9695901|NCT04773093|Placebo Comparator|Placebo|Patient will recieve placebo (NaCl 0.9% infusion)
9695902|NCT04773041||Patients with DLB|Patients diagnosed with DLB enrolled from the HealthPartners Neuroscience Center.
9686146|NCT04309916|Experimental|Tegoprazan 50mg|Tegoprazan 50mg tablet, once daily, oral administration
9686147|NCT04309916|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg tablet, once daily, oral administration
9686148|NCT04291950||Control group|Hispanic and NHW women undergoing either a benign breast surgery or prophylactic mastectomy.
9686149|NCT04291950||Newly diagnosed TNBC|Hispanic and NHW with newly diagnosed TNBC. Patients with TNBC will be eligible regardless of whether their treatment plan is surgery first or chemotherapy first (neoadjuvant chemotherapy).
9976174|NCT01348867|Experimental|Structured Care|"120 patients will be randomised to the structured care group, and these patients will receive repeated follow-ups and contact with the structured care team in between the two comprehensive assessments at week 0 and week 52.~Patients will be seen by Diabetes Nurse Consultant at week 0, 6, 12, 24 38 during the year. At each visit, clinical and laboratory measurements will be performed; treatment compliance and self care will be assessed and medications will be adjusted to optimise metabolic and cardiovascular risk factors control.~Patients will be seen by the doctors in their clinic follow up at week 0, 24 and 52.~Technical service assistance will telephone patient at week 18, 30 and 44 to reinforce patient to take medications, attend clinical follow up."
10179614|NCT03801330|Active Comparator|Usual Care|Participants in the Usual Care Pulmonary Rehabilitation will receive usual care pulmonary rehab program. Usual care programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is usual care exercise and education, which is personalized for each participant. No drugs are being tested in this study.
10179615|NCT03801330|Experimental|Software Tool|Participants in the Pulmonary Rehabilitation Software-Based Home Program will use a digital software tool (APP) to obtain the pulmonary rehab home program. Home programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is exercise and education, which is personalized for each participant. No drugs are being tested in this study.
9976175|NCT01348880|Experimental|Arm1|
9686152|NCT04284397|Experimental|Critical Environmental Limits|Subjects will perform exercise at ~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.
9686153|NCT04284397|Experimental|Aspirin Supplementation|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will repeat critical environmental limits trials. As before, subjects will perform exercise at ~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.
9686154|NCT04275999|Other|Control Group|In the control group, all subjects will receive ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea. Subjects will not receive any follow-up intervention from the study team.
9686155|NCT04275999|Experimental|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their use ivermectin generated by Causa Research; in addition to receiving ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
9686156|NCT04275999|Experimental|GPSkin group|The GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin once daily. Subjects also are receiving the ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
9686157|NCT04275141|Other|Mauriac syndrome|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
9686158|NCT04275141|Other|Type 1 diabetes mellitus|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 30-min cycling exercise at time 300 min.
9686159|NCT04270474|Experimental|Active Intervention (ACT)|Pharmacist-based Deprescribing
9686160|NCT04270474|Sham Comparator|Usual Care (UC)|Usual Care
9686161|NCT04267172|Experimental|Surgical Residents with additional simulation training|Surgeon participant Group 1a: Interventional group ('StR's'): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving additional simulation training.
9686162|NCT04267172|Active Comparator|Surgical Residents with routine training|Surgeon participant Group 1b: control group (StR's): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving routine and normal training.
9686163|NCT04267172|Active Comparator|Orthopaedic Surgeon 'Experts & Fellows'|Consultant Orthopaedic Surgeons (n=5), and nationally appointed Arthroplasty Fellows (n=8). Surgeon participants within this group will not undergo any interventions.
9686164|NCT04245215|Placebo Comparator|1. Subcutaneous ustekinumab every 8 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
9686165|NCT04245215|Active Comparator|2. Subcutaneous ustekinumab every 4 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
9686166|NCT04243941|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
9686167|NCT04230577|Active Comparator|Real LED Intervention|Participants receive 15 Real (active) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal). Parameters: NIR, 810nm, pulsed at 10 Hz, 50% duty cycle, synchronized for a 20-minute treatment time. Total Energy Dose per head set plus intranasal: 225 J/cm2+ 15 J/cm2 = 240 J/cm2 per 20 min LED treatment. Total Energy Dose delivered (3x/Week, 5 Weeks) = 3600 J/cm2. The light from these LEDs is not visible to the eye. There is no potential for eye damage because the LEDs are not laser light. The head frame device falls within the FDA category General Wellness, low-risk devices, and no medical claims are made. It is approved for use by the VA Boston Healthcare System Safety Committee and Institutional Review Board.
9695903|NCT04773041||Patients with Alzheimer's disease (AD)|Patients diagnosed with AD age and sex-matched, selected from the ADNI database.
9976176|NCT01348880|Placebo Comparator|Arm2|
10187457|NCT03726112|Sham Comparator|Sham Specs|Eyeglasses with spots placed in peripheral zones previously identified as neutral
9686168|NCT04230577|Sham Comparator|Sham LED Intervention|Participants receive a series of 15 Sham (control) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal) containing Sham LEDs, synchronized for a 20-minute treatment time (3x/Week, 5 Weeks). Sham and Real devices are identical in look and feel, except no photons are emitted from the Sham devices.
9686169|NCT04223154|Experimental|Real iTBS to the dlPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
9686170|NCT04223154|Sham Comparator|Sham iTBS to the dlPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
9686171|NCT04189107|Experimental|Experimental|High dose Dexamethasone
9686172|NCT04189107|Placebo Comparator|Control|Standard dexamethasone dosage and placebo
9686173|NCT04170075|No Intervention|Usual Care (UC)|Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire.
9686174|NCT04170075|Experimental|Whole body vibration (WBV)|Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
9686175|NCT04168242|Experimental|Experimental arm|Patients have scalp cooling during the chemotherapy period
9686176|NCT04168242|Placebo Comparator|Control arm|Patients do not have scalp cooling during the chemotherapy period
9686177|NCT04151108||Old medical patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.~Will be assessed at admission"
9686178|NCT04151108||Geriatric patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, gait-speed, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), body composition.~Blood tests, physical function measures and body composition will be assessed at both admission and discharge."
9686179|NCT04149002|Other|Intervention Arm: Weekly IP3 text messages|"A narrated powerpoint presentation describing the logistical details and medical rationale for components of the IP3. Participants will view the chapters of the presentation that are relevant to their specific IP3. There are a total of 4 possible chapters (lifestyle modifications, cervix length screening/cerclage, progesterone therapy, low dose aspirin). Each chapter of the presentation is ~ 10 - 15 min in length. Each chapter also includes a 4- 5 questions pre-test and the same questions are delivered as a post-test after the presentation.~Print materials including a letter explaining the importance of prenatal care for preterm birth prevention to employers.~Text messages sent weekly to encourage the patient to continue with their IP3 and provide basic pregnancy information~Formal letter of encouragement from provider at 28 weeks gestation"
9686180|NCT04149002|Active Comparator|Control Arm: General pregnancy text messages|"a pre-intervention questionnaire~a narrated powerpoint with general information about the clinic~a post-presentation questionnaire~text messages sent approximately weekly with general pregnancy information (e.g. today your baby is about the size of an apple)~an exit interview"
10179616|NCT03801252|Experimental|Cefazolin + Azithromycin|Women will be randomized 1:1 to receive cefazolin 2 grams intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and azithromycin 500 mg intravenously once at the start of the labor induction
9686181|NCT04138017|Experimental|ViviGen Cellular Bone Matrix|Patients will receive the vivigen cellular bone matrix
9686182|NCT04134091|Experimental|Treatment A|LPCN 1144 Formulation A
9686183|NCT04134091|Experimental|Treatment B|LPCN 1144 Formulation B
9686184|NCT04134091|Placebo Comparator|Treatment C|Placebo
9686185|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA Layered|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
9686186|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
9686187|NCT04133363|Experimental|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF alone
9686188|NCT04117958|Experimental|Dose-exploration phase|The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 199 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
9686189|NCT04117958|Experimental|Dose-expansion phase|The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.
9976177|NCT01348893|No Intervention|Physical education as usual|High school physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
10187458|NCT03726099|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy containing esomeprazole, amoxicillin, tetracycline and furazolidone.
9695904|NCT04773041||Patients with normal cognition (CN)|Patients diagnosed with normal cognition age and sex-matched, selected from the ADNI database.
9695905|NCT04772794|Active Comparator|hyperoxygenation group|Intraoperative administration of a mixture of 80% oxygen and 20% air
9976178|NCT01348893|Experimental|Yoga during physical education|
9976179|NCT01348906|Experimental|Intermittent normoxia|Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
9976180|NCT01348932||Asthma|The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma
9976181|NCT01348945|Experimental|Stump Preserving ACL Surgery|Patients of partial tear ACL injury fulfilling inclusion criteria received stump preserving ACL surgery, entered conventional ACL reconstruction rehabilitation program
9976182|NCT01348945|Active Comparator|ACL Reconstruction|Patients with complete tear ACL injury received ACL reconstruction entered conventional ACL rehabilitation program
9686194|NCT04112095|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time every day for up to 24 weeks
9686195|NCT04099485|No Intervention|Current State|Clinicians of patients randomized to this arm will have access to the Atrial Fibrillation Decision-Support Tool (AFDST) embedded in our EHR (as they do now), but will not receive BPAs alerting them to patients who might benefit significantly from a change in anticoagulation treatment.
9686196|NCT04099485|Experimental|AFDST with BPA|Clinicians of patients randomized to this arm will receive BPAs when they are in the medical record of an AF patient who might gain significantly from a change in anticoagulation treatment. In addition, clinicians will have the ability to refer patients to a pharmacist-staffed AF Thromboprophylaxis Shared Decision-Making Service based in our Anticoagulation Clinic.
9686197|NCT04090658|Experimental|RSV_PreF3_AS01B Group|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
9686198|NCT04090658|Placebo Comparator|Placebo Group|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
9686199|NCT04088734|Experimental|ABO-102|Dose of 3x10^13 vg/kg
9686200|NCT04056416|Experimental|HIIT Exercise Program|Exercise on a MedBIKE 3 times a week for 8 weeks with pre- and post-CPET testing, questionnaires and qualitative interviews.
9686201|NCT04052971|Experimental|Escalation phase|"Drug: ABN401~Route of Administration: Oral~The study will follow a single patient cohort approach for the first 3 regular dose levels followed by classic 3+3 design. The starting dose is 50mg QD."
9686202|NCT04052971|Experimental|Expansion phase|"Drug: ABN401~Route of Administration: Oral~Once the MTD or highest escalation cohort has been reached, or notable efficacy has been observed at a given dose level, a decision as to RP2D will be determined. Upon the establishment of RP2D, up to 4 expansion cohorts of 10-29 patients will be recruited representing various c-Met amplification or mutant tumor types of interest."
9686203|NCT04050553|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) in one of two study periods.
9686204|NCT04050553|Placebo Comparator|Placebo|Placebo administered SC in one of two study periods.
9686205|NCT04049331|Experimental|Testosterone|Testosterone undecanoate injection 750 MG/3 ML
9686206|NCT04049331|Placebo Comparator|Placebo|clinical grade saline 0.9% sodium chloride injection
9686207|NCT04037813|Active Comparator|Laparoscopic tubal occlusion|54 patients will undergo laparoscopic tubal occlusion.
9686208|NCT04037813|Active Comparator|Hysteroscopic tubal occlusion|54 patients will undergo hysteroscopic tubal occlusion.
9686209|NCT04007666|Experimental|Cognitive Processing Therapy (CPT)|CPT is a gold-standard evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms. It can be delivered in group and individual formats, but will be delivered in a group format in this project due to feasibility in the setting. Structure will be based on feedback obtained during completion of Aim 2 while remaining within the range evaluated in prior research (i.e., 8-12 sessions, 1-2x per week, each lasting 1.5-2 hours).
9686210|NCT04007666|Active Comparator|Coping Skills Group|The Coping Skills Group will match for attention and dose, without adding any cost to the system. Exact content will be determined during completion of Aim 2; however, project sites already provide coping-focused programming and coping-skill approaches to trauma treatment are a common alternative to evidence-based therapies for PTSD, such as CPT, that deal more directly with the index trauma. To provide an enhanced standard of care, the investigator will review treatment materials (workbooks, handouts) already used in prison settings and arrange a curriculum of skills similar to those in coping-focused trauma-informed interventions (e.g., psychoeducation, assertiveness).
9686211|NCT04000880|Experimental|Project 1: Diet-Exercise|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
9695906|NCT04772794|Placebo Comparator|control group|intraoperative administration of 30% oxygen and 70% air
9976183|NCT01348958|Experimental|Post-operative knee replacement|Subjects that have had a hemi knee replacement of one knee at least 8 weeks ago had the post-operative knee scanned using the orthopedic hip application and the Lunar orthopedic knee application.
9976184|NCT01348971|Experimental|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
9976185|NCT01348971|Placebo Comparator|Placebo|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
9976186|NCT01348984|Active Comparator|group 1|group 1 = transdermal fentanyl patch
9976187|NCT01348984|Placebo Comparator|group 2|placebo patch
9976188|NCT01348997|Active Comparator|Project Onward website + 16 person social network|
9976189|NCT01348997|Active Comparator|Project Onward website + 8 person social network|
9976190|NCT01349010|Placebo Comparator|Placebo|Placebo Arm: Placebo 1 tablet bid. p.o
10179617|NCT03801252|Placebo Comparator|Placebo + Placebo|Women will be randomized 1:1 to receive placebo intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and placebo intravenously once at the start of the labor induction
10179618|NCT03800966|Experimental|Intervention|The intervention leaflets will contain information on the TI's tactics to get young people to smoke.
10179619|NCT03800966|Placebo Comparator|Control|The control leaflets will contain information on the tobacco control in Hong Kong.
9686212|NCT04000880|Experimental|Project 2: Exercise-Diet|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
9686213|NCT04000880|Experimental|Project 3: Survivorship Topics- Combined Diet and Exercise|For the first six months of the study, participants will be in the Survivorship Topics group, where they receive health information on topics other than diet and exercise. Participants will then join the intervention, receiving the diet and exercise content simultaneously in combined web-based sessions. Participants will receive and participate in web-based sessions that focus on diet and exercise for 12 months. Participants will be encouraged to track their diet, weight and physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
9686214|NCT03999879||Cognitively Normal|having 30 participants with normal cognition
9686215|NCT03999879||Amnesic MCI|aMCI Group having 15 participants with a CDR of 0.5-1 and a Mini-Mental State Examination (MMSE) of 20-25.
9686216|NCT03994679||cleft patient requiring bone graft|Patients presenting at the division of maxillofacial surgery at the AZ Sint-Jan Brugge-Oostende av (Belgium) or the 1st department of pediatrics at the USemmelweis (Hungary) for bone graft surgery of the unilateral cleft receive a complete routine work-up, including a cone-beam CT (CBCT).
9686217|NCT03987464|Experimental|Patients with MCI|Participants diagnosed with mild cognitive impairment (MCI) and their study partners
9686218|NCT03968419|Experimental|canakinumab monotherapy|All patients will receive canakinumab (ACZ885) prior to surgery
9686219|NCT03968419|Experimental|canakinumab + pembrolizumab|All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery
9686220|NCT03968419|Experimental|pembrolizumab monotherapy|All patients will receive 2 doses of pembrolizumab prior to surgery
9686221|NCT03955471|Experimental|Niraparib+Dostarlimab (TSR-042)|Participants will receive both Niraparib and TSR-042 to evaluate the efficacy and safety of the combination of both drugs. Niraparib will be administered once daily (QD) continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) will be administered via a 30-minute intravenous (IV) infusion on Day 1 every 3 weeks (Q3W) during Cycles 1 through 4. Beginning at Cycle 5, dostarlimab (TSR-042) will be administered via a 30-minute IV infusion on Day 1 of each 6-week cycle until PD or toxicity, for a maximum of 3 years.
9686222|NCT03954431|Experimental|CE-BCT|All subjects will undergo contrast-enhanced breast CT (CE-BCT)
9686223|NCT03946891|Experimental|Arm A|
9686224|NCT03946891|Experimental|Arm B|
9686225|NCT03941379||Patients previously participated in an Aura Biosciences study|Patients with Choroidal Melanoma or Indeterminate Lesions.
9686226|NCT03937466|Experimental|Experimental Cooling Mattress Pad|Subjects will use a cooling mattress pad nightly for approximately 8 weeks
9686227|NCT03935308|Experimental|MR-guided SBRT With SIB to the DILs to Prostate Cancer|Dose escalation to the DIL(s) will be performed in the traditional Phase I 3+3 design. Patients will be treated in four cohorts (three patients per dose level) starting with a dose of 9 Gy to the DIL(s). If no dose limiting toxicity (DLT), defined below, is observed after 90 days, then an additional three patients will be entered at the next dose level. Dose to the DIL(s) will be escalated at 1 Gy increments until DLT is observed or if maximum dose level (60 Gy in 5 fractions of 12 Gy) is reached with no observed DLT. If one of the three patients experience a DLT at a particular dose level an additional three patients will be enrolled at that level. If two or more patients experience a DLT a lower dose level will be explored to define the maximum tolerated dose (MTD). The three patients within any cohort can be enrolled simultaneously or sequentially without any waiting period among them.
9686228|NCT03934684|Experimental|Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter.~Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression"
9686229|NCT03934684|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted.~Lenalidomide 25 mg is taken orally on days 1 to 21.~Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination."
9686230|NCT03913949|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
9976191|NCT01349010|Active Comparator|Probucol|Probucol Arm: Imported Probucol 250 mg (1 tablet) bid. p.o
10179620|NCT03801213|Active Comparator|Urinary catheterization|
10179621|NCT03801213|Experimental|manual bladder stimulation Technique|
10179622|NCT03801187|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
10179623|NCT03801187|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
10179624|NCT03801187|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
10179625|NCT03801291|Active Comparator|Transvaginal repair|Repair of anterior rectocele via the vagina
10179626|NCT03801291|Active Comparator|Transperineal repair|Repair of anterior rectocele via the perineum
10179627|NCT03801226|Experimental|10% dextrose in sterile water|Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
10179628|NCT03801226|Active Comparator|Dianeal Low-Calcium with 4.25% Dextrose|Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.
10179629|NCT03801031|Active Comparator|Lidocaine|Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
10179630|NCT03801031|Placebo Comparator|Placebo|Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.
10179631|NCT03801239||patients with Overactive Bladder (OAB)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
9686231|NCT03911453|Experimental|Treatment (rucaparib)|"Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of programmed cell death-1 with ligand (PD-L1) by immunohistochemistry (IHC)~. Starting Dose 600 mg twice daily Dose Level -1 500 mg twice daily Dose Level -2 400 mg twice daily Dose Level -3 300 mg twice daily"
9686232|NCT03910530|Experimental|INCMGA00012|Single-agent INCMGA00012.
9686233|NCT03910530|Experimental|INCB001158 75 mg|Single-agent INCB001158.
9686234|NCT03910530|Experimental|INCB001158 100 mg|Single-agent INCB001158.
9686235|NCT03910530|Experimental|INCMGA00012 + INCB001158|Combination of INCMGA00012 and INCB001158.
9686236|NCT03882268|Experimental|MIYCN interventions|8 facilities run by 2 NGOs that will receive intensified MIYCN interventions.
9686237|NCT03882268|No Intervention|Comparison facilities|8 facilities run by 2 other NGOs, which will not receive any standardized MIYCN interventions.
9686238|NCT03871049|Placebo Comparator|group 1|intathecal bupivacaine
9686239|NCT03871049|Active Comparator|group 2|intrathecal bupivacaine with dexamethasone
9686240|NCT03852472|Placebo Comparator|Group A|Placebo b.i.d
9686241|NCT03852472|Active Comparator|Group B|Avacopan 10 mg b.i.d
9686242|NCT03852472|Active Comparator|Group C|Avacopan 30 mg b.i.d
9686243|NCT03851068|Experimental|Tria Aortic Valve|Patients receiving the Foldax Tria Aortic Valve
9686244|NCT03849625||NSAID sensitivity|Patients diagnosed with an immediate reaction to aspirin/NSAIDs/or paracetamol
9686245|NCT03834961|Experimental|Treatment (larotrectinib)|Patients receive larotrectinib PO or by NG or G-tube BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity, or complete surgical resection of tumor.
9686246|NCT03830788|Active Comparator|Brachytherapy|radiation by brachytherapy: brachytherapy by Iodine 125 delivering 144 Gy to the prostate
9686247|NCT03830788|Experimental|stereotactic body radiotherapy (SBRT)|radiation by SBRT: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate. The prostate can be tracked/localized/treated thanks to the Cyberknife or a conventional linac equipped with an ExacTrac or a Calypso4D system.
9686248|NCT03826264||Korea Centers|Seoul, Korea All Patients undergoing TAVR
9686249|NCT03826264||Stanford University|California, USA All Patients undergoing TAVR
9686250|NCT03826264||Northwestern University|Evanston, Illinois, USA All Patients undergoing TAVR
9686251|NCT03826264||Cheng-Hsin Hospital|Taipei, Taiwan All Patients undergoing TAVR
9686252|NCT03824652|Experimental|Usual Diet + Walnuts|Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
9686253|NCT03824652|Active Comparator|Usual Diet|Usual diet for 4-10 weeks
9686254|NCT03811028|Experimental|SOBI003|"SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to administration. For a bodyweight < 25 kg, the total infusion volume is 100 mL. For a bodyweight ≥ 25 kg, the total infusion volume is 250 mL.~SOBI003 is administered as i.v. infusions given once weekly for a duration of 80 weeks (from Week 25 until Week 104 following the first 24 weeks of SOBI003 administration in the FIH study (SOBI003-001) study. The SOBI003 dose will be adjusted to the highest dose that has been declared safe by the safety review committee on the FIH study.Hence, dose adjustments may occur a couple of times on the extension study until the final decided dose has been determined."
9686255|NCT03769844|Experimental|IV GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
9686256|NCT03769844|Experimental|SQ GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
9686257|NCT03769844|Experimental|IV GM-CSF 250 mcg/m2/dose|If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
9686258|NCT03769844|Experimental|SQ GM-CSF 250 mcg/m2/dose|If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
9686259|NCT03760068|Active Comparator|MYL-1601D Product (100 U/mL)|
9686260|NCT03760068|Active Comparator|FlexPen NovoLog® (100 U/mL)|
9686261|NCT03755804|Experimental|Low-Risk|Participants receive 2 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
9976192|NCT01349023|Experimental|Standard Energy content/Standard ED|
9976193|NCT01349023|Experimental|Standard Energy content/Reduced ED|
9976194|NCT01349023|Experimental|Reduced Energy content/Standard ED|
9976195|NCT01349023|Experimental|Reduced Energy content/Reduced ED|
9686262|NCT03755804|Experimental|Intermediate-Risk|Participants receive 3 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
9686263|NCT03755804|Experimental|High-Risk|Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
10179632|NCT03801239||patients with Mixed Urinary incontinence (MUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
9686264|NCT03750175||Colorectal cancer patients|"Clinical utility of ctDNA analysis for treatment decision~Use of ctDNA for KRAS, NRAS and BRAF testing prior to potential anti-EGFR monoclonal antibody treatment for metastatic colorectal cancer"
9686265|NCT03748680|Active Comparator|A|Intensified follow-up schedule
9686266|NCT03748680|Experimental|B|Adjuvant chemotherapy + intensified follow-up schedule
9686267|NCT03744429|Experimental|Mediterranean Meal Plan|This is a single arm study in which participants will receive meals that follow a Mediterranean diet plan for 4 weeks. Breast milk samples will be collected before, during, and after the intervention period.
9686268|NCT03743415|Experimental|Handbook|The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
9686269|NCT03743415|Experimental|TIP-C plus Handbook|Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
9686270|NCT03742986|Experimental|HER2-negative, including TNBC or HR-positive|
9686271|NCT03742986|Experimental|HER2-positive, independent of HR status|
9686272|NCT03737799||Group 1 Age 18-50 at diagnosis|Diagnosed with diabetes within the previous 1 year. Aged between 18 and 50 years at the time of diabetes diagnosis
9686273|NCT03737799||Group 2 Late Onset (insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated with insulin therapy
9686274|NCT03737799||Group 3 Late Onset (no insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated without insulin
9976196|NCT01349062|Other|"Kallunk oxide (Immunotherapy)"|"The participants will be received a daily regimen of Kallunk oxide(Immunotherapy) ."
9976197|NCT01349075||TheraSphere|
10179633|NCT03801239||patients with Stress Urinary Incontinence (SUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
10179634|NCT03801135|No Intervention|Electrolyte&Albumin Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
10179635|NCT03801135|Experimental|Fibrinogen Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
10179636|NCT03801135|Active Comparator|FFP Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
10179637|NCT03801161|No Intervention|Healthy infants|
10179638|NCT03801161|Experimental|Infants with an inflammatory condition|Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
10179639|NCT03801317|Experimental|BC/ egg|4.3 grams egg powder + 5.7 grams bovine colostrum
10179640|NCT03801317|Placebo Comparator|Control|15 grams corn-soya blend
10179641|NCT03801057|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
10179642|NCT03801057|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
10179643|NCT03800953|Experimental|Avelumab (Bavencio)|This is a single arm, and open label study. All the subjects recruited will receive Avelumab.
9686277|NCT03665597|Experimental|Pembrolizumab Sequence 1|Participants receive a single dose of pembrolizumab (pembro) in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A subcutaneously (SC); Cycle 2 Day 1: pembro Dose B intravenously (IV); Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
9976198|NCT01349088|Experimental|Motesanib|Eligible patients will be enrolled to receive ixabepilone, capecitabine, plus motesanib.
9976199|NCT01349127|Active Comparator|20µg Vitamin D3|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol).
10179644|NCT03800927|Placebo Comparator|Sham Ultrasound Device|No ultrasound treatment
10179645|NCT03800927|Active Comparator|Active Ultrasound Device|Active treatment
9686278|NCT03665597|Experimental|Pembrolizumab Sequence 2|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A SC; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
9686279|NCT03665597|Experimental|Pembrolizumab Sequence 3|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
9686280|NCT03665597|Experimental|Pembrolizumab Sequence 4|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose B IV; Cycle 3 Day 1: pembro Dose A SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
9686281|NCT03665597|Experimental|Pembrolizumab Sequence 5|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose A SC: Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
9686282|NCT03665597|Experimental|Pembrolizumab Sequence 6|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
9686283|NCT03665597|Experimental|Pembrolizumab Dose D|Participants receive a single dose of pembro Dose D IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).
9686284|NCT03663946||Patients taking combination therapy with Yervoy and Opdivo|Medical records will be reviewed for safety and treatments for specific ADR
9686285|NCT03640793|Experimental|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
9686286|NCT03628781|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
9686287|NCT03628781|Other|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
9686288|NCT03625323|Experimental|1st line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
9686289|NCT03625323|Experimental|2nd line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
9686290|NCT03625323|Experimental|HNSCC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
9686291|NCT03624790|Experimental|Group 1: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
9686292|NCT03612973|Active Comparator|non cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
9686293|NCT03612973|Active Comparator|cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~Fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
9686294|NCT03597438||Patient|patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery
9686295|NCT03597438||Volunteer|Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study
9686296|NCT03589014|No Intervention|Control|Standard Treatments recommended for CCM
10179646|NCT03801018||Parents who have used the donation of gametes|
10179647|NCT03801018||Children born of gametes donation|
10179648|NCT03801070||Less than median number necrosectomies|Group one includes patients who underwent less than median number necrosectomies
10179649|NCT03801070||At least the median number of necrosectomies|Group two includes patients who underwent at least the median number of necrosectomies
10179650|NCT03801096|Experimental|Narrative Based Therapuetic Assessment|
10179651|NCT03801096|Active Comparator|Health Education (HE)|
10179652|NCT03800914|Experimental|High Intensity Interval Training|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
10179653|NCT03800914|Active Comparator|Traditional pulmonary rehabilitation|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
10179654|NCT03800940|Experimental|Fistulography and trans-drain occlusion|Fistulography is performed to assess the condition of the fistula, and trans-drain occlusion is performed by injecting glue (NBCA and Lipiodol) through the drain to occlude the tract.
9686297|NCT03589014|Experimental|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
9686298|NCT03583255|Experimental|Arm I (dexamethasone, exercise)|Participants receive dexamethasone PO BID for 7 days. Participants also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
9686299|NCT03583255|Active Comparator|Arm II (placebo, exercise)|Participants receive placebo PO BID for 7 days. Participants also complete resistance training and moderate intensity walking as in Arm I.
9686300|NCT03560206|Experimental|Family SWaP intervention|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
9686301|NCT03560206|Active Comparator|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
9686302|NCT03557918|Experimental|Tremelimumab|Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.
9686303|NCT03551782|Experimental|Cohort 1|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer [t-SCNC]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
9686304|NCT03551782|Experimental|Cohort 2|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1.
9686305|NCT03551782|Experimental|Cohort 3|Biomarker-positive participants who progressed on AA-P will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
9686306|NCT03551782|Experimental|Cohort 4|Biomarker-positive participants who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
9686307|NCT03551782|Experimental|Cohort 5|Biomarker-negative participants with t-SCNC who progressed on treatment with AA-P, apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
9686308|NCT03503838|Experimental|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
9686309|NCT03503838|No Intervention|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
9686310|NCT03492424||Focal therapy for prostate cancer|"All men >18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion.~The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy."
9686311|NCT03456843|Experimental|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
9686312|NCT03456843|Experimental|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
10179655|NCT03800940|Sham Comparator|Fistulography|Fistulography is performed to assess the condition of the fistula, without trains-drain occlusion.
10179656|NCT03800706|Experimental|TQB2450|
9686315|NCT03442114|Experimental|Hydroxyurea SDM Toolkit (H-SDM)|During the H-SDM toolkit condition, sites will develop methods for identifying Eligible Patients & Monitoring Progress, have the opportunity to use Implementation Tools, and will use the Visit Decision Aids. The H-SDM toolkit has four visit decision aids to support parents in their decision about hydroxyurea: pre-visit brochure, in-visit issue card, after-visit booklet and video narratives {videos of parents telling their story about how they made a decision about hydroxyurea).
9686316|NCT03442114|Active Comparator|Clinician Pocket Guide|In this condition, sites will provide current guidelines for offering hydroxyurea and use the American Society of Hematology (ASH) pocket guide as a reference. ASH developed 'The Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease' clinician pocket guide based on the National Heart, Lung, and Blood Institute's Evidence Based Management of Sickle Cell Disease: Expert Panel Report, 2014.'
9686317|NCT03441464|Experimental|1st Tier Dose Level|3 patients administered single dose of LUM015 at 0.5 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
9686318|NCT03441464|Experimental|2nd Tier Dose Leel|3 patients administered single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
10187459|NCT03726073|Experimental|Intervention group|Electrical stimulation will be given 30min before anesthesia and during surgery, auricular acupressure will be given in postoperative 3 days
10187460|NCT03726073|Sham Comparator|Non-intervention group|Usual care
9686319|NCT03441464|Experimental|3rd Tier Dose Level|After evaluation of the fluorescence signal observed with the LUM imaging device in the three other cohorts,the subsequent 3 patients will receive a dose of 0.5-1.5 mg/kg.
10179657|NCT03800888|Experimental|Arm A|Participants in Arm A will receive a Wisepill device for Real- time monitoring plus Daily SMS reminders plus Social Supporter notifications (for 3 months) sent according to participant's preferred time and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
10179658|NCT03800888|Experimental|Arm B|Participants in Arm B will receive a wisepill device for Real-time monitoring plus Weekly SMS reminders plus Social support notifications (for 3 months) sent according to participant's preferred time and date and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
9686320|NCT03441464|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients to measure baseline tissue fluorescence. The tissue will still be imaged ex-vivo using the LUM Imaging Device
9686321|NCT03428126|Experimental|Durvalumab + Trametinib|"Participants take Trametinib tablets by mouth every day. Trametinib taken alone for the first 7 days of the study then participants begin receiving it in combination with Durvalumab.~Participants receive Durvalumab by vein every 4 weeks.~Each cycle is 28 days."
10179659|NCT03800888|No Intervention|Arm C|Participants in Arm C will receive only the Wise pill device (No SMS)
10179660|NCT03800901|Active Comparator|Control|The Control arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will not be offered Continuing Medical Education (CME) or American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
10187461|NCT03726060|Other|splint therapy|"Alginate impressions will be taken and the plaster models of the dental arches will be made.~The splint will be subsequently delivered to the patient with the relative indications of use.~The splint therapy consist in the use of neuromuscoral splint every the night for 6 months."
9686322|NCT03417960|Experimental|iTBS|accelerated iTBS to Left DLPFC
9686324|NCT03375164|Experimental|Cohort A: SRP-9001|Participants will receive a single IV infusion of SRP-9001 on Day 1.
9686325|NCT03375164|Experimental|Cohort B: SRP-9001|Participants will receive a single IV infusion of SRP-9001 on Day 1.
9686326|NCT03352934|Experimental|Avelumab|10 mg/kg Avelumab every 2 weeks
9686327|NCT03341689|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
9686328|NCT03341689|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
9686329|NCT03341689|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
9686330|NCT03341689|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
9686331|NCT03340766|Experimental|Cohort Ia: Blinatumomab 9/28 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion (CIVI) for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days then 28 µg/day for the remaining days of treatment.~Starting on Day 15 participants also received 200 mg pembrolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) until disease progression or for up to 35 cycles."
9686332|NCT03340766|Experimental|Cohort IIa: Blinatumomab 9/28/56 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 56 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
9686333|NCT03340766|Experimental|Cohort IIIa: Blinatumomab 9/28/112 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 112 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
9686334|NCT03340766|Experimental|Expansion Cohort|This cohort will test the maximum tolerated dose of blinatumomab in combination with pembrolizumab identified in Part 1 of the study.
9686335|NCT03327493|Other|Refractory cardiogenic shock under ECLS|
9686336|NCT03300817|Experimental|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
9695907|NCT04772898|Experimental|Hippotherapy|Both children with autism spectrum disorder and with typical development will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.
9827572|NCT02461160|Experimental|BA/FE Cohort 10 Group 1: C,A,B|Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.
9686337|NCT03292484|Experimental|Treatment Pathway 1, 2, 3, 4, 5|Subjects will be assigned to one of five treatment pathways when first enrolled into ARC008, which is dependent on the treatment received (AR101 or placebo) during the parent study and their tolerance of this treatment regimen (e.g., daily or non-daily schedule).
10179661|NCT03800901|Experimental|CME|The CME arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will be offered Continuing Medical Education (CME) and American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
10179662|NCT03800680|No Intervention|Usual Care (Arm 1)|Participants will receive usual care by their diabetes clinics.
10179663|NCT03800680|Experimental|DMP (Arm 2)|Participants will receive usual care by their diabetes clinics and the Diabetes Management Package (DMP).
10179664|NCT03800680|Experimental|DMP + M-POWER Rewards (Arm 3)|Participants will receive usual care by their diabetes clinics, the Diabetes Management Package (DMP), and the financial incentive program, M-POWER Rewards.
10179665|NCT03800810|Experimental|Control|Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
10179666|NCT03800810|Experimental|Intervention 1|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
10179667|NCT03800810|Experimental|Intervention 2|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
9686338|NCT03280628|Active Comparator|Absorbable Sutures|30 patients will have their laceration closed with sutures that absorb on their own and do not need to be removed.
9686339|NCT03280628|Experimental|Steri-Strips|"30 patients will have their laceration closed with a special medical tape called Steri-Strips."
9686340|NCT03280628|Experimental|Dermabond|"30 patients will have their laceration closed with a special skin glue called Steri-Strips."
9686341|NCT03277703|Experimental|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
9686342|NCT03277703|Active Comparator|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
9686343|NCT03257033|Experimental|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
9686344|NCT03257033|Active Comparator|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
9686345|NCT03250663|Active Comparator|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
9686346|NCT03250663|Experimental|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
9686347|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
9686348|NCT03192397|Experimental|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
9686349|NCT03190330|Experimental|Ibrutinib|Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
9686350|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (neutral)|
9686351|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (marijuana)|
9686352|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (neutral)|
9686353|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (marijuana)|
9686354|NCT03123978|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9686355|NCT03048331|Experimental|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
10179668|NCT03800810|Experimental|Intervention 3|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
10179669|NCT03800563|Experimental|Laser assisted liposuction|Laser Assisted Liposuction with the LipoLife system.
10179670|NCT03800875|Experimental|Insulin-Pramlintide Closed-Loop Strategy|Fast-acting insulin will be delivered using two separate infusion pumps. The pumps' infusion rates will then be changed manually based on the computer-generated recommendation. The computer-generated recommendations are based on a dosing algorithm. With no-meal announcement or carbohydrate counting, the dual-hormone closed-loop system will be fully reactive, and insulin and pramlintide dosages will be based solely on sensor readings
10179671|NCT03800875|Active Comparator|Insulin-alone Closed Loop Strategy|"Fast-acting insulin will be delivered by a subcutaneous insulin infusion pump based on an algorithm that automatically adjusts insulin rates based on a dosing algorithm. The carbohydrate content for every ingested meal will be entered into the algorithm to calculate the insulin prandial bolus based on each participant's insulin-to-carbohydrate ratio. The carbohydrate content will be entered at the onset of the meal.~Drug(s): Insulin (FiAsp)"
9686356|NCT03048331|No Intervention|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
9686357|NCT03043599|Experimental|Combination Therapy|Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy. Radiotherapy, followed by a 14 to 21 day break between radiotherapy and the beginning of study drug treatment.
9686358|NCT03028831|Active Comparator|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
9686359|NCT03028831|Placebo Comparator|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
9686360|NCT02968381|Experimental|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
9686361|NCT02968381|Active Comparator|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
9686362|NCT02877550|Experimental|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)~Part B - dose expansion:~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
9686363|NCT02720185|Experimental|Dasatinib 100mg|Dasatinib 100mg for 7-10 days until day prior to surgery
9686364|NCT02706847|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
9686365|NCT02706847|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
9686366|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
9686367|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
9686368|NCT02701777|Active Comparator|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
9686369|NCT02701777|Active Comparator|STDP + Training|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
9686370|NCT02701777|Active Comparator|Sham STDP + Training|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times. Motor training will follow stimulation.
9686371|NCT02701777|Other|Multisite-STDP + Training|Prospective Single Cohort Multisite-Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
9686372|NCT02677896|Experimental|Enzalutamide + Androgen Deprivation Therapy (ADT)|Participants received enzalutamide orally once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
9686373|NCT02677896|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants received matching placebo orally once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
9695908|NCT04773028||PATİENT GROUP(GROUP 1)|This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
9977724|NCT01364636||Acute Heart Failure|Patients admitted to emergency room in Acute Heart Failure at Hospital PróCardíaco and Hospital Universitario Antonio Pedro
10179672|NCT03800719|Experimental|Intervention Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, regular messages through Instant Messaging (IM), psychosocial support and referral to SC services through IM
10179673|NCT03800719|Active Comparator|Control Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, SMS message on general health
10179674|NCT03800667|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1000 mg of vitamin C for one month,
9686374|NCT02657434|Experimental|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
9686375|NCT02657434|Active Comparator|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants received IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
9686376|NCT02564900|Experimental|Part 1 Dose escalation|Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.
9686377|NCT02564900|Experimental|Part 2 Dose expansion|Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), HER2 expressing other solid malignant tumor (Part 2d); HER2 expressing breast cancer (Japan only; Part 2e)
9686378|NCT02561299|Experimental|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
9686379|NCT02561299|Active Comparator|DCB angioplasty|014 Drug Coated Balloon angioplasty
9686380|NCT02548143|Experimental|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
9686381|NCT02520427|Experimental|Group 1: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)|
9686382|NCT02520427|Experimental|Group 2: Minimal Residual Disease Positive (MRD+) AML|
9686383|NCT02520427|Experimental|Group 3: Myelodysplastic syndrome (MDS)|
9686384|NCT02520427|Experimental|Group 4: R/R AML with alternative pretreatment|
9686385|NCT02520427|Experimental|Group 5: R/R AML with alternative dose schedule|
9686386|NCT02496780|Placebo Comparator|placebo|once or 3x daily injectable placebo (insulin diluent)
9686387|NCT02496780|Experimental|basal insulin levemir|once daily basal insulin therapy with insulin levemir
10179675|NCT03800667|No Intervention|Women not taking vitamin C|Women who are undergoing elective gynecological surgeries and who are randomized not to take any vitamin C for one month.
9686388|NCT02496780|Experimental|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
9686389|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
9686390|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
9686391|NCT02393859|Active Comparator|High Risk Consolidation 3 (HC3) Chemotherapy|One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m^2/day intravenous [IV] on Days 1-6), vincrisitne (1.5 mg/m^2/day IV on Days 1 and 6), daunorubicin (30 mg/m^2 IV over 24 hours on Day 5), methotrexate (1 g/m^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m^2 IV for 1 hour on Days 2-4), and pegylated [PEG]-asparaginase (1000 U/m^2 IV for 2 hours or intramuscularly [IM] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m^2 IV or IM every 48 hours for a total of 6 doses).
9686392|NCT02393859|Experimental|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
9686393|NCT02352103|Active Comparator|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
10179676|NCT03800745|No Intervention|No Medication|No intervention is assigned in Arm A.
10179677|NCT03800745|Experimental|Colace|This is Arm B. Docusate sodium(Colace) is prescribed as100mg twice daily orally. Patients will be instructed to begin taking this the evening of surgery through postoperative day five.
9686394|NCT02352103|Experimental|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
9686395|NCT02273362|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).
9977725|NCT01364675|Experimental|Metformin+Enalapril+Simvastatin|
10179678|NCT03800745|Experimental|Miralax|This is Arm C. Miralax 17 grams oral powder pack daily is prescribed to be taken with breakfast. Patients will be instructed to begin taking this the morning after surgery through postoperative day five.
9686396|NCT02265042|Experimental|electrical stimulation|electrical Stimulation using the Stimulette device
9686397|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
9686398|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
9686399|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
9686400|NCT02178358|Experimental|150 milligram (mg) Galunisertib Monotherapy|150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).
9686401|NCT02178358|Experimental|150 mg Galunisertib + 400 mg Sorafenib Therapy|"150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
9686402|NCT02178358|Placebo Comparator|400 mg Sorafenib + Placebo Therapy|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
9686403|NCT02157610|Experimental|Standard Treatment (ST)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
9686404|NCT02157610|Experimental|Motivation + Problem Solving (MAPS)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline.Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months. 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
9686405|NCT02073279|Experimental|Satralizumab|Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
9686406|NCT02073279|Placebo Comparator|Placebo|Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
9686407|NCT01865617|Experimental|ALL (high tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg"
9686408|NCT01865617|Experimental|ALL (high tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
9686409|NCT01865617|Experimental|ALL (high tumor burden) dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg"
9686410|NCT01865617|Experimental|ALL (low tumor burden) dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg"
9686411|NCT01865617|Experimental|ALL (low tumor burden) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg"
10179679|NCT03800771|Experimental|Practice dual-task tests|"The study consists to practice these dual-task tests with a new device which name is Cycléo BRAU that allows to the patients to achieve carefully an attentional task: cycle. Results will be compared tothe results obsvered during the routine GAITRITE analysis ( a validated tool for elderly patients and gait analysis)."
10187999|NCT03720522||Group 3: Patients suffering from stunned neurogenic myocardium|"Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels and presence of wall motion abnormalities (WMA) have potential WMA due to neurogenic myocardial stunning. They will be allocated to group 3.~These patients will undergo a follow-up CMR without adenosine-perfusion after 3 months to confirm improvement/normalization of WMA.~Patients with normal (< 0.015mg/L) hsTnT levels and presence of WMA will also be allocated to group 3."
10179680|NCT03800862||CTP and CT-FFR|"This will be a prospective, observational study designed to include a convenience sample of all qualifying patients undergoing myocardial CTP and CT-FFR.~The study will enroll patients who have chest discomfort and will require further evaluation for the presence of coronary artery disease. Patients in the study will include those who have had a clinically indicated CCTA for suspicion of coronary artery disease and are determined to have a coronary stenosis ≥50% and ≤99%. However, patients with Left main disease greater than 50% and occluded vessels Coronary Artery Disease Reporting and Data System (CAD RADS 5) will be excluded from the study. CCTA is a clinically indicated and standard of care procedure at Lancaster General Hospital.~."
10179681|NCT03800498|Experimental|Intervention|For twelve weeks, only intervention group were given DASH education
9686412|NCT01865617|Experimental|CLL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg"
9686413|NCT01865617|Experimental|CLL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg"
9686414|NCT01865617|Experimental|CLL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg"
9686415|NCT01865617|Experimental|CLL (ibrutinib) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg"
9686416|NCT01865617|Experimental|NHL dose level 1|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg"
9686417|NCT01865617|Experimental|NHL dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
9686418|NCT01865617|Experimental|NHL dose level 3|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg"
9686419|NCT01865617|Experimental|NHL (dose dense) dose level 2|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg"
9976200|NCT01349127|Active Comparator|20µg Vitamin D3 + 500 mg Calcium|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol) and one tablet of calcium carbonate containing 500mg of calcium.
10179682|NCT03800498|No Intervention|Controlled|Controlled group not received DASH education
9686422|NCT01838174|Experimental|Acthar Gel (ACTH)|15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
9686423|NCT01838174|Active Comparator|IV methylprednisolone (steroids)|3 days of IV methylprednisolone (steroids) followed by 11 days of oral prednisone
9686424|NCT01730781||Schizophrenia|Patients diagnosed with schizophrenia both on medication and off medication
9686425|NCT01730781||Cannabis dependence|Frequent users of cannabis
9686426|NCT01730781||Family history of alcoholism|Healthy volunteers with a first degree relative with alcoholism
9686427|NCT01730781||Prodrome for psychotic illness|Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
9686428|NCT01730781||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
9686429|NCT01730781||PTSD-Post Traumatic Stress Disorder|Patients diagnosed with Post Traumatic Stress Disorder
9686430|NCT01730781||Opioid Use Disorder|Patients diagnosed with Opioid Use Disorder
9686431|NCT01613144||OsseoScrew|Test Product: OsseoScrew Spinal Fixation System
9686432|NCT01613144||Fenestrated Screw|Control Product: Any commercially available fenestrated screw system augmented with PMMA
9686433|NCT01582087||acute or chronic hepatic failure|All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma
9686434|NCT01544127|Experimental|MI-SI+TAU|Motivational Interviewing to Address Suicidal Ideation
9686435|NCT01544127|Experimental|MI-SI-R+TAU|Motivational Interviewing to Address Suicidal Ideation Revised
9686436|NCT01544127|Other|TAU Alone|Treatment as usual
9686437|NCT01532310||Pregnant women taking belimumab|Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
9686438|NCT01532310||Infants|Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
9686439|NCT01495637|Experimental|GM-CSF|GM-CSF is given in one of four treatment regimens (three days at a dose of 30, 62, or 125 mcg/m2/day, or extended dosing at 125 mcg/m2 through post-trauma day 6) to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
9686440|NCT01272050|Active Comparator|Arm A: 64 Gy - Radiation Therapy|Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
9686441|NCT01272050|Active Comparator|Arm B: 70 Gy - Radiation Therapy|Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
9686442|NCT01260402|Active Comparator|Epicardial|
9686443|NCT01260402|Experimental|Endocardial|
9686444|NCT01243190|Experimental|Ofatumumab|Loading dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
9686445|NCT01042015|Active Comparator|Concurrent controls|These subjects would undergo standard resuscitative efforts.
9686446|NCT01042015|Experimental|Emergency preservation and resuscitation|These subjects would undergo the complete EPR protocol, including rapid induction of hypothermia, resuscitative surgery, and resuscitation with cardiopulmonary bypass.
9686447|NCT01027858|Experimental|1|AT (aerobic-based exercise training)
9686448|NCT01027858|Active Comparator|2|CON (control; usual care)
9686449|NCT00964977|No Intervention|no irradiation|Patients within this arm only receive curative intended radical surgery
9686450|NCT00964977|Active Comparator|Radiation|Patients receive radiation within 6 weeks after curative intended radical surgery.
9686451|NCT00806390|Active Comparator|Metoprolol|Receiving metoprolol
9686452|NCT00806390|No Intervention|Control|Not receiving metoprolol
9686453|NCT00566618|Experimental|Dasatinib + Zoledronic Acid|"Dasatinib Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Zoledronic Acid Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort. Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
9686454|NCT00442559|Experimental|Montelukast|Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
9686455|NCT00442559|Active Comparator|Inhaled Corticosteroids (ICS)|Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
9686456|NCT00117338|Placebo Comparator|1|Placebo
9686457|NCT00117338|Active Comparator|2|montelukast sodium
9686458|NCT00095420|Experimental|1|Participants with autism will receive social skills training targeting children with autism
9686459|NCT00095420|Experimental|2|Participants without autism will receive social skills training to increase acceptance of peers with autism
9686460|NCT00095420|Experimental|3|Participants with and without autism will receive a combination treatment of social skills/education about autism
9686461|NCT00095420|Active Comparator|4|Participants with and without autism will receive usual training provided by their school district
9686462|NCT04877626|Active Comparator|AQ+AS|Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).
9686463|NCT04877626|Active Comparator|AM+L|Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)
9686464|NCT04877600||gender difference|dual task performance
9686465|NCT04877925|Active Comparator|Standard Group|Patients with 2 standard chest tubes
9686466|NCT04877925|Experimental|Coaxial Group|Patients with 1 coaxial tube
9686467|NCT04877704|Experimental|Symprove|Symprove probiotic
9686468|NCT04877704|Placebo Comparator|Placebo|Matched placebo provided by Symprove. Identical in appearance to Symprove probiotic.
10179683|NCT03800693|Active Comparator|2-hour infusion group|Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9686469|NCT04877509||Over 50 year's COVID-19 patients hospitalized at HCL from 1st March to 29th May 2020.|
9686470|NCT04877483|Experimental|Group GB20|Group GB20 will received acupuncture at acupoint GB20 twice a week 8 weeks for efficacy evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
9686471|NCT04877483|Experimental|Group GB20 plus BL2|Group GB20 plus BL2 will received acupuncture at acupoint GB20 plus BL2 twice a week 8 weeks for efficacy evaluation. And we could use the proteomics, oral microbiota, Schirmer's test, Tear breakup time, 6-GSI, OSDI, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
9686472|NCT04877483|Other|Healthy control|Healthy control group will not received any treatment. And we could use the proteomics, oral microbiota, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability to find the difference with the comparison between the dry eye syndrome and healthy control.
9686473|NCT04877418|Experimental|TeleCIMT group|"One month after baseline evaluations, patients will receive a 3-week program through TeleCIMT.~Task Oriented Repetitive Training~Use of the Affected Upper Extremity~Transfer Package"
9686474|NCT04877535|Experimental|Intervention|ML will be used to create a report card for each patient that summarizes the preoperative assessment and intraoperative data. Report card data will be made available to providers through multiple methods: integration into electronic health records workflows, electronic health records notifications, mobile device notifications, and print outs in the paper chart
9686475|NCT04877535|No Intervention|Pre-intervention|The standard of care. The report card will be electronically generated (to determine eligibility) but it will not be visible to clinicians.
9686476|NCT04877496||Immunocompetent controls|Participants aged at least 18 years, no history of COVID19, no history of anti-CD20 treatment
9686477|NCT04877496||Patients with a treatment history of rituximab|Participants aged at least 18 years, no history of COVID19, history of at least 1 dose of anti-CD20 treatment received since 01/01/2010
9686478|NCT04877353|Experimental|Group N|50 patients.NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
9686479|NCT04877353|No Intervention|group C|50 patients recieved conventional oxygen therpy.
9686480|NCT04877275|Experimental|Arm I: Selinexor+Pegylated liposomal doxorubicin +Dexamethasone|Arm I is given XDd regimen (ATG-010(Selinexor) 80mg/d QW, Pegylated liposomal doxorubicin 25mg/m2, d1and Dexamethasone 40mg/d QW) in approximately 25 subjects. 4 weeks per cycle and include a total of 12 cycles.
9686481|NCT04877275|Experimental|Arm II: Selinexor+Cyclophosphamide+Dexamethasone|Arm II is given XCd regimen (ATG-010 100mg/d QW, Cyclophosphamide 300mg/m2, d1and Dexamethasone 40mg/d QW). 4 weeks per cycle and include a total of 12 cycles.
9686482|NCT04877210|Experimental|Topical Insulin|Insulin (Actrapid) diluted in normal saline
9686483|NCT04877210|Placebo Comparator|Normal Saline|Normal saline eyedrops
9686484|NCT04877210|Active Comparator|Standard Artifical Tear|Gutt systane ultra
9686485|NCT04877431||De Nova Participants|De nova participants who had received teduglutide after marketing authorization will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
9686486|NCT04877431||Legacy Participants|Legacy participants who received teduglutide treatment prior to marketing authorization under expanded access type of program will be enrolled in this study and monitored by their physicians according to local clinical practice then followed for 24-weeks unless treatment discontinuation or lost to follow-up.
9686487|NCT04877223||CF|Patients with Cystic Fibrosis
9686488|NCT04877470||Newly referred patients visiting the spine-centre|Newly referred patients visiting the spine-centre at Zuyderland Medical Centre Heerlen in 2019, from 01.01.2019 until 31.12.2019.
9686489|NCT04877340|Other|Standard FNA 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a standard FNA 22G needle
9686490|NCT04877340|Experimental|Franseen 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a FNB 22G needle. The sequence of the use of needles will be randomized.
9686491|NCT04877444|Experimental|Aerobic exercise (AEx) + upper extremity rehabilitation|Subject will receive a total of 24 intervention sessions. In each session, subjects will perform 15 minutes of AEx followed by 200 repetitions of an upper extremity rehabilitation program.
9686492|NCT04877444|Experimental|Stretching (CON) + upper extremity rehabilitation|Subjects will perform 15 minutes of lower extremity stretching. Following lower extremity stretching subjects will receive 200 repetitions of DDP.
9686493|NCT04877067|Active Comparator|WJ-MSC combine witf rEMS|WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.
9686494|NCT04877067|Active Comparator|Only rEMS|rEMS applications were repeated 10 times with a 1-week interval.
9686495|NCT04877067|Active Comparator|Only WJ-MSC|WJ-MSC was applied only one time for both eyes.
9686496|NCT04877145|Experimental|single drill|one drill to place the implants 3.25mm diameter stainless steel drill was used.
9686497|NCT04877145|Active Comparator|sequential drills|For the control group, four drills (2.2mm, 2.75mm, 3.25mm and 4mm diameter),
9686498|NCT04877184|Experimental|Transcranial ultrasound stimulation and rehabilitation|The investigators expect to enroll 10 people in the experimental group.
9686499|NCT04877184|Active Comparator|Rehabilitation|The investigators expect to enroll 10 people in the control group.
9686500|NCT04877301|Experimental|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter.
9686501|NCT04877301|Active Comparator|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter.
9686502|NCT04877171|Experimental|telemedicine neurology consultation|Starting on day 12-14 post-discharge, participants will receive a phone call for a drug conciliation. Participants at 1-month post-discharge will receive a telemedicine consultation, another at 3 months and 6 months.
9686503|NCT04877171|Active Comparator|in-person neurology consultation|Starting at 1-month post-discharge, participants will attend an in-person neurology consultation and the following consultations depend on their physician's criteria until completed 6 months post-discharge.
9686504|NCT04877106|Active Comparator|Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®)|JANUMET®, 50mg/850mg, batch no. M047893, manufactured by MSD Pharma (Singapore) Pte.Ltd
9686505|NCT04877106|Experimental|Sitagliptin Phosphate/metformin Hydrochloride Tablets|50mg/850mg, batch no. 161006, manufactured by Tonghua Dongbao Pharmaceutical Co., Ltd.
9686506|NCT04877158|Experimental|Self-Blame and Perspective-Taking Intervention|These participants are enrolled with intent to participate in the group therapy intervention.
9686507|NCT04877314|Experimental|Intermittent fasting|
9686508|NCT04877236|Experimental|Green Sun Medical Brace|This study only has one arm, administration of the Green Sun Medical Whisper Brace.
9686509|NCT04877249|Experimental|Gait training for stroke|
9686510|NCT04877249|Active Comparator|Gait training for healthy|
9686511|NCT04876976|Experimental|Cases of group (I) cyanoacrylate glue|Cases of group (I) underwent multilayered closure using dartos facial flap and cyanoacrylate glue as an interposition layer.
9686512|NCT04876976|Active Comparator|Cases of the control group (II) , classic repair|Cases of the control group (II) underwent the same procedure without using cyanoacrylate.
9686513|NCT04877002|Experimental|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participated in two arms of the study:~One arm was for obtaining performance data of the Sona Saliva C-19 Rapid test and the comparator arm was to obtain data from the primary care route using approved RT-PCR testing."
9686514|NCT04877080|Experimental|Fast Dual CAR-T treatment|CD19+ R/R B-NHL patients be treated with a single dose of Fast Dual CAR-T cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
9686515|NCT04877041|Experimental|Exercise (Intradialytic Cycling)|Participants will receive a standardized baseline exercise counseling session as per control and then participate in a supervised intradialytic cycling program for 12-weeks
9976201|NCT01349127|Placebo Comparator|Placebo|Arm will receive one gelatin capsule containing 0µg (0IU) of vitamin D3 (Cholecalciferol).
10179684|NCT03800693|Experimental|6-hour infusion group|Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10179685|NCT03800485|Experimental|IMT-GE|the participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will increase from the 15% of the maximal inspiratory preassure until the 60% of the maximal inspiratory preassure.
9686516|NCT04877041|No Intervention|Usual Care|Participants will receive a standardized baseline exercise counseling session. Participants in the control group will not undergo formal exercise intervention, but will not be prohibited from participating in exercise outside of hemodialysis. They will be asked to not to participate in intradialytic cycling during the study (16 weeks total).
9686517|NCT04876989|Active Comparator|US-SGB|5 ml of 1% mepivacaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
9686518|NCT04876989|Active Comparator|US-TPVB|10 ml of 1% mepivacaine is injected for thoracic paravertebral block using the Ultrasound(US)-guided sagittal approach at the second thoracic paravertebral space.
9686519|NCT04876950|Experimental|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-2 intervention will take biophysical measurements with the RAM technology, complete a daily recovery survey, complete video visits with a virtual care clinical team, and take would photos during the 30 days after randomization. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician.
10179686|NCT03800485|Placebo Comparator|IMT-GP|The participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will be the 10% of the maximal inspiratory preassure during all the 8 weeks
9686520|NCT04876950|No Intervention|Standard Care|Standard post-surgical care.
9686521|NCT04876768|Experimental|Use of 80% oxygen(high oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 80% FIO2(supplemental perioperative high oxygen fraction). 80% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of > 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter > 92%.
9686522|NCT04876768|Active Comparator|Use of 30% oxygen(normal oxygen fraction) during ERCP|Anesthetist will open the envelope of randomly assigned groups which will assign patients to 30% FIO2 (normal oxygen fraction). 30% FIO2 will be maintained during the ERCP procedure. Maintaining oxygen saturation of > 92% through administration of oxygen via nasal cannula, mask or ventilator will be per anesthetist discretion. Additional supplemental oxygen will be given to patients at any time, as necessary, to maintain oxygen saturation as measured by pulse oximeter > 92%.
9686523|NCT04876716|Active Comparator|Azole monotherapy|"Azole monotherapy~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care."
9686524|NCT04876716|Experimental|Azole + Anidulafungin|"Azole + Anidulafungin~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care.~Anidulafungin (Ecalta) is available as an intravenous formulation only. It will be used at the licensed dose of a 200mg loading dose on day 1 and 100mg QD thereafter. No dose adjustment is needed in patients with renal or hepatic insufficiency of any grade."
9686525|NCT04876664|Experimental|Ambulatory monitoring solution|this study has only one arm
10179687|NCT03800589|Active Comparator|phaco and Ex-Press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to phacoemulsification with implantation of the Ex-Press
10179688|NCT03800589|Active Comparator|deep sclerectomy, phaco and Ex-press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to deep sclerectomy, phacoemulsification, ExPress implantation
9686526|NCT04876651|Experimental|Group A|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care
9686527|NCT04876651|Active Comparator|Group B|Participants will receive the Standard of Care
9695909|NCT04773028||CONTROL GROUP(GROUP 2)|This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
9695910|NCT04772807||Healthy|
9695911|NCT04772807||Patients infected by COVID- 19 with no symptoms|
9695912|NCT04772807||Patients infected by COVID- 19 with symptoms|
9695913|NCT04772807||Patients diagnosed with atrial fibrillation|
9695914|NCT04772807||Hypertensive patients|
9695915|NCT04772807||Heart failure patients, EF < 40%|
9695916|NCT04772807||Heart failure patients, EF > 40% and < 60%|
9695917|NCT04772807||Heart failure patients, EF > 60%|
9695918|NCT04772781|Experimental|S (+) - Ibuprofen|
9695919|NCT04772781|Active Comparator|Ibuflex® - ibuprofen|
9695920|NCT04772950||Healthy adults|
9695921|NCT04772950||Patients with non-specific low back pain|
9695922|NCT04772690|Experimental|BAL|A resource-orientered, individual and group-based intervention addressing balance in everyday life, activities and QoL among people with chronic or advanced cancer.
9827573|NCT02461160|Experimental|ESSD Cohort 11: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
9977726|NCT01364675|Placebo Comparator|Placebo tablet|
9686528|NCT04876820|Experimental|Pharmacist-led intervention|
9686529|NCT04876820|Sham Comparator|Standard of care|
9686530|NCT04876911|No Intervention|Control/Usual Care|No intervention delivered and care is provided as usual.
9686531|NCT04876911|Experimental|Simulated Presence Therapy (SPT)|Participants begin to receive the SPT.
9686532|NCT04876833||HC，healthy control|18-65 years old，no smoking history，normal pulmonary function，normal compatible computed tomography.
9686533|NCT04876833||HG，high-risk COPD group|18-60 years old，≥10 pack-years smoking history，normal pulmonary function，normal compatible computed tomography.
9686534|NCT04876833||EG，early COPD group|"18-60 years old，≥10 pack-years smoking history，and with any of the following abnormalities：~Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 80%;~Compatible computed tomography abnormalities：airway abnormality and/or emphysema，air trapping, or bronchial thickening；~FEV1 decline (≥60 mL per year)."
9686535|NCT04876833||MG，mild and moderate COPD group|18-65 years old，FEV1/FVC<70%，FEV1%predicted ≥50%.
9686536|NCT04876859|Active Comparator|Conventional Radiofrequency Group|Will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (Betamethasone Dipropionate 5 mg/ml + Betamethasone Sodium Phosphate 2 mg/ml) for each branch, followed by denervation with CRF (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° C in a single cycle of 90 min.
9686537|NCT04876859|Sham Comparator|Anesthetic plus steroid group|The sham group will be submitted to the same anesthetic block as described in the intervention group, followed by a simulation of CRF use.
9686538|NCT04876872||pediatric patients|whole pediatric patients who admitted to the pediatric emergency unit in Farabi Hospital, Trabzon, Turkey
9686539|NCT04876885|Other|General public|The individuals recruited to the study will include those who are age 16 and older. Due to recruitment feasibility we will focus efforts on individuals living in Ontario. We intend to recruit individuals from COVID-19 assessment centres that are partnering in our study as well as through social media posts (Facebook, Twitter, LinkedIn).
9686540|NCT04876885|Other|Healthcare professionals and public health professionals|The individuals recruited to the study will include healthcare professionals and public health professionals impacted by infectious disease outbreaks. Social media will be used to disseminate surveys to physicians, nurses, nurse practitioners, pharmacists, and healthcare workers. Public health units will disseminate surveys to their workforce.
9686541|NCT04876742|Experimental|0.5 liters of alcoholic beer|
10179689|NCT03800550|Experimental|Treatment Sequence 1: Bedaquiline and Clarithromycin|Participants will receive bedaquiline on Day 1 in Period 1, followed by clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 2. There will be washout period of at least 28 days starting on Day 1.
10179690|NCT03800550|Experimental|Treatment Sequence 2: Clarithromycin and Bedaquiline|Participants will receive clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 1, followed by bedaquiline on Day 1 in Period 2. There will be a washout period of at least 28 days starting after bedaquiline administration on Day 5.
10179691|NCT03800186||Trauma femoral fracture|Patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury. Patients were grouping into five subgroups as patients with fracture of proximal type A, proximal type B, proximal type C, femoral shaft, and distal femur.
10179692|NCT03800238|Experimental|Telehealth Delivery Format|This group will participate in the Powerful Tools for Caregivers program using a telehealth delivery method.
10179693|NCT03800238|Active Comparator|Standard Delivery Format|This group will participate in the Powerful Tools for Caregivers program in person.
10179694|NCT03800251|Other|Fasting parturients at term|Fasting parturients at term, admitted for elective cesarean section, who consent to partake in the study
10179695|NCT03800459|Experimental|Experimental: Intervention group|Experimental: Intervention group
10179696|NCT03800459|No Intervention|Control:no intervation group|Control:no intervation group
9686542|NCT04876742|Active Comparator|0.5 liters of non-alcoholic beer|
9686543|NCT04876807|Experimental|Part 1 (Acidic formulation)|In Part 1 of the study, the participants will receive Dose 1 of ACP-196 (reference or acidic formulation as applicable) with 240 mL water in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
9686544|NCT04876807|Experimental|Part 2 (Orange drink)|In Part 2 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or acidic beverage as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
9686545|NCT04876807|Experimental|Part 3 (Grapefruit juice)|In Part 3 of the study, the participants will receive Dose 1 of ACP-196 (reference formulation) with 240 mL water or grapefruit as applicable in 4 treatment schedules on Day 1, Day 3, Day 8 (with omeprazole), and Day 10 (with omeprazole).
9686546|NCT04876417|Active Comparator|tDCS and fatigue|This group will receive the active form of tDCS.
9686547|NCT04876417|Sham Comparator|Sham and fatigue|This group will receive the sham form of tDCS.
9686548|NCT04876430|Experimental|Meropenem plus Best Available Therapy plus|"Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~Polymyxin B or colistimethate;~Amikacin or gentamicin;~Tigecycline;~Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
9686549|NCT04876430|No Intervention|Best Available Therapy|"The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~Polymyxin B or colistimethate;~Amikacin or gentamicin;~Tigecycline;~Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team."
9686550|NCT04876313|Experimental|Combined Drugs|Participants received 4x3 weekly cycles of 360 mg Nivolumab + 125 mg/m^2 Nab-paclitaxel IV on days 1 and 8, then they had cystectomy after that partecipants received adjuvant nivolumab 360 mg IV Q3W X13 cycles
9977727|NCT01364688|Experimental|Treatment|oral alfacalcidol
9686551|NCT04876612|Placebo Comparator|Patients who received placebo after transforminal epidural steroid injection|Patients who took placebo for 12 weeks after TFESI
9686552|NCT04876612|Experimental|Patients who received limaprost (Opalmon®) after transforaminal epidural steroid injection|Patients who took limaprost (Opalmon®) for 12 weeks after TFESI
9686553|NCT04876404||Parkinson's Disease|Individuals with early stage Parkinson's Disease (diagnosed within the last 5 years)
10179697|NCT03800264|Active Comparator|BISOPROLOL|BISOPROLOL 5mg per oral (P.O.) in the evening of the operation and then one dose (5 mg) every twenty four hours during the next two days.
9686554|NCT04876404||Healthy Controls|Healthy control individuals with no neurological or mood disorders.
9686555|NCT04876755|Experimental|Cohort 1|Cohort 1 patients will administered 600 mg/day of MBM-02 for 20 weeks.
9686556|NCT04876755|Experimental|Cohort 2|Cohort 2 patients will administered 1000 mg/day of MBM-02 for 20 weeks.
9686557|NCT04876755|Experimental|Cohort 3|Cohort 3 patients will administered 1200 mg/day of MBM-02 for 20 weeks.
9686558|NCT04876755|Experimental|Cohort 4|Cohort 4 patients will administered 600 mg/day of MBM-02 for 20 weeks.
9686559|NCT04876755|Experimental|Cohort5|Cohort 5 patients will administered 600 mg/day of MBM-02 for 20 weeks.
9686560|NCT04876755|Experimental|Cohort 6|Cohort 6 patients will administered 600 mg/day of MBM-02 for 20 weeks.
9686561|NCT04876573|Experimental|Cyproheptadine|
9686562|NCT04876469|Active Comparator|Radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level) in both groups.~In patients in the Radiocontrast media group, contrast material will be given before the application, and primarily the localization of the DRG will be determined. After this stage, the needle will be directed towards the detected localization. Finally, the localization of the dorsal root ganglion will be confirmed by sensory and motor stimuli."
9686563|NCT04876469|Active Comparator|Non-radiocontrast media group|"Pulsed radiofrequency (PRF) treatment will be applied to the dorsal root ganglion (DRG) by fluoroscopy-guidance at the level of nerve root compression due to disc herniation (L5 level).~In patients in the Non-radiocontrast media group, the localization of the dorsal root ganglion will be determined just by sensory and motor stimuli."
9686564|NCT04876287||patients treated by 1.1 GBq|
9686565|NCT04876287||patients treated by 3.7 GBq|
9686566|NCT04876521|Experimental|Amisulpride Group|The patients will receive low dose Amisulpride at 100-300 mg/day.
9686567|NCT04876521|Active Comparator|Olanzapine-Fluoxetine Group|the patients will receive Olanzapine-Fluoxetine Combinations at 5/10-5/20 mg/day.
9686568|NCT04876339|Experimental|"Gait rehabilitation with sonification"|"The rehabilitation exercises with sonification are supported by the musical component (see Interventions section for details)."
9686569|NCT04876339|Active Comparator|Standard gait rehabilitation (without sonification)|The same rehabilitation exercises are performed without musical support.
9686570|NCT04876534|Experimental|Tocilizumab|32 patients with active moderate-severe GO treated with i.v. tocilizumab; Tocilizumab weight adjusted, 8 mg/kg, 1 intravenous infusion every four weeks (+/- 72 hours) for 12 weeks
9686571|NCT04876534|Active Comparator|Methylprednisolone|32 patients with active moderate-severe GO treated with i.v. methylprednisolone; Methylprednisolone, 500 mg infusion weekly (+/- 48 hours) for 6 weeks, followed by 250 mg infusion weekly (+/- 48 hours) for another 6 weeks
9686572|NCT04876482|Sham Comparator|Control|Without the willingness of surgery, those participants waiting for oral appliance (Device), losing weights and using continuous positive airway pressure (Device) were distribute to control group.
9686573|NCT04876482|Experimental|Transoral robotic surgery (TORS)|The participants underwent TORS. TORS is a kind of surgery that the surgeons would remove the tonsils and the fat tissue of tongue base and suspend the soft palate.
9686574|NCT04876482|Experimental|TORS+OPR|The participants started OPR 6 weeks after TORS. Each exercise was repeated 10 times, 1-3 cycles per day, 3-5 sessions per week at their home and performed for 3 months. Patients were supervised by physical therapist once a week for 30 minutes.
9686575|NCT04876456|Experimental|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
10179698|NCT03800264|Active Comparator|hydrocortisone|hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the next two days.
10179699|NCT03800472|Experimental|GLPG3312 SAD IR (Part 1)|Single doses of GLPG3312 IR
9686576|NCT04876508|Experimental|Acupressure group|Patients in the acupressure group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
9686577|NCT04876508|No Intervention|Control group|No intervention will be applied
9686578|NCT04876183|Active Comparator|Intervention Group|Web-based intervention (Selfapy for Binge Eating Disorder)
9686579|NCT04876183|No Intervention|Waitlist Control Group|12-week waiting period
9686580|NCT04876495|Active Comparator|Whey protein|Whey protein isolate (45.5g total protein content)
9686581|NCT04876495|Active Comparator|Potato protein|Potato protein isolate (45.3g total protein content)
9686582|NCT04876495|Active Comparator|Rice protein|Rice protein isolate (45.5g total protein content)
9686583|NCT04876170|Active Comparator|VS-EFP Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, participants will receive musical feedback driven by their own VS-EFP
9695923|NCT04772872||Group A:Naturally conceived singleton|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
9977728|NCT01364688|No Intervention|Control|No drug
10179700|NCT03800472|Placebo Comparator|Placebo SAD IR (Part 1)|Single doses of Placebo IR
10179701|NCT03800472|Experimental|GLPG3312 SAD MR (Part 2)|Single doses of GLPG3312 MR
9686584|NCT04876170|Sham Comparator|Yoked sham Neurofeedback|"Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, the musical feedback will be provided based on another participant's VS-EFP signal. Hence, each participant from the sham group is paired with a participant from the test group, thus receiving feedback based on the paired test participant. This way, both groups are exposed to the exact proportion of sound manipulation that indicates their success level. To account for a possible contribution of the temporal order of feedback presentation, in half of the control participants, the feedback pattern will be replayed forward (maintaining the original temporal pattern of VS-EFP that the paired participant has received), and in half - backward (flipping the original temporal pattern right-to-left)."
9686585|NCT04876443||Alcohol-related liver disease|
9686586|NCT04876326|Active Comparator|Autologous Adipose MSC Group|This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month
9686587|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.
9686588|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC and Adipose Secretome Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month.
9686589|NCT04876261|Active Comparator|Group A|Group A will receive Oliphenolia® bitter on intervention visit 1 followed by Oliphenolia® on intervention visit 2 and followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on the third and final intervention visit
9686590|NCT04876261|Active Comparator|Group B|Group B will receive Oliphenolia® on intervention visit 1 followed by La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 2 and followed by Oliphenolia® bitter on the third and final intervention visit
9686591|NCT04876261|Active Comparator|Group C|Group C will receive La Vialla Extra Virgin Olive Oil with 5 mg hydroxytyrosol on intervention visit 1 followed by Oliphenolia® bitter on intervention visit 2 and followed by Oliphenolia® on the third and final intervention visit
9686592|NCT04876560|Active Comparator|CDSS (intervention) group|Personalised nutritional advice: daily dietary programme with specific meals, products, recipes, food portions (in grams) based on the Meditteranean diet together with physical activity guidelines, all generated by a food database clinical decision support system (CDSS). Scheduled phone interviews every 15 days with the appointed dieticians assisted nutritional and lifestyle consultation.
9686593|NCT04876560|Other|Control group|"General lifestyle advice: based on the updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention via scheduled phone interviews every 15 days."
9686594|NCT04876235|Experimental|LAMS group|place LAMS under endoscopic ultrasound. Direct endoscopic necrosectomy(DEN) was performed through the LAMS with a forward viewing gastroscope if necessary
9686595|NCT04876235|Active Comparator|DPPS group|Place DPPS under endoscopic ultrasound. When required, DEN was performed once the cystogastrostomy/duodenostomy tract had matured. This was done by first removing the stents followed by dilation of the tract with a radial expansion balloon and insertion of a forward viewing gastroscope through the tract for DEN
9686596|NCT04876222|Active Comparator|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
9686597|NCT04876222|No Intervention|Subacute CAG|The patient is triaged to the coronary care unit (CCU) for rhythm surveillance, and additional diagnostics, and in case there is found indication for CAG, it is planned for the coming day in daytime (12-24 hours after cardiac arrest). Revascularization is performed if indicated according to guidelines.
9686598|NCT04876547||In pregnancy|Appendectomy in pregnancy (n=12)
9686599|NCT04876547||In postpartum|Appendectomy in postpartum first six week (n=20)
9686600|NCT04876196|Active Comparator|Intervention Group|Web-based intervention (Selfapy for Bulimia Nervosa)
9686601|NCT04876196|No Intervention|Waitlist Control Group|12-week waiting period
9686602|NCT04876014|Experimental|GMBPMI group|Participants in the experimental group will receive GMBPMI. A new participant (a pregnant woman in the second trimester) is expected to complete the 6 EBMI lessons in 6 weeks, and do the mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. Participants will also be asked to keep log of daily mindfulness practice from T0 to T3 using Google Form. The project RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice. The RA is backed up by the PI and co-I's who are experienced mental health practitioner and mindfulness teacher. One of them is an obstetrics and gynaecology specialist.
9976202|NCT01349153|Active Comparator|Facebook-based Self-help Comparison|Participants will receive a pedometer and twelve weekly messages with links to Internet resources that have educational materials related to exercise and cancer survivorship.
10179702|NCT03800472|Placebo Comparator|Placebo SAD MR (Part 2)|Single doses of Placebo MR
10179703|NCT03800472|Experimental|GLPG3312 FE MR (Part 3)|Single dose of GLPG3312 MR in fed and fasted state
10179704|NCT03800472|Experimental|GLPG3312 MAD MR (Part 4)|Multiple doses of GLPG3312 MR
10179705|NCT03800472|Placebo Comparator|Placebo MAD MR (Part 4)|Multiple doses of Placebo MR
10179706|NCT03800472|Experimental|GLPG3312 MAD MR optimized (Part 4)|Multiple doses of GLPG3312 MR
10179707|NCT03800472|Placebo Comparator|Placebo MAD MR optimized (Part 4)|Multiple doses of Placebo MR
10179708|NCT03800394||HIV only|Adolescents aged 10-19 years with HIV infection
10179709|NCT03800394||HIV/TB|Adolescents aged 10-19 years with HIV and TB coinfection
10179710|NCT03800797|Experimental|LX-P group|loxoprofen sodium hydrogel patch (LX-P) 100 mg per day for 4 weeks
9686603|NCT04876014|Active Comparator|Perinatal Psycho-education group|To control for attention and placebo effects, every new participant in the control group will receive weekly web-based psychoeducation program for perinatal care. The project RA will also be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences of the psychoeducation program.
9686604|NCT04876157|Experimental|Artificial intelligence-aimed ultrasound image interpretation|
9686605|NCT04875897|Experimental|treatment with keepMED PAP device|Therapy night is performed with the keepMED PAP during a polysomnography in the sleep lab
9686606|NCT04875832|Experimental|Intervetion Group|EMDR intervention group
9686607|NCT04875819|Experimental|Menveo + Bexsero|
9686608|NCT04875819|Experimental|Prevenar13 + Pneumovax23|
10179711|NCT03800797|Active Comparator|LX-T group|loxoprofen sodium tablet (LX-T) 60 mg t.i.d. for 4 weeks
9686610|NCT04876144|No Intervention|Usual care group - clinical|Usual prenatal and postpartum psychiatric care involves regular visits with a psychiatrist from the perinatal psychiatric outpatient clinic of the National Institute of Mental Health, Czechia.
9686611|NCT04876144|No Intervention|Usual care group - general|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
9686612|NCT04876144|Experimental|Kogito - clinical|Usual prenatal and postpartum psychiatric care in perinatal psychiatric outpatient clinic of the National Institute of the National Institute of Mental Health, Czechia plus use of the Kogito app.
9686613|NCT04876144|Experimental|Kogito - general|Usual prenatal/postpartum care plus use of the Kogito app.
9686614|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose < 4.0 mmol/L|16g of carbohydrates will be given when glucose levels are below 4.0 mmol/L (management per guidelines)
9686615|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 4.5 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 4.5 mmol/L.
10179712|NCT03800342|Experimental|Healthy|Healthy individuals will participate in two separate days of cardiopulmonary exercise testing (CPET) (separated by a minimum of two, maximum of 7 days apart) prior to starting the aerobic exercise training program (AET). Individuals will then complete a 4-5 week (4x/week x 17 sessions) continuous, high-intensity AET. Each training session will consist of cycling for 3-5 minutes to warm-up, 45 minutes at 70% of heart rate reserve (HRR-determined from pre-training CPET), and 5-10 minutes to cool down. Following the AET, individuals will repeat the two separate days of CPET performed pre-training.
10187462|NCT03726060|Other|physical therapy with splint therapy|"The treatment consists of a series of interventions: advice on self-treatment techniques to be performed at home and administering manual therapy techniques addressed to: temporomandibular district, cervical and cervico-thoracic junction.~Each session will be carried out individually and will last for 45 minutes. This duration will be divided as follows: 25 minutes dedicated to the temporomandibular district, 15 minutes to the cervical and cervico-thoracic junction, 5 minutes to teaching self-treatment techniques to be carried out at home and to verify the correct way of performing them.~The cycle will consist of 10 sessions distributed over 3 months."
10187463|NCT03726034|Experimental|Life story book training|The migrant caregivers will receive training (six weekly 1.5-hour sessions) about life story approach by a part-time trained interventionist with psychology or social work background with at least three years of working experience working with older people and have basic knowledge about the life story work. After training, the migrant caregivers will be asked to produce the life story book individually at home with the older adults
10187464|NCT03726034|Active Comparator|Communication skills training|The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
10187465|NCT03726021|Experimental|experimental arm|Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.
10187466|NCT03726008|Experimental|Experimental group|The experimental group will receive the perinatal health promotion program and regular prenatal care
10187467|NCT03726008|No Intervention|Control group|The control group will receive the regular perinatal care
10188000|NCT03720522||Group 4: Control|Patients with normal (< 0.015mg/L) high sensitive troponin T (hsTnT) levels without late enhancement, without myocardial infarction and without wall motion abnormalities will serve as control group and will be classified to group 4.
10188001|NCT03720496|Experimental|CD19-TriCAR-T|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
10188002|NCT03720483|Experimental|N-acetyl cysteine then placebo|This arm will receive NAC followed by placebo
9686616|NCT04876079|Active Comparator|16g of carbohydrates - Plasma glucose ≤ 5.0 mmol/L|16g of carbohydrates will be given when glucose levels are equal or below 5.0 mmol/L.
9686617|NCT04876027|Experimental|GLP-1 RAs and calorie restrict diet group|Intervention with GLP-1 RAs and calorie restrict diet until reaching the target weight loss(7%)
9686618|NCT04876027|Active Comparator|calorie restrict diet group|Intervention with calorie restrict diet until reaching the target weight loss(7%)
9686619|NCT04876001|Experimental|Face-to-face BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call."
9686620|NCT04876001|Experimental|Web-based BBTI|"The BBTI consists of two in-person sessions on week 1 and 3 and two session on week 2 and 4 as the booster delivered by phone call. All treatments will be delivered using pre-established web and telephone."
9686621|NCT04876001|No Intervention|Waiting-list|The participant in this arm will be asked to filled the online questionnaires at weeks 0 (baseline), 1 (mid-treatment), 2 (post-treatment), 4 and 12 (follow up). After the final follow up, all participants will be allowed to join the web-based BBTI treatment.
9827574|NCT02461290||Combination Therapy|Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.
9827575|NCT02461433|Experimental|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
9686622|NCT04875793|Experimental|List of health centers that randomly allocated to receive the intervention|The intervention is the integrated system which is composed of psychologist, endoscopy physician, family physician, community outreach, and audiovisuals in the waiting area. In addition to text messages of information, education and communication (IEC) delivered to the participants at the outreach, and education campaigns to mobilize individuals going for screening.
9686623|NCT04875793|No Intervention|List of health centers that randomly allocated to receive routine care|The comparators will be individuals with an average risk of colorectal cancer of both genders attending the randomly selected health centres
9686624|NCT04875806|Experimental|NC762|NC762 for IV infusion of various dose strengths administered in 14 day dosing cycles
9686625|NCT04875624||Hypoglycemic neonates|Preterm or small for gestational age neonates at risk for hypoglycemia who were found to be hypoglycemic during the screening for hypoglycemia
9686626|NCT04875624||Normoglycemic neonates|Preterm or small for gestational age neonates who were found to be normoglycemic during the screening for hypoglycemia
9686627|NCT04875962|Experimental|Cohort 1 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
9686628|NCT04875962|Experimental|Cohort 2 - UCB0599|Participants will be randomized to receive a predefined dosage of UCB0599.
9686629|NCT04875962|Placebo Comparator|Cohort 1 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
9686630|NCT04875962|Placebo Comparator|Cohort 2 - Placebo|Participants will be randomized to receive a predefined dosage of Placebo.
9686631|NCT04875845||6-hours fasting gastric volume|gastric volume measured after 6-hours fasting
9686632|NCT04875845||8-hours fasting gastric volume|gastric volume measured after 8-hours fasting
9686633|NCT04875663|Experimental|Lifestyle medicine intervention with self-tracking tools|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.
9686634|NCT04875663|Experimental|Pure lifestyle medicine intervention|Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.
9686635|NCT04875663|No Intervention|Care-As-Usual|continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments
9686636|NCT04875598|Active Comparator|Group 1|30 patients will be injected with local anesthetic into the fascia between the transversus abdominis and internal oblique muscles with the help of ultrasound from the designated area (Before the operation starts, TAPBwith 20 ml 0.25 % bupivacaine will be applied to the surgical side under ultrasonography)
9686637|NCT04875598|Active Comparator|Group 2|30 patients, local anesthetic injection will be made to the same area under laparoscopic direct vision. 50 mg Bupivacaine (0.25 % 20 ml bupivacaine solution) has been determined as the application dose and this amount will be applied in both groups.
9686638|NCT04875546|Active Comparator|Standard treatment|"A 5'A' and '5'R' models~STAR method for quitting"
9686639|NCT04875546|Active Comparator|Integrated Intervention|"A 5'A' and '5'R' models~Receive brief advice on alcohol use based on the FRAMES model~Complete the Alcohol Use Disorders Identification Test"
9686640|NCT04875546|Sham Comparator|Control|Participants will receive two leaflets.
9686641|NCT04875767|Experimental|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|Those allocated to the scaffold treatment group will have 30 ml of BMA harvested from the ipsilateral iliac crest under fluoroscopic guidance. The hip arthroscopy will then be resumed, and the damaged cartilage lesion will be debrided using a mechanical shaver to remove loose and calcified tissue. Once the walls of the lesion are confirmed to be stable with a probe, the exact size of the defect will be measured for templating of the scaffold. The biodegradable HA-based scaffold (Hyalofast®; Anika Therapeutics, Bedford, MA, USA) will be prepared by cutting it to fit the focal defect. Once the cartilage lesion is dried manually, this scaffold will be implanted into the defect after it has been soaked in the BMA. The scaffold will then be secured to the defect in a press-fit fashion to the surrounding cartilage. In the case where additional fixation of the scaffold is needed, such as uncontained shoulder of cartilage, fibrin glue will be used to secure the scaffold.
9686642|NCT04875767|Active Comparator|Microfracture|As per current standard of care for focal articular cartilage lesions of the acetabulum, the unstable cartilage will be debrided and removed from the subchondral bone using a mechanical shaver until a stable margin is obtained. A ring curette will be used to remove the calcified cartilage layer and create a border of healthy cartilage tissue that can support the marrow clot. Through the mid-anterior portal, specialized 90˚ awls will then be placed with the tip perpendicular to the subchondral bone of the acetabulum, and a mallet will be used to penetrate the subchondral bone with perforations 3 mm deep to access the bone marrow elements. This is done until the defect is homogeneously covered with micro-perforations 2-3 mm apart.
9686643|NCT04875728|Active Comparator|Arm A (cefazolin, surgical resection)|Patients receive cefazolin IV and then undergo standard of care surgical resection within 1 hour.
9686644|NCT04875728|Experimental|Arm B (surgical resection)|Patients undergo standard of care surgical resection.
9686645|NCT04875702|Active Comparator|TTT-SU|The participants randomized to the Treat-to-Target-Serum Urate (TTT-SU) group will be counseled about gout, generalized lifestyle and dietary issues and will be provided with a three-month supply of allopurinol as well as a treatment to prophylax against attacks that might occur during the up-titration of urate lowering therapy. Allopurinol dose increases will occur until SU concentrations achieve a target level < 6.0 mg/dL.
9686646|NCT04875702|Active Comparator|TTASx|Subjects randomized to the treat-to-avoid-symptoms (TTASx) group will receive the same education as the TTT-SU group. In addition, they will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone); enough to treat up to six flares over the ensuing three months.
9686647|NCT04875949|Experimental|Anti-AChRs Abs positive patients|Immunoabsorption
9686648|NCT04875585|Experimental|Treatment Arm|neoadjuvant therapy with Pembrolizumab/Lenvatinib in combination with surgical resection of primary tumor followed by adjuvant Pembrolizumab therapy
9686649|NCT04875858|Active Comparator|healthy old adults aged 70-75 years who received PPSV23|Recruitment of 254 healthy 70-75-year healthy old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
9686650|NCT04875858|Experimental|old adults who have diabetes mellitus aged 70-75 years who rec|Recruitment of 254 healthy 70-75-year diabetic old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
10179713|NCT03800316|Experimental|Synchronous Video Consultation|Testing the feasibility of a synchronous video consultation in the field prior to emergency department arrival.
9686651|NCT04876118|Experimental|Fat Reduction|The treatments are designed to see if the appearance of cellulite can be reduced on the outer thigh with a new applicator design.
9686652|NCT04875442|Experimental|Memowave emitting sound|Patients worn Memowave during one night, and the device emits sounds to increase slow brain signals
9686653|NCT04875442|Placebo Comparator|Memowave not emitting sound|Patients worn Memowave during one night, and the device doesn't emit sounds
9686654|NCT04875650|Experimental|Physics Forceps|
9686655|NCT04875650|Other|Conventional Forcep|
9686656|NCT04875741|Active Comparator|Neural mobilization|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Neural mobilization technique will be applied to the subjects in addition to conventional treatment.
9686657|NCT04875741|Experimental|Muscle energy technique|Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Muscle energy technique will be applied to the subjects in addition to conventional treatment.
9686658|NCT04875611|Experimental|Experimental therapy:OPDIVO (Nivolumab)|
9686659|NCT04875559||Breast cancer surgery patients.|Patients scheduled for day-case unilateral breast conserving surgery or mastectomy with or without axillary lymph node dissection or sentinel lymph node biopsy. No intervention.
10179714|NCT03800277|Experimental|Cranberry and Agaves|Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)
10179715|NCT03800277|Experimental|Cranberry and placebo|Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)
9686660|NCT04875689|Experimental|Group A (Experimental)|Patient receive laser therapy along with conventional therapy
9686661|NCT04875689|Other|Group B: Conventional treatment|patient will receive conventional therapy
9686662|NCT04875910|Experimental|Stroke survivors participants|"Subjects who have been diagnosed with stroke 6 months or more.~1)Either right and left hemiparesis. 2) Subjects able to walk with or without assistive device. 3) age between 40-80. 4) Subjects can understand and follow commands.~Exclusion criteria is: 1) subjects with uncontrolled Blood pressure, heart rate or breathing problems. 2) Having an orthopedic problem or"
9686663|NCT04875390|Other|group E|Intraoperative Erector spina plane block ( 0.3 ml/kg bupivacaine 0.25% at thoracic level 7 and 0.3 ml/kg bupivacaine 0.25% bupivacaine at thoracic level 11, totaling 0.6 ml/kg of 0.25% bupivacaine) will be performed after the surgery is completed.
9686664|NCT04875390|Other|group L|Intraoperative local infiltration (0.6 ml/kg of 0.25% bupivacaine will be given to the wound lips at the end of the surgery.
9686665|NCT04875637|Other|MEMR Diagnostic Evaluation|Middle Ear Muscle Reflex using wideband acoustic reflectance to assess hearing status.
9686666|NCT04875260||Critically ill patients|Patients received critical care in the intensive care units
9686667|NCT04875377|Experimental|Reformulated pizza|Participants must consume a nutritionally balanced pizza reformulated with seaweed (Ascophyllum nodosum) as an ingredient 3 times a week for 24 weeks
9686668|NCT04875377|Placebo Comparator|Control pizza|Participants must consume a nutritionally balanced pizza without seaweed, 3 times a week for 24 weeks
9686669|NCT04875377|Experimental|Seaweed capsule|Participants must consume a capsule containing powdered Ascophyllum nodosum 3 times a week for 24 weeks
10179716|NCT03800277|Experimental|Placebo and Agaves|Placebo (2 capsules) + Agaves powder (1 single-dose packet)
10179717|NCT03800277|Placebo Comparator|Placebo and placebo|Placebo (2 capsules) + Placebo powder (1 single-dose packet)
10179718|NCT03800446|Other|Intervention|All patients will undergo testing with the study intervention (point of care) and routine testing with serum ferritin (venous blood sample).
10179719|NCT03800290|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
9686670|NCT04875377|Placebo Comparator|Control capsule|Participants must consume an empty capsule 3 times a week for 24 weeks
9686671|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
9686672|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 2 kg|press on the spinous processes with the algometer perpendicularly.
9686673|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with 3 kg|press on the spinous processes with the algometer perpendicularly.
9686674|NCT04875273|No Intervention|Pre: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
9686675|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
10179720|NCT03800290|Placebo Comparator|Placebos|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
10179721|NCT03800147|Active Comparator|High-fat diet|"Participants will follow a high-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
10179722|NCT03800147|Active Comparator|Low-fat diet|"Participants will follow a low-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
10179723|NCT03800303|Experimental|two-week family-based treatment|Active treatment includes a two-week family-based partial hospitalization treatment utilizing and integrated therapeutic design.
9686676|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
9686677|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
9686678|NCT04875273|Experimental|Post Exp: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
9686679|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 1kg|press on the spinous processes with the algometer perpendicularly.
9686680|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 2kg|press on the spinous processes with the algometer perpendicularly.
9686681|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with 3kg|press on the spinous processes with the algometer perpendicularly.
9686682|NCT04875273|Placebo Comparator|Post Pla: pain assessment in the spinous processes of the spine with maximum pressure|press on the spinous processes with the algometer perpendicularly.
9686683|NCT04875273|No Intervention|Pre: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
9686684|NCT04875273|Placebo Comparator|Post Pla: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
9686685|NCT04875273|Experimental|Post Exp: Right Ankle Dorsiflexion|Range of motion in right ankle dorsiflexion is measured with LegMOtion®
9686686|NCT04875273|No Intervention|Pre: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
9686687|NCT04875273|Placebo Comparator|Post Pla: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
9686688|NCT04875273|Experimental|Post Exp: Left Ankle Dorsiflexion|Range of motion in left ankle dorsiflexion is measured with LegMOtion®
9686689|NCT04875572|Experimental|Study group|Since this is a single group study, all patients enrolled will receive the same care, as described in the study description above.
9686690|NCT04875299||adalimumab TDM|Patients with active ankylosing spondylitis receiving adalimumab treatment.
9686691|NCT04875520|Active Comparator|Weekly Screening testing plus symptomatic testing|Among 16 middle and high schools, 8 will be randomized to offer students and staff weekly SARS-CoV-2 testing. Additionally, these schools will offer testing for symptomatic students, staff, household members in all age groups.
9686692|NCT04875520|Active Comparator|Symptomatic testing|All 16 schools will have testing available for individuals that have symptoms or need a test for other reasons.
9686693|NCT04875312|Experimental|Group USC|Effect of ultrasound cavitation sessions on sex hormones in obese infertile patients with poly cystic ovarian syndrome
9686694|NCT04875312|Experimental|Group EA|Effect of electro acupuncture on sex hormones in obese infertile patients with poly cystic ovarian syndrome
9686695|NCT04875182||group delirium|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score over 14 points will be included in the Group Delirium. And second blood samples for zonulin and interleukin-8 levels will be taken at the time of diagnosis.~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
9686696|NCT04875182||group control|"Patients who are over 65 years of age and scheduled for femur fixation surgery will be included in the study. Blood samples for zonulin and interleukin-8 levels will be taken at the day prior to the surgery. All patients will be evaluated by Delirium Rating Scale for delirium development at the postoperative 1., 2. and 3. days. Patients with a Delirium Rating Scale score under 14 points for postoperative 72 hours will be included in the Group Control. And second blood samples for zonulin and interleukin-8 levels will be taken at the postoperative 72. hour.~Postoperative pain scores of the patients will recorded by using a numerical rating scale."
9686697|NCT04875494|Experimental|Physical Exercise|
10179724|NCT03800524|Experimental|Tauroursodeoxycholic acid (TUDCA)|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
10179725|NCT03800524|Placebo Comparator|Reference therapy|"Placebo capsules identical to active compound~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
10187468|NCT03725995|Active Comparator|A (Midazolam)|21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
9686698|NCT04875494|Active Comparator|Counseling/support group therapy|
9686699|NCT04875494|No Intervention|Control|no intervention
9686700|NCT04875468|Active Comparator|Zirconia crown cemented by adhesive resin cement|MultiRein link adhesive resin cement (non MDP, non-calcium and fluoride releasing cement)
9686701|NCT04875468|Experimental|Zirconia crown cemented by self-adhesive resin cement|TheraCem self-adhesive resin cement (MDP, calcium and fluoride releasing cement)
9827576|NCT02461433|Active Comparator|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
9686702|NCT04875130||confirmed pulmonary embolism|"Patients with intermediate high and high risk of an acute pulmonary embolism with clinical symptoms.~On image based procedures confirmed pulmonary embolism (TTE, contrast CT-angiography).~Age under 18.~Written agreement to the examination."
9686703|NCT04875351||Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Testing|Female patients diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph node-positive (LN+, with 1-3 positive nodes) early-stage invasive breast cancer, who are distant recurrence-free.
9686704|NCT04875286||Observational (medical record review, questionnaires))|Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
9976203|NCT01349153|Experimental|Facebook-based Messages/Website|Participants will receive a pedometer, twelve weekly messages, and be encouraged to participate in sixteen Facebook group discussions and use a website for exercise goal-setting and tracking activity.
9686705|NCT04875026|Experimental|5-fluorouracil 4% (Tolak) + Dexeryl|This group will apply 5-FU once daily for 4 weeks, and Dexeryl once daily for 8 weeks.
9686706|NCT04875026|Other|5-fluorouracil 4% (Tolak)|This group will only apply 5-FU once daily for 4 weeks.
9686707|NCT04875117||Intervention|Participants who are due to receive their first-ever hearing aid(s) as part of their routine audiological care.
9686708|NCT04875117||Control|Participants with hearing loss who have not experienced any change in hearing aid status for at least 1 year.
9686709|NCT04875325|Experimental|Standardized surveillance|Standardized surveillance strategy with routine imaging and serum tumor marker testing.
9686710|NCT04875325|No Intervention|Non-standardized surveillance|Non-standardized surveillance strategy according to current clinical practice.
9686711|NCT04875156|Other|normal volunteers|normal volunteers between 18 and 40 years old, men and women. Measurement of the range of motion of the metacarpophalangeal joint with a goniometer and pinch strength of the thumb with a dynamometer
9686712|NCT04875143|Placebo Comparator|PLACEBO|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
9686713|NCT04875143|Experimental|Citrus aurantium L.|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.
10179726|NCT03800368|Experimental|High-endurance group|This group of subjects will receive 2-3 sessions of high-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will interchange between the aerobic and anaerobic state.
9686715|NCT04875481||ASD group|450 ASD from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
9686716|NCT04875481||TD group|100 healthy typical developing control (TDC) from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.
9686717|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
9686718|NCT04875169|Experimental|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
9686719|NCT04875169|Placebo Comparator|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
9686720|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
9686721|NCT04875169|Experimental|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
9686722|NCT04875000|Active Comparator|UltraEZ|"Group of patients randomly assigned to receive the the application of the commercial fluoride remineralizing and desensitizing agent UltraEZ (Ultradent Products, Inc, South Jordan, UT, USA) after teeth bleaching"
9686723|NCT04875000|Experimental|Arginine|Group of patients randomly assigned to receive the the application of the 2.5% arginine solution after teeth bleaching
9686724|NCT04875000|Experimental|Nano-hydroxyapatite|Group of patients randomly assigned to receive the application of the 2.5% nano-hydroxyapatite solution after teeth bleaching
9686725|NCT04874818||lymphopenia|lymphocyte counts (<1.0 x10e9/L)
9686726|NCT04874818||normal lymphocyte numbers|lymphocyte counts ((1.0 - 3.5 x10e9/L))
9686727|NCT04875403|Experimental|Respiratory muscle training group|Inspiratory muscle training with linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).The resistance training protocol will consist of the exercises of the front pull, the extension chair and the vertical bench press, covering large muscle groups in the dorsal region of the quadriceps and chest, respectively. Each year consist of three sets of 10 repetitions with a load equivalent to 60% of a test Repetition Maximum (1RM), which will be changed every week (1 to week 60%, 2 to week 65%;. 3 the . week 70%, 4 to week. 75%, 5 to week 80%).
9827577|NCT02461563|Experimental|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
9976204|NCT01349205|Experimental|Caffeine and Sodium Benzoate 10 mg/kg IV|Group 1 of randomized study.
9976205|NCT01349205|Experimental|Caffeine and Sodium Benzoate 20 mg/kg IV|Group 2 of randomized study
9976206|NCT01349205|Placebo Comparator|0.9 NS Saline|Control group of randomized study.
10179727|NCT03800368|Experimental|Low-endurance group|This group of subjects will receive 2-3 sessions of low-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will maintain at an aerobic level.
9686728|NCT04875403|Active Comparator|Aerobic exercise group|Exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate, training has to be equivalent to 40% to 60%% target intensity.
9686729|NCT04874844|Other|Test drug group|Phase II Dose Addition Stage JY025 12MG / KG and 16mg / kg Q3W Givenate Combined EGFRTKI (Gifan Totibi 250mg or Erlotini 150mg) QD scheme, 6 cases of each dose group in group (Gifanibini 3 cases of Erlotini); 1 or 2 doses of JY025 in dose expansion phase Q3W administration combined with EGFR-TKI (50mg or Ellotini 150mg) QD scheme, each dose group 6 Examples of subjects (3 cases of Gifeng Tinib and Ellotini).
9686730|NCT04874844|Active Comparator|Group type|Phase III 396 patient JY025 injection and placebo combined with Notes Totibi / Erlotini (Gifeng Totibi 250mg or Erlotini 150mg) Q3W QD treatment group is randomly packet in 1: 1 ratio (in each group) Gifanibi and Erlotini are 2: 1)
9686731|NCT04874870|Active Comparator|No Splint Group|This group will receive Xiaflex injection only
9686732|NCT04874870|Active Comparator|Splint Group|This group will receive Xiaflex injection and hand-based custom orthosis to maintain finger extension
9695924|NCT04772872||Group B: Singleton conceived from fresh embryo transfer(IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
9695925|NCT04772872||Group C: Singleton conceived from frozen embryo transfer (IVF/ICSI)|"Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~Apgar score will be represented by the variance of degree of scores.~Birth weight will be measured in grams."
9695926|NCT04772664|Experimental|Participants with Major Depression receiving a multi-strain probiotic|Participants with Major Depression receiving a multi-strain probiotic
9695927|NCT04772664|Placebo Comparator|Participants mit Major Depression receiving a placebo|Participants mit Major Depression receiving a placebo
9695928|NCT04772664|Experimental|Healthy volunteers receiving a multi-strain probiotic|Healthy volunteers receiving a multi-strain probiotic
9695929|NCT04772664|Placebo Comparator|Healthy volunteers receiving a placebo|Healthy volunteers receiving a placebo
9695930|NCT04772677|Experimental|BEAM - Infant|BEAM Infant will be delivered via mobile application to mothers with a 6-17 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
9695931|NCT04772677|Experimental|BEAM - Preschool|BEAM Preschool will be delivered via mobile application to mothers with a 18-36 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting Videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
9695932|NCT04772846|Experimental|Chloroquine group|
9695933|NCT04772846|Placebo Comparator|Placebo drug group|
9695934|NCT04772820|Other|Primary Aim|Brief Behavioral Activation coaching will be delivered by telephone and other remote technology by trained coaches. Over 10 sessions, the coaches will help people to find meaningful activities to decrease loneliness, increase physical activity and improve nutrition.
9695935|NCT04772729|Active Comparator|Insulin Aspart|Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.
9695936|NCT04772729|Experimental|Insulin Fiasp|Patients will use the continuous subcutaneous insulin infusion of insulin faster aspart (Fiasp, Novo Nordisk) and RT-CGM for 4 weeks.
9695937|NCT04772976||Patient group|Patients with Ankylosing Spondylitis
9695938|NCT04772976||Healthy controls|Healthy controls
9695939|NCT04772833||Autopsy group|Patients with COVID-19 infection confirmed by PCR, whose death is related to active COVID-19 infection or its complications.
9695940|NCT04772924|Experimental|fasting group|those preferred to take long time fasting
9695941|NCT04772924|Active Comparator|non fasting|those preferred not to take fasting
9695942|NCT04772365|Experimental|Treatment group A|
9695943|NCT04772365|Placebo Comparator|Treatment group B|
9695944|NCT04772430|No Intervention|Control group|The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure
10179728|NCT03800368|Active Comparator|Psycho-education|This group of subjects will receive 2-3 sessions of psycho-education class per week, for a total of 12 weeks. The content of the class includes non-exercise related psycho-education content to participants (e.g., food hygiene, psychological well being, food nutrition, etc).
10179729|NCT03800225|Experimental|Repair|Anterior cruciate ligament repair with internal brace after anterior ligament rupture.
9695945|NCT04772430|Experimental|Experimental group|The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure.
9695946|NCT04772508|Sham Comparator|Group A|15 sites received only scaling and root planing
9695947|NCT04772508|Active Comparator|Group B|15 sites received scaling and root planing with subgingival placement of amnion membrane
10179730|NCT03800225|Active Comparator|Patella tendon graft|The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture.
10179731|NCT03800433|No Intervention|control|23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.
10179732|NCT03800433|Experimental|test|23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.
10179733|NCT03800511||repeated caesarean section|full term pregnant women with singleton baby with a history of at least previous one caesarean section
9695948|NCT04772508|Active Comparator|Group C|15 sites received scaling and root planing with subgingival placement of amnion membrane hydrated with Taurine
10179734|NCT03800108|Other|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
10179735|NCT03799848|Experimental|Vadadustat|Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)
10179736|NCT03799835|Active Comparator|Arm A : control arm|"BCG therapy only~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1)."
10179737|NCT03799835|Experimental|Arm B: experimental arm|"BCG therapy + administration of atezolizumab~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).~atezolizumab is administered by IV infusion every 3 weeks (21 [± 2] days) for 1 year (18 cycles as a maximum)."
10179738|NCT03799796|Experimental|Flash Glucose Monitoring with Online Peer Support|Pre-Test-Post-Test
10179739|NCT03799809|Active Comparator|Voriconazole|Will receive 400 mg of Intrabronchial Voriconazole every week for 4 weeks along with standard medical therapy.
10179740|NCT03799809|No Intervention|Control|Will receive standard medical therapy alone (hemostatics, anti-tussive and others as deemed appropriate by treating physician)
10179741|NCT03799978|Experimental|Treatment A: ACT-541468 50 mg under fasted conditions|Single oral dose administered on Day 1 under fasted conditions.
10179742|NCT03799978|Experimental|Treatment B: ACT-541468 50 mg under fed conditions|Single oral dose administered on Day 1 administered after food intake.
10179743|NCT03799679|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1* 12 cycles ( weekly), followed by epirubicin 90mg/m2, iv, d1 + cyclophosphamide 600mg/m2, iv, d1 * 4 cycles (14 days per cycle)
10179744|NCT03799640|Experimental|Standard Yoga|Yoga will be performed using linear forward and backward movements.
10179745|NCT03799640|Experimental|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
10179746|NCT03799640|Experimental|Educational Control|Lectures on Health and Wellness
10179747|NCT03799692|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
10179748|NCT03799575||A|Two samples of ILM per patient are harvested, group A will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
10179749|NCT03799575||B|Group B sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
10179750|NCT03799536|Experimental|Sequence AB|Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10179751|NCT03799536|Active Comparator|Sequence BA|Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10179752|NCT03799510|Experimental|Group 1|Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
10179753|NCT03799510|Experimental|Group 2|School children with an infectious history of S. haematobium and-or S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
9695949|NCT04772443|Experimental|DWJ1506|
9695950|NCT04772443|Experimental|DWJ1507|
9695951|NCT04772443|Active Comparator|DWC202011|
9695952|NCT04772443|Active Comparator|DWJ1177|
9695953|NCT04772326||PrEP patients undergoing follow-up at Tourcoing hospital|
9695954|NCT04772521|Experimental|Intervention|Personalized chat-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for intervention group
9686733|NCT04874974|Experimental|Metacognitive and Defusion Training|All participating patients are allocated to the same five-week experimental group therapy, which consists of three different modules (Module I: Psychoeducation on cognitive processes and rational of the therapy - week 1; Module II: Metacognition - week 2+3; Module III: Cognitive Defusion - week 4+5). Group therapy will start with a psychoeducation session of 60 minutes in the first week and will then take place twice a week with each session lasting 60 minutes.
9686734|NCT04875078|Experimental|UVA-1 Treated hand|This hand will be treated with UVA-1 phototherapy.
9686735|NCT04875078|No Intervention|The untreated hand|This hand will be gloved when the patient undergoes UVA-1 phototherapy treatments.
9686736|NCT04875039|Active Comparator|Perineural dexamethasone|Addition of dexamethasone 2mg to local anesthetics in infraclavicular brachial plexus block
9686737|NCT04875039|Experimental|Perineural dexamethasone plus dexmedetomidine|Addition of dexamethasone plus dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
9686738|NCT04874740||Kidney transplant recipients|Collection of data from kidney transplant patients at regular outpatient check-ups.
9686739|NCT04874701|Experimental|Capsimax|
9686740|NCT04874701|Placebo Comparator|Placebo|Placebo, 2 capsules per day, for 12 weeks
9686741|NCT04874896|Active Comparator|Control|Patients of this branch will not have autotransplantation of gut microbiota in capsules and will follow their usual post-transplant treatment
9686742|NCT04874896|Active Comparator|Microbiota autotransplantation|Patients in this branch will receive autotransplantation of intestinal microbiota in capsules for 6 months post-transplantation
9686743|NCT04874688|Active Comparator|IYCF-Only|Infants in the IYCF-only arm will receive white maize and SQ-LNS daily from 6 months of age, and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
9686744|NCT04874688|Experimental|IYCF-Plus|Infants in the IYCF-plus arm will receive orange provitamin A-fortified maize and SQ-LNS daily from 6 months of age, plus powdered NUA-45 sugar beans, moringa leaf powder, and powdered whole egg; and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
9686745|NCT04874883|Active Comparator|Intervention Group|You will receive 6 grams of the symbiotic (association of fructooligosaccharides, prebiotics, and four probiotic strains: Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus Acidophilus, and Bifidobacterium bifidum) either enterally or twice a day.
9686746|NCT04874883|Placebo Comparator|Control Group|Will receive 6 grams of the maltodextrin placebo (carbohydrate easily absorbed and digested, not fermented by colonic bacteria and which does not interfere in the microbial ecology of the gastrointestinal tract or in the metabolism and function of the intestine), either enterally or orally in two sachets times a day
9686747|NCT04874805|Experimental|Major patient admitted to the ICU for COVID|
9686748|NCT04874961|Experimental|Standardized olive extract (Tensiofytol)|3 capsules/day during dinner Per day: 334 mg olive leave dry extract and 106 mg olive fruit dry extract (Olea europaea), equivalent to 100 mg oleuropeïne and 20 mg hydroxytyrosol
9686749|NCT04874961|Experimental|Combination preparation (Cholesfytol NG)|"3 capsules/day during dinner~Per day:~67.2 mg red yeast rice powder (Monascus purpureus; equivalent to 2.9 mg monacoline K)~1000 mg amla dry extract (Phyllanthus emblica)~100 mg walnut leave dry extract (Juglans regia)~50 mg olive dry extract (Olea europaea; equivalent to 10 mg hydroxytyrosol)"
9686750|NCT04874961|Placebo Comparator|Placebo|3 capsules/day during dinner
9686751|NCT04874727||Study Population|The five or six individual patients enrolled are the members of the sole group, the study population. These individuals all have been diagnosed with obstructive sleep apnea and have take a Cone-beam CT scan with and without the new bite technique.
9686752|NCT04874610||BMI > 95|Cohort 1: greater than or equal to 95%ile body mass index
9686753|NCT04874610||BMI < 95|Cohort 2: less than 95%ile body mass index
9686754|NCT04874675|Active Comparator|Diclofenac /Acetaminophen/Codeine|routine pain medication used in post extraction pain management
9686755|NCT04874675|Active Comparator|Ibuprofen/Acetaminophen/codeine|routine pain medication used in post extraction pain management
9686756|NCT04874649|Experimental|Balloon-blowing breathing|"Start by measuring the vital capacity using a balloon to determine. The width of the balloon diameter for each blow and used the value to make a balloon size control device to give to the sample group and parents to use it for home training.~Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks"
9686757|NCT04874649|Experimental|Sustained maximal inspiration breathing|Participants sitting in a chair, back and head close to the wall. Inhale through their nose fully and hold for 3 seconds for a full breath, then slowly exhale through their mouth and hold for 1 second of exhalation, counted as 1 breathing cycle.Do this 3 times in a row for 1 set. Practice each time doing a total of 3 sets, with 1 minute rest between sets. Participants were required to complete breathing exercise 5 times per week for 8 weeks.
9686758|NCT04874558||Low-dose contrast-enhanced chest CT exam|Subjects will undergo a low-dose contrast-enhanced chest CT exam with coverage from the neck base through the lungs to the upper abdomen on a third-generation dual-source CT scanner as part of their routine clinical visit based on current guidelines.
9686759|NCT04874337|Experimental|Experimental group|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.
9686760|NCT04874337|No Intervention|Control Group|
9686761|NCT04874454|Experimental|vocal cord movement among the stroke patients|
9686762|NCT04874363||smoker|active smokers
9686763|NCT04874363||non-smoker|Patients who have never smoked
9695955|NCT04772521|Placebo Comparator|Control|Regular text-based support and nicotine replacement therapy sampling (NRT-S) for continued smokers at 6 months for control group
9695956|NCT04772391|Other|Exercise Treatment Group|Exercise Sessions
9686764|NCT04874506|Experimental|Cohort 1|"Cohort 1 will receive standard of care concomitantly with1000 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
9686765|NCT04874506|Experimental|Cohort 2|"Cohort 2 will receive standard of care concomitantly with1200 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
9686766|NCT04874506|Experimental|Cohort 3|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
9686767|NCT04874506|Experimental|Cohort 4|"Cohort 2 will receive standard of care concomitantly with1400 mg/day of MBM-02.~Patients will receive standard of care treatment for newly diagnosed Glioblastoma multiforme consisting of four sequential periods:~1 week run-in with MBM-02 prior to radiotherapy;~6 weeks of radiotherapy and concomitant temozolomide;~4 weeks of rest post-radiotherapy and concomitant temozolomide; and~Adjuvant temozolomide treatment post 4-week rest period. Patients will be administered daily MBM-02 during all four sequential periods."
9686768|NCT04874324|Experimental|WCK 2349|"WCK 2349 800mg, 1000mg, and 1200mg . 1 dose given orally twice daily at 12 hourly interval for five days.~Dosage form : Oral"
9686769|NCT04874324|Placebo Comparator|Placebo|Matching Placebo administered as Oral
10179754|NCT03799510|No Intervention|Group 3|School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
10179755|NCT03799458|Active Comparator|Active Stimulation|Active HD-tDCS will be delivered while subjects perform sensory training tasks.
10179756|NCT03799458|Sham Comparator|Sham Stimulation|Sham HD-tDCS will be delivered while subjects perform sensory training tasks.
9686770|NCT04874779||Acute kidney injury (AKI) group|Acute kidney injury (AKI) group met the guidelines of Kidney Disease, Improving Global Outcomes (KDIGO)
9686771|NCT04874779||NON-Acute kidney injury (non-AKI) group|NON-Acute kidney injury (non-AKI) group not met the guidelines of Kidney Disease Improving Global Outcomes (KDIGO)
9686772|NCT04874389||Recreationally active males and females|"Subjects to be considered recreationally must regularly engage in >150 min/wk of physical activity (e.g., resistance training, sport or activity specific exercise, group exercise, or aerobic exercise). Healthy participants, defined as not currently injured, or recovering from an injury within the past 12 months, or undergone surgery within the last 12 months, or with any known history of moderate to severe traumatic brain injury resulting in impaired judgment or inability to make sound decisions or mild traumatic brain injury (mTBI, also commonly named concussion) within the last 12 months."
9686773|NCT04874389||Athletes or performing artists with reported history of concussion|Participants will be considered if they are recreationally active or considered an athletic performer (i.e.,history of participation in athletics at the university, amateur, elite or professional levels, or a military veteran), or a performing artist (i.e., stunt actors, circus artists, dancers or acrobats) with reported history of concussion incident(s), with most recent incident occurring >1 month and less than five years from the study testing dates.
9686774|NCT04874259|Experimental|Colorectal cancer liver metastasis|Liver transplantation for the treatment of unresectable colorectal cancer liver metastasis
9686775|NCT04874246|Active Comparator|Diluted Vasopressin Group 1|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 50 ml of normal saline to make a total of 100 ml) was injected before uterine serosal incision.
9686776|NCT04874246|Active Comparator|Diluted Vasopressin Group 2|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 200 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
9686777|NCT04874246|Active Comparator|Diluted Vasopressin Group 3|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 400 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
9686778|NCT04874493||Observational (questionnaire)|Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.
9686779|NCT04874285|No Intervention|control group|Women with risk factors for abortion, treated with progesterone
9686780|NCT04874285|Experimental|study group|Women with risk factors for abortion, treated with progesterone and a dietary supplement containing hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
9695957|NCT04772625||PFA|The cohort consists of all patients operated with patellofemoral arthroplasty for isolated patellofemoral osteoarthritis in Denmark from Jan 1 2008 to Dec 31 2015. The number of patients is expected to be around 500. A patellofemoral arthroplasty is defined as an arthroplasty consisting of a metal trochlear component and a polyethylene patella component. The definition of isolated patellofemoral osteoarthritis in the study is pragmatic and given by the operating surgeon.
9827578|NCT02461563|Experimental|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
10179757|NCT03799458|No Intervention|Imaging Only|40 subjects will undergo initial testing only as a healthy control group.
10179758|NCT03799406|Active Comparator|Intervention group|cholecalciferol at dose of 100 IU/Kg/day
10179759|NCT03799406|Placebo Comparator|Placebo group|placebo
10179760|NCT03799328|Experimental|multi-OIT|Low dose OIT with multiple allergens
10179761|NCT03799302|No Intervention|Standard Consultation|Sites in this arm will receive the standard consultation from the TFCO or MDFT purveyors
9686781|NCT04874298|Experimental|Intervention Arm 1 (Ginger Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use ginger oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
9686782|NCT04874298|Experimental|Intervention Arm 2 (Peppermint Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
9686783|NCT04874298|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
9686784|NCT04874428|Experimental|Rivaroxaban|Pharmacokinetics and pharmacodynamics of rivaroxaban
9686785|NCT04874428|Experimental|Apixaban|Pharmacokinetics and pharmacodynamics of apixaban
9686786|NCT04874571|Experimental|Muscle Energy Technique group|In the first group, according to Lewit's post-isometric relaxation (Muscle energy technique) method, scalene (anterior / medius / posterior), levator scapula, sternocleidomastoid, trapezius, pectoral muscles, serratus anterior and latismus dorsi muscles are set 3 days a week ( Each set includes three repetitions) The treatment will be applied for 4 weeks. The hypertonic muscle will be taken to the first point that resists movement without straining. The patient will be asked to perform an isometric contraction for 7 seconds, corresponding to 20% of the maximum isometric contraction force where the restriction is felt. After the application, the patient will be asked to exhale and relax completely. 30 seconds will be waited for each stretching and then the neck will be taken back to the barrier point and three repetitions per session will be performed.
10179762|NCT03799302|Experimental|SIC Coaching Consultation|In addition to the standard consultation from the TFCO or MDFT purveyors, sites in this arm will also receive feedback on how they are doing in terms of completing expected activities in their efforts to implement the designated EBP.
9686787|NCT04874571|Other|Home Exercise|The individuals in the second group will be asked to do the home exercise program shown to them for 4 weeks, 3 days a week. Individuals included in this group will be given a program that includes stretching and posture exercises for the same muscle groups. Individuals in the control group will be called weekly during the 4-week period. Before, after, and 6 weeks after the study, re-evaluation parameters will be applied to all individuals included in the study.
9686788|NCT04874142|Experimental|A Group|Two cohort, single sequence
9686789|NCT04874142|Experimental|B Group|Two cohort, single sequence
9686790|NCT04874051|Experimental|Experimental Group (EG)|In the EG the subjects will perform balance exercises using the OAK system under the supervision of a trained physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
9686791|NCT04874051|Active Comparator|Control Group (CG)|In the CG the subjects will be asked to perform conventional balance exercises under the supervision of a physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
9686792|NCT04873973|No Intervention|Control|Participants in this group are routinely treated.
9686793|NCT04873973|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
9686794|NCT04874103||EUS guided gallbladder drainage and cholecystoscopy|"EUS-GBD will be performed using LAMS (such as Hot-AxiosTM device). A 10mm x 10mm stent system will be used if the largest gallstone is smaller than 10mm in size and a 15 x 10mm stent will be used if the largest gallstone is larger than 10mm.~Colecystoscopy will be subsequently performed after at least 2 weeks using standard or therapeutic gastroscope. Lithotripsy will be performed using mechanical lithotripsy or laser lithotripsy."
9686795|NCT04874129|Other|A Group|Two-way Crossover
9686796|NCT04874129|Other|B Group|Two-way Crossover
9686797|NCT04874181|Experimental|Silverfit 3D|The subject will use SIlverfit 3D for rehabilitation of his/her shoulder/knee strength post stroke.
9686798|NCT04873921|Experimental|Group 1: Sterile Kinesio tape application|Sterile Kinesio Taping application will be applied with Sterile Web Cut Kinesio Tape (Sterile Kinesio Tex Tape, Alberquerque, USA) without tension.
9686799|NCT04873921|No Intervention|Group 2: Control group|Group 2 will not receive any taping
9686800|NCT04874090|Experimental|Interventional group|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program.
9686801|NCT04874090|Other|Exercises group|Patients will perform only neck exercises.
9827579|NCT02461563|Experimental|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
10179763|NCT03800095|Experimental|Conventional haematological care|Patients with haematological malignancy Conventional haematological care
10179764|NCT03800095|Experimental|Conventional care associated with a monthly consultation|Patients with haematological malignancy Conventional care associated with a monthly consultation realized by a palliative and supportive care team
10179765|NCT03799237|Experimental|GOS trap and dengue NS1 antigen kit|Gravid Oviposition Sticky (GOS) traps will be placed to trap adult Aedes mosquitoes and changed weekly. NS1 will be used to detect dengue in trapped Aedes mosquitoes. When dengue NS1 positive mosquitoes are found, community will be alerted via flyers, banners and other means. Routine Aedes/dengue control and surveillance will be carried out as usual as per the current Ministry of Health guidelines.
10179766|NCT03799237|No Intervention|Control|The GOS traps will be placed randomly in the control arm once per month for entomological survey. Routine Aedes control and surveillance will be carried out as per the current Ministry of Health guidelines. Dengue control measure will be initiated by the health authorities when human cases are reported from this arm.
10179767|NCT03799224|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for recurrent and refractory acute leukemia at the time of HLA-mismatched HSCT~Details:~The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2"
10179768|NCT03799224|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD (minimal residual disease) at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3."
10179769|NCT03799718|Experimental|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
10179770|NCT03799315|Experimental|Jail-Based Use of Smoking Cessation Treatment (JUST)|Participants will receive guidline-based smoking cessation counseling while in jail and phone-based smoking cessation counseling sessions and nicotine lozenges after release from jail.
10179771|NCT03799315|No Intervention|Enhanced Treatment As Usual (TAU)|Participants will receive the usual, limited smoking cessation treatment while in jail, plus an additional health and wellness education session in jail. Nicotine lozenges will be offered at the end of the study to those who did not quit smoking.
10179772|NCT03799172||Echinocandin group|Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
10179773|NCT03799172||Triazole group|Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
10179774|NCT03799133|Experimental|Patients with Florence device|Patients with the Florence catheter placed and connected to the Florence monitor to measure XL trend.
10179775|NCT03799120|Placebo Comparator|tamsulosin QD + Placebo|0.4 mg tamsulosin QD + Placebo QD
10179776|NCT03799120|Experimental|tamsulosin BID|0.4 mg tamsulosin BID
10179777|NCT03799094|Experimental|Experimental group|75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.
10179778|NCT03799094|Experimental|Control group|75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)
10179779|NCT03799081|Other|Fetoscopy in missed abortion|Women who have decided to undergo fetoscopy in missed abortion
10179780|NCT03799068|Active Comparator|suprazygomatic maxillary nerve block|the group were given a bilateral suprazygomatic maxillary nerve block with 0.125% bupivacaine, 2 ml on each side, the total dose of bupivacaine not exceeding 2 mg/kg.
10179781|NCT03799068|Active Comparator|surgical site infiltraion|the group were given peri-incisional infiltration with 0.125% bupivacaine, 2 ml on each side. In all cases the block was given by the anaesthetist and the infiltration by the surgeon.
10179782|NCT03799042|Experimental|Vitural Reality|Virtual Reality 3D glass
10179783|NCT03799042|Active Comparator|Inter-generation interaction|Elders-teenager interaction
10179784|NCT03799250|Experimental|Goal Directed Hemodynamic Therapy|"The GDT (Goal Directed Therapy) group will not receive any maintenance fluid. Fluid boluses will be given according to the flowchart attached.~Baseline MAP and HR will be measured in the pre-anesthetic clinic or if not available will be recorded according to community medical record.~Measurements of hemodynamic variables including heart rate and automatic non-invasive blood pressure measurements as well pulse oximetry as routine procedures will be recorded and stored by Metavision system (iMDsoft company) at regular intervals, all according to standard clinical practice.~Blood gases measurement will be performed upon admission and at discharge. Urine output will be measured and recorded every hour.~Other laboratory exams will be taken based on the physician discretion unrelated to the participation in the study."
10179785|NCT03799250|Active Comparator|Control Group|The control group will receive standard care which includes fluid maintenance program as dictated by the operating room anesthesiologist and as needed boluses through the PACU (Post Anesthesia Care Unit) stay.
10179786|NCT03799029|Active Comparator|active control group low-intensity|Low intensity version of the same cognitive training program Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
10179787|NCT03799029|Experimental|experimental training group cognitive training|a multifactorial cognitive program that tackles working memory, attention, inhibition, planification and reasoning Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
10179788|NCT03799029|No Intervention|control healthy participants|Just a control group including healthy participants No intervention
10179789|NCT03798990||users of French roads|all road users circulating on French roads outside over-seas
9686802|NCT04873895|Experimental|TACE+axitinib+HCQ|2 weeks of axitinib 5mg BID and hydroxychloroquine 600 mg BID followed by lobar or segmental trans arterial chemoembolization monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity.
10179790|NCT03798964||Elective term cesarean|Low-risk women undergoing elective term cesarean section
10179791|NCT03798964||Term vaginal delivery|Low-risk women undergoing term vaginal delivery
9686803|NCT04874116|Experimental|Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging|Participants receive Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging for 12 months.
9686804|NCT04874116|Active Comparator|Mobile phone text messaging|Participants receive mobile phone text messaging alone for 12 months.
10179792|NCT03798964||Preterm vaginal delivery|Women undergoing preterm vaginal delivery
10179793|NCT03798912|Active Comparator|Intravenous octreotide group|Octreotide 100 mcg will be injected intravenously and serial blood samples will be collected for PK analysis
10179794|NCT03798912|Experimental|RaniPill A group|In 20 subjects, a RaniPill with a small balloon size will be administered and serial blood samples will be collected for PK analysis
10179795|NCT03798912|Experimental|RaniPill B group|In 20 subjects, a RaniPill with a larger balloon size will be administered and serial blood samples will be collected for PK analysis
10179796|NCT03798912|Experimental|RaniPill C group|In 20 subjects, a RaniPill with a different size will be administered and blood samples will be collected for the presence of drug
10179797|NCT03798899|Experimental|Penthrox® (Methoxyflurane)|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
10179798|NCT03798899|Placebo Comparator|Normal Saline|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
10179799|NCT03798873|Experimental|FeelWell™ Compression garment use with increase mobility|"Subjects are randomized to wear custom-fitted FeelWell™ Compression garment daily during regular and exercise activities.~Subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity."
10179800|NCT03798873|Other|Increase mobility|For the control group, subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity. The control group will not be assigned a compression garment during the trial.
10179801|NCT03798886||Natural frozen embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. After spontaneous ovulation, embryo transfer will be planned. Luteal phase support will not be used.
10179802|NCT03798886||modified natural embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. When follicle diameter is 16-17 mm we will apply hCG (recombinant hCG). After ovulation, embryo transfer will be done. Luteal phase support will not be used.
10179803|NCT03798834|Experimental|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
10179804|NCT03798834|Placebo Comparator|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
10179805|NCT03798821|Experimental|Experimental|One capsule a day will be consumed. At breakfast for the six weeks.
10179806|NCT03798821|Placebo Comparator|Comparator|One capsule a day will be consumed. At breakfast for the six weeks.
10179807|NCT03798808|Experimental|Family Nutriathlon group|Web-based nutrition program (encouraging consumption of fruits, vegetables and dairy products through an online platform)
10179808|NCT03798808|No Intervention|Control group|General nutrition guidelines (e.g. following Canada's Food Guide)
10179809|NCT03798769|Experimental|Supportive Oncology Care at Home|"The Supportive Oncology Care at Home intervention entails the following:~patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers for phone calls and home visits by Medically Home based on a clinician-derived algorithm~scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
10179810|NCT03798730|Experimental|Solid Model|"Cake~-Control Vanilla Cake and Protein Fortified Vanilla Cake~Biscuit -Control Lemon Biscuit and Protein Fortified Lemon Biscuit"
10179811|NCT03798730|Experimental|Liquid Model|"Whey Protein Beverages~Native sample (protein unheated)~Denatured whey protein (protein heated to denature)"
10179812|NCT03798652||Patients referred for CABG|Patients with known coronary artery disease referred for isolated surgical revascularisation, who will be invited to attend our facility for a research CMR scan, a research 3D transthoracic echocardiogram and a 6 minute walk test
10179813|NCT03798782|Experimental|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root.
10179814|NCT03798782|Active Comparator|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
10179815|NCT03798613|Active Comparator|Apple Watch 4 Series Device|Apple watch 4 series heart rate monitoring device
10179816|NCT03798613|Active Comparator|Continuous Telemetry|Standard continuous telemetry monitoring device
10179817|NCT03798600||Critically ill patients|"20 patients consecutively admitted in the ICU with severe sepsis or septic shock requiring caspofungin therapy will be considered for this observational study.~Inclusion Criteria:~Adult ICU patients (>18 yrs) with severe sepsis or septic shock undergoing caspofungin therapy based on clinical judgement (empiric therapy) or microbiological result (targeted therapy).~Exclusion criteria:~Concomitant ciclosporin or rifampicin therapy. Pregnancy Continuous renal replacement therapy Severe Liver failure (Child Pugh score > 6)"
9686805|NCT04873947||healthy adult volunteer|Subject is 18 to 50 years of age. Subject is a non-smoker or who has not smoked within 2 days prior to the study.
9686806|NCT04873791||Group 1|"Assessment Geriatric Individuals Living at Home were joined in Group 1.~Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
9686807|NCT04873791||Group 2|"Assessment Geriatric Individuals Living in Nursing Home were joined in Group 2. Demographic and social characteristics, cognitive functions, balance, pain, depression, quality of life, and activities of daily living of elderly individuals living in a nursing home and home environment were evaluated.~Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), Standardized Mini-Mental Test (SMMT) score, Visual Analog Scale (VAS) score, Berg Balance Scale (BBS) score, Geriatric Depression Scale (GDS) score, Barthel Index score, Short Form-36 (SF-36) score were used for evaluations.~Assessments were made as described in section of outcome measures, in one session."
9686808|NCT04873726|No Intervention|Pre: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
10179818|NCT03798587||OS patients|"Patients with age ≥18 years that were/can be recruited within the IRCCS Istituto Ortopedico Galeazzi BioBanca (ethical committee approval n. 29/INT/2017).~Patients with age <18 years: will be additionally recruited besides the IRCCS Istituto Ortopedico Galeazzi BioBanca.~The target group corresponds to patients hospitalized at Istituto Ortopedico Galeazzi, undergoing surgical eradication of primary osteosarcoma.~Patients will be considered eligible for enrollment in the study if able to sign the consent to the procedure after appropriate information from the reference surgeon or signed by parents or legal guardian after appropriate information from the reference surgeon (if age <18).~Inclusion Criteria:~Indication for primary OS eradication surgery~Patients hospitalized in Istituto Ortopedico Galeazzi~Exclusion criteria:~-Patients not able to sign the Informed Consent."
9686809|NCT04873726|No Intervention|Pre: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
9686810|NCT04873726|No Intervention|Pre: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
9686811|NCT04873726|Experimental|Post Exp: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
9686812|NCT04873726|Experimental|Post Exp: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
9686813|NCT04873726|Experimental|Post Exp: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
9686814|NCT04873726|Placebo Comparator|Post Pla: pain AP|Pain assessment in the spinous processes of the spine with algometer anteroposterior pressure
9686815|NCT04873726|Placebo Comparator|Post Pla: pain Pinch test|perceived pain over the paravertebral skin at each level of the spine using Pinch test
9686816|NCT04873726|Placebo Comparator|Post Pla: pupil diameter|the pupil responses were measured with the fully automated Vorteq® system (Micromedical Technologies, Inc) to record the pupil reaction.
9686817|NCT04873804|Active Comparator|LEFT DLPFC|The anode electrode of tDCS was applied to the left DLPFC and the cathode electrode was connected to the contralateral shoulder.
9686818|NCT04873804|Active Comparator|RİGHT PPC|The anode electrode of tDCS was applied to the right PPC and the cathode electrode was connected to the contralateral shoulder.
9686819|NCT04873804|Sham Comparator|Sham|Placebo was applied by placing the electrodes in the right PPC and left DLPFC without applying current.
9686820|NCT04873635||Patients who had excised pathological jaw lesions and will receive implant rehabilitation|
9686821|NCT04873752|Experimental|UDI-001|Four cycles with 8 administrations
9686822|NCT04873843|Experimental|Functional digital game training group|These functional digital game programs have been developed to improve the intelligence and vitality in the community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
9686823|NCT04873843|Experimental|Individual cognitive training|Individual cognitive training has been used to improve the intelligence and cognitive function in community-dwelling elderly. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
9686824|NCT04873531|Experimental|Neostigmine|"For the Neostigmine (N) group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
9686825|NCT04873531|Placebo Comparator|Normal saline|"For the Normal saline (NS) group, normal saline with a same volume of the N group will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
9686826|NCT04873713|No Intervention|No Intervention: internal hip rotation|internal hip rotation pre measurement with knee and hip flexion at 90º, internal hip rotation will be performed
9686827|NCT04873713|Experimental|Experimental: internal hip rotation|internal hip rotation post experimental application measurement with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
9686828|NCT04873713|Placebo Comparator|Placebo Comparator: internal hip rotation|internal hip rotation post placebo application measurement with Placebo tape Application with knee and hip flexion at 90o, internal hip rotation will be performed
9686829|NCT04873674||ASD group|240 ASD patients (aged 4-25 years)
9686830|NCT04873674||Unaffected siblings of ASD|60-100 unaffected siblings of ASD probands
9686831|NCT04873674||TD group|120 age-, and sex matched TDC from the same geographic areas of the ASD group via referral by teachers, or advertisement at college or community.
9827580|NCT02461563|Experimental|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
9686832|NCT04874467|Experimental|Keratinized Mucosa ≥ 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
9686833|NCT04874467|Experimental|Keratinized Mucosa < 2 mm|Supportive periodontal therapy, in teeth by means of ultrasonic devices and manual curettes. In implants using the same devices but made of titanium. Oral hygiene instructions
9686834|NCT04873687|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention therapy (i.e eligible stable angina pectoris patients in intervention arm who agree to participate)
9686835|NCT04873687|No Intervention|Control|Eligible stable angina pectoris patients in the control arm will receive no intervention therapy
9686836|NCT04873544|Experimental|Common protocols for TKA|Common protocols for TKA
9686837|NCT04873648|Experimental|food addiction and binge eating follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric reduced -intermitted fasting diet
9686838|NCT04873648|Active Comparator|food addiction and binge eating follow caloric restriction diet|Obese women diagnosed with binge eating disorder and food addiction follow caloric restriction diet
9686839|NCT04873648|Experimental|binge eating disorder follow follow caloric reduced -intermitted fasting diet|Obese women diagnosed with binge eating disorder follow caloric reduced -intermitted fasting diet
9686840|NCT04873648|Active Comparator|binge eating disorder follow caloric restriction diet|Obese women diagnosed with binge eating disorder follow a caloric restriction diet
9686841|NCT04873648|Placebo Comparator|obese women without food addiction and binge eating follow caloric restriction diet|Obese women without eating disorder follow a caloric restriction diet
9686842|NCT04873778|Experimental|Dynamic taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
9686843|NCT04873778|Experimental|kinesio taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
9686844|NCT04873778|Placebo Comparator|control group|use Kinesio taping for placebo effect
9686845|NCT04873609|No Intervention|No primary care provider (PCP) appointment, No patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
9686846|NCT04873609|Active Comparator|No PCP appointment, Patient outreach|400 patients that did not have an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
9686847|NCT04873609|No Intervention|PCP appointment, No patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to control group and did not receive a patient portal message with order for HCV antibody screening
9686848|NCT04873609|Active Comparator|PCP appointment, Patient outreach|400 patients that had an upcoming PCP appointment in 6 months were randomly assigned to receive a patient portal message with order for HCV antibody screening
9686849|NCT04873440|Experimental|Manganese plus Radiotherapy|Subject received standard-of-care radiotherapy or stereotactic body radiation therapy (SBRT) to one metastatic site. Manganese inhalation began 1 week after the start of radiotherapy and lasted up to 6 months. The same systemic therapy before the enrollment will be maintained.
9686850|NCT04873570|Experimental|Test Group|Subjects will be given one Mofest® 400mg (Moxifloxacin HCl) Tablet (1x400mg) manufactured by SAMI Pharmaceuticals (Pvt.) after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
9686851|NCT04873570|Active Comparator|Reference Group|Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
9686852|NCT04873661|Experimental|Hypnosis|In the hypnosis-based intervention, patients (in groups of approximately 10 participants) will participate in 8 weekly sessions (2 hours each) during which they will benefit from guided hypnosis exercises, and learn how to implement self-hypnosis. They will also receive a CD with hypnosis exercises for home practice. At-home practice is encouraged between sessions.
9686853|NCT04873661|Experimental|Cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
9686854|NCT04873661|Experimental|Meditation|The meditation-based intervention will consist of 8 weekly sessions (2h45 each) in groups of approximately 10 participants, as well as half a day of intensive practice between the fifth and the sixth session. Participants will learn how to implement self-compassion meditation, through practical exercises proposed during the sessions. At-home practice is encouraged between sessions.
9686855|NCT04873661|No Intervention|Control group|Participants in the control group will not receive any intervention during the whole duration of the study. They will be assessed at the same times and in the same ways than the 3 experimental groups. After the study, they will have the opportunity to participe in one of the 3 interventions if they want to.
9686856|NCT04873427||early metastatic prostate cancer patients|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
9686857|NCT04873427||non-relapsing/non-metastatic patients with indolent malignant disease|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
9695958|NCT04772469|Experimental|Promoter training, multiple self-test kits, and incentives|Promoters in the intervention group will receive HIVST training, multiple HIVST for distribution to other men, and a small amount of remuneration (transport voucher) for themselves and to distribute to men in their networks.
10179819|NCT03798561|Experimental|82 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 82 µg/cm2 single application in 7 days or Placebo TG (6 subjects ASN008: 2 subjects placebo) (6:2)
10179820|NCT03798561|Experimental|164 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 164 µg/cm2 single application in 7 days or Placebo (6:2)
10179821|NCT03798561|Experimental|328 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 328 µg/cm2 single application in 7 days or Placebo (6:2)
10179822|NCT03798561|Experimental|492 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 492 µg/cm2 single application in 7 days or Placebo (6:2)
10179823|NCT03798561|Experimental|ASN008 TG TBD Cohort 1 or Placebo|Part B: ASN008 TG Cohort 1 daily application for 15 days or Placebo (9 subjects ASN008: 3 subjects Placebo) (9:3)
10179824|NCT03798561|Experimental|ASN008 TG TBD Cohort 2 or Placebo|Part B: ASN008 TG Cohort 2 daily application for 15 days or Placebo (9:3)
10179825|NCT03798561|Experimental|ASN008 TG TBD Cohort 3 or Placebo|Part B: Placebo TG Cohort 3 daily application for 15 days or Placebo (9:3)
10179826|NCT03798548|Experimental|Brief Bedside CBT|
10179827|NCT03798548|No Intervention|Treatment As Usual|
10179828|NCT03798574||IMD Case|No intervention
10179829|NCT03798574||Control|No intervention
10179830|NCT03798522|Experimental|erector spinae plane block group (ESPB) n=14|Bilateral ultrasound guided erector spinae plane block will be performed in the lateral position at T7 vertebrae and before induction of GA. 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will be injected in-plane into the ESP. This procedure will be repeated on the other side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine) and then GA will be conducted .
10179831|NCT03798522|Active Comparator|general anesthesia group (GA) n= 14|these patients will receive iv nalbuphine in dose of 2mg /kg according to ideal body weight after induction of GA
10179832|NCT03798509|Experimental|Human CD19 targeted T Cells Injection|
10179833|NCT03798470|Experimental|Cohort|Intervention with FAVOR peer recovery coaching. Patients identified in the ED as opioid overdose and enrolled in the current study.
10179834|NCT03798457||Patients with CAP hospitalized in IM|Data of Patients with Community-acquired pneumonia (CAP) hospitalized in Internal Medicine Units will be collected for this study; no intervention is planned for this study
10179835|NCT03798444||Bone mineral denstiy|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry in all subjects.Accroding to The World Health Organization, we defined osteoporosis as a T-score ≤-2.5,and the non osteoporosis as T-score>-2.5.
10179836|NCT03798444||Vertebral fractures|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray. A visual semi-quantitative method was used, with fractures defined as a vertebral height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra.
9686858|NCT04873492|Other|Retrospective Aggressive MS patients|Patients from who the clinical outcome is already known and classified as poor based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
9686859|NCT04873492|Other|Retrospective Non Aggressive MS patient|Patient from who the clinical outcome is already known and classified as non-aggressive based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
10179837|NCT03798431|Experimental|M-ROCC|Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
10179838|NCT03798418|Active Comparator|exercise group|elastic band strengthening exercise
10179839|NCT03798418|Experimental|exercise combine diet counseling group|elastic band strengthening exercise combined diet counseling.
10179840|NCT03798405|Experimental|Proactive|"Proactive Analgesic Inpatient Narcotic-Sparing:~Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a protocol."
10179841|NCT03798405|No Intervention|Reactive (Control Group)|Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.
10179842|NCT03798392|Active Comparator|SP group|
10179843|NCT03798392|Active Comparator|Baska group|
10179844|NCT03798353|Experimental|Experimental group|"The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.~In addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.~PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix ."
10179845|NCT03798353|Active Comparator|Control group|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.
9686860|NCT04873492|Other|Healthy volunteers|Prospective arm use as comparator.
9686861|NCT04873492|Other|Prospective MS patients|MS patients from who the clinical outcome will be established at the end of the follow up. Blood sample will be collected after the first event to validate molecules of interest from OMIC results by using FACS a different technology and classify MS patient.
9686862|NCT04873557|Experimental|Copper Intervention|Intervention with copper-based surfaces plus copper-enriched linen
9686863|NCT04873557|No Intervention|Control Group|Control group without copper intervention
10179846|NCT03799276|Experimental|Opticare study|"Phase I: Identification and Selection of study population The first step will include an active search by OPTICARE team for vulnerable and lost to follow up patients~Phase II: Implementation of the individualized follow-up program The patients who agree to participate to the program will be defined as the OPTICARE population."
10179847|NCT03798340|Experimental|Vibratory perturbed task-specific movement training|Intervention: 10 minutes of traditional sensorimotor facilitation followed by 20 minutes of vibratory perturbed task-specific movement training
9686864|NCT04873505|Experimental|Troches|25 persons take one probiotic troche after each meal.
10179848|NCT03798340|Active Comparator|Traditional task-oriented facilitation|Intervention:10 minutes of traditional sensorimotor training followed by 20 minutes of reach-to-grasp and hand release training.
9686865|NCT04873505|Placebo Comparator|Troches do not contain probiotics|25 persons take one troche that does not contain probiotics after each meal.
9686866|NCT04873206||Functional/ Cyclical Endometrial group.|cases of normal endometrium will be obtained from hystrectomy specimens done for causes other than hyperplasia or adenocarcinoma, for example; uterine fibroids, uterine prolapse.
9686867|NCT04873206||Hyperplastic Endometrial group.|cases of endometrial hyperplasia obtained by D&C or hystrectomy will be stained by H&E stain and categorized into typical or atypical hyperplasia.
9686868|NCT04873206||Primary Endometrial Adenocarcinoma group.|cases of primary endometrial adenocarcinoma obtained by D&C or hystrectomy operations
9686869|NCT04873141||Case Group|All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.
9686870|NCT04873479|Experimental|test group|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
9686871|NCT04873479|Other|control group|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.2-0.3ug/kg,Etomidate 0.2-0.3mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.1-0.3ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
9686872|NCT04872998|Experimental|Reduced Activity|Reduction of daily step count by 70% for two weeks
9686873|NCT04873219|Active Comparator|CAD/CAM milled complete denture|the dentures were milled out of a block of pre-polymerized PMMA resin (Avadent, Global dental Science, Netherlands)
9686874|NCT04873219|Experimental|CAD/CAM rapid prototyped complete denture|the dentures will be 3D-printed from a liquid PMMA, including the teeth (NexDent, Netherlands)
9686875|NCT04873349|Active Comparator|Olive leaf capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a 50% standardized olive leaf capsule 750 mg (700 mg oleuropein/day; the active principle in olive leaf) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the active comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
9686876|NCT04873349|Placebo Comparator|Starch capsules|Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a placebo starch capsules (750 mg) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the placebo comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
9686877|NCT04873115|Active Comparator|Sialanar|Sialanar administered as per the SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
9686878|NCT04873115|Placebo Comparator|Placebo|Placebo administered as per the Sialanar SmPC - titration over 4 weeks to reach a dose balancing efficacy with tolerability.
9686879|NCT04873284|Experimental|Fosaprepitant|Patients received intravenous Granisetron plus dexamethasone followed by fosaprepitant infusion
9686880|NCT04873284|Experimental|Aprepitant|Patients received intravenous Granisetron plus dexamethasone followed by oral aprepitant
9686881|NCT04873128|Experimental|Healthy adults|"Healthy adults who had no infection with SARS-CoV-2 virus before or had recovered from COVID-19 and plan to take the various COVID-19 experimental vaccine candidates or had already one dose of COVID-19 vaccine and are going to have the second vaccination with a different vaccine.~Study related procedures:~1-3 days before application of the first vaccine dose (blood sample 1) 7-10 days after first dose of vaccine (blood sample 2), 1-3 days before second dose of vaccine (blood sample 3) 7-10 days after second vaccine dose (blood sample 4) 6-12 Months after second vaccine dose (blood sample 5, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
9686882|NCT04873128|Experimental|COVID-19 vaccinated subjects with side effects|"COVID-19 vaccinated subjects with diagnosed central thrombosis, anaphylactic shock or other major or minor complications such as dermatitis.~Study related procedures: Blood sample will be taken without time frame 1-3 days after admission to the hospital (severe side effects) or consulting a doctor (mild side effects) (blood sample 1) during treatment (blood sample 2) After subject is recovered (blood sample 3) 6-12 Months after recovering (blood sample 4, optional) Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
9686883|NCT04873466|Experimental|Enzyme-rich malt extract|Enzyme-rich malt extract (15 ml b.i.d with food)
9686884|NCT04873076|Experimental|Audiovisual distraction using 2d video glasses from HappyMed GmbH|"During the catheter ablation, the patients in the intervention group receive 2D video glasses with headphones. Immediately before and after the procedure they receive a questionnaire. During the procedure vital parameters of all patients regardless of the studygroup are monitored using Zoll X-Series Monitor Defibrillator. The study includes blood pressure (in mmHg), heart rate (in beats per minute) and patient's level of alertness, which is assessed using the Richmond Agitation-Sedation Scale(RAAS). During the procedure the patients in the intervention group receive the glasses and remote control. All patients receive their individual dosage to ensure painless ablation. The drugs used are limited to the opioids remifentanil and benzodiazepine midazolam."
9827581|NCT02461563|Experimental|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
10179849|NCT03798379|Active Comparator|Exercise group|Eligible patients who were planned to receive neurotoxic chemotherapy
10179850|NCT03798379|No Intervention|Control group|Patients eligible for the study and received the 3rd cycle of chemotherapy
9686885|NCT04873076|No Intervention|Controll arm|"In patients in the control group, catheter ablation is performed as usual without the use of video glasses. They receive immediately before and after the ablation the same questionnaire as the patients in experimental arm. (Omitting the question about the videoglasses).~While the procedure is performed, the analgosediation is as well in the controll arm as in the experimental arm titrated until the patient is treated, sedated and painless."
9686886|NCT04873167|Experimental|Low Fat Diet|subjects subjected to a low-fat dietary regime
9686887|NCT04873167|Experimental|Mediterranean Diet|subjects subjected to a mediterranean dietary regime
9686888|NCT04873414|Experimental|Treatment group|Subjects in the Treatment Group are given 200 ml of Plasma collected from Convalescent Patients recovered from COVID-19 at two-day intervals in addition to standard supportive treatment
9686889|NCT04873414|No Intervention|Control group|Subjects in the Control Group are given standard supportive treatment
9686890|NCT04872933|Other|Non-Waitlist|Patient will attend a total of 3 virtual assessments whilst in the study: at baseline, at 12 weeks then at 6 months. The online intervention will commence straight after completing the baseline visit.
9686891|NCT04872933|Other|Waitlist|Patient will be complete assessments at baseline and 12 weeks but will only start the online intervention after the 12-week assessment.
9686892|NCT04872946|Experimental|InnerCalm+skin care|An oral supplement and topical agent will be assigned.
9686893|NCT04872946|Experimental|InnerCalm only|An oral supplement will be assigned.
9686894|NCT04872946|Experimental|Skincare Only|A topical agent only will be assigned.
9686895|NCT04873102|Experimental|Danazol in Treatment of Cytopenias|AGENT: Danazol 600mg, Oral, Daily for 24 months
9686896|NCT04873011|Experimental|Quinine hydrochloride|The bitter tastant, quinine hydrochloride, will be acutely infused via a nasogastric feeding tube into the stomach. 320 mg of quinine hydrochloride is dissolved in 10 mL of water and all is infused.
9686897|NCT04873011|Placebo Comparator|Placebo|10 mL of water is infused via a nasogastric feeding tube into the stomach.
9686898|NCT04873089||RV3278A arm|RV3278A study product is applied twice a day (morning and evening) on the face during the whole study.
9686899|NCT04873089||Control Group|Subjects included in the control group did not receive the test product or other associated product
9686900|NCT04872985|Experimental|Arm 1: Pyrotinib+ AC/EC followed by T|400 mg Pyrotinib orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
9686901|NCT04872985|Placebo Comparator|Arm 2: Placebo+ AC/EC followed by T|400 mg placebo orally once per day with four cycles of epirubicin (100 mg/m2) (or doxorubicin hydrochloride liposome injection 30mg/m2) and cyclophosphamide (600 mg/m2) intravenously, once every 3 weeks, followed by four cycles of docetaxel (100 mg/m2) intravenously, once every 3 weeks (or 12 cycles of weekly nab-paclitaxel 120mg/m2 intravenously) .
9686902|NCT04873063|Experimental|Reference/Test|"3 mg BDP suppositories (R product) delivered twice daily for 7 days~Washout period (at least 7-day and preferably no more than 9 days)~6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product."
9686903|NCT04873063|Experimental|Test/Reference|"6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product.~Washout period (at least 7-day and preferably no more than 9 days)~3 mg BDP suppositories (R product) delivered twice daily for 7 days"
9686904|NCT04872972|Other|Before/After|Before and after simulation; Institutional faculty and facilities
9686905|NCT04872712|Active Comparator|Press Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with Press Needles treatment will be treated with 2-week needle retention, 20-second pressing 3 times a day and needle replacement performed every 5 days. The needles are inserted 0.9 mm deep at the acupuncture points HT7 Shenmen, PC6 Neiguan, ST36 Zusanli and SP6 Sanyinjiao.
10179851|NCT03798314|Experimental|Treatment (nivolumab and pomalidomide)|Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
10179852|NCT03800199|Experimental|Perceptive Rehabilitation (PR-group)|Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.
10179853|NCT03798249|Active Comparator|Gluten|Patients will receive acutely 16 g of gluten and 2 muffins glutenfree with 8 g of gluten, twice a day, during 5 days
10179854|NCT03798249|Placebo Comparator|Placebo|Patients will receive acutely 16 g of whey protein and 2 glutenfree muffins, twice a day, during 5 days
10179855|NCT03798275|Active Comparator|the study group|healthy pregnant women with borderline oligohydramnios who accept to drink a cup of coffee
10179856|NCT03798275|No Intervention|the control group|healthy pregnant women with normal amniotic volume
10188003|NCT03720483|Experimental|Placebo then N-acetyl cysteine|This arm will receive placebo followed by NAC
10188004|NCT03720457|Experimental|Human CD19 targeted T Cells Injection|
9686906|NCT04872712|Active Comparator|Filiform Needles|The subjects/population of this study is Health Workers with insomnia symptoms who work at at Cipto Mangunkusumo Hospital treating COVID-19 patients. Subjects group with filiform needles treatment will be treated with 20-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The needles are inserted approximately 12 mm deep at the acupuncture points HT7 Shenmen and PC6 Neiguan and 25 mm deep at the ST36 Zusanli and SP6 Sanyinjiao.
9686907|NCT04872907|Experimental|adhesive system + flowable composite|Side of the mouth randomlly assigned to this arm will receive self etch adhesive system and flowable composite combination on temporary molars and self etch adhesive system on anterior temporary teeth at baseline, M6, M12, M18
10179857|NCT03798288|Experimental|Usual care + selfBACK|"The selfBACK system constitutes a data-driven decision support system that uses case-based reasoning to capture and reuse participant cases to suggest the most suitable self-management plan for participants. The system is an intelligent system delivering self-management plans tailored to individual participant characteristics. Information about participant characteristics is collected via a (baseline) questionnaire, weekly self-reports via the app on symptom progression etc., and a wristband that detect daily number of steps. The weekly plans are presented in an app to participants.~The weekly plan includes three categories of content;~information/education~recommended daily number of steps~recommended strength and flexibility exercises"
10179858|NCT03798288|Active Comparator|Usual care|Any diagnostic or treatment-related pathway (e.g. receive information, advice or treatment) as instructed by their health care professional. Patients are allowed to seek care, treatment or help elsewhere as normal.
9686908|NCT04872907|Active Comparator|Fluoride varnish|Side of the mouth randomly assigned to this arm will receive the fluride varnish at baseline, M6, M12, M18 on the temporary teeth
9695959|NCT04772469|No Intervention|Short training and referral for testing|Promoters in the control group will a short training on the basics of HIV prevention and treatment and will be encouraged to refer men in their networks for standard of care testing at the local health facilities- this may include HIV testing with a counselor or HIV self-test from the local health clinic, depending on what is available.
9695960|NCT04772092||Seniors|70 years of age and over, inpatients or outpatients
9695961|NCT04772287|Experimental|Toripalimab|
9695962|NCT04772287|Placebo Comparator|Placebo|
9695963|NCT04772105|Experimental|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route of administration: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: once every 4 weeks, 6 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
9695964|NCT04772105|Experimental|4mg of BAT5906|Specification: 16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4mg/eye/time, 50μl; medication duration: once every 4 weeks, 3 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
9695965|NCT04772495||Study group|with Multiple sclerosis
9695966|NCT04772495||Control group|not Multiple sclerosis
9695967|NCT04772053|Experimental|Participants undergoing tumor biopsy|
9695968|NCT04772040|Experimental|Young loading dose group|Participants (18-35) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the old group.
9695969|NCT04772040|Experimental|Old loading dose group|Participants (60y+) will receive a loading dose of fish oil supplementation during the first 4 weeks of the intervention period of the study. In the last 8 weeks participants will receive a maintenance dose of fish oil supplementation. The total amount of EPA/DHA received throughout the supplementation period will be the same as the young group.
9695970|NCT04772040|Experimental|Young constant dose group|Participants (18-35y) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
9695971|NCT04772040|Experimental|Old constant dose group|Participants (60y+) will receive a constant dose of fish oil supplementation throughout the intervention period of the study. Total amount of EPA/DHA received throughout the 12 weeks supplementation period will be the same as the loading groups.
9695972|NCT04772638|Experimental|PLAY intervention|The PLAY intervention with educators, parents and children
9695973|NCT04772638|Placebo Comparator|Wait list control|
9695974|NCT04772014||e-cigarette users|daily e-cigarette use (additional smoking of traditional tobacco cigarettes is not an exclusion criterion)
9695975|NCT04772014||nicotine-naïve|lifetime consumption of less than 20 cigarettes or e-cigarettes
9695976|NCT04772066||Non adherent patients|Non adherent patients
9695977|NCT04772066||Adherent patients|Adherent patients
9695978|NCT04772352|Experimental|Experimental group: Lifestyle intervention + febuxostat (40mg, once a day, orally)|participants accept febuxostat treatment in addition to lifestyle intervention for 0-48 week.
9695979|NCT04772352|Active Comparator|Control group: Lifestyle intervention|participants receive lifestyle intervention for 0-24 week. If the results of the 0-24 week study showed that the liver fat content of subjects in the experimental group was significantly lower than that in the control group, control group will accept febuxostat treatment in addition to lifestyle intervention in the next 25-48 week.
9695980|NCT04772339||Healthy Adults|Healthy adults aged between 18-30
9695981|NCT04772235|Experimental|Advanced and/or metastatic EGFR mutant NSCLC|Eligible advanced and/or metastatic EGFR mutant NSCLC patients will receive the combination of osimertinib and repotrectinib.
9695982|NCT04771949||All patients coming to the University Clinic of Dentistry|All patients coming to the dental University Clinic will be screened for the inclusion in the study.
9695983|NCT04772027||Muscular dystrophies group|40 patients with limb girdle muscular dystrophie
9695984|NCT04772027||Comparator group|40 healthy volunteers without neuromuscular or squeletic disorder
9695985|NCT04772001|Experimental|CCRT+Anlotinib|Classical chemoradiotherapy will be conducted by clinical routine method. Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks. Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime and for patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug. Hydrochloride anlotinib will be orally taken daily at a dose level of 12mg for 14 days. Then rest for 7 days and start a new cycles for a total of 3 cycles. First capsule of anlotinib will be taken 7 days before the first radiation.
10179859|NCT03798262|Active Comparator|Gluten|Patients receive 16 g of gluten acutely and afterwards 2 glutenfree muffins with 8 g of gluten for 5 days sub-acutely
10179860|NCT03798262|Placebo Comparator|Placebo|Patients receive 16 g of whey protein acutely and afterwards 2 glutenfree muffins for 5 days sub-acutely
10179861|NCT03798236|Experimental|PBF-1650 40mg|
10179862|NCT03798236|Experimental|PBF-1650 80mg|
10179863|NCT03798236|Experimental|PBF-1650 120mg|
10179864|NCT03798236|Experimental|PBF-1650 240mg|
10179865|NCT03798236|Placebo Comparator|Placebo|
10179866|NCT03798210|Placebo Comparator|Placebo|Look and taste-alike placebo tablets in white plastic vials.
10179867|NCT03798210|Experimental|Lactobacillus reuter's|Lactobacillus reuteri tablets in white plastic vials.
10179868|NCT03798197|Active Comparator|30 mg estetrol (E4) without food (fasted)|Treatment A (reference): One 30 mg E4 tablet administered orally following an overnight fast of at least 10 hours.
9686909|NCT04872608|Experimental|Letrozole, Palbociclib, and Onapristone ER|This study has two stages: a dose-finding stage and a dose expansion stage. Stage 1 of the study will utilize a standard 3+3 dose de-escalation design with a total of three dose levels of onapristone ER, 30mg PO BID, 40mg PO BID, and 50mg PO BID given on a 28-day cycle. Onapristone ER will be given in addition to letrozole 2.5mg QD and each patient's pre-enrollment dose of palbociclib.
9686910|NCT04872764||COVID-19 patients with acute kidney injury|COVID-19 patients with acute kidney injury
10179869|NCT03798197|Experimental|30 mg estetrol (E4) with food (fed)|Treatment B (test): One 30 mg E4 tablet administered orally 30 min after the start of an FDA prescribed high-fat breakfast preceded by at least a 10 hours overnight fast.
10179870|NCT03800069||Arm 1|A finger stick sample is collected and tested on the study device.
10179871|NCT03800082|No Intervention|Control|Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
10179872|NCT03800082|Experimental|Treatment|Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check. A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness. Participants will be directed to the PC for technical problems.
10179873|NCT03798145|Experimental|Surgical Retinotomy|Surgical retinotomy will be constructed in the area of the scotoma.
10179874|NCT03798106|Experimental|durvalumab+pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
10179875|NCT03798119|Experimental|Switch to TAF|Subjects who meet the inclusion and exclusion criteria will switch prior NUCs to TAF 25 mg/day for 96 weeks
10179876|NCT03798184|Experimental|Selective-etch with bioglass surface roughening|
10179877|NCT03798184|Active Comparator|Selective-etch without bioglass surface roughening|
9686911|NCT04872764||COVID-19 patients without acute kidney injury|COVID-19 patients without acute kidney injury
9686912|NCT04872738||Vaccinated Breast Cancer Patients|Patients who enroll in the trial and decided to get the COVID-19 vaccine will complete surveys to indicate their experiences, side effects, location of vaccination (i.e. right arm, left arm, or leg). This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
10179878|NCT03798184|Experimental|Self-etch with bioglass surface roughening|
9686913|NCT04872738||Unvaccinated Breast Cancer Patients|Patients who enroll in the trial and did not choose to receive the COVID-19 vaccine once it was available to them with complete a survey to indicate why they chose not to receive the vaccine. This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
9686914|NCT04872881|Active Comparator|ETT Group|"ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
9686915|NCT04872881|Active Comparator|LMA Group|"After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a Failed Airway and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)"
9686916|NCT04872829||multifocal IOL group|patients with unilateral and bilateral multifocal IOL
9686917|NCT04872829||monofocal IOL group|patients with unilateral and bilateral monofocal IOL
9686918|NCT04872530|Experimental|Pea-protein concentrate|Pea-protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
9686919|NCT04872530|Experimental|Fava-bean protein concentrate|Fava-bean protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
9686920|NCT04872530|Experimental|Chickpea protein concentrate|Chickpea protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
9686921|NCT04872530|Experimental|Red lentil protein concentrate|Red lentil protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
9686922|NCT04872530|Experimental|Non-essential amino acid blend|Non-essential amino acid blend dosed at 0.33 g/kg body mass in 500 ml of water.
10179879|NCT03798184|Active Comparator|Self-etch without bioglass surface roughening|
10179880|NCT03798054|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.
10179881|NCT03798054|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
9686923|NCT04872530|Experimental|Whey protein concentrate|Whey protein concentrate dosed at 0.33 g/kg body mass in 500 ml of water.
10188005|NCT03720444||MDT (mechanical diagnosis and therapy) method|
9686924|NCT04872517|Experimental|34 head and neck cancer patients, expected to proceed chemotherapy or radiotherapy in hospital.|Total 34 anticipants will recruit in this research. Age was limited between 20years old to 75 years old. All of anticipants agree to join this trail and be followed through treatment , and without underlying disease that threaten life.
9686925|NCT04872647|No Intervention|Usual Diabetic Care|Usual diabetic care for this study will include a diabetic visit with their primary care provider at the beginning and end of the 12 weeks. They will also be asked to continue their current level of physical activity and eating habits.
9686926|NCT04872647|Experimental|Usual Diabetic Care Plus Virtual Health Coaching|"For the duration of the 12 weeks, Healthy at Home will provide health coaching in 10-20 minute phone calls weekly. They will request daily blood glucose logs as this is part of Healthy at Home's normal procedure. The health coach and subject will choose a patient-directed overarching goal such as lose weight, or improve my blood sugar numbers, etc. that the health coach will then help the patient turn into a SMART goal. They will do this by utilizing a list of lifestyle change categories as top priority goals from which to choose from in their patient-directed health coaching sessions. Texting will be utilized to request daily blood glucose and provide real-time coaching via text."
9686927|NCT04872634|Experimental|SNK01 (4ⅹ10^9 cells) + GC|Administration of SNK01 4ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
9686928|NCT04872634|Experimental|SNK01 (4ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 4ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
9686929|NCT04872634|Experimental|SNK01 (6ⅹ10^9 cells) + GC|Administration of SNK01 6ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks
9686930|NCT04872634|Experimental|SNK01 (6ⅹ10^9 cells) + GC + Cetuximab|Administration of SNK01 6ⅹ10^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops
9686931|NCT04872465|Active Comparator|Experimental|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
9686932|NCT04872465|Placebo Comparator|Sham Comparator|Participants will receive sham (placebo) TBS treatment the same as experimental group
9686933|NCT04872569|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
9686934|NCT04872556|Experimental|Laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
9686935|NCT04872556|Sham Comparator|Pseudo-laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day 3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
9686936|NCT04872816|Experimental|Continuous airway positive pressure|All participants in continuous airway positive pressure arm will use CPAP (model S10-Resmed®) with expiratory relief and nasal mask.
9686937|NCT04872816|Sham Comparator|SHAM continuous airway positive pressure|Individuals in SHAM continuous airway positive pressure arm will use CPAP (model S7-Resmed®) with expiratory relief and nasal mask. The Sham-CPAP consists of a modified CPAP so that the pressure in the mask was less than 1 cm H2O. In this study, the Sham-CPAP equipment includes an increase in the expiratory orifice of the CPAP mask to eliminate airflow resistance, and a resistor with a small orifice was placed between the CPAP and the circuit. The noise produced by the ventilator and the airflow through the mask will be very similar to that of the effective CPAP. The diameter of the expiratory orifice was 10 cm H2O, and a 4 mm diameter resistor was placed between the trachea and the CPAP flow generator.
9686938|NCT04872959|No Intervention|Usual Care Arm|Will not use HealthReveal to titrate the doses of Entresto/ other treatments for HFrEF.
9686939|NCT04872959|Experimental|Interventional- Health Reveal|"The interventional arm will be provided tools to augment quality of care and build the patient and physician relationship through trust and shared goal-setting.~Prior to each patient appointment, on a customized GDMT Dashboard, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' electronic health record (EHR). The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, patient-reported outcomes/QOL will be assessed."
9686940|NCT04872504|Experimental|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen
9686941|NCT04872361|Placebo Comparator|Low PEEP|Low positive end-expiratory pressure (PEEP) and no recruitment maneuver (RM)
9686942|NCT04872361|Active Comparator|High PEEP|High positive end-expiratory pressure (PEEP)
9686943|NCT04872361|Active Comparator|High PEEP/RM|High positive end-expiratory pressure (PEEP) and recruitment maneuver (RM)
9686944|NCT04872296|Active Comparator|Early weight bearing|Participants treated for an ankle fracture will be allowed to weight bear early after surgery starting at 2 weeks post operatively
9686945|NCT04872296|Active Comparator|Postponed weight bearing|Participants treated for an ankle fracture will be treated with standard protocol of non-weight bearing for 6 weeks post operatively.
9686946|NCT04872270|Active Comparator|Caffeine Group|2 week supply of 100mg caffeine + aspirin 325mg + standard pain regimen (experimental)
9827582|NCT02461563|Experimental|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
9827583|NCT02461589|Experimental|Semaglutide 0.05 mg/day|
10179882|NCT03798054|Active Comparator|Lyxumia (lixisenatide)|Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
10179883|NCT03799965|Active Comparator|ERAS protocol are evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital~It is to compare the incidences of complications of the groups"
9686947|NCT04872270|Active Comparator|No Caffeine Group|aspirin 325mg + standard pain (control)
9686948|NCT04872413|Experimental|Screening (biospecimen collection)|Patients undergo blood, saliva or tissue sample collection for mRNA analysis and drug efficacy testing. Patients assigned treatment per the results are followed every 1 cycle of therapy for 1 year, every 2 months for 1 year, every 4 months for 1 year then every 6 months thereafter.
9686949|NCT04872218|Experimental|Abatacept|
9686950|NCT04872218|Placebo Comparator|Placebo|
9686951|NCT04872400|No Intervention|Control|Subjects randomized to the Control Arm will receive standard of care open fracture wound care (no powder) by the clinical team.
9686952|NCT04872400|Experimental|Vancomycin|Subjects randomized to the Intervention arm will receive standard of care plus 1 gram of vancomycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
9686953|NCT04872400|Experimental|Tobramycin|Subjects randomized to the Intervention arm will receive standard of care plus 1.2 grams of tobramycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
9686954|NCT04872348||Eyes receiving OMNI intervention after medication washout|
9686955|NCT04872348||Eyes receiving OMNI intervention without medication washout|
9686956|NCT04872374|Experimental|Young adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
9686957|NCT04872374|Active Comparator|Older adults|participants will perform an eccentric exercise bout after 10 days of dietary supplementation
9686958|NCT04871984||Holmium laser lithotripsy|Stone fragmentation are performed with Holmium laser in ureteroscopy
9686959|NCT04871984||Thulium laser lithotripsy|Stone fragmentation are performed with Thulium laser in ureteroscopy
9686960|NCT04872387|Experimental|BAY2586116 Dose step 1 and Placebo|"Each participant of Dose step 1 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
9686961|NCT04872387|Experimental|BAY2586116 Dose step 2 and Placebo|"Each participant of Dose step 2 will receive a single dose of BAY2586116 or placebo.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
9686962|NCT04872387|Experimental|BAY2586116 Dose step 3 and Placebo|"Each participant of Dose step 3 will receive single and multiple doses of BAY2586116 or placebo administered once daily (OD) for 5 consecutive days.~In this dose step, 12 participants will be included (9 on active treatment, 3 on placebo)."
9686963|NCT04872309||Asthma Patients|Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above).
9686964|NCT04872309||COPD Patients|Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018)
9686965|NCT04872309||ICU COVID-19|Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation)
9686966|NCT04872309||Moderate/Severe COVID-19|Adults hospitalised with COVID-19
9686967|NCT04872309||Mild- Non-hospitalised COVID-19|Adult with proven COVID-19 infection, not hospitalised for COVID-19
9686968|NCT04872309||Non-hospitalised symptomatic (long-COVID group)|Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms.
9686969|NCT04872192|Active Comparator|transversus|patients received transversus thoracic muscle plane block and injection of 15 ml bupivacaine 0.25% on each side.
9686970|NCT04872192|Sham Comparator|general anaesthesia group|the same bilateral technique was done on both sides and 15 ml saline was injected during each side of TTPB technique.
9686971|NCT04872231|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
9686972|NCT04872231|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
9686973|NCT04872114|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
9686974|NCT04872335|Experimental|Gong's Mobilization|Subjects received gong's mobilization three times in a week for 4 weeks.
9827584|NCT02461589|Active Comparator|Liraglutide 0.3 mg/day|
10179884|NCT03799965|Active Comparator|ERAS protocol are not evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital~It is to compare the incidences of complications of the groups"
10179885|NCT03798028|Experimental|UC-MSCs treatment|the participants will receive the single-dose UC-MSCs (1×10^6 cells/kg ) in combined with the present treatment.
9686975|NCT04872335|Experimental|Gradually Graded Exercise Therapy|Subjects received gradually graded exercise therapy three times in a week for 4 weeks.
9686976|NCT04872283|Active Comparator|Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive 30 mg of IV ketorolac during surgery as well as 20 mg ketorolac pills to take after surgery for pain
9695986|NCT04771936|No Intervention|Control Group|The control group who shall be awaiting surgery and not receiving a regular physiotherapy exercise intervention
9695987|NCT04771936|Active Comparator|Conventional Exercise Group|The conventional exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000).
9827585|NCT02461589|Placebo Comparator|Placebo 50 µL|
10179886|NCT03798028|No Intervention|no UC-MSCs treatment|the participants will receive the placebo in combined with the present treatment.
9686977|NCT04872283|Active Comparator|No Ketorolac administration|Participants who have surgery for great toe (1st metatarsophalangeal joint) fusion will receive the standard treatment of 30 tablets of oxycodone-acetaminophen to take as needed for pain
9686978|NCT04872244|Experimental|patients with isthmosele that mirena ( levonorgestrel releasing intrauterine device) was applied|outcome measures of patients suffering from postmenstruel spotting due to ısthmosele whom mirena ( levonorgestrel releasing intrauterine device) was applied
9686979|NCT04872166|Experimental|BTX-A51 Dose Cohort 1|Starting dose (SD) of BTX-A51 administered orally 5 times per week in a 28-day cycle
9686980|NCT04872166|Experimental|BTX-A51 Dose Cohort 2|Up to 2-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
9686981|NCT04872166|Experimental|BTX-A51 Dose Cohort 3|Up to 3.5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
9686982|NCT04872166|Experimental|BTX-A51 Dose Cohort 4|Up to 5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
9686983|NCT04872166|Experimental|BTX-A51 Dose Cohort 5|Up to 7-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
9686984|NCT04872166|Experimental|BTX-A51 Dose Cohort 6|Up to 10-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
9686985|NCT04872127|Experimental|CAS with proximal protection|using proximal embolism protection device during CAS
9686986|NCT04872127|Active Comparator|CAS with distal protection|using distal protection device during CAS
9686987|NCT04872023|Experimental|Patients|All patients will have a extra blood sampling before first cycle of treatment and after one cycle. They also have an extra bone marrow sampling after the first cycle of treatment
9686988|NCT04872062||Chronic hypercapnic respiratory failure treated by home non-invasive ventilation (NIV)|
9686989|NCT04872075|Experimental|Experimental|People at the concert
9686990|NCT04872075|Active Comparator|Control|People staying at home
9686991|NCT04872322|Active Comparator|Standard Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive an initial injection of 0.5% ropivacaine as the initial anesthetic followed by continuous injection of 0.25% ropivacaine.
9686992|NCT04872322|Active Comparator|Partial Popliteal Nerve Block|Participants undergoing foot or ankle surgery will receive 0.25% ropivacaine initially followed by the usual continuous injection of 0.25% ropivacaine during surgery
9686993|NCT04871958|Experimental|rtCGM/MDI|Real-time CGM, insulin therapy by multiple daily injections managed according to CGM
9686994|NCT04871958|Experimental|rtCGM/V-Go|Real-time CGM, insulin therapy by V-Go insulin pump managed according to CGM
9686995|NCT04871958|No Intervention|blindCGM/MDI|Blind CGM, insulin therapy by multiple daily injections managed according to standard care (capillary glucose measurements)
9686996|NCT04872153|Experimental|Intervention Group|The patients allocated to the intervention group will conduct simultaneously combined cognitive-motor training in form of exergames using the Dividat Senso in addition to the standard rehabilitation treatment plan. Both the Dividat Senso and the training games are specifically developed considering the needs and requirements of older adults but also clinicians/therapists.
9686997|NCT04872153|No Intervention|Control Group|The patients of the control group follow the standard rehabilitation treatment plan including: 3x 30min physiotherapy, 8x 30min group therapy, 3x 45min group therapy (group therapy includes body- focused therapy, mindfulness therapy, respiratory therapy, gymnastics, hiking etc.)
9686998|NCT04871828|Experimental|Treatment|"Zafirlukast plus the standard treatment according to Saudi CDC protocol (combination experimental arm)~Description of investigational drug Zafirlukast is leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet and is usually dosed twice daily. It is approved by USFDA and currently commercially marketed under the name of Accolate 20 mg oral tablet. The drug will be acquired from the pharmacy and will be received by the patient during the hospital admission via research coordinator. The study drug will be stored in at room temperature (15 - 25 c) in the hospital's pharmacy and a delegated pharmacist will be responsible for dispensing and return of any drugs.~The study drug will be administrated to the patient in the dose of 20 mg orally twice daily for 10 days (fixed dose with no staring or escalating dose)."
9686999|NCT04871828|Placebo Comparator|Control|placebo plus the standard treatment according to Saudi CDC protocol
9687000|NCT04871789||Patients with severe COVID-19 pneumonia|
9687001|NCT04871789||Patients who had an asymptomatic COVID-19 3 months ago|
9687002|NCT04871789||People who had close contact with patients with confirmed COVID-19 3 months ago but did not get sick|
9687003|NCT04871841||Sputnik V Vaccinees|Participants (healthy adults aged >=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.
9687004|NCT04871685||Covid Center UOC Vanvitelli, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687005|NCT04871685||Covid Center Cotugno Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687006|NCT04871685||"Covid Center Del Mare Hospital, Naples"|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687007|NCT04871685||Covid Center Santa Maria delle Grazie Hospital, Pozzuoli|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687008|NCT04871685||Covid Center Monaldi Hospital, Naples|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687009|NCT04871685||Covid Center Vannini Hospital, Rome|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687010|NCT04871685||Covid Center Bassini Hospital, ASST Milano Nord|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687011|NCT04871685||Covid Center Melfi Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687012|NCT04871685||Covid Center Messina University Hospital|Patients hospitalized due to Sars-Cov-2 disease either in emergency or ordinary medicine/intensive care units
9687013|NCT04871724|Experimental|EDP-938 and Fluconazole interaction|
9687014|NCT04871802|Experimental|Taxifolin Aqua group|Taxifolin Aqua 30 mg per day in addition to standard therapy
9687015|NCT04871802|No Intervention|Control group|No intervention
10179887|NCT03797989|Experimental|Phase A: Group 1|Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
10179888|NCT03797989|Experimental|Phase A: Group 2|Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
10179889|NCT03797989|Experimental|Phase A: Group 3|Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
10179890|NCT03797989|Experimental|Phase B: Group 4|The six volunteers from Groups 1, 2 and 3 in will undergo secondary challenge using the optimal inoculum, as determined in Phase A of the study. They will constitute 'Group 4' in Phase B. This will occur approximately eight months (and up to nine months) later after their primary challenge.
10179891|NCT03797989|Experimental|Phase B: Group 6|Three new malaria naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls to Group 4.
10188006|NCT03720431|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
9687016|NCT04871633|Active Comparator|Remdesivir|patients having drug Remdesivir in addition to conventional treatment according to disease grade (steroids, anticoagulants, antibiotics if needed, oxygen therapy, paracetamol, antihistamine)
9687017|NCT04871633|Other|Conventional|patients having Standard Conventional therapy only.
9687018|NCT04871880|Experimental|Dietitian led life style modification intervention.|Lifestyle changes supervised by dietitians
9687019|NCT04871880|Experimental|Conventional care (control)|Receive routine care
9687020|NCT04871906|Experimental|Stretching exercises|Interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks.
9687021|NCT04871906|No Intervention|Control group|Maintain their daily activity level in the 8 weeks. We use the study desigh-''waiting list control'' in this group.
9687022|NCT04871750|Experimental|Soy protein|30 g powder/day, contains 50 mg of isoflavones
9687023|NCT04871750|Placebo Comparator|Casein protein|30 g powder/day, no isoflavones
9687024|NCT04871464|Experimental|Probiotics|Bifidobacterium triple viable capsules（BIFICO），containing Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis(each ≥ 1.0×10^7 CFU/capsule)，Day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
9687025|NCT04871464|Placebo Comparator|Placebo|Placebo，day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
9687026|NCT04871464|No Intervention|Healthy control|Healthy subjects without constipation matched for age and sex to PD subjects
9687027|NCT04871932||Recently unvaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, human papillomavirus [HPV] vaccine, and severe acute respiratory syndrome [SARS]-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Female)．
9687028|NCT04871932||Recently unvaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently unvaccinated group (Male)．
9687029|NCT04871932||Recently vaccinated group (Female)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Female)．
9687030|NCT04871932||Recently vaccinated group (Male)|This study intends to collect peripheral blood from healthy adults aged 18 to 50 years. Gender and vaccination may be independent potential factors that affect the changes in peripheral blood immune cells. This study collects basic clinical information from volunteers, and classifies the population based on gender and whether they have been vaccinated recently (including influenza vaccine, HPV vaccine, and SARS-CoV-2 vaccines and others), aiming at systematically classify the peripheral blood mononuclear cells of healthy adults under different conditions and search for molecular markers related to different cell types. This group is Recently vaccinated group (Male)．
9687031|NCT04871646|Experimental|CKD-314|Treatment with CKD-314 + SOC
9687032|NCT04871646|Placebo Comparator|CKD-314 Placebo|Treatment with CKD-314 Placebo + SOC
9687033|NCT04871542||Observational (biospecimen collection, questionnaire)|Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients will have the option of providing blood samples at several time points during the study.
10179892|NCT03797989|Experimental|Phase C: Group 5|The six volunteers from Group 4 in Phase B will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 5 in Phase C. This will occur approximately sixteen months (and up to twenty months) later after their secondary challenge.
9687034|NCT04871477||Observational (audio recording)|Patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the Supportive Care Center.
10179893|NCT03797989|Experimental|Phase C: Group 7|The three volunteers from Group 6 who underwent primary challenge in Phase B undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will now form Group 7 in Phase C. This will occur approximately six months (and up to nine months) later after their primary challenge.
9687035|NCT04871620||Hemodynamic optimization|Patients scheduled for intermediate and high-risk abdominal surgery were eligible to participate
9687036|NCT04871334|Experimental|Dose Escalation Cohort|Six dose levels of TWP-101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.
9687037|NCT04871334|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
9687038|NCT04871581|Active Comparator|Device|Subjects receiving the FDA-cleared device
9687039|NCT04871581|Placebo Comparator|Placebo|Subjects receiving the sham device
9687040|NCT04871555||mesio-temporal epilepsy|patients suffering from mesiotemporal epilepsy type
9687041|NCT04871555||basal temporal epilepsy|patients suffering from basal temporal epilepsy type
9687042|NCT04871555||temporal lateral epilepsy|patients suffering from temporal lateral epilepsy type
9687043|NCT04871555||operculo insular epilepsy|patients suffering from operculo insular epilepsy type
9687044|NCT04871555||temporo-insular epilepsy|patients suffering from temporo- insular epilepsy type
9687045|NCT04871555||healthy subjects|non epileptic patients
9687046|NCT04871347|Experimental|Dose Escalation Cohort|Three dose levels of TWP-101 will be tested by a conventional 3 + 3 study design.
9687047|NCT04871347|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
9687048|NCT04871321||Gem/Cis/nab-P|Gemcitabine + Cisplatin + Nab-Paciltaxel
9687049|NCT04871256|Experimental|Inver|"Intervention: after screening, patient´s obstruction will be evaluated by anterior rhinomanometry (RNMa), and quality of life wil be scored through ESPRINT scale. ESPRINT is a validated Spanish questionnaire about daily life activity, sleep, psychology and perception of affection by allergic rhinitis.~Symptoms will be evaluated with visual analogue scale (VAS) and clinical history. Symptoms like sneezing, itchy nose, ocular symptoms and/or nasal obstruction. Also medication (intranasal corticosteroid, antileukotrienes, antihistamine eye drops, antihistamine) frequency use will be registered"
9687050|NCT04871490|Other|Study Group|All eligible participants.
9687051|NCT04871451|Experimental|ABP-450 - Between Low Dose and High Dose|ABP-450 Between Low Dose and High Dose - Intramuscular injections into affected neck muscles with investigator's determined dose within the range of low dose and high dose - 4 injection cycles at 3-month intervals.
9687052|NCT04871191|Active Comparator|Rituximab + cDMARD|Rituximab will be administered at 375 mg/m²/week for four consecutive weeks. Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52. The choice of the cDMARD will be left to the treating clinician and will include either methotrexate, azathioprine or mycophenolate mofetil, but the choice will be preferably methotrexate. Methotrexate will be administered orally or subcutaneously at 0.3 mg/kg/week, azathioprine orally at 2-3 mg/kg/d and mycophenolate mofetil orally at 2-3 g/d.
9687053|NCT04871191|Experimental|Tocilizumab|Tocilizumab will be administered subcutaneously every week at a fixed dose of 162 mg per week.
9687054|NCT04871191|Experimental|Abatacept|Abatacept will be administered subcutaneously every week at a fixed dose of 125 mg per week.
9687055|NCT04871386|Experimental|Acceptance and commitment therapy (ACT)|"14 consecutive days of exercises (prompted via email every morning) derived from acceptance and commitment therapy (ACT); the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
9687056|NCT04871386|Experimental|Positive psychology intervention (PP)|"14 consecutive days of exercises (prompted via email every morning) derived from positive psychology (PP) interventions; the instructions were text-based, contained a brief introduction to the general goal and the exercise of the day; the exercises were designed to be completable individually in 20 minutes. Additionally: completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?)"
9687057|NCT04871386|No Intervention|Control group|"completion of a daily review questionnaire (online diary) including two open questions (Relevant events during the day? Helpful things for coping positively with the current situation?); no additional intervention"
10179894|NCT03797989|Experimental|Phase C: Group 9|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 5 and 7.
10188007|NCT03720418|Experimental|OXB-102 Dose Level 1|OXB-102 Dose Level 1 Single Administration (Part A: open-label)
9976207|NCT01349218|Experimental|Blood sample drawn from a vein and from a heel stick|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis. A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
9976208|NCT01349270|Experimental|immunoglobulin|patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months
9695988|NCT04771936|Experimental|Conventional Exercise Group with added core exercises|This exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000) and core exercises aimed at the activation of the core muscles as adapted from Imai et al (2010).
9827586|NCT02461589|Experimental|Semaglutide 0.05/0.1 mg/day|
10179895|NCT03797989|Experimental|Phase D: Group 8|The three volunteers from Group 7 in Phase C will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 8 in Phase D. This will occur approximately five months (and up to ten months) after their secondary challenge.
10179896|NCT03797989|Experimental|Phase D: Group 10|The four to eight volunteers from Group 9 in Phase C will undergo secondary challenge, using the optimal inoculum as determined in Phase A, and form Group 10 in Phase D. This will occur approximately six months (and up to nine months) later after their primary challenge.
10179897|NCT03797989|Experimental|Phase D: Group 12|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 8 and 10.
10179898|NCT03797989|Experimental|Phase E: Group 11|The four to eight volunteers from Group 10 in Phase D will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 11 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
10179899|NCT03797989|Experimental|Phase E: Group 13|The four to eight volunteers from Group 12 in Phase D will undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 13 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
10179900|NCT03797989|Experimental|Phase E: Group 15|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 11 and 13.
9687061|NCT04870983||SAE group|SAE was defined as cerebral dysfunction in the presence of sepsis or septic shock and the absence of any of the exclusion criteria. For patients undergoing sedation during the ICU stay, the GCS scores were evaluated before sedation; for patients who have been sedated prior to ICU admission, the assumed GCS scores, i.e., the scores measured before any administration of sedative/relaxant drug were used for analysing; for postoperative patients, the GCS scores measured before surgery was used. The CAM-ICU was assessed daily by the nurse or the physician in charge of the patient during the ICU stay. For patients who were sedated, spontaneous awakening trials were performed daily; the longest evaluate time after withdrawal of sedation was 24 h during the trials. In this evaluation period, patients should be awake to evaluate their consciousness, and they were diagnosed of SAE if the patients were not awake.
9687062|NCT04870983||non-SAE group|The patient was diagnosed with sepsis or septic shock but could not be diagnosed with SAE
9687063|NCT04871139|Experimental|Diagnostic (iodine-based contrast, CEM)|Patients receive iodine-based contrast agent IV and the undergo CEM over 10-15 minutes.
10179901|NCT03797989|Experimental|Phase F: Group 14|The four to eight volunteers from Group 13 in Phase E will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 14 in Phase F. This will occur approximately five months (and up to ten months) after their secondary challenge.
10188008|NCT03720418|Experimental|OXB-102 Dose Level 2|OXB-102 Dose Level 2 Single Administration (Part A: open-label)
9687064|NCT04870996|Experimental|Active transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent active tDCS and CT on five consecutive days. The participants received a ramp-up of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then a ramp-down of 30 seconds.
9687065|NCT04870996|Sham Comparator|Sham transcranial Direct Current Stimulation (tDCS) + Cognitive training (CT)|Twenty-three participants received five treatment sessions of concurrent sham tDCS and CT on five consecutive days. The current was only delivered in the 30-second ramp-up and 30-second ramp-down periods.
9687066|NCT04871178|No Intervention|Control Group|Care as usual: (i.e. best medical treatment)
9687067|NCT04871178|Experimental|Mindfulness-Based Intervention|Care as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based educational and training program.
9687068|NCT04871399|Active Comparator|Conventional Right hemicolectomy (Non-CME)|Patients will undergo conventional non-CME procedure.
9687069|NCT04871399|Experimental|Right hemicolectomy with CME+CVL|Patients will undergo Right hemicolectomy CME+CVL procedure.
9687070|NCT04871308|Placebo Comparator|Control|Placebo group using normal saline infusion
9687071|NCT04871308|Active Comparator|Dexmedetomidine|From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins.
9687072|NCT04871204|No Intervention|Control|Standard treatment
9687073|NCT04871204|Experimental|Octreotide|3 monthly intramuscular injections of 10 mg Octreotide
9687074|NCT04871126||LVT group|left ventricular thrombus in acute anterior myocardial infarction patients with left ventricular dysfunction
9976209|NCT01349270|Active Comparator|prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
9687075|NCT04871126||non-LVTgroup|acute anterior myocardial infarction patients with left ventricular dysfunction while without LVT
9687076|NCT04871269|Experimental|Drug: Dronabinol before the trauma film paradigm|
9687077|NCT04871269|Experimental|Drug: Dronabinol after the trauma film paradigm|
9687078|NCT04871269|Placebo Comparator|Placebo before and after the trauma film paradigm|
9687079|NCT04871035||Immunoadsorption|
9687080|NCT04871035||Plasma Exchange|
9687081|NCT04870905|Experimental|ICRT arm|
9687082|NCT04871230||Pregnant women suspected TB|This group enrolled as cases
9687083|NCT04871230||Pregnant women without signs suspected TB|This group enrolled as controls
9687084|NCT04870892||Norepinephrine variation|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to modify the norepinephrine dose.
9827587|NCT02461589|Active Comparator|Liraglutide 0.3/0.6 mg/day|
9976210|NCT01349283|Experimental|HepavaxGene Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
9976211|NCT01349283|Active Comparator|Comparator vaccine Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
9976212|NCT01349283|Experimental|HepavaxGene Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
9687085|NCT04870892||Fluid infusion|Patients with septic shock, cardiac output monitoring device with the PICCO2 system and decision by the physician in charge to give fluid infusion
10179902|NCT03797989|Experimental|Phase F: Group 16|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Group 14.
9687086|NCT04870931||TEM-Group|All patients that underwent TEM
9687087|NCT04870931||TEM-ESD-Group|All patients that underwent TEM-ESD
9687088|NCT04870957|Experimental|MBSR (mindfulness-based stress reduction)|Run-in treatment then MBSR.
9687089|NCT04870957|Experimental|PT and exercise|Run-in treatment then PT and exercise
9687090|NCT04870957|Experimental|Acupressure|Run-in treatment then Acupressure
9687091|NCT04870957|Experimental|Duloxetine|Run-in treatment then Duloxetine
9687092|NCT04870957|Experimental|MBSR then PT and exercise|Run-in treatment then 8 weeks of MBSR, and then 8 weeks of PT and exercise.
9687093|NCT04870957|Experimental|MBSR then Acupressure|Run-in treatment, then 8 weeks of MBSR, and then 8 weeks Acupressure.
9687094|NCT04870957|Experimental|MBSR then Duloxetine|Run-in treatment, then 8 weeks of MBSR, and then approximately 8 weeks of Duloxetine
9687095|NCT04870957|Experimental|PT and exercise then MBSR|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of MBSR.
9687096|NCT04870957|Experimental|PT and exercise then Acupressure|Run-in treatment, then 8 weeks of PT and exercise, and then 8 weeks of Acupressure
9687097|NCT04870957|Experimental|PT and exercise then Duloxetine|Run-in treatment, then 8 weeks of PT and exercise, and then approximately 8 weeks of Duloxetine
9687098|NCT04870957|Experimental|Acupressure then MBSR|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of MBSR
9687099|NCT04870957|Experimental|Acupressure then PT and exercise|Run-in treatment, then 8 weeks of Acupressure, and then 8 weeks of PT and exercise.
9687100|NCT04870957|Experimental|Acupressure then Duloxetine|Run-in treatment, then 8 weeks of Acupressure, and then approximately 8 weeks of Duloxetine
9687101|NCT04870957|Experimental|Duloxetine then MBSR|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of MBSR.
9687102|NCT04870957|Experimental|Duloxetine then PT and exercise|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks of PT and exercise
9687103|NCT04870957|Experimental|Duloxetine then Acupressure|Run-in treatment, then approximately 8 weeks of Duloxetine, and then 8 weeks Acupressure.
10179903|NCT03799822|Active Comparator|Control|Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
9687104|NCT04870957|Experimental|PainGuide|Run-in treatment only with no additional treatments.
9687105|NCT04871152||Patients with chronic migraine|In the same group of patients, the response to triptans will be analyzed at 3 different times with respect to the start of treatment with onabotulinumtoxinA: before treatment, after 4 months and after 7 months of treatment.
9687106|NCT04871022|Active Comparator|Double layer unlocked uterine closer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
9687107|NCT04871022|Experimental|Purse uterine closer|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
9687108|NCT04871373|Experimental|Experimental group|A trained periodontist delivered oral hygiene instructions and motivational interviewing sessions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
9687109|NCT04871373|Active Comparator|Control group|A trained periodontist delivered only oral hygiene instructions. All the participants received a G.U.M. kit with special orthodontic hygiene tools.
9687110|NCT04870723|Experimental|Immediate|Behavioral: Motivational interviewing (MI)-based peer counseling: MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness.
9687111|NCT04870723|Other|Waitlist|"Behavioral: Motivational interviewing (MI)-based peer counseling: After the immediate group completes the intervention, the waitlist group will receive the intervention.~MI-based peer counseling will comprise of 3 weekly 1-hour sessions administered online addressing 1) Covid-19 knowledge; 2) Assessing risk for infection and understanding and practicing public health-recommended protective behaviors (masking, physical distancing, handwashing); and 3) Understanding psychosocial issues and maintaining mental wellness."
9687112|NCT04870632|Sham Comparator|Control group|Patients in control group received the education booklet with words and pictures.
9687113|NCT04870632|Experimental|Video group|Patients in intervention group watched YOUTUBE videos to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
9687114|NCT04870632|Experimental|Booklet group|Patients in intervention group read education booklet with words and pictures to rehab and recorded the intensity after the exercise by RPE scores. During the intervention, a physical therapist would have weekly telephone calls or LINE calls for 6 times to monitor and modify the intensity of exercise.
9687115|NCT04870840|Experimental|Treatment (proton therapy)|Patients undergo radiation therapy QD 5 days a week (Monday through Friday) for the first 18 days and then BID for 15 days in the absence of disease progression or unacceptable toxicity.
9687116|NCT04870801|No Intervention|Low Oxygen Visits without Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
10179904|NCT03799822|Experimental|rivaroxaban|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
9687117|NCT04870801|Experimental|Low Oxygen Visits with Respirogen Micro-Oxygen|During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures.
9827588|NCT02461589|Placebo Comparator|Placebo 50/100 µL|
9827589|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2 mg/day|
10179905|NCT03799822|Experimental|rivaroxaban + K2|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements
10179906|NCT03799887|Active Comparator|0% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
10179907|NCT03799887|Experimental|10% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
10179908|NCT03799887|Experimental|20% unweighed BWSTT|20% unweighed Body Weight Supported Treadmill Training
10179909|NCT03799900|Experimental|Part 1, Cohort 1: Ketamine Low Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
10179910|NCT03799900|Placebo Comparator|Part 1, Cohort 1: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
10179911|NCT03799900|Experimental|Part 1, Cohort 2: Ketamine Medium Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
9687118|NCT04870853||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
9687119|NCT04870749||lower urinart tract syptoms|Lower urinary tract symptoms (LUTS) are common in older men and one of the main reasons for this is the enlargement in prostate gland volume caused by hormonal changes.
9687120|NCT04870697|Experimental|ACT group|In addition to usual care, participants in the ACT group will receive ACT intervention. ACT intervention will be conducted in an individual-based format with four weekly sessions. The first session is a face-to-face format and the other three sessions are online live format.
9687121|NCT04870697|Other|Control group|Participants in the control group will receive usual care in the study setting delivered by clinical staff. The rationale for adopting usual care as a control group is not only because it is more commonly used but also for practical and ethical considerations, as usual care is what is already being delivered clinically, therefore the results of the study can support any necessity of changes to clinical practice or not.
9687122|NCT04870879|Experimental|Study arm|Liver transplant
9687123|NCT04870879|Other|Parallel arm|Chemotherapy
9687124|NCT04870372|Experimental|Selegiline|Subjects who meet all of the inclusion and none of the exclusion criteria will be received Selegiline.The study medication dosage will be escalated from 5mg/daily to the target dose(5~10mg/daily) in 2 weeks and then maintained for the remaining 6 weeks.
9687125|NCT04870450||Healthcare professionals|No intervention. Gathering data on their experiences of using video diaries.
9687126|NCT04870450||Family members of ICU patients|No intervention. Gathering data on their experiences of using video diaries.
9687127|NCT04870411||Patients with auto-immune or autoinflammatory diseases|Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants and/or biologics
9687128|NCT04870411||Patients without auto-immune or autoinflammatory diseases|Patients without auto-immune or autoinflammatory diseases and not treated with immunosuppressants and/or biologics
9687129|NCT04870736||Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
9687130|NCT04870736||Resusci Anne QCPR AED (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
9687131|NCT04870736||Resusci Baby QCPR (Laerdal)|medical students trained as BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
9687132|NCT04870710|Experimental|cathodal transcranial direct current stimulation (tDCS)|Two, twenty minute sessions of cathodal tDCS to the bilateral extrastriate visual cortex for 5 days (10 total sessions).
9687133|NCT04870710|Experimental|Anodal transcranial alternating current stimulation (tACS)|Two, twenty minute sessions of anodal tACS delta phase aligned for 5 days (10 total sessions).
9687134|NCT04870398|Active Comparator|MTA partial pulpotomy|Profound local anesthesia of the tooth and the surrounding tissues will be achieved The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of MTA. After the placement of MTA, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
9695989|NCT04771806||Observational (MRI)|Patients undergo MRI with and without contrast immediately before radiotherapy (for radiation planning) and at mid treatment (week 3). Patients also undergo MRI without contrast on weeks 1, 2, 4, 5, and 6 of radiotherapy. Patients may also undergo neurocognitive function testing over 70 minutes before treatment, at the end of each week of treatment, and at 3 and 6 months after completion of treatment.
9827590|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2 mg/day|
9827591|NCT02461589|Placebo Comparator|Placebo 50/100/200 µL|
9976213|NCT01349283|Active Comparator|Comparator vaccine Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
9976214|NCT01349283|Experimental|HepavaxGene Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
10179912|NCT03799900|Placebo Comparator|Part 1, Cohort 2: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
10179913|NCT03799900|Experimental|Part 1, Cohort 3 (Optional): Ketamine High Dose|Optional: some participants will be administered a single IV dose of ketamine on Day 1.
9976215|NCT01349283|Active Comparator|Comparator vaccine Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
9976216|NCT01349296|Experimental|BIBF 1120 + RAD001|
9977729|NCT01364701|Active Comparator|Maximal dose sildenafil|4 tablets of sildenafil 100mg are given for on demand use
10179914|NCT03799900|Placebo Comparator|Part 1, Cohort 3 (Optional): Placebo|Optional: some participants will be administered a single IV dose of placebo on Day 1.
9687135|NCT04870398|Active Comparator|Total Fill partial pulpotomy|The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of Total Fill BC. After the placement of the material, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
9687136|NCT04870671|Experimental|High Adherence|TDF/FTC (300/200 mg), 7 pills/week. Total of 14 pills
9687137|NCT04870671|Experimental|Low Adherence|TDF/FTC (300/2200 mg), 3 pills/week. Total of 6 pills
9687138|NCT04870866|Experimental|NR treated|Nicotinamide ribonuceloside (NR), sold under the trade name Niagen™
9687139|NCT04870489|Active Comparator|Isotretinoin + Co2 ablative laser|Isotretinoin treatment while being treated with CO2 laser
9687140|NCT04870489|Active Comparator|Co2 ablative laser|6 months to 1 year without isotretinoin treatments to start second side of face with CO2 ablative laser only
9687141|NCT04870541|Active Comparator|Patients receiving Ondansetron|
9687142|NCT04870541|Active Comparator|Patients receiving Nefopam|
9687143|NCT04870385|Experimental|Treatment|5-week online prevention program
9687144|NCT04870385|Other|Control|Waitlist control
9687145|NCT04870814|Active Comparator|SOFTT® Gen 4 tactical tourniquet|The SOFTT® Gen 4 (Tactical Medical Solutions, Anderson) tactical tourniquet will be assessed.
9687146|NCT04870814|Active Comparator|CAT® Gen 7 tactical tourniquet|The CAT® Gen 7 (C-A-T® Resources, Rock Hill) tactical tourniquet will be assessed.
9687147|NCT04870814|Active Comparator|SAM XT® tactical tourniquet|The SAM XT® (SAM Medical Products®, Wilsonville) tactical tourniquet will be assessed.
9687148|NCT04870814|Active Comparator|RMT® 1.5 tactical tourniquet|The RMT® 1.5 (m2®, Winooski) tactical tourniquet will be assessed.
9687149|NCT04870684||sucess of revascularization|group of patients for whom after thrombolysis neurological improvement will be observed and recanalization on imaging will be seen.
9687150|NCT04870502|Active Comparator|Clomiphene citrate and Ubiquinol|Controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals).
9687151|NCT04870502|Active Comparator|Human Menopausal Gonadotropins (hMG)|Controlled ovarian stimulation (COS) was done by Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response.
10179915|NCT03799900|Experimental|Part 2, Qualification Phase: Ketamine|Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.
10179916|NCT03799900|Placebo Comparator|Part 2, Qualification Phase: Placebo|Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.
10179917|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
10179918|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Medium Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
10179919|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
10179920|NCT03799900|Active Comparator|Part 2, Treatment Phase: Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
10179921|NCT03799900|Placebo Comparator|Part 2, Treatment Phase: Placebo|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
10179922|NCT03799926|Experimental|Stratum 1: 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
10179923|NCT03799926|Experimental|Stratum 1: 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
10179924|NCT03799926|Experimental|Stratum 1: placebo of 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
10179925|NCT03799926|Experimental|Stratum 1: placebo of 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
9687152|NCT04870567|Active Comparator|High dose rate brachytherapy|After spinal anesthesia steel or plastic needle placement performed under TRUS guidance. Pre- and post-insertion ultrasound based planning is obligatory in all cases. Two fractions of 13Gy are delivered with 2 separate implantations and 2-3 weeks interval. The CTV was defined as the prostate capsule with 1mm (low-risk) - 3 mm (intermediate risk) expansion plus proximal 1/3 of seminal vesicles. The PTV was equal to CTV. The rectum, bladder and urethra are contoured as organs at risk. The dosimetry plan objectives are the following: prostate D90 - above 104% and V100% - above 92%; urethra D10 < 110% , rectum D2cc<75% (below 75Gy EQD2).
9687153|NCT04870567|Experimental|Stereotactic ablative radiotherapy|"Before SBRT three fiducial markers are obligatory inserted into the prostate.Planning MRI on diagnostic table with subsequent fusing with simulation CT is obligatory. CTV to planning target volume (PTV) expansion was 3-5 mm in all direction except posteriorly (in the direction of the rectum) where it is 1-3 mm. Dose must be delivered as 5 fraction of 7.25Gy. V100% for PTV ≥ 95%. Main dose constraints are as follows: D 2cm³ ≤ 36Gy for rectum (below 75Gy EQD2)., V 37.5 Gy <5 cm³ for bladder, V 20 Gy <10 cm³ for femoral heads. Androgen deprivation therapy is not permitted.~All treatments must be performed on conventional linear accelerators with cone beam CT guidance before each fraction, intrafractional motion monitoring is optional."
9687154|NCT04870437|Experimental|Extracorporeal phototherapy|
9827592|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
10179926|NCT03799926|Experimental|Stratum 2: 8.4 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
9687155|NCT04870359|Active Comparator|Pre-emptive Treatment (Prednisolone and/or AZA/MMF)|"Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~Adjustment of the 2nd agent would be as follows:~For patients who receive AZA <75mg/day; increase the dose of AZA to 75 mg/day.~For patients who receive MMF <1g/day, increase the dose of MMF to 1g/day."
9687156|NCT04870359|No Intervention|Control|Current immunosuppressive regimen and dosage should remain unchanged until the development of renal or extra-renal flares which required increase/change in immunosuppression.
9687157|NCT04870463|Active Comparator|Gold Standard Group|Patients treated with multi-braces fixed appliances and a conventional sequence of aligning and levelling arches (Ni-Ti arches with the same force in all sections)
9687158|NCT04870463|Experimental|Intervention Group|Patients treated with multi-braces fixed appliances and a different sequence of aligning and levelling arches (some arches provide individual forces for each group of teeth (incisors, premolars and molars))
9687159|NCT04870554|No Intervention|Continuous Feeding|Enteric feeding will be given continuously.
9687160|NCT04870554|Experimental|Timed Feeding|Enteric feeding will be given four times per day, approximating breakfast, lunch, a snack, and dinner.
9687161|NCT04870918|Experimental|self-care intervention|First, health education will be carried out by the nurse. The consultations will be individual, weekly (Wednesdays), the others, therefore, will be biweekly, extending to the 30/30 days the following, individually in order to observe the difficulties and doubts of each patient. Counting the meetings in a total of 12 in the first 6 months.
9687162|NCT04870918|No Intervention|usual care|The control group will go through medical consultations as instructed by the doctor and will not receive intervention for health education by the nurse.
9687163|NCT04870476|Experimental|"Internet-delivered treatment: One step at the time"|"Internet-delivered treatment: One step at the time. All participants receive the internet-delivered therapist-assisted 11-modules treatment program One step at the time."
9687164|NCT04870268||PD group|percutaneous drainage group
9687165|NCT04870268||END group|endoscopic approach group
9687166|NCT04870268||INT group|surgical internal derivation of WON group
9687167|NCT04870268||NE group|surgical necrosectomy group
9687168|NCT04870645|Experimental|Diagnostic (advanced MRI)|Patients undergo conventional and advanced MRI over 60 minutes within 14 days before the start of scheduled brain radiation treatment. Patients then undergo 7 additional MRI over 60 minutes each between 4-16 weeks apart.
9687169|NCT04870203|Experimental|baricitinib + adalimumab|
9687170|NCT04870203|Placebo Comparator|baricitinib + placebo|
9687171|NCT04870177|Experimental|Advanced gynecological neoplasms|
9687172|NCT04869956|Other|control|patients will receive standard nutritional recommendations
9687173|NCT04869956|Experimental|intervencion|high-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
9687174|NCT04870008|Active Comparator|2 mm|The side of patient's scar that will receive the sutures placed at 2 mm from wound edge.
9687175|NCT04870008|Active Comparator|5 mm|The side of patient's scar that will receive the sutures placed at 5 mm from wound edge.
9687176|NCT04870242||pediatric surgery patients|all pediatric surgery patients, aged from 6 months up to 18 years, underwent surgery between January 2017 to December 2018
10179927|NCT03799926|Experimental|Stratum 2: 16.8 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
9687177|NCT04870307|Other|Primary Care Practices|A practice-based implementation study will be conducted with 50 practices, with baseline data collection, and overlapping with interim measurements of care quality and process outcomes, followed by a final data collection at the end of the intervention (including baseline measures plus semi-structured interviews. The practice based approach to increasing testing will be compared to a community-based approach using mobile-setting to increase testing. Additional, non-clinical trial components of this study include patient surveys to understand facilitators and barriers to SARS-CoV-2 testing and identification of legal/ethical, socioeconomic, and behavioral implications of increased testing. Patients are not direct subjects in this part of the study. Intervention will target practices and practice members.
9687178|NCT04870229|Active Comparator|Carnosine|Each participant will be given a daily oral dose 1g of methycellulose powder for 6 months
9687179|NCT04870229|Placebo Comparator|Placebo|Each participant will be given a daily oral dose 1g of placebo for 6 months
9687180|NCT04870190|Experimental|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
9687181|NCT04870190|Active Comparator|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
9687182|NCT04869969|Experimental|supine percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the supine position
9687183|NCT04869969|Active Comparator|prone percutaneous nephrolithotomy|percutaneous nephrolithotomy to be done in the prone position
9695990|NCT04771650|Experimental|CAMI/CAMI booster|Culturally Adapted Motivational Interview. Participants will receive a single session, 75 minute addiction counseling discussion that focuses on the causes of addictive behavior. They will receive a CAMI booster session at 2 months and standard care in a primary care setting.
9695991|NCT04771650|No Intervention|Control|Assessment plus standard care. Participants will complete an assessment, including measures on drinking and drug use. They will also receive standard care in a primary care setting.
10179928|NCT03799926|Experimental|Stratum 3: 8.4 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
10179929|NCT03799926|Experimental|Stratum 3: 16.8 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
10179930|NCT03799939|Active Comparator|Intervention group|Polyvinylidene fluoride mesh used in this trial (Dynamesh IPST) is synthetic mesh with central tube to accommodate bowel tightly and designed to prevent and treat parastomal hernia.
10179931|NCT03799939|No Intervention|Control group|Participants in control group are operated with no preventive mesh.
10179932|NCT03797976|Experimental|Parkinson's Disease Group|MIP and MEP Respiratory Function Test Strength Test
9976217|NCT01349309|Experimental|Swallowing Exercise Group|Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.
10179933|NCT03798002|Experimental|Neuro-muscular exercise training Group|Neuro-muscular exercise training will be administer to Knee OA patients.
10179934|NCT03798002|Active Comparator|quadriceps training program|quadriceps stretching and strengthening exercises will be administer to Knee OA patients.
10179935|NCT03799757|Active Comparator|Bupivacaine|The wound was installed by 40ml of 0.25% bupivacaine through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes.
10179936|NCT03799757|Placebo Comparator|Placebo|The wound was installed by 40ml of 0.9% normal saline through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes. (placebo group)
10179937|NCT03799913|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
10179938|NCT03799666|Experimental|Pulmonary Rehabilitation Group|Patients will participate in a 12-week community-based pulmonary rehabilitation programme.
10179939|NCT03799666|Active Comparator|Standard Care Group|Patients will continue to receive the standard care, which means the daily medication prescribed by the pshysician from the primary care centre team.
10179940|NCT03797833|No Intervention|Standard treatment|ECV according to standard practice.
10179941|NCT03797833|Active Comparator|Spinal anaesthesia|ECV after low dose spinal anaesthesia (Bupivacain 2,5 mg plus Sufentanil 5 micrograms (µg)
10179942|NCT03797846|Active Comparator|Corneal Suture|intraoperative fixation with the suture in clear cornea qualified to the combined glaucoma surgery
9687184|NCT04870021|Experimental|Intervention Arm|"After birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy."
9687185|NCT04870021|Other|Control Arm|"In this arm of the study, after birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations were administered as per the expanded program on immunization schedule in Pakistan."
9687186|NCT04869904||Patients with Alzheimer's disease|
9687187|NCT04869904||patients without Alzheimer's disease|
9687188|NCT04870060|No Intervention|Control|Patients in this arm received only standard supportive care
9687189|NCT04870060|Experimental|Curcumin|Patients in this arm received curcumin lozenges (4 lozenges BD) along with standard supportive care
9687190|NCT04870151|Experimental|Anterolateral approach|"The minimally invasive anterolateral approach (Watson-Jones approach) is performed with the patient in supine position. An oblique incision is made from just dorsal to the anterior superior iliac spine, and extended distally to the greater trochanter. After the fascia is incised, deep dissection continues in the plane between the tensor fasciae latae and the gluteus medius muscles. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the fascia, subcutis and skin is closed in separate layers with sutures."
9687191|NCT04870151|Active Comparator|Direct lateral approach|"The direct lateral approach (Hardinge approach) is performed with the patient in a lateral decubitus position. A straight or curved longitudinal incision is made over the greater trochanter, and the fascia is incised longitudinally. The anterior aspect of the gluteus medius and minimus muscles are separated from the greater trochanter. The joint capsule is exposed and opened. The femoral head and neck are resected and the femoral canal is reamed according to the preoperative plan.~A femoral stem (Link Lubinus SPII) is fixed using bone cement (Heraeus Medical Palacos R+G pro) and connected to a bipolar femoral head (Zimmer Multipolar).~After implantation of the prosthesis, the gluteus medius and minimus muscles are reinserted using osteosutures. The fascia, subcutis and skin is closed in separate layers with sutures."
9695992|NCT04771910|Experimental|Topical cream with live probiotic bacteria (YUN)|Patients with atopic dermatitis using topical cream with live probiotic bacteria
10179943|NCT03797846|Active Comparator|Muscle Suture|intraoperative fixation with the bridle suture for superior rectus muscle qualified to the combined glaucoma surgery
10179944|NCT03797898|Experimental|Intervention|Parents will meet with a Parent Coach during child's routine well visits, and have access to the parent coach between visits for additional follow up and concerns, and have access to a preventive care text messaging services (Healthy Txt).
10179945|NCT03797898|No Intervention|Control|usual care well child care
10179946|NCT03799601|Experimental|combination of docetaxel, carboplatin and anlotinib|
10179947|NCT03797755||Palliative Cancer Patients|Stage IV cancer patients evaluated for palliative radiotherapy.
10179948|NCT03797885||Patients with type 2 diabetes mellitus (T2DM)|Patients with type 2 diabetes, at the hospital setting.
9687192|NCT04870073|Experimental|Retrograde autologous priming + mannitol|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
9687193|NCT04870073|Experimental|Retrograde autologous priming alone|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
9687194|NCT04870073|Experimental|Conventional priming + mannitol|Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
9687195|NCT04870073|Active Comparator|Conventional priming alone|Participants will receive conventional priming alone.
10179949|NCT03797885||Patients with T2DM and established cardiovascular disease|Subgroup of patients with type 2 diabetes and established cardiovascular disease
10179950|NCT03797768|Experimental|Intervention|
10179951|NCT03797768|No Intervention|Control|
9687196|NCT04870294|Active Comparator|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material, considered a control group.
9687197|NCT04870294|Experimental|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
9687198|NCT04869748|Experimental|experimental group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Perfetti method on affected elbow flexor.Immediate after session, last outcome assessment was collected.
9687199|NCT04869748|Active Comparator|control group|After recruitment, signed inform consent and allocation, researcher collected demographic data of each participant. First outcome assessment was done before session. Participants received a 15-minute session of Passive stretching on affected elbow flexor.Immediate after session, last outcome assessment was collected.
9687200|NCT04869774|Active Comparator|Virtual Monitoring|Patients discharged from hospital after colorectal surgery will have virtual monitoring of their surgical incision and symptoms, using the mobile application How2Trak, post-operatively.
9687201|NCT04869774|No Intervention|Standard of Care|Patients discharged from hospital after colorectal surgery will receive standard of care with no virtual monitoring of their surgical incision and symptoms.
9687202|NCT04869800|Experimental|Sequence 1|"Period 1: Reference drug(CKD-501, D745)~Period 2: Test drug(CKD-398)"
9687203|NCT04869800|Experimental|Sequence 2|"Period 1: Test drug(CKD-398)~Period 2: Reference drug(CKD-501, D745)"
9687204|NCT04869852|Experimental|Mango|85g mango, 4x/week
9687205|NCT04869852|No Intervention|No Mango|No mango intake
9687206|NCT04869865|Experimental|Intervention|Detoxification cleanse
9687207|NCT04869826||Outpatients Complicated Hypertension Clinic|This study population consists of approximately 200 adult male and female patient participants (≥ 19 years of age; minimum 30% male/female) who are referred to the Complicated Hypertension Clinic at the Saint John Regional Hospital (SJRH) and who are willing to volunteer to consent to participate in the study.
9687208|NCT04869436|Experimental|Dupilumab group|Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.
9687209|NCT04869423|No Intervention|Control group|Participants in this group will simply continue with their daily living and therapies. Assessments will be conducted before and after the 7wk program but patients in this group will not take part in it
9687210|NCT04869423|Experimental|Experimental group|Participants in this group will take part in 7 dog-assisted therapy sessions (1 per week). This therapy will be added to their usual daily living and therapies. Assessments will be conducted before and after the 7-week program.
9687211|NCT04869592|Experimental|Phase 1 low-dose group|
9687212|NCT04869592|Experimental|Phase 1 high-dose group|
9687213|NCT04869592|Placebo Comparator|Phase 1 placebo group|
9976218|NCT01349309|No Intervention|Control|Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.
10179952|NCT03797950|No Intervention|Control|No active intervention
10179953|NCT03797950|Experimental|Voice Reminder (Group A)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Enrolled women will receive reminders via mobile phone to highlight the importance of early vaccinations for newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Information on where and when these vaccines will be available in the woman's community will be provided."
10187469|NCT03725995|Experimental|B (Lidocaine-Midazolam)|21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
9687214|NCT04869592|Experimental|Phase 2 low-dose group A|
9687215|NCT04869592|Experimental|Phase 2 low-dose group B|
9687216|NCT04869592|Experimental|Phase 2 low-dose group C|
9687217|NCT04869592|Experimental|Phase 2 low-dose group D|
9687218|NCT04869592|Experimental|Phase 2 high-dose group A|
9687219|NCT04869592|Experimental|Phase 2 high-dose group B|
9687220|NCT04869592|Experimental|Phase 2 high-dose group C|
9687221|NCT04869592|Experimental|Phase 2 high-dose group D|
9687222|NCT04869592|Placebo Comparator|Phase 2 placebo group A|
9976219|NCT01349335|Experimental|1. tolvaptan|15 mg, P.O., Qd, for 7 days,
9687223|NCT04869592|Placebo Comparator|Phase 2 placebo group B|
10187470|NCT03725995|Placebo Comparator|C (Placebo)|21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.
9687224|NCT04869592|Placebo Comparator|Phase 2 placebo group C|
9687225|NCT04869592|Placebo Comparator|Phase 2 placebo group D|
9687226|NCT04869566||Athletes with traumatic knee injury|Youth athletes, aged 16-19, with traumatic knee injury
9687227|NCT04869475|Experimental|Experimental|arsenic trioxide 7mg/m2 ivgtt d1-14, q3w
9687228|NCT04869683|Other|MDS follow up|it is a description MDS patients study
9687229|NCT04869735||With information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is given
9687230|NCT04869735||Without information about booster vaccination|Adults aged 25 years in 2020 without delivery of DTPolio vaccine in 2019 or 2020, to whom information concerning this vaccination is not given.
9687231|NCT04869722|Experimental|Liquid Model|Whey protein beverages varying in protein levels
9687232|NCT04869722|Experimental|Solid Model|Protein fortified scones varying in fat levels
9687233|NCT04869384|Experimental|Intervention|Subjects will receive reminders and feedback to improve their adherence via a sensor attached to Easyhaler inhaler and mobile application
9687234|NCT04869384|Active Comparator|Usual care|Subjects do not receive reminders and feedback, but receive treatment as usual.
9687235|NCT04869332|Active Comparator|three-screw group|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck
9687236|NCT04869332|Experimental|four-screw group|the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
9687237|NCT04869579|Experimental|Selenious Acid + Standard Of Care (SOC)|Participants who are moderately-ill, severely-ill, or critically ill will receive a Selenious Acid infusion of 2000µg on day 1 as a loading dose infusion, followed by a continuous infusion of Selenious Acid at a maintenance dose of 1000µg daily on days 2-14 together with continued Standard Of Care therapy.
10187471|NCT03725969|Experimental|Healthy individuals (camel milk)|
9687238|NCT04869579|Active Comparator|Standard Of Care (SOC) + Placebo|Participants will receive a Saline-based placebo infusion of 2000µg on day 1 as a loading dose, followed by continuous infusion of a Saline-based placebo at a maintenance dose of 1000µg daily on days 2-14. Standard Of Care is to be determined according to patients' clinical picture and may include Dexamethasone, Azithromycin, Ceftriaxone, Remdesivir, Convalescent Plasma.
9687239|NCT04869709|Active Comparator|Late Preterm Steroids 2 Days|
9687240|NCT04869709|Active Comparator|Late Preterm Steroids 7 Days|
9687241|NCT04869631||Aortic valve stenosis undergoing aortic valve replacement|Aortic valve stenosis undergoing aortic valve replacement.
9687242|NCT04869657|Active Comparator|Sustainment 1: Coaches with CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by Children's Hospital of Philadelphia (CHOP) research consultants. In Year 2, schools in Sustainment 1 will receive reduced support for Tier 2 interventions provided by school district coaches. The coaches will in turn receive diminished support from research consultants. In Year 3, schools in both conditions will implement Tier 2 interventions with support from school district coaches; coaches will not receive direct assistance from research consultants.
9687243|NCT04869657|Active Comparator|Sustainment 2: Coaches without CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by CHOP research consultants. In Years 2 and 3, schools in Sustainment 2 will receive support from school district coaches but coaches will not receive help from research consultants.
9687244|NCT04869397|Experimental|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Intravenous administration, 1 dose, for 20 minutes
9687245|NCT04869397|Placebo Comparator|Placebo|Intravenous administration, 1 dose, for 20 minutes
10187472|NCT03725969|Experimental|Healthy individuals (cow milk)|
10187473|NCT03725956|Experimental|endoscopic sinus surgery|Single group of patients with nasal polyposis eligible for endoscopic sinus surgery
9687246|NCT04869410|Active Comparator|Broselow Tape|Patient will given an intubation using uncuffed endotracheal tube size based on Modified Broselow Tape
9687247|NCT04869410|Active Comparator|Cole Formula|Patient will given an intubation using uncuffed endotracheal tube size based on Cole Formula
9687248|NCT04869306|Active Comparator|Hyaluronic acid|hyaluronic acid gel application after lower third molar removal
9687249|NCT04869306|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier after lower third molar removal
9687250|NCT04869306|No Intervention|Standard treatment|standard treatment after lower third molar removal (i.e., blood clot only)
9687251|NCT04869293|Experimental|3D virtual reality|Use of Hypnosis 3D virtual reality headset
9687252|NCT04869293|No Intervention|Control|Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone
9687253|NCT04869085|Experimental|e-PainSupport Condition|e-PainSupport is a self-administered, digital pain application. Over the course of the two weeks, caregivers and patients will record the severity of patient's pain and how much pain medicine they use to control patient's pain in the e-PainSupport application.
9687254|NCT04869085|No Intervention|Standard Care Condition|Patients and caregivers will be given a paper copy of the same list of resources for pain management included in the Education Module of the e-PainSupport condition at baseline.
9687255|NCT04869033|Experimental|Farinelli's breathing group|Complete Farinelli's breathing exercise 5 times per week for 8 weeks.
9687256|NCT04869033|Other|Diaphragmatic breathing group (control group)|Complete Diaphragmatic breathing exercise 5 times per week for 8 weeks.
9687257|NCT04869163|Active Comparator|red meat consumers|Consumes red meat 3 times a week
9687258|NCT04869163|Experimental|non-red meat consumers|Consumes a non-red meat comparison product 3 times a week
9687259|NCT04869176|Experimental|On Caffeine, maintenance dose|During receiving maintenance dose of 5 mg/kg caffeine citrate (i.e. 2,5 mg/kg caffeine) in the form of solution, orally or intravenously, Holter electrocardiogram and vital functions were monitored for 40 minutes.
9687260|NCT04869176|Experimental|Off caffeine|100 hours after caffeine withdrawal Holter electrocardiogram and vital functions were monitored for 40 minutes.
9687261|NCT04869254||Hematopoietic stem cells transplantation|patients undergone allogeneic or autologous bone marrow transplant who received immunomodulatory therapy with Thymoglobulin
9687262|NCT04869150||those with myocardial bridges|
9687263|NCT04869150||those without myocardial bridges|
9687264|NCT04869098|Experimental|Whey protein preload condition|Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.
9687265|NCT04869098|Placebo Comparator|Placebo condition|Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,
9687266|NCT04869280||Cohort-1: Pregnant Women Exposed to Prucalopride Prior to Enrollment|Pregnant women diagnosed with chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C) who have been exposed to prucalopride during pregnancy and prior to enrollment will be observed.
9687267|NCT04869280||Cohort-2: Pregnant Women Not Exposed to Prucalopride|Pregnant women diagnosed with CIC or IBS-C who have not been exposed to prucalopride will be observed.
9687268|NCT04869241|Experimental|Experimental group|Group measuring shoulder muscle activities by surface EMG with carrying backpacks forward
9687269|NCT04868877|Experimental|MCLA-129|
9687270|NCT04868981|Experimental|GST-HG141|GST-HG141 tablets at varying dosages by mouth for 28 days
9687271|NCT04868981|Placebo Comparator|Matching Placebo for GST-HG141|Placebos for GST-HG141 tablets at varying dosages by mouth for 28 days
9687272|NCT04869046|Experimental|Levobupivacaine group|Instillation of 0,1 ml/kg (0,5 mg/kg) levobupivacaine 0,5% in surgical wound before fascia closure
9687273|NCT04869046|Placebo Comparator|Control Group|Instillation of 0,1 ml/kg 0,9% Sodium Chloride in surgical wound before fascia closure
9687274|NCT04868994|Experimental|ENMG and muscle analyses on whole body muscles MRI.|Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
9687275|NCT04869215|Experimental|EverVita Pro consumed at breakfast followed by an ad lib meal|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include EverVita Pro bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
9687276|NCT04869215|Placebo Comparator|Control consumed at breakfast followed by an ad lib meal.|Before breakfast, a Motivation to Eat and a GI symptom questionnaire will be completed. They will then be given a standard breakfast which will include the control bread, followed by an ad lib pizza meal 1.5h later. Subjects will be asked to fill out the VAS Motivation to Eat Questionnaire before being given the meal and at 10-minute intervals after they start consuming the test meal until they are given the ad lib pizza meal and 30 min after the start of the ad lib pizza meal.
9687277|NCT04868890|Experimental|Active|Ampion
9687278|NCT04868890|Placebo Comparator|Control|Placebo
9687279|NCT04869111|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
9687280|NCT04868955|Experimental|Intervention group|Usual care and oral screen (IQoro®) training.
9687281|NCT04868955|No Intervention|Control group|Usual care.
9687282|NCT04869007||Patients with a history of cesarean section and a hysterosonographically diagnosed isthmocoele|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
9687283|NCT04869007||Patients with a history of cesarean section without isthmocoele hysterosonographically diagnosed|"For patients who agreed to participate in the study, a specific measurement is made during the hysterosonography examination in order to determine the presence or absence of an isthmocele. Inclusion in the study is validated after a successful hysterosonography examination that confirms the presence or absence of an isthmocele. The patients are then attributed either to the: isthmocele + group or isthmocele - group."
9687284|NCT04868903|Active Comparator|Low Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 400 IU/day) for 9 continuous months.
9687285|NCT04868903|Active Comparator|Medium Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 4,000 IU/day) for 9 continuous months.
9976220|NCT01349335|Experimental|2 tolvaptan|30 mg, P.O., Qd, for 7 days,
9976221|NCT01349335|Experimental|3. Placebo|30mg,P.O.,Qd, for 7 days.
9976222|NCT01349348|Experimental|Tolvaptan 15mg|Tablet;15mg/tab
9976223|NCT01349348|Experimental|Tolvaptan 7.5mg|Tablet;7.5mg/tab
9976224|NCT01349348|Placebo Comparator|Placebo|Tolvaptan 0mg/tab
9976225|NCT01349361|Experimental|Daylight-PDT|
9976226|NCT01349374|Experimental|Group1|healthy volunteers
9687286|NCT04868903|Active Comparator|High Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 10,000 IU/day) for 9 continuous months.
9687287|NCT04868786|Experimental|Mycophenolate Mofetil|
9687288|NCT04868760|Active Comparator|Group B: ipilimumab|Ipilimumab, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
9687289|NCT04868760|Experimental|Group A: IBI310|IBI 310, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.
9687290|NCT04868747|Experimental|study group|The study group receives the intravenous 1% lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h during surgery and 1.0 mg/kg/h until 24 hours after surgery (Max.<120 mg/h).
9976227|NCT01349374|Experimental|group2|Unaffected siblings of MODY patients
9976228|NCT01349374|Experimental|Group3|Type2 Diabetic patients
9976229|NCT01349374|Experimental|Group4|MODY patients
10179954|NCT03797950|Experimental|Cash Incentive (Group B)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Volunteers will encourage enrolled women to seek early vaccination for their newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Volunteers will provide information on where and when these vaccines will be available in the woman's community. Volunteers and enrolled women will receive small monetary rewards via mobile money for receiving OPV0 and BCG vaccinations on time."
10179955|NCT03797716|No Intervention|Standard Care arm|"Participants will receive standard of care from the pre-assessment clinic until discharge.~A typical preparatory National Health Service pathway would include: meeting a specialist nurse in the preoperative assessment clinic; a preoperative anaesthetic and surgical consultation; interaction with health play specialists on the day of surgery; and distraction interventions such as hand-held tablets during induction of anaesthesia. Participants may have inhalation or intravenous induction depending on the primary management plan of the anaesthetist in charge.~Participants in the standard care arm will also receive a virtual reality cardboard headset, which can be taken home, personalised and decorated before use with virtual reality apps available to download from the app stores."
10179956|NCT03797716|Experimental|Intervention arm|Participants allocated to the intervention arm will receive the same peri-operative management as the standard care arm and will also receive an access code enabling them to use the Little Journey app in the weeks leading up to their operation. We suggest the Little Journey app is used in the days to weeks leading up to the child's operation depending on their age. On downloading the app, if parents/carers insert the age of the child and date of surgery into the Little Journey app they will be sent a push notifications reminding them when to use it according to their child's age. However, it can be used as frequently as the child and/or their parents or carers wish before the operation.
10179957|NCT03797742||NC|Patients without heart failure.
10179958|NCT03797742||DCM|Dilated cardiomyopathy patients.
10179959|NCT03797742||ICM|Ischemic cardiomyopathy patients.
9687291|NCT04868747|Placebo Comparator|control group|The control group receives intravenous normal saline 0.15 ml/kg bolus followed by 0.15 ml/kg/h during surgery and 0.1 mg/kg/h until 24 hours after surgery.
9687292|NCT04868669|Experimental|Intervention|In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
9687293|NCT04868669|No Intervention|Control|Pregnant women in this arm will receive standard antenatal care.
9695993|NCT04771910|Placebo Comparator|Placebo cream (YUN)|Patients with atopic dermatitis using placebo cream (same formulation as probiotic cream except live probiotic bacteria)
9695994|NCT04771728|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
9695995|NCT04771728|Experimental|Metronidazole vagianl and Probiotics(Umeta-mimi)|Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days）
9695996|NCT04771832||ERAS|Perioperative care with Enhanced Recovery After Surgery (ERAS) protocol
9695997|NCT04771780|Experimental|KHK7791|"During the dosing period, subjects administer KHK7791 twice daily just before meals.Subjects will be underwent tests at scheduled visits at least weekly until Week 12, at least once every 2 weeks after completion of Week 12 test.~KHK7791 and phosphate binders are adjusted with the goal of controlling serum phosphorus concentration within a certain range based on the dose adjustment criteria described in the study protocol.It should be considered that phosphorus adsorbent should be switched to KHK7791 whenever feasible."
9695998|NCT04771884||Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)|The use of antimicrobial agents depends on the clinical practice.
9695999|NCT04771754|Experimental|Arm 1|"Dolutegravir - 50 mg once daily, orally administered for the first 28 days of the study.~No treatment for the last 44 days of the study."
9696000|NCT04771754|Experimental|Arm 2|"No treatment for the first 28 days of the study.~Dolutegravir - 50 mg once daily, orally administered for the last 28 days of the study (day 44-72)."
9696001|NCT04771663|Experimental|Hypoxic|In this phase, participants inhale the hypoxic mixture for five minutes.
9696002|NCT04771663|Experimental|Hypoxic and Hypercapnic|In this phase, participants inhale the hypoxic and hypercapnic mixture for five minutes.
9696003|NCT04771585|No Intervention|Study Part A|Aerosol number and size spectrum characterization of 30 subjects, stratified by age groups, including 10 professional singers. Subjects will be examined twice within 14 days to assess reproducibility of aerosol emission.
9696004|NCT04771585|Experimental|Study Part B|From the 30 subjects of Part A, the 10 highest-emitting subjects will be assessed a third time, wearing four different classes of face masks consecutively with increasing aerosol filtering capacity.
9696005|NCT04771559|Other|Cancer patients|Covid-19 antibody levels of patients will be measured
9696006|NCT04771559|Other|Healthy control|Covid-19 antibody levels of healthy controls will be measured
9696007|NCT04771702|Experimental|Edmon arm|
9696008|NCT04771858||Study Group|No intervention
9696009|NCT04771793||Group A- before implentation of physical restraint protocols|
9696010|NCT04771793||Group B- after implentation of physical restraint protocols|
9696011|NCT04771767|Experimental|Ketamine + eCBT|Over 14 weeks, participants receive weekly sessions of asynchronous online cognitive-behavioural therapy as well as 6 sub-anesthetic infusions of Ketamine
9696012|NCT04771767|No Intervention|Waitlist-Control|Participants are on a waitlist during which time they will not receive the experimental treatment and will have no change in their treatment regimen. These patients will receive the experimental treatment after their participation in the experiment is complete.
9696013|NCT04771845||EEG-grid-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using electroencephalogram grid guided navigation
9696014|NCT04771845||MRI-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using MRI guided navigation
9696015|NCT04771845||NACC controls|National Alzheimer's Coordinating Center matched controls
9827593|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
10179960|NCT03797638|Experimental|Patients with writer's cramp|Patients with writer's cramp
9687294|NCT04868552|Experimental|Naloxone education|These participants will receive a pre-hospital naloxone education module during their pre-operative joint class
9687295|NCT04868552|No Intervention|Standard Education|These participants will receive the standard pre-hospital education including pain management and opioid safety, but will not specifically be given the new naloxone-education module in the pre-hospital setting
10179961|NCT03797638|Other|Control subjects|Control subjects, without writer's cramp, matched with case subjects with age, gender and hand writing
10179962|NCT03797703|Experimental|Treatment|Patients will be randomly allocated into the treatment group. The treatment group will receive a 15 mL lidocaine gel enema rectally immediately following completion of the procedure.
9687296|NCT04868864||Moderate to severe COVID-19 infection|COVID-19 patients with radiographic changes on CXR or CT which had not resolved or had persistent hypoxia due to COVID-19 at the time of discharge will be enrolled. All participants will undergo a LDCT and PFT.
9687297|NCT04868864||Persistent LDCT or PFT abnormalities|Participants with abnormalities on LDCT and or PFT will be invited to continue with a follow-up sub-study. This will involve follow up with repeated LDCT and PFT at subsequent time points to monitor and manage the abnormalities detected until the abnormalities fully resolve or to the last time point at 9 months of the study.
9687298|NCT04868578|Experimental|PPI+Eti placebo|the patient take PPI caps and Etidronate placebo caps
9687299|NCT04868578|Active Comparator|PPI placebo+Eti|The patient take PPI placebo caps and Etidrontate caps
9687300|NCT04868851|Active Comparator|Here for Health only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
9687301|NCT04868851|Experimental|mHealth technology assisted exercise counselling (mHealth)|Patients will complete the Here for Health Healthy Lifestyle intervention before completing a 12 week mHealth technology assisted exercise counselling intervention. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
9687302|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) as varnish in all teeth on all faces as a promotion strategy on the reduction of S. mutans.
9687303|NCT04868513|Experimental|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) and 1% chlorhexidine (Cervitec, Ivoclar Vivadent AG™), both applied as varnish, with a 1 min interval between applications, in all teeth on all faces, using the standardized technique indicated by the manufacturer as a promotion strategy on the reduction of S. mutans.
9687304|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
9687305|NCT04868513|No Intervention|Children of the pregnant women to whom it was applied silane fluoride + 1% chlorhexidine|The children not given any intervention, they were only subjected to a microbiological and clinical examination.
9687306|NCT04868695|Experimental|Bilateral Spheno-Ethmoidectomy:|
9687307|NCT04868695|Experimental|Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b|
9687308|NCT04868695|Experimental|Draf Typ 3|
9687309|NCT04868812|Experimental|Patient|All participants will be screened to ensure inclusion/exclusion criteria are met. A biopsy will be taken from each patient one month before the first laser treatment and one month after the last laser treatment. The MonaLisa treatment will be performed monthly for 3 months. A clinical evaluation will be recorded for each patient using validated questionnaires at baseline and one month after the last procedure.
9687310|NCT04868838|Experimental|Daratumumab|Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).
9687311|NCT04868643|Other|In-Center arm|Subjects undergo In-Center treatment in Phase 2 as defined.
9687312|NCT04868643|Other|In-Home arm|"Subjects undergo In-Home treatments in Phase 4 as defined.~Subjects in Phase 2 and Phase 4 will be the same."
9687313|NCT04868773|Experimental|Cabozantinib in Combination with TAS-102 (trifluridine/tipiracil)|Subjects will receive cabozantinib in combination with TAS-102. Patients will receive cabozantinib on Days 1 - 28 and TAS-102 on Days 1-5 and Days 8-12, for a cycle length of 28 days.
9687314|NCT04868448||Vaccinated participants|Participants who received 1or 2 doses of the Covid-19 vaccines
9687315|NCT04868448||Unvaccinated participants|Participants who have not received any dose of the Covid-19 vaccines
9687316|NCT04868422|Experimental|Telemonitoring|After CPAP titration, patients will be followed with telemonitoring device attached to the fixed pressure CPAP device
9687317|NCT04868422|No Intervention|Usual care|Patients with fixed pressure CPAP will be followed according to routine protocol without telemonitoring
9687318|NCT04868825|Experimental|Experimental (Intervention)|
9687319|NCT04868825|Active Comparator|Active Comparator|
9687320|NCT04868487|Experimental|Intervention|The intervention group received four weekly training sessions of health literacy education. Each educational session lasted an average of 50 minutes. The students were divided into four groups with an average of 25 students in each group.
9827594|NCT02461589|Placebo Comparator|Placebo 50/100/200/300 µL|
9827595|NCT02461589|Experimental|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
10179963|NCT03797703|No Intervention|Control|Patients will be randomly allocated into the control group. The control group will not receive a rectal enema.
10179964|NCT03797807|Experimental|MINST|Minimally invasive non surgical treatment
10179965|NCT03797807|Active Comparator|MIST|Minimally invasive surgical treatment
10179966|NCT03797807|Active Comparator|GTI + MINST|Minimally invasive non surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
10187474|NCT03725943|Experimental|Healthy adults|Dreem
9687321|NCT04868487|No Intervention|Control|The control group had no educational interaction with the researcher after the pre-test. The control group was administered the one-week and three-month posttest THLS-32 by the researcher simultaneously with the intervention group.
9687322|NCT04868630||Outpatients; Atlantic Sleep Centre & SJRH Respiratory Clinic|The study population consists of approximately 80 adult, outpatient participants recruited from the Atlantic Sleep Centre and the Respiratory Clinic at the Horizon Health Network, Saint John Regional Hospital.
10179967|NCT03797807|Active Comparator|GTI + MIST|Minimally invasive surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
10179968|NCT03797937|Experimental|Multiple sclerosis (MS) patients|Patients will undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
9687323|NCT04868617|Experimental|Test Product|The non-CE marked test product is a stoma product based on the flat SenSura® Mio 1-piece (1-pc) and the flat 2-piece with mechanical coupling (2-pc MC) product that includes a novel skin protective layer in the baseplate.
9687324|NCT04868617|Active Comparator|Sensura Mio Comparator - Standard of Care|"The following comparator products will be used in this investigation:~SenSura® Mio 1-piece (1-pc) flat, Midi bag with normal outlet and~SenSura® Mio 2-piece with mechanical coupling (2-pc MC) flat, Maxi or Midi bag with normal outlet"
9687325|NCT04868656|Active Comparator|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
9687326|NCT04868656|Experimental|Enhanced REP|Enhanced REP begins with the same activities as Foundational REP. Sites that do not meet adoption benchmarks within 6 months will continue with Foundational REP and also receive higher intensity support for a period of 4-6 months. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship and CONNECT, a complexity science-based bundle of interaction-oriented activities designed to supplement implementation efforts by promoting team function and readiness for change. Facilitation will be provided by Function QUERI team members.
9687327|NCT04868721|No Intervention|control side|Conventional side Canine retraction was commenced without micro-osteoperforations.
9687328|NCT04868721|Experimental|single Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed for one time only distal to the maxillary canine before starting retraction.
9687329|NCT04868721|Experimental|Multiple Micro-osteoperforations side|Three flapless micro-osteoperforations (MOPs) was performed on repeated basis distal to the maxillary canine evey 28 days before canine retraction.
9687330|NCT04868331|Experimental|AIS girls|Girls between the ages of 10-16 will be recruited if they have a diagnosis of AIS.
9687331|NCT04868331|Active Comparator|Healthy Controls|Healthy adolescent girls matched in age and puberty maturity without spinal deformity
9687332|NCT04868383|Experimental|Single pilot arm|In this single arm pilot study, all participants will receive access to a novel smartphone app designed to support PrEP uptake and adherence for a 6 month period.
9687333|NCT04868175|Active Comparator|Group 1|control (hypromellose), then Timolol, then Travatan
9687334|NCT04868175|Active Comparator|Group 2|Timolol, then Travatan, Hypromellose
9687335|NCT04868175|Active Comparator|Group 3|Travatan, then Hypromellose, Timolol
9687336|NCT04868136|Experimental|Warm-up, then no warm-up|Participants' visit 2 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session. Participants' visit 3 consisted of the 30 minute exercise session without a warm-up.
9687337|NCT04868136|Experimental|No warm-up, then warm-up|Participants' visit 2 consisted of the 30 minute exercise session without a warm-up. Participants' visit 3 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session.
9687338|NCT04868591|Active Comparator|Single session APP arm|Participants in this group will received one session with the advanced practice physiotherapist.
9687339|NCT04868591|Experimental|Multiple sessions APP arm|Participants in this group will received 6 sessions (in 12 weeks) with the advanced practice physiotherapist.
9687340|NCT04868396||Glioblastoma patients|Glioblastoma patients selected to undergo surgical removal of a glioblastoma (based on MRI image).
9687341|NCT04868201|Experimental|0-anxiety|0-anxiety is based on the principles of VRT and CBT, which currently is the most researched and used treatment for anxiety disorders. The 0-anxiety intervention is an app-based intervention consisting of six modules that can be followed according to a user's own timing and without the intervention of a therapist.
9687342|NCT04868201|No Intervention|wait-list condition|
9687343|NCT04868227|Experimental|INTERVENTION STUDY|TREATED WITH 3200IU FULTIUM VITAMIN D3
9687344|NCT04868357|Experimental|Hypnosis|Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group hypnosis. It includes 1 hypnotic induction, multiple suggestions of relaxation and a feeling of air entering the lungs, and a closing exercise. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness. This arm is structured following the classic format of didactic hypnosis interventions, were patients discover the exercise by doing it, and receive keys to be able to recreate the hypnotic state on their own.
9696016|NCT04771520|Experimental|Treatment (avapritinib)|Patients receive avapritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9696017|NCT04771546|Experimental|Intervention (Colpofix)|Intravaginal gel with Carboxymethyl-β-glucan and Polycarbophil
10179969|NCT03797937|No Intervention|Healthy controls|Healthy controls will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
10179970|NCT03797937|No Intervention|Multiple sclerosis (MS) patients undergoing a relapse|Multiple sclerosis (MS) patients undergoing a relapse will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
10179971|NCT03797937|No Intervention|Multiple sclerosis (MS) patients from multiplex MS families|Multiple sclerosis (MS) patients from multiplex MS families will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
10179972|NCT03797612|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the active treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
10179973|NCT03797612|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal injection of placebo as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
10179974|NCT03797651|Active Comparator|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
9687345|NCT04868357|Active Comparator|Relaxation|"Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group dynamic relaxation. It includes 1 exercise to liberate tension, 3 exercises to increase proprioception and calmness, and 3 exercises for calming and regulating the breath. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness.~Provides additional care that motivates the patients to participate in the control group.~Allows the controlling of number of group interventions accross arms (2).~Allows to control for motivation, as both arms are introduced identically: the benefits and interest of using self-relaxation techniques for complementary care in anxiety and anxiety-related dyspnea are underscored.~It allows the disentanglement of hypnosis and relaxation effects . This was crucial, inasmuch as hypnosis too includes physical relaxation and breathing exercises."
9687346|NCT04868526|Experimental|Control-Dietary Intervention|Control condition first, then to Dietary intervention
9687347|NCT04868526|Experimental|Dietary intervention-Control|Dietary intervention first, then to Control condition.
9687348|NCT04868461|Active Comparator|Unheated whey protein (UWP)|"Participants are given a preload of 200 mL of unheated whey protein (UWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
9687349|NCT04868461|Active Comparator|Heated whey protein (HWP)|"Participants are given a preload of 200 mL of heated whey protein (HWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
9687350|NCT04868461|Active Comparator|Casein (Cas)|"Participants are given a preload of 200 mL of Casein (Cas) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
9687351|NCT04868461|Placebo Comparator|Water|The water has the same banana flavor and sweetness to match the protein beverages. Participants receive the same amount of water like protein beverages - 200mL.
9687352|NCT04868110|No Intervention|Usual Care|Women in the usual care group, will received standard care from the obstetrician.
9687353|NCT04868110|Experimental|High fiber|Women in high fiber group will receive education on consuming a high fiber diet, including weekly lessons and daily snacks.
9687354|NCT04868188||Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support|Adult (>18 years) patients with severe influenza / Covid-19 supported on ECMO and with confirmed or suspected aspergillosis infection.
9687355|NCT04868084|Experimental|Intervention group|"Physical Literacy in the early years. The intervention was delivered by an external provider and designed to provide nursery teachers, teaching assistants and others working with children under age five the knowledge, skills and confidence to deliver enjoyable and engaging lessons which focus on the development of core fundamental skills. The course was developed in conjunction with leading Physical Education (PE) consultants, Sports Scientists and Office for Standards in Education, Children's Services and Skills (Ofsted) advisors which covered both the theory about FMS and physical literacy, and practical demonstrations of age-appropriate ways to teach and develop FMS. Staff from the Intervention settings received the six-hour training session. After the training session, school nurseries which were encouraged to speak with the training provider to follow-up the understanding of the training and provide additional help for implementation of the practice learned."
9687356|NCT04868084|No Intervention|Control|The control nurseries followed their usual practice.
9687357|NCT04868149|Experimental|Laparoscopic ALPPS|Laparoscopic ALPPS procedure
9687358|NCT04868149|Active Comparator|Open ALPPS|Open ALPPS procedure
9687359|NCT04868019|Experimental|Group A|Groups A will receive solution A .i.e fenofibrate suspension
9687360|NCT04868019|Placebo Comparator|Group B|Group B will receive solution B i.e placebo.
9687361|NCT04868344|Experimental|MRG003|Phase Ia: MRG003 will be administrated by an IV infusion of escalating doses (0.1, 0.3, 0.6, 1.0, 2.0, 2.5, 3.0 mg/kg) on Day 1 of every 3 weeks (Q3W); Phase Ib: MRG003 will be administrated by an IV infusion of MTD/RP2D.
9687362|NCT04867967|Experimental|Iyengar Yoga Intervention|"8-week yoga class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
9687363|NCT04867967|Active Comparator|Mindfulness-based stress reduction|"8-week MBSR class; once weekly; 90 minutes~Note: First administered face-to-face, due to Covid-restrictions changed to online classes"
9687364|NCT04867967|No Intervention|Waitlist control|Waitlist control, ususal care
9687365|NCT04868266|Experimental|end tidal carbon dioxide monitoring|
9687366|NCT04868266|No Intervention|Oxygen saturation monitoring|
9687367|NCT04867980|Experimental|ABCD|Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be >= 5 days between each dose.
9687368|NCT04867980|Experimental|BDAC|Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be >= 5 days between each dose.
9687369|NCT04867980|Experimental|CADB|Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be >= 5 days between each dose.
9687370|NCT04867980|Experimental|DCBA|Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be >= 5 days between each dose.
9696018|NCT04771546|No Intervention|Control|No intervention (standard of care)
9696019|NCT04771507|Experimental|Intermittent ibrutinib|Intermittent treatment with ibrutinib.
9687371|NCT04868253|Experimental|EMB-001|EMB-001 will be administered utilizing capsules which contain 240 mg of metyrapone and 8 mg of oxazepam (240/8 mg). Subjects will be prescribed 3 capsules (total of 720 mg metyrapone and 24 mg oxazepam) taken twice daily for a total of 12 weeks. After week 12, or if indicated and possibly for a subject who is being discontinued early, subjects will take one capsule of EMB-001, 240/8 mg, twice a day for one additional week (taper dose).
9687372|NCT04867850|Active Comparator|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice. Usual care for clinicians includes a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm.
10179975|NCT03797651|Experimental|Very-short DAPT within 1 month|Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
10179976|NCT03797677|Experimental|Home based airway clearance with Metaneb|"Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.~The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device, cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The MetaNeb® 4 System with application for homecare environment."
10179977|NCT03797781|Experimental|High protein|
10179978|NCT03797781|Experimental|Low protein|
9687373|NCT04867850|Experimental|Clinician Nudge|Clinicians receive a nudge consisting of targeted text messages identifying patients at high risk of predicted 6-month mortality based on a validated machine learning prognostic algorithm as well as performance feedback compared to peers.
9687374|NCT04867850|Experimental|Patient Nudge|Patients receive a nudge consisting of a normalizing message prompting patients to complete an electronic questionnaire designed to prime patients towards having an SIC.
9687375|NCT04867850|Experimental|Clinician and Patient Nudge|Both strategies described above will be used.
9687376|NCT04867993|Active Comparator|asphyxiated neonates treated with amikacin and hypothermia|Amikacin (Likacin®; 500 mg/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
9687377|NCT04867993|Placebo Comparator|asphyxiated neonates treated with amikacin|Amikacin (Likacin®; 500m g/2mL vial; Lisapharma S.p.A., Erba, Italy) is given to the neonate, as an IV infusion via umbilical vein over 20 min by use of a syringe-pump (Braun; B. Braun Medical Inc., Bethlehem, PA USA). Infusion is followed by slow 0.5 mL Sodium chloride 0.9% flush.
9687378|NCT04868162|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
10179979|NCT03797781|Experimental|Minimum protein|
10179980|NCT03797729|Placebo Comparator|Normal saline|
9687379|NCT04868058|Experimental|1 AF SAPB|Atrial fibrillation. Serratus anterior plane block
9687380|NCT04868058|Experimental|2 AF ESPB|Atrial fibrillation. Erector spinae plane block
9687381|NCT04868058|Experimental|3 VT SAPB|Ventricular Tachycardia.Serratus anterior plane block
9687382|NCT04868058|Experimental|4 VT ESPB|Ventricular Tachycardia. Erector spinae plane block
9687383|NCT04868058|Experimental|5 ISNT SAPB|Inappropriate Sinus node tachycardia. Serratus anterior plane block
9687384|NCT04868058|Experimental|6 ISNT ESPB|Inappropriate Sinus node tachycardia. Erector spinae plane block
9687385|NCT04868565|Experimental|ongoing caffeine with oxygen supplement (group 1)|"samples assigned to the ongoing caffeine with oxygen supplement (group 1) will continue caffeine administration combining with oxygen supplement until the patients are weaned from oxygen."
9687386|NCT04868565|Active Comparator|discontinuing caffeine with oxygen supplement (group 2)|"samples assigned to the discontinuing caffeine with oxygen supplement (group 2) will discontinue caffeine immediately after randomization, while oxygen supplement is going on."
9687387|NCT04868474|Active Comparator|Usual care training|A refresher training course will be the equivalent of 'enhanced' usual care. Enhanced because the course will likely augment short-term knowledge of smoking cessation treatments, and participation in the study could trigger more discussions about smoking cessation than routine practice. However, it will be impossible to have any blinding between groups without at least some training.
9687388|NCT04868474|Experimental|Intervention training|The training course and decision aid aim to make treatment of tobacco use the default choice
9687389|NCT04868071|Experimental|High-Speed Resistance Training|Participants performed exercises 8 times (sets) with 3-5 repetitions at 70%-75% of the maximal strength.
9687390|NCT04868071|Experimental|Low-Speed Resistance Training|Participants performed exercises 4 times (sets) with 8-10 repetitions at 70%-75% of the maximal strength.
9687391|NCT04868071|No Intervention|Control Group|No activities
9687392|NCT04868045|Experimental|Patients with a history of thyroid hormone suppression (TSH<0.5 mU/L) for at least 5 years|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
9977730|NCT01364701|Active Comparator|Tadalafil 20mg maximal dose|4 tablets of tadalafil 20mg are given for on demand use
10179981|NCT03797729|Experimental|Tirofiban|
10179982|NCT03797924|Active Comparator|ICBN with ropivacaine|Participants will receive ICBN with ropivacaine. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
10179983|NCT03797924|Placebo Comparator|No ICBN block|Participants will have the site prepped, but no ICBN block given. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
10179984|NCT03797794|Experimental|PESF-treatment|The group undergoing the pulsating electrostatic field intervention
9687393|NCT04868045|Experimental|Patients with no history of TSH suppression|Study subjects will be given 200mcg of TRH as a single intravenous (IV) bolus in endocrine clinic on Day 1 and Day 5. LT3 will be administered orally, twice a day (12 hours apart i.e. 8 AM and 8 PM) at a dosage of 10 mcg on Day 2-4. Levothyroxine will be taken after the TRH stimulation tests on Day 1 and day 5. Levothyroxine will be taken on Days 2-4 of the study. *Patients will take their own LT4 that they are prescribed by their endocrinologist. The dose of Levothyroxine is titrated for each patient.
9687394|NCT04867811|Experimental|group A|received conventional therapy
9687395|NCT04867811|Experimental|group B|received TENS in addition to conventional therapy
9687396|NCT04867811|Experimental|group C|received cupping therapy with conventional therapy
9687397|NCT04867811|Experimental|group D|TENS and cupping therapy plus conventional therapy
9687398|NCT04867876|Experimental|Intervention Cohort|Physical Therapy
9687399|NCT04868032|Experimental|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
9687400|NCT04868032|Active Comparator|Enhanced Usual Care Control|Participants randomized to this condition will be provided with a Fitbit, but will not receive any intervention phone calls or the written manual.
9687401|NCT04867629|Experimental|Rapeseed oil|Participants asked to consume 20mL of rapeseed oil raw every day for 12 weeks
9687402|NCT04867629|Active Comparator|Sunflower oil|Participants asked to consume 20mL of sunflower oil raw every day for 12 weeks
9687403|NCT04867629|No Intervention|Habitual diet|Participants asked to maintain their habitual diet for 12 weeks
9687404|NCT04867720|Experimental|CertiroBell Tablet|Use in combination with Tacrolimus at least 6 months after liver transplantation.
9977731|NCT01364701|Active Comparator|Combination half dose|4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use
9687405|NCT04867772|Other|Usual Care|Participants will receive the care that would usually be received in the local hospital setting. this has been determined as between 1 and 6 sessions of physiotherapy
9687406|NCT04867772|Experimental|Intervention|Participants will receive a home based rehabilitation programme with 1-7 sessions of physiotherapy delivered over 12 weeks.
9687407|NCT04867941|Experimental|Part1: Mild hepatic insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
9687408|NCT04867941|Experimental|Part 1: Moderate hepatic insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
9687409|NCT04867941|Experimental|Part 1: Normal hepatic function|Participants with normal hepatic function will receive a single oral dose of 50 mgACP-196 (2 x 25 mg capsules) on Day 1 of the study.
9687410|NCT04867941|Experimental|Part 2: Severe hepatic insufficiency|Participants with sever hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
9687411|NCT04867889|Active Comparator|Active Treatment iTBS|Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 20 sessions on 20 week days, one session per day.
9687412|NCT04867889|Sham Comparator|Sham treatment|Sham treatment given either with a sham stimulation coil or by flipping an active coil 90 degrees.
9687413|NCT04867824|Active Comparator|Control|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
9687414|NCT04867824|Experimental|Case|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure vanilla essential oil (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
9687415|NCT04867512|Experimental|Intervention Group|Participants will be taking one liquid tincture orally per day as well as 2 capsules orally at night. At week 10, non-responders will take another supplement consisting of 2 capsules orally along with the liquid tincture until week 14.
9687416|NCT04867525||Colorectal Cancer Metastatic|
9687417|NCT04867733|Experimental|Micropatch application|All participants will complete this arm. Three sites each on the upper arm, volar (inner) forearm, and palm will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, and color will be made at each site. Baseline optical coherence tomography (OCT) scans will be made at each site. Color will only be measured at baseline. One site at each location will undergo the following interventions: 1) micropatch application and an occlusive covering, 2) micropatch application, but remain uncovered, 3) occlusive covering, no micropatch application. Micropatch application will only occur on the first day and does not contain any drug substance. Trans-epidermal water loss and electrical resistance are re-measured after micropatch removal, along with an additional OCT scan. Electrical resistance and OCT scans will be repeated at all sites for 2 days. Measurements from the 2nd and 3rd sites allow each subject to serve as their own control in data analysis.
9687418|NCT04867668|Experimental|Digital intervention|Participants will be randomized to receive variable levels of exposure (including no exposure control) of digital anti-vaping and anti-smoking messages. We will evaluate the effects of experimental condition and exposure on outcomes (tobacco product use).
9977732|NCT01364714||ICU survivors|Male ICU survivors 12 month after discharge
10179985|NCT03797794|Sham Comparator|Placebo-treatment|The group undergoing the SHAM Pulsating Electrostatic Field
10179986|NCT03797625|Experimental|Endostar Combined With IP|Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1
9687419|NCT04867668|No Intervention|Control|No exposure control condition
10179987|NCT03797664|Experimental|Experimental: CDX-6114|7.5, 15.0 and 22.5g
9687420|NCT04867642|Experimental|Part A Sequence 1|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
9687421|NCT04867642|Experimental|Part A Sequence 2|Study participants randomized to Part A will receive single ascending doses of UCB0022 or placebo (PBO) at pre-specified time points during the Treatment Period of alternating cohorts in a crossover design.
9687422|NCT04867642|Experimental|Part B UCB0022|Study participants randomized to Part B will receive multiple ascending doses of UCB0022 at pre-specified time points during the Treatment Period of cohorts in a parallel design.
9687423|NCT04867642|Placebo Comparator|Part B Placebo|Study participants randomized to Part B will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period of cohorts in a parallel design.
9687424|NCT04867642|Experimental|Part C UCB0022|Study participants randomized to this cohort in Part C will receive fixed multiple doses of UCB0022 at pre-specified time points during the Treatment Period.
9687425|NCT04867642|Placebo Comparator|Part C Placebo|Study participants randomized to this cohort in Part C will receive placebo (PBO) comparator at pre-specified time points during the Treatment Period.
9687426|NCT04867460|Experimental|Ultrasound guided venous access|Vascular access of the axillary vein will be performed using an ultrasound system (Siemens Acuson Freestyle) with a wireless vascular ultrasound probe (L8-3 or L13-5). One or more vascular punctures will be performed, as needed.
9687427|NCT04867460|No Intervention|Standard of care|Vascular access of the axillary or subclavian vein will be performed using anatomical landmarks, fluoroscopy and/or injection of X-ray contrast in the antecubital vein, at the choice of the implanter. One or more vascular punctures will be performed, as needed.
9687428|NCT04867681|Experimental|Administration of a short psycho-education programme|
9687429|NCT04867681|No Intervention|Control group|
9687430|NCT04867304||Healthy controls|Individuals without any known illnesses and normal labs./USG w/a. This group was used to compare baseline depression, magnetic resonance spectroscopy and plasma metabolites.
10179988|NCT03797664|Placebo Comparator|Placebo Comparator: Placebo|Phosphate Buffer Diluent Solution
9687431|NCT04867304||Chronic pancreatitis without depression|This group contains patients with CP who does not have depression based on the Beck Depression inventory.
9687432|NCT04867304||Chronic pancreatitis with depression|This group contains patients with CP who has depression based on the Beck Depression inventory.
9687433|NCT04867291|Experimental|Pizza|Consumption of a portion of Eat Balanced pizza equivalent to 200 µg of iodine (half a pizza) consumed with 450 mL water. Collection of urine for 36 hours following pizza ingestion. Collection of one fecal sample up to 24 hours following pizza ingestion.
9687434|NCT04867291|Experimental|Seaweed Sheets|Consumption of a portion of Itsu Crispy Seaweed Thins equivalent to 200 µg of iodine (10g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
9687435|NCT04867291|Experimental|Seaweed Powder|Consumption of a portion of seaweed powder in a capsule equivalent to 200 µg of iodine (0.25g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
9687436|NCT04867291|Experimental|Potassium Iodide Supplement|Consumption of a portion of Piping Rock Potassium Iodide supplements equivalent to 200 µg of iodine (1.3 tablets) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
9687437|NCT04867421||TANOs|Adult patients with osteosarcoma or chondrosarcoma
9687438|NCT04867369|Experimental|Pecs II block|80 patients scheduled for open biceps tenodesis
9687439|NCT04867369|Active Comparator|Surgical infiltration|80 patients scheduled for open biceps tenodesis
9687440|NCT04867343|Experimental|HR020602 injection|
9687441|NCT04867343|Active Comparator|fentanyl injection + remifentanil injection|
9687442|NCT04867226|Active Comparator|colchicine drug|participant in this group will be given a colchicine tablet alone or add to their Current treatment, Colchicine 0.5 mg twice daily (reduced to 0.5 mg/day, in patients with low body weight or develop side effect like gastrointestinal symptoms ),For 14 days or until symptoms subsides.
9687443|NCT04867226|Active Comparator|usual care|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
9687444|NCT04867356|Active Comparator|Spinal Stabilization Exercises (SSE)|
9687445|NCT04867356|Experimental|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|
9687446|NCT04867447||Case-Immigrants psychotic patients|"Individuals who have presented at least one non-affective psychotic episode with an immigrant status, defined as a person who migrates to another country, usually for permanent residence"
9687447|NCT04867447||Control-Non immigrants psychotic patients|Individuals who have presented at least one non-affective psychotic episode who do not have an immigrant status.
9687448|NCT04867239|Other|A two-day education program|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise for metabolic syndrome. Participants visited at 3- and 6-month after camp for follow-up.
9687449|NCT04867330|Experimental|conventional treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
9687450|NCT04866979|Experimental|Combination of continuous TBS plus cognitive training (cTBS + CT)|Continuous mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
9977733|NCT01364714||Controls|Age and gender matched controls
9977734|NCT01364753||Pilots|No intervention; observational study
9977735|NCT01364792|Experimental|Valaciclovir|The patients in the experimental group will be treated with 4 times 2 grams valaciclovir per day for seven days.
10187475|NCT03725930|Active Comparator|Clonidine|This arm will receive intra nasal Clonidine as a premedication before surgery
9687451|NCT04866979|Experimental|Combination of intermittent TBS plus cognitive training (iTBS + CT)|Intermittent mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
9687452|NCT04866979|Experimental|Continuous TBS only (cTBS)|TBS in continuous mode application, only (without cognitive training).
9687453|NCT04866979|Experimental|Intermittent TBS only (iTBS)|TBS in intermittent mode application, only (without cognitive training).
9687454|NCT04866979|Active Comparator|Cognitive training only (with sham TBS) (CT).|"TBS Sham will be implemented using the same set-up as a true TBS protocol but with sham stimulation. Directly following sham stimulation (as in the true combination of stimulation + cognitive training protocols), patients will undergo 25 minutes of cognitive training."
9687455|NCT04867564||NSCLC patients treated with curative radiotherapy|Consecutive NSCLC patients treated with standard RT with curative intent with or without platinum-based CHT
9687456|NCT04867252|Active Comparator|Combination Therapy Group|ARM 1: Resveratrol (1000mg Twice a day) Myoinositol (1000mg Twice a day)
9687457|NCT04867252|Other|Standard Therapy Group|ARM 2:Metformin 500mg (Twice a day) Pioglitazone (15mg Twice a day)
9687458|NCT04867161||Patients with COVID-19 pneumonia without superinfection|Patients with confirmed COVID-19 pneumonia not fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
9687459|NCT04867161||Patients with COVID-19 pneumonia with superinfection|Patients with confirmed COVID-19 pneumonia fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )
9687460|NCT04867044||STUDY GROUP|patient diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
9687461|NCT04867044||CONTROL GROUP|healthy women volunteers
9687462|NCT04866914|Experimental|ACT for Insomnia|
9687463|NCT04866914|Active Comparator|CBT for Insomnia|
9687464|NCT04866914|No Intervention|Wait List|
9687465|NCT04867577||vertebral osteoporotic compression fracture|Patients with osteoporotic vertebral compression receiving vertebroplasty or cemented screws reconstruction
9687466|NCT04866875|Active Comparator|Rapid weight loss|Participants in this group will be deprived in 1000 kcal/day (calculated based on their individual energy requirements) for 10 weeks
9687467|NCT04866875|Experimental|Slow weight loss|Participants in this group will be deprived in 500 kcal/day (calculated based on their individual energy requirements) for 20 weeks
9687468|NCT04867265|Active Comparator|Professional Adult Medium Skin CPR-AED Training Manikin with CPR Monitor (Prestan)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
9687469|NCT04867265|Active Comparator|Resusci Anne QCPR AED (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
9687470|NCT04867265|Active Comparator|Resusci Baby QCPR (Laerdal)|medical students trained BLS trainers and medical students trained in BLS will provide 2 minutes cycle of BLS according to ERC guidelines 2021 wearing the breathable self-sterilizing nanofiber respirators with accelerated copper
9687471|NCT04867005|Active Comparator|Online traininig group. A|This arm included 5 primary care teams, that carried out a 10 hours online course.
9687472|NCT04867005|Experimental|online and face-to-face training group. B|This arm included 5 primary care teams, that carried out a 10 hours online course plus a 6h hours face-to-face course
9687473|NCT04866940|Experimental|Sequence validation|This research aims to provide a generic framework to test the feasibility of MRI sequences requested as part of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of images obtained.
9687474|NCT04866862|Experimental|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+ Camrelizumab 200mg d1; Repeated every 4 weeks
9687475|NCT04866888|Experimental|pregnant women with placenta accreta spectrum|"Bladder will be dissected and mobilized down to the vagina after skeletonization and securing of bridging vessels either by electro-coagulation or ligation. Uterus will be incised 5mm above the placenta bulge, delivering the fetus followed by Carbetocin 100 microgram /1 ml intravascular. Repair of the uterine wall defect will be done. If extrauterine bleeding is excessive we may revert to internal iliac artery ligation followed by insertion of intra-peritoneal drain and regular abdominal wall closure.~After 3 months from delivery, ultrasound with different modalities will be done to all patients and outpatient hysteroscopy if symptomatic patients or with abnormal sonography."
9687476|NCT04867200|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)~Period 2: Test drug(CKD-344 60 mg)"
9687477|NCT04867200|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)~Period 2: Reference drug(Lixiana 60 mg)"
9687478|NCT04867148|Experimental|Gait analysis|Gait analysis of patients with ankylosing spondylitis, patients with adoldescent idiopathic scoliosis and control group.
9687479|NCT04867057|Experimental|Experimental: Trichomylin for SAD|6 out of 8 subjects will be randomized to receive Trichomylin in a single dose.
9687480|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for SAD|2 out of 8 subjects will be randomized to receive placebo in a single dose.
9687481|NCT04867057|Experimental|Experimental: Trichomylin for MAD|6 out of 8 subjects will be randomized to receive Trichomylin in multiple doses.
9687482|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for MAD|2 out of 8 subjects will be randomized to receive Placebo in multiple doses.
9687483|NCT04866927||Adults|"Inclusion criteria: Healthy, non-pregnant women, adults aged 18-65 years, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range.~Exclusion criteria: Children and elderly (over 65), pregnant women, individuals diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study."
9977736|NCT01364792|Placebo Comparator|Placebo|Patient receives placebo four times a day for seven days.
10187476|NCT03725930|Placebo Comparator|Placebo|This arm will receive intra nasal Placebo as a premedication before surgery
10179989|NCT03797586|Experimental|Electroacupuncture group|Bilateral ST25,SP14, ST37 will be used in the EA group. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal , where patients will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
10179990|NCT03797586|Sham Comparator|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
10179991|NCT03797599|Experimental|20 minutes of mindfulness practice|Two sessions a week for two weeks of: 5 minutes listening to audio book excerpts followed by 20 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
10179992|NCT03797599|Active Comparator|5 minutes of mindfulness practice|Two sessions a week for two weeks of: 20 minutes listening to audio book excerpts followed by 5 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
9687484|NCT04866849||STUDY GROUP|"patient diagnosed with bruxism The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
9687485|NCT04866849||CONTROL GROUP|healthy volunteers
9687486|NCT04866797|Active Comparator|cyclic merocyanine long-UVA absorber|
9687487|NCT04866797|Placebo Comparator|placebo|
9687488|NCT04866667||antidiabetic drugs including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs including GLP-1 RAs
9687489|NCT04866667||antidiabetic drugs not including GLP-1 RAs|Apply Type 2 Diabetes mellitus patients with high risk of ASCVD with antidiabetic drugs not including GLP-1 RAs，such as metformin，insulin
9696020|NCT04771533|Experimental|Passive stabilization of the trunk and the upper extremity|The intervention (passive stabilization of the trunk and the upper arm) was tested in post-stroke patients (study group) and in patients with back pain, but without neurological deficits (control group)
9696021|NCT04771455|Experimental|Condition 1|Behavioral weight loss intervention
9696022|NCT04771455|Experimental|Condition 2|Behavioral weight loss intervention and decrease negative affect
9696023|NCT04771455|Experimental|Condition 3|Behavioral weight loss intervention and decrease unhealthy weight control practices
9696024|NCT04771455|Experimental|Condition 4|Behavioral weight loss intervention, decrease unhealthy weight control practices, and decrease negative affect
9696025|NCT04771455|Experimental|Condition 5|Behavioral weight loss intervention and decrease overvaluation of weight and shape
9696026|NCT04771455|Experimental|Condition 6|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease negative affect
9696027|NCT04771455|Experimental|Condition 7|Behavioral weight loss intervention, decrease overvaluation of weight and shape, and decrease unhealthy weight control practices
9696028|NCT04771455|Experimental|Condition 8|Behavioral weight loss intervention, decrease overvaluation of weight and shape, decrease unhealthy weight control practices, and decrease negative affect
9696029|NCT04771143|Experimental|AFQ056|Experimental study drug
9696030|NCT04771143|Placebo Comparator|Placebo|Matching placebo
9696031|NCT04771260||Case study #1|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696032|NCT04771260||Case study #2|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696033|NCT04771260||Case study #3|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696034|NCT04771260||Case study #4|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696035|NCT04771260||Case study #5|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696036|NCT04771260||Case study #6|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696037|NCT04771260||Case study #7|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696038|NCT04771260||Case study #8|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696039|NCT04771260||Case study #9|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696040|NCT04771260||Case study #10|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
9696041|NCT04771377|Experimental|standard protein supplementation (SPS)|0.8g protein/ IBW/ day
9696042|NCT04771377|Experimental|High protein supplementation (HPS)|1.2g protein/ IBW/ day
9687490|NCT04867031|Experimental|White fish (cod)|Participants will consume 1 portion (~130g) of white fish (Bird's Eye Inspirations Cod Fillets with Tomato & Rosemary), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
10179993|NCT03797599|Placebo Comparator|Audio book control|Two sessions a week for two weeks of: 25 minutes listening to audio book excerpts (with non mindfulness practice). Participants will be asked not to engage in formal mindfulness practice during the study.
10179994|NCT03797573|Active Comparator|active tDCS|Patients will receive tDCS (bilateral fronto-central stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
10179995|NCT03797573|Sham Comparator|sham tDCS|Patients will receive sham tDCS (5 seconds of stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
10179996|NCT03799419|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
9687491|NCT04867031|Experimental|Semi-skimmed milk|Participants will consume 1 portion (~450mL) of milk (Tesco UHT Semi-Skimmed), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
10179997|NCT03799419|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
10187477|NCT03725917|Experimental|Experimental Group|The intervention will be a progressive physiotherapy protocol formed by therapeutic exercise and manual therapy
9687492|NCT04867031|Experimental|Dried seaweed sheets|Participants will consume 1 portion (~6g) of dried seaweed sheets (Itsu Crispy Seaweed Thins), providing approximately 140µg of iodine, alongside 452mL of water. Urine will be collected for 36 hours following test food consumption.
9687493|NCT04866732|Experimental|Needs assessment and feasibility group|Based on our target population's needs/preferences, an existing Physical Activity (PA) program will be modified and tailored to the needs of the target population. We anticipate that this PA program will include the following components: a) PA component - ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to CVD risk factors prevention; c) daily diary to record if they are facing any barriers in completing various components of the intervention; d) problem-solving sessions
9687494|NCT04866745|Experimental|Magnetotherapy plus exercise|"The patients will receive a total of 12 sessions, 3 sessions per week of magnetotherapy. The duration of treatment will be 20 minutes with a magnetic field frequency of 50Hz and a power of 100 Gauss.~After the magnetotherapy treatment, the patient will have to perform 12 sessions, 3 sessions per week of a program of therapeutic exercise with a duration of 25 minutes. This exercise program will be the same in the microwave and sham groups."
9687495|NCT04866745|Placebo Comparator|Sham Magnetotherapy plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of sham magnetotherapy. For the simulated/sham magnetotherapy group, it will be applied in the same way as the real MT group, but the equipment will be programmed to apply 0 Gauss. The physiotherapist performing the application will not have access to the magnetotherapy parameters on the display of the device, but will only have to enter the code. After the application of sham magnetotherapy, the patient will have to perform a program of therapeutic exercise.
9687496|NCT04866745|Active Comparator|Microwave plus exercise|The patients will receive a total of 12 sessions, 3 sessions per week of microwave therapy. The duration of the session will be 20 minutes, 10 minutes on the anterior side and 10 minutes on the posterior side of the joint in case of unilateral knee osteoarthritis. In the case of bilateral knee osteoarthritis, the MW will be applied 20 minutes over the anterosuperior side of both knees. After the microwave session, the patient will have to perform a program of therapeutic exercise.
9687497|NCT04866719|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
9687498|NCT04866836|Experimental|tislelizumab combined with radiotherapy|To observe and evaluate the effectiveness and safety of tislelizumab combined with radiotherapy in the treatment of patients with advanced biliary malignancies.
9687499|NCT04866771|Experimental|Transcranial Direct Current Stimulation (tDCS)|Facilitatory transcranial direct current stimulation (tDCS)
9687500|NCT04866771|Sham Comparator|Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group|Sham tDCS followed by a switch to anodal tDCS.
9687501|NCT04866784|Experimental|High Sensation TENS|"Active TENS is delivered for 30mins at a frequency of 100 Hz and pulse duration of 100μsec using the EMPI Select TENS unit (calibrated using an oscilloscope prior to study). The intensity will be increased until patients feel a maximally strong but comfortable sensation to ensure an analgesic effect."
9687502|NCT04866784|Placebo Comparator|Low Sensation TENS|Placebo TENS parameters will be identical to Active TENS (100 Hz and 100 μsec), but a novel placebo TENS unit, previously tested and validated will be used (Rakel et al., 2010). The placebo device provides a current for 30sec and ramps off over 15sec to zero output. An indicator light remains on so it appears to the subject that the unit is still producing current. This unit has demonstrated nearly 100% blinding of investigators such that the investigator applying the TENS is unable to distinguish between the active and the placebo unit; approximately ~50% of subjects are successfully blinded using this unit.
9687503|NCT04866784|No Intervention|No Treatment Control|The No Treatment Control includes application of TENS electrodes identical to the other 2 conditions, but the unit remains off. This condition will control for potential effects of repeat testing and any placebo effect.
9687504|NCT04867213||SARS-CoV-2 Positive|Clinically tested for SARS-CoV-2 (as completed by standard laboratory testing e.g. RT-PCR) and with a positive result and clinical features in keeping with COVID-19 illness. The investigators aim to collect breath samples within 7 days of symptom onset in 50% of Covid positive patients, with the remaining patients breath samples collected after 7 days of symptoms onset.
9687505|NCT04867213||SARS-CoV-2 Negative|Patients with a negative RT-PCR COVID-19 test and without any clinical features to suggest COVID-19 illness.
9696043|NCT04771377|Experimental|HPS + PA|1.2g protein/ IBW/ day + PA 3 times a week/ 12 weeks
10179998|NCT03799419|Experimental|Approach avoidance training with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
10179999|NCT03799419|Sham Comparator|Inactive sham approach avoidance training|Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training
9687508|NCT04866498||Analgosedation in ICU patients after head and neck tumor resection in general anesthesia|Head and neck tumor resections were performed in general anesthesia. Midazolam and etomidate or propofol were used in introduction and then anesthesia was maintenance with sevoflurane. Patients received intravenous continuous infusion of oxycodone as an analgesic component and sedatives (propofol/dexmedetomidine/midazolam) during analgosedation in ICU.
9687509|NCT04866511|Experimental|NET intervention|This study will follow a single case design and will involve delivering and evaluating the child-friendly protocol of NET. Therefore, there will only be one arm (NET intervention) and no comparators.
9687510|NCT04866641|Experimental|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit will be administered via intravenous infusion once every 4 weeks. T-1201 Injection 100 mg Kit is required to be reconstituted with its specific Injection Diluent supplied in the kit, then further diluted with 5% Dextrose solution prior to the intravenous infusion in patients.
9687511|NCT04866524||ICSI technique|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
9687512|NCT04866524||Conventional IVF|In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
9687513|NCT04866628|Experimental|Helichrysum italicum|1 g of milled plant material (Helichrysum italicum) immersed in hot water (200 mL, 100 °C) for 10minutes
9687514|NCT04866628|Active Comparator|Helichrysum arenarium|1 g of milled plant material (Helichrysum arenarium) immersed in hot water (200 mL, 100 °C) for 10minutes
10180000|NCT03799445|Experimental|Treatment (nivolumab, ipilimumab, IMRT)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
9687515|NCT04866953||<30 units PRBC|Patients who underwent surgery within 24 hours of admission and received less than 30 units of pRBC within 24 hours.
9687516|NCT04866953||>/=30 units PRBC|Patients who underwent surgery within 24 hours of admission and received >/=30 units of pRBC within 24 hours.
9687517|NCT04866537||Pregnant women who received a fetal heart ultrasound between 2015 and 2019.|Pregnant women who received a fetal heart ultrasound between 2015 and 2019.
9687518|NCT04866654|Experimental|Study group|Nivolumab, total dose 5760 mg milligram
9687519|NCT04866394|Experimental|Hypofractionated Pelvic Radiation|
9687520|NCT04866446||normal airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
9687521|NCT04866446||normal airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
9687522|NCT04866446||difficult airway manikin with standard uniform|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
9687523|NCT04866446||difficult airway manikin with personal protective equipment|The participants will carry out intubation procedure using macintosh direct laryngoscope, GlideScope video laryngoscope, C-Mac video laryngoscope and Frova intubation catheter and laryngeal mask insertion using ProSeal LMA and I-gel LMA, respectively.
9687524|NCT04866966|Experimental|Intervention Group|The group undergoing the intervention will participate in 90-minute group visits occurring weekly for 4 weeks, then biweekly for a total of 26 weeks/15 visits. Each visit will focus on intensive lifestyle changes. Further, these patients will each have the opportunity to meet one-on-one with a member of the research team at the end of each visit in order to discuss individual goals and progress. Pharmacotherapy therapy changes will be recommended to reduce or avoid use of medication which may contribute to weight gain and medications for weight loss will be prescribed as an individualized treatment strategy during one-on-one time with the pharmacist or physician if the patient can afford it and no contraindications exists.
9687525|NCT04866966|No Intervention|Control Group|The control group will have their measurements done at the beginning and end of the study. They will continue with usual medicare care during the study and will not receive any education from the investigators during the study. They will be offered the option of a delayed intervention after the completion of the study.
9687526|NCT04866615||50 patients newly diagnosed SLE with no treatment|OCT & OCTA for newly diagnosed SLE patients
9687527|NCT04866615||50 patients SLE on treatment by (HCQ) at doses of less than 6.5 mg/kg per day for less than 5 years|OCT & OCTA for on treatment SLE patients
9687528|NCT04866615||50 normal subjects as control group of similar age and gender|OCT & OCTA for normal subjects
9687529|NCT04866134|Experimental|Dose Escalation (Part A): ERAS-007 Monotherapy, BID-QW dosing|ERAS-007 monotherapy will be administered BID-QW in sequential ascending doses to participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
9687530|NCT04866134|Experimental|Dose Expansion (Part B): ERAS-007 Monotherapy, QW dosing|ERAS-007 monotherapy will be administered at 250 mg QW to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
9687531|NCT04866134|Experimental|Dose Expansion (Part C): ERAS-007 Monotherapy, BID-QW dosing (if necessary)|Depending on data generated from Part A, ERAS-007 monotherapy may be administered at the BID-QW RD to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
10180001|NCT03797456|Experimental|ICP-022|
9687532|NCT04866212||Children with Type 1 Diabetes Group|"Children with type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
9687533|NCT04866212||Children without Type 1 Diabetes Group|"Children without type 1 diabetes were evaluated in terms of their hand skills, visual motor integration, participation in daily life activities and academic success.~Hand skills were evaluated using the Jebsen Taylor Hand Function Test. Participation was evaluated with Participation and Environment Measurement-Children and Youth. Visual motor integration was evaluated with Beery-Buktenica Developmental Test of Visual Motor Integration. Academic success was evaluated with the course success score."
9687534|NCT04866225|Experimental|Study arm|One arm of healthy male participants administered a single oral dose of [14C]PF-06865571; followed by a single dose of unlabeled PF-06865571, and IV administration of [14C]PF-06865571 three hours later.
9687535|NCT04866069|Experimental|Low-Dose Group (Group A)|20 participants will receive 10 µg-3M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
9687536|NCT04866069|Experimental|High-Dose Group (Group B)|20 participants will receive 20 µg-6M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine
9687537|NCT04866069|Placebo Comparator|Placebo Group|10 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
10180002|NCT03797287|Experimental|Tensor Tunnler|The Tensor Tunneler (Chattanooga, TN) will be used to create the bone tunnels during the arthroscopic procedure. This is an FDA approved device and is used currently in routine clinical practice.
9687538|NCT04866277|Experimental|Intervention|"Women who present at least one of the four risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will be eligible to receive the intervention. The intervention will be the activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study. All pregnant women referred by the STOP LBW project would have access to consultations or other health activities, such as counselling and group meetings, within a maximum of seven days, in reference services available in each metropolitan area. The activation of the fast-track referral will be the responsibility of the doctor/nurse who applies the questionnaires to identify the risk factors. The intervention ends with childbirth, abortion or if the participant decides to abandon the study."
9687539|NCT04866277|No Intervention|Standard of care|Women who present at least one of the risk factors - smoking, risk alcohol consumption, risk of depression, physical violence - will receive the standard of care currently existing in each PHCU. The standard of care varies across the various PHCU and may include several approaches: routine screening with care by the antenatal care provider; routine screening with referral to other health professional in the same health unit; and routine screening with referral to other health services, with the time elapsed for consultation depending on the health resources available in each area. In each PHCU, different standards of care may exist for each of the four risk factors.
9687540|NCT04866407|Experimental|Mentha x piperita|A diluted solution of Mentha x piperita in carrier oil will be applied to the subject's interventional extremity.
9687541|NCT04866407|Experimental|Eucalyptus globulus|A diluted solution of Eucalyptus globulus in carrier oil will be applied to the subject's interventional extremity.
9687542|NCT04866407|No Intervention|No intervention|Each participant will have one extremity that receives no essential oil intervention.
9687543|NCT04866381|Experimental|SHR-6390|SHR-6390
9687544|NCT04866381|Experimental|SHR-6390 combined with Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
9687545|NCT04866381|Experimental|Camrelizumab (SHR-1210) combined with SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
9687546|NCT04866355|Experimental|Lumbar spine manipulation|Application of lumbar spine manipulation by a physical therapist.
9687547|NCT04866355|Active Comparator|Lumbar spine manipulation plus pharmacological therapy|Application of lumbar spine manipulation by a physical therapist along with pharmacological therapy.
9687548|NCT04866355|Active Comparator|Pharmacological therapy|Application of pharmacological therapy
9687549|NCT04866485|Experimental|HBM4003+pembrolizumab|HBM4003 combined with pembrolizumab in subjects with advanced NSCLC and other solid tumors
9687550|NCT04866108|Experimental|Experimental|Fruquintinib, 4mg/d, qd po, 2 weeks on, 1 week off; Capecitabine: 825mg/m2, bid po, 2 weeks on, 1 week off
9687551|NCT04866264|Active Comparator|Outpatient Group|"After signing the informed consent, outpatients will be invited for a clinical baseline visit at the Center on Aging and Mobility (CAM), where they will complete the dietary assessment with the eNutrition optimizer at the CAM guided by the study physicians, who will also interpret the immediate results and recommendations produced by the tool to the study participant.~For validating the eNutrition-Optimizer tool, participants will be asked to report their dietary intake in the past 24h during a 24-h diet recall phone call conducted by a trained interviewer on random days (weekday and weekend), so the participant cannot prepare or alter their habits. This 24h diet recall phone calls will be performed 4 times during the second half of the follow-up (month 4 to 6). In addition participants will complete the System Usability Scale at baseline and the subjective effectiveness questionnaire at month 6."
10180003|NCT03797287|Active Comparator|Smith and Nephew PEEK Helicoil Anchor|The anchors used in this trial are FDA approved and are used currently in routine clinical practice (Anchor Rotator Cuff Repair).
10180004|NCT03797534|No Intervention|Standard anticoagulant group|
10180005|NCT03797534|Experimental|Bayesian model group|
10180006|NCT03797508|Other|threatened miscarriage|ultrasound ,CA125,progesterone
10180007|NCT03797417||Disease|patients with vitiligo
10180008|NCT03797417||Healthy Control|healthy control
10180009|NCT03797339||Discovery cohort|1000 cases of coronary heart disease follow-up cohort was used for multi-omics target discovery.During the follow-up period, the information about the occurrence and risk factors of adverse cardiovascular events will be collected.
10187478|NCT03725917|No Intervention|Control Group|The control group will not receive physiotherapy treatment.
10187479|NCT03725904|Experimental|IVF/FET|
10180010|NCT03797339||Validation corhort|3000 coronary heart disease follow-up cohorts was used for validating the results from the discovery corhort. During the follow-up period, the occurrence and risk factors of adverse cardiovascular events.Predictive mathematical models based on multi-omics combination will be constructed finally.
10180011|NCT03797300|Experimental|Primary|
9687552|NCT04866264|Active Comparator|Inpatient Group|After signing the informed consent, inpatients (Senior trauma center/heart surgery) will do the dietary assessment with the eNutrition optimizer with supervision of a trained study physician to assess user feasibility in the inpatient setting. In addition they will have a follow-up phone call at month 3 to 6 to assess the subjective effectiveness of the eNO.
9687553|NCT04866238|Active Comparator|Vestibular fixed appliances|Adult patients in this group will be treated using fixed appliances.
9687554|NCT04866238|Experimental|Clear aligners|Adult patients in this group will be treated using clear aligners.
9687555|NCT04866368|Active Comparator|The erector spinae plane block|The ultrasound-guided Erector spinae plane block (ESPB) with 1 ml/kg 0,25 % bupivacaine at the lumbar vertebral level will perform before surgery to all patients in the ESPB group.
9687556|NCT04866368|Active Comparator|The penile block|The penile block with 0,5ml/kg 0,25 % bupivacaine will be performed after the patients give standard general anesthesia and a laryngeal mask is applied.
9687557|NCT04866121|No Intervention|Standard Treatment|Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
9687558|NCT04866121|Active Comparator|Single point (P6) Acupuncture|"Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol to the P6 point bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards.~Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia."
9687559|NCT04866121|Experimental|Double point (P6+ST36) Acupuncture|Prior to the anesthesia induction, the same certified medical doctor will perform a standard acupuncture protocol both to the P6 and ST36 points bilaterally. For P6 acupuncture stimulation 0,25x25mm steel needles will be immersed for 2cm. For ST6 acupuncture stimulation 0,25x50mm steel needles will be immersed for 5cm. For stimulation, the needles will be turned clock-wise 3 times. This stimulation will be repeated for 3 times with 10 seconds intervals. The needles will be held in place for 20 minutes and will be removed afterwards. Following 8 hours fasting, standard anesthesia protocol, 3 mg kg-1 Propofol, 0.6 mg kg-1 rocuronium and 2 µg kg-1 fentanyl will be administered. Laparoscopic cholecystectomy will be performed. Twenty minutes prior to the completion of the operation tramadol 100mg will be administered for analgesia.
9687560|NCT04866251|Active Comparator|Healthy young subject|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
9687561|NCT04866251|Active Comparator|Healthy older subjects|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
9687562|NCT04866251|Active Comparator|Acute stroke patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
9687563|NCT04866251|Active Comparator|Patients with Parkinson´s Disease|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
9687564|NCT04866251|Active Comparator|Patients with Multiple Sclerosis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
9687565|NCT04866251|Active Comparator|Patients with Myasthenia gravis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
9687566|NCT04866251|Active Comparator|Geriatric patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
9687567|NCT04866056|Experimental|Treatment(Jaktinib+Azacitidine)|Patients receive azacitidine subcutaneously (SC) on days 1-7 and Jaktinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9687568|NCT04866030||NostraData Database|All prescriptions for Intuniv available in the NostraData database in Austrialia will be analyzed in this study.
9687569|NCT04866030||Physician Survey|Physician will collect medical record data of 100 participants who have been prescribed Intuniv at least once during the study period to treat participants with ADHD.
9687570|NCT04865900||Covid19 Vaccinated Patients|Patients who are planning to receive Pfizer-BioNTech BNT162b2 vaccines against Covid19
9687571|NCT04865718||neurovascular surgery group|Subjects undergoing neurovascular surgery including aneurysm clipping
10180012|NCT03797118|Experimental|FFRct|Patients will receive cCTA, ICA, FFRct, and FFRinv per protocol.
10180013|NCT03797352|No Intervention|Control|Receive healthy ageing advice every 3 months for the duration of 12 months
10180014|NCT03797352|Experimental|Intervention|To participate in supervised Multicomponent exercise (combined exercise and cognitive activity) up to three times a week for 6 months and receive healthy ageing advice
10187480|NCT03725891|Active Comparator|Aspirin 162 mg|Aspirin 81mg tow tablet once a day from recruitment until 37 weeks or labor whichever comes first
9687572|NCT04865848|Experimental|Mandibular infiltration dental anesthesia with Articaine|"Step-by-step:~Reflect tissue to expose injection site.~Orient bevel of the needle to be parallel to the bone and insert needle into mucobuccal fold~Proceed to the depth that approximates the apices of the buccal roots of the primary molars.~Aspirate.~Deposit bolus of local anesthetic slowly at a rate of 1 ml/min.~Remove needle.~A subsequent lingual infiltration is delivered.~The armamentarium includes: 4% articaine HCl with 1:100,000 epinephrine (Septocaine ®, Septodont, Lancaster, Penn. USA) in 1.7 ml cartridges and 30-gauge short needle manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
9687573|NCT04865848|Active Comparator|Inferior Alveolar Nerve Block with Lidocaine|"Step-by-step:~Dry injection site with gauze.~The barrel of the syringe should be directed on a plane between the two primary molars on the opposite side of the arch. It is advisable to inject a small amount of the solution as soon as the tissue is penetrated and to continue to inject minute quantities as the needle is directed toward the mandibular foramen.~Insert to the depth that is adjacent to bone.~Aspirate.~Slowly inject bolus of anesthetic at a rate of 1 ml/min.~Remove needle.~The armamentarium includes 2% lidocaine HCl with 1:100,000 epinephrine (Henry Schein ® Lidocaine, Novocol, Cambridge, Ontario, Canada) in 1.7 ml cartridges, as well as 27-gauge long needles manufactured by Henry Schein® (Melville, N.Y., USA). All injections are given using a self-aspirating syringe (A-Titan, Orchard Park, N.Y., USA)."
10180015|NCT03797365|Active Comparator|Classical rehabilitation|Twenty women will benefit from two-phases perineal rehabilitation: first phase pelvic floor muscles (PFM)'s analytic rehabilitation, then a functional rehabilitation.
10180016|NCT03797365|Experimental|Classical and cognitive associated rehabilitation|Twenty women will receive, added to the classic perineal rehabilitation, the cognitive rehabilitation and will have to execute twice a day the rehabilitation protocol.
10180017|NCT03797040|Experimental|4 million PLX-R18 cells/kg-up to a maximal dose of 400 million|
10180018|NCT03797053||Cohort 1 : metastatic cohort|Cohort1: Cohort of patients with stage III inoperable or IV metastatic melanoma This cohort will enable the achievement of objectives 1 (proof of concept) and 2 (establishment of prognostic and predictive value).
9687574|NCT04865965|Experimental|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
9687575|NCT04865965|No Intervention|No Exercise|No Exercise Session
9687576|NCT04866316||GSH Participants|"Qualitative - Semi-structured focus group discussions with care recipients~Quantitative - Pre-test post-test design using survey-based data collection~Quantitative - Retrospective cohort design with propensity score matched comparators"
9687577|NCT04866316||Policy owners, implementers & care partners, health and social care professionals|"Qualitative - Semi-structured in-depth interview with key policy and programme decision-makers~Qualitative - Semi-structured focus group discussions with health and social care professionals~Qualitative - Participant observations~Quantitative - Longitudinal monitoring of process indicators"
9687578|NCT04865952|Experimental|intra-surgical HA application (treatment group - HA)|periodontal surgery + intra-surgical HA application + buccal attached gingival (G) biopsies 24 hr after surgical procedure
9687579|NCT04865952|Other|NO intra-surgical HA application (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
9687580|NCT04865757|Experimental|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
10180019|NCT03797053||Cohort 2 : adjuvant cohort|"Cohort 2: Cohort of patients with melanoma who are candidates for sentinel lymph node analysis.~This group includes patients with melanoma in whom sentinel lymph node testing is performed. According to current French recommendations, these are patients whose primary melanoma has a Breslow index (thickness) of more than 1 mm or ulcerated primary melanoma (loss of the epidermis)."
10180020|NCT03797248||Cohort 1|adjuvant chemotherapy combined with Chinese herbal medicine
9687583|NCT04865705|Experimental|Tilelizumab+Albumin Paclitaxel + Carboplatin/Cisplatin|Tilelizumab 200mg d1 Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1IV,Q3W *2cycles
9687584|NCT04865744|Active Comparator|Oral semaglutide 7 mg|The semaglutide 7 mg tablet taken orally with 120 ml of water.
9687585|NCT04865744|Placebo Comparator|Placebo|The placebo tablet taken orally with 120 ml of water.
9687586|NCT04865991|Experimental|TCI propofol group|Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
9687587|NCT04865991|Active Comparator|sevoflurane group|Subjects in the sevoflurane group received sevoflurane 2 volume%, which were titrated up/down every 5 minutes to get a targeted BIS score of 40-60.
9687588|NCT04865822|Experimental|Pain Education|Participant will attend a single session pain education course
9687589|NCT04865822|No Intervention|wait list control|Participants will be wait listed then receive intervention
9687590|NCT04865666|Experimental|movr App Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior for the 8-week intervention period and to avoid any specialized exercise training for that time period, but they were also asked to use the movr app to supplement their current activity.
9687591|NCT04865666|No Intervention|Waitlist Control Group|Participants were instructed to maintain their usual physical activity, diet, and sleep behavior over the 8-week study period and to avoid any specialized exercise training for that time period. Following the 8-week study period, individuals in the control group were permitted to download and use the movr app if they chose to.
10180021|NCT03797248||Cohort 2|adjuvant chemotherapy only
10180022|NCT03797131|Experimental|KB195 Arm|
10180023|NCT03797079|Active Comparator|Group A (ESP block)|Ultrasound-guided ESP block will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
10180024|NCT03797079|Active Comparator|Group B (TEA)|TEA will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
10180025|NCT03797105|No Intervention|Control, 0 days|control group, no intervention
10180026|NCT03797105|Experimental|1 day|received the intervention 1 day/week
10180027|NCT03797105|Experimental|3 days|received the intervention 3 days/week
10180028|NCT03797105|Experimental|5 days|received the intervention 5 days/week
10180029|NCT03797092|Active Comparator|Active|Allogeneic adipose-derived stromal cells (CSCC_ASC)
9687592|NCT04865692|Experimental|Interventional group|The interventional group received resisted knee extension 20% of 1RM with blood flow restriction along with routine physical therapy.
9687593|NCT04865692|Other|Control Group|The Control group received routine physical therapy alone including knee isometrics and resisted knee extension
9687594|NCT04865640||Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
9687595|NCT04865640||Pathologic Cohort|The target population for this cohort is adult patients who have been diagnosed with cardiopulmonary conditions. These can include chronic pulmonary conditions, chronic cardiac conditions, and those who are taking diuretic medications, living with heart failure, Chronic Obstructive Pulmonary Disorder (COPD), or recovering from coronary-artery disease-related events. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders as well as conditions outlined above (e.g. at least 5 each of COPD, HF, recovering from a coronary artery disease-related event, and taking diuretic medication)
9687596|NCT04865484|Experimental|SRES group|Surgical resection plus endoscopic stricturotomy for multiple fibrous stenosis
9687597|NCT04865484|Active Comparator|SRS group|Surgical resection plus strictureplasty for multiple fibrous stenosis
9687598|NCT04865523|Experimental|Manual Lymphatic Drainage|
9687599|NCT04865523|No Intervention|No intervention|
9687600|NCT04865549|Experimental|TAD arm|Sentinel Node Biopsy + Targetted Axillary Dissection (Clipped cN1 node) extraction + lymphadenectomy.
9687601|NCT04865510|Active Comparator|Citrate|The RCA group CRRT were performed with Prisma flex or (Baxter Healthcare/Gambro Spain) or Informed machine with citrate pump. The function mode was continuous venovenous hemodiafiltration (CVVHDF) in postdilution mode with ST 150 filter sets. The substitution fluid was Accusol or Prismocal B22 .The dose of dialysis was 20-25 ml/kg/hr with blood flow 150-200 ml/min. Trisodium citrate solution (4%,136mmol/L) was infused into the arterial line prior to the blood pump at a dose of 4 mmol/L of plasma flow. Calcium chloride (5% 340 mmol/L elemental calcium) was infused into the venous return to maintain systemic ionized calcium in the normal range (0.99-1.30 mmol/L) and the targets values for ionized calcium (iCa2+) after the dialysis membrane were 0.25-0.35 mmol/L. The rale of calcium infusion was adjusted in a timely manner based on repeated measurements of calcium concentration
9687602|NCT04865510|Placebo Comparator|Heparin-free|The heparin- free group The circuit was periodically flushed with 50 ml saline via access limb every 30 minutes .When pre-filter pressure started to rise, additional saline flushes would be given.
9687603|NCT04865575||controlled asthmatics|moderate-to-severe asthmatic children with good asthma control
9687604|NCT04865575||uncontrolled asthmatics|moderate-to-severe asthmatic children with poor asthma control / recurrent exacerbations
9687605|NCT04865627||independent walking with walking aid|the participant is able to walk with a walking aid and does not need further assistance.
9687606|NCT04865627||dependent walking with walking aid|the participant is able to walk with assistance and a walking aid
9687607|NCT04865211|Experimental|Liposomal Bupivicaine|Administration of a combination of lioposomal bupivicane 20ml/266mg mixed with 20mL of 0.375% bupivicaine
9687608|NCT04865211|Active Comparator|Bupivicane|Administration of 40 ml of 0.375% Bupivicaine with epinephrine 1:400,000
9687609|NCT04865211|Placebo Comparator|Placebo|Saline injection with 40mL preservative-free saline
9687610|NCT04865198||Patients with Autism Spectrum Disorder (ASD)|Patients diagnosed with ASD in a child psychiatry clinic.
9687611|NCT04865198||Patients with High Functioning Autism (HFA)|Patients diagnosed with ASD in a child psychiatry clinic and with an IQ above 70.
9687612|NCT04865198||Healty control|Healthy volunteers who are in the age range compatible with the patient groups.
9687613|NCT04865120|Active Comparator|merocyanine|
9687614|NCT04865120|Placebo Comparator|placebo|
9687615|NCT04865445|Experimental|AT-527 550 mg + midazolam (simultaneous)|n=12
9687616|NCT04865445|Experimental|AT-527 mg + midazolam (staggered)|n=12
9687617|NCT04865471|Experimental|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
9687618|NCT04865458|Experimental|HEC89736 treatment|HEC89736 tablets,25 mg, 50 mg, 100 mg, 150 mg, 200 mg, QD, 28 days for each cycle
9687619|NCT04865250|Experimental|treatment|ATEZOLIZUMAB; Carboplatin; Nab-Paclitaxel
9687620|NCT04865354|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9687621|NCT04865354|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9687622|NCT04865328||OAB group|Group with diagnosed overactive bladder.
9687623|NCT04865315||Low grade glioma patients|Patients who have a MRI lesion suspected for a low grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
9687624|NCT04865315||High grade glioma patients|Patients who have a MRI lesion suspected for a high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
9687625|NCT04865562|Experimental|testosterone|7mg testosterone propionate
9687626|NCT04865562|Placebo Comparator|placebo|125 mg 0.5% cholorbutanol, 50mg saline, pH5
9687627|NCT04865380|No Intervention|No Tranexamic Acid|The anesthesiologist will not administer Tranexamic Acid at any point.
9687628|NCT04865380|Experimental|Intravenous Tranexamic Acid|1g of Tranexamic Acid will be administered intravenously prior to the start of the operation.
9687629|NCT04865146||TRIGEN™ INTERTAN™|Confirmed femoral fracture subjects who are scheduled for repair using INTERTAN 10S Nail
9687630|NCT04865185|Active Comparator|Xylocaine spray 100mg/ml|Topical application
10180030|NCT03797092|No Intervention|Control group|No treatment
10180031|NCT03797027|Other|No cushion|Patients in no cushion group undergo prone percutaneous nephrolithotomy without an abdominal cushion
10188009|NCT03720418|Experimental|OXB-102 Dose Level 3|OXB-102 Dose Level 3 Single Administration (Part A: open-label)
9687631|NCT04865185|Placebo Comparator|Ethanol|Topical application
9687632|NCT04865159|Other|Single Group Assignment|Single Arm - Drug administered on Days 1-7 and Days 15-21 of a 28-day treatment cycle. Series of Pharmacokinetics and ECGs will be done during cycle 1.
9687633|NCT04865107|Experimental|MSCs Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
9687634|NCT04865107|Placebo Comparator|Placebo Arm|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
9687635|NCT04865094|Active Comparator|cyclic merocyanine|long-UVA absorber
9687636|NCT04865094|Placebo Comparator|placebo|
9687637|NCT04865068|Experimental|African migrant's population located in la region New Aquitaine.|Echocardiography norms will be harvested data on SSA participants located in la region New Aquitaine, France
9687638|NCT04865081|Experimental|VACCIN box group|The anesthesiologist will intubate the participants in the VACCIN box group while using the VACCIN box that will be placed over the participants' head.
10180032|NCT03797027|Other|5 cm cushion|Patients in 5 cm cushion group undergo prone percutaneous nephrolithotomy with an 5 cm abdominal cushion
10180033|NCT03797027|Other|10 cm cushion|Patients in 10 cm cushion group undergo prone percutaneous nephrolithotomy with an 10 cm abdominal cushion
9687639|NCT04865081|No Intervention|Control group|Enrolled participants in the control group will be intubated without the use of the VACCIN intubation box (standard anesthesia).
9687640|NCT04865172||Patient-caregiver dyads, patients with behavioural variant frontotemporal dementia|20 patient-caregiver dyads, patients with behavioural variant frontotemporal dementia
9687641|NCT04865172||Patient-caregiver dyads, patients with Alzheimer disease|20 patient-caregiver dyads, patients with Alzheimer disease
9687642|NCT04865172||Healthy control dyads|20 healthy control dyads
9687643|NCT04865341|Experimental|IMB|Individuals randomized to this arm will receive a behavioral intervention based on the Information-Motivation-Behavior (IMB) model designed to increase HIV self-testing, among other protective behaviors.
9687644|NCT04865341|No Intervention|No Intervention|Individuals randomized to this arm will receive no intervention.
9687645|NCT04865003||DNI group|patients with infection of two or more deep neck spaces (DNI group)
9687646|NCT04865003||DNI + DNM group|patients with infection of two or more deep neck spaces with secondary descending necrotizing mediastinitis (DNI + DNM group)
9687647|NCT04864977|Experimental|LY2963016|Participants with type 2 diabetes will be started on insulin glargine and dose will be titrated. Insulin glargine will be delivered via insulin pen each evening subcutaneously (SC). They will also check fasting blood glucose values on a study meter and prior to treating hypoglycemia. Participants will be asked to report the time and dose of their last administration.
9687648|NCT04864938||Patients: ICU treated covid-19 patients|Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
9687649|NCT04864938||Control group 1, covid-19 patients treated in the regular wards|As above, without 6 minute walk test or routine chest x-ray
9687650|NCT04864938||Control group 2, persons with covid-19 without hospitalization|As above, but without respiratory testing
9687651|NCT04864938||Control group 3, non-covid controls|As control group 2
9687652|NCT04864769|Experimental|Krill Protein Hydrolysate|Krill Protein Hydrolysate
10180034|NCT03796936|Experimental|3MDR With Eye Movement Component (EM+)|All participants will complete 10 treatment sessions (3 preparatory, 6 3MDR and 1 concluding), led by a trained therapist, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component. For those in the EM+ intervention group, the EM component starts after the participant has thoroughly discussed a picture with the therapist; a red ball starts at one edge of the screen, moves rapidly back and forth across it, and upon reaching either edge, a 2-digit number appears superimposed in white on the ball. The number changes every time the ball meets either edge. The participant is asked to track the ball and call out the displayed numbers.
10180035|NCT03796936|Active Comparator|3MDR Without Eye Movement Component (EM-)|All participants will complete 10 treatment sessions (three preparatory sessions, six 3MDR sessions and one concluding session; see Table 1), led by a therapist who has been completed training in the conduct of this form of therapy, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component.There will be no exposure to the distractor stimulus (red ball) for those in the EM- intervention group.
10180036|NCT03797443|Experimental|AA NABPLAGEM|Ascorbic Acid Paclitaxel protein-bound cisplatin gemcitabine
9687653|NCT04864769|Active Comparator|Soy protein isolate|Soy Protein isolate
9687654|NCT04864769|Active Comparator|Whey protein isolate|Whey protein isolate
9687655|NCT04864769|Sham Comparator|Control|Water
9687656|NCT04864795||Single Cohort|Patient data will be collected from patient records and/or during a routine clinical visit. This will include treatments prescribed, routine assessments and measurements collected at routine clinical visits, as well as hospitalisations and other relevant patient data.
9687657|NCT04864860|Experimental|intervention arm|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). This dose was selected to be similar to previous studies that shows no harm or sever adverse effect on participants (12, 14)."
9687658|NCT04864860|Placebo Comparator|placebo arm|"The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
9687659|NCT04864782|Experimental|Cohort A|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6)
10180037|NCT03796884|Experimental|Arm I (linaclotide)|Patients receive linaclotide PO daily on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
10180038|NCT03796884|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
9687660|NCT04864782|Experimental|Cohort B-arm1|On Day 1 of each 21-day cycle, participants receive an IV infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)
9687661|NCT04864782|Experimental|Cohort B-arm2|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)
9687662|NCT04864821|Other|T cell injection targeting CD276 chimeric antigen receptor|
9687663|NCT04864951|Other|Transpeople|"1x urine sampling for HPV analysis~1x survey"
9687664|NCT04864873|Active Comparator|Standard diagnostic pathway|Part of each patient sample will be tested using current standard microbiological techniques.
9687665|NCT04864873|Experimental|mNGS pathway|Part of each sample will be testing using mNGS methodology, which will be compared to the standard diagnostic pathway.
9687666|NCT04864704|Active Comparator|Infraspinatus|Subjects infraspinatus stiffness was measured and observed
9687667|NCT04864704|Active Comparator|Erector spinae|Subjects erector spinae stiffness was measured and observed
9687668|NCT04864704|Active Comparator|Gastrocnemius|Subjects gastrocnemius stiffness was measured and observed
9687669|NCT04864652|Experimental|Single Arm|CHILLS Procedure
9696044|NCT04771390|Experimental|Part 1: Group A|Participants will receive 3 single doses of selitrectinib in adult tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
9696045|NCT04771390|Experimental|Part 1: Group B|Participants will receive 3 single doses of selitrectinib in pediatric tablet formulation sequentially in 3 treatment periods. The washing-out period between each dose is at least 3 days
9696046|NCT04771390|Experimental|Part 2 (Group A): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
9696047|NCT04771390|Experimental|Part 2 (Group A): Dose B-C-A-D|Participants will receive dose B, C, A and D sequentially. The washing-out period between each dose is at least 3 days
9696048|NCT04771390|Experimental|Part 2 (Group A): Dose C-A-B-D|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
9696049|NCT04771390|Experimental|Part 2 (Group B): Dose A-B-C-D|Participants will receive dose A, B, C and D sequentially. The washing-out period between each dose is at least 3 days
9696050|NCT04771390|Experimental|Part 2 (Group B): Dose B-D-A-C|Participants will receive dose B, D, A and C sequentially. The washing-out period between each dose is at least 3 days
9696051|NCT04771390|Experimental|Part 2 (Group B): Dose C-A-D-B|Participants will receive dose C, A, B and D sequentially. The washing-out period between each dose is at least 3 days
9696052|NCT04771390|Experimental|Part 2 (Group B): Dose D-C-B-A|Participants will receive dose D, C, B and A sequentially. The washing-out period between each dose is at least 3 days
9696053|NCT04771468||Sovratentorial ischemic stroke|
9696054|NCT04771247|Experimental|CLEAR|Patients with GERD post LSG will undergo CLEAR (cardia band ligation).
9696055|NCT04771195||Class of 2023|Stanford undergraduate students who are expected to graduate in Spring of 2023
9696056|NCT04771195||Class of 2024|Stanford undergraduate students who are expected to graduate in Spring of 2024
9696057|NCT04771325|Other|Arm 1|Women are normally escorted to the health facilities by one or more family members and or friends. Women usually labor in an open first stage room where more than one woman is admitted sometimes with curtains to separate the beds with one person allowed besides her to provide support. The support persons do not have designated roles to play during this process. Routine analgesia is not given neither is continuous fetal monitoring. Midwives,
9696058|NCT04771325|Experimental|Arm 2|One session of training on admission in labor. The training will focus on emotional and physical support; emotional support including being Present, demonstrating a caring and positive attitude, saying calming verbal expressions, using humor, praise, encouraging and acknowledging efforts during the process of pushing the baby. Physical support including supporting her to change position favoring upright positions, walking with her, giving her drinks and food, massage, reminding her to go and pass urine, helping her find a comfortable position for pushing, wipe her face with cool cloth and help her breast feed
9696059|NCT04771286|Experimental|BI 1015550 (C-14)|
10180039|NCT03796845|Experimental|No-limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
9696060|NCT04771091|Experimental|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist.
9696061|NCT04771494|Experimental|Trained|Participants with at least 6 months of training with unstable devices
9696062|NCT04771494|Experimental|Untrained|Participants with no previous instability experience
9696063|NCT04771104|Active Comparator|Allocated to intervention at first experimental day|
9696064|NCT04771104|Placebo Comparator|Allocated to intervention at second experimental day|
9696065|NCT04771312|Active Comparator|Information-only intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the information-only condition could respond to daily questions in a diary.
9696066|NCT04771312|Experimental|Social support network intervention|Participants are randomly assigned to 6-person peer networks in a mobile app. Participants in the social support condition could use an online chatting tool where they can send messages to their own network.
10180040|NCT03796845|Active Comparator|Limited movement after surgery|Participants should move their arms with restricted movements on the first postoperative day, with maximum amplitude of 90º for flexion and abduction of the shoulder, until withdrawal surgical points. Actual hospital's routine.
10180041|NCT03796754|Active Comparator|YoBEKA Intervention|
10180042|NCT03796754|No Intervention|Control group|
10180043|NCT03797222|Experimental|Vitamin E Supplementation|Daily oral supplementation with Vitamin E (alpha-tocopherol) for 2 weeks.
10180044|NCT03796702|Experimental|Early closure of preventive ileostomy|A preventive ileostomy is closed 30 days after the primary surgery
10180045|NCT03796702|Experimental|Late closure of preventive ileostomy|A preventive ileostomy is closed 90 days after the primary surgery
10180046|NCT03796780|Active Comparator|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks
10180047|NCT03796780|Placebo Comparator|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil for 6 weeks
10180048|NCT03796975|Experimental|Combination of Pioglitazone and Metformin Tablets|dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
9687670|NCT04864717|Active Comparator|Doxycycline|Doxycycline 100mg po once daily x 6 months
9687671|NCT04864717|Active Comparator|Isotretinoin|Isotretinoin 40mg po once daily x 6 months
9687672|NCT04864691|Experimental|endovascular recanalization plus standard medical treatment|patients with symptomatic non-acute intracranial artery occlusion treated by endovascular recanalization and standard medical treatment after procedure
9687673|NCT04864691|Active Comparator|standard medical treatment|Patients take aspirin 100 mg/day or clopidogrel 75mg/day for the entire follow-up period (EVR patients take aspirin 100 mg/day and clopidogrel 75mg/day for 30-90 days after procedure)
9687674|NCT04865055|Active Comparator|cyclic merocyanine|cyclic merocyanine long-UVA absorber
9687675|NCT04865055|Placebo Comparator|placebo|
9687676|NCT04864808|Experimental|Behavioral Parenting Training|
9687677|NCT04864756|Experimental|Before/After|Grade performance before and after introduction of simulation based learning
9687678|NCT04864730||CT scans|No intervention Data of voxels will be integrated to the final model
9687679|NCT04865029|Experimental|Treatment Arm|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission and Progesterone 200mg by mouth daily for 5 days starting at admission.
9826768|NCT02431806|Experimental|Levomilnacipran 40 mg|Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
10180049|NCT03796975|Active Comparator|Metformin Hydrochloride Tablets|dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
10180050|NCT03797001|Experimental|anakinra|Anakinra subcutaneous injection, 100 mg daily for 24 weeks
10180051|NCT03797001|Placebo Comparator|placebo|Placebo subcutaneous injection, daily for 24 weeks
9687680|NCT04865029|Other|Control Arm|"Standard of Care along with placebo injection and placebo pill~Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines"
9687681|NCT04864600|Active Comparator|Standard Stearin Candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
9687682|NCT04864600|Experimental|Modified low emission candle|Several candles will be lit. We will be using realistic burning cycles i.e. burning candles which extinguish and new ones being lit.
9687683|NCT04864600|No Intervention|Clean Air|No candles in the chamber.
9687684|NCT04865016|Active Comparator|MIOL Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with a low add (+2.75 Diopters [D]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group).
9687685|NCT04865016|Active Comparator|EDOF Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with an EDOF (Tecnis Symfony [ZXR00]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
9687686|NCT04864587||Restorative colectomy with ileoanal pouch|Patients with restorative colectomy with ileoanal pouch who receive pouchoscopy for detection of pouchitis or neoplasm
9687687|NCT04864899|Experimental|Recovered COVID-19 patients|
9687688|NCT04864899|Experimental|Recovered non-COVID-19 viral respiratory infections patients|
9687689|NCT04864899|Experimental|Age and gender matched controls|
9687690|NCT04864574|Experimental|Group 1 - Intervention|Participating children have daily access to the fruit and vegetable garden beginning Year 1.
9687691|NCT04864574|Experimental|Group 2 - Wait-list control (delayed intervention)|Participating children have daily access to the fruit and vegetable garden beginning Year 2.
9687692|NCT04864574|No Intervention|Group 3 - Control|No intervention
9687693|NCT04864327|No Intervention|control|Usual care
9687694|NCT04864327|Other|intervention|5 minutes brief smoking cessation advise
9687695|NCT04864379|Experimental|RFA+PD-1+iNeo-Vac-P01|Patients will undergo radiofrequency ablation. At Week 3, patients will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks. At Week 12,all patients,regardless of their disease status,iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
9687696|NCT04864379|Experimental|RFA+iNeo-Vac-P01+PD-1|Patients will undergo radiofrequency ablation. At Week 12, patients will receive iNeo-Vac-P01(300mcg per peptide)+ GM-CSF (40mcg) on days 1, 4, 8, 15, 22, 52, and 82 from week 12. Additional booster vaccines might be administered depending on ethics and patients' potential benefit. At Week 16, patients,regard of their disease status,will receive PD-1 at a dose of 200mg administered by intravenous infusion (IV) every 2 weeks.
9687697|NCT04864431|Active Comparator|Vitamin D group|Daily vitamin D3 2000 IU on day 1 through day 180 Intervention: vitamin D3 2000 IU
9827596|NCT02461628|Experimental|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
10180052|NCT03796871|Experimental|Dermapol|Use of the experimental medical device
9687698|NCT04864431|Placebo Comparator|Control group|Daily placebo (saccharum lactis) on day 1 through day 180 Intervention: placebo
9687699|NCT04864522|Experimental|SLAMF7 BATs|Participants will undergo apheresis to collect cells to make SLAMF7 BATs. These cells will be allowed to grow in the lab and a drug will be added to them to make them activated against multiple myeloma. About 4 weeks after apheresis, participants will start receiving SLAMF7 BATs. Throughout treatment, participants will have blood taken for labs, to check disease status and also to look at immune response. Study treatment will stop if the participant has disease progression.
9687700|NCT04864210|Experimental|Liposomal bupivacaine|The patient will receive an intercostal nerve block by the surgeon in the operating room after anesthetic has been administered. The surgeon will use thoracoscopic guidance to administer the intercostal nerve block. The medication used in this block will liposomal bupivacaine (Exparel).
9687701|NCT04864210|Active Comparator|Bupivacaine|The patient will receive a paravertebral block by the anesthesiologist staffing the pain service area within the hospital prior to surgery. This regional anesthesia will be done using ultrasound guidance. The medication used in this block will be plain bupivacaine with epinephrine.
9687702|NCT04864457||Normal|Patients without coronary atherosclerotic burden
10180053|NCT03797235|Experimental|Dominant Arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the dominant forearm
10180054|NCT03797235|Active Comparator|Non-dominant arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the non-dominant forearm.
9687703|NCT04864457||Chronic coronary syndrome (CCS)|"CCS covers the different stages of development of coronary heart disease in addition to the clinical manifestations dominated by acute coronary thrombosis, including asymptomatic myocardial ischemia, vasospasm, and microcirculatory lesions. The six most common types of CCS include:Suspected coronary heart disease and stable angina symptoms, whether or not patients with dyspnea; Patients with newly emerged heart failure or left ventricular dysfunction suspected of CAD; Patients with no symptoms or stable symptoms within 1 year after ACS, or patients with recent revascularisation; Patients with or without symptoms more than 1 year after initial diagnosis or revascularization; Patients with angina pectoris, suspected vasospasm or microcirculatory diseases; Asymptomatic patients with coronary heart disease are found during screening."
9687704|NCT04864457||Acute coronary syndrome (ACS)|ACS is a group of clinical syndromes commonly characterized by acute myocardial ischemia, including unstable angina pectoris (UA); Acute non-ST-segment elevation myocardial infarction (NSTEMI); Acute ST-segment elevation myocardial infarction (STEMI).
9687705|NCT04864236|Experimental|Intervention group|This group will undergo airway management in the operating room as part of the anesthesia for surgery in the presence of the novel isolation device.
10180055|NCT03796923|Active Comparator|Intervention I|Intervention (I): early follow-up visit from the community nurse within 24 hours after discharge
10180056|NCT03796923|Experimental|Intervention II|Intervention (II): early follow-up by the geriatric team within 24 hours after discharge
10180057|NCT03796923|Other|Control|Usual care: individualized follow-up performed by the GP and municipality services
10180058|NCT03796910|Experimental|SPR720 for SAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
10180059|NCT03796910|Placebo Comparator|Placebo for SAD|2 out of 8 subjects per cohort will be randomized to receive placebo
10180060|NCT03796910|Experimental|SPR720 for MAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
9687706|NCT04864236|No Intervention|Control group|
9687707|NCT04864314|Placebo Comparator|Control group|Group supplemented with a daily dose of placebo
9687708|NCT04864314|Experimental|Experimental group|Group supplemented with a daily dose of TetraSOD®
9687709|NCT04864366||Treatment naive patients|"HBV DNA> 20000 IU/ml~ALT>2×ULN；or ALT>1×ULN，but liver biopsy showed inflammation greater than or equal to G2, or/and liver fibrosis greater than or equal to S2~No treatment with NA or/or αIFN within 1 year"
9687710|NCT04864366||ETV treatment experienced patients|"ETV treatment for 1 to 2 years before~HBsAg>5000IU/mL~HBV DNA<20IU/mL~ALT<1×ULN~No other NA therapy prior to entecavir treatment~Patients had a desire to convert to TAF therapy"
9687711|NCT04864340|Experimental|threshold stimulation (tetanic)|
9687712|NCT04864340|Experimental|upper threshold stimulation (tetanic)|
9687713|NCT04864340|Experimental|threshold stimulation (pressure)|
9687714|NCT04864340|Experimental|upper threshold stimulation (pressure)|
9687715|NCT04864340|Placebo Comparator|non nociceptive procedure (fine touch)|
9687716|NCT04864444|Experimental|MDA with DHA-PPQ + SLD-PQ|Participants in intervention villages will be given three rounds of MDA with DHA-PPQ and SLD-PQ. Prior to the intervention, participants will have received piperonyl butoxide (PBO) treated LLINs and proactive community case management. Unlike control villages, MDA-randomized villages will not receive SMC.
9687717|NCT04864444|No Intervention|Standard malaria control interventions|Participants in the control villages will receive standard malaria control interventions as implemented by the Senegal PNLP. This will include the distribution of PBO LLINs, proactive case management, and SMC.
9687718|NCT04864197|Experimental|prf group|prf membrane placement over implant site for gingival thickening
9687719|NCT04864197|Experimental|control group|no prf placement
9687720|NCT04864067|Experimental|Short Course Radiotherapy and Consolidation Chemotherapy|This arm will receive short course radiotherapy (5x5 Gy) during 1 week. Between 7 to 14 days after radiotherapy, patient will receive 9 cycles of FOLFOX. CapeOX may be given as alternative for FOLFOX.
10180061|NCT03796910|Placebo Comparator|Placebo for MAD|2 out of 8 subjects per cohort will be randomized to receive placebo
10180062|NCT03796793|Experimental|Wound Edge Debridement Group|Participants in this group will receive wound edge debridement in addition to standard of care (SOC) treatment for up to 4 weeks.
10180063|NCT03796793|Active Comparator|Standard care group|Participants in this group will receive only the standard care of treatment for up to 4 weeks.
10180064|NCT03796715||Red Cell Distribution Width (RDW)|RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer
10180065|NCT03796715||Presepsin (sCD14-ST)|Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)
10180066|NCT03796624|Experimental|Investigational Device Micropure 1.2.3.|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. in one of the eyes of the study subject"
10180067|NCT03796624|Active Comparator|Comparator PODEYE|"Implantation of monofocal intraocular lens (IOL) PODEYE in the contralateral eye of the study subject"
10180068|NCT03796572|Experimental|Infraclavicular Regional Block|This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
10180069|NCT03796572|Sham Comparator|Puncture Wound|This group is given the same puncture wound and dressing given to the experimental group.
10180070|NCT03796897|Experimental|Leucine-enriched protein + exercise|whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein), vitamin D, and free leucine
10180071|NCT03796897|Sham Comparator|Habitual diet + exercise|habitual diet only
9687721|NCT04864509|Active Comparator|Melatonin 10mg|Nightly oral dose
9687722|NCT04864509|Placebo Comparator|Placebo|nightly oral dose
9687723|NCT04864301|Active Comparator|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
9687724|NCT04864301|Active Comparator|Conventional Measurement technique|The control group (N=12) will receive no intraoperative ICI. Following maximal corporal dilatation, cylinder length will be estimated conventionally by adding up the internally measured distal and proximal corpora to the length of the corporotomy.
9687725|NCT04864418|Experimental|Cohort group of AST-021p for dose-escalation|"4 cohort groups for AST- 021p administration:~Group 1) 1.2mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 2) 2.4mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 3) 3.6mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF~Group 4) 4.8mg AST- 021p, Montanide ISA 51 VG and rhuGM-CSF"
9687726|NCT04864496|Active Comparator|Prescribe N-acetylcysteine tablets|
9687727|NCT04864496|Placebo Comparator|Prescribe placebo tablets|
9687728|NCT04864353|Experimental|Experimental: Intervention|Participants will after baseline receive a guided intervention with weekly therapist support.
9687729|NCT04864353|No Intervention|Control: Waitlist|Participants will not receive intervention until 7 weeks after baseline.
9687730|NCT04863976|Experimental|Dynamic stretching|
9687731|NCT04863976|Active Comparator|Passive stretching|
9687732|NCT04863976|Active Comparator|Self-stretching|
9687733|NCT04863924||Advanced NSCLC|Patients with radiologic evidence of advanced (unresectable stage III or IV) non-small cell lung cancer
9687734|NCT04864015|Placebo Comparator|Conventional mouthpiece|Patients undergoing standard EGD using a conventional mouthpiece
9687735|NCT04864015|Active Comparator|Droplet reduction mouthpiece|Patients undergoing standard EGD using a new droplet reduction mouthpiece
9687736|NCT04864288||1|male patients (age ≥ 21) with erectile dysfunction (ED) and non-responders to intracorporal injection
9687737|NCT04864288||2|age matched thirty men with normal erectile function
9687738|NCT04863963||Milligan Morgan|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Milligan-Morgan hemorrhoidectomy surgery.
9687739|NCT04863963||Dearterialization with mucopexy|Patients aged ≥18 years-old, with Goligher's grade III haemorrhoidal disease, who underwent elective Doppler-guided or non-Doppler guided HAL surgery associated with mucopexy
9687740|NCT04864028|Experimental|Healthy volunteer|
9687741|NCT04864041||Patients hospitalised in ICU for vaso-occlusive crisis|
9687742|NCT04864132||Subjects survived from COVID-19|The subjects who had confirmed COVID-19 infection aged between 18-30/years
9687743|NCT04864132||Subjects never had COVID-19|"The subjects aged between 18-30/years who have not been diagnosed with COVID-19 as of March 11of 2020 and who have not been in contact and risky according to the Life Fits Into Home application"
9687744|NCT04864145|Active Comparator|Medical therapy|Patients in medical therapy will receive conservative care, mainly including angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
9687745|NCT04864145|Experimental|Transcatheter Aortic Valve Implantation|Patients in TAVR group will receive transcatheter aortic valve replacement.
9687746|NCT04863898|Other|Pre-post with HIV care and treatment clinic staff|Pre-post with HIV care and treatment clinic staff
9687747|NCT04863937|Experimental|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
9687748|NCT04863989|Experimental|Small sized chest tube|Insertion of small sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
9687749|NCT04863989|Active Comparator|Large sized chest tube|insertion of large sized chest tube in patients with traumatic hemothorax, pneumothorax or hemopneumothorax.
9687750|NCT04864262|Experimental|Photovoice|
9687751|NCT04863755|Other|DASH diet only|Patients receive a DASH diet and orientation to maintain their physical activity
9687752|NCT04863755|Other|DASH diet with pedometer|Patients receive a DASH diet and orientation to increase their physical activity with a pedometer steps count
9687753|NCT04863599|Other|OMS procedure under general anesthesia or sedation|Questionnaire
9696067|NCT04771338|Experimental|Treatment group|Job interview training protocol for 12 sessions
9696068|NCT04771338|No Intervention|Control group|No participation in any intervention protocol
10180072|NCT03796663|Active Comparator|Mindful Parenting Only|"Participants in this arm will receive only the Mindful Parenting Program at the start of the study. Bögels and Restifo's (2014) Mindful Parenting Program is an adaptation for parents of MBCT, and MBSR; the program will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will be asked continue to participate in data collection for the post-intervention assessment time point (i.e. 8 weeks after the completion of the Mindful Parenting group sessions) and for the 2-month follow up assessment time point (i.e. 16 weeks after the completion of the Mindful Parenting group sessions). After they have completed both assessments, they will be offered the opportunity to participate in the MATCH BPT program if they so choose (no data will be collected)."
10180073|NCT03796663|Experimental|Mindful Parenting and BPT Combined|"Participants in this arm will receive the Mindful Parenting Program at the start of the study, which will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will receive receive individually-implemented MATCH BPT sessions, which will consist of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 1 hour sessions. The MATCH manual is comprised of 33 modules (i.e. coping, giving effective instructions, learning to relax, etc.). For the purpose of this study we will be utilizing the section on BPT, which consists of 12 modules with corresponding handouts and worksheets."
10180074|NCT03796585|Experimental|Intervention|Pharmacists assigned to this group will receive an immunization registry training program and informational flyer.
9687756|NCT04863560||Hoehn & Yahr stage I (H&YI)|- 20 Hoehn & Yahr stage I (early disease, minimal symptoms)
9687757|NCT04863560||Hoehn & Yahr stage II (H&YII)|- 30 Hoehn & Yahr stage II (mild disease, no balance issues)
9687758|NCT04863560||Hoehn & Yahr stage III (H&YIII)|- 30 Hoehn & Yahr stage III (moderate disease, balance issues)
10180075|NCT03796585|Active Comparator|Control|Pharmacists assigned to this group will receive an informational flyer. They will not receive training.
9687759|NCT04863521|Experimental|MHP Users|A subset of the population within the clinical setting will be requested to participate in this pilot while the rest of the population will receive standard of care.
9687760|NCT04863742|Experimental|Dextenza Arm|
9687761|NCT04863742|Active Comparator|Prednisolone Acetate 1%|
9687762|NCT04863781|Experimental|Intervention|All 11 modules will include the following elements: introduction to the topic; two types of assessments (1) adherence to at-home relaxation training practice (following week 2) and (2) 3-5 topic-specific questions to tailor video-based content; a cognitive component; a relaxation component; and a wrap up that includes a brief assessment of module comprehension. Each user will view 5-7 videos per module. Videos will be tailored to user and will last between 2 and 4 minutes. Total time per module will be 20 to 30 minutes. Between modules, users will receive (based on their timing preferences) supportive texts intended to motivate continued engagement or to affirm the life experiences of African American women
9687763|NCT04863781|Active Comparator|Control|Two mobile courses: Introduction to Stress Management and Techniques for Coping with Stress. Users will be informed that the courses will be completed on their phone, that they are video-based, and that they should spend between 20 and 30 minutes each week, for the next 11 weeks, learning the material. The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
9687764|NCT04863508||Low-risk hypertensive patients|Patients without diabetes, chronic kidney disease, hypertension-mediated organ damage, or established cardiovascular diseases
9687765|NCT04863508||With-risk hypertensive patients|Patients with diabetes, chronic kidney disease, hypertension-mediated organ damage, but without established cardiovascular diseases
9687766|NCT04863508||Hypertensive patients with cardiovascular diseases|Patients with established cardiovascular diseases
9687767|NCT04863586||Tested positive for SARS-CoV-2|Eligible participants who have had a positive SARS-CoV-2 test will be included in the case group of the study.
9687768|NCT04863586||Not tested for SARS-CoV-2|A random sample of age, sex, and DMT matched people with MS who have not been tested for SARS-CoV-2 will be included in the control group of the study.
9687769|NCT04863547||Exposed|Patients hospitalized for COVID-19 with SARS-CoV-2 variant 20I / 501Y.V1
9687770|NCT04863547||Non exposed|Patients hospitalized for COVID-19 to SARS-CoV-2 corresponding to wild type 20A variants. EU1 or 20A. EU2
9687771|NCT04863703||One group with HBV/HDV coinfection|Measurement of HVPG before antiviral treatment of HBV/HDV coinfection and one year after treatment initiation with Bulevirtide. Administration of Bulevirtide and HVPG measurement is independent from this study.
9687772|NCT04863807||Thoracic epidural for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare National Health Service (NHS) Trust 'Invasive rib fracture management pathway'
9687773|NCT04863807||Erector Spinae block for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
9687774|NCT04863807||Serratus Anterior block for rib fracture management|Patients aged > 18 years of age presenting with traumatic rib fractures in a major trauma centre over the past 5 years that meet the criteria for the Imperial College Healthcare NHS Trust 'Invasive rib fracture management pathway'
10180076|NCT03796494|Active Comparator|Control Group|The control group is considered, using the company's classic multi-position straight anti-rotational abutment
9687775|NCT04863729|Experimental|Intervention|The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).
9687776|NCT04863729|No Intervention|Control|Girls and their female caregivers randomized to the control group will receive 4 retention incentives that are mailed to them monthly. These incentives will each be <$10 per dyad, examples include: water bottles, lanyards, pencil cases and tote bags. The control condition was selected by community members and allows for minimal contamination and/or overlap between the AB curriculum and control group
9687777|NCT04863638|Experimental|A1 aged ≥ 71|300 subjects age ≥ 71 （A1）receive 3 doses of vaccine
9687778|NCT04863638|Experimental|A2 aged ≥ 71|200 subjects age ≥ 71 （A2）receive 3 doses of vaccine
10180077|NCT03796494|Experimental|Test group|The test group is considered, where the new multi-position straight esthetic anti-rotational slim abutment is used
9687779|NCT04863638|Experimental|A3 aged ≥ 71|200 subjects age ≥ 71 (A3) receive 3 doses of vaccine
9687780|NCT04863638|Experimental|B1 aged 60-70|300 subjects age 60-70 (B1) receive 3 doses of vaccine
10180078|NCT03796533|Other|Posaconazole pharmacokinetics|Patients with AML over the age of 18 years treated with intensive chemotherapy in induction and consolidation whose was under antifungal prophylaxis by PCZ formulation tablets.
10180079|NCT03796520||Patients suspected for epilepsy|The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.
10180080|NCT03796403|Experimental|diclofenac and bupivacaine group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
10180081|NCT03796403|Placebo Comparator|bupivacaine only group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.
9687781|NCT04863638|Experimental|B2 aged 60-70|200 subjects age 60-70 (B2) receive 3 doses of vaccine
9687782|NCT04863638|Experimental|B3 aged 60-70|200 subjects age 60-70 (B3) receive 3 doses of vaccine
9687783|NCT04863638|Experimental|C1 aged 18-59|300 subjects age 18-59 (C1) receive 3 doses of vaccine
9687784|NCT04863638|Experimental|C2 aged 18-59|200 subjects age 18-59 (C2) receive 3 doses of vaccine
9687785|NCT04863638|Experimental|C3 aged 18-59|200 subjects age 18-59 (C3) receive 3 doses of vaccine
9687786|NCT04863638|Experimental|C4 aged 18-59|300 subjects age 18-59 (C4) receive 2 doses of vaccine
9687787|NCT04863638|Experimental|D1 aged 9-17|300 subjects age 9-17 (D1) receive 3 doses of vaccine
9687788|NCT04863638|Experimental|D2 aged 9-17|200 subjects age 9-17 (D2) receive 3 doses of vaccine
9687789|NCT04863638|Experimental|D3 aged 9-17|200 subjects age 9-17 （D3）receive 3 doses of vaccine
9687790|NCT04863638|Experimental|D4 aged 9-17|300 subjects age 9-17 （D4）receive 2 doses of vaccine
9687791|NCT04863638|Experimental|E1 aged 3-8|300 subjects age 3-8 （E1） receive 3 doses of vaccine
9687792|NCT04863638|Experimental|E2 aged 3-8|200 subjects age 3-8 （E2）receive 3 doses of vaccine
9687793|NCT04863638|Experimental|E3 aged 3-8|200 subjects age 3-8 （E3）receive 3 doses of vaccine
9687794|NCT04863638|Experimental|E4 aged 3-8|300 subjects age 3-8 （E4）receive 2 doses of vaccine
9687795|NCT04863872|Active Comparator|Proactive Care Management|
9687796|NCT04863872|Experimental|Proactive Care Management + my hypo compass education program|
9687797|NCT04863690|Experimental|Sleep Intervention System - No Coaching|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations), as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks.
9687798|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will also work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
9687799|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching plus Human Coaching|The procedure will be identical to Group 2 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
9687800|NCT04863690|No Intervention|Control|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery), plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and (depending on group), sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
9687801|NCT04863651||Securely Attached Parturients|Parturients who have a secure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
9687802|NCT04863651||Insecurely Attached Parturients|Parturients who have an insecure attachment style according to the Revised Adult Attachment Scale (Collins, 1996)
9687803|NCT04863482|Active Comparator|Critical view of Safety (CVS-WL)|Group CVS-WL (control group): the visualization of the biliary tree is achieved in white light, without the utilization of an intraoperative imaging technique, the CVS in white light was selected as the control group since it constitutes the actual recognized standard in clinical practice.
9687804|NCT04863482|Experimental|Intra-operative Cholangiography (IOC)|Group IOC: the visualization of the biliary tree is achieved with the help of intraoperative cholangiography
9687805|NCT04863482|Experimental|Near-Infra Red Cholangiography (NIR-C)|Group NIR-C: the visualization of the biliary tree is achieved with the help of near-infrared fluorescence cholangiography
9687806|NCT04863456|Experimental|HIPA group of Puget grade 1|the tumor abuting or displacing the hypothalamus in the preoperative MR images
9687807|NCT04863456|Experimental|HIPA group of Puget grade 2|hypothalamic involvement (the hypothalamus is no longer identifiable) in the preoperative MR images
9687808|NCT04863430|Experimental|Apatinib with chemotherapy|Apatinib with oxaliplatin and S-1 treatment
9687809|NCT04863326|Experimental|Making Proud Choices|This evaluation tests the effect of the MPC School Edition, the version of the MPC 5th Edition designed for implementation in school. This edition includes 9.5 hours of content implemented in 14 40-minute modules. Schools assigned to the MPC condition received MPC in a targeted class.
9687810|NCT04863326|Active Comparator|Business as usual|The control group continued with their regular programming in the targeted class, which was often a health or Reserve Officer Training Corps (ROTC) class.
10180082|NCT03796507|Experimental|Temozolomide Arm|This study will only include one treatment group who will receive oral temozolomide at 75 mg per square meter of body surface area daily for 21 days before progressing to standard chemoradiation treatment.
9687811|NCT04863378|Experimental|Walkers|Walkers continuously wear an actigraph watch to assess activity level. Daily sleep behavior is captured on an under-the-mattress sleep sensor. Participants walk 1-mile routes in triads, three times a week for 16 weeks while engaging in prompted conversational reminiscence recorded for a digital archive.
9687812|NCT04863183|Active Comparator|Group 1 (control-Triamcinolone acetonide)|Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).
9687813|NCT04863183|Experimental|Group 2 (experimental- CELLISTEM-OA)|CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time).
9687814|NCT04863066|Experimental|CAR-T-cell therapy|Four patients with plasma HIV RNA <50 copies/ml and CD4+T cell count more than 350 cells/μl receiving at least one-year antiviral treatment are injected intravenously with 1×10^5 CAR-T cells/kg body weight. If the dosage of 1×10^5 CAR-T cells/kg body weight is well tolerated, 5×10^5 CAR-T cells/kg body weight will be infused for another 4 subjects who meet the inclusion and exclusion criteria.
9687815|NCT04863404|Experimental|Bone-anchored maxillary protraction group|Face mask with hybrid-hyrax
9687816|NCT04863404|Experimental|Tooth-borne maxillary protraction group|Face mask with conventional bonded RME
9687817|NCT04863404|No Intervention|Control group|Control group consisting of 14 non-treated Class III malocclusion subjects
9687818|NCT04863092|Experimental|Underrepresented Population|A primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty
9687819|NCT04863391||early/none vs.|For identification of early/none (i.e., non-referral level) Age Related Macular Degeneration (ARMD)
9687820|NCT04863391||intermediate/late AMD|intermediate/late (i.e., referral level) Age Related Macular Degeneration (ARMD)
9687821|NCT04863274||Expanded consultation group|In an expanded consultation group is being conducted in the study group on the importance of primary prevention of cardiovascular diseases and on the reduction of cardiovascular risk by taking statins. Patients are given brochures and information materials on the risk factors for cardiovascular diseases and the possibility of their correction. Also, the patients of the study group are regularly reminded (2 times a month) with the help of SMS mailings and calls of health workers about the need to follow the doctor's recommendations for taking atorvastatin and returning to the medical institution.
9687822|NCT04863300|Experimental|Intervention group|Participants in the intervention group will receive a collaborative stepped care programme provided by registered social workers and trained Peer Supporters from aged care service units - the Districts Elderly Community Centres (DECC), and mental health service units - the Integrated Community Centre on Mental Wellness (ICCMW), all are local NGOs. In the collaborative stepped care model (see attachment Table 1), older persons are matched to the intervention module that most suits their current needs. The person does not have to start at the lowest level of intervention to progress to the next level of intervention. Rather, they enter the service with the intervention level aligned to their needs, e.g., level of risks, symptom severity (measured by the Patient Health Questionnaire, PHQ-9), and intervention response. Home visits or other format of contact will be delivered by trained Peer Supporters employed by the NGOs to detect and engage hidden cases.
9687823|NCT04863235|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week, and set a physical activity goal. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Monitoring Physical Activity Session 4: Action and Coping Planning. Session 5: Self-Efficacy (master and vicarious experiences). Session 6: Self-Efficacy (modeling experiences, verbal persuasion). Session 7: Physical Activity Enjoyment and Barriers. Session 8: Making long-term Change. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, blood pressure, cholesterol, benefits of water, benefits of vitamin D, the Infodemic).
9687824|NCT04863235|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk, discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week and set a physical activity goal. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Introduction to self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Mindfulness and Resistance. Session 6: Meeting Difficult Emotions. Session 7: Embracing the Good. Session 8: Applying Self-compassion to Physical Activity and Moving Forward.
9687825|NCT04863365|Placebo Comparator|Placebo treatment|A matching placebo ophthalmic solution, TID
9687826|NCT04863365|Experimental|PHP-201 treatment|PHP-201 0.5% ophthalmic solution, TID
9687827|NCT04863196|Experimental|Laser therapy Treatment Group|"Treatment evaluation and follow-up will be done for 15 days. The application of the laser at first will be done three times a week.~The application will be by points with continuous or selective technique, which will depend on each patient. The device is a pen type that will be by contact or without contact with the lesion, irradiation and the dose will be according to the calculation for each patient, using power in milliwatt and fluency, where the dose will vary according to area and patient, and may vary from 0.1 to 1J / cm² as calculated.~The laser tip will be disinfected before each use with 70% alcohol and later coated with plastic film. Patients, companion and operator will wear specific eye protection glasses and all biosafety rules will be followed during therapy."
10180083|NCT03796442|Experimental|AVALUS group|patients who will undergo aortic valve replacement with Avalus bioprosthesis
9687828|NCT04863196|Active Comparator|Barrier Dust Treatment Group|"The evaluation and follow-up of the treatment will be done for 15 days. The principle application will be made three times a week using the protective barrier powder over the entire affected area, forming a protective barrier when adhering to the skin.~For all patients, the injured area will be previously cleaned with 0.9% saline solution."
9687829|NCT04863417|Experimental|Cohort 1 (2000 cm2 Body Surface Area)|
9687830|NCT04863417|Experimental|Cohort 2 (4000 cm2 Body Surface Area)|
9687831|NCT04863079|Experimental|Pembrolizumab for Postoperative Adjuvant Treatment of ESCC|Participants receive pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance as postoperative adjuvant treatment of ESCC with pN+.
9687832|NCT04863131|Experimental|EXG-5003|
9687833|NCT04863131|Placebo Comparator|Placebo|
9687834|NCT04863157|Experimental|Survivor-SHIP|Parents/guardians will take part in 3 education sessions over a one month period. During the sessions, they will learn more about common sleep problems following cancer treatment and ways to understand their child's unique patterns. They will then be educated about behavioral changes they can make to improve their child's sleep.
9687835|NCT04863118|Experimental|Strength training protocol performed in shallow water and dry land|Parkinson Disease and healthy individuals
9687836|NCT04863118|Experimental|High-intensity training protocol performed in shallow and deep water|Parkinson Disease and healthy individuals
9687837|NCT04863053||Stable CHD patient|Patients aged ≥ 18 years who have a history of stable coronary heart disease (CHD) receiving long-term mono-antiplatelet therapy with aspirin (80 mg once daily)
9687838|NCT04863040|No Intervention|Usual classroom teaching methodology|Students in the CG will receive mandatory lessons on Spain (one 45-minute session of Psychomotor/Physical Education), and the usual classroom teaching methodology. Teachers in the CG schools will be asked not to make any changes to their methodology during the time of the study, with the promise by the research team to share and explain the MOVI-HIIT materials once the interventions are completed.
9687839|NCT04863040|Experimental|Usual classroom teaching methodology + MOVI-HIIT intervention|The design of the MOVI-HIIT intervention is framed within the socio-ecological model of behavior modification, in such a way that it will be designed to intervene in the individual, family and school environment. It will have a duration of one school year and will consist of two 5-minute daily physical activity breaks based on intervallic training, five days a week.
9696071|NCT04771052||CORE program|Patients admitted to a dedicated COVID-19 units (CHUS Hôtel-Dieu de Sherbrooke - CIUSSS de L'Estrie - CHUS) with medical clearance (physical deconditioning; hemodynamically stable; oxygen therapy by nasal cannula < 4 L/min for saturation > 92%; resting respiratory rate < 24; and heart rate between 50 and 120 beats per minute).
9696072|NCT04771052||Control|Patients admitted to a dedicated COVID-19 units (CHAUR de Trois-Rivières, CIUSSS de la Mauricie-et-du-Centre-du-Québec) receiving usual care, matched to CORE a patient with similar characteristics (sex, age, preadmission provenance).
9696073|NCT04771026|No Intervention|Control|Receiving routine conduct of general anaesthesia for supraglottic airway device
9696074|NCT04771026|Experimental|Dexamethasone|Receiving pre-operatively single dose nebulised dexamethasone 8mg prior to induction of general anaesthesia
9696075|NCT04770974||Urothelial Carcinoma|"Patients over the age of 18 known for urological interventions for the following pathologies will be considered for enrollment in the group of cases:~- Bladder cancer~The exclusion criteria will be:~Age under 18~Pregnancy~Lack of informed consent~Inability to provide informed consent~Patients included in the study, who meet the inclusion criteria, have an operative note for:~Transurethral Resection of Bladder Neoplasia (TURBT)~Radical Cystectomy for Bladder Neoplasia"
9696076|NCT04771039||patients with chronic inflammatory bowel disease who consulted in ophthalmology|
9696077|NCT04770883|Experimental|Internet based cognitive behavioral therapy group|80 patients will be randomized to receive iCBT. Psychological therapy is effective in IBS patients. The treatment takes 10 weeks and is divided into five successive steps. Patients have to report that they have worked through a treatment step to get access to the next. The patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half of the treatment on step 5, in which exposure exercises are introduced. A psychologist/CBT therapist will manage the online therapeutic contact with the patients.
9696078|NCT04770883|Experimental|Low FODMAP group|80 patients will then be randomized to receive Low FODMAP diet. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) are poorly absorbed short-chain carbohydrates including fructose (in excess of glucose), lactose, polyols, fructans and galacto-oligosaccharides. The concept of considering all these molecules collectively as a treatment for IBS is relatively new. Understanding of FODMAPs comprises mechanisms of action such as luminal distension from their osmotic effect and rapid fermentation to hydrogen. These findings have led to increased application of the low FODMAP diet to manage IBS symptoms. Treatment will undergo 10 weeks supervised monotherapy with low FODMAP diet. This will be done with the help of professional dieticians in Örebro region, who will meet the patients and inform them how this diet works as well as follow up.
9696079|NCT04770883|Active Comparator|Control group|The control Group (40 patients) will wait for 10 weeks before being randomised to treatment with either iCBT or low FODMAP diet.
9696080|NCT04771000|Experimental|Ambrisentan|Ambrisentan, reconstituted oral solution, 125µg twice a day for up to 28 days
9696081|NCT04771000|Placebo Comparator|Placebo|Placebo, oral solution, twice a day for up to 28 days
9696082|NCT04770987||hyperlaxity|30 individuals with systemic hyperlaxity as defined by a score of 5 or greater on the Beighton Hypermobility Scale
10180084|NCT03796442|Active Comparator|CEPME group|patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
10180085|NCT03796377|Other|Rivaroxaban|Single oral dose of 20 mg rivaroxaban
10180086|NCT03796377|Other|Rivaroxaban after CYP- and P-gp induction|Single oral dose of 20 mg rivaroxaban after pretreatment with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
10180087|NCT03796351|Experimental|MT10107(botulinum toxin type A)|Subjects will be administered a single equivalent dose of MT10107 by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
9687840|NCT04863105|Experimental|Conference-Abiraterone acetate tablet|Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)
9687841|NCT04863105|Experimental|test-Abiraterone acetate tablet|Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd)
9687842|NCT04862923||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
9687843|NCT04862637|Experimental|pull through group|the patients receiving the pull though method during the tongue cancer surgery
9687844|NCT04862637|Placebo Comparator|mandibular-lip split group|the patients receiving the traditional mandibular lip split method during the tongue cancer surgery
9687845|NCT04862546|Experimental|Laser Acupoint|Laser will be performed 3 times per week for 2-week measurement. The duration of each cession will be 10 minutes treatment.
9687846|NCT04862546|Active Comparator|Tap water iontophoresis|Tap water iontophoresis will be performed 3 times per week for 2-weeks. The duration of each cession will be 20 minutes treatment session.
10180088|NCT03796351|Active Comparator|BOTOX® 50U(botulinum toxin type A)|Subjects will be administered a single equivalent dose of BOTOX® 50U by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
10180089|NCT03796299||1|Patients with bladder cancer
10180090|NCT03796299||2|Patients with upper urinary tract cancer
10180091|NCT03796299||3 (control)|Controls
10180092|NCT03796312|Experimental|Tub Bathing|In this group, preterm infants were given tub bathing.
10180093|NCT03796312|Active Comparator|Sponge Bathing|Separate cotton cloths were prepared for each body area in the sponge bath. The room temperature was set to 26-27°C to prevent hypothermia. The temperature of the water used for sponge bathing was set to 37-38°C. Alongside the bath, the infant was placed on a flat, protected surface and washed from a bowl of water, using the same mild cleanser. The eyes, face, and head were wiped and dried while the baby was wrapped in a blanket. The wrap was opened so that body parts could be washed, dried, and then immediately rewrapped, after which infants were diapered.
9687847|NCT04862598|No Intervention|Control|The patient will be positioned on the operating table and have routine monitoring attached (ECG, blood pressure, O2 saturations, end tidal carbon dioxide monitoring (ETCO2). A surgical safety time out will be performed. The patient will receive routine operative and nursing care. The study team member will record highest and lowest heart rate and blood pressure as well as lowest O2 saturation and the total intra-operative dose of fentanyl and midazolam administered to the patient. At the end of the procedure, the patient is assisted into a wheelchair and will return to the recovery area. After 15 minutes of recovery, a member of the study team will give them the post-operative questionnaires which will consist of answering how anxious they felt during the procedure and the 11 question Iowa Satisfaction with Anesthesia scale (ISAS). The patient will then be free to leave once they have met the standard discharge criteria.
9687848|NCT04862598|Experimental|VR Group|The patient wears the VR headset after being positioned on the table and the surgical time out has been completed. The VR scene and accompanying music will continue until the end of the procedure or until the patient wishes for it to be removed. The patient will receive standard operative and nursing care. The study team member will record the intra-operative vitals as detailed in the control group procedure. At the end of the procedure, the patient will be moved to recovery and will receive standard care. At 15 minutes, they will be provided with the anxiety questionnaire and the ISAS. Additional questions will be asked; their level of VR immersion and if they would like to receive the VR technology again if they were to undergo another procedure in the future. They will then be free to leave once they have met the standard discharge criteria.
9687849|NCT04862884|Experimental|HRS4800 tablets|
9687850|NCT04862884|Placebo Comparator|placebo|
9976230|NCT01349387|Experimental|Arm1|"During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry).~After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31."
9687852|NCT04862624|Experimental|Story-based media|Participants will receive a link to our story-based media with Latina characters.
9687853|NCT04862624|Active Comparator|Attention control media|Participants will receive a link to non-story based media that is informational and does not involve story characters.
10180094|NCT03796429|Experimental|GS+Toripalimab|
10180095|NCT03796338||Critically ill patients|age > 18 years
9687856|NCT04862702|Active Comparator|ProTaper Next rotary file system (Dentsply Sirona)|
9687857|NCT04862702|Experimental|TruNatomy rotary system (Dentsply Sirona)|
10180096|NCT03796390|Experimental|CD123 CAR-T cells|Patients will be be treated with CD123 CAR-T cells
10180097|NCT03796078|Active Comparator|Bimaxillary surgery (MMA)|Bimaxillary Orthognathic Surgery. MMA
10180098|NCT03796078|Active Comparator|monomaxillary surgery (Isolated MaxS)|Monomaxillary surgery (Isolated MaxS)
10180099|NCT03796078|Active Comparator|monomandibullary surgery (Isolated MandS)|Monomandibular surgery (Isolated MandS)
10180100|NCT03796364|Active Comparator|control group|standard SRILI treatment
10180101|NCT03796364|Experimental|observation group|Endostar® plus standard treatment
10180102|NCT03795974|Active Comparator|MNC & MSC with Control|One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity
10180103|NCT03795974|Experimental|MNC & MSC|Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients
10180104|NCT03796000||colonoscopy: obese and smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
10180105|NCT03796000||colonoscopy: obese and non-smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
10180106|NCT03796000||colonoscopy: lean and smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
10180107|NCT03796000||colonoscopy: lean and non-smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
10180108|NCT03796000||gastroscopy: obese and non-smoker undergoing bariatric surgery|"6 small tissue samples of the gastric corpus and 6 of the Duodenum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample~1cm long piece of the jejunum, which is usually disposed during bariatric surgery."
10180109|NCT03796000||gastroscopy: lean and non-smoker|"6 small tissue samples of the gastric corpus and 6 of the Duodenum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
10180110|NCT03796091|Active Comparator|Educational Brochure|Participants will read an educational brochure from the National Eating Disorder Association and will receive referral resources.
9687858|NCT04862793|Experimental|Feedback|Feedback system through CoPS and CoRS
9687859|NCT04862793|No Intervention|Standard procedure|Performing the standard procedure in accordance with the departments usual conduct.
9687860|NCT04862455|Experimental|Treatment (NBTXR3, RT, pembrolizumab)|Patients receive hafnium oxide-containing nanoparticles NBTXR3 via injection intratumorally or intranodally on day 1. Beginning as early as day 3 and within 8 days of NBTXR3 injection, patients undergo SBRT QOD or hypofractionated RT QD over 1-2 weeks at the discretion of the treating radiation oncologist. Starting on the same day as radiation therapy, patients also receive pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
9687861|NCT04862767|Experimental|TASO-001|level 1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)(3+3) next than level 2 or level -1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)
9687862|NCT04862845|Active Comparator|Patients in group I (PD group)|
9687863|NCT04862845|Active Comparator|patients in group II (P group)|
9687864|NCT04862845|Sham Comparator|patients in group III (C groups)|
9687865|NCT04862819|Active Comparator|scaling root planning|patients in this group will have a scaling root planing procedure only
9687866|NCT04862819|Experimental|scaling root planning with new local drug delivery|patients in this group will have a scaling root planing procedure and a drug administered
10180111|NCT03796091|Active Comparator|Body Project Traditional|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project group therapy program (Stice & Shaw, 2001).
10180112|NCT03796091|Active Comparator|Body Project Expanded|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project Expanded group therapy program (Green et al., 2017).
10187481|NCT03725891|Active Comparator|Aspirin 81 mg plus placebo|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
10187482|NCT03725878|Experimental|Interventional|Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
9687867|NCT04862806|Experimental|Israel CLL study group|BNT162b2 mRNA vaccine
9687868|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging undergoing thrombectomy|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention.
9687869|NCT04862507||Stroke Patients with an ASPECTS of 0-5 on baseline neuroimaging not undergoing thrombectomy|acute stroke patients treated with or without thrombolysis
9687870|NCT04862494||diaphragmatic eventation with medical surveillance|Patients with a diagnosis of diaphragmatic eventration without respiratory or digestive consequences, thus not requiring surgical repair.
9687871|NCT04862494||diaphragmatic eventration treated with plication|Patients with a diagnosis of diaphragmatic eventration with respiratory or digestive repercussion, requiring surgical repair.
9687872|NCT04862559|Experimental|NovaCross|Subjects in this arm are treated with the investigational device, NovaCross micro-cetheter, to facilitate the opening of a chronic total occlusion (CTO)
9687873|NCT04862403|Experimental|Intervention group I|In intervention group I - clamped at a distance of 2 cm - umbilical cord was measured 2 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 2 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group I.
9687874|NCT04862403|Experimental|Intervention group II|In intervention group II - clamped at a distance of 3 cm - umbilical cord was measured 3 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 3 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group II.
9687875|NCT04862403|No Intervention|Control group|Control group - clamped without measuring - no intervention was made in defining the distance at which the umbilical cord of the newborn would be clamped. Another healthcare workers measured the distance at which the umbilical cord had been clamped. The same researcher used a standard measuring tape to measure the distance between the umbilical cord to the clamping point.
9687876|NCT04862351|Experimental|TecHCR|12 weeks Hybrid between supervised exercise training and video call sessions Educational videos Dietary and exercise log
10187483|NCT03725878|Active Comparator|Control|Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
10187484|NCT03725865|Experimental|iNSC treatment group|
10187485|NCT03725839|Experimental|Arm|F&P Interface will be used by OSA participants in-home for 2 weeks.
10187486|NCT03725813|Experimental|Person-centred inpatient care|Person-centred inpatient care
10187487|NCT03725787|Experimental|CuroCell S.A.M. ® pro mattress|Mattresses of eligible participants will be replaced by a static air pressure redistribution mattress (CuroCell S.A.M. ® Pro).
9687877|NCT04862351|Other|Centre-based|12 weeks usual care provided by the centre-based, outpatient cardiac rehabilitation clinic Dietary and exercise log
9687878|NCT04862091|Experimental|Abiraterone Acetate Tablets (I)|
9687879|NCT04862091|Active Comparator|ZYTIGA®.|
9687880|NCT04862208|Experimental|Carbohydrate-based breakfast + exercise|maltodextrin
10180113|NCT03796052|Experimental|Avena Sativa Skincare Regimen|Avena sativa-containing body wash, body cream, and anti-itch balm
10180114|NCT03796117|Experimental|Experimental Group 1: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
9687881|NCT04862208|Experimental|Protein-based breakfast + exercise|whey
9687882|NCT04862208|Experimental|Fasted breakfast + exercise|water
9687883|NCT04862208|Sham Comparator|Carbohydrate-based breakfast + no exercise|maltodextrin
9687884|NCT04862377|Active Comparator|Standard treatment group|"Infants randomised to the standard treatment arm will receive intratracheal surfactant as per usual clinical indications of respiratory distress syndrome in these preterm infants.~In that sense, and based in those clinical indications, we have developed a risk calculator for surfactant administration in preterm infants ≤32 weeks GA. We will use it to decide what patients will receive surfactant (calculator available on: https://1drv.ms/x/s!Arjkl83HIXSngP8TWh8O6oi6Ztdw3w?e=gNCMxP)."
9687885|NCT04862377|Experimental|Interventional treatment group|"Infants randomised to the interventional treatment arm will receive intratracheal surfactant mixed with budesonide. Indication of surfactant, as equal as for the standard treatment arm, will be decided using the calculator."
9687886|NCT04862377|No Intervention|Control group|Infants ≤32 weeks with no indications for surfactant administration. Their clinical management will be the usual in our neonatal unit.
9687887|NCT04862169|Placebo Comparator|Control group|"In the control group, they will only receive electronic version of the modules. They are able to access the module on their own devices.~The observation arm will receive the link of eLOK at the end of data collection and follow-ups (week 14). With this link, then they are able to access modules, videos and case studies provide in SPARK."
9687888|NCT04862169|Experimental|Intervention group|The intervention on this RCT is an educational training program: SPARK (Strengthening PAlliative caRe in the community by enhancing nurses' Knowledge). This is an educational intervention using an online method with learning method system (LMS) eLOK hosted by Universitas Gadjah Mada Yogyakarta (Affiliation of authors' team). The intervention includes online discussions and access to eLOK for study materials (modules and videos) and some synchronous meetings.
9687889|NCT04862325|No Intervention|Usual care|"Control group will follow the standard preoperative measures Enhanced Recovery After Surgery (ERAS®) established in the protocols of our hospital. Standard preoperative measures: recommendation of nutritional and physical activity and advice to stop smoking and reduce alcohol intake; optimization of preoperative pathologies including anaemia. An information document on ERAS® measures in our center will be attached to all of them."
9687890|NCT04862325|Experimental|Multimodal prehabilitation|Patients following the standard preoperative policies of our institution and the multimodal prehabilitation program
9687891|NCT04861974||Robotic Distal Pancreatectomy|
9687892|NCT04861974||Laparoscopic Distal Pancreatectomy|
9687893|NCT04861974||Robotic Gastrectomy|
9687894|NCT04861974||Laparoscopic Gastrectomy|
9687895|NCT04861974||Robotic Funduplication|
9687896|NCT04861974||Laparoscopic Funduplication|
9687897|NCT04861974||Robotic Hernioplasty|
9687898|NCT04861974||Laparoscopic Hernioplasty|
9687899|NCT04861974||Robotic Rectal Resection|
9687900|NCT04861974||Laparoscopic Rectal Resection|
9687901|NCT04862078|Experimental|Shared decision making group|The Study arm - shared decision making when deciding surveillance strategy
9687902|NCT04862078|Other|Usual surveillance group|The control arm - surveillance with usual care
9687903|NCT04862000||Endometriosis or adenomyosis|participants suffering pelvic endometriosis, endometrioma, deep infiltrating endometriosis or adenomyosis
9687904|NCT04862273||Native T1 CMR|Diagnostic accuracy of native T1 CMR and ATTR probability estimator are tested against the reference methods (99mTc-DPD scintigraphy, laboratory screening for multiple myeloma / AL amyloidosis; or cardiac biopsy, if noninvasive evaluation is inconclusive)
9687905|NCT04862312|Experimental|VideoDine|Use of video chat to eat a meal with a dining partner.
9687906|NCT04862234|Experimental|Dulaglutide|Dulaglutide is a fusion protein of a GLP-1 analogue and a modified IgG Fc fragment, leading to a longer acting, relatively flat insulinotropic profile with increased plasma half-life suitable for once-weekly administration.
9687907|NCT04862234|Placebo Comparator|Placebo|Saline placebo.
9687908|NCT04861883||76 healthy the Middle and Third Trimester pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
9687909|NCT04861883||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
9687910|NCT04862026||Telemonitoring group|The telemonitoring group will be connected to electronic medical systems, through which medical workers will remotely assess clinical and emotional status, adherence to drug therapy, and carry out nutritional adjustments.
9687911|NCT04862026||Control group|Patients with standard administration.
9687912|NCT04862104|Experimental|Intervention group (Discharge Training)|In addition to the general care provided by health professionals, the study group received discharge training created according to the Nursing Interventions Classification.
9687913|NCT04862104|No Intervention|Control group (Usual Care)|The control group continued to receive the routine care
9687914|NCT04861857|Experimental|Parmigiano Reggiano|participants will consume 50 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
9687915|NCT04861857|Active Comparator|Whey Protein|participants will consume 20 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week
10180115|NCT03796117|Experimental|Experimental Group 2: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
10180116|NCT03796130|Experimental|(A)Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomlyallocated intotwo groups.~In group (A): myomectomy will be performed before ART~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
10180117|NCT03796130|No Intervention|(B) No myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (B):women will have their trial of ART without myomectomy"
9687916|NCT04862052|Active Comparator|Xience chromium-cobalt everolimus eluting stent|The Xience chromium-cobalt everolimus eluting stent will be evaluated in prior implanted coronary drug eluting stent restenosis.
10180118|NCT03795961|Experimental|Active tDCS group|This group will include 42 patients with CTS Intervention (active transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
9687917|NCT04862052|Experimental|Emperor paclitaxel coated balloon|The Emperor paclitaxel coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
9687918|NCT04862052|Experimental|Magic Touch sirolimus coated balloon|The Magic Touch sirolimus coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
9687919|NCT04861948|Experimental|Cohort A|
9687920|NCT04861948|Experimental|Cohort B|
9687921|NCT04861948|Experimental|Cohort C|
9687922|NCT04861948|Experimental|Cohort D|
9687923|NCT04862039|Experimental|Virtual Reality (VR) devices|intervention group (VR).
9687924|NCT04862039|No Intervention|control group|the standard of care (control group, no VR)
9687925|NCT04862117|Active Comparator|Active stimulation QD|
9687926|NCT04862117|Active Comparator|Active stimulation QID|
9687927|NCT04861896|Experimental|"My Guide (psychoeducation & self management program)"|Smartphone-based program plus standard clinical care.
9687928|NCT04861740|Experimental|Screening + Autism ALERT|Clinics in the intervention arm receive Autism ALERT plus an ASD screening intervention (START Autism).
9687929|NCT04861740|Active Comparator|Screening Only|Clinics in the comparison intervention (control) arm receive the ASD screening intervention only (START Autism).
9687930|NCT04861909||AT LISA tri 839MP|Patients implanted with AT LISA tri 839MP
9687931|NCT04861636|Experimental|HealthTRAC|Both the standard behavioral weight control (SBWC) and HealthTRAC interventions include 4 months of intensive treatment, followed by monthly maintenance sessions for a 12-month program. SBWC includes attention to diet and activity coupled with behavioral modification strategies. HealthTRAC integrates these key constructs with an emotion regulation intervention with documented efficacy in teens.
9687932|NCT04861636|Active Comparator|Standard Behavioral Weight Control (SBWC)|4 months of intensive treatment focused on attention to diet and activity coupled with behavioral modification strategies, which is then followed by monthly maintenance sessions for a 12-month program.
10180119|NCT03795961|Sham Comparator|Sham tDCS group|This group will include 42 patients with CTS Intervention (sham or inactive transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
10180120|NCT03796169|Experimental|Endoscopist|Intervention for personal notification, open notification and colonoscopy quality education by a GI faculty
9687933|NCT04861649|Experimental|Effect and mechanism of fecal microbiota transplantation on patients with COPD malnutrition|"During COPD stable period, nasal and intestinal tubes were placed and fecal bacteria were transplanted from healthy people (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
9687934|NCT04861701|Experimental|Stretching exercise group (SE)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
9687935|NCT04861701|No Intervention|Control group (CON)|All subjects will be assigned to the experimental or control group by randomization. Thus, there will be totally 2 groups : Stretching exercise group (SE) and Control group (CON).
9687936|NCT04861688|Active Comparator|NeuroAiD II™ (MLC901)|Recommended treatment is 2 capsules orally, 3 times a day (i.e. 6 capsules per day). Treatment is 12 weeks.
9687937|NCT04861688|Placebo Comparator|Placebo|Capsule 2 capsules orally, 3 times a day
9687938|NCT04861792|No Intervention|Usual Care|Patients seen before the randomly assigned intervention launch date.
9687939|NCT04861792|Experimental|Quality Improvement Intervention|Patients seen after the randomly assigned intervention launch date.
9687940|NCT04861792|Experimental|Quality Improvement Intervention Plus Decision Aid|Patients at 50% of practices (nested within waves) that are randomized to receive the patient decision aid for AUD in addition to the Michigan SPARC intervention.
9687941|NCT04861753||Reiki|"The modern-day Reiki (pronounced ray-kee) practiced in the United States originated in Japan with Mikao Usui in the early 1900s. Reiki is a complementary and adjuvant therapeutic technique. Reiki, which is classified as an energy healing therapy, is a technique of channeling universal energy in order to reduce stress, promote relaxation, and enhance well-being."
9687942|NCT04861753||Back massage|Massage therapy involves the manipulation of the soft tissues of the body by touch. It consists of gentle movements such as effleurage, petrissage and percussion.
9687943|NCT04861753||Control|Routine postoperative care was given to the control group without any intervention
9687944|NCT04861779|Experimental|Phase 1a Dose Escalation|Multiple dose levels of HSK29116 to be evaluated; determination of MTD/Phase 1b recommended dose
9696083|NCT04770987||control|30 healthy, age and gender matched individuals without hyperlaxity
10188010|NCT03720418|Experimental|OXB-102 Selected Dose|Selected Dose of OXB-102 Single Administration (Part B: double-blind)
10180121|NCT03796286|Placebo Comparator|Control bar (0 g fiber)|Each subject will be randomly assigned to consume a control sports bar-type product (0 grams of fiber) at one treatment visit.
10180122|NCT03796286|Experimental|Medium-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 10 grams of fiber) at one treatment visit.
10180123|NCT03796286|Experimental|High-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 20 grams of fiber) at one treatment visit.
10180124|NCT03796143|Experimental|ACT self-help book condition|Participants in this condition will be asked to read The Mindfulness and Acceptance Workbook for Depression by Strosahl and Robinson (2008), a self-help book based on acceptance and commitment therapy.
10180125|NCT03796143|Active Comparator|CBT self-help book condition|Participants in this condition will be asked to read Cognitive Behavioral Workbook for Depression by Knaus (2006), a self-help book based on acceptance and commitment therapy.
10180126|NCT03796143|Other|Choice of two self-help books|Participants in this condition will have the option of receiving either the self-help book by Strosahl and Robinson (2008) or the book by Knaus (2006).
10180127|NCT03796026|Experimental|Seltorexant Followed by Placebo|Participants will receive seltorexant (40 milligram [mg] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.
9687945|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R CLL or SLL|CLL/SLL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
9687946|NCT04861779|Experimental|Phase 1b Dose Expansion in R/R MCL|MCL patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
9687947|NCT04861779|Experimental|Phase 1b Dose Expansion in other R/R B-cell Malignancy|Patients must have received at least one systemic treatment and failed or relapsed, of which at least half of the subjects must have received covalent BTK inhibitors and have BTK C481 mutation.
9687948|NCT04861675||Prospective follow up cohort study|Assessment of Changes in Oral Health-related Quality of Life , Oral Hygiene status and Body Growth in Egyptian Children with Special Health Care Needs following Dental Treatment under General Anaesthesia
9687949|NCT04861961|Active Comparator|Laparoscopic duodenal switch (DS)|Standard duodenal switch (double anastomoses). Roux-en-Y reconstruction.
9687950|NCT04861961|Active Comparator|Laparoscopic Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S)|"Simplified duodenal switch with one anastomosis. Duodeno-ileal omega reconstruction (Billroth II-like)."
9687951|NCT04861961|Active Comparator|Laparoscopic one anastomosis gastric bypass (OAGBP)|Gastric bypass of one anastomoses. Gastro-jejunal omega reconstruction (Billroth II).
9687952|NCT04861467|Experimental|Experimental: Camrelizumab|camrelizumab as maintenance therapy after Chemoradiation(evaluation results：PR/SD)
9687953|NCT04861467|No Intervention|observation|observation after Chemoradiation
9687954|NCT04861467|Experimental|Exploration：Camrelizumab|camrelizumab for maintenance after chemoradiation( evaluation results：CR)
9687955|NCT04861922|Experimental|Unfractionated Heparin|A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour), which last 5 days or until the death or discharge.
9687956|NCT04861922|Placebo Comparator|Normal saline|The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.
9687957|NCT04861519||adult subjects who underwent a clinically indicated invasive coronary angiography|adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.
9687958|NCT04861818|Experimental|Morning group|Participant are assigned to the morning group (7-9am) for 30-min exercise/rest interventions.
9687959|NCT04861818|Experimental|Afternoon group|Participant are assigned to the afternoon group (3-5pm) for 30-min exercise/rest interventions.
10180128|NCT03796026|Experimental|Placebo Followed by Seltorexant|Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.
10188011|NCT03720418|Sham Comparator|Imitation Surgical Procedure|General anesthesia with bilateral skin incisions (Part B: double-blind)
9687960|NCT04861714|Active Comparator|Regeneten|Standard subscapularis repair with Regeneten augmentation group
9687961|NCT04861714|Other|Standard repair|Standard subscapularis repair
9687962|NCT04861493||Smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and smoking at least 10 cigarettes /day for a minmum of 5 years.
9687963|NCT04861493||Non-smokers with stage III,IV periodontitis|patients with stage III,IV periodontitis having CAL>5 mm and PD>5 mm in one or more sites and bleeding on probing >30% and they are never smoked before.
9687964|NCT04861493||Healthy patients|patients free from periodontitis or any systemic disease and never smoked before.
9687965|NCT04861324|No Intervention|Prenatal Care/Nutrition Education|Standard prenatal care with primary care physician with USDA-based federal guidelines
9687966|NCT04861324|Experimental|Fruit/veggie + postprandial physical activity|Nutrition education on increasing fruit and vegetable consumption and physical education on increasing postprandial physical activity for the duration from GDM diagnosis till delivery
9687967|NCT04861506||acute or subacute thromboembolic occlusions of lower extremity|The patients are confirmed with acute or subacute thromboembolic occlusions of lower extremity, and which are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as PMT pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
9687968|NCT04861571|Experimental|Single arm|All subjects will receive VLCD for 8 weeks.
9687969|NCT04861402||Non-intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h Non-intubated during the monitoring carried out in the study Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
9687970|NCT04861402||Intubated COVID-19 group|Men and women (not pregnant) Older than 18 years old Diagnosis of COVID-19 confirmed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) Subjects intubated Time between admission and study inclusion ≤ 72h For intubated group time between IUC admission and study inclusion ≤ 72h Time between onset symptoms and study inclusion ≤ 14 days No neurological acute disease No cutaneous injury in the head to impossibility the ICP monitoring No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously.
9687971|NCT04861402||Health control group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring No symptoms of COVID-19 on the last 15 days~• For healthy group: No previous neurological disease No chronic disease as Diabetes Mellitus Type 2, Chronic Obstructive Pulmonary Disease (COPD), Heart Failure, hypertension or Chronic Kidney Disease (CKD) No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
9687972|NCT04861402||Non-COVID-19 and non-neurological disease intubated group|"Men and women (not pregnant) Older than 18 years old No cutaneous injury in the head to impossibility the ICP monitoring~• For intubated group: ICF signed by the participant or his/her legal representative* Intubated patients for others causes than COVID-19 or neurological diseases IUC admission and study inclusion ≤ 72h No symptoms of COVID-19 on the last 15 days No cutaneous injury in the head to impossibility the monitoring with the transcranial doppler helmet Patients who have not been submitted to decompressive craniectomy previously."
9687973|NCT04861428|Experimental|IQOS / Smoking as usual|Two weeks of IQOS, followed by two weeks of cigarette smoking as usual.
9687974|NCT04861428|Active Comparator|Smoking as usual / IQOS|Two weeks of cigarette smoking as usual, followed by two weeks of IQOS.
9687975|NCT04861480|Experimental|C-4-29 cells|Infusion of C-4-29 cells by dose-escalating
9687976|NCT04861233||All Participants|Participants diagnosed with constipation who have been prescribed with lubiprostone for the first time in a real-world setting will be observed prospectively and followed up for 12 months after initiation of study medication. Treatment regimen, frequency of laboratory and clinical assessments will be determined by investigator in a routine clinical practice.
9687977|NCT04861662|No Intervention|Keratinized Mucosa Sufficient (KMS)|Implants exhibiting the width of keratinized mucosa (KM) ≥2 mm at the midbuccal aspect
9687978|NCT04861662|No Intervention|Keratinized Mucosa Deficient (KMD)|Implants exhibiting KM<2 mm at the midbuccal aspect
9687979|NCT04861662|Experimental|Free Gingival Graft (FGG)|Implants with KM<2 mm initially and having surgically increased keratinized mucosa with free gingival graft after prothesis delivery
9687980|NCT04861246|Experimental|Experimental|Epidermal pigmented lesion
9687981|NCT04861337|Experimental|Remimazolam Group|Remimazolam infusion is initiated after induction of general anesthesia at a rate of 0.25 mg/kg/h and stopped 15 minutes before the end of surgery.
9687982|NCT04861337|Placebo Comparator|Placebo Group|Placebo (0.9% saline) infusion is initiated after induction of general anesthesia at the same rate as in the remimazolam group and stopped 15 minutes before the end of surgery.
9687983|NCT04861129|Experimental|Bowen therapy group|The experimental group will receive Bowen therapy according to ISBT Bowen Therapy® (Black & Murray, 2005). It may include sequences 1, 4, 2, hamstrings (movements 1-6) and sacrum sequences in the prone position, and hamstrings sequence (7-18 movements) and 3 in the supine position,. The sequences may also include Bowen movements in the scalenes, trapezius, all erector spinae, sacro-iliac joint ligaments, gluteus maximus and medius, tensor fasciae latae, and gastrocnemius. The application of Bowen sequences is varied between sessions and participants depending on the presenting functional deficit and treatment response.
9687984|NCT04861129|Sham Comparator|Sham Bowen Therapy group|The control group will receive a sham Bowen therapy with the same number of treatment session, treatment time and rest time, that received in the experimental group. However, it consists of gently placing the hands over the areas just enough to maintain contact for the desired time as required by Bowen Therapy, without applying Bowen movement, which is considered the active principle of this technique.
9687985|NCT04861116|Experimental|Intervention program for test anxiety|12 weekly ICT-delivered individual sessions.
9687986|NCT04861116|No Intervention|Control|Waiting list that will have access to the intervention program after the 6-month follow-up assessment.
9687987|NCT04861376|Experimental|Pueraria lobata group|Pueraria lobata will be made into granules.
9687988|NCT04861376|Experimental|Pueraria thomsoni group|Pueraria thomsoni will be made into granules.
9687989|NCT04861376|Placebo Comparator|Placebo group|The dosage form, specifications and packaging of the placebo will be no different from those of Pueraria lobata and Pueraria thomsoni Granules, and the smell and taste will be basically the same.
9687990|NCT04861194|Experimental|Neurovascular-sparing 5x7.25 Gy MRgRT|MRgRT to the prostate in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb
9687991|NCT04861415|Active Comparator|Conventional Fractionated Radiation|"Prostate Only Radiation - 37.5Gy in 15 daily fractions to the prostate and proximal/entire seminal vesicle~Prostate + Nodal Radiation - 46Gy in 23 daily fractions to the prostate, seminal vesicle and regional lymph nodes"
9687992|NCT04861415|Experimental|Stereotactic Body Radiotherapy|"Prostate Only Radiation - 25Gy in 5 fractions to the prostate and proximal/entire seminal vesicle~Prostate + Nodal Radiation - 25Gy in 5 fractions to the prostate, seminal vesicle and regional lymph nodes"
10187488|NCT03725774|Experimental|Quasi-experimental uncontrolled, before-and-after|The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action
9687993|NCT04861142||Patients adherent to the anti-osteoporotic medication|
9687994|NCT04861142||Patients non-adherent to the anti-osteoporotic medication|
9687995|NCT04861051|Other|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
9687996|NCT04861168|Experimental|Driving pressure guided ventilation|Patients will be mechanically ventilated with driving pressure guided ventilation with VT 6-8 ml /kg of predicted body weight, and after recruitment we will return to the baseline PEEP 5 cmH2O that will be increased by 2 cmH2O until reaching the lowest possible driving pressure for every patient. Each PEEP level will be applied for 10 respiratory cycles and DP will be calculated at the last cycle.
9687997|NCT04861168|Active Comparator|Conventional protective lung strategy|Patients will be mechanically ventilated with conventional protective lung strategy with VT 6-8 ml /kg of predicted body weight, after recruitment, we will return to the baseline PEEP 5 cmH2O and will be maintained until the end of surgery.
9687998|NCT04860934|Active Comparator|Physical therapy|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks
9687999|NCT04860934|Experimental|Physical therapy + Dual Task Training Program|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the selected physical therapy program as control group three times weekly for 8 successive weeks.
9688000|NCT04860999|Experimental|Somatic Dysfunction|This is the single study arm. All participants completed an osteopathic postural examination and an osteopathic manipulative treatment. Participants also completed a biomechanical assessment prior to and following the osteopathic manipulative treatment to evaluate effects of the treatment on the gait asymmetry.
9688001|NCT04860908||covid exposed|women who were exposed to covid 19 during pregnancy
9688002|NCT04860908||covid vaccinated|women who were vaccinated to covid 19 during pregnancy
9688003|NCT04860895|Other|Nasopharyngeal swabs|Nasopharyngeal swabs samples of volunteers who is referred with suspicion of Covid19.
9688004|NCT04860869||Post-COVID|32 patients with Post-COVID syndrome
9688005|NCT04860596|Experimental|collaborative health management model program|nursing education and self care program
9688006|NCT04860596|No Intervention|Routine care|Tranditional education program
9688007|NCT04860622||Pregnant women|500 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment, and are TPOAb negative. Serum thyroid function tests will be obtained on the first visit.
9688008|NCT04860648|Experimental|LUS group|patients receive lung ultrasound examination, and doctors give the treatment according to the LUS results
9688009|NCT04860648|No Intervention|Control group|patients receive no lung ultrasound examination and other intervention
9688010|NCT04860817|Experimental|Target CD7 CAR-T cells|Three dose levels will be evaluated. The CAR-T cells will be administered with Cytoxan and fludarabine.
9696084|NCT04770649||COVID-19 vaccine recipients|Subjects who have an appointment to receive a COVID-19 vaccine, and are able to provide samples prior to and after their first vaccine dose.
9696085|NCT04770662|Other|research group|patients who are willing to participate in the study
9696475|NCT04766554|Active Comparator|Cerebral Oxymetry Monitoring|"The following procedures should be performed sequentially in the event of cerebral desaturation after 30 seconds:~The positioning of the head, the presence of facial plethora, and bad position of catheters should be corrected;~In case of arterial hypotension, the causal factors should be assessed and treated;~In the presence of arterial hypoxemia, the causal factors should be assessed and treated to maintain a PaO2 > 150 mmHg;~In the presence of hypercapnia, adjust the ventilation parameters avoiding hyperventilation;~In the presence of anemia, the causal factors should be assessed, and the decision to undergo transfusion should also take into consideration the presence of tissue hypoperfusion;~In cases of SvO2 below 70% and signs of hemodynamic instability, optimize fluid replacement and ventricular global contractility;~Assess the increase of brain consumption of O2, avoiding the superficial level of anesthesia, hyperthermia, and tremors."
9696476|NCT04766554|No Intervention|Control Group|Patients will be treated according to the attending anesthesiologist, without the monitoring of cerebral oximetry, but to maintain a heart rate between 70 - 100 bpm, lactate levels <3 mmol/L and urine output> 0.5mL/Kg/h. In case of arterial hypotension the causal factors should be assessed and treated; in case of SvO2 below 70% and signs of hemodynamic instability, optimize volume replacement and global ventricular contractility through inotropic agents (epinephrine, dobutamine or milrinone); in the presence of anemia (Hb <6 to 7g/dL during CPB or Hb <8g/dL in the pre-CPB or post-CPB period), the causal factors should be assessed and the decision to transfuse should also take into account the presence of hypoperfusion tissue (increased lactate, low SvO2, acidosis); in episodes of bradycardia with hemodynamic instability, atropine may be used.
9696477|NCT04766528|Experimental|Mediterannen diet|The MED diet was abundant in fiber, micronutrients and plant-based proteins. The diet was rich in essential FA like monounsaturated fatty acids (MUFA) and n-3.
9696478|NCT04766528|Experimental|Canadian diet|The NAM diet had a high content in saturated fatty acids (SFA) and simple sugar and was low in fiber.
9696479|NCT04766632|Experimental|one group|patients with high grade glioma
9696480|NCT04766658|Other|Water Swallow Intervention First|Subjects will complete voice recordings after water swallows and then perform voice recordings after gargle phonation.
9696481|NCT04766658|Other|Gargle Phonation Intervention First|Subjects will complete voice recordings after gargle phonation and then perform voice recordings after gargle phonation.
9696482|NCT04766489|Experimental|Complete Deongestive Therapy|Patients will be given complete decongestive therapy for 5 days a week and for a mean of 20 sessions. Each session will be of approximately 2 hours and 15 minutes in duration, although short stretch bandaging will be left on for 23 hours a day.
9827597|NCT02461628|No Intervention|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
9827598|NCT02461693|Experimental|Caffeine|One-time treatment with 200mg caffeine pill
9827599|NCT02461693|Placebo Comparator|Placebo|One-time treatment with lactose-based placebo pill
10180129|NCT03796234|Experimental|Dietary and physiotherapy|A multidisciplinary program was developed. 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
10180130|NCT03796234|Experimental|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
10180131|NCT03795987|Experimental|Open Label Treatment Arm|Intervention with NightWare Therapeutic System
10180132|NCT03795896|Experimental|Optic nerve sheath diameter|The intracranial pressure will be measured by optic nerve sheath diameter while the patient in supine position with 30 -degree bed position .The linear probe in the two -dimensional mode will be placed gently on the upper eyelid without pressure .In linear horizontal orientation for both right and left optic nerve sheath will be measured
10180133|NCT03795909|Experimental|Ruxolitinib and Placebo|Ruxolitinib 2.5 mg twice daily by oral
9688011|NCT04860570||Open Appendectomy (OA) + Double-ring wound-edge protector (2RWEP)|Intervention group: Patients with diagnosis of acute appendicitis treated by open appendectomy using a double-ring wound-edge protector.
9688012|NCT04860570||Laparoscopic Appendectomy (LA)|Control group: Patients with diagnosis of acute appendicitis treated by laparoscopic appendectomy.
10180134|NCT03795909|Placebo Comparator|Placebo and Ruxolitinib|Sugar pill 2.5 mg twice daily by oral
9688013|NCT04860739|Experimental|VACCINATION|One standard dose of COMIRNATY in adult subjects (18 years old) having received prior VAXZEVRIA vaccination.
9688014|NCT04860739|No Intervention|NO INTERVENTION|No vaccination in adult subjects (18 years old) having received prior VAXZEVRIA vaccination. If primary analysis at day 14th confirms the starting hypothesis, subjects randomized to this arm will be considered for administration of one dose of COMINARTY at day 28th according to Public Health Department of the Ministry of Health recommendations on heterologous vaccination.
10180135|NCT03795935|Experimental|Treatment|Patients who were previously implanted with a traditional DBS lead and have subsequently developed stimulation induced side effects will gain significantly more tremor control without side effects when re-implanted with a directional DBS lead. We expect these patients' quality of life will improve. These patients typically will have had significant tremor relief (greater than 75% reduction from preoperative tremor rating scale) without side effects at their one year post operative follow-up. With the expected disease progression they will have had to increase their DBS stimulation to the degree that their DBS now causes side effects in order to block their tremor
9688016|NCT04860609|Active Comparator|Conventional Physiotherapy|It includes the pre-physiotherapy session by conventional physiotherapy
9688017|NCT04860609|Experimental|Lumber spinal decompression|It includes the pre-physiotherapy session iby lumber spinal decompression along with conventional therapy.
9688018|NCT04860726|Experimental|GROUP A|Joint mobilization
9688019|NCT04860726|Experimental|GROUP B|Myofascial release
9688020|NCT04860726|Experimental|GROUP C|Joint Mobilization & Myofascial release
9688021|NCT04861103|Experimental|Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing|Therapeutic Lovenox dosing split into three times a day dosing for 5 day. Xa levels a measured.
9688022|NCT04860674|Experimental|PD-1+ICE|PD-1 inhibitor combined with icyclophosphamide, carboplatin, etoposide chemotherapy
9688023|NCT04860440||End-Stage Renal Disease on haemodialysis|Wearing accelerometer (fitness tracker) for 7 days.
9688024|NCT04860440||Low clearance pre-dialysis patients|Wearing accelerometer (fitness tracker) for 7 days.
10180136|NCT03795948|Other|PROM Evaluation for stroke patients|Patient will be enrolled and PROMs will be collected.
9688026|NCT04860856|Experimental|Hematoma block|Fracture site injection of 20 mL of 0.5% ropivacaine with an 18-gauge needle (150 mm length).
9688027|NCT04860856|Placebo Comparator|Normal saline injection|Fracture site injection of 20ml of normal saline.
9688028|NCT04860505|Experimental|Doxycycline and Biktarvy|Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.
9688029|NCT04861207|Experimental|Cladribine|
9688030|NCT04861389|Experimental|Distal transradial access (dTRA)|Distal transradial access for primary percutaneous coronary intervention in STEMI patients
9688031|NCT04861389|Active Comparator|Transradial access (TRA)|Transradial access for primary percutaneous coronary intervention in STEMI patients
9688032|NCT04860531|Active Comparator|Group (I) Platelet Rich Plasma|The participants are randomly assigned for intra-articular injection with autologous platelet rich plasma . The treated segments are determined by clinical signs and MRI detected facet joint synovitis .
9688033|NCT04860531|Active Comparator|Group (II) Corticosteroids|The participants are randomly assigned for intra-articular injection with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .
9688034|NCT04860492|Active Comparator|Renalof|Patients will be given and, advised to take Renalof tablets 325mg three times a day for 90 days
9688035|NCT04860492|Placebo Comparator|Placebo|Patients will be given and, advised to take Placebo three times a day for 90 days
9688036|NCT04860414|Experimental|Major Cognitive Impairment|
9688037|NCT04860414|Experimental|Minor Cognitive Impairment|
9688038|NCT04860414|Active Comparator|No Cognitive Impairment|
9688039|NCT04860557||problematic video game player|
9688040|NCT04860557||control subjects|
9688041|NCT04860479||Infants: 28 days - 12 month|inguinal sonoanatomy
9688042|NCT04860479||small children: 13 months - 36 months|inguinal sonoanatomy
9688043|NCT04860479||preschool age: 37 months - 72 months|inguinal sonoanatomy
9688044|NCT04860479||school age: 73 months - 9 years|inguinal sonoanatomy
9688045|NCT04860479||Preadolescant: >9 years - 12 years|inguinal sonoanatomy
9688046|NCT04860479||Adolescants: >12 years - 18 years|inguinal sonoanatomy
9688047|NCT04860284|Active Comparator|Intervention arm|Participants will receive 400mg of hydroxychloroquine tablets 12-hourly on day 1 and 200mg 12-hourly on day 2 to day 5 in addition to standard of care treatment for COVID-19
10180137|NCT03795844|Active Comparator|Nathanson retractor|Liver retraction in group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved.
9688048|NCT04860284|No Intervention|Control arm|Participants will receive only standard of care treatment for COVID-19
9688049|NCT04860388|Active Comparator|unilateral labially impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of labially impacted maxillary canines compared with the contralateral canines that served as control teeth.
9688050|NCT04860388|Active Comparator|unilateral palatally impacted maxillary canines|Distalization of the maxillary molars and/or protrusion of the maxillary and mandibular incisors made for creating sufficient space for impacted maxillary canines. After sufficient space for impacted maxillary permanent canine was obtained combine surgical-orthodontic treatment was performed via closed eruption technique. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The periodontal health of palatally impacted maxillary canines compared with the contralateral canines that served as control teeth.
9688051|NCT04860323|Experimental|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 703/HPTN 081 (NCT02568215).
9688052|NCT04860362|Experimental|Treatment|PEERS weekly sessions - parallel teens and parent/caregiver groups
9688053|NCT04860362|Other|Wait List Control|Offered intervention at a later date
9688054|NCT04860310||21 years old group|
9688055|NCT04860310||28 years old group|
9688056|NCT04860310||35 years old group|
9688057|NCT04860310||42 years old group|
9688058|NCT04860310||49 years old group|
9688059|NCT04860427|Active Comparator|Trapezoidal condylar plate|Trapezoidal condylar plate open reduction and internal fixation of subcondylar fractures
9688060|NCT04860427|Active Comparator|two miniplates|two miniplates open reduction and internal fixation of subcondylar fractures
9688061|NCT04860258|Experimental|CVnCoV Vaccine|Participants will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29.
9688062|NCT04860141|Experimental|Gabapentin group|The patient in this group will take gabapentin 600mg PO 2 hours prior to his or her surgery.
9688063|NCT04860141|Placebo Comparator|Placebo group|The patient in this group will take a placebo that looks like gabapentin PO 2 hours prior to his or her surgery.
9688064|NCT04860128|Experimental|"RUNKEEPER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
9688065|NCT04860128|Experimental|"ADIDAS Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
9688066|NCT04860128|Experimental|"SAMSUNG Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
9688067|NCT04860128|Experimental|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
9688068|NCT04860128|No Intervention|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
10180138|NCT03795844|Active Comparator|snake retractor|Liver retraction in group 2 ; 5 mm incision under the xiphoid will be used. Snake retractor was placed and liver left lobe retraction would be achieved.
10180139|NCT03795844|Active Comparator|fan retractor|Liver retraction in group 3 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus
10180140|NCT03795844|Active Comparator|CONTROL GROUP|Liver retraction in group 4 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools
9688069|NCT04860180|Experimental|A, surgery|adrenalectomy
9688070|NCT04860180|No Intervention|B, observation|conservative follow up
9688071|NCT04860167|No Intervention|Group A|The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.
9688072|NCT04860167|Active Comparator|Group B|The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
9688073|NCT04860167|Active Comparator|Group C|Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure & topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
9688074|NCT04860115|Experimental|Block group|Patients in a Block group will be anesthetized and receive PECS II+PIFB with dexmetomidine prior to their surgery.
9688075|NCT04860115|No Intervention|Control group|Patients in a Control group will receive a standard general anesthesia the same way as patients in the interventional group but without regional anesthesia.
9688076|NCT04860154|Experimental|PDT with stent|Before photodynamic therapy, candidate patients undergoing biliary biopsy and biliary duct drainage. If pathology shows a bile duct malignancy, PDT therapy will carry out until total bilirubin drops below 100 μmol/L.Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or metal stent will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
9688077|NCT04860154|No Intervention|ERCP stent|After obtaining bile duct biopsy, the candidates were placed with biliary plastic stents or metal stents directly.
9688078|NCT04860011|Experimental|SGLT2i|Sodium-glucose Co-transporter-2 inhibitors
9688079|NCT04860011|Experimental|Thiazide|Thiazide or thiazide like diuretic
9688080|NCT04860050|Experimental|TPG|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 24 weeks
9688081|NCT04860050|Placebo Comparator|Control|76 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (colored acacia gum) product during 24 weeks
9688082|NCT04859894||Covid19|Patients aged >18 years with confirmed Covid19 disease with symptoms >12 weeks, not better explained by other disease
9688083|NCT04859738|Experimental|Experiment I Group (Lidocaine Spray)|Lidocaine Spray was applied to Experiment I group before peripheral intravenous catheter application.
9688084|NCT04859738|Experimental|Experiment II Group (Benzokain Sprey)|Benzokain Sprey was applied to Experiment II group before peripheral intravenous catheter application.
9688085|NCT04859738|Placebo Comparator|Placebo Group|Alcohol was administered to the placebo group prior to peripheral intravenous catheter application.
9688086|NCT04859777|Experimental|Part A:|Dose-escalation oral MPT-0118 BID
9688087|NCT04859777|Experimental|Part B:|Dose-escalation oral MPT-0118 BID + pembrolizumab (IV)
9688088|NCT04859777|Experimental|Part C:|Dose-expansion oral MPT-0118 BID + pembrolizumab (IV)
9688089|NCT04859751|Experimental|VB4-845 Injection|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
9688090|NCT04859686|Experimental|Treatment|Participants underwent intervention.
9688091|NCT04859686|No Intervention|Waitlist|Participants received no intervention.
9688092|NCT04859712||Trial group: 45 patients with lumbar disc herniation|"The Pulse Detection System of Sound Waves  was used to collect three parts and five layers of pulsed sound waves from the hands of 45 patients with lumbar disc herniation."
9688093|NCT04859712||Control group :45 relatively healthy people|"The Pulse Detection System of Sound Waves  was used to collect the three-parts and five-layers pulse sound waves of the hands of 45 relatively healthy people."
9688094|NCT04859933||AVNA group|Group of historical controls beeing treated with AV-node ablation
9688095|NCT04859933||AVNI group|Inculudes all patients beeing treated with AV-node isolation
9688096|NCT04859803|Active Comparator|Group R (RIB)|patients will receive rhomboid intercostal block under ultrasound guidance.
9688097|NCT04859803|Sham Comparator|Group C|patients will receive sham block
9688098|NCT04860063|Placebo Comparator|Placebo|Placebo three times daily for 6 months
9688099|NCT04860063|Experimental|Berberine|Berberine 500 mg three times daily for 6 months
9688100|NCT04860024||ADHD|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
9688101|NCT04860024||Healthy|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
9688102|NCT04859881||Barotrauma/cases|Cases were defined as patients with barotrauma consulted with the Surgery Department
9688103|NCT04859881||No braotruma/Controls|Controls were selected from a random sample of the COVID-19-ARDS cohort.
9688104|NCT04859998|No Intervention|Control group|Participants in this group will simply continue with their daily living and therapies. They will be assessed before and after the 10 week program but will not take part in it.
9688105|NCT04859998|Experimental|Experimental group|Participants in this group will take part in the 20 session dog-assisted therapy. This therapy will be added to their usual daily living and therapies. They will be assessed before and after the 10 week program.
9688106|NCT04859673|Active Comparator|study group|Patients will received 3,000 pulses, 1,500 pulses per site at a frequency of 12 Hz per session with the submaximal pressure between 0.39 and 1.95 mJ/mm2 (1.0 and 5.0 bar), depending on the level which the patient can tolerate without local anesthetics.
9688107|NCT04859673|Sham Comparator|control group|The patients in this group will be treated by sham radial extracorporeal shock wave therapy. Stimulation will not deliver as the transmitter head will be removed. The patients will receive the same frequency of air pressure and sound
9688108|NCT04860219|No Intervention|Control Group|None of the participants in the Control Group received lactoferrin
9688109|NCT04860219|Active Comparator|200 mg lactoferrin orally once daily Group|received 200 mg lactoferrin orally once daily
9688110|NCT04860219|Active Comparator|200 mg lactoferrin orally twice daily Group|received 200 mg lactoferrin orally twice daily
9688111|NCT04859816|Experimental|Roux-en-Y gastric bypass operated participants|Roux-en-Y gastric bypass operated participants in weight stable phase > 1 year from surgery
9688112|NCT04859816|Experimental|Control participants|Age, sex, and BMI-matched un-operated participants.
9688113|NCT04859855|Experimental|Restrictive strategy (arm A)|Transfusion of RBC if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
9688114|NCT04859855|Experimental|Liberal strategy (arm B)|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL.
9827600|NCT02461745|Active Comparator|Genotype 1a|Study participants with chronic Hepatitis C Genotype 1A receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) and RBV (ribavirin tablets) for 12 weeks.
9688115|NCT04859790|Active Comparator|Active SCAR Intervention|In this arm, participants will complete baseline measures, receive the SCAR intervention, and complete follow-up measures one month following the intervention.
9688116|NCT04859790|No Intervention|Waitlist Control|Participants assigned to the waitlist control condition will complete baseline measures and measures one month following their baseline appointment. After they complete the follow-up measures, they will be offered the SCAR intervention.
9688117|NCT04859660|Experimental|Tamsulosin- intervention group|
9688118|NCT04859660|Placebo Comparator|Placebo group|
9688119|NCT04859647|Other|Therapy Intervention|Method of Levels Therapy Intervention - Clients will choose how many sessions to attend during the 6 months therapy window. Clients will also choose how often to attend sessions and the duration of each session.
9688120|NCT04859634||Zhongshan Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
10180141|NCT03795818|Other|IPT-A|Interpersonal psychotherapy for adolescents (IPT-A) is a psychosocial treatment for adolescents. It has been shown to be effective for adolescents with depression. It is now being studied as to its benefit for adolescents who meet criteria for PTSD or have subthreshold PTSD symptoms.
10180142|NCT03795792|Experimental|Curcumin|Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
9688121|NCT04859634||Shenzhen Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
9688122|NCT04859634||Beijin Tongren Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
9688123|NCT04859634||Xudong Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
9688124|NCT04859634||IKang Physical Examination Center|The participant only needs to take an ultra-widefield fundus image as usual.
9688125|NCT04859634||Yangxi General Hospital People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
9688126|NCT04859634||Guangdong Provincial People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
9688127|NCT04859907|Experimental|Clamp-like system|
9688128|NCT04859907|Active Comparator|Plates and screws|
9688129|NCT04859725|Experimental|Hyperspectral Imaging with Snapscan camera|"Included patients will undergo a resection of the low grade glioma as standard-of-care. Hyperspectral imaging data will be acquired by the SnapScan HSI camera mounted on the (standard) surgical microscope.~As such, the surgical procedure does not deviate from the common, standard-of-care surgical procedures, apart from the acquisition of intraoperative scanning images using the SnapScan HSI camera on the microscope. The objective of this all is to get an initial high quality in vivo dataset to start exploring the potential of the technology."
9688130|NCT04859621|Experimental|Vitamin D3 4000 IU|4000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
9688131|NCT04859621|Experimental|Vitamin D3 2000 IU|2000IU Vitamin D3 Oral Tablet plus standard antibiotic therapy
9688132|NCT04859621|Placebo Comparator|Placebo|Placebo Oral Tablet plus standard antibiotic therapy
9688133|NCT04859556|Experimental|10k 25G cutter|New cutter, with a 10,000 cut per minute blade
9688134|NCT04859556|Active Comparator|5k 25G cutter|Traditional cutter, with a 5,000 cut per minute blade
9688135|NCT04859569|Experimental|LY01011|Subcutaneous injection of LY01011 120 mg (1.7ml) every 4 weeks for a maximum of 13 consecutive doses up to week 49.
9688136|NCT04859569|Active Comparator|Xgeva®+LY01011|After subcutaneous injection of Xgeva® 120 mg (1.7ml) every 4 weeks 3 times, patients of Xgeva® group continue to receive LY01011 120 mg (1.7ml) every 4 weeks for ten doses consecutively.
9688137|NCT04859478|Other|All eligible patients|All patients undergo the same CT protocol in addition to standard care.
9688138|NCT04859387|Experimental|group A|set of pragmatic shoulder techniques
9688139|NCT04859387|Active Comparator|group B|traditional physical therapy
9688140|NCT04859400|Experimental|Intervention|"standardized nutritional program including a nutritional supplement~standardized exercise program~app for monitoring."
9826769|NCT02431806|Experimental|Levomilnacipran 80 mg|Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.
10180143|NCT03795792|Placebo Comparator|Hydrollased collagen|Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
9688141|NCT04859400|No Intervention|Control|"standard of care~limited version of the app (e.g. without the help function)."
9688142|NCT04859413||the young group|healthy participants age between 20 and 40
9688143|NCT04859413||the elder group|healthy participants age over 60
9688144|NCT04859426|Experimental|Mild Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
9688145|NCT04859426|Experimental|Moderate Hepatic Impairment|Subjects will receive a single dose of 100 mg DBPR108.
9688146|NCT04859426|Experimental|Normal hepatic function|Subjects will receive a single dose of 100 mg DBPR108.
9688147|NCT04859530|Experimental|AVC test|
9688148|NCT04859374|Other|Treatment as usual (TAU)|Any pharmacological therapy used for managing chronic pain or chronic migraine
9688149|NCT04859374|Other|TAU plus behavioral approach|Any pharmacological therapy used for managing chronic pain or chronic migraine added with behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
9688150|NCT04859439|Experimental|Mild Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
9688151|NCT04859439|Experimental|Moderate Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
9688152|NCT04859439|Experimental|Severe Renal function|Subjects will receive a single dose of 100 mg DBPR108
9688153|NCT04859439|Experimental|Kidney failure|Subjects will receive a single dose of 100 mg DBPR108
9688154|NCT04859439|Experimental|Normal Renal function|Subjects will receive a single dose of 100 mg DBPR108
10180144|NCT03795584||Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized.
9688155|NCT04859504|Active Comparator|Active tACS|Active tACS will be applied twice daily for 5 days. In each session, dual-channel high-density theta(7Hz) tACS stimulations will be delivered over the right DLPFC (one anodal electrode at F4, between -1.2mA and 1.2 mA; two cathodal electrodes at AF4 and FC6, between -0.6mA and 0.6mA) and cerebellum (one anodal electrode at Oz, between -1 mA and 1mA; two cathodal electrodes at PO3 and PO4, between -0.5mA and 0.5mA) lasting 20 minutes.
9688156|NCT04859504|Sham Comparator|Sham tACS|Sham tACS will be also applied twice daily for 5 days.The parameters of tACS electrodes numbers, locations, and current duration are all the same with active tACS. But sham tACS begin with a fade in over 3s to the peak, followed immediately by no current stimulation for 20 minutes and a fade out of 3s.
9688157|NCT04859959|Experimental|68Ga-Pentixafor PET/CT scan|Intravenous Inject 68Ga-Pentixafor and perform PET/CT scan 1h later.
9688158|NCT04859205|Experimental|Intervention|"All participants partaking the SUPPORT-Pro study will receive the full intervention for 3 months which implies: (1) Full access to the platform (2) a newsletter sent by email every 2 weeks to inform them on the new blogs posted on the platform.~During the following 9 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase)."
9688159|NCT04859283|Active Comparator|DEX-group|intranasal dexmedetomidine 1 µg/kg
9688160|NCT04859283|Placebo Comparator|PLACEBO-group|intranasal saline 10 µL/kg
9688161|NCT04859452|Experimental|The DDI of DBPR108 tablets and Metformin hydrochloride tablets|Subjects will receive a single dose of metformin hydrochloride on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of metformin hydrochloride on Day 8.
9688162|NCT04859452|Experimental|The DDI of DBPR108 tablets and Glibenclamide tablets|Subjects will receive a single dose of Glibenclamide on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Glibenclamide on Day 8.
9688163|NCT04859452|Experimental|The DDI of DBPR108 tablets and Valsartan Capsules|Subjects will receive a single dose of Valsartan on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Valsartan on Day 8.
9688164|NCT04859452|Experimental|The DDI of DBPR108 tablets and Simvastatin tablets|Subjects will receive a single dose of Simvastatin on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Simvastatin on Day 8.
9688165|NCT04859309|Experimental|ActiveHip Intervention|"The ActiveHip tele-rehabilitation mobile application.~The program consists of a multidisciplinary home-based tele-rehabilitation program delivered through a mobile application. It is comprised by an occupational therapy program and a physical exercise program.~The intervention group have the opportunity to perform three online-based sessions per week (two sessions of physical exercise and one of occupational therapy), each lasting 30-60 min. It is able to realize a fourth session, called bonus session.~In addition, the intervention group will receive the educational program, which has a total of 7 modules. 5 modules are for patients and caregivers, and 2 modules are specific for caregivers."
9688166|NCT04859309|Active Comparator|Standard care|Participants of this group will receive the standard care for hip fracture patients at hospital discharge.
9688167|NCT04859348|Experimental|Group-A ( RPT+ Insulin Therapy)|Group A includes participants received the routine physical therapy only.
9688168|NCT04859348|Experimental|Group-B (RPT+ Antenatal Exercises+ Insulin therapy)|Group B includes participants were given antenatal exercise program from 20- 24 weeks of gestation to till the date of delivery, with addition of the routine physical therapy plan.
9688169|NCT04859361|Experimental|Treatment with imiquimod|Colposcopy with PAP smear and punch biopsy is scheduled at 10 weeks to rule out progression, and at 20 weeks to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present and additional biopsies will be performed on any visible lesions. At 20 weeks, in case of disease progression or persistence, treatment with LLETZ will be offered.
9688170|NCT04859361|Active Comparator|Treatment with LLETZ|Standard treatment will be scheduled after patients' first period.
9688171|NCT04859335|Other|Schwannomas patients needing gammaknife radiosurgery|"Patients will undergo balance and hearing questionnaires before and after gammaknife radiosurgery.~This is a before/after analysis needing only one arm: the before data will serve as control to the after data"
9688172|NCT04859322|Experimental|Healthy Participants|20 healthy participants included in the arm for 3 experimental days each. On each experimental day infusions of stable isotope glucose (0,6 micromol/kg/min), glucagon (1 hour low; 0,6 ng/kg/min, 2 hours high; 4,0 ng/kg/min), somatostatin (450 micrograms/hour) and insulin (0,1 mU/kg/min) will be administered. Between the first two experimental days the participants will follow a sedentary lifestyle combined with a high-calorie diet intervention
9688173|NCT04859595|Experimental|telephone follow-up arm|"The experimental arm corresponds to the patient benefiting from a monthly telephone follow-up during the first 6 months of their discharge from the reeducation center : CRIL (from M1 to M6). They will be contacted each month by CRIL's speech therapist for a telephone interview (20 to 30 minutes)."
10180145|NCT03795688||Basic, non-imaging group|"Pregnant women who will deliver by planned caesarian. Participants enrolled in the study that are not eligible for the imaging subgroup.~All participants start in the basic program. Includes collection of blood, cerebrospinal fluid, saliva, hair, placenta tissues, umbilical cord blood and psychometrics."
9688174|NCT04859595|No Intervention|control arm|The comparison group will follow the standard follow-up protocol. A technician will contact the patients in the control arm to obtain the TIMES score each month. No further telephone follow-up will be carried out.
9688175|NCT04859244|Experimental|Part 1: GS-441524 (QD, 7 days)|750 mg GS-441524 administered QD for 7 days
9688176|NCT04859244|Experimental|Part 2: GS-441524 (TID, 3 days)|750 mg GS-441524 administered TID for 3 days
9688177|NCT04859543|Other|Diagnostic group|Tumor and blood samples will be collected from each patient and broad molecular profiling will be performed. The results of the evaluation of the tumor specimens will determine if the patient's tumor has an actionable mutation for which treatment is available.
10180146|NCT03795688||Extended, imaging group|A subgroup of 70 pregnant women who will deliver by planned caesarian selected towards either high (N=35) or low (N=35) risk for perinatal depression will undergo brain imaging in addition to the elements of the basic program. The extended imaging program includes functional and structural magnetic resonance imaging, positron emission tomography (PET) and a semistructured interview for depression symptoms (HAM-D17).
10180147|NCT03795571|Experimental|R2-GOD|
10180148|NCT03795636|Experimental|Garlic extracts root canal irrigation group|"Experimental group treated with garlic extract~A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water"
9688178|NCT04859140|Experimental|Foam rolling|The foam rolling routine consisted in unilateral exercises alternatively performed on both legs and bilateral exercises on lower and back muscles. All participants started with the feet in a standing up position with a lacrosse ball. Then, participants performed on the ground the foam rolling exercises with the foam roller targeting leg and back muscles.
9688179|NCT04859140|Experimental|Manual massage|Participants in the manual massage group received manual massage by a professional physiotherapist who was blinded to the purpose of the experiment (20 years of registered practice). Participants were lying in the prone position on a massage table. To facilitate the physiotherapist's maneuvers, massage oil was used. The manual massage protocol reproduced several features of the foam rolling intervention, i.e., order of the areas massaged, massage time per muscles and total duration of the session.
9688180|NCT04859140|Active Comparator|Autogenic relaxation|Participants in the relaxation group listened to a 16 min relaxation audio tape, based on the autogenic training method. Participants were lying on the massage table in supine position, wearing headphones. During this desensitization-relaxation technique, they were guided to visualize bodily perceptions of heaviness and warmth in their arms, thorax and legs. To facilitate concentration, participants were left alone in a dark room.
9688181|NCT04859114|Active Comparator|Text-only outcome data, 30% survival|Participants in this arm are provided a repeat of the outcome data in a text-only format, displaying a 30% chance of survival.
9688182|NCT04859114|Active Comparator|Text-only outcome data, 60% survival|Participants in this arm view a repeat of the outcome data in a text-only format, displaying a 60% chance of survival.
9688183|NCT04859114|Experimental|Static pictograph outcome data, 30% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 30% chance of survival.
9688184|NCT04859114|Experimental|Static pictograph outcome data, 60% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 60% chance of survival.
9688185|NCT04859114|Experimental|Iterative pictograph outcome data, 30% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 30% chance of survival.
9688186|NCT04859114|Experimental|Iterative pictograph outcome data, 60% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 60% chance of survival.
9688187|NCT04858997|Experimental|Palbociclib-AI|ER(+)/HER2(-) patients with histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease receive palbociclib PO daily on days 1-21, combined with AI as first-line treatment Disease assessments measured by CT imaging will be performed at first 4 weeks, 8weeks, then every 8weeks (± 7 days) from the date of randomization until radiographic/clinical documentation of progressive disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
9688188|NCT04858893||Subjects affected from Parkinsonims|Scores of MMSE, FAB MoCA were summarized to calculate the CoMDA scores, than they were used to develop the Neural Net 91 classificator
9688189|NCT04858893||Health Controls|CoMDA was administered and total score was calculate to develop the Neural Net 91 classificator
9688190|NCT04858763||2020 Cohort|This is the 2020 MS cohort who experienced a clinician confirmed relapse during April - June 2020, during the first wave of the COVID-19 pandemic.
9688191|NCT04858763||2019 Cohort|2019 MS cohort who experienced a clinician confirmed relapse during April - June 2019.
9688192|NCT04858802|Experimental|PROPEL Contour Sinus Implant|Following successful in-office bilateral balloon dilation, placement of PROPEL Contour Sinus Implant in the randomized side.
9688193|NCT04858802|Active Comparator|Balloon Sinus Dilation Alone|Following successful in-office bilateral balloon dilation, placement of no implant on the contralateral side.
9688194|NCT04859127||Patient Group|"The criteria for inclusion in the study were determined as voluntary patients between the ages of 18-65 with neck pain lasting more than 3 months who were clinically diagnosed with chronic neck pain by a specialist physician.~Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc."
9826770|NCT02431806|Active Comparator|Fluoxetine 20 mg|Participants received over-encapsulated fluoxetine 20 mg/day tablets orally starting at a dose of 10 mg/day in Week 1 and 20 mg/day in Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
10180149|NCT03795636|Active Comparator|Sodium hypochlorite root canal irrigation group|Control group which treated conventionally using .5 ml of 5.25% NaOCl (COLTENE®ENDO, Switzerland)
10180150|NCT03795649|No Intervention|The control group (Group K)|The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.
10180151|NCT03795649|Active Comparator|Group A, Tranexamic acid|The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later
10180152|NCT03795649|Other|Group B, autologous transfusion|The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.
10180153|NCT03795649|Other|Group C, alogenous transfusion|The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability.
9688195|NCT04859127||Control Group|Asymptomatic individuals between the ages of 18-65 who have not experienced neck pain during the last 1 year will be included in the control group. Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology etc.
9696086|NCT04770701|Experimental|Ahah drug|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~Dermatitis, mouth ulcers, skin rash, itching, weight loss~Hepatitis C virus (HCV) (+), Hepatitis B virus (HBV) (+), Tuberculosis (+)~Ahah composition contains the following ingredients (concentrated extracts of plants):~Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg"
9696087|NCT04770701|Experimental|Ahah Placebo|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~Dermatitis, mouth ulcers, skin rash, itching, weight loss~Hepatitis C virus (HCV)(+), Hepatitis B virus (HBV)(+), Tuberculosis (+)~Ahah composition placebo (Ahah not containing concentrated extracts of plants Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)"
9696088|NCT04770714|Other|Breast MRI|Patients in this arm will be randomized to receive a Breast MRI in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
10180154|NCT03795597|Experimental|Carfilzomib IV at dose: 20 mg/m2|The participants will receive Carfilzomib IV at dose: 20 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and Granulocyte-Colony stimulating factor (G-CSF) given daily until engraftment occurs.
10180155|NCT03795597|Experimental|Carfilzomib IV at dose: 27 mg/m2|The participants will receive Carfilzomib IV at dose: 27 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
10180156|NCT03795597|Experimental|Carfilzomib IV at dose: 36 mg/m2|The participants will receive Carfilzomib IV at dose: 36 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
9696089|NCT04770714|Other|Contrast Enhanced Mammography|Patients in this arm will be randomized to receive a Contrast Enhanced Mammograph in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers
9696090|NCT04770545|Experimental|Pegcetacoplan, 15 mg/100 μL, monthly for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered monthly intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or monthly sham will receive IVT pegcetacoplan (15 mg/100 μL) monthly for up to approximately 36 months.
9696091|NCT04770545|Experimental|Pegcetacoplan, 15 mg/100 μL, every other month (EOM) for up to 36 months|Participants from Study APL2-103 (NCT03777332) or those who completed the treatment at Month 24 from either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600) and were administered every other month (EOM) intravitreal (IVT) pegcetacoplan (15 mg/100 μL) or EOM sham will receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to approximately 36 months.
9696092|NCT04770740|Active Comparator|Experimental: Vitamin K2|Patients with COVID-19 who get our dietary supplement vitamin K2, three tablets of 333mcg a day, for 14 days or until discharge, whichever occurs earlier.
9696093|NCT04770740|Placebo Comparator|Control: Placebo|Patients with COVID-19 who get placebo as control, three tablets a day, for 14 days or until discharge, whichever occurs earlier.
9696094|NCT04770818|Active Comparator|Modified Brostrum procedure|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL (anterior talo-fibular ligament), CFL (calcanealfibular ligament), lateral ankle capsule and extensor retinaculum.
9696095|NCT04770818|Active Comparator|Modified Brostrum procedure with InternalBrace ligament augmentation|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL, CFL, lateral ankle capsule and extensor retinaculum with InternalBrace fixation using a 4.75mm BioComposite SwiveLock.
9696096|NCT04770792|Experimental|Experimental group|2% chlorhexidine gluconate with mineral trioxide aggregate.
9696097|NCT04770792|Active Comparator|Control group|Mineral trioxide aggregate.
9696098|NCT04770844||premature child|300 premature child will be included. They will have three acquisitions during hospitalization.
9696099|NCT04770727|Experimental|Workshop Intervention|A psychoeducation workshop will be provided alongside a workbook containing the content to review and refresh skills learnt. The psychoeducational intervention will be delivered by trainee clinical psychologists with interests in food allergy and delivered in line with a protocol.
9826771|NCT02432040|Experimental|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
9688196|NCT04858984|Experimental|Virtual reality group|"All participants experienced an immersive guided meditation virtual reality (VR1) and an interactive game virtual reality (VR2) experience during labour. Both VR interventions were offered for 10 minutes. Before and immediately after an intervention, the patient was asked to fill out a Numeric Rating Scale (NRS) score for pain.~During the 30-minute intermission after the VR intervention the patient completed the post-intervention questionnaire.~VR1 consisted of a video of an exotic location guided by the sound of the waves and a calm English-speaking voice. VR2 required women to use the controller to throw snowballs in order to catch presents and reach the next level. Patients were allowed to stop using the VR at any moment during the intervention.~Five days post-partum all participants who completed both VR interventions were contacted by telephone for an interview."
9688197|NCT04859023|Experimental|mass screening SARS-COV-19|"20 0000 participant will be included during mass screening SARS-COV-19 of the population of the city of Saint-Etienne.~They will have two strategies both based on self-samples: (i) a saliva sample combined to an anterior nare self-swabbing tested by antigenic test versus (ii) a saliva sample tested by RT-PCR."
9688198|NCT04859036||Transchateter VSD closure group|VSD cases treated with transcatheter closure method.
9688199|NCT04859036||Control group|Healty children
9688200|NCT04858815|Experimental|Administration of yogic breathing program|This will be a single arm longitudinal trial designed to evaluate the feasibility and estimate the efficacy of implementing a self-administered yogic breathing program for stress reduction among anesthesiology practitioners at one academic medical center.
9688201|NCT04858919|Other|study group|virgins with genital tract lesion
9688202|NCT04858737|Experimental|e-predicD-Work intervention|In this arm, worker participants will receive an online personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS).
10180157|NCT03795597|Experimental|Carfilzomib IV at dose: 45 mg/m2|The participants will receive Carfilzomib IV at dose: 45 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
10180158|NCT03795597|Experimental|Carfilzomib IV at dose: 56 mg/m2|The participants will receive Carfilzomib IV at dose: 56 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
10180159|NCT03795831||Cohort|Adult patients, undergoing surgery requiring general anesthesia, planned to be monitored with a system that accurately measures and stores the intra-arterial waveform.
10180160|NCT03795779|Experimental|CLL1-CD33 cCAR T cells|CLL1-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs
10180161|NCT03795532|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).
9688203|NCT04858737|Active Comparator|m-Health control|In this arm, worker participants will continue receiving the usual care from their health providers. In addition, they will use an App with the same appearance as the e-predictD-Work App but it will only send weekly short messages about stress and general health that will be extracted from brochures and websites of official agencies.
9688204|NCT04858841|Experimental|Levetiracetam|The group receives oral levetiracetam.
9688205|NCT04858841|Experimental|Perampanel|The group receives oral perampanel.
9688206|NCT04858841|Placebo Comparator|Placebo|The group receives oral placebo.
10180162|NCT03795532|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
9688207|NCT04858958|Experimental|treated subjects will receive Furmonertinib 160mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
9688208|NCT04858958|Experimental|treated subjects will receive Furmonertinib 240mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
9688209|NCT04858958|Experimental|treatment-naïve subjects will receive Furmonertinib 240mg/day|Treatment naïve patients with EGFR exon 20 insertion mutation positive NSCLC
9688210|NCT04858880|Experimental|Continued salvage radiotherapy + lymph node irradiation (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present) + the addition of lymph node irradiation (46 Gy/23 fractions) given in sequence. Total number of fractions: 35 + 8 = 43 with 15 of the lymph node irradiation fractions delivered concomitant with the prostate bed/local recurrence irradiation. These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
9688211|NCT04858880|Active Comparator|Continued salvage radiotherapy (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
9688212|NCT04858880|No Intervention|Continued salvage radiotherapy (responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as responders according to weekly PSA measurements during the first 4 weeks of radiotherapy, and are not followed according to the study protocol, follow up according to clinical practice.
9688213|NCT04858698|Experimental|Reduced fluoroscopy arm|Patients exposed to 20 seconds or less of fluoroscopy to implant a single chamber device with aid of ultrasound / echocardiography.
10180163|NCT03795545|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
10180164|NCT03795545|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
9688214|NCT04858698|Active Comparator|Conventional arm|Patients exposed to more than 20 seconds of fluoroscopy to implant a single chamber device with/without the aid of ultrasound / echocardiography.
9688215|NCT04858906|Active Comparator|from neutral to sniffing position|The patients in this group will be assessed firstly in the neutral position then subsequently in the sniffing position.
9688216|NCT04858906|Active Comparator|from sniffing position to neutral position|The patients in this group will be assessed firstly in the sniffing position then subsequently in the neutral position.
9688217|NCT04858659|Experimental|PK101 group|
9688218|NCT04858659|Active Comparator|PK101-002 group|
9688219|NCT04858529|Experimental|THP|
9688220|NCT04858529|Active Comparator|TCHP|
9688221|NCT04858646|Experimental|Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
9688222|NCT04858646|Active Comparator|Conventional physical therapy|Traditional physical therapy The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes. Treatment duration for both groups will be 30 minutes. Each subject received total 30 sessions of the treatment, with 5 treatment sessions per week for 6 weeks. Post treatment reading were collected after end of 6th weeks.
9688223|NCT04858438|Active Comparator|Standard Insufflation Group|Patients will receive standard insufflation during surgery (15 mm Hg).
9688224|NCT04858438|Experimental|Low Insufflation Group|Patients will receive a lower level of insufflation during surgery (12 mm Hg or lower).
9688225|NCT04858516|Experimental|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib|
9688226|NCT04858607||Immunocompromised individuals|Patients with primary or secondary immunodeficiency planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
9688227|NCT04858607||Healthy individuals|Healthy people planning on vaccination against SARS CoV-2 according to the Austrian vaccination plan.
9688228|NCT04858243|Active Comparator|Facility-Based ART|Men escorted to nearest health facility for ART initiation and continuation.
9688229|NCT04858243|Experimental|Home-Based ART|Home-based ART initiation and continuation provided for 3-months.
9688230|NCT04858581|Other|Healthcare workers who had a diagnosis confirmed by a nasopharyngeal RT-PCR test with SARS-CoV-2|Survey, RT-PCR test and blood test.
9688231|NCT04858633|Active Comparator|PEP group|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg)
9688232|NCT04858633|Placebo Comparator|Control group|Placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
9688233|NCT04858282|Experimental|shared decision-making group (SDMG)|Receiving mobile application( BC-SDM)
9688234|NCT04858282|No Intervention|usual care group (UCG)|Receiving material health education
9688235|NCT04858399||Mild Severity OSAS|Mild sleep apnea: An Apnea-Hypopnea Index (AHI) of five to 14 events per hour.
9688236|NCT04858399||Moderate Severity OSAS|Moderate sleep apnea: An Apnea-Hypopnea Index (AHI) of 15 to 29 events per hour.
9688237|NCT04858399||High Severity OSAS|Severe sleep apnea: An Apnea-Hypopnea Index (AHI) of 30 or more events per hour
9688238|NCT04858477|Other|Colonoscopy Patients + their Gastroenterology Fellows|Inpatient and outpatient colonoscopies performed by fellows at NYU Langone Health, NYU Langone Hospital Brooklyn, Bellevue Hospital Center, and Manhattan VA Medical Center from October 2020 - March 2021. These will include all colonoscopies with polyps done in adults age 45 and above.
9688239|NCT04858503|Experimental|internet-based cardiac rehabilitation enhancement intervention|internet-based cardiac rehabilitation enhancement intervention
9688240|NCT04858503|No Intervention|conventional cares as arranged by hospital or community centers|Participants will receive conventional cares as arranged by hospital or community centers
9688241|NCT04858308|Active Comparator|Test Group|Take both YYC506 and Placebo(Control)
9688242|NCT04858308|Active Comparator|Control Group|Take both Contral and Placebo(YYC506)
9688243|NCT04858165|No Intervention|CONTROL|without MY GERYFS
9688244|NCT04858165|Other|INTERVENTION|with MY GERYFS
10180165|NCT03795662||Community-acquired pneumonia|Adults over 18 years old admitted with confirmed community-acquired pneumonia.
9688245|NCT04858464||Patients group|Individuals with primary Sjögren's syndrome
9688246|NCT04858321|Experimental|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature ~38.5 °C and <39 °C) sessions over a period of 14 days.
9688247|NCT04858373|Experimental|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9688248|NCT04858373|Experimental|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9696100|NCT04770727|No Intervention|Treatment as usual|Adolescents randomised to the control arm will continue treatment as usual and receive the workshop materials after the active treatment group have completed their final follow-up at 3 months.
9688249|NCT04858373|Experimental|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9688250|NCT04858373|Experimental|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 12hr fast, consumed 50g available carbohydrates from D-glucose, three times, in different visits as reference food along with 300ml water; and 50g available carbohydrates from emmer bread from Greek emmer seeds, emmer bread from Italian emmer seeds, and whole wheat commercial soft bread, tested once, in different visits. there was a washout period of 2 days between visits. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9688251|NCT04858230|Experimental|LymphoPilot|Patient will be implanted with the medical device under investigation, LymphoPilot, through a surgical procedure performed in loco-regional anesthesia. Lymphedema outcomes will be monitored for 8 weeks after implantation and compared to baseline values before device implantation. Safety data will be collected throughout the study.
9688252|NCT04858191||Pediatric PCD|Pediatric participants with PCD
9688253|NCT04858139|Placebo Comparator|placebo|patients will be injected with placebo
9688254|NCT04858139|Active Comparator|Lactate|patients will be injected with lactate solution
9688255|NCT04858087||All students|All participating students were screened for Pf infection using malaria rapid diagnostic tests (mRDTs) and treated if positive. All were followed 1, 2, and 6 weeks after screening-and-treatment.
9688256|NCT04857892|Experimental|Part 1 : Treatment sequence ABC|Participants will receive a single oral dose of GSK3640254 25 milligrams (mg) (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 1, followed by a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 2. In Period 3, participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C).
9688257|NCT04857892|Experimental|Part 1 : Treatment sequence BCA|Participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B) in Period 1, followed by a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A).
9688258|NCT04857892|Experimental|Part 1 : Treatment sequence CAB|Participants will receive a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 x bilayer tablet) FDC administered under moderate fat and calorie conditions (Treatment C) in period 1, followed by a single oral dose of GSK3640254 25 mg (2 x tablets), GSK3640254 100 mg (1 x tablet) and DTG 50 mg (1 x tablet) administered together under moderate fat and calorie conditions (reference) (Treatment A) in Period 2. In Period 3 participants will receive a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 x monolayer tablet) FDC administered under moderate fat and calorie conditions (Treatment B).
9688259|NCT04857892|Experimental|Part 2 : Treatment sequence DE|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 2.
9688260|NCT04857892|Experimental|Part 2 : Treatment sequence ED|Participants will receive a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions (Treatment E) in Period 1 followed by a single oral dose of selected FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions (Treatment D) in Period 2.
10180166|NCT03795805|Other|TKA and Tourniquet|Total knee arthroplasty and use of tourniquet limb cuff at 270 mmHg
9688261|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app with motivational messages (A)|After study entry and baseline assessments, subjects will attend the one-month IDEA group sessions aimed at promoting physical activity and exercise. Participants randomly assigned to this study arm will use the smart band and the app with the motivation set enabled, allowing participants to receive the messages according to their compliance and adherence to the personalised prescriptions. After group sessions (week 4), study subjects will start receiving motivational messages up until the end of the trial (8 consecutive months).
9688262|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app without motivational messages (B)|Subjects will follow the same procedure as intervention A, with the difference that the app will have the motivation set disabled, therefore participants will not receive any messages regarding their compliance. After group sessions, study subjects will be expected to continue using the smart band and app up until the end of the trial (8 consecutive months).
9688263|NCT04857944|Sham Comparator|Fitness tracker + app without motivational messages (CG)|After study entry and baseline assessments, all patients assigned to the control group will receive both the app and the smart band, but the motivation set will be disabled. Study subjects will be expected to use the smart band and app up until the end of the trial.
9688264|NCT04858100|Experimental|Surgery|Each patient will receive the surgical excision of the lesion and subsequent follow-up
9688265|NCT04858100|Active Comparator|Wait and see|Each patient will receive clinical follow-up of the lesion with periodical incisional tissue biopsy.
10180167|NCT03795805|Experimental|Intraarticular lidocain|Total knee arthroplasty with Intaarticular lidocain
10180168|NCT03795714||Intravascular Imaging and Physiologic Assessment|330 patients with suspected ischemic heart disease and who underwent IVUS or OCT assessment and invasive physiologic assessment.
10180169|NCT03795519|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-olinciguat
9688266|NCT04857970||Electronic HRQoL questionnaires with feedback to physicians|40 patients allocated in this arm will answer HRQOL questionnaires using an electronic form in CHES Software. The HRQoL scores, presented as graphics, will be transmitted to physicians.
9688267|NCT04857970||Paper-pencil HRQoL questionnaires w.o. feedback to physician|"40 patients allocated in this arm will answer HRQOL questionnaires using pencil-paper, without transmission of the HRQoL scores to physicians."
9688268|NCT04858048||Group with general anesthesia performed during the forefoot surgery|
10180170|NCT03795623|Sham Comparator|Conventional arm|Muted audio recordings of the patients relatives.
10180171|NCT03795623|Experimental|Voice-Weaning arm|Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
10180172|NCT03795727|Experimental|Sectional matrix|precontoured sectional matrix band
10180173|NCT03795727|Active Comparator|Circumferential matrix|Circumferential matrix band applied by tofflemire retainer
10180174|NCT03795740|Experimental|Precise|precise PEA therapy with the guide of 3-D imaging techniques
9688269|NCT04858048||Group with WALANT anesthesia performed during the forefoot surgery|
9688270|NCT04857983|Placebo Comparator|TCT + PBO|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
9688271|NCT04857983|Active Comparator|TCT + MEM|"Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A proof of concept for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this proof of concept, a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders."
9688272|NCT04857658|Active Comparator|extraction treatment|patients will be referred for extraction of the upper and lower first premolars to relieve the crowding.
9688273|NCT04857658|No Intervention|non-extraction treatment|Leveling and alignment of the moderate crowding will be performed through a recall visits of 4 weeks for wire activation. inter-proximal reduction step might be done if needed.
9688274|NCT04857957|Experimental|Cohort 1|300 mg oral dose TID
9688275|NCT04857957|Experimental|Cohort 2|600 mg oral dose TID
9688276|NCT04857957|Experimental|Cohort 3|800 mg oral dose TID
9688277|NCT04857957|Experimental|PDN cohort|Dose based on safety in healthy Cohorts 1-3
9688278|NCT04857905|Other|Microsurgical Resection of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after counseling~-> Patients who after counseling decide for microsurgical resection of their brain metastasis"
9688279|NCT04857905|Other|Radiosurgery of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after study counseling~-> Patients who after counseling decide for dose-staged radiosurgical treatment of their brain metastasis"
9688280|NCT04857736||Trial group: 62 healthy female college students during menstruation|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during menstruation will be collected by thePulse Detection System of Sound Waves."
9688281|NCT04857736||Control group :62 healthy female college students during non-menstrual period|"The pulse sound waves of three parts and five layers of each of the two hands of 62 healthy female college students during non-menstrual period will be collected by the Pulse Detection System of Sound Waves."
9688282|NCT04858113|Placebo Comparator|Baby Shampoo|Conventional Baby shampoo
9688283|NCT04858113|No Intervention|No intervention|Baseline condition without intervention
9688284|NCT04858113|Experimental|Blephaclean|Intervention
9688285|NCT04857775|Experimental|Intervention group|A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups. Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal.
9696101|NCT04770675||Treatment group|Any subject who is scheduled to undergo bronchoscopy as per routine clinical practice
10180175|NCT03795740|Placebo Comparator|Placebo|traditional PEA therapy solely by surgical probe and traditional CT scanning/pulmonary angiography method
10180176|NCT03795506|Experimental|Active TLA Device|12 week overnight treatment with the active Temperature Controlled Laminar Airflow device.
10180177|NCT03795506|Placebo Comparator|Placebo TLA Device|12 week overnight treatment with the placebo Temperature Controlled Laminar Airflow device.
10180178|NCT03795441|Experimental|Ad26.RSV.preF|Participants will receive one intramuscular injection of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on Day 1.
10187489|NCT03725761|Experimental|IMMU-132 Treatment|Subjects enrolled in this study will receive IMMU-132 as treatment for Castrate-Resistant Prostate Cancer. Dose will be calculated per protocol in milligrams based on the subject's body weight at the beginning of each cycle or more frequently if weight changes >10%. Subjects will be treated on days 1 and 8 in a 21-day cycle, minimum 3 cycles.
9688286|NCT04857697|Experimental|Supportive care (biospecimen collection, probiotic)|Patients undergo collection of blood samples at baseline and time of surgery, and collection of stool samples at baseline and after completion of probiotic regimen. Patients receive probiotics PO once on day 1, and then BID or TID for 2-4 weeks before standard of care surgery. Patients also undergo collection of tissue samples during standard of care surgery.
9688287|NCT04857710|Active Comparator|Control (CONT)|A control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations
9688288|NCT04857710|Experimental|Conventional neuromuscular electrostimulation (CONV)|The CONV (conventional) modality allows us to compare with the current clinical application and the majority of the literature on the adaptations induced by NMES (neuromuscular electrostimulation) training.
9688289|NCT04857710|Experimental|Wide-pulse neuromuscular electrostimulation (WP)|The use of wide-pulse (WP) stimulations allows, in addition to the direct activation of the muscle fibers, the use of sensory pathways. This more global solicitation of the neuromuscular system (i.e. information going back to the spinal cord and even to the brain) prejudges more nervous adaptations and therefore a greater functional benefit.
9688290|NCT04857593|Experimental|Intervention|"M4M online is a 6-week intervention for mothers with PND. The original M4M programme would be delivered face-to-face in groups of 8-12 mothers in weekly sessions lasting one hour. However, due to the current situation with COVID-19, we will therefore modify the original face-to-face intervention for this online study, as follows:~Run groups of around 15-17 women to ensure that all participants can be visible on one screen during online delivery to create a stronger sense of community and connection~Offer 6 weeks of intervention, also building on the evidence from the face-to-face intervention that by 6 weeks there is already a significant improvement in depressive symptoms compared with control interventions24~Introduce a two-week lead-in period before the beginning of the six-session course, where mothers will be able to use WhatsApp and at least one (monitored) Zoom session to get to know each other."
9688291|NCT04857840|Experimental|Arm A: Investigational Product /Period 1,2 and 3 if any (open label)|Firibastat 1000 mg tablets QD - 12 weeks
9688292|NCT04857840|Placebo Comparator|Arm B: Placebo/Period1 only|Placebo tablets QD 12 weeks in Period 1 only, followed by open label Period 2 and 3 if any.
9688293|NCT04858126|Experimental|Single Group Assignment|ECOM endotracheal cardiac output monitor in patients undergoing cardiac and liver surgery.
9688294|NCT04857749|Active Comparator|Control group|Data from patients in the control group will be collected as in the experimental group. In the first interview, the patients in the control group will be given a training booklet. Apart from this, the standard approach, treatment and care of the clinic will be applied to all patients.
9688295|NCT04857749|Experimental|Navigation grup|While the standard treatment approaches of the hospital are applied to all patients, a nursing navigation program will be applied in addition to the patients in the experimental group. The navigation program will be started on the first day of radiotherapy by giving a 30-minute visual training and handbook related to expected side effects. Afterwards, patient follow-up will continue with phone reminders and weekly follow-up for seven weeks.
9688296|NCT04857866|Experimental|Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B or C|
9688297|NCT04857866|Placebo Comparator|Single Ascending Dose - Placebo Subcutaneous injection of placebo|
9688298|NCT04857879|Experimental|Good Life with Osteoarthritis (GLA:D) Program|Participants will attend 2 sessions aimed at providing disease-specific education followed by 12 sessions of neuromuscular exercises, each 1 hour in length, delivered twice a week over 6 weeks.
9688299|NCT04857879|Active Comparator|Control intervention group|Participants allocated to the control intervention will receive disease-specific education and training to learn home exercises in a 1-hour group session. They will receive a booster session 4-weeks after the first session.
9688300|NCT04857489||Patients with Relapse Remitting Multiple Sclerosis|Blood sample
9688301|NCT04857489||Healthy Controls|Blood Sample
9688302|NCT04857554|Experimental|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9688303|NCT04857554|Experimental|White bread as reference food|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9688304|NCT04857554|Experimental|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9696102|NCT04770688|Experimental|Osimertinib + Anlotiib|Escalating doses and expanding doses of Anlotinib administered with Osimertinib
9696103|NCT04770597|Experimental|Intervention|CO2 values on sensor visible to staff
9696104|NCT04770597|Sham Comparator|Sham control|CO2 values on sensor not visible to staff
9696105|NCT04770610|Experimental|OT-101 alone|Atropine Sulfate 0.01% Ophthalmic Solution through year 4
9696106|NCT04770610|Experimental|OT-101 plus vehicle|Atropine Sulfate 0.01% Ophthalmic Solution through year 3 followed by vehicle for 1 year
10187490|NCT03725748|No Intervention|no irrigation group|nothing used for irrigation of cs scar
9688305|NCT04857554|Experimental|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
10180179|NCT03795480|Experimental|MOOD|"The online program MOOD is based on methods of cognitive behavior therapy (KVT) and contains elements of mindfulness and metacognition. Participants can contact a moderator (trained psychologists) if they have any questions. However, this function is optional. The program consists of nine interactive modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention."
9688306|NCT04857554|Experimental|Cocoa drink|Twelve healthy, normal weight subjects (male: 6, female: 6) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from white bread, white bread and apricot jam, cereal bar with cranberries, and cocoa drink, tested once, in different weeks along with 250ml water or 500ml fat-free milk for the cocoa drink. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
9688307|NCT04857853|Experimental|Exercise Without Rest Breaks|Exercise Without Rest Breaks
9688308|NCT04857853|Experimental|Exercise With Rest Break|Exercise With Rest Break
9688309|NCT04857853|Experimental|Rest Break|Rest Break
9688310|NCT04857541||Health adult|
9688311|NCT04857541||COPD-like|
9688312|NCT04857541||COPD|
9688313|NCT04857294|Experimental|Discectomy|Unilateral Discectomy
9688314|NCT04857268|Experimental|ATP-C120 application|ATP-C120 will be applied to the high patients for new-onset atrial fibrillation
9688315|NCT04857320|Experimental|Main Experimental|Each subject will receive doses applied to the skin of 0.075 IUs / Kilogram Body Weight, 0.1 IUs/Kilogram Body Weight and 0.15 IUs /Kilogram Body Weight
9688316|NCT04857567|Experimental|Three Self-Commitment (TSC) program|
9688317|NCT04857333||Pulmonary Nodule|Patients are recommended for using antibiotics, solely follow-up or surgical resection according to the current clinical guideline for management of indeterminate pulmonary nodule. No intervention is administered for this observatory study.
9688318|NCT04857229||All patient|All recruited patient will have their margins assessed with the confocal microscope with comparison of accuracy against gold standard histology.
9688319|NCT04857346|Experimental|Controlled Type 2 diabetes mellitus|
9688320|NCT04857346|Experimental|Uncontrolled Type 2 diabetes melltius|
9688321|NCT04857346|Active Comparator|Non-diabetic patients|
9688322|NCT04857450|Sham Comparator|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
9688323|NCT04857450|Active Comparator|Ketamine-Etomidate|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
9688324|NCT04857463|Experimental|Nutritional supplement drink|Nutritional supplement, this group receives a nutritional supplement for a period of 12 weeks.
9688325|NCT04857463|Placebo Comparator|Nutritional education|Qualified clinical dietitians provide regular nutrition education and ensure the effectiveness of nutrition education
10180180|NCT03795480|No Intervention|Control|The wait-list control group does not receive additional treatment. However, previously started therapies (psychotherapy/ psychopharmacotherapy) may be continued during the study. Individuals of the wait-list control group receive access to MOOD after completion of the post-assessment.
10180181|NCT03795454|Experimental|Singing Kangaroo|The parent is singing during the skin-to -skin sessions Musical therapeutist gives the instructions
10180182|NCT03795454|No Intervention|Silent Kangaroo|The parent is silent during the skin-to -skin sessions Musical therapeutist gives the instructions
9688326|NCT04857476|Other|skin psoriasis participants|Single arm study
9688327|NCT04857424||ERCP|Subjects with benign and malignant biliary obstruction who have or will undergo endoscopic retrograde cholangiopancreatography (ERCP)
9688328|NCT04857424||PTBD|Subjects with benign and malignant biliary obstruction who have or will undergo percutaneous trans-hepatic biliary drainage (PTBD).
9688329|NCT04857216||Infraclavicular Group|Block Characteristics of Ultrasound Guided Infraclavicular Block with the Perfusion Index
9688330|NCT04857216||Costoclavicular Group|Block Characteristics of Ultrasound Guided costoclavicular Block with the Perfusion Index
9688331|NCT04857177|Experimental|CKD-701|Drug: CKD-701 (proposed ranibizumab biosimilar)
9688332|NCT04857177|Active Comparator|Lucentis®|Drug: Lucentis® (ranibizumab)
9688333|NCT04857203||Group 1|Low levels of Vitamin D
9688334|NCT04857203||Group 2|High levels of Vitamin D
9688335|NCT04857112|Experimental|Low Dose|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
9688336|NCT04857112|Experimental|High Dose|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
9688337|NCT04857112|Placebo Comparator|Placebo|Matching placebo, QD (Day 1-85)
9688338|NCT04857125|Active Comparator|Multicomponent intervention|Pre-, intra- and postoperative interventions applied using the Fast-IM method.
9688339|NCT04857125|No Intervention|Standard care|Patients are receiving standard care.
9688340|NCT04857515||Cigarette Smokers|Adult cigarette smokers who only smoke combustible cigarettes
9688341|NCT04857515||Dual-Users|Adult smokers who smoke both combustible cigarettes and vape
9688342|NCT04857073|Active Comparator|Control group - glucose check every day|Patients will be instructed to check their glucose 4 times a day, every day. This is currently the standard of care.
9688343|NCT04857073|Experimental|Experimental group - glucose check every other day|Patients will be instructed to check their glucose every other day, 4 times glucose monitoring
9688344|NCT04856995||working in the operating|operating room workers exposed to surgical smoke
10180183|NCT03795090|Active Comparator|Regular Patient privacy curtain|Control arm is a regular patient privacy curtain, washed and dried in hospital laundry using commercially available sodium hypochlorite and hydrogen peroxide.
10180184|NCT03795090|Experimental|Antimicrobial Coated Curtains|Treatment arm is an antimicrobial coated curtains, which is obtained by dipping the hospital laundered curtains into the antimicrobial coating. The curtains are then dried and provided to the nursing/supporting staff.
9688345|NCT04856995||working in internal units|Internal unit workers not exposed to surgical smoke
9688346|NCT04857086||Group1|About 1400 DTC patients with more than 5 years long-term follow-up from the date of signing the informed consent form (ICF) in DTCC 1st to signing ICF in DTCC 2nd will be collected data retrospectively.
9688347|NCT04857047|Experimental|Group A|"[Period1] administration of BR9003A 1mg twice a day for six days~- Wash out for 9days -~[Period2] administration of BR9003 2mg once a day for six days"
9688348|NCT04857047|Experimental|Group B|"[Period1] administration of BR9003 2mg once a day for six days~- Wash out for 9days -~[Period2] administration of BR9003A 1mg twice a day for six days"
9688349|NCT04856709|Other|study group|Women with stage 2 to 4 uterine prolapse. BMI from ≤ 35 kg\m2. Women of any parity including nulliparas will be included. Age of female patients ranges from 20 to 40 years.
9688350|NCT04856761||Cape Group|In this group, capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
9688351|NCT04856761||S-1 Group|In this group, S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
9688352|NCT04856839||syringomyelia group|
9688353|NCT04856839||Other neurodegenerative diseases|such as hydrocephalus
9688354|NCT04856839||Normal group|
9688355|NCT04857021|Active Comparator|GABA|Take GABA capsule once daily before sleep for 14 days.
9688356|NCT04857021|Placebo Comparator|Placebo|Take placebo capsule once daily before sleep for 14 days.
9688357|NCT04856852|Experimental|Iodine-125+Chemotherapy|Iodine-125; Temozolomide
9688358|NCT04856852|Active Comparator|Surgical resection+Radiochemotherapy|Surgical resection; Radiotherapy; Temozolomide:
9688359|NCT04856670||Control patients undergoing manual cataract surgery|As above
9688360|NCT04856670||Control patients undergoing FLACS|Femtosecond laser assisted cataract surgery
9688361|NCT04856670||Diabetic patients undergoing manual cataract surgery|As Above
9688362|NCT04856670||diabetic patients undergoing FLACS|As Above
9688363|NCT04856878|Experimental|Intervention|Standard of care (SOC) + single-dose intravenous vancomycin 15mg/kg
9688364|NCT04856878|No Intervention|Control|Standard of care (SOC)
9688365|NCT04856956|Experimental|Intervention (Use of diagnostic decision support software)|Trainee or nurse practitioner sees patient and uses diagnostic decision support software in developing their differential diagnosis and plan
9688366|NCT04856956|No Intervention|Control (Current process)|Trainee or nurse practitioner sees patient but doesn't use diagnostic decision support software in developing their differential diagnosis and plan
9688367|NCT04856774|Experimental|SHR -1701 + BP102|
9688368|NCT04856943|Experimental|smartconsent group|Intervention group: : the principal investigator upon receiving the tablet enters with his/her user and password, registers his/her signature, selects the patient (anonymized), selects the intervention and then the tablet will be given to the patient and he/she will be instructed to follow the indications in order to be able to project the video and digitally sign the informed consent.
9688369|NCT04856943|Placebo Comparator|control group|Control group: The informed consent paper document (official format) will be printed with the patient's name, signed by the physician (principal investigator) and given to the patient to read and sign.
9688370|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX（Phase 2）|
9688371|NCT04856787|Experimental|SHR-1701 in combination with BP102 and XELOX （Phase 3）|
9688372|NCT04856787|Placebo Comparator|placebo in combination with BP102 and XELOX|
9688373|NCT04856683||Patients with endocrine and metabolic diseases|Patients with endocrine and metabolic diseases (hypothalamic-pituitary-gonadal and adrenal diseases, type 2 diabetes mellitus and bone diseases)
10180185|NCT03795064|Experimental|Immediate Intervention|Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).
10180186|NCT03795064|Active Comparator|Early Intervention|Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).
10180187|NCT03795051|Experimental|Navigated TMS|Each participant will receive 30 sessions of 10 Hz or 20 Hz navigated transcranial magnetic stimulation over the left DLPFC.
9696107|NCT04770610|Placebo Comparator|Vehicle|Vehicle (Investigational Product minus active ingredient) through year 4
9696108|NCT04770961|Sham Comparator|Cryoablation|1. Cryoablation of intercostal nerves + Sham ESP catheter with saline infusion.
9696109|NCT04770961|Experimental|ESP + Cryoablation|2. Cryoablation of intercostal nerves + ESP catheter with local anesthetic infusion.
9696110|NCT04770558|Experimental|Exergame group|The exergame group will receive exergame training for 12 weeks, 2 times a week and 60 min per session.
9696111|NCT04770558|No Intervention|Control group|The control group will not receive any intervention and maintain their lifestyle for 12 weeks.
9696112|NCT04770948|Experimental|19G|19 gauge EBUS-TBNA needle
9696113|NCT04770948|Active Comparator|22G|22 gauge EBUS-TBNA needle
9696114|NCT04770506||Lithiasis patients|Lithiasis patients: diagnosis of recurrent NL confirmed by URO CT with presence of idiopathic hypercalciuria and metabolic workup available.
9696115|NCT04770506||Control group|Control group: patients without NL matched for age and sex and who had a bone mineral densitometry or abdominal CT.
9696116|NCT04770181|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
10187491|NCT03725748|Placebo Comparator|saline irrigation group|saline used for irrigation the cs scar before closure
10180188|NCT03795259|Active Comparator|Sevoflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 2% sevoflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
10180189|NCT03795259|Active Comparator|Desflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 6% desflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
10180190|NCT03795077|No Intervention|Control group|Control group followed traditional lectures about professional ethics during 3 months as usual.
10180191|NCT03795077|Experimental|Experimental group|Experimental group followed the programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used. Techniques used: concept maps, glossaries, brainstorming, four corners activity, aquarium, philip 6-6, kahoot, Realm Individual-Process Situation, reduced groups, guided debates, and discussion groups.
9688377|NCT04856969|Active Comparator|Arm A|ATB-1011: 1tab/d for 5days , ATB-1011+ATB-1012: each 1tab/d for 5days
10187492|NCT03725748|Experimental|betadine irrigation group|betadine used for irrigation of cs scar
9688378|NCT04856969|Active Comparator|Arm B|ATB-1012: 1tab/d for 5days / ATB-1011+ATB-1012: each 1tab/d for 5days
9688379|NCT04856553|Experimental|Handgrip exercise (morning)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the morning.
9688380|NCT04856553|No Intervention|Control|In the control session, the participants will remain at rest for the same period of time as in the handgrip exercise protocol.
9688381|NCT04856553|Experimental|Handgrip exercise (afternoon)|The handgrip exercise session will be executed with four series (two in each arm) of two minutes of isometric contraction at 30% of maximum voluntary contraction, with a one-minute interval between series in the afternoon.
9688382|NCT04856735|Active Comparator|IPLA:intraperitoneal local anesthetic|intraperitoneal local anesthetic:after the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon. The 20 ml solution containing bupivacaine and lidocaine was injected into the uterine peritoneal region by spraying 5 mL to each quadrant of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer was sutured or left open at the surgeon's preference. At the end of the operation, 20 ml of saline solution was applied subcutaneously in the form of LWI instead of the incision before the skin was closed.
9688383|NCT04856735|Active Comparator|LWI:Surgical wound infiltration|Surgical wound infiltration:a solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed.
9688384|NCT04856735|Active Comparator|C: CONTROL GROUP|one of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
9688385|NCT04856644|Experimental|4-month regimen (2HZPM/2HPM)|"Eight weeks of daily treatment with isoniazid (H), pyrazinamide (Z), rifapentine (P), and moxifloxacin (M), followed by~Nine weeks of daily treatment with isoniazid, rifapentine and moxifloxacin"
9688386|NCT04856644|No Intervention|Standard 6-month regimen (2HERZ/4HR) historical control|"a standard, six-month regimen, with~Eight weeks of daily treatment with isoniazid (H), rifampin (R), pyrazinamide (Z) and ethambutol (E) followed by~Eighteen weeks of daily treatment with isoniazid and rifampin, with or without ethambutol"
9688387|NCT04857060|No Intervention|Usual Care|Subjects in this arm do not meet with ACP Educator during their index hospitalization.
9688388|NCT04857060|Experimental|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
9688389|NCT04856501|Experimental|PALS intervention condition|
9688390|NCT04856501|Active Comparator|Control condition|
9688391|NCT04856579|Other|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
9688392|NCT04856618||Massive Transfusion Positive|Massive Transfusion Positive
9688393|NCT04856618||Massive Transfusion Negative|Massive Transfusion Negative
9688394|NCT04856371|Experimental|CYH33 + fulvestrant|Participants will receive CYH33 in combination with a standard fixed dose of fulvestrant 500 mg.
9688395|NCT04856371|Experimental|CYH33 + fulvestrant + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of fulvestrant (500 mg) and palbociclib (125 mg).
9688396|NCT04856371|Experimental|CYH33 + letrozole + palbociclib|Participants will receive CYH33 in combination with standard fixed dose of letrozole (2.5 mg) and palbociclib (125 mg)
9688397|NCT04856514|Experimental|Treatment Group|Participation in 16 week telehealth administration of the PEERS protocol for teens (parallel teen and parent/caregiver groups)
9688398|NCT04856397|Other|Control group|"Responders will be in this category. These patients will be maintained on intravitreal anti-VEGF therapy for 1 year, with a monthly PRN (as needed) treatment regimen post 5 monthly loading doses."
10180192|NCT03795116|Experimental|LED-RL phototherapy|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
10180193|NCT03795116|Sham Comparator|Mock irradiation|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
9688399|NCT04856397|Experimental|Early switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 3 monthly loading intravitreal eylea.
10180194|NCT03795285||Septic neonates:|fifty neonates with sepsis.
10180195|NCT03795285||Controls:|twenty healthy neonates.
9688400|NCT04856397|Experimental|Late switch|Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 6 monthly loading intravitreal eylea
9688401|NCT04856397|Other|Non-switch|Suboptimal responders who continue to receive monthly intravitreal anti-VEGF injections.
9688402|NCT04856345|Experimental|Music with synchronising|walking to music that one can synchronise to
9688403|NCT04856345|Active Comparator|Music without synchronising|walking to music that one cannot synchronise to
9688404|NCT04856345|Sham Comparator|No music|walking without music.
9688405|NCT04856267||Systemic AL Amyloidosis study cohort|"Eligible patients will undergo subcutaneous implantation of a cardiac monitor device (Brand name - LINQ device, Medtronic - referred to in the application as implantable loop recorder or ILR)"
9688406|NCT04856163|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 24 weeks post-partum. Services will be available through mobile phone app.
9688407|NCT04856163|No Intervention|ebook|Participants in the control arm will receive care as usual. They will also receive a ebook with content on infant care.
9688408|NCT04856462|Experimental|Education Support Group|Caregivers receiving structured education and support
9688409|NCT04856462|Active Comparator|Control Group|Caregivers participating in weekly support calls
9688410|NCT04856449|Experimental|DBT Skills Training|This intervention will consist of a 6-month-group DBT-skills training continuation, in which participants will be trained in mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.
9688411|NCT04856449|Active Comparator|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR will consist of individual therapy sessions that will be focused on processing traumatic memories. Participants will receive up to 16 individual EMDR sessions, of 60 min each.
9688412|NCT04856137|Experimental|single arm|ruxolitinib, paclitaxel, and rituximab
9688413|NCT04856189|Experimental|Treatment (selinexor, pembrolizumab)|Patients receive selinexor PO on days 1, 8 and 15, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
9688414|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 2 capsules, Batch A|
9688415|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 2 capsules with charcoal, Batch A|
9688416|NCT04856098|Experimental|Part 1 Ultibro Breezhaler 1 capsule, Batch A|
9688417|NCT04856098|Experimental|Part 2 Ultibro Breezhaler 2 capsules, Batch A|
9688418|NCT04856098|Experimental|Part 2 Ultibro Breezhaler 2 capsules, Batch B|
9688419|NCT04856280|Experimental|The kinesiological taping (KT) group (n=15)|6 sessions of taping was applied to the kinesiological taping group, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended. Using the KT ligament technique, it was applied to the supra pubic region with 100% tension in order to reduce contraction in the uterus
9688420|NCT04856280|Active Comparator|The aerobic exercise (AE) group (n=15)|"In the AE group, walking and climbing stairs were given during the menstrual cycle, 45 minutes session per day, 3 days a week over 3 weeks. The exercise protocol consists of 5 minute warm up, 35 min AE and 5 minute cool-down exercises. Warm-up and cool-down exercises include an active range of motion (ROM) exercises for upper and lower extremity. Aerobic exercise includes 30 min of moderate walking and climbing stairs. The aerobic exercise was performed in accordance with the definition of moderate-intensity exercise of the World Health Organization; It was given to the participants that during moderate exercise, the individual should walk with a tempo in a way that he can speak but cannot sing"
9688421|NCT04856280|No Intervention|The control group (n=15)|No intervention was applied to the control group.
9688422|NCT04855981|Experimental|whole body vibration|the subjects will receive whole-body vibration three times per week for twelve weeks +supplementations
9688423|NCT04855981|Experimental|aerobic exercise|the subjects will receive aerobic exercise three times per week for twelve weeks+supplementations
9688424|NCT04855981|Active Comparator|supplementations|the subjects will receive supplementations three times per week for twelve weeks
9688425|NCT04856059|Other|Cardiac MRI, ECG and Blood Biomarkers|Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.
9688426|NCT04856111|Active Comparator|Pirfenidone|Pirfenidone will be started at a dose of 600 mg/day. The dose will be escalated by 600 mg/day every 3-7 days up to a targeted dose of 2400 mg/day. The subjects will be administered the maximum tolerated dose for a total period of 24 weeks from randomization.
9688427|NCT04856111|Active Comparator|Nintedanib|Subjects in this group will be administered nintedanib at a dose of 150 mg twice daily. The liver function tests will be monitored as above. The dose will be reduced to 100 mg twice daily, if there is intolerance to 300 mg/day dose.
9688428|NCT04855942|Experimental|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
9688429|NCT04855942|Active Comparator|Physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
9688430|NCT04856384|Experimental|persons with Multiple Sclerosis|
9688431|NCT04856384|Experimental|Healthy controls|
9688432|NCT04855968|Active Comparator|control (CON)|will receive the usual standard of care post-operative pain pills for the involved shoulder (Control Group)
9688433|NCT04855968|Experimental|Mindfulness/Meditation (MM)|will receive the usual standard of care post-operative pain pills for the involved shoulder with the addition of access to the Headspace application for mindfulness/meditation (Mindfulness/Meditation Group)
9688434|NCT04856124||Treatment resistant depressed outpatients|Subjects had a clinically meaningful response to IV racemic ketamine and remained on other psychotropic medications during treatment with both IV ketamine and IN esketamine. Concomitant medication classes included CNS stimulants (n = 7), atypical antipsychotics (n = 6), selective serotonin reuptake inhibitors (n = 5), serotonin/norepinephrine reuptake inhibitors (n = 4), anticonvulsants (n = 3), antipsychotics (n = 3), mood stabilizers (n = 3), benzodiazepines (n = 2), norepinephrine/dopamine reuptake inhibitors (n = 2), alpha 2 antagonists (n=1), and sedative hypnotics (n = 1). Two patients (20%) previously underwent ECT with partial but transient relief from depressive symptoms, two (20%) failed TMS, and no patients reported any period of greater than 50% improvement during their current depressive episode prior to ketamine treatment.
9688435|NCT04856306||Myomectomy|After routine patient counseling on fibroid treatments, this group chooses surgical myomectomy of any type (abdominal/laparoscopic/hysteroscopic)
9688436|NCT04856306||Uterine artery embolization|After routine patient counseling on fibroid treatments, this group chooses uterine artery embolization procedure.
9688437|NCT04856306||Elagolix|After routine patient counseling on fibroid treatments, this group chooses the following medication: every morning (AM), 300mg elagolix, 1mg estradiol, and 0.5mg norethindrone acetate capsules taken in one combined capsule and every evening (PM), 300mg elagolix capsule. In our study, this medication will be administered for 12 months unless the subject withdraws from the study. It is FDA-approved for continuous use of up to 24 months.
9688438|NCT04856150|Experimental|Q-1802|Q-1802 dose exploration and Q-1802 dose extension
9688439|NCT04855825|Experimental|Robotic Exoskeleton Therapy|Gait rehabilitation provided using a wearable robotic exoskeleton
9688440|NCT04855825|Active Comparator|Conventional Gait Therapy|Gait rehabilitation provided using traditional gait therapy under the supervision of a licensed PT
9688441|NCT04856423||Us-qFIT group|People in this group will detect fecal hemoglobin concentration by us-qFIT before colonoscopy.
9688442|NCT04855994|Active Comparator|paravertebral group|The investigators performed Paravertebral block to that patient group for postoperative analgesia
9688443|NCT04855994|Active Comparator|pectoral group|The investigators performed pectoral block to that patient group for postoperative analgesia
9688444|NCT04856033|Experimental|TM|Transcendental Mediation
9688445|NCT04856033|Active Comparator|PCT|Present Centered Therapy
10180196|NCT03795272|Experimental|Rucaparib|Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
10180197|NCT03795272|Placebo Comparator|Placebo|Patients will be treated with oral placebo twice daily for 24 months
10180198|NCT03795194|Other|8-day|8-day course of ampicillin clavulanate antibiotic
10180199|NCT03795194|Other|4-day|4--day course of ampicillin clavulanate antibiotic
9688450|NCT04856410|Experimental|2-Month Arm|Astronauts on 2-month International Space Station missions will be exposed to spaceflight for a duration of 2 months. Biometric and cognitive data will routinely be collected.
9688451|NCT04856410|Experimental|6-Month Arm|Astronauts on 6-month International Space Station missions will be exposed to spaceflight for a duration of 6 months. Biometric and cognitive data will routinely be collected.
9688452|NCT04856410|Experimental|12-Month Arm|Astronauts on 12-month International Space Station missions will be exposed to spaceflight for a duration of 12 months. Biometric and cognitive data will routinely be collected.
9688453|NCT04856410|Experimental|No Intervention|Subjects matched to 12-month astronauts that stay on Earth and are investigated at similar time points.
9688454|NCT04856072|Experimental|Treatment|All patients will be implanted with a deep brain stimulation system and will receive personalized fornix stimulation; parameters will be selected based on the dose finding cognitive tests.
9688455|NCT04855812|Experimental|MyoPro|Receiving MyoMo training in-clinic and at home for 6-weeks
9826772|NCT02432040|Placebo Comparator|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
10180200|NCT03795415||Immediate Arm (G1)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G1 will receive the intervention Gundo-So immediately. (From month 3 to month 6).~112 women will be in immediate arm in 14 groups of 8 women."
10180201|NCT03795415||Delayed Arm (G2)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G2 will receive the intervention Gundo-So 3 months after. (From month 6 to month 9).~112 women will be in delayed arm in 14 groups of 8 women."
9688456|NCT04855812|Active Comparator|Myo-SB|Receiving MyoMo training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
10187493|NCT03725735|Experimental|CBT for PG with emotion regulation|A new treatment protocol for problem gamblers, CBT for problem gambling with emotion regulation, has a focus on emotion regulation, a component that has been lacking in current published research.
9688457|NCT04855812|Active Comparator|Control|Receiving conventional therapy/training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
9688458|NCT04855916|Experimental|ABLE Exoskeleton - KAFO|Participants belonging to this arm start the study by performing the training program using the ABLE Exoskeleton. After the resting period, they repeat the training program using KAFO orthoses.
9688459|NCT04855916|Experimental|KAFO - ABLE Exoskeleton|Participants belonging to this arm start the study by performing the training program using the KAFO orthoses. After the resting period, they repeat the training program using the ABLE Exoskeleton.
9688460|NCT04855838|Experimental|Intervention group|Intensive training with oral neuromuscular device (intervention group) and traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
9688461|NCT04855838|No Intervention|Control group|Traditional compensatory swallowing training under 8 weeks with start 4 (±1) weeks post-operation.
9688462|NCT04855682||A|Endoscopic discectomy
10187494|NCT03725709||All patients|spinal anesthesia
9688463|NCT04855682||B|Microdisectomy
9688464|NCT04855682||C|Hemilaminectomy
9688465|NCT04855565|Active Comparator|ALY688-SR|single dose subcutaneous injection
9688466|NCT04855565|Placebo Comparator|Matching placebo for ALY688-SR|single dose subcutaneous injection
9688467|NCT04855890|Active Comparator|Cryo-Ablation|Cryo-Balloon (Arctic Front Advance ProTM, Medtronic, Minneapolis, MN, USA) will be advanced to the LA and navigated to the PV's using an inner-lumen circular mapping catheter (Achieve AdvanceTM, Medtronic, Minneapolis, MN, USA). After confirming complete PV sealing by the CB using occlusion angiograms cryothermal energy will be applied for min 120 seconds aiming at PV isolation of all PV's according to the clinical standard.
9688468|NCT04855890|Active Comparator|High Power Short Duration-Ablation|"A detailed electroanatomical map of the left atrium during sinus rhythm will be acquired using Ensite (Abbott, St. Paul, MN, USA).~Upon completion of the LA map, a second transseptal puncture will be performed in order to insert an ablation catheter. To achieve antral PVI irrigated radiofrequency current ablation will be performed using a power of 70W and a flush rate of 8-30ml/min with a duration of 5 seconds for the anterior and 7 seconds for the posterior LA. Ablation catheters used will contain Flexibilty (Abbott, St. Paul, MN, USA) and TactiFlex (Abbott, St. Paul, MN, USA)."
9688469|NCT04855773|Experimental|PrEPmate|Participants randomized to this study arm will receive the PrEPmate mHealth intervention (bi-directional text messaging with PrEP navigators/clinic staff) to support PrEP adherence and continuation.
9688470|NCT04855773|Experimental|Dot Diary mobile application|Participants randomized to this study arm will download and use the Dot Diary mobile application on a personal device, to support PrEP adherence and continuation.
10180202|NCT03795311|Experimental|Administration of chemotherapy molecules|"The treatment period is divided into 15-day periods.~Schema of the administration to the treatments which will proceed in the same way with each cycle:~Bevacizumab (5 mg/kg; during 30 min) + Oxaliplatine (85 mg/m2, during 2 hours) + Acide folinique (400 mg/m2) or Levofolinate de calcium (200 mg/m2) AND Irinotecan (during 2 hours) + 5-fluorouracile (2400 mg/m2 ; 46 hours) + Irinotecan (1 hour)"
10180203|NCT03795129|Experimental|SleepLife Application w/FitBit|"Subject receives a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subject physicians will receive subject sleep data. Subject and physicians have the option of messaging each other through the SleepLife application."
9688471|NCT04855734|Experimental|FACE-Rare Intervention|"FACE-Rare is a behavioral intervention that combines the CSNAT Pediatric Approach and the Respecting Choices® Next Steps ACP over 3 sessions.~Sessions 1&2: CSNAT is an evidence-based process of family caregiver assessment and support in specialized medical (palliative) care. The CSNAT tool is structured around 16 categories of family caregiver support. With the goal to decrease caregiver burden, this process consists of 5 stages wherein a nurse or practitioner works with the caregiver to create a shared support plan for the child.~Session 3: Respecting Choices® Next Steps- This advanced care planning (pACP) conversation engages families in a process for how to make future medical decisions consistent with their goals and values. The interview is structured in 6 stages to achieve 2 main goals: to facilitate conversations with the family about their child's medical condition, history, fears, values, beliefs, and hopes; and to set the stage for the family's future healthcare decisions."
9688472|NCT04855734|No Intervention|Treatment-as-Usual (TAU) Control|To minimize the burden to families, we have chosen a Treatment-as-Usual (TAU) comparison condition, where patients will receive their normal standard of care. Both study arms will receive palliative (specialized medical) care information at enrollment and complete questionnaires before and after the intervention or TAU period. Current practice for minors with life-limiting illnesses is to defer initial discussions of advanced care planning (pACP) until a medical crisis, so this is what the TAU control arm condition will consist of.
9688473|NCT04855903|Experimental|Arm 1 (early phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 3 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 5 weeks"
9688474|NCT04855903|Experimental|Arm 2 (mid phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 4 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 4 weeks"
9688475|NCT04855903|Experimental|Arm 3 (late phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 5 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 3 weeks"
9688476|NCT04855877|Active Comparator|Oral Tranexamic Acid|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
9688477|NCT04855877|Placebo Comparator|Placebo|52 patients scheduled for primary anteriori cruciate ligament surgery by arthroscopy
9688478|NCT04855448|Experimental|Surgeon A|This group is consisted of 56 cases performed using the Micro Hand S robot and da Vinci robot by one single surgeon in low anterior resection for rectal cancer
9688479|NCT04855448|Active Comparator|Surgeon B|This group is consisted of 56 cases performed using the da Vinci robot by one single surgeon in low anterior resection for rectal cancer
9688480|NCT04855591|Experimental|SHR-1703 Dose Level 1|Dose level 1 SHR-1703
9688481|NCT04855591|Experimental|SHR-1703 Dose Level 2|Dose level 2 SHR-1703
9688482|NCT04855591|Experimental|SHR-1703 Dose Level 3|Dose level 3 SHR-1703
9688483|NCT04855591|Experimental|SHR-1703 Dose Level 4 (optional)|Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review
9826773|NCT02432105|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
10180204|NCT03795129|Active Comparator|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
10180205|NCT03795220|Active Comparator|Vaginal progesterone + transfer 6. day|Lutinus + blastocyst warming and transfer 6 days after hCG trigger
10180206|NCT03795220|Active Comparator|Vaginal progesterone + transfer 7. day|Lutinus + blastocyst warming and transfer 7 days after hCG trigger
10180207|NCT03795220|Active Comparator|No progesterone + transfer 6. day|No Lutinus + blastocyst warming and transfer 6 days after hCG trigger
9688484|NCT04855864|Other|BCR TKA|Patients with intact and functional ACL and PCL will be treated with the BCR design
9688485|NCT04855864|Other|BCS TKA|Patients with an afunctional or absent ACL and/or PCL will be treated with the BCS design
9688486|NCT04855539||wave 1|
9688487|NCT04855539||wave 2|
9688488|NCT04855292|Experimental|TG103 injection 15 mg|TG103 injection (15 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
9688489|NCT04855292|Experimental|TG103 injection 22.5 mg|TG103 injection (22.5 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
9688490|NCT04855292|Experimental|TG103 injection 30 mg|TG103 injection (30 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.
9688491|NCT04855279|Placebo Comparator|Control|
9688492|NCT04855279|Active Comparator|Topical neutral sodium fluoride|
9688493|NCT04855279|Active Comparator|ACP-CCP gel|
9688494|NCT04855279|Active Comparator|nano-hydroxyapatite solution|
9688495|NCT04855331|Active Comparator|Minimally invasive radical pancreatectomy|After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent laparoscopic or robotic radical pancreatectomy.
9688496|NCT04855331|Active Comparator|Open radical pancreatectomy|After neoadjuvant chemotherapy, patients with pancreatic ductal adenocarcinoma underwent open radical pancreatectomy.
9688497|NCT04855552|Experimental|Single-Arms Longitudinal Group|Behavioral weight-loss program via telehealth (video conferencing). Participants will receive weekly group sessions of lifestyle counseling for the first 20-weeks, followed by every other week sessions in weeks 22 and 24, for a total of 6-months of intervention.
9688498|NCT04855214||Body-powered Prosthesis User|Individuals who use a prosthesis that relies on a system of cables or harnesses which are operated using other parts of the body like the shoulders, chest, or elbows.
9688499|NCT04855214||Single degree-of-freedom (DOF) myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform only one movement.
9688500|NCT04855214||Multi-DOF myoelectric prosthesis users|Individuals who use a myoelectric prosthesis that can perform more than one movement.
9688501|NCT04855214||Sensory Augmentation|Individuals who experience augmented prosthesis sensory feedback through vibrating devices or pressure bladders, using electrical stimulation applied to the residual limb, or using neural implants.
9688502|NCT04855227||Laparoscopic ventral hernia repair|These subjects will undergo a laparoscopic primary umbilical or incisional hernia repair.
10180208|NCT03795220|Active Comparator|No progesterone + transfer 7. day|No Lutinus + blastocyst warming and transfer 7 days after hCG trigger
10180209|NCT03795324|Experimental|Redlove Apple|"Redlove Apple intervention~This product is a biofortified cultivar apple with anthocyanins."
10180210|NCT03795324|Experimental|Green Apple|"Green Apple intervention~This product is a common cultivar apple without anthocyanins."
10180211|NCT03795324|Experimental|Aronia Drink|"Aronia drink intervention~This product is an infusion of aronia fruit extract rich in anthocyanin."
9688503|NCT04855227||Robotic-assisted ventral hernia repair|These subjects will undergo a robotic-assisted primary umbilical or incisional hernia repair.
9688504|NCT04855266|Experimental|Iron Sucrose Group|Subjects will receive intravenous iron sucrose during a tilt table test
9688505|NCT04855266|Placebo Comparator|Placebo Group|Subjects will receive intravenous placebo during a tilt table test
9688506|NCT04855435|Experimental|MBS8(1V270)|Treatment arm (single arm study)
9688507|NCT04855383|Experimental|The group of frozen embryo transfer with intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
9688508|NCT04855383|No Intervention|The group of frozen embryo transfer without intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Embryo transfer will be done without human chorionic gonadotropin intramuscular injection.
9688509|NCT04855695|Experimental|Acalabrutinib, Venetoclax, and Obinutuzumab|"This study will consist of 2 parts (Parts A and B) and begin in the relapsed/refractory (R/R) MCL setting (Part A) with the phase 1 portion consisting of a dose finding stage to determine the recommended phase 2 dose (RP2D).The phase 1 dose finding stage will follow a 3+3 dose finding schema, such that there will be a safety pause and evaluation after the first 3 participants at any given dose level have completed therapy through cycle 5, day 1. If there are no dose limiting toxicities (DLTs) seen, an additional 3 participants will be treated at the same dose level and if there are 0 or 1 DLTs seen, the RP2D will have been determined.~Each study drug is given according to a different schedule.~Each treatment cycle lasts 28 days (4 weeks).~Acalabrutinib:~Obinutuzumab:~Venetoclax:"
9688510|NCT04855370|Experimental|Patients diagnosed with Pulmonary Embolism|Patients requiring intensive care unit (ICU) level care with a confirmed diagnosis of pulmonary embolism (PE) by computed tomography (CT) angiogram or endobronchial ultrasound (EBUS) prior to or within 4 hours of initiation of any PE therapy or intervention.
9688511|NCT04855409||Bipolar Depression|Subjects with bipolar type I disorder depressive episode diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
9688512|NCT04855409||Healthy|Healthy control subjects matched with bipolar depressive patients by age and sex
9688513|NCT04855422||Stable SPK recipients without rejection and/or BKV viremia|All SPK transplant recipients are monitored for routine labs twice a week first month, weekly at 2nd and 3rd month, every 2 weeks between 3-6 months, once a month between 6-12 months and then once every 2 months.
9826774|NCT02432105|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
9826775|NCT02432105|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
10180212|NCT03795402||Group A|Three microneedle device samples will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1. Two skin biopsies of 4 millimeter (mm) will be performed on Day 1. No investigational drug product will be administered during this study.
9688514|NCT04855422||Acute T-Cell Mediated Rejection (TCMR )|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
9688515|NCT04855422||Antibody Medicated Rejection (ABMR)|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
9688516|NCT04855422||BKV viremia|All patients will be monitored for BKV viremia monthly after transplantation up to 6 months and at 9, 12 and 24 months. Luminex SAB will be monitored at 1, 3, 12 and 24 months. Spot urine protein and creatinine and HbA1c will be monitored every 3 months after transplantation
9688517|NCT04855422||Follow-up of subjects with acute TCMR, ABMR and BKV viremia after treatment|BKV viremia, Luminex SAB, spot urine protein and creatinine is studied at the time clinically indicated biopsy and/o worsening kidney function and proteinuria.
9688518|NCT04855149||WALANT|anesthesia performed with WALANT technique
9688519|NCT04855149||BAx|anesthesia performed with axillary block under ultrasound control
9688520|NCT04855253|Experimental|Dose level 1 : E7777 at 5 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
9688521|NCT04855253|Experimental|Dose level 1 : E7777 at 7 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
9688522|NCT04855253|Experimental|Dose level 1 : E7777 at 9 mcg/kg|Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
9688523|NCT04855253|Experimental|MTD from phase 1|Single dose of E7777 (Maximum tolerated dose level identified in phase 1) given on Day -7 two days prior to the start of lymphodepleting chemotherapy
9688524|NCT04855188|Experimental|YVOIRE Y-Solution 540|
10180213|NCT03795402||Group B|One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
10187495|NCT03725696||Observational group|Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.
9688525|NCT04855188|Active Comparator|YVOIRE volume plus|
9688526|NCT04854850|Experimental|Apollo|Participants will all receive Apollo devices.
9688527|NCT04855071|Active Comparator|Interventional group|"The intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.~Furthemore, active RF will be applied intracavitary, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session)."
9688528|NCT04855071|Sham Comparator|Comparator group|The intervention will be the same that in IG (exercises to balance the pelvis and their muscles, etc) an also standards of water, urination, food, defecation, postural hygiene and physical activity for their generalization at home and life habit advices. The application of RF in the control group will follow the same application procedure as in the intervention group with the only difference that no parameter is applied to the RF device (in terms of temperature, power, frequency and dose); that is, it remains off for the entire duration of the session.
9688529|NCT04855175|Active Comparator|Autograft group|The autologous group will receive bone harvested from the patient's own body
9688530|NCT04855175|Active Comparator|Allograft group (ClearFit)|The allograft group will receive a synthetic bone known as ClearFit
9688531|NCT04854915|Active Comparator|Liverpool Overweight and Obesity Programme (LOOP) only|Patients will continue to follow the LOOP@ Alder Hey programme.
9688532|NCT04854915|Experimental|LOOP + mHealth technology assisted exercise counselling|Patients will continue to work with the LOOP MDT. However, exercise and physical activity advise will be taken over by an exercise specialist. Participants will co-develop a 3-month structured exercise and PA programme, with support from an exercise specialist. All participants will have 5 exercise consultations with their exercise specialist. The intervention will be supported by 3 mHealth elements; 1) a wrist worn fitness watch, 2) a smartphone app for patients, and 3) a coaching website for the exercise specialist. The 3 elements will be synced, allowing data to be transferred between platforms.
9688533|NCT04854785||Group 1 (DNP-mild)|Participants that have recovered from mild COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
9688534|NCT04854785||Group 2 (DNP-moderate)|Participants that have recovered from moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
9688535|NCT04854785||Group 3 (Healthy Control Participants)|Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
9688536|NCT04855084|Experimental|Complete Digital Fixed Dental Prosthesis|"Following the Digital Impression using 3 Shape Trios Intraoral scanner, digital design, and manufacturing of the Monolithic Zirconia FDPs.~Monolithic FDPs: before adjustment~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs before the occlusal adjustment.~Monolithic FDPs: after adjustment~Using Intraoral Scanner, occlusal relationship assessment of the Monolithic FDPs after the occlusal adjustment."
9826776|NCT02432144|Experimental|UX003|4 mg/kg UX003 every other week (QOW)
9826777|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
9688537|NCT04855084|Active Comparator|Analog Fixed Dental Prosthesis|"Following the Conventional Impression, transfer to the articulator with Face bow. Manufacturing of the FDPs with lost wax technique and veneering.~Metal fused porcelain FDPs: before adjustment~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs before the occlusal adjustment.~Metal fused porcelain FDPs: after adjustment~Using Intraoral Scanner, occlusal relationship assessment of the metal fused to porcelain FDPs after the occlusal adjustment."
10180214|NCT03795207|Experimental|Arm SBRT + DURVALUMAB|"Radiation (SBRT) + Immunotherapy treatment (Durvalumab)~64 patients will be enrolled in this arm~Durvalumab, will be started one month prior to SBRT and then given for a total of 12 months.~Patient will receive one injection per months (1500 mg/cycle)~SBRT will be started one month after Durvalumab and patients will receive 3 fractions of radiation"
10180215|NCT03795207|Active Comparator|Arm SBRT|"Radiation (SBRT)~32 patients will be enrolled in this arm~Patients will receive only 3 fractions of radiation"
10180216|NCT03795389|Experimental|3.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).
9688538|NCT04854980||Experimental:|Blood Sample Taken
9688539|NCT04855110|Active Comparator|Day 2 warfarin group|warfarin will be administered on day 2 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
9688540|NCT04855110|Active Comparator|Day 5 warfarin group|warfarin will be administered on day 5 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
9688541|NCT04855006|Experimental|Vaginal Microbiome Transplant|Women are given the vaginal microbiome transplant at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
9688542|NCT04855006|Placebo Comparator|Vaginal Microbiome Transplant Placebo|Women are given the vaginal microbiome transplant placebo at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
9688543|NCT04855006|Experimental|Vaginal Microbiome Donors|Women allocated in the donor group will donate their vaginal secretion, which will be processed and analyzed throughy before it is used as a transplant. In total, the donors will each provide approximately 10 donations of vaginal secretion.
9688544|NCT04854876|Experimental|Vaccinated with 1st dose of COVID-19 Vaccine & treated with 5-ALA Phosphate/SFC|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) and that will be treated with 150mg 5-ALA Phosphate/SFC for 28 days
9688545|NCT04854876|No Intervention|Vaccinated with 1st dose of COVID-19 Vaccine|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) only (Control)
9688546|NCT04854837||Hemodialysed patients received remdesivir|Remdesivir: day-1: 200 mg intravenously; day 2-5: 100 mg intravenously
9688547|NCT04854837||Hemodialysed patients not received remdesivir|Standard of care
9688548|NCT04854889|Experimental|Decitabine|Subjects will receive low-dose decitabine for 4 cycles and for another 6 cycles in extension study for patients achieving response during the first 4 cycles.
9688549|NCT04854902|Experimental|Cyanoacrylate|The graft is stabilized and the donor site is coated with cyanoacrylate.
9688550|NCT04854902|Active Comparator|Suture|6/0 polyvinylidene fluoride sutures are used for stabilization, while the donor site is left untreated.
9688551|NCT04854759|Experimental|Study group|
9688552|NCT04854759|Placebo Comparator|Control group|
9688553|NCT04855136|Experimental|Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)|bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.
9688554|NCT04855136|Experimental|Arm B- bb2121 in combination with BMS-986405 (JSMD194)|bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion.
9688555|NCT04855136|Experimental|Arm C-bb2121 in combination with Daratumumab+pomalidomide+low-dose dexamethasone or POM +bortezomib|"bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agents will be administered as follow:~Cohort 1 (DPd) DARA, POM and dexamethasone at M3D1 until disease progression.~Cohort 2 (PVd) POM, BTZ and dexamethasone at M3D1 until disease progression"
10180217|NCT03795389|Experimental|5.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
10180218|NCT03795389|Experimental|8.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
9688556|NCT04854928|Experimental|LTX-109 treatment|Single Dose by Nasal application of LTX-109 gel 3%, 250 microliters in each nostril.
9826778|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
10180219|NCT03795350|Experimental|TRIMBOW|"Experimental: BDP/FF/GB~4 puffs of 99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI"
10180220|NCT03795337|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
10180221|NCT03794960|Experimental|TOL-3021|
10180222|NCT03794960|Placebo Comparator|TOL-3021 Placebo|
9688557|NCT04854928|Placebo Comparator|Placebo|Single Dose by Nasal application of placebo gel, 250 microliters in each nostril.
9688558|NCT04854668|Experimental|Anlotinib + CapeOx|Anlotinib combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Anlotinib combined with Capecitabine.
9688559|NCT04854668|Active Comparator|Bevacizumab + CapeOx|Bevacizumab combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Bevacizumab combined with Capecitabine.
9826779|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
10180223|NCT03794973|Experimental|TOL-3021|TOL-3021 2 mg/mL
10180224|NCT03794973|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
10180225|NCT03794895|Experimental|Single arm clinical trial|
10180226|NCT03794856||Asthma patients|Asthma patients will undergo behavioral testing and imaging at a single timepoint.
10180227|NCT03794856||Healthy Volunteers|Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
9688560|NCT04854733||Referees|There will be no interventions. Motor and cognitive assessments will be conducted.
9688561|NCT04854733||Athletes|There will be no interventions. Motor and cognitive assessments will be conducted.
10180228|NCT03795012|Active Comparator|Eribulin monotherapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
10180229|NCT03795012|Active Comparator|eribulin plus endocrine therapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
10180230|NCT03795025|Experimental|3x10RM + no training|
10180231|NCT03795025|Experimental|6x10RM + no training|
10180232|NCT03795025|Experimental|3x10RM + 6x10RM|
9688562|NCT04854772|Experimental|Mind Body Syndrome Therapy for Long Covid|"The participants will receive an initial one-on-one interview, followed by 1 to 2 hour biweekly group interactive, educational sessions for 12 weeks. This program also includes a day-long retreat at the end of the required course period. Participants will also be provided reading materials to study during the intervention period"
9688563|NCT04854655|Active Comparator|Control|Conventional resin composite
10180233|NCT03795025|No Intervention|Control|This arm includes 3 weeks of testing and 7 weeks of no intervention and post tests, followed by 7 weeks of progressive unilateral strength training 3 times per week for 7 weeks. Both legs exercises individually with 3 sets of 10 maximal repetitions.
10180234|NCT03794947|Experimental|Remote Ischaemic Conditioning|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg (arm) and 220 mmHg (leg). RIC will be completed 3 times weekly for 4 weeks.
9688564|NCT04854655|Experimental|Intervention 1|Activa Presto
9688565|NCT04854655|Experimental|Intervention 2|Giomer
10180235|NCT03794947|Sham Comparator|Sham Intervention|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The arm and leg blood pressure cuffs in the sham intervention will inflate to 20mmHg. Sham will be completed 3 times weekly for 4 weeks.
9688566|NCT04854720|Experimental|Group 1 (Fuji II LC-Fuji Triage)|In Group 1, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Fuji® II LC, GC Corporation, Tokyo, Japan) (test 1). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
9688567|NCT04854720|Experimental|Group 2 (Clinpro XT Varnish-Fuji Triage)|In Group 2, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Clinpro™ XT Varnish, 3M ESPE, St. Pauls, Miniapolis, MN, USA) (test 2). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
10187496|NCT03725683|Experimental|Incrementing groups|Each of the Increased caliber balloon capsules was predilated one by one, and the order of the increased balloon capsules was as follows: Balloon 2 diameter = target lesion reference vessel diameter minus 1; Balloon 3 diameter = target lesion reference vessel diameter;
10187497|NCT03725683|Experimental|matching groups|Pre-dilatation of the matched caliber balloon, whose diameter = the target lesion's diameter as a reference vessel, was applied.
9528132|NCT03213613|Placebo Comparator|Active Control|The active control group will engage in 15 hours of at-home training on an iPad game ('Boing'). Individuals will complete game play for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with research personnel, and monetary rewards. Compliance will be monitored similarly to the adaptive attention training group.
9688568|NCT04854720|Experimental|Group 3 (Beautiful Flow- Fuji Triage)|In Group 3, newly erupted mandibular permanent first molars were sealed with Giomer containing fissure sealant material (Beautifil Flow, Shofu, Kyoto, Japan) (test 3). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
9696117|NCT04770181|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
9696118|NCT04770155|Active Comparator|Beetroot juice (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).
9696119|NCT04770155|Placebo Comparator|Placebo (Aim 1a)|Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).
9696120|NCT04770155|Active Comparator|L-citrulline (Aim 1b)|Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.
9696121|NCT04770155|Placebo Comparator|Placebo (Aim 1b)|Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.
9696122|NCT04770155|Active Comparator|Sildenafil (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.
9696123|NCT04770155|Placebo Comparator|Placebo (Aim 1c)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
9696124|NCT04770155|Active Comparator|Bosentan (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.
9696125|NCT04770155|Placebo Comparator|Placebo (Aim 2)|Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
9696126|NCT04770077||Group S|Spray before intubation
10187498|NCT03725670|Experimental|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
9688569|NCT04854681|Experimental|TQB2928 injection|Dose Escalation: intravenous (IV) infusion of TQB2928 as monotherapy
9688570|NCT04854421||healthy adults|Community dwelling and have no life-threatening conditions or diseases that would alter body composition from what is typical for their age, sex, ethnicity, and BMI.
9688571|NCT04854473|Experimental|Impedance measurement|Subjects with Exero's Smart Drain Device Attached This arm contains subjects which will have Exero's leak detection Device used: Exero Smart Drain is placed on their large bowel during colonic resection surgery (either open, laparoscopic or robotic). The study aims to demonstrate that the parameters measured by the device in in-vivo, non-disrupted tissue are different than parameters measured in ischemic tissue. Once this data is collected a detection algorithm can be trained. This procedure will add no more than 20 minutes to the existing procedure that is performed per hospital standard overall and will enable collection of control vs. ischemia induced clinical data, essential to developing the detection algorithms.
9688572|NCT04854460|Experimental|T test|Test drug (Revemact) 1 tablet contains 6 mg Ivermectin
9688573|NCT04854460|Active Comparator|B reference (first dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
9688574|NCT04854460|Active Comparator|B reference (second dose)|Reference drug (Stromectol) 2 tablets contain 3 mg each Ivermectin
9688575|NCT04854551|Experimental|Healthy adults: placebo first|This arm will receive placebo first, then active medication second
9688576|NCT04854551|Experimental|Healthy adults: active medication first|This arm will receive active medication first, then placebo second
9688577|NCT04854356|Experimental|HIE with BFR during exercise phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
9688578|NCT04854356|Active Comparator|HIE with BFR during interval phase|BFR with 40% Arterial occlusive pressure cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each during the interval
9688579|NCT04854356|No Intervention|HIE without BFR|Cycling at 85% VO2max for 3 minutes and rest interval for 3 minutes (4 sets) each time during exercise
9688580|NCT04854564||End-stage liver disease (ESLD) patients|These potential liver transplant candidates are patients with end-stage liver disease (ESLD) who have been assigned to the liver transplant waitlist.
9688581|NCT04854564||Caregivers of potential liver transplant candidates|They are the primary caregivers for the patients.
9688582|NCT04854291|Experimental|Donor FMT|FMT from a healthy donor
9688583|NCT04854291|Placebo Comparator|Placebo|NaCl + glycerol mixture (carrier solution of FMT arm)
9688584|NCT04854577|Experimental|"Intervention group: Opioid Free Anesthesia with a pecto-intercostal fascial plane block"|Patients to whom a standardized opioid free anesthesia consisting of esketamine, lidocaine and dexmedetomidine will be administered with a pre-incisional pecto-intercostal fascial plane block.
9688585|NCT04854577|Active Comparator|"Control group: Traditional Opioid-based Anesthetic Regimen"|Patients who will receive a traditional opioid based anesthetic regimen. The administered dose of opioids is at the discretion of the attending anesthesiologist.
9688586|NCT04854538|Experimental|T test|Test drug (Ekmasonid) 1 tablet contains 9 mg Budesonide
9688587|NCT04854538|Experimental|B reference (first dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
9688588|NCT04854538|Experimental|B reference (second dose)|Reference drug (Uceris) 1 tablet contains 9 mg Budesonide
9688589|NCT04854603|Experimental|Chocolate milk with a regular added sugar content|Dairy product with a regular sugar content
9688590|NCT04854603|Experimental|Chocolate milk with a reduced added sugar content|Dairy product with a reduced sugar content
9688591|NCT04854603|Experimental|Yogurt with a regular added sugar content|Dairy product with a regular sugar content
9688592|NCT04854603|Experimental|Yogurt with a reduced added sugar content|Dairy product with a reduced sugar content
9688593|NCT04854603|Experimental|Energy-free control|Potable water
9688594|NCT04854395|Active Comparator|Group A: Active FTB + Active PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml for IFCN + 10 ml Marcain 5 mg/ml is used for PPB
9688595|NCT04854395|Active Comparator|Group B: Active FTB + Sham PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml is used for IFCN
9688596|NCT04854395|Active Comparator|Group C: Sham FTB + Sham PPB + Active ACB|Single shot bolus of 25 ml Marcain 5 mg/ml is used for ACB
9688597|NCT04854187|Active Comparator|Intervention Arm - Indoor air purifier and N95 mask|Intervention arm will be for 4 weeks. Blood pressure and/or blood glucose will be recorded on day 0; end of week 2 and end of the intervention. Participants in the intervention group will be asked to use an indoor air purifier (Atlanta Healthcare 7-Stage 43-Watt Air Purifier) daily for 4 weeks between the hours of ¬8 PM and 8 AM. The purifier will be placed in their bedroom or in the room where participants sleep at night. When the participants are outdoors (commuting, working outdoors, running errands, etc.), they will be asked to use a N95 mask (PureMe Reusable N95 Anti-Pollution Mask). It is a reusable mask which can be washed by the participants. Every 2 weeks, the filter of the mask will be replaced, and the filter of the indoor purifier will be washed.
9688598|NCT04854187|No Intervention|Washout period - No intervention|At the end of either control or intervention arm, participants will have a washout period of 2 weeks, after which participants will be crossed over to the other group for the subsequent 4 weeks. For example, after Participant AB is in intervention arm for 4 weeks, he/she will then have a wash out period of 2 weeks in which they will return to their usual state of living. At the end of the washout period, the participant AB will be put in the control arm for 4 weeks.
9696127|NCT04770077||Group C|Intubation directly
9696128|NCT04770064|Experimental|High-dose/short-duration Fisetin (FIS-hi)|
10187499|NCT03725644|Experimental|parent-training program|Parents in the treatment group received the parent-training program based on the DIR model. The parent-training program encouraged child-initiated activities according to the functional developmental levels. The treatment intensity and duration were the same for both groups including 3-week courses and 11-week home programs. The investigators in this study are two registered pediatric occupational therapists who have at least five years of early intervention experience and had studied the DIR model.
10180236|NCT03794804|Active Comparator|ColdZyme|"ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
10187500|NCT03725644|Experimental|traditional program|Parents in the control group received the traditional program based on the developmental approach. The traditional program provided parent-lead activities that fit child's developmental stage.
9688599|NCT04854187|Sham Comparator|Controlled Arm - Indoor air purifier and N95 mask with sham filter|Control arm will be for 4 weeks. Blood pressure, blood glucose and indoor air pollution level will be recorded similarly as in the intervention group on day 0, end of week 2 and week 4. The participant will be provided an air purifier and a N-95 mask (of the same manufacturer), with the filter removed. At the end of two weeks, the health worker will make dummy adjustments to the mask and indoor air purifier, to maintain blinding of the participant.
9688600|NCT04854525||One Stage Reconstruction With pre-reconstruction Radiotherapy|
9688601|NCT04854525||Two Stage Reconstruction With pre-reconstruction Radiotherapy|
9688602|NCT04854525||Autologous Reconstruction With pre-reconstruction Radiotherapy|
9688603|NCT04854525||One Stage Reconstruction Without pre-reconstruction Radiotherapy|
9688604|NCT04854525||Two Stage Reconstruction Without pre-reconstruction Radiotherapy|
9688605|NCT04854525||Autologous Reconstruction Without pre-reconstruction Radiotherapy|
9688606|NCT04854343||Case|200 patients with a suspicion of prostate cancer
9688607|NCT04854343||Control A|(a) 50 patients with benign prostate hyperplasia (BPH)
9688608|NCT04854343||Control B|(b) 30 male subjects older than 50 years with neither prostate disease nor any other neoplasia
9688609|NCT04854044|Experimental|Arm I (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks, and receive ONC201 PO daily on days 1, 2, 8, and 9. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. Beginning 7 days from last pre-surgery dose of ONC201, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
9688610|NCT04854044|Experimental|Arm II (ONC201, radiation therapy, resection)|Patients undergo radiation therapy for 10 fractions over 2 weeks. Beginning 24 hours after completion of radiation therapy, patients undergo surgical resection. After recovery from surgery, patients receive ONC201 PO daily on two consecutive days weekly (2 days on/5 days off) in the absence of disease progression or unacceptable toxicity.
9688611|NCT04854057|Active Comparator|Intermittent Hypoxia (AIH) + Transcutaneous Electrical Spinal Cord Stimulation (TESS)|"Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes~TESS + Functional Task Practice Duration: 45 minutes"
9688612|NCT04854057|Sham Comparator|Intermittent Room Air (SHAM) + Transcutaneous Electrical Spinal Cord Stimulation (TESS)|"Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes~TESS + Functional Task Practice Duration: 45 minutes"
9688613|NCT04854148||Experimental|Each participant will perform a Smartphone movement health assessment and a series of 12 gold standard tests under the supervision of a licensed physical therapist or other research study staff
9688614|NCT04853979|Experimental|PRONE|Any combination of prone or side position for 3 hours, 3 times a day for 3 days.
9688615|NCT04853979|Active Comparator|NO PRONE|Usual care
9688616|NCT04854161|Experimental|Compassion and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Compassion training program is based on Compassion Cultivation Training, CCT
9688617|NCT04854161|Active Comparator|Focusing and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Focusing training program is based on Focusing-Oriented Therapy
9688618|NCT04854122|Experimental|Combined exercise intervention Down syndrome|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week.In the exercise sessions, the participant will work with the trainer on their strength, balance and aerobic endurance. Each session consists of 10 min of strength exercises (Foundational Exercise), 10 min of Hip Strengthening, 10 min of Vestibular and Balance Exercise, and 20 min of Aerobic Exercise, and starts with a warming up and ends with stretching/cooling down. Each new exercise will be introduced in easy steps and practiced until the participant is comfortable executing it.
9688619|NCT04854122|Sham Comparator|Usual care Down Syndrome|The control condition consists of usual activities.
9688620|NCT04854122|No Intervention|Reference group without Down syndrome|This reference group of age- and sex-matched inactive individuals without Down syndrome will undergo the same baseline testing as the other groups but without intervention or post-intervention measures.
9688621|NCT04854330|Active Comparator|Ketone ester|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml. Immediately following ingestion of the ketones, participants will be given 20 ml of calorie-free sparkling spring water (The Holywell Water Company Ltd, UK) in an attempt to remove any remaining flavour of the supplement.
9688622|NCT04854330|Placebo Comparator|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
9826780|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, >4 hours).
9826781|NCT02432235|Experimental|3 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
9688623|NCT04854239|Experimental|Machine-driven group|In the machine-driven group, after guided implant bed preparation, implant insertion was performed with contra-angled handpiece.
9688624|NCT04854239|Experimental|Manual group|In the manual group, after guided implant bed preparation, implant insertion was performed with torque-wrench.
9688625|NCT04854226|Experimental|Macronutrient_CARB|High carbs, low fat composition.
9688626|NCT04854226|Active Comparator|Macronutrient_FAT|Low carbs, high fat composition.
9688627|NCT04854135|Experimental|CGM Intervention|All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent.
9688628|NCT04854252|Experimental|Inflammatory response to opioid vs opioid free anesthesia|Patients were randomly assigned to two anesthesia groups: opioid-containing (n=20) or opioid-free (n=20). The opioid used in the opioid-containing anesthesia group was fentanyl.
9688629|NCT04853927|Active Comparator|Proxalutamide + Standard of Care|Proxalutamide + standard of care as determined by the PI
9688630|NCT04853927|Placebo Comparator|Placebo + Standard Care|Placebo + Standard of care as determined by the PI
9688631|NCT04854174|Experimental|Healthy Volunteer|Healthy Volunteer
9688632|NCT04853966|Experimental|Counseling group|
9688633|NCT04853966|No Intervention|Control Group|
9688634|NCT04853888|Other|Intervention group|"A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups.~Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal."
9688635|NCT04854018|Experimental|Single Arm|Injection of Indocyanine Green at doses detailed on summary of product characteristics for each age range
9688636|NCT04853732||Chronic Low Back Pain Cases|
9688637|NCT04853732||Chronic Pain-Free Controls|
9688638|NCT04853758|Active Comparator|Sacubitril/Valsartan|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan.
9688639|NCT04853758|Active Comparator|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril.
9688640|NCT04853771|Experimental|experiment|28-29. Between the weeks of gestation, one-time progressive muscle relaxation exercise training prepared by the researcher will be given to the pregnant women. Exercise will be demonstrated in training. Later, pregnant women will be asked to explain and practice the exercise. Women will be repeated until they do the exercise completely correctly (Check-list 1). After the training, pregnant women will be asked to do progressive relaxation exercises at least 3 times a week (every other day). With the progressive muscle relaxation exercise daily follow-up schedule prepared by the researcher, the pregnant women will be followed for 8 weeks and weekly reminders will be made (via whatsapp® or text message). The final test application (36-37 weeks) will be done online at the end of 8 weeks to the pregnant women. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
9688641|NCT04853771|No Intervention|control|No intervention will be applied to pregnant women, other than the routine training given in the pregnancy school. In the maternity school, training is given on physiological and psychological changes that occur during pregnancy, baby care, postpartum period, family planning. However, pregnant women are not given any information about RLS, coping methods, creating a healthy lifestyle, and progressive muscle relaxation exercises. Final test application to pregnant women; 36-37. It will be held online between weeks. In pre-test and post-test applications, RLS Severity Rating Scale form, Johns Hopkins Restless Leg Syndrome Quality of Life Scale and Pittsburg Sleep Quality Index will be used.
9688642|NCT04853745||sodium bicarbonate group|Sodium bicarbonate-based powder (CLASSIC®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
9688643|NCT04853745||glycine group|Glycine-based powder (PERIO®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
9696129|NCT04770064|Experimental|Low-dose/sustained duration Fisetin (FIS-lo)|
9696130|NCT04770064|Placebo Comparator|Placebo|
9696131|NCT04770116|Experimental|Intervention group|Participants in this group will receive all-night auditory stimulation during sleep over one week using a portable, in-home device (MHSL-SleepBand).
9696132|NCT04770116|Sham Comparator|Control group|Participants in this group will receive sham-stimulation, i.e. the device will be applied (biosignals will be recorded), but no tones will be played.
9826782|NCT02432235|Experimental|5 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles.
10180237|NCT03794804|Placebo Comparator|Placebo|"Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
9688644|NCT04853745||erythritol group|Erythritol-based powder (PLUS®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
9688645|NCT04853667||Patients with hereditary epidermolysis bullosa|Minor patients with hereditary epidermolysis bullosa
9688646|NCT04853667||Parents|Parents of patients with hereditary epidermolysis bullosa
9688647|NCT04853680|Experimental|Treatment|Use of Anti-adhesion barrier on the thyroidectomy space. After the thyroidectomy, anti-adhesion barrier will be applied on the thyroidectomy space, around the trachea, cricothyroid muscle and platysma muscle before the closure of surgical wound.
9688648|NCT04853680|No Intervention|Control|No use of anti-adhesion barrier. After the thyroidectomy, don't use the anti-adhesion barrier before the wound closure.
9688649|NCT04853797|Active Comparator|Ivabradine|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of ivabradine (15 mg orally).
9688650|NCT04853797|Placebo Comparator|Placebo|Infusion of levcromakalim (2.5 nmol minutes-1 over 20 minutes) followed by oral administration of placebo.
9688651|NCT04853875|Experimental|Group A (Tetracycline, Metronidazole, and Bismuth)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Tetracycline 2g, Metronidazole 2g, and Bismuth subcitrate 480 mg
9688652|NCT04853875|Active Comparator|Group B (Amoxicillin, Metronidazole, and Clarithromycin)|Intraluminal Therapy for Helicobacter pylori Infection - Single dose medicament containing Amoxicillin 3g, Metronidazole 2g, and Clarithromycin 1g
9688653|NCT04853784||Totally laparoscopic colon surgery|Totally laparoscopic colon surgery/intracorporeal anastomosis
9688654|NCT04853784||Laparoscopic-assited colon surgery|Laparoscopic-assited colon surgery/extracorporeal anastomosis
9688655|NCT04853615||Group 1|1st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast
9688656|NCT04853615||Group 2|2nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily
9688657|NCT04853615||Group 3|3rd group will receive the SGLT2i empagliflosin 25 mg once daily
9688658|NCT04853615||Group 4|4thwill receive allopurinol and empagliflosin.
9688659|NCT04853446|Placebo Comparator|Placebo|Capsulated glucosemonohydrate will be used as placebo. Two capsules of placebo will be adminstered.
9688660|NCT04853446|Experimental|Dexamethasone 12 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. One capsule of 12 mg dexamethasone and one capsule of placebo for a total dose of 12 mg of dexamethasone will be administered.
9688661|NCT04853446|Experimental|Dexamethasone 24 mg|Dexamethasone tablets of 4 mg encapsulated in pairs of three. Two capsules of 12 mg dexamethasone for a total for 24 mg of dexamethasone will be administered.
9688662|NCT04853810||Major diabetic subjects having used a system with adhesives|Major diabetic subjects, whatever the etiology of diabetes, using or having used in the last 10 years a system with skin adhesives, i.e. insulin patch pump (e.g. OMNIPOD®, cell Novo®), pump with externalized catheter (e.g. MINIMED 640G®, YpsoPump®) or continuous glucose measurement system (Free Style®, DexCom® sensors, Enlite® sensors).
9688663|NCT04853537|Experimental|study group|• 126 women will fast 16 consecutive hours per day including sleeping hours. and follow them from 26w till 36w by GTT(glucose tolerance test) and the weight gain and incidence of gestational diabetes
9688664|NCT04853537|No Intervention|control group|• 126 women will not fasting with the same life style and follow the incidence of gestational diabetes
9688665|NCT04853719|Experimental|Vascular dose|Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months
9688666|NCT04853719|Active Comparator|Aspirin|Aspirin 100 mg OD for 6 months
9688667|NCT04853706|Other|Delirium|
9688668|NCT04853589|Active Comparator|Hyaluronic acid|hyaluronic acid gel application
9688669|NCT04853589|Active Comparator|Hyaluronic acid+carrier|hyaluronic acid gel application together with a carrier
9688670|NCT04853589|No Intervention|Standard treatment|standard treatment (i.e., blood clot only)
9688671|NCT04853628|Experimental|Alerta Alcohol|The EC-1 receives Alerta Alcohol, which consists of session 1 or baseline, two sessions in three scenarios: at home, celebrations, and public places, and two follow-up evaluations. The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, four booster sessions are given at home to reinforce the contents of the three scenarios. Evaluations take place after six and twelve months.
9688672|NCT04853628|Experimental|Alerta Alcohol 2.0|The EC-2 receives an improved version of Alerta Alcohol (Alerta Alcohol 2.0) using animated videos and new gamification strategies. Evaluations take place after six and twelve months.
9826783|NCT02432235|Experimental|8 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
9688673|NCT04853628|No Intervention|Control condition|The CC just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list). Evaluations take place after six and twelve months from baseline.
9688674|NCT04853524|Experimental|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) plus JNJ-56136379|Participants will receive a single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 1. Multiple oral doses of JNJ-56136379 once daily on Day 6 to Day 24. A single oral dose of the combination of BIC plus FTC plus TAF tablet on Day 20.
9688675|NCT04853901|Experimental|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone 1-2mg/kg for 5-7 days
9688676|NCT04853901|Active Comparator|Standard of care therapy|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days + Methylprednisolone 1-2mg/kg for 5-7 days
9688677|NCT04853511||OCT-FLIM dual modal intravascular imaging with serial 18F-FDG-PET/CT assessment|Group of patients undergoing PCI with comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular imaging followed by serial 18F-FDG-PET/CT imaging
9688678|NCT04853472||Early Stage Peri-Menopause|Mild cycle irregularity over the last 3-6months (minimum), variation of >6 days in length between consecutive cycles including shortened and longer cycles (but not >60 days in length)
9688679|NCT04853472||Late Stage Peri-Menopause|Late stage peri-menopause: Irregular cycles with prolonged periods of amenorrhea >60 days in length (but less than 12 months)
10180238|NCT03794791||education|Education will be used to see whether or not improve the HCV screening and diagnosis in HBsAg(+) patients. Blood test ,HCV-RNA quantification test and HCV genotyping will be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
9688680|NCT04853472||Post-Menopause|Greater than 12 months since last menstrual period
9688681|NCT04853485|Active Comparator|Active TMS targeting both cerebellum and right dorsolateral prefrontal cortex.|Subjects identified as with prominent negative symptoms will be randomized into active group, who will receive active rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
9688682|NCT04853485|Sham Comparator|Sham TMS targeting both cerebellum and right dorsolateral prefrontal cortex|Subjects identified as with prominent negative symptoms will be randomized into sham group, who will receive sham rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
9688683|NCT04853485|Active Comparator|Active TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into active group, who will receive active rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
9688684|NCT04853485|Placebo Comparator|Sham TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into sham group, who will receive sham rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
10180239|NCT03794791||no education|There is no education at all.Screening and diagnosis of HCV infection in HBsAg(+) patients are based on voluntary. Blood test ,HCV-RNA quantification test and HCV genotyping will still be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
9688685|NCT04853485|Active Comparator|Active deep TMS using Brainways H7 coil targeting ACC|Subjects identified as with positive symptoms will be randomized into active group, who will receive active deep rTMS over ACC using H7 coil.
9688686|NCT04853485|Placebo Comparator|Sham deep TMS using Brainways H7 coil targeting ACC|Subjects identified with positive symptoms will be randomized into sham group, who will receive sham deep rTMS over ACC using H7 coil.
9688687|NCT04853823|Experimental|PDC-APB|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
9688688|NCT04853823|Placebo Comparator|Vehicle|Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
9688689|NCT04853199|Experimental|Quercetin group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
9688690|NCT04853199|Placebo Comparator|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
9688691|NCT04853316||Case: Exposed (SARS-CoV-2 positive)|Participants found positive by SARS-CoV-2 testing.
9688692|NCT04853316||Control: Unexposed (SARS-CoV-2 negative)|Participants found negative by SARS-CoV-2 testing.
10180240|NCT03794765|Experimental|Antibiotic|Standard of Care (steroids, prophylactic anticoagulation, oral nutrition) And Antibiotics (Inj Ceftriaxone 1 gram intravenous twice daily And Inj Metronidazole 500 mg intravenous thrice daily) for initial 48 hours
10180241|NCT03794765|Placebo Comparator|Placebo|Standard of care (steroids, prophylactic anticoagulation, oral nutrition) And Placebo infusions similar to the active drugs
10180242|NCT03794934|Placebo Comparator|Control|Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
10180243|NCT03794934|Active Comparator|Intervention|provide structured education when applying CGM for 3 months
9688693|NCT04853277|Experimental|Education Group|Participants will receive an educational intervention focusing on psychosocial stressors and timeline of symptoms associated with the transplant/CAR-T experience.
9688694|NCT04853953||COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
9688695|NCT04853953||Non-COVID-19 ARDS patients requiring veno-venous ECMO support|Critically ill Non-COVID-19 patients with ARDS requiring ECMO support will be analyzed in this group. Patients from all three study sites will be assessed for participation.
9688696|NCT04853303|Experimental|Hypnosis VR|The experimental group will receive a 15-minute hypnosis using virtual reality when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain.
9688697|NCT04853303|No Intervention|Control|The control group will receive no intervention.
9688698|NCT04853134|Placebo Comparator|Standard Care|Standard of care as determined by the PI
9688699|NCT04853134|Active Comparator|Proxalutamide + Standard Care|Proxalutamide + standard of care as determined by the PI
9688700|NCT04853069|Active Comparator|Oestrogen Therapy|Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.
9688701|NCT04853069|No Intervention|Control Group|Patients will receive only standard care.
9688702|NCT04853342|Experimental|Furmonertinib|Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
9688703|NCT04853342|Placebo Comparator|Placebo Furmonertinib|Matching placebo for Furmonertinib (80 mg orally, once daily), in accordance with the randomization schedule.
9688704|NCT04852913|Experimental|Bowen's Technique|Bowen's Technique The session lasted for 20 minutes, 3 sessions/week 6th week
9688705|NCT04852913|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy with myofascial release The session lasted for 20 minutes, 3 sessions/week 6th week
9688706|NCT04852900|Experimental|Decompression with 30%|Decompression with 30% and mobilization
9688707|NCT04852900|Experimental|Decompression with 40%|Decompression with 40% and mobilization
9688708|NCT04852900|Experimental|Decompression with 50%|Decompression with 50% and mobilization
9688709|NCT04852991|Active Comparator|Modified Purandare cervicopexy|Apical prolapse will be corrected by Modified Purandare cervicopexy
9688710|NCT04852991|Active Comparator|Abdominal sacrohysterpexy|Apical prolapse will be corrected by Abdominal sacrohysterpexy
9688711|NCT04852939|Experimental|Bowen's Technique|Bowen's Technique
9688712|NCT04852939|Active Comparator|Conventional Physical Therapy|Conventional Physical Therapy including stretching and strengthening exercises
9688713|NCT04853173|Experimental|ambulatory protocol after adult tonsillectomy|prescription of analgesics for outpatient procedure with hospital surveillance
9688714|NCT04852848|Experimental|Connect2Test Intervention|A brief MI intervention to motivate individuals to participate in COVID-19 testing after receiving syringe exchange services
9688715|NCT04852848|No Intervention|Control|Services as usual
10180244|NCT03794700|No Intervention|Control|
9688716|NCT04853160||All Participants With Gout|Participants with gout, initiating febuxostat therapy on or after 01 June 2016 will be included in the study.
9688717|NCT04853225||Main cohort|COPD, chronic bronchitis and healthy participants (never smoker) from Type A and Type B hospitals will be included.
9688718|NCT04853225||Sub-cohort|COPD, chronic bronchitis and healthy participants (never smoker) from selected Type A hospitals will be included.
9688719|NCT04852744|Other|Borderline girls with PTSD|"female~Age between 13 and 17 years inclusive~Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)~Post-traumatic stress disorder according to DSM-5 criteria (American Psychiatric Association, 2013; K-SADS-PL)~Level of general psychopathology compatible with participation in the study (score> 20 on the CGA-S)~Oral and written comprehension of the French language~Affiliation to the social security scheme~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
9688720|NCT04852744|Other|Borderline girls without PTSD|"female~Age between 13 and 17 years inclusive~Diagnosis of borderline personality disorder according to the criteria of the Diagnostic and Statistical Manual for mental disorders, fifth edition (DSM-5; American Psychiatric Association, 2013; SIDP-IV)~Level of general psychopathology compatible with participation in the study (score> 20 on the CGA-S)~Oral and written comprehension of the French language~Affiliation to the social security scheme~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
9688721|NCT04852744|Other|Healthy controls|"female~Age between 13 and 17 years inclusive~Absence of mental disorder according to DSM-5 (American Psychiatric Association, 2013 ; K-SADS-PL et SIDP-IV)~Oral and written comprehension of the French language~Affiliation to the social security scheme~Informed consent signed by the legal representatives holding the exercise of parental authority and the adolescent herself"
9688722|NCT04853030|Experimental|Minimed 670G 4.0 closed loop with Faster Insulin aspart|
9688723|NCT04853030|Active Comparator|Minimed 670G 4.0 closed loop with Standard Insulin aspart|
9688724|NCT04852523|Experimental|18F fluciclovine Administration|"Initial normal standardized uptake values (SUV) of the pancreas, liver, and blood pool will be obtained from 50archived previous 18F-Fluciclovine studies, as there are no normal ranges in the literature. This will be done by retrospective medical record review after a waiver of consent/authorization is obtained from the local IRB.~Informed consent will be obtained from 10 patients with pancreatic allografts, and each will undergo an 18F-Fluciclovine study. These patients will not be suspected of having current rejection or allograft dysfunction. Timing of 18F-Fluciclovine PET/CT scans will be planned to coincide with standard-of-care imaging studies and laboratory tests.~The 18F-Fluciclovine study will be compared with the patients' standard-standard-of-care US and/or CT with the assessment of ease of visualization of the pancreatic allograft."
9688725|NCT04852549|No Intervention|No intervention group|The control group continued with routine training after evaluations.
10187501|NCT03725631|Experimental|Biopsy proven NAFLD patients|150 subjects who are diagnosed with NAFLD with biopsy from September 2016 to October 2018.
9688726|NCT04852549|Experimental|Oculomotor exercise group|After the evaluation, the intervention group performed oculo-motor exercises for 4 weeks, 6 days a week, morning and evening, twice a day for 10 minutes, in addition to normal ball training. While doing the exercises, individuals were taught to focus on the purpose they held in their hands, move their head, and aim fast enough to see the image clearly. Two repetitions each week were added to the exercise numbers. Ten seconds rest between two sets and five seconds rest between movements.
10180245|NCT03794700|Other|Intervention|Participants will receive hospice decisional support materials and be asked to review them. Participants will provide feedback on tools and complete feasibility, efficacy and knowledge assessments.
10180246|NCT03794674||MPI test group|50 eligible patients. Frailty level independently assessed by two reviewers based on the medical records and assessed by one research assistant based on bedside testing.
10180247|NCT03794713|Experimental|Patient support tool group|Subjects were managed the HR by using the Patient Support Tool through a smart phone application and a wristband and be guided by physicians
9688727|NCT04852380||Patients treated by PRP injection|
10180248|NCT03794713|No Intervention|Control group|Subjects were received a usual patient care at baseline, which left to the discretion of physicians, without any specific intervention at follow-up period
9688728|NCT04852393||Block|Patients undergoing ultrasound-guided cervical medial branch blocks as part of their usual care
9688729|NCT04852406|Experimental|Intervention group|Participants in this group receive protocol-based management of perioperative antithrombotic therapy.
9688730|NCT04852406|Sham Comparator|Control group|Participants in this group receive routine management of perioperative antithrombotic therapy.
9688731|NCT04852640|Experimental|Active Rehabilitation Program (ARP)|Participants will be treated for symptomatic shoulder instability with the evidence-based, targeted treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. Exercises in the ARP include: Low-load and high-duration rotator cuff strengthening exercises, progressive scapular muscle endurance training, plyometric strengthening exercises, and surface electromyographic (EMG) biofeedback. Each prescribed exercise in the ARP will be increased to match the participant's function at the discretion of the study clinician. Although the components of the ARP will be pre-determined, the parameters and volumes of the components will be determined and documented over the treatment phase.
10180249|NCT03794908|Experimental|Light therapy A via the Re-Timer®|"60 minutes/day~For the first hour after waking"
10180250|NCT03794908|Active Comparator|Light therapy B via the Re-Timer®|"60 minutes/day~For the first hour after waking"
10180251|NCT03794687||Distal Radial Artery|Left heart catheterization via the distal radial artery (dorsal aspect of the hand at the base of the thumb).
10180252|NCT03794843|Experimental|Nimodipine Injection (II)|The specification of this injection is 5 ml: 4 mg , which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:16 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
10180253|NCT03794843|Experimental|Nimodipine Injection|The specification of this injection is 50 ml: 10 mg ,which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:4 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
10180254|NCT03794505|Active Comparator|Shoulder infiltration|Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg
10180255|NCT03794505|Experimental|Suprascapular nerve block|Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg
10180256|NCT03794869|Experimental|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of the core: awareness of breathing, front and side plate abdominal, glute bridge/hip elevations, lift extended leg, pelvic tilt, hamstring stretch, strengthening lower abdominals, cat-camel posture, trunk rotations with flexed knees, rolling in sitting and lumbar extension with hip extensión in prone
9826784|NCT02432235|Experimental|13 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles.
9826785|NCT02432235|Experimental|20 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
9826786|NCT02432235|Experimental|30 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
10180257|NCT03794869|Active Comparator|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
10180258|NCT03794544|Experimental|Durvalumab 1500 mg|Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
10180259|NCT03794544|Experimental|Durvalumab 1500 mg + Oleclumab 3000 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
10180260|NCT03794544|Experimental|Durvalumab 1500 mg + Monalizumab 750 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
9688732|NCT04852640|Experimental|Nonspecific Passive Intervention (NPI)|Participants will be treated for symptomatic shoulder instability with the non-specific, generalized treatment intervention. For eight weeks, there will be two treatment sessions per week lasting 30-45 minutes. The NPI consists of a general approach to treating shoulder pain with passive modalities for pain modulation. These interventions are commonly practiced but have little evidence to support their use in the treatment of symptomatic shoulder instability. Although the components of the NPI will be pre-determined, the parameters and volumes of the components will be determined and documented by a study clinician over the treatment phase.
9688733|NCT04852705|Experimental|candidate vaccine|
9688734|NCT04852705|Placebo Comparator|Placebo|
10180261|NCT03794544|Experimental|Durvalumab 1500 mg + Danvatirsen 200 mg|Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
10180262|NCT03794921|No Intervention|Usual Care|Patients referred to conventional PR or eligible for PR but declined. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
9688735|NCT04852770|Experimental|Trial-Based Cognitive Therapy|TBCT (de Oliveira, 2008) is a novel transdiagnostic approach (Wenzel, 2017). It has been shown to be effective for depression (Hemanny et al., 2019), social anxiety disorder (Neufeld et al., 2020; Caetano et al., 2018; de Oliveira et al., 2011; Powell et al., 2013), and PTSD (Duran et al., 2020). TBCT differs from other CBT approaches in that it introduces a new, organized, and systematic approach to change dysfunctional negative core beliefs, and allows cognitive, emotional, and experiential work to be done simultaneously (de Oliveira, 2016). Interestingly, it incorporates a courtroom metaphor to challenge dysfunctional core beliefs conceptualized as self-accusations (de Oliveira, 2016). TBCT is an example of assimilative psychotherapy integration that relies on Beckian CBT (de Oliveira, 2016). It incorporates and integrates components of other psychotherapies (Delavechia et al., 2016).
9688736|NCT04852770|Active Comparator|Mindfulness-Based Health Promotion|The Mindfulness-Based Stress Reduction (MBSR) program was created by Jon Kabat-Zinn and colleagues at the University of Massachusetts Medical Center in 1979, and it is an intervention whose effects on mental health and quality of life has produced several studies worldwide, both in clinical and non-clinical populations. Several protocols have been developed based on the MBSR aimed at specific publics, such as the Mindfulness-Based Health Promotion (MBHP) program developed by the Mente Aberta - Brazilian Center for Mindfulness and Health Promotion. The MBHP program was inspired by the original MBSR model but adapted to the context of the Brazilian Health Care (SUS) system, addressing chronic conditions and mental disorders as well (TROMBKA et al., 2018; LOPES et al., 2019; SALVO et al., 2018).
9688737|NCT04852770|Active Comparator|Positive psychotherapy|Positive psychotherapy (PPT) seeks to understand positive emotions, psychological potentialities and healthy human / social / institutional functioning, and to apply this knowledge to help people and institutions, with a focus on prevention and promotion of mental health (SELIGMAN et al., 2005). Originally, PP focused on happiness and subjective well-being (SELIGMAN, 2010; SELIGMAN; CSIKSZENTMIHALYI, 2000). Then, the studies gained a broader view of psychological well-being and another similar proposal entitled PERMA, which is composed of the following five spheres: positive emotions - P; engagement - E; relationships - R; meaning - M; and achievement - A. (RYFF, 2013; SELIGMAN, 2012). Although positive psychology aims to be a way of looking at life, some psychotherapeutic proposals, such as positive psychotherapy (PPT), have been developed, and clinical studies have been replicated in different clinical and cultural contexts (RASHID; SELIGMAN, 2019; RICHES et al., 2016).
9688738|NCT04852458|Experimental|Intravenous hydrocortisone|
9688739|NCT04852458|No Intervention|Observational|Participants will complete assessments/surveys only.
9688740|NCT04852250||FOLFOXIRI plus bevacizumab and centralized tumour board|
9688741|NCT04852250||FOLFOXIRI plus bevacizumab but no centralized tumour board|
9688742|NCT04852510|Active Comparator|Group A|Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA).
9688743|NCT04852510|Active Comparator|Group B|A combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
9688744|NCT04852562|Experimental|Modified radical endoscopic sinus surgery(MRESS)|The experimental group intends to adopt a modified radical endoscopic sinus surger to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate resection to achieve a radical cure of ethmoid sinus. Antrostomies of frontal and sphenoid sinuses were then performed with meticulous operation and preserve the mucosa intactly.
9688745|NCT04852562|Experimental|Functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique, operation procedures including full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
9826787|NCT02432235|Experimental|45 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
10187502|NCT03725618|Experimental|One-fifth fractional dose|One-fifth fractional dose (0.1 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
10187503|NCT03725618|Experimental|One-half fractional dose|One-half fractional dose (0.25 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
10187504|NCT03725618|Experimental|Full dose|Full dose (0.5 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
10187505|NCT03725605|Experimental|LTX-315 plus TIL infusion|LTX-315 intratumoural 5mg per injection time point (number of injections per dosing days is dependent upon lesion size), TILs expansion and infusion.
9688746|NCT04852315|Experimental|Caffeine supplementation|Acute caffeine supplementation
9688747|NCT04852315|Placebo Comparator|Placebo supplementation|Acute placebo supplementation
9688748|NCT04852263|Other|Group I|Fiberoptic intubation was carried out without nasopharyngeal airway
9688749|NCT04852263|Other|Group II (NPA group)|Fiberoptic intubation was performed with a modified nasopharyngeal airway.
9688750|NCT04852536||HD-tDCS4x1|All data will be acquired from patients of the triple-blind clinical trial that will investigate the effectiveness of treatment for neuropathic pain after brachial plexus injury with HD-tDCS. There will be collection and analysis of EEG data before the clinical trial protocol, to later assess the prediction of response to the technique employed. At the end, they will be grouped into responders and non-responders to HD-tDCS, according to the numerical scale of pain, with assignments serving as targets for the analyzes with machine learning. The labels for clinical improvement used to classify machine learning will be determined based on the data obtained in the baseline and post-treatment assessments, according to similar studies. Thus, the EEG data of these patients will be retrospectively examined, identifying possible neurophysiological characteristics and biomarkers related to the frequency bands that allow predicting which patients are most likely to improve with this treatment.
9688751|NCT04852432|No Intervention|Control group|Nasal prong is applied, but sedation is performed without oxygen administration.
9688752|NCT04852432|Experimental|Low flow group|Oxygen administration by nasal cannula
9688753|NCT04852432|Experimental|High flow group|Oxygen is administered at a rate of 2L/kg/min using an Optiflow device
9688754|NCT04852172|Active Comparator|Arm 1 (L-citrulline)|25 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
9688755|NCT04852172|Active Comparator|Arm 2 (L-citrulline)|50 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
9688756|NCT04852172|Active Comparator|Arm 3 (L-citrulline)|100 mg/kg bolus + 9 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
9688757|NCT04852172|Active Comparator|Arm 4 (L-citrulline)|100 mg/kg bolus + 11 mg/kg/hr continuous infusion of L-citrulline for up to 7 hours
9688758|NCT04852172|Active Comparator|Part 2 Arm 1 (L-citrulline)|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio. L-citrulline will be administered to the active arm.
9688759|NCT04852172|Placebo Comparator|Part 2 Arm 2 (normal saline (0.9% NaCl) D5 ½)|Subjects will be randomized to 2 of the doses selected from Part 1 and placebo in a 1:1:1 ratio.
9688760|NCT04852653||Patients with adenocarcinoma of rectum histologically proven|
9688761|NCT04852484|Active Comparator|local anesthetic and morphine group|paravertebral block with local anesthetic and morphine, followed by a continuous infusion of local anesthetic and morphine in the paravertebral space
9688762|NCT04852484|Active Comparator|local anesthetic and ketamine group|paravertebral block with local anesthetic and ketamine, followed by a continuous infusion of local anesthetic and ketamine in the paravertebral space
9688763|NCT04852484|Active Comparator|local anesthetic group|paravertebral block with local anesthetic only, followed by a continuous infusion of local anesthetic only in the paravertebral space
9688764|NCT04852445||Stroke|We will include: 60 patients aged 18 years or older with clinical symptoms of hemispheric ischemic stroke due to occlusion of a large cerebral blood vessel, onset within 48 hours and NIHSS of 1 or more;
9688765|NCT04852445||Controls|30 healthy controls, age- and sex- matched with stroke study population
9688766|NCT04852445||Carotid arterectomy after stroke|10 patients undergoing carotid endarterectomy within 30 days after stroke
9688767|NCT04852445||Carotid endarterectomy for asymptomatic stenosis|3 patients without stroke undergoing carotid endarterectomy for asymptomatic carotid stenosis.
9688768|NCT04852341||Corneal horizontal diameter ≤9.00mm group|
9688769|NCT04852341||Corneal horizontal diameter 9.00mm~9.50mm group|
9688770|NCT04852341||Corneal horizontal diameter 9.50mm~10.00mm group|
9688771|NCT04852341||Corneal horizontal diameter >10.00mm group|
9688772|NCT04851938|Active Comparator|Active TENS 1 Group|
9688773|NCT04851938|Active Comparator|Active TENS 2 Group|
9688774|NCT04851938|Placebo Comparator|Placebo Group|
9688775|NCT04851938|Sham Comparator|Control Group|
9688776|NCT04852237||Pregnancies from ICSI-TESE cycles for obstructive azoospermia.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI-TESE cycles for obstructive azoospermia.
9688777|NCT04852237||Pregnancies from ICSI cycles with ejaculated sperm.|Pregnancies occurred between January 2010 and December 2019 at Humanitas Fertility Center after ICSI cycles with ejaculated sperm.
9688778|NCT04852146||Professional|The sample of professionals will be made up of doctors and nurses of the emergency structures (pre and intra-hospital), doctors and nurses of interventional cardiology and ambulance drivers practising in an establishment of the 7 participating SAMU zones
9688779|NCT04852146||Patient|The patient sample will consist of patients included in the REANIM registry during the study period (the entire period of the stepped wedge randomised controlled trial).
9688780|NCT04852068|Experimental|Investigational Vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
9688781|NCT04852068|Experimental|Investigational Vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
9688782|NCT04852068|Active Comparator|Control vaccine - 5-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
9688783|NCT04852068|Active Comparator|Control vaccine - 4-dose program|Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
9688784|NCT04851743|Experimental|Dry needling Group|Participants will be used as their own controls, with 1 lower extremity randomly receiving intervention. The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
9688785|NCT04851743|No Intervention|Control Group|Participants will be used as their own controls, with 1lower extremity randomly receiving intervention. The control extremity did not receive any intervention, and outcomes were assessed 2 minutes apart.
10180263|NCT03794921|Experimental|Every Step Counts Intervention|Patients referred to conventional PR or eligible for PR but declined. After randomization to ESC, participants will be mailed detailed instructions about the website. They will be asked to wear the lightweight, unobtrusive pedometer every day, except while asleep or showering/bathing, during the 12-week intervention period. Subjects will be instructed to upload their date and time-stamped step-count data to the study website as often as they wish, but at least weekly. Each week, the study computer will run the goal calculation algorithm and provide each participant with his/her daily step-count goal for the week. The week's step-count goal will be prominently displayed on each subject's personal study web page. Participants will be instructed to exercise and reach their individualized step-count goals with walking of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover.
9688786|NCT04851782|Experimental|Braun Infusomat Pump and ivEAD tubing|ivEAD tubing
9688787|NCT04851782|No Intervention|Braun Infusomat Pump and standard tubing|Standard tubing
9688788|NCT04851782|Experimental|Standard pump and ivEAD tubing|ivEAD tubing
9688789|NCT04851782|No Intervention|Standard infusion pump and standard tubing|Standard tubing
9688790|NCT04851795|Experimental|interventional study|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
9688791|NCT04851795|Other|control group|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
9688792|NCT04851769|Experimental|alirocumab plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
9688793|NCT04851769|Active Comparator|standard statin therapy|Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target <100 mg/dL.
9688794|NCT04852094||Parents|parents of hospitalized children, speaking and understanding enough French, not presenting psychiatric disorders, voluntary to participate in focus groups
9688795|NCT04852094||Professionals|Nurses, assistant nurses, psychologist, physiotherapist, physicians, residents and fellows
9688796|NCT04851821|Experimental|Quercetix group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
9688797|NCT04851821|Placebo Comparator|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
9688798|NCT04851951||patients treated by one-shot PRP injection|
9688799|NCT04851691|Experimental|EHR CDS tool|Multi-pronged electronic health record (EHR) clinical decision support (CDS) tool intervention to reduce physician prescriptions of new antipsychotic medications among older adults with ADRD
9688800|NCT04851691|Experimental|Control|Physicians will not receive intervention and perform duties as usual.
9688801|NCT04851561||Cases|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), cases will be defined as such if fulfill for the following criteria: individuals who report on lasting fatigue symptoms which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis and the lasting fatigue symptoms are present for at least six weeks.
9688802|NCT04851561||Controls|Adults recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), did not report fatigue symptoms at any time point following their diagnosis with COVID-19.
9688803|NCT04851639|Experimental|Proof of principle|Proof of principle of the efficacy and utility of the WATapp
9688804|NCT04851977|Experimental|Cohort 1: low dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
9688805|NCT04851977|Placebo Comparator|Cohort 2: low dose|IM injection on Day 0 and at Day 30 (12 active, 3 placebo) with follow up at 7 days post vaccination (Day 7 ± 1 day and Day 37 ± 1 day) and Day 60 ± 5 days and a final follow up/ EOS teleconference assessment at Day 90 ± 5 days.
9688806|NCT04851977|Experimental|Cohort 3: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
9688807|NCT04851977|Placebo Comparator|Cohort 4: high dose|IM injection on Day 0 (12 active, 3 placebo); with follow up at 7 days ± 1 day post vaccination and at Day 30 ± 5 days and a final follow up/end of study (EOS) teleconference assessment at Day 60 ± 5 days.
9688808|NCT04852042|Experimental|mHealth Group|12 month text messaging program about diet and physical activity behavioral goals
9688809|NCT04852042|Experimental|mHealth+Community Health Worker (CHW) support|same as mHealth group + monthly behavioral phone counseling by a CHW
9688810|NCT04852042|No Intervention|Control group|Assessments only
9688811|NCT04851990|Experimental|Large Patch|"To Better Days Large Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
9688812|NCT04851990|Experimental|Small patch|"To Better Days Small Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
9826788|NCT02432235|Experimental|60 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles.
9688813|NCT04852016|Experimental|Digital Educational Platform|Study participants randomized to the DEP+SVC group (intervention) will be presented with an iPad with a link to an interactive DEP module discussing the indications for LC, alternatives, risks, complications, expectations and anticipated recovery. They will be asked to review the DEP module at their own pace and will be required to confirm understanding of all of the material presented on the DEP. Upon completion of the module, a member of the surgery team will ask the patient if they have any additional questions or require further clarification regarding the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery. Once all of participant's questions are answered, an informed paper-based consent form for LC will be signed.
9688814|NCT04852016|Active Comparator|Standard Verbal Consent|Study participants randomized to the SVC group (control) will discuss the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery with a member of the surgery team. The study participant will be given the opportunity to ask questions and once all of the questions have been answered, an informed paper-based consent form for LC will be signed.
9688815|NCT04851574||Group I with dose of Sugammadex of 0.5 Mg/kg|After general anesthesia children received one dose of 0.5 Mg/kg of Sugammadex to reverse neuromuscular blockade.
9688816|NCT04851574||Group II with dose of Sugammadex of 1.0 Mg/kg|After general anesthesia children received one dose of 1.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
9688817|NCT04851574||Group III with dose of Sugammadex of 2.0 Mg/kg|After general anesthesia children received one dose of 2.0 Mg/kg of Sugammadex to reverse neuromuscular blockade.
9688818|NCT04851860|Other|allergic rhintis children|sublingual immunotherapy is used for allergic rhintis children by dosing Allergen immunotherapy extract as sublingual drops which were kept under the tongue for a couple of minutes and then swallowed. The sublingual drops were administered in the morning on an empty stomach .
9688819|NCT04851704|Experimental|Intervention: Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
9688820|NCT04851704|No Intervention|Control: Business as usual|"Control groups have business as usual, and then get offered the intervention program after 6 months follow-up assessment."
9688821|NCT04851535|Experimental|Jaktinib 100mg Bid|Jaktinib twice daily for 6 consecutive 28-day cycles, orally, empty stomach
9688822|NCT04851548|Active Comparator|Group A (control)|"preoperative cone-beam computed tomography (CBCT) scans N=9~open flap debridement.~use membrane without hyaluronic acid. (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments|)"
9688823|NCT04851548|Active Comparator|Group B (test)|"preoperative cone-beam computed tomography (CBCT )scans N= 9~open flap debridement.~use membrane and 8% hyaluronic acid gel (The first monitor will be done after three months. The data will be recorded. After another three months, the patients will undergo an x-ray check again, and the data will be registered. The goal is to have the patients exposed to x-ray twice not to be compromised to a high radiation dose. The evaluation to be done for the 3-month interval will only be clinical assessments|)."
9688824|NCT04851756|Experimental|CRet Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis
9688825|NCT04851756|Sham Comparator|CRet Sham Group|30 min CRet with F.M on the rectus femoris and gastrocnemius medialis and lateralis with turned on CRet device at power 0
9688826|NCT04851509|Active Comparator|Dynamic rotational locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The helical screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance less than 25mm. The compression nut will be used to compress the fracture. The helical screw will be rotationally locked by using the 5mm hex flexible screwdriver by advancing the set screw until it stops completely. The screw will then be turned counterclockwise by a ½ turn.
9688827|NCT04851509|Experimental|Static locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The helical screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance of less than 25mm. The compression nut will be used to compress the fracture. The helical screw will then be statically locked using the 6Nm torque-limiting blue handle with 6mm hex coupling to completely lock the set screw down on the helical screw.
9688828|NCT04851626|Experimental|Intervention group - hypnotic intervention for persistent pelvic pain|Participants underwent education about persistent pain and a 7 week 7 recording online hypnotic intervention. Women with persistent pelvic pain.
9688829|NCT04851626|Other|Control group - waitlist control|Control group of women with persistent pelvic pain no intervention completed assessment and concluding measures but did not undergo hypnotic intervention.
9688830|NCT04852081||patients with HR+, HER2- advanced or metastatic breast cancer|patients with HR+, HER2- advanced or metastatic breast cancer
9688831|NCT04851457|Experimental|Intervention group|The participants in the experimental group will receive intravenous tirofiban combined with a standard MT protocol recommended by the current guidelines for the management of AIS
9688832|NCT04851457|No Intervention|Control group|Patients are treated with MT therapy with no antiplatelet drugs (intravenous or intra-arterial) are administered. Besides, they will receive a standard pharmacological treatment as per current clinical guidelines.
9688833|NCT04851444|Experimental|SI-F019|SI-F019 administered intravenously (IV).
9688834|NCT04851392|Experimental|THC condition|"THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC. A 75kg person receives 8mg of THC.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in < 18 minutes."
10180264|NCT03794778|Experimental|study group|pegylated liposomal doxorubicin 30 mg/m2, i.v.,d1; carboplatin AUC 5,i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
9688835|NCT04851392|Experimental|THC+CBD condition|"THC+CBD condition: Cannabis with THC and CBD (i.e. THC+CBD condition). 0.107mg/kg of THC and 0.320mg/kg of CBD. A 75kg person receives 8mg of THC and 24mg of CBD.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in < 18 minutes."
9688836|NCT04851392|Placebo Comparator|PLA condition|"PLA condition: Placebo cannabis with no THC or CBD.~Route of administration: vaporised and inhaled.~Frequency: once.~Duration: inhaled in < 18 minutes."
9688837|NCT04851431|Experimental|One-to-One Peer Mentoring|Caregiver will be matched based on characteristics such as age, date of patient injury, level of patient injury, cause of patient injury, marital status, work status before and after patient injury, interests, and leisure activities. After participant is matched with a peer mentor, they will be required to have at least one weekly one-to-one interaction from time of match until 30 days post- discharge.
9688838|NCT04851431|Active Comparator|Usual Care|Participants received the usual discharge planning and family support services offered by the ABI program. These services include nurse instruction in care routines, case management support for discharge, peer support services, referral to family counseling and community services as indicated, and general information resources about brain injury. Participants in both the intervention and usual care groups also had access to the online peer support community created for ABI caregivers (facebook.com/shepherdbi.peers). In addition, usual care participants could request one-to-one visits with peer mentors and, indeed, most usual care participants received at least one peer mentoring visit.
9688839|NCT04851314|Active Comparator|ICU certified ventilator|Participants assigned to receive ventilation with the ICU certified ventilator
9688840|NCT04851314|Active Comparator|Non-ICU certified ventilator|Participants assigned to receive ventilation with the Non-ICU certified ventilator
9688841|NCT04851600||Early introduction|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
9688842|NCT04851418||Possible NSTE-ACS|All patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion. In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy. All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care). Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).
9688843|NCT04851236|Active Comparator|Massage Arm|Standard of care treatment.
9688844|NCT04851236|No Intervention|Usual Care|
9688845|NCT04851275|Experimental|Shared decision making for men with lower urinary tract symptoms|Participants used the Visual Analogue Uroflowmetry Score so report their symptoms and were attended by Primary Care Physicians trained in shared decision making
9688846|NCT04851275|Active Comparator|No shared decision making for men with lower urinary tract symptoms|Participants did not use the Visual Analogue Uroflowmetry Score to report their symptoms and received usual care by Primary Care Physicians not trained in shared decision making
9688847|NCT04851730|Experimental|Orthopedic Intervention|All subjects are receiving an orthopedic intervention that is specific to their presentation but made up of all intervention categories: Manual therapy, dry needling, deep breathing, stretching, strengthening, and progressive overload.
9688848|NCT04851093|Experimental|TCM granule plus conventional drug|The experimental group will receive three types of TCM granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
9688849|NCT04851093|Placebo Comparator|TCM placebo granule plus conventional drug|The control group will receive three types of TCM placebo granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
9688850|NCT04851223||Pre Diabetics|
9688851|NCT04851067|Active Comparator|Dry Needling and Therapeutic Exercises (DNTEx)|"Dry Needling - A fine needle, of 5-10 mm, will be used to penetrate the skin, subcutaneous tissues, and muscle with the intent to stimulate Myofascial Trigger Point (MTrP) or mechanically disrupt tissue without the use of an anesthetic.~Therapeutic Exercises - Are exercises will be performed to achieve a specific physical benefit, including increasing and maintaining range of motion, strengthening weak muscles, increasing joint flexibility, or improving cardiovascular and respiratory function."
9688852|NCT04851067|Active Comparator|Manual Therapy and Therapeutic Exercises (MTTEx)|"Joint Mobilization - A manual therapy technique comprising of a continuum of skilled passive movements to the joint complex will be applied at varying speeds and amplitudes. It will include a low-grades/velocity (grades I and II), high grades (grades III and IV), and small- or large-amplitude passive movement techniques within the patient's physiological range of motion and within the patient's control with the intent to restore optimal motion, function, and/ or to reduce pain.~Joint Manipulation - A passive, high velocity, low amplitude thrust will be applied to a localized joint segment/s within its anatomical limit with the intent to restore optimal motion, function, and/ or to reduce pain."
9688853|NCT04851028|Experimental|One2One|1) Weekly individual (one2one) Music Therapy intervention lasting 5 months (n=20 sessions)
9688854|NCT04851028|Experimental|Small-group|2) Weekly small group (max 8 people per group) Music Therapy intervention lasting 5 months (n=20 sessions)
10180265|NCT03794778|Active Comparator|chemotherapy|paclitaxel 175 mg/m2, i.v.,d1; carboplatin AUC 5, i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
10180266|NCT03794739||Healthy subjects|"Healthy subjects without diabetes, no recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
10180267|NCT03794739||T1D individuals|"Type 1 diabetic individuals with at least 3-year of duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
10180268|NCT03794739||T2D individuals|"Type 2 diabetic individuals with at least 5-year duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
9688855|NCT04851028|No Intervention|Control|Standard weekly music social listening in large group available in all care-homes. Lasting 5 months (n=20 sessions)
9688856|NCT04851171|Active Comparator|Semi-rigid Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo semi-rigid ureteroscopy for treatment of the stone.
9688857|NCT04851171|Active Comparator|Flexible Ureteroscopy|Patient with upper ureteric stone who are randomized in this arm will undergo flexible ureteroscopy for treatment of the stone.
9688858|NCT04851184|Active Comparator|Usual Vestibular Rehabilitation Care|Participants in this arm will perform typical PT in the clinic and home environment. They will be asked to keep a log to track their HEP.
9688859|NCT04851184|Experimental|Home Exercises Using Virtual Reality Device|Participants in this arm will perform typical PT in the clinic, but will use the virtual reality device as part of their HEP.
9688860|NCT04851184|No Intervention|Healthy Control|Age-matched healthy control subjects will perform all balance, gait, vestibular, and patient reported outcome measure assessments, including performing 30 seconds of each level of gaze stability exercise for an active comparison to outcomes obtained to those with vestibular disorders.
9688861|NCT04851015|Experimental|Reduced dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 10mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as a dose of 10mg/kg/day open label with additional placebo tablets or intravenous placebo solution given to simulate 15mg/kg/day. All doses will be adjusted for obesity and renal function.
9688862|NCT04851015|Active Comparator|Standard dose TMP-SMX|Trimethoprim-Sulfamethoxazole at a total dose of 15mg/kg/day. Oral or intravenous drug will be administered at discretion of treating team. This will be given as 10mg/kg/day open label plus an extra masked 5mg/kg/day of tablets or intravenous solution. All doses will be adjusted for obesity and renal function.
9688863|NCT04851158|Experimental|ShotBlocker|ShotBlocker will be used on 35 patients. For the patient group that is applied ShotBlocker, after cleansing the skin, the protruding surface of the device is placed facing the skin surface. The injection is applied with the appropriate technique, then ShotBlocker is removed and a light pressure is applied to the area with a cotton pad for 15-20 seconds.
9688864|NCT04851158|Experimental|Local Vibration|Local Vibration will be used on 35 patients. For the patient group that was subject to local vibration, local vibration was applied to the region with a vibrator for five minutes prior to injection, following a previous study on this subject. After that, 70% alcohol was used to cleanse the skin. The injection was applied with the appropriate technique, then a light pressure was applied to the area with a cotton pad for 15-20 seconds.
9688865|NCT04851158|No Intervention|Control|For the control group (n=35), IM injection into the ventrogluteal region without using any tools is performed with the appropriate technique.
9688866|NCT04851054||Patients after surgery for colon cancer with intention to cure|Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, who will undergo elective surgical resection with potentially curative intention
9688867|NCT04850924||children impact by the Alex storm|
9688868|NCT04851262|Experimental|Intervention|The intervention is a 12-week home-based resistance training programme with phased progression. The intervention will have three phases: (i) an initial phase focused on training the target muscle(s)/movements with minimal or no external weight; (ii) an intermediate phase targeting muscle strength with increased practice resistance; and (iii) an advanced phase targeting the further enhancement of muscle strength by challenging multiple muscle groups. Each phase will involve exercises targeting the trunk, back, hip, upper-limb and lower-limb muscles.
9688869|NCT04851262|Other|Waitlist control|The waitlist control participants will start the intervention 12 weeks after the baseline assessment.
9688870|NCT04851041|Experimental|Potato group|The participants in this group consume every day 150g of boiled potatoes for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well
9688871|NCT04851041|Active Comparator|Pasta/rice|"The participants in this group consume every day either rice or pasta for 12 weeks, preferably during dinner. The participants are allowed to eat this portion during lunch as well.~The portion of rice and pasta must be as isocaloric as 150g of boiled potatoes."
9688872|NCT04851002|Experimental|CGF TEST GROUP|Concentrated growth factor liquid applied into the implant cavity. Also CGF membrane covered the implant and the socket. That is the only difference between CGF control group and CGF test group
9688873|NCT04851002|Experimental|A-PRF TEST GROUP|Advanced Platelet Rich Fibrin liquid applied into the implant cavity. Also A-PRF membrane covered the implant and the socket. That is the only difference between A-PRF control group and A-PRF test group
9688874|NCT04851002|Experimental|CGF CONTROL GROUP|Dental implant applications were made with traditional methods.
9688875|NCT04851002|Experimental|A-PRF CONTROL GROUP|Dental implant applications were made with traditional methods.
9688876|NCT04851197|Experimental|control group|"The students in the control group will be filled with the Introductory and Self-Testicular Examination Characteristics Question Form, Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale, which will be prepared with Microsoft teams forms before the training. Later, the students will be given an average of 20-30 minutes of training from Powerpoint presentation and video presentation. Students' questions will be answered in the last 10 minutes. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and KKTM Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled out."
9696133|NCT04770350|Experimental|Experimental|Participants will undergo ten to thirty minutes of transcranial ultrasound treatment. The sanitation device will be aimed at the hypothalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
9696134|NCT04770363|Experimental|Bihemispheric Stimulation Group|The first group tDCS bihemispheric stimulation consisted of 20 minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex M1 (C3 and C4 of the international 10 -20 EEG electrode system).
9688877|NCT04851197|Experimental|Intervention|"Before the training, the students in the intervention group will fill the Introductory and Characteristics Question Form on Testicular Cancer and Self Testicular Examination Knowledge Test and Champion's Health Belief Model Scale. Educational materials (lecture presentation, video) will be loaded on the system in accordance with the inverted learning model, and students will be asked to come prepared for the planned lesson. Classical presentations will not be made to the students, and the education will be given in the form of question and answer discussion. After two weeks after the training, the students will be asked to fill in the Testicular Cancer and Self Testicular Examination Knowledge Test and a Visual Analogue Scale that includes their satisfaction with the training method. After 6 weeks, Champion's Health Belief Model Scale will be filled."
10180269|NCT03794739||AutoAb+ individuals|"Individuals at risk for type 1 diabetes, with one or more autoantibody detected. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
9688878|NCT04851366|Experimental|PROCARE+ (with add-on modules)|In addition to core UP-A preventive intervention, PROCARE will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include, but not limited to social, parental, stress-related (including CoVid19 impact) risk factors, and health. Dosage (number of modules) will be included as covariate in all subsequent analyses.
9688879|NCT04851366|Experimental|PROCARE (UP-A for selective purposes)|To ensure cost-effectiveness, PROCARE core intervention will be designed as a brief 8-session child-focused programme which aims to build resilience for adolescents by adapting the core modules from UP-A, along with one individual session with adolescent and parents. Sessions will be delivered in reduced groups, using a typical selective preventive intervention format focused on cost-effectiveness.
9688880|NCT04851366|Active Comparator|Active control condition.|"The active control condition will be based on the U talk programme developed by Prf. Jill Ehrenreich-May at University of Miami and colleagues. It follows a similar structure as the UP-A original programme and allows for two alternative compare conditions to PROCARE. The U Talk programme support-based group condition will be used as active control condition."
9688881|NCT04851249||Adult participants operated for Hallux Valgus deformity|All adult participants accepted for hallux valgus corrective surgery at østfold hospital trust (ØHT) is asked to participate in the study. The goal is to include 200-250 participants.
9688882|NCT04851288|Experimental|MitoQ, 20 mg/day|Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
9688883|NCT04851288|Placebo Comparator|Placebo|Matched placebo capsules.
9688884|NCT04851080||Schoolchildren|Schoolchildren of Vladikavkaz secondary schools aged 13-16 years
9688885|NCT04851080||Students|Students of North-Ossetian State Medical Academy at the age of 19-22 years
9688886|NCT04851080||Volunteers|Scientists of the North Caucasian Research Institute of Mountain and Foothill Agriculture at the age of 30-56 years
9688887|NCT04850911|Experimental|Ketamine|Participants in this arm will receive a single intravenous, antidepressant dose of ketamine hydrochloride (0.5mg/kg)
10180270|NCT03794830|Experimental|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
10180271|NCT03794830|Active Comparator|electrotherapy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions of electrotherapy).
10180272|NCT03794622||Bone marrow concentration group|Consecutive patients receive intramedullary nail fixation with bone marrow concentration.
10180273|NCT03794622||Historical control group|Previous age- and gender-matched patients who receive intramedullary nail fixation only.
9528133|NCT03213613|Placebo Comparator|Low-dose Adaptive Attention Training|The low-dose training group will engage in 1 hour of at-home training on 'Engage'. Individuals will complete two 30-minute sessions at the beginning and middle of a six-week period. Compliance will be monitored similarly to the adaptive attention training group.
9688888|NCT04850911|Placebo Comparator|Placebo|Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride).
9688889|NCT04851405|Active Comparator|Otago Exercise Programme+ Intervention Group (OEP+)|"Physiotherapists receive OEP training, a 2 hour workshop on the coaching protocol using the OEP app, and online training on the Brief Action Plan Approach.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up OEP app and Fitbit. PT will return bi-weekly over the course of two months (four visits total) for follow-up. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit. Between Months 7-12, PTs will continue to a phone call follow-up once a month to review the exercise routine.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also have access to the OEP app which allows the PT to prescribe exercises and record the participant's exercise goal."
9688890|NCT04851405|Placebo Comparator|Otago Exercise Programme Group (OEP)|"Physiotherapists receive OEP Training and a 2 hour workshop on just the coaching protocol.~Each PT will deliver exercise program to 8 older adults. PTs will help older adults to set-up the Fitbit. For the first two months, PTs will provide bi-weekly home visits. During months 3-5, PTs will call participants three times times to review the exercise plan. The last visit will be an at-home visit which will occur 6 months after the initial visit.~Older Adults will receive an OEP manual and cuff weights to be used with the strength training. They will also receive a Fitbit. Between Months 7-12, older adults will receive follow-up phone calls from the research staff."
9688891|NCT04851132|Experimental|Exprimental Arm|IMRT plus Durvalumab
9688892|NCT04850885|Experimental|Dexamethasone Group ( Group DXN)|Group DXN has received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml)
9688893|NCT04850885|Active Comparator|Adreanaline Group ( Group ADN)|Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline)
9826789|NCT02432235|Experimental|80 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles.
9688894|NCT04850872|Experimental|Experimental|PLAYwithHEART Programme is a manualized mindfulness, acceptance, and compassionate-based group intervention for adolescent competitive athletes. It included 8 weekly group sessions, 45 minutes each, run in small groups (ranging from 8 to 12 participants). Participants of this group complete also self-report measures.
9688895|NCT04850872|No Intervention|Control|Participants of control group do not receive the intervention Programme (PLAYwithHEART), nor any other program, and only complete self-report measures.
9688896|NCT04851106||Patient with a solid pancreatic lesion of an undetermined nature|Patient with a solid pancreatic lesion of an undetermined nature
9688897|NCT04850976|Experimental|Self-Assembled Modified Macintosh Videolaryngoscope (SAM-VL) group|The self-assembled modified Macintosh videolaryngoscope (SAM-VL) used in this study was constructed from a portable video camera with Wi-fi connection (Wi-fi Endoscope Video Camera model YPC99) attached to a no. 4 Macintosh Laryngoscope blade (Riester® no.7040). The video signal is transmitted to an Android-based mobile phone (Android version 7.0). The portable 2 megapixels video camera is 8 mm in diameter with 8 Light Emitting Diode (LED) lights for adjustable lighting level and 3 meters cable length. Video resolution output is 640x480 pixels (VGA) and 1280x720 pixels (HD). The camera has 70º visual angle with focus length of 4- 6cm and is water-resistant. The camera was taped to the Macintosh blade at a distance of 5 cm from the distal end of the blade, using transparent waterproof Leukofix® tape.
9688898|NCT04850976|Active Comparator|McGrath MAC® videolaryngoscope (McGrath) group|The McGrath MAC® videolaryngoscope used in this study was equipped with disposable blade no.4
9688899|NCT04850950|Experimental|Arm 1|Tenofovir alafenamide fumarate discontinued at delivery date.
9688900|NCT04850950|Experimental|Arm 2|Tenofovir alafenamide fumarate discontinued at postpartum month 1.
9688901|NCT04851353|Active Comparator|GT+VC|Gentle touch +Verbal comfort
9688902|NCT04851353|Experimental|GT+VC+Smell|Gentle touch +Verbal comfort+ Smell breast milk
9688903|NCT04851353|Experimental|GT+VC+Smell+Taste|Gentle touch +Verbal comfort+ Smell breast milk+ Taste milk
9688904|NCT04850859||group of scapulae bones|Human adult dry scapulae bones 40 of unknown sex and age will be collected.
9688905|NCT04850859||group of hip bones|Human adult dry hip bones 40 of unknown gender and age will be collected
9688906|NCT04850937|Experimental|Group S|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction During administration, blood pressure and heart rate were observed.
9688907|NCT04850937|Placebo Comparator|Group C|The control group will receive the same amount of normal saline after anesthesia induction
9688908|NCT04850742|Experimental|Cryopreserved aorta|After resection of a segment of tracheal or bronchial lesion, reconstruct the airway with cryopreserved aortic allograft.
9688909|NCT04850638|Experimental|SHR4640 tablets|
9688910|NCT04850755|Experimental|patients with advanced solid malignancies|Patients will be dosed with selinexor once a week continuously in a 6 week cycle. Nivolumab will be administered on biweekly of each cycle . Ipilimumab will be dosed only on D1 of each cycle . Ipilimumab will continue for a maximum of 4 cycles. Nivolumab and selinexor will continue for up to 24 months or until discontinuation criteria is met.
9688911|NCT04850586|Experimental|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
9688912|NCT04850586|No Intervention|Control Group|Routine education was given to the patients in the control group. Routine education was administered by a nurse working in the clinic after the patients were admitted to the hospital. The patients in this group were not trained by a multidisciplinary team. In the routine training, patients were only informed about preoperative preparation.
9688913|NCT04850482|Experimental|Intervention Arm|Participants get immediate access to the intervention on completion of baseline assessment.
9688914|NCT04850482|No Intervention|Wait list control Arm|Participants get access to the intervention in 10 weeks after completion of the baseline and follow up assessment.
9688915|NCT04850625||Pyrotinib Plus Vinorelbine|lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2)
9688916|NCT04850625||Lapatinib Plus Capecitabine|pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days)
9688917|NCT04850378|No Intervention|Coagulation profile in Nephrotic syndrome|Investigation of the biochemical coagulation profile in patients with nephrotic syndrome.
9688918|NCT04850378|Experimental|Nephrotic syndrome|Nephrotic patients without diabetes.
9688919|NCT04850378|Experimental|Membranous nephropathy and nephrotic syndrome|Membranous nephropathy and nephrotic syndrome.
9688920|NCT04850378|Active Comparator|Atrial fibrillation|Atrial fibrillation with no kidney disease.
9688921|NCT04850612||Healthcare professionals and researchers (HCPR)|All researchers and healthcare professionals involved in the management of patients with CSDH
9688922|NCT04850612||Patients and carers|Patients who have previously had a diagnosis of CSDH, and their carers
9688923|NCT04850560|Experimental|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|
9688924|NCT04850430|Experimental|Gastric venous congestion following total pancreatectomy|The gastric venous outflow will be reconstructed after TP. The patients will be assessed concerning gastric venous congestion and gastric ischemia intraoperatively before and after venous outflow reconstruction through onsite evaluation by the surgeon, endoscopic examination, indocyanine green, gastric venous drainage flowmetry, and spectral imaging.
9688925|NCT04850690||Children with hemiparetic Cerebral palsy|15 children with CP, between 9-15 years old
9688926|NCT04850677||Total|All subjects in the study belong to the same group/cohort. As this is an observational study there is no intervention planned.
10180274|NCT03794648|Experimental|Intervention Group|
9688927|NCT04850664|Experimental|CBOT + TAU|CBOT consists of 40 cycles of olfactory stimulation and OFC training tasks, lasting ~45 minutes, once daily over 3 months. Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
9528134|NCT03213717|Experimental|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
9688928|NCT04850664|Sham Comparator|Sham + TAU|Sham is a CBOT device that uses artificially-scented compressed room air instead of olfactory stimulants and has no OFC cognitive tasks. Similar to the CBOT, sham will be used daily for 45 minutes. TAU is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
9688929|NCT04850768||Periodontitis|Individuals with Periodontitis
9688930|NCT04850768||Gingivitis|Individuals with Gingival Inflammation
9688931|NCT04850768||Healthy|Individuals with Periodontally Healthy
9688932|NCT04850391|Active Comparator|Lean-overweight|BMI 18.5 - 30 kg/m2
9688933|NCT04850391|Active Comparator|Obese|BMI > 30 kg/m2
9688934|NCT04850391|Active Comparator|Obese OSA|OSAS patients with BMI > 30 kg/m2
9688935|NCT04850404|Experimental|the group of abdominal nerve block combined with moderate NMB|The patients of group N-M received the rectus abdominis block combined with transverse plane block.
9688936|NCT04850404|No Intervention|moderate NMB group|The patients of group M received moderate NMB through the surgery.
9688937|NCT04850417|Experimental|Beta-blockers and Short Antiplatelet Therapy|"Beta-blockers (experimental) and Short Antiplatelet Therapy (experimental). Aspirin alone recommended for Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
9688938|NCT04850417|Experimental|Beta-blockers and Long Antiplatelet Therapy|"Beta-blockers (experimental) and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
9688939|NCT04850417|Experimental|No Beta-blockers and Short Antiplatelet Therapy|"No Beta-blockers and Short Antiplatelet Therapy (experimental). Aspirin alone recommended in Short Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
9688940|NCT04850417|Active Comparator|No Beta-blockers and Long Antiplatelet Therapy|"No Beta-blockers and Long Antiplatelet Therapy. Aspirin and Clopidogrel recommended in Long Antiplatelet Therapy~(The main comparison of this randomized clinical trial (2x2, factorial design) is beta-blockers vs no beta-blockers and short vs long-term antiplatelet therapy)"
9696135|NCT04770363|Experimental|Unihemispheric Stimulation Group|The second group unilateral stimulation, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone.
9696136|NCT04770363|Sham Comparator|Sham Group|The third sham group, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone, but delivering no current.
9696137|NCT04770142|Experimental|TIRA|treated with transcatheter RF ablation system (TIRA catheter with its supplemental devices)
9696138|NCT04770298|Experimental|Halliwick Assessment Group|8 children with GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM (GMFCS) I, 13 children with GMFCS II, 7 GMFCS III children, 8 GMFCS IV children and 4 children with GMFCS V. Intervention in water environment (Halliwick Concept), 1 times/week- 1 intervention on land/week, 9 months duration.
9696139|NCT04770298|Experimental|Bobath Assessment Group|7 children with GMFCS I, 12 children with GMFCS II, 8 children with GMFCS III, 6 children with GMFCS IV and 2 children with GMFCS V. Intervention on land ( Bobath), 2 times/week, 9 months duration.
9696140|NCT04770298|No Intervention|No intervention group|1 children with GMFCS I, 1 child with GMFCS III, 1 child with GMFCS IV and 2 GMFCS V children. No intervention.
9696141|NCT04770389|Placebo Comparator|Placebo|placebo obicetrapib + placebo ezetimibe; once daily
9696142|NCT04770389|Experimental|Combination therapy|5 mg obicetrapib + 10 mg ezetimibe; once daily
9696143|NCT04770389|Experimental|Obicetrapib monotherapy|5 mg obicetrapib + placebo ezetimibe; once daily
9696144|NCT04770389|Experimental|Ezetimibe monotherapy|placebo obicetrapib + 10 mg ezetimibe; once daily
9696145|NCT04770168|Experimental|CBT Curriculum - First Cohort|Students will receive the 3-month cognitive behavioral therapy curriculum in the first half of the academic year.
9696146|NCT04770168|Experimental|CBT Curriculum - Second Cohort (Waitlist Controls)|Students will receive the current school board curriculum as usual for the first half of the academic year, serving as wait-list controls. Since this is a stepped wedge trial, the winter cohort will receive the identical intervention as the fall cohort in the second half of academic year.
9696147|NCT04770376||Cohort A: patients treated with chemotherapy (I-II line) associated to bevacizumab|Quantification of biomarkers will be performed on 100 patients treated with bevacizumab through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
9696148|NCT04770376||Cohort B: patients treated with chemotherapy (I-II line, not associated to antiangiogenic drugs)|Quantification of biomarkers will be performed on 50 patients treated with chemotherapy through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
9826790|NCT02432235|Experimental|100 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles.
10180275|NCT03794648|No Intervention|Control Group|
10180276|NCT03794635|Experimental|Patients|Latino/a advanced cancer patients
10180277|NCT03794635|Experimental|Caregivers|Caregivers of Latino/a advanced cancer patients
10180278|NCT03794570|Sham Comparator|Control|Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
9688941|NCT04850703|Experimental|Premature Ejaculation participants who receive Brain Weak Currents in IFG brain cortex|"Participants receive tRNS (weak currents < 2 mA) sessions at IFG brain cortex for 25 minutes 2 times a day 3 times per week during 3 weeks.~After 4 hours they end the last session, a new brain mapping is performed."
9688942|NCT04850703|Active Comparator|Premature Ejaculation participants who take Dapoxetine|Participants take 1 tablet of the drug between 1 and 3 hours before the brain mapping
9688943|NCT04850703|Sham Comparator|Placebo Group|Participants who do not take medication or receive tRNS sessions
9688944|NCT04850703|Other|Controls|44 Healthy humans not clinically not diagnosed with LPD and withouth expression the LPE endophenotype. In this way, the investigators what would be the patients diagnosed clinically with LPE who present the endophenotype or neurophysiological biomarker of LPE.
9688945|NCT04850534||EGD+NSBB|Patients receiving both endoscopic therapy and non-selective beta-blockers for treating high-risk esophagogastric varices
9688946|NCT04850534||EGD|Patients receiving mono endoscopic therapy for treating high-risk esophagogastric varices
9688947|NCT04850352|Experimental|Heukcha Extracts|Take Heukcha Extracts capsule once daily for 8 weeks.
9688948|NCT04850352|Placebo Comparator|Placebo|Take placebo capsule once daily for 8 weeks.
9688949|NCT04850209|Other|Control group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg , amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education
9688950|NCT04850209|Experimental|Wechat group|Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg ,amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education. And patients will be invited into a Wechat group to obtain interactive education through question and answer,which is provided by medical professionals.
9688951|NCT04850235|Experimental|TPX neoadjuvant chemotherapy +CCRT|Patients receive neoadjuvant chemotherapy with Nab-PTX (150/175/200/225/250 mg/m2, D1) , cisplatin (75 mg/m2, D1) and capecitabine (1000 mg/m2, BID, D1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100 mg/m2) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT)
9688952|NCT04850261|Active Comparator|Intervention A: hCG injection|Ovulation induction by subcutaneous injection of 5.000 IU hCG
9688953|NCT04850261|Experimental|Intervention B: nasal application of Nafarelin|Ovulation induction by nasal application of 200 microgram Nafarelin
9688954|NCT04850287|Placebo Comparator|Control|
9688955|NCT04850287|Experimental|Intervention|
9688956|NCT04850287|Experimental|Optimal|
9688957|NCT04850053||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
9688958|NCT04850053||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
9688959|NCT04850053||Cognitively normal controls|Individuals with normal cognitive function
9688960|NCT04850326|Experimental|AP green tea extract|
9688961|NCT04850326|No Intervention|No intervention control|
9688962|NCT04850014||Poisoned patients|All subjects with paracetamolemia in the context of paracetamol poisoning
9688963|NCT04850014||Control group|Acetaminophen-poisoned patient being non-obese
9688964|NCT04850027||Lower rectal cancer patients with a LLN ≥ 5mm|Patients with lateral lymph node short diameter ≥ 5mm evaluated by MRI were included.
9688965|NCT04850040|Experimental|Camrelizumab+Apatinib Mesylate+Oxaliplatin|An study of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.
9688966|NCT04850131|Active Comparator|Desarda|Forty-one patients who were randomly assigned to the Desarda group underwent the Desarda repair for their problem. Patients were followed for various data point values during operation, immediately after the operation, and for a period of one year post-operatively.
9688967|NCT04850131|Active Comparator|Lichtenstein|Forty-one patients randomly assigned to the Lichtenstein group underwent the standard mesh repair and were followed for the same data point values and variables for the same specified period of time.
9688968|NCT04850183|Experimental|Intervention group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the intervention group at baseline. The patients were assigned to the intervention group at random and participated in a one-to-one training program consisting of a 30-min onset session. The Rheumatoid Arthritis Patient Education Booklet prepared by the researchers was administered to patients in the intervention group during education. In the 3rd month, all forms were applied again to the patients in the intervention group.
9688969|NCT04850183|No Intervention|Control group|Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the control group at baseline. In the 3rd month, the same forms were applied to the untrained patients in the control group.
10180279|NCT03794570|Experimental|Blood Flow Restriction (BFR) Therapy|Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
10180280|NCT03794518|Experimental|Pioglitazone Plus dapaglifliozin|Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
10180281|NCT03794518|Placebo Comparator|Placebo|Beta blockers, ACEI, ARB, and aldosterone
10180282|NCT03794557|Experimental|PUL-042|PUL-042 Inhalation Solution
10180283|NCT03794557|Placebo Comparator|Placebo|Sterile Water for injection
10180284|NCT03794479||Travellers|Adults planning for travel
10180285|NCT03794492|Experimental|Mycophenolate mofetil|One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
10180286|NCT03794596|Experimental|(Arm A) Avelumab + PPI|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
10180287|NCT03794596|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
10180288|NCT03794219|Experimental|Kinesio tape plus NSAID|Kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions in addition to 750 mg/day oral naproxen.
10180289|NCT03794219|Active Comparator|NSAID|750 mg/day oral naproxen is administered for 10 days.
9688970|NCT04849949|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
9688971|NCT04849949|Experimental|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
9688972|NCT04849949|Experimental|English Walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
9976231|NCT01349400|Experimental|watchful waiting|"After informed consent and randomization into the watchful waiting group patients will receive standardized verbal information and written instructions on symptoms of acute incarceration. In case of acute symptoms they will be told to visit a physician immediately. On follow-up visits at 1 month, 12 months and 24 months the hernia size will be determined by physical examination, and the pain/ discomfort and the functional status will be monitored.~Control intervention/ reference test:~Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented."
10180290|NCT03794375|Active Comparator|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
9688975|NCT04850118|Active Comparator|Group 1: Low Dose|Male subjects 8-50 years of age treated by subretinal injection with the low dose of AGTC-501
9688976|NCT04850118|Active Comparator|Group 2: High Dose|Male subjects 8-50 years of age treated by subretinal injection with the high dose of AGTC-501
9688977|NCT04850118|Other|Group 3: Control|Male subjects 8-50 years of age in the untreated control group. Subjects randomized to the untreated control group will be followed for a minimum of 12 months. After this time, they will be treated by subretinal injection with the high dose of AGTC-501.
9688978|NCT04850313|No Intervention|Conventional Treatment|"Corneal ulcer scraping sent for microbial culture~Admission to the hospital for initiation of fortified vancomycin 25mg/mL every 1 hour alternating with fortified tobramycin 15mg/mL every 1 hour, preservative free artificial tears every 2 hours, and doxycycline 100mg twice daily.~After 48 hours of conventional treatment, consent will be obtained regarding the use of experimental treatment with ProKera Plus® versus continuing conventional method of treatment"
9688979|NCT04850313|Experimental|ProKera Plus® Treatment|1. Experimental Treatment Arm , ProKera Plus® will be placed in the eye with the corneal ulcer
9688980|NCT04850001||Patient Group|Asymptomatic intracranial stenosis patients who receive standard medical treatment without stenting
9688981|NCT04850001||Healthy Control|Healthy control are free from intracranial stenosis
9688982|NCT04849923|No Intervention|controll group|This group has no additional strength training
9688983|NCT04849923|Experimental|1 training per week|This group performs one strength training session per week
9688984|NCT04849923|Experimental|3 trainings per week|This group performs two strength training sessions per week
9688985|NCT04849936||evaluation of fecal biomarkers|comparison of the biomarker levels between different gastrointestinal diseases
9688986|NCT04849845|Experimental|Afrezza|The test product is defined as Afrezza [insulin human] inhalation powder administered using the Afrezza inhaler. In addition, subjects will take their personal basal insulin while enrolled in the study.
9688987|NCT04849780|Experimental|ARM 1|Eligible subjects will be randomized to the TEST lens to wear in both eyes for approximately 2 weeks.
9688988|NCT04849780|Experimental|ARM 2|Eligible subjects will be randomized to the CONTROL lens to wear in both eyes for approximately 2 weeks. Then the subject will receive the TEST lens to wear in both eyes for approximately 2 weeks.
9688989|NCT04850339|Active Comparator|ANXV single dose|ANXV in a single ascending dose pattern in four dose levels.
9688990|NCT04850339|Placebo Comparator|Placebo single dose|Placebo in a single ascending dose pattern in four dose levels.
9688991|NCT04850339|Active Comparator|ANXV multiple dose|ANXV in a multiple ascending dose pattern in three dose levels.
9688992|NCT04850339|Placebo Comparator|Placebo multiple dose|Placebo in a multiple ascending dose pattern in four dose levels.
9688993|NCT04849858|Active Comparator|Bupivacaine TAP Block|The first 15 patients enrolled will receive perioperative plain bupivacaine TAP blocks.
9688994|NCT04849858|Active Comparator|Liposomal Bupivacaine TAP Block|After enrolling all 15 participants in the first arm, the next 15 patients enrolled will receive perioperative single-dose Liposomal Bupivacaine TAP blocks.
9688995|NCT04849858|Active Comparator|Liposomal Bupivacaine TAP Block with Re-dosing|After enrolling all 30 patients in the first two arms, the final 15 patients enrolled will receive perioperative Liposomal Bupivacaine TAP blocks followed by redosing of the TAP blocks in 48-60 hours.
9688996|NCT04850066|Experimental|Equine-assisted intervention|Brief program (3 sessions)
9688997|NCT04850066|No Intervention|Control|Standard care with treatments as usual
9688998|NCT04849962|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
9688999|NCT04849962|Experimental|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
9689000|NCT04850157|Experimental|Tislelizumab+IMRT|
9689001|NCT04849819||never receive systemic medications|
9689002|NCT04849819||ever user of systemic medications|
9826791|NCT02432235|Experimental|150 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
9826792|NCT02432235|Experimental|300 μg/kg|A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles).
9689003|NCT04849819||current user of systemic medications|
10180291|NCT03794375|Experimental|Telehealth|"The patients will be discharged from the HCPA thyroid disease outpatient clinic, being instructed to seek the primary care level according to their place of residence to schedule a routine consultation in up to six months.~After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed."
9976232|NCT01349400|Active Comparator|Hernia repair|Intervention: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented.
9976233|NCT01349413|Placebo Comparator|Placebo|Identical looking placebo (once daily)
9689006|NCT04849897|Active Comparator|Active Comparator: Audio Only Guided Imagery Audio Recordings of Guided Imagery via tablet|Listen to narrative scripts based on traditional GI audio recordings. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the GI experience.
9689007|NCT04849897|Experimental|Experimental: Virtual Reality Guided Imagery Platform and VR Headset|VR headset for guided imagery with audiovisual computer-generated VR content to accompany the GI narration. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the VR-GI experience.
9689008|NCT04849559|Experimental|Tradipitant|Oral Capsule
9689009|NCT04849559|Placebo Comparator|Placebo|Oral Capsule
9689010|NCT04849494||Late preterm AGA infants/Group 1|According to the new BALLARD scoring system gestational age was 34-36 6/7 and those who were at the 10-90th percentile according to the Fenton growth curves
9689011|NCT04849494||Newborns with Intrauterine growth restriction/Group 2|Term or preterm infants below 10th percentile according to the values calculated according to Fenton growth curves
9689012|NCT04849494||Control/Group 3|the healthy term (gestation week 38-42 weeks), AGA newborns, who born between January 2006 and December 2008
9689013|NCT04849533|Experimental|Group D Bela/EVR|rATG induction/belatacept/everolimus/early steroid withdrawal rATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) Everolimus started within 24hours at 2mg BID and dosed to level 3-8ng/ml
9689014|NCT04849533|Active Comparator|Group E Bela/MMF|rATG induction/belatacept/mycophenolate/chronic steroidsrATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) and then 5mg po daily thereafter MMF 1gm BID started pre-op and then continued throughout study
10180292|NCT03794245|Experimental|Men-Centered HIV Testing|Mobile HIV testing is conducted at sites in the community where men gather.
10180293|NCT03794245|Active Comparator|Clinic-based HIV Testing|Men are referred to the nearest clinic for HIV counseling and testing
9689015|NCT04849572|Active Comparator|Sleep Education|Also referred to as Arm 1. Arm 1 receives sleep education initially.
9689016|NCT04849572|Active Comparator|Delayed Sleep Education|Also referred to Arm 2. Arm 2 receives no initial sleep education.
9689017|NCT04849702||Postoperative complication after colorectal resection|Documentation of all postoperative complications after colorectal resections
9689018|NCT04849377|Experimental|Group I - 50 Gy/200 mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1,T2 N0 RT 5 days per week for 6 weeks and Cisplatin weekly for 5 weeks
9689019|NCT04849377|Experimental|Group II - 54 Gy/200mg/m2|Patient Characteristics: <20 Pack-Years, HPV16, OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
9689020|NCT04849377|Experimental|Group III - 60 Gy/240 mg/m2|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T1-T2, N1-N2b, T3 N0-N2b RT 5 days per week for 6 weeks and Cisplatin weekly for 6 weeks
9689021|NCT04849377|Experimental|Group IV - TPF Induction followed by 60 Gy and Carboplatin AUC 1.5|Patient Characteristics: 20-40 Pack-Years, Non-HPV16, Non-OP, T4, N2c, >3 nodes, ENE, or Matted Nodes Induction Therapy: Cisplatin, Docetaxel, Fluorouracil followed by RT 60 GY + Carboplatin AUC 9.0 Docetaxel every 21 days for 3 cycles, Cisplatin every 21 days for 3 cycles, Fluorouracil continuous infusion over 4 days (every 21 days for 3 cycles). Followed by RT 5 days per week for 6 weeks and Carboplatin weekly for 6 weeks.
9689022|NCT04849624||ICU COVID-19 patients|COVID-19 patients that are admitted into the ICU and fulfilled the eligibility criteria
9689023|NCT04849624||ICU non-COVID-19 patients|Non-COVID-19 patients that are admitted into the ICU matched with ICU COVID-19 patients that are recruited and fulfilled the eligibility criteria
9689024|NCT04849767||Transgender people living with HIV|Transgender person Living with HIV Followed in clinical service
9689025|NCT04849429|Placebo Comparator|Placebo|Placebo (trigger point injection under C-arm)
9689026|NCT04849429|Experimental|Platelet rich plasma (PRP) with exosomes|PRP with exosomes at the center of the nucleus pulposus (2ml)
9689027|NCT04849286|Experimental|Group 1|10 mg dose, CSF sample 2 hours post-dose
9689028|NCT04849286|Experimental|Group 2|10 mg dose, CSF sample 6 hours post-dose
10180294|NCT03794245|Experimental|Linkage to Care for HIV+ Men|The patient coordinator arranges an appointment time at the clinic and accompanies the patient to the initial visit
9689029|NCT04849286|Experimental|Group 3|20 mg dose, CSF sample 2 hours post-dose
9976234|NCT01349413|Experimental|Esomeprazole 20mg daily|Esomeprazole 20mg daily Oral for 8 weeks
9976235|NCT01349426|Experimental|LigaSure|"Arm 1~Patients undergoing lung surgery"
9976236|NCT01349426|Active Comparator|Automatic Staplers|"Arm 2~Patients undergoing lung surgery"
10180295|NCT03794245|Active Comparator|Clinic Referral for HIV+ Men|Men diagnosed with HIV are referred to the nearest clinic for treatment of HIV
10180296|NCT03794102|Active Comparator|Ureteroscopy with water irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Water will be used as the irrigation fluid during the ureteroscopy.
9689030|NCT04849286|Experimental|Group 4|20 mg dose, CSF sample 6 hours post-dose
9689031|NCT04849195||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
9689032|NCT04849455|Experimental|Active Treatment|This group will receive a continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 120 minutes with 2ml/hr continuous infusion (14mls total every 2 hours per catheter)
9689033|NCT04849455|Placebo Comparator|Placebo|This group will receive a superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
9689034|NCT04849468|Active Comparator|Diclofenac (D) group|Diclofenac (D) group which will receive 75 mg (3ml) intramuscular Diclofenac in a 5ml syringe in the holding area 30 minutes before spinal block
9689035|NCT04849468|Active Comparator|Saline (S) group|Saline (S) group which will receive 3ml intramuscular saline in a similar 5ml syringe in the holding area 30 minutes before spinal block
9689036|NCT04849754|Other|Patients with transthyretin related cardiac amyloidosis|Bone scintigraphy
9689037|NCT04849390|Experimental|ESO-101|Oral use of 1 hard gelatin capsule (800 μg)
9689038|NCT04849390|Placebo Comparator|Placebo|Oral use of 1 hard gelatin capsule
9689039|NCT04849130|Active Comparator|Static reconstruction technique according to Schöttle|Static reconstruction technique according to Schöttle
9689040|NCT04849130|Active Comparator|Dynamic reconstruction technique according to Becher|Dynamic reconstruction technique according to Becher
9689041|NCT04849351|Experimental|Relapsed/Refractory MZL and FL|Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
10180297|NCT03794102|Active Comparator|Ureteroscopy with saline irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Saline will be used as the irrigation fluid during the ureteroscopy.
10180298|NCT03794063||Robson group 1|Nulliparous women, single cephalic, more than or equal to 37 weeks, in spontaneous labour
9689042|NCT04849182|Active Comparator|Vertistop D|Patients with deficiency (<20 ng/mL, <50 nmol/L) or insufficiency (20-30 ng/mL, 50-75 nmol/L) of Vitamin D
9689043|NCT04849182|Active Comparator|Vertistop L|Patients with normal vitamin D levels (>30 ng/mL, >75 nmol/L)
9689044|NCT04849182|No Intervention|Control group|Patients meeting the inclusion criteria with normal levels of vitamin D (>30 ng/mL, >75 nmol/L)
9689045|NCT04849065|Experimental|MNC (Mononuclear cells)|"MNC (Mononuclear cells) (patients in which stem cells will be injected into the two muscles on one side and placebo -vehicle- in the two contralateral muscles).~This group would consist of 74 patients."
9689046|NCT04849065|Placebo Comparator|Saline|(patients in which placebo -vehicle- will be injected into both muscles on both sides). This group would consist of 26 patients.
9689047|NCT04849013|Placebo Comparator|Placebo + Placebo|
9689048|NCT04849013|Active Comparator|Mescaline-100 + Placebo|
9689049|NCT04849013|Active Comparator|Mescaline-200 + Placebo|
9689050|NCT04849013|Active Comparator|Mescaline-400 + Placebo|
9689051|NCT04849013|Active Comparator|Mescaline-800 + Placebo|
9689052|NCT04849013|Active Comparator|Mescaline-800 + Ketanserin|
9689053|NCT04849026|Experimental|Group A|"Period 1: WID-CLZ18~Period 2: Clozaril 100 mg (Clozapine)"
9689054|NCT04849026|Experimental|Group B|"Period 1: Clozaril 100 mg (Clozapine)~Period 2: WID-CLZ18"
9689055|NCT04849104||COPD high-risk patients|age <60 years old, long-term smoker (≥10 pack years), CT without macroscopic airway abnormalities and/or mild or moderate emphysema, air retention or bronchial thickening, normal lung function
9689056|NCT04849104||Early-stage COPD patients|"those who are younger than 60 years old, long-term smokers (≥10 pack years) and have any of the following abnormalities:~Forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) <lower limit of normal value (LLN, 80%);~CT abnormalities: abnormal airway and/or emphysema, air retention or bronchial wall thickening;~FEV1 drops rapidly (≥60 mL/year);"
9689057|NCT04849104||patients with mild to moderate COPD|Patients with mild to moderate COPD: age <65 years, FEV1/FVC<70%, FEV1 predicted value ≥50%
9689058|NCT04848948|Experimental|F.X.Mayr & Biofeedback|two weeks of F.X. Mayr diet and biofeedback
9689059|NCT04848948|Active Comparator|F.X.Mayr|two weeks of F.X. Mayr diet
9826793|NCT02432274|Experimental|Cohort 1: Single-Agent Dose-Finding|Children and adolescents with relapsed or refractory solid malignant tumors.
9826794|NCT02432274|Experimental|Cohort 2A: Single-agent Expansion (DTC)|Children and adolescents with 131 iodine-refractory DTC.
9826795|NCT02432274|Experimental|Cohort 2B: Single-agent Expansion (Osteosarcoma)|Participants with relapsed or refractory osteosarcoma.
9826796|NCT02432274|Experimental|Cohort 3A: Combination Dose-finding|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
10180299|NCT03794063||Robson Group 2|Nulliparous women, single cephalic, more than or equal to 37 weeks, induced or Caesarean section before labour
10180300|NCT03794063||Robson Group 3|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more than or equal 37 weeks gestation in spontaneous labour
10180301|NCT03794063||Robson Group 4|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more or equal 37 weeks gestation who had labour induced or were delivered by Caesarean section before labour
10180302|NCT03794063||Robson Group 5|All Multiparous women with at least one CS with a single cephalic pregnancy, more or equal to 37 weeks gestation
9689060|NCT04848948|Experimental|VLCD & Biofeedback|two weeks of very low calorie diet and biofeedback
9689061|NCT04848948|Active Comparator|VLCD|two weeks of very low calorie diet
9976237|NCT01349439|Experimental|Propranolol + Memory Reactivation|This arm involves recalling the traumatic event after administration of propranolol
10180303|NCT03794063||Robson Group 6|All nulliparous women with a single breech pregnancy
9689062|NCT04849247|Experimental|177Lu-DOTA-FAPI dose escalation therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. Patients with sufficient lesion uptake of 68Ga DOTA-FAPI PET/CT will be offered therapy. Escalating doses of 30-150 mCi of 177Lu-DOTA-FAPI will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
10180304|NCT03794063||Robson Group 7|Multiparous women with a single breech pregnancy including women with previous Caesarean section
10180305|NCT03794063||Robson Group 8|All women with multiple pregnancies including women with previous Caesarean sections
10180306|NCT03794063||Robson Group 9|All women with a single pregnancy with a transverse or oblique lie, including women with previous Caesarean Section (s)
10180307|NCT03794063||Robson Group 10|All women with a single cephalic pregnancy less than 37 weeks gestation, including women with previous Caesarean section (s)
9689063|NCT04849247|Experimental|Recommended Phase 2 dose 177Lu-DOTA-FAPI therapy study|Patients will be undergo 68Ga-DOTA-FAPI PET/CT scans to confirm eligibility for the 177Lu-DOTA-FAPI therapy. 10 patients will be enrolled in the dose expansion cohort and received the highest dose achieved in the 177Lu-DOTA-FAPI dose escalation therapy study
9689064|NCT04849234||New born|New born population aged 37 Weeks of Amenorrhea (SA) to 42 Weeks of Amenorrhea (SA) will be included. Their cries will be longitudinally registered.
9689065|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (simultaneous)|n=12
9689066|NCT04849299|Experimental|AT-527 550 mg + cyclosporine (staggered)|n=12
9689067|NCT04849091||iReadMore users|"Participants will be iReadMore users who completed a baseline reading test between XX/XX/XXXX and XX/XX/XXXX, and who performed at least 5 hours of reading training and a second (interval) reading test.~iReadMore users will self-register to participate in the study."
9689068|NCT04849039||Mechanicaly ventilated adult patients for non-pulmonary conditions|
9689069|NCT04849403|Other|The group USG was applied|USG was applied to the patients who underwent Laparoscopic sleeve gastrectomy for research trocar site hernia after 2-4 years from the surgery. Carter Thomasson suture passer was used to close fascial defect in all patients.
9689070|NCT04848922|Experimental|Intervention Group|Took a hot shower intervention and usual care.
9689071|NCT04848922|No Intervention|Control Group|No intervention other than usual care.
9689072|NCT04848844||Patient transplanted due to ACHD and heart failure|Patients successfully transplanted due to congenital heart failure.
9689073|NCT04848844||ACHD listed due to heart failure for heart or heart and combined organ transplantation|Patients on the actual waiting list for heart or heart and combined organ transplantation. They can have either outcome transplantation or the primary outcome death on the waiting list or delisting due to clinical worsening. The secondary outcome is as well delisting due to clinical improvement.
9689074|NCT04848844||ACHD evaluated for heart transplantation|All patients evaluated for heart or heart and combined organ transplantation at the hospital level
9689075|NCT04848727||Atelectasis or Pneumothorax|Infants with asymmetric lung disease (i.e. atelectasis or pneumothorax) confirmed by chest radiograph
9689076|NCT04848987|Active Comparator|Etch-and-rinse (Variolink N) resin cement|For etch-and-rinse resin cement, 40 inlays were cemented by Variolink N resin cement.
9689077|NCT04848987|Placebo Comparator|Self-etch (Panavia F2.0) resin cement|Regarding self-etch resin cement, 40 inlays were cemented by Panavia F2.0 resin cement.
9689078|NCT04848987|No Intervention|Self-adhesive (RelyX Unicem) resin cement|For self-adhesive resin cement, 40 inlays were cemented by RelyX Unicem resin cement.
9689079|NCT04848974|Experimental|Treatment (uproleselan, cladribine, cytarabine)|"INDUCTION THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q 12 hours on days 2-12, cladribine IV over 1-2 hours on days 1-5 and cytarabine SC BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR or CRi after cycle 1 may receive a second induction cycle.~CONSOLIDATION/MAINTENANCE THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q12 hours on days 2-1. Patients who have achieved at least CR/CRi or morphologic leukemia-free state after induction therapy receive uproleselan IV QD on days 1-12. Patients also receive cladribine IV over 1-2 hours on days 1-3 and cytarabine SC BID on days 1-10. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
9689080|NCT04848857|Experimental|Treatment Group|colchicine (0.5mg), one pill a day, oral intake
9689081|NCT04848857|Placebo Comparator|Control Group|placebo, one pill a day, oral intake
10180308|NCT03794128||1 - patient-specific neoantigen cancer vaccine production|
9689082|NCT04848701|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
9689083|NCT04848792|Experimental|SFN supplement|The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.
9689084|NCT04848792|Placebo Comparator|Placebo|Placebo capsules provided by Cell-Logic.
9976238|NCT01349439|Experimental|Placebo + Memory reactivation|This arm involves recalling the traumatic event after administration of a placebo
9689086|NCT04849117||Systemic analgesia|Patients received only systemic analgesia : Acetaminophen, Ketoprofen, and Nefopam were administered systematically. Morphine was administered if necessary, according to our institutional pain management protocol.
9689087|NCT04849117||Bilateral TTMP block + systemic analgesia|Patients received the same protocol of systemic analgesia associated with a bilateral TTMP block performed during the first four hours after ICU admission, before tracheal tube removal.
9689088|NCT04848532|Experimental|Adolescent-specific behavioral weight loss treatment|
10180309|NCT03794128||2 - shared neoantigen cancer vaccine screening|
10180310|NCT03794453||Stroke patients|
10187506|NCT03725579|Experimental|mepivacaine hydrochloride|2% Mepivacaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
10180311|NCT03793985|Experimental|A (R+T+R+T)|Period 1 : R Period 2 : T Period 3 : R Period 4 : T
9689089|NCT04848493||HEMATOLOGICAL MALIGNANCIES|"1a. Newly diagnosed patients with ANY haematological malignancy requiring treatment (No.=100).~1b. Patients with ongoing treatments or with treatments completed within 6 months (chemotherapy and target therapies) other than antibodies. More specifically: patients with ongoing or completed chemotherapy (No.=50) or patients with ongoing or completed Ibrutinib (No.=50) or patients with ongoing or completed ruxolitinib (No.=50)~1c. Patients treated with anti-CD19 or CD20 or CD22 or CD30 or anti-PD1 antibodies with or without chemotherapy OR patients receiving CAR-T cells: patients treated anti-B-cell (No.=50) or patients treated anti-CD30 (No.=50) or patients treated anti-PD1 (No.=50).~1d. Patients at three months after autologous or allogeneic transplantation without active immune suppressive therapy: after autologous transplantation (No.=50) or after allogenic transplantation (No.=50)."
9689090|NCT04848493||SOLID TUMORS|"2a. Chemotherapy in adjuvant therapy. All patients with a diagnosis of solid tumors apart resected basal-cell or squamous-cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, and carcinoma in situ of the Breast. Under curative surgery (stage II-III) for the solid tumor or hemotherapy alone or in combination with target therapies or radiotherapy (No.=100).~2b. Chemotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing chemotherapy alone or in combination with immunotherapy or target therapy (No.=100).~2c. Immunotherapy in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), undergoing immunotherapy alone (No.=100).~2d. Target therapies in metastatic Disease. All patients with a diagnosis of solid tumors with Metastatic disease (stage IV), Undergoing target therapy alone (No.=100)"
9689091|NCT04848493||IMMUNORHEUMATOLOGICAL DISEASES|3a. Patients with ANCA-associated vasculitis classified according to Chapel Hill Consensus Conference nomenclature, treated with immunodepressants agents with/without glucocorticoids (No.=50) or treated with RTX with/without glucocorticoids (No.=50) 3b. Interstitial Lung Disease in Autoimmune Conditions. Patients with a diagnosis of a specific CTD, myositis or rheumatoid arthritis based on validated classification criteria, and clinically significant ILD defined as disease treated with traditional immunodepressants or rituximab and fibrotic and/or inflammatory changes on chest CT not attributable to infection, and no evidence of obstructive lung disease. Patients treated with traditional immunodepressive agents with/without glucocorticoidspatients (No.=50) or patients treated with rituximab with/without glucocorticoids (No.=50)
9689092|NCT04848493||NEUROLOGICAL DISEASES|"4a. Patients with a diagnosis of multiple sclerosis, age < 60 years with relapsing-remitting MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50) or with secondary/primary progressive MS on Ocrelizumab (anti-CD20 monoclonal antibody) (No.=50).~4b. Generalized Myasthenia Gravis, on immunosuppressive polytherapies or on B-cell targeted biological treatments, with lymphocytes count < 1 cell/microliter, or with thymoma (No.=100)"
9689093|NCT04848818|Active Comparator|K-wire group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
9689094|NCT04848818|Active Comparator|Activa-IM Nail group|Children with closed or grade I. open, severly displaced distal radial and/or complete forearm metaphyseal fractures between the age 3-13.
9689095|NCT04848675|Experimental|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
9689096|NCT04848675|Active Comparator|Brisk walking|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
9689097|NCT04848545||Live-born sons (with and without testicular cancer diagnosis) from a Danish pregnancy Cohort|"Pregnancy cohort: Biological samples from 128,702 of pregnant women were stored for research purposes in the Danish National Biobank, in the period from 1976-2004.~Present study: live-born sons (with/without testicular cancer ascertained via data linkage in the Danish Cancer Registry)"
10180312|NCT03793985|Active Comparator|B (T+R+T+R)|Period 1 : T Period 2 : R Period 3 : T Period 4 : R
10180313|NCT03794440|Experimental|Sintilimab +IBI305|
10180314|NCT03794440|Active Comparator|Sorafenib|
9689101|NCT04848467|Experimental|Group 1: Co-ad group|Participants will receive CVnCoV at the same visit as QIV: first dose of CVnCoV and a dose of QIV in opposite arms at Day 1, the second dose of CVnCoV at Day 29, and a placebo injection at Day 57.
9689102|NCT04848467|Experimental|Group 2: Control group|Participants will receive QIV and CVnCoV at two different visits: one dose of placebo and one dose of QIV in opposite arms at Day 1, the first dose of CVnCoV at Day 29 and the second dose of CVnCoV at Day 57.
9689103|NCT04848909|Experimental|Men with prostate cancer post-prostatectomy|Men with localized prostate cancer who are considered candidates for post-prostatectomy radiation.
9689104|NCT04848298|Experimental|Mobile Health Arm|
9689105|NCT04848298|No Intervention|Control Arm|The Control Arm will receive standard of care including tailored prescription of physical activity
9689106|NCT04848649|Experimental|Arm 1|
9689107|NCT04848259|Placebo Comparator|Control|No drug given before surgery
9689108|NCT04848259|Active Comparator|Dexamethason|Dexamethason will be given IV before surgery
9689109|NCT04848259|Active Comparator|Natural honey|Honey will be placed locally after impaction removal
9689110|NCT04848259|Active Comparator|Dexamethason and natural honey|Dexamethason will be given IV before surgery and Honey will be placed locally after impaction removal
9826797|NCT02432274|Experimental|Cohort 3B: Combination Expansion|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
10180315|NCT03794037|Active Comparator|control|dydrgesterone 10 mg( tab)/12hs/14 days
10180316|NCT03794037|Experimental|study|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
10180317|NCT03794232|Experimental|Test group|NIUCHANG（Soluble dietary fiber + prebiotics）：Oral, 1 bag (15g) once a day, taking 24 weeks
9528135|NCT03213717|Active Comparator|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
10180318|NCT03794232|Placebo Comparator|Control group|Placebo（inactive drug ingredient）：Oral, 1 bag (15g) once a day, taking 24 weeks
9689111|NCT04848311|Experimental|ICG group|Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
9689112|NCT04848311|No Intervention|CLgroup|Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.
9689113|NCT04848324|Active Comparator|Intervention group|14 patients (14 hands) who received US-guided corticosteroid hydrodissection
9689114|NCT04848324|Active Comparator|Control group|14 patients (14 hands) who received US-guided corticosteroid injection
9689115|NCT04848519|Experimental|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for propranolol hydrochloride and every 3 or 6 weeks for pembrolizumab for up to 2 years in the absence of disease progression or unacceptable toxicity.
9689116|NCT04848233|Other|Drink intervention|Placebo and two drinks containing a blend of five amino acids and chromium picolinate, are included with every main meal and served in a standardized, non-randomised order.
9689117|NCT04848571|Placebo Comparator|control group|Pregnant women who received IVF and not taken Chinesene fetal protection medicine until sampling
9689118|NCT04848571|Experimental|medicine group|Pregnant women who received IVF and have taken Chinesene fetal protection medicine from the fourth week during early pregnancy
9696149|NCT04770051|Experimental|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
9696150|NCT04770402|Experimental|Acupuncture|
9696151|NCT04770402|Active Comparator|Standard of Care|
9696152|NCT04770207|Experimental|Tumor diameter|Comparison of tumor diameter one month after injection of drug-eluting microspheres
9696153|NCT04769895|Experimental|MaaT013|"Route of administration: rectal (enema)~Study drug dose: 4 enemas in total:~Week 1:~D0-D1: vancomycin pre-treatment (250mg per os, 4 times a day for 2 days)~D2: 1 dose~Between D3 to D5: 1 dose Week 2: 1 dose (7 +/- 2 days after the last dose) Week 3: 1 dose (7 +/- 2 days after the last dose) A supplementary dose can be prescribed in case of GvHD relapse or massive antibiotic use during the study."
9696154|NCT04769908|Experimental|Systemic Chemotherapy, Lenvatinib Plus Sintilimab|
9696155|NCT04769986|Experimental|Mobile Mindfulness-Based Relapse Prevention (mMBRP)|Participants will complete the Mindfulness Coach app program that is enhanced with additional modules containing MBRP content.
9696156|NCT04769986|Active Comparator|Active control|Participants will complete a course of an exercise/healthy eating app program that is matched in time and effort to the intervention condition app.
9696157|NCT04770194|Experimental|Cohort 1: 200mg SP-8008 Prototype Capsule A|Treat 200 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
9696158|NCT04770194|Experimental|Cohort 2: 400mg SP-8008 Prototype Capsule A|Treat 400 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
9696159|NCT04770194|Experimental|Cohort 3: 800mg SP-8008 Prototype Capsule A|Treat 800 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
9696160|NCT04770194|Experimental|Cohort 4: 800 mg SP-8008 Prototype Capsule B|Treat 800 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
9696161|NCT04770194|Experimental|Cohort 5: 1200 mg SP-8008 Prototype Capsule B|Treat 1200 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
9696162|NCT04770194|Experimental|Cohort 6: 1800 mg SP-8008 Prototype Capsule B|Treat 1600 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
9696163|NCT04769973||Work Packages 1 - 3|"Work Package 1: Interviews with 15-20 people with Parkinson's and 15-20 caregivers.~Work Package 2: National Survey with up to 2000 participants~Work Package 3: Two to four Focus Groups with key stakeholders (6-10 participants per focus group)"
9696164|NCT04769921||All-on-4 TiUltra and Xeal|Patients rehabilitated in the edentulous maxilla or mandible with an implant supported prosthesis through the All-on-4 Concept (2 anterior implants in the axial position and 2 posterior implants inserted with distal tilting). The implants used will be NobelParallel Conical Connection, with TiUltra surface. The abutments used will be Multi-unit abutments of internal connection with Xeal surface. The immediate prosthesis will be a high-density acrylic and 4 titanium cylinders. The definitive prosthesis will be a Titanium infrastructure with acrylic resin artificial gingiva and either acrylic or ceramic crowns.
9696165|NCT04769687|Experimental|Symbiotic Treatment : probiotic Vivomixx® + prebiotic Orafti®Synergy1|"The prebiotic, Orafti®Synergy1, is made from a volume-to-volume mixture of oligofructoses and Raftiline HP. Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets that can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~The probiotic, Vivomixx®, consists of 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus and L. delbrueckii subsp. Bulgaricus) from 3 strains of Bifidobacterium (B. longum, B. breve, and B. infantis) and a strain of streptococcus (S. salivarius subsp thermophilus). Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria which can be administered orally. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).~For the study, the symbiotics will be packaged by the probiotic manufacturer in the same sachet (at the same doses as mentioned above) whether for the symbiotics or for the placebo."
9696166|NCT04769687|Placebo Comparator|Placebo|
10180319|NCT03794271|Experimental|Pupilometer group|In this group, intraoperative analgesia is performed using pupilometer guided anesthesia.
9528136|NCT03213717|Active Comparator|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
9689119|NCT04848246|Experimental|Bupropion|
9689120|NCT04848246|Experimental|Behavioural Change Communication|
9689121|NCT04848246|No Intervention|Control|
9689122|NCT04848207|Other|Digital impression technique|- 3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
9689123|NCT04848207|Other|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
9689124|NCT04848272|Placebo Comparator|Saline control|Saline control
9689125|NCT04848272|Experimental|Lanadelumab 30 mg|Lanadelumab 30 mg
9689126|NCT04848272|Experimental|Lanadelumab 100 mg|Lanadelumab 100 mg
9689127|NCT04848272|Experimental|Lanadelumab 300 mg|Lanadelumab 300 mg
9689128|NCT04848363|Experimental|Study group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before the operation, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml.
9689129|NCT04848363|Placebo Comparator|Control group|patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. In this group, after induction of anesthesia before surgery, bilateral blockade of the square dorsi muscle is performed under ultrasound guidance using 20 ml of saline.
9689130|NCT04848350|Placebo Comparator|placebo group|Only a saline solution was applied to the placebo group
9689131|NCT04848350|Active Comparator|lavender group|The lavender essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
9689132|NCT04848350|Active Comparator|frankincense group|The frankincense essential oil was added to the nebulizer and operated on in the SWL room before the procedure,
9689133|NCT04848766||De-escalation treatment group|Patients diagnosed as acute coronary syndrome, and who receive de-escalation antiplatelet therapy after percutaneous coronary intervention
9689134|NCT04848766||Conventional treatment group|Patients diagnosed as acute coronary syndrome, and who receive conventional (non-de-escalation) antiplatelet therapy after percutaneous coronary intervention
9689135|NCT04848181|Active Comparator|cyproterone acetate|20 patients received cyproterone acetate 50 mg twice per day for two weeks before TURP
9689136|NCT04848181|Active Comparator|finasteride group|20 patients received finasteride 5 mg once per day for two weeks before TURP
9689137|NCT04848181|Placebo Comparator|control group|20 patients received no treatment before TURP
9689138|NCT04848376||Spine surgery|"Use these system:~(1) SmartLoc (2) SmartLoc Evo(3) Winloc (4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L"
9689139|NCT04848142||Primary Group (parent-child)|parents (i.e., guardians/caregivers) and children age ≥ 8 years,will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment. Optional qualitative interviews may be completed individually for participants (age ≥ 12 years with P/LP variant and aware of results, or their parent)
9689140|NCT04848142||Parent Only Group|parents of children age < 8 years, will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment.
9689141|NCT04848116|Experimental|Cohort 1|Nivolumab + HuMax (BMS-986253) will be administered as an IV infusion.
9689142|NCT04848116|Experimental|Cohort 2|Nivolumab + Cabiralizumab will be administered as an IV infusion.
9689143|NCT04848116|Experimental|Cohort 3|Nivolumab + another agent (which will be determined depending on results from Cohort 1 and Cohort 2) will be administered as an IV infusion.
9689144|NCT04847960|Experimental|L.reuterii probiotic lozenges from BioGaia|Subjects were willing to provide 2 samples of saliva, dental plaque and gingival fluid (gum fluid), on the first day (before consuming lozenges) and on the 14th day after the subject consumed lozenges containing L. reuteri probiotic. Probiotics are taken once a day for two weeks after breakfast and brushing their teeth.
9689145|NCT04848051|Experimental|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
9689146|NCT04848051|Experimental|CRC Reminder & Short message|Participants randomized to the CRC Reminder & short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
9689147|NCT04848051|Experimental|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
9696167|NCT04769557|Experimental|Paracetamol|Paracetamol
10180320|NCT03794271|Active Comparator|SPI group|In this group, intraoperative analgesia is performed using SPI guided anesthesia
10180321|NCT03794310|Experimental|NPF-08 （1-day treatment）|
10180322|NCT03794310|Experimental|NPF-08 （2-day split dose）|
10180323|NCT03794310|Active Comparator|Moviprep（1-day treatment）|
10180324|NCT03794154|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
10180325|NCT03794154|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
9689148|NCT04848051|Experimental|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
9689149|NCT04847986|Experimental|acceptance and commitment therapy (ACT) group|8 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
10180326|NCT03794323|Experimental|BI 764122|
9689150|NCT04847986|Sham Comparator|Control group|care as usual with psychoeducation materials provided
9689151|NCT04848012|No Intervention|Usual non-invasive ventilation|The usual therapy the participant is receiving via non-invasive ventilator.
10180327|NCT03794323|Placebo Comparator|Placebo|
10180328|NCT03794167|Experimental|busulfan cyclophosphamide etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
9689152|NCT04848012|Experimental|Auto-titrating non-invasive ventilation|A novel auto-titrating non-invasive ventilator
9689153|NCT04847791|Experimental|Group A|Standard Anti-Covid-19 Therapy + Oral Administration of Bovine Lactoferrin 400mg (two capsules of Mosiac 200 product) every 12 h (i.e., fixed dose 800 mg / day) for 30 days and still away from meals
9689154|NCT04847791|Placebo Comparator|Group B|Standard anti-Covid-19 therapy + Placebo administration (capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
9689155|NCT04847830|Experimental|Laser|One side of the mouth will undergo root surface debridement using hand instruments and ultrasonic scaler, with the addition of the Er:YAG laser
9689156|NCT04847830|Placebo Comparator|Control|The other side of the mouth undergo root surface debridement using hand instruments and ultrasonic scaler alone
9689157|NCT04847765|Experimental|Combined pressure measurement and MRI|Gastric motility is evaluated simultaneously by means of the investigational medical device and by means of cine-MRI.
9689158|NCT04848103|Experimental|Radial extracorporeal shockwave therapy|
9689159|NCT04848064|Experimental|Treatment (mogamulizumab, chemotherapy, NK cells)|Patients receive mogamulizumab IV over 60 minutes on day -7 and fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive NK cell infusion on day 0. Patients then receive mogamulizumab IV over 60 minutes on days 0, 7, 14, and 28, then every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
9689160|NCT04847804||Positive case|The sample will be tested by microfluidic device and shows positive
9689161|NCT04847804||Negative control|The sample will be tested by microfluidic device and shows negative
9689162|NCT04847817||Index cases|Patients infected by SARS-Cov2 Polymerase Chain Reaction (PCR) and hospitalized in a referral center for COVID-19 .
9689163|NCT04847817||Households cases|Household contacts of SARS-Cov2 hospitalized COVID-19 patients.
9689164|NCT04847700|Active Comparator|Minimally invasive vestibular neurectomy|
9689165|NCT04847700|Active Comparator|Tenotomy of the stapedius and tensor tympani muscles|
9689166|NCT04847999|Experimental|Conventional Dark Chocolate|A standard dark chocolate bar.
9689167|NCT04847999|Experimental|Ross Dark Chocolate|A dark chocolate bar sweetened with stevia, erythritol, and inulin.
9689168|NCT04847869|Experimental|NIR laser treatment 200mW/cm2 dose|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
9689169|NCT04848077|Experimental|Very high dose|Very large proportional increase in stepcount relative to baseline stepcount.
10180329|NCT03794167|Active Comparator|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
10180330|NCT03793972|Experimental|Triage with referral to primary care|Triage and referral according to eMTS.
10180331|NCT03793972|Active Comparator|Triage without referral to primary care|Weekends with usual care
9528137|NCT03213483|Active Comparator|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
9689170|NCT04848077|Experimental|High dose|Large proportional increase in stepcount relative to baseline stepcount.
9689171|NCT04848077|Experimental|Intermediate dose|Medium proportional increase in stepcount relative to baseline stepcount.
9689172|NCT04848077|Active Comparator|Active controls|Small proportional increase in stepcount relative to baseline stepcount.
9689173|NCT04847934|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the intramuscular injection
9689174|NCT04847934|Experimental|Manual Pressure Vibration Technique Group|Application of manual pressure vibration technique to the area where the intervention will be made
9689175|NCT04847934|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be injected
10180332|NCT03794180|Experimental|TJ003234|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion
10180333|NCT03794180|Placebo Comparator|Placebo|0 mg/kg via single IV infusion
10180334|NCT03794141|Experimental|Tervas|Follow up group from an earlier study. Information on risk gene status. All test persons were given information on healthy diet and life style.
10180335|NCT03794141|Experimental|Informed|Information on risk gene status was given before intervention. All test persons were given information on healthy diet and life style.
10180336|NCT03794141|Active Comparator|non informed|Information on risk gene status was not given before intervention. All test persons were given information on healthy diet and life style.
10180337|NCT03794297|Experimental|Treatment (dabrafenib mesylate, trametinib dimethyl sulfoxide)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9689176|NCT04847934|No Intervention|Control Group|Standart care
10180338|NCT03794050|Experimental|resistance training exercise|All participants complete one session of resistance training exercise
9689177|NCT04847921|Experimental|people who use drugs with severe Gram-positive infections|As per inclusion and exclusion criteria
10180339|NCT03794050|Experimental|aerobic training exercise|All participants complete one session of aerobic training exercise
10180340|NCT03793959|Experimental|Synbiotic Supplement|Daily synbiotic supplement (5g prebiotic fiber + 8 billion CFU probiotic B. lactis, identical to Placebo-- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
10180341|NCT03793959|Placebo Comparator|Placebo Supplement|Daily placebo supplement (5g maltodextrin, identical to Experimental -- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
10180342|NCT03794414|Experimental|fluid responder|patients with 10% or more increase in stroke volume after fluid challenge. Both arms receive PEEP challenge.
10180343|NCT03794414|Experimental|fluid non-responder|patients with no increase or less than 10% increase in stroke volume after fluid challenge. Both arms receive PEEP challenge
9689178|NCT04847635|Experimental|Subthreshold laser group|To evaluate the efficacy of Subthreshold laser in the treatment of reticular pseudodrusen.
9689179|NCT04847635|Sham Comparator|Sham group|The light from the retinal illumination system on the laser device will be used instead of the laser beam in all follow-up evaluations.
9689180|NCT04847895||Lucentis|Patients administered Lucentis by prescription
9689181|NCT04847856|Experimental|List of health centers that randomly allocated to receive the intervention|The intervention was structured Diabetes self-care information, education, and communication (IEC) delivered to the participants at the selected primary health care center level. The Information, education, and communication intervention were delivered by relevant and trained health animators working in chronic care clinics. The intervention was composed of sessions and the participants were planned to attend five structured sessions on diabetes self-care at months: 1, 2, 3,4,5&6. Besides, the participants were provided with a single-page checklist with a to-do list of activities and simple advice that covering the various aspects of diabetes self-care.
9689182|NCT04847856|No Intervention|List of health centers that randomly allocated to receive routine care|The comparators were type II diabetic patients of both genders attending the selected primary health care centres that receiving routinely provided diabetic care including advice from the health care providers. Participants were interviewed at the start of the trial to collect the baseline data about self-care with measurements of blood glucose level, serum cholesterol level, blood pressure, BMI, and waist circumference. At the end of the trial, the sam participants were interviewed to collect end-line data and similar measurements.
9689183|NCT04847882||Cystic fibrosis, children from 6 to 17.|This group is made up of children with cystic fibrosis followed at the Strasbourg pediatrics CRCM, aged from 6 to 17 years old, not hospitalized at the time of inclusion, without any other criterion prejudging the seriousness of the pathology.
9689184|NCT04847882||Control group, children from 6 to 17.|"This group is the control group. It is made up of children consulting in pediatric surgical emergencies, aged 6 to 17 years. Surgical emergencies were chosen because it is a point of consultation, rather accidental, where sleep has often not been impacted in the previous months and where the frequency of chronic pathology is not higher than the general population.~An other criteria is that these children are accompanied by at least one of their parents and that they can read and understand French well."
9689185|NCT04847947|Experimental|Interventional group|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks.
9689186|NCT04847947|Placebo Comparator|Control Group|Oral capsule Placebo once daily and Calcium Lactate 500 mg once daily for 12 weeks.
9689187|NCT04847843|Experimental|Mindfulness Orientated Recovery Enhancement (MORE) Intervention|8-week MORE intervention adapted for preventing weight regain
9689188|NCT04847843|Active Comparator|Control Intervention|8-week control intervention based on the Diabetes Prevention Program's Prevent T2 for Life program.
9689189|NCT04847570|Experimental|Music listening experience|It is a single-arm non-randomised study. The same inclusion and exclusion criteria applies to all the participants.
9689190|NCT04847622||Target Population|Adults with COVID-19 diagnosed and treated with Remdesivir after Aug 31st2020.
9689191|NCT04847661|Active Comparator|Mefloquine arm|"Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.~30kg≤BW<45kg: 825mg followed by 275mg after 6-8 hours~45kg≤BW<60kg: 825mg followed by 550mg after 6-8 hours~60kg≤BW: 825mg followed by 550mg after 6-8 hours and then 275mg 6-8 hours after the second dose"
9696168|NCT04769557|Placebo Comparator|Placebo|placebo
10180344|NCT03793946|Experimental|AB-assistant|Use of the AB-assistant app by physicians in intervention wards.
10180345|NCT03793946|No Intervention|Standard antimicrobial stewardship|Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
10180346|NCT03793894|Active Comparator|Enhanced usual care|"All trial participants will receive smoking cessation counseling (standard of care) and will be given the AHRQ Is Lung Cancer Screening Right for me? patient decision aid to review independently while in the hospital."
10180347|NCT03793894|Experimental|Inpatient SDM + CHW Navigation|In addition to the smoking cessation counseling and decision aid received by all subjects, intervention subjects will receive shared decision making (SDM) + CHW navigation.
10180348|NCT03793920|Experimental|PEA patients without alcohol disorder|A group of 36 PEA patient without alcohol-dependence (AD), performing 6 behavioral tasks.
10180349|NCT03793920|Sham Comparator|PEA patients with alcohol disorder|A group of 36 PEA participants, currently alcohol-dependent, performing 6 behavioral tasks.
10180350|NCT03793920|Sham Comparator|Healthy controls with AD father|A group of 36 non-alcohol-dependent controls whose father was alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
10180351|NCT03793920|Sham Comparator|Healthy controls without AD father|A group of 36 non-alcohol-dependent controls whose father was not alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
10180352|NCT03793699||case group : realized a suicide attempt|adults having realized a suicide attempt and without histories of suicide attempt.
10180353|NCT03793699||control group : only suicidal ideas|adults having suicidal ideas without suicidal acting out and without histories of suicide attempt.
10180354|NCT03793790|Experimental|Group 1|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
10180355|NCT03793790|Experimental|Group 2|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
10180356|NCT03793790|Experimental|Group 3|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
10180357|NCT03793790|Experimental|Group 4|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
10180358|NCT03793790|Sham Comparator|Group 5|Sham conditioning of nocebo effects on pain (induction) and extinction (attenuation).
10180359|NCT03793647|Active Comparator|Low Intensity EMS|Conventional Stimulation
10180360|NCT03793647|Experimental|High Intensity EMS|Russian Stimulation
10180361|NCT03793647|Placebo Comparator|Placebo|no Stimulation, supported by phone contact
9689192|NCT04847661|Placebo Comparator|Control arm|A similar tablet of non-active gradients was specifically manufactured for the study by EVA Pharma company. The placebo tablets exactly resemble the active treatment mefloquine tablets (the same shape, size and color).
9689193|NCT04847505|Experimental|Neuroendocrine cancer patients|"All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician.~Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed."
9689194|NCT04847713||Fabry's disease|children and adults male or female between 6 and 70 years old, patients with diagnosis of FD, treated and non-treated
10180362|NCT03794258|Experimental|SOF+DCV+CDI-31244|Subjects will receive two weeks of sofosbuvir, daclatasvir, and CDI-31244 if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
10180363|NCT03794258|Experimental|SOF+DCV+CDI-31244+ASV|Subjects will receive two weeks of sofosbuvir, daclatasvir, CDI-31244 and asunaprevir if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
10180364|NCT03793621|Experimental|BI 730357|
10180365|NCT03793621|Placebo Comparator|Placebo|
9689195|NCT04847713||Healthy controls|age and sex-matched group of healthy subjects with a negative family history for lysosomal storage disorders and no clinical signs of FD.
9528138|NCT03213483|Experimental|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
9689196|NCT04847687||Group 1|Patients who are started on 1 mg/kg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
9689197|NCT04847687||Group 2|Patients who are started on 250 mg/day methylprednisolone. Demographic data of the patients, length of hospital stay, follow-up in intensive care unit and prognosis will be recorded.
9689198|NCT04847544|Experimental|ADX-629 300 mg administered orally twice daily (BID) for up to 28 days.|
9689199|NCT04847544|Placebo Comparator|Placebo administered orally BID for up to 28 days.|
9689200|NCT04847518|Experimental|Kan Jang|70 patients take Kan Jang, two capsules three times a day for the two weeks in the treatment period. Daily dose - 90-120 mg of andrographolides.
9689201|NCT04847518|Placebo Comparator|Placebo|70 patients take Placebo, two capsules three times a day for the two weeks in the treatment period
9689202|NCT04847479|Experimental|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to their close contacts.
9689203|NCT04847479|Active Comparator|Test referral distribution|Participants in the test referral arm receive text messages providing testing information to send to their close contacts.
9689204|NCT04847492|Active Comparator|Traditional corticotomy|Adult patients will be treated by en-masse retraction associated with traditional corticotomy.
10180366|NCT03793712|Experimental|Lu AF11167 low dose|
10180367|NCT03793712|Experimental|Lu AF11167 high dose|
10180368|NCT03793712|Placebo Comparator|Placebo|
10180369|NCT03793777|Placebo Comparator|placebo|microcrystalline cellulose supplementation
10180370|NCT03793777|Experimental|Aronia|aronia melanocarpa supplementation
10180371|NCT03793764|Active Comparator|Group T|At the end of the surgery USG guided TAP block will be performed with 20 mL of 0.25% isobaric bupivacaine.
10180372|NCT03793764|Active Comparator|Group Q|At the end of the surgery USG guided QL block will be performed with 20 mL of 0.25% isobaric bupivacaine.
10180373|NCT03793764|No Intervention|Group C|In this group no intervention will be performed after the end of operation.
10180374|NCT03793868|Experimental|Low dose|Perampanel 4mg PO x1
10180375|NCT03793868|Placebo Comparator|Placebo|Receiving placebo
10180376|NCT03793868|Experimental|High dose|Perampanel 8 mg PO x1
10180377|NCT03793816|Active Comparator|BiZact™ device|"BiZact™ device will be used appropriately to its purpose to remove one tonsil by:~Incision of the anterior palatal arch~Locating of the cranial pole of the tonsil~Dissection of the tonsil capsule~Localized coagulation of bleeding vessels~Detaching of the inferior pole from the pharynx tissue"
10180378|NCT03793816|Active Comparator|Cold steel dissection (CD)|Cold steel dissection (CD) with localized cauterization for hemostasis serves as the comparative procedure within each patient (cross-over).
10180379|NCT03793608|Experimental|Dupilumab|Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
9689205|NCT04847492|Experimental|Flapless corticotomy|Adult patients will be treated by en-masse retraction associated with flapless corticotomy.
10180380|NCT03793725|Experimental|SHR-1210 + Apatinib|Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd
9689206|NCT04847375|Experimental|Nebulized Surfactant|The patients in this group will receive exogenous surfactant using nebulizer mask as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19; in addition they will receive standard care based on the national guidelines
9689207|NCT04847375|No Intervention|Standard Care|The patients in this group will receive standard care based on the national guidelines as soon as they are admitted in the hospital (ward or emergency department) with a diagnosis of COVID-19
9689208|NCT04847414||prospective group|all needed data will be collected from patients in this group through performing full medical examination and doing all necessary investigations for them
9689209|NCT04847414||retrospective group|all needed data will be collected from medical records either electronic or paper based from different diabetes clinics in upper Egypt
9689210|NCT04847219|Placebo Comparator|Professional flash glucose mornitoring|Professional flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via capillary blood glucose tests, but nor FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
9689211|NCT04847219|Active Comparator|Personal flash glucose mornitoring|Personal flash glucose mornitoring will be used in patients once a month for 3 months to monitor glucose level. Patients can learn their blood glucose levels via FGM duing FGM, and doctors will adjust their anti-diabetic therapy according to their FGM results after each monitoring.
9689212|NCT04847180|Experimental|Instability shoulder group|Patients operated for an antero-inferior shoulder instability
9689213|NCT04847180|Other|Non instability shoulder group|Patients without shoulder instability, operated for another reason.
9689214|NCT04847076|Experimental|m-health version of WWWT intervention|Include: a) Psychoeducational information for understanding and managing infant behavior and on parenting. This information will be delivered through instant messaging service for mobile phones (i.e., Whatsapp) 3 times a week for four-week period. Each module will include a very brief video offering information regarding a specific topic, a proposed personal exercise and the invitation to assess the perceived usefulness of the information received. Some modules include links to external, complementary information from the Chilean Infancy Policy. b) Contact with the program facilitator. It will allow mothers to ask questions that arise from the topics addressed in the psychoeducational videos. The answers seek to promote the understanding and elaboration of the contents, and operate by providing expert support; c) A virtual group meeting.
9689215|NCT04847076|Other|TREATMENT AS USUAL|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age. The objective of the routine health care check is to carry out a comprehensive evaluation of the child's development and growth, guide parents and caregivers regarding child development, health and upbringing of the child. Also, promoting exclusive breastfeeding, healthy mother/child bonding (by detecting relevant alterations in this area) and encouraging paternal participation in upbringing and care of the child. Finally, in the health check-ups at 2 and 6 months of age of the child, Edinburgh Postpartum Depression Scale is used for screening depressive symptoms in mothers. At risk cases are referred for mental health assessment and care.
9689216|NCT04847037|Experimental|Connected Tools|For the experimental group, the postoperative procedure requires the use of personal connected tools: a smartphone, a digital tablet or a computer with internet connection. A scale and a connected watch will also be loaned to patients so that they can take the necessary measures. Before returning home, patients must be trained to take correct measures and inform them on the dedicated platform.
9689217|NCT04847037|No Intervention|No Connected Tools|Patients randomized to the control group will be operated according to the same protocol as the experimental group. For them, there will be no home follow-up, so no special procedure to follow.
9689218|NCT04847024|Experimental|Parecoxib|Parecoxib 40 mg reconstituted in 2ml of saline solution, to pass IV as a bolus, every 12hrs + acetaminophen 1g in 100cc of saline solution to pass IV in 15 minutes, every 6hrs.
9689219|NCT04847024|Experimental|Dexketoprofen|Dexketoprofen 50 mg in 100 cc of saline solution, protected from sunlight, to be given IV in 15 minutes, every 8hrs + acetaminophen 1g in 100 cc of saline solution to be given IV in 15 minutes, every 6hrs.
9689220|NCT04847336||Women|Women of any age who gave births in hospitals from WHO European Region, from 1 march 2020
9689221|NCT04847336||Health workers|Health workers directly involved in assistance at childbirth (pregnancy, childbirth and peripartum) at hospital level in WHO European Region, from 1 march 2020
10180381|NCT03793582||Study group|All subjects agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
10180382|NCT03793517|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of HLA-mismatched HSCT.~Details:~The conditioning therapy for human eukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2."
10180383|NCT03793517|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3."
10180384|NCT03793686|Experimental|Experimental|PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
10180385|NCT03793686|Placebo Comparator|Placebo|Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
9689222|NCT04847245|Active Comparator|Pregabalin group|Pregabalin capsules were administered orally (75 mg, tid), combined administration of duloxetine.
9689223|NCT04847245|Experimental|0.125 mg/kg esketamine group|Intravenous administration of esketamine 0.125 mg/kg，and duloxetine is co- administered orally.
9689224|NCT04847245|Experimental|0.25 mg/kg esketamine group|Intravenous administration of esketamine 0.25mg/kg，and duloxetine is co- administered orally.
9689225|NCT04847245|Experimental|0.50 mg/kg esketamine group|Intravenous administration of esketamine 0.50 mg/kg，and duloxetine is co- administered orally.
10180386|NCT03793569|No Intervention|Control group|Participants will be recruited and asked to complete Edinburgh Postnatal Depression Scale (EPDS) at specific timepoints postpartum.
9689226|NCT04847297||Preoperative biliary drainage and pancreatoduodenectomy|Patients receiving preoperative biliary drainage before the removal of the tumor.
9689227|NCT04847297||Pancreatoduodenectomy only|Patients undergoing only surgical intervention, without preoperative drainage.
9689228|NCT04847284|Experimental|Single arms|To determine the efficiency and safety of IORT with low-energy photons to the cavity after resection of brain metastases
9689229|NCT04847011|Experimental|RA - longitudinal arm|
9689230|NCT04847011|Experimental|PD - longitudinal arm|
9689231|NCT04847011|No Intervention|RA - crosssectional arm|
9689232|NCT04847011|No Intervention|PD - crossectional arm|
9689233|NCT04847011|No Intervention|Healthy controls - crosssectional arm|
9689234|NCT04847323|Active Comparator|V-bend Bonded Retainer|"The V-bend retainer is bonded in the lingual surface of the anterior teeth. The retainer is constructed using 0.024 stainless steel wires. Differently from the conventional bonded retainers, this retainer presents V-bends in the sagittal direction, parallel to the occlusal plane in each interproximal contact point of the incisors and canines.~The retainers will be bonded after adequate etching with phosphoric acid and application of adhesive with a low viscosity resin."
9689235|NCT04847323|Active Comparator|Vacuum-formed Retainer|The removable Vacuum-formed retainers will be made of acetate 1mm thickness. They will be made at the same appointment of debonding using plaster models. The patients will be instructed to use the retainers only during nights.
9689236|NCT04847401||Group 1|patients with Irritable Bowel Syndrome
9689237|NCT04847401||Group 2|normal
9689238|NCT04847115|Active Comparator|Operative|The patients in this arm will be treated operatively with intramedullar screw osteosynthesis. In addition to this, they will weight bear as tolareted in a walking boot orthosis for six weeks.
9689239|NCT04847115|Active Comparator|Non-operative|The patients in this arm will have non-operative treatment with a walking boot orthosis for six weeks. They will weight bear as tolerated
9689240|NCT04846998|Experimental|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 1: A-B-C"
9689241|NCT04846998|Experimental|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 2: A-C-B"
9689242|NCT04846998|Experimental|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 3: B-A-C"
9689243|NCT04846998|Experimental|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 4: B-C-A"
9689244|NCT04846998|Experimental|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 5: C-A-B"
9689245|NCT04846998|Experimental|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 6: C-B-A"
9689246|NCT04846972||Control group|After inclusion, patients will receive standard care. Women allocated in this group will have the standard care.
9689247|NCT04846972||FASTRACS intervention group|Women allocated in the FASTRACS intervention group will follow a structured care pathway comprising three successive steps (end of chemotherapy interview with a nurse, transitional visit with their GP, pre-RTW visit with their OP), plus one optional step (late visit with an OP- RTW to work coordinator). Four tools will be used during the intervention (RTW guide or checklist for the patient, the GP, the OP and the employer).
9689248|NCT04846959||Pregnant Women Exposed to Risankizumab|Pregnant women of any age in the United States (US) who are diagnosed with plaque psoriasis and exposed to risankizumab at any time during pregnancy.
9689249|NCT04846959||Pregnant Women Not Exposed to Risankizumab|Pregnant women of any age in the US who are diagnosed with plaque psoriasis and not exposed to risankizumab, but who are exposed to other medications in the same class or line of therapy as risankizumab at any time during pregnancy.
9689250|NCT04846764|Active Comparator|Healthy volunteers|"60 healthy volunteers (aged 18-40 and 60-80) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~Neuropsychological tests~A cranial MRI~Visit 2~• Neuropsychological tests"
9689251|NCT04846764|Experimental|Patients with neurological diseases of the central nervous system|"36 patients will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~Neuropsychological tests~A cranial MRI~Visit 2~• Neuropsychological tests"
9689252|NCT04846842|Experimental|Gimatecan group|In Phase II study, patients will receive gimatecan at fixed dose level (0.8mg/m2/d, oral, every 4 weeks) until progressive disease (PD)、complete remission（CR）).
9689253|NCT04846699||group 1|bulls eye localization
9689254|NCT04846699||group 2|stone targeted technique renal access
9689255|NCT04846699||group 3|triangulation renal access technique
9689256|NCT04846686||preeclampsia group|"25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized.~Placenta pathological examination will be performed."
10180387|NCT03793569|Experimental|Intervention group|Participants will be recruited, asked to complete Edinburgh Postnatal Depression Scale at specific timepoints postpartum, and attend a peer discussion group.
9689257|NCT04846686||control group|"10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized.~Placenta pathological examination will be performed."
9689258|NCT04847089|Experimental|Motor Imagery BCI training|Complete intervention with motor imagery BCI training. Patients recruited by physiotherapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
9689259|NCT04846751|Active Comparator|AEROBIC EXERCISE|50 min of aerobic exercise by pedaling a cycleergometer at 60% of VO2max
9689260|NCT04846751|Placebo Comparator|PLACEBO REST|No exercise, resting during 50 min.
9689261|NCT04846673|Experimental|Pregabalin and alpha-lipoic acid combination therapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
9689262|NCT04846673|Experimental|Pregabalin monotherapy|Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.
9689263|NCT04846673|Active Comparator|Alpha-lipoic acid monotherapy|Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.
10180388|NCT03793491||Patients having Parkinson's disease|Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.
9689264|NCT04846946|No Intervention|Control|Time attention control condition.
9689265|NCT04846946|Experimental|Intervention, Module 1 - Knowledge|20-minute module that aims to improve HIV prevention knowledge.
9689266|NCT04846946|Experimental|Intervention, Module 1 - Stigma|20-minute module that aims to reduce SGM- and HIV- related stigma.
9689267|NCT04846946|Experimental|Intervention, Module 1 - Prevention|20-minute module that aims to promote HIV prevention strategies including testing and PrEP.
9689268|NCT04846621|Other|group Nicorandil|women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours
9689269|NCT04846621|Other|group Nifedipine|Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours
9689270|NCT04846829|Placebo Comparator|Placebo infusion|Placebo comparator to active study drug
9689271|NCT04846829|Active Comparator|intravenous citalopram hydrochloride (CIT)|A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
9689272|NCT04846829|Experimental|intermittent Theta Burst Stimulation|"10 sessions of treatment with cTBS to right DLPFC~TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
9689273|NCT04846829|Experimental|continuous Theta Burst Stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC~TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
9689274|NCT04846712||patients with a first ankle sprain|100 patients with a first ankle sprain will be included. Data will be collected of medical record.
9689275|NCT04846790|No Intervention|Control|The control group will complete the first three assessments similar to the two treatment groups but will not participate in the nature-based or virtual mindfulness interventions. At the end of their study participation (~week 3), they will be offered the opportunity to partake in the nature-based and virtual mindfulness interventions.
9689276|NCT04846790|Active Comparator|Nature Only|The nature-based intervention is three days long, is offered at various locations throughout the United States, and includes activities such as hiking, mountain-biking, and kayaking. The healthcare workers can participate in the programs that are offered locally pending availability. Each program will enroll between 15 and 30 healthcare workers. All First Descents nature-based interventions have been intentionally designed with input from more than 450 hospital partners nationwide to improve psychosocial health, nurture supportive peer relationships, and better position healthcare workers to carry out their critical mission. There is no cost to attend, and meals and lodging are included. Special precautions against SARS-CoV-2 transmission are implemented.
9689277|NCT04846790|Experimental|Nature+Mindfulness|In the combined nature-based and virtual mindfulness intervention, participants will complete the nature intervention followed by the mindfulness intervention. The virtual mindfulness intervention is 10 days long and offered online. Each day the participant will receive a notification that a new mindfulness audio is ready for viewing, which is from 10 to 25 minutes long. Mindfulness exercises include mindful breathing, body scan, and loving-kindness meditation. Participants can view the daily audio as many times as they wish but cannot view the next day's content to maintain treatment fidelity. At the end of each day, participants will be asked to indicate if they viewed the mindfulness audio to track adherence.
9689278|NCT04846738||brain damaged patients|"All major brain damaged patients (stroke or head trauma) admitted to reanimation will be included.~In the usual practice, they have a Transcranial Doppler and the measurement of the photomotor reflex by quantitative Pupillometry.~It is planned to collect the simultaneous values of the different parameters during 2,000 measurements.~The data will be collected retrospectively from 01/12/2020, and prospectively from 01/04/2021."
9689279|NCT04846855|Experimental|Ropivacaine 35%|Local Anesthesia with Ropivacaine
9689280|NCT04846660|Experimental|Production pressured environment|Participants in this group were exposed to 4 audio recordings applying standardized pressure. Unlimited time.
9689281|NCT04846660|No Intervention|Regular environment|The control group was asked to complete the same task also with unlimited time. They were not exposed to the audio recordings.
9689282|NCT04846725||Retrievable Inferior Vena Cava Filters (IVCF)|The population study includes patients with a Retrievable Inferior Vena Cava Filters (IVCF) inserted between April 2012 and November 2019. Follow up data is collected up to July 2020.
9826798|NCT02432287|Experimental|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
9826799|NCT02432287|Experimental|Placebo|Placebo
9826800|NCT02432300|Experimental|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
9976239|NCT01349439|Experimental|Placebo + No Memory Reactivation|This arm involves administration of a placebo without recalling the traumatic event
9976240|NCT01349439|Experimental|Propranolol + No Memory Reactivation|This arm involves administration of propranolol without recalling the traumatic event
9689285|NCT04846634|Experimental|neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab|
9689286|NCT04846634|Experimental|neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
9689287|NCT04846634|Experimental|neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.|
10180389|NCT03793413|Experimental|Surgical group|
10180390|NCT03793413|No Intervention|Observation group|
10180391|NCT03793530|Experimental|Bone marrow concentration group|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
9689288|NCT04846777|Experimental|Mindfulness ecological momentary intervention|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
9689289|NCT04846777|Placebo Comparator|Self-monitoring placebo|The SMP condition was developed to parallel the treatment while eliminating its theorized active therapeutic elements - open monitoring, acceptance, attending to small moments, breathing retraining, continual practice of mindfulness. Therefore, it did not mention anything about mindfulness at all. Instead, SMP participants were instructed to notice their cognitions and emotions and how distress they might be. No instruction on accepting their thoughts and feelings as they are were given.
9689290|NCT04846543|Other|MRI scan 1st and 2nd year|Additionally to routinely follow up, there will be an MRI scan of enrolled patients after one and two years in some of the study sites
9689291|NCT04846556||venous thromboembolic event related to cancer|Patients admitted for a venous thromboembolic event related to their cancer will be included A data collection will be realized. Patients admitted between 2017 and 2019 at Saint-Etienne University Hospital, Louis-Mourier Hospital (AP-HP) and Amiens University Hospital.
9689292|NCT04846426||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9689293|NCT04846426||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9689294|NCT04846426||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9689295|NCT04846426||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9976241|NCT01349439|Other|Open-label Propranolol + Memory Reactivation|All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.
9689297|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 1|
9689298|NCT04846491|Experimental|Nucleot(s)ide-treated patients-Experimental Group 2|
9689299|NCT04846491|Active Comparator|Nucleot(s)ide-treated patients-Control Group|
9689300|NCT04846491|Other|Treatment Naive Group|
9689301|NCT04846595|Other|Self questionnaire|The study will be offered to all patients who have been treated for HIV infection for at least 6 months, during a follow-up consultation. A self questionnaire will be administered only once per patient during the usual consultation, there is no follow-up planned.
10180392|NCT03793530|Active Comparator|Control group|Transforaminal lumbar interbody fusion with local bone graft
10180393|NCT03793634|Experimental|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
9689302|NCT04846569|Experimental|Transition Theory-based Intervention|Participants in the intervention arm will receive the Transition Theory-based intervention consisting of 4 sessions with a community health worker (2 during pregnancy, 2 postpartum) to support their transition from pregnancy to postpartum.
9689303|NCT04846569|Active Comparator|Enhanced Standard of Care Control|Participants in the control arm will receive the standard of care plus one session with a community health worker.
9689304|NCT04846283||Biomarker-group|We considered for the study all patients aged >16 y undergoing elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure. Both patients undergoing open and minimally invasive surgery were considered eligible.
9689305|NCT04846452|Experimental|NSCLC patients with negative driver genes|Patients with negative driver genes advanced or metastatic NSCLC will receive sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens as first-line treatment.
9689306|NCT04846894|Experimental|Biochemical Recurrence|Prostate cancer patient with biochemical recurrence
9976242|NCT01349452|Experimental|Ganciclovir|
9976243|NCT01349452|Sham Comparator|Artificial tear|
9976244|NCT01349478|Experimental|study arm|
9976245|NCT01349504||Mesalmine|
9976246|NCT01349517|Other|MIE Group|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
10180394|NCT03793634|Active Comparator|Topical Triamcinolone Acetonide|topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.
10180395|NCT03793595|Experimental|Seated Battle Ropes Protocol|
10180396|NCT03793595|Active Comparator|Seated Upper Extremity Arm Bike|
10180397|NCT03793387|Experimental|Pre-op|
10180398|NCT03793387|Active Comparator|Intra-op|
10187507|NCT03725579|Active Comparator|articaine hydrochloride|4 % Articaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
10180399|NCT03793192|Experimental|PACE2 Intervention|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity. In addition, participants randomized to the PACE2 intervention will receive written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
9689307|NCT04846478|Experimental|Dose Escalation Talazoparib + Tazemetostat|"Standard 3+3 dose escalation will be followed, participants will initially receive talazoparib and tazemetostat at a dose of 75% of the starting dose for their FDA-approved indications.~During each 28 day study treatment cycle participants will take:~Talazoparib once daily.~Tazemetostat twice daily."
9689308|NCT04846478|Experimental|Dose Expansion Talazoparib + Tazemetostat|"Participants will receive talazoparib and tazemetostat at the safe dose identified in the first part (dose escalation) of the study.~During each 28 day study treatment cycle participants will take:~Talazoparib once daily.~Tazemetostat twice daily."
9689309|NCT04846335|Experimental|Active Bassado|patients with D178N/M129 mutation on prion protein will be treated with Bassad
9689310|NCT04846335|Placebo Comparator|Placebo|subject without the mutation will be treated with plac
9689311|NCT04846153|Other|Human-based Quantification|No intervention. No support tool will be used for quantifying airway stenosis from the bronchoscopic images collected previously.
9689312|NCT04846153|Active Comparator|Computer-based Quantifiction|Computer based support tool will quantifying airway stenosis from the bronchoscopic images collected previously.
9689313|NCT04846192||Patients|
9696169|NCT04769765|Experimental|All patients on the basic diabetic program, eligible for an individualized care pathway.|This research aims to demonstrate the feasibility of telemedicine through collaborative tele-expertise for the collegial definition of an individualized care pathway, in the context of diabetic patients with unscheduled hospitalizations repeated throughout the year (≥ 2/year). The feasibility will be assessed by the number of patients who have had at least 3 of the 4 planned follow-up visits, that is to say, who are eligible for the individualized care pathway.
9696170|NCT04769609||Concentrated growth factor (CGF) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CGF
9696171|NCT04769609||Collagen membrane (CM) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CM
9696172|NCT04769713|Experimental|Hepatic hilar nerve block in ablation patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
9696173|NCT04769713|Placebo Comparator|Placebo procedure in ablation patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
9696174|NCT04769713|Experimental|Hepatic hilar nerve block in chemoembolization patients|15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
9696175|NCT04769713|Placebo Comparator|Placebo procedure in chemoembolization patients|15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.
9696176|NCT04770038||Patient Group|60 BPD patients
9696177|NCT04770038||Control Group|30 Healthy participants
9696178|NCT04769791|Experimental|cuff inflation by the residual volume|LMA will be inserted with the initial inflating volume correspondent to residual volume group ( RV group): volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 ml syringe without plunger is connected to the laryngeal cuff for 5 minutes.
9696179|NCT04769791|Experimental|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group):
9696180|NCT04769791|Experimental|unchanged cuff inflation volume|LMA will be inserted with the initial inflating volume correspondent to unchanged volume group (NV group): LMA is unpacked and used without inflating or deflating the cuff.
9696181|NCT04769635|Experimental|CPAP ttt|
9696182|NCT04770025|Experimental|MI with tACS|Motivational interviewing with concurrent active stimulation
9696183|NCT04770025|Sham Comparator|MI with sham|Motivational interviewing with concurrent sham stimulation
9696184|NCT04770025|Active Comparator|MI-only|Motivational interviewing only, delayed treatment control
9696185|NCT04769583|Active Comparator|concomitant quadruple therapy (QC)|PPI (esomeprazole: 40 mg x 2 per day) with the amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day) for 14 days
9696186|NCT04769583|Placebo Comparator|triple therapy (TT)|PPI (esomeprazole: 40 mg x 2 per day) with amoxicillin (1 g x 2 per day) and clarithromycin (500 mg x 2 per day) AND PLACEBO for 14 days.
9696187|NCT04769622||patients affected by untreated Periodontitis|patients coming to the Unit of Periodontics at the University of Siena will be screened for the inclusion in the study. All patients eligible for the inclusion in the study will undergo non-surgical periodontal treatment and will be administered a questionnaire about lifestyles (adherence to mediterranean diet, sleep quality, physical activity, perceived stress). Patients will be then reevaluated at 3 months after the completion on non-surgical periodontal therapy.
9696188|NCT04769778|Experimental|Valsartan|Treatment with valsartan
9696189|NCT04769778|No Intervention|no treatment|no treatment received
9696190|NCT04769882|Active Comparator|Er:YAG laser therapy group|The removal of caries was performed with Er:YAG laser (Doctor Smile, Lambda SRL,Italy) with BOOST handpiece to cut the enamel and open the cavity, and 90° handpiece to remove the carious dentin with tips of 800 µ in diameter and 8 mm or 12 mm in length, in relation to the depth and distance of the lesion.
9696191|NCT04769882|No Intervention|Traditional therapy group|The removal of caries was performed with manual and rotating instruments, such as dentin spoon (ASA Dental S.p.a.), turbine (NSK Dental Italy S.r.l.) with diamond burs (Kerr Dental Italia S.r.l.) to cut the enamel and open the cavity and drill handpiece (KaVo Dental Italia S.r.l.) with tungsten carbide burs (Kerr Dental Italia S.r.l.) to remove the infected dentin.
10180400|NCT03793192|No Intervention|Enhanced Usual Care|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity.
10180401|NCT03793101||BiMICS 1.4|Group 1.4 - Patients operated with 1.4 mm BiMICS technique
10180402|NCT03793101||BiMICS 1.8|Group 1.8 - Patients operated with 1.8 mm BiMICS technique
9689314|NCT04846166||Control|
9689315|NCT04846166||Periodontitis|
9689316|NCT04846465||male|normal Sohag healthy male (≥18 & ≤ 60 years)
10180403|NCT03793361|Experimental|Arm A|Regorafenib
10180404|NCT03793361|Placebo Comparator|Arm B|Placebo
10180405|NCT03793231||Fungal Cases|Patients with confirmed invasive fungal infections according to internationally accepted criteria identified by active manual surveillance. Clinical data will be sent to fungalAi platform technology for disease classification.
10180406|NCT03793231||Control patients|Patients without invasive fungal infections.Clinical data will be sent to fungalAi platform technology for disease classification.
10180407|NCT03793127|Other|Young group|20-40 years of age
10180408|NCT03793127|Other|Old group|60-80 years of age
10180409|NCT03793270||patients|"1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).~drugs described in the clinic."
9689317|NCT04846465||female|normal Sohag healthy female (≥18 & ≤ 60 years)
9689318|NCT04846088|Experimental|Product usage order ABICHDGEF|Subjects will use each of the 9 products (ABICHDGEF) during a familiarization period, followed by a 3 hour Test Session
9689319|NCT04846088|Experimental|Product usage order BCADIEHFG|Subjects will use each of the 9 products (BCADIEHFG) during a familiarization period, followed by a 3 hour Test Session
10180410|NCT03793270||patients 2|2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
9689320|NCT04846088|Experimental|Product usage order CDBEAFIGH|Subjects will use each of the 9 products (CDBEAFIGH) during a familiarization period, followed by a 3 hour Test Session
9689321|NCT04846088|Experimental|Product usage order DECFBGAHI|Subjects will use each of the 9 products (DECFBGAHI) during a familiarization period, followed by a 3 hour Test Session
9689322|NCT04846088|Experimental|Product usage order EFDGCHBIA|Subjects will use each of the 9 products (EFDGCHBIA) during a familiarization period, followed by a 3 hour Test Session
9689323|NCT04846088|Experimental|Product usage order FGEHDICAB|Subjects will use each of the 9 products (FGEHDICAB) during a familiarization period, followed by a 3 hour Test Session
9689324|NCT04846088|Experimental|Product usage order GHFIEADBC|Subjects will use each of the 9 products (GHFIEADBC) during a familiarization period, followed by a 3 hour Test Session
9689325|NCT04846088|Experimental|Product usage order HIGAFBECD|Subjects will use each of the 9 products (HIGAFBECD) during a familiarization period, followed by a 3 hour Test Session
9689326|NCT04846088|Experimental|Product usage order IAHBGCFDE|Subjects will use each of the 9 products (IAHBGCFDE) during a familiarization period, followed by a 3 hour Test Session
9689327|NCT04846088|Experimental|Product usage order FEGDHCIBA|Subjects will use each of the 9 products (FEGDHCIBA) during a familiarization period, followed by a 3 hour Test Session
9689328|NCT04846088|Experimental|Product usage order GFHEIDACB|Subjects will use each of the 9 products (GFHEIDACB) during a familiarization period, followed by a 3 hour Test Session
9689329|NCT04846088|Experimental|Product usage order HGIFAEBDC|Subjects will use each of the 9 products (HGIFAEBDC) during a familiarization period, followed by a 3 hour Test Session
9689330|NCT04846088|Experimental|Product usage order IHAGBFCED|Subjects will use each of the 9 products (IHAGBFCED) during a familiarization period, followed by a 3 hour Test Session
9689331|NCT04846088|Experimental|Product usage order AIBHCGDFE|Subjects will use each of the 9 products (AIBHCGDFE) during a familiarization period, followed by a 3 hour Test Session
10180411|NCT03793270||healthy donors|3. Group 3: 30 healthy controls. No drugs.
10180412|NCT03793036|No Intervention|FAST group|preoperative fasting
10180413|NCT03793036|Experimental|CHO group|preoperative nutrition The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
9689332|NCT04846088|Experimental|Product usage order BACIDHEGF|Subjects will use each of the 9 products (BACIDHEGF) during a familiarization period, followed by a 3 hour Test Session
9689333|NCT04846088|Experimental|Product usage order CBDAEIFHG|Subjects will use each of the 9 products (CBDAEIFHG) during a familiarization period, followed by a 3 hour Test Session
9689334|NCT04846088|Experimental|Product usage order DCEBFAGIH|Subjects will use each of the 9 products (DCEBFAGIH) during a familiarization period, followed by a 3 hour Test Session
9689335|NCT04846088|Experimental|Product usage order EDFCGBHAI|Subjects will use each of the 9 products (EDFCGBHAI) during a familiarization period, followed by a 3 hour Test Session
9689336|NCT04846114|Active Comparator|Control group (Cg)|"The control group (Cg) comprised 20 procedures performed in patients not on OAT.~Buccal and palatal-lingual flaps were repositioned and sutured with simple stitches using 5/0 monofilament nylon yarn, and a dry gauze was applied for 30 minutes."
9689337|NCT04846114|Experimental|Tranexamic acid group (TXAg)|TXAg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound for 30 minutes using a gauze soaked in the contents of a 500mg ampoule of TXA, after which a new gauze soaked in the contents of a 500mg ampoule of TXA was applied for two hours.
9696192|NCT04769804||Patients with recurrent pityriasis versicolor|
10180414|NCT03793348|Experimental|Micro-exisional skin removal|Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.
10180415|NCT03793309|Experimental|Low dose|Subjects in this group receive 400 IU vitamin D daily for 4 weeks.
10180416|NCT03793309|Experimental|High dose|Subjects in this group receive 800 IU vitamin D daily for 4 weeks.
10180417|NCT03793322|Experimental|Indocyanine-Green(ICG) injection group|
10187508|NCT03725566|Experimental|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
10180418|NCT03793283||Continous Subcutaneous Insulin Infusion|"All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII.~Forty-five patients are actually treated with CSII in our hospital."
10180419|NCT03793283||Multiple dose insulin injections (MDI):|"Forty-five T1DM adult patients attended in Ciudad Real General University Hospital and treated with MDI.~MDI patients will be selected through simple random sampling (1:1) from our T1DM patient database."
9689338|NCT04846114|Experimental|Bismuth subgallate group (BSg)|BSg group comprised 20 procedures performed in patients OAT. At the moment of surgery, the contents of an anestube (1.8 ml) were mixed with a sufficient amount of BS powder to obtain a paste similar in consistency to tooth-paste (29). A thin layer of the paste was applied on the bone ridge, and buccal and palatal-lingual flaps were then repositioned and sutured as in the Cg. compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
9689339|NCT04846114|Experimental|Dry gauze group (DGg)|DGg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
9689340|NCT04846205||Patients who underwent a systematic etiological|Patients who underwent a systematic etiological assessment in the context of their cryptogenic ischemic stroke between 2015 and 2020. A collect data in medical record will be realized.
9689341|NCT04846075||Ramadan Group|Diurnal fasting and spiritual practices. Operationally assessed by the level of compliance to Sawm, Salat, and Zakat.
9689342|NCT04845906||Healthy volunteers|There will be 4 separate StatLock™ devices being tested, which will be randomly applied to the participants on their inner (ventral) forearms. Each participant will have 2 separate devices applied, one to each arm. Those participants who have the StatLock ™ Arterial Plus, StatLock™ Dialysis II, or the StatLock IV Select, will also have the foam strip applied.
9689343|NCT04846049||Comprehensive Care|"Veterans with complex medical conditions that may need more help. This intervention will provide extra care coordination after a complete assessment of their health.~Research team will assess veteran's memory, physical function, strength, balance, and from there, find the areas they need the most help with and coordinate services at home. This is in addition to their regular primary care provider."
9689344|NCT04846049||Standard Care|Veterans receiving standard of care
9689345|NCT04846023|Experimental|amplitude EEG (aEEG) via VEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes.
9689346|NCT04846062|Active Comparator|Intervention|Intervention arm will receive nutrition behavior Children's mothers/caregivers will receive explanatory education and behavior about micronutrient essentiality and utilization. Also, dietary diversification and demonstration in the process of enriching child complimentary food will be given for participants every month for the consecutive six months. Posters and video shows will be used.
9689347|NCT04846062|Active Comparator|control|Control arm will not receive nutrition behavior
9689348|NCT04845776|Experimental|Treatment Group|This group receives the vitamin/mineral supplement, ANRC Essentials Plus, for 3 months
9689349|NCT04846010|Active Comparator|antigen|The antigen is the cell that is destroyed by inflammation, which can perform as swollen, fatty, apoptosis, necrosis, and lethal pathological states. Some pathological cells can be saved and returned to customary conditions, like swollen, fatty, early apoptosis, but necrosis, lethal.
9689350|NCT04846010|Active Comparator|Internal environment|The internal environment is critical to the damaged cells recovering. Mainly it is covered by two major parts: metabolites and thrombus.
9689351|NCT04846010|Active Comparator|Communication between cells|The communication between organs, cells, helps the damaged cells recover and reduce symptoms.
9689352|NCT04846179|Experimental|Ginkgo biloba extract group|Group receiving ginkgo biloba extract supplementation
9689353|NCT04845971|Experimental|Adult male and female patients who are hospitalized with COVID-19-induced pneumonia.|Eligible patients will be treated with Saisei MAF capsules stronger version, oral administration 2-3 capsules, 3 times per day, 30 minutes before food or in the morning, afternoon and before bed time. The treatment duration will be 21 days. Patients are also provided with nutritional supplementation of Vitamin D3, 10.000 IU per day, monitoring the blood levels of such a vitamin. Efficacy and safety assessments will be performed on Days 0, 7, 14, 21, and 28.
9689354|NCT04845789||Family caregivers|Family caregivers who were main caregiver to the person with dementia and who spent at least 10 hours a week providing care to the person with dementia.
9689355|NCT04845698|Experimental|With i-Dashboard|Multi-disciplinary rounds are conducted with the assistance of i-Dashboard.
10180420|NCT03793296|Experimental|Paravalvular leak|After transcatheter- or surgical valve replacement
10180421|NCT03793244||Experimental: TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
10180422|NCT03793244||Active Comparator: TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
10180423|NCT03793153|No Intervention|Control|Standard Lower Segment Cesarean Section (LSCS) will be done.
10180424|NCT03793153|Active Comparator|Study|Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
10180425|NCT03792997|Active Comparator|control|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid
10180426|NCT03792997|Experimental|study|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid but the investigators add in this arm lipid emulsion & prednisolone & LMWH
10180427|NCT03793374||Axillary osmidrosis patients|Patients with axillary malodor and require surgical intervention. The subcutaneous apocrine glands shaving were used.
9689356|NCT04845698|No Intervention|Without i-Dashboard|Multi-disciplinary rounds are conducted without the assistance of i-Dashboard. The team members collect data using standard electronic medical records.
9689357|NCT04846101|Experimental|Anterior restorations using single shade OMNICHROMA composite|Anterior class III and Class IV cavities will be restored using single shade composite material according to standard protocols of etching, bonding and composite placement.
9689358|NCT04846101|Active Comparator|Anterior restorations using multi-shade composite|Shade selection for the tooth will be performed prior to the placement of the restoration. Anterior class III and Class IV cavities will be restored using multi-shade composite material according to standard protocols of etching, bonding and composite placement.
10180428|NCT03793075|Placebo Comparator|Propofol group (P)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of propofol 17 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
10180429|NCT03793075|Active Comparator|Ketamine group ((K)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of ketamine 5 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
10180430|NCT03793218|Experimental|Latera Device|The LATERA (Spirox Inc., Menlo Park, CA) device, an absorbable nasal implant comprised of a 70:30 blend of poly(L-lactide) and poly(D-lactide), is designed to provide support to the upper and lower lateral cartilages, thereby correcting nasal wall collapse. The implant was first used in the US and cleared by the FDA in 2016. It is designed as a ribbed cylindrical structure with a forked distal end. The implant is delivered endonasally, with a 16-gauge catheter, lateral to the upper and lower lateral cartilages and over the ascending process of the maxilla. The forked end rests on the ascending process of the maxilla and the flexible implant provides support the nasal sidewall soft tissue and cartilage. This non-toxic, biocompatible co-polymer has an extensive use in a variety of medical devices including suture materials and implants. In vivo studies demonstrate the copolymer to reliably decompose over an 18-24 month period.
10180431|NCT03793218|Active Comparator|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
9689359|NCT04845880|Other|SARS Cov_2 Incidence of Healthy Health Workers|
9689360|NCT04845867||Measurement and digital documentation|continuous measurement and digital documentation with alarms and display off
9689361|NCT04845737|Other|Fibromyalgia patient group|Sympathetic skin response measurements will be made in patients who meet the diagnosis criteria of fibromyalgia. Vitamin D levels will be measured and hemogram values will be checked in these patients.
9689362|NCT04845737|Other|Control Group|The participant in this group will be chosen from healthy volunteers. Sympathetic skin response will be measured of the participants. Vitamin D levels and hemogram values will be recorded.
9689363|NCT04845841|Experimental|Participants receive study medication on time point 1|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
9689364|NCT04845841|Experimental|Participants receive study medication on time point 2|Participants will receive two single doses of elinzanetant in two different treatments in a randomized sequence (Treatment A, Treatment B).
9689365|NCT04845607|Experimental|Prophylactic amiodarone|
9689366|NCT04845607|No Intervention|Conventional management|
9689367|NCT04846413||Patients|Patients affected by neurologic disorders showing a prominent voice impairment.
9689368|NCT04846361|Experimental|Hygiene wash plus metronidazole|Hygiene wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
9689369|NCT04846361|Placebo Comparator|placebo wash plus metronidazole|Placebo wash once daily at night for two weeks plus oral metronidazole 400mg three times daily for 1 week
10180432|NCT03793205|Experimental|Long-acting G-CSF group|Patients in long-acting G-CSF group accept long-acting with or without short-acting G-CSF.
9689370|NCT04846361|No Intervention|Healthy control|Asymptomatic healthy women with BV negative test
9689371|NCT04845659|Experimental|Intervention|Avatrombopaq administration
9689372|NCT04845724|Active Comparator|Standard Diet|The standard diet was based on the current dialysis diet sheet. The standard diet main meal contained a higher proportion of foods with a higher phosphorus to protein ratio (salmon and dairy), and foods with higher phosphorus bioavailability (cake). The diet was tailored for each participant to provide 1.1g protein/kg ideal body weight. The major differences between the diets were at the main meal.
9689373|NCT04845724|Experimental|Modified Diet|The modified diet, representative of the proposed modified phosphorus diet used food of lower phosphorus to protein ratio such as beef and less dairy. Approximately 30% dietary phosphorus in the modified diet came from foods with significant phytate content such as pulses, nuts and whole grains. The modified diet was tailored for each participant to provide 1.1g protein/kg ideal body weight.
9689374|NCT04845672|Experimental|2% chlorhexidine gluconate|4% Chlorhexidine gluconate solution and one to one water will be used to create a 2% Chlorhexidine gluconate solution.
9689375|NCT04845672|Active Comparator|soap-free body cleaning solution|It supports and protects the natural barrier function of the skin's natural protective layer.
9689376|NCT04845802|Experimental|Training Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily [morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
9689377|NCT04845802|Sham Comparator|Sham Group|Dancers in this group will perform inspiratory muscle training for 30 breaths, twice daily [morning: between 7:00 and 13:00 and evening: between 16:00 and 22:00], 7 days per week for 8 weeks, with a breathing frequency of 15 breaths per minute and a duty cycle of 0.5. One exercise session will be supervised in a clinic per week, other sessions will be performed at home in every week during the training.
9689378|NCT04845750|Experimental|Rodeo Micro Mapping Catheter|Determination of pulmonary vein isoation during cryoablation procedure
9689379|NCT04845763||Intervention|Each patient complete the french version of the QoR-15 score (FQoR-15) at 3 times (before surgery, on Day 1, on Day 2).
9696193|NCT04769804||Healthy age and sex-matched controls|
10180433|NCT03793205|Experimental|Short-acting G-CSF group|Patients in long-acting G-CSF group only accept short-acting G-CSF.
10180434|NCT03793114|Experimental|Detectable levels of adrenal hormones|Patients with detectable serum levels of adrenal hormones will go through cosyntropin stimulation testing.
9689380|NCT04845646|Experimental|ASC41 + Itraconazole group|"ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 11.~Itraconazole oral capsule 200 mg po qd (2 capsules given 1x/day or 200 mg/day) on days 6-16."
9689381|NCT04845646|Experimental|ASC41 + Phenytoin group|"ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 19.~Phenytoin oral capsule 300 mg (100 mg 3 x/day) on days 6-19."
9689382|NCT04845646|Experimental|ASC41 group|(1) ASC41 5 mg po. One 5 mg ASC41 tablet on day 1.
9976247|NCT01349517|Other|Three-incision esophagectomy group|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
9689384|NCT04845711|Placebo Comparator|Control group|patients will receive general anesthesia only.
9689385|NCT04845711|Experimental|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
9689386|NCT04845711|Experimental|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
9689387|NCT04846387||Females with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A urinary pouch will be used to collect the participant's urine while in the scanner."
9689388|NCT04846387||Males with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A condom catheter will be used to collect the participant's urine while in the scanner."
9689389|NCT04845594|Experimental|MySmileBuddy|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will receive a family-focused intervention called MySmileBuddy.
9689390|NCT04845594|No Intervention|Control|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will not receive any intervention.
9689391|NCT04845633|Other|Healthy children using conventional toothbrush|
9689392|NCT04845633|Experimental|Healthy children using toothbrush with Customized Handle|
9689393|NCT04845633|Other|Children with Down syndrome using conventional toothbrush|
9689394|NCT04845633|Experimental|Children with Down syndrome using toothbrush with Customized Handle|
9689395|NCT04845555||Patients with hemophilia A|Patients suffering from moderate or severe hemophilia A (FVIII <5%) over the age of 12 years.
9689396|NCT04845542|Experimental|ReStoreD|8-week intervention that is remotely delivered, consisting of psychoeducation and positive psychology activities. Participants complete two activities individually and two together each week.
9689397|NCT04845542|No Intervention|Waitlist-control|Participants will be waitlisted for 8 weeks.
9689398|NCT04845230|Active Comparator|Enhanced Usual Care|"The control group in this study will still receive some services above and beyond the usual standard of care offered to pregnant women on Medicaid. In addition to the case management services offered through their managed care provider, Operation Food Search will offer this group access to the hunger hotline, a service provided by Operation Food Search to help them find food assistance around St. Louis; assistance in enrolling in public nutrition assistance programs like SNAP and WIC; and guidance on food pantry access in St. Louis."
9689399|NCT04845230|Experimental|Treatment 1: Nutrition Services|"This treatment group will receive all the services offered to the control group, as well as the following services:~Weekly food deliveries of fresh food meal kits with step-by-step recipes from the time of program enrollment through 60 days post-partum. Access to necessary cooking tools for their kitchen (e.g., spatulas, cutting boards , etc.), should they need them. Access to online cooking resources to help guide them on culinary skills and recipe preparation. Nutrition education and counseling provided by a registered dietitian."
9689400|NCT04845230|Experimental|Treatment 2: Integrated Care Services|This treatment group will receive all the services offered to Treatment Group 1, as well as the services of a Licensed Masters Social Worker who will provide trauma-informed integrative care services to participants. These services will focus on an array of potential needs that may emerge in participants' lives, such as assistance in finding stable housing, assistance navigating social services, connections with other community organizations, and other needs.
9689401|NCT04845256||SOMAVAC 100 Sustained Vacuum System|New sustained vacuum system
9976248|NCT01349517|Other|Ivor-Lewis esophagectomy group|The patients in this group would underwent Ivor-Lewis esophagectomy
9976249|NCT01349517|Other|Sweet esophagectomy group|The patients in this group would underwent Sweet esophagectomy.
9689404|NCT04845464||Study Group|A group of young adults aged between 18 to 25
9689405|NCT04845503|Experimental|MR-guided Radiotherapy (5 x 7,5 Gy)|5 x 7,5 Gy prescribed on the PTV
9976250|NCT01349530|Experimental|Anticoagulation clinic care|Monitoring by CREATIF
9976251|NCT01349530|Active Comparator|Usual care|Monitoring by GP.
9976252|NCT01349543|Experimental|Viral Challenge|
9976253|NCT01349556|Experimental|Tretinoin pre-treatment|
9976254|NCT01349582|Active Comparator|flow diversion|
9976255|NCT01349582|Active Comparator|Best standard treatment|
9689406|NCT04845243|Other|Emotion recognition training|All participants have to complete the online emotion recognition training E.V.A. as well as the pre- and post training tasks: GERT and social decision making task.
9689407|NCT04845477|No Intervention|internal hip rotation pre measurement|with knee and hip flexion at 90º, internal hip rotation will be performed
10180435|NCT03793114|Active Comparator|Controls with undetectable hormone levels|Twenty patients without detectable serum levels of adrenal hormones will serve as controls in cosyntropin stimulation testing.
10180436|NCT03793114|No Intervention|Undetectable levels of adrenal hormones|Patients without detectable serum levels of adrenal hormones. Cosyntropin stimulation testing will not be performed.
10180437|NCT03793114|Other|Congenital adrenal hyperplasia (CAH) control group|Mapping adrenal steroid profile in patients with congenital adrenal hyperplasia (CAH) with confirmed total deficiency of 21-hydroxylase.
9689408|NCT04845477|Experimental|internal hip rotation post experimental application measurement|with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
9689409|NCT04845477|Placebo Comparator|internal hip rotation post placebo application measurement|with Placebo tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
9689410|NCT04845204|Active Comparator|Relaxation Treatment|Relaxation treatment (RT) is applied additional to standard physiotherapy treatment. RT includes 8 sessions (2 times a day, for four days after surgery) of relaxation exercises.
9689411|NCT04845204|Active Comparator|Standard Exercises|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
9689412|NCT04845399|Experimental|Arm 1|Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.
9689413|NCT04845334|Experimental|Clinical RR intervention|Clinical RR intervention
9689414|NCT04845334|No Intervention|Standard care|Standard care
9689415|NCT04845412||Children of GDM parents|Children of mothers who have gestational diabetes mellitus
9689416|NCT04845412||Children of non-diabetic parents|Children of mothers without diabetes
9689417|NCT04845529|Experimental|1 tDCS Parietal|Anodal tDCS applied to the right inferior parietal cortex
9689418|NCT04845529|Experimental|2 tDCS Frontal|Anodal tDCS applied to the medial frontal cortex
9689419|NCT04845529|Sham Comparator|3 Sham|Sham tDCS (control, no stimulation delivered). Following a standard sham protocol, in this condition the tDCS will be active the first 30seconds and the last 30seconds of the session, but silent during the other 19minutes
9689420|NCT04845360|Experimental|pregnancy and differences in gender can be found in the radial arterial pulse|Establishing the meridian through harmonics of blood pressure waves could be a powerful tool to qualitatively and quantitatively indicate physiologic and pathologic factors.
9689421|NCT04845295|Experimental|Fast Tempo|Performed training intervention with a tempo of 1 second for eccentric and 1 second for concentric phase
9689422|NCT04845295|Experimental|Slow Tempo|Performed training intervention with a tempo of 4 seconds for eccentric and 1 second for concentric phase
9689423|NCT04845373|Experimental|Mediterrenean diet|Mediterranean diet:Target macronutrient energy contributions were 40% from carbohydrate, 35%-40% from fat (with <10% of energy as saturated fat), and 20% of energy as protein.Participant in this group were trained to consume fish, legumes at least 2-3 times a week, walnuts and olive oil every day in accordance with the Mediterranean diet model.
9689424|NCT04845373|Active Comparator|Low fat diet|Low fat diet:Target macronutrient energy contributions for the low fat diet diet were 50-60% from carbohydrate, <30% from fat (with <10% of energy as saturated fat), and 20% from protein.Participants in this group were especially recommended to consume low-fat foods.
9689425|NCT04845386||TOF Cuff on arm and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
9689426|NCT04845386||TOF Cuff on lower leg and TOF Scan on adductor pollicis|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
9689427|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on toe|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
9689428|NCT04845386||TOF Scan on adductor pollicis and TOF Cuff on arm|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
9689429|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
9689430|NCT04845438|Active Comparator|hand-sewn gastroenteroanastomosis|
9689431|NCT04845438|Active Comparator|stapler gastroenteroanastomosis|
9689432|NCT04845100|Experimental|Intervention|"The Effect Of Animal Assisted Activities On The Stress And Social Anxiety Levels Of Disabled Children~Animal Assisted Activity Program (HayDAP)"
9689433|NCT04845100|Other|Control group|No intervention
9689434|NCT04845217|Experimental|Peppermint Oil|Participants in the intervention (peppermint oil) arm will receive soft gels of enteric-coated peppermint oil (0.2mL=200mg). The enteric coated peppermint oil soft gel utilized in this study is Peptogest Peppermint Oil from Schwabe North America (Nature's Way Brand).
9827601|NCT02461745|Active Comparator|Genotype 1b|Study participants with chronic Hepatitis C Genotype 1B receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) for 12 weeks.
10180438|NCT03793114|Other|Bilaterally adrenalectomized control group|Mapping adrenal steroid profile in patients who are bilaterally adrenalectomized.
10180439|NCT03793114|Experimental|Diurnal variation in residual adrenocortical hormone levels|Patients with detectable serum levels of adrenal hormones will go through a 30-hour ambulatory sampling of interstitial fluid for mapping of any diurnal variation in endogenous adrenocortical secretion.
9689435|NCT04845217|Placebo Comparator|Coconut Oil|Participants in the placebo (coconut oil) arm will receive soft gels of enteric coated coconut oil. The enteric coated coconut oil soft gel utilized in this study is Coconut Oil from Schwabe North America (Nature's Way Brand).
9689436|NCT04845139|Experimental|Nivolumab administration|Nivolumab administration Q2W intrathecally by lumbar punctuation
9689437|NCT04845048||Health care professionals between 18 and 59 years old|
9689438|NCT04845048||General population 75 years old or more|
10180440|NCT03793114|Experimental|Repeated cosyntropin testing in newly diagnosed patients|Newly diagnosed patients will be invited to go through repeated cosyntropin testing to delineate the natural progression of adrenocortical failure.
10180441|NCT03793114|Active Comparator|Cardiovascular and inflammatory biomarkers|Compare cardiovascular and inflammatory biomarker profiles in patients with and without residual production of adrenocortical steroids
9689439|NCT04845048||General population 60 and 74 years old|
9689440|NCT04844996|Experimental|Ezetimibe group|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the 9 rats in the ezetimibe group for 28 days postoperatively.
9689441|NCT04844996|Placebo Comparator|Control groups|The endometriosis model was developed surgically in all 18 rats and pretreatment sizes of the endometriotic explants were measured. After randomization saline (1 ml/kg/day) was administered orally with gavage methodology to the 9 rats in the control group for 28 days postoperatively.
9689442|NCT04845009|Experimental|progressive muscle relaxation|progressive muscle relaxation tape guided
9689443|NCT04845009|Placebo Comparator|usual care|usual care
9689444|NCT04845087|Experimental|Trial Group|Patients from this group will receive treatment with ozonized water.
9689445|NCT04845087|Placebo Comparator|Placebo Group|Patients from this group will receive placebo with water.
9689446|NCT04845061|Placebo Comparator|nebivolol then placebo|Comprises15 copd patients, after recruitment in study and written informed consent, patient's administered nebivolol (1.25 mg for one week then2.5mg fore another one week and 5 mg at 8am for 10 weeks)and washout period4 weeks then shifted to placebo for 12 weeks
9689447|NCT04845061|Active Comparator|placebo then nebivolol|Contain 15 copd patient's after recruitment and Written informed consent administered placebo for 12 weeks and washout period for 4 weeks then shifted to nebivolol for 12 weeks
9689448|NCT04844879|Experimental|Single-arm|Patients suitable to receive Medacta GMK® Sphere system for primary TKA will be invited to take part to the study during the preoperative visit. Follow-ups are performed after 2, 6 and 12 months. Data collection includes clinical and radiological data for preoperative and postoperative assessments, as well as intraoperative details.
9689449|NCT04844853|Experimental|Preterm 2|2-year-olds born prematurely
9689450|NCT04844853|Experimental|Term 2|2-year-olds born at term
9689451|NCT04844853|Experimental|Typical 6|6-year-olds with typical developement
9689452|NCT04844853|Experimental|NDD 6|6-year-olds with neurodevelopmental disorders
9689453|NCT04844827||malignant pleural effusion|Patients with malignant pleural effusion who underwent pleural biopsies and blood tests under general anesthesia
9689454|NCT04844814|Experimental|Anakinra|Anakinra 100 mg/d+Placebo of Prednisone
9689455|NCT04844814|Active Comparator|Prednisone|Prednisone 30 mg/d+Placebo of Anakinra
9689456|NCT04844775|Experimental|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"0.1mL of DREP-HIV-PT1 will be diluted with saline (Sodium Chloride for Injection, 0.9%) and administered intramuscularly (total volume of 0.5mL) in the LEFT deltoid muscle using a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
9689457|NCT04844775|Experimental|Drep-HIV-PT1 1.0mg and CN54gp140/MPLA-L|"0.5mL of DREP-HIV-PT1 will be administered intramuscularly in the LEFT deltoid muscle using the a needle-free device (Pharmajet Stratis®)~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
9689458|NCT04844775|Experimental|DNA HIV PT123 4mg and CN54gp140/MPLA-L|"1ml of DNA-HIV-PT123 will be injected into the LEFT deltoid muscle using a needle and syringe.~0.4mL of MPLA-L from a vial containing 0.55mL of MPLA-L (25µg/mL) and add this to a vial containing 0.35mL of CN54gp140 (500µg/mL). The vial contents will be mixed by gentle agitation and 0.45mL of will be withdrawn from the vial to make a concentration of 100µg CN54gp140 and 5µg MPLA-L . The combined products will be injected into the RIGHT deltoid muscle using a needle and syringe."
9689459|NCT04844580|Placebo Comparator|Standard Treatment + Placebo|Standard medical treatment, as deemed appropriate by physicians, is going to be according to the Turkish Republic COVID-19 (SARS-CoV-2 INFECTION) ADULT PATIENT TREATMENT GUIDELINES published by the Ministry of Health, General Directorate of Public Health. The management of all additional complications and / or symptoms that develop in patients will be managed in the same way as specified in these guidelines. If these guidelines are changed by the Turkish Republic Ministry of Health General Directorate of Public Health, a protocol amendment will be planned. The necessary changes within the scope of urgent security measures will be reflected in the standard treatment in accordance with the necessary regulations.
10180442|NCT03792867|Experimental|Radical Resection and HIPEC|
10180443|NCT03792776|Active Comparator|Air|Endotracheal tube cuff inflation with air
10180444|NCT03792776|Experimental|Lidocaine 1%|Endotracheal tube cuff inflation with Lidocaine 1%
9689460|NCT04844580|Experimental|Standard Treatment + Inhaled Aviptadil|In addition to the standard medical treatment mentioned above, patients randomized to this arm will be given Inhaled Aviptadil 2 times a day, 30 minutes apart. Aviptadil treatment is aimed to be a minimum of 7 days and a maximum of 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. The dose of inhaled Aviptadil was determined by evaluating the results of the Phase 1 and Phase 2 studies.
10180445|NCT03792776|Experimental|Lidocaine 2%|Endotracheal tube cuff inflation with Lidocaine 2%
10180446|NCT03792893|Experimental|Higher Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
9689461|NCT04844801|Active Comparator|Risk control strategy|Magnesium sulfate + control of the modifiable NOSVA risk factors
9689462|NCT04844801|Active Comparator|Rate control strategy|"Risk-control + low-dose amiodarone"
9689463|NCT04844801|Active Comparator|Rhythm control strategy|"Risk-control + high-dose amiodarone +/- electrical cardioversion"
9689464|NCT04844710|Experimental|Treatment|Manual acupuncture and standard care
9689465|NCT04844710|Other|Control|Standard care only
9689466|NCT04844645|Experimental|a mini program trial group|Pharmacists conducted a standardized education session to teach the participants how to operate the mobile phone, use mini program, assess pain. The participants in the trial group were asked to complete initial and final pain assessment questionnaires and Medication compliance on the mobile phones provided to them. Participants were encouraged to use mini program as much as possible to record their pain status.
9689467|NCT04844645|Sham Comparator|a control group|The control group received conventional pharmaceutical care. Initial and final pain and Medication compliance data were collected. Before the patient was discharged from the hospital, the clinical pharmacist conducted detailed medication education (including medication methods, prevention and treatment of adverse reactions, and precautions) and asked the patient to attempt to maintain a paper version of the pain diary.
9689468|NCT04844385|Experimental|Toripalimab plus Paclitaxel/Nedaplatin followed by concurrent chemoradiotherapy|Patients in experimental group receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, then followed by daily simultaneous modulated accelerated radiotherapy combined with Capecitabine.
9689469|NCT04844489|Other|Blood samples|
9689470|NCT04844398|Experimental|Clown visits (four times)|Children and adolescents in psychiatric care participate in clown visits in a group setting on a weekly basis over four consecutive weeks.
9689471|NCT04844502|No Intervention|Control Group|Frequent life activities.
9689472|NCT04844502|Experimental|Intervention Group|Protocol of physical exercises
9689473|NCT04844437||Digital examination of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by digital examination and fetal head station evaluated by two clinicians.
9689474|NCT04844437||Transperineal assessment of fetal head decent in pregnant women|Pregnant women at 36 weeks or over gestational age in the active phase of the first stage or second stage of labor were examined by transperineal ultrasound and fetal head station evaluated by two experienced clinicians.
9689475|NCT04844151||Acute myocarditis|Patients hospitalized for an acute myocarditis.
9689476|NCT04844112|Experimental|Experimental arm|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
9689477|NCT04844008|Experimental|Nanobubble|Sports drink nanobubble drink
9689478|NCT04844008|Placebo Comparator|control|Flavoured drink- no active ingredients
9689479|NCT04844164|Experimental|Cushing's Disease|
9689480|NCT04844164|Experimental|Acromegaly|
9689481|NCT04844164|Experimental|Diabetes Mellitus Type 1|
9689482|NCT04844164|Experimental|Primary Hyperparathyroidism|
9689483|NCT04844164|Experimental|Control group|
9689484|NCT04844203||Patients with unsteadiness|Patients with unsteadiness referred for an ENMG
9689485|NCT04844333|Experimental|Extubation under deep anesthesia|When the patient is in sedation or anesthesia state, including no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, stable circulation, the endotracheal tube is removed.
9689486|NCT04844333|No Intervention|Awake extubation|When the patient is in awake state, including bispectral index >70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 < 45mmhg, regular waveform, the cough and swallowing reflex are obvious and the circulation is stable, the endotracheal tube is removed.
9689487|NCT04844086|Experimental|Infusion RPM CD19-mbIL15-CAR-T cell|"In this study, anti-CD19 autologous chimeric antigen receptor T-cells infusion produced by rapid personalized manufacture are used to treat patients with relapsed/refractory Advanced Lymphoid Malignancies.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to RPM CD19-mbIL15-CAR-T cell infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
9689488|NCT04844320|Active Comparator|> 50 %EWL|Postoperative weight loss in first year > 50 % EWL
9689489|NCT04844320|Active Comparator|50 - 25 % EWL|Postoperative weight loss in first year 25 - 50 % EWL
9689490|NCT04844320|Active Comparator|< 25 % EWL|Postoperative weight loss in first year < 25 % EWL
9689491|NCT04844242||Group 1|Prior SARS-CoV2 infection as defined by being positive for IgG
10180447|NCT03792893|Experimental|Lower Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
10180448|NCT03792828|Active Comparator|Control|Duloxetine HCl 30mg is not used.
10180449|NCT03792828|Experimental|Duloxetine|One capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.
9689492|NCT04844242||Group 2|COVID-19 disease as defined as children positive by RT-PCR
9689493|NCT04844242||Group 3|Children with MIS-C according to the WHO or CDC criteria
10180450|NCT03792724|Experimental|Cohort A|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg every 4 weeks (Q4W) from Cycle 3 and beyond
9689494|NCT04844242||Group 4|Control children who are negative for both RT-PCR and antibody
9689495|NCT04844190|Experimental|Addition of ADM and EndoFLIP to pre-G-POEM evaluation|During the preoperative upper endoscopy, the EndoFLIP catheter is inserted through the mouth with endoscopic guidance and placed through the gastric pylorus. Once deployed, water is sequentially added at set volumes to a balloon that can be used to measure pyloric diameter, cross-sectional area, pressure, and distensibility at set volumes of 30, 40, and 50 mL for at least five seconds. We will record this data for each patient. The EndoFLIP catheter will then be removed. Subsequently, a high resolution ADM catheter will be inserted through the nose and placed through the pylorus to measure baseline intragastric, transpyloric, and intraduodenal pressures. The patient will be observed for up to four hours to assess a migrating motor complex (MMC). After the MMC is observed, the patient will be given a meal and observed for meal response with the manometry catheter. The meal will be water and two pieces of toast/bread. Following the meal, the catheter will be removed.
10180451|NCT03792724|Experimental|Cohort B|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg Q4W from Cycle 3 and beyond
9696194|NCT04769999|Experimental|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
9696195|NCT04769752||No beta-blocker|Patient do no treat with beta-blocker before the surgery
9696196|NCT04769752||Beta blocker|Patient treat with beta-blocker in accordance to international guidelines
9696197|NCT04769752||Beta blocker2|Patient treat with beta-blocker without respect of international guidelines
9696198|NCT04769830||AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
9696199|NCT04769830||non-AGI group|Collect the characteristic data of intestinal sound, such as 24-hour average intestinal rate, duration of gastrointestinal sound, amplitude, maximum frequency, average frequency, etc., and detect citrulline, intestinal fatty acid binding protein and so on.
9696200|NCT04769362|Experimental|β-blocker discontinuation arm|Discontinuation of β-blocker therapy after at least 1 year of β-blocker therapy after acute myocardial infarction
9696201|NCT04769362|No Intervention|β-blocker maintenance arm|Continuation of β-blocker therapy after acute myocardial infarction
9696202|NCT04769258||Patients with IBD treated with immunomodulatory drugs|
9696203|NCT04769258||Patients with IBD not treated with the immunomodulatory drugs|
9696204|NCT04769297|Experimental|Sublingual Micro-Dose Ketamine|Ketamine micro-dose 37.5mg compounded sublingual daily administration
9696205|NCT04769076|Experimental|Paclitaxel(Album-bound)|Subjects will receive neoadjuvant therapy with paclitaxel (albumin-bound) combined with cisplatin and PD-1 inhibitor (sintilimab) as well as radical concurrent radiotherapy and chemotherapy.
9696206|NCT04769219|Experimental|secondary prevention training|Secondary prevention training will be given to 43 randomly selected patients between the fourth and sixth hours after AMI (in accordance with the patient's request). Secondary protection training will be carried out in two parts. First of all, the anatomical structure and functions of the heart, the definition of AMI, its causes, symptoms and risk factors will be explained, and then the issues to be considered after AMI will be explained. The content of the training will also be given to the participants in a written booklet.
9696207|NCT04769219|No Intervention|nursing care|43 randomly selected patients will form the control group and this group will be provided with routine care and follow-up in the clinic. No intervention will be made.
9696208|NCT04769063|Experimental|Hip|
9696209|NCT04769063|Experimental|Knee|
9696210|NCT04769063|No Intervention|Control|
9696211|NCT04769193|Experimental|Adipeau face cream|Cosmetic cream
9696212|NCT04769141||Hypertension patients|a prospective 4-month, cohort feasibility study will evaluate blood pressure (n=20) using the CURATE.AI platform.
9696213|NCT04769141||Diabetic patients|a prospective 4-month, cohort feasibility study will evaluate glycaemic (n=20) control using the CURATE.AI platform.
9696214|NCT04769037|Active Comparator|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
9696215|NCT04769037|Placebo Comparator|Placebo|Lactose identical in appearance and taste to the active supplement
9696216|NCT04769115|Other|Response to Alerts|Monitor patients daily for response to temperature changes and provide referral to doctor as needed
9696217|NCT04769102|Experimental|Spastic Cerebral Palsy|spastic Cerebral palsy children will be adapted in adaptive seat with flat and then Contoured cushions while kinematic changes of upper limb reaching movement are monitored through video capture with kinovea 2D software motion analysis system.
10180452|NCT03792789|Experimental|mCIMT with real rTMS|Modified Constraint Induced Movement Therapy (mCIMT) with real Repetitive Transcranial Magnetic Stimulation (rTMS). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with real rTMS over contralateral primary motor cortex.
9696218|NCT04769440|Active Comparator|M group (Mg sulphate )|patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes
9696219|NCT04769440|No Intervention|C group (control )|patients will receive 100 ml of normal saline intravenously over 30 minutes followed by saline infusion for 90 minutes
9696220|NCT04769271|Active Comparator|Scaling and Root Planing (SRP)|
9696221|NCT04769271|Experimental|Scaling and Root Planing with tea tree oil|
9696222|NCT04769024|Active Comparator|LUMEEN activities|Participants will benefit from LUMEEN activities for 8 weeks (2 session/week)
9696223|NCT04769024|Sham Comparator|USUAL activities|Participants will benefit from the thematic group workshops for 8 weeks (2 sessions/week)
9696224|NCT04769505|Experimental|Intervention group|Participants receive a digital mindfulness-based intervention (MBI) + treatment as usual.
9689496|NCT04844177|Experimental|intervention/treatment|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~Cyclophosphamide 120 mg/kg (days -5, -4, -3)~Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~Melphalan 180 mg/m2 (day -2)~Rituximab 100 mg/m2 (day -1)~Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
9689497|NCT04844294|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|
9689498|NCT04844294|Active Comparator|Present-Centered Therapy (PCT)|
9689499|NCT04844216|Experimental|Nasolabial fold treated with experimental device|"STYLAGE® L Lidocaine is a hyalorunic acid injectable gel whose intended purpose is the filling of skin depressions on the face by dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
9689500|NCT04844216|Active Comparator|Nasolabial fold treated with comparator|"The active comparator is a hyalorunic acid injectable gel whose intended purpose is the filling of mid and/or deep depressions of the skin via mid and/or deep dermal injection.~Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 1 month after on the same nasolabial fold (touch-up)."
9689501|NCT04844060||Patients with cognitive impairment|All patients with cognitive disorders observed at the memory center of Strasbourg and in whom a lumbar puncture is performed as part of the patient's diagnosis.
9689502|NCT04844255|Other|Pre and post intervention group|Same individuals are examined before and after taking 2 tablets of salt
9689503|NCT04844125|Experimental|SHR-1209|
9689504|NCT04844125|Placebo Comparator|SHR-1209 Placebo|
10180453|NCT03792789|Sham Comparator|mCIMT with sham rTMS|Modified Constraint Induced Movement Therapy with sham Repetitive Transcranial Magnetic Stimulation (using sham coil). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with sham rTMS over contralateral primary motor cortex using sham coil which simulated sound and touch of real coil but has no electro-magnetic waves.
10180454|NCT03792971|Experimental|Fixed Sequence|
10180455|NCT03792646|Experimental|Experimental|The experimental group will inject 20 grams of whey protein diluted in water after the exercise training.
10180456|NCT03792646|Placebo Comparator|Placebo|The placebo group will inject 20 grams of maltodextrin diluted in water after the exercise training.
10180457|NCT03792698|Experimental|Aidcube utilization|"Aidcube is a fully customizable, commercially available digital app-based platform to deliver home-based pulmonary rehabilitation for patients. On the patient-facing side, patients can view their daily exercise prescription, descriptions and videos demonstrating correct execution of the exercises, document completion of exercises, and message their health-care provider. On the provider-facing side, from over 150 available exercises, surveys, and activities, providers can design a fully-customized exercise prescription. Based on real-time patient feedback, the exercise prescription can be progressed (i.e., advanced and/or modified) by adding repetitions or time to specific exercises or adding new activities. The provider can also message the patient from within the Aidcube environment."
10180458|NCT03792984|Placebo Comparator|Metformin + Placebo|
9689505|NCT04843865|Experimental|Chinese Herbs|Participants received standardized Chinese Herbs treatment orally twice daily for 1 week.
9689506|NCT04843930|Experimental|AKL-T01 Intervention|Participants in the experimental group will complete 6 weeks of the AKL-T01 intervention. Participants enrolled in the intervention arm will play the game via an iPad application for 20-25 minutes daily for at least 5 days a week (but up to 7 days a week). Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms and gameplay adherence.
9689507|NCT04843930|No Intervention|Waitlist Control|Participants in the Waitlist Control arm will not be engaging in any active control condition. Participants in the waitlist control arm will continue any ongoing self- or provider-based cognitive intervention (or no intervention) during the initial 6-week waitlist period. Participants will also have weekly check-in visits via phone or a secure HIPAA compliant videoconferencing platform (Zoom) with a care manager, who will monitor mood symptoms. The control arm will be offered the intervention at the end of 6 weeks waitlist period to ensure all participants ultimately have access to the intervention.
9689508|NCT04844047|Active Comparator|FAST|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in the community. Participants attended a 30-minute fall prevention education session once per week. FAST followed the same principles as Standard, with the addition of the following goals: 1) Increase UE strength (shoulder girdle/arm) utilizing both concentric and eccentric contractions, 2) Improve trunk and neck postural control during slow and fast body motions, 3) Optimize forward descent strategies via practice of quick response reaching, landing and controlled descent with hands on the wall or on the floor as able. Training progression for strength and body control included increasing the distance standing from the wall, progressing to one arm descents, increasing reps and speed and moving to greater gravity and body weight resistance such as hands and knees position on the floor as able. Quick movement practice targeted unexpected reaching activities, balloon and ball toss
9696225|NCT04769505|No Intervention|Wait list control group|Participants receive treatment as usual during the intervention period. They are provided with the digital mindfulness-based intervention (MBI) after their study completion.
9696226|NCT04769167|Placebo Comparator|Healthy Non Pregnant Women (HNPW)|HNPW are healthy women and not pregnant
10180459|NCT03792984|Experimental|Calcium carbonate + Vitamin D3 + Metformin|
10180460|NCT03792802|Active Comparator|classic port sites|. Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent
10180461|NCT03792802|Active Comparator|same dermatome port sites|One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port.
10180462|NCT03792815|Experimental|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2
10180463|NCT03792685|Experimental|Normal weight|Normal weight men. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
10180464|NCT03792685|Experimental|Overweight/obesity|Men with overweight or obesity. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
9689509|NCT04844047|Placebo Comparator|Standard|Twice per week exercise program, 45 minutes duration for 12 weeks conducted in a community site (assisted living residence). Participants also attended a 3o minute fall prevention education session once per week. The Standard intervention consisted of a fall prevention exercise program designed for community-dwelling older adults. Exercises focussed on balance, leg strength, walking and mobility exercises designed to decrease fall risk.
9689510|NCT04844229|No Intervention|Control group|21 patients will receive conservative management for PDPH in the form of oral paracetamol 1000 mg/8hours, and caffeine 300-500 mg/day, 1000 mL 0.9% normal saline infusion over the initial 4 hours with increasing oral fluids and bed rest to be maintained. After 6 hour of starting treatment if the above measures failed to control pain with the VAS ≥ 4 non-steroidal anti-inflammatory drugs (NSAID) will be added in the form of ketorolac 30 mg IV which can be repeated every 12 hours if needed. Participants will be followed up after 1 hour, 6 hours and 24 hours with assessment of VAS score, modified Lybecker clas¬sification score and TCD parameters. EBP will be considered after 24 hours of treatment if pain still not controlled with VAS ≥ 4 and modified Lybecker clas¬sification score ≥ 2 and after patients' consent.
9689511|NCT04844229|Active Comparator|Interventional group|"21 patients will receive the same conservative management as in control group together with bilateral transnasal sphenopalatine ganglion block.~After one hour Participants who will show improvement in pain scores will be followed up after 6 hours and 24 hours, while, patients who will show persistent headache will be subjected for bilateral ultrasound guided greater occipital nerve block.~then these patients will be assessed after 1 h, 6 h, and 24 h of the block. If still suffering epidural blood patch will be indicated and performed after gaining patients' consent."
9689512|NCT04843748|Experimental|single arm|single arm open label study
9689513|NCT04844099|Experimental|Intervention arm|The intervention will be oral dihydroartemisinin (20mg) and piperaquine (160 mg) and administered once weekly at approximate doses of dihydroartemisinin 2.5mg/kg/day and piperaquine 20mg/kg/day based on participants' weight categories
10180465|NCT03792685|Experimental|Diabetes|Men with prediabetes or type 2 diabetes mellitus. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
10180466|NCT03792932|Active Comparator|Laparoscopic distal pancreatectomy|
9689514|NCT04844099|Active Comparator|Comparator|The active control will be Sulphadoxine-Pyrimethamine (SP), the current standard of care for malaria chemoprevention for SCA in Uganda and Malawi. This will also be provided by Guilin Pharmaceutical Co. Ltd as their generic World Health Organization-approved sulphadoxine-pyrimethamine 500/25mg tablets. It will be administered as monthly single-day courses of SP at approximate doses of S=25mg/kg and P=1.25mg/kg.
9689515|NCT04843956|Experimental|Patients with solid pancreatic lesions|Patients who will undergo endoscopic ultrasound biopsy. Samples of at least 3 passes will be obtained, each pass obtained with a different technique (capillary with suction, capillary without suction and wet suction)
9689516|NCT04843969|Experimental|Stress task and smoking cue|Exposure to a psychosocial stress task followed by smoking video cues
9689517|NCT04843969|Experimental|Stress task and neutral cue|Exposure to a psychosocial stress task followed by neutral video cues
9689518|NCT04843969|Active Comparator|Control task and smoking cue|Exposure to a control task followed by smoking video cues
9689519|NCT04843969|Active Comparator|Control task and neutral cue|Exposure to a control task followed by neutral video cues
9689520|NCT04843826|Experimental|delayed implant|"Patients 18 years or older.~Periodontally and systemically healthy.~Sufficient bone width and height for implant placement~Adequate mesiodistal width and inter-arch space for placement of a delayed implant.~Full mouth plaque index less than 15% (Bentley and Disney, 1995)~cooperative patients who will comply to follow up visits"
9689521|NCT04843982|Experimental|esketamine plus propofol|"After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).~After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days."
9689522|NCT04843982|No Intervention|propofol|After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).
9689523|NCT04844073|Experimental|MVC-101|CD3 engaging conditionally active bispecific protein binding EGFR and CD3
9689524|NCT04843878||Positive|Subjects that tested positive for COVID-19 based on the clinical gold standard PCR test.
9689525|NCT04843878||Negative|Subjects that tested negative for COVID-19 based on the clinical gold standard PCR test.
9689526|NCT04843891|Experimental|Healthy Volunteers|In 10 healthy volunteers the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied.
9689527|NCT04843891|Experimental|Cardiovascular Disease|In 30 subjects with a history of recent myocardial infarct, the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the infarct site will be correlated with cardiac MRI.
9689528|NCT04843891|Experimental|Cancer|In 30 subjects with an epithelial malignancy the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
9689529|NCT04843891|Experimental|Sarcoidosis|In 30 subjects with sarcoidosis the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
9689530|NCT04843943|Experimental|Sintilimab+Bevacizumab|
9696227|NCT04769167|Active Comparator|Diabetic Non Pregnant Women (DNPW)|DNPW are diabetic and not pregnant
9696228|NCT04769167|Placebo Comparator|Healthy Pregnant Women (HPW)|HNPW are healthy women and currently pregnant
10180467|NCT03792932|Active Comparator|Open distal pancreatectomy|
10180468|NCT03792906|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
9689531|NCT04843904|Experimental|Venetoclax|"Participants will be separated into two cohorts: Cohort A: Patients at low risk for TLS. Cohort B: Patients with both median and high risk for TLS.~Five (5) participants from cohort A will be initially enrolled, if these first 5 participants tolerate the accelerated ramp-up, cohorts A and B will enroll simultaneously.~All participants will be hospitalized and receive venetoclax daily with accelerated dose increases over 5 days to reach full dose. After reaching full dose, participants will be discharged and continue daily venetoclax at home.~Per doctor assessment, some participants may also receive rituximab or obinutuzumab as part of the treatment regimen with venetoclax.~Rituximab: Given every 28 days starting on the second study cycle and continuing for up to 6 cycles as per standard of care.~Obinutuzumab: Days 1, 2, 8, and 15 of cycle 1 and once every 28 days there after for up to 6 cycles as per standard of care."
9689532|NCT04843813|Experimental|Lutein|
9689533|NCT04843813|Placebo Comparator|Safflower Oil|
9689534|NCT04843839|Experimental|Test Eye|These eyes will be given the Test drug, that is Nepafenac Eye Drops 0.1% w/v, at the dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
9689535|NCT04843839|Placebo Comparator|Control Eye|These eyes will be given the placebo, that is Carboxy-methylcellulose sodium lubricant eye drops 0.5%w/v, at the same dosage of 4 drops to be instilled in the eye 1 drop 4 times a day (every 4 hourly).That is at morning, afternoon, evening and at night. This is to be continued for a 6 months duration.
9689536|NCT04843670||patients operated for pancreas tumors|duodenopancreatectomy for head of the pancreas tumors
9689537|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 1|Intervention: SLV213, 8 subjects will receive 200mg oral doses twice a day for seven consecutive days.
9689538|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 1|Intervention: Placebo, 4 subjects will receive an equivalent number of oral doses twice a day for seven consecutive days.
9689539|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 2|Intervention: SLV213, 8 subjects will receive 400mg oral doses twice a day for seven consecutive days.
9689540|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 2|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses twice a day for seven consecutive days.
9689541|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 3|Intervention: SLV213, 8 subjects will receive 800mg oral doses once a day for seven consecutive days.
9689542|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 3|Intervention: Placebo, 4 subjects will receive the equivalent number of oral doses once a day for seven consecutive days.
9689543|NCT04843787|Experimental|Experimental: Multiple Ascending Dose Cohort 4|Intervention: SLV213, 30 subjects will receive the MTD (200mg twice a day, 400mg twice a day or 800 mg once a day) oral doses for seven consecutive days.
9689544|NCT04843787|Placebo Comparator|Placebo Comparator: Multiple Ascending Dose Cohort 4|Intervention: Placebo, 15 subjects will receive the equivalent number of oral doses once a day or twice a day for seven consecutive days.
9689545|NCT04843592||Type II diabetes|using mobile app
9689546|NCT04843553|Active Comparator|active|Participants receiving oral vitamin B-3
9689547|NCT04843553|Placebo Comparator|placebo|Participants receiving oral inactive pill
9689548|NCT04843462|Experimental|edupression.com® + treatment-as-usual|Patients are receiving treatment with edupression.com® in addition to TAU (treatment-as-usual) with esketamine nasal spray
9689549|NCT04843462|Active Comparator|treatment-as-usual|Patients are receiving TAU (treatment-as-usual) with esketamine nasal spray
9689550|NCT04843475||MPNs patients who have echocardiographic probability of PH.|
9689551|NCT04843475||MPNs patients who do not have echocardiographic probability of PH|
9689552|NCT04843566|Active Comparator|Transrectal|Patients will receive a transrectal MRI-guided prostate biopsy.
9689553|NCT04843566|Active Comparator|Transperineal|Patients will receive a transperineal MRI-guided prostate biopsy.
9689554|NCT04843696|Experimental|NPV group|"The hospital-based maintenance NPV program includes NPV support, breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice. The patients in the NPV group undergo the hospital-based NPV once per week in the maintenance program at least three times per month.~The patients received NPV with breathing training via a cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy) for 60 min, once per week.~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
9689555|NCT04843696|Active Comparator|Control group|"Control group receives breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) in daily clinical practice.~Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)."
9689556|NCT04843228|Experimental|Active Cognitive Bias Modification Group|This group of participants will receive 4 sessions of CBM targeting their interpretation biases for perfectionism and intolerance to uncertainty.
9689557|NCT04843228|Placebo Comparator|Placebo-Control Cognitive Bias Modification Group|This group of participants will receive 4 sessions of inactive CBM.
9689558|NCT04843189||Da Vinci Robotic Surgery Group|Da Vinci Robotic Surgery Group
9689559|NCT04843189||Laparoscopy-assisted surgery group|Laparoscopy-assisted surgery group
9689560|NCT04843163|Experimental|Wave A (Immediate NAMI Basics)|Once a participant has completed the questionnaires, that participant will be randomly assigned to either an immediate NAMI Basics class (Wave A), or an 8-week delay (Wave B) condition. Those in the immediate condition will be assigned to take the next available NAMI Basics class. Participants in both groups will be assessed at three time points. Participants in the immediate Basics group (Wave A) condition will be assessed pre-class, post-class, and 6 months after class has ended.
9689561|NCT04843163|No Intervention|Wave B (Waitlist Control)|Participants in the 8-week delay condition will be able to participate in a NAMI Basics class immediately following the 8-week time frame. Participants in the 8-week delay group (Wave B) will be assessed before the 8-week delay, after the 8-week delay (prior to their Basics course), and after the Basics course.
9689562|NCT04843176|Active Comparator|Prototype AI algorithm|In-house prototype deep learning artificial intelligence algorithm
10180469|NCT03792906|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion.
10180470|NCT03792633|Experimental|Newly Diagnosed VHR B-ALL or High-Risk Relapse of B|
10180471|NCT03792633|Experimental|Poor Response to Prior B Cell Directed Engineered cell therapy|
9826801|NCT02432456|Placebo Comparator|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
9826802|NCT02432456|Experimental|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
10180472|NCT03792529||breast cancer with HER2 overexpression|
10180473|NCT03792529||hormone receptor-positive breast cancer|
10180474|NCT03792529||triple negative breast cancer|
10180475|NCT03792945|Active Comparator|extracorporeal shock wave therapy|ESWT will be applied to Group 1 once a week for a total of 3 weeks. Modus ESWT device will be used. The patient's wrist will be applied at a pressure of 4 bar and 2000 Hz at a frequency of 5 Hz. Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
9689563|NCT04843176|Placebo Comparator|LI_RADS interpretation|LI-RADS criteria will be assessed independently by two specified abdominal radiologists with at least 10 years of experience in cross-sectional abdominal imaging
9689564|NCT04843449|Experimental|Inhibitor group|"ASC40 50mg, once daily on the 1st and 11th days before meal;~Itraconazole 200mg, once daily from the 6th day to the 15th day."
9689565|NCT04843449|Experimental|Inducer group|"ASC40 50mg, once daily on the 1st and 19th days before meal;~Rifampicin 600mg, once daily from the 6th day to the 19th day."
9689566|NCT04843488|Active Comparator|Ridge Augmentation with a perforate PTFE mesh|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
9689567|NCT04843488|Experimental|Ridge Augmentation with a perforate PTFE mesh covered with a collagen membrane|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The mesh will be covered with a native collagen membrane. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
9689568|NCT04843644|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
9689569|NCT04843644|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
9689570|NCT04843644|Placebo Comparator|control|Routine care to encourage oral care three times a day.
9689571|NCT04843371||Patient Group|All patients undergoing an echocardiogram at Tulane Medical Center may be asked to participate in the study. Doctors, including PI and co-PI, will identify eligible patients from their clinic using their clinical knowledge and expertise and the patients' medical history and records. They will provide patients with information regarding the study and if interested, patients will be consented prior to their scheduled echocardiogram.
9689572|NCT04843293|Experimental|Experimental Group: Olfactory stimulation group|Preterm newborns in the initiative group were sniffed the smell of breast milk before and during feeding, except for routine application
10180476|NCT03792945|Active Comparator|local injection|40 mg of local Depomedrol (methylprednisolone) injection will be applied to group 2 once. Injection will be made from wrist with carpal tunnel syndrome.Patients will be given a splint at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
10180477|NCT03792945|No Intervention|carpal tunnel wrist brace|"Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day.~Participants will use the carpal tunnel wrist brace 3 months."
9689573|NCT04843293|No Intervention|Control Group|Premature newborns in the control group feeds gavage according to the routine of the clinic, and no attempt will be made during feeding.
9689574|NCT04843540|Experimental|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of rifampin on Day 4 through Day 15, with a single oral dose of CTP-543 being co-administered on Day 14.
9689575|NCT04843215|Experimental|Experimental group/D2 radical gastrectomy with partial omentectomy|Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.
9689576|NCT04843215|No Intervention|Control group/D2 radical gastrectomy with total omentectom|Control group with total omentectomy
9696229|NCT04769167|Active Comparator|Diabetic Pregnant Women (DPW)|DNPW are diabetic and currently pregnant
10180478|NCT03792763|Experimental|Arm A, denosumab|"Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]~Every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
10180479|NCT03792763|Placebo Comparator|Arm B, placebo|"Placebo 1.7 ml Subcutaneous Solution~SC every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
9528139|NCT03213431||IQ of <90 and ≥40|Patient-Reported Outcomes (PRO) will be evaluated in a group of 30 childhood cancer survivors with global neurocognitive impairment classified by IQ of <90 and ≥40 and 30 of their parents.
10180480|NCT03792594||Bone marrow concentration group|The patients receive arthroscopic repair with bone marrow concentration.
10180481|NCT03792594||Historical control group|The patients receive arthroscopic repair only
9689577|NCT04843384|Experimental|Reiki|"One of these methods, reiki, has roots which go back thousands of years. Modern reiki was rediscovered and introduced by Mikao Usui in Japan at the end of the 19th century. Reiki means universal life energy . The aim in reiki, in which healing energy is purposefully directed, is to provide restoration of unbalanced energy layers which might be the source of physical, emotional or psychological pain."
10180482|NCT03792620|Experimental|Cyclo Thal Dex Daratumumab|"Eligible patients will be enrolled and treated according to the following elicited schema: Cyclo Thal Dex- Daratumumab (cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week (28 days cycle)- 4 cycles. ) + Daratumumab 16mg/Kg every week on cycles 1 and 2 and every other week at cycles 3 and 4- (total of 12 doses). Then Daratumumab 16mg/Kg after D+30, every other week as pre consolidation until starts full consolidation D+90-120 every other week (total of 4 doses) + thal100mg D1-28 during sixteen weeks as full consolidation. Follow by Daratumumab 16mg/Kg once a month as maintenance until progression or limiting adverse event (total of 28 planning doses).~Total scheme Daratumumab doses= 50 doses = PROTOCOL MAXDARA."
10180483|NCT03792542|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
10180484|NCT03792568|Experimental|ALK mutation|
10180485|NCT03792581|Active Comparator|EV1000 monitor|MAP management will be done as usual ( adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
10180486|NCT03792581|Experimental|EV1000 monitor + closed-loop system|fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
10180487|NCT03792503|Experimental|Apatinib，Pemetrexe|Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
10180488|NCT03792490|Experimental|Fasudil 30 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 30 mg/ day Frequency: 2 x 15 mg Duration of treatment: 20 days
9689578|NCT04843384|Sham Comparator|Sham reiki|With the Sham Reiki patients, a nurse without reiki training performed Sham Reiki randomly for approximately, following a protocol which did not include the body's energy centers or chakras.
9689579|NCT04843384|No Intervention|Control|The control group received no intervention beyond routine care.
9689580|NCT04843280|Active Comparator|Traditional Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of formal outpatient physical therapy
9689581|NCT04843280|Active Comparator|Internet Based Physical Therapy|Participants who have undergone primary unilateral knee arthroscopy will undergo 6 weeks of internet based rehabilitation regime in the home through the online recovery program, FORCE Therapeutics
9689582|NCT04843397||Single Arm|Patients referred for clinically indicated EGD, without known precancerous condition. Patients will receive endoscopy with standardised biopsy and photodocumentation protocol
9689583|NCT04843410|Experimental|Experimental: exercise group|
9689584|NCT04843410|No Intervention|No Intervention: Control Group|
9689585|NCT04843306|Experimental|ABC technique plus biofeedback|Patients will utilize biophysical feedback and coaching during the planning and treatment sessions for radiotherapy to help patients with the ABC technique.
9689586|NCT04843306|Active Comparator|Standard of care ABC technique.|Patients will standard of care instructions for using the ABC technique during the planning and treatment sessions for radiotherapy.
9689587|NCT04843345||Reduced Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen positive for reduced salivary flow
9689588|NCT04843345||Normal Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen negative for reduced salivary flow
9689589|NCT04843098|Experimental|Single arm, open label|Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D
9689590|NCT04843358|Experimental|Emotional Disclosure|Participants in the emotional disclosure arm will be told to write continuously for 20 min about their deepest thoughts and feelings regarding their breast cancer experience
9689591|NCT04843358|Active Comparator|Non-Emotional Writing|Participant allocated to the control group will be asked to describe in detail their daily activities in a non-emotional manner in accord with Pennebaker's published instructions
9689592|NCT04843124|Experimental|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
9689593|NCT04843124|Active Comparator|Control group|Traditional hearing aid adjustment
9826803|NCT02432703|Experimental|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
10180489|NCT03792490|Experimental|Fasudil 60 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 60 mg/ day Frequency: 2 x 30 mg Duration of treatment: 20 days
10180490|NCT03792490|Placebo Comparator|Placebo|Sodium chloride (NaCl) 0.9% Dosage form: intravenous, application over 45 minutes Dosage: 100 ml Frequency: 2 x Duration of treatment: 20 days Do2 x 1 ml, NaCl 0.9%
9826804|NCT02432703|Placebo Comparator|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
9827602|NCT02461758|Other|Control Group|A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
10180491|NCT03792217|Experimental|1.3% NaOCl|Root canal irrigation done using 1.3% NaOCl.
10180492|NCT03792217|Active Comparator|5.25% NaOCl|Root canal irrigation done using 5.25% NaOCl.
10180493|NCT03792204||PD patients with wearing-off effect|"people who have been clinically diagnosed with Parkinson's disease (PD) and have received anti PD therapy would be recruited into the study. The anti -PD treatment would not be changed in the population of the participants.~We would use the tool of 'Wearing-off 9 questionnaire' to determine the prevalence of Wearing-off phenomenon in Parkinson's patients in Shanghai"
10180494|NCT03792230|Experimental|Video|This group received educatıon via video material
10180495|NCT03792230|Experimental|Brochure|This group received education via written material (brochure)
10180496|NCT03792230|No Intervention|Control|This group received standart clinical education
9689594|NCT04843059|Other|the resident memory T-cell infiltrate in perilesional vitiligo skin|"To compare the resident memory T-cell infiltrate in perilesional vitiligo skin after 6 months of treatment with OMP and UVB, between three groups of patients suffering from non-segmental vitiligo, using flow cytometric analysis.~First group will include patients with a long-lasting disease (more than 2 years) and no new or growing lesions for at least 2 years: Old vitiligo with Old lesions~The second group will include patients with a long-lasting disease (more than 2 years) and with at least one new lesion developed in the last 6 months: Old vitiligo with new lesions~The third one will include patients developing, for the first-time, vitiligo lesions with all the lesions no older than 6 months: New vitiligo"
9689595|NCT04843085||O1|the more aggressive subgroup of oligodendroglioma samples of 30 patients
9689596|NCT04843085||O2|subgroup 2 of oligodendroglioma samples of 30 patients
9689597|NCT04843085||O3|subgroup 3 of oligodendroglioma samples of 30 patients
9689598|NCT04843085||IDH-mutant astrocytomas|patients with IDH-mutant astrocytomas, samples of 15 patients
9689599|NCT04843085||IDH-wildtype glioblastomas|patients with IDH-wildtype glioblastomas, samples of 15 patients
9689600|NCT04842812|Experimental|TILs/CAR-TILs treatment|Obtain TILs/CAR-TILs from advanced solid tumor patients and infuse them back to evaluate safety and clinical efficacy of the treatment.
9689601|NCT04842825|Experimental|kidney-tonifying and blood-regulating herbs treatment group|the treatment group will receive sequential treatment with the Chinese herbal formula for tonifying the kidney, nourishing the blood, and activating the blood 2 months before the proposed ET to regulate menstruation and improve ovarian reserve function. Treatment with the Chinese herbal formula will continue on the 5th day of menstruation after entering the super-ovulation cycle.
9689602|NCT04842825|Active Comparator|Western medicine group|The control group will be treated with conventional Western medicine
9689603|NCT04842890|Other|Stereotactic body radiation therapy (SBRT) with Pencil Beam Scanning (PBS) proton therapy|
9689604|NCT04842981|Experimental|Interleukin 6 receptor antibody|Tocilizumab, 162 mg subcutaneous, once every week OR Sarilumab, 200 mg subcutaneous, once every two weeks.
9689605|NCT04842916||Gastric cancer patients|gastric cancer patients with histologically confirmed, potentially resectable adenocarcinoma of the stomach or the gastroesophageal junction receiving the standard of medical care in Europe
9689606|NCT04842903|Experimental|Experimental Group|Therapeutic touch and standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
9689607|NCT04842903|No Intervention|Control Group|Only standard nursing care of the clinic (such as breathing exercise, postural drainage) was applied.
9689608|NCT04842721|Active Comparator|Hypertonic Saturated Saline Mouth Rinse Active Arm|The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited.
9689609|NCT04842721|Placebo Comparator|Plain Water Control Arm|The Control Rinse is a 25 ml of Plain Tap Water.
9689610|NCT04843046|Active Comparator|CBT + pioglitazone|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a pioglitazone (45 mg) capsule every day during weeks 1-12.
9689611|NCT04843046|Placebo Comparator|CBT + placebo|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a placebo capsule every day during weeks 1-12.
9689612|NCT04843072|Experimental|Evolut R/Pro bioprosthesis|Study subjects will receive a self-expanding-valve (either the Evolut R or PRO device)
9689613|NCT04843072|Active Comparator|Edwards Sapien S3/Ultra bioprosthesis|Study subjects will receive a balloon-expanding-valve (either the Edwards Sapien S3 or Ultra)
9689614|NCT04842942|Experimental|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
9689615|NCT04843033|Experimental|Daily oral administration of SH3809 tablet|
9689616|NCT04842799|Experimental|Digital delivery of genetic pre-test information|Half of participants will be provided with genetic pre-test information via the BRCA-DIRECT digital platform.
9689617|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss genetic pre-test information|Half of participants will be provided with genetic pre-test information via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
9689618|NCT04842799|Experimental|Digital delivery of BRCA-gene testing results|97.5% of participant's with a negative (normal) result will receive their BRCA-gene testing result via the BRCA-DIRECT digital platform.
9689619|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss BRCA-gene testing results|2.5% of participants with a negative (normal) result and those with positive results will receive their BRCA-gene testing result via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
10180497|NCT03792139|Experimental|LY3200882|LY3200882 administered orally.
10180498|NCT03792139|Experimental|Itraconazole + LY3200882|Itraconazole + LY3200882 administered orally.
10180499|NCT03792269|Experimental|Multi-channel chemotherapy|Patients will receive intraperitoneal irinotecan (50mg, d1, q2w).
10180500|NCT03792269|Active Comparator|Control Group|Patients will receive intravenous oxaliplatin (130mg/m^2, d1, q3w), and oral capecitabine (1.0g, d1-14, q3w).
10180501|NCT03792178|Active Comparator|Nano resin composite|are types of synthetic resins which are used in dentistry as restorative material or adhesives.
10180502|NCT03792178|Experimental|Bulk fill composite|Bulk- ll composites are claimed to be restorative materials used in deep preparations and effectively photoactivated in layers up to 4 mm.
9689620|NCT04843020|Experimental|Drug subcutaneous injection|Monthly injection of ION 682884, administered subcutaneously at a dose of 45 mg.
9689621|NCT04842877|Experimental|Experimental arm|Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.
9827603|NCT02461758|Other|Vedolizumab Group + standard dose influenza vaccine (SDIV)|A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
10180503|NCT03792295|Experimental|Multimodal Therapy|Patients will receive scheduled ibuprofen 400mg po q 4 hours and acetominophen 1gram po q 8 hours during the post operative phase and oxycodone 5mg po q 4 to 6 hours as needed for pain control.
10180504|NCT03792295|Active Comparator|Classic/standard opiod Therapy|Patients will receive oxycodone 5mg po q 4 to 6 hours as needed during their post operative phase for pain control.
9689622|NCT04842656|Experimental|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique. ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformis and direct pressure is applied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times(22).
9689623|NCT04842656|Experimental|Post isometric relaxation alongwith conventional treatment|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions(32)
9689624|NCT04842838|Experimental|DCB strategy|
9689625|NCT04842838|Active Comparator|DES strategy|
9689626|NCT04843137||Individuals with cervical spinal cord injury|Cohort of individuals who have experiences a chronic spinal cord injury at the cervical level (specifically C5-C7).
9689627|NCT04842565|Experimental|TACE+Sintilimab|
9689628|NCT04842695|Active Comparator|kegel´s exercise (pelvic floor exercise)|A midwife/nurse works with the women according to the following protocol: 1.-identify anal sphincter, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2.- identify elevator ani muscle and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting, bent forward, elbows on knees; 3.- contract elevator ani muscle with a position of sitting, lying, and standing; 4.- contract anal sphincter with a position of sitting, lying, and standing. The sessions are conducted by the same midwife/nurse to women in both groups/arms to be performed by the women at home. .
9689629|NCT04842695|Experimental|Electroacupuncture group|"Acupuncture point called bilateral R7 receive acupuncture with 0.25*40 mm needle with a perpendicular puncture 1.5 cun. The electrical stimulator is applied to bilateral R7, with dilatation wave 50 Hz and direct electric current of 1 milliamperes.. Each session lasts 30 minutes per day. Participants are treated 1 time per week for 12 weeks, total 12 sessions for each patient.~Equipment:~Electroacupuncture device.~device made in China"
9689630|NCT04842760||No platelet disorders or no HIT|Patients without platelet disorders or without HIT, without anti-PF4/H antibodies, without anti-aggregant treatment.
9689631|NCT04842760||HIT patients with anti-PF4/H antibodies|patients with anti-PF4/H antibodies but for whom HIT was ruled out.
9689632|NCT04842760||platelet dysfunction or HIT|Patients with platelet dysfunction or suffering from HIT
9689633|NCT04842994|Experimental|IONM arm|Intra operative nerve monitoring (IONM) is a technique of monitoring the RLN during surgery, to help identification and safe guarding of the nerve during total thyroidectomy as well as central compartment clearance (CCC). This is a well established technique with many centers in the world routinely using monitoring during surgery.
9689634|NCT04842994|No Intervention|Visual Identification arm|Patients randomized to this arm will undergo total thyroidectomy as per standard procedures with visual identification of the RLNs
9689635|NCT04842968|Experimental|Methylene blue|Methylene blue solution (50 mg in 30 ml of saline solution) was injected in the cannulated main supplying artery of the freshly removed specimen, ex vivo. Colorectal specimen was then processed in the routine pathological work-up way.
9689636|NCT04842968|No Intervention|Control|Colorectal specimens were processed in the routine pathological work-up way.
9689637|NCT04842617|Experimental|Treatment group A|
9689638|NCT04842617|Placebo Comparator|Treatment group B|
9689639|NCT04842669|Experimental|Low level laser therapy|Low level laser therapy
9689640|NCT04842669|Active Comparator|Conservative treatment|Conservative treatment
9689641|NCT04842539|Experimental|FMT Arm|FMT Arm:30 grams stool homogenized with 100 mL normal saline and filtered administered a single time via nasojejunal tube.
9689642|NCT04842539|Other|Standard of care (SOC) Arm|Standard of care treatment with nutritional supplementation and other supportive care
9689643|NCT04842513|Experimental|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
9689644|NCT04842500|Experimental|"Cheap Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
9689645|NCT04842500|Experimental|"Cheap Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, minus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
9689646|NCT04842500|Experimental|"Expensive Unit Price, Establishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the beginning of the relevant appointment, before within-appointment reinforcer consumption has had an opportunity to approximate demand.
10180505|NCT03792152|Experimental|rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd(15mg If creatinine clearance is between 30-49 ml/min ).
10180506|NCT03792152|Active Comparator|Warfarin|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
10180507|NCT03792347|Experimental|Arm 1|Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 15 and 29. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.
9689647|NCT04842500|Experimental|"Expensive Unit Price, Abolishing Operation"|Pre-extinction baseline unit price for the programmed reinforcer will be its Pmax, plus one half of the distance between its Pmax and its breakpoint. Extinction will be introduced at the end of the relevant appointment, after within-appointment reinforcer consumption has approximated demand.
9689648|NCT04842578|Experimental|group of thin cross- section of CT|Anatomic Segmentectomy with the Guidance of Thin Cross- Section of CT
9689649|NCT04842578|Active Comparator|group of thin 3D simulation|Anatomic Segmentectomy with the Guidance of 3D simulation
9689650|NCT04842357|Other|video - then self-study|Group A will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group A will watch a standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group A will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
9689651|NCT04842357|Other|self-study, then video|Group B will be video recorded during the performance of the two skills on simulators (i.e. Donati suture and intraosseous venous access) (timepoint: T0). Then group B will do self-study, then will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 to 2 weeks group B will watch the standardised video about the skills, then will be again video recorded during the performance of the two skills on simulators (timepoint: T2).
9689652|NCT04842682|Experimental|Active intervention|"Solo groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml)~Combi groups : CD40.HIVRI.Env vaccine (solution at 5.0 mg/ml) adjuvanted with Poly-ICLC (Hiltonol, solution at 1.8 mg/ml) and combined with DNA-HIV-PT123 HIV-1 vaccine (solution at 4.0 mg/ml)"
9689653|NCT04842682|Placebo Comparator|Placebo|Commercial Sodium Chloride at 0.9% (NaCl 0.9%)
9689654|NCT04842370|Experimental|Dose escalation and expansion of PHI-101|
9689655|NCT04842435|Experimental|Stage 1. Group 1|Group 1 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 1 mL/kg in addition to standard therapy
9689656|NCT04842435|Experimental|Stage 1. Group 2|Group 2 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 2 mL/kg in addition to standard therapy
9689657|NCT04842435|Experimental|Stage 1. Group 3|Group 3 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 4 mL/kg in addition to standard therapy
9689658|NCT04842435|Placebo Comparator|Stage 1. Group 4|Group 4 - 39 subjects who will receive a single intravenous infusion of placebo at a dose of 1 mL/kg in addition to standard therapy
9689659|NCT04842435|Active Comparator|Stage 2. Group 1|Group 1 - 110 subjects who will receive a single intravenous infusion of COVID-globulin at a dose defined at Stage 1 in addition to standard therapy
9689660|NCT04842435|Placebo Comparator|Stage 2. Group 2|Group 2 - 110 subjects who will receive a single intravenous infusion of placebo at a dose equal to the COVID-globulin dose in addition to standard therapy
9689661|NCT04842487|Experimental|Treatment arm|"Lenalidomide：25mg po QN,D1-10~Rituximab: 375mg/m2, ivdrip, D1~CTX: 750mg/m2, iv or ivdrip, D1~THP: 50mg/m2, iv or ivdrip, D1~VCR： 1.4 mg/m2 , iv（max：2mg）, D1~Pred: 60mg/m2, po, D1-5"
9689662|NCT04842396|Experimental|Experimental: Motorized cycle ergometer|"The exercise group cycles 20 minutes per session on the MOTOmed Muvi 3 days per week for 6 weeks at an intensity guided by the perception of effort.~A cycling cadence is fixed between 25 and 30 rpm for all sessions since that cadence is comfortable for every participant. Researchers adjust resistance on the motorized cycle to increase the external load until it reached the level required to reach the intensity of effort programmed by the OMNI-RPE. The six weeks are programmed in the form of two intensity-differentiated training phases of three weeks. In the first training phase (i.e., the first three weeks), participants are requested to cycle simultaneously with the upper and lower limbs at an intensity equivalent to a perception of 3 (i.e., easy to somewhat moderate) on the OMNI-RPE (0-10)."
9689663|NCT04842396|No Intervention|Control group|Participants are evaluated the week before and the week after the experimental group finishes the training period (pre- vs. postintervention) to facilitate an examination of the changes in body composition, functional performance, and resting cardiovascular state.
9696230|NCT04769232|Active Comparator|Standard Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by standard imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (estimation of the number of eosinophilic neutrophils according to the following categories 1: 0, 2: 1-6, 3. 7-14, 4. 15-50, 5. :50-100, 6. > 100, together with an estimation of an absolute number of eosinophilic neutrophils) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently for all other 10 biopsies using this imaging modality by endoscopist.
9826805|NCT02432716|Experimental|Insulin (glulisine), then Placebo|Participants first receive one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril). After a washout period of 2 weeks, they then received one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril).
10187509|NCT03725553|Experimental|Intramyometrial Vasopressin|the experimental group received a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
9689664|NCT04842591||kidney transplant candidates|Patients listed for first kidney transplantation
9689665|NCT04842136||Myofascial Temporomandibular Disorder (TMD) with Sleep Bruxism (SB)|Patients with Myofascial TMD and with sleep bruxism with the diagnosis of regular or frequent teeth grinding sounds during the sleep, and one or more following clinical signs, such as jaw muscle pain or fatigue on waking up in the morning, temporal headache, hypertrophy of the masseter muscle, abnormal tooth wear, and/or jaw locking were included in the group.
9689666|NCT04842136||Myofascial Temporomandibular Disorder (TMD) without Sleep Bruxism (SB)|Patients with Myofascial TMD without sleep bruxism were included in the group.
9689667|NCT04842344|Experimental|Noninvasive ventilation and ECCO2R|
10180508|NCT03792412|Experimental|Intervention: Usability Questionnaire|Patients hand over the usability questionnaire to evaluate the self developed structured follow-up program in form of a so-called pass to their family doctor twice in six months. Family doctors examine the postbariatric patient using the pass and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator.
10180509|NCT03792412|Other|Control: Usability Questionnaire|"Patients hand over the usability questionnaire to evaluate the state of the art guideline for postbariatric follow up appointments in form of a folder Metabolische Chirurgie und die perioperative Betreuung to their family doctor twice in six months. Family doctors examine the postbariatric patient using the guideline and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator."
9689668|NCT04842344|No Intervention|Noninvasive ventilation|
9689669|NCT04842305||G1: Control group|SARS-CoV-2 naïve persons who have neither been vaccinated nor have had COVID-19 (controls)
9689670|NCT04842305||G2: COVID-19 infected|Persons who have had COVID-19
9689671|NCT04842305||G3: COVID-19 vaccinated|Persons who have been vaccinated with Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1-S
10180510|NCT03792321|Active Comparator|Testosterone|Testosterone arm patients were receiving testosterone undecanoate 1000 mg intramuscular injections two years; according to the protocol every 10 weeks
9689672|NCT04842305||G4: COVID-19 infected and vaccinated|Individuals who have been infected with COVID-19 and subsequently been vaccinated
9689673|NCT04842149|Active Comparator|Bif195 capsules|The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
9689674|NCT04842149|Placebo Comparator|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
9689675|NCT04842266||Treatment of Impending and Actual Pathologic Fractures in the Pelvis from Metastatic Bone Disease|The patient will undergo surgery and will be treated with the IlluminOss implant. Patients will be evaluated and given questionnaires post operatively at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months
9689676|NCT04842266||Treatment of Geriatric Pelvic Fractures with IlluminOss Pelvic Implant|Geriatric pelvic fracture patients will be treated with the IlluminOss Pelvic Implant. Patients will be evaluated and given questionnaires post operatively at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months
9689677|NCT04842474|Experimental|Gaze stability and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
9689678|NCT04842318|Experimental|BR+R|Induction Therapy: Rituximab Combined With Bendamustine Maintenance Treatment: Rituximab
10180511|NCT03792321|Placebo Comparator|Placebo|Placebo arm patients were receiving placebo throughout the first year of this study and testosterone undecanoate 1000 mg intramuscular injections during second year.
9689679|NCT04842318|Experimental|RCHOP+R|Induction Therapy: Rituximab Combined With Cyclophosphamide, Vincristine, Doxorubicin, Prednisone Maintenance Treatment: Rituximab
9689680|NCT04842318|Experimental|R2+R2|Induction Therapy: Lenalidomide Combined With Rituximab Maintenance Treatment: Lenalidomide Combined With Rituximab
9689681|NCT04842292|Experimental|Nebulized heparin|Nebulized heparin 25,000 units in 3 mL inhalation every 6 hours
9689682|NCT04842292|Placebo Comparator|Nebulized placebo|Sodium chloride 0.9% 5 mL inhalation every 6 hours
9689683|NCT04842188|Active Comparator|L-PRF|Leukocyte platelet rich fibrin as a sole graft material in class II furcation
9689684|NCT04842188|Active Comparator|L-PRF with aPDT|Leukocyte platelet rich fibrin combined with antibacterial photodynamic therapy in class II furcation
10180512|NCT03792386|Active Comparator|Ultrasound guidance with fluoroscopic confirmation|Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation
10180513|NCT03792386|Active Comparator|Fluoroscopic guidance with ultrasonographic confirmation.|Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.
10180514|NCT03792425|Other|implant with immediate temporization|Immediate nonfunctional loading
9689685|NCT04842383|Active Comparator|Half strength Hemp Oil Preparation|The topical preparation contains only 500mg of cannabinoids per ounce. The other ingredients are the same in both arms.
9689686|NCT04842383|Active Comparator|Full strength Hemp Oil Preparation|The topical preparation contains 1000mg of cannabinoids per ounce. The other ingredients are the same in both arms.
9689687|NCT04842240||Patients undergoing implant based immediate breast reconstruction.|Patients will undergo either pre- or sub-pectoral implant based immediate breast reconstruction.
9689688|NCT04842448|Experimental|Hyperbaric oxygen treatment|HBO2 240 kPa, 90 min, maximum 10 treatments
9689689|NCT04842448|Placebo Comparator|Sham treatment|Air 134-120 kPa, 90 min, maximum 10 treatments
9689690|NCT04842526|Experimental|Anlotinib and irinotecan combined with temozolomide|
9689691|NCT04842214||Oncologic disorders|"All patients assigned for oncological rehabilitation with the diagnosis Cancer are included to this cohort."
9689692|NCT04842253|Experimental|High flow nasal cannula|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen during deep sedation.
10180515|NCT03792425|Other|Delayed implant without temporization|Conventional loading protocol
10180516|NCT03792243||Parastomal hernia|Patients undergoing parastomal hernia repair in Denmark between 2007 and 2017
9689693|NCT04842253|No Intervention|Low flow nasal cannula|Participants in the current standard of care will receive low flow nasal cannula during deep sedation.
9689694|NCT04842110|Experimental|1064 Full Abdomen|eonTM FR 1064 nm device Patient will be treated with the eonTM FR 1064 nm device
9689695|NCT04842331|Experimental|RESP301 + Standard of Care (SOC)|
9689696|NCT04842331|Active Comparator|Standard of Care (SOC)|
9689697|NCT04842162|Experimental|Patients with head and neck cancer|
9689698|NCT04841993|Experimental|Oral formulation: Cannabis decoction|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%) ,cannabis decoction will be prepared at the moment by putting female inflorescences in cold water brought to a boil, boiling for 15 minutes and using 500 mg of medicinal cannabis for 500 ml of water.
9689699|NCT04841993|Experimental|Oral formulation: Cannabis oil|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), cannabis oil is prepared the day before the experimental session with 500 mg of female inflorescences in 5 ml of olive oil from the European Pharmacopoeia, heating in a water bath (approximately 98 ° C) for 120 minutes and cooling the oil samples. at room temperature.
9689700|NCT04841993|Experimental|Vaporized formulation: Cannabis vaporized|From a standardized preparation cannabis Cannabis FM2 (THC) (~ 6%) and (CBD) (~ 8%), 100 mg of Cannabis inflorescences of FM2 standardized cannabis were administered through Volcano vaporizer .
9689701|NCT04841915|Experimental|Micellar Cassein Isolate High-Protein Diet|4weeks eucaloric intake on high-protein diet with micellar cassein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
9689702|NCT04841915|Experimental|Whey Protein High-Protein Diet|4weeks eucaloric intake on high-protein diet with whey protein as primary protein source followed by 20weeks hypocaloric intake on equivalent protein rich diet.
9689703|NCT04841915|Placebo Comparator|Normal Diet|4weeks eucaloric diet with normal protein content (15E%) followed by 20weeks hypocaloric intake on equivalent diet.
9689704|NCT04841954|Experimental|Prick-test|
9689705|NCT04841980|Active Comparator|Antibiotics|
9689706|NCT04841980|Active Comparator|Dietary based therapy|
9689707|NCT04841772|Active Comparator|Vegan Protein|
9689708|NCT04841772|Placebo Comparator|Placebo|
10180517|NCT03792399|Experimental|Immediate feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to immediate feedback after data downloaded into computer.
10180518|NCT03792399|Other|Delayed feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to delayed feedback (standard care, i.e., CGM graphs interpretation at scheduled 3 months outpatient visit).
10180519|NCT03792373||frailty|
10180520|NCT03792373||nonfrailty|
10180521|NCT03792308|Experimental|SPR206|"SAD Cohorts: Subjects will receive single doses of SPR206 via IV infusion over one hour. Planned doses to be studied are: 10, 25, 50, 100, 200, 300, 350 and 400mg. If the 300 mg dose is not deemed safe and well-tolerated, a dose of 250 mg will be used.~MAD Cohorts: Subjects will receive SPR206 via IV infusion over one hour q8h for 7 consecutive days (Cohorts 9 - 12) and over one hour q8h for 14 consecutive days (Cohort 13). Up to five dose groups will be studied. Planned doses will be 25 mg, 50 mg, 100 mg and 150 mg with dosing occurring q8h for 7 consecutive days (Cohorts 9 - 12) and q8h for 14 consecutive days (Cohort 13). Cohort 13 participants will be dosed at a dose deemed safe and tolerable, not to exceed the maximum dose tested in previous MAD dose cohorts.~."
9689709|NCT04841928|No Intervention|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
9689710|NCT04841928|Experimental|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
9689711|NCT04841928|Experimental|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
9689712|NCT04841928|Experimental|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
9689713|NCT04841928|Experimental|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component. Total number of sessions: 4 (4 contact hours).
9689714|NCT04841928|Experimental|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
9689715|NCT04841928|Experimental|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
9689716|NCT04841928|Experimental|Mindful attention + Decentering + Value-based action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component. Total number of sessions: 6 (6 contact hours).
9689717|NCT04841629|Experimental|PreBioGyn Gel|Topical administration to forearm
9689718|NCT04841629|Active Comparator|Trimosan Gel|Topical administration to forearm
9689719|NCT04841629|Active Comparator|RepHresh Gel|Topical administration to forearm
9689720|NCT04841720|Experimental|HSK16149|HSK16149（D1-D5）
9689721|NCT04841720|Experimental|Metformin|Metformin
9689722|NCT04841720|Experimental|HSK16149+Metformin|HSK16149+Metformin
9689723|NCT04841603|Active Comparator|Treatment as usual|Treatment as usual
9689724|NCT04841603|Experimental|Mindshift CBT|Treatment as usual + Access to Mindshift CBT app
9689725|NCT04841850||Hazelnut allergic children under oral immunotherapy|"Children Under eighteen years of age~Convincing clinical history of hazelnut allergy~Positive hazelnut prick test or specific IgE~Under IOT hazelnut protocol in pneumology and allergology-paediatric departement of the Mother and Child Hospital in Bron"
10180522|NCT03792308|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD Cohorts: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over one hour.~MAD Cohorts: Subjects will receive q8h infusions of placebo over 1 hour for 7 consecutive days (Cohorts 9 - 12) and q8h infusions of placebo over 1 hour for 14 consecutive days (Cohort 13)."
10187510|NCT03725553|Placebo Comparator|Placebo|the placebo group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)immediately after delivery, as soon as the umbilical cord was clamped.
9689726|NCT04841824||Critically ill patients with sepsis|
9689727|NCT04841824||Critically ill patients without sepsis|
9689728|NCT04842097|Experimental|Mindfulness-based stress reduction intervention|Online 8-week group program, once per week
9689729|NCT04842097|No Intervention|Waiting list|Controls will not receive any intervention during this time. They are on chronic pain clinics waiting list
9689730|NCT04841616|Experimental|Contrast-enhanced EUS (CH-EUS) Arm|After initial evaluation, 2.5ml of second-generation contrast media, SonoVue (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
9689731|NCT04841616|Active Comparator|Conventional EUS Arm|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is < 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed
9689732|NCT04841941|Experimental|single arm|G4 Multifocal soft contact lens with a 54% water content for presbyopia
9689733|NCT04841668||Patients with recently diagnosed T2DM|This group will consist of 36 recently diagnosed T2DM, according to the World Health Organization (WHO) patients (last 6 months), who have not received treatment with metformin.
9689734|NCT04841668||Patients with long-term T2DM|The group will consist of 100 patients with long-term T2DM, according to the WHO classification, regardless of whether they take metformin or another treatment.
9689735|NCT04841837|Experimental|Time-restricted feeding|Restrict all calorie intake within a self-selected 10-hours window for 12 weeks, without necessarily altering diet quality and quantity
9689736|NCT04841863|Active Comparator|Drug Code Active Patient o DCAP|"Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
9689737|NCT04841863|Placebo Comparator|Standard care|"Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.~Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge."
9689738|NCT04841811|Experimental|Postoperative Almonertinib continuous treatment group|Operable subjects were randomly assigned to groups A and B after surgery: Group A received 110 mg of Almonertinib once a day for 2 years.
9689739|NCT04841811|Experimental|Postoperative ctDNA dynamic monitoring guided the Almonertinib treatment group|Operable subjects were randomly assigned to groups A and B after surgery:Group B received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months Test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib until ctDNA turns positive and receive Almonertinib treatment again).
9689740|NCT04841811|Experimental|Almonertinib continuous treatment group after radical radiotherapy|Inoperable subjects were randomly assigned to groups C and D after radical radiotherapy.Group C continued to receive Almonertinib 110 mg once a day for 2 years.
9689741|NCT04841811|Experimental|ctDNA dynamic monitoring guided the Almonertinib treatment group after radical radiotherapy|Inoperable subjects were randomly assigned to groups C and D after radical radiotherapy.Group D received Almonertinib ctDNA dynamic monitoring guided treatment (every 3 months Test ctDNA once, if it is positive, continue to receive Almonertinib 110 mg once a day, if it is negative, stop Almonertinib until ctDNA turns positive and receive Almonertinib treatment again).
9689742|NCT04841694|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day
9689743|NCT04841681|Experimental|Video-based Psychotherapy|The group received the intervention of video-based psychotherapy.
9689744|NCT04842058||Orthostatic tolerant patients (OT)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
9689745|NCT04842058||Orthostatic intolerant patients (OI)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
9689746|NCT04842071|Experimental|18F-NaF eligible patients|
9689747|NCT04841746|Experimental|Cycling rehabilitation with functional electrical stimulation|
9689748|NCT04841746|Active Comparator|Cycling rehabilitation|
9689749|NCT04841590|Experimental|Experimental Group|The experimental group (EG) will receive treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
9689750|NCT04841590|Sham Comparator|Control Group|The control group (CG) will not receive any treatment
10180523|NCT03792009|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
10180524|NCT03792009|Placebo Comparator|Paracervical block with normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
10180525|NCT03792165|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
10180526|NCT03792165|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
9689751|NCT04841590|Placebo Comparator|Placebo Group|Subjects belonging to this group will receive the application of off ultrasound applied to the abdominal region for approximately 10 minutes.
9689752|NCT04841733|Experimental|Protocol I: Foam Roller (FR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Cold-Water Immersion (CWI)
9689753|NCT04841733|Experimental|Protocol II: Stretching (STR) + Cold-Water Immersion (CWI)|Stretching (STR) Cold-Water Immersion (CWI)
9689754|NCT04841733|Experimental|Protocol III: Foam Roller (FR) + Stretching (STR)|Foam Roller (FR) Stretching (STR)
9689755|NCT04841733|Experimental|Protocol IV: Foam Roller (FR) + Stretching (STR) + Cold-Water Immersion (CWI)|Foam Roller (FR) Stretching (STR) Cold-Water Immersion (CWI)
10180527|NCT03792061|Experimental|Strategy Training|Strategy training is an activity intervention training approach developed based on the theoretical tenets of metacognitive training. The purpose of strategy training is to guide individuals to generate problem-solving skills to address challenges that they identify in daily activities.
10180528|NCT03792061|No Intervention|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
10180529|NCT03792100|Experimental|SmofKabiven emulsion for infusion|SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
10180530|NCT03792100|Active Comparator|"Hospital compounded All in one emulsion for PN"|"Hospital compounded All in one emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%."
10180531|NCT03791957||Group A - Healthy Periodontium|Absence of clinical signs of inflammation like bleeding on probing, erythema, edema, attachment loss, bone loss, patient symptoms, (bone levels at 1-3mm apical to CEJ) n=20
10180532|NCT03791957||Group B - Gingivitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla, n=20
9689762|NCT04841551|Other|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
9689763|NCT04841525||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
9689764|NCT04841525||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
9689765|NCT04841174|Experimental|Abdominal Massage|"Participants in the experimental group will be given an abdominal massage twice a day for 15 minutes and three days in a row by the researcher. The massage will be done 2 hours after the child has been fed. Abdominal massage will be done using the I love u technique."
9689766|NCT04841174|No Intervention|Intraabdominal pressure|Intra-abdominal pressure measurements will be made twice a day before the abdominal massage is given to the participants. This measurement will be made in line with a protocol. The intraabdominal pressure will be measured using the bladder passage method. This measurement will be made in both control and experimental groups.
9689767|NCT04841174|No Intervention|Gastric measurements|In the experimental and control groups, the abdominal circumference will be measured by the researcher twice a day for three days in a row. The gastric residual volume will be checked during the nurses' care time. The presence of vomiting and defecation will be checked during the care time of the nurses.
9689768|NCT04841161|Other|Healthy subjects|The healthy adults who have not any neurological, musculoskeletal or rhematogical disease, a history of orthopedic surgery on spine or lower extremity. Their age should be ranged between 20 - 75 years.
9689769|NCT04841161|Experimental|Stroke subjects|Stroke patients were included if they were: (1) diagnosed with unilateral ischemic or hemorrhagic stroke; (2) a minimum of six months post stroke ; (2) able to stand without support for 1 minutes; (3) able to understand and follow verbal instructions. and (4) medically stable with physician release.
9689770|NCT04841200|Experimental|Chinese medicine compound combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound based on TCM syndrome differentiation in addition to symptomatic treatments.
9689771|NCT04841200|Placebo Comparator|Chinese medicine compound placebod combined with symptomatic treatments|Patients in this arm will receive Chinese medicine compound placebo based on TCM syndrome differentiation in addition to symptomatic treatments.
9689772|NCT04841135|Other|Alzheimer disease group|
9689773|NCT04841135|Other|Control|
9689774|NCT04841239|Experimental|Herbal topical formulation|
9689775|NCT04841239|No Intervention|Control|
9689776|NCT04841421|Experimental|89Zr-CD147 1mCi±10% 10mg dose group|The activity administered was 1mCi±10% and the mass of radiolabeled CD147 was 10 mg.
9689777|NCT04841421|Experimental|89Zr-CD147 3mCi±10% 10mg dose group|The activity administered was 3mCi±10% and the mass of radiolabeled CD147 was 10 mg.
10180533|NCT03791957||Group C - Periodontitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla,periodontal pocketing, clinical attachment loss, radiographically assessed bone loss n=20
9689778|NCT04841421|Experimental|89Zr-CD147 5mCi±10% 10mg dose group|The activity administered was 5mCi±10% and the mass of radiolabeled CD147 was 10 mg.
9689779|NCT04841096|Experimental|Group A: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day
9689780|NCT04841096|Experimental|Group B: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day
9689781|NCT04841278|Experimental|EUS/ERCP|Patients with liver graft dysfunction enrolled sequentially for proposed protocol: EUS with possible interventions and possible ERCP
9689782|NCT04841369|Experimental|1A|Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)
9689783|NCT04841369|Active Comparator|1B|Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)
9689784|NCT04841369|Experimental|2A|Subjects received four doses of PCV13i at 3 months of age
9689785|NCT04841369|Experimental|3A|Subject received three doses of PCV13i at 7 to 11 months of age
9689786|NCT04841369|Active Comparator|3B|Subject received three doses of PCV13 at 7 to 11 months of age
9689787|NCT04841369|Experimental|4A|Subjects received two doses of PCV13i at 12 to 23 months of age
9689788|NCT04841369|Active Comparator|4B|Subjects received two doses of PCV13 at 12 to 23 months of age
9689789|NCT04841369|Active Comparator|5A|Subjects received one dose of PCV13i at 2 to 5 years old.
9689790|NCT04841369|Active Comparator|5B|Subjects received one dose of PCV13 at 2 to 5 years old.
9689791|NCT04841356|Experimental|ICG|Immediate Compression Garment
9689792|NCT04841317|Experimental|Single-arm: Blood pressure intervention|Participants will use a mobile technology system comprising of a remote home blood pressure monitoring cuff and a mobile application integrated with a clinician-facing component to view and manage remote blood pressures. Participants will use this for 12 weeks, with assessment of blood pressure outcomes and anonymous surveys regarding the technology at 12 weeks.
9689793|NCT04841460|Experimental|Low-fat ground beef|Participants will consume 25 low-fat ground beef patties, 5 patties per week for 5 weeks.
9689794|NCT04841460|Experimental|High-fat ground beef|Participants will consume 25 high-fat ground beef patties, 5 patties per week for 5 weeks.
9689795|NCT04841395||PE|Premature ejaculation group
9689796|NCT04841395||CG|Control group (Healthy subjects)
9689797|NCT04841148|Experimental|HCQ|Patients will receive HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
9689798|NCT04841148|Experimental|Avelumab|Patients will receive Avelumab, 10 mg/kg, IV, D1 and D15 of each 28-day cycle.
9689799|NCT04841148|Experimental|Palbociclib and Avelumab|Patients will receive Palbociclib 125 mg daily, by mouth on D1-21 concurrently with Avelumab, 10 mg/kg IV on D1 and D15 of each 28-day cycle
9689800|NCT04841148|Experimental|Palbociclib and HCQ|Patients will receive Palbociclib 75 mg daily, by mouth on D1-28 concurrently with HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
9689801|NCT04841213|Active Comparator|Group after vitamin D3 level stabilization|Patients with loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who will undergo dental implant placement after stabilization of vitamin D3 levels
9689802|NCT04841213|Active Comparator|Group before vitamin D3 level stabilization|Patients with the loss of teeth and mineral metabolism disorders due to vitamin D3 imbalance (n=192) who undergo the dental implantation during treatment by an endocrinologist
9689803|NCT04841434|Experimental|Dose escalation|Patients will receive up to 6 cycles of HD-MTX Treatment Dose escalation will be performed using three dose levels of MTX: 3.0 g/m2, 3.5 g/m2, 4.0 g/m2
9689804|NCT04841265|Active Comparator|Vitamin D3|The Vitamin D3 (intervention) arm will receive a total of 800 IU vitamin D3 supplementation per day.
9689805|NCT04841265|No Intervention|Control|The control arm will receive 400 IU vitamin D3 per day from routine antenatal multivitamin supplementation.
9689806|NCT04840758|Experimental|SABR+Sintilimab|Stereotactic ablation radiotherapy (SABR) was performed sequentially on the primary and secondary lesions. Sintilimab was used 2 weeks after the end of SABR. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles.
9689807|NCT04840862|Experimental|rifabutin|Rifabutin PO [two 150mg capsules] ; Trikafta PO [one orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
9689808|NCT04840966||HOS: hospitalized COVID19 patients|Patients positive to COVID19 hospitalized
9689809|NCT04840966||HI: Home-isolated COVID19 patients|Home-isolated patients positive to COVID19
9689810|NCT04840966||CTRL: Healthy controls|Healthy COVID19 negative subjects
9689811|NCT04840784|Experimental|ETH-155008|Dose level: 10mg/day, 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 3-6 subjects, taking ETH-155008 tablets once daily.
9689812|NCT04841031|Experimental|NET Treatment|Narrative Exposure Therapy (NET) Treatment: Treatment group consists of eligible individuals who are randomly assigned to receive NET treatment and are part of the study sample. Within each health center, treated individuals are randomly selected over several cohorts. In every cohort, the treatment group contained 6 individuals who received NET.
9689813|NCT04841031|Other|Control|This group contains eligible individuals who are randomly assigned to the control group and are part of the study sample. In every cohort, the control group contained 6 individuals.
9696231|NCT04769232|Experimental|High Magnification Imaging|In 20 randomly assigned patients, the area of endoscopically highest activity will be biopsied as determined by high magnification imaging. A total of 10 biopsies will be taken in 4 sets: 1 = one single biopsy at best guess of highest activity; 2 = one single biopsy at second best guess of highest activitiy, 3 = 4 biopsies in proximal esophagus with presumed activity, 4 = 4 biopsies in distal esophagus with presumed activity. Overall qualitative (eosinophilic inflammation present vs. absent) and semi-quantitative (see above) inflammatory activity will be rated for the presumed localization of maximal histologic activity and subsequently all other 10 biopsies using this imaging modality by endoscopist.
9696232|NCT04769180||Patients affected with NCWS|100 patients with a definitive diagnosis of NCWS, based on DBPC gluten/wheat challenge.
10180534|NCT03791944|Experimental|3DV+TPS/VARIAN|Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
9689814|NCT04840927|Experimental|Cohort 1: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 1: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 2: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 3: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
9689815|NCT04840927|Experimental|Cohort 2: E7386 40 mg|"Participants will be randomized to one of the 3 treatment sequences:~Treatment sequence 4: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 5: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~Treatment sequence 6: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4.~A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3."
9689816|NCT04841330||Healthy volunteers|A minimum of 100 healthy volunteer participants (14yo and older)
9689817|NCT04841083|Experimental|Allay lamp (narrow band green light)|Subjects who purchased the Allay Lamp are asked to document the effects of spending time in the narrow band of green light it emits, on their headache or any of its associated symptoms.
9689818|NCT04841044|Experimental|Intervention ( Cetoleic acid)|"6x mackerel oil (cetoleic acid: 16A%, estimated: 135 mg/g (FFA)) capsules every morning for 4 weeks~(A%= area percent)"
9689819|NCT04841044|Placebo Comparator|Control oil|"6x capsules control oil (Control oil= mix of anchovy oil, olive oil, high-oleic sunflower oil, rapeseed oil (cetoleic acid: 0,7 A% estimated: 6 mg/g (FFA)) every morning for 4 weeks~(A%= area percent)"
9689820|NCT04840732|Experimental|Experimental: Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
9689821|NCT04840732|Placebo Comparator|No Intervention: usual care|Chemotherapy training as usual care (for training chemotherapy skill).
9689822|NCT04841018|Experimental|Control|Higher dose of dexamethasone (0.5mg/kg) that is known to enhance the analgesic quality of caudal block from previous study
9689823|NCT04841018|Experimental|Dexamethasone|Lower, antiemetic dose of dexamethasone (0.15mg/kg)
9689824|NCT04840992|Experimental|A1a Phase I low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
9689825|NCT04840992|Placebo Comparator|A1b Phase I placebo low 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
9689826|NCT04840992|Experimental|A2a Phase I medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
9689827|NCT04840992|Placebo Comparator|A2b Phase I placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
9689828|NCT04840992|Experimental|A3a Phase I high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
9689829|NCT04840992|Placebo Comparator|A3b Phase I placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
9689830|NCT04840992|Experimental|A4a Phase I combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
9689831|NCT04840992|Placebo Comparator|A4b Phase I placebo combine 2 doses|6 subjects, Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
9689832|NCT04840992|Experimental|A5a Phase I single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
9689833|NCT04840992|Placebo Comparator|A5b Phase I placebo single dose|6 subjects, Placebo containing 0 vp, 1 dose Aerogen Solo
9689834|NCT04840992|Experimental|B1a Phase II low 2 doses|Ad5-nCoV containing 0.5E10 vp, 2 doses 56 days apart, Aerogen Solo
9689835|NCT04840992|Placebo Comparator|B1b Phase II placebo low 2 doses (18-59)|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
9689836|NCT04840992|Experimental|B2a Phase II medium 2 doses|Ad5-nCoV containing 1E10 vp, 2 doses 56 days apart, Aerogen Solo
9689837|NCT04840992|Placebo Comparator|B2b Phase II placebo medium 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
9689838|NCT04840992|Experimental|B3a Phase II high 2 doses|Ad5-nCoV containing 2E10 vp, 2 doses 56 days apart, Aerogen Solo
9689839|NCT04840992|Placebo Comparator|B3b Phase II placebo high 2 doses|Placebo containing 0 vp, 2 doses 56 days apart, Aerogen Solo
9689840|NCT04840992|Experimental|B4a Phase II combine 2 doses|1 dose Intramuscular Injection, Ad5-nCoV containing 5E10 vp, 1 dose Aerogen Solo, Ad5-nCoV containing 2E10 vp, 56 days apart
9689841|NCT04840992|Placebo Comparator|B4b Phase II placebo combine 2 doses|Placebo containing 0 vp, 1 dose Intramuscular Injection, 1 dose Aerogen Solo, 56 days apart
10180535|NCT03791944|Active Comparator|TPS/VARIAN|Use imported Varian TPS to map targets and develop treatment plans.
10180536|NCT03791944|Experimental|3DV+TPS/ Domestic accelerator|Use 3DV+TPS to map targets and develop treatment plans.
10180537|NCT03791944|Active Comparator|TPS/ Domestic accelerator|Adopt domestic TPS hook target and develop treatment plan.
10180538|NCT03791996|No Intervention|"Late cranioplasty"|Subjects undergoing cranioplasty within 3 months after craniectomy.
10180539|NCT03791996|Experimental|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
10180540|NCT03792074|Experimental|SCT510 combined paclitaxel and carboplatin|SCT510 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
10180541|NCT03792074|Active Comparator|Bevacizumab combined paclitaxel and carboplatin|Bevacizumab 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
9689842|NCT04840992|Experimental|B5a Phase II intramuscular single dose|Ad5-nCoV containing 5E10 vp, 1 dose Intramuscular Injection
9689843|NCT04840992|Placebo Comparator|B5b Phase II placebo intramuscular single dose|placebo containing 0 vp, 1 dose Intramuscular Injection
9689844|NCT04840992|Experimental|B6a Phase II Aerogen Solo single dose|Ad5-nCoV containing 1E10 vp, 1 dose Aerogen Solo
9689845|NCT04840992|Placebo Comparator|B6b Phase II placebo Aerogen Solo single dose|placebo containing 0 vp, 1 dose Aerogen Solo
9689846|NCT04840485|Experimental|Treatment group A|
9689847|NCT04840485|Experimental|Treatment group B|
9689848|NCT04840485|Placebo Comparator|Treatment group C|
9689849|NCT04840524|Other|Conventional preparation design (Chamfer finish line with Butt joint incisal preparation design)|conventional treatment
9689850|NCT04840524|Experimental|New preparation design (Feather edge finish line with feather edge incisal preparation design)|New preparation design
9689851|NCT04840433|Experimental|MACE|Patients will receive MACE for IDA.
9976256|NCT01349582|Other|Registry for flow diversion|Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
9976257|NCT01349608|Experimental|Health coaching|
9689854|NCT04840498||Magic Camp Session #1|Children ages 9-18
9689855|NCT04840498||Magic Camp Session #2|Children ages 9-18
9689856|NCT04840550|Experimental|Tegoprazan 25mg|Tegoprazan 25mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
9689857|NCT04840550|Active Comparator|Lansoprazole 15mg|Lansoprazole 15mg capsules will be orally administered, once a day, with NSAIDs, for up to 6 months.
9689858|NCT04840537|Active Comparator|cytological brushing followed by cholangioscopy in case of failure|
9689859|NCT04840537|Experimental|cholangioscopy from the start|
9689860|NCT04840407|Experimental|SHARP coach arm|The SHARP Peer Coach supports the direct care HHA and indirectly support the patient/family caregiver to enhance the patient's post-stroke recovery through two main pathways: 1) culturally sensitive, patient-centered reinforcement of rehabilitation regimens (prescribed physical/occupational exercises/training); and 2) early recognition and reporting of barriers to the rehabilitation therapist regarding adherence and recovery, including: a) environmental obstacles, b) family-related issues, c) psychological/clinical barriers (e.g., depression/anxiety).
10180542|NCT03792113|Experimental|Autologous fibrin glue|The periodontal flap will be approximated on the test site using autologous fibrin glue on the under surface of the raised flap up to 2 mm from the coronal margin and repositioned back on to the root surface. Thereafter, the tissues will be kept in position with a gentle pressure using a wet gauze for 30 - 60 seconds.
9528140|NCT03213431||IQ of ≥90|Patient-Reported Outcomes (PRO) will be evaluated in a group of 10 childhood cancer survivors with global neurocognitive unimpairment classified by IQ of ≥90 and 10 of their parents.
9689861|NCT04840407|No Intervention|Usual care arm|
9689862|NCT04840563|Experimental|Kalifilcon A lenses|Commercially available kalifilcon A lenses (Bausch + Lomb)
9689863|NCT04840563|Active Comparator|Dailies Total1|Dailies Total1 (Alcon)
9689864|NCT04840563|Active Comparator|Precision1|Precision1 (Alcon)
9689865|NCT04840576|Placebo Comparator|Conventional Dressing|waterproof sterile dressing OPSITE Post-Op Visible, Smith & Nephew, UK
9689866|NCT04840576|Experimental|Prophylactic negative wound pressure dressing|PICO-7, Smith & Nephew, UK
9689867|NCT04840706|Active Comparator|Airvo|Patients allocated to use Airvo device
9689868|NCT04840706|Placebo Comparator|Control|Patients not using Airvo, standard care
9689869|NCT04840420|Active Comparator|Intervention|"Inpatient~The WBCs conducts approximately daily visits to:~collect demographics and baseline data;~co-develop personalised social prescription plan with the participant based on Social Determinants of Health (SDoH) using SBAR4;~referring and accompanying the participant to attend inpatient activities that suit the participant's interests and preferences; and~informing and seeking the participant's agreement with community assets identified for the participant together with CNS.~About 1-week post-discharge, the WBCs will call to check his/her transition back to community and readiness to start attending community activities or receiving services. For community activities, the WBCs and CNS will visit the participant, accompanying him/her to the activity premise on the first day of the activity session and send the participant home after the session."
9689870|NCT04840420|Other|Control|"Usual Care~Inpatient phase For the control group, the interviewer will conduct approximately 2 visits to collect demographics and baseline data. The duration of each visit will range from 15 to 30 minutes.~Community phase For the control group, no intervention will be administered."
9689871|NCT04840394|Experimental|BDB018 in Monotherapy|"A single subject will be enrolled at each dose level in the single agent arm.~Then dosage escalation will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB018 is reached."
9689872|NCT04840394|Experimental|BDB018 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB018 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, approximately twenty additional subjects will be enrolled in the expansion phase of the study."
9696233|NCT04769180||Patients affected with CD|50 patients affected with CD, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
9696234|NCT04769180||Patients affected with IBS not related to NCWS or other food allergies/intolerances|50 patients affected with IBS, according to the Rome IV criteria, not related to NCWS or other food allergies/intolerances, sex- (± 5%) and age-matched (± 2 years) with the NCWS patients, selected at random during the study period.
9696235|NCT04769336||Patient|Each patient will undergo simultaneous testing with two different CBC analyzers.
9826806|NCT02432716|Experimental|Placebo, then Insulin (glulisine)|Participants first receive one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril). After a washout period of 2 weeks, they then received one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril).
10180543|NCT03792113|Active Comparator|4-0 silk suture|The periodontal flap will be approximated using 4-0 black silk suture.
9689874|NCT04840511|Experimental|lidocaine group|The study group receives perioperative lidocaine infusion with general anesthesia for robot-assisted prostatectomy
9689875|NCT04840511|Placebo Comparator|control group|The control group receives normal saline infusion with with general anesthesia for robot-assisted prostatectomy
9689876|NCT04840810|Active Comparator|Out of plane/ short axis central venous cannulation|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
10187511|NCT03725540||I-gel group|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
9689877|NCT04840810|Active Comparator|In-plane/long axis central venous cannulation|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
9689878|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 3.75mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
9689879|NCT04840745|Experimental|CKD-841 A-1(=leuprorelin acetate 1.88mg)|Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
9689880|NCT04840745|Experimental|CKD-841 D(=leuprorelin acetate 2.92mg)|Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
9689881|NCT04840745|Active Comparator|Leuplin Inj.(=leuprorelin acetate 3.75mg)|Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.
9689882|NCT04840381||Nonagenarians and Centenarians|Nonagenarians and Centenarians borned and living for most of their life in the Abruzzo region.
9689883|NCT04840251|Experimental|Intervention|The treatment group will have a physiotherapy well-being review and be referred for rehabilitation. They will be seen after 6 months for follow-up
9689884|NCT04840251|No Intervention|Control|The control group will have initial assessments then receive brief advice on exercise. They will also be followed up after 6 months
9689885|NCT04840251|Other|Qualitative|to understand how it feels to take part in the well-being review, we will interview some participants who have already had this kind of treatment and ask questions about their experiences of it and how it was for them. We are also interested to know what differences they felt it made so that we can help to decide about the things we want to measure as outcomes in the interventional of the study.
9689886|NCT04840212|Experimental|Study Group|Patients currently hospitalized in multiple service lines (surgical intensive care unite [SICU], surgical progressive care unit [SPCU], burns, trauma, plastics, general surgery, orthopedics, surgical specialties, and inpatient rehabilitation) will be included. Lavender-Sandalwood scented aromatherapy sticker will be used throughout the patient hospital stay.
9689887|NCT04840212|No Intervention|Control Group|The historical control group will be comprised of hospitalized patients in multiple service lines from the previous year with the same time period, demographic characteristics, service line, and relevant clinical information.
9976258|NCT01349621||Standard and polarized light colposcopy|Standard and polarized light colposcopy
9976259|NCT01349634|No Intervention|Comparison group|This arm will use the salt that is on the open market, which is primarily non-iodized salt. Iodized salt may enter in these communities through the normal trade route. No active interference with salt trade will occur in these communities.
9689890|NCT04840160|Placebo Comparator|Placebo|Participants supplied with 30 ml of a low fruit (<1%) cordial mixed with maltodextrin and protein diluted in 100 ml water twice daily, once in the morning and evening.
9689891|NCT04840160|Experimental|Cherry juice|Participants supplied with 30 ml of a tart cherry juice concentrate (CherryActive, United Kingdom; (containing 36.8 mg of anthocyanins) diluted in 100 ml of water twice daily, once in the morning and evening.
9689892|NCT04840095|Experimental|Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
9689893|NCT04840095|Experimental|Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
9826807|NCT02432729||Study population|"Adult smokers who are willing to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.~Smokers who are not continuously abstinent from smoking or any nicotine/tobacco containing product from the actual quit date will be discontinued from the study."
9826808|NCT02432742|Experimental|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
10187512|NCT03725540||BASKA Group|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
10187513|NCT03725527|Active Comparator|Rectus sheath catheter block|Patients will receive ultrasound-guided rectus sheath block with catheter insertion performed after induction of general anesthesia and before surgery.
9976260|NCT01349634|Experimental|Early delivery of iodized salt|Iodized salt that is produced nationally for the open market (which meets only about 10% of national needs) will be directed to these communities through the normal trade system or by direct delivery to the communities.
10180544|NCT03791905|Experimental|TP Arm|Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
9689894|NCT04840095|Experimental|Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, we will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while we simultaneously use MRS to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
9689895|NCT04840238|Experimental|Cholecalciferol|Cholecalciferol 30,000IU weekly orally
9689896|NCT04840238|Placebo Comparator|Placebo|Placebo tablets weekly orally
9689897|NCT04840134|Experimental|From Hardship to Hope: Financial Wellness Intervention|"From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk~Over the course of this study, the investigators will develop and pilot a financial wellness intervention to work in tandem with clinical treatment. The intervention will support individuals experiencing financial hardship and suicide risk to address their financial difficulties (e.g., debt, inability to meet basic needs) by coaching them on financial management techniques, facilitating a financial wellness plan, and connecting them with community-based financial supports (e.g., free financial counseling). The intervention will be facilitated by trained peer specialists, who are individuals with lived experience of financial hardship and suicidal ideation or suicidal behaviors who are state certified peer specialists (having met formal training and experience requirements)."
10187514|NCT03725527|Active Comparator|Epidural Catheter block|Patients will receive thoracic epidural at the level of T7 performed before anesthesia induction.
10187515|NCT03725514|Active Comparator|conventional|Conventional blood clot technique
9689898|NCT04840290|Experimental|Sintilimab Plus Platinum Doublet Chemotherapy|Specified dose on specified days Sintilimab
9689899|NCT04840342|Experimental|Eplerenone Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
9689900|NCT04840342|Experimental|Amlodipine Arm|We posit that individuals who carry the LSD1 risk allele have increased mineralocorticoid receptor activity, which results in hypertension. Thus, our mechanistic clinical study will assess whether hypertensive LSD1 risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the LSD1 risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
9689901|NCT04840355||Subjects with no irAEs|
9689902|NCT04840355||Subjects with degree 1-2 irAEs|
9689903|NCT04840355||Subjects with degree 3-4 irAEs|
9689904|NCT04840173|Experimental|Music at home|Caregivers will use Singing, music listening, or moving with music twice a week for 30 minutes with their care recipient.
9689905|NCT04840069|No Intervention|MRI-guided radiotherapy|Patients will undergo standard of care MRI-guided radiotherapy.
9689906|NCT04840069|Experimental|MRI + Fluciclovine PET-guided radiotherapy|Patients will undergo MRI + Fluciclovine PET-guided radiotherapy
9689907|NCT04840303|Experimental|Hub user group|This group receives community-based mental wellness youth hub services for young people to enhance personal strengths and overall mental well-being.
9689908|NCT04840303|No Intervention|non-hub user active control group|This group does not receive the community-based mental wellness youth hub services but other generic youth services in the community.
9689909|NCT04840303|No Intervention|non-hub user community control group|This group does not receive any youth services in the community.
9689910|NCT04840186|Active Comparator|2nd line chhemotherapy|Patients in this arm will be receiving the standard care which is 2nd line chemotherapy. Type of chemotherapy determined by treating oncologist.
9689911|NCT04840186|Active Comparator|2nd line chemotherapy + resection|Patients in this arm will be treated with liver resection and/or ablation at Oslo University Hospital followed by adjuvant 2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist.
9689912|NCT04840225||Endocarditis|100 patients diagnosed with infectious endocarditis according to DUKE criteria. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 6 months after discharge.
9689913|NCT04840225||TAVI/TEVAR patietns|30 patients undergoing elektive TAVI/TEVAR procedures. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to procedure and followed undtill 3 months after discharge.
9689914|NCT04840225||Patients with bacterial infections without endocarditis|30 patients diagnosed with with bacterial infections, without endocarditis. Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at diagnosis and followed undtill 3 months after discharge.
9689915|NCT04840225||Healthy blood donors|Detailed characterization of inflammation, anemia and markers of iron hemostatis will be made at directly prior to blood donation and approximately 1 week after blood donations
9689916|NCT04840277|Experimental|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
9689917|NCT04840277|No Intervention|Control group|Traditional hearing aid adjustment
9689918|NCT04840316||Post operative|Nil Intervention - observational cohort study
9689919|NCT04840329|Experimental|Education Arm|
9689920|NCT04840329|No Intervention|Waitlist Control Arm|
9689921|NCT04840368|Experimental|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
9689922|NCT04840368|Active Comparator|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min, and a cool down of 10 min (muscle stretching and relaxation). They will be performed individually, outside, at a self-selected intensity, with no supervision.
9689923|NCT04840082|Experimental|Collecting of Clinical Specimens for COVID-19 Testing|Nasopharyngeal swab is performed on all participants to collect specimens for Rapid antigen COVID-19 Testing
9689924|NCT04840108|Experimental|Support Person Coaching Intervention|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail. Support persons in this arm will also complete a one-session coaching intervention (15-25 minutes) delivered virtually by research staff via phone.
9689925|NCT04840108|Active Comparator|Support Person Written Materials|Support persons in the intervention arm will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
9689926|NCT04840043|Experimental|Osteopathy Group|Stimulation on the sympathetic truncus and prevertebral ganglia
9689927|NCT04840043|Sham Comparator|Control Group|Stimulation on similar areas with lighter touch and shorter duration
9689928|NCT04840004|Other|Aprepitant|One arm study.
9689929|NCT04839666||Propofol|
9689930|NCT04839939|Active Comparator|Control Group|Children in this group received conventional physical therapy program in form of Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training were all part of the treatment plan, which was based on the neurodevelopmental approach.
9689931|NCT04839939|Experimental|AFO Group|Children in this group received the same conventional treatment plus they were provided with solid community-prescribed AFO with a wearing schedule of 6-12 hours per day. Parents were given a detailed demonstration about how to use the AFO probably and watching for areas of skin overpressure. AFO needs to be worn with a smooth, long sock underneath with the child's heel is right down in the AFO with the ankle strap and/or shoe fastened firmly.
9689932|NCT04839939|Experimental|Combination Taping Group|"Children in this group received the same conventional treatment plus the combination taping technique, which was performed by one qualified physical therapist with over five years of experience. The technique started with the application of two 5-cm wide Kinesio tape I straps. The first strap was applied from the lateral condyle of the tibia to the base of the first metatarsal bone with the ankle joint in plantar flexion. The tape was not stretched for 5 cm from the initial site and was then stretched up to 30% for the remaining parts15. The second I strap While the therapist holds the ankle in dorsiflexion, he applied the distal end of the tape 10 cm below the ankle joint. With almost 70% tension, the proximal end is applied 10 cm above the ankle joint. While one hand was holding each end of the tape, the child was asked to move the joint into plantar flexion. Finally, both hands moved towards the middle of the joint to apply the remaining tape."
9689933|NCT04839965|Experimental|IV Ampion|Ampion administered via intravenous infusion
9689934|NCT04839965|Placebo Comparator|IV placebo|Placebo administered via intravenous infusion
9689935|NCT04840017|Experimental|Study group I|excessive body weight and flat feet
9689936|NCT04840017|Experimental|Study group II|normal body weight and flat feet
9689937|NCT04840017|No Intervention|Study group III|control, healthy children
9689938|NCT04839822|Experimental|Intervention Arm: Psychoeducation with elements of CBT & mood chart.|Patients will receive full access to edupression.com® immediately after inclusion. This intervention includes all medical mechanisms of action of edupression.com®: Psychoeducation with elements of CBT (learning content and exercises) and a mood chart (depression symptom monitoring).
9689939|NCT04839822|Active Comparator|Active control arm: (occupational) interventions and progress monitoring.|These patients will also receive an edupression.com® account with different content. This content will be limited to medically useful tips, that have have not been shown to be effective in improving depressive symptoms in RCTs. Patients of both arms will be instructed to use chat functions to contact study personnel and to fill out questionnaires and tests to collect outcome and additional measures.
9689940|NCT04839835|No Intervention|standard waiting room|standard chemoterapy waiting room
9689941|NCT04839835|Experimental|waiting room enriched with art objects|waiting room enriched with music, paintings and artificial plants
9689942|NCT04839900|Active Comparator|Proactive iCCM|Community health workers (CHWs) will conduct weekly visits of all households in their communities to detect children < 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. Weekly household visits will be conducted year round. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
9826809|NCT02432742|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
10187516|NCT03725514|Experimental|PRF|Platelet Rich Fibrin Technique
9689943|NCT04839900|No Intervention|Standard Passive iCCM|Community health workers (CHWs) will provide case management per national iCCM policy to all who are brought for consultation, but will not conduct household visits to provide active case detection. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
9689944|NCT04839679|Active Comparator|Standard of Care Mayo Clinic booklet|Subjects will receive the standard Mayo Clinic educational booklet in preparation for clinically indicated radiation therapy treatment
9689945|NCT04839679|Experimental|Culturally Oriented Education|Subjects will receive a culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner in addition to the standard Mayo Clinic booklet
9689946|NCT04840030|No Intervention|Standard health advice (SHA-control)|"The participant will receive verbal information of risk factors and information, reassessment, and written materials regarding approved recommendations on active and healthy aging on topics such as diet, physical activity, cognitive training as well as risk factor control following the state of the art and published guidelines by the Department of Health of the Basque Government/ Basque Country Public Health System (Osakidetza) and the WHO (Guidelines for risk reduction of cognitive decline and Dementia and the Guidance on person-centered assessment and pathways in primary care - ICOPE). Participants in this group will receive the best standard health care from their primary care and specialist health teams according to already established routines as well as usual social services assessments and care as needed."
10180545|NCT03791905|Experimental|FOLFOX Arm|Patients with baseline PET scan assigned to this Arm will receive three cycles of 2-weekly schedule of induction chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU), consisting of oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2, and 5-FU 2 g/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to TP regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
9689947|NCT04840030|Experimental|Multidomain intervention (MM-Int)|Participants in this group will receive the same verbal and written recommendations as to the ones in the SHA-Control group but then they will perform a 2 year structured program with periodic individual and group visits regarding 1) Risk factor control (vascular factors, polypharmacy); 2) Cognitive training, 3) Physical activity, 4) Dietary changing program and 5) emotional counseling and social engagement.
9689948|NCT04839731|Placebo Comparator|Placebo group|10 patients will be divided into 7 and 14 day treatment groups with 5 patients each. They will apply Nourivan base cream from Pure Science Rx, twice per day for their designated time.
9689949|NCT04839731|Experimental|7 day medication group|The 7 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 7 days.
9689950|NCT04839731|Experimental|14 day medication group|The 14 day medication group will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 14 days.
9689951|NCT04839796||Participants residing in urban areas|Urban residents enjoy convenient transportation, have access to abundant medical resources, have more job opportunities, and are on average younger but are also exposed to more air pollution.
9689952|NCT04839796||Participants residing in rural areas|Rural residents have less access to transportation, medical resources, and job prospects comparatively and are comparatively older. However, Rural residents are exposed to less pollution in general.
9689953|NCT04839926|Experimental|0.5mg CY150112|single oral CY150112 while fasting on day 1.
9689954|NCT04839926|Experimental|1.5mg CY150112|single oral CY150112 while fasting on day 1.
9689955|NCT04839926|Experimental|4.5mg CY150112|single oral CY150112 while fasting on day 1.
9689956|NCT04839926|Experimental|10mg CY150112|single oral CY150112 while fasting on day 1.
9689957|NCT04839926|Experimental|18mg CY150112|single oral CY150112 while fasting on day 1.
9689958|NCT04839926|Experimental|24mg CY150112|single oral CY150112 while fasting on day 1.
9689959|NCT04839848||Permanent suture|Mesh fixation with permanent suture
9689960|NCT04839848||Long-term absorbable|Mesh fixation with long-term absorbable suture
9689961|NCT04839848||Short-term absorbable|Mesh fixation with short-term absorbable suture
9689962|NCT04839848||Fibrin glue|Biologic glue/sealant produced from human donor blood
9689963|NCT04839848||Progrip|Pre-fabricated absorbable fixation hooks, integrated in mesh. Progrip is a registered trademark owned by Medtronic
9689964|NCT04839653|No Intervention|Control group: standard care|Patients in the standard care group will be prospectively evaluated to determine pre-defined clinical outcomes.
9689965|NCT04839653|Experimental|Selective digestive decontamination group|"Oral paste (0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B q6h~In the NGT 10 ml of suspension containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B and 500 mg of vancomycin q6h~A 3-day course of intravenous cefotaxime 1 g q6h/ceftriaxone 1 qd"
10180546|NCT03792087|Experimental|SmofKabiven Peripheral|Continuous intravenous Infusion for SmofKabiven Peripheral via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
10180547|NCT03792087|Active Comparator|Hospital compounded emulsion|Continuous intravenous Infusion for Hospital compounded emulsion via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
10180548|NCT03791892|Experimental|Shoulder mobilization Group|Kaltenborn mobilization will be applied to patient in experimental group only.
10180549|NCT03791892|Active Comparator|Conventional treatment Group|Application of conventional treatment that includes stretching and strengthening exercises of shoulder.
9689966|NCT04839536|Active Comparator|Target controlled infusion (TCI) propofol|For TCI propofol group, all patients will receive nasal CPAP mask and nasal breathing with oxygen of 3 litre/min. We will utilize the Schneider model to target effect-site (Cet) starting from 0.5 mcg/ml and with a gradual 0.5mcg/ml increment every 30s until OAAS score of 3 is achieved. For any patients with OAAS score < 3, Cet will be decreased by a decremental 0.5 mcg/ml. The deepest level of sedation will be recorded.
9689967|NCT04839536|Experimental|Sevoflurane sedation|Patients randomised to this arm will be given time to familiarise with the nasal continuous positive airway pressure (CPAP) mask and nasal breathing with oxygen 3 litre/min via a Bain anaesthetic circuit before the introduction of sevoflurane. Once the patient starts to adapt to nasal CPAP mask, sevoflurane will be delivered, starting with a concentration of 0.2% and increase stepwise by 0.2% every 30s until sedation score of OAAS of 3 is achieved. Anaesthetist in charge will assess and maintain sedation endpoint to OAAS 3. If patient is over sedated, sevoflurane concentration will be reduced by 0.2% until OAAS 3. The deepest level of sedation will be recorded.
9976261|NCT01349647|Experimental|Vaccine and Chemotherapy|This is a pilot trial evaluating the safety and immunogenicity of a pentavalent vaccine for patients with small cell lung cancer (SCLC). Patients with SCLC who have completed all planned initial therapy and have maintained a partial or complete response will be enrolled.
9689969|NCT04839549|Experimental|Dextenza (Intracanalicular ) 0.4mg|Dextenza for the treatment of Ocular Rosacea
9689970|NCT04839549|Active Comparator|Fluoromethalone .01%|Fluoromethalone .1% BID for 2 weeks then once daily for 2 weeks for the treatment of Ocular Rosacea
9689971|NCT04839575|Active Comparator|Latiglutenase|IMGX003
9689972|NCT04839575|Placebo Comparator|Placebo|Placebo
9689973|NCT04839627||serum progesterone measurement|
9689974|NCT04839640|Active Comparator|reinforced acrylic resin denture teeth|Shufo acrylic denture teeth
9689975|NCT04839640|Experimental|Composite resin denture teeth|Bredent denture teeth
9689976|NCT04839614|Experimental|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY|"Upon enrollment in the study at first appointment with gynecologic oncologist, referral to the BWH Center for Metabolic and Bariatric Surgery (CMBS).~Schedule a series of appointments with a bariatric surgeon, nutritionist and psychologist, which is part of the approval process for weight loss surgery.~Hysterectomy and weight loss surgery will then be scheduled on the same day within 8 weeks from first visit with the gynecologic oncologist for endometrial cancer or 12 weeks if you have endometrial pre-cancer.~Series of post-operative visits with the bariatric surgeon and gynecologic oncologic surgeon as well as the nutritionist and psychologist."
9689977|NCT04839445|Active Comparator|General anesthesia + TAP block|Induction: remifentanil in total intravenous anesthesia (TIVA), Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Transversus abdominis plane (TAP) block: 20 minutes before surgery. Ropivacaine 0.37% 20ml + dexamethasone 2mg per side. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the bispectral index system (BIS) values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and train of four (TOF) monitoring. Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev. Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev.
9689978|NCT04839445|Active Comparator|General anesthesia + ESP block|"Erector spinae plane (ESP) block: 20 minutes before surgery. T8 level bilaterally, ropivacaine 0.37% 20ml + dexamethasone 2mg per side.~Induction: Remifentanil in TIVA, Propofol 2 mg/kg/h and Rocuronium 0.6 mg/kg. Maintenance: TIVA with Propofol, the infusion rate will be adjusted according to the BIS values (30 <BIS <50). Patients will receive additional remifentanil by infusion at 0.02 mcg/kg/min per time if blood pressure and heart rate values exceed 20% pre-operative baseline values. Additional rocuronium 0.1 mg/kg based on clinical needs and TOF monitoring.~Analgesic starter bolus: 30 minutes before the end of the surgery, paracetamol 1 gr ev and ketorolac 30 mg ev.~Postoperative pain: paracetamol 1 gr ev every 8 hours for 36 hours; ketorolac 30 mg ev if NRS >4 / morphine 2 mg ev if NRS >4 30 min after ketorolac administration. In case of nausea and vomiting ondansetron 4 mg ev."
9689979|NCT04839406|Experimental|Intervention|"Structured follow up at the ICU~1-3 days after admittance: Map caregivers' prioritized symptoms, needs and preferences with a digital assessment tool, followed by a meeting with a nurse to address these issues.~Every 1-2 weeks: Repeat assessment of symptoms and needs with the assessment tool followed by a meeting with a nurse.~At discharge: Structured conversation focusing on information and preparation for the transition to a regular ward or to another hospital including a card with information and support.~Bereavement: Individualized support based on caregiver expressed needs, preferences and previous mapping, including a card with information and support.~Follow up: Caregivers or bereaved will be contacted after 4-6 weeks, and will be offered a follow up conversation either on phone or at the unit."
9689980|NCT04839406|No Intervention|Follow up as usual (Control)|Follow up as usual at the ICU
9689981|NCT04839263|Active Comparator|"FAST TRACK protocol"|"FAST TRACK protocol Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~Hospitalization on surgery day~No prolonged fasting~Perioperative strategy:~Pain control based on limited systemic opioid therapy use~Anti-nausea prophylaxis~Anaesthesia via IV propofol / remifentanyl~Bladder catheter removal postoperative~Postoperative strategy:~Pain control using balanced analgesia~Gum chewing~Early oral refeeding and rapid mobilization~Venflon removal 6 hours post-op"
9689982|NCT04839263|No Intervention|"Conventional setting protocol"|"Conventional setting protocol~Preoperative strategy:~Hospitalization on surgery day~Fasting as of midnight prior to the day of surgery~Perioperative strategy:~- Balanced anaesthesia via halogens gases~Postoperative strategy:~Same day refeeding and mobilization minimum 6 hours post operation~Bladder catheter and Venflon removal on day 1"
9689983|NCT04839432||Crystalloids group|Patients had only a balanced crystalloid solution in the priming of the cardiopulmonary bypass (pre interventional group)
9689984|NCT04839432||albumin group|Patients had only a 4% albumin solution in addtion to a very low volume of a balanced crystalloid solution in the priming of the cardiopulmonary bypass (post interventional group)
9689985|NCT04839224|Experimental|Carbogen group|
9689986|NCT04839224|Active Comparator|Phenylephrine group|
9689987|NCT04839211|Experimental|Inspiratory muscle training|High-intensity inspiratory muscle training
9689988|NCT04839211|Sham Comparator|Sham inspiratory muscle training|Unloaded inspiratory muscle training
9689989|NCT04839458|Experimental|Dental Prescale II used|
10180550|NCT03791931|Other|Patients|Oxidative stress measurement in cleavage state embryos
10180551|NCT03791879|Active Comparator|• Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k|
10180552|NCT03791879|Active Comparator|• Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.|
9689990|NCT04839497|Experimental|Volar Fibroblast Treatment|Volar fibroblasts are injected into the residual limb of transtibial amputees
9689991|NCT04839497|No Intervention|Cryoprotectant|Vehicle Control. Interdermal injection of cryoprotectant
9689992|NCT04839276|Experimental|Injection Laryngoplasty with PRF and Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is added to 4 mL of PRF and is smoothed by pushing it back and forth 15 times on a 2-tube 10 mL piston tube connected to a three-way connector. 3 mL of the mixture of fat and PRF is injected using a 12 G laryngoplasty syringe until medialization is achieved.
9689993|NCT04839276|Active Comparator|Injection Laryngoplasty with Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is mashed by pushing it back and forth 15 times in a container of 2 piston tubes (10 mL) connected to a three-way connector. The crushed fat is injected as much as 3 mL using a 12 G laryngoplasty syringe until medialization is achieved.
9689994|NCT04839471|Experimental|BI-754091 plus afatinib|BI-754091 plus afatinib
9689995|NCT04839328|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
9689996|NCT04839328|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
9689997|NCT04839302||Patients with possible nectrotizing fascitis|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
9689998|NCT04839484|Experimental|Lumina|Lumina Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
9689999|NCT04839484|Active Comparator|Restylane Defyne|Restylane Defyne Dermal Filler injected into 1 nasolabial fold. Optional Touch-up at 3 week visit with same.
9690000|NCT04839250|Experimental|cataract surgery performed by heads-up method|
9690001|NCT04839250|No Intervention|Traditional surgery|Traditional surgery was performed under a surgical microscope.
9690002|NCT04839198|Experimental|Adaptive Treatment plus usual care|
9690003|NCT04839198|Active Comparator|Usual care|
9690004|NCT04839341|Experimental|A Phase I, open-labeled multicenter study|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)
9690005|NCT04839237|Experimental|Liraglutide|Obese patients with HbA1C lower than 9.0%,receive Liraglutide alone for 3 months.
9690006|NCT04839237|Experimental|Liraglutide combined with metformin|Obese patients with HbA1C ≥9.0%, receive Liraglutide in combination with metformin for 3 months.
9690007|NCT04839120|Active Comparator|MDPK67b|
9690008|NCT04839120|Placebo Comparator|Placebo|
9690009|NCT04839081||RA patients|RA patients diagnosed according to the 1987 ACR Criteria
9690010|NCT04839081||Control|Age- and sex-matched control subjects with nociceptive/mechanical pain complaint other than in hand, lasting more than three months
9690011|NCT04839159|Experimental|SCD Patient|
9690012|NCT04839055|Experimental|Experimental: Coenzyme A 200U|Coenzyme A 200U per day
9690013|NCT04839055|Placebo Comparator|Placebo Comparator: Placebo|Abiraterone without coenzyme A
9690014|NCT04839068||First is retrospective part|: by obtaining the data from the patients records in a period between January 1st 2019 to December 31st 2019, and from May 1st 2020 to December (excluding women conceived before April 1st 2020)
9690015|NCT04839068||Second is prospective part|the same data will be obtained from the patient records in the same way in a period from the January 1st 2021 to the December 31st to assess the pregnancy outcomes in pregnant women who conceived after occurrence of Covid 19 pandemic in Egypt.
9690016|NCT04838821|Experimental|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
9690017|NCT04838821|Experimental|Placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
9690018|NCT04838652|Experimental|Pembrolizumab plus Chemotherapy|All patients will receive 1 dose of 200 mg pembrolizumab IV as single agent upfront, followed by 2 cycles of IV P-ICE (pembrolizumab, ifosfamide, carboplatin, etoposide) and a PET/CT-based restaging. Following a PET-guided treatment strategy, patients will then receive either another 2 cycles of IV P-ICE in case of a negative PET (i.e., Deauville score 1-3), or 2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin) in case of a positive PET (i.e., Deauville score > 3). After completion of treatment with P-ICE or P-DHAP, respectively, patients will receive a consolidation therapy with pembrolizumab for another 6 cycles. In case of non-CR after at least 4 cycles of combination therapy (4x P-ICE or 2x P-ICE + 2x P-DHAP), physicians may decide to go for HDCT or an alternative standard of care treatment option.
9690019|NCT04838730|Experimental|single-arm|Hanita CleaRing device (CE approved; AMAR Certificate)
9690020|NCT04838704|Experimental|RUX group|
9690021|NCT04838704|Active Comparator|Control group|
9690022|NCT04838951|Experimental|Intervention arm|CADe system will be used during withdrawal phase of colonoscopy.
9690023|NCT04838951|No Intervention|Control arm|Colonoscopy will be performed according to hospital protocol.
10180553|NCT03791879|Active Comparator|• Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/|
10180554|NCT03791879|Active Comparator|• Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.|
10180555|NCT03791918|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10180556|NCT03791918|Active Comparator|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
10180557|NCT03792022||Group 1|Adherence to timely vaccine uptake
10180558|NCT03792048|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
9690024|NCT04838665|Active Comparator|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)|20 infants were enrolled in Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI)
9690025|NCT04838665|Experimental|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)|Single instillation of 0.5% tropicamide + 0.5% phenylephrine (SI)
9690026|NCT04838665|Experimental|1 instillation of 0.5% tropicamide +0.5% phenylephrine w/a cotton wick placed in the inferior fornix|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick placed in the inferior fornix (SIW)
9690027|NCT04838847|Experimental|Participants / Healthy Participants Aged ≥65 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9690028|NCT04838847|Experimental|Participants / Healthy Participants Aged 18-45 Years|Participants will be vaccinated with CVnCoV 12 μg mRNA on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9690029|NCT04838873|Active Comparator|Open Radical Cystectomy|Standard open radical cystectomy.
9690030|NCT04838873|Experimental|Laparoscopic-assisted radical cystectomy.|Laparoscopic-assisted radical cystectomy.
9690031|NCT04838808|Active Comparator|Rivaroxaban|Rivaroxaban 2.5mg oral twice daily for 90-days
9690032|NCT04838808|Placebo Comparator|Placebo|Oral placebo tablet twice daily for 90-days
9690033|NCT04838691|Experimental|interpersonal relations counseling applied|8 sessions of interpersonal relations counseling, each lasting 40 minutes, were applied for 2.
9690034|NCT04838691|No Intervention|no application|No action taken.
9976262|NCT01349647|Experimental|Vaccine Alone|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
10180559|NCT03792048|No Intervention|Manual Anastomosis|Manual Anastomosis for bilioenteric anastomosis and pancreaticojejunostomy
9690037|NCT04838886|Experimental|Exercise group|The intervention group will be received telerehabilitation-based pilates training three times a week for 6 weeks.
9690038|NCT04838886|No Intervention|Waitlist|The control group will be a wait-list group without any additional specific treatment.
9690039|NCT04838860|Active Comparator|Parallel Arm of iMCD Patients|Enrolling in Stage 1a of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
9690040|NCT04838860|Active Comparator|Parallel Arm of TAFRO-iMCD Patients|Enrolling in Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.
9690041|NCT04838899|Experimental|Treatment Arm|All metastases that fulfill the definition of oligoprogression seen on conventional imaging will be treated with standard SABR dose fractionation schemes routinely used at Sunnybrook Odette Cancer Centre. The prostate (if present and not previously treated) will be treated to a dose of 35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Spine metastases will be treated to a dose of 24 Gy in 2-3 fractions or 30-40 Gy in 5 fractions. Involved lymphadenopathy will be treated to a dose of 30-40 Gy in 5 fractions. Similarly, brain, lung, liver, and adrenal metastases will be treated with standard Sunnybrook SABR doses. Patients will remain on abiraterone during and after SABR treatments.
9690042|NCT04839016|Experimental|Treatment group A|
9690043|NCT04839016|Placebo Comparator|Treatment group B|
9690044|NCT04838587||6750 Children <3 years ( 5 sites)|A total of 6750 children from the will be identified from the respective health facility catchment area during the Census stage of the study. Each of the 5 health facilities will identify 1350 children under 3 years of age in their respective catchment area. During the Surveillance stage, the participants will be enrolled into the study if and when they present with diarrhoea at the Health facility.
9690045|NCT04838288|Experimental|Change from Prograf to Envarsus|All participants will be switched from Prograf to Envarsus
9690046|NCT04838392|Experimental|CGM System|Blood draw and glucose challenge will be performed to evaluate performance of CGM system compared to reference measurement during in in-clinic visits.
9696236|NCT04769128|Active Comparator|Group (A) (control group)(traditional physical therapy programme)|Group (A) (control group): Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training. 3 sessions/ week for 12 weeks.
10180560|NCT03792035|Experimental|Experimental group|First time given 8 capsules of Tongxinluo, then given 4 capsules of Tongxinluo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
10180561|NCT03792035|Placebo Comparator|Control group|First time given 8 capsules of placebo, then given 4 capsules of placebo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
9690047|NCT04838171||Specimen collection to support development of engineering Treg|
9690048|NCT04838262|Experimental|Assessment of Daily Stress Processes|Subjects will report cumulative exposure, perceived severity, and emotional responsiveness to commonly occurring everyday psychosocial stressors utilizing an ecological momentary assessment approach for 8 consecutive days.
9690049|NCT04838405|Experimental|CT-388|SC dose of CT-388
9690050|NCT04838405|Placebo Comparator|Placebo|SC dose of placebo matching CT-388 dose
9690051|NCT04838301|Experimental|Allo group|Allopregnanolone 4mg IV 30-minute infusion once per week for 12 months.
9690052|NCT04838301|Placebo Comparator|Control group|Placebo (normal saline) IV 30-minute infusion once per week for 12 months.
9690053|NCT04838314|No Intervention|Standard of cares|Peri operative analgesia by opioids
9690054|NCT04838314|Experimental|regional analgesia|Peri operative analgesia by continuous bilateral ESP catheters
9690055|NCT04838210|Experimental|Group Prenatal Care|Group prenatal care model
9690056|NCT04838210|Active Comparator|Individual Prenatal Care|Individual prenatal care
9690057|NCT04838509||Patients with elevated creatine kinase|
9690058|NCT04838340|Active Comparator|Standart care|Standart care group will leave in the hospital's usual care and no intervention will be applied.
9690059|NCT04838340|Experimental|Hypnobirthing group|Hypnobirthig training intervention will be applied to the Hypnobirthing group for 4 weeks and 3 hours a week and usual care will be provided by healthcare professionals.
9690060|NCT04838535|Other|PCOS follicular fluid|
9690061|NCT04838483|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
9690062|NCT04838379|Placebo Comparator|group Bupivacaine|will include 30 patients: each one will receive 2.5 mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
9690063|NCT04838379|Active Comparator|group bupivacaine&dex|2 will include 30 patients: each one will receive 2.5mg/kg of 0.25% bupivacaine plus 2 µ/kg of dexmedetomidine diluted in a 20 mL syringe of normal saline , 10 minutes before skin incision
9690064|NCT04838548|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
9690065|NCT04838249||Female Control|"n = 20; Inclusion criteria~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
9690066|NCT04838249||Male Control|"n = 20; Inclusion criteria~informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m² Exclusion criteria severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.) only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head/neck region, claustrophobia etc.)"
9690067|NCT04838249||Female cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
9690068|NCT04838249||Male cross-sex hormone therapy|"n = 20; Inclusion criteria~transsexual patients undergoing cross-sex hormone therapy informed consent, if <18 years from all legal guardians only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months BMI ≤ 30 kg/m²~Exclusion criteria~severe medical impairments (e.g., uncontrolled cardiovascular disease, etc.) self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders Chronic pulmonary disorders Diagnosed gastrointestinal diseases History of HIV infection or ongoing chronic infection only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan"
9690069|NCT04838275|Experimental|Exercise Arm|antifibrotic therapy + mHealth monitoring + 12-wk mHealth home exercise prescription
10180562|NCT03791814|Experimental|Zepatier treatment|Open-label Zepatier (grazoprevir 100 mg and elbasvir 50 mg) will be administered in this study. Daily treatment of Zepatier for a 12-week duration will be administered.
10180563|NCT03792126|No Intervention|Standard Care|
10180564|NCT03792126|Experimental|Implicit Learning Approach|
10180565|NCT03791801|Active Comparator|Neostigmine|Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1
10180566|NCT03791801|Active Comparator|Sugammadex|Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).
10180567|NCT03791983|Experimental|Therapy Group|
10180568|NCT03791983|Other|Control Group|
10180569|NCT03791788||QFR Group|Patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, NSTEMI (non ST-segment elevation myocardial infarction), or STEMI (ST-segment elevation myocardial infarction) with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
9690070|NCT04838275|No Intervention|Non-Exercise Arm|antifibrotic therapy + mHealth monitoring
9690071|NCT04838496|Experimental|Single-arm study|All patients will receive induction chemotherapy consisting of 4-6 cycles of FOLFOXIRI. Restaging will be performed after 4 cycles with a pelvic MRI and a thoraco-abdominal CT-scan. In case of stable or responsive disease, the remaining 2 cycles of FOLFOXIRI will be provided. In case of progressive, but still resectable disease, chemoradiation will be provided immediately, without the remaining 2 cycles of FOLFOXIRI. Restaging will be performed after chemoradiation. In case of resectable disease, surgery is performed.
9690072|NCT04838366|Experimental|Intervention|The study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). We will provide glucose-D.
9690073|NCT04838366|No Intervention|Usual care|The control group will be kept in fasting condition from midnight as a traditional practice in existence.
9690074|NCT04838158|Active Comparator|Intervention group|Those cases who underwent operative treatment and isokinetics evaluation.
10180570|NCT03791866|Experimental|30% target total enteral nutrition|
10180571|NCT03791866|Experimental|60% target total enteral nutrition|
9690075|NCT04838158|Other|Control group|Those who were control group of healthy subjects to compare to normative data
10180572|NCT03791866|Active Comparator|100% target total enteral nutrition|
10180573|NCT03791775|Experimental|Polidocanol 3% Foam|Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany).
9690076|NCT04838145|Active Comparator|Active treatment|Pleconaril: 5 mg/kg x2 times a day for 26 weeks up to 40 kg. Max dose 300mg x2. Ribavirin:15 (7.5) mg/kg/day divided in two doses daily for 26 weeks: Max dose 1000mg/24h if body weight<75kg and 1200mg if body weight>75kg.
9690077|NCT04838145|Placebo Comparator|Placebo|Receives placebo, on a double blind basis
9690078|NCT04838184||Dental patients|Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible
9690079|NCT04838119||Patients with a preoperative asymptomatic COVID screening test|
9690080|NCT04838132|Experimental|Transversus thoracis muscle plane and rectus sheath block with ropivacaine|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.3% ropivacaine respectively.
9690081|NCT04838132|Experimental|Transversus thoracis muscle plane and rectus sheath puncture with saline|Using the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle (TTP block) and rectus sheath block, give 15ml and 10ml 0.9% saline respectively.
9690082|NCT04838093||Patient cohort:|all patients with vascular disorders consecutively admitted at our tertiary care hospital from March 16 to December 07, 2020
9690083|NCT04838093||Control cohort:|data of two nationwide PCR-based studies conducted in a representative random sample, from April 1-6, and November 12-14, 2020, collected by the Austrian Ministry of Science and the Austrian Red Cross to estimate the spread of SARS-CoV-2 infection among the non-hospitalized Austrian population.
9690084|NCT04838093||HCP cohort:|HCP worker data, including nurses, nurse technicians, physicians, surgical personal, physical therapists, nurse practitioners, environmental service workers, administrative staff, and dietitians, working in close proximity to admitted patients at our tertiary care hospital from March 16 to December 07, 2020.
9690085|NCT04838028||StdPPM|Standard pure polypropylene mesh
9690086|NCT04838028||LWM|Lightweight mesh
9690087|NCT04838028||Tacks, metal|Metal staples or tacks
9690088|NCT04838028||Tacks, absorbable|Absorbable synthetic staples or tacks
9690089|NCT04838028||Fibrin glue|Biologic glue/sealant produced from human donor blood
9690090|NCT04838028||Non-fixation|Mesh is deployed without fixation
10180574|NCT03791827||Corticosteroid|Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid
10180575|NCT03791827||Corticosteroid and cyclophosphamide|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide
9690091|NCT04838002|Active Comparator|Focus ESWT|
9690092|NCT04838002|Active Comparator|Radial ESWT|
9690093|NCT04838002|Sham Comparator|Sham ESWT|
9976263|NCT01349686|Experimental|Oral intake of fluids|Intake of oral fluids during labour.
10180576|NCT03791827||Corticosteroid and mycophenolate mofetil|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil
10180577|NCT03791827||Corticosteroid and azathioprine|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine
10180578|NCT03791827||Corticosteroid and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus
10180579|NCT03791827||Corticosteroid and cyclosporine A|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A
10180580|NCT03791827||Corticosteroid, mycophenolate mofetil and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus
10180581|NCT03791827||Retuximab|An option for refractory lupus nephritis
10187517|NCT03725501|Experimental|Ranibizumab + ALS-L1023 600mg|"ALS-L1023 600 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
10180582|NCT03791697|Active Comparator|Telephone Group|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes."
10180583|NCT03791697|No Intervention|In Person Clinic Visit Group|For the patient randomized into the clinic group, the clinic visit will entail questions about common postoperative complications (including fever, nausea/vomiting, pain, urinary symptoms, constipation, etc.). As per usual, vital signs and a focused physical examination will be completed at the clinic visit. All clinic visits will be performed by an FPRMS fellow and/or attending physician
9690094|NCT04837950|Experimental|Before pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview before pulling diaphragmatic suture
9690095|NCT04837950|Experimental|After pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview after pulling diaphragmatic suture
9690096|NCT04837911|Other|Patients using the Spirobank Smart|Use of a portable spirometry
9690097|NCT04837859|Experimental|Arm A age 18-60|Patients at the age of 18-60 years at enrollment will receive 2 initial doses of 200 mg tislelizumab in 21-day intervals followed by an interim positron emission tomography (PET-2). Following a PET-guided approach, patients with a negative PET-2 (i.e. Deauville score 1-3) according to central review will continue receiving tislelizumab for another 4 doses of 300 mg in 28-day intervals. Patients with a positive PET-2 (i.e. Deauville score >3) will receive 4 cycles of combined 300 mg tislelizumab on day 1 and AVD chemotherapy on day 1 and 15 in 28-day cycles (4x T-AVD). For all patients, 30 Gy involved-site radiotherapy (IS-RT) will only be applied in case of PET positivity after completion of (chemo-) immunotherapy.
9690098|NCT04837859|Experimental|Arm B Age 60+|Patients above the age of 60 years will be enrolled in a separate, exploratory cohort and receive PET-guided treatment with tislelizumab or T-AVD as described above. However, all patients in the exploratory cohort for older patients will receive consolidating 30 Gy IS-RT.
9690099|NCT04837885|Experimental|68Ga-DOTA-peptides PET/CT|68Ga-DOTA-peptides injections for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
9690100|NCT04837885|Experimental|LUTATHERA® by intra-arterial hepatic injection (IAH)|One treatment dose of LUTATHERA® by intra-arterial hepatic injection after conventional treatment by 4 intravenous administrations
9690101|NCT04837781|Experimental|Normal vitamin D|Include patients with normal vitamin D level (above 30ng/ml). Vitamin D level will be measured at the beginning of treatment if there is deficiency then the patient refer to specialized physician to be supplied with vitamin D supplement to optimized the level to normal then start orthodontic treatment
9690102|NCT04837781|Experimental|Vitamin D deficiency|Include patients with unknown vitamin D level until time of canine retraction where we measure level if deficiency exist (below 30ng/ml) then the patient will be referred to specialized physician to be supplied with vitamin D supplement.
9690103|NCT04837781|Experimental|Control|includes patients with unknown vitamin D level until the completion of canine retraction where we measure level. If deficiency exists (below 30ng/ml) then we will refer the patient to specialized physician to be supplied with vitamin D supplement
9690104|NCT04837924|Experimental|B (FICB)|Participants receiving fascia iliaca compartment block (FICB)
9690105|NCT04837924|Sham Comparator|A (PLACEBO)|Participants receiving sham injection matching fascia iliaca compartment block (FICB)
9690106|NCT04838080|Experimental|Low dose vaccine|Inactivated COVID-19 Vaccine 4 µg/0.5 ml
9690107|NCT04838080|Experimental|High Dose Vaccine|Inactivated COVID-19 Vaccine 6 µg/0.5 ml
9690108|NCT04838080|Placebo Comparator|Placebo|0.9 % NaCl
9690109|NCT04838067|Experimental|Cefaly Intervention|Cefaly
9690110|NCT04837573|Experimental|Group 1 Intervention, Weeks 1-8|During Weeks 1-8, Group 1 receives the Intervention and Group 2 receives no treatment.
9690111|NCT04837573|Active Comparator|Group 2 Intervention, Weeks 9-16|During Weeks 9-16, Group 2 receives the Intervention and Group 1 receives no treatment.
9690112|NCT04837664|Experimental|Rose Bengal-mediated Photodynamic therapy|Participants belonging to the rose bengal mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer rose bengal was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
9690113|NCT04837664|Experimental|Curcumin-mediated photodynamic therapy|Participants belonging to the curcumin mediated photodynamic therapy, their dentures and oral cavity were illuminated using the LED device for 26 minutes (37.5 J/cm2). The photosensitizer curcumin was sprayed on the palate and dentures for half-hour. To irradiate the palate, the investigator handled the other LED device; the circular platform having LEDs was put within the patient's oral cavity and the illumination of the palate was carried out for 20 minutes (122 J/cm2). The PDT was carried out thrice per week for a half month (6 sessions) in each participant.
9690114|NCT04837664|Active Comparator|Nystatin therapy|Participants belonging to the Nystatin group were administered the topical nystatin-based antifungal drug.
9690115|NCT04837469|Experimental|Universal Adhesive|universal adhesive
9690116|NCT04837469|Experimental|Etch-And-Rinse Adhesive|Etch-And-Rinse Adhesive
9690117|NCT04837872|Experimental|Multimodal Physical Therapy (MPT)|The multimodal physical therapy (MPT) program consisted of manual therapy, therapeutic exercise, and utilization of a static progressive splint (Joint Active Systems SPS Knee, Effingham, IL). Although the primary focus of this study was on improving knee flexion ROM, two protocols were developed: one to improve flexion deficits and one to improve extension deficits. Participants in the MPT group received physical therapy 2x per week for 4 weeks. They were instructed to use the static progressive splint(s) 3x per day for 30 minute sessions (90 minutes total per day) for each splint (e.g., 90 minutes for flexion splint, 90 minutes for extension splint).
10180584|NCT03791684|Active Comparator|Accelerated Cross Linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 18mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 5 min, delivering a dose of 5.4 J/cm2.
10180585|NCT03791684|Active Comparator|Standard Cross linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 3mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 30 min, delivering a dose of 5.4 J/cm2.
9690119|NCT04837898|Active Comparator|Haskap berry|A commercially available haskap berry freeze-dried) powder
9690120|NCT04837898|Placebo Comparator|Placebo|Black cherry KoolAid (Kraft Foods, USA) with added maltodextrin to match carbohydrate and calorie content
9690121|NCT04837443|Experimental|Synchronous working group|
9690122|NCT04837443|Sham Comparator|Asynchronous working group|
9690123|NCT04837625||Myasthenic Crisis Cohort|
9690124|NCT04837742|Experimental|ESPB group|ESPB injection at T8 region with levobupivacaine 100mg (20 ml)+ Iohexol 10 ml
9690125|NCT04837742|Sham Comparator|Control group|ESPB injection at T8 region with 0.9% normal saline 20ml + Iohexol 10ml
9690126|NCT04837417||Pathologic group|At least 10 male participants who underwent anterior cruciate ligament arthroscopic reconstruction using semitendinosus and gracilis tendons graft, between 6 and 18 months before the tests
9690127|NCT04837690||UEMR|
9690128|NCT04837612||Subjects with dilated cardiomyopathy|Subjects diagnosed with dilated cardiomyopathy by medical history, physical examination and echocardiography.
9690129|NCT04837560|Experimental|Temporarily or permanently wheelchair users which suffer from Venous Edema|Temporarily or permanently wheelchair users which suffer from Venous Edema
9690130|NCT04837651||Ocrelizumab Treated Multiple Sclerosis Patients|
9690131|NCT04837651||Natalizumab Treated Multiple Sclerosis Patients|
9690132|NCT04837989|Experimental|Diabetes Body Project|Participants randomized to the experimental condition will receive virtual Diabetes Body Project groups immediately.
9690133|NCT04837989|Active Comparator|Educational|Participants randomized to the control condition will receive an education brochure and will be offered the Diabetes Body Project after 6 months.
9690134|NCT04837404|Other|ultrasound guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Ultrasound guided femoral access will be used.
9690135|NCT04837404|Other|fluoroscopy guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.
9690136|NCT04837599|No Intervention|Pentax i 10|Patient gets normal colonoscopy without Endocuff or activation of artifical intelligence
9690137|NCT04837599|Active Comparator|Pentax i 10 with artificial intelligence Discovery TM|Normal Pentax i 10 colonoscope with on the special monitor acitvated artificial intelligence
9690138|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM|Endocuff cap is mounted on the tip of the endoscope a cheap assistance device proven in former studies to increase adenoma detection rate.
9690139|NCT04837599|Active Comparator|Pentax i 10 with Endocuff TM and artificial intelligence Discovery TM|Endocuff cap is mounted on the tip of the endoscope and artificial intelligence is activated on the monitor. hypothesis is that probably artificial intelligence and Endocuff combined potentiate their effect.
9690140|NCT04837456|Experimental|Calorie restricted diet and excecise intervention|a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement [36]. Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%[36].Each session was approximately 150 minutes one week for six months and consisted of aerobic exercises, resistance training, and exercises to improve flexibility and balance.
10180586|NCT03791671|Experimental|individual balance training|"After the initial assessments, the three week intervention time begins, which is completed with the reassessments.~The patients receive 2x weekly individual balance training for 25 minutes each. This runs in addition to the normal, prescribed rehabilitation program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period."
10180587|NCT03791671|Active Comparator|group balance training|"The patients receive 2x weekly group balance training for 25 minutes each. This runs in addition to the normal, prescribed rehab program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period.~In group therapy are 3 to 6 patients with different neurological diagnoses. As it is usual in rehabilitation everyday life."
10180588|NCT03791710|Placebo Comparator|control group|this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
9690141|NCT04837456|Experimental|libitum diet and waiting list control group|participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
9690142|NCT04837456|Experimental|Early APM group|Early APM group participants received APM with syndrome within 3 to 6 months
9690143|NCT04837456|Experimental|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
9690144|NCT04837391||Urologic oncology surgery in elderly|Elective urologic oncology surgeries such as radical nephrectomy, radical cystectomy, radical prostatectomy in older than 65 years
9690145|NCT04837339|Other|Patients with lung disease requiring transplantation or who have undergone lung transplantation|There is no intervention to be administered.
9690146|NCT04837118|Experimental|Supportive care (resistance training)|SEE DETAILED DESCRIPTION.
9690147|NCT04837300|Experimental|Experimental-1|Resisted Sprint Training
9690148|NCT04837300|Experimental|Experimental-2|Plyometric Training
9690149|NCT04837300|No Intervention|Control|No Training
9690150|NCT04837131|Experimental|Ixazomib in patients with scleroderma-interstitial lung disease (ILD)|Participants will be administered oral ixazomib for six cycles (each cycle is 28 days duration).
9690151|NCT04837014|Experimental|Acetaminophen and naproxen only arm|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration.
10180589|NCT03791710|Active Comparator|fat grafting group|this group of patients will have the autologous fat grafting for their burn wounds
10180590|NCT03791970|Experimental|DCB for post-dilation|DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
9690152|NCT04837014|Active Comparator|Acetaminophen, naproxen and dilaudid arm|Patient allocated to the control group will be discharged home with a prescription for regular acetaminophen, naproxen, and 5 tabs of hydromorphone 1 mg, with instruction to prioritize non opioid analgesic as first line.
9690153|NCT04837170|Experimental|S (+)-Ketamine group|"Drug: Conventional therapy + S (+)-Ketamine In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection,but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~Bolus intravenous injection before skin incision, the dose is 0.1~0.5 mg/kg;~Bolus intravenous injection (dose 0.1~0.5 mg/kg) before skin incision +continuous intravenous infusion (dose of 0.1~0.25 mg/kg/h) during operation;~Continuous intravenous infusion after surgery with a dose of 0.02~0.1 mg/kg/h for 24~48 h."
9690154|NCT04837170|Active Comparator|Control group|Drug: Conventional therapy Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
9690155|NCT04837053|Experimental|Intervention cluster|EKIT tool
9690156|NCT04837053|Active Comparator|Control Cluster|routine care
9690157|NCT04837144|Experimental|Intervention Group|The Intervention Group will receive 9 physical rehabilitation sessions using the MAK device. Each session will consist of approximately 90 minutes.
9690158|NCT04837287|Active Comparator|Static Stretching Exercise for 10 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
9690159|NCT04837287|Active Comparator|Static Stretching Exercise for 30 Seconds|After the participants are given one session of training, the participants do the exercises themselves at home.
9690160|NCT04837274|Placebo Comparator|Placebo|Dextrose (480 mg)
9690161|NCT04837274|Experimental|Active|Tart Cherry (480 mg)
9690162|NCT04837157|Experimental|Intervention Group|9 treatment sessions will be performed with the ATLAS2030 exoskeleton. The rehabilitation sessions last approximately 90 minutes. Two sessions are scheduled per week, for two weeks.
9690163|NCT04837248|Active Comparator|Group 1. Conventional treatment|Patients will be treated with a physiotherapy programme without digital support.
9690164|NCT04837248|Experimental|Group 2. Experimental treatment.|Patients will be treated using a digitally supported physiotherapy programme.
9690165|NCT04836962|Placebo Comparator|control|normal saline is administrated to patients.
9690166|NCT04836962|Experimental|dexamethasone|0.5mg/kg dexamethasone is administered to patients.
9690167|NCT04837313|Experimental|Parkinson's Disease with Constipation|Fecal microbiota transplantation will be performed.
9690168|NCT04837326|Experimental|Heel Lance Blood Sampling in Facilitated Tucking Position|The infants were put in facilitated tucking position by an experienced newborn nurse. They were put in facilitated tucking position so that their arms and legs were in a flexed midline position close to their trunk in a side-lying position. They were positioned so that they could move their extremities freely. They were held in facilitated tucking position for 120 seconds before the procedure. They were kept in facilitated tucking position until the blood sample was taken from the right heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
9690169|NCT04837326|Experimental|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|The mother, whose privacy was protected, embraced the infant for 120 seconds before the procedure. The infant was embraced by the mother during the heel lance blood sampling from the left heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
10180591|NCT03791970|Active Comparator|POBA for post-dilation|POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
10180592|NCT03791736|Experimental|Sandostatine|Injection of Sandostatine
10180593|NCT03791762|Experimental|WaveOne Gold|Root canal preparation with WaveOne Gold instrumentation system in a reciprocating manner
10180594|NCT03791762|Experimental|Reciproc Blue|Root canal preparation with Reciproc Blue instrumentation system in a reciprocating manner
10180595|NCT03791762|Experimental|ProTaper Next|Root canal preparation with ProTaper Next instrumentation system in a rotating manner
10180596|NCT03791840||Ultrasound evaluation|Eligible patients undergo lymph node biopsy or lymph node dissection. Before surgery, the status of axillary lymph node status was evaluated using ultrasound. After surgery, all lymph node specimens would be collected and be assessed using ultrasound in a special evaluation system in vitro.
10180597|NCT03791372|Placebo Comparator|Placebo|0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
10180598|NCT03791372|Experimental|Cord Blood Mononuclear Cells(CBMNC)|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells>1*10^7/kg). The infusion speed is 1ml/min.
10180599|NCT03791749|Experimental|Breastfeeding Support|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. Mothers will be asked to perform a simple technique while breastfeeding at least once a day.
10180600|NCT03791749|No Intervention|Standard Care|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. No intervention will be administered.
10180601|NCT03791502|Experimental|Pilates Method Exercises - lower volume|The prescription will consist of 18 exercises, performed in a single series of seven to 10 repetitions, 60 seconds rest between exercises. Each week the exercises will be changed and the same exercise can only be repeated every three weeks. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises, but without modifying the repetitions. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
10180602|NCT03791502|Experimental|Pilates Method Exercises - higher volume|The participants will conduct a Pilates exercise program based on the recommendations of the American College Medicine of Sports. The prescription will consist of 12 exercises, performed in three sets of seven to ten repetitions and 60s of rest between sets. Every four weeks the exercises will be changed. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
10180603|NCT03791502|No Intervention|Group control|The subjects allocated in the control group will remain with their usual activities, and after the reevaluation will be offered the intervention that presents the greater size of effect.
10180604|NCT03791723|Experimental|Sacubitril/valsartan|After catheter ablation, during a single blind, run-in period, participants received placebo. Then started with 50 mg sacubitril/valsarta for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
9690170|NCT04837326|Experimental|Heel Lance Blood Sampling Using White Noise|The 'Don't Let Your Baby Cry, PT.2' track from the 'Colic' album by Orhan Osman using the 'The Happiest Baby' album by Dr. Harvery Karp which was composed only of intrauterine was made listened to the infants via Xperia Ultra Mp3 Player for 120 seconds before and 120 seconds after the heel lance blood sampling procedure. While white noise was made listened to the infants before, during and after the procedure, Digital Sound LeverMeter brand noise measurement device was put at a distance of 50 cm from the infant and the ambient noise level was adjusted as 55 dB. The blood samples were taken by the researcher after inserting the lancet in the first try.
9690171|NCT04837326|No Intervention|Control Group|Suitable environmental conditions (ambient temperature, silent environment, etc.) were ensured in the study room for the infant's comfort. A saturation probe was inserted to the right wrist of the infant to monitor him/her. A video record was taken for 120 seconds without any intervention to the infants before and after the heel lance blood sampling procedure. The blood samples were taken by the researcher after inserting the lancet in the first try. Heel lance was performed in clinical routine for preterm infants in the control group.
9690172|NCT04836949|Experimental|Shear Wave Elastography Group|
9690173|NCT04836949|Active Comparator|Conventional ultrasonography Group|
9690174|NCT04836702||Left ventricular function|"Depressed LV function~LV ejection fraction < 50%~LV systolic function; defined as mild / mod / sev decreased~LV diastolic function; defined as mild (g1 ) / mod (g2) / sev ( g3) decreased~Normal LV function"
9690175|NCT04836702||Right ventricular function|"Depressed RV function~a. RV systolic function defined as mild / mod / sev decreased~Normal RV function"
9690176|NCT04836702||Valvular lesions|"Moderate or severe valvular lesions~Aortic stenosis~Aortic regurgitation~Mitral stenosis~Mitral regurgitation~Tricuspid regurgitation~Clinically normal valvular lesions~No valvular lesion~Mild stenosis / regurgitation of above mentioned lesions"
9690177|NCT04836923|Experimental|LIFT subgroup|PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
9690178|NCT04836923|Experimental|LIFT + REAP subgroup|"PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members. We will also employ Realistic Effort Action Planning (REAP), a form of personality-informed motivational interviewing in a subset of patients to potentially enhance patient engagement and adherence to the home-exercise prescription."
10180605|NCT03791723|Active Comparator|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40mg Valsartan twice daily qd for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
9690179|NCT04836663|Experimental|TQ-B3525 tablet|
9690180|NCT04836806|Experimental|cetirizine and famotidine|Participants testing positive for COVID-19 who are randomized to take cetirizine and famotidine for 10 days.
9690181|NCT04836806|Placebo Comparator|Placebo|Participants testing positive for COVID-19 who are randomized to take a placebo to match cetirizine and famotidine for 10 days.
9690182|NCT04836676|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid Cath or C-REX RectoAid Cath.
9690183|NCT04836598|Active Comparator|Multiport laparoscopic cholecystectomy|controlled group
9690184|NCT04836598|Active Comparator|Bikini line laparoscopic cholecystectomy|bikini line 2 ports
9690185|NCT04836793||Patients with cancer|"Patients with active treatment in adjuvant/induction setting,~Patients with active treatment in metastatic/relapse setting,~Patients without active treatment (last treatment above 6 months)."
9690186|NCT04836793||Patients without cancer but aged above 70 years|
9690187|NCT04836793||Healthy person|
9690188|NCT04836728|Experimental|arm 1|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W.
9690189|NCT04836728|Active Comparator|arm 2|IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2;
9690190|NCT04836741|Experimental|Micro Hand S robot-assisted surgery|This group is consisted of 40 cases performed using the Micro Hand S robot by one single surgeon for rectal cancer
9690191|NCT04836741|Active Comparator|Laparoscopic surgery|This group is consisted of 65 cases performed using the laparoscope by one single surgeon for rectal cancer
9690192|NCT04836624|Experimental|Co-designing personalised aids of daily living|Participants will be involved in up to 6 interactive sessions spread over 3 months with the researcher. Participants will work with the researcher to help develop their own assistive device to overcome challenges of daily living they experience.
9690193|NCT04836689|Other|30 breaths per minutes|Using NIPPV with rate of 30 for 1 hour. Measuring trans cutaneous CO2
10180606|NCT03791528|Active Comparator|Kinesio-taping Treatment Group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the sacroiliac joint (SIJ), and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
9690194|NCT04836689|Other|10 breaths per minute|Using NIPPV with rate of 10 for 1 hour. Measuring trans cutaneous CO2
9690195|NCT04836572|Other|Wear Period|
9690196|NCT04836611|Other|regular cannabis consumer patients|
9690197|NCT04836650|Placebo Comparator|Flat Insole (no metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles.
9690198|NCT04836650|Experimental|Flat Insole (with 2 millimeters metatarsal bar)|Postural stability and electromyographic activity in the dominant leg will be assessed with the subject shod (closed clog) and with 1.2 millimeters flat polyester resin insoles with a 2 millimeters polyester resin metatarsal bar.
9690199|NCT04836533|Experimental|Computerized Cognitive Training|Those assigned to the computerized cognitive training arm prior to antidepressant trial enrollment will receive computerized cognitive training that includes games that scale in difficulty.
9690200|NCT04836533|Active Comparator|Solitaire Training|Those assigned to the solitaire training arm prior to antidepressant trial enrollment will receive computerized solitaire games.
9690201|NCT04836533|Experimental|Open-label antidepressant treatment|Those assigned to receive open-label antidepressant treatment will begin with 10 mg of escitalopram. If the participant cannot tolerate or has an adverse reaction to escitalopram, duloxetine will be offered instead.
9690202|NCT04836533|Placebo Comparator|Placebo-controlled antidepressant treatment|Those assigned to the placebo-controlled group will be told that they have a 50/50 chance of receiving either escitalopram or placebo.
9690203|NCT04836637|Placebo Comparator|Product with placebo (no calcium supplementation).|Maltodextrin with 0 mg calcium in capsules and sachets consumed orally daily for one year.
9690204|NCT04836637|Active Comparator|Product with calcium-carbonate|800 mg calcium as calcium-carbonate in capsules and sachets consumed orally daily for one year.
9690205|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac"|800 mg of calcium from calcium-enriched permeate in capsules and sachets consumed orally daily for one year.
9690206|NCT04836637|Experimental|"Product with calcium-enriched permeate Capolac and Inulin"|800 mg of calcium from calcium-enriched permeate and 12 g inulin in capsules and sachets consumed orally daily for one year.
9690207|NCT04836819|Active Comparator|Group L|IV lidocaine infusion (1-2 mg/kg/h) up to postoperative 12 hours.
9690208|NCT04836819|Active Comparator|Group K|IV ketamine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
9690209|NCT04836819|Active Comparator|Group D|IV dexmedetomidine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.
9690210|NCT04836871|Experimental|Double filtration plasmapheresis (DFPP) combined with chemotherapy|
9690211|NCT04836780|Experimental|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
9690212|NCT04836780|Active Comparator|Standard of care|Standard care therapy
9690213|NCT04836715||Parkinson's Disease|Individuals with idiopathic Parkinson's Disease and no other neurological disease
9690214|NCT04836715||Other Neurological Disorders|Individuals with one neurological disorder other than Parkinson's Disease (e.g. Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Parkinsonism)
9690215|NCT04836715||Healthy|Individuals without any neurological disorder
9690216|NCT04836507|Experimental|CRC01|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CRC01.
9690217|NCT04836481||LEV8|Levetiracetam 1000 mg every 8 hours
9690218|NCT04836481||LEV12|Levetiracetam 1000 mg every 12 hours
9690219|NCT04836078|Placebo Comparator|Plain chitosan gel group|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement . Randomization will be performed and concealment from the assessors. For root conditioning purpose, Group (I) ; will be injected subgingivally with chitosan 2% gel .
9690220|NCT04836078|Active Comparator|Chitosan gels containing free Simvastatin|Will be injected subgingivally with simvastatin microsponges dispersed into chitosan 2% gel. .
9690221|NCT04836078|Experimental|Chitosan gels containing Simvastatin microsponges|This group will be injected subgingivally with free simvastatin dispersed into chitosan 2% gel containing .
9690222|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for triple negative early breast cancer|Patients with triple negative subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
9690223|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for luminal like early breast cancer|Patients with luminal like subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
9690224|NCT04836234|Experimental|intervention group|Participants will receive Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum. They will be instructed to chew the gum for pain relief after the separator and initial arch wire placement if required. Chew the gums for 10-12 minutes and as much as they want whenever they feel discomfort or pain. They are free to take any medication when necessary and respond to the questionnaires on the amount of chewing gum and analgesics used.
9690225|NCT04836234|No Intervention|Control group|Participants will not receive any prescription after the separators and initial arch wires placement. They will be specifically asked not to chew chewing gum. As in the intervention group, they can take any medication when they feel necessary and respond to the questionnaires on the amount of analgesics used.
9976264|NCT01349686|Placebo Comparator|Fasting|No intake of oral fluids during labour.
9976265|NCT01349699|Active Comparator|Iron loading|Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.
10180607|NCT03791528|No Intervention|Control Group|Without Kinesio-taping treatment evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
10180608|NCT03791476|Placebo Comparator|Control Group|Intervention is saline solution placebo (0.9% Sodium Chloride IV to equal volume of investigational arm: intraoperatively, and then every 12 hours x 2 = total of 3 doses)
10180609|NCT03791476|Experimental|rhC1INH|Intervention is rhC1INH 100 U/kg intraoperative followed by 50 U/kg every 12 hours x 2 = total of 3 doses (200 U/kg)
9690226|NCT04836130|Active Comparator|(ZMC) Fractures reduction Using Patient Specific Guide (PSG)|
10180610|NCT03791580|Experimental|Commitment nudge|Primary care clinicians in the practice assigned to this arm will receive only the commitment nudge.
10180611|NCT03791580|Experimental|Justification nudge|Primary care clinicians in the practice assigned to this arm will receive only the justification nudge.
9690227|NCT04836130|Active Comparator|(ZMC) Fractures reduction Using Conventional Technique|
9690228|NCT04836338||Participants|Anesthesia and emergency medicine providers who perform pediatric orotracheal intubations
9690229|NCT04836052|Experimental|omega-3-oil arm|patients admitted to ICU in HMC on any kind of oxygen support will get omega-3-oil 2 gm PO/NGT/OGT twice daily for 28 days or till ICU discharge or till death .
9690230|NCT04836052|No Intervention|standard of care arm ( no omega -3-oil )|patients admitted to ICU in HMC on any kind of oxygen support will get ( standard of care= No Omega-3-oil ) but their labs will be monitored
9690231|NCT04836299|Experimental|Ivermectin|Participants will receive a single 600 µg / kg dose of ivermectin.
9690232|NCT04836299|Placebo Comparator|Placebo Comparator|Participants will receive a single dose of placebo.
9690233|NCT04836403||Rhinosinusitis without treatment group|children aged 2 and 12 years with rhinosinusitis not receiving treatment
9690234|NCT04836403||Rhinosinusitis with treatment group|children aged 2 and 12 years with rhinosinusitis receiving treatment
9690235|NCT04836403||healthy volunteers|children aged 2 and 12 years without rhinosinusitis
9690236|NCT04836312|No Intervention|Attention Control|Patients will be instructed via text message and email to fast at least 16 hours per day every day. For the next 18 weeks, they will receive a daily text message via the Way to Health platform asking if they fasted for at least 16 hours over the past 24 hours. If they fail to respond, reminder text messages will be sent. Once per week, they will receive a text message asking them to weigh themselves and check their blood pressure, and reply with the results via text message
9690237|NCT04836312|Experimental|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
9690238|NCT04836091|Experimental|Immediate intervention|From baseline to 2-month post-test, participants in the intervention arm will have access to the OurPlan program app.
9690239|NCT04836091|Experimental|Waitlist-delayed intervention|Participants in this study arm will not have access to the OurPlan program in the app from baseline to day 30 (month 1) of the trial. From day 31 to day 60, participants in this study arm will be given access to the OurPlan program in the app.
9690240|NCT04836169|Experimental|InCaveo EOA System|InCaveo EOA System (including integrated CBT but without tapering) group
9690241|NCT04836169|No Intervention|Control Group-usual care with pill bottles|UCPB group-usual care with pill bottles
9690242|NCT04836351|Experimental|Concentrated rehabilitation|3+ 1-2 day concentrated rehabilitation for patients with persistent symptoms post COVID-19.
9690243|NCT04836325|Experimental|Experimental: transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of Transcranial Static Magnetic Field Stimulation (tSMS) in the primary motor cortex with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
9690244|NCT04836325|Sham Comparator|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment with a duration of 30 minutes, 5 times a week, during 4 weeks, for a total of 20 sessions.
9690245|NCT04836117|Experimental|Informed|"Blood draw for SomaSignal Test and laboratory assessments at baseline, and 6 months (±30 days); SomaSignal Test results to be sent to investigators as available. Review and discussion of results with the participant from baseline and 6 months within 30 days (2-4 weeks to get SomaSignal results) after blood draw. Initiation of changes in medical management as soon as test results are known and discussed with patient.~Patients will have a blood draw performed at baseline and 6 months for lipid panel, hemoglobin A1C, CBC, and BMP."
9690246|NCT04836117|No Intervention|Uninformed|"Blood draw for SomaSignal Test at baseline and 6 months (+30 days). However, results will not be provided to clinician and participant until study conclusion. Patients contacted within 30 days (2-4 weeks) after baseline and 6-month visits to discuss treatment strategy (nothing, add/ remove medication, etc.) made at visit. Patients will have a blood draw performed at baseline and for lipid panel, hemoglobin A1C, CBC, and BMP~SomaSignal Test results to be sent to investigators AFTER study conclusion. Patients will be provided with SomaSignal Test results after the 6 month post-test timepoint."
9976266|NCT01349699|Active Comparator|Iron chelation|Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.
10180612|NCT03791580|Experimental|Commitment + Justification nudges|Primary care clinicians in the practice assigned to this arm will receive both the commitment nudge and the justification nudge.
10180613|NCT03791580|No Intervention|Non-participating|Primary care clinicians in Northwestern-affiliated practices other than the 3 pilot-participating practices will not receive any study interventions.
10180614|NCT03791385|Experimental|Study subjects|Children with ASD and their parents/caregivers were trained on tooth-brushing twice, two weeks apart using Picture Exchange Communication System (PECS) PECS as a pictures/cards series showing a structured tooth-brushing method.
9690247|NCT04836442|Experimental|Alcohol-PTSD-PFI (AP-PFI)|Hazardous drinkers with at least subclinical PTSD and elevated AS (N=100) recruited from the community will be randomly assigned to receive Alcohol-PTSD-PFI (AP-PFI) or an attention information control condition (C-PFI).
9690248|NCT04836442|Other|Attention Information control condition (C-PFI).|Hazardous drinkers with at least subclinical PTSD and elevated AS (N=100) recruited from the community will be randomly assigned to receive Alcohol-PTSD-PFI (AP-PFI) or an attention information control condition (C-PFI).
9690249|NCT04836000|Placebo Comparator|Placebo Group|In addition to the conservative treatment of the control group, low-level laser therapy (turned off) will be applied for 12 weeks. In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions.
9690250|NCT04836000|Experimental|Experimental Group|In addition to the conservative treatment of the control group, low-level laser therapy will be applied for 12 weeks.
9690251|NCT04836000|Active Comparator|Control Group|For 12 weeks, all three groups will receive five sessions per week of a protocolised treatment based on therapeutic exercises, analgesic electrotherapy and cryotherapy.
9690252|NCT04836026||HF20™ for Pediatric CRRT|Pediatric patients in an intensive care unit requiring CRRT for acute kidney injury (AKI)
9690253|NCT04836013|Experimental|Probiotic group|Lactobacillus reuteri LMG P-27481 and Lactobacillus rhamnosus GG (ATCC 53103), sucralose and isomalt as an oral stick formulation of 1,6 g with a concentration of probiotic of 2x100bilion colony forming unit (CFU) per stick.
9690254|NCT04836013|Placebo Comparator|Placebo group|The placebo will contain 1.6 g per stick of sucralose and isomalt
9528141|NCT03213470|Other|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed based on the clinical and radiological (including MRI) diagnoses at the symptom onset after Jan-01-2016
9690255|NCT04835740|Active Comparator|Conventional Rehabilitation|Based on the functional capacity of each participant, customized Aerobic exercise plan was designed by the on-site physiotherapist.
9690256|NCT04835740|Experimental|Combined Training (conventional rehabilitation plus high-intensity interval training):|The patients received 40 minutes of High intensity interval treadmill training in addition to their normal conventional rehabilitation.
9690257|NCT04835870|Experimental|R-CHOP + Zanubrutinib|Zanubrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
9690258|NCT04835727|Experimental|Semi-vegetarian diet|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
9690259|NCT04835948||Multiple doses of anti-thymocyte globulin (ATG)|Control group that received fractionated doses of 1.5 mg/kg adding up to a total of 6 mg/kg
9690260|NCT04835831|Experimental|adapted physical activity + Dietetic advice|
9690261|NCT04835831|No Intervention|Dietetic advice only|
9690262|NCT04835623|Experimental|Cyclosporine|Participants receive Cyclosporine 0.09% Ophthalmic Solution (Cequa), 1 drop, each eye, twice a day for 12 weeks
9690263|NCT04835935||subject who developed atopic disease|
9690264|NCT04835935||subject who did not develop atopic disease|
9690265|NCT04835792||Previously Treated for Lyme Disease|
9690266|NCT04835792||Healthy Volunteers|
9690267|NCT04835922|Experimental|Intercostal Nerve Block|• In Group I (ICBN group): Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine at the termination of PCNL under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each).
9690268|NCT04835922|Active Comparator|Peritract infiltration|In Group P (PTI): Single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given on completion of PCNL by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position). Then the surgical wound and intervention site will be covered with an occlusive dressing.
9690269|NCT04835675||Cancer Arm|Participants with new diagnosis of hepatobiliary malignancies, from whom blood samples will be collected
9690270|NCT04835675||Benign Diseases Arm|Participants with benign diseases of the hepatobiliary system, from whom blood samples will be collected
9690271|NCT04835896|Experimental|Study treatment|
9690272|NCT04835662|Other|Complementary feeding promotion|Intervention
9690273|NCT04835883|Experimental|Assigned interventions|Subjects enrolled into the CS20AT04 with corticosteroid taper regimen arm will receive two infusions of CS20AT04 (2.0×10^6cell/kg), on 0 day and on 12 weeks post-enrollment.
9690274|NCT04835909|Experimental|Behavioral: modern board and card games|Participants will play modern board and card games in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
9690275|NCT04835909|Active Comparator|Behavioral: paper and pencil tasks|Participants will do cognitive paper and pencil tasks in groups at medical center 2 times per week for at least 1 hour over a period of 16 weeks.
9690276|NCT04835909|No Intervention|Wait-list|Participants will be in a wait-list over a period of 16 weeks. Then, they received the board and card games' or paper and pencil tasks' intervention.
9690277|NCT04835753|Experimental|study group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training plus shock wave on the muscle belly of the planter flexor hypertonic muscles.
9690278|NCT04835753|Other|control group|received the traditional physical therapy program as muscle stretching and strengthening and neurodevelopmental techniques, proprioceptive training, and balance and gait training .these traditional therapy had been approved by previous studies its effectiveness in management cerebral palsy child
9690279|NCT04835779||SFN Patients|Patients with diagnosed Small Fibre Neuropathy
9690280|NCT04835779||Patients undergoing chemotherapy|Patients undergoing chemotherapy and are expected to develop SFN as a result
10180615|NCT03791515|Active Comparator|Calcitonin Gene-Related Peptide (CGRP)|"30 patients with PPTH will be allocated to receive intravenous infusion of 1.5 µg/min calcitonin-gene related peptide over 20 minutes~Other Name: CGRP"
9690281|NCT04835779||Healthy Volunteer|Healthy test person
9690282|NCT04835519|Experimental|chimeric antigen receptor T cell treatment|
9690283|NCT04835610||PVI values|PVI values measured at the finger and forehead areas in pediatric patients
9690284|NCT04835610||no control group|no control group
9690285|NCT04835454||control group|The control group consisted of healthy men with no cancer and no chronic diseases. They will be age-matched with patient group and recruited among men subjected to the routine periodic medical examination.
9690286|NCT04835454||Prostate cancer group|Patients who are confirmed to have prostate cancer based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue with no other coexisting cancers or prostate cancer treatment
9690287|NCT04835454||benign prostatic hyperplasia group|Patients who are confirmed to have benign prostatic hyperplasia based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue
9690288|NCT04835701|Experimental|Music Intervention group|Subjects randomized to the music group will choose 10 songs, which will be played during the procedure, from the time of positioning through completion of IUD insertion and speculum removal. Participants will otherwise undergo standard protocol for IUD insertion in an outpatient clinic setting. Total participation is predicted to last approximately 30 minutes.
9690289|NCT04835701|No Intervention|Control group|Participants to undergo same standard protocol for IUD insertion in an outpatient clinic setting. No music will be played during the procedure.
9690290|NCT04835389|Experimental|AlloGen Liquid|A single-dose, intra-articular (IA) injection of 2.0 mL of AlloGen Liquid administered to the affected knee.
9690291|NCT04835389|Placebo Comparator|Saline|A single-dose, intra-articular (IA) injection of 2.0 mL of saline administered to the affected knee.
9690292|NCT04835337|Experimental|Air purifier|Participants in this group receive an intervention of real air purifiers placed in the indoor environment.
9690293|NCT04835337|Sham Comparator|Control|Participants in this group receive an intervention of sham air purifiers, we just remove the filter in the purifiers, and the other treatments are the same as the real purification group.
9690294|NCT04835467|Experimental|Intracoronary imaging|Intracoronary imaging during PCI
9690295|NCT04835350|No Intervention|Hybrid closed loop group|Patients using AID system Pancreas4ALL in mode hybrid closed loop.
9690296|NCT04835350|Experimental|Closed loop meal announcment|Patients using AID system Pancreas4ALL in mode meal announcment. They only announce what amout of carbs going to eat. They calculate no bolus
9690297|NCT04835350|Experimental|Full closed loop|Patients using AID system Pancreas4ALL in mode full closed loop. They eating with no permission and they do not calculate and sending bolus anymore.
9690298|NCT04835545|Experimental|Wet Perlite, 2L air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with 2L air pocket
9690299|NCT04835545|Experimental|Wet Perlite 2L air pocket with resistance compensation|Breathing in the simulated avalanche snow. Breathing into model of wet perlite 2L air pocket with resistance compensation
9690300|NCT04835545|Experimental|Wet Perlite, no air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with no air pocket
9690301|NCT04835532|Experimental|Control group|"Vertical alveolar bone augmentation was performed by GBR technique before implantation.~BIO-OSS+ BIO-GIDE barrier membrane"
9690302|NCT04835532|Experimental|Treatment group 1|"Vertical alveolar bone augmentation was performed by GBR technique and tenting screws before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws"
9690303|NCT04835532|Experimental|Treatment group 2|"Vertical alveolar bone augmentation was performed by GBR technique in combination with tenting screws and A-PRF, I-PRF before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws+A-PRF, I-PRF"
9690304|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 1|The standard percussor palm cups are made out of a soft vinyl material molded into shape. The outer diameter of the infant palm cup is 1-3/4 inches and there is a 1-inch diameter pocket inside this product similar to a suction cup.
9690305|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 2|This product was developed by MMRI personnel using a small custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
9827604|NCT02461758|Other|High dose influenza vaccine (HDIV)|"This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
9976267|NCT01349699|Placebo Comparator|Placebo|Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration
9976268|NCT01349712||Coumadin (warfarin)|Subjects are required to be currently receiving coumadin (warfarin) treatment.
9976269|NCT01349725|Experimental|ARRY-502|
9976270|NCT01349725|Placebo Comparator|Placebo|
9976271|NCT01349738||Positive Group|Positive for ASB
9976272|NCT01349738||Negative Group|Negative for ASB
9976273|NCT01349751|Active Comparator|isobaric levobupivacaine|spinal isobaric levobupivacaine
9976274|NCT01349751|Active Comparator|hyperbaric levobupivacaine|hyperbaric levobupivacaine
10180616|NCT03791515|Placebo Comparator|Placebo|"30 patients with PPTH wil be allocated to receive 40 mL Placebo (isotonic saline) over 20 minutes.~Other Name: Isotonic Saline"
10180617|NCT03791632|No Intervention|witness|2 control CE2 classes without oral sensitization actions
10180618|NCT03791632|Experimental|group intervention 1|2 CE2 classes with a classical lecture style presentation
9690306|NCT04835376|Experimental|Randomized Crossover: Percussion Palm Cup Safety and Usability - Cup 3|This product was developed by MMRI personnel using a large custom 3D printed plastic handle and a 0.93-inch, single bellow, Buna-N rubber suction cup. The handle was made on the MMRI's 3D printer using ABS plastic and the suction cup was sourced from McMaster Carr (#5427A106). The handle is made up of three pieces; top, base and a pin that is designed to fix the top, base and suction cup to each other. There is a small hole through the pin which helps relieve some of the pressure that builds in the suction cup during use. It is not shown in the image to the right, but the handle will be coated in Plasti Dip for added user comfort.
10180619|NCT03791632|Experimental|group intervention 2|2 CE2 classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
9690307|NCT04835428|Experimental|Treatment with AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
9690308|NCT04835428|Active Comparator|Treatment with PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
9690309|NCT04835259|Active Comparator|Group 1(treatment group)|"Topical application of a cream of a combination of antioxidants once daily at night for 6 months Name: Selenium ACE cream (Interpharma UK company, Egypt)~Ingredients:~Selenium (Selenium amino acid chelate) 0.5% Vitamin C (Sodium ascorbyl phosphate - stay C) %1 Vitamin E (Tocopheryl acetate) % 0.5 Vitamin A (Retinyl palmitate) %1 Emulsifiers ( Ceteareth 20 , Glycerol monostearate , Cetyl alcohol) Emollient(Caprylic capric triglycerides)"
9690310|NCT04835259|Active Comparator|Group 2 (positive control)|Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)
9690311|NCT04835259|Placebo Comparator|Group 3 (Negative control)|Topical application of a panthenol cream once daily at night for 6 months (panthenol 2% cream, El Nile company, Egypt)
9690312|NCT04835363|No Intervention|Control group|Usual care.
9690313|NCT04835363|Experimental|OT intervention.|Patients and their caregivers assigned to the experimental group are included in an early occupational therapy intervention program.
9690314|NCT04835298||Myotonic dystrophy type 1|adult patients with myotonic dystrophy type 1
9690315|NCT04835558||Group I|Subjects with obesity hypoventilation sydrome (30 < body mass index < 40 kg/m2)
9690316|NCT04835558||Group II|Subjects with obesity hypoventilation sydrome (body mass index > 40 kg/m2)
9690317|NCT04835558||Control Group|Age and sex-matched obese subjects (30 < body mass index < 40 kg/m2) with low risk of obstructive sleep apnea (STOP-BANG score < 3)
9690318|NCT04835220|No Intervention|Control Group|Electronic pill bottle cap (MEMs bottle cap) with no Telehealth calls
9690319|NCT04835220|Other|Telehealth intervention group|Electronic pill bottle cap (MEMs bottle cap) with regular telehealth visits to the veterans at the VAMCs on the stewardship program. These visits will involve contacting the veterans by telephone, administering a questionnaire to review their medication-taking behavior for oral chemotherapy, and potentially contacting the treating oncologist in the event that the veterans are at risk of non-adherence (based on their responses).
9690320|NCT04835233|Experimental|methyldopa|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
9690321|NCT04835233|Active Comparator|captopril|postpartum exchange methyldopa for captopril 25 mg 01 tablet every 8 hours, doubling the dose depending on pressure levels, up to 15 days postpartum
9690322|NCT04835246|Experimental|Spectra IMDx|"The physician will be asked to give a diagnosis of the lesion under White light endoscopy (WLE) firstly and the endoscopic diagnosis result will be recorded on case report form. Then the physician will introduce the probe of Spectra IMDx system to contact and assess the lesion. The Spectra IMDx system will detect the scattering light signal from the lesion and assess the risk of the lesion being high-grade intraepithelial neoplasia or gastric cancer, and display the result on the Spectra IMDx screen. The Spectra IMDx assessment will be recorded on case report form. Both the patient and doctor will be blinded from the results from Spectra IMDx system.~After Spectra IMDx system examination, the physician takes biopsy sample(s) in suspected lesion for further histopathological diagnosis."
9690323|NCT04836039||Physiotherapists|Individuals between the ages of 22-65 who continue to work as a self-employed or employee physiotherapist.
9690324|NCT04836286|Experimental|single group repeated design|The Emotive Intelligent Spaces (EIS) leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
9690325|NCT04836273|Experimental|120 µg dasiglucagon|Subcutaneous 120 µg dasiglucagon self-administration
10180620|NCT03791632|Experimental|group intervention 3|2 CE2 classes with digital media intervention
10180621|NCT03791541|No Intervention|No Intervention|Only surveys will be done and re admissions tracked. No additional interventions based on survey results will be done.
10180622|NCT03791541|Experimental|Intervention|"Pharmacist Services~Surveys plus increased outpatient pharmacist/pharmacy student services including but not limited to pre and post clinic visit phone calls, prescription counseling, and helping with adherence and compliance with medications. Increased services will be given based on survey results."
10180623|NCT03791463|Experimental|After meal|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
10180624|NCT03791463|Experimental|Fasting|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered at the end of a 10-hour fast.
9690326|NCT04836273|Placebo Comparator|Placebo|Subcutaneous placebo self-administration
9690327|NCT04835974|Experimental|diabetic patients with reflow phenomenon|All Assiut University heart Hospital patients ,and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their intervention procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis.
9690328|NCT04835142|Experimental|Double blind control period|"experiment arm： All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.~control arm: All eligible subjects will receive Erbitux in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks."
9690329|NCT04835142|Experimental|Open single period|All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.
9690330|NCT04835571|Experimental|CARMA study participants|All patients in the study are in the same treatment arm: all were treated for 12 months according to routine care and international guidelines for cardiovascular disease prevention in patients with very high cardiovascular risk. Through study physicians patients received an individual assessment and optimized cardiovascular risk management, including life style advice and adjustments in their medical preventive treatment, based on drugs used in standard care (eg. lipid lowering medication, anti-hypertensive-treatment, anti-thrombotic treatment). All treatment goals were set in accordance with current guidelines at the time for study participation.
9690331|NCT04834856|Experimental|ensovibep dose 1|
9690332|NCT04834856|Experimental|ensovibep dose 2|
9690333|NCT04834986|Experimental|Tislelizumab combined with Lenvatinib|
9690334|NCT04835051|Other|Breastfeeding promotion|The breastfeeding promotion intervention included training for health workers, interpersonal communication (in person and digital) between providers and pregnant/breastfeeding women, and mass media.
9690335|NCT04835051|No Intervention|Comparison|
9690336|NCT04834921|Experimental|MCO-CVVHD|CVVHD with MCO filter for 24 hours
9690337|NCT04834921|Active Comparator|HFF-CVVHDF|CVVHDF with high flux filter for 24 hours
9690338|NCT04835194||Lean/Elderly/Multimorbid (anticipated)|Lean/Elderly/Multimorbid phenotype of HFpEF patients with concurrent DM, HTN (anticipated from a multicentered HFpEF study in Vietnam: https://www.hindawi.com/journals/crp/2021/4587678/)
9690339|NCT04835194||Congestive/Metabolic (anticipated)|Congestive/Metabolic phenotype of HFpEF patients with concurrent DM, HTN (anticipated from a multicentered HFpEF study in Vietnam: https://www.hindawi.com/journals/crp/2021/4587678/)
9690340|NCT04834947||Prone position in non-intubated COVID19 , before and after.|Patients with non-intubated COVID19 pneumoniae for whom the clinician has decided to try prone positioning to increase the PaO2 in a context of hypoxemia with O2 requirement.
9690341|NCT04835064|Experimental|Nab-paclitaxel and Gemcitabine|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15;Gemcitabine 1000 mg/m2 was given intravenously for more than 30min on days 1, 8, and 15, and repeated every 4 weeks.
9690342|NCT04835064|Experimental|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
9690343|NCT04834934||COVID-19 first wave patients|1700 patients retrospectively enrolled in 15 Italian hospitals from 16/2/2020 to 29/4/2020.
9690344|NCT04834934||COVID-19 second wave patients|300 patients prospectively enrolled in IRCCS San Raffaele Hospital from 19/10/2020 to 31/12/2020.
9690345|NCT04834895|Active Comparator|mhealth exercise group|home exercise program is given to patients via mobile application
9690346|NCT04834895|Experimental|brochure exercise group|home exercise program is given to patients via brochure
9690347|NCT04835116|Other|Local Anesthesia|Group A patients received peri tract local anaesthesia infiltration with 0.25% Bupivacaine.
9690348|NCT04835116|Other|Intravenous Analgesics|Group B patients received postoperative intravenous analgesia.
9690349|NCT04834908|Experimental|Equine COVID-19 Antiserum [F(ab')2] (BSVEQAb) Along with Standard of care|"Dose of BSVEQAb - 5 mg/kg or 10 mg/kg body weight. It is administered as a single dose intravenously after diluting in 100 -150 ml saline. The infusion will be done over 1 to 2 hours.~Standard of care for treatment of COVID-19 positive patients"
9690350|NCT04834908|Active Comparator|Standard of care.|Treatment as per current treatment guidelines and institutional practice for COVID-19 positive patients will be administered
9690351|NCT04834791|Experimental|Letrozole|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles.
9690352|NCT04834791|Active Comparator|Gonadotropins|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
9690353|NCT04835181|Experimental|Electroacupuncture combined with umbilical moxibustion|
9690354|NCT04835181|Active Comparator|Electroacupuncture|
9690355|NCT04834960|Other|MOV Intervention|Pre-intervention and post-intervention design
9690356|NCT04835077|Experimental|Structured Aerobic Exercises|"Following the training on aerobic exercise content and effectiveness;~First Week; participants 5 minutes warm-up, 20 minutes of aerobic exercise with 60-70% of maximum heart rate, and 5 minutes of cool down.~In the following weeks, the aerobic exercise duration of all participants will be increased by 5 minutes compared to the previous week.~The duration of the sessions in the 7th and 8th weeks will progressively progress to 40 minutes and the intensity to 75-80% of the maximum heart rate."
9827605|NCT02461758|Other|Standard dose influenza vaccine (SDIV)|"This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
9690357|NCT04835077|Experimental|Postural Stabilization Exercises|"Exercises; It will consist of postural exercises to be done in prone, supine, side lying, crawling, sitting and standing positions. All exercises will be done in 2 sets per day, the number of repetitions will be determined individually and progressed.~Breathing exercises~Four-way stretching and strengthening of the neck muscles~Shoulder girdle stretching and strengthening exercises~Hip flexors, hamstring, itb, lumbar extensor stretching and strengthening~Lying down exercises in the crawling position~Shuttle movement~Plank movement~Toe taps~Bridging~Straight leg lift~Straight leg raises in side-lying~Prone knee flexion"
9690358|NCT04835077|No Intervention|Control|The individuals without any treatment will continue their normal lives and will be included in the study as a control group. Exercise will be given after 8 weeks.
9690359|NCT04835155|Experimental|experimental group|The researcher applied Premature Infant Oral Motor Intervention to the experimental group for 5 minutes per day for 14 consecutive days, 15-20 minutes before a sheduled feeding at either the 09:00 or 12:00 feeding. On the first day, the baseline sucking capacity of babies in experimental group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials. Growth measures were collected on the 1st and 14th days and the day of disharge.
9690360|NCT04835155|No Intervention|control grup|The researcher did not apply any intervention. On the first day, the baseline sucking capacity of babies in control group was measured before any intervention. On the following 8th, 11th and 14th days, the measures of sucking capacity were repeated and followed by oral feeding trials.
9690361|NCT04835103|Other|Set a case management model for somatoform patients|Somatoform patients receiving case management, single group assignment, open label
9690362|NCT04835103|Other|Time-limited psychotherapy for somatoform patients|Somatoform patients receiving psychotherapy (based on cognitive-behavioral therapy and biofeedback therapy) vs treatment as usual, open label, non-randomized
9690363|NCT04835025||Control group (radiotherapy group)|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesion (without limitation of dose and treatment method for radiotherapy) , but not receiving immunotherapy. Those patients would enter the control group. After patients experiencing disease progression(PD) in this group, follow-up treatment does not include immunotherapy until tumor progression again or death.
9690364|NCT04835012||Treatment|"Subjects in this treatment group had their medical debt forgiven by a non-profit charity, RIP Medical Debt. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
9690365|NCT04835012||Control|"No intervention was given to subjects in this control group. This protocol will administer a survey to measure subjects' health care utilization, mental health, and subjective well-being."
10180625|NCT03791645|Experimental|SKY Intervention|Participants in the intervention group will get to participate in the SKY program, for 5 days with each day session taking 3 hours/day. SKY program involves a) specific breathing exercises and social interaction with other participants in the program. Following completion of the program, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use. After completion of the 5 day SKY program, participants will practice SKY every day at home for 30 days. They will also need to attend 4 weekly group sessions during this period and each session is expected to last 1 hour. At the end of the 30 day period, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use.
9690366|NCT04834817|Experimental|LED treatment|LED treatment with Celluma POD device after laser test area
9690367|NCT04834817|No Intervention|Control|No treatment after laser test area
9690368|NCT04834830||Patients with pleural effusion|In patients with pleural effusion and indication for diagnostic and/or therapeutic procedures (thoracocentesis, drainage of fluid, indwelling pleural catheter (IPC) management, and/or video-assisted thoracoscopic surgery), pleural fluid will be examined for various cytokines and PD1-lymphoctyes.
9690369|NCT04834882||Healthcare workers|Medical and paramedical staff in Reims University Hospital and EPSM Marne working in COVID-19 units and non COVID-19 units
9690370|NCT04834804|Experimental|Suspension training group|
9690371|NCT04834804|Experimental|Free weight training group|
9690372|NCT04834804|No Intervention|Control group|
9690373|NCT04834609|Experimental|Injection with adipose tissue|Injection of freshly collected autologous adipose tissue
9690374|NCT04834531|Experimental|Zhuli capsule|Base on the standard medical treatment, the patients in this group will be used Zhuli capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
9690375|NCT04834531|Placebo Comparator|Placebo|Base on the standard medical treatment, the patients in this group will be used placebo capsule, 2 capsules (1.2 g) once, three time a day for 7 days.
9690376|NCT04834752||Patients tested for COVID-19|Patients who were tested for COVID-19 nasopharyngeal polymerase chain reaction (PCR)
9690377|NCT04834726|Active Comparator|1: Usual Care|Patients will receive a phone call to schedule their appointment from an Access Center representative. Access Center representatives will make up to 3 attempts to schedule an appointment with the patient. Patients randomized to this arm will not receive any text messaging.
9690378|NCT04834726|Experimental|2A: Call Back + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
9690379|NCT04834726|Experimental|2B: Call Back + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
9690380|NCT04834726|Experimental|2C: Call Back + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
9690381|NCT04834726|Experimental|2D: Call Back + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-outWill include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
10180626|NCT03791645|No Intervention|Usual treatment|Participants assigned to the control group will not have access to the SKY program but will continue with usual care. They will also complete questions after 5 days and again after 30 days.
9690382|NCT04834726|Experimental|3A: In-Bound Call + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
9690383|NCT04834726|Experimental|3B: In-Bound Call + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
9690384|NCT04834726|Experimental|3C: In-Bound Call + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
9690385|NCT04834726|Experimental|3D: In-Bound Call + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-out. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
9690386|NCT04834505||Derivation sample|The patients conclusively diagnosed as FAIP or PC are retrospectively collected.
9690387|NCT04834505||Validation sample|The patients with difficulty in distinguishing between FAIP and PC are prospectively enrolled.
9690388|NCT04834401||Natalizumab|Natalizumab (minimum of 6 doses at standard interval)
9690389|NCT04834401||Fumarates|Fumarates (dimethyl fumarate or diroximel fumarate)
9690390|NCT04834401||Interferon Beta 1a|Interferon Beta 1a (or pegylated Interferon Beta-1a)
9690391|NCT04834401||Ocrelizumab|Ocrelizumab (minimum of 2 full cycles of 600mg)
9690392|NCT04834674|Experimental|DEB-TACE combined with apatinib and PD-1 antibody|The participants will receive the combined treatment of local therapy (DEB-TACE, oxaliplatin and gemcitabine), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
9690393|NCT04834700|No Intervention|hands-on group|The doctors who participated in the study will be educated ocular ultrasound scanning method by hands-on about 20 minutes, and perform ocular ultrasound scans on two standard patients.
9690394|NCT04834700|Other|online group|The doctors who participated in the study will be educated ocular ultrasound scanning method by online lecture about 20 minutes, and perform ocular ultrasound scans on two standard patients.
9696237|NCT04769128|Experimental|Group (B) (experimental or manipulative group)|"Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training in addition to T3-T4 thoracic manipulation (Maitland screw technique grade V) 3 sessions/ week for 12 weeks."
9696238|NCT04769245||Single donor convalescent plasma|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma
9696239|NCT04769245||ACB- IP 1.0|Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma
9696240|NCT04769089|Experimental|Pulse Dye Laser|Treatment with PDL alone.
9696241|NCT04769089|Experimental|CO2 Laser|Treatment with CO2 alone.
9696242|NCT04769089|Experimental|Combination|Treatment with both PDL and CO2 laser.
9696243|NCT04769089|Active Comparator|No treatment|No laser treatment.
9696244|NCT04769492|Other|Pilot Intervention|Tailored violence prevention intervention (#ChopViolence/#ChopHIV) for B-YGBMSM and B-TW in the Chicago HBC.
9696245|NCT04768998||Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, POP).
9696246|NCT04768998||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (HAP, SUEP).
9696247|NCT04768998||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensus data set GECOO), with other NAPKON study platforms (POP, SUEP).
9696248|NCT04768933|Experimental|Toddler Milk Group|All enrolled subjects with be provided a new toddler milk for 28 days. Aligned with clinical and label recommendations, they will be required to intake at least 3 servings of 130 ml per day.
9696249|NCT04768842|Experimental|LY3209590 Lyophilized Formulation|LY3209590 as lyophilized formulation administered subcutaneously (SC) in one of the two study periods.
10180627|NCT03791658|Other|Asthmatics|"From the patients file the following information will be collected by the investigators:~Age~Sex~FEV1 derived from the last spirometry (including spirometry performed on day of study visit).~GINA step (Global Initiative for Asthma).~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.~FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The Asthma Control Test (ACT)"
10187518|NCT03725501|Experimental|Ranibizumab + ALS-L1023 1200mg|"ALS-L1023 1200 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
9696250|NCT04768842|Experimental|LY3209590 Solution Formulation|LY3209590 as solution formulation administered SC in one of the two study periods.
10180628|NCT03791658|Other|COPD-patients|"From the patients file the following information will be collected by the investigators:~Age~Sex~Pack Years~GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The COPD Assessment Test (CAT)"
10180629|NCT03791437|Experimental|Experiment groups|Post chest operative use Digital chest drainage system until Patient's discharge day
10180630|NCT03791437|Active Comparator|Control groups|Post chest operative use traditional drainage system until Patient's discharge day Not use Digital chest drainage system
9690395|NCT04834570||Breast Cancer Survivors|Women who have survived breast cancer for at least 1 year (12 months) and 2 years (24 months) after the end of primary treatment
10180631|NCT03791333||multi trauma patients group|
9690396|NCT04834544|Experimental|DCVAC/OvCa arm|
9690397|NCT04834544|Placebo Comparator|Placebo arm|
9690398|NCT04834687|Experimental|Rope-skipping group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
9690399|NCT04834687|Experimental|Diet intervention group|Participants would be required to take part in a diet plan , including a high-fiber diet and time-restricted eating.
9690400|NCT04834687|Experimental|Combined intervention group|Participants will receive both rope-skipping and diet interventions at the same time.
9690401|NCT04834687|No Intervention|Control group|Participants would be required to maintain existing diet patterns and physical activity levels.
9690402|NCT04834596||patients without hepatic metastases|hepatic scanner of 100 patients with colorectal cancer without hepatic metastases will be analysed
9690403|NCT04834596||patients with synchronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with synchronous hepatic metastases will be analysed
9690404|NCT04834596||patients with metachronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with metachronous hepatic metastases will be analysed
9690405|NCT04834739|Active Comparator|Study group (30 volunteer healthcare workers who had Covid-19|30 volunteer healthcare workers who had Covid-19 and stayed in hospital or at home were included.
9690406|NCT04834739|Active Comparator|Control group (30 volunteer healthcare workers who had not have Covid-19)|In control group, 30 volunteer healthcare workers who were matched for age ande gender with study group were included and these persons had not have Covid-19.
9690407|NCT04834713||Mild patients|defined as patients who had kidney injury without oliguria and hypotension
9690408|NCT04834713||moderate patients|defined as patients who had uremia, effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with typical oliguria
9690409|NCT04834713||severe patients|defined as patients who had severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension and AKI with oliguria (urine output of 50-500 mL/day) for ≤ 5 days or anuria (urine output of < 100 mL/day) for ≤ 2 days
9690410|NCT04834713||critical patients|defined as patients who usually had one or more of the following complications compared with the severe patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with oliguria (urine output of 50-500 mL/day) for > 5 days or anuria (urine output of < 100 mL/day) for > 2 days
9690411|NCT04834713||healthy control|defined as people without HFRS
9690412|NCT04834427|Experimental|S (+)-Ketamine group|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction, maintenance or postoperative analgesia.
9690413|NCT04834427|Active Comparator|Control group|Patients who undergo conventional therapy without S (+)-Ketamine hydrochloride injection during perioperative period.
9690414|NCT04834622|Experimental|Melodies for Mums|Mothers will start a block of 10-week classes and continue with their group for the duration of the course. Classes will take place in Children's Centres (or online). Mothers will attend with their babies and will sit in a socially-distanced circle on the floor surrounded by soft play cushions and mats. Classes will start with welcome songs, introducing everyone to one another, and involve a range of singing and music activities. Mothers will be required to respect social distancing guidelines. Music activities will include learning songs from around the world and will be accompanied by instruments that the mothers and babies can play together. Instruments will not be shared and will be disinfected before and after the singing sessions. Mothers will also work to write some of their own songs over the weeks. Recordings of the group singing the songs together will be made for the mothers to listen to at home. Classes will be led by professional workshop leaders trained by Breathe.
9690415|NCT04834622|Active Comparator|Control (mother-baby community sessions)|Our control group will be a 'active' control. During the first 10 weeks (during the study period), mothers in the control group will receive details of other non-music classes available to them in the community (or online if necessary, depending on the programs available at the time and government guidelines) and will receive the same schedule of texts and phone calls to encourage them to join these activities. They will still be seen by the researchers to collect clinical measures and biological samples (including the pre-post saliva samples) and to monitor engagement in other activities. Following the first 10 weeks, the mothers in the control group will be offered a place on the singing programme, but these data will not be part of the study, and they will not join groups with women who are in the study
9690416|NCT04834284||Helicopter Emergency Medical Services (HEMS)|Patients transported to the comprehensive stroke centre at least in some part by a HEMS unit
9690417|NCT04834284||Ground Emergency Medical Services (GEMS)|Patients transported to the comprehensive stroke centre solely by an ambulance
9690418|NCT04834388|Experimental|Anakinra High dose|500mg i.v. loading dose, followed by continuous iv infusion with 2mg/kg/h over 3 days
9690419|NCT04834388|Experimental|Anakinra Low dose|100mg s.c. loading dose, followed by subcuteanous administration of 100mg twice daily for 3 days.
9690420|NCT04834388|No Intervention|Standard care|Standard care group
9690421|NCT04834375|No Intervention|Standard dexamethasone dose|Dexamethasone 6 mg IV daily for 10 days
9690422|NCT04834375|Experimental|Weight-based dexamethasone dose|Dexamethasone 0.2 mg/kg/day IV (maximum 20 mg daily) for 10 days
9690423|NCT04834310|Experimental|Intraoperative and Postoperative Antibiotics|The experimental group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by oral antibiotics for 5 days postoperatively.
9690424|NCT04834310|Placebo Comparator|Intraoperative Antibiotics and Placebo|The control group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by a placebo for 5 days postoperatively
9690425|NCT04834323|Active Comparator|group (1)|included 42 patients who were subjected to distal mesogastric fixation after laparoscopic sleeve gastrectomy
9690426|NCT04834323|No Intervention|group (2)|included 42 patients who were subjected to laparoscopic sleeve gastrectomy alone without distal mesogastric fixation
9690427|NCT04833985|Experimental|transesophageal echocardiography guidance|
9690428|NCT04833985|Experimental|intracardiac echocardiography guidance|
9690429|NCT04833985|Experimental|fluoroscopy only guidance|
9690430|NCT04833998|Placebo Comparator|Placebo|Placebo will be cream without the active ingredient. It will be matched in appearance, smell, consistency, and color to Extremecare topical cream. Patients will be instructed to apply the placebo cream to the hand and feet.
9690431|NCT04833998|Experimental|Extremecare|Extremecare is a moisturizing cream based on Thoitaine, Aloe Vera and Calendula for topical use. Patients will be instructed to apply the moisturizing cream to the hand and feet.
9690432|NCT04834050|Experimental|Rheumatoid arthritis patients|
9690433|NCT04834050|Experimental|Knee Osteoarthritis patients|
9690434|NCT04834050|Experimental|Healthy patients|
9690435|NCT04834037|Experimental|Experimental|"Patients in the experimental group were provided with information in addition to routine nursing care and supportive care interventions were made. The information leaflet was explained to the patients in the experimental group face to face by the researchers and the information was repeated according to the patient's needs.~As a pre-test measure, blood gases were taken from the patients in the experimental and control groups, their vital signs were measured, their state of consciousness was evaluated, and DASS-21 (anxiety and stress sub-dimension) and RASS (agitation dimension) were practiced by face-to-face interviews with the patients. As the last test, the same measurements were made 5 days after the first measurement and before the patients were transferred to the normal service. An information pamphlet consisting of textual material about NIV treatment was developed."
9690436|NCT04834037|No Intervention|No intervention|Routine nursing care was practiced to the control group in the intensive care clinic where the patients were located.
9690437|NCT04834141||Kyphotic Group|"Participants with kyphosis angle ≥ 40 degrees joined the kyphosis group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
9690438|NCT04834141||Control Group|"Participants with kyphosis angle < 40 degrees for the control group. FlexiCurve ruler method was used, which is a reliable tool for measuring kyphosis height and kyphosis index. In addition, it is non-invasive, inexpensive, and easy to use in a clinical setting.~Static balance Assessment:~Objective evaluation of the static balance evaluated by the NeuroCom Balance Manager System ® static posturography device (45 × 45 cm NeuroCom® System Version 8.1 Balance Manager International, Clackamas, Oregon, USA)"
9690439|NCT04833920|Active Comparator|active tDCS|tDCS targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days
9690440|NCT04833920|Sham Comparator|sham tDCS|tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds
9690441|NCT04833959|Experimental|89Zr-Panitumumab|Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.
9690442|NCT04834219||On-pump CABG|Patients with an on-pump indication by the cardiovascular surgery department will be included in the study.
9690443|NCT04834219||Off-pump CABG|Patients with an off-pump indication by the cardiovascular surgery department will be included in the study.
9690444|NCT04834180|Sham Comparator|Vaccaria seeds plus diet therapy|Vaccaria seeds at the exterior side of the ear area, standard points were selected according to clinical experience in traditional Chinese medicine: Shenmen (TF4), Stomach (CO4), Hunger, Mouth (CO1), Point Zero HX1) and Sanjiao (CO17). Mustard seeds (Vaccaria ear seeds, Beijing Zhongyan Taihe Medicine, Beijing, China) were used, plus diet therapy prescribed by a licensed nutritionist.
9690445|NCT04834180|Active Comparator|ASP needles plus diet therapy|ASP needles on the outside of the ear standard points were selected according to clinical experience in traditional Chinese medicine: ASP gold needles, strengthening the centre with point 0 (the umbilicus) in the dominant ear, Porta Fortunae in the non-dominant ear, Barbiturate in the non-dominant ear, Psychosomatique key point in the dominant ear and the point Aggression, plus diet therapy prescribed by a licensed nutritionist.
9690446|NCT04834180|No Intervention|only diet therapy|only diet therapy prescribed by a licensed nutritionist.
9690447|NCT04834115|Experimental|Ivermectin|Ivermectin 200mcg/kg single dose, maximum dose 18mg
9690448|NCT04834115|Placebo Comparator|Placebo|Inactive medication tablets indistinguishable from ivermectin tablets
9690449|NCT04834089|Experimental|Experimental product group (Stage A)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
9690450|NCT04834089|Placebo Comparator|Placebo group (Stage C)|Saline solution Administration Route: Intravenous
9690451|NCT04834089|Experimental|Experimental product group (Stage B)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
9690452|NCT04834089|Experimental|Experimental product group (Stage C)|Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous
9690453|NCT04834154|Active Comparator|Mindfulness group visit|Participants will attend 6 weekly educational and mindfulness sessions
9690454|NCT04834154|Placebo Comparator|Wait list control|Participants will be placed on a wait list
10180632|NCT03791554|Active Comparator|Group A : Lateral closed Tunnel|"Laterally closed tunnel procedure with subepithelial connective tissue graft (sCTG) After local anesthesia, root planing will be performed. Recession defect - a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~• Recipient site; Using either single or mattress sutures, the graft will be pulled and fixed mesially and distally at the inner aspect of the pouch. The graft will be adapted to the CEJ by means of a sling suture. Margins of the pouch will be pulled together over the graft and sutured with interrupted sutures to accomplish tension-free complete or partial coverage of the graft as well as the denuded root surface."
10180633|NCT03791554|Active Comparator|Group B : Tunneling|"Tunnel procedure with subepithelial connective tissue graft (sCTG) - Control:~At the recipient site (recession defect): a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~Then the graft is placed and secured in the recipient site. The flap is displaced to be in a coronal position using a sling suture with no suturing to approximate the margins together."
10180634|NCT03791424|Experimental|Midazolam|Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
10180635|NCT03791424|Placebo Comparator|Control|Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
10180636|NCT03791177|Experimental|Study Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
9690455|NCT04834271|Active Comparator|Exercise without blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) without blood flow restriction.
9690456|NCT04834271|Experimental|Exercise with 40% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% of arterial occlusion pressure blood flow restriction.
9690457|NCT04834271|Experimental|Exercise with 80% of arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% of arterial occlusion pressure blood flow restriction.
9690458|NCT04834349|Experimental|Cohort I (NBTXR3, SBRT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo SBRT QOD on days 15-29. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9690459|NCT04834349|Experimental|Cohort II (NBTXR3, IMRT/IMPT, pembrolizumab)|Patients receive NBTXR3 IT on day 1. Patients then undergo IMRT/IMPT QD on days 15-50. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9690460|NCT04834258|Experimental|Walking and respiratory muscle training group|"Walking and respiratory muscle training group (W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged."
9690461|NCT04834258|Active Comparator|Respiratory muscle training group|In the Respiratory muscle training group (RMT), Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged
9690462|NCT04834245|Experimental|hydrogel/nano silver-based dressing|hydrogel/nano silver-based dressing
9690463|NCT04833972|Experimental|Experimental: V1: Binary Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has binary (yes/no) response options."
9690464|NCT04833972|Experimental|Experimental: V2: Categorical Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has categorical response options: all or almost all; more than half, but fewer than 90%; fewer than half, but more than 10%; very few, or no one"
9690465|NCT04833972|Experimental|Experimental: V3: Open-Ended Numerical Estimate|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire permits the study participant to provide an open-ended numerical estimate."
9690466|NCT04834206|Other|DNF-N|"Induction chemotherapy:~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~Concurrent chemoradiotherapy:~three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~Radiotherapy: radical intense modulated radiation therapy"
9690467|NCT04834167|Experimental|Treatment|Eligible patients will receive ten picopulse treatments for bi-monthly.
9690468|NCT04833907|Experimental|3.7 x 10^13 v.g. rAAV-Olig001-ASPA|3.7 x 10^13 v.g. of rAAV-Olig001-ASPA administered as a single dose neurosurgically to the brain via 4 pre-defined intracerebroventricular sites
9690469|NCT04833881||The control group|
9690470|NCT04833881||Experimental group|
9690471|NCT04833517||Lu177 PSMA RLT|Lutetium-177 prostate-specific membrane antigen (Lu177 PSMA) radioligand therapy (RLT) according to standard local protocol
9690472|NCT04833517||Ac225 PSMA RLT|Actinium-225 prostate-specific membrane antigen (Ac225 PSMA) radioligand therapy (RLT) according to standard local protocol
9690473|NCT04833517||Tandem Lu177 / Ac225 PSMA RLT|Combined Lu177 / Ac225 PSMA radioligand therapy according to standard local protocol
9690474|NCT04833517||Ra223 chloride|Bone-targeted Radium-223 (Ra223) radionuclide therapy in standard application
9690475|NCT04833517||Sm153 EDTMP|Bone-targeted Samarium-153 (Sm153) EDTMP radionuclide therapy in standard application
9690476|NCT04833517||Y90 microshperes|Radioembolization with yttrium-90 (Y90) microspheres, standard methodology
9690477|NCT04833647|Other|Term|7-10 years old born at 37-42 weeks gestation
9690478|NCT04833647|Other|Late preterms|7-10 years old born at 34.0-36.6 weeks gestation
9690479|NCT04833647|Other|Preterms with BPD|7-10 years old born before 30 weeks gestation with the diagnosis of BPD: the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation
9690480|NCT04833647|Other|pretermas without BPD|7-10 years old born before 30 weeks gestation without the diagnosis of BPD (without the need for oxygen at 36 weeks gestation and/or flow or 3LPM or more, and/or the need for CPAP or invasive ventilation)
9690481|NCT04833660|Experimental|rTMS group|"Each patient will receive five consecutive sessions (Monday to Friday for 1 week).~Patients in the rTMS group will administer rTMS over the optimal scalp site at 10 Hz, with an intensity of 90% of the MT and a duration of 5 seconds, for a total of 20 trains separated by 55-second intertrain pauses (a total of 1,000 pulses). The coil will be placed tangentially to the scalp at an approximate angle of 45° tilted backward and laterally. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods."
9690482|NCT04833660|Sham Comparator|sham group|Patients in the sham group will administer sham stimulation using the same protocol, except that the angle of the coil is 90° (i.e., perpendicular, rather than tangential) to the skull. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods.
9690483|NCT04833530||Woman undergoing an gastric ultrasound assessment.|Woman undergoing general anesthesia for oocyte retrieval during in vitro fertilization, will undergo an gastric ultrasound assessment.
9690484|NCT04833608|Active Comparator|Vktory Carbon fiber insoles|VKTRY insoles were initially designed to increase ground force leading to a harder push off for faster running or higher jumping. To enable energy return the insole needed to be extremely rigid and therefore consists out of a full length Carbon-Fiber base. Unexpectedly the Carbon fiber base makes this a highly rigid construct which will likely benefit those patients with MTP arthritis as it will take away much movement of the MTP joint, without having an uncomfortable shape, i.e. patients can use this insole in their own shoes, possibly leading to a higher patient compliance and, simultaneously, to better outcome
9690485|NCT04833608|Active Comparator|Morton's extension insoles|Based on expert opinions, it seems the Morton extensions may alleviate pain but are also poorly tolerated by patients due to its uncomfortable shape, coincidently leading to a low patient compliance rate.
9690486|NCT04833543|Active Comparator|Tilt Table|
9690487|NCT04833543|Experimental|Robotic Mobility Device (REX)|
9690488|NCT04833569|Experimental|Indocyanine green mediated photodynamic therapy (ICG-PDT)|Delivery of ICG solution at a concentration of 1 mg/mL will be used. The photosensitizer will be applied until the bottom of the peri-implant pocket using a 1 ml syringe. An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J will be used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction.
9690489|NCT04833569|Placebo Comparator|Peri-implant mechanical debridement|Non-surgical peri-implant mechanical debridement (PIMD) through ultrasonic device with a carbon tip.
9690490|NCT04833699|No Intervention|Control|Group A served as the control group who did not receive any intervention except our clinical standard postoperative care
9690491|NCT04833699|Experimental|Study|Group B served as the hot pack group that warm water (80 C) was put in a hot pack (Fig 1) and then placed on the patients umbilicus at 6, 12, and 18 h after the operation for 45 minutes in addition to clinical standard postoperative care.
9690492|NCT04833738|Active Comparator|Electrotherapy|
9690493|NCT04833738|Active Comparator|corticosteroid|
9690494|NCT04833738|Active Comparator|hyaluronic acid|
9690495|NCT04833556||Postpartum haemorrhage|Patients undergoing cesarean delivery with postpartum haemorrhage (blood loss more than or equal to 1,000 ml.)
9690496|NCT04833751||Anesthesia for cardio/neurovascular surgery or procedure|Patients undergoing anesthesia in an operating room or hybrid room for cardio/neurovascular surgery or procedure.
9690497|NCT04833686|Active Comparator|Sonata for 2 pianos in D major, K.488 by Mozart|An Mp3 player, upload with music by Mozart. Music was played using headphones suitable and approved for use in children.
9690498|NCT04833686|Active Comparator|"Instrumental music (To the Point, by Dean Evenson & Tom Barabas)"|An Mp3 player, upload with instrumental music. Music was played using headphones suitable and approved for use in children.
9690499|NCT04833686|Active Comparator|Silence|An Mp3 player, upload with silence. Silence was played using headphones suitable and approved for use in children.
9690500|NCT04833621|Active Comparator|NMES GROUP|NMES TREATMENT AND PHYSICAL TREATMENT
9690501|NCT04833621|Active Comparator|CONTROL GROUP|JUST PHYSICAL TREATMENT
9690502|NCT04833465||JIA|Patients ages 5-21 with a diagnosis of JIA.
9690503|NCT04833465||SLE|Patients ages 5-21 with a diagnosis of SLE.
9690504|NCT04833465||FM|Patients ages 5-21 with a diagnosis of FM.
10187519|NCT03725501|Placebo Comparator|Ranibizumab + Placebo|"Placebo - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
9827606|NCT02461771|Experimental|Pegcetacoplan Cohort 1|4 mg of pegcetacoplan 100 μL IVT injection
9827607|NCT02461771|Experimental|Pegcetacoplan Cohort 2|10 mg of pegcetacoplan 100 μL IVT injection
9827608|NCT02461771|Experimental|Pegcetacoplan Cohort 3|20 mg of pegcetacoplan 100 μL IVT injection
10180637|NCT03791177|Sham Comparator|Control Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
10180638|NCT03791021||third trimester pregnant women|the group of participants in this research would include approximately 100 subjects in the third trimester of their pregnancy. the participants would be collected in the central area of Israel from various socioeconomic groups. each participant would be asked to make draw a person (DAP) test, and answer a number of questionnaires including Edinburgh Postnatal Depression Scale (EPDS), Beck Depression Inventory II (BDI-II), and Traumatic Events Questionnaire (TEQ).
9690505|NCT04833725||COPD combined with OSA|All patients collect sleep monitoring information through wearable devices, together with demographic characteristics, pulmonary function tests, blood routines, biochemistry, electrocardiogram, chest radiograph, COPD assessment scale, modified British Medical Research Association dyspnea index, St. George's Quality of Life Questionnaire, Sleep Apnea Clinical Score, Berlin Questionnaire, Epworth Sleepiness Scale, Etc. This study estimates patient health status from the collected information, then diagnoses sleep apnea and calculates sleep apnea prevalence.
9690506|NCT04833829|Active Comparator|Clinic Patients During the Pre-implementation Period|Patients visiting one of the study clinics prior to implementation of the CHIMES intervention. The Baseline time period consists of study Months 1 - 12. Data are retroactively abstracted from medical records of patients who had clinic visits that occurred between January 1, 2019 and December 31, 2019.
9690507|NCT04833829|Experimental|Clinic Patients During the Implementation Period|Patients visiting one of the study clinics during the Implementation period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 13 - 27.
9690508|NCT04833829|Experimental|Clinic Patients During the Maintenance Period|Patients visiting one of the study clinics during the Maintenance period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 28 - 33.
9690509|NCT04833790|Experimental|Free distribution of ORS + standardized patient with ORS preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
9690510|NCT04833790|Experimental|Free distribution of ORS + standardized patient with Antibiotic preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
9690511|NCT04833790|Experimental|Free distribution of ORS + standardized patient with no preference|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
9690512|NCT04833790|Experimental|Free distribution of ORS + standardized patient with no preference + no financial incentive|Providers assigned to this arm will receive 3 months supply of ORS. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
9690513|NCT04833790|Experimental|Status quo ORS supply + standardized patient with ORS preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for ORS.
9690514|NCT04833790|Experimental|Status quo ORS supply + standardized patient with Antibiotic preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates a preference for Antibiotics.
9690515|NCT04833790|Experimental|Status quo ORS supply + standardized patient with no preference|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment.
9690516|NCT04833790|Experimental|Status quo ORS supply + standardized patient with no preference + no financial incentive|Providers assigned to this arm will have status who ORS supply. Roughly 4 weeks later, they will receive a visit from a standardized patient (outcomes assessor) who poses as a caretaker for their child with diarrhea and indicates no preference for treatment and indicates that they will purchase whatever the provider recommends from a relative's drug shop.
9690517|NCT04833491||Senile cataract|
9690518|NCT04833491||Traumatic cataract|
9690519|NCT04833491||Congenital cataract|
9690520|NCT04833491||Lens dislocation group|
9690521|NCT04833491||Complicated cataract|
9690522|NCT04833478|Experimental|Application|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
9690523|NCT04833478|Experimental|Dental Song|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
9690524|NCT04833478|Experimental|Tell Show Do|Measuring anxiety level of the patients using Facial Image Scale and Pulse Oximeter
9690525|NCT04833673|Experimental|PMR|"The PMR intervention involving tensing and relaxing the body muscles accompanied with deep breathing. The researchers told each~participant to sit in a soundless and breathable room and in a comfortable position before each session at their home. The participants performed tensing and relaxing for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed with deep breathing. The participants were instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Moreover, throughout this exercise, the participants imagined a wave of relaxation flowing over their body."
9827609|NCT02461966|Other|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
9690526|NCT04833673|Experimental|BRT|Within the scope of this technique, first of all, the participants were asked to focus on a word that relieves them such as love, health or well-being. And so, the participants were asked to be in comfortable position in a silent and breathable room with the closed eyes, relax their muscles from the sole of their feet and progressing up to their face gradually, keep them relaxed, accompanied with deep breathing, be aware of their breathing, exhale gently. They continue these practices for 20 minutes and try to relax their muscles. After finishing the duration, they sit quietly for several minutes with eyes closed and later with eye opened.
9690527|NCT04833673|No Intervention|CG|"Regarding CG, the participants were invited to the same room and received only a single time attention-matched education on Living with MS; including definition of MS, dietary advices for MS patients. The attention-matched education was performed face to face and lasted for 10 min. All participants in the three study groups also received usual treatment and care."
9690528|NCT04833777|Active Comparator|Lidocaine|Administration of subcutaneous lidocaine as local anesthetic prior to carpal tunnel release (lidocaine intervention)
9690529|NCT04833777|Experimental|Bupivacaine|Administration of subcutaneous bupivacaine + lidocaine as local anesthetic prior to carpal tunnel release (bupivacaine intervention)
9690530|NCT04833595|Experimental|Mindfulness Arm|"A recommendation on healthy food intake will be sent to participants. At the end of each week, participants will be required 1) to submit THREE photos of the meals that they are most satisfied with in terms of healthiness and 2) using the photos to answer a questionnaire about their diet. The photos and completed questionnaire must be submitted to the research investigator each week for a total of 8 weeks. After 8 weeks, participants will be required to get tested for your fasting total cholesterol and blood glucose level in the appointed pharmacy for the second time. It is estimated to require 15-30 minutes of their time weekly.~The questionnaire used for experimental group contains reflective questions as part of the mindfulness intervention."
9690531|NCT04833595|Active Comparator|Non-mindfulness Arm|Everything is similar to the experimental arm. However, the questionnaire used for control group does not contain reflective questions to serve as control group.
9690532|NCT04833868|Experimental|hippotherapy combined with Schroth Exercise|received hippotherapy combined with Schroth Exercise hippotherapy session for 30 minutes of walking and sitting trot training, 15 sessions split into 2 phases over ten weeks in addition to 60-minute session Schroth's intervention, 3 times/ week for 10 weeks
10180639|NCT03791294|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
9690533|NCT04833868|Active Comparator|Schroth Exercise|received Schroth's intervention for a 60-minute session, 3 times/ week for 10 weeks
9690534|NCT04833712|Experimental|Stereotactic Radioablation|"Noninvasive Stereotactic Radioablation will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.~Pulmonary vein isolation will be assessed by using Cardioinsight non-invasive mapping system"
9690535|NCT04833842|Experimental|Web-based birth preparation program supported by motivational interview|A web-based childbirth preparation program prepared based on the Health Belief Model and supported by motivational interviews will be applied to primigravida women in the initiative group.
10180640|NCT03791294|No Intervention|Control|No treatment
9690536|NCT04833842|Experimental|web-based birth preparation program|A web-based birth preparation program based on the Health Belief Model will be applied to primigravida women in the control group.
9690537|NCT04833452|Active Comparator|Wide fenstrum Endoscopic DCR|
10180641|NCT03791099|Experimental|Metronidazole|19,8 mg of metronidazole in one polymer matrix
9690538|NCT04833452|Active Comparator|Narrow Fenstrum Endoscopic DCR|
9690539|NCT04833205|Experimental|Leptomeningeal metastases received EGFR-TKI and Nimotuzumab|The patients received Nimotuzumab 200 mg,which was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping.And the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks.One the other hand,the patient received the third generation of EGFR-TKI
9690540|NCT04833218|Active Comparator|propranolol group|we will give propranolol 40 milligram tablet twice daily in orogastric or nasogastric tube
9690541|NCT04833218|Active Comparator|propranolol clonidine|we will give propranolol 20 milligram tablet twice daily and clonidine 150 microgram tablet twice daily in orogatric or nasogastric tube
9690542|NCT04833218|No Intervention|control group|we will give conventional treatment, no propranolol nor clonidine
9690543|NCT04833231||High eGFR group (eGFR ≥60 mL/ min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) ≥60 mL/ min/1.73 m2 as high eGFR group
9690544|NCT04833231||Low eGFR group (eGFR <60 mL/min/1.73 m2)|Patients with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 as low eGFR group
9827610|NCT02461966|Other|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
10180642|NCT03791099|No Intervention|Only SRP|standard non-surgical treatment- scaling/root planing
10180643|NCT03791138|Experimental|intervention group|Care as usual and an online patient decision aid
10180644|NCT03791138|No Intervention|control group|Care as usual with a standard information leaflet
10180645|NCT03791047|Experimental|Experimental Group: Balance analysis|Sixty older subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
10180646|NCT03791047|Active Comparator|Control Group:Balance Analysis|Sixty young subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
10180647|NCT03791255|Experimental|Resin Modified Calcium Silicate|light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
10180648|NCT03791255|Active Comparator|Light Cured Calcium Hydroxide|gold standard for pulp capping, It allows for the formation of a reparative dentine bridge through cellular differentiation, extracellular matrix secretion and subsequent mineralization.
10180649|NCT03791112|Experimental|50mg QD|Participants received 50 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
10187520|NCT03725488||Active|Evaluate stress among dental students by Questionnaire
10180650|NCT03791112|Experimental|100mg QD|Participants received 100 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
10180651|NCT03791112|Experimental|200mg QD|Participants received 200 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
10180652|NCT03791112|Experimental|300mg QD|Participants received 300 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
10180653|NCT03791112|Experimental|400mg QD|Participants received 400 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
10180654|NCT03791112|Experimental|500mg QD|Participants received 500 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
10180655|NCT03791268||Group A|Gastric Cancer Patients who underwent Chemotherapy and will have gastric cancer surgery.
10180656|NCT03791307|Experimental|Traditional Pilates group|This group will perform only exercises based on the traditional Pilates method
10180657|NCT03791307|Experimental|Modified Pilates group|This group will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer
10180658|NCT03791307|No Intervention|Control group|This group will not perform any physical exercise during the trial period.
10180659|NCT03791203|Experimental|Calorie restriction (MACR)|Participants restricted 70% of their energy needs over 24 hours on a calorie restriction day alternate with a feeding day for the next 24 hours, where they were allowed eating (ad libitum). The calorie restriction and feeding days begun at 9 am each day, and on the calorie restriction day, meals were consumed between 2 pm and 8 pm to ensure that they underwent the same duration of calorie restriction. On each calorie restriction day, they were allowed energy-free beverages and sugar-free gum and encouraged to drink plenty of water. Diet plans were self-selected using detailed individualized food portion lists, meal plans, and recipes. Participants received phone calls from the investigator and four 2-weekly appointments with a dietitian. Adverse experiences were assessed every 2 weeks.
10180660|NCT03791203|No Intervention|Control group|Participants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
10180661|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 30mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
9690545|NCT04833283|Experimental|the intervention group intermittent hypoxic-hyperoxic training|"the intervention group is patients performing intermittent hypoxic-hyperoxic training before operation. ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)~Intervention Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s)."
9690546|NCT04833283|Placebo Comparator|the control group|intermittent hypoxic-hyperoxic training control group will be identical to the main group, also underwent four daily procedures before surgery using 40 min training periods with simulation of intermittent hypoxic-hyperoxic trainings by using the same equipment, whereas moistened air will be delivered through a placebo mask
9690547|NCT04833114|Experimental|Experimental Arm: Pola-R-ICE|combination of standard chemotherapy with polatuzumab vedotin (Pola-R-ICE) Application
9690548|NCT04833114|Active Comparator|Standard Arm: R-ICE|conventional treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE)
9690549|NCT04833387|Experimental|PD-1 antibody + capecitabine + radiation|
9690550|NCT04833374|Experimental|1-2-3 Group|Patients in 1-2-3Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
9690551|NCT04833374|Active Comparator|1-3-5 Group|Patients in 1-3-5 Group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-3rd-5th month ,then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
9690552|NCT04833400|Experimental|Intelligent cardiopulmonary rehabilitation system (ICRS)|The ICRS is very likely to the conventional stationary biking, but with an algorithm that automatically controls the resistance of pedalling, considering the instant heart rate and cadence, to keep the heart rate within the targeted heart rate zone.
9690553|NCT04833400|Active Comparator|Traditional aerobic exercise training (TAET)|"The TAET is performed with stationary biking, with intensity being set as subjective rating of perceived exertion at a somewhat hard to hard level. The resistance of pedaling is ad-justed by the user or physical therapist."
9690554|NCT04833244|Active Comparator|Interventional|Patients are taught to draw their shoulders away from their heads and necks, activating the subscapularis and pectoralis muscles. When asked immediately afterwards to abduct and flex their shoulders, these muscles perform the action that generally engages the injured supraspinatus muscle, causing significant pain. However, when these muscles are substituted for the injured supraspinatus, abduction and flexion subsequently occur painlessly.
9690555|NCT04833244|Placebo Comparator|Control|Patients are taught a sham maneuver that does little or nothing to alleviate the pain of abduction and flexion of the shoulders. Therefore their pain levels before and after learning the maneuver are likely to be similar.
10180662|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 60mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
10180663|NCT03790982|Experimental|AD-35 30 mg+Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
10180664|NCT03790982|Experimental|AD-35 60 mg|AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
10180665|NCT03791281|Experimental|BASIS|Received a 3-hour BASIS implementation strategy.
10180666|NCT03791281|Active Comparator|Attention Control|Received a 3-hour session designed to control for dose, information provided, and presenter effects.
9690556|NCT04833127|Active Comparator|Masibambane - Gender-Enhanced|"A virtual (online) group-based interactive Gender-Enhanced (GE) Workshop (using the WhatsApp® platform). The intervention has components that are conducted by participants on their own time as well as a real-time live interactive session."
10180667|NCT03790839|Experimental|Sequential arm ABC|A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
9690557|NCT04833127|Other|Individually accessed|In this condition women are given access to a PrEP video and to websites that provide information on PrEP and on contraception options.
9690558|NCT04833335|Experimental|Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versus|Inclusion visit, 1 month later, 6 month later
9690559|NCT04833322|Experimental|Single arm group|Galactose supplementation
9690560|NCT04833062||Diabetes mellitus group|Based on DM type, all women will be divided into four groups: prepregnancy/preexisting DM insulin-dependent or independent (types I and II; classes B, C, and D) and gestational DM (GDM) with or without the need for insulin therapy (DM classes A1 and A2). In the case of gestational DM, the gestational week at the time of diagnosis will be registered. We will consider whether women are diagnosed with another preexisting disease (endocrinological or another one) before or during pregnancy, in order to check the relationship of this disease and their DM and potential risks for pregnancy.
9690561|NCT04833062||Nondiabetic group|Nondiabetic women who received birth assistance at our referral centers and who agreed to participate in the study were included in the control group. A control of healthy (non-diabetic women) mothers so to compare characteristics and outcomes across diabetic groups will comprise the control group.
9690562|NCT04833166|Experimental|Full glottic view on CMAC- D blade|Deliberately obtaining a full glottis view is deﬁned as negotiation and advancement of CMAC D blade tip positioned at the vallecula. Occasionally, external laryngeal pressure may be needed to assist in obtaining a full glottic view. The full glottic view is defined as a percentage of glottic opening (POGO) approximate 100%.
9690563|NCT04833166|Active Comparator|Partial glottic view on CMAC- D blade|The partial glottis view is deﬁned as a percentage of glottic opening <50%. This is achieved by deliberately position the CMAC D-blade tip proximally away from the vallecular.
9690564|NCT04833049|Experimental|TAK-994 Dose 1 + [14C]TAK-994 Dose 2 + [14C]TAK-994 Dose 3|TAK-994 Dose 1, tablet, orally, on Day 1, followed by [14C]TAK-994 Dose 2, infusion, intravenously, on Day 1 of Part A, followed by a washout period of at least 8 days, further followed by [14C]TAK-994 Dose 3, suspension, orally, on Day 1 of Part B.
9690565|NCT04833257|Experimental|GP combine with Tislelizumab neoadjuvant therapy+CCRT|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
9690566|NCT04833179|Experimental|fecal transplant|Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. The treatment will be given in the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment.
9690567|NCT04833179|Placebo Comparator|placebo|Placebo capsule that can not be differentiate from the focal transplant capsule will be given in the same interval as the fecal transplant procedure written above.
9690568|NCT04832997|Experimental|mpMRI plus Micro-US|Patients with a clinical suspicion of csPCa will receive mpMRI and Micro-US in two different visits (randomized sequence). The results of the diagnostic procedures will determine how many and which type of prostate biopsies patients will undergo.
9690569|NCT04833101|Experimental|"0-28 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 28, and a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
9690570|NCT04833101|Placebo Comparator|"0-28 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 28, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
9690571|NCT04833101|Experimental|"0-56 days vaccine group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of subunit vaccine (ZF2001) against COVID-19 on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
9690572|NCT04833101|Placebo Comparator|"0-56 days placebo group"|One dose of recombinant Ad5 vectored COVID-19 vaccine on day 0, the second dose of a commercial influenza vaccine on day 56, a third of subunit vaccine (ZF2001) against COVID-19 on month 4.
9690573|NCT04833036|Active Comparator|c-CetuIRI|Irinotecan combined with cetuximab
9690574|NCT04833036|Experimental|s-IRI-CetuIRI|single irinotecan first, then irinotecan plus cetuximab sequentially after PD
9690575|NCT04833023|Active Comparator|Haloperidol Arm|Haldol 2mg/ml oral solution
9690576|NCT04833023|Active Comparator|Olanzapine Arm|Olanzapine Actavis 5mg orodispersible tablet
9690577|NCT04833153|Experimental|PFP intervention|PFP 10 week continuing education intervention
9690578|NCT04833153|No Intervention|Control arm|Usual care
9690579|NCT04833270|Experimental|KM non-pharmacological treatment group|Non-pharmacological treatment including Korean medicine will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
9690580|NCT04833270|Active Comparator|Pharmacological treatment group|Pharmacological treatment will be implemented to the participants twice a week for total 8 weeks. The specific intervention will be determined according to the physician's choice, and information will be recorded in the case report form.
9690581|NCT04833439|Experimental|Fasting Mimicking Diet|2 cycles of 3-day fasting mimicking spaced by a 2 week interval
9690582|NCT04832893|Active Comparator|Use of FFP2 respirator|Using of FFP2 respirator during the 30 minutes test
10180668|NCT03790826|Experimental|Cystoscopic Inspection|"Comparison of bladder damage with traditional Foley catheter and the Kohli Atraumatic catheter.~Interventions: cystoscopy"
10180669|NCT03791242|Active Comparator|Group 1|33 morbidly obese patients with severe OSAS and suitable for gastric bypass surgery, who underwent 4 weeks of CPAC treatment (these patients will not be required to change their eating habits) according to the standard
10180670|NCT03791242|Active Comparator|Group 2|33 morbidly obese patients with severe OSAS and BS candidates who underwent CPAC + KMED treatment for 4 weeks
10180671|NCT03790995||High risk prostate cancer|"Patients with initial cT2c-3-4, cN +, Gleason score (GS) more than 7 or PSA > 20ng/mL were labelled as high-risk prostate cancer.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
10180672|NCT03790995||Low - intermediate risk prostate cancer|"Initial PSA levels less or equal than 20 ng/mL with GS of 7 or less and cT1-2a-2b, 2 were labelled as low and intermediate risk prostate cancer and served as a control group.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
10180673|NCT03791164|Experimental|Pain Toolkit plus the Back Book|Participants who are being discharged from the regional back pain pathway who are allocated the 'Pain Toolkit' booklet along with the control intervention 'the Back Book'. They follow the interventions in the 'PainToolkit' for 12 months and are followed up 6 months and 1 year.
10180674|NCT03791164|Active Comparator|Back Book|Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
10180675|NCT03790930||thin layer CT|Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm.
10180676|NCT03791190|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
10180677|NCT03791190|Experimental|Regional citrate anticoagulation|"Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.~Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.~Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level."
10180678|NCT03791125|Experimental|Experimental|
10180679|NCT03791125|Placebo Comparator|Placebo|
10180680|NCT03790969|Experimental|26 gauge needle|intervention group
10180681|NCT03790969|Active Comparator|23 gauge needle|control group
10180682|NCT03790735||Diagnostic test|Targeted chromosomal aberrations detection by FISH (MDA TEST).
10180683|NCT03790800|Experimental|Intervention group|If systolic blood pressure>180:IV Urapidil 25mg If systolic blood pressure>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
10180684|NCT03790800|No Intervention|control group|To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is >220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
10180685|NCT03790891|Experimental|CD19-TriCAR-T/SILK|CD19-TriCAR-T/SILK cells will be administered intravenously
10180686|NCT03790787|Experimental|Sequential arm ABC|A: Empagliflozin 25 mg QD in the morning on Days 1-5; B: Empagliflozin 25 mg in the morning and Dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
10180687|NCT03790722|Experimental|Higher Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
9690583|NCT04832893|Active Comparator|Use of surgical mask|Using of surgical mask during the 30 minutes test
9690584|NCT04832893|Sham Comparator|no mask|The 30 minutes test will be carried out without mask
9690585|NCT04832828||COVID+ Group|Patients diagnosed with Covid19 positive in last 7 days
10180688|NCT03790722|Experimental|Lower Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
10187521|NCT03725488||the present level of stress, comfort zone & coping with stress|Evaluate how stress was coped, the coping mechanisms used through Questionnaire
10187522|NCT03725462|Experimental|Cardioskin|Subjects performed a monitoring with Cardioskin. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Cardioskin, either by an opinion of an expert.
10187523|NCT03725462|Experimental|Neuronaute|Subjects performed a monitoring with Neuronaute. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Neuronaute, either by an opinion of an expert.
10187524|NCT03725423|Experimental|experimental group|Oral administration of 250mg of apatinib daily, with or without chemotherapy
10187525|NCT03725397|Experimental|Outpatients with a transcervical Foley catheter|Women with a transcervical Foley catheter in place that will spend the night at home.
10187526|NCT03725397|Active Comparator|Inpatients with a transcervical Foley catheter|"Women to be admitted to the hospital overnight which has been a standard of care."
9528142|NCT03213496|Experimental|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
9528143|NCT03213496|Other|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
9690586|NCT04832906|Active Comparator|"Group A Ulipristal Acetate (UA) - Fibristal group (n=35)"|Patients within this group received oral Ulipristal Acetate (Fibristal ©) 5 mg / day starting from the first day of menstrual bleeding, and for 3 months (period of the study).
10180689|NCT03790852|Experimental|KSI-301 2.5 mg|KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
9690587|NCT04832906|Active Comparator|"Group B Uterine artery embolization (UAE) group (n=35)"|Patients within this group underwent bilateral selective uterine artery embolization, during which polyvinyl alcohol (PVA) particles was administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected. The gelatin sponge cap was thought to both complete the occlusion of the uterine artery and to prevent PVA particles from being drawn out of the uterine artery by the Venturi effect, which would result in non-target embolization.
9690588|NCT04833348|Experimental|Patients|Infants with spinal muscular atrophy cared by the Neuromuscular Reference Center at Necker Hospital and eligible for innovative therapy (gene therapy or pharmacogenetics)
9690589|NCT04832815|Experimental|Equine Therapy|
9690590|NCT04832815|No Intervention|Treatment as Usual (TAU)|
9690591|NCT04832815|Experimental|Therapeutic Horsemanship Program|
10180690|NCT03790852|Experimental|KSI-301 5 mg|KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
10180691|NCT03790696|Experimental|Active Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
10180692|NCT03790696|Sham Comparator|Sham Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
10180693|NCT03790904|Active Comparator|Co. mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
10180694|NCT03790904|Placebo Comparator|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
10180695|NCT03790904|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
10180696|NCT03790644|Experimental|exoskeleton assist|walking with assist of a powered exoskeleton
10180697|NCT03790761|Experimental|PREP 8.0 Curriculum|All participants enrolled in the program will be given the PREP 8.0 curriculum - there will be no comparison group.
10180698|NCT03790670|Experimental|Leukine Treatment|24 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
10180699|NCT03790774|Experimental|Neurofeedback|Three times per week, for six weeks, participants will receive biofeedback about the quality of their electroencephalograms (EEG; neurofeedback) during a letter identification task.
10180700|NCT03790748|Experimental|Conventional Epidural Technique|Procedure: Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L4-5 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
10180701|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|Procedure: 25G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
10180702|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 27G Whitacre needle|Procedure: 27G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
10180703|NCT03790709|Experimental|High dose ANAVEX2-73|High dose active once daily orally
10180704|NCT03790709|Experimental|Mid dose ANAVEX2-73|Mid dose active once daily orally
10180705|NCT03790709|Placebo Comparator|Placebo oral capsule|Placebo dose once daily orally
10180706|NCT03790813|Experimental|Eligible patients|
10180707|NCT03790631||imipenem TDM|Adult patients receiving imipenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
10180708|NCT03790631||meropenem TDM|Adult patients receiving meropenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
10180709|NCT03790631||piperacillin TDM|Adult patients receiving piperacillin (with or without tazobactam) for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
10180710|NCT03790631||flucloxacillin TDM|Adult patients receiving flucloxacillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
10180711|NCT03790631||amoxicillin TDM|Adult patients receiving amoxicillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
10180712|NCT03790631||ceftazidime TDM|Adult patients receiving ceftazidime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
10180713|NCT03790631||cefepime TDM|Adult patients receiving cefepime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
10180714|NCT03790592|Experimental|trifocal IOL|patients implanted with a trifocal intraocular lens
10180715|NCT03790540|Experimental|Injection with the aid of DentalVibe|"1 mL of Mepivacaine HCl 2%, 1/20000 Levonordefrin will be injected using a 27 gauge dental needle.~DentalVibe is a small, handheld cordless device that has a charging docking station. A demonstration of DentalVibe (DV) will be performed by putting it into direct contact with the children's nails before applying the device intraorally. Then, the device will be placed on the oral mucosa to enclose the injection site before administering local anesthesia and Potential subject-expectancy effects and pressure from the placement of DV will be controlled. The device will be turned on to stimulate the area of needle penetration. After 5 seconds of vibration, the needle will be inserted. The device will continue vibrating during needle insertion and anesthetic injection."
10187527|NCT03725358|Experimental|Control: no training, low subsidies|No provider training and low (status quo) subsidies received: business as usual
10187528|NCT03725358|Experimental|No training, medium-level subsidies|No provider training, but receiving medium-level PBF payments for contraceptive methods provided
9690592|NCT04832919|Experimental|Nurse-Community Health Worker-Family Partnership|The experimental arm will receive the Nurse-Community Health Worker-Family Partnership intervention
9690593|NCT04832919|No Intervention|Standard of Care|The control arm will receive standard access to NYC Department of Health COVID-19 testing sites and standard COVID-19 public health messaging
9690594|NCT04832880|Experimental|Control arm (dexamethasone arm)|IV dexamethasone 6 mg for 10 days
9690595|NCT04832880|Experimental|Remdesivir arm|IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10
9690596|NCT04832880|Experimental|Baricitinib arm|IV dexamethasone 6 mg for 10 days + baricitinib 4 mg die for 10 days. For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days.
9690597|NCT04832880|Experimental|Remdesivir + baricitinib arm|"IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10 + baricitinib 4 mg die for 10 days.~For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days."
10180716|NCT03790540|Active Comparator|Injection with topical benzocaine 20%|Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
10180717|NCT03790605|Experimental|1% curcumin chip|Following routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)
10180718|NCT03790605|Placebo Comparator|Placebo chip|Following routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)
10180719|NCT03790501||People living with HIV (PLHIV).|We will recruit and enroll 850 people living with HIV (PLHIV) to participate in this longitudinal observational study.
10180720|NCT03790449|Experimental|PreLiFe-programme|A Mobile Preconception Lifestyle programme
10180721|NCT03790449|Other|Attention Control|Attention Control Programme
10180722|NCT03790527|Experimental|CBM training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the CBM training group; Each participant will do these task twice( e.g. Before training and after training)"
10180723|NCT03790527|Sham Comparator|Sham training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the sham training group; Each participant will do these task twice( e.g. Before training and after training)"
10180724|NCT03790345|Experimental|Experimental group 1|15 subjects will be randomly assigned to adjuvant treatment with 200mg of vitamin B6 (pyridoxine).
10180725|NCT03790345|Experimental|Experimental group 2|15 subjects will be randomly assigned to adjuvant treatment with 2mg of vitamin B12 (cobalamin).
10180726|NCT03790345|Sham Comparator|Placebo oral tablet|15 subjects will be randomly assigned to adjuvant treatment with placebo.
10180727|NCT03790618|Placebo Comparator|Placebo|Subjects will attend one session during which they will receive a placebo capsule.
10180728|NCT03790618|Experimental|Low dose MDMA|Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
10180729|NCT03790618|Experimental|High dose MDMA|Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
10180730|NCT03790618|Experimental|Methamphetamine|Subjects will attend one session during which they will receive 20mg methamphetamine.
10180731|NCT03790566|Experimental|Erector spinae plane block|With the patient in lateral decubitus position (surgical side up), the transverse processes of T10-T12 vertebrae and erector spinae (ES) fascia are visualized 1-2 cm lateral to the vertebral spine using a linear ultrasound probe. A 22G peripheral block needle is introduced with in-plane technique under the ES muscle and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
10180732|NCT03790566|Active Comparator|Transversus abdominus plane block|With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
10180733|NCT03790475|No Intervention|Current screening practice.|Subjects randomized into this group will receive named invitations for colonoscopy with pre-specified date, contact details of dedicated screening center. Invitations will be sent 6 weeks prior to suggested date of screening test. All subjects not responding to the invitation will receive a reminder letter 3 weeks prior to proposed appointment date. Additionally, a re-invitation for colonoscopy (screening test in 6 weeks) will be sent to participants not responding to the first invitation and the reminding letter.
10187529|NCT03725358|Experimental|No training, high-level subsidies|No provider training, but receiving high-level PBF payments for contraceptive methods provided
10187530|NCT03725358|Experimental|Training, low-level subsidies|Providers being trained on modern contraception, but receiving low-level (status quo) PBF payments for contraceptive methods provided
10187531|NCT03725358|Experimental|Training, medium-level subsidies|Providers being trained on modern contraception, but receiving medium-level (status quo) PBF payments for contraceptive methods provided
9827611|NCT02461966|Other|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
9690598|NCT04832958|Experimental|Radioguided surgery|"68Ga-PSMA PET/MRI acquisition~99mTc-PSMA-I&S intravenous injection the day before surgery~99mTc-PSMA-I&S SPECT/CT imaging~99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations~Robot-assisted ePLND followed by RP~99mTc-PSMA-RGS to detect an increased count rate in the prostatic fossa after removal of the primary tumor~Histopathological examination~Monitoring of adverse events and perioperative outcomes after surgery"
9690599|NCT04832945||Ivermectin Group|Healthcare personnel receiving Ivermectin weekly PrEP
10180734|NCT03790475|Experimental|Sequential screening strategy.|"Subjects randomized into this group will be initially invited to participate in a screening colonoscopy as per group 1. All subjects who will refuse colonoscopy or do not respond to invitation within 6 weeks since the first letter, will receive another invitation letter with FIT test enclosed.~The screening office will contact persons with a positive test result in order to determine the date of the colonoscopy appointment.~A negative test result will be sent together with a recommendation to have another screening test performed 2 years later and information about the possible delivery of the test in two years."
10180735|NCT03790475|Experimental|Multiple options screening strategy.|"Subjects in this group will receive a letter with an offer to choose between colonoscopy or FIT screening.~The first letter will include an invitation with a scheduled date of colonoscopy (in 6 weeks) and a FIT kit.~Three weeks before a scheduled date of colonoscopy subjects randomized into this group will receive a reminder letter with an information about proposed screening methods. After the scheduled date of the colonoscopy examination, subjects who will not respond to the invitation for colonoscopy and will not send the FIT test back to the laboratory will receive another invitation for colonoscopy (in 6 weeks) and a FIT kit."
9690600|NCT04832945||Control Group|Healthcare personnel not receiving Ivermectin
9690601|NCT04832464|Active Comparator|Balance Training Home plan|"The Control group is undergoing balance training only, 3 days a week, and will be for 8 weeks. Balance training includes 10minutes of warm-up and 30 minutes of balance exercises. A force plate will be used to measure the postural sways. Measurements will be taken at a base-line, after the first session, at mid-level (4th week) and at the end (8th week).~These exercises include Static Balance exercises(1-2weeks): Romberg with eyes open & close, Tandem standing with eyes open & close with alternate feet, Single leg stance.~Static/ Dynamic/ Anticipatory Postural Control (3-4weeks): Sit to Stand, FRT( forward reach test) that is forward, sideways, cross reach, and timed up and go test.~Static/ Dynamic/ Anticipatory? Reactive Postural Control (5-6weeks): Perturbations:~Controlled by the therapist in sitting & standing, Throwing a ball, kicking a ball.~(7-8weeks): Combination of All"
9690602|NCT04832464|Experimental|BRACE Protocol: Balance training along with resistance, aerobic and cognitive excercises|"BRACE protocol for balance training 3 days a week for 8 consecutive weeks on alternate days.~These exercises include Static Balance exercises(1-2weeks) plus Chair rise 30 sec without using hands, 6-minute walk, count reverse from 50, push the wall, and reverse count from 20.~Static, dynamic, anticipatory postural control (3-4weeks) plus Stair climbing without using rails, marching in space, remember 5 words, name 5 animals, repeat 5 words, spell the word like APPLE, spell backward again.~Static, dynamic, anticipatory postural control (5-6weeks) plus Squatting, cycling, count even numbers from 1-50.~calculation: Addition, subtraction, multiplication, division. (7-8weeks): Combination of all."
9690603|NCT04832594|Experimental|Supplemental MRI|Women randomized to MRI will be examined using a shortened MRI protocol on a Signa Premier 3T MRI scanner. The MRI examination will be reviewed by two radiologists and assigned BI-RADS score. Appropriate clinical work-up will follow according to the BI-RADS score. BI-RADS 3 or higher at initial MRI will be recalled for a second look ultrasound.
9690604|NCT04832594|No Intervention|No MRI (standard-of-care)|"Standard-of-care. Both arms will have had a regular screening mammography examination prior to randomization. The No MRI arm will have no further intervention."
9690605|NCT04832672||The upfront radiotherapy group|
9690606|NCT04832672||The upfront targeted-therapy group|
9690607|NCT04832581|Experimental|Experimental Group|The experimental group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. The experimental group was included in the program based on the Orem Self Care Model. The program includes anatomical, physiological and hormonal changes during pregnancy, urinary system infections and preventive measures. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. Both groups were informed that the study was concluded.
9690608|NCT04832581|No Intervention|Control Group|The control group was informed that they participated in a study. After the data collection forms were introduced, written and verbal consents were obtained. Information has been received. A phone call was scheduled 2 weeks later. Second evaluation forms were applied. After the research was completed, information was given in order to avoid bias and the brochure was delivered. Both groups were informed that the study was concluded.
9690609|NCT04832633|Experimental|test bolus(TB) I|We use the TB method with biphasic injection, followed by the saline flush. Initially, we inject the 10 ml of test contrast media with a velocity of 3ml/s and apply the ROI at the bifurcation of PA and descending aorta at the same level. The dynamic curve demonstrates the time to peak enhancement of P second and A second. The first phase of contrast media injection uses a velocity of 2ml/s and the volume of contrast is measured as 2ml/s multiply (A-P) second. The second phase of contrast media injection uses a velocity of 3ml/s and the volume of contrast media is 70ml minus the amount of first phase injection. The total volume of the contrast media is 80ml, including the 10ml for pre-diagnostic test bolus images. We performed the saline flush following the administration of the contrast media with 20 ml normal saline. The start time of the diagnostic scan is at the A second.
9690610|NCT04832633|Experimental|test bolus(TB) II|This group is similar to the TB I. However, we use the lesser contrast media in the second phase of injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus the amount of first phase injection. The total volume of the contrast media is 70 ml, also including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The start time of the diagnostic scan is at the A second as well.
9827612|NCT02461992|Experimental|Intravenous infusion of Xyntha|observation arm
9690611|NCT04832633|Experimental|bolus-tracking(BT) I|Initially, 10ml of test contrast media was administrated but no calculation was performed for these pre-diagnostic test bolus images in this group. Unlike the TB method, we use 10 seconds as the fixed interval of (A-P) in this group. The first phase of contrast media injection uses a velocity of 2ml/s and thus the volume of contrast is 20ml. The second phase of contrast media injection is administered with a velocity of 3ml/s and the volume of the contrast media is 70ml minus 20ml. The total volume of the contrast media is 80 ml. The following saline flush uses 20 ml of normal saline. The tracking scan started after contrast injection was initiated for 15 seconds. The ROI is placed in the descending aorta at the same level of PA bifurcation and the diagnostic CT scan is triggered when the density in the ROI achieves the baseline density plus 150HU.
10180736|NCT03790215|Experimental|cohort for treatment|Participants enrolled are given dydrogesterone tablet of 10mg twice a day, from day 15 to day 24 of the menstrual cycle over a period of 3 months.
10180737|NCT03790228|Experimental|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
10180738|NCT03790189|Experimental|Bone Marrow Concentrate|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
10180739|NCT03790241|Experimental|Young males of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
10180740|NCT03790241|Experimental|Young females of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
10180741|NCT03790241|Experimental|Aged males of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
9690612|NCT04832633|Experimental|bolus-tracking(BT) II|This group is similar to the BT I. The first phase of injection is the same as the BT I group. We use lesser contrast media in the second phase of contrast injection. The second phase of contrast media injection is applied with a velocity of 3ml/s and the volume of the contrast media is 60ml minus 20ml. The total volume of the contrast media is 70 ml, including the 10ml for pre-diagnostic test bolus images. The following saline flush uses 30 ml of normal saline. The protocol for triggering diagnostic CT scan is the same as that in BT I.
9690613|NCT04832776|Experimental|FOLFOXIRI+C225|
9690614|NCT04832776|Active Comparator|FOLFOXIRI+BEV|
9690615|NCT04832698||Observational (survey administration)|Participants complete a survey over 10 minutes before and after completing training and using the Mentice endovascular simulator device.
9690616|NCT04832555|Experimental|Open: non elective irradiation|Patients within inclusion criteria will be enrolled in the experimental treatment: a radiation therapy addressed to non elective site of disease and with a simultaneous integrated boost
9690617|NCT04832789|No Intervention|Best conventional ventilation|
9690618|NCT04832789|Experimental|Ultra-protective ventilation with ECMO|
9690619|NCT04832763|Experimental|Physical function testing, questionnaire|Patients on active treatment complete questionnaires and undergo collection of blood samples and physical function assessments at baseline, and at 3 and 6 months. Survivors in surveillance complete questionnaires and undergo collection of blood sample and physical function assessment at baseline.
9690620|NCT04832711||the low-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
9690621|NCT04832711||the high-risk group for OSA|A Chinese translation of the BQ was used to classify subjects into high risk and low risk for OSA.
9690622|NCT04832529|Active Comparator|Perianal abscess cavity packing|
9690623|NCT04832529|Experimental|Perianal abscess cavity no packing|
9690624|NCT04832750||Major Depressive Episode|At least one failed pharmaco trial in current episode
9690625|NCT04832750||Major Depressive Episode with comorbid Borderline Personality Disorder|At least one failed pharmaco trial in current episode
9690626|NCT04832750||Healthy Controls|
9690627|NCT04832737|Experimental|Intervention|SDT theory-based psychotherapeutic treatment model
9690628|NCT04832737|No Intervention|Control|Wait List
9696251|NCT04768946||Adolescents with Acquired Brain Injury|Adolescents with traumatic brain injury, stroke, and other acquired brain injury ages 12 - 17 will participate in interviews about home safety. They also will have the opportunity to look at and, if desired, try the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
9827613|NCT02462057|No Intervention|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
10180742|NCT03790241|Experimental|Aged females of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
10180743|NCT03790241|Experimental|Obese young males|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
10180744|NCT03790241|Experimental|Obese young females|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
10180745|NCT03790241|Experimental|Obese aged males|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
9528144|NCT03213561|Experimental|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
10180746|NCT03790241|Experimental|Obese aged females|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
10180747|NCT03790202||single cohort of up to 30 patients|patients with acute or chronic lower limb wounds to be treated with the VistaCare® device
10180748|NCT03790176|Other|A - patients on automated peritoneal dialysis|each of n=8 patients will receive one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours. Subsequently, PK of CAZ/AVI will be determined in plasma and peritoneal dialysis fluid (and urine, if applicable) at protocol-defined time points over 24 hours.
10187532|NCT03725358|Experimental|Training, high-level subsidies|Providers being trained on modern contraception, but receiving high-level (status quo) PBF payments for contraceptive methods provided
10180749|NCT03790176|Other|B - critically ill patients with pneumonia|following one intravenous dose of 2g/0.5g CAZ/AVI (which patients will receive based on clinical indication by their treating physician), PK of CAZ/AVI will be determined at protocol-defined time points over one dosing interval in plasma and in epithelial lining fluid (ELF).
9690629|NCT04832451|Experimental|Intervention Group|"The Beck Depression Inventory[BDI] (inclusion criteria) was applied face to face to the students who constituted the population (n=385). After the BDI scores were evaluated, the students who met the inclusion criteria were randomly assigned to the intervention and control groups.~In a preliminary interview held with the intervention group (n=10), they were informed about the subject of the research, the duration and content of the implementation process, session rules, and that sessions would be audio-recorded. Informed consent forms were obtained from them, and pre-tests (BDI, Coping Styles Inventory[CSI]) were applied.~A total of 21 90-minute Interpersonal Relational Role Analysis (IRRA) sessions (two sessions a week) were held with the intervention group.~21 sessions of IRRA were applied to the intervention group, once the sessions were completed, post-tests (BDI, CSI) were applied. Three months later, a follow-up test (BDI, CSI) was applied to intervention group."
9690630|NCT04832451|No Intervention|Control Group|The students in the control group were informed about the research, informed consents were obtained from them, and pre-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to them. No intervention was applied to the control group (n=10). Once the Interpersonal Relational Role Analysis sessions were completed, post-tests (Beck Depression Inventory, Coping Styles Inventory) were applied to the control group. Three months later, a follow-up test (Beck Depression Inventory, Coping Styles Inventory) was applied to control groups. After the follow-up test, the participants in the control group were referred to the psychological support unit of the university.
9690631|NCT04832412|Experimental|BrainPhyt Low dose|220 mg BrainPhyt and 500 mg 100 % sunflower oil for 4 weeks, followed by 220 mg for 20 weeks
9690632|NCT04832412|Experimental|BrainPhyt high dose|440 mg BrainPhyt for 4 weeks, followed by 500 mg 100 % sunflower oil for 20 weeks
9690633|NCT04832412|Placebo Comparator|Placebo|1000 mg 100 % sunflower oil for 4 weeks, followed by 500 mg 100 % sunflower oil for 20 weeks
9690634|NCT04832399||Natalizumab|Natalizumab 300 mg is administered by intravenous infusion once every 4 weeks.
9690635|NCT04832360|Experimental|Control (CTL)|Participants do not receive financial incentive intervention
9690636|NCT04832360|Experimental|Single Target (ST)|One member of each dyadic-smoking couple will receive financial incentive intervention
9690637|NCT04832360|Experimental|Dyadic Target (DT)|Both members of each dyadic-smoking couple will receive financial incentive intervention
9690638|NCT04832373|Other|Humanoid Robot|
9690639|NCT04832022||Vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who accepted vaccination against SARS-CoV2
9690640|NCT04832022||Non vaccinated|Seronegative Chronic Inflammatory Rheumatism (CIR) who refused vaccination against SARS-CoV2
9690641|NCT04832009|Experimental|Glucose Infusion|Hyperglycemia (glucose infusion) will receive an I.V. Glucose infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
9690642|NCT04832009|Experimental|Lipid Infusion|Hyperlipidemia (lipid infusion) will receive an I.V. Lipid infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
9690643|NCT04831957|Other|Patient underwent TAVI procedure|- Elderly patients who will undergo a TAVI procedure coming to the geriatric day hospital
9690644|NCT04832139|Experimental|Marstacimab Prefilled Pen (PFP), then marstacimab Preflled Syringe (PFS)|Participants will first receive single dose PFP, then PFS, then repeating single dose PFP, then single dose PFS with a minimum of 21 days between single doses.
9690645|NCT04832139|Experimental|Marstacimab PFS, then marstacimab PFP|Participants will first receive single dose PFS, then PFP, then repeating single dose PFS, then single dose PFP with a minimum of 21 days between single doses.
9690646|NCT04832126||Patient|patients with channelopathies
9690647|NCT04832126||Family|relatives of patients with channelopathies
9690648|NCT04832269||MP exposed group|children and adolescents (aged 8 to 18 years) of mothers with prenatal exposition to MP in the context of an MS relapse therapy
9690649|NCT04832269||MP non-exposed group/control group|children and adolescents of mothers suffering from MS aged 8 to 18 years
9690650|NCT04832230||Healthy individuals|This group is composed of healthy individuals without previous noise exposure.
9690651|NCT04832230||Acute acoustic trauma patients|This group is composed of patients suffering from acute acoustic trauma.
9690652|NCT04832048|Experimental|High intensity training (HIT) group|The HIT group performed the exercises with loads at 80-90% of HRF.
9690653|NCT04832048|Experimental|Low-moderate intensity training (LMIT) group|The HIT group performed the exercises with the loads at 50-70% of the HRF
9690654|NCT04832048|Placebo Comparator|No training group|They did not perform any type of programmed physical exercise during the study.
9690655|NCT04832035|Experimental|"Standard psychotherapeutic care + coordinated and peer supported mental health care"|"Participants receive standard psychotherapeutic care in the public healthcare system. For participants and therapists in this group standard care and additional organisational support is available which is labeled coordinated and peer supported mental health care. This includes several additional organisational assistance components that are currently not part of the services of the public mental health care system, i.e. a coordination center, trained peers to support treatment utilisation, a support and training center for therapists, and an interpreter pool.This is Treatment as Usual plus coordination and peer support."
9690656|NCT04832035|Other|"Standard psychotherapeutic care"|Participants receive standard psychotherapeutic care in the public healthcare system. For participants in this group no additional organisational support is available. This is Treatment as Usual.
9690657|NCT04832165|Experimental|Muscle inspiratory strength training|An 8-week muscle inspiratory muscle strength training
9690658|NCT04832165|No Intervention|No training program|No intervention
9827614|NCT02462057|Active Comparator|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
10180750|NCT03790267||Hip arthroplasty|
10180751|NCT03790267||Knee arthroplasty|
10180752|NCT03790267||Shoulder arthroplasty|
10180753|NCT03790462|Experimental|Music intervention group 1|"Raga A will be played for 10 minutes & data collected."
10180754|NCT03790462|Experimental|Music intervention group 2|"Raga B will be played for 10 minutes & data collected."
10180755|NCT03790462|Experimental|Music intervention group 3|"Raga C will be played for 10 minutes & data collected."
9690659|NCT04832243|Experimental|Experimental: V1: List No. 1|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The first version of the questionnaire includes 6 sets of 3 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully. The statements on food and water insecurity that are included in the experimental version are omitted."
9690660|NCT04832243|Experimental|Experimental: V2: List No. 2|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. The second version of the questionnaire includes 6 sets of 4 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully for 3 of the true-false statements. One statement in each set relates to food and water insecurity and is designed to determine the extent to which social desirability bias may influence responses to food and water insecurity questions."
9690661|NCT04832347|Experimental|Exercise group|Exercise group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
9690662|NCT04832347|Experimental|Vagus group|Vagus therapy will be applied to Group 2 for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
9690663|NCT04832347|No Intervention|Control group|Control group will be followed as a control group and no application will be made.
9690664|NCT04832256||High Flow anesthesia|administered 4 L/min fresh gas flow during general anesthesia
9690665|NCT04832256||Low Flow Anesthesia|administered 1 L/min fresh gas flow during general anesthesia
9690666|NCT04832100||Patients with primary fibromyalgia|Adults with complaints of chronic widespread pain at the outpatient department of KMUH were consecutively enrolled over a 5-year period from July 2017 to June 2022. Participants were interviewed by experienced neurologists , and those who fulfilled the 2011 American College of Rheumatology (ACR) criteria for FM were recruited .
9690667|NCT04832100||Healthy controls|Age- and sex-matched subjects without pain and soreness were also prospectively recruited as healthy controls.
9690668|NCT04832217|Experimental|Pyrenees' beef group|"In the first period, 24 participants were randomly assigned to a beef (Pyrenees' beef group).~In the second period, 23 participants were randomly assigned to a beef (Pyrenees' beef group)."
9690669|NCT04832217|No Intervention|Conventional Chicken group|"In the first period, 23 participants were randomly assigned to a conventional chicken-based group (control group).~In the second period, 24 participants were randomly assigned to a conventional chicken-based group (control group)."
9690670|NCT04832204|Experimental|solid tumor with only liver metastases after first line treatment|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
9690671|NCT04832308|Experimental|SVS SET Program|Participants enroll in SVS Program which includes 1) educational information on PAD, exercise and nutrition, 2) weekly health coaching, and 3) walking therapy prescription.
9690672|NCT04832308|No Intervention|Usual Care|This usual care arm will allow sites to direct patients as they usually do. This could include an in-person exercise therapy program or simply exercise instruction during an office visit.
9690673|NCT04832282|Other|Roux-en-Y gastric bypass patients with weight regain|The study population is Roux-en-Y gastric bypass (RYGB) patients with weight regain undergoing an endoscopy at Bellevue Hospital Center or Brigham and Women's Hospital.
9690674|NCT04832321|No Intervention|No intervention: V1: Control|This version of the survey questionnaire depicts a young man with no symptoms of alcohol use disorder
9690675|NCT04832321|Experimental|Experimental: V2: Alcohol Use Disorder|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder."
9690676|NCT04832321|Experimental|Experimental: V3: Alcohol Use Disorder + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with complete response."
10180756|NCT03790462|No Intervention|Control group|Subject relaxes without music for 10 minutes and electrophysiological parameters will be collected
10180757|NCT03790371|Active Comparator|misoprostol group|misoprostol (misotac® sigma pharmaceutical industries) 200 mcg vaginally applied ten and four hours prior to the second attempt of IUD insertion
10180758|NCT03790371|Placebo Comparator|placebo|while the control group received a placebo tablet in the same regimen as the study group.
10180759|NCT03790319||Single Workshop 'The Emotional Backpack'|Subjects of this group are participating in one single workshop over three days.
10180760|NCT03790319||Year Program 'The Power of Feelings'|Subjects of this group are participating in three workshops of over 3 days each in a continuing group over nine months. They are animated to deal with the content inbetween the workshops through biweekly e-mails and to exchange in couples.
10180761|NCT03790163|Placebo Comparator|levobupivacaine at ( 23˚C)|Levobupivacine hydrochloride at ( 23˚C) will be received 3.5 ml levobupivacaine at the operating room temperature 23˚C will be administered
10180762|NCT03790163|Active Comparator|Warm levobupivacaine at (30˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (30˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
10180763|NCT03790163|Active Comparator|Warm levobupivacaine at (37˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (37˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
10180764|NCT03790410|Active Comparator|Control group-Complex pulmonary rehab.|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings."
10180765|NCT03790410|Active Comparator|Inspiratory muscle training group|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.~Inspiratory muscle training~The training program contains strengthening exercises on the diaphragm muscle."
10180766|NCT03790436|Experimental|Betaquik|
10180767|NCT03790358|Placebo Comparator|Placebo|Placebo
10180768|NCT03790358|Experimental|low dose MDMA|6.5ug dose of serotonin agonist
10180769|NCT03790358|Experimental|medium dose|13ug dose of serotonin agonist
10180770|NCT03790358|Experimental|high dose|26ug dose of serotonin agonist
10180771|NCT03790488|Experimental|JTX-4014|Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
10180772|NCT03790384|No Intervention|Bacillus Calmette-Guérin|Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
10180773|NCT03790384|Experimental|Mytomicin and Bacillus Calmette-Guérin|Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
10180774|NCT03790514|Experimental|Heat Wrap Group|
10180775|NCT03790514|Placebo Comparator|Control Group|
10180776|NCT03790423|Experimental|18F-ASIS PET|One injection of 18F-ASIS (app. 200 MBq) followed by 3 PET/CT scans 1 hour, 2 hours and 4hours post-injection
10180777|NCT03790280|Experimental|Standard of Care PLUS HFO|Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1).
10180778|NCT03790280|No Intervention|Standard of Care|Surgery is tailored by standard ECoG alone (arm 2).
10180779|NCT03790293|Experimental|Rituximab|Rituximab in combination with reduced corticosteroids is administrated
10180780|NCT03790293|Active Comparator|Standard corticosteroid|Standard corticosteroid is administrated
10180781|NCT03790150||Mechanically Ventilated Patients|All patients admitted to the critical care unit and require mechanical ventilation
10180782|NCT03790033|Experimental|UCHA group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Shinhwa Pharmaceutical company
10180783|NCT03790033|Placebo Comparator|Placebo group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Tsumura Co., Tokyo, Japan
10180784|NCT03790020|Active Comparator|transversus abdominis plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
10180785|NCT03790020|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
10180786|NCT03790020|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the appendix excision area-periappendiciall area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periappendicial area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
10180787|NCT03790020|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
10180788|NCT03790059|Experimental|RFA combined with H101 group|The experimental group was RFA combined H101.H101 has oncolysis in HCC after RFA and reduce tumor recurrence.
10180789|NCT03790059|Other|Conventional RFA group|The standard control group was the conventional RFA.Using RFA for the treatment of small HCC.The efficacy was compared with that of the experimental group combined with H101.
10180790|NCT03790072|Experimental|Treatment Arm|"After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0."
9690677|NCT04832321|Experimental|Experimental: V4: Alcohol Use Disorder + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder who is successfully treated with partial relapse."
10180791|NCT03789929||The Emotional Backpack|Healthy adults participating in the offered online-course on their own initiative.
10180792|NCT03789929||Feelings as Powers|Healthy adults participating in the offered online-course on their own initiative.
10180793|NCT03789890|Experimental|Healthy men|Healthy male adults from Germany receiving BAY1902607 during study period 1 (length = 6 days) and BAY1902607 + Itraconazole during study period 2 (length = 15 days), separated by a washout phase.
10180794|NCT03789838||Before of sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
10180795|NCT03789838||Sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
10180796|NCT03789942|Active Comparator|1. Local anaesthesia for oral surgery|Administration of local anesthesia, 40mg.epinephrine once. Oral surgery procedures Suturing End of procedure
10180797|NCT03789942|Active Comparator|2. Local anesthesia with Midazolam|"Administration of 40mg. epinephrine once, and Oral Sedation with Midazolam 0,5 mgr per kilo once.~Oral surgery procedures Suturing End of procedure"
10180798|NCT03789942|Active Comparator|3. Local anesthesia and sedation|"Administration of 40mg. epinephrine once, and Inhalation Sedation by Nitrous Oxide / Oxygen.~Nitrous oxide sedation Oral surgery procedures Suturing End of procedure Reduce nitrous oxide concentration"
10180799|NCT03790085|Experimental|Risperidone|It can be used after schizophrenia is diagnosed. Risperidone affects prolactin and may affect menstruation in young women, so we will try not to use it in such patients. Patients were randomized to a single Risperidone control trial for 8 weeks to evaluate the clinical efficacy of the patients. Risperidone routine daily 2-6 mg, up to 8 mg, can be taken orally twice a day.
10180800|NCT03790085|Experimental|Olanzapine|It can be used after schizophrenia is diagnosed. Olanzapine is not generally used in patients with diabetes and hyperlipidemia. Patients were randomized to a single Olanzapine control trial for 8 weeks to evaluate the clinical efficacy of the patients. Olanzapine is available once or twice a day, starting at 5 mg daily and up to 20 mg daily.
9690678|NCT04832321|Experimental|Experimental: V5: Alcohol Use Disorder + Economic Impact|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances."
9690679|NCT04832321|Experimental|Experimental: V6: Alcohol Use Disorder + Economic Impact + Treatment with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with complete response."
9690680|NCT04832321|Experimental|Experimental: V7: Alcohol Use Disorder + Economic Impact + Treatment with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young man with symptomatic, untreated alcohol use disorder whose untreated alcohol use disorder negatively affects his family's finances, who is then successfully treated with partial relapse and continued negative economic impact."
10180801|NCT03790085|Experimental|Aripiprazole|It can be used after schizophrenia is diagnosed. Aripiprazole has no specific contraindications. Patients were randomized to a single Aripiprazole control trial for 8 weeks to evaluate the clinical efficacy of the patients. Aripiprazole is taken orally once a day, starting at 10 mg daily and up to 30 mg daily.
9690681|NCT04831931|Experimental|Supervised Exercise Group|"Telerehabilitation will be applied in this group, which will last 4 weeks, and include the following processes~Exercises that will be performed every Monday will be taught and applied face-to-face under the supervision of the therapist with online videoconferencing method. Then, videos of weekly exercises that will be prepared by the therapist will be transmitted online to patients.~Patients will be asked to perform these exercises 4 days a week in the same week, on Wednesdays, Fridays and Sundays.~Also, a video call will be made on Fridays to evaluate whether the movements are done effectively and correctly, and questions of patients (if any) will be answered.~Patients will be informed by the physiotherapist that they should send messages on Wednesdays and Sundays to show that they are doing the exercises.~The exercise program of new week will be taught every Monday for 4 weeks, the prepared video will be sent, and the program will be advanced and completed."
9690682|NCT04831931|Active Comparator|Exercise Group|Exercise recommendations will be made to this group. Videos and photographs of weekly exercises prepared by the therapist will be sent online to the patient every Monday for 4 weeks, patients will be advised to repeat these exercises 4 days a week.
10180802|NCT03789916|Experimental|DAPT|"Dual antiplatelet therapy: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die"
9690683|NCT04831931|No Intervention|Control Group|No exercise application will be done in this group.Evaluation tests will be applied for 4 weeks only online.
9690684|NCT04831866||Surveillance Cohort|Surveillance Cohort: Schools participating in this cohort will be performing surveillance testing weekly on approximately 10-20% of students and 100% of staff.
9690685|NCT04831866||Exposure Cohort|Exposure Cohort: Schools participating in this cohort will be performing exposure testing on students and staff who have been identified as having close contact with school members diagnosed with SARS-CoV-2 infection.
9690686|NCT04831918|Experimental|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of the Mueller cemented cup as acetabular component.
9690687|NCT04831853|Experimental|Supervised self-swabbing followed by conventional swabbing|the subjects will first benefit from a 5 minutes explanation on how to perform self-swabbing and will then performed the swabbing under the supervision of a trained healthcare professional
9690688|NCT04831853|Experimental|Conventional swabbing followed by supervised self-swabbing|the subject will undergo conventional nasopharyngeal swabbing performed by a trained healthcare professional first.
9690689|NCT04831840||Female participants with recurrent urinary tract infections (RUTI).|Patients with RUTIs (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
9690690|NCT04831840||Female control patients without RUTIs|Patients without RUTIs (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
9690691|NCT04831671|Active Comparator|Infra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an infra-patella approach.
9690692|NCT04831671|Experimental|Supra-patella nailing|Participants will have their closed tibial shaft fracture treated with an intra-medullary nail inserted through an supra-patella approach.
9690693|NCT04831463|Experimental|experimental group|The experimental (N = 49) received a short-term IHAPIM program by one-on-one interview (5 week, 1 hr per week, 10 hr in total).
9690694|NCT04831463|No Intervention|control group|Firstly, Pre-tests were applied to the men in the control group. No intervention was applied to this group. Post-tests were made 3 months after finished intervention which applied to experimental group.
9690695|NCT04831905|Experimental|Pilote study|Micro-wave ablation of index lesion identified on MRi on prostate cancer
10180803|NCT03789916|Active Comparator|SAPT|"Single antiplatelet therapy: acetylsalicylic acid 100 mg/die"
10180804|NCT03790137|Experimental|Treatment group|The treatment group will include approximately 10 pediatric and young adult patients (ages 4-25 years) seen by Elizabeth A. Thiele, M.D., Ph.D. at MGH's Pediatric Epilepsy Clinic. Subjects will be treated on an outpatient basis and will not require hospital admission. The treatment group will receive the investigational new drug, Fenfluramine Hydrochloride for up to 6 months.
9528145|NCT03213548|Experimental|Alar facial groove Incision|Alar Base surgical modification with surgical inions in the alar facial groove
9528146|NCT03213548|Active Comparator|Alar facial groove spared|Alar Base surgical modification with surgical incisions 1mm above the alar facial groove
10180805|NCT03789955|Experimental|Fluoroscopic-guided TEB|After assessment of the epidural space using the loss of resistance technique with air under fluoroscopic guidance, six fluoroscopic views will be obtained: true anteroposterior, contralateral oblique (CLO) at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral for comparison CLO view with lateral view.
10180806|NCT03789981||At diagnosis|Immunogenic profile in patients affected by primary or secondary AML at diagnosis
10180807|NCT03789981||At relapse|Immunogenic profile in patients affected by primary or secondary AML at relapse
10180808|NCT03790007|Active Comparator|Transversus Abdominis Plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
10180809|NCT03790007|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
10180810|NCT03790007|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the gallbladder excision area-periportal area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periportal area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
10180811|NCT03790007|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
10180812|NCT03789994|Experimental|Affective touch group|"Survivors in the intervention group will receive a total of 36 sessions of a 15-minute affective touch intervention performed by their family caregivers in their homes. Sessions will be scheduled for every alternate weekday (three times a week) for 12 weeks. A trained research nurse (RN) will conduct three 30-minute caregiver training sessions to support the caregivers in delivering the affective touch.~To put caregivers in a more relaxed mood for delivering the intervention, the RN will work with them to identify a time that they feel less burdensome, and teach them to perform deep breathing for relaxation before the affective touching begins. Also, the survivor-caregiver dyad will be asked to sit in a comfortable position and switch off television or radio during the intervention."
10180813|NCT03789994|Other|Fine motor group|To address the additional attention given by caregivers during affective touch, the control group will be asked to sit beside the survivors when they go through the fine motor exercises which are commonly used for rehabilitation. Caregivers will be instructed to provide only necessary help in preparing the equipment, and to avoid touching or talking to the survivors during the 15-minute exercise session. Two such sessions will be arranged for survivors to master the skills needed, and for caregivers to practise the required level of interaction during the exercise training. Participants will be instructed to do the exercise three times a week (every alternate weekday) over 12 weeks.
10180814|NCT03789708|Experimental|A|Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.
10180815|NCT03789708|Placebo Comparator|B|Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.
10180816|NCT03789708|Experimental|C|Patients will receive 20 g of Gum Arabic supplementation daily for four weeks
10180817|NCT03789708|Experimental|D|Patients will receive 40 g of Gum Arabic supplementation daily for four weeks
10180818|NCT03789695|Experimental|Dabigatran etexilate|Dabigatran etexilate (Pradaxa) 110 mg b.i.d. or 150 mg b.i.d. according SmPC during 2 years
10180819|NCT03789695|Active Comparator|Warfarin|Warfarin under the control of INR once a month (target range 2.0 - 3.0) during 2 years
10180820|NCT03789851|Experimental|core needle biopsy|All patients enrolled in this study received a ultrasound-guided multipoint core needle biopsy after surgery.
10180821|NCT03789799|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
10180822|NCT03789799|Placebo Comparator|Placebo|From the first postoperative day for ten days, single vaginal capsule per day of sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
10180823|NCT03789682||FUSCC cystectomy cohort|patients underwent cystectomy in Fudan University Shanghai Cancer Center
10180824|NCT03789786||Cases (+SDR)|Patients with cerebral palsy that underwent an SDR
10180825|NCT03789786||Controls (-SDR)|Matched patients with cerebral palsy but did not undergo an SDR
10180826|NCT03789734|Experimental|BLS-M22 or Placebo 500mg group|Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
10180827|NCT03789734|Experimental|BLS-M22 or Placebo 1,000mg group|Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
10180828|NCT03789734|Experimental|BLS-M22 or Placebo 2,000mg group|Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
10180829|NCT03789734|Experimental|Multiple Ascending Dose group|Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration
10180830|NCT03789643|Experimental|JTT-251 Dose 1|One dose of study drug by mouth daily for 24 weeks
10180831|NCT03789643|Experimental|JTT-251 Dose 2|One dose of study drug by mouth daily for 24 weeks
10180832|NCT03789643|Experimental|JTT-251 Dose 3|One dose of study drug by mouth daily for 24 weeks
9690696|NCT04831632||people aged 50-75|men and women aged 50-75 who belong to Hospital El Cruce's coverage area and do not have personal history of colorectal cancer or inflammatory bowel disease, personal or family history of syndromes of predisposition to known cancers, or family history of colorectal cancer in a first-degree relative aged less than 60
9690697|NCT04831567|Experimental|Interventional|The participants will be submitted to metaiodobenzylguanidine 4 doses of 7.400 Mbq (million of Becquerels) (200 mCi). Each dose will be repeated with a minimum interval of 60 days.
10180833|NCT03789643|Placebo Comparator|Placebo|One dose of study drug by mouth daily for 24 weeks
10187533|NCT03725358|Experimental|Training+App, low-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving low-level (status quo) PBF payments for contraceptive methods provided
10180834|NCT03789435||Amputees|Patients underwent trans-tibial and trans-femoral amputation of any etiology at the Rizzoli Orthopedic Institute from 2015 to 2017 with the presence of analgesia data for surgery in a computerized record (SIR, Rizzoli information system). A questionnaire for the detection of residual limb pain will be administrate to all the survivors.
10180835|NCT03789552|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 8 weeks."
10180836|NCT03789552|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~Subjects in this group will use four T89 capsules each time by oral administration twice daily for 8 weeks."
10180837|NCT03789552|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 8 weeks.
10180838|NCT03789565||Group 1. Healthy individuals from periodontal perspective:|GI < 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
10180839|NCT03789565||Group 2. Individuals diagnosed with Gingivitis|GI > 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
10180840|NCT03789565||Group 3. Individuals diagnosed with CP|GI > 1, PD ≥ 5 mm, CAL ≥ 3 mm, with apparent bone loss on radiography.
10180841|NCT03789812|Active Comparator|Manual Toothbrush with Superfloss|Patients in this group will receive Manual Toothbrush (Oral B) and Superfloss (Oral B) and will be instructed to use them three times a day.
10180842|NCT03789812|Experimental|Electric Toothbrush with Superfloss|Patients in this group will receive Electric Toothbrush (JETPIK) and Superfloss (Oral B) and will be instructed to use them three times a day.
10180843|NCT03789812|Experimental|Manual Toothbrush with Water Flosser|Patient in this group will receive Manual Toothbrush and Dental Water Jet and will be instructed to use them three times a day.
10180844|NCT03789812|Experimental|Electric Toothbrush with Water Flosser|Patient in this group will receive Electric tooth brush (JETPIK) and water flosser and will be instructed to use them three times a day.
10180845|NCT03789578|Experimental|Semaglutide plus insulin 287|Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
10180846|NCT03789578|Experimental|Semaglutide alone|Participants will get a single dose of semaglutide (treatment B) alone.
10180847|NCT03789578|Experimental|Insulin 287 alone|Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
10180848|NCT03789448|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
10180849|NCT03789448|Experimental|Early Access to ART for All|HIV-positive individuals who are aged 18 years or older are initiated on ART regardless of client's immunological and clinical staging (excluding pregnant or breastfeeding women)
10180850|NCT03789370|Active Comparator|Propofol|Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
10180851|NCT03789370|Active Comparator|Sevoflurane|Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
10180852|NCT03789526|Experimental|Group 1|Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.
10180853|NCT03789526|No Intervention|Group 2|Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance.
10180854|NCT03789630||Monitoring arm|Monitoring subjects undergoing total knee replacement surgery using the wearable biosensor to continuously monitor physiology biomarkers.
10180855|NCT03789487|Experimental|Non-responders to CRT|Non-responders to CRT who will undergo an electrical optimization of the settings of their device
10180856|NCT03789396||Pre-implementation|The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
10180857|NCT03789396||Post-implementation|The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.
9690698|NCT04831541|Experimental|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
9690699|NCT04831593||Group Elective|In our clinic, pediatric patients who will undergo elective surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in elective pediatric patients before general anesthesia.
9690700|NCT04831593||Group Emergency|In our clinic, pediatric patients who will undergo emergency surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in emergency pediatric patients before general anesthesia.
9690701|NCT04831736|Experimental|Treatment|
9690702|NCT04831736|Placebo Comparator|Control|
9690703|NCT04831801||Female patients with overactive bladder (OAB)|Patients with urgency and frequency syndrome with or without pelvic pain (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
10180858|NCT03789539|Active Comparator|LD Universal Influenza Vaccine Uniflu|low dose of Uniflu vaccine 0.5 ml (20 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
10180859|NCT03789539|Active Comparator|HD Universal Influenza Vaccine Uniflu|high dose of Uniflu vaccine 0.5 ml (40 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
10180860|NCT03789539|Placebo Comparator|Placebo|saline 0.5 ml
10180861|NCT03789253||AS cohort with progression|AS cohort with tumor progression
10180862|NCT03789253||AS cohort without progression|AS cohort without tumor progression
10180863|NCT03789344|Experimental|Acupuncture treatment|
10180864|NCT03789344|Active Comparator|Psychotherapy|
10180865|NCT03789344|Placebo Comparator|blank control|
9690704|NCT04831801||Female control patients without LUTS|Patients without LUTS (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.
10180866|NCT03789422|Active Comparator|Association drugs|levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
10180867|NCT03789422|Active Comparator|one drug|Levocetirizine 20 mg/day for a month
9690705|NCT04831489||deep sedation|Anesthesia will be induced using titrated doses of propofol (0.5-1.5 mg/kg) and fentanyl (25-50 μg) initially to carefully maintain spontaneous breathing yet maintaining airway patency. Once adequate jaw relaxation is achieved, the endoscopy probe will be inserted. Maintenance of sedation will be carried out using propofol infusion between 80-120 mcg/kg/min. Additional dose 25-50 mg propofol will be given to the patient if spontaneous movement occurs
9690706|NCT04831489||Genral anesthesia|"After mask pre-oxygenation, anesthesia will be induced with (2 mg/kg) propofol and (1 μg /kg) fentanyl. The neuromuscular blockade will be achieved with (0.5 mg/kg) atracurium followed by tracheal intubation. Anesthesia will be maintained to keep the end-tidal anesthetic concentrations within 1 MAC for sevoflurane.~The neuromuscular blockade will be maintained with intermittent doses of atracurium (0.1mg/kg). Mechanical ventilation is adjusted with fresh gas flow oxygen in air 30-40% at a rate of 2 L/min to maintain end-tidal carbon dioxide of 35-40 mm Hg. Reversal of neuromuscular blockade will be achieved by intravenous administration of neostigmine 0.05 mg/kg and atropine 0.02 mg/kg."
9690707|NCT04831879|Experimental|Group A AMPS - sham|Treatment phase 1: AMPS Treatment phase 2: sham
9690708|NCT04831879|Experimental|Group B sham - AMPS|Treatment phase 1: sham Treatment phase 2: AMPS
9690709|NCT04831814|Experimental|Near Focus NBI|Use of the Near Focus NBI to make optical diagnosis
9690710|NCT04831814|Active Comparator|Standard Focus NBI|Use of the Standard Focus NBI to make optical diagnosis
9690711|NCT04831775|Experimental|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice over 8 weeks. Classes 1 & 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 & 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on. The intervention group will be asked to practice 20 minutes, 7 days a week.
9690712|NCT04831775|Active Comparator|Brain Games Only|An active control group will be used. The differing variable between the two groups is the class sessions. Those randomized to the control group will only receive a link to the BrainHQ games site. A specific amount of practice will not be prescribed, but the frequency and duration of participant's practice will be obtained from BrainHQ. Participants will receive a weekly phone call to maintain connection to the study. Data collection will be on the same schedule as the intervention group.
9690713|NCT04831528||No secondary changes of drug resistance|
9690714|NCT04831528||Secondary mutations of RAS|
9690715|NCT04831528||Secondary mutation of BRAF|
9690716|NCT04831528||HER2 amplification|
9690717|NCT04831528||Other secondary mutations|
9690718|NCT04831710|Experimental|Sintilimab+Chidamide|Participants will receive Sintilimab,200mg, ivd, d1; Chidamide,30mg,po,biw,d1-21; repeated every 3 weeks(up to 1 year) until disease progression, intolerable toxicity, death, or termination of the study for any reason.
9690719|NCT04831372|Active Comparator|On Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.~The control group will be using the first method, which is the on-table method, which uses a specialized surgical table, called a traction table. This table involves placing both feet in specialized boots that are then hooked up to the table, and allows for positioning of the operative leg with aid of the table.~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
9690720|NCT04831372|Experimental|Off Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.~The experimental group will be using the second method, which is the off-table method. In this method the patient is placed on a standard operating room table and the operative leg is manually positioned by the surgeon during the procedure . This obviates the need for the additional staff members or purchase of a specialized table.~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
9690721|NCT04831034|Experimental|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
9690722|NCT04831151|Active Comparator|Drospirenone group: 0,03 mg ethinylestradiol + 3 mg drospirenone|generic name:yasmin dosage form:oral dosage: 0,03 mg ethinylestradiol + 3 mg drospirenone frequency: once a day duration: 3 months
10180868|NCT03789266|Experimental|Drain ablation - Non Aspiration mode|Drain ablation will be done in non Aspiration mode
10180869|NCT03789266|Other|Drain ablation - Aspiration mode|Drain ablation will be done in Aspiration mode
10180870|NCT03789331||Transgender Male individuals|"Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery.~Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
10180871|NCT03789331||Normal healthy female individuals|"Group Description: Healthy women with normal sexual orientation.~Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
10180872|NCT03789227|Placebo Comparator|Group C|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 4 ml saline in a total volume 12 ml.
10180873|NCT03789227|Active Comparator|Group D|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 8 mg dexamethasone with 4 ml saline in a total volume 12 ml.
9690723|NCT04831151|Active Comparator|cyproterone acetate group: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate|generic name:diane 35 dosage form:oral dosage: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate frequency: once a day duration: 3 months
9690724|NCT04831320|Experimental|nab-Paclitaxel + Nivolumab|"nab-Paclitaxel 125 mg/m^2 intravenous (IV) on days 1, 8 & 15 of each 28-day cycle.~Nivolumab 480 mg IV Day 1 of each 28-day cycle."
10180874|NCT03789227|Active Comparator|Group K|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 15 mg ketorolac with 4 ml saline in total volume 12 ml.
10180875|NCT03789409|Experimental|Intermittent Fasting|Over rehabilitation treatment during and admission (at least 1 week), intermittent fasting (IF) for more than 12 hours (water can be allowed). For subgroup assignment, participants can choose IF1 (eat early in the evening and late in the morning) or Post-IF2 (eat the remaining two meals without breakfast), depending on own their faver.
10180876|NCT03789409|No Intervention|Ad libitium|Participants will be allowed to have hospital meals and all the desired intake without time limit.
10180877|NCT03789357||Single Arm|All patients admitted to the Acute Stroke Unit
10180878|NCT03789136||Primary colon cancer|
10180879|NCT03789136||Liver metastases|
10180880|NCT03789136||Inguinal hernia (control)|
10180881|NCT03789136||Abdominal hysterectomy (control)|
10180882|NCT03789123|Experimental|Study Group (patients with OMA)|"I) Untreated patients (n=142)~II) Dienogest (n=142)~III) Dienogest/Estradiol valerate+Dienogest (n=142)"
10180883|NCT03789123|Sham Comparator|Control Group(patients without OMA)|"I) Untreated patients (n=142)~II) Dienogest/Estradiol valerate+Dienogest (n=142)"
10180884|NCT03789149|Experimental|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
10180885|NCT03789071||Patient scheduled for general anesthesia with intubation|Patients in this group (only group) will have clinical airway assessment and external ultrasound assessment of the airway
10180886|NCT03789214|Placebo Comparator|Placebo|Placebo sleep medication (Placebo oral capsule)
10180887|NCT03789214|Active Comparator|Low Dose Suvorexant|Low dose sleep medication
10180888|NCT03789214|Active Comparator|High Dose Suvorexant|High dose sleep medication
10180889|NCT03788954|Active Comparator|Kinesiotaping on FCU|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. flexor carpi ulnaris.
10180890|NCT03788954|Active Comparator|Kinesiotaping on ECR|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. extensor carpi radialis.
10180891|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on FCU|Same kinesiotape used on m. flexor carpi ulnaris without any taping techniques.
10180892|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on ECR|Same kinesiotape used on m. extensor carpi radialis without any taping techniques.
10180893|NCT03788915|Active Comparator|Online dietician lifestyle counseling|Online dietetic lifestyle counseling
10180894|NCT03788915|Placebo Comparator|Usual care|Usual care
10180895|NCT03789058|Active Comparator|Surgical with conventional NSAID 3 times/day|Control group will have surgical intervention to remove wisdom tooth and receive conventional NSAID treatment three times per day
10180896|NCT03789058|Experimental|Surgical with conventional NSAID 2 times/days|The experimental group will have surgival intervention to remove wisdom tooth and receive NSAID treatment only two times per day: once after breakfast and once after lunch, but not at night.
10180897|NCT03788889|Active Comparator|Lorazepam + Ketamine + Placebo A|"Ketamine - infusion (0.15 - 0.4 mg/kg/hr) and placebo injections titrated by increases of 0.075 mg/kg/hr every 30 minutes for Clinical Institute Withdrawal Assessment for Alcohol (revised version) (CIWA-Ar) greater than or equal to 10 in addition to lorazepam symptom-triggered therapy~Ketamine dosing will be based on ideal body weight~Ketamine infusion will be discontinued once CIWA-Ar less than 10 for 4 hours"
10180898|NCT03788889|Active Comparator|Lorazepam + Phenobarbital + Placebo B|"Phenobarbital - IV push (260 mg loading followed by 130 mg q1 hour) with placebo infusion until CIWA-Ar less than 10 with a maximum daily dose of 10mg/kg in addition to lorazepam symptom-triggered dosing for recurrent symptoms (Gold 2007)~Maximum daily dose will be used in order to prevent over sedation as well as provide adequate storage in pharmacy monitored refrigerators for study drugs"
10180899|NCT03788889|Placebo Comparator|Lorazepam + Placebo A + Placebo B|Lorazepam will be administered every 30 minutes as indicated based on CIWA-Ar protocol for Cottage Health in addition to placebo injections and placebo infusion
10180900|NCT03788824||pCLE group|pCLE is used to distinguish the inflammation activity of UC, and compared with histology
10180901|NCT03788902|Experimental|ADHD group|This group was examined twice - once after taking Ritalin and once after taking placebo
10180902|NCT03788902|No Intervention|Healthy control|Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
10180903|NCT03789084|Experimental|Cognitive-Behavioral Therapy|Brief Cognitive-Behavioral Therapy for Health Anxiety
10180904|NCT03789084|Other|Referral to mental health provider|Provider makes referral to a mental health provider
10187534|NCT03725358|Experimental|Training+App, medium-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving medium-level (status quo) PBF payments for contraceptive methods provided
10187535|NCT03725358|Experimental|Training+App, high-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving high-level (status quo) PBF payments for contraceptive methods provided
10187536|NCT03725306|Experimental|Librata|Librata Endometrial Ablation Device
10187537|NCT03725280||Transgender men I|Transgender men after testosterone treatment
9690725|NCT04831086|Experimental|Intervention|"In the intervention arm, the management will be optimized according to the risk of the predictive model. The predictive model of intra-amniotic infection includes maternal C-reactive protein (CRP) (in mg/L) and amniotic fluid glucose (in mg/dL), and the predictive model of spontaneous preterm delivery within 7 days includes gestational age (in weeks), cervical length (in mm), amniotic fluid glucose (in mg/dL) and Interleukin (IL)-6 (in a log10 scale). High risk will be defined when the risk is > 10% in the predictive model of spontaneous delivery in 7 days and > 20% in the predictive model of intra-amniotic infection:~If low-risk: we will optimize the standard management reducing the dose of steroids (e.g not administering second doses), tocolysis duration and facilitating discharge home.~If high-risk: we will follow the standard management of each center and we will treat with antibiotics"
9690726|NCT04831086|No Intervention|Control|In the control arm the standard management of each center will be followed regarding doses of steroids, duration of tocolysis or maternal stay length duration.
9690727|NCT04831047|Experimental|Upneeq Group|Participants in this group will receive a one-time dosing of oxymetazoline hydrochloride 0.1% (1 drop applied to ocular surface of each eye of patients in the treatment group)
9690728|NCT04831047|Sham Comparator|Control Group|Participants in this group will receive a one-time dosing of balanced saline solution (1 drop applied to ocular surface of each eye of patients in the control group)
9690729|NCT04831060||Case (patients with stage 3 or 4 periodontitis)|
9690730|NCT04831060||Control (healthy periodontium)|Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries or aesthetic surgeries
9690731|NCT04831346|Experimental|low level laser|"A low-level gallium arsenide diode (Biolase, USA) at a 940 nm wavelength with 0.2 W output power and 2 J energy. The device was calibrated, and the probe was disinfected prior to every treatment.~The Masseter and Temporalis muscles will be bilaterally assessed with constant pressure to define tenderness.~LLLT applied perpendicular to each tender point of the intended muscles for 10 seconds with an energy density of 2.5 J/cm2.~Sessions are scheduled 3 days a week (every other day)"
9690732|NCT04831346|Experimental|Occlusive splint therapy|"A soft occlusal splint (vacuum-formed ) made from a 2-mm-thick elastic rubber sheets will be used.~Splints were individually designed ( in the out patient clinic of the college of dentistry) for the upper arch of each patient. An alginate imprint of the maxillary arch will be taken to fabricate a master cast of the maxilla.~A vacuum pressure device was utilized for molding the rubber sheets (13 x 13 cm /2-mm thickness).~Sheets were removed after it has been appropriately adjusted to the mold in the vacuum former. Edges will be properly trimmed, and the palate part is detached to obtain the end shape.~Participants are instructed to wear the splint at all times except during mealtimes and oral hygiene."
9690733|NCT04831346|No Intervention|Control|This group will be a wait list group recieving no intervention except for the regular analgesic prescribed by the reffering dentist
9690734|NCT04831333||Active CMVR|The UWF images of cytomegalovirus retinitis (CMVR) included various patterns: hemorrhagic necrotizing lesion, granular lesion, frosted branch angiitis, and optic neuropathy lesion. Active CMVR lesion was defined as obvious opacity (mild, moderate, severe, very severe)
9690735|NCT04831333||Inactive CMVR|Inactive CMVR lesion was defined as a lack of opacity or questionable/equivocal activity.
9690736|NCT04831333||Non-CMVR|The non-CMVR images included normal retina and other retinopathies such as HIV-related microvascular retinopathy, diabetic retinopathy, retinal detachment, vitreous hemorrhage.
9690737|NCT04831255|Experimental|ZILRETTA|Single injection of triamcinolone acetonide extended-release injectable suspension, injected in the glenohumeral joint under ultrasound guidance.
9690738|NCT04831424|Experimental|Healthy controls|No diagnosis of mitochondrial disease
9690739|NCT04831424|Experimental|Mutation|Participants carrying the m.3243A>G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
9690740|NCT04831424|Experimental|Mutation with MELAS|Participants carrying the m.3243A>G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
9690741|NCT04831424|Experimental|Deletion|Participants carrying a single, large-scale mtDNA deletion
9690742|NCT04831294|Experimental|Cannabidiol (CBD)|A tincture containing 125mg broad spectrum CBD oil (6.7%), 24mg sunflower lecithin (1.3%), 56mg peppermint oil (3.0%), and 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
9690743|NCT04831294|Placebo Comparator|Placebo|A tincture containing 149mg sunflower lecithin (8.0%), 56mg peppermint oil (3.0%), 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
9690744|NCT04831216|Experimental|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
9690745|NCT04831268|Experimental|Glucose as reference food|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
9690746|NCT04831268|Experimental|Lentils and lupins mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
10180905|NCT03788863||Pregnant women exposed to glucocorticoids|Pregnant women exposed to any glucocorticoid or corticosteroid or steroids in early pregnancy or first trimester of pregnancy
10180906|NCT03788863||Non-exposed pregnant women|Women not using any glucocorticoid or corticosteroid or steroids during pregnancy
10180907|NCT03788837|Experimental|intravenous Ilomedin|a first dose of Ilomedin of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
10180908|NCT03788837|Placebo Comparator|Intravenous Placebo|Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
10180909|NCT03788941||LAAC plus Catheter ablation|Patients will receive both left atrial appendage closure and catheter ablation of atrial fibrillation for treatment.
10180910|NCT03788941||Catheter ablation|Patients will only receive catheter ablation of atrial fibrillation for treatment.
10180911|NCT03788876|Active Comparator|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
10180912|NCT03788876|Sham Comparator|Conventional care|The protocol of physiotherapy by the physiotherapists of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
10180913|NCT03788772|Experimental|Adults patients hospitalized in ICU|Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)
10180914|NCT03789032|Experimental|Rabeprazole and Vadadustat|Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
10180915|NCT03788798|No Intervention|Standard clinical pathway|A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
10180916|NCT03788798|Experimental|Patient Infotainment Terminal|Patients who have additional access to an integrated infotainment system and are cared by a standard clinical pathway. The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
10180917|NCT03788733|Experimental|Melatonin|Melatonin ORAL FILM 3mg will be taken by the subject once a day for 8 weeks
10180918|NCT03788733|Placebo Comparator|placebo|ORAL FILM 3mg placebo will be taken by the subject once a day for 8 weeks
10180919|NCT03788785|Experimental|Experimental arm|The specific tobacco cessation intervention of the treatment group will begin during the diagnostic phase of the HNSCC by three ½ hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days top. The most important point is that this intervention will be provided by trained nurses of the health care team within the ENT department, rather than in an external smoking cessation center.
10180920|NCT03788785|Other|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
10180921|NCT03788694|Experimental|Intranasal Ketamine|Subjects will receive study medication, intranasal ketamine.
10180922|NCT03789006|Active Comparator|ATG|Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
10180923|NCT03789006|Active Comparator|BAS|Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
10180924|NCT03788720|Experimental|Suture|Women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas.
10180925|NCT03788720|Sham Comparator|No suture|Women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.
10180926|NCT03789019|Experimental|BP-C1|"Dose-response part: patients who have completed the first 32-day treatment period with BP-C1 under Protocol BMC2011-1/Protocol MBC-BPC1/IIB or Protocol BMC2012-4, and having a maximum of moderate toxicity at the end of treatment are offered to continue in the second 32-day treatment period with BP-C1 under the protocol BMC2011-02. Patients completing 64-day treatment period with BP-C1 will be followed up for 28 days.~Follow-up study: the patients will be given BP-C1 as long as they obtain benefit from the treatment (i.e. until disease progression or increase in toxicity not above moderate grade)."
10180927|NCT03788616|Active Comparator|Group I|Group I : will consist of 30 teeth that will be restored by high-viscosity glass ionomer (Fuji IX Extra) with ART approach
10180928|NCT03788616|Active Comparator|Group II|Group II : will consist of 30 teeth that will be restored by bioactive restorative material (ACTIVA KIDS bioactive restorative material) with ART approach.
10180929|NCT03788759|Experimental|Experimental group|25 subjects will be randomized to 100mg of alpha-lipoic acid.
10180930|NCT03788759|Placebo Comparator|Placebo group|25 subjects will be randomized to placebo.
10180931|NCT03788668|Active Comparator|Hyoid suspension with barbed reposition pharyngoplasty|
10180932|NCT03788668|No Intervention|barbed reposition pharyngoplasty|
10180933|NCT03788681|Active Comparator|"oral estradiol  estradiol valerate"|"this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI .This group will receive oral estradiol  estradiol valerate  (Cyclo-Progynova® , 2mg , Bayer Schering Pharma Ag , Germany ) from within 24 hours ovum pickup of the cycle."
10180934|NCT03788681|Placebo Comparator|placebo|this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI . This group will receive oral placebo (tablets) from within 24 hours ovum pickup of the cycle
9690747|NCT04831268|Experimental|Trahanas with tomato sauce mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
9690748|NCT04831268|Experimental|Halva with currants mixed meal|"Twelve healthy, normal weight subjects (male: 7, female:~7) after 10-14 hr fast, consumed 25g available carbohydrate from D-glucose, three times, in different weeks as reference food along with 250ml water; and 25g available carbohydrates from lentils and lupins, trahanas with tomato sauce and halva with currants, tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink."
9690749|NCT04831177|Active Comparator|Patients planned to undergo Femtosecond laser FS assisted LASIK|In FS group, Allegretto WaveLight FS-200 femtosecond laser was used to create flaps with flap thickness planned to be 100 um.
9690750|NCT04831177|Active Comparator|Patients planned to undergo Microkeratome MK assisted LASIK|In MK group, Moria 2 Microkeratome was used to create flaps with flap thickness planned to be 100 um.
10180935|NCT03788707|Experimental|Passive leg raising|Passive leg raising for 3 minutes after 20 seconds of lying flat
10180936|NCT03788603|Experimental|Rogaratinib (BAY1163877)|Eligible patients will be selected based on the confirmation of high fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 mRNA expression levels in archival or fresh tumor biopsy specimens collected before the start of screening
9690751|NCT04830995|Experimental|diet program|moderate restricted diet (1800-2000 kcal/day) for four weeks, 3 sessions weekly
9690752|NCT04830995|Experimental|high intensity interval training|high intensity interval training for four weeks, 3 sessions weekly
9690753|NCT04830982|Experimental|Diazoxide|IV Diazoxide as additive to hypothermic hyperkalemic cardioplegia.
9690754|NCT04830982|Placebo Comparator|Placebo|Placebo as additive to hypothermic hyperkalemic cardioplegia.
9690755|NCT04830969|Experimental|A: Diabetic + SRP + SPT|The first group, A, includes diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
9690756|NCT04830969|Experimental|B: Non-Diabetic + SRP + SPT|The second group, B, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
9690757|NCT04830969|Active Comparator|C: Diabetic + SRP|The third group, C, includes diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
9690758|NCT04830969|Active Comparator|D: Non-Diabetic + SRP|The second group, D, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
9690759|NCT04831125||Individuals receiving conduction system pacing|
10180937|NCT03788629|Experimental|Study Group 1|Bobath Concept+ Talocrural joint Mulligan MWM techniques were applied to this group.
10180938|NCT03788629|Active Comparator|Study Group 2|Subtalar joint Mulligan MWM techniques were applied to this group in addition to Bobath Concept+ Talocrural joint Mulligan MWM techniques
10180939|NCT03788486|Experimental|2-3 Joule light device for MGD/Dry eye|patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month. Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
10180940|NCT03788408|Experimental|Intensive Psychotherapy Case Management|Treatment group received Intensive Psychotherapy and Case Management (IPCM) delivered by psychotherapists and social worker with expertise in refugee trauma and mental health.
10180941|NCT03788408|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual group received ongoing care from their primary care providers without the involvement of CVT (except for the collection of outcomes). TAU patients could be referred to a full range of outpatient and community-based behavioral health services by their primary care physician.
9690760|NCT04830878|Experimental|Treatment|Methotrexate treatment
9690761|NCT04831008|Active Comparator|Figure-of-eight|Using the figure-of-eight closure technique when closing access for structural heart therapies.
9690762|NCT04831008|Active Comparator|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
9690763|NCT04830800|Experimental|COVIVAC 1mcg|1mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
9690764|NCT04830800|Experimental|COVIVAC 3mcg|3mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
9690765|NCT04830800|Experimental|COVIVAC 10mcg|10mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
9690766|NCT04830800|Experimental|COVIVAC 1mcg + CpG1018 1.5mg|1mcg + CpG1018 IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
10180942|NCT03788538|No Intervention|group 1 with no dexmedetomidine|
10180943|NCT03788538|Experimental|group 2 with dexmedetomidine 0.25μg/kg/h|
9690767|NCT04830800|Placebo Comparator|Placebo|Phosphate buffered saline (pH 7.2) for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
10180944|NCT03788538|Experimental|group 2 with dexmedetomidine 0.5μg/kg/h|
10180945|NCT03788330|Experimental|Fresh air system with filtration|A fresh air ventilation system combined with PM2.5 filtration is applied in one primary school classroom.
9696252|NCT04768946||Caregivers of Adolescents with Acquired Brain Injury|Caregivers of adolescents with traumatic brain injury, stroke, and other acquired brain injury will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
10180946|NCT03788330|Placebo Comparator|Fresh air system with no filtration|A fresh air ventilation system with no PM2.5 filtration is applied in a parallel classroom.
9690768|NCT04830943|Other|Olfactory and gustatory disorders after covid 19 infection|Cerebrolysin Dose:10 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 8 more weeks.
9690769|NCT04830930|Experimental|Sequence 1|Period 1: fasted condition/ Period 2: fed condition
9690770|NCT04830930|Experimental|Sequence 2|Period 1: fed condition/ Period 2: fasted condition
9690771|NCT04831073||Acute type A aortic dissection|Patients who underwent surgery for acute type A aortic dissection
9690772|NCT04830813|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
10180947|NCT03788330|No Intervention|Natural ventilation|Natural ventilation system was applied in the 3rd classroom as normal.
10180948|NCT03788304|Active Comparator|Non invasive ventilation|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O.~Pressure support (PS): 12-20 cmH2O.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
10180949|NCT03788304|Experimental|High flow nasal cannula|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C~Flow rate 30: 50 L/min.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
10180950|NCT03788343|Experimental|Phenylalanine|"Capsules containing 250 mg Phenylalanine (Phe). The daily dose will be chosen according to gender and weight at the time of T1 and will be divided in 3 separate doses. The assigned dose of the IMP will be kept throughout the whole study and weight fluctuations will not be considered.~Female~<60 kg: 1500 mg per day (divided in 3 doses): 250 mg 2-2-2-0~≥60 kg: 2000 mg per day (divided in 3 doses): 250 mg 2-2-4-0~Male~<60 kg: 2500 mg per day (divided in 3 doses): 250 mg 4-2-4-0~≥60 kg: 3000 mg per day (divided in 3 doses): 250 mg 4-4-4-0~Phe capsules can be ingested before, during or after a meal or together with other amino acid supplements. The last capsule of the given intervention period will be timed to be ingested with the last meal before the study visit.~Patients will take Phe for 4 weeks."
9690773|NCT04830813|Placebo Comparator|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
10180951|NCT03788343|Placebo Comparator|Placebo|"Capsules containing 250mg Placebo. Placebo capsules will be administered in identical manner to Phe capsules.~Patients will take the Placebo for 4 weeks."
10180952|NCT03788395|Experimental|Symbicort Turbohaler plus Turbo+|10 asthmatic children
10180953|NCT03788395|Active Comparator|Symbicort Turbohaler without Turbo+|10 asthmatic children
10180954|NCT03788278||PTSD patients|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
9690774|NCT04830904|Experimental|Use of lycra garments|the subjects are assessed with and without wearing the device
9690775|NCT04830670||Large sinus|same patient, sinus width > 12mm measured at 10mm from the alveolar crest at the planned implant site
9690776|NCT04830670||narrow sinus|same patient, sinus width < 12mm measured at 10mm from the alveolar crest at the planned implant site
9690777|NCT04830748|Active Comparator|Therapeutic exercises group|The first group will receive therapeutic exercises in the form of stretching and strengthening exercises of the knee.
9690778|NCT04830748|Experimental|Therapeutic exercises and mechanical traction group|The experimental group will receive the same exercise program of the first group preceded by continuous mechanical traction of the knee.
9690779|NCT04830644|Experimental|Iguratimod 1|orally 25mg twice a day
9690780|NCT04830644|Experimental|Iguratimod 2|orally 20mg twice a day
9690781|NCT04830644|Experimental|Iguratimod 3|orally 10mg twice a day
9690782|NCT04830644|Placebo Comparator|Placebo|orally twice a day
9690783|NCT04830579|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in Period 1 and a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9690784|NCT04830579|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 120 mg dose of the reference product Arcoxia® (1 x 120 mg tablet), marked as R in the sequence, in Period 1 and a single 120 mg dose of the test product Etoricoxib (1 x 120 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9690785|NCT04830657|Experimental|Distant reiki group|The application will be carried out by the researcher who has received level 2 reiki training. Reiki energy will be sent to the individuals who have undergone hemodialysis with the intention of healing. The Reiki practitioner is enabled to send the Reiki remotely in a quiet and lonely room. The practitioner moves to the right side of the individual, imagining as if he is next to the individual, and his aura (the energy that exists around the body) is corrected 3 times from above and from the head to the feet. The practitioner's hands are held side by side. Starting from the beginning of the application, reiki energy is sent to the 7 main chakras in an average of 3 minutes, from top to bottom. Each session is approximately 21-25 minutes. After the session, the chakra equalization process is applied to help the frequencies of the chakras to work in harmony with each other. 15 minutes in total. Balancing is done.
9690786|NCT04830657|Other|Control|Patients will receive routine treatment in accordance with the institution policy without any intervention in the control group.
9690787|NCT04830566|Experimental|Myofascial release technique group|
9690788|NCT04830566|Sham Comparator|Simulated myofascial release technique group|
9690789|NCT04830722|Active Comparator|Sculptra Aesthetic Side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.
10180955|NCT03788278||Non PTSD participants|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
10180956|NCT03788369||Multivessel coronary artery disease|must include left anterior descending artery
10180957|NCT03788239|Experimental|Arm 1|Right knee wound closure by staples and Left Knee wound closure by sutures
9690790|NCT04830722|Placebo Comparator|Placebo side|the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side
10180958|NCT03788239|Experimental|Arm 2|Right knee wound closure by sutures and Left Knee wound closure by staples
10180959|NCT03788447|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
10180960|NCT03788447|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
10180961|NCT03788499|No Intervention|Control arm|routine oral care and functional exercise.
10180962|NCT03788499|Experimental|Massage arm|Massage of Maxillofacial and oral cavity plus routine oral care and functional exercise
10180963|NCT03788460||childrens population with lack of Factor VI|"We will check PT levels, we will concentrate the data in the table, along with personal information such as age and gender.~We will try to conduct a statistical relationship between the PT values and Factor VII levels, to look for statistical significance, we will try to find a model for predicting the level of factor VII based on PT"
10180964|NCT03788525|Experimental|Reduced recreational screen time|Reducing recreational screen-based media use for a period of 2 weeks
10180965|NCT03788525|Experimental|Timed recreational screen time|Reduced and timed recreational screen-based media use for a period of 2 weeks
10180966|NCT03788590|Experimental|Jenscare TAVI|Patients undergoing a Jenscare TAVI and delivery system
10180967|NCT03788200|Active Comparator|post-injury bracing with rigid cervical collar|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
10180968|NCT03788200|Active Comparator|posterior C1-2 instrumented fusion|Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
10180969|NCT03788265|Experimental|injection|
9690791|NCT04830540|No Intervention|Control|Participants assigned to the control group will be asked to continue wearing their typical shoes and to complete every two weeks the footwear and injury log provided
10180970|NCT03788434|Experimental|VE303 High Dose|Study subjects assigned the the high dose VE303 arm will take 10 capsules containing VE303 per day for 14 days.
10180971|NCT03788434|Experimental|VE303 Low Dose|Study subjects assigned to the low dose VE303 arm will take 2 capsules containing VE303 per day for 14 days.
10180972|NCT03788434|Placebo Comparator|Placebo|Study subjects assigned to the placebo dose arm will take placebo capsules each day for 14 days. The capsules will not contain any VE303.
10180973|NCT03788226|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
10180974|NCT03788226|Active Comparator|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
10180975|NCT03788356|Experimental|Diaphragmatic breathing|Diaphragmatic breathing exercise for 15 minutes.
10180976|NCT03788356|Experimental|10% inspiratory muscle training|Inspiratory muscle training at 10% intensity of maximal inspiratory pressure for 15 minutes
10180977|NCT03788356|Experimental|30% inspiratory muscle training|Inspiratory muscle training at 30% intensity of maximal inspiratory pressure for 15 minutes
10180978|NCT03788356|Experimental|60% inspiratory muscle training|Inspiratory muscle training at 60% intensity of maximal inspiratory pressure for 15 minutes
10180979|NCT03788252|Active Comparator|Renamezin|oral treatment duration: three times a day, 7 capsules (2g) once, for 48 weeks
10180980|NCT03788252|No Intervention|Non-Renamezin|no use of Renamezin
10180981|NCT03788057|Other|stable asthma|"In patients with previously stable course of the asthma, every 3 months the symptoms are evaluated and the dose of ICS is customized - in accordance with the GINA guidelines. This decision is based solely on clinical data (control of symptoms) and is the same as in patients not participating in the study.~In patients participating in the study, inflammatory parameters are also measured (sputum eosinophilia, eNO, EBT, bronchial reactivity), but results are not known to clinician taking decision about possible ICS dose reduction."
10180982|NCT03787992|Experimental|Alflutinib Mesylate (AST2818) +placebo|AST2818 (80 mg or 40 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule
10180983|NCT03787992|Active Comparator|Gefitinib + placebo AST2818|Gefitinib (250 mg orally, once daily) + placebo AST2818 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
10180984|NCT03788031|Experimental|Perceptual learning group - Amblyopia|Visual training
9690792|NCT04830540|Experimental|Intervention|Individuals assigned to the intervention group will be provided with 2 styles of the OOFOS recovery shoes, and will be asked to wear the OOFOS slide, sandal and/or closed toe shoes as their primary footwear outside training and competition for the 6 weeks between study visits. Intervention participants will also be asked to complete a daily shoe wear log and a shoe comfort assessment survey every other week.
9690793|NCT04830527|Experimental|Intervention group|Patients in experimental group will receive EMA prompts. Therapists in this group will receive a summarized PDF report before the beginning of the first psychotherapy session. The report will include graphic summarized data from the EMA prompts.
9690794|NCT04830527|Active Comparator|Control group|"Patients in control group will receive the EMA prompts in the same manner as patients in the experimental group.~Therapists in this group will not receive the PDF reports, and instead will get raw scores from a screening evaluation conducted with patients in the recruitment phase of the study."
10180985|NCT03788031|Active Comparator|Perceptual learning group - Control|Visual training
9690795|NCT04830475|Experimental|NIV Group|In poostoperative period, patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
9690796|NCT04830475|Active Comparator|Control Group|In the postoperative period, patients were offered VenturiMask with Fio2 60% at 15 l / m.
10180986|NCT03788031|Placebo Comparator|Occlusion therapy - Amblyopia|Patching
10180987|NCT03788005|Active Comparator|Intervention group|"Early mobilization as soon as possible, within a maximum of 12 hours post-surgery.~Subdural drains will be closed when the patient is allowed to mobilize and will be open during a nocturnal period of 8 hours. Subdural drains will be removed past 48 hours of surgery."
10180988|NCT03788005|No Intervention|Control Group|Bed rest with head of bed at 0 degrees for 48h. Subdural drains will be removed past 48 hours of surgery.
10180989|NCT03788044|Experimental|Application-driven education (AF-EduApp substudy)|Education will be given via a newly developed application. Medication adherence (oral anticoagulation) will be measured using a special bottle cap that fits on a medication bottle. The patients in this group will receive feedback (notification and/or alarm) during the entire study period via this application when these patients have to take their medication.
9690797|NCT04830683||ICU Covid-19 patients|Covid-19 patients admitted for refractory respiratory failure despite conventional oxygen therapy requiring Intensive Care Unit (ICU) admission and oxygenation through either High Flow Nasal Cannula (HFNC) therapy or endotracheal intubation with mechanical ventilation
9690798|NCT04830683||non-ICU Covid-19 patients|Covid-19 patients admitted at hospital requiring conventional oxygen or continuous positive airways pressure (cpap)
9690799|NCT04830683||matched control subjects|Healthy subjects matched for similar cardiovascular risk factors than ICU Covid-19 patients
9690800|NCT04830683||ICU septic shock patients|Septic shock patients corresponded to refractory hypotension in response to an infection, in non Covid-19 patients, requiring ICU hospitalisation for vasopressors to maintain mean arterial pressure (MAP) > 65mm Hg despite adequate volume resuscitation according to the Surviving Sepsis Campaign
10180990|NCT03788044|Experimental|In-person education (AF-EduCare study)|Education will be given on regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
9690801|NCT04830449|Experimental|HCP1904-2|
9690802|NCT04830449|Active Comparator|RLD2001-2|
9696253|NCT04768946||Healthcare Workers|This cohort includes health professionals involved in discharge planning and community re-integration of adolescents with ABI. Healthcare workers will participate in interviews about home safety. They also will have the opportunity to look at the virtual simulation training system and provide feedback about how to make it more appropriate for adolescents with brain injury, including gamifying it and ensuring appropriate hazards.
10180991|NCT03788044|Experimental|Online education (AF-EduCare study)|Education will be given on regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
10180992|NCT03788044|No Intervention|Standard care (AF-EduCare study and AF-EduAppsub study)|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
10180993|NCT03788109|Other|device: combined solid state HRiM|combined solid state high resolution esophageal impedance and manometry (HRiM)
10180994|NCT03788096|Experimental|PS-PICS Peer Support Intervention|ICU mentors will be responsible for providing support to survivor participants randomized to the PS-PICS peer support intervention. Mentors will be trained in motivational interviewing techniques to engage mentees in goal setting and emotional management that is not readily accessible as part of discharge planning.
10180995|NCT03788096|Placebo Comparator|Usual Care Group|A control intervention will be used to provide comparison data consistent with usual care (absence of structured peer support telephone intervention) to evaluate the impact of the PS-PICS peer support intervention.
10180996|NCT03787979|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
10180997|NCT03787979|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
10180998|NCT03787901|Experimental|Morula Vitrification Arm|
10180999|NCT03787901|Active Comparator|Blastocyst Vitrification Arm|
10181000|NCT03787940|Active Comparator|Standard INH for Non-rapid acetylators|Participant with slow or intermediate acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid)
10181001|NCT03787940|Active Comparator|Standard INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid )
10187538|NCT03725280||Transgender men II|Transgender men before testosterone treatment
10187539|NCT03725280||IVF- PCOS|IVF- PCOS patients with high testosterone levels
10181002|NCT03787940|Experimental|High dose INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with high dose isonized treatment (3 months HRZE followed by 9 months HRE with high dose isoniazid)
10181003|NCT03788161|Experimental|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
10181004|NCT03788161|Placebo Comparator|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
10181005|NCT03788083|Placebo Comparator|placebo|
10181006|NCT03788083|Active Comparator|TriMix|
10181007|NCT03787953||Anti-PD-1/PD-L1 antibodies|Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy
10181008|NCT03788018|Experimental|Effect of IV lidocaine and dexmedetomidine on PONV|
10181009|NCT03788018|Experimental|Effect of IV saline on PONV|
10181010|NCT03788122|Other|Parents eligible for fetal surgery|Parents eligible for fetal surgery will undergo two or three in-depth face-tot-face interviews, to determine their perception of acceptability of fetal surgery.
10181011|NCT03787914|Experimental|Intervention arm|Intervention arm patients were served by outreach mobile teams for oral anti-TB treatment under DOTS at the place of their convenience by health care professionals
9690803|NCT04830319|Experimental|Test-control group (TCG)|The test-control group (TCG) will initiate the protocol with exercises of the Pilates method, which includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. The TCG group will then conduct 20 task-oriented training sessions
9690804|NCT04830319|Active Comparator|Control-test group (CTG)|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
9690805|NCT04830462|Other|LTBI and DM|Participants with LTBI and DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
9690806|NCT04830462|Other|LTBI without DM|Participants with LTBI without DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
9690807|NCT04831099|Experimental|Testosterone|Testosterone gel (20 mg/day) for 8 weeks per period.
9690808|NCT04831099|Placebo Comparator|Placebo|Placebo gel (20 mg/day) for 8 weeks per period.
9690809|NCT04831203|Experimental|Protein-hydrolysate|Dietary supplement: an egg-protein hydrolysate (NWT-03) Study volunteers will receive a daily powder of 5 g of protein hydrolysate to mix with 200 mL of water for 36 weeks.
9690810|NCT04831203|Placebo Comparator|Control|Control: 5 g of maltodextrin powder mixed with 250 mL of water for 36 weeks.
9690811|NCT04831112|Experimental|Honey|Topical honey to be used for dressing 4ml per square inch.
9690812|NCT04831112|Active Comparator|EUSOL|EUSOL soaked gauze to be placed over the wound as dressing.
9690813|NCT04830384|Experimental|Fully Active|LLLT & Music Therapy
9690814|NCT04830384|Active Comparator|LLLT Only|LLLT Therapy
10181012|NCT03787914|Active Comparator|Control arm|Control arm patients were given the traditional facility based DOTS treatment. Control arm was not served by the outreach mobile teams.
10181013|NCT03788174|Experimental|Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
10181014|NCT03787836|No Intervention|Controls|The primary purpose of the control participants are to provide a measure of variability. They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
10181015|NCT03787836|Experimental|Exercisers (Maintained)|The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.
10181016|NCT03787836|Experimental|Exercisers (Increased Intensity)|The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.
10187540|NCT03725280||Egg donors|IVF- egg donors patients
10187541|NCT03725267|Experimental|Melatonin|Patients will receive 1 pill each day with 30 mg of Melatonin during polymyxin B treatment for a maximum of 14 days.
10187542|NCT03725267|Placebo Comparator|Placebo|Patients will receive 1 pill each day with Placebo during polymyxin B treatment for a maximum of 14 days.
9690815|NCT04830384|Placebo Comparator|Music Only|Music Therapy
9690816|NCT04830384|Sham Comparator|Placebo|No Therapy
9690817|NCT04830176|Active Comparator|moringa|First phase of subjects were given dentifrice for brushing
9690818|NCT04830176|Active Comparator|miswak|second phase of subjects were given dentifrice for brushing
9696254|NCT04768738|Experimental|Above Threshold Group|In the above threshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
9690819|NCT04831229|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
9690820|NCT04831229|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
10181017|NCT03787927|Other|5 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
10181018|NCT03787927|Other|5 day RTP, then 5 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
10181019|NCT03787927|Other|5 day RTP, then 10 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
9690821|NCT04830358|Experimental|EuPCV15|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
9690822|NCT04830358|Active Comparator|Prevenar13|Single dose of Pneumococcal Conjugate Vaccine will be administered intramuscularly at Day 0.
9690823|NCT04830189|Experimental|shoulder slings|Patients were used shoulder sling in addition to conservative treatment.
9690824|NCT04830189|Active Comparator|forearm sling|Patients were used forearm sling in addition to conservative treatment.
9690825|NCT04830150|Experimental|supportive interventions group|Supportive and educational nursing interventions about reducing maternal stress levels in the experimental group included the following: the NICU was physically described to mothers on the first day they visited their infants, mothers were introduced to team members, and given information about how to obtain information about their baby, visiting hours and conditions.
9690826|NCT04830150|No Intervention|control group|Mothers did not have any other intervention applied by the researchers during routine operation while their infants were in the unit.
9690827|NCT04830163|Experimental|Paired corticomotoneuronal stimulation during sensorimotor mu rhythm trough phases|
9690828|NCT04830163|Active Comparator|Paired corticomotoneuronal stimulation during random sensorimotor mu rhythm phases|
9690829|NCT04830085|Experimental|Patients with adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was diagnosed with histopathological assessment.
9690830|NCT04830085|Active Comparator|Patients without adenomyosis|Hysterectomy (abdominal or vaginal or laparoscopic) Histopathological assessment Adenomyosis was excluded with histopathological assessment.
9690831|NCT04830280|Active Comparator|Posterior quadratus lumborum block|
9690832|NCT04830280|Sham Comparator|control group|
9690833|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #1)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.
9690834|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #2)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.
9690835|NCT04830371|Experimental|Arm A (Vi-CRM197, Batch #3)|Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.
9690836|NCT04830371|Active Comparator|Arm D (Typbar-TCV)|Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.
9690837|NCT04830410|Experimental|Fructan powder|2 g of fructan powder 3 times per day for 7 days
9690838|NCT04830410|Placebo Comparator|Placebo|2g of placebo (maltodextrin) 3 times per day for 7 days.
9690839|NCT04830332|Other|Study group|Women with endometrial carcinoma
9690840|NCT04830254|Active Comparator|study group(A)|Group (A) included 20 patients who received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs) for 45 min per session, three times per week, and for 12 weeks.
9690841|NCT04830254|Sham Comparator|Control group(B)|The control group(B) included 20 patients who received placebo TENS stimulation but with a voltage level falling to zero after 10 s of stimulation
9690842|NCT04830215|Other|Brexpiprazole|Brexpiprazole as a flexible dose; 0.5 to 2 mg/day and patient will continue on the stable dose of ADT that they were taking at screening.
9690843|NCT04830267|Active Comparator|Camrelizumab alone|Camrelizumab 200mg IV every 2 weeks
9690844|NCT04830267|Experimental|Stereotactic body radiotherapy plus Camrelizumab|Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks
10181020|NCT03787927|Other|5 day RTP, then 15 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
10181021|NCT03787927|Other|10 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
10181022|NCT03787927|Other|15 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
10181023|NCT03787875||Control|The control group included 10 periodontally healthy subjects without signs or symptoms of periodontal disease.
10181024|NCT03787875||Study|"The study group included 15 subjects diagnosed with mild or advanced chronic periodontitis. Each periodontal patient had one non-affected single-rooted tooth (healthy site) and another single-rooted tooth with periodontitis (periodontitis site) with the following features:~Healthy site: a single-rooted tooth with probing depths below or equal to 3 mm without recession and without bleeding on probing.~Periodontitis site: another single-rooted tooth from the same patient with clinical attachment loss equal to or greater than 6 mm and bleeding upon probing."
10181025|NCT03787667||Patients with pathologically diagnosed colorectal cancer|Patients with pathologically diagnosed colorectal cancer
10181026|NCT03787563|Active Comparator|Active Herbal tea|One tea bag infusion three times a day each before breakfast, lunch and dinner.
10181027|NCT03787563|Placebo Comparator|Placebo Tea|Similar looking tea bag infusion three times a day each before breakfast, lunch and dinner.
10181028|NCT03787550||Model building group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
10181029|NCT03787550||Model validation group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
9827615|NCT02462057|Active Comparator|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
10181030|NCT03787823|Other|Retzius-sparing RARP|Arm B randomizes men with an indication for radical robotic Prostatectomy (RARP) to retzius-sparing transdouglas RARP
10181031|NCT03787823|Other|anterior transperitoneal RARP|Arm A randomizes men with an indication for radical robotic Prostatectomy (RARP) to anterior transperitoneal RARP
10187543|NCT03725254|Active Comparator|radical surgery|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.
9690845|NCT04830111|Experimental|heart rate variability biofeedback training group|The goal of heart rate variability biofeedback is to increase heart rate variability through paced breathing exercises, which have shown to be effective in reducing stress and anxiety in general adult populations.
9690846|NCT04830111|No Intervention|Care as usual|In this condition, all of this group take care by hospital routine and the questionnaires were completed over a period with similar intervals.
9690847|NCT04830059|Experimental|High intensity intermittent training|HIIT exercise program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes.
9690848|NCT04830059|Experimental|HIIT with pollution reduction|HIIT program: 20 minutes HIIT exercise (1min 100% VO2max and 1min 50% VO2max alternately), and warm-up and relaxation before and after exercise for 10 minutes; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
9690849|NCT04830059|Experimental|Moderate intensity continuous training|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise.
9690850|NCT04830059|Experimental|MICT with pollution reduction|MICT program: 20 minutes of 70-75% VO2max exercise and 10 minutes of warm-up and relaxation before and after exercise; Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10.
9690851|NCT04830059|Experimental|Stretch control group|Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.
9690852|NCT04830059|Experimental|Control with pollution reduction|"Stretching control group: 30 minutes stretching, posture adjustment and rehabilitation courses is taught by professional therapist.~Environmental pollution intervention program: air purification system is used order to reduce the PM2.5 and PM10."
9690853|NCT04829799|Active Comparator|Control Group|Subjects will receive intracameral 1% preservative-free lidocaine following paracentesis
10181032|NCT03787732|Active Comparator|Fluid Bolus|For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
10181033|NCT03787732|Active Comparator|No Fluid Bolus|For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
10181034|NCT03787589|Experimental|Exercise Intervention|Participants in this arm will receive standard of care along with the exercise prescription intervention
10181035|NCT03787589|No Intervention|Standard of Care|This group will receive standard of care treatment including regular verbal encouragement to exercise (monthly) by dialysis unit staff.
10181036|NCT03787784|Experimental|AI visible group|
9690854|NCT04829799|Experimental|Study Experimental Group|Subject will receive Omidria (phenylephrine and ketorolac (1.0%/0.3%) added to the ophthalmic irrigating solution during the cataract extraction procedure
10181037|NCT03787784|No Intervention|AI invisible group|
10181038|NCT03787719|Experimental|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment (Monday and Friday or Tuesday and Saturday).
9690855|NCT04829734|Experimental|Active PBMT-sMF|Active PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
9690856|NCT04829734|Placebo Comparator|Placebo PBMT-sMF|Placebo PBMT-sMF will be applied two times a week (three to four days apart), for three consecutive weeks, yielding six treatment sessions.
10181039|NCT03787719|No Intervention|Thrice per week dialysis|Standard thrice-weekly 4 hour dialysis treatment (Monday, Wednesday and Friday or Tuesday, Thursday and Staurday)
10181040|NCT03788135|Experimental|Quadriceps cooling|Participants in this group will receive a cold pack on anterior thigh muscles for 20 minutes.
10181041|NCT03788135|Experimental|Hamstring cooling|Participants in this group will receive a cold pack on posterior thigh muscles for 20 minutes.
10181042|NCT03788135|Experimental|Calf cooling|Participants in this group will receive a cold pack on posterior leg muscles for 20 minutes.
10181043|NCT03788135|Experimental|Back cooling|Participants in this group will receive a cold pack on posterior low back muscles for 20 minutes.
10181044|NCT03788135|No Intervention|Control|The participants in the control group will be rested for 20 minutes without any intervention.
10181045|NCT03787745|Active Comparator|Ischemic postconditioning|In addition to state of the art primary PCI in patients with TIMI0-1 ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed, however thrombectomy will not be allowed
10181046|NCT03787745|Placebo Comparator|Conventional|State of the art primary PCI in patients with TIMI0-1 will be performed, however thrombectomy will not be allowed
9690857|NCT04830098|Experimental|Stabilization group|Stabilization group will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
9690858|NCT04830098|Experimental|Manipulation group|Manipulation group be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
9690859|NCT04830098|Experimental|Stabilization and Manipulation group|Stabilization and Manipulation group will be given both stabilization exercises and manipulation exercises.
9690860|NCT04830098|No Intervention|Control group|No application will be made in the control group.
9690861|NCT04829721|Experimental|Educational Video Workshop|A single 20 minute video workshop on pelvic floor disorders.
9690862|NCT04829708|Active Comparator|PCI Arm|Patients received PCI (recommended hippocampal protection) within 6 weeks after first-line treatment, with a total dose of 25 Gy, 2.5 Gy each time, once a day, 5 times a week, a total of 10 times. Brain enhancement MRI examination is performed every 3 months in first two years, and then performed every 6 months until the brain metastasis occur.
9690863|NCT04829708|Experimental|MRI Arm|Patients undergo enhancement MRI examination every 3 months in first two years, and then performed every 6 months until the brain metastasis occur. Once brain metastases occur, brain radiotherapy and systemic treatment should be conducted with the follow-up observation of brain enhancement MRI continuing.
9690864|NCT04829864|Experimental|STEP|Participants will participate, online or in-person, to the 8-9 sessions of the program addressing the psychological experience of pregnancy and supporting reflective capacities in relation to trauma and motherhood.
9690865|NCT04829864|No Intervention|Usual prenatal cares|Participants of the comparison group will receive usual prenatal cares (ex. prenatal classes)
10181047|NCT03787459|Active Comparator|oseltamivir plus placebo|
10181048|NCT03787459|Experimental|oseltamivir plus arbidol|
10181049|NCT03787394|Experimental|FAAA-enriched|food products enriched with FAAA-conjugates
10181050|NCT03787394|Placebo Comparator|Plain|Food products without FAAA-conjugates
10181051|NCT03787706|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
10181052|NCT03787706|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
10181053|NCT03787381|Other|Intervention|Uterine scar will be evaluated by vaginal ultrasound examination
10181054|NCT03787524||Dysphagia group|Acute stroke patients who will be diagnosed dysphagia according to VFSS results.
9690866|NCT04829955|No Intervention|Observation phase|After screening and randomization for either the eccentric orientated intervention group or the concentric orientated intervention group, all measurements will be made for the first time by investigators at point A1. An observational phase for six weeks will follow to achieve an intern acceptance sampling for the measurements which will be used.
9690867|NCT04829955|Active Comparator|Eccentric training group|"Subjects in the eccentric training group (GEC) will attend six weeks of eccentric orientated training. The eccentric orientated training will use the cadence 3-0-1 for eccentric - break - concentric.~3 sessions/week~60 minutes per session including a warming up and cool down phase~6 exercises~total of 18 sessions"
9690868|NCT04829955|Active Comparator|Concentric training group|"The concentric training group (GCO) will attend six weeks of concentric orientated training. Each group will perform a manual resistance/bodyweight resistance training accentuating the concentric phase of the movement. The concentric orientated training will use the cadence 1-0-3 for eccentric - break - concentric.~3 sessions/week~60 minutes per session including a warming up and cool down phase~6 exercises~total of 18 sessions"
9690869|NCT04830046||Multiple Myeloma-MM patients|People with Multiple Myeloma-MM receiving covid 19 vaccine
9690870|NCT04830046||Waldenstrom's macroglobulinemia-WM patients|People with Waldenstrom's macroglobulinemia-WM receiving covid 19 vaccine categorized by treatment naïve, actively receiving BTK inhibitor,currently or previously treated.
9690871|NCT04829916|Experimental|RMC-035|Participants will receive RMC-035 intravenously
9690872|NCT04829916|Placebo Comparator|Placebo|Participants will receive matching placebo solution intravenously
9690873|NCT04829838|Experimental|Intravenous levetireacetam|Drug:Intravenous levetireacetam will be given at a loading dose of 20-30mg/kg then it will be added in maintainance dose of (5-30mg/kg/day)
9690874|NCT04829838|Experimental|intravenous phenytoin|Intravenous phenytoin will be given in loading dose of 20mg/kg then it will be added in maintainance dose i-e 5-8mg/kg/day
9690875|NCT04829942|Experimental|experimental|A 12-week training program will be applied to the experimental group. Pre-tests will be applied before the trainings begin, and height and weight measurement, nutrition, health perception and behavior scale and physical activity scale will be applied to the experimental group and the control group within the 3rd and 6th month after the training program begins. Scale applications will be applied within 2 days, taking into account the attention span of the students.
9690876|NCT04829942|No Intervention|no intervention|Power point presentations will be given to the control group
9690877|NCT04829786|Experimental|Japanese group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
9690878|NCT04829786|Experimental|non-Asian group|The subjects will receive in Period 1 either the low-dose or high-dose first, and in Period 2 they will receive the alternate dose. There is a washout period between periods.
9690879|NCT04829851||Health Care Professionals|Registered health care professional, such as a General Practitioner/ Dietitian/ Nutritionist/ Registered Exercise Professional (REPs) etc. who sees clients for assistance with weight management and / or iron deficiency or diet quality.
9690880|NCT04829851||Adults who are Overweight|Adults (> 18 years) who are considered to be overweight (25 - 30 kg/m2) but are otherwise in good physical health and a regular android smart phone/ tablet user.
9690881|NCT04829851||Adults with Iron Deficiency Anaemia|Adults (> 18 years) who have been diagnosed with Iron deficiency anaemia but are otherwise in good physical health and a regular android smart phone/ tablet user.
9690882|NCT04829851||Adults with Low- Fruit/ Vegetable Intake|Adults ( > 18 years) with a low fruit and vegetable intake (2-3 portions/ d) but are otherwise in good physical health and a regular android smart phone/ tablet user.
9690883|NCT04829773|Experimental|PK Cohort 1|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence A-B-C: Subjects received a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
9690884|NCT04829773|Experimental|PK Cohort 2|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence B-C-A: Subjects received a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; and then followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast)."
9690885|NCT04829773|Experimental|PK Cohort 3|"Subjects received three single oral doses of palovarotene on Days 1, 6, and 11, separated by 5-day washout periods.~Sequence C-A-B: Subjects received a single oral dose of palovarotene sprinkled on 1 teaspoon of apple sauce, administered 30 minutes after the start of a standardized high-fat, high-caloric breakfast; followed by a single oral dose of palovarotene whole capsule under fasting conditions (at least a 10-hour overnight fast); and then followed by a single oral dose of palovarotene whole capsule 30 minutes after the start of a standardized high-fat, high-caloric breakfast."
9690886|NCT04829773|Experimental|Drug-Drug interaction (DDI) Cohort|On the morning of Day 1, subjects received a single dose of midazolam 30 minutes after the start of a standardized breakfast. On Day 2 (after the 24-hour midazolam blood draw) through Day 15, subjects received a daily, single dose of palovarotene in the morning 30 minutes after the start of a standardized breakfast. A second dose of midazolam was administered on Day 15 in the morning (immediately following the palovarotene dose) 30 minutes after the start of a standardized breakfast.
9690887|NCT04829760|Experimental|Psyllium|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to at least 8 ounces (240 mL) of cold water or a beverage that is typically consumed. Participants will ingest the intervention each morning and evening for eight weeks.
9690888|NCT04829760|Experimental|Coarse wheat bran|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to a food they normally eat.
10181055|NCT03787524||No dysphagia group|Acute stroke patient who showed no dysphagia according to VFSS results.
9690889|NCT04829760|Placebo Comparator|Maltodextrin|Volume equivalent to the psyllium. Participants will be instructed to divide the daily dose into 2 doses and ingest by adding the product to a food or to 8 ounces (240 mL) of a beverage that is typically consumed.
9690890|NCT04829695|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
9690891|NCT04829695|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
9690892|NCT04829643|Experimental|PET/MRI|Patients with early breast cancer up to 3 cm without overt nodal involvement who are candidates to upfront surgery
9690893|NCT04829331|Experimental|Restrata with a split-thickness skin graft|
9690894|NCT04829331|No Intervention|Split-thickness skin graft alone|
9690895|NCT04829253|Experimental|b-DBT (Brief Dialectical Behavioral Therapy)|3 months of and intensive modified DBT intervention.
9690896|NCT04829253|Active Comparator|s-DBT (standard Brief Dialectical Behavioral Therapy)|6 months of a standard DBT intervention (this is a shorter version of the original 12-month DBT, but includes all four active components delivered over 6 months)
9690897|NCT04829279|Experimental|Case|Emergency patient transferred by CONNECT AI system
9690898|NCT04829279|No Intervention|Control|Emergency patient transferred by conventional EMS
9690899|NCT04829435|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
10181056|NCT03787355|Experimental|Cone Morse Connection Implants|2 neighboring Morse connection Implants
9690900|NCT04829435|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Two ascending dose cohorts: Cohort A (3 capsules thrice daily (TID) for a total of 9 capsules per day) and Cohort B (5 capsules thrice daily (TID) for a total of 15 capsules per day) will be evaluated for 7 days for each cohort.
9690901|NCT04829552||Control group: low dose group.|patients treated with subcutaneous low molecular weight heparin 40 mg once daily or unfractionated heparin 5000 IU twice or three times daily for at least 5 days.
9690902|NCT04829552||Study group: high dose group.|Patients treated with subcutaneous low molecular weight heparin 1 mg/kg twice daily or 1.5 mg/kg daily or a continuous intravenous infusion of unfractionated heparin for at least 5 days.
9690903|NCT04829396|Experimental|Fibre mixture|"Dietary supplement. A mixture of fibres will be administered consisting of 10g of acacia gum powder and 3g of carrot powder.~The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day."
9690904|NCT04829396|Placebo Comparator|Placebo for Fibre mixture|A placebo of the mixture of fibres will be administered.
9690905|NCT04829578|Other|Hypnosis|hyspnosis treatment
9690906|NCT04829487|Experimental|Vitamin D|Vitamin D 50,000 IU orally weekly for 8 weeks
9690907|NCT04829487|Placebo Comparator|Placebo|Placebo capsules orally weekly for 8 weeks
9690908|NCT04829344|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
9690909|NCT04829344|Placebo Comparator|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
9690910|NCT04829500|No Intervention|Pre-Intervention Baseline Collection Phase|All sites will start with a baseline collection phase without exposure to the intervention, consistent with the stepped wedge cluster randomized trial design. A sequential randomized crossover to the intervention (MAP-VA) will be assigned, which cannot be reversed once it has been introduced.
9690911|NCT04829500|Experimental|MAP-VA Intervention|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities such as implicit learning, procedural memory, reading abilities. Staff training provides practice with: 1) pre-developed activities and templates, 2) a simple reading assessment to inform development of external cues; and 3) identifying opportunities for increased independence and resident contribution to community routines. Staff are also introduced to concrete strategies that improve dignity, control, and independence.
9690912|NCT04829565|Experimental|botulinum toxin|50 IU of botulinum toxin
9690913|NCT04829565|Placebo Comparator|placebo|50 IU of placebo
10181057|NCT03787355|Active Comparator|platform matched implants|2 neighboring platform matched implants.
9690914|NCT04829045|Experimental|Acupuncture plus diabetic routine care|Subjects will receive acupuncture treatment using press needles
9690915|NCT04829045|Placebo Comparator|Placebo plus diabetic routine care|Subjects are given placebo
9690916|NCT04829071|Experimental|Evaluating motor learning and brain structures post-stroke|We will use a single arm design to determine the impact of post-stroke cognitive impairment on two forms of motor learning (implicit and explicit) and evaluate the structural integrity of relevant brain structures in 65 individuals post stroke
9690917|NCT04829292|Experimental|Open treatment|Supportive therapy followed by CBT
10181058|NCT03787641|Other|Protamine doze|Protamine Sulfate will be administered through an infusion pump in aliquots at a predefined rate (25 mg/min). Blood samples will be withdrawn after each aliquot and quantified for anti-Xa, IIa and ACT.
10181059|NCT03787238|Experimental|non-invasive Vagus Nerve Stimulation|nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
10181060|NCT03787238|No Intervention|Standard of Care|Standard of Care treatment
10181061|NCT03787342|Experimental|"DFI Double Flap Incision"|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
10181062|NCT03787342|Experimental|"MPRI Modified PRI"|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
10181063|NCT03787342|Experimental|"CALF Coronally Advanced Lingual Flap"|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
10181064|NCT03787342|Active Comparator|"PRI Periosteal Releasing Incision"|A full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured as a whole unit.
10181065|NCT03787511|Other|Diabetic patients with chronic cough|Diabetic patients with chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
10181066|NCT03787511|Other|Diabetic patients without chronic cough|Diabetic patients without chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
9690918|NCT04829097|Experimental|SIB-IMRT|1. New auxiliary TMZ period: oral TMZ 75mg/m2, qd, continued until the beginning of radiotherapy. 2. Concurrent radiotherapy and chemotherapy period: 4 weeks in total. Prior to treatment, radiotherapy positioning and planning were established, using SIB-IMRT technology, the irradiation range, the tumor residual area 60Gy/20f/4w, the tumor bed area 40Gy/20f/4w, 1 time/d, 5 times/w. During radiotherapy, TMZ will continue to be administered orally simultaneously, the specific dose: TMZ 75mg/m2 qd, until 42 days. 3. Intermediate rest period: 4 weeks in total. ;4. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; after cycles 3, 6, 9, and 12 of adjuvant chemotherapy Head functional magnetic resonance examination was performed to assess the size of residual lesions and edema.
9690919|NCT04829097|Active Comparator|CRT|1. Concurrent radiotherapy and chemotherapy period: 6 weeks in total. Radiotherapy positioning and planning before treatment, using CRT technology, irradiation range, tumor bed area, 60Gy/30f/6w, 1 time/d, 5 times/w, simultaneous TMZ oral administration on the first day of radiotherapy, specific dose: TMZ 75mg/m2 qd for 42 consecutive days; head functional magnetic resonance imaging was performed at the end of radiotherapy to assess the size of residual lesions and edema. 2. Intermediate rest period: 4 weeks in total. The patient will go to the hospital to recheck blood routine every week;3. TMZ adjuvant chemotherapy period: 6 to 12 months in total. Cycle 1: TMZ 150mg/m2, d1-5, q28d; if the patient can tolerate it, cycles 2-12: TMZ 200mg/m2, d1-5, q28d; head functional magnetic resonance imaging was performed after adjuvant chemotherapy in cycles 3, 6, 9, and 12 to assess the size of residual lesions and edema.
10181067|NCT03787693|No Intervention|Stroke Symmetric Non-VR|In this control arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
10181068|NCT03787693|Experimental|Stroke Symmetric VR|In this experimental arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
10181069|NCT03787693|No Intervention|Stroke Asymmetric Non-VR|In this control arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
10181070|NCT03787693|Experimental|Stroke Asymmetric VR|In this experimental arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
10181071|NCT03787329||Bone marrow concentration group|The patients receive core decompression surgery with bone marrow concentration.
10181072|NCT03787329||Historical control group|The previous age-, gender-, and stage-matched patients who received core decompression surgery only.
10181073|NCT03787225|Experimental|NNC0174-0833 (0.3 mg)|Participants will receive single dose of NNC0174-0833
10181074|NCT03787225|Experimental|NNC0174-0833 (0.9 mg)|Participants will receive single dose of NNC0174-0833
10181075|NCT03787225|Experimental|NNC0174-0833 (1.8 mg)|Participants will receive single dose of NNC0174-0833
10181076|NCT03787225|Placebo Comparator|Placebo (NNC0174-0833)|Participants will receive placebo (NNC0174-0833)
10181077|NCT03787186|Experimental|GLPG1690 oral and IV|GLPG1690 film-coated tablets followed by [14C]-GLPG1690 solution for infusion
10181078|NCT03787186|Experimental|[14C]-GLPG1690 capsules|[14C]-GLPG1690 capsules
10181079|NCT03787316|Experimental|Experimental group|4-weeks use of specially produced shock absorbing insoles and the daily home exercise program during this 4 weeks. Daily exercises include M. gastrocnemius, soleus, tibialis anterior, tibialis posterior stretching, strengthening of the anterior, lateral, posterior compartmental and foot intrinsic muscles of the foot, eccentric exercise of gastrocnemius and soleus.
10181080|NCT03787407|Experimental|Mindfulness training with neurofeedback|mindfulness training with neurofeedback using mobile application instruction and review of the application will be provided
10181081|NCT03787407|Active Comparator|Mindfulness training|mindfulness training using mobile application instruction and review of the application will be provided
10181082|NCT03787407|No Intervention|Self-care|
10181083|NCT03787420|Active Comparator|traditional communication system|
10181084|NCT03787420|Experimental|intelligent communication system|
10181085|NCT03787446||Multiple Sclerosis (MS) patients|3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
10181086|NCT03787446||Healthy Controls (HC)|3 Healthy volunteers aged between 18-60 years of age
9690920|NCT04829227|Experimental|face and/or neck and/or submental zones|the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck
9690921|NCT04829227|Experimental|"off the face areas"|"off the face areas: abdomen, or arms or thighs or Décolleté."
9690922|NCT04829201||Obstructive sleep apnea (OSA)|OSA patients who are eligible for either functional septorhinoplasty or oropharyngeal/orthognathic surgery
9690923|NCT04829162|Experimental|Mother with obesity, daughter with obesity|Image of a mother with obesity and a daughter with obesity.
9690924|NCT04829162|Experimental|Mother with obesity, daughter without obesity|Image of a mother with obesity and a daughter without obesity.
9690925|NCT04829162|Experimental|Mother without obesity, daughter with obesity|Image of a mother without obesity and a daughter with obesity.
9690926|NCT04829162|Experimental|Mother without obesity, daughter without obesity|Image of a mother without obesity and a daughter without obesity.
9690927|NCT04829162|Experimental|Mother with obesity, son with obesity|Image of a mother with obesity and a son with obesity.
9690928|NCT04829162|Experimental|Mother with obesity, son without obesity|Image of a mother with obesity and a son without obesity.
9690929|NCT04829162|Experimental|Mother without obesity, son with obesity|Image of a mother without obesity and a son with obesity.
9690930|NCT04829162|Experimental|Mother without obesity, son without obesity|Image of a mother without obesity and a son without obesity.
9690931|NCT04829162|Experimental|Father with obesity, daughter with obesity|Image of a father with obesity and a daughter with obesity.
9690932|NCT04829162|Experimental|Father with obesity, daughter without obesity|Image of a father with obesity and a daughter without obesity.
9690933|NCT04829162|Experimental|Father without obesity, daughter with obesity|Image of a father without obesity and a daughter with obesity.
9690934|NCT04829162|Experimental|Father without obesity, daughter without obesity|Image of a father without obesity and a daughter without obesity.
9690935|NCT04829162|Experimental|Father with obesity, son with obesity|Image of a father with obesity and a son with obesity.
9690936|NCT04829162|Experimental|Father with obesity, son without obesity|Image of a father with obesity and a son without obesity.
9690937|NCT04829162|Experimental|Father without obesity, son with obesity|Image of a father without obesity and a son with obesity.
9690938|NCT04829162|Experimental|Father without obesity, son without obesity|Image of a father without obesity and a son without obesity.
9690939|NCT04829032||Hartmann's procedure|Evaluate the role of Hartmann's procedure in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
9690940|NCT04829032||Colonic resection with primary anastomosis|Evaluate the role of colonic resection with primary anastomosis in emergency setting for left-sided acute surgical colonic disease (perforated diverticulitis with purulent or fecal peritonitis; colon cancer perforation-obstruction; ischemic colitis; abdominal trauma).
9690941|NCT04829123|Experimental|Single dose of 0.5 mg HEC88473|Healthy subjects, receiving a single dose of 0.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
9690942|NCT04829123|Experimental|Single dose of 1.7 mg HEC88473|Healthy subjects, receiving a single dose of 1.7 mg HEC88473 (N=6) or placebo(N=2) after meal.
9690943|NCT04829123|Experimental|Single dose of 5.1 mg HEC88473|Healthy subjects, receiving a single dose of 5.1 mg HEC88473 (N=6) or placebo(N=2) after meal.
9690944|NCT04829123|Experimental|Single dose of 10.2 mg HEC88473|Healthy subjects, receiving a single dose of 10.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
9690945|NCT04829123|Experimental|Single dose of 17.0 mg HEC88473|Healthy subjects, receiving a single dose of 17.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
9690946|NCT04829123|Experimental|Single dose of 25.5 mg HEC88473|Healthy subjects, receiving a single dose of 25.5 mg HEC88473 (N=6) or placebo(N=2) after meal.
9690947|NCT04829123|Experimental|Single dose of 34.0 mg HEC88473|Healthy subjects, receiving a single dose of 34.0 mg HEC88473 (N=6) or placebo(N=2) after meal.
10181087|NCT03787108||Children with suspected NAFLD|Children with overweight or obesity. Both children that are and children that are not suspected of having NAFLD (based on ultrasound and laboratory findings) are included.
10181088|NCT03787134|Experimental|2016-0500-Healthy YoungAdults|working memory and attention
10181089|NCT03787264|Experimental|BAAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated~Induction: 6 cycles (q 28d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance treatment will be continued until (whichever occurs first):~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity~maintenance cycle 8~progression of CLL or start of a subsequent therapy~unacceptable toxicity"
10187544|NCT03725254|Experimental|radical chemoradiotherapy|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.
10187545|NCT03725241|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
10187546|NCT03725241|Experimental|Experimental: Glutathione|Intervention: Dietary Supplement: Glutathione supplement
10187547|NCT03725228|Active Comparator|Magnesium Sulfate|Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
10187548|NCT03725228|Experimental|Lidocaine|Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
9690948|NCT04829123|Experimental|Single dose of 44.2 mg HEC88473|Healthy subjects, receiving a single dose of 44.2 mg HEC88473 (N=6) or placebo(N=2) after meal.
9690949|NCT04829123|Experimental|Multiple doses of 1.7 mg HEC88473|Healthy subjects, receiving a weekly dose of 1.7 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
9690950|NCT04829123|Experimental|Multiple doses of 5.1 mg HEC88473|Healthy subjects, receiving a weekly dose of 5.1 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
9690951|NCT04829123|Experimental|Multiple doses of 10.2 mg HEC88473|Healthy subjects, receiving a weekly dose of 10.2 mg HEC88473 (N=10) or placebo (N=2) for 5 consecutive weeks after meal.
9690952|NCT04829266|Experimental|process simulation group|an experimental group with process simulation with elements of relaxation
9690953|NCT04829266|Experimental|outcome simulation group|an experimental group with outcome simulation with elements of relaxation
9690954|NCT04829266|Other|control group|a control group with no process and outcome simulations, but with elements of relaxation
9690955|NCT04829019|Active Comparator|whole-brain irradiation (WBI) plus Osimertinib|Osimertinib plus WBI, with Osimertinib at a dose of 80 mg once per day.
9690956|NCT04829019|Active Comparator|Osimertinib|Osimertinib with WBI sequential therapy, with Osimertinib at a dose of 80 mg once per day.
9690957|NCT04828967|Experimental|Hypnosis group|Hypnosis is added to the conventional group.
9690958|NCT04828967|No Intervention|conventional group|only conventional group
10181090|NCT03787160|Active Comparator|CDH Group|10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
9690959|NCT04829188|Active Comparator|Structured Telephone Support (STS)|Post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care provider (PCP) within seven days post-discharge.
9690960|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Standard Response Team (RPM-Low, Standard Team)|Questions are pushed to members patients times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
9690961|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Standard Team (RPM-High, Standard Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' primary care provider (PCP) or specialist to coordinate care and ensure timely follow-up.
9690962|NCT04829188|Active Comparator|Low-intensity Remote Patient Monitoring (RPM) + Enhanced Team (RPM-Low, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives).
9690963|NCT04829188|Active Comparator|High-intensity Remote Patient Monitoring (RPM) plus the Enhanced Team (RPM-High, Enhanced Team)|Questions are pushed to patients multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team. RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans.Team members (e.g., CRNP, social workers, nurses) address RPM triggers, meet with the patient three times, pharmacy review, develop care plans, and discuss advance directives).
10181091|NCT03787160|Other|Control Group|10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).
10181092|NCT03787485||LINKS Participants|Study participants who took part in the LINKS intervention.
10187549|NCT03725215|Experimental|Split-Belt Treadmill Training 1:2|Split-Belt Training with a steady ratio of 1:2.
10187550|NCT03725215|Experimental|Split-Belt Treadmill Training 3:4|Split-Belt Training with a steady ratio of 3:4.
10181093|NCT03787485||Electronic Medical Record Controls|The principal analytical strategy is propensity score matching, which will lead to the generation of a natural control group from the health centers existing electronic medical records. Propensity matching is highly effective in addressing selection bias of known confounders and enables causal inferences when randomization is not possible, feasible or appropriate, by creating matched groups with similar covariate distributions. Matched controls will be extracted from the electronic medical record from the participating clinics.
10181094|NCT03787199|Experimental|Andago|Application of walking over-ground with body-weight support in the Andago
10181095|NCT03787199|Active Comparator|Treadmill|Application of walking on a treadmill with body-weight support
9690964|NCT04828980|Active Comparator|Mindfulness Virtual Reality Experience|Patients will be provided with a mindfulness VR experience for use up to 15 minutes at bedside.
9690965|NCT04828980|Active Comparator|Gaming Virtual Reality Experience|Patients will be provided with an active gaming VR experience for use up to 15 minutes at bedside.
10181096|NCT03786939|Other|On-pump CABG.|On-pump CABG.
10181097|NCT03786939|Other|Off-pump CABG.|Off-pump CABG.
9690966|NCT04829370|Active Comparator|PLT|All subjects are treated with fractional carbon dioxide laser, then applied 2 mL PLT solution (dissolved in normal saline) on the right face.
9690967|NCT04829370|Placebo Comparator|Saline|All subjects are treated with fractional carbon dioxide laser, the left face (control group) be applied 2 mL normal saline
9690968|NCT04828941|Experimental|Electronic Headache Diary|The electronic headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
9690969|NCT04828941|Active Comparator|Paper Diary|The paper headache diary registers: total number of days with headache per month, number of days with migraine per month, number of days with tension headache per month, number of days taking SOS medication per month, number of days with incapacity for work per month, number of days in which patient goes to the emergency department.
10181098|NCT03786939|Other|Pump-assisted CABG.|Pump-assisted CABG.
10187551|NCT03725215|Experimental|Split-Belt Treadmill Training Changing|Split-Belt Training with changing ratios between 3:4 to 1:2.
10187552|NCT03725215|Active Comparator|Split-Belt Treadmill Training Tied-Belt|Split-Belt Training with tied belts.
10187553|NCT03725189|Experimental|PPG Group|Testing of PPG device in healthy adult population doing cardiovascular exercise
10187554|NCT03725163|Experimental|Treatment|This arm will begin treatment immediately after completing the initial intake assessment.
9690970|NCT04828954|Active Comparator|2 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint for 2 weeks following their thumb CMC arthroplasty
9690971|NCT04828954|Active Comparator|6 weeks of immobilization|Subjects randomized to this arm will be rigidly immobilized in a plaster postoperative thumb spica splint, transitioned to cast, for a total of 6 weeks following their thumb CMC arthroplasty
9690972|NCT04829149||Statin therapy group (No interventional)|Observational. Statin therapy group: Once daily administered per the locally approved product information of rosuvastatin, simvastatin, atorvastatin, pitavastatin etc,. (except Rosuzet Tab.)
9690973|NCT04829149||Rosuzet tablet group (No interventional)|Observational. Rosuzet Tab.(ezetimibe/rosuvastatin) group: once daily administered per the locally approved product information of Rosuzet Tab. 10/5mg, 10/10mg, 10/20mg
9690974|NCT04828928|Experimental|proportion of patients with neuropathy|to prospectively study patients with a wild-type amyloid cardiopathy condition to identify and describe the associated neuropathy
9690975|NCT04828824|Experimental|COCR Arm|Participants in the COCR arm will receive three packs of combined oral contraceptive pills (35mcg ethinyl estradiol/norgestimate) and a specific protocol for their use for bothersome bleeding.
9690976|NCT04828824|No Intervention|SOC Arm|Participants in the SC arm will be offered care according to our standardized protocol, which may include STI testing, reassurance and monitoring, prescription of COCs if desired, or removal.
9690977|NCT04828720|Active Comparator|PRF group|"The PRF was prepared according to Choukroun et al. [5] immediately before surgery, a 10 ml blood sample was taken by venipuncture of the antecubital vein without anticoagulant. The tubes were centrifuged immediately by a dedicated centrifuge at 3,000 rpm for 10 minutes.~A structured fibrin clot was produced by such preparation protocol in the middle of the tube, with the erythrocytes at the bottom and acellular plasma at the top. Following elimination of acellular plasma, a sterile scissors was used to separate the PRF from the erythrocytes. A membrane of PRF was formed by squeezing it gently between two pieces of gauze. Folding of the membrane was performed to achieve the required thickness (1.0 mm) with accurate trimming to match the palatal wound. The obtained membrane was then placed at the palatal donor site and compressed with gauze. Then, it was secured with 3-0 black plaited silk and a stent was placed."
9690978|NCT04828720|Placebo Comparator|Control group|the palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in control group used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
9690979|NCT04828720|Experimental|ozonated group|the palatal wound in ozanaited group will be painted by ozainated oil 2ml daily for 1 week, Patients used a soft stent to protect the palatal donor wound site . Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
9690980|NCT04828681||Patients with Angio-IMR>40 Unit|Patients with angio-IMR>40U in the culprit vessel after successful primary PCI.
10187555|NCT03725163|Other|Waitlist Control|Participants assigned to the waitlist control condition will begin a 12-week waiting period after completing the initial intake assessment before starting treatment.
10187556|NCT03725137||Group A (young stroke)|Young stroke patients (≤ 55); Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), cognitive tests; structural MRI
10187557|NCT03725124||Patients|Women with inflammatory bowel disease (IBD.
9690981|NCT04828681||Patients with Angio-IMR≤40 Unit|Patients with angio-IMR≤40U in the culprit vessel after successful primary PCI.
10181099|NCT03787433||ARC - Assisted Rehabilitation Care|All study participants will be asked to use ARC during for their post-stroke home based rehabilitation for up to 6 months.
10181100|NCT03787056|Other|Cancer patients|420 patients affected by different types of cancer and treated in a curative or a palliative intent. In total 17 cohorts will be open, including: breast cancer, head and neck carcinomas, renal cell carcinoma, prostate carcinoma, lung carcinoma, hepatocellular carcinoma, colorectal carcinoma, thyroid cancer, pancreatic adenocarcinoma, ovarian adenocarcinoma, glioblastoma, endometrial adenocarcinoma, bladder carcinoma, oesophago-gastric carcinoma, B-cell lymphoma, gastric carcinomas. Patients enrolled in curative intent treatment cohorts will never have been previously treated for their cancer. Patients enrolled in non-curative intent treatment cohorts will have never been treated for their metastatic cancers previously, or have developed advanced/metastatic diseases as relapses of localized cancers previously treated with curative intent therapeutic strategies. Other cohort will be open (stability cohorts) : nychtemer cohort and post-operative kinetic cohort.
10181101|NCT03787147|Other|Spinal Injection|Adults receiving Spinal Injection(SI) without Virtual Reality(VR).
9690982|NCT04828863||Index subjects|25 young adults with MSUD who are between the ages of 21 and 35 years-old
9690983|NCT04828863||Control subjects|25 age-matched siblings or acquaintances who do not have MSUD and are between ages 21-35 years old
9696255|NCT04768738|Experimental|Subthreshold Group|In the subthreshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
9696256|NCT04768738|Sham Comparator|Control Group|In the control group, bicycle exercise was performed under the same load with the current-free headset produced for sham applications for 5 minutes. Participants were shown that the device was working, but no current was given.
9696257|NCT04768673|Experimental|Group 1|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation I / Period 3: CKD-393 Formulation II
9696258|NCT04768673|Experimental|Group 2|Period 1: CKD-393 Formulation I / Period 2: CKD-393 Formulation II / Period 3: CKD-501, D759, H053
9696259|NCT04768673|Experimental|Group 3|Period 1: CKD-393 Formulation II / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation I
9696260|NCT04768673|Experimental|Group 4|Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation II / Period 3: CKD-393 Formulation I
9696261|NCT04768673|Experimental|Group 5|Period 1: CKD-393 Formulation I / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation II
9696262|NCT04768673|Experimental|Group 6|Period 1: CKD-393 Formulation II / Period 2: CKD-393 Formulation I / Period 3: CKD-501, D759, H053
9696263|NCT04768712|Experimental|Weight bearing aerobic exercise|
9696264|NCT04768712|No Intervention|Lifestyle counseling|
9696265|NCT04768556|Experimental|ADHD group|ADHD group: 20 participants having received a positive diagnosis of ADHD
9696266|NCT04768556|Other|Control group 1|Control group 1: 20 participants having received a negative diagnosis of ADHD
9696267|NCT04768556|Other|Control group 2|Control group 2: 20 participants as healthy volunteers
9696268|NCT04768985|Experimental|Treatment sequence 1: Treatment AB|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment A; Treatment B) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
10181102|NCT03787147|Active Comparator|Google Cardboard|Adults receiving SI while using Google Cardboard Virtual reality head mounted display powered by a iPod touch
10181103|NCT03787147|Active Comparator|Oculus|Adults receiving SI while using VR with Oculus Rift.
9696269|NCT04768985|Experimental|Treament sequence 2: Treatment BA|Participants will be randomized to receive one of the two different treatment sequences. In each treatment sequence participant will receive fixed single doses of 100 mg acalabrutinib orally (Treatment B; Treatment A) in 2 treatment periods, under fasted conditions. Treatment A will include acalabrutinib tablet and Treatment B will include acalabrutinib capsule.
9696483|NCT04766710|Experimental|Community-based ART delivery (CAD)|The CAD model intervention will take place for 24 months. A total of 2000 registered stable people living with HIV will form into the CAD group. The investigators have developed the implementation guide, monitoring tools, quality assurance checklist, and lists of people living with HIV in selected ART clinics for the CAD model intervention. The first step will be to extract the data disaggregated by gender, age, and type of sub-populations, including adolescents, female entertainment workers, men who have sex with men, transgender women, and people who use drugs from the national database using the definitions introduced by the WHO. Once the list is completed with patient ART codes, a consultative meeting combined with the project orientation will be convened. Providers from the selected ART clinics and implementing partners at each site will divide stable people living with HIV into their respective groups based on the ART sites.
9696484|NCT04766710|Active Comparator|ART multi-month dispensing (MMD)|A total of 2000 registered stable people living with HIV will form into the control group and received standard services under the MDD model. The control-arm participants will visit the ART clinics and collect their ARVs from the facility-based staff.
10181104|NCT03786861|Active Comparator|42 eyes in aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free in aberration free group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
9696485|NCT04766307|Experimental|experimental group|"Experimental group regimen:2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR+Interleukin-2 （500000 units daily, subcutaneous injection in the first month）~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
10181105|NCT03786861|Active Comparator|24 eyes in corneal WFG group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing corneal WFG patterns in corneal WFG group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
10181106|NCT03786887|Experimental|Nalbuphine|
10181107|NCT03786978|Experimental|Structured pharmaceutical care|Patients receive a structured pharmaceutical care until one year after hospital discharge
10181108|NCT03786978|Active Comparator|Comparator group|Patient received a single phone call 30 days after basal hospital discharge.
10181109|NCT03786848|Experimental|MiniPDX Group|Patients medication plan based on MiniPDX drug sensitivity test.
10181110|NCT03787043|Experimental|Sequence Group A|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fed"
10181111|NCT03787043|Experimental|Sequence Group B|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fed~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted"
10181112|NCT03787017|Experimental|Sequence Group A|"1st period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted~2nd period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted"
10181113|NCT03787017|Experimental|Sequence Group B|"1st period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted~2nd period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted"
10181114|NCT03787004|Experimental|Part 1 Cohort 1 (Single Dose)|Single 100 mg oral dose of CNTX-6970 (film-coated tablet or enteric-coated tablet)
10181115|NCT03787004|Experimental|Part 1 Cohort 2 (Single Dose)|Single 100 mg oral dose of CNTX-6970 film-coated tablet
10181116|NCT03787004|Experimental|Part 2 (Multiple Ascending Dose)|100 mg, 300 mg, and 600 mg CNTX-6970 oral tablet
10181117|NCT03787004|Placebo Comparator|Part 2 Placebo|Placebo oral tablet
10181118|NCT03786913||children with muscle disease|fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.
9690984|NCT04828759|Experimental|VR-treatment, then Treatment as usual|Participants will receive 8 weeks of VR-treatment. Participants are allowed to practice as much as they wish during the VR-intervention. However, they are given a recommendation of the amount of practice (5 h / week). Before the VR-intervention, the participants will receive a guidance for using the VR-devices (i.e. orientation period) by the SLT. Participants will be able to contact the SLT freely during the 8 weeks VR-intervention period. After the orientation period, the participants will be practicing at their homes independently. However, they will receive remote guidance by the SLT. The guidance includes weekly remote guidance sessions by SLT (8 x 45 min) to ensure that training is fluent and unproblematic. Additionally, the content of exercises can be modified during these sessions. The SLT is also able to monitor the training of participants with the system. Devices: VR headset and controller, Tablet computer.
9690985|NCT04828759|Experimental|Treatment as usual, then VR-treatment|Wait list control group: During the waitlist period the participants will receive the traditional speech and language therapy rehabilitation offered by (if offered) the general health care system in their own home municipality. The amount of rehabilitation is not controlled during the wait list period. However, the amount of received traditional speech and language rehabilitation in waitlist period will be documented. The waitlist control group will receive the same VR intervention period after the 8 weeks waitlist period.
9690986|NCT04828889|Experimental|research|The subjects in the study group will undergo a series of 4 treatments by 2 certified physiotherapists for pelvic floor treatment that will include instruction in self-use of anal dilators once a week for four weeks. The anal dilation will be performed using Dilatan® anal dilators (Enterprises Sapimed, Alessandria) in varying sizes of 22, 23 and 27 mm. In the first week, a 20 mm dilator will be inserted twice a day for at least 10 minutes. In the second week, a 23 mm extender will be inserted into the anus, twice a day for at least 10 minutes. In the last two weeks, a 27 mm extender will be inserted twice a day for at least 10 minutes. To facilitate the insertion of the extender, patients will use lubricating cream. At the end of each week, patients will meet with a pelvic floor physiotherapist to make sure that the insertion is done properly, that there are no side effects and that it is possible to move on to the next step.
9690987|NCT04828889|No Intervention|waiting|The subjects in the waiting group will be able after a month to choose to undergo surgery or also receive treatment by extenders.
10181119|NCT03786913||control group|20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline
10181120|NCT03786809|Experimental|Experimental|Women will use Cimifuga Racemosa for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
10181121|NCT03786809|Placebo Comparator|Placebo|Women will use Placebo for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
10181122|NCT03786822|Experimental|Non-fluoroscopic Cryoballoon PVI|"Observation of pressure waveform change at the tip of the cryoballoon catheter from left atrial pressure to pulmonary vein pressure waveform.~Intracardiac echocardiography (ICE) imaging with no Doppler color evidence of peri-balloon high velocity leaks.~Intracardiac echo imaging showing no evidence of leak during agitated saline contrast injection into cryoballoon catheter positioned at pulmonary vein ostium."
10181123|NCT03786822|Active Comparator|Fluoroscopic Cryoballoon PVI|Standard cryoballoon PVI using radio opaque contrast pulmonary vein angiography
10181124|NCT03786757|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy.
10181125|NCT03786757|No Intervention|dual antiplatelet therapy (DAPT)|Conventional dual antiplatelet therapy will be adopted.
10181126|NCT03787030|Experimental|Vitamin E acetate|Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
10187558|NCT03725124||Partners|Partners of women with IBD.
10187559|NCT03725124||Healthcare Professionals|Healthcare professionals working with women with IBD.
10187560|NCT03725111|Experimental|arterio venous leg ulcers|
9690988|NCT04828889|Active Comparator|surgery|The subjects in the surgery group will undergo surgical treatment only.
9690989|NCT04828876|Experimental|Yoga practice|The yoga practice will be held 2 days a week for 6 weeks, a total of 12 sessions. Each session is set as one hour
9690990|NCT04828876|No Intervention|Control group|Routine maintenance will be applied
9690991|NCT04828798|Active Comparator|Directional deep brain stimulation|Deep brain stimulation delivered in a directional manner within an axial plane
9690992|NCT04828798|Active Comparator|Nondirectional deep brain stimulation|Deep brain stimulation delivered in a nondirectional manner within an axial plane
9690993|NCT04828616|Experimental|DP303c injection|"Part1:Patients with HER2-expressing advanced ovarian cancer will be treated with DP303c injection at 2.0 mg/kg or 3.0 mg/kg every 3 weeks (Q3W) to determine the recommended phase 2 dose (RP2D).~Part2a:Patients with HER2-overexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D.~Part2b:Patients with HER2-lowexpressing advanced ovarian cancer will be treated with DP303c injection at RP2D."
9690994|NCT04828785|Experimental|Medically Tailored Meal (MTM)|The Medically Tailored Meal (MTM) intervention consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
10181127|NCT03787030|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
9690995|NCT04828785|Active Comparator|Food Subsidy|As a comparison group, those not randomized to receive the MTM intervention will receive usual care provided by their clinicians not associated with the study, plus a food subsidy ($30/month) for 6 months, along with healthy eating information to guide use of that subsidy.
10181128|NCT03786835|No Intervention|Control (No intervention)|Participants will not undergo any treatment. Continue with usual daily activities and diet for 6 months.
10181129|NCT03786835|Experimental|Nutrition group|Participants will receive protein enriched food to supplement the diet for 6 months.
10181130|NCT03786835|Experimental|Exercise group|Participants will exercise 3 times a week for 60 minutes each time over 6 months.
10181131|NCT03786835|Experimental|Nutrition + Exercise group|Participants will receive protein enriched food to supplement the diet and exercise 3 times a week for 60 minutes each time over 6 months.
9690996|NCT04828525|Experimental|Experimental|participants will be given corticosteroids in addition to conventional treatment
9690997|NCT04828525|Placebo Comparator|Placebo|participants will be given normal saline in addition to conventional treatment
9690998|NCT04828512||normal glucose tolerance (NGT)|In the 75-g OGTT, an FPG level of < 100 mg/dL or a 120-min PG level of < 140 was diagnosed as NGT.
9690999|NCT04828512||impaired glucose intolerance (IGT)|In the 75-g OGTT, an FPG level of 100-125 mg/dL (5.6-6.9 mmol/L) or a 120-min PG level of 140-200 mg/dL (7.8-11.1 mmol/L) was diagnosed as IGT.
9691000|NCT04828512||newly diagnosed DM (subclinical DM)|In the 75-g OGTT, a basal FPG level ˃126 mg/dL (7.0 mmol/L) or a 120-min PG level ˃200 mg/dL (11.1 mmol/L) was considered as newly diagnosed DM (hereafter referred to as subclinical DM).
9691001|NCT04828642|Active Comparator|Supplementation group|Antioxidant vitamins (Vitamin C (1000 mg) + Vitamine E (235 mg))
9691002|NCT04828642|Placebo Comparator|Placebo group|Placebo supplementation with the same aspect as supplementation
9691003|NCT04828655|No Intervention|CONTROL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity. Specific micronutrient intake focused on improving cardiovascular parameters and body composition.
9691004|NCT04828655|Experimental|EXPERIMENTAL GROUP|Recommendations on healthy eating habits based on the Mediterranean diet and moderate physical activity through an application based on machine learning. Intake of specific micronutrients focused on improving cardiovascular parameters and body composition.
10181132|NCT03786601||Group A,|High-risk HPV infection in postmenopausal women
10181133|NCT03786601||Group B|High-risk HPV negative in postmenopausal women
10181134|NCT03786601||Group C|High-risk HPV infection in gestational women
10181135|NCT03786601||Group D|High-risk HPV negative in gestational women
10181136|NCT03787069|Experimental|Lignocaine group|This group will be given 1.5 mg/kg I/V lignocaine before intubation
10181137|NCT03787069|Placebo Comparator|Placebo|This group will be given 6 ml normal saline before intubation
10181138|NCT03786679|Active Comparator|Orthosis group|An orthosis with the broken arm in neutral position fixed for four weeks. After these four weeks the patient is instructed to start rehabilitation.
10181139|NCT03786679|Active Comparator|Early rehabilitation group|The patient is instructed to start early rehabilitation about one week after the trauma.
10181140|NCT03786731|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
10181141|NCT03786731|No Intervention|CAU group|Care-As-Usual group
10181142|NCT03786705||Trauma patients' SBP ≥ 90 mm Hg with EMS|Only patients who were transferred by emergency medical service from the accident site with a systolic blood pressure ≥ 90 mm Hg at the ER were included in this study. The enrolled trauma patients divided into 2 groups, those who had received blood transfusion ≥ 10 U (massive transfusion) and those who had not (non-massive transfusion).
10181143|NCT03786874|Active Comparator|20 teams the first year (G1)|control group
10181144|NCT03786874|Experimental|20 teams second year (G2)|case group with implementation of the multi-unit team accompaniment intervention.
9691005|NCT04828629||Identification of prognostic factors in patients who have recovered from COVID-19|Selected prognosis factors will be analyzed in patients who have recovered from COVID-19
9691006|NCT04828694|Experimental|BICX104|BICX104 is an eroding implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.
9696270|NCT04768699|Experimental|TQG203(30µg/kg)|
9696271|NCT04768699|Experimental|TQG203(90µg/kg)|
10181145|NCT03786523|Experimental|TRF|Time Restricted Feeding
9691007|NCT04828694|Active Comparator|Vivitrol|Vivitrol intramuscular injection containing 380 mg of naltrexone. Three consecutive doses will be administered once every 28 days for 84 days.
9691008|NCT04828564|Experimental|Ribavirin Arm|"Ribavirin dosage: 200 mg oral ribavirin capsules for 5 days~Regimen: 1200 mg loading dose on day-1 (three capsules in the morning and three capsules in the evening) followed by 800 mg/day maintenance dose (two capsules in the morning and two capsules in the evening) on day-2 to day-5."
10181146|NCT03786523|Active Comparator|CER|Continuous Energy Restriction
10181147|NCT03786588||Group A|Vaginal microbiota in gestation CPP women without HPV infection
10181148|NCT03786588||GroupB|Vaginal microbiota in gestation women without CPP and HPV infection
10181149|NCT03786510|Active Comparator|Active control|The control group received Community Center for Dementia's usual care of regular health check-up.
10181150|NCT03786510|Experimental|Intensive + Maintenance program|The INT+MNT group participated in a 4-week intensive program followed by a 20-week maintenance program
10181151|NCT03786510|Experimental|Intensive program only|The INT only group participated in a 4-week intensive program
9691009|NCT04828564|Active Comparator|Favipiravir Arm|"Favipiravir dosage: 200 mg oral favipiravir tablets for 5 days~Regimen: 2x1600 mg loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5."
9691010|NCT04828551|Other|MGH and UCSD Study subjects|"This study will enroll patients with suspected or confirmed diagnosis of NAFLD. Based on protocol-specified FIB-4 values, about one-third are expected to have low, one-third to have intermediate, and one-third to have high likelihood of advanced fibrosis.~Sex: 50:50 - Note- no stratification will be done based on sex Age: ≥ 18 yrs Demographic group: Patients with a high probability of NAFLD based on the eligibility criteria General health status: Patients with suspected or confirmed diagnosis of NAFLD Geographic location: Boston, MA (greater metropolitan areas) and San Diego, CA (greater metropolitan areas)"
9691011|NCT04828915||Training cohort|Randomly selection of 80% of the study population. The machine learning algorithm is trained on this dataset
9691012|NCT04828915||Validation cohort|Randomly selection of 20% of the study population. The machine learning algorithm which was trained on the basis of the training data cohort is validated on the validation cohort.
9691013|NCT04828772||Cohort 1|COVID-19 participants receiving anticoagulants
9691014|NCT04828772||Cohort 2|COVID-19 participants not receiving anticoagulants
9691015|NCT04828447|Experimental|High Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet high in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
9691016|NCT04828447|Experimental|Low Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet low in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
9691017|NCT04828499|Experimental|Progressive Cracking Technique|Patients with hard nucleus cataract were treated with Progressive Cracking Technique.
9691018|NCT04828499|Experimental|Conventional Chop Technique|Patients with hard nucleus cataract were treated with Conventional Chop Technique.
9691019|NCT04828369||EUS-guided coil and cyanoacrylate injection|Patients who received EUS-guided coil embolization combined with endoscopic cyanoacrylate injection
9691020|NCT04828369||BRTO|Patients who received balloon-occluded retrograde transvenous obliteration (BRTO)
9691021|NCT04828122||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9691022|NCT04828122||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9691023|NCT04828122||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9691024|NCT04828122||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9691025|NCT04828135|Experimental|subjects with diagnosis of COVID-19 (Long-hauler)|23 subjects with a confirmed diagnosis of COVID-19 infection, and after 60 days or longer
9691026|NCT04828031|Experimental|Vitamin D 50,000 IU PO every week|Vitamin D 50,000 IU PO every week for 12 weeks
9696272|NCT04768699|Active Comparator|NovoSeven®(90µg/kg)|NovoSeven®,manufactured by Novo Nordisk Inc.
9696273|NCT04768699|Experimental|TQG203(180µg/kg)|
9696274|NCT04768894|Active Comparator|14-28 days|In group 1,the time interval between initial and re-TUR was 14-28 days,
10181152|NCT03786562|Placebo Comparator|Placebo group|
10181153|NCT03786562|Active Comparator|Nalbuphine group|
10181154|NCT03786614|Active Comparator|Discontinuation arm|This group will be discontinued from serotonergic antidepressants and shifting them to other categories of antidepressants, i.e., medications that work through dopamine or nor-epinephrine, or by reducing the serotonin signal rather than increasing synaptic serotonin, as might be accomplished with low dose, sub-anti-psychotic doses of some second-generation anti-psychotics.
10181155|NCT03786614|Active Comparator|Continuation arm|This group will continue taking serotonergic antidepressants which is the standard care of treatment.
10181156|NCT03786575|Experimental|NGS detection group|Before treatment, the patients in the study group underwent NGS detection of ctDNA and formulated endocrine treatment plan according to the test results. After 2 months of endocrine therapy, all patients underwent NGS detection of ctDNA, and the efficacy was evaluated according to RECIST v1.1 standard.
10181157|NCT03786536|Experimental|Treatment|All volunteers will receive the same treatment
10181158|NCT03786315||Usual care|Older patients with multimorbidity and the GPs with whom they consult, from across five GP practices in Devon
9691027|NCT04828213|Experimental|Tooth-borne RME appliance (Hyrax)|"In the Tooth-borne RME expander group, bands were placed to the maxillary right and left upper 1st premolar and 1st molar teeth. The impression of the upper jaw was obtained with the bands in mouth by using alginate impression material. In the laboratory process, a hyrax (Forestadent, Pforzheim, Germany; Forestadent USA, St Louis, Missouri, USA) expansion appliance with an expansion screw in the middle was prepared on the models by the same technician under standard conditions.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
9691028|NCT04828213|Experimental|Hybrid hyrax RME appliance|"Rapid Maxillary Expansion Treatment. In the Hybrid hyrax RME appliance group, mini-screws of 2 mm diameter and 9 mm length (Benefit mini-implants; PSM Medical Solutions; Tuttlingen, Germany) were placed 3 mm posterior and 1 to 5 mm paramedian to the incisive foramina.~RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months."
10181159|NCT03786328|Other|Clinical cases of Mental Disorder|The group of individuals identified with a clinical mental disorder on the basis of the diagnostic interviews This group will be assigned to Standard Psychiatric Treatment
10181160|NCT03786328|Other|Subclinical cases of Mental Disorder|The group of individuals identified with a sub-clinical mental condition on the basis of the diagnostic interviews This group will be assigned to Preventive Psychological Treatment
9691029|NCT04828421|Experimental|Probiotic group|Participants will be treated with a daily capsule of a multi-species probiotic (3.3 billion Lactobacillus rhamnosus and Bifidobacterium lactis) during 10 weeks.
9691030|NCT04828421|Placebo Comparator|Placebo group|Participants will receive a harmless substance (potato starch) during 10 weeks.
10181161|NCT03786289|Experimental|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection
10181162|NCT03786289|Active Comparator|Recombinant human erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection
9691031|NCT04828044||Microwave Ablation/ Coagulation Arm|These patients will receive microwave ablation using MedWaves Microwave Ablation/ Coagulation System.
9691032|NCT04828356|Experimental|Foot reflexology group|The first researcher received hands-on training about reflexology application before the study started. The researcher applied foot reflexology on the patients with liver transplantation in the experimental group in one session (30 minutes) after the operation. Patient confidentiality was maintained in all procedures. The patient identity form was implemented before reflexology application. Pain and comfort levels were assessed as the pre-test. Then, venous blood was taken to determine the plasma β-End level. Foot reflexology was first applied on the right foot, which is effective on the sympathetic nervous system, for 15 min and then, on the left foot, which is effective on the parasympathetic nervous system, for 15 min. Same process was performed on the left foot and the reflexology application was completed within 15 min. Venous blood was taken again to assess the β-End level as the post-test after the application, and the NPS and PCQ were implemented again.
9691033|NCT04828356|No Intervention|No treatment group|The patient identity form, NPS and PCQ were applied on the patients in the control group as the pre-test. After the questions were answered, venous blood was taken to determine the plasma β-End level. No intervention other than clinical protocol was applied on the control group, and after taking venous blood after 30 minutes to determine β-End level, the NPS and PCQ were re-applied as the post-test.
10181163|NCT03786276|Experimental|Exercise-Only|Exercise-Only condition, 12 exercise sessions on a stationary recumbent bicycle over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
10181164|NCT03786276|Experimental|VR-WMR-Only|Virtual Reality Working Memory Retraining-Only condition, 12 working memory retraining sessions over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
10181165|NCT03786276|Experimental|Active VR-WMR|After 4 weeks in one of the first two arms, the participants will have a 1-week washout followed by the Active VR-WMR arm. Participants will complete 12 Active VR-WMR sessions on a stationary recumbent bicycle over 4 weeks.
10181166|NCT03786419|Experimental|Atezolizumab|Participants with unresectable or advanced malignant pleural mesothelioma who have progressed after platinum-based chemotherapy will receive atezolizumab 1200 mg every 21 days, until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
9691034|NCT04828187||Study group|8 patients aged between 18 to 75 years with Uncorrected Distance Visual Acuity ≥ 5/10
9691035|NCT04828252|Experimental|808nm|The wavelength of this experimental group was 808nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
9691036|NCT04828252|Active Comparator|660nm|The wavelength of this experimental group was 660nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
9691037|NCT04828252|Placebo Comparator|Control|The wavelength of control group, total power: 0.0072W, 15 minutes a session, 3 times a week for 8 weeks
9691038|NCT04828174|Experimental|anti-TRBC1 CAR-T cell|Administration with anti-TRBC1 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients.
9691039|NCT04828096|Active Comparator|Penta-one retainer|Penta-one retainer is one wire that is been in use for many years. Penta-one retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retainers are going to be bonded with sandblasted enamel and half without.
9691040|NCT04828096|Experimental|Ortho-FlexTech retainer|Ortho-Flextech chain wire is relatively new in the market and needs to be evaluated. Ortho-Flextech retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
9696275|NCT04768894|Active Comparator|29-42 days|In group 2, the time interval between initial and re-TUR was 29-42 days
10187561|NCT03725072|Experimental|Evobrutinib|
10181167|NCT03786263||Prospective Treatments for NS|"Observation of children (between the ages of 1 and 17) who are diagnosed with Nephrotic Syndrome at their initial presentation, first or second relapse.~Observation of children who receive Glucocorticoids to treat Nephrotic Syndrome.~Observation of children who receive other drugs (Second Line Agents) for Nephrotic Syndrome."
10181168|NCT03786224|Experimental|Abstinent|
9691041|NCT04828096|Experimental|Memotain retainer|Memotain wire is relatively new in the market. It requires digital scanning and the technique is said to be very exact. Memotain retainer is to be bonded on the lower anterior 6 teeth (canine-to-canine)- Half of the retianers are going to be bonded with sandblasted enamel and half without.
9691042|NCT04828200||sarcopenic patints with knee ostheoarthritis|12 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients with sarcopenia.All subjects were evaluated by the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria for the diagnosis of sarcopenia.
10181169|NCT03786341|Experimental|with auxiliary illuminator|the walking training was by conventional strategy with lase quad-cane.
9691043|NCT04828200||non sarcopenic patients with knee ostheoarthritis|90 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients.
9691044|NCT04828200||control group|33 patients between the ages of 50-70, who have been followed up not being exposed to be sarcopenia or knee OA
9691045|NCT04828018||Key Staff|Key Staff will take part in one interview lasting up to 60 minutes
9691046|NCT04828018||In-Pensioners|Royal Hospital Chelsea In-Pensioners will take part in one interview lasting up to 90 minutes and complete n=2 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF) at the start of their qualitative interview.
9691047|NCT04828018||New In-Pensioner|New In-Pensioners wil be asked to complete a total of n=4 Quality of Life Questionnaires (ICECAP-A and WHOQOL-BREF), n=2 on admission to Royal Hospital Chelsea and n=2 six months after admission.
9691048|NCT04828083|Active Comparator|Ultrasound-guided adductor canal block with local anesthetic|Single shot Ultrasound-guided adductor canal block with 0.5% ropivacaine 30 ml
9691049|NCT04828083|Sham Comparator|Ultrasound-guided adductor canal block with saline|Single shot Ultrasound-guided adductor canal block with 30 mL of normal saline (Sodium chloride)
9691050|NCT04828291|Experimental|Online Mindfulness Intervention (OMI)|Before beginning the daily practices, this group will be introduced to the OMI via an online platform and answer any questions about the practice. Then, each day, this group will be guided through a series of mindfulness practices offered online (www.bemindfulonline.com) delivered on their smartphones or laptops.
9691051|NCT04828291|Experimental|OMI paired with peer support (OMI+)|Before beginning the daily OMI, in addition to being briefed, this group will be paired with a peer to be in touch with and guide and support each other in this process. Then they will start the OMI program and will follow parallel instructions as the OMI group. The peer support will include five brief (30-minute) weekly meetings to support and encourage each other to continue practicing mindfulness and to complete the online intervention. Each week we will provide prompts and topics for participants to discuss and at the end of each meeting, participants will then complete a short, 5-10 minute post-meeting survey to assess the well-being and attitudes of their partner (see additional materials for meeting prompts and post-meeting survey questions). The first of these meetings will occur on Day 8, and subsequent weekly meetings during the intervention period will be scheduled based on the shared availability of both participants in each pair.
9691052|NCT04828291|Active Comparator|Active control receiving cognitive exercises|Instead of the OMI, this group will be receiving cognitive exercises in the intervention period.
9691053|NCT04828278|Placebo Comparator|Treatment 1|1,600 mg of Placebo (maltodextrin)
9691054|NCT04828278|Active Comparator|Treatment 2|1,500 mg of ASI (bonded arginine silicate) + 100 mg of inositol (nooLVL)
9691055|NCT04828226|Experimental|Intervention|"The study drug (clonidine 2 mcg/kg) is diluted in 100 ml sodium chloride 0.9 % by trained post-anaesthesia care staff not involved in the study.~At admission, electrocardiogram, non-invasive blood pressure and pulse oximetry is installed, a peripheral venous line established and supplemental oxygen applied.~The study drug will be given intravenously over 10 minutes at least 10 minutes before induction of anaesthesia.~Electroconvulsive therapy will be conducted according to hospital standard (Etomidate 0.2 mg/kg, Suxamethonium 1.0 mg/kg, isolated limb technique, THYMATRON® SYSTEM IV, Somatics Inc., Lake Bluf, Illinois, USA) adjusted to the patient's condition. Seizure quality will be assessed, prolonged seizure activity terminated with propofol 0.2 - 0.3 mg/kg. Severe agitation (Richmond Agitation and Sedation Score (RASS) > 1) needing intervention will be treated with propofol or lorazepam. Patients will be assessed for delirium using CAM-ICU at 20 minutes after induction."
9691056|NCT04828226|Placebo Comparator|Control|The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application. The container will be identically labelled as the verum. The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing. All other parts of the procedure are identical as to the procedure described above.
9691057|NCT04827966|Active Comparator|Fluoride Varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride. 0.2-0.5ml of the varnish is applied onto the tooth surface after through cleaning. One coats of the varnish will be applied and patient will be instructed not to rinse with water or eat for 30 minutes. This is based on the manufacturer's instructions.
9691058|NCT04827966|Active Comparator|Tooth Mousse|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization. One tube of the Tooth Mousse will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
10181170|NCT03786341|Placebo Comparator|control group|Ambulation training WITHOUT laser quad-cane.
10181171|NCT03786354|Experimental|Arm A (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy over 5 weeks.
9691059|NCT04827966|Active Comparator|MI Paste|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes. Recent studies have investigated the remineralization potential of CPP-ACP combined with fluoride and have found a synergistic effect when these are administered together, which is the composition in MI paste. One tube of the MI Paste will be prescribed to the patient. Patient will be instructed to apply the product using finger every night after brushing and flossing. This is continued till the prescribed product is finished. This is approximately calculated to be about 8 to 12 weeks.Patient is instructed to leave the paste for about 3 minutes and then rinse. This is based on the manufacturer's instructions.
9691060|NCT04827966|Active Comparator|Acidulated phosphate fluoride gel|A stable thixotropic gel providing 1.23% fluoride ion. This is only for professional use and applied by the dentist. The teeth is cleaned and polished and the gel is applied onto a tray. It is filled upto one third of the tray according to manufacturer's instructions. The tray is then inserted into the mouth and the patient is asked to gently bite down lightly for 1 to 4 minutes.The tray is then removed and patient is asked to expectorate any material in the mouth. The patient is instructed not to eat, rinse or drink for 30 minutes.
9691061|NCT04827966|Active Comparator|Fluoride Mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts.
9691062|NCT04828304|No Intervention|control group|
9691063|NCT04828304|Experimental|treatment group|
9691064|NCT04827940|Experimental|intervention arm|"Data from the study was collected during the implementation of the Nursing Surgical Diseases class. Students who completed the 4-hour training program on sleep, relaxation exercises and survey practice have been pollsters of the study.~Relaxing music for sleep, prepared by the Turkish Psychological Association, is uploaded to patients' mobile phones. Patients were asked to perform relaxation exercises for a week at bedtime, lasting an average of 30 minutes, and with music every day, taking advantage of nurse observation at the clinic with the patient's declaration in check. Students who took part in the practice served as reminders of patients' compliance with the exercises."
9691065|NCT04827940|Other|Control arm|Those who did not do progressive muscle relaxation exercises or did not practice regularly for a week constituted the control group.
9691066|NCT04827511||cohort group|80 children with disabilities like autism, ADHD, Down syndrome, deafness, phocomelia, dyslexia, different motor problems
9691067|NCT04827511||control group|81 healthy children, not known or diagnosed with a chronic disease of any kind
9691068|NCT04827654|Experimental|Intervention group|Families in the intervention arm will receive a program of 4 weeks of access to fruit and vegetables through direct access (produce box) and a gift card to the grocery store for purchase of preferred produce.
10181172|NCT03786354|Experimental|Arm B (3DCRT)|Patients undergo 3-Dimensional Conformal Radiation Therapy over 5 weeks.
9691069|NCT04827654|No Intervention|Control Group|Families in the control group will not receive any produce boxes or gift cards during the study period. At the end of the study period they will receive gift cards of equivalent amount.
9691070|NCT04827693||Immediate|implants are placed immediately after tooth extraction
9691071|NCT04827693||Delayed|implants are placed months after the tooth has been extracted
9691072|NCT04827615|Other|High Risk|"Group 2: Of all adults in (1), those at high risk of diabetes and hypertension, defined as having a score >4 based on the following criteria:~Age 40-49 years (+1), age ≥50 years (+2)~Used to smoke or use smokeless tobacco products or sometimes currently use (+1), currently use daily (+2)~Currently consume alcohol daily (+1)~Waist circumference 81-90 cm (women)/91-100 cm (men) (+1), >90 cm (women)/>100cm (men) (+2)~Physical activity <150 minutes per week (+1)~Parent and/or sibling with high blood pressure, diabetes, or heart disease (+2)"
9691073|NCT04827615|Other|Eligible adults|Group 1: All adults ≥30 years old living in the 12 target villages who meet eligibility criteria and provide informed consent
9691074|NCT04827680|Experimental|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
9691075|NCT04827667||Patients with lung cancer|In lung cancer patients with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
9691076|NCT04827667||Patients wiht interstitial lung disease|In patients with interstitial lung disease with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
9691077|NCT04827667||Patients with asthma|In patients with asthma with indication for bronchoscopy, bronchoalveolar lavage is performed to assess PD1-lymphocytes.
9691078|NCT04827823||Group 1- Amalgam restorations|Multi-surface amalgam restorations performed by dental students and are in function for about 5 years.
9691079|NCT04827823||Group 2- Composite restorations|Multi-surface composite restorations performed by dental students and are in function for about 5 years.
9691080|NCT04827628|Experimental|Obese with Oryza sativa extract|The group with a body mass index of more than 25 kg/m2 that receive the Oryza Sativa Extract
9691081|NCT04827628|Active Comparator|Obese with control|The group with a body mass index of more than 25 kg/m2 that receive the citric acid and sorbitol mixture
9691082|NCT04827628|Active Comparator|Normal Body Mass Index|The group with a body mass index of less than 25 kg/m2 that receive the citric acid and sorbitol mixture
9691083|NCT04827589|Experimental|Tirabrutinib|Participant will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 8 weeks.
10181173|NCT03786172|Experimental|Smoking cessation Intervention|Standardised counseling session + motivational gadget + Nicotine replacement therapy (NRT)
10181174|NCT03786172|Active Comparator|Usual care|A 10-second brief advice to quit smoking
10181175|NCT03786458|Experimental|Cancer and Fertility Decision making|Cancer and Fertility Decision aid
9691084|NCT04827589|Placebo Comparator|Placebo|Participants will receive placebo twice daily in addition to their standard-of-care therapy for up to 8 weeks.
9691085|NCT04827589|Experimental|Tirabrutinib, Open Label Extension|At Week 8, participants who have not discontinued the study drug will receive tirabrutinib twice daily in addition to their standard-of-care therapy for up to 16 weeks.
9691086|NCT04827875|Experimental|AIV001 Treatment Dose 1|Intradermal, Dose 1
9691087|NCT04827875|Experimental|AIV001 Treatment Dose 2|Intradermal, Dose 2
9691088|NCT04827784|Experimental|Auriculotemporal Nerve Block Administration|A total of 3 doses of Auriculotemporal Nerve Block (ATNB) were administered to involved participants. Local anesthetic solutions containing Articaine Hydrochloride (80 mg / 2 ml) and epinephrine bitartrate (0.02 mg / 2 ml) were used for ATNB application. The injections were repeated on follow-up visits in the first and fourth weeks. The maximal mouth opening amounts, pain intensity values (via VAS scale), and self-reported outcomes were evaluated at the pre-injection, first week, fourth week, and sixth-month follow-up controls.
9691089|NCT04827862|Experimental|Pembrolizumab and Radiation Therapy|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
9691090|NCT04827849|Experimental|Experiment group|The study group will be provided physical examination, pregnancy monitoring and training on transition to motherhood within the direction of nursing care based on Meleis's Transition Period Theory, in addition to the usual care provided by healthcare professionals.
9691091|NCT04827849|No Intervention|Control group|The control group continued to receive the routine care
9691092|NCT04827719|Experimental|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
9976275|NCT01349764||No vitamin D replacement|The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
9976276|NCT01349764||Vitamin D3 tabs|The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.
9976277|NCT01349777|Experimental|Pregrel®|clopidogrel
9976278|NCT01349777|Active Comparator|Plavix®|clopidogrel
10181176|NCT03786302|Experimental|TAMP bioglass|Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
9691093|NCT04827888||underweight|patients who underwent one of the 25 common orthopaedic surgeries and have a body mass index (BMI) of <18.5kg/m2
9691094|NCT04827888||normal-weight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 18.5kg/m2 and 24.9kg/m2
9691095|NCT04827888||overweight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 25kg/m2 and 29.9kg/m2
9691096|NCT04827888||mildly obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 30kg/m2 and 34.9kg/m2
9691097|NCT04827888||moderately-to-severely obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI ≥35kg/m2
9691098|NCT04827797|Experimental|birth ball|The positions and movements for birth ball in the active and latent phases: kneeling on the ground and leaning on the spherical birthing ball, sitting on the ball with front support, sitting positions on the spherical birthing ball, full rotation of hip, moving to the right/left, back and forth. Positions and movements were repeated every 30 minutes. The 30-minute intervals were interrupted in cases where the women were not feeling well.
9691099|NCT04827797|Experimental|peanut ball|The positions and movements for the pregnant women in peanut ball: upright sitting position, forward bending positions, with backward and forward movement and swaying right and left on the peanut ball
9691100|NCT04827550||STUDY GROUP|diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
9691101|NCT04827550||CONTROL GROUP|90 healthy volunteers
9691102|NCT04827563||Participants with Normal Baseline Endothelial Function|
9691103|NCT04827563||Participants with Abnormal Baseline Endothelial Function|
9691104|NCT04827602||Allergy tested group|Patients who have completed penicillin allergy testing
9691105|NCT04827498||Myocardial ischemia without obstructive coronary stenosis|
9691106|NCT04827472|Experimental|Part1(Cohort1) : DWJ1521 Amg|
9691107|NCT04827472|Experimental|Part1(Cohort2) : DWJ1521 Bmg|
9691108|NCT04827472|Experimental|Part1(Cohort3) : DWJ1521 Cmg|
9691109|NCT04827472|Experimental|Part1(Cohort4) : DWJ1521 Dmg|
9691110|NCT04827472|Experimental|Part2 : DWJ1521 Xmg|
9691111|NCT04827472|Experimental|Part2 : DWP14012 Tablet|
9691112|NCT04827446|Experimental|Intervention Arm|Light intervention delivered through SYNC app + blue-light blocking glasses.
9691113|NCT04827446|Active Comparator|Control Arm|Placebo light intervention delivered through SYNC app + clear glasses.
9696276|NCT04768894|Active Comparator|43-56 days|In group 3, the time interval between initial and re-TUR was 43-56 days
9976279|NCT01349842|Experimental|Circulating Tumor Cells|Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.
10181177|NCT03786302|Active Comparator|Biodentine ™|Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.
10181178|NCT03786211|Active Comparator|IANB without panoramic|They will get Ianb without using panoramic
9691114|NCT04827433||Women having a persistent low-lying placenta with an IOD between 6 and 20 mm|Women having a persistent low-lying placenta with an IOD between 6 and 20 mm who will be offered a vaginal birth, considering 3 subgroups: 1) 6-10 mm; 2) 11-20mm; 3) > 20 mm (resolution of previa or low-lying placenta)
9691115|NCT04827433||Women with normal located placenta|Women with a normally located placenta at the II trimester scan will represent the control group.
9691116|NCT04827329||Patients with a sleep disorder|Patients with a sleep disorder recording performed in the Sleep Unit in Montpellier University Hospital.
9691117|NCT04827329||Patients with a narcolepsy|Patients with a narcolepsy (type 1 or type 2) / a idiopathic hypersomnia or a restless legs syndrome.
10181179|NCT03786211|Experimental|IANB with panoramic|They will get IANB by the guide of panoramic
9691118|NCT04827316||Patients undergoing clinically indicated CCTA|Patients undergoing clinically indicated CCTA
9691119|NCT04827407|Experimental|Basic therapy + Efferon LPS|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)
9691120|NCT04827407|No Intervention|Baseline therapy|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis.
9691121|NCT04827277|Active Comparator|Reverse total shoulder replacement|Participants will receive a reverse total shoulder arthroplasty
9691122|NCT04827277|Active Comparator|Anatomic total shoulder replacement|Participants will receive an anatomic total shoulder arthroplasty
9691123|NCT04827368||Crohns Disease|
9691124|NCT04827368||Ulcerative Colitis|
9691125|NCT04827368||Non-IBD|
9691126|NCT04827264||Return to Play Testing using Checklist|"Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with the Safe return to play following ACL reconstruction checklist"
9691127|NCT04827264||Return to Play Testing using Clinical Judgment|Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with clinical judgement
9691128|NCT04827251|Other|Caffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume caffeinated coffee during 28 days, followed by decaffeinated coffee during more 28 days.
9691129|NCT04827251|Other|Decaffeinated coffee|Patients will be instructed to abstain from caffeinated beverages during 22 days. After this period, they will consume decaffeinated coffee during 28 days, followed by caffeinated coffee during more 28 days.
9691130|NCT04827134|Experimental|Cohort 1: Treatment sequence AB|Participants will receive pediatric TRIUMEQ as a dispersion to be taken immediately after a high calorie meal (Treatment A) in Period 1 followed by pediatric TRIUMEQ administered as a dispersion under fasted conditions (Treatment B) in Period 2.
9691131|NCT04827134|Experimental|Cohort 1: Treatment sequence BA|Participants will receive pediatric TRIUMEQ as a dispersion under fasted conditions (Treatment B) in Period 1 followed by pediatric TRIUMEQ administered as a dispersion to be taken immediately after a high calorie meal (Treatment A) in Period 2.
9691132|NCT04827134|Experimental|Cohort 2: Treatment sequence CD|Participants will receive pediatric DOVATO as a dispersion to be taken immediately after a high calorie meal (Treatment C) in Period 1 followed by pediatric DOVATO administered as a dispersion under fasted conditions (Treatment D) in Period 2.
9691133|NCT04827134|Experimental|Cohort 2: Treatment sequence DC|Participants will receive pediatric DOVATO as a dispersion under fasted conditions (Treatment D) in Period 1 followed by pediatric DOVATO administered as a dispersion to be taken immediately after a high calorie meal (Treatment C) in Period 2.
9691134|NCT04827069|Experimental|Arm 1|Clifutinib Besylate:10 mg
9691135|NCT04827069|Experimental|Arm 2|Clifutinib Besylate:20 mg
9691136|NCT04827069|Experimental|Arm 3|Clifutinib Besylate:40 mg
9691137|NCT04827069|Experimental|Arm 4|Clifutinib Besylate:55 mg
9691138|NCT04827069|Experimental|Arm 5|Clifutinib Besylate:70 mg
9691139|NCT04827121|Active Comparator|Fascial iliac compartment block group|Patients in this group will recieve supra-inguinal fascial iliac compartment block after anesthesia induction.
9691140|NCT04827121|Active Comparator|Quadratus lumborum block group|Patients in this group will recieve quadratus lumborum block after anesthesia induction.
10181180|NCT03786393||Fibromyalgia|100 participants diagnosed with fibromyalgia according to ACR 1990 criteria.
9691141|NCT04826887||Solep Arm|Use of SOLTIVE Thulium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
10181181|NCT03786393||Control|
10181182|NCT03786133||type 2 diabetics|Analysis of microbiological tests in chronic periodontitis patients with type 2 diabetes mellitus
9691142|NCT04826887||Control Arm|Use of Holmium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure
9691143|NCT04826874|Experimental|Affect Labeling_direct|Randomized to immediate two-week, internet delivered psychoeducative course in affect labeling
9691144|NCT04826874|No Intervention|Wait-list|Randomized to a two-week wait-list control
9691145|NCT04827186|Experimental|highly sensitized patients with either a positive FCXM, or positive CDC cross-match|highly sensitized patients that receive a donor offer and have either a positive FCXM (T or B cell positive) or positive CDC cross-match (B cell positive); a positive CDC cross-match (T cell positive) remains a contraindication at this time.
9691146|NCT04827186|No Intervention|historical cohort of highly sensitized patients with a positive FCXM, or positive CDC cross-match|The control group, as comparison, will be an historical cohort of highly sensitized patients with positive flow (B and T) or positive B standard crossmatch, which received kidney transplant alone or simultaneous kidney and pancreas transplant and followed our standard protocol
9691147|NCT04827043|Experimental|Quadratus lumborum block|QLB group: will receive 0.3ml/Kg bupivacaine 0.25% ( keeping in mind not to exceed the maximum recommended toxic dose of plain bupivacaine which is 2.5 mg/Kg & 3mg/Kg with epinephrine), single injection sonar guided.
9691148|NCT04827043|Experimental|Thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
9691149|NCT04827147|Experimental|MPP first, FPP second|Participants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period.
9691150|NCT04827147|Experimental|FPP first, MPP second|Participants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period.
9691151|NCT04826965|Active Comparator|Wound vac application|Wound vac application for open upper/lower extremity open wound
9691152|NCT04826965|Active Comparator|Wound vac application including irrigation|Wound vac application WITH irrigation for upper/lower extremity open wound
9691153|NCT04826939|Experimental|Device usage|All participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device
9976280|NCT01349842|Other|Clinical and radiological criteria|Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.
9691155|NCT04827225||PoPPY Group|Mother, Father and child born prematurely
9691156|NCT04826718||Cohort|All Health Care Worker (HCW) from Hospital in Santiago and S. Vicente islands, Cabo Verde
9691157|NCT04826718||Control|HCW who report no SARS-CoV-2 infection in the period prior to the interview and/or suspected COVID-19 in the period prior to the interview
9691158|NCT04826718||Cases|HCW who report positive SARS-CoV-2 infection confirmed by performing a positive PCR test and/or positive Rapid Antigen Test in the period prior to the interview
9691159|NCT04827082|Experimental|Diacutaneous fibrolysis group|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
9691160|NCT04827082|No Intervention|Control group|Participants will be used as their own controls, with one lower extremity randomly receiving intervention. The control extremity will not receive any intervention
9691161|NCT04826757|No Intervention|standard care|standard care for low back pain management by general practioners (GPs). the physiotherapist and occupational health services can be solicited independently by the patient or GP.
9691162|NCT04826757|Experimental|coordinated care|"Coordinated care between general practioners, physiotherapist and occupational health services.~An intervention training will be performed before the start of the study for any care professional's to elaborate coordination tools and have an active communication."
9696277|NCT04768816|Placebo Comparator|Placebo Comparator|Placebo 0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
9696278|NCT04768816|Experimental|Experimental|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells#1*10^7/kg). The infusion speed is 1ml/min.
9696279|NCT04768647||Main cohort|Main cohort of all patients
9696280|NCT04768647||Subgroup of patients with imbalance|Subgroup of patients with imbalance
9696281|NCT04768621|Experimental|Winter residents of Southern and Antartic French Lands,|people exposed to stressors over long periods including winter
9696282|NCT04768621|Active Comparator|Country people going to Southern and Antartic French Lands|people going to Southern and Antarctic French Lands who benefit from milder conditions and only make short stays
9696283|NCT04768660|Other|normal|people will not use chewing gums after whipple operation
10181183|NCT03786133||non-diabetics|Analysis of microbiological tests in chronic periodontitis patients without type 2 diabetes mellitus
9696284|NCT04768764|Active Comparator|Group 1 Middle Adductor Canal Block|"Ultrasound Guided Middle Adductor Canal Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for middle adductor canal block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
9696285|NCT04768764|Active Comparator|Group 2 Femoral Nerve Block.|"Ultrasound Guided Femoral Nerve Block:~20 ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution."
9696286|NCT04768790|Experimental|Multidisciplinary Group|Description of the interventions of the multidisciplinary program: multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
9696287|NCT04768790|Active Comparator|General Group|Description of the interventions of the general program: exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
9696288|NCT04768595|Placebo Comparator|Placebo|1g corn oil capsules
9696289|NCT04768595|Experimental|Ceto 10|1g capsules containing oil from north atlantic fish containing broad spectrum marine oil.
9696290|NCT04768595|Active Comparator|Omega-3|1 g capsules containing traditional, commericially available omega-3 marine oil.
9696291|NCT04768582|Experimental|Efient group|ACS patients who received oral Prasugrel after coronary angiography been done
9696292|NCT04768634|No Intervention|Observation|Patients will be observed for arrhythmias and treated if they occur.
9696293|NCT04768634|Experimental|Testing|Patients will undergo provocative electrophysiology testing, and antiarrhythmic medication considered if arrhythmias can be induced.
9976281|NCT01349855|Experimental|Cohort 1|Dose Level 1
9976282|NCT01349855|Experimental|Cohort 2|Dose Level 2
9976283|NCT01349894||SNaP® Wound Care System|
10181184|NCT03786120||1|First 25 subjects
10181185|NCT03786120||2|Second cohort of 25 subjects
10181186|NCT03786094|Active Comparator|Eribulin|
9691163|NCT04826822|Experimental|Treatment|"After randomisation (Day 1): Spironolactone [100 mg 1x/day] + dexamethasone [2 mg 2x/day, 12/12h] Days 2-12*: Spironolactone [50 mg 2x/day, 12/12h] + dexamethasone [2 mg 2x/day, 12/12h] Days 13-20: Spironolactone [25 mg 2x/day, 12/12h] Days 21-28: Spironolactone [25 mg 1x/day] Standard treatment is according to the treatment protocol for 2019-nCoV infection.~*In case of cortisol levels above 100 nmol/L on days 3 and 4, the dexamethasone dose should be increased to 3 mg in the morning and in the evening (total 6 mg per day)."
9691164|NCT04826822|Active Comparator|Control|Patients receiving standard-of-care treatment for SARS-CoV-2 infection as regulated by the relevant guidelines of the Ministry of Healthcare of the Russian Federation
9691165|NCT04827160||COVID-19|Patients with COVID-19
9691166|NCT04826835|Experimental|Prehabilitation intervention|Participants in the intervention group will follow a 2-week prehabilitation program before lung resection.
9691167|NCT04826835|Active Comparator|Health education control|Participants in the control group will receive health education classes during 2 weeks before lung resection.
9691168|NCT04826900|Experimental|Robotic Group|Training session included 45 minutes Robotic Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
9691169|NCT04826900|Experimental|Robotic Mirror Group|Training session included 45 minutes Robotic Mirror Therapy, followed by 15-minute functional training. The robotic group will receive 3 sessions per week, for 8 weeks.
9691170|NCT04826653|Experimental|Timing suture removal_1 week|
9691171|NCT04826653|Experimental|Timing suture removal_2 weeks|
9691172|NCT04826653|Experimental|Timing suture removal_3 weeks|
9691173|NCT04827199|Experimental|ARTUS MONO AUS|The subjects will be implanted with the experimental medical device ARTUS MONO Artificial Urinary Sphincter (AUS) during the surgical procedure and will be trained to the use of the Remote Control to control themselves the micturition.
9691174|NCT04827173|Experimental|Healthy volunteers|
9691175|NCT04826679|Experimental|Experimental|"Camrelizumab + Cisplatin + Nab-paclitaxel~Camrelizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Cisplatin (IV), dose=60mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
9691176|NCT04826861|Other|Intervention for overweight pregnant women|Intervention will be delivered during antenatal visits in maternity care
9691177|NCT04826796|Experimental|Whatsapp intervention group|In addition to standard care, participants will be included into a peer support Whatsapp group on Whatsapp with other participants and trained peer supporters after study entry. Standard weekly prompt text messages will be sent to the group by peer supporters to encourage questions and discussion related to breastfeeding. Peer supporters will provide breastfeeding and emotional support. Intervention will last for 6 months after birth.
9691178|NCT04826796|No Intervention|Control group|Participants in the control group will continue to receive standard care.
9691179|NCT04826783|Experimental|Diode laser|
9691180|NCT04826783|Experimental|Er,Cr:YSGG laser|
9691181|NCT04826783|Experimental|Er:YAG LAser|
9691182|NCT04827004|Experimental|Anlotinib Hydrochloride Capsules|This is a multi-target receptor tyrosine kinase inhibitor.
9691183|NCT04826601|Experimental|Experimental|
9691184|NCT04826198|Experimental|AsiDNA in addition to Niraparib|Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
9691185|NCT04826445||Patients included in PENTOCLO protocol|We perform a prospective study with inclusions of all consecutive patients with osteoradionecrosis eligible for PENTOCLO.
9691186|NCT04826562|Experimental|dolutegravir/lamivudine|dolutegravir/lamivudine
9691187|NCT04826211|Experimental|Node positive BC patients undergoing PST|Patients with breast cancer of any size with positive axillary nodes and candidates to PST will undergo PET/MRI both prior to PST and after PST before surgery
9691188|NCT04826575|No Intervention|Control|No intervention will be done in this group.
9691189|NCT04826575|Experimental|Pre-Habilitation|Two weeks of high intensity respiratory muscle training, optional smoking cessation and psychological support.
9691190|NCT04826406|Experimental|Camrelizumab+Apatinib|
10181187|NCT03786094|Experimental|Balixafortide + eribulin|
10181188|NCT03785951|Experimental|Whey Protein Isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks
10181189|NCT03785951|Experimental|Wheat Protein|Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks
9691191|NCT04826380|Other|Trapeziectomy|Simple trapeziectomy for treating CMC I arthritis
9691192|NCT04826380|No Intervention|Conservative|Conservative measures (e.g. splint, NSAID, activation modification) for treating CMC I arthritis
9691193|NCT04826250|Experimental|Hypertensive patients - nighttime medication|Hypertensive patients will be instructed to take their medication in the evening for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the morning for four weeks.
9691194|NCT04826250|Experimental|Hypertensive patients - morning medication|Hypertensive patients will be instructed to take their medication in the morning for four consecutive weeks. At the end of this period, participants will switch the timing of medication to the evening for four weeks.
9691195|NCT04826263|Experimental|ESWT Group|The patients in the ESWT group will receive ESWT treatment and a home exercise program.
9691196|NCT04826263|Experimental|LLLT Group|The patients in the LLLT Group will receive LLLT treatment and a home exercise program.
9691197|NCT04826536||Cohort 1|Participants with psoriasis
9691198|NCT04826185|Experimental|IMB-1018972 200mg|
9691199|NCT04826185|Placebo Comparator|Placebo|
9691200|NCT04826172|Experimental|IMB-1018972 200mg|
9691201|NCT04826172|Placebo Comparator|Placebo|
10181190|NCT03785951|Experimental|Wheat protein with leucine|Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks
10181191|NCT03786406||T2DM patients seen in routine practice|All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
10181192|NCT03785873|Experimental|Nal-Irinotecan and Nivolumab|
10181193|NCT03786185|Experimental|Adolescents with dyslexia|MusicPlast training
10181194|NCT03786185|Active Comparator|Adolescents without dyslexia|MusicPlast training
9691202|NCT04826432|Experimental|Pasireotide|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
9691203|NCT04826432|Placebo Comparator|Placebo|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
9691204|NCT04826497|Experimental|Nicorandil|Patients who received intracoronary and intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
9691205|NCT04826497|Placebo Comparator|Placebo （normal saline）|Patients who received intracoronary and intravenous placebo before and after reperfusion with primary percutaneous coronary intervention
9691206|NCT04826510|Active Comparator|Lithium carbonate group|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
9691207|NCT04826510|Experimental|Perospirone hydrochloride group|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
10181195|NCT03786185|Experimental|Young Adults|MusicPlast training
9691208|NCT04826510|Experimental|Lithium carbonate + perospirone hydrochloride group|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
9691209|NCT04826224|Experimental|Subjects with Osteoarthritis of the shoulders|Subjects diagnosed with Osteoarthritis of the shoulders will be injected with concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
9691210|NCT04826159|Experimental|IMB-1018972 200 mg|
10181196|NCT03786185|Active Comparator|Young Adults Control|MusicPlast Control, in a similar design as MusicPlast
10181197|NCT03786185|Experimental|Seniors|MusicPlast training
10181198|NCT03786198|Experimental|a) Home-based walking intervention|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy
9691211|NCT04826146||CONOX|Patients are monitored with BIS and CONOX
10181199|NCT03786198|Active Comparator|b) Physical activity according to standard recommendations|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
10181200|NCT03786237|Experimental|Treatment Oral Capsules / Intravenous|
10181201|NCT03785938|Experimental|Probiotic|"Participants will start the course of liquid probiotic on the first day of their course of chemotherapy. This can be taken orally, or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day"
10181202|NCT03785938|Placebo Comparator|Placebo|"Participants will start the course placebo on the first day of their course of chemotherapy. This can be taken orally or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day~Placebo will be delivered in similar, packaging, appearance and taste."
10181203|NCT03786055|Experimental|Somatic Yoga and Meditation (SYM)|Participants will engage in 16 sessions of somatic yoga and meditation with appropriate props as needed over 8 weeks and continue with a home practice. Application of SYM throughout activities of daily living is reinforced. All sessions are facilitated by trained yoga therapists.
10181204|NCT03785795||Uncertain diagnosis of true labor|Patients who cannot be accurately classified as experiencing true labor or false labor based on standard clinical assessments.
10181205|NCT03785704|Experimental|Xinmailong injection group|given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen (EC-T) as those in the control group.
9691212|NCT04826042|Active Comparator|contrast group|injection of contrast medium 6 cc during thoracic epidural catheterization
9691213|NCT04826042|Placebo Comparator|normal saline group|injection of normal saline 6 cc during thoracic epidural catheterization
9691214|NCT04825782||Pregnant Women exposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
9691215|NCT04825782||Pregnant Women unexposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
9691216|NCT04826068|Experimental|Emotional Processing|The intervention looks at emotional processing of face interpretation.
9691217|NCT04826068|Placebo Comparator|Control intervention|The control group is seeing the same faces and are asked questions regarding them.
9691218|NCT04825938|Experimental|Toripalimab + Carboplatin + Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
9691219|NCT04825951|Active Comparator|CS 2000 appliance|treating growing skeletal Class III patients
9691220|NCT04825951|Active Comparator|Reversed Forsus Fatigue resistant appliance|treating growing skeletal Class III patients
9691221|NCT04825951|No Intervention|Control|"A group of untreated skeletally growing class III patients will be recruited to account for the possible effects of growth in the treatment groups.~This group matches the treated groups in malocclusion, stages of skeletal maturation, and mean observation period. Those patients will be treated after the period of the study."
10181206|NCT03785704|No Intervention|control group|receive conventional EC-T regimen chemotherapy (Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles).
10187562|NCT03725046|No Intervention|Usual information transmission after ED admission|The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
10181207|NCT03785886|Experimental|Walking group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
9691222|NCT04826016|Experimental|PHASE Ib - ARM A: POL6326 (balixafortide) + eribulin|On day 1 and 8 of each 21-day cycle (+/- 1 day) fixed eribulin dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) combined with increasing doses of POL6326 (balixafortide) starting at a dose of 11 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Eribulin will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 2 to 5 min. Up to 4 additional cohorts may be introduced
9691223|NCT04826016|Experimental|PHASE Ib - ARM B: POL6326 (balixafortide) + nab-paclitaxel|On day 1, 8 and 15 of each 28-day cycle (+/- 1 day) fixed nab-paclitaxel dose of 100 mg/m2 combined with increasing doses of POL6326 (balixafortide) starting at a dose of 5.5 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Nab-paclitaxel will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 30 min. Up to 5 additional cohorts may be introduced
9691224|NCT04826016|Experimental|PHASE 2 - ARM A: POL6326 (balixafortide) + eribulin|MTD/RDP2 POL6326 (balixafortide) (from arm A phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 1.4 mg/m2 eribulin over 5 min Intravenous infusion on days 1 and 8 in 21-day cycles (+/- 1 day).
9691225|NCT04826016|Experimental|PHASE 2 - ARM B: POL6326 (balixafortide) + nab-paclitaxel|MTD/RDP2 POL6326 (balixafortide) (from arm B phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 100 mg/m2 nab-paclitaxel over 30 min Intravenous infusion on days 1, 8 and 15 in 28-day cycles (+/- 1 day).
9691226|NCT04826107|Experimental|Part 1: Dose-finding stage|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at 2.0 mg/kg，2.5 mg/kg or 3.0 mg/kg every 3 weeks to determine the recommended dose.
9691227|NCT04826107|Experimental|Part 2: Cohort A|Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at the recommended dose.
9691228|NCT04826107|Experimental|Part 2: Cohort B|Patients with HER2-positive advanced or metastatic gastric cancer after receiving ≥ 2nd-line treatment will be treated with DP303c injection at the recommended dose.
9691229|NCT04826107|Experimental|Part 2: Cohort C|Patients with advanced or metastatic gastric cancer with HER2 low expression after receiving ≥1st-line treatment will be treated with DP303c injection at the recommended dose.
9691230|NCT04826107|Experimental|Part 2: Cohort D|Patients with advanced or metastatic gastric cancer with HER2 low expression or HER2-positive expression after receiving ≥1st-line treatment will be treated with DP303c injection combined with PD-1/PD-L1 treatment.
9691231|NCT04825795||DPP4-inhibitor|Patients who were prescribed DPP4-inhibitor during the period between two coronary CT scan.
9691232|NCT04825795||No DPP4-inhibitor|Patients who were not prescribed DPP4-inhibitor during the period between two coronary CT scan.
9691233|NCT04825808||Patients|Consecutive elderly (≥55 years) patients, recruited and registered in the stroke database of two centres (Nîmes University Hospital and Montpellier University Hospital, France), presenting with cSAH with suspected, possible, or probable CAA.
9691234|NCT04826055|Active Comparator|loop bypass with fixed biliary limb length|in all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
9691235|NCT04826055|Experimental|loop bypass with a biliary limb is a percentage of the small intestine|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
9691236|NCT04825821||Low transverse hysterotomy closed by double-layer unidirectional barbed suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by double-layer unidirectional barbed suture
9691237|NCT04825821||Low transverse hysterotomy closed by conventional double-layer smooth suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by conventional double-layer smooth suture
9691238|NCT04825925|Experimental|DEB-BACE|
9691239|NCT04826133|Active Comparator|Acute Pretreatment with Calcitriol|To explore the effects of acute pre-treatment with Calcitriol on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
9691240|NCT04826133|Placebo Comparator|Acute Pretreatment with Placebo|To explore the effects of acute pre-treatment with placebo on attempts to self-administer and ultimate number of infusions/boluses of cocaine, in experienced, non treatment-seeking users of the drug
9691241|NCT04826120|Active Comparator|PCEA group|Patients of this group had intermittent epidural analgesia via PCEA associated to systematic 8 ml boluses every 60 min during the second stage of labor.
9691242|NCT04826120|Experimental|CEI Group|Patients of this group had continuous epidural infusion at the rate of 8 ml/h during the second stage of labor.
9691243|NCT04825769|Experimental|Intervention|Red light irradiation was conducted at school from Monday to Friday and at home everyday in summer and winter holiday twice a day for 3 minutes per time, with an interval of 4 hours
9691244|NCT04825769|No Intervention|Control|No intervention
9691245|NCT04825899||NGS Panel|patients who had NGS 481 gene mutation detected
9976284|NCT01349985|Experimental|AGATE|To evaluate whether AGATE, a smartphone medication reminder and assessment system, effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking.
9976285|NCT01349985|Active Comparator|SASED|The control condition for the proposed study is a smartphone alcohol and side-effects diary (SASED, a smartphone alcohol and side effects diary).
10181208|NCT03785886|Experimental|Chinese Square Dancing group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
10181209|NCT03785886|Experimental|Control group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
10181210|NCT03786029|Experimental|A (Acetaminophen)|22 children will receive 320mg (10ml) 30 minutes before the local anesthesia injection.
10181211|NCT03786029|Placebo Comparator|B (Placebo)|22 children will receive 10ml 30 minutes before the local anesthesia injection.
9691246|NCT04825730|Experimental|Long Term Follow-up after Jointstem Transplantation|
9691247|NCT04825639||Sepsis|"Patients admitted to PICU who are selected from registry based on primary diagnoses with codes for the following search codes were selected:~Sepsis is defined as per the International Consensus Conference pediatric sepsis definition (2005) [citation 1].~In silico analysis will be carried out in the sepsis cohort comparing admissions with Acute Kidney Injury (AKI) and those without AKI to identify factors associated with AKI.~In those selected admissions to PICU, information on Renal Function, Chloride levels, clinical outcome and medication use as well as fluid resuscitation will be collected from hospital online resources such as discharge summaries, results portal and the PICANet database. In addition the Paediatric Index of Mortality 3 severity of illness scores will be reported for all admissions.~Sepsis will be defined based on the International Pediatric Consensus Conference definition of sepsis (2005)"
9691248|NCT04825639||Diabetic Ketoacidosis (DKA)|"This group is defined based on the British Society of Paediatric Endocrinology and Diabetes.case definition for Diabetic Ketoacidosis [citation 2].~The data collected will be similar to the sepsis cohort. In silico analysis will be carried comparing those with AKI and without AKI in the DKA cohort."
10181212|NCT03786029|Experimental|C (Ibuprofen)|22 children will receive 200mg (10ml) 30 minutes before the local anesthesia injection.
9691249|NCT04825418|Experimental|Therapeutic Hypothermia Group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Decompressive Hemicraniectomy care based on international guidelines except therapeutic hypothermia using surface cooling device.
9691250|NCT04825249|Experimental|The traditional suture bridge technique group|For the TSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
9691251|NCT04825249|Experimental|The modified suture bridge technique group|For the MSB group, if the tear type is confirmed to be medium-sized during the operation, TSB technique will be performed
9691252|NCT04825691||cases diagnosed as prostatic acinar adenocarcinoma|
9691253|NCT04825457|Active Comparator|Anchoring-tip EMR|AEMR, the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins.
9691254|NCT04825457|Active Comparator|Conventional EMR|After injection of normal saline solution mix, snaring was tried for CEMR.
9691255|NCT04825496|Experimental|ssCART-19 Cells|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to ssCART-19 cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
9691256|NCT04825353|Experimental|ECIRS-Group|
9691257|NCT04825353|Active Comparator|SPCNL-GRoup|
9691258|NCT04825405|Active Comparator|The use of the active Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the active TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
9976286|NCT01350011|Active Comparator|Innovative System (IS)|The innovative intervention uses the treatment system to support motivational counseling treatment entrance and treatment utilization. It has two components, a Motivational Intervention component via Expert System Counseling, and a Treatment Component that incorporates both pharmacological and behavioral long-term components. An innovative aspect of the IS is the use of the pharmacist as an intervention agent, who queries participants on their readiness to quit smoking, encourages involvement in the motivational intervention and in treatment, and who, along with the counselors, is available to answer medication questions.
10181213|NCT03785782||Women scheduled for biopsy|40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
10181214|NCT03785782||Women scheduled for neoadjuvant chemo|40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.
9691259|NCT04825405|Placebo Comparator|The use of the passive Tip Stim device to achieve coordinated of the hand.|Influence of the tested position and the use of the passive TipStim Glove device on the improvement of motor coordination and grip force in patients after a stroke.
9691260|NCT04825574|Experimental|Patients with GIST previously enrolled in avapritinib clinical trials|
9691261|NCT04825535|Experimental|Standard psychiatry and cognitive behavioural online intervention|The online group CBT-M program combines software-based workbooks with phone-based Navigator-Coaching that coordinates software interactions (e.g., secure text messaging, Fitbit tracked walking, food monitoring via photography). Navigation coaching is supplied by students who were pursuing graduate degrees (MSc, MA, PhD) in kinesiology and health science, education, and psychology.
10181215|NCT03785769|Active Comparator|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by HVGIC restoration.
9691262|NCT04825535|Active Comparator|Standard psychiatry and cognitive behavioural in-person intervention|The on-site, usual-care CBT group follows the structure of the Mind Over Mood workbook in reviewing CBT concepts and procedures. A series of work sheets assist participants in differentiating moods, and in differentiating moods from thoughts and situational influences, leading to modifications of thinking, behaviour, emotion and mood. Group leaders are standard leaders in the CAMH group-CBT program who have Masters-level degrees in psychology, social work and occupational therapists.
9691263|NCT04825665|Experimental|Continuous force|A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar on one side
9691264|NCT04825665|Experimental|Intermittent force|A buccally directed tipping force of 150 g removed every 21 days for a 7-day rest period applied to the maxillary first premolar on one side
9691265|NCT04825366|Active Comparator|Standard educational program|Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.
9691266|NCT04825366|Active Comparator|Standard educational program combined with high intensity interval training|"Participants will be closely followed by a team of diabetes specialists. Participants will attend two education sessions to discuss the following topics: avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a continuous glucose monitor (CGM) and understand CGM reports to adjust insulin doses.~Each study participant will be asked to train 3 times per week following the home-based program that will be provided to them. Participants will be asked to perform at least 2 training sessions per week with the exercise specialist on a virtual platform. The training session will consist of a 3 to 5-minute low-intensity warm-up followed by 6 to 12 1-minute bouts of high-intensity exercise interspersed with 1-minute bouts of low-intensity exercise. Each session will end with a 3-minutes cool-down period."
9691267|NCT04825587|Experimental|Concomitant ACL and ALL reconstruction|The participant will undergo both the ACL and ALL reconstruction surgery.
9691268|NCT04825587|Experimental|ACL reconstruction alone|The participant will undergo only ACL reconstruction surgery.
9691269|NCT04825509||Successful weaning group|Patients will be in this group according to primary outcome, if they will succeed spontaneous breathing trial for 120 minutes and will be extubated successfully without need for invasive or non-invasive ventilation for 48 hours
9691270|NCT04825509||Weaning failure group|"Patients will be in this group according to primary outcome, if they will fail spontaneous breathing trial or extubation within 48 hours~Weaning failure will be considered if:~Patients will need MV during spontaneous breathing trial within 120 minutes, or~patients will need invasive or non-invasive ventilation within 48 hours"
9691271|NCT04825392|Experimental|HX008|
10181216|NCT03785769|Experimental|HVGIC restoration with non pre-etching|HVGIC restoration without the pre-etching of the surface.
10181217|NCT03785990||preterms with enterostomy|GA 23±0/7 - 31±6/7 with clinically indicated operations because of NEC (necrotising enterocolitis) or FIP (focal intestinal perforation). Operation after birth (within 14 days) and at term (enterostomy closure) Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)
9691274|NCT04825314|Active Comparator|Bactiguard urethral catheter|Group A: Fifty Patients with urethral catheter using noble metal alloy coated catheter (Bactiguard AB, Stockholm ,Sweden).
9691275|NCT04825314|Active Comparator|Silicone Foley urethral catheter|Group B: Fifty Patients with urethral catheter using silicone Foley catheter (Well Lead, Guangzhou, China).
9691276|NCT04825340|Experimental|Study vaccine|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
9691277|NCT04825340|Placebo Comparator|Placebo|commercial normal saline
10181218|NCT03785990||preterms without enterostomy|"GA 23±0/7 bis 31±6/7 with a clinically indicated operation (e.g. herniotomy) at term, without any abdominal problems.~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
9691278|NCT04825015||OLTx|Liver insufficiency patients undergoing transplantation surgery
9691279|NCT04825002|Experimental|Urinary multimarker sensor arm|A urine of this group will be collected and measured using a newly developed urinary multimarker sensor (ANXA3, PSMA, ERG, ENG)
9691280|NCT04825041||Infertilite women|Subjected to three successive hysteroscopic tests
9691281|NCT04824976|Active Comparator|Blueberry|Freeze-dried pure blueberry powder
9691282|NCT04824976|Placebo Comparator|Placebo|Maltodextrin powder.
9691283|NCT04824924|Experimental|HVAG regimen|
9691284|NCT04825093|Experimental|Intervention group|Women allocated to this group will be supplemented with 2,000 UI of vitamin D3.
10181219|NCT03785990||term infants|"GA ≥34±0/7 with a clinically indicated operation directly after birth (within 14 days) (e.g. gastroschisis).~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
10181220|NCT03785717|Active Comparator|ROG only|cancellous (1-2 mm) & cortical (250-1000 mm) bone allograft and pericardium membrane without extracorporeal shockwave therapy
10181221|NCT03785717|Active Comparator|ROG & ESWT|cancellous 1-2mm & cortical 250-1000mm Bonegrafts and membrane with extracorporeal shockwave therapy
9691285|NCT04825093|Active Comparator|Control group|The control group will consist of pregnant women supplemented with 400 UI of vitamin D3.
9691286|NCT04824950|Other|Monitoring of Circulating Tumor DNA|
9691287|NCT04824768|Experimental|Experimental group|30 min session of CRet with functional massage on the rectus femoris, and gastrocnemius.
9691288|NCT04824768|Sham Comparator|Control group|30 min session of CRet with functional massage on the rectus femoris, and gastrocnemius. Sham stimulation was provided by only turn on the device but dose is 0.
9691289|NCT04825145||Preeclamptic women|Pregnant women who is diagnosed with preeclampsia during anytime of pregnancy.
9691290|NCT04825145||Healthy pregnant women|Pregnant women without preeclampsia. Will be matched for body mass index, gestational age and age.
9691291|NCT04824638|Experimental|Group 1: SARS-CoV-2 naive participants|participants without antecedent of SARS-CoV-2 infection
9691292|NCT04824638|Experimental|Group 2: Previously SARS CoV-2 infected participants|participants with antecedent of SARS-CoV-2 infection (more than 5 months)
10181222|NCT03785899|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
10181223|NCT03785899|Experimental|SPOCnew and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
10181224|NCT03785899|Experimental|SPOCnew and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
10181225|NCT03785899|Active Comparator|SPOCold and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
10181226|NCT03785899|Active Comparator|SPOCold and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
10181227|NCT03785821|Experimental|BMSO|Bitter melon seed oil supplementation
9691293|NCT04824716|Experimental|postconditioning|Patients that underwent postconditioning after primary percutaneous coronary intervention.
9691294|NCT04824716|Other|control|Patients that underwent primary percutaneous coronary intervention.
9691295|NCT04825119||MND patients|Patients with ''clinically definite ALS'' or ''clinically probable ALS'' or ''clinically probable ALS - laboratory supported'' according to the revised El Escorial diagnostic criteria or with the diagnosis of PMA or PLS will be included.
10181228|NCT03785821|Placebo Comparator|OO|Olive oil supplementation
10181229|NCT03785808|Experimental|Diet A (low carbohydrate)|Dietary Intervention A will be a low-carbohydrate/high fat, ketogenic-type diet. The diet will include salads, leafy green and non-starchy vegetables, nuts and seeds, eggs, fish and shellfish, and meats in most meals. Grains and added sugars will be excluded, and starchy vegetables, fruits, berries, and legumes will be limited to below 10% of total calorie intake. In addition full fat yogurt, cheeses, and butter will be allowed in moderate amounts. Participants will be encouraged to eat freely from whole-foods rich in fats such as avocados, nuts, seeds, olives, coconut and to use coconut, medium-chain triglyceride (MCT), olive, and avocado oils for cooking and baking on that diet. Participants will aim to fulfill at least 65% of their total calorie requirements from fats.
10181230|NCT03785808|Experimental|Diet B (low fat)|Dietary Intervention B will be low-fat, high carbohydrate whole-foods, plant-based diet. Most animal products and concentrated plant-based protein sources (such as soy isolates) will be excluded. Whole grains, particularly in their cooked form, legumes, vegetables, and fruits will be encouraged while excluding added sugars and refined grains. Added fats and oils will be discouraged on this diet as dietary fat should comprise less than 10% of total energy. Participants can eat freely from all types of fruits, vegetables, and cooked whole grains. Legumes will be emphasized as a replacement for meat and dairy products. Proteins similar to beef, pork, poultry, and dairy products, should be strictly limited, while lean proteins such as eggs, fish, and shellfish may be included occasionally.
9691296|NCT04825119||SMA patients|SMA patients type I, II, III, and IV will be included.
9691297|NCT04824586|Experimental|Insulin infusion regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin infusion regimen.~Fast-acting human insulin (Actrapid®) was used in this group."
9691298|NCT04824586|Experimental|Insulin bolus regimen|"Adult type II diabetic patients, who were admitted to hospital for cardiac surgery. These group received their dose of insulin; Insulin bolus regimen.~Fast-acting human insulin (Actrapid®) was used in this group."
9691299|NCT04824755|Experimental|Demographics and clinic characteristics of children in different ages|
9691300|NCT04824755|Experimental|PedEyeQ domain scores|
9691301|NCT04824755|Experimental|Boxes represent first, median, and third quartile values.|
9691302|NCT04824755|Experimental|Parent of kids aged 0-4y and 5-11y PedEyeQ domain scores|
9691303|NCT04825054|Experimental|A 60-min trial ventilated with NAVA|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
9691304|NCT04825054|Experimental|A 60-min trial ventilated with PCV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
9691305|NCT04825054|Experimental|A 60-min trial ventilated with PSV|Patients underwent surgical repair of right ventricular hypertrophic congenital heart disease. Each patient will undergo three 60-min trials with 30-min wash out during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
9691306|NCT04824742|Experimental|neoadjuvant PDT + radical surgery|Photodynamic therapy for neoadjuvant treatment of cholangiocarcinoma
9691307|NCT04824742|Active Comparator|radical surgery|Patients with cholangiocarcinoma undergo radical surgical resection
10181231|NCT03785808|Active Comparator|Diet C (USDA control)|The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which ~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
9696295|NCT04768543||Exposure|Patients with moderate to severe OSA treated with UAS (Inspire Medical Systems, Inc)
10181232|NCT03785860|Placebo Comparator|Placebo|On the Placebo arm of the intervention, participants will consume a placebo powder.
10181233|NCT03785860|Active Comparator|Dietary Fiber|On the Dietary Fiber arm of the intervention, participants will consume a fiber powder.
10181234|NCT03786042|Active Comparator|E-cigarette ad exposure|Participants in the e-cigarette ad exposure condition will view e-cigarette ads on the computer screen while having their eye movements tracked
9691308|NCT04824599|Active Comparator|PECS+subcutaneus local anesthetic infiltration|Preoperative ultrasound-led PECS II blockade with ropivacaine 3,75mg/ml (2mg/kg). After surgery - wound infiltration by the surgeon with ropivacaine 2mg/ml (1mg/kg).
9691309|NCT04824599|Active Comparator|Local anesthetic infiltration|Prior to scrubbing surgeon infiltrates the thought incision area with ropivacaine 3,75/ml (1mg/kg). Perioperatively after removal of the tumor follows the deep infiltration of the wound with ropivacaine 3,75mg/ml (2mg/kg).
9691310|NCT04824898|Experimental|simvastatin 1.2%gel|simvastatin 1.2%gel applied after open flap debridment in group I
9691311|NCT04824898|Experimental|I-prf|Injectable plasma rich fibrin will be collected from each patient in group II and the applied after open flap debridment
9691312|NCT04824937|Experimental|Telaglenastat + Talazoparib|"During 28 day study cycles, participants will receive:~Telaglenastat 2x daily at a predetermined dose~Talazoparib 1x daily at a predetermined dose"
9691313|NCT04824937|Experimental|Telaglenastat + Talazoparib Staggered|If a beneficial response is seen with the Arm 1 Telaglenastat + Talazoparib combination, participants will receive telaglenastat alone 2x daily at a predetermined dose with the addition of talazoparib at 1x daily at a predetermined dose if the disease gets worse.
9976287|NCT01350011|Active Comparator|Standard Treatment Control|After a baseline interview, patients in this condition will be given a packet of brochures on quitting, including descriptions of self-quitting and help-lines. Participants in this condition will continue to have access to their primary care providers, and through that system have access to pharmacotherapy for smoking cessation, if they wish to receive it. They will receive written instructions on how to approach their primary care provider about smoking cessation medication, and a written description of the medications used in smoking cessation and a list of those that are available to them through the public health system. At each assessment, patients will be queried about their use of these resources.
10181235|NCT03786042|Sham Comparator|non e-cigarette ad exposure|Participants in the non e-cigarette ad exposure condition will view non e-cigarette ads on the computer screen while having their eye movements tracked
9691314|NCT04824690|Experimental|Virtual Reality Group|The virtual reality group watched a 1.5-minute VR video showing the operating theater and explaining the perioperative process. After the surgery, this group watched cartoons during the first standard nursing procedures after the effect of the anesthesia wore off.
9691315|NCT04824690|No Intervention|Control Group|The control group received conventional care and education regarding the perioperative process of surgery.
9691316|NCT04824872|Experimental|Sequence 1|Dasiglucagon high dose, followed by placebo, followed by dasiglucagon low dose
9691317|NCT04824872|Experimental|Sequence 2|Dasiglucagn low dose, followed by dasiglucagon high dose, followed by placebo
9691318|NCT04824872|Experimental|Sequence 3|Placebo, followed by dasiglucagon low dose, followed by dasiglucagon high dose
9691319|NCT04824872|Experimental|Sequence 4|Dasiglucagon high dose, followed by dasiglucagon low dose, followed by placebo
9691320|NCT04824872|Experimental|Sequence 5|Placebo, followed by dasiglucagon high dose, followed by dasiglucagn low dose
9691321|NCT04824872|Experimental|Sequence 6|Dasiglucagon low dose, followed by placebo, followed by dasiglucagon high dose
9691322|NCT04824573|Experimental|Inspiratory Muscle Training (IMT)|The program of the IMT group (n=16) consists of individual sessions of approximately 20 minutes and the Powerbreathe device (IMT Technologies Ltd., Birmingham) was used for training.
9691323|NCT04824573|Experimental|Manual Therapy|In the manual therapy group (n=19), in addition to the approaches applied to the individuals in the IMT group, a total of eight sessions of manual therapy (manipulation, joint mobilization, and soft tissue mobilization) approaches, two days a week for four weeks and at least two days between sessions, were applied by an experienced physiotherapist in manual therapy. Manual therapy applications; included techniques targeting the cervical and thoracic regions. Techniques for the thoracic region; while it consists of manual diaphragm release, thoracic mobilization and High Velocity Low Amplitude (HVLA) thrust manipulation; the techniques applied to the cervical region consisted of soft tissue and joint mobilization.
9691324|NCT04825106|Active Comparator|Expected|Anaphylactic shock occurs after the injection of a drug known to cause allergic reactions
9691325|NCT04825106|Active Comparator|Unexpected, no distractor|Anaphylactic shock occurs unexpectedly, but their is no medical distractor
9691326|NCT04825106|Active Comparator|Unexpected, with distractor|Anaphylactic shock occurs unexpectedly. Scenario is set up such, that a tension pneumothorax may be a likely explanation
9691327|NCT04824612|Sham Comparator|Sham Group|"intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide (Triancil®, Apsen Farmacêutica S.A.) - two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.~Sham PBM in the preoperative and postoperative periods of keloid removal surgery: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month."
9976288|NCT01350024|Active Comparator|Frontal Nerve Block|Patients will receive a frontal nerve block for anesthesia
9976289|NCT01350024|Active Comparator|Subconjucntival Injection|Patients will receive a subconjunctival injection for anesthesia
9976290|NCT01350037|Active Comparator|remifentanil|sedative mixture for PCS consisting of propofol 10mg/ml 20 ml and remifentanil 50 mkg/ml 5 ml
10181236|NCT03785730|Experimental|Non-restorative cavity control - NRCC|Enlargement with metallic sandpaper associated with toothbrushing/1000 ppm fluoride toothpaste.
10181237|NCT03785730|Active Comparator|Resin composite restoration - RCR|Selective carious lesion removal and restoration with resin composite.
9691328|NCT04824612|Experimental|Experimental Group|"Transcutaneous PBM will be performed on the keloid in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J). Frequency: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month.~Intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide: two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies."
9691329|NCT04824794|Experimental|Treatment|GEN3014
9691330|NCT04825028||Internal Diagnostic Accuracy Cohort|Consecutive patients with available CZT-SPECT within 3 months of measuring FFR in the left anterior descending coronary artery. In these patients, correlation between angiography-derived IMR and hyperemic microvascular resistance will be assessed.
9691331|NCT04825028||External Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (J Nucl Cardiol. 2020 Sep 30. doi: 10.1007/s12350-020-02252-8.), INOCA patients and normal controls confirmed by CZT-SPECT and angiography will be included for the assessment of angiography-derived IMR in diagnosing microvascular dysfunction.
10181238|NCT03785756|Experimental|Prolonged Release Group|Ibuprofen 300 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
10181239|NCT03785756|Active Comparator|Immediate Release Group|Ibuprofen 200 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
10181240|NCT03785756|Placebo Comparator|Placebo Group|Placebo of IR tablet Placebo of PR tablet
10181241|NCT03785652|Experimental|LY03005 extended-release tablets|LY03005 extended-release tablets at 4 doses 40 mg, 80mg, 120mg or 160mg
10181242|NCT03785652|Placebo Comparator|Placebo|Placebo tablet
9691332|NCT04825028||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the target vessel after successful revascularization. Those patients have follow-up data after 2 years from index procedure.
9691333|NCT04824911|Experimental|Intervention group|"This group will receive dual antiplatelet and high-intensity statin treatment.~Dual antiplatelet treatment: loading of clopidogrel 300mg plus aspirin 300mg, followed by clopidogrel 75 mg/day and aspirin 100 mg/d from day 2 to day 21, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.~High-intensity statin treatment: Atorvastatin 40-80mg/day or Rosuvastatin 20 mg/day for 90 days."
9691334|NCT04824911|Active Comparator|Historical control|A historical control group of patients receiving single antiplatelet therapy but no high-intensity statin treatment will be drawn from previous prospective observation studies. Antiplatelet therapy includes aspirin(100-300mg/day) or Clopidopgrel (75mg/day).
9691335|NCT04824560|Other|BP Education|All participants enrolled receive blood pressure education.
9691336|NCT04824313||COVID-CAVA PE|Patients with RT-PCR proven COVID-19 disease and CTA proven pulmonary embolism
9691337|NCT04824313||COVID-CAVA non-PE|Patients with RT-PCR proven COVID-19 disease and no evidence of pulmonary embolism on CT
9691338|NCT04824300|Active Comparator|erector spinae plane block group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.Group ESPB was applied before general anesthesia by the same anesthesiologist with block experience. In the sitting position, using an ultrasound-guided linear probe (6-13 MHz) on the side to be operated, T3 is marked 3 cm from the lateral of the spinous processes and with the in-plane technique, a 22G block needle (100mm, B-Braun, Germany) in the cranio-caudal direction first After it was observed that the erector spina muscle was separated from the transverse process with -2 ml normal saline, 20 ml 0.5% bupivacaine and 100 mg lidocaine were administered. And the drug was found to spread to the craniocaudal line at the ESP on ultrasound.Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
9691339|NCT04824300|No Intervention|non block control group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.15 minutes before the end of the surgery, 1 gr paracetamol and 100 mg tramadol were given to the control group. Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
9691340|NCT04824339|Experimental|Immediate Intervention Group|The intervention is an 8-week combined aerobic and resistance program, with virtual, group-based, supervised exercise sessions twice per week (60 min). The intervention also includes optional education on healthy eating.
9691341|NCT04824339|Experimental|Delayed Intervention Group|Usual lifestyle control for 8 weeks and then invited to participate in the exercise intervention.
9691342|NCT04824352|Experimental|apatinib+IE|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA < 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
9691343|NCT04824404|No Intervention|Standard Treatment As Usual (TAU)|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly or bi-weekly visits (at the discretion of the provider) to the clinic to meet with their provider and provide a sample of blood.
9691344|NCT04824404|Experimental|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professional
9691345|NCT04824495||Patients with acute COVID-19|
10181243|NCT03785496|Experimental|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
10181244|NCT03785392|Active Comparator|Group 1 Inplane|Study with the technique Inplane group
10181245|NCT03785392|Active Comparator|Group 2 out of plane|Study with the technique out of plane
10181246|NCT03785483|Experimental|Motivation|Using implementation intention techniques such as action planning. Every week, participants state when, where, and what kind of prescribed exercises they will do.
10181247|NCT03785483|Active Comparator|Mindfulness|10 minutes of audio recordings daily. Recordings contain: awareness of the breath, acceptation of thoughts and emotions, awareness of postures, awareness during stretching, awareness of a single movement (moving legs up while standing).
9691346|NCT04824170|Experimental|Neural glide|Neural mobilization of median nerve which includes gliding and sliding was given
9691347|NCT04824170|Experimental|Rhythmic stabilization technique|Proprioceptive Neuromuscular Facilitation (Rhythmic stabilization technique will be Given)
9691348|NCT04824508|Active Comparator|Conventional position (head position)|Leaderposition at the patient's head
9691349|NCT04824508|Active Comparator|Remote position|Leaderposition remote from patient and hands-off
9691350|NCT04824443|Experimental|Participants who were hospitalized for COVID-19|Participants will be post-cancer treatment patients who were hospitalized for COVID-19.
9691351|NCT04824365|Experimental|treatment of COVID-19 or influenza infected patients with a sodium pyruvate nasal spray|In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVIV-19 and influenza infections.
9691352|NCT04824365|Placebo Comparator|Placebo control treatment of COVID-19 or influenza infected patients|In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVIV-19 and influenza infections.
9691353|NCT04824235|Experimental|Amnoitic Chorion Membrane and xenograft|extraction sockets where ridge preservation will be performed using Chorion Membrane with Xenograft
9691354|NCT04824235|Active Comparator|Amnoitic Chorion Membrane only|extraction sockets where ridge preservation will be performed using Chorion Membrane Alone
9691355|NCT04824287|Experimental|Experimental|pelvic floor exercise
9691356|NCT04824287|No Intervention|control group|no intervention
9691357|NCT04824456|Experimental|bilateral sagittal split osteotomy using chisels.|The final split is completed with Smith forceps and flag separators
9691358|NCT04824248|Experimental|Experimental intervention|10 weeks online therapy delivered using a blended approach. The online therapy consists of instructive video's, challenges to complete, 1-on-1 video calls with the therapist, online quizzes, online booklets, and online diaries/workbooks. . The experimental group will receive a behavioral weight reduction program combined with pain neuroscience education plus cognition-targeted exercise therapy. The combined therapy will adhere to guidelines for patient-centered care
9691359|NCT04824248|Active Comparator|Control intervention|Identically to the experimental intervention, the therapy is provided online within 10 weeks. Also identical to the experimental intervention, the control intervention will adhere to guidelines for patient-centered care. The control group will receive pain neuroscience education in combination with cognition-targeted exercise therapy alone.
9691360|NCT04824222|Experimental|A - SOC+IMP|The FMT (fecal microbiota transplantation) will be administered along with the standard COVID 19 pharmacological treatment (SOC- Standard of care). The FMT will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
9691361|NCT04824222|Placebo Comparator|B - SOC+placebo|Using standard COVID 19 pharmacological treatment (SOC- Standard of care). The placebo will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules).
9691362|NCT04824261|Active Comparator|group 1|randomized 50 otomycosis patients will receive Clotrimazol solution 1%
9691363|NCT04824261|Active Comparator|group 2|randomized 50 otomycosis patients will receive 4%boric acid in distilled water
9691364|NCT04824430||SLH 3M|Second look hysteroscopy (SLH) performed 3 months post-ablation
9691365|NCT04824430||SLH 6M|Second look hysteroscopy (SLH) performed 6 months post-ablation
9691366|NCT04824430||SLH 12M|Second look hysteroscopy (SLH) performed 12 months post-ablation
9691367|NCT04824378||label 1|Baseline data measurement of this group of patients: arm circumference（positive） and ICG (positive).
9691368|NCT04824378||label 2|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (positive).
9691369|NCT04824378||label 3|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (negative).
9691370|NCT04824391|Experimental|3 mcg/0.5 ml Vaccine|Low dose vaccine
9691371|NCT04824391|Experimental|6 mcg/0.5 ml Vaccine|Medium dose vaccine
9691372|NCT04824391|Placebo Comparator|Placebo|Placebo
9691373|NCT04824209||AP group|Healthy patients between 25-55 years with Apical Periodontitis
9691374|NCT04824209||Control Group|Healthy patients between 25-55 years without Apical Periodontitis
9691375|NCT04824196|Experimental|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirror.Anterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear movements were performed for five minutes
9691376|NCT04824196|Active Comparator|propriocetion therapy|"Alternate knee flexion-extension with extended trunk posture using both hands for support.~Hip and knee flexion-extension with swiss ball between the back and wall.~Hip aises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises.~then perform all exercise on gym ball"
9691377|NCT04824014|Experimental|4FMFES-PET imaging at 0, 6 and 18 months|Patients burdened with ER+ advanced breast cancers and recruited in the trial will undergo an experimental 4FMFES-PET imaging within a 4-week interval of a medically-prescribed FDG-PET. The 4FMFES-PET procedure will be repeated at 6 and 18 months following the initial scan.
9976291|NCT01350037|Active Comparator|alfentanil 0.04 mg/ml|sedative mixture for PCS consisting of propofol10 mg/ml 20 ml,alfentanil 0.5 mg/ml 2 ml, NaCL 9 mg/ml 3 ml
10181248|NCT03785483|No Intervention|Treatment as usual|Physical activity prescribe 120 minutes per week.
10181249|NCT03785418|Experimental|Experimental Arm|Multicomponent Risk Factor Modification Intervention focused on healthy eating, regular exercise and behavioural therapy
10181250|NCT03785418|No Intervention|Control Arm|Standard Clinical Practice
10181251|NCT03785431|Experimental|Intervention|Patient diagnosed with ST elevation myocardial infarction will undergo bioresorbable stent deployment in culprit lesion.
10181252|NCT03785535|Experimental|Actual treatment|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (2-90 Hz), low intensity and long daily duration (3h).
10181253|NCT03785535|Sham Comparator|Sham|Sham treatment will be applied using identical instruments and with power and duration programmed identically. However, in this case, the output will not be the signal activating the vibration motors, but rather an electrical signal turning on an incorporated pilot light indicating that the (simulated) treatment was operating
10181254|NCT03785587|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 24 weeks
10181255|NCT03785691|Experimental|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
9691378|NCT04824482|Experimental|Robot-assisted gait training (RGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
9691379|NCT04824482|Active Comparator|Therapist-assisted gait training (TGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
9691380|NCT04824326|Experimental|Pythagorean Self Awareness Intervention for Children and Adolescence(PSAI-CA)|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
9691381|NCT04823962|Experimental|GM-CSF|rhGM-CSF (molgramostim) + hydrogel
9691382|NCT04823962|Placebo Comparator|Placebo|Hydrogel
9691383|NCT04823832|Active Comparator|ERCP group|endoscopic retrograde cholangiopancreaticography with plastic stent insertion
9691384|NCT04823832|Active Comparator|PTD group|ultrasound guided percutaneous transhepatic catheter insertion
9691385|NCT04823936|No Intervention|control group|received the selected physical therapy program for one hour, three times weekly for two successive months including facilitation of balance and protective reactions from kneeling, half kneeling and standing position, standing alone on balance board, standing on one leg, open gait training alone (walking on the balance beam, walking on the stepper and walking on wedges), training stair climbing, and strengthening of the back and abdominal muscles.
9691386|NCT04823936|Active Comparator|study group|received the selected physical therapy program for one hour, three times weekly in addition to core stability training program for 30 minutes
9691387|NCT04824053|Experimental|UNICLA-A2 milk and its subproducts|Participants (n=17) ingest milk and dairy products made from cows homozygous for beta casein A2 during 3 months. These products are also enriched in insaturated fatty acids and selenium. The daily intake reflects the habitual consumption habits. Recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day.
9691388|NCT04824053|Placebo Comparator|Placebo|"Participants (n=17) ingest conventional dairy products and milk daily during 3 months. As happens in the UNICLA-A2 arm, the daily intake reflects habitual dairy consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, recommended amounts are 250 mL of milk, a yogurt and 50 g fresh cheese per day."
9691389|NCT04824040||Study group|Patients with a genetically confirmed dysferlinopathy.
9691390|NCT04824040||Control group|Healthy Volunteers
9691391|NCT04823793||Healthy group : Stool specimens from participants with healthy colon|"Stool specimens will be collected from participants before having a colonoscopy.~If the participant's colon has a healthy colon without any cancerous lesion, the stool specimen will be included in the healthy group."
9691392|NCT04823793||Disease group : Stool specimens from participants with adenoma/colorectal cancer|"Stool specimens will be collected from participants before having a colonoscopy.~If the participant's colon has precancerous lesion, such as adenoma, the stool specimen will be included in the disease group.~Also, specimens from confirmed colorectal cancer patients are included in the disease group."
9691393|NCT04824001||STEMI|ST-segment elevation myocardial infarction (STEMI) is defined by symptoms of myocardial ischemia accompanied by a persistent elevation of the ST segment on the electrocardiogram (ECG) and the subsequent release of biomarkers of myocardial necrosis.
9691394|NCT04824001||NSTEMI|If there is elevation of the blood markers suggesting heart damage, but no ST elevation seen on the EKG tracing, this is known as a non ST-elevation myocardial infarction (NSTEMI).
9691395|NCT04823884|Active Comparator|open distal chevron osteotomy|Hallux valgus correction is provided by using the traditional open distal v-shaped chevron osteotomy.
9691396|NCT04823884|Active Comparator|minimally invasive distal chevron osteotomy|Hallux valgus correction is provided by using a minimally invasive distal v-shaped chevron osteotomy.
9691397|NCT04823689|Sham Comparator|Dorsal decubitus|The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.
9691398|NCT04823689|Experimental|Ventral decubitus|The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula.
9691399|NCT04823728||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
10181256|NCT03785691|Experimental|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
9691400|NCT04823585|Placebo Comparator|subcutaneous injections of placebo|Subcutaneous injections of placebo (physiological sodium chloride solution) once per month for 16 weeks. A total of 4 injections.
9691401|NCT04823585|Experimental|subcutaneous injections of Mepolizumab 100 mg|Subcutaneous injections of Mepolizumab 100 mg once per month for 16 weeks. A total of 4 injections.
9691402|NCT04823533|Experimental|Probiotic|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
9691403|NCT04823533|Placebo Comparator|Placebo|Placebo formulation containing only the excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
9691404|NCT04823624|Experimental|MG MBG453|Participants will be given MBG453 On Day 1 of each cycle 28 days (4 weeks) study cycle
9691405|NCT04823507||Concussion patients treated with Photobiomodulation|"Patients between the ages of 15-65 years clinically diagnosed with a mild Traumatic Brain Injury by a health professional and currently not undergoing any treatment during a 1 year period from January 2018 to December 2018.~Documentation of the history of a qualifying mild Traumatic Brain Injury within 3 months of traumatic incident and/or diagnosis with persistent symptomatology after 3 months. For reference, International Classification of Diseases, Tenth Revision (ICD-10) clinical criteria require a history of TBI and the presence of three or more of the following eight symptoms: 1) headache, 2) dizziness, 3) fatigue, 4) irritability, 5) insomnia, 6) concentration or 7) memory difficulty, and 8) intolerance of stress, emotion, or alcohol4."
9691406|NCT04823819|Active Comparator|rTMS stimulation|20 sessions of stimulation with increasing intensity, reaching maximum in the 4th session.
9691407|NCT04823819|Active Comparator|tDCS stimulation|The stimulation time will be 20 minutes, the current intensity will be 2mA.
9691408|NCT04823819|Sham Comparator|Sham rTMS stimulation|20 sessions of stimulation, but without current.
9691409|NCT04823819|Sham Comparator|Sham tDCS stimulation|The stimulation time will be 20 minutes, but without current.
9691410|NCT04823767|Experimental|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
9691411|NCT04823715||TACE- hypofractionated radiation therapy|Patients will receive one course of transarterial chemoembolization followed 1 to 4 weeks later by hypofractionated radiation therapy up to a total dose of 45 to 60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
9691412|NCT04823715||Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma
9691413|NCT04823572|Active Comparator|A-PRF Advanced Platelet-Rich Fibrin|Comparing healing effect of an autologous product with open flap debridement.
9691414|NCT04823572|Active Comparator|OFD Open Flap Debridement|Comparing healing effect of an autologous product with open flap debridement.
9691415|NCT04823520|Active Comparator|Group 15% concentration|30 patients MDA will be done to one half of the face then TCA 15% will be applied to the whole face.
9691416|NCT04823520|Active Comparator|Group 20 % concentration|30 patients will receive MDA to one side of the face , TCA 20% will then be applied to the whole face.
9691417|NCT04823559|No Intervention|Usual practice|Usual practice
9691418|NCT04823559|Experimental|Intervention|Receives educational workshop
9691419|NCT04823494|Active Comparator|Pro-Fit|Hearing aids fit by a professional hearing care provider using best practices.
9691420|NCT04823494|Experimental|Self-Fit|Hearing aids fit by patient.
9691421|NCT04823429|Experimental|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
9691422|NCT04823429|Experimental|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
9691423|NCT04823429|No Intervention|Control group|Without any exercise training
9691424|NCT04823949|No Intervention|Standard care|Patient will be scheduled for a blood pressure check in the office 7-10 days postpartum
9691425|NCT04823949|Experimental|Intervention|Patient will receive a Babyscripts blood pressure cuff(brand: A&D Medical) and Babyscripts MyJourney phone app with which to monitor their blood pressures twice daily for 16 days after discharge
9691426|NCT04823598|Active Comparator|Reference group|Coached pushing and Finnish manual perineal protection
9691427|NCT04823598|Experimental|Study group|Uncoached pushing and Hands-poised perineal protection
9691428|NCT04823871|Other|High risk patients for breast and/or ovarian cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
10181257|NCT03785691|Placebo Comparator|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
10181258|NCT03785353|Experimental|PNE Group|A group of Spanish-speaking individuals will listen to a translated lecture related to PNE (PNE lecture). They will fill out the R-NPQ pre and post the lecture.
10181259|NCT03785613|Experimental|Test Product T1: Buprenorphine patch (9 mg)|"Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T1: simultaneous application for 96 hours on the upper back."
10181260|NCT03785613|Experimental|Test Product T2: Buprenorphine patch (3.8 mg)|"Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters. Single application of patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T2: simultaneous application for 96 hours on the upper back."
10181261|NCT03785613|Active Comparator|Reference Product R: Transtec patch (20 mg)|"Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to R: simultaneous application for 96 hours on the upper back."
10181262|NCT03785522||Tresiba®|Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.
10181263|NCT03785379|Active Comparator|Caloric restriction and early SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
9691429|NCT04823871|Other|Suspected Ovarian Epithelial Cancer|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
9691430|NCT04823546|Experimental|Activity based therapy|"Activity based training was done in 2 phases. exercise involve~Standing and reaching~Sit-to-stand~Stepping forward and backward Phase 2 Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise.~(10) Walking on a treadmill;"
9691431|NCT04823546|Active Comparator|strength training|Strength training for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
9691432|NCT04823416|Active Comparator|Stoma|
9691433|NCT04823416|Active Comparator|Resection and stoma|
9691434|NCT04823741||PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
9691435|NCT04823806|Experimental|Healthy participants and participants with depressive disorder: dietary spermidine supplementation|Dietary Supplement: Polyamine 21 days of spermidine supplementation (3 sachets/day = 6mg spermidine/day)
9691436|NCT04823806|Placebo Comparator|Healthy participants and participants with depressive disorder: dietary placebo supplementation|Dietary Supplement: Placebo 21 days of Placebo supplementation (3 sachets/day)
9691437|NCT04823390|Other|Anesthetist controlled group|15 patients undergoing cataract surgery will receive sedation given by the anesthetist together with local anesthesia according to the depth of sedation in the form of intravenous Midazolam and Fentanyl.
9691438|NCT04823390|Other|Patient-controlled group|15 patients undergoing cataract surgery under local anesthesia will administer sedation to themselves through a pump.
9691439|NCT04823442|Active Comparator|Study A|Metabolic PET study with mirabegron
9691440|NCT04823442|Experimental|Study B|Metabolic PET study with mirabegron and bisoprolol
9691441|NCT04823377|Other|Period A: Usual management|Period of end-of-life care as usual
9691442|NCT04823377|Other|Period B: Process of optimization of the medical decision|Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.
9691443|NCT04823468|Experimental|Experimental group|In addition to conventional dietary instruction and individualized nutritional counselling, patients were given additional ONS (Abbott®Ensure of 55.8 g tid) from the beginning to the end of radiotherapy.
9691444|NCT04823468|Other|Control group|Conventional dietary instruction and individualized nutritional counselling from the beginning to the end of radiotherapy.
9691445|NCT04823351|Other|FFP2 Mask|Universal FFP2-masking for every healthcare worker with patient contact, compared to selective FFP2-masking, which means that FFP2 masks are worn only during aerosol-generating procedures such as tube manipulation;
9691446|NCT04823351|Other|Surgical Mask|Universal surgical mask IIR type masking for healthcare workers in contact with COVID-19 patients.
9691447|NCT04823364|Active Comparator|Medically healthy adults diagnosed with ADHD|Medically healthy adults diagnosed with ADHD (men and women) ages 18-40 years (N= 35), treated with Amphetamines (Mixed Amphetamine salts (Attent) or short-acting methylphenidate (Ritalin)
9691448|NCT04823364|No Intervention|Control|HCS (N= 25) volunteers ages 18-40 years, who did not report ADHD or any other illness or medical conditions, and who do not take chronically medications, will be enrolled from the general population.
10181264|NCT03785379|Active Comparator|Caloric restriction and late SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
10181265|NCT03785444||Intensive Care Patients|Postoperative patients who have been admitted to intensive care
9691449|NCT04823403|Experimental|Patients with heptaocellular carcinoma|"Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.~Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels*.~(D1) Starting dose : 50 mg; n=3 to 6~(D2) 2nd dose-level : 100 mg; n=3 to 6~(D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) *Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (>1/3 DLT at D1)"
9691450|NCT04823325||Surgery patients|Otherwise healthy patients with Skeletal Class III problem
9691451|NCT04823286|Experimental|Virtual reality health platform during hemodialysis|During 12 weeks subjects will use a VR platform during hemodialysis. The intervention will be virtual reality exercise, nutritional advice and psychological wellbeing support plus cognitive training.
9691452|NCT04823286|No Intervention|Control group-usual care|During 12 weeks subjects will carry on with the usual care in the hemodialysis unit
9691453|NCT04823156|Active Comparator|Adequate energy and adequate calcium|All dietary food and water will be provided for 19 days. The energy content of the diet will be prescribed, according to exercise levels, to elicit an energy availability of 45 kcal per kg of fat free mass per day. Foods high in calcium will be removed and participants will be provided with a calcium and vitamin D food supplement (two daily 500 mg calcium and 400 IU vitamin D3 supplements) (total calcium intake 1500 mg per day and 800 IU vitamin D3 per day).
9691454|NCT04823156|Experimental|Low energy and adequate calcium|All dietary food and water will be provided for 19 days. The energy content of the diet will be prescribed, according to exercise levels, to elicit an energy availability of 45 kcal per kg of fat free mass per day for the first 7 days and 15 kcal per kg of fat free mass per day thereafter. Foods high in calcium will be removed and participants will be provided with a calcium and vitamin D food supplement (two daily 500 mg calcium and 400 IU vitamin D supplements) (total intake 1500 mg calcium per day and 800 IU vitamin D3 per day).
9691455|NCT04823156|Active Comparator|Low energy and low calcium|All dietary food and water will be provided for 19 days. The energy content of the diet will be prescribed, according to exercise levels, to elicit an energy availability of 45 kcal per kg of fat free mass per day for the first 7 days and 15 kcal per kg of fat free mass per day thereafter. Foods high in calcium will be removed and participants will be provided with a vitamin D food supplement (two daily 400 IU vitamin D supplements) (total intake <500 mg calcium per day and 800 IU vitamin D3 per day).
9691456|NCT04823117||Music therapy group|Music therapy lasted 30 minutes every day for a total of 20 days.
9691457|NCT04823117||Control group|No treatment given.
9691458|NCT04823169|Experimental|podobarometry|podobarometric measures at day7 and day 30
9691459|NCT04823104|Experimental|Intervention group with home visitation|pregnant women who are included in this group will be assigned an intervention by home visitation for pregnancy follow-up
9691460|NCT04823104|No Intervention|control group without home visitation|pregnant women will be free to choose their pregnancy follow-up without home visitation
9691461|NCT04823182||Cases|Cases - Recent COVID-19 infection ≥ 6 weeks and ≤ 12 months before enrolment, as evidenced by positive reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 swab
9691462|NCT04823260|Active Comparator|Arm A = 300 mg NMN supplement (n = 20)|Subjects who are assigned to 300 mg arm (NMN) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
9691463|NCT04823260|Placebo Comparator|Arm B = Placebo 300 mg (n=07)|Subjects who are assigned to 300 mg arm (placebo) will be instructed to take 2 capsules after breakfast once a day with ambient temperature water for 60 days.
9691464|NCT04823260|Active Comparator|Arm C = NMN Supplement 600 mg (n= 20)|Subjects who are assigned to 600 mg arm (NMN) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
9691465|NCT04823260|Placebo Comparator|Arm D = Placebo 600 mg (n=07)|Subjects who are assigned to 600 mg arm (Placebo) will be instructed to take 4 capsules after breakfast once a day with ambient temperature water for 60 days.
9691466|NCT04823260|Active Comparator|Arm E = NMN Supplement 900 mg (n=10)|Subjects who are assigned to 900 mg arm (NMN) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
9691467|NCT04823260|Placebo Comparator|Arm F = Placebo 900 mg (n=06)|Subjects who are assigned to 900 mg arm (Placebo) will be instructed to take 6 capsules after breakfast once a day with ambient temperature water for 60 days.
9691468|NCT04823013|Experimental|high power pain threshold ultrasound which the dose was kept constant group (HPPT-US 1)|Participants in HPPT-US 1 group received one session of HPPT-US treatment which the dose was kept constant. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
9691469|NCT04823013|Experimental|high power pain threshold ultrasound which the dose reduced to one half group (HPPT-US 2)|Participants in HPPT-US 2 group received one session of HPPT-US treatment which the dose reduced to one half. The technique delivers sound waves directly to the myofascial trigger points and results in immediate pain relief.
9691470|NCT04823013|Experimental|ischemic compression group|Participants in IC group received one session of ischemic compression therapy. Ischemic compression is a therapy technique used in manual therapy, where blockage of blood in an area of the body is deliberately made, so that a resurgence of local blood flow will occur upon release.
10181266|NCT03785444||Non-Intensive Care Patients|Postoperative patients who have not been admitted to intensive care but to the normal ward
10181267|NCT03785470|Experimental|Fructose and physical inactivity|Subjects will consume 6 cans of soda per day and restrict their physical activity.
10181268|NCT03785327|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
9691471|NCT04823000|Experimental|Repeated MSCs treatment in MS patients|Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)
9691472|NCT04823338|Experimental|Conectar Jugando Online Program|The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Sherlock Express (Kermarrec, 2019), Streams (Itsubaki, 2011) and Blurble (Bernard, 2013). The play sessions were carried out in groups of between 2 and 4 boys and girls of similar ages (same school stage) formed according to the availability of the participants. In the sessions, the physical games were projected on the videoconference tool by the researcher and the participating boys and girls carried out their actions using their voice and the platform tools. The program was gamified though a narrative about a space travel to different planets in discovering new games and get different mission badges and super team badges in their logbook.
9691473|NCT04823338|No Intervention|Wait-list group|Wait-list
9691474|NCT04823312|Experimental|Medtronic Duo Extended Set|These subjects will be using 4 Duo Extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
9691475|NCT04823078|Active Comparator|Activity base therapy|
10181269|NCT03785327|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
10181270|NCT03785327|Experimental|Autism Training Program|Training program designed to increase autism understanding followed by behavioral testing Intervention:Training program
10181271|NCT03785327|No Intervention|Social interaction without intervention|Control condition: Behavioral testing without an intervention component
10181272|NCT03785340|Experimental|OCU-310|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks
10181273|NCT03785340|Placebo Comparator|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks
10181274|NCT03785314|Active Comparator|injection under sitting position|saline injection under sitting position during thoracic epidural catheterization
10181275|NCT03785314|Active Comparator|injection under lateral decubitus position|saline injection under lateral decubitus position during thoracic epidural catheterization
10181276|NCT03785158|Active Comparator|Melatonin|3 mg of liquid melatonin by oral route for 8 days. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
10181277|NCT03785158|Placebo Comparator|Placebo Group|Similar looking/tasting 3 mg (5 ml) placebo syrup administered preoperatively by oral route and for the next 7 days or until discharge. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
10181278|NCT03785132||cardiac surgery|Patients who underwent cardiac surgery with cardiopulmonary bypass
10181279|NCT03785223|Experimental|Methylphenidate Hydrochloride Controlled-Release Capsules|Flexibly dosed at 25-100 mg per day
10181280|NCT03785223|Placebo Comparator|Placebo Capsules|1-4 capsules daily
10181281|NCT03785002|Experimental|vegetarian|Individuals who do not consume meat (vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
9691476|NCT04823078|Other|Strength training|
9976292|NCT01350037|Active Comparator|alfentanil 0.08 mg/ml|sedative mixture for PCS consisting of propofol 10 mg/ml 20 ml, alfentanil 0.5 mg/ml 4 ml,NaCl 9mg/ml 1ml
9976293|NCT01350050|Active Comparator|articaine|Pharyngeal anesthesia with articaine 4% or placebo should randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of Articaine 4%solution or placebo (NaCl 0,9%) will be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with articaine (or placebo) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
9976294|NCT01350050|Placebo Comparator|placebo|Pharyngeal anesthesia with placebo or articaine 4% should be randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of placebo or Articaine 4% solution should be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with placebo(or articaine) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
9976295|NCT01350063|Experimental|Aquatabs and Safe Storage Vessel|Households in this group will receive Aquatabs for water purification, a safe water storage container to prevent contamination during storage in the home, and training and encouragement to treat and safely store their water using the provided products.
10181282|NCT03785002|Active Comparator|non vegetarian|Individuals who do consume meat (non vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
10181283|NCT03785015|Experimental|Withold aspirin till after endoscopic haemostasis|Withhold the standard treatment of aspirin within 12 hours after endoscopic haemostasis.
10181284|NCT03785015|Active Comparator|Withold aspirin till 72 hours|Withhold the standard treatment of aspirin till 72 after endoscopic haemostasis.
10181285|NCT03785288|Active Comparator|HDR VBT 3 fxs of 7Gy|Arm 1: HDR vaginal brachytherapy 3 fractions of 7Gy
10181286|NCT03785288|Active Comparator|HDR VBT 6 fxs of 4Gy|Arm 2: HDR vaginal brachytherapy 6 fractions of 4Gy
10181287|NCT03785184|Experimental|Venetoclax + Lenalidomide + Dexamethasone|Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
9691477|NCT04822974|Experimental|STUDY ARM|blood samples collection
9691478|NCT04823026||Group 1|"70 young infants with proven bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
10181288|NCT03785119||Standard strategy|According to embryo quality (morphologic criteria)
9976296|NCT01350063|Experimental|Safe Storage Vessel|Households in this group will receive a safe water storage container, and training and encouragement to safely store their water using the provided products. If our study shows that treatment of tubewell water at the household level is effective in protecting children's health, they will receive a six-month supply of water treatment tablets at the end of the study.
9976297|NCT01350063|Other|Standard practice|Households in this group will not receive any water treatment or storage intervention during the study. They will continue their usual water collection and storage practices. If our study shows that treatment and safe storage of tubewell water at the household level is effective in protecting children's health, they will receive the same safe water storage container as Groups 1 and 2 as well as a six-month supply of water treatment tablets at the end of the study.
9691479|NCT04823026||Group 2|"70 young infants with non-bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
9691480|NCT04823026||Group 3|"30 young infants without infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
9691481|NCT04822922|Experimental|low dose|hUC-MSCs 4*10^5/kg/each time
9691482|NCT04822922|Experimental|middle dose|hUC-MSCs 8*10^5/kg/each time
9691483|NCT04822922|Experimental|high dose|hUC-MSCs 12*10^5/kg/each time
9691484|NCT04822909|Experimental|Apremilast group|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids."
9691485|NCT04822857||1|AMH > cut-off point
9691486|NCT04822857||2|AMH < cut-off point
9691487|NCT04822831|Experimental|Long-term Ventilator-dependent Patients with intervention|45 Degree Semi-recumbent Position With Upper Limb Exercise Training on Long-term Ventilator-dependent Patients
9691488|NCT04822831|Experimental|Long-term Ventilator-dependent Patients without intervention|There is no intervention on Long-term Ventilator-dependent Patients ,and just keep routine treatment.
9696296|NCT04768920|Experimental|Teletx|The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 ~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc).
9696297|NCT04768530|Active Comparator|Scaling and Root Planing (SRP)|
9696298|NCT04768530|Experimental|Scaling and Root Planing with Nitazoxanide hydrogel|
9696299|NCT04768959|No Intervention|No Intervention: TAU + waiting list|This control group is a waiting list group. Participants received treatment as usual (TAU). Once the RCT is finished, participants have the chance to participate in the intervention group.
9696300|NCT04768959|Experimental|Experimental: TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
9696301|NCT04768465||Combined Immunotherapy|"MG patients are treated with tacrolimus combined with low-dose prednisone (0.25mg/kg/d).~Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d)."
9696302|NCT04768465||Tacrolimus monotherapy|MG patients are treated with tacrolimus as initial immune monotherapy. Symptomatic treatment like pyridostigmine bromide can be added to relieve symptoms (≤480mg/d).
9696303|NCT04768491||dacomitinib treatment|Sequential Therapy with Dacomitinib as First-line Treatment Followed by 3rd generation EGFR-TKI in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
9696486|NCT04766307|Active Comparator|Control regimen group|"The control group regimen: 2H(Isoniazid)R(Rifampicin)Z(Pyrazinamide)E(Ethambutol)/4HR~Dosage: isoniazid 300mg(given once daily),rifampin 450mg(less than 50kg,given once daily) or 600mg(more than 50kg,given once daily),pyrazinamide 1500mg(less than 50kg,given once daily) or 30mg/kg(more than 50kg,given once daily),ethambutol 750mg(less than 50kg,given once daily) or 1000mg(more than 50kg,given once daily)."
9976298|NCT01350076|Active Comparator|control group|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
9976299|NCT01350076|Experimental|study group|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
9976300|NCT01350089|Placebo Comparator|Placebo|
10181289|NCT03785119||Experimental strategy|Association of embryo quality and sCD146 rate
10181290|NCT03784950|Experimental|Rating tool only|Rating eConsults from peer specialists in first phase
10181291|NCT03784950|Experimental|Feedback only|Receiving feedback from peer specialists in first phase
10181292|NCT03784950|Experimental|Rating Tool plus Feedback|Both rating and feedback in second phase.
10181293|NCT03785301|Experimental|FGM group|Diabetic patients will use FreeStyle Libre Flash Glucose Monitoring (FGM) system(unmasked) to monitor glucose level once a month for 3 months.
10181294|NCT03785301|No Intervention|SMBG group|Diabetic patients will use Standard Blood Glucose Monitoring (SMBG) to monitor glucose level for 3 months. A 14-day masked wear of FreeStyle Libre H Flash Glucose Monitoring system is included for these subjects once a month, to collect glycaemic variability data for comparison to the intervention group of the study.
10181295|NCT03785054|Experimental|Cohort 1|6 subjects receiving a single dose of 1 mg capsule HTL0014242 and 2 subjects receiving matching placebo oral capsule
10181296|NCT03785054|Experimental|Cohort 2|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
10181297|NCT03785054|Experimental|Cohort 3|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
10181298|NCT03785054|Experimental|Cohort 4|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
9691489|NCT04822792||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
9691490|NCT04822792||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
9691491|NCT04822792||Healthy Arm|Participants without known presence of malignancies or benign disease, from whom blood samples will be collected
9691492|NCT04822779|Active Comparator|Active Group|"This group will receive ultrasound therapy.~Respondents will conduct individual medical-gymnastics: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
9691493|NCT04822779|Sham Comparator|Control Group|"This group will receive sham ultrasound therapy.~Respondents will conduct the same individual medical-gymnastics, as in the active group: unloading pendular exercises if strength exercises cannot be started immediately, shoulder range exercises, and rotator cuff and scapula stabilizer exercises for 30 minutes per treatment."
9691494|NCT04823065|No Intervention|Control group|4FMFES injection is performed as usual, no supplemental medication is used.
10181299|NCT03785054|Experimental|Cohort 5|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
9691495|NCT04823065|Experimental|Loperamide|Patients will receive 4 mg loperamide per os 15 minutes prior injection of the 4FMFES radiotracer dose. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
9691496|NCT04823065|Experimental|Hyoscine-N-butylbromide|In a similar fashion that what is used for some gastro-intestinal radiological examinations, repeated intravenous injection of 20 mg hyoscine-N-butylbromide will be applied at 0, 20 and 40 minutes following 4FMFES injection. As a peristalsis inhibitor, it is expected that this medication will slow down the intestinal progression of the radio-metabolite bolus and thus spare the lower abdomen (where the assessed organs of interest are) of overwhelming background that could impair diagnosis.
9691497|NCT04823130|Experimental|Dupilumab|Double dose on Day 1 and followed by single dose every 2 weeks (Q2W).
9691498|NCT04822896|Experimental|Kinesthetic Motor Imagery|They will be asked to imagine the exercises kinesthetically from a first person perspective (as if they were doing it themselves).
9691499|NCT04822896|Experimental|Visual Motor Imagery|They will be asked to imagine the exercises visually from a third person perspective (as if they were watching from the mirror / from the mirror while doing it themselves).
9691500|NCT04822896|Active Comparator|Real Physical Movements|They will be asked to actually do the exercises shown in the video.
9976301|NCT01350089|Active Comparator|Comparator 1 (with alcohol)|
9976302|NCT01350089|Active Comparator|Comparator 2 (with alcohol and coffeine)|
9691503|NCT04822688||Basic Science (Biospecimen collection)|Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.
9691504|NCT04822428|Experimental|study group(A)|Group (A): included Twenty patients who received osteopathic manipulative techniques, 1 session per week for 3 weeks.
9691505|NCT04822428|No Intervention|Control group(B)|Group (B): included twenty patients who received analgesic drugs only.
9691506|NCT04822493|Experimental|Counseling Aid|"A. Complete the demographic questionnaire, the survey questions, and then complete the counseling aid. Receive standard counseling as part of routine prenatal care.~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
9691507|NCT04822493|No Intervention|Standard Care|"A. Complete the demographic questionnaire and survey questions without watching the educational video. Receive standard counseling as part of routine prenatal care.~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
9691508|NCT04822506|Experimental|Routine perioperative management and PEA|Routine perioperative management and perioperative electroacupuncture (preoperative, intraoperative, postoperative)；
9691509|NCT04822506|Active Comparator|Routine perioperative management and postEA|Routine perioperative management and postoperative electroacupuncture
9691510|NCT04822558|Other|Ankle and hindfoot reconstruction surgery|Patients who underwent an ankle- or hindfoot reconstruction surgery
9976303|NCT01350089|Experimental|Comparator 3 (with alcohol and energy drink)|
9976304|NCT01350154|Experimental|Sildenafil (Revation) 20 mg|This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
9976305|NCT01350154|Experimental|Placebo|This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
10181300|NCT03785054|Experimental|Cohort 6|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
9691511|NCT04822805|Experimental|Treatment with Anlotinib|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
9691512|NCT04822649|Other|Heart failure with preserved ejection fraction|Adenosine stress echocardiography, body composition, and cardiopulmonary exercise test will be done in all of the enrolled patients. Left ventricular end-diastolic pressure will be assessed during coronary angiography.
10181301|NCT03785054|Experimental|Cohort 7|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
10181302|NCT03785054|Experimental|Cohort 8|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
10181303|NCT03785054|Experimental|Cohort 9|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
10181304|NCT03785041|Active Comparator|Levobupivacaine and tramadol Preemptive|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.
10181305|NCT03785041|Active Comparator|Tramadol and levobupivacaine postoperative|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.
10181306|NCT03785041|Active Comparator|Tramadol and levobupivacaine preemptive and postoperative|20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.
9691513|NCT04822571|Other|Adolescent volunteers|Adolescent males aged 12-16 years old
9691514|NCT04822571|Other|Adult volunteers|Adult males aged 25-35 years old
9691515|NCT04822584|Experimental|Phototherapy associated with active treatment|"Baricitinib 4 mg/day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of baricitinib)"
9691516|NCT04822584|Placebo Comparator|Phototherapy associated with placebo|"Placebo once a day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of placebo of baricitinib)."
9691517|NCT04822636|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
9691518|NCT04822636|Active Comparator|Standard of care, then family-based mental health navigation|During wait-list period receive standard of care engagement practices and services-as-usual, and after the wait-list period the participants receive the family-based navigator intervention combined with mHealth practices
9691519|NCT04822623||MS|
9691520|NCT04822623||NMOSD|
9691521|NCT04822623||Control|
9691522|NCT04822415|Experimental|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
10181307|NCT03785041|Active Comparator|Levobupivacaine|20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.
10181308|NCT03784859||All patients in study|5 consecutive patients with breast cancer or a breast cancer-causing gene that elect to undergo bilateral breast reconstruction will be Insertion of Tissue Expander with Fluid Reservoir as the first stage of reconstruction. Post-surgical care will be similar as patients with conventional expanders, except that during office visits, fluid will be transcutaneously aspirated from the fluid reservoir on each side.
9691523|NCT04822415|Active Comparator|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
9691524|NCT04822532|Experimental|Pharmacogenetic based-model (GSTA1)|
9691525|NCT04822532|Active Comparator|The most performing method based on age and weight - McCune's model|
9691526|NCT04822454|Experimental|Night shift shadowing program|Medical students who participated in a night shift shadowing program prior to their first official night shifts
9691527|NCT04822454|No Intervention|No night shift shadowing program|Medical students who did not participate in the night shift shadowing program prior to their first official night shifts
9691528|NCT04822844|Experimental|Aromatherapy with Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
9691529|NCT04822675|Experimental|Percutaneous mitral repair|Percutaneous mitral repair +/- coronary artery bypass grafting within 14 days of mitral repair.
9691530|NCT04822675|Active Comparator|Mitral valve surgery|Surgical mitral valve surgery +/- coronary artery bypass grafting
9691531|NCT04822714|Experimental|Mobile Career Competencies Intervention|The intervention protocol has five main components and is designed in English language. The first component consists of an educational session. The second component focuses on one's reflection on motivation and qualities. The third component assists users in working out strategies with others. The fourth component prompts users to reflect on and narrate their emerging career stories through goal-setting identification activities. The fifth component includes the government's human resource practices, training programs offered, and policies. The fourth and fifth component require users to reflect on their work exploration and career control career competencies.
9691532|NCT04822714|No Intervention|Waitlist control|Waitlist control group attended work and basic training from the organization as usual. They only receive the mobile intervention after the intervention group completing of the intervention.
9691533|NCT04822870|Experimental|quadratus lumborum block|Parturients receive ultrasound-guided quadratus lumborum block as post-operative analgesia.
10181309|NCT03784976|Experimental|Intervention|Patients in the intervention group will first undergo 3 months of regular care and then 3 months of biweekly yoga classes. Participants will complete surveys at baseline, 3 months (after of control care), 6 months (after 3 months of biweekly yoga classes), and 12 months (after 6 months of observation and optional yoga practice).
10181310|NCT03784976|No Intervention|Control|The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end
9691534|NCT04822870|Experimental|iliohypogastric/ilioinguinal nerve block|Parturients receive ultrasound-guided iliohypogastric/ilioinguinal nerve block as post-operative analgesia.
9691535|NCT04822870|Active Comparator|epidural analgesia|Parturients receive epidural morphine via epidural catheter placed during anesthesia as post-operative analgesia.
9691536|NCT04822311|Experimental|Investigate the effects of an exercise intervention on retired APF players|20 retired APF players (≥ 18 years of age), who suffer from chronic pain, will be enrolled.
10181311|NCT03785080|Experimental|restart NOAC very early|restart NOAC within 24 hours
10181312|NCT03785080|Active Comparator|restart NOAC early|restart NOAC at 72 - 84 hours
9691537|NCT04822324|Experimental|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion.~shoulder flexion with elbow extension.~circumduction with compression~circumduction with distraction~shoulder abduction and internal rotation with elbow flexion.~shoulder adduction and external rotation with elbow flexion~stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
9691538|NCT04822324|Active Comparator|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
9691539|NCT04822285|Experimental|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition& follow up).
9691540|NCT04822285|Active Comparator|Routine Psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
9691541|NCT04822246|Other|Control: Hand instrumentation for caries excavation|Hand instrumentation for caries excavation
9691542|NCT04822246|Experimental|Intervention 1: EMS Airflow device for caries excavation|Powder/water jet prophylaxis device (EMS Airflow) for caries excavation
9691543|NCT04822246|Experimental|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|Hand excavation and Powder/ jet prophylaxis device (EMS Airflow) for caries excavation
9691544|NCT04822064|Experimental|intranasal dexmedetomdine and kemtaine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
9976306|NCT01350167|Active Comparator|Triphasic CT|Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
10181313|NCT03784781||Asthmatic children|Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
9691545|NCT04822064|Active Comparator|oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
9691546|NCT04822116|No Intervention|standard of care|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol."
9691547|NCT04822116|Active Comparator|goal directed intraoperative haemodynamic optimization|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol. Additional application of a non-invasive haemodynamic optimization protocol in the post anaesthesia care unit."
9691548|NCT04822220|Experimental|Experimental|Fatigue Self-management Programme
9691549|NCT04822220|No Intervention|Controlled|The control group received routine treatment and nursing care
9691550|NCT04821973|Active Comparator|Control Respiratory Monitoring Group|
9691551|NCT04821973|Experimental|Experimental Respiratory Monitoring Group|
9691552|NCT04822012||Female|Female patients going through an egg retrival procedure and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
9691553|NCT04822012||Male|male patients going through an in vitro fertilization cycle and were identified as post COVID-19 vaccine/ post COVIS-19 infection or not post vaccine/post disease and screened negative for COVID-19 in the week prior to the procedure.
9691554|NCT04822233|Experimental|Hall Technique (HT)|
9691555|NCT04822233|Experimental|Modified Hall Technique (MHT)|
9691556|NCT04822233|Active Comparator|Conventional Technique (CT)|
9691557|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and dietary recommendations|Patients with scleroderma and hypovitaminosis D who receive dietary recommendations
9691558|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and Vitamin D supplementation|Patients with scleroderma and hypovitaminosis D who receive Vitamin D supplementation
10181314|NCT03784781||Controls|Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.
10181315|NCT03784794|Experimental|Thromboelastometry|Decision to treat will be guided with thromboelastometry results, for fribrinogen deficiency the investigators will treat with fibrinogen concentrate (human), for correction of factor deficiency Prothrombin Complex Concentrates, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
9691559|NCT04822077|Experimental|Proton radiotherapy|"Proton radiotherapy with RBE doses:~Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
9691560|NCT04821921||Patients with diabetes mellitus|Approximately 750 patients with diabetes mellitus from 3 GP practices specialized on diabetes treatment
9691561|NCT04821882|No Intervention|Control|Healthy participant
9691562|NCT04821882|Experimental|Dextrose treatment|IC/PBS patients had been treated by intravesical instillations of hyaluronic acid and/or botox for more than 6 months
9691563|NCT04821856|Experimental|Cannabidiol 100mg/ml|"The starting dose of cannabidiol (CBD) will be 5 mg/kg/day and will be administered orally twice daily in doses of 2.5 mg/kg (up titration phase from day 1 to 7). After one week, the dose of CBD will be increased to 10 mg/kg/day in two daily doses of 5mg/kg (8-week maintenance phase from day 8 to 63). On completion of the maintenance phase the dose of CBD will be decreased to 5mg/kg/day for one week (day 64 to 70), after which the CBD administration will cease.~A ceiling dose of 1000mg/day will be administered to all participants weighing 100kg or greater. These participants will receive a dose of 500mg/day during up- and down-titration.~Doses will be rounded to the nearest 10mg (0.1mL)."
9691564|NCT04821856|Placebo Comparator|Placebo|"The control group will receive placebo medium-chain triglyceride (MCT) oil which is indistinguishable from the active medication in appearance, smell and taste.~Dose will be matched for volume to the cannabidiol arm, and administered twice daily for 10 weeks (including up- and down-titration)."
9691565|NCT04821947|Active Comparator|RIB Group|Drug: Bupivacaine 0.25% patients will receive 20 ml of bupivacaine 0.25% in the rhomboid plane under rhomboid major muscle
9691566|NCT04821947|Active Comparator|LA Group|Drug: Bupivacaine 0.25% patients will receive wound infiltration of VATS incision, single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine .
9691567|NCT04822090||Group I|HHA patients with acute symptomatic HPV-B19 infection
9691568|NCT04822090||Group II|HHA patients without acute symptomatic HPV-B19 infection
9691569|NCT04822207|Experimental|Acupuncture group|In the acupuncture group, those patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
9691570|NCT04822207|No Intervention|Control group|In the control group, these patients do not receive any treatments during embryo transfer cycle. These patients should be checked including endometrial receptivity index and fill in SAS anxiety scale form.
9691571|NCT04822051|Experimental|Psychoeducation Group|"Uncertainty Management Psychoeducation Program was given."
9691572|NCT04822051|No Intervention|Control Group|No attempt was made by the researcher during the study. Only data collection was carried out.
9691573|NCT04821843|Experimental|(Neoadjuvant chemotherapy) nCT|This arm received chemotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
9691574|NCT04821843|Placebo Comparator|(Neoadjuvant Chemoradiation) nCRT|This arm received chemoradiotherapy with or without immunotherapy/targeting agents as neoadjuvant treatment.
9691575|NCT04821817|Placebo Comparator|Group C (Control group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
9691576|NCT04821817|Experimental|Group R (rocuronium group)|Patients in this group will receive peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
9691577|NCT04821700||Patients with Carotid stenosis|Ischemic stroke patients with atrial fibrillation and carotid stenosis
9691578|NCT04821700||Patients without Carotid stenosis|Ischemic stroke patients with atrial fibrillation without carotid stenosis
9691579|NCT04821778|Placebo Comparator|Definitive Chemoradiation|This arm received chemoradiation without immunotherapy/targeting agents as definitive treatment.
9691580|NCT04821778|Experimental|Chemoradiation Combined With Immunotherapy/targeting agents|This arm received chemoradiation with immunotherapy/targeting agents as definitive treatment.
9691581|NCT04821479|Experimental|Repeated MSCs treatment in ALS patients|Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10^6 MSCs per kg body weight in 3 ml saline.
9691582|NCT04821466|Experimental|Virtual Reality Headset|VR headset, programmed with a selection of 7 wellbeing programs to identify if use will improve participants wellbeing
9691583|NCT04821492||Hyperhomocysteinemia|
9691584|NCT04821492||Normal Hcy levels|
9691585|NCT04821739|Experimental|Treatment with AGN1 LOEP SV Kit|VCF is treated with the AGN1 LOEP SV Kit
9691586|NCT04821427|Experimental|Brief mHealth Intervention + mobile messaging|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages
9691587|NCT04821427|No Intervention|Assessment Only|This is an assessment only condition. No intervention following completion of baseline surveys will be administered.
9691588|NCT04821583|Experimental|Hydrocortisone|Hydrocortisone (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The hydrocortisone periods last 10 weeks per period. In total, there are two hydrocortisone periods.
9691589|NCT04821583|Placebo Comparator|Placebo|Placebo (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The placebo periods last 10 weeks per period. In total, there are two placebo periods.
9691590|NCT04821518||The study group (post-stroke)|The study group consisted of 26 patients in whom ischaemic brain stroke occurred within 14 days before the admission to the Clinical Department, and were hospitalised at the Department of Neurological Rehabilitation of the Clinical Department of Rehabilitation in the Wiktor Dega Orthopaedic and Rehabilitation Clinical Hospital in Poznań
9691591|NCT04821518||The control group|The control group was composed of 26 healthy individuals recruited from the hospital staff who did not experience stroke.
9691592|NCT04821635|Experimental|Rower|Single group of 35 traumatic paraplegic patients meeting the inclusion criteria will benefit from the FES-ROW protocol during 9 months
10181316|NCT03784794|Active Comparator|STANDARD COAGULATION TEST ALGORITHM|Decision to treat will be guided by standard cogulation lab test (Thrombine time, Active Thromboplastine time, Clauss fibrinogen, platelets count etc) for fribrinogen deficiency the investigators will treat with cryoprecipitates, for correction of factor deficiency fresh frozen plasma, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
10181317|NCT03784768|Experimental|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
9691593|NCT04821440|Active Comparator|Lower Limb Lymphedema|Patients suffering from unilateral lower-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
9691594|NCT04821440|Active Comparator|Upper Limb Lymphedema|Patients suffering from unilateral upper-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
9691595|NCT04821765|Experimental|Chemoradiotherapy Combined With PD-1 Antibody|The arm received chemoradiotherapy, 50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week) to recurrent sites combined with chemotherapy（Cisplatin 75 mg/m2/day 1, and albumin paclitaxel 150 mg/m2/day 1 , every 3 weeks, 2 cycles ).PD-1 antibody (Tislelizumab) was performed simultaneously with concurrent chemoradiotherapy (Triprizumab 200mg，d1，every 3 weeks，2 cycles). After completion of chemoradiotherapy, PD-1 antibody was given continuously with 2-4 cycles of chemotherapy (the same regimen with concurrent chemotherapy) until 1 year or desease progression.
9691596|NCT04821323|Experimental|Indomethacin Challenge|Participants will receive challenge agent as two single oral doses of Indomethacin, one on Day -1 and one on Day 1. In addition, participants will receive lactulose-mannitol solution on Day -4 (baseline) and on Day 1 (post Indomethacin challenge).
9691597|NCT04821596|Experimental|Multiple Sclerosis Patients|Multiple Sclerosis Patients usually followed by Dr. Bourre as part of his consultation at the Rouen University Hospital will be offered the opportunity to participate in this study if they meet the selection criteria.
9691598|NCT04821453|Placebo Comparator|Conventional Flow Triggered Mechanical Ventilation (CMV)|Subjects will be ventilated with conventional mechanical ventilation with data collected for the 5 day time frame to compare to the experimental arm
9691599|NCT04821453|Experimental|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be ventilated on neurally adjusted ventilatory assist (NAVA) mode with data collected for the 5 day time frame to compare with placebo arm
9691600|NCT04821804|Experimental|Experimental|local application of HYADENT BG on both donor and recipient sites
9691601|NCT04821804|Placebo Comparator|control|application of normal saline on both donor and recipient sites
9691602|NCT04821687|Experimental|Opicapone 50mg|
9691603|NCT04821687|Active Comparator|Levodopa 100mg|
9691604|NCT04821336||Thyroid tissue samples|from 30 patients, tissue samples , frozen and embedded paraffin have been collected and preserved for research. For this study, tumoral tissue and healthy tissue will be used;
9691605|NCT04821557|Experimental|Microbial Protease Supplement|A microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) is taken with a 25g pea protein beverage. The test article will be provided in 250mg capsule form. Capsules will be opened and mixed into protein shake 5 minutes before ingestion.
9691606|NCT04821557|Placebo Comparator|Placebo (Maltodextrin)|The placebo (maltodextrin) article will be provided in 250mg capsule form. Capsules will be opened and mixed into 25g pea protein shake 5 minutes before ingestion.
9691607|NCT04821505|Experimental|Meditation|The Transcendental Meditation program is described as a simple natural technique practiced for 20 minutes twice daily for deep rest and relaxation. Previous studies have shown its feasibility, validity, and reliability in Blacks at risk for CVD.
9691608|NCT04821505|Active Comparator|Health Education|Health education program matched to the experimental intervention for time, attention, and other non-specific factors.
10181318|NCT03784768|Active Comparator|Control Group|Patients in the control group will be received 60-minute conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
9691609|NCT04821167|Other|Laparoscopic orchiopexy for intra-canalicular (emergent or peeping) testis|This is a prospective study conducted on male children with intermittent palpable (peeping) UDT to evaluate the safety and efficiency of laparoscopic orchiopexy of intra-canalicular (emergent or peeping) testis.
10181319|NCT03785067|Experimental|Triple Pill (Active Treatment)|"Main Study: Fixed low-dose combination BP-lowering pill (Triple Pill) telmisartan 20mg + amlodipine 2.5mg + indapamide 1.25mg~Sub-Study: single-arm"
10181320|NCT03785067|Placebo Comparator|Placebo|"Main Study: Matched placebo, received via blinded study capsules~Sub-Study: single-arm"
10181321|NCT03784729|Experimental|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted."
10181322|NCT03784729|Sham Comparator|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm.
10181323|NCT03784664|Active Comparator|Arterial blood gas|
10181324|NCT03784664|Experimental|Veinous blood gas|
10181325|NCT03785171||Moyamoya disease|The cohort includes patients with Moyamoya disease diagnosed by DSA examination who are treated by surgical revascularization.
10181326|NCT03785093||Chinese Family|Chinese parents and their offsprings
10181327|NCT03784885|Experimental|30 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 30 μg of AD07010
9691610|NCT04821388|Experimental|intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries.|
9691611|NCT04821297|Experimental|Supportive care (message)|Patients receive text messages for 1-2 months before scheduled appointment. Patients also complete a survey at baseline and after standard of care colposcopy and an interview after standard of care colposcopy.
9691612|NCT04821349|Other|Single arm study|Standard reading Group vs AI-assisted reading Group
9691613|NCT04821232|Experimental|interventional|"Students in the intervention group will be given a total of 120 minutes out of 40 minutes, and 24 sessions of yoga for 8 weeks, 3 days a week. The researcher who will make yoga with each student will be sent videos on the online platform, including a yoga introduction and a full yoga session with the students after a yoga session. The students were asked to do yoga 3 times a week in accordance with the video and the researcher will be called twice a week to get information about the process. Content of education;~Breath Awareness Training (10 minutes)~Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
9691614|NCT04821232|Other|Control groups|No intervention will be applied to students in the control group.
9691615|NCT04821102|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
9691616|NCT04821102|Placebo Comparator|Saline|saline
9691617|NCT04821063|Experimental|Therapeutic dose: ITF2357 100 mg|Participants will receive a single dose of ITF2357 100 mg administered as 10 milliliters (mL) of ITF2357 10 milligrams per milliliter (mg/mL) oral suspension and 20 mL of placebo matched to ITF2357 oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
9691618|NCT04821063|Experimental|Supratherapeutic dose: ITF2357 300 mg|Participants will receive a single dose of ITF2357 300 mg administered as 30 mL of ITF2357 10 mg/mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
9691619|NCT04821063|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matched to ITF2357 administered as 30 mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
9691620|NCT04821063|Active Comparator|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg tablet under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
9691621|NCT04821401|Experimental|Males study product|25 men will be randomized to Rejuvant
9691622|NCT04821401|Placebo Comparator|Males placebo|25 man will be randomized to placebo
9691623|NCT04821401|Experimental|Females study product|25 women will be randomized to Rejuvant
9691624|NCT04821401|Placebo Comparator|Females placebo|25 women will be randomized to placebo
9691625|NCT04821076|Active Comparator|Energy balance|
9691626|NCT04821076|Experimental|Energy restriction|
9691627|NCT04821076|Active Comparator|Energy balance + exercise|
9691628|NCT04821076|Experimental|Energy restriction + exercise|
9691629|NCT04821206||Cases|Patients with diagnosis of RA, PsA and SpA
9691630|NCT04821206||Controls|Patients with diagnosis of RA, PsA and SpA
9691631|NCT04821258|Experimental|MICODIGEST 2.0 supplement|Treatment with MICODIGEST 2.0 will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20mL/day (10mL before breakfast and 10 mL before dinner) for 4-6 weeks.
9691632|NCT04821258|Placebo Comparator|Placebo|Treatment with placebo will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20 mL/day (before breakfast and before dinner) for 4-6 weeks.
9691633|NCT04821180||patients treated by angle stable plate PHILOS|
9691634|NCT04821180||patients treated by reverse total shoulder arthroplasty SMR|
9691635|NCT04821193|Experimental|Experimental Group 1|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 5% NaHCO3 water solution group Grup number: 20
9691636|NCT04821193|Experimental|Experimental Group 2|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 2% Chlorhexidine Gluconate solution group Grup number: 21
9691637|NCT04821193|No Intervention|Control Group|Cleansing the skin with an antiseptic solution before intravenous catheterization Skin antisepsis with 70% Alcohol solution group Grup number: 21
9691638|NCT04821037|Experimental|ACT|"A digitally-based ACT program will be conducted in two half-day workshops via meeting software (e.g. Zoom) consisting of:~mindfulness exercises, for stress reduction and to guide nurses to observe their painful thoughts and feelings that they are attempting to avoid;~ACT-metaphors, to let nurses realize the cost of struggling with psychological distress often create more distress;~experiential exercises, to guide nurses to notice their own experiences in providing nursing care throughout their nursing career and explore any special qualities;~explore the nurses' values with respect to different areas in their lives."
9691639|NCT04821050|Experimental|Treatment|Sacral nerve stimulation
9691640|NCT04821050|Sham Comparator|Control|Sham stimulation
9691641|NCT04821024||mild-moderate disability|Those whose neck disability index value is 5-34
9691642|NCT04821024||high disability|Those whose neck disability index value is 35 and above
9691643|NCT04820777|Experimental|perturbation based training|External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
9691644|NCT04820777|Active Comparator|Conventional' balance training|"Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor.~Rehash with your correct leg, exchanging to and fro between legs for a sum of 20 repitions (10 on every leg).~Situated Marching Starting with a situated position, lift your effected leg towards your chest, making an honest effort to keep up controlled development."
9691645|NCT04820790|Experimental|Experimental Group 1|The efficiency of the mobile app in the follow-up of patients with home oxygen will be evaluated during 6 months
9691646|NCT04820790|No Intervention|Intervention Group 2:|Regular monitoring of the home oxygen without mobile app during 6 months
9691647|NCT04820725|Experimental|Study group|Patients whose BASMI score is 2 will be included in the study
9691648|NCT04820725|Experimental|Control group|Patients whose BASMI score is 0 and 1 will be included in the study
9691649|NCT04821128||Patients who improved surgical treatment for oral cavity cancer|T1 T2 and T3 OSCC tumor, patients who have a recent evaluation cervico thoracic scanner in their medical files.
9691650|NCT04820751|Experimental|Cyproheptadine and standard care|"Start Cyproheptadine 8mg three times a day during 5 days. Dose will be reduced to 4mg three times a day if GFR inferior to 30ml/min/1.73m²~Standard management of COVID-19 infection according to current international guidelines"
9691651|NCT04820751|No Intervention|Standard care|Standard management of COVID-19 infection according to current international guidelines
9691652|NCT04821011||Newborn birth between 28 and 40 Weeks of Gestational Age (wGA)|"Newborn birth between 28 and 40 Weeks of Gestational Age (wGA) will be included. The mother's newborn will be have a record of her heartbeats.~The newborn will be have an acoustic listening of their mother's heartbeat and a record of their own heartbeats."
9691653|NCT04820946||various episodic mood disturbances patient group|A group of patients with various episodic mood disturbances was used as a clinical case control group.
9691654|NCT04820946||Disruptive Mood Dysregulation Disorder (DMDD) patient group|DMDD patients referred to the hospital for suicidal behaviors between 2013 and 2018 in terms of diagnostic stability, psychiatric comorbidity, and psychosocial factors.
9691655|NCT04820985||Women undergoing IVF|
9691656|NCT04820933|Experimental|Doravirine plus emtricitabine and tenofovir alafenamide fumarate|PIFELTRO (doravirine) 100 mg tablet one daily for 3 months Descovy (200 mg emtricitabine + 10 mg tenofovir alafenamide fumarate) tablet one daily for 3 months
9691657|NCT04820868||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
10181328|NCT03784885|Experimental|45 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 45 μg of AD07010
9691658|NCT04820868||Healthy Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
9691659|NCT04820803|Experimental|Cetylpyridinium Chloride (CPC) 0,07%|patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds
9691660|NCT04820803|Placebo Comparator|Placebo: Distilled water with the same flavor and coloring as the product to be evaluated|patients who rinse with distilled water mouthwash for 60 seconds
9691661|NCT04820634|Experimental|VR-JIT|In this arm, participants would participate in simulated interviews utilizing a software program and virtual interviewer, once a week for 90 minutes.
9691662|NCT04820634|Placebo Comparator|Wonderworks|In this arm, participants would participate in a similar intervention, also once a week for 90 minutes. However, in this arm, the intervention would be in a virtual office environment completing office tasks.
9696304|NCT04768127|Experimental|Early aftercare (intervention group 1)|Patients in this group will begin the ACHT program immediately after their bariatric metabolic operation. 3 weeks post surgery, they will attend the initial examination and meet their case manager. The obesity guide will then set up an electronic case file for the patient and introduce the patient to the obesity app. Through the next 18 months the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 2 patients visit a sports physician who assesses their mobility and physical capacity to compile a personal training plan, which will be uploaded onto the patient's case file and thus be available to the patient via the app. In months 3,6,9.12 and 18, patients will attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined by a physician and receive tailored dietary advice from a nutritional advisor. In month 18 patients revisit the surgical centre for the follow-up examination
9696305|NCT04768127|Experimental|Mid-term to long-term aftercare (intervention group 2)|Patients in this group first visit the study center 18 months after their bariatric surgery for the initial examination and start the program in month 19 post-op. At the center, they will meet their obesity guide who will set up an electronic case file for the patient and introduce the patient to the obesity app. Throughout the next 18 months, the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 19 post-surgery, patients visit a sports physician who assesses their mobility and devises a personal training plan. This plan will be uploaded onto the patient's case file and made available to the patient via the app. In months 19,21,24, 30 and 36, patients attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined and receive tailored dietary advice. In month 36, patients will be reexamined at the study center.
9696306|NCT04768127|No Intervention|control group 1 (early aftercare)|"Analogous to intervention group I, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination (18 months after the operation) at the obesity centre.~If interested, patients in this group can be included in intervention group II until the required number of cases (140 patients) has been reached."
9696307|NCT04768127|No Intervention|control group 2 (mid-term to long-term aftercare)|Analogous to intervention group II, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination at the study center 36 months after the operation.
9696308|NCT04768179|No Intervention|Arm1 (Control group)|standard of care
9696309|NCT04768179|Experimental|Arm 2|Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
9696310|NCT04768179|Experimental|Arm 3|3-day Ivermectin 600 mcg/kg/day/14-day 75mgASA/day + standard of care (Intervention 2)
10181329|NCT03784885|Active Comparator|AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine
10181330|NCT03784742|Active Comparator|Nitrate-rich Beetroot juice|Nitrate-rich beetroot juice equivalent to 3.7 mg nitrate per kg body weight daily for 8 weeks.
10181331|NCT03784742|Placebo Comparator|Placebo beetroot juice|Placebo beetroot juice (equivalent volume to the amount of nitrate-rich beetroot juice consumed) daily for 8 weeks.
10181332|NCT03784534|Experimental|Healthy volunteers|"Subjects will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each subject to evaluate their motor skills: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer~anatomical MRI (T1 and tensor imaging) scan)"
9691663|NCT04820504|Placebo Comparator|Blinded to visual feedback from AIR device|Providers did not receive AIR device feedback during newborn mannequin ventilation
9691664|NCT04820504|Experimental|Not blinded to visual feedback from AIR device|Providers did receive AIR device feedback during newborn mannequin ventilation
9691665|NCT04820816||Posterior pelvic tilt group|"patients with chronic low back pain or repeated non-specific back pain for more than three months.~Both sex with posterior pelvic tilt (-0.7 ± 6.5°) and decreased lumbar lordosis~Their ages were ranged from 20-35 years~Body Mass Index from 18-25 Kg/m²"
9691666|NCT04820816||Normal anterior pelvic tilt group|"patients with chronic low back pain or repeated non-specific back pain for more than three months.~Both sex with anterior pelvic tilt (5° and 13°) and normal lumbar lordosis~Their ages were ranged from 20-35 years~Body Mass Index from 18-25 Kg/m²"
10181333|NCT03784534|Experimental|Patients|"Patients will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each patient to assess their motor recovery progress: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, Fugl Meyer, test of Ashworth~anatomical MRI (T1 and tensor imaging) scan)"
10181334|NCT03784495|Placebo Comparator|Placebo (P)|Placebo.
9691667|NCT04820907|Experimental|HCP1904-1|
9691668|NCT04820907|Active Comparator|RLD2001-1|
9691669|NCT04820829|Active Comparator|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
9691670|NCT04820829|Active Comparator|Moderate RM, moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
9691671|NCT04820829|Active Comparator|Low RM, high NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
10181335|NCT03784495|Experimental|Melatonin (M)|1 mg/day of melatonin.
9691672|NCT04820543|Experimental|Simplified Method|In this method, a uniform BTX-A injection technique with single-site injection of 2 U BTX-A (total, 4 U) at both right and left levator labii superioris alaeque nasi muscles (LLSAN) was administered. The injection points located at the muscle bulge at the uppermost part of the nasolabial fold.
9691673|NCT04820543|Experimental|Individualized Method|In this method, the patients were administered BTX-A after 8 months when the effect of the previous injection vanished. And A dosage and injection sites were individualized according to the degree of severity of anterior GE presented pretreatment. For mild GS (3 to< 5mm), 2 U BTX-A was injected at bilateral LLSAN. For moderate (5 to < 7mm) and severe GS (≥ 7mm), 3 U and 5 U of BTX-A were injected per side (total, 6 U and 10U). And The injection points located at both LLSAN and the Yonsei point, with half doses at each point.
10181336|NCT03784495|Experimental|Essential Aminoacids (eAA)|4 g/day of essential aminoacids
10181337|NCT03784495|Experimental|Essential Aminoacids + Melatonin (eAAM)|4 g/day of essential aminoacids and 1 mg/day of melatonin
10181338|NCT03784469|Experimental|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
10181339|NCT03784469|No Intervention|Control group|No changing body position in bed,remaining supine position in complete bed rest and immobilized for four hours.
10181340|NCT03784599|Experimental|Trastuzumab-emtansine and osimertinib|"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks~Osimertinib 80 mg once daily, orally, continuous~Treatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
10181341|NCT03784638|Experimental|lingually-based triangle flap design|In the experimental group, an incision will be made adjacent to the distal surface of the mandibular second molar, and extended along the sulcus to the distobuccal corner of the mandibular second molar. An oblique vestibular incision will made and extended into the vestibular fornix of the mandible, aligned with the mesiobuccal cusp of the second molar. It was continued posterosuperiorly towards the anterior border of mandibular ramus. The lingually-based triangle flap design will be used.
9691674|NCT04820608|Experimental|Customized, transepithelial cross-linking|All study patients will be treated according to the customized remodeled vision protocol
9976307|NCT01350167|Active Comparator|Ultrasound|Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
10181342|NCT03784638|Placebo Comparator|buccally based triangle flap design|In the control group, an incision will be made from the anterior border of the mandibular second molar. It will be extended along the sulcus to the distobuccal corner of the second molar crown. The incision will be continuous with vertical incision. The buccally based triangle flap design will be used.
10181343|NCT03784573|Active Comparator|Dog + handler|
9691675|NCT04820699|Experimental|post isometric relaxation|Group A received Post isometric relaxation technique (MET).The participants performed isometric contractions using 20% of their strength, 5 second holds with 5 seconds rest time in between each contraction
9691676|NCT04820699|Experimental|mulligan bent leg raise|Group B: Mulligan bent leg raise technique. Isometric contraction of hamstring muscle for progressively five greater position of hip flexion; three pain-free repetitions with 5 second hold was performed by participants
9691677|NCT04820738|Experimental|Experimental group|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking).
9691678|NCT04820738|Active Comparator|Control group|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
9691679|NCT04820283|Experimental|Care manager intervention (nurse)|
9691680|NCT04820283|Active Comparator|Internet-based CBT|
9691681|NCT04820361|Placebo Comparator|Placebo|oral spray
9691682|NCT04820361|Active Comparator|Sativex®|.It contains Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
9691684|NCT04820660|Experimental|Task oriented Strength training group|Standing and reaching in different directions Sit-to-stand Stepping forward and backward Stepping sideways onto blocks
9976308|NCT01350193|Active Comparator|Saline Nasal Irrigation|Saline Nasal Irrigation is actively being used as the standard of care. It does not contain any active ingredients.
9691685|NCT04820660|Experimental|Balance Training|Stepping forward, backward, and sideways on the exercise step; Stepping over blocks of various heights; Standing up from a chair, From a sitting position on a 65-cm Swiss ball, Arms; bending the trunk forward and side to side); Performing double-legged stance Performing tandem stance Rising from a chair without the use of the arms; Walking forward and backward with a tandem walking pattern Performing single- legged stance
9691686|NCT04820296|Experimental|Experimental group|Pregnant women in the experimental group will be given 4 sessions Solution-Oriented Approach program, starting at the 32th week of pregnancy. Pregnants in the experimental group will be administered the Wijma Birth Expectation/Experience Scale (W-DEQ-A) and Pregnancy Psychosocial Health Assessment Scale (PPHAS) before the intervention. After the program is completed, a training booklet will be provided for pregnant women and (W-DEQ-A) and PPHAS will be applied again. With pregnant women, 37-40. between gestational weeks, they will be contacted again, face-to-face interview method (W-DEQ-A) and PPHAS again will be evaluated. The pregnant women will inform the researcher by phone after the delivery and the researcher will visit the hospital within the first 24 hours after the delivery to evaluate the mothers' birth fear levels Scale (W-DEQ-B). At the end of the first postpartum week, the postnatal senses of security of the mothers will be evaluated by telephone follow-up counseling.
9691687|NCT04820296|No Intervention|Control group|Pregnant women in the control group will only receive routine care. Pregnant women in the control group will be administered the same scales simultaneously with the experimental group.
9976309|NCT01350193|Experimental|Manuka Honey Irrigation|Manuka Honey Irrigation involves the experimental treatment of manuka honey nasal irrigation.
10181344|NCT03784573|Placebo Comparator|No dog|
9691690|NCT04820205|Experimental|intranasal dexmedetomdine and kemtaine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
9691691|NCT04820205|Active Comparator|oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
10181345|NCT03784612|Experimental|App-technology group|"Participants in the App-technology group arm will use a newly developed smartphone application (app), containing a 12-week healthy eating program.~Intervention: App-technology for healthy eating habits."
10181346|NCT03784612|No Intervention|Control group|The control group will receive standard care.
9691692|NCT04820322|Placebo Comparator|control cookie|a sugarsnap cookie baked specifically for this trial
9691693|NCT04820322|Active Comparator|Fibersym cookie|a sugarsnap cookie baked using the same methodology for the control cookie but with the resistants starch RS4, Fibersym, added
9691694|NCT04820439|Experimental|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|
10181347|NCT03784690|Experimental|Individualized BP group|Individualized intraoperative BP management
9691695|NCT04820439|Active Comparator|Perjeta ®|
10181348|NCT03784690|Placebo Comparator|Standard treatment group|Standard intraoperative BP management
10181349|NCT03784703|Experimental|Atrovastatin|atorvastatin (40 mg per day) for 6 months
9691696|NCT04820374|No Intervention|traditional extubation indications and traditional restoration indoor requirements|
9691697|NCT04820374|Experimental|Extubate the tube according to the pupil index and leave the recovery room|
9691698|NCT04820413|Experimental|FMT|
9691699|NCT04820621|Experimental|Participants with mild hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
9691700|NCT04820621|Experimental|Participants with moderate hepatic impairment|All participants will receive a single oral dose in the fasted state on Day 1.
9691701|NCT04820621|Experimental|Participants with normal hepatic function|All participants will receive a single oral dose in the fasted state on Day 1.
9691702|NCT04820400|Experimental|VR-360 group (VR-group)|Patients will watch a VR-360 distraction video during dressing change. The patient will be asked or helped to wear the HMD write in full at the onset of a procedure and watch the VR-360 video during the dressing change procedure. When experiencing pain, the patient may indicate the need for further analgesic medication during the procedure, the patient will be asked to push a button in their hand that will trigger a light-based signal for the nurse to provide further analgesic medication. Should their hands both be involved in the burn injury, the patient will indicate the same verbally.
9691703|NCT04820400|No Intervention|Control Group (standard treatment)|The patients will receive standard treatment and will be instructed to use the same button to indicate their pain.
9691704|NCT04820231|Other|PRP injection group|"Intra-articular PRP injection with ultrasound guidance~Three times PRP injections with an interval of one week"
9691705|NCT04820270|Experimental|Autologous Tregs in allogenic islet transplantation|Autologous Tregs are given simultaneously to the patient with the islets
9691706|NCT04820036|Other|Patients with Obesity and NASH scheduled/recommended for P-ESG Procedure|We will perform a 12-month prospective, single-center, pilot observational study on patients with obesity and NASH with advanced fibrosis who are undergoing P-ESG. A total of 15 patients will undergo EUS-LB with EUS-PPG measurement in a single session prior to and at 12 months following P-ESG
10181350|NCT03784703|Experimental|Rosuvastatin|Rosuvastatin (10 mg per day) for 6 months
10181351|NCT03784807||Infected|Patients with prosthetic joint or osteoarticular infection
10181352|NCT03784807||Not infected|Patients with implant failure not due to infection
10181353|NCT03784677|Experimental|Treatment (TRPV6 calcium channel inhibitor SOR-C13)|Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10181354|NCT03784560||study group|anesthesia residents with 24 hours working shift
10181355|NCT03784443|Active Comparator|Iluvien Arm|Participants assigned to the Iluvien treatment arm will receive Iluvien 0.19 MG Drug Implant to the study eye under aseptic condition at baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
9691707|NCT04820114|Active Comparator|Control group|Wrist passive mobilizations; Actives exercises; Reeducation for Activity daily life.
9691708|NCT04820114|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
10181356|NCT03784443|Sham Comparator|Control Arm|To maintain double-masking, participants assigned to the control arm will receive Sham Intravitreal Injection at the baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
9691709|NCT04820153|Other|Study Participants|Study participants will participate in both the Physical Activity Monitoring Device intervention and the Lifestyle Redesign Coaching intervention simultaneously. Both interventions are complementary to one another.
9691710|NCT04820088|Experimental|Intervention Arm|The educational intervention will be TTACS, the training program with simulated roleplays. Each participant will be asked to schedule 10 hours of time to utilize the simulation. In order to ensure all participants adhere to the minimum intervention requirements, each will be asked to schedule training time with a member of the research team. Participants will attend an initial training session where each participant will receive a short orientation about the product and its capabilities. Participants will attend an initial training session at one of two sites Psychology Department at Towson University or SIMmersion's office in Columbia, MD based on participant preference. Subsequent training sessions may be completed at Towson, SIMmersion or can be completed individually. Participants will receive confirmation emails the day before a scheduled session and a phone call to reschedule any missed sessions.
9691711|NCT04820088|No Intervention|Contro Arm|Students randomized to the control group will be given an electronic copy of the Guidelines for Psychological Practice with Transgender and Gender Non-Conforming People (APA, 2015) and asked to take notes in the pdf document. The amount of time students spend on the document and note-taking will be recorded and notes will be analyzed for content. As an incentive, the participants in the control group will be given access to TTACS after they complete the post-intervention assessment.
9691712|NCT04819893||Women giving birth prematurely|Delivery before 29 WA
9691713|NCT04819893||Women giving birth at term|Childbirth between 39WA and 31WA+6 days
9691714|NCT04819932|Experimental|group1|subject take DWC202008 and DWC2020091 on a fasted condition, and after wash out period, take DWJ1451 with on a fasted condition
9691715|NCT04819932|Experimental|group2|subject take DWJ1451 on a fasted condition, and after wash out period, take DWC202008 and DWC202009 with on a fasted condition
9691716|NCT04819971|Experimental|TTC|
9691717|NCT04819789|Experimental|Fermotein™ dry|Fermotein™ powder presented in the form of a porridge.
9691718|NCT04819789|Experimental|Fermotein™ wet|Fermotein™ wet presented in the form of a porridge.
9691719|NCT04819789|Experimental|Fermotein™ modified wet|Fermotein™ modified wet presented in the form of a porridge.
9691720|NCT04819789|Active Comparator|Mycoprotein|This mycoprotein product presented in the form of a porridge.
9691721|NCT04819906|Experimental|T-ST-P-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691722|NCT04819906|Experimental|ST-M-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691723|NCT04819906|Experimental|P-T-M-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691724|NCT04819906|Experimental|M-P-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691725|NCT04819906|Experimental|ST-P-T-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691726|NCT04819906|Experimental|P-M-ST-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691727|NCT04819906|Experimental|T-ST-M-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691728|NCT04819906|Experimental|M-T-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691729|NCT04819906|Experimental|P-T-ST-M|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691730|NCT04819906|Experimental|T-M-P-ST|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691731|NCT04819906|Experimental|ST-P-M-T|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9696311|NCT04768192||Pediatric patients with acquired brain injury|Subjects with a acquired brain injury occurred in the last 10 months prior the beginning of the treatment
10181357|NCT03784404|Active Comparator|Non surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
9691732|NCT04819906|Experimental|M-ST-T-P|"Treatment T: Therapeutic E4 dose (20 mg): one E4 20 mg tablet plus four E4 placebo tablets~Treatment ST: Supratherapeutic E4 dose (100 mg): five E4 20 mg tablets~Treatment P: Placebo: five E4 placebo tablets~Treatment M: Moxifloxacin: 1 moxifloxacin 400 mg tablet"
9691733|NCT04820192||Post-acute concussion (<6 months) or Post-Concussion Syndrome (PCS) (≥ 6 months)|Patients were divided into cohort groupings to compare outcomes of applying CranioSacral Therapy to their unique constellations of persistent symptoms attributed to their concussion injury. Symptoms less than 3-6 months duration may be part of the usually rate of injury resolution through rest along. Symptoms persisting after 6 months are considered PCS. Less than 6 months since injury were considered post-acute concussion stage of recovery.
10181358|NCT03784404|Active Comparator|Surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
9691734|NCT04820192||Athletes (A) or Non-athletes (NA)|Reporting of symptoms that exist and/or persist may differ between patients who are/were athletes and concussions were sustained during their sporting events. Non-athletes may report differently. The types of injuries involved in the concussion were also captured.
9691735|NCT04820192||Traditional gender.|Symptoms and response to rest has been reported to have differences between male and female patients. Age under 14 years was considered an exclusion due to immaturity in insight and reporting. Thus, young adult ages and older were included and observations between gender reporting was noted.
9691736|NCT04820075|Other|Process about performance of the preoperative shower|Implementation of a process aimed at improving the preoperative shower in programmed surgery
9691737|NCT04819776|Experimental|Iloperidone|
10181359|NCT03784378|Experimental|Participants previously enrolled on Study of RXDX-105|Participants were previously enrolled on Study of RXDX-105
9691738|NCT04819776|Placebo Comparator|Placebo|
9691739|NCT04820101|Experimental|Every preterm newborns 26+0 -36+6 wGA with RDS needing surfactant therapy|Every preterm newborns 26+0-36+6 wGA who undergoes LISA procedure will receive sedation with dexmedetomidine in order to evaluate its efficacy in achieving pain control and comfort.
9691740|NCT04819750|Active Comparator|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
9691741|NCT04819750|Placebo Comparator|Headphones with noise reduction|Headphones with noise reduction without music
9691742|NCT04819672|Experimental|Low Intensity Training associated with Partial Blood Flow|In the experimental group, a cuff with compression at 60% of the pressure required for total arterial occlusion will be placed, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff with partial blood flow restriction will be used during knee extension and squat exercises.
9691743|NCT04819672|Sham Comparator|Low Intensity Training associated with Partial Blood Flow-Sham|In the sham group, the cuff will be placed, but there will be no arterial occlusion pressure, 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps (knee extension and squat). The cuff without partial blood flow restriction will be used during knee extension and squat exercises.
9691744|NCT04819529|Experimental|Experimental Group - Early and intensive Occupational Therapy|These sessions will be implemented by occupational therapists trained in ICU, who will conduct 20 sessions of 30 min, distributed depending on the level of sedation, i) SAS (Sedation-Agitation Scale) 1 patients have one session each 48 h, evaluating the change of sedation level each 24 h; ii) SAS 2 patients have one session each 24 h, iii) SAS 3-5 have two sessions every day. The sessions will begin once the patient needs mechanical ventilation for at least 12 h
9691745|NCT04819529|No Intervention|Control group - Standard Analgesia,Sedation, Delirium and Mobilization (ASDM) Protocol|The ASDM protocol will be implemented to mechanically ventilated patients in the ICU, following the aspects recommended by experts and the current evidence. For this, the team of medical, nurses, and physiotherapist will be trained to understand and facilitate the ASDM actions that each one must implement.
9691746|NCT04819516|Experimental|HIFU with REGOTORI|
9691747|NCT04819685|Experimental|test group|Intervention:Anti-radiation spray (liquid dressing)
9691748|NCT04819685|No Intervention|control group|
9691749|NCT04819633||Study Group|30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
9691750|NCT04819633||Control Group|30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.
9691751|NCT04819867|Experimental|propolis|propolis will be applied to the affected teeth
9691752|NCT04819867|Active Comparator|gluma desensitizer|Gluma desensitizer will be applied to the affected teeth
9691753|NCT04819646|Experimental|Inflammation|Marine Lipid Oil concentrate softgel and dietary supplement capsule
10181360|NCT03784430|Active Comparator|Implant|Immediate dental implant placement
9696312|NCT04768231|Experimental|R35HZE|Participants treated with rifampicin at a dose of 35 mg per kilogram of body weight per day, added to the standard doses of isoniazid, pyrazinamide and ethambutol.
10181361|NCT03784430|Experimental|Implant+CTG|Immediate dental implant placement with CTG.
10181362|NCT03784547||multiple sclerosis patients|multiple sclerosis patients receiving ocrelizumab 600 mg endovenous every 6 months
10181363|NCT03784508||Bariatric surgery|200 consecutive patients that will undergo bariatric surgery as a routinary procedure at our site
9691754|NCT04819451|Experimental|MACSF group|In the experimental group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with non-aneurysmal subarachnoid hemorrhage were included in the stratified random method. Use Magnesium-Rich Artificial Cerebrospinal Fluid(MACSF) in the CSF replacement, and the remaining treatments should strictly follow the guidelines as same as the control group. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
9691755|NCT04819451|No Intervention|NS group|In the control group, patients with intracerebral hemorrhage ruptured into the ventricle and patients with non-aneurysmal subarachnoid hemorrhage were included according to the stratified random method. Use the normal saline (0.9% Sodium Chloride Injection) in the CSF replacement, and the remaining treatments should strictly follow the guidelines. The total amount of replacement was generally 30ml, and the replacement was performed once every 3 days. When the RBC count in CSF is less than 100×10^6/L, the CSF is considered to be cleared. Cerebrospinal fluid replacement is performed up to four times.
10181364|NCT03784352|Experimental|Virtual Reality (VR)|The intervention will consist of standard of care (SOC) in addition to the use of virtual reality. SOC consists of the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device) Patients assigned to the VR group will interact with VR through mobile-based VR googles.
10181365|NCT03784352|No Intervention|No Virtual Reality (VR)|This arm will receive regular standard of care (SOC), the same that would be received if they were not enrolled in the study. SOC will include the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device)
9691756|NCT04819802||Covid-19 patients|Adult Covid-19 patients admitted to intensive care units
9691757|NCT04819763|Experimental|Physical training of the lateral pterygoid muscle|Static stretching and isometric contraction exercises of the lateral pterygoid muscle are used to strengthen and restore a physiological lateral movement of the mandible.
9691758|NCT04819763|Active Comparator|Stabilization appliance therapy|Hard acrylic splint with anterior canine guidance for the lower jaw.
9691759|NCT04819711|Active Comparator|Intervention|Thinking Healthy group intervention integrated into antenatal pregnancy school classes
9691760|NCT04819711|No Intervention|Control|Participants randomized to the control arm will not be offered the THP intervention but will attend the 5 sessions of the routine group antenatal pregnancy school classes. The class provides education about pregnancy, birth and new-born care and offers support to women. The women will also be able to access all usual care and support offered by the participating hospitals
9691761|NCT04819412|Experimental|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
9691762|NCT04819412|Experimental|ROTAVAC 5C -F2|ROTAVAC5C formulation BBIL-R2014-2
9691763|NCT04819412|Active Comparator|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
9691764|NCT04819477|Other|Cate Plots|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The first group (Arm 1) receives a Cates plot and then another survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior.
9691765|NCT04819477|Other|Fact box only|after being asked about current referral practices and assessment of benefits and risks of lung cancer screening, all respondents will receive the Fact box after which they will be randomized into two equal groups. The second group (Arm 2) receives then a survey about assessment of benefits and risks of lung cancer screening and potential change in referral behavior
9691766|NCT04819724|Other|Group 1: patient group (unilateral rotator cuff tear)|Group 1: 75 patients with unilateral rotator cuff tear
9691767|NCT04819724|Other|Group 2: (healthy volunteers)|Group 2: (healthy volunteers) 25 asymptomatic control subjects (age and sex distribution matching the patient group)
9691768|NCT04819984|Experimental|Continuous PtC02 evaluation|Continuous PtC02 measured by TCM5 monitor during ventilatory weaning test of 30 minutes when available
9691769|NCT04819607||BMFS patients|Patients with BMFS attending Peter MacCallum Cancer Centre haematology clinic.
9691770|NCT04819581|Experimental|SP-103 (1 topical system)|One topical system applied to the skin on the back for 12 hours.
9691771|NCT04819581|Experimental|SP-103 (2 topical systems)|Two topical systems applied to the skin on the back for 12 hours.
9691772|NCT04819581|Experimental|SP-103 (3 topical systems)|Three topical systems applied to the skin on the back for 12 hours.
9691773|NCT04819581|Active Comparator|ZTlido|Three topical systems applied to the skin on the back for 12 hours.
9691774|NCT04819503|Other|Active and then sham repetitive transcranial magnetic stimulation|"Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.~Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS."
9691775|NCT04819503|Other|Sham and then active repetitive transcranial magnetic stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.Sham stimulation is delivered with a sham coil placed in the helmet encasing the active rTMS coil. Sham rTMS sessions will use exactly the same parameters of stimulation as active rTMS.
9691776|NCT04819347|Experimental|Early treatment of infection|"HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
9696313|NCT04768205|Active Comparator|Study group|The therapy and Kinesio tex gold tape that was affixed to stretched and neck localised were applied
9691777|NCT04819347|Experimental|Chronic period of infection treatment|"Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.~Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks."
9691778|NCT04819438|Experimental|Riluzole orodispersible film (Test)|The subjects will be treated with one orodispersible film containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
9691779|NCT04819438|Active Comparator|Rilutek® (Reference)|The subjects will be treated with one film-coated table containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence
9691780|NCT04819828|Experimental|Tamsulosin|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed plus oral tamsulosin (0.4 mg/day) for eight weeks.
10181366|NCT03784456|Experimental|25% protein group|This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
10181367|NCT03784456|Active Comparator|15% protein group|This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
9691781|NCT04819828|Active Comparator|Control|At the end of the ESWL session, the patients received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed
9691782|NCT04819139|Active Comparator|Thumb exercises +orthosis|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain."
9691783|NCT04819139|Experimental|Thumb exercises +orthosis+ proprioceptive program exercises|"Participants will be instructed to perform daily exercises grouped in 3 sets of 10 repetitions in the absence of pain for 4 weeks. If the patient experienced pain, the number of repetitions dropped sequentially until the exercise was performed pain free. Exercises consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle. Each participant will also engaged in a one month re-education/joint protection program for thumb use during ADL's and completed a weekly record sheet for monitoring purposes.~In addiction, they will received a thumb whale orthosis to wear at night and during ADL's as needed for pain. In addiction, patients will received a proprioceptive program exercises using also a online program with a laptop."
9691784|NCT04819022||Musculoskeletal disorder|
9691785|NCT04818996|Experimental|Mediterranean Diet|In the study, the participants were applied a diet compatible with the Mediterranean diet for 8 weeks.
9691786|NCT04818983||NSCLC cohort|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
9691787|NCT04818983||ED-SCLC cohort|Patients with extensive disease small cell lung cancer who are planning to provide atezolizumab combination therapy as the most appropriate medical care
9691788|NCT04818931|Experimental|Antibiotics|Cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
9691789|NCT04818931|No Intervention|No antibiotics|
9691790|NCT04819087|Experimental|Patients|Patients with Pelvic Floor Dysfunction Related Temporamandibular Joint Problems and Tinnitus
9691791|NCT04819061|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training
9691792|NCT04819061|Sham Comparator|Sham group|In the group G2 will be administered: tDCS sham + dual-task motor training
10181368|NCT03784365|Active Comparator|First group|This group will receive an intravenous antibiotic for three days. The first dose will be given within half hour before the POEM procedure.
9691793|NCT04819204|Experimental|GnRH antagonist alone|Intervention: Cetrorelix acetate (Cetrotide)
9691794|NCT04819204|Experimental|GnRH antagonist + Testosterone add-back|Intervention: Cetrorelix acetate (Cetrotide) + Testosterone gel (Androgel)
9691795|NCT04818970|Experimental|Phototherapy of narrow band ultraviolet Light B-Band NB-UVB|Daavlin Series 1 Phototherapy Unit that emits UVB light between 280nm and 320nm.
9691796|NCT04818970|Placebo Comparator|Placebo - Light|Daavlin Series 1 Phototherapy Unit that does not emit UVB light between 280nm and 320 nm.
9691797|NCT04819217|Other|Active bamboo charcoal|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
9691798|NCT04819217|Other|Probiotics|Based on these previous findings, we will conduct a prospective randomized open blinded end-point (PROBE) study to see if oral uremic toxin absorbent + probiotics prevent CKD progression.
10181369|NCT03784365|Experimental|Second group|This group will receive only one dose of intravenous antibiotic within half hour before the POEM procedure
10181370|NCT03784339|Placebo Comparator|Physiotherapy|Participants will receive standard physiotherapy care, which will involve strength exercises and taping.
9696314|NCT04768205|Placebo Comparator|Sham control group|The therapy and Kinesio tex gold tape that was affixed to different neck localised as no-stretched were applied
10181371|NCT03784339|Experimental|Physiotherapy + education|Physiotherapy + education Standard physiotherapy care plus 30 minute education session addressing fear of movement and catastrophizing thoughts.
10181372|NCT03784391||Treatment|Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox
9528147|NCT03213574|Active Comparator|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
9691801|NCT04819048|Experimental|Low-Level Laser Therapy+acupuncture|"The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.~After LLLT irradiation,the following acupuncture points will be selected: Jiache,Xiaguan,Quanliao,Baihui,Fengchi, Hegu.The needles will be inserted and rotated manually with a frequency of about 100 turns per minute clockwise and counterclockwise ,as above vertically into a depth of 25-30 mm to achieve the proper feel called Deqi in every point on the affected side, and then the needles will be retained for 30 minutes."
9691802|NCT04819048|Active Comparator|Low-Level Laser Therapy|The laser light will be applied in 6 points on the affected side: anterior to the mandibular condyle and intraauricular toward the temporomandibular joint; 2 points irradiation on the superficial masseter muscle and 2 points on the anterior temporal muscle bundle. Each point will be irradiated for 30 seconds for a total of 180 seconds.
9691803|NCT04819165||COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with confirmed COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
9691804|NCT04819165||non COVID-19 patients|Patients with invasive mechanical ventilation admitted to the Intensive Care Unit (UCI) of the Anchorena San Martín Clinic, San Martín, Buenos Aires with negative COVID-19 diagnosis (positive polymerase chain reaction in nasopharyngeal swab).
9691805|NCT04819230|Experimental|Bias Modification|Attention (ATT) and interpretation (ITT) bias training. Participants complete the ATT and ITT tasks twice per week for four weeks. The ATT trains attention toward neutral stimuli and away from negative stimuli. On trials with one neutral and one threat word, the probe will always follow the location of the neutral word. Therefore, there is a contingency between the valence of the word and the location of the probe. Participants will be asked to indicate which type of probe had appeared in each trial by pressing a corresponding button as rapidly and accurately as possible. The ITT trains participants to make benign (vs. threatening) interpretations of socially-ambiguous scenarios. For each trial, a word suggesting a socially threatening or benign interpretation is presented then replaced by a sentence describing a socially-ambiguous scenario. Participants indicate if they thought the word and sentence were related. Participants will receive corrective feedback after each trial.
10181373|NCT03784391||Reference|Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment
10181374|NCT03784131|Experimental|Personalized Tissue Engineered Vein|P-TEV
10181375|NCT03784092|No Intervention|control|
10181376|NCT03784092|Experimental|feedback|
9691806|NCT04819230|Placebo Comparator|Control Condition|"A combination of attention (ATT-C) and interpretation (ITT-C) control tasks~These tasks are identical to the experimental tasks (ATT and ITT) with the exceptions that:~ATT-C: It is designed to train attention toward neither neutral nor the threat stimuli. This will be achieved by having an equal number of probes follow the location of the threatening word and the neutral word.~ITT-C: It is not designed to train benign interpretations of ambiguous social scenarios. Thus, no feedback will be given during the inter-trial interval, rather participants will see a blank screen between trials.~Participants will complete both the ATT-C and ITT-C tasks twice per week for four weeks, totaling to eight experimental sessions."
9691807|NCT04819321|Experimental|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
9691808|NCT04819126|Experimental|Nintendo Wii Virtual Reality Application In Older People With Alzheimer's Dementia|"The study included a total of 32 volunteers between the ages of 65-80, who stayed in Karaman Ahmet Mete Nursing Home, Elderly Care and Rehabilitation Center, with mild or moderate Alzheimer's dementia diagnosed by a neurologist. As a result of the power analysis, it was calculated that at least 16 individuals could be included in each group (at least 32 individuals in total). Randomization was performed by the sealed-envelope method. According to this method, 4 females and 12 males were determined to be in the control group, while 5 females and 11 males were determined to be in the training group.~The evaluation was completed before the intervention. The same evaluation was conducted after 6 weeks.~The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes, and each patient was trained with the same games."
9691809|NCT04819126|No Intervention|Older People With Alzheimer's Dementia|In the control group, no application was performed during this period, and routine medical treatments were continued. The training group was evaluated before and after the training, while the control group was re-evaluated at the end of the 6th week after the first evaluation. After the study was completed, the volunteers from the control group were also given training.
9691810|NCT04819282||One group|Physical performance was evaluated with the Senior Fitness Test in one group of geriatric individuals.
9691811|NCT04818905|Experimental|Helichrysum italicum infusion|1 g of milled plant material (Helichrysum italicun) immersed in hot water (200 mL, 100 °C) for 10 minutes.
9691812|NCT04818905|Placebo Comparator|Hot water|The control beverage contained only hot water (200 mL, 100 ˚C).
9691813|NCT04819243|Experimental|Atezolizumab+Talazoparib|"st line treatment~Palbociclib 125mg po D1-21~AI : Prescribed as per local guideline~GnRH agonist: Prescribed as per local guideline~nd line treatment~Talazoparib 1mg po~Atezolizumab 1200mg IV (3week)"
10181377|NCT03784144|Experimental|Cognitive Strategy|Performing a mathematical subtracting task (starting at 300, by sevens)
10181378|NCT03784144|Active Comparator|Control|The patients will perform both tests without any cognitive condition
10181379|NCT03784105|Experimental|Codeine|
10181380|NCT03784105|Placebo Comparator|Siripus simplex|
10181381|NCT03784248||asymptomatic carrier|
10181382|NCT03784248||uninfected subjects|
10181383|NCT03784313|Experimental|Perforators flaps (PF group)|
10181384|NCT03784313|Sham Comparator|Secondary intention wound healing|
9691814|NCT04819243|Experimental|Talazoparib|"st line treatment~Palbociclib 125mg po D1-21~AI : Prescribed as per local guideline~GnRH agonist: Prescribed as per local guideline~nd line treatment - Talazoparib 1mg po"
10181385|NCT03784014|No Intervention|Arm No NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. Thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment.~Note that for these participants and under specific conditions, subsequent NGS analyses may be allowed within the scope of the trial"
9691815|NCT04818879|Experimental|Interventional group|
9691816|NCT04818879|Sham Comparator|Control group|
9691817|NCT04818593|Experimental|ZyMot Separation|Treatment
9691818|NCT04818593|Active Comparator|Density Gradient Centrifugation|Control
9691819|NCT04818619||chronic myeloid leukemia patients|
9691820|NCT04818619||Healthy individuals|
9691821|NCT04818697||Patients with heart rhythm disorders|Having been diagnosed with heart rhythm disorders such as atrial fibrillation, atrial tachycardia, ventricular tachycardia, and ventricular extrasystole
9691822|NCT04818697||Healthy individuals|Healthy individuals without chronic disease
9691823|NCT04818723|Experimental|Montelukast Group|53 in Case Group (given montelukast 5mg at bed time). All patients were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
9691824|NCT04818723|Placebo Comparator|Placebo Group|Patients in this groups were induced with prednisolone 2mg/kg single morning dose with breakfast for total 4 weeks. Patients who did not achieve remission after 4 weeks' full dose were labeled steroid resistant nephrotic syndrome (SRNS). Children with steroid sensitive nephrotic syndrome SSNS were further treated by prednisolone 1.5 mg/kg single morning dose with breakfast every other day for the next 4 weeks. Prednisolone was then tapered by reducing 25% dose fortnightly and completely stopped in 8 weeks. Patients in the Case Group continued taking montelukast after stopping steroids. All patients were followed up every 4-8 weeks for a minimum of 12 months to look for response to treatment, side effects of medications, other co-morbidities, and the number of relapses. Relapses were treated with repeat prednisolone doses according to the protocol of treatment for relapse.
9691825|NCT04818515|Experimental|Atogepant, Ubrogepant, and Coadministration|Participants will receive oral tablets of ubrogepant, followed be oral tablets of atogepant, followed by administration of oral tablets of atogepant and ubrogepant in combination, for a 30 day interventional period and a 7 day follow up period.
9691826|NCT04818710|Placebo Comparator|skin incision with a scalpel|In the scalpel group, the incision was made by the traditional method, with proper homeostasis by applying pressure to skin blood vessels and ligating the subcutaneous bleeding.
9691827|NCT04818710|Active Comparator|skin incision with diathermy|In the diathermy group, the incision made using a small flat blade pen electrode, set on cutting mode and delivering a 120 watt (maximum) sinusoidal current, electrosurgical cutting performed without pressure or mechanical displacement.
9691828|NCT04818684||Physician|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
9691829|NCT04818684||Psychologists|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
9691830|NCT04818684||Caregivers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
9691831|NCT04818684||Nurses|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
9691832|NCT04818684||Social and Educational Assistants|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit.
9691833|NCT04818684||Volunteers|at least 3 years of seniority in palliative care unit will be required, including 1 year in the participating palliative care unit. The representative participating in the study will preferably be the volunteer coordinator.
9691834|NCT04818684||Relatives|"Relative of a patient who died in the palliative care unit at least 6 months ago Person to trust or to prevent if not designated Relative understanding and speaking sufficient French Relative not a health professional~Relative who visited the palliative care unit during the last 3 days of the patient's life and who met the care team:~Traceability of the arrival of the loved one in the last 2/3 days of the patient's hospitalization~Traceability of a meeting of the loved one with a member of the team over the last 3 days of his hospitalization or verification during telephone contact with the loved one after drawing lots Relative with an email address (to be verified during telephone contact with the loved one after drawing lots)"
9528148|NCT03213574|Experimental|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
9528149|NCT03213587|Experimental|apatinib|
9691835|NCT04818658||Preformed Metal Crowns using Hall Technique|
9691836|NCT04818658||Compomer Restoration|
9691837|NCT04818736|Experimental|COVID-19|mRNA-1273 vaccine
9691838|NCT04818736|Experimental|Control|Usual care
9691839|NCT04818775|Experimental|HemaClear|
9691840|NCT04818775|Active Comparator|Pneumatic Tourniquet|
9696315|NCT04768088|Experimental|One-week training of falling techniques on landing biomechanics associated with ACL loading|Participants will perform one-week training of single-leg falling techniques, a post-training assessment, a two-week break, and a retention assessment.
10181386|NCT03784014|Experimental|Arm NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. After tumor assessment at the end of first-line systemic treatment and regardless of tumor response as per RECIST v1.1, participants will be discussed within a multidisciplinary tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant.~Patients for whom a targetable genomic alteration has been highlighted will be proposed to enter in a subsequent single-arm phase II sub-trials. Otherwise, thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment"
9691841|NCT04818437|Experimental|Balance training|"Balance training~Trunk, head, and upper limbs rotation from kneeling.~Upper limbs flexion and extension with simultaneous head movement from kneeling.~Pelvic bridging followed by raising one lower limb and extending knee.~Lifting opposite upper and lower limbs from Quadruped position.~6-Heel and toe raises, alternate rising ofthe right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed"
9691842|NCT04818437|Active Comparator|Core stability exercise|"Core stability exercises:~Abdominal bracing while lying in supine position.~Abdominal bracing with heel slide while lying in supine position.~Abdominal bracing with Leg lifts while lying in supine position.~Abdominal bracing with bridging while lying in supine position.~Abdominal bracing while Standing 6-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying."
9696316|NCT04768140|Experimental|Bobath group|A conventional physiotherapy program was applied to this group. Additionally, Bobath treatment approach was applied for 10 repetitions during a 30-min session in the experimental group, in addition to the conventional physiotherapy program.
9696317|NCT04768140|Active Comparator|Conventional physiotherapy group|Only conventional physiotherapy program was applied to this group.
10181387|NCT03784014|Experimental|Arm NGS - Targeted therapy|Targeted therapy from a list of 10 targeted treatment strategies, guided by the genomic analyses: Nilotinib capsule per os 400 mg bd, continuous dosing ; Ceritinib capsule per os 450 mg od, continuous dosing; Capmatinib tablet per os 400 mg bd, continuous dosing; Lapatinib tablet per os 1500 mg od, continuous dosing; Trametinib tablet per os 2 mg od, continuous dosing; association of Trametinib tablet per os 2 mg od and Dabrafenib capsule per os 150 mg bd, continuous dosing; association of Olaparib tablet per os 300 mg bd, continuous dosing and Durvalumab intra-veinous 1500 mg on day 1, Q4W; Palbociclib capsule 125 mg od, 3 weeks on/1 week off; Glasdegib tablet per os 300 mg od, continuous dosing; TAS-120 tablet per os 20 mg od, continuous dosing.
9696318|NCT04768257||Patients with COVID-19, treated in intensive care|
10181388|NCT03784170|Experimental|Treatment|FemPulse System at one device setting
10181389|NCT03784170|Sham Comparator|Control|FemPulse System at a different device setting
9696319|NCT04768257||Patients with COVID-19, treated in hospital ward|
9696320|NCT04768257||Patients with COVID-19, treated at home|
9696321|NCT04768387|Experimental|Personalized microbiome diet|Six weeks of AI-based microbiome diet was introduced.
9696322|NCT04768387|Active Comparator|Standard IBS diet|Six weeks of standard IBS diet was introduced.
9696323|NCT04768413||Group A|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
9696324|NCT04768413||Group B|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
9696325|NCT04768309|Experimental|CKD group|CKD adult patients stage 4-5 Without diabetes BMI between 18 and 30 kg/m2
9696326|NCT04768309|Other|Healthy volunteers group|Adult without chronic treatment, without renal dysfunction
9696327|NCT04768400|Experimental|rocuronium|Neuromuscular blockade will be performed using rocuronium.
9696328|NCT04768283|No Intervention|Control group|Cardiac rehabilitation physical training program included: respiratory muscle training (7 days/week, for 15 minutes) and aerobic exercises on cycle ergometers (6 days/week, for 10-30 minutes, 30-50% watts or 30-50% HRmax).
9696329|NCT04768283|Experimental|Intervention group 1|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training and strength exercises with weights, elastic resistance rubbers."
9696330|NCT04768283|Experimental|Intervention group 2|"Combinated physical training program:~Respiratory exercises, aerobic training will be the same as in the control group.~Additional exercises: balance training with static and dynamic balance training device Biodex Balance System TM SD and strength exercises with HUR strength training machines."
9696331|NCT04768075|Experimental|Camrelizumab group|"subject will receive Camrelizumab intravenously(IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by Camrelizumab ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
10181390|NCT03784183|Experimental|moderate AD-experimental|Experimental Intervention: The CS shall be carried out in groups (5-7 participants), twice a week. Each session lasts 90 minutes. CS sessions begin with a training for temporal and spatial orientation in which participants are asked to recognize and recall the date and the place with the help of some environmental aids (calendars, clocks, pictures and maps). Then the participants complete an array of cognitive tasks for memory, attention, language, visuo-spatial functions and executive functions. These tasks range from individual paper-and-pencil exercises to verbal-learning exercises that have to be solved by the group.
10181391|NCT03784183|Experimental|mild AD-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
10181392|NCT03784183|Experimental|MCI-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
10181393|NCT03784183|No Intervention|moderate AD-placebo|
10181394|NCT03784183|No Intervention|mild AD-placebo|
10181395|NCT03784183|No Intervention|MCI-placebo|
10181396|NCT03784326|Experimental|Treatment (oxaliplatin, fluorouracil, atezolizumab, surgery)|Patients receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Within 4-6 weeks of treatment completion, patients undergo surgical resection. Beginning 6 weeks after surgery, patients continue to receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive atezolizumab monotherapy IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10181397|NCT03784196||Acute Whiplash Associated Disorders|People suffering from acute WAD at the time of recruitment.
10181398|NCT03784196||Healthy controls|Participants with no neck pain during the past 6 months, chronic pain or other medical disorders relevant to this study.
10181399|NCT03784274||Stakeholders|Key stakeholders involved program and policy making
10181400|NCT03784222|Experimental|treatment group|188 first episode schizophrenia patients, receiving blonanserin treatment, 60 of the patients receive MRI and serum BDNF test
9691843|NCT04818827||Ketamine group|This cohort includes patients who received ketamine as a sedative analgesic agent during mechanical ventilation
10181401|NCT03784222|Other|control group|60 subjects without schizophrenia, only receiving MRI and/or serum BDNF
9691844|NCT04818827||Non Ketamine group|This cohort includes patients who received sedatives other than ketamine during mechanical ventilation
9691845|NCT04818606|Experimental|Intervention (MORE) Group|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings. Pre-recorded guided meditations created by study personnel using scripts from the MORE manual will be provided to participants to facilitate their daily practice.
9691846|NCT04818606|No Intervention|Control Group|This group will undergo treatment as usual (TAU) over the course of the eight-week time period of parallel group comparison. This may or may not involve regularly scheduled, standard visits with other medical personnel, including primary care, specialized medical services, or complementary and integrative health practitioners (e.g., acupuncture). Participants will be asked to refrain from altering therapeutic approaches to pain management during this time unless medically necessary and will be asked to report any changes made to their treatment plan on a daily basis.
9691847|NCT04818580|Experimental|Right-Sided Progressive Tension Sutures|
9691848|NCT04818580|Active Comparator|Left-Sided Progressive Tension Sutures|
9691849|NCT04818762||Preterm neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
9691850|NCT04818762||Preterm neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
9691851|NCT04818762||Term neonates with infection|Preterm neonates (30+0 - 36+6 weeks of gestation) with clinical and laboratory signs of early onset infection (within 72 hours after birth).
9691852|NCT04818762||Term neonates without infection|Preterm neonates (30+0 - 36+6 weeks of gestation) without clinical and laboratory signs of early onset infection (within 72 hours after birth).
9691853|NCT04818411|Active Comparator|Routine physical therapy treatment with the Stabilization exercises|Stabilization exercises
9691854|NCT04818411|Experimental|Routine physical therapy treatment + High-velocity thrust manipulation|High-velocity thrust manipulation
9691855|NCT04818749|Placebo Comparator|Placebo|Participants allocated to this arm will have placebo administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
9691856|NCT04818749|Active Comparator|Dexamethasone 12 mg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and placebo administered intravenously after induction of general anaesthesia.
9691857|NCT04818749|Experimental|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Participants allocated to this arm will have dexamethasone 12 administered intravenously before block performance and dexmedetomidine 1 mcg/kg administered intravenously after induction of general anaesthesia.
9691858|NCT04818528|Experimental|Constraint Induced Movement Therapy and Routine Physical Therapy|Patients received constrained induced movement therapy and routine physical therapy for up to 6 hrs/day, 5 days/week for 4 weeks.
9691859|NCT04818528|Active Comparator|Routine Physical Therapy|Patients received routine physical therapy for 5 days/week for 4 weeks.
9691860|NCT04818476||HR-T1a|Patients who weretreated by radical endoscopic resection for a high-risk mucosal EAC (HR-T1a N0M0)
9691861|NCT04818476||LR-T1b|Patients who were treated by radical endoscopic resection for a low-risk submucosal EAC (LR-T1b N0M0)
9691862|NCT04818476||HR-T1b|Patients who were treated by radical endoscopic resection for a high-risk submucosal EAC (HR-T1b N0M0)
9691863|NCT04818385||Participants Receiving Risankizumab|Participants will receive risankizumab as prescribed by their physician.
9691864|NCT04818385||Participants Receiving All Other Biologics|Participants will receive all other biologics as prescribed by their physician.
9691865|NCT04818242|Active Comparator|POC testing with Blinded CGM Group (Standard of Care Group)|Patients in the standard of care group will wear a blinded CGM and receive POC testing before meals and bedtime, with providers adjusting oral agents or insulin dose based on POC results.
9696487|NCT04766359|Experimental|Albumin-Bound paclitaxel combined with radiotherapy|"Albumin paclitaxel (100mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
9528150|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
10181402|NCT03784261|Active Comparator|SAR, usually subucutaneous injection every 2 weeks|
9691866|NCT04818242|Experimental|Dexcom CGM with Glucose Telemetry System Group (CGM-GTS Group)|Patients in the intervention CGM group will have a single daily fasting POC testing and will wear a real-time Dexcom G6 with GTS, and providers will adjust oral or insulin therapy based on CGM-GTS profile information.
9691867|NCT04818359|Experimental|Interventional Arm|Supervised exercise program: MoviS Training. Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
10181403|NCT03784261|Active Comparator|TCZ, usually subucutaneous injection every 2 weeks|
10181404|NCT03784261|Active Comparator|ABT, usually subucutaneous injection every week|
10181405|NCT03783897|Experimental|EDP-305 and Oral Contraceptive|
10181406|NCT03784287|Experimental|AX 250|All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
10181407|NCT03783910|Experimental|GRT9906|"Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).~Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks."
9691868|NCT04818359|No Intervention|Control Arm|Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
9691869|NCT04818203|Experimental|Test Group|Participants receive 1 mL of clusters of autologous dermal fibroblast to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
9691870|NCT04818203|Placebo Comparator|Placebo|Participants receive 1 mL of placebo solution to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.
9691871|NCT04818125|Other|Patients with breast cancer|
10181408|NCT03783910|Placebo Comparator|Placebo|Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks.
9691872|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
9691873|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Forward Skin Stretch|Adaptation to Altered Auditory Feedback + Forward Skin Stretch
9691874|NCT04818021|Experimental|Adaptation to Altered Auditory Feedback + Backward Skin Stretch|Adaptation to Altered Auditory Feedback + Backward Skin Stretch
9691875|NCT04818021|Experimental|Speech Repetition Control|Speech Repetition Control
9691876|NCT04818008|Experimental|Otago Exercise Program|Patients will receive the Otago Exercise Program for 8 weeks plus health awareness videos about topics related to MS.
9691877|NCT04818008|No Intervention|Control group|Patients will receive health awareness videos only about topics related to MS.
10181409|NCT03784053||Immersive virtual reality|Participants will receive eight 30-minute sessions of immersive virtual reality.
9691878|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback|Adaptation to Altered Auditory Feedback
9691879|NCT04818268|Experimental|Auditory Sensory Memory|Auditory Sensory Memory
9691880|NCT04818268|Experimental|Somatosensory Sensory Memory|Somatosensory Sensory Memory
10181410|NCT03784027|Experimental|Automated closed loop insulin delivery (intervention arm)|"Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 16 weeks.~Intervention: Device: CamAPS FX"
10181411|NCT03784027|Active Comparator|Sensor augmented pump therapy (control arm)|Sensor augmented pump therapy over 16 weeks.
9691881|NCT04818268|Experimental|Adaptation to Altered Auditory Feedback + cTBS to 46v|Adaptation to Altered Auditory Feedback + cTBS to 46v
9691882|NCT04818268|Experimental|Sensory Memory + cTBS to 46v|Sensory Memory + cTBS to 46v
9691883|NCT04818333|Experimental|SHR-A1811|SHR-A1811 was administered intravenously every 3 weeks (Q3W) until discontinuation treatment
9691884|NCT04817930|Experimental|Patient specific chin implant|A patient specific chin peek implant was used for chin augmentation
9691885|NCT04817930|Experimental|computer guided advancement genioplasty|Computer guided advancement genioplasty using patient specific cutting and positioning guides
9691886|NCT04818307|Experimental|Macquarie Injury Management group|
9691887|NCT04818307|Active Comparator|Mulligan Mobilization with Movement|
9691888|NCT04818047|Experimental|Experimental: VID-KIDS Intervention Program Group|Experimental: VID-KIDS Intervention Program Group RN review photos of infant engagement/ disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
10181412|NCT03783949|Active Comparator|Standard arm (arm A)|Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w)
10181413|NCT03783949|Experimental|First experimental arm (arm B)|Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w)
10181414|NCT03783949|Experimental|Second experimental arm (arm C)|Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w)
9691889|NCT04818281|Experimental|Low-Dose Group (Group A)|12 participants will receive 10 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
9691890|NCT04818281|Experimental|High-Dose Group (Group B)|12 participants will receive 40 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)
9691891|NCT04818281|Placebo Comparator|Placebo Group|12 participants will receive 1 ml of 0.9% sodium chloride (NaCl)
9691892|NCT04817904|Experimental|Statin-Treated|"This arm will be receiving:~Cisplatin along with conventional nephroprotective interventions (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)~Rosuvastatin 10 mg/day"
9691893|NCT04817904|No Intervention|Statin-Free|"This arm will be receiving:~-Cisplatin along with conventional nephroprotective interventions only (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)"
9691894|NCT04817917|Experimental|3JEV-I (Group 1)|"Retrospective: 3 doses of JE vaccines. 2 doses of Inactivated JE Vaccine (JEV-I, 7-10 days apart) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
9691895|NCT04817917|Experimental|JEV-L+JEV-I (Group 2)|"Retrospective: 2 doses of JE vaccines.~1 dose of JE attenuated live vaccine (JEV-L) at 8 months of age and 1 dose of JEV-I at 2 years old.~Prospective: 1 booster dose of JEV-I at 6 years old."
9691896|NCT04817917|Experimental|JEV-L+2JEV-I (Group 3)|"Retrospective: 3 doses of JE vaccines.~1 dose of JEV-L at 8 months of age and 2 dose (7-10 days apart) of JEV-I at 2 years old."
9691897|NCT04817917|Experimental|2JEV-I+JEV-L (Group 4)|Retrospective: 3 doses of JE vaccines. 2 doses of JEV-I (7-10 days apart) at 8 months of age and 1 dose of JEV-L at 2 years old.
9691898|NCT04817917|Experimental|2JEV-L (Group 5)|Retrospective: 2 doses of JE vaccines. 2 doses of JEV-L respectively administered at 8 months of age and 2 years old.
9691899|NCT04817878||Late preterm infant group|Gestational age 33 weeks-36 weeks
9691900|NCT04817878||Very premature infant group|Gestational age 28 weeks-32 weeks
9691901|NCT04817878||Super preterm infant group|Gestational age less than 28 weeks
9691902|NCT04817826|Experimental|Cohort 1|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~Patients in Cohort 1 will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed by an active follow-up every 12 weeks for two years and then a standard follow-up every six months until the end of the fifth year from surgery."
9691903|NCT04817826|Experimental|Cohort 2|"Pre-operative treatment with tremelimumab 300 mg single administration (day 1) and durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).~In Cohort 2, patients with no evidence of complete clinical response will undergo standard gastrectomy with D2 lymphadenectomy and then they will be followed up. Patients with complete clinical response will undergo a non-operative management (NOM) with an active follow-up phase every 12 weeks for two years, followed by standard follow-up every six months until the end of the fifth year. At any time during follow-up, in case of clinical suspicion or confirmation of residual gastric cancer, patients will undergo standard surgery according to the clinical practice at their Centre."
9691904|NCT04817852|Experimental|CBCT data of C-shaped canal in mandibular second molar will Be assessed for age.|Detection of variation in root canal morphology by using CBCT.
9691905|NCT04817865||Standard Pre-Procedural Urine Culture|This is a control cohort that follows standard pre-procedural protocol by implementing antibiotic prophylaxis and treatment regimens based on dipstick urine analysis (UA) followed by reflexed traditional urine culture and sensitivity (C&S) methods performed before injection.
9691906|NCT04817865||Pre-Procedural M-PCR/P-AST|This is an experimental cohort that implements Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST) for pre-procedural UTI screening. The cohort follows an antibiotic treatment regimen based on the results of M-PCR/P-AST.
9691907|NCT04817982|Experimental|Perineural dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Dexamethasone will be added perineurally in this arm on the same day as the 'systemic dexamethasone' group.
9691908|NCT04817982|Active Comparator|Systemic dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as the 'perineural dexamethasone' group. Thereby, this ulnar nerve block will only be affected by the perineurally added dexamethasone that is absorbed and redistributed systemically.
9691909|NCT04817982|Placebo Comparator|Placebo|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as lidocaine group. This will be the actual placebo group.
9691910|NCT04817982|Active Comparator|Perineural lidocaine|Bilateral ulnar nerve blocks with bupivacaine. Lidocaine will be added perineurally in this arm on the same day as the actual placebo group.
9691911|NCT04818190|No Intervention|DIEP reconstruction, no neurotization|DIEP reconstruction No sensory neurotization
9691912|NCT04818190|Experimental|DIEP reconstruction, neurotization|DIEP reconstruction With sensory neurotization
9691913|NCT04817995|Experimental|Intervention group|The intervention group will get a 6-week internet-based stress recovery intervention.
9691914|NCT04817995|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
9691915|NCT04818099|Experimental|routine supportive psychotherapy and votioxetine|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given votioxetine 10mg/tablet, one tablet each time, once a day, for 2 months.
9691916|NCT04818099|Placebo Comparator|routine supportive psychotherapy and control|On the basis of general psychotherapy, cognitive behavior therapy and supportive psychotherapy, the patients were given placebo, one tablet each time, once a day, for 2 months.
9691917|NCT04817748||Acute ST segment elevation myocardial infarction（STEMI）|the patients' coronary and venous blood were drawn for metabolomics study
9691918|NCT04817748||Acute non ST segment elevation myocardial infarction（NSTEMI）|the patients' coronary and venous blood were drawn for metabolomics study
9691919|NCT04817748||Acute myocardial infarction with no obstructive coronary atherosclerosis（MINOCA）|the patients' coronary and venous blood were drawn for metabolomics study
9691920|NCT04817748||Patients with normal coronary artery（NCA)|the patients' coronary and venous blood were drawn for metabolomics study
9691921|NCT04817969|Other|Persona Ti-Nidium|Primary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System
9691922|NCT04818151||ESRD patients with VTE treated with warfarin|Warfarin as primary treatment of VTE
9691923|NCT04818151||ESRD patients with VTE treated with apixaban|Apixaban as primary treatment of VTE
9691924|NCT04817800|Experimental|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|
9691925|NCT04817800|Experimental|100 μg Beclomethasone dipropionate, Nasal Spray|
9691926|NCT04817800|Active Comparator|RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)|
9691927|NCT04817488||Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed with tele-supervision.
9691928|NCT04817488||Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed without tele-supervision.
9691929|NCT04817527|Experimental|Edaravone Dexborneol|
9691930|NCT04817527|No Intervention|conventional therapy|conventional therapy of acute ischemic stroke after Endovascular Therapy based on Chinese guidelines for endovascular therapy
10181415|NCT03783936|Other|Induction and Maintenance|"Cycles 1-9; Induction; Cycle = 14 days~mFOLFOX6~oxaliplatin 85 mg/m2 IV Day 1 and~leucovorin 400 mg/m2 IV Day 1 and~5 fluorouracil 400 mg/m2 IV bolus and 2400 mg/m2 IV over 46 hours Day 1 and~Trastuzumab 6 mg/kg IV loading dose C1D1 then Trastuzumab 4 mg/kg IV Day 1 and~Avelumab 800 mg IV Day 1~Cycles 10 and subsequent; Maintenance; Cycle = 14 days~Trastuzumab 4 mg/kg Day 1 and Avelumab 800 mg Day 1"
10181416|NCT03784040|Experimental|(Arm A) OTSGC-A24 + nivolumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.
9976310|NCT01350206|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
10181417|NCT03784040|Experimental|(Arm B) OTSGC-A24 + nivolumab + ipilimumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 …) of each 28 day cycle for up to 24 months.
10181418|NCT03783988|Other|Open uncontrolled pharmacokinetic study|Single armed - All subjects receive one dose of topical combination gel containing TRIAC and DHEA
10181419|NCT03783858|Other|Single|
9691936|NCT04817592||Age1(20-25)|The groups are divided as per age
9691937|NCT04817592||Age2(25-30)|
9691938|NCT04817592||Age3(30-35)|
9691939|NCT04817592||Age4(35-40)|
9691940|NCT04817592||Age5(40-45)|
9691941|NCT04817475||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
9691942|NCT04817436|Active Comparator|Without adapted physical activity program (APA)|
9691943|NCT04817436|Experimental|With adapted physical activity program (APA)|
9691944|NCT04817709||Arm 1|Patients view a video and read a workbook over 30 minutes about breast reconstruction surgery before their appointment. Patients also complete a questionnaire over 5-10 minutes before and after the video and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
9691945|NCT04817709||Arm 2|Patents receive an educational booklet about breast reconstruction surgery during appointment. Patients also complete a questionnaire over 5-10 minutes before and after talking with the plastic surgeon. Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
9691946|NCT04817644|Experimental|Oral semaglutide|All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.
9691947|NCT04817371|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
9691948|NCT04817371|Other|Symptomatic patients with positive PCR for other respiratory virus|Patients with symptomatic respiratory disease of infectious origin with negative RT-PCR for SARS-CoV-2 and positive RT-PCR for other respiratory viruses
9691949|NCT04817371|Other|Asymptomatic patients or healthy volunteers|Patients or healthy volunteers with negative RT-PCR and negative serology
9691950|NCT04817371|Other|Volunteers or patients vaccinated against COVID-19|Volunteers or patients vaccinated against COVID-19 (complete vaccination scheme)
9691951|NCT04817566|Experimental|stimulation group|Anodal tDCS+ intensive cognitive Training
9691952|NCT04817566|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
9691953|NCT04817332|Experimental|Brensocatib|Brensocatib oral tablet, 25mg once per day for 28 days
9691954|NCT04817332|Placebo Comparator|Placebo|Placebo oral tablet, 25mg once per day for 28 days
9691955|NCT04817423||Model training and test group|Data set will be split into training group and test group, where training group will be used for model building, and test group for subsequent evaluation and verification.
9691956|NCT04817384|Experimental|Graston technique group|For Graston practice, instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
9691957|NCT04817384|Experimental|Classical massage group|The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
9691958|NCT04817280||Ice Swimmers Group.|No intervention. Data obtained from Polish ice swimmers reported by them retrospectively in the questionnaire.
9691959|NCT04817462||Liver Biopsy|All patients undergo a liver biopsy only
9691960|NCT04817176|Experimental|MI-CBT KNA Program|The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
9691961|NCT04817176|Active Comparator|KN Information-Only Program|6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
9691962|NCT04817540|Experimental|Single arm, Herzuma arm|
9691963|NCT04817202|Experimental|Group A1 (hzVSF-v13 50mg, intravenous, single dose)|Single administration (intravenous) of 50mg hzVSF-v13 on Day 1.
9691964|NCT04817202|Experimental|Group A2 (hzVSF-v13 100mg, intravenous, single dose)|Single administration (intravenous) of 100mg hzVSF-v13 on Day 1.
9691965|NCT04817202|Experimental|Group A3 (hzVSF-v13 200mg, intravenous, single dose)|Single administration (intravenous) of 200mg hzVSF-v13 on Day 1.
10181420|NCT03783845|Experimental|test group|"Metronidazole 400mg,three times daily for two weeks~Amoxicillin 500mg,three times daily for two weeks."
9691966|NCT04817202|Experimental|Group A4 (hzVSF-v13 400mg, intravenous, single dose)|Single administration (intravenous) of 400mg hzVSF-v13 on Day 1.
9691967|NCT04817202|Experimental|Group A5 (hzVSF-v13 800mg, intravenous, single dose)|Single administration (intravenous) of 800mg hzVSF-v13 on Day 1.
9691968|NCT04817202|Experimental|Group A6 (hzVSF-v13 1200mg, intravenous, single dose)|Single administration (intravenous) of 1200mg hzVSF-v13 on Day 1.
9691969|NCT04817202|Experimental|Group A7 (hzVSF-v13 100mg, subcutaneous, single dose)|Single administration (subcutaneous) of 100mg hzVSF-v13 on Day 1.
9691970|NCT04817202|Experimental|Group B1 (hzVSF-v13 100mg, intravenous, multiple dose)|Multiple administration (intravenous) of 100mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
9691971|NCT04817202|Experimental|Group B2 (hzVSF-v13 400mg, intravenous, multiple dose)|Multiple administration (intravenous) of 400mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
9691972|NCT04817202|Placebo Comparator|Placebo (intravenous, single dose)|Single administration (intravenous) of placebo on Day 1.
9691973|NCT04817202|Placebo Comparator|Placebo (subcutaneous, single dose)|Single administration (subcutaneous) of placebo on Day 1.
9691974|NCT04817202|Placebo Comparator|Placebo (intravenous, multiple dose)|Multiple administration (intravenous) of placebo on Day 1, Day 15, Day 29, Day 43, Day 57.
9691975|NCT04817449||Suspected Ovarian Cancer|Patients referred or self presenting to secondary care with signs or symptoms of ovarian cancer.
9691976|NCT04817137|Other|All Enrolled Patients|Patients will wear the Caretaker Pulse Decomposition Analysis (PDA) Device, which will record the patient's blood pressure.
9691977|NCT04817514|Experimental|specific shoulder rehabilitation protocol group (SRG);|
9691978|NCT04817514|Experimental|specific protocol of shoulder rehabilitation plus aerobic exercise group (ARG)|
9691979|NCT04817163|Experimental|Stepped care CBT-I|
9691980|NCT04817293||COVID-19 positive|
9691981|NCT04817293||COVID-19 negative|
9691982|NCT04817215|Experimental|Patients who are Drug naïve or diet controlled|
9691983|NCT04817215|Experimental|Patients on Metformin only|
9691984|NCT04817215|Experimental|Patients on two or three oral glucose-lowering agents|
9691985|NCT04817605|Experimental|Exercise Therapy|
9691986|NCT04817306||Cancer Arm|Participants with new diagnosis of cancer, from whom blood samples will be collected
9691987|NCT04817306||Benign Diseases Arm|Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected
9691988|NCT04817306||Non-tumor (Healthy) Arm|Participants without known presence of malignancies or benign diseases, from whom blood samples will be collected
9691989|NCT04817059|Experimental|Head mold on|
9691990|NCT04817059|No Intervention|Head mold off|
9691991|NCT04817358||Demirjian method|According to the Demirjian method, the development of the seven left mandibular permanent teeth (except the third molar) were rated on the eight-stage scale from A to H. Each stage of mineralization was given a score, total dental maturity score was evaluated according to standard tables for boys and girls
9691992|NCT04817358||Willems method|Willems' method was determined using the Demirjian calcification stages but scores were evaluated according to Willems' specific tables
9691993|NCT04817358||Nolla method|In the Nolla method, the development of seven left mandibular and maxillar teeth were defined on 10 stages. If the tooth was between stages an appropriate fraction (0.2, 0.5 or 0.7) was added. The total score was determined according to the tables prepared for girls and boys as recommended by Nolla
9691994|NCT04817150|Experimental|3D-laparoscopy|patients who underwent 3D laparoscopic ventral rectopexy
9691995|NCT04817150|Active Comparator|2D-laparoscopy|patients who underwent conventional 2D laparoscopic ventral rectopexy
9691996|NCT04817319|Experimental|Major patients diagnosed with Covid + requiring oral care.|
9691997|NCT04816903|Experimental|Symptomatic vaginitis patients|All participants will be enrolled according to their complaints, All will be tested by the Gyni system, Only in the second group the physician will be unblinded to the Gyni results.
10181421|NCT03783845|No Intervention|control group|no intervention during study period
10181422|NCT03783728||Untreated Latent Tuberculosis Infection|Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
10181423|NCT03783754|Experimental|Triple Pill (Active Treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
10181424|NCT03783754|Placebo Comparator|Placebo|received via blinded study oral capsules
10181425|NCT03783572|Experimental|Stroke patients|40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
9691998|NCT04816968|Experimental|Arm A - Cefepime|Continuous infusion of Cefepime at home.
9691999|NCT04816968|Experimental|Arm B - Piperacillin/tazobactam|Continuous infusion of Piperacillin/tazobactam at home.
9692000|NCT04816968|Experimental|Arm C - Meropenem|Continuous infusion of meropenem at home.
9692001|NCT04816968|Experimental|Arm D - Vancomycin|Continuous infusion of vancomycin at home.
9692002|NCT04816994|Experimental|High dose cannabis oil|Single-dose 20.0 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic.
9692003|NCT04816994|Experimental|Low dose cannabis oil|Single-dose 10 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
9692004|NCT04816994|Placebo Comparator|Control|Single-dose Olive oil that is similar in appearance and taste to cannabis oil
9692005|NCT04816877||Patient controlled analgesia (PCA) group|Patients in this group will be allocated to the PCA arm, i.e., they will be receiving a PCA pump for administration of opioids.
9692006|NCT04816877||Physician directed analgesia (PDA) group|Patients in this group will be allocated to the PDA arm, i.e., they will be receiving opioids administered by the nurse, as and when directed by the physician.
9692007|NCT04817111|Other|Open Label - MIB-626|MIB-626
9692008|NCT04816825|Experimental|Exergaming|The combination of 1) game-console based exercise programs, 2) specifically designed by professional physiotherapists with focus on subjects with a chronic lung disease and 3) weekly distant monitoring with close supervision by a physiotherapist. Individually prescribed exercise program based on tests of patient's physical fitness.
9692009|NCT04816825|Active Comparator|Standard rehabilitation|Standard rehabilitation at the COPD-Center. This includes recommendations about physical activity according to the general guidelines, however, individualized after each subject's physical fitness level.
9692010|NCT04816838|Experimental|N/A(Single Arm)|
9692011|NCT04816864|Active Comparator|ECANS started from the right vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
9692012|NCT04816864|Active Comparator|ECANS started from the left vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
9692013|NCT04816786||Group 1: Admitted to ICU and died during the hospital stay.|
9692014|NCT04816786||Group 2: Admitted to ICU was were discharged.|
9692015|NCT04816942|Experimental|Convalescent Plasma|Patients receiving Two units of ABO compatible COVID-19 convalescent plasma will be administered.P
9692016|NCT04816929|Experimental|Bobath Method Group|The Bobath based exercises for 60 minutes will be formed according to the needs of the individual and will involve trunk exercises such as placing, stretching, functional reach, rotations, functional strengthening and, balance and walking exercises etc. It will be performed 3 days a week for 8 weeks.
9692017|NCT04816929|Active Comparator|Task-Oriented Approach Group|The task-oriented approach for 60 minutes will be formed according to the needs of the individual and involve exercises targeting functional tasks determined. It will be performed 3 days a week for 8 weeks.
9692018|NCT04816851||Ozaki group|Patients undergoing aortic valve reconstruction using autologous pericardium (OZAKI technique) at Assiut University Hospitals in conjunction with Al-Nas hospital in cairo.
9692019|NCT04816448|Experimental|Studygroup|cervical mobilization (Headache SNAG) with baseline treatment (Hot pack for 10 minutes, TENS 10 minutes, Neck isometrics and stretching).
9692020|NCT04816448|Active Comparator|Control Group|Sub-occipital myofascial release with baseline treatment (Hot pack for 10 minutes, TENS for 10 minutes, Neck isometrics and stretching
9692021|NCT04817124|Experimental|stimulation group|Anodal tDCS+ intensive cognitive Training
9692022|NCT04817124|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
9692023|NCT04816500|Experimental|RIC group|Device: Remote ischemic conditioning RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
9692024|NCT04816500|Other|Regular treatment|
9692025|NCT04816682|Active Comparator|LAGOSA ARM|Consecutively admitted patients will be allocated silymarin tablets (150 mg each) T.I.D. 3-2-2
9692026|NCT04816682|No Intervention|Control arm|Consecutive patients with the same inclusion/exclusion criteria as in active arm, hospitalised at the same department before the initiation of the study (historical controls)
9692027|NCT04816890|Experimental|M1 Pram P037|Multi daily administration of M1 Pram P037 by subcutaneous injection
9692028|NCT04816890|Active Comparator|Insulin lispro|Multi daily administration of insulin lispro (Humalog®) by subcutaneous injection
9692029|NCT04816955|Experimental|Nutrient-based recommendations|Participants in this group will be given nutrient-based recommendations to reduce free sugar intakes.
9692030|NCT04816955|Experimental|Nutrient- and food-based recommendations|Participants in this group will be given nutrient- and food-based recommendations to reduce free sugar intakes.
9692031|NCT04816955|Experimental|Nutrient- and food-based recommendations with food swaps|Participants in this group will be given nutrient- and food-based recommendations and advice on food swaps to reduce free sugar intakes.
9692032|NCT04816955|Placebo Comparator|Control|Participants in this group will not be given any recommendations to reduce free sugar intakes.
9692033|NCT04816344||Group MP (n=35)|"The patients were separated into four groups according to the anaesthetic agents given.~Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage."
9692034|NCT04816344||Group MK (n=35)|Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg ketofol (10% ketamine + 10% propofol) iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg iv ketofol was given as additional dosage.
9692035|NCT04816344||Group DP (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage.
9692036|NCT04816344||Group DK (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg ketofol iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg ketofol iv was given as an additional dosage.
9692037|NCT04816396|Experimental|experimental|For 8 weeks, Reminiscence Therapy based on Roy Adaptation Model will be applied
9692038|NCT04816396|No Intervention|No İntervention|No intervention will be applied to this group.
9692039|NCT04816695|Experimental|VOC analysis|VOC analysis in exhaled air in patients hospitalised for COPD exacerbation
9692040|NCT04816370|Experimental|pSS group|primary Sjögren's syndrome group
9692041|NCT04816370|Experimental|Control Group|Control group
9692042|NCT04816370|Experimental|pSS Premenopausal|primary Sjögren's syndrome premenopausal patients
9692043|NCT04816370|Experimental|pSS Postmenopausal|primary Sjögren's syndrome postmenopausal patients
9692044|NCT04816656|Experimental|Experimental arm|All patients were presented the digital PROMs platform during their chemotherapy
9696332|NCT04768075|Placebo Comparator|placebo group|"subject will receive placebo intravenously (IV) PLUS pemetrexed or paclitaxel or albumin paclitaxel PLUS cisplatin or carboplatin AUC 5 on Day 1 of each 3-week cycle(Q3W) for 4-6 cycles followed by placebo ± pemetrexed IV Q3W until progression (up to approximately 2 years).~Whether the subject accepts intracranial radiotherapy will be decided by investigators according to the guidelines and the conditions of the subjects."
9696333|NCT04768374|Experimental|VR group|Enrolled into 12 week VR intervention with Microsoft Kinect (twice a week, for 45 minutes) and conventional occupational therapy.
10181426|NCT03783572|Active Comparator|Control Group|The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
10181427|NCT03783715||Ketoprofen|Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
9696334|NCT04768374|Active Comparator|Control group|Control group only received conventional occupational therapy for 12 weeks
9696335|NCT04768439|Experimental|200 IU/d vitamin D|Patients will receive low-dose vitamin D (200 IU/d)
9696336|NCT04768439|Experimental|1600 IU/d vitamin D|Patients will receive high-dose vitamin D (1600 IU/d)
10181428|NCT03783637|Other|Whole Grain Oat|Volunteers will consume a breakfast meal containing whole grain oats after 7 days of a whole grain free diet.
9696337|NCT04767945||Adults with liver cirrhosis admitted to hospital liver unit|Consenting adults admitted with liver cirrhosis; recorded/uploaded are demographic, clinical, laboratory and imaging data
9696338|NCT04767789|Experimental|NZ-GHMH-01|Dietary supplement in shape of capsule to be taken once per day in the evening.
9696339|NCT04767789|Placebo Comparator|Placebo|The placebo is in shape of capsule to be taken once per day in the evening and in which only the active ingredients are not present.
9696340|NCT04767724|Experimental|Extracorporeal shock wave|Participants received three ESWT sessions once per week for three consecutive weeks. The probe of the ESWT machine (FT-174; Swiss Dolor Class; Switzerland) was placed perpendicularly on the patient's palm over the median nerve on the carpal tunnel after application of the ultrasound gel as a coupling agent. Afterward, the ESWT was administered with 1000 shots, 1.5 bar of pressure, and a frequency of 6 Hz
9696341|NCT04767724|Active Comparator|Local corticosteroid injection|A single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
9696342|NCT04767841|Experimental|Metformin|Metformin 1000 mg daily plus Celecoxib 200mg capsule
9696343|NCT04767841|Experimental|Placebo|Placebo tablet daily plus Celecoxib 200mg capsule
9696344|NCT04767919|Active Comparator|Standard Percutaneous Nephrolithotomy (sPCNL)|The first arm will consist of a Standard of Care standard percutaneous nephrolithotomy (sPCNL)- performed using a 30 Fr access sheath following balloon dilation.
9696345|NCT04767919|Active Comparator|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|The second arm will consist of a Standard of Care mini percutaneous nephrolithotomy (mPCNL)- performed using an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
9696346|NCT04768023|Other|Control group|The group after 6 weeks of the research will receive placebo treatment.
9696347|NCT04768023|Active Comparator|Control group with physical activity|The group after 6 weeks of the research will receive placebo treatment. The group will be prompt to do 3500-8000 steps per day.
9696348|NCT04768023|Placebo Comparator|Placebo group|The group will receive placebo treatment for all the time of the research.
9696349|NCT04768023|Placebo Comparator|Placebo group with physical activity|The group will receive placebo treatment for all the time of the research. The group will be prompt to do 3500-8000 steps per day.
9696350|NCT04768023|Experimental|Vitamin D3 group|The group will receive vitamin D3 supplementation.
9696351|NCT04768023|Experimental|Vitamin D3 group with physical activity|The group will receive vitamin D3 supplementation. The group will be prompt to do 3500-8000 steps per day.
9696352|NCT04767815|Experimental|Sequence 1|"Period 1: A (Fasting)~Period 2: B (30 minutes after a High-fat meal)~Period 3: C (2 hours after a High-fat meal)"
9696353|NCT04767815|Experimental|Sequence 2|"Period 1: B (30 minutes after a High-fat meal)~Period 2: C (2 hours after a High-fat meal)~Period 3: A (Fasting)"
9696354|NCT04767815|Experimental|Sequence 3|"Period 1: C (2 hours after a High-fat meal)~Period 2: A (Fasting)~Period 3: B (30 minutes after a High-fat meal)"
9696355|NCT04767815|Experimental|Sequence 4|"Period 1: A (Fasting)~Period 2: C (2 hours after a High-fat meal)~Period 3: B (30 minutes after a High-fat meal)"
9696356|NCT04767815|Experimental|Sequence 5|"Period 1: C (2 hours after a High-fat meal)~Period 2: B (30 minutes after a High-fat meal)~Period 3: A (Fasting)"
9696357|NCT04767815|Experimental|Sequence 6|"Period 1: B (30 minutes after a High-fat meal)~Period 2: A (Fasting)~Period 3: C (2 hours after a High-fat meal)"
10181429|NCT03783637|Other|Whole Grain Wheat|Volunteers will consume a breakfast meal containing whole grain wheat after 7 days of a whole grain free diet.
9692045|NCT04816318||Social and public health measures against COVID-19|Public Health and Social measures against COVID-19. This group refers to the population exposed to public health and social measures against COVID-19
9692046|NCT04816318||Control|The comparator is the pre-intervention period
10181430|NCT03783793|Experimental|Mindfulness Training App|
9692047|NCT04816487|Active Comparator|Silver Diamine Flouride|Discoloration of primary carious teeth treated by SDF
9692048|NCT04816487|Experimental|Glutathione|Discoloration rate of primary carious teeth treated by SDF + Glutathione
9692049|NCT04816487|Experimental|Potassium iodide|Discoloration rate of primary carious teeth treated by SDF + KI
9692050|NCT04816266||Myopic patients|
9692051|NCT04816266||Hypermetropic patients|
9692052|NCT04816266||Emmetropic people|
9692053|NCT04816461|Experimental|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with standard HRP2-RDT and treatment with DHAPPQ if positive
9692054|NCT04816461|Experimental|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive|SMC+ roommates screening with highly sensitive RDT and treatment with DHAPPQ if positive
9692055|NCT04816461|Active Comparator|SMC alone|No roommates screening and treatment
9692056|NCT04816409|Experimental|(Neurodevelopmental therapy)|"Starting Posture Start and evaluate the supreme effective posture to move from(usually straight) Reassemble to mid plane (head/trunk)~•Neutral position of body Identify the Missing Components Detect starting posture and compare to normal.~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.~Developmental movement patterns training:~Obstacle crawl, hold swing's ropes in kneeling anhalf kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of sustaining exercise positions in children.4. Ambulation training, suitable to the motor"
9692057|NCT04816409|Active Comparator|Conventional treatment|Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,
9692058|NCT04816292|Active Comparator|Hot Snare Polypectomy|If an eligible polyp 5-15 mm (as compared by the size of the snare) is found, according to the randomized group, HSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 2 biopsies (polyps 5-9mm) or 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
9692059|NCT04816292|Experimental|Cold Snare Polypectomy|If an eligible polyp 5-15 mm (as compared by the size of the snare) is found, according to the randomized group, CSP is performed for the removal of all eligible polyps in this patient. After polypectomy, the resection site is washed thoroughly with saline water. After the endoscopist carefully examines the resection site for residual adenomatous tissue, eventually another resection with the same method is indicated. Afterwards 2 biopsies (polyps 5-9mm) or 4 biopsies (polyps 10-15mm) are performed from the resection margin to reveal presence or absence of residual neoplastic tissue.
9692060|NCT04816422|Experimental|Proprioceptive neuromuscular facilitation|Bilateral upper extremity pattern for trunk by Chopping, Lifting 2. Bilateral lower extremity pattern for trunk. 3. Trunk lateral flexion. 4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion.
9692061|NCT04816422|Active Comparator|Conventional treatment|"Procedure Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
9692062|NCT04816305|Experimental|rTMSc + physiotherapy|A conventional high-frequency rTMS (rTMSc) will be applied over the lesioned hemisphere over the motor cortex. After rTMSc, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
9692063|NCT04816305|Experimental|rTMSp + physiotherapy|A personalized high or low-frequency rTMS (rTMSp) will be applied to the lesioned or non-lesioned hemisphere depending on cortical biomarkers assessment guide a personalized stimulation for each patient in this group. After rTMSp, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
9692064|NCT04816305|Sham Comparator|tDCS sham + physiotherapy|The sham protocol will be delivered to each patient of this arm imitating the exat sound of the equipment and structure of the experimental arms. After rTMS sham, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
9692065|NCT04816279||First Audit cycle|
9692066|NCT04816279||Second Audit cycle|
9696358|NCT04767685||All patients|Consenting patients undergoing non-emergency surgery with anesthesia
9696359|NCT04768036|No Intervention|Usual Medical Care|As per standard of care
9696488|NCT04766359|Experimental|Cisplatin combined with radiotherapy|"Cisplatin (40mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
10181431|NCT03783793|Active Comparator|Cognitive Training With 2048|
10181432|NCT03783494|Experimental|Target-controlled infusion (TCI)|Target-controlled infusion (TCI) with propofol up to 5.5µg/ml during an anticipated average maximal time of 15 minutes
10181433|NCT03783663|Experimental|Sleep education plus Misfit Shine 2|This arm receives sleep education from the study nurse and also receives a Misfit Shine 2 to wear for 12 weeks to self-monitor sleep.
9692067|NCT04816331||Neonatal Encephalopathy (NE)|This study is a follow up of children at 2-3 years of age who were enrolled in the HRB-funded Neonatal Inflammation and Multiorgan dysfunction and Brain injUry reSearch group (NIMBUS) project. These babies had Neonatal Encephalopathy and required Therapeutic Hypothermia and are matched with controls. Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management were collected. In addition, details of Therapeutic Hypothermia treatment including initiation, duration and clinical examination, investigations including cranial USS, MRI, EEG and placental histology analysis performed as were recorded.
9692068|NCT04816331||Controls|The controls include age-matched normal children born at term with a normal delivery and postnatal course.
9692069|NCT04816253|Placebo Comparator|Normal saline|Normal saline irrigation after extraction and No drug placed in tooth socket
10181434|NCT03783663|No Intervention|sleep education only|This arm receives only sleep education from the study nurse.
10181435|NCT03783481|Experimental|Mobile community group|join the mobile community via the smartphone application
10181436|NCT03783481|Active Comparator|No community group|
9692070|NCT04816253|Active Comparator|Gengigel|Gengigel (Hyaluronic acid) placed after extraction
9692071|NCT04816253|Active Comparator|Methylprednisolone|Methylprednisolone will be given intravenous to a patient half an hour before the surgery
9692072|NCT04816253|Active Comparator|Methylprednisolone and Gengigel|Methylprednisolone will be given intravenous to a patient half an hour before the surgery and Gengigel (Hyaluronic acid) placed after extraction
9692073|NCT04816383|Experimental|Experimental Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources. The participant will also receive the Apple breastfeeding application in the office once enrolled in the study between 32 to 36 weeks gestation. The participant will be taught how to use the application, and will have access to the study to continue use throughout the duration of follow-up.
9692074|NCT04816383|No Intervention|Control Arm|The participant will receive usual breastfeeding care such as counseling by her physician, access to lactation consults, nursing assistance in the hospital, access to our online resources.
9692075|NCT04816227||Amyotrophic Lateral Sclerosis (ALS)|Blood draw
9692076|NCT04816227||asymptomatic carriers of ALS mutations|Blood draw
9692077|NCT04816227||patients with motor impairment other than ALS|Blood draw
9692078|NCT04816227||healthy controls|Blood draw
10181437|NCT03783624|Experimental|Hypnosis|"This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: in this deeply relaxed state, you can imagine that your feet are covered in anesthetic… a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again…."
9692079|NCT04815915|Experimental|Study Group|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
9692080|NCT04816071|Experimental|EAA - non-vaccinated|18 g/day
9692081|NCT04816071|Placebo Comparator|Placebo - non-vaccinated|18 g/day
9692082|NCT04816071|Experimental|EAA - vaccinated|18 g/day
9692083|NCT04816071|Placebo Comparator|Placebo - vaccinated|18 g/day
9692084|NCT04815980|No Intervention|Control|The control group performed no Pilates intervention. They continued with their typical activities of daily living.
9692085|NCT04815980|Experimental|Pilates|Participants in this group performed a 30 minute mat-based Pilates intervention 3 times/week for 12 weeks.
9692086|NCT04816110|Experimental|mineralized plasmatic matrix with collagen membrane|
9692087|NCT04816110|Active Comparator|mineralized plasmatic matrix without collagen membrane|
9692088|NCT04816097|Active Comparator|Steroid Group|Participants will receive 4 doses of dexamethasone 6mg IM 48h before elective CS.
9692089|NCT04816097|No Intervention|No Steroid Group|Participants will receive No treatment before elective CS.
10181438|NCT03783624|Placebo Comparator|Open Label placebo|This consists in information provided with a placebo pill. Patients are asked to take the placebo pills as a self-healing ritual. The information relies on 4 points of explanation, i.e. (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the full duration of treatment is critical.
10181439|NCT03783624|No Intervention|Usual care|Patients continue with their usual treatments
10181440|NCT03783676|Experimental|Remifentanil group|Will receive remifentanil bolus and infusion guided by an algorithm
10181441|NCT03783676|Placebo Comparator|Control group|Will receive normal saline bolus and infusion guided by the remifentanil algorithm
10181442|NCT03783650|Experimental|Cohort 1|0-6 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist, Registry & BP measurement 7-12 months: QIC with Subspecialist to improve communication and standardize, 13-18 months: Hub and Spoke co-management QIC with Primary care and Subspecialist 19-24 months: Sustainability of changes
9692090|NCT04816045|Active Comparator|Intervention|Electrochemotherapy with bleomycin
9692091|NCT04816045|Active Comparator|Control|Electroporation with saline
9692092|NCT04816188|Experimental|Exercise and Activity Modification|
9692093|NCT04815850||Patients on haemodialysis|Patients receiving haemodialysis
9692094|NCT04815850||Healthy controls|Participants with no chronic kidney disease or history of immunosuppression
9692095|NCT04816240|Experimental|Midodrine + Albumin +Standard Medical Treatment|SMT + Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (>75 mm and <90).
10181443|NCT03783650|Active Comparator|Cohort 2|0-6 months: Control condition Usual Care and Registry & BP measurement, 7-12 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist 13-18 months: QIC with Subspecialist to improve communication and standardize 19-24 months: Hub and Spoke co-management QIC with Primary care and Subspecialist
10181444|NCT03783819|Active Comparator|Active treatment|One forearm will be treated with ointment containing Hypericum perforatum oil. Forearm (left or right) will be chosen according to randomization protocol.
9692096|NCT04816240|Active Comparator|Albumin + Standard Medical Treatment+ Placebo|80grams/week for 2 weeks followed by 40gram/week + Placebo
9692097|NCT04815941|Experimental|Soft ball tissue release exercises|
9692098|NCT04816201|Experimental|Electroacupuncture|Participants in the electroacupuncture group received acupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36). After skin disinfection, sterile adhesive pads were placed on these acupoints, and acupuncture needles were inserted through the adhesive pads approximately 50 to 60 mm into the skin. Paired electrodes from the electroacupuncture apparatus were attached to the needle handles of Xuanji (CV21) and Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), bilateral Liangmen (ST21), and bilateral Zusanli (ST36). The electroacupuncture stimulation lasted for 30 minutes with an intermittent wave of 50 Hz and a current intensity of 1 to 5mA (preferably with the skin around the acupoints shivering mildly without pain). Participants received 1 treatment session per day until the success of ventilator weaning (up to 21 days).
9692099|NCT04816201|Sham Comparator|Sham electroacupuncture|Participants in the sham electroacupuncture group received sham electroacupuncture with a pragmatic placebo needle on sham acupoints. The sham Xuanji (CV21) point was 1 cun (≈20 mm) above to Xuanji (CV21), the sham Danzhong (CV27) point was 1 cun(≈20mm) above to Danzhong (CV27), the sham Qihai (CV06) point was 1 cun(≈20mm) above to Qihai (CV06), the sham Guanyuan (CV04) point was 1 cun(≈20mm) above to Guanyuan (CV04), the sham Liangmen (ST21) point was 1 cun(≈20mm) lateral to Liangmen (ST21), and the sham Zusanli (ST36) point was 1 cun(≈20mm) lateral to Zusanli (ST36). Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no skin penetration or electricity output.
9692100|NCT04816123|Experimental|[14C]Donafenib|
9692101|NCT04816032|Experimental|Pennebaker's expressive writing|Three consecutive days for 20 minutes daily of expressive writing. The topic of the traumatic traveling experience, focalizing the attention on the deeper emotions, thoughts, and feelings.
9692102|NCT04816032|Active Comparator|Writing about different aspects of their knowledge|Three consecutive days for 20 minutes daily of neutral writing. Different topics of own knowledge Description of the city, their room, their place where they live, or easy procedure like, how to make a coffee (or something else), their population, trying to remain free from deep emotions, thoughts, or feelings.
9692103|NCT04816032|No Intervention|Control|No intervention
9692104|NCT04816136||patients with a sleep recording performed|patients with a sleep recording performed in the sleep unit in Montpellier University Hospital, who had an ischemic stroke before the recording.
9692105|NCT04816084|Experimental|Population|Voluntary people over 18 from the staff of the University of Reims Champagne Ardenne
9692106|NCT04815954|Experimental|Early group|Early urinary catheter removal: 24±6 hours after completion of surgery.
9692107|NCT04815954|Active Comparator|Delayed group|Delayed urinary catheter removal: 72±6 hours after completion of surgery.
9692108|NCT04815863||Elderly|Over 60 years old
9692109|NCT04815863||Non-Elderly|Under 60 years old
9692110|NCT04815837|Experimental|Intervention|"Participants received the following interventions:~Viewing a video promoting Human Papillomavirus (HPV) vaccination~Receiving discount coupons~Visiting the project webpage~Receiving follow-up reminders"
9692111|NCT04815889|No Intervention|Control group|Recruitment of the control group is done through the county parts that have not yet been included in the clinical trial of new methods. This means that children / families are not withheld from treatment they would otherwise receive.
9692112|NCT04815889|Active Comparator|PRIMUS parent training group and preschool teacher training group|The parents have undergone PRIMUS Group-based parent support program for 5 half days This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The preschool teachers may participate for half a day in education together with the parents as a practical implementation in the child's everyday life.
9692113|NCT04815889|Other|Demand-driven intervention|"The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~Support in the child's everyday environment home / preschool~Targeted parent training group: toilet, sleep, food, everyday structure, handle behavioural problems~Web Courses Each individual intervention is evaluated afterwards with the study questionnaire."
9692114|NCT04815811|Experimental|Children suffering from acute inflammatory processes.|"The study population will consist of male and female children, aged from 6 months to 7 years old, admitted to the hospital for one of the three following types of acute inflammatory processes:~Urinary tract infection caused by Escherichia coli~Pneumonia with pleural effusion caused by Streptococcus pneumoniae~Sepsis"
9692115|NCT04815811|Other|Control group|Male and female children, aged from 6 months to 7 years old, admitted to the hospital for a scheduled operation for a non-inflammatory pathology.
9692116|NCT04815707|Other|Surgery|Occult hernia found will be repaired at the same time as the initial inguinal hernia
9692117|NCT04815707|No Intervention|Expectant Management|No surgery will be done if an occult hernia is found during the initial inguinal hernia surgery
9692118|NCT04815668|Experimental|Acupuncture group|
9692119|NCT04815668|Placebo Comparator|Placebo acupuncture group|
10181445|NCT03783819|Placebo Comparator|Placebo treatment|Other forearm will be treated with placebo ointment. Forearm (left or right) will be chosen according to randomization protocol.
10181446|NCT03783806||Osteoarthrosis (OA)|Patients with primary osteoarthrosis, waiting for a total hip replacement. Determination of functional status, posturography measurements, postural tests.
10181447|NCT03783806||Rheumatoid arthritis (RA)|Patients with rheumatoid arthritis affecting hip joint. Determination of functional status, posturography measurements, postural tests.
10181448|NCT03783806||Control (C)|The healthy reference group was matched with the patient groups for age, gender and body mass index (BMI). Determination of functional status, posturography measurements, postural tests.
9692120|NCT04815668|Other|Rescue medication|
9692121|NCT04815460|Experimental|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
9692122|NCT04815460|Experimental|Ｍoderate intensity-continuous (MCT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
9692123|NCT04815460|No Intervention|Control group|Without any exercise training
9692124|NCT04815499|Experimental|Food supplement|One tablet a day, during 12 months
9692125|NCT04815499|Placebo Comparator|Placebo|One tablet a day, during 12 months
9692126|NCT04815538||industrial workers|Active workers more than 1 year in petrochemical plant, fertilizer factory , electrical station and food industry
9692127|NCT04815538||control group|office work unexposed
9692128|NCT04815603|Experimental|BGE-117|BGE-117 Capsules (4mg or 12mg) to be taken by mouth once a day for 84 days.
9692129|NCT04815603|Placebo Comparator|Placebo|Placebo Capsules to be taken by mouth once a day for 84 days.
9692130|NCT04815486|Experimental|Bilateral rTMS combined with MI through a BCI training platform in VR with NeuRow|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks, and Motor Imagery (MI) treatment through the BCI training paradigm in VR (NeuRow) for 12 non-consecutive sessions (Monday, Wednesday and Friday) in four weeks.
9692131|NCT04815486|Active Comparator|Repetitive TMS in bilateral cortical primary motor area|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks.
9692132|NCT04815733|Active Comparator|Mandatory ventilation|deep neuromuscular block and mandatory ventilation (PCV-VG);
9692133|NCT04815733|Experimental|Pressure support ventilation|partial neuromuscular block and pressure support ventilation (PSVpro).
9692134|NCT04815577||CHD group|The CHD group is made up of the children included in the first study. From these 496 children with CHD, children with a second CPET more than one year from the first referral CPET were included. If several CPETs were performed in the follow-up, we retain the most distant CPET from the first, excluding the CPETs that were performed after a cardiopulmonary rehabilitation program implemented in the region in 2018. The group corresponding to the first CPET was called. Among the initial 496 children, if patients had not had a second CPET, the cause was indicated. As a reminder, the patients included in the initial study were aged 5-18 years old and they were referred by their paediatric cardiologists to one of the two CPET laboratories after their annual medical check-up. The anatomical and clinical classification of congenital heart diseases was used to define the type of malformation. The demographic, clinical, echocardiographic data were collected during the first CPET.
9692135|NCT04815577||Controle|The controle Group consisted of children referred for nonsevere functional symptom linked to exercise (murmur, palpitations or dyspnea) or for a medical sports certificate. We included controlled children from 2015 to 2020 period who will be added to the controlled patients of the initial study. These patients only had one CPET.
9692136|NCT04815746|Experimental|Psychosocial Symptom Management Intervention (PSMI) Experimental Condition Arm|Participants in this group will receive the Cognitive Behavioral Therapy (CBT)-based skills over a 10-week period.
9692137|NCT04815746|Active Comparator|Usual Clinical Care Control Arm|Participants in this group will receive standard education.
9692138|NCT04815447||CCS group|Patients under 25 were recruited in the pediatric CPET laboratory of Montpellier University Hospital after a regular paediatric cardiology outpatient visit.
9692139|NCT04815447||Control|The control group consisted in children referred for a non-severe functional symptom linked to exercise (murmur, palpitation, or dyspnoea) or for a medical sports certificate. These children were classified in the control group only after a completely normal check-up, including physical examination, electrocardiogram, echocardiography, and spirometry.
9692140|NCT04815694|Experimental|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction >13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI > 13.1 will underwent RT dose intensification on GTV + 3 mm to 60.1 Gy with a Simultaneous Integrated Boost (SIB).
9692141|NCT04815694|No Intervention|LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction < 13.1|All patients will be treated on MRgRT, at the second week , patients with an ERI < 13.1 will underwent standard RT dose of 55Gy on tumor and corresponding mesorectum
9692142|NCT04815785|Experimental|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and loading system
9692143|NCT04815512||exposed group|workers in The Petroleum Pipelines Company who are occupationally exposed to petroleum products will be included in the study.
9692144|NCT04815512||Comparison group (control group)|healthy administrative workers in assiut university
9692145|NCT04815421|Experimental|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The therapy duration was 6 days.
9692146|NCT04815421|Experimental|the meridian group|Patients in the meridian group were treated with dredging the same side Hand yang meridian techniques
9692147|NCT04815265|Experimental|Experimental group|Participants in the experimental group received remimazolam for sedation
9692148|NCT04815265|Active Comparator|Control group|participants in the control group received dexmedetomidine for sedation
9692149|NCT04815759||Pre pandemic|
9692150|NCT04815759||Post pandemic|
9692151|NCT04815252|Experimental|CHIME Intervention|Participants will complete an 8-week compassion and mindfulness-based intervention with a group facilitator. The curriculum focuses on providing mindfulness-based stress reduction techniques for use in the early childhood education environment.
9692152|NCT04815252|No Intervention|Waitlist control|Participants are placed on a wait-list to receive the intervention.
9692153|NCT04815382|Experimental|Dynamic Upper Limb Orthosis group|"The dynamic upper limb orthosis group will receive a treatment based on the use of a dynamic upper limb orthosis.~Participants of this group will continue to receive their regular therapy"
9692154|NCT04815382|No Intervention|Control group|The control group will not receive any type of intervention Participants of this group will continue to receive their regular therapy
9692155|NCT04815434||Adults with disabilities and complex health conditions|Interviews, experience of the mouth and oral health and function
9692156|NCT04815408|Experimental|NIC|"Neoadjuvant treatment BGB-A317 200mg q3 weeks (total 3 dosing) Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~Interval debulking surgery and HIPEC~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
9692157|NCT04815408|Active Comparator|NC|"Neoadjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~Interval debulking surgery and HIPEC~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
9692158|NCT04815395|Experimental|Oral Oxytocin|Oxytocin (24IU) orally
9692159|NCT04815395|Experimental|Intranasal Oxytocin|Oxytocin (24IU) intranasally
9692160|NCT04815395|Placebo Comparator|Oral Placebo|Placebo orally
9692161|NCT04815122||Carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity carriers of the Met allele of the COMT Val158Met polymorphism
9692162|NCT04815122||Non-carriers of the Met allele of the COMT Val158Met polymorphism|Women with obesity non-carriers of the Met allele of the COMT Val158Met polymorphism
9692163|NCT04815018||Patients with New Cases of SARS-CoV-2|Newly recruited residents who have been identified as positive through Ohio's Post-Acute Regional Rapid Testing (PARRT) Program will undergo at at least 4 weeks, but no more than 8 weeks, of nasal swab and exhaled breathe particles specimen collection for Covid testing. Previously enrolled residents will submit weekly collections of nasal swab specimens and exhaled breathe particles once they exhibit respiratory-related symptoms, or once a test is ordered by the provider for suspicion of exposure. Collection will continue until these subjects fulfill their 8 weeks of testing.
10181449|NCT03783598|Experimental|intervention group|The intervention group received problem solving therapy as 6 modules. Each module was included at least 1 session per week that is nearly 60 minutes, and the amount of weekly sessions was arranged according to the needs of the person.Individuals has an opportunity was provided for identify problems meaningful for themselves and to start their change from the activities they valued by using the COPM.
10181450|NCT03783598|No Intervention|control group|Control group had not any intervention we have an education to control group about diabetes and healthy life conditions.
9692164|NCT04815018||Patients without SARS-CoV-2|This cohort will consist of previously enrolled residents who submitted nasal swabs and exhaled breathe particles for Covid testing once a week for 8 weeks. The patients will have been identified as negative for a SARS-CoV-2 infection each week.
9692165|NCT04814992|Active Comparator|Computer-Assisted Preoperative CBT Intervention|"Patients will receive the computer-assisted preoperative CBT intervention (n=75). A particularly promising internet-based CBT pain program for the population of interest, PAINTrainer, demonstrated improved pain, function, coping and global health in patients with chronic knee arthritic pain in comparison to an internet education control, with benefits persisting for up to 52 weeks. In addition to the PAINTrainer, there will be an integration of a motivational interviewing (MI) intervention delivered by a trained coach across the sessions about (1) the benefits of opioid tapering for post-operative pain control, (2) approaches for safely tapering, (3) identifying and managing withdrawal symptoms patients may experience."
9692166|NCT04814992|No Intervention|Treatment-as-usual (control)|Patients scheduled to undergo total joint arthroplasty at the study site are automatically enrolled in a mandatory 4-hour education class delivered by a nurse educator or physical therapist. Utilizing an in-person Powerpoint presentation format, patients are informed about pre-habilitation exercises to do prior to surgery; what to expect the day of surgery; the multimodal analgesia protocol used in the perioperative period; options for anesthesia and analgesia; and the expectation of physical therapy after surgery.
9692167|NCT04815096|Experimental|[18F]F-AraG|"Radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
9692168|NCT04814979|Experimental|Experimental Group|Low-intensity pulsed ultrasound along with routine physical therapy
10181451|NCT03783455|Active Comparator|Non arthroscopic joint lavage (NAJL)|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper.
10188012|NCT03720379|Active Comparator|Fluoride Varnish - Fluor PROTECTOR S|"Fluor Protector S - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor, 1.5% ammonium fluoride (7700 ppm fluoride), additional ingredients~APPLICATION OF Fluor Protector S will be performed AT BASELINE, after 3,6 months (control 1) and after 9 and 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
9528151|NCT03213379|No Intervention|Referent group|"The patient of the referent group will have 2 measures of actimetry:~A first one at baseline before the apomorphim set-up:the report will be provided to the investigator and a second one before the 6 months follow-up visit but this report will not be provided to the investigator."
9692169|NCT04814979|Active Comparator|Control Group|Routine physical therapy alone
9692170|NCT04815135||2020 group (COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the lockdown period due to the COVID19 pandemic
10181452|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the NAJL plus corticosteroid group was given an intra-articular injection containing 40 mg of triamcinolone acetonide.
10181453|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the patients were given an intra-articular injection containing 4 ml of a bioengineered hyaluronic acid.
10181454|NCT03783455|Active Comparator|Intraarticular injection of hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
9692171|NCT04815135||2019 group (pre COVID19 group)|Patients who were admitted to the surgical ward via the emergency department during the similar period in 2019
10181455|NCT03783455|Active Comparator|Intraarticular injection of corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 40 mg of triamcinolone acetonide.
10181456|NCT03783585|Experimental|cognitive behavioral therapy for insomnia (CBT-I)|Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
10181457|NCT03783585|Experimental|CBT-I + biweekly support|Participants randomized to this arm will participate in a 6-week web-based CBT-I program. In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
10181458|NCT03783559|Experimental|Arm A|TACE plus chemotherapy ± target therapy
10181459|NCT03783559|Active Comparator|Arm B|chemotherapy ± target therapy
10181460|NCT03783364|Experimental|preoperative|preoperative radiotherapy
10181461|NCT03783364|Active Comparator|postoperative|postoperative radiotherapy
10181462|NCT03783533|Experimental|Adolescents|Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.
9692172|NCT04815005||HoFH|Patients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.
9692173|NCT04815161|Other|Pilloxa pillbox|Patients receiving the Pilloxa pillbox for drug administration
9692174|NCT04815213|Experimental|Arm 1|Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
9692175|NCT04815148|Experimental|Phase Ia: MH004 (0.1%) in healthy volunteers|SAD and MAD
9692176|NCT04815148|Experimental|Phase Ia: MH004 (0.3%) in healthy volunteers|SAD and MAD
9692177|NCT04815148|Experimental|Phase Ia: MH004 (1%) in healthy volunteers|SAD and MAD
10181463|NCT03783520|Experimental|Er,Cr:YSGG Laser|In laser group, each root canal was dried with paper points and then Er,Cr:YSGG (Biolase™, Waterlase™, San Clemente, CA, USA) was used for intracanal disinfection with the following parameters: panel output power of 0,75 W, pulse frequency of 20 Hz, and 1% water pressure to 10% air pressure ratio laser with RFT3 tips (415 µm diameter radial firing tip RFT3 Endolase, Biolase Technology, Inc; calibration factor of 0.85). The fiber was placed at 1mm short of the WL. Irradiation was delivered along the entire length of the root canal with helicoradial movements, 1mm per seconds in speed. This procedure was repeated three times and kept for 20 seconds between each irradiation.
10181464|NCT03783520|Active Comparator|Sodium hypochlorite|In control group, each canal were irrigated with 6 ml of 2,5% NaOCl. For the final irrigation, 5 ml of sterile saline were used. During irrigation, needle was inserted 1 mm short of the WL.
9692178|NCT04815148|Experimental|Phase Ia: MH004 (3%) in healthy volunteers|SAD and MAD
10181465|NCT03783247|Experimental|FIB|hip fracture with fascia Iliaca block
10181466|NCT03783247|Experimental|PENG|Hip fracture with Pericapsular nerve group block
10181467|NCT03783507|Experimental|Order 1|Meal 1, Meal 2, Meal 3, Meal 4
10181468|NCT03783507|Experimental|Order 2|Meal 2, Meal 3, Meal 4, Meal 1
10181469|NCT03783507|Experimental|Order 3|Meal 3, Meal 4, Meal 1, Meal 2
10181470|NCT03783507|Experimental|Order 4|Meal 4, Meal 1, Meal 2, Meal 3
10181471|NCT03783338|Active Comparator|Physical therapy group|Group A will consist of 15 children and will receive the conventional physical therapy program only. This group will be used to compare the results of the other two groups.
10181472|NCT03783338|Experimental|Physical therapy and aerobic exercises group|Group B will consist of 15 children and will receive the conventional physical therapy program and aerobic exercises.
10181473|NCT03783338|Experimental|Physical therapy, aerobic exercises and vitamin D group|Group C will consist of 15 children and will receive the conventional physical therapy program, aerobic exercises and an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) .
9692179|NCT04815148|Experimental|Phase Ib-1: MH004 (0.1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
9692180|NCT04815148|Experimental|Phase Ib-1: MH004 (0.3%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
9692181|NCT04815148|Experimental|Phase Ib-1: MH004 (1%) in Atopic Dermatitis|28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis
10181474|NCT03783312|Placebo Comparator|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
10181475|NCT03783312|Active Comparator|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
10181476|NCT03783312|Active Comparator|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
9692182|NCT04815148|Experimental|Phase Ib-2: MH004 (0.3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
9692183|NCT04815148|Experimental|Phase Ib-2: MH004 (1%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
9692184|NCT04815148|Experimental|Phase Ib-2: MH004 (3%) in Rheumatoid Arthritis|28-Day Repeated Dosing in Participants with Mild to Moderate Rheumatoid Arthritis
9692185|NCT04815187|Experimental|Montelukast 10 mg|Subjects will be instructed to take one pill at night for 90 days
9692186|NCT04815187|Placebo Comparator|Placebo|Subjects will be instructed to take one pill at night for 90 days
9692187|NCT04815200|Other|Nickel titanium NiTi arch wire (Gold Standard, control group)|Patient will receive 0.014 round Nickel titanium NiTi archwire and will be ligated using a ligature wire with Follow up for 2 months.
9692188|NCT04814914||KB109 + Self Supportive Care (SSC)|
9692189|NCT04814914||Self Supportive Care (SSC) Alone|
9692190|NCT04814693|Experimental|Interventional arm|Subjects randomized to the control device arm will undergo treatment with the EndoRotor System, which is a powered debridement tool intended for use in endoscopic procedures to resect and remove necrotic debris during direct endoscopic necrosectomy (DEN) for walled-off necrosis. The system consists of capital components including a power console, roll stand, vacuum pump, and foot control; as well as disposable components including a single-use catheter, purge kit, and suction bag. The EndoRotor System has CE-Mark 613797 and is cleared for use by the FDA in the United States.
9692191|NCT04814693|Active Comparator|Control arm|Subjects randomized to the control device arm will undergo conventional DEN as per the standard of care. Investigators will choose conventional DEN instruments according to their preference.
9692192|NCT04814797||"CF children with gas trapping"|"CF children with gas trapping will be defined by a ratio between the difference of functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of >10%"
9692193|NCT04814797||"CF children without gas trapping"|"CF children without gas trapping will be defined by a ratio between the difference of the functional residual capacity (FRC) obtained by plethysmography (FRCpleth) and FRC obtained by helium dilution method (FRCHe) divided by the FRCpleth of ≤10%"
9692194|NCT04814641||Infants with hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, with hypophosphatemia in the first 5th days
9692195|NCT04814641||Infants without hypophosphatemia|Infant less than 3 months with severe bronchiolitis admitted in a pediatric intensive care unit, without hypophosphatemia
9692196|NCT04814875|Experimental|Part 1 - ACD (Safety)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
9692197|NCT04814875|Experimental|Part 2 - ACD (Efficacy)|ATX-101 plus carboplatin and pegylated liposomal doxorubicin (ACD)
9692198|NCT04814836|Other|Group I|Total-etch mode with 35% phosphoric acid
9692199|NCT04814836|Other|Group II|Selective-etch mode with 35% phosphoric acid
10181477|NCT03783390|No Intervention|Orientation|Informed consent, height, weight, and blood pressure measurement. A link to an online survey the participant and their parent can fill out at home about the participant's medical history will be given.
10181478|NCT03783390|No Intervention|Measurement session Pre/Post Intervention|Questionnaires completed, blood draws, and fixed and ad lib meals completed to measure appetite and hormones. DXA completed.
10181479|NCT03783390|No Intervention|Home Assessments Pre/Post intervention|24-hour dietary recalls. Physical activity measured by monitors (Actigraph, ActivPAL).
9692200|NCT04814836|Other|Group III|Total-etch mode with laser (Er,Cr:YSGG)
9692201|NCT04814836|Other|Group IV|Selective-etch mode with laser (Er,Cr:YSGG)
9692202|NCT04814836|Other|Group V|Self-etch mode
9692203|NCT04814576|Experimental|Group 1|Collaborative nursing care
9692204|NCT04814576|No Intervention|Group 2|Traditional nusing care
9692205|NCT04814537|Experimental|Dural Puncture Epidural Technique|Laboring women receiving the Dural Puncture Epidural (DPE) Technique with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
9696489|NCT04766255|Active Comparator|Control Group|Implant placement and prosthetic rehabilitation of the missing tooth
9696490|NCT04766255|Experimental|SCTG group|Implant placement, soft tissue augumentation of Connective Tissue Graft (from the palate) (SCTG) at the implant site and prosthetic rehabilitation of the missing tooth.
9976311|NCT01350206|Experimental|TACE group|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
9976312|NCT01350219|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations.
9692206|NCT04814537|Active Comparator|Epidural Technique|Laboring women receiving the Conventional Epidural Technique (EPL) with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
9692207|NCT04814719|Experimental|Pentosan Polysulfate Sodium|Pentosan Polysulfate Sodium (PPS) at Dose and frequency selected in Stage 1 of Parent Study for 6 weeks
9692208|NCT04814719|Placebo Comparator|Placebo|Placebo for 6 weeks
9692209|NCT04814823||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
9692210|NCT04814615|Experimental|CD38-positive multiple myeloma|Patients with CD38 positive multiple myeloma with be enrolled. Patients will undergo pretreatment evaluation with standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Patients will then undergo a course of standard of care therapy as defined by a medical oncologist. Following therapy, patients will repeat standard of care diagnostic tests, as well as experimental 89Zr-daratumumab PET/CT. Data analysis will be performed to evaluate 89Zr-daratumumab against standard of care diagnostic tests for the detection and localization of active disease before and after therapy.
9692211|NCT04814706||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery.
9692212|NCT04815083|Placebo Comparator|Standard of Care Arm|Patients in this arm will receive the placebo orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence-guided resection will not be performed in patients in this arm.
9692213|NCT04815083|Experimental|PD G 506 A + Fluorescence-Guided Resection Arm|Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue.
9692214|NCT04815057|Experimental|Education|wellness education
9692215|NCT04814420|Experimental|Experimental group|The group will include 15 patients with OSA 5 with mild OSA 5 with moderate OSA 5 with severe OSA
9692216|NCT04814420|Other|Control group|This group will include 5 patients with no OSA
9692217|NCT04814407||Lung cancer patients|Patients age over 20, with suspected or confirmed diagnosis of lung cancer.
9692218|NCT04814407||Indeterminate subjects|Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
10181480|NCT03783390|No Intervention|Physical Activity Session Pre/Post intervention|DXA, and Fitness testing to measure VO2submax and VO2max. Cognitive assessments will be administered.
10181481|NCT03783390|No Intervention|fMRI Session Pre/Post intervention|The participant will have an fMRI completed and answer questions related to 60 food and activity images while in and out of the fMRI machine.
9692219|NCT04814407||Control subjects|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
9692220|NCT04814277||MRI Data Collection|A group of 34 subjects will be scanned on a 3Tesla (3T) and on a 7T MRI scanner. The images will be compared.
9692221|NCT04814290||living liver donors|cases already underwent hepatectomy for living-donor liver transplantation.
9692222|NCT04814290||matched controls|healthy persons who attended the preoperative clinic while preparing for donation but were rejected because of an ABO blood group mismatch.
9692223|NCT04814303|Active Comparator|ITM|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added.
9692224|NCT04814303|Active Comparator|ACB|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, the short-bevel echogenic needle is advanced in-plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in this group received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
9692225|NCT04814303|Active Comparator|PAI|spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral and Intrathecal morphine 150 μg will be added. PAI intra-operatively will be performed with 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone.
9696360|NCT04768036|Experimental|"SMART on FHIR application of the IMPROVE DD VTE CPR"|"This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients.~Health outcomes and health resource utilization will be assessed for the duration of patient hospitalization until 90 days post-discharge by review of health records.~2 hospitals will be randomized to the experimental arm and 2 hospitals will be randomized to the No Intervention arm."
9976313|NCT01350284|Experimental|Dietary supplementation|3g of cinnamon or placebo control were added to a test-meal.
9976314|NCT01350297|Experimental|Patients|Patients
10181482|NCT03783390|Experimental|Exercise Intervention/Newsletter|After completion of the initial fMRI session the participant will be randomly assigned to intervention for 3 months and then complete another round of assessments described as above (except for the orientation session).
10181483|NCT03783611|Experimental|Intervention group|The intervention group has access to the MyPlan 2.0. eHealth intervention. MyPlan is a eHealth intervention designed to increase physical activity. The intervention is based on the self-regulation theory and focuses on pre- and post-intentional processes to increase physical activity.
9692226|NCT04814498|Experimental|Geneva cocktail (less fexofenadine) & BLD-0409|Following an overnight fast of at least 10 hours, subjects will be administered IP in a fixed sequence.
9692227|NCT04814771|Experimental|[14C] TS-142|Participants will receive oral [14C] TS-142 under fasted conditions
9692228|NCT04814329||effective group|After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.
9692229|NCT04814329||stable group|After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.
9692230|NCT04814329||Early progressed group|After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.
9692231|NCT04814459|Experimental|HOP-UP-PT Program|HOP-UP-PT Program group will participate in the 7-month HOP-UP-PT program
10181484|NCT03783611|No Intervention|control group|The control group receives no intervention
9692232|NCT04814459|No Intervention|Normal Level of Activity|Normal Level of Activity group will be instructed to continue their normal level of activity throughout the 7-months after which they will be offered the opportunity to receive the HOP-UP-PT program
9692233|NCT04814511|Other|Standard therapy with InfectoScab 5 % Creme|
9692234|NCT04814511|Experimental|Escalated therapy with InfectoScab 5 % Creme (arm E5)|
9692235|NCT04814511|Experimental|Escalated therapy with Permethrin 10 % Creme (arm E10)|
9692236|NCT04814511|Experimental|Escalated therapy with InfectoScab 5 % Creme in combination with Driponin 3 mg Tabletten (arm EK)|
9692237|NCT04814121|Experimental|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
9692238|NCT04814121|Placebo Comparator|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 180 days
9692239|NCT04814485|Experimental|SHR-1020 combined with albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel
9692240|NCT04814160|Active Comparator|autogenous bone graft|autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
9692241|NCT04814160|Experimental|mix of bioactive glass and autogenous bone graft|1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
9692242|NCT04814238||mini-David|
9692243|NCT04814238||mini-Yacoub|
9692244|NCT04814238||mini-Bentall|
9692245|NCT04814212|Experimental|Drug-coated balloon (DCB)|The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.
9692246|NCT04814212|Active Comparator|Drug-eluting stent (DES)|The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.
9692247|NCT04814043|Experimental|PD-1 antibody and lenvatinib plus TACE-HAIC|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
10181485|NCT03783429|Active Comparator|Intervention group|The intervention group will receive low-dose digoxin
10181486|NCT03783429|Placebo Comparator|Placebo group|The placebo group will receive a matching placebo
10181487|NCT03783182|Active Comparator|Betapred|16 'Betamethason Sodium Phosphate' tablets dissolved in one ml of water as part of the premedications given to the patient 30 min before the surgery
10181488|NCT03783182|Placebo Comparator|Placebo|One ml of 10% glucose solution as part of the premedications given to the patient 30 min before the surgery
9692248|NCT04814030|Experimental|AIPD-1|Trans hepatic artery infusion of PD-1 antibody, chemoembolization, FOLFOX-based infusion chemotherapy
9692249|NCT04813978|No Intervention|Group B (control)|Head phone will be placed and music will not be played, will get normal nursing care
9692250|NCT04813978|Experimental|Group A (music intervention)|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
9692251|NCT04813965|No Intervention|Control|Participants in the control group received standard information on treatment side-effects.
9692252|NCT04813965|Experimental|Information without self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information group received standard information with additional written information about potential chemotherapy-related cognitive symptoms.
9692253|NCT04813965|Experimental|Information with self-affirmation|Before completing the study's online baseline survey (pre-chemotherapy), participants in the information+SA group (SA=self-affirmation) received standard and additional written information about potential chemotherapy-related cognitive symptoms with a subsequent self-affirmative text.
10181489|NCT03783377|Experimental|ARO-APOC3|
9692254|NCT04813835||suicidal depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
9692255|NCT04813835||depressed patients|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
9692256|NCT04813835||control|psychiatric history suicidal scale mental state examination screening for sleep disturbance electroencephalography
9692257|NCT04814017|Experimental|Radial shock-wave group|Group I (15 subjects) received radial shock-wave application one times a week for six weeks and home based stretching exercises.
9692258|NCT04814017|Experimental|Control|Group II (15 subjects) received home based stretching exercises for six weeks.
9692259|NCT04814589|Experimental|ezetimibe Tablets|ezetimibe tablets test formulation at a single dose of 10 mg
9692260|NCT04814589|Active Comparator|ezetimibe tablets(Ezetrol ®)|ezetimibe tablets reference formulation at a single dose of 10 mg
9692261|NCT04814004|Experimental|hCD19.IL15.CAR-iNKT cells|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
9692262|NCT04813913|Experimental|bevacizumab|bevacizumab in combination with IV fluoropyrimidine chemotherapy.
9696491|NCT04766255|Experimental|CM group|Implant placement, soft tissue augumentation of porcine collagen matrix (CM) at the implant site and prosthetic rehabilitation of the missing tooth.
9692263|NCT04813952|Active Comparator|Group M|Group M is minimal flow anesthesia group with fresh gas flow 0,5 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 0,5 L.min-1 flow under general anesthesia.
9692264|NCT04813952|Active Comparator|Group H|Group H is high flow anesthesia group with fresh gas flow 4 L.min-1. Thirty five patients with ASA class I-II and between the ages of 18-65 undergoing elective laparoscopic cholecystectomy will be included. These patients were planned to be administered sevoflurane anesthesia with 4 L.min-1 flow under general anesthesia.
9976315|NCT01350310|Experimental|Intramyocardial Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
10181490|NCT03783377|Placebo Comparator|Placebo|
9692269|NCT04813783||Control group|The first group of 26 volunteers who meet the inclusion criteria of the study will form the control group. These participants will be given clinical routine training about mucositis care.
9692270|NCT04813783||Intervention Group|In the study, in order to prevent/minimize the flow of information between the control and intervention groups, the data of the control group will be collected first. Data collection will be suspended in the clinic for three months after the control group data is completed. After this period, data of the enterprise group will be collected. Participants in the intervention group will be provided with mucositis training within the scope of the Mucositis Care Protocol in line with the MASCC / ISOO 2019 Recommendations.
9692271|NCT04814056|Experimental|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
9692272|NCT04814381|Experimental|Ketamine + Magnesium|patients in the experimental group will receive 0.5mg/kg of ketamine over 2 hours, diluted in 50cc of NaCl 0.9% and 3g of magnesium sulfate over 30 minutes diluted in 250cc of NaCl 0.9%.
9692273|NCT04814381|Active Comparator|Control|patients in the control group will receive 25mg of hydroxyzine over 2 hours, diluted in 50cc of NaCl 0.9% and 250cc of NaCl 0.9% over 30 minutes
9692274|NCT04813809|Experimental|BARRIER EasyWarm|This is an open, non randomised, single arm study
9692275|NCT04813770|Experimental|Theory-based messages|Theory-based health messages about COVID-19 and COVID-19 vaccination, the necessity of COVID-19 vaccination to oneself and others, and COVID-19 vaccine regulatory approval processes. These messages are based on publicly available information and are hypothesised to increase perceived necessity and reduce concerns about vaccination, and target known barriers to vaccine uptake.
9692276|NCT04813770|Active Comparator|General messages|General messages about the COVID-19 virus and the vaccination programme. These messages do not target necessity and concerns, but are anticipated to promote understanding of the pandemic.
9692277|NCT04814095|Experimental|Targeted therapy|
9692278|NCT04813744|Experimental|Investigation of atraumatic restorative treatment in adults with a high risk of caries|The study group included a total of 25 healthy individuals with high caries risk who had molar teeth in their mouth with 3-4 mm depth occlusal dentin caries. In the clinical study, the infected and demineralized dentin was cleaned manually with a sterile excavator. The dentin sample was taken from the last removable and affected dentin layer at the cavity floor by one excavation for microbiological assessment. The teeth were restored with a conventional glass ionomer cement. In the 6th month, restorations were removed by using low-speed round steel bur, and the dentin samples were removed with an excavator from the cavity floor to repeat the microbiological assessment. In the first week and 6th month of atraumatic restorative treatment, the impressions were taken from the restored teeth to prepare replicas. The replicas of the twenty teeth out of 25 were randomly selected to evaluate of marginal adaptation under scanning electron microscopy.
9692279|NCT04813874||neuraxial analgesia only|Receiving neuraxial analgesia only for labor
9692280|NCT04813874||NO2 and neuraxial analgesia|Receiving nitrous oxide and neuraxial analgesia for labor
9692281|NCT04813848|Experimental|Varnish fluoride|Varnish fluoride to be applied on the surface of exposed dentin
9692282|NCT04813848|Active Comparator|Bonding agent|Bonding agent to be applied on the surface of exposed dentin
9692283|NCT04813380|Active Comparator|Sublingual immunotherapy group|one drops under tongue for ten days then three Drops for another ten days then five drops for another ten days for three successive months then five drops every two days per week for two months then five drops one day per week for one months
9692284|NCT04813380|Placebo Comparator|Placebo|one drops under the tongue then three drops then five drops for three successive months then five drops every two days per week for two months then five drops one day per week for one months
9692285|NCT04813679||Neutropenic Enterocolite patients assessed with bed side ultrasound sonography|"From March 2007 through the entire study period all patients admitted eighter in our chemotherapy-ward or BMT-ward to receive intensive chemotherapy (chemo) for any hematological malignancies, or chemotherapy (CHT) for both auto transplant (ASTC) and allogeneic transplant (AlloTx), were prospectively enrolled in the study. When the patient received more than one chemo cycle, each ward access was considered a new observational period.~Patients who received CHT and experienced CHT-induced neutropenia (CHTNP) were enrolled in the study. We defined one observational period each admission on the ward to receive CHT, in which CHT and length of stay could vary from the previous admission. One observational period ended with the discharge of the pts form the ward. If a pts experienced a new chemo related NECe during another admission, it was considered as e new NECe."
9692286|NCT04813679||Neutropenic Enterocolite negative patients assessed with bed side ultrasound sonography|NEC negative patients received bed-side ultrasound sonography after three days of neutropenia.
9692287|NCT04813367||Twisted fallopian tubes cohort|Description of girls who went through surgery for twisted fallopian tubes
9692288|NCT04813718|Active Comparator|Synbiotic|Omni-Biotic Pro Vi 5
10181491|NCT03783260|Experimental|Single|All participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
10181492|NCT03783299|Experimental|Village-based MTAT|"Intervention: For all households in intervention villages, after obtaining informed consent, MTAT will be conducted with all household members aged 18 months and older.~The MTAT team will test each individual using both a standard RDT and HS-RDTs. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
10181493|NCT03783299|Experimental|Peer navigator-led FTAT|"Intervention: Peer navigators will actively seek non-village based HRPs in forested areas, rice fields and plantations, and any other non-permanent settlements within target health center catchment areas, and conduct FTAT among all consenting individuals.~The Peer Navigators will test each individual using both a standard RDT and HS-RDT. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
10181494|NCT03783104|Experimental|250μg of vitamin B12 supplementation|Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
10181495|NCT03783104|Active Comparator|50μg of vitamin B12 supplementation|Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
9692289|NCT04813718|Placebo Comparator|Placebo|similar looking and tasting
9692290|NCT04813640|Placebo Comparator|Single Vision Spectacles|Commercially available conventional single vision spectacles
9692291|NCT04813640|Active Comparator|Commercially available myopia control spectacles|Commercially available myopia control spectacles
9692292|NCT04813640|Experimental|Novel Myopia control spectacles - Prototype I|Experimental myopia control spectacles
9692293|NCT04813640|Experimental|Novel Myopia control spectacles - Prototype II|Experimental myopia control spectacles
9692294|NCT04813705|Experimental|Reduced dose group|The patients achieving CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
9692295|NCT04813705|Active Comparator|Conventional dose group|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
9692296|NCT04813341|Experimental|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles
9692297|NCT04813341|Active Comparator|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
9692298|NCT04813757|Experimental|intervention group|Participants in the intervention group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy. The exercise program will include 2 scapular and rotator cuff strengthening exercises emphasizing scapular upward rotation and posterior tilt and one additional flexibility exercise. These exercise will be repeated at home on the days in between the therapy sessions.
9692299|NCT04813757|Active Comparator|control group|Participants in the control group will receive 12 treatment sessions over a 6-week period. Three sessions during the first 2 weeks, 2 sessions per week during weeks 3 and 4 , and one session during weeks 5 and 6. Each session will be 30 minutes including 10 minutes of manual therapy and 20 minutes for review and/or modification of the exercise program. The manual therapy will include trigger point manual therapy, posterior shoulder stretching, and mobilization-with-movement into shoulder elevation. The exercise program will include 2 exercises focusing on scapular and rotator cuff strengthening without a special emphasis on scapular upward rotation as well as one additional flexibility exercise. These exercises will be performed at home on the days on between the therapy sessions.
10181496|NCT03783273|Experimental|Whey protein complex-bound D3 + juice|200 microgram vitamin D3 in a whey protein-complex added to 500 mL of juice.
10181497|NCT03783273|Active Comparator|D3 + juice|200 microgram vitamin D3 added to 500 mL of juice.
10181498|NCT03783273|Active Comparator|D3 + milk|200 microgram vitamin D3 added to 500 mL of skimmed-milk.
10181499|NCT03783273|Active Comparator|D3 droplets|200 microgram vitamin D3 as droplets + 500 mL of water.
10181500|NCT03783273|Placebo Comparator|No vitamin D|500 mL of Water.
10181501|NCT03783221|Experimental|High-fat diet|
10181502|NCT03783221|Active Comparator|High-residue diet|
10181503|NCT03783208|Experimental|G-CSF|Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
10181504|NCT03783208|Placebo Comparator|Control group|Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
10181505|NCT03783169||Symptomatic patients|All pregnant women (under the care of the Maternal-Fetal Medicine physicians or Faculty Medical Center physicians with MFM involvement) experiencing a hypertensive emergency (sustained systolic blood pressure > 160 mmHg or sustained diastolic blood pressure > 110 mmHg {or both} on at least two consecutive occasions 15 minutes apart). All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
10181506|NCT03783169||Asymptomatic patients|All asymptomatic pregnant women who are undergoing routine obstetric ultrasound evaluations at any gestational age who elect to undergo cardiovascular sonographic assessment for research purposes at no cost. All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
9692300|NCT04813666|Active Comparator|TB group|
9692301|NCT04813666|Placebo Comparator|Non TB group|
10181507|NCT03783117|Experimental|Magnetic field treatment|Each subject will place his/her right arm into a bore of the Magnetic Blood Pressure Lowering (MBPL) Device for magnetic treatment of 15 minutes, while the blood pressure is monitored with the left arm. The MBPL device produces a magnetic field around 1T parallel to the blood flow inside the arm. The subject's blood pressure will be lowered. The subject needs to come back to check the blood pressure 24 hours after the treatment.
9692302|NCT04813588|Experimental|Pantomimng|In experimental group pantomiming treatment will be administered
9692303|NCT04813588|Active Comparator|Easy onset|In active comparator group easy onset method will be administered
9692304|NCT04813523|Experimental|Experimental: Pembrolizumab+Cisplatin+5-FU|Participants receive preoperative pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 600 mg/m^2/day IV infusion on Days 1 to 5. There are 3 cycels of preoprative therapy and 3 cycles of postoperative therapy.
9692305|NCT04813536||nurses in Assiut university hospitals|currently working nurses exposed to shift work
9692306|NCT04813536||control group|currently working nurses not exposed to shift work
9692307|NCT04813419|Active Comparator|right face|The right side of face of subjects
9692308|NCT04813419|Experimental|left face|The left side of face of subjects
10181508|NCT03782987|Experimental|Treatment T|BI 730357 plus Itraconazole
9692310|NCT04813575|Experimental|Intervention arm|Experimental arm patients will have cryobiopsies for histological analysis of the ongoing pathology
9692311|NCT04813575|No Intervention|control group|This arm will be control group and will be observed prospectively
9692312|NCT04813471|Experimental|Endothelial Dysfunction Protocol|"Experimental: Endothelial Dysfunction Protocol~Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin(or home statin), nicorandil, l-arginine, folic acid and vitamin B complex) in critically Ill patients already on optimal medical therapy for the treatment of COVID-19 virus. Protocol will be given for a total of 14 days or until discharge from the hospital~Patients already on home statin will continue their medication or if the are eligible for statins they will recieve 40 mg tablet to be given PO once daily.~Nicorandil Nicorandil 10 mg PO BID for the first 7 days and then if no contraindications escalated to 20 mg PO BID for the remaining 7 days~Folic Acid Folic Acid 5 mg po once daily~L-Arginine L-Arginine 1 g po TID~Vitamin B complex (Becozyme) 1 ampoule IV daily"
9692313|NCT04813471|No Intervention|Standard of care|Standard of Care
9692314|NCT04813653|Experimental|cyclosporine in combination with carfilzomib and dexamethasone|cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed multiple myeloma refractory to carfilzomib with high expression of the PPIA gene in myeloma cells
9692315|NCT04813393||Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire Group|The CPHP-Q was administered as a caregiver-report questionnaire. It aims to measure home program adherence of parents of children with CP. Parents applied this instrument in the study.
9692316|NCT04813406|Experimental|Anlotinib + Sintilimab|
9692317|NCT04813068||Interview arm|Group of patients who have agreed to have a qualitative interview on the topic of recurrence of lung cancer
9692318|NCT04812977|Experimental|Group A|A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
9692319|NCT04812977|Active Comparator|Group B|Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
9692320|NCT04813302|Experimental|Gingival recession treatment|Gingival recession treatment by means of a coronally advanced flap and a connective tissue graft
10181509|NCT03782987|Experimental|Treatment R|BI 730357 alone
10181510|NCT03783065|Experimental|Experimental group|Procedure: Laparoscopic splenectomy and pericardial devascularization Drug: Propranolol
10181511|NCT03783065|Active Comparator|Control group|Procedure: Endoscopic therapy Drug: Propranolol
10181512|NCT03782961|Experimental|Stand up|After application of the product (sodium lactate and combination of polymers) will remain standing for 30 minutes
9692321|NCT04813315|Experimental|Kendall exercise|Experimental group 1 got this intervention containing Kendall exercise for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
9692322|NCT04813315|Experimental|Gong's mobilization|Experimental group 1 got this intervention containing Gong's mobilization for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
9692323|NCT04813133|Experimental|Synchronized Lifestyle Modification Program|Synchronized Lifestyle Modification Program
9692324|NCT04813133|Experimental|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronized Lifestyle Modification Program and Physiotherapy
9692325|NCT04813133|Experimental|Physiotherapy|Physiotherapy included Aerobics, Resistance exercise, Flexibility exercise, and Balance exercise.
9692326|NCT04813133|No Intervention|Control Group|No intervention will be given to this Group
9692327|NCT04813289||Anaesthesia type|"Inhalational anaesthesia without Remifentanil use~Inhalational anaesthesia with Remifentanil use~Total intravenous anaesthesia"
9692328|NCT04813289||Blood pressure monitoring|"Intraarterial line use~Non-invasive blood pressure monitoring"
9692329|NCT04813146|Experimental|Synchronized Lifestyle Modification Program (SLP)|Synchronized Lifestyle Modification Program ( Synchronization of dietary intake with the natural circadian rhythm of the body)
9692330|NCT04813146|Experimental|Synchronized Lifestyle Modification Program along with Physiotherapy|Synchronized Lifestyle Modification Program along with Physiotherapy (Synchronization of dietary intake and Physiotherapy including aerobic, resistance, flexibility and balance exercises)
9692331|NCT04813146|Experimental|Physiotherapy|Physiotherapy (aerobics, resistance, flexibility and balance exercises)
10181513|NCT03782961|Experimental|Lying down|After application of the product (sodium lactate and combination of polymers) remained lying down with the legs stretched for 30 minutes;
9692332|NCT04813146|No Intervention|Control Group|No Intervention will be given to this group ( conventional medicine will be given to these patient )
9692333|NCT04813198|Active Comparator|TIPSTART|Following baseline testing, the study orientation and randomization, the TIPSTART group will engage in 5.5 hours (30 minutes, on 11 separate occasions, over 10 weeks) of training delivered through Zoom and supported by instructional and communication apps, and that is further supervised by our TIPSTART study navigators who will provide motivational support and detailed lifestyle behavioral prescriptions (150 to 300 minutes per week of aerobic and strength training, with mental practice of material discussed each week). Participants will also be asked to complete approximately 3 total hours of repeated testing that occurs online via surveys and face-to-face interviews for the 12-week study.
9692334|NCT04813198|No Intervention|Wait-list Control|Following baseline testing, the study orientation and randomization, the wait-list control group will be asked to continue living life as usual until their delayed TIPSTART program is initiated. Participants will be asked to complete repeated online surveys and face-to-face interviews during the first 12 weeks, concurrently, with participants assigned to the TIPSTART intervention.
9692335|NCT04813185|No Intervention|Treatment as usual|Adults who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
9692336|NCT04813185|Experimental|In-hospital intervention|Adults randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 6-months of community case management and a firearm counseling program.
9692337|NCT04813211|Experimental|Trial group|20 patients with cervical spondylosis undergoing mobile artificial cervical vertebrae replacement
9692338|NCT04813211|Experimental|Control group|20 patients with cervical spondylosis undergoing anterior cervical corpectomy and fusion
9692339|NCT04813029|Experimental|Straight Leg Raise|Patients perform straight leg raise maneuver at the end of High-resolution Manometry test
9692340|NCT04813081|Active Comparator|Free gingival graft around dental implant patients|Test Group (TG) consists of patients have free gingival graft around dental implant patients
9692341|NCT04813081|Active Comparator|Free gingival graft around the teeth|Control Group (CG) consists of patients have free gingival graft around the teeth.
9692342|NCT04813042|Experimental|Working Out Dads|Fathers allocated to the Working Out Dads (WOD) arm will receive the intervention program. WOD is a 6-week manualised program. The weekly 90 minute sessions combine a one hour facilitated discussion by a male facilitator trained in delivery of WOD and a 30-minute gym workout provided by a personal trainer. The group size ranges from 6-10 fathers, with 14 groups running over the study period. The weekly sessions are provided in the evenings, in local gyms or a community setting (e.g., maternal child health centre, local council rooms, local hall, local park, Tweddle Child & Family Health Service).
9692343|NCT04813042|Active Comparator|Usual Care|Fathers allocated to the Usual Care arm will receive the clinical care typically provided to parents experiencing mental health difficulties by an Early Parenting Centre or community health service. Within 2 weeks of baseline assessment, Usual Care participants will receive a brief psychological consultation from Tweddle's Clinical Manager.
9692344|NCT04813224|Experimental|TRAUMA CENTERED EMDR-BASED TREATMENT|"Phase 1) Client history before session 1 Phase 2) Preparation for the treatment of the traumatic event, with psycho education and regulation strategies.~Phases 3 to 6) Gives the sense of Safety (safe place, past resource, desired future-PC, timeline) control structure, order, differentiation of past & present (move concretely between past danger to present safety) EMD strategy gives containment boundaries to current T-Episode.~Phase 7) Session closure A group debriefing of the experience will take place, and some of the stabilization exercises Phase 8) Re-Evaluation This phase will take place immediately after the group intervention. It assesses which participants may need individual attention and which may need further evaluation to identify the nature and extent of their symptoms."
9692345|NCT04813224|Active Comparator|TRAUMA-FOCUSED CBT-BASED TREATMENT|TF-CBT is an evidence-based therapeutic approach to improve symptoms of PTSD as well as affective or cognitive and behavioral problems. The treatment will consist of three phases that will include: Psychoeducation, Relaxation-Mindfulness, Emotional regulation skills, Cognitive coping skills, Narration and processing of trauma, Exposure / Desensitization of memories of the trauma, Self-esteem and future goals. The treatment is composed by 3 phases: 1) Phase 1: TF-CBT Coping Skills for Complex Traumas. Phase 2: Narration of trauma and processing of complicated trauma. Phase 3: Consolidation and closure of the treatment. Each case is delivered to the participants in a maximum of 3 sessions per phase.
9692346|NCT04813094|Experimental|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Participants will have their own account and passwords to log in to the system via mobile phones or computers. Everyone will have their own area to ensure the privacy of participants. The research nurse will have sent messages every day to care about the participant's condition.
9692347|NCT04813094|Active Comparator|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
9692348|NCT04812990||hepatitis c patients|50 patients will be recruited for study group from consecutive patients previously diagnosed by hepatitis C regardless of the etiology of the condition and regularly attending at Soad Kafay hospital. Participants with history of smoking and alcoholism that could affect their oral health status were excluded.
9696361|NCT04767659|Experimental|Women candidate for clinical trial|Twenty adult women with a recent diagnosis of breast cancer, candidate for NAC, besides assessing the response to neoadjuvant chemotherapy using standard imaging evaluation, will undergo optical imaging at six selected time points from prior to commencement of NAC/baseline to the completion of NAC treatment (prior to surgery).
9696362|NCT04767646|Experimental|C-BNP with intensive rehabilitation program|
10181514|NCT03783078|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)
10181515|NCT03783052|Other|Healthy volunteers|11 Healthy volunteers
10181516|NCT03783052|Other|Obese volunteers|11 Obese Volunteers
10181517|NCT03783052|Other|Roux-en-Y Gastric Bypass patients|6 volunteers with a Roux-en-Y Gastric Bypass
9692349|NCT04812990||clinically healthy patients|populations will be randomly recruited from the out-patient of dental diagnosis clinic in Misr University For science & technology university to include total 50 clinically healthy participants, with no history of liver disease, or any other chronic debilitating illness, or habit of smoking or drinking, , as well as history of an intervention or condition that could affect the oral mucosa (e.g., history of radiotherapy and/or not receiving any medication that could affect oral health.
9692350|NCT04812847||Gram negative infection, MDR present|Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
9692351|NCT04812847||Gram negative infection, MDR absent|Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.
9692352|NCT04813003||Surgery group (group 1)|5 adults with class II-III obesity (BMI≥35kg/m2) planned for bariatric surgery will undergo functional imaging and neurobehavioural tasks before and six months after bariatric surgery.
9692353|NCT04813003||Control group (group 2)|5 healthy adults with normal body mass (BMI 18.5-24.9kg/m2) matched for age-, sex- and education will serve as a control group and undergo the same experiment on a single occasion.
9692354|NCT04813250|Sham Comparator|Group R|IMV(intermittent mandatory ventilation) Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight)
9692355|NCT04813250|Experimental|Group RP|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O
9692356|NCT04813250|Experimental|Group RI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + Reverse IE ratio ventilation( I:E=1:1)
9692357|NCT04813250|Experimental|Group RPI|Regular Ventilation with Tidal volume with 7ml/ kg (Predicted body weight) + PEEP : 6 cm H2O + Reverse IE ratio ventilation( I:E=1:1)
9692358|NCT04812782|Experimental|EVOO-Butter|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with EVOO and the second with butter.
9692359|NCT04812782|Experimental|Butter-EVOO|All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with Butter and the second with EVOO
9692360|NCT04812769|Experimental|Intervention|Two nursing homes will receive the eCARE-ID intervention
9692361|NCT04812769|Placebo Comparator|Control|One control nursing home will receive infectious disease consultations and antibiotic stewardship services per routine practice.
9692362|NCT04812691|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in 1 x 10^8 CAR+T cells dose level
9692363|NCT04812756|Experimental|Texting intervention|This is a single arm study in which all participants received a pedometer and text messages for the 12 week intervention period. Participants received a content message and a message requesting them to report the number of steps from their pedometer daily.
9692364|NCT04812613|Other|Phase 2 Intervention|This study will utilize a mixed methods CBPAR approach. A peer-driven recruitment strategy will be implemented to enroll 20 at-risk youth who attend alternative schooling and drop-in activities at OCH. The investigators will select with the help of OCH staff, youth peer researchers that will be rigorously trained, similar to the PROMPT project. Peer researchers will be paid honoraria ($15/hr) to compensate for the time spent on research activities. Qualitative data through focus groups will also be collected from youth and key informants at OCH. This information will be used to design an individualized and focused social support intervention for youth. All youth in this arm will also have option to meet with a licensed mental health and substance use nurse to discuss treatment options. Youth's progress in the intervention will be followed with monthly interviews. The involvement of the research team will be limited to referring interested youth to said licensed health professional.
9692365|NCT04812561|Experimental|Bronch™ group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day, 800 mg/day as Bronch™)
9692366|NCT04812561|Placebo Comparator|Placebo group|2 times a day, 1 pill for 1 time, after breakfast/dinner meal(1,600 mg/day)
9692367|NCT04812600||Cardiac Rehabilitation|Individuals assigned to phase II (outpatient) cardiac rehabilitation program will undergo their normal exercise routines while the investigators make the measurements pre and post exercise at 0 week, and following 1 and 4 weeks of exercise.
9692368|NCT04812587|Experimental|Experimental group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
9696363|NCT04767698|Experimental|Belimumab + short-term Ocrelizumab|Participants will receive Belimumab and Ocrelizumab.
9696364|NCT04767698|Active Comparator|Continued Ocrelizumab|Participants will receive Ocrelizumab only.
10181518|NCT03783052|Other|Sleeve Gastrectomy patients|6 volunteers with a Sleeve Gastrectomy
10181519|NCT03783052|Other|Volunteers with obesity|6 obese volunteers
10181520|NCT03783156|Other|hot snare|polypectomy with hot snare
10181521|NCT03783156|Other|cold snare|polypectomy with cold snare
10181522|NCT03782935|Experimental|prenatal multivitamin mineral supplement|received prenatal multivitamin mineral supplement at time of enrollment TheraVit multivitamin/mineral prenatal supplement with instructions to take 1 per day through the remainder of pregnancy
10181523|NCT03782935|Experimental|prenatal multivitamin mineral supplement plus choline|received prenatal multivitamin mineral supplement plus additional choline supplemental vitamin TheraVit multivitamin mineral supplement plus 750 mg. choline with instructions to take1 multivitamin mineral supplement and 750 mg. per day of choline through the remainder of pregnancy
10181524|NCT03782935|No Intervention|Comparison|Advised to follow obstetrics standard of care which is to take a prenatal vitamin/mineral supplement
9692369|NCT04812587|No Intervention|Comparison group|The healthy elderly will be were recruited to participate in this study. All the subjects were independent in basic daily living activities, but at least one or more given assistance in the instrumental IADL assessment (ability to use telephone, shopping, food preparing, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances). Their age should be ranged between 65 - 81 years.
9692370|NCT04813055||Therapeutic EUS|Procedures involving Linear Echoendoscopes to create a communication between the gastrointestinal tract and a target organ (biliary tree, pancreatic duct, fluid collection, gallbladder, downstream gastrointestinal tract) through plastic or metal stents.
9692371|NCT04813055||Controls|Patients eligible for T-EUS procedures, but undergoing alternative surgical interventions, percutaneous interventions (e.g. Percutaneous Biliary Drainage) or non-EUS based endoscopic procedures (e.g. enteral stenting)
9692372|NCT04813159|Active Comparator|Remote Ischaemic Conditioning (RIC)|Consented STEMI participants presenting < 24 hours who are randomised to the RIC protocol, will receive blood pressure cuff inflation by the automated RIC blood pressure device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
9692373|NCT04813159|Sham Comparator|Sham-control|Consented STEMI participants presenting < 24 hours who are randomised to the sham protocol will receive low-pressure cuff inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff. The sham control protocol will be repeated daily for the next 2 days.
9692374|NCT04813159|No Intervention|Observational|Consented STEMI participants presenting > 24 hours but within 72 hours of MI onset will be recruited into the observational arm of the study which will have the same study endpoints as the RCT. These participants will not be randomised or receive any trial intervention.
9976316|NCT01350310|Active Comparator|Intracoronary Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
10181525|NCT03782974|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
9692377|NCT04812457|Experimental|Physiological cures using pure hyaluronic acid (Hialucic®)|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding
9692378|NCT04812457|Active Comparator|Control group using traditional cure (Betadine Gel).|After the intervention of unilateral onychocryptosis, the partial matricectomy technique with phenol / alcohol,next to Povidone Iodine Gel (Betadine Gel®) will be applied following the same procedure.
9692379|NCT04812418|Experimental|Group (A)|120 mg of eschscholtzia extract and 50 mg of valerian extract by tablet, without support 28 days
10181526|NCT03782974|Placebo Comparator|Placebo|Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.
9692380|NCT04812418|Placebo Comparator|Group (B)|Placebo 28 days
9692381|NCT04812886|Experimental|Epidemiological study|
10181527|NCT03783013|Other|No Soy and Low Lycopene Juice|Participants will consume two cans daily of a low lycopene tomato juice in addition to a diet low in lycopene and isoflavones.
10181528|NCT03783013|Other|Soy and Lycopene Juice|Participants will consume two cans daily of a high lycopene tomato juice with added soy germ extract in addition to a diet low in lycopene and isoflavones.
10181529|NCT03782896||mastectomy group|All patients who received the mastectomy (breast conserving surgery and sentinel lymph node dissection)
9692382|NCT04812405|Other|Teeth|Occlusal examination
9692383|NCT04812470|Experimental|Autologous tumor infiltrating lymphocytes (TIL)|Autologous TIL administered via hepatic arterial infusion followed by low dose Interleukin-2 after preconditioning chemotherapy with Melphalan.
9692384|NCT04812704|Experimental|Nutritional complement|"A prospective study will be carried out including adult patients with neoplasia who should benefit in their therapeutic strategy from oncological surgery. About fifty patients will be recruited in the oncology / surgery department at the Saint-Luc University Clinics in Brussels. Patients will be assessed at the initial consultation and after the pre-habilitation period, ie the day before the operation.~Dietary monitoring will be carried out in parallel with a physical and respiratory preparation program (prehabilitation) and the intake of protein nutritional supplements in the form of powder to be diluted will be carried out after each exercise session."
9696365|NCT04767828|Experimental|One arm exploratory research|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition. Pyrrotini: 400 mg once a day, oral within 30 minutes after breakfast for 21 days. Cassitabine: twice a day, 800 mg / m2 orally within 30 minutes after each meal (one morning and one night, 12 hours apart, equivalent to a daily dose of 1600 mg / m2, one dose in the morning and one dose in the morning)
10181530|NCT03782857|Experimental|Intervention group|Initiation/stepwise escalation of antihypertensive medication in case of blood pressure above individual target Initiation/stepwise escalation of cholesterol lowering medication in case of LDL-cholesterol above individual target Advice on healthy lifestyle and life long adherence to preventive medication
10181531|NCT03782857|No Intervention|Control group|Participants had the usual treatment: all patients were invited to one visit in the outpatient clinic three months after discharge with a diagnosis of stroke/TIA
9696366|NCT04767932|Experimental|control group|the control group will receive regular exercise training at same time.
10181532|NCT03782766|Experimental|piezosurgery|group 1 consisted of 18 molars (13 molars from patients with bilateral first molar extraction space and 5 molars from patients with unilateral first molar extraction space) where piezocesion was performed immediately before molar protraction
10181533|NCT03782766|No Intervention|No piezocision|group 2 consisted of 21 molars (13 from patients with bilateral first molar extraction space and 8 molars from patients with unilateral first molar extraction space) where molar protraction was performed with no piezocesion
10181534|NCT03782766|Other|Late piezocision|group 3 consisted of 21 molars (group 2 subjects where piezocession was carried on after 3 months of molar protraction with no piezocesion.
10181535|NCT03782688||Single-arm cohort|Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
10181536|NCT03782831|Experimental|TACE plus PD-1 antibody|Patients received hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10181537|NCT03782831|Active Comparator|TACE alone|Patients received hepatic intra-arterial infusion with lipiodol mixed with hemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received placebos intravenously every 2 weeks
10181538|NCT03783000|Experimental|All subjects|Treatment T followed by Treatment R
10181539|NCT03782948|Active Comparator|Controls|"In each session, the group will undergo standard gait training on BART without pelvic perturbations, i.e.,~walk a virtual track on the BART without pelvic perturbations (i.e., the pelvic brace of the BART device will be set to follow the patient's motion) for 10 minutes;~practise gait symmetry and take-off using visual feedback without pelvic perturbations in two 10-minute sessions."
10181540|NCT03782948|Experimental|Experimental|"In each session, the group will undergo robotised gait training with BART with pelvic perturbations, i.e.,~walk a virtual track on the BART with pelvic perturbations during virtual uphill walk and virtual curved walk for 10 minutes;~practise gait symmetry and take-off using visual feedback with pelvic perturbations for 10 minutes;~practise dynamic gait balance using pelvic perturbations during treadmill walking for 10 minutes."
10181541|NCT03782779|Experimental|Breathing program and regular exercise|Diaphragmatic Breathing Program plus regular upper and lower limb exercises
10181542|NCT03782779|Active Comparator|Regular Exercise|Regular upper and lower limb exercises
10181543|NCT03782909|Experimental|Behaviour change intervention|Intensive behaviour change for 6 weeks, followed by a maintenance phase for 6 weeks
9692385|NCT04812860|Experimental|HR18042 100mg|
9692386|NCT04812860|Experimental|HR18042 125mg|
9692387|NCT04812860|Experimental|HR18042 200mg|
9692388|NCT04812860|Active Comparator|Tramadol hydrochloride ER 100mg|
9692389|NCT04812860|Placebo Comparator|Placebo to match HR18042 and Tramadol hydrochloride ER|
9692390|NCT04812535|Experimental|Arm A: IFX-1 monotherapy|IFX-1 monotherapy
10181544|NCT03782675|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device the device is turned on or not.
10181545|NCT03782675|Experimental|Air Barrier System|In the experimental (interventional) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
10181546|NCT03782805|Experimental|treatment group|Group receiving a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) to be taken 3 times a week for a period of six months.
10181547|NCT03782805|Placebo Comparator|Placebo group|Group receiving a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months
10181548|NCT03782753||Group A|25 LRRK2-PD patients
10181549|NCT03782753||Group B|25 idiopathic PD patients
10181550|NCT03782753||Group C|25 HC subjects
10181551|NCT03782922|Experimental|Exercise Training Program|
10181552|NCT03782922|No Intervention|Control|
10181553|NCT03782818|Experimental|Olaparib|After a 4-week pre-treatment phase to ensure that patients are on stable doses of PAH medication, patients will be given progressive doses of olaparib up to 300 mg BID for 24 weeks.
9692391|NCT04812535|Experimental|Arm B: IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
9692392|NCT04812509|Experimental|MW032|MW032 injection(120mg) was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
9692393|NCT04812509|Active Comparator|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
9692394|NCT04812639|Experimental|buccal infiltartion technique|
9692395|NCT04812639|Active Comparator|Inferior alveolar nerve block technique|
9692396|NCT04812678|Active Comparator|Physiotherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines"
9692397|NCT04812678|Experimental|Physiotherapy and Fasciatherapy|"Conventional physiotherapy, in line with french Haute Autorité de Santé guidelines, associated with Fasciatherapy Danis Bois Method"
9692398|NCT04812678|Experimental|Fasciatherapy|Fasciatherapy Danis Bois Method
9692399|NCT04812392|Experimental|Acute Physical Inactivity|Subjects will undergo 5 days of reduced physical activity.
10181554|NCT03782662|Experimental|RV521 plus Itraconazole|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive
10181555|NCT03782662|Experimental|RV521 plus Verapamil|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive
10181556|NCT03782662|Experimental|RV521 plus Rifampicin|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive
9692400|NCT04812431|Experimental|PSA-NCAM(+) NPC|Cells are administered through intrathecal injection. Injection is administered to a total of five areas.
10181557|NCT03782662|Experimental|RV521 plus Midazolam|RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
10181558|NCT03782662|Placebo Comparator|Placebo plus Midazolam|Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
10181559|NCT03782844|Experimental|Conventional fixed CPAP and simple CPAP|Participants in this group were manually titrated . They were treated with conventional fixed pressure CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
10181560|NCT03782844|Experimental|Auto CPAP and simple CPAP|Participants in this group after being manually titrated were treated with Auto RemStar CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
10181561|NCT03782714|Experimental|Low-level laser therapy group|This group of teeth received laser irradiation after amputation of coronal pulp
9692401|NCT04812574|Experimental|Hypertonic Saline (10%) Injection|Periurethral hypertonic saline (10%) injection was performed in female patients with Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.
9692402|NCT04812353|Other|Foot and ankle arthrodesis or osteotomy|Patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
9692403|NCT04812236|Experimental|Single decoction group: Wulingsan single decoction granules|Wulingsan single decoction granules, Alisma orientalis (15g), Polyporus (10g), Baizhu (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
9692404|NCT04812236|Other|Co-decocting group: Wulingsan co-decocting granules|Wulingsan co-decoction granules, Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day.Take 12 weeks as a course of treatment.
9692405|NCT04812236|Other|Powder group: Wuling powder powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. Take 5g each time with warm water twice a day.Take 12 weeks as a course of treatment.
9692406|NCT04812236|Placebo Comparator|Simulant group: Simulant of granular dosage form|Granule simulant, the composition is Alisma orientalis (15g), Polyporus (10g), Atractylodes (10g), Poria (10g), Guizhi (6g). Take 1 bag each time with warm water twice a day. Take 12 weeks as a course of treatment.
9692407|NCT04812262|Experimental|Group A1 - Single Ascending Dose|DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
9692408|NCT04812262|Experimental|Group A2, Single Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
9692409|NCT04812262|Experimental|Group A3, Single Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
9692410|NCT04812262|Experimental|Group A4, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
9692411|NCT04812262|Experimental|Group B2 - Multiple Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
9692412|NCT04812262|Experimental|Group B3 - Multiple Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
9692413|NCT04812262|Experimental|Group B4 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
9692414|NCT04812262|Experimental|Group B5 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
9692415|NCT04812262|Experimental|Group B6 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
9692416|NCT04812262|Experimental|Group A5, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
9692417|NCT04812262|Experimental|Group A6, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
9692418|NCT04812093||Medical Tool|Spectroscopic otoscope
9692419|NCT04812275|Active Comparator|Non absorbable suture|Wound closure with non absorbale suture. Dimension and brand at the discretion of the surgeon.
9692420|NCT04812275|Experimental|Absorbable suture|Wound closure with absorbale suture. Dimension and brand at the discretion of the surgeon.
10181562|NCT03782714|No Intervention|Formocresol group|This group of teeth received the gold standard medication (formocresol) after coronal pulp amputation
10181563|NCT03782610||Primary Study Cohort|450 Infants
10181564|NCT03782610||Validation Cohort|225 Infants. Will allow subsequent validation of models derived from the Primary Study Cohort.
10181565|NCT03782649|Experimental|RSP-08|All subjects undergo the same procedures. Subjects will be subjected to measurements on the IMD (Working Model 3.4NR), FreeStyle Libre, Dexcom, microdialysis, venous and capillary blood collection.
10181566|NCT03782584|Experimental|Modified Pilates Exercise Group|they will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week.
10181567|NCT03782584|Other|Control Group|they will be given daily life advises to prevent neck pain
9692421|NCT04812197|Other|Skin Biopsies|Patients undergo punch biopsies of inflamed and non-inflamed skin and a blood sample collection.
9692422|NCT04812301||Group 1|Egg-white sandwich is added with 1 mCi Tc-99m sodium phytate, then Abbott Vital® added with 1 mCi Tc-99m sodium phytate
9692423|NCT04812301||Group 2|Abbott Vital® is added with 1 mCi Tc-99m sodium phytate, then egg-white sandwich added with 1 mCi Tc-99m sodium phytate
9692424|NCT04811989|Experimental|Video Watching Group|Participants will watch an instructive video on diabetic foot care and will receive face-to-face teaching on diabetic foot care.
9692425|NCT04811989|Experimental|Real-time Leaflet Reading Group|Participants will receive a leaflet with diabetic foot care information, whose reading will be guided in real-time by the Researcher, and will also receive face-to-face teaching on diabetic foot care.
9692426|NCT04811989|Active Comparator|Standard Care Group|Participants will receive the standard care that includes face-to-face teaching about diabetic foot care and will take a leaflet on diabetic foot care to read at home.
9692427|NCT04812028|Experimental|Prospective Experimental Group|Participants in this group will prospectively receive the intervention.
9692428|NCT04812028|No Intervention|Retrospective Review Group|Participants in this group will have their medical records retrospectively reviewed.
10181568|NCT03782480|Active Comparator|Intrarosa|Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
10181569|NCT03782480|Placebo Comparator|Placebo|Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
10181570|NCT03782428|Active Comparator|Probiotic group|27 participants received probiotics twice daily for six months
9692429|NCT04812184|Experimental|Surgical Tape to bridge of nose|placed a piece of tape to the bridge of the nose, adhering a face mask to the patient's face
9692430|NCT04812184|No Intervention|Standard of care|Patients given a mask with no intervention to the mask
9692431|NCT04812223|Active Comparator|Delayed Clamping|In this group, the umbilical cord will be clamped 60 seconds after the baby is born.
9692432|NCT04812223|Active Comparator|Early Clamping|In this group, the umbilical cord will be clamped 15 seconds after the baby is born.
9692433|NCT04812223|Active Comparator|Milking Clamping|In this group in which the umbilical cord will be milked, the cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
9692434|NCT04812132|Active Comparator|Women|
9692435|NCT04812132|Active Comparator|Men|
9692436|NCT04812054|Experimental|Hypothermic oxygenated machine perfusion|Allografts will be subject to end-ischemic hypothermic oxygenated perfusion at 12 degrees Celsius through both hepatic artery and portal vein after a period of simple cold storage at 4 degrees Celsius and immediately prior to implantation. The perfusion will last at least 2 hours and the period will be prolonged in case of ongoing hepatectomy, in order to perform graft implantation immediately after perfusion.
9692437|NCT04812054|Active Comparator|Simple cold storage|Allografts will be stored in perfusate at 4 degrees Celsius from the procurement until implantation.
9692438|NCT04811937|Experimental|Artificial intelligence for real-time Computer decision support of resection of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information about polypectomy procedures.
9692439|NCT04812119||Patients with the CTNNB1 mutation|Patient with a diagnosed CTNNB1 mutation.
9692440|NCT04812041||Intensive care unit delirium|Covid-19 patients in ICU are screened for delirium and rated the severity with CAM-ICU 7 scores.
9692441|NCT04811846|Active Comparator|TURBT (Transurethral Resection of Bladder Tumor)|For patients undergoing bipolar transurethral resection, bladder tumor is resected in a piecemeal manner.
9692442|NCT04811846|Active Comparator|PKVB (Plasma Kinetic Vaporization of Bladder Tumor)|For patients undergoing bipolar plasma kinetic vaporization of bladder tumor, bladder tumor is vaporized.
9692443|NCT04811833||Monoplus®|Adult patients undergoing an elective, primary surgery within the gastrointestinal tract with the need for anastomosis.
9692444|NCT04811885||child with ASD of school going age|Questionnaire complete by parent with children with ASD semi structure interview complete by parent with children
9692445|NCT04811703|Experimental|Combined PIPAC / IV chemotherapy treatment|Patients will undergo 3 cycles of combined chemotherapy, consisting of PIPAC (cisplatin-doxorubicin, escalating doses) and systemic chemotherapy (paclitaxel-carboplatine, standard doses). First patient will be treated at the lowest dose: doxorubicin 2.1 mg/m² and cisplatin 10.5 mg/m². Subsequent patients will be treated at the dose recommended by the CRM algorithm in the absence of dose-limiting toxicity. A total of 6 dose levels with a factor between 1 and 3 are considered. The maximum dose considered will be doxorubicin, 6.3 mg/m² and cisplatin, 31.5 mg/m². The doses of intravenous chemotherapy will be defined in a standard way, according to the habits of the investigating clinicians and in accordance with the doses received previously. Each cycle will last 28 days and will begin at day 1 with PIPAC procedure and will be completed at day 8 with systemic chemotherapy. Combined chemotherapy will be repeated every 4 weeks for up to 3 cycles in the absence of unacceptable toxicity.
9692446|NCT04811573|Experimental|Tfasted|T: Test Treatment fasted: under fasted conditions
9692447|NCT04811573|Experimental|R1fasted|R1: Reference 1 Treatment fasted: under fasted conditions
9692448|NCT04811573|Experimental|R2fasted|R2: Reference 2 Treatment fasted: under fasted conditions
9692449|NCT04811573|Experimental|Tfed|T: Test Treatment fed: under fed conditions
9692450|NCT04811573|Experimental|R1fed|R1: Reference 1 Treatment fed: under fed conditions
9692451|NCT04811690|Experimental|claim and imagery|control condition (status quo) showing a front-of-package (FOP) vitamin C claim and fruit imagery on all fruit-flavored drinks.
9692452|NCT04811690|Experimental|imagery only|FOP fruit imagery on all fruit-flavored drinks, no vitamin C claim on drinks high in added sugars (>=20 %DV)
9692453|NCT04811690|Experimental|claim only|FOP vitamin C claim on all fruit-flavored drinks, no fruit imagery on drinks high in added sugars
10181571|NCT03782428|Placebo Comparator|Placebo group|25 participants received placebo twice daily for six months
10181572|NCT03782363|Experimental|Autologous CIK Dose level 1|autologous CIK at dose level 1
10181573|NCT03782363|Experimental|Autologous CIK Dose level 2|autologous CIK at dose level 2
10181574|NCT03782363|Experimental|Autologous CIK Dose level 3|autologous CIK at dose level 3
10181575|NCT03782363|Experimental|Autologous CIK Dose level 4|autologous CIK at dose level 4
10181576|NCT03782454||intensive care patients with sepsis|Adult patients with verified or suspected sepsis admitted to the intensive care department from the emergency department
10181577|NCT03782441|Experimental|RSP-19|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 42 days.
9692454|NCT04811690|Experimental|no claim or imagery|No FOP vitamin C claim or fruit imagery on drinks high in added sugars
9692455|NCT04811690|Experimental|claim, imagery, and % juice disclosure|FOP fruit imagery, vitamin C claim, and % juice disclosure on all fruit-flavored drinks
9692456|NCT04811690|Experimental|claim, imagery, and added sugar warning|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning on drinks high in added sugar
10181578|NCT03782220|Experimental|Kinesio taping group|"Kinesio taping group~Application of kinesio taping to sternocleidomastoid, upper trapezium, levator scapulae muscles.~Once a week , for 4 weeks"
9692457|NCT04811690|Experimental|claim, imagery, and added sugar warning with teaspoons of added sugar disclosure|FOP fruit imagery and vitamin C claim on all fruit-flavored drinks; added sugar warning with teaspoons of added sugar disclosure on drinks high in added sugar
9692458|NCT04811599||deep learning algorithm group|Before patients going through colonoscopy or gastroscopy ,taking them tongue images and collecting basic information by mobile phone with Anymed.After examination,endoscopic report and histology analysis is collected .Categorizing the images by gastrointestinal diseases，developing and validating a deep learning algorithm for the diagnosis of digestive tract diseases depending on tongue images.Extracting tougue coating,gastric mucosa and stool DNA by high-throughput sequencing,and analyzing their composation,adundance and diversity.
9528152|NCT03213379|Experimental|Actimetry group|"The patient of the Actimetry group will have at least 4 measures of actimetry and the reports will be all provided to the investigator:~One at baseline before the apomorphim set-up/ the second one 8 days after the hospitalisation/ the third one 28 days after the hospitalisation and the last one before the 6 months follow-up visit One optional measure can be performed 84 days after the hospitalisation."
9692459|NCT04811742|Experimental|immersion bathing group|Immersion bathing was started by placing the baby's whole body, except for the head and neck, into a bathtub of warm water with a depth of 13-14 cm. The baby was shampooed and cleaned in the tub. Then, the baby was taken out of the water and rinsed over the tub. Finally, the baby was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
9692460|NCT04811742|Experimental|showering group|Shower was started by keeping the baby's face down and firmly gripping the baby from his/her armpit and head by one of the nurse's hands. The baby was washed under running water with the other hand. The second nurse assisted to ensure the flow of water. After the baby was rinsed, he/she was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
9692461|NCT04811768|Experimental|Bony wall group|In the bony wall group, following piezosurgery the retrieved bony wall was repositioned.
9692462|NCT04811768|Experimental|Collagen membrane group|In the collagen membrane group, the lateral window was created by rotary instruments, covered via a native collagen membrane (collprotect, botiss biomaterials GmbH, Zossen, Germany).
9692463|NCT04811651|Experimental|Treatment group|intravenous umbilical cord derived mesenchymal stem cells
9692464|NCT04811651|Placebo Comparator|Placebo Comparator|intravenous placebo solution with the same appearance as the treatment group.
9692465|NCT04811586|Experimental|one-step Hybrid Coronary Revascularization (HCR)|One-step HCR is defined as off-pump MIDCAB LIMA-LAD revascularization immediately followed by PCI for at-least one non-LAD lesion(or LAD-diagonal lesion) with DES implantation in a hybrid operating room.
9692466|NCT04811586|Active Comparator|Percutaneous Coronary Intervention (PCI)|PCI will be performed using standard technique at the discretion of interventional cardiologist with DES implantation in a routine catheter lab.
9692467|NCT04811859|Experimental|Study Group|In the study group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 40% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The patients will come for a control once a week, the maximum inspiratory pressure will be measured again and the new training intensity will be determined at 40% of the new maximum inspiratory pressure.
9692468|NCT04811859|Sham Comparator|Control group|In the control group, Inspiratory Muscle Training will be applied with Threshold IMT device (Respironics, USA) at 10% of the maximum inspiratory pressure value for eight weeks, every day of the week, twice a day for 15 minutes. The exercise workload will not be increased and will remain the same. It will run at 10% of maximum inspiratory pressure for eight weeks.
9692469|NCT04811872|Experimental|Intact umbilical cord milking (I-UCM)|
9692470|NCT04811872|Experimental|Cut-umbilical cord milking(C-UCM)|
9692471|NCT04811872|Experimental|Delayed Cord Clamping (DCC )|
9692472|NCT04811781||Cancer Patients with SARS-COV-2 infection.|
9692473|NCT04811664|Experimental|Immediate Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 1 and Day 29.
9692474|NCT04811664|Experimental|Delayed Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 113 and Day 141.
9692475|NCT04811664|No Intervention|Vaccine Declined|Participants who prefer not to be vaccinated, If requested, participant will be offered vaccine if they have not received vaccine outside of the study
9692476|NCT04811612|Experimental|Infants sampled for warmed and unwarmed heel stick glucose measurements|This single study arm will be samples for blood glucose measurement using both a warmed and unwarmed heel.
9692477|NCT04811547||Ankle-Brachial Index value|Valid participants were separated into 0-0.60, 0.61-0.90, 0.91-0.99, and 1.00-1.40 four ABI subgroups.
9692478|NCT04811794||Group A (largest part of the cohort)|Children, adolescents, and adults who are still in follow-up care (data are collected retrospectively until 2016 at the most)
9692479|NCT04811794||Group B (very small part of the cohort)|Children, adolescents, and adults who left follow-up care (data are collected retrospectively until 2016 at the most)
9692480|NCT04811911|Active Comparator|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
9692481|NCT04811911|Active Comparator|Methotrexate group|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
9692482|NCT04811911|No Intervention|healthy individuals as control group|
9692483|NCT04811339|Experimental|BSS&PBO|All patients will be assigned to the treatment group for the first 10 patients treated with open label BSS.
9692484|NCT04811339|Placebo Comparator|SOC control group|The Subsequent 25 patients will be randomized to either placebo or BSS. The patients will be assigned by envelope containing a symbol for either active drug or placebo (or other suitable randomization event) by a member of the research team not directly involved in the clinical trial.
9696367|NCT04767867|Experimental|Facemask oxygen (FM)|100% oxygen administered via facemask through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'breathe normally'
9696368|NCT04767867|Active Comparator|High-flow nasal oxygen (HFNO)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Participant instructed to 'keep the mouth closed and breathe normally'
9692485|NCT04811456||MIS-C|"Cases fulfilling following criteria:~fever ≥3 days~at least two of the following:~rash or bilateral conjunctivitis or mucocutaneous inflammation signs~hypotension~features of myocardial dysfunction, pericarditis, or coronary artery abnormality, based on echocardiographic findings or elevated B-type natriuretic peptide (BNP)/N-terminal-pro-BNP (NT-proBNP) or troponin~evidence of coagulopathy~acute gastrointestinal problems~elevated inflammatory markers AND~no other apparent microbial cause~evidence of COVID-19 (positive real-time polymerase chain reaction, antigen test or serology), or personal history of COVID-19 or contact with a proven COVID-19 case"
9692486|NCT04812730|Other|ASD with decompensated sagittal misalignment|Adults suffering from a spinal deformity with a decompensated sagittal misalignment
9692487|NCT04812730|Other|ASD with compensated sagittal misalignment|Adults suffering from a spinal deformity with a compensated sagittal misalignment
9692488|NCT04812730|Other|ASD without sagittal misalignment|Adults suffering from a spinal deformity without a sagittal misalignment
9692489|NCT04812730|Other|Control group|Asymptomatic adults not suffering from a spinal deformity
9692490|NCT04812743|Experimental|Colorectal Health Research Champion trainees|Colorectal Health Research Champion (CHRC) trainees receive 5 education sessions on colorectal cancer, clinical research, biospecimen donation, ethics, and presentation skills. The CHRCs will invite others in their social networks to present to them this educational information, following the train the trainer model of health education.
9692491|NCT04811495|Experimental|patient with temporomandibular joint disorders|
10181579|NCT03782220|Placebo Comparator|Shame taping group|"Shame taping group~Application of kinesio band to same muscles except for the defined method which is considered to be ineffective.~Once a week , for 4 weeks"
9692492|NCT04812327||Prospective Observational Diagnostic Evaluation|Potential participants will be recruited at study sites where they are admitted/held for COVID-19 isolation. On the first day of isolation (ideally on the day they first test positive for SARS-CoV-2), potential participants will be asked to participate in the study. After consent (Study Day 0), two nasopharyngeal swabs (NP swabs) and one nasal swab will be collected. One NP swab will be tested via viral culture and the other nasal swab will be tested by RT-PCR for SARS-CoV-2. The nasal swab will be tested on the BD Veritor System. Specimen collection and testing will be repeated every 2 days for 6 days (Study Day 2, Day 4, and Day 6) or until the RT-PCR Ct value is >30, whichever comes first. Participants will be monitored for symptoms of COVID-19 throughout the study.
9692493|NCT04811326|Active Comparator|NB-UVB radiation|will expose to 2 sessions/week of NB-UVB radiation, for 3 months.
9692494|NCT04811326|Active Comparator|Latanoprost|latanoprost 0.005%, will be applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches. The procedure will be repeated once weekly for 3 months (12 sessions).
9692495|NCT04811326|Active Comparator|latanoprost + NB-UVB|(latanoprost + NB-UVB group): latanoprost 0.005%, will be applied after microneedling of vitiligenous patches in the same day of NB-UVB sessions in the same manner of group 2.
9692496|NCT04811326|No Intervention|healthy individuals|healthy individuals as control group
9692497|NCT04811144|Experimental|Cavity group|The 35 participants accepted Er:YAG laser treatment for dental cavity. Each participant was collected their data including history records, affected range check, X-ray&photo, treatment, pain index check, return visit check after two weeks by researchers.
9692498|NCT04811144|Experimental|Sensitive Teeth group|The 35 participants accepted Er:YAG laser treatment for sensitive teeth. Each participant was collected their data including history records, sensitive check, X-ray&photo, treatment, pain index and effectiveness check, return visit check after two weeks by researchers.
9692499|NCT04811144|Experimental|Abnormal Frenum Attachment group|The 35 participants accepted Er:YAG laser treatment for Abnormal Frenum Attachment. Each participant was collected their data including history records, abnormal position check, photo, cutting, pain index check, return visit check after three, five and seven days. by researchers.
9692500|NCT04811144|Experimental|Peri-implantitis intervention group|The 12 participants accepted Er:YAG laser treatment for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
9692501|NCT04811144|No Intervention|Peri-implantitis control group|The 12 participants accepted mechanical debridement for Peri-implantitis. Each participant was collected their data including History records, measure periodontal pocket depth, anaerobes collect, X-ray, photo, CT, treatment, pain index check, return visit check after one week, two weeks, four weeks and three months, and six month check the effectiveness and collect anaerobes during every return visit. In the last return visit, X-ray and CT would be included
9692502|NCT04811170|Experimental|Counselling group|Counselling sessions will be conducted at the designated centers operated by the Zubin foundation. According to the level of the DASS score, 6 to 10 sessions (based on the algorithm) of counselling service will be provided to the participants by three registered counsellors. A lead counsellor will oversee all cases and services. The counselling program consists of 6-10 60-minute sessions, and the sessions can be flexibly delivered over 1 to 2 weeks, ranging from one 60-minute session biweekly or weekly.
9692503|NCT04811170|Other|Waiting group|For participants in the waiting list control group, they will receive monitoring service over phone calls during the 8-12 weeks wait period. Counselling service will be offered after the post-treatment assessment.
9692504|NCT04811274||Patients|Minor patients with alveolar proteinosis by mutations of the MARS gene.
9692505|NCT04811274||Controls|Minors patients without alveolar proteinosis.
9692506|NCT04811430||Randomized Traditional|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
10181580|NCT03782389||Elite football players aged 16-40 years|
10181581|NCT03782012|Experimental|Knowledge Supported|Students will have 30 seconds to view pictures of the knowledge base items and discuss relations among items.
10181582|NCT03782012|Experimental|Knowledge Not Supported|Students will be provided 30 seconds to view pictures of the knowledge base items.
9692507|NCT04811430||Radomized Cue Needle Tracking technology|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
9692508|NCT04811157|Experimental|Test group|Healthy adults consuming test product
9692509|NCT04811157|Placebo Comparator|Control group|Healthy adults consuming control product
9692510|NCT04811209||single group, open labelled observational study with no blinding.|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
9692511|NCT04811378|Active Comparator|HaemoCer|
9692512|NCT04811378|No Intervention|No HaemoCer|
10181583|NCT03782311||2 groups: OHSE-high and OHSE-low|"OHSE-high: Group with ≥ 50 OHSE scores received motivation and oral hygiene instructions .~OHSE-low: Group with < 30 OHSE scores received motivation and oral hygiene instructions ."
9692513|NCT04811391||Vaccinated participants|Participants who have received 2 doses of the pfizer Covid-19 vaccine or 1 or dose of the Astra Zeneca Covid-19 Vaccine
9692514|NCT04811391||Unvaccinated participants|Have not received any doses of any form of COVID-19 vaccine
9692515|NCT04811443||Patients with solid tumors who have received myelosupressive therapy|
9692516|NCT04811313|Active Comparator|T group|each participant will receive 15 mg/kg of tranexamic acid diluted in a 10 mL syringe slowly over 10-15 minutes, 15 minutes before skin incision.
9692517|NCT04811313|Active Comparator|TC group|each participant will receive 10 mg/kg of tranexamic acid diluted in a 5 mL syringe slowly over 5 minutes, 15 minutes before skin incision, and A caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
9692518|NCT04811313|Active Comparator|C group|each participant will receive a caudal epidural block with 1 mL/kg of 0.25% bupivacaine.
9692519|NCT04811313|Placebo Comparator|P group|participants will receive the regular standard care without adding tranexamic acid or caudal epidural block
9692520|NCT04811222|Experimental|Ga-DOTATATE PET/MRI scan|Patients with abdominal aortic aneurysm will undergo Ga-DOTATATE PET/MRI scan
9692521|NCT04811235|Experimental|Arm 1|NIRS monitoring of spinal cord oxygenation and hemodynamics
9692522|NCT04811014|Experimental|MOUD induction and behavioral interventions among opioid-dependent youths|Induction into medication for opioid use disorder (MOUD) treatment and behavioral interventions
9692523|NCT04810897||Parkinson's disease|The neurologists will inform the individuals with PD that we are doing this research and we will attach the research advertisement at Movement Disorder Clinic, Division of Neurology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Only individuals with PD who meet the inclusion and exclusion criteria will be invited to participate in the study. The researcher will inform participants about the purpose, procedure, and advantage of the study prior to participation in the study. Individuals with PD will be asked to sign an informed consent if they agree to participate in the study.
9692524|NCT04811131|Active Comparator|Active IP and Active Phototherapy|ARQ-252 cream 0.3% BID with phototherapy.
9692525|NCT04811131|Active Comparator|Active IP and Sham Phototherapy|ARQ-252 cream 0.3% BID with sham phototherapy
9692526|NCT04811131|Placebo Comparator|Vehicle and Active Phototherapy|ARQ-252 Vehicle cream BID with active phototherapy
9692527|NCT04811131|Placebo Comparator|Vehicle and Sham Phototherapy|ARQ-252 Vehicle cream BID with sham phototherapy
9692528|NCT04811066|Experimental|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
9692529|NCT04811066|Experimental|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
9692530|NCT04811066|Sham Comparator|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
10181584|NCT03782038|Experimental|Micro-coring of scars with MCD|Micro coring of acne scars and straie will be conducted in up to 3 treatments and followed 6 months post last treatment with MCD.
10181585|NCT03781999|Experimental|Actiful|a supplement containing 500 mg orange extract and 200 mg pomegranate actives
9692531|NCT04810871|Experimental|Treatment (surgery)|Patients undergo surgery as indicated clinically when applicable.
10181586|NCT03781999|Placebo Comparator|Placebo|Maltodextrin
10181587|NCT03782025||Patients with increased PK-INR|Critically ill patients with spontaneously increased prothrombin complex (PK-INR) who are given phytomenadione intravenously at the discretion of the treating physician
10181588|NCT03781947|Experimental|90 mg s.c.|A single s.c. injection of 90 mg teverelix TFA administered on Day 1
10181589|NCT03781947|Experimental|60 mg s.c.|A single s.c. injection of 60 mg teverelix TFA administered on Day 1
9692532|NCT04811105|Active Comparator|steam ablation|The fistula tract which treated with steam ablation
9692533|NCT04811105|Active Comparator|control group|The fistula tract which do not take any treatment
9692534|NCT04810858|Other|HIV+ marijuana user|Participants with HIV who report marijuana use
9692535|NCT04810858|Other|HIV+ non-drug user|Participants with HIV who report no drug use
9692536|NCT04810858|Other|HIV- marijuana user|Participants without HIV who report marijuana use
9692537|NCT04810858|Other|HIV- non-drug user|Participants without HIV who report no drug use
9692538|NCT04811183||Experimental group|Adult patients hospitalized with diabetes and polymedicated. Selected to benefit from a pharmaceutical consultation before their return home.
9692539|NCT04811001|Experimental|Arm A (Osimertinib->Dacomitinib)|"Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal.~At treatment discontinuation patients maintaining the original EGFR mutation will switch to Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal."
9692540|NCT04811001|Experimental|Arm B (Dacomitinib->Osimertinib)|"Dacomitinib 45 mg/day until progression, unacceptable toxicity or patient refusal.~At treatment discontinuation, patients harboring the EGFR-T790M will receive Osimertinib 80 mg/day until progression, unacceptable toxicity or patient refusal."
9692541|NCT04810936|Experimental|Early ONS intervention group|Patients in early ONS intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy) and ONS intervention in the beginning of radiotherapy. The ONS is prescribed to increase oral intake of patients and to ensure total energy supply is more than 30 kcal/kg/day and protein intake more than 1.2 g/kg/day.
9692542|NCT04810936|No Intervention|Standard nutrition intervention group|Patients in standard nutrition intervention group will receive nutritional counseling (follow-up visits once a week during radiotherapy and at the 1st and 3rd months after radiotherapy).
10181590|NCT03781947|Experimental|90 mg i.m.|A single i.m. injection of 90 mg teverelix TFA administered on Day 1
10181591|NCT03781947|Experimental|120 mg s.c.|A single s.c. injection of 120 mg teverelix TFA administered on Day 1
9692543|NCT04812444|Experimental|Zylox Peripheral Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
9692544|NCT04812444|Active Comparator|Zilver Vena Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
9692545|NCT04811053|Experimental|Treatment group A|
9692546|NCT04811053|Placebo Comparator|Treatment group B|
9692547|NCT04810806|Experimental|Immediate coronary angiography group|Immediate coronary angiography group will routinely receive coronary angiography within 2 hours after randomization.
9692548|NCT04810806|Active Comparator|Delayed coronary angiography group|Delayed coronary angiography group will receive coronary angiography during hospitalization after stabilization of symptoms and signs of heart failure.
9692549|NCT04810832|Experimental|Whole group|"The whole group undergo the two phases of the study:~1/ They listen successively the 3 oddball paradigms in the department of neurophysiology : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice~2/ They listen successively the same 3 oddball paradigms in the neurosurgical department, during their intractable epilepsy presurgical evaluation : P3 own-name recorded by listening to a smiling voice P3 own-name recorded by listening to a neutral voice P3 own-name recorded by listening to a rough voice"
9692550|NCT04810819|Experimental|Experimental group|
9692551|NCT04810819|Placebo Comparator|control group|
9692552|NCT04810845|Experimental|Patients undergoing coronary angiography with planned PCI|Patients with a known coronary artery disease admitted for elective coronary angiography with planned PCI would be enrolled
9692553|NCT04812158|Active Comparator|Control group|participants in the control group receive gold standard physiotherapy intervention 5 times a week for 6 weeks
9692554|NCT04812158|Experimental|Experimental group|3 min video-aided mindful deep breathing (VAMDB) or visual guiding on deep breathing with 6 deep breath per minute along with standard physiotherapy (SP) protocol and the control group was given standard physiotherapy (SP) protocol 5 times a week for 6 weeks
9692555|NCT04812158|No Intervention|Healthy control|Active healthy participants who engaged in regular collegial sports
9696369|NCT04767867|Active Comparator|High-flow nasal oxygen plus mouthpiece oxygen (HFNO+MP)|100% oxygen administered via high-flow nasal cannulae at 50 L/min. Additionally, 100% oxygen administered via mouthpice through circle system with adjustable pressure-limiting valve at 0 cmH20. Participant instructed to 'keep the mouth closed and breathe normally'.
9696370|NCT04767958|Experimental|Patients consulted upon by ICU, internal medicine, or cardiology for hospital admission|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
10181592|NCT03782064|Experimental|Nivolumab+DC/myeloma fusions/GM-CSF|"Nivolumab will be given every two weeks~The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle"
9696371|NCT04767958|Experimental|patients undergoing cardiac testing/procedures|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
9696372|NCT04767958|Experimental|patients awaiting surgery|All patients will have both standard care and point-of-care (experimental) NP swabs performed.
9696373|NCT04767958|Experimental|Health Care Workers|Health Care Workers who are being screened for COVID-19 will have both standard care and point-of-care NP swabs performed.
9696374|NCT04767880|Experimental|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast in the women's own environment.
9696375|NCT04767880|Placebo Comparator|Placebo|The placebo will be ingested 30 min. prior to an OGTT (3 hours). The placebo will also be ingested 30 min prior to breakfast in the women's own environment.
9696376|NCT04767737|Experimental|Topical lavender oil group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
10181593|NCT03782129||Diabetic patients with DFU|Diabetic patients with DFU diagnosed in 2010
10181594|NCT03782155|Experimental|HMB and glutamine supplementation|Patients with type 2 diabetes with supplementation HMB 3g, powder once a day and glutamine powder 14g once a day supplementation during 15 days.
10181595|NCT03782155|Placebo Comparator|placebo patients|Patients with type 2 diabetes with placebo( calcium caseinate) supplementation during 15 days 17g of powder once a day
10181596|NCT03782090|Active Comparator|Control|Endobronchial intubation using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA)
10181597|NCT03782090|Experimental|Experimental|Endobronchial intubation using novel left-sided double-lumen endobronchial tube (Ankor®,Insung Medical, Wonjou, S. Korea)
10181598|NCT03782194|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MRI data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
9692556|NCT04810689|Experimental|XFBD Arm|XFBD (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
9692557|NCT04810689|Placebo Comparator|Placebo Arm|Placebo (administered as 1 packet of granules dissolved in warm water) orally twice daily for 14 day, 1 hour after food in the morning and at night with at least 8 hours in between doses
9692558|NCT04810923|Experimental|i-PRF group|arthrocentesis procedure plus four consecutive intra-articular injection of i-PRF.
9692559|NCT04810923|Experimental|Control group|arthrocentesis procedure alone.
9692560|NCT04810715||Patient Group|Anklyosing Spondilitis
9692561|NCT04810624|Experimental|Relapse Prevention and Changing Habits +|Treatment consists of 5 carefully selected components that can reasonably be expected to reduce the rate of weight loss following acute weight restoration: behavioral, cognitive, motivation, monitoring, and skill consolidation. The manualized treatment is provided by a clinician via telehealth. Treatment consists of an orientation to treatment session prior to discharge, followed by 45-minute video telehealth sessions, twice weekly for 6 weeks and then once weekly.
9692562|NCT04810637|Experimental|GX-I7|Patients randomised on experimental arm will receive GX-I7 drug
9692563|NCT04810637|Placebo Comparator|GX-I7 vehicle|Patients randomised on comparator arm will receive placebo
9692564|NCT04810650|Experimental|Dynamic Prevention Intervention|
9692565|NCT04810650|Experimental|Dynamic Treatment Intervention|
9692566|NCT04810650|Active Comparator|Control|
9692567|NCT04810468|Other|Children in primary school|anthropometric measurment will take from each participiant in study to asses wheight ,height ,BMl and also use aquestionnaire yo asses the Sociodemographic data,dietary habits ,hygiene information
9692568|NCT04810455|Experimental|Purrble -- Intervention design and logic model|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing; see (Theofanopoulou et al 2019, Slovak et al 2018) for the design and data from previous deployments.~The toy is introduced to the child as an anxious creature that needs kind attention from humans. When picked up, the toy emits a frantic heartbeat that slows down if the child uses calm stroking movements. If the toy is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to children in emotional moments when they would attempt to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in children's ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
9692569|NCT04810455|Active Comparator|Non-interactive plush toy -- active control group|"The investigators argue that a comparison with a non-active control-such as waiting list / treatment-as-usual (i.e., nothing)-would not allow us to distinguish the hypothesised impact on in-the-moment soothing of interactivity vs. the emergence of new family routines; and would be also open to unequal social desirability bias.~However, from the perspective of the hypothesised logic model (Levels 1-3), it is not necessary for the active control to have exactly the same form factor as the active toy, as long as it is comparable in size, shape, and appeal. In fact, the investigators have explicitly decided not to use deactivated Purrble units as active controls due to the increased risk of unblinding, whereby the participants search for or come across Purrble online (or notice the plastic enclosure with electronics inside the toy), and assume their unit is malfunctioning."
9692570|NCT04810754|Experimental|Daratumumab subcutaneous|open label daratumumab s.c., unblinded
9692571|NCT04810286|Experimental|Experimental Group|3D-print myofunctional appliance
9692572|NCT04810286|Active Comparator|Control Group|Prefabricated myfunctional appliance
9692573|NCT04810403|Experimental|SOMEBODY Eating Disorder Prevention Program|All participants will be recruited to participate in the SOcial MEdia (SOME) adaptation of activities from the BODY Project (SOMEBODY).
9692574|NCT04810312|Experimental|Intervention group|Back extensor strengthening with oral protein supplementation
9692575|NCT04810533|Experimental|[14C] SH-1028|Volunteers will receive 200 mg [14C] SH-1028 containing a nominal 88 μCi activity, administered by mouth, as a solution.
9692576|NCT04810273|Experimental|early mobilization (ER) group|Participants in the EM group will undergo the progressive early mobilization protocol in the trauma ICU in a manner consistent with the our hospital practice guidelines indicated by the Modified Trauma ICU Mobility Scale for progressive mobilization during the ICU stay. The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay
9692577|NCT04810273|Active Comparator|standard early rehabilitation (SER) group|Patients in the SER group will receive standard physiotherapy including passive range of motion exercises, active exercises, bed mobility, and respiratory therapy during their ICU stays. In the SER group, out-of-bed mobilization (>=Level III in the Modified Trauma ICU Mobility Scale) will be started as soon as possible after ICU discharge.
9692578|NCT04810507|Experimental|Anagliptin arm|Anagliptin 100 mg twice a day
9692579|NCT04810507|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg once a day
9692580|NCT04810442|Experimental|Nap Group|This group will be involved with taking a nap in between the two scanning procedures.
9692581|NCT04810442|No Intervention|No-Nap Group|This group will not be taking a nap in between the two scanning procedures, and instead will be silently watching a film for the 45 minute period.
9692582|NCT04810676|Experimental|Sequence 1|"Peroid 1: CKD-501, D745, D150 -PO~Peroid 2: CKD-383- PO"
9692583|NCT04810676|Experimental|Sequence 2|"Peroid 1: CKD-383- PO~Peroid 2: CKD-501, D745, D150 -PO"
9692584|NCT04810728|Experimental|Extract Psidii guava|2 Capsule of extract Psidii guava, three times daily
9692585|NCT04810728|Active Comparator|Standard therapy|Standard therapy for Covid-19 patient (vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
9692586|NCT04810572|Active Comparator|Group 1 - composition with Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition with Silymarin (Silybum marianum), in a diary dose of 140 mg for 90 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
9692587|NCT04810572|Active Comparator|Group 2 - composition without Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 90 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
9692588|NCT04810572|Active Comparator|Group3 - Low-mineral composition without Silymarin (L5)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 90 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
9692589|NCT04810585|Experimental|Treatment|
9692590|NCT04810416|Experimental|Texting- 10 minutes|Assigned participants will do texting for 10 minutes.
9692591|NCT04810416|Experimental|Writing- 10 minutes|Assigned participants will do writing for 10 minutes.
9692592|NCT04810416|Experimental|Texting- 15 minutes|Assigned participants will do texting for 15 minutes.
9692593|NCT04810416|Experimental|Writing-15 minutes|Assigned participants will do writing for 15 minutes.
9692594|NCT04810416|No Intervention|Control group|No hand activities.
9692595|NCT04810481|No Intervention|Standard Practice|Anesthesia will be provided at the discretion of the anesthesiologist following cardiovascular variables in accordance with usual clinical indications.
9692596|NCT04810481|Active Comparator|BIS Group|Anesthesia will be titrated to achieve a BIS value of 45-60 during maintenance of anesthesia. Additional intervention will be provided only if the subject is in distress.
9692597|NCT04810429|Placebo Comparator|Placebo|TMJ arthroscopy and Saline solution NaCl 0,9% in 2 syringes with 1 ml each. Injected in Right Masseter (0.5ml), Left Masseter (0.5ml), Right Temporalis (0.5ml) and Left Temporalis (0.5ml).
9692598|NCT04810429|Active Comparator|IncobotulinumoxinA|TMJ arthroscopy and Dose of IncobotulinumoxinA to be injected 100 U distributed in 2 syringes with 1 ml each: 25U (0.5ml) in Right Masseter / 25U (0.5ml) in Left Masseter / 25U (0.5ml) in Right Temporalis / 25U in Left Temporalis.
9692599|NCT04810117||COVID-19 PCR positive patients who are not yet vaccinated|Patients test positive with PCR and recovered from COVID-19
9692600|NCT04810117||COVID-19 patients with obvious symptoms who are not yet vaccinated|COVID-19 patients with obvious symptoms but PCR test was not conducted for them
9692601|NCT04810117||COVID-19 suspected patients with no symptoms who are not yet vaccinated|COVID-19 suspected patients with no symptoms but came in obvious contact with infected environmental/biological samples
9692602|NCT04810117||COVID-19 PCR positive patients who are vaccinated|COVID-19 suspected patients who have got either one or two doses of vaccine
9692603|NCT04810117||Healthy Individuals who are vaccinated|Control group
9528153|NCT03213340|Experimental|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
9692604|NCT04810117||Healthy Individuals who are not vaccinated|Control group
9692605|NCT04809779|Experimental|Sintilimab|
9692606|NCT04809818|Experimental|Part A - LT3001 Drug Product|Multiple doses of LT3001 administered by intravenous infusion
9692607|NCT04809818|Placebo Comparator|Part A - Placebo|Multiple doses of Placebo administered by intravenous infusion
9692608|NCT04809818|Experimental|Part B - LT3001 and Aspirin|Multiple doses of LT3001 and Aspirin administered
9692609|NCT04809818|Experimental|Part B - LT3001 and Clopidogrel|Multiple doses of LT3001 and Clopidogrel administered
9692610|NCT04809818|Experimental|Part B - LT3001 and Apixaban|Multiple doses of LT3001 and Apixaban administered
9692611|NCT04809818|Experimental|Part B - LT3001 and Dabigatran|Multiple doses of LT3001 and Dabigatran administered
9528154|NCT03213340|Experimental|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
9692612|NCT04809935|Active Comparator|EUS-CPB|Chemical ablation of the coeliac plexus
9692613|NCT04809935|Active Comparator|EUS-CPA|Radiofrequency ablation of the coeliac plexus
9692614|NCT04809870||LC (liver cirrhotic patients)|Patients with concomitant liver cirrhosis
9692615|NCT04809870||Non-LC (non liver cirrhotic patients)|Patients without concomitant liver cirrhosis
9692616|NCT04809857|Experimental|Plyometric Exercise Group|Plyometric exercise training 3 days a week for 6 weeks
9692617|NCT04809857|Active Comparator|Isokinetic Exercise Group|Isokinetic exercise training 3 days a week for 6 weeks
9692618|NCT04809857|No Intervention|Control Group|no exercise intervention
9692619|NCT04809792|Experimental|Head and neck cancer|In this arm patients with head and neck cancers treated with SBRT are recruited.
9692620|NCT04810182||Glioblastoma Patients treated with Regorafenib|Patients with a confirmed diagnosis of Glioblastoma for whom a decision to treat with regorafenib has been made (by the treating physician).
9692621|NCT04810104|Experimental|Active drug: AZD0328|Participants will receive AZD0328 capsules for oral administration.AZD0328 is a selective α7 nicotinic receptor agonist, The total daily dosage of AZD0328 is 1mg per day; administered as 0.5mg twice daily / BID. The study treatment period is 12-weeks.
9692622|NCT04810104|Placebo Comparator|Placebo|Participants will receive identical-appearing placebo capsules for oral administration.Participants will be instructed to take 2 capsules in the morning and 2 capsules in the evening for a 12-week period.
9692623|NCT04810156|Active Comparator|Mycophenolate mofetil|"If less than 20 percent reduction in ALT/AST or bilirubin during treatment with corticosteroids or corticosteroids plus UDCA at day 4 or at day 7 respectively, the patient will undergo block-randomized to an add on of MMF or tacrolimus Meanwhile tapering of corticosteroids in patients with sufficient response.~MMF will be stopped 8 weeks after treatment stop of corticosteroids."
9692624|NCT04810156|Active Comparator|Tacrolimus|"If less than 20 percent reduction in ALT/AST or bilirubin during treatment with corticosteroids or corticosteroids plus UDCA at day 4 or at day 7 respectively, the patient will undergo block-randomized to an add on of MMF or tacrolimus Meanwhile tapering of corticosteroids in patients with sufficient response.~Tacrolimus will be stopped 8 weeks after treatment stop of corticosteroids."
9692625|NCT04809753|Experimental|Eustachian tube dilation|Eustachian tube dilation with an endovascular balloon
9692626|NCT04809909|Experimental|Peripheral stimulation of acupuncture points (PSAP)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of acupuncture points.
10181599|NCT03782194|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
10181600|NCT03782051|Active Comparator|Phacovisco group|group had combined phacoemulsification and viscocanalostomy
9692627|NCT04809909|Active Comparator|Peripheral nerve field stimulation (PNFS)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of the painful area.
9692628|NCT04809974|Placebo Comparator|Placebo|Placebo: 40 participants will take placebo in the form of a capsule.
9692629|NCT04809974|Experimental|Niagen|Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
9692630|NCT04810052|Experimental|Condition I (contribution)|Patients do 1 nice thing (can be as large or as small as they wish) BIW for 4 weeks for their caregivers while at home.
9692631|NCT04810052|Experimental|Condition II (gratitude)|Patients write a letter or note of gratitude BIW for 4 weeks to their caregivers who have helped with their treatment or recovery.
9692632|NCT04810052|Active Comparator|Condition III (daily activities tracking)|Participants keep track of their daily activities.
9692633|NCT04810065|Other|SingStrong for Pulmonary Fibrosis|"This arm of the project explores Singing as an intervention for people suffering from Pulmonary Fibrosis specifically.~It is a 10 week programme. All other aspects of the intervention are the same in terms of delivery and length of classes.~Different outcome measures, namely the St Georges Respiratory Questionnaire is used in this trial. This is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations."
9692634|NCT04810091|Experimental|Arm A (telotristat ethyl, SSA)|Patients receive telotristat ethyl PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
9692635|NCT04810091|Active Comparator|Arm B (placebo, SSA)|Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
9692636|NCT04810000||Group A|Group A ( Tourniquet release before wound closure and hemostasis ensured )
9692637|NCT04810000||Group B|Group B ( Tourniquet release after wound closure )
9692638|NCT04810039||doctor working in neuro-intensive unite care|doctor predicting the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
9692639|NCT04809727|Experimental|Biopsy|four quadrant biopsy
9692640|NCT04809675|Active Comparator|HOS-HOS-FCM-FCM sequence|Use of a hard occlusal splint (HOS) for the first two weeks, followed by a week off, and a flexible customized mouthguard (FCM) for the fourth and fifth week.
9692641|NCT04809675|Active Comparator|FCM-FCM-HOS-HOS sequence|Use of a flexible customized mouthguard (FCM) for the first two weeks, followed by a week off, and a hard occlusal splint (HOS) for the fourth and fifth week.
9692642|NCT04809688|Experimental|Single arm|Single arm
9692643|NCT04809662||Main cohort|This is a split-body study, with patients acting as their own controls between lesional and nonlesional skin. All patients will apply imiquimod.
9692644|NCT04809441|Experimental|Weight loss group|Participants were rigorously evaluated by the same endocrine doctor and podiatrist at baseline (Session 1) and at the end of the study after weight loss intervention (Session 2), when each participant had lost between 11-12% of its corporal weight. Therefore, we obtained 2 weight related with the two sessions: Session 1 - Weight 1; Session 2 - Weight 2.
9692645|NCT04809428||vNOTES Salpingectomy|Elective bilateral salpingectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery approach
9692646|NCT04809428||LS Salpingectomy|Elective bilateral salpingectomy by conventional laparoscopy
9692647|NCT04809545|Experimental|Intervention|The study intervention consists of the delivery of a soundscape in the private rooms of the participant during the morning and evening. The soundscape is personalized and consists of a collection of natural sounds, birdsongs, kitchen sounds, music, bell sound, outdoor sounds, water/rain sounds, and similar.
9692648|NCT04809545|Active Comparator|Treatment as Usual|As part of usual care, patients on the Specialized Dementia Unit receive a comprehensive assessment of their health and symptoms of dementia involving consultation by a geriatric psychiatrist, geriatrician, physical therapist, occupational therapist, and recreation therapist, and pharmacological and non-pharmacological treatment plans are developed and executed. All participants in the study will receive this standard of care
9692649|NCT04809558|Active Comparator|Max intensity with no visual biofeedback|Tongue resistance exercises completed at maximum intensity with no visual biofeedback.
9692650|NCT04809558|Active Comparator|Progressive intensity with no visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with no visual biofeedback.
9692651|NCT04809558|Active Comparator|Max intensity with visual biofeedback|Tongue resistance exercises completed at maximum intensity with visual biofeedback of performance.
10181601|NCT03782051|Active Comparator|OloPhacovisco group|group had combined phacoemulsification and viscocanalostomy and Ologen
10181602|NCT03781960|Experimental|Abemaciclib & Nivolumab|Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.
10181603|NCT03781908|Experimental|Silver Nitrate Pleurodesis|Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
9692652|NCT04809558|Active Comparator|Progressive intensity with visual biofeedback.|Tongue resistance exercises completed at a progressive intensity with visual biofeedback of performance.
9692653|NCT04809402|Other|Telemonitoring|Subjects in the telemonitoring group will have post-operative follow-up measurements involving teleconsultations, remote eye exams and health questionnaires.
9692654|NCT04809402|No Intervention|Usual care|Subjects in the usual care group will receive regular post-operative care, mostly involving in-hospital consultations.
9692655|NCT04809389|Experimental|Test Product|DelNS1-nCoV-RBD LAIV at 1×107 EID50 and 1×107.7 EID50, 2 doses 4 weeks apart, intranasal administration
9692656|NCT04809389|Placebo Comparator|Reference Product|Matching placebo, 2 doses 4 weeks apart, intranasal administration
10181604|NCT03781908|Active Comparator|Indwelling Pleural Catheter|Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
10181605|NCT03781921||BN|Females with a current diagnosis of Bulimia Nervosa between 18 and 50 years old
10181606|NCT03781921||Controls|Females with no current or past diagnosis of any eating disorder; between 18 and 50 years old
10181607|NCT03781895|Placebo Comparator|A0|"A0- On day 0,before intervention placebo,~Microcrystalline Cellulose (303.8gm)~Butylated Hydroxy Toluene (0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
10181608|NCT03781895|Placebo Comparator|A90|"A90- On day 90,after intervention placebo,~Microcrystalline Cellulose (303.8gm)~Butylated Hydroxy Toluene (0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
10181609|NCT03781895|Active Comparator|B0|"B0- On day 0,before intervention cholecalciferol,~Cholecalciferol (40,000IU)~Microcrystalline Cellulose (58.1 gm)~Butylated Hydroxy Toluene ( 0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
10181610|NCT03781895|Active Comparator|B90|"B90- On day 90,after intervention cholecalciferol,~Cholecalciferol (40,000IU)~Microcrystalline Cellulose (58.1 gm)~Butylated Hydroxy Toluene ( 0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
9692657|NCT04809649|Experimental|SUBA-itraconazole|Drug: SUBA-itraconazole Dosage Form: 65 mg capsules Dosage: 260 mg/day Frequency: 130 mg twice daily (BID) Duration: Up to 180 days
9692658|NCT04809272|Experimental|ParentChat for parents of children ages 2-17|The ePLH parent support groups will be delivered over a 8 week period (i.e., 7-8 short online interactive group sessions, two per week). ePLH facilitators will moderate discussions around the parenting theme, support parents on an individual basis, and encourage them to apply the parenting skills at home. The facilitators will begin the next group engagement with a brief voice summary of the feedback and address possible solutions to 2-3 key challenges. Facilitators will also be provided with weekly supervision by an ePLH coach or trainer. A designated research assistant will provide parent support groups with needed technical support during the implementation - including IT-related support. Data bundles will be provided for internet access and to incentivise engagement.
9692659|NCT04809259|Experimental|Continuous infusion of meropenem|The meropenem solution will be administered continuously using elastomeric pumps which will be changed every 24 hours and which will be inserted in an isothermal pouch to ensure that the antibiotic solution is maintained at a temperature between 10° and 15°
9692660|NCT04809480||Non-COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from January 2017 up to February 2020
9692661|NCT04809480||COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from February 2020 up to December 2020 with positive COVID19 PCR test
9692662|NCT04809532|Experimental|Group A|Transverse abdominis plane (TAP ) block via 20ml 0.25% bupvicaine on both sides of midline will be given at end of surgery
9692663|NCT04809532|No Intervention|Group B|At the end of surgery, no additional intervention will be done.
9692664|NCT04809506||Patient consulting the Centre for Screening and Prevention of Atherosclerosis|2 additional blood samples (2 x 7ml) at every visit
10181611|NCT03781882|Active Comparator|Intervention group|All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds
10181612|NCT03781882|Active Comparator|Control group|All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma
9692667|NCT04809337|Experimental|Stabilization Exercise Group|
9692668|NCT04809337|Experimental|Therapeutic Exercise Group|
10181613|NCT03781843|Active Comparator|Genicular nerve block with lidocaine|The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 6 mL of a solution containing 6 mL of 2% lidocaine or 6 mL dextrose or 6 mL saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves Interventions: Drug: 6 mL 2% lidocaine Procedure: Genicular nerve block
10181614|NCT03781843|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Saline Procedure: Genicular nerve block"
9692669|NCT04809415|Sham Comparator|Sham Group (G-S)|The LED blanket will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
9692670|NCT04809415|Experimental|300J Infrared Blanket LED Group (Blanket-300J)|The LED blanket with a wavelength of 940nm, energy of 300J, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
9692671|NCT04809415|Experimental|300J Infrared Cluster LED Group (Cluster-300J)|The LED Cluster with a wavelength of 850 nm, energy of 300 J, will be applied to the quadriceps (5 points) and hamstrings (5 points), bilaterally, just before the strength training protocol.
9692672|NCT04809116|Experimental|open-label pimavanserin 34mg at bedtime for 6 weeks|Subjects enrolled into treatment with open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
9692673|NCT04809129|Experimental|External mechanical loading|"Following bariatric surgery (RYGB or SG) patients will be asked to wear a weighted vest for a minimum of 8 hours daily and during physical exercise for three months postoperatively.~Weight will be incrementally added on a weekly basis to maintain the baseline weight as patients lose weight following surgery up to a maximum of 15%."
9692674|NCT04809129|No Intervention|Standard postoperative care|Patients following bariatric surgery (RYGB or SG) will receive standard postoperative care.
9692675|NCT04809038|Experimental|dry needling|dry needling will be received twice a week for four weeks
9692676|NCT04809038|Experimental|magnesium sulphate iontophoresis|magnesium sulphate iontophoresis will be received twice a week for four weeks
10181615|NCT03781843|Placebo Comparator|Genicular nerve block with dextrose|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a dextrose was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Dextrose Procedure: Genicular nerve block"
9692677|NCT04809038|Active Comparator|stretching exercise|stretching will be received twice a week for four weeks
9692678|NCT04808986|Other|serology COVID-19|Serology of COVID-19 will be proposed to all health professionels and household members included in the study
9692679|NCT04808999|Experimental|Pembrolizumab|Neoadjuvant Phase: 200 mg IV infusion, every 3 weeks (Day 1 of each 3-week cycle, 2 cycles) Adjuvant Phase: Day 1 of each 3-week cycle, 15 cycles
9692680|NCT04808908|Experimental|N-803|All participants will receive the intervention, N-803 treatment.
9692681|NCT04808921|Experimental|SARS-CoV-2 Antigen Rapid Test|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
9692682|NCT04809103|Experimental|Intratumoral Cisplatin Arm|Single arm approach. There is no comparator or placebo group. Cisplatin will be administered directly into a non-small cell lung cancer, following imaging verification and pathologic diagnosis, during a single bronchoscopic procedure.
9692683|NCT04808869|Sham Comparator|Control|Cycling at 70 rpm 3 times/week without any blood flow restriction cuffs
9692684|NCT04808869|Experimental|BRF 60% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in one leg.
9692685|NCT04808869|Experimental|BFR 80% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in one leg.
9692686|NCT04808869|Experimental|BFR Bilateral 60%|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in both legs.
9692687|NCT04808869|Experimental|BFR 80% Bilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in both legs.
9692688|NCT04808882|Experimental|Low dose prophylactic anticoagulation|LD-PA : 3500 IU/24h
9692689|NCT04808882|Experimental|High dose prophylactic anticoagulation|HD-PA : 7000 IU/24h.
9692690|NCT04808882|Experimental|Therapeutic anticoagulation|TA : 175 IU/kg/24h.
9692691|NCT04809142|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
9692692|NCT04809142|Active Comparator|Chemotherapy|Capecitabine tablets combined with oxaliplatin injection or gemcitabine hydrochloride injection. Each cycle is 3 weeks.
9692693|NCT04809181|Experimental|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation|MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation
9692694|NCT04808635||general surgery residents|
9692695|NCT04808635||orthopedic surgery residents|
9692696|NCT04808635||urology residents|
9692697|NCT04808635||OBGYN residents|
9692698|NCT04808700|Other|Focal cartilage lesion|Patients with focal cartilage lesions who underwent a knee surgery using the Episealer implant
9692699|NCT04808752|Experimental|Almonertinib high-dose group|Patients who meet the criteria for inclusion and exclusion will be included in the high-dose almonertinib treatment group and receive oral almonertinib 165 mg once a day
9692700|NCT04808713|Experimental|Treatment condition|
9692701|NCT04808713|No Intervention|Waitlist condition|
9692702|NCT04808726|Other|Control Group|standard breastfeeding education and counseling service to another group
10181616|NCT03781869|Experimental|Anlotinib + Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, and Anlotinib 12mg/d on day 1 to day 14 , repeated every 21 days, a total of 4-6 cycles, and then continue to take Anlotinib 12mg/d on day 1 to day 14, repeated every 21 days until progressive Disease(PD).
9692703|NCT04808765|Experimental|VAC group|A randomized group of patients receiving negative pressure wound therapy dressing (Avelle-ConvaTec) on closed incision
9692704|NCT04808765|Active Comparator|ST group|A randomized group of patients receiving standard dressing (sterile gauze and medical tape) on closed incision
9528155|NCT03213340|Experimental|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
9692705|NCT04808856|Experimental|ACTH|Adrenocorticotropic Hormone
9692706|NCT04808856|Active Comparator|Methylprednisolone|Methylprednisolone
9692707|NCT04808648|Experimental|Itraconazole and SH-1028|In the itraconazole study, patients received single-dose SH-1028 200 mg on Days 1 and 12 and itraconazole(200 mg twice daily) on Days 8-14 orally.
9692708|NCT04808648|Experimental|Rifampicin and SH-1028|In the rifampicin study, patients received SH-1028 200mg once daily on Days 1 and 14 and rifampicin 600 mg once daily on Days 8-16
9692709|NCT04808895|Active Comparator|Acetylsalicylic acid|Tablets of 100 mg acetylsalicylic acid (one 100 mg daily dose. On the first day a loading dose of 300 mg will be administered)
9692710|NCT04808895|Placebo Comparator|Placebo|Tablets of placebo, identical to active comparator (one tablet daily dose. On the first day 3 tablets will be administered)
9692711|NCT04808661|Experimental|Intervention group|Thoracic endovascular aortic repair plus optimal medical therapy
9692712|NCT04808661|Active Comparator|Conservative group|Optimal medical therapy
9692713|NCT04809155|Experimental|Girl2Girl|Girls receive text messages that address the information, motivation, and behavioral skills components need to prevent unwanted pregnancy.
9692714|NCT04809155|No Intervention|Control - Healthy lifestyle|Girls receive text messages about a 'healthy lifestyle', including healthy social media use and self-esteem.
9696377|NCT04767737|Placebo Comparator|Placebo group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients. No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
9696378|NCT04767737|No Intervention|Control groups|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured.No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
9696379|NCT04767633|Active Comparator|group A (PMC standard-dose)|Group A (PMC standard-dose): patients will receive two oral doses of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 17:00 and 4 hours later in the evening prior to the colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
9696380|NCT04767633|Active Comparator|Group B (PMC split-dose)|Group B (PMC split-dose): patients will receive the first oral doses of PMC diluted in 150 ml of water (Picoprep; Ferring Italia, Milan, Italy) at 19:00 of the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy (¼ sachet for children < 6 years, ½ sachet for children 6-12 years, and one sachet for children >12 years). Intake of at least 40-50 ml/kg (maximum 2 L) of clear fluids (cold tea, gatorade etc..) will be recommended after each dose. The age-adjusted dosage is dictated by the instructions of the manufacturing company. No solid food intake will be allowed during the 24 hours prior to the examination according to the instructions of the manufacturing company.
9696381|NCT04767763||Patients with Acute Kidney Injury|Patients with acute kidney injury and indications for initiation of continuous renal replacement therapy (CRRT) were included to this study irrespective of their gender, race and age.
9696382|NCT04767672|Experimental|Test product|Food ingredient containing non digestible carbohydrates, in shape of powder
9696383|NCT04767672|Placebo Comparator|Placebo|Food ingredient containing containing 95% of maltodextrin
9696384|NCT04767230|Active Comparator|A heart-healthy diet + Flaxseed + Olive oil|A heart-healthy diet with a specified number of food servings from different food groups (including vegetables, fruits, grains, dairy products, meats) + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil (equivalent to 4 tablespoons; 2 tablespoons for lunch and 2 tablespoons for dinner) for 3 months
9696385|NCT04767230|Placebo Comparator|A heart-healthy diet|Recommendations for a heart-healthy diet, such as those of the American Heart Association for 3 months. These include eating at least 5 servings of vegetables and fruits daily, reduction in the consumption of sources of saturated and trans fats by avoiding the consumption of high-fat red meats and replacing them with low-fat meat or with poultry and fish, replacing low-fat dairy sources with regular or high-fat ones; consumption of regular vegetable oils such as canola and sunflower; reduction in salt consumption; and reduction in the consumption of simple sugars for 3 months
9696386|NCT04767425|Experimental|Experimental|
9696387|NCT04767243|Sham Comparator|open flap debridement and filled with A-PRF|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
9696388|NCT04767243|Active Comparator|open flap debridement and filled with Bioactive glass (Perioglas®)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
10181617|NCT03781869|Placebo Comparator|Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, repeated every 21 days, a total of 4-6 cycles, and then follow up observation until PD.
10181618|NCT03781830|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
10181619|NCT03781856|Experimental|La Vida Buena Program|Administered in a group setting over the course of 8 weeks in a community setting.
9528156|NCT03213353|Experimental|Treatment sequence AB|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
9692715|NCT04808804||DM|Patients With Type 2 Diabetes Mellitus without any signs of diabetic retinopathy or with mild non proliferative diabetic retinopathy
9692716|NCT04808804||Healthy|healthy controls
9692717|NCT04809077|Other|Reverse total shoulder replacement|Patients who underwent a total shoulder replacement using a reverse type implant (Delta Xtend or Zimmer TM)
9692718|NCT04808791|Experimental|Single Arm iTTO treatment|"Patients will receive the combination of irinotecan, TAS-102, and Oxaliplatin on a 28 day cycle with the following doses;~Irinotecan 160mg/m2 IV infusion over 60-90 mins on day 1~Oxaliplatin 100mg/m2 IV infusion over 2 hours on day 1~TAS-102 (Trifluridine/Tipiracil) 25mg/m2 twice a day, on days 1-5 and 8-12 every 28days."
9692719|NCT04808570|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
9692720|NCT04808687|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 2-4 cycles
9692721|NCT04808622|Experimental|TSC 0.5 mg/kg|TSC 0.5 mg/kg given as a one-time IV bolus injection
9692722|NCT04808622|Experimental|TSC 1.0 mg/kg|TSC 1.0 mg/kg given as a one-time IV bolus injection
9692723|NCT04808622|Experimental|TSC 1.5 mg/kg|TSC 1.5 mg/kg given as a one-time IV bolus injection
9692724|NCT04808622|Experimental|TSC 2.0 mg/kg|TSC 2.0 mg/kg given as a one-time IV bolus injection
9692725|NCT04808622|Experimental|TSC 2.5 mg/kg|TSC 2.5 mg/kg given as a one-time IV bolus injection
9692726|NCT04808622|Placebo Comparator|Placebo|7 mL normal saline given as a one-time IV bolus injection
9692727|NCT04808453|Experimental|CPI-300|Dose Escalation Group: CPI-300 will be administered via intravenous infusion once every 2 weeks for up to 6 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design
9692728|NCT04808557|Active Comparator|Trial Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Biorepair Total Protection for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
9692729|NCT04808557|Active Comparator|Control Group|Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Sensodyne Repair & Protect for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
9692730|NCT04808778||Participants with sickle cell anemia identified with neurological morbidity|"Successful completion of screening procedures inclusive of 1.) Cerebral blood flow velocity greater than or equal to 200 cm/sec measured twice or 2.) At least one measurement greater than or equal to 220 cm/sec in the middle cerebral artery or 3.) Two TCD measurements above 190 cm/sec within a three-month interval;~MRI showing cerebral infarcts with or without (based on Silent Cerebral Infarct Trial (SIT) criteria) neurological deficits on standard neurological examination;~Informed consent from a participant (> 18 years) or parent/legal guardian for participants (< 18 years) and assent of the participant completed;~Acceptance of hydroxyurea therapy for one year as standard care. After one year of therapy, the participant will have the option to continue therapy with follow-up visits to monitor adherence to therapy with his or her care provider."
9692731|NCT04808778||Participants with sickle cell anemia identified to be without neurological morbidity|"Successful completion of screening procedures inclusive of cerebral blood flow velocity less than or equal to 199 cm/sec in the middle cerebral artery;~Normal MRI and MRA;~No focal neurological deficit on standard neurological examination;~Informed consent from a participant (> 18 years), or parent/legal guardian for participants (< 18 years) and assent from the participant;~Agreement to be followed for at least one year in the study."
9692732|NCT04808830||Pulmonary arterial hypertension|Adult patients with pulmonary arterial hypertension
9692733|NCT04808674|Experimental|Group-based cognitive remediation program|Patients are admitted to the day hospital 2 days a week for 6 weeks and participate in a group-based (4 patients per group) rehabilitation program conducted by a multidisciplinary team including a PMR doctor, a neuropsychologist, an occupational therapist, and a physical activity monitor).
9692734|NCT04808674|Experimental|One-on-one cognitive remediation program|Patients are admitted to the day hospital 5 days a week for 6 weeks and participate in a one-on-one intensive rehabilitation program conducted by a multidisciplinary team including a speech therapist, neuropsychologist, occupational therapist, physiotherapist, physical activity monitor and a psychologist.
9692735|NCT04808141|Experimental|Digital Rehabilitation|Home-based rehabilitation with a digital biofeedback system
9692736|NCT04808141|Active Comparator|Conventional rehabilitation at an outpatient clinic|
9692737|NCT04808089|Experimental|Health Lung App. +ezOxygen|"Health Lung App. (AstraZeneca Pharmaceuticals LP) is the application for mobile phone to help asthma care and is available freely in Google Play. Health Lung can be connected to the mobile spirometry, ezOxygen (Genius Holding Co.,Ltd Taiwan Branch).~The functions of Health Lung App. include asthma control monitor, lung function monitor, controller and reliver inhaler reminder and recording, asthma educational topics in brief and information of air quality~Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~he physicians in charge will get the information about control status score by ACT, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
9692738|NCT04808089|Active Comparator|Usual care|The research assistant assess/ teach inhaler technique, offering the asthma education as the regular clinical service.
9692739|NCT04808323|Experimental|Cohort A|Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
9692740|NCT04808323|Experimental|Cohort B|Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
9692741|NCT04808323|Experimental|Cohort C|Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
9692742|NCT04808154|Experimental|test drug|Powder for oral solution of SNP-630.
9692743|NCT04808336|Active Comparator|PRP injection group|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
9692744|NCT04808336|Active Comparator|surgical group..|Group 2: thirty patients underwent surgery
10181620|NCT03781856|Active Comparator|Brief educational session|Administered one on one or in a group setting in a one-hour session at the clinic
10181621|NCT03781739|Experimental|MANP|subjects receiving MANP (2.5 micrograms/kg, single subcutaneous injection)
10181622|NCT03781739|Placebo Comparator|Placebo|subjects receiving placebo (saline solution, single subcutaneous injection)
10181623|NCT03781687|Active Comparator|Bilateral|Bilateral ESP block will be performed
9692745|NCT04808271|Active Comparator|Bif195 capsules|The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
10181624|NCT03781687|Active Comparator|Unilateral|Unilateral ESP block will be performed
9692746|NCT04808271|Placebo Comparator|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
9692747|NCT04808401|Experimental|Normoxaemia First + Hyperoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
9692748|NCT04808401|Experimental|Normoxaemia First + Normoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive normoxic concentrations.
9692749|NCT04808401|Experimental|Hyperoxia First + Hyperoxia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
9692750|NCT04808401|Experimental|Hyperoxia First + Normoxaemia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive normoxic concentrations.
9692751|NCT04808362|Experimental|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
9692752|NCT04808167|Experimental|Therapeutic Group|Therapeutic group receives remote ischemic conditioning.
10181625|NCT03781596|Experimental|Fluticasone and omeprazole|These patients will be prescribed swallowed fluticasone and omeprazole to be taken together for the 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
10181626|NCT03781596|Placebo Comparator|Fluticasone and placebo|These patients will be prescribed swallowed fluticasone and a placebo medication that appears identical to omeprazole to be taken together for an 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
9692753|NCT04808167|No Intervention|Control Group|Control group does not receive remote ischemic conditioning.
9692754|NCT04808102|Experimental|IER serious game|A serious game training interpersonal emotion regulation strategies.
9692755|NCT04808102|Sham Comparator|control game|A control puzzle game without psychoeducational content.
10181627|NCT03781622|Experimental|WOLF Thrombectomy Device Arm|Patients enrolled in the study who received the treatment and who met all Inclusion and Exclusion Criteria
10181628|NCT03781674|Active Comparator|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg(4 tablets) daily beginning at 18-22 weeks gestational age
10181629|NCT03781674|Active Comparator|progesterone 200mg plus placebo to progesterone 200 mg|Women received vaginal progesterone suppositories in a dose of 200 mg(2 tablets) daily beginning at 18-22 weeks gestational age plus 2tablets placebo to vaginal progesterone
10181630|NCT03781674|Placebo Comparator|placebo to progesterone 400 mg|Women received 4 tablets placebo to vaginal progesterone suppositories
10181631|NCT03781648|Other|WL withdrawal method|Active Comparator: WL was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
9692756|NCT04808219||Driver|Ambulance driver who was involved in a traffic collision - video analysis of the collision records and in-depth interview aiming to find the cause of the collision.
9692757|NCT04808063|Experimental|Algorithm use for prphylactic mesh after emergency laparotomy|Patients with emergency surgery in whom algorithm for prophylactic mesh is use to help decide abdominal wall mesh reinforcement or not.
9692758|NCT04808128|Experimental|Drink A + SC|In t0 the group will receive 250 ml XL energy drink + 20 gr sucrose.
9692759|NCT04808128|Active Comparator|Drink B + SC|In t0 the group will receive 250 ml Fanta soft drink + 20 gr sucrose.
9692760|NCT04808128|Active Comparator|Drink C + SC|In t0 the group will receive 250 ml soda water + 47 gr sucrose.
9692761|NCT04808128|Experimental|Drink A + CC|In t0 the group will receive 250 ml XL energy drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
9692762|NCT04808128|Active Comparator|Drink B + CC|In t0 the group will receive 250 ml Fanta soft drink + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
9692763|NCT04808128|Active Comparator|Drink C + CC|In t0 the group will receive 250 ml soda water + 27gr sucrose + 20gr complex carbohydrates from one slice of bread (30g) and one spoon of hummus.
9692764|NCT04808310|Active Comparator|Angiography|The indication to further coronary intervention will be based on angiographic diameter stenosis.
9692765|NCT04808310|Experimental|Quantitative flow ratio (QFR)|The indication to further coronary intervention will be based on QFR.
10181632|NCT03781648|Experimental|NBI withdrawal method|Experimental: NBI was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
9692766|NCT04808037|Experimental|Cohort 1, First Part|12 patients are anticipated to receive Belantamab Mafodotin 2.5 Q8W = 2.5 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
9692767|NCT04808037|Experimental|Cohort 2, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
9692768|NCT04808037|Experimental|Cohort 3, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
9692769|NCT04808037|Experimental|Group A, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose Modification Guidelines for Corneal-Related Adverse Events Associated with belantamab mafodotin"
9692770|NCT04808037|Experimental|Group B, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose modification guidance based on visual acuity"
10181633|NCT03781635|Active Comparator|bolus of intravenous ketamine|A bolus of 0.25mg.kg-1 of ketamine will be first administered at the time of incision (T0) then every single hour for the rest of the surgery. Study starts at incision (T0) for ketamine administration and ends when the surgical team starts closing the deep layers of the abdominal incision.
10181634|NCT03781635|Experimental|continuous infusion of intravenous ketamine|An infusion of 0.25 mg.kg-1.h-1 is started at T0 (incision) with an infusion pump and is kept at the same rate until the surgical team starts closing the deep layers of the abdominal incision. Consumption of the infusion pump is noted at T0 (incision) and at each hour during the surgery until the infusion is discontinued.
9692773|NCT04808076|Active Comparator|iNPH patients|Shunt operation
9692774|NCT04808076|No Intervention|Healthy Individuals|Healthy individuals without any neurological disease.
9692775|NCT04808024|Experimental|Players of amateur football leagues|The players of amateur football leagues who will receive SelfMyofascial Release intervention
9692776|NCT04808024|No Intervention|Control group|The players of amateur football leagues who will receive no intervention
9692777|NCT04808232|Experimental|health education and progressive muscle relaxation exercise|Health education and progressive muscle relaxation exercise training was given to women in this group.
9692778|NCT04808232|Experimental|progressive muscle relaxation exercise|Progressive muscle relaxation exercise training was given to women in this group.
9692779|NCT04808232|No Intervention|Control group|women in this group were not intervened.
9692780|NCT04807868||Biopsy Group|Adults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason
10181635|NCT03781531||Venous thromboembolism|Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
9692781|NCT04807868||Non-Biopsy Group|Adults without any history of NAFLD
9692782|NCT04807803|Experimental|Patients with compensated cirrhosis and portal hypertension|
9692783|NCT04807855|Experimental|the experimental arm|All subjects, the ptosis group and the normal group receive the same intervention.
9692784|NCT04807816|Experimental|Experimental Arm A: treatment by berzosertib combined with gemcitabine|Patients with advanced leiomyosarcomas will be treated with berzosertib combined with gemcitabine
9692785|NCT04807816|Other|Standard Arm B: treatment by gemcitabine alone|Patients with advanced leiomyosarcomas will be treated with with gemcitabine alone (control arm)
9692786|NCT04807790|Experimental|Telerehabilitation based structured home program group|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
9692787|NCT04807790|No Intervention|Routine physiotherapy and rehabilitation group|Routine physiotherapy and rehabilitation practices, consist of activities organized by physiotherapists as one or two sessions per week according to the functional levels of children with CP. Routine physiotherapy and rehabilitation applications include increasing postural control, gaining motor development steps, strengthening training, balance training, long-term stretching training, manual therapy, hydrotherapy, hippotherapy and neurodevelopmental therapy approaches.
9692788|NCT04807959||20Lighter Program Participants|All enrolled subjects will have completed a 20Lighter anti-obesity program prior to enrollment.
9692789|NCT04807699||Total participants|3500 participants that will have their medical forms checked
9692790|NCT04807829|Experimental|Nabilone|Patients in the treatment group will be administered oral Nabilone 2 mg once daily for 3 days in addition to treatment as usual according to current clinical guidelines and standard of care.
10181636|NCT03781544|Experimental|Diclofenac|Diclofenac (Diclofenacum natricum) A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
10181637|NCT03781544|Active Comparator|Paracetamol|"Paracetamol (Paracetamol Sintetica):~A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm)."
10181638|NCT03781544|Experimental|Tramadol|"Tramadol (Tramadol-Mepha):~A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm)."
10181639|NCT03781518|Experimental|ridge splitting|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic mandible and splinting with screws
9692791|NCT04807829|Placebo Comparator|Placebo Comparator|Patients in the Placebo Comparator group will receive placebo once daily for 3 days plus treatment as usual.
9692792|NCT04807933|Experimental|Experimental group (BFB training)|The participants assigned to the experimental group will do the biofeedback training using the Emwave software during the intervention period (T2-T3). The biofeedback software (Emwave Pro®) includes a photoplethysmography sensor that can be positioned on the earlobe. The installation of the program and the explanations needed for using it, will be done during the second session (T2). According to the guidelines, a fractional training is proposed 5 minutes, 3 times a day for 24 days (T2-T3).
9692793|NCT04807933|No Intervention|Control group (no BFB training)|The participants assigned to the experimental group will not do a specific exercise during the intervention period (T2-T3).
9692794|NCT04807426|Active Comparator|Multi Sensory stimulation exercises|only Multisensory stimulation Exercises
9692795|NCT04807426|Experimental|Task Oriented Exercises|Task-oriented exercises without Multisensory stimulation Exercises
9692796|NCT04807426|Experimental|Task oriented exercises and Multisensory stimulation exercises.|Task-oriented exercises with Multisensory stimulation Exercises
10181640|NCT03781518|Active Comparator|khoury shell technique|bone block is taken from the ramus to augment deficient posterior mandible and splinting with screws
9692799|NCT04807569|Experimental|Experimental group|"10 sessions of non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation."
9692800|NCT04807569|Experimental|Control group|one-month course of drug therapy with alpha-1-adrenoblocker according to the standard scheme
9692801|NCT04807491|Active Comparator|Kabat Technique's|Kabat exercises on Upper fulcrum, Intermediate fulcrum and lower fulcrum
9692802|NCT04807491|Experimental|Neuromuscular Re-Education:|For initiation, Facilitation, Movement control and movement control
9692803|NCT04807608||Healthy Users|Each subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).
9692804|NCT04807634|Other|Group A (control)|Group A (control): that will receive the traditional supportive treatment for acute antipsychotic drugs overdose
9692805|NCT04807634|Other|Group B (case)|that will receive the traditional supportive treatment for acute antipsychotic drugs overdose plus administration of 1.5 ml/kg ILE (20%) as a bolus over 1-2 minutes, followed by a continuous rate infusion of 0.25 ml/kg/min for the next 30 to 60 minutes
9692806|NCT04807738|Active Comparator|"Neuroproprioceptive facilitation and inhibition"|"ARM 1 - Neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT), with former positive probative evidence on MS and are recommended for MS intervention."
9692807|NCT04807738|Experimental|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"ARM 2. Experimental group, neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) through virtual reality and software inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). We believe that the VR environment might lead to better results due to greater motivation effect, novelty effect, entertainment effect, as well as activating the reward system. We believe the VR might enhance the activation of mirror neurons, it might also activate proprioception. The present physiotherapist is to ensure proper execution of the tasks. The correlation of the two arms of the study should indicate, whether virtual reality and the software used are as effective, or more effective in sustaining the hand motor function and axial stability, than traditionally led therapy."
9692808|NCT04807777|Experimental|Ruxolitinib|"In a safety lead-in of 6 patients, subjects will receive 15mg of ruxolitinib twice daily (BID). After 4 weeks, if dose-limiting toxicities (DLT) are observed in 1 or fewer patients, the study will enter stage 1 of the Simon two-stage design where all subsequent patients will receive a starting dose of ruxolitinib 15mg BID.~Subjects will have regularly scheduled study visits at the clinical site on Day 1 and Day 15 (± 3 days) of the first 2 cycles, then on Day 1 (± 3 days) of every subsequent cycle (starting cycle 3), where safety assessments, including laboratory assessments, vital signs, and physical examinations will be performed."
9692809|NCT04807413|Experimental|Study Arm: The balloon will be opened to deliver nitric oxide at 40 ppm.|Nitric oxide balloon will be connected to the CPB machine. Participants randomized to this group will receive 40 ppm nitric oxide through the pump.
9692810|NCT04807413|Active Comparator|Control Arm: The balloon will be closed and no nitric oxide will be delivered.|Participants in this group will receive standard of care treatment. Participation in the trial will not affect surgery management in any way.
9692811|NCT04807660||Prospective cohort|Middle ear fluid sample for each enrrolled children
9692812|NCT04807465|Other|G-Premio universal adhesive used in smoker participants|Participants who smoke at least 10 cigarettes per day
9692813|NCT04807465|Other|G-Premio universal adhesive used in non-smoker participants|participants who non-smoke have never smoked before
9692814|NCT04807621|Active Comparator|Platelets|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, a platelet transfusion.
9692815|NCT04807621|Experimental|Fibrinogen|Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, fibrinogen concentrate.
9692816|NCT04807673|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)|"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), paclitaxel 135mg/m^2 IV on Day 2 Q3W, and cisplatin 80 mg/m^2 IV on Day 2 Q3W, a total of three cycles. All treatments will be beginning on Day 1 of each 3-week dosing cycle. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. After surgery, pembrolizumab 200 mg IV on Day 1 Q3W lasting one year.~Surgery: McKeown esophagectomy"
9692817|NCT04807673|Experimental|neoadjuvant chemoradiotherapy+ Surgery (114)|"neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m^2 on D1 and Cisplatin 25mg/m^2 D1, repeated every week. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment.~Surgery: McKeown esophagectomy"
10181641|NCT03781557|Experimental|High-concentrated DHA|High-concentrated DHA fish oil softgels
10181642|NCT03781557|Experimental|High-concentrated EPA|High-concentrated EPA fish oil softgels
9692818|NCT04807517|Experimental|Buspirone|Subjects will receive buspirone 2.5 mg each morning at the start of the trial. The dose will be increased by 2.5 mg per week in two divided doses daily depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 2.5 mg and the maximum total daily dose will be 30 mg. Medication will be dosed twice daily due to the short half-life (2-3 hours) of this medication.
9692819|NCT04807543|Active Comparator|study group|17-hydroxyprogesterone caproate (17P) (250 mg in castor oil, 1 mL total volume)intramuscular injection
9692820|NCT04807543|Placebo Comparator|control group|castor oil, 1 mL total volume intramuscular injection
9692821|NCT04807686|Active Comparator|traditional algorithm|
10181643|NCT03781557|Placebo Comparator|Olive Oil|Olive Oil softgels
10181644|NCT03781661|Experimental|Intervention Group|The participants in the intervention group will be provided with extended information of the advantages of the CT examination of the heart's arteries. This will be given to the participants both orally and written in form of a leaflet. In addition will they be given the opportunity for a visual go-through of their own calcium score images. After this they will be informed of the normal examination result.
10181645|NCT03781661|No Intervention|Control group|Control Group receives standard care.
9692822|NCT04807686|Experimental|notched-type algorithm|
9692823|NCT04807452|Active Comparator|Strength and balance training|Exercises like ROMS, stretching, static balance and dynamic balance
10181646|NCT03781713|Active Comparator|STUDY GROUP|patients who triggered triggers and had interventions. Kdigo: interventions to prevent renal replacement therapy Delta SOFA: interventions to improve SOFA score Hypoglycemia: Interventions to prevent new episodes of hypoglycemia in the next 24 hours Drug interaction risk D or X - Intervention in the therapeutic plan in order to avoid adverse drug reactions. Antimicrobial stewardship: optimization of antimicrobial therapy based on Gram stain, MALDI TOF, MIC, antimicrobial susceptibility
10181647|NCT03781713|No Intervention|CONTROL GROUP|patients who did not triggered triggers
10181648|NCT03781505|Experimental|Intravenous paracetamol with Caudal Ropivacaine|"Paracetamol is widely accepted and most commonly used as an adjuvant for postoperative analgesia. It also improves the quality of recovery by attenuating the pain associated with the surgical position. Adverse effects associated with the paracetamol are rare <1/10000, which includes malaise, increased level of hepatic transaminases and hypersensitivity reaction. It has been studied in combination with caudal analgesia with bupivacaine through the rectal route 7,8 with variable results.~Caudal anaesthesia is effective in alleviating pain below the umbilicus. Also if the caudal block is administered at the beginning of surgery, the effect will start wearing off 2 to 3 hours post surgery. Administration of paracetamol towards end of surgery may help with both these issues. In this study we aim to investigate the effect of adding intravenous paracetamol in combination with caudal analgesia with ropivacaine, hoping that it may improve quality of postoperative analgesia and recovery."
9692824|NCT04807452|Experimental|Aerobics training|Control Group received aerobic training.
9692825|NCT04807751|Experimental|Delgocitinib cream 20 mg/g|topical occlusive administration
9692826|NCT04807751|Placebo Comparator|Delgocitinib cream vehicle|topical occlusive administration
9692827|NCT04807751|No Intervention|Untreated skin|topical occlusive administration
9692828|NCT04807140|Experimental|Toripalimab|Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days
9692829|NCT04807140|Experimental|Toripalimab + Carboplatin+ Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
9692830|NCT04807010|Active Comparator|Prostate artery embolization|
9692831|NCT04807010|Sham Comparator|Sham|
9692832|NCT04807192|Experimental|Arm 1: SBRT|
9692833|NCT04807192|Experimental|Arm 2: CMP-001 + SBRT|
9692834|NCT04807309|Placebo Comparator|Placebo|Placebo comparison
9692835|NCT04807309|Active Comparator|Danazol Pill|Danazol 200mg orally twice a day
9692836|NCT04807166|Experimental|Anlotinib Combined With Carboplatin/Paclitaxel|Anlotinib Combined With Carboplatin/Paclitaxel
9692837|NCT04807062|Experimental|DTPFs treated with structural bicortical autologous ICBG combined with TBTM|
9692838|NCT04807335|Experimental|Investigational medicinal product CT001|intranasal dosage of CT001
9692839|NCT04807335|Active Comparator|Comparator 1|Ketamine 10mg iv
9692840|NCT04807335|Active Comparator|Comparator 2|Sufentanil 10mcg iv
9692841|NCT04807101|No Intervention|midazolam and fentanyl|Patients in this arm will receive standard conscious sedation with midazolam and fentanyl
9692842|NCT04807101|Experimental|midazolam alone|Patients in this arm will receive conscious sedation with medazepam alone
9692843|NCT04807322||Elective cases|Patients, who received a RTSA for degenerative reasons like cuff arthropathy or osteoarthritis
9692844|NCT04807322||Fracture cases|Patients, who received a RTSA for a proximal humerus fracture
9692845|NCT04807296|Active Comparator|TFLEP|Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.
9692846|NCT04807296|Active Comparator|m-HoLEP|The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.
9692847|NCT04807244|Other|Treatment of deep carious lesions: Randomized-controlled trail|Teeth with reversible pulpitis will be included accordingly to the inclusion criteria (see below). After randomization, teeth will be treated either with selective caries removal (indirect pulp capping) or partial pulpotomy pursuant to the below described clinical protocol. The intention of this study arm is to evaluate both therapies.
9692848|NCT04807244|Other|Treatment of deep carious lesions: Prospective non-controlled intervention trial|Teeth with reversible pulpitis according to the inclusion criteria (see below) will be included. Depending on the clinical situation, a partial or full pulpotomy will be conducted accordingly to the defined clinical protocols (see below). In this study arm, we want to evaluate 1) different times of pulpal bleeding before pulp capping and 2) partial versus full pulpotomy on the clinical outcome in teeth with irreversible pulpitis.
9692849|NCT04807283|Experimental|Treatment|
9692850|NCT04807127||ICI-pneumonitis|Cancer patients experiencing ICI-pneumonitis
10181649|NCT03781505|Placebo Comparator|Placebo|Intravenous Normal Saline with Caudal Ropivacaine
10181650|NCT03781700|Experimental|Prednisolone|Prednisolone
9692851|NCT04807127||Radiotherapy induced pneumonitis|Cancer patients experiencing RT-pneumonitis
9692852|NCT04807127||TKI-induced pneumonitis|Cancer patients experiencing TKI-induced pneumonitis
10181651|NCT03781700|Placebo Comparator|Placebo|Placebo oral tablet
9692853|NCT04807361||Subjects|
9692854|NCT04807270|Active Comparator|T-LAB / PRP KIT|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP KIT injection in 3 sessions will be applied.
9692855|NCT04807270|Active Comparator|T-LAB / PRP INJECTION SYRINGE|In the first group, Platelet-rich plasma (PRP) prepared with T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied.
9692856|NCT04807270|Active Comparator|SALINE|In the first group, Platelet-rich plasma (PRP) prepared with SALINE injection in 3 sessions will be applied.
9692857|NCT04806932|Active Comparator|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
9692858|NCT04806932|Placebo Comparator|The conventional approach|The first three attempts via the conventional approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
9692859|NCT04806945|Experimental|HLX10|HLX10 + chemotherapy
9692860|NCT04806945|Placebo Comparator|Placebo|Placebo + chemotherapy
9692861|NCT04806698|Experimental|Menicon Z Night|The experimental arm includes a group of children wearing Menicon Z Night orthokeratology contact lenses for 7 years
9692862|NCT04806698|Active Comparator|Control|The active comparator arm includes a control group of children wearing distance, single-vision glasses or soft contact lenses
9692863|NCT04806568|Experimental|PwMS-CogTr|Adult individuals with Multiple Sclerosis that will follow a cognitive training intervention.
9692864|NCT04806568|No Intervention|PwMS-Con|Adult individuals with Multiple Sclerosis serving as passive controls.
9692865|NCT04806711|Experimental|Menicon Z Night|The experimental arm consist of a group of Menicon Z Night orthokeratology contact lens wearers
9692866|NCT04806711|Active Comparator|Control|The active comparator arm consist of a control group of distance, single-vision glasses and contact lens wearers
9692867|NCT04806958|Experimental|Conventional Emergency Dispatch PLUS PulsePoint notification|Eligible 911 calls randomized to the experimental arm of the study will undergo usual dispatch of emergency services personnel as per pre-existing local protocols and activation of the PulsePoint system. When triggered, the system will push location data to all PulsePoint mobile application users within 400 meters of the emergency. Devices receiving the alerts from the PulsePoint system will alarm with auditory, tactile and visual stimuli. The application will present a map showing the exact location of the emergency and the closest public access defibrillator.
9692868|NCT04806958|No Intervention|Conventional Emergency Dispatch|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures as per pre-existing local protocols (e.g. dispatch of emergency vehicles, attempted dispatch-assisted CPR) without activation of the PulsePoint system. 911 calls randomized to the control arm will not be associated with any PulsePoint alerts.
9692869|NCT04807114||NSCLC st.IV (PD-L1 > 50%)|Anti-PD-1 monotherapy
9692870|NCT04807114||NSCLC st.IV (PD-L1 < 50%)|Combination anti-PD-1 + chemotherapy
9692871|NCT04806789||Children with suspected acute appendicitis|"Cohort: Children with suspected acute appendicitis. Clinical examination (including history of nausea, vomiting, temperature, information of rebound tenderness, right iliac fossa pain, duration of symptoms, gender and weight) and blood samples will be obtained at the emergency department (blood gas, C-reactive protein, neutrophiles and white blood cell count). Radiology (ultrasound and/or computed tomography) will be performed thereafter.~Outcome measures~Primary outcome measure: Plasma sodium. To investigate if plasma sodium is an independent predictor of perforation in children with acute appendicitis. In advance, five variables (Plasma sodium, C-reactive protein, symptom duration, age and temperature) will be included in the final multivariable analysis"
9692872|NCT04806763|Experimental|Menicon Z Night|The experimental group is allocated to wear Menicon Z Night orthokeratology contact lenses for two years
9692873|NCT04806763|Active Comparator|Glasses|The active comparator includes a group that was allocated to wear distance, single-vision glasses for two years
9692874|NCT04806893|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
10181652|NCT03781609|Active Comparator|Roller system group (RG)|A group performing motor learning manual wheelchair propulsion repetitions on a roller system.
10181653|NCT03781609|Active Comparator|Overground group (OG)|A group performing motor learning manual wheelchair propulsion repetitions overground.
10181654|NCT03781609|Placebo Comparator|Placebo - Wheelchair skills group (WSG)|A group receiving conventional manual wheelchair skills training.
10181655|NCT03781466|Active Comparator|Cervical cerclage|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm
10181656|NCT03781466|Active Comparator|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
10181657|NCT03781466|Active Comparator|Cervical cerclage plus vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm plus Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
9692875|NCT04806893|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
9692876|NCT04806659|Experimental|SH1573 Capsules|SH1573 capsules administered orally. Multiple doses will be administered by effiacy and safety to determine the RP2D.
9692877|NCT04806646|Experimental|Single Arm Treatment|"One cycle of therapy is defined as 28 days of sonidegib. The patient will start with TS1 schedule.~TS1: assumption 14 days on and 14 days off. TS1 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, at treatment resumption they will start the TS2 schedule.~TS2: assumption 7 days on and 21 days off. TS2 may be temporary interrupted for any grade 2 or 3 toxicity (excluding alopecia) until return to grade 1. If the patient experiences any grade 3 or 2 side effects lasting for more than 28 days, he/she is discontinued from the study.~If progression of disease is observed (during TS1 or TS2) the patient is discontinued from the study."
9696389|NCT04767243|Active Comparator|with open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF.|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) along with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
9696390|NCT04767464|Other|Compass Course|Virtual Compass Course
9696391|NCT04767269|Experimental|cuminum cyminum mouthwash|cuminum cyminum mouthwash in chronic gingivitis patients
9696392|NCT04767269|Active Comparator|herbal mouthwash|herbal mouthwash in chronic gingivitis patients
9696393|NCT04767399|Experimental|Single visit|root canal treatment will be done in one visit
9696394|NCT04767399|Experimental|multiple visit|root canal treatment will be done in multiple visit
9696395|NCT04767490|Active Comparator|BPD-DS|Biliopancreatic diversion with Duodenal Switch (BPD-DS), with Sleeve gastrectomy, including a 100cm common channel and 150cm stric alimentary limb
9696396|NCT04767490|Experimental|SADI|Single-Anastomosis Duodeno-Ileal anastomosis (SADI) with Sleeve Gastrectomy, including a 250cm common channel
9696397|NCT04767451||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
9696398|NCT04767451||Control group|The study population will consist of 50 women with POI as a study group and 50 patients with normal healthy women as a control group. A volunteer group of healthy women who will be visited the gynecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
9696399|NCT04767347|Experimental|Fixed Work Rate|Participants will walk on a treadmill at 3 mph and the grade will be adjusted to elicit 430 W of metabolic heat production (the most common work intensity). This study will systematically examine the NIOSH recommendations for prescribing work-to-rest ratios with increasing environmental heat stress (defined as Wet Bulb Globe Temperature, WBGT) at this fixed rate of metabolic heat production on kidney function.
10181658|NCT03781427|Active Comparator|Standard care|Cardiac resynchronization therapy: Usual output programming
10181659|NCT03781427|Experimental|High output|Cardiac resynchronization therapy: High output programming
10181660|NCT03781388|Experimental|Starting dose of Bupivacaine (9 mg)|The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
10181661|NCT03781388|Experimental|Subsequent dose|
9696400|NCT04767347|Experimental|Fixed work-to-rest ratio|This study will systematically examine the NIOSH recommendations on changes in kidney function when the work-to-rest ratio is fixed at 30 min per hour (the most commonly prescribed work-to-rest ratio), but the rate of metabolic heat production and environmental heat stress differs (Figure 2). As described in Study 1, the appropriate rate of metabolic heat production will be elicited by having participants walk on a treadmill at 3 mph and the grade will be adjusted accordingly.
9696492|NCT04766255|Experimental|PADM group|Implant placement, soft tissue augumentation of Porcine acellular dermal matrix (PADM) at the implant site and prosthetic rehabilitation of the missing tooth.
10181662|NCT03781258|Other|Anit-thrombotic monotherapy|Patients with HeartMate 3 LVAS transitioning from Warfarin and Acetylsalicylic Acid (ASA) therapy to receive anti-thrombotic monotherapy (ASA).
10181663|NCT03781271|Experimental|Fraction 1-Addition of EMN|During the fraction 1 insertion, the custom MRI-compatible vaginal cylinder will be placed in the patient, and will contain the 6 degree-of-freedom (DOF) sensor. The electromagnetic navigation system and computer will have been setup in the operating room (OR) prior to the procedure and will be used to actively insert up to 25 catheters into the target. The catheters will be inserted using a custom metallic stylet that has a custom 5-DOF sensor embedded in the tip for tracking its position in real-time. The physician may use ultrasound for assistance in target visualization as well. Catheter deflections will be detected and corrected for in real-time by the radiation oncologist as the catheter is inserted into the patient during the procedure, this will occur when the EM system is in use.
10181664|NCT03781271|Experimental|Fraction 3-Addition of EMN|For the second group of patients in the trial the same protocol will be followed as in the first group, the only difference will be that the electromagnetic navigation is used during the second implantation procedure immediately preceding fraction 3 as opposed to fraction 1, the time at which it was used for the first group of patients.
10181665|NCT03781102|Experimental|Intervention|Arm 1, or intervention participants (n=60), will participate in a 16-week face-to-face diabetes prevention group program '16-Week Diabetes Prevention Program for Mothers and Children' and then will transition to a 16-week follow-up period.
10181666|NCT03781102|Other|Wait-listed Control|Arm 2, or wait-listed controls (n=60), will receive the typical standard of care during the first 16-weeks, followed by the 16-week face-to-face group diabetes prevention program '16-Week Diabetes Prevention Program for Mothers and Children'.
9692878|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 1|"Participants will each be administered L dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: L"
9692879|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 2|"Participants will each be administered M dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: M"
9692880|NCT04806581|Experimental|Allogeneic Hepatocyte Cohort 3|"Participants will each be administered H dose for one time. With 28days follow-up after the cells infusion.~Allogeneic hepatocyte cell numbers: H"
9692881|NCT04807088|Experimental|Intervention Group|Tactile-kinesthetic stimulation (TKS) was performed with a specific baby oil provided by the investigator. Tactile stimulation was performed while the neonate was in prone position. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Every massage was performed for 2 × 5 seconds, with a total duration of 5 minutes. Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 2 × 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 10 consecutive days.
9692882|NCT04807088|Placebo Comparator|Control Group|Control group was not given TKS.
9692883|NCT04806880||users|Users of web-application
9692884|NCT04806620||People with ME/CFS|No intervention will be administered.
9692885|NCT04806620||People with Long-COVID|No intervention will be administered.
9692886|NCT04806620||Healthy Controls|No intervention will be administered.
9692887|NCT04806737|Active Comparator|IMP|Teriflunomide 14 mg tablets, first 7 days 5 tablets once pr day, thereafter 1 pr day for another 6 days.
10181667|NCT03781310|Experimental|Dose reduction|Reduce the Tocilizumab dose at the baseline visit (week 0) and maintain that dose until 20 weeks of follow-up. The reduced dose is dependent of the tocilizumab serum concentration, measured at the screening visit, and is calculated according to the pre-defined dose-reduction algorithm.
10181668|NCT03781310|Active Comparator|Maintain dose|Maintain the original dose at baseline visit (week 0) until 20 weeks of follow-up.
10181669|NCT03781076|Experimental|Sleep Intervention|1-hour brief behavioral intervention to improve sleep consolidation and nocturnal sleep duration.
9692888|NCT04806737|Placebo Comparator|Placebo|Sham tablets
10181670|NCT03781076|No Intervention|Control|"In this care as usual arm, no specific behavioral sleep intervention is provided."
9692889|NCT04806633|Active Comparator|Dapagliflozin|Patients who will be randomized to receive dapagliflozin following cardiac catheterization and PCI
9692890|NCT04806633|Placebo Comparator|Placebo|Patients who will be randomized to receive placebo following cardiac catheterization and PCI
9692891|NCT04806906|Experimental|CC-486|subjects will receive 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
9692892|NCT04806828||HF|Preoperative classification of inguinal hernia
9692893|NCT04806542|Experimental|TMR-group|8-week program for schoolchildren called TMR (Training for Resilience and Mindfulness).
9692894|NCT04806542|Active Comparator|Treatment as Usual|Individual counselling.
9692895|NCT04806399|No Intervention|Usual Care Control Group|
9692896|NCT04806399|Active Comparator|Outreach Contact with Decision Counseling Group|
9692897|NCT04806360|Experimental|ACRF group|ACRF is a new surgical procedure that previously proposed by our team, it combines the advantages of both the conventional anterior and posterior approach. Eligible patients in this group will receive ACRF surgery.
9692898|NCT04806360|Active Comparator|conventional anterior surgery group|Eligible patients in this group will receive conventional anterior surgery, including anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
9692899|NCT04806360|Active Comparator|conventional posterior surgery group|Eligible patients in this group will receive conventional posterior surgery, including laminectomy and fusion surgery or laminoplasty surgery.
9692900|NCT04806308|Experimental|Intervention group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
9692901|NCT04806308|No Intervention|Control group|Cross over study so each participant will have 3 control days without intervention and 3 intervention days with stretching exercise.
9692902|NCT04806516|Experimental|Summit RC+S DBS Implant for OCD|All subjects will receive surgical implantation of RC+S DBS system with ECoG paddles
9692903|NCT04806516|Experimental|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
9692904|NCT04806529|Experimental|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|The experimental group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
9692905|NCT04806529|Placebo Comparator|The Comparator Group - Placebo|The comparator group will receive a 2-dose series of 0.5 mL of the study vaccine, administered intramuscularly (IM) into the deltoid muscle, preferably in the non-dominant arm, Day 1 and Day 29 (e.g. 28 days apart)
9692906|NCT04806464|Experimental|Single Arm|"Part1:~1.0*10^8 PFU on Day 1~1.0*10^8 PFU on Days 1 to 2~1.0*10^8 PFU on Days 1 to 3~1.0*10^8 PFU on Days 1 to 4~1.0*10^8 PFU on Days 1 to 5~Part2:~Depends on the recommended dose in Part1"
10181671|NCT03781232|Experimental|RSP-09-01|Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
9692907|NCT04806425|Active Comparator|IL group|receive 1.5 ml /kg intralipid 20% through Central venous line after sternotomy over 1 hour
9692908|NCT04806425|Placebo Comparator|NS group|recieve 1.5 ml /kg normal saline 0.9% through central venous line after sternotomy over 1 hour
9692909|NCT04806841|Experimental|Intervention group|Participants will have access to 4 weekly supervised training sessions for 3 months. The intervention group will also take part in 3 group meetings (behavioral intervention) and will receive follow-up phone calls from month 4 to 6.
9692910|NCT04806841|Experimental|Control group|Participants will have access to 4 weekly supervised training sessions for 3 months without any behavioral intervention.
9692911|NCT04806685|Experimental|Intervention|Diet therapy plus sleep education
9692912|NCT04806685|Other|Control|Diet therapy
9692913|NCT04806490||Chinese participants with Yin Deficiency Syndrome|"The participants with Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
9692914|NCT04806490||Chinese participants without Yin Deficiency Syndrome|"The participants without Yin Deficiency syndrome were included in this study. Chinese Medicine Experts evaluated the main symptoms of Yin Deficiency syndrome, diagnosed those participants.~And the participants were measured by the standard scale for syndrome differentiation of Yin Deficiency syndrome. The participants were followed up for 12 months to observe whether there were any manifestations of Yin Deficiency syndrome during the observation period."
9692915|NCT04806321|Experimental|Project SOLVE|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents solve, rather than be overwhelmed by, everyday problems. The program includes: (1) An introduction to problem solving; (2) Testimonials from valued others (older adolescents; celebrities) describing their use of problem solving skills; (3) Evidence from studies that our brains are capable of problem solving and that problem solving can be helpful; and (4) Activities designed to enable adolescents to practice sequential problem solving using a few steps (SOLVE Steps)."
9692916|NCT04806321|Active Comparator|Project SUCCESS|"This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents improve their study skills. This program includes: (1) An introduction to study skills; (2) Testimonials from valued others describing their use of study skills; (3) Description of helpful and commonly used study skills (e.g., note-taking); and (4) Activities designed to encourage adolescents to practice these skills in their daily lives."
9692917|NCT04806204|Experimental|music therapy before the angiography|Patients in the Intervention 1 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes before the CAG procedure. Since individuals are in the CAG unit collectively before the procedure, headphones will be used in order not to disturb other individuals. After the interviews, musical types will be arranged as instrumental, non-verbal, at 70 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice. Instrumental works will be uploaded to the portable MP3 player provided by the researchers.
9692918|NCT04806204|Experimental|music therapy during the angiography|Patients in the Intervention 2 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the CAG hall during the CAG procedure. After the interviews, musical types will be arranged as instrumental, non-verbal, 75 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice.
9692919|NCT04806204|No Intervention|control group|After the polyclinic controls of the patients, on the day of the CAG procedure, data collection forms will be applied in the CAG unit 30 minutes before the procedure. Routine care will be applied to patients in this group and music therapy will not be applied. The physiological parameters of the patient will be measured by the clinical nurse 15 minutes after the procedure, and data collection forms will be applied again 20 minutes later.
9692920|NCT04806438|Active Comparator|Group A (nebulized lignocaine group)|Patients will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
9692921|NCT04806438|Active Comparator|Group B (nerve block group)|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice.
9692922|NCT04806126||Virtual Mentoring Program Participants|Physicians credentialed at Satellite Healthcare will be eligible to participate along with nephrology fellows from training programs affiliated with credentialed physicians.
9692923|NCT04806230||Observed|
9692924|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - telemedicine before face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone telemedicine consultation before face-to-face evaluation
9692925|NCT04806477|Active Comparator|Adult patients with respiratory tract symptom - only face-to-face evaluation|We included adults (≥18 years of age) who had at least one acute symptom compatible with Respiratory Tract Infection (sore throat, nasal obstruction, coryza, new or growing cough, sputum, hoarseness, dyspnea) with or without symptoms related to the infection (fever ≥ 38oC, chills, sweating, myalgia) who have undergone only face-to-face evaluation
9827616|NCT02462057|Active Comparator|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
9692926|NCT04806152|Experimental|Sarcopenia and combined-modality high intensity supervised exercise training|Participants were given Treadmill exercise training, lower extremity progressive resistance training using a Cybex leg press machine, and a 1-hour adaptive physical activity (APA) programme in which participants were required to walk for 12 minutes through an obstacle course in which they must clear 10 cm high boards, climb 3 steps and walk sideways through hula-hoops placed on the floor all the while dual-tasking i.e. waving at strategically placed signs, conversing while walking and picking up objects. Participants also performed exercises at the parallel bars which included weight-shifting from leg to leg and half-squatting; they were also guided through seated upper- and lower-limb stretching exercises for range of motion and trunk mobility. All exercise sessions were supervised by physiotherapists. For two of the weekdays on which participants did not attend supervised training, they were asked to walk for 30 minutes at home and perform the APA exercises described above.
9692927|NCT04806152|Active Comparator|Sarcopenia and 'usual care' unsupervised exercise|Participants were required to do 5-12 chair rises and also 30-minutes walking 5 days per week. Upper limb and trunk flexibility exercises were also taught.
9692928|NCT04806373|Placebo Comparator|Talc Slurry Pleurodesis (TSP) plus placebo|Patients who sign informed consent may be randomized to receive TSP alone (talc, 5 gm in 50 ml NS) with placebo (50 ml Normal saline (NS)) through the chest pleural catheter.
9692929|NCT04806373|Experimental|Talc Slurry Pleurodesis (TSP) plus Cathflo Activase|Patients who sign informed consent may be randomized to receive TSP (Talc, 5mg in 50ml Normal saline (NS)) with cathflo activase (4 mg in 50 ml NS) through the chest pleural catheter
9692930|NCT04806256|Experimental|CDSS group|Subjects' treatment regimens were influenced by the CDSS, which was the recommended system for Tradictional Chinese Medicine treatment of dry eye.
9692931|NCT04806256|Active Comparator|non-CDSS group|The treatment of the subjects was routine and not affected by the CDSS for Tradictional Chinese Medicine.
9692932|NCT04806178|Active Comparator|BCG intradermal vaccine|Intradermal BCG Group (n=16): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
9692933|NCT04806178|Placebo Comparator|Placebo|Placebo group (n = 16): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
9692934|NCT04806009|Experimental|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program. The MLWI Intervention was developed and presented by the Principle Investigator (PI) who is a psychiatrist and have completed the Training of Mindfulness Facilitation (TMF) program at the Mindful Awareness Research Center of University of California, Los Angeles.
9692935|NCT04806009|Active Comparator|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|Participants in the Control Group will receive CBT-I after follow the WeChat mini-program. The CBT-I was developed and presented by a researcher who is a psychiatrist/psychologist and have many years' experiences in CBT.
9692936|NCT04806191|Experimental|Intervention|Patients will be assessed by GPs who have attended an outreach workshop and trained at using an evidence based strategy for shoulder examination and treatment. GPs will have access to a decision support tool and patients is offered a tailored information package for self management.
9692937|NCT04806191|Active Comparator|Treatment as usual (TAU)|The participants enrolled in the control period will receive treatment as offered in general practice.
9692938|NCT04806243|Experimental|Carelizumab Combined With Regorafenib arm|
9692939|NCT04805788|Experimental|Treatment (SBPT)|Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
9692940|NCT04805931|No Intervention|Control|Will receive a text message with standard messaging used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
9692941|NCT04805931|Experimental|Scarcity|Will receive a text message with a behavioral scarcity message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
9692942|NCT04805931|Experimental|Social good|Will receive a text message with a behavioral social good message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
9692943|NCT04806113|Other|Vaccine|Study participants (People with rheumatic diseases and age matched controls).
9692944|NCT04805736|Experimental|Microwave Ablation alone|Microwave Ablation+ Breast Surgery
9692945|NCT04805736|Experimental|Camrelizumab alone|Camrelizumab+ Breast Surgery
9692946|NCT04805736|Experimental|Microwave Ablation & Camrelizumab|Microwave Ablation + Camrelizumab + Breast Surgery
9692947|NCT04806139|Experimental|Intervention Group - Remote Enhance Fitness|Participants assigned to the intervention group will participated in a 16-week remote exercise intervention. Following a home/space environment and technology needs assessment, participants will attend a one-on-one orientation and practice class with a research assistant. Participants will join a live-streamed, instructor-led group Enhance Fitness exercise session for 1-hour, 3 days/week for 4 months (16-weeks).
9692948|NCT04806139|No Intervention|Waitlist Control|Participants randomized to the waitlist control group will be offered the opportunity to participate in the Remote Enhance Fitness class after study measures are completed. Cuff weights will be provided along with technical orientation, support, and equipment as needed.
9692949|NCT04805775|Active Comparator|Desflurane Inhalant Product Group|Anesthesia maintenance: desflurane inhalation (mac1.0-1.2) sufentanil 0.3-0.5 μ g / (kg · h) atracurium CIS benzenesulfonate 1-3 μ g / (kg · min)
9692950|NCT04805775|Experimental|Propofol Group|Anesthesia maintenance: propofol TCI: 3-4ug / ml sufentanil 0.3-0.5 μ g / (kg · h) cisatracurium besylate 1-3 μ g / (kg · min)
9696401|NCT04767295|Experimental|Camrelizumab, Albumin Paclitaxel, Carboplatin|"ESCC participants in this study will be given intravenous administration of Camrelizumab (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration.~Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment."
10181672|NCT03781232|Experimental|RSP-09-02|Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
10181673|NCT03781349|Active Comparator|MENS|MENS are applied through placement of six electrodes (size of 4x4cm), of which four were placed exactly like the TENS electrodes and the other two, one in the palm and the other at the height of the asteroid ganglion. Duration of the intervention was 24 min for a total of 15 sessions. The frequency was 50 Hz and the intensity was 100 μA.
9692951|NCT04805723|Experimental|Patients with pulmonary nodule scheduled VATS|"Patients with pulmonary nodule scheduled VATS were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
9692952|NCT04805723|Experimental|Patients with pulmonary nodule scheduled thoracotomy|"Patients with pulmonary nodule scheduled thoracotomy were included in this study. Inclusion and exclusion criteria were considered.~Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery."
9692953|NCT04806061|Experimental|sodium bicarbonate|iv sodium bicarbonate 8.4%
9692954|NCT04806061|Experimental|control|standard care
9692955|NCT04805801||Hemophilia A with FVIII inhibitors|Hemophilia A patients with FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
9692956|NCT04805801||Hemophilia A without FVIII inhibitors|Hemophilia A patients without FVIII inhibitors will administer Emicizumab at a loading dose of 3 mg/kg/week SC for the first 4 weeks of treatment followed by 1.5 mg/kg QW SC or 3mg/kg Q2W or 6mg/kg Q4W
9692957|NCT04805957|Experimental|Treatment|All subjects will receive 1.47umol/kg/day sulforaphane for 12 weeks. Pills are taken once a say with a meal.
9692958|NCT04805944||DTG treated (A)|80 HIV-infected adults treated with dolutegravir (as a component of their usual provider-prescribed antiretroviral regimen)
9692959|NCT04805944||BIC treated (B)|30 HIV-infected adults treated with bictegravir (as a component of their usual provider-prescribed antiretroviral regimen)
9692960|NCT04805944||DTG discontinued due to neuropsychiatric adverse event (C)|50 HIV-infected adults having stopped dolutegravir due to neuropsychiatric adverse effects (insomnia, depression, anxiety)
9692961|NCT04805944||Shifting to DTG (D)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing dolutegravir
9692962|NCT04805944||Shifting to BIC (E)|20 virally controlled and immunologically functional HIV-infected adults shifting (as per standard care) from another ARV class to an antiretroviral regimen containing bictegravir
9692963|NCT04805814|Active Comparator|Intervention Group|All randomised participants will receive stratified medicine. The subjects will undergo stress perfusion CMR as an adjunct to invasive coronary angiography. The CMR results will be disclosed to the clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and CMR findings.
9692964|NCT04805814|Sham Comparator|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also undergo stress perfusion CMR but the results will not be disclosed. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and CMR findings.
9692965|NCT04805866||Healthy Age-matched controls|Healthy individuals ages 18-85
9692966|NCT04805866||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-85
9692967|NCT04805749|Experimental|Osteopathic manipulation|Spinal Mobilisation / Cranial Osteopathy therapy / Circulatory Techniques / Visceral osteopathic therapy
9692968|NCT04805905||Skin graft|
9692969|NCT04805905||Local flap|
9692970|NCT04805827|Experimental|Gabapentin|1 tablet contains 600 mg Gabapentin
9692971|NCT04805827|Active Comparator|Neurontin|2 capsule contains 2*300 = 600 mg Gabapentin
9692972|NCT04805710|No Intervention|clopidogrel combined with aspirin arm|Patients selected in the clopidogrel combined with aspirin arm will receive clopidogrel 75 mg once daily and aspirin 100 mg once daily.
9692973|NCT04805710|Experimental|clopidogrel combined with rivaroxaban arm|Patients selected in the clopidogrel combined with rivaroxaban arm will receive clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily.
9692974|NCT04805684|Active Comparator|lung ultrasound 12|12 zone lung ultrasonography protocol
9692975|NCT04805684|Active Comparator|lung ultrasound 14|14 zone lung ultrasonography protocol
9692976|NCT04805697|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
9692977|NCT04805697|Experimental|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
9692978|NCT04805853||type 2 diabetes without polycystic ovary syndrome|The treatment of type 2 diabetes is based on the Chinese Medical Association Diabetes Branch '2017 China Type 2 Diabetes Prevention Guidelines' for lifestyle adjustment and diabetes drug treatment.The research physician decides the diabetes treatment measures of the research object; the blood sugar control goal is that glycosylated hemoglobin is less than 7%.
9692979|NCT04805853||polycystic ovary syndrome without type 2 diabetes|The treatment of polycystic ovary syndrome is based on the '2018 Polycystic Ovary Syndrome Chinese Diagnosis and Treatment Guidelines' by the Endocrinology Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association and the Guide Expert Group '2018 Polycystic Ovary Syndrome Expert consensus on diagnosis and treatment of endocrinology' for lifestyle and drug treatment.
9692980|NCT04805853||polycystic ovary syndrome with type 2 diabetes|Treatment is as above.
9692981|NCT04805619|Experimental|Arm 1|Patients with long or very long lesions (≥ 30 mm) in native coronary arteries.
9692982|NCT04805645||Non-Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit which died before or on day 28 post ICU admission
10181674|NCT03781349|Active Comparator|TENS|TENS are applied through the placement of four electrodes on either side of the deltoid muscle, on the front and back surfaces of the shoulder joint for 20 min and each patient received 15 sessions (five per week). A constant current of high frequency was used (100 HZ) and its intensity was initiated at 10mA and was then gradually increased to 15mA
9692983|NCT04805645||Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit whom are still alive on day 28 post ICU admission
10181675|NCT03781063|Experimental|Lasofoxifene|5 mg/d of oral lasofoxifene
10181676|NCT03781063|Active Comparator|Fulvestrant|500 mg fulvestrant intramuscular (IM)
9692984|NCT04805476|Experimental|Non invasive mechanical ventilation|The subjects in the immediate intervention group (GI) will be extubated and placed in NIV the moment they enter the recovery room through a portable ventilator (Esprit ® or BiPAP Vision ®, Respironics) in face mask. The parameters will be adjusted as follows: FiO2 = 50%, positive expiratory pressure (EPAP, starting at 4-6 cmH2O and adjusting 1-2 cmH2O to avoid snoring, apnea, paradoxical breathing and desaturations) and adjusted inspiratory positive pressure (IPAP) to maintain a tidal volume of 400 to 500 ml, maintaining IPAP <15cmH2O17. Individuals will receive this ventilatory support for 1 hour. After this period the patients will be submitted to the same care of GP patients.
9692985|NCT04805476|Active Comparator|Usual care|Subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to the team routine and patient need.
9692986|NCT04805463|Experimental|control group|After gingivectomy and released into the secondary wound healing gingivoplasty group.
9692987|NCT04805463|Experimental|PRF group|The group in which PRF was applied to the wound surface after gingivectomy and gingivoplasty.
10181677|NCT03781206|No Intervention|Standard of Care (SOC)|After stoma reversal, patients of SOC group will be treated as for normal clinical practice, using a simple adhesive wound dressing.
9692988|NCT04805463|Experimental|CGF group|The group in which CGF was applied to the wound surface after gingivectomy and gingivoplasty.
9692989|NCT04805463|Experimental|AFG group|The group in which AFG was applied to the wound surface after gingivectomy and gingivoplasty.
9692990|NCT04805450|Active Comparator|ES before SEMS placement|ERCP with ES before biliary fully covered SEMS placement.
9692991|NCT04805450|Active Comparator|no ES before SEMS placement|ERCP without ES before biliary fully covered SEMS placement.
9692992|NCT04805437|Experimental|3D TLSO|A 3-dimensional Boston brace will be designed to the patient's individual type of scoliosis. In-brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
9692993|NCT04805437|Active Comparator|Standard TLSO|A standard Boston brace will be designed to the patient's individual type of scoliosis. In brace radiographs will be performed after prescription. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. Patients are encouraged to use the brace for 20 hours per day and to also continue with physical activities for the entirety of the study. Compliance will be monitored with a heat sensor built in the brace that measures wearing time.
9692994|NCT04805346|Experimental|Therapeutic Group|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada). The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol).
9692995|NCT04805346|No Intervention|Control Group|A control group will undergo a similar procedure, but the cuff will not be inflated.
9692996|NCT04805554|Experimental|Joint Insights Decision Aid|Participants view the entire Joint Insights decision aid for knee osteoarthritis including: Education Module with information about knee osteoarthritis and risks and benefits of various treatment options, Preferences and Values elicitation questions, and Personalized Risk/Benefit Report.
9692997|NCT04805554|Active Comparator|Education Module Only|Participants view the Joint Insights Education Module only
9696402|NCT04767477|Other|Face-to-face rehabilitation and Telerehabilitation|The Face-to-face rehabilitation and Telerehabilitation protocol will consist of flexibility exercises, aerobic and resistance training, with two sessions per week.
10181678|NCT03781206|Experimental|Negative Pressure Wound Therapy (NPWT)|PICO™ 7 will be applied after stoma reversal
10181679|NCT03781167|Experimental|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 52 weeks.
9692998|NCT04805372|Experimental|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
9692999|NCT04805372|Placebo Comparator|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
9693000|NCT04805333|Experimental|Dose 1 - 450mg Artemisia annua|Participants in this group will consume 1 cup of decaffeinated coffee (450 mg Artemisia annua).
9693001|NCT04805333|Experimental|Dose 2 - 900mg Artemisia annua|Participants in this group will consume 2 cups of decaffeinated coffee (900 mg Artemisia annua).
9693002|NCT04805333|Experimental|Dose 3 - 1350mg Artemisia annua|Participants in this group will consume 3 cups of decaffeinated coffee (1350 mg Artemisia annua).
9693003|NCT04805333|Experimental|Dose 5 - 1800mg Artemisia annua|Participants in this group will consume 4 cups of decaffeinated coffee (1800 mg Artemisia annua).
9693004|NCT04805333|Experimental|Dose Expansion - Recommended Phase II Dose|This cohort will be an expansion of 6 patients for further tolerability and secondary endpoints analysis. They will consume the recommended phase II dose (dependent on prior analysis).
9693005|NCT04805606|Experimental|Sequence 1|CKD-843 A - 27mg, Single Dose
9693006|NCT04805606|Experimental|Sequence 2|CKD-843 A - 45mg, Single Dose
9693007|NCT04805606|Experimental|Sequence 3|CKD-843 A - 56mg, Single Dose
9693008|NCT04805606|Experimental|Sequence 4|CKD-843 B - 45mg, Single Dose
9693009|NCT04805606|Active Comparator|Sequence 5|CKD-843-R
9693010|NCT04805515|Experimental|Nicotine Corrective Messages|Participants in the nicotine corrective messages condition will receive 8 brief nicotine corrective public education messages delivered online during 4 waves of the 12 week study. The messages will communicate misperceptions about nicotine's role in health harms as well as misperceptions that reduced nicotine content cigarettes are less harmful than tobacco cigarettes and that e-cigarettes contain less nicotine than tobacco cigarettes.
9693011|NCT04805515|No Intervention|Delayed Message Control|Participants in the control condition will be exposed to the nicotine corrective messages after the completion of the final assessment at the end of the 12 week study.
9693012|NCT04805580|Active Comparator|intrathecal block|patients (25) will receive unilateral intrathecal block using 1.5 ml of hyperbaric bupivacaine
9693013|NCT04805580|Active Comparator|Quadratus lumborum block|patients (25) will receive quadratus lumborum block by an anterior approach using 30 ml of bupivacaine 0.25%
9693014|NCT04805359|Experimental|Normoxic exercise (NE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 21%O2 in air (NE) for 30 minutes per day, 5 days per week for 6 weeks
9693015|NCT04805359|Experimental|Hypoxic exercise (HE)|The subjects were trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax) under 15%O2 in air (HE) for 30 minutes per day, 5 days per week for 6 weeks
9693016|NCT04805359|No Intervention|Normoxic control|Without any exercise training
9693017|NCT04805203|Other|blood samples|4 blood samples per patient maximum (at diagnosis of covid19, during intensive care if applicable, at revecory of covid 19 and 6 months after recovery.
9693018|NCT04805567||Patients with polyps and adenomas|The inclusion criteria are: (i) CRC screening; (ii) post-polypectomy surveillance; (iii) diagnostic assessment (anemia, lower gastrointestinal bleeding, abdominal pain, recent change in bowel habits); and (iv) age over 50 years.
9693019|NCT04805229||Patients undergoing surgery|Retrospective cohort of patients who underwent surgery between 1/1/13 to 12/31/19 and were sampled from the Truven Health MarketScan Database.
9693020|NCT04805268|Experimental|One subject with possible Luft's disease|18F-FDG will be administered I.V., approximately 1 hour prior to PET/CT scan.
9693021|NCT04805281|Active Comparator|Lithium Disilicate IPS e.max crowns in posterior teeth|
9693022|NCT04805281|Experimental|Monolithic Zirconia (5Y-TZP/3-YTZP) crowns in posterior teeth|
9693023|NCT04805242|Active Comparator|Dextrose prolotherapy groups|In the first group, dextrose prolotherapy injection will be applied.
9693024|NCT04805242|Sham Comparator|Saline groups|In the second group, physiological saline injection will be applied.
9693025|NCT04805073|Experimental|Promethazine|The treatment will consist of a blinded syringe of 1cc clear liquid 25mg/ml Promethazine
9693026|NCT04805073|Placebo Comparator|Placebo|The treatment will consist of a blinded syringe of 1cc 0.9% Sodium Chloride
9693027|NCT04805034||HBeAg positive/HBsAg positive|
9693028|NCT04805034||HBeAg seroconversion /HBsAg loss|
9693029|NCT04804956||Early-rectal cancer|The patients to be included in this group will be those with Stage I (initial tumor stage). The tumors classified in stage I will be tumors in which the invasion of the submucosa and / or the invasion of the muscularis propria occur. This group will include patients diagnosed preoperatively with tumor stage T1-T2 N0.
9693030|NCT04804956||Advanced-rectal cancer|The patients to be included in this group will be those with Stages II and III, that is, advanced tumors at the time of preoperative diagnosis. Tumors included in this group invade the perirectal fat and / or the surface of the visceral peritoneum and / or invade or adhere to adjacent organs or structures. In addition, any tumor stage with lymph nodes without distant metastases will be included in this group.
9693031|NCT04804956||Synchronous metastasis -rectal cancer|The patients to be included in this group will be those with Stage IV (disseminated tumor stage) in the initial study of the disease. Patients with distant metastases in one organ or more than one organ will be included.
10181680|NCT03780998||Group-1 (n: 50): Healthy cases|Control group
9693032|NCT04805086|Experimental|MON002|Minimum of 1x10~7 cells to maximum of 2x10~6 cells/kg. Single infusion.
9693033|NCT04804943|Experimental|NOA-001 group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
9693034|NCT04804943|No Intervention|Standard treatment group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard therapy.
9693035|NCT04804943|Experimental|NOA-001 group (ARDS caused by COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
9696403|NCT04767217|Active Comparator|artemether-lumefantrine (ALN)|
9696404|NCT04767217|Active Comparator|dihydroartemisinin-piperaquine (DHA-PPQ)|
9693036|NCT04804878||Biospeciman Repository and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
9693037|NCT04804995||Heathy participants|
9693038|NCT04804995||migraine patients|
10181681|NCT03780998||Group-2 (n:50): Grade 1 hemorroid|With perianal examination diagnosed of grade 1 hemorroidal disease
9693039|NCT04804852||study population|Patient diagnosed with head & neck carcinoma at diagnosis
9976317|NCT01350310|Active Comparator|Ischemic heart disease|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure
9976318|NCT01350323|Active Comparator|Type 3 NV|Wet-AMD related type 3 neovascularization
9693042|NCT04805164|Experimental|Innovative strategy|usual medical and surgical care with corticotomy and use of a bone substitute (Cerament-G) delivering gentamicin locally (± skin and soft-tissue/muscle flap) and antibiotic therapy.
9693043|NCT04805164|Active Comparator|Reference strategy|Medico-surgical usual care with corticotomy (± skin and soft-tissue/muscle flap), and antibiotic therapy.
10181682|NCT03780998||Group-3 (n:50): Grade 2 hemorroid|With perianal examination diagnosed of grade 2 hemorroidal disease
9693044|NCT04805060|Experimental|TQB2858 injection|TQB2858 administered intravenously (IV) once every 3 week
9693045|NCT04805112|Experimental|Provision of multiple self-tests|Participants randomized to the intervention group will be given 2-3 HIV oral self-tests to offer to their sexual partner(s). The participant will be instructed to encourage their partner to test himself alone [partner testing] or with the participant [couple testing]; the partner will also be given a card with information on testing and a list of facilities where he can go for confirmatory testing. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
9693046|NCT04805112|No Intervention|Referral vouchers for clinic testing|Participants randomized to the control group will be given multiple referral coupons for HIV testing at pre-selected HIV testing services (HTS) sites. The participant will be instructed to give the coupon to their sexual partner(s) and encourage him to go for HIV testing at pre-selected HTS sites, either alone [partner testing] or together with the participant [couple testing]. The coupon will also have information on testing and a list of facilities where he can go for HTS. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
9693047|NCT04804917||Participants in the MindMyMind RCT|"The study participants comprise the 396 youths (and their parents) who participated in the Mind My Mind RCT. The study participants were randomized to the experimental MMM intervention (n=197) or MAU (n=199) and followed in the trial until 26 weeks after randomization, from September 7, 2017, to August 28, 2019.~The MMM consisted of 9-13 weekly, individual therapy sessions. The CBT methods were organized in modules for anxiety, depression and behavioral problems. Flowcharts described the sequencing and dosing of modules to match the problems at hand. The therapy was completed within 17 weeks, followed by a booster session after four weeks.~The MAU was enhanced by two care-coordination visits (week 2 and 17). The MAU interventions included anonymous counseling, pedagogical advice, network meetings, educational support, psychological treatment, or no treatment."
9693048|NCT04804865||population|"The population includes adult patients.~Patients died from refractory or relapsed diffuse large-cell lymphoma.~Patients <65 years of age eligible for an autologous transplant should have relapsed after the autologous transplant.~Patients >65 years of age or not eligible after an autologous transplant must have received at least one RCHOP-type treatment line (2 cycles)."
9976319|NCT01350323|Active Comparator|Type 2 NV|Wet-AMD related type 2 neovascularization
9693050|NCT04804618||Healthy control group|aged ≥55 years old, no dementia, MCI or no family history of AD.
9693051|NCT04804618||Alzheimer's disease high-risk group|aged ≥55 years old, immediate family members of AD patients
9693052|NCT04804618||Alzheimer's disease group|aged ≥55 years old, diagnosed as AD patients
9693053|NCT04804618||Mild cognitive impairment group|patients ≥55 years of age, diagnosed with MCI
9693054|NCT04804683|Other|Cohort of patients with Fibromuscular Dysplasia|Intervention consists in blood/urine sampling
9693055|NCT04804501|Experimental|Blue Light Glasses (experimental)|These subjects will wear the device (glasses) while performing a reading task.
9693056|NCT04804501|Other|No Glasses (control)|These subjects will not wear the device (glasses) while performing a reading task.
9696405|NCT04767438||Pregnant women|All singleton pregnancies that present to the 12-week scan in the Obstetrics Unit of the participant hospitals. Singleton pregnancies; Gestational age less than 14 weeks, estimated according to Crown-Rump Length (CRL); Blood sample between 8 and 14 weeks of pregnancy; Patients who accept to participate in the study and sign the informed consent.
10181683|NCT03780998||Group-4 (n:50): Anal fissure cases|With perianal examination diagnosed of anal fissure cases
10181684|NCT03780998||Group-5 (n:50): Simple perianal fistula|With perianal examination diagnosed of uncomplicated, simple perianal fistula cases
10187563|NCT03725046|Experimental|Optimized information transmission after ED admission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
9693057|NCT04804631||Gastrostomy tube|Prophylactic gastrostomy placed prior to bone marrow transplant.
9693058|NCT04804631||Nasogastric tube|Nasogastric tube placed during admission.
9693059|NCT04804410|Experimental|Dielectric Properties of Tissue Samples from Thoracic Malignancies and Corresponding Normal Tissues|Our plan is to analyze 3-5 tissue probes acquired from 30 patients with a variety of thoracic malignancies. The investigators will plan to acquire tissue from each type of malignancy including: lung cancer, esophageal cancer and pleural based tumors. Tissue will be acquired in the operating room. Impedance measurements will be collected on multiple sections of excised tissue and will be translated into dielectric properties. After acquisition of data, the investigators will assess the data and continue to acquire patients to obtain significant estimates of overall tissue properties in each type of tumor. After undergoing an informed consent process in accordance with IRB approval, patients with be formally enrolled. All tumor electric property data will be stored securely and remain anonymous of patient identifying data.
9693060|NCT04804670|Experimental|Sonic-Floss toothbrush and small brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
9693061|NCT04804670|Experimental|Sonic-Floss toothbrush and full size brush head|sonic toothbrush used for 2 minutes and water flosser used for 1 minute
9693062|NCT04804670|Active Comparator|Manual brushing and flossing|American Dental Association standard manual toothbrush used for 2 minutes and dental floss all teeth
9693063|NCT04804657|Active Comparator|Sage extract|Two hours before the endurance test, participants were asked to absorb two capsules of sage extracts (600mg each - cognivia™)
9693064|NCT04804657|Placebo Comparator|placebo|Two hours before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance than active comparator).
9693065|NCT04804696|Experimental|TPC treatment|Neoadjuvant treatment of toripalimab, paclitaxel and cisplatin
9693066|NCT04804397|Experimental|Sucrose|Sucrose: 1l sucrose sweetened soft drink per day for 8 weeks (1650 KJ, 97g carbohydrate per day) as 4 25cl drinks
9693067|NCT04804397|Placebo Comparator|Aspartame|Aspartame: 1l aspartame sweetened soft drink per day for 8 weeks as 4 25cl drinks
9693068|NCT04804449||Rheumatoid arthritis and psoriatic arthritis|Patients with rheumatoid arthritis or psoriatic arthritis, who require an intra-articular corticosteroid injection
9693069|NCT04804423|Active Comparator|Fluoride varnish (Duraphat®)|Fluoride varnish application is recommended by the German National Health System for managing hypersensitivity and dental caries. Sodium fluoride varnish (Duraphat®) will be applied on hypersensitive active carious lesions (ICDAS 5).
9693070|NCT04804423|Experimental|Silver fluoride and potassium iodide (Riva Star®)|Silver fluoride and potassium iodide (Riva Star®) is primarily indicated for relieving hypersensitivity will be applied on hypersensitive active carious lesions (ICDAS 5) following isolation of the affected teeth and according to manufacturer's instructions.
9693071|NCT04804475|Active Comparator|Training Group|Throughout 3 weeks SSE training was administered 4 days a week for a length of 45 minutes in each session. All the analyses were conducted at the start and at the end of 3-week long training.
9693072|NCT04804475|No Intervention|Control Group|This group has no intervention. Evaluations were only made at the start and at the end of 3-week long.
9693073|NCT04804462|Experimental|Virtual Reality Meditation for Fatigue|Participants will experience Virtual Reality Meditation in the comfort of their own home.
9693074|NCT04804761|Experimental|Real EA group|
9693075|NCT04804761|Sham Comparator|Sham EA group|
9693076|NCT04804436|Experimental|Patients with nephrolithiasis|The real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
9693077|NCT04804436|Experimental|Healthy control group|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
9693078|NCT04804384|Experimental|Experimental|
9693079|NCT04804280||Preterm children (PT)|"gestational age at birth: 26+0 to 31+6 weeks;~absence of documented neurological pathology;~absence of sensory deficits;~absence of malformative syndromes and/or major malformations."
9693080|NCT04804280||Full-term children (FT)|"gestational age at birth ≥ 37 weeks;~birth weight ≥ 2,500g;~APGAR 5' ≥ 7~delivery without any complications for baby and/or mother;~no prenatal and/or postnatal clinical conditions;~no hospitalizations at the time of birth or postpartum;~absence of malformative syndromes and/or major malformations."
9693081|NCT04804371|Other|18F-FDG PETCT scan|18F-FDG tracer (5 MBq/kg body weight of FDG; up to 550 MBq) will be injected into the intravenous
9693082|NCT04804111|Placebo Comparator|Placebo|maintain the initial dose, without increasing the dose.
9693083|NCT04804111|Active Comparator|URC102 3mg|Administer 3 mg of URC102 for 12 weeks
9693084|NCT04804111|Active Comparator|URC102 6mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 11 Weeks.
9693085|NCT04804111|Active Comparator|URC102 9mg|Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 1 Weeks, maintain 9 mg of URC102 dose
9693086|NCT04804111|Other|Febuxostat 80 mg|maintain the initial dose, without increasing the dose.
9693087|NCT04804124|Experimental|Short Sleepers|Reported nightly sleep time of ≤6 hours
9693088|NCT04804124|Experimental|Long Sleepers|Reported nightly sleep time of ≥9 hours
9693089|NCT04804124|Experimental|Average Duration Sleepers|Reported nightly sleep time of 7-8 hours
9693090|NCT04804098|Active Comparator|15 Minute Non-linear Compression Profile|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
9976320|NCT01350323|Active Comparator|Type 1 NV|Wet-AMD related type 1 neovascularization
10181685|NCT03781284|Experimental|PET/MRI with bowel purgation|
10181686|NCT03781284|Experimental|PET/MRI without bowel purgation|
9693091|NCT04804098|Active Comparator|15 Minute Linear Compression Profile|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
9693092|NCT04804137||Group|adult patients with adenocarcinoma type non-small cell lung cancer
9693093|NCT04803968|Experimental|control group|"After the evaluations are completed, the participants will be randomly divided into two groups using a computer-assisted randomization program.~The cardiac rehabilitation program will be a total of 30 sessions, 5 days a week x 6 weeks. All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training"
9693094|NCT04803968|Experimental|intervention group|The combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.
9693095|NCT04804020|Active Comparator|NC (Natural cycle)|Performing the first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
9693096|NCT04804020|Active Comparator|mMC (modified Natural cycle)|Performing the first ultrasound scan on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
9693097|NCT04804020|Active Comparator|AC (Artificial cycle)|Preparing the endometrium by using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
9693098|NCT04804202|Other|Virtual Reality|This is a single arm study in which all participants will execute the same tasks over two sessions.
9693099|NCT04804072|Experimental|Integrated health services delivered in the mobile unit and peer navigation|Participants in the intervention arm will be provided integrated health services delivered in the mobile unit and peer navigation for 26 weeks.
9693100|NCT04804072|Active Comparator|Peer navigation to connect them to health services available at community-based agencies|Participants in the active control arm will be provided 26 weeks of peer navigation to connect them to health services available at community-based agencies.
9693101|NCT04804176|Active Comparator|5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation|The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.
9693102|NCT04804176|Active Comparator|GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation|The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS
9693103|NCT04804176|Sham Comparator|the control group|The instrument is not working, only in exhaust mode.
9693104|NCT04804215|Experimental|The experimental group in Intraductal transanastomotic stent|"Inclusion criteria~19 years old or older ~ under 70 years old~Patients eligible for liver transplantation ③ Patients who have consented to written consent~Intraductal transanastomotic stent was used during biliary reconstruction"
9693105|NCT04804215|Experimental|The controled group in non-Intraductal transanastomotic stent|"Inclusion criteria~19 years old or older ~ under 70 years old~Patients eligible for liver transplantation ③ Patients who have consented to written consent~No stent was used during biliary reconstruction"
9693106|NCT04803929|Experimental|Anti-ILT3 CAR-T cells|All subjects were intravenous administrated with anti-ILT3 CAR-T cells
9693107|NCT04803981|Experimental|Standard diet with daily SpoonfulONE|Participants will receive one serving of SO (one of three possible forms of SO: mix-ins, puffs, or crackers) daily in addition to a standard diet. The SO form fed on a given day will be at the discretion of the parent/guardian.
9693108|NCT04803981|No Intervention|Standard diet|Participants will feed on a standard diet only, with no intervention, and complete questionnaires
9693109|NCT04804189|No Intervention|Control Group|25 4-H Shooting Sport Clubs that will not receive The Reframe intervention.
9693110|NCT04804189|Experimental|Intervention Group|25 Randomized 4-H Shooting Sport Clubs that will receive The Reframe intervention.
10181687|NCT03781128|Other|LSD, Placebo|Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo
10181688|NCT03781128|Other|Placebo, LSD|Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide
10181689|NCT03781115|Experimental|Ziprasidone|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug ziprasidone (Geodon). The investigators will start with a single 20mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 40 and 60mg tablets). If Ziprasidone causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG) taken.
9693111|NCT04804267|Experimental|Experimental|Linaclotide Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
9693112|NCT04804267|Active Comparator|Active Comparator|LINZESS® Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
9693113|NCT04804267|Placebo Comparator|Placebo Comparator|Placebo Drug: Placebo orally once daily
9693114|NCT04804150|Experimental|Medical Device active or inactive|The medical device will be active, or inactive. Randomization will define when and how long time the medical device will plugged and active, and when and how long time the medical device will be unplugged and inactive. The patient won't know if the medical device is active or not
9693115|NCT04803955|Experimental|16mg,KB|Group A:16mg,Q8h±3min,Day1-Day7
9693116|NCT04803955|Placebo Comparator|Placebos|Group B:Placebos,Q8h±3min,Day1-Day7
9693117|NCT04803890|Experimental|No touch radiofrequency ablation|A total of 150 patients who have decided to participate in the study will be included, and prospective study will be performed to these patients for radio-frequency ablation using octopus electrodes, combined high-frequency transmission mode, and the 'No touch' technique.
9693118|NCT04803539|Active Comparator|Capecitabine|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day by mouth for 1 year
9693119|NCT04803539|Experimental|Capecitabine + Apatinib + Camrelizumab|Patients assigned to this group will receive oral capecitabine at a dose of 650 mg/m2 twice a day, Camrelizumab 200mg intravenously, once every two weeks (Q2W), oral apatinib, 250mg, PO, qd for 1 year
9693120|NCT04803734|Experimental|Test|Albuterol Sulfate inhalation aerosol
9693121|NCT04803734|Active Comparator|Reference|Proair HFA (albuterol sulfate) Inhalation Aerosol
9693122|NCT04803825|Experimental|Heavy Slow Exercise|One dedicated physiotherapist will supervise and instruct the exercise program on an individual basis. If the patient doesn't have access to a dumbbell, it will be offered free rental from the physiotherapy ward. Follow-up on the exercises will be scheduled as needed and tele rehabilitation will be offered as an option. Additionally to HSR exercises, participants will be instructed to perform daily stretches of the forearm.
9693123|NCT04803825|Active Comparator|Extracorporeal Shock wave therapy|The patients will receive rESWT (SwissDolodClast/EMS) once a week for three sessions. The treatment will be given by a physiotherapist trained in using rESWT. The rESWT is given on the ECRB tendon insertion area.
9693124|NCT04803825|Active Comparator|Information and advice|The information and advice group are given a single face-to-face session with a physiotherapist, lasting up to 60 minutes.
9693125|NCT04803708|Experimental|Part A- Cohort 1|8 eligible subjects with non-infected DFU will be enrolled (Cohort 1) and receive IP three times weekly (TIW) every other day for up to one week. Of these 8 enrolled subjects, 6 subjects will be randomized to TP-102 and 2 to placebo. Subjects will be followed-up for 7 days.
9693126|NCT04803708|Experimental|Part B- Cohort 2|"18 subjects with a DFU with a grade 2 or 3 infection, as per PEDIS classification, and at least one bacterial strain susceptible to bacteriophage cocktail will be included in Cohort 2. Subjects will receive IP TIW, every other day, up to four weeks and will be randomized at a 2:1 randomization rate to either:~TP-102 q.d 3x weekly up to four weeks (n=12)~Placebo q.d. 3x weekly up to four weeks (n=6)~Subjects will be followed-up for 7 days."
9693127|NCT04803682|Experimental|Prevention (ASPIRE, mentorship)|"Participants complete online ASPIRE course over 3.5-4 hours.~HIGH SCHOOL MENTORS: Eleventh grade high school students receive mentor training over 4-5 hours on how to mentor ninth grade students.~ALL STUDENTS: Mentors and mentees are paired up so that eleventh grade high school students mentor the ninth grade high school students over 30 minutes for 7 sessions about the different types of tobacco products (such as cigarettes, cigars, hookah, and so on) and the dangers of these products."
9693128|NCT04803721||Patient with a myelodysplastic syndrome|Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR=IPSS-R<4.5) or high risk (HR=Revised International P rognostic Scoring System>4.5)
9693129|NCT04803721||Control patient|Healthy blood donor (regardless of age) Or Patient >60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse), having expressed his non opposition to participate in the study
9693130|NCT04803864|Experimental|Roxadustat|Early and short-term Roxadustat treatment
9693131|NCT04803864|No Intervention|Control|Patients only receive conventional therapies as recommended by guidelines.
9693132|NCT04803617||Patient's group|geriatric patients with interstitial lung disease
9693133|NCT04803617||Control group|healthy volunteers selected from the geriatric population
9693134|NCT04803656|Other|Assesment|Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), clinical (diagnosis period) and medical status, personal history and family history, COPD stage, COPD Assessment Test (CAT) score, emergency and hospital admissions numbers in the last 3 months, exacerbation and hospitalization numbers in the last one year were recorded. Respiratory and peripheral muscle strengths are evaluated. Also pulmonary functions test results obtained.
9693135|NCT04803760||mild disability|Those whose neck disability index value is 25 and below
9693136|NCT04803760||high disability|Those whose neck disability index value is 25 and above
9693137|NCT04803799|Experimental|Experimental Arm|Training programme using Exergame as a support over a 12 week period
9693138|NCT04803851|Experimental|Treatment group|Anlotinib plus AK105
9693139|NCT04803630|Experimental|Treatment of depression (thermal therapy)|Patients undergo thermal therapy over 2.5 hours.
9693140|NCT04803773|Experimental|Experimental Arm|
9693141|NCT04803903||HPI + GDHT treatment|HPI + GDHT treatment using the FlowTraQ sensor and EV1000 monitor with the HPI algorithm incorporated following our protocol for hemodynamic treatment (fluids, vasopressors and inotropes) administered
9693142|NCT04803903||Control|Conventional treatment with invasive blood pressure monitoring. Administration of fluids and/or vasopressors are guided by standard hemodynamic parameters at the discretion of the attending physician.
9693143|NCT04803838||Patiens|Patients With symptomatic or asymptomatic carotid stenosis (> 50%, NASCET criteria)
9693144|NCT04803838||Controls|For study 1: Healthy Controls, volunters (mostly blood donors) For study 2 and 3: Spouses/someone living in the same household as the patient.
9693145|NCT04803565|Experimental|Custom-Made Insole|"This Group will receive a custom-made shoe insole designed on the foot shape of the subjects.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
9693146|NCT04803565|Sham Comparator|Sham Insole|"This group will receive a Sham shoe insole without any specific custom-made design.~The group will also receive Physiotherapy and Occupational Therapy according to current guidelines"
9693147|NCT04803578||Knee Arthroplasty Group|Subjects that received knee arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
9693148|NCT04803578||Hip Arthroplasty Group|Subjects that received hip arthroplasty 2-3 days before admission to undergo a rehabilitation period in our rehabilitation hospital.
9693149|NCT04803578||Age-Matched healthy Group|Subjects age-matched with those included in the knee and hip group. Subjects are asked to walk at their self-selected speed and at low speed matchable with those of the knee and hip group
9693150|NCT04803500|Active Comparator|Simvastatin group|simvastatin gel (1.2 mg/0.1 ml of solid lipid nanoparticles) was locally applied to fill the jumping distance.
9693151|NCT04803500|Placebo Comparator|Control group|the solid lipid nanoparticles carrier was injected into the jumping distance.
9693152|NCT04803318|Experimental|Combination treatment of 3 inhibitors|Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.
9693153|NCT04803422|Active Comparator|Arm 1- Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.~Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim."
9693154|NCT04803422|Active Comparator|Arm 2 - Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.~Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin."
9693155|NCT04803331|Experimental|cT1-2N0M0 oral cancer patients|Patients undergo routine sentinel lymph node procedure (99mTc injection, planar imaging, SPECT-CT and surgery) for clinical purposes. After 99mTc injections and imaging has been executed peritumoral SPIO injections are performed by a medical doctor. A T2*-weighted iron sensitive MRI scan is made 1 hour later.
9693156|NCT04803188|Experimental|A: patients will perform non-contrast MRI|A: 355 patients will perform non-contrast MRI regardless their serum PSA value
9693157|NCT04803188|Experimental|B: patients will perform non-contrast MRI|B: 355 patients will perform non-contrast MRI when serum PSA value is increased (>4 ng/ml or 2.5 ng/ml if positive family history)
9693158|NCT04803266|Experimental|Internal mammary node irradiation|
9693159|NCT04803266|Active Comparator|No internal mammary node irradiation|
9693160|NCT04803292||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
9693161|NCT04803292||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
9693162|NCT04803292||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
9693163|NCT04803279||Ponto 3 SuperPower users|"Patients who are fitted either unilaterlaly or bilatterally on abutment since the device came to the market in 2016, and who have follwoed the clinics normal routine fitting and follow up visits.~They must also have undergone the normal procedures performed as part of the clinics routine for fitting and following up. Data will be collected from these routine visits."
9693164|NCT04803110|Experimental|Immediate Implant with SST (SST)|Patients who will receive immediate implant placement using the Socket-Shield Technique.
9693165|NCT04803110|Active Comparator|Immediate Implant with biomaterial (GAP)|Patients who will receive immediate implant placement using bone biomaterials to fill the gap after complete extraction of the tooth.
9696493|NCT04766372|Experimental|Menu of physical activity options|"Participants in all 4 groups will receive this booklet with suggestions of ways to be physically active, e.g. YouTube workouts, cycling or jogging, sports, or design their own using a home-based exercise booklet. Participants are asked to do 3 exercise sessions of 30 minutes per week. Participants are asked to record what activity they did and the duration of the session using a method most convenient for them, e.g. notes on their phone, wall calendar or using an activity log template which we will provide.~."
10181690|NCT03781115|Experimental|Olanzapine|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug olanzapine (Zyprexa). The investigators will start with a single 2.5 mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 5, 7.5, and 10 mg tablets).If olanzapine causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG).
10181691|NCT03781115|Placebo Comparator|Placebo Comparator|The investigators have prepared a placebo which duplicates the exact color and size of the study drug capsule to use as a non-drug control.
10181692|NCT03780985|Active Comparator|intrauterine device insertion with a suture fixation|Intruterine device through hysterotomy incision during cesarean section with a suture fixation
10181693|NCT03780985|Active Comparator|intrauterine device insertion without a suture fixation|IUD through hysterotomy incision during cesarean section without a suture fixation
9693166|NCT04803162||patients with eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group. EoE patients were then treated for 8 weeks with PPs - omeprazole in the dose of 20 mg twice daily. After 8 weeks, each patient in the EoE group again passed all the tests (the protocols were identical to those used for qualifying patients to the project).
9693167|NCT04803162||patients without eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group.
9693168|NCT04803175||Sacubitril/valsartan|Patients undergoing continued treatment with sacubitril/valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
9693169|NCT04803175||Valsartan|Patients undergoing continued treatment with valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment. Dose and titration schedule will be individualized by discretion of the attending physician.
9693170|NCT04803136|Other|Bone SPECT/CT|Gamma Camera with computed tomography
9693171|NCT04803136|Other|Spine surgeries|spine stabilization and fusion surgeries
9693172|NCT04803344|Experimental|Experimental Group|After the childbirth, writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the pregnancy.
9693173|NCT04803344|Active Comparator|Control Group|
9693174|NCT04803253|Experimental|Participants using the ORTHOPUS set of prosthetic solution|
9693175|NCT04803357|Experimental|Blinded Continuous Glucose Monitoring Devise|If you are in the control group, you will wear a continuous glucose monitor with the read out screen covered so you can not see your continuous glucose level. You will be taught how to test your blood sugar by pricking your finger and using a standard blood glucose meter as per the standard of care used by your provider in the obstetrics clinic.
9693176|NCT04803396|Placebo Comparator|Placebo|Placebo was administered once a day (oad) as matching oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
9693177|NCT04803396|Experimental|50 mg DF2755A|"The experimental drug was administered once a day (oad) as one oral capsule of 50 mg.~The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions."
9693178|NCT04803396|Experimental|150 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
9693179|NCT04803396|Experimental|300 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
9693180|NCT04803396|Experimental|600 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
9693181|NCT04803487|Experimental|the Micro Hand S robot group|41 patients were randomly allocated in the Micro Hand S robot group and cholecystectomy was performed using the Micro Hand S robot.
9693182|NCT04803487|Other|the da Vinci robot group|41 patients were randomly allocated in the da Vinci robot group and cholecystectomy was performed using the da Vinci robot.
9693183|NCT04803123|Experimental|Copanilisib|
9693184|NCT04803448|No Intervention|Control|No statement is provided before asking the health care question. Example: What is your weight in pounds?
9693185|NCT04803448|Experimental|Benefit Statement|A statement of benefit will be given (see intervention) after the health question.
9693186|NCT04803448|Experimental|Risk Statement|A statement of risk will be given (see intervention) after the health question.
9976321|NCT01350323|Other|Controls|Aqueous sample (0.1ml) in patients undergoing cataract extraction
9693187|NCT04803448|Experimental|Privacy Statement|A statement of privacy will be given (see intervention) after the health question.
9693188|NCT04803448|Experimental|Benefit + Privacy statement|A statement of benefit and privacy will be given (see intervention) after the health question.
9693189|NCT04803448|Experimental|Risk + privacy statement|A statement of risk and privacy will be given (see intervention) after the health question.
9693190|NCT04803097||pediatric cataract group|Children who underwent cataract surgery and primary IOL implantation at the Eye Hospital of Wenzhou Medical University (Hangzhou, China) between 2016 and 2019 were included in the study. Every surgery included posterior capsulorhexis or capsulotomy and anterior vitrectomy. Patients accept slit-lamp-adapted anterior segmental photography at 1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
9693191|NCT04803474||Klinefelter|Patients with Klinefelter syndrome
9693192|NCT04803474||Turner|Patient with Turner syndrome
9693193|NCT04803370|Other|Control group|Standard treatment for COVID-19 (according to clinical guidelines for COVID-19).
9976322|NCT01350349|Experimental|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
10181694|NCT03781050|Experimental|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
9693194|NCT04803370|Experimental|Intervention group|Convalescent patient plasma 300 ml given in 2 consecutive days, plus standard treatment for COVID-19 (according to clinical guidelines).
9693195|NCT04803058|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
9693196|NCT04803071|Experimental|Adjuvant therapy trial group|N-3pufas improved cognitive formula adjuvant therapy intervention group
9693197|NCT04803071|Active Comparator|Adjuvant treatment control group|General fish oil formula product adjuvant treatment control group
10181695|NCT03781011|Experimental|TMAO high producer|Low carnitine/choline diet intervention
10181696|NCT03781011|Active Comparator|TMAO low producer|Low carnitine/choline diet intervention
9693198|NCT04803071|Placebo Comparator|Placebo assisted treatment control group|
9693199|NCT04803071|No Intervention|Healthy group|
9693200|NCT04803045||Follow Up Email|Patients received a follow up email 3 months after an initial consult with a physician but did not return to care.
9693201|NCT04803045||No follow up|Patients who did not receive any follow up after their initial consult, following clinic standard of care.
9693202|NCT04803032|Experimental|Superficial parotidectomy using trident landmark technique|A modified Blair incision was made along the preauricular skin crease with the same steps of the routine parotid surgery. Dissection was performed using bipolar cautery and blunt instrument; from the tragal cartilage (the anterior surface) until the bony anterior wall of the external auditory canal (EAC); from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle; it is the lower point of the landmark. The facial nerve is located in the region between these two structures.
9693203|NCT04803006|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
9693204|NCT04803006|Experimental|Arm 2|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
9693205|NCT04803006|Experimental|Arm 3|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
9693206|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70 years and older|All patients in the registry aged 70 years and older with right-sided pancreatic ductal adenocarcinoma
9693207|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 70-79 years|All patients in the registry aged 70-79 years with right-sided pancreatic ductal adenocarcinoma
9693208|NCT04802993||All patients with pancreatic ductal adenocarcinoma aged 80 years and older|All patients in the registry aged 80 years and older with right-sided pancreatic ductal adenocarcinoma
9693209|NCT04802993||All patients resected with pancreaticoduodenectomy, all ages|All patients in the registry resected with pancreaticoduodenectomy during the study period
9693210|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 70-79 years|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 70-79 years
9693211|NCT04802993||All patients resected with pancreaticoduodenectomy, aged 80 years and older|All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 80 years and older
9693212|NCT04802915|Other|epiretinal membrane group|Patient with epiretinal fibrosis confirmed by OCT with BCVA< 0,6 and complaints of metamorphopsies
9693213|NCT04802668||Circulatory failure patients|Circulatory failure patients requiring fluid responsiveness evaluation
9693214|NCT04802694|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
10181697|NCT03780972|Active Comparator|Cohort 1 Dose A|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 1
9693215|NCT04802694|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube.
9693216|NCT04802694|Active Comparator|Adhesive product|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube.
9693217|NCT04802967|Experimental|KLS-GABA (part A and B)|"KLS-GABA 80 mg-34 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules are administered with 240 mL of water.~KLS-GABA (40 mg-17mg, 80 mg-34 mg, or 160 mg-68 mg) in Part B are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.~To maintain he blind, subjects assigned to receive 160 mg-68 mg KLS-GABA are administered two co-crystal KLS-GABA 114 mg (80 mg-34 mg) capsules, and subject assigned to receive 40 mg-17 mg KLS-GABA or 80 mg-34 mg KLS-GABA also receive a placebo capsule (dummy placebo)."
9693218|NCT04802967|Active Comparator|KLS (part A and B)|"KLS 80 mg capsules are administered once in the morning of Day 1 in Part A in Treatment Periods 1 and 2 in the fasted state, according to the randomisation schedule. Capsules will be administered with 240 mL of water.~In the part B KLS (40 mg, 80 mg or 160 mg) are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water. To maintain the blind, subjects assigned to receive 160 mg KLS alone are administered two KLS 80 mg capsules and subjects assigned to receive either 40 mg KLS alone or 80 mg KLS alone also receive a placebo capsule (dummy placebo)."
10181698|NCT03780972|Active Comparator|Cohort 2 Dose B|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 2
10181699|NCT03780972|Active Comparator|Cohort 3 Dose C|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 3
10181700|NCT03780972|Active Comparator|Cohort 4 Dose D|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 4
10181701|NCT03780946||Magnetic group|Magnetic anastomosis for pancreaticojejunostomy
10181702|NCT03780946||Control group|Traditional hand-sewn for pancreaticojejunostomy
10181703|NCT03780933|No Intervention|control group|conventional treatment (corticosteroids, mechanical ventilation)
10181704|NCT03780933|Experimental|test group (vitamin C)|high dose vitamin c iv infusion
9693219|NCT04802967|Active Comparator|Gabapentin (part B)|Gabapentin 300 mg are administered as capsules once in the morning of Day 1 in the fasted state. Capsules are administered with 240 mL of water.To maintain the blind, subjects assigned to receive 300 mg gabapentin also receive a placebo capsule (dummy placebo).
9693220|NCT04802967|Placebo Comparator|Placebo (part B)|To maintain the blind subjects assigned to receive placebo receive 2 placebo capsules. Capsules will be administered with 240 mL of water.
9693221|NCT04802928|Placebo Comparator|A|Placebo tablets.
9693222|NCT04802928|Experimental|B|
9693223|NCT04803019|Active Comparator|DEB-TACE or chemoembolization with microspheres|The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F)
9693224|NCT04803019|Active Comparator|TAE or embolization with microspheres|The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F)
9693225|NCT04802850|Experimental|Real MWM|Real mobilization with movement
9693226|NCT04802850|Sham Comparator|Sham MWM|sham or placebo mobilization with movement
9693227|NCT04802785|Experimental|The study Group|"Before the flight in the conditions of the clinic's medical treatment room: Citicoline 500 mg(Vitaae®) and Cytochrome10 mg (Cytochrome C®) per os.~30 minutes before the flight: dilute 1 sachet of ORS® (Sodium Chloride 2.6 g+Potassium Chloride 1.5 g+Sodium Citrate 2.90 g+Dextrose 13.5 g) in 1 liter of water. Drink half of the solution (0.5 l) 30 minutes before the flight (at the airport). Also, 0.5 L of the solution will be provided on the plane during landing. If the flight lasts more than 1.5 hours, then dilute the second sachet of ORS® with 0.5-1 liters of water.~30 minutes before the flight (per os): Domperidone (Motilium ®) (1 tablet), Simethicone (Gas-X®) (3-4 capsules), Acetylsalicylic acid 150 mg and magnesium hydroxide 30,39 mg (Cardiomagnyl®)(1 tablet), probiotic (Bactistatin®) (1 capsule) per os."
9693228|NCT04802785|Active Comparator|Control group|Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
9693229|NCT04802785|No Intervention|Explanatory group:|12 participants without any intervention.
9693230|NCT04802876|Experimental|Spartalizumab (PDR001)|400mg/intravenous every 28 days
9693231|NCT04802889|Experimental|cadaver eyes|The Central region of the retina and preretinal structures of cadaver eyes are examined
9693232|NCT04802980|Experimental|HB002.1T + Oxaliplatin+ Capecitabine|21-24 patients with advanced gastric cancer administeredHB002.1T+ Oxaliplatin+ Capecitabine combination every 3 weeks in a 21-day cycle, total 18cycles
9693233|NCT04802980|Experimental|HB002.1T + Paclitaxel + Carboplatin|21-24 patients with advanced ovarian cancer, cervical cancer, head and neck cancer or lung cancer (not limited to the above tumor types) administered HB002.1T + Paclitaxel + Carboplatin combination every 3 weeks in a 21-day cycle, total 18cycles
9693234|NCT04802980|Experimental|HB002.1T + Gemcitabine + Cisplatin|21-24 patients with advanced biliary tract tumor, pancreatic cancer, bladder cancer or nasopharyngeal carcinoma (not limited to the above tumor types) administered HB002.1T + Gemcitabine + Cisplatin combination every 3 weeks in a 21-day cycle, total 18cycles
9696406|NCT04767308|Experimental|Arm 1|"The tolerability and safety of CT125A cells will be assessed according to the 3+3 dose escalation design. There will be three dose levels, 1×10^6, 2×10^6, and 3×10^6, CAR+T cells/kg. For each level, 1-3 subjects will be enrolled. If no dose limited toxicity (DLT) occurs, next level will be assessed for DLT. If DLT occurs in one subject, 3 more subjects will be enrolled in this cohort for the evaluation of DLT. If DLT occurs in ≤ 1/6 subjects, next level will be assessed for DLT. If DLT occurs in ≥ 2 subjects, no more subjects will be enrolled in this cohort and dose escalation will be canceled. For each cohort, following subjects can only receive CT125A infusion at least 14 days after the first subject received CT125A infusion. If DLT occurs in 2 subjects at Dose Level 1, whether to explore a lower dose will be determined by the investigator. After dose escalation phase is completed, the dose for extension phase will be determined based on safety and PK data."
9696407|NCT04767321|Experimental|LTX-109 treatment|Nasal application of LTX-109 gel 3% (w/w), 250 mikroliters in each nostril, 4 times in one day, every two hours.
9696408|NCT04767321|Experimental|Placebo|Nasal application of placebo, 250 mikroliters in each nostril, 4 times in one day, every two hours.
10181705|NCT03780842|Experimental|Invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in intubated newborns
10181706|NCT03780842|Experimental|Non-invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in newborns with non-invasive NAVA ventilation (= with a nasal interface).
9696409|NCT04767581|Active Comparator|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
9696410|NCT04767581|Placebo Comparator|Placebo|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
9696411|NCT04767412|Active Comparator|aerobic exercise|
9696412|NCT04767412|Active Comparator|aerobic exercise and inspiratory muscle training|
9696413|NCT04767204|Experimental|Peer support service|Peer support workers co-lead and assist workplace problem-solving and care skills training in an extended vocational rehabilitation program
10181707|NCT03780816||Pilot Site: Norris Cotton Cancer Center|Observation and interview protocols will be piloted at this site. The content of these observations and interviews will not be analyzed for content.
10181708|NCT03780816||Karmanos Cancer Institute|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
10181709|NCT03780816||UNC Lineberger Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
9693235|NCT04802603|Other|Radiotherapy|Cohort 1 (De novo) No Prior radiotherapy Cohort 2 (Prior radiotherapy) Prior radiotherapy
9693236|NCT04802941|Experimental|Neoadjuvant Chemotherapy by CDSS|
9693237|NCT04802941|Active Comparator|Neoadjuvant Chemotherapy in General practice|
9693238|NCT04802954|Experimental|High risk group|Patients with hepatocellular carcinoma greater than 1 cm in size. All patients from an ultrasound screening programme who have been diagnosed with a nodule larger than 1 cm and referred to our centres will be included in this group. They will then be excluded of this group if the diagnosis of hepatocellular carcinoma is not retained according to the radiological or histological reference diagnostic standards (gold standard).
9693239|NCT04802954|Experimental|Low risk group|Patients without hepatocellular carcinoma. A 1-year interval ultrasound will be performed to confirm the absence of new nodule in the year following inclusion.
9693240|NCT04802434|Experimental|Strengthening Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member, or friend) will attend weekly 3 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach cognitive compensation and mindfulness-based emotion regulation skills. Strategies from the PEERS Social Skills Program will also be taught. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
9693241|NCT04802434|Active Comparator|PEERS Social Skills Program|Adults with ASD and their study partners (i.e., spouse, parent, other family member or friend) will attend weekly 1.5 hour meetings for 16 weeks, during which, behavioral intervention strategies will be used to teach skills for improving social relationships and handling social rejection. Participants will be assigned homework assignments each week to practice skills they are learning in a real-world setting.
9693242|NCT04802434|No Intervention|Delayed Treatment Control Group|Participants in the delayed treatment control group will participate in a 10-month wait period, during which they will complete data collection procedures at three time points (Baseline, Post, and 6-month follow-up).
9693243|NCT04802369|Active Comparator|Identyfication of prognostic factors in VO2max<17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max<17 ml/kg/min
9693244|NCT04802369|Sham Comparator|Identyfication of prognostic factors in VO2max>17 ml/kg/min|Selected prognostic factors will be analyzed in patients with VO2max>17 ml/kg/min
9693245|NCT04802564|Experimental|Multisensory-based music treatment|Using a multisensory-based music treatment synchronizing with vibrotactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
9693246|NCT04802564|Active Comparator|Traditional sensory reeducation intervention|Using constant and moving tactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
9693247|NCT04802265||ILM peeling|ILM is peeled during epiretinal membrane surgery
9693248|NCT04802265||without ILM peeling|ILM is not peeled during epiretinal membrane surgery
9693249|NCT04802291|Experimental|Healthy HomeStyles|Online educational intervention addressing salient factors affecting school-age children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, irregular breakfast consumption, limited physical activity, and inadequate sleep as well as children's limited food preparation skills.
9693250|NCT04802291|Active Comparator|Safe HomeStyles|Online educational intervention addressing aspects of home safety issues, such as indoor air quality, mold & moisture, hazardous household products, carbon monoxide, home safety, foodborne illness, and refrigerator temperatures.
9693251|NCT04802252||62 patients with benign prostatic hyperplasia in the experimental group|The pulse sound waves of three parts and five layers of each of the two hands of 62 patients with benign prostatic hyperplasia were collected by acoustic pulse detection system.
9693252|NCT04802252||62 relatively healthy men without benign prostatic hyperplasia in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 62 relatively healthy men without benign prostatic hyperplasia were collected by acoustic pulse detection system.
9693253|NCT04802304|Experimental|Treatment|
9693254|NCT04802304|No Intervention|Control|
9693255|NCT04802460|Experimental|virtual reality|Patients assigned to the VR group will be engaged with the VR using a publicly available VR set. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
9693256|NCT04802460|No Intervention|control arm|Patients in the control arm will undergo standard of care office hysteroscopy. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
10181710|NCT03780816||UAB O'Neal Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
9693257|NCT04802499||persons who using telehealth (patients)|patients who have received telehealth
9693258|NCT04802499||caregivers|family member of the patients who recieved telehealth
9693259|NCT04802499||health professions|persons who use the telehealth.
9693260|NCT04802512||patients|patients who were used telehealth
9693261|NCT04802512||health professional|health professional who were used telehealth.
9693262|NCT04802525|Experimental|Moderate-intensity aerobic exercise training without dietary control group|
9693263|NCT04802525|Experimental|Low-fat diet program without exercise intervention group|
9693264|NCT04802525|Experimental|Moderate-intensity aerobic exercise training plus a low-fat diet program group|
9693265|NCT04802486|Experimental|Arm 1: Exercise Intervention and Standard Care|A home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
9693266|NCT04802486|No Intervention|Arm 2: Standard Care|Standard care for your cancer as prescribed by your oncologist
9693267|NCT04802317||Control|Health people without any respiratory diseases
9693268|NCT04802317||Bronchial asthma|Patients with asthma
9693269|NCT04802317||COPD|Patients with chronic obstructive pulmonary disease
9693270|NCT04802239|Active Comparator|calm waking group|calm waking state group
9693271|NCT04802239|Experimental|hypnosis session|hypnosis session group
9693272|NCT04802226|Experimental|optimized self-exclusion procedure A|optimized self-exclusion procedure including content optimization with brief intervention, normative feedback, motivational approach, a personal story of a peer who had a positive experience using the tool, re-contact before the end of the self-exclusion period to propose an extension of the period outside the gambling plateform
9693273|NCT04802226|Other|standard self-exclusion B|standard self-exclusion with a single neutral notification email
9693274|NCT04802213|Active Comparator|Rehabilitation exercise|1.perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)
9693275|NCT04802213|Experimental|Rehabilitation exercise + joint mobilization device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)"
9693276|NCT04802213|Experimental|Rehabilitation exercise +joint mobilization device treatment + laser acupuncture device treatment|"perform rehabilitation exercise for patients with frozen shoulders (10 repetitions of each exercise, three times a day, 3 days a week for 8 weeks)~perform joint mobilization device treatment for patients with frozen shoulders (The treatment time was total of 30 minutes. Three times a week for 8 continuous weeks.)~perform laser acupuncture device treatment for patients with frozen shoulders ( three sessions per week for 8 consecutive weeks. patients in each treatment session received laser at a dosage of 4 joules/cm2 for the eight chosen position. )"
9693277|NCT04802551|Experimental|Intervention group|
9693278|NCT04802551|No Intervention|Control group|
9693279|NCT04802278||Babies born to mothers convalescent from antenatal COVID-19|
9693280|NCT04802278||Babies born to healthy mothers|
9693281|NCT04802278||Vaccinated mothers|Lactating mothers who received COVID-19 vaccination
9693282|NCT04802187|Other|RADx CHCs testing intervention strategy|Six Massachusetts community health center partnerships implementing both a common testing expansion implementation strategy plus tailored strategies designed for community partner needs.
9693283|NCT04802187|Other|Usual care control|
9693284|NCT04802473|Experimental|Gingival recession treatment|Gingival recession treatment by means of tunnel technique and OrACell dermal matrix.
9693285|NCT04802421|Active Comparator|CPAP30|a 30 secondes 30 cmH2O continuous positive airway pressure applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
9693286|NCT04802421|Active Comparator|STEP30|a stepwise increase (+5 cmH2O) in postivie airway pressure from +5 cmH2O to +30 cmH2O and decrease (-5 cmH2O) from +30 cmH2O to +5 cmH2O applied after the orotracheal intubation will be checked and secured following induction of general anesthesia
9693287|NCT04802330||Female genital mutilation|Assessment of FGM prevalence in Beni Suef localities and its impact on studied women.
9693288|NCT04802148|No Intervention|control (natural healing)|Extraction socket is naturally healed
9693289|NCT04802148|Experimental|Test 1 (membrane guided regeneration)|Extraction socket is filled with graft (FDBA) and covered with collagen membrane
9693290|NCT04802148|Active Comparator|Test 2 (collagen plug)|Extraction socket is filled with a collagen plug
9693291|NCT04802382|Experimental|Arm 1 - CimetrA-1|a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
9693292|NCT04802382|Experimental|Arm 2 - CimetrA-2|a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
9693293|NCT04802382|Placebo Comparator|Arm 3 - Placebo|composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
9693294|NCT04802122|Experimental|Sevoflurane group|Patients in this group will receive Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) for induction to anesthesia and to facilitate endotracheal intubation (without the use of muscle relaxant) and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia plus muscle relaxant until study completion.
9693295|NCT04802122|Active Comparator|Propofol group|Patients in this group will receive a standard anesthesia induction involving Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% for induction to anesthesia and to facilitate endotracheal intubation and thereafter Sevoflurane 1 MAC will be used for maintenance of anesthesia.
9693296|NCT04801732|Experimental|mulligan group|Patients in the study group will treated with SNAGS techniques on thoracic spine with traditional treatment consist of ice application, supervised exercises (stretching and strengthening exercise) for 3 times/week for one month.
9693297|NCT04801732|Active Comparator|exercising group|will receive only traditional treatment (ice application and supervised exercise ) for 3 times/week for one month.
9693298|NCT04801823|Active Comparator|Home Introduction of Individual tree nuts|Current standard of care which is to advise families of infants diagnosed with peanut allergy to introduce tree nuts individually via a standardized, graded and cautious home introduction protocol. Day 1: smear of nut paste to the inside of lip; Day 2: 1/8 teaspoon; Day 3: 1/4 teaspoon; Day 4: 1/2 teaspoon; Day 5: 1 teaspoon. Repeat process with each individual tree nut.
9696414|NCT04767568|Experimental|Blood test|"In Cohort A: 200 patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) OR with gross bleeding~In cohort B: 200 patients who have already performed colonoscopy candidates for surgery on their colorectal tumor"
9976323|NCT01350349|Active Comparator|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
10181711|NCT03780881|Experimental|Expectation confirmation|The participants in this group receive manipulated feedback indicating that their performance was very good in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
9693299|NCT04801823|Experimental|In hospital multi-tree nut (almond, cashew hazelnut and walnut) oral food challenge (OFC)|Infant will be booked for a 4-nut butter (Almond, Hazelnut, Walnut, and Cashew) graded and supervised OFC in the allergy clinical trials unit at the Murdoch Children's Research Institute. The nut butter contains a 1g dose of each nut protein in a total weight of 20g. Doses will be administered every 15minutes (1. Smear to inside of lip, 2.1/8 teaspoon, 3.1/4 teaspoon, 4.1/2 teaspoon, 5.1 teaspoon, 6.remainder of 20g nut butter paste) If challenge negative, infants continue home introduction of tree nuts as per written instructions provided. If challenge positive, infants will have additional SPT (for full tree nut panel) and single tree nut OFC as per protocol to determine tolerance/allergic status (and +/- home introduction recommendation) for each tree nut.
9693300|NCT04801836|Experimental|Treatment Arm|Subjects will receive 15 mg E4 orally once daily for 21 consecutive days
9693301|NCT04801836|Placebo Comparator|Placebo Arm|Subjects will receive matching placebo orally once daily for 21 consecutive days.
9693302|NCT04802070|Experimental|CIK|
9693303|NCT04801875|Experimental|Violin Performers|Violin performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
9693304|NCT04801875|Experimental|Ney Performers|Ney performers received three 40-45 minute exercise sessions each week for eight weeks. The selected exercise program designed to correct postural alignment.
9693305|NCT04801914||Matrix Metalloproteinases|Value of serum matrix metalloproteinase activity before and one month after PTBD
9693306|NCT04801719|Experimental|Experimental arm - endoluminal RFA|standard treatment protocol for malignant biliary stenosis + endoluminal RFA prior metal stent insertion
9693307|NCT04801719|No Intervention|Control arm|standard treatment protocol for malignant biliary stenosis which includes metal stent insertion
9693308|NCT04801992||MINI WELL Ready (SIFI SpA, Italy)|Extended depth of focus intraocular lens implantation
9693309|NCT04801953|Active Comparator|Nimodipine|During surgery a nimodipine soaked gel foam pad is administered to the cranial nerves VII and VIII
9693310|NCT04801953|Placebo Comparator|Placebo|During surgery a sodium chloride soaked gel foam pad is administered to the cranial nerves VII and VIII
9693311|NCT04801888|Experimental|Combined immunization group|The combined immunization group is randomly divided into two subgroups, 120 subjects in each group. The combined immunization subgroup Ⅰ receive SARS-CoV-2 inactivated vaccine (Vero cell)&Quadrivalent Influenza Vaccine on day0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) on day 28.The combined immunization subgroup Ⅱ receive SARS-CoV-2 inactivated vaccine (Vero cell) on day 0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) & Quadrivalent Influenza Vaccine on day 28.
9693312|NCT04801888|Experimental|Non combined immunization group|The non combined immunization group receive SARS-CoV-2 inactivated vaccine (Vero cell)(first dose) on day 0, Quadrivalent Influenza Vaccine on day 14 and SARS-CoV-2 inactivated vaccine (Vero cell)(second dose) on day 28.
9693313|NCT04801940|No Intervention|Standard Care|Participant receives usual post-hospital care.
9693314|NCT04801940|Active Comparator|Apixaban|Intervention: Drug: Apixaban.
9693315|NCT04801940|Active Comparator|Atorvastatin|Intervention: Drug: Atorvastatin.
9693316|NCT04802005|Experimental|Aerobic interval|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure (target expenditure ~450-500kcal/session). Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity at 70-85% of predicted HRmax, and for the second period the intensity will be reduced to 60-65% of predicted HRmax for 2 minutes. The training sessions will be carried out outdoors at the trails located on campus. The activity will consist of walking and/or light jogging. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion (RPE) as needed. The RPE for the first period range will be 13-17 (15-17 at the end of the period) and 10-12 for the second period.
9693317|NCT04802005|No Intervention|Control group|Participants in the control group will not participate in the training programs.
9693318|NCT04801784|Experimental|Fluid balance neutralization|Fluid balance neutralization using increased net ultrafiltration, aiming to neutralize the cumulative fluid input received over the first 72 hours of study participation.
9693319|NCT04801784|Active Comparator|Standard care|Active control group of positive fluid balance during the first 72 hours of study participation with zero or near-zero net ultrafiltration.
9693320|NCT04801966|Experimental|Treatment|"All participants will have an individualised treatment plan. The possible treatments that can be prescribed are as follows, they may be given as a single agent or in combination~Trametinib 2 mg/day~Cobimetinib 60 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~Binimetinib 45 mg/ twice a day~Alpelisib 300 mg/day~Vemurafenib 960 mg twice a day~Dabrafenib 150 mg twice a day~Encorafenib 450 mg/day~Palbociclib 125 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~Ribociclib 600 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off~Abemaciclib 150 mg twice a day~Olaparib 300 mg twice a day~Talazoparib 1 mg/day~Nivolumab 240 mg IV once every two weeks~Atezolizumab 1200 mg IV on day 1 of a 21 day cycle~Pembrolizumab 200 mg IV on day 1 of a 21 day cycle"
9693321|NCT04802031|Experimental|Treatment (isatuximab)|Participants receive their first rapid infusion of isatuximab IV over 30 minutes. If a >=Grade 2 iRR occurs, then participants will revert to a SOC infusion time and be removed from the study. If a Grade 1 or no IRR occurs, then participants will receive another rapid infusion of 30 minutes. Participants will continue to receive RI and IRR assessment after each dose up to at least 6 doses or until a grade 2 or higher IRR occurs.
9693322|NCT04801680||Mpact 3d metal|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. The
9693323|NCT04801745|Experimental|Healthy Vegan Diet|Education on healthy vegan diet
9693324|NCT04801745|Experimental|Healthy Vegan Diet with Amla fruits|Education on healthy vegan diet, 3g of powdered amla fruits per day
9693325|NCT04801745|Active Comparator|My Plate - Low Purine|"Education on My Plate diet with emphasis on choosing low purine protein options."
10181712|NCT03780881|Experimental|Expectation disconfirmation|The participants in this group receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
10181713|NCT03780751|Experimental|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
10181714|NCT03780751|Experimental|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
10181715|NCT03780751|No Intervention|Waitlist|Participants will receive no immediate treatment but will be able to choose either MIND or COPE after a six months waiting period.
10181716|NCT03780673|Experimental|Simvastatin 20 mg + Rifaximin 400 mg|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 months
10181717|NCT03780673|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin|Placebo of simvastatin and placebo of rifaximin orally for 12 months
10181718|NCT03780686|Active Comparator|Dopamine and norepinephrine infusion|Infusion doppamine (2-5mcg/kg/min) and norepinephrine (3mcg/kg/h) with restricted fluid
10181719|NCT03780686|Active Comparator|Norepinephrine|Infusion norepinephrine (3mcg/kg/h) with restricted fluid.
9693326|NCT04801745|Experimental|My Plate - Low Purine with Amla Fruits.|"Education on My Plate diet with emphasis on choosing low purine protein options and with an addition of 3g of amla powder per day."
9693327|NCT04801433|Experimental|Boleda Supramolecular Active Zinc|Boleda Supramolecular Active Zinc (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
9693328|NCT04801433|Active Comparator|Capotetriol scalp solution|30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
9693329|NCT04801433|Placebo Comparator|Supramolecular Hydrogel|30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
9693330|NCT04801498||Healthy controls|Men and women ages 18-65 years old with no major medical problems and no history of chronic pain or opioid use.
9693331|NCT04801498||Chronic pain patients not taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) that have not used any opioid medication within the past one year.
9693332|NCT04801498||Chronic pain patients taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) using chronic daily opioid use for longer than 3 months duration and taking stable doses of opioid medications for at least 30 days prior to study visit.
9693333|NCT04801446|Active Comparator|Transcranial Direct Current Stimulation|
9693334|NCT04801446|Sham Comparator|Sham Stimulation|
9693335|NCT04801511|Experimental|Experimental|"Preoperative concurrent chemoradiotherapy and high-dose intravenous vitamin C :~The eligible subjects will be treated with concurrent chemoradiotherapy and high-dose intravenous vitamin C preoperatively. IMRT will be delivered to PTV-CTV (plan target volume-clinical target volume) with a dose of 45Gy/25fraction/5weeks. If necessary. During IMRT, 2-3 cycles of concurrent chemotherapy (mFOLFOX6) will be delivered. High-dose intravenous vitamin C ( 24g/d，QD ) will be delivered on the day of radiotherapy from the beginning to the end of IMRT.~preoperative consolidation chemotherapy: Three additional cycles of neoadjuvant chemotherapy (mFOLFOX6) will be given after the end of IMRT.~TME （total mesorectal excision）or sphincter preserving surgery will be performed approximately the 10th-12th weeks after the end of IMRT. Whether or not to select watch and wait needs to refer to the tumor location, tumor regression, surgeon's opinion and patient's will."
9693336|NCT04801303|Experimental|Friedreich's Ataxia patients|"Friedreich's Ataxia patients that will receive treatment with Calcitrol 0.25mcg/24h for a year.~During the clinical trial:~The effects of Calcitriol in the neurological symptoms of Friedreich's Ataxia patients will be evaluated before starting the treatment and after a year. The following scales will be used: SARA scale, 9-Hole Peg test, 8 meters walking test, PATA velocity test and Quality of life test with the SF36 questionnaire.~The changes in the Frataxin's levels during the treatment with Calcitriol will be measured: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment."
9693337|NCT04801472|Other|Patients with oral cavity or oropharyngeal squamous cell carcinoma|
9693338|NCT04801589|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 4 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr."
9976324|NCT01350362|Experimental|Tideglusib 1000 mg Q.D.|Group dosed with 1000 mg once daily for 26 weeks/extension
9976325|NCT01350362|Experimental|Tideglusib 1000 mg Q.O.D.|Group dosed with 1000 mg once every other day for 26 weeks/extension
10181720|NCT03780686|No Intervention|Standard fluid management|Standard fluid managements.
10181721|NCT03780855|Experimental|nerve scaffold group|the experimental group of cases with peripheral sensory nerve injuries will be treated with nerve scaffold.
10181722|NCT03780855|No Intervention|non-nerve scaffold group|the control group of cases will be treated without nerve scaffold.
10181723|NCT03780920|Active Comparator|Osteopathic treatment|
10181724|NCT03780920|No Intervention|Control group|
10181725|NCT03780556|Active Comparator|Lornixicam|Patients received lornoxicam 8 mg intravenous to control pain
10181726|NCT03780556|Active Comparator|Pethidine|Patients received pethidine 50mg intravenous to control pain
9693339|NCT04801589|Active Comparator|Midazolam|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 0.5 mg/mL midazolam. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr."
10181727|NCT03780868|Active Comparator|external DCR|"A curvilinear incision of 10-15 mm length was made along the anterior lacrimal crest .~The smaller end of the blunt dissector was used to fracture Lamina papyracea, the parchment like bone of the posterior half of the lacrimal fossa. the nasal mucosa was stripped from lacrimal bone with the help of Traquair's periosteal elevator, An osteotomy of approximately 12.5 x10mm was created with successive punching of bone by Cittelli's punch. Lacrimal sac and nasal mucosa were opened in a 'H' fashion with the no.11 Bard-Parker blade and Bowman's probe was in place, to form a large anterior and smaller posterior flap."
10181728|NCT03780868|Active Comparator|silicone intubation with MMC|"Bowman's probe was gently inserted into the inferior canalicular system, until a hard stop was felt in the lacrimal sac, after which it was rotated into the NLD to reach below the inferior concha. The probe was then withdrawn via the inferior punctum and the process was repeated for the upper canaliculus.~After irrigation with normal saline to confirm duct patency, irrigation was performed by introducing 1 ml of MMC (0.5 mg/ml) into the duct with a syringe, the ocular surface then irrigatedby normal saline. Intubation was done by a silicone tube connected by each of its end to a malleable steel guide. A grooved director was placed under the inferior turbinate to guide the probe out of the nose, after which the steel guide was cut from the silicone tube"
10181729|NCT03780621|Experimental|Andrographis and Withania|Active ingredient: 550 mg of Andrographis paniculata (standardized to 40 mg andrographolides) and Withania somnifera (standardized to 10 mg withanolides) taken twice daily, once in the morning and once in the evening
10181730|NCT03780621|Placebo Comparator|Placebo|550 mg capsule visually identical to the active dietary supplement, containing brown sugar, microcrystalline cellulose, corn starch, and magnesium stearate
10181731|NCT03780907|Experimental|E2007 1 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
9693340|NCT04801485|Active Comparator|Myo-inositol|
9693341|NCT04801485|Placebo Comparator|Placebo|
9693342|NCT04801537||normal body temperature and warm extremities|standard set of environmental temperature is done, and the infant's body temperature is normal and extremities are warm
9693343|NCT04801537||normal body temperature and cold extremities|standard set of environmental temperature is done, and infant's body temperature is normal and extremities are cold
9693344|NCT04801407|Active Comparator|radiofrequency group|it is the group that will be treated with Percutaneous Radiofrequency Rhizotomy
9693345|NCT04801407|Active Comparator|Microvascular decompression group|it is the group that will be treated with Microvascular decompression
9693346|NCT04801394|Experimental|Mesh Group|Patient with large incisional hernia treated with FLaPp® mesh as neoperineium
9693347|NCT04801342|Experimental|Unilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with unilateral hippocampal avoidance and Concurrent use of Memantine HCL
9976326|NCT01350362|Experimental|Tideglusib 500 mg Q.D.|Group dosed with 500 mg once daily for 26 weeks/extension
9976327|NCT01350362|Placebo Comparator|Placebo|Once daily administration for 26 weeks/extension
9693348|NCT04801342|Active Comparator|Bilateral Hippocampal Avoidance WBRT with Memantine|Conformal whole brain radiotherapy with bilateral hippocampal avoidance and Concurrent use of Memantine HCL
9693349|NCT04801355|Other|laparoscopic resection|patients with colonic adenomas who will undergo to laparoscopic segmental resection
9693350|NCT04801355|Experimental|full-thickness laparo-endoscopic colon adenomas excision|patients with colonic adenomas who will undergo to laparo-endoscopic full-thickness colon resection
9693351|NCT04801381|Active Comparator|Aquablation therapy|Aquablation therapy: Computer-assisted transurethral ablation of prostate tissue using a high-pressure water jet. Subsequent removal of residual ablated tissue at the bladder neck and haemostasis by transurethral electroresection (TUR).
9693352|NCT04801381|Active Comparator|Transurethral laser enucleation|Transurethral laser enucleation of the prostate using thulium laser (ThuLEP) or holmium laser (HoLEP).
9693353|NCT04801264|Experimental|68Ga-PSMA, PET/CT and 177Lu-EB-PSMA-617 therapy|All patients diagnosed with ACC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
9693354|NCT04801212|Experimental|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
9693355|NCT04801212|Active Comparator|core stability exercises alone|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
9976328|NCT01350375|Placebo Comparator|Saline|
9976329|NCT01350375|Active Comparator|Botox|
9976330|NCT01350427|Experimental|Leucine|
9976331|NCT01350427|Experimental|BCAA|
9976332|NCT01350427|Placebo Comparator|Placebo|
9976333|NCT01350440|Experimental|IVIG|Intravenous Immune Globulin
9976334|NCT01350466||FESS patients|
9976335|NCT01350466||Controls|
10181732|NCT03780907|Experimental|E2007 2 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
10181733|NCT03780907|Placebo Comparator|Placebo|Tablet, once daily to be taken in the morning, one hour before breakfast, with a glass of water.
10181734|NCT03780634|Experimental|HAIC plus PD-1 antibody|Participants received PD-1 antibody intravenously and hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
9693356|NCT04801238|Active Comparator|LCBDE + LC|Laparoscopic common bile duct exploration with laparoscopic cholecystectomy
9693357|NCT04801238|Active Comparator|ERC + LC|Endoscopic retrograde cholangiography with laparoscopic cholecystectomy
9693358|NCT04801524|No Intervention|Holdout Arm|In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
9693359|NCT04801524|Experimental|Self-benefit sub-arm|In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
9693360|NCT04801524|Experimental|Prosocial-benefit sub-arm|In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
9693361|NCT04801524|Experimental|Early-access and self-benefit sub-arm|In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
9693362|NCT04801524|Experimental|Early-access and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
9693363|NCT04801524|Experimental|Fresh start and self-benefit sub-arm|In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
9693364|NCT04801524|Experimental|Fresh start and prosocial-benefit sub-arm|In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
9693365|NCT04801654||Ion released group|First 30 patients will be assessed for metalic ion released by blood sample. the patients will be monitored until 10 years follow-up for long term performance of the device
9693366|NCT04801654||Other group|The remaining 125 patients will be not assessed for metalic ion released; they will be monitored until 10 years follow-up for long term performance of the device
9693367|NCT04801420|Experimental|Part A+B - Group 1|Part A: VLA15 at Month 0, 2 and 6 - Part B: VLA15 or placebo depending on schedule selection
9693368|NCT04801420|Experimental|Part A+B - Group 2|Part A: VLA15 at Month 0 and 6, placebo at Month 2 - Part B: VLA15 or placebo depending on schedule selection
9693369|NCT04801420|Placebo Comparator|Part A+B - Group 3|Placebo
9693370|NCT04801563|Other|SINGLE ARM|
9693371|NCT04801628|Active Comparator|Active Tecar|"Transfer Electrode Capacitive and Resistive (TECAR) Therapy (radio frequency therapy; INDIBA, Spain) will be used. In CET mode, heat transfer is concentrated on the skin and superficial muscles, which are tissue with high electrolytes, while the RET mode focuses heat transfer on bones, tendons, joints, and deep muscles. In this study, both CET and RET modes will be applied to the participant' quadriceps for 15-20 minutes at stable frequency of 448 KHz. According to the manufacturer's guidelines for safety, the CET mode will be first implemented for 5 minutes. Then will be continued in RET mode using for the rest of the treatment. Participants will be asked to lie down comfortably, and treatment will be beginning.~The intensity of the current will be set at the level of comfort between 0%-100%, averaging about 40%. TECAR therapy will be applied by a physical therapist for all participants."
9693372|NCT04801628|Placebo Comparator|Placebo Tecar|the same procedure as in active Tecar but the device not provide any radio frequency
9693373|NCT04801082|Active Comparator|EUS-CPB|Endoscopic Ultrasound Guided Coeliac Plexus Block
9693374|NCT04801082|Active Comparator|EUS-CPA|Endoscopic Ultrasound Guided Coeliac Plexus Radiofrequency Ablation
9693375|NCT04801329||Adults diagnosed with transthyretin-mediated amyloidosis (ATTR-CM)|
9693376|NCT04801134|Other|Food insecurity|Food insecure families will be assigned education and community resources needed.
9693377|NCT04800978|Experimental|BVAC-C+Durvalumab|"• Part A: The primary objective of the part A is to assess the maximum tolerable dose of BVAC-C combined with durvalumab 1500 mg as defined by dose-limiting toxicities (DLTs), and to find the maximum tolerated dose (MTD) that can be safely used for Part B (single arm phase II).~• Part B: The primary objective of the part B is to evaluate the safety and clinical efficacy, as measured by 6-month PFS rate, of the combination therapy of durvalumab and BVAC-C in patients with HPV 16 or 18 positive cervical cancer recurrent after or refractory to first-line platinum-based chemotherapy +/-bevacizumab."
9693378|NCT04801225|Experimental|VItalFlow Stimulation Treatment|"Enrolled subjects shall receive a VitalFlow stimulation after other standard-of-care treatments are initiated. VitalFlow treatment is initiated by powering on the System and positioning the two (Left and Right) VItalFlow coils on each side of the head (by the ear).~The operator controls the VItalFlow Stimulation through the accompanying console with simple button operation. Once treatment is initiated, the VitalFlow provides continuous, biphasic pulses at a preset power cycle with the total treatment time under 5 min (fixed time). After treatment is completed, the coils are removed and replaced on the VitalFlow System."
9693379|NCT04801108|No Intervention|Medical management group|COPD patients with severe emphysema and incomplete lobar fissures will be placed on maximal medical therapy for 3 months. At the end of this 3 month period, patients will fill in an additional set of quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. New pulmonary function testing will be performed and crossover to the intervention group will be offered.
10181735|NCT03780634|Active Comparator|HAIC plus sorafenib|Participants received sorafenib capsules 400mg bid in continuous 21-day treatment cycles, and received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10181736|NCT03780478|Experimental|SPG Block|Sphenopalatine ganglion block
10181737|NCT03780478|Placebo Comparator|Placebo Control|Saline injection
10181738|NCT03780491|No Intervention|Control|The first 50 patients will have usual care with providers conducting the visit in their typical manner.
10181739|NCT03780491|Experimental|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
9693380|NCT04801108|Experimental|Intervention group|COPD patients with severe emphysema and incomplete lobar fissures will undergo video-assisted thoracic surgery fissure completion and valves placement. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
9693381|NCT04801108|Experimental|Crossover group|Subjects allocated to the medical management group will be offered to crossover after the 3 months follow-up period. The same procedure as in the intervention group will be performed. Follow-up after surgery will be the same as in the intervention group.
9693382|NCT04801160|Experimental|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
9693383|NCT04801160|Active Comparator|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
9693384|NCT04801056|Experimental|TB006|"During the SAD study, subjects will receive a single dose of TB006 (at the dosage level of 10 ~ 50 mg/kg) administered via i.v. infusion for 60 mins.~In addition, a sentinel cohort of 5 mg/kg will be open for enrollment and double-blinded randomization first, with 2 patients randomized to active/TB006 arm, to assess preliminary safety and tolerability of study drug, and to determine cohort expansion and dose escalation. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
9693385|NCT04801056|Placebo Comparator|Placebo|"During the SAD study, subjects will receive a single dose of the placebo administered via i.v. infusion for 60 mins.~In addition, the corresponding sentinel placebo group will include 1 patient to placebo arm. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
9693386|NCT04801017|Experimental|OT-101 + Artemisinin + Standard of Care|"OT-101 - Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days.~Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral"
9693387|NCT04801017|Placebo Comparator|Placebo + Artemisinin + Standard of Care|Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral
9693388|NCT04801251|Other|Resident|Full history.complete systemic and cardiac physical examination
9693389|NCT04801251|Other|Assistant Lecturer|Echocardiographic examination
9693390|NCT04801095|Experimental|WM-S1-030|Dose escalation (part 1) and Dose expansion (part 2)
9693391|NCT04801069|Experimental|Auto-Adaptative Servo-Ventilation|
9693392|NCT04801069|No Intervention|Control|
9693393|NCT04800952|Other|To establish the appropriate dosing regimens of newly available antibiotics during CRRT|High dose (world standard dose) and low dose CRRT (Japan local) CRRT protocol Vascular access will be obtained by inserting a double-lumen dialysis catheter into the internal jugular or femoral veins. High dose CRRT in Australia, Blood flow through the extracorporeal circuit will be maintained at 150 ml/min. The CVVHF replacement volume will be set at 25ml/kg/hour and bicarbonate-buffered replacement fluids will be added in post-dilutional mode. Low dose CRRT in Japan, Blood flow through the extracorporeal circuit will be maintained at 80 ml/min. CVVHF replacement volume will be set at 15ml/kg/hour and bicarbonate-buffered replacement fluids will be added in the post-dilutional mode. Fluid balance, volume removal and the duration of CVVHF will be determined by the ICU physician based on the patient's individual clinical status.
9693394|NCT04801199|Experimental|CPL-2009-0031 140 mg|Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks
9693395|NCT04801199|Active Comparator|Sitagliptin 100 mg|Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks
9693396|NCT04800965|No Intervention|Holdout Arm|In the Holdout arm, patients will not receive text messages about COVID-vaccine.
9693397|NCT04800965|Experimental|Simple Text Sub-arm|In the Simple Text sub-arm, participants will not receive any additional information.
9693398|NCT04800965|Experimental|Simple Text + Video Sub-arm|In the Simple Text+Video sub-arm, together with the appointment link, participants will also receive a link to a 2-minute video in the text message. The video contains information about the prevalence of COVID-19 and the effectiveness and safety of the COVID-19 vaccine.
9693399|NCT04800965|Experimental|Enhanced Text sub-Arm|In the Enhanced Text sub-arm, in addition to the appointment link, the text message will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
9693400|NCT04800965|Experimental|Enhanced Text + Video Sub-arm|In the Enhanced Text+Video sub-arm, in addition to the appointment link, the text message will encourage patients to watch a 2-minute video (the same as in the Simple Text+Video sub-arm) and use enhanced language aimed at reducing patients' psychological barriers of following through on scheduling an appointment.
9693401|NCT04800848||Mask/No Mask|"The group will perform both situations in a randomized cross-over design:~1. Scholars will perform the fitness test with the use of a N95/FFP2 face mask~2. Scholars will perform the fitness test without the use of a N95/FFP2 face mask"
9696494|NCT04766372|Experimental|Physical activity programme|Participants in the second group with receive the activity menu (as described above) as well as a detailed physical activity programme. This programme includes supportive weekly text messages, access to live workouts and access to an online social community.
10181740|NCT03780582|Experimental|Probabilistic Classification|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan."
10181741|NCT03780582|Experimental|Classification Plus Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. They also see ROIs identified by the AI that represent lung nodules."
10181742|NCT03780582|Experimental|Classification With Delayed Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions."
9693402|NCT04801277|Active Comparator|Acupuncture on PC6 and LI4|Acupuncture on bilateral acupoints, that are PC6 and LI4. The pericardium meridian PC6 point (Neiguan) is defined as follows. The patient's four fingerbreadths will be placed on the medial aspect of their forearm with the edge of the 4th finger on the wrist crease. This is then subtracted from the width of the interphalangeal joint of her thumb. The point between the tendons of extensor carpi radialis and palmaris longus was the pericardium meridian PC6 point (Neiguan). The large intestine LI4 point (Hegu) located on the dorsum of the hand, between the first and second metacarpal bones, at the midpoint of the second metacarpal bone and close to its radial border.
9693403|NCT04801277|Sham Comparator|Acupuncture on Sham acupoints|Acupuncture on bilateral non acupoints. In sham/placebo group, patient will have the acupuncture needles inserted at non-acupoint 2cm radial to PC6 and between 2nd and 3rd metacarpal bone bilaterally, superficial skin piercing (adequate depth to let patient feels needle is inserted)
9693404|NCT04801147|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
9693405|NCT04800796||Intervention Group|Intervention Group with audiovisually blended learning concept
9693406|NCT04800796||Standard group|Standard Group receiving the Standard operating procedures via E-Mail and Confirmation when reading.
9693407|NCT04800926|Experimental|Xavier wheelchair controller|Surface electromyography control of wheelchair
9693408|NCT04800757|Experimental|individual (Brief Motivational Intervention)|
9693409|NCT04800757|Experimental|Group (Group Problem Solving)|
9693410|NCT04800757|Placebo Comparator|Standard of Care|
9693411|NCT04800666|Experimental|Facial Nerve Block Group|Facial Nerve Block and oral Mecobalamin Tablets
9693412|NCT04800666|Experimental|Stellate Ganglion Block Group|Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
9693413|NCT04800666|Experimental|D Group|Facial Nerve Block
9693414|NCT04800666|Other|C Group|control
9693415|NCT04800705||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
10181743|NCT03780764|Active Comparator|Conventional fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch."
10181744|NCT03780764|Experimental|Self ligating fixed appliance|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side."
9693416|NCT04800705||Control group|The study population will be consisted of 70 women with POI as the study group and 70 patients with normal healthy women as the control group. A volunteer group of healthy women who will be visited the gynaecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
9693417|NCT04800731||Group 1|Group 1 will consist of 100 patients COVID-19 positive patients older than 70 years old hospitalized in UZ Brussel from February 2020 until September 2020 with a positive RT-PCR test for SARS-CoV-2.
9693418|NCT04800731||Group 2|Group 2 will consist of 100 patients older than 70 years old hospitalized in UZ Brussel for acute infections other than COVID-19.
9693419|NCT04800731||Group 3|Group 3 will consist of healthy aged people defined as in the modified SENIEUR protocol (12, 13). This group is recruited from a previously conducted study. These are community dwelling individuals above the age of 70 and considered as almost healthy with some conditions that are present in the majority of old people such as osteoporosis, osteoarthritis or atherosclerosis.
9693420|NCT04801121||Pregestational diabetic pregnant|Cases: Women with type 1 or type 2 diabetes before start of pregnancy
9693421|NCT04801121||Non-diabetic pregnant|Controls: Women without metabolic disease before start of pregnancy
9696415|NCT04767334|Experimental|Gait training on Lower body positive pressure|"All participants will have gait training for 40 minutes a day, for three days a week, for six weeks. On session one, the lower body positive pressure chamber will be set to unload 50% of patient's body weight.On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
9696416|NCT04767360|Other|Open labele BIONESS-Training|Four-week therapeutic treatment of foot drop with the electrical stimulation device Bioness L300. This treatment will be performed five times a week for at least 30 minutes
9696417|NCT04767178||Ibuprofen group|Infants that received oral ibuprofen were categorized into the ibuprofen group
9696418|NCT04767178||Paracetamol group|Infants that received oral paracetamol were categorized into the paracetamol group
9696419|NCT04767620|Experimental|study groups|The study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses.
9696420|NCT04767620|No Intervention|control groups|The control group was treated with observational treatment and follow-up in outpatient clinic.
9696421|NCT04767542|Sham Comparator|Paracetamol|Patients with emergency LC will be administered intravenously 1 gr vial of paracetemol in 30 minutes during the awakening phase.
9696495|NCT04766372|Experimental|Individual behaviour change support|"Participants in the third group with receive the activity menu (as described above) as well as individual behaviour change support. Each participant is partnered with a trainee sport psychology (Activity Mentor) who they have weekly video calls with to support their health behaviour change."
9693422|NCT04800380|No Intervention|Routine training|Nursing students in the control group will receive training in routine metric and drug dose calculation in virtual environment.
9693423|NCT04800380|Experimental|Edpuzzle application|Students in the intervention group will watch the routine metric and drug dose calculation training in virtual environment, as well as interactive videos prepared by the first researcher and uploaded to the Edpuzzle application.
9976336|NCT01350518|Placebo Comparator|Study prepared meals and placebo|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will not receive any fiber (Benefiber) supplementation in their TrueLemon mixture.
9693424|NCT04800458|Experimental|thrombocytopenic patients|
9693425|NCT04800653|Experimental|Stellate ganglion block|Before the operation, the right stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
9693426|NCT04800653|No Intervention|Control|Do nothing
9693427|NCT04800497||Patients resected for hepatocellular carcinoma|
9693428|NCT04800497||Patients who underwent surgery for benign diseases|
9693429|NCT04800419|Experimental|Acceptance and Commitment Therapy (ACT)|ACT will be conducted in a group of 10 for each session. The ACT modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
9693430|NCT04800419|Experimental|Mindfulness-based Stress Reduction (MBSR)|MBSR will be conducted in a group of 10 for each session. The MBSR modules covered over 8 sessions, 1 hour in each session. The sessions will be held every week according to the patient's appointment date for chemotherapy treatment.
9693431|NCT04800419|No Intervention|Control|The subjects in the control group will be assigned in the wait-list where either ACT or MBSR will be provided after the study has been completed.
9693432|NCT04800471|Active Comparator|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
9693433|NCT04800471|Placebo Comparator|Point of Care Glucose Group|Participants in this group will be monitored by point of care glucose values
9693434|NCT04800575|Experimental|Semi-permeable film dressing|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
9693435|NCT04800575|Other|sterile gauze and tape dressing|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
9693436|NCT04800601|Experimental|Experimental group|
9693437|NCT04800601|Active Comparator|Control group|
9693438|NCT04800432|Experimental|Feasibility and acceptability of ADAPT+|ADAPT+ is a family-based obesity intervention for high-risk Latino youth and their parents living in rural communities that incorporates culture-specific components and mindfulness-based approaches to promote adaptive health behaviors in a high-risk and underserved population.
9693439|NCT04800432|Active Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) provides publicly available material in both English and Spanish on the role of diet and exercise in pediatric obesity in a one-time information session.
9693440|NCT04800588|Experimental|Older participant group|We will evaluate the performance of healthy older participants (N = 500, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. The goal is to characterize changes in performance to aging and task experience in a group of older subjects. Subjects will undergo APOE genetic testing with saliva samples.
9693441|NCT04800588|Experimental|CCAB vs. manual test group|We will compare the performance of normal participants (N = 100, age range 18 to 89) on computerized and manually administered cognitive tasks.
10181745|NCT03780777|Experimental|Home Hazard Removal Group|A tailored home-modification (home-hazard removal) intervention for residents with a high fall risk, delivered in the home by occupational therapists over one to two visits and with a booster session at three months.
9693442|NCT04800588|Experimental|Younger participant group|We will gather normative data from younger participants (N = 400, ages 18 to 59) for three days at enrollment. A subset of these subjects (N=150) will undergo longitudinal testing at 6-month intervals for three years thereafter.
9693443|NCT04800588|Experimental|Screening test group|We will examine the performance of participants (N=1000, ages 18 to 89) on a 30-min computerized cognitive screening test. Testing may be repeated at 6-month or 1-year intervals.
9693444|NCT04800549|Experimental|METHOD|The power of the test in the study was calculated by using G*Power 3.1 program. While Type I error is 0.05 and the power of the test is 0.80 (α= 0.05, 1-β= 0.80), minimal sample size was calculated as 62 children (31 children in each group). By considering the losses that may occur from the sample during the study due to any reason, it was planned to include 40 children in both experimental and control groups. Follow-up lost occurred in 5 patients from experimental group and 6 patients in the control group during the study. The study was completed with 69 paediatric patients including 34 in the experimental group and 35 in the control group.
9693445|NCT04800679|Active Comparator|intravitreal bevacizumab injections and then rescue|
9693446|NCT04800679|Active Comparator|PRP group|
9693447|NCT04800679|Active Comparator|IVB injections and a modified laser|
9693448|NCT04800640|No Intervention|No Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
9696496|NCT04766372|Experimental|Activity Programme & Behaviour Change Support|Participants in the fourth group will receive all of the above (exercise menu, live workouts, social community, support texts and weekly calls with an Activity Mentor).
9696497|NCT04766177|Experimental|bumetanide group|Bumetanide a dose of 0.5 mg twice per day
10181746|NCT03780738||Control|Chinese Han people to do physical examination in physical examination center of Guangdong Provincial People's Hospital
10181747|NCT03780738||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Guangdong Provincial People's Hospital
9693449|NCT04800640|Experimental|Electroanalgesia|The sample will consist of 132 individuals, of both sexes, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia through TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia
9693450|NCT04800367|Experimental|Romosozumab followed by denosumab|Romosozumab 210 mg subcutaneous injection, once a month for 12 months followed by denosumab 60 mg subcutaneous injection, once every six months for 12 months.
9693451|NCT04800341||Patients ESADA follow-up|Patients included in the ESADA European database and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire.
9693452|NCT04800445||Case group of fullterm neonates with neonatal sepsis|
9693453|NCT04800445||Healthy fullterm neonates|
9693454|NCT04800042|Other|Patients with scheduled major surgery|Patients with scheduled major surgery
9693455|NCT04800120|Active Comparator|Study Group|Identified COVID 19 patients receiving the intervention of Hyperbaric Oxygen Therapy
9976337|NCT01350518|Active Comparator|Nutritional Counseling with fiber|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions will focus on knowledge, self-regulation, motivation, experience and environment. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture .
9976338|NCT01350518|Placebo Comparator|Nutrition counseling and placebo|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions (interventions) will focus on knowledge, self-regulation, motivation, experience and environment.Participants will receive no fiber supplementation in their TrueLemon mixture .
9693456|NCT04800120|No Intervention|Control Group|Historical control of COVID 19 patients who were previously treated and did not receiving Hyperbaric Oxygen Therapy
9693457|NCT04800211|No Intervention|Control|Continue smoking under ad libitum use of subjects' own brand of conventional lit-end cigarettes, without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.
9693458|NCT04800211|Experimental|Test 1|"Exclusive ad libitum use of test e-Vapor Product NuMark LLC, MarkTen® XL Bold CLASSIC* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~*Product no longer sold commercially"
9976339|NCT01350518|Active Comparator|Study prepared meals and fiber|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture.
9976340|NCT01350531|Experimental|Skills training|
10181748|NCT03780712||Sepsis Risk Group|419 infants born from mothers at risk to deliver babies with neonatal infections in Cotonou hospitals (Benin) 166 infants without sepsis born from mothers enrolled in a study to monitor pregnancy-associated malaria and Intrauterine growth restriction in Benin
9693459|NCT04800211|Experimental|Test 2|"Exclusive ad libitum use of test e-Vapor Product Nu Mark LLC, MarkTen® XL Bold MENTHOL* without use of any other type of tobacco/nicotine containing product, for the entire duration of study participation.~*Product no longer sold commercially"
9693460|NCT04800224|Placebo Comparator|Placebo|Patients in the Placebo group will receive an identical number of capsules containing 900 mg / day of placebo (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
9693461|NCT04800224|Active Comparator|Propolis|Participants in the Propolis group will receive propolis EPP-AF at a dose of 900 mg / day (3 capsules of 100 mg each, divided into 3 daily doses); for 10 days.
9693462|NCT04800029|Experimental|TIPS Alone|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
9693463|NCT04800029|Experimental|TIPS and ED-SAFE|"Half of the ED discharged patients with suicide risk will also be invited to receive post-discharge telephone counseling originally developed by Principal Investigator in a previous study, Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE). The participant will receive three calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
9693464|NCT04800029|Active Comparator|No intervention, Treatment as Usual|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
9693465|NCT04800159|Active Comparator|THC Cannabis|13.03% THC/ 0.13% CBD
9693466|NCT04800159|Active Comparator|CBD Cannabis|0.44% THC/ 12.32% CBD
9693467|NCT04800159|Placebo Comparator|Placebo|≤ 0.01% THC/ ≤ 0.01% CBD
9693468|NCT04800146||Cohort 1|patients with solid tumors treated with chemotherapy (ongoing or completed no more than 6 months before enrollment). Specific type of chemotherapy inducing similar immunosuppression will be selected (including but not limited to platinum-based combinations, anthracycline combinations, triweekly docetaxel).
9693469|NCT04800146||Cohort 2|patients with solid tumors treated with single agent immune-check points inhibitors (ongoing or completed no more than 6 months before the enrollment
9693470|NCT04800146||Cohort 3|patients with solid tumors treated with hormonal agents (ongoing or completed no more than 6 months before enrollment): any anti-androgen for prostate cancer and any anti-estrogen for breast cancer patients.
9693471|NCT04800146||Cohort 4|patients with previously untreated mature B cell tumors in watch and wait
9976341|NCT01350531|Experimental|Contingency Management|
9976342|NCT01350557|No Intervention|Control group|Patients receive only usual hospital care
9693472|NCT04800146||Cohort 5|patients with mature B cell tumors treated with anti-CD20 monoclonal antibody either alone or in combination with chemotherapy (ongoing or completed no more than 12 months before enrollment
9693473|NCT04800146||Cohort 6|patients with hematological malignancies treated with pathway inhibitors (ongoing or completed no more than 12 months before enrollment). Different type of targeted agents can be considered, including Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors or phosphoinositide-3 kinase (PI3K) inhibitors
9693474|NCT04800146||Cohort 7|patients with hematological malignancies who have received autologous stem cell or allogenic transplant within 12 months
9693475|NCT04800146||Cohort 8|non-cancer subjects (age and gender matched) referred to the Division of Infectious Diseases, Lugano, EOC for vaccination against SARS-CoV-2.
9693476|NCT04800081|Experimental|Sacubitril/Valsartan|receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan
9693477|NCT04800081|Active Comparator|Valsartan|receive once-daily treatment with 80-320 mg of Valsartan
9693478|NCT04799847|Experimental|Catumaxomab|In the dose escalation phase, 3 dose levels of catumaxomab will be explored.
9693479|NCT04799951||Breast Surgeon|surgeons having experience in and regularly conducting breast conservation surgery and mastectomy surgeries
9976343|NCT01350557|Other|Subacute care group|Patients receive hospital usual care and subacute care. Subacute care consisted of geriatric consultation, a rehabilitation program, and early discharge planning.
9976344|NCT01350557|Experimental|Comprehensive care group|Patients receive not only the subacute care (geriatric consultation, rehabilitation program, and discharge planning), but also health-maintenance interventions to prevent falls, consult on nutrition, and manage depression.
9976345|NCT01350570|Experimental|acupuncture group 1|Acupoints ST25 and BL25 will be used in the group. ST25 locate at the abdomen, while BL25 locate at the back.
9976346|NCT01350570|Experimental|acupuncture group 2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
9976347|NCT01350570|Experimental|acupuncture group 3|All acupoints used in acupuncture group1 and acupuncture group2 will be used in this group.
9693485|NCT04799925||Intervention group|Hyperuricemic group will be treated with uric acid lowering drug (febuxostat 80 mg once daily for 6 months).
9693486|NCT04799925||Placebo group|Hyperuricemic group will take placebo pills.
9693487|NCT04799977||COVID19 infection with olfaction disorder|Patients, ≥18 ans, who suffered from an olfaction disorder while going through a COVID19 infection
9693488|NCT04799977||COVID19 infection without olfaction disorder|Patients, ≥18 ans, who suffered from a COVID19 infection without any olfaction disorders
9693489|NCT04800003||Dry human mandibles, selected for evaluation|51 dry mandibles with posterior region endetulism and sufficient bone integrity to make the necessary measurements were evaluated. CBCT images of the 51 dry human mandibles included in the study were obtained using the Planmeca Promex-3D (Helsinki, Finland) device in our faculty Dentomaxillofacial Radiology department. Gonial angle was measured on CBCT images as the angle between the tangent line drawn posterior to the border of the ramus of the mandible and the tangent line drawn to the lower border of the mandible. While determining the depth of the submandibular fossa, a line was drawn to connect the most dislocated upper and lower points on the inner surface of the mandible in the coronal plane sections obtained with CBCT, and the length of the line drawn at a right angle from the deepest point of the fossa to this line was measured as the depth of the submandibular fossa.
9976348|NCT01350570|Active Comparator|Loperamide|Loperamide will be used as an active comparator to the acupuncture groups.
9976349|NCT01350596|Active Comparator|Reference Drug|
9693490|NCT04799938|Active Comparator|İntevention group|Prediabetic patients with age 30-50 and overweight Standart recommendations Exercise intervention will be made.
9693491|NCT04799938|No Intervention|Control group|Prediabetic patients with age 30-50 and overweight Only Standart recommendations
9693492|NCT04799938|No Intervention|Metformin Group|Prediabetic patients who received metformin Standart recommendations
9693493|NCT04799899|Experimental|Virtual MBCT Intervention|Participants will participate in 8 weekly virtual group sessions of MBCT. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
9693494|NCT04799899|Experimental|Virtual Health Enhancement Control|Participants will participate in 8 weekly virtual group sessions that focus on cardiac health and depression education. Participants will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30-60 minutes).
9693495|NCT04799730||SLE cases in remission|according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI <5
9693496|NCT04799730||SLE cases in activity|according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5
9693497|NCT04799730||Control group|Healthy age and sex matched subjects.
9693498|NCT04799782|Active Comparator|Mirtazapine|The drug will be taken for a one week peroid.
9693499|NCT04799782|Placebo Comparator|Placebo|The drug will be taken for a one week peroid.
9693500|NCT04799678||Participants|Current user of the Smart Asthma app
9693501|NCT04799704||symptomatic patient|The first part of our study is to confirm the detectability of the SARS-nCoV-2 in the tear film of symptomatic patients.
9693502|NCT04799860|Experimental|health promotive work-way|Six primary care units that voluntarily enrolls as experimental units. The units will receive implementation support based on previous research and tailored to the specific prerequisits and context for each unit. Strategies includes involvement of target groups; informationa and interactive education;use of external and internal facilitators tarined for the purpose; systematic feedback and learning dialogs during the project. The implementation support will take approximately 12 months.
9693503|NCT04799860|No Intervention|Control|Six primary care centers of similar size and socioeconomic background in the population listed to each center.
9696498|NCT04766177|Placebo Comparator|Placebo|Placebo twice daily
9976350|NCT01350596|Active Comparator|Test Drug|
10181749|NCT03780647||Patients with suspicion of thoracic outlet syndrome|
10181750|NCT03780218||Experimental Group:Respiratory function|Patients with burn injury will be included in this study. Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed on the discharge week.
10181751|NCT03780218||Control Group:Respiratory function|Healthy subjects will be included in this study.Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed.
10181752|NCT03780192||Treatment|Bifurcation lesion treatment using provisional stent technique
10181753|NCT03780569|Experimental|NovoTTF-200A/Radiotherapy/Temozolomide|Patients will receive multiple 1 month courses of continuous NovoTTF-200A treatment together with standard Radiotherapy/Temozolomide followed by maintenance Temozolomide.
10181754|NCT03780205||Bilateral Group|Patients have bilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 each eye.
9664667|NCT05302440||single-group|All care staff who manage the system will complete a very brief survey (1-minute) after each work shift for 14 days. Detection of abnormal vital signs will be recorded by the system. Hospital admission and further medical assistance due to the use of the system will be documented by the care team. The staff will be interviewed about their perceived benefits and acceptability of the system.
9664668|NCT05302427|Experimental|Massage group|The massage group will be shown live one-to-one baby massage training via Microsoft Teams by the researcher, and the mother will be asked to apply it to her baby at the same time. Baby massage training; It consists of leg massage, face-abdominal massage, arm-chest massage and back massage and will be completed in four weeks.
9664669|NCT05302427|No Intervention|Control group|Infant massage training will not be given to the mothers of the babies in the control group until the 20th week.
9664670|NCT05302414|Experimental|board game-based learning|game-based learning
9664671|NCT05302414|Active Comparator|simulation-based learning|simulation education
9664672|NCT05302414|Placebo Comparator|lecture-based learning|lecture education
9664673|NCT05302401|Experimental|Women receiving uninterrupted midwife support during the intrapartum period|28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. Researcher Meserret Aslan will provide six hours of online pregnancy training to pregnant women in the experimental group and provide uninterrupted midwife support during the intrapartum period.Within the first half hour of postpartum after birth, saliva cortisol samples of women will be repeated by researcher Meserret Aslan. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the experimental group.
9664674|NCT05302401|No Intervention|Women who do not receive uninterrupted midwife support during the intrapartum period|Between the 28th and 36th weeks, the pregnancy diagnosis form will be applied by the researcher to the pregnant women in the control group. 28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. After birth, postpartum from control groups will be repeated by researcher Meserret Aslan in the first half hour. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the control groups.
9664675|NCT05302362|Sham Comparator|Sham tDCS Group|Sham transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, 0mA stimulation for 19 min 30 sec.
9664676|NCT05302362|Active Comparator|Conventional tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, continuous 1.5mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
9664677|NCT05302362|Experimental|Tailored tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 2.0mA, continuous 2.0mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
9664678|NCT05302349|Experimental|Core Exercise Group|Core Exercise Group will performe core stabilization exercises and routine physiotherapy exercises.
9664679|NCT05302349|Active Comparator|Routine Therapy Group|Routine Therapy Group will performe routine physiotherapy exercises.
9664680|NCT05302271|Experimental|First Dose Cohort|AAVrh.10hFXN will be administered intravenously.
9664681|NCT05302271|Experimental|Second Dose Cohort|AAVrh.10hFXN will be administered intravenously.
9664682|NCT05302258||Obesity|BMI of 95 th percentile or more
9664683|NCT05302258||Normal weight|BMI of 85 th percentile or less
9664684|NCT05302245||Caregivers of ABI survivors|Unpaid caregivers of acquired brain injury survivors living in Nova Scotia
9664685|NCT05302232|Experimental|Lidocaine plus steroid|
9664686|NCT05302232|Placebo Comparator|Steroid only|
9664687|NCT05302219|Experimental|Measurement of plethysmography curve|Calm measurement of plethysmography curve using pulse oximetry with simultaneous monitoring of the breath cycle. In this experimental arm, participants will vary their breath cycle (different respiratory rates and different tidal volumes).
9664688|NCT05302206|Experimental|patients with ileostomy without type 2 diabetes|colonic glucose or saline infusion via ileostomy
9664689|NCT05302206|Experimental|patients with ileostomy with type 2 diabetes|colonic glucose or saline infusion via ileostomy
9664690|NCT05302193|Experimental|Blood pressure and heart rate measurement|Calm measurement of blood pressure and heart rate simultaneously by smartwatch and vital signs monitor. Each participant will undergo this measurement a total of 6 times.
9664691|NCT05302180|Experimental|Synchronous online group|The synchronous online pain neuroscience education program (EducaDor program) will be held in groups at until 12 participants, at 10 weekly synchronous meetings on the Whereby® platform.The professional will conduct each synchronous meeting with dialogued exhibition class using multimedia material shared on the computer screen
10181755|NCT03780205||Unilateral Group|Patients have unilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 in the amblyopic eye; and interocular difference of best-corrected visual acuity at least two logMAR lines.
9693504|NCT04799743|Experimental|Resveratrol group|Resveratrol group (treatment group) will be instructed to consume with capsules (1.0 g, orally once a day) for six months.
9693505|NCT04799743|Placebo Comparator|Placebo group|Placebo group (control group) will be instructed to orally take placebo (edible paraffin, 1.0) once a day.
9693506|NCT04799600||Acute Renal Failure in ICU|COVID-19 Patients with Acute Renal Failure in ICU
9693507|NCT04799808||BioNTech cohort|The BioNTech cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by comirnaty vaccine from BioNTech. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised solid organ transplant recipients, and the staff caring for them in the nephrology dispensaries.
9976351|NCT01350609|Experimental|Nifedipine/Candesartan (fixed dose)|
9976352|NCT01350609|Active Comparator|Nifedipine/Candesartan (loose)|
9693508|NCT04799808||Moderna cohort|The Moderna cohort is composed of 1000 study participants who will be protected from SARS-CoV-2 infection by Moderna Biotech vaccine. The study participants consist of mildly immunocompromised dialysis patients, severely immunocompromised kidney transplant recipients, and the staff caring for them in the nephrology dispensaries.
9693509|NCT04799470|Experimental|PD with DBS|Patients with Parkinson's Disease who were implanted with Medtronic Percept PC for DBS and consent to participate in the study.
9693510|NCT04799821|Experimental|Intervention|Daily walnut consumption
9693511|NCT04799821|Other|Control|No walnut consumption
9693512|NCT04799444||Adult patients with complications post COVID-19|
9693513|NCT04799444||Children with complications post COVID-19|
9693514|NCT04799626||Treatment|The use of antimicrobial agents depends on the clinical practice.
9693515|NCT04799457|No Intervention|Classical caesarean group|Care providers are applying standard caesarean procedure for participants.
9693516|NCT04799457|Experimental|Study caesarean group|Care providers are applying additional sutures to standard caesarean procedure for participants.
9693517|NCT04799340|Experimental|holistic face training|
9693518|NCT04799340|Experimental|holistic face training + repetition lag training|
9693519|NCT04799340|No Intervention|waitlist control|
10181756|NCT03780166|Experimental|Parsaclisib|
9693521|NCT04799366||MC|MC patients with either dominant (Thomsens) or recessive (Becker) myotonia.
9693522|NCT04799366||Healthy Controls|Healthy controls age- and gender matched.
9693523|NCT04799613|No Intervention|Natural walking|
9693524|NCT04799613|Experimental|fast walking|
9693525|NCT04799613|Experimental|normal walking passing through narrow pathway|
9693526|NCT04799613|Experimental|fast walking passing through narrow pathway|
9693527|NCT04799613|Experimental|Natural walking with dual task|
9693528|NCT04799613|Experimental|fast walking with dual task|
9693529|NCT04799613|Experimental|Natural walking passing through narrow pathway and during cognitive dual task|
9693530|NCT04799613|Experimental|fast walking passing through narrow pathway and during cognitive dual task|
9693531|NCT04799613|Experimental|Natural walking reducing the best side|
9693532|NCT04799613|Experimental|fast walking reducing the best side|
9693533|NCT04799613|Experimental|Natural walking reducing the best side passing through narrow pathway|
9693534|NCT04799613|Experimental|fast walking reducing the best side passing through narrow pathway|
9693535|NCT04799613|Experimental|Natural walking reducing the best side with cognitive dual task|
9693536|NCT04799613|Experimental|fast walking reducing the best side with cognitive dual task|
9693537|NCT04799613|Experimental|Natural walking reducing the best side passing through narrow pathway and during cognitive dual task|
9693538|NCT04799613|Experimental|fast walking reducing the best side passing through narrow pathway and during cognitive dual task|
9693539|NCT04799262|Experimental|Tofacitinib+Prednisone|Tofacitinib was given at the dose of 10mg daily through the 24 weeks. Patients were to receive prednisone in a dosage of 15mg daily at baseline and decreased to 10mg daily at week 2. The PMR-AS was determined every two weeks; if ≤10, the prednisone dosage was decreased by 2.5 mg every two weeks; and if >17 the dosage was increased to previous dosage; if 10≤PMR-AS ≤17, the dosage was maintained at previous stable dose.
9693540|NCT04799561|Experimental|Teleprehabilitation cohort|Patients in this single-arm study will receive multimodal teleprehabilitation.
9693541|NCT04799574|Experimental|music therapy activity|The music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle.
9693542|NCT04799574|Placebo Comparator|Health education lecture|routine activities of community
9693543|NCT04799652||Doctors within Belgian Hospitals|
9693544|NCT04799496||Vedolizumab|Participants with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-α) antagonist and have initiated vedolizumab treatment in a routine clinical practical setting in South Korea, will be observed prospectively.
9696499|NCT04766346|Experimental|Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form.
9976353|NCT01350622|Experimental|Pennsaid|Active Pennsaid and oral placebo
9976354|NCT01350622|Active Comparator|Oral Diclofenac|Oral diclofenac and placebo lotion (2.3% DMSO solution)
9976355|NCT01350661||Asthma control level assessment|
9976356|NCT01350674|Experimental|EBUS|patients undergoing EBUS
9976357|NCT01350700||Patients that were treated in MW2004-011-02 study with Debrase|
10181757|NCT03780374|Active Comparator|Sound Processing Principle 1|Sound Processing Principle 1 will be applied in the hearing aid.
10181758|NCT03780374|Experimental|Sound Processing Principle 2|Sound Processing Principle 2 will be applied in the hearing aid.
10181759|NCT03780374|Experimental|Sound Processing Principle 3|Sound Processing Principle 3 will be applied in the hearing aid.
10181760|NCT03780387|Experimental|Inhaled Allergen Challenge|Felis Catus sensitive, mild asthmatics will undergo inhaled allergen challenge.
9693545|NCT04799535||Observational (ultrasound)|"AIM 1: Participants undergo a breast ultrasound over 15 minutes.~AIM 2: Participants undergo breast ultrasounds over 15 minutes before starting the chemotherapy, 2 months after start of chemotherapy, and after the completion of chemotherapy before surgery. Participants may also undergo breast ultrasounds at 2 weeks after start of chemotherapy and 1 month after start of chemotherapy.~AIM 3: Patients with suspicious breast masses or known breast cancer who are scheduled for axillary lymph node biopsy undergo ultrasound over 15 minutes at the same visit of the breast mass study."
10181761|NCT03780465|Active Comparator|Oral idronoxil|10 male and female subjects randomised to 400 mg active Oral idronoxil suspension or oral placebo suspension (n=8 active; n= 2 placebo).
9693546|NCT04799418|Experimental|Experimental Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
9693547|NCT04799639|Experimental|paclitaxel + cisplantin + Sindilimab|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles paclitaxel 150mg/m2，ivdrip,>3 hours cisplantin 70mg/m2，ivdrip，>1 hours Sindilimab 200mg，ivdrip, >0.5 hours
9693548|NCT04799314|Experimental|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose 200mg frequency 1 time for 2 months duration 2 years
9693549|NCT04799314|No Intervention|No intervention|No intervention
9693550|NCT04799223|Experimental|Group receiving the 4 designed foods|The experimental group consumes the 4 foods designed for the study and will follow healthy eating guidelines.
9693551|NCT04799223|Active Comparator|Group with no designed foods|The control group follows healthy eating guidelines.
9693552|NCT04799093||Cannabis users|
9693553|NCT04799093||Normals|
9693554|NCT04798976||CDSS (MedicBK) Analysis|
9693555|NCT04798976||Core Laboratory Analysis|
9693556|NCT04798937|Experimental|Intervention group|Youth in this group received usual care, consisting of medical consultations, in combination with a health education program based on motivational interviewing provided by a nurse
9693557|NCT04798937|No Intervention|Control group|Youth in this group received usual care only consisting of medical consultations
9693558|NCT04799119|Experimental|DAID dog training|'Do As I Do' (DAID) dog training employs operant conditioning to train dogs to copy the behavior of their owner upon hearing the verbal cue 'Do it', similar to teaching a dog the rules behind the game 'Simon Says'. Once this rule has been established and generalized, something that can be achieved in dogs by practicing with only 3-6 initially learned behaviors, owners can demonstrate new actions and use the cue 'Do it' to prompt a matched, imitative, behavioral response.
9693559|NCT04799119|No Intervention|Control|No intervention (waitlisted and will be provided with the experimental condition post-study completion).
10181762|NCT03780465|Experimental|NOX66 400 mg|10 male and female subjects randomised to 400 mg active NOX66 (A) suppository or 400 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
10181763|NCT03780465|Experimental|NOX66 600 mg|10 male and female subjects randomised to 600 mg active NOX66 (A) suppository or 600 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
9693560|NCT04799002|Active Comparator|Topotecan|Topotecan intraocular injection during chemotherapy
9693561|NCT04799002|Experimental|Melphalan|Melphalan intraocular injection during chemotherapy
9693562|NCT04798885|No Intervention|Enhanced usual care|Participants will be informed about typical Post Concussion Symptoms and the process of typical recovery as well as given reassurance concerning the prognosis. Advice concerning the use of pain relief medication will also be provided.
9693563|NCT04798885|Experimental|GAIN 2.0 intervention|An eight-week, interdisciplinary intervention program based on principles from cognitive behavioural therapy (CBT) and gradual return to activities.
9693564|NCT04799041|Active Comparator|GTX 2/3|Dose level administered of GTX 2/3 was 80 mcg. Dose was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of GTX 2/3 was injected. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 40 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
9976358|NCT01350700||Patients that were treated in MW2004-011-02 with SOC|
9693565|NCT04799041|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered as IM paravertebral injections, 1 mL per site. Total of 2 mL of placebo was injected.
9976359|NCT01350713|Experimental|povidone iodine|
9693567|NCT04799184|Experimental|Group I Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug/ml completing a volume of 20 ml."
9693568|NCT04799184|Active Comparator|Group II no Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine completing a volume of 20 ml."
9976360|NCT01350713|Active Comparator|cold water|treatment by cold water after burn
9976361|NCT01350726||Normal control|Subjects without liver cirrhosis and normal volunteers.
9976362|NCT01350726||Cirrhosis group|Subjects with liver cirrhosis.
9976363|NCT01350739|Other|intraumbilical incision|an intraumbilical vertical incision is made
9976364|NCT01350739|Other|infraumbilical incision|incision is done in circular fashion at the inferior boarder of umbilicus
9976365|NCT01350752|No Intervention|Control|"In Cameroon: Existing practice (with microscopy widely available)~In Nigeria: Expected practice (RDTs will be provided with basic instructions)"
10181764|NCT03780348|Experimental|New Method|'New' weight-for-height method will be used to assess children assigned to this arm
10181765|NCT03780348|Active Comparator|Existing Method|'Existing' weight-for-height method will be used to assess children assigned to this arm
10181766|NCT03780348|Experimental|Health Extension Workers|Health Extension workers will do weight-for-height assessment using the new method
9693569|NCT04798859|Experimental|Family-centered in home rehabilitation|"Seven individualized meetings with the family (7 sessions whereof most will be videoconferences, with the possibility of 1-2 of the sessions being home visits), one parent group seminar and 4 meetings (three videoconferences and one phone call) with school and local care providers during a period of 4-5 months.~Based on target outcomes areas noted by children and parents, individual goals will be established (2-5 per family). Strategies to meet goals will be established for each goal, and goal attainment scaling will be used to quantify goal attainment."
9693570|NCT04798859|Active Comparator|Control group|Usual health care and rehabilitation services provided in the municipality, including school.
9693571|NCT04799171|Active Comparator|Young Adults (Age group 18-39)|31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
9693572|NCT04799171|Active Comparator|Middle Aged Adults (Age group 40-59)|31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
9693573|NCT04799171|Active Comparator|Old Adults (Age group >60)|31P-Magentic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
9693574|NCT04798807||Hospitalized non-critical services patients|"Patients, who were hospitalized in the clinics (hematology, neurology, gastroenterology, nephrology, endocrine, pulmonary disease and cardiology) of Malatya Training and Research Hospital, were screened both Nutritional Risk Screening 2002 (NRS-2002) and Subjective Global Assessment (SGA) tools within the first days of admission to the patients.~The nutritional status of patients categorized according the screening tools.~Nutritional Risk Screening 2002 (NRS-2002) : The patients were classified as being nutritionally risk (NRS+): total score ≥ 3 or nutritionally risk-free (NRS-): total score < 3 according to NRS 2002 results.~Subjective Global Assessment (SGA) The SGA screening provides three alternative categories for nutritional classification: well nourished (A); mild-to-moderately malnourished (B); or severely malnourished (C)."
9693575|NCT04798963|Other|On-clamp partial nephrectomy|Patients who are assigned to on-clamp partial nephrectomy.
9693576|NCT04798963|Other|Off-clamp partial nephrectomy|Patients who are assigned to off-clamp partial nephrectomy.
9693577|NCT04799028|Active Comparator|Traditional children's fortified cow's milk|
9693578|NCT04799028|Experimental|New toddler milk with synbiotics and fat blend|
9693579|NCT04799028|Other|Toddlers consuming habitual diet|
9693580|NCT04798820|Active Comparator|SE-STG|simplified dietary education arm in subtotal gastrectomy group.
9693581|NCT04798820|Active Comparator|IE-STG|intensive dietary education arm in subtotal gastrectomy group
10181767|NCT03780361|Experimental|Aflibercept injection group|"drug: Eylea (aflibercept) (11.12mg/0.278ml) dose: 2mg (0.05ml) usage: With topical anesthesia and intravitreal injection of aflibercpt in aseptic condition.~frequency and duration: monthly intravitreal aflibercept injections."
9693582|NCT04798820|Active Comparator|SE-TG|simplified dietary education arm in total gastrectomy group.
9693583|NCT04798820|Active Comparator|IE-TG|intensive dietary education arm in total gastrectomy group
9693584|NCT04798690||Growth hormone|Growtropin®-II
9693585|NCT04798846|Active Comparator|External fixator|patient treated by external fixator
9693586|NCT04798846|Active Comparator|Dorsal plate|patient treated by dorsal spanning plate
9693587|NCT04798677|Experimental|Influenza vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Influenza vaccine followed by 30 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
9693588|NCT04798677|Placebo Comparator|Influenza vaccine + placebo|Influenza vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
9693589|NCT04798677|Experimental|Covid-19 vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Covid-19 vaccine followed by 35 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
9693590|NCT04798677|Placebo Comparator|Covid-19 vaccine + placebo|Covid-19 vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
9693591|NCT04798742|Experimental|Gait performance preop vs postop|Pre and postop
9693592|NCT04798742|Experimental|Gait performance postop vs controls|Postop vs controls
9693593|NCT04798547|Placebo Comparator|Standard Length Myotomy|Patients randomized to received 8 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
9693594|NCT04798547|Experimental|Short Length Myotomy|Patients randomized to received 4 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
9693595|NCT04798703|Experimental|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|
9693596|NCT04798456||Patients with DoC|
9693597|NCT04798456||Caregivers/ legal guardian of patients with DoC|
9693598|NCT04798404||Exercise Intervention in 20 collective sessions|104 elders recruited among the community (mean age: 82.1 ± 5.7, 72 women and 32 men), diagnosed in initial consultation with mobility disability risk (sedentary or/and pre-frail/frail or/and sarcopenia at least probable) who participated in 20 collective sessions twice a week and two hours per week, and have been seen for reassessment in final consultation.
9693599|NCT04798638|Experimental|Arm1: TY-9591 + Osimertinib + TY-9591|Participants will receive TY-9591 tablets under fasted condition in period 1 , followed by Osimeritinib Mesylate tablet under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
9693600|NCT04798638|Experimental|Arm2: Osimertinib + TY-9591 + TY-9591|Participants will receive Osimeritinib Mesylate tablet under fasted condition in period 1 , followed by TY-9591 tablets under fasted condition in period 2. In period 3, participants will receive TY-9591 tablet in fed state (high-fat meal). The washout will be no less than 21 days between each treatment.
9693601|NCT04798508|Other|Whole group|"The whole group listen successively the 3 paradigms :~P3 own-name recorded by listening to a smiling voice~P3 own-name recorded by listening to a neutral voice~P3 own-name recorded by listening to a rough voice"
9693602|NCT04798599|Experimental|Intervention|In the intervention group there will be the application of the intervention - use of telemonitoring and teleorientation applied to children in primary care in Dentistry.
10181768|NCT03780530|Active Comparator|subcuticular suturing|
10181769|NCT03780530|Active Comparator|surgical glue|
9693603|NCT04798599|Active Comparator|Waiting list|In the control group, children waiting to be booked to the intervention (in implementation in the unit because of the pandemic) will be evaluated for the outcomes. Only after the evaluation, the control group's children will be invited to perform the teleconsultation (proposed intervention).
9696422|NCT04767542|Active Comparator|Transversus Abdominis Plane Block|With USG, the lateral part of the latissumus dorsi muscle attaches to the external lip of the iliac crest, just behind the middle axillary line and the end is directed slightly cranially, first through the external oblique muscle and fascia, then the internal oblique muscle and fascia, and after hydrodissection with saline for about 15-20 ml of local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally
9696423|NCT04766957|Experimental|Idracare|The treatment will be applied 2 times a week, preferably at night before going to bed.
9696424|NCT04766853|Active Comparator|Dexamethasone|
9696425|NCT04766853|Experimental|Dexamethasone+Hyaluronic Acid|
9696426|NCT04767035|Active Comparator|MELT-100 3/25|MELT-100 3mg midazolam / 25 mg ketamine
9696427|NCT04767035|Active Comparator|MELT-100 2 x 3/25|MELT-100 2 doses of 3mg midazolam / 25mg ketamine
9696428|NCT04767035|Active Comparator|ketamine IV 18mg|
9696429|NCT04767035|Active Comparator|Midazolam IV 3.5mg|
9696430|NCT04766827|Experimental|albumin-bound paclitaxel combined with cisplatin (AP regimen)|Paclitaxel (albumin combined type) 260 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; Cisplatin: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles;
9696431|NCT04766827|Active Comparator|docetaxel combined with cisplatin (TP regimen)|docetaxel: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; cisplatin: 75 mg/m2, d1 every three weeks for a cycle, a total of dosing 2 cycles;
9696432|NCT04766944||Critically ill trauma patients of 50 years old and above|Patients of 50 years old and above admitted to the Montreal General Hospital intensive care unit for trauma
9696433|NCT04766840|Experimental|IM73 CAR-T|"Drug: IM73 CAR-T Cells~Fludarabine~Cyclophosphamide"
9976366|NCT01350752|Active Comparator|Provider Intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment. This involved 1-day training on: 1) Malaria Diagnosis; 2) Rapid Diagnostic Testing; 3) Malaria Treatment. These modules explain that all febrile patients should be tested for malaria; procedures for using an RDT; that confirmed cases of uncomplicated malaria should be treated with an ACT; and test-negative patients should not be given an antimalarial.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment. This involved a 2-day training workshop and support visits. The training covered the following topics: causes and symptoms of malaria; demonstration on how to use an RDT; updated malaria guidelines; and communications skills. The training used a combination of seminars and facilitated small-group work, such as a treatment algorithm game, problem-solving exercises, self-developed participatory drama and role-playing."
9976367|NCT01350752|Active Comparator|Extended intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment AND enhanced provider training on improving quality of care. Clinicians received 3-days of training: the first day was identical to the basic intervention, while the remainder of the course covered three additional modules targeting improvements in quality of care: 4) Adapting to Change; 5) Professionalism; 6) Communicating Effectively.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment AND School-based malaria education intervention (with drama, peer-health education and distribution of health education materials). In addition, teachers and Peer Health Educators were offered support to hold malaria events in which parents, guardians, and other community members could participate in the same types of activities."
9696436|NCT04767048|Experimental|Experimental Arm|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
9696437|NCT04767048|Active Comparator|Control Arm|Tonsillectomy alone (unilateral or bilateral at the choice of the investigator)
9696438|NCT04767074|Experimental|Non-pharmacological Cough control therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Sessions will be designed to target participants' needs and expectations according to the semi-structured theme.~Session 1 General assessment Prescription of cough technique~Session 2 Cough principles of cough Cough control~Session 3 Breathing pattern retraining and laryngeal hygiene~Session 4 Reinforcement of cough control therapies"
9976368|NCT01350765|Experimental|Intervention|This would be the interventional arm of the study, where the LHWs would receive additional training for identification and management of birth asphyxia, lbw, and sepsis.
10181770|NCT03780530|Active Comparator|adhesive steri-strip tape|
9696441|NCT04766905|Experimental|Issa1|Dr.A.Sayed Issa and his team
10181771|NCT03780595|Experimental|Passiflora|
10181772|NCT03780595|Placebo Comparator|Control|
10181773|NCT03780426|Experimental|tSMS left motor cortex (sham right)|30 min of tSMS applied to the left motor cortex with sham on the right motor cortex
10181774|NCT03780426|Experimental|tSMS right motor cortex (sham left)|30 min of tSMS applied to the right motor cortex with sham on the left motor cortex
9696442|NCT04767009|Experimental|SBRT for oligoprogressive NSCLC|
9696443|NCT04766931|Experimental|A1 FB2001 or Placebo|single dose
9696444|NCT04766931|Experimental|A2 FB2001 or Placebo|single dose
9696445|NCT04766931|Experimental|A3 FB2001 or Placebo|single dose
9696446|NCT04766931|Experimental|A4 FB2001 or Placebo|single dose
9696447|NCT04766931|Experimental|A5 FB2001 or Placebo|single dose
9696448|NCT04766931|Experimental|A6 FB2001 or Placebo|single dose
9696449|NCT04766931|Experimental|A7 FB2001 or Placebo|single dose
9696450|NCT04766931|Experimental|B1 FB2001 or Placebo|Once daily for 5 days
9696451|NCT04766931|Experimental|B2 FB2001 or Placebo|Once daily for 5 days
10181775|NCT03780413|Active Comparator|PR-ESSENCE treatment|The treatment group receives PR-ESSENCE for 10 weeks. Outcome measures are collected pre- and post-treatment, and after 6 months and one year.
10181776|NCT03780413|Active Comparator|Control (TAU)|"The control group receives 10 weeks of treatment as usual (TAU) (that is the standard psychoeducation, support and treatment given to all youth after neuropsychiatric assessment at our clinic), followed by 10 weeks of PR-ESSENCE. Outcome measures were collected pre- and post-treatment, and after 6 months and one year."
9693604|NCT04798521|Experimental|Tele-HCV Treatment|Participants allocated to telemedicine intervention arm are scheduled for treatment assessment by a study clinician. For a majority of participants, this will also be the treatment initiation visit. If additional studies are necessary for routine treatment decision making, peers will assist participants in navigating health system barriers and arrangement of second telemedicine visit.
9693605|NCT04798521|Active Comparator|Community Linkage to Care|Participants allocated to the community linkage-to-care arm will complete screening, be offered enrollment, and undergo informed consent as in the telemedicine arm. Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment.
9693606|NCT04798664|No Intervention|Basic Usual Care|Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
9693607|NCT04798664|Active Comparator|Enhanced Usual Care|Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
9693608|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives|Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
9693609|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives plus Mobile Health Application|"Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the future is now between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner."
9693610|NCT04798534|Experimental|Intervention group|CHW in the intervention arm will receive intervention through a combination of in-person training sessions and internet support. MMT patients in the intervention arm can use a specially designed online platform to communicate with their CHW.
9693611|NCT04798534|No Intervention|Control group|The control group CHW will perform business as usual. Both control group CHW and MMT patients do not have access to the online platform.
9693612|NCT04798417|Experimental|Probiotic|
9693613|NCT04798417|Experimental|Prebiotic|
9693614|NCT04798417|Placebo Comparator|Maltodextrin|
9693615|NCT04798612|Experimental|Intervention arm|Two 45 mikrogram doses of interferon-alfa2a (Pegasys). Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
9693616|NCT04798612|Placebo Comparator|Placebo|Two 1 ml doses of saline liquid. Both will be applied subcutanously. First dose is at least one week before surgery. Second dose on the day of surgery before the procedure.
9693617|NCT04798560||Patients undergoing Whipple operation|After Whipple operation patients will be observed for complications and emphasis will be given on the presence of postoperative pancreatic fistula (POPF) according to the ISGPF 2016 definition. There will be to arms of patients. The first will include patients that do not develop POPF or either develop Biochemical Leak (Grade A). The second group consist of patients that develop either Grade B or Grade C POPF
9693618|NCT04798443|Active Comparator|Subureteral endoscopic injection|The endoscopic procedure was done under general anesthesia, and all patients received antibiotic prophylaxis. We used the subureteral injection technique (STING), as described by O'Donnell and Puri (1984). The volume of Dx/HA was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
9693619|NCT04798443|Active Comparator|open ureteral reimplantation (lich-gregoir)|extravesical ureteral reimplantation (lich-gregoir) by open surgery
9693620|NCT04798313|Experimental|MW031|MW031 injection (60mg) by subcutaneous injection once on the first day of treatment.
9693621|NCT04798313|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day of treatment.
9693622|NCT04798287||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
9693623|NCT04798287||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
9693624|NCT04798326|Experimental|MW032|MW032 injection (120mg) by subcutaneous injection once on the first day of treatment.
9693625|NCT04798326|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day of treatment.
9693626|NCT04798391|Experimental|Dexamethasone with lignocaine|
9693627|NCT04798105|Sham Comparator|tDCS sham|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in sham mode.
9693628|NCT04798105|Active Comparator|tDCS anodal|Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (dlPFC) in anodal/excitatory mode.
9693629|NCT04798183||Healthy participants|
9693630|NCT04798183||Amyotrophic Lateral Sclerosis with bulbar involvement patients|
9693631|NCT04798430|Experimental|LIB003 (lerodalcibep)|300 mg monthly (Q4W) by subcutaneous injection
9693632|NCT04797988|Experimental|eon FR 1064 nm Device|Patient will be treated with the eon FR 1064 nm device.
9693633|NCT04798144|Experimental|Cryotherapy group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at 2.5°C in the refrigerator using EndoVac negative pressure irrigation system.
9693634|NCT04798144|Placebo Comparator|Control group|Final canal irrigation will be done for 5 minutes with 20 mL of distilled water kept at room temperature in the refrigerator using EndoVac negative pressure irrigation system.
9693635|NCT04797923|Experimental|Intraperitoneal paclitaxel with systemic chemotherapy|
10181777|NCT03780309|Active Comparator|EXERCISE|Participants participated in a the exercise training program and engaged in exercise self-monitoring.
9693636|NCT04798157|Experimental|Children with Hemoglobinopathies|children from 2-18 years old , diagnosed to have hemoglobinopathy disease
9693637|NCT04798001|Experimental|Cohort A / Dosage Group 1 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
9693638|NCT04798001|Experimental|Cohort A / Dosage Group 2 (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
9693639|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
9693640|NCT04798001|Experimental|Cohort A / Dosage Group 3a (intranasal drops) / Two Doses|Participants in this arm (18-55 years) will receive an intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1. These participants will receive a second, identical dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 36.
9693641|NCT04798001|Experimental|Cohort A / Dosage Group 3b (intranasal spray) / Single Dose|Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of a nasal spray on Day 1.
9693642|NCT04798001|Experimental|Cohort B / Dosage Group 4 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
9693643|NCT04798001|Experimental|Cohort B / Dosage Group 5 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
9693644|NCT04798001|Experimental|Cohort B / Dosage Group 6 (intranasal drops) / Single Dose|Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
9693645|NCT04798040|No Intervention|Control group|"Routine treatment and nursing care of the clinic will be applied to the patients without any application.~Routine interventions applied to the control group during silicone drain removal in the clinic:~The patient will be informed about the procedure.~The consent of the patient who agrees to participate in the study will be obtained.~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale .~The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.~The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
9693646|NCT04798040|Experimental|Cold application group|The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale. A gel pad with a temperature of -10 ° C and a homogeneous distribution when cooled will be placed so that the patient is in full contact with the silicone drain.Since the skin temperature must fall below 13.6 ° C for cold application to have a local analgesic effect, the application will be terminated when the patient's skin temperature is 13.6 ° C by measuring every one minute during the cold application and the physician will be informed that the patient is ready.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale15 minutes after the removal of the silicone drain.
9693647|NCT04798040|Experimental|Lavender oil group|"All patients who accept the study will be tested for lavender oil before the procedure to exclude sensitivity to lavender. Patients in the lavender group will be given oxygen with a lavender oil covered face mask 15 minutes before the silicone drain is removed. Two drops of 2% lavender oil will be applied with a cotton swab inside the oxygen face mask.~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
9693648|NCT04797871|Experimental|Exercise|Resistance training
9693649|NCT04797871|Active Comparator|Standard care|Non-supervised ACSM exercise guidelines
9693650|NCT04798300|Other|tested material|Newly Introduced Gradient Monolithic Zirconia (Intervention)
9693651|NCT04798300|Active Comparator|comparator material|Full Strength Monolithic Zirconia (Comparator)
9693652|NCT04798365|Experimental|Intervention group|The main components of the intervention are 1) two sessions of voluntary continuing medical education on the urinary tract infection program in each LTCF for physicians and nursing staff, 2) distribution of educations materials such as written guidelines on antibiotic prescribing including a smart phone friendly version, 3) implementation of the project homepage as a platform to distribute guidelines and educational videos and to enable physicians to ask questions which will be answered by an infectious disease physician.
9693653|NCT04798365|No Intervention|Control group|No intervention until end of the stuy.
9693654|NCT04797936|Active Comparator|Treatment group BNO 1030|BNO 1030
9693655|NCT04797936|Other|Control group|Standard care
9693656|NCT04797806|Experimental|combination therapy|Anlotinib Combined With Icotinib
9693657|NCT04797806|Other|monotherapy|Icotinib
9693658|NCT04797975|Experimental|KDS-1000|NK cells expanded ex vivo using PM21 membrane particles:
9693659|NCT04797975|Placebo Comparator|Control|0.9% Normal Saline
9693660|NCT04797949|Active Comparator|Randomized to USPSTF Criteria|Women randomized to knowing their risk of preeclampsia and therefore, candidates for low dose aspirin.
9693661|NCT04797949|Active Comparator|Randomized to Universal aspirin receipt|Women randomized to receiving low dose aspirin without knowing their risk status.
9693662|NCT04798222|Experimental|Group 1: Treatment Sequence ABECD|Participants will receive a single oral dose of Treatments A, B, E, C, and D in Treatment periods 1 to 5 on Day 1 of the study.
9693663|NCT04798222|Experimental|Group 1: Treatment Sequence BACED|Participants will receive a single oral dose of Treatments B, A, C, E, and D in Treatment periods 1 to 5 on Day 1 of the study.
9693664|NCT04798222|Experimental|Group 1: Treatment Sequence CDBEA|Participants will receive a single oral dose of Treatments C, D, B, E, and A in Treatment periods 1 to 5 on Day 1 of the study.
9696452|NCT04767087|Active Comparator|Honey and Nigella sativa Arm|0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds
10181778|NCT03780309|Experimental|EXERCISE+PEH|Participants participated in the exercise training program and engaged in exercise self-monitoring and blood pressure self-monitoring (daily and before and after exercise).
10181779|NCT03780270|Active Comparator|Control|"Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application at Day 0 and Day180.~=> Group: Fluoride Varnish"
9693665|NCT04798222|Experimental|Group 1: Treatment Sequence EADBC|Participants will receive a single oral dose of Treatments E, A, D, B, and C in Treatment periods 1 to 5 on Day 1 of the study.
9693666|NCT04798222|Experimental|Group 2: Treatment Sequence AFHG|Participants will receive a single oral dose of Treatments A, F, H, and G in Treatment periods 1 to 4 on Day 1 of the study.
9693667|NCT04798222|Experimental|Group 2: Treatment Sequence FGAH|Participants will receive a single oral dose of Treatments F, G, A, and H in Treatment periods 1 to 4 on Day 1 of the study.
9693668|NCT04798222|Experimental|Group 2: Treatment Sequence GHFA|Participants will receive a single oral dose of Treatments G, H, F, and A in Treatment periods 1 to 4 on Day 1 of the study.
9693669|NCT04798222|Experimental|Group 2: Treatment Sequence HAGF|Participants will receive a single oral dose of Treatments H, A, G, and F in Treatment periods 1 to 4 on Day 1 of the study.
9693670|NCT04797741|Experimental|IDEA3 Intervention|
9693671|NCT04797624||Baseline group|The baseline group included the patients diagnosed with gastric cancer between January 1, 2019, and December 31, 2019, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
9693672|NCT04797624||Pandemic group|The pandemic group included the patients diagnosed with gastric cancer during the period between March 1, 2020, and December 31, 2020, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
9693673|NCT04797819||Serum sST2 level < 14.5 ng/mL|
9693674|NCT04797819||14.5 ng/mL ≤ Serum sST2 level < 20.5 ng/mL|
9693675|NCT04797819||20.5 ng/mL ≤ Serum sST2 level < 25.9 ng/mL|
9693676|NCT04797819||Serum sST2 level ≥ 25.9 ng/mL|
9693677|NCT04797728|Experimental|Elacestrant|400 mg given orally (PO), once a day, in a continuous schedule (QD). 4 weeks (+/- 2 days) of elacestrant treatment
9693678|NCT04797832|Active Comparator|Treatment|100 patients receiving IV Iron during index hospitalisation.
9693679|NCT04797832|No Intervention|No treatment|100 patients not receiving IV Iron above standout treatment.
9693680|NCT04797546|Experimental|Adductor Canal Block|With mild sedation, a continous bupivacaine 0.1% infusion catheter is placed in the adductor canal. Afterwards, patients are placed under General Anesthesia, and surgery starts. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
9693681|NCT04797546|Active Comparator|Patient Controlled Morphine Analgesia|Patients are placed under General Anesthesia, and after surgery, a Morphine patient controlled analgesia delivery system is installed. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
9693682|NCT04797793|Experimental|Adapalene gel 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9693683|NCT04797793|Active Comparator|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9693684|NCT04797793|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9693685|NCT04797702|Experimental|Experimental group|Glumetinib combined with Toripalimab
9693686|NCT04797845|Experimental|telemonitoring of non invasive ventilation at home|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months. Ventilation machines make it possible to carry out remote monitoring, with the help of healthcare providers.
9693687|NCT04797377|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
9976369|NCT01350765|Active Comparator|Control|This would be the comparative group of the study in which the LHWs would perform the usual routine tasks assigned to them by their program.
9976370|NCT01350778||Biomatrix stent|patients treated with Biomatrix stent
9976371|NCT01350791||Promus Element stent|Patients receiving Promus Element stents
9976372|NCT01350817|Active Comparator|Docetaxel|
10181780|NCT03780270|Experimental|Test1|"Single application of Curodont Repair (P11-4) at Day 0 followed by a Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application. Another fluoride Varnish application at Day180.~=> Group: Curodont Repair + Fluoride Varnish"
9693688|NCT04797494|No Intervention|Control Group|No acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear.
9693689|NCT04797494|Experimental|Experimental Group|A acrylic Removable Appliance (RA) was prescribed for patients prior to restorative treatment of generalized severe tooth wear. Patients were asked to wear the RA 3 weeks prior to restorative treatment for 24h per day, except for when eating.
9696453|NCT04767087|Placebo Comparator|Placebo Arm|empty capsule with sugar water
9696454|NCT04767113|Experimental|Heparin group|Continuous infusion of heparin was used to maintain the patency of CVC.
9696455|NCT04767113|Placebo Comparator|Control group|Continuous infusion of heparin was used at the corresponding speed.
9976373|NCT01350817|Experimental|Erlotinib|
9976374|NCT01350830|Active Comparator|pre-trasversalis mesh repair group|
9976375|NCT01350830|Active Comparator|trans-inguinal preperitoneal patch group|
9976376|NCT01350843|Experimental|Orange Juice|Juice high in flavonoids
9976377|NCT01350843|Placebo Comparator|Orange Drink|Sugars matched, low flavonoids orange drink
9976378|NCT01350856|Active Comparator|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
9693690|NCT04797676||EUS-FNB group|Each patient participated in the EUS-FNB group and the surgery group. The procedure of EUS-FNB with wet suction technique is as follow: before the needle was inserted into the biopsy channel, the stylet was removed, and the needle was flushed with saline solution until the fluid dripped out of the needle tip. The air column was replaced with the fluid. A 10-mL syringe was prefilled with 2 mL of saline solution, and the valve was closed. The syringe was loaded to the 5-mL position (i.e. a 3-mL vacuum) and then attached to the proximal port and used for biopsy after inserting into the biopsy channel and puncturing the lesion. Each patient was performed 1-2 passes to obtain specimens for subsequent experiments.
9693691|NCT04797676||surgery group|Each patient participated in the EUS-FNB group and the surgery group. The patient underwent EUS-FNB with wet suction technique first, followed by surgery (palliative surgery without excising tumor is not included) for pancreatic cancer. According to the size of the specimen, 0.5cm3-1cm3 tumor specimen was used for subsequent experiments.
9693692|NCT04797572|Other|Treated group|Patients in whom the free margin cusp sizer will be used to measure the free margin of the three leaflets of the aortic valve during aortic valve repair.
9693693|NCT04797507|Experimental|Treatment Group|SHR-1210 plus Anlotinib
9693694|NCT04797468|Experimental|HLX23|HLX23 administered IV.
9693695|NCT04797598|Active Comparator|Virtual Reality group|In this group patients will be treated with virtual reality . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The virtual reality group will receive 30 minutes virtual reality training and 30 minutes conventional treatment.
10181781|NCT03780270|Experimental|Test2|"Single application of Curodont Repair (P11-4) at Day 0. Curodont Protect (tooth gel containing P11-4 matrix) is handed out and subjects are asked to apply it 2x weekly at home after regular teeth cleaning in the evening for the whole study period (Day 360).~=> Group: Curodont Repair + Curodont Protect"
10181782|NCT03780075|Experimental|1.11GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
10181783|NCT03780075|Experimental|1.85GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
9693696|NCT04797598|Active Comparator|Cyclic training group|In this group patients will be treated with cyclic training . This group will receive therapy session for 1 hour, two times in a week and for 12 weeks, total session will be 24. The cyclic training group will receive 30 minutes cyclic training and 30 minutes conventional treatment
9693697|NCT04797481|Experimental|Novel Intervention|Novel Intervention Exercise group.
9693698|NCT04797481|Active Comparator|Control|Self-managed Exercise group.
9693699|NCT04797364|Experimental|Pharmacogenetic Testing|Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)
9693700|NCT04797637|Experimental|Treatment Group|Patients randomized to the treatment group will have the ABBy device applied by study personnel at the time of randomization, followed by a continuation of usual postoperative care.
9693701|NCT04797637|No Intervention|Standard of Care|The control group will have postoperative care per usual care
10181784|NCT03780075|Experimental|3.70GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
10181785|NCT03779815|Experimental|[18F]Florbetaben PET/CT imaging|"Maximally 18 subjects with multiple myeloma (up to 6 subjects in whom amyloidosis in suspected and up to 12 subjects in whom amyloidosis is not suspected)~Intravenous injection of [18F]Florbetaben and PET/CT scanning~Intervention: Drug ([18F]Florbetaben)"
10181786|NCT03779893|Active Comparator|conventional group|Conventional resin based Pits & fissures sealant 3M™ Clinpro™ Sealant is administrated
10181787|NCT03779893|Experimental|bioactive group|Bioactive Pits & fissures sealant BioCoat® by Premier®.
10181788|NCT03780062|Experimental|S100B protein dosing|
9693702|NCT04797351|Experimental|Condition 1 - Experimental Group|"Pre-treatment session + 12 Sessions Group Intervention~TAU - Treatment as usual (Psychiatric support through Public health system)"
9693703|NCT04797351|No Intervention|Condition 1 - Control Group|"TAU - Treatment as usual (Psychiatric support through Public health system)~Waiting list (will have access to the intervention program BI-REAL after the 3 month follow up assessment)"
9693704|NCT04797351|Experimental|Condition 2 - Experimental Group|"Pre-treatment session + 12 Sessions Group Intervention~TAU - Treatment as usual (Psychiatric support through Public health system)~Specialized support for Bipolar Disorder (members of an association - ADEB - that provides psychoeducation about BD, and psychological support)"
9693705|NCT04797351|No Intervention|Condition 2 - Control Group|"TAU - Treatment as usual (Psychiatric support through Public health system)~Specialized support for Bipolar Disorder (members of an association - ADEB - that provides psychoeducation about BD, and psychological individual support)~Waiting list (will have access to the intervention program BI-REAL after the 3 month follow up assessment)"
9693706|NCT04797403|Experimental|Intervention|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
10181789|NCT03779776|Experimental|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d, containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
10181790|NCT03779776|Placebo Comparator|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d,VD 80 IU/kg/d ) within daily on parenteral nutrition until fed 120ml/kg.
10181791|NCT03780049|Experimental|HAIC plus H101|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and recombinant human type-5 adenovirus 0.5ml via hepatic artery
10181792|NCT03780049|Active Comparator|HAIC|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and normal saline via hepatic artery
10181793|NCT03780036|Experimental|porous collar|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous, to allow for bone ingrowth and stabilization of the implant.
10181794|NCT03780036|Experimental|porous collar with hydroxyapathite|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous and covered with hydroxyapathite particles, to allow for bone ingrowth and stabilization of the implant.
10181795|NCT03779945|Active Comparator|posteriolateral lumbar fusion +bone graft+ PRP|the addition of autologous platelet rich plasma to the bone graft
9693707|NCT04797403|No Intervention|Enhanced Usual Care|Enhanced usual care will include an education session on the ACC/AHA hypertension guideline to providers and proper BP measurement to providers and staff at enhanced usual care clinics.Otherwise, no active intervention will take place, and all usual care clinics will follow their routine clinic practice.
9976379|NCT01350856|Experimental|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
9976380|NCT01350869||Xience stent|Real world patients treated with XIENCE stents
9693710|NCT04797247|Experimental|LIB003 (lerodalcibep)|300 mg subcutaneously monthly (Q4W)
9693711|NCT04797247|Placebo Comparator|Placebo|matching placebo subcutaneously monthly (Q4W)
9693712|NCT04797234|Experimental|Control|There will be no intervention to the control group.
9693713|NCT04797234|Experimental|Experiment|The experimental group will be trained for 6 weeks.
9693714|NCT04797689|Experimental|Trauma Informed Yoga|Participants will receive 12 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
9693715|NCT04797689|Experimental|Trauma Informed Psychotherapy|Participants will receive 12 x 120 min group-based psychotherapy sessions, delivered synchronously over Zoom.
9693716|NCT04797689|No Intervention|Control|These participants will not receive an intervention.
9693717|NCT04797455|Experimental|PI+ Inpatient Treatment as Usual|"Standard inpatient treatment delivered in the context of an adolescent psychaitric inpatient unit plus an 4 session DBT-based parenting intervention PI)~Intervention: Behavioral: DBT-Based Parenting Intervention"
9693718|NCT04797455|Active Comparator|Inpatient Treatment alone|"No parenting intervention provided beyond what is part of the inpatient treatment as usual.~Intervention: Behavioral: Treatment as Usual"
9693719|NCT04797338|Active Comparator|GnRHa treatment based luteal support|Patients will initiate intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be stopped.
9693720|NCT04797338|Active Comparator|Estrogen and progesterone supplementation|Patients will start treatment with a combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of progesterone retard 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum hCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
9693721|NCT04797273|Experimental|Internet-based cognitive behavior therapy|
9693722|NCT04797273|Active Comparator|Internet-based structured treatment-as-usual|
9693723|NCT04797182|Experimental|blank control|No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.
9693724|NCT04797182|Experimental|primary prevention|"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.~Drug-withdrawal indications:~PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.~When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued"
9693725|NCT04797663|Active Comparator|Nd-YAG laser|laser hair removal
9693726|NCT04797663|Experimental|TCA 20%|chemical peel
9693727|NCT04797286|Experimental|Sildenafil|Sildenafil 20 mg by mouth three(3) times each day
9693728|NCT04797286|Placebo Comparator|Placebo|Placebo by mouth three(3) times each day
9693729|NCT04797416|Active Comparator|1-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 1 hour.
9693730|NCT04797416|Experimental|6-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 6 hours.
9693731|NCT04797416|Experimental|12-hour group|The time between the activation of the sensor and the storage of the first blood glucose value is 12 hours.
10181796|NCT03779945|Active Comparator|posteriolateral lumbar fusion+bone graft only|posteriolateral lumbar fusion with adding autologus bone graft alone posteriolateral lumbar fusion only
10181797|NCT03779802|Experimental|CRT device|Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes
10181798|NCT03780608|Experimental|GC|Patients with refractory gastric cancer who have failed secondary chemotherapy treatments for advanced disease will be enrolled. Patients must have imaging confirmed progression on previous chemotherapy for gastric cancer treatment with at least one measurable lesion per modified RECIST 1.1. GC patients must not have received previous therapy with immune checkpoint inhibitors. Prior exposure to AZD6738 is not allowed.
9693732|NCT04797013|Active Comparator|rhTNK-tPA (0.25mg/kg)|rhTNK-tPA (0.25mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.
10181799|NCT03780608|Experimental|Melanoma|Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.
10181800|NCT03780296|Experimental|Real-Time Action Observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
10181801|NCT03779789|Experimental|vortioxetine|
10181802|NCT03779789|Active Comparator|SSRIs|
10181803|NCT03779971|Placebo Comparator|Control|The placebo comparator will be a fully controlled diet made from typical American foods and containing no beans or pulses.
10181804|NCT03779971|Experimental|Lentil|The lentil arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain lentils.
10181805|NCT03779971|Experimental|Chickpeas|The chickpea arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain chickpeas.
10181806|NCT03779919|Experimental|High Energy|Extracorporeal shock wave therapy with 0.3 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
10181807|NCT03779919|Experimental|Low Energy|Extracorporeal shock wave therapy with 0.05 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
10181808|NCT03779919|Placebo Comparator|Sham|Extracorporeal shock wave therapy with 0 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
10181809|NCT03780283|Experimental|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
10181810|NCT03780283|No Intervention|placebo|observation
10181811|NCT03779958||Study Group|All patients will be given information about a mobile app to use during the recovery period to assist with hand therapy activities
10181812|NCT03780335||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
10181813|NCT03780335||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
10181814|NCT03780088|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
10181815|NCT03779737|Active Comparator|Habitual training|The control group will be monitored passively for the detection of adverse or secondary events.
10181816|NCT03779737|Experimental|Muscular resistance training|This phase includes the execution of the study with three arms, one group will be assigned to strength training and the other to aerobic capacity training, taking into account the plan of sessions per week.
10181817|NCT03779737|Experimental|Cardiorespiratory training|In stage, a combined program of strength and aerobic capacity will be implemented, which will last six months more than will be compared with the previously defined control group.
10181818|NCT03779750||End Stage Renal Disease Patients|complete blood picture blood urea s.creatinine urine analysis calcium phosphorus parathyroid hormone. 4- Hepatitis BsAg,HCV-Abs and HIV.
10181819|NCT03779698|Experimental|BiodentineTM pulpotomy group|A Bioactive Dentine Substitute (BiodentineTM, Septodont Ltd., Saint Maur des Faussés, France) was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface.
10181820|NCT03779698|Active Comparator|Formocresol pulpotomy group|A sterile cotton pellet moistened with 1:5 concentration formocresol (Buckley's Formocresol, Sultan Healthcare, Englewood, NJ, USA) then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing.
10181821|NCT03779685|Active Comparator|General anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
10181822|NCT03779685|Experimental|Regional anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
10181823|NCT03779633|Experimental|Linoladiol Estradiol|Linoladiol Estradiol cream 6 weeks before surgery of pelvic organ prolapse
10181824|NCT03779633|Placebo Comparator|Placebo|Placebo cream 6 weeks before surgery of pelvic organ prolapse
10181825|NCT03779542||open-angle group|ACD > 2.68 measured by the swept source AS-OCT and angle > Shaffer 2 in four quadrants under gonioscope
10181826|NCT03779542||narrow-angle group|ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope
10181827|NCT03779516|Active Comparator|Group C|In Control Group, 4 mL of saline solution was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
10181828|NCT03779516|Active Comparator|Group L|In Lidocaine Group 4 mL of 4% lidocaine was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
10181829|NCT03779607|Active Comparator|IPS e.max Press(lithium di silicate)|Lithium disilicate reinforced glass ceramics are available in the market in two forms according to the technique of manufacturing, either heat pressed ingots or CAD/CAM blocks for milling. The heat pressed lithium disilicate glass ceramic consists of approximately 70% lithium disilicatecrystals(the main crystal phase) having a needle like shape that are embedded in a glassy matrix. The crystals length is about 3 to 6 μm. The heat pressed ingots are fully crystallized and the restoration is fabricated by the lost wax technique where the lithium disilicate ingots are pressed into the investment mold at high temperature. The pressed lithium disilicate has strong flexural strength values(range 400 ± 40 MPa)
10181830|NCT03779607|Experimental|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
9693733|NCT04797013|Active Comparator|rt-PA (0.9mg/kg)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the remainder in 1 hour. Maximum dose 90mg.
10181831|NCT03779451|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery
10181832|NCT03779451|Active Comparator|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily at bedtime starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
10181833|NCT03779451|No Intervention|control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
10181834|NCT03779555||Patients taking lenalidomide for multiple myeloma|-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)
10181835|NCT03779594|Experimental|treatment group|patients who met the inclusion criteria will be allocated to the treatment group, and will receive acetazolamide from time of diagnosis until shunt surgery (2-6 weeks).
10181836|NCT03779464|Experimental|S/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
10181837|NCT03779464|Active Comparator|Gem/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)
10181838|NCT03779568|Experimental|Dose adjustment of bupivacaine|Patient will receive isobaric bupivacaine based on previous patient experience.
10181839|NCT03779581|Experimental|Exercise Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting. In addition, 7 of the randomly selected patients received De-rotation Breathing Exercises.
10181840|NCT03779581|Active Comparator|Control Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting.
10181841|NCT03779659|Experimental|Synapse TENS device|SYnapse TENS device will be used for alleviating pain through electrical stimulation. This is a battery powered device where an electrical current is applied intra-orally on the buccal and lingual sides using an intra-oral pad applicator. This device has been cleared for marketing by the Food and Drug Administration (FDA) and the prescribed electrical field falls almost a 10 factor level lower than routine pulp testing devices used in dentistry. The TENS device was previously tested in a pilot study with promising results. Chair side application and at-home use of the device by the patient was shown to drastically reduce pain and discomfort associated with orthodontic tooth movement.
10181842|NCT03779659|Active Comparator|Topical anesthetic gel|Topical anesthetic Gel is the active comparator in this study. The topical anesthesia (anesthetic gel) Centrix LolliCaine with 20% benzocaine in single package of 0.3 ml will be used. The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure. This will be done based American Association of Pediatric Dentistry guidelines for the use of local anesthesia.
10181843|NCT03779646|Experimental|bisoprolol fumarate|In this arm, the participants will receive different dose of bisoprolol fumarate.
10181844|NCT03779646|No Intervention|Control|In the control (no beta blocker) group, the patients not taking beta blocker will receive outpatient clinic or video visit every 8 weeks and provide their cardiac symptoms, heart rate, blood pressure and ECG. After 12 months , the patients will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG,BNP and echocardiography records.
10181845|NCT03779672|Active Comparator|Memantine Hydrochloride 10 mg Placebo|"Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.~Dose regimen:~Memantine Hydrochloride~Week #1: 5 mg id (am), 1 caps~Week #2: 5 mg bid (am and pm), 2 caps~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps~Washout (Weeks #7-8)~Placebo~Week #9: id (am), 1 caps~Week #10: bid (am and pm), 2 caps~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps"
10181846|NCT03779672|Placebo Comparator|Placebo Memantine Hydrochloride 10 mg|"Placebo~Week #1: id (am), 1 caps~Week #2: bid (am and pm), 2 caps~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps~Washout (Weeks #7-8) Memantine Hydrochloride~Week #9: 5 mg id (am), 1 caps~Week #10: 5 mg bid (am and pm), 2 caps~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
10181847|NCT03779399||Patient with benign ovarian tumor|25 patients with benign ovarian tumor (cystadenoma) were admitted to IInd Department of Gynecology, Lublin Medical University, Lublin, Poland.
10181848|NCT03779399||Patient with borderline tumor|11 women with borderline ovarian tumor were admitted to IInd Department of Gynecology
10181849|NCT03779399||Patient with ovarian cancer|24 women with ovarian cancer were admitted to IInd Department of Gynecology
10181850|NCT03779399||Patient without ovarian pathology|20 patient with unexpleined infertility were admitted to IInd Department of Gynecology
10181851|NCT03779282||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving ketodex
10181852|NCT03779282||study|pediatric patients undergoing outpatient strabismus surgery, and receiving ketodex
10181853|NCT03779321|Other|Lean panelists|Lean panelists or normal weight panelists with a BMI between 18.5 and 24.9 Acceptability was assessed
10181854|NCT03779321|Other|Obese panelists|Obese panelists with a BMI between 25 and 29.9 Acceptability was assessed
10181855|NCT03779425|Experimental|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
10181856|NCT03779256||Women with bowel endometriosis.|"Women with symptomatic bowel endometriosis scheduled for surgical treatment investigated with 2D transvaginal ultrasound before surgery at Hospital St John of God, Vienna, Austria; Oslo university hospital, Oslo, Norway and Nepean Hospital, Sydney, Australia.~The women recruited at Oslo university hospital, Norway will also have a magnetic resonance imaging (MRI) of the abdomen and pelvis before surger."
10181857|NCT03779386|Experimental|Music during labor and delivery|Music during labor and delivery
10181858|NCT03779386|No Intervention|No music during labor and delivery|No music during labor and delivery
10181859|NCT03779412|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Happiness Trap by Harris (2008), a self-help book based on acceptance and commitment therapy.
9693734|NCT04797130|No Intervention|Control group|All subjects eligible for inclusion in this study receive usual care physiotherapy as prescribed by the physician. The number of treatment sessions and content of physiotherapy treatment sessions will depend on the diagnosis and needs of the individual patient. This study will not interfere with the content of the usual care physiotherapy treatment. Patients in the control group will receive an accelerometer, measuring PA, which is applied by the physiotherapist during the first treatment. They receive no other additional intervention. Usual care physiotherapy sessions will take approximately 20-30 minutes per session.
10181860|NCT03779412|Active Comparator|MBSR self-help book condition|Participants in this condition will be assigned to read A Mindfulness-Based Stress Reduction Workbook by Stahl and Goldstein (2010), a self-help book based on Mindfulness-Based Stress Reduction.
10181861|NCT03779477|Experimental|Coping with Stress Course|The Coping with Stress Program that consists of 8 sessions will be implemented to the experimental group. 8-10 adolescents will be included in this program. The session frequency will be one session per week. After the completion of 8 sessions, two 90-minute sessions will be carried out each month in the following two months.
10181862|NCT03779477|No Intervention|Control|There will be no intervention in the control group. If the program will be effective, this group will also undergo the Coping with Stress Program after the termination of the study.
10181863|NCT03779360|Active Comparator|Subjects 1-6|7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
10181864|NCT03779360|Experimental|Subjects 7-24|7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
10181865|NCT03779360|Active Comparator|Subjects 25-30|0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
10181866|NCT03779347|Experimental|Schistosomiasis treated during pregnancy|Praziquantel 40mg/kg once will be given during pregnancy at second to third trimester
10181867|NCT03779347|Active Comparator|Schistosomiasis treated after pregnancy|Praziquantel 40mg/kg once will be given to parturient after delivery during lactation
10181868|NCT03779347|Experimental|All study participants|UCP-LF CAA and composite diagnostic reference test based on extensive egg microscopy, plus serology, plus qPCR on egg DNA, and plus POC-CC will be used to detect schistosomiasis infection in pregnant women
10181869|NCT03779529|Active Comparator|Arm label extra-vergin olive oil (EVOO)|Participants will ingest two tablespoons of extra-vergin olive oil (EVOO) Coratina during the day: one spoon containing 10g of olive oil (>5mg of total biophenols/kg of olive oil) at lunch and one at dinner. The total biophenols ingested per day will be >10mg.
10181870|NCT03779529|Active Comparator|Arm label refined olive oil (ROO)|Participants will ingest two tablespoons of refined olive oil during the day: one spoon containing 10 g of refined olive oil at lunch and one at dinner.
10181871|NCT03779373|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
10181872|NCT03779373|Experimental|EV1000 monioring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
10187564|NCT03725020|Experimental|Fluoride varnish|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply the test varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The NFV test varnish has mint flavour and the active ingredient is ammonium fluoride dissolved in ethanol, water and an acrylate polymer.
10187565|NCT03725020|Placebo Comparator|Varnish without Fluoride|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply either the placebo varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The placebo varnish has an identical composition as the test varnish except for the ammonium fluoride. Thus, taste, colour and handling properties are the same.
10187566|NCT03724955|Experimental|Treatment Group|The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
10187567|NCT03724955|Placebo Comparator|Placebo Group|The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
10187568|NCT03724929|Experimental|Ulcerative Colitis patients|"To determine if the best cut-off points of vedolizumab (VDZ) trough levels measured at W6 capable to identify UC patients who will achieve a clinical response at week 10 with VDZ and also the best cut-off points of VDZ trough levels measured at W14 capable to identify UC patients who will achieve a clinical remission to maintenance therapy with VDZ :~Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.~Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52, to evaluate treatment efficacy.~In cases of loss of response, rectosigmoidoscopy will be performed before and four weeks after optimization."
9693735|NCT04797130|Experimental|Intervention group|Patients in the intervention group will receive usual care physiotherapy and use Hospital Fit 2.0 (HF) additionally. After the last treatment session (max. 7 days), the therapist will remove the accelerometer and participation in the study will end.
9693736|NCT04797143||control group|patients in control group receive standard care
9693737|NCT04797143||intervention group|intervention group after implementation of a MCP
9693738|NCT04797169|Experimental|Noom Health|
9693739|NCT04797169|Active Comparator|Noom Digital Health|
9693740|NCT04796987||cervical myelopathy|MR images of patients with cervical myelopathy
9693741|NCT04796987||normal|normal section of the MRI of patients with cervical myelopathy
9693742|NCT04797117|Other|blood sample|The blood samples for the study for each patient will be collected in the form of additional tubes.
9693743|NCT04797052|Experimental|Post operative patients|Post operative patient in orthopedic and digestive surgery
9693744|NCT04797104|Experimental|LIB003 (lerodalcibep)|300 mg (1.2 mL) SC Q4W
10181873|NCT03779178|Experimental|Landiolol group|Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours
9693745|NCT04797104|Placebo Comparator|Placebo|1.2 mL SC Q4W
10181874|NCT03779178|Placebo Comparator|Placebo group|Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours
10181875|NCT03779438|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
10181876|NCT03779438|Placebo Comparator|placebo to 17-OHPC|patients received weekly placebo to 17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
10181877|NCT03779308|Experimental|Intervention|The participants will receive whole body vibration therapy while standing with hand support on a vibration platform.
10181878|NCT03779217||group A|In this group there are women in that the mammography shows a breast represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue.
10181879|NCT03779217||group B|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue
10181880|NCT03779217||group C|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range 25-50% and the rest is from fibro-glandular tissue.
10181881|NCT03779217||group D|In this group there are women in that the mammography shows a breast represented by almost entirely fibro-ghiandular tissue.
10181882|NCT03779139|Active Comparator|Intrahepatic islets alone|
10181883|NCT03779139|Experimental|Intrahepatic and omental pouch islets|
10181884|NCT03779139|Sham Comparator|Normal Volunteers|
10181885|NCT03779204|Experimental|Rent subsidies + Mentorship|Participants in this arm (n = 12) will receive rent subsidies (ranging from $400 - $500/month) for 24 months as part of the intervention and be matched with an adult mentor recruited by one of the community partners.
10181886|NCT03779204|Active Comparator|Rent subsidies only|Participants in this arm (n = 12) will receive rent subsidies only (ranging from $400 - $500/month) for 24 months as part of the comparator group intervention. This group will not receive mentorship.
10181887|NCT03779035|Experimental|Gemcitabine plus Capecitabine|Gemcitabine (1000 mg per square meter) on days 1 and 8 Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
10181888|NCT03779035|Active Comparator|Capecitabine|Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
10181889|NCT03778814|Experimental|TCR-T cell therapy group|Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.
10181890|NCT03778918||inflammatory bowel disease|inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
10181891|NCT03778918||IBS or Normal Control|irritable bowel syndrome patients normal patients
9693746|NCT04796753||Youth basketball players who belonged to basketball developmental teams (U12, U14,U16,U17).|All participants completed the same ten-minute neuromuscular warm-up consisting of the following exercises: joint mobility exercises, dynamic stretching exercises, jumps, multidirectional displacements and changes of direction. Following, subjects were allowed three practice trials for each test. Consistent feedback was provided throughout to ensure proper technique. The performance of each test was recorded using two cameras (Iphone XS, Apple). To allow visible tracking of the different joints, participants were required to wear shorts with the hem at approximately mid-thigh. When scoring performance, each test was viewed in both planes (sagittal and frontal views).
9693747|NCT04796805|Experimental|Essential oil application group|The experimental group received 20% black pepper essential oil in a base of aloe vera gel applied topically to the forearm using a rollerball 10 min before venipuncture. Twelve swipes were applied using the rollerball applicator. The maximum dose of the black pepper/aloe vera gel mixture was 3 mL. Sphygmomanometer cuff was placed on the right arm, and the cuff was inflated until it reached the patient's diastolic blood pressure level. When the pointer reached the desired value, the period was commenced by the researcher. The nurse determined the right vein. After selecting the right vein, the period was ended as the nurse successfully placed a catheter.
10181892|NCT03779191|Experimental|Intervention|Patients in this intervention arm will receive the therapeutic combination of Alectinib dosed PO 600 mg bis in die (BID) with meals and Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
10181893|NCT03778892|Experimental|Novel Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
10181894|NCT03778892|No Intervention|Standard Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
10181895|NCT03779087|Experimental|10d TL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
10181896|NCT03779087|Active Comparator|10d AL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, amoxicillin 500 mg and metronidazole 250 mg q.i.d. for 10 days
10181897|NCT03779100|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10181898|NCT03778801||fibromyalgia syndrome|Thirty patients with a diagnosis of fibromyalgia syndrome according to the 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria and a disease duration of longer than three months
10181899|NCT03778801||chronic neck pain|30 patients with chronic neck pain lasting for more than three months and didn't meet 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria.
10181900|NCT03778801||healthy controls|30 healthy controls without pain or additional disease
10181901|NCT03778970|Experimental|Pain Neuroscience Education + Exercises|The PNE will follow the principles established by Explain Pain, addressing reconceptualization of pain, emphasizing modern neuroscience concepts. The PNE workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic.
10181902|NCT03778970|Active Comparator|Self-Management Education + Exercises|"The Self-Management Education (SME) strategy will be aligned with the Back Book concepts, focused on behavior change and encouraging participants to be active despite of the pain. The SME workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic."
10181903|NCT03778853|Experimental|Anlotinib Hydrochloride|Anlotinib Hydrochloride p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
10181904|NCT03778749|Experimental|electromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
10181905|NCT03778749|Experimental|acceleromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
10181906|NCT03778749|Experimental|acceleromyographic NMT monitoring at the eyebrow|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
10181907|NCT03778866|Experimental|Bicarbonate-buffered Medium|
10181908|NCT03778866|No Intervention|HEPES-MOPS-buffered Medium|
10181909|NCT03778762|Active Comparator|Blind tracheal intubation through AirQ|Patients were intubated through the air-Q blindly
10181910|NCT03778762|Placebo Comparator|Fiberscopic tracheal intubation through AirQ|Patients were intubated through the air-Q using fibreoptic bronchoscope
10181911|NCT03778905||stroke patient with complete post-acute care hospitalization|This study aims on stroke patients with complete rehabilitative program in post acute care institution and we try to assess their functional improvements after rehabilitative training.
9693748|NCT04796805|No Intervention|Control group|Diastolic blood pressure and body temperature of the patients in the control group were measured. A sphygmomanometer cuff was placed on the arm that was not actively used by the patient. Until the cuff's pointer reached the diastolic blood pressure level of the patient, it was inflated. When the tip came to the desired value, the period was noted by the researcher. Without any extra attempts being made, the catheter was placed by the nurse. The period ended with the successful catheter placement by the nurse. Period of appropriate vein selection, the period of placing the catheter successfully, patient and nurse satisfaction were recorded.
9693749|NCT04797078|Active Comparator|Transrectal fusion biopsies of the prostate|"Transrectal approach, patient in left lateral position, local anestesia 10ml lidocaine 1% at prostate base laterally and apex if indicated.~MRI-ultrasound fusion-guided biopsies with 4 biopsy cores per lesion, where clinically indicated. 18G biopsy needle.~Standard 12-core template for systematic biopsies. 18G biopsy needle.~Antibiotic prophylaxis with 750mg ciprofloxaicin, single dose p.o."
9693750|NCT04797078|Experimental|Transperineal free hand fusion biopsies of the prostate|"Men randomized to the experimental arm undergoes free-hand targeted transperineal fusion biopsies as defined below.~Patient is placed supine in the lithotomy-position. The perineal area is prepared with chlorhexidine 0,5ml/ml.~Ropivacain 7,5mg/ml is used as an anesthetic agent. Up to 40ml's (equivalent to 300mg) can be used to anestitize the skin, caudal and cranial part of the urogenital diaphragm and periprostatic tissue.~Free-hand MRI-ultrasound fusion-guided biopsies with at least 4 biopsy cores per lesion. Coaxial technique with 18G biopsy needle.~10-12 Systematic biopsies according to the modified Barzell 12-core template.~No antibiotic profylaxis unless warranted by immunosuppression, previous sepsis or urinary tract infection."
9693751|NCT04797091||Patients with SARS-CoV-2-infection|Patients with evidence of SARS-CoV-2-infection
9693752|NCT04797091||Control group|Controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization.
9693753|NCT04796818|Experimental|Diagnostic (IVIM DWI)|Patients undergo IVIM DWI over 10 minutes during standard of care MRI within 30 days of starting chemotherapy and after 4-6 cycles of preoperative chemotherapy.
10181912|NCT03779022||Sensitive|Sensitive group was defined ad complete response (CR) and/or partial response (PR). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
10181913|NCT03779022||Resistant|Resistant group was defined ad progression disease (PD) and/or stable disease (SD). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
10181914|NCT03778996|Experimental|Maintenance Treatment: Ewing's Sarcoma|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus
10181915|NCT03778996|Experimental|Salvage Treatment: Sarcoma|Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
10187569|NCT03724864|Experimental|Stevia snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
10181916|NCT03779048|Active Comparator|Behavioral Treatment + Placebo|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
10181917|NCT03779048|Active Comparator|Behavioral Treatment + Medication|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
10181918|NCT03778879|Experimental|Group 1:With CCX872-B|Concurrent SBRT 25 Gy in 5 fractions over 5-7 days, and 21 days of CCX872-B therapy. CCX872-B 150 mg by mouth twice daily approximately 12 hours apart.
10181919|NCT03778879|No Intervention|Group 2:Without CCX872-B|SBRT Alone: 25 Gy in 5 fractions over 5-7 days
10181920|NCT03778723|Experimental|Total intravenous anesthesia (TIVA)|Patients will receive total intravenous anesthesia using Propofol and Midazolam
10181921|NCT03778723|Active Comparator|Inhalation Anesthesia|Patients will receive Inhalation anesthesia using Sevoflurane
10181922|NCT03779061|Experimental|Remimazolam Tosilate|
10181923|NCT03779061|Active Comparator|Propofol|
10181924|NCT03778775||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and liver stiffness measurement by FibroTouch.
10181925|NCT03778697|Experimental|Adolescent Endosleeve|Patients who will undergo endoscopic sleeve gastroplasty
10181926|NCT03778788|Active Comparator|App group|Participants will receive the MetS mobile application (MetS app) instalment and briefing by a research assistant (RA2) after the educational talk. They will be able view the booklet content in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting for their exercise plan and exercise record.
10181927|NCT03778788|Active Comparator|Booklet group|The participants will additionally receive a Hong Kong version Lifestyle Intervention Programme (LIP) booklet to take home and use for 20 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
10181928|NCT03778788|Active Comparator|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
10181929|NCT03778619|Experimental|single arm|"Phase 1~MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly~Group 1: 1 x 10^7 cells/㎏~Group 2: 3 x 10^7 cells/㎏~Group 3: 9 x 10^7 cells/㎏~Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.~Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)~Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle~Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1."
10181930|NCT03778684|Experimental|Normal Body mass index without central obesity|
10181931|NCT03778684|Experimental|High Body mass index with central obesity|
10181932|NCT03778632|Experimental|Study Group|Intensive stuttering group therapy which was included individualized desensitization exercises was applied with the study group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
10181933|NCT03778632|Active Comparator|Control Group|Standard intensive stuttering group therapy was applied with the control group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
10181934|NCT03778736|Experimental|Cumulase denudation|
10181935|NCT03778736|No Intervention|Hyaluronidase denudation|
10181936|NCT03778450||Analgesics, Opioid|Patients are only included if they have been diagnosed in at least three quarters in the study period with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3. At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
10187570|NCT03724864|Active Comparator|Maltitol snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
10187571|NCT03724864|Placebo Comparator|Sugared snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
9693754|NCT04796831|Experimental|All Participants|Participants who will receive a single, oral dose of 60 mg quizartinib and a single, IV administration of 50 μg 14C-quizartinib solution for infusion at 4 hours post-oral dosing.
9693755|NCT04796857|Experimental|Tislelizumab in Combination With Lenalidomide|On the day of tislelizumab infusion, lenalidomide should be taken 30 minutes after the end of tislelizumab infusion
9693756|NCT04796623|Experimental|TQB3616 capsules combined with fulvestrant injection|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle. Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
9693757|NCT04796766|Experimental|Healthy volunteers|HFS / LFS in healthy volunteers at two different points in time
9693758|NCT04796766|Experimental|Migraine patients|HFS / LFS in migraine patients at a single point in time
9693759|NCT04796766|Experimental|Patients with Botulinum toxin or CGRP-targeted therapy|HFS / LFS before and under treatment with Botulinum toxin or CGRP-targeted therapy
10181937|NCT03778450||Non-Opioid Analgesic|Patients are only included if they have been diagnosed in at least three quarters in 2012 with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3.At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
10181938|NCT03778346|Experimental|CAR-T therapy in multiple myeloma|In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10^6-10^7/Kg transduced CAR-T cells at one time.
10181939|NCT03778398|Experimental|Neurologic music therapy|Patients will receive 2 days of 40 minutes per week, total 3 months of customized piano training. Each session will be started with finger warming exercises, then with the right hand, left handed and with both hands, a simple pentatonic array will be played. In the following lessons, notes will be marked with colors and simple songs will be taught.
10181940|NCT03778333|Experimental|Open label single arm study|All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks.
10181941|NCT03778476|Experimental|Isometric Exercise|Participants will perform a submaximal voluntary contraction of the quadriceps muscle to task failure.
10181942|NCT03778476|No Intervention|Quiet Rest|Participants will sit quietly for a period of time that mimics the exercise.
10181943|NCT03778463|Experimental|Synovectomy|
10181944|NCT03778463|No Intervention|No synovectomy|
10181945|NCT03778307||Trauma exposed without PTSD|Individuals with a history of trauma exposure who do not have current PTSD
10181946|NCT03778307||Trauma exposed with PTSD|Individuals with a history of trauma exposure and a current diagnosis of PTSD
10181947|NCT03778411||cACLD|200 people with compensated advanced chronic liver disease who have not undergone liver transplant
10181948|NCT03778411||cACLD-post transplant|100 people with compensated advanced chronic liver disease who have previously undergone liver transplant
10181949|NCT03778359||Gonadotropin-releasing hormone agonist treatment|Endometriosis post-operative Gonadotropin-releasing hormone agonist treatment
10181950|NCT03778359||Intrauterine device treatment|Endometriosis post-operative intrauterine device treatment
10181951|NCT03778359||Hormone therapy|Endometriosis post-operative hormone therapy
10181952|NCT03778359||Oral contraceptive|Endometriosis post-operative oral contraceptive
10181953|NCT03778281|Experimental|Baclofen group|Treatment of Chemotherapy-related Hiccups With Baclofen
10181954|NCT03778281|Other|Methoxyclopramide group|Treatment of Chemotherapy-related Hiccups With Methoxyclopramide
10181955|NCT03778281|Experimental|Baclofen group 2|After 3 days, if the metoclopramide treatment is ineffective, it will cross into the baclofen group 2.
10181956|NCT03778281|Other|Methoxyclopramide group 2|After 3 days, if the baclofen treatment is ineffective, it will cross into the metoclopramide group 2.
10181957|NCT03778320|Experimental|CTP-692|
10181958|NCT03778320|Active Comparator|D-Serine|
10181959|NCT03778515||Cases - Ankylosing Spondylitis Cohort|20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
10181960|NCT03778515||Controls - w/o Ankylosing Spondylitis|5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI
10181961|NCT03778528||Down syndrome|Individuals with Down syndrome undergoing cataract surgery.
10181962|NCT03778528||Control|Age-matched controls undergoing cataract surgery.
10181963|NCT03778567|Other|lamivudine + nucleotide analogue|At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued
10181964|NCT03778541|Experimental|CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
10181965|NCT03778541|Active Comparator|RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
10181966|NCT03778580|Experimental|pyridoxamine|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year
10181967|NCT03778580|Placebo Comparator|identical placebo|identical placebo po bid for one year
10181968|NCT03778372||study|pediatric patients undergoing outpatient strabismus surgery, and receiving methadone
10181969|NCT03778372||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving methadone
10181970|NCT03778593|Experimental|mFOLFIRINOX|D1 Oxaliplatin 65 mg/m2 + 5% dextrose water (5DW) 200 mL mix IV over 2 hours followed by, D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1 liter (1L) continuous IV over 23 hours repeat every 2 weeks
10181971|NCT03778216|Experimental|FBT-ARFID|Family Based Treatment of child ARFID
10181972|NCT03778216|No Intervention|Usual Care|Continued usual care for ARFID with the exception of any Family Based Treatment
10181973|NCT03778437|Active Comparator|landmark techniques|Subclavian vein catheterization is performed without the guidance of ultrasound. The needle was inserted 1 cm inferior and 1 cm lateral to the junction of the middle and medial thirds of the clavicle (infraclavicular approach)
10181974|NCT03778437|Experimental|ultrasound-guided with aiming method|Subclavian vein catheterization is performed with our newly proposed aiming method with the guidance of ultrasound.
10181975|NCT03778437|Experimental|ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique.
10181976|NCT03778164|Experimental|Fast Track Intervention|This arm refers to the new Partner Services-Sexual Health intervention offered to contacts by the Partner Services program
10181977|NCT03778164|Active Comparator|Standard of Care|This arm refers to the current standard practice for partners contacted by the Partner Services program
10181978|NCT03778385|Experimental|Isometric Exercise|Submaximal isometric resistance exercise of the arm.
10181979|NCT03778385|Experimental|Dynamic Exercise|Submaximal dynamic resistance exercise of the arm.
10181980|NCT03778268|Experimental|Undergoing sentinel lymph node biopsy|This group of patients will undergo sentinel lymph node biopsy.
10181981|NCT03778008|Experimental|Recombinant bovine basic fibroblast growth factor|
10181982|NCT03778008|Active Comparator|Quadruple mixture|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
10181983|NCT03778255|Experimental|Undergoing sentinel lymph node biopsy|
10181984|NCT03778242|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1 gm tranexamic acid ( 2 ampoules) in 100 ml saline by slow infusion
10181985|NCT03778242|Active Comparator|oxytocin plus placebo to TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus2 placebo ampoules to tranexamic acid(TA) in 100 ml saline by slow infusion
10181986|NCT03778112|Experimental|Negative mpMRI Prostate Scan|SBRT to the whole prostate
10181987|NCT03778112|Experimental|Positive mpMRI Prostate Scan|IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions
10181988|NCT03778047|Experimental|enzalutamide|160mg
10181989|NCT03778047|Experimental|HC-1119|To be determined
10181990|NCT03778021|Experimental|Intervention Group|Students in the intervention group will receive the curriculum and school garden during the second academic school year (Year 2)
10181991|NCT03778021|Active Comparator|Delayed Intervention Group|For the delayed intervention group schools, students will receive the intervention at the beginning of Year 3
10181992|NCT03778177|Experimental|Trigeminal Neuralgia Pain Diagnosis|Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
10181993|NCT03778034||Female with forward head posture|post-pubertal females suffering from (FHP) with Craniovertebral angle (CVA) less than 49 degrees(study group)
10181994|NCT03778034||healthy female without (FHP)|post-pubertal females expected to exhibit an average normal CVA within 10degrees range from 49 to 59 (control group)
10181995|NCT03778138|Experimental|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
10181996|NCT03778086||cataractous eyes|eyes of children with unilateral or bilateral cataract
10181997|NCT03778086||fellow eyes|fellow eyes of children with unilateral cataract
10181998|NCT03777956|Active Comparator|Lacosamide|Lacosamide (50 mg) are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
10181999|NCT03777956|Placebo Comparator|Placebo|Placebo are given as capsules, same as lacosamide, and taken orally twice a day, without active ingredient.
10182000|NCT03778151|Active Comparator|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus to modulate DMN activity. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
10182001|NCT03778151|Sham Comparator|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The SHAM protocol will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
10182002|NCT03778099|Experimental|Cinnamon Group|Two capsules of cinnamon 500mg twice per day after meals (2g/day). All capsules will be given simultaneously with the clomiphene citrate medication (standard treatment for infertility in women with PCOS). Participants will be asked to keep their normal lifestyle including daily food and physical activity level.
10182003|NCT03778099|Placebo Comparator|Placebo Group|"Placebo capsules will contain 450 mg of starch and 50 mg of cinnamon powder (to improve blindness regarding taste and odor). Color, shape, and size of placebo capsules will be exactly the same as the cinnamon capsules.~2g/day along with clomiphene citrate"
10182004|NCT03777852|Experimental|Pre-surgery First Breast Q|Women with proven breast cancer diagnosis. Respond to the First Breast Q questionnaire..
10182005|NCT03777852|Active Comparator|Post-surgery Second Breast Q|The Second Breast Q questionnaire will be applied to this group that will be composed of the women of the first group submitted to reconstructive breast cancer surgery.
10182006|NCT03777943||Cytoreductive surgery (CRS)|In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
10187572|NCT03724851|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Pembrolizumab will be administered as a dose of 200 mg every 3weeks.
10187573|NCT03724838|Active Comparator|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours
9693760|NCT04796688|Experimental|Fludarabine + Cyclophosphamide + AT19 cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on days -5, -4, and -3, followed by the infusions of AT19 cells on day 0-2. The study will be divided into three groups: B-ALL, B-CLL, and B-cell lymphoma. Doses of 0.5×10^7, 1.0×10^7, and 2.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.
9693761|NCT04796480|Active Comparator|YOGURT|Group 1 children were given home made plain yogurt in treatment of acute diarrhea
10182007|NCT03777878|Active Comparator|Carbetocin plus placebo to TA and placebo to oxytocin|100 μg carbetocin ampoule or separate placebo ampoule was diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby plus two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion
10182008|NCT03777878|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1gm TA in 100ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
10182009|NCT03777878|Active Comparator|oxytocin plus placebo to TA and placebo to carbetocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
10182010|NCT03777813|Experimental|Arm A|"Concomitant administration of durvalumab (dose: 1500 mg):~Every 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)~Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
10182011|NCT03777813|Active Comparator|Arm B|"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
10182012|NCT03777891|Experimental|group A|received Silicone gel phonophoresis: Silicone gel (strataderm) was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes. The Ultrasound Device is Sonopulse 590: Nonius, sonopuls 590, S.NO.03-202 type 14663.900 was a therapeutic ultrasound device manufactured by Enraf Holland.
10182013|NCT03777891|Experimental|group B|received Contractubex phonophoresis: Contractubex (Merz Pharma, Frankfurt, Germany was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes.
10182014|NCT03777891|Experimental|group C|received Corticosteroid phonophoresis: A thin film of coupling medium (gel) was put on the hypertrophic scar and sufficient quantity of Triamcinolone was put by a syringe over the whole scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes
10182015|NCT03777800|Experimental|Body Therapy|Participants in the intervention condition will be assigned to a 6-month body therapy treatment focused on 24 individual body treatments including conversations and direct physical treatment of the body combined with home-based daily practice of meditation.
10182016|NCT03777800|Active Comparator|Treatment As usual|Participants in the control condition will be offered treatment as usual, which is psychiatric medication and/or individual psychotherapy as deemed relevant by the psychiatrist.
10182017|NCT03777683|Experimental|Dietary Supplement (OLIGOPIN)|Intervention group will receive French maritime pine bark extract supplement (OLIGOPIN) in the form oral capsules containing 50 mg French maritime pine bark extract plus 130 mg Microcrystalline Cellulose. OLIGOPIN powder of each capsule are dissolved in 10 ml deionized water and given to patients via gavage (3 capsule per day) for 10 days
10182018|NCT03777683|Placebo Comparator|Placebo|Control group will receive oral capsules containing 130 mg Microcrystalline Cellulose with 10 ml of deionized water via gavage (3 capsule per day) for 10 days.
10182019|NCT03777670||Cases|Infants with suspected sepsis
10182020|NCT03777670||Controls|Infants with no suspicion of sepsis
10182021|NCT03777748|Experimental|Two dental implants in the edentulous maxilla and mandible|Edentulous maxilla und mandible are treated with two diameter-reduced tissue level implants (Straumann, Basel) and anchored with CM LOC® and CM LOC Flex® attachments (Cendres+Métaux SA, Bienne).
10182022|NCT03777930|Experimental|chemotherapy group|the patients were recepted chemotherapy alone
10182023|NCT03777930|Experimental|chemotherapy combined with TH and MG group|the patients were recepted chemotherapy combined with thalidomide and megestrol
10182024|NCT03777930|Experimental|the best supportive treatment group|the patients were recepted the best supportive without chemotherapy
10182025|NCT03777930|Experimental|the best supportive treatment combined with TH and MG group|the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
10182026|NCT03777774|Active Comparator|No subgaleal drains|Drains will be placed during closing stage of craniectomy but will be clamped so that no drainage takes place. Drains can be opened if needed
10182027|NCT03777774|Active Comparator|Passive subgaleal drains|Passive non-vacuum drains will be placed during closing stage of craniectomy
10182028|NCT03777774|Active Comparator|Vacuum subgaleal drains|Active vacuum drains will be placed during closing stage of craniectomy
10182029|NCT03777410||Vanguard|(CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
10182030|NCT03777410||Relapsed/Refractory MM|BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
10182031|NCT03777579|Experimental|JS001 Plus Nab-Paclitaxel|Participants assigned to JS001 plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
10182032|NCT03777579|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
10182033|NCT03777696|Active Comparator|Misoprostol with TA|400 μg of buccal misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
10182034|NCT03777696|Active Comparator|Misoprostol with placebo to TA|400 μg of buccal misoprostol (two tablets) plus 110 ml saline by iv rout
10182035|NCT03777696|Placebo Comparator|placebo to Misoprostol and TA|placebo to misoprostol plus placebo to tranexamic acid
10182036|NCT03777423|Experimental|PEEK framework partial dentures|High performance ketone polymers introduced lately.These polymer-based frameworks provide better esthetics, higher elasticity, lighter in weight, have low water sorption and solubility, and are easily repaired and reproduced.
10182037|NCT03777423|Active Comparator|Cobalt-chromium framework partial dentures|it is considered the gold standard framework. These frameworks are less bulky with high strength, conduct heat and electricity well, and have good durability. some disadvantages include hypersensitivity, adverse tissue reactions and bad aesthetics.
10182038|NCT03777787|Experimental|Bitter|A single intragastric administration of denatonium benzoate (1 µmol/kg)
10182039|NCT03777787|Placebo Comparator|Placebo|A single intragastric administration of placebo (water)
10182040|NCT03777540||Age; timing of gastric resection|Patients 80-85 years; Patients > 85 years; Elective and urgent surgery.
10182041|NCT03777644|Experimental|TPVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
10182042|NCT03777644|Placebo Comparator|placebo TPVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with morphine
10182043|NCT03777449||Vertical bone loss|Infra-osseous defects
10182044|NCT03777449||Horizontal bone loss|Supra-osseous defects
10182045|NCT03777449||Combined bone loss|Combined supra-osseous and infra-osseous defects
10182046|NCT03777631|No Intervention|Standard medical therapy group|The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
10182047|NCT03777631|Active Comparator|Catheter ablation group|Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed >100 CA annually were participated in the present study in principle.
10182048|NCT03777657|Experimental|Tislelizumab (BGB-A317) + chemotherapy|Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
10182049|NCT03777657|Placebo Comparator|Placebo + chemotherapy|Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
10182050|NCT03777553|Experimental|VETNET|Narrative Exposure Therapy for Justice-Involved Veterans
10182051|NCT03777592|Active Comparator|ESPB with local agent|ESPB will be performed using 20ml of 0.5% ropivacaine.
10182052|NCT03777592|Sham Comparator|ESPB with saline|ESPB will be performed using 20ml of saline.
10182053|NCT03777605|Experimental|"NTG1523, rapid absorbable capsule"|"Nitroglycerine 0.4 milligram taken as ordinary tablets or NTG1523 rapid absorbable capsule once in the morning, and subsequently blood samples and observations for 2 hours are performed"
10182054|NCT03777475|Experimental|low dose|low oxaliplatin (85mg/m2)
10182055|NCT03777475|Active Comparator|high dose|high oxaliplatin (135mg/m2)
10187574|NCT03724838|Active Comparator|Esomeprazole alone plus placebo to Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
10187575|NCT03724838|Placebo Comparator|placebo to Esomeprazole plus placebo to Sildenafil Citrate|Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
9693762|NCT04796480|Active Comparator|LACTOSE FREE FORMULA MILK|Group 2 children were given lactose free formula milk in treatment of acute diarrhea
9693763|NCT04796389|Experimental|Recorded music|Recorded music intervention
10187576|NCT03724799|Experimental|single arm|Intravenous low level laser therapy
10187577|NCT03724786|Experimental|Calculated collection|"Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the 6-hour collection will be multiplied by four, and the result will serve as the calculated collection, for pregnancy management. The additional 18 hour collection will serve for: 1. Patient blinding. 2. Calculation of the total 24-hour protein collection for reference."
10187578|NCT03724786|No Intervention|Control collection|Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the total 24-hour collection will serve for pregnancy management. The initial 6-hour collection will serve for patient blinding.
10187579|NCT03724773|Active Comparator|Long-Arm Cast|Reduction and long-arm cast application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
10187580|NCT03724773|Active Comparator|Sugar-Tong Splint|Reduction and sugar-tong splint application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
10187581|NCT03724760|Experimental|Feedback|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve feedback regrding the number of steps taken by them at two time points.
9693764|NCT04796389|No Intervention|Control|Standard of care
9693765|NCT04796402|Active Comparator|Control|Standard of care
10187582|NCT03724760|No Intervention|Control|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve no feedback regrding the number of steps taken by them.
10187583|NCT03724734|Experimental|Adaptive DBS|We will use our custom-built externalized research system (ERS) to deliver adaptive stimulation to the subthalamic nuclei.
10182056|NCT03777501|Experimental|non-random whole body vibration group|Each participant will receive the non-random type whole body vibration treatment about one hour after the administration of medicine.
10182057|NCT03777501|Active Comparator|conventional therapy group|For the conventional therapy group, participants will receive the occupational therapy including dynamic balance training and functional ambulatory training. Each session is 10 minutes.
10182058|NCT03777735||human bone graft screw|The patients will receive human bone graft screws surgically.
10182059|NCT03777761|Experimental|Treatment Sequence ABC|tucatinib + placebo + moxifloxacin (administered in sequential treatment periods)
10182060|NCT03777761|Experimental|Treatment Sequence CAB|moxifloxacin + tucatinib + placebo (administered in sequential treatment periods)
10182061|NCT03777761|Experimental|Treatment Sequence BCA|placebo + moxifloxacin + tucatinib (administered in sequential treatment periods)
10182062|NCT03777761|Experimental|Treatment Sequence CBA|moxifloxacin + placebo + tucatinib (administered in sequential treatment periods)
10182063|NCT03777761|Experimental|Treatment Sequence ACB|tucatinib + moxifloxacin + placebo (administered in sequential treatment periods)
10182064|NCT03777761|Experimental|Treatment Sequence BAC|placebo + tucatinib + moxifloxacin (administered in sequential treatment periods)
10182065|NCT03777488|Experimental|Tranexamic acid Group 1|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Intramuscular Third Dose: Oral"
10182066|NCT03777488|Experimental|Tranexamic acid Group 2|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Oral Third Dose: Intramuscular"
10182067|NCT03777488|Experimental|Tranexamic acid Group 3|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Intravenous Third Dose: Oral"
10182068|NCT03777488|Experimental|Tranexamic acid Group 4|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Oral Third Dose: Intravenous"
10182069|NCT03777488|Experimental|Tranexamic acid Group 5|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intravenous Third Dose: Intramuscular"
10182070|NCT03777488|Experimental|Tranexamic acid Group 6|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intramuscular Third Dose: Intravenous"
10182071|NCT03777514|Active Comparator|IV iron|"Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.~Participants in this group will also receive oral vitamin C as a placebo."
10182072|NCT03777514|Active Comparator|oral iron|Ferrous sulfate 325 mg (oral) tabs morning and evening. Participants in this group will also receive intravenous normal saline as a placebo.
10182073|NCT03777566||group A|35 patients with an indication for hysterectomy without gross uterine pathology
10182074|NCT03777566||group B|150 infertile patients in the childbearing age without gross uterine pathology
10182075|NCT03777111|Active Comparator|Single Task Training Group|"Gait and balance exercises will be applied in single task training group.~Semi-tandem, tandem stand with eyes open and close~One leg stance with eyes open and close~Gait exercises; walking forwards, backwards, sidewards, semi-tandem and tandem walking~Reaching forward and sidewards with eyes open and close"
10182076|NCT03777111|Experimental|Dual Task Training Group|"The exercises given in the single task training group will be combined with the cognitive tasks.~Semi-tandem, tandem stand with recall a sequence of numbers~One leg stance with writing pre-defined letters or words with other foot~Semi-tandem or tandem walking with saying previous number (one or two previous) from number that researcher has given before~Walking sidewards with collecting numbers that researcher has given~Walking backwards with counting forward by one (then two or three)~Reaching forward with counting backward one (then two or three)~Reaching sidewards with saying next number (one or two next) from number that researcher has given before"
10182077|NCT03777085|Experimental|TQB2303|
10182078|NCT03777085|Active Comparator|Rituximab|
10182079|NCT03777124|Experimental|SHR-1210 +apatinib|subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day
10182080|NCT03777124|Active Comparator|chemotherapy|Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W
10182081|NCT03777150|Experimental|Group ICU|Group ICU:patients are admitted directly into the ICU for postoperative care
10182082|NCT03777150|Experimental|Group Ward|Group Ward:patients are admitted directly into the standard ward for postoperative care
10182083|NCT03777293|Experimental|training cohort|ultrasound viscoelasticity
10182084|NCT03777293|Other|testing cohort|ultrasound viscoelasticity
10182085|NCT03777254|Experimental|RC28-E|"·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"
10182086|NCT03777358||Three-dimensional transvaginal ultrasonography (3D-TVS)|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then, hysteroscopy will be performed.
10182087|NCT03777202|Experimental|High-flow nasal oxygen during sleep endoscopy|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
10182088|NCT03777202|Active Comparator|Low-flow nasal oxygen during sleep endoscopy|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
10182089|NCT03777189|Experimental|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
10182090|NCT03777241|Active Comparator|Behavioral Intervention Team|The participants in this arm will receive the Behavioral Intervention Team.
10182091|NCT03777241|Active Comparator|Standard of Care|The participants in this arm will receive the standard of care.
10182092|NCT03777280|Experimental|peek framework Removable partial denture|polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
10182093|NCT03777280|Active Comparator|cobalt chromium framework Removable partial denture|it's the gold standard framework which has many benefits such as they are used in thin sections and are less bulky,provide high strength and stiffness,and some disadvantages include hypersensitivity,metal display and oral galvanism,
10182094|NCT03777163|Other|Butantan Trivalent Influenza Vaccine|"Butantan Institute Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
10182095|NCT03777163|Other|Sanofi Trivalent Influenza Vaccine|"Sanofi Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
10182096|NCT03776981|No Intervention|Baseline Gait Comparisons of Groups|Determine if kinetic (time to first peak ground reaction force [T1] and second peak ground reaction force [F2], both in the sagittal plane) and kinematic (peak stance knee flexion angle [KFA] and external knee adduction moment [KAM]) gait variables, and speed, differ between patients with KOA and age and gender matched controls during self-selected paced ambulation, and determine which ones have predictive relationships with Knee Injury and Osteoarthritis Outcome Score (KOOS) scores in the patients with KOA.
10182097|NCT03776981|Experimental|Gait with core activation|Determine if volitional core activation alters gait kinetics (T1 and F2), kinematics (KFA and KAM), and speed in patients with and without KOA during self-selected paced ambulation when compared to ambulating without volitional core activation, and whether the subjective pain complaints are significantly changed in the group with KOA. Determine whether there are baseline differences in core activation between those with and without KOA.
10182098|NCT03776981|Experimental|Knee OA Gait After core stabilization|Determine if a six-week core stabilization program alters KOOS score, and the kinetics (T1 and F2), kinematics (KFA and KAM), and speed of gait in patients with KOA during self-selected paced ambulation as compared to their pre-intervention baselines. Determine if there is a predictive relationship between the number of completed intervention sessions performed and these observed changes.
10182099|NCT03777033|No Intervention|Control Group|Patients after thyroidectomy will be managed as usual. Oral or IV supplements of Calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia.
10182100|NCT03777033|Experimental|Study group|Intervention: the patients will be given prophylactically ca and vit D. Patients after thyroidectomy will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb Intervention: The patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. Afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days)
10182101|NCT03776903||endemic|Samples collected from areas endemic for zika. Subject specimens underwent testing with the study device and reference method.
10182102|NCT03776903||non-endemic|Samples collected from areas non-endemic for zika. Subject specimens underwent testing with the study device and reference method.
10182103|NCT03776851|Experimental|Erythropoietin|Erythropoietin plus standard of care (RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability)
10182104|NCT03776851|No Intervention|No Intervention|Standard of care: RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability
10182105|NCT03777046|No Intervention|Screen fail subjects|Mothers and their babies that meet inclusion criteria for the study, but score less than 10 on the Edinburgh Postpartum Depression Scale (EPDS)
10182106|NCT03777046|Active Comparator|PPD Control subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
10182107|NCT03777046|Experimental|PPD Intervention subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
10182108|NCT03776916|Experimental|Group 1|"Simethicone administration 20-30 min before the procedure:~Patients intake simethicone solution 20-30 min before the procedure."
10182109|NCT03776916|Experimental|Group 2|"Simethicone administration 31-60 min before the procedure:~Patients intake simethicone solution 31-60 min before the procedure."
10182110|NCT03776916|Experimental|Group 3|Simethicone administration >60 min before the procedure; Patients intake simethicone solution >60 min before the procedure.
10182111|NCT03776968|Experimental|HC1119|Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;
10182112|NCT03776838|Experimental|SoC+NOL analgesia guided fentanyl administration|"A bolus of 2 mcg/kg of IV Fentanyl will be given at the induction of the anesthesia. A bolus of 1 mcg/kg of IV Fentanyl will be given at the time of incision. During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administered following a pre determinate algorithm based on NOL index + heart rate + mean arterial blood pressure variations.~Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery."
10182113|NCT03776838|Active Comparator|SoC analgesia guided group|"A bolus of IV Fentanyl at the discretion of a physician will be given at the induction of the anesthesia. A bolus of IV Fentanyl at the discretion of a physician will be given at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.~Intervention will be here to use Heart rate and blood pressure to administer intraoperative intravenous fentanyl."
10182114|NCT03777007|Experimental|Experimental|The application used is build upon the company's category-defining, SPARTA Platform and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
10182115|NCT03777345|Active Comparator|cobalt-chromium framework partial dentures|It's the gold standard biocompatible metal alloy used in thin sections, provide high strength and stiffness ,conduct heat and cold for a more natural experience, and is resistant to corrosion but their disadvantages include esthetic issues with metal display, oral galvanism, adverse tissue reactions,and osteolysis of abutment teeth.
10182116|NCT03777345|Experimental|PEEK framework partial dentures|It's a promising polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
10182117|NCT03776721|Experimental|Active treatment|
10182118|NCT03776721|Placebo Comparator|Placebo treatment|
10182119|NCT03776617|Experimental|Group Ropivacaine|general anesthesia + scalp block with 20 ml xylocaine 1% and 20ml ropivacaine 0.5%
10182120|NCT03776617|Experimental|Group Ropivacaine-Dexmedetomidine|general anesthesia + scalp block with 20 ml xylocaine 1%, 20ml ropivacaine 0.5% and 1mcg/kg dexmedetomidine
10182121|NCT03776617|No Intervention|Group control|general anesthesia
10182122|NCT03776617|Sham Comparator|Group sham|general anesthesia + Scalp block with 40ml Normal Saline
10182123|NCT03776734|Experimental|cryotherapy application|effect of cold application
10182124|NCT03776890|Experimental|DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=30) will be recruited to participate.
10182125|NCT03776825||Perianal Crohn's Disease|Permacol Paste injection
10182126|NCT03776747|Experimental|Group One: Prone MRI Scans|Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
10182127|NCT03776747|Active Comparator|Group Two: Supine MRI scans|Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
10182128|NCT03776708|Experimental|Spinal manipulation|The spinal manipulation is located between the fifth and eighth thoracic vertebrae, on a level and a side pain-free to a light palpation. The maneuver is of high velocity and low amplitude, oriented posterior to anterior, on the transverse process area of the chosen thoracic vertebrae.
10182129|NCT03776708|Sham Comparator|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires."
10182130|NCT03776786|Experimental|Safety Arm - 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
10182131|NCT03776786|Placebo Comparator|Safety Arm - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10182132|NCT03776786|Experimental|Safety Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes.
10182133|NCT03776786|Experimental|Safety Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
10182134|NCT03776786|Experimental|Safety Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes.
10182135|NCT03776786|Experimental|Safety Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes.
10182136|NCT03776786|Experimental|Efficacy Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182137|NCT03776786|Placebo Comparator|Efficacy Arm - 2 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182138|NCT03776786|Experimental|Efficacy Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182139|NCT03776786|Placebo Comparator|Efficacy Arm - 5 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182140|NCT03776786|Experimental|Efficacy Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182141|NCT03776786|Placebo Comparator|Efficacy Arm - 10 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182142|NCT03776786|Experimental|Efficacy Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182143|NCT03776786|Placebo Comparator|Efficacy Arm - 20 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
10182144|NCT03776773|Active Comparator|patients AR (+) and sleep apnea (+)|Patients with AR and obstructive sleep apnea (OSA) will have sleep and pollution exposure recordings
10182145|NCT03776773|Active Comparator|AR (-) and sleep apnea (+)|Patients without allergic rhinitis (+ sleep apnea) will have sleep and pollution exposure recordings
10182146|NCT03776773|Active Comparator|AR (+) and sleep apnea (-)|Patients with allergic rhinitis but no sleep apnea will have sleep and pollution exposure recordings
10182147|NCT03776773|Sham Comparator|AR (-) and sleep apnea (-)|Volunteers without allergic rhinitis and no sleep apnea will have sleep and pollution exposure recordings
10182148|NCT03776578||Head and neck Cancer surgery not treatment and rehabilitation|The patients with oral cavity cancer who weren't treated by radical operation and free flap reconstruction,and can't provide them with preventive swallowing rehabilitation
10187584|NCT03724734|Active Comparator|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous stimulation to the subthalamic nuclei.
10187585|NCT03724721|Experimental|pneumothorax drainage|Pneumothorax drainage with vacuum bottle plus intercostal catheter
10187586|NCT03724708|Experimental|Hang up technique|"where the enrolled patients will have the IUD applied in the middle of the uterine cavity and then attached to the fundus of the uterus by an absorbable suture Hang up technique"
10187587|NCT03724708|Active Comparator|Postpartum insertion|will include patients where IUD will be inserted after 6 weeks post-partum.
10182149|NCT03776578||Head and neck Cancer surgery treatment and rehabilitation|Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, It is well accepted that pre-treatment swallow function is indicative of post-treatment status and is helpful in identifying patients with high risk of aspiration and dysphagia.Preventive swallowing rehabilitation including evaluation patient's swallowing function and propose rehabilitation and adaptive maneuver or change in food texture. The aim is to ensure safe swallowing and prevent deglutitive muscles from deconditioning. Investigators include patients with advanced oral cavity cancer who were treated by radical operation and free flap reconstruction, and provided them with preventive swallowing rehabilitation.Investigators then analyze the swallowing function, oral intake status, and nasogastric tube dependence rate and tracheostomy tube dependence rate.
10182150|NCT03776955|Experimental|Oral Carvedilol|6.25 mg or 12.5 mg if tolerated
10182151|NCT03776955|Placebo Comparator|Oral Placebo|
9693766|NCT04796402|Experimental|Intervention|Administration of Bamlanivimab
10182152|NCT03776877||Arterial Ischemic Stroke (AIS)|"All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion.~The participation in the study will consist in:~Plasmatic collection at the time of AIS, for study of plasma biomarkers~Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score."
10182153|NCT03776929|No Intervention|Standard Care|No intervention - Standard care only. Group of 32 subjects
10182154|NCT03776929|Experimental|Dialectical Behavioral Therapy|Dialectical Behavioral Therapy in addition to standard care. Four hour and a half group sessions (or one-on-one sessions, if not enough for a group session) commencing after surgery while still inpatient. Each session is designed to stand-alone, allowing for enrolling patients on a rolling basis.
10182155|NCT03776656|Experimental|Allopurinol|Oral administration of Allopurinol (Zyloric®) for 12 months without exceeding 400 mg / day in children and 900 mg / day in adults, with dosage adjustment in case of renal failure
10182156|NCT03776591|Experimental|Open D3|Right colectomy Open surgery Central lymphadenectomy and vascular ligation
10182157|NCT03776591|Active Comparator|Laparoscopic CME with CVL|Right colectomy Laparoscopic surgery Central lymphadenectomy and vascular ligation
10182158|NCT03776604|Experimental|PEG-rhG-CSF|"Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
10182159|NCT03776526||Postoperative Hip fracture patients|The target population will include patients aged 65 years or older admitted with hip fracture to the orthopedic ward at the Juravinski Hospital, a site of Hamilton Health Sciences Corporation in Ontario, Canada.
10182160|NCT03776994|Experimental|Group 1A 2 µg VEE Vaccine Alone|"Subgroup 1A, 2 µg VEE VLP Vaccine Alone Venezuelan equine encephalitis VLP Vaccine candidate~Vaccinations on Day 0, Day 28, and Day 140"
10182161|NCT03776994|Experimental|Group 2A 10 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 2A, 10 µg VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
10182162|NCT03776994|Experimental|Group 3A 20 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 3A, 20 µg VEE VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
10182163|NCT03776994|Experimental|Group 1B 2 µg VEE Vaccine and Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 1B, 2 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
10182164|NCT03776994|Experimental|Group 2B 10 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 2B, 10 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
10182165|NCT03776994|Experimental|Group 3B 20 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 3B, 20 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
10182166|NCT03776565||Operative hysteroscopy|women with an operative hysteroscopy planned
10182167|NCT03776565||Planned caesarean section|Pregnant women with a planned caesarean section
10182168|NCT03776682||Acute inflammation|Patients with RA and active inflammation (by exam or inflammatory markers)
10182169|NCT03776682||Chronic remission|Patients with RA who are in remission (clinically)
10182170|NCT03776422|Experimental|Mobile self-help intervention|This study uses automated self-help interventions designed as a kit of smartphone tools.
10182171|NCT03776409||vancomycin plus piperacillin/tazobactam|Critically ill patients who received the combination of VAN (vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and PTZ were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
10182172|NCT03776409||vancomycin plus other beta-lactams|Critically ill patients who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
10182173|NCT03776448|Experimental|Sativa Nigra oil arm|A total of 15 subjects randomly allocated to the treatment arm will receive 2000mg a day of 'Sativa Nigra oil' softgels for 30 consecutive days. The total daily dose is divided in 4 doses taken 6 hourly (each softgel contains 500mg). This supplement is manufactured by [Bioextract Ltd, Sri Lanka] and is available commercially.
9693767|NCT04796519|Experimental|Unilateral TKA|Unilateral total knee arthroplasty group (UTKA) consisted of patients who did not undergo a second TKA within 3 months of the first TKA
9693768|NCT04796519|Experimental|Bilateral TKA|bilateral total knee arthroplasty group (BTKA) were those who had a second TKA within 12 months after initial TKA
9693769|NCT04796532|No Intervention|Control|No intervention. The control group will maintain their normal physical and dietary activity.
9693770|NCT04796532|Experimental|Homebased HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Homebased HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. This group will have 16 week follow-up.
9693771|NCT04796532|Experimental|Traditional HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional-HIIT group participants will attend presential HIIT workout sessions supervised. This group will have 16 week follow-up.
10182174|NCT03776448|Placebo Comparator|The charcoal arm|Subject randomly allocated to the control arm will receive 1040mg a day of activated charcoal softgels for 30 consecutive days. The total daily dosage is divided in 4 doses taken 6 hourly (each softgel contains 260mg). This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially.
10182175|NCT03776383|Active Comparator|Antibiotic use feedback letter 1|Antibiotic use feedback letter 1 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic prescribing for acute respiratory conditions
10182176|NCT03776383|Active Comparator|Antibiotic use feedback letter 2|Antibiotic use feedback letter 2 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic durations for common infections
10182177|NCT03776383|No Intervention|Control|Controls will not receive a letter
10182178|NCT03776487|Experimental|Treatment (chemotherapy, immunotherapy, IMRT)|"INDUCTION CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours and fluorouracil IV over 48 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients also receive fluorouracil IV continuously for 5 days per week and undergo 25 fractions of IMRT for 5 weeks. Patients undergo surgical resection 5-7 weeks after completing radiation therapy.~Within 8-12 weeks post-surgery, patients with residual disease may receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 courses (16 weeks) then every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
10182179|NCT03776357|Experimental|Experimental|The application used is build upon the company's category-defining, FDA- cleared Virtual Exercise Rehabilitation Assistant (VERA™) and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
10182180|NCT03776500|Experimental|Panel A - Active|N = 6, 150 mg twice daily of PBTZ169
10182181|NCT03776500|Placebo Comparator|Panel A - Placebo|N = 2, 150 mg twice daily of PBTZ169 matching placebo
10182182|NCT03776500|Experimental|Panel B - Active|N = 6, 300 mg twice daily of PBTZ169
10182183|NCT03776500|Placebo Comparator|Panel B - Placebo|N = 2, 300 mg twice daily of PBTZ169 matching placebo
10182184|NCT03776500|Experimental|Panel C - Active|N = 6, 600 mg once daily of PBTZ169
10182185|NCT03776500|Placebo Comparator|Panel C - Placebo|N = 2, 600 mg once daily of PBTZ169 matching placebo
10182186|NCT03776500|Experimental|Panel D - Active|N = 6, 600 mg twice daily of PBTZ169
10182187|NCT03776500|Placebo Comparator|Panel D - Placebo|N = 2, 600 mg twice daily of PBTZ169 matching placebo
9693772|NCT04796571|Experimental|Care Coordination Arm|Patients were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care.
9693773|NCT04796571|No Intervention|Usual Care|Participants in the usual care arm underwent symptom monitoring through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. Results of the monthly PRO instrument were available to their treating IBD doctor with interventions at their discretion.
10182188|NCT03776435||CT-exposed group|
10182189|NCT03776435||CT-unexposed group|
10182190|NCT03776552|Active Comparator|Low energy diet (LED)|8-week LED (<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks <1300 kcal/day and 4 weeks <1500 kcal/day)
10182191|NCT03776552|Active Comparator|Gradual weight loss (GWL)|16-week standard GWL-course (controls)
10182192|NCT03776474||Allergic|Minors allergic to cow's milk and/or eggs
10182193|NCT03776474||Non-allergic|Minors without history of allergy to cow's milk and/or eggs
10182194|NCT03776474||Acquired tolerance|Minors formerly allergic to cow's milk and/or eggs
10182195|NCT03776331||Myeloma Patients|
10182196|NCT03776331||Controll group|
10182197|NCT03776812|Experimental|Continuous Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
10182198|NCT03776812|Experimental|Intermittent Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
10182199|NCT03776812|Active Comparator|Nab-paclitaxel Comparator|Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
10182200|NCT03776513|Experimental|experimental group|Thirty obese boys (12-17 years old) undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
10182201|NCT03776513|Other|control group|Thirty healthy boys (12-17 years old) paired for pubertal stage, level of education and socio-economic level undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
10182202|NCT03776110|Experimental|GRT9906 80-mg dose group|"In one period, 80 mg GRT9906 (2 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4.~In the second period, a total of 7 doses of placebo (2 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
10187588|NCT03724708|Active Comparator|Control|will serve as our control group where the enrolled patients will have the IUD just applied into the middle of the uterine cavity at the level of the fundus without attachment
10182203|NCT03776110|Experimental|GRT9906 120-mg dose group|"In one period, 120 mg GRT9906 (3 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on the day before Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (3 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
10182204|NCT03776110|Experimental|GRT9906 160-mg dose group|"In one period, 160 mg GRT9906 (4 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (4 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
10182205|NCT03776110|Experimental|GRT9906 200-mg dose group|"In one period, 200 mg GRT9906 (5 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 120 mg was administered on Day T. The dose administration on Day T was performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (5 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
10182206|NCT03776097||Defect Fill.|Observational study of the patients that were treated with biomaterials at the surgery in the previous study
10182207|NCT03776097||No defect Fill.observational|Observational study of the patients that were not treated with biomaterials at the surgery of te previous study
10182208|NCT03776292||supine position group= Group (S)|1st group of 20 patients will undergo urinary bladder cystectomy and orthotopic urinary diversion lying supine with ring abdominal retractors
10182209|NCT03776292||lateral position group = Group (L)|2nd group of 20 patients will undergo surgical open nephrectomy lying lateral position with self retaining abdominal retractors
10182210|NCT03776279|Experimental|Mitoxantrone Hydrochloride Liposome Injection|4 weeks is a treatment cycle, and the first day of each cycle is administered.
10182211|NCT03776136|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
10182212|NCT03776162|Active Comparator|ACL Reconstruction(BPTB Graft)|Procedure/Surgery ACL Reconstruction (Bone Patellar Tendon Bone Graft): Standard of care surgical procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
10182213|NCT03776162|Experimental|Bridge Enhanced ACL Repair|Procedure/Surgery Bridge Enhanced ACL Repair (BEAR): The surgical repair of the ACL using the BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to group into.
10182214|NCT03776305|Experimental|Imipenem ECMO|1-h infusion of 0.5 g of imipenem, q6h
10182215|NCT03776240|Experimental|HD201|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
10182216|NCT03776240|Active Comparator|EU-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
10182217|NCT03776240|Active Comparator|US-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
10182218|NCT03776344|Experimental|Virtual Reality|Patients randomized to the experimental group will benefit from the usual standard care following surgery and during the second day the opportunity to use virtual reality for 15 minute. Along VR, they will complete the psychological and physiological measures.
10182219|NCT03776344|No Intervention|Non-VR condition (Standard of Care)|Patients randomized to the control group will benefit from the usual standard care following surgery and during the second day will complete the psychological and physiological measures.
10182220|NCT03776058|Experimental|Cinacalcet|Participants received 65 mg cinacalcet orally twice a day for 4 weeks.
10182221|NCT03776058|Placebo Comparator|Placebo|Participants received placebo to cinacalcet orally twice a day for 4 weeks.
10182222|NCT03776318||Safety Group|STX-015-18-01 Clonidine Micropellet long-term safety follow-up
10182223|NCT03776318||Sham Control|STX-015-18-01 Sham control long-term safety follow-up
10182224|NCT03776019|Experimental|Modulated|modulated music
10182225|NCT03776019|Sham Comparator|Typical|typical music
10182226|NCT03776045|No Intervention|Standard care|This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study.
9693774|NCT04796571|No Intervention|passive control arn|To explore whether our usual care arm was influenced by the monthly PRO measurements required for examination of our primary outcome, we compared IBD charges, total charges, ED visits, hospitalizations, and medication utilization at 12 months in the usual care arm to a passive control arm consisting of patients who met eligibility criteria, but were not enrolled in the intervention or usual care arms.
9693775|NCT04796376|Other|Cutting seton|A piece of surgical thread that's left in the fistula for several weeks to keep it open. This allow it to drain and help its heal.
10182227|NCT03776045|Experimental|Standard care plus exercise|This group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy.
10182228|NCT03776084||Patients SAHS with CPAP|Continuous Positive Airway Pressure treatment
10182229|NCT03776032|Experimental|Darbepoetin alfa|Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
9693777|NCT04796792|Experimental|Treatment group|This study is currently in Phase 1 where all subjects undergo the investigational study.
9693778|NCT04796714|Sham Comparator|Double antiplatelet therapy group|Patient randomized in this group will receive 1 tablet containing clopidogrel 75 mg and 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
10182230|NCT03776032|Placebo Comparator|Placebo|Participants received once a week placebo, administered by subcutaneous injection for up to 12 weeks.
10182231|NCT03776006||TPLA|
10182232|NCT03775993|Active Comparator|GHD|
10182233|NCT03775993|Placebo Comparator|Placebo|
10182234|NCT03775616|Experimental|Supportive (financial navigation program)|Participants receive financial navigation program intervention consisting of a financial navigation video, monthly one-one financial counselling session, monthly phone or email consultation with patient navigators for 6 months and complete surveys at baseline, 3, 6, and 12 months.
10182235|NCT03775889|Experimental|Behavioral|Behavioral Gardening Exposure
9693779|NCT04796714|Experimental|Aspirin group|Patients randomized in this group: will receive 1 bag containing aspirin 160 mg as treatment. This treatment will start on the day of LAAC procedure and continued for 3 months.
9693780|NCT04796441|Experimental|CAR--γδT|Patients will be treated with CAR--γδT cells
10182236|NCT03775629|Experimental|Polmacoxib and Tramadol combination|Tramadol HCl 300mg once/day + 2 mg Polmacoxib capsule once/day for 14 days
10182237|NCT03775629|Active Comparator|Polmacoxib|Polmacoxib 2mg 14days
10182238|NCT03775629|Active Comparator|Tramadol|Tramadol hydrochloride (HCl) 150mg 5days
10182239|NCT03775876|Active Comparator|Propofol|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Propofol. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 2mg/Kg/h and modified to a maximum of 4 mg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four.
10182240|NCT03775876|Active Comparator|Dexmedetomidine|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
10182241|NCT03775759|Experimental|Study arm|Tricuspid valve ring annuloplasty or replacement at the time of LVAD implantation plus medical therapy
10182242|NCT03775759|Active Comparator|Control arm|LVAD implantation plus medical therapy
10182243|NCT03775668|Experimental|1 µCi of 14C-AAI101 + 500 mg AAI101|14C-AAI101 + 500 mg AAI101 iv infusion
10182244|NCT03775863||Latin American multicenter Cohort|Transplanted patients with HCC in LATAM from 2005-2011
10182245|NCT03775863||French mutlicenter Cohort|Transplanted patients with HCC in France from 2003-2005
10182246|NCT03775863||Italian multicenter Cohort|Transplanted patients with HCC in Italy from 2005-2011
9693781|NCT04796428|Active Comparator|canagliflozin|100 mg (or 50/850 mg and 50/1000 mg of the fixed association with metformin) or 300 mg (or the 150/850 mg and the 150/1000 mg fixed association with metformin).
10182247|NCT03775707|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
10182248|NCT03775902|Experimental|Healthy subjects|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
10182249|NCT03775902|Experimental|Pre and/or type 2 diabetics|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
10182250|NCT03775772|Other|Oral Health - Test Group|- study population is randomly assigned to control and test group
9693782|NCT04796428|Active Comparator|dapagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 10/5 mg of the fixed dapagliflozin / saxagliptin combination)
9693783|NCT04796428|Active Comparator|empagliflozin|10 mg (or 5/850 mg and 5/1000 mg of the fixed association with metformin; or 5/5 mg of the empagliflozin / linagliptin combination) or 25 mg (or the 12.5/850 mg and the 12.5/1000 mg fixed association with metformin; or the 12.5/5 mg empagliflozin / linagliptin combination).
9696500|NCT04766190|Other|Group 1: Usual Care|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be video recorded at their appointment. The oncologist has agreed to be video recorded. Immediately after this appointment, the patient will be asked to complete another brief survey that takes about 20 minutes. The questions will ask about how the meeting went. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study."
10182251|NCT03775772|Other|Bite Force/Chewing Efficacy-Test Group|- study population is randomly assigned to control and test group
10182252|NCT03775577||HFpEF|Participants with Heart Failure with Preserved Ejection Fraction
10182253|NCT03775577||HFrEF|Participants with Heart Failure with Reduced Ejection Fraction
10182254|NCT03775577||Hypertensive Subjects|Participants with Hypertension
10182255|NCT03775577||Healthy Subjects|Participants without heart failure and without commodities
10182256|NCT03775551|No Intervention|Control|The participants belonging to the hospitals assigned to the control group the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC following usual practice.
10187589|NCT03724682|Experimental|Single arm|Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,
9693784|NCT04796545|Experimental|Tsert SI System model NG SI IMT 3X|All participants will be implanted with the Tsert SI System model NG SI IMT 3X.
10182257|NCT03775551|Experimental|Improvement cycle|In participants belonging to the hospitals assigned to the intervention group,the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC using innovative intervention to assure continuity of care and assistant level approach. This innovations will be crafted from the rapid improvement cycles considering the environment and key aspects of the every day care at the participating centers.
10182258|NCT03775642|Experimental|Intervention video|The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.
10182259|NCT03775642|Placebo Comparator|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.
10182260|NCT03775824||MTX start|Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
10182261|NCT03775824||TNF start|Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
10182262|NCT03775655|Active Comparator|LD-DEX|This group will receive 7mg hyperbaric bupivacaine (about 1.4 ml of hyperbaric bupivacaine 0.5%) and 10μg dexmedetomidine (10 unit by U-100 insulin syringe using a preservative free dexmedetomidine 100μg/ml).
10182263|NCT03775655|No Intervention|Control group|This group will receive 12 mg hyperbaric bupivacaine (about 2.2 ml of hyperbaric bupivacaine 0.5%).
10182264|NCT03775720|Experimental|Low genetic risk group|Dietary advice to maintain salt intake to 6g/day
10182265|NCT03775720|Experimental|High genetic risk group|Dietary advice to reduce salt intake to 4g/day
10182266|NCT03775564|Experimental|REMEDRUGBY|TAU + RemedRugby Program
10182267|NCT03775564|Active Comparator|TAU + TOUCH RUGBY|TAU + Touch Rugby Program
10187590|NCT03724656|Experimental|acupuncture treatment|"Patients in the TAES treatment group received Transcutaneous Acupoint Electrical Stimulation(TAES) 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
10187591|NCT03724656|Sham Comparator|Sham acupuncture treatment|"The control group was treated with non-acupoint shallow acupuncture method. The needle was inserted 5 cm beside the acupoint and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
10187592|NCT03724643|Experimental|Protocolized Wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
10187593|NCT03724643|No Intervention|Usual Care|In the UC group, the SBT type and extubation decision was determined by the attending intensivist on service based upon neurologic status, airway competence (gag, cough, suction requirements), and negative inspiratory force (NIF) or RSBI measurements.
10187594|NCT03724617|Experimental|stem cell therapy|
10187595|NCT03724604||high NAR|Neuron-Specific Enolase to Albumin Ratio is higher than 3.2×10-7
10187596|NCT03724604||low NAR|Neuron-Specific Enolase to Albumin Ratio is lower than 3.2×10-7
10187597|NCT03724591|Experimental|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
10187598|NCT03724591|Active Comparator|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
10187599|NCT03724578|Sham Comparator|standard preventive measures|the participants will only follow standard preventive measure twice a day brushing with fluoride toothpaste and flossing once a day
10187600|NCT03724578|Active Comparator|antimicrobial and fluoride mouth wash|participants will use mouth wash contains both chlorhexidine and fluoride in addition to standard preventive measures
9693785|NCT04796675|Experimental|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on day -5, -4, and -3, followed by one infusion of CAR-NK-CD19 cells on day 0. The study will be divided into three groups: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, and Non Hodgkin's Lymphoma. Doses of 0.01×10^7, 0.1×10^7, 1.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
10187601|NCT03724578|Experimental|grape seeds extract mouth wash|the intervention is grape seeds extract mouth wash
10187602|NCT03724565||Endoscopic procedural area|air quality check of endoscopic procedural room
10187603|NCT03724565||Recovery area for patients|air quality check of recovery area for patients in endoscopic unit
10187604|NCT03724565||Cleansing area for equipments|air quality check of cleansing area for equipments in endoscopic unit
10187605|NCT03724552|Experimental|Transcranial LED Therapy|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm) is applied to forebrain.
9693786|NCT04796350|Experimental|Treated group|Subject receives standard of care to repair the index hip fracture and AGN1 LOEP treatment on the target unfractured contralateral hip
9693787|NCT04796350|No Intervention|Control group|Subject receives standard of care to repair the index hip fracture and no AGN1 LOEP treatment on the target unfractured contralateral hip
9693788|NCT04796454|Active Comparator|CisGem/GemOx|"Cisplatin/Gemcitabine (3-week cycle):~Cisplatin IV 25 mg/m² d1 and day8~Gemcitabine 1000 mg/m² d1 and d8~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years.~In case of unacceptable toxicity the CisGem regimen can also be switched to a GemOx regimen (4-week cycle):~Oxaliplatin IV 100 mg/m² d1 and day15~Gemcitabine 1000 mg/m² d1 and d15"
10182268|NCT03775590|Active Comparator|Water|Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
10182269|NCT03775590|Active Comparator|Bleach|Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
10182270|NCT03775590|Active Comparator|Acetic acid|Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen
10182271|NCT03775746|Experimental|Clopidogrel with Rivaroxaban|Clopidogrel 75mg o.d. and Rivaroxaban 2.5mg b.i.d.
10182272|NCT03775746|Active Comparator|Clopidogrel|Clopidogrel 75mg o.d.
10182273|NCT03775746|Active Comparator|Ticagrelor|Ticagrelor 90mg b.i.d.
10182274|NCT03775928|Experimental|Apatinib + Capecitabine|Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
10182275|NCT03775928|Active Comparator|Capecitabine|capecitabine 1000mg/m2 bid d1-14, q21d
10182276|NCT03775733|Experimental|Hydrolysed red ginseng extract|Hydrolysed red ginseng extract 2.4g/day for 12 weeks
10182277|NCT03775733|Placebo Comparator|Placebo|Placebo for 12 weeks
10182278|NCT03775525|Experimental|Experimental: monotherapy|GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
10182279|NCT03775837|Experimental|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
10182280|NCT03775837|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
10182281|NCT03775538|Experimental|CDNF mid-dose (400 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
10182282|NCT03775538|Experimental|CDNF high-dose (1200 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to high-dose (1200 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
10182283|NCT03775434|Experimental|B244|B244 suspension in 30ml/bottle
10182284|NCT03775460|Placebo Comparator|control|Participants will receive placebo+ prednisolone. Participants will start receiving 4 dummy tablets per week, than participants weighing less than 60 kg will receive 6 dummy tablets from week 8. The placebo will be prescribe weekly. Participants weighing 60 kg or more will receive 8 dummy tablets from week 8. Participants will receive dummy tablets for 52 weeks. Along with prednisolone. The start dose of prednisolone will be 40 mg per day decreasing dosage for 20 weeks.
10182285|NCT03775460|Experimental|intervention|Participants will receive Methotrexate(MTX)+prednisolone. All participants in intervention arm will receive an initial dose of MTX 10 mg. The MTX will be increased to 15 mg the following week. Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing 60 kg or more will receive MTX 20 mg from week 8. At week 48 the MTX will be reduced to 10 mg for two weeks followed by 5 mg for two weeks and then stopped. In total participants will receive 52 weeks of MTX along side prednisolone, which will be the same as the control arm.
10182286|NCT03775330|Experimental|SRS|Stereotactic radiosurgery
10182287|NCT03775330|Experimental|SRS plus WBRT|Stereotactic radiosurgery plus whole brain radiation
10182288|NCT03775447||Parkinson's Disease Patients|"A diagnosis of Parkinson's disease in the opinion of the enrolling investigator~Disease duration: any~Male or female age 18 years or older at time of PD diagnosis."
10182289|NCT03775447||Healthy Control (HC) Subjects|• Male or female age 18 years or older at Screening.
10182290|NCT03775278|Experimental|Experimental|PHP-303, multiple oral dose, up to 5 ascending dose cohorts
10182291|NCT03775278|Placebo Comparator|Placebo|Placebo, multiple oral dose, up to 5 ascending dose cohorts
10182292|NCT03775317|Experimental|Video Laryngoscopy|
10182293|NCT03775317|Active Comparator|Direct Laryngoscopy|
10182294|NCT03775135||Children with neuromuscular diseases|Questionnaires will be administered by children with neuromuscular disease between 12 and 25 years and their parents
10182295|NCT03775161|Experimental|V-LAP™ System|Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home
10182296|NCT03775122|Placebo Comparator|Group 1 sedation group|"Elderly patients under colonoscopy with sedation, but no real TAES neiguan(pc6)~sedation is using the typical protocol for the following: Slowly peripheral intravenous injection(0.5ml/s) of fentanyl 50μg, then followed with 1.5-2.5mg/kg propofol until loss of eyelash reflex, the Observer's Assessment of Alertness/Sedation Scale (OAAS) score Level3-5."
10182297|NCT03775122|Experimental|Group 2 sedation+TAES group|"Elderly patients under colonoscopy both have TAES neiguan(pc6) and sedation.~sedation is begun followed TAES. sedation is same as group2 do. TAES is same as group3 do."
10182298|NCT03775109|Active Comparator|Canakinumab 150mg/ml solution for injection|150mg/ml solution for injection
10182299|NCT03775109|Placebo Comparator|Dextrose|
10182300|NCT03775369|Active Comparator|Endurance training|"Endurance Training (warm-up; endurance on bike; brisk walking; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
10182301|NCT03775369|Active Comparator|Resistance training|"Resistance Training (warm-up; resistance training units; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
10182302|NCT03775369|Active Comparator|Control condition|"Control condition (individualized counselling, but not intended as a bona fide intervention, that is to say: not intended to actively improve participants' well-being):~6 weeks, social support and counseling,1-2 sessions/week; 30 min/session"
10182303|NCT03775291||Low pre-test likelihood for sleep apnea|Subjects at low risk for having sleep apnea due to lack of known risk factors and no complaints of symptoms related to sleep apnea (e.g., excessive daytime sleepiness)
10182304|NCT03775291||High pre-test likelihood for sleep apnea|Suspected sleep apnea patients who are undergoing sleep tests as part of normal medical care or are also known to be non-compliant with therapy.
10182305|NCT03775382|Placebo Comparator|Placebo|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
10182306|NCT03775382|Active Comparator|Ascorbic Acid|"Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
10182307|NCT03775031|Active Comparator|Fraxel 1927nm|Treatment setting for Fraxel 1927 nm: 20 mJ, Treatment level 8, 6 passes
10182308|NCT03775031|Active Comparator|Fraxel 1550nm|Treatment setting for Fraxel 1550 nm: 70 mJ, Treatment level 6, 6 passes
10182309|NCT03775031|Active Comparator|25% TCA Peel|25% TCA on 5 x 5 cm of sun exposed back
10182310|NCT03775031|Placebo Comparator|Control|Patient serves as their own control
10182311|NCT03775252|Experimental|Ketogenic diet|Group of patients treated with ketogenic diet after the first neurophysiological screening.
10182312|NCT03775239|Other|Treatment-as-usual|Those who are randomly selected to treatment-as-usual will receive a minimum of 6 sessions at Sexological Clinic.
10182313|NCT03775239|Other|Treatment-as-usual + MSIR|Those who are randomly selected to receive Mindfulness in Sex Therapy and Intimate Relationships (MSIR) will first receive 6 weeks of mindfulness followed by treatment-as-usual. The intervention will take place at Sexological Clinic.
10182314|NCT03775044|Experimental|Experimental: Medherent Device|All participants get the Medherent device. There is only one arm to this study.
10182315|NCT03775226|Experimental|Single are|This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.
10182316|NCT03775096|Experimental|carvedilol therapy|The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125 mg twice/daily, the target dose will be 25mg twice daily (50 mg/day) and participants will take 50 mg/day carvedilol for 6 months.Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.
10182317|NCT03775395|Experimental|HAIC plus Lenvatinib|
10182318|NCT03775395|Active Comparator|HAIC plus Sorafenib|
10182319|NCT03775499|Other|Period 1: Placebo - Period 2: BL NCC 2705|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
10182320|NCT03775499|Other|Period 1: BL NCC 2705 - Period 2: Placebo|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
10182321|NCT03775057|Experimental|MyDose Coach app intervention|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
10182322|NCT03775148|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
10182323|NCT03775148|No Intervention|CAU Group|Care-As-Usual group
10182324|NCT03775356|No Intervention|1 - Blinded|EEG and Entropy will be blinded. The anesthesiological management will be performed by the anesthetist according to clinical standard operations.
10182325|NCT03775356|Active Comparator|2 - Unblinded|EEG and Entropy will be unblinded. The intervention starts with the start of a positive burst suppression rate. In the case of a concurrent hypotension the anesthetist treats the hypotension according to clinical standard operations in the first step. Hypotension means blood pressure values blow the baseline value which is defined by the lowest, preoperatively measured value. If after this treatment and a reevaluation of the BSR, BSR remains positive, the anesthetist is going to reduce the concentration of anesthetics in a second step. In case of positive BSR and a blood pressure value ≥ the baseline value, the concentration of anesthetics will be reduced as a first measure. The aim is to figure out whether one or both of these interventions can reduce to total, cumulative BSR.
10182326|NCT03775070|Experimental|Simvastatin|Simvastatin, 0.5mg/kg/d(maximum 20mg), once daily
10182327|NCT03775018|Experimental|Transversus abdominis plain blockade|The patients will undergo Transversus abdominis plain blockade, associated with intravenous analgesia
10182328|NCT03775018|Active Comparator|Intravenous analgesia|The patients will receive intravenous analgesia with Acetaminophen (1g/6h)
10182329|NCT03775005|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
10182330|NCT03775005|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
10182331|NCT03774940|Experimental|fever|patients that have fever after PNL
10182332|NCT03774940|Active Comparator|No fever|Patients without fever after PNL
10182333|NCT03774901|Experimental|avelumab maintenance|Avelumab will be administered at a dose of 10 mg/kg every 2 weeks with appropriate supportive care
10182334|NCT03774797||Pre-Implementation Patients|Enrolled patients will take online surveys following a prenatal or a postpartum visit.
10182335|NCT03774797||Post-Implementation Patients|All enrolled patients will take online surveys following a prenatal or a postpartum visit. A subset will be interviewed after the postpartum survey.
10182336|NCT03774797||Post-Implementation Providers|All enrolled providers will take online surveys at 6-12 months after program implementation, and a subset will be interviewed.
10182337|NCT03774849|Experimental|Picoway™ 532nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 532nm fractional handpiece
10182338|NCT03774849|Experimental|PicoWay™ 730nm wavelength|PicoWay™ 730nm wavelength. Subjects will receive up to four study treatments with the PicoWay™ 730nm wavelength.
10182339|NCT03774849|Experimental|PicoWay ™1064nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 1064nm fractional handpiece
10182340|NCT03774979|Experimental|SHR-1701|intravenous infusion
10182341|NCT03774537|Experimental|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.
10182342|NCT03774537|Other|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
10182343|NCT03774732|Experimental|Pembrolizumab+ Chemotherapy + Radiotherapy|"In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.~Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.~Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).~Irradiated tumor size will be ≤5 cm (GTV <65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints."
10182344|NCT03774732|Active Comparator|Pembrolizumab+ Chemotherapy|"Squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )~Non squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)~Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status."
10182345|NCT03774719|Experimental|Hand-carried ultrasound arm|This is the only arm of the study. It will be comprised of 154 inpatients who had a renal ultrasound ordered or performed within the past 4 hours. The intervention will be performing hand-carried ultrasound to evaluate for presence and degree of hydronephrosis.
10182346|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort A, non-ALL)|This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
10182347|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort B, ALL).|This cohort is for patients with refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
10182348|NCT03774953|Experimental|Intervention group|protein and vitamin supplementation
10182349|NCT03774953|No Intervention|Control group|No supplementations
10182350|NCT03774628|Experimental|Chengdu Kanghua (one booster shot)|one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
10182351|NCT03774628|Experimental|Chengdu Kanghua (two booster shots)|two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
10182352|NCT03774706|Active Comparator|Misoprostol with TA|two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv
10182353|NCT03774706|Active Comparator|Misoprostol with placebo to TA|two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv
10182354|NCT03774771|Placebo Comparator|Placebo|In Part 1 participants received placebo capsules orally once a day for 6 weeks. In Part 2 participants received placebo capsules twice a day for 15 days.
10182355|NCT03774771|Experimental|Cinacalcet 50 mg QD|In Part 1 participants received 50 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 30 mg cinacalcet capsules twice a day for 15 days.
10182356|NCT03774771|Experimental|Cinacalcet 75 mg QD|In Part 1 participants received 75 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 40 mg cinacalcet capsules twice a day for 15 days.
10182357|NCT03774771|Experimental|Cinacelcet 100 mg QD|In Part 1 participants received 100 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 50 mg cinacalcet capsules twice a day for 15 days.
10182358|NCT03774667||Placenta Previa|Pregnant women is diagnosed with placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
10182359|NCT03774667||None-Placenta Previa|Pregnant women is diagnosed without placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
10182360|NCT03774758||Cohort 1A: Benign nodule on screening CT|"High-risk patients eligible for lung cancer screening but with negative radiographic findings on CT screening (Lung RADS ≤2).~≥30 pack-year history of cigarette smoking~≥55 years of age~Current smoker or quit within the past 15 years"
10182361|NCT03774758||Cohort 1B: Incidental benign nodule|"Patients with lung nodules ≥ 6 mm on routine (non-lung cancer screening) CT evaluation deemed suspicious for malignancy by initial physician judgment but not malignant by ≥2 years of radiographic stability and consensus clinical opinion.~1- Age ≥40 years."
10182362|NCT03774758||Cohort IC: Presumed lung cancer|"Patients with lung cancer (histologically proven or presumed by consensus opinion of tumor board); prior to definitive therapy.~1- Age ≥40 years."
10182363|NCT03774758||Cohort 2A: Suspicious nodule|"High-risk patients with newly diagnosed suspicious nodule of Lung RADS ≥3 on CT screening.~≥30 pack-year history of cigarette smoking~≥55 years of age~Current smoker or quit within the past 15 years"
10182364|NCT03774758||Cohort 2B: Suspicious incidental nodule|"Patients with newly diagnosed incidentally-found lung nodules ≥ 6 mm on routine CT evaluation deemed suspicious for malignancy by physician judgment.~1- Age ≥40 years."
9693789|NCT04796454|Experimental|PamTMZ|"Pamiparib + temozolomide (4-week cycle):~Pamiparib 60 mg PO twice a day d1-d28 Temozolomide 60 mg PO daily d1-d7~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years."
9693790|NCT04796064|Experimental|low-intensity aerobic training group|
10182365|NCT03774758||Cohort 2C: Post-treatment lung cancer|"Patients with previously treated lung cancer (histologically proven or by consensus opinion); status-post completion of definitive therapy (resection +/- chemotherapy or SBRT with curative intent) within the previous year with no current evidence of disease.~1- Age ≥40 years."
10182366|NCT03774927|Experimental|10 Hz treatment group|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
10182367|NCT03774927|Experimental|20 Hz treatment group|In active rTMS, 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
10182368|NCT03774927|Sham Comparator|Control Group|In sham rTMS, all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
10182369|NCT03774693|Active Comparator|GS [General anesthesia]|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
10182370|NCT03774693|Active Comparator|GR [General anesthesia + regional block]|"Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.~Also patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block. Fentanyl boluses of 0.5 mcg.Kg-1 will be given when needed to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1."
10182371|NCT03774836|Active Comparator|Tramadol 50 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
10182372|NCT03774836|Active Comparator|Morphine 4 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
10182373|NCT03774836|Placebo Comparator|Placebo|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
10182374|NCT03774680|Active Comparator|Cetuximab nanoparticles goup|A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
10182375|NCT03774680|Placebo Comparator|Oral approved anticancer drug|A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
10182376|NCT03774966|Active Comparator|Adductor Canal Block + Catheter|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine
10182377|NCT03774966|Experimental|Adductor Canal Block + Catheter & IPACK|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine, IPACK block: 15 ml of 0.25% ropivacaine.
10182378|NCT03774615|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
10182379|NCT03774602|Experimental|MCSP package of interventions|MCSP package of interventions for health promotion and provision of RMNCH services
10182380|NCT03774810|Experimental|Continuous|Nightly active dose (QHS). The intervention is zolpidem tartrate 5 mg or 10 mg.
10182381|NCT03774810|Experimental|Partial Reinforcement 1|1 active dose per week with 6 placebos interspersed between the active dose. The intervention is zolpidem tartrate 5 mg or 10 mg.
10182382|NCT03774810|Experimental|Partial Reinforcement 3|3 active doses per week with 4 placebos interspersed between the active doses. The intervention is zolpidem tartrate 5 mg or 10 mg.
10182383|NCT03774810|Experimental|Low Frequency Intermittent Dosing|1 to 3 active doses per week PRN. The intervention is zolpidem tartrate 5 mg or 10 mg.
10182384|NCT03774589|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
10182385|NCT03774589|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
9693791|NCT04796064|Experimental|high-intensity aerobic training group|
9693792|NCT04796051|Experimental|Neck orthosis group, posterior cervical weight orthosis|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull. Neck orthosis group will use a cervical orthosis (with the posterior cervical neck weight) for 10 minutes / 3 times a day, for a total of 30 minutes a day
10182386|NCT03774511|Active Comparator|Study group 1|High Intensity Interval Excercise
10182387|NCT03774511|Active Comparator|Study group 2|Moderate Intensity Interval Exercise
10182388|NCT03774511|No Intervention|Control group|No Intervention
10182389|NCT03774498|Active Comparator|Sensodyne repair and protect|NovaMin & fluoride toothpaste
10182390|NCT03774498|No Intervention|Sensodyne Daily Care Toothpaste 0.315%|Sodium fluoride toothpaste
10182391|NCT03774524|Active Comparator|Misoprostol with TA|400 μg of sublingual misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
10182392|NCT03774524|Active Comparator|Misoprostol with placebo to TA|400 μg of sublingual misoprostol (two tablets) plus 110 ml saline by iv rout
10182393|NCT03774524|Placebo Comparator|placebo to Misoprostol with placebo to TA|placebo to misoprostol plus placebo to tranexamic acid
10182394|NCT03774342||CABG-patients|We will study one group of patients all scheduled for a Coronary Artery Bypass Grafting-procedure. This observational study consists of one group.
9693793|NCT04796051|Active Comparator|Deep cervical flexors exercise|Deep cervical flexors exercise group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
9693794|NCT04796090||Adolescents with genital warts (Study Group)|The Study group included adolescents who was diagnosed as positive for genital warts during the examination.
9693795|NCT04796090||Healthy adolescents (Control Group)|The Control group was composed of healthy adolescents who admitted for only contraceptive counselling.
9693796|NCT04796207|Experimental|Fish Oil Capsules|Participants in the treatment arm will receive 3 grams of DHA and EPA (2:1 weight ratio) 3 times a week for 25-weeks during regular football season.
10182395|NCT03774329|Experimental|physical activity program|Child with an adapted physical activity program
10182396|NCT03774329|Other|Usual care|
10182397|NCT03774407|Other|urogenital symptoms|To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
10182398|NCT03774407|Experimental|remyelination|To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
10182399|NCT03774290|Experimental|PBF-680 10 mg|10 mg of PBF-680 once a day
10182400|NCT03774290|Placebo Comparator|Placebo oral capsules|Placebo once a day
10182401|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - PRP Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to undergo platelet rich plasma injection
10182402|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - ESWT Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to extracorporeal shock wave therapy
10182403|NCT03774277|Experimental|Intervention Communities|Packed Promise for a Healthy Heart intervention, free Tribal Wellness Center membership, a Fitbit, and the AYA culturally based mobile walking app.
10182404|NCT03774277|No Intervention|Control Communities|Free Tribal Wellness Center membership, Fitbit, and the AYA culturally based mobile walking app
10182405|NCT03774303|Experimental|mobile intervention|families to be prepared for day surgery with a mobile application
10182406|NCT03774303|Active Comparator|control group|families to be prepared for day surgery with current practice
10182407|NCT03774212|Experimental|Group A|On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
10182408|NCT03774212|Experimental|Group B|Patients will spend night 1 wearing Active Noise Cancelling headphones playing white noise. On Study night 2, these patients will receive standard care (no headphones provided).
10182409|NCT03774368|Other|Website about emergency contraception|Subjects are randomly assigned to view an existing website about emergency contraception. The website contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
10182410|NCT03774368|Other|Video about emergency contraception|Subjects are randomly assigned to view an existing video about emergency contraception. The video is two minutes in length and contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
10182411|NCT03774238|Experimental|COPD patients|FMD analysis Endothelial progenitors Exercise test Exercise training
10182412|NCT03774238|Experimental|Healthy subject|FMD analysis Endothelial progenitors Exercise test
10182413|NCT03774472|Experimental|Treatment (hydroxychloroquine, palbociclib, letrozole)|"PHASE I: Patients with advanced, metastatic (stage IV) breast cancer receive hydroxychloroquine PO QD, palbociclib PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients with early stage (stage I-III) breast cancer receive hydroxychloroquine PO QD on days 15-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive palbociclib PO QD, and letrozole PO QD on days 1-28, followed by standard of care surgery at week 5. If there is a proliferative benefit with CCCA by biopsy at 4 weeks, cycles may repeat every 28 days for up to 20-24 weeks in the absence of disease progression or unacceptable toxicity, followed by standard of care surgery during weeks 20-24."
10182414|NCT03774459|Experimental|High dose ANAVEX2-73|High dose ANAVEX2-73
10182415|NCT03774459|Experimental|Mid dose ANAVEX2-73|Mid dose ANAVEX2-73
10182416|NCT03774459|Placebo Comparator|Placebo oral capsule|Placebo oral capsule
10182417|NCT03774017|Other|Traditional microsurgery group|Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater. No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed. The DSA will be performed in 3 days after the operation.
10182418|NCT03774017|Experimental|Hybrid operation group|Patients receive microsurgical operation under the assistance of intraoperative DSA, endovascular embolization and/or balloon occlusion in the one-staged hybrid operating theater.
9693797|NCT04796207|Placebo Comparator|Safflower Oil Capsules|Participants in the treatment arm will receive 3 grams of high-oleic safflower oil) in a 1:1 allocation ratio for 25-weeks during regular football season.
9693798|NCT04796298|Experimental|Ballistic Hamstring Stretching Group|Ballistic Hamstring Stretching
9693799|NCT04796298|Experimental|Hamstring Extender Exercise Group|Hamstring Extender Exercise
9693800|NCT04796298|Experimental|Kinesiotape Group|Kinesiotape
9693801|NCT04795934|Active Comparator|Laparoscopic Nissen Fundoplication (LNF)|Control
9693802|NCT04795934|Active Comparator|Combo Transoral Incisionless Fundoplication (CTIF)|Treatment
9693803|NCT04796025|Experimental|T-Double|TACE Combined With Sintilimab Plus Bevacizumab Biosimilar
9693804|NCT04796168|Active Comparator|post operative Ankle fractures with splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive splint post operative
9693805|NCT04796168|No Intervention|post operative Ankle fractures without splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive NO splint post operative
9693806|NCT04796077|Experimental|Pop-Up Book|Patients read an interactive pop-up book about general anesthesia induction in addition to standard consultation with an anesthesia provider.
9693807|NCT04796077|No Intervention|Standard Care|Patients received standard consultation with an anesthesia provider (standard care).
10182419|NCT03773991||Maintenance Hemodialysis Patients|"Patients on chronic hemodialysis therapy due to end-stage renal disease.~Proton Lung MRI~Sodium MRI of the leg~Chest CT~Transthoracic Echocardiography~Fractional Exhaled Nitric Oxide~Six-Minute Walk Test~Pulmonary Function Tests~Blood sampling~Self-administered dyspnea questionnaires"
10182420|NCT03774030|Experimental|hearing impaired participants|Hearing impaired participants with mild or severe hearing loss
9693808|NCT04796155||labour arrest|Pregnant women whose labour progress is delayed and suspected or diagnosed as labour arrest according to the NICE guidelines. Intrapartum ultrasound will be performed at the suspicion of labour arrest in the active phase of the first and second stage of labour. Amniotomy will be performed as routine obstetric care according to the local clinical protocols in accordance with the NICE guideline. Later, diagnosis of labour arrest will be made in slow progress following amniotomy (<1cm cervical dilatation in 2 hours) where a sonographic examination will be repeated.
9693809|NCT04796246|Experimental|Leap Motion Controller|Intervention Group: which will receive treatment with Leap Motion Controller
9693810|NCT04796246|Active Comparator|Conventional Physiotherapy|Control Group: who will receive treatment with conventional physiotherapy.
10182421|NCT03773939||Derivation cohort|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624, NCT03577405, and NCT03553069)
9693811|NCT04795973|Experimental|IF group|intermittent fasting intervention for 4 weeks
9693812|NCT04796142|Experimental|Reconciliation|Interventional trial without drugs
9693813|NCT04795817||Single arm|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA
9693814|NCT04796038|Experimental|Rise SC|All patients will receive the Rise semi-compliant balloon catheter as per treatment.
9693815|NCT04795960|Experimental|Low serine diet|
9693816|NCT04795960|Experimental|High serine diet|
9693817|NCT04795778||Patients with breast cancer|Breast cancer patients with or without breast cancer surgery, with or without mastectomy, with or without lymphedema
9693818|NCT04795778||Control group|Healty individuals with no disease
9693819|NCT04795830|Active Comparator|Control group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of GC Corporation's EQUIA Forte High Translucency glass ionomer restorative (GC EQUIA Forte HT Fil Capsule) will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
9693820|NCT04795830|Active Comparator|Control group with Restoration|"After pulpotomy and hemostasis, MTA powder and liquid will be mixed according to the manufacturer's instructions and applied via MTA applicator to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
9693821|NCT04795830|Experimental|Study group with Restoration|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber and restore the tooth."
9693822|NCT04795830|Experimental|Study group with Stainless Steel Crown (SSC)|"After pulpotomy and hemostasis, BC RRM Fast setting putty will be applied from the manufacturer's syringe using a plastic instrument to cover the amputated pulp stumps.~Using a glass ionomer gun, a capsule of glass ionomer restorative GC EQUIA Forte HT Fil Capsule will be injected to fill the pulp chamber.~Finally, the tooth will be restored with a stainless steel crown."
9693823|NCT04795843|Experimental|Progressive exercise therapy and patient education|6-months
9693824|NCT04795843|Active Comparator|Usual Care|6-months
10182422|NCT03773939||External validation cohort|We will create a multicenter cohort based on prospectively collected data derived from the Dutch National Intensive Care Evaluation (NICE) registry
10182423|NCT03774199|Other|Pulse oximeter calibration population|
9693827|NCT04795570||Cases. Patients who develop urethral stricture|Patients who develop urethral stricture within 6 months after TUR P/B
9693828|NCT04795570||Controls. Patients who DO NOT develop urethral stricture|Patients who DO NOT develop urethral stricture within 6 months after TUR P/B
9693829|NCT04795726|Experimental|Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
9693830|NCT04795726|Placebo Comparator|Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
9693831|NCT04795414||Vaccination Group|Participants vaccinated with inactivated SARS-CoV-2 vaccine are studied for safety and antibody response.
9693832|NCT04795505||Intervention group|A tertiary A-level hospital WeChat-based intervention
9693833|NCT04795505||Control group|Traditional community hospital intervention
9693834|NCT04795752|Experimental|TearCare Group (Study Device)|
10182424|NCT03773900|Experimental|Chitin-Glucan supplementation|
10182425|NCT03773900|Placebo Comparator|Placebo supplementation|
10182426|NCT03774043|Experimental|Single session of Acute Intermittent Hypoxia (AIH)|
9693835|NCT04795752|Active Comparator|Restasis Group (Control)|
9693836|NCT04795349|Experimental|NAC Patients.|Breast cancer patients after NAC completion, prior to surgery
9693837|NCT04795765||Patients treated with SpineJack system|SpineJack system procedure
9693838|NCT04795765||Patients treated with vertebral augmentation|Vertebral augmentation procedures may include either balloon kyphoplasty (BKP) or vertebroplasty (VP).
9693839|NCT04795648|Experimental|Spatial Repellent|Transfluthrin
9693840|NCT04795648|Placebo Comparator|Placebo|Inert ingredients
9693841|NCT04795492|Experimental|Intervention group|Remote intervention
9693842|NCT04795492|Active Comparator|Control group|Routine outpatient follow-up
9693843|NCT04795609|Active Comparator|Interventional group|Early mobilization postoperative programme based on supervised aerobic exercise, resistance and flexibility training or to standard rehabilitation care
9693844|NCT04795609|No Intervention|Control group|Bed restriction strategy for 5 days
10182427|NCT03774043|Placebo Comparator|Single session of Sham Acute Intermittent Hypoxia (Sham AIH)|
10182428|NCT03774043|Experimental|Two successive sessions of AIH|
10182429|NCT03774043|Placebo Comparator|Two successive sessions of Sham AIH|
10182430|NCT03774056|Experimental|dose group|Drug name L:HC-1119 Dosage: 40 mg, 80 mg, 160 mg, and 200 mg
10182431|NCT03774355|Experimental|CG1801|Dosing 'CG1801' followed by dosing 'CGL1802'
9693845|NCT04795518||Cross sectional study by questionnaire among group of pediatric dentistry|"An interviewed questionnaire is divided into two parts. The first part of the questionnaire will investigate the socio-demographic characteristics of the respondents. The second part of the questionnaire is divided into five sections to cover the following items:~Use of antibiotics pattern~Knowledge about antibiotics~Sources of information"
10182432|NCT03774355|Experimental|CGL 1802|Dosing 'CGL1802' followed by dosing 'CG1801'
9693846|NCT04795635|Experimental|CMM + Axon Therapy|"Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days). Participants randomized to the CMM plus Axon Therapy group will return to the clinic for Axon Therapy treatments as follows:~Month 1: 6 treatments~WEEK 1: 3 treatments (consecutive treatments are best)~WEEK 2-4: Weekly treatments~Month 2: Bi-monthly treatment~Months 3-12: Treatments every 2-4 weeks~In addition to in-clinic assessments and treatments, all participants will a receive weekly phone follow-up to assess pain intensity and occurrence of adverse events after treatment starts. Weekly phone follow-ups will only occur during weeks when the participant is not in clinic for treatment."
9693847|NCT04795635|No Intervention|CMM Only|Participants will return to the clinic for assessment at Day 30 (± 14 days), Day 90 (± 14 days), Day 180 (± 30 days) and Day 365 (± 30 days)
9693848|NCT04795453||assessment of usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
9693849|NCT04795453||assessment of score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
9693850|NCT04795375|Experimental|Intervention|The intervention group will receive Physical activity counseling and guidance by a certified Nurse during the six months after the surgery, additional to the routine follow-up after bariatric surgery at Hadassah-Ein Kerem Hospital.
9693851|NCT04795375|No Intervention|Control|"The control group will receive the routine follow-up followed at Hadassah-Ein Kerem Hospital after bariatric surgery, which includes long term follow-up with the surgeon and a dietitian.~Participants at the Control group will receive Physical activity counseling by a certified nurse at the end of trial."
9693852|NCT04795687||Ischemic stroke patients|
9693853|NCT04795687||Control|
9693854|NCT04795401|Experimental|FRAME Group|"Patients will be enrolled during their hospitalization/consultation in vascular surgery department. After asking questions, his given free, informed and written consent will be collected, and recorded in his medical file by the investigator.~During this hospitalization, the pre-procedure forming part of the usual care is carried out. The specific acts of research are: Cardiac echocardiography and Quality of life survey SF-36 The plication procedure will be performed according to the FRAME FR. All pre-, peri-, and post- operative routine patient management will be carried out as usual.~Follow up visits will be held at 6, 12 months post procedure. All follow up visits will include the assessments as usual.~The specific acts of research are as follows: Cardiac echocardiography at 12 months and quality of life survey SF-36."
9693855|NCT04795401|No Intervention|Control Group|"Control group corresponds to the historical patients over a period of time sufficient to have at least 20 patients according to inclusion criteria. The information form will be sent to each patient eligible for the study by post. Without any feedback from him within 30 days, it is considered that the patient does not object to the use of its data.~As part of this research, no additional examination will be performed. The data used correspond to the data collected in the usual care of patients."
9693856|NCT04795479|Experimental|Treatment Sequence 1|Participants will receive relacorilant 400 mg once daily (QD) for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693857|NCT04795479|Experimental|Treatment Sequence 2|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693858|NCT04795479|Experimental|Treatment Sequence 3|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693859|NCT04795479|Experimental|Treatment Sequence 4|Participants will receive relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693860|NCT04795479|Experimental|Treatment Sequence 5|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693861|NCT04795479|Experimental|Treatment Sequence 6|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
10182433|NCT03774225|Experimental|Manual and verbal guidance (MVG)|The MVG Group will be done by experimental group with the manual and verbal guidance of a physiotherapist using four games of X-Box Kinect system®
10182434|NCT03774225|Experimental|No manual and verbal guidance (NMVG)|The NMVG Group will be done by experimental group using four games of X-Box Kinect system® in the presence of a physiotherapist that will care about the safety of the participants without interfere in their moviment pattern.
10182435|NCT03774225|Active Comparator|Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
10182436|NCT03774173|Experimental|Aramchol 300 mg|Aramchol 300 mg twice daily (every 12 hours)
9693862|NCT04795479|Experimental|Treatment Sequence 7|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693863|NCT04795479|Experimental|Treatment Sequence 8|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693864|NCT04795479|Experimental|Treatment Sequence 9|Participants will receive placebo to relacorilant QD for 5 days in Period 1, followed by relacorilant 400 mg QD for 5 days in Period 2, followed by relacorilant 800 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693865|NCT04795479|Experimental|Treatment Sequence 10|Participants will receive relacorilant 400 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 2, followed by placebo to relacorilant QD for 5 days in Period 3, followed by relacorilant 800 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693866|NCT04795479|Experimental|Treatment Sequence 11|Participants will receive relacorilant 800 mg QD for 5 days in Period 1, followed by placebo to relacorilant QD for 5 days in Period 2, followed by placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 3, followed by relacorilant 400 mg QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693867|NCT04795479|Experimental|Treatment Sequence 12|Participants will receive placebo to relacorilant QD for 4 days and moxifloxacin 400 mg on Day 5 in Period 1, followed by relacorilant 800 mg QD for 5 days in Period 2, followed by relacorilant 400 mg QD for 5 days in Period 3, followed by placebo to relacorilant QD for 5 days in Period 4. Treatment periods will be separated by a washout of at least 10 days.
9693868|NCT04795102|Experimental|L-PRF with ATBG around implant|L-PRF clots to cover ATBG around immediately placed dental implants in the extraction sockets
9693869|NCT04795102|Active Comparator|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
9693870|NCT04794998||"Recommended schedule cohort"|COVID-19 patients who have applied the proposed treatment recommendation algorithm at the onset of or within few days from the beginning of symptoms.
9693871|NCT04794998||"control cohort"|COVID-19 patients enrolled in the ORIGIN study of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, and treated at home by their family doctors with drug regimens other than those proposed in the recommendations
9693872|NCT04795271|Experimental|Orthopedic treatment|"Participants who are referred for orthopedic treatment as indicated by the treating traumatologist or rehabilitating doctor will be evaluated and treated by one of the three orthopedists participating in this study.~After the orthopedic evaluation, the professional will determine the most suitable insole according to the plantar discharge needs required by the patient. The intervention in the insole can include modifications or corrections at the forefoot, midfoot, or hindfoot. The material used in each insole will also be specified. When the insole requires many modifications and raises the height of the subject's foot, the use of orthopedic footwear will also be added to prevent pressure on the dorsum of the foot that could be caused by normal footwear."
9693873|NCT04795128|Other|IBI322|Single arm
9693874|NCT04795180|No Intervention|Non-irrigations|No irrigations trough the efferent limb of loop ileostomy
9693875|NCT04795180|Experimental|Butyrate irrigations|Butyrate irrigations trough the efferent limb of loop ileostomy
9693876|NCT04795180|Sham Comparator|Saline irrigations|Saline irrigations trough the efferent limb of loop ileostomy
9693877|NCT04795011|Active Comparator|control group|Standard rehabilitation protocol will be administered to the control group. In the standard rehabilitation protocol for the first three days after surgery, 3 sets of exercises will be applied as 10 repetitions. The treatment will be initiated for the patients with tolerable coughing and deep breathing exercises. Active dorsi-plantar flexion of the ankle, isometric contraction for the quadriceps, hamstrings and gluteus maximus, for the knee in the supine position on the bed; active heel shift exercises, straight leg raising and standing knee and hip flexion, active hamstring curling, and self-hamstring stretching will be performed. After the exercise, the morning treatment protocol will be completed with a walker at a tolerable distance. The patient will be given assignment in the form of walking and repetition of morning exercises at a tolerable level at least twice during the day.
9693878|NCT04795011|Experimental|manual lymphatic drainage group|manual lymphatic drainage (MLD) will be applied to the second group (MLD group) in addition to the standard rehabilitation protocol
9693879|NCT04794933|Active Comparator|Conventional therapy (CT)|Cold pack (15 minutes); pulsed ultrasound therapy (1 watt/cm², 3 MHz, 1:2 pulsed mode; 3 minutes); transcutaneous electrical nerve stimulation (60-120 Hz; 20 minutes) and exercises (20 minutes). The exercises included stretching, strengthening and posture exercises.
9693880|NCT04794933|Experimental|CT+ PNF in extremity pattern|PNF in the extremity pattern, were instructed to actively move through the PNF flexion-abduction-external rotation diagonal pattern for 10 repetitions with manual facilitation and the treatment was performed within the range in which pain did not occur. Rhythmic stabilization and repeated contractions were applied from the PNF techniques.
9693881|NCT04794933|Experimental|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|PNF in scapula and upper trunk patterns in addition to PNF in the extremity pattern. The scapular pattern application was performed by positioning the affected extremity in a relaxed position above the stable side in the side-lying position. Rhythmic stabilization and repeated contractions were applied from the anterior-elevation position in the direction of posterior-depression. Extension, lateral flexion and rotation to the affected side were performed in the trunk patterns in rhythmic stabilization and repeated contractions.
9693882|NCT04795050|Experimental|Intervention|
9693883|NCT04795050|No Intervention|Control|
9693884|NCT04795310|Experimental|Pulsed Dye Laser|PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD)
9693885|NCT04795310|Active Comparator|Intense Pulsed Light|Vascular wavelength bands of 530-650nm and 900-1200nm
9693886|NCT04795193|Experimental|MICS-CABG|Patients undergoing MICS-CABG.
9693887|NCT04795193|Active Comparator|OPCABG|Patients undergoing thoracotomy OPCABG.
10182437|NCT03774173|Experimental|Aramchol 600 mg|Aramchol 600 mg once daily (every 24 hours)
10182438|NCT03774108|Experimental|Metformin Experimental Arm|Metformin 850mg/12 hours, oral, 8 weeks
10182439|NCT03774108|Placebo Comparator|Placebo Comparator Arm|Placebo pills/12hours, oral, 8 weeks
10182440|NCT03773913||Four facilities in Kozah District|Baseline estimated population of 33,412 served by four public sector facilities in Kozah District.
9693888|NCT04795206||Cohort 1: Main Cohort|All eligible participants with CHM in IRIS Registry will be included.
10182441|NCT03774446|Experimental|Seliciclib|Up to 800 mg/day oral seliciclib for 4 days each week for 4 weeks
10182442|NCT03774095|No Intervention|No oil|6-hour oral glucose tolerance test
10182443|NCT03774095|Active Comparator|Hydrolyzed pine nut oil|6g hydrolyzed pine nut oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
10182444|NCT03774095|Active Comparator|Hydrolyzed pine nut oil and olive oil|3g hydrolyzed pine nut oil and 3g olive oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
9693889|NCT04795206||Cohort 2: Trial-Matched Cohort|Only male participants with CHM from Cohort 1 to match Biogen's IST study population using propensity score matching will be included.
9693890|NCT04795167||FlowTriever Arm|
9693891|NCT04795167||Context Arm|
9693892|NCT04795167||Prior Therapy Arm|
9693893|NCT04795284||Patients with symptomatic lumbar spinal stenosis|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
10182445|NCT03773887|Other|acute alcoholic hepatitis|collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)
10182446|NCT03773887|Other|Alcoholic cirrhosis|collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)
10182447|NCT03773887|Other|Without chronic liver disease|collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)
9693894|NCT04795284||Healthy elderly|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
9693895|NCT04794972|Experimental|Study treatment|Patients receive GNC-039 as intravenous infusion for one cycle. Participants with no intolerable AEs could continue for another three cycles. Participants with a clinical benefit after four cycles' treatment could also receive additional treatment for another two cycles at the same dose level.
9693896|NCT04795063|Experimental|Total Robotic Distal Gastrectomy|After exploration and randomization, patients received total robotic distal gastrectomy
9693897|NCT04795063|Active Comparator|Robotic-Assisted Distal Gastrectomy|After exploration and randomization, patients received robotic-assisted distal gastrectomy.
10182448|NCT03773926|Experimental|Neuro-feedback therapy|"EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.~Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback."
10182449|NCT03774381|Experimental|Bifidobacterium breve B-3 group|160 mg mg of Bifidobacterium breve B-3 was orally administered per day for 12 weeks.
10182450|NCT03774381|Placebo Comparator|Control group|160 mg of placebo was orally administered per day for 12 weeks.
10182451|NCT03773861|Other|Participants|Active BLS- Instructors at the Bern Simulation and CPR- Center (BeSiC), at the Bern University Hospital, Bern, Switzerland. Participants have to oversee a BLS instructional session, where standardized errors are performed by trained volunteers.
10182452|NCT03773718||Russkoe pole|400 patients
10182453|NCT03773835|Experimental|HSK3486|0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,
9693898|NCT04795297||recurrent BCC|recurrent BCC
10182454|NCT03773679|Experimental|Exercise Group|"Daily exercise program involved Range of Motion (ROM) exercises against extremity resistances and extension and flexion in upper and lower extremities. Exercises were implemented on wrists, elbows, shoulders, ankles, knees, and hip joints of the infants by the same researcher (YSE). The daily exercise program was repeated 5-8 times, 1 session/day (a similar time of the day), for 30 days. Each session continued for 7-10 minutes."
9693899|NCT04795297||resected BCC|resected BCC
9693900|NCT04795154|No Intervention|Pre-test group|pregnant women> 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg without treatment.
9693901|NCT04795154|Experimental|Post-test group|pregnant women > 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg got yoga exercise, and post group was got yoga exercise was 30 minutes every 2 weeks for two months (4 times treatment). Yoga exercises technique used stretching and posture exercises (asanas) combined with deep breathing (pranayama) and meditation, to unify body, mind, and spirit (Babbar S, Parks-Savage AC, Chauhan SP, 2012).
9693902|NCT04794946|Experimental|Liver Cirrhosis|Evidence of liver cirrhosis established during the clinical investigations and/or hospital stay, as evidenced by clinical, endoscopic, radiological and/or histological criteria.
9693903|NCT04794946|Active Comparator|Non Liver Cirrhosis (Healthy Control)|No major respiratory, cardiac comorbid illnesses or malignancy or immunosuppressed state
9693904|NCT04794894||Telerehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at home via telecommunication technologies.
9693905|NCT04794894||Clinic-based rehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at a local facility.
9693908|NCT04795089||Patients|Patients with iNPH and shunt surgery.
9693909|NCT04795089||Healthy individuals|Healthy controls with similar gender and age distribution as the patients.
9696502|NCT04766190|Other|Group 3: The DISCO App + Booster|"The patient will be asked to arrive 30 minutes early to their next scheduled appointment with their oncologist so they can complete a survey.~The patient will be shown an iPad with an app while waiting to see your oncologist. The app includes a short video and asks questions about your financial concerns. The app will give the patient a list of questions they may want to ask their oncologist during their appointment. The patient will then meet with their oncologist. The meeting with their oncologist will be video recorded. The oncologist has agreed to be video recorded. Immediately after meeting their oncologist, they will complete another brief survey. The questions will ask about how the meeting went and what they thought of the app. The patient's meeting with the oncologist will not be delayed or changed in any way because of this study. Two months after that appointment, the patient will be sent a reminder of the information that was presented on the app."
10204331|NCT03081910|Experimental|Autologous CD5.CAR/28zeta CAR T cells (Group A)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
9696503|NCT04766424|Experimental|Behavioral sleep extension group|Participants in the sleep extension group will receive a fitbit, weekly coaching calls and educational materials for 8 weeks. In months 3-6, they will receive educational materials and an email from the coach each month.
9696504|NCT04766424|Other|Health education|Participants in the health education group will receive 8 weekly health education emails and telephone calls to confirm their receipt and clarify any concepts from the materials. In months 3-6, they will receive monthly health education materials.
9696505|NCT04766151|Experimental|Transdermal glyceryl trinitrate patches|
9696506|NCT04766151|Placebo Comparator|Transdermal placebo patches|
9696507|NCT04766684|Experimental|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream|
9696508|NCT04766684|Active Comparator|L.M.X.4 cream with J-Tip saline injection|
9696509|NCT04766112|Experimental|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training which consist of 10 positions
9696510|NCT04766112|Active Comparator|Group II|Group B will receive yang style Tai chi exercise which consist of 10 positions
9696511|NCT04766463|Experimental|Treatment group A|
9696512|NCT04766463|Experimental|Treatment group B|
9696513|NCT04766463|Placebo Comparator|Treatment group C|
9696514|NCT04766463|Active Comparator|Treatment group D|
9696515|NCT04766450|Active Comparator|Group 1, NAC group|Group 1, NAC group (n=30): Patients will receive conventional therapy for diabetic neuropathy in addition to High Dose N-acetyl cysteine (2400 mg/day divided into two doses) daily for 3 months
9696516|NCT04766450|No Intervention|Group 2, Control group|Group 2, Control group (n= 30): Patients will receive conventional therapy for diabetic neuropathy alone for 3 months.
9696517|NCT04766229|Experimental|Single Arm|All participants in single arm study
9696518|NCT04766138|Experimental|Fecobionics studies|Single-arm study
9696519|NCT04766216|Experimental|Warfarin Patient Self-Management|Patients managing decisions relating to warfarin dose and next INR test based on the results of current INR test
9696520|NCT04766216|Active Comparator|Historical Control|Patients managed by anticoagulation providers prior to transitioning to warfarin patient self-management
9696521|NCT04766125|Other|Standard adverse event information|
9696522|NCT04766125|Other|Elaborated adverse event information|
9696523|NCT04766281|Active Comparator|MLC901 (NeuroAiD II)|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
9696524|NCT04766281|Placebo Comparator|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
9696525|NCT04766203|No Intervention|Global screening of high-performance athletes for REDS|This arm collects data with an online survey to assess prevalence and signs and symptoms of REDS in elite female and male elite and recreational athletes and para-athletes over the age of 15 years across the world.
9696526|NCT04766203|No Intervention|Basic screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline blood sample and potentially (where abnormalities are present) a follow-up 6 months later.
9696527|NCT04766203|No Intervention|Advanced screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline test for bone density (DXA scans), resting metabolic rate and exercise testing. Potentially (where abnormalities are present) a follow-up 6 months later.
9696528|NCT04766203|Experimental|Treatment of Canadian athletes with REDS: a holistic intervention arm|In this arm, varsity level to elite Canadian athletes and para-athletes with REDS will participate in a nutritional intervention aiming to improve energy availability and thus, REDS status.
9696529|NCT04766242|Experimental|Intervention group|The intervention group will receive 10 healing session of 45-60 minutes as an adjunct to usual care, approximately once a week.The usual care will consist of the treatment plan made by their GP when they were diagnosed with moderate depression.
9696530|NCT04766242|Other|Control group|The control group will receive usual care as prescribed by their GP when they were diagnosed with moderate depression.
9696531|NCT04765917|Active Comparator|Selected Physical Therapy group|The Control group will receive a selected physical therapy program for 60 minutes, 3 times/week for 3 successive months including the following exercises
9696532|NCT04765917|Experimental|Motor imagery training|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 30 min in addition to 30 minutes motor imagery training program
9696533|NCT04765904|Active Comparator|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding drilling
9778261|NCT01102426|Active Comparator|Dexamethasone|dexamethasone single agent
9696534|NCT04765904|Experimental|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a topical therapeutic agent for managing caries lesions in young children
9696535|NCT04765813|Experimental|CBT and active smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components
9696536|NCT04765813|Active Comparator|CBT and control smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with a control App
9696537|NCT04765943||Study population|Patients with LVEF equal to or less than 40% determined by echocardiogram on the 4th day after acute myocardial infarction.
10205355|NCT02557672|Experimental|Prothrombin complex concentrate|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
9696538|NCT04765683||Patients|Attending surgical outpatients
9696539|NCT04765683||Surgeons|Running surgical outpatients
9696540|NCT04765826|Experimental|high dose oral steroids|(20 patients) will receive high dose oral mini pulse steroids (dexamethasone 5 mg on two consecutive weekly days for 3 months).
9696541|NCT04765826|Experimental|low dose oral steroids|(20 patients) will receive low dose oral mini pulse steroids (2.5mg dexamethasone on two consecutive weekly days for 3 months
9696542|NCT04765826|Experimental|topical treatment|(20 patients) chosen lesions of comparable size and location in each patient in this group will receive either; super potent topical steroids once every other day, Tacrolimus ointment twice daily for 3 months, or nothing to serve as a control.
9696543|NCT04765748||TAAA patients with Cytosorb|Patients suffering from a TAAA larger than 55mm
9696544|NCT04765748||TAAA patients without Cytosorb|Patients suffering from a TAAA larger than 55mm
9696545|NCT04765774|Experimental|The Effect of Expressive Touch and Music Applied After Lumbar Disc Herniation Surgery|
9696546|NCT04765839|Experimental|Intervention Arm - Receives COVID-19 Vaccine messages|Group to receive COVID-19 Vaccine messages during the first two weeks of the study.
9696547|NCT04765839|Experimental|Delayed Intervention Arm|Group to receive COVID-19 Vaccine messages during the last two weeks of the study.
9696548|NCT04765709|Experimental|BRIDGE single arm|"Treatment plan:~Part 1: induction with durvalumab plus histology-based chemotherapy regimen.~Part 2: patients with a sufficient tumor shrinkage to be considered eligible for part 2 and they will be treated concomitantly with durvalumab and radiotherapy.~Part 3: patients with partial response or stable disease after part 2 will be eligible for durvalumab maintenance, for up to 2 years or until disease progression or unacceptable toxicity."
9696549|NCT04765878|Experimental|Humidification|
9696550|NCT04766047|Active Comparator|DEXMEDETOMIDINE AND AKI|The patients of the group undergoing EVAR under general anesthesia will receive dexmedetomidine intraoperatively.
9696551|NCT04766047|No Intervention|CONTROL AND AKI|The patients of the group undergoing EVAR under general anesthesia will not receive dexmedetomidine intraoperatively.
9696552|NCT04765800|Active Comparator|Unified Psychodynamic Protocol for Emotional Disorders (UPP-EMO)|focus on core psychodynamic treatment principles (Leichsenring & Steinert, 2018); no use of imagery-based interventions
9696553|NCT04765800|Experimental|Guided Imagery Psychotherapy for Emotional Disorders (GIP-EMO)|regular sessions with and focus on work with guided affectice imagery
9696554|NCT04765995|Experimental|HZBio1 0.96mg/kg|Participants will receive intramuscularly 0.96 milligram per kilogram (mg/kg) of HZBio1.
9696555|NCT04765995|Experimental|HZBio1 3mg/kg|Participants will receive intramuscularly 3 milligram per kilogram (mg/kg) of HZBio1.
9696556|NCT04765995|Experimental|HZBio1 6mg/kg|Participants will receive intramuscularly 6 milligram per kilogram (mg/kg) of HZBio1.
9696557|NCT04765995|Experimental|HZBio1 9mg/kg|Participants will receive intramuscularly 9milligram per kilogram (mg/kg) of HZBio1.
9696558|NCT04765995|Experimental|HZBio1 12mg/kg|Participants will receive intramuscularly 12 milligram per kilogram (mg/kg) of HZBio1.
9696559|NCT04765891|Experimental|Positional Release Therapy|Participants were randomly assigned the positional release therapy treatment group. The participants underwent the treatment.
9696560|NCT04765891|Experimental|Therapeutic Massage|Participants were randomly assigned the therapeutic massage treatment group. The participants underwent the treatment.
9696561|NCT04765930|Active Comparator|PRP Injection|Half of the face
9696562|NCT04765930|Placebo Comparator|Saline injection|Other half of the face
9696563|NCT04765670|Experimental|Instrument Assisted Soft Tissue Mobilization|"The instruments will be applied to the soft tissue at 30º-60º angles, with multi-directional stroking movements. Instrument Assisted Soft Tissue Mobilization will be applied to the trapezius and sternocleidomastoideus muscles of the participants for 90 seconds."
9696564|NCT04765670|Experimental|Kinesiotape Application|The application will be made from the insertion of the upper trapezoidal muscle to its origo . During taping, the patient will be allowed to sit in an upright position in a chair with a back, with the scapula fixed, without supporting the arms. Before taping, the patient will be positioned with the shoulder in adduction and the head in lateral flexion towards the contralateral side. The patient will be asked to perform shoulder abduction against resistance, and the insertion area of the upper trapezius fibers will be palpated. The initial 2-3 cm part of the band will be glued to the lateral of the acromion without stretching, after full (100%) stretching is applied to the 2-3 cm part of the band from the insertion area of the upper trapezoid fibers, the patient's head is rotated to the affected side and the arm part of the band is stretched along the muscle fibers. it will be glued up to the hairline without doing it.
9696565|NCT04766021|Placebo Comparator|Placebo|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
9696566|NCT04766021|Experimental|100 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
10188062|NCT03720015|Experimental|Concurrent training|Three sessions per week of concurrent training during radiotherapy period. Each session will begin with warm-up (5-min cardiovascular activity at low-moderate intensity, joint mobility and one set of resistance exercises circuit at 30-40% 1RM). Resistance training will follow the warm-up, including 9 standard exercises involving major muscle groups of the lower and upper body: vertical bench press, parallel bar dip for triceps, seated rowing, standing dumbbell curl for biceps, leg press, deadlift and shoulder press. All these exercises will be realized following circuit training with 4 sets of 8-12 repetitions, using a training load of 70-80% RM. When patient will able to complete more than 12 repetitions, load will be increased progressively 10%. Cardiovascular training will be completed 20-30 min after resistance training, and it will include High-Intensity Interval Training (HIIT) of 3 min near to the second ventilatory threshold and 2 min near to the first ventilatory threshold.
9696567|NCT04766021|Experimental|150 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
9696568|NCT04766021|Experimental|200 mg Mirabegron|Given once, followed by observation for 6 hours in a 20 degree Celsius (68 degree Fahrenheit) room
9696569|NCT04765319||Vets|Veterans receiving care from the PTSD Clinical Team at the Salt Lake City VAMC. All participants are adults with a diagnosis of PTSD. This study plans on reviewing data collected as part of standard clinical practices. The study will have no impact on the treatment provided to the patient.
9696570|NCT04765631||Patients with Type 2 diabetes|Subjects from 3 cohorts (QUALYOR, OFELY, STRAMBO) presenting type 2 diabetes
9696571|NCT04765631||Control subjects without Type 2 diabetes|Controls patients from 3 cohorts (QUALYOR, OFELY, STRAMBO) without type 2 diabetes
9696572|NCT04765605|Experimental|WeFlow-Tbranch Stent Graft System|Participants will be treated with WeFlow-Tbranch Stent Graft System
9696573|NCT04765332||Included patients|Fill patient questionnaires at inclusion visit, around 3 months and 12 months
9696574|NCT04765553|Active Comparator|Emapalumab|Emapalumab i.v infusion
9696575|NCT04765553|Placebo Comparator|Placebo|Saline i.v. infusion
9696576|NCT04765475|Experimental|MotivationaI Interviewing Group|Participants in this study group will receive a brief, culturally appropriate, and age-tailored motivational interviewing (MI) intervention targeting facilitators and barriers to appropriate testing, isolation, and care-seeking among young adults and elders. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental, or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
9696577|NCT04765475|Experimental|COVID-19 Symptom Monitoring System Group|Participants in this study group will receive daily COVID-19 symptom (CS) text-based monitoring system to prompt more rapid testing at the onset of symptoms. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
9696578|NCT04765475|Experimental|MotivationaI Interviewing and COVID-19 Symptom Monitoring System Group|Participants in this group will receive both motivational interviewing and daily COVID-19 symptom (CS) text-based monitoring system. This group will also receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask-wearing, how to prevent the spread in the home and managing stress during COVID-19.
9696579|NCT04765475|Other|Control Group|Participants in this group will only receive supportive services. Participants will be provided with referrals to needed medical, mental or behavioral health care and a hygiene kit containing basic hygiene supplies. Additionally, participants will be provided with information on COVID-19 and nearby testing locations. This will include basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19
9696580|NCT04765579||4in1|4in1 block will be applied in the operation room
9696581|NCT04765579||medical|medical analgesics will be applied in the service
9696582|NCT04765397|Active Comparator|Group M|Patients are in this group with monopolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
9696583|NCT04765397|Active Comparator|Group B|Patients are in this group with bipolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
9696584|NCT04765306|Active Comparator|Traditional Direct Fascial Closure|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed under traditional direct visualization without laparoscopic guidance using a single interrupted suture of 0-vicryl.
9696585|NCT04765306|Active Comparator|Fascial Closure Device|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed using direct laparscopic visualization with the Carter-Thomason fascial closure device with a single interrupted suture of 0-vicryl.
9696586|NCT04765410||Patients with solid pancreatic masses|Patients with solid pancreatic masses
9696587|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Zinc.|Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma
9696588|NCT04765267|Active Comparator|Topical Corticosteroid with Systemic Vitamin D|Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals
9696589|NCT04765267|Other|Topical Corticosteroid|Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm
9696590|NCT04765592|Experimental|WeFlow-Arch Modeler Embedded Branch Stent Graft System|Participants will be treated with WeFlow-Arch Modeler Embedded Branch Stent Graft System
9696591|NCT04765514|Active Comparator|Standard Arm: TMZ with concurrent RT (combined modality arm)|"Patients will receive a total of 21 days of Temozolomide (TMZ), with 15 days of TMZ administered daily with concurrent RT. TMZ will be delivered at a dose of 75 mg/m2, given daily with RT for 15 days, one hour before each session of RT.~After a 4-week break, patients will receive six cycles of adjuvant TMZ according to the standard 5-day schedule (days 1-5) every 28 days, up to 6 cycles as tolerated by the patient. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events, intractable nausea or fatigue."
9696592|NCT04765514|Experimental|Biomarker based treatment|"MGMT (+) Temozolomide monotherapy: Patients will receive Temozolomide (TMZ) at a dose of 75 mg/m2 daily for 21 consecutive days. This will be followed by six cycles of TMZ according to the standard 5-day schedule (days 1-5) every 28 days. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events. Dose will be determined using body surface area (BSA) calculation.~MGMT methylation (-) RT monotherapy: Participants will receive radiation treatment with 40Gy / 15 fractions over a period of 21 days (3 weeks)."
10188063|NCT03720015|Experimental|Nutritional management|Prescribed diet controlling macronutrients according to patient body weight (~4g/kg/day for carbohidrates, ~2g/kg/day for proteins, and ~1g/kg/day for fats). Patient will take one single dosage per day of probiotics (Arkoprobiotics® Defenses), 1 or 2 capsules of omega-3 fish oil concentrate (Solgar®, 600-1200mg depending on fat sources intake during the day), and a combine ingestion of 3g beta-hydroxybeta-methylbutyrate (HMB), 14g arginine, and 14g glutamine (HSN Raw Series®, all pure ingredients and making the ingestion adding each of them individually in a solution with 300-400 ml of water). During concurrent training sessions, between resistance exercise and HIIT, patient will also take 6g of BCAA's (HSN Raw Series®, 2:1:1) along with a banana. Additionally, patient could take whey isolated protein (Amix® IsoPrime CFM) to meet with some of the prescribed proteins intakes.
9696593|NCT04765254||control group|COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health
9696594|NCT04765254||diabetic group|COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs
9696595|NCT04765527|Experimental|Turmeric|Dietary supplement, Turmeric Strength for Joint, containing turmeric root extract (with 350 mg curcumin), black pepper extract, boswellia gum resin extract, devil's claw root extract, and ginger root; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
9696596|NCT04765527|Placebo Comparator|Placebo|Placebo tablets; 2 tablets each day in the morning prior to breakfast, 2 weeks, and Monday through Friday of exercise and recovery.
10188064|NCT03719989|Experimental|Treatment arm|This study is sing-arm study. Therefore, all enrolled patients will be treated with azacitidine plus R-GDP regimen
9696597|NCT04765540|Active Comparator|T1: Business as Usual (BAU)|Handwashing station plus standard BRAC programming, i.e. in-person community WASH (water, sanitation and hygiene) demonstrations conducted in households/communal areas, and sticker signs/posters placed on walls in the 'catchment area' of the handwashing station, alerting people to the stations and roughly pointing the way.
9696598|NCT04765540|Experimental|T2: BAU + Low Intensity Nudges|"T1 plus a bundle of 'low-intensity' passive interventions, including:~Large mirrors installed above handwashing station sinks to attract more people to the station~7 to 8 large hand-shaped signposts pointing to the station and leading up to the station, placed on the ground in the vicinity of the station, starting from the nearest 'busy spot'"
9696599|NCT04765540|Experimental|T3: BAU + High Intensity Activities|"T1 plus an additional bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks provided to handwashing station users in regular giveaways at key times, along with encouragement to return to the station and to spread the word.~A 'community message board' along with encouragement to make a mark on a scoreboard at the top of the board before/after use of the station to increase commitment and as an additional social cue. This will also visually show cumulative number of uses as a persistent cue of the social norm.~General encouragement to use the stations, provided by the intervention delivery team while they are at the station. Intervention team members are equipped with a loudhailer to assist this.~In addition, village handwashing station committees will be encouraged to try out their own ideas for encouraging more people to use the stations."
9696600|NCT04765501||Patients group|Individuals with headache
9696601|NCT04765228|Experimental|Pegylated liposomal doxorubicin + Anlotinib|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2~4 cycles
9696602|NCT04765293|Experimental|Gravity group|"GRAVITY® system exercise is conducted on a machine. The tasks were non-weight bearing, and the only external load was the body mass of the trainee. The degree of unloading (the level of exercise) was chosen depending on the patient's body mass, their current health and the difficulty of the exercise. The machine allowed for exercising any chosen muscle group at chosen setting of the bench, platform and ropes. GRAVITY® system exercise aimed at general posture improvement and at strengthening the desired movement path, along with strengthening the deep spinal and abdominal muscles.~GRAVITY therapy group had therapy twice a week for 4 weeks for 40 minutes that made 2x40 minx 4 weeks=320 minutes."
9778262|NCT01102491|Experimental|Ramosetron prophylaxis|ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery
10188065|NCT03719963||cochlear implant|Cochlear implantation is a powerful tool for helping children with severe to profound sensorineural hearing loss to gain the ability to hear, and to achieve age appropriate communication skills. Evaluating the development of auditory, speech, language skills and the personality of implanted child is useful for the parent, the teacher, the therapist, and the subsequent rehabilitation progress
9696603|NCT04765293|Active Comparator|Control group|Control group had standard, two weeks ambulant every day physical therapy sessions ( laser therapy, cryotherapy, magnetotherpy, TENS and interference currents), 5 times a week 30 min, that is 10 sessions 30 min x10=300 min.
10188066|NCT03719937|Experimental|anterior chest wall weight|moderate to severe ARDS patients in whom prone positioning is contraindicated. Patients will have a 100 g/kg weight placed on the anterior chest wall, while in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
9696604|NCT04765488|Experimental|Study group|"A group of patients in relation to whom the Wash In / WashOut procedure will be applied. In this group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
9696605|NCT04765488|No Intervention|Control group|A group of patients in relation to whom will be applied the traditional method of recovery from anesthesia. In this group during the period of awakening we stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness.
9696606|NCT04765163||physician group with assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group using assistive equipment
9696607|NCT04765163||Physician group without assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group without assistive equipment
9696608|NCT04765085|Experimental|CBIT Group|Patients in this group would only receive the CBIT treatment.
9696609|NCT04765085|Experimental|Drug therapy Group|Patients in this group would only receive the drug therapy.
9696610|NCT04765033|Active Comparator|5% Hypertonic saline|5% hypertonic saline nebuliser 4 mls twice in a day for 3 months
9696611|NCT04765033|Placebo Comparator|Placebo|0.9% saline nebuliser 4 mls twice in a day for 3 months
9696612|NCT04765007|Experimental|Mindfulness group|This arm will be treated with a mindfulness-based stress reduction therapy.
9696613|NCT04765007|Other|Control group|This arm will be treated with a minimal intervention.
9696614|NCT04765020|Experimental|Intervention group|12 weeks moderate to high-intensity exercise program
10188067|NCT03719911|Experimental|Live diabetes coaching program|Live diabetes coaching program
10188068|NCT03719898|Experimental|Brigatinib|90 mg daily orally for 7 days, then 180 mg daily orally during first cycle; 180 daily orally thereafter during every subsequent cycle. Each cycle has 28 days
10188069|NCT03719872||Participants undergoing laparoscopy|Participants undergoing laparoscopic abdominal surgery with surgical insufflation receiving pre-operative transabdominal ultrasound and post-operative transabdominal ultrasound.
10188070|NCT03719859|Experimental|Physical Therapy (PT) Group|Subjects will attend formal physical therapy after surgery.
10188071|NCT03719859|Active Comparator|Home Therapy (HT) Group|Subjects will receive instruction from clinical staff regarding home therapy exercises after surgery.
10188072|NCT03719833||1-control group-T1-T2 N0 M0|"Breast cancer patients in T1 N0 M0 stage at time of diagnose who initial undergo surgical treatment (quadrantectomy/mastectomy + sentinel lymph node biopsy).~All patients will be followed for 5 years after surgery"
10188073|NCT03719833||2-T2-T3 N0 M0|"Breast cancer patients in T2-T3 N0 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by surgery (quadrantectomy/mastectomy + sentinel lymph node biopsy). For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made.~All patients will be followed for 5 years after surgery"
10188074|NCT03719833||3-T1-T3 N1-N2 M0|"Breast cancer patients in T1-T3 N1-N2 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by ultrasound reevaluation of axillary lymph nodes that indicate complete clinical axillary remission. Surgical procedure that would be performed is quadrantectomy/mastectomy + sentinel lymph node biopsy.~Before initiating neoadjuvant treatment biopsy (FNA) proven positive node will be marked with titanium clip and at the time of surgery removed and pathological examined regardless presenting as a sentinel node or not.~For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made All patients will be followed for 5 years after surgery"
10188075|NCT03719820||Intracranial Atherosclerosis|First-ever stroke patients attributed to intracranial artery stenosis (> 50% or occlusion) who receive aggressive medical management
9696615|NCT04765020|No Intervention|Control group|exercise recommendations
9696616|NCT04765215||Breast or lung cancer patients receiving active chemotherapy and 2 doses of CoronaVac vaccine|
9696617|NCT04765215||Healthy volunteers who received two doses of coronavac vaccine|
9696618|NCT04765111|Experimental|Treatment (acalabrutinib, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 3-4 hours on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2-12, 14, 18, 20, 22, and 24. Cycles repeats every 28 days for up to 24 months or until complete remission is achieved in the absence of disease progression or unacceptable toxicity.
9696619|NCT04764981|Experimental|Experimental Group 1: Essences Oils|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19 that will be submitted to clinical exams, olfactory test and MRI imaging, after that, participants will undergo an olfactory training with essences oils. Each participant in this group will receive a kit with four 30 ml bottles, each containing a circular piece of watercolor paper soaked in one of the four essences oils (rose, eucalyptus, lemon and cloves) used in olfactory training, a manual to make the olfactory training at home and a self-assessment diary which should be filled weekly. Each participant of this group will use the training kit for three months, the olfactory training consists of inhaling each of the substances for 30 seconds, with an interval of 30 seconds between them, twice a day, upon waking up and before bed, the participants will be reassessed with CCCRT after each month of training. The results of this group will be compared with the other groups.
9778263|NCT01102491|No Intervention|Control|no antiemetic prophylaxis
9696620|NCT04764981|No Intervention|Experimental Group 2: Clinical follow-up|The individuals of this group are 150 individuals with olfactory disorder related to COVID-19. that will be submitted to clinical exams, olfactory test and MRI imaging, after three months they will be reassessed.
9696621|NCT04764981|No Intervention|Control Group|The individuals of this group are 50 healthy individuals, without previous COVID-19 infection, that will be submitted to clinical exams, olfactory test, MRI imaging and the participants will be tested for the ability to identification of the essence oils utilized by Experimental group 1.
9696622|NCT04764760|Other|Phase 1:Study role tissue tensile strength|The tensile strength of the orifice of Frauchad was augmented by implantation of a Accordion fold shaped prosthesis.
9696623|NCT04764760|Other|Phase 2:Curative implantation of a custom designed bio-mechanically compatible Tensiflex prosthesis|The wing shaped custom designed tensiflex prosthesis in the groin was impanted as a curative technique since it provided seamless augmenation of the tensile tissue strength.
9696624|NCT04764786|Experimental|EVOO+POLY|Acute test meal
10188076|NCT03719807|Active Comparator|Control Group|Usual Care No routine outpatient physiotherapy following discharge home post-operatively in line with standard care.
10188077|NCT03719807|Experimental|Intervention Group|12 x Exercise//Rehabilitation sessions Begin at 6 weeks. 6 x weekly sessions Followed by 6 x bi-weekly sessions In line with Accelerated Rehabilitation protocol
10188078|NCT03719794|Active Comparator|Probiotics arm|The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
10188079|NCT03719794|Placebo Comparator|Placebo arm|The placebo comparator arm will be of a 12-week placebo supplement regimen.
9696625|NCT04764786|Active Comparator|OO-POLY|Acute test meal
9696626|NCT04764877|No Intervention|Standard Care|Standard teaching and physical exam for any patient that would be seen at our Hilltop Primary Care center asthma clinic. This included baseline PFTs. FOR THIS STUDY a second set of PFTs were obtained at the end of the visit
9696627|NCT04764877|Experimental|OMT arm|As above BUT with the addition of standardized OMT focusing on lung functionality. OMT provided by either our OMM attending at that time (Dr Wolf) or residents trained by her for this study (Drs. Regan, Jones, Pe and Bryant)
9696628|NCT04764955|Placebo Comparator|Group A (Placebo)|Prenatal Period 0 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
9696629|NCT04764955|Experimental|Group B (4200:0 IU/week)|Prenatal Period 4200 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
9696630|NCT04764955|Experimental|16800:0 IU/week|Prenatal Period 16800 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
10188080|NCT03719781||Group1|patients undergoing pituitary tumor removal surgery will be tested with standardized minimental testing.
9696631|NCT04764955|Experimental|28000:0 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
10188081|NCT03719742|Experimental|Sponsor Test Products|"Baby Bee Foaming Cleanser(at least once daily)~BB Baby Ultra Gentle Lotion (twice daily)"
9696632|NCT04764955|Experimental|28000:28000 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 28000 IU/week (delivery-6 months postpartum)
10188082|NCT03719729|Experimental|Single|Each subject will receive rifaximin 550 mg twice a day for up to one year.
10188083|NCT03719716|Experimental|Early support group|This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
10188084|NCT03719716|No Intervention|Usual care group|No change to standard care from oncology services and primary care
10188085|NCT03719703||Case 1|Children conceived by frozen embryo transfer
10188086|NCT03719703||Case 2|Children conceived by fresh embryo transfer
9696633|NCT04764734|Experimental|PSG and NightOwl|During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with the informed consent form. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
9696634|NCT04764825|Experimental|Methadone, induction|"Patients receive methadone 0.15-0.2 mg/kg ideal bodyweight 10 minutes prior to surgery start (Syringe A).~45 minutes before expected extubation patients will receive saline (syringe B)."
9696635|NCT04764825|Experimental|Methadone, end of surgery|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive methadone 0.15-0.2 mg/kg ideal bodyweight (syringe B).
9696636|NCT04764825|Active Comparator|Morphine|Patients receive saline 10 minutes prior to surgery start (Syringe A). 45 minutes before expected extubation patients will receive morphine 0.15-0.2 mg/kg ideal bodyweight (syringe B).
9696637|NCT04764890|Experimental|Electroacupuncture and manual therapy|Electroacupuncture in several points and manual therapy in the lumbar spine
9696638|NCT04764890|Active Comparator|Manual therapy|Manual therapy in the lumbar spina
9696639|NCT04764838|Experimental|Intervantion|Pregnant Yoga
9696640|NCT04764838|No Intervention|Control|The clinic will receive routine care
10188087|NCT03719703||Control|Naturally conceived children
10188088|NCT03719690|Experimental|AIM-HN|Tipifarnib, Oral Tablet. Dose Level 1 orally, bid on days 1-7 and 15-21 of 28-day treatment cycles
10188089|NCT03719690|No Intervention|SEQ-HN|To obtain historical information of first line therapy in subjects enrolled in AIM-HN, in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
10188090|NCT03719664|Experimental|Cohort 1: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
10188091|NCT03719664|Experimental|Cohort 2: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
10188092|NCT03719664|Active Comparator|Control Arm 1: Baseline ART|Subjects continuing on baseline ART
10188093|NCT03719664|Experimental|Cohort 3: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
10188094|NCT03719664|Experimental|Cohort 4: albuvirtide & 3BNC117|albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
9696641|NCT04764968|No Intervention|Usual care|During the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension.
9696642|NCT04764968|Experimental|Dasiglucagon|During the 'dasiglucagon' period, participants will use pen-administered low-dose (80 µg) dasiglucagon to treat or prevent episodes of hypoglycemia.
9696643|NCT04765098|Active Comparator|Etoposide|
10188095|NCT03719664|Experimental|Optimal Dose: albuvirtide & 3BNC117|albuvirtide and 3BNC117 every 2 or 4 weeks
10188096|NCT03719664|Active Comparator|Control Arm 2: Baseline ART|Subjects continuing on baseline ART
9696644|NCT04765098|Experimental|Tamoxifen|
10188097|NCT03719651|Experimental|Intervention|"When clinics join the intervention arm, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
9696645|NCT04764708|Active Comparator|Control Group|Cognitive behavioral therapy plus standard psychopharmacological treatment.
9696646|NCT04764708|Experimental|Experimental Group|A Third Wave Cognitive Therapy that integrates Compassion Focused Therapy and Metacognitively Oriented Psychotherapy.
9696647|NCT04764916|Experimental|Exparel/Intervention group|Will receive 10mL of standard 0.5% bupivacaine followed by 10mL of liposomal bupivacaine as adductor canal field block preoperatively
9696648|NCT04764916|Active Comparator|Standard of Care group|Will receive 20mL of standard 0.5% bupivacaine as adductor canal field block preoperatively
9696649|NCT04764903||LUTS/Nocturia|Patients with LUTS / Nocturia
9696650|NCT04764994|Active Comparator|Control Group|"Participants who will participated in the control group will receive a conventional physical therapy program for two hours. It will include two parts, each of them will be one hour and 15 minutes rest in between. The first part will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises. The second part will include: arm-reaching tasks, arm-hand tasks, manipulative tasks (grasping and release activities) and upper limb self-dependent tasks and the inclusion of the more affected upper limb in functional tasks of daily living activities.~The conventional treatment program will be applied for both groups by therapists, experienced in stroke rehabilitation.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
9696651|NCT04764994|Experimental|Study Group|"Participants of study group will receive two hours treatment program that will include three parts, the first and the second parts (similar to that will be applied for participants in control group) will be together for one hour following by 15 minutes rest, then the third part will apply for one hour. The third part of the program will be one hour virtual reality intervention program by using Armeo Spring to simulate a range of upper limb tasks related to arm-reaching to target, reach and grasp (arm-hand activities) and manipulative tasks through using different games and soft-wares.~The conventional treatment part of the program will be applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program will be applied by another experienced physiotherapists, who are well trained in using Armeo Spring System.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
9696652|NCT04764851|Other|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Cocktail given on 2 separate days:~midazolam: 1 µg infused IV~caffeine: 200 mg oral tablet~omeprazole: two 20 mg oral tablets~dextromethorphan: 1.6mL (containing ~10 mg) oral solution"
9696653|NCT04764851|Other|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Cocktail given on 3 separate days:~midazolam: 10 µg/mL given as 1mL oral solution.~dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
9696654|NCT04764851|Other|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Cocktail given on 2 separate days:~- bupropion: 100mg oral tablet"
9696655|NCT04764630|Experimental|A. Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min)
9696656|NCT04764630|Experimental|B. Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
9696657|NCT04764630|Active Comparator|C. Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
9696658|NCT04764695|Experimental|Patients diagnosed with ALL with individualized nutritional treatment|As it is a pre-test / post-test design, the child himself will be the control at the end of the intervention. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.
9696659|NCT04764643|Active Comparator|sodium thiosulfate solution arm|20ml of 5% sodium thiosulfate solution were prepared with 1g sodium thiosulfate crystal dissolved in normal saline in a 20 ml syringe
9696660|NCT04764643|Experimental|N-acetylcysteine solution arm|20ml of 3% N-acetylcysteine solution were prepared with one piece of N-acetylcysteine effervescent tablet （ net weight 0.6g ）dissolved in normal saline in a 20 ml syringe
9696661|NCT04764318||Remote patient monitoring for hypertension|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
10188098|NCT03719651|Active Comparator|Control|"Clinics that are not yet included in the intervention arm, the leaders will not receive any leadership training (LOCI).~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
10188099|NCT03719638|Active Comparator|D-blade group|Intubation will be done using D-blade of videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
9696662|NCT04764318||Remote patient monitoring with care management|All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM. In addition, PCPs will receive lists of candidate patients. Care managers will assist with the outreach to patients to offer RPM when recommended by the PCP, will monitor and support patient use of the remote monitor, and will promote action on the part of the patient or PCP when uncontrolled hypertension is present.
9696663|NCT04764318||Usual care|Medicare patients from non-intervention primary care practices in Northwestern Medical Group will contribute EHR data but will not have any new procedures put in place.
10188100|NCT03719638|Active Comparator|Macintosh group|Intubation will be done using Macintosh videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
9696664|NCT04764409||Group 1|This group includes patients who underwent chemoembolization of hepatic arteria
10188101|NCT03719625|Experimental|norepinephrin group|The patients of this group will recieve 0.5 micro gr/kg of norepinephin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
9696665|NCT04764409||Group 2|This group includes patients who underwent chemoinfusion of hepatic arteria
9696666|NCT04764565|Experimental|Nuun Instant|2 servings of Nuun instant in 1 liter water
9696667|NCT04764565|Placebo Comparator|Control|1 liter of water
9696668|NCT04764565|Experimental|Nuun Electrolyte|2.1 servings of Nuun Electrolyte in 1 liter water
9696669|NCT04764604|Experimental|Muscle Tension Group|"10 participants with a diagnosis of muscle tension dysphonia will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
9696670|NCT04764604|Experimental|Vocal Fold Palsy Group|"10 participants with a diagnosis of (unilateral) vocal fold palsy will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
9696671|NCT04764604|Experimental|Presbylaryngis Group|"10 participants with a diagnosis of presbylaryngis will carry out two experimental interventions, with a 30 minute vocal rest period in between interventions:~Three minutes of semi-occluded vocal tract exercise with both Acapella Choice~Three minutes of tube-in-water semi-occluded vocal tract exercise.~Aerodynamic, acoustic and electroglottographic baselines will be taken before each intervention and repeated immediately post-intervention as outcomes.~Participants will also provide a self-assessment of voice quality, perceived ease of voice production and perceived strength of voice before and after each intervention.~Participants will additionally answer qualitative questions following each intervention regarding their perceptions of the task: ease performing, pleasantness, effort, practicality and likelihood of carrying out the task on a daily basis as a form of therapy."
9696672|NCT04764500||travellers to Southeast Asia|Clients planning to travel to Southeast Asia will be recruited
10188102|NCT03719625|Experimental|Ephedrin group|The patients of this group will recieve 0,3mg/kg of Ephedrin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
9696673|NCT04764461|No Intervention|Control Group|The control group will continue with the standard practice of antenatal care using Mc Donald's rule for fundal heights measurements.
9696674|NCT04764461|Experimental|Intervention Group|Intervention group will follow the same antenatal visit plan as the control group with the use of customised GROW Charts for fundal height measurements.
9696675|NCT04764396|Experimental|Heparin priming biopsies|
10188103|NCT03719573|Experimental|Geriatric intervention|A comprehensive geriatric assessment and intervention, including exercise program.
9696676|NCT04764396|Active Comparator|Standard of care (saline)|
9984332|NCT04212013|Placebo Comparator|Ibrutinib/Placebo|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis. Placebo capsules will be similarly dosed at 4 capsules daily.
10188104|NCT03719573|No Intervention|control.|Usual treatment and care.
10188105|NCT03719560|Experimental|CNS prophylaxis protocol|Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.
10188106|NCT03719534|Active Comparator|Haplo-SCT|people enrolled in this arm will receive a typical haplo-identical donor SCT
10188107|NCT03719534|Experimental|Haplo-cord SCT|people enrolled in this arm will receive a co-infusion of cord blood unit in addition to a typical haplo-identical donor SCT
10188108|NCT03719521|Experimental|Intervention Arm|"Community-based provision of an integrated package of services over a 24 month period.~For all those aged 16-24 years residing in the intervention clusters: HIV testing, Sexual and reproductive health services (condoms, menstrual hygiene management, contraception, syndromic sexually transmitted infection (STI) treatment, referral for voluntary medical male circumcision, cervical screening), General health information and counselling. For those who are aged 16-24 years and test HIV-positive (or known HIV positive) within the intervention clusters: ART initiation and community-based treatment, adherence support."
10188109|NCT03719521|Active Comparator|Control Arm|Routine existing services
10188110|NCT03719482|Experimental|[18F]MNI-1054|To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.
10188111|NCT03719469||Green tea group|A total of 100 subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University,After starting green tea supplement (4 to 6 cups/day; 60 to 125 mg catechins), patients were evaluated for therapeutic response at baseline and 12, and 24 weeks.
10188112|NCT03719469||control group|fifty healthy normal subjects were included in this study as controls.
9696677|NCT04764227|Experimental|Concurrent chemoradiotherapy group|"Interventions:~Chemotherapy: Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5~Radiotherapy: A total dose of 50.4Gy will be delivered in 28 fractions at 1.8Gy/fraction, 5 fractions per week in 6 weeks. The CTV encompassed the bilateral supraclavicular, superior mediastinal, and subcarinal regions."
9696678|NCT04764279|Experimental|OPTIFAST Arm|Participants in the intervention group will be given OPTIFAST® meal replacement shakes, 4 per day to achieve 900kcal/day, for the first 12 weeks of the study. The second phase will consist of partial meal replacement and food reintroduction over a 4 week period. When the intervention group begins to reintroduce foods, all study participants will be provided a workbook, created for the study, to explain optimal lifestyle changes for DMII management. The third phase will be a 8-month follow-up of participants on continued healthy lifestyle as described in the workbook.
9696679|NCT04764279|No Intervention|Control/Usual Care Arm|Usual Care : A gift card will be offered to participants in the control group to stabilize the incentive of the intervention. Participants in the control group will receive usual diabetes care based on the current Canadian Diabetes Association guidelines by their family physician. Participants in the control group will receive the same workbook as the intervention group at 16 weeks into the study.
9696680|NCT04764344|Experimental|Haloperidol|2.5 mg of IV haloperidol diluted to a final concentration of 5 mL with 0.9% sodium chloride
9696681|NCT04764344|Active Comparator|Ondansetron|4 mg of IV ondansetron diluted to a final concentration of 5 mL with 0.9% sodium chloride
10188113|NCT03719443|Experimental|VIS649|A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.
9696682|NCT04764435||Patients receiving dialysis at a physician-owned dialysis facility|All adults with Medicare fee-for-service in 2017 who received dialysis at a physician-owned dialysis facility. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
10188114|NCT03719443|Placebo Comparator|Placebo|Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
10188115|NCT03719404|Experimental|sodium hypochlorite group|sodium hypochlorite and EDTA are used in endodontic retreatment cases
10188116|NCT03719404|Experimental|chlorhexidine group|chlorhexidine and citric acid are used in endodontic retreatment cases
10188117|NCT03719391|Experimental|JUUL 5% Virginia Tobacco ENDS|Treatment with JUUL Virginia Tobacco flavored 5.0% ENDS product.
9696683|NCT04764435||Patients receiving dialysis at a dialysis facility not owned by a physician|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility not owned by a physician. If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
9696684|NCT04764435||Patients receiving dialysis at a facility owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
9696685|NCT04764435||Patients receiving dialysis at a facility NOT owned by a large dialysis organization|All adults with Medicare fee-for-service in 2017 who received dialysis at a dialysis facility NOT owned by a large dialysis organization (Davita or Fresenius). If a patient received dialysis at more than one facility in 2017, patients will be assigned to the facility that provided the plurality of dialysis in 2017.
9696686|NCT04764526|Experimental|Protein-enriched ice cream|Two protein-enriched ice cream daily (afternoon and evening) in two days in addition to the normal menu
9696687|NCT04764526|No Intervention|Control|Standard menu in two days
9696688|NCT04764539|Active Comparator|Stimuli administered via 2D format on an iPad Pro|50% of participants were given the video modeling stimuli in a 2D format (iPad Pro).
9696689|NCT04764539|Active Comparator|Stimuli administered in 3D format via VR goggles and bone conduction headphones|50% of participants were given the video modeling stimuli in 3D format via VR goggles with integrated bone conduction headphones.
9696690|NCT04764383|Experimental|PK/PD Group|Participants in the Pharmacokinetic (PK)/pharmacodynamic (PD) Group will receive L-Histidine and Lodosyn daily for 7 consecutive days.
9696691|NCT04764383|Placebo Comparator|L-Histidine and Lodosyn followed by Placebo Group|Participants in this group will receive L-Histidine and Lodosyn daily for 2 consecutive weeks followed by Placebo for an additional 2 consecutive weeks with a 1-week wash-out period in between.
10188118|NCT03719391|Experimental|JUUL 5% Cool Mint ENDS|Treatment with JUUL Cool Mint flavored 5.0% ENDS product.
10188119|NCT03719391|Experimental|JUUL 5% Mango ENDS|Treatment with JUUL Mango flavored 5.0% ENDS product.
10188120|NCT03719391|Experimental|JUUL 5% Creme Brulee ENDS|Treatment with JUUL Creme Brulee flavored 5.0% ENDS product.
10188121|NCT03719391|Active Comparator|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine product.
10188122|NCT03719391|Active Comparator|Nicotine Gum|Treatment with nicorette white ice mint 4mg nicotine polacrilex gum product.
10188123|NCT03719391|Active Comparator|Usual Brand Combustible Cigarette|Treatment with usual brand combustible cigarette.
9696692|NCT04764383|Experimental|Placebo followed by L-Histidine and Lodosyn Group|Participants in this group will receive Placebo daily for 2 consecutive weeks followed by L-Histidine and Lodosyn for an additional 2 consecutive weeks with a 1 week wash out period in between.
10188124|NCT03719365|Experimental|NAVAPSV|Each patient enrolled in the study will be submitted to 3 ventilation trials during PSV and NAVA ventilation modes, assigned in a randomized order.
9696693|NCT04764487|Other|Standard follow-up|Patients will have no intervention. It is the comparator group. Patients will have the usual follow-up for clinical, biological and imaging exams.
10188125|NCT03719352|Experimental|Deep dry needling|Deep dry needling will be applied in the upper trapezius myofascial trigger point
9696694|NCT04764487|Experimental|KidneyPRO web-application follow up|"Patients will have to connect to the KidneyPRO web-application weekly to complete a questionnaire about their symptoms in addition to usual follow-up.~Appropriate care will be offered if necessary (depending on the symptoms assessment)"
9696695|NCT04764201|Other|Sequence 1|Period 1: HGP2001, Period 2: HIP2001
9696696|NCT04764201|Other|Sequence 2|Period 1: HIP2001, Period 2: HGP2001
9696697|NCT04764123||AVNRT Cohort|"Patients admitted for electrophysiological study and ablation due to AVNRT tachycardia.~During the study and before the ablation high density electroanatomical mapping will be performed."
9696698|NCT04764084|Experimental|Treatment group|Niraparib-Anlotinib combination therapy
9696699|NCT04763967||PedSCath|Subjects in this arm will be catheterized with the PedSCath Pediatric Urinary Cather.
9696700|NCT04763967||Retrospective Control|Generated from 2016 and 2018 anonymized subject data from the clinical sites.
9696701|NCT04764110|Experimental|Cyplexinol|900 mg daily (2 capsules) for 15 days
9696702|NCT04764110|Placebo Comparator|Placebo|2 capsules daily for 15 days
9696703|NCT04764175|Experimental|Telephone All Nations Breath of Life|This is a culturally targeted smoking cessation program developed for American Indian communities. It includes individual telephone counseling, text messaging, and educational materials.
9696704|NCT04764175|Active Comparator|Comparison Program|This is a non-culturally targeted smoking cessation program. It includes individual counseling, text messaging, and educational materials.
9696705|NCT04764071|Active Comparator|percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F. Pneumatic lithotripter is used for fragmentation and stone removal is accomplished with retrieval graspers through a rigid 22F nephroscope. An 18-24 F nephrostomy tube is placed at the end of the operation.
9696706|NCT04764071|Experimental|ultra-mini percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6 F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath. Then, a 9.5-F, rigid ureteroscope (KARL STORZ Medical Instruments) was introduced to the sheath. The renal stones were broken into pieces using holmium laser lithotripsy. Finally, the ureteroscope and sheath were removed and the tract site was packed for 2-3 min. then placement of double J stent will be done according to the decision of the operating surgeon for 3 to 4 weeks.
9696707|NCT04764149||PFll Group|Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/ m2) on day 1 and day 28, every 60 days. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
9696708|NCT04764149||Non-PFLL Group|Patients were treated with other platinum-based chemotherapy every 21 days including: PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1. TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
9696709|NCT04763954|Experimental|Game|Group that receives the game intervention (the trial version and the access to level 2 and level 7
9696710|NCT04763954|No Intervention|Control|Group without intervention
9696711|NCT04763954|Experimental|Guidance|Group that receives the game (the same levels as group 1) and email coaching one day after completing the game.
9696712|NCT04764214|Experimental|3rd generation EGFR-TKI+ SBRT|
10188126|NCT03719352|Experimental|Superficial dry needling|Superficial dry needling will be applied in the upper trapezius myofascial trigger point
10188127|NCT03719352|Placebo Comparator|Placebo Gastrocnemius dry needling|A technique simulating dry needling will be applied in the gastrocnemius myofascial trigger point with a needle guard guide tube, without any therapeutic manoeuvre will be applied.
9696713|NCT04764266|Experimental|Normothermic Machine Perfusion|Blood sampling at 5 time points after transplantation Perfusate collection at 3 time points during normothermic machine perfusion prior to transplantation
9696714|NCT04764045|Active Comparator|Ropivacaine injection in trigger points|Ropivacaine injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
9696715|NCT04764045|Placebo Comparator|Placebo injection in trigger points|Saline injection 1 ml in all trigger points in and around scar after operation in knee, shoulder and foot, one time, duration 3 minutes
10188128|NCT03719313|Experimental|Group 1|Lonafarnib 50 mg BID + Ritonavir 100 mg BID
9984333|NCT04211753|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
9696716|NCT04763785||Patients with keratoconus corneas|Corneal tomography on patients with keratoconus diagnosis
9696717|NCT04763785||participants with healthy corneas|Corneal tomography on healthy participants
10188129|NCT03719313|Experimental|Group 2|Lonafarnib 50 mg BID + Ritonavir 100 mg BID + PEG IFN alfa-2a 180 mcg QW
10188130|NCT03719313|Active Comparator|Group 3|placebo Lonafarnib + placebo Ritonavir + PEG IFN-alfa-2a 180 mcg QW
9696718|NCT04763785||retrospective part|fully anonymised Picture data of existing 4500 patients
9696719|NCT04763876|Active Comparator|15 mg ketorolac intramuscular|Patients who received a single 15 mg dose of ketorolac administered intramuscularly
10188131|NCT03719313|Placebo Comparator|Group 4|placebo Lonafarnib + placebo Ritonavir
9696720|NCT04763876|Active Comparator|60 mg ketorolac intramuscular|Patients who received a single 60 mg dose of ketorolac administered intramuscularly
10188132|NCT03719287||Hospital #1|Patients who meet inclusion criteria in the first of three participating Brazil hospitals
10188133|NCT03719287||Hospital #2|Patients who meet inclusion criteria in the second of three participating Brazil hospitals
10188134|NCT03719287||Hospital #3|Patients who meet inclusion criteria in the third of the three participating Brazil hospitals
10188135|NCT03719274|Experimental|non-surgical vitamin c depigmentation|locally injected vitamin c is used to depigment the hyperpigmented gingival tissues
9696721|NCT04764058|Other|Montherapy|Thirty patients will receive IV Imipenem in doses of 15 to 25 mg/kg every 6 hours
9696722|NCT04764058|Other|Combination|Thirty patients will receive IV Colistin in dosages of 50,000-75,000 IU/kg/day in three divided doses, infused IV in 10mL normal saline over 30 minutes with IV Imipenem in doses of 15 to 25 mg/kg every 6 hours¬.21,22,24 Colistin formulation consists of 2 million IU per vial.
9696723|NCT04763824|Active Comparator|cluster-randomized controlled trial, with delayed start control arm|Control arm/Delayed Onset
9696724|NCT04763824|Experimental|cluster-randomized controlled trial, intervention|Intervention arm
9696725|NCT04763889|Experimental|CBT workshop|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. In the intervention group participants will attend a day workshop or two half day workshops focused on using CBT to manage their anxiety and stress.
9696726|NCT04763889|No Intervention|Self-help control treatment as usual group|Participants will be randomly allocated to either a self-help control group or a CBT workshop group. Participants in the treatment as usual group will receive the workshop materials after the active treatment group have completed their final follow-up at 3 months
9696727|NCT04763863||Ostomates|Ostomates with leakage issues and stoma created at least 3 months ago
9696728|NCT04763850|Experimental|Walking decline|Walking decline on an instrumented treadmill under 3 different conditions
9696729|NCT04763798|Experimental|Dominant|All subjects will receive the three stretching techniques on dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will be one week. Stretching exercises will be perform in a random order. A random-number generator will be used for randomization
9696730|NCT04763798|Active Comparator|Non dominant|All subjects will receive the three stretching techniques on non dominant leg. Interventions will be performed in three different days and only one of the three stretching exercises will be performed in each session. The rest period between sessions will bé one week. Stretching exercises will be perform in a random order. A random-number generator will bé used for randomization
9696731|NCT04763811||Older 65 people|Older 65 people who live alone in their house will be included. They will have focus groups and Individual interviews.
9696732|NCT04763707||Group 1 : Hepatocellular carcinoma HCC patients with HCV|40 HCV-related liver cirrhosis patients with HCC on top (Group 1).
9696733|NCT04763707||Group 2 : Cirrhotic patients with HCV|30 HCV-related liver cirrhosis patients(Group 2).
9696734|NCT04763707||Group 3 : Healthy control|20 healthy volunteers will be included as controls(Group 3).
9696735|NCT04763694|Experimental|Treatment arm|Subjects wore multifocal soft contact lenses for 12 months.
9696736|NCT04763590|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) had 3 principal components: (1) psychoeducation, (2) cognitive restructuring, and (3) exposure. In this treatment, derived from an empirically-supported treatment for panic disorder, psychoeducation consisted of teaching about the interrelationship between thoughts, feelings, and physical sensations during weaning. The cognitive component taught patients how to challenge their thoughts, with a particular focus on identifying thoughts that over-estimated the probability of negative medical events. The behavioral component consisted of reducing the need for mechanical ventilation in a step-wise, graduated, manner.
9696737|NCT04763642|Active Comparator|Laparoscopic Pancreaticoduodenectomy (LPD)|
9696738|NCT04763642|Active Comparator|Robotic Pancreaticoduodenectomy (RPD)|
9696739|NCT04763642|Placebo Comparator|Open Pancreaticoduodenectomy (OPD)|
9696740|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness in patients with type 2 diabetes|N=21 patients with type 2 diabetes
10188136|NCT03719274|Active Comparator|surgical depigmentation|the conventional scalpel surgical technique is used to depigment the hyperpigmented gingival tissues
10188137|NCT03719261|Active Comparator|sodium hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
10188138|NCT03719261|Experimental|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
10188139|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR alone(n=10)|HTEA Group + N(LVMI)+ AVR alone(n=10)
10188140|NCT03719248|Active Comparator|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)
10188141|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR + CABG(n=10)|HTEA Group + N(LVMI)+ AVR + CABG(n=10)
10188142|NCT03719248|Active Comparator|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)
10188143|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)
10188144|NCT03719248|No Intervention|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)
10188145|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR + CABG(n=10)|(GA) Group+ N(LVMI)+ AVR + CABG(n=10)
10188146|NCT03719248|No Intervention|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)
10188147|NCT03719235|Other|column|ultra-low dose CBCT versus digital panoramic radsiography
10188148|NCT03719209|Placebo Comparator|Standard Practice|Patients and families will be shown images of their endoscopic procedure per standard practice.
10188149|NCT03719209|Experimental|Virtual Reality|Patients and families will be showed the results of their endoscopic procedure via a virtual reality application called HealthVoyager, in addition to standard practice images.
10188150|NCT03719196|Experimental|Reading glass provided|"Randomization took place after conducting the census survey. Participants were selected based on the inclusion criteria.~423 random households were surveyed at the baseline. These households have been given reading glasses free of cost."
10188151|NCT03719196|No Intervention|Non-reading glass|A total of 824 households were surveyed at the baseline survey. Among them, 423 households have been provided reading glasses. The 401 remaining households were not given reading glasses during the baseline survey. The endline survey will be conducted in March 2018. Upon completing the endline survey, the non-reading glasses group will be provided reading glasses.
9696741|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness for healthy individuals|N=27 healthy individuals
9696742|NCT04763629|Experimental|Interval Training (IT)|Patients randomized to this group will perform 45 minutes of exercise on treadmill, alternating intervals of ten minutes at 50-60% of VO2 peak and two intervals five miutes at 85-90% of VO2 peak
10188152|NCT03719157|Active Comparator|Unilateral ESP Block|Before general anaesthesia, Ultrasound guided unilateral ESP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
10188153|NCT03719157|Active Comparator|Unilateral OSTAP block|Under general anaesthesia, Ultrasound guided unilateral OSTAP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
10188154|NCT03719157|Active Comparator|Injection of Local Anesthetic to Trocar Insertion|After the laparoscopic surgery was completed, the trocar incision sites were closed. Following the infiltration rules, local anesthetic (15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine) was applied to the trocar sites of skin, fascia, muscle, and preperitoneal area by the surgical team after the operation. A total of 20 mL of local anesthetic was used, with 6 mL for trocar sites of 10 mm, and 4 mL for trocar sites of 5 mm .Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
9696743|NCT04763629|Experimental|Compbined Training (CT)|Patients randomized to this group will perform 45 minutes of exercise in which they will perform aerobic continuous training on tradmill (20 minutes) and resistance training (25 minutes)
9696744|NCT04763434|Active Comparator|RS group|20 ml mixture of 37.5 mg ropivacaine with 5 mg dexamethasone
9696745|NCT04763434|Active Comparator|RM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine
9696746|NCT04763434|Experimental|RSM group|20 ml mixture of 37.5 mg ropivacaine with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group)
9696750|NCT04763746||Sub-protocol 1|"Blood pressure, oxygen saturation and heart rate measured from participants selected because of their blood pressure.~Within each study session, participants will have their blood pressure, oxygen saturation and heart rate measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
9696751|NCT04763746||Sub-protocol 2|"Respiratory rate and oxygen saturation measured from any participant.~Within each study session, participants will have their respiratory rate and oxygen saturation measured twice using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
9696752|NCT04763746||Sub-protocol 3|"Oxygen saturation measured from participants expected to have low oxygen saturation.~Within each study session, participants will have their oxygen saturation measured twice using standard-of-care equipment. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
9696753|NCT04763746||Sub-protocol 4|"Blood pressure, heart rate, respiratory rate and oxygen saturation measured from adults lacking capacity.~Within each study session, participants will have their blood pressure, heart rate, respiratory rate and oxygen saturation measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
9696754|NCT04763473|Placebo Comparator|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
9696755|NCT04763473|Experimental|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
9696756|NCT04763993|Active Comparator|RYGBP|RYGBP: Roun-en-Y Gastric Bypass
9696757|NCT04763993|Experimental|SG|SG: Sleeve Gastrectomy
9696758|NCT04763187|Active Comparator|Control group|Lower molar extraction and filling of post-extraction alveolus with hemostatic sponge containing gentamicin.
9696759|NCT04763187|Experimental|PRGF group|Post-extraction alveolus is filled with PRGF.
9696760|NCT04763187|Experimental|PRF group|Post-extraction alveolus is filled with PRF.
9984334|NCT04211753|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
9984335|NCT04210661|Active Comparator|classic prediction software|test with classic precition software
9696763|NCT04763369|Experimental|Sub-tenon injection group|In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.
9696764|NCT04763369|Experimental|Suprachoroidal injection group|A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs.
9696765|NCT04763668||Pregnant HIV positive women on ART|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV positive and have been on ARTs for at least four months before pregnancy. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
10188155|NCT03719157|Sham Comparator|multimodal analgesia|Perioperative and postoperative routine analgesic protocol will be performed with no additional regional anesthesia method.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
10188156|NCT03719144||Patients|Patients registered on ResearchMatch.org with Atrial Fibrillation as a medical condition; or who participate in afib-related social media platforms and confirm a diagnosis of afib, will be invited to participate in this study. Patients will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
9696766|NCT04763668||Pregnant HIV negative women|Sub-Saharan women with singleton uncomplicated 11-14 week old pregnancies at recruitment, HIV negative. Participants must not have type 2 diabetes, gestational diabetes, renal / cardiovascular diseases or any critical health condition.
9696767|NCT04763668||Babies born to HIV positive mothers on ARTs|All babies born to pregnant HIV positive women on ARTs who were in the first arm of the study
9696768|NCT04763668||Babies born to HIV negative mothers|All babies born to pregnant HIV negative women who were in the first arm of the study.
9696769|NCT04763213||Invasive treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
9696770|NCT04763213||Medically treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
9696771|NCT04763382|Other|Experimental grups: Training of caregivers|"Application of data collection:~Tools as pre-test, post-test and retention test to participants in the experimental group,~Education:It includes the training given to the caregivers in the experimental group, delivery of the guide booklet at the end of the training~Android phone application: Installing on the phones of the caregivers in the experimental group of the android application, which includes the frequency of CIC application, the CIC application process steps and hospital appointments, created by the nurse for the caregivers in the experimental group and the software is made by the computer engineer.~One home visit and three phone calls were made in order to solve the problems that the caregivers in the experimental group experienced with the use of CIC or android use.~Urinalysis for children who are inserted and put into the study:All participants in the study were asked to give urine tests three times with an interval of one month after discharge."
9696772|NCT04763382|Other|Control: Control grups|"As in the experimental group, the caregivers in the control group were pre-tested and post-tested using data collection tools.~No intervention was made to the caregivers in the control group.~However, caregivers in the control group performed urinalysis three times with an interval of one month after discharge."
9696773|NCT04763395||non-severe COVID19|"Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types.~A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura."
9696774|NCT04763395||Severe Covid19|Severe COVID19 was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR >-30 times/minute; ii) hypoxia: oxygen saturation (resting state) <-93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) <- 300 mmHg (millimeters of Mercury), or iv) the occurrence of respiratory or another organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
9696775|NCT04763304|Active Comparator|PPE-G (gown) followed by PPE-C (coverall)|"Placement of PPE-G (personal protective equipment including a gown for body protection) fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning."
9696776|NCT04763304|Active Comparator|PPE-C (coverall) followed by PPE-G (gown)|"Placement of PPE-C (personal protective equipment including a coverall for body protection), fluorescent solution full-body spray, removal of PPE-C and assessment of self-contamination through ultraviolet light scanning.~Placement of PPE-G (personal protective equipment including a gown for body protection), fluorescent solution full-body spray, removal of PPE-G and assessment of self-contamination through ultraviolet light scanning."
9696777|NCT04763486|Experimental|Prophylactic antibiotic treatment|Will be given Cefamezin antibiotic within 6 hours of delivery
9696778|NCT04763486|No Intervention|No intervention|Will not get antibiotic prophylactics
9696779|NCT04763291|No Intervention|Control group|Continue habitual diet and lifestyle.
9696780|NCT04763291|Experimental|Fruit, Vegetable and Berry (FVB) group|Participants have to ingest an encapsulated juice powder concentrate, otherwise continue their habitual diet and lifestyle.
9696781|NCT04763291|Experimental|Omega group|Participants have to ingest a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
9696782|NCT04763291|Experimental|Fruit, Vegetable, Berry and Omega (FVBO) group|Participants have to ingest an encapsulated juice powder concentrate along with a plant-based fatty acid supplement, otherwise continue their habitual diet and lifestyle.
9696783|NCT04763460|Active Comparator|Baseline CRT programming|The comparator arm patients will remain at baseline CRT programming for the first 6 months, and then will crossover to the experimental arm and CRT device will be programmed to optimal settings derived from the electrocardiographic assessment for the following 6 months.
9696784|NCT04763460|Experimental|Electrocardiography-guided optimal CRT programming|The experimental arm patients will have CRT device programmed based on the electrocardiographic assessment for 12 months.
9778264|NCT01102738||Premature babies (<32 weeks)|All premature babies born at less than 32 completed weeks gestation who are admitted to an Imperial College NHS Healthcare Trust Neonatal Intensive Care Unit (St. Mary's Hospital or Queen Charlotte's & Chelsea Hospital), and whose parents/guardians have given their consent will be eligible to enter the study.
10188157|NCT03719144||Providers|Providers who have contributed at least 25 Atrial Fibrillation patients to the Symphony pharmacy claims dataset will be contacted to participate. Interested providers will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
10188158|NCT03719131|Active Comparator|Arm A (standard of care)|This is standard of care arm: induction with 4 cycles (21 days each) of Ipilimumab and nivolumab followed by continuation with nivolumab alone every month X1 year (13 doses).
9696785|NCT04763616|Experimental|Isatuximab and Cemiplimab combined therapy|"Drug : Isatuximab~1 cycle : 10mg/kg IV every week. It is administered on Day 2, Day 9, Day 16, Day 23.~2~6 cycle : 10mg/kg every 2 weeks . It is administered on Day 2, Day 16.~7th cycle and beyond : 10mg/kg IV every 3 weeks. It is administered on Day 2.~Drug : Cemiplimab~1st - 6th cycle : 250mg IV every 2 weeks. It is administered on Day 1, Day 15.~7th cycle and beyond : 350mg every 3 weeks. It is administered on Day 1."
10188159|NCT03719131|Experimental|Arm B (rituximab, hyaluronidase human)|This includes induction with 4 cycles of ipilimumab and nivolumab X 4 cycles followed by continuation with nivolumab alone every month for 1 year as in standard of care arm. Each induction cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. In addition, patients will receive 4 weekly doses of Rituxan (first dose intravenously and then 3 weekly doses subcutaneously). First dose of Rituxan will be administered one week following the start of cycle 1 of ipilimumab and nivolumab. All treatments will have a +/-3 business day window for administration.
9696786|NCT04763122||Thyroid Cancer Cases|
9696787|NCT04763265|Active Comparator|Group A (n=100): BoNT/A-DP (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures..~A volume of 0.5 mL of the properly reconstituted BoNT/A-DP should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
9696788|NCT04763265|Active Comparator|Group B (n=100): Botox Cosmetic (20 U, 0.5 mL)|"The injection sites should be prepared according to standard clinical procedures.~A volume of 0.5 mL of the properly reconstituted Botox Cosmetic should be drawn into the sterile syringe and any air bubbles in the syringe barrel expelled. The needle used to reconstitute the product should be removed and replaced with a sterile insulin or tuberculin-type syringe of 1 mL volume with 0.01 mL graduation and with the gauge range of 30 to 33 G, which the investigator routinely uses for toxin administration.~Each subject will receive a total of five i.m. injections of 4 U/0.1 mL (total of 20 U)."
9696789|NCT04763083|Experimental|Phase 1 Dose escalation|Up to 9 sequential cohorts including both CLL/SLL and MCL patients
9696790|NCT04763083|Experimental|Phase 2|CLL/SLL and MCL cohorts
9696791|NCT04763070|Other|Ciprofloxacin|
9696792|NCT04763057|Experimental|indirect pulp treatment with NeoPUTTY MTA|
9696793|NCT04763057|Active Comparator|indirect pulp treatment with calcium hydroxide|
9696794|NCT04763096|Experimental|tacrolimus|conversion to Advagraf
9696795|NCT04762914||Prehabilitation (PH)|Patients who underwent prehabilitation prior to colorectal cancer resection
9696796|NCT04762914||Non-Prehabilitation (NPH)|Patients who did not undergo prehabilitation prior to colorectal cancer resection
9696797|NCT04762940|Active Comparator|Control group|They will receive 24 robotics sessions with Amadeo robot three times a week for movement, but without specifically receiving vibration therapy.
9696798|NCT04762940|Experimental|Experimental group|They will recieve three times a week with 24 sessions plus vibration duration of approximately 20 minutes with a high vibration frequency. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible will be conducted prior to robotic treatments with Amadeo.
9696799|NCT04762849|Experimental|laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR)|Laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. A ring with shape memory put on the gastric pouch
9696800|NCT04762849|Active Comparator|laparoscopic one anastomosis gastric bypass (MGB/OAGB) without band: standard surgery|Laparoscopic one anastomosis gastric bypass (MGB/OAGB) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
9696801|NCT04762953|Experimental|SingleArm: Systemic therapy and IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis|Patients will receive sequential intraperitoneal paclitaxel along with intravenous paclitaxel, 5-FU, and leucovorin on Days 1 and 8 of every 21 day cycle for 3 months.
9696802|NCT04762823|Experimental|PD-ctDCS|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
9696803|NCT04762823|Sham Comparator|PD-sham|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
9696804|NCT04762823|Active Comparator|NH-ctDCS|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
9696805|NCT04762823|Sham Comparator|NH-sham|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
9696806|NCT04762992|Experimental|Intervention group, enoxaparin|Enoxaparin subcutaneous injections
10188160|NCT03719118|Experimental|Genotyping group|The patients undergo pretreatment of genotyping for three genes (TPMT, NUDT15 and FTO)
10188161|NCT03719118|Active Comparator|Non-genotyping group|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping.
9696807|NCT04762992|Placebo Comparator|Placebo, normal saline|Normal saline subcutaneous injections
9696808|NCT04762966||Therapeutic|Patients with metformin blood concentration in the therapeutic ranges.
9696809|NCT04762966||Supratherapeutic|Patients with metformin blood concentration above the therapeutic ranges.
9696810|NCT04763031|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy - IORT
9696811|NCT04762693||Cough monitoring|All enrolled participants will be asked to install the acoustic surveillance software in their smartphones and use it to record night-time coughs for a minimum 30-day period.
9696812|NCT04762641|Experimental|ABL503|ABL503 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
9696813|NCT04763005|No Intervention|Healthy controls|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry.
9696814|NCT04763005|Experimental|Hypertensive Patients|A cross-sectional investigation of 24h blood pressure, macro- and microvascular health, physical activity and fitness as well as anthropometry. In addition, randomization to an eight-week high-intensity interval intervention or control condition with physical activity recommendations.
9696815|NCT04762732|Experimental|Experimental: negative pressure wound therapy (PREVENA™ Incision Management System)|Wound of ALT donor site will be cared under PREVENA™ Incision Management System
9696816|NCT04762732|Placebo Comparator|Placebo Comparator: conventional dressing|Wound of ALT donor site will be cared by traditional dressing and care.
9696817|NCT04762667|Experimental|Patients will undergo reverse shoulder arthroplasty with patient-specific instrumentation.|The patients underwent preoperative planning. A 3D model was made based on CT. The optimal position of the components of the endoprosthesis has been calculated. patient-specific instrumentation were created for each scapula and humerus using 3D modeling software. Individual guides use during operation for exact position of the components of the endoprosthesis.
9696818|NCT04762667|Other|Patients will undergo conventional reverse shoulder arthroplasty.|This group of patients was examined according to the standard method, Rg and CT of the shoulder joint were performed. According to the study, the sizes of the endoprosthesis were selected. Installation of the components of the endoprosthesis during the operation was carried out using standard (included in the set) guides. Orientation was performed according to the anatomical landmarks of the glenoid and the neck of the humerus, without taking into account the individual characteristics of the bones.
9696819|NCT04762550||Patients undergoing Liver Transplantation|This is a prospective observational study that intends to offer participation to all patients undergoing liver transplantation at Toronto General Hospital. Parameters that will be measured include Thrombin generation, viscoelastic testing utilizing ROTEM, and conventional laboratory testing (INR, aPTT and Fibrinogen level) at five time points: (a) Prior to cross-clamp application; (b) within the first 30 minutes of venous cross clamp removal; (c) after 30 minutes of reperfusion; (d) On arrival in the intensive care unit (ICU) or post-anesthesia recovery unit; and (5) 12 hours post-operatively.
9778265|NCT01102764|Experimental|Arm 1: PE via telemedicine|PE via telemedicine
9778266|NCT01102764|Active Comparator|Arm 2: PE in person|PE in person
9778267|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
9778268|NCT01102777|Other|Internet-mediated Walking Program|"participants in the intervention arm are asked to participate in a walking program~automated internet-mediated walking program: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress"
9778269|NCT01102803|Placebo Comparator|Sugar Pill|Participants will receive placebo augmented cognitive behavioral therapy
9778270|NCT01102803|Experimental|D-Cycloserine|Participants will receive D-Cycloserine augmented cognitive behavioral therapy
9778271|NCT01102894|Experimental|Low fiber and High Fiber|Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
9778272|NCT01102972|Experimental|ATV + ABC/3TC|Subjects will change to ATV 400mg administered as two 200mg capsules orally, once daily and to the fixed-dose combination tablet of ABC 600mg/3TC 300mg (EPZICOM) administered as one tablet orally, once daily for 48 weeks. The subject's pre-study RTV will be discontinued.
9778273|NCT01102972|Active Comparator|ATV + RTV + TDF/FTC|Subjects will continue their pre-study therapy, un-modified, of ATV 300mg administered as one capsule orally, once daily plus RTV 100mg administered orally, once daily plus fixed dose combination tablet tenofovir 300mg/emtricitabine 200mg administered as one tablet orally, once daily for 48 weeks.
9778274|NCT01103063|Experimental|AZCQ|Azithromycin/chloroquine
9778275|NCT01103063|Active Comparator|SP|sulfadoxine-pyrimethamine (Fansidar)
9778276|NCT01103141|Active Comparator|Micropuncture|
9778277|NCT01103141|Active Comparator|Standard|
9778278|NCT01103232|Experimental|Electrical Muscle Stimulation|Electrical muscle stimulation of the right wrist flexor muscles was applied
9778279|NCT01103232|Sham Comparator|Control|Transcutaneous electrical nerve stimulation was applied
9778280|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 300|"Hydrochlorothiazide (HCTZ) 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg (ALI 150) daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 300mg ((ALI 300) for 1 month"
9778281|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25mg (SPL 25) daily for one month"
9778282|NCT01103245|Active Comparator|HCTZ plus SPL 25 then SPL 50|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg (SPL 25) daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 50 mg daily for one month"
10188162|NCT03719105|Experimental|Cohort 1|"Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.~Chemotherapy Regimen:~mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.~Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.~Allogeneic Stem Cell Transplant if donor available and not in PD."
10188163|NCT03719105|Experimental|Cohort 2|"Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).~Chemotherapy Regimen:~Cycle 1 & 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 & 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 & 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD."
10188164|NCT03719079||Heart Failure Patients|Patients with primary diagnosis as heart failure
10188165|NCT03719066|Active Comparator|DIG 1 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered two weeks after the first dose.
9696820|NCT04762537|Active Comparator|Standard Induction Method|The Standard Method (13-day long) includes 5-days of buprenorphine taper followed by 7-day washout period
9696821|NCT04762537|Experimental|Rapid Induction Method|The Rapid Method includes one day of buprenorphine followed by a day of washout and 3-4 days of oral naltrexone titration with adjunctive medications
9696822|NCT04762615||Patients with renal pathology treated with immunosuppressive drugs|Female in reproductive age suffering from renal disease that is or was previously treated with immunosuppressive drugs
9696823|NCT04762615||Patients with renal pathology without treatment|Control group
9696824|NCT04762615||Patients after renal transplantation taking immunosuppressive drugs|Female in reproductive age after renal transplantation taking immunosuppressive drugs
9696825|NCT04762810|Experimental|Cyclophosphamide and Glucocorticoids|Through the selective depletion of proliferating lymphocytes, cyclophosphamide has an inhibitory effect on both humoral and cellular immunity. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
10188166|NCT03719066|Experimental|DIG 2 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 6 months after the first dose.
9696826|NCT04762810|Active Comparator|Glucocorticoids monotherapy|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
9696827|NCT04762797||Non-neoplastic group|"Gallbladder polyps with pathological diagnosis of cholesterol polyps or inflammatory polyps are classified into Non-neoplastic group."
9696828|NCT04762797||Neoplastic group|"Gallbladder polyps pathologically diagnosed as adenocarcinoma, adenoma, adenomyosis, or other malignancies are classified into Neoplastic group."
10188167|NCT03719066|Experimental|DIG 3 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 11 months after the first dose.
9696829|NCT04762745|Experimental|Phase I, Cohort 1|The combination of bendamustine, 60mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
9696830|NCT04762745|Experimental|Phase I, Cohort 2|The combination of bendamustine, 70mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
9696831|NCT04762745|Experimental|Phase I, Cohort 3|The combination of bendamustine, 80mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
9696832|NCT04762745|Experimental|Phase II|The combination of MTD dosage of bendamustine with pomalidomide and dexamethasone will be administrated in an expanded relapsed or refractory multiple myeloma cohorts for 8 cycles, then under the combination of pomalidomide and dexamethasone as maintenance therapy until progression or intolerable toxicities.
9696833|NCT04762563|Experimental|Experimental: Study Group|Patients in the IASTM group were asked to lie face down on a stretcher, exposing the entire lumbar region. IASTM was applied to all paraspinal muscles for a total of 5 minutes after massage cream was applied. Immediately afterwards, the same application was performed for the right and left hamstring muscles from the gluteal line to the bottom of the popliteal fossa for 3 minutes after massage cream was applied. IASTM application was performed vertically, horizontally and diagonally using instruments of different sizes and shapes at an angle of 45 degrees to the skin surface.
9696834|NCT04762563|Active Comparator|Active Comparator|"KT application (Kinesio Tape® Tex Gold) was performed using the muscle technique. In lumbar region application, while the patient was standing, the tape was cut as a Y-strip with a base of 5 cm."
9696835|NCT04762628|Experimental|MAF capsules|MAF capsules 148 mg TID for 14 days + Standard of care
9696836|NCT04762628|Experimental|M capsules|M capsules 148 mg TID for 14 days + Standard of care
9696837|NCT04762628|Active Comparator|Comparison|Standard of care
10188168|NCT03719053|Experimental|Truvada|single oral dose of Truvada® (300 mg tenofovir disoproxil fumarate)
9984336|NCT04210661|Experimental|prediction software with spell checker|test with prediction software with spell checker
10188169|NCT03719027|Experimental|Study population|Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
9696840|NCT04763018|Active Comparator|Treatment|This arm will receive a function iTEAR
9696841|NCT04763018|Sham Comparator|Sham|This arm will receive sham treatment device
10188170|NCT03719014|Experimental|NovaCross|the NovaCross is a guidewire positioning and support micro-catheter for improving chronic total occlusion (CTO) crossability. The NovaCross gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extandable segment, both at its distal tip.
10188171|NCT03719001|Experimental|Phenylephrine|Phenylephrine (100 ug/ml) infusion will be used to increase blood pressure by 20 mmHg
10188172|NCT03719001|Experimental|Dexmedetomidine|Dexmedetomidine infusion will be used to increase blood pressure by 20 mmHg
10188173|NCT03719001|Experimental|Clevidipine|Clevidipine infusion will be used to increase blood pressure by 20 mmHg
10188174|NCT03719001|Experimental|Calcium Chloride|Calcium Chloride will be administered to increase blood pressure and to increase blood calcium concentration
10188175|NCT03719001|Experimental|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be used to increase peripheral vascular tone
10188176|NCT03719001|Experimental|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm.
10188177|NCT03718988|Experimental|Meat Phase first|Participants will be asked to consume traditional meat products for 8 weeks, then switch to plant-based meat alternative products for another 8 weeks.
9696842|NCT04762342|Experimental|Training Group Multiple Sclerosis|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.~Balance- and functional exercises are included from week 10."
9696843|NCT04762342|No Intervention|Control Group Multiple Sclerosis|Habitual lifestyle including standard care.
9696844|NCT04762342|Experimental|Training Group Healty Control|"24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.~Balance and functional exercises are included from week 10."
9696845|NCT04762342|No Intervention|Control Group Healthy Control|Habitual lifestyle
10188178|NCT03718988|Experimental|Plant Alternative Phase first|Participants will be asked to consume plant-based meat alternative products for 8 weeks, then switch to traditional meat products for another 8 weeks.
10188179|NCT03718975|Experimental|Successor of Phonak Audéo B90|The successor of the Phonak Audéo B90 is a Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
10188180|NCT03718975|Active Comparator|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
9696846|NCT04762524|Experimental|Initiation on CVVH|Patients in this arm were initiated on CVVH, rather than CVVHD
10188181|NCT03718962|Active Comparator|needling|needling + phototherapy
10188182|NCT03718962|Placebo Comparator|phototherapy|phototherapy
10188183|NCT03718884|Experimental|Drug Cocktail|Drug cocktail administered orally once in Period 1
10188184|NCT03718884|Experimental|Mirikizumab + Drug Cocktail|Drug cocktail administered orally once in Period 2 (day 116). Mirikizumab administered subcutaneously (SC) on multiple occasions in Period 2.
10188185|NCT03718845||Peer Counselors|Mind-Body Medicine Curriculum
10188186|NCT03718806|Experimental|Regimen A|3 g zoliflodacin oral suspension; oral administration after an overnight fast
10188187|NCT03718806|Experimental|Regimen B|3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
10188188|NCT03718806|Experimental|Regimen C|4 g zoliflodacin oral suspension; oral administration after an overnight fast
10188189|NCT03718806|Experimental|Regimen D|4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
10188190|NCT03718780|Experimental|A1: Patient in intensive care|"Patient in intensive care (n=10):~in patients in the intensive care unit of the Centre Hospitalier Metropole Savoie (Chambéry, France), where repeated arterial blood gas analysis is routinely performed (Patients equipped for their usual care with an arterial catheter, enabling repeated arterial blood gas determination ).~PaCO2 and Pt CO2 will be measured simultaneously at rest, and during conditions inducing PaCO2 modifications (ventilator settings modifications, or exercise as per routine rehabilitation) Comparison will be done between arterial PaCO2 and PtCO2"
10188191|NCT03718780|Experimental|A2: Healthy subjects|"Healthy subjects performing a voluntary hyperventilation, in the laboratory room where routine exercise testing is usually done.~Comparison will be done between arterialized PaCO2 and PtCO2, at rest, and during an induced voluntary hyperventilation."
10188192|NCT03718780|Experimental|B1: Healthy subject|"Subjects, referred for exercise diagnostic testing, and whose results indicate normal cardiac and pulmonary exercise physiology.~Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points."
10188193|NCT03718780|Experimental|B2: Chronic Obstructive Pulmonary Disease|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
10188194|NCT03718780|Experimental|B3: Interstitial Lung Disease (ILD)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
10188195|NCT03718780|Experimental|B4: Chronic heart failure (CHF)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
10188196|NCT03718780|Experimental|B5: Pulmonary Arterial Hypertension (PAH)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
9696847|NCT04762524|Active Comparator|Initiation on CVVHD|Patients in this arm were initiated on CVVHD, rather than CVVHDH
9696848|NCT04762576||Cardiac Surgical Patients|All consenting adults undergoing cardiac surgery at Toronto General Hospital.
9696849|NCT04762316|Experimental|PP6 Drug|Use PP6 drugs to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
9696850|NCT04762316|Placebo Comparator|PP6 Placebo|Use PP6 placebo to lose the size of Uterine Fibroids on Women the Pregnancy. Measuring the size of uterine fibroid. Monitor the disappearance of uterine fibroids from 4 - 40 weeks
9696851|NCT04762407|Experimental|Sequence 1|Period 1 : Fasted state + HGP1910 + HGP1909, Period 2 : Fasted state + HCP1903
9696852|NCT04762407|Experimental|Sequence 2|Period 1 :Fasted state + HCP1903, Period 2 : Fasted state + HGP1910 + HGP1909
9696853|NCT04762511|Experimental|HSV lower dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV lower dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
9696854|NCT04762511|Placebo Comparator|Placebo Step 1 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
9696855|NCT04762511|Experimental|HSV low dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV low dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
9696856|NCT04762511|Placebo Comparator|Placebo Step 2 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
9696857|NCT04762511|Experimental|HSV medium dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV medium dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
9696858|NCT04762511|Placebo Comparator|Placebo Step 3 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
9696859|NCT04762511|Experimental|HSV high dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV high dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
9696860|NCT04762511|Placebo Comparator|Placebo Step 4 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
9696861|NCT04762498|Experimental|Pegloticase 16mg cohort|16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly
9696862|NCT04762498|Experimental|Pegloticase 24/32mg cohort|24 or 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly
9696863|NCT04762290|Active Comparator|Active Group|This group will receive the intervention in the first 10 weeks of the study. The intervention is a dance intervention that consists of a series of expressive movements.
9696864|NCT04762290|Other|Waitlist Control|This group will receive the intervention in the second 10 weeks of the study (after the active group and after pre-post assessments in the first 10 weeks during the time of no intervention).
9696865|NCT04763044|Other|Period 1|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
9696866|NCT04763044|Other|Period 2|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
9696867|NCT04763044|Other|Period 3|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
9696868|NCT04763044|Other|Period 4|0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
9696869|NCT04763044|Other|Period 5|1100 ppm SnF2 toothpaste only
9696870|NCT04762784|Experimental|Tocilizumab treatment|Tocilizumab is a recombinant humanized monoclonal antibody against human interleukin-6 (IL-6) receptor. Tocilizumab acts by inhibiting the activity of IL-6 receptor. IL-6 is a pro-inflammatory cytokine whose release can trigger a series of downstream pro-inflammatory responses. Tocilizumab inhibits IL-6 signal transduction by blocking the binding of IL-6 to soluble and membrane-bound IL-6 receptors, thereby reducing pathological inflammatory responses.
9696871|NCT04762784|Active Comparator|Glucocorticoids monotherapy|Glucocorticoids has fast onset of action and multiple anti-inflammatory effects.The conventional protocol is oral prednisone, followed by a slow tapering over 4 weeks. Besides, precautionary measures need to be taken against possible complications brought by the application of corticosteroids such as infections, diabetes mellitus, hypertension, Cushing's syndrome and osteoporosis, etc.
10188197|NCT03718780|Experimental|B6: inappropriate hyperventilation syndrome|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
10205356|NCT02536365|Experimental|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
10205357|NCT02536365|Active Comparator|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
9696872|NCT04762420||Sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience.|
9696873|NCT04762420||Dose of Sugammadex determined by quantitative monitoring (QSD).|
9696874|NCT04762901|Experimental|Stage 1 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles, followed by AC IV every 21 days
9696875|NCT04762901|Experimental|Stage 1 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
9696876|NCT04762901|Experimental|Stage 1 Arm 3|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, 15, and 22 every 28 days
9696877|NCT04762901|Experimental|Stage 1 Arm 4|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, and 15 every 21 days and carboplatin IV every 21 days
9696878|NCT04762901|Experimental|Stage 2 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles
9696879|NCT04762901|Experimental|Stage 2 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
9696880|NCT04762303|Experimental|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
9696881|NCT04762303|No Intervention|No MedReviewRx|During the control phase, MedReviewRx will not be accessible to health care professionals at the nursing homes. This serves to obtain baseline deprescribing levels for each nursing home.
9696882|NCT04762355|Experimental|Dose 1|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
9696883|NCT04762355|Experimental|Dose 2|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
9696884|NCT04762355|Experimental|Dose 3|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
9696885|NCT04762485|Experimental|CD38 positive relapsed or refractory acute leukemia|Biological/Vaccine: Humanized CD7 CAR-T cells Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5- 10)x10^6 CD7 CAR-T cells/kg
9696886|NCT04762264|Active Comparator|Short term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 1 to 3 months before to assess tissue incorporation into the 3D scaffold
9696887|NCT04762264|Active Comparator|Mid term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor from 4 to 7 months before to assess tissue incorporation into the 3D scaffold
9696888|NCT04762264|Active Comparator|Long term post inguinal hernia repair with ProFlor|MRI of the pelvic area in patients who underwent inguinal hernia repair with ProFlor after 8 months and beyond to assess tissue incorporation into the 3D scaffold
9696889|NCT04762173|Experimental|Online self-help intervention|Participants are provided access to two online self-help programs provided by SilverCloud Health. One program is designed to support general stress resilience using principles and techniques from positive psychology and cognitive-behavioral therapy. The other program is designed to support coping with pandemic-related stressors using psychoeducation and cognitive-behavioral therapy and grief therapy principles. Participants have access to both programs and can proceed through them in the order and pace of their choosing. The online self-help intervention is fully self-guided.
9696890|NCT04762173|No Intervention|Care as usual|Participants are provided information about how to contact the counseling center at their college and/or in the local community using the phone number and website of their counseling center (if available), as well as the Substance Abuse and Mental Health Services Administration treatment locator.
9696891|NCT04762251|Experimental|Time-restricted eating (TRE)|The TRE group will be instructed to follow TRE (9 h/day) every day for 12 months with no other dietary instructions or advice provided. The TRE group will attend the same consult schedule as the CP group, but consultations will focus on timing of dietary intake and strategies to promote adherence. No dietary guidance regarding quantity or quality will be provided. Participants will be able to self-select the precise 9-h schedule that will best suit their lifestyles, with the caveat that the latest time of eating will be set at 7:00 pm. Outside of the elected eating window, participants will be allowed to consume water and black coffee and/or tea.
9778283|NCT01103245|Active Comparator|HCTZ plus SPL 25 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25 mg daily for one month"
9696892|NCT04762251|Active Comparator|Current Best Practice (CP)|This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. No specific advice will be provided regarding time of day to start and finish eating and/or drinking (since this information is not outlined in current practice guidelines).
10188198|NCT03718741|Experimental|Adiuvant Radiotherapy +/- CT|"The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:~R0: PTVb + PTVn 50 Gy in 25 fractions~R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy~Patients with ECOG PS<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery."
9696893|NCT04762329|Experimental|Patient group using Manage My Pain (MMP) digital application for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits, on the Manage My Pain (MMP) digital application
9696894|NCT04762329|No Intervention|Patient group using paper format for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits on paper format or phone interviews.
9696895|NCT04762056||COVID-19 patients after ICU discharge|Patients who suffered COVID-19 pneumonia and stayed in ICU and discharged
9696896|NCT04761900||participants were followed for the incidence of T2DM in a cohort study|performed a cohort analysis for T2DM. For incident T2DM cases, calculate the follow-up time from the date of enrollment into our study to the date of T2DM diagnosis.
9696897|NCT04761900||participants were followed for the incidence of hypertension in a cohort study|performed a cohort analysis for hypertension. For incident hypertension cases, calculate the follow-up time from the date of enrollment into our study to the date of hypertension diagnosis.
9696898|NCT04761900||participants were followed for the incidence of carotid atherosclerotic plaque in a cohort study|performed a cohort analysis for carotid atherosclerotic plaque. For incident carotid atherosclerotic plaque cases, calculate the follow-up time from the date of enrollment into our study to the date of carotid atherosclerotic plaque diagnosis.
9696899|NCT04762108||Sjögren's syndrome|Sjögren's syndrome with childhood-onset
9696900|NCT04762108||Healthy control|Age matched healthy control
9696901|NCT04761952|Experimental|n-3PUFA treatment group|On the basis of routine treatment, oral supplement of n-3PUFA was given to CD patients since 2-week-postoperative till 1-year-postoperative.
9696902|NCT04761952|Placebo Comparator|Conventional treatment group|Treatment of azathioprine (daily orally) or infliximab (intravenously, at 0, 2,6 weeks with every 8-week-interval later) was given since 2-week-postoperative till 1-year-postoperative.
9696903|NCT04761757|Active Comparator|Control Arm|
9696904|NCT04761757|Active Comparator|Intervention Arm|
9696905|NCT04762030|Experimental|Experimental Group|
9696906|NCT04762004|Experimental|Maternal speech|During the intervention, mothers were asked to speak to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
9696907|NCT04762004|Experimental|Maternal singing|During the intervention, mothers were asked to sing to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
9696908|NCT04762004|Active Comparator|Standard care|During the control condition (without the mother), the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
9696909|NCT04761874|No Intervention|In-Person (Conventional) Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from December 1, 2019-March 15, 2020 that were evaluated, managed, and treated by the stroke care team in person.
9696910|NCT04761874|Experimental|Telestroke Stroke Care|Ischemic stroke patients admitted to a single academic, comprehensive stroke center from March 16, 2020-June 29, 2020 that were evaluated, managed, and treated by the stroke care team remotely via telestroke.
9696911|NCT04762134|Experimental|STI PrEP arm|doxycycline capsules 100mg orally daily for 12 months. Though the usual treatment dose of doxycycline is 100mg twice daily
9696912|NCT04762134|Experimental|STI PEP arm|doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
9696913|NCT04762134|No Intervention|Control/Standard of care arm|routine STI screening and care, which for sexually active gbMSM would not include any chemoprophylaxis for STI, as no clinical guidelines currently recommend its use
9696914|NCT04761705|Experimental|Randomized Part 2, Arm 1|Dose 1 selected in Part I
9696915|NCT04761705|Experimental|Randomized Part 2, Arm 2|Dose 2 selected in Part I
9696916|NCT04761705|Active Comparator|Randomized Part 2, Arm 3|
9696917|NCT04762082|Experimental|Treatment A: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
9696918|NCT04762082|Active Comparator|Treatment B: Reference|Single oral dose of tadalafil oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
9696919|NCT04762082|Experimental|Treatment C: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
10188199|NCT03718715||prospective cohort|All participants receive Metformin in accordance to the ordinary therapy practice. They will be part of one subject group/cohort. After onset of metformin treatment the subjects who develop gastrointestinal side effects will be compared with cases without gastrointestinal side effects.
10188200|NCT03718702|Experimental|Intervention group|ePain will be accessible by the intervention group.
10188201|NCT03718702|No Intervention|Control group|No intervention will be applied to control group and they can download an educational pamphlet only.
9696920|NCT04762082|Experimental|Treatment D: Test|Single oral dose of tadalafil gummy 10 mg, chewed, administered with no water, under fasted conditions
9696921|NCT04762082|Experimental|Treatment E: Test|Single oral dose of tadalafil gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
9696922|NCT04762147|Experimental|Paracetamol group-P|Paracetamol 15mg/Kg was dministered 30 minutes before the start of surgery
9696923|NCT04762147|Active Comparator|Fentanyl group-F|Fentanyl 2mcg/kg was administered at the time induction of anaesthesia
9696924|NCT04761744|Experimental|Nivolumab|
9696925|NCT04761926|Experimental|single arm|Asessments for the hearing with Ponto 4 sound processor on the implanted ear(s).
9696926|NCT04761679|Experimental|Intervention Group|
9696927|NCT04761679|No Intervention|Control Group|
9696928|NCT04761783||Prospective arm|Patients will receive SIGNATERA™ test results and the immunotherapy treatment regimen, dosing schedule, duration of treatment, number of cycles, and modifications during treatment will be at the discretion of the HCP. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
9696929|NCT04761783||Control arm|Control cases must have undergone immunotherapy treatment and have follow-up data available in their medical record at the participating site for two years following initiation of immunotherapy or death.
9696930|NCT04761731|Experimental|ADVAGRAF®|One arm: Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
9696931|NCT04761692|Experimental|Arm 1|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan
9696932|NCT04761692|Experimental|Arm 2|This arm will include 5 churches who will receive some study activities in the Vaccine Education Promotion Management Plan
9696933|NCT04761692|Experimental|Arm 3|This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan following completion of Arm 1 and 2.
9696934|NCT04761575||FFQ validation|All participants to complete all aspects of the study.
10188202|NCT03718689|Experimental|Group L|The second group of teeth (Group L) were etched with Er:YAG laser.
10188203|NCT03718689|Experimental|Group A+L|The third group of teeth (Group A+L) were etched with both Er:YAG laser and phosphoric acid.
10188204|NCT03718689|No Intervention|Group A|The first group of teeth (Group A) were not etched with Er:YAG laser.
10188205|NCT03718676|Other|Ferric sulphate|Group FS. Teeth in this goup will pulpotomized with ferris-sulphate.
10188206|NCT03718676|Experimental|Orto-mta|Group O-MTA.Teeth in this goup will pulpotomized with Ortho-mta.
10188207|NCT03718676|Experimental|Retro-mta|Group R-MTA. Teeth in this goup will pulpotomized with Retro-mta.
10188208|NCT03718663||Knee OA patients (part 1)|Painful knee OA patients signed up for standardized exercise therapy
10188209|NCT03718663||Healthy subjects (part 2)|Healthy subjects (age 18-28) signed up military service in Defence Command Denmark
10188210|NCT03718650|Experimental|Scans, Surgical Resection and Assessment|Pre-surgery scans, surgical resection and post-surgery pathological assessment. All patients will receive standard of care imaging and blood tests. If suitable, non-standard of care abdominal MRI imaging will be done. 16-24 hours prior to surgery, patients will be administered a single dose of 0.5 g/m^2 pimonidazole (HydroxyProbe).
10188211|NCT03718624|Experimental|paclitaxel,apatinib and S-1|
10188212|NCT03718611|Experimental|Sequence 1|BR900A - Wash out - BR9001
9696935|NCT04761380||stable COPD subjects|
9696936|NCT04761380||age-matched control subjects subjects who did not have any pulmonary disease|
9696937|NCT04761601|Experimental|Dose Finding as Monotherapy - Part 1|
9696938|NCT04761601|Experimental|Expansion as Monotherapy - Part 2|
9696939|NCT04761601|Experimental|Dose Finding in Combination - Part 3|
9696940|NCT04761341|Experimental|AMD|
9696941|NCT04761341|Active Comparator|healthy control|
9696942|NCT04761445|Experimental|Straumann Standard Plus (SP)|Patients receiving Straumann SP implants of 4.1 mm in diameter and length of 10 mm.
9696943|NCT04761445|Experimental|JDental care Octa (JD Octa)|Patients receiving JD Octa implants of 4.3 mm in diameter and 10 mm in length.
9696944|NCT04761549|Other|Adolescent Idiopathic Scoliosis|
9696945|NCT04761562|Active Comparator|Control group|Patients will be treated with a standard surgical procedure - tympanoplasty.
9696946|NCT04761562|Experimental|PVRP group|Patients will be treated with a standard surgical procedure - tympanoplasty combined with PVRP. PVRP will be applied to the reconstructed tympanic membrane.
9696947|NCT04761458|Experimental|Patients scheduled for elective surgery aged 65 and +|
9696948|NCT04761666||static verticalization device|children with severe cerebral palsy (GMFCS IV & V) with static verticalization device
9696949|NCT04761666||non verticalization device|children with severe cerebral palsy (GMFCS IV & V) without static verticalization device
9696950|NCT04761289|Active Comparator|Control group. Health education program|The participants in this group will undergo the usual clinical practice: compliance and adherence to the prescribed drug treatment will be explained, as well as the established guidelines for individualized health care. A Health Education Program will also be added at discharge, mainly aimed at reinforcing and promoting an active and healthy life.
9778284|NCT01103271|Experimental|Open-label Placebo Immediate Treatment|Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.
9778285|NCT01103271|Placebo Comparator|Open-label Placebo Waitlist Treatment|Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.
9696951|NCT04761289|Experimental|Experimental Group. Multimodal Exercise and Functional Rehabilitation Program|"Prescription of multimodal physical exercise. A supervised and structured home program will be carried out for one month. It will be carried out daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. Each session will be structured in a warm-up, a main part and a cool-down and relaxation (14).~Reeducation of Activities of Daily Living (ADL). Specific training will be carried out after the evaluation and before the discharge of the patients from the university healthcare complex. It is intended to identify the factors that are interfering with the performance of activities of daily living. The intervention will consist of three parts: Direct intervention on Activities of Daily Living (ADL), carried out in situ in the hospitalization and generalizable to their daily environment; teaching in Energy Saving Techniques (APR).~Prescription of support products and adaptations of the environment."
9696952|NCT04761328|Experimental|Cessation of treatment|
9696953|NCT04761276||Lucidis Intra-ocular lens (IOL)|Adult patients with significant reduction in visual acuity and/or visual comfort from cataract who will receive Lucidis Intra-ocular lens
9696954|NCT04761406|Experimental|Phaeosol group|Daily supplementation of Phaeosol softgel capsule (218mg/d), active ingredients of Microphyt. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
9696955|NCT04761406|Placebo Comparator|Placebo group|Daily supplementation of placebo softgel capsule (218mg/d of 100% sunflower oil) with the same appearance and packaging than experimental product. Each randomized subject will consume 1 softgel capsule (before breakfast) per day during 12 weeks
9696956|NCT04761497|Experimental|active music therapy|Each session consisted of: song of welcome (patients had to greet and introduce themselves), rhythmic exercise (three songs were used; therapist and patients kept rhythm by clapping their hands), dance exercises (three songs were used; patients should make free body movements in response to music), game of recognition of songs and interpreters (four songs were used) and song of goodbye.
9696957|NCT04761497|Experimental|passive music therapy|The therapist and the patients were seat listening to the music recorded in a CD. The therapist told patients which the name and the interpreter of each song of the list.
10188213|NCT03718611|Experimental|Sequence 2|BR9001 - Wash out - BR900A
10188214|NCT03718598||Carpal tunnel syndrome|Patients with mild and moderate carpal tunnel syndrome
10188215|NCT03718598||normal|Patients without mild and moderate carpal tunnel syndrome
10188216|NCT03718585||nocturnal group|Chronic kidney disease patients with nocturnal hypertension
10188217|NCT03718585||non-nocturnal group|Chronic kidney disease patients without nocturnal hypertension
9696958|NCT04761497|Placebo Comparator|control|Patients were watching nature videos for the same duration than the interventions. A therapist was with them facilitating the activity.
9696959|NCT04761536||A|patients undergoing ARR with primary anastomosis between November 2016 and December 2020 after centralization of rectal cancer cases
9696960|NCT04761536||B|patients undergoing ARR with primary anastomosis between January 2006 and October 2016
9696961|NCT04761146|Experimental|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT Diffusing Alpha-emitters Radiation Therapy using the DaRT applicator and seeds, inserted for 14 days prior to removal.
10188218|NCT03718585||non-CKD group|patients without chronic kidney disease
9696962|NCT04761471|Experimental|TI stimulation|Temporal interference (TI) stimulation is a type of low-intensity transcranial electrical stimulation with alternating current (tACS). In case of TI stimulation, 2 electric fields in kHz range are delivered to 4 electrodes, which are placed on the surface of the skull, to modulate neural oscillations.
9696963|NCT04761302|Experimental|Group 1: Intravenous Ketorolac and oral acetaminophen|Group 1 will be composed of patients receiving the following standard pain control protocol: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group. Patients who determine pain to be unbearable and wish to opt out of the non-opioid group will receive may do so.
10188219|NCT03718572||Scoring factors|
10188220|NCT03718572||Difficulty criteria|
10188221|NCT03718559|Experimental|Edoxaban alone|
9696964|NCT04761302|Active Comparator|Group 2: Intravenous Morphine and oral oxycodone|Group 2 will be composed of patients receiving the following pain control protocol: morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
9696965|NCT04761185|Experimental|HIPEC using Raltitrexed|
9696966|NCT04761354||University Medical Center Utrecht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696967|NCT04761354||University Medical Center Groningen|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696968|NCT04761354||Vu University Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696969|NCT04761354||University Medical Center Maastricht|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696970|NCT04761354||Academic Medical Center Amsterdam|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
10188222|NCT03718559|Active Comparator|Combination of edoxaban plus single antiplatelet|
10188223|NCT03718546||Sibling pediatric donors|
10188224|NCT03718546||Sibling recipients and caregivers|
10188225|NCT03718546||Non-donor sibling|From the donor-recipient families
10188226|NCT03718546||Non-donor siblings|Of patients receiving unrelated transplants
10188227|NCT03718546||Healthy comparison|A matched sample
10205358|NCT02536365|No Intervention|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
10205359|NCT02535884|Experimental|Stimulation group|Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
9696971|NCT04761354||Istituto di Semeiotica Chirurgica Roma|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
10188228|NCT03718533|Experimental|Eltrombopag|Patients will receive eltrombopag orally once daily up to 36 weeks.
9696972|NCT04761354||University of California San Francisco|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696973|NCT04761354||Northwestern Memorial Hospital|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
10188229|NCT03718507|Active Comparator|GROUP Fentanyl|patients will receive atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes) before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
10188230|NCT03718507|Experimental|GROUP Sucrose|patients will be given atropine (0.01-0.02 mg/kg i.v. bolus) and oral sucrose 24% (0.5 ml) 2 minutes before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
9696974|NCT04761354||Weill Cornell Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696975|NCT04761354||Columbia University Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696976|NCT04761354||University of Chicago Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696977|NCT04761354||M.D. Anderson Cancer Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696978|NCT04761354||Boston Medical Center|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696979|NCT04761354||University Health Network Toronto|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696980|NCT04761354||Montreal General Hospital - McGill University|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696981|NCT04761354||University of Sydney|Patients who underwent adrenalectomy for primary aldosteronism in case of an aldosterone-producing-adenoma
9696982|NCT04761432|Experimental|Intervention arm|Thirty (30) adult patients will be enrolled in this study. Each patient will be monitored simultaneously with the neoGuard device and a conventional patient monitor. Paired readings for temperature, respiratory rate, pulse rate and oxygen saturation will be captured every second for a maximum observation period of 1 hour.
10188231|NCT03718494|Experimental|Follow up|Subjects will receive F-18 Florbetapir PET
10188232|NCT03718494|Experimental|Follow up - Mayo Clinic Sites only|Subjects will receive F-18 AV-1451 PET and F-18 Florbetapir PET
10188233|NCT03718481||Surgical Trainees|Trainee membership of the Association of Surgeons in Training (ASiT) in the UK and the Republic of Ireland
9696983|NCT04761484|Experimental|Intervention|Insertion of peripheral venous catheter on admission to the NICU
9696984|NCT04761484|No Intervention|Control|Insertion of and umbilical venous catheter on admission
9696985|NCT04761393||Patients with emphysema and eosinophilia in blood and sputum|blood eosinophils ≥300 cells/μL and sputum eosinophils >3%
9696986|NCT04761393||Patients with emphysema and paucicellular inflammation|sputum neutrophils <65% and eosinophils <3%
9696987|NCT04761393||Patients with emphysema and sputum neutrophilia|sputum neutrophils >65% and sputum eosinophils < 3%
9696988|NCT04761367|Other|INTERVENTION GROUP|The IG will participate in a 6-month exercise program based on the PAIR exercise protocol and will receive educational sessions and material on the importance of maintaining an active life style after THR or TKR
9696989|NCT04761367|No Intervention|CONTROL GROUP|The CG will receive only educational sessions and material on the importance of maintaining an active life style after THR or TKR
9696990|NCT04761237|Experimental|Group 1|(H-P) : Pcv-aCO2≥6mmHg between T base and T 0h.;
10188234|NCT03718468|Experimental|GC Flu Quadrivalent|
10188235|NCT03718468|Active Comparator|Fluarix tetra|
10188236|NCT03718442||Breast cancer patients - lumpectomy|Women who are 18 years or older, have Ductal carcinoma in situ (DCIS) or invasive breast-conserving surgery, have not had previous chest radiotherapy. 20 patients who meet above study population criteria will be enrolled in this study.Shaved margins for each lumpectomy site will be excised with either Bovie (3 sides) or PhotonBlade (3 sides) for each patient. The effect of PhotonBlade vs Bovie on pathology assessment of lumpectomy shaved surgical margins will be compared.
10188237|NCT03718429|Experimental|aspirin|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
10188238|NCT03718429|Experimental|aspirin and clopidogrel|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
10188239|NCT03718429|Experimental|aspirin and ticagrelor|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
10188240|NCT03718429|No Intervention|rivaroxaban|A control cohort of subjects with atrial fibrillation on full dose rivaroxaban (20 mg/qd) as per standard of care will be recruited and will undergo a single PD assessment.
9696991|NCT04761237|Experimental|Group 2|(L-P) : Pcv-aco2< 6mmHg at T base and≥6mmHg at T 0h
9696992|NCT04761133|Experimental|Pleural irrigation with antiseptic|Two applications of 100-250 ml solution of 2% povidone-iodine will be irrigated into the pleural space of eligible patients 12 hours apart. The tube will be clamped for 15 minutes after irrigation and the patient will be asked to change position frequently during this period. The first dose will be applied 24-72 hours after tube insertion.
9696993|NCT04761133|No Intervention|No pleural irrigation|Standard care
9696994|NCT04761198|Experimental|Squamous cell carcinoma of the head and neck|Advanced and/or recurrent or metastatic squamous cell carcinoma of the head and neck
9696995|NCT04761198|Experimental|Cervical cancer on or after chemotherapy|Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1
9696996|NCT04761198|Experimental|Gastric or gastroesophageal junction adenocarcinoma|Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
10188241|NCT03718403|Experimental|Single arm open labeled intervention study|Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
10188242|NCT03718390|Experimental|Sentinel Group 1 LYN-PLT|Sentinel dosing in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
9696997|NCT04761198|Experimental|Endometrial carcinoma post-platinum <3L treatment|Advanced and/or metastatic endometrial carcinoma
9696998|NCT04761198|Experimental|Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors|Advanced or metastatic tumor mutational burden-high (TMB-H)
9696999|NCT04761198|Experimental|Rare disease with high prevalence of TIGIT expression|Select rare tumors
9697000|NCT04761198|Experimental|Ovarian cancer|Recurrent high grade serous and endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer following front-line platinum-based therapy
9697001|NCT04761198|Experimental|Endometrial carcinoma post standard of care therapy|Advanced and/or metastatic endometrial carcinoma
9697002|NCT04761224|No Intervention|control group|heated blanket + unheated NaCL instillation (operating room ambient temperature: around 17°C).
9697003|NCT04761224|Experimental|Heated group|heating blanket + instillation of NaCl at 38-39°C by Fluido® Irrigation fluid heating system
9697004|NCT04761107||GU participants with active or past infection of SARS-Co-V-2|GU patients from medical records with active or past infection of SARS-Co-V-2
9697005|NCT04760886||Urban trauma cohort|All paediatric trauma admissions in an urban, MTC treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
9697006|NCT04760886||Rural trauma cohort|All paediatric trauma admissions in a rural district general, treated operatively, isolated from a departmental trauma list between 1st April 2019- 1st April 2021
9697007|NCT04761003|Active Comparator|Group I (Cryobiopsy group):|patients where patients will be subjected to thoracoscopic cryobiopsy.
9697008|NCT04761003|Active Comparator|Group II (Forceps group)|patients where patients will be subjected to thoracoscopic forceps biopsy.
9697009|NCT04761029|Active Comparator|grup R|Unilateral Rhomboid intercostal and subserratus block + intravenous patient-controlled analgesia
9697010|NCT04761029|Placebo Comparator|Group P|intravenous patient-controlled analgesia
9697011|NCT04760821|No Intervention|Usual Care|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2. Usual Care means the clinical protocol approved by the enrolling center.
9697012|NCT04760821|Experimental|Trimetazidine|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2 plus trimetazidine.Usual Care means the clinical protocol approved by the enrolling center.
9697013|NCT04760977||Trauma patients in shock|The study focuses on hypotensive trauma patients assisted by HEMS teams
9697014|NCT04760860|Placebo Comparator|Placebo Control Arm|Participants in this arm will receive placebo during the trial for 15 weeks, the placebo will follow the same schedule as the Terazosin group; the placebo capsules will have the same appearance as the Terazosin capsules.
9697015|NCT04760860|Experimental|Terazosin Arm|Participants in this arm will receive Terazosin during the trial for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
9697016|NCT04760743|Experimental|low dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 30μg/dose), 1 dose each on Day 0 and 28
9697017|NCT04760743|Experimental|high dose level cohort|2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 50μg/dose), 1 dose each on Day 0 and 28
9697018|NCT04760743|Placebo Comparator|Placebo group|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
9697019|NCT04761016|Active Comparator|Control|Control group participants will receive access to the same I-POP Health resources without CHW navigation until the end of 10-months (delayed CHW navigation). The current usual care model is outlined. Participants will complete study measures at baseline, 6-months, and 10-months timepoints. Upon completion of 10-months measures, these individuals will be assigned a CHW and receive delayed navigation.
9697020|NCT04761016|Experimental|I-POP CHW Intervention|I-POP+CHW participants will be paired with a CHW at baseline to assist with navigation for 10-months between health and wellness services in the selected zip codes: 75210, 75215, 75216, 75217, 75223, or 75227. Participants will receive a multi-level intervention utilizing the current I-POP Health model that includes: 1) Access to health services (including oral health), 2) Access to clinical prevention services, 3) Access to education and facilities to increase physical activity and improved nutrition choices, and 4) Scheduled visits with CHWs for education and navigation. Individuals will complete study measures at baseline, 6-months, and 10-months.
9697021|NCT04761042|Experimental|Wilderness program|A one-week (8 days) wilderness program, 3-month online support, and a follow-up visit for four days.
9697022|NCT04761042|Other|Holiday program (Attention control)|A one-week (8 days) holiday program, 3-month online contact, and a follow-up visit for four days.
9697023|NCT04760756|Experimental|This refers to Fragility Fracture Integrated Rehabilitation Management|This refers to Fragility Fracture Integrated Rehabilitation Management and will include comprehensive rehabilitation program and assessment
9697024|NCT04760704||Experimental group|Persons aged 65 and over, residing in an institution for dependant elderly or in a long-term care unit
9697025|NCT04760704||control group|Health and medico-social professionals between 40 and 65 years of age
9778286|NCT01103284|Experimental|DiaPep277|Administration of 1 mg DiaPep277®, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
10188243|NCT03718390|Experimental|Sentinel Group 2 LYN-PLT|Sentinel dosing (second) in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
10188244|NCT03718390|Experimental|Group 3 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind). and evaluation of gastric retention by MRI
9697026|NCT04760587||study group|smart devices in adolescent
10188245|NCT03718390|Experimental|Group 4 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI
9697027|NCT04760600||IBD GROUPS|PATIENT WITH IBD DISEASE
9697028|NCT04760600||IBS GROUP|PATIENT WIT IBS DISEASE
9697029|NCT04760600||CONTROL 1|CONTROL WITH POSITIVE PARASITIC INFECTION AN POSITIVE GIT SYMTOMS
9697030|NCT04760600||CONTROL2|HEALTHY VOLUNTEARS
9697031|NCT04760665|Experimental|Fecal microbiota transplantation|
9697032|NCT04760665|Placebo Comparator|Placebo|
9697033|NCT04760366|Experimental|Group A (Experimental)|Patients in this group will receive interventional therapy through fascial- muscular lengthening therapy .Patients in this group will also receive the conventional therapy
9697034|NCT04760366|Other|Group B: Conventional treatment|Patients in this group will receive the conventional therapy
9697035|NCT04760470|Experimental|Technological-assisted upper extremity rehabilitation|Technological-assisted upper extremity rehabilitation.
9697036|NCT04760470|No Intervention|Wait list control|Continue their normal lives.
9697037|NCT04760535|Experimental|Arm A: Invisalign® First clear aligners|"The Invisalign® First aligners are fabricated in a multilayer aromatic thermoplastic polyurethane/co-polyester 0.75mm (.030)-thick with a fine 3D manufacturing process."
9697038|NCT04760535|Active Comparator|Arm B: tooth-borne Hyrax-type maxillary expander|The Hyrax-type maxillary expander is a tooth-borne expansion appliance that is fixed to the upper second deciduous molars (or to the first permanent molars) using bands and includes a midline 12-mm self-locking screw (Forestadent, Pforzheim, Germany; 0.9 mm, complete turn). The expansion screw is connected to the conventional molar bands or printed clasps, modeled surrounding the molars, via a framework of 0.9mm stainless-steel wire. The framework is soldered to the bands and extending on the palatal side to the deciduous canines. The expander will be fabricated by qualified laboratory technician.
9697039|NCT04760574||Case group|HIV infected men who have sex with men
9697040|NCT04760574||Control group|HIV non-infected men
9697041|NCT04760314|Experimental|Lebrikizumab Regimen A + Topical Corticosteroid|Lebrikizumab Regimen A administered by subcutaneous (SC) injection in combination with topical corticosteroid
9697042|NCT04760314|Experimental|Lebrikizumab Regimen B + Topical Corticosteroid|Lebrikizumab Regimen B administered by SC injection in combination with topical corticosteroid
9697043|NCT04760314|Placebo Comparator|Placebo + Topical Corticosteroid|Placebo administered by SC injection in combination with topical corticosteroid
9697044|NCT04760197||patient under cancer immunotherapy with inflammatory ophthalmological manifestations|patient(>18 years old) under cancer immunotherapy with inflammatory ophthalmological manifestations
9697045|NCT04760405|Experimental|Tai Chi Easy Intervention|Tai Chi Easy: TCE is a standardized protocol used in several prior studies. TCE has been manualized and has a formal training program for instructors. The protocol is taught as a series of repeated and simple-to-learn movements. Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
10188246|NCT03718390|Experimental|Group 5 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI.
9697046|NCT04760379|Active Comparator|Conventional Therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
9697047|NCT04760379|Experimental|Vibration Therapy|Focal muscle vibrator (FMV) (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
9697048|NCT04760327|Experimental|Electrochemotherapy of gynecological cancers|
9697049|NCT04760418|Experimental|4 week baseline|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
9697050|NCT04760418|Experimental|6 week baseline|Participants in this arm are randomized to a 6-week baseline period with repeated weekly assessment after the initial intake. This is followed by 12 sessions of weekly individual manualized Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
9697051|NCT04760457|Active Comparator|IL-FLS|Immediate loading (IL) and Flapless surgery (FLS)
9697052|NCT04760457|Active Comparator|IL-FPS|Immediate loading (IL) and Flapped surgery (FPS)
9697053|NCT04760457|Active Comparator|DL-FLS|Delayed loading (DL) and Flapless surgery (FLS)
9697054|NCT04760457|Active Comparator|DL-FPS|Delayed loading (DL) and Flapped surgery (FPS)
9697055|NCT04760431|Active Comparator|Group A|Trastuzumab, Taxanes and Pertuzumab
9697056|NCT04760431|Experimental|Group B|Trastuzumab, Taxanes and TKIs
9697057|NCT04760301|Experimental|local tranexamic acid injection to cervix|1 gr of Tranexamic acid diluted in 10 ml saline
9697058|NCT04760301|Placebo Comparator|local normal saline injection to cervix|20 ml of saline
9697059|NCT04760301|Experimental|IV 1 g tranexamic acid|1 gr of Tranexamic acid diluted in 100 ml saline- IV
9697060|NCT04760301|Placebo Comparator|IV 1 g normal saline|100 ml saline- IV
9697061|NCT04760652|Active Comparator|CBT Cognitive Behavioral Therapy|Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.
9697062|NCT04760652|Other|TAU Treatment As Usual|Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).
9778287|NCT01103284|Placebo Comparator|Placebo|Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
10205360|NCT02535884|Sham Comparator|Non-stimulation group|Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
9697063|NCT04760210|Active Comparator|Control Group|"Pre-physiotherapy session:~Tens~Infrared/Moist Heat heat for 10 minutes at the low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan with lumbar Sacral Support~Bed rest after the controlled treatment is recommended for this group."
9697064|NCT04760210|Active Comparator|Decompression|"Pre-physiotherapy session:~Tens~Infrared/Moist Heat heat for 10 minutes at the low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Decompression therapy session after the controlled treatment is recommended for this group."
9697065|NCT04760210|Active Comparator|ELDOA|"Pre-physiotherapy session:~Tens~Infrared/Moist Heat heat for 10 minutes at low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Segmental Spinal ELDOA Exercise after the controlled treatment is recommended for this group."
9697066|NCT04759963||Group A|follow up for 6 women who gave birth through a cesarean delivery with Midline approach epidural anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
9697067|NCT04759963||Group B|follow up for 13 women who gave birth through a cesarean delivery with Midline approach spinal anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
9697068|NCT04759963||Group C|follow up for 7 women who gave birth through a cesarean delivery with general anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
9697069|NCT04759963||Group D|follow up for 12 women who are the control group (who did not experience any pregnancy or anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
9697070|NCT04760158|Experimental|Taping group|A new star taping technique and exercises were applied to participants.
9697071|NCT04760158|Sham Comparator|Sham Taping Group|Sham patellar taping and exercises were applied to participants.
9697072|NCT04760158|Other|control group|Only exercises were applied to participants.
9697073|NCT04760145|Experimental|Intervention Group|Multicomponent exercise with blood flow restriction
9697074|NCT04760145|Active Comparator|Control Group|Multicomponent exercise without blood flow restriction
9697075|NCT04760002||Atrial Fibrillation Patients|"Atrial fibrillation patients are to be investigated for sleep apnea by the a home-monitoring device.~Other inclusion criteria are:~>18 years <90 years"
9697076|NCT04759859||Carotid Endarterectomy (CEA)|70 participants undergoing CEA
10188247|NCT03718377|Experimental|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
9697077|NCT04759859||Other Peripheral Vascular Surgery|30 participants undergoing other peripheral vascular surgical procedures
9697078|NCT04759846|Experimental|Group with normal hepatic function|Normal hepatic function
9697079|NCT04759846|Experimental|Group with moderate hepatic impairment|Moderate hepatic impairment (Child-Pugh Class B)
9697080|NCT04759846|Experimental|Group with severe impairment|Severe impairment (Child-Pugh Class C)
9697081|NCT04760067||Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
9697082|NCT04760067||Artificial Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
9697083|NCT04760067||Wood Parquet|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
9697084|NCT04759911|Experimental|Treatment (selpercatinib)|Patients receive selpercatinb PO BID on days 1-28. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
9697085|NCT04760119|Active Comparator|Vein bypass surgery first strategy|
9697086|NCT04760119|Active Comparator|Endovascular treatment first (drug coated balloon angioplasty) strategy|
9697087|NCT04759872|Experimental|Metabolic Study Visit|Participants will complete a study visit for metabolic phenotyping and determination of the impact of hyperinsulinemia on outcomes of interest.
9697088|NCT04760171||Group 1|Patients diagnosed with medullary thyroid cancer (MTC) who are undergoing standard surgical treatment for their disease. This will be either hemithyroidectomy or total thyroidectomy. Patients with laryngeal amyloidosis (LA) who are undergoing standard surgical treatment of this disease. This will be microlaryngoscopy & biopsy/debulking
9697089|NCT04760093|Other|Low-to-High group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 1 will first receive low polyphenol concentration EVOO for consumption, followed by high polyphenol concentration EVOO for consumption following a 14- day washout phase.
9697090|NCT04760093|Other|High-to-Low group|As this is a crossover study, each participant will be assigned to each treatment intervention. Participants (randomly) assigned to Arm 2 will first receive high polyphenol concentration EVOO for consumption, followed by low polyphenol concentration EVOO for consumption following a 14- day washout phase.
9697091|NCT04759976|Experimental|Robotic motor training|Participants will perform motor tasks (i.e. movements) with upper limb robotic devices applying different strategies (e.g. supporting or challenging the subject, or being fully compliant).
9697092|NCT04759885|Experimental|NTC015 low dose|One day single dose preparation same day of colonoscopy
9697093|NCT04759885|Experimental|NTC015 medium dose|One day single dose preparation same day of colonoscopy
9697094|NCT04759885|Experimental|NTC015 high dose|One day single dose preparation same day of colonoscopy
9697095|NCT04759885|Active Comparator|Polyethylene glycol plus ascorbate solution (2L PEG ASC) (Moviprep®)|Two litres of Moviprep® taken according to split-dose regimen (to commence in the evening before colonoscopy)
9697096|NCT04760054|Experimental|HUBOD martial arts practice|Participants will be trained in the Hubod exercise over 5 separate training sessions. Sessions will last approximately 30 minutes, involving a warm up, review of material from the previous session and the learning of the next movement in the HUBOD sequence. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate cardiovascular exercise as in the active comparator.
9697097|NCT04760054|Active Comparator|Active Comparator - Stationary Bicycle|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of mild to moderate intensity cardiovascular training on a stationary bicycle. Heartrate will be monitored periodically to make sure the intensity of exercise is consistent with mild to moderate exercise as in the Experimental group.
9697098|NCT04760054|Placebo Comparator|Attentional Control Group|Participants will be given 5 separate sessions, each approximating 30 minutes in duration, of watching videos on martial arts training methods and techniques. These sessions will be completely sedentary.
9697099|NCT04759820|Experimental|Nano carbon group|Injection of carbon nanoparticle
9697100|NCT04759820|Active Comparator|Indocyanine green group|Injection of indocyanine green
9697101|NCT04760223|Experimental|Video intervention 1|We presented a 100-second video to study participants to reduce stigma towards depression (a boy presenter). The protagonist discussed his own depression and how getting help assist him.
9697102|NCT04760223|Experimental|Video intervention 2|We presented a 100-second video to study participants to reduce stigma towards depression (a girl presenter). The protagonist discussed his own depression and how getting help assist her.
10188248|NCT03718377|Active Comparator|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
10188249|NCT03718351|Active Comparator|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
10188250|NCT03718351|Experimental|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
10188251|NCT03718338||Clinical Evaluations|Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
10188252|NCT03718312|Experimental|Arm 1|Patients with aortic clamping withpre-conditioning
9697103|NCT04760223|Placebo Comparator|control video 1|A 100-second video presenting a boy without depression
9697104|NCT04760223|Placebo Comparator|control video 2|A 100-second video presenting a girl without depression
9697105|NCT04759807|Placebo Comparator|Placebo|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
9697106|NCT04759807|Active Comparator|PUR1800 250 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
10188253|NCT03718312|No Intervention|Arm 2|Patients with aortic clamping without pre-conditioning
9697107|NCT04759807|Active Comparator|PUR1800 500 μg|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to 250 μg and 500 μg nominal dose strengths of RV1162. Subjects will receive 14 doses administered once daily in the morning.
10188254|NCT03718273|Active Comparator|Digoxin|Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance <60ml / min,
10188255|NCT03718273|Experimental|Ivabradine|Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
10188256|NCT03718234|Experimental|Subcutaneous Hydrocortisone via Infusion Pump|Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
10188257|NCT03718234|Active Comparator|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
10188258|NCT03718208|Experimental|Paediatric formula|"Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake."
10188259|NCT03718195|Other|Pediatric formula|"Each child will receive a new formula for a period of seven days. The new formula is a nutritionally complete standard enteral tube feed, with ingredients derived from real food. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube"
10188260|NCT03718182|Active Comparator|Arm A - Cholecalciferol 400iu|Vitamin D3 (Cholecalciferol) 400 iu. Daily oral capsule. To be taken for 24 weeks (6 months)
10205361|NCT02529930|Experimental|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
10188261|NCT03718182|Experimental|Arm B - Cholecalciferol 3200iu/800iu|"Vitamin D3 (Cholecalciferol) supplement 3,200iu daily oral capsule. To be taken for 12 weeks (3 months).~Then switch to vitamin D3 supplement 800iu daily oral capsule. To be taken for 12 weeks (3 months)."
10188262|NCT03718169||Hong Kong female smokers|Hong Kong female smokers will be invited to fill in questionnaires about their current smoking situation and quit intention.
10188263|NCT03718156|Experimental|PREPARED Trial Intervention|Participating nursing staff will be trained to apply the PREPARED Trial interventions, and will apply this knowledge to modify the therapeutic nursing plans of residents under their care who are enrolled in the study, accordingly.
10188264|NCT03718156|No Intervention|Care as Usual|Participating nursing staff will only be provided with general information about delirium, but will not be trained or instructed to modify the therapeutic nursing plans that are in place for residents enrolled in the study. However, at the end of the follow-up period, nursing staff in the control arm will be provided with the PREPARED Trial intervention training program (including bedside coaching), which they can then use after the study has ended at their facility.
10188265|NCT03718130|Experimental|Group 1: 0.6 mg HTNV - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
10188266|NCT03718130|Experimental|Group 2: 3.0 mg HTNV - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
10188267|NCT03718130|Experimental|Group 3: 0.6 mg PUUV - Intradermal (ID)|0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
9697108|NCT04759794|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
9697109|NCT04759989|Active Comparator|30cc/kg ideal body weight (IBW)|"30cc/kg intravenous fluids based on the patients calculated ideal body weight will be administered when randomized to this arm~Using Devine's formula. (men: 50kg + 2.3kg * (height(in) - 60); women: 45.5kg + 2.3kg * (height(in) - 60)"
9697110|NCT04759989|Active Comparator|30cc/kg adjusted body weight (AdjBW)|"30cc/kg intravenous fluids based on the patients calculated adjusted body weight will be administered when randomized to this arm~Calculated by the following formula: AdjBW = IBW + 0.4(ABW - IBW)."
9697111|NCT04759989|Active Comparator|30cc/kg actual body weight (ABW)|"30cc/kg intravenous fluids based on the patients actual body weight will be administered when randomized to this arm~Patients will receive an initial fluid bolus of 30 cc/kg of actual body weight"
9697112|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the wrist during active video games playing|In one session the accelerometer will place on the dominant wrist Individuals will instructed not to remove and instruct them to wear the device during the session.
9697113|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the hip during active video games playing|"In one session the accelerometer will place on a flexible belt by attaching to the hip area at the intersection of the dominant wrist and axillary line.~Individuals will instructed not to remove and instruct them to wear the device during the session."
9697114|NCT04759508|Active Comparator|500 mg BD Flax Oil Capsule with Antihypertensive drug|Flax Oil Capsule 500 mg twice a day will be administered alongside antihypertensive drug in newly diagnosed hypertensive subjects
9697115|NCT04759508|Placebo Comparator|Placebo(Soya Oil) Capsule with Antihypertensive drug|No flax oil capsule,only placebo(soya oil) capsule will be administered alongside equivalent antihypertensive drug in newly diagnosed hypertensive subjects.
9697116|NCT04759703|Experimental|Pramipexole|Medication arm; 0.25 or 0.5 mg of pramipexole
9697117|NCT04759703|Placebo Comparator|Placebo|Placebo arm; 0.25 or 0.5 mg of placebo
9697118|NCT04759599|Active Comparator|Group 1|Group 1 will undergo Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks
9697119|NCT04759599|Active Comparator|Group 2|Group 2 will undergo Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
9697120|NCT04759716|Experimental|intervention arm|intervention arm will receive weight control program
9697121|NCT04759716|No Intervention|control arm|routine care
9697122|NCT04759729|Experimental|PRO+D group|Participants will receive probiotic as well as vitamin D supplementation.
9697123|NCT04759729|Experimental|PL+D group|Participants will receive placebo instead of probiotics and vitamin D supplementation.
9697124|NCT04759469|Experimental|High-intensity interval training (HIIT)|A high-intensity interval training program for 3 days/week (day after day) for 12 weeks on atreadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program intensity.
9697125|NCT04759469|Active Comparator|Moderate intensity interval training (MIIT)|A moderate intensity interval training program for 3 days/week (alternate days) on a treadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program.
9697126|NCT04759482||Patients with sleep apnea|We selected 150 patients recorded by polysomnography between january 2019 and june 2020 in the Center for Sleep Medecine and Research in Nancy.
9697127|NCT04759742|Experimental|group Ropivacaine|The recommended administration concentration of ropivacaine in the subarachnoid space was 0.5% and the dose was 2-3ml (practical clinical anesthesiology). Based on previous clinical experience, the starting dose of ropivacaine was set at 12.5mg (2.5ml) and Dixon's up-and down method was adopted (Dixon WJ, Massey FJ Jr. Introduction to Statistical Analysis. NY: McGraw-Hill;1969. P. 344.) The dose of ropivacaine in the next patient was adjusted to 0.5mg (0.1 mL) according to the results of the previous patient's trial.
9697128|NCT04759391|Experimental|Exercise group|Lifestyle recommendations as well as digital pelvic floor muscle training to the exercise group
9697129|NCT04759391|Active Comparator|Control group|Lifestyle recommendations will be given to the control group
9697130|NCT04759352|Experimental|Telephone post-test genetic counseling|Post-test genetic counseling delivered by telephone
9697131|NCT04759352|No Intervention|In-person post-test genetic counseling|Post-test genetic counseling delivered in-person
10188268|NCT03718130|Experimental|Group 4: 3.0 mg PUUV - Intramuscular (IM)|0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
9697132|NCT04759300|Active Comparator|Group C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS.
9697133|NCT04759300|Placebo Comparator|Group C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
10188269|NCT03718130|Experimental|Group 5: 1.2 mg HTNV/PUUV (0.6 mg each) - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
9697134|NCT04759313|Experimental|Imagenarrative treatment group|INI Sessions: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
9697135|NCT04759313|Experimental|Wait List Control Group|In weeks 6 through 10, the same program will be delivered to the wait list control group.
9697136|NCT04759430|Active Comparator|Supervised Group|24 individuals will participate in the Supervised group. Patients in the supervised group will be treated individually by the researcher at the hospital. During the application, individuals will apply ten different stabilization exercises in company with a physiotherapist. Exercises will be applied under the supervision of a physiotherapist in the center where the work will be done for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks. The exercises program to be applied to the participants in the group is listed below: Supine position; Abdominal bracing, while continuing the abdominal bracing; heel slides, bridging, 90 degrees hip flexion. Quadruped position; Abdominal bracing while continuing the abdominal bracing; single arm lift, single leg lift, cross-arm leg raises activities. Standing position; Abdominal bracing.
9697137|NCT04759430|Experimental|Telerehabilitation Group|24 individuals will participate in the Telerehabilitation group. Patients in the telerehabilitation group will attend the treatment from their homes. The exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone. The same stabilization exercises will be applied to the participants in the supervised group. Exercises will be applied for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks.
9697138|NCT04759430|No Intervention|Control Group|
9697139|NCT04759495|Experimental|rtCGM|Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring).
9697140|NCT04759495|Experimental|FGM|Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).
9697141|NCT04759638||Rectal Cancer|Rectal Cancer
9697142|NCT04759573|Experimental|Early Vocal Contact|"The EVC will take place in the hospital room while infants are in their individual incubators or open cribs. In the intervention group, mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.~Early Vocal Contact will be performed by mothers three times a week for 2 weeks, more than one hour after afternoon feeding. It will begin when the newborns are in an active sleep state, in calm awake state or in active awake state, but not in deep sleep or crying. Preterm infants will be enrolled from 25+0 to 32+6 weeks of GA, following the established inclusion criteria."
10188270|NCT03718130|Experimental|Group 6: 6.0 mg HTNV/PUUV (3.0 mg each) - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
9697143|NCT04759573|Active Comparator|Behavioral observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
9697144|NCT04759378|Experimental|IBS patients who have upper GIT symptoms|
9697145|NCT04759521||Group 1|Inactive HBsAg carriers were patients with HBsAg positivity for more than 6 months
9697146|NCT04759521||Group 2|Patients diagnosed with chronic hepatitis B were patients with HBsAg positivity for more than 6 months
9697147|NCT04759521||Group 3|The control group was composed of healthy individuals who were not infected with hepatitis B virus and did not fit any exclusion criteria.
9697148|NCT04759404|Active Comparator|Deep Oscillation Group|Individuals in the deep oscillation group will be treated by the researcher. During the application, individuals will be positioned face down on the stretcher. After the powder is applied to the lumbar region, deep oscillation treatment with a frequency of 80% -100% with a frequency of 150 Hz for the first 10 minutes and 60 Hz for 5 minutes will be applied with the Physiomed Deep Oscilation device. Each individual will be given a home exercise program (stretching and strengthening for waist, back and abdominal) consisting of stretching and strengthening. Individuals will be asked to come to the center where the research will take place, for a total of six sessions for two weeks, three times a week.
10188271|NCT03718104||Naltrexone|Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
9778288|NCT01103323|Experimental|Regorafenib (Stivarga, BAY73-4506)+BSC|Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
10205362|NCT02529930|Experimental|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
10188272|NCT03718104||Buprenorphine/Naloxone|Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
9697149|NCT04759404|Active Comparator|Myofascial Release Group|Individuals in the myofascial relaxation group will be treated by the researcher. During the application, individuals will lie face down on the stretcher. Myofascial release therapy will be applied in the lumbar region and each individual will be given home exercise (stretching and strengthening for waist, back and abdominal). Individuals will be asked to come to the center where the research will be conducted for a total of six sessions for two weeks, three times a week.
9697150|NCT04759404|No Intervention|Control Group|
9697151|NCT04759287|Active Comparator|VS group|include patients undergoing awake intubation using the C-MAC VS
9697152|NCT04759287|Placebo Comparator|FOB group|will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
9697153|NCT04759365|Experimental|ASN51|ASN51 will be administered as an oral capsule
9697154|NCT04759365|Placebo Comparator|Placebo|Placebo will be administered as an oral capsule
10188273|NCT03718104||Naltrexone - alcohol use disorder|Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
9697156|NCT04759261|Other|Study group|
9697157|NCT04759235||neoadjuvant chemoradiotherapy of local advanced ESCC|All the patients receive paclitaxel/cisplatin chemotherapy and concurrent radiotherapy. Each patient receives radiation of 41.4 Gy / 23 fractions complied by intensity modulated radiotherapy or volumetric modulated arc therapy. Patients without disease progression after nCRT will be scheduled for surgery and patients with disease progression (PD) will continue to receive chemoradiation or additional treatments. Surgery will be performed 6 to 8 weeks after completion of chemoradiotherapy.
9697158|NCT04760522|Experimental|WGS Diagnostic|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease.~Study related procedures: Blood sampling, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics)."
9697159|NCT04759534|Experimental|Treatment group 1|Received abdominal subcutaneous injection of IBI306 150 mg Q2W
9697160|NCT04759534|Experimental|Treatment group 2|Received abdominal subcutaneous injection of IBI306 150 mg Q4W
9697161|NCT04759534|Placebo Comparator|Placebo Group 1|Received a subcutaneous injection of placebo Q2W in the abdomen
9697162|NCT04759534|Placebo Comparator|Placebo Group 2|Received a subcutaneous injection of placebo Q4W in the abdomen
9697163|NCT04759547|Experimental|Handheld ultrasound-assisted technique|Participants will be received labor combined epidural-spinal analgesia using handheld ultrasound
9697164|NCT04759547|Active Comparator|Conventional palpation-guided technique|Participants will be received labor combined epidural-spinal analgesia using conventional landmark-guided technique
9697165|NCT04760080||Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine.|"Patients with a metastatic melanoma treated by dabrafenib/trametinib and hydroxychloroquine after acquired resistance to dabrafenib/trametinib.~Patients treated~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~From January 2008 to June 2020~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~who became resistant to dabrafeib/trametinib~and received after disease progression a treatment by dabrafenib/trametinib and hydroxychloroquine"
9697166|NCT04760080||Patients with a metastatic melanoma treated by cytotoxic chemotherapy.|"Patients with a metastatic melanoma treated by cytotoxic chemotherapy after acquired resistance to dabrafenib/trametinib.~Patients treated~for a BRAF mutated metastatic melanoma in Pr Dalle's dermatology ward at Centre Hospitalier Lyon Sud,~From January 2008 to June 2020~who received a treatment by immunotherapy before receiving a treatment by dabrafenib/trametinib~who became resistant to dabrafeib/trametinib~and received after disease progression under dabrafenib/trametinib a treatment by cytotoxic chemotherapy"
9697167|NCT04760262||Group Propofol|anesthesia was maintained with TIVA (intravenous 125-250 µg/kg/min propofol + 0.1-0.25 µg/kg/min remifentanil infusion)
9697168|NCT04760262||Group Sevoflurane|anesthesia was maintained with inhalation (sevoflurane concentration of 1-2% in 50-50% O2-air mixture).
9697169|NCT04759105|Experimental|Autologous BM-MSC injection|"Two interventions:~Bone marrow harvesting from the posterior superior iliac crest region~Single injections of a dose of 15 million of autologous BM-MSC each disc affected by IDD (up to 4 discs) via imaging control"
9697170|NCT04759105|Sham Comparator|Sham Procedure|"Two sham procedures:~Simulated bone marrow harvesting without insertion into the posterior iliac crest region~Simulated injection under only local anaesthesia without disc injection, without placebo injection."
9778289|NCT01103323|Placebo Comparator|Placebo+BSC|Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).
9778290|NCT01103362|Experimental|flibanserin 100mg|flibanserin 100mg po qd
9778291|NCT01103414|Experimental|Mitoglitazone 50 mg capsules|Mitoglitazone 50 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
10188274|NCT03718078|Experimental|Confocal Laser Endomicroscopy|lt includes patients will undergo probe-based Confocal Laser Endomicroscopy during laparoscopic hepatic masses resection.
10188275|NCT03718039|Experimental|Treatment Group 1|HTX-011
10188276|NCT03718039|Experimental|Treatment Group 2|aprepitant
9984337|NCT04209855|Experimental|mirvetuximab soravtansine (MIRV; IMGN853)|MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)
10188277|NCT03718039|Experimental|Treatment Group 3|HTX-011 and a scheduled multimodal analgesic regimen (oral ibuprofen and acetaminophen).
10188278|NCT03718026||Patients with Multiple Sclerosis|"The timed 360° turn test~Berg Balance Scale~Timed Up and Go test~Functional Reach Test~One-leg stance test~Four square step test"
10188279|NCT03718026||Healthy Controls|-The timed 360° turn test
9697171|NCT04759118|No Intervention|Control group|The participant in his group is a pregnant woman. The facilitators of the control groups were midwives who are already providing prenatal education classes at the clinics. The classes followed the government curriculum, which consists of three classes per month and does not invite husbands to participate. However, in this study, participants in the control group have four classes over a one-month period to better match the program of the intervention group. The material for the standard curriculum includes anatomical and physiological changes during pregnancy, pregnancy care, birth, and postpartum care. The classes also address family planning after giving birth, newborn care, preventing infectious disease, and procedures for obtaining a birth certificate. The midwives also discuss and debunk unhealthy local myths, beliefs, and cultural practices surrounding pregnancy, childbirth and the postpartum period
9697172|NCT04759118|Experimental|Experimental group|The modified childbirth education program was applied in the experimental group. the intervention covered modification of content material, learning methods, and involving husband or other relatives during the class.
10188280|NCT03718013|Experimental|accelerated dTMS|
9697173|NCT04759040|Active Comparator|MigraineGuard|Active supplement treatment , MigraineGuard capsule containing Coq10 , Magnesium ,Vit B2 , Skullcap Extract , Feverfew Extract , Piperine
9697174|NCT04759040|Placebo Comparator|Placebo for MigraineGuard|Placebo capsules non identifiable from Migraineguard capsules were used as control comparator
9697175|NCT04758936|Experimental|Clonidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (clonidine) will be administered as soon as possible, The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
9697176|NCT04758936|Experimental|Dexmedetomidine|Given that agitated delirium requires rapid medical intervention, α-2 agonist therapy (dexmedetomidine) will be administered as soon as possible. The α-2 agonist treatment that will be started will depend on the allocation of the previously randomized unit. The sedative and analgesic treatments will be administered and titrated according to the scales on the usual protocol of the service (evaluation of sedation (NICS) and analgesia (VAS, BPS, BPS-NI). In case of excessive sedation assessed by the scores and administration of combined treatments (α-2 agonist and other sedatives), the reduction of the doses of other sedatives will be preferred over the α-2 agonist treatment. In case of insufficient sedation despite maximal doses of α-2 agonist, other sedatives (choosen by the attending physician) will administered and titrated according to the scales for pain and sedation evaluation.
9697177|NCT04758871|Experimental|Dydrogesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using dydrogesterone 10 mg 3 times daily
9697178|NCT04758871|Active Comparator|Micronized progesterone|Luteal phase support for hormone replacement therapy frozen embryo transfer cycles using micronized progesterone 2x200 mg twice daily vaginally
9697179|NCT04758858|Active Comparator|VLCHF (Very Low CHO High Fat) Diet|10% of energy from CHO, 15% proteins, and 75% lipids
10188281|NCT03718013|Active Comparator|standard dTMS|
10188282|NCT03717987|Active Comparator|Botulinum toxin A injection|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
10188283|NCT03717987|Active Comparator|Zinc supplementationj prior to Botulinum toxin A injection|"Patients in the intervention group will take zinc supplement tablets to increase zinc levels for 4 days before botulinum toxin injections. While patients in the control group will take placebo tablets 4 days prior to the injections. All tablets will be placed in envelopes for blinding the operator, and numbered by a supervisor to allocate patients again in their groups for statistical results. Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
10188284|NCT03717948|Experimental|CTL - BFR|CTL Exercise then BFR Exercise
9697180|NCT04758858|Active Comparator|Low-CHO Diet|30% of energy from CHO, 15% proteins and 55% lipids
9697181|NCT04758858|Placebo Comparator|Control Diet|50% of energy from CHO, 15% proteins and 35% lipids
9697182|NCT04759092|Experimental|Treatment with tDCS|Home based treatment with tDCS for four months
9697183|NCT04759053|Active Comparator|FNB|
9697184|NCT04759053|Active Comparator|Core biopsy|
10188285|NCT03717948|Experimental|BFR - CTL|BFR Exercise then CTL Exercise
9697185|NCT04758754|Experimental|Single leg knee extension training (SLKE)|Active 8-week training involving lower limbs. SLKE participants will be involved in a 8-week aerobic training protocol involving the knee extensor muscles. The training will be held on an Anderson and Saltin ergometer, 3 times per week, with a single session duration of 33.3 min. Total weekly duration: 100 min.
9697186|NCT04758754|Active Comparator|Passive static stretching training (PST)|Passive 8-week training involving lower limbs. PST participants will be involved in a 8-week passive static training training involving the knee extensor muscles. The training will have a frequency of 5 times per week, with a single duration of 20 min. Total weekly duration: 100 min
9697187|NCT04758754|No Intervention|Control (CTRL)|CTRL will not receive any intervention.
9697188|NCT04759079|Experimental|Acupuncture Needles and Antiemetic Drug|
9697189|NCT04759079|Active Comparator|Antiemetic Drug|
9697190|NCT04758897|Experimental|Single Arm|"5.0*10^7 on D1~1.0*10^8 on D1~2.0*10^8 on D1~2.0*10^8 on D1 and D2~2.0*10^8 on Days 1 to 3~2.0*10^8 on Days 1 to 4~2.0*10^8 on Days 1 to 5"
10188286|NCT03717922|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MR data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
10188287|NCT03717922|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
10188288|NCT03717909|Experimental|Experimental Group|Sodium Valproate 200Mg E/C Tablet (active treatment)
9697191|NCT04758884|Experimental|Telemedicine group|"Visits by videoconference in months 0, 1, 2, 3, 4 and 6. Additionally, availability to send intermediate messages with a response from the endocrine in less than 72 hours.~The videoconference will be held safely through the SocialDiabetes® App. Patients will be provided with a glucometer that transfers the data directly to the App without the patient having to enter it to avoid bias in time and value. Videoconferences will NOT be recorded.~Patients with CGM will additionally have all their values on the platform that corresponds to their sensor (Libreview® for the Freesyle libre® sensor and Clarity® for the Dexcom G5 sensor)."
9697192|NCT04758884|No Intervention|Conventional management group|Initial visit, 3 and 6 months.
9697193|NCT04758793|Other|patients without liver disease,|taking blood samples and biopsy of muscular wall
10188289|NCT03717909|Placebo Comparator|Control Group|Sodium Valproate matched placebo (inactive treatment)
9697194|NCT04758793|Other|patient with chronic liver disease without cirrhosis,|taking blood samples and biopsy of muscular wall
9697195|NCT04758793|Other|patients with compensated cirrhosis,|taking blood samples and biopsy of muscular wall
10188290|NCT03717883||Healthy subjects|
9697196|NCT04758793|Other|patient with severe cirrhosis|taking blood samples and biopsy of muscular wall
9697197|NCT04758806|Experimental|Fecal microbial transplantation from unrelated donor|Fecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days
10188291|NCT03717883||Subjects with ADPKD|
10188292|NCT03717870|Experimental|Surgery|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
10188293|NCT03717870|Active Comparator|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
9697198|NCT04759196|Active Comparator|NESIS - Levetiracetam|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator."
9697199|NCT04759196|Experimental|NESIS - Topiramate|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression."
9697200|NCT04759196|Active Comparator|Non NESIS - Levetiracetam|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator.~Levetiracetam should be as efficient as Topiramate in a group a participant with epileptic discharges."
9697201|NCT04759196|Experimental|Non-NESIS - Topiramate|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression.~Topiramate should be as efficient as Levetiracetam in a group a participant with epileptic discharges."
9697202|NCT04758845|Experimental|Cocktail|Subjects will consume 1 capsule containing 2B CFU containing .5B CFU Bacillus subtilis DE111, .5B CFU Bacillus coagulans CGI314, .5B CFU Bacillus megaterium MIT411, and .5B CFU Bacillus clausii CSI08 for 45 days.
9697203|NCT04758845|Experimental|CGI314|Subjects will consume 1 capsule containing 1B CFU of Bacillus coagulans CGI314 for 45 days.
9697204|NCT04758845|Experimental|CSI08|Subjects will consume 1 capsule containing 1B CFU of Bacillus clausiiCSI08 for 45 days.
9697205|NCT04758845|Experimental|MIT411|Subjects will consume 1 capsule containing 1B CFU of Bacillus megaterium MIT411 for 45 days.
9697206|NCT04758845|No Intervention|Placebo|Subjects will consume 1 capsule containing maltodextrin for 45 days.
9697207|NCT04759183|Experimental|Arm I (Angry Birds, TRIPP)|Patients participate in a VR intervention (Angry Birds) over 15 minutes before standard of care surgery and then participate in a VR intervention (TRIPP) over 15 minutes after surgery.
9697208|NCT04759183|Experimental|Arm II (TRIPP, Angry Birds)|Patients participate in a VR intervention (TRIPP) over 15 minutes before standard of care surgery and then participate in a VR intervention (Angry Birds) over 15 minutes after surgery.
9697209|NCT04759001|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
9697210|NCT04759001|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of water)
9697211|NCT04758910|Active Comparator|High Flow Oxygen Therapy|Tracheostomized patients will undergo a spontaneous breathing trial with high flow oxygen therapy.
9697212|NCT04758910|Active Comparator|T-piece|Tracheostomized patients will undergo a spontaneous breathing trial with T-piece as a standard of care.
10188294|NCT03717857||Caregiver InDepth Interviews|Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.
10205363|NCT02504151|Experimental|Order 1|The subject will receive treatment with CBD for four weeks, followed by a two week washout period, followed by four weeks of placebo.
10205364|NCT02504151|Experimental|Order 2|The subject will receive placebo for four weeks, followed by a 2 week washout period, followed by four weeks of treatment with CBD.
9697213|NCT04758923|Active Comparator|Two-Stage|Two-stage approach The treatment process commenced with an intial treatment phase. This will be udertaken Under General anaesthesia and entailed ERCP and endoscopic sphincterectomy
10188295|NCT03717857||Focus Groups|"Three focus groups with middle school students [N = 5], caregivers [N =5], and school staff [N = 5] will be conducted to inform the development of the intervention.~Criteria for caregiver and middle school student selection is similar to the in-depth interviews and the pilot clinical trial. Inclusion criteria specify that participants must 1) be between the ages of 11-13 , 2) be in 6th-8th grades, or have a child that meets that criteria 3) reside in one of the targeted public school districts identified by zip code, 4) attend one of the schools within these districts.In RI, caregivers will have to identify as Latino.~The school staff focus group will include school personnel from the targeted schools."
10188296|NCT03717831||Healthy|Healthy subjects will be enrolled as age and activity matched controls for muscle power assessment at one time-point to establish normative values.
10188297|NCT03717831||ICU|Observational, subjects enrolled initially in the ICU and followed for six months after hospital discharge. ICU subdivided based on diagnosis
10188298|NCT03717818|Experimental|Good Psychiatric Management-Brief|
10188299|NCT03717818|Placebo Comparator|Treatment as Usual-Brief|
10188300|NCT03717805|Experimental|Intervention group|Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
9697214|NCT04758923|Active Comparator|Single stage|Single stage approach Under General anaesthesia a5 trocar method will be used to access the abdominal cavity. Aconventional approach to laparoscopic cholecystectomy will be first udertaken with dissection of calot's triangle. The cystic duct will be pulled laterally to facilitate exposure of the anterior wall of the CBD, and the CBD will be opened longitudinally for a distance of approximately 1 to 1.5 cm using laparoscopic scissors. A5 mm flexible choledoscope will be used to identify the cbd stone which will be removed by flushing with sterile saline, passing a stone basket or electrohydroulic lithotripsy as neccesary to clear the CBD. A T-tube will be inserted into the CBD via the choledochotomy which will be closed by interrupted resorbable sutures before completing the cholecystectomy.
9697215|NCT04758507|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
9697216|NCT04758507|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of saline solution)
9697217|NCT04758455|Experimental|P53 IHC|P53 staining density and intensity will be calculated. To assess P53 density in a semiquantitative way, a score of 0 will be given assigned if less than 5% of tumour cells expressed p53, 1 if 5% to 50% expressed p53 and 2 if more than 50% stained positive for p53. To evaluate P53 intensity, a score of 0 means weak or absent staining, 1 refers to the intermediate intensity and 2 stands for strong intensity.
9697218|NCT04758455|Experimental|Ki67 IHC|Ki67 proliferation index will be used to detect rapidly proliferating cells which means the percentage of positive Ki67 cells over 5 high power fields. It will be semiquantitatively graded as low, moderate, or high and correlated with histological staging.
9697219|NCT04758455|Experimental|Cyclin A IHC|Regarding Cyclin A, a standard peroxidase-conjugated streptavidin-biotin labelling was used for visualization, with 3,3 diaminobenzidine as chromogen. Level of cyclin A expression will be classified as absent (-), focal (+), moderate (++) diffuse (+++).
9778292|NCT01103414|Experimental|Mitoglitazone 100 mg capsules|Mitoglitazone 100 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
9778293|NCT01103414|Experimental|Mitoglitazone 150 mg capsules|Mitoglitazone 150 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
9778294|NCT01103414|Active Comparator|Pioglitazone 45 mg capsules|Pioglitazone 45 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
9778295|NCT01103414|Placebo Comparator|Matching placebo|Placebo capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
9778296|NCT01103440|Other|Conventional Strategy|Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure
9778297|NCT01103440|Active Comparator|Aggressive Strategy|Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
9778298|NCT01103466|Active Comparator|New ostomy appliance (Atlas)|Atlas= new base plate. Due to company confidentiality the product is just called Atlas and this is not short for any other names
9778299|NCT01103466|Active Comparator|SenSura|Commercially available ostomy appliance
9778300|NCT01103466|Active Comparator|Conform 2|Commercially available ostomy appliance
9778301|NCT01103479|No Intervention|Control|Participants will complete interviewer-administered pre- and post-test
9778302|NCT01103479|Experimental|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer screening guidelines, communication skills, and health literacy training
10188301|NCT03717805|No Intervention|Control group|Participating couples of the control group will receive care as usual (as will participating couples of the intervention group) and will not get access to the preparatory information movie on oocyte aspiration (POAM).
10188302|NCT03717779||HF/HFpEF|patients with heart failure with a preserved ejection fraction(HFpEF) perform LUS
10188303|NCT03717779||HF/HFrEF|patients with heart failure with a reduced ejection fraction(HFrEF) perform LUS
10188304|NCT03717766||Patients|Intraaxial brain tumors that are tributary to surgical treatment. Prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors.
10188305|NCT03717753|No Intervention|Before Group|We plan to have 70 patients studied prior to initiation of a pathway.
10188306|NCT03717753|Experimental|After Group|We plan to have 70 patients studied after initiation of a pathway.
9697220|NCT04758598|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Direct Selective Laser Trabeculoplasty (DSLT): employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
9697221|NCT04758598|Active Comparator|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
9697222|NCT04758559|Placebo Comparator|Usual care|Patients receive usual care concerning dietary advice.
9697223|NCT04758559|Experimental|myfood24|Patients receive myfood24 a new online app to support tracking of food and nutrient intakes, and allows patients and healthcare professionals to communicate, seeing results of intakes to promote healthy dietary behaviour changes.
9697224|NCT04758559|Experimental|myfood24 + diet optimisation|Personalised feedback. Patients use myfood24 with an additional feature of new technology providing guidance of how to optimise their diets against targets, using information they provide about current intakes.
10188307|NCT03717740|Experimental|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
9697225|NCT04758585|Active Comparator|Study Group|
9697226|NCT04758585|No Intervention|Control Group|
9697227|NCT04758572|Experimental|Manual Therapy|"Mobilization. Axial decoaptation, talar mobilization, global and specific articulatory mobilization of the foot, mobilization of the fibular head, femorotibial mobilization, hip mobilization. In addition, lumbar joint mobilization is applied. The articulatory techniques last 15 minutes. Subsequently, Trigger Point Inhibition is applied. in the medial gastrocnemius, soleus, and square plantar muscles. The application of this technique lasted 15 minutes.~Plantar fascia massage. A deep friction technique was applied longitudinally and transversely to the plantar fascia and the triceps surae. It lasted 15 minutes.~Passive stretching. Stretches were applied to the plantar fascia, the gastrocnemius muscles and the soleus muscles in order to relax these muscles. The duration was 5/10 minutes."
9697228|NCT04758572|Sham Comparator|Placebo massage|Consist of gentle kneading and rubbing without intention to treat for 15 minutes.
9697229|NCT04758429||Development or Training Cohort|will provide the data to be used for algorithm development and training.
9697230|NCT04758429||Test or Validation Cohort|will provide data to be used for algorithm validation.
9697231|NCT04758403|Experimental|Navigation Bronchoscopy ALONE|"This research study involves a screening period, a procedure and follow up visits~Procedure Visit Navigation Bronchoscopy Alone~Follow-Up Visits at Week 1, 4 and 12"
9697232|NCT04758403|Experimental|CBCT-GUIDED Navigation Bronchoscopy|"This research study involves a screening period, a procedure and follow up visits Procedure Visit- Cone Beam Computed Tomography - Guided Navigation Bronchoscopy for Peripheral Pulmonary Nodules~-Follow-Up Visits at Week 1, 4 and 12"
9697233|NCT04758494||Stroke1-hemiparesis|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis.
9697234|NCT04758494||Stroke 2-mild stroke|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a mild stroke.
9697235|NCT04758494||Stroke 3-speech disorder|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a speech disorder.
10188308|NCT03717740|Placebo Comparator|Placebo|Patients will take Placebo Oral Tablet once a daily oral tablet from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
10188309|NCT03717714|Active Comparator|Glucosamine 1500mg|Glucosamine 1500 mg per day for 12 weeks
10188310|NCT03717714|Experimental|Polycan & Glucosamine 750mg|Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks
10188311|NCT03717714|Experimental|Polycan & Glucosamine 1500mg|Polycan 50 mg + Glucosamine 1500 mg per day
10188312|NCT03717701|Experimental|metformin and esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day plus single dose of metformin 1000mg orally single dose once a day
10188313|NCT03717701|Placebo Comparator|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
10188314|NCT03717688|Placebo Comparator|Placebo|No treatment. Participants are subjected to a standardized meal
10188315|NCT03717688|Active Comparator|Entrestro as single dose|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
10188316|NCT03717688|Active Comparator|Sitagliptin as single dose|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
9697236|NCT04758494||Stroke 4-hemiparesis mainly of upper limb|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis mainly of upper limb.
9697237|NCT04758494||Stroke 5-memory loss and depression|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of memory loss and depression.
9697238|NCT04758494||Multiple Sclerosis|Patients diagnosed with multiple sclerosis.
9697239|NCT04758351||Cases - Patients with chronic cough|Patients referred to secondary care clinic for investigation and treatment for explained chronic cough, refractory chronic cough, and unexplained chronic.
9697240|NCT04758676|Experimental|Nutritional and physiotherapy protocol, BIA|Study subjects randomized into this study arm will be indicated for nutritional and physiotherapy protocol, based upon the obtained results of the measurements, using bioimpedance analysis.
9697241|NCT04758676|Active Comparator|Standard of care|Study subjects randomized into this study arm will be provided the current standard of care.
10188317|NCT03717688|Active Comparator|Entrestro + sitagliptin as single dose|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
9697242|NCT04758715|Other|Food provided|Food provided from a commercial meal service provider for a week
9697243|NCT04758624|Experimental|Deep Brain Stimulation(DBS)|
9697244|NCT04758533|Experimental|AloCELYVIR|Patients will received weekly infusion of AloCELYVIR during 8 weeks.
10188318|NCT03717675|Experimental|Interventional|Interventional arm, where the NovaCross™ CTO micro-catheter will be placed in study subjects during the Total Occlusion opening procedure.
9697245|NCT04758663|Experimental|Declarative memory|Napping v. wake effect on declarative memory in habitual and non-habitual nappers.
9697246|NCT04758663|Experimental|Overnight Physiology|Napping v. wake effect on overnight physiology in habitual and non-habitual nappers.
9697247|NCT04758546|Experimental|Aggressive screening criteria + high minimal ventilatory settings|
9697248|NCT04758546|Experimental|Aggressive screening criteria + low minimal ventilatory settings|
9697249|NCT04758546|Experimental|Conservative screening criteria + high minimal ventilatory settings|
9697250|NCT04758546|Active Comparator|Conservative screening criteria + low minimal ventilatory settings|
9697251|NCT04758689|Experimental|Laser acupuncture and aerobic exercise|
9697252|NCT04758689|Experimental|Aerobic exercise|
9697253|NCT04758728|Active Comparator|Group A|Group A - great saphenous vein stripping with local adrenaline use for hemostasis
9697254|NCT04758728|Sham Comparator|Group B|Group B - great saphenous vein stripping with local normal saline use for hemostasis
9697255|NCT04758728|Sham Comparator|Group C|Group C - great saphenous vein stripping with traditional hemostatic practice
9697256|NCT04758481|Experimental|Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy|The patients, in whom disease stabilisation/partial regression will be achieved, will undergo primary tumour radiotherapy and stereotactic body radiotherapy, followed with maintenance radiotherapy.
9697257|NCT04758442|Experimental|Vancomycin|Subjects with hematologic cancer who received intravenous vancomycin for a suspected or confirmed infection.
9697258|NCT04758260|Experimental|Antioxidant Treatment|Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men
9697259|NCT04758182|Experimental|Experimental group|Experimental group: HILT + sham ultrasound therapy In the experimental group, participants received HILT treatment 1 session per day over a period of 2 consecutive weeks (5 days/week); total 10 sessions. In this study we used HIRO 3.0 device applied to the hemiplegic shoulder and the area of following muscles include upper trapezius, supraspinatus, deltoid, pectoralis minor muscles and the tender points. The treatment consisted of high peak power (3kW), a wavelength of 1064 nm. Two phases of treatment were performed according to Rotator cuff tendinopathy protocol of the device. The total energy administered will be approximately 2500 J. The total treatment time was approximately 10 minutes. They also received sham ultrasound therapy, which performed by applying probe with gel without turning on the device, for 10 minutes.
9697260|NCT04758182|Active Comparator|Control group|"Control group: sham HILT + ultrasound therapy In control group, participants received continuous ultrasound therapy for 10 minutes in the same area as an experimental group with Chattanooga intellect mobile ultrasound device. The device was operated at the frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100% in the same area of the HILT group. They also received sham HILT, by applying the applicator with pre-recorded sound without starting the device, for 10 minutes. Ultrasound therapy and sham ultrasound were delivered according to the predefined protocol by the physiotherapists.~Both groups received 3 ROM exercise sessions per day. Participants and their caregiver were educated about proper positioning and manual handling"
9697261|NCT04758195|Experimental|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
10188319|NCT03717662|Experimental|Brief counseling and NRT|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers (including all types of tobacco products such as shisha, electronic cigarettes and heat-not-burn (HNB) which are available in the market) who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
10188320|NCT03717649|Active Comparator|Conventional 2-stage venous cannulation|The two-stage venous cannula 36Fr and 51Fr (size) for each of the two stages (91251C, Medtronic)
10188321|NCT03717649|Active Comparator|Conventional 3-stage venous cannula|The standard three-stage cannula (91437C, Medtronic) is 29Fr, 46Fr and 37Fr for each of the three stages.
10188322|NCT03717649|Experimental|Fenestrated 3-stage venous cannula|The fenestrated three-stage cannula (MC2X, Medtronic) is 29Fr, 29Fr and 29Fr for each of the three stages.
9697262|NCT04758195|Active Comparator|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
10188323|NCT03717636|Experimental|Hospital Day|Patients in the Hospital-Day group will return for medical evaluation 7-14 days in the specific unit.
10188324|NCT03717636|Other|Outpatient clinic|The patients in control group will return for medical evaluation 30 days at the outpatient clinic.
10188325|NCT03717610|Experimental|Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min|
9697263|NCT04758130|Experimental|App Group|Patients in this group are provided with a link to download the application and their application usage is tracked by the clinic.
9697264|NCT04758130|Placebo Comparator|Placebo Group|Patients in this group are not provided with the clinic link to the application.
9836104|NCT02769065|Experimental|SRD: Cohort 22: TAK-071 80 mg+Donepizil|TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.
9697265|NCT04758169|Experimental|Enhanced Homestead Food Production|Participant in this arm will receive the Helen Keller's EHFP model which involves homestead food production, nutrition and WASH education and gender transformative sessions (intervention group). Participants will also receive interventions related to parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH and basic life-skill trainings.
9697266|NCT04758169|Experimental|Control|Participants in this arm will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings. This particular arm will not receive any homestead food production intervention over the course of the implementation.
9697267|NCT04758156|Experimental|CleanViewAL|1L polyethylene glycol+ascorbic acid split dose
10188326|NCT03717558|Active Comparator|Stromectol R|Stromectol R = ivermectin 3mg (tablet)
9697268|NCT04758156|Placebo Comparator|SUPREP|Oral sulfate solutiom
9697269|NCT04758221|Experimental|Single arm : Composite coronal build up strip crown|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
9697270|NCT04758013|Experimental|Laparoscopic gastric surgery with Epidural injection|Patients with laparoscopic gastric surgery who received epidural injection through an thoracic epidural catheter.
9697271|NCT04758013|Experimental|Laparoscopic gastric surgery without Epidural injection|Patients with laparoscopic gastric surgery who don't received epidural injection through an thoracic epidural catheter.
9697272|NCT04758013|No Intervention|Open gastric surgery|Patients with open gastric surgery.
9697273|NCT04758286|Active Comparator|Successful outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
9697274|NCT04758286|Active Comparator|Complicated outcome|It will include the anesthetic and operative data and the incidence of intraoperative or postoperative complication
9697275|NCT04758273|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
9697276|NCT04758273|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
9697277|NCT04758273|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
9697278|NCT04758273|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697279|NCT04758273|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697280|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
9697281|NCT04758273|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697282|NCT04758273|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697283|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
9697284|NCT04757896|Active Comparator|Costoclavicular block lateral aproach|An 80-100 mm needle will be directed from the lateral to the medial with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
9697285|NCT04757896|Active Comparator|Costoclavicular block medial aproach|An 80-100 mm needle will be directed from the medial to the lateral with the ultrasound guided in-plane technique and the blockage procedure will be completed by injecting
9697286|NCT04757792||No NSAID|included patients who did not receive NSAID prior to having COVID-19 disease
9697287|NCT04757792||Apsirin|included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease
9697288|NCT04757792||Celecoxib|included patients who received celecoxib (CEL) prior to having COVID-19 disease
9697289|NCT04757792||Miscellaneous|included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease
9697290|NCT04757987||Pain-free|Report persistent pain at enrolment
9697291|NCT04757987||Persistent pain|Report no pain at enrolment
9697292|NCT04758299|No Intervention|Standard care|information from an FDA authorized home test kit for what actions to take for a negative or positive COVID-19 test
9697293|NCT04758299|Experimental|Decision science-based design|Information from a decision science-based design (of similar length to the FDA authorized home test kit information) for what actions to take for a negative or positive COVID-19 test
9697294|NCT04757922||Intervention: bilateral salpingectomy|Premenopausal women between 35 and 45 years of age, who will undergo sterilization through Opportunistic Salpingectomy will be asked to participate in the STOPOVCAyoung study.
9697295|NCT04757922||Control: tubal ligation or no sterilization|The control group will consists of women who chose for sterilization by clips/tubal ligation supplemented by friend/acquaintances, around the same age, who are not planning to undergo sterilization.
10188327|NCT03717558|Experimental|ivermectin T1|T1= ivermectin low grade particle Size Distribution
10188328|NCT03717558|Experimental|ivermectin T2|T2= ivermectin medium grade particle Size Distribution
9697296|NCT04757805|Experimental|Spinal anesthesia|Infants receiving spinal anesthesia for standard of care procedure
9697297|NCT04757909|Experimental|Monthly Haemoglobinometry|
9697298|NCT04757909|No Intervention|Routine monitoring|
9697299|NCT04757818|Experimental|0.07% cetylpyridinium chloride (CPC) in mouthwash|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
9697300|NCT04757818|Placebo Comparator|Distilled water with the same colorant as the experimental product|Single dose. A mouthwash and gargles with 15 ml of product for 1 minute.
9836105|NCT02769247|Experimental|Placebo|Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
10188329|NCT03717558|Experimental|ivermectin T3|T= ivermectin high grade particle Size Distribution
10188330|NCT03717545|Experimental|intervention arm|second allogeneic stem cell transplantation
10188331|NCT03717532|Experimental|Patients with Patellopain syndrome with Cuff|Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
9697301|NCT04757948|Experimental|Acupuncture|Sterile needles are inserted into acupuncture points P-6 and St-36 bilaterally and retained for a total of 20 minutes. Halfway through the treatment, the needles are manipulated in order to re-create the acupuncture sensation. The needles are removed after 20 minutes of treatment prior to the second gag measurement.
9697302|NCT04757948|Experimental|TENS|Gel pads are affixed to the acupuncture points P-6 and St-36, bilaterally. The amplitude of the TENS device will be gradually increased up to a maximum setting of 8/10, with the subject asked to notify the examiner as soon as any sensation is noticed. Once a gentle buzzing sensation is noticed, the amplitude will be reduced slightly for comfort and then the device will remain for the duration of 20 minutes. The pads are then removed prior to the second gag reflex measurement.
9697303|NCT04757948|Placebo Comparator|Sham-TENS|For the sham-TENS group, the protocol is identical to the TENS group, however the electrical wires have been severed and re-attached in the control unit. As such, the unit will flash a light but there will be no current delivered. The subject is told that no sensation is required. The amplitude will be turned up to a maximum setting of 8/10 and left there for 20 minutes, then the device turned off and pads removed.
9697304|NCT04757844|Experimental|Young healthy voluntary adults|30 young healthy voluntary adults
9697305|NCT04758000|Experimental|Metformin|"Metformin will be administrated according with patients body mass index (BMI). The study is divided into 2 groups.~Group 1: Localized osteosarcoma that have presented a response ≤ 60% to the pre-operatory chemotherapy).~Group 2: Osteosarcoma and Ewing sarcoma patients with complete remission after the first relapse."
9697306|NCT04758078|Experimental|Corticosteroids|Patients will receive inhaled corticosteroids (Budesonide 2 mL = 1000 microgram)
9697307|NCT04758078|Placebo Comparator|Placebo|Patients will receive nebulized 0.9% saline
9697308|NCT04758065|Active Comparator|1-Goup: Control group|Home-based cervical therapeutic exercise and manual therapy.
9697309|NCT04758065|Experimental|2-Group: Radial pressure waves Group|Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves.
9697310|NCT04758052|Experimental|simultaneous tracheostomy with gastrostomy (TSG)|This arm include the patients assigned to placement of gastrostomy immediately after tracheostomy.
9697311|NCT04758052|No Intervention|non-simultaneous or delayed approach tracheostomy and gastrostomy (TDG)|"This arm include the patients who proceed with usual care placement of tracheostomy and gastrostomy as per Neurocritical care Unit service standard."
9697312|NCT04757974|Experimental|Part 1: Treatment sequence ABC|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
9697313|NCT04757974|Experimental|Part 1: Treatment sequence BCA|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
9697314|NCT04757974|Experimental|Part 1: Treatment sequence CAB|Participants will receive FTR 600 mg ER tablet in Period 1 (Treatment C, reference) followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
9697315|NCT04757974|Experimental|Part 1: Treatment sequence ACB|Participants will receive FTR 3×200 mg ER tablets (Treatment A) in Period 1 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 3.
9697316|NCT04757974|Experimental|Part 1: Treatment sequence BAC|Participants will receive FTR 3×200 mg ER tablets (Treatment B) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 2 followed by FTR 600 mg ER tablet (Treatment C, reference) in Period 3.
9697317|NCT04757974|Experimental|Part 1: Treatment sequence CBA|Participants will receive FTR 600 mg ER tablet (Treatment C, reference) in Period 1 followed by FTR 3×200 mg ER tablets (Treatment B) in Period 2 followed by FTR 3×200 mg ER tablets (Treatment A) in Period 3.
9697318|NCT04757974|Experimental|Part 2: Treatment sequence DE|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets in a fasted state (Treatment D) in Period 1 and following a high fat high calorie meal (Treatment E) in Period 2.
9697319|NCT04757974|Experimental|Part 2: Treatment sequence ED|Participants will receive the selected low-dose formulation of FTR 3 × 200 mg ER tablets following a high fat high calorie meal (Treatment E) in Period 1 and in a fasted state (Treatment D) in Period 2.
9697320|NCT04757753|Experimental|ready-to-use root canal sealer: PA1704|PA1704 is used in combination with gutta percha points for the permanent obturation of root canals.
9697321|NCT04757753|Other|root canal sealer: BioRoot™ RCS|BioRoot™ RCS is used in combination with gutta percha points for the permanent obturation of root canals.
9697322|NCT04757779|Experimental|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach. Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle). On Day1 and Day8, subjects are required to inject irinotecan(65mg/m2) or docetaxel(60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
9827802|NCT02469077|Experimental|6 week aerobic exercise intervention|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
9836106|NCT02769247|Experimental|Naproxen/Normal saline|Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
10188332|NCT03717532|Placebo Comparator|Patients with Patellopain syndrome with Placebo Cuff|
10188333|NCT03717519||s-CRLM|Patients with synchronous colorectal liver metastases who underwent surgical resection
10188334|NCT03717493|Experimental|Affect Regulation Training (ART)|Affect Regulation Training (ART; Berking & Whitley, 2014) is a transdiagnostic, group-based intervention aiming to enhance general affect regulation skills in individuals who meet criteria for mental disorders or are at-risk of developing mental-health problems.
10188335|NCT03717493|No Intervention|Waitlist Control Condition (WLC)|In order to control for the effects of time, we compared changes during ART with changes during WLC. Participants in the WLC condition received no treatment within the study but were offered to participate in ART after completing all assessments.
10188336|NCT03717480|Experimental|TCR α/β Reagent System|"The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.~CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device"
10188337|NCT03717467|Placebo Comparator|S group|Isotonic saline as placebo will be given.
10188338|NCT03717467|Active Comparator|M group|Magnesium sulfate will be given
10188339|NCT03717454|Experimental|Drug treatment|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.
10188340|NCT03717454|Experimental|Surgery|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.
9697323|NCT04757545|Active Comparator|HM-PRO intervention|The intervention group will have a predetermined nurseled consultation planned to assess medical status and symptom control at 0, 6 and 12 months. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients.
9697324|NCT04757545|No Intervention|Standard outpatient follow-up care|The control group will receive standard care in the outpatient clinic. The patient has a predetermined consultation appointment at the hospital one time a year with a doctor to evaluate medical status and symptom control.
9697325|NCT04757558|Active Comparator|C-MAC-VS group|C-MAC-VS will be used to facilitate intubation
9697326|NCT04757558|Placebo Comparator|control group|direct laryngoscopy using Macintosh laryngoscope will be done for DLT insertion.
9697327|NCT04757415|Experimental|Traction straight leg raise technique for hamstring.|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions along with traction straight leg raise technique. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
9697328|NCT04757415|Experimental|Gluteal activation exercises|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
9697329|NCT04757740|Active Comparator|Platelet rich fibrin Group|Platelet rich fibrin. Group P
9697330|NCT04757740|Active Comparator|Methylprednisolone acetate|Group S
9697331|NCT04757597|Experimental|RIC group|RIC treatment and regular treatment.
9697332|NCT04757597|No Intervention|Regular treatment|Regular treatment alone.
9697333|NCT04757467|Active Comparator|Standard physiotherapy neuro-rehabilitation|Control Group: Patients included in the control group will receive standard physiotherapy neurorehabilitation protocols.
9697334|NCT04757467|Experimental|Repetition-CIMT|In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr
9697335|NCT04757467|Experimental|Hour-CIMT|The task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours.
9697336|NCT04757480|Experimental|Thoracolumbar Interfascial Plane Block (TLIP)|
9697337|NCT04757480|Experimental|Bilateral Erector Spinae plane Block (ESB)|
9697338|NCT04757506|Placebo Comparator|Placebo|cellulose-filled capsule
9697339|NCT04757506|Experimental|Naltrexone|single 50 mg oral dose naltrexone (capsule)
9697340|NCT04757623|No Intervention|Group B : conventional primary closure|allileostomies are reversed with conventional method
9697341|NCT04757623|Experimental|Group A: Purse string closure|the ileostomy reversal circular incision used with stitches of continuous and non-absorbable. The wound of skin was closed by using (Proline No. 1) that leaving 0.5 cm defect on middle in the skin.
10188341|NCT03717415|Experimental|Part 1|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks
10188342|NCT03717415|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin~Triple-negative breast cancer~Platinum-sensitive Ovarian cancer~Mesothelioma"
10188343|NCT03717363|Active Comparator|Control group|Educational talk: an educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
10188344|NCT03717363|Experimental|Interventional group|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
10188345|NCT03717350|Placebo Comparator|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously
10188346|NCT03717350|Active Comparator|Antibiotic|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously
10188347|NCT03717337|Experimental|Single visit pulp regeneration|Regenerative endodontic procedure not involving placement of intracanal medicament will be done in single visit
10188348|NCT03717337|Active Comparator|Two visit pulp regeneration|Regenerative endodontic procedure involving placing intracanal medicament will be done in two visit
10188349|NCT03717324||First evaluation group (survey_1)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA)
10188350|NCT03717324||Co-creation group|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA) who want to participate in the co-creation workshop
10188351|NCT03717324||Second evaluation group (survey_2)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA), after improvements are made
9977885|NCT01366261|Experimental|semirigid thoracoscopy|Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
9977886|NCT01366261|Active Comparator|rigid thoracoscopy|The rigid instrument was autoclavable OP EndoEYE WA50120A (Olympus Tokyo, Japan) video thoracoscope. The length of the instrument was 29 cm with 00 direction of view and 700 field of view. The external diameter of the instrument was 10 mm with 5,2 mm inner channel diameter. The instrument was compatible with Olympus Visera OTV-S7V and EVIS Exera II CV-180 video processors. Cusps of rigid forceps had outer diameter 5 mm and length 10 mm.
9977887|NCT01366274|Active Comparator|Usual method of MHI|
9977888|NCT01366274|Experimental|Protective MHI|
9697347|NCT04757441|Experimental|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire (ELDOA)|Participants will receive conventional treatment along with ELDOA stretching exercises protocol at L5, S1.
9697348|NCT04757441|Other|Group B: Conventional treatment|Participants will receive only conventional treatment (Control)
9697349|NCT04757532|Experimental|Bupropion|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h post-administration.
9697350|NCT04757532|Experimental|Anastrozole|Subjects receive a single-dose treatment. Urine samples will be collected until 7 days after administration in 7 fractions: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h post-administration.
9697351|NCT04757532|Experimental|Testosterone cyclopentylpropionate|Subjects receive a single-dose treatment. Urine samples will be collected until 20 days after administration in 20 fractions: first urine of the day, every day.
9697352|NCT04757532|Experimental|Danazol|Subjects receive a single-dose treatment. Urine samples will be collected until 2 days after administration in 6 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h post-administration.
9697353|NCT04757532|Experimental|Chlorthalidone|Subjects receive a single-dose treatment. Urine samples will be collected until 3 days after administration in 4 fractions: 0-12h, 12-24h, 24-48h y 48-72h post-administration.
9977889|NCT01366287|Experimental|Suspension/fasted|
9977890|NCT01366287|Experimental|Tablet/fasted|
9697356|NCT04757376|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)
9697357|NCT04757376|Active Comparator|US-licensed Prolia|60 mg/mL single dose administration, Solution for injection in PFS
9697358|NCT04757428|Active Comparator|Lithium disilicate|The intervention will be: Prosthetic endocrown
9697359|NCT04757428|Active Comparator|Hybrid nanoceramic|The intervention will be: Prosthetic endocrown
9697360|NCT04757727||EDB|Adult women (> 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or recessive) followed at the Nice University Hospital or at the St Louis Hospital of the APHP
9697361|NCT04757701||General dentists and dental hygienists in North Carolina|This objective will be met by administering a quantitative survey to active and licensed NC dentists and dental hygienists.
9697362|NCT04757701||Directors of Service-Learning Centers and their partnering FQHCs|This objective will be met by conducting qualitative assessments with ECU's SoDM's CSLCs and their partnering community clinic/FQHCs. The investigators will interview the Directors of the eight existing CSLCs and focus groups with clinical staff at each CSLC. In collaboration with the Directors of the CSLCs, the investigators will identify key stakeholders in the co-located/partnering medical clinics, and conduct interviews with the administrators and focus groups with medical clinic staff.
9697363|NCT04757350||cataract|Research subjects should meet the following criteria: Signed and dated informed consent form Commitment to abide by the research procedures and cooperate with the implementation of the whole process of research 18-90-year-old cataract patients or patients after cataract surgery
9697364|NCT04757337|Active Comparator|Doxorubicin|Intravenous Doxorubicin 60 mg/m² Cycle 1 then 75 mg/m² Cycle 2 to Cycle 6 D1-D21 with granulocyte-colony stimulating factor (G-CSF) and dexrazoxane.
9697365|NCT04757337|Experimental|Cyclophosphamide|Cyclophosphamide per os 100 mg twice a day, 1 week on, 1 week off until 2 years, or unacceptable toxicity, disease progression, withdrawn of consent or death.
9697366|NCT04757181|Experimental|IBD patients|IBD patients will be used as their own control. Participants will start the study in a baseline phase (4 weeks) and intervention phase (8 weeks)
9697367|NCT04757168|Experimental|NOGA TM probe|
9697368|NCT04757194|Experimental|Intervention|Calculation of risk assessment score by machine learning algorithm and display of risk assessment information to dispatch nurses. Staff encouraged but not required to comply with suggested ranking.
10188352|NCT03717311|Experimental|13C enriched bran biscuit|The volunteers will consume 5 biscuits (100g) enriched with 13C bran with a 200 ml hot beverage in 15 minutes
10188353|NCT03717285|Experimental|Group 1:Under direct vision|Patients in Group 1 insert the UAS under direct vision.In this procedure,the investigators will insert the ureteroscope into urinary bladder beside the guidewire to observe the process of uas insertion into the ureter.
9697369|NCT04757194|No Intervention|Control|Ambulance dispatch per standard of care
9697370|NCT04757025|Experimental|Electrical Impedance Tomography|patient monitored by Electrical Impedance Tomography
9977891|NCT01366287|Experimental|Tablet/fed|
9977892|NCT01366300|Active Comparator|Intravenous lidocaine infusion|Intravenous lidocaine infusion during total intravenous anesthesia with propofol administered by target controlled infusion
9697371|NCT04757025|Active Comparator|Peripheral arterial Saturation|patient monitored by Peripheral arterial Saturation alone
9697372|NCT04756960|Experimental|CHF6001|single dose of CHF6001 DPI co-administered with an intravenous microdose of [14C]-labelled CHF6001
10188354|NCT03717285|Active Comparator|Group 2:Under non direct vision|Patients in Group 2 insert the UAS under non direct vision.In this procedure,the investigators will insert the UAS under fluoroscopy control.
9697373|NCT04757038|Experimental|Hyalodisc injection|"• Group 1: One single X-ray-guided intradiscal injection (25 gauge) of 8 mg/mL of HYALODISC combined with PEP. The investigator will use one syringe for each involved disc, up to a maximum of three discs.~The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided. Both groups (Group 1 and Group 2) will be treated with PEP according to a standardized protocol."
10188355|NCT03717272|Experimental|AEF0117|AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
10188356|NCT03717272|Placebo Comparator|Placebo oral capsule|corn oil capsules once a day for 5 consecutive days.
9697374|NCT04757038|No Intervention|Physical exercise program (PEP)|Group 2: PEP alone
9697375|NCT04756973|Active Comparator|Standard weight loss|A 12 week small group weight loss intervention delivered via video teleconference technology.
9697376|NCT04756973|Experimental|Standard weight loss plus self-compassion skills training|A 12 week small group weight loss intervention delivered via video teleconference technology.
9697377|NCT04757233|Other|Single arm|Intervention: GlucoType Single arm study; all participants assigned to use the intervention
9697378|NCT04757324|Experimental|education arm|Breastfeeding training was given to the training arm
9697379|NCT04757324|No Intervention|control arm|Breastfeeding training not given to control arm
9697380|NCT04757077||GROUP 1|Patients 6-24 weeks after delivery with postpartum PGP (Patients with symptoms and signs of PGP, PGP confirmed with dedicated functional tests).
9697381|NCT04757077||GROUP 2|Patients 6-24 weeks after delivery, with no symptoms and signs of PGP.
9697382|NCT04756947||Pelvic injury|Paediatric patients (age ≤ 18 years) with a single pelvic bone fracture or pelvic ring injury, excluding pathological fractures.
9697383|NCT04756947||Pelvic and acetabular injury|Paediatric patients (age ≤ 18 years) with a combined pelvic and acetabular injury or an isolated acetabular fracture, excluding pathological fractures.
9697384|NCT04757220|Experimental|Patients with schizophrenia|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
9697385|NCT04757220|Experimental|Patients with depression|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
9697386|NCT04757220|Active Comparator|Healthy controls|"5 subjective questionnaires~4 cognitive tasks with EEG recordings"
9977893|NCT01366300|Placebo Comparator|Intravenous 0.9% saline infusion|Intravenous 0.9% saline infusion during total intravenous anesthesia with propofol administered by target controlled infusion
10188357|NCT03717259|Active Comparator|Open nephrectomy|These patients will undergo an open nephrectomy.
10188358|NCT03717259|Active Comparator|Hand-assisted laparoscopic nephrectomy|These patients will undergo a hand-assisted nephrectomy.
9697390|NCT04757064|Experimental|Standard Rehabilitation Group|"Standard Rehabilitation Group: will receive the standard protocol of king Hussein hospital 6 weeks post-operative which is:~Start aggressive knee flexion exercises and increase the extensor strength. Consider CPM/dynasplint if flexion <60_ MUA contraindicated.~Examination under anesthesia can be done to assess the cause of limited knee flexion. Surgical release is indicated if knee flexion is < 60 degrees at six months after surgery."
9697391|NCT04757064|Experimental|Supervised Rehabilitation Group|Supervised Rehabilitation Group: will receive supervised rehabilitation program 1 session / week for 45 minutes-1 hour.
9697392|NCT04757129||thrombolysis success group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
9697393|NCT04757129||thrombolysis failure group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
9697394|NCT04756752||Fit and Vitaal program|People with a lower-limb amputation participating in the Fit and Vitaal rehabilitation program
9697395|NCT04756934|Experimental|Ia: LP002 dose escalation-1mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 1mg/kg, Q3W for up to 1 year.
9697396|NCT04756934|Experimental|Ia: LP002 dose escalation-3mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 3mg/kg, Q3W for up to 1 year.
10188359|NCT03717259|Active Comparator|Laparoscopic nephrectomy|These patients will undergo a pure laparoscopic nephrectomy.
9697397|NCT04756934|Experimental|Ia: LP002 dose escalation-5mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 5mg/kg, Q3W for up to 1 year.
9697398|NCT04756934|Experimental|Ib: Expansion|Approximately 30 participants will receive HX008 of 200mg, Q3W plus LP002 of the recommended dose, Q3W for up to 1 year.
9697399|NCT04756934|Experimental|Ib: Control|Approximately 15 participants will receive LP002 of recommended dose, Q3W for up to 1 year.
9697400|NCT04756999|Experimental|Intervention|informed consent forms, nine sessions of foot reflexology massage will be given to reflex points including the solar plexus, brain, pituitary, thyroid, diaphragm, upper lymphs, lung, spinal cord and adrenal glands for 3 weeks. Then data collection tools were applied.
9697401|NCT04756999|Placebo Comparator|Control|informed consent forms, foot massage were performed. Then data collection tools were applied.
9697402|NCT04756908|Experimental|Opira AIOL|
9697403|NCT04756908|Active Comparator|Monofocal AIOL|
9697404|NCT04756908|Active Comparator|Multifocal AIOL|
9697405|NCT04756986|Experimental|malic acid group|patients will receive a topical spray containing 1% malic acid
9697406|NCT04756986|No Intervention|placebo group|patients will receive a topical placebo spray
9697407|NCT04756921||Patients cohort|Patients with HER2 positive MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included.
10205365|NCT02485418|Experimental|Propofol infusion|"All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:~20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes"
9697408|NCT04756856|Experimental|Muscle-target oral nutritional supplementation|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D
9697409|NCT04756882|Experimental|study group|6 patients received 12.5 speywood unit/cm (SU/cm) Dysport intramuscular & intradermal injections, within the first 5 postoperative days of the trauma
9697410|NCT04756882|No Intervention|control group|of 6 patients that acted as the control group and received no treatment
9778303|NCT01103479|Experimental|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational digital video disc (DVD) on CRC and CRC screening
10188360|NCT03717246|Experimental|Sleep Smart Latino|Sleep Smart Latino is a sleep hygiene intervention culturally tailored to be consistent with the beliefs, behaviors and needs of urban Latino middle school children and families. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting, and 2 60-minute long home based sessions that involve the student and their caregiver. The intervention focuses on sleep education, including effective sleep hygiene practices, use of electronics and caffeine and their impact on sleep.
10188361|NCT03717246|Active Comparator|Basic Sleep Education and Child Health|The basic sleep education and child health condition includes education regarding sleep hygiene , and the effects of sleep on child functioning integrated with additional child health topics such as nutrition, physical activity and safety. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting
10188362|NCT03717246|No Intervention|No treatment control|Students randomly assigned to this arm, will receive standard of care , which is no treatment and will not participate in any group sessions.
9778304|NCT01103492|Experimental|Ablation catheter|Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.
9778305|NCT01103505|Other|ForeseeHome AMD Monitoring Device|Participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device in addition to standard care
9778306|NCT01103505|No Intervention|Standard care alone (control) arm|Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD and routine eye exams
9778307|NCT01103713|Experimental|AZCQ|Azithromycin/Chloroquine
9778308|NCT01103778|Experimental|Velcade® therapy|Patients with greater than 1gm of proteinuria per day will receive Velcade®.
10188363|NCT03717233|Experimental|Primary Arm|Participants will be used as their own controls. Participants will be evaluated using exo-skeletons with non-motorized spring elements in parallel to the Achilles tendon. Up to 5 different levels of spring force will be evaluated to evaluate the impact upon plantar pressure and measures of fall risk.
10188364|NCT03717220|Other|flaps|flap transferring is used for reconstruction of multiple small-to-moderate soft-tissue defects
10188365|NCT03717207||type 2 diabetes mellitus (T2DM) patients|T2DM patients affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
9778309|NCT01103934|Active Comparator|Fluticasone Propionate plus Vitamin D3|Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season
9778310|NCT01103934|Placebo Comparator|Fluticasone Propionate plus Placebo|Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season
9778311|NCT01103960|Experimental|Telmisartan80mg+Amlodipine5mg|combination therapy
9778312|NCT01103960|Active Comparator|amlodipine 5 mg|Monotherapy
9778313|NCT01103973|Placebo Comparator|Control (Spa Certificate)|For every three months in the study control subjects received $50 spa gift certificates.
9778314|NCT01103973|Experimental|Mind/Body Program|Ten week group mind/body program. Skills include relaxation training, cognitive strategies, and lifestyle modifications.
10188366|NCT03717207||patients without T2DM|Patients without T2DM affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
10188367|NCT03717194|Experimental|Ertugliflozin|Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor
10188368|NCT03717194|Placebo Comparator|Control group|Placebo in addition to their preexisting metformin and/or DPP4 inhibitor
10188369|NCT03717168|Active Comparator|Recombinant human growth hormone|Patients who received growth hormone immediately after tracheostomy.
10188370|NCT03717168|Active Comparator|Control|Patients who did not receive growth hormone and followed the conventional weaning trials
10188371|NCT03717142|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients, in each indication, to measure baseline tissue fluorescence. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
10188372|NCT03717142|Experimental|1st Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
10188373|NCT03717142|Experimental|2nd Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
9778315|NCT01104025|Experimental|Induction Therapy|ATG, rabbit: intravenous, 5 mg/kg/dose, 5 consecutive days Dexamethasone: intravenous, 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days Etoposide: intravenous, 150 mg/m2 weekly, starting 7 days after first dose of Thymoglobulin Methotrexate and hydrocortisone: intrathecal to patients with central nervous system involvement, age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg, on day 7, 14, 21 and 42
9778316|NCT01104090|Experimental|C-MAC direct laryngoscopy, then C-MAC indirect laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and then using C-MAC with indirect laryngoscopy.
9778317|NCT01104090|Experimental|C-MAC indirect laryngoscopy, then C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with indirect laryngoscopy first and then using C_MAC with direct laryngoscopy.
9697411|NCT04756895|Experimental|Bayesian method|Pharmacists will perform vancomycin dose adjustments according to AUC0-24h/MIC using the Bayesian method with a web application
9697412|NCT04756895|Active Comparator|Standard method|Pharmacists will perform vancomycin dose adjustments according to trough levels of vancomycin.
9697413|NCT04757285||control group|25 healthcare personnel volunteers not working in quarantine hospitals of matched age
9697414|NCT04757285||healthcare providers worked in Intensive Care Units|"35 physicians (28 males and 7 females) and 35 nurses (10 males and 25 females). All volunteers were in good physical health Exclusion criteria included hypertension, diabetes mellitus, obesity BMI ≥30, subjects with serum sodium ≤135 or ≥ 145 mmol /L at baseline or females receiving contraceptive pills.~Assigned participants were clinically evaluated for as hypertension, DM, dyslipidemia, renal function."
9697415|NCT04756635|Experimental|Experimental Group|Measures taken before and after the defined IF periods. Two groups of participants will be included in this project: 1) resistance trained group (tested for neuromuscular function, anaerobic capacity and body composition); 2) endurance trained group (tested for aerobic and anaerobic capacity and body composition). Experimental condition: pre- and post-4 weeks of IF. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48- hour interval) to ensure full recovery.
9697416|NCT04756635|Other|Control Group|Participants of each group serving as their own controls. Control condition: pre- and post4 weeks of normal diet. Measurements will be taken during the morning period (between 07:00 and 11:00 am) in the fasted state. Neuromuscular function and anaerobic capacity will be assessed on separate days (with at least a 48-hour interval) to ensure full recovery.
9697417|NCT04756674||Control Group|"Non-Covid -19 associated community acquired pneumonia with oxygen therapy required.~n=12"
9697418|NCT04756674||Oxygen Therapy|"Confirmed COVID-19 infection via PCR swab, with a new oxygen therapy requirement. NB the researchers will not be involved in the clinical decision of if the participant requires oxygen, this will be the clinical-teams decision.~n=12"
9697419|NCT04756674||Non-Invasive ventilation therapy|"Confirmed COVID-19 infection via PCR Swab, with a clinical need for non-invasive ventilation.~NB the researchers will not be involved in the clinical decision if the participant requires non-invasive ventilation, this will be the clinical-teams decision.~n=12"
9697420|NCT04756622|Experimental|N acetyl cysteine|NAC dissolved in water at a dose of 600 mg three times per day from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
9697421|NCT04756622|No Intervention|Control|No intervention
9697422|NCT04756518||COVID 19 group|The COVID 19 group will consist of peripheral blood smear slides from patients who are in the hospital who had qPCR results positive for COVID-19.
10188374|NCT03717142|Experimental|3rd Tier Dose Level|After an interim analysis, the dosing for the 3 patients, in each indication, will be administered a single dose of LUM015 of no greater than 3.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
10188375|NCT03717116||control-normocalcemia group|
9697423|NCT04756518||CONTROL group|A control group will consist of i) peripheral blood smear slides from patients with no viral infection and ii) from those with a non-SARS-CoV-2 viral infection. Control group peripheral blood slides will be randomly selected from the laboratory slides archive within the facility. The laboratory slides used will be inclusive of slides archived prior to the emergence of COVID-19 infection in the United Kingdom.
9697424|NCT04756466|Placebo Comparator|Control group|Control group that will receive a daily placebo capsule consisting of maltodextrin during 3 months
10188376|NCT03717116||hypocalcemia group|
10188377|NCT03717090||Patients with PJI|
10188378|NCT03717077|Experimental|Learned resourcefulness intervention|The learned resourcefulness program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
10188379|NCT03717077|No Intervention|Usual home care service|The control group maintains home care service
9697425|NCT04756466|Experimental|Probiotic group|Experimental group that will receive one capsule with the probiotic strain per day (3x10 9 CFU / day) during 3 months
9697426|NCT04756830|Other|Vaccination|All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
9697427|NCT04756648|Experimental|CT0180 cells|CT0180 Cells infusion after lymphocyte-depleting with fludarabine and cyclophosphamide.
9697428|NCT04756453|No Intervention|Standard|Standard endoscopic submucosal dissection
9697429|NCT04756453|Active Comparator|Interventional|Mandatory use of the clip-traction device
9697430|NCT04756661|Experimental|Carbetocin|Patient received 100 mcg of carbetocin intravenous over one minute immediately after delivery of the baby.
9697431|NCT04756661|Active Comparator|Oxytocin plus misoprostol|Patient received 10 units of oxytocin IV drip and 400 mcg of misoprostol rectally after anesthesia.
9697432|NCT04756323|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
9697433|NCT04756323|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
9697434|NCT04756323|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
10188380|NCT03717038|Experimental|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1 Day 1, followed by weekly doses of 6 mg/kg beginning Cycle 1 Day 8.
10188381|NCT03717038|Active Comparator|Arm B (TAS-102)|TAS-102 is commercially available and will be administered as per local prescribing instructions.
10188382|NCT03717025|Active Comparator|Mini Punch Grafting|
10188383|NCT03717025|Active Comparator|Suction Blister Epidermal Grafting|
10188384|NCT03717025|Active Comparator|Non Cultured Epidermal Cell Suspension|
10188385|NCT03716999||Palliative Care Patients|Palliative care Patients meeting criteria will receive Starlight Therapy
10188386|NCT03716986|Other|SatO2|
10188387|NCT03716973|Experimental|High density programming|High density programming of spinal cord stimulator for paraesthesia-free therapy.
9697435|NCT04756323|Experimental|medium dosage on day 0, 28(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
9697436|NCT04756323|Experimental|high dosage on day 0, 28(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
9697437|NCT04756323|Placebo Comparator|placebo on day 0, 28(18~59years)|Two doses of placebo on the schedule of day 0,28
9697438|NCT04756323|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697439|NCT04756323|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697440|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
9697441|NCT04756323|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697442|NCT04756323|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
9697443|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
9697444|NCT04756713|Active Comparator|Chemotherapy|Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
9697445|NCT04756713|Experimental|Uterine evacuation|Patients randomized to undergo a second curettage will undergo manual or electronic vacuum aspiration under ultrasound guidance. Following discharge after the second curettage patients will return to weekly hCG monitoring. If hCG levels are decreasing, patients will remain on weekly hCG follow-up until the first normal hCG (<5 IU/L) is achieved. Then they will have monthly hCG monitoring for 12 months. If patients do not attain remission and develop persistent GTN as established by FIGO 2000, the tumor will be re-staged and appropriate chemotherapy will be initiated.
9697446|NCT04756557|Experimental|Tooth Brushing HAP Toothpaste|"Experimental: Tooth Brushing HAP HAP-Toothpaste Tooth Brushing HAP Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite two x daily over the duration of the study (18 months).~Procedure: Tooth Brushing HAP"
9697447|NCT04756557|Active Comparator|Tooth Brushing F Toothpaste|Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (1450 ppm F-), (two x daily over the duration of the study (18 months).
9697448|NCT04756284||Bladder Tumor Positive|Patients with previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy or suspected bladder tumor undergoing surveillance cystoscopy.
9697449|NCT04756284||Bladder Tumor Negative|Patients with no suspected bladder tumor.
9697450|NCT04756336|Experimental|LTX-109 treatment|Patients are treated with LTX-109 gel, 3% w/w twice daily (morning- evening) by application on active hidradenitis lesions during the intervention period of 6 weeks
9697451|NCT04756310|Placebo Comparator|Control|"Patients receiving Theavit food supplement considered as a placebo treatment for AMD condition.~Two capsules/day before breakfast each day for 2 years"
9697452|NCT04756310|Experimental|Retilut|Patients receiving Retilut food supplement. Two capsules/day before breakfast each day for 2 years
9697453|NCT04756544|Experimental|Depressive Disorders + probiotic|
9697454|NCT04756544|Placebo Comparator|Depressive Disorders + placebo|
9697455|NCT04756544|Experimental|Depressive disorder + metabolic syndrome + probiotic|
9697456|NCT04756544|Placebo Comparator|Depressive disorder + metabolic syndrome + placebo|
9697457|NCT04756349|Active Comparator|Clearfil SE|
9697458|NCT04756349|Active Comparator|Optibond All-in-One|
9697459|NCT04756349|Active Comparator|Prime & Bond Universal|
9697460|NCT04756388|Active Comparator|Executive Training|The Executive Training (ET) condition will consist of the ET intervention that Dr. Best previously developed and evaluated. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, at home between sessions. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
9697461|NCT04756388|Experimental|Strategy Development only|In Strategy Development only participants will engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life. Between sessions, participants will be encouraged to practice their cognitive strategies in their daily life and track their strategies using the strategy worksheet. There will be no computerized cognitive training in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
9697462|NCT04756388|Experimental|Computerized Cognitive Training only|In Computerized Cognitive Training only participants will spend the entire one-hour session practicing computerized training exercises. Between sessions participants will be encouraged to practice the computerized exercises at home for 40 minutes per day. There will be no strategy development in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
9697463|NCT04756193||Asymptomatic/Mild COVID-19 Group|50 confirmed COVID-19 patients who showed no or only mild respiratory/GI symptoms (not admitted to the hospital at all)
9778318|NCT01104103|Experimental|BOA(R)|Nurse or paramedic uses the BOA(R)-Constricting IV Band to attempt placement of an upper extremity IV in an adult
10188388|NCT03716960|Experimental|Pumpkin Seed Oil|This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
10188389|NCT03716960|Placebo Comparator|Placebo|This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
9697464|NCT04756193||Moderate COVID-19 Group|50 confirmed COVID-19 patients who were able to maintain oxygen saturation above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs (admitted to the hospital, but never to the ICU and no obvious cardiac complications during the stay)
9697465|NCT04756193||Severe COVID-19 Group|50 confirmed COVID-19 patients who had oxygen saturation lower than 92% at rest and PaO2/FiO2 between 200 and 300 (High-flow oxygen group, mostly in the ICU, and may have some cardiac complications)
9697466|NCT04756193||Critical COVID-19 Group|50 confirmed COVID-19 patients who had PaO2/FiO2 less than 200 or required mechanical ventilation (in the ICU, need mechanical ventilation and more likely to have cardiac complications)
9697467|NCT04756193||Control Group|50 age and sex-matched controls from our hospital admission database
9697468|NCT04756154|Experimental|SP|
9697469|NCT04756154|Active Comparator|SPFF|
9697470|NCT04756154|Placebo Comparator|S|
9697471|NCT04756609|Experimental|Systematic offer of nurse-driven SARS-CoV-2 screening + usual practice|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice
9697472|NCT04756609|Active Comparator|Control group: Usual emergency department practice|Usual emergency department practice with physician-directed diagnostic testing
9697473|NCT04756180|Experimental|Omacor|Omacor 2gm/day for first 4 week followed by 4gms/day for 8 weeks
9697474|NCT04756180|Placebo Comparator|Placebo|Omacor Placebo 2gm/day for first 4 week followed by 4gms/day for 8 weeks
9697475|NCT04756206|Active Comparator|Dutasteride|Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo.
9697476|NCT04756206|Placebo Comparator|Placebo|same form and color of Dutasteride tablet was given at the same regimen to act as a placebo
9697477|NCT04756128|Experimental|Colchicine-Only Arm|"Patients randomized to a colchicine-containing treatment arm will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00. Patients experiencing gastrointestinal side effects (nausea, vomiting, and diarrhea) on twice daily dosing may have the dose decreased to 0.6 mg daily. Dosing will continue twice daily unless there is a change that requires a dose adjustment or an exclusion criterion is met. Dosing deviations above the study protocol will be allowed if medically necessary for the treatment of an additional indication (e.g. colchicine for viral pericarditis).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
9697478|NCT04756128|Experimental|"Colchicine and Naltrexone (Combined) Arm"|"Patients randomized to a colchicine-containing treatment arm (including the combined arm) will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00.~Patients in the combined arm will also receive naltrexone. Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
9697479|NCT04756128|Experimental|Naltrexone-Only Arm|"Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
9697480|NCT04756128|No Intervention|Standard of Care Arm|Patients in this arm will receive the investigating institution's current standard of care for patients with COVID-19. For example, all patients requiring supplemental oxygen (assuming no contraindications) would be candidates for both remdesivir 200 mg x 1 IV dose followed the next day by 100 mg q24h IV x up to 4 doses, as well as dexamethasone 6 mg q24h x 10 up to 10 doses.
9697481|NCT04755959||Stroke|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of Ischemic Stroke, between the years 2016-2020 as documented in an institutionally approved data base of stroke, who will consent to provide access to their data from Google Take Out service.
9697482|NCT04755959||Acute myocardial infarction|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of acute myocardial infarction as documented in an institutionally approved data base of myocardial infarction, who will consent to provide access to their data from Google Take Out service.
9697483|NCT04755959||Healthy controls|Unaffected spouses or volunteers who will consent to provide access to their data from Google Take Out service.
9697484|NCT04755985|Experimental|ARM 1|Period 1 : Reference Drug(AD-2132) Period 2 : Test Drug(AD-213-B)
9697485|NCT04755985|Experimental|ARM 2|Period 1 : Test Drug(AD-213-B) Period 2 : Reference Drug(AD-2132)
9697486|NCT04755920|Experimental|Patients with colorectal brain metastases|10 mg SGM-101, administration 3 to 5 days prior to surgery.
9697487|NCT04756089|Experimental|Breast stimulation|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
10188390|NCT03716947|Active Comparator|ORBIT Mechanical disc prosthesis|"Surgical procedure with total disc replacement using mechanical disc prosthesis device, ORBIT, Globus Medical"
10188391|NCT03716947|Experimental|ZACK viscoelastic disc prosthesis|"Surgical procedure with total disc replacement using viscoelastic disc prosthesis device, ZACK, FH Orthopaedics"
10188392|NCT03716947|Active Comparator|ORBIT SASCA|Surgical procedure with total disc replacement (TDR) using ORBIT disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
10188393|NCT03716947|Experimental|ZACK SASCA|Surgical procedure with total disc replacement (TDR) using ZACK disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
10188394|NCT03716882||Infant at the birth|"Infant at the birth will be included. Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights.~At every cry, parent should answer the questionnaire of cry in infant."
9697488|NCT04756089|Active Comparator|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
9697489|NCT04755829||Group 1|Normal screening mammogram (BIRADS 1 or 2)
9697490|NCT04755829||Group 2|Abnormal screening mammogram (BIRADS 3 to 6)
10188395|NCT03716869|No Intervention|Targeted Screening Arm (Current Process)|Students randomized to the targeted screening arm will complete their routine school-based health screenings. Students will be followed through the academic year for referrals to the Student Assistance Program (SAP). SAP currently exists in all Pennsylvania (PA) schools and functions like a triage service. If a student exhibits behavior concerning for MDD (raised by any contact, e.g. teachers, nurse, parent, peer, or even self-referral), SAP will triage the student and based on the initial assessment provide recommendations for school or community-based services.
10188396|NCT03716869|Experimental|Universal Screening Arm (Intervention)|"Students randomized to the universal screening arm will complete the Patient Health Questionnaire (PHQ-9) during the academic year. This screening tool includes nine close-ended questions with a scoring system ranging from 0 to 27. Scores >10 are considered a positive screen. Students with a positive PHQ-9 result will then proceed to SAP triage as per the current process for those referred via the targeted screening arm."
10188397|NCT03716856|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
10188398|NCT03716843||Pressure monitoring system for AIS|"Adolescent idiopathic scoliosis (AIS) patients~(1) all target subjects are aged 10 to 15 years old with immature skeletons (Risser grade 0-2); (2) they are diagnosed with AIS with a Cobb angle between 25-45° and high risk for curve progression; (3) the types of scoliosis are classified by the Lenke classification system; and (4) the subjects have received rigid brace treatment."
10188399|NCT03716830|Experimental|verum acupuncture + real tDCS|
10188400|NCT03716830|Experimental|sham acupuncture + real tDCS|
10188401|NCT03716830|Experimental|verum acupuncture + sham tDCS|
10188402|NCT03716830|Sham Comparator|sham acupuncture + sham tDCS|
10188403|NCT03716817|Experimental|Tetric CAD Crown|Tetri CAD crowns will hand polished and cemented with a dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
10188404|NCT03716804|Experimental|Intervention group|"Intervention:~To the prescribers- Educational intervention about guideline and present sensitivity trend.~To the Patients- Tablet Nitrofurantoin(100 mg), two times daily at 12 hours interval for 7 days."
10188405|NCT03716804|Active Comparator|Control Group|"Intervention:~To the Patients- Tablet Ciprofloxacin, 500 mg or,Tablet Cefixime 200 mg or,Tablet Cefuroxime 250 mg (According to physician's personal choice)."
10188406|NCT03716791|Placebo Comparator|Placebo Control Group|pill capsules containing white rice flour
10188407|NCT03716791|Active Comparator|Methylsulfonylmethane Group|pill capsules containing MSM
10188408|NCT03716778|Other|Classical exercise training modality in concentric mode (CON)|Description: Control group, usual medical care according to the rehabilitation recommendations
10188409|NCT03716778|Experimental|experimental, active group (ECC)|Patients perform a mixed program combining eccentric pedalling session with the usual sessions
10188410|NCT03716765|Experimental|non-surgical periodontal regeneration|non-surgical periodontal regeneration using locally injected vitamin d to treat the infrabony defect
10188411|NCT03716765|Active Comparator|surgical peridoontal regeneration|surgical periodontal regeneration using bone graft and collagen barrier
10188412|NCT03716752|Active Comparator|bone graft and collagen barrier|peridoontal regeneration using bone graft and collagen barrier as treatment of vertical bony defects with recession defect
10188413|NCT03716752|Experimental|Modified connective tissue graft wall with wing technique|peridoontal regeneration using bone graft and modified connective tissue graft wall with wing as treatment of vertical bony defects with recession defect
10188414|NCT03716739|Active Comparator|Treatment Arm|Weekly IM administration of 100 mg testosterone cypionate for 12 weeks.
10188415|NCT03716739|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks.
9697491|NCT04755907||Group A|colorectal cancer patients at resectable stage II/III who will receive adjuvant chemotherapy after surgery
9697492|NCT04755907||Group B|colorectal cancer patients at locally advanced stage who will receive neoadjuvant chemotherapy before surgery and adjuvant chemotherapy after surgery
9697493|NCT04755907||Group C|colorectal cancer patients with liver metastases
9697494|NCT04756141|Experimental|CGM Use|Determine CGM accuracy when compared with POC (point of care) glucometers.
9697495|NCT04756102||FBS lower than 80|Those pregnant patients with FBS less than 80 mg/dl
9697496|NCT04756102||FBS 80-120|Those pregnant patients with FBS between 80-120
9697497|NCT04755998|Experimental|Experimental Group|The Experimental Group watched cartoons with virtual reality glasses during vaccination applications.
9697498|NCT04755998|No Intervention|Control Group|Pre-test and post-tests were applied to the non-intervention group
9778319|NCT01104103|Active Comparator|Standard care|Nurse or paramedic uses standard IV starting technique in the upper extremity of adults
9778320|NCT01104155|Active Comparator|eribulin mesylate, 21 day cycle|
9778321|NCT01104155|Active Comparator|eribulin mesylate, 28 day cycle|
9697499|NCT04756167|Active Comparator|Conventional Group|The treatment of 21 individuals in the conventional group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes) and exercise(passive and active range of motion) approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week.
9697500|NCT04756167|Active Comparator|Myofascial Release Group|Treatment of 21 individuals in the Myofascial Release group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes),exercise(passive and active range of motion) and myofascial release to subscapularis and serratus anterior muscles approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week. Myofascial release will be done in the first five sessions of treatment programs.
9697501|NCT04755868|Experimental|Maintenance therapy with talazoparib|Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
9697502|NCT04755868|Active Comparator|Maintenance therapy with placebo|Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
9697503|NCT04756011||Group A (insulin pump)|30 patients who are on insulin pump.
9697504|NCT04756011||Group B (MDI)|30 patients who are on multiple daily injection.
9697505|NCT04755894|Experimental|group A|
10188416|NCT03716713|Experimental|CeraShield Endotracheal Tube|Subjects who are expected to require mechanical ventilation for 24 hours or longer will be intubated with the CeraShield ETT.
9697506|NCT04755894|Active Comparator|group B|
9977894|NCT01366313|Experimental|Paracetamol|initial doses was 1.5g g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
9977895|NCT01366313|Experimental|Morphine|Initial doses of morphine was 5mg, with dose adjustment intervals of 1 mg .
9697509|NCT04755946|Experimental|roflumilast arm|
10188417|NCT03716700||Cohort 1|Cohort1 will include the participants who have been transitioned to CUVITRU at the time of enrollment in the study.
10188418|NCT03716700||Cohort 2|Cohort 2 will include participants 6 months (±2 weeks) after CUVITRU initiation.
9697510|NCT04755946|Placebo Comparator|placebo arm|
9697511|NCT04755881||All anaphylaxis reactions seen during the phase 2 period of the SHARED study.|All patients presenting to the 3 sites emergency departments (Chicoutimi, Alma, Jonquière) diagnosed with an anaphylactic reaction or a severe allergic reaction that is rapidly evolving towards anaphylaxis in the opinion of the treating physician.
9697512|NCT04756245|Experimental|Virtual Reality|Participants engage in intervention procedures using virtual reality software.
9697513|NCT04756245|Active Comparator|Video Conference|Participants engage in intervention procedures using video conference software.
9697514|NCT04756219|Experimental|Contact Video|Participants randomized to this group will watch a video of a person talking about his recovery after attempting suicide.
10188419|NCT03716700||Cohort 3|Cohort 3 will include participants 12 months (-1 or +2 months) after CUVITRU initiation.
9697515|NCT04756219|Experimental|Contact Text|Participants randomized to this group will read a personal story of a person who survived a suicide attempt.
9697516|NCT04756219|Experimental|Education Video|Participants randomized to this group will watch a video of a psychiatrist presenting facts about suicide and suicide prevention.
9697517|NCT04756219|Experimental|Education Text|Participants randomized to this group will read a text containing facts about suicide and suicide prevention.
10188420|NCT03716687|Experimental|ciNPWT|"Prophylactic negative pressure wound dress (Hartmann) is set up for 5 days right after operation.~Continous -90 Hgmm negative pressure mode selected. No change of wound dress until 5 days completed."
9697518|NCT04756219|Placebo Comparator|Control Contact|Participants randomized to this group will read a personal story of a person who survived a heart attack.
9697519|NCT04756219|Placebo Comparator|Control Education|Participants randomized to this group will read a text containing facts about heart-attacks and their prevention.
9697520|NCT04756050|Experimental|corner pocket|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
9697521|NCT04756050|Experimental|corner+intracluster|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) 10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
9778322|NCT01104207|Experimental|Arm 1|Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.
9778323|NCT01104207|Sham Comparator|Arm 2|Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.
10188421|NCT03716687|No Intervention|Traditional wound dressing|Control group with traditional, dry laparotomy wound dressing.
10188422|NCT03716674|Experimental|Parkinson's Disease patients|
10188423|NCT03716661|No Intervention|Control|Arm 1/control group: Participants who are treated with conservative plaster following National Clinical Guidelines.
10188424|NCT03716661|No Intervention|Conservative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 2: Patients randomized to conservative plaster treatment"
10188425|NCT03716661|Other|Operative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 3: Patients randomized to operative treatment (ORIF)"
10188426|NCT03716648|Active Comparator|Subjective titration|After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
10188427|NCT03716648|Experimental|DISE-assisted titration|Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated.
9697522|NCT04756050|Experimental|multi|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
9697523|NCT04756115||CASES|Adults (age<18 years) diagnosed with a first episode of critical limb ischemia revascularized at our center from January 2016 to July 2019.
9697524|NCT04755595|Experimental|Facial aesthetic treatment|Study participants will receive all three injectables: Botox Cosmetic (onabotulinumtoxinA), Juvéderm Voluma XC (hyaluronic acid gel filler), and Juvéderm Volbella XC (hyaluronic acid gel filler) during a single procedure, with an optional touch-up treatment at 2 weeks.
9697525|NCT04755751||Pediatric Pompe patients|A retrospective - prospective study evaluating pediatric patients with Pompe before and 2 days after ERT on multiple occasions and different dosing. Evaluation included cardiopulmonary exercise testing (CPET), 6 minute-walking test (6MWT), motor function test (GMFM-88) and self-collected blood samples (on a Guthrie card) for enzyme blood levels.
9697526|NCT04755608|Experimental|Low Intensity Blood Flow Restriction Group|
9697527|NCT04755608|Active Comparator|High Intensity Resistant Training Group|
10188428|NCT03716648|Experimental|PSG-guided titration|An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced.
10188429|NCT03716635|Experimental|cryotherapy|2.5c cold saline as a final flush after chemicomechanical debridement
9697528|NCT04755647|Experimental|Nitric Oxide-Releasing Solution (NORS)|Five litre foot bath delivery NORS
9697529|NCT04755647|Placebo Comparator|Saline|Five litre foot bath delivery NORS
9697530|NCT04755634|Experimental|Single Arm|This is a prospective, single-arm, single-center study
9697531|NCT04755725|Active Comparator|Epidural Group|epidural catheter inserted pre induction
9697532|NCT04755725|Active Comparator|Rectus sheath catheter Group|rectus sheath catheter inserted by the surgeon at the end of surgery
9697533|NCT04755764||Beta blockade|Beta blocker (labetalol or atenolol) will be given for a cardiac output >8 l/min.
10188430|NCT03716635|Other|normal saline|room temperature saline is used as a final flush after chemicomechanical preparation
9697534|NCT04755764||Nifedipine|Nifedipine will be given for a mean arterial pressure >100.
9697535|NCT04755673|Experimental|Experimental: Atrantil (Medical Food)|All participants in the trial will take two capsules of Atrantil three times a day for 28 days.
9697536|NCT04755686|Experimental|Fast-tracking at geriatric medicine ward|Fast-tracking hip fracture patients at geriatric medicine ward. The goal is to optimize the medical care of older hip fracture patients at a geriatric ward and to shorten the time to operation.
9697537|NCT04755686|No Intervention|Regular admission|Regular admission and care of hip fracture patients at the emergency room prior to surgery.
9697538|NCT04755933|Experimental|Intervention|An online learning tool, designed to helps parents develop a calm, consistent behaviour management style, whilst learning skills to discourage children's avoidance.
9697539|NCT04755933|No Intervention|Control|The participants in the control arm will not receive access to the online course, but will complete the same sets of questionnaires at each of the timepoints.
9697540|NCT04755517|Active Comparator|A1|Frequent information of screening results for cytology and/or HPV DNA at the ages of 25 (cytology only) and 28 (cytology only) vs A2
9697541|NCT04755517|No Intervention|A2|infrequent information of cytological screening/ HPV DNA results, only at the age 28 years.
9697542|NCT04755517|Active Comparator|C|The third arm with at 8000 participants devoid of herd effect protection and frequent screening at ages 25 and 28 is enrolled for comparative analyses between A1 vs. C and A2 vs. C.
9697543|NCT04755556|Other|Experimental group|Intensive bimanual training with routine physical therapy
9697544|NCT04755556|Other|control group|routine physical therapy
9697545|NCT04755621|Experimental|Core stability Group|
9697546|NCT04755621|Active Comparator|Control Group|
9697547|NCT04755738|Experimental|Almonertinib plus Microwave ablation group|Patients in the group were treated with both targeted therapy and microwave ablation. Patients were treated with Almonertinib with the dose of 110mg once daily firstly. When the best response achieved, microwave ablation was conducted in the primary tumors, and then followed by Almonertinib treatments.
9697548|NCT04755738|Active Comparator|Almonertinib group|Patients in the group were treated with Almonertinib with the dose of 110mg once daily until disease progression, death or intolerable adverse events.
9697549|NCT04755543|Experimental|I-A|LP002 dose escalation (3+3 design): 6-12 patients with malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment will receive LP002 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W), for up to 2 year.
10188431|NCT03716622|Active Comparator|bismuth-clarithromycin-containing group|Patients in bismuth-clarithromycin-containing group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 500mg po bid for 14d
9697550|NCT04755543|Experimental|I-B|If the safety profile in Arm A is acceptable, 9-12 patients with malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments will receive LP002 600mg or 900 mg IV on Day 1, Q2W, for up to 2 year.
9697551|NCT04755543|Experimental|I-C|If the safety profile in Arm A is acceptable, 15-20 patients with metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W,for up to 2 year.
9697552|NCT04755543|Experimental|I-D|Perioperative treatment: If the safety profile in Arm A is acceptable, 15-20 patients with gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W, for 3 cycles, 4-6 weeks before operation of the tumor and receive additional 6 cycles of the same therapy 4 weeks after the operation.
9697553|NCT04755543|Experimental|I-E|Dose escalation (3+3 design) of OH2 (an oncolytic virus) + LP002 900mg：If the safety profile in Arm A is acceptable, 15-30 patients with advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments will receive LP002 900mg IV on Day 1, Q2W, and OH2 10^6 or 10^7 or 10^8 CCID50/mL by intra-tumoral injection, Q2W, for up to 2 year.
9697554|NCT04755439|Other|undergoing deep hypothermic cırculatory arrest patients|Difüsıon magnetic rezonans imaging , neuron spesific enolase enzym level , deep hypotermic cırculatory arrest
9697555|NCT04755270|Experimental|vr-supported hypnofertility|Relaxation, visualization, imagination and affirmation and techniques based on the hypnofertility philosophy were applied to women in the experimental group in four stages
9697556|NCT04755270|No Intervention|Control|Any initiative was not applied to the control group
9697557|NCT04755374||Group 1|Discharged from palliative care unit in equal or less than 21 days
9697558|NCT04755374||Group 2: Prolonged discharged in longer than 21 days|Discharged from palliative care unit in longer than 21 days
9697559|NCT04755179||Complex appendicitis without abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis without clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
9697560|NCT04755179||Complex appendicitis with abscess or mass formation|All children (<18 years old) that present with a suspicion of complex appendicitis with clinical or radiological signs of abscess or mass formation. Preoperative suspicion of complex appendicitis is based upon a previously developed clinical scoring system.
9697561|NCT04755322|Active Comparator|hydroxychloroquine group|hydroxychloroquine 400 mg+ Folic Acid 5 mg+ Low-dose aspirin 75 mg
9697562|NCT04755322|Placebo Comparator|Placebo group|Folic Acid 5 mg+ Low-dose aspirin 75 mg+ Placebo oral tablet
9697563|NCT04755296|Experimental|Low level laser therapy and aerobic exercises group|They received low level laser therapy and aerobic exercises using a treadmill, 3 sessions per week for 12 weeks.In addition to traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
9697564|NCT04755296|Active Comparator|Control group (aerobic exercises group)|They received aerobic exercises 3 times weekly for 12 weeks.In addition to the same traditional physical therapy program.
9697565|NCT04755478||Lung lobectomy via open thoracotomy|participants scheduled for lung lobectomy via open thoracotomy
9697566|NCT04755478||Lung lobectomy via VATS|participants scheduled for lung lobectomy via video-assisted thoracoscopic surgery
9697567|NCT04755504|Experimental|EEG evaluation|All patients will be evaluated during 1 night by standard polysomnography and additionally EEG will be evaluated by 2 electrodes behind each ear connected to a recording device (Sensor Dot)
9697568|NCT04755426||Patients with severe aortic stenosis|Adults with severe aortic stenosis who either have faced or are facing a decision about valve replacement (depending on the phase of the research)
9697569|NCT04755426||Health care providers|HCPs who guide decisions about managing AS, including interventional cardiologists, cardiac surgeons and advanced practice providers (APPs), including nurse practitioners and physician assistants.
9697570|NCT04755400|Active Comparator|Potassium Nitrate|4 days treatment with 24 mmol potassium nitrate capsules
9697571|NCT04755400|Placebo Comparator|Potassium Chloride|4 days treatment 24 mmol potassium chloride capsules
9697572|NCT04755309|Experimental|Typical development infants - experimental|Children without familial risk for language disorders, who participate to the rhythmic intervention.
9697573|NCT04755309|No Intervention|Typical development infants - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
9697574|NCT04755309|Active Comparator|Typical development infants - control|Children without familial risk for language disorders, who are exposed to passive auditory stimulation.
9697575|NCT04755309|Experimental|Infants at familial risk - experimental|Children with familial risk for language disorders, who participate to the rhythmic intervention.
9697576|NCT04755309|No Intervention|Infants at familial risk - spontaneous development|No intervention is provided and typical development in children without familial risk for language disorders is evaluated.
9697577|NCT04755387|Other|Ticagrelor 90mg|Standard strategy group receive ticagrelor 90mg twice daily
9778324|NCT01104246|Experimental|Testosterone Transdermal Systems|Testosterone
9778325|NCT01104285||Standard care|Treatment of pleural effusion with diuresis
10188432|NCT03716622|Experimental|bismuth-furazolidone-containing quadruple group|patients in bismuth-furazolidone-containing quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 240mg po bid, and furazolidone (Liteling) 100mg po bid for 14d
9697578|NCT04755387|Experimental|Ticagrelor 60/45mg|De-escalation strategy group receive ticagrelor 60 mg twice daily or 45mg twice daily if patients with body weight <60kg, or age >75 years old.
9697579|NCT04755348|Experimental|Product usage order ABFCED|Subjects will use each of the 6 products (ABFCED) during an familiarization period, followed by a 4 hour Test Session
9697580|NCT04755348|Experimental|Product usage order BCADFE|Subjects will use each of the 6 products (ABECD) during an familiarization period, followed by a 4 hour Test Session
9697581|NCT04755348|Experimental|Product usage order CDBEAF|Subjects will use each of the 6 products (CDBEAF) during an familiarization period, followed by a 4 hour Test Session
9697582|NCT04755348|Experimental|Product usage order DECFBA|Subjects will use each of the 6 products (DECFBA) during an familiarization period, followed by a 4 hour Test Session
9697583|NCT04755348|Experimental|Product usage order EFDACB|Subjects will use each of the 6 products (EFDACB) during an familiarization period, followed by a 4 hour Test Session
10188433|NCT03716596|Experimental|SBRT and PD-1|Stereotactic body radiotherapy, radiation dose is 40-50 Gy in total. Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
9697584|NCT04755348|Experimental|Product usage order FAEBDC|Subjects will use each of the 6 products (FAEBDC) during an familiarization period, followed by a 4 hour Test Session
9697585|NCT04755491||Chloride transfer by continuous veno-venous hemofiltration|Chloride transfer over 24h of continuous veno-venous hemofiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
9697586|NCT04755491||Chloride transfer by continuous veno-venous hemodialysis|Chloride transfer over 24h of continuous veno-venous hemodialysis in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
9697587|NCT04755491||Chloride transfer by continuous veno-venous hemodiafiltration|Chloride transfer over 24h of continuous veno-venous hemodiafiltration in mechanically ventilated ICU patients presenting with stage III AKI according to Kidney Disease: Improving Global Outcome (KDIGO) classification. Chloride concentrations will be measured in the serum, the urine, and the effluent of included patients every 4 to 6h from inclusion to H24.
9697588|NCT04755127|Active Comparator|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
10188434|NCT03716583|Experimental|Melatonin/DMSO|25 mg melatonin in 1 g cream twice daily for the duration of the radiation therapy
9697589|NCT04755127|Experimental|arthroscopic synovectomy|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
9697590|NCT04755166|Experimental|100:0|100 % bone substitute, 0% autogenous bone
9697591|NCT04755166|Experimental|90:10|90% bone substitute, 10% autogenous bone
9697592|NCT04755062|Experimental|Micronutrient-dense plant-rich Intervention|The intervention will consist of a 2-hour 'immersion' group session, followed by weekly 1-hour group sessions over the following 11 weeks. Groups of no more than 15 individuals will meet weekly for 12 weeks with a trained Lifestyle Coach. Group sessions, held at the Twin Arrows Casino, will provide participants with instructions, assistance with goal setting, support, encouragement, cooking demonstrations, Casino (workplace) dining tours, and will socially engage with other participants. Participants will be requested to follow the mNDPR nutrition protocol for the first 12 weeks. Each week the participants will use a simple tracking method to self-monitor their daily compliance with the nutrition protocol. Lifestyle Coaches will monitor adherence and verify attendance. Instructional materials discussed each week will provide resources and methods to overcome common barriers to dietary change including (i) meal prepping, (ii) social gatherings, and (iii) family resistance.
9697593|NCT04755062|Active Comparator|Wait-list Control|Participants in the wait-list control group will be requested to maintain their typical eating patterns during a 12-week waiting period, until they are scheduled to start the intervention 13-weeks later.
9697594|NCT04755218|Experimental|Vaginal Misoprostol|Patients will receive vaginal misoprostol 25 micrograms given every 3 hours for a maximum of 5 doses
9697595|NCT04755218|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
9697596|NCT04755023|Experimental|Treatment Arm|Administration of 6 cycles of chemotherapy
9697597|NCT04754997|No Intervention|Control group|This group will not take any exercise intervention.
9697598|NCT04754997|Active Comparator|Traditional exercise training group|This group will get traditional therapy that is include range of motion exercises and resistance exercise training.
10188435|NCT03716583|Placebo Comparator|Placebo|1 g of cream once daily
9697599|NCT04754997|Experimental|Specific exercise training group|This group will get a specific programme that combinated with closed kinetic chain exercises and core exercises training
9697600|NCT04754906||young neurotypical subjects|people from 18 to 40 years old
9697601|NCT04754906||elderly neurotypical subjects|people over 70 years of age
9697602|NCT04754906||Elderly subjects with mild cognitive impairment|people over 70 years of age, with a diagnosis of mild cognitive impairment
9697603|NCT04754919|Active Comparator|Transition intervention group|Intervention group -will be working with the specialist diabetes transition nurse. The nurse will follow a specific protocol involving visits, clinic support, community support and appointment rearranging. She will also maintain communication with the Hospital based adult and paediatric diabetes teams and the participants General Practitioner and relevant community health care professionals.
9697604|NCT04754919|Placebo Comparator|Post Transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
9697605|NCT04754958|Experimental|VR|In addition to standard care during MRI scan, patient receives VR intervention.
9697606|NCT04754958|No Intervention|No VR|Standard of care during MRI scan.
10188436|NCT03716570|Experimental|Cohort 1: BIIB054 Dose A|Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
10188437|NCT03716570|Experimental|Cohort 2: BIIB054 Dose B|Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
9697607|NCT04754880||non-CTO|This group was defined as no chronic obstruction, except for non-critical stenosis, who underwent coronary angiography with the diagnosis of stable angina pectoris.
9697608|NCT04754880||CTO|This group was defined as the presence of complete occlusion in one artery and no critical lesions (> 50%) in the other arteries undergoing coronary angiography with the diagnosis of stable angina pectoris.
9697609|NCT04754841|Experimental|SURVIVAL AND FUNCTIONALITY INVITRO IN CRYOPRESERVED PLATELETS|Platelet concentrates will be administered 3 alternatives of cryopreservative solution: 5% dimethylsulfoxide (solution 1), 5% dimethylsulfoxide plus 160 mg of 5% dextrose (solution 2) and 5% dimethylsulfoxide plus 2% albumine (solution 3 ). They will then be frozen at -80 ° C and their survival and functionality will be subsequently evaluated in vitro.
9778326|NCT01104285||Chest tube|Treatment of pleural effusion with diuresis and chest tube
9778327|NCT01104311|Experimental|Aggressive BP lowering|Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
9778328|NCT01104311|Active Comparator|Modest BP lowering|Lowering of systolic blood pressure between 130mmHg and 140mmHg
10188438|NCT03716570|Experimental|Cohort 3: BIIB054 Dose C|Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
10188439|NCT03716570|Placebo Comparator|Cohorts 1-3: Placebo|Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
9778329|NCT01104376|Experimental|CYP2B6|"Healthy volunteers will receive Efavirenz and Vericonazole as follow:~In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
9778330|NCT01104402|No Intervention|Standard Care|Subjects will receive education about signs and symptoms indicative of worsening CF.
10188440|NCT03716557|Experimental|Spinal Cord Stimulation 4000Hz|Patients will trial Spinal Cord Stimulation 4000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
10188441|NCT03716557|Experimental|Spinal Cord Stimulation 10000Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
10188442|NCT03716557|Active Comparator|Spinal Cord Stimulation 40Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
10188443|NCT03716544|No Intervention|Waiting list control group|There will be no treatment for 12 months.
10188444|NCT03716544|Experimental|Hearing aid group|Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
10188445|NCT03716544|Active Comparator|Customized music group|Customized music according to participants hearing level will be made available in an iPod. The iPod will deliver ear-specific therapeutic sound for asymmetrical hearing profile. Participants will have to listen to the therapeutic sound at a comfortable volume for two hours daily for 12 months.
9778331|NCT01104402|Active Comparator|Home monitoring|Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
9778332|NCT01104415|Experimental|Telotristat etiprate - Core Phase|Following a 2-week Run-In Period, participants received telotristat etiprate capsules at a starting dose of 150 mg, orally three times daily (TID) for 14 days in the Core Phase. Dose escalations (250 mg, 350 mg, 500 mg) occurred serially every 14 days, up to a maximum dosage of telotristat etiprate 500 mg TID, as guided by specific clinical criteria for dose escalation. Upon completion of 12 weeks of treatment, participants were eligible to receive telotristat etiprate in the optional Open-label Extension Period.
9778333|NCT01104415|Experimental|Telotristat etiprate - Extension Period|Participants received telotristat etiprate at their highest tolerated dose (250 mg or 500 mg), orally, TID for 124 weeks in the Open-label Extension Period. If neither dose was tolerated participants were discontinued from the study and completed the 2-week Follow-up Visit.
9836107|NCT02769247|Experimental|Placebo oral medication/Lidocaine|Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
9836108|NCT02769247|Experimental|Naproxen/Lidocaine|Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
10188446|NCT03716531|Experimental|IORT|"IORT will be administered as determined to be best practice by the treating radiation oncologist,~Electron beam intraoperative radiation therapy will occur in a hybrid operating room with a portable linear accelerator"
10188447|NCT03716518|Experimental|TCM group|Tonifying Spleen and Kidney Sequential Regimen(TSKSR) will be prescribed to the participants in each course of chemotherapy.
10188448|NCT03716518|Placebo Comparator|Placebo group|Placebo of Tonifying Spleen and Kidney Sequential Regimen(TSKSR)similar in color,smell and texture with TSKSR will be prescribed to participants in each course of chemotherapy.
9836109|NCT02769312|Sham Comparator|Sham Stimulation|A sham coil is being used to compare against active coil.
10188449|NCT03716505|Active Comparator|gammaCore Sapphire active|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
10205366|NCT02419976|Experimental|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
10205367|NCT02413801||Psoriasis|Individuals with psoriasis
9697610|NCT04754581|Other|All Participants|
9697611|NCT04754971|Experimental|Table|
9697612|NCT04754945|Experimental|Treatment (isatuximab, chemotherapy)|"All patients will receive Isatuximab plus dexamethasone 4 mg PO/IV days weekly. Based on tolerance, patients will add to their treatment subcutaneous Velcade (earliest time to add Velcade is cycle 1 day 15) and intravenous cyclophosphamide (earliest time to add cyclophosphamide is cycle 4 day 1)~Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month for 12 months in the absence of disease progression or unacceptable toxicity."
9697613|NCT04754620|No Intervention|Standard face to face visit|This group will receive a traditional outpatient visit
9697614|NCT04754620|Experimental|Online visit|This group will receive a smartphone-based real-time video conference visit
9697615|NCT04754724|Experimental|GIMate|Individuals with suspected lactose intolerance who start with GIMate use first
10188450|NCT03716505|Sham Comparator|gammaCore Sapphire Sham|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
9697616|NCT04754724|Active Comparator|H2 Check|Individuals with suspected lactose intolerance who start with H2 Check use first
9697617|NCT04754659|Experimental|Suprarenal|Individuals that are treated with a suprarenal stentgraft for a previously diagnosed AAA.
9697618|NCT04754659|Active Comparator|Infrarenal|Individuals that are treated with an infrarenal stentgraft for a previously diagnosed AAA.
9836110|NCT02769312|Active Comparator|Active Stimulation|An active coil is being used to compare against sham coil.
10188451|NCT03716479|Experimental|0 fiber|0 grams fiber added to orange juice
9697619|NCT04754685|Active Comparator|Mild knee osteoarthritis|30 patients had mild knee osteoarthritis
9697620|NCT04754685|Active Comparator|Moderate knee osteoarthritis|30 patients had moderate knee osteoarthritis
9697621|NCT04754685|Active Comparator|Severe knee osteoarthritis|30 patients had severe knee osteoarthritis
10188452|NCT03716479|Experimental|low fiber|20 grams of acacia gum added to orange juice
9697622|NCT04754737|Other|Prophylactic antibiotic|These patients will receive the current standard of care, which is to receive a single dose of prophylactic antibiotics just prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy. The specific prophylactic antibiotics will vary depending on patient's prior urine culture sensitivities and patient medication allergies/sensitivities and medical comorbidities.
9697623|NCT04754737|Experimental|No antibiotics|These patients will receive no prophylactic antibiotics prior to receiving intravesical injection of Onabotulinumtoxin A via cystoscopy.
9778334|NCT01104493|Experimental|1|Single dose of monovalent vaccine
9778335|NCT01104493|Placebo Comparator|2|Placebo
10188453|NCT03716479|Experimental|high fiber|40 grams of acacia gum added to orange juice
10188454|NCT03716466||Endotracheal intubation|Cases with prophylactic endotracheal intubation during urgent endoscopy procedure for upper gastrointestinal bleeding .
10188455|NCT03716466||No airway intervention|Cases without airway intervention during urgent endoscopy procedure for upper gastrointestinal bleeding
10188456|NCT03716453|Placebo Comparator|Control group|Intraoperative fentanyl administration will be guided by standard protocol
10188457|NCT03716453|Experimental|ANI group|Intraoperative fentanyl administration will be guided by ANI protocol
10188458|NCT03716440|Experimental|Nature group|Nature exposure intervention.
10188459|NCT03716440|Active Comparator|Non-nature group|Non-nature exposure intervention.
10188460|NCT03716427|Experimental|Active Treatment- CT1812 560 mg|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole)
10188461|NCT03716414||Experimental SLN arm|"Experimental SLN arm~Intra-operative sentinel lymph node (SLN) mapping with indocyanine green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceed to a total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy including complete pelvic lymphadenectomy and aortic lymph node dissection.~If only unilateral SLN or non SLN are detected, surgeons will proceed to complete pelvic lymphadenectomy and aortic lymph node dissection."
10188462|NCT03716401||Bari: Biopsy Arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bari site will have an additional renal biopsy at baseline."
10188463|NCT03716401||Bordeaux: MRI Follow-up arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bordeaux site will have an additional ultrasound US and MRI in Follow-up year 2."
10188464|NCT03716401||Exeter: Microvascular arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Participants at the Exeter site will undergo microvascular measurements including estimating glycocalyx thickness at baseline and at 2 years follow-up."
10188465|NCT03716401||Leeds: Microstructure MRI arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection.~Participants at the Leeds' site will have an extended MRI scan at baseline including novel microstructure MRI measurements."
10188466|NCT03716401||Turku: PET arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Turku site will undergo a renal Positron Emission Tomography (PET) scan at the baseline timepoint."
10188467|NCT03716388|Experimental|FMT Vs Placebo|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus placebo granules (4g/day)
10188468|NCT03716388|Active Comparator|FMT Vs Mesalamine|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
10205368|NCT02413801||Healthy|Individuals that are healthy
9697624|NCT04754672|Experimental|Continuous aerobic and resistance exercise (AE+RE)|"Two 60 min moderate-to-high intensity exercise sessions per week supervised by a physiotherapist.~Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Resistance exercise (25 min): 6 exercises targeting large muscle groups vertical row, squat, bench press, pull over, abdominal crunch, and lunge. 2sets of 10 repetitions at 70-80% of 1 RM. To ensure adequate training load over time, tests are repeated every 3 weeks aligned with the chemotherapy cycle.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
9697625|NCT04754672|Experimental|Continuous aerobic and aerobic interval exercise (AE+AI)|"Continuous aerobic exercise: 15-20 min continuous aerobic exercise (e.g. walking) of moderate intensity (Borg 13-14 'somewhat hard').~Aerobic interval (25 min): cycling with high intensity intervals alternated with recovery intervals. Intensity of the interval: between 85% and 95% of estimated maximum heart rate, adjusted to Borg 16-18 'hard - very hard'. In between the intervals, light intensity cycling will be performed for active recovery at 30% of Wmax estimated from Steep ramp test and adjusted to Borg < 12.~One additional (third) session from home at moderate intensity for at least 30 min.~A brochure with exercise guidelines is provided."
9697626|NCT04754672|No Intervention|Usual care control group|Patients in the usual care group receive care as usual. In addition, a brochure with exercise guidelines for cancer survivors is provided
9697627|NCT04754763|Experimental|Propolis|Propolis was applied by disposable micro brush on particular sensitive teeth and left undisturbed for 60 seconds to let it dry. Followup was done at 7th, 15th and 30th day
9697628|NCT04754763|Active Comparator|Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE)|Application of Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE) on sensitive surfaces was applied single coated for 20 seconds, gently applied air for 5 seconds and cured for 10 seconds (as per manufacturer's instructions). Followup was done at 7th, 15th and 30th day
9697629|NCT04754828|Active Comparator|Bedside|The bedside rounding team will perform patient presentations at the bedside, with a focus on the patient, and will ensure nursing involvement when rounding on each patient,
9697630|NCT04754828|Active Comparator|Hallway|The hallway rounding team will present patients outside of the patient's room, without an emphasis on nurse participation.
9697631|NCT04754568|Experimental|Virtual reality instructional design|Completion of virtual reality simulation of an outpatient physical therapy evaluation.
9697632|NCT04754568|Active Comparator|Role-playing instructional design|Completion of traditional role-playing of a scripted outpatient physical therapy evaluation
9697633|NCT04754750|Active Comparator|INVEGA Sustenna|INVEGA Sustenna is a one month long-acting injection (PP1M)
9697634|NCT04754750|Active Comparator|INVEGA Trinza|INVEGA Trinza is a three month long-acting injection (PP3M)
9977896|NCT01366313|Experimental|Paracetamol-morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
9977897|NCT01366326|Experimental|Arm 1|Methylnaltrexone bromide
9697638|NCT04754789|Active Comparator|group for loading with statin before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive two 80-mg loading doses of atorvastatin, the first loading dose will be administered in the Emergency Room before transfer to Cath Lab, the second dose of 80-mg atorvastatin will be administered 24 hours afterthe first dose."
9697639|NCT04754789|Placebo Comparator|group receive the routine guidelines management before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive only the routine management."
9697640|NCT04754867|Experimental|"discontinued-smoker age-progressed"|"Participants in the discontinued smoker age-progressed virtual reality condition will see two rendering of themselves in optimal health twenty years into the future, a frontal and profile view."
9697641|NCT04754867|Experimental|"discontinued-smoker + continued smoking age-progressed"|"Participants in the discontinued smoker + continued smoking age-progressed virtual reality condition will see two frontal renderings of themselves twenty years in the future, one in optimal health and one incorporating appearance-related medical consequences of moderate-heavy smoking over twenty years (e.g., skin that is dry and discolored, increased wrinkles, etc.)."
9697642|NCT04754867|Experimental|Current self virtual reality images|Participants in the current self virtual reality condition will see their present age self in a virtual reality rendering.
9697643|NCT04754464|Active Comparator|synbiotic|synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)
9697644|NCT04754464|Placebo Comparator|microcrystalline cellulose|microcrystalline cellulose
9697645|NCT04754555||subacute phase|between 7 days and 6 months post-stroke;
9697646|NCT04754555||chronic phase|minimum 6 months post-stroke
9697647|NCT04754451|No Intervention|Group P(placebo)|Attach two placebo patches for 12 hours, above and below the incision site.
9697648|NCT04754451|Experimental|Group L(lidocaine patch)|Attach two lidocaine patches for 12 hours, above and below the incision site.
9697649|NCT04754295|Experimental|STANDARD|In this arm standard monitoring of vital signs will be used during operation.
9697650|NCT04754295|Experimental|GDT|A non-invasive hemodynamic monitor STARLINK™SV will be used in addition to standard monitoring.
9697651|NCT04754347|No Intervention|Control|Routine Colonoscopy
9697652|NCT04754347|Experimental|Experimental|Routine Colonoscopy with the use of Skout
9697653|NCT04754126|Experimental|Intervention Group|Educators and students complete a baseline survey. Educators will implement 6 lessons, each 45 minutes, in the classroom. Educators are free to choose the time between lessons, so some can implement all in one week, others can choose to implement once per week. Educators are given a maximum of 6 weeks to implement the curriculum. Educators and students complete a post-program survey. Students complete a 6- and 12-month follow-up survey.
10188469|NCT03716388|Active Comparator|Placebo Infusion Vs Mesalamine|Placebo infusion (colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
9697654|NCT04754126|No Intervention|Control Group|This group will only complete online surveys that match the time when intervention group is complete the surveys. There is a baseline survey and then a post-survey 6 weeks later for both educators and students. Additionally, students will complete a 6- and 12-month follow-up survey.
9697655|NCT04754399|Experimental|Cannabidiol (CBD)|Oral solution given 2x daily.
10188470|NCT03716375|Experimental|use of fibrinolytic agent|Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
10188471|NCT03716375|No Intervention|no use of any drug|Chest tube drainage
10188472|NCT03716362||Neonates who will be admitted at Neonatal Intensive Care Unite|
9697656|NCT04754438|Experimental|e-CBT|12 weekly sessions of approximately 30 slides and interactive content, delivered through OPTT. The e-CBT module content mirrors in-person standard CBT content, including different weekly topics, general information, skill overviews, and homework. Participants are instructed to go through the content and complete homework at the end of the session which helps them practice skills they learned through that session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases.
9697657|NCT04754438|Experimental|Mental Health Coaching|"Weekly interactions with the therapist using general questions on the following topics:~Week 1 (Mood) Week 2 (Sleep) Week 3 (Activity) Week 4 (Hobbies) Week 5 (Friendship) Week 6 (New Events) Week 7 (Job/Study) Week 8 (Diet/Food) Week 9 (Books/Movies/Shows) Week 10 (Phone/Apps/Games) Week 11 (Habits) Week 12 (Accomplishments)"
9697658|NCT04754009|Active Comparator|Treatment as Usual (TAU)|Participants assigned to treatment as usual group are required to see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
9697659|NCT04754009|Experimental|Trauma-Sensitive Yoga + TAU|Participants assigned to the Trauma-Sensitive Yoga group will attend a 1-hour long session of yoga once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
9697660|NCT04754009|Experimental|Chen Style Tai Chi + TAU|Participants assigned to the Chen Style Tai Chi group will attend a 1-hour long session of tai chi once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
9697661|NCT04753944|Active Comparator|Probiotic group|Patients will be introduced for 5 weeks with probiotic therapy (in the study group). They will take Ecologic®Barrier (Winclove Probiotics BV, Amsterdam, The Netherlands), consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58. The probiotic dose is going to be 4 capsules daily (one capsule contains 500 million CFUs of living probiotic strains). The treatment will be administered two times a day, during breakfast and supper. The probiotic formula will be Provided by polish distributor of Winclove products, namely Sanprobi sp. z o. o. sp. k
9697662|NCT04753944|Placebo Comparator|Placebo group|Patients will be introduced for 5 weeks with placebo that consist of maize starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily (one capsule). The treatment will be administered two times a day, during breakfast and supper.
9697663|NCT04753918|Experimental|Novel light delivery methods for photodynamic therapy|High refraction-index contrast medium: Lipiodol injected in the bronchial tree can enhance the treatment extension of the photodynamic therapy
9697664|NCT04754178||Down syndrome|Down syndrome patients and their parents
9697665|NCT04754178||Control group|Healthy children and their parents
9697666|NCT04754048|Experimental|Traumatic wounds|Treatment with negative pressure wound therapy.
9697667|NCT04754048|Experimental|Subacute wounds (e.g., dehisced wounds)|Treatment with negative pressure wound therapy.
9697668|NCT04754048|Experimental|Flaps and Grafts|Treatment with negative pressure wound therapy.
9697669|NCT04753892|Experimental|Arm 1|The 3Sm peptide is conjugated to a mutant diphtheria carrier protein (CRM197) and the resulting challenge agent (3SM2-G-CRM197) will be mixed with a squalene adjuvant before intramuscular administration at Months 0, 1, 2 and 4, at a dosage of 32 micrograms of 3SM2-G-CRM197 and 9.7 micrograms of adjuvant.
9697670|NCT04753866|Experimental|Rehabilitated|Initial lip support condition of the patient when presents himself/herself at the office with indication for full arch implant rehabilitation. Then, the patient is facially scanned before and after the implant surgery.
9697671|NCT04754152|Experimental|TBS Group|On the basis of drug treatment, a course of TBS treatment is performed every three months and 4 courses of treatment a year.
9697672|NCT04754152|Placebo Comparator|Drug Group|Stable doses of cholinesterase inhibitors for the treatment and primary care guidance.Once every 3 months follow-up.
9697673|NCT04754074|Experimental|Behavioral Education and personalized coaching|
9836111|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
10188473|NCT03716336|Other|aerobic exercise|walking on treadmill
10188474|NCT03716336|Other|resistive exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs
10188475|NCT03716323|Experimental|immediate premolar implant with xenograft and allograft|Immediate Implant Placement in Maxillary Premolar zone with grafting the jumping gap using xenograft and allograft
10188476|NCT03716310||septic shock patients|Inclusion criteria of the study were diagnosis of septic shock and a platelet count >150*103/mcL.
10188477|NCT03716245|Experimental|supraclavicular lymph node dissection and raidiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy
10205369|NCT02407808|Active Comparator|THC|Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
9836112|NCT02769442|Experimental|Terumo SurFlash Plus catheter|Patients randomized to the Terumo catheter
10188478|NCT03716245|Active Comparator|supraclavicular area radiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy
10188479|NCT03716232|Active Comparator|Multiple plastic stents|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
9697674|NCT04754308|Other|Patients referred to social nurse|"After obtaining informed consent, the social nurse reviews the online-questionnaire with the patient and performs a lung function examination requiring the patient to blow into a plastic tube. If a patient is identified as having obstructive reduction of lung function, they are offered a referral to a local pulmonary medicine department or GP for further investigation - regardless of whether or not they have a diagnosed or undiagnosed lung disease.~In addition, participants are questioned about their motivation for smoking cessation and are informed of the options for this (in hospital and/or referral to the municipality)."
9697675|NCT04753983|Experimental|Anterior Nucleus of the Thalamus (ANT) Deep Brain Stimulation (DBS)|"Subjects that have undergone DBS placement for treatment of refractory epilepsy will undergo a fMRI scan. During the fMRI, the subject will undergo alternating short periods of their DBS in the on and off state with high- and low frequency settings to measure the brain activation changes induced by the DBS."
10188480|NCT03716232|Experimental|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
10188481|NCT03716219|Other|Healthy Subjects|Healthy control group which received the same exercise training intervention as the experimental group
9697676|NCT04753775|Experimental|22 patients were assigned to Group-A|22 patients were assigned to Group-A
10188482|NCT03716219|Experimental|Subjects with Asthma|Subjects with asthma who received exercise training
10188483|NCT03716206|Experimental|exergames group|The exergames intervention is one hour per day, four or five days per week for three weeks.
10188484|NCT03716206|Active Comparator|conventional group|The conventional group intervention is one hour per day, four or five days per week for three weeks.
10188485|NCT03716193|Experimental|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
10188486|NCT03716193|Experimental|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
10188487|NCT03716193|Experimental|Cohort 3|Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
10188488|NCT03716193|Experimental|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
9697677|NCT04753775|Placebo Comparator|22 patients were assigned to Group-B|22 patients were assigned to Group-B
9697678|NCT04753606|Placebo Comparator|Placebo|once-daily placebo
9697679|NCT04753606|Experimental|obicetrapib 5 mg|once-daily obicetrapib
10188489|NCT03716167|Experimental|Laser Treatment|Summus Laser treatment with infrared light
10188490|NCT03716167|Sham Comparator|Sham treatment|Sham Summus Laser treatment with no infrared light
10188491|NCT03716154|Experimental|SRP and diode laser|In a split mouth design either left or right sites randomly treated by SRP and diode laser as an adjunct
10188492|NCT03716154|No Intervention|SRP alone|The other sites in the other side will be treated by SRP alone
9697680|NCT04753606|Experimental|obicetrapib 10 mg|once-daily obicetrapib
9697681|NCT04753840|Experimental|Experimental A: Drug group+lifestyle intervention|Experimental group A used only one antihypertensive drug (ACEI / ARB, beta blocker, calcium channel blocker, diuretic, etc.) plus lifestyle intervention to control blood pressure.
9697682|NCT04753840|Experimental|Experimental B: RIPC group+lifestyle intervention|The experimental group B received ripc treatment of upper limbs every day plus lifestyle intervention until the end of the follow-up. The treatment time was 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles.
9697683|NCT04753840|Other|Experimental c: lifestyle intervention|The control group take lifestyle intervention to control blood pressure, such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
9697684|NCT04753554|Active Comparator|Conventional group|The patient group that whose oxygenation will be managed by blood gas analysis.
9697685|NCT04753554|Experimental|ORI group|The patient group that whose oxygenation will be managed by ORI values
9697686|NCT04753645|Experimental|HBCC and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
9697687|NCT04753645|Experimental|No HBCC project and no soap|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
9836113|NCT02769442|Active Comparator|BD Insyte Autoguard catheter|Patients randomized to the BD catheter
9977898|NCT01366339|Experimental|Arm 1|Oral methylnaltrexone
9697688|NCT04753645|Experimental|Soap received but no HBCC|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
9697689|NCT04753645|Experimental|Both HBCC project and Soap received|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
9697690|NCT04753580|Experimental|group 1|healthy adult 20-35 years old
9697691|NCT04753580|Experimental|group 2|healthy elderly 65+ years old
10188493|NCT03716141|Active Comparator|Autologous Platelets Rich Plasma|In this group we will be managing diabetic wounds with platelet rich plasma treatment.
10188494|NCT03716141|Active Comparator|Conventional Saline dressing|In this group we will be managing diabetic wounds with normal saline dressing.
10188495|NCT03716128||Low turnover bone disease|PTH<150 pg/ml
10188496|NCT03716128||High turnover bone disease|PTH>300 pg/ml
10188497|NCT03716128||Normal renal function|Patients under examination for prostate cancer
10188498|NCT03716115|Experimental|Colostrum|Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
9697692|NCT04753580|Experimental|group 3|Frail elderly 65+ years old
9697693|NCT04753476|Experimental|Secretome-MSCs (n=24)|This group will be given Covid-19 standard therapy with intramuscular Hypoxic S-MSC secretome
9697694|NCT04753476|Other|Control (n=24)|This group will receive standard Covid-19 therapy with the best supportive care
9697695|NCT04753723|Experimental|Platform wound device with antibiotic|Antibiotic cream will be applied to study wounds and then dressed with the platform wound device.
9697696|NCT04753723|No Intervention|Standard of Care|Study wounds will be treated per the standard of care.
9697697|NCT04753801|Experimental|Best Possible Self (writing only)|Participants are asked to think and write about their best possible future self (15 min).
9697698|NCT04753801|Experimental|Best Possible Self (writing+imagining)|Participants are asked to think and write about their best possible future self (15 min) and, then to imagine their positive future (5 min).
9697699|NCT04753801|Experimental|Best Possible Self (writing+mindfulness)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief mindfulness sequence (5 min).
9697700|NCT04753801|Experimental|Best Possible Self (writing+recall)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief recall imagination task about the past two days (5 min).
9697701|NCT04753801|Active Comparator|Writing about the past|Participants are asked to think and write about activities of the past two days (15 min).
9697702|NCT04753515|Active Comparator|Group DMR|dexmedetomidine combined with midazolam and remifentanil.
9697703|NCT04753515|Active Comparator|Group PMR|propofol combined with midazolam and remifentanil.
9697704|NCT04753736|No Intervention|No recurrent implantation failure|
9697705|NCT04753736|Experimental|Recurrent implantation failures|
9697706|NCT04753736|Experimental|Recurrent miscarriage|
9697707|NCT04753632||Cerebral palsy patients and caregivers|Cerebral palsy patients and caregivers
10188499|NCT03716115|Experimental|GInNAC|N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
9697708|NCT04753632||Healthy people and their caregivers|Healthy people and their caregivers
9697709|NCT04753489|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
9697710|NCT04753489|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
10188500|NCT03716115|Experimental|Teduglutide|Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
10188501|NCT03716115|Experimental|Budenoside|Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
10188502|NCT03716115|No Intervention|Standard care|Standard care following WHO guidelines for management of SAM.
10188503|NCT03716102|Experimental|Svelte DES|Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug
10188504|NCT03716089||Group A (Study group)|Group for laparoscopic resection of GIST with unfavorable group (Unfavorable group)
10188505|NCT03716089||Group B (Control group)|Group for laparoscopic resection of GIST with favorable group (favorable group)
10188506|NCT03716063|Experimental|test group|The test group will oral Jianpi Huatan dispensing granule , once a day in the morning and evening, once a month for a course of treatment, a total of three courses.
10188507|NCT03716063|Placebo Comparator|control group|The control group will oral drug:low-dose control granules (containing 1/10 of the dose of the experimental group) , once a day in the morning and evening, once a month for a course of treatment, a total of three courses
10188508|NCT03716037|Experimental|Physical Activity|Physical Activity for Life (PAL) is an 8-week exercise program, meeting three times per week for one hour sessions.
9697711|NCT04753619|Experimental|Niclosamide group: NCS group|NCL + standard therapy
9697712|NCT04753619|No Intervention|Control group|Control group
9697713|NCT04753567|Experimental|Actual pain patch|
9697714|NCT04753567|Placebo Comparator|Sham patch|
9697715|NCT04753463||Residents of Ophthalmology working on COVID-19 departments|Residents of ophthalmology working on COVID-19 departments and dealing with SARS-CoV-2 positive patients
10188509|NCT03716037|No Intervention|Contact Control|those in the attentional contact control group will receive a phone call from research personnel three times per week asking them about their physical exercise routines.
10188510|NCT03716011|Other|DAPT 3M or DAPT 12M|After stent implantation in DAPT 3M or DAPT 12M
10188511|NCT03715998|Experimental|Group 1: firibastat 50 mg|Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.
10188512|NCT03715998|Experimental|Group 2: firibastat 250 mg|Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.
10188513|NCT03715998|Active Comparator|Group 3: ramipril 2.5 mg|Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.
10188514|NCT03715972||Anemia Observation|The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients. Diamox (acetazolamide) will be administered during MRI.
10188515|NCT03715972||Anemia Intervention|"Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose.~non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop."
10188516|NCT03715972||Healthy Controls|40 control subjects recruited from first degree relatives of the sickle cell disease population. Diamox (acetazolamide) will be administered during MRI.
10188517|NCT03715920|Active Comparator|High Voltage Pulsed Galvanic Current|HVPG current is a new form of neuromuscular electrical stimulation.The total output voltage of the device ranged from 0 to 500 volts and the current intensity was increased until the sensible contraction of the applied muscle was achieved without causing too much sense of discomfort
10188518|NCT03715920|Placebo Comparator|Russian Current|"Russian currents are a high frequency current of 2500 Hz and reduce the resistance of the skin and it would penetrate deeper and reach deeper motor nerves.Russian movement, a protocol developed by Kots, also known as Russian Technique, was used in the literature. There were 10 muscle contractions per treatment session in this protocol. Each contraction lasted for 10 seconds and a resting time of 50 seconds were given for the next contraction (transition: rest ratio was 1/5)."
10188519|NCT03715920|Sham Comparator|Isometric Exercise|"Isometric or static strength training is exercises performed without joint movement and changing muscle length during muscle contraction.~The body and knee of the participants in the isometric exercise group were positioned and stabilized at 75 ° flexion and 60 ° flexion angle, respectively as in the stimulation groups. Participants were asked to do 10 repetitions as 10 seconds of maximum voluntary contractions and 10 seconds of rest."
10188520|NCT03715907|No Intervention|Control: W34|Members receiving the Control intervention for the W34 (3- to 6-year-old well visit) gap will not receive a mailer.
10188521|NCT03715907|Experimental|Information only: W34|Members receiving the Information Only intervention for the W34 care gap will receive a mailer informing them of that gap, but not of financial incentives for closing the care gap.
10188522|NCT03715907|Experimental|Incentives: W34|Informational W34 mailer and incentive to close gap
10188523|NCT03715907|No Intervention|Control: LSC|Members receiving the Control intervention for the LSC (lead screening in children) gap will not receive a mailer.
10188524|NCT03715907|Experimental|Information only: LSC|Informational LSC mailer and incentive to close gap
10188525|NCT03715907|Experimental|Incentives: LSC|Members receiving the Incentives intervention for the LSC care gap will receive a mailer informing them of the gap and eligibility for a gift card if they close the gap.
10188526|NCT03715907|No Intervention|Control: IMA|No mailer for IMA (immunizations) gap
10188527|NCT03715907|Experimental|Information only: IMA|Informational IMA mailer
10188528|NCT03715907|Experimental|Incentives: IMA|Informational IMA mailer and incentive
10188529|NCT03715907|No Intervention|Control: CDC|No mailer for CDC (clinical diabetes care) gap
10188530|NCT03715907|Experimental|Information only: CDC|Informational CDC mailer
10188531|NCT03715907|Experimental|Incentives: CDC|Informational CDC mailer and incentive
10188532|NCT03715907|No Intervention|Control: CCS|No mailer for CCS (cervical cancer screening)
10188533|NCT03715907|Experimental|Information only: CCS|Informational CCS mailer
10188534|NCT03715907|Experimental|Incentives: CCS|Informational CCS mailer and incentive
10188535|NCT03715907|No Intervention|Control: AWC|No mailer for AWC (adolescent well-care visit) gap
10188536|NCT03715907|Experimental|Information only: AWC|Informational AWC mailer
10188537|NCT03715907|Experimental|Incentives: AWC|Informational AWC mailer and incentive
10188538|NCT03715894||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 aortic transcatheter valve Implantation, who are with a high risk for PPI
10188539|NCT03715881|Active Comparator|Oral prednisolone administration|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
10188540|NCT03715881|Active Comparator|Intravenous Erythropoietin injection|2. 1000 units of erythropoietin every 12 hours for three days
10188541|NCT03715868|Active Comparator|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
10188542|NCT03715868|No Intervention|Milked derived protein source formula diet|Formula diet based on a milked derived protein source
10188543|NCT03715842|Experimental|Tub shaped design|The tub-shaped preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
10205370|NCT02407808|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
9697716|NCT04753463||Residents of Ophthalmology working on general ophthalmic departments|Residents of Ophthalmology working on general ophthalmic departments and not dealing with SARS-CoV-2 positive patients
9697717|NCT04753333|Experimental|Experimental|The participants in the experimental group will receive Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for four weeks.
9697718|NCT04753333|Placebo Comparator|Control|The participants in the experimental group will receive Sham EMG-BF guided isometric quadriceps strengthening without patellar taping five days a week for four weeks.
10188544|NCT03715842|Active Comparator|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
9697719|NCT04753346||Mild Disease|Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.
9697720|NCT04753346||Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO2 ≥ 90% on room air
9697721|NCT04753346||Severe Pneumonia|Patients with clinical signs of pneumonia (fever, cough, dyspnoea,fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 < 90% on room air.
9697722|NCT04753346||Critical Disease|Patients have one of the following: acute respiratory distress syndrome; sepsis; or septic shock.
9697723|NCT04753307||Patients at least 45 years at-risk for cardiovascular complications|
9697724|NCT04753281|Other|Lifestyle counselling|Participants will receive an assessment appointment and up to 8 follow up sessions with a Health Psychologist to help them set goals and monitor changes of their own self management behaviour.
9697725|NCT04753281|No Intervention|Treatment as usual|Treatment as usual
9697726|NCT04753151|Experimental|Tranexamic acid|Patients scheduled for liver transplantation and allocated for treatment with tranexamic acid (Group 1).
9697727|NCT04753151|Placebo Comparator|Placebo|Patients scheduled for liver transplantation and allocated for treatment with placebo (Group 2).
9697728|NCT04753112|Experimental|Treatment|"All the subjects will receive sacubitril/valsartan from weeks 6 to 12. From weeks 1-6 and 12-18 patients will be treated with standard therapy for HFpEF according to PA pressures (diuretics and systemic vasodilators if concomitant hypertension).~All the subjects will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).~Device: Patients eligible for this study are those with an already implanted CardioMEMS device.~Drug: Sacubitril/Valsartan Target dose:97/103mg bid"
9697729|NCT04753203|Experimental|A single arm study with Alpelisib plus Capecitabine|A phase lb/ll, open label, single arm study with Alpelisib plus Capecitabine in patients with PIK3CA mutant metastatic colorectal cancer
10188545|NCT03715816|No Intervention|No breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory.
9697730|NCT04753398|Experimental|Telemonitoring group|Additional telemonitoring devices: Blood Pressure Monitor, medication dispenser, telemonitoring technology
9697731|NCT04753398|No Intervention|Control group|usual care, without telemonitoring
9697732|NCT04752982|Active Comparator|c-SIGHT intervention|Grasp, lift and balance three wooden rods of different lengths.
9697733|NCT04752982|Sham Comparator|c-SIGHT attentional control|Grasp and lift three wooden rods of different lengths from one end only (no attempt to balance rods).
9697734|NCT04753034|Experimental|TER-101|BID (twice daily) application
9697735|NCT04753034|Placebo Comparator|Vehicle|Vehicle ointment, BID (twice daily) application
9697736|NCT04752995|Other|high tibial osteotomy|Under general anesthesia, a one-cm vertical skin incision was done at the medial subcutaneous border of the tibia, one fingerbreadth below the tibial tuberosity. This was confirmed by intra-operative C-arm images. Longitudinal periosteal incision was done with minimal dissection. Incomplete medial transverse osteotomy including both anterior and posterior cortex was performed using drill bit or small thin osteotome.Osteotomy was completed manually by osteoclasis of the lateral cortex to provide postoperative stability by the preserved lateral periosteum. No fibular osteotomy was needed in the present study.
9697737|NCT04753125|Active Comparator|compliance treatment|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance for 3, 6. 9 and 12 months
9697738|NCT04753125|Active Comparator|compliance for blood test|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance, follow-up via a game in a smartphone app through an interactive game with stimuli to pass the phase as the treatment was completed and blood tests were performed in 3,6,9 and 12 months.
9697739|NCT04753125|Placebo Comparator|demographic socio-economic and sexuality questionnaire|Questionnaire applied to all patients with positive VDRL
9697740|NCT04753073|Experimental|NIPP|Treatment of the NIPP group with physical low-temperature plasma, subsequently within 8 weeks LEEP-Exzision
9697741|NCT04753073|No Intervention|Controll|LEEP-Exzision
9697742|NCT04753021|Experimental|Exercise|Progressive exercise training
9697743|NCT04753177|Experimental|Neoadjuvant combined hormone therapy|Ribocyclib, fulvestrant, triptorelin
9697744|NCT04753177|Active Comparator|Chemotherapy (the control)|doxorubicin, cyclophosphamide, paclitaxel
9697745|NCT04753099|Experimental|Intervention|Receives occupation-based coaching via telehealth
9697746|NCT04753099|No Intervention|Control|No intervention Will receive the occupation-based coaching via telehealth after the 12-weeks
9697747|NCT04753190|Placebo Comparator|Dim Room Light Control|Participants in the dim room light control group will not receive any bright light exposure.
9697748|NCT04753190|Experimental|Morning Bright Light Only (MBL)|"Participants in the morning bright light (MBL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive mornings in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
10188546|NCT03715816|Experimental|Passive breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they can have a rest.
10188547|NCT03715816|Experimental|Active breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they will be performing some mobilisation exercises for the back, shoulder, and neck.
10188548|NCT03715777|Experimental|BoNTA Injection|"Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.~Name of each active substance (INN or proposed INN if available):~Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U"
10188549|NCT03715738|Experimental|arm 1 : Creaform3D + MyotonPRO|"A clinical questionnaire is completed by the investigator (chest circumference, thorax turn, breast measurements).~The breast density is assessed by the surgeon and scored from 1 to 5 (Likert scale) and then by the MyotonPRO The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair during 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~Intraoperatively, the weight of tissues removed is weighed (in grams), recorded in the observation notebook.~In post-operative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete"
9697749|NCT04753190|Experimental|Afternoon Light Only (ABL)|"Participants in the afternoon bright light (ABL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive afternoons in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
9697750|NCT04753190|Experimental|Morning + Afternoon Light (MBL+ ABL)|"Participants in the morning bright light + afternoon bright light (MBL+ ABL) group will receive bright light from 2 light boxes on 3 consecutive days in the laboratory. The morning exposure will be 1.5 h and the afternoon exposure will be 1.5 h. Bright light exposures will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
9697751|NCT04753008|Experimental|Dopamine group|Cardiac surgery patients receiving dopamine to support their cardiac function (as part of the routine post-operative care).
9697752|NCT04753008|No Intervention|Control group|Cardiac surgery patients receiving no positive inotrope drug.
10188550|NCT03715725||Registry cohort|Registries in Norway are nation-wide and provision of the information is mandatory, which eliminates the risk of both selection and re-call bias. The large and detailed dataset also makes it possible to adjust for other risk factors on which information is available.
10188551|NCT03715725||Electronic Medical Records (EMR) cohort|Patients with NVAF diagnosis will be identified through extraction of patient-level data from EMRs from a number of hospitals in Norway, in order to describe these patients more closely regarding their clinical characteristics that are not available in nation-wide registers (e.g., in-patient treatments, anthropometric data and laboratory test results).
10188552|NCT03715712|Experimental|Standard|Standardized blood pressure management with a target of mean blood pressure greater than 65mmHg and systolic blood pressure lower than 160mmHg
9697753|NCT04753138|Experimental|SCT with BC sealer|The teeth will be obturated with the single cone technique and BC sealer
9697754|NCT04753138|Active Comparator|WVC with AH+ sealer|The teeth will be obturated with warm vertical compaction and AH+ sealer
9697755|NCT04753294|Experimental|Avance Solo NPWT System|Treatment with negative pressure wound therapy for Venous leg ulcers, Diabetic foot ulcers, and Pressure ulcers.
9697756|NCT04753294|Experimental|Avance Solo Adapt NPWT System|Treatment with negative pressure wound therapy for Pressure ulcers.
9697757|NCT04752943|Experimental|Children and caregivers receiving TipsByText messages|
9697758|NCT04752943|No Intervention|Children and caregivers not receiving TipsByText texts|
9697759|NCT04752787|Experimental|Experimental|Experimental group 1: Breastfeeding training for successful breastfeeding in twin babies will be given to the online training group. The training will be carried out by the researchers (DM) and (SYC) using visual training tools (power point presentation, simultaneous breastfeeding animations in twin babies and breastfeeding guide). Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. In the first session, about 45 minutes of online slide-assisted training on successful breastfeeding in twin babies and the importance of breast milk will be conducted and questions of pregnant women will be answered. Total training will take approximately one and a half hours.
9697760|NCT04752787|Active Comparator|Active comparator|"Experimental group 2: Breastfeeding training for successful breastfeeding in twin babies will be given to the QR supported online training group. Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. Total training will take approximately one and a half hours.~In the guideline, there will be 4 vieos ralted to Breastfeeding and Feeding with Breast Milk in Twin Babies, Breastfeeding Techniques and Positions in Twin Babies, Expressing Breastfeeding, Storing and Feeding it to Babies and Problems Encountered in Breastfeeding and its Solutions, and simultaneous breastfeeding used in breastfeeding twin babies and also there will be a total of 7 QR codes, 3 of which are related to the animations (Animation 1-2-3) of the positions (double cradle grip, double football grip, combination of armpit and cradle grip-parallel grip)."
9697761|NCT04752787|No Intervention|Control Groups|Pregnant women in the control group will be followed up in line with the routine health monitoring and information of the hospital.
9697762|NCT04752917|Experimental|Intervention|Headphones
9697763|NCT04752917|No Intervention|Control|Standard of care
9697764|NCT04753060|Active Comparator|Waxing|Waxing of patients donor site who are undergoing a skingraft procedure, prior to surgery taking place.
9697765|NCT04753060|No Intervention|Standard care|Standard wound preparation
10188553|NCT03715712|Active Comparator|Individualized|Individualized blood pressure management of 20% within the preoperative ward blood pressure
9697766|NCT04752930|Experimental|ctDNA monitoring|ctDNA monitoring will be performed at protocol-specified intervals and requirement
9697767|NCT04752930|Active Comparator|Imageology (SOC)|Imaging examination will be performed at protocol-specified intervals and requirement
9697768|NCT04752839||Exposed Workers|Workers who have been exposed during COVID 19 pandemic.
9697769|NCT04752709|Experimental|Active Group A|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.
9697770|NCT04752709|Active Comparator|Active Group B|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.
9697771|NCT04752891|Experimental|AOM diagnosis with app|
9697772|NCT04752891|Other|AOM diagnosis without app|
9697773|NCT04752969||Hypothyroidia|20 subjects diagnosed with hypothyroidism
9697774|NCT04752969||Hyperthyroidia|20 subjects diagnosed with hyperthyroidism
9697775|NCT04752969||Healthy|20 age-matched healthy control subjects
9697776|NCT04752683||Organisation 1|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
9697777|NCT04752683||Organisation 2|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
9697778|NCT04752800|Experimental|active tDCS|"Participants will receive 10 ETCC sessions, for 20 minutes, on alternate days (3 times a week). The electrodes will be positioned on the primary motor cortex (position C3 or C4 according to the international electroencephalogram system - EEG 10/20), with the anode positioned on the affected hemisphere and the cathode on the supraorbital region in the hemisphere contralateral to the injury. The electrodes will be wrapped with sponges of 5 x 7 cm and moistened with saline (NaCl 0.9%).~The current intensity will be defined based on computational modeling, using the patient's magnetic resonance as a basis, in order to estimate and individualize the dosage to be administered."
9697779|NCT04752800|Sham Comparator|Sham tDCS|The protocol for placebo stimulation will be identical, but the device will stop emitting current 30 seconds after the start of stimulation.
9697780|NCT04752592|Experimental|SeroSelectTB|The participants in this arm, after providing informed concent, will be tested using the SeroSelectTB rapid assay.
9697781|NCT04752592|No Intervention|Standard of Care|The participants in this arm, after providing informed consent, will receive the established standard of care.
9778336|NCT01104545|Experimental|Panel A - Healthy|Healthy participants receive single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast except for Period 3. Period 3 dose was administered after the ingestion of a high-fat breakfast.
9778337|NCT01104545|Experimental|Panel B - Healthy|Healthy participants receive single oral dose of MK-3614 0.5 mg. 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast
9778338|NCT01104545|Experimental|Panel C - Hypertensive|Hypertensive participants receive single oral dose of MK-3614 0.75 mg. 0.5 mg. 0.75 mg, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing period. All doses were administered after an 8-hour fast
9778339|NCT01104584|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) [0.1 ml/kg bw] as an intravenous injection (i.v.) at a rate of 2 ml/sec. Unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.
9778340|NCT01104636||Single group prospective treatment cohort (varenicline)|
9778341|NCT01104662|Experimental|Daptomycin, Bacteremia, Severe Renal Impairment|Cohort 1. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with Creatinine Clearance (CLcr) below 30 milliliters per minute (mL/min) and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 14 to 42 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 14 to 42 days based on disease resolution or Investigator discretion.
9778342|NCT01104662|Active Comparator|Vancomycin or SSP, Bacteremia, Severe Renal Impairment|Cohort 1. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by Methicillin-Susceptible Staphylococcus Aureus (MSSA) could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered intravenously (IV) until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
9778343|NCT01104662|Experimental|Daptomycin, Bacteremia, Moderate Renal Impairment|Cohort 2. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 14 to 42 days based on disease resolution or Investigator discretion.
9784994|NCT01239732|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first). Participants will receive paclitaxel 175 mg/m^2 IV on Day 1 every 3 weeks or 80 mg/m^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first).
9784995|NCT01239745||1|
9784996|NCT01239797|Active Comparator|Lenalidomide + Dexamethasone|
9697782|NCT04752852|Experimental|Dexamethasone|Patients with odd numbers were assigned to group A. 8 mg/2 ml dexamethasone was injected intravenously sixty minutes before the induction of anaesthesia
9697783|NCT04752852|Placebo Comparator|Placebo|Patients with even numbers were assigned to group B. Two millilitres (ml) normal saline (0.9%) was given intravenously 60 minutes before the induction of anaesthesia.
9697784|NCT04752813|Experimental|BPM31510, Vitamin K1, RT and TMZ|"Subjects will receive a BPM31510 96hr infusion once weekly for 8 wk. Prophylactic Vitamin K1 at a recommended dose of 10 mg will be given intramuscular (IM) to all subjects prior to the beginning of each week of therapy.~After 2 wk of treatment with BPM31510, subjects will start concurrent standard RT and TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment."
9697785|NCT04752631|Experimental|TNK-tPA|TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.
9697786|NCT04752631|No Intervention|Routine Therapy|Patients will be treated with standard of care in compliance with guidelines for acute stroke
9697787|NCT04752657|Experimental|Experimental Group|The experimental group will receive the physical function survey at weeks 2, 10, 18, and 26; the physical activity survey at weeks 2, 14, and 26; the events survey at weeks 2, 6, 10, 14, 18, 22, and 26. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
9697788|NCT04752657|Active Comparator|Control Group|The control group will receive the physical function survey at weeks 0, 8, 16, and 24; the physical activity survey at weeks 0, 12, and 24; the events survey at weeks 0, 4, 8, 12, 16, 20, and 24. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
9697789|NCT04752410|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
9697790|NCT04752956|Active Comparator|Grup1|Nasal steroid spray only (NS) (Each dose contains 27.5 micrograms of fluticasone furoate; administered single dose per day as 1 puff through both nostrils)
9697791|NCT04752956|Active Comparator|Grup 2|NS + administered ambient temperature normal saline (NSS) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (NSS; 0,09% NaCl, pH:4-5)
9697792|NCT04752956|Active Comparator|Grup 3|NS + administered ambient temperature hyaluronic acid (HA) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (Nasorinse plus pediatric® Ingredients: water, sodium chlorine, sodium bicarbonate, and HA; pH balanced)
9697793|NCT04752644|Experimental|Group1: MVA-BN-RSV|"Participants will receive one intramuscular injection of MVA-BN-RSV (nominal titre 5 x 10*8 Inf.U per 0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
10188554|NCT03715699|Experimental|Group 1|Patients treated with single glucocorticoid
10188555|NCT03715699|Experimental|Group 2|Patients treated with Leflunomide and glucocorticoid
10188556|NCT03715673||Cases:Active IBD patients|23 patients with active inflammatory bowel disease for whom von willlebrand antigen and activity will be done
9697794|NCT04752644|Placebo Comparator|Group 2: Placebo|"Participants will receive one intramuscular injection of Tris-Buffered-Saline (0.5 mL) given on day -28 before RSV challenge on day 0.~On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants"
9697795|NCT04752280|Experimental|Arm A: Proton irradiation|Irradiation applied with protons
9697796|NCT04752280|Active Comparator|Arm B: Photon IMRT|Photon irradiation applied as intensity-modulated radiotherapy
9697797|NCT04752579|Experimental|Pilates exercise program|Participants allocated to this group will receive a 10-week Pilates exercise program with each session having a duration of 45'.
9697798|NCT04752579|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home-based general exercise sheet
9697799|NCT04752423||PATIENT group|Adult patients shedule for general anesthesia
9697800|NCT04752423||NURSE group|Nurse anesthesist in charge of the corresponding patient
9697801|NCT04752436|Experimental|Supra high intensity interval training|The experimental group will engage in the high intensity interval training.
9697802|NCT04752267|Experimental|Diagnostic (18F-FMAU, PET/CT, mpMRI)|Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.
9697803|NCT04752306||residents|"10 residents~Minimum 1x > 1week had experience with incontinence material~MMSE score >23~good verbal communication"
9697804|NCT04752306||healthcare workers|8 healthcare workers working in setting, no exclusion criteria
9697805|NCT04752306||policymakers|2 policymakers responsible for the purchase of incontinence material
10188557|NCT03715673||Control:Inactive IBD patients|23 patients with inactive inflammatory bowel disease; VWF antigen and activity will be done for them
10188558|NCT03715660|Experimental|Xpert monitor- evaluated patients|Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.
9697806|NCT04752319|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
10205371|NCT02367105|Active Comparator|Testosterone plus Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training
10205372|NCT02367105|Placebo Comparator|Placebo plus Lifestyle Therapy|Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training
9697807|NCT04752319|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
10205373|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
9697808|NCT04752605|Experimental|Intervention|play sessions included as a part of normal early childhood education; parents' evening for all parents; parents' group for the parents of children that have difficulties in self-regulation and that are offered more individualized small group activity
9697809|NCT04752605|No Intervention|Control|normal early childhood education
9697810|NCT04752462|No Intervention|Standard of Care with provider|Participant will continue follow up for sleep apnea with provider.
9697811|NCT04752462|Experimental|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
9697812|NCT04752748||Woman with Early Rheumatoid Arthritis|
9697813|NCT04752384|Experimental|Drug Treatment|The main objective of this study is to provide preliminary evidence that FDA approved dose of transdermal buprenorphine in conjunction with oral tramadol can provide adequate analgesia of radiation-induced mucositis pain during treatment and follow up period in head and neck cancer patients.
9697814|NCT04752163|Experimental|Cohort A and B (DS-1594b)|Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9697815|NCT04752163|Experimental|Cohort C (DS-1594b, venetoclax, azacitidine)|Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9697816|NCT04752163|Experimental|Cohort D (DS-1594b, mini-HCVD)|Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.
9697817|NCT04752163|Experimental|Drug-Drug Interaction (DS-1594b, posaconazole, voriconazole)|Patients receive DS-1594b PO BID on days 1-8 and 19-28, and posaconazole PO BID on day 9 and QD on days 10-18 or voriconazole PO BID on days 9-18 in the absence of disease progression or unacceptable toxicity.
9697818|NCT04752163|Experimental|Food-Effect (DS-1594b)|Patients receive DS-1594b PO BID on days 1-8 within 30 minutes after eating a standard meal and PO BID on days 9-15 under fasting conditions in the absence of disease progression or unacceptable toxicity.
9697819|NCT04752163|Experimental|Phase I (DS-1594b)|Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
9697820|NCT04752176||Tinnitus group|At least 20 patients suffering from tinnitus will be enrolled in the study.
10188559|NCT03715647||Sepsis|"The puerperal / postpartum women who evolved with sepsis, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
9697821|NCT04752176||Hyperacusis group|At least 20 patients suffering from hyperacusis will be enrolled in the study.
9697822|NCT04752345|Active Comparator|Control group|Pharmacoinvasive strategy, fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early invasive strategy (in case of successful fibrinolysis)
9697823|NCT04752345|Experimental|Experimental group|Reduced-dose fibrinolysis combined with immediate invasive therapy
10188560|NCT03715647||HELLP Syndrome|"The puerperal / postpartum women who evolved with HELLP syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
9697824|NCT04752241|Experimental|IMAP|Inferior Mesenteric Artery Preservation Performing left hemicolectomy and anterior rectal resection the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
10205374|NCT02352948|Active Comparator|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
10205375|NCT02352948|Experimental|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
10205376|NCT02352948|Active Comparator|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
9697825|NCT04752241|Active Comparator|IMAS|Inferior Mesenteric Artery Ligation Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
9697826|NCT04752046|Active Comparator|obturator group|patients with resected maxillary defects were managed with surgical obturator
9697827|NCT04752046|Active Comparator|scapular flap group|
9697828|NCT04752228|Experimental|ACE Screen|"At the initial visit, the Philadelphia ACE Survey, a validated ACE questionnaire, will be administered by a research coordinator. A Lifestyle Assessment package will also be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire. Patients who test positive for ACE will receive a 3-page printed ACE Resource Pack.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
9697829|NCT04752228|Other|Lifestyle Assessment|"At the initial visit, no Philadelphia ACE Survey will be administered. The Lifestyle Assessment packaged will be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
9697830|NCT04752059|Experimental|T-DXd 5.4 mg|Single arm phase II trial
9697831|NCT04752202|Experimental|Test group (group A)|The women were randomly assigned to group A. Test group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
9697832|NCT04752202|Other|Control group (group B)|The women were randomly assigned to group B. Control group included 50 women aged 18-65 years with previously diagnosed Hashimoto's disease and obesity. Hashimoto's disease (AITD) was diagnosed by a specialist based on the ultrasound image characteristic of AITD and high levels of anti-thyroid antibodies.
9697833|NCT04752020|Experimental|Netarsudil use|Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance
9697834|NCT04752111|Experimental|Group E (esmolol infusion)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .
9697835|NCT04752111|Placebo Comparator|Group T (TAP block)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.
9697836|NCT04751994|Experimental|Iron supplement/ ferrous sulphate syrup|administration of daily iron drops, 1.5mg/kg/day iron as ferrous sulphate
9697837|NCT04751994|Placebo Comparator|supplement with placebo|administration of daily placebo drops
9697838|NCT04751981|Experimental|Patient Specific Guide|Patients randomized into this group will have pedicle screws placed with the aid of patient specific surgical guides.
9697839|NCT04751981|Other|Navigation|Patients randomized into this group will have pedicle screws placed with conventional navigation.
9697840|NCT04751838||Survivor cohort; Non-survivor Cohort|All patients were categorized according to the state of departure from the hospital, named survivor or non-survivor.
10188561|NCT03715647||Respiratory Distress Syndrome, Adult|"The puerperal / postpartum women who evolved with Adult Respiratory Distress Syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
10188562|NCT03715634|Experimental|Depot buprenorphine (INDV-6200)|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive depot buprenorphine
9697841|NCT04751838||Training Cohort, Validation Cohort|the eligible patients randomly (7:3) into training cohort and validation cohort. The training cohort were used to build nomogram model, while the validation cohort validated the model.
9697842|NCT04751955|Experimental|Olinvacimab plus Capecitabine|A single arm study with Olinvacimab plus Capecitabine
10188563|NCT03715634|Placebo Comparator|Placebo|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive volume-matched placebo
10188564|NCT03715608|No Intervention|Control group|Patients in the control group received routine TKA surgery and perioperative management without any other interventions.
9697844|NCT04751760||People with sensitization or allergy|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
9784997|NCT01239797|Experimental|Lenalidomide + Dexamethasone +Elotuzumab|
10188565|NCT03715608|Experimental|Intervention group|The patients in the intervention group received professional psychological interventions include psychological counseling and corresponding medication after the operation. Other perioperative treatments were the same as the patients in the control group. Psychotherapy was based on the clinical expertise of the psychosocial specialist, who selected the most appropriate plan for each patient.
10188566|NCT03715595|Experimental|SSDM group|The patients in will use the SSDM at home every month for one year.
10188567|NCT03715595|No Intervention|Control group|The patients will receive the conventional therapy for half a year. After half a year, all the patients will use the SSDM at home monthly for half a year.
10188568|NCT03715582|Experimental|trimetazidine|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours before the procedure.
10188569|NCT03715582|Experimental|placebo|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When randomized to the placebo oral tablets group, the patient will receive placebo (orally, 2 single dose tablets) also 2 hours prior to PCI.
10188570|NCT03715569||Cohort with CNS infections|"Otoacoustic emissions (OAE), Wide Band Tympanometry (WBT), Vestibular function tests. Audiometry. MOCA, eGOS are cognitive tests.~Biomarker is a protein found in the inner ear examined in the cerebral fluid."
9697845|NCT04751851|Experimental|A.1: Medium duration withdrawal programme with ACT|Medium duration withdrawal programme with Acceptance and Commitment Therapy
9697846|NCT04751851|Experimental|A.2: Long duration withdrawal programme with ACT|Long duration withdrawal programme with Acceptance and Commitment Therapy
9697847|NCT04751851|Active Comparator|B.1: Medium duration withdrawal programme without ACT|Medium duration withdrawal programme without Acceptance and Commitment Therapy
9697848|NCT04751851|Active Comparator|B.2: Long duration withdrawal programme without ACT|Long duration withdrawal programme without Acceptance and Commitment Therapy
10188571|NCT03715569||OAE/WBT control: Healthy individuals|Otoacoustic emissions in normal position with head. Otoacoustic emission in different head positions.
9697849|NCT04751968|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
9697850|NCT04751968|Other|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
9697851|NCT04751890|Experimental|Structured home-based exercise|Program will include two 10-minute sessions/day (6 days/week) of intermittent walking (1-minute work and 1-minute rest while seated) at a prescribed speed converted into a walking cadence and followed at home using a metronome. The walking sessions will be preferably performed indoors at home or on a treadmill. During the study, 2 follow-up visits (at weeks 8 and 16) will be performed to evaluate patient adherence to the program and to update the exercise program with the duration of each session that remained constant. The walking intensity of each exercise regime will be progressively modified to increase the training load. The patients will be asked to fill out a daily training record indicating completion of the exercise and any associated symptoms. Patients will have the ability to contact the rehabilitation team, composed of a physician and a sports science expert, throughout the entire study period via phone.
9697852|NCT04751890|Active Comparator|Walking advice|Patients will receive advice to walk as suggested by the guidelines. In particular, a team member will recommend patients to gather almost 30 minutes of walking at least 3 times per week; when the patient will face claudication pain, he/she will be allowed to rest, and restart walking as soon as possible. A daily log to be compiled will be provided to each patients to record the amount of walk performed.
9697853|NCT04751864|Experimental|Active Arm|Participants receive active device for the full 8 week study
9697854|NCT04751864|Sham Comparator|Sham Arm|Participants receive sham device for the first 4 weeks, and then at the week 5 cross over, receive the active device.
9697855|NCT04752124|Active Comparator|HIIT+CT|HIIT combined with conventional rehabilitation.
9697856|NCT04752124|Placebo Comparator|Conventional therapy|Conventional rehabilitation will be provided to this group of patients.
10188572|NCT03715569||OAE/WBT control: Systemic infection|Otoacoustic emission during admission
9697857|NCT04751799|No Intervention|Control Group (no VR)|Patients undergoing colposcopy and colposcopically-guided biopsy without further intervention
9697858|NCT04751799|Experimental|VR before and during colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy as well as during colposcopy.
9697859|NCT04751799|Experimental|VR before colposcopy|Patients undergoing colposcopy and colposcopically-guided biopsy with a VR headset for 15 minutes before colposcopy but not during colposcopy.
9697860|NCT04751695|Experimental|CoronoVac Vaccine Group|
9697861|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib Monotherapy (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~Monotherapy : Participants will receive Abemaciclib orally 2x daily"
9697862|NCT04751929|Experimental|Biomarker-Unselected Abemaciclib + Atezolizumab (Randomized)|"Participants in the Biomarker-Unselected Cohort, defined as those whose tumors are not known to have mutations in the CDK12 gene will be randomized to either receive Abemaciclib as monotherapy or in combination with Atezolizumab~Combination Therapy: Participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
9697863|NCT04751929|Experimental|CDK12 Mutation Atezolizumab Monotherapy (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Atezolizumab monotherapy will be given to participants 1-5, these participants will receive Atezolizumab intravenously Day 1 of each 21-Day cycle"
9697864|NCT04751929|Experimental|CDK12 Mutation Abemaciclib + Atezolizumab (Non-Randomized)|"Participants in the CDK12 Mutation Cohort defined as those whose tumors are known to have mutations in the CDK12 gene are not randomized but are assigned to receive either Atezolizumab monotherapy or in combination with Abemaciclib based on how many participants in this cohort previously received study treatment.~Combination Therapy will be given to participants 6-21, these participants will receive Abemaciclib orally 2x daily and Atezolizumab intravenously Day 1 of each 21-Day cycle"
9697865|NCT04751565|Experimental|BOP-positive within 30 sec (drop or line) at 1-2 sites/implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients who presented BOP-positive within 30 sec (drop or line) at 1-2 sites/implant.~Primary outcome~The primary outcome will be based on probing depth (PD)"
10188573|NCT03715569||OAE/WBT control: ICP changes|Otoacoustic emission on patients without an CNS infection before and after elective lumbare puncture with measurement of intracranial pressure (ICP).
9697866|NCT04751565|Experimental|BOP-positive within 30 sec (drop or line) at 3-4 sites/implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients who presented BOP-positive within 30 sec (drop or line) at 3-4 sites/implant.~Primary outcome~The primary outcome will be based on probing depth (PD)"
9697867|NCT04751565|Experimental|BOP-positive within 30 sec (drop or line) at 5-6 sites/implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients who presented BOP-positive within 30 sec (drop or line) at 5-6 sites/implant.~Primary outcome~The primary outcome will be based on probing depth (PD)"
9697868|NCT04751552|Active Comparator|Levobupivacaine group|Patients receive an ESPB with the local anaesthetic levobupivacaine
9697869|NCT04751552|Placebo Comparator|Placebo group|Patients receive an ESPB with 0,9% saline
9697870|NCT04751513|Experimental|Experimental group|The experimental group will receive acupressure on six auricular points.
9697871|NCT04751513|No Intervention|Control group|The control group will receive no intervention.
9697872|NCT04751500|Experimental|Outpatient Hysteroscopy|Outpatient hysteroscopic morcellation of retained products of conception
9697873|NCT04751500|Active Comparator|Standard Treatment|Standard treatment of retained products of conception in the form of expectant management, medical management, antibiotic therapy and/or surgical management (manual vacuum aspiration/suction curettage/dilatation and curettage)
9697874|NCT04751903|Experimental|Oral motor stimulation|After the infants were assessed by a neonatologist, Oral motor stimulation was administered to the experimental group thrice a day (at 9:00, 12:00, 15:00 hours) for 15 minutes right before feeding, over a 14-day period.
9697875|NCT04751903|No Intervention|Control group|The preterm infant' the control group were only fed by the researcher thrice a day (at 9:00, 12:00, 15:00 hours) over a 14-day period.
9697876|NCT04751617|Experimental|Pulmonary rehabilitation (intervention)|This group will be covered by pulmonary rehabilitation.
9697877|NCT04751656|Experimental|Steady Intervention|Participants asked to engage in Steady Intervention for 12 months
9977899|NCT01366339|Experimental|Arm 2|Oral methylnaltrexone
10188574|NCT03715569||Biomarker control|Inner ear biomarkers in patients without CNS infection. Inner ear fluid examination from patients that underwent elective cochlea implantation.
9977900|NCT01366339|Experimental|Arm 3|Oral methylnaltrexone
9977901|NCT01366339|Placebo Comparator|Arm 4|Oral placebo
9977902|NCT01366352|Experimental|Arm 1|MNTX tablet
9697882|NCT04751721|Experimental|CoronoVac Vaccine Group|
9697883|NCT04751669|Experimental|Micronutrient dietary supplement effervescent tablet|"Tablet containing:~Retinol (Vitamin A) 700 mcg~Cholecalciferol (Vitamin D3) 10 mcg~Alpha-Tocopherol (Vitamin E) 45 mg~Ascorbic acid (vitamin C) 1000 mg~Pyridoxine (Vitamin B6) 6.5 mg~Cyanocobalamin (Vitamin B12) 9.6 mg~Folic acid 400 mg~Iron 5 mg~Zinc 10 mg~Selenium 110 mg~Copper 0.9 mg~Excipients"
9697884|NCT04751669|Placebo Comparator|Placebo dietary supplement effervescent tablet|"Effervescent tablet with only the excipients.~Sucralose 13 mg~Sodium Chloride 20 mg~Potassium Acesulfam 22.5 mg~Orange P 55 mg~Sodium Carbonate 70 mg~Betacarotene 100 mg~Malic Acid 800 mg~Citric Acid 960 mg~Sodium bicarbonate 1,000 mg~Isomalt 1,459.50 mg"
9697885|NCT04751474|Experimental|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
9697886|NCT04751474|No Intervention|Control group|The control group did not receive any intervention.
9697887|NCT04751409|Experimental|Group 1, Arm I (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years consisting of restaging with CT-chest and imaging of the primary site.
9697888|NCT04751409|Experimental|Group 1, Arm II (limited follow-up)|Patients undergo limited follow-up every 6 months for 2 years consisting of restaging with either CT-chest or CXR and imaging of the primary site.
9697889|NCT04751409|Experimental|Group 2 (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years as in Group 1, Arm I.
9697890|NCT04751708|Active Comparator|best medical management|Unless contra-indicated patients are treated with a standard full dose of open-label IV rt-PA (0.9mg/kg; 90mg maximum). IVT has to be initiated within 4.5 hours of estimated time of basilar artery occlusion. For the patients in whom the rtPA is contraindicated, the standard medical treatment follows the current guidelines for the early management of patients with acute ischemic stroke from the American Heart Association/American Stroke Association.
9697891|NCT04751708|Experimental|endovascular treatment+ best medical management|Device: endovascular treatment For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
9697892|NCT04751539|Experimental|AND017 single dose escalation|Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.
9697893|NCT04751539|Placebo Comparator|AND017 repeated dose escalation|Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.
9697894|NCT04751539|Placebo Comparator|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
9697895|NCT04751682|Experimental|BBV154: Single Dose|Group 1 (Single dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on day 0 and with placebo on day 28 via intranasal route.
9977903|NCT01366352|Experimental|Arm 2|MNTX tablet
9977904|NCT01366365|Experimental|Arm 1|IV methylnaltrexone (MNTX)
9977905|NCT01366365|Placebo Comparator|Arm 2|placebo
9977906|NCT01366378|Experimental|Arm 1|methylnaltrexone (MNTX)
9977907|NCT01366391|Other|Metformin|study parallel with one arm only.
10205377|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
10205378|NCT02352948|Experimental|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
10188575|NCT03715556|Active Comparator|Amiodarone|Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated. Administration of the drug will be blinded within the first hour to the principal investigator.
10188576|NCT03715556|Placebo Comparator|No intervention|The Liberal group will receive only 0.9% physiological solution, also blinded to the principal investigator.
10188577|NCT03715543|Experimental|Surgical Resection Arm|Surgical Resection of the Greater Splanchnic Nerve
10188578|NCT03715517|Experimental|Intrathecal morphine|"Spinal anesthesia with intrathecal morphine~Bolus (pre-induction): High-spinal anesthesia with 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75% plus 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)~Postoperative analgesia: IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)"
10188579|NCT03715517|Active Comparator|Thoracic epidural analgesia|"Continuous thoracic epidural analgesia~Bolus (pre-induction): 0.25 mg⋅kg-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹ hydromorphone (0.1 mL⋅kg-¹)~Infusion (initial): 0.25 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹⋅h-¹ hydromorphone (0.1 mL⋅kg-¹⋅h-¹)~Infusion (range): 0.19-0. 3 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 0.75-1.25 mcg⋅kg-¹⋅h-¹ hydromorphone (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹)~Postoperative analgesia: (1) Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range as above (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹), continued for a maximum of 72 h postoperatively; (2) IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)."
9697896|NCT04751682|Experimental|BBV154: Two Dose|Group 2 (Two-dose group): In this group, 70 participants will be recruited and administered with vaccine (BBV154) on both day 0 and on day 28 via intranasal route.
9697897|NCT04751682|Placebo Comparator|Placebo|Group 3 (Placebo): In this group, 35 participants will be recruited and administered with placebo on both day 0 and day 28 via intranasal route.
9697898|NCT04751643|Experimental|TPE + usual treatments in intensive care unit according to the current state of knowledge.|"TPE + usual treatments in intensive care unit according to the current state of knowledge : 3 TPE sessions i.e. one per day during 3 consecutive days on day 1-3 (day 0 = inclusion Visit date)) + usual treatments in intensive care unit.~Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)"
10188580|NCT03715478|Experimental|GSK2857916 with Pomalidomide and Dexamethasone|This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.
9697899|NCT04751643|Active Comparator|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
9697900|NCT04751344|Experimental|Liposomal Bupivacaine|The liposomal bupivacaine study arm will receive 8cc (13.3 mg/mL) liposomal bupivacaine via intravenous route at the completion of the procedure.
9697901|NCT04751344|Active Comparator|Bupivacaine HCl|The Bupivacaine HCl study arm will receive 10cc (5mg/mL) of bupivacaine HCl via intravenous route at the completion of the procedure.
9697902|NCT04751331|Experimental|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113) administered as an intravenous bolus.
10188581|NCT03715439||Leucocyte- and Platelet-rich Fibrin|Dental implant placed into post-extraction sites preserved with leucocyte- and platelet-rich fibrin
10188582|NCT03715439||Control|Dental implant placed into non-preserved post-extraction sites
9697903|NCT04751331|Placebo Comparator|Placebo|Placebo (same volume of 0.9% saline) administered as an intravenous bolus
9697904|NCT04751448||Observational|All patients going on study will be put in the observational grouping for blood and tissue collection with option for stool collection.
9697905|NCT04751526|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
9697906|NCT04751526|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
9697907|NCT04751227||1|Modafinil 100-200 mg daily for wakefulness in a cohort of adult patients admitted to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020
9697908|NCT04751318|Experimental|Duloxetine Test Produc|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
10188583|NCT03715413|Other|Tamoxifen group|they was received Tamoxifen 10 mg daily.
10205379|NCT02341534|Other|BioMonitor arm|BioMonitor group (implantation with investigational device + transfer of information via Home Monitoring)
9697909|NCT04751318|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
9697910|NCT04751240|Experimental|SIT and Resistance|Participants will complete 10 weeks of a SIT and resistance training paradigm.
9697911|NCT04751604|Experimental|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide [1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)] for 4 weeks
9697912|NCT04751604|Placebo Comparator|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
9784998|NCT01239992|Experimental|Niacin/ Laropiprant|
9784999|NCT01240122|Active Comparator|Biotrue MPS|
9785000|NCT01240122|Experimental|Investigational MPS|
9977908|NCT01366430|Active Comparator|Gefoni manenuver|Gefoni manenuver for Geotropic HC-BPPV
9977909|NCT01366430|Active Comparator|sham maneuver|sham maneuver for geotropic HC-BPPV
9697913|NCT04751305|Experimental|ACE Remote Maintenance Program with Health Coaching|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels. Additionally, the health coaching intervention received weekly zoom calls that were focused on being participant-centered, built on a coach participant relationship, and included participant-determined goals, a self-discovery process to find solutions, patient accountability, and education.
9697914|NCT04751305|Active Comparator|Only ACE Remote Maintenance Program|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also participants received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels.
9697915|NCT04751279||Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (<5 years)|Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score <2) and recent diagnosis (<5 years)
9697916|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (<5 years|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (<5 years)
9697917|NCT04751279||Patients with pulmonary sarcoidosis without signs of activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis without signs of activity (Benamore score <2), persistent form (>5 years)
9697918|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (>5 years)
9697919|NCT04751253|Active Comparator|1500 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 1500 J plus exercises.
9697920|NCT04751253|Active Comparator|3000 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 3000 J plus exercises.
9697921|NCT04751253|Sham Comparator|exercises + sham LASER|consist of 17 patients, they will apply exercises plus sham LASER.
9697922|NCT04751149|Experimental|Early Urinary Catheter Removal|Urinary Catheter will be removed the first postoperative day after rectal resection
9697923|NCT04751149|Experimental|Medium Urinary Catheter Removal|Urinary Catheter will be removed the third postoperative day after rectal resection
9697924|NCT04751149|Experimental|Late Urinary Catheter Removal|Urinary Catheter will be removed the fifth postoperative day after rectal resection
9697925|NCT04751292||Lowlanders|People living at low (<1500 m) altitude
9697926|NCT04751292||Highlanders|People living at high (>2500 m) altitude
9697927|NCT04751097|Experimental|Digital Platform|
9697928|NCT04751097|No Intervention|Routine Care|
9697929|NCT04751175|Experimental|Ketamina bolus plus Dexamethasone bolus plus infusion ketamine|Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)
9697930|NCT04751175|Experimental|Ketamine bolus plus ketamine infusion|Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.
9697931|NCT04751175|Active Comparator|Dexametasone arm|Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA
9697932|NCT04751175|Placebo Comparator|Saline bolus|Saline bolus + saline bolus + saline infusion up to three hours after admission to the URPA
9697933|NCT04751188|Experimental|Bezafibrate and Ursodeoxycholic acid|Bezafibrate 200 mg every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
9697934|NCT04751188|Placebo Comparator|Placebo and Ursodeoxycholic acid|Placebo tablet every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 6 months.
9697935|NCT04751084|Active Comparator|treatment group|20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer
9697936|NCT04751084|Placebo Comparator|control group|2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer
9697937|NCT04751136|Active Comparator|Intervention Arm|infants were given Cerebrolysin®, manufactured by Neuro Pharma Gmbh, in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).
9697938|NCT04751136|No Intervention|Non-intervention Arm|No medication was given
9697939|NCT04750811||Small Bowel obstruction|Patients admitted with a diagnosis of small bowel obstruction at 1 of the 6 participating centres
9697940|NCT04750902|Active Comparator|0.24% Sodium Fluoride Dentifrice|Toothpaste
9697941|NCT04750902|Experimental|1.5% Arginine Dentifrice|Toothpaste
9697942|NCT04750902|Experimental|4.0% Arginine Dentifrice|Toothpaste
9697943|NCT04750902|Experimental|8.0% Arginine Dentifrice|Toothpaste
9697944|NCT04750980||Food allergy|Childen with food allergy
9697945|NCT04750980||Respiratory allergy|Children with respiratory allergy
9697946|NCT04750980||Healthy controls|Healthy subjects
9697947|NCT04750850|Experimental|Core stability exercises group|30 minutes of core stability exercises program at a light intensity and take a rest breaks if is necessary. They will be instructed in the use of the 4-5 points of the Borg 10 Rating of Perceived Exertion for self-monitoring of exercise intensity. The exercises will performed twice a day for 5 days a week during 5 weeks. A physiotherapist conducted an initial home visit to ensure correct execution of the exercises. He or she will teach the exercises and then the patient will perform them alone in your home. Once a week the physiotherapist will phone the patient and will ask her/him for doubts.
9977910|NCT01366430|Active Comparator|barbecue maneuver|barbecue maneuver for geotropic HC-BPPV
9697948|NCT04750850|Active Comparator|Control group|The patients to continue as normal and not change their routine in terms of exercise and physical activity during the period of study.
9697949|NCT04750772|Experimental|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
9697950|NCT04750772|Experimental|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
9697951|NCT04751006|Experimental|Gaze Group|Participants performed balance training with gaze stabilization exercises
9697952|NCT04751006|Other|Control Group|Participants performed balance training with saccade eye exercises
9697953|NCT04750837|Active Comparator|Platelet rich plasma group|chronic diabetic foot ulcer was treated by platelet rich plasma
9697954|NCT04750837|Sham Comparator|conventional dressing group|chronic diabetic foot ulcer was treated by conventional dressing
9697955|NCT04750876|Active Comparator|Conventional support|
9697956|NCT04750876|Experimental|Specific care, including the intervention of a psychologist and a physical therapist.|
9697957|NCT04750746|Active Comparator|Control Group|Control group will get conventional treatment.
9697958|NCT04750746|Experimental|Experimental Group|This group will get base line treatment with exer gaming.
9697959|NCT04750668|Experimental|Multisensory Balance Training Group|Multisensory balance training manipulate sensory inputs of vision, vestibular and proprioception.
9697960|NCT04750668|No Intervention|Control Group|Participants in control group maintain their regular activity without any intervention.
9697961|NCT04750694|Experimental|RT + BFRE|High intensity Resistance training combined with Blood Flow
9697962|NCT04750694|Active Comparator|RT|Resistance training alone
9697963|NCT04750655|Placebo Comparator|Intraoperative antibiotics (Abx) only; no postoperative topical antibiotics|intraoperative/ intracameral antibiotic (moxifloxacin) only; no postoperative topical antibiotic drops
9697964|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics four times a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops four times a day for 1 week
9697965|NCT04750655|Active Comparator|Intraoperative antibiotics (Abx); Postoperative topical antibiotics once a day for 1 week|intraoperative/ intracameral antibiotic (moxifloxacin); postoperative topical antibiotic drops once a day for 1 week
9697966|NCT04750551|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
9697967|NCT04750551|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
9697968|NCT04750681|Placebo Comparator|Control|Each capsule contained 275mg of maltodextrin. Capsules were similar to the saffron investigation product (chlorophyll capsules).
9697969|NCT04750681|Experimental|Saffron|Each capsule contained 259,5mg of maltodextrin and 15,5mg of saffron extract (Saffr'activ® SAF 3C PIM) that corresponds to 1,6mg of dry saffron extract, 0,9mg of crocins (5.82%) and 0,7mg of safranal (4.6%).
9778344|NCT01104662|Active Comparator|Vancomycin or SSP , Bacteremia, Moderate Renal Impairment|Cohort 2. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
9778345|NCT01104662|Experimental|Daptomycin, cSSSI, Severe Renal Impairment|Cohort 3. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr below 30 mL/min and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 7 to 14 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 7 to 14 days based on disease resolution or Investigator discretion.
9778346|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Severe Renal Impairment|Cohort 3. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
9778347|NCT01104662|Experimental|Daptomycin, cSSSI, Moderate Renal Impairment|Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.
9785001|NCT01240135|Other|FID 114576A / renu fresh|FID 114675A used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after which renu fresh used for contact lens care for an additional 14 days.
9785002|NCT01240135|Other|renu fresh / FID 114675A|Renu fresh used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after FID 114675A used for contact lens care for an additional 14 days.
9785003|NCT01240200|Active Comparator|Vial & Syringe (Period 1) / Pen (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine vial and syringe in Period 1 and Insulin glargine SoloSTAR pen in Period 2.
9697970|NCT04750603|Placebo Comparator|Salbutamol|Salbutamol (Salbutrim, Trima) inhaler (400 µg) via spacer + Relvar® Ellipta placebo
9697971|NCT04750603|Active Comparator|FF/VI|Placebo Salbutamol inhaler + Relvar® Ellipta (92/22 µg, GSK, UK)
9697972|NCT04750512|Experimental|real ESP, placebo TAP|US-guided ESP block + sham US-guided TAP block
9697973|NCT04750512|Active Comparator|real TAP, placebo ESP|sham US-guided ESP block + US-guided TAP block before laparoscopic hernia repair
10188584|NCT03715413|Active Comparator|Tamoxifen and pulsed radiofrequency group|they was received Tamoxifen 10 mg daily and pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.
10188585|NCT03715400|No Intervention|Control|The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
9697974|NCT04750525|Experimental|BreEStim 120, then EStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
9697975|NCT04750525|Experimental|EStim 120, then BreEStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
10188586|NCT03715400|Experimental|Positive Virtual Reality Training Intervention|The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
10188587|NCT03715387|Experimental|Tacrolimus Treatment|Tacrolimus Topical 0.1% Topical Ointment
9697976|NCT04750590|Experimental|en bloc resection group|Patients scheduled for laser en bloc tumor resection with subsequent morcellation of exophytic part of the tumor
9697977|NCT04750590|Experimental|piecemeal resection group|Patients scheduled for piecemeal bladder tumor TUR with subsequent removing of tissue using the instrument loop or Janet's syringe.
10188588|NCT03715387|Placebo Comparator|Control|Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).
10188589|NCT03715374|Experimental|PRF+ABB treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A prf membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
9697978|NCT04750499|Experimental|Treatment|Patients with complex anal fistulas, non related to Crohn's disease.
10188590|NCT03715374|Active Comparator|Collagen Membrane + ABB treated patients|Periodontal surgery with collagen membrane is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A collagen membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
10188591|NCT03715361||Patients|Patients (500 patients ≤ ) who undergo out- or inpatient treatment and who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
10188592|NCT03715361||Control Group|Fifty volunteers who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
10188593|NCT03715348|Active Comparator|Fresh Frozen Plasma (FFP)|"Patients randomised to the comparator arm will receive Fresh Frozen Plasma (FFP)~FFP will be provide as a solution for intravenous administration, once thawed.~The dose of the FFP will be ~ 15 mL/kg.~Subjects may receive multiple doses of FFP as required if bleeding continues, as per usual care"
10188594|NCT03715348|Experimental|Prothrombin Complex Concentrate (PCC)|"Patients randomised to the experimental arm will receive PCC at ~15 IU/kg. PCC will be reconstituted into a solution for intravenous administration.~Subjects will receive a single dose of PCC, and if bleeding continues, standard treatment will be administered"
10188595|NCT03715322|Active Comparator|tobramycin inhalation|300mg tobramycin dissolved in 5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
10188596|NCT03715322|Placebo Comparator|natural saline inhalation|5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
10188597|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
10188598|NCT03715309|Experimental|Revlimd|
10188599|NCT03715283|Experimental|Home Lower Extremity Strengthening|Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing.
10188600|NCT03715283|Experimental|No intervention|In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs.
9697979|NCT04750473|Experimental|Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV and undergo a PET/CT scan over 30 minutes.
9697980|NCT04750460|Experimental|Teriparatide group (10 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, who will receive subcutaneous injections ot recombinant parathyroid hormone (Teriparatide) after surgery in addition to the standard local protocol for hypocalcemia treatment.
9697981|NCT04750460|No Intervention|Control group (10 patients)|Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, receiving standard local protocol for hypocalcemia treatment (2 micrograms of alphacalcidol plus 4 grams of oral calcium daily).
9697982|NCT04750616|Experimental|Oral niacinamide|
9697983|NCT04750616|Placebo Comparator|Matched placebo|
9697984|NCT04750317|Experimental|Patients with reduced oxygen saturation ≤93% treated with tofacitinib|Patients with oxygen saturation ≤93% on admission treated with tofacitinib and standard of care treatment
10205380|NCT02341534|No Intervention|Control arm|Control group (standard of care)
10188601|NCT03715270||breast reconstruction surgery patients|Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
10188602|NCT03715257|Active Comparator|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
10188603|NCT03715257|Active Comparator|Tube changing catheter|"Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
9697985|NCT04750317|No Intervention|Patients with reduced oxygen saturation treated with SoC|Patients with oxygen saturation ≤93% on admission treated with standard of care only
9697986|NCT04750317|Experimental|Patients with preserved oxygen saturation >93% on admission treated with tofacitinib|Patients with oxygen saturation >93% on admission treated with tofacitinib and standard of care
9697987|NCT04750317|No Intervention|Patients with preserved oxygen saturation >93% on admission treated with SoC|Patients with oxygen saturation >93% on admission treated with standard of care only
9697988|NCT04750421|Experimental|Transillumination Venolux®|Transillumination using Venolux was used to visualize veins in the hemiface before hyaluronic acid injections
9697989|NCT04750421|No Intervention|Comparator group|No vascular exploration methods were used on the other hemiface
9697990|NCT04750538|Experimental|BreEStim 120, then BreEStim 240|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
9697991|NCT04750538|Experimental|BreEStim 240, then BreEStim 120|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
10188604|NCT03715244||Study group 1|n=220 patients for routine data of spinal anesthesia with short-acting local anesthetics
9697992|NCT04750356||Cohort A1|Healthcare workers and patients that have previously undertaken a swab or serology test to detect for the presence of SARS-CoV-2. Without the need to seek retrospective consent for the SARS CoV 2 Longitudinal Study, residual samples and derivatives from the Crick COVID -9 Consortium Testing centre and data will be used for the study
9697993|NCT04750356||Cohort A2|3,000 SARS-CoV-2 positive and 3,000 SARS-CoV-2 negative participants (randomly selected) from cohort A1 will be prospectively consented to the study. In addition, vaccine status will also be used to stratify the participants and recruit to the study.
10188605|NCT03715244||Study group 2|n= 220 patients for routine data of general anesthesia (current standard)
10188606|NCT03715244||No intervention: Control group postoperative cognitive deficit|n= 90 control subjects aged 18 years or older (without surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
9697994|NCT04750356||Cohort B|Employees at participating centres including but not limited to UCLH and The Francis Crick Institute who have their serology tested and/or are swabbed for viral (SARS-CoV-2 and seasonal viruses) detection as well as participants who are vaccinated will be prospectively consented to the study.
9697995|NCT04750356||Cohort C|Individuals recruited to other REC approved research studies where their samples are processed by the Crick COVID 19 Consortium Testing centre will also be consented in their existing study to allow the use of leftover study samples already collected and to be collected, for use in this longitudinal study.
10188607|NCT03715218|Experimental|Mother Touch Program|Post natal care provided by trained carer after the birth. 6 weeks of care included massage, special diet, physical and mental relaxations.
10188608|NCT03715218|Other|Usual care Program|Usual care and supervision was provided as usual.
9697996|NCT04750564|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
9697997|NCT04750564|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
9697998|NCT04750330||Severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the Intensive Care Unit (ICU) during hospitalisation
9697999|NCT04750330||Non-severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the hospital but NOT to the Intensive Care Unit (ICU) during hospitalisation
9698000|NCT04750330||Minor COVID-19|Patients, diagnosed with COVID-19, who were NOT admitted to the hospital and could recover at home
9698001|NCT04750278|Experimental|FP-025 100 mg|Low dose for patient treatment.
9698002|NCT04750278|Experimental|FP-025 300 mg|High dose for patient treatment.
9698003|NCT04750278|Placebo Comparator|Placebo|Dose without any study drug, to make it a controlled study.
9698004|NCT04750629||SARS-Cov-2 RT-PCR AND CoviDx Rapid Antigen Testing|Sequentially enrolled symptomatic patients who present for COVID-19 testing and have a swab collected for high-sensitive, SARS-CoV-2 RT-PCR testing per Standard of Care AND a swab for CoviDx™ Rapid Antigen testing.
9698005|NCT04750382|Experimental|HX008+Cisplatin+Gemcitabine|
9698006|NCT04750200|No Intervention|Control Arm|Patients randomized to the control arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH.
9785004|NCT01240200|Experimental|Pen (Period 1) / Vial & Syringe (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine SoloSTAR® pen in Period 1 and Insulin glargine vial and syringe in Period 2.
9698007|NCT04750200|Experimental|Interventional Arm|Patients randomized to the interventional arm will undergo institutional standard of care treatment (surgical drainage and/or medical management for the CSDH as per the standard of care in the institution. These patients will then undergo EMMA within 48 hours after finishing the surgical drainage. The embolic agent and use of general anesthesia vs conscious sedation will be left to operators' preference and the institutional protocol. All patients will be followed as per the institutional standard of the care. Any peri-procedural complications and change in clinical status will be recorded.
9698008|NCT04750187|Experimental|Hypo-pressive abdominal exercise program|
9698009|NCT04750187|No Intervention|No training program|
9698010|NCT04749940|Experimental|Hospitalized burn patients|Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.
9698011|NCT04749979|Active Comparator|giving agonist ( eg. decapeptyl )|Giving women agonist
9698012|NCT04749979|Active Comparator|Giving HCG (eg. choriomon )|Giving women HCG
9698013|NCT04749914|Experimental|Lasmiditan + Dabigatran (Part 1)|Participants will receive single doses of dabigatran followed by combination of lasmiditan along with dabigatran etexilate administered orally.
10188609|NCT03715205|Experimental|Cohort A: Melanoma|Participants with unresectable or metastatic melanoma receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.
10188610|NCT03715205|Experimental|Cohort B: NSCLC|Participants with NSCLC who are either treatment naïve or have progressed after prior treatment receive 200 mg of pembrolizumab as an IV infusion every Q3W for up to 35 cycles.
10188611|NCT03715192|Experimental|LY3462817 - IV|Escalating doses of LY3462817 administered as a single intravenous (IV) infusion in healthy participants
10188612|NCT03715192|Placebo Comparator|Placebo|Normal saline administered as a single IV infusion in healthy participants
10188613|NCT03715192|Experimental|LY3462817 - SC|Single dose of LY3462817 administered as subcutaneous (SC) injections in healthy participants
10188614|NCT03715179||Standard of Care|Individuals living with an ostomy and their caregivers. Participants use their own ostomy pouching systems per their clinician's standard of care
9698014|NCT04749914|Experimental|Lasmiditan + Rosuvastatin (Part 2)|Participants will receive single doses of rosuvastatin followed by combination of lasmiditan along with rosuvastatin administered orally.
9698015|NCT04749862||Breast Cancer Participants-Before Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
9698016|NCT04749862||Colorectal (bowel) Cancer Participants-Before Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time.
10188615|NCT03715140|Experimental|Patients who will recieve crucumin|patients who prescribing crucumin 80 mg daily for three months will be evaluated. A sample will be taken before taking the drug.
10188616|NCT03715140|Placebo Comparator|Patients who will receive placebo|Patients who prescribing placebo daily for three months will be evaluated. A sample will be taken before taking the placebo.
9698017|NCT04749862||Breast Cancer Participants-After Phase|Breast cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
9698018|NCT04749862||Colorectal (bowel) Cancer Participants-After Phase|Colorectal cancer patients (16 years old or over) who have completed active treatment will complete a series of patient reported outcomes at baseline, 3, 6 and 12 months time. In addition they will also complete an online symptom report from home with self-management advice (frequency of completion to be determined in phase 2)
10188617|NCT03715114|Experimental|GV-971 900 mg|900 mg oral
10188618|NCT03715114|Experimental|GV-971 1200 mg|1200 mg oral
9698019|NCT04750096||Esophagectomy post enhanced recovery after surgery|Patients undergoing esophagectomy due to oesophageal cancer under Enhanced Recovery After Surgery protocol.
10188619|NCT03715114|Experimental|GV-971 1500 mg|1500 mg oral
10188620|NCT03715114|Placebo Comparator|Placebo|Oral placebo
9698020|NCT04749953|Active Comparator|Autogenous bone graft alone|Maxillary sinus floor augmentation with particulated autogenous bone graft alone from the zygomatic buttress area and simultaneously implant placement
9698021|NCT04749953|Experimental|Mixture of 50% autogenous bone graft and 50% Symbios biphasic biomaterial|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios biphasic bone graft material (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placementand
9977911|NCT01366456|Active Comparator|Shingigu|Treat with Shingigu
10188621|NCT03715101|Experimental|Rosuvastatin 20 mg PO|Rosuvastatin 20 mg daily for 21 days
10188622|NCT03715088|Experimental|Older Adults (BMI ≥30 kg/m2)|Individuals aged 65-75 living with obesity will perform the Resistance Training Intervention.
10188623|NCT03715088|Experimental|Younger Adults (BMI ≥30 kg/m2)|Individuals aged 18-30 living with obesity will perform Resistance Training Intervention.
10188624|NCT03715075||Post-caesarean section group|This single cohort observational study shall recruit women undergoing elective caesarean section within the Simpson's Centre for Reproductive Health (SCRH).
10188625|NCT03715062|Experimental|Intervention group|Receives education in diagnosing urinary tract infection and use of observation, reflection and communication tool.
10188626|NCT03715062|No Intervention|Control group|No intervention
10188627|NCT03715049|Other|Fraxel Laser Treatment|Using the energy and density settings within the FDA approved limits (5-40mJ at 30-100% density) that were narrowed down by the pre-clinical portion of the study, and analysis of abdominal and facial tissue treated in Objective 1, up to thirty (30) subjects will be recruited and treated one (1) time in the perioral region of the upper lip and followed for 6 months (study design below). The acute effects of the laser application will be determined by subjective analysis using the wrinkle severity scores.
10205381|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
9698022|NCT04749953|Experimental|Mixture of 50% autogenous bone graft and 50% Symbios xenograft granules|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios xenograft granules (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placement
10188628|NCT03715036|No Intervention|Fundal height|Patients will have routine fundal height measurement
9698023|NCT04750018||COVID-19 2019|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
9698024|NCT04750018||COVID-19 2020|Patients receiving biopsies with a BI-RADS assessment of 4 or 5 from mammographic or ultrasonographic exams or combinations of tests were analyzed [4]. We further categorized the biopsy data as ultrasound-guided or mammograph-guided biopsy based on procedure coding. Ultrasound-guided core needle biopsy (CNB) was performed for breast lesions visible on ultrasound.
9698025|NCT04749888|Experimental|Targeted nurse-led home visiting|The intervention group will receive 25-29 home visits during pregnancy and the first 2 years of life conducted by child health nurses. The frequency of home visits will be determined by nurses based on the needs of the families. The content of each home visit is individually tailored to the mother's needs, skills, strengths, and capacity using parenting education materials.
9698026|NCT04749888|No Intervention|Control group|The control group will receive existing maternal and child health services (usual care) except for the targeted nurse-led home visits.
9698027|NCT04750122|Experimental|Neoadjuvant therapy base on PTC drug screenning|Patients will receive neoadjuvant therapy including trastuzumab, pertuzumab, and chemotherapy based on PTC drug screening.
9698028|NCT04750135|Placebo Comparator|Control group|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
9698029|NCT04750135|Experimental|Metformin group|participants will receive 500 mg Metformin TID for 8 consecutive weeks in addition to the standard therapy
9698030|NCT04750174|Active Comparator|Kinesiotape Group|In active group, KT was applied with stretching to the suprahyoid muscles with right method.
9698031|NCT04750174|Sham Comparator|Sham Kinesiotape Group|In sham group, KT was applied without stretching to the suprahyoid region and not including the origins of mylohyoid and digastric muscles
9698032|NCT04750044|Experimental|early refeeding group|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.
9698033|NCT04750044|Active Comparator|delayed refeeding group|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2.
10188629|NCT03715036|Experimental|Point-of-care US|Patients will receive POC US for DVP and AC.
9698034|NCT04750161||Psoriasis Vulgaris|
9698035|NCT04750161||Atopic Dermatitis|
9698036|NCT04750161||Ichthyosis Vulgaris|
9698037|NCT04750161||Healthy Controls|
9698038|NCT04750148||Cancer|Individuals with an oncology disease will be included in the study.
9698039|NCT04750083|Experimental|phase II|Thirty-sixty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
9698040|NCT04750083|Experimental|phase III-experimental|Three hundred and twenty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
9698041|NCT04750083|Experimental|phase III-control|Three hundred and twenty participants will receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
9698042|NCT04749706|Active Comparator|Normal weight|the normal weight women will receive the 12-week physical activity intervention and serve as a control group.
9698043|NCT04749706|Experimental|constitutionally lean women - Physical training only|women will receive the 12-week physical activity intervention
9698044|NCT04749706|Experimental|constitutionally lean women - Physical training + proteins|women will receive the 12-week physical activity intervention in addition to a protein supplementation
9698045|NCT04749563|Active Comparator|Active|IGC AD1
9698046|NCT04749563|Placebo Comparator|Placebo|IGC AD1 Placebo
9698047|NCT04749589||iron deficient|ferritin<30 or Transferine saturation<.2
9698048|NCT04749589||iron replete|opposite of the other group
9698049|NCT04749576|Active Comparator|Low dose saffron|healthy, mild-moderate ulcerative colitis for low dose
9698050|NCT04749576|Active Comparator|High dose Saffron|healthy, mild-moderate ulcerative colitis for high dose
9698051|NCT04749576|Placebo Comparator|Placebo|healthy, mild-moderate ulcerative colitis for placebo
9698052|NCT04749472|Experimental|Study Group|Participants received intervention.
9698053|NCT04749797|Placebo Comparator|Saline group|The surgeon will administer injectable saline as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
9785005|NCT01240356|Experimental|Phase I: Healthy Volunteers|Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
9785006|NCT01240356|Experimental|Phase II: 0-3 hour Patients|Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
10188630|NCT03715023|Experimental|Active + SoC|Daily doses of PC786 for 3 days + SoC
10188631|NCT03715023|Placebo Comparator|Placebo + SoC|Daily doses of Placebo for 3 days + SoC
10188632|NCT03715010|Active Comparator|Brain Chain Amino Acid (BCAA)|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
9698054|NCT04749797|Active Comparator|Bupivacaine|The surgeon will administer bupivacaine as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
10188633|NCT03715010|Placebo Comparator|Placebo|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
10188634|NCT03714997|Experimental|High Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates close to 80% of heart rate reserve.
9698055|NCT04749797|Experimental|Liposomal Bupivacaine|The surgeon will administer Exparel (liposomal bupivacine) as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). 20 mL of Exparel will be diluted with saline to constitute 60 mL total. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.
9698056|NCT04749537||Ankylosing Spondylitis|100 patients who were diagnosed with AS between the ages of 18-65
9698057|NCT04749537||Healthy Volunteers|100 healthy volunteers compatible with age.
9698058|NCT04749654|Experimental|Fixed space maintainers|band-and-loop type fixed space maintainers were applied
10205382|NCT02305641||Cohort|Method of continuous surveillance per standard of care
9698059|NCT04749654|Experimental|Removable space maintainers|All removable space maintainers were produced of an acrylic base and retention elements that were a vestibule arch, (Adam's and C clasps).
9698060|NCT04749810||Elizaria®|Eculizumab
9698061|NCT04749745|Active Comparator|L-Theanine|Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
9698062|NCT04749745|Placebo Comparator|Placebo|Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
9698063|NCT04749719|Experimental|DLPFC stimulation|F3-SO montage or OLE optimized with 2 mA stimulation for up to 30 min during memory and metamemory task.
9698064|NCT04749719|Sham Comparator|Sham tDCS|F3-SO montage or OLE optimized with sham stimulation for up to 30 min during memory and metamemory task.
9698065|NCT04749771|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly sessions lasting 30-45 minutes. The process begins with an initial session in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
9698066|NCT04749771|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 sessions each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
9698067|NCT04749498|Active Comparator|White Bread|White bread with a standard test breakfast
9698068|NCT04749498|Active Comparator|Whole Wheat Bread|Whole wheat bread with a standard test breakfast
9698069|NCT04749498|Experimental|Barley Bread|Barley bread with a standard test breakfast
9698070|NCT04749498|Experimental|Oat Bread|Oat bread with a standard test breakfast
9698071|NCT04749641|Experimental|Open surgical biopsy|A total of 15 subjects with open surgical biopsy indications will receive microsurgical resection, followed by conformal radiotherapy and administration of the researched vaccine.
9698072|NCT04749641|Experimental|Stereotactic biopsy|A total of 15 subjects without open surgical biopsy indications will receive stereotactic biopsy, followed by conformal radiotherapy and administration of the researched vaccine.
9698073|NCT04749784|Experimental|High dose IP|Two tablets IP daily for 12 weeks
9698074|NCT04749784|Experimental|Low dose IP|One tablet IP + one tablet placebo daily for 12 weeks
9698075|NCT04749784|Placebo Comparator|Placebo|Two tablets placebo daily for 12 weeks
9698076|NCT04749329|No Intervention|Control Group|no mesh was used for end colostomy fashions
9698077|NCT04749329|Experimental|Mesh Group|Mesh of Bio A was used for end colostomy fashions
9785007|NCT01240382|Experimental|3% DE-089|
10205383|NCT02274571|Experimental|Drug|TSEC (Duavee™, combination of CE and BZA)
10205384|NCT02274571|Placebo Comparator|Placebo|Non active comparator
10188635|NCT03714997|Active Comparator|Low Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates from 30% to 40% of heart rate reserve.
9698078|NCT04749394|Experimental|Experimental Arm|Camrelizumab plus apatinib as consolidation therapy
9698079|NCT04749758|Experimental|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is approved by Andorra's Government authorities.
10188636|NCT03714971|Experimental|Receiving WhatsApp messages|Among patients applying to the smoking cessation outpatient clinic between March and October 2017, >18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
10188637|NCT03714971|No Intervention|Not receiving WhatsApp messages|"In not receiving WhatsApp messages group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group."
9698080|NCT04749342|Experimental|Complete Decongestive Therapy|Complete decongestive therapy (CDT) is also known as complex decongestive therapy. It involves a two-stage treatment protocol. The first stage consists of skin care, manual lymph drainage, exercises and compression with multi-layered bandages. The second stage aims to optimize and conserve the volume reduction obtained in stage one. This is achieved by using a low-stretch elastic garment in combination with skin care and exercises
10188638|NCT03714958|Experimental|combination HDM201 - Trametinib|"HDM201: Therapeutic class HDM2 inhibitor, given Per Os every D1 and D8 over a 28 day cycle. Four dose-levels possible in dose escalation part: 40 mg, 80mg, 100 mg, 120mg.~Trametinib: Therapeutic class Protein kinase inhibitor of MEK1 and MEK2 activation and kinase activity. Administrated daily, countinous dosing , twodose-level possible in dose escalation: 1.5 mg and 2mg"
10188639|NCT03714945||Case Group with Allergic Rhinitis|"- Inclusion Criteria~Both genders of 11-14 years, diagnosed with allergic rhinitis on basis of screening instruments, medical history, clinical assessment (by general ORL examination including nasal endoscopy)~Chinese in ethnicity~Positive skin prick test with wheal diameter >= 3mm~Ability to understand the nature, scope, and possible consequences of the study~Capability and willingness to comply with the requirements of the protocol"
9698081|NCT04749342|Experimental|Compression Bandaging|External compression is the mainstay of management for all stages of lymphedema. The efficacy of compression therapy alone, or combined with MLD, has been supported by randomized clinical trials
9977912|NCT01366456|Active Comparator|Charcoal|Treat with Charcoal
9977913|NCT01366482|Experimental|Drug-eluting balloon|Subjects are randomized to have a lesion treated with a paclitaxel-coated balloon Intervention: Cotavance Drug-Eluting Balloon
9698084|NCT04749524||Newborns|Otoacoustic Emissions to be measured with and without suppression noise
9698085|NCT04749524||Newborns failing initial hearing screening test|Otoacoustic Emissions to be measured with and without suppression noise
9698086|NCT04749524||Adults with normal hearing|Otoacoustic Emissions to be measured with and without suppression noise
10188640|NCT03714945||Control Group without Allergic Rhinitis|"- Inclusion Criteria~Both genders of 11-14 years~Chinese in ethnicity~Subjects who have not been diagnosed with a long term medical or psychiatric problem~Subjects who are not currently undergoing any long term medical treatment."
10188641|NCT03714906|Experimental|Treatment|Patients randomized to the Treatment arm will be assigned to receive a stellate ganglion block. While in the hospital after surgery, patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
9698087|NCT04749524||Adults with hearing loss|Otoacoustic Emissions to be measured with and without suppression noise
9698088|NCT04749316|Experimental|AcuTENS|Patients treated with TENS over Acupuncture points for faecal incontinence
9698089|NCT04749316|Sham Comparator|Sham|Sham treatment arm with no electrical stimulations over acupuncture points
9698090|NCT04749381|Experimental|TCM group|Rectal cancer patients randomized to this group will have acupoint application with traditional Chinese medicine.
9698091|NCT04749381|Placebo Comparator|Control group|Rectal cancer patients randomized to this group will have acupoint application with placebo .
9698092|NCT04749602|Experimental|Intrapleural instillation of the nivolumab|Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed.
9698093|NCT04749225||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
9698094|NCT04749225||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
9698095|NCT04749225||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°)to assist the nasotracheal tube passing the nasal cavity, oropharynx and advanced into the trachea
9698096|NCT04749485|Experimental|HX008|
9698097|NCT04749420||Patients group|Individuals with cervical radiculopathy
10205385|NCT02226458|Experimental|EPI-743|15 mg/kg oral solution three times per day, maximum of 200 mg per dose
9698098|NCT04749433|Experimental|Participants with diagnosis of ALS|Participants with a diagnosis of ALS will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
9785008|NCT01240382|Active Comparator|0.1% HA|
9977914|NCT01366482|Experimental|Plaque excision + drug-eluting balloon|Subjects are randomized to have a lesion treated with plaque excision (PE) followed by treatment with a paclitaxel-coated balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
10188642|NCT03714906|No Intervention|Control|Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
9698099|NCT04749433|Experimental|Healthy Participants without a diagnosis of ALS|Healthy participants (without a diagnosis of ALS) will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
9698100|NCT04749238|Experimental|Treatment with NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm.
10188643|NCT03714880|Experimental|Mifepristone|Participants ingest mifepristone 200 mg oral medication once 18-24 hours prior to dilator placement
9698101|NCT04749004|Experimental|Intervention Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~Setting-up of a commitment contract on the individual's goal of monthly steps taken~Provision of financial incentives upon achievement of one's goal of steps taken~Provision of nudges (reminders)"
9698102|NCT04749004|No Intervention|Control Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~To keep incentives constant the control group will also receive the flat payment of €10 to disentangle the effects between the contract and financial incentives."
9698103|NCT04749030|Other|Faecal microbiota transplantation (FMT)|Donor faeces is obtained from thoroughly screened healthy blood donors and processed in compliance with the European Tissue and Cells Directive.
10188644|NCT03714880|Placebo Comparator|Placebo|Participants ingest placebo oral medication once 18-24 hours prior to dilator placement
10188645|NCT03714867|Experimental|Treatment|Treatment arm intervention consists of patients who will be administered a single enteral dose of concealed over-encapsulated Pregabalin 150mg in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
10188646|NCT03714867|Placebo Comparator|Control|Treatment arm consists of patients who will be administered a single enteral dose of concealed over-encapsulated placebo capsules in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
10188647|NCT03714841|Experimental|CRP value|The patients point of care CRP value is known by the treating physician
10188648|NCT03714841|Active Comparator|CRP value unknown|The patients point of care CRP value is not known by the treating physician
10188649|NCT03714802|Experimental|Szabo T-Stenting Technique|Patients received 2-stents implantation guided with Szabo technique in bifurcation lesion.
10188650|NCT03714802|Placebo Comparator|T-Stenting Technique|Patients received 2-stents implantation guided with T-stenting technique in bifurcation lesion.
10188651|NCT03714789||Meropenem|Patients requiring dialysis and receiving meropenem for infection or suspended infection.
10188652|NCT03714789||Vancomycin|Patients requiring dialysis and receiving vancomycin for infection or suspended infection.
10188653|NCT03714789||Ceftriaxone|Patients requiring dialysis and receiving ceftriaxone for infection or suspended infection.
10188654|NCT03714763|Experimental|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
10188655|NCT03714763|Experimental|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
10188656|NCT03714750|Active Comparator|DK crush|Percutaneous revascularization of true coronary bifurcation stenosis (Medina 1,1,1 or 0,1,1) with double kissing and crush technique
10188657|NCT03714750|Experimental|Reverse TAP|Percutaneous revascularization of true coronary bifurcation Stenosis (Medina 1,1,1 or 0,1,1) with reverse T and protrusion technique
10188658|NCT03714737|Experimental|Experimental 1|Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
9698104|NCT04749030|Placebo Comparator|Placebo|Placebo capsules will be identical in terms of visual appearance, weight, and vials and number
9698105|NCT04749303|Active Comparator|Large screen|This is a high definition screen which gives a 76cm height and 67cm width (area: 5092cm2) endoscopic image.
9785009|NCT01240551|Active Comparator|Mets via NaF-18 PET/CT|Patients with known bone metastases (i.e. mets).
10188659|NCT03714737|Active Comparator|Positive control 1|Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
10188660|NCT03714737|Experimental|Experimental 2|Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
10188661|NCT03714737|Experimental|Experimental 3|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
10188662|NCT03714737|Active Comparator|Positive control 2|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
10188663|NCT03714737|Experimental|Experimental 4|Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
10188664|NCT03714737|Active Comparator|Positive Control 3|Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
10188665|NCT03714737|Experimental|Experimental 5|Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
10188666|NCT03714737|Active Comparator|Positive Control 4|Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
10188667|NCT03714724|Active Comparator|Group 4|"Patients who received 0-4 cmH2O PEEP in mechanical ventilation were referred to as Group 4.~Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded."
10205386|NCT02207062|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
9698106|NCT04749303|No Intervention|Standard screen|This is a high definition screen which gives a 37.5cm height and 32.5cm width (area: 1218.75cm2) endoscopic image.
10188668|NCT03714724|Active Comparator|Group 8|Patients who received 5-8 cmH2O PEEP in mechanical ventilation were referred to as Group 8. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
10188669|NCT03714724|Active Comparator|Group 12|Patients who received 9-12 cmH2O PEEP in mechanical ventilation were referred to as Group 12. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
9698107|NCT04749095|Active Comparator|Erector block|
9698108|NCT04749095|Active Comparator|sham block|
9698109|NCT04749277||Endoscopist characterization on WLI and BLI modes|Optical characterization of an identified polyp, first in WLI and then in BLI mode, with CAD EYE® OFF. This evaluation should be systematically performed by two independent endoscopists in the exam room, preferably (but not necessarily) an experienced endoscopist and a trainee. The presence of at least one experienced endoscopist is mandatory. An independent evaluation is guaranteed. First step - The 1st endoscopist (who performing colonoscopy) request the polyp evaluation and record written by the 2nd endoscopist (who not performing the colonoscopy) - blinded evaluation since 1st endoscopist doesn't verbalize his evaluation); 2nd step - when the 2nd endoscopist signals that he completed his record, the 1st endoscopist verbally explicit his classification, which is recorded by the 2nd endoscopist. This evaluation should include polyp histological type (hyperplastic, adenoma, sessile serrated lesion or other type) and the level of confidence of the evaluation performed (high or low).
9698110|NCT04749277||CAD EYE® characterization on BLI mode|Optical characterization mode of CAD EYE® (CAD EYE® ON) in BLI mode should be activated for the evaluation of CAD EYE® optical characterization, in hyperplastic or neoplastic polyps, as well as the level of characterization (graduated from 1 to 3). The evaluation of the CAD EYE® should also be recorded by the endoscopist in the exam room who is not performing the colonoscopy, on its own record sheet. The iconographic record of evaluated polyps in WLI and BLI modes and the evaluation video using CAD EYE® in BLI characterization mode should be done.
10188670|NCT03714698|Active Comparator|Pilates Exercise Group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
10188671|NCT03714698|Placebo Comparator|Control Group|the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
9698111|NCT04749199|Experimental|Enhanced mirror therapy group|Participants in this group will perform complex and randomized finger opposition and reposition movements based on the training protocol, along with enhanced complexity and altered clarity of the displayed image.
9698112|NCT04749199|Sham Comparator|Standard mirror therapy group|Participants in this group will perform simple and sequential finger opposition and reposition movements, along with a clear image showing the exercising hand of the participants.
9698113|NCT04749056|Experimental|EPAS screening (intervention)|"Patients undergo EPAS (electronic psycho-oncological adaptive screening), a tablet-based screening application consisting of three adaptive tests and one supportive care checklist. EPAS provides immediate feedback via a printed results page, which presents and interprets the level of distress and contains individualized recommendations for psychosocial services.~The results pages are printed by research assistants immediately after the screening on a mobile printer and given to the participants together with a brochure containing information about all psychosocial services available at the health care institution.~The treating physicians also receive a slightly modified results page, but are not expected to discuss these with the patient unless they are highly distressed.~Before and during the screening, patients are explained how to use the program by the research assistance and supported if needed.~The whole screening process takes about 30 minutes."
9698114|NCT04749056|No Intervention|Care as usual (control)|"Patients complete the assessment paper pencil. The same instruments as in the intervention condition are used except for the 3 adaptive tests (i.e., the supportive care checklist and the outcomes).~Neither patients nor physicians receive any feedback of the results. Psychosocial services are recommended by the physicians on their own discretion only, and patients are not handed out the information brochure."
9698115|NCT04749121|Experimental|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes.The protocol was conducted in accordance with the protocol from the OSHA respiratory protection standard , including the number, type, and duration of the exercise, and the seal checks in accordance with the manufacturer's instructions[15] 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol)
9698116|NCT04749264||Mindfulness Meditation Retreat|6 to 7-days mindfulness meditation retreat
9698117|NCT04749264||No intervention, Matched control|Adults participants will be recruited from social media and local community of meditation practitioners, and will be matched to the retreat group by gender, age and level of experience in meditation.
9698118|NCT04748978|Experimental|symptomatic uterine fibroids|patients aged between 18 and 48 years with clinical and/or ultrasound diagnosis of uterine fibromatosis
9698119|NCT04749407||chemoradiotherapy|
9698120|NCT04748991|Experimental|Intravenous Vernakalant|Patients randomized to Vernakalant will receive a bolus of 3mg/kg over 10 minutes and an observation period of 15 minutes, if the patient is still in AF, they will receive an additional 2.0mg/kg bolus of Vernakalant.
10188672|NCT03714685|Experimental|Firibastat prototype tablet formulations|Firibastat (QGC001) 500 mg modified release prototype tablet formulations or immediate release capsule formulation - 1 tablet or 1 capsule administered per period
10188673|NCT03714646|Placebo Comparator|Placebo|
10188674|NCT03714646|Active Comparator|beta glucan|
10188675|NCT03714646|Experimental|beta glucan and Resistant Starch|
10188676|NCT03714620|Active Comparator|0.15 mg/kg IV Ketamine|
10188677|NCT03714620|Active Comparator|0.3 mg/kg IV Ketamine|
9785010|NCT01240551|Active Comparator|No-Mets via NaF-18 PET/CT|Patients with no clinical evidence of bone metastases
10188678|NCT03714607|Experimental|Laser|Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies
10188679|NCT03714607|No Intervention|Control|No intervention
9698121|NCT04748991|Active Comparator|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive 150mg IV bolus and an amiodarone infusion of 1mg/hr x 6 hours followed by 0.5mg/hr x 12 hours.
9698122|NCT04749147|Experimental|Black and White Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in black and white and feature black and white graphics.
9698123|NCT04749147|Experimental|Red Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in red text and feature red graphics.
10188680|NCT03714594|Active Comparator|Dapagliflozin 10mg|Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.
9698124|NCT04749043|Active Comparator|Virtual Reality then Nitrous Oxide|30 minute exposure to virtual reality, 5 minute washout period, then 30 minute exposure to nitrous oxide
10205387|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
9698125|NCT04749043|Active Comparator|Nitrous Oxide then Virtual Reality|30 minute exposure to nitrous oxide, 5 minute washout period, then 30 minute exposure to virtual reality
9698126|NCT04749069|Experimental|Continuous infusion of remifentanil|In continuous infusion group of patients, remifentanil was infused at a dose of 0.1 µg/kg/min and the additional bolus dose of 0.1 µg/kg was given if required. Before start of the operation, in both groups of patients, intravenous remifentanil at a bolus dose of 0.1 µg/kg was administered slowly in a duration of 60 seconds.
9698127|NCT04749069|Experimental|Patient-controlled sedoanalgesia (PCSA) of remifentanil|In PCSA group of patients, remifentanil was given by bolus PCSA using a pump (Pain Management Provider, Abbott Laboratories and Eczacibasi-Baxter, Ireland). In PCSA group of patients, remifentanil infusion was at a dose of 0.05 µg/kg, a bolus dose of 0.1 μg/kg with a lock-out time of three minutes.
9698128|NCT04749160||Rheumatoid arthritis (RA) with connected device|"RA with DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD.~the physical activity and sleep quality measured with connected device"
9698129|NCT04748913|No Intervention|No intervention|
9698130|NCT04748913|Other|Remineralization|
9698131|NCT04748887||nonsmokers copd cases ,|Fourty subjects of COPD who are non-smokers or stopped smoking for more than 6 months
9698132|NCT04748887||non smokers healthy control|Thirty subjects of non smokers healthy control
9698133|NCT04748562|Active Comparator|400 mg progesterone group|Taking 400 mg vaginal progesterone
9698134|NCT04748562|Active Comparator|200 mg progesterone group|Taking 200 mg vaginal progesterone
9698135|NCT04748874|Experimental|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
9698136|NCT04748874|No Intervention|Postponed mNC-FET|Standard procedure where mNC-FET is performed at least one full menstrual cycle after failed fresh embryo transfer or freeze-all cycle.
9698137|NCT04748809|Active Comparator|Arm_1|Anti-inflammatory diet 1
9698138|NCT04748809|Experimental|Arm_2|Anti-Inflammatory diet 2
9698139|NCT04748744||Patients undergoing colorectal surgery|
9698140|NCT04748822|Other|Quality of life of patients with AUD.|Patients' demographic data, socioeconomic status, physical diseases, medication use, clinical features of AUD, psychiatric variables, impulsivity, autonomy, sexual functioning, sleep quality, and cognitive functioning will be measured at baseline. The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
9698141|NCT04748575|Experimental|Acai smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the acai smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the placebo smoothie.
9698142|NCT04748575|Experimental|Placebo smoothie consumption|Participants (n=5) in this arm were randomly allocated to consume the placebo smoothie at the first intervention. After a 7 day wash-out period, the participants consumed the acai smoothie.
9698143|NCT04748614||Before SARS-Cov2|Before SARS-Cov2
9698144|NCT04748614||After SARS-Cov2|After SARS-Cov2
9778348|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Moderate Renal Impairment|Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
9778349|NCT01104701|Active Comparator|Group A|2 mg exenatide once weekly subcutaneous (SC). This arm is used as a reference arm in the study.
9778350|NCT01104701|Experimental|Group B|Low dose 5 mg exenatide once monthly suspension SC.
9778351|NCT01104701|Experimental|Group C|Medium dose 8 mg exenatide once monthly suspension SC.
9778352|NCT01104701|Experimental|Group D|High dose 11 mg exenatide once monthly suspension SC.
9778353|NCT01104766|Experimental|Cariprazine 3mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
9778354|NCT01104766|Experimental|Cariprazine 6mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
9785011|NCT01240590|Experimental|Ph I Level -1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 8 mg/m(2) Crolibulin
10188681|NCT03714594|Active Comparator|Saxagliptin 5mg|Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
10188682|NCT03714594|Active Comparator|Saxagliptin 5 mg + dapagliflozin 10 mg|Please see Arm 1 and 2
10188683|NCT03714581|Experimental|Laser|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
9698145|NCT04748757|Placebo Comparator|Placebo|Normal saline, 50 ml infusion over 30 minutes every 12 hours for 7 days
9698146|NCT04748757|Experimental|Low dose|50 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
9698147|NCT04748757|Experimental|High dose|100 microg/kg SY-005 in 50 ml saline infused over 30 minutes every 12 hours for 7 days
9698148|NCT04748679|Experimental|Worry Intervention|The Worry Intervention uses cognitive-behavioral therapy (CBT) techniques to support the patient in reducing the amount of time they worry throughout the week. It is an 8-week manualized treatment with 5 modules. Each session is 45-60 minutes.
9698149|NCT04748679|Active Comparator|Befriending|Befriending therapy controls for the general factors of therapy (warmth, engagement) without any 'active' interventions. Individuals in the befriending arm will spend sessions talking with the therapist about things that interest them. It will also be conducted over 8-weeks with 45-60 minute sessions.
9698150|NCT04748731|Experimental|Experimental Group. Video-feedback intervention.|A weekly online brief intervention using video-feedback and psycho-educational materials on early parenting (detailed description of the intervention on section 5).
9698151|NCT04748731|Other|Control Group. Psycho-educational intervention|They will receive weekly information on parenting in the 1st year of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
9698152|NCT04748770||patients with BMI≥30 kg/m2|
9698153|NCT04748770||patients with 25≤BMI≤30 kg/m2|
9698156|NCT04748484|Other|KCC active or inactive|The medical device KCC will be active, or inactive. Randomization will define when and how long time the medical device will be active, and when and how long time the medical device will be inactive. The patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
9698157|NCT04748692|Experimental|Local exercise therapy|The local exercise therapy group focused on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients trained with the support of a physiotherapist. The physiotherapist gradually increased the intensity of the exercises improving muscle endurance. The exercises were supplemented with mobilisations of the patellofemoral joint. Twice a week, patients trained at home following a prescribed exercise program writing down their work-out in an exercise journal.
9698158|NCT04748692|Experimental|Spinal manual therapy|The spinal manual therapy group was treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots were used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment included manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation was conducted if a restriction of range of motion was found in any of the regions. Patients were also asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
9698159|NCT04748705|Experimental|IMC-1 Oral Tablet|2X IMC-1 Tablet taken orally, each morning and evening.
9698160|NCT04748705|Placebo Comparator|Placebo|2X Placebo Tablet taken orally, each morning and evening.
9698161|NCT04748796|Experimental|Experimental group|2 days with landiolol IV + usual care
9698162|NCT04748796|Active Comparator|Control group|usual care according to the attending physician and following the guidelines of surviving sepsis campaign.
9698163|NCT04748380|Experimental|CRC DA|Stratifying by sex, 30 participants will be randomized to receive the CRC DA pamphlet.
9698164|NCT04748380|Other|Home Safety Pamphlet|Stratifying by sex, 30 will be randomized to receive the home safety information at the visit.
9698165|NCT04748328||ACL Reconstruction Group|This group received reconstruction treatment in Gatot Subroto Hospital, Jakarta
9698166|NCT04748328||Rehabilitation Group|This group received rehabilitation treatment with optional delayed reconstruction in Arifin Achmad Hospital, Pekanbaru
9698167|NCT04748393||Study cohort|Consecutive female patients between the ages of 18 and 50 with child bearing potential and objectivated, symptomatic VTE, who fulfil all the inclusion criteria and meet none of the exclusion criteria, are eligible for inclusion.
9698168|NCT04748354|Active Comparator|Usual Care|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months.
9698169|NCT04748354|Experimental|Usual Care with Exercise|Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months. In addition, they will receive the Otago Exercise Program, an individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist.
9698170|NCT04748211|Experimental|Infraclavicular Block|Group I received USG and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
9778355|NCT01104766|Active Comparator|Aripiprazole 10mg|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
9698171|NCT04748211|Experimental|Interscalen Block|Group II received USG and neurostimulator guided interscalen block. 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
9698172|NCT04748289|Experimental|NICU patients|All patients admitted to the Neurointensive Care Unit (NICU)
9698173|NCT04748471|Experimental|18-45 years old|18 - 45 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
9698174|NCT04748471|Experimental|65-74 years old|65 - 74 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
9698175|NCT04748471|Experimental|At least 75 years old|At least 75 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
9698176|NCT04748367|Experimental|Intervention group|Children wear VR headset during immunisation
9698177|NCT04748367|No Intervention|Control group|Children did not wear VR headset during immunisation( usual care)
9698178|NCT04748406|Active Comparator|Peloid Therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week(16).
9698179|NCT04748406|Active Comparator|ESWT(Extracorporeal Shock Wave Therapy)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied(4).
9698180|NCT04748315|Experimental|SEMT(1:1)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:1.
9698181|NCT04748315|Experimental|SEMPT(1:3)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:3.
9698182|NCT04748315|No Intervention|Control|Participants in this arm will receive no intervention
9698183|NCT04748263||Fronto-Temporal Dementia (FTD)|10 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
9698184|NCT04748263||Alzheimer's Dementia (AD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
9698185|NCT04748263||Parkinson's Disease (PD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
9698186|NCT04748263||Healthy volunteers|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
10188684|NCT03714581|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
10188685|NCT03714568|Experimental|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
9698187|NCT04748198|Experimental|Study group|Intracorneal ring segments are implanted for treatment of keratoconus, and posterior corneal surface is assessed preoperatively and postoperatively.
9698188|NCT04748341|Active Comparator|Traditional Group|Group A will be taught through the two steps traditional method (2 lectures/week + 1 skill lab/week). First, learn through didactic Lectures and then practice skills on the Mannequins. The educational lecture content will be the same for both groups.
9698189|NCT04748341|Experimental|Pedagogical Group|Group B will learn through the 5-step method [ 2 lectures/week + video + 2skill lab/week (1 session under instructor + 1 session for skill maintenance)], learn skill, see the video on resuscitation, practice on simulator, prove through practice, observe skill on clinical rotation and lastly maintain it through clinical supplemented with simulation.
9698190|NCT04748432||Multi-drug resistant group (MDR)|Patients with resistant NFGNB isolate as MDR group
9698191|NCT04748432||Non-Multi-drug resistant group (Non-MDR)|Patients with sensitive NFGNB isolate as Non-MDR group
9698192|NCT04748432||Control group (Control)|Patients without suspicion of VAP and other signs of nosocomial infection as the control group
10188686|NCT03714568|Experimental|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
10188687|NCT03714555|Active Comparator|Nab-Paclitaxel/Gemcitabine + DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Nab-Paclitaxel-Gemcitabine with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
9698195|NCT04748237|Experimental|Coronary computed tomopraphic angiography|"Patients randomized to strategy including early CCTA will receive standard care according to responsible physician and referred to a CCTA as soon as possible, preferably within 24 hours, but not later than within 7 days. Local scanning protocols can be used on ≥64-slice multi-detector CT scanners able to perform ECG-gated coronary angiography.~The coronary angiography will be classified as normal (or near normal) or as having atherosclerosis (CAD). The report will also classify each vessel (left main, prox LAD, mid or distal LAD, LCX and RCA regarding degree of stenosis (no stenosis, 0-49%, ≥50%, or not possible to estimate because of calcification or technical reason).~The result will be presented to the responsible physician as soon as possible and who will plan further care of the patients."
9698196|NCT04748237|No Intervention|No Coronary computed tomopraphic angiography|"Patients randomized to a strategy not including early CCTA will receive further care (including examinations) according to responsible physician but not include early CCTA. These patients will often undergo a non-invasive functional test, such as Exercise-ECG, stress echocardiography or nuclear imaging according to local routines, but not always.~Regardless of diagnostic strategy, the responsible physician is encouraged to initiate secondary prevention measures if the investigations indicate signs of CAD, including medication with aspirin and statins."
9698197|NCT04748666|Experimental|3 PST sessions and no boosters|
9698198|NCT04748666|Experimental|3 PST sessions with monthly boosters for 6 months|
9698199|NCT04748666|Experimental|6 PST sessions, no boosters|
9698200|NCT04748666|Experimental|6 PST sessions with monthly boosters for 6 months|
9698201|NCT04748419|Experimental|Hypofractionated radiation therapy (hfRT) with Durvalumab|Combining consolidative radiation therapy (RT) using a hypofractionated regimen (hfRT) of 10Gy x 2 fractions for boosting the residual primary lung cancer with adjuvant anti-PD-L1 therapy (durvalumab), dose of 10 mg/kg infusion every two weeks concurrently for up to 12 months or disease progression.
10205388|NCT02162420|Experimental|Treatment Plan for Dyskeratosis Congenita|Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.
9698202|NCT04748536|Experimental|Group 1: Dose A IRL201104 or placebo|IRL201104 IV once daily for 5 days OR Placebo IV once daily for 5 days
9698203|NCT04748536|Experimental|Group 2: Dose B IRL201104 or placebo|IRL201104 IV once daily for 7 days OR Placebo IV once daily for 7 days
9698204|NCT04748133|Active Comparator|acupuncture|"Patients in the acupuncture group will receive a standardised treatment with 12 needles (sharp tip, stainless steel needles, size 0.3 X 40 mm) at 7 acupuncture points Du 26 and Ren 17 (on the middle body line), and bilateral LI 4, HE 7, LV 3, ST 36 and PC 6). Application of the needles is performed by a licensed medical acupuncturist.~The needles will be inserted after endotracheal intubation and mechanical ventilation and will be removed immediately before patient extubation."
9698205|NCT04748133|Placebo Comparator|placebo|no treatment
9698206|NCT04748159|Experimental|Infants in prone position|The purpose of this intervention study is to evaluate short-term effects (within one hour) of prone positioning on vital signs in infants under 12 months of age with acute RSV bronchiolitis.
9698207|NCT04748107|No Intervention|Provider preference: Control group|Provider will prescribe blood pressure medication based on his professional expertise.
9698208|NCT04748107|Experimental|ICG directed therapy group|ICG directed therapy will be used to determine which blood pressure medication is received.
9698209|NCT04748042|Experimental|Abiraterone, ADT, Radiation and Olaparib|Abiraterone, ADT, radiation to all metastases and Olaparib.
10188688|NCT03714555|Active Comparator|FOLFIRINOX +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with FOLFIRINOX and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
9698210|NCT04748081||Surgery cohort|Patients who underwent hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4) between 2000 and 2012 were identified as the surgery cohort.
9698211|NCT04748081||Control cohort|Patients without any record of hepatectomy between 2000 and 2012 were defined as the control cohort.
9698212|NCT04747717|Experimental|Mitomycin C and cisplatin regimen|mitomycin C at 10 mg/m2 and cisplatin at 100 mg/m2
9698213|NCT04747717|Active Comparator|Paclitaxel and carboplatin regimen|paclitaxel at 175 mg/m2 and carboplatin AUC5-6
9698214|NCT04747834|Active Comparator|Cohort 1|Subjects with mild to moderate cataracts (Grade 1 to 2) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion.
9698215|NCT04747834|Active Comparator|Cohort 2|Subjects with moderate to dense cataracts (Grade 2+ to 3+) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion..
9698216|NCT04747665||Patients|Patients who have undergone or refused to undergo colonoscopy
9698217|NCT04747665||Endoscopists|Endoscopists who perform or are training to perform colonoscopy
9698218|NCT04747756|Other|Study participants|No participants will be randomized. All participants will have an opportunity to participate in the study procedures.
9698219|NCT04748016|Experimental|3D-printed models plus CT imaging|Fracture repair surgery using sterilized 3DP models, CT-MPR and CT-3DR for planning and intraoperative visualization
9698220|NCT04748016|Active Comparator|CT imaging alone|Fracture repair surgery using CT-MPR and CT-3DR for planning and intraoperative visualization
9698221|NCT04747782||COVID positive|Patients admitted to the ICU with respiratory distress found to be COVID19 positive.
9698222|NCT04747782||COVID negative|Patients admitted to the ICU with respiratory distress found to be COVID19 negative
9698223|NCT04747782||COVID positive delayed|Patients admitted to the ICU for an indication other than respiratory distress, found to be COVID19 positive.
9698224|NCT04747782||never-ICU|Patients admitted to the internal medicine ward with respiratory distress found to be COVID19 positive.
9698225|NCT04747990||Baseline (Pre-Covid19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2019
9698226|NCT04747990||Pandemic (During Covid-19) group|All patients admitted to the participating surgical departments with a clinical and radiological diagnosis of biliary acute pancreatitis in 2020
9698227|NCT04748068|Experimental|Glidesheath Slender|The transradial procedure will be performed using the 7-Fr glidesheath slender (studied sheath)
9698228|NCT04748068|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 7- French radial sheath (comparator sheath)
9698229|NCT04747691||Patients assessed with postoperative bedside gastric ultrasound|This patient population will include postoperative patients who received a gastrointestinal surgery and are being assessed with the bedside gastric ultrasound.
9778356|NCT01104766|Placebo Comparator|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
10188689|NCT03714555|Active Comparator|Single-Agent Gemcitabine +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Single-Agent Gemcitabine and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
10188690|NCT03714542|Other|Pre- and postoperative MRI|All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.
10188691|NCT03714529|Experimental|Treatment arm|"The vaccine consists of 500µl of 100µg PD-L1 peptide, dissolved in DMSO and PBS reconstituted with 500 µl Montanide ISA-51.~Patients will be vaccinated Q2W for 10 weeks, and a further 12 weeks if a clinical response is measured."
10188692|NCT03714503|Other|One day post-operative head positioning|patients will be assigned to remain a one-day post operative head positioning following retina re-attachment surgery
10205389|NCT02162420|Experimental|Treatment for Severe Aplastic Anemia|Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
10205390|NCT02157324|Experimental|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
9698230|NCT04747912|Experimental|Treatment Arm - Induction/Consolidation Phase - All Participants|"All participants in this arm will receive the same first round of treatment as part of induction/consolidation therapy. This treatment will use inotuzumab ozogamicin combined with anti-cancer drugs. The additional treatment that participants receive after this first round of treatment will vary based on the participant's response to induction therapy. This phase of treatment will last for 60 days. All participants in this arm will receive the following treatment:~Treatment Course I (Induction Phase, 28 days):~Dasatinib 140mg daily continuous~Dexamethasone 10mg/m^2 PO or IV Days 1-7 and Day 15-Day 22~InO 0.8mg/m2 Day 8; 0.5mg/m2 D15, 0.5mg/m2 Day 22~Intrathecal methotrexate 15mg Day 1, Day 28~Treatment Course II (Consolidation Phase, 28 days):~Dasatinib 140mg daily continuous~InO: If in CR/CRi 0.5mg/m2 Day 1, Day 8, Day 15; If not in CR/CRi 0.8mg/m2 on Day 1, 0.5mg/m2 Day 8 and Day 15~Intrathecal methotrexate 15mg Day 1, Day 28"
9698231|NCT04747912|Experimental|Treatment Arm - Interim/Maintenance Phase - Participants in CMR|"This study arm is for participants who no longer show any detectable signs of BCR-ABL1 (a cancer-causing gene) in response to the previous phase of induction/consolidation treatment (also known as being in complete molecular remission or CMR). Participants in this arm will receive 3 courses of interim/maintenance treatment using dasatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the fourth course of treatment. These treatments will be given in 28-day and 84-day cycles.~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, then the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission, they will complete 3 additional courses of maintenance treatment."
9698232|NCT04747912|Experimental|Treatment Arm - Interim/Maintenance Phase - Participants Not in CMR|"This study arm is for participants whose cancer responded to induction/consolidation treatment, but still shows detectable signs of BCR-ABL1 (a cancer-causing gene), so they are not in complete molecular remission. Participants in this arm will receive 3 courses of treatment using ponatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the 4th treatment course. These treatments will be given in 28-day and 84-day cycles.~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission (CMR), they will complete 3 additional courses of maintenance treatment.~If the participant doesn't achieve CMR after 4th treatment course, they will be removed from the study."
9698233|NCT04747808|Experimental|LL-BMT1|Group 4 extended-wear contact lens printed with bimatoprost
9698234|NCT04747964|Experimental|A single lowest dose of treatment group|
9698235|NCT04747964|Experimental|A single low dose of treatment group|
9698236|NCT04747964|Experimental|A single intermediate dose of treatment group|
9698237|NCT04747964|Experimental|A single high dose of treatment group|
9698238|NCT04747964|Experimental|A single highest dose of treatment group|
9698239|NCT04747938|Experimental|Energy accumulator|Energy Accumulator was a portable handheld device invented for local heat therapy for healthcare purpose. All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts.
9698240|NCT04747938|Experimental|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
9698241|NCT04747743||Egyptian dental practitioners|170 dental practitioners in Egypt (professionals both academic and nonacademic).
9698242|NCT04747951|Experimental|total neoadjuvant therapy|Total neoadjuvant therapy consisted chemoradiotherapy with capecitabine and nine weeks of consolidation chemotherapy with XELOX prior to surgery and adjuvant therapy if necessary.
9698243|NCT04747951|Active Comparator|standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
9698244|NCT04747821|Experimental|First group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the first week of study The vaccine is administrated in two doses with a four-weeks interval
9698245|NCT04747821|Experimental|Second group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the second week of study The vaccine is administrated in two doses with a four-weeks interval
9698246|NCT04747821|Experimental|Third group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the third week of study The vaccine is administrated in two doses with a four-weeks interval
9698247|NCT04747821|Experimental|Fourth group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the fourth week of study The vaccine is administrated in two doses with a four-weeks interval
10188693|NCT03714490|Experimental|Experimental group|The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.
9778357|NCT01104779|Experimental|Cariprazine (3-6 mg/day)|Cariprazine once daily fixed-flexible low dose
9778358|NCT01104779|Experimental|Cariprazine (6-9 mg/day)|Cariprazine once daily fixed-flexible high dose
10188694|NCT03714490|Active Comparator|Control group|The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.
10188695|NCT03714477|Active Comparator|Treatment Arm|immediate extracorporeal shock wave lithotripsy - subject will have SWL arranged in the next available list
10188696|NCT03714477|No Intervention|Control Arm|delayed extracorporeal shock wave lithotripsy - subject will have SWL done 6 months later
9698248|NCT04747873|Experimental|e-CBT|12 weekly sessions with approximately 30 slides and interactive content, delivered through OPTT designed to mirror in-person standard CBT. Participants go through the content and complete homework at the end of the session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases. On average, developing this feedback takes a therapist 15-20 minutes per patient. In addition to the weekly feedback, participants have the option to message their therapist through the platform throughout the week regarding any questions or concerns they may have.
9698249|NCT04747873|Experimental|e-CBT + Stepped Care|"1 - Participant will receive message from assigned care provider on OPTT who check-in with them about strategies and techniques they have discussed and remind them of weekly homework due date.~2.- Participant will receive phone call from therapist who will check-in on them, remind them of therapy strategies, and verbally remind them of weekly homework due date.~3 - Participant will receive phone call from assigned care provider who will check-in on them, remind them of some therapy strategies and techniques and weekly session due date, and provide CBT summary of previously reviewed CBT concepts.~4 - articipant will receive video call (Microsoft Teams) from their therapist who will check-in on them, remind them of weekly session due date, and provide CBT content support to participant.~5 - Participant will receive CBT sessions in live video call (Microsoft Teams) with research psychiatrist involved in care."
9698250|NCT04747795|Placebo Comparator|standard care + placebo|The 'standard care' group will receive intermittent infusion of normal saline (3 ampoules of 5 ml 9mg/ml normal saline diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
9698251|NCT04747795|Active Comparator|standard care + Vitamin C|The 'standard care + Vitamin C' group will receive intermittent infusion of Vitamin C (3 ampoules of 500 mg/5ml Vitamin C diluted in 50 ml of normal saline, every 6 hours) during 4 days or until hospital discharge and is started within 6 hours after presentation (time of triage) in the ED.
9698252|NCT04747392|Other|Sequence A|The test drug (SAL001) is administrated once by subcutaneous injection in the first period, and the reference drug (FORSTEO) is administrated once by subcutaneous injection in the second period.
9698253|NCT04747392|Other|Sequence B|The reference drug (FORSTEO) is administrated once by subcutaneous injection in the first period, and the test drug (SAL001) is administrated once by subcutaneous injection in the second period.
9698254|NCT04747405|No Intervention|A standard|standard of care
9698255|NCT04747405|Experimental|B therapy group|standard of care and therapy group
9698256|NCT04747340|Experimental|Training for Awareness, Resilience and Action (TARA)|12 weekly online sessions, each 90 minutes, 6 participants/group. For participants <18 years at CAP, parents/legal guardians will participate in parts of the sessions. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
9698257|NCT04747340|Active Comparator|Standard Treatment|Standard treatment (ST) as given at each participating study site. ST is based on the health practitioners' knowledge, experience, current guidelines and both the practitioners' and participants' preferences. For young people with depression The Swedish National Board of Health and Welfare recommends social support and psychoeducation (as first priority), Selective Serotonin reuptake inhibitors (as second priority) and cognitive behavioral therapy (as second priority). These recommendations are generally followed and given as stand-alone treatment or in different combinations. In our study we have no control over which of these treatments are given in the ST-arm, nor the combination or timing of them. To obtain data on what treatment has been given in the ST-arm we will go through the individual medical records of all participants at the conclusion of data collection.
9698258|NCT04747327|No Intervention|general health topic|Those in this arm will receive a message about how people have different health preferences.
9698259|NCT04747327|Experimental|specific health incentive information 1|Those in this arm will learn about a financial incentive (with a relatively large sum) or a social incentive
9698260|NCT04747327|Experimental|specific health incentive information 2|Those in this arm will learn about a financial incentive (with a relatively small sum) or a social incentive
9698261|NCT04747327|Experimental|facts only|Those in this arm will receive a statement about vaccine safety.
9698262|NCT04747327|Experimental|mandatory language|Those in this arm will receive a statement about how vaccination may be mandatory.
9698263|NCT04747327|Experimental|freedom language|Those in this arm will receive a statement about how vaccination is currently not required and they have the freedom to choose what they want to do.
9778359|NCT01104779|Placebo Comparator|Placebo|Placebo
9778360|NCT01104792|Experimental|Cariprazine|Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.
9778361|NCT01104870|Active Comparator|Dose Group 1|UT-15C 0.25 mg twice daily
9778362|NCT01104870|Active Comparator|Dose Group 2|UT-15C 1.25 mg twice daily
10188697|NCT03714464|Experimental|Whole Apple|"Participants will be given 350g of whole apple and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
10188698|NCT03714464|Experimental|Apple Puree|"Participants will be given 384g of apple puree and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
9698264|NCT04747574|Other|EXO-CD24 exosome treatment|"Group 1, 5 patients are treated with 1x10^8 exosome particles per 2 ml saline.~Group 2: 5 patients are treated with 5x10^8 exosome particles per 2 ml saline.~Group 3: 20 patients are treated with 1x10^9 exosomes particles per 2 ml saline.~Group 4: 5 patients are treated with 1x10^10 exosomes particles per 2 ml saline.~The drug is aerosolized in normal saline for inhalation and administered via a standard hospital-grade inhalation device, QD for 5 days. Study treatment is given as an add-on to the standard of care."
9698265|NCT04747444|Other|100% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 100% full body weight loading
9698266|NCT04747444|Other|50% body weight walking|Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 50% full body weight loading
10188699|NCT03714464|Experimental|Apple Juice|"Participants will be given 338g of apple juice and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes"
10188700|NCT03714438|Experimental|Medicago sativa|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
10188701|NCT03714438|Placebo Comparator|Placebo|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
10188702|NCT03714425|Active Comparator|High frequency device|Subjects will use high frequency Quell devices.
10188703|NCT03714425|Sham Comparator|Low frequency device|Subjects will use low frequency Quell devices.
9698271|NCT04747639|Active Comparator|verum 500|500 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
9698272|NCT04747639|Placebo Comparator|control 500|500 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
10188704|NCT03714412|Experimental|Implantation|Eligible patients will undergo implantation with the Cardiovalve system
9698273|NCT04747639|Active Comparator|verum 250|250 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
9698274|NCT04747639|Placebo Comparator|control 250|250 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
9698275|NCT04747535|No Intervention|Control|Regular treatment
9698276|NCT04747535|Experimental|Auto CPAP|Auto CPAP, AirSense 10 AutoSet, ResMed Inc, max pressure 10 cm water, min pressure 5 cm water
9698277|NCT04747535|Other|CPAP since before|Patients with CPAP since before will all continue using CPAP. They will not attend the randomization process. They will be regarded as a separate group.
9698278|NCT04747483|Active Comparator|Extension Oriented Treatment Approach|"The EOTA intervention involves three components. The first component is a series of active extension- oriented exercises: Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension.~The second component of the EOTA is subject education. Subjects are being educated to maintain the natural lordosis of the lumbar spine while sitting, and are being instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension.The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
9698279|NCT04747483|Experimental|EOTA+ Mechanical Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
9698280|NCT04747301|Other|Double-balloon catheter group|Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA).
9698281|NCT04747301|Other|Vaginal insertion Prostaglandin E2 group|Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).
9698282|NCT04747288||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG). Exclusion Criteria: NA.
9698283|NCT04747288||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 and 1997 revised Systemic lupus erythematosus criteria. Exclusion Criteria: NA.
9698284|NCT04747288||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min. Exclusion Criteria: NA.
9698285|NCT04747288||non AIDDES Healthy Controls|Non AIDDES Healthy Controls were enrolled with inclusion criteria: (1) aged between 20 and 75 years; (2) without any Chronic disease. Exclusion Criteria: any Sjögren's syndrome, Systemic lupus erythematosus, or Dry eye syndrome.
9698286|NCT04747262|Experimental|SPACE INTERVENTION|counseling
9778363|NCT01104870|Active Comparator|Dose Group 3|UT-15C individual Maximum Tolerated Dose
10188705|NCT03714386|Experimental|expanded hemodialysis (HDx)|HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
10188706|NCT03714386|Active Comparator|online hemodiafiltration (HDF-OL)|OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
10188707|NCT03714373|Experimental|DCCR|75 - 450 mg DCCR
10188708|NCT03714360|Experimental|TXA tranexamic acid|a single dose of 10 mg/kg of TXA, with a maximum dose of 1g. Administered as IV injection and marked as 'project-drug' and amount (mL) in the medical record.
9698287|NCT04747223|Experimental|Retraining (RT) Group|The retraining group will receive a watch accelerometer to use for monitoring their step rate with instructions to increase their preferred step rate by 7.5% over the ten in-field training sessions.
10188709|NCT03714360|Placebo Comparator|Sodium Chloride 0,9%|an equivalent volume 0.9 % Sodium Chloride.
9698288|NCT04747223|No Intervention|Control (CON) Group|The control group will receive the same device to monitor their pace but receive no instruction to change their preferred step rate over the ten in-field training sessions.
9698289|NCT04747002|Active Comparator|Administration Group|Patients who are injected with DSP-7888.
9698290|NCT04747002|No Intervention|Non-administration Group|Patients who are only under observation.
9698291|NCT04747028||Primary dentition|Children from 4 to 6 years old suffering from malnutrition
9698292|NCT04747028||Age 13 to 16|Adolecentsfrom 13 to 16 suffering from malnutrition at present time or during their childhood
10188710|NCT03714347|Active Comparator|Group Control|routine monitoring will be applied to this group
10188711|NCT03714347|Active Comparator|Group Oxygen|cerebral oxygen monitoring is applied to this group
10188712|NCT03714334|Experimental|DNX-2440 injection|all the patients included will be treated with the experimental agent
10188713|NCT03714321|Experimental|Mechanical insufflation-exsufflation arm|MIE will be given as prescribed by physician responsible at the intermediate care unit, typically every 4 hours. MIE will be administered with standard settings of insufflation 20 cm H2O and exsufflation 20 cm H2O, with possible individual changes from 10/-10 H2O up to 40/-40 H2O, and oxygen flow up to 15 l/min. The standard settings will be set to five cycles of 2 seconds insufflation, 3 seconds exsufflation with a three second pause between each cycle. Every treatment session consists of five rounds of five cycles, in all 25 insufflation/exsufflation, with time between each cycle of 30 seconds, meant used for suction.
9698296|NCT04747015|Active Comparator|Cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus
9698297|NCT04747015|Active Comparator|Active management|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
9698298|NCT04746937|Placebo Comparator|Control Group|They will receive standard therapy plus placebo
9698299|NCT04746937|Active Comparator|Nitazoxanide Group|They will receive standard therapy plus nitazoxanide
9698300|NCT04747080|Experimental|TAC and HD-DXM|"Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).~Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks."
9698301|NCT04747080|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14) .
9698302|NCT04747093|Experimental|ITNK group|
9698303|NCT04746898|Experimental|Virtual Reality Training Group (VR group)|The students in the first group received basic life support practice training with virtual reality applications.
10188714|NCT03714321|No Intervention|CPAP arm|CPAP will be given as prescribed by the physician responsible at the intermediate care unit, typically every 4 hours. CPAP will be administered with standard settings of H2O and an oxygen flow of 15L/min.
10188715|NCT03714295||Use of interdental brushes|The group use interdental brushes one time each day and wash teeth with a classical brush two times a day
10188716|NCT03714295||No use of interdental brushes|The group wash teeth with a classical brush two times a day
10188717|NCT03714282|Experimental|Noninvasive Spinal Stimulation with Gait Training|May receive up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
10188718|NCT03714282|Active Comparator|Conventional Gait Training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
10205391|NCT02157324|Experimental|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
10205392|NCT02050997||B|Unresectable or metastatic PDAC patients who will receive standard treatment of CT +/- radiotherapy
9698304|NCT04746898|Experimental|High Fidelity Simulation Training Group (HFS group)|The students in the second group received basic life support practice training with high fidelity simulators.
9698305|NCT04746898|Experimental|Low Fidelity Simulation Training Group (LFS group)|The students in the third group received basic life support practice training with the classical method, low-reality mannequin.
9698306|NCT04747171|Active Comparator|magnesium intrathecal|
9698307|NCT04747171|Active Comparator|dexamethasone intrathecal|
9698308|NCT04747171|Active Comparator|dexmedetomidine intrathecal|
9698309|NCT04747106|Experimental|plasma exchange|when ADP inhibition >30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
9698310|NCT04747106|No Intervention|standard medical treatment|standard medical treatment
9698311|NCT04747041|Experimental|Alternating each month for 1 year between Phytocyst herbal tea and Cyscontrol|Alternating each month (From Day1 to DAY15) for 1 year between Phytocyst herbal tea and Cyscontrol = Preventive Treatment In case of episode of cystitis : AROMAFEMINA, Capsules for the comfort of the urinary tract Oleocaps 2 : 2 capsules before meals, 3 times a day for 5 consecutive days.
9698312|NCT04747145|Experimental|Pulsed reduced dose-rate radiotherapy|Chemoradiation, adjuvant chemotherapy.
9698313|NCT04747184||Asthmatic patients|Asthmatic patients aged 14-year-old, and more were included in the study. Knowing that patient with the age of 14-year is treated as adults at Al Bashir Hospital. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
9698314|NCT04747184||Healthy subjects|Healthy subjects aged 14-year-old, and more were included in the study. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
9698315|NCT04747158|Experimental|Convalescent plasma|COVID-19 convalescent plasma
9698316|NCT04747197|Experimental|EYP-1901 440 ug|EYP-1901 440 ug, single dose
9698317|NCT04747197|Experimental|EYP-1901 2060 ug|EYP-1901 2060 ug, single dose
10188719|NCT03714282|Other|Healthy Control Group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
10188720|NCT03714269|Experimental|Children with cerebral palsy of the spastic type|
10188721|NCT03714243|Experimental|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
9698318|NCT04747197|Experimental|EYP-1901 3090 ug|EYP-1901 3090 ug, single dose
9698319|NCT04747132|Experimental|Intervention group|Individualized geriatric medical counseling, psychological counseling, nutritional counseling and physical activity counseling through the internet
9698320|NCT04747132|No Intervention|Control group|Health guidance through standardized audiovisual educational material through Intenert
9698321|NCT04746885|Other|Group A|(interventional group/ DHA): A minimum of 40 preterm infants will be included to receive 100mg DHA daily administered by enteral route for 30 days. This group will be subdivided into breast fed / artificially fed infants.
9698322|NCT04746885|Other|Group B|(control group / Placebo): 40 of preterm infant controls will be included to receive placebo (physically matched solution). This group will be subdivided into breast fed / artificially fed infants.
9698323|NCT04747210|Active Comparator|Trainig workshop and Coaching one-on-one|Ten-hour training workshop that was divided into three sessions outside working hours. Coaching one-on-one in the daily routines and natural environment.
9698324|NCT04747210|Active Comparator|Trainig workshop|Assistants receive ten-hour training workshop that was divided into three sessions outside working hours.
9698325|NCT04747119|Experimental|study group|received the conventional selected exercise program in addition to muscle energy technique
9698326|NCT04747119|Experimental|control group|received the conventional selected exercise program
9698327|NCT04746599|Experimental|Patients with critic limb ischemia|"Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions.~After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs."
9698328|NCT04746690|Active Comparator|Slider neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch on one nerve end and slackness on the other end.
9698329|NCT04746690|Active Comparator|Tensioner neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch of both nerve ends.
9698330|NCT04746690|Active Comparator|Stretching exercises of back extensors, hamstrings and gastrocnemius muscles|Stretching exercises of back extensors, hamstrings and gastrocnemius to relief the pressure on the nerve.
9698331|NCT04746677|Experimental|Complex abdominal aortic aneurysm (AAA)|Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm
9698332|NCT04746677|Experimental|Thoracoabdominal aortic aneurysm (TAAA)|Includes Type I, Type II, and Type III TAAA
10188722|NCT03714217|Experimental|Intervention|Telenutrition counseling
10188723|NCT03714204|Experimental|Transcendental Meditation Group|Participants assigned to this group each received the intervention of 5 initial class instructions in the Transcendental Meditation technique, followed by 6 additional classes over the 4-month study period. Group participants were expected to practice the technique for 20 minutes twice per day for 4-months.
10188724|NCT03714204|No Intervention|Control Group|Participants assigned to this group served as wait-list controls
10188725|NCT03714191||Improved outcomes|
10188726|NCT03714191||Regulatory reminder|
10188727|NCT03714191||Billing and documentation|
9698333|NCT04746677|Experimental|Type B aortic dissection|
9778364|NCT01105065|Experimental|Patients with RVD|Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.
9778365|NCT01105091|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
9778366|NCT01105091|Active Comparator|2|Flolan®
9778367|NCT01105117|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
9778368|NCT01105117|Active Comparator|2|Flolan®
9778369|NCT01105130|Placebo Comparator|Arm I - Placebo|Patients receive oral placebo twice daily (total of 6 capsules per day).
9778370|NCT01105130|Experimental|Arm II - low dose|Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
9778371|NCT01105130|Experimental|Arm III - high dose|Oral L-arginine twice daily = 6 capsules per day.
9778372|NCT01105247|Experimental|PCI-32765|
9785012|NCT01240590|Active Comparator|Ph I Level 1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
9785013|NCT01240590|Active Comparator|Ph I Level 2: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
10188728|NCT03714178|Experimental|FARAPULSE Endocardial Ablation|Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.
10188729|NCT03714152|Experimental|ABI-H2158|ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
10205393|NCT02050997||A|Resectable PDAC patients who will receive standard treatment of CT +/- radiotherapy
9698334|NCT04746612|Experimental|HH30134|HH30134 administered orally on a continuous once daily(QD), start from 100mg QD.
10188730|NCT03714152|Placebo Comparator|Matching Placebo for ABI-H2158|Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days
10188731|NCT03714139|Experimental|Immediate implant Loading|Immediate loading is defined as the placement of the implant and immediate prosthetic restoration
9698335|NCT04746742|Active Comparator|Tunneled femoral catheter|20 patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
9698336|NCT04746742|Active Comparator|Femoral artery-femoral arteriovenous graft|a straight or loop configuration 28patients with end stage renal disease and exhausted upper-extremity and chest-wall vascular accesses will be randomly allocated to this group
9698337|NCT04746651|Experimental|Guided Self Help|"Four guided self-help booklets were used; Why do I feel so bad? covered formulation/understanding feelings, I can't be bothered doing anything centred on activity scheduling, Why does everything always go wrong? focused on thought-challenging, and How to fix almost everything incorporated problem solving. Linked worksheets were adapted following feedback from Prison Officers."
9698338|NCT04746755|Experimental|Experimental: Lower back pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced lower back pain; the subjects selection was corroborated by a physiotherapist.
9698339|NCT04746755|Experimental|Experimental: Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the heels of their feet; the subjects selection was corroborated by a physiotherapist.
9698340|NCT04746755|Experimental|Experimental: Knee to Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced Knee to Heel pain; the subjects selection was corroborated by a physiotherapist.
9698341|NCT04746755|Experimental|Experimental: Arch pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the arch of their feet; the subjects selection was corroborated by a physiotherapist.
9698342|NCT04746664|Other|Nutrition counselling|The intervention will be home-to-home-visit once per week lasting 30 minutes to one hour for one month period. The convenience day and time will be selected in the discussion.
9698343|NCT04746508||Unilateral Flat Foot (UniFF)|Participants with flat foot unilaterally (Only one foot's Calcaneal pitch angle ≤ 20 degree)
9698344|NCT04746508||Bilateral Flat Foot (BiFF)|Participants with flat foot bilaterally (Both feet's Calcaneal pitch angle ≤ 20 degree)
9977915|NCT01366482|Experimental|Severely Ca++ Group|Subjects with a severely calcified lesion will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
9977916|NCT01366508|Other|Visit B|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
9698347|NCT04746716||Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who had a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
9698348|NCT04746716||No Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who hadn't a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
9698349|NCT04746781|Active Comparator|Risk notification/education arm|We will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk
9698350|NCT04746781|Experimental|Mobile 360° Video intervention arm|After risk notification and education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.
9698351|NCT04746781|Experimental|Motivation and Problem Solving (MAPS) arm|After risk notification and education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting goals related to their health, and addressing any practical barriers to enrolling/engaging in the DPP if that is consistent with their health goals. Per their preference, participants will receive up to 5 phone calls from the health coach over a 4 week period.
9698352|NCT04746482||exposure group|subjects in this group are single visit
9698353|NCT04746469|No Intervention|Control|This group will receive standard FIT mailer protocol (includes mailed FIT kit plus standardized messaging via EHR portal)
9698354|NCT04746469|Experimental|Intervention|This group will receive standard FIT mailer protocol (as above) PLUS delayed automated phone reminder
9698355|NCT04746768|Experimental|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
9698356|NCT04746443||STUDENTS|COLLEGE STUDENTS WITH POSITIVE COVID-19 TEST
9698357|NCT04746430|Experimental|Intervention|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
9698358|NCT04746430|No Intervention|Control|Only remote monitoring
10188732|NCT03714139|No Intervention|non implant loading|there is not immediate prosthetic restoration
9698362|NCT04746287|Experimental|Part A|Single dose administration
9698363|NCT04746287|Experimental|Part B|Multiple dose administration (food Effect)
9698364|NCT04746287|Experimental|Part C|Multiple dose administration
9698365|NCT04746287|Placebo Comparator|Placebo|Matching placebo
9698366|NCT04746300||Group 1: no sequencing|Participants in this group, for which DNA sequencing could not be reported due to a variety of (quality/technical) reasons, will be treated with standard of care therapy. This group is therefore comparable to patients treated outside the Radboudumc.
9698367|NCT04746300||Group 2: no druggable aberration|Participants in this group received a DNA sequencing report identifying no biomarkers to which a logical treatment option can be connected. These participants will also receive standard of care therapy.
9698368|NCT04746300||Group 3: allocated to personalized treatment|Participants in this group received a DNA sequencing report which identified presence of a biomarker allowing the participant to be treated with a personalized therapy. This therapy could range from immunotherapy, or PARP inhibitors, to other medication.
9698369|NCT04746196||45 ankylosing spondylitis patients.|Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.
9698370|NCT04746196||35 controls|Healthy controls
9698371|NCT04746365|Experimental|ivermectin|ivermectin was given as a total daily dose of 36 mg on days 0, 3, 6. The daily dose was divided into 3 equal doses of 12 mg (2 tablets) every 8 hours
9698372|NCT04746365|Experimental|hydroxychloroquine|hydroxychloroquine was given as 200 mg (one tablet) every 12 hours for 5 days
9698373|NCT04746365|Placebo Comparator|Placebo|Unlabelled standard treatment according to the clinical condition of patients
9698374|NCT04746326|Other|Conservative treatment|Conservative treatment stopping oral intake, intravenous antibiotic therapy.
9698375|NCT04746326|Other|Operative treatment|Operative procedure Right hemicolectomy Wedge resection of cecum Diverticulectomy + appendectomy Diverticulectomy Appendectomy + drainage
9698376|NCT04746339|Active Comparator|Apixaban Group|
9698377|NCT04746339|Placebo Comparator|Placebo Group|
9698378|NCT04746313||Patients with systemic sclerosis|The study will be systematically offered to any scleroderma patient seen in scheduled hospitalization
9698379|NCT04746313||Healthy subjects|Healthy subjects who will donate blood to the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex
9698380|NCT04746222|Experimental|Treatment|Single dose of 30 oral capsules containing FMT from a stool bank
9698381|NCT04746222|Placebo Comparator|Placebo|Single dose of 30 oral placebo capsules
9698382|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Myeloablative HCT|Patients who are MRD Negative by Flow cytometry but are MRD Positive by High Throughput Sequencing, will receive a myeloablative conditioning regimen which includes total body irradiation (TBI) followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
9698383|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Reduced Intensity HCT|Patients who are MRD Negative by Flow cytometry and are MRD Negative by High Throughput Sequencing, will receive a reduced intensity conditioning regimen followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
9698384|NCT04746261|Experimental|ASSIP plus treatment as usual|ASSIP according to manual. Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
9698385|NCT04746261|Active Comparator|Treatment as usual|Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
9698386|NCT04746391|Experimental|Solacea_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
9698387|NCT04746391|Experimental|Solacea_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
9698388|NCT04746391|Experimental|Solacea_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
9698389|NCT04746391|Experimental|FX800_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
9698390|NCT04746391|Experimental|FX800_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
9698391|NCT04746391|Experimental|FX800_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
9698392|NCT04746157|Experimental|Intervention group|Patients will have a directly contact with the lead nurse by telephone during the study. The referent nurse will provide support and will promote engagement of patient to adequate secondary prevention measures. In addition, she will provide education based on stroke risk and identified vascular risk factors by Stroke Riskometer.
9698393|NCT04746157|No Intervention|Usual care|Usual care
9698394|NCT04746352|Experimental|BES-SMFR group|Using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. Three standardized programs were used in our study: (1) Tens electricity (first program): 5 min of 50-280 Hz frequency and a pulse duration of 50 µs. (b) Endorphin electricity (second program): 5 min of 1-10 Hz frequency and a pulse duration of 200 µs. (c) Spasmolysis electricity (third program): 5 min of 1-2 Hz frequency and a pulse duration of 300 µs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive.
9785014|NCT01240590|Active Comparator|Ph II Level 3: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 20 mg/m(2) Crolibulin
9785015|NCT01240590|Active Comparator|Ph II Level 4: Cisplatin|100mg/m(2) Cisplatin
9785016|NCT01240746|Active Comparator|Group 1: Licensed 2010-2011 TIV|Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.
9698395|NCT04746352|Active Comparator|BES group|"A standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use.~Patients were required to participate in intensive training regarding myofascial release techniques. (I) Pressing: press directly on a specific MTrP with gentle, slow pressures (2kg/cm2) using a flat palpation, the pressure was sustained until the participant perceived the pain decreased and taut band released, and then gradually increased to previous level of MTrPs tension and maintained until a reduction of pain again. The process was usually 3 to 5 repetitions for 90 sec. (II) Stretching: stretch in parallel to the direction of the myofascial to facilitate elongation of a contracted muscle. (III) Strumming: stroking and strumming the affected muscles region with the fingertips to aid in MTrPs tension release, the initial pressure was small and increased gradually until the patients adapted."
9698396|NCT04746170|Experimental|Multiparous|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
9698397|NCT04746170|No Intervention|Multiparous Control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
9698398|NCT04746170|Experimental|Primipar|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
9698399|NCT04746170|No Intervention|Primiparous control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
9698400|NCT04746118|No Intervention|CONTROL|During routine clinical visits the patients will receive a written standard general guidelines for diet and physical activity.
9698401|NCT04746118|Experimental|DIET CHANGE|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive a written general guidelines for exercising without supervision.
9698402|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY|In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision.
9698403|NCT04746118|Experimental|DIET CHANGE + PHYSICAL ACTIVITY + INTEGRATIVE PRACTICES|"In scheduled nutritional care the patients will receive an individual program with social media supervision. Those patients will also receive an exercise physical program prescription with fitness evaluation and close supervision and submitted to orientated mind-fullness, auriculotherapy and laying on of hands approaches that belong to health integrative practices."
9698404|NCT04746183|Experimental|CST-2 EIDD-2801|"EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
9698405|NCT04746183|No Intervention|CST-2 Control|Phase 1b only (standard of care)
9698406|NCT04746183|Placebo Comparator|CST-2 Placebo|Phase II placebo blinded controlled
9698407|NCT04746183|Experimental|CST-3A Nitazoxanide|Phase Ia Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur
9698408|NCT04746183|Experimental|CST-5 VIR-7832|Single doses of VIR-7832 will be administered by intravenous (IV) infusion. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated.
9698409|NCT04746183|Active Comparator|CST-5 VIR-7831|Phase II: 500 mg dose of VIR-7831 will be given by IV infusion.
9698410|NCT04746183|Placebo Comparator|CST-5 Placebo|Phase I and II placebo blinded controlled
9698411|NCT04746183|Experimental|CST3B Nitazoxanide|
9698412|NCT04746183|No Intervention|CST3B Control|Standard of care
9698413|NCT04746248|No Intervention|Baseline|The baseline arm includes participants from before the implementation of the outpatient regime. All participants are induced according to the standard inpatient protocol.
9698414|NCT04746248|Active Comparator|Women choosing to stay at the hospital|Include women who choose to stay at the hospital after implementing an outpatient alternative.
9698415|NCT04746248|Experimental|Women choosing to go home|Include women who choose the outpatient regime.
9977917|NCT01366508|Other|Visit A|At approximately 13:00 the subject will be given a standard high calorie lunch that the subject is required to finish
9977918|NCT01366547|Experimental|Single Arm|Subjects will be randomized in a three-way crossover design to receive a single dose of each of two different tablet formulations of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg or dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg). There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
9698418|NCT04746053|Other|patient with a mutation in the HNF1B gene|Patient with a mutation in the HNF1B gene and which are followed in the reference centers
9698419|NCT04746040|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
9698420|NCT04746040|Active Comparator|Reference Product|ADVAIR DISKUS 250/50
9977919|NCT01366560|Experimental|GSK962040|The subjects will be administered GSK962040 125 mg tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
9698421|NCT04745767|Experimental|Group 1: A1(T1), B(T2), C(T2 Fed)|Participants will be randomly placed into 6 sequences within Group 1. All participants in Group 1 will receive TAK-994 as Treatment A1 (T1 Formulation) and Treatment B (T2 Formulation) under fasted conditions and Treatment C (T2 Formulation) under fed conditions at different times within three periods.
9785017|NCT01240746|Experimental|Group 2: Investigational TIV|Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain
9698422|NCT04745767|Experimental|Group 2: A2(T1), D(T3), E(T3 Fed)|Participants will be randomly placed into 6 sequences within Group 2. All participants in Group 2 will receive TAK-994 as Treatment A2 (T1 Formulation) and Treatment D (T3 Formulation) under fasted conditions and Treatment E (T3 Formulation) under fed conditions at different times within three periods.
9698423|NCT04745767|Experimental|Group 3: A3(T1), F(T4), G(T4 Fed), H(T5)|Participants will be randomly placed into 6 sequences within Group 3. Participants in Group 3 will receive TAK-994 as Treatment A3 (T1 Formulation), Treatment F (T4 Formulation), and Treatment F (T5 Formulation) under fasted conditions and Treatment G (T4 Formulation) under fed conditions at different times within 4 periods.
9698424|NCT04745611||COVID-19 non-ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
9698425|NCT04745611||COVID-19 ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
9698426|NCT04745611||COVID-19 non-ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
9698427|NCT04745611||COVID-19 ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
9698428|NCT04745741||IB-positive group|Patients with level IB metastasis and histologically confirmed positive by biopsy.
9698429|NCT04745793||Thyroids|The aim is to identify and preserve the parathyroid glands during the total or partial removal of the thyroid. Repeating of the procedure for each lobe
9698430|NCT04745793||Parathyroids|The aim is to selectively remove the pathological parathyroid gland(s). Repeating of the procedure for each removed gland
9698431|NCT04745780|Experimental|Study Arm|Treated with a formulation containing Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months.
9698432|NCT04745780|Placebo Comparator|Placebo Arm|Treated with Placebo - Two-times daily on an empty stomach, for 6 months.
9698433|NCT04745858|Experimental|Bowen's Technique|Sequence of short gentle moves are applied over Hamstrings.Skin slack is taken to lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are be given for 4 weeks. The treatment time for each session is 20 minutes.
9698434|NCT04745858|Active Comparator|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
9698435|NCT04745936|Experimental|C-curve group (group C)|In group C, stylet curvature is made similar to the natural curvature of endotracheal tube.
9698436|NCT04745936|Active Comparator|Hockey stick curve group (group H)|In group H, stylet curvature is made similar to hockey stick shape.
9698437|NCT04745923||Patients with chronic kidney disease|Having been diagnosed with chronic kidney disease
9698438|NCT04745923||Healthy individuals|Healthy individuals without chronic disease
10188733|NCT03714126||HF patients|HF patients will use the Cordio Medical app to record in their hospital visits and at home.
10188734|NCT03714113|Experimental|Kidney transplant recipients.|Patients who undergo kidney transplant in 2018 or 2019.
9698439|NCT04745663|Experimental|Povidone-Iodine 0.3 %|A tampon is soaked in diluted PI 0.3% and placed on the inside of the lower eyelid of one eye, where it will release iodine molecules for 20 minutes before being removed.
9698440|NCT04745663|Active Comparator|Povidone-Iodine 5 %|Eye drops of 5% PI is the standard disinfection before eye surgery. The drops will be dripped in one eye and allowed to work for 2 minutes.
9698441|NCT04745806|Experimental|ActiGraft|Whole blood clot (WBC) gel
9698442|NCT04745598||Control group: Dental model|Patients diagnosed with periodontal disease stage I/II/III
9698443|NCT04745598||Computer-assisted teaching format group|Patients diagnosed with periodontal disease stage I/II/III
9698444|NCT04745598||Plaque-disclosing group|Patients diagnosed with periodontal disease stage I/II/III
10188735|NCT03714100|Experimental|MFBB intervention|All participants will attend Tai Ji Quan: Moving for Better Balance classes twice a week for 16 weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
9698445|NCT04745598||Intra-oral Camera group|Patients diagnosed with periodontal disease stage I/II/III
9698446|NCT04745533||SARS-CoV2 contacts|Subjects considered close contacts of COVID-19 patients according to the definition of the Ministry of Health in the health area of Cáceres.
10188736|NCT03714087|Experimental|T1 Conventional treatment before aligner|T1 before aligner: Conventional orthodontic treatment patients before the essix aligner
10188737|NCT03714087|Experimental|T2 After essix aligner|T2 after the aligner: Essix aligner appliance with setup for 3 weeks full time
9698447|NCT04745871|Experimental|Intervention|All patients with prostate cancer undergo PSMA PET/CT as part of the trial in addition to standard methods (abdo-pelvic MRI and a bone scan).
9698448|NCT04745572|Experimental|High Carbohydrate Diet|Enrollment in State of Slim (SOS) weight loss program with high carbohydrate diet plan.
10188738|NCT03714087|Active Comparator|Historic control group|Conventional orthodontic treatment without finishing protocol UdeA2
10188739|NCT03714074|Experimental|PEEK abutment|PEEK abutment restored with PEEK superstructure
10188740|NCT03714074|Experimental|Zirconia abutment|zirconia abutment restored with PEEK superstructure
9698449|NCT04745572|Experimental|Reduced Carbohydrate Diet|Enrollment in State of Slim (SOS) weight loss program with reduced carbohydrate diet plan.
9785018|NCT01240746|Experimental|Group 3: Investigational QIV|Participants will receive the investigational Quadrivalent Influenza Vaccine
9698450|NCT04745260|Experimental|Intranasal Midazolam and Intranasal Fentanyl|Study participants assigned to the combination (experimental) group will receive a weight-based dose of intranasal Fentanyl (50mcg/mL concentration at 2mcg/kg up to 100mcg) followed by intranasal Midazolam (5mg/mL concentration at 0.2mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
10188741|NCT03714061|Experimental|Pain Neuroscience Education (PNE)|The PNE will be administered following Explaining Pain concepts (Butler and Moseley, 2013), initially contextualizing the importance of the program. The program will be administered as interactive workshops lasting 50 minutes. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
9698451|NCT04745260|Active Comparator|Intranasal Midazolam|Study participants assigned to the control (active comparator) group will receive only intranasal Midazolam (5mg/mL concentration at 0.3mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
9698452|NCT04745247|Experimental|RSS|Repetitive somatosensory stimulation (RSS)
9698453|NCT04745247|Placebo Comparator|Sham RSS|Sham Repetitive somatosensory stimulation (RSS)
10188742|NCT03714061|Active Comparator|Self-Management Education (SME)|The SME education will be administered as an interactive workshop lasting 50 minutes. The program is based on the Back-book material (Roland et al, 2011), focusing on concepts targeting change of behavior and beliefs. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
10188743|NCT03714048||Perioperative|
10188744|NCT03714048||Cardiogenic shock minus arrest|
9698454|NCT04745338|Placebo Comparator|low caloric diet|low caloric diet (1200cal/day)
9698455|NCT04745338|Active Comparator|cryolipolysis|cryolipolysis 3 sessions one session every 6 weeks by 3max cool shaping device
10188745|NCT03714048||Cardiogenic shock plus arrest|
9698456|NCT04745520|Experimental|Rib fixation (medical devices)|Surgery and pain medication. The pain of patients will be treated with rib fixation and pain medication.
9698457|NCT04745520|Active Comparator|Pain medication (comparator treatment)|Pain medication only.
9698458|NCT04745546|Experimental|WeFlow-JAAA Stent Graft System|Participants will be treated with WeFlow-JAAA Stent Graft System
10188746|NCT03714048||Preventive|
10188747|NCT03714009|Active Comparator|Fasting group|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. They should take adequate water and non calorie beverages intake daily (2-3 liters)"
9698459|NCT04745286|Experimental|S-ketamine group|
9698460|NCT04745286|Placebo Comparator|saline group|
9698461|NCT04745325|Experimental|Smartphone app - full access|"A smartphone app containing 5 modules: 1) personalized feedback on alcohol use (containing normative feedback by age and sex for those located in the Canada), 2) self-monitoring and goal setting tool, 3) tool to choose a designated driver, 4) blood alcohol content (BAC) calculator, and 5) educational information on alcohol use and its consequences (i.e. fact sheets)."
9698462|NCT04745325|Active Comparator|Smartphone App - education only|"A version of the Smartphone app containing only the module with the educational information on alcohol use and its consequences (i.e. fact sheets)."
9698463|NCT04745182|Experimental|MASTERY|For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and will contain space to write a specific physical activity goal and to track physical activity (e.g., through step counter data) over the subsequent week. At the in-person visit #2, interventionists will explain PP exercise 1 and MI session 1 to the participants. Calls will last ~30 minutes. Participants will then independently complete PP exercises and MI-based goals and review them at phone sessions over 12 weeks. PP and MI components will be delivered stepwise within sessions (rather than intertwined) based on our experience, participant feedback, and pilot work.
9698464|NCT04745273|Active Comparator|Ondansetron|Participants will receive Kemoset 4 mg iv intraoperatively
9698465|NCT04745273|Placebo Comparator|Salin solution|Participants will receive Salin solution 2ml (iv) intraoperatively
9698466|NCT04745364|Experimental|Session One|Session One participants undergo the 4-week course from 2/21/2021 to 3/15/2021
9698467|NCT04745364|Experimental|Session Two|Session Two participants undergo the 4-week course from 3/22/2021 to 4/12/2021
9698468|NCT04745442|Experimental|Best available treatment + Antithrombin|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
9698469|NCT04745442|Active Comparator|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
9698470|NCT04745416||Leukemia and COVID-19|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization and confirmed diagnosis of COVID-19 by RT-PCR test
9698471|NCT04745416||Leukemia|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization without suspicion of COVID-19
9698472|NCT04745429|Experimental|Intervention|19 people suffering from psoriasis were performing excersises for 10 weeks
9698473|NCT04745429|No Intervention|Control|19 people suffeing from psoriasis that didn't train the exercises
9785019|NCT01240785|Active Comparator|Metformin|Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
10188748|NCT03714009|Other|Non fasting group|no fasting, patients will have usual balanced diet as 3 meals and 2 snacks all over the day. They should take adequate water and non calorie beverages intake daily (2-3 liters)
10188749|NCT03713996|Experimental|CBT-I intervention|The intervention includes several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components.
10188750|NCT03713996|Active Comparator|Diabetes Education|Sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity will be delivered for the Health Education group. During all sessions, subjects will be encouraged to engage in the discussion through open questions about their experience in diabetes, lifestyle, and understanding about provided materials.
10188751|NCT03713970|Experimental|Celtra duo press|Celtra duo press ingot 20g for three laminate veneers
9698474|NCT04745468|Experimental|Apheresis Group|"20 patients receive 2 apheresis treatments at intervals of 24 ± 12 h (additionally to the standard therapy after bypass surgery). The first treatment starts within 24 h postoperatively. If the CRP concentration increases to at least 30 mg/L 6-18 h after the end of the second treatment, a third treatment is performed.~For each treatment the 1 - 2.5-fold plasma void is processed. The duration of each treatment is 4-6 h."
10188752|NCT03713970|Active Comparator|IPS e.max press|IPS e.max press ingot 20g for three laminate veneers
10188753|NCT03713957|Experimental|GRF6021|Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
10188754|NCT03713957|Placebo Comparator|Placebo|Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
9698475|NCT04745468|No Intervention|Control group|17 patients of the control group receive the standard therapy after bypass surgery.
9698476|NCT04745403|Experimental|mRNA HBV/TCR T-cells|Escalating regime from 1x10e5 to 5-10x10e6 cells/kg bodyweight (BW) every 2 weeks.
9698477|NCT04745390|Active Comparator|Standard Dose Radiation|Patients in the standard arm will receive a standard dose of 2000cGy in 5 fractions using simple CT planning. IMRT is allowed. Treatment will be every second day excluding weekends and holidays.
9698478|NCT04745390|Experimental|Personalized Dose Selection Radiation|Patients in the experimental arm will receive individually selected prescription dose guided by radiobiological parameters described below, preferably delivered in 5 fractions every other day, excluding weekends and holidays. Volumetric-modulated arc therapy (VMAT) is the preferred planning technique. Typical planning uses 2 arcs, <=10MV and FFF mode where possible as almost all liver treatments are gated). In the event of multiple lesions, multiple isocentres are allowed. Often lateral isocentre shifts are significant and therefore arc ranges should be chosen to minimize collision risk. Treatment will be every second day excluding weekends and holidays.
9698479|NCT04745481|Experimental|Trunk stabilization training device|Participants will receive conventional rehabilitation and use trunk stabilization training device 30min each daily, 20 times for 4weeks.
9698480|NCT04745481|Active Comparator|Conventional rehabilitation|Participants will receive conventional rehabilitation 60min daily, 20times for 4weeks.
9698481|NCT04745494|Active Comparator|OT administration|All participants will receive a single dose of 24IU OT (40.32µg, Syntocinon) delivered via a nasal spray.
9698482|NCT04745494|Placebo Comparator|Placebo administration|All participants will receive a single dose of a placebo delivered via a nasal spray.
9698483|NCT04745195||Complement-mediated thrombotic microangiopathy|
9698484|NCT04745195||Thrombotic microangiopathty with normal complement regulation|
9698485|NCT04745208|No Intervention|standard discharge education|The control group will receive only the standard discharge education.
9698486|NCT04745208|Experimental|standard discharge education+Simulation based education|The intervention group will receive standard discharge education and then simulation based education will be performed
9698487|NCT04745377||Control Group|Healthy volunteers from hospital personnel vaccinated for covid-19, who sign informed consent for recording of outcomes and monitor of antibody titers in 3 timepoints
9698488|NCT04745377||Cancer patients|Cancer patients with solid tumours, with active disease and/or undergoing active systemic treatment, who will be vaccinated for covid-19
9698489|NCT04744805||mask wear|
9698490|NCT04744805||dry eye|
9698491|NCT04744883|Experimental|SMT plus placebo/naloxone|Participants are randomly assigned to an 8 week SMT treatment group conducted by certified physical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
9698492|NCT04744883|Experimental|MT plus placebo/naloxone|Participants are randomly assigned to an 8 week MT treatment group conducted by certified clinical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
9698493|NCT04745130|Experimental|Intervention arm 1|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
9698494|NCT04745130|Experimental|Intervention arm 2|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with or without cetuximab 500mg/m2 q2w
9698495|NCT04744909|Experimental|Percutaneous tracheotomy using a new device|
9698496|NCT04744922|Experimental|Auraptene and Naringenin Arm|One capsule a day for 9 months
9698497|NCT04744922|Placebo Comparator|Control Arm|One capsule a day for 9 months
9698498|NCT04744961||Surgical site infections|
9698499|NCT04744961||Normal would healing|
9698500|NCT04744857|Experimental|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
9698501|NCT04744987||Hypovolemic hyponatremia|Patients with any cause of hypovolemic hyponatremia were included.
9698502|NCT04744987||Euvolemic hyponatremia|Only patients with euvolemic hyponatremia secondary to Syndrome of inappropriate antidiuresis were included.
9836114|NCT02769481|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
10188755|NCT03713918|Experimental|Reinforced lithium silicate endocrown|Device: Endocrown restoration
9698503|NCT04744753|Active Comparator|study group|. This group involved 75 patients with history of fertilization failure in which oocytes were activated by calcium ionophores
9698504|NCT04744753|No Intervention|control group|This group involved 75 patients with history of fertilization failure in which oocytes were not activated by calcium ionophores
9698505|NCT04744974|Experimental|Mediterranean diet|Participants will be given dietician counseling on a Mediterranean diet
9698506|NCT04744974|Experimental|DASH diet|Participants will be given dietician counseling on a DASH diet
9698507|NCT04744779|No Intervention|Observation|Observation only.
9698508|NCT04744779|Experimental|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
10188756|NCT03713918|Active Comparator|Reinforced lithi silicate crn e post|Device: Post retained reinforced lithium silicate crowns
10188757|NCT03713892|Experimental|CKD-504|investigational Drug
9698509|NCT04744948|Placebo Comparator|low caloric diet|low caloric diet 1200cal/day
9698510|NCT04744948|Experimental|treadmill|treadmill aerobic exercise training
10188758|NCT03713892|Placebo Comparator|Placebo|investigational Drug
9698511|NCT04744935|Active Comparator|Standard|1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
9698512|NCT04744935|Active Comparator|Slow|1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
9698513|NCT04744766|Active Comparator|Hadfield technique group|central/mammary duct excision is done by the ordinary method described by Hadfield
9698514|NCT04744766|Active Comparator|Al Masad technique group|same procedure with de-epithelization of the upper pararaeolar area
9698515|NCT04745117||Women with suspected breast cancer|"All women referred under the diagnosis suspected breast cancer will be asked to fill out the questionnaire READHY."
9698516|NCT04745039|Experimental|Endopatch System|Participants will be treated with Endopatch System
9698517|NCT04744740||PTSD+Suicidal Ideation|US Military Veterans diagnosed with PTSD and identified via the REACH VET or local high-risk list as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
9698518|NCT04744740||PTSD-Suicidal Ideation|US Military Veterans diagnosed with PTSD not identified as requiring intensified surveillance by their VA's Suicide Prevention Coordinators in collaboration with their Primary Care Providers
9778373|NCT01105312|Experimental|panobinostat (LBH589) and letrozole|Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks. There are two phases of the study. The first phase determines the maximum tolerated dose for LBH589 in combination with letrozole. The second phase is to assess and confirm the response rate and safety profile of LBH589 in combination with letrozole.
10188759|NCT03713879|Experimental|indomethacin|rectal indomethacin 100 mg to be administered before or after ERCP
10188760|NCT03713879|Experimental|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
9778374|NCT01105377|Experimental|Treatment (entinostat, azacitidine)|Patients receive azacitidine subcutaneously on days 1-5 and 8-10 and oral entinostat on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9778375|NCT01105533|Experimental|Cohort 1|
9778376|NCT01105533|Experimental|Cohort 2|
9778377|NCT01105533|Experimental|Cohort 3|
9778378|NCT01105533|Experimental|Cohort 4|
9778379|NCT01105533|Experimental|Cohort 5|
9778380|NCT01105533|Experimental|Cohort 6|
9778381|NCT01105533|Experimental|Cohort 7|
9778382|NCT01105533|Experimental|Cohort 8|
9778383|NCT01105533|Experimental|Cohort 9|
9778384|NCT01105533|Experimental|Cohort 10|
9778385|NCT01105650|Experimental|Arm 1: CsA|Patients receiving Cyclosporine (CsA) and Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
10188761|NCT03713879|Experimental|indomethacin plus pancreatic stenting|"[rectal indomethacin 100 mg to be administered before or after ERCP] plus [a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire]"
9778386|NCT01105650|Experimental|Arm 2: CsA plus Methylprednisolone (10mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer cells (NK) infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
9778387|NCT01105650|Experimental|Arm 3: CsA plus Methylprednisolone (1 mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
9778388|NCT01105650|Experimental|Arm 4: CsA minus Methylprednisolone|Patients receiving Cyclosporine (CsA), no methylprednisolone, eliminating IL-2 doses 4-6 and receiving Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 3 doses given post NK cell infusion.
9778389|NCT01105702|Experimental|TBL/RT|"Cycle 1(One 42-day cycle)~Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment~Radiation within 3-5 weeks of surgery~Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks~Treatment Cycles 2-7 (28 days per cycle)~Temozolomide at a dose of 150 mg/m^2 on Days 1-7~Bevacizumab 10 mg/kg on Day 8 and Day 22~Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L."
9778390|NCT01105754|No Intervention|Standard Care|Parents of children in the standard care group will complete the baseline assessment, but no asthma prompt will be created for either the caregiver or provider, and no information regarding the interview will be shared with the provider. After the baseline assessment, the office visit will proceed according to usual care.
9778391|NCT01105754|Experimental|Multifaceted Prompting Intervention|Multifaceted Prompting Intervention
9778392|NCT01105767|No Intervention|Group 1 Standard|Trainees received a preventive medicine briefing augmented with SSTI and MRSA SSTI prevention information and personal hygiene instructions. Trainees seeking medical care for an SSTI received standardized SSTI care (e.g., antimicrobial therapy, wound management, patient education) at the Troop Medical Clinic. High-touch common surfaces within the battalion areas were cleaned with standard Environmental Protection Agency-registered disinfectants.
10188762|NCT03713853||Total hip arthroplasty + ORIF|Patients will receive acute primary total hip arthroplasty (THA) with open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
10205394|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
10188763|NCT03713853||Surgical Fixation (ORIF)|Patients will receive open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
9698519|NCT04744818|Active Comparator|Immediate iron treatment|Iron and multivitamin syrup
9698520|NCT04744818|Placebo Comparator|Delayed iron treatment|Multivitamin syrup
10188764|NCT03713840|Experimental|Healthy Beverages in Child Care|Child care centers in the experimental arm received 12-week intervention that promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
10188765|NCT03713840|No Intervention|Control|Child care centers in the control arm received access to intervention materials at a later date.
9698521|NCT04745052||Patients with acute ischemic stroke|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
9698522|NCT04744792||Patients|All the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
9698523|NCT04744792||Spouses|Spouses of the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
9698524|NCT04745000||Pulmonary Hypertension Participants|Children with Primary Pediatric Pulmonary Arterial Hypertension
9698525|NCT04745000||Control Participants|Children with a healthy heart and lungs
9698526|NCT04744727|Active Comparator|paracetamol group|Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
9698527|NCT04744727|Active Comparator|pethidine group|Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor [roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%].
9698528|NCT04744896|Experimental|cryolipolysis|3max cool shaping device is administered 3 times for each patient, one session every 6 weeks, each session is 40 minutes.
9698529|NCT04744896|Experimental|treadmill|aerobic training in form of high intensity interval training, three times per week for 3 weeks by treadmill(jkexer focus 8020A) each session is for 20 minutes.
9698530|NCT04744896|Active Comparator|treadmill+cryolipolysis|aerobic training 3 times per week and cryolipolysis once every 6 weeks
9698531|NCT04744844|Experimental|DNA-amplification selection|In the experimental arm, all blastocysts will undergo routine morphological assessment, with the 3 top-scoring blastocysts undergoing blastocoel fluid biopsy (BF-biopsy) and whole-genomic amplification. A single blastocyst with no DNA amplification will be selected for transfer in a frozen embryo transfer cycle.
9698532|NCT04744844|Active Comparator|Morfological-score selection|In the active comparator arm, all blastocysts will undergo routine morphological assessment. The (single) top-scoring blastocyst will be selected for transfer in a frozen embryo transfer cycle.
9698533|NCT04744714||GDM group|questionnaire survey and clinical follow-up
9698534|NCT04744714||non-GDM group|questionnaire survey and clinical follow-up
9698535|NCT04744688||48 cytoreductive surgery with HIPEC patients|48 patients with peritoneal metastases from colorectal cancer undergoing cytoreductive surgery with HIPEC (cytoreductive surgery with HIPEC patients)
9698536|NCT04744688||48 minimally invasive patients|48 rectal cancer patients undergoing minimally invasive rectal cancer resection
9698537|NCT04744376||Major GIS Surgery|"The cohort includes all the patients who undergone major gastrointestinal (GIS) surgery.~Major GIS surgery includes:~Gastric surgery~Duodenal surgery~Pancreatic surgery~Hepatobiliary surgery~Colonic surgery~Rectal surgery"
9836115|NCT02769481|Active Comparator|Glimepiride|Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
10188766|NCT03713827|Active Comparator|"composite resin, Ceram-x One Universal"|"tooth restoration with nano-ceramic composite resin Ceram-x one Universal"
10188767|NCT03713827|Active Comparator|"glass ionomer cement, Equia Forte"|"Tooth restoration with glass ionomer cement (Glass hybrid restorative system) Equia Forte"
10205395|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
9698538|NCT04744649|Active Comparator|XELOX or SOX|XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.
9698539|NCT04744649|Experimental|JS001+XELOX or SOX|XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1. JS001: 240mg, ivdrip, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Capecitabine: 1000mg/m2 Bid, d1-14, q3w; Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.
9698540|NCT04744402|Experimental|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
9698541|NCT04744402|Active Comparator|Microfracture surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate.
9698542|NCT04744506|Experimental|TAD ARM|
9698543|NCT04744675|Experimental|Treatment|"The intervention group will receive:~Suprascapular nerve block - 3 mL of 0.5% Bupivacaine and 1 mL of 40 mg/mL Kenalog~Median nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog~Ulnar nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog"
9698544|NCT04744675|Placebo Comparator|Placebo|"Placebo~The placebo group will receive:~Suprascapular nerve injection - 4 mL of normal saline~Median nerve injection - 4 mL of normal saline~Ulnar nerve injection - 4 mL of normal saline"
9698545|NCT04744480|Experimental|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
10188768|NCT03713814|Experimental|Experimental Group|8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.
9698546|NCT04744480|No Intervention|The routine induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia.In the routine induction group，all procedures will be the same as those of the topical anesthesia group, The drug will be replaced with constant volume saline.
9698547|NCT04744584||Patients with medication reconciliation|Patient with medication reconciliation during 1st hospitalization
9698548|NCT04744584||Patients without medication reconciliation|Patient without medication reconciliation (MR) at 1st hospitalization but with retrospective MR at the next one (3 to 6 months after)
9698549|NCT04744545|Experimental|Meru Health Program plus adjunctive curcumin (MHP-CUR)|Meru Health Program (12 week program) with participants taking 2 turmeric supplements (1500mg/day) curcumin.
9698550|NCT04744545|Active Comparator|Meru Health Program (MHP-ONLY)|Meru Health Program (12 week program)
9698551|NCT04744558|Experimental|Ketogenic|Low carb high fat ketogenic diet
9698552|NCT04744558|Active Comparator|Non-ketogenic|Low carb high fat non-ketogenic diet
9698553|NCT04744493|Experimental|treatment arm of Exablate 4000 as a single arm|Only one arm of treatment by Exablate 4000 was established.
9698554|NCT04744324|Experimental|Self-supporting Care Group|Self-supporting Care in home
9698555|NCT04744324|Active Comparator|Control group|Home Health Education
9698556|NCT04744623|Experimental|effect of large dose corticosteroids with intra-lestional injection in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I)
9698557|NCT04744623|Experimental|effect of of (MMF), dapsone and cortisone in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
9698558|NCT04744610|Other|4-hour delayed radiographs|The follow-up radiographs was taken 4 h after the HSG operation.
9698559|NCT04744662|Experimental|Treatment Group A|ONL1204 Ophthalmic solution (dose A) administered by intravitreal injection
9698560|NCT04744662|Experimental|Treatment Group B|ONL1204 Ophthalmic solution (dose B) administered by intravitreal injection
10188769|NCT03713814|No Intervention|Control group|After the 8 weeks of intervention, the pilots will receive explanation and handbook demonstration of the same exercises.
9698561|NCT04744662|Sham Comparator|Treatment Group C|sham injection without penetrating the eye
9698562|NCT04744571|Experimental|DCB group|Patients treated with Drug-Coated Balloon Angioplasty after revascularization of Chronic Total Occlusions
9698563|NCT04744571|Active Comparator|DES group|Patients treated with Drug eluting stents Angioplasty after revascularization of Chronic Total Occlusions
9698564|NCT04744467|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
10188770|NCT03713788|Experimental|Experimental pain group|subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. They were instructed to immerse it to wrist-level and keep the hand open.
10188771|NCT03713788|No Intervention|Control group|Participants rested in a seated position for 5 minutes.
10205396|NCT01981720|Experimental|1.0 mg/kg|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
10205397|NCT01859130|Other|Persona TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
10205398|NCT01822652|Experimental|iC9-GD2 T Cells - fresh - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
10205399|NCT01822652|Experimental|iC9-GD2 T Cells - frozen - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
9698565|NCT04744597|Experimental|Real execution group|The real execution group will perform the acute intervention by the actual performance of the Fitt's law task.
9698566|NCT04744597|Experimental|Motor imagery group|The motor imagery group will perform the acute intervention by simulating (mental process) the Fitt's law task.
9698567|NCT04744597|Active Comparator|Control group|The control group will perform skip counting.
9698568|NCT04744532|Experimental|Drug: Bosutinib|"3 to 6 ALS patients will be enrolled in each of the 4 bosutinib dose lelvels [100 mg/day (dose level 1), 200 mg/day (dose level 2), 300 mg/day (dose level 3), or 400mg/day (dose level 4)] to evaluate the safety and tolerability of the investigational drug (bosutinib) under a 3+3 dose escalation study design. The dose will be escalated by 1 dose level at a time; no skipping will be allowed.~Dose escalation and MTD will be determined by the safety assessment committee comprising oncologist, hematologist, ALS Expert based on the incidence of DLT in 4 weeks of treatment among 3 subjects enrolled (6 subjects if additionaly enrolled) in each dose level."
9698569|NCT04744428|Experimental|Autism Parent Navigators Intervention|Autism Parent Navigators Intervention is a manualized, in-home, peer support model for parents with a young child recently diagnosed with ASD.
9698570|NCT04744428|Active Comparator|Peer mentoring|Peer mentors will offer an equivalent number of in-home or telephone visits for families, providing non-manualized peer support.
9698571|NCT04744337|Other|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliance for skeletal class II, Angle's class II division 2 malocclusion.
9698572|NCT04744259|Experimental|Behavioural activation|The treatment is designed to be delivered to individuals alongside a carer who provides regular support to them. It is a structured, time limited, manualised psychological therapy, developed to treat those with an intellectual disability and depressive symptoms.
9698573|NCT04744259|No Intervention|Treatment as usual|This will include the existing treatments available in NHS and social care for adults with intellectual disability with depression, including anti-depressants, mood stabilizers, and any available psychological interventions. Additionally, for all those in the study, we will provide their General Practitioner with a summary of the NICE guidelines on treatment of depression for adults with intellectual disabilities.
9698574|NCT04744142|No Intervention|Placebo|Received 10% protein in nutrition + placebo supplement
9698575|NCT04744142|Experimental|Ketone|Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day
9698576|NCT04744142|Experimental|High protein|Received 30% protein in nutrition + placebo supplement
9698577|NCT04744142|Experimental|High protein + ketone|Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day
9698578|NCT04744064|Experimental|Soccer and protein supplementation|Soccer training and post exercise supplementation of protein enriched beverage
9698579|NCT04744064|Experimental|Soccer and carbohydrate supplementation|Soccer training and post exercise supplementation of carbohydrate enriched beverage
9698580|NCT04744064|No Intervention|Control group|A preliminary control group continueing normal lifestyle
9698581|NCT04744129|Active Comparator|NN414|To investigate the role of NN414 compared with placebo in migraine patients.
10188772|NCT03713775|Experimental|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Weight Loss Programme with behavioural support. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counsellors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients. The programme conventionally includes the 3 phases (meal replacement phase, transition phase, and weight maintenance phase) but the Consultant will have full discretion to modify and tailor this programme to suit each individual participant.
9698582|NCT04744129|Placebo Comparator|Saline|To investigate the role of NN414 compared with placebo in migraine patients.
9698583|NCT04744038|Experimental|Investigational Device|Participants will then be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device. Participants will use their own mask with the investigational device for the duration of this study.
9698584|NCT04744012||unique group|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
9698585|NCT04743986|Experimental|Platelet Rich Plasma (PRP)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. Injection was 3-5ml at the site of tendon pathology with the remainder of the PRP preparation infiltrated into the subacromial space. A leukocyte-poor preparation was used from a pre-packaged kit (RegenLab, Lausanne, Switzerland). The samples were centrifuged at 1500g for 5 mins to yield approx 5.5ml of 80% platelets at 1.6x concentration. The supernatant was then resuspended by inverting the tube several times and was drawn into a separate 5-ml syringe for subacromial injection.
9698586|NCT04743986|Active Comparator|Corticosteroid (CS)|Patients had 10ml venous blood drawn. Injection was performed under ultrasound guidance by one of two musculoskeletal radiologists. The blood sample was kept for a similar time delay for centrifugation prior to injection, and was then discarded. 1ml of 40-mg/ml triamcinolone was suspended in 2ml of 0.5% bupivicaine. Injection was performed through a lateral subacromial approach after needle fenestration of the supraspinatus tendon under ultrasound visualization. CS was infiltrated into the subacromial bursa and not the tendon itself.
9785020|NCT01240785|Active Comparator|insulin|NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
10188773|NCT03713775|Active Comparator|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min at the John Radcliffe Hospital, Oxford) together with supporting written information (i.e. a copy of the booklet 'Facts not fads - Your simple guide to healthy weight loss.')
10188774|NCT03713762|Experimental|Group 1 LB|Peribulbar block 1 was performed received 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml
10188775|NCT03713762|Experimental|Group 2 LBF|Peribulbar block 2 was performed received 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
10188776|NCT03713749|Experimental|Robot Esophagectomy (RE)|Patients in the RE group will receive robotic-assisted esophagectomy with standard total two-field lymphadenectomy.
10188777|NCT03713749|No Intervention|Video-assisted thoracoscopic esophagectomy (VATE)|Patients in the VATE group will receive thoracoscopic esophagectomy with standard total two-field lymphadenectomy.
10188778|NCT03713736|Other|Female patients with spondyloarthritis or rheumatoid arthritis|Female patients (18 to 65 years old) with spondyloarthritis or rheumatoid arthritis will undergo HPV screening and a have a close gynecologic follow-up.
10188779|NCT03713723||Patients undergoing IVF treatment with hemodynamic monitoring|Fifty health women aged 18-45 undergoing their first, second or third cycle of IVF treatment will be monitored with the non invasive NICaS bioimpedance
10188780|NCT03713710|Experimental|Pap testing|Women assigned to this arm will be scheduled a Pap testing appointment at the local health department
9698587|NCT04744194|Active Comparator|Nordic hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
9698588|NCT04744194|Experimental|Single leg bridge exercise program|The single leg bridge is performed with the participant lying on the ground in supine with one heel on a box that is approximately 60cm in height and the knee in approximately 20 degrees of flexion. The participant then crosses their arms across their chest and pushes down through the heel to lift their hips off the ground so that their hips extend into a position of zero degrees flexion. The participant then allows their hips/buttocks to slowly lower to the ground.
9698589|NCT04744220|Experimental|Yoga Training Group|"Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session.~During the program, the perceived fatigue intensity of the patients will be questioned with the Modified Borg Scale.~Yoga Session~1-4 weeks and duration~Breathing Exercises 5 min~Instant Relaxation Technique 2 min~Warm-up Exercises 10 min~Quick Relaxation Technique 3 min~Asanas (Posture Exercises) 15 min~Deep Relaxation Technique 3 min~4-8 weeks and duration~Breathing Exercises 5 min~Instant Relaxation Technique 2 min~Warm-up Exercises 10 min~Quick Relaxation Technique 3 min~Asanas (Posture Exercises) 15 min~Alternative Breathing Exercises 10 min~Deep Relaxation Technique 3 min"
9698590|NCT04744220|No Intervention|Control group|"Training: The exercise program will include respiration exercises that they can do at home.~Before the exercise program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters and tests used in the evaluation. Respiratory control, breathing exercises, relaxation techniques and the reasons, importance and effects of exercise training in the treatment program will be explained.~Breathing Exercises (10 min) Pursed-lip breathing training, Chest breathing exercise (10 repetitions), Diaphragmatic breathing exercise (10 repetitions), Bilateral basal expansion breathing exercises (10 repetitions) Warm-up Period Stretching and flexibility exercises (5 minutes) Strengthening exercises with theraband (15-20 minutes) Exercises to strengthen lower extremity and upper extremity muscles Cooling Period Stretching and flexibility exercises (5 minutes)"
9698591|NCT04743752||Group OSA+NSCLC|According to the baseline sleep monitor results, participants will be divided into Group OSA+NSCLC if apnea hypopnea index(AHI) no less than 15.
9698592|NCT04743752||Group NSCLC|According to the baseline sleep monitor results, participants will be divided into Group NSCLC if apnea hypopnea index(AHI) less than 15.
9698593|NCT04744246|Active Comparator|Without Load|5 kilometer walk with no load carried
9698594|NCT04744246|Experimental|With Load|5 kilometer walk with load
9698595|NCT04743817|Experimental|OtoSet - Ear Cleaning Sytem|
9698596|NCT04743700|Experimental|Piezocision on Experimental Side A|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome to accelerate maxillary canine retraction
9698597|NCT04743700|Experimental|Micro-osteoperforations on Experimental side B|Three MOPs with the help of mini-implant screw driver,mesial and distal to canine(in a vertical line) with the help of minisrew implant driver to accelrate maxillary canine retraction
9698598|NCT04743895|Active Comparator|Stainless Steel Wire Cerclage|Sternotomy closure using Stainless Steel Wire Cerclage
9698599|NCT04743895|Active Comparator|FiberTape Cerclage|Sternotomy closure using FiberTape
9698600|NCT04744168|Experimental|Acupuncture|In the experimental arm, pregnant women at term will benefit one or two acupuncture sessions with five points : 4GI, 6RP, 34VB,36E,3F. The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both.
9698601|NCT04744168|Placebo Comparator|Placebo acupuncture|"In the placebo arm, pregnant women will benefit one or two acupuncture sessions with one point which is located outside the acupuncture meridian.~The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both."
9698602|NCT04744233|Active Comparator|Freshly squeezed orange juice (FS)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juice assayed was freshly squeezed (FS). Six subjects consumed FS-orange juice.
9698603|NCT04744233|Active Comparator|Commercially available low pasteurized orange juice (LP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was commercially available low pasteurized juice (LP). All participants consumed the LP orange juices.
9698604|NCT04744233|Active Comparator|High-pressure processed orange juice(HPP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was high-pressure processed (HPP). All participants consumed the HPP orange juices.
9698605|NCT04744233|Active Comparator|Pulsed electric fields treated orange juice (PEF)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was those treated with pulsed electric fields (PEF). Six participants consumed the PEF-orange juice.
10188781|NCT03713710|Experimental|Choice|Women assigned to this arm will be given a choice between scheduling an appointment for a Pap testing at the health department or engage in self-sampling for HPV testing at home
10188782|NCT03713697|Experimental|Pap testing|Women assigned to this arm were invited to get a Pap testing at the Basic Health Unit
9785021|NCT01240811|No Intervention|Control-No IUD|Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.
9785022|NCT01240811|Experimental|Levonorgestrel IUS|Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
10188783|NCT03713697|Experimental|Self-Collection for HPV testing|Women assigned to this arm were provided with a kit to engage in self-collection for HPV testing
10188784|NCT03713697|Experimental|Choice|Women assigned to this arm were given a choice between a Pap testing at the local Basic Health Unit or self-collection for HPV testing
9698606|NCT04743869|Active Comparator|KYPHON® ActivOs™10 Bone Cement with hydroxyapatite|As a reference device KYPHON® ActivOs™10 Bone Cement with hydroxyapatite (Medtronic) for treatment of vertebral compression fractures will be used. It is a polymethylmethacrylate (PMMA) bone cement containing hydroxyapatite (HA) for use in the treatment of patients with vertebral compression fractures (VCFs) who are undergoing minimally invasive surgery with KYPHON® Balloon Kyphoplasty. This bone substitute has already been approved and is in use in the patients at the age of 50 or older.
9698607|NCT04743869|Experimental|KyphOs FS™|The test device KyphOs FS™ will be used in patients at the age of 50 and older in order to prove its superiority over the currently used PMMA bone cement.
9698608|NCT04743934|Experimental|Flibanserin + ADT|Flibanserin at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
9698609|NCT04743934|Placebo Comparator|Placebo + ADT|Placebo at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
9698610|NCT04744103|Experimental|TCA peal|Patients will have their actinic cheilitis treated with a TCA peal.
9698611|NCT04743739|Active Comparator|Rituximab monotherapy|Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to the CD19+ B cells count.
9698612|NCT04743739|Experimental|Rituximab combined with cyclosporine|"Rituximab 1000mg I.V. on Days 1 and 181, and will be retreated or not on Days 15 and 195 according to CD19+ B cells count.~cyclosporine (CsA) will be started at a dose of 3mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Doses of CsA will be adjusted according to the blood levels of CsA. CsA will be tapered after 6 months and discontinued over a 3 month period."
9698613|NCT04743960|Experimental|Nighttime cycled parenteral feeds followed by daytime cycled parenteral feeds|Patients will follow nighttime feeding regimen for one week, and then advance their feeds (approximately 12 hours earlier) to daytime feeding regimen for one week.
9698614|NCT04743882||A|
9698615|NCT04743882||B|
9698616|NCT04743882||C|
9698617|NCT04744077|Sham Comparator|Control|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
9698618|NCT04744077|Experimental|Student|Student Co-PI will manage this Instagram account created for the study. Although the student is a Kinesiology student and works within the health field, she will not disclose this information on the account. Instead, she will present herself as a general college student. By withholding her major and career aspirations, we hope to get unbiased feedback on what participants think about the content being presented. The content presented will be identical to study arm #3.
9698619|NCT04744077|Experimental|Scientist|"The PI will manage this Instagram account created for the study. The PI is a certified exercise physiologist and holds a PhD in Rehabilitation Sciences. She will disclose this information on the account. This group is the study's gold standard because it will provide evidence-based content delivered by an exercise scientist."
9698620|NCT04743973|Experimental|Practicing Physicians|Practicing physicians at Mayo Clinic caring for patients during the COVID 19 pandemic will receive the Muse S™ Headband system, and will be asked to utilize it at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
9698621|NCT04743726||Endoscopy|Chinese volunteers who are scheduling for gastro-colonoscopy
9698622|NCT04743687|Experimental|Zanuburutinib|Oral Zanuburutinib 160mg twice a day
9698623|NCT04743648|Experimental|Intervention Group|After determining the experimental and control groups, pre-tests were performed.The program was applied to students in the experimental group.The program was implemented for six weeks based on the theme of innovative thinking.The program developed a training program based on the Tyler Taba model. This model, which is often used in developing educational programs, includes all the necessary steps to teach and accept a new concept. In the ITDP training program, an interactive educational content has been created in which knowledge will be transformed into behavior.In the training, subjects were taught in units, workshops were held, seminars were given. Post-tests were applied at the end of the training.
9698624|NCT04743648|No Intervention|Control Group I|Pre-test and post-tests were applied to the non-intervention group
9698625|NCT04743648|No Intervention|Control Group II|Pre-test and post-tests were applied to the non-intervention group
9698626|NCT04743557|Experimental|Cohort 1|Weekly infusions of DYN101 at the starting dose level
9698627|NCT04743518|Active Comparator|anti-TNF|
9698628|NCT04743518|Active Comparator|vedolizumab|
9698629|NCT04743518|Active Comparator|tofacitinib|
9698630|NCT04743440||Physicians|We will include specialists in anaesthesiology who work at the Anaesthesiology Department, Hillerød hospital, during the trial period. It is an inclusion criterion that they take part in the Anaesthesiology Department's specialist in-house on-call rotation (i.e., attending physician). Each of the included physician participants will be responsible for conducting the airway management in four patient participants; two who have been randomised to the i-gelTM LMA, and two to the Ambu® AuraGainTM LMA, respectively.
9698631|NCT04743427|Experimental|physical therapy inervention|"hot pack~Three active exercises"
10188785|NCT03713658|Experimental|Oral Risperidone|Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
10205400|NCT01822652|Experimental|iC9-GD2 T cells,Cytoxan,Fludara,Keytruda|Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
9698632|NCT04743427|Experimental|Body-blade exercises in addition to physical therapy intervention|"Three Body-blade exercises will be performed in random order (Two sets of, 3-minute exercise and 5-minute break, for each exercise )~hot pack~Three active exercises"
9698633|NCT04743349|Experimental|Experimental arm|Steam inhalations
9698634|NCT04743349|No Intervention|Control arm|No intervention
10205401|NCT01821690|Experimental|Buspirone Treatment|starting at 15 mg/day and ending at 60 mg/day as prescribed
10188786|NCT03713658|Experimental|Paliperidone Palmitate Once Monthly (PP1M)|Participants will receive 50, 75, 100 or 150 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
10188787|NCT03713658|Experimental|Paliperidone Palmitate Every 3 Months (PP3M)|Participants will receive 175, 263, 350 or 525 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
9698635|NCT04743375|Experimental|Sericin dressing with collagen|Sericin dressing with collagen
9698636|NCT04743375|Active Comparator|Bactigras|Commercial dressing
9698637|NCT04743466||Observational (biobank review)|Patients' records from institutional or national biobanks are reviewed.
9698638|NCT04743414|Experimental|CTP-543|On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of itraconazole on Day 4 through Day 8, with a single oral dose of CTP-543 being co-administered on Day 7.
10188788|NCT03713606||Overall eligible participants|Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.
9698639|NCT04743544||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
9698640|NCT04743336||Normal weight (<25 kg/m2)|
9698641|NCT04743336||overweight (25-29.9 kg/m2)|
9698642|NCT04743336||obese (≥30 kg/m2)|
9698643|NCT04743492|Experimental|CBT group|cognitive behavioral therapy (CBT)+routine medical care
9698644|NCT04743492|Experimental|exercise therapy group|physiotherapy-exercise therapy+routine medical care
9698645|NCT04743492|Experimental|breathe training group|using biofeedback devices to train breathing speed+routine medical care
9698646|NCT04743492|No Intervention|usual care|accepting only routine medical care
9698647|NCT04743622|Experimental|Monoprost (preservative-free latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
9698648|NCT04743622|Active Comparator|Xalatan (preserved latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
9698649|NCT04743401|Experimental|Tele-exergame arm|COVID-19 patients or PUI (persons under investigation) admitted to the MEDVAMC (n=60), with an anticipated length of stay of at least 3 days will be recruited. Participants will be randomized (n=1:1) to either intervention (IG) or control (CG) groups. Both groups will receive standard of care. IG will additionally receive Tele-Exergame MP therapy. Tele-Exergame sessions will range from 3-10 minutes based on patient ability and completed twice daily. They will complete assessments at baseline and at one-month post-hospital discharge.
9698650|NCT04743401|No Intervention|Convention care or control group|Standard of care only
9698651|NCT04743531|Experimental|Intervention|Families living in rural Colorado will participate in the HEROs intervention in Fall 2019.
9698652|NCT04743531|Experimental|Staggered Intervention|Families in the staggered intervention arm will serve as controls for the first intervention arm during Fall 2019. Families the staggered intervention arm will then participate in the HEROs intervention in Spring 2020.
9698653|NCT04743219|Active Comparator|Biodentine Group|Biodentine group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin with Biodentine as indirect pulp capping material before placement of a definitive direct composite resin restoration.
9698654|NCT04743219|Experimental|No base Group|The experimental group or No Base group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin without the placement of a bioactive material as a base and restored directly with a definitive direct composite resin restoration.
9698655|NCT04743271|Experimental|High-Fat Diet|50% fat, 35% carbohydrate and 15% protein; 33% of each mono, poly and saturated fat
9698656|NCT04743271|Active Comparator|Low-Fat Diet|30% fat, 55% carbohydrate and 15% protein
9698657|NCT04743323||Study Participants|"Participants will be recruited whilst hospitalized for an acute episode of pancreatitis. They will be interviewed about their health behaviors including alcohol consumption during the two weeks immediately preceding the onset of pancreatitis. Blood and urine bio-specimens will be collected at this time.~Following discharge from hospital (5-26 weeks) the same participant will be interviewed again during an asymptomatic control period and blood and urine bio-specimens will be collected. This study will compare the participant's exposure immediately preceding the onset of pancreatitis to that of an asymptomatic control period from the same participant.~Participants will be followed for 24 months via review of their medical records every 6 months to assess any recurrent disease or progression of disease."
9698658|NCT04743245|Experimental|PCI with SSO2 therapy|
9698659|NCT04743245|Active Comparator|anterior AMI patients treated with PCI and stenting within 6 hours|
10188789|NCT03713567|Placebo Comparator|Experimentally induced plaque|Induced inflammation by suspension of oral hygiene
10188790|NCT03713567|Experimental|Experimentally induced plaque GAP|Induced inflammation by suspension of oral hygiene in patients with history of Generalized Aggressive periodontitis
9984338|NCT04209855|Active Comparator|Investigator's choice of chemotherapy|"Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle~Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)~Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)"
9698661|NCT04743128|No Intervention|Control group|The control group received written recommendations to exercise three times per week, for a period of 12 weeks but they did not attend the training sessions.
9698662|NCT04743128|Experimental|Exercise group|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
9698663|NCT04743050|Active Comparator|Control Group|The control group will be a group without EFA supplementation.
9785023|NCT01240811|Experimental|Copper T380A IUD|Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
9698664|NCT04743050|Experimental|1st Experimental Group|The first experimental group will receive supplementation with pure ALA fraction of EFA esters. 5 ml a day of OmegaRegen Original containing 2.9 g of ALA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
9698665|NCT04743050|Experimental|2nd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen EPA+DHA containing 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
10188791|NCT03713541||Patients with Anorexia nervosa (AN)|Female patients with Anorexia nervosa (AN, ICD-10: F50.0/1) of 14 years and older, receiving an initial treatment due to their AN (start of initial treatment no longer than 3 months ago, inpatient care: at least 7 days inpatient; outpatient care: at least 5 sessions with the same therapist) with sufficient language skills and no serious organic or psychiatric illnesses and no acute suicidality will be consecutively included in the study. No intervention.
10188792|NCT03713541||Carers of patients with AN|Significant caregivers in AN patients aged 14 to 15 years: parents; in AN patients aged 16 years and over: parents or other significant carer. No intervention.
9698666|NCT04743050|Experimental|3rd Experimental Group|The second test group will receive supplementation of the EPA and DHA fraction of EFA esters. 5 ml a day of OmegaRegen MAMA containing 2.9 g of ALA, 0.032 g of EPA, 0.192 g of DHA, 0.9 g of oleic acid and 0.8 g of linoleic acid for six months.
9698667|NCT04743180||LUMINOR© drug eluting balloon|
9698668|NCT04743258|Experimental|EXTRACTION|treatment of class II div 1 malocclusion with bilateral maxillary premolar extraction
9698669|NCT04743258|Experimental|DISTALIZATION|treatment of class II div 1 malocclusion with distalization using zygomatic miniplates
9698670|NCT04743037|No Intervention|Standard of Care (SOC)|The 15 attentional control group stroke survivors will receive phone calls over the 12-week intervention checking in with them on how they are doing in their everyday life. They will also receive stroke education materials, but they will not receive the same iSMART intervention as the intervention group.
9698671|NCT04743037|Experimental|iSMART|"The 15 iSMART participants will engage in video conference sessions between the pre and post visits. A health coach will collaboratively work with the participant to practice treatment strategies and set goals in weekly individual sections. In addition, all participants will engage in weekly group sessions with a health coach in order to learn and practice specific self-management skills and strategies in a group context. In addition, iSMART entails using an interactive SMS to provide ongoing support and self-monitoring of behavior change goals. The SMS is programmed to touch participants daily; the SMS system prompts participants to report their daily activities and progress in achieving goals via check-in messages and sends immediate, tailored feedback about their progress. If a participant is making progress toward their goal, the SMS system will suggest a change to the participant's goal between visits."
9698672|NCT04743011|Placebo Comparator|Placebo|Participants will receive inhalation with 5mL 0.9% saline solution (placebo), 4/4h, during the day period (5 doses).
9698673|NCT04743011|Active Comparator|Heparin sodium|Participants will receive inhalation with 5mL 0.9% saline solution + 2,5mg of high molecular weight heparin - enriched heparin, 4/4h, during the day period (5 doses).
9698674|NCT04743297|Active Comparator|Propess Vaginal Delivery System|Propess - Prostaglandin E2 Vaginal Delivery System. Slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
9698675|NCT04743297|Active Comparator|Prostin Tablet|Prostaglandin E2 Vaginal Tablet 3 mg dinoprostone
9698676|NCT04743063||New users of angiotensin receptor neprilysin inhibitor|
9698677|NCT04743063||New users of angiotensin II receptor blockers|
9698678|NCT04742972|Experimental|SABR|
9698679|NCT04742972|Placebo Comparator|SOC|
9698680|NCT04742985|Experimental|Green tea combined extracts group A|This group takes Green tea combined extracts (62.5 mg) for 8 weeks.
9698681|NCT04742985|Experimental|Green tea combined extracts group B|This group takes Green tea combined extracts (125 mg) for 8 weeks.
9698682|NCT04742985|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
9698683|NCT04743076|Experimental|Intervention group|Standard medical treatment plus endovascular treatment
9698684|NCT04743076|Active Comparator|Control group|Standard medical treatment alone
9698685|NCT04743115|Experimental|the Dose Escalation Level|"In the first 3-patient cohort, the dose of BS HH 002.SA will be 0.2 mg/m2/day. Enrollment to the next higher dose cohort will be initiated only if none of the 3 patients exhibits a DLT in the first 28-day cycle. Dose escalation will proceed according to a modified Fibonacci scheme, eg, increments of 100%, 100%, 66%, and 33% and the dose of BS-HH-002.SA will be 0.4, 0.8, 1.3, 1.7 mg/m2/day.~The dose will be administered subcutaneously once daily on Days 1 through 6 and on Days 10 through 15 of a 28 day cycle."
9698686|NCT04743154||In-hospital complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions at least 24 hours after STEMI and before hospital discharge.
9698687|NCT04743154||After-discharge complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions after hospital discharge within 4-6 weeks after STEMI.
9698688|NCT04743193||sevoflurane 8 %|In the initial phase, after reaching 1 (MAK) level with 1lt / min fresh gas flow and 8% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
9698689|NCT04743193||sevoflurane 2.5 %|In the initial phase, after reaching 1 MAK level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.
9698690|NCT04743089|Experimental|Spyglass arm|Patients who underwent IHD/EHD stone removal by ERCP with SpyGlass™ DS Direct Visualization System.
10188793|NCT03713541||Physicians of patients with AN|Resident general practitioner, pediatrician, internist or gynecologist with at least one medical patient contact within the last 12 months. No intervention.
10188794|NCT03713489|Experimental|Platelet transfusion group|Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
10188795|NCT03713489|No Intervention|standard medical treatment group|standard medical treatment
10188796|NCT03713450|Experimental|Control with imaging guidance|
10188797|NCT03713450|Active Comparator|Control without imaging guidance|
9698691|NCT04743089|Other|PTCS arm (historical cohort)|Patients who underwent IHD/EHD stone removal by PTCS
9698692|NCT04742881|Experimental|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
9698693|NCT04742881|Active Comparator|Low pressure + standard instruments|Low pressure pneumoperitoneum (5-7mmHg) and use of standard instruments (5mm and 10mm instruments)
9698694|NCT04742998||Patients treated for an oral or oropharyngeal tumor for at least 6 months|Patients treated for an oral or oropharyngeal tumor for at least 6 months
9698695|NCT04743024||Household|Household carer-child pairs will be included according to age and consent criteria
9778393|NCT01105767|Active Comparator|Group 2 Enhanced Standard|Trainees received the components of the Standard group as well as supplemental training, education and hygiene. They were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit. Supplemental SSTI education for trainees and drill sergeants was also provided (e.g., pocket cards, posters). Drill sergeants received briefings on SSTI and skin inspection/minor wound care.
9778394|NCT01105767|Active Comparator|Group 3 Chlorhexidine|Trainees received the components of the Standard and Enhanced Standard groups and were offered chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) to use with a wash cloth after using their personal soap for the additional once-weekly shower. Trainees were provided with verbal and written/graphic instructions for use.
9778395|NCT01105936|Experimental|Paracetamol caplets|Two 665 mg sustained release paracetamol caplets administered orally with water.
9778396|NCT01105936|Placebo Comparator|Placebo caplets|Two placebo caplets administered orally with water.
9778397|NCT01105975|Experimental|30 milligram (mg) LY2484595 monotherapy|
9778398|NCT01105975|Experimental|100 mg LY2484595 monotherapy|
9778399|NCT01105975|Experimental|500 mg LY2484595 monotherapy|
9778400|NCT01105975|Placebo Comparator|Placebo|
9778401|NCT01105975|Active Comparator|20 mg Atorvastatin monotherapy|
9778402|NCT01105975|Experimental|100 mg LY2484595 + 20 mg Atorvastatin|
9778403|NCT01105975|Active Comparator|40 mg Simvastatin monotherapy|
9778404|NCT01105975|Experimental|100 mg LY2484595 + 40 mg Simvastatin|
9778405|NCT01105975|Active Comparator|10 mg Rosuvastatin monotherapy|
9778406|NCT01105975|Experimental|100 mg LY2484595 + 10 mg Rosuvastatin|
9778407|NCT01106014|Experimental|1|Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
9778408|NCT01106014|Placebo Comparator|2|Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed
9778409|NCT01106027|Experimental|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery. Patients will be given 900 mg of eculizumab on Day 1 post-transplant. Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant.~At week 4, patients will be assessed for donor specific anti-donor human leukocyte antigen (HLA) antibody (DSA). Patients with total DSA normalized values <5000 will stop eculizumab treatment. Patients with total DSA normalized values >5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly."
9778410|NCT01106040|Experimental|Lymphoseek, Lymphatic mapping, Injection|
9778411|NCT01106092|Experimental|GSK2036874A GROUP 1|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0.
9778412|NCT01106092|Experimental|GSK2036874A GROUP 2|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0.
9778413|NCT01106092|Experimental|GSK2036874A GROUP 3|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0.
9778414|NCT01106092|Active Comparator|ZILBRIX/HIB/POLIORIX GROUP|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively.
9778415|NCT01106157|Experimental|Anti-Thymocyte Globin plus pegylated GCSF|Subjects will receive an infusion of Anti-Thymocyte Globin (ATG) followed by 6 doses of pegylated GCSF every 2 weeks for 10 weeks.
9778416|NCT01106157|Placebo Comparator|Placebo|Saline infusion will be given on both Day 1 and Day 2 followed by placebo injection given in identical volumes in identical syringes in the identical subcutaneous manner
9778417|NCT01106248|Other|Eribulin Mesylate|
10188798|NCT03713437||Cystic Fibrosis|Serum sample will be drawn once
10188799|NCT03713437||Healthy, age-matched controls|Serum sample will be drawn once
10188800|NCT03713424|Active Comparator|Clav|4-day 125 bid oral capsule administration
10188801|NCT03713424|Placebo Comparator|Placebo|4-day, twice-daily oral capsule administration
10188802|NCT03713385||Aged group (n =49)|Determined the optimal endotracheal tube size according to age of the child (internal diameter [ID] in mm = [age in years + 16] /4) suggested by Cole
10188803|NCT03713385||Subglottic diameter group (n =49)|The subglottic transverse diameter was estimated with ultrasonography on the middle of the anterior region of the neck at the level of cricoid cartilage
9698696|NCT04742868|Experimental|Arm 1 QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with bone will be used as graft for the surgery.
9698697|NCT04742868|Experimental|Arm 2 HAMSTRING TENDON GRAFT|Hamstring tendon with bone will be used as graft for the surgery
9698698|NCT04742868|Experimental|Arm 3. QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without bone will be used as graft for the surgery.
9698699|NCT04743102|Experimental|Biopsy cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, we add multi-points and full-thickness Biopsy to further improve the accuracy of cCR after neoadjuvant therapy for rectal cancer.
9698700|NCT04743102|Active Comparator|Conventional cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, to study accuracy of cCR after neoadjuvant therapy for rectal cancer.
9698701|NCT04742803|Other|Epistamp Needling Treatment Without RF|Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Epistamp needling without RF (Radio Frequency)
9698702|NCT04742803|Other|Epistamp Needling Treatment With RF|Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Epistamp needling with RF (Radio Frequency)
9698703|NCT04742764|Active Comparator|Group A|Patients randomized to standard medical therapy.
9698704|NCT04742764|Active Comparator|Group B|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 12 hours.
10188804|NCT03713385||Epiphyseal diameter group (n =49)|The epiphyseal transverse diameter of the distal radius was estimated with ultrasonography.
10188805|NCT03713372|Experimental|Anti-EGFR monoclonal antibody|6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
9698705|NCT04742764|Active Comparator|Group C|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 24 hours.
9698706|NCT04742946|Experimental|TR Group|Personalized Telerehabilitation program during 8 weeks. One session per day. Web and mobile application
9698707|NCT04742946|Active Comparator|Control Group|Standard of care. Rehabilitation program in their hospital or primary care or a health education program to be carried out at home.
9698708|NCT04742855||Group A|It will consist of 10 adults and 5 children. They will get the yogurt strains
9698709|NCT04742855||Group B|It will consist of 10 adults and 5 children. They will get the Bifidobacterium strains.
9698710|NCT04742855||Group C|It will consist of 10 adults and 5 children. They will get the placebo.
9698711|NCT04742829|Experimental|GROUP 1|Patients treated with INTRAVIT® tablets
9698712|NCT04742829|No Intervention|GROUP 2|patients who will not take any medical therapy to overlap with the activity described for INTRAVIT® tablets.
9698713|NCT04742790|Experimental|Patients|The study will recruit volunteers (1) suffering from disabling post-operative pain for more than two weeks following surgery (thoracotomy, sternotomy and breast cancer surgery), (2) currently being treated for their post-operative pain with an opioid analgesic - along with possible other treatments - and (3) for which the treating physician is about to introduce an additional non-opioid drug for the treatment of their pain (e.g. an antiepileptic or an anti-depressant).
9698714|NCT04742530|Experimental|Fasted Evening Exercise|Exercise will take place in the evening, following a 7 hour period of fasting.
9698715|NCT04742530|Active Comparator|Fed Evening Exercise|Exercise will take place in the evening, after having consumed a carbohydrate-containing meal 2 hours prior.
9698716|NCT04742530|Active Comparator|Fed Morning Exercise|Exercise will take place in the morning, after having consumed a carbohydrate-containing meal 2 hours prior.
9698717|NCT04742504||BENRA Treated Patients|Patients with severe eosinophilic asthma who will be treated with benralizumab (Fasenra®, Astra Zeneca) will be able to participate in a volunteer manner in the study after sing informed consent.
9698718|NCT04742504||Non BENRA TREATED PATIENTSP|patients with controlled severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without oral corticosteroids) but without request of benralizumab (Fasenra®, Astra Zeneca) treatment will be recruited
9698719|NCT04742465|Experimental|Augmented reality|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
9698720|NCT04742426|Active Comparator|WHO group|minimal setting of personal protective equipment (COVID 19) recommended by WHO
10188806|NCT03713359|Active Comparator|Trial arm (MRVAC)|"Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components:~Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection"
9698721|NCT04742426|Experimental|Super-safe setup|maximal super-safe setup of personal protective equipment
9698722|NCT04742686|No Intervention|Usual care|
9698723|NCT04742686|Experimental|Intervention|
9698724|NCT04742582|Active Comparator|Preterm Infants - fed fermented formula|Feeding infants with fermented formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
9698725|NCT04742582|Placebo Comparator|Preterm Infants - fed standard formula|Feeding infants with standard formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
9698726|NCT04742582|Other|Reference Group: Pre-term Infants - breastfed|The breastfeeding infants were the reference group
9698727|NCT04742699|Experimental|Z-Drug-mono cohort|Patients being treated with Z-drug monotherapy at registration
10205402|NCT01821690|Placebo Comparator|Buspirone Placebo|placebo tablets as prescribed
10205403|NCT01816165|Experimental|Acipimox|Drug: acipimox
9698728|NCT04742699|Experimental|SUV-mono cohort|Patients being treated with SUV monotherapy at registration
9698729|NCT04742699|Experimental|SUV-combination cohort|Patients being treated with SUV and BZRA combination therapy at registration
9698730|NCT04742699|Experimental|RMT-combination cohort|Patients being treated with RMT and BZRA combination therapy at registration
9698731|NCT04742517|Experimental|Single ascending dose of ASP1128|Participants (6 for each cohort) will receive a single dose of ASP1128.
9698732|NCT04742517|Placebo Comparator|Single ascending dose of Placebo|Participants (2 for each cohort) will receive a single dose of matching Placebo.
9698733|NCT04742517|Experimental|Multiple ascending dose of ASP1128|Participants (9 for each cohort) will receive daily doses of ASP1128 for 7 consecutive days.
9698734|NCT04742517|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort) will receive matching Placebo for 7 consecutive days.
9698735|NCT04742660|Placebo Comparator|group R|Participants are administered a dose of 0.3mg of ramosetron (conventional antiemetics) intravenously followed by continuous infusion of 120mL normal saline at a rate of 10mL/min.
9698736|NCT04742660|Active Comparator|group G|participants are administered a dose of 0.3mg of ramosetron followed by continuous infusion of mixture of 20mL glycyrrhizin and 100mL normal saline (total 120mL) at a rate of 10mL/min.
9698737|NCT04742452|Active Comparator|Superior Capsular Reconstruction|
9698738|NCT04742452|Placebo Comparator|Partial Rotator Cuff Repair|
9698739|NCT04742543|Experimental|Virtual reality glasses|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure with Virtual reality glasses on
9698740|NCT04742543|No Intervention|No intervention. standard treatment|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure without virtual reality glasses (no intervention)
9698741|NCT04742647|Experimental|Single Cerclage|Standard single cervical cerclage will be placed
9698742|NCT04742647|Experimental|Double Cerclage|Double cerclage placement
9698743|NCT04742478||Eligible subjects who underwent RA prior to PCI (with informed consent taken to join the study)|Informed consent to be obtained either prior to PCI with rotational atherectomy planned or within 48 hours after rotational atherectomy. There will be data collection of history/demographics, laboratory results, symptoms, any serious adverse events recording for this cohort as well as a telephone follow up at 12months post rotational atherectomy.
9698744|NCT04742478||Eligible subjects who underwent RA prior to PCI (without informed consent taken to join the study)|Subjects that were demised or refused to give consent will fall under this cohort. The data collection of this cohort will be done through screening of in-hospital data via available local PCI database/registry.
9698745|NCT04742491|Experimental|Immediate Intervention Arm Descovy in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
9698746|NCT04742491|Experimental|Deferred Intervention Arm Descovy in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Descovy (emtricitabine 200 mg and tenofovir alafenamide 25mg, FTC/TAF) one tablet daily in the US
9698747|NCT04742491|Experimental|Immediate Intervention Arm Truvada in Brazil|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
9698748|NCT04742491|Experimental|Deferred Intervention Arm Truvada in Brazil|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in Brazil
9698749|NCT04742491|Experimental|Immediate Intervention Arm Truvada in the US|PrEP provision, STI screening and treatment, gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
9698750|NCT04742491|Experimental|Deferred Intervention Arm Truvada in the US|0-6 months PrEP provision, STI screening and treatment. From months 6-18 gender affirming hormonal therapy, peer-health management using strengths-based management using Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, FTC/TDF) one tablet daily in the US
9698751|NCT04742413||A|Patients who are prescribed to switch to lurasidone (lurasidone cohort)
9698752|NCT04742413||B|Patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort)
9698753|NCT04742374|Experimental|Group A|Patients alternating single plasma exchange followed by double filtration plasmapheresis etc.
9698754|NCT04742374|Experimental|Group B|Patients alternating double filtration plasmapheresis followed by single plasma exchange etc.
9698755|NCT04742296|Active Comparator|Treatment group of low level laser therapy|
9698756|NCT04742296|Placebo Comparator|Sham group of low level laser therapy|
9698757|NCT04742088|Experimental|Orthosis group|
9698758|NCT04741971|Experimental|Probiotics group|Will give Probiotics with Vit.D 3
9698759|NCT04741971|Placebo Comparator|Non-probiotics group|Will give Vit. D3 as placebo
9698760|NCT04742101|Experimental|S65487 with azacitidine|
9698761|NCT04741919|Active Comparator|Superior LPI placement|Each participant will be randomized to receive an LPI placement superiorly in one eye.
9698762|NCT04741919|Active Comparator|Temporal LPI placement|Each participant will be randomized to receive an LPI placement temporally in one eye.
9698763|NCT04742127||Patients with septic arthritis of the native hip|
9778418|NCT01106287|Experimental|Treatment Sequence 1|Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg
9778419|NCT01106287|Experimental|Treatment Sequence 2|Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo
9778420|NCT01106287|Experimental|Treatment Sequence 3|Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg
10205404|NCT01816165|Placebo Comparator|Placebo|Drug: Placebo
9698764|NCT04741958|Experimental|ultra sound guided percutaneous core needle biopsy|60 patients that had radiographic evidence of thoracic mass suspected of malignancy .Twenty masses were in the lung, seventeen lesions were in the pleura, ten masses were in the mediastinum, eleven enlarged palpable lymph nodes, and two masses were in chest wall. The sensitivity, PPV and accuracy for detection of chest tumors in chest wall, mediastinum, lung, and pleura were (100 %) for all, and in LN (88.9, 100 and 90.9 %) respectively. The overall diagnostic performance of sonar guided true cut needle biopsy in diagnosis was 97.78 % sensitivity, 98.18% accuracy, and 100 % PPV
9698765|NCT04742348|Placebo Comparator|Control, Placebo|Similar looking tablet(s) to active drug will be administered in a single dose to those who are randomly assigned to this group.
9698766|NCT04742348|Experimental|Active Drug, Carbidopa + Levodopa|Single dose of immediate release carbidopa-levodopa (50mg/500mg).
9698767|NCT04742218|Experimental|Fasted-Fed|Single dose of K-877 administered in a fasted condition on Day 1 (Treatment Period 1) and postprandially on Day 4 (Treatment Period 2)
9698768|NCT04742218|Experimental|Fed-Fasted|Single dose of K-877 administered postprandially on Day 1 (Treatment Period 1) and in a fasted condition on Day 4 (Treatment Period 2)
9698769|NCT04742244|Placebo Comparator|Placebo|0 mg LVE/capsule, 2capsule/day, 14days
9698770|NCT04742244|Experimental|Lemon Verbena extract|200 mg LVE/capsule, 2capsule/day, 14days
9698771|NCT04742205|Active Comparator|tranexamic acid|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
9698772|NCT04742205|Placebo Comparator|Sodium Chloride|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
9698773|NCT04742322|Placebo Comparator|Placebo|1x capsule/day - maltodextrin, period of 10 to 14 days
9698774|NCT04742322|Experimental|B Lactis|1x capsule/day - 9x10x10 UFC, period of 10 to 14 days
9698775|NCT04742257|Experimental|Active Stimulation|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
9698776|NCT04742257|Sham Comparator|Sham Stimulation|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
9698777|NCT04742049|Experimental|Telerehabilitation|Telerehabilitation based exercise training will be given to the study group.
9698778|NCT04742049|Experimental|Exercise brochure|Exercise training will be provided by sending a document to the control group
9698779|NCT04742153|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
9698780|NCT04742166|Experimental|Side to side gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~a blood test for albumin and prealbumin~a GIQLI questionnaire (quality of life score) to be completed by the patient"
9698781|NCT04742166|Active Comparator|Terminolateral gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~a blood test for albumin and prealbumin~a GIQLI questionnaire (quality of life score) to be completed by the patient"
9698782|NCT04741906||Previous tooth extraction|Cancer patients (breast, prostate or multiple myeloma) with bone metastases on high dose antiresorptive treatment who have had previous tooth extraction
9698783|NCT04741906||Previous resection|Cancer patients (breast, prostate or multiple myeloma) with bone metastases on high dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence
9698784|NCT04741906||Simultaneously with resection|Cancer patients (breast, prostate or multiple myeloma) with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)
9698785|NCT04741893|Experimental|faecally incontinent patients|faecally incontinent patients are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
9698786|NCT04741893|Experimental|Asymptomatic individuals|asymptomatic individuals are all assessed using EndoFLIP as well as anorectal manometry and endoanal ultrasound
9698787|NCT04741932|No Intervention|Care as usual|
9698788|NCT04741932|Experimental|Intervention|
9698789|NCT04741867|Experimental|receiving health education|
9698790|NCT04741867|Experimental|Level of compliance|
9698791|NCT04741867|Experimental|Coping with stress|
9698792|NCT04741880|Experimental|Group L (Lidocaine)|Lidocaine bolus 1.5 mg.kg-1 intravenous before the onset of lidocaine infusion Lidocaine 2mg.kg-1.h-1
9698793|NCT04741880|Placebo Comparator|Group S (saline solution)|Lidocaine bolus 0.75 mg.kg-1 intravenous before the onset of saline infusion Saline solution infusion
9698794|NCT04741620|Active Comparator|Capsaicin 10microM|10mL capsaicin 10microM solution 3 times/day during 14 consecutive days (2 weeks).
9698795|NCT04741620|Active Comparator|Piperine 150microM|10mL Piperine 150microM solution 3 times/day during 14 consecutive days (2 weeks).
9698796|NCT04741620|Active Comparator|Cinnamaldehyde 756,6microM + zinc 70microM|10mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
9698797|NCT04741620|Active Comparator|Citric acid 457,5microM (pH=3,5)|10mL Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
9698798|NCT04741620|Active Comparator|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5)|10mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
9698799|NCT04741620|Placebo Comparator|Placebo|10mL placebo solution 3 times/day during 14 consecutive days (2 weeks).3 times/day during 14 consecutive days (2 weeks).
10205405|NCT01813929|Experimental|Metformin|
10205406|NCT01813929|Placebo Comparator|Placebo|
9698800|NCT04741568|Experimental|Parental Psychoeducational Intervention|A brief (one-day or two half days) psychoeducation workshop will be provided alongside a website with downloadable content will be made available to review and refresh any skills and techniques. The psychoeducational intervention will be delivered by a research fellow and research assistant with a background in psychology and delivered in line with a protocol.
9698801|NCT04741568|No Intervention|Wait List Control|Parents randomised to the control arm will be put on the waiting list (wait-list controls) to receive the group intervention after the active treatment group have completed their final follow-up at 3 months.
9698802|NCT04741672|Experimental|Intervention group|Providing guidance and calling after discharge routine procedure.
9698803|NCT04741672|Experimental|Control group|Discharge routine procedure.
9698804|NCT04741711|Experimental|Interventional group|The heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava
9698805|NCT04741711|Other|Control group|Usual care (i.e. without ultrasound guidance) will be provided.
9698806|NCT04741828|Experimental|Vi-DT Typhoid Conjugate Vaccine|Participants receive 1 dose (0.5ml) Vi-DT Typhoid Conjugate Vaccine, intramuscularly.
9698807|NCT04741685||SAP with LGS|Type 1 diabetes adults patients treated with sensor-augmented insulin pump with low glucose predictive suspension function
9698808|NCT04741646|Experimental|Treatment Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Ferric Citrate (FC). The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
9698809|NCT04741646|Placebo Comparator|Control Arm|During the 12-month trial, participants will be given a fixed weight-based dose of Placebo. The full medication dose will be 3g/day for participants weighing <31 kg, 5g/day for those weighing >31 - <51 kg, and 6g/day for participants >51 kg. These doses will be divided into three doses to be taken with meals.
9698810|NCT04741854|Experimental|Investigational Device|Participants will be asked to take home the investigational device to use at night while they sleep in place of their own device. The participant's therapy and comfort settings will be copied from their own device to the investigational device.
9698811|NCT04741607|Active Comparator|Control group|Delayed implant placement
10188807|NCT03713359|Active Comparator|Control arm|"Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm.~Subcutaneous injection"
10188808|NCT03713346|Other|Lactose digester|
10188809|NCT03713346|Other|Lactose maldigester|
10188810|NCT03713333|Experimental|Technology-Enabled Visitations|Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.
10188811|NCT03713333|No Intervention|Standard-Care Visitations|Standard-care is defined as the range of services available during usual patient care. Handheld Imaging and digital health screening will be performed in the control group after the patient-physician encounter. As such, patients and physicians will be blinded to the diagnostic findings unless an abnormal finding is detected that requires physician review and triage for further care.
10188812|NCT03713268||Healthy (ocular health) participants|"Adult subjects with normal, ocular health will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system for reproducibility testing in humans, provide feedback to engineers, and verify that the system functions to produce high quality images of the desired areas of the eye after ex vivo development before surgical use.~Each healthy subject will be imaged by the MIOCT system. There will be no surgery or intervention on these healthy volunteer subjects. We anticipate that a portion of the volunteer subjects would have repeat imaging (e.g. for reproducibility testing)."
10188813|NCT03713268||Surgeons as research subjects|Duke Eye Center surgical trainees (residents and fellows), attending surgeons, and surgeons from other medical institutions will be enrolled as subjects as we will test their performance with and without microscope integrated optical coherence tomography and with and without advances in 4D MIOCT in model surgeries in the research wet lab to better understand the utility of specific aspects and of this next generation MIOCT as a whole for specific anterior segment and retinal surgical tasks.
10188814|NCT03713268||Surgical patients|Adult and minor (> 4 months of age) surgical patients will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system during clinically indicated vitreoretinal and anterior segment surgical procedures.
10188815|NCT03713255|Active Comparator|PVB group|paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
10188816|NCT03713255|Experimental|MTP block group|MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
10188817|NCT03713255|Sham Comparator|control group|local anesthetic infiltration subcutaneous 1% lidocaine
10205407|NCT01780675|Active Comparator|Prophylactic Cranial Irradiation|Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)
10205408|NCT01780675|Experimental|Hippocampal Avoidance PCI|Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).
10205409|NCT01747096|Experimental|68-Ga-DOTANOC|
10205410|NCT01726309||Stage IV CRC|
10205411|NCT01726309||Stage IV NSCLC|
10205412|NCT01722890||Cohort 1|TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
9698812|NCT04741607|Experimental|Test group|Immediate implant placement
9698813|NCT04741542|Experimental|Group A|Study subjects will receive a 14mg/kg starting dose of SP-420 three times a week
9698814|NCT04741542|Experimental|Group B|Study subjects will receive a 28mg/kg starting dose of SP-420 three times a week
9698815|NCT04741542|Experimental|Group C|Study subjects will receive a 42mg/kg starting dose of SP-420 three times a week
9698816|NCT04741542|Experimental|Group D|Study subjects will receive a 56mg/kg starting dose of SP-420 three times a week
9698817|NCT04741529|Experimental|Massed condition|Participant will be asked to use the HMP app for 20 minutes per day in one 20-minute meditation session.
10205413|NCT01722890||Cohort 2(Control Group)|TNM stage II-IV breast cancer patients with trastuzumab-refractory disease.
10188818|NCT03713242|Experimental|Group A: ACT-541468 in subjects with mild hepatic impairment|Single oral dose administered on Day 1.
9698818|NCT04741529|Experimental|Spaced condition|Participant will be asked to use the HMP app for 20 minutes per day in two 10-minute meditation sessions.
10188819|NCT03713242|Experimental|Group B: ACT-541468 in subj. with moderate hepatic impairment|Single oral dose administered on Day 1.
9698819|NCT04741490|Experimental|treatment group|The adjuvant treatment of radiotherapy combined with carrilizumab lasted for 6 cycles
9698820|NCT04741737|Experimental|reSLNB arm|repeat SLNB procedure is performed in when the patient is diagnosed with ipsilateral breast tumor recurrence, who had undergone partial mastectomy and sentinel lymph node biopsy for primary operation.
9698821|NCT04741477|Experimental|Topical CBD Product with low level of THC|Participants will topically apply a high CBD-product that also contains low levels of THC.
9698822|NCT04741477|Placebo Comparator|Placebo topical product|Participants will topically apply a placebo product that does not contain cannabinoids.
9698823|NCT04741763|Placebo Comparator|Placebo|Maltodextrin Placebo: Experimental is 1:2
9698824|NCT04741763|Experimental|Active|Eye Promise Visual Edge containing 8 mg zeaxanthin & 4 mg lutein Placebo: Experimental is 1:2
9698825|NCT04741724|Experimental|transcutaneous electrical diaphragmatic stimulation (TEDS)|"Subjects received daily TEDS (30min/day, 5days/week ) until the end of the weaning trial.~During TEDS, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was performed by applying biphasic waves at a stimulation frequency of 30 Hz, pulse width of 400 μs. TEDS intensity was gradually increased until visible muscle contraction was observed. Each session lasts for 30 min day."
9698826|NCT04741724|No Intervention|Control group|Subjects in the control group did not received TEDS program. Subjects in the control group received the same pre- and post-measurement as those in TEDS group. The control group received medical treatment as those in TEDS group. The pulmonary function was measured at the beginning and end of the intervention.
9698827|NCT04741360|Experimental|Modified Story Memory Technique|
9698828|NCT04741360|Other|Control|
9698829|NCT04741438|Experimental|Arm A|"Arm A (Experimental arm).~Nivolumab 3 mg/kg~Ipilimumab 1 mg/kg"
9698830|NCT04741438|Active Comparator|Arm B|Arm B (Control arm). Pazopanib 800 mg/day
9698831|NCT04741373|Placebo Comparator|Group of health education|
9698832|NCT04741373|Active Comparator|Group of health education and rehabilitation exercise|
9698833|NCT04741373|Experimental|Group of health education,exercise and ONS|
9698834|NCT04740957|No Intervention|Observational cohort|"100 patients undergoing elective left colonic or rectal resection with a primary anastomosis will be recruited pre-operatively throughout the study period. This study will not affect or delay the intended treatment for study participants.~Patients will undergo serial endoscopic examination of the anastomosis post-operatively. Blood, urine, stool, and mucosal biopsies will be serially collected."
9698835|NCT04740957|Experimental|Distal limb feeding cohort|"This interventional arm will demonstrate the safety of re-introducing ileostomy effluent into the downstream (distal) limb of an ileostomy. The preliminary data will enable exploration of the association between microbiome and post-operative function and enable adequate powering of future interventional studies.~A subgroup of 20 patients undergoing a resection with a covering ileostomy will be recruited to the intervention arm. Complete healing of the colorectal anastomosis will first be confirmed by water-soluble contrast enema 8 weeks post-operatively (this is standard practice). Patients will be taught how to inject the output from the proximal ileostomy limb into the distal limb (this connects to the colon and thus the colorectal anastomosis) daily until the ileostomy closure date."
9698836|NCT04741295|No Intervention|Control Group|Adenomyosis patients in control group have normal luteal progesterone support.
9698837|NCT04741295|Experimental|Low molecular weight heparin Group|Adenomyosis patients in Low molecular weight heparin group have Low molecular weight heparin in addition to normal luteal progesterone support.
9698838|NCT04741113|Experimental|Intervention group -educational module|"The study intervention will include an online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion. The module will be sent to participants via secured link."
9698839|NCT04741113|No Intervention|Control group|No intervention
9698840|NCT04741035|Experimental|Modified sternal precautions|Interventional group (Modified sternal precautions)
9698841|NCT04741035|Active Comparator|Conventional sternal precautions|Control group (Conventional sternal precautions)
9698842|NCT04741412||Hypohidrotic Ectodermal Dysplasia|all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder
9698843|NCT04741412||Control|individuals of the same age group, but without HED, including pregnant women
9698844|NCT04741152||Revealed insulinoma|Cases when the tumor was revealed by the preoperative diagnostics and confirmed after the tumor elimination
9698845|NCT04741152||Hidden Insulioma|Group when the insulinoma haven't been revealed preoperative and intraoperatively and the blind resection was performed.
9698846|NCT04741022||CAD with OSA|coronary artery disease with Obstructive sleep apnea
9698847|NCT04741022||CAD without OSA|coronary artery disease without Obstructive sleep apnea
10188820|NCT03713242|Experimental|Group C: ACT-541468 in subjects with severe hepatic impairment|Single oral dose administered on Day 1.
10188821|NCT03713242|Experimental|Group D: ACT-541468 in healthy subjects.|Single oral dose administered on Day 1.
10188822|NCT03713216|Experimental|Naldebain|Subjects will receive one dose of Naldebain before surgery.
10188823|NCT03713216|Active Comparator|Morphine|Subjects will receive morphine after surgery.
10188824|NCT03713203|Experimental|Pagetex PDT|"PAGETEX medical device for photodynamic therapy (PDT). Composed of the association: Laser source + optical fiber + diffuser support incorporating luminous textiles + drug photosensitizer (Metvixia®)"
10188825|NCT03713190|Active Comparator|Empagliflozin|SGLT-2 inhibitor
9698848|NCT04741165|Experimental|Experimental: HX008+Bevacizumab|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.
9698849|NCT04741165|Experimental|Experimental: HX008+Lenvatinib|Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD).
9698850|NCT04741243|Experimental|Extracorporeal shock wave therapy|was used for 15 minutes in a prone position for both groups (A&B) before the treatment. shock wave were used to heat small areas, and allow for decrease pain, muscle spasm, and provide vasodilatation of the blood vessels supplying the area
9698851|NCT04741243|Experimental|dietary modification|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level.
9698852|NCT04741178||Patient with Covid-pneumonia|Patient with CT scan of pulmonary infiltrates suggestive of Covid pneumonia
9698853|NCT04741269||Lack of knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
9698854|NCT04741269||Full knee flexion|"During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion. Patients in group 2 don't have any asymmetric full knee flexion.~All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift"
9698855|NCT04741061|Active Comparator|Sputnik Light Vaccine|study group (4500 receiving the Sputnik-Light vector vaccine) against the SARS-СoV-2-induced coronavirus infection.
9698856|NCT04741061|Placebo Comparator|Placebo Group|control group (1500 subjects receiving placebo)
10188826|NCT03713190|Placebo Comparator|placebo|A substance without specific pharmacology principles.
9698857|NCT04740944|Experimental|Intervention group|the intervention group was subjected to salutogenic approach-based interview consisting of 16 sessions twice a week.
9698858|NCT04740944|No Intervention|Control group|The control group continued their routine activities and was interviewed face-to-face 5 times.
9698859|NCT04740983|Experimental|Heliotherapy|will receive 16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values along with olive oil (in-house formulation)
9698860|NCT04740983|No Intervention|Control|only will receive olive oil (in-house formulation)
9698861|NCT04741191|Experimental|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown)
9698862|NCT04741191|Active Comparator|Conventional therapy|Patient education and counseling, In bed activities, Ambulation
9698863|NCT04741048|Experimental|CI624 Slim 20 Electrode|
9698864|NCT04740970|Experimental|JNJ-64304500|Participants will receive JNJ-64304500 dose 1 subcutaneous (SC) injection at Week 0 and then dose 2 SC injection every 2 weeks from Week 2 through Week 22.
9698865|NCT04740970|Placebo Comparator|Placebo|Participants will receive matching placebo SC injection at Week 0 and then every 2 weeks from Week 2 through Week 22.
9698866|NCT04741321||Pre-test group|After translation to Spanish, VQ-6 questionnaire is given to 20 patients to assess understanding by the patient.
9698867|NCT04741321||Test and re-test group|80 patients will be recruited to answer VQ-6 questionnaire and SF-12 questionnaire. After 3-4 weeks, these patients will be re-asked with the same questionnaires.
10188827|NCT03713177||Ministry of health - Cairo|Dentists working for Egyptian ministry of health - Cairo
10188828|NCT03713177||Interns|Dental interns of Cairo University
10188829|NCT03713164|Active Comparator|Pomegranate Juice (PJ)|single dose of 8oz Pomegranate Juice (PJ)
10188830|NCT03713164|Active Comparator|Ellagic Acid (EA)|500 mg Ellagic Acid (EA) capsules
10188831|NCT03713151|Experimental|Dividat FIT: Computer based exercise|One arm with 10-15 Haemophilia patients and 10-15 Myositis patients.
10188832|NCT03713138|Experimental|Intervention Flaxseed powder|"Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Intervention/ Dietary Supplement:~Flax seed powder~Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Other Name: intervention"
9698868|NCT04740853|Experimental|Sensory Integration Therapy+Special Education|"The therapy program was prepared and applied according to the Ayres theory and based on the basic principles of sensory integration therapy prepared by Parham depending on the evaluation results. Therapy was applied to the intervention group, with a 45-minute session+15 minutes of family information once a week for eight weeks, in addition to the special education sessions they received twice a week in special education institutions. The sensory integration therapy included sensory diet practices and activities consisting of vestibular, tactile, proprioceptive, auditory and visual stimuli.~The intervention group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. In the special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied."
9698869|NCT04740853|Active Comparator|Special Education|The control group continued special education sessions in special education and rehabilitation centers twice a week for eight weeks. Within the scope of special education sessions, reading, writing, sequencing, arithmetic, language, organization, memory studies were applied.
9698870|NCT04740866|Active Comparator|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy [IMRT] technique.
10188833|NCT03713138|No Intervention|Control group; Comparison group|"The controlled group was given no intervention. No intervention was done to this group.~Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
10188834|NCT03713112|Active Comparator|Weekly MDT deprescribing rounds|Weekly MDT deprescribing rounds for certain drugs will be performed on top of usual care.
9698871|NCT04740866|No Intervention|Observation after radical Cystectomy|observation following radical cystectomy
9698872|NCT04740840|Experimental|Levamlodipine group|Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate
9698873|NCT04740840|Sham Comparator|Amlodipine group|To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate
10188835|NCT03713112|No Intervention|Control (Usual Care)|"Usual Care includes the following:~De-prescribing at the discretion of the ward doctors~Initial medication reconciliation by pharmacist on admission~Ward rounds to be conducted 3 weekdays per week for rehabilitative patients and daily on weekdays for sub-acute patients."
10188836|NCT03713099|Experimental|Microwave Ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach performed by an interventional pulmonologist or thoracic surgeon.
10188837|NCT03713060|Other|Women with RYGB and fetus/ child|20 pregnant women with previous gastric bypass surgery. During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
9698874|NCT04740502|Other|Concordant preoperative studies|Patients with concordant neck ultrasound and MIBI scan
9698875|NCT04740502|Other|Unclear preoperative studies|Patients with discordant or negative neck ultrasound and MIBI scan
9698876|NCT04740749|Other|Prospective group|Patients who have to undergone the implant surgery
9698877|NCT04740749|Other|Retrospective group|Patients that have already undergone the implant surgery
9778421|NCT01106287|Experimental|Treatment Sequence 4|Period 1: 60 mg - Period 2: 80 mg - Period 3: Placebo - Period 4: 120 mg - Period 5: 140 mg
9778422|NCT01106326|Experimental|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
9778423|NCT01106352|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
9778424|NCT01106352|Active Comparator|Docetaxel|Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
9778425|NCT01106391|Experimental|AAA stent graft system|Abdominal aortic aneurysm stent graft system
9778426|NCT01106404|Other|6-week AdaptiveStim followed by 6-week manual programming|
10188838|NCT03713060|Other|Matched controls and fetus/ child|20 pregnant women matched on age, prepregnancy-BMI and parity (n = 20). During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
10188839|NCT03713008|Experimental|Fluid bolus|Patients included in the study will receive fluid bolus.
9778427|NCT01106404|Other|6-week manual followed by 6-week AdaptiveStim programming|
9778428|NCT01106430|Experimental|Lisdexamfetamine Dimesylate|
9778429|NCT01106430|Active Comparator|Atomoxetine Hydrochloride|
9778430|NCT01106456|Experimental|All Nations Breath of Life (ANBL)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
9778431|NCT01106456|Experimental|Nontailored (NT)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
9778432|NCT01106586|Experimental|Stribild|
9778433|NCT01106586|Active Comparator|ATV/r + FTC/TDF|
9778434|NCT01106625|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
9778435|NCT01106625|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
9778436|NCT01106625|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
9778437|NCT01106651|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
9778438|NCT01106651|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
9778439|NCT01106651|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
9778440|NCT01106677|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
9778441|NCT01106677|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
10188840|NCT03712995|Experimental|Cutler-Beard modified with graft|Reconstruction of Upper Eyelid With a Newly Modified Cutler-Beard Technique With Tarsoconjunctival Graf
10188841|NCT03712969|Experimental|Intervention group|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
10188842|NCT03712969|No Intervention|Control group|Patients receive conventional adjuvant chemotherapy.
10188843|NCT03712956|Experimental|Caelyx® for 8 courses|Caelyx® administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.
9698878|NCT04740593|Experimental|Group 1 - High refractive error: Intervention|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the intervention group
9698879|NCT04740593|Other|Group 2 - High refractive error: Control|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the control group
9698880|NCT04740593|Other|Group 3 - Mild or no refractive error|Children with mild or no refractive error (i.e. not exceeding the AAPOS 2003 criteria) at age one
9698881|NCT04740788||Monofocal IOL|Patients already implanted with a monofocal IOL
10188844|NCT03712904|Experimental|A. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
9977920|NCT01366560|Placebo Comparator|Placebo|The subjects will be administered placebo tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
9698882|NCT04740632||Mothers of children with IgE-mediated food allergy diagnosed by a multidisciplinary team|Mothers of children with IgE-mediated FA diagnosed for at least 6 months who plan to visit a specialized level III center for the management of pediatric FA for the first time
9698883|NCT04740632||Mothers of children with IgE-mediated food allergy diagnosed by a non-multidisciplinary team|Mothers of children with IgE-mediated AA diagnosed for at least 6 months who plan to undergo a follow-up visit at a specialized level III center for the management of FA in pediatric age which they have already been followed for at least 6 months
9698884|NCT04740554||Duchenne Muscular Dystrophy group with Deflazacort|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of deflazacort.
9698885|NCT04740554||Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which make use of Prednisone/Predinisolone.
9698886|NCT04740554||Duchenne Muscular Dystrophy group without Corticosteroids therapy|Individuals Duchenne Muscular Dystrophy, with age 11 to 18 years which don't use of corticosteroids.
9698887|NCT04740554||Control Group Typically Developing|Individuals with typical development age 11 to 18 years which don't use of corticosteroids.
9698888|NCT04740762|Experimental|Intervention group|The study group were provided with individual counseling program and followed in this study, in addition to the usual care provided by healthcare professionals.
9698889|NCT04740762|No Intervention|Control group|The control group continued to receive the routine care
9698890|NCT04740710|Active Comparator|Standard Breathing and Attention Training|The standard breathing and attention training (BAT) includes guided instructions on deep breathing and relaxation. Participants will practice standard BAT once a day for 15 minutes for 5 days in a row.
9698891|NCT04740710|Experimental|Focused Breathing and Attention Training|The focused BAT is similar to the standard BAT in most ways but includes extra instructions to help focus and alter breathing patterns. Participants will practice focused BAT once a day for 15 minutes for 5 days in a row.
9698892|NCT04740541|Experimental|Threonine Requirement in CD Patients|Males aged 18 - 49 with stable Crohn's disease will be seen for pre-study They will be studied up to 5 times for different levels of threonine intakes.
9698893|NCT04740450|Experimental|study side|receive KT technique described by Gozluklu et al in 2020
9698894|NCT04740450|Placebo Comparator|Control side|tapped with wound tape following the same technique
9698895|NCT04740216|Experimental|exercise therapy plus jaw device|exercise therapy plus jaw device
9698896|NCT04740216|Placebo Comparator|exercise therapy|exercise therapy
9698897|NCT04740138|Experimental|DBT Skills + Parent Training|
9698898|NCT04740255|Other|Epistamp Needling Treatment Without RF|Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Epistamp needling without RF (Radio Frequency)
9698899|NCT04740255|Other|Epistamp Microneedling Treatment With RF|Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Epistamp needling with RF (Radio Frequency)
9698900|NCT04740320||Healthy Volunteers|Volunteers asked to register details on a SARS-CoV-2 specific web page UKcovidchallenge.com. They will be contacted with a short webform questionnaire to be performed prior to a follow-up telephone questionnaire or will be asked to complete a telephone questionnaire. If inclusion/exclusion criteria are met, appointment for a screening visit will be scheduled. Screening appointments will be conducted at hVIVO. Written consent for screening will be obtained prior to any history-taking, examination or tests are carried out. Medical history will be requested from GP to assess suitability. Once the SARS-CoV-2 characterization study is approved, potential participants will be given the study specific PIS detailing the full study and experimental procedures. The opportunity to discuss further and ask questions will be available prior to booking a study visit.
9698901|NCT04740190|Experimental|interventional arm|Single fraction, low dose (2Gy) whole brain radiation therapy, followed by combination talazoparib and carboplatin
9698902|NCT04740281||Medical Doctors at Aarhus University Hospital, Denmark|Medical Doctors from different subspecialties at Aarhus University Hospital, Denmark. Blinded for the purpose of the trial, their footwear will be evaluated by trial responsible personal.
9698903|NCT04740333||Group A- Normal ICU admission blood glucose level|Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).
9698904|NCT04740333||Group B- High ICU admission blood glucose level|Patients with admission blood glucose level higher than 180 mg / dL.
9698905|NCT04740359|Active Comparator|Control|Routine training; mat exercises and perturbation training
9977921|NCT01366573|Experimental|GSK1521498 &amp; alcohol|GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)
9977922|NCT01366573|Experimental|GSK1521498 & orange juice|GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour
9977923|NCT01366573|Experimental|Placebo &amp; alcohol|Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)
9698906|NCT04740359|Experimental|Study|Trunk training; Functional training, mat exercises and perturbation training
10188845|NCT03712904|Experimental|B. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
10188846|NCT03712878|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT, tacrolimus, MMF)|"Description CONDITIONING REGIMEN: Participants undergo TBI BID on days -9 to -6.~TRANSPLANT: Participants receive donor lymphocytes IV on day -6 after the last dose of TBI.~CONDITIONING REGIMEN: Participants receive cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Participants undergo hematopoietic stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Participants receive tacrolimus IV beginning on day -1 with taper beginning on day 42 in the absence of GVHD, a suspicion of GVHD, or previous history of GVHD requiring a taper delay. Participants also receive mycophenolate mofetil IV BID beginning on day -1 through day 28 in the absence of GVHD."
9698907|NCT04740398|Experimental|Ia stage - CBP-1008 Dose escalation/ Ib stage - CBP-1008 monotherapy|"Ia:Patients will receive CBP-1008 IV infusion every 2 weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.~Ib:Patients will receive CBP-1008 RP2D IV infusion every two weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue."
9698908|NCT04740073||Patients|Persons undergoing total knee arthroplasty
9698909|NCT04740073||Controls|Persons not undergoing total knee arthroplasty who are age and sex-matched to the patient group.
9698910|NCT04740112|Placebo Comparator|Control breakfast bar with low dietary fiber without product claims|
9698911|NCT04740112|Experimental|Test breakfast bar with high dietary fiber without product claims|
9698912|NCT04740112|Experimental|Test breakfast bar with high dietary fiber with product claims|
9698913|NCT04740203|Experimental|CAR-T therapy|Administration of CD19 and CD22 CAR T-cells
9698914|NCT04740411|Experimental|Common Elements Toolbox (COMET)|
9698915|NCT04740411|No Intervention|Wait-list control condition|
9698916|NCT04740242||Cohort of exposed patients (Group 1)|All patients admitted for decompensated HF and presenting MA at the time of admission
9698917|NCT04740242||Cohort of unexposed patients (Group 2)|All patients admitted for decompensated HF and who do NOT present MA at the time of admission
9698918|NCT04740021|Experimental|Experimental: LP002+EP|Participants recieve LP002 10 mg/kg intravenous (IV) on day 1 PLUS carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on day 1 PLUS etoposide 100 mg/m^2 IV on days 1, 2 and 3 of each 21-day cycle
9698919|NCT04740229|Experimental|Moderate-intensity flow-based Yoga|The intervention will consist of participants engaging in a progressive series of moderate-intensity, flow-based yoga poses, along with breathing and relaxation, for eight weeks. The intervention will be titrated in terms of supervision, with first two weeks being completely supervised, followed by partial supervision for three weeks, and three weeks of unsupervised sessions. The sessions will be ~50 minutes long, 3 times/week. All supervised sessions will be conducted online through Google Meet (GM), which is a live video interaction platform. Videos will be provided to guide unsupervised sessions. Sessions will be led by a certified yoga instructor. An orientation will be provided in the first week, given that the participants will have no or minimal experience with yoga. The intervention will consist of basic sun salutations of hatha yoga sun salutation A, sun salutation B and flow sequences, and breathing exercises, and relaxation.
9698920|NCT04740229|No Intervention|Waitlist control|Participants in this group will not receive the 8-week intervention during the course of the study, and will be asked to engage in their regular activities. They will be asked to not start any new activities during the study period. After they complete the study, they will be provided with the same intervention (live instruction, feedback and supportive videos).
9698921|NCT04740099|Experimental|SOONER Training (Intervention)|Arm receives video training and kit designed by SOONER team.
9698922|NCT04740099|Other|Standard of care training (control)|Participant referred to standard of care (community based Naloxone training)
9698923|NCT04739852|Active Comparator|Healthy Participants|
9698924|NCT04739852|Active Comparator|Metabolic Syndrome|
9698925|NCT04739852|Active Comparator|Rheumatoid Arthritis|
9698926|NCT04739826||flumatinib|flumatinib 600mg QD, fasting administration
9698927|NCT04739826||nilotinib|nilotinib 300mg BID, fasting administration
9698928|NCT04740268|Other|Epistamp Needling Treatment Without RF|Non-Randomized treatment for patients without atrophic acne skin conditions using the Epistamp Needling without RF (Radio Frequency)
9698929|NCT04740268|Other|Epistamp Needling Treatment With RF|Non-Randomized treatment for patients with atrophic acne skin conditions using the Epistamp needling without RF (Radio Frequency)
9698930|NCT04739943|Experimental|Mobile Monitoring|Participants will be asked to use a smartphone or tablet application for remote monitoring or respiratory health. They will be followed over time with surveys as well as chart review to assess effects of adding these mobile monitoring elements to their standard care.
9698931|NCT04739774|Experimental|Treatment R|Single dose of CHF6001
9698932|NCT04739774|Experimental|Treatment T|Single dose of CHF6001 administered after repeated doses of oral Itraconazole
9698933|NCT04739878|Experimental|Ultrasound Airway|Ultrasound Airway for subglottic secretion
9778442|NCT01106677|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
9778443|NCT01106677|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin will be given with protocol-specified doses of metformin immediate release.
9977924|NCT01366573|Placebo Comparator|Placebo &amp; orange juice|Placebo and orange juice approximately matching alcoholic beverage for volume and colour
9977925|NCT01366599||Patients enrolled in IHCIS in 2006|Patients enrolled in IHCIS in 2006
9698934|NCT04739631|Experimental|acupuncture group|The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture.The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3 mm×30 mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
9698935|NCT04739631|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
10188847|NCT03712839||Acquired Brain Injury group with anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. To determine the presence of anosognosia, patients must present an overestimation value of their capacities greater than 5 (>5) in the discrepancy index on the Patient Competency Rating Scale (PCRS) (Prigatano et al., 1998).
10188848|NCT03712839||Acquired Brain Injury group without anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. These patients must present a score of < 5 on the PCRS Scale.
9698936|NCT04739631|No Intervention|waitlist-control group|As an waitlist-control group, no acupuncture will be performed.
9698937|NCT04739917|Experimental|Arm N Vaccine|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
9698938|NCT04739917|Placebo Comparator|Arm N Placebo|30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
9698939|NCT04739917|Experimental|Arm S Vaccine|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
9698940|NCT04739917|Placebo Comparator|Arm S Placebo|30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
9698941|NCT04739722|Experimental|ColonoSight Test|All participants will be evaluated with the Colonosight Test system and a colonoscopy.
9698942|NCT04739904||Preterm born|Premature born but otherwise healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
9698943|NCT04739904||Full-term control|Full-term born healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
9698944|NCT04739670|Experimental|Atezolizumab, Bevacizumab, Gemcitabine and Carboplatin|Atezolizumab 1200 mg Day 1 of each 21 day cycle IV, Bevacizumab 15 mg/kg Day 1 of each 21 day cycle IV, Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle IV, Carboplatin AUC 5 Day 1 of each 21 day cycle IV
9698945|NCT04739748||Respiratory ICU patient|patient in RICU that developed ventilator-associated pneumonia
9698946|NCT04739501||TACE in HCC group 1|the patient did undergo tace
9698947|NCT04739618|Experimental|Single arm. Subjects receiving treatment.|Efficacy of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria
9698948|NCT04739553|Experimental|His Pacing|Implant of a supplementary His pacing lead in addition to a traditional RV pacing lead.
9698949|NCT04739644|Experimental|Experimental: WRISTBOT Group|"The patients in the WRISTBOT Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation by WRISTBOT device"
9698950|NCT04739644|Active Comparator|Control group|The patients in the Control Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation performed by physiotherapist.
9698951|NCT04739488|Experimental|Breathing exercise and inhaler training|This group were given pursed lip breathing exercise and inhaler training.
9698952|NCT04739488|Experimental|inhaler training|This group were given only inhaler training
9698953|NCT04739280||Single center registry for WACE|We propose a single center registry for patients requiring diagnostic, screening, or surveillance for potential or existing cardiac illness. All eligible patients will undergo an MCG with periodic follow-ups. No treatment decisions will be based on the MCG findings, until CardioFlux has appropriate FDA labelling for clinical use.
9698954|NCT04739566|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib 150 mg orally (PO) twice daily, trametinib 2mg PO once daily for 3 months
9698955|NCT04739579||Anastomotic Leak|
9698956|NCT04739579||Non-Anatomotic Leak|
10188849|NCT03712839||Control group|Healthy participants matched in age, gender and educational level with the others two groups.
9698957|NCT04739410|Experimental|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12mg stat per oral and then 12 mg per oral after 12 hours and 12mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue. and any side effects of the drugs were noted as well.
9698958|NCT04739410|Placebo Comparator|SOC standard of care|These participants were given standard of care without Ivermectin standard of care only symptomatic treatment
9698959|NCT04739436|Other|Bilateral hearing aid fitting group|
9698960|NCT04739436|Active Comparator|Unilateral hearing aid fitting group|
9698961|NCT04739397||Cataract|Patients with bilateral cataracts with Lens grade 2+ or greater, cataract classification nuclear, cortical or posterior subcapsular
9698962|NCT04739397||Non-Cataract|patients with bilateral clear lenses (no cataracts)
9698963|NCT04739332|Experimental|NBO intervention for at-risk mothers|NBO intervention for at- risk mothers. 3 NBO sessions added to the routine follow-up delivered once per week during the first month postpartum. The intervention is delivered by a nurse certified in the NBO system.
9698964|NCT04739332|No Intervention|Treatment as usual|Participants receive 3 routine follow-up by the local health visitor/midwife during the first month
9698965|NCT04739241|Experimental|Group A (experimental arm)|Premixed insulin therapy
10188850|NCT03712826|Experimental|anti TNF|Crohn patient with antiTNF treatment
10188851|NCT03712826|Experimental|Ustekinumab|Crohn disease with ustekinumab treatment
10188852|NCT03712800|Experimental|Rhythmical massage|Participants who receive rhythmical massage for three months.
10188853|NCT03712800|Experimental|HRV biofeedback|Participants who perform HRV biofeedback for three months.
10188854|NCT03712800|No Intervention|Control group|Participants who do not receive an intervention during the three-month intervention period but are advised to stay with their usual care during menstrual pain. For ethical and compliance reasons, these participants receive a series of rhythmical massage treatments after the initial three-month intervention/control period.
9698966|NCT04739241|Active Comparator|Group B (active comparator)|Basal bolus insulin therapy
9698967|NCT04739202|Experimental|Patients with tumors positive for EBV or microsatellite instable tumors (group 1)|Atezolizumab IV (1200 mg every 3 weeks) + Ipatasertib tablet (400 mg a day continuously).
9698968|NCT04739202|Experimental|Patients with genomically stable tumors (group 2)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
9698969|NCT04739202|Experimental|Patients with tumors with chromosomal instability (group 3)|Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).
9698970|NCT04739137||Study group|100 patients with diagnosed macular edema will be enrolled
9698971|NCT04739215|Experimental|Clinical Trial: Experimental Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Dapagliflozin (Forxiga) 10 mg, one capsule per day orally.
9698972|NCT04739215|Placebo Comparator|Clinical Trial: Placebo Arm|Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Placebo in a similar pattern.
9698973|NCT04739215|No Intervention|Descriptive Study|Patients with heart failure with preserved ejection fraction but with no type 2 diabetes mellitus (n=10).
9698974|NCT04739514|Active Comparator|Mild dysphagia|
9698975|NCT04739514|Active Comparator|Moderate dysphagia|
9698976|NCT04739514|Active Comparator|Severe dysphagia|
9698977|NCT04739033|Experimental|Experimental group|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
9698978|NCT04739033|Active Comparator|Control Group|The control group will receive the same webbased lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
9698979|NCT04739319||Age-Related Macular Degeneration|Participants with Age-Related Macular Degeneration
9698980|NCT04739228|Experimental|Guided Written Disclosure Protocol Group|Guided Written Disclosure Protocol is a short-term psychological intervention that stimulates emotional expression, promotes a cognitive reworking of stressful illness events and facilitates the integration between emotional and cognitive processing of traumatic experiences. Intervention aimed at enhancing patients' quality of life, psychological well-being, and emotional regulation, and reducing psychosocial distress.
9698981|NCT04739228|Active Comparator|Active Control Group|
9698982|NCT04738955|Experimental|High dose group|micafungin sodium ≥ 200, ≤ 300 mg/time, once a day, intravenous drip
9977926|NCT01366625|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
10188855|NCT03712774||neoadjuvant chemoradiation|Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
10188856|NCT03712774||definitive chemoradiation|Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
10188857|NCT03712761||Supplementation with Enriched Protein®|Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
10188858|NCT03712761||Low protein breakfast|No supplementation
10188859|NCT03712761||High protein breakfast|No supplementation
10188860|NCT03712748|Experimental|Imaginal Exposure Session|
10188861|NCT03712735|Active Comparator|Group A|"Bupivacaine 0.08% - fentanyl 2mcg on the following pump settings:~PIEB flow rate = high; interval = 60 min"
9698983|NCT04739176|Experimental|One-on-one rehabilitation program|
9698984|NCT04739085||Defocus curve group|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to the distances of 30 cm, 40 cm, 60 cm, and 80 cm, respectively.
9698985|NCT04739085||wDDART group|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
9698986|NCT04739124||Diabetic patients|Patients presenting type 1 or type 2 diabetes, eligible for the prescription of Freestyle Libre
9698987|NCT04739124||Caregivers|Caregiver caring for diabetic patients and practicing therapeutic education on a regular basis
9698988|NCT04739345||Group 1|Non-severe patients should meet all following conditions: (1) Epidemiology history, (2) Fever or other respiratory symptoms, (3) Typical CT image abnormities of viral pneumonia, and (4) Positive result of RT-PCR for SARS-CoV-2 RNA.
9698989|NCT04739345||Group 2|Severe patients should meet at least one of the following conditions: (1) Shortness of breath, RR ≥ 30 times/min, (2) Oxygen saturation (Resting state) ≤ 93%, (3) PaO2/FiO2 ≤ 300 mmHg.
9698990|NCT04739111|Experimental|Experimental Arms|All participants will receive treatment with LDP combined with CDP1. In the dose-escalation phase, a fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the dose-expansion phase.
9698991|NCT04738903|Active Comparator|Custom Q treatment group|For every patient, the eye with the greater myopic spherical equivalent (SE) will be assigned for the Custom-Q treatment group.
9698992|NCT04738903|Active Comparator|Wave-front optimized (WFO) group|For every patient, the other eye with the lesser myopic SE will be assigned for the WFO treatment group
10188862|NCT03712735|Experimental|Group B|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = high; interval = 45 min
9698993|NCT04738760||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with standard dose vitamin D in addition to standard COVID-19 management.
9698994|NCT04738760||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with high dose vitamin Din addition to standard COVID-19 management.
9698995|NCT04738851|Experimental|healthy volunteers|Virtual mirror therapy task : TMV Classic mirror therapy task : TMC Control task :TC
9698996|NCT04738981|Experimental|UC-MSC and anti-CD25 mAb|UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.
9698997|NCT04738981|Active Comparator|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment.
9698998|NCT04739306|Experimental|CT-P42|
9698999|NCT04739306|Active Comparator|Eylea|
9699000|NCT04738968|Experimental|Cochlear implant for single-sided deafness|Children with single-sided deafness, cochlear implant in the deaf ear
9699001|NCT04738968|No Intervention|Control single-sided deafness|Children with single-sided deafness, no intervention
9699002|NCT04738968|No Intervention|Control normal hearing|Children with normal hearing, no intervention
9699003|NCT04738929|Experimental|Normal weight|Normal weight subjects (BMI=18.5-25)
9699004|NCT04738929|Experimental|Obese|Obese subjects (BMI=30-34.99)
9699005|NCT04738994|Experimental|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
9699006|NCT04738994|Active Comparator|Control group|Standard hospital diet
9699007|NCT04739046|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and radiation therapy
9699008|NCT04738656||Mediterranean-style diet plan|"Mediterranean-style diet plan (6 months): 22% proteins, 53% carbohydrates, and 25% of lipids.~52 participants."
9699009|NCT04738656||Open protein diet plan|"Open protein presents (6 months) 40% of proteins, 29% carbohydrate and 31% of lipids.~26 participants."
9699010|NCT04738630|Experimental|Experimental: HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
9699011|NCT04738786|Active Comparator|Wide surgical safety margin|1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer
9699012|NCT04738786|Active Comparator|Narrow surgical safety margin|1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer
9699013|NCT04738695||Nursing home residents/staff members|Follow-up of seroprevalence
9699014|NCT04738734|Experimental|CellFX Procedure|CellFX device using pre-defined energy protocols
9699015|NCT04738734|Active Comparator|Cryosurgical Procedure|Cryosurgery will be standardized across all investigational sites. Investigators will perform the Cryosurgical procedure using the Brymill Cry-Ac B700 Liquid Nitrogen Sprayer.
9699016|NCT04738747|Experimental|Study arm (receive a WHOOP device)|Participants randomized to the WHOOP group will be given WHOOP wrist and arm bands to wear 24/7 after an orientation on their use
9699017|NCT04738747|No Intervention|Control arm (no intervention)|The control group will not have any intervention
9699018|NCT04738838|Experimental|Oxytocin Nasal Spray|Single dose of intranasal oxytocin (48 IU) prior to testing protocol.
9699019|NCT04738838|Placebo Comparator|Placebo Nasal Spray|Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
9699020|NCT04738812|Experimental|Intensified TB treatment|"Increased doses of rifampicin (R) to 35±5 mg/kg daily and isoniazid (H) 10±2 mg/kg daily together with standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E) 15-20 mg/kg daily for 8 weeks (initial phase of TB treatment).~Prednisone 40 to 80 mg once a day (OD) according to weight bands for 2 weeks, followed by 20 to 40 mg OD according to weight bands for 2 weeks, then 10 to 20 mg OD according to weight bands for the last 2 weeks (total duration: 6 weeks). Because of the corticosteroid treatment, albendazole 400 mg OD will be given to participants for 3 days.~Continuation phase: 16 weeks of RH."
9699021|NCT04738812|Active Comparator|WHO standard TB treatment|"Standard-dose of R 8-12 mg/kg daily + H 4-6 mg/kg daily + Z 20-30 mg/kg daily + E 15-20 mg/kg daily for 8 weeks.~Continuation phase: 16 weeks of RH."
10188863|NCT03712735|Experimental|Group C|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = low; interval = 45 min
10188864|NCT03712722||rCDI|Adult patients with recurrect Clostridium difficile infection
10188865|NCT03712709||Case Detection Group|Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled
9699022|NCT04738916|Experimental|Vibration Group|The vibration group was included in the low frequency (25 Hz), low amplitude (2mm), fixed six-week training on two non-consecutive days of the week.
9699023|NCT04738916|No Intervention|Control Group|No training was given to the control group.
9699024|NCT04738864|Experimental|behcet's disease patient|patient who presented with manifestation of behcet disease
9699025|NCT04738864|Experimental|Healthy people|healthy control people
9778444|NCT01106690|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.
9778445|NCT01106690|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
9699026|NCT04738604|Active Comparator|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) is the ideal choice for single-tooth restorations, both in the anterior and the posterior region. It has an ultrafine, radiopaque porcelain filler for use in adhesive filling treatment. It can be polished to a high lustrer due to the ultra- fine particle filler, extremely homogeneous restorations can be placed which are easily polished to a high luster. The mechanical properties of a light-cured dental composite material are particularly dependent on its filler content, the type of incorporated fillers and the efficiency of the filler-resin coupling, so high Vickers hardness, compressive strength and flexural strength are recorded refereed to Zenit filler content 83% by weight (70% by volume) and size 0.7 microns
9699027|NCT04738604|Experimental|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany)|contains organically modified ceramic nanoparticles (2 to 3 nm) and nano-fillers (10 nm) that are combined with conventional glass fillers (mean particle size: 1.1 to 1.5 μm). Nanoparticles and nano-fillers comprise a polysiloxane backbone and have methacrylate groups available for polymerization. According to the manufacturer's data, filler concentration is 76% by weight and 57% by volume. Furthermore, most of the conventional resin matrix is replaced by a matrix full of highly dispersed methacrylate modified polysiloxane particles (2- 3 nm).These nano-ceramic particles are inorganic-organic hybrid particles. Both, nano-ceramic particles and nano- fillers have methacrylate groups available for polymerization. CeramX does not contain triethylene glycol dimethacrylate (TEGDMA) as it was found mutagenic and cytotoxic in vitro
9778446|NCT01106690|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
10188866|NCT03712709||Drug Resistant TB Group|In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).
10188867|NCT03712696|Experimental|DIGNICAP™|DigniCap® System
9778447|NCT01106833|Active Comparator|calcineurin inhibitor|Sirolimus + calcineurin inhibitor + prednisone
9778448|NCT01106833|Experimental|Sirolimus and prednisone|Sirolimus + prednisone
9778449|NCT01106846|Placebo Comparator|Group A: Saline group|Group A: Saline group , infusion of saline intravenously
10188868|NCT03712683|Experimental|Sub clinical hypothyroid women|"Levothyroxine sodium(Euthyrox 50µg and 25 µg MerckSerono) treatment was initiated and the women were followed in a combined clinic of endocrinologist and Gynecologist.~2.5 µg of Thyroxine daily was prescribed to women with TSH more than 2.5 mIU/L. Women with TSH more than 4mIU/L were given 50 µg daily . When pregnancy was confirmed Thyroxine was continued till 13 weeks gestation ."
10188869|NCT03712670|Active Comparator|AM group|Intravitreal aflibercept monotherapy
9778450|NCT01106846|Active Comparator|Group B: 1% Ketamine group|Group B: Infusion of ketamine 1% intravenously
9778451|NCT01106859|Active Comparator|zopiclone|Zopiclone is taken at bedtime 9 hours before driving. The middle-of-the-night medication is a placebo matching zolpidem tartrate sublingual tablet.
9778452|NCT01106859|Experimental|zolpidem 3 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
9778453|NCT01106859|Experimental|zolpidem 4 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 4 hours prior to driving.
9778454|NCT01106859|Placebo Comparator|Placebo|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is a placebo matching zolpidem tartrate sublingual tablet.
9778455|NCT01106898|Experimental|Treatment (chemotherapy with or without maintenance therapy)|"SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity."
9778456|NCT01106950|Experimental|Treated Patients|Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
9778457|NCT01106976||Group 1 Parkinson disease subjects|Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.
9778458|NCT01107015|No Intervention|Group 1: Usual Care|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
9778459|NCT01107015|Active Comparator|Group 2: patient intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
9778460|NCT01107015|Active Comparator|Group 3: patient-physician intervention|Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
10188870|NCT03712670|Experimental|AP group|Intravitreal aflibercept along with 0.1% pranoprofen
10188871|NCT03712670|Experimental|AN group|Intravitreal aflibercept plus daily supplementation of nutraceutical tablets
10188872|NCT03712657|Experimental|ERAS group|interventions: 1.preoperative pain control; 2.avoiding application of ureter; 3.avoiding application of gastric tube; 4.avoiding application of irrigation; 5.avoiding application of drainage; 6.early exercising postoperatively; 7.early oral feeding postoperatively; 8.early discharging.
10188873|NCT03712657|No Intervention|conservative group|normal treatment
10188874|NCT03712644|No Intervention|Conservative|Patients will receive primarily optimal medical therapy alone and followed, according to protocol. Any further cardiologic investigation will be performed only in case of clinical suspicion of myocardial ischemia related symptoms.
10205414|NCT01693783|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving objective response or stable disease continue to receive maintenance therapy comprising ipilimumab IV over 90 minutes once every 12 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
10205415|NCT01658930|Active Comparator|Radical Hysterectomy|
10205416|NCT01658930|Experimental|Simple Hysterectomy|
10205417|NCT01580761|Experimental|Sleep restriction|Sleep restriction
9699028|NCT04738773|Active Comparator|Patients receiving Naltrexone|
10188875|NCT03712644|Experimental|Invasive|"In the Invasive group in addition to optimal medical therapy elective coronary angiography will be performed. Coronary catheterization is preferably scheduled within a maximum of 14 days after peripheral revascularization~All lesions of 50-90% diameter stenosis in a major coronary artery will be evaluated by fractional flow reserve (FFR) and intervened by percutaneous coronary intervention (PCI) if FFR≤0.80 or left for medical therapy if FFR>0.80. All lesions of ≥90% diameter stenosis in a major coronary artery will be intervened. This includes also efforts to recanalize chronic total occlusions (CTO) of large supplied viable myocardial territory.~For complex cases revascularization by coronary artery bypass surgery might be considered, however PCI is preferred whenever possible."
10188876|NCT03712631|Active Comparator|bone without a collagen membrane|not covering bone with collagen membrane
10188877|NCT03712631|Experimental|bone with collagen membrane|covering bone with collagen membrane
10188878|NCT03712592|Experimental|160km|
9699029|NCT04738773|Placebo Comparator|Patients receiving Placebo|
9699030|NCT04738565|Experimental|Probiotic|The mixture of 3 probiotic strains in the following proportions: 50% Lactobacillus casei ŁOCK 0919, 25% Lactobacillus rhamnosus ŁOCK 0908, 25% Lactobacillus rhamnosus ŁOCK 0900 (Latopic® preparation, Biomed S.A., Cracow, Poland).
9699031|NCT04738565|Placebo Comparator|Maltodextrin|Maltodextrin - a substance in which probiotic strains have been suspended.
9699032|NCT04738474|Experimental|PRISM Intervention|Subjects in this group will receive the PRISM intervention
10188879|NCT03712592|Experimental|40km|
10188880|NCT03712592|Experimental|100km|
9699033|NCT04738474|Placebo Comparator|Usual Care|Subjects in this arm will receive usual care
10188881|NCT03712592|Experimental|4x40km|
9699034|NCT04738344|Experimental|Percutaneous coronary intervention and stent implantation using one long stent|Long coronary lesions will be treated percutaneously with a single long stent (more than 40 mm in length) and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
10188882|NCT03712579|Experimental|SFA-Rich Meal|Participants will consume a SFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
10188883|NCT03712579|Experimental|MUFA-Rich Meal|Participants will consume a MUFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
9699035|NCT04738344|Experimental|Percutaneous coronary intervention and stent implantation using more than one overlapping stents|Long coronary lesions will be treated with more than one overlapping stents and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
9699036|NCT04738461|Experimental|Telerehabilitation|Telerehabilitation program will be applied 5 days a week for 3 weeks to patients in the telerehabilitation group. A physiatrist will meet with patients via videoconferencing over the internet and guide the program.
9699037|NCT04738461|Active Comparator|Standard Physiotherapy|Patients in the standard physiotherapy group will receive one-to-one physiotherapy sessions in the hospital 5 days a week for 3 weeks. In these sessions, active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
9699038|NCT04738461|Active Comparator|Home exercise group|The home exercise program was explained to the patients in the control group by the physiotherapist and the relevant brochures were delivered to the patients. Home exercise program will consist of telerehabilitation group exercises. However, patients will be not under any supervision and exercise themselves at home.
9699039|NCT04738513|Active Comparator|Conventional preparation technique|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
9699040|NCT04738513|Experimental|Vertical preprartion|Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using Vertical preparation technique.
9699041|NCT04738708|Experimental|Telemedicine|
9699042|NCT04738708|Active Comparator|Control|
9699043|NCT04738526|Active Comparator|natural tooth|
9699044|NCT04738526|Experimental|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate (IPS e-max) ceramic crown for crowns in esthetic zone
10188884|NCT03712566||MASST|Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head & Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
9699045|NCT04738526|Experimental|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|
9699046|NCT04738253||Study group|Stroke patients with limitation of range of motion on the affected shoulder.
10188885|NCT03712553|Active Comparator|A1: Opt-In, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of an opt-in message encouraging participants to contact their primary care provider for Hepatitis C screening.
10188886|NCT03712553|Experimental|A2: Opt-Out, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of a message and a written laboratory order from primary care provider to complete Hepatitis C screening.
10205418|NCT01580761|No Intervention|Normal sleep|Normal sleep
9699047|NCT04738305|Other|Dignity Therapy Intervention|All the patients that accepted to participate in the study were provided with Dignity Therapy Intervention. A short-term intervention aimed at reducing existential distress of patients facing with advanced illness.
9699048|NCT04738370||Pregnancy of unknown location|Patients will be approached for recruitment following PUL classification. Sample collection at time of classification +/- 48 hours later, timed for when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
9699049|NCT04738370||Ectopic Pregnancy|Patients will be approached for recruitment following Ectopic Pregnancy diagnosis. Ectopic pregnancies that are recruited as PUL do not need to be re-approached as they are already part of the study. Sample collection at time of diagnosis when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.
9699050|NCT04738357|Experimental|HSK21542|
9699051|NCT04738357|Placebo Comparator|placebo|
9699052|NCT04738409||Ov/Ob group|PCOS subjects (Overweight/Obesity)
9699053|NCT04738409||N group|PCOS subjects (Normal weight)
9699054|NCT04738409||H group|Healthy control subjects
9699055|NCT04738682|Active Comparator|Group 1 (Digital -> Conventional)|Patients allocated to Group 1 (Digital -> Conventional) will undergo three days of digital dietary registration, using mobile devices, followed by three days of conventional dietary registration, using pen and paper.
9699056|NCT04738682|Active Comparator|Group 2 - (Conventional -> Digital)|Patients allocated to Group 2 - (Conventional -> Digital) will undergo the exact opposite sequence, commencing with three days of conventional dietary registration, using pen and paper, followed by three days of digital dietary registration, using mobile devices.
9699057|NCT04738383|Experimental|Version 1: Paramedic|Physician is replaced by a paramedic, but the physician still acts as a supervisor.
9699058|NCT04738383|Experimental|Version 2: Physician-on-call|Physician is not present, but is on call.
9699059|NCT04738383|Experimental|Version 3: Trained instructor|Physician acts as a supervisor, but is not constantly present. The instructor received a special training preparing for emergency cases.
9699060|NCT04738383|No Intervention|Control group|The sessions take place in the usual way, meaning that a physician is present in every session.
9699061|NCT04738227|Experimental|Low level Laser Therapy Group|"Laser therapy will be performed with a continuous wave diode laser device previously calibrated by the manufacturer.~6 points that will be the skin overlying the right hand side parotid gland and 3 points on the skin overlying the location of the right hand side submandibular gland).~Following are the parameters which will be employed for the laser:~Wavelength - 635nm (visible spectrum), Output power 100 milliwatt, Mean dose per point - 3 J/cm2 , Irradiation time per point 15 s Energy per point 3 J Energy per session 60 J , Laser spot tip will be 0.08cm2 Two laser sessions will be done each week, during 12 weeks, which will bring the total number of laser sessions to All the major salivary glands will be treated with the tip of the laser hand-piece in contact with patients tissues.~A sum total of 22 points will receive LLLT per session involving all three major salivary glands."
9699062|NCT04738539||Patients with or being evaluated for neurogenic bladder|Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics testing.
9699063|NCT04738669|No Intervention|Control Arm|No intervention is being conducted in this arm. Routine care is being given to these patients. The patients will be followed up for any readmissions during the intervention period.
9699064|NCT04738669|Experimental|mHealth Arm|"This arm will receive first receive weekly telephone call followed by the SMS in Urdu regarding medication adherence according to the discharge instructions.~The calls and SMS will be sent on 7, 14, 21 and 30th day post-index discharge. The patients will be followed up for any readmissions during the intervention period."
9699065|NCT04738669|Experimental|Teach back arm|"The trained doctors thoroughly explained the discharge instructions, medication schedule and any other self-care instructions to these participants and asked them to repeat what they have understood from the doctor verbal counselling.~If the instructions were not clearly comprehended by the patients, then the same would be repeated by the consultant doctor.~The patients will be followed up for any readmissions during the intervention period."
9699066|NCT04738240|Experimental|Intra-operative endoscopy|The intervention arm will have an intra-operative endoscopy performed per rectum once the anastomosis has been performed. The anastomosis will be graded from 1 to 3 in the endoscopic group. Grade 1 is defined as circumferentially normal appearing peri-anastomotic mucosa. Grade 2 is defined as ischemia or congestion involving <30% of either the colon or rectal mucosa. Grade 3 is defined as ischemia or congestion involving >30% of the colon or rectal mucosa or ischemia/congestion involving both sides of the staple line. If appearances are grade 2 a suture re-inforcement or re-anastomosis will be performed; if appearances are grade 3 a re-anastomosis will be performed. Images will be obtained via the endoscopy stack during the assessment.
9699067|NCT04738240|No Intervention|Standard air leak test|The control arm will receive an intra-operative leak test. This involves insufflation of air per rectum via bladder syringe while the anastomosis is bathed in sterile water. The presence of air bubbles from the anastomosis denotes a positive test.
9699068|NCT04738500|Active Comparator|PENG Block|PENG Block combinate with PCA
9699069|NCT04738500|Sham Comparator|CONTROL|PCA
9699070|NCT04738058|Experimental|Preterm infants diagnosed as feeding intolerance will receive bovine lactoferrin|they will receive bovine lactoferrin 100mg/day with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
9699071|NCT04738058|Placebo Comparator|Preterm infants diagnosed with feeding intolerance will receive placebo|they will receive the placebo with feeding for 4 weeks or until discharge for preterm that was diagnosed as feeding intolerance
9699072|NCT04738188|Experimental|Drug-eluting bead transarterial chemoembolization(DEB-TACE)|
9699073|NCT04738188|Active Comparator|conventional transarterial chemoembolization(cTACE)|
9699074|NCT04738084|Experimental|Meru Health Program|The Meru Health Program (MHP) is a 12-week online mobile digital mental health clinic delivered via Smartphone app that includes components of several evidence-based treatments (Cognitive Behavioral Therapy, Behavioral Activation Therapy, Mindfulness Meditation) and also several promising therapies (heart rate variability-biofeedback [HRVB], nutritional psychiatry, sleep training) and a group support component that is overseen by a licensed clinical therapist.
9699075|NCT04738084|No Intervention|Waitlist|12 week waitlist
9699076|NCT04738097|Experimental|intervention|Intervention group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.
9699077|NCT04738097|Active Comparator|control|control gruop will be treat with ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.
10188887|NCT03712553|Experimental|B1: Active MPM User, UC Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
9699078|NCT04738136|No Intervention|Standard of Care (SOC)|Subjects will only receive standard of care treatment for moderate severity COVID19 bronchiolitis/pneumonia.
10188888|NCT03712553|Experimental|B2: Active MPM User, BE Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a letter with behavioral economic (BE) principles encouraging them to contact their primary care provider for Hepatitis C screening.
10188889|NCT03712553|Active Comparator|B3: Active MPM User, UC MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic usual care (UC) message on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
10188890|NCT03712553|Experimental|B4: Active MPM User, BE MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic message with behavioral economic principles on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
10188891|NCT03712553|Active Comparator|B5: Non-MPM User, UC Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
10188892|NCT03712553|Experimental|B6: Non-MPM User, BE Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a letter with behavioral economic principles (BE) encouraging them to contact their primary care provider for Hepatitis C screening.
10188893|NCT03712540|Experimental|BMS-986278 + Rifampin|Treatment period A: BMS-986278 alone Treatment period B: Rifampin followed by BMS-986278
10188894|NCT03712501|Experimental|Exercise|Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1. Participants will return the following day and consume a high fat breakfast and lunch.
10188895|NCT03712501|No Intervention|Control|Participants will rest on day 1. Participants will return the following day where they will consume a high fat breakfast and lunch.
10188896|NCT03712475|Experimental|Phudialin Hard Capsules|Phudialin Hard Capsules Dosing Regimen: Single dosing
10188897|NCT03712475|Active Comparator|Lyrica Hard Capsule|Lyrica Hard Capsule Dosing Regimen: Single dosing
10188898|NCT03712462|Experimental|ABBT Weight Loss Therapy for BED|Acceptance-Based Behavioral Weight Loss Therapy for BED
10188899|NCT03712462|Active Comparator|Standard Behavior Therapy|Standard Behavioral Weight Loss Therapy
10188900|NCT03712436|Experimental|patients receiving palliative care|Patients receiving standard oncologic care plus palliative care.
10188901|NCT03712436|Active Comparator|patients receiving standard oncological care|Patients receiving standard oncologic care.
10188902|NCT03712423|Experimental|Patients [89Zr]-Df-CriPec® docetaxel|Day 1 of the Run-in a low dose of [89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed < 2 h by a second low dose of [89Zr]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of [89Zr]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).
9699079|NCT04738136|Experimental|Standard of Care(SOC) + S-1226 at either 4% 8% or 12% CO2|Subjects will receive SOC plus the highest tolerated dose of S-1226 at either 4% 8% or 12% CO2 twice daily for up to 5 consecutive days.
9699080|NCT04738045|Placebo Comparator|control|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily for 5 days.
10188903|NCT03712397|Experimental|nal-IRI in Head & Neck cancer|nal-IRI 80 mg/m2 for 90 minutes in sequence at day 1, every 14 days counted as one cycle
9699081|NCT04738045|Experimental|interventional|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
9699082|NCT04738162|Experimental|5-Aminolevulinic Acid (5-ALA)|Application of 5-ALA oral solution followed by fluorescence-guided brain tumor resection
9699083|NCT04737798|Experimental|oil pulling with coconut oil|patients used oil pulling therapy with coconut oil for 4 days
9699084|NCT04737798|Active Comparator|oil pulling with sesame oil|patients used oil pulling therapy with sesame oil for 4 days
9699085|NCT04737707|Experimental|Dialectical Behavior Therapy (DBT)|Psychotherapy (duration 5 months) will begin within a maximum of 1 month (the time to set up the group) and will be accompanied by individual follow-up. Evaluations will be carried out within 6 months of the end of the psychotherapy in order to measure its effects.
9699086|NCT04737707|Other|Therapy|waiting list for 5 months before starting psychotherapy (duration 5 months). During this time, the patient can continue your usual therapeutic follow-ups. Likewise, assessments will be carried out within 6 months after the end of the psychotherapy in order to measure its effects. the patient will thus benefit from DBT regardless of the group.
9699087|NCT04737824|Experimental|Experimental group A|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise."
9699088|NCT04737824|No Intervention|Control group A|No intervention was applied.
9699089|NCT04737824|Experimental|Experimental group B|"Participants executed two sets of twelve repetitions of an adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home."
9699090|NCT04737824|No Intervention|Control group B|No intervention was applied.
9699091|NCT04737850|Experimental|PartA, open-label|Hetrombopag plus standard of care
9699092|NCT04737850|Experimental|PartB, double-blind treatment group|Hetrombopag plus standard of care
9699093|NCT04737850|Placebo Comparator|Placebo Comparator|Placebo plus standard of care Part B, double-blind treatment group
9699094|NCT04737993|Active Comparator|prf shoulder joint|pulsed rf stimulation of joint capsel and prf stimlation of subscapular nerve
9699095|NCT04737993|Active Comparator|prf subscapular nerve|pulsed RF stimulation of subscapular nerve
9699096|NCT04737993|Active Comparator|subscapular nerve block|lidocain injection of subscapular nerve
9699097|NCT04737681||Normal BMI|BMI 18.5-24.9 kg/m2
10188904|NCT03712384||Young adult with severe anorexia|Young adult with severe Anorexia hospitalized during adolescence at Institut Mutualiste Montsouris
9699098|NCT04737681||Obese BMI|BMI ≥ 30 kg/m2
9699099|NCT04737889|Experimental|RL-MT|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen: Methotrexate, 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle, Temozolomide, 150mg/m2/d oral administration on day 1 to 10.~Consolidation Treatment: Autologous hematopoietic stem cell transplantation or reduced whole brain radiotherapy after high-dose chemotherapy.~Maintenance Treatment: Lenalidomide, 10mg oral administration on day 1 to 21 of each 4-week cycle for 12 months."
10188905|NCT03712345|Experimental|Group A|Will receive IFX-1 low dose regimen diluted in sodium chloride solution
9699100|NCT04737629|Experimental|Expectancy and Water Condition|
9699101|NCT04737629|Experimental|No Expectancy and Water Condition|
9699102|NCT04737629|Experimental|No Water Condition|
9699103|NCT04737928|Experimental|latanoprost switch to tafluprost|POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months.
9699104|NCT04737915|Experimental|Virtual Reality Exposure|Participants completed a single session of exposure administered via a virtual reality headset. The exposure exercise involved looking over virtual railings into an atrium at various floor levels (the virtual environment was designed to look like the atrium in the in vivo exposure condition). Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
9699105|NCT04737915|Experimental|In Vivo Exposure|Participants completed a single session of exposure administered in vivo. The exposure exercise involved looking over actual railings into an atrium at various floor levels. Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
9699106|NCT04737915|No Intervention|Waitlist Control|Participants watched a neutral video during the time participants in other conditions were completing the exposure exercise. Participants received no exposure-based intervention.
9699107|NCT04737980|Experimental|Experimental Group: Interscalene block with liposomal bupivacaine combined with bupivacaine|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 10 ml of liposomal bupivacaine 1.3% (133 mg) combined with 10 ml of 0.5% bupivacaine hydrochloride.
9699108|NCT04737980|Active Comparator|Control Group: Interscalene block with ropivacaine combined with dexamethasone|Interscalene nerve block was performed utilizing ultrasound guidance with infiltration of 30ml of 0.5% ropivacaine combined with a 2 ml volume of 8mg of dexamethasone.
9699109|NCT04737967|Experimental|Venlafaxine Treated Arm|
9699110|NCT04737967|Experimental|Memantine Treated Arm|
9699111|NCT04737902||VATS with ESPB|Study subjects underwent anaesthesia and VATS without a change in their routine care. At the end of the surgery, an erector spinae plane block was performed for acute pain control following our institutional protocol for perioperative care.
9699112|NCT04737941|Experimental|Immediate foam sclerotherapy|Immediate foam sclerotherapy group patients are treated with immediate (first-visit) foam sclerotherapy and truncal vein endothermal ablation is scheduled when anatomy is suitable. Compression therapy is started immediately.
9699113|NCT04737941|Active Comparator|Scheduled treatment|Scheduled treatment group patients are treated with scheduled endovenous ablation including foam sclerotherapy and/or endothermal ablation depending on reflux anatomy. Compression therapy is started immediately.
9699114|NCT04737837||children|Children aged 4~16 years with focal onset seizures
9699115|NCT04737837||Adult|Adults aged >16 years with focal onset seizures
9699116|NCT04737863|Experimental|selective root canal retreatment|retreatment process is performed to the affected root only
9699117|NCT04737863|Active Comparator|traditional root canal retreatment|retreatment process is performed to all roots
9699118|NCT04737577|Experimental|Supramarginal resection (intervention arm)|Planned resection beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
9699119|NCT04737577|Other|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
9699120|NCT04737486|Experimental|Single Ascending Dose Cohort 1-4|Intervention: AV-001, 6 subjects per cohort will receive single doses of 1.4 µg/kg up to 56 µg/kg of AV-001 by intravenous bolus injection.
9699121|NCT04737486|Placebo Comparator|Single Ascending Dose Cohort 1-4, Placebo|Intervention: Placebo, 2 subjects per cohort will receive single doses of D-PBS placebo by intravenous bolus injection.
9699122|NCT04737486|Experimental|Multiple Ascending Dose Cohort 1-2|Intervention: AV-001, 6 subjects per cohort will receive multiple doses of 1.4 µg/kg/day up to 56 µg/kg/day of AV-001 daily for 7 consecutive days by intravenous bolus injection.
9699123|NCT04737486|Placebo Comparator|Multiple Ascending Dose Cohort 1-2, Placebo|Intervention: Placebo, 2 subjects per cohort will receive multiple doses of D-PBS placebo daily for 7 consecutive days by intravenous bolus injection.
9699124|NCT04737655|Active Comparator|TRIMBOW + Standard of care|"Inclusion~Maintenance therapy (LAMA or LABA) for COPD~Age >18~Admission for AE of COPD~Signed Inform consent (see protocol attached)~Admitted in ICU >24h and less than 72h~Exclusion~No CI for studied medication~Not treated with studied medication for at least 3 months~Admitted in ICU for AE of COPD within the past 3 months~Intolerance to studied medication~Hospitalized since >6 days~ARDS condition (PAFI <200)~Admitted in ICU >72H~Patient with severe asthma~The use of high dose of ICS as baseline therapy~Right/left heart failure~Immunocompromized~Acute myocardial infaction~Left heart insufficiency (LVEF<35%)~Stroke <6 months prior to hospital admission~Patients will be separated in 2 randomized groups (Trimbow + SOC versus SOC) 1:1."
10188906|NCT03712345|Experimental|Group B|Will receive IFX-1 high dose regimen diluted in sodium chloride solution
9699125|NCT04737655|No Intervention|standard of care|
9699126|NCT04737447|Active Comparator|Group A (Control Group)|20 participants treated with standardized urophysiotherapy twice a week, once for 45 Minutes and then for 15 Minutes. Urophysiotherapy is a well manifested and standardized therapy in the treatment für children's incontinence after the age of five years.
10188907|NCT03712345|Placebo Comparator|Group C|Will receive placebo
9699127|NCT04737447|Active Comparator|Group B (Study Group)|20 participants treated with standardized urophysiotherapy and Whole Body Vibration training (WBVT). These patients are treated with the standardized urophysiotherapy once a week and furthermore they train with WBVT twice a week for each time 15 minutes. Criteria for modifying the device utilization are based on participant's age and therapy progress. The utilized frequency of the device is individually adapted to the participant. Older patients (> ten years old) are allowed to higher frequency standards than younger participants (< 10 years old). The amplitude (0.5 mm - 2 mm) is alternated to the participant's age and height. If side effects occur (e.g. dizziness), frequency can be alternated. The intended frequency level is between 10 an 20 Hz.
10188908|NCT03712332|Experimental|Distress Tolerance Group|6 session inpatient distress tolerance group intervention twice a week for 1.5 hours for up to three weeks.
10188909|NCT03712319|Experimental|Group 1: App.|"Participants use application REM Volver a casa on their cell phones during 8 weeks. Codes are provided to the students in order to unlock the different stages of the training free of charge. The application provides short videos and audios for training. Students practice on their own, in accordance with the instruction of completing a stage a week."
9699128|NCT04737499|Experimental|CASCADe Intervention|Intervention consisted of eight weekly sessions of health education and diabetes management. Topics covered include recognition of diabetes and its complications, risk factors, nutrition knowledge, dietary practices, exercise, behavioral self-monitoring, medication adherence, and stress management. Intervention also included a home visit for training of monitoring devices use, WeChat app and acquiring family support, and weekly WeChat follow-up on education tips, monitoring data summary, and group discussion. The monitoring system used a smartphone to coordinate cloud data transmission from a set of wireless devices to capture daily monitoring data on physical activity, body weight, blood pressure and blood glucose levels.
10188910|NCT03712319|Active Comparator|Group 2: MBSR.|Participants attend a presence-based training during 8 weeks. The Mindfulness-Based Stress Reduction program involves a session of two and a half hours each week.
10188911|NCT03712319|No Intervention|Group 3: Waiting list.|Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
9699129|NCT04737512|Experimental|Mindfulness-Based ADHD Treatment for Children|
9699130|NCT04737512|Active Comparator|Medication|
9699131|NCT04737512|Active Comparator|Combined (MBAT-C + medication)|
9699132|NCT04737733|Other|The dementia friendly hospital program|The dementia-friendly hospital program comprised three parts; 1) Educational program for health practitioners to increase the staff's knowledge and awareness of patients with cognitive impairment and/or delirium; 2) Screening, for early identification of cognitive impairment and delirium, using the Four Assessment Test (4AT); 3) Delirium risk factor modification and management for patients defined with potential cognitive impairment and risk of delirium, implying that risk factor modifications should be implemented in the patient's care plan. For patients with suspected delirium, the program promoted an additional delirium management plan.
9699133|NCT04737460|Experimental|AAV9/CLN7|"AAV9/CLN7 is an intrathecally administered AAV9-based gene therapy vector that expresses the fully functional form of MFSD8 under the control of a synthetic promoter. AAV9/CLN7 is designed to achieve stable, potentially life-long expression of MFSD8 in non-dividing cells.~The first participant will receive a low dose of 5X1014 vg, subsequent participants will receive a higher dose of 1x1015 vg of the AAV9/CLN7 agent."
9699134|NCT04737785||Case group|HSCT recipients who developed a CNS disorder after HSCT
9699135|NCT04737785||Control group|HSCT recipients whom did not develop a CNS disorder
9699136|NCT04737564|Experimental|ABC10 + SEEK|Participants assigned to this arm will receive the standard Attachment and Biobehavioral Catch-up intervention (ABC 10) as well as SEEK (Safe Environment for Every Kid).
9699137|NCT04737564|Experimental|ABC3 + SEEK|Participants assigned to this arm will receive an abbreviated version of the Attachment and Biobehavioral Catch-up intervention (ABC 3) as well as SEEK (Safe Environment for Every Kid).
9699138|NCT04737564|Active Comparator|SEEK Only|Participants assigned to this arm will receive SEEK (Safe Environment for Every Kid) only.
9699139|NCT04737525|Experimental|Test group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and porcine-derived membrane.
9699140|NCT04737525|Experimental|Control group|Immediate implant placement and temporization of tapered implants after tooth extraction with buccal augmentation using allogenic bone and connective tissue grafting (CTG).
9699141|NCT04737408|Active Comparator|"Usual care"|"Usual care prevention: atorvastatin 40 mg per day for 18 months"
9699142|NCT04737408|Experimental|"Intensive care"|"Intensive care prevention: rosuvastatin 40 mg + ezetimib 10 mg per day for 18 months"
9699143|NCT04737356|Experimental|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
9699144|NCT04737356|No Intervention|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
9699145|NCT04737590|Active Comparator|Bioactive glass|20 bone cysts (in 20 patients) are filled with bioactive glass
9699146|NCT04737590|Active Comparator|Allogenic bone|20 bone cysts (in 20 patients) are filled with allogenic bone
9699147|NCT04737434|Experimental|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave
9699148|NCT04737434|Placebo Comparator|electromagnetic field with no wave|electromagnetic field with no wave
9699149|NCT04737616|Experimental|CO2 Laser +OCT|Postmenopausal women with genitourinary syndrome of menopause who will receive CO2 vaginal laser treatment
9699150|NCT04737616|Experimental|OCT only|Premenopausal, peri-menopausal and postmenopausal women who will only get one time OCT scan
10188912|NCT03712306|No Intervention|Control group|No intervention. Participants will only receive a brochure on general healthy eating habits.
10188913|NCT03712306|Experimental|Dietary advice|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products.
9699151|NCT04737811||Study group|The group consists of Parkinson's disease patients with dysphagia complaints. The participants will be given the Turkish version of the Swallow Disturbance Questionnaire (SDQ-T), which consisted of 15 questions and two scales evaluated with the fiberoptic endoscopic evaluation of swallowing. After two weeks, all participants will be given the SDQ-T for sampling.
9699152|NCT04737252|Experimental|COMPASS|Immediately receives 8-12 sessions of couple intervention aimed to improve self-injury thoughts and behaviours, emotion dysregulation, borderline personality disorder symptoms, and intimate relationship dysfunction.
9699153|NCT04737538|Experimental|Experimental Dentifrice|Participants assigned to this arm will apply full ribbon of toothpaste (containing sodium bicarbonate, sodium hyaluronate and sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
9699154|NCT04737538|Active Comparator|Positive control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
9699155|NCT04737538|Active Comparator|Negative control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 1100ppm fluoride as sodium fluoride [Crest Cavity Protection]) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
9699156|NCT04737291|Experimental|Angioplasty by DCB|angioplasty of stenotic , ocluded or recoil segment using drug coated ballon
9699157|NCT04737382|Other|Biopsy and blood|A histological core biopsy of a tumor lesion and a blood sample for ctDNA analysis will be collected
9699158|NCT04737278|Experimental|Cunermuspir|Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.
9699159|NCT04737278|Placebo Comparator|Placebo|Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm
9699160|NCT04737642|Experimental|Papillary ballon dilatation|
9699161|NCT04737551||No adjuvant treatment|Pancreatic cancer patients who received surgery without subsequent adjuvant treatment.
9699162|NCT04737551||Adjuvant chemotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemotherapy.
9699163|NCT04737551||Adjuvant chemoradiotherapy|Pancreatic cancer patients who received surgery and only adjuvant chemoradiotherapy.
9699164|NCT04737551||Adjuvant chemoradiotherapy + adjuvant chemotherapy|Pancreatic cancer patients who received surgery and both adjuvant chemoradiotherapy and chemotherapy.
9699165|NCT04737395|Experimental|"Device-assisted therapy (Meditouch,MSQUARE)"|40 hours of therapy with the the Hand Tutor (MediTouch) device and a wearable vest (MSQUARE) for arm rehabilitation
9699166|NCT04737174|Experimental|ES-481|Administered as 25 mg oral gelatin capsules
9699167|NCT04737161|Experimental|T regulatory cell infusion|Infusion will be administered to the patient within 72 hours of collection from donor.
9699168|NCT04737213|Experimental|SGM-101|Patients included with colorectal lung metastases, SGM-101 7.5-12.5mg, 3-5 days prior to surgery
9699169|NCT04737239||Patient with CTS/Mild EMG|
9699170|NCT04737239||Patient with CTS/Negative EMG|
9699171|NCT04737473|Experimental|Opiod Free Anesthesia (OFA) group|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium 0.6mg/kg. Anesthesia will be maintained using isofluorane through volume controlled ventilation, and a mixture of magnesium sulfate 40mg/kg (without exceeding 2.5g/24h), lidocaine 1.5mg/kg, ketamine 25mg, and clonidine 1ug/kg in an electric pump syringe at 10 - 15 ml/h.
9699172|NCT04737473|Active Comparator|General anesthesia (GA) group|The GA protocol described in the intervention arm
9699173|NCT04737421||Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP)|Subjects will be enrolled into Group 1 and treated with NobelActive TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
9699174|NCT04737421||Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP)|Subjects will be enrolled into Group 1 and treated with NobelParallel CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
9699175|NCT04737421||Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with NobelReplace CC TiUltra implants, only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
9699176|NCT04737421||Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP)|Subjects will be enrolled into Group 1 and treated with Nobel Biocare N1 TiUltra TCC implants , only if it is driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic.
9699177|NCT04736953|Active Comparator|Sirolimus|Sirolimus 1 to 2 mg bid
9699178|NCT04736953|Placebo Comparator|Placebo|Placebo 1 to 2 mg bid
9699179|NCT04737057|Active Comparator|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding injections and drilling. It is one of a number of biologically orientated strategies for managing dental decay
9699180|NCT04737057|Experimental|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a promising therapeutic agent for managing caries lesions in young children and those with special care needs
9699181|NCT04737018|Experimental|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
9699182|NCT04737018|Sham Comparator|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
9699183|NCT04736836|Active Comparator|interventional|50 patient take rifaximin plus lactulose for 6 months
9699184|NCT04736836|Placebo Comparator|control|50 patient take lactulose for 6 months
9699185|NCT04737083||clubfoot fetuses|
9699186|NCT04737044|No Intervention|Study 1: Normal sugar|Control group will be required to continue consuming normal sugar intake for 8 weeks.
9699187|NCT04737044|Experimental|Study 1:Minimally refined brown sugar (MRBS)|Intervention group will be required to consume MRBS as added sugar based on their habitual diet for 8 weeks intervention.
9699188|NCT04737044|No Intervention|Study 2: Normal sugar intake|- The control group will have no intervention and will continue with their normal daily intake for six months.
9699189|NCT04737044|Experimental|Study 2: White sugar|"Intervention group I will be advised to reduce sugar intake to no more than 10% from total energy intake.~Intervention group I will be given white sugar for daily usage.~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~For the first three months, one-to-one diet counseling will be conducted.~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
9699190|NCT04737044|Experimental|Study 2: MRBS|"Intervention group II will be advised to reduce sugar intake to no more than 10% from total energy intake.~Intervention group II will be given MRBS for daily usage.~Participants in this group will be exposed to the nutrition education module (45 minutes per session, once a week) for six months, attend lecture classes and communicate with health educators through communication applications.~For the first three months, one-to-one diet counseling will be conducted.~Participants' intake of free sugar, as well as other nutrients (carbohydrate, protein, fats, fibre and others) will be closely monitored to ensure compliance to dietary recommendations."
9699191|NCT04737005|Other|Nano-ceramic hybrid (Grandio Blocs) Endo-crown.|Nano-ceramic hybrid ( intervention)
9699192|NCT04737005|Active Comparator|Lithium di-silicate Ceramic (E.max CAD blocks) Endo-crown|Lithium di-silicate Ceramic ( Control)
9699193|NCT04736823|Experimental|Part1 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
9699194|NCT04736823|Experimental|Part1 Cohort2(AK112 + Pemetrexed +Carboplatin)|Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
9699195|NCT04736823|Experimental|Part1 Cohort3(AK112 + Docetaxel)|Subjects receive AK112 plus Docetaxel on Day 1 of every 3-week cycle (Q3W) until progression.
9699196|NCT04736823|Experimental|Part2 Cohort1(AK112 + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive AK112 plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive AK112 plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 until progression."
9699197|NCT04736823|Experimental|Part2 Cohort2(Penpulimab(AK105) + Pemetrexed or Paclitaxel+Carboplatin)|"non-Squamous NSCLC:Subjects receive Penpulimab(AK105) plus Pemetrexed and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by Penpulimab(AK105) plus Pemetrexed until progression.~Squamous NSCLC:Subjects receive Penpulimab(AK105) plus Paclitaxel and Carboplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by Penpulimab(AK105) until progression."
9699198|NCT04736784|Experimental|Beetroot juice|115 ml of beetroot juice per day for seven days
9699199|NCT04736784|Experimental|Leafy green vegetable juice|250 ml of green leafy vegetable juice per day for seven days
9699200|NCT04736914|Experimental|Zanubrutinib+R-CHOP/R-DHAOx|"Induction:~Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~ASCT conditioning~Maintenance:~Zanubrutinib, 160mg PO BID, continuously for 2 year~Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT~Requirements for start of maintenance:~ANC ≥ 1,000 cells/mm³ (1.0 X 109/L);~Platelets ≥ 50,000 cells/mm³ (50 X 109/L);"
9699201|NCT04736966|Experimental|Guselkumab 30mg|
9699202|NCT04736966|Experimental|Guselkumab 70 mg|
9699203|NCT04736966|Experimental|Guselkumab 100mg|
9699204|NCT04736901||Group 1|Enoxaparin therapeutic dose
9699205|NCT04736901||Group 2|Enoxaparin prophylactic dose
9699206|NCT04736901||Group 3|Rivaroxaban therapeutic dose
9699207|NCT04736901||Group 4|Rivaroxaban prophylactic dose
9699208|NCT04736901||Group 5|Apixaban therapeutic dose
9699209|NCT04736901||Group 6|Apixaban prophylactic dose
9778461|NCT01107015|Active Comparator|Group 4: data analyzed intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations
9778462|NCT01107197|Active Comparator|Isonitrogenous isocaloric formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula isonitrogenous isocaloric to the experimental one
9778463|NCT01107197|Experimental|Enriched nutrition formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula enriched in arginine, zinc and antioxidant oligoelements
9778464|NCT01107353|Active Comparator|First Imipramine Pamoate, then Tofranil-PM|First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)
9778465|NCT01107353|Active Comparator|First Tofranil PM, then imipramine pamoate|First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)
9778466|NCT01107379||Balloon catheter device|Dilation of sinuses using Relieva Balloon Sinuplasty System
9778467|NCT01107392|Experimental|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
9699210|NCT04736927|Experimental|GLPG3667 + Midazolam|
9699211|NCT04736810|Experimental|AK105 plus Cisplatin, Gemcitabine and Anlotinib Hydrochloride|
10188914|NCT03712306|Experimental|Dietary advice and advice on timing|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products, as well as advice regarding the consumption of protein rich food products in close proximity of usual physical activity.
10188915|NCT03712293|Experimental|BBB Disruption with Chemotherapy Arm|All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
10188916|NCT03712241|Experimental|Treatment A|K-285 dose/application method A
10188917|NCT03712241|Experimental|Treatment B|K-285 dose/application method B
10188918|NCT03712241|Experimental|Treatment C|K-285 dose/application method C
9699212|NCT04736810|Experimental|AK105 plus Cisplatin and Gemcitabine|
9699213|NCT04736810|Experimental|AK105 plus Gemcitabine and Anlotinib Hydrochloride|
9699214|NCT04736654||Patients group|Individuals with headache
9699215|NCT04736680||Lost Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and missed.
9699216|NCT04736680||Attended Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and attended.
9699217|NCT04736446|Experimental|I-gel® group|Continuous chest compressions from the start of the CPR with early i-gel® device insertion and asynchronous ventilations
9699218|NCT04736446|Other|Standard group|Basic (standard) management by using a ratio of 30 compressions and 2 face mask ventilations
9699219|NCT04736667||Subjects fail screening for TMVI|Subjects with symptomatic mitral valve disease who after referral for TMVI, are deemed not to be candidates for TMVI.
9699220|NCT04736498|No Intervention|Control arm|Control group will follow the standard procedure in our centre and will not undergo USG assessment before spinal anaesthesia. The spinal anaesthesia procedure will be standardized. Under strict aseptic precautions spinal anesthesia will be performed at L3-L4 inter-space using a 25 Gauge Quincke spinal needle (B. Braun Medical SA, Melsungen, Germany) in sitting position. 3 ml of hyperbaric bupivacaine 0.5% (15 mg) will be injected with the needle orifice oriented cranially. After injection, patients will be immediately positioned supine. Meanwhile, the non-invasive blood pressure will be measured and recorded every 3 minute for 30 min and then every 5 min throughout surgery and anesthesia.
9699221|NCT04736498|Experimental|USG arm|In the IVC USG group, USG assessment and volume optimisation using collapsibility index will be done prior to spinal anaesthesia. all patients will be lying supine, for at least 5 min before IVC examination. Ultrasound measurements will be performed using a Sonosite M-Turbo (Sonosite Inc., USA) machine and phased array 5-1 Megahertz transducer (Sonosite Inc.) set to abdominal mode by an M-mode modality through the subcostal view. All IVC measurements will be performed by principal investigator before spinal anaesthesia. Principal investigator should have performed more than 25 scans before the commencement of the study.
9699222|NCT04736641||Patients group|Individuals with hip disease and chronic pain on hip
9699223|NCT04736485|Experimental|FLOT regimen plus Spartalizumab|"Standard FLOT regimen~Docetaxel 50 mg/m² IV infusion on D1~Oxaliplatine 85 mg/m² IV infusion on D1~Leucovorin 200 mg/m² IV infusion on D1~Fluorouracile 2600 mg/m² 24 h IV infusion on D1~with Spartalizumab PDR001 Patients will received the fixed dose of 400 mg per IV infusion on D1 every four weeks (q4w) for 2 pre-operative cycles (8 weeks) and 2 post-operative cycles (8 weeks)"
10188919|NCT03712241|Active Comparator|Treatment D|Indomethacin capsule
10188920|NCT03712215|Experimental|Experimental Group 1|synchronized FES mode, according to the parameters based on the Gueddes et al., (1991): current frequency (F) 30 Hz; pulse width (T) 0,4 ms; upload time (Rise) 1s; time of muscle contraction (On time) 1 s; down time (Decay) 2s e muscle relaxation time (Off time) 1 s.
9699224|NCT04736732||COVID-19 positive patients|"Patients who had previous asymptomatic or mild COVID-19 (mild=never required supplemental oxygen during the acute phase of the infection)~Patients who had previous moderate or severe COVID-19 (moderate=required supplemental oxygen by nasal cannula during the acute phase of the infection; severe=required supplemental oxygen by either high-flow nasal cannula, non-invasive positive pressure ventilation or intubation~Patients who had COVID-19 but did not have signs or symptoms related to COVID-19 lasting beyond 4 weeks from the date of COVID-19 symptom-onset or diagnosis"
9699225|NCT04736732||COVID-19 negative patients|COVID-19 negative control group
9699226|NCT04736693||Raloxifene|Reference Group
9699227|NCT04736693||Zoledronic Acid|Exposure Group
9699228|NCT04736459|Experimental|Washed Catheter|Washed catheter arm: will be washed with culture medium before insemination
9699229|NCT04736459|Sham Comparator|Unwashed Catheter|Unwashed catheter arm: will not be washed with culture medium.
9699230|NCT04736719||Warfarin|Reference group
9699231|NCT04736719||Apixaban|Exposure group
9699232|NCT04736563|Experimental|patients with painful arthritis of the knee|Administration of joints and muscle gel Puressentiel containing of 14 essential oils
9699233|NCT04736758|Experimental|GP681 tablet 40mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 40mg orally once with 240mL water.
9699234|NCT04736758|Experimental|GP681 tablet 20mg|Patients in the GP681 tablet 40mg group is treated with GP681 tablet 20mg orally once with 240mL water.
9699235|NCT04736758|Placebo Comparator|Placebo group|Patients in the Placebo group is treated with GP681 Simulant orally once with 240mL water.
9699236|NCT04736797||Patient|Transgender people who seek hormone treatment
9699237|NCT04736797||Control participants|volunteers without gender dysphoria
9699238|NCT04736433||ACE Inhibitors|Reference group
9699239|NCT04736433||Sacubitril/Valsartan|Exposure group
9699240|NCT04736420||Warfarin|Reference group
9699241|NCT04736420||Rivaroxaban|Exposure group
9778468|NCT01107392|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
9778469|NCT01107405|Active Comparator|Loteprednol etabonate base (QD)|Loteprednol etabonate ophthalmic base dosed once/day.
9699242|NCT04736589|Experimental|Inetetamab plus Rapamycin plus Chemotherapy|"Drug: Inetetamab Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks, until disease progression (PD) or other termination criteria are met;~Drug: Rapamycin Oral 2mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
9699243|NCT04736589|Active Comparator|Pyrotinib plus chemotherapy|"Drug:Pyrotinib Oral 400mg, once a day;~Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage."
9699244|NCT04736407||Repositioned|Allocated to sampling performed around a standard clinical repositioning (lateral side to side), or a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling.
10188921|NCT03712215|Experimental|Experimental Group 2|the same apparatus will be used, differing in the parameters that will be based on the studies of Cancelliero et al., (2012) for the EDET procedure, being used in synchronized FES mode, with frequency of 30 Hz; pulse width (T) 0,4 ms, climb (ramp) of 0,7 s (maximum value). The support was of 0.4 s, already standardized and fixed in the apparatus
9699245|NCT04736407||Non-repositioned|Allocated to sampling performed with a 10 minute wait period between two serially drawn CSF samples, for each biweekly routine CSF infection surveillance sampling
9699246|NCT04736329|Active Comparator|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of their heart failure therapy.
9699247|NCT04736329|No Intervention|Enalapril|Enalapril (2.5 up to 20mg ) for RAAS inhibition, as part of their heart failure therapy.
9699248|NCT04736381||Kidney transplanted patients treated with Nulojix|Patients treated with Simulect as induction, and with Nulojix®, mycophenolic acid and steroids as maintenance therapy during the first year of kidney transplant.
9699249|NCT04736095||3D ultrasound for diagnosis of submucous myomas|
9699250|NCT04736095||Hysteroscopy for diagnosis of submucous myoma|
9699251|NCT04736368|Experimental|EDIP Group|CD participants will receive EDIP diet information
10188922|NCT03712215|No Intervention|Control Group|The control group (CG) with the same characteristics of the experimental groups will perform conventional physiotherapy
9699252|NCT04736368|Placebo Comparator|Control Group|CD participants will be given diet suggestions according to routine experience.
9699253|NCT04736108|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before radical prostatectomy
9699254|NCT04736238|Experimental|Trial group|The patients who receive arthroscopic surgery.
9699255|NCT04736238|Other|Control group|The patients who receive BrostrÖm surgery.
9699256|NCT04736225|Experimental|ISTE Group|This program includes a 60-min small-group lesson, a 20-min individual instruction. The education program's goal is to teach patients to self-titrate their insulin doses every six days to maintain their six-day average blood glucose levels < 120 mg/dl
9699257|NCT04736225|Placebo Comparator|Non-ISTE Group|The usual care (a 15-min individual education) was giving at the Diabetes Health Education Center. They were taught how to self-inject insulin and test and record their before-breakfast and before-dinner blood glucose levels daily at home.
9699258|NCT04736069|Active Comparator|Inpatient physical therapy program|The group received 21 sessions of physical therapy program including electrotherapy, superficial- deep heat applications and basic knee exercise program at inpatient clinic.
9699259|NCT04736069|Active Comparator|Outpatient physical therapy program|The group received the same physical therapy program including electrotherapy, superficial-deep heat applications and basic knee exercise program at outpatient clinic.
9699260|NCT04735939||morning dosing radiotherapy|
9699261|NCT04735939||evening dosing radiotherapy|
9699262|NCT04736186|Experimental|Loperamide|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21)
9699263|NCT04736186|Experimental|Loperamide and gold bifid|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + gold bifid2g T.I.D.
9699264|NCT04736186|Experimental|Loperamide and Montmorillonite SAN|Loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21) + Montmorillonite SAN 3 g, T.I.D.
9699265|NCT04736186|No Intervention|Non-intervention|Do not intervene and stop diarrhea as needed
10188923|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 1)|
9699266|NCT04736030|Experimental|Conmigo PA Intervention|12-week program (90 minutes/week)
9699267|NCT04736030|No Intervention|Delayed Abbreviated Intervention|No intervention during experimental phase; participants in control group receive abridged program after the final measurement point (wait list control).
9699268|NCT04736264|Active Comparator|Rehabilitation group|"This is the phase 3 of the entire research protocol. Phase 3 will be initiated once the phase 2 (development of rehabilitation module) is completed. A user friendly and inexpensive device and program with minimal usage of low vision aid will be designed and piloted. There are 3 different rehabilitation modules.~A total of 300 primary glaucoma patients will be recruited and randomized using SNOSE: 150 intervention group and 150 non-intervention group. The intervention group will comprised of 150 primary glaucoma patients who will be assigned to different rehabilitation program:~navigation and mobility (50 patients)~physical activities including special exercise (50 patients)~reading (50 patients) There will be no patient who will be involved in more than one rehabilitation program at anytime."
9699269|NCT04736264|No Intervention|Non-rehabilititation group|Group of primary glaucoma patients who are not taught and practiced the new rehabilitation module for navigation, physical activity (exercise) and reading. They will be asked to continue their regular activities and provided with the similar reading material (book) to read daily.
9699270|NCT04736290||Noncardiac surgery|Calculation of the NLR and PLR in patients undergoing noncardiac surgery under general anesthesia
10188924|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 2)|
10188925|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 3)|
10188926|NCT03712163|Experimental|Norketotifen or Placebo (Multiple Dose)|
10188927|NCT03712150||Healthy|"Healthy adults~- Participants will receive single session of tdcs after application"
9699271|NCT04736043||Patients with resected pancreatic cancer who require adjuvant chemotherapy|
9699272|NCT04735991|No Intervention|Control group|The patient's family members need to fill in the family member quality of life questionnaire during the screening and follow-up period. They are able to contact the doctor for questions in terms of medical treatment.
9699273|NCT04735991|Experimental|Study group|The family members of the patients need to fill in the family member quality of life questionnaire during the screening period and follow-up period, and are involved in an interactive management program on the mobile terminal, full participation required.
9699274|NCT04736316|Experimental|Early CCLAD|Early community client-led ART delivery groups
9699275|NCT04735874||Children ages 10.0 to 18.0|
9699276|NCT04735978|Experimental|Dose escalation of RP3 - superficial and/or deep/visceral tumors|Dose escalation of RP3 alone in 2 cohorts with intratumoral (IT) injections including use of imaging guided injection for deep tumors.
9699277|NCT04735978|Experimental|Dose combination of RP3 and anti-PD1 therapy - superficial and/or deep/visceral tumors|Dose combination of RP3 and anti-PD1 therapy. IT injections of RP3 including use of imaging guided injection for deep tumors.
9699278|NCT04735978|Experimental|Seronegative cohort|Doses of RP3 (IT) in HSV seronegative participants.
9699279|NCT04736277||Noncardiac surgery|Documentation of HbA1c in patients undergoing noncardiac surgery under general anesthesia
9699280|NCT04735809|Placebo Comparator|Placebo|Microcystalline Cellulose
9699281|NCT04735809|Experimental|Treatment|Whole Cell Algae Fermentate
9699282|NCT04735926|Placebo Comparator|Group 1A|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
9699283|NCT04735926|Experimental|Group 1B|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
9699284|NCT04735926|Experimental|Group 1C|Subjects corresponding to Cohort 1 (25-OH-D baseline level > 10 to < 20 ng/mL)
9699285|NCT04735926|Placebo Comparator|Group 2A|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
9699286|NCT04735926|Experimental|Group 2B|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
9699287|NCT04735926|Experimental|Group 2C|Subjects corresponding to Cohort 2 (25-OH-D baseline level ≤ 10 ng/mL)
9699288|NCT04735848|Experimental|6mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
9699289|NCT04735848|Experimental|30mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
9699290|NCT04735848|Experimental|60mg iron-supplement|All participants will be in this arm. Everyone will take all three different doses of iron-supplement (6mg; 30mg;60mg).
9699291|NCT04735848|No Intervention|Baseline|Baseline measurement
9699292|NCT04735887|Experimental|SADL-eM & conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive a copy of the SADL-eM in addition to conventional therapy.
9699293|NCT04735887|No Intervention|Conventional therapy|Patients with SCI treated in an inpatient rehabilitation setting who receive conventional therapy.
9699294|NCT04735952||AIM 1|No-Intervention. Participants in this group will have 1 study visit only. During that visit, breath and sputum samples will be collected.
9699295|NCT04735952||AIM 2|No-Intervention. Participants in this group will have up to 8 study visits over a 2 year period. During the study visits, breath and sputum samples will be collected.
9699296|NCT04735900|Experimental|First-line FOLFOX/FOLFIRI and panitumumab.|Chemotherapeutic agents will be given as an intravenous infusion at a dose and interval consistent with standard institutional practice.
9699297|NCT04735523||Warfarin|Reference group
9699298|NCT04735523||Dabigatran|Exposure group
9699299|NCT04735601|Experimental|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve coated with PLGA is implanted in secondary glaucoma in Sturge Weber syndrome
9699300|NCT04735601|Active Comparator|Ahmed valve implanted in secondary glaucoma in Sturge Weber syndrome|Ahmed valve will be implanted alone with no PLGA
9699301|NCT04735757||Healthy volunteers|Healthy volunteers, matched by age and gender to patient groups.
9699302|NCT04735757||COVID-19 patients|Patients discharged from the ICU after invasive ventilation for COVID-19.
9699303|NCT04735757||ICU patients|Patients discharged from the ICU after invasive ventilation for ARDS.
9699304|NCT04735445|Active Comparator|Conventional screening|Standard screening in the participating centers, adjusted to the recommendations of the European AIDS Society (EACS).
9699305|NCT04735445|Experimental|Enhanced screening|Expanded screening for early detection of lung, liver, anal, cervical, breast, prostate, colorectal and skin cancer.
9699306|NCT04735783|Experimental|Very low-energy, viscous placebo breakfast|Participants will consumed a viscous breakfast meal from a standard bowl with a standard spoon. The volume of the meal will be 5 mL/kg body mass, consisting of 15% (0.75 mL/kg body mass) low-energy flavoured squash, with the remainder made up of tap water. To thicken the solution and increase the perception of energy intake, 0.1 g/kg xanthan gum (a soluble fibre often used as a low-energy thickening agent) will be added and the mixture will be blended thoroughly. An additional 3 mL/kg tap water will be consumed as a drink alongside the meal in this trial.
9699307|NCT04735783|Active Comparator|Typical, whole-food breakfast|Participants will consume a standardised meal consisting of puffed rice cereal, semi-skimmed milk, white bread, seedless strawberry jam, and apple juice. This meal will provide 20% of estimated energy requirements, determined by multiplying estimated resting metabolic rate by a physical activity level of 1.6. A measured volume of tap water will be consumed alongside this meal, in order to match total water content of the typical whole-food breakfast to the very low-energy, viscous placebo breakfast.
9699308|NCT04735783|Active Comparator|Water-only control|Participants will consume 8 mL/kg body mass of plain tap water to match the total water content of the typical whole-food breakfast and the very low-energy, viscous placebo breakfast.
9699309|NCT04735497||Failed Weaning|Patients who failed to be liberated from mechanical ventillation
9699310|NCT04735497||Successful Weaning|Patients who were liberated from mechanical ventillation and needed no respiratory support
9699311|NCT04735640|Experimental|Nurse-led teleconsultation group|9-month nurse-led telephone-based personalized behavioural intervention.
10188928|NCT03712111|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
9699312|NCT04735640|Active Comparator|SMS group|Behavioural intervention by means of short text messages.
9699313|NCT04735770|Experimental|LTAP|Patients receive laparoscopically inserted TAP block with levobupivacain and local wound anesthesia injections with saline.
9699314|NCT04735770|Active Comparator|Local wound analgesia|Patients receive laparoscopically inserted TAP block with saline and local wound anesthesia injections with levobupivacaine.
10188929|NCT03712111|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
9699315|NCT04735692||Control|Evaluation of serum and salivary MMP-9
9699316|NCT04735692||Periodontitis|Evaluation of serum and salivary MMP-9
9699317|NCT04735692||Cardiovascular disease|Evaluation of serum and salivary MMP-9
9699318|NCT04735692||Periodontitis + cardiovascular disease|Evaluation of serum and salivary MMP-9
9699319|NCT04735614|Experimental|ThoraxBelt|Received ThoraxBelt after the surgery. Standard care for pain management will be the same as the Standard Care Arm.
9699320|NCT04735614|No Intervention|Standard care|Standard care with IV PCA and on-request oral painkiller.
9699321|NCT04735510|Other|Single arm|This is a single arm study in which all subjects will receive study medication.
9699322|NCT04735549|Experimental|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks.~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
9699323|NCT04735549|Active Comparator|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms.
9699324|NCT04735549|Experimental|Laser Treatment + Topical hormone|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks. During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.~At the same time local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms."
9699325|NCT04735705|Experimental|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation.
9699326|NCT04735484||Case|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
9699327|NCT04735484||Control|Participants will attend one data collection appointment wearing form-fitting sports clothing and trainers. Participants will wear infrared markers and wearable devices whilst walking over level ground and on a treadmill. Data will be collected using a motion capture system and the wearable devices themselves. Data collection will take approximately 90 minutes
9699328|NCT04735744||Prospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
9699329|NCT04735744||Retrospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
9699330|NCT04735471|Experimental|ADI-001 Dose Escalation|ADI-001 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal ADI-001 dose (Part 1).
9699331|NCT04735471|Experimental|ADI-001 Dose Expansion|ADI-001 is administered via infusion to 3 NHL subtypes to confirm dose (Part 2).
9699332|NCT04735471|Experimental|ADI-001 in combination with Interleukin-2|ADI-001 is administered via infusion in combination with subcutaneously administered IL-2 (Part 3).
9699333|NCT04735419||Cases|Cases are defined as infants who develop invasive GBS disease (iGBS disease= isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life.
9699334|NCT04735419||Controls|Controls are defined as infants who are exposed to the same serotype of GBS at birth as the case - but who do not develop iGBS disease in the first 90 days of life.
9699335|NCT04735289||GROUP 1 - 215 Patients and 430 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included~Localized and metastatic~Male and female~Control cases matched by age, sex and italian geographic area"
9699336|NCT04735289||GROUP 2 - Pilot Phase :55 Patients and 110 Control cases (1:2)|"Patients of >= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included Localized and metastatic Male and female~Control cases matched by age, sex, and geographic area"
10188930|NCT03712085|Active Comparator|Treatment Group A|Abdominal acupuncture and upper limb rehabilitation training
10188931|NCT03712085|Sham Comparator|Treatment Group B|Sham abdominal acupuncture and upper limb rehabilitation training
10188932|NCT03712085|No Intervention|Control Group|Upper limb rehabilitation only
9699337|NCT04735302||Sarcoidosis, Nonsarcoidosis|
9699338|NCT04735302||Malign, benign|
9699339|NCT04735211||Children whom develop chronic postsurgical pain|Children whom had chronic pain at 3 moths after surgery
9699340|NCT04735211||Children whom not develop chronic postsurgical pain|Children whom not develop chronic pain at 3 moths after surgery
9699341|NCT04734899|Active Comparator|Control grup|"All individuals participating in the study will be taught the exercises given to strengthen weakened muscles, stretch shortened structures and increase proprioception by the physiotherapist and will be asked to do these exercises at least twice a day for 8 weeks.~The home program will be followed by the exercise daily form."
9699342|NCT04734899|Experimental|Foot core grup|In addition to the exercise program given to the control group, foot core training will be added and taught by the physiotherapist and they will be asked to do these exercises at least twice a day for 8 weeks.
10188933|NCT03712072||Children with Cerebral Palsy|Data from the participants with Cerebral Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
10188934|NCT03712072||Children with BPBP|Data from the participants with Brachial Plexus Birth Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the TMS session.
9699343|NCT04734912|Other|Gastroscopy in transnasal technique|All patients with indication for gastroscopy in transnasal techqiue are included.
10188935|NCT03712072||Typically Developing Children|Data from the typically developing participants will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
10188936|NCT03712059||Screening group|All patients receive FIT test and colonoscopy, whose age, sex, family history, smoking history, body mass index (BMI), diabetes and other risk factors are collected by researchers through pad, equipped with a specially designed database and app. Using colonoscopy results as the gold standard, the diagnostic value of risk prediction model for the Chinese population is explored, and the optimal strategy of colonoscopy practice for the Chinese established initially.
9699344|NCT04735120|Experimental|Laser to reduce pain intraoperatively and post operatively|Diode lasers are used to assess its efficacy in reducing intraoperative and postoperative pain following root canal treatment in mandibular molar teeth with acute irreversible pulpitis
10188937|NCT03712059||Adenoma resection group|During the polypectomy of 2000 patients, for all pathologically confirmed or NBI-predicted adenomas with size<10mm, 1-2 biopsies were randomly performed on the edge after resection to determine the completion rate of the polypectomy.
9699345|NCT04735328|Other|Intervention|"When clinics join the intervention, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR and CT-PTSD)."
9699346|NCT04735016||Treatment Arm|Patients enrolled and treated with the DiamondTemp™ Ablation System
9699347|NCT04734951|Active Comparator|Power/resistance exercise|Participants on a power/resistance exercise program
9699348|NCT04734951|Active Comparator|HMB oral supplementation|Participants on HMB oral supplementation
9699349|NCT04734951|Experimental|Power/resistance exercise + HMB|Participants on combined power/resistance exercise program + HMB oral supplementation
9699350|NCT04735146|Experimental|Experimental Group|The Experimental Group will be involved in 1 weekly session of adapted physical activity lasting 1 hour for 6 weeks within the normal cycle of accompanying birth meetings provided by the University Hospital of Bologna.
9699351|NCT04735146|No Intervention|Control Group|The control group is expected to participate in 6 birth accompaniment meetings held online, 1 hour of which will be dedicated to the topic of exercise and physical activity recommendations in pregnancy.
9699352|NCT04735029|Experimental|Thermal Gun group|"The thermal gun applied on acupressure points in TCM. The thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
9699353|NCT04735029|Active Comparator|Heat Pack group|A hydrocollator heat pack used to simulate traditional thermal therapy. The application of the heat pack was wrapped with six layers of terry towels to bring the temperature down to around 43°C.
9699354|NCT04735237|Experimental|Autogenous fat injection|Fat will first be harvested from the abdomen, then injected into the lip
9699355|NCT04735237|Active Comparator|Surgical revision with orbicularis oris muscle reconstruction|
9699356|NCT04735133|Experimental|intervention grpup|pNPWT device was placed in the pNPWT group for seven days. The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
9699357|NCT04735133|No Intervention|control group|"The wound of the control group was covered with a sterile gauze dressing. After the wound was left closed for 48 hours in the clinical routine, the surgical site was left open, supporting healing. Therefore, the dressing of the control group was removed after 48 hours, and the wound was left open.~The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI."
9699358|NCT04735250||45° group|Uses the video stylet with 45 degree(The tip of the trachway in 45°-55°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
9699359|NCT04735250||70° group|Uses the video stylet with 70 degree(The tip of the trachway in 60°-70°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
9699360|NCT04735250||90° group|Uses the video stylet with 90 degree(The tip of the trachway in 80°-90°) to assist the orotracheal tube passing the oral cavity, oropharynx and advanced into the trachea
9699361|NCT04735042||SGLT2 and DPP-4 inhibitors|Patients undergoing SGLT2i and DPP4i.
9699362|NCT04735042||SGLT2 inhibitors only|Patients undergoing SGLT2i alone.
9699363|NCT04734964|No Intervention|Control group|Participants underwent only common physical education classes twice per week for 45 minutes each and no additional after-school exercises.
9778470|NCT01107405|Active Comparator|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base dosed two times/day
9699364|NCT04734964|Experimental|Coordinative exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
9699365|NCT04734964|Experimental|Cardiovascular exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
9699366|NCT04735081||First group before practice change|Infectious spondylodiscitis when prolonged immoblization in bed was recommanded in our hospital
9699367|NCT04735081||Second group after practice change|Infectious spondylodiscitis when early verticalization was recommanded in our hospital
9699368|NCT04735198|Active Comparator|Experimental group|Patients with midgut neuroendocrine tumor who will undergo only primary tumor surgery.
9699369|NCT04735198|Experimental|Control group|Patients with midgut neuroendocrine tumor that will undergo through primary tumor surgery combined with prophylactic cholecystectomy.
9699370|NCT04734938|No Intervention|Habitual Diet|All volunteers will participate in this arm, continuing this habitual diet for 1 week
9699371|NCT04734938|Experimental|100% Huel|All volunteers will participate in this arm of the study and consumer 100% Huel as their food for 4 weeks
9699372|NCT04735055||Artificial intelligence (AI) machine learning group|"90% machine learning part has also been divided into 2 parts as 70% for AI learning and 30% for testing the learning.~70% of the acute pancreatitis patients (approximately 840 pts) will form the model training group of the study. 30% of the acute pancreatitis patients (approximately 360 pts) will form the testing group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
9699373|NCT04735055||Validation group|"10% of the acute pancreatitis patients (approximately 134) will form the validation group of the study.~Since cross-validation will also be applied to the model here, the data will also change within itself, and also the distribution will be optimized to increase the predictive power."
9699374|NCT04735107|Experimental|Reinforcement|Low anterior resection + mucosa flap reinforcement + vacuum sponge endoluminal drainage
9699375|NCT04735159|Active Comparator|Study group-SCS Impanted|30 patients with chronic pain (at least 6 months) with pre- and post-surgery evaluation (imaging and clinical evaluation) implanted with Precision SpectraTM for the validation study and for the construction of the predictive model.
9699376|NCT04735159|No Intervention|Comparator-chronic pain|20 patients with chronic pain (at least 6 months) with degenerative spine pain. Non-specific low-back pain, nociceptive pain / mixed neuropathic. This will be the comparator group
9699377|NCT04735159|No Intervention|Control-healthy volunteers|10 volunteers without pain or related disease, age less than 25 years, to establish a control group whose pattern is used as a comparator with chronic pain groups. This is the control group
9699378|NCT04734522|Experimental|The specified PAL design wearers|Subjects who have been already wearing any from specified design type of PAL
9699379|NCT04734522|Active Comparator|The other PAL design wearers|Subjects who have been already wearing any from the other design type of PAL
9699380|NCT04734639|Experimental|Obese adolescents|20 adolescents with obesity are involved and will perform the three conditions.
9699381|NCT04734561|Experimental|Inspiratory muscle training group|Participants will perform an inspiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
9699382|NCT04734561|Sham Comparator|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
9699383|NCT04734561|Experimental|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training by a threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
9699384|NCT04734561|Sham Comparator|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training by a placebo threshold device at home, twice a day for 8 weeks supervised by a physiotherapist through a virtual platform.
9778471|NCT01107405|Active Comparator|Loteprednol etabonate base (QID)|Loteprednol etabonate ophthalmic base dosed four times/day.
9778472|NCT01107405|Active Comparator|Loteprednol etabonate suspension (QID)|Loteprednol etabonate ophthalmic suspension dosed four times/day
9778473|NCT01107405|Placebo Comparator|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate, dosed either QD, BID, or QID
9778474|NCT01107418|Experimental|1|
9778475|NCT01107418|Experimental|2|
9778476|NCT01107418|Experimental|3|
9778477|NCT01107418|Experimental|4|
9778478|NCT01107444|Experimental|LY2181308 + Docetaxel|"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.~Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."
9778479|NCT01107444|Active Comparator|Docetaxel|Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.
9778480|NCT01107457|Experimental|10 mg Ixekizumab|"Part A:~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
9699385|NCT04734678||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.
9699386|NCT04734678||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.
10188938|NCT03712059||Identification and classification group|For 12000 patients regardless of cancer diagnosis or polypectomy, if there is polyp, NBI (magnification) observation is required, with 4 white light and NBI images collected and reserved, respectively. If there is magnifying endoscopy, another 4 endoscopic images of magnification are also required. Endoscopists are invited to predict the pathology of polyps according to the NICE classification principle and endoscopic images, and upload the pathological results and endoscopic images within 2-4 week after colonoscopy.
10188939|NCT03712046|Experimental|Main arm|PET-CT imaging of the ankles and feet following injection of 18F-FDG
9699387|NCT04734587||Chronic Total Occlusion|Chronic total occlusion patients undergoing percutaneous coronary intervention.
9699388|NCT04734587||Non-Chronic Total Occlusion|Non-Chronic total occlusion patients undergoing percutaneous coronary intervention.
9699389|NCT04734717|Experimental|COVID19|
9699390|NCT04734717|Experimental|Controll|
9699391|NCT04734756|Experimental|Dragonfly Mitral Valve Repair System|The experimental group is allocated to use a novel mitral valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
9699392|NCT04734769||Cycles of embryo transfer from patients with at least one euploid embryo (no rebiopsy group)|Collect retrospectively clinical data on reproductive outcomes
9699393|NCT04734769||Rebiopsy group:|Collect retrospectively clinical data on reproductive outcomes
10188940|NCT03712033||TEC4Home Stroke Cohort|"All participants or caregiver involved will be instructed to measure BP per the TEC4Home BP Telemonitoring Protocol. Participants will measure their BP daily, 4x/day, for the first week. After the first week, all weekly BP measurements will be done 3 days/week with 4 measurements a day. All readings must be taken before administration of antihypertensive medications, twice in the morning, 5 minutes apart and twice in the evening, 5 minutes apart.~The TEC4Home telemonitoring nurse will review the BP measurements and contact the participant on a weekly basis until the end of the 6-month monitoring period. The telemonitoring nurse will adjust the antihypertensive medication doses as per the TEC4Home Stroke - Hypertension Management Algorithm."
9699394|NCT04734847|Active Comparator|High-frequency rTMS|"Intensity: rTMS treatment intensity determined using resting motor threshold (RMT). Treatment will be delivered at 80% of the RMT.~Site of Stimulation: Region of supplementary motor area (SMA) that regulates pelvic floor muscle activity. This target is defined in Montreal Neurological Institute (MNI) Coordinates of X=-2, Y=-16, and Z=68 mm.~Frequency: 10 Hz.~Duration: 20 Trains, 10 second duration, 50 second inter-train interval.~Total number of pulses per session: 2000.~Total number of session: 5 (one session per day for 5 consecutive days)."
9699395|NCT04734847|Sham Comparator|Sham rTMS|"Identical to the High-frequency rTMS arm except delivered with an inert sham stimulation coil."
9699396|NCT04734730|Experimental|Treatment (talazoparib, androgen deprivation therapy)|Patients receive talazoparib PO QD, abiraterone acetate PO QD, and prednisone PO QD on days 1-28. Patients also receive androgen deprivation therapy consisting of degarelix SC on day 1; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of subsequent cycles; leuprolide acetate IM on day 1 and bicalutamide PO QD on days 1-28 of cycle 1 and then leuprolide acetate IM on day 1 of cycles 2, 5, 8, and 11; or goserelin acetate SC monthly or every 3 months. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9699397|NCT04734496||Chronic Liver Disease|Patients with end-stage liver disease. Standard of care treatment will be nutrition and exercise as per European Association Study of Liver nutrition guidelines.
9699398|NCT04734496||Rheumatoid Arthritis/Psoriatic arthropathy|Patients requiring biological therapy due to ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
9699399|NCT04734496||Inflammatory Bowel Disease|Patients with Crohns or Ulcerative Colitis with ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
9699400|NCT04734496||Healthy volunteers (n=20)|Healthy volunteers
9699401|NCT04734782||Protective Mothers (high IGG titers)|Protected group Newborns with congenital heart disease + high titers of anti-RSV IGG in the mother's serum before birth
9699402|NCT04734782||Non-protective mothers (low IGG titers)|Unprotected group Newborn with congenital heart disease + negative anti-RSV IGG titers in the mother's serum before birth.
9699403|NCT04734509|Experimental|Porter Brown Breathing system|"The Porter Brown has a double mask system that is characterized by a mask-within-a-mask scavenging system. The system includes easy to remove inner masks which vent into the outer mask. This helps in cleaning and sterilization. The soft inner part of the mask system provides a comfortable fit and an excellent seal around the patient's nose.~This mask is routinely used in inhalation sedation for children's dental treatment.~This is a sterilisable system."
9699404|NCT04734509|Experimental|Silhouette Breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
9699405|NCT04734483|Active Comparator|functional findings|Participants with laryngeal stenosis
9699406|NCT04734483|Active Comparator|to find anatomic feathers of larynx|Participants with laryngeal stenosis
9699407|NCT04734483|Active Comparator|to determine the type of stenosis of larynx and method of surgical treatment|Participants with laryngeal stenosis
9699408|NCT04734483|Active Comparator|determining the motor abilities of the muscles of the larynx|Participants with laryngeal stenosis
9699409|NCT04734704|Experimental|vitiligo patients|Adult patients diagnosed with Vitiligo according to usual criteria
9699410|NCT04734704|Experimental|metastatic melanoma patients under anti-PD-1 who did not develop cutaneous irAEs|metastatic melanoma patients under anti-PD-1 who did not develop Cutaneous Immune-Related Adverse Events (cutaneous irAEs).
10188941|NCT03712007|Experimental|MAMP therapy with MARPE expander|The experimental group will comprise 20 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-bone-borne expander as anchorage in the maxillary arch. The miniscrew assisted rapid palatal expander (MARPE) will be used.
10188942|NCT03712007|Active Comparator|MAMP therapy with Hyrax expander|The active comparator group will comprise 15 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-borne expander as anchorage in the maxillary arch. The conventional hyrax expander will be used.
10188943|NCT03711994|No Intervention|Repeat C/S Control|Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
9699411|NCT04734704|Experimental|Metastatic melanoma patients under anti-PD-1 who developed vitiligo lesions|patients with metastatic melanoma, under anti-PD-1 who developed vitiligo lesions
10188944|NCT03711994|Active Comparator|Repeat C/S Treatment|Repeat C/S done with spinal with Alkantis ice pack.
10188945|NCT03711994|No Intervention|Primary C/S - Control|Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
9699412|NCT04734704|Experimental|metastatic melanoma patients with vitiligo lesions under anti-PD-1 who discontinued|Metastatic melanoma who developed vitiligo lesions under anti-PD-1 who discontinued the treatment
9699413|NCT04734665|Experimental|experimental|Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous
9699414|NCT04734834|Placebo Comparator|Placebo|"Placebo will be provided orally to the Placebo Group. Placebo will be blinded and labeled either as A or B."
9699415|NCT04734834|Active Comparator|"Prodovite® VMP35"|"Prodovite® VMP35 will be provided orally to the Treatment Group. Prodovite® VMP35 will be blinded and labeled either as A or B."
9699416|NCT04734691|Experimental|Experimental Arm|
9699417|NCT04734691|Active Comparator|Control Arm|
9699418|NCT04734600|Experimental|aerobic training program|group a:twenty patients who will receive aerobic training program combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
9699419|NCT04734600|Active Comparator|myofascial release technique|group B: twenty patients who will receive myofascial release technique combine with traditional burger exercises for 45 mints, 3 times per week for two months as a total treatment period in addition to their medical treatment.
9699420|NCT04734743|Other|Cystic fibrosis|
9699421|NCT04734431||Survivors|Patients admitted in geriatrics that survived of a bacterial infection after 30 days (still admitted or discharged), and treated by antibiotics.
9699422|NCT04734431||Death|Deceased individuals admitted for a bacterial infection in geriatrics, despite receiving an antimicrobial therapy.
9699423|NCT05314894|Experimental|initiative group|The first session will be right after the pre-test, the second session will be 15 days after the first session, and the last session will be 15 days after the second session. After the training is over, a total of 40 messages will be sent to the students in the initiative group, taking into account the factors that affect, strengthen and activate the main communication via the WhatsApp program.
10188946|NCT03711994|Active Comparator|Primary C/S Treatment|Primary C/S done with Epidural with Alkantis ice pack.
9699424|NCT05314894|No Intervention|control group|No intervention will be made
9699425|NCT05314881|Experimental|SLE patients|
9699426|NCT05314868||Primary cohort|Pediatrics or adults who underwent cardiac repair surgery that nessecitated the use of a PhotoFix patch.
10188947|NCT03711981|Active Comparator|TAP block of 10cc Liposomal bupivacaine|Patients in this arm of the study would receive a bilateral Laparoscopic Assisted TAP block with 10cc Liposomal bupivacaine, 10cc 0.25% bupivacaine and 10cc normal saline each bilaterally at the beginning of their surgery.
10188948|NCT03711981|No Intervention|Routine pre-incisional injections at trocar incision sites|The patients in the control arm of the study would receive routine pre-incisional injections at the trocar incision sites using a total of 20cc 0.25% bupivacaine.
10188949|NCT03711968|Active Comparator|Treatment group|"Rehabilitative treatment protocol:~Therapeutic exercise 8 mono-weekly sessions, 5 patients per group, duration 60 minutes and two sessions of single treatment, duration 60 minutes (duration of treatment about two months, considering also any recovery sessions)"
10188950|NCT03711968|No Intervention|Waiting list|Intervention: The WL patients will be taken into the same treatment at the end of the experimental protocol, after T2 evaluation. In this period they act like a control group.
9699427|NCT05314855||Obese individuals with normal insulin sensitivity|
9699428|NCT05314855||Obese individuals with impaired insulin sensitivity|
9699429|NCT05314855||Obese patients with type 2 diabetes|
9699430|NCT05314842|Active Comparator|control group|the group that have caries in primary molars and treat them with formocresol
9699431|NCT05314842|Experimental|experimental group|the group that have caries in primary molars and treat them with premixed bioceramic MTA
9699432|NCT05314829||Study group|Data will be collected from 2 child advocacy centers
9699433|NCT05314803|Experimental|Yoga|Participants receive online, group-based yoga classes 2 times/week for 60 minutes/class over 12 weeks.
9699434|NCT05314790||control group (CG)|Without intervening Educational Program
9699435|NCT05314790||training group (TG)|Group who has received an Educational Program (EP). The implementation of an EP based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1.
9699436|NCT05314777|Experimental|Low dose ESWT application group|Exercise Training Low dose ESWT application
9699437|NCT05314777|Experimental|High dose ESWT group|Exercise Training High dose ESWT application
9699438|NCT05314777|Active Comparator|Control group|Exercise Training Sham ESWT
9699439|NCT05314764|Experimental|Cefiderocol|Participants will receive intravenous cefiderocol at a dosing regimen consistent with the current prescribing information and according estimated renal function. Each dose will be infused over 3 hours.
9699440|NCT05314738|Experimental|Group 1 / Cohort 1|Blind/Partially sited eyes Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
9699441|NCT05314738|Sham Comparator|Group 2 / Cohort 2|Sham Solution with no exposure to NXL System
9699442|NCT05314738|Active Comparator|Group 3 / Cohort 2|Riboflavin Solution + Exposure to NXL system to achieve total energy level 1
9699443|NCT05314738|Active Comparator|Group 4 / Cohort 2|Riboflavin Solution + Exposure to NXL system to achieve total energy level 2
9699444|NCT05314738|Active Comparator|Group 5 / Cohort 2|Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
9699445|NCT05314725|Experimental|SGLT-2 inhibitor|
9699446|NCT05314725|Placebo Comparator|placebo|
9699447|NCT05314712|Other|Sleep Intervention|Pre and post test of 9-week intervention
10188951|NCT03711955|Experimental|Aerobic training group (AET)|Each AET sessions are to last one hour, with 40 minutes being allocated to the aerobic exercise training component, 10 minutes allocated to warm-ups, 5 minutes allocated to cool-downs, and one 5 minute rest period between the 20 minutes spent on each machine (20 minutes of cycling, 5 minute rest, 20 minutes seated row). The AET program consists of 20 minutes of cycling on the stationary bicycle and 20 minutes of seated row on the kinesis Technogym machine. This is to be preceded by 10 minutes of static stretching during warm up, and 5 minutes of post-exercise recovery (dynamic stretches).
9699448|NCT05314699|Experimental|resistance-aerobic exercise group, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
9699449|NCT05314699|Experimental|aerobic-resistance exercise group, AR|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
9699450|NCT05314699|No Intervention|reading control group, RC|Participants conduct reading for 35 minutes.
9699451|NCT05314686||Technical validity of data transmitted remotely.|The first twenty participants will participate in the step of the study aimed at assessing the technical validity of data transmitted remotely from devices connected to the telerehabilitation system.
9699452|NCT05314686||Clinical feasibility.|The last twenty participants will perform their pulmonary rehabilitation program at home using the telerehabilitation system over an eight-week period.
9699453|NCT05314673|Active Comparator|Preoperative intralesional injection of bevacizumab + pterygium excision+ autograft|Patients receiving intralesional injection of 0.05 ml (1.25 mg) of Bevacizumab, one month before surgical treatment. Surgical treatment consisted of lesion excision and conjunctival autograft performed by a single trained surgeon.
9699454|NCT05314673|Active Comparator|pterygium excision+ autograft|Patients undergoing only pterygium surgical treatment.
9699455|NCT05314647|Experimental|Lutein|5 mg lutein gummy taken daily for 180 days
9699456|NCT05314647|Placebo Comparator|Placebo|0 mg lutein gummy taken daily for 180 days
9699457|NCT05314634|Experimental|concurrent exercise group, CE|Participants conduct 5-min warm up, 12-min aerobic exercise, 13-min resistance exercise, and 5-min cool down.
9699458|NCT05314634|Experimental|aerobic exercise group, AE|Participants conduct 5-min warm up, 25-min aerobic exercise, and 5-min cool down.
9699459|NCT05314634|No Intervention|reading control group, RC|Participants conduct reading for 35 minutes.
9699460|NCT05314621|Active Comparator|Pataday® Once Daily Relief Extra Strength and Saline Nasal Spray|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and saline nasal spray will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
9699461|NCT05314621|Active Comparator|Tears Naturale® II and Flonase® Allergy Relief|Tears Naturale® II will be administered bilaterally and Flonase® Allergy Relief (fluticasone propionate) will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.
9699462|NCT05314608||Subjects with subchondral bone pathology|Subjects with subchondral bone pathology
9699463|NCT05314595|Experimental|modified technique|women were underwent modified technique (PPC+ bilateral uterine artery ligation)
9699464|NCT05314582||TURP patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic prostatectomy (TURP).
9699465|NCT05314582||TURP patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic prostatectomy (TURP).
9699466|NCT05314582||TUR-BT patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic bladder tumor resection (TUR-BT).
9699467|NCT05314582||TUR-BT patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic bladder tumor resection (TUR-BT).
9699468|NCT05314582||Open prostatectomy patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent open prostatectomy (OP).
9699469|NCT05314582||Open prostatectomy patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent open prostatectomy (OP).
9699470|NCT05314569|Placebo Comparator|Control group(C)|anesthesia will be maintained using Isoflurane 1.2MAC keeping the bispectral index( BIS) between 40-60%.
9699471|NCT05314569|Active Comparator|Ketamine-dexmedetomidine group( KD)|After induction of anesthesia , dexmedetomidine will be given(1 ug /kg ) over 10 min, then ketamine(2 m/kg) . maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing Dexmedetomidine( 0.5 μg/.kg /.h r)) ketamine,( 1 m/kg/hr),
9699472|NCT05314569|Active Comparator|. Fentanyl- midazolam group (FM)|After induction of anesthesia fentanyl( 3 μg/kg), midazolam( 100 ug /kg over 2 to 3 minutes) maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing midazolam (1 ug /kg /min)-fentanyl( 2 μg/kg/h ).
9699473|NCT05314556|Experimental|Intervention|Group psychotherapy
9699474|NCT05314543|Experimental|Track cyclists and rowers (males and females)|All female and male rowing and track cycling athletes at the national or international national or international level, registered in a selection process and likely to represent France at the likely to represent France at the 2024 Olympics will be asked to take part to take part in this study.
9699475|NCT05314530|Experimental|Intervention group|Will receive a rehabilitation intervention
9699476|NCT05314530|Active Comparator|Controll|Will receive conventional rehabilitation
9699477|NCT05314491||Multigen Plus CCK|
10188952|NCT03711955|Experimental|Instability training group (IRT)|Each IRT sessions are to last one hour, with time being allocated to a 10 minute warm up, consisting of static stretches, a 5 minute cool down, consisting of dynamic stretches, and a series of IRT exercises performed in a circuit setting over the duration of 40 minutes. In the sessions, five resistance exercises will be performed. A linear periodization will occur, in which the training load will progress from high-volume low-intensity to low-volume high-intensity loads over the duration of eight weeks to maximize training adaptations. Additionally, there will be a progressive increase in load/resistance by 1-2 lbs and the degree of instability of each exercise during the course of the eight week program. Unstable devices will be changed from the least unstable to the most unstable device throughout the program, but only when participants showed a considerable decrease in body sway/movement and force production increased when performing exercises.
10188953|NCT03711942|Active Comparator|Periodontally Healthy IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar.
9699478|NCT05314491||Multigen Plus CCK in combination with AMF TT cones|
9699479|NCT05314478|Experimental|Participants|Participants will be required to attend a single consultation and screening appointment to discuss the investigation procedure, and this will occur at least a week before the Continuous Laryngoscopy during Exercise (CLE) test. Participants will then attend one appointment for the CLE test. There will be no follow up assessments using the headgear.
10188954|NCT03711942|Experimental|Periodontally Healthy Base|2mm thick base was applied in periodontally health teeth.
10188955|NCT03711942|Experimental|Periodontally healthy control|coronal access was restored with composite resin without any base.
10188956|NCT03711942|Active Comparator|Periodontally diseased IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar
10188957|NCT03711942|Active Comparator|Periodontally diseased Base|2mm thick Base of GIC was applied under composite restoration
10188958|NCT03711942|Active Comparator|Periodontally diseased control|coronal access was restored with composite resin without any base
10188959|NCT03711916|Experimental|Breast flap creation with PlasmaBlade|During participant's scheduled bilateral mastectomy, breast flap on one breast will be created using low thermal dissection device (PlasmaBlade) on one breast and standard Bovie cautery in the contralateral breast.
10188960|NCT03711916|No Intervention|Breast flap creation with Bovie Cautery|During participant's scheduled bilateral mastectomy, breast flap will be created using standard Bovie cautery on the breast contralateral to the one that was created using PlasmaBlade.
10188961|NCT03711903|Experimental|Treatment arm|The study drug, CN-105, will be administered at 1.0 mg/kg every 6 + 2 hours. The calculated volumes of study agent will be removed from the vials and transferred to 250 mL of normal saline (0.9% sodium chloride injection, USP). The recorded weight at baseline will be used to determine the appropriate amount of CN-105 drug product to administer. Each dose of CN-105 or placebo will be administered as a slow IV bolus over 30 minutes.
9699480|NCT05314465|Experimental|Median nerve mobilization|
9699481|NCT05314439|Experimental|ION904|Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection.
10188962|NCT03711903|Placebo Comparator|Placebo arm|The Placebo arm will be given 0.9% NaCL
10188963|NCT03711890|Experimental|Diagnostic (resection, OCT)|Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
9699482|NCT05314439|Placebo Comparator|Placebo|Up to 4 monthly doses of placebo will be administered by SC injection.
9699483|NCT05314400|Active Comparator|Full Protocol|Routine Primovist MRI
9699484|NCT05314400|Experimental|Abbreviated Protocol|Shortened Primovist MRI
9699485|NCT05314387||SMR TT Hybrid Glenoid without Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid without Cementless Finned Short Stem
10188964|NCT03711864|Experimental|IM21 CAR-T cells|IM21 CAR-T cells
10188965|NCT03711851|Experimental|Web-based|Self-help Acceptance and commitment therapy (Web-based)
9699486|NCT05314387||SMR TT Hybrid Glenoid with Cementless Finned Short Stem|Patients implanted with SMR TT Hybrid Glenoid with Cementless Finned Short Stem
9699487|NCT05314374|Experimental|Bile Acid Supplement Group|Subjects with obesity and abnormal satiety phenotype will receive ileocolonic-release conjugated bile acid supplements
9699488|NCT05314374|Placebo Comparator|Placebo Group|Subjects with obesity and abnormal satiety phenotype will receive matching-placebo
9699489|NCT05314348|Active Comparator|Motor Neuron Disease|High-density surface EMG Ultrasound
9699490|NCT05314348|Active Comparator|Healthy controls|High-density surface EMG Ultrasound
9778481|NCT01107457|Experimental|25 mg Ixekizumab|"Part A:~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
9778482|NCT01107457|Experimental|75 mg Ixekizumab|"Part A:~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
10188966|NCT03711851|Experimental|Bibliotherapy|Self-help Acceptance and commitment therapy (bibliotherapy)
10188967|NCT03711851|Active Comparator|Education pamphlets on pain|Self-help Education on Chronic pain (pamphlet style pdf documents)
10188968|NCT03711825|Experimental|Sentinel/Main|Sentinel dosing of two subjects in clinic of LYN-057 (50 mg), followed by Main, i.e. remaining 6 subjects, for total of 8 subjects doses; followed by imaging assessment (MRI/abdominal U/S)
10188969|NCT03711812|Active Comparator|Serratus Anterior Plane Catheter|
10188970|NCT03711812|Placebo Comparator|Thoracic Epidural|
9699491|NCT05314335|Experimental|Reflexology socks+Walking|In the first interview; patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Afterwards, the reflexology socks designed by the researcher for the patients; will be told to wear and walk 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday). Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale, and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 30th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
9699492|NCT05314335|Other|Just walking|In the first interview, patient diagnosis form and Constipation Quality of Life scale will be applied. In order to evaluate the routine bowel habits of the patients, no application will be made in the first week and the patients will be asked to complete the Defecation Diary, Visual Comparison Scale and the Bristol Stool Consistency Scale for 1 week when defecation occurs. Subsequently, patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks. The patients will be administered the Defecation Diary, the Visual Comparison Scale and the Bristol Stool Consistency Scale when defecation occurs daily during the application. In addition, on the 130th day of the application, the Constipation Quality of Life Scale will be administered to the patients again.
9699493|NCT05314322|Experimental|High frequency group|Deep brain stimulation's parameter: Frequency adjusted to 130Hz, with other parameters fixed
9699494|NCT05314322|Experimental|Low frequency group|Deep brain stimulation's parameter: Frequency adjusted to 60Hz, with other parameters fixed
9699495|NCT05314309||mtFIT|Individuals who consent to participate in the study, will be asked to take two stool samples from the same bowel movement. In a central laboratory these two samples then will be analyzed. One with the standard of care faecal immunochemical test (FIT) and the other with the multi-target faecal immunochemical test (mtFIT). If either one of these two tests is positive, individuals will be referred to undergo a colonoscopy procedure. The performance of mtFIT, in comparison to FIT, will be evaluated against the colonoscopy findings.
9699496|NCT05314283|Experimental|DV3395 C1|
9699497|NCT05314257|Active Comparator|Group G|IV granisetron 1mg
9699498|NCT05314257|Placebo Comparator|Group C|IV 5ml of 0.9% normal saline
9699499|NCT05314244|Experimental|pylorus resecting group|The patients who underwent pylorus resecting pancreaticoduodenectomy for periampullary tumors
9699500|NCT05314244|No Intervention|pylorus preserving group|The patients who underwent pylorus preserving pancreaticoduodenectomy for periampullary tumors
9699501|NCT05314231|Experimental|ALXN1720|Participants will receive a single dose of ALXN1720, given as a SC infusion at a dose of 1500 mg.
9699502|NCT05314192||Healthy|Healthy cohorts with no underlying systemic or periodontal disease
9699503|NCT05314192||stage 2 periodontitis|patients with periodontitis but no underlying systemic periodontal disease
9699504|NCT05314192||MI patients with stage 4 periodontitis|patients who had MI and having stage 4 periodontitis patients
9699505|NCT05314192||MI patients without periodontitis|patients who had MI without periodontitis
9699506|NCT05314179|Experimental|DOULA -AC|Four hours/week of Doula and Patient engagement.
9977927|NCT01366625|No Intervention|Maintenance of Medications|Maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
9699509|NCT05314153|Experimental|Open Label - Active Drug|Brexanolone (zulresso) infusion arm. All patients enrolled will receive active treatment with brexanolone.
9699510|NCT05314140||Coronary artery calcium score evaluation|Patients with diabetes and having a CT scan for evaluation of their coronary artery calcium score will be consecutively include. The indication of the scanner is at the choice of the clinician (usually cardiologist and/or diabetologist), in compliance with the recommendations
9699511|NCT05314127|Experimental|Tazarotene|20 patients of verruca plana receiving daily topical Tazarotene 0.1% gel at night
9699512|NCT05314127|Active Comparator|Imiquimod|20 patients with verruca plana will be treated with imiquimod cream 5% applied once daily at night
9699513|NCT05314127|Experimental|5- fluorouracil|20 patients with verruca plana will be treated with topical 5- fluorouracil 5% cream applied once daily at night
9699514|NCT05314127|Placebo Comparator|Petrolatum|20 patients with verruca plana will be treated with petroleum jelly once daily at night.
9699515|NCT05314101|Experimental|TAS-102 combined with bevacizumab and tislelizumab|TAS-102 combined with bevacizumab and tislelizumab third-line or above in the treatment of liver metastasis in colorectal cancer
9699516|NCT05314088|Experimental|RISE+ Resilience Intervention|Participants in the intervention group will come to the lab for four two-hour weekly sessions in small groups of 3-4. The intervention includes psychoeducational videos and individual written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience. The intervention will be facilitated by a trained research assistant but as in the pilot study, he/she will be minimally involved (i.e., only administering the videos and explaining the activities) to keep the private reflective nature of the program that participants liked. Upon completion of the program, participants will be given handouts with summaries of the program material. We will gather qualitative and quantitative feedback on the intervention at the one-month posttest.
9699517|NCT05314088|Placebo Comparator|Stress Reduction Control|Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games. As with the intervention group, participants in the control group will come to the lab for four two-hour weekly sessions in small groups of 3-4. Facilitator involvement will be the same as the intervention group (e.g., the research assistant will explain computer activities and games but will otherwise not interact with the participant).
9699518|NCT05314075|Active Comparator|Upper Body|
9699519|NCT05314075|Active Comparator|Under body|
9699520|NCT05314062|Active Comparator|Ferrous sulfate (FeSO4)|FeSO4 supplements containing 54 mg elemental iron
9699521|NCT05314062|Experimental|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|Ao iron supplements containing 54 mg elemental iron
9699522|NCT05314049|Experimental|Experimental Group|
9699523|NCT05314049|Active Comparator|Active Comparator Group|
9699524|NCT05314010|Experimental|MIL62|
9699525|NCT05314010|Placebo Comparator|Placebo|
10188971|NCT03711786|Active Comparator|Basic implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
10188972|NCT03711786|Experimental|Enhanced implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
9699526|NCT05313984||Patients planned for the 2-staged tined-lead procedure.|"Patients with the following indications:~Overactive bladder without urgency urinary incontinence.~Overactive bladder with urgency urinary incontinence.~Non-obstructive urinary retention.~Dysfunctional voiding or Fowler Syndrome.~Fecal incontinence."
9699527|NCT05313971|Experimental|Intervention|3-week recruitment period of portuguese medical students wanting to attend the 28-hour online course
9699528|NCT05313971|No Intervention|Control|The control group was recruited in order to match the age, gender, academic year and teaching faculty variables with the intervention group and people with these characteristics were invited to participate.
9699529|NCT05313958|Experimental|treatment arm|"The patients in this arm will receive SCCLG-M5 2022 regimen for newly dignosed acute monocytic leukemia (M5) ,including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period and followed by three courses(HA1M, HA2E, HA3) in consolidation therapy prescribed as the NOPHO-AML 2004 protocol.~The targeted drugs sorafenib 200mg/m2/day orally is used for FLT3 positive acute monocytic leukemia until molecular biology remission for 2 years."
9699530|NCT05313932|Experimental|Sleep deprivation|Two hours of sleep deprivation (Six hours of sleep)
9699531|NCT05313932|No Intervention|No intervention|No sleep deprivation (Eight hours of sleep)
9699532|NCT05313919||1. Coronary microcirculatory disease|
9699533|NCT05313919||2. Epicardial vasospastic angina|
9699534|NCT05313919||3. Microvessel vasospastic angina|
9699535|NCT05313919||4. Non-cardiac disorder|
9699536|NCT05313906|Experimental|exprimental group|RC48 plus AK105 and cisplatin
9699537|NCT05313893|Experimental|Quadrivalent influenza vaccine|Subjects received 2 doses of 0.5 mL of quadrivalentinfluenza vaccine, 4 weeks apart. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
9699538|NCT05313867|Placebo Comparator|Placebo|1 sequence of 10 tablets containing only excipients
9699539|NCT05313867|Experimental|Trace elements|Nutri VX1 in a single dose (1 sequence of 10 tablets). Nutri VX1 is a complex of trace elements with the status of a food supplement.
9699540|NCT05313828||group 1'|patients with viral ulcers will receive antiviral medication with antibiotics
9699541|NCT05313828||group 2|patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
9699542|NCT05313828||group 3|patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
9699543|NCT05313828||group 4|patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
9699544|NCT05313815|Experimental|Moderate Hypofracitonated Boost to the Prostate with Pelvic Radiation Therapy|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
9699545|NCT05313789||Intensive Care Patients (Cardiovascular)|Intensive care unit patients, mechanically ventilated and lacking communication. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
9699546|NCT05313789||Intensive Care Patients (Internal diseases)|Intensive care unit patients, both mechanically ventilated and lacking communication and mechanically ventilated and conscious. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
9699547|NCT05313789||Intensive Care Patients (Obese)|Intensive care unit patients. Will examine whether the positive inotropic/vasoconstrictor agents will have any effect on Analgesia Nociception Index.
9699548|NCT05313776||Post-stroke|"People with a first ever ischemic stroke of the middle cerebral artery presenting severe motor deficits of the upper-limb at onset.~The patients"
9699549|NCT05313776||Controls|Age and sexe matched healthy subjects without known neurological and or psychological deficits.
9699550|NCT05313763|Experimental|Conventional physical therapy group|Conventional physical therapy is the first line of treatment in cervical spondylosis.
9699551|NCT05313763|Active Comparator|Kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Kinesio-tape applications will be applied in 6 sessions during conventional physical therapy, twice a week at four-day intervals.
9699552|NCT05313763|Sham Comparator|Sham kinesio-tape Group|Conventional rehabilitation program will be applied five days a week, 3 weeks, a total of 15 sessions. Sham kinesio-tape applications will be applied twice a week at four-day intervals, 6 sessions during conventional physical therapy.
10188973|NCT03711773|Experimental|Group Physical Therapy Class|Group Physical Therapy Classes. Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
10188974|NCT03711760|Experimental|intervention|telepsychology treatment
10188975|NCT03711760|No Intervention|usual care|standard of care
10188976|NCT03711734|Experimental|Acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally with electrostimulation at Shen men and Hypothalamus at 30 hz."
9699553|NCT05313750|Experimental|sitafloxacin group|Oral sitafloxacin (0.1g one time daily) for 10 days
9699554|NCT05313750|Active Comparator|levofloxacin group|Oral levofloxacin (0.4g one time daily) for 10 days
9699555|NCT05313737|Experimental|Automated phone opt-in message|Audiocare message requiring Veteran to confirm that they would like to participate in screening and have consult sent
9699556|NCT05313737|Experimental|Opt-out scheduling|Consult automatically sent and Veteran called to schedule screening
9699557|NCT05313724|Experimental|Mind-Body Online Therapy|
9699558|NCT05313724|No Intervention|TAU (treatment as usual)|
9778483|NCT01107457|Experimental|150 mg Ixekizumab|"Part A:~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344."
9778484|NCT01107457|Placebo Comparator|Placebo|"Part A:~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
9778485|NCT01107457|Experimental|120 mg Ixekizumab|"Part B: (optional)~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
9778486|NCT01107457|Experimental|80 mg Ixekizumab|"Part B: (optional)~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
9778487|NCT01107535||Infants receiving Synagis (palivizumab) immunoprophylaxis|Infants born <= 32 weeks of gestation and are younger than 6 months of age, children with bronchopulmonary dysplasia who have received medical treatment in the last 6 months until the first year of life, and children 12 months or younger with hemodynamically significant acyanotic congenital heart disease (pulmonary hypertension or heart failure in treatment) prescribed Synagis (palivizumab) immunoprophylaxis according to the usual clinical practice.
9778488|NCT01107626|Experimental|Arm A (Induction then Maintenance with Bevacizumab)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm A receive bevacizumab IV over 30-90 minutes on day 1 of every cycle until progression or unacceptable toxicity."
9778489|NCT01107626|Experimental|Arm B (Induction then Maintenance with Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm B receive pemetrexed IV over 10 minutes on day 1 of every cycle until progression or unacceptable toxicity."
9778490|NCT01107626|Experimental|Arm C (Induction then Maintenance with Bevacizumab & Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm C receive bevacizumab as in arm A and pemetrexed as in arm B."
9778491|NCT01107665|Experimental|Pazopanib and Paclitaxel|Treatment on study will be administered in 4-week cycles. Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
9778492|NCT01107730|Active Comparator|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
9778493|NCT01107730|Active Comparator|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
9778494|NCT01107730|Active Comparator|Placebo|
10188977|NCT03711734|No Intervention|No acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will not have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally."
9699559|NCT05313685||Mayo Clinic hiccup educational materials|
9699560|NCT05313685||Mayo Clinic hiccup educational materials + updated supplementary content|
9699561|NCT05313672||IPF patients with UIP pattern requiring NIV|
9699562|NCT05313672||ARDS patients requiring NIV|
9699563|NCT05313659|Experimental|group-K|
9699564|NCT05313659|No Intervention|group-S|
9699565|NCT05313646|Experimental|batch 1 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101001.
9699566|NCT05313646|Experimental|batch 2 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101002.
9699567|NCT05313646|Experimental|batch 3 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202102003.
9699568|NCT05313620|Experimental|Ulcerative colitis patients treated with tofacitinib|Tofacitinib 5 mg/day oral per clinical practice
9699569|NCT05313620|Active Comparator|Ulcerative colitis patients treated with an anti-TNFα drug|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice
10188978|NCT03711721|Experimental|Food basket|
9699570|NCT05313620|No Intervention|healthy controls|
9699571|NCT05313581|Active Comparator|START NOW as web-based group training guided by a facilitator|"In condition 1, participants will be required to attend weekly sessions of the group training (6 to 12 participants) guided by a facilitator, which will either be a staff member (caretaker) of the institution who has received a training in START NOW (face-to-face setting), or a member of the START NOW facilitator team of Universitäre Psychiatrische Kliniken (UPK) Basel (videoconference setting). All participants will have access to the WebApp during the entire intervention and follow-up phase to complete additional exercises or review content.~Institutions randomized to group training guided by a facilitator condition will receive the complete pretraining (12 hours à 3 blocks: Theoretical Background; WebApp and Facilitator Material; Running Sessions) with individual coaching. Supervision will be provided twice during the intervention phase. Additionally, it can be reached out via e-mail to START NOW study coordinators for further guidance."
9699572|NCT05313581|Active Comparator|START NOW as web-based pure self-help training|Participants in condition 2 will use the START NOW web-based pure self-help training. Using the same session contents as in the group training guided by a facilitator, sessions have been adjusted so that participants can complete them individually and participants receive one session each week. Institutions randomized to pure self-help training will receive the first block of the pretraining and the material from the second block (facilitator training material) prior to interventions start.
9699573|NCT05313581|No Intervention|Treatment as usual (TAU)|Participants in condition 3 will not receive any health promotion services during the skills training or follow-up period beyond what is offered at their respective institution. They will also be excluded from any group trainings similar to START NOW. For ethical reasons and to increase study-related commitment, they will be provided with the web-based pure self-help training after completion of the study. Institution staff will receive the first block of the pretraining and material from the second block after the end of the intervention. Supervision for participating caretakers and facilitators will not be provided during the intervention phase.
10188979|NCT03711721|Experimental|Ready-to-Use Therapeutic Food|
10188980|NCT03711708|Experimental|Zoloft Oral Solution|50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.
9699574|NCT05313568|Active Comparator|static stretching group|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
9699575|NCT05313568|Experimental|self massage group|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
10188981|NCT03711708|Active Comparator|Zoloft Tablets|Zoloft 50 mg tablet.
10188982|NCT03711695||Group A|Subjects presenting for catheter ablation for cardiac arrhythmias (e.g. atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia)
10188983|NCT03711695||Group B|Subjects judged based on the clinical evaluation of high, greater than 75%, atrial pacing or ventricular pacing burden or known pacing dependence with planned device interrogation for: 1) pacemaker (single or dual chamber), 2) implantable cardioverter-defibrillator (single or dual chamber), or 3) cardiac resynchronization therapy with or without defibrillator (single or dual chamber plus left ventricular pacing).
10188984|NCT03711695||Group C|Subjects for clinically indicated defibrillation threshold testing (DFT) (with a transvenous or subcutaneous implantable cardioverter defibrillator (ICD) lead system)
10188985|NCT03711682|Experimental|Cinnamon (Intervented)|
10188986|NCT03711682|Placebo Comparator|Wheat Flour (Placebo)|
10188987|NCT03711656|Experimental|isCGM and Physical exercise tracker|"Participants will perform CGM during 12 weeks using an isCGM (intermittently scanned Continuous Glucose Monitoring), Freestyle Libre, (Abbott Diabetes Care, Witney, Oxon, UK). Insulin dose (rapid-acting and long acting), carbohydrates and Self-monitoring blood glucose (SMBG) per day will be recorded by the patient in the reader or in the App (LibreLink, Abbott Diabetes Care, Witney, Oxon, UK). Moreover, participants will be instructed to collect data about moderate or high intensity exercise, illness and other disturbances occurring during the study period at home.~Patients will wear a physical exercise tracker (Fitbit Alta HR® wristband (Fitbit, Inc., San Francisco, California, USA)) to track physiological variables such as heart rate, steps, activity level and sleep quality."
10188988|NCT03711643|Experimental|Optimizing pain management|An experimental group receive a standard pain management and benefit the hypnotic mask (Hypnos pro).
10188989|NCT03711643|Active Comparator|standard pain management|
9699576|NCT05313568|Experimental|Manual Stimulation Group|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
9699577|NCT05313555|Active Comparator|Ultraviolet lights (UV-B)|
9699578|NCT05313555|Experimental|Ultraviolet lights (UV-C)|
9699579|NCT05313542|Experimental|Physical Activity Group (PA group)|The PA group will receive a 6-week home-based self-defence training programme consisting of 120 min video training (including daily practice time) per week. Self-report questionnaires will be collected at baseline, immediate post-intervention, and 4-week follow up assessments.
9699580|NCT05313542|Other|Waitlist Group (WL group)|The waitlist group will receive access to the programme at the end of study.
9699581|NCT05313529|Experimental|Liraglutide|"Liraglutide will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated.~Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
9699582|NCT05313529|Experimental|Empagliflozin|"Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study.~Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Empagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
9699583|NCT05313529|Experimental|linagliptin|"linagliptin will be initiated at 5mg/ day every morning. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but linagliptin could not be adjusted.~If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
9699584|NCT05313516|Experimental|OKKO Health app|Use of OKKO Health app for home monitoring.
9699585|NCT05313503|Experimental|Ketogenic Diet|Ketogenic diet
9699586|NCT05313490|Active Comparator|Beetroot Juice|The subject will ingest 140mL of a nitrate-rich beetroot juice each day for 7 consecutive days.
9699587|NCT05313490|Placebo Comparator|Placebo Beetroot Juice|The subject will ingest 140mL of a placebo (nitrate-depleted) beetroot juice each day for 7 consecutive days.
9699588|NCT05313477|Active Comparator|Supplement group|"Vitamin D2 supplement based on initial vitamin D level~≥ 20ng/mL -> vitamin D2 20,000unit/week~10-19.9ng/mL -> vitamin D2 40,000unit/week~<10ng/mL -> vitamin D2 60,000unit/week Calcium carbonate 1000mg/day"
9699589|NCT05313477|No Intervention|No supplement group|no medication supplement
9699590|NCT05313464|Experimental|nutrition pushed by parents|enteral nutrition pushed by parents
9699591|NCT05313464|Active Comparator|syringe pump|Enteral nutrition with syringe pump
9699592|NCT05313451|Experimental|Soluble fiber|Participants ingest 15 g daily of the experimental product for 2 months and receive the influenza vaccine at the end of the first month.
9699593|NCT05313451|Placebo Comparator|Placebo|Participants ingest 15 g daily of the placebo product for 2 months and receive the influenza vaccine at the end of the first month.
9699594|NCT05313425||Ectoine Eye|The right eye of the studied group will be given 2% Ectoine containig , 0.2% sodium hyaluronate eye drops(Ectohylo) hourly.
9699595|NCT05313425||Control eye|The left eye of the studied group will be give Carboxymethyl cellulose, 0.2% sodium hyaluronate eye drops(Polyfresh Extra) hourly.
9699596|NCT05313412|Experimental|Test silicone hydrogel contact lenses (Lens A)|Test Lens A
9699597|NCT05313412|Active Comparator|Control silicone hydrogel contact lenses (Lens B)|Control Lens B
9699598|NCT05313399|Active Comparator|control group|the group have open bite caused by non-nutritive sucking habits and treat them with palatal crib.
9699599|NCT05313399|Experimental|experimental group|the group have open bite caused by by non-nutritive sucking habit and treat them with bonded spur.
9699600|NCT05313386|Experimental|Cohort 1- 120 Micrograms|"120 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
9699601|NCT05313386|Experimental|Cohort 2- 180 Micrograms|"180 Micrograms film or Placebo film are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
9699602|NCT05313386|Experimental|Cohort 3- 240 Micrograms|"Two 120 Micrograms films or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
9778495|NCT01107743||Amlodipine and Atorvastatin Combination Tablet|Subjects taking Amlodipine and Atorvastatin Combination Tablets
9778496|NCT01107834||Healthy Control|HIV-negative children born to healthy, HIV-negative women
9778497|NCT01107834||Exposed to HIV/HAART|HIV-negative children exposed to HIV and HAART in utero
10188990|NCT03711630|Experimental|Meditation|The study cohort will participate in self-guided meditation practice over the course of eight weeks.
10188991|NCT03711565|Active Comparator|Regular Nasal CPAP using a conventional ventilator|Regular nasal CPAP for management of respiratory distress Patient will have regular nasal CPAP placed via nasal prongs with level of pressure adjusted and level of oxygen adjusted as needed for acceptable oxygenation and ventilation
10188992|NCT03711565|Active Comparator|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation
9699603|NCT05313386|Experimental|Cohort 4- 300 Micrograms|"One 120 Micrograms film and one 180 Micrograms film or two Placebo films are given to patients in 3:1 ratio respectively.~Repeat doses may be administered in increments of 120 μg every 3 to 6 hours post first dose (StartD) only if the RASS score remains ≥ +1. For subjects 65 years and older, repeat doses may start in increments of 60 μg every 3 to 6 hours post first dose only if RASS is still ≥+1."
9699604|NCT05313347||Healty Participants with varying BMI|30 healthy participants with a body mass index ranging from 17.5 to 35kg/m2.
10188993|NCT03711552||Quality of recovery|All enrolled patients will be asked to complete the ObsQoR-11 and QoR-15 questionnaires pre-surgery if feasible and at 24 and 48 hours post-surgery.
9699605|NCT05313321||Primary total hip arthroplasty receiving the Insignia Stem|Patients undergoing primary total hip arthroplasty that will likely receive the Insignia Stem and associated Stryker Acetabular Component.
10188994|NCT03711539||Lifelong Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
10188995|NCT03711539||Late-onset Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
10188996|NCT03711539||Healthy Non-athletes|Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than >3 hours / week, ii) have a history of smoking (> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.
9699606|NCT05313308||Midazolam|Participants will receive a single age-specific dose midazolam oromucosal solution through buccal mucosa upon onset of seizures. Dose will be dependent by age of participants as follows: >= 52 weeks and < 1 year; 2.5 mg/dose of midazolam, for >= 1 year and < 5 years; 5 mg/dose of midazolam, for >= 5 years and < 10 years; 7.5 mg/dose of midazolam, for >= 10 years and < 18 years; 10 mg/dose of midazolam. Participants received interventions as part of routine medical care.
9699607|NCT05313295|Experimental|Home-based Physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques) + 3 hours extra of home-based physiotherapy (stretching, active mobilizations)
9699608|NCT05313295|Active Comparator|Usual physiotherapy|Two days a week of physical therapy (mobilizations, manual therapy, stretching, respiratory techniques)
9699609|NCT05313282|Experimental|treatment group|combination of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX7) , targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
9699610|NCT05313282|Active Comparator|control group|combination of targeted drugs (Apatinib 250mg), and anti-PD-1 immunotherapy (Camrelizumab 200mg)
9699611|NCT05313256|Experimental|Experimental group|In this arm patients will receive for epidural extension a Lidocaine epinephrine buffered with sodium bicarbonate.
9699612|NCT05313256|Active Comparator|Comparator group|In this arm patients will receive for epidural extension only Lidocaine epinephrine.
9699613|NCT05313243|Experimental|Brentuximab vedotin (brentuximab) and pembrolizumab|"All patients are scheduled to receive up to 16 cycles of combinatorial treatment with brentuximab + pembrolizumab, followed by up to 19 additional cycles of pembrolizumab monotherapy.~After receiving 35 total doses of pembrolizumab (i.e. scheduled for 16 doses in the combinatorial setting and 8 doses as monotherapy), a patient's pembrolizumab treatment will be complete."
9699614|NCT05313230||CITRASAFE|Patient underwent CITRASATE dialysis session
9699615|NCT05313217|Experimental|neural tension testing|All participants in this arm will undergo four tests: KEA, SLR, Slump, and Extended Slump
9699616|NCT05313204||Pregnant with Multiple Sclerosis|Pregnant individuals (> 13 weeks) with a Multiple Sclerosis diagnosis.
9699617|NCT05313204||Pregnant without Multiple Sclerosis|Pregnant individuals (> 13 weeks) without Multiple Sclerosis.
9699618|NCT05313204||Postpartum with Multiple Sclerosis|Postpartum individuals (< 1 year since delivery) with a Multiple Sclerosis diagnosis.
9699619|NCT05313204||Postpartum without Multiple Sclerosis|Postpartum individuals (< 1 year since delivery) without Multiple Sclerosis.
9778498|NCT01107886|Experimental|Saxagliptin|
9778499|NCT01107886|Placebo Comparator|Placebo|Placebo
9778500|NCT01107899|Active Comparator|clopidogrel 600 mg|
9778501|NCT01107899|Active Comparator|prasugrel 60 mg|
9778502|NCT01107899|Experimental|prasugrel 30 mg|
9778503|NCT01107912|Experimental|5 milligrams (mg) prasugrel|
9778504|NCT01107912|Active Comparator|10 mg prasugrel|
9778505|NCT01107912|Active Comparator|75 mg clopidogrel|
9778506|NCT01107925|Experimental|5 mg prasugrel|
9778507|NCT01107925|Active Comparator|10 mg prasugrel|
10188997|NCT03711513|Experimental|Exposure only|Psycho-education (PE) (plus homework) + 4 x Exposure (EX) (plus homework): 20 participants will receive four exposure group sessions after the psycho-education session. In the four sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
9699620|NCT05313191|Experimental|Cohort 1: Central Nervous System|"Group 1 Definitive Reirradiation Phase II~Patients w/history of intracranial or spinal (extradural, intradural, and/or intramedullary) CNS tumors for which radiation therapy was prev. delivered either to gross disease or in the postoperative setting~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Subgroup analysis: receipt of surgery for recurrence/second IC tumor; concurrent ST; tumor histology~Group 2 CNS Reirradiation Registry~Patients for whom a repeat course of RT to the CNS is indicated for recurrent disease or secondary primary~Postop or intact setting~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Histologically/clinically documented recurrent CNS tumor (benign or malignant)~Glioblastoma (histologic or molecular including IDH wildtype)~Astrocytoma (molecular IDH1 mutant)~Oligodendroglioma (molecular 1p19q co deleted)~Meningioma~Ependymoma~Chordoma/chondrosarcoma"
9699621|NCT05313191|Experimental|Cohort 2: Head/Neck|"Group 1 Full Dose Reirradiation Phase II~Patients w/history of HNC for which RT was delivered definitively, now with recurrence to h/n amenable to full dose reRT~Gross unresected disease or PORT 2/2 RF~Received at least 40 Gy overlapping w/new target region~Min. 6 month interval b/w RT courses~Overlap of prior RT field (50% IDL)~Subgroup analysis: surgery, HPV status, concurrent ST~Group 2 Early (<6months for prior RT) Palliative H/N ReRT Phase I~Patients w/history of HNC for which RT was delivered definitively/adjuvant setting, now with biopsy proven recurrence to h/n with indication for palliative RT~At least 30 Gy prior RT overlapping with new treatment volume~<6 month interval between RT courses~Group 3 Head/Neck ReRT Registry~Patients w/history of HNC for which RT was delivered now with recurrence/secondary primary requiring reRT~Postop or definitive~Prior RT dose at least 30 Gy overlapping w/new treatment volume~Min.6 month interval b/w RT courses"
9699622|NCT05313191|Experimental|Cohort 3: Breast|"Group 1 Partial Breast Reirradiation (Phase II)~Patients with a history of breast cancer s/p BCT, now with small (≤3cm), unicentric, ipsilateral breast cancer recurrence receiving repeat BCT~Node negative~Negative margins~No LVI~Lumpectomy cavity:whole breast <30%~Minimum 1 year interval between RT courses~Group 2: Regional LN and Breast/CW ReRT (Phase II)~Patients with a history of breast cancer s/p RT , now with recurrence or new primary with indication for reirradiation to the breast/chest wall and regional LN~Minimum 1 year interval between RT courses~Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~Excludes concurrent chemotherapy~Group 3: Breast Reirradiation Registry~Patients with a history of breast cancer s/p RT , now with recurrence or new primary breast cancer with indication for reirradiation~Some overlaps of dose with prior RT course~Negative metastatic workup (PET/CT or CT C/A/P + bone scan)~Excludes concurrent chemotherapy"
9699623|NCT05313191|Experimental|Cohort 4: Thoracic|"Group 1: Definitive Reirradiation for Locally Advanced Disease~Single arm, prospective, phase II study~Patients with a history of lung cancer s/p definitive RT , now with local recurrence of new primary centrally located and w/I 50% IDL of prior RT field~Definitive reRT concurrent systemic therapy~Adequate pulmonary function defined as an FEV1 of >35% (with or without bronchodilator) within 90 days prior to registration~Minimum 6 month interval between RT courses~Negative metastatic workup~Group 2: Thoracic Registry Study~Registry design~Patients with histologically confirmed thoracic malignancy (NSCLC, SCLC , mesothelioma, thymoma, carcinoid, intrathoracic sarcoma) with prior thoracic RT~Minimum 3 month interval between RT courses~Negative metastatic workup"
9699624|NCT05313191|Experimental|Cohort 5: Gastrointestinal|"Group 1 Esophagus & GEJ Reirradiation Phase II~Patients w/history of E/GEJ cancer s/p RT, now w/recurrent/new primary nonmetastatic E/GEJ cancer for which salvage RT is recommended~Negative metastatic workup~Group 2 Liver Reirradiation Phase II~Patients w/history of HCC, cholangiocarcinoma or liver mets (any histology), s/p prior EBRT, now with in field recurrence/new primary/met, for which definitive reRT is recommended~CTP A or B7~Excl. prev. Y 90/radioembolization~Allow prior TACE~Overlap w/50% IDL prior RT~Adequate bone marrow function~Group 3 Lower GI Reirradiation Phase II~Patients w/history of rectal/anal cancer s/p RT now w/recurrent/new primary nonmetastatic rectal/anal cancer for whom salvage RT is recommended +/ chemotherapy~Negative metastatic workup (PET/CT or CT C/A/P)~Group 4 GI Reirradiation Registry~•Patients w/histologically document recurrent or new GI malignancy with prior history of RT w/overlap of current RT volume by the 50% IDL"
9778508|NCT01107925|Active Comparator|75 mg clopidogrel|
9778509|NCT01107964|Active Comparator|Omega-3-acid ethyl esters|
9778510|NCT01107964|Placebo Comparator|Corn oil capsule|
9778511|NCT01108003|Experimental|Arm I|Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity.
9778512|NCT01108003|Placebo Comparator|Arm 2|Patients receive mango juice alone.
9778513|NCT01108068|Experimental|Lithium|patients with OPPG will be treated with lithium for 6 months
9778514|NCT01108068|No Intervention|Unaffected controls|Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.
9778515|NCT01108081|Experimental|Arm 1|Physical activity
9778516|NCT01108081|Experimental|Arm 2|Diet
9778517|NCT01108081|Active Comparator|Arm 3|Health education
10188998|NCT03711513|Experimental|Cognitive restructuring plus exposure|PE (plus homework) + Cognitive Restructuring (CR) (plus homework) + CR (plus homework) + EX (plus homework) + EX: 20 participants will receive two cognitive restructuring group sessions after the psycho-education session. In these two session they will practice identifying dysfunctional cognitions and formulating more functional (alternative/helping) cognitions. After the cognitive sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
9778518|NCT01108081|Experimental|Arm 4|Combined physical activity and diet
10188999|NCT03711513|Experimental|Relaxation plus exposure|PE (plus homework) + Relaxation (RE) (plus homework) + RE (plus homework) + EX (plus homework) + EX: 20 participants will receive two relaxation exercises group sessions after the psycho-education session. In these two session they will practice muscle relaxation and breathing exercises. After the relaxation sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
10189000|NCT03711500|Experimental|D-serine|
10189001|NCT03711500|Placebo Comparator|Placebo|
10189002|NCT03711487|Experimental|Ironing therapy|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
9699625|NCT05313191|Experimental|Cohort 6: Genitourinary|"Group 1 Locally recurrent prostate cancer w/in prev. radiation field Phase II~Patients w/recurrent prostate adenocarcinoma w/in prev. irradiated field w/indication for repeat course of radiation~Min. 1 year interval b/w RT courses~Prostate gland or recurrent tumor <100 cc or 6 cm in largest dimension~No persistent grade 2+ toxicity from prior radiation~Negative metastatic workup (bone scan, CT scan or PSMA/axumin scan~Group 2 Regional prostate cancer recurrence adjacent to the previous field Phase II~Patients w/recurrent prostate adenocarcinoma beyond prior RT field (outside 50% IDL) but w/in pelvis)~Min.1 year interval b/w RT courses (EBRT or brachy)~No persistent grade 2+ toxicity from prior radiation~Group 3 Prostate Reirradiation Registry~Patients w/recurrent prostate adenocarcinoma (prostate gland, postop bed, or pelvi c LN) who require RT to the prostate or pelvis in the setting of prior pelvis RT~No DM~Concurrent chemotherapy excl."
9699626|NCT05313191|Experimental|Cohort 7: Gynecological|"Group 1: Locally recurrent gynecological cancer within previous field~Single arm, prospective, phase II study design~Patients with history of gyn cancer for which definitive or adjuvant/salvage PORT was given, now with recurrence within 50% IDL recommended for radiotherapy~At least 1 year between RT courses~No persistent grade 3+ toxicity from prior RT~Concurrent chemotherapy excluded~Uncontrolled or widely metastatic disease~Life expectancy >6 months"
9699627|NCT05313191|No Intervention|Cohort 8: Registry|"Registry design~Any cancer patient for whom RT is indicated in the setting of prior RT and do not meet eligibility criteria for other cohorts~Overlap of 50% IDL of current treatment volume with prior RT field"
9699628|NCT05313178|Placebo Comparator|Milk Protein|25-gram dose of milk protein concentrate
9699629|NCT05313178|Experimental|Milk Protein and Probiotic|25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
9699630|NCT05313165|Experimental|Treated with LimFlow|Treatment with the LimFlow Stent Graft System
9699631|NCT05313152|Experimental|TAVO103A Low Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
9699632|NCT05313152|Experimental|TAVO10A Medium Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
9699633|NCT05313152|Experimental|TAVO103A High Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
9699634|NCT05313152|Placebo Comparator|Placebo|Placebo single ascending dose IV infusion.
10189003|NCT03711487|No Intervention|No intervention|No intervention.
9699635|NCT05313139||Unvaccinated participants|Participants who did received the rVSV-ZEBOV vaccine nor had any prior close contact with EBOV patients nor presenting a travel history to East DRC
9699636|NCT05313139||Primary vaccinated participants|Participants who received a first rVSV-ZEBOV vaccine dose as part of the WHO vaccination campaign organized in Goma region (end of 2021), of which vaccination date and brand is known
9699637|NCT05313139||Participants vaccinated < 1 year ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose less than a year prior to inclusion of which vaccination date and brand is known
9699638|NCT05313139||Participants vaccinated 1-2 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose between 1-2 years prior to inclusion of which vaccination date and brand is known
10189004|NCT03711474|Experimental|Treatment 1; Dexamethasone|"Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision."
9699639|NCT05313139||Participants vaccinated 2-3 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose between 2-3 years prior to inclusion of which vaccination date and brand is known
9699640|NCT05313139||Participants vaccinated > 3 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose > 3 years prior to inclusion of which vaccination date and brand is known
9699641|NCT05313126|Experimental|sterile male Aedes albopictus-exposed|Sterile male Aedes albopictus are released in the area.
9699642|NCT05313126|No Intervention|control|Sterile male Aedes albopictus are not released in the area.
9699643|NCT05313113|Experimental|Experimental group|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
9699644|NCT05313113|No Intervention|Control Group|The pregnant women continued to their routine prenatal care. No intervention was applied to the pregnant women in addition to their routine prenatal care.The pregnant women were called about whether continuing their routine care or having any problems during the research.
9699645|NCT05313087||Controls - who are NOT in any of the groups listed below|Adults and children age 5 and over.
9699646|NCT05313087||Previous COVID infection|Adults and children age 5 and over.
9699647|NCT05313087||Asthma receiving immunomodulator medications|Adults and children age 5 and over.
9699648|NCT05313087||Asthma receiving chronic oral steroids|Adults and children age 5 and over.
9699649|NCT05313087||Asthma - NOT receiving immunomodulator medications or chronic oral steroids|Adults and children age 5 and over.
9699650|NCT05313087||Chronic Obstructive Pulmonary Disease (COPD|Adults
9699651|NCT05313087||Rheumatoid Arthritis receiving immunomodulator medications|Adults and children age 5 and over.
9699652|NCT05313087||Rheumatoid Arthritis NOT receiving immunomodulator medications|Adults and children age 5 and over.
9699653|NCT05313087||Interstitial lung disease|Adults and children age 5 and over.
9699654|NCT05313087||Cancer patients receiving chemotherapy|Adults and children age 5 and over.
9699655|NCT05313087||Bronchiectasis|Adults and children age 5 and over.
9699656|NCT05313087||Cystic fibrosis|Adults and children age 5 and over.
9699657|NCT05313061|Active Comparator|MTX continue|Group will continue MTX after vaccination
9699658|NCT05313061|Experimental|MTX 1 week hold|Group will continue MTX for 1 week after vaccination
9699659|NCT05313022|Experimental|ZR-202-CoV|Adult healthy subjects (60 years of age above, inclusive) receive ZR-202-CoV at Day 0 and Day 28
9699660|NCT05313022|Placebo Comparator|Placebo|Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28
9699661|NCT05313009|Experimental|STAGE 1: SAFETY LEAD IN (n=6-18, depending on number of DLs explored)|SAFETY LEAD IN (n=6-18, depending on number of DLs explored) 3+3 design dependent on DLTs
9699662|NCT05313009|Experimental|STAGE 2: EFFICACY (n=12)|EFFICACY (n=12)
9699663|NCT05312996|Experimental|Hypertension|Hypertension test group.
9699664|NCT05312996|Other|Active Comparator|Non Hypertension compare group.
9699665|NCT05312983|Experimental|people over the age of 40 who agree to participate in the research.|They are either people who have a hearing loss about 20 years older than their age and wear a hearing aid (or come in for a hearing aid), or people with normal hearing for their age.
9699666|NCT05312970|Active Comparator|Varithena®|Varithena® (polidocanol injectable foam) 1%
9699667|NCT05312970|Active Comparator|FDA-approved ETA systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
9699668|NCT05312957|Active Comparator|Group ESP|The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected and When the block needle touched the transverse process,Then, 20 ml of 0.25% bupivacaine was administered to this area, and an ESP block was applied
9699669|NCT05312957|No Intervention|Group Control|Group Control: Tramadol HCL was administered from vein with a patient-controlled analgesia device after extubation.
9699670|NCT05312931||Group A|students who underwent original concept of First Aid
9699671|NCT05312931||Group B|student who underwent new concept of First Aid
9699672|NCT05312892|Placebo Comparator|Placebo|Subjects will received 2 weeks of capsules containing placebo.
10205419|NCT01555281|Experimental|Nelfinavir and Lenalidomide/Dexamethasone|"Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients~Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21"
9699673|NCT05312892|Active Comparator|Amlodipine|Subjects will received 2 weeks of capsules containing amlodipine.
9699674|NCT05312892|Experimental|Moxonidine|Subjects will received 2 weeks of capsules containing moxonidine.
9977928|NCT01366651|Experimental|Doripenem|Doripenem Type=exact number unit=mg/kg number=10 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.,Doripenem Type=exact number unit=mg/kg number=30 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age. Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.
9699679|NCT05312866|Sham Comparator|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
9699680|NCT05312866|Active Comparator|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
9699681|NCT05312840|Other|Routine dose group|Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2, Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
9699682|NCT05312840|Other|Low dose group|Low dose group: Every three weeks as a cycle. Gemcitabine 750mg / m2, Cisplatin 56mg / m2 or Carboplatin auc3 were injected intravenously on the first day of each cycle 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously. After 4 or 6 cycles of treatment, if there is no disease progression, continue to use Cindilimab 200mg every three weeks until the disease progresses.
9699683|NCT05312827|Experimental|Telehealth|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
9699684|NCT05312801|Experimental|LMY-920 dose escalation|Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
9699685|NCT05312788|Placebo Comparator|Whole wheat bread|Whole wheat bread will be used as control bread.
9699686|NCT05312788|Experimental|Barley supplemented wheat bread|Barley supplemented wheat bread (50% substitution) will be used as experimental bread.
9699687|NCT05312775|Active Comparator|Single-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
9699688|NCT05312775|Active Comparator|Double-layer uterine closure|Women will undergo a CD following a standard way with respect to the mode of hysterotomy, non-closure of the peritoneum. In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
9977929|NCT01366664|Experimental|001|Treatment sequence 1 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days)
10205420|NCT01502085|Experimental|Vorinostat, Lenalinomide, Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
9699691|NCT05306275|Experimental|CSL312 AI Abdomen|CSL312 administered subcutaneously (SC) in the abdomen via a prefilled syringe assembled to an autoinjector (AI)
9699692|NCT05306275|Experimental|CSL312 AI Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to an AI
9699693|NCT05306275|Experimental|CSL312 AI Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to an AI
9699694|NCT05306275|Experimental|CSL312 NSD Abdomen|CSL312 administered SC in the abdomen via a prefilled syringe assembled to a needle safety device (NSD)
9699695|NCT05306275|Experimental|CSL312 NSD Thigh|CSL312 administered SC in the thigh via a prefilled syringe assembled to a NSD
9699696|NCT05306275|Experimental|CSL312 NSD Arm|CSL312 administered SC in the upper arm via a prefilled syringe assembled to a NSD
9699697|NCT05296785|Other|Participants|patients undergoes intramedullary nail with Limb Reconstruction System
9699698|NCT05296759|Active Comparator|botulinum toxin A injection|botulinum toxin A injection
9699699|NCT05296759|Active Comparator|gabapentin|gabapentin
9699700|NCT05296759|Active Comparator|duloxetine|duloxetine
9699701|NCT05296694||Coronary Care Patients|All patients admitted to coronary care unit with cardiovascular diseases.
9699702|NCT05296668|Experimental|Cuffed ETT group|(group C) to receive a cuffed ETT for airway management.
9699703|NCT05296668|Active Comparator|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
9699704|NCT05296096|Active Comparator|Standard protein and exercise|All enrolled patients randomized to this arm will receive a baseline nutrition and nurse-driven mobility pathway and other evidence-based bundled strategies as standard of care.
9699705|NCT05296096|Experimental|High protein plus exercise|"High protein nutrition: To achieve the prescribed age-appropriate high protein target, dietitians will use EN preferentially, or if EN is contraindicated, PN may be used. High-protein EN formulas and/or protein supplements (powder or liquid) will be added to formula/breast milk feedings or administered separately in divided bolus doses. Dietitians routinely employ and customize these solutions in their scope of practice. When EN is insufficient to meet protein targets, PN may be prescribed to make up the deficit on or after the end of PICU day 3. Energy and protein delivery adequacy (% of prescribed goal) will be monitored daily by the study team.~Patients in this arm will also be prescribed the age-appropriate highest-level of mobility by the rehabilitation team with a goal of 30 minutes duration, twice daily."
9699706|NCT05295589|Active Comparator|Arm I (standard of care chemotherapy)|Patients receive either paclitaxel IV over 60 minutes on days 1, 8, 15, and 22, OR pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, OR topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9699707|NCT05295589|Experimental|Arm II (copanlisib, olaparib)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9699708|NCT05295511|Experimental|Team Handball 1|Team handball group participants were instructed to perform one weekly 60-min recreational team handball training sessions for 16 weeks.
9699709|NCT05295511|Experimental|Team Handball 2|Team handball group participants were instructed to perform two weekly 60-min recreational team handball training sessions for 16 weeks.
9699710|NCT05295511|Experimental|Team Handball 3|Team handball group participants were instructed to perform three weekly 60-min recreational team handball training sessions for 16 weeks.
9699711|NCT05295511|No Intervention|Control Group|The control group participants were instructed to keep their regular daily physical activity for 16 weeks.
9699712|NCT05295420|Experimental|platelet-rich plasma|to assess the role of platelet-rich plasma in the treatment of SUI as a non-invasive method
9699713|NCT05294081|Experimental|Exposure (EXP)|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
9778519|NCT01108094|Experimental|Cohort A - Itraconazole 400 mg|Oral itraconazole 400 mg as 200 mg twice daily, for 1 month, stratified by prior vismodegib history
9778520|NCT01108094|Experimental|Cohort B - Itraconazole 200 mg|Oral itraconazole 200 mg as 100 mg twice daily, for up to 3 months
9699714|NCT05294081|Active Comparator|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
9699715|NCT05294068||All subjects with cognitive impairments|
9699716|NCT05294068||All subjects with neuromotor impairments|
9699717|NCT05294068||All subjects with sensory impairments|
9699718|NCT05294029||All subjects with neuromotor disability|
9699719|NCT05294016|Other|Patient group|
9699720|NCT05294016|Other|Control group|
9699721|NCT05293418||ICU mechanically ventilated COVID-19 patients|Patients admitted to Milano Fiera ICU for COVID-19 requiring mechanical ventilation from October 2020 through May 2021
9699722|NCT05293340|Experimental|Hispanic/Latino adults with or at risk of T2D- Active Group|Eligible participants receive vouchers for free avocados.
9699723|NCT05293340|No Intervention|Hispanic/Latino adults with or at risk of T2D- Control Group|Eligible participants will not receive vouchers for free avocados.
10189005|NCT03711474|Placebo Comparator|Treatment 0; Placebo|"Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision."
10189006|NCT03711461|Active Comparator|nonintubated|patients received nonintubated during thoracoscopy
10189007|NCT03711461|Experimental|intubated|patients receiving intubated during thoracoscopy
9699724|NCT05292976|Placebo Comparator|Zero dose:|
9699725|NCT05292976|Active Comparator|Reference 0.09 mg|
9699726|NCT05292976|Active Comparator|Reference 0.18 mg|
10189008|NCT03711435||control group|15 subjects was enrolled in the control group，they are healthy controls
9699727|NCT05292976|Experimental|Test 0.09 mg|
9699728|NCT05292976|Experimental|Test 0.18 mg|
9699729|NCT05292261|Experimental|Team handball group|The team handball group participants were encouraged to performed at least two out of three weekly supervised team handball training sessions of 60 min each, for 36 weeks.
9699730|NCT05292261|No Intervention|Control group|The control group participants were instructed to keep their regular daily physical activity for 36 weeks.
10189009|NCT03711435||training IPF group|30 subjects was enrolled in the training IPF group，they are IPF patients，the group is designed to identify differential metabolites between IPF and control groups.
10189010|NCT03711435||Validation group|15 subjects was enrolled in the Validation IPF group，they are IPF patients，the group is designed to validate differential metabolites identified in the previous groups.
10189011|NCT03711422|Experimental|Part A|Standard dose oral afatinib. If patients in Part A do not benefit from the regimen, they can be enrolled into Part B
10189012|NCT03711422|Experimental|Part B|Intermittent high dose oral afatinib
9699731|NCT05292222|Experimental|Intermittent theta burst stimulation|All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 10-12 weeks.
9699732|NCT05291767|Experimental|Diet: high fat meal|Participants will consume either a high fat or a high carbohydrate meal.
9699733|NCT05291767|Experimental|Exercise: medium intensity exercise|After consuming the meal, participants will either exercise at moderate intensity for 30 minutes or rest.
9699734|NCT05291637||Medical management cohort|Patients who have undergone medical management stroke treatment from 1/01/2003 to 01/01/2022; this could include intravenous thrombolysis.
9699735|NCT05291637||EVT management cohort|Patients who have undergone EVT stroke treatment from 01/01/2015 to 01/01/2022
9699736|NCT05291598|Active Comparator|Ketorolac group|Participants will receive the institution specific joint replacement pain protocol.
9699737|NCT05291598|Experimental|IV meloxicam group|Participants will be given IV meloxicam for pain management post total knee and hip arthroplasty.
9699738|NCT05290844|Other|Pediatric cricoid force|one arm 135 pediatric patients
9699739|NCT05290350||OSA Cohort|Patients With post COVID-19 condition and OSA
9699740|NCT05290350||Control Cohort|Patients With post COVID-19 condition without OSA
9699741|NCT05288751|No Intervention|Treatment as usual (TAU)|These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months.
9699742|NCT05288751|Experimental|Attendance-only CM|Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments.
9699743|NCT05288751|Experimental|Attendance + abstinence CM|Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program.
9699744|NCT05288348|Experimental|DSUVIA (sufentanil)|Subjects will receive a single dose of 30 micrograms DSUVIA (sufentanil) tablet utilizing a sublingual applicator
9699745|NCT05288348|Active Comparator|Standard Care|Subjects will receive standard care pain management
9699746|NCT05286554|Experimental|Group 1|Will receive routine LPS and additional single GnRH-a bolus, triptorelin 0.1 mg subcutaneous injection on the 6th day after oocyte retrieval.
9699747|NCT05286554|Experimental|Group 2|Will receive routine LPS and additional multiple mid-luteal GnRH-a, triptorelin 0.1 mg subcutaneous injection on the 5th, 7th and 9th days after oocyte retrieval.
9699748|NCT05286554|Active Comparator|Group 3 (Control)|Will receive the routine LPS without GnRH-a
9699749|NCT05286190|Active Comparator|Transversus Abdominis Plane Block|US-guided Transversus Abdominis Plane Block was applied with 0.5 ml/kg of %25 Bupivacaine at each side before the surgical incision
9699750|NCT05286190|Active Comparator|Caudal Epidural Block|US-guided Caudal Block was applied with 0.7ml/kg of %25 Bupivacaine before the surgical incision
9699751|NCT05285475|Experimental|Group A|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
9699752|NCT05285475|No Intervention|Group B|The participants in this group will be asked neither to do any exercise nor to change their daily basis routine.
9699753|NCT05283915|Experimental|Mild hepatic impairment group|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
9699754|NCT05283915|Experimental|Normal hepatic function group|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
9699755|NCT05283863|Experimental|high-frequency stimulation|Patients will randomly be assigned to receive sub-threshold high-frequency spinal cord stimulation for 2 weeks.
9699756|NCT05283863|Sham Comparator|placebo stimulation|Patients will randomly be assigned to receive sham spinal cord stimulation for 2 weeks.
9699757|NCT05283863|Active Comparator|conventional spinal cord stimulation|Patients will receive conventional spinal cord stimulation for 2 weeks prior to both the high-frequency or sham stimulation.
9699758|NCT05282017||Case Group|Meets the COVID-19 like case definition AND Tests positive for at least one SARS-CoV-2 RT-PCR test or Quick-Test (Antigen) with specimens collected between 14 days prior to and including within 24 hours of the day of hospital admission (day 0).
9699759|NCT05282017||Control Group|Meets the COVID-19 case definition AND Tests negative for all SARS-CoV-2 RT-PCR or Quick-Test (Antigen) tests with specimens collected between 14 days prior to and including a negative test the day at hospital admission (day 0).
9699760|NCT05278598|Active Comparator|ESPB group|Erector Spinae Plane Block
9699761|NCT05278598|Active Comparator|TPVPB group|Thoracic Paravertebral Plane Block
9699762|NCT05278598|Active Comparator|QLPB group|Quadratus Lumborum Plane Block
9699763|NCT05278520||OA cases|Twenty-five adult patients who have hip osteoarthritis.
9699764|NCT05278520||RA cases|Twenty-five adult patients who have rheumatoid arthritis in the hip joint.
9699765|NCT05278520||Non-arthritic controls|Fifteen adult patients who go through trauma-based emergency total hip arthroplasty and do not have arthritis.
9699766|NCT05278104|Experimental|Atomoxetine|
9699767|NCT05278104|Placebo Comparator|Placebo|
9699768|NCT05277727|Experimental|Fucoidan|"Fucoidan in Capsule~Intervention: Dietary Supplement: Probiotic"
9699769|NCT05277727|Placebo Comparator|Placebo|"Non active ingredients in a capsule~Intervention: Other: Placebo"
9699770|NCT05276973|Experimental|Treatment (paclitaxel, carboplatin, ipatasertib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ipatasertib PO QD until 24 hours before surgery in the absence of disease progression or unacceptable toxicity.
9699771|NCT05275907|Active Comparator|A first, then B|6 weeks of drug A followed by a 2-week washout period completed with 6 weeks of drug B
9699772|NCT05275907|Active Comparator|B first, then A|6 weeks of drug B followed by a 2-week washout period completed with 6 weeks of drug A
9699773|NCT05275790|Experimental|Vestal active device|10 subjects to receive an active device plus a diet plan for 12 weeks.
9699774|NCT05275530|No Intervention|Standard of Care|"No Intervention-Standard Care~UCLA Health has a mailed FIT outreach program. This group will receive standard FIT mailer protocol. They will receive a tailored MyChart message indicating the importance of CRC screening and not be presented with a choice for screening modalities."
9699775|NCT05275530|Experimental|FIT Choice|This group will receive a tailored message via MyChart with information about CRC screening and using the FIT kit for noninvasive screening. They will then have to actively choose if they want CRC screening with a FIT kit vs no screening. If they opt for screening, the investigators will mail them a FIT kit.
9699776|NCT05275530|Experimental|Colonoscopy Choice|This group will receive a tailored message via MyChart with information about CRC screening and colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a colonoscopy vs no screening. If they opt for screening, the investigators will direct them to our patient navigators to get scheduled for a colonoscopy.
9699777|NCT05275530|Experimental|Dual Choice|This group will receive a tailored message via MyChart with information about CRC screening and using either the FIT kit or colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a FIT kit, a colonoscopy, or no screening. If they opt for screening, the investigators will either mail them a FIT kit or direct them to our patient navigators to schedule a colonoscopy, depending on their choice.
9699778|NCT05273697|Active Comparator|Underwater cold snare polypectomy group|Cold snare polypectomy after complete immersion of the polyp in the water
9699779|NCT05273697|Active Comparator|Conventional cold snare polypectomy group|Cold snare polypectomy in colon lumen dilated with air
9778521|NCT01108094|No Intervention|Untreated Control|Patients otherwise eligible but unwilling to take itraconazole were enrolled onto the control arm of the study and received no treatment
9778522|NCT01108185||Acute Respiratory Infections|Slovak patients with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
9699780|NCT05272384|Experimental|Treatment (nivolumab, decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3 or 1-5 and nivolumab IV over 30 minutes on day 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
9699781|NCT05271643|Experimental|CF-CBT-A intervention|Participants will meet with a therapist, a mental health provider on their cystic fibrosis care team who has received training in CF-CBT-A, for a baseline interview and introduction plus 9 weekly sessions of CF-CBT-A.
9699782|NCT05271292|Experimental|Study arm (35 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
9699783|NCT05271292|Experimental|Study arm (50 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally
9699784|NCT05271292|Experimental|Study arm (65 mg)|Phase 1b: Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35, 50, and 65 mg, orally)
9699785|NCT05270993|Active Comparator|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
9699786|NCT05270993|Experimental|I-CREST group|A 6-week home-based remote supervision cardiac rehabilitation programme with an I-CREST application and smartwatch. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
9699787|NCT05270668|Experimental|PRA023|PRA023 IV administered by IV infusion
9699788|NCT05270668|Placebo Comparator|Placebo|Placebo administered by IV infusion
9699789|NCT05269537||Study Group|Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.
9699790|NCT05268744|Experimental|Micronutrient|In this open-label trial, all subjects will receive the daily dose of micronutrient, in the form of one lightning stick per day, which contains 2.9 grams of micronutrients per stick. It will be delivered in a powder form taken sublingually.
9699791|NCT05267639|No Intervention|Comparator Baseline|The subject will wear their usual Microprocessor Knee (MPK) for 3 months, as well as in the lab to complete outcome measures.
9699792|NCT05267639|Experimental|Power Knee|The subject will wear the Ossur PK in place of their usual MPK for 3 months, as well as in the lab to complete outcome measures.
9699793|NCT05266404|Experimental|Treatment A (Test Formulation): Dapagliflozin/Sitagliptin FDC tablet|Subjects will receive single dose of dapagliflozin/sitagliptin fixed dose combination (FDC) (test formulation).
9699794|NCT05266404|Active Comparator|Treatment B (Reference Formulation): Dapagliflozin+Sitagliptin|Subjects will receive single dose of dapagliflozin 10 mg tablet + sitagliptin 100 mg tablet co-administered as individual tablets (reference formulation).
9699795|NCT05263895|Active Comparator|Treatment A: PF-0732133/ritonavir|PF-07321332 ritonavir
9699796|NCT05263895|Experimental|Treatment B: PF-07321332/ritonavir|PF-07321332 ritonavir
9699797|NCT05263895|Experimental|Treatment C: PF-07321332/ritonavir|PF-07321332 ritonavir
9699798|NCT05263895|Experimental|Treatment D: PF-07321332/ritonavir|PF-07321332 ritonavir
9699799|NCT05263895|Experimental|Treatment E: PF-07321332|PF-07321332
9699800|NCT05263596|Other|No Sarcopenia (Control Group)|healthy participants
9699801|NCT05263596|Other|Sarcopenia is probable|"Low muscle strength (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
9699802|NCT05263596|Other|Sarcopenia is confirmed|"Low muscle strength + low muscle quantity (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
9699803|NCT05263401|Experimental|Ketone salt|Na-D/L-3-hydroxybutyrate dissolved in tap water.
9699804|NCT05263401|Experimental|Ketone ester|(R)-3-Hydroxybutyl (R)-3-hydroxybutyrate
9699805|NCT05263401|Placebo Comparator|Placebo|Tap water
9699806|NCT05259722|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for up to 24 weeks
9699807|NCT05259722|Active Comparator|Alitretinoin capsules 30 mg per capsule|1 capsule per day for up to 24 weeks
9699808|NCT05257174|Experimental|Jing Si Herbal Tea LIQUID PACKETS|one packet oral twice daily for three months
9699809|NCT05257174|Placebo Comparator|Placebo|one packet oral twice daily for three months
9699810|NCT05252741|Active Comparator|Group 1: patients with psoriasis|
9699811|NCT05252741|Placebo Comparator|Group 2: age-, sex-, BMI-, and weight-matched control subjects.|
9699812|NCT05250830|Experimental|TrueRelief device|Patients receive an experimental procedure using a TrueRelief device.
9699813|NCT05250830|Sham Comparator|Sham TrueRelief device|Patients receive a placebo procedure using a sham TrueRelief device that looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
9699814|NCT05250570|Experimental|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.
9699815|NCT05250570|Active Comparator|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training.
9699816|NCT05248464||Rheumatic diseases patients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences
9699817|NCT05245474|Experimental|CRT+concurrent PD-1 inhibition (Experiment Arm 1)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 8 of radiation therapy. TME surgery is scheduled in 8~12 weeks after completion of radiation.
9778523|NCT01108237|Other|TruMatch™ Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch™ Personalized Solutions
10189013|NCT03711409|Experimental|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of the muscles around the shoulder. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
9699818|NCT05245474|Experimental|CRT+sequential PD-1 inhibition (Experiment Arm 2)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 15 after completion of radiation therapy. TME surgery is scheduled in 8~12 weeks after completion of radiation.
10189014|NCT03711409|Experimental|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
10189015|NCT03711383|Placebo Comparator|Placebo|isocaloric maltodextrin the day before CIDs
10189016|NCT03711383|Active Comparator|Inulin|12 g of inulin + isocaloric maltodextrin the day before CID
9699819|NCT05245474|Active Comparator|CRT without PD-1 inhibition (Control Arm)|Long-course chemoradiation plus PD-1 inhibition with no PD-1 inhibition. TME surgery is scheduled in 8~12 weeks after completion of radiation.
9699820|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of modified release evobrutinib tablet-1 (MR-T1) on Day 1 in treatment period 1, followed by single oral dose of modified release tablet-2 (MR-T2) on Day 1 in treatment period 2, followed by two single oral doses of immediate release (IR) oral tablet [Ref (TF2)] on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or multiparticulate system capsules (MUPS-C) formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9699821|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MR-T1 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
10189017|NCT03711383|Experimental|Inulin and Resistant Starch|12 g inulin + 7.5 g resistant starch the day before CID
10189018|NCT03711370|Experimental|Opaque Bottle Group|This group will be given a set of opaque bottles that are to be used during infant feedings for a full 12-week period.
10189019|NCT03711370|Active Comparator|Clear Bottle Group|This group will be given a set of clear bottles that are to be used during infant feedings for a full 12-week period.
10189020|NCT03711357|Active Comparator|laser|980 nm diode laser (maximum output of 3 watts and coupled with a fiber optic tip of 200 µm diameter) will be used for four irradiations, of 5 seconds each, after chemo-mechanical preparation procedures.
10189021|NCT03711357|Placebo Comparator|Placebo|After chemo-mechanical preparation procedures, the diode laser fiber optic tip will be inserted inside the root canals but not activated.
9699822|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 3|Participants will receive two single oral doses of Ref (TF2) on Day 1 in treatment period 1, followed by single oral dose of MR-T1 on Day 1 in treatment period 2, followed by single oral dose of MR-T2 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9778524|NCT01108237|Other|Historical Control|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional and CAS surgical techniques without TruMatch™ instrumentation.
9778525|NCT01108263|Active Comparator|Integra Flowable on wound bed|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
9778526|NCT01108263|Active Comparator|INTEGRA Flowable on wound & injected subcutaneously|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
10189022|NCT03711344|Experimental|Culturally adapted Cognitive Behavioral therapy|The experimental group will receive the culturally adapted version of cognitive behavioral therapy.
10189023|NCT03711344|Active Comparator|Non-adapted Cognitive Behavioral therapy|The control group will receive the original (non-adapted) version of cognitive behavioral therapy.
10189024|NCT03711331|Experimental|FilmArray® Pneumonia panel plus strategy|patients benefiting from the new strategy based on the system Unyvero ®
10189025|NCT03711331|Sham Comparator|Standard care|patients benefiting from usual standard care
10189026|NCT03711292|Experimental|Stepped Wedge Cluster Randomized|Antibiotic stewardship intervention
10189027|NCT03711279|Experimental|SHR-1210 plus Apatinib|
10189028|NCT03711279|Active Comparator|ADM Plus IFO or IFO Alone|
10189029|NCT03711253|Other|Biktarvy|All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study
10189030|NCT03711240|Experimental|bevacizumab+mFOLFOXIRI|
10189031|NCT03711227||Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level. These patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the Emergency Department and while an inpatient. Then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qSOFA score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.
9699823|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 4|Participants will receive single oral dose of modified release evobrutinib tablet-3 (MR-T3) on Day 1 in treatment period 1, followed by single oral dose of modified release tablet-4 (MR-T4) on Day 1 in treatment period 2, followed by two single oral doses of immediate release (IR) oral tablet [Ref (TF2)] on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or multiparticulate system capsules (MUPS-C) formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
10189032|NCT03711201|Active Comparator|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
9699824|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 5|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MR-T3 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9699825|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 6|Participants will receive two single oral doses of Ref (TF2) on Day 1 in treatment period 1, followed by single oral dose of MR-T3 on Day 1 in treatment period 2, followed by single oral dose of MR-T4 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
10189033|NCT03711201|No Intervention|Group NoIORE|The patient's hemodynamic data will be measured in the evening service before surgery. The patient will be brought to the operating room by the anesthesiologist on the day of surgery and hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured in the preop unit. The hemodynamic data and the ST-STAI scale will measure the anxiety level in the operating room.
9699826|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of MUPS-C1 evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C2 on Day 1 in treatment period 2, followed by two single oral doses of Ref (TF2) on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9699827|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 2|Participants will receive single oral dose of MUPS-C2 evobrutinib on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MUPS-C2 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9699828|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 3|Participants will receive two single oral doses of Ref (TF2) evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C1 on Day 1 in treatment period 2, followed by single oral dose of MUPS-C2 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9699829|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 4|Participants will receive single oral dose of MUPS-C3 evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C4 on Day 1 in treatment period 2, followed by two single oral doses of Ref (TF2) on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9699830|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 5|Participants will receive single oral dose of MUPS-C4 evobrutinib on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MUPS-C3 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9836116|NCT02769624|Experimental|Treprostinil|A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
10189034|NCT03711162|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
9699831|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 6|Participants will receive two single oral doses of Ref (TF2) evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C3 on Day 1 in treatment period 2, followed by single oral dose of MUPS-C4 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
9699832|NCT05243628|Experimental|Afrezza + Automatic Insulin Delivery|Subjects in this group will use Afrezza for their bolus (mealtime) insulin and a CSII pump with an AID algorithm using RAA for their basal and correction insulin coverage.
10189035|NCT03711162|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
10189036|NCT03711162|Placebo Comparator|Placebo|Placebo to match will be administered as film-coated tablets for oral use once daily.
10189037|NCT03711149|Experimental|Intervention Arm|Intervention: Activity monitor feedback loop: (1) Subjects will receive activity monitor with feedback on daily step count from the in-room TV screen, and (2) access to the Art Tour application
9699833|NCT05243628|Experimental|Afrezza + Insulin Degludec|Subjects in this group will use Afrezza for their bolus (mealtime and correction) insulin and insulin degludec for basal insulin coverage.
9699834|NCT05243628|Active Comparator|AID Control|Subjects in this group will use a CSII pump with an AID algorithm using RAA for all bolus (mealtime and correction) and basal insulin coverage (control group).
9699835|NCT05240898|Experimental|KSQ-4279 Monotherapy and KSQ-4279 + Combination (Dose Escalation and Expansion)|KSQ-4279 will be administered orally once daily (QD) continuously as monotherapy. Once the maximum tolerated dose (MTD) for KSQ-4279 monotherapy has been reached, KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor). These cohorts will be enrolled in parallel.
9699836|NCT05240807|Experimental|Clinical Coronary CTA Cohort|Subjects scheduled for a clinically indicated coronary CTA will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT
9699837|NCT05240807|Experimental|Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort|Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test will receive a research contrast-enhanced coronary CT angiogram using photon-counting CT at rest and after administration of a cardiac stress agent
9699838|NCT05239195|Active Comparator|Video Laryngoscope Group|For patients assigned to the video laryngoscope group, the operator will use a video laryngoscope on the first laryngoscopy attempt. A video laryngoscope will be defined as a laryngoscope with a camera and a video screen. Trial protocol will not dictate the brand of video laryngoscope.
9699839|NCT05239195|Active Comparator|Direct Laryngoscope Group|For patients assigned to the direct laryngoscope group, the operator will use a direct laryngoscope on the first laryngoscopy attempt. A direct laryngoscope will be defined as a laryngoscope without a camera or a video screen. Trial protocol will not dictate the brand of direct laryngoscope or the blade shape.
9699840|NCT05239013|Experimental|Treatment Group|Subjects who receive the intervention
10189038|NCT03711149|No Intervention|Standard-of-care Arm|"Subjects in the control arm will receive a blinded activity monitor post-op (without feedback on step count) and the usual standard of care. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods of observation."
10189039|NCT03711136||Frozen elephant trunk surgery|
10189040|NCT03711136||Standart surgery|
10189041|NCT03711123|Experimental|Group metacognitive therapy (GMCT)|10 weekly sessions of GMCT With 90 minutes duration
9699841|NCT05238285||Healthy adult population aged 18 to 80 years|Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.
9699842|NCT05236803|Other|Epidemiology|Recording of participant's performance during eye, fine motor and gross motor tests Passing self and hetero questionnaires.
10189042|NCT03711123|Active Comparator|Clinical Management|10 weekly individual sessions with up to 60 minutes duration
10189043|NCT03711110|Experimental|Primary prevention strategy|Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.
10189044|NCT03711110|Other|Secondary prevention strategy (control)|Current clinical practice: cardiac care is based on the onco-hematologist criteria.
9699843|NCT05236270|No Intervention|Condition 1|Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
9699844|NCT05236270|Experimental|Condition 2|Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
9699845|NCT05236270|Experimental|Condition 3|Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
9699846|NCT05236270|Experimental|Condition 4|Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
10189045|NCT03711097|No Intervention|Control|Upper left or right central and lateral incisor
10189046|NCT03711097|Experimental|Varnish Intervention|Upper central and lateral incisor contralateral to control upper central and lateral incisor
10189047|NCT03711084|Placebo Comparator|Water|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
10189048|NCT03711084|Experimental|Natural high potency sweetener from leaf extract|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
10189049|NCT03711084|Experimental|Glucose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
9699847|NCT05236270|Experimental|Condition 5|Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
9699848|NCT05236270|Experimental|Condition 6|Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
9699849|NCT05236270|Experimental|Condition 7|Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
9699850|NCT05236270|Experimental|Condition 8|Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
9977930|NCT01366664|Experimental|002|Treatment sequence 2 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
9977931|NCT01366677|Experimental|Yoga Therapy|
9699853|NCT05235750|Experimental|Writing|This is a single-group study with one arm only.
9699854|NCT05235061|Experimental|PTE Participant Group 1|"PTE Participant Group 1 will receive the HOBSCOTCH-PTE intervention consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam)~1 educational session (on webcam)~6 telephone sessions~1 wrap-up session (webcam or telephone)"
10189050|NCT03711084|Experimental|Sucrose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
9699855|NCT05235061|Other|PTE Participant Group 2|"PTE Participant Group 2 will be on a 3-month wait list after which they will receive HOBSCOTCH-PTE consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam)~1 educational session (on webcam)~6 telephone sessions~1 wrap-up session (webcam or telephone)"
9699856|NCT05235061|Experimental|PTE Caregiver Group 1|Caregiver Group 1 will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 1 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
9699857|NCT05235061|Other|PTE Caregiver Group 2|Caregiver Group 2 will be on a 3 month wait list with their PTE patient after which time they will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 2 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
9699858|NCT05231057|Experimental|experimental group|Patients in the study group received Pilates exercises plus conventional physical therapy program
9699859|NCT05231057|Experimental|control group|Patients in the control group received conventional physical therapy
9699860|NCT05230498|Active Comparator|Cochlear Implant (CI) with default fitting then anatomy-based fitting|Cochlear Implant with default fitting first during 6 weeks then with anatomy-based fitting during 6 weeks
9699861|NCT05230498|Active Comparator|Cochlear Implant (CI) with anatomy-based fitting then default fitting|Cochlear Implant with anatomy-based fitting during 6 weeks then with default fitting during 6 weeks
9699862|NCT05230082|Experimental|Immediate Start|Patients will receive acupuncture treatment two times per week for 12 weeks.
9699863|NCT05230082|Active Comparator|Delayed start|Patients will act as control group for the first 12 weeks then will receive acupuncture treatment two times per week for 12 weeks.
9977932|NCT01366690|Experimental|Peer Support|Peer supporter assigned to participant.
9699865|NCT05228912||BNT162b2 mRNA|Group of patients of any age, any sex, that will receive a complete scheme of approved BNT162b2 mRNA vaccination , assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
9699866|NCT05228912||mRNA-1273|Group of patients of any age, any sex, that will receive a complete scheme of approved mRNA-1273 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
9699867|NCT05228912||ChAdOx1-S|Group of patients of any age, any sex, that will receive a complete scheme of approved ChAdOx1-S vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
9699868|NCT05228912||Ad26.COV2|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad26.COV2 vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
9699869|NCT05228912||Ad5-nCoV|Group of patients of any age, any sex, that will receive a complete scheme of approved Ad5-nCoV vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
9699870|NCT05228912||Gam-COVID-Vac|Group of patients of any age, any sex, that will receive a complete scheme of approved Gam-COVID-Vac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
9699871|NCT05228912||Coronavac|Group of patients of any age, any sex, that will receive a complete scheme of approved Coronavac vaccination, assigned by a local government vaccination campaign. It can also include patients that receive a third or fourth boost.
9699872|NCT05223153||Amblyopic eye group|
9699873|NCT05223153||Sound eye group|
9977933|NCT01366690|No Intervention|Standard of Care|No peer assigned. Current standard of care.
10189051|NCT03711084|Experimental|Maltodextrin|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
10189052|NCT03711071|Experimental|Intervention Group|The Intervention Group is allocated to a Workshop of communication training before data collection covering theoretical background and clinical implementation of ICE communication in association with frequent consultation contents.
10189053|NCT03711071|No Intervention|Control Group|This group will not get the intervention before data collection.
9699874|NCT05222555|Experimental|Treatment (Tafasitamab + Lenalidomide)|"Treatment:~Tafasitamab will be combined with lenalidomide in R/R DLBCL patients.~Dose:~Cohort 1: The dose of tafasitamab will be level 1 high dose in combination with the approved dose~Cohort 2: The dose of tafasitamab will be level 2 high dose in combination with the approved dose~Expansion Cohort: The dose of tafasitamab will be the dose that is deemed safe and tolerable as determined from cohort 1 & cohort 2~Treatment consisting of tafasitamab and lenalidomide combination will be administered until disease progression, unacceptable toxicity, or discontinuation for any other reason, whichever comes first. Lenalidomide can be given for up to 12 cycles in total, after which patients can continue with tafasitamab as monotherapy until progression or unacceptable toxicity."
10189054|NCT03711045||Suicide Risk Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) also have a history of suicide attempt in the past 6 months.
10189055|NCT03711045||Disorder Control Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) and without suicide ideation or behavior.
10189056|NCT03711045||Healthy Control Group|
10189057|NCT03711006|Experimental|FMT treated patients|Seven patients with active Ulcerative Colitis treated with 25 multi-donor FMT Capsules daily.
10189058|NCT03710980||Healthy Adult Volunteer|
10189059|NCT03710967|Experimental|Bilateral TMS|
10189060|NCT03710967|Active Comparator|Unilateral TMS|
9699875|NCT05222516|Experimental|OM-85|Daily administration of OM-85 (Broncho-Vaxom) 3.5 mg capsules
9699876|NCT05222516|Placebo Comparator|Placebo|Daily administration of Placebo capsules
9699877|NCT05221151|Active Comparator|melatonin|26 patients will receive melatonin 10 mg
9699878|NCT05221151|Active Comparator|pregabalin|26 patients will receive gabapentin 600 mg
9699879|NCT05221151|Active Comparator|melatonin and pregabalin|26 patients will receive melatonin 5 mg plus gabapentin 300 mg
9699880|NCT05220956|Other|Intermittent fasting|This arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks.
9699881|NCT05220956|Other|DGE diet|This control arm is not a subject to any time restrictions concerning eating, solely patients will be trained according to the 10 rules of healthy nutrition of the DGE.
9699882|NCT05220735|Experimental|Experimental|Participants will receive three fish oil capsules daily for 14 weeks, and fractional iron absorption from test meals provided without and with ascorbic acid will be determined at baseline and endpoint.
9699883|NCT05220605|Experimental|Bromac (100ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (100micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
9699884|NCT05220605|Experimental|Bromac (150ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (150micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
9699885|NCT05220605|Experimental|Bromac (200ug/20mg)|"The nurse/investigator will fill the jet nebuliser canister supplied on the ward with the 5ml of BromAc (200 micrograms bromelain and 20mg acetylcysteine). The cannister will be collected to the mask and attached to the wall compressed air supply, with flow of between 6-8L per minute. The mask will be placed on the participant immediately upon generating aerosol. The nebulisation will continue until the chamber is empty, estimated 15 minutes, unless otherwise indicated, such as adverse event.~The nurse/investigator will undertake clinical observations including heart rate, respiratory rate, SpO2 and blood pressure, every 5 minutes during nebulisation and then at 30 minutes, 1 hour and 2 hours. Cardiorespiratory auscultation will occur at the end of nebulisation and prior to discharge.~This will be repeated once daily for three consecutive days.~Blood tests will be taken before the first dose is given on day 1, and two hours after the last dose is given on day 3."
9699886|NCT05220514||Non-COVID-19 Diagnosis Control Group|Subjects hospitalized and receiving intensive care for diagnosis of an acute neurological disease other than COVID-19
10189061|NCT03710954|Experimental|Experimental Group|All the volunteers were evaluated through numerical evaluation of pain that assumes a subjective condition, the researcher showed the numerical scale of pain, being 0 without pain, 1 to 4 mild pain, 5 moderate pain, 6 to 9 severe pain and 10 worse pain possible pain, which was interpreted by the volunteer. In the Fuzzy Pain Scale, the evaluation of the range of motion was done where the evaluator used the goniometer (plastic instrument that verifies the angulation of the joint movement) and supplied the Fuzzy system with these data.
10189062|NCT03710941|Experimental|REGN2477+REGN1033|Single, sequential, repeat-dose IV or matching placebo
10189063|NCT03710941|Experimental|Placebo|Single, sequential, repeat-dose IV
10189064|NCT03710902|Experimental|Intervention|
10189065|NCT03710902|No Intervention|Control|Standard diagnostic work-up, follow-up, and treatment of hypertension.
10189066|NCT03710863|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
10189067|NCT03710837|Experimental|Pain neuroscience education|Intervention: Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
9699887|NCT05220514||COVID-19 Diagnosis Case Group|Subjects previously hospitalized at Mayo Clinic Hospital for treatment of PCR test confirmed COVID-19
10189068|NCT03710837|Experimental|Red flag education|Intervention: Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
10189069|NCT03710811||Type 2 Diabetes|drug naive Type 2 Diabetes received insulin therapy
10189070|NCT03710811||normal control|healthy volunteers as normal control
10189071|NCT03710798|Experimental|Low carbohydrate high fat diet|Low carbohydrate high fat (LCHF) diet
10189072|NCT03710759|Experimental|Assistive Autogenic Drainage|Autogenic drainage (AD) is a breathing technique that uses controlled breathing and least amount of coughing to clear secretions from your chest. It involves you hearing and feeling your secretions as you breathe out and controlling the urge to cough until secretions are high up and easily cleared with little effort.
10189073|NCT03710746|Experimental|Mixed Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the food-focused response and attention training intervention.
10189074|NCT03710746|Experimental|Mixed Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the generic response and attention training intervention.
10189075|NCT03710746|Experimental|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
10189076|NCT03710746|Experimental|Female Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the generic response and attention training intervention.
10189077|NCT03710746|Experimental|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
10189078|NCT03710746|Experimental|Male Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the generic response and attention training intervention.
10189079|NCT03710733|Active Comparator|Sequential boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus sequential boost 10 Gy/4 fx (2.5 Gy/fx) to lumpectomy cavity
10189080|NCT03710733|Experimental|Concomitant boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus concomitant boost 8 Gy/15 fx (0.53 Gy/fx) to lumpectomy cavity
10189081|NCT03710707|Experimental|DNL201 low dose|
10189082|NCT03710707|Experimental|DNL201 high dose|
10189083|NCT03710707|Placebo Comparator|Placebo|
10189084|NCT03710694|Experimental|DAV132 group|Patients randomized to the DAV132 arm will be administered DAV132 concomitantly with fluoroquinolones.
10189085|NCT03710694|No Intervention|No DAV132 group|Patients randomized to the No DAV132 arm will receive only fluoroquinolones, according to local standard of care.
10189086|NCT03710681|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks
10189087|NCT03710681|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks
10189088|NCT03710655|Experimental|treatment group|skin test, dose escalation, final dose of 1.5mg weekly over 16 weeks of Apitox pure honeybee toxin
10189089|NCT03710655|Placebo Comparator|placebo group|histamine placebo administered intradermally in dose escalation, final dose of 1.5mg weekly over 16 weeks
10189090|NCT03710629||NSCLC patients with driver genes|NSCLC patients and driver genes
10189091|NCT03710603|Active Comparator|Velcade Lenalidomide dexamethasone (VRd)|VRd: subjects will receive VRd for induction and consolidation, followed by lenalidomide (R) maintenance until disease progression or unacceptable toxicity.
10189092|NCT03710603|Experimental|Daratumumab + VRd (D-VRd)|D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
10189093|NCT03710551|Experimental|Experimental Infant Formula|Experimental Infant Formula with a new fat blend plus L. reuteri
10189094|NCT03710551|Active Comparator|Standard Infant Formula|Standard bovine milk-based infant formula.
10189095|NCT03710512||hydroset|patients receiving hydroset at osteotomy site
10189096|NCT03710512||Control|patients not receiving hydroset at osteotomy site
10189097|NCT03710499|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 8 consecutive weeks.
10189098|NCT03710486||Cohort 1: Vedolizumab|Participants diagnosed with UC or CD, who have initiated vedolizumab treatment between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index vedolizumab treatment initiation during the eligibility period, and then from date of index vedolizumab treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when vedolizumab treatment was initiated.
9699888|NCT05219708|Experimental|Calorie and protein nutritional supplementation|Study participants randomized to the intervention will receive 30 days worth of the nutritional supplement (i.e. Ensure Original) to be consumed twice per day in between meals in addition to standard of care for heart failure.
9699889|NCT05219708|Active Comparator|Control|The control group will receive standard of care for heart failure.
9699890|NCT05218213||Healthy young|Healthy young adults
9699891|NCT05218213||Healthy elderly|Healthy elderly adults
9699892|NCT05218213||Parkinson's disease|Elderly with Parkinson's disease
9699893|NCT05218148|Experimental|Group A|Group A: SOX regimen (oxaliplatin + Seggio) ) + sintilimab + trastuzumab; 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
9699894|NCT05218148|Active Comparator|Group B|Group B: SOX regimen, 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery
9699895|NCT05217927|Experimental|Rimegepant 75mg daily dosing|
9699896|NCT05217927|Experimental|Rimegepant 75mg every other day dosing|
9699897|NCT05217927|Placebo Comparator|Placebo comparator dosing|
9699898|NCT05216666|Active Comparator|Lateral approach|290 participants receive their hip prosthesis through a lateral approach. The anterior third of m. gluteus medius along with the corresponding part of m. vastus lateralis are detached from the greater trochanter and the anterior capsule is excised for the exposure of the hip joint. After implant insertion, the gluteus medius is reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
9699899|NCT05216666|Active Comparator|Posterior approach|290 participants receive their hip prosthesis through a posterior approach. The m. piriformis gemelli and obturator internus are detached from the greater trochanter and the posterior capsule is incised for the exposure of the hip joint. After implant insertion, the posterior capsule as well as m piriformis and the external rotators are reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
9699900|NCT05216601|Active Comparator|MVC-COV1901|15 mcg of S-2P protein with adjuvant
9699901|NCT05216601|Experimental|MVC-COV1901(Beta)-15|15 mcg of S-2P protein(Beta) with adjuvant
9699902|NCT05216601|Experimental|MVC-COV1901(Beta)-25|25 mcg of S-2P protein(Beta) with adjuvant
9699903|NCT05214560||All participants|Participants who require a BD Spinal needle
9699904|NCT05213910|Experimental|Patients using the product|
9699905|NCT05208697|Experimental|Tele-Harm Reduction (THR)|THR utilizes 2 components. Component 1: telehealth technology facilitated by a peer harm reduction counselor to connect the participant with medical case managers and enroll patients in Ryan White/AIDS Drug Assistance Program (ADAP). Component 2: utilizes the syringe services program (SSP)-based peer harm reduction counselor to work with participants in identifying individual-specific barriers and facilitators to medication adherence.
9699906|NCT05208697|Active Comparator|off-site linkage to HIV care|introduces the participant to an SSP HIV/HCV linkage specialist and discusses linkage to a traditional Ryan White clinic
9699907|NCT05208359|Experimental|STRONG immediate group|Small mental health support group delivered immediately
9699908|NCT05208359|Other|STRONG delayed group|Small mental health support group delivered after a delay of approximately 3 months
9699909|NCT05207748||patients with a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
9699910|NCT05207748||patients without a history of falls|"Demographic characteristics and medical histories (age, height, weight, smoking, alcohol use, comorbidities, medications, stroke onset date, stroke side, total number of rehabilitation received, assistive device use, history of falls) of all patients participating in the study will be recorded.~Detailed physical examinations (mini-mental status assessment, brunstrum stages, spasticity assessments, orthosis use) will be performed. Berg Balance Scale, which will reveal the balance states; Functional ambulation scores and Timed Up and Go test will be applied to determine their functional status. In addition, the International Fall Efficiency Scale questionnaire will be administered. Bone mineral density will be evaluated to assess patients' bone health."
9699911|NCT05207670|Experimental|Cohort A|Participants with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
9699912|NCT05207670|Experimental|Cohort B|Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
9699913|NCT05207670|Experimental|Cohort C|Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
9699914|NCT05207670|Experimental|Cohort D|Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
9977934|NCT01366703||heart failure patients|stable heart failure patients, NYHA 1-2, EF > 35%, no AF, No OAC, CHADS score >2
10189099|NCT03710486||Cohort 2: Other Biologic|Participants diagnosed with UC or CD, who have initiated other biologic treatment (infliximab, adalimumab, or golimumab [UC only]) between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index other biologic treatment initiation during the eligibility period, and then from date of index other biologic treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when other biologic treatment was initiated.
10189100|NCT03710460|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
9827803|NCT02469077|Active Comparator|Normal exercise (control)|Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
9827804|NCT02469090|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
9827805|NCT02469090|Placebo Comparator|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
9827806|NCT02469116|Experimental|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles~Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
9827807|NCT02469168|Experimental|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
9827808|NCT02469168|Active Comparator|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
10189101|NCT03710460|Experimental|Dapagliflozin plus metformin XR|Dapagliflozin plus metformin XR capsules, 10/1000 mg, one per day before breakfast during 12 weeks.
10189102|NCT03710460|Experimental|Metformin XR|Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.
9827809|NCT02469246|Experimental|F/TAF (Double-Blind)|"F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
9827810|NCT02469246|Active Comparator|ABC/3TC (Double-Blind)|"ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
9827811|NCT02469246|Experimental|Open-Label F/TAF|After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
9827812|NCT02469298|Experimental|Danirixin + Oseltamivir matching placebo|Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
10189103|NCT03710447|Experimental|HIIT + WB-EMS|High-intensity interval training (HIIT) combined with whole-body electromyostimulation (WB-EMS) Sequence of application: HIIT - WB-EMS
10189104|NCT03710447|Experimental|WB-EMS + HIIT|Whole-body electromyostimulation (WB-EMS) combined with High-intensity interval training (HIIT) Sequence of application: WB-EMS - HIIT
10189105|NCT03710447|Experimental|HIIT + CST|High-intensity interval training (HIIT) combined with conventional low-volume strength training (CST) Sequence of application: HIIT - CST
10189106|NCT03710447|Experimental|CST + HIIT|Conventional low-volume strength training (CST) combined with high-intensity interval training (HIIT) Sequence of application: CST - HIIT
10189107|NCT03710434|Experimental|Part A - nano-suspension|Subjects will receive single dose of AZD4635 50mg nano-suspension (reference) in the fasted state.
10189108|NCT03710434|Experimental|Part A - solid oral formulation|Subjects will receive single dose of AZD4635 50mg solid oral formulation, in the fasted state.
10189109|NCT03710434|Experimental|Part B-solid oral formulation with food|Subjects will receive a single dose AZD4635 solid oral formulation after high fat meal.
10189110|NCT03710434|Experimental|Part B - solid oral formulation with PPI|Subjects will receive 30 mg lansoprazole BID and a single dose of AZD4635 solid oral formulation in the fasted state.
10189111|NCT03710434|Experimental|Part B - dose exploration 1|If dose adjustment is required, subjects will receive a different single dose (XX mg) of AZD4635 solid oral formulation, in the fasted state.
10189112|NCT03710434|Experimental|Part B - dose exploration 2|If dose adjustment is required, subjects will receive a different single dose (YY mg) of AZD4635 solid oral formulation, in the fasted state.
10189113|NCT03710434|Experimental|Part B - variant 1|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state and optional [14C] AZD4635 IV microtracer.
10189114|NCT03710434|Experimental|Part B - variant 2|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
10189115|NCT03710408|Experimental|Subcutaneous hydration|
10189116|NCT03710408|Active Comparator|Intravenous hydration|
10189117|NCT03710395|Active Comparator|Wild homozygous for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C>A.
10189118|NCT03710395|Experimental|Variant genotypes for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C>A.
10189119|NCT03710382|Experimental|Walking epidural|Parturients will receive a lower concentration of bupivacaine in their epidural infusion and will be encouraged to walk during labor.
10189120|NCT03710369|Sham Comparator|Normoxia|Exercise in room air (normoxia). Sildenafil
10189121|NCT03710369|Active Comparator|Hypoxia|Exercise in hypoxic air (reduced O2 concentration) that simulates 2500m elevation for 30-40 minutes with Sildenafil. Placebo
10189122|NCT03710356|Experimental|Danazol|Danazol
10189123|NCT03710343|Experimental|Metformin|Metformin oral tablet will be taken by mouth, once or twice a day for 16 weeks.
10189124|NCT03710343|Placebo Comparator|Placebo|The placebo oral tablet will be taken by mouth once or twice a day for 16 weeks.
10189125|NCT03710330|Placebo Comparator|normal saline|the patients receives 110 ml normal saline IV just before skin incision
10189126|NCT03710330|Active Comparator|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
10189127|NCT03710330|Active Comparator|0.5 gm tranexamic acid|0.5 gm tranexamic acid (1 ampoule of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
10189128|NCT03710317|Active Comparator|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
10189129|NCT03710317|Experimental|Tranexamic acid plus misoprostol|400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
10189130|NCT03710304|Active Comparator|oxytocin|20 IU oxytocin ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal(ranitidine) plus 110 ml saline iv
10189131|NCT03710304|Active Comparator|Tranexamic acid plus misoprostol|400 μg misoprostol (2 tablets of 200 μg) or two placebo tablets were given buccally after spinal anesthesia and few minutes before skin incision; then 1 gm TA will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision, plus 500 ml normal saline intravenous solution infusion over 15 min after delivery of the baby
10189132|NCT03710278||LPat Device|Performing Lumbar Puncture assisted by LPat
10189133|NCT03710252|Experimental|Single|Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)
10189134|NCT03710239|Active Comparator|Dilapan-S|Synthetic osmotic dilator
10189135|NCT03710239|Active Comparator|Laminaria|Seaweed-based osmotic dilator
10189136|NCT03710226||cases|women with recurrent miscarriage (two or more consecutive miscarriages)
10189137|NCT03710226||controls|women without recurrent miscarriage and delivered at least once before
10189138|NCT03710213|No Intervention|Usual Care|Usual care includes (1) bowel preparation instructions that are delivered via mail or through a secure online messaging portal, (2) a phone call from the endoscopy staff in the week prior to colonoscopy, and (3) the option to call the endoscopy staff during business hours to have any questions answered on demand.
10189139|NCT03710213|Experimental|Text Message-based Intervention|In addition to usual care, the text message-based intervention consists of the subject receiving text messages per a pre-determined protocol starting 7 days prior to the date of scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program. Of note, if a patient in the intervention arm cancels or reschedules their colonoscopy after randomization, they will not receive any additional protocol text messages as part of this trial.
10189140|NCT03710200|Active Comparator|Bologna 00+S. cerevisiae yeast|Bread made with Bologna flour (type 00) (modern variety)+S. cerevisiae yeast
10189141|NCT03710200|Experimental|Bologna 1+S. cerevisiae yeast|Bread made with Bologna flour (type 1) (modern variety)+S. cerevisiae yeast
10189142|NCT03710200|Experimental|Bio2+S. cerevisiae yeast|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+S. cerevisiae yeast
10189143|NCT03710200|Experimental|ICARDA+S. cerevisiae yeast|Bread made with Icarda mix (type 1) (heritage mix varieties)+S. cerevisiae yeast
10189144|NCT03710200|Experimental|Bologna 1+sourdough|Bread made with Bologna flour (type 1) (modern variety)+sourdough
10189145|NCT03710200|Experimental|Bio2+sourdough|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+sourdough
10189146|NCT03710200|Experimental|ICARDA+sourdough|Bread made with mix Icarda flour (type 1) (heritage mix varieties)+sourdough
10189147|NCT03710200|Experimental|Grossi+sourdough|Bread made with mix Grossi flour (type 1) (heritage mix varieties)+sourdough
10189148|NCT03710174|No Intervention|Control group|Without bruxism and no intervention. They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.
10189149|NCT03710174|Experimental|LED group|The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables. During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later. They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.
10189150|NCT03710174|Experimental|Occlusal splint group|They will be treated using the standard protocol of a rigid occlusal splint. After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
10189151|NCT03710174|Placebo Comparator|Placebo group|Subjects with bruxism. The same procedures as LED group, but the device will be turn off.
10189152|NCT03710122|Experimental|Vancomycin|
10189153|NCT03710122|Placebo Comparator|Placebo|
10189154|NCT03710109||Concussion|Individuals who have sustained a recent concussion
10189155|NCT03710109||Control Healthy Volunteers|No Intervention
10189156|NCT03710096|Experimental|Mac grath group|
10189157|NCT03710096|Active Comparator|Macintosh Group|
10189158|NCT03710070|Experimental|Intervention|In the presence of a significant coronary artery stenosis and randomization to the intervention group: Catheter-based permanent occlusion of the ipsilateral (to the culprit coronary lesion) IMA will be performed at the projected height of inferior vena cava confluence and right atrium using a dedicated occlusion device (Amplatzer vascular plug 4, CE0086).
10189159|NCT03710070|Sham Comparator|Sham-Control|In the presence of a significant coronary artery stenosis, and randomization to the sham-procedure: IMA will be selectively intubated using an appropriate catheter. Angiography of the IMA and the pericardiacophrenic branch will be performed.
10189160|NCT03710044|Experimental|Cyclosporine A treatment|Oral cyclosporine A treatment
10189161|NCT03710031||HSCT Survivors|PNS tracking will occur through blood and stool samples to track the interplay among psychoneurologic symptoms (PNS) as they relate to diminished QOL among survivors of HSCT.
10189162|NCT03710018||A Patient who underwent open cavity BCS|Patients undergoing Open cavity Breast Conservative Surgery
9699915|NCT05207670|Experimental|Cohort E|Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
9699916|NCT05206838|Experimental|Surgical reconstruction|22 patients undergo surgical reconstruction of gluteus medius with allograft consisting of Achilles tendon with calcaneus block. The calcaneus block is fixed into the greater trochanter and the Achilles tendon i passed through the gluteus medius muscle, tensioned and sutured into the muscle. Postoperatively, partial weight bearing for 2 months followed by physiotherapy for 10 months.
9699917|NCT05206838|No Intervention|Physiotherapy|22 patients receive non-operative treatment for their limp with physiotherapy alone during a 12-month period.
9699918|NCT05205954|Experimental|Hepatology Hospital at Home|
9699919|NCT05205512|Experimental|Group I (telehealth exercise)|Patients participate in telehealth exercise intervention for 30 minutes per day, 3 days a week for 8 weeks.
9699920|NCT05205512|Active Comparator|Group II (delayed control)|Patients maintain current levels of physical activity for 8 weeks. Patients may then participate in telehealth exercise intervention for 8 weeks.
9699921|NCT05204589|Experimental|Group A|Subjects in safety cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
10189163|NCT03710018||B Patient who underwent close cavity BCS|Patients undergoing Close cavity Breast Conservative Surgery
10189164|NCT03710018||C Patient who underwent oncoplasty|Patients undergoing oncoplasty for breast cancer
9699922|NCT05204589|Experimental|Group B|Subjects in immunogenicity cohort will receive one heterologous booster dose of aerosolized Ad5-nCoV
9699923|NCT05204589|Experimental|Group C|Subjects in immunogenicity cohort will receive one homologous booster dose of ICV.
9699924|NCT05204225|Experimental|Tablet Application|An exercise program based on the current evidence will be provided through a tablet application (ReHand) along with the face-to-face conventional approach of each recruitment centres. A follow-up of the use of the application will be carried out. The treatment protocol will last 4 weeks, including daily exercise sessions of 30-60 minutes of duration at home though the application tablet.
9699925|NCT05204225|Active Comparator|Conventional Treatment|Participants included in this group will receive the conventional treatment protocol usually prescribed on each recruitment centres. Participants will be asked to perform an exercise program on paper during 4 weeks at home, along with face-to-face sessions.
9699926|NCT05201196|Active Comparator|Conventional physical therapy|Conventional physical therapy Muscle strengthening and Muscle Stretching, TENS.
9699927|NCT05201196|Experimental|Task Oriented Training|Experimental group was given Task Oriented protocol including different task specific functional activities
9699928|NCT05197153|Experimental|Half dose of MVC-COV1901|7.5 mcg of S-2P protein with adjuvant
9699929|NCT05197153|Experimental|Full dose of MVC-COV1901|15 mcg of S-2P protein with adjuvant
9699930|NCT05197153|Experimental|AZD1222|5*10^10 viral particles of AZD1222
9699931|NCT05197153|Active Comparator|Half dose of mRNA-1273|50 mcg mRNA encoding the pre-fusion stabilized S protein
9699932|NCT05195996|Active Comparator|beta blocker|Will be given Propranolol 1mg in 10 ml distilled water intravenous every 6 hours for 48 hours
9699933|NCT05195996|Placebo Comparator|placebo|Will be given normal saline 10 ml every 6 hours for 48 hours
9699934|NCT05195008|Experimental|Part A [Single Ascending Dose (SAD)]: BIIB113 Cohort 1|Participants aged 18 to 64 years will receive Dose 1 of BIIB113, orally, once daily (QD), on Day 1 of Part A of the study.
9699935|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 2|Participants aged 18 to 64 years will receive Dose 2 of BIIB113, orally, QD, on Day 1 of Part A of the study
9699936|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 3|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, on Day 1 of Part A of the study.
9699937|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 4|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Day 1 of Part A of the study.
9699938|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 5|Participants aged 18 to 64 years will receive Dose 5 of BIIB113, orally, QD, on Day 1 of Part A of the study
9699939|NCT05195008|Placebo Comparator|Part A (SAD): BIIB113-Matching Placebo (Cohorts 1-5)|Participants aged 18 to 64 years will receive BIIB113-matching placebo, orally, QD, on Day 1 of Part A of the study.
9699940|NCT05195008|Experimental|Part B [Multiple Ascending Dose (MAD)]: BIIB113 Cohort 6|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, up to Day 14 of Part B of the study.
9699941|NCT05195008|Experimental|Part B (MAD): BIIB113 Cohort 7|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
9699942|NCT05195008|Experimental|Part B (MAD): BIIB113 Cohort 8|Participants aged 18 to 64 years will receive Dose 6 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
9827813|NCT02469298|Placebo Comparator|Danirixin matching placebo + Oseltamivir matching placebo|Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
10189165|NCT03710005|Experimental|Ascent Intervention Treatment|Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
10189166|NCT03710005|Active Comparator|Standard Treatment|Standard treatment arm will receive a standard Corticosteroid injection
10189167|NCT03709992|Active Comparator|Trospium|Patients will receive 30 mg of Trospium chloride tablet twice daily
10189168|NCT03709992|Active Comparator|Tamsulosin|Patients will receive 0.4 mg of Tamsulosin tablet once daily
9699943|NCT05195008|Placebo Comparator|Part B (MAD): BIIB113 Cohort 9|Participants aged 65 to 75 years will receive BIIB113, orally, QD, on Days 1 to 14 of Part B of the study. The calculated dose level will be adaptive by design based on review of the safety, tolerability, and PK data from Cohorts 1 to 7.
9699944|NCT05195008|Placebo Comparator|Part B (MAD): BIIB113-Matching Placebo (Cohorts 6 to 9)|Participants aged 18 to 75 will receive BIIB113-matching placebo, orally, QD, on Days 1 to 14 of Part B of the study.
10189169|NCT03709979|Active Comparator|C-MAC with folded towel position|Children will be intubated by C-MAC videolaryngoscope with placing a folded towel under the shoulder.
10189170|NCT03709979|Placebo Comparator|C-MAC with flat position|Children will be intubated by C-MAC videolaryngoscope with flat position (non-inserted a folded towel)
10189171|NCT03709966|Experimental|FitBit|Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.
10189172|NCT03709966|Active Comparator|Routine|Physical activity promotion supported by a kinesiologist
10189173|NCT03709953|Experimental|apatinib|apatinib, 500 mg, po, QD; 28 days every cycle
10189174|NCT03709940|Experimental|Placebo, MPH|"Dose order: placebo, methylphenidate (MPH)~Participants receive a placebo tablet (ascorbic acid 50 mgs) on DAY 1 and a clinically effective dose of short-acting MPH (20 mgs) on DAY 2."
10189175|NCT03709940|Experimental|MPH, Placebo|"Dose order: methylphenidate (MPH), placebo~Participants receive a clinically effective dose of short-acting MPH (20 mgs) on DAY 1 and a placebo tablet (ascorbic acid 50 mgs) on DAY 2."
10189176|NCT03709927|Experimental|Therapeutic ZTI-01 6 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g
9699945|NCT05195008|Experimental|Part C (OGA-PET SAD): BIIB113|Participants aged 20 to 64 will receive single dose of BIIB113, orally, QD, on Day 1 of Part C of the study, followed by a radiotracer specific to OGA ([11^C]BIO-1819578), on Days 1 to 4 of Part C of the study.
9827814|NCT02469298|Experimental|Danirixin + Oseltamivir|Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
10189177|NCT03709927|Experimental|Supra-therapeutic ZTI-01 12 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g
10189178|NCT03709927|Active Comparator|moxifloxacin 400 mg PO|oral moxifloxacin 400mg film coated tablets - Avelox(TM)
10189179|NCT03709927|Placebo Comparator|Placebo IV|IV 0.9% normal saline solution
10189180|NCT03709901|Experimental|Active Allograft|Injection of viable allograft
10189181|NCT03709901|Placebo Comparator|Placebo|Injection of saline
10189182|NCT03709901|No Intervention|Conservative Care|Continued conservative care treatment
10189183|NCT03709875|Experimental|TR Treatment|TR will be delivered by means of an advanced video-conferencing system, and patients will be provided with low-cost monitoring devices, able to collect data about the health status and QoL. All treatments from remote are based on scheduled videoconferences between the patient's home and the Clinical Units, and therapists can control and modify the exercises. A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech and cognitive exercises will be delivered from the two Research Institutes to the patient's home.
10189184|NCT03709875|Other|Conventional Treatment|"In this group patients will be treated with conventional physiotherapy and speech training, adjusted in reason of the clinical needs, as usually. Treatments for motor limbs activity will be focused on functional active-assistive and active exercises. Conventional paper and pencil training will be used to improve cognitive function."
10189185|NCT03709849|Experimental|experimental group|Intervention, dosage and frequency: drug: Bushen Culuan Decoction 13g tid and Clomiphene Citrate Tablets placebo 50mg qd; Dosage form: Bushen Culuan Decoction is dissolved medicine and Clomiphene Citrate Tablets placebo is tablets; Duration: the medicine will be taken from 5th day of a menstrual cycle, Bushen Culuan Decoction is taken for 14 days while Clomiphene Citrate Tablets placebo being taken for 5 days. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
10189186|NCT03709849|Active Comparator|control group|Intervention, dosage and frequency: drug: Clomiphene Citrate Tablets 50mg qd and Bushen Culuan Decoction placebo 13g tid; Dosage form: Clomiphene Citrate Tablets is tablet and Bushen Culuan Decoction placebo is dissolved medicine; Duration: the medicine will be taken from 5th day of a menstrual cycle, Clomiphene is taken for 5 days while Bushen Culuan Decoction placebo being taken for 14 days while. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
10189187|NCT03709797|Experimental|Experimental group|Experimental group will receive dry needling treatment.
10189188|NCT03709797|Sham Comparator|Control group|Control group will receive sham dry needling treatment.
10189189|NCT03709771||VEGF inhibitor alone|
10189190|NCT03709771||Immune Checkpoint Inhibitor (ICI) alone|
10189191|NCT03709771||Combination (VEGF inhibitor + ICI, or combination of ICI)|
10189192|NCT03709771||No treatment|
10189193|NCT03709745|Active Comparator|Aflibercept|Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
10189194|NCT03709745|Active Comparator|Ranibizumab|Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.
10189195|NCT03709719|Experimental|blinatumomab|
10189196|NCT03709693||SternaLock Blu|All patients will receive SternaLock Blu for closure of full mid-line sternotomy.
10189197|NCT03709641|Experimental|Restylane Defyne receiver|Participants will receive Restyane Defyne injected into punctum of one eye.
10189198|NCT03709628|Experimental|Patients with active Crohn's disease|EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.
10189199|NCT03709615|No Intervention|Wait list|Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.
10189200|NCT03709615|Experimental|Intervention- active treatment|Internet delivered CBT for social anxiety disorder
10189201|NCT03709589||Group-A|Patients with Modified Early Warning Score of ≥ 5
10189202|NCT03709589||Group-B|Patients with Modified Early Warning Score of < 5
10189203|NCT03709563|Active Comparator|Oral Nutraceutical Supplement|
10189204|NCT03709563|Placebo Comparator|Placebo|
10189205|NCT03709550|Experimental|Treatment (decitabine, enzalutamide)|Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10204332|NCT03081910|Experimental|Allogeneic CD5.CAR/28zeta CAR T cells (Group B)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
10204333|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
10204334|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study."
10204335|NCT03081858|Experimental|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route.~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
10204336|NCT03057678|Experimental|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
10204337|NCT03053362|Experimental|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
10204338|NCT03053362|Other|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
10204339|NCT02985411|Active Comparator|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
10204340|NCT02985411|Active Comparator|Delayed Gardening Intervention|Individuals in this group will serve as their own control
10204341|NCT02928887|Experimental|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480nm) light for the 24 hour photoperiod prior to surgery and for the 24 hour photoperiod immediately after surgery
10204342|NCT02928887|No Intervention|Ambient light|Exposure to ambient, white fluorescent light
10204343|NCT02906332|Experimental|Pembrolizumab + lenalidomide|"This is an open label study.~Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.~This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
10204344|NCT02887482|Experimental|Placebo|Placebo at 0 mg DNA/dose
10204345|NCT02887482|Experimental|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
10204346|NCT02849626|Experimental|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
10204347|NCT02815124|Active Comparator|Standard of Care|Cochlear Implant programming using standard of care
10204348|NCT02815124|Experimental|Image-Guided Cochlear Implant Programming|Cochlear Implant programming using Image-Guided Cochlear Implant Programming
10204349|NCT02809443|Experimental|GLS-5700 at 1 mg|DNA/dose
10204350|NCT02809443|Experimental|GLS-5700 at 2 mg|DNA/dose
9699946|NCT05195008|Experimental|Part C (OGA-PET MAD): BIIB113|Participants aged 20 to 64 years will receive multiple doses of BIIB113, orally, QD, on Days 1 to 14 of Part C of the study, followed by a radiotracer specific to OGA ([11^C]BIO-1819578) on Day 1 and either of Day 15, Day 16 or Day 17 of Part C of the study.
9699947|NCT05194579|Other|PF-06881894 by on-body injector (OBI)|PF-06881894 given by on-body injector (OBI) as test arm, 6 mg administered as a single SC injection
9699948|NCT05194579|Other|PF-06881894 by prefilled syringe (PFS)|PF-06881894 given by prefilled syringe (PFS) as reference arm, 6 mg administered as a single SC injection
9699949|NCT05194007|Experimental|Experimental -Frondanol|Eligible participants will receive Frondanol capsule orally (1000 mg capsule twice daily) for 6 months
9699950|NCT05194007|Placebo Comparator|Placebo|Eligible participants will receive placebo capsule (twice daily) for 6 months
9699951|NCT05191355||subjects with familial hypercholesterolemia|blood test
9699952|NCT05191355||healthy subjects|blood test
9699953|NCT05190354|Experimental|Xtremity Prosthesis|Xtremity Prosthesis fitting
9699954|NCT05189691|Experimental|behavior change and walking exercise|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale, Short Form 36 (SF-36) scales and continuously recorded step counts will be evaluated at week 0, 4 and at the end of week 12.
9699955|NCT05189691|No Intervention|behavior change|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) scales will be evaluated at week 0, 4 and at the end of week 12.
9699956|NCT05186948||Breast cancer patients (stages I-IIIA)|200 patients with an initial diagnosis of breast cancer stages I-IIIA and scheduled chemotherapy, fulfilling the eligibility criteria
9699957|NCT05186948||healthy control|Group of 30 healthy control participants, matched for age and sex, with no evidence or history of significant neurodegenerative disorder affecting brain function.
9699958|NCT05182502|Experimental|Tixel treatment arm|subjects will receive 3 monthly treatments with the Tixel device
9699959|NCT05177900|Active Comparator|Biphasic pulse without interphase gap|
9699960|NCT05177900|Experimental|Biphasic pulse with interphase gap|
9699961|NCT05174403||SPG5 patients|Adult SPG5 patients with diagnostic confirmed by the identification of two mutations in the CYP7B1 gene
9699962|NCT05172258|Experimental|Arm I (ipatasertib, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ipatasertib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity.
9699963|NCT05172258|Active Comparator|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for a period of 24 months in the absence of disease progression or unacceptable toxicity.
9699964|NCT05169515|Experimental|Arm 1|Participants will receive subcutaneous (SC) mosunetuzumab + CC-220 or SC mosunetuzumab + CC-99282.
9699965|NCT05169515|Experimental|Arm 2|Participants will receive intravenous (IV) glofitamab + CC-220 or IV glofitamab + CC-99282.
10189206|NCT03709537|Experimental|Mental Health Peer Workforce Support|Sites assigned to this group will engage in Co-Learning Collaborative, several trainings, and the creation of Implementation Teams--all part of the intervention and designed to support their peer workforce.
9699966|NCT05167877||Control group|Participants without CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices.
10189207|NCT03709537|No Intervention|Control Group|Sites assigned to this group will continue practice as usual and not receive any additional peer worker training or technical assistance.
10189208|NCT03709524|Active Comparator|insertion time|1 minute Airtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
10189209|NCT03709524|Active Comparator|intubation time|2 minutesAirtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
10189210|NCT03709485|Experimental|prostate biopsy patients|a cohort o consecutive patients referred to prostate biopsies. In all patients, a rectal swab will be taken prior to biopsy and antimicrobial treatment. The swab will be cultured and analyzed in the lab for characterization of the microbiome.
9699967|NCT05167877||Active group|Participants with CLBP. Measurements include: bio-physiological, neurophysiological measurements at baseline. Remote monitoring of gait, physical activity for 7 days using inertial measurement unit (IMU) with wearable devices. Self-reported measures of pain and type of activity for 7 days using electronic dairy.
9699968|NCT05165901|Experimental|Nociceptive pain|patients with joint pain (knee and shoulder), myofascial pain syndrome
9699969|NCT05165901|Experimental|Neuropathic pain|patients with postherpetic neuralgia, peripheral nerve injury (CRPS type II, brachial plexopathy, nerve entrapment syndrome)
9699970|NCT05165901|Experimental|Mixed pain|patients with spine or SIJ origin back and buttock pain or neck pain and SPINE-origin back pain과 neck pain, SIJ-origin back and buttock pain
9699971|NCT05165888|Experimental|Communication and Bias Mitigation Training|This is a communication training session based on a culturally-based program developed with rural, southern Black patients and families and modified for an urban, northern population. A strategy of bias mitigation successfully used with medical students will be adapted for practicing clinicians using results of phase 1. This strategy is based on transformational learning theory and incorporates critical reflection, guided dialogue, perspective taking exercises, role plays and strategy development. If specific communication behaviors are found related to bias and stereotyping in phase 1, these will be discussed and targeted using these techniques. Otherwise, these techniques will be used to address racial bias generally. The intervention will be incorporated within the communication training session.
9699972|NCT05165888|Active Comparator|Communication Training Only|This is a communication training session based on standard palliative care techniques to listen empathically, share prognostic information and treatment options, elicit patient and family goals and values related to their treatment, and facilitate shared decision-making regarding end-of-life treatment.
9699973|NCT05162794|Other|Active Surgery|
9699974|NCT05162794|Other|Diagnostic Surgery|
10189211|NCT03709433|Experimental|ACT groups and mobile app|Participants will receive six two-hour weekly sessions of acceptance and commitment therapy (ACT) in a group format. They will also access the ACT Daily mobile app, which helps participants practice ACT skills in the moment, for the duration of the study (10-14 weeks depending on when the participant completes the baseline assessment.) Sessions use metaphors, experiential exercises, and discussion to target core ACT skills: acceptance, defusion, present-moment awareness, self-as-context, values, and committed action. The mobile app includes metaphors and experiential exercises to aid with all of these skills except self-as-context. Participants will be asked to use the app to practice these skills and to complete behavioral commitments linked to their values between sessions.
9699975|NCT05162794|Other|No-surgery control|
9699976|NCT05162014||Patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus (T2DM)
9699977|NCT05162014||Patients with T2DM initiating other oral non-incretin/non-SGLT2i-based hypoglycaemic agents|Type 2 diabetes mellitus (T2DM); Sodium glucose co-transporter-2 inhibitors (SGLT2i)
9699978|NCT05161754|Experimental|Treatment 1|Participants left tonsil: cold dissection and hot hemostasis. Participants right tonsil: cold dissection and cold hemostasis.
9699979|NCT05161754|Experimental|Treatment 2|Participants right tonsil: cold dissection and hot hemostasis. Participants left tonsil: cold dissection and cold hemostasis.
10189212|NCT03709420|Placebo Comparator|Placebo|Matching placebo capsule
10189213|NCT03709420|Experimental|FOR-6219|"Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.~Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.~Part III: Multiple oral doses of 10 mg, 25 mg, 75 mg and 150 mg BID"
10189214|NCT03709407|Experimental|cervical stimuli|Godoy´s maneuver with traction-sliding in supraclavicular fossa
10189215|NCT03709407|Experimental|terminus|Vodder´s maneuver with medial and anterior traction in supraclavicular fossa
10189216|NCT03709407|Sham Comparator|placebo|maneuver with sliding ON clavicular
9699980|NCT05161195|Other|Ribociclib|All participants will receive ribociclib in combination with other drugs at the same dose/schedule as in the parent study.
9699981|NCT05158530|Experimental|Interventional Group|Pulmonary exercises + Aerobic training, 40%-60% intensity 3 days/ week for 4 weeks
9699982|NCT05158530|Placebo Comparator|Control group|Pulmonary exercises, 3 sessions per week and 3-5 repetitions in a session for 4 weeks.
9699983|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort A|Eligible participants will receive BIVV020 and SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
9699984|NCT05156710|Other|Standard of Care (SOC) Cohort A|SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
9699985|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort B|Eligible participants will receive BIVV020 and SOC which includes plasmapheresis, IVIg, corticosteroids, rixutimxab.
9699986|NCT05156710|Other|Standard of Care (SOC) Cohort B|SOC includes plasmapheresis, IVIg, corticosteroids, rixutimxab.
9699987|NCT05148923|Active Comparator|Rational energy algorithm|150 J, 360 J, 360 J biphasic DCCV
9699988|NCT05148923|Active Comparator|Maximum fixed energy algorithm|3x 360 J biphasic DCCV
9699989|NCT05145127|Experimental|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
9699990|NCT05142696|Experimental|Dose Level 1 (DL1)|Dose Level 1 (DL1): [177Lu]Lu-DOTA-TATE 100 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 100 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
9699991|NCT05142696|Experimental|Dose Level 2a (DL2a)|Dose Level 2a (DL2a): [177Lu]Lu-DOTA-TATE 150 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 150 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
9699992|NCT05142696|Experimental|Dose Level 2b (DL2b)|Dose Level 2b (DL2b): [177Lu]Lu-DOTA-TATE 150 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
9699993|NCT05142696|Experimental|Dose Level 3a (DL3a)|Dose Level 3a (DL3a): [177Lu]Lu-DOTA-TATE 200 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
9699994|NCT05142696|Experimental|Dose Level 3b (DL3b)|Dose Level 3b (DL3b): [177Lu]Lu-DOTA-TATE 200 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
9699995|NCT05142696|Experimental|Dose Level 4 (DL4)|Dose Level 4 (DL4): [177Lu]Lu-DOTA-TATE 250 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
9977935|NCT01366716|Experimental|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
10189217|NCT03709407|No Intervention|Control group|only lying down
10189218|NCT03709394|Active Comparator|Group A: Full utrasound guidance|Full utrasound guidance of cathether insertion. Intervention: Ultrasound portable device used for the identification of the target vein and for the ultrasound control of proper catheter placement during the procedure of peripheral venous cannula insertion.
10189219|NCT03709394|Active Comparator|Group B: Partial ultrasound guidance|Catheter insertion under partial ultrasound guidance. Intervention: Ultrasound portable device used only for the identification of the target vein, the catheter placement will be done by conventional approach.
10189220|NCT03709394|Active Comparator|Group C: No ultrasound guidance|Catheter insertion by conventional approach, without ultrasound guidance
10189221|NCT03709381|Experimental|ACTH stim test arm|Cosyntropin 1 mcg IV (low dose) will be given to subjects at t=0 minutes, and Cosyntropin 250 mcg (high dose) IV will be given to subjects at t=60 minutes. (All subjects were in the same arm and had the same protocol).
10189222|NCT03709342|Experimental|All Patients|
9699999|NCT05139342|Active Comparator|PD patients|patients diagnosed with PD will be allocated to this arm
9700000|NCT05139342|Active Comparator|MSA patients|patients diagnosed with MSAwill be allocated to this arm
9700001|NCT05139342|Active Comparator|4RT patients|patients diagnosed with 4RT will be allocated to this arm
9700002|NCT05139121|Experimental|MR-100A-01|MR-100A-01 is a transdermal delivery system designed to deliver daily hormone exposure of Norelgestromin and Ethinyl Estradiol
9700003|NCT05138952|Experimental|Mindfulness Meditation|30-day program of mindfulness meditation comprising weekly group meditation tuition and support sessions and daily app-based mediation practice.
9778527|NCT01108341|Experimental|Bendamustine and Ofatumumab|There are 6 planned and 2 optional 28-day cycles in which participants are administered both bendamustine and ofatumumab in the following doses: Bendamustine administered at 90 mg/m^2 intravenously (iv) on study days 1 and 2. Ofatumumab administered at 300 mg iv on day 1 and 1000 mg iv on day 8 of cycle 1. Ofatumumab administered at 1000 mg iv on day 1 of all additional cycles.
9778528|NCT01108406|Experimental|SoundBite Hearing System|"The objective of this study was to assess the long-term safety and quality of life impact of the SoundBite™ Hearing System.~Safety was measured in terms of dental, audiological and medical adverse events related to device or procedure.~Quality of Life was measured in terms of changes in Abbreviated Profile of Hearing Aid Benefit (APHAB) and as reported in a quality of life survey (SSD Questionnaire).~The duration of the study was 6 months with measures taken at Day 1, 3 months and 6 months."
9778529|NCT01108445|Active Comparator|RAD001|Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
9778530|NCT01108445|Active Comparator|Sunitinib|Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
9778531|NCT01108458|Experimental|Pertuzumab plus Erlotinib Hydrochloride|"Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks~Erlotinib hydrochloride 150 mg/day by mouth"
9778532|NCT01108510|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo + ATV + FTC/TDF once daily
9778533|NCT01108510|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo + ATV + FTC/TDF once daily
9778534|NCT01108718|Experimental|Participants: Tempur Pedic first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder who receive the Tempur-Pedic mattress first, then the Control Mattress.
9778535|NCT01108718|Placebo Comparator|Participants: Control Mattress first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic mattress.
9778536|NCT01108731|Active Comparator|Patients taking the drug Milnacipran|Randomize patients signing informed consent and give 50% of them Milnacipran -- blinded to the investigators.
9778537|NCT01108731|Placebo Comparator|Patients taking the placebo|Randomize patients signing informed consent and give 50% of them the placebo -- blinded to the investigators.
9778538|NCT01108757|Experimental|Drug|
9778539|NCT01108757|Placebo Comparator|Placebo|
9778540|NCT01108796||Patients at cardiovascular risk|
9778541|NCT01108809||Patients with arterial hypertension|
9778542|NCT01108835|Active Comparator|comprehensive care programme|Comprehensive care involving multidisciplinary input.
9778543|NCT01108835|No Intervention|Control group|Control arm with usual care
9778544|NCT01109056|Experimental|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
9778545|NCT01109056|Placebo Comparator|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
9778546|NCT01109069|Experimental|PCI-32765|
9778547|NCT01109108||Children <2 years of age|Children <2 years of age with and without respiratory tract infection
9778548|NCT01109108||Children 2<5 years of age|Children 2<5 years of age with and without respiratory tract infection
9778549|NCT01109147|Active Comparator|aripiprazole|"Imagery: A fMRI session is conducted on schizophrenic patients under aripiprazole (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
9778550|NCT01109147|Active Comparator|risperidone|"Imagery: A fMRI session is conducted on schizophrenic patients under rsiperidone (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
9778551|NCT01109147|Other|control|Imagery: A fMRI session is conducted on healthy volunteers. Genetic: pharmacogenetic sampling. One sample was collected for each subject.
9778552|NCT01109173|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
9778553|NCT01109173|Active Comparator|NEVANAC|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
9778554|NCT01109173|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Ophthalmic Suspension 0.3% Vehicle, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
10189223|NCT03709329|Experimental|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
10204351|NCT02808208|Experimental|Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Subjects who receive a radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)
9700004|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 1|Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.
9700005|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 2|Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.
9700006|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 3|Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.
9700007|NCT05137236|Experimental|Part A: mRNA-1283.211 Dose Level 1|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.
9700008|NCT05137236|Experimental|Part A: mRNA-1283.211 Dose Level 2|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.
9700009|NCT05137236|Active Comparator|Part A: mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1.
9700010|NCT05137236|Experimental|Part B: mRNA-1283.529 Dose Level 1|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.
9700011|NCT05137236|Experimental|Part B: mRNA-1283.529 Dose Level 2|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 2 on Day 1.
9700012|NCT05136196|Experimental|Treatment (nivolumab and cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cabozantinib PO BID. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
9700013|NCT05133700||Qualitative interviews and focus group|Qualitative semi-structured individual interviews and focus groups to be held with people living in care homes (with and without nursing), health and social care staff supporting these people, commissioners and regulators.
9700014|NCT05133700||Qualitative medicines monitoring tools|Submission of current medicines monitoring tools by care homes and services supporting care homes including community pharmacies.
9700015|NCT05129358|Experimental|Dehydration A|The subject is brought to light dehydration (loss of 1.5% of body weight) through physical exercise.
9700016|NCT05129358|Experimental|Dehydration B|The subject is brought to light dehydration (loss of 1.5% of body weight) through i.v. injection of up to 40ug Furosemide
9700017|NCT05120037|Experimental|Active|
9700018|NCT05120037|Sham Comparator|Sham|
9700019|NCT05115838|Experimental|Islatravir 47 mg|Participants receive an ISL 47 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
9700020|NCT05115838|Experimental|Islatravir 52 mg|Participants receive an ISL 52 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
9700021|NCT05115838|Experimental|Islatravir 57 mg|Participants receive an ISL 57 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
9700022|NCT05115838|Placebo Comparator|Placebo|Participants receive a placebo implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
9700023|NCT05111145|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
9700024|NCT05110846|Placebo Comparator|Placebo|Placebo
9700025|NCT05110846|Experimental|CT-868 Low Dose|CT-868
9700026|NCT05110846|Experimental|CT-868 Maximum Tolerated Dose|CT-868
9700027|NCT05109728|Experimental|Group 1 - Newly diagnosed GB (methylated MGMT)|Participants with newly diagnosed glioblastoma with methylated MGMT, will receive [177Lu]Lu-DOTA-TATE every 4 weeks +/- 2 days, starting 7 to 10 days prior to initiation of Radiotherapy (RT) and Temozolomide (TMZ)
9700028|NCT05109728|Experimental|Group 2 - Newly diagnosed GB (unmethylated MGMT)|Participants with newly diagnosed glioblastoma with unmethylated MGMT, will receive [177Lu]Lu-DOTA-TATE every 4 weeks +/- 2 days for the first 3 doses (starting 7 to 10 days prior to initiation of Radiotherapy (RT) and at week 4 and week 8 after Radiotherapy (RT) initiated) and every 3 weeks +/- 2 days for the following doses
9700029|NCT05109728|Experimental|Group 3 - Recurrent GB|Participants with recurrent glioblastoma will receive [177Lu]Lu-DOTA-TATE as single agent therapy every 3 weeks +/- 2 days
9700030|NCT05104450|Experimental|lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention in addition to usual care.
9700031|NCT05104450|No Intervention|usual care control|Participants in this arm will continue with usual care without the lifestyle intervention.
9700032|NCT05103657|Experimental|BI 1358894|
9700033|NCT05103657|Placebo Comparator|Placebo|
9700034|NCT05098028|Experimental|Low Dose Rifaximin ER|twice daily
9700035|NCT05098028|Experimental|Low Dose Rifaximin DER|twice daily
9700036|NCT05098028|Experimental|High Dose Rifaximin ER|twice daily
9700037|NCT05098028|Experimental|High Dose Rifaximin DER|twice daily
9700038|NCT05098028|Placebo Comparator|Placebo|twice daily
9700039|NCT05095376|Active Comparator|Arm I (radiation therapy, temozolomide)|Patients undergo radiation therapy 5 days per week and receive temozolomide PO QD for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
9827815|NCT02469298|Active Comparator|Danirixin matching placebo + Oseltamivir|Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
9700040|NCT05095376|Experimental|ARM II (radiation therapy, temozolomide, lomustine)|Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 and temozolomide PO QD on days 2-6. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
9700041|NCT05091307|Experimental|Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-dose (SD) Influenza Vaccine and Placebo|Participants aged greater than or equal to (>=) 18 years will receive a single intramuscular (IM) injection of Ad26.COV2.S and a seasonal Q SD influenza vaccine on Day 1 and placebo on Day 29.
9700042|NCT05091307|Placebo Comparator|Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S|Participants aged >=18 years will receive a single IM injection of placebo and a seasonal Q SD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
9700043|NCT05091307|Experimental|Group 3: Ad26.COV2.S + Q High-dose (HD) Influenza Vaccine and Placebo|Participants aged >=65 years will receive a single IM injection of Ad26.COV2.S and a seasonal Q HD influenza vaccine on Day 1 followed by placebo on Day 29.
9700044|NCT05091307|Placebo Comparator|Group 4: Placebo + Q HD Influenza Vaccine and Ad26.COV2.S|Participants aged >=65 years will receive a single IM injection of placebo and a seasonal Q HD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
9700045|NCT05089084|Experimental|ARO-APOC3|4 doses or ARO-APOC3 by subcutaneous (sc) injection
9700046|NCT05089084|Placebo Comparator|Placebo|calculated volume to match active treatment by sc injection
9700047|NCT05083975|Experimental|Buzzy System|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after activating the buzzy device extra orally proximal to the site of injection for 30-60 seconds.
9700048|NCT05083975|Active Comparator|Control|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after application of 20% Benzocaine topical anesthestic gel.
9700049|NCT05075018||Healthcare Workers with COVID-19 Infection|Healthcare workers who have been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
9700050|NCT05075018||Healthcare Workers without COVID-19 Infection|Healthcare workers who have not been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
9700051|NCT05073237|Experimental|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. Recommended and only FDA approved dosage is one CE/BZA tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications.
10189224|NCT03709329|Active Comparator|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
9700052|NCT05073237|Placebo Comparator|Placebo|Participants assigned to placebo will receive a daily tablet. To assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication. Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about CE/BZA and its potential side effects and contraindications, again to maintain the blind.
9700053|NCT05065424|Experimental|IV Atropine and Fentanyl Premedication Arm|Participants will receive premedication regimen of 20 micrograms/kilogram intravenous atropine and 0.5 micrograms/kilogram intravenous fentanyl prior to performance of LISA.
9700054|NCT05065424|Placebo Comparator|IV Normal Saline Placebo Arm|Participants will receive two intravenous Normal Saline infusions in quantities equivalent to the calculated volumes of atropine and fentanyl for participant's weight prior to performance of LISA.
9700055|NCT05063344||Sexually active persons who self-select for syphilis testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
9700056|NCT05063344||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
9700057|NCT05063344||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior
9700058|NCT05059522|Experimental|Arm 1|Avelumab monotherapy as specified by sub-study protocol B9991001C
9700059|NCT05059522|Experimental|Arm 2|Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
9700060|NCT05059522|Experimental|Arm 3|Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
9700061|NCT05059522|Experimental|Arm 4|Avelumab monotherapy as specified by sub-study protocol B9991009C
9700062|NCT05059522|Experimental|Arm 5|Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
9700063|NCT05059522|Experimental|Arm 6|Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
9700064|NCT05059522|Experimental|Arm 7|Avelumab in combination with Axitinib as specified by sub-study B9991027C.
9700065|NCT05059522|Experimental|Arm 8|Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
9700066|NCT05056376|Experimental|Fully-Automated Digital Diabetes Prevention Program|Participants will receive Sweetch Digital Diabetes Prevention Program consists of a smartphone app and bluetooth-enabled digital body weight scale that syncs with the app.
9700067|NCT05056376|Active Comparator|Human Coach-Based Diabetes Prevention Program|Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
9700068|NCT05055297|Experimental|SELUTION SLR™ DEB 014|
9700069|NCT05055297|Active Comparator|Plain (Uncoated) Balloon Angioplasty (PTA)|
9700070|NCT05052957|Experimental|stem cell mobilization after radiation therapy|Participants at University Hospitals-Seidman Cancer Center (UH-SCC) will receive stem cell mobilization after 6 weeks of standard of care (SOC) radiotherapy. Followed by SOC chemotherapy.
10189225|NCT03709316|Experimental|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
9700071|NCT05052957|Active Comparator|stem cell mobilization after surgery|Participants at the NIH Cancer Center (NIH-CC) will receive stem cell mobilization following SOC surgery prior to SOC radiotherapy. Followed by SOC chemotherapy.
9700072|NCT05051904||Warfarin users|
9700073|NCT05051904||Dabigatran users|
9700074|NCT05051904||Rivaroxaban users|
9700075|NCT05051644|Experimental|Steps 2 Change (S2C)|Participants randomized to S2C will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks in the outpatient OAT clinic. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting after Session 1. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain and benefits of activity. Session 2 and 3 will emphasize benefits of low impact physical activity and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
10189226|NCT03709316|Placebo Comparator|Placebo|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
10189227|NCT03709303||SCD patients|Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
10189228|NCT03709290||1st group|30 patients were diagnosed with MS according to revised MacDonald's criteria 2017 & collected from Neuropsychiatry department in Assuit university hospital
10189229|NCT03709290||2nd group|30 healthy volunteers subjects matched with age, sex & education level were recruited from outpatient clinic neuropsychiatry department and included only if they had no current or previous history of any neurological illness and their neurological examination was free
10189230|NCT03709251|Experimental|High Intensity Walking|HIW (70-80% Heart Rate max)
9700076|NCT05051644|Active Comparator|Control|Participants randomized to control will be scheduled for 60-minute weekly treatment sessions held over four consecutive weeks focused on problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
9700077|NCT05034952|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
9700078|NCT05034952|Active Comparator|Hydrocodone bitartrate/ acetaminophen (HB/APAP)|Participants will receive HB/APAP.
9700079|NCT05034952|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
9700080|NCT05030441|Experimental|Ivosidenib|-Ivosidenib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg daily for up to 17 months (approximately 18 28-day cycles), with each cycle being 28 days.
9977936|NCT01366716|Experimental|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
10189231|NCT03709251|Experimental|Casual Speed Walking|Self selected pace
10204352|NCT02808208|No Intervention|No Treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Patients receive standard of care.
9700084|NCT05015023|Experimental|Intervention|The behavioral intervention will be conducted on the experimental group for consecutive six months. The components of the intervention will be group health education, provision of IEC materials/Leaflets, and home visits.
9700085|NCT05015023|No Intervention|Control|The routine care will be continued in the control group.
9700086|NCT05014256|Experimental|STEPS Health System Surveillance and Outreach intervention|
9700087|NCT05014256|No Intervention|Usual Kidney Care|
9700088|NCT05004688|Placebo Comparator|Placebo|Placebo immunization
9700089|NCT05004688|Active Comparator|BCG|Active BCG immunization
9700090|NCT04998747|Experimental|AMG 701: dose exploration|Cohorts of 3 to 6 participants each will be administered AMG 701 at different doses to determine the RP2D based on occurence of dose-limiting toxicities (DLTs) and on emerging safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy data.
9700091|NCT04998747|Experimental|AMG 701: dose expansion|Participants will be administered AMG 701 at the RP2D determined from dose exploration stage to further assess the safety, PK, PD, and efficacy of the selected dose.
9700092|NCT04994483|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 52 weeks
9700093|NCT04994483|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 52 weeks
9700094|NCT04988555|Experimental|Phase 1 Arm A without Antifungals|Patients not taking antifungals within 7 days of study entry
9700095|NCT04988555|Experimental|Phase 1 Arm B with Antifungals|Patients receiving anti-fungals that are moderate to strong cytochrome CYP3A4/5 inhibitors (i.e. Posaconazole, voriconazole, fluconazole)
9700096|NCT04988555|Experimental|Phase 2 Arm A AML with MLL (KMT2A) gene rearrangements|Patients with R/R AML w/MLL (KMT2A) gene rearrangements
9700097|NCT04988555|Experimental|Phase 2 Arm B: AML with NPM1c mutations|Patients with R/R AML w/ NPM1c mutations
9700098|NCT04987203|Experimental|Tivozanib in Combination with Nivolumab|Subjects with advanced RCC will receive 0.89 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment [for nivolumab] whichever occurs first.
9700099|NCT04987203|Experimental|Tivozanib|Subjects with advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.
9700100|NCT04983472||Observational Group|Individuals diagnosed with Chronic Obstructive Pulmonary Disease by the Department of Pulmonology of the Faculty of Medicine of Bolu Abant Izzet Baysal University will be referred to the Department of Physiotherapy and rehabilitation of the Faculty of Health Sciences of Bolu Abant Izzet Baysal University
9700101|NCT04979247|Experimental|Oliceridine|Patients receive Oliceridine for pain control.
9700102|NCT04975256|Experimental|Dose escalation|Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination
10189232|NCT03709225|Experimental|Music-based meditation|"The music therapy intervention consists of four in-person sessions (45 minutes) over twelve weeks. Content includes:~Introduction to music therapy and mindfulness~Music-based meditation~Using personal music to shift energy, mood, and support relaxation~Mindfulness through active music making~Discuss bringing mindfulness to daily activities"
10189233|NCT03709212||Individual semi-structured interview|"20 participants will undergo individual semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.~Participants will be recruited from three ethnic backgrounds; Black African/ Caribbean, South Asian and White Caucasian."
10189234|NCT03709212||Focus Group 1|10 participants female black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
10189235|NCT03709212||Focus Group 2|10 participants male Black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
10189236|NCT03709212||Focus Group 3|10 participants female South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
10189237|NCT03709212||Focus Group 4|10 participants male black South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
10189238|NCT03709212||Focus Group 5|10 participants female White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
10189239|NCT03709212||Focus Group 6|10 participants male White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
10189240|NCT03709173||Premanifest HDGEC participants|
10189241|NCT03709173||Early-manifest HDGEC participants|
10189242|NCT03709173||Companions of Premanifest HDGEC|
10189243|NCT03709173||Companions of Early-manifest|
10189244|NCT03709160|Experimental|BUMETANIDE|we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.
10189245|NCT03709160|Active Comparator|INDAPAMIDE|we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.
10189246|NCT03709147|Experimental|FAME arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg~every-three week, 5-day Fasting-mimicking diet (FMD), up to a maximum of 4 cycles"
10189247|NCT03709147|Experimental|MERCY arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg"
10189248|NCT03709147|No Intervention|BORN arm|Standard clinical approach.
10189249|NCT03709108|Other|Experimental-Control|Subjects randomized to this Arm would go through the Experimental Admission (SI-informed bolus calculator) first and Control Admission (regular bolus calculator) second
10189250|NCT03709108|Other|Control-Experimental|Subjects randomized to this Arm would go through the Control Admission (regular bolus calculator) first and Experimental Admission (SI-informed bolus calculator) second
10189251|NCT03709095|Active Comparator|Moderate Intensity Continuous Training|Training was performed three times a week for five weeks. Each session began with a 2 minute warm up, and concluded with a 3 minute cool down. Following the warm-up, participants performed 20 minutes of arm cycling at a self-selected cadence at 45-65% of their peak power output. Total training duration was 25 mins.
10189252|NCT03709095|Experimental|Sprint Interval Training|"The SIT protocol was adopted from Gillen and colleagues (See Ref), and consisted of 3 x 20 second all-out efforts at ≥ 100% of an individuals peak power output. Each sprint was interspersed by 120 seconds of active recovery at 10% of an individuals peak power output. Total training duration was 10 mins."
10189253|NCT03709082|Experimental|Phase 1: Palbociclib 75 mg|Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
10189254|NCT03709082|Experimental|Phase 1: Palbociclib 100 mg|Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
10189255|NCT03709082|Experimental|Phase 1: Palbociclib 125 mg|Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
10189256|NCT03709082|Experimental|Phase 2: RP2D|Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
10189257|NCT03709069|No Intervention|Traditional Group|"Traditional group receives diet from hospital kitchen quantity of which calculated depending on calorie requirement per kg body weight. This diet is same for all burn patients fulfilling the inclusion criteria of the study and it will be labelled as routine diet.~Wounds of patients will be managed by closed dressing to be changed on every third day."
10189258|NCT03709069|Experimental|Albumin Group|Interventional group receiving enteral supplemental albumin 2mg per kg body weight along with routine hospital kitchen diet same as group A and same wound management with closed dressing to be changed on every third day similar to group A.
10189259|NCT03709056|Experimental|HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg|
10189260|NCT03709056|Active Comparator|Propofol 2.0/1.0mg/kg group|
10189261|NCT03709043|Experimental|Kudzu|Standardized kudzu
10189262|NCT03709043|Placebo Comparator|Control|Placebo
10189263|NCT03709030|No Intervention|Standard Care|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with abdominal ultrasound as first line imaging, as per standard care
10189264|NCT03709030|Experimental|Direct MRCP|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with magnetic resonance cholangiopancreatography (MRCP) as first-line imaging
10189265|NCT03709004|Experimental|Pacifier|Mother given a pacifier during birth hospitalization, along with other baby items
10189266|NCT03709004|No Intervention|Control|Mother not given a pacifier, just the other baby items
10189267|NCT03708991||IVF combined with PGT-A|5000-10000 motile sperm will be added to the oocyte
10189268|NCT03708991||ICSI combined with PGT-A|1 motile sperm will be injected into the oocyte
10189269|NCT03708978||mammography group|women who receives mammography because of suspected breast lesion(s)
10189270|NCT03708939|Experimental|glucose|
10189271|NCT03708939|Experimental|aspartame|
10189272|NCT03708939|Experimental|sucralose|
10189273|NCT03708939|Experimental|saccharin|
10189274|NCT03708939|Experimental|Stevia|
10189275|NCT03708939|Experimental|No supplement control|
10189276|NCT03708926|Experimental|abaloparatide|abaloparatide 80 mcg subcutaneously once daily for 90 days
10189277|NCT03708926|Placebo Comparator|placebo|placebo formulated similarly but without active abaloparatide injected subcutaneously once daily for 90 days
10189278|NCT03708913|Experimental|Open-Label Lateral Hypothalamic DBS Stimulation|Open-label lateral hypothalamic DBS stimulation for 1 year.
10189279|NCT03708900|Experimental|LCI699 (osilodrostat)|Subjects with cushing's disease taking LCI699 (osilodrostat)
10189280|NCT03708887|Experimental|Low dose group|Low dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1 gram per day for 1 year.
10189281|NCT03708887|Experimental|High dose group|High dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 gram per day for 1 year.
10189282|NCT03708887|Placebo Comparator|Control group|Control drug, matching placebo capsules, 1 gram per day for 1 year.
10189283|NCT03708874||Group 1.Intraoperative bupivacaine|intraperitoneal bupivacaine wash-emergency laparoscopic cholecystectomy
10189284|NCT03708874||Group 2.Intravenous paracetamol|intravenous paracetamol-emergency laparoscopic cholecystectomy
10189285|NCT03708861|Experimental|MVC + ATV/r|maraviroc (300 mg tablet, 300 mg per day every 24 hours) + atazanavir/ritonavir (300 and 200 mg capsule, 300 and 200 mg per day every 24 hours / 100 mg capsule, 100 mg per day every 24 hours)
10189286|NCT03708848|Experimental|Tailored Therapy|Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.
10189287|NCT03708835|Experimental|Transitional Care Model is applied|Types of interventions that are applied to stroke caregivers and patient based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training. Multiple interventions including at least three face-to-face interviews at the hospital, distance education via Web and telephone communication for three months,and one home visit within seven days after discharge will be performed in order to increase health literacy levels and caregiving competence of the caregivers and to reduce burnout. In pre-tests and post-tests to be applied to the caregivers. Rate of return to the hospital, risk of pressure sore, and time of access to home health services will be assessed in stroke patients
10189288|NCT03708835|No Intervention|Routine hospital schedule|In the first interview after the admission to the hospital, the pretest will be applied to intervention and control groups and the posttest would be applied to the groups at the end of three months after discharge. After taking the posttest, the website will be made available to the control group.
10189289|NCT03708822|Experimental|Docetaxel and Cisplatin and Nimotuzumab|
10189290|NCT03708783|Experimental|No. 10 Lymph Node Dissection group|Patients with locally advanced upper or middle third gastric cancer will receive laparoscopic total gastrectomy and D2 lymphadenectomy with spleen-preserving No.10 lymph node dissections
10189291|NCT03708757|Experimental|Post isometric relaxation - Group I|"Group I will receive post isometric relaxation techniques in order to reduce hamstring spasticity. This technique induces relaxation and decreases spasticity in muscles~Post isometric relaxation (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercises (10 reps 3sets) hold for 2 sec"
10189292|NCT03708757|Active Comparator|Eccentric Muscle contraction - Group II|"Eccentric Muscle contraction lengthens the spastic muscles and enhance joint flexibility.~Hot Pack for (10 MINTS) Eccentric stretching (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercise(10 reps 3sets) hold for 2 sec In both experimental groups PIR and Eccentric stretching is applied on hamstring to"
10189293|NCT03708718|Active Comparator|Prednisolone|"Prednisolone 5mg enteric-coated tablets, over-encapsulated in a hard gelatine capsule and filled with lactose BP. The prednisolone will be self-administered, orally with water before or after a meal once a day. Dosing will be continuous for a total of 6 months.~The total dose prescribed will be equivalent to approximately 0.3mg/kg/day. The minimum dose prescribed will be 10mg per day (2 capsules) and a maximum of 30mg per day (6 capsules).~From August 2020: The prednisolone is no longer over-encapsulated. Prednisolone 5mg enteric-coated tablets will be prescribed and taken as above."
9700103|NCT04975256|Experimental|Dose expansion|Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963
9700104|NCT04958421|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
9700105|NCT04958421|Experimental|PiCSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
9700106|NCT04957719|Experimental|Selatogrel|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
9700107|NCT04957719|Placebo Comparator|Placebo|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
10189294|NCT03708718|Placebo Comparator|Placebo oral capsule; From August 2020 - 'no additional treatment'|"The placebo will be a hard gelatine capsule filled with lactose BP and identically matched to the prednisolone capsules. The placebo will be self-administered once a day, orally with water before or after a meal. Dosing will be continuous for a total of 6 months.~From August 2020 - no placebo capsule will be administered."
10189295|NCT03708705||Relapse|Relapse of tumor within two years after liver transplantation
9700108|NCT04955626|Experimental|10 µg dose|1 dose
9700109|NCT04955626|Placebo Comparator|Placebo|1 dose
9700110|NCT04955626|Experimental|30 µg dose|1 dose
9700111|NCT04955626|Experimental|60 µg dose|1 dose
9700112|NCT04949711|Experimental|Intervention|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive ridesharing vouchers.
9700113|NCT04949711|Sham Comparator|Control|Participants will be asked to complete 3 surveys over 2 weeks to collect in information on their alcohol use and about themselves, and receive online shopping voucher.
9700114|NCT04948892||Father/partner present, Kolding hospital|All father/partners, mothers and hospital staff involved in hyperacute cesarean section category 1 in general anesthesia (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) in Kolding Hospital, where the father is present in the OR during the cesarean section category 1
9700115|NCT04948892||Father/partner not present, Aabenraa hospital|"All father/partners and mothers involved in hyperacute cesarean section category 1 in general anesthesia in Aabenraa hospital, where the father is not present in the OR during the cesarean sectio category 1.~All relevant hospital staff, who sometimes participates in cesarean sectio category 1 (obstetrician, anesthesiologist, OR-nurse, midwife, anesthetic nurse, pediatrician) will be asked to fill in a questionnaire on their thoughts and opinions on having the father/partner present during hyperacute cesarean sectio category 1."
9700116|NCT04943783|Experimental|Atorvastatin|Atorvastatin, 20mg once a day, for six months
10189296|NCT03708705||Non-relapse|Non-relapse of tumor within two years after liver transplantation
9700117|NCT04943783|No Intervention|No drug|no drug
9700118|NCT04942106|Other|Side-lying position followed by Supine position|In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position.
9700119|NCT04942106|Other|Supine position followed by Side-lying position|In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position.
9700120|NCT04935801|Sham Comparator|LD Vehicle_GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (14.8ug) without peptides
9700121|NCT04935801|Experimental|LD PepGNP-Dengue|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (14.8ug) plus peptides
9700122|NCT04935801|Sham Comparator|HD vehicle-GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (44.5ug) without peptides
9700123|NCT04935801|Experimental|HD PepGNP-Dengue|High dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (44.5ug) plus peptides
9700124|NCT04933253|Experimental|Experimental|this cohort will receive 2 L of warm 37celsius saline irrigation of the mediastinum prior to closure of the chest
9700125|NCT04933253|No Intervention|Control|this cohort will receive the normal standard of care as established by the primary surgeon
9700126|NCT04930536|Experimental|Acalabrutinib Capsule|Single-arm study
9700127|NCT04925713|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion|One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
9700128|NCT04921072|Experimental|CG - Constant practice condition group|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
9700129|NCT04921072|Experimental|VG - Variable practice condition group|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
10189297|NCT03708692||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
10189298|NCT03708692||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
10189299|NCT03708679||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
9700130|NCT04918186|Experimental|Durvalumab + BA3011|
9700131|NCT04918186|Experimental|Durvalumab + BA3021|
9700132|NCT04918186|Experimental|Sub Study X (etc.)|
9700133|NCT04912427|Experimental|Isatuximab + Boretezomib + Dexamethasone|"Each cycle is 28 days~Cycle 1~Days 1, 8, 15, and 22: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~Cycles 2-8~Days 1 and 15: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~Days 8 and 22: Dexamethasone at start time and Bortezomib at 30 minutes after start time~Cycles 9+~Days 1 and 15: Dexamethasone at start time and Isatuximab at 30-60 minutes after start time"
10189300|NCT03708679||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
10189301|NCT03708666|Other|Telemonitoring of blood pressure|Patients measure their blood pressure and register their results on the app or website.
9700134|NCT04905407|Experimental|Part 1: Tamibarotene/Venetoclax/Azacitidine|"Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination as follows: Azacitidine (intravenously or subcutaneously) at 75 milligrams (mg)/square meter (m^2) once daily, on Days 1 through 7 of each 28-day therapy cycle (per VIDAZA USPI). Alternative dosing of azacitidine (Days 1 through 5, 8, and 9) will be permitted throughout the study.~Venetoclax (orally) daily on Days 1 through 28 per standard of care. Standard of care daily dosing is 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and beyond.~Tamibarotene 6 mg twice daily (BID) orally, on Days 8 through 28 of each 28-day therapy cycle."
9700135|NCT04905407|Experimental|Part 2: Tamibarotene/Venetoclax/Azacitidine|Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination at the dose and regimen selected in Part 1.
9700136|NCT04905407|Active Comparator|Part 2: Venetoclax/Azacitidine|Participants will receive the venetoclax/azacitidine combination at the dose and regimen selected in Part 1.
9700137|NCT04905407|Experimental|Part 3: Tamibarotene/Venetoclax/Azacitidine|Part 2 participants treated with venetoclax/azacitidine who experience progressive disease, relapse after initial CR or CRi response, or treatment failure may begin subsequent treatment in Part 3, where tamibarotene will be added to their regimen.
9700138|NCT04903509|Experimental|BI 1820237|Part 1 and part 2 of the trial.
9700139|NCT04903509|Placebo Comparator|Placebo|Part 1 and part 2 of the trial.
9700140|NCT04903509|Experimental|BI 1820237 + liraglutide|Part 3 of the trial.
9700141|NCT04903509|Placebo Comparator|Placebo + liraglutide|Part 3 of the trial.
9700142|NCT04903496||Group A: Diabetic patients with CVD, CKD or at risk|The group A includes all Patients with diagnosis of diabetes, and with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
9700143|NCT04903496||Group B: Diabetic patients without CVD, CKD or at risk|The group B includes all patients with diagnosis of diabetes, but not with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
9700144|NCT04903496||Group C: Non-diabetic patients with CVD, CKD or at risk|The group C includes all patients with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, but not with diagnosis of diabetes.
10189302|NCT03708653||PHN(+)|Patients who have persistent pain more than three months after the onset of herpes zoster.
10189303|NCT03708653||PHN(-)|Patients whose pain disappear within three months.
10189304|NCT03708640|Placebo Comparator|Physical Activity Counseling|"Group receives baseline physical activity counseling.~Group does not receive personalized, health coaching via smart text messages."
10189305|NCT03708640|Experimental|Digital Activity Tracker/Smart Text Messaging|"Group receives baseline physical activity counseling.~Group receives personalized, health coaching via smart text messages informed by digital activity tracker."
9700145|NCT04903496||Group D: Non-diabetic patients without CVD, CKD or at risk|The group D includes all patients without diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, and without diagnosis of diabetes.
9700146|NCT04892472|Experimental|Study Arm|Pembrolizumab and TTFields
9700147|NCT04892147|Experimental|Experimental group|Randomly selected to participate first in MOBA group
9700148|NCT04892147|Other|Wait-list-control group|Randomly selected for study assessments parallel with experimental group. Participates in MOBA after completion of the experimental group
9700149|NCT04888988|Experimental|Arm 1 (EXCAP exercise)|Patients undergo the EXCAP exercise intervention consisting of a home-based, self-directed, individually tailored progressive walking and resistance program for up to 6 weeks. In addition, patients meet with a certified exercise instructor over 45 minutes at baseline and 2 additional booster meetings over 15-30 minutes during weeks 2 and 3 or weeks 4 and 5.
10189306|NCT03708614|Other|Controlled energy intake with elevated protein intake|Dietary intervention - Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks.
10189307|NCT03708588|Experimental|Experimental: Chewed ticagrelor|Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)
10189308|NCT03708588|Active Comparator|Active Comparator: Integral pill|Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL of water. (180mg)
9700150|NCT04888988|No Intervention|Arm 2 (usual care)|Patients receive usual care for 6 weeks. At the end of the study, patients may receive the exercise kit and complete the EXCAP program as in Arm 1.
9700151|NCT04864548|Experimental|Group 1A: Low dose challenge|"Intranasal viral challenge with 1 x 10^1 TCID_50 in previously infected volunteers~N= 6-8 participants"
9700152|NCT04864548|Experimental|Group 1B: Mid-dose challenge|"Intranasal viral challenge with 1 x 10^2 TCID_50 in previously infected volunteers~N= 6-8 participants"
9700153|NCT04864548|Experimental|Group 1C: High-dose challenge|"Intranasal viral challenge with 1 x 10^3 TCID_50 in previously infected volunteers~N= 6-8 participants"
9700154|NCT04864548|Experimental|Group 1D: High-dose challenge|"Intranasal viral challenge with 1 x 10^4 TCID_50 in previously infected volunteers~N= 4-8 participants"
9700155|NCT04864548|Experimental|Group 2: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 1a-d (1x10^1, 1x10^2, 1x10^3 or 1x10^4 TCID_50)~N=10-40 participants"
9700156|NCT04864548|Experimental|Group 3a: Low dose challenge|"Intranasal viral challenge with 1 x 10^2 TCID_50 in previously uninfected, vaccinated volunteers~N=6-8 participants"
9700157|NCT04864548|Experimental|Group 3b: High dose challenge|"Intranasal viral challenge with 1 x 10^3 TCID_50 in previously uninfected, vaccinated volunteers~N=6-8 participants"
9700158|NCT04864548|Experimental|Group 3c: High dose challenge|"Intranasal viral challenge with 1 x 10^4 TCID_50 in previously uninfected, vaccinated volunteers~N=4-8 participants"
9700159|NCT04864548|Experimental|Group 4: Safety & Dose confirmation Group|"Intranasal viral challenge with the dose identified from Group 3a-c (1x10^2, 1x10^3, 1x10^4 TCID_50)~N=10-40 participants"
9700160|NCT04864054|Experimental|ECT204|A minimum of twelve (12) subjects will be treated to determine the RP2D.
9700161|NCT04849507|Active Comparator|active taVNS|We will deliver taVNS via the BabyStrong system, with pulses paired with oral feeding, off with rest during 2 feeds a day. Current will be delivered at 0.1milliAmpere (mA) < perceptual threshold (PT), 500microseconds, 25 Hertz (Hz).The ear electrode will be positioned on left tragus for active taVNS.
10189309|NCT03708536|Experimental|bevacizumab plus s-1|
9700162|NCT04849507|Sham Comparator|sham taVNS|The ear electrode positioned on left tragus as for active taVNS. We will test the PT with active stimulation, and then program a sham setting on the BabyStrong unit to deliver no current after the PT is determined.
9700163|NCT04844866|Experimental|MB-CART2019.1|Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight.
9700164|NCT04844866|Active Comparator|SoC|Immunochemotherapy will be administered from the following 2 predefined regimens: R-GemOx (8 cycles of 14 days each) or BR plus polatuzumab vedotin (6 cycles of 21 days each). BR plus polatuzumab vedotin will be capped at a maximum of 10% of participants; i.e. a maximum of 8 participants will be randomised to the BR plus polatuzumab vedotin regimen.
10189310|NCT03708536|Active Comparator|bevacizumab plus capecitabin|
9700165|NCT04832685|Experimental|UP and DOWN-Modulation|All participants will receive UP- and DOWN-modulation of the posterior cingulate cortex (PCC).
9700166|NCT04831450|Experimental|Cemiplimab After CRT in HNSCC|Participants will receive Cemiplimab for 6 consecutive months (a total of 8 cycles) 14-42 days after completion of standard of care CRT.
9700167|NCT04818814|Experimental|Mindfulness Meditation (MM) App|Participants randomized to the MM condition will be asked to download and use the free Mindfulness Coach app (available for iOS and Android platforms) developed by the Veteran Affairs National Center for PTSD. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes. Participants will attend a live videochat orientation to the study with the research coordinator (RC) to receive assistance in downloading and using the app. Participants will be asked to listen to at least one, and ideally two, audio-guided meditation exercises using the app daily for six weeks. The RC will ask participants to complete weekly logs of their MM app use via a Qualtrics survey sent via email.
9700168|NCT04818814|Active Comparator|Engagement and Distraction (ED) App|Participants randomized to the Engagement and Distraction condition will be asked to download and use the free TED Talk app (available for iOS and Android platforms). The app offers many videos of engaging and distracting presentations about technology, entertainment, and design. The research coordinator will work with the participant to create a customized list of Ted Talk videos, each lasting 6-12 minutes, based on participants' personal interests. Participants will be asked to listen to or watch at least one, and ideally two, presentations using the app daily for six weeks. The research coordinator will ask participants to complete weekly logs of their TED Talk app use via a Qualtrics survey sent via email.
9700169|NCT04816526|Experimental|Descartes 08|
9700170|NCT04814186|Experimental|Chinese participants treated with Tafamidis|treatment group with tafamidis
9700171|NCT04795531|Experimental|Once weekly insulin icodec + once daily placebo|Participants will get once daily and once weekly injections
9700172|NCT04795531|Experimental|Once weekly placebo and once daily insulin degludec|Participants will get once daily and once weekly injections
9700173|NCT04774718|Experimental|ALK-Fusion Positive|Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle
9700174|NCT04769726|Experimental|treatment|20% en from almonds
9700175|NCT04769726|No Intervention|control|standard diet
9700176|NCT04759664|Experimental|LUT014 Gel (Dose 1)|
9700177|NCT04759664|Experimental|LUT014 Gel (Dose 2)|
9700178|NCT04759664|Placebo Comparator|Placebo|
10189311|NCT03708510|Experimental|Filtek Silorane-Er,Cr:YSGG Laser|
10189312|NCT03708510|Experimental|Filtek Silorane- Diamond Bur|
10189313|NCT03708510|Experimental|Kalore- Er,Cr:YSGG Laser|
10189314|NCT03708510|Experimental|Kalore- Diamond Bur|
10189315|NCT03708497|Active Comparator|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
9700179|NCT04758338|Experimental|CTS Program Arm|6-week intervention delivered via telehealth using the VUMC telehealth services.
9700180|NCT04758338|Active Comparator|Education Attention Control Arm|Receive educational materials either online, by email, or in print form.
9700181|NCT04757402|Active Comparator|Control arm|All eligible candidates will be receiving standard preoperative counselling as per the hospital standards and protocols. The patient will fill five-points Amsterdam Preoperative Anxiety and Information Scale (APAIS) form for anxiety evaluation and Seven-points Likert Scale form for satisfaction regarding the counselling.
10189316|NCT03708497|Experimental|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
10189317|NCT03708497|Active Comparator|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
10189318|NCT03708484|Active Comparator|Aerobic Interval Training|Aerobic Interval Training is active comparator
10189319|NCT03708484|Experimental|Aerobic + Resistive Interval Training|Aerobic + Resistive Interval Training is experimental
10189320|NCT03708471|Experimental|Two-stage hybrid abltaion|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will receive percutaneous catheter ablation and recommendations about cardiovascular risk control.
10189321|NCT03708471|Active Comparator|Thoracosopic surgical ablation|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will only receive recommendations about cardiovascular risk control.
10189322|NCT03708458|Active Comparator|Control group|Control group - patients receiving 100 mg indomethacin suppository immediately post ERCP
10189323|NCT03708458|Active Comparator|Group A|Group A - patients receiving N-acetylcysteine (NAC) 600 mg before performing ERCP and indomethacin suppository 50 mg before and after performing ERCP
10189324|NCT03708458|Active Comparator|Group B|Group B - patients receiving indomethacin suppository 50 mg before and 50 mg after ERCP
9700182|NCT04757402|Experimental|NSQIP Arm|All eligible candidates will be receiving standard preoperative counselling as per the control arm PLUS the risk will be explained using the scores from the NSQIP surgical risk calculator. The anxiety and the satisfaction scores will be recorded as in the control arm.
9700183|NCT04755465|Experimental|Resistance Exercise Group|The lower extremity resistance exercise (REx) program was designed by reviewing the exercise principles recommended by the ACSM and the literature on physical activity and hematological cancer patients. The patients were treated for 40-60mins, 20 sessions. The exercise program includes active movements of the upper and lower extremities, stretching exercises, and resistance exercises for the lower extremities. REx to be applied with resistance bands of different resistance or with the patient's body weight. Clinical force generation of therapy bands follows a progression. Our proposed training protocol includes 4-6 different exercises for each extremity. Intensity, sets, and reps were adjusted to a target score of 12 to 14 using the Borg scale. Patients performed 1 set of 10 repetitions of each REx based on their fatigue level. Resistance increased every three rounds.
9700184|NCT04755465|Experimental|NMES Training Group|In addition to resistance exercises, NMES will be applied to the quadriceps muscles in both legs of the patients in this group. The application will be made with a portable device using disposable electrodes. One of the electrodes will be placed proximally, that is, at the midpoint of the quadriceps muscle, while the second electrode will be placed on the distal part. Stimulation intensity will be adjusted individually for each limb to achieve the maximum tolerated intensity. In order to ensure that the patients get used to the device, low-intensity current with a frequency range of 5 Hz, 10-30 minutes. Afterwards, the treatment program will continue with a high frequency current with a frequency range of 50 Hz, 15 minutes. The duration of treatment will likewise be increased as adaptation is made to the patient.
9700185|NCT04752215|Experimental|BI 765049 single treatment group|BI 765049
10189325|NCT03708445|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
10189326|NCT03708432||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
9700186|NCT04752215|Experimental|BI 765049 + BI 754091 combination treatment group|BI 765049 + BI 754091
9700187|NCT04737187|Experimental|trifluridine/tipiracil in combination with bevacizumab|
9700188|NCT04737187|Active Comparator|trifluridine/tipiracil monotherapy|
9700189|NCT04734288|Experimental|Immune response|This is a single-arm study. All subjects will be treated equally and will receive the same type and amount of nutritional supplements.
9700190|NCT04730791||Chronic Pain Patients|Adult patients 18-65 years, with chronic pain lasting for 3 or more months, with a pain intensity of at least 3 on a 0-10 numerical pain rating scale on most days.
9700191|NCT04730791||Control Group|Free pain participants
9700192|NCT04729205|Experimental|Promitil 1.6 mg/kg|PROMITIL (1.6 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
9700193|NCT04729205|Experimental|Promitil 2.0 mg/kg|PROMITIL (2.0 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
9700194|NCT04719897|Experimental|FIRST: Repairing Thoughts|
9700195|NCT04716907||Case : COVID-19 positive patients|patients hospitalized for COVID-19 infection
9700196|NCT04716907||Control : COVID-19 negative patients|patients hospitalized for other reasons
9700197|NCT04716881|Experimental|Vivitrol (naltrexone)|Intramuscular injection of Vivitrol (naltrexone), 380 mg. Six doses given 28 days apart.
9700198|NCT04714983|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
9700199|NCT04714983|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
9700200|NCT04714983|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
9700201|NCT04710212||Induction Chemotherapy for Acute Leukemia|Receiving induction chemotherapy for acute leukemia, and receiving fluoroquinolone (FQ) prophylaxis.
9700202|NCT04710212||Hematopoietic stem cell transplantation (HCT)|Undergoing hematopoietic stem cell transplantation (HCT), and receiving fluoroquinolone (FQ) prophylaxis.
9700203|NCT04708834|Experimental|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
9700204|NCT04706013|Experimental|Single Arm Active|Pyridoxal 5'-Phosphate
9700205|NCT04701203|Experimental|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
9700206|NCT04701203|Placebo Comparator|Placebo|Placebo for TransCon PTH delivered once daily by subcutaneous injection
9700207|NCT04697498|Active Comparator|The Control Group|The control group will include patients who will undergo surgery under general anesthesia.
9700208|NCT04697498|Experimental|The Study Group|The study group will include patients who will undergo surgery under general anesthesia using a bilateral bi-level Erector spine plane block.
10189327|NCT03708406||Children with Cleft lip and palate|Children with Cleft lip and palate
10189328|NCT03708406||Children with Cleft palate|Children with Cleft palate
10189329|NCT03708380|Experimental|Dietary intervention|Community-based dietary intervention to Black and African American barbers identified as having previously undiagnosed diabetes and prediabetes
10189330|NCT03708341|Experimental|Melatonin|Patients will be administered melatonin 5 mg at a fixed time every day during their ICU stay (from day of admission till day of discharge from ICU)
9700209|NCT04696692|Other|Patient with histologically confirmed diffuse large B-cell lymphoma|
9700210|NCT04694950||Group feasibility|Adults undergoing elective urologic laparoscopic robotic surgery.
9700211|NCT04691648||Xospata|Patients who receive Xospata® 40 mg tablet in routine clinical practice according to the drug label approved at the time of marketing authorization.
9700212|NCT04691375|Experimental|Part A: PY314 Single agent dose level 1|PY314 single agent dose level will depend on any safety signal observed in this cohorts only. Following the determination of the safety and tolerability of at least two PY314 dose levels by the safety review committee.
10189331|NCT03708341|Placebo Comparator|Placebo|Patients will be administered a placebo pill that is identical in shape and color to the melatonin pill, at a fixed time every day during their ICU stay
9700213|NCT04691375|Experimental|Part A: PY314 Single agent dose level 2|PY314 single agent dose level 2 dose escalation of PY314 as a single agent will continue in the absence of unacceptable dose limiting toxicity to the maximum administered dose as defined in the predefined dose escalation schema.
9700214|NCT04691375|Experimental|Part A: PY314 Single agent dose level 3|PY314 single agent dose level 3 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314
9700215|NCT04691375|Experimental|Part A: PY314 Single agent dose level 4|PY314 single agent dose level 4 to characterize the pharmacokinetic profile of PY314 as a single agent.
9700216|NCT04691375|Experimental|Part A: Combination dose level 1|Combination dose level 1 to characterize the safety and tolerability of PY314 as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including refractory to check point inhibitor.
9700217|NCT04691375|Experimental|Part A: Combination dose level 2|PY314 combination dose level 2 to identify the maximum tolerated dose and/or to determine the recommended dose for expansion of PY314 administered alone and in combination with pembrolizumab.
9700218|NCT04691375|Experimental|Part A: Combination dose level 3|PY314 combination dose level 3 to characterize the pharmacokinetic profile of PY314 as a single agent and in combination with pembrolizumab.
10189332|NCT03708302|Active Comparator|Study Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.2% ropivacaine.
10189333|NCT03708302|Sham Comparator|Control Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.9% saline.
9700219|NCT04691375|Experimental|Part A: Combination dose level 4|PY314 combination dose level 4 to describe, in subjects selected by pre-specified tumor histology, anti-tumor activity of PY314 administered alone and in combination with pembrolizumab.
9700220|NCT04691375|Experimental|Part B: Single agent dose expansion dose level 1|PY314 single agent dose expansion dose level 1 to define further the safety and tolerability of PY314 alone.
9700221|NCT04691375|Experimental|Part B: Combination dose expansion cohort 1|PY314 in combination with pembrolizumab dose expansion cohort 1 to define the safety and tolerability of PY314 alone and in combination with pembrolizumab over multiple treatment cycles in subjects with pre-defined tumor histologies and confirmed TREM2 expression.
9700222|NCT04691375|Experimental|Part B: Combination dose expansion cohort 2|PY314 in combination with pembrolizumab dose expansion cohort 2 to further characterize the PK profile of PY314 as a single agent and in combination with pembrolizumab.
9700223|NCT04691375|Experimental|Part B: Combination dose expansion cohort 3|PY314 in combination with pembrolizumab dose expansion cohort 3 to characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
9700224|NCT04691375|Experimental|Part B: Combination dose expansion cohort 4|PY314 in combination with pembrolizumab dose expansion cohort 4 to evaluate the incidence of ADA formation and TREM2 expression.
9700225|NCT04691375|Experimental|Part B: Combination dose expansion cohort 5|PY314 in combination with pembrolizumab dose expansion cohort 5 to further explore and characterize the anti-tumor activity of PY314 alone and in combination with pembrolizumab in subjects with selected prespecified tumor histologies and known TREM2 expression.
9700226|NCT04687969||COHORT A: PROSTATE CANCER PATIENTS|"Primary prostate cancer patients scheduled to undergo radical prostatectomy.~Twenty five (25) prostate cancer patients will undergo two [18F]DCFPyL PET/MRI scans and~Sixty (60) additional prostate cancer patients will undergo one [18F]DCFPyL PET/MRI scan."
9700227|NCT04687969||COHORT B: SOLID TUMOR PATIENTS|"Patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma).~Up to fifty (50) patients will undergo up to three [18F]DCFPyL PET/MRI scans"
9778555|NCT01109173|Placebo Comparator|NEVANAC Vehicle|Nepafenac 0.1% vehicle, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
9778556|NCT01109316|Active Comparator|Insulin Lispro 2 Day|
10189334|NCT03708276|Experimental|My MS Toolkit|20 Participants asked to use My MS Toolkit.
10189335|NCT03708237|Placebo Comparator|Placebos|Placebo Dose: Not Applicable Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
10189336|NCT03708237|Experimental|Ropinirole|Drug: ropinirole Dose: 0.25 - 2 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
10189337|NCT03708237|Experimental|Gabapentin|Drug: gabapentin Dose: 100 - 300 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
10189338|NCT03708198|Other|Intercostal Nerve Block|The study participants will be given a standard 266 mg single dose injection of liposomal bupivacaine by the surgeon at the start of the surgery.
10189339|NCT03708185|Experimental|HIIT + beta-alanine|Participants will ingest an active supplement containing beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
10189340|NCT03708185|Experimental|HIIT + placebo|Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
10189341|NCT03708172|Active Comparator|rTMS + Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive active cognitive training (CT) which consists of completing computer-based tasks designed to enhance executive function.
9700228|NCT04685421|Experimental|Liposomal Bupivacaine PK|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
9700229|NCT04677907|Active Comparator|Cemented knee replacement|total knee replacement with cemented modular knee replacement as per current standard for total knee replacements.
10189342|NCT03708172|Sham Comparator|rTMS + Sham Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive sham cognitive training (CT) which consists of completing computer-based tasks.
10189343|NCT03708146|Experimental|Cohort 1 (BIA 5-1058 /50 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
9700230|NCT04677907|Experimental|Uncemented knee replacement|total knee replacement with uncemented modular knee replacement, which is CE certified and accepted in the field.
10189344|NCT03708146|Experimental|Cohort 2 (BIA 5-1058 /25 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 25 mg (as 1 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
10189345|NCT03708146|Experimental|Cohort 3 (BIA 5-1058 /100 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
9700231|NCT04675840|Active Comparator|intrathecal morphine|Spinal injection of 15mg Bupivakain and 0,25mg morphine before surgery.
9700232|NCT04675840|Active Comparator|opiate po/iv|Patient given 10mg Oxycodone orally before surgery.
9700233|NCT04673825|Experimental|Intervention: patient initiated care + telemonitoring|Patients in the intervention group will only have a scheduled outpatient visit at baseline and after 1 year. Patients will answer questionnaires and have routine blood tests done before every visit. At 6 months, there will be a remote monitoring check-up and results will be checked by the physician. If indicated, a telephone or video call can take place or a physical visit can be planned. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
9700234|NCT04673825|No Intervention|Control group|The standard care group will have a scheduled outpatient visit at baseline and after 1 year, and in between as usual, scheduled at the discretion of the treating rheumatologist. Prior to each visit, patients complete questionnaires in SpA-Net and have routine blood tests done. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
9700235|NCT04673409||Suspected myocarditis of undefined aetiology|Patients with signs and symptoms of acute myocarditis (as defined by the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases).
9700236|NCT04673409||Suspected myocarditis with autoimmune rheumatic disease|Patients with suspected myocarditis due to an underlying AIRD.
9700237|NCT04668742|Experimental|Arm 1: DYNAtraq - tracheostomy fixation device|Use of DYNatraq installed in chest with skin adhesive and fixed to tracheostomy tube
9700238|NCT04668742|No Intervention|Arm 2: Usual management of tracheostomy|No interventions will be used additional to usual management
9700239|NCT04665999||Free-cycling females|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
9700240|NCT04665999||Females taking Monophasic contraception|Continuous glucose monitor (CGM) data will be collected for three (3) full menstrual cycles. At the end of data collection, data will be analyzed to track insulin sensitivity and glycemic variability changes across the menstrual cycle. Participants will be asked to record meals consumed and free-cycling females will be asked to confirm ovulation by means of study-provided ovulation kits. Participants will be asked to record dates of beginning of menses and ovulation. Participants will also be provide an activity tracker to wear during the duration of the trial.
9700241|NCT04662684|Experimental|Rivaroxaban|Rivaroxaban 10mg OD for 35+/- 4 days post-hospital discharge
9700242|NCT04662684|No Intervention|No intervention|control
9700243|NCT04662060|Experimental|Acebilustat|Participants are randomized to receive acebilustat for 28 days.
9700244|NCT04662060|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match acebilustat for 28 days.
9700245|NCT04661202|Experimental|Exercise training group|"Aerobic exercise~Resistance exercise (including pelvic floor muscle training with biofeedback)~Stretching exercise~Home exercise"
9700246|NCT04661202|No Intervention|Control group|"．Usual care~After baseline assessment, the participants will receive health and lifestyle advices related to bowel symptoms, which include maintaining moderate physical activity, healthy diet, and ideal defecation posture, and establishing a personal bowel schedule and other behavioral changes that promote regular bowel movements.~Upon request, the participants will be provided with the same intervention program as the exercise training group after 8 weeks participation."
9700247|NCT04659005|Experimental|Nurse-led decision counseling group|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
9700248|NCT04659005|Other|Control group|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises.
9700249|NCT04652960|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO QD or BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9700250|NCT04646005|Experimental|Cemiplimab+ISA101b|
9778557|NCT01109316|Experimental|Insulin Lispro 6 Day|
9778558|NCT01109316|Active Comparator|Insulin Aspart 6 Day|
10189346|NCT03708146|Experimental|Cohort 4 (BIA 5-1058 /50 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo 12 active and 3 placebo)
9700251|NCT04644315|Experimental|ALK-positive Solid Tumors|Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
9977937|NCT01366716|No Intervention|Non-CM Control|Participants in the non-CM control condition will provide urine specimens during the 12-week period as do the two experimental conditions, but will receive no contingent rewards other than praise from the RAs.
9977938|NCT01366729|Experimental|TheraTogs|
9977939|NCT01366729|Active Comparator|Cane walking|
9700255|NCT04642027|Active Comparator|Conventional|Conventional sEBRT
9700256|NCT04642027|Experimental|Hypofractionation|Hypofractionated sEBRT
9700257|NCT04637230||Sinus Rhythm|Subjects/patients in normal sinus rhythm
9700258|NCT04637230||Atrial Fibrillation|Patients with atrial fibrillation
9700259|NCT04637230||Atrial Premature Complexes|Patients with atrial premature complexes in between sinus beats
9700260|NCT04637230||Ventricular Premature Complexes|Patients with ventricular premature complexes in between sinus beats
9700261|NCT04637230||Ventricular Tachycardia, Nonsustained|Patients with episodes of nonsustained ventricular tachycardia in between sinus beats
9700262|NCT04636697|Placebo Comparator|Placebo|Placebo (0.5 mL)
9700263|NCT04636697|Experimental|3.75 µg of CoVLP Vaccine adjuvanted|3.75 µg of CoVLP adjuvanted vaccine with AS03 adjuvant (0.5 mL)
9700264|NCT04636190|Other|Triathlon All-Polyethylene Tibia Knee|All subjects enrolled will have received the Triathlon All-Polyethylene Tibia Knee device.
9700265|NCT04634682|Experimental|MYODM|MYODM, three times a day, orally
9700266|NCT04634682|No Intervention|No intervention|Patients will follow the same evaluation schedule but will not receive MYODM
9700267|NCT04633239|Experimental|Treatment (abemaciclib, olaparib)|Patients receive olaparib PO BID on days 1-28 and abemaciclib PO BID on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9700268|NCT04631302|Experimental|Mindfulness|
9700269|NCT04631302|Active Comparator|Light Physical Exercise|
10189347|NCT03708146|Experimental|Cohort 5 (BIA 5-1058 /150 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 150 mg (as 1 x 100 mg and 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
10189348|NCT03708146|Experimental|Cohort 6 (BIA 5-1058 /75 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 75 mg (as 3 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
9700272|NCT04629625|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
9700273|NCT04629625|Active Comparator|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
9700274|NCT04629625|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
9700275|NCT04627025|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
9700276|NCT04627025|Placebo Comparator|Placebo|Placebo for apraglutide, SC injection once weekly
9700277|NCT04618471|Experimental|WaveWriter Settings|
9700278|NCT04614480|Other|Metastatic breast cancers|
9700279|NCT04614480|Other|Metastatic prostate cancers|
9700280|NCT04614480|Other|Metastatic lung cancers|
9700281|NCT04614480|Other|Metastatic colorectal cancers|
9700282|NCT04614480|Other|metastatic otorhinolaryngeal cancer|
9700283|NCT04614480|Other|metastatic ovarian cancer|
10189349|NCT03708146|Experimental|Cohort 7 (BIA 5-1058 /200 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
9700284|NCT04614480|Other|Pancreatic cancers|
9700285|NCT04614480|Other|Others metastatic cancers|
9700286|NCT04614441||Idiopathic Pulmonary Fibrosis (IPF)|
9700287|NCT04614441||Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
9700288|NCT04614441||Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)|
9700289|NCT04614363|Experimental|68 Ga PSMA|Comparison between the results of 68 Ga-PSMA PET/CT to conventional imaging (bone scan, CT) in men with high risk prostate cancer.
9700290|NCT04611035||Patient|Patient with first-line gastrointestinal cancers and patient with advanced and refractory GI cancers (>1 line of treatment), or post-progression biopsy)
9700291|NCT04609423|Experimental|Cod liver oil|supplementation for 6 months
9700292|NCT04609423|Placebo Comparator|Corn oil (placebo)|supplementation for 6 months
9778559|NCT01109381|Experimental|Treatment with GT08|Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid
9778560|NCT01109524|Experimental|Cetuximab + Cisplatin + Vinorelbine|
9778561|NCT01109576|Experimental|DSL workshop participants|Three to five Veterans with DSL.
9977940|NCT01366742||HPV Cohort|Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.
9977941|NCT01366768|Experimental|Oral amino acid mixture|Oral administration of amino acid mixture in healthy volunteers
9977942|NCT01366768|Experimental|Intravenous amino acid administration|Intravenous infusion of amino acid mixture in healthy volunteers
9977943|NCT01366781|Experimental|Healthy males|Meal ingestion in healthy males
9977944|NCT01366781|Experimental|Healthy females|Meal ingestion in healthy females
9977945|NCT01366794|Experimental|Type 2 diabetes|Administration of macronutrients in type 2 diabetes
9977946|NCT01366794|Experimental|Healthy volunteers|Administration of macronutrients in healthy volunteers
9977947|NCT01366833|Active Comparator|Self-expanding stent alone|All patients in Arm A will receive self-expanding stent alone
9977948|NCT01366833|Experimental|Brachytherapy and Stent therapy|
9977949|NCT01366859|Experimental|Whey Protein (Immunocal®)|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
9700293|NCT04605913|Experimental|Modified GCN+TTF treatment|The trial will compose of 2 parts with a total of 40 subjects. The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1. If 6 patients tolerate the dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
9700294|NCT04600375|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP~Survey A~Routine clinic visit~Verbal consultation only~Survey B~Verbal consultation AND Written Action Plan~Survey C"
9700295|NCT04600375|Experimental|Experimental: Written Action Plan|"INTERVENTION GROUP~Survey A~Routine clinic visit~Verbal consultation AND Written Action Plan~Survey C"
10189350|NCT03708146|Experimental|Cohort 8 (BIA 5-1058 /100 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
10189351|NCT03708146|Experimental|Cohort 9 (BIA 5-1058 /400 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
10189352|NCT03708146|Experimental|Cohort 10 (BIA 5-1058 /200 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
10189353|NCT03708146|Experimental|Cohort 11 (BIA 5-1058 /400 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
10189354|NCT03708133|Experimental|Test Treatment + Reference Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Test treatment~Reference treatment"
9700296|NCT04594941|Experimental|Group 1|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the HPLC method
9700297|NCT04594941|Experimental|Group 2|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the SPE method
9700298|NCT04594941|Experimental|Group 3|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method
9700299|NCT04594941|Experimental|Group 4|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method
9700300|NCT04593459|Experimental|Probiotic|"Probiotic product consisting of these 7 bacterial strains:~Lactobacillus salivarius W57~Lactobacillus casei W56~Lactobacillus rhamnosus W71~Lactococcus lactis W58~Enterococcus faecium W54~Lactobacillus plantarum W62~Lactobacillus acidophilus W22~Additional ingredients: Corn starch, maltodextrin, fructo-oligosaccharides, galacto-oligosaccharides, polydextrose, plant proteins, potassium chloride, magnesium sulfate, bacterial strains, manganese sulfate, lactose, 2000 IU vitamin D~Participants ingest one sachet of powder (5 grams) in 200 ml of water per day for 6 months"
9700301|NCT04593459|Placebo Comparator|Placebo|"Similar to probiotic product in optics and smell, less ingredients and no bacterial strains or vitamin D~Ingredients: Corn starch, maltodextrin, potassium chloride, magnesium sulphate, manganese sulphate"
9700302|NCT04593459|Active Comparator|Metformin|"Metformin is an established drug for treating PCOS-related symptoms. The investigators are comparing the probiotic not only to a placebo group, but also to the benchmark treatment.~Participants in the metformin arm will start treatment with 500 mg daily for the first week, then increasing the dose to 2x500 mg daily for the duration of the intervention."
9700303|NCT04593303|Active Comparator|Internal iliac artery group|Bilateral internal Iliac artery ligation will be done followed by urinary bladder dissection then bilateral uterine artery ligation then manual removal of the placenta then cervico isthmic compression suture. (holding the upper border of the cervix by 4 Allis's forceps then suturing the cervix with the anterior uterine wall using continuous suture), Nelaton catheter18 gauge or Hegar's dilator will be inserted inside cervical canal during Cervico isthmic tamponed suture to ensure patency of cervical canal. .
9700304|NCT04593303|Other|No internal iliac artery group|Bladder dissection then bilateral uterine artery ligation then cervico isthmic suture without internal iliac artery ligation
9700305|NCT04593277|Experimental|Arm I (INSPIRE, telehealth care)|Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.
9700306|NCT04593277|Active Comparator|Arm II (control website)|Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.
9700307|NCT04593277|Active Comparator|Group 0 (INSPIRE, printed material)|Patients have access to the digital INSPIRE program and receive printed SCP materials without telehealth.
9700308|NCT04593251|Experimental|CALY-002|
9700309|NCT04593251|Placebo Comparator|Placebo|
10189355|NCT03708133|Experimental|Reference Treatment + Test Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Reference treatment~Test treatment"
10189356|NCT03708120|Experimental|Consumer Dose and Tick Repellency|Consumer dose: Dosimetry test of insect repellent application to forearms. Tick repellency: Treatment of forearm with insect repellent and exposure to ticks every 15 minutes for 10 hours.
9778562|NCT01109602|Experimental|Arm 1: Yoga Group|"Yoga Group, 8 week bi-weekly in-person yoga training focused on strength, flexibility, and balance~Yoga focused on strength, flexibility, and balance"
10204353|NCT02808208|Experimental|Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at time of first stage of BBF
9700310|NCT04591119|Active Comparator|Transversus Thoracic Muscle Plane Block (TTMPB) Group|At the TTMPB group, the block will be performed by the surgeon before the closure of the sternum by visualizing the muscles and identifying them. In the TTMPB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between internal intercostal muscle and transversus thoracic muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space.
9700311|NCT04591119|Active Comparator|Parasternal Intercostal Block (PSIB) Group|At the PSIB group, the block will be performed by ultrasound guidance after completion of surgery. PSIB Blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesist.In PSIB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally.
9700312|NCT04591119|No Intervention|Control Group|At the control group, no intervention for pain management will be done.
10204354|NCT02808208|Experimental|AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at first and second stage of BBF
9700313|NCT04590495|Active Comparator|300 mg Cannabidiol (CBD) oil|
9700314|NCT04590495|Placebo Comparator|Placebo|
9700315|NCT04588246|Experimental|Arm I (salvage SRS, memantine, HA-WBRT)|Patients undergo HA-WBRT daily (5 times weekly) for 2 weeks for a total of 10 fractions in the absence of disease progression or unacceptable toxicity. Within 1 week prior to or following HA-WBRT, patients undergo salvage SRS. Prior to HA-WBRT or no later than the 4th treatment, patients also receive memantine PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
9700316|NCT04588246|Active Comparator|Arm II (salvage SRS)|Patients undergo salvage SRS.
9700317|NCT04588207|Experimental|On Urea, Then Off Urea|Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
9700318|NCT04588207|Experimental|Off Urea, Then On Urea|Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)
9700319|NCT04581733|Experimental|Single Arm|Male and female Participants <18 years
9977950|NCT01366859|Placebo Comparator|Placebo: Rice Protein|The control or placebo study arm will consist of thirty children who will receive a dose of 0.5 g/kg of weight a day up to 18 kg of weight a day or a dose of 10 g/day for those over 18 kg for three months.
9700321|NCT04580693||Healthy Volunteers/Control|Age and body surface area (BSA) matched volunteers who are sedentary or normally active. Normally active is defined as less than 5 hours of exercise per week. Healthy volunteer subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
9700322|NCT04580693||Hypertrophic Cardiomyopathy/HCM|HCM subjects are patients that are age and BSA-matched with the athletes who then have an established clinical diagnosis of HCM without left ventricular (LV) outflow tract obstruction. There can be no anticipated changes to baseline exercise program (if any) over the study period. HCM subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
9700323|NCT04580693||Endurance Athletes|Official participation in a collegiate athletic varsity rowing team OR participation in competitive endurance athletics. Competitive endurance athletics is defined as greater than or equal to 10 hours of exercise training per week with the majority dedicated to endurance activities such as cycling, rowing, or running. Endurance athlete subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
9700324|NCT04579640|No Intervention|Control|Standard of care (national recommendation of 400 IU/day vitamin D)
9700325|NCT04579640|Experimental|Intervention: Lower-dose vitamin D|Offer of a daily dose of 800 IU (20 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
9700326|NCT04579640|Experimental|Intervention: Higher-dose vitamin D|Offer of a daily dose of 3200 IU (80 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
9700327|NCT04579172|Experimental|Group A|Circular isthmic-cervical sutures
9700328|NCT04579172|Experimental|Group B|Resection of the infiltrated part of anterior uterine wall
9700329|NCT04576091|Experimental|Treatment (pembrolizumab, BAY1895344, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Starting on day 7, patients also receive BAY1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
9700330|NCT04575948|Experimental|Moringa Oleifera mouth wash|According to part I of the study, we will select the most effective (Non-toxic, anti-bacterial effect) Moringa extract to prepare the mouth wash.
9700331|NCT04575948|Placebo Comparator|Base formula of mouth wash|Base formula of mouthwash
9700332|NCT04575948|Active Comparator|Chlorhexidine|Commercial 0.12% chlorhexidine digluconate mouthwash
9700333|NCT04573231|Experimental|18F-DCFPyL PSMA-based PET/CT|"18F-DCFPyL whole body PET/CT scan~Review of relevant imaging and medical record information~Blood draw for circulating tumor cells (CTCs)~Analysis of diagnostic tissue specimens"
9700334|NCT04571333|Experimental|Mi2000 Cochlear Implant surgery|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
9700335|NCT04570267|Experimental|CSL324 (Low dose)|One low dose of CSL324 administered subcutaneously on Day 1
9700336|NCT04570267|Experimental|CSL324 (High dose)|One high dose of CSL324 administered subcutaneously on Day 1
9700337|NCT04570267|Placebo Comparator|Placebo|One dose of placebo administered subcutaneously on Day 1
9700338|NCT04569136|Experimental|Intervention group|"Educating the patient about mastitis and self-management strategies~Treating with therapeutic ultrasound~Administering and teaching breast massage"
9700339|NCT04569136|Sham Comparator|Sham group|"Educating the patient about mastitis and self-management strategies~Receiving sham ultrasound~Administering and teaching breast massage"
9700340|NCT04569136|Other|Usual care group|Receiving usual obstetric care, which may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff
9700341|NCT04567498|Experimental|Presumptive TB patients (395 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
9700342|NCT04567498|Experimental|Residents of area with high risk of TB (1383 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
9700343|NCT04565691|Experimental|Bacteremia inducing arm|As mentioned the participants will be their own controls at the different time-points.
10189357|NCT03708107|Experimental|Percutaneous Microelectrolysis (MEP)|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP.~MEP® will be applied with a 0,30 x 25 mm acupuncture needle. The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
10189358|NCT03708107|Experimental|Ischemic compression|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP with a marker.~Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
9700344|NCT04558905|Active Comparator|Usual Medical Care Model|All the patients will receive face-to-face medical visits
9700345|NCT04558905|Experimental|Hybrid Medical Care Model|The patients will receive alternating face-to-face medical visits and video medical consultations
9700346|NCT04558879|Experimental|Cardiovascular training|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and through a linear progression will reach vigorous intensity; then, this intensity will be maintained until the end of the intervention. Each session will include five minutes of warm-up and cool-down performed at the beginning and the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool down. CT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
9700347|NCT04558879|Experimental|Resistance training|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low-intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start with five-minute of warm-up performed on a recumbent stepper and will end with five-minute of stretching (cool-down). RT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
9977951|NCT01366911||stem cell QCT testing|
9977952|NCT01366924|No Intervention|Muscle protein turnover and intracellular signaling at rest|Muscle protein turnover and intracellular signaling are measured at rest for comparison to post-exercise muscle metabolism.
9700350|NCT04556773|Experimental|Module 1: T-DXd + capecitabine|T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use
9700351|NCT04556773|Experimental|Module 2: T-DXd + durvalumab + paclitaxel|T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use
9700352|NCT04556773|Experimental|Module 3: T-DXd + capivasertib|T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use
9700353|NCT04556773|Experimental|Module 4: T-DXd + anastrozole|T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral
9700354|NCT04556773|Experimental|Module 5: T-DXd + fulvestrant|T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use
9700355|NCT04556383|Experimental|GB004 Dose A|GB004 dose A for oral administration for 36 weeks
9700356|NCT04556383|Experimental|GB004 Dose B|GB004 dose B for oral administration for 36 weeks
9700357|NCT04556383|Placebo Comparator|Placebo|Placebo for oral administration for 36 weeks
9700358|NCT04556383|Experimental|Open-Label GB004 Dose A|GB004 dose A for oral administration for 24 weeks
9700359|NCT04552769|Experimental|Abemaciclib|Each cycle of therapy will be 28 days long. A completed cycle will be twice daily abemaciclib. Number of Cycles: until progression or unacceptable toxicity develops
9700360|NCT04547803|Experimental|Video Visit and Standard of Care|Participants will participate in a video visit and standard of care
9700361|NCT04547803|Active Comparator|Standard of Care|Participants will participate in standard of care for discharged patients.
9700362|NCT04543786|Experimental|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation on lower back for 30-60 minutes for 5 consecutive days.
9977953|NCT01366924|Active Comparator|Muscle metabolism after endurance exercise|Post-exercise muscle protein metabolism was measured to determine if endurance exercise affects muscle metabolism compared to rest.
9977954|NCT01366924|Experimental|Muscle Metabolism after endurance exercise|Muscle metabolism response to endurance exercise with essential amino acid supplementation
9977955|NCT01366924|Experimental|Muscle anabolism after endurance exercise|Muscle anabolism after endurance exercise with essential amino acid supplementation.
9977956|NCT01366950|Experimental|Excercise group|
9977957|NCT01366950|No Intervention|Reference|
10189359|NCT03708081||Group 1|Root canal treatments will be completed by ProTaper Next instruments with rotational motion
10189360|NCT03708081||Group 2|Root canal treatments will be completed TF Adaptive instruments with adaptive motion.
10189361|NCT03708055|Experimental|Prevention (weight bearing exercise program)|Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
10189362|NCT03708042|Experimental|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day.
10189363|NCT03708042|Active Comparator|Neoadjuvant Radiochemotherapy|Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
10189364|NCT03708029|Experimental|Intervention Treatment|Will receive Revita allograft for wound treatment
10189365|NCT03708029|No Intervention|Control|Will receive current standard of care for wound treatment
10189366|NCT03708016|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
10189367|NCT03708016|Active Comparator|Robot gait training without brain stimulation|Lokomat robot training and sham tDCS on the leg motor areas
10189368|NCT03707990|Experimental|NNC0165-1875|Participants will receive NNC0165-1875 alone in cohorts 1-5 (part 1) and NNC0165-1875 along with semaglutide in cohorts 6-11 (part 2).
10189369|NCT03707990|Placebo Comparator|Placebo|Participants will receive placebo alone in cohorts 1-5 (part 1) and placebo along with semaglutide in cohorts 6-11 (part 2).
10189370|NCT03707977|Experimental|Group PK-A: ART + VRC01LS|In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
10189371|NCT03707977|Experimental|Group PK-B: ART + 10-1074|In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
10189372|NCT03707977|Experimental|Steps 1-3 Participants (ART + 10-1074 + VRC01LS)|In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.
10189373|NCT03707964|Placebo Comparator|Control|Subjects allocated to the control arm will receive standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles, as part of their regular teaching schedule.
10189374|NCT03707964|Experimental|Intervention|Subjects allocated to the intervention arm will receive education on crisis resource management (CRM) and teaching targeting the cognitive skills required to monitor and challenge a superior's decision, and conflict resolution tools, in addition to standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
10189375|NCT03707951|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks; administered orally
10189376|NCT03707951|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 8 weeks; administered orally
10189377|NCT03707938|Experimental|Treatment (brigatinib, LCT)|Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10189378|NCT03707899|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
10189379|NCT03707899|Active Comparator|Group II (Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
10189380|NCT03707886|Experimental|Pain SMART (Intervention Arm)|The Intervention Arm will be invited to participate in a one-time group intervention, Pain SMART
10189381|NCT03707886|Placebo Comparator|Minimally Enhanced Usual Care|The Minimally Enhanced Usual Care group will receive educational information via mail.
10189382|NCT03707873|Experimental|In-person education|Education will be given on a regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
10189383|NCT03707873|Experimental|Online education|Education will be given on a regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
10189384|NCT03707873|No Intervention|Standard Care|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
10189385|NCT03707860||head and neck radiotherapy patients|(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.
10189386|NCT03707847|Experimental|Crizotinib + etoposide capsule+Auto-HSCT|"Crizotinib and etoposide capsule followed by autologous hematopoietic stem cell transplantation.~Crizotinib: 250mg, bis in die （BID）, PO.~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle.~Patients will receive the treatment of crizotinib and etoposide capsule, and those who have achieved CR（complete response）or VGPR（very good partial response）will undergo the Auto-HSCT."
10189387|NCT03707834|No Intervention|WIC Standard Care (SC)|Participants assigned to the WIC standard care arm will receive usual care offered to pregnant women at WIC.
10189388|NCT03707834|Experimental|Antenatal Obesity Treatment (AO)|The AO arm consists of a multi-component, theory- and evidence-based intervention and includes weight-related behavior change through goal setting and self-monitoring, behavioral skills training, interpersonal support, and social modeling strategies.
10189389|NCT03707795|Experimental|Arm 1 - Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
9700363|NCT04543513|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
10189390|NCT03707795|Active Comparator|Arm 2 - Familial Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
10204355|NCT02808208|Placebo Comparator|Placebo treatment in brachiobasilic arteriovenous fistula|Subjects will receive placebo at first and second stage of BBF
10204356|NCT02808195|Experimental|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
10204357|NCT02808195|Experimental|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
9700364|NCT04542148|Experimental|Sliding Scale Insulin|Addition of supplemental sliding scale insulin to home insulin regimen for maximum of 5 days after antenatal corticosteroids
9700365|NCT04542148|Experimental|Up-Titration of Home Insulin|Increase in home insulin regimen based on standardized algorithm for maximum of 5 days after antenatal corticosteroids
9700366|NCT04542148|Experimental|Continuous Insulin Infusion|Discontinuation of home insulin regimen and receipt of continuous insulin infusion for maximum of 5 days after antenatal corticosteroids
9700367|NCT04535921||Prostatectomy|FCR7 questionnaire pre and postoperative
9700368|NCT04535921||Cystectomy|FCR7 questionnaire pre and postoperative, 6 months follow
9700369|NCT04535921||Nephrectomy|FCR7 questionnaire pre and postoperative
9700370|NCT04535921||Orchidectomy|FCR7 questionnaire pre and postoperative
9700371|NCT04531410|Experimental|Linoleic|Linoleic acid 13 g and 600 mg algal docosahexaenoic acid (DHA)
9700372|NCT04531410|Active Comparator|Oleic|Oleic acid 13 g and 600 algal DHA
9700373|NCT04529174|Active Comparator|Active HDL supplement|25 subjects (ages 18-85 years old) will receive an active HDL supplement (CardioLux™HDL). They will take 2 capsules twice a day with food for 12 weeks. Total daily dosing is four (4) capsules.
9700374|NCT04529174|Placebo Comparator|Placebo|25 randomly selected subjects (ages 18-85 years old) will receive a matching Placebo. They will take 2 capsules twice each day with food for 12 weeks. Total daily dosing is four (4) capsules.
9700375|NCT04527237|Experimental|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total.Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.~Application to acupressure points in a certain order; Baihui, Susanli, Hegu, Shenmen and Quchi will be held.~After 2-3 minutes of approach to the patient and proper positioning, 20 seconds of preparation of each of the notes will be prepared and then 2 minutes acupressure application will be applied to each point."
9700376|NCT04527237|Placebo Comparator|placebo|The false acupressure application steps (temperature of the environment, patient's position, application time, frequency and repetition, evaluation period etc.) will be the same as the acupressure application steps. Unlike acupressure, it will only be in contact with wearing gloves to reduce the electrical effect of touch, away from the actual acupressure points. Touching any part of the body or making skin contact can be an effect alone, as well as other meridians and points are located near the existing meridian and selected points, and entering their area of influence, pressing or scrubbing can cause other effects to be activated.
9700377|NCT04524962|Experimental|Descartes 30|
10204358|NCT02808156|Experimental|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
10204359|NCT02808156|Experimental|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
10204360|NCT02801279|Experimental|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
9700378|NCT04524598|Experimental|Limbix Spark|A 5 week CBT-based intervention
10204361|NCT02801279|Experimental|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
10204362|NCT02795988|Experimental|Phase 1b|10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
9700379|NCT04524598|Active Comparator|Psychoeducation|5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention
9700380|NCT04521972|Active Comparator|Group 1|Natural non-augmented labor with room lights ON. This is what is currently done in the hospital, and thus does not change any current medical practices.
9700381|NCT04521972|Active Comparator|Group 2|Augmented labor with room lights ON. This group will be a subgroup of Group 1 (Natural non-augmented labor with room lights ON), as labor-augmentation cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
10204363|NCT02795988|Experimental|Phase 2 - IMU 131 plus chemotherapy|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
10204364|NCT02795988|Experimental|Phase 2 - Chemotherapy only|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
9700382|NCT04521972|Experimental|Group 3|Natural non-augmented labor with reduced or red room lights.
9977958|NCT01366963||Normal Controls / Healthy Volunteers|Age and gender matched individuals without postural orthostatic tachycardia syndrome
10204365|NCT02786329|Active Comparator|TIVA + lidocaine|"TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.~Interventions: TIVA+lidocaine"
10204366|NCT02786329|Placebo Comparator|TIVA+placebo|TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)
10204367|NCT02786329|Placebo Comparator|Sevoflurane+placebo|"Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).~Intervention: sevoflurane anesthesia +placebo (saline infusion)"
10189391|NCT03707769|Experimental|Fistula treatment|Treatment of fistula with TIPS microspheres
10189392|NCT03707730|Experimental|AGY|capsule containing egg yolk with AGY
10189393|NCT03707730|Placebo Comparator|placebo|capsule containing plain egg yolk
10189394|NCT03707717|Experimental|Bimekizumab-SS|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.
10189395|NCT03707717|Experimental|Bimekizumab-AI|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.
10189396|NCT03707717|Experimental|Bimekizumab-TN|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.
10189397|NCT03707704||SCI patients in primary rehabilitation|
10189398|NCT03707691|Experimental|Cochlear implant users|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
10189399|NCT03707691|Experimental|Participants with Congenital Amusia|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
10189400|NCT03707691|Experimental|Control Participants|
10189401|NCT03707678|Experimental|Subjects receiving GSK2245035|Eligible subjects will be administered 20 nanograms (ng) of GSK2245035 nasal spray solution using a metered Valois VP7 pump (1 spray=10 ng per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol metered dose inhaler (MDI) will be given for symptom relief from screening to the end of the study.
10189402|NCT03707678|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be administered placebo nasal spray solution using a metered Valois VP7 pump (1 spray per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol MDI will be given for symptom relief from screening to the end of the study.
9700383|NCT04521972|Experimental|Group 4|Augmented labor with reduced or red room lights. This group will be a subgroup of Group 3, as augmented labor cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
9700384|NCT04518943|Experimental|F1M1P1R1|Financial Reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
9700385|NCT04518943|Experimental|N1M1P1R1|Non-financial reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
9700386|NCT04518943|Experimental|N1M1P1R0|Non-financial reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
9700387|NCT04518943|Experimental|N1M1P0R0|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
9700388|NCT04518943|Experimental|N1M1P0R1|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
9700389|NCT04518943|Experimental|N1L1P1R1|Non-financial reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
9700390|NCT04518943|Experimental|N1L1P1R0|Non-financial reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
9700391|NCT04518943|Experimental|N1L1P0R0|Non-financial reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
9700392|NCT04518943|Experimental|N1L1P0R1|Non-financial reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
9700393|NCT04518943|Experimental|F1M1P1R0|Financial Reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
9700394|NCT04518943|Experimental|F1M1P0R0|Financial Reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
9700395|NCT04518943|Experimental|F1M1P0R1|Financial Reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
9700396|NCT04518943|Experimental|F1L1P1R1|Financial Reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
9700397|NCT04518943|Experimental|F1L1P1R0|Financial Reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
9700398|NCT04518943|Experimental|F1L1P0R0|Financial Reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
9700399|NCT04518943|Experimental|F1L1P0R1|Financial Reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
9700400|NCT04514744|Experimental|Unilateral Immobilization|One leg will undergo 8 days of single-leg immobilization, by means of a removable knee brace.
9700401|NCT04514744|Experimental|Unilateral Resistance Exercise|One leg will undergo 4 sessions of unilateral resistance exercise, over the course of 8 days. Specifically, participants will be asked to perform leg press and leg extension.
9700402|NCT04514484|Experimental|Treatment (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity.
9700403|NCT04513691||Sample|Asymptomatic newborns 35 weeks or greater GA born at Banner - University Medical Center Phoenix whose mothers were determined or suspected to have CAM.
10189403|NCT03707652|Experimental|Cohort A (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
10189404|NCT03707652|Experimental|Cohort A (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
10189405|NCT03707652|Experimental|Cohort A (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
9700404|NCT04513444|Other|Standard arm (A): music listening therapy|
9700405|NCT04513444|Experimental|Experimental arm (B): music listening and hypnosis therapy|
9700406|NCT04508725|Experimental|Doppler Ultrasound|Patients receiving standard of care anti-angiogenesis inhibitor plus immune checkpoint inhibitor will have power doppler imaging at baseline, 3 weeks and 6 weeks.
9700407|NCT04502433|No Intervention|Control cohort|"Approximately 28 patients will be included in this main control cohort.~The above-mentioned control cohort population will continue receiving the SoC"
9700408|NCT04502433|Experimental|Poractant alfa treated cohort|42 patients will be treated with CUROSURF® (poractant alfa).
9977959|NCT01366963||Patients with Postural Tachycardia Syndrome (POTS)|Individuals with Postural Tachycardia Syndrome
10189406|NCT03707652|Experimental|Cohort A (oral supplement A)-1 or 4 capsules|Oral supplement A (1 or 4 capsules) administered daily for 3 days
9700409|NCT04499547|Experimental|Physical activity intervention|Will receive twice-weekly, YouTube-delivered aerobic and muscle-strengthening physical activity videos for 8 weeks.
9700410|NCT04499547|No Intervention|General health education control|Will receive twice-weekly, YouTube-delivered videos with general health education information for 8 weeks.
9700411|NCT04497246||Elderly patients|Elderly patients (over 65 years old) hospitalized for COVID-19 within the CHU Brugmann Hospital
9700412|NCT04497246||Health Care professionals|Health Care professionals working within the CHU Brugmann Hospital
9700413|NCT04491032|Active Comparator|Low Volume|Caudal anesthesia will be performed with 0.8 ml/kg of the local anesthetic solution
9700414|NCT04491032|Active Comparator|High Volume|Caudal anesthesia will be performed with 1.25 ml/kg of the local anesthetic solution
9700415|NCT04485637|Other|Communication with basic table|Blood pressure communication showing a basic table representing only the normal range of blood pressure readings
9700416|NCT04485637|Other|Communication with enhanced table|Communication showing an enhanced table (Fig 1B) with more reference information for interpreting blood pressure readings, including how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
9700417|NCT04485637|Other|Communication with enhanced graph|Communication showing an enhanced graph (adapted from Blood Pressure UK) for interpreting blood pressure readings, showing the same color-coded ranges as the enhanced table, with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
9700418|NCT04483947|Experimental|Cohort 1|15 participants will receive AZD2693 dose 1 and 5 participants will receive placebo
9700419|NCT04483947|Experimental|Cohort 2|15 participants will receive AZD2693 dose 2 and 5 participants will receive placebo
9977960|NCT01366989||Total Ankle Arthroplasty with calcaneal stem|Patients received the TAA with calcaneal stem between 12/6/05 & 11/13/07 at approximately 28 sites.
9977961|NCT01367015|Experimental|Early Feeding|Early feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours after randomization followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
9700420|NCT04483947|Experimental|Cohort 3|15 participants will receive AZD2693 dose 3 and 5 participants will receive placebo
9700421|NCT04482959|Experimental|Carbetocin group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of carbetocin (100 mcg/ml) IV over 1 minute.
9700422|NCT04482959|Placebo Comparator|• Control group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of sodium chloride 0.9% IV over 1 minute.
9700423|NCT04477577|Experimental|New Parent Intervention|
10189407|NCT03707652|Experimental|Cohort A (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
9700424|NCT04477577|Active Comparator|Safety Control|
9700425|NCT04474314|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
9700426|NCT04474314|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
9700427|NCT04474314|Placebo Comparator|Placebo|Oral administration of once daily Placebo
9700428|NCT04472767|Experimental|Cabozantinib with Ipilimumab/Nivolumab and TACE|"Subjects receive Cabozantinib 40 mg daily on days 1-28 of a 28 day cycle, this is to be started 7-14 days after the last TACE procedure.~Nivolumab 480 mg IV on day 1 of a 28 day cycle (cycle 2 and beyond), this is to be started 7-14 days after the last TACE procedure.~Nivolumab: 3mg/kg IV on day 1 of a 21 day cycle x 1 dose.~Ipilimumab: 1 mg/kg on day 1 of a 21 day cycle x 1 dose~TACE: Within 3-4 weeks of cycle 1 day 1; may be done up to 3 times (9-12 weeks total), the intervals between each TACE treatment can vary based on investigator's discretion"
9700429|NCT04466371||MIU students and staff members|All students and staff members in MIU
9977962|NCT01367015|Active Comparator|Late feeding|Late feeding group was kept NPO for a period of 48 hours after randomization followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
9977963|NCT01367028|Other|A: Trastuzumab+Docetaxel|
9977964|NCT01367028|Experimental|B: Trastuzumab+Docetaxel+Bevacizumab|
9977965|NCT01367028|Experimental|C: Trastuzumab+Docetaxel+NPLD|
9977966|NCT01367028|Experimental|D: Trastuzumab+Docetaxel+NPLD+Bevacizumab|
9977967|NCT01367041|Experimental|Bone loss|Postmenopausal women with osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
10189408|NCT03707652|Experimental|Cohort A (oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
10189409|NCT03707652|Experimental|Cohort B (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
10189410|NCT03707652|Experimental|Cohort B (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
10189411|NCT03707652|Experimental|Cohort B (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
10189412|NCT03707652|Experimental|Cohort B (oral supplement C)- 1 or 4 capsules|Oral supplement C (1 or 4 capsules) administered daily for 3 days
9700430|NCT04458909|Experimental|Arm I (nivolumab, gemcitabine, cisplatin, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 30-60 minutes or carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 4 weeks, patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9700431|NCT04458909|Active Comparator|Arm II (gemcitabine, cisplatin, carboplatin)|Patients receive gemcitabine and cisplatin or carboplatin as in Arm I.
9700432|NCT04452305|Experimental|Spermatogonial Stem Cell Transplant & Testicular Tissue Graft|Stem cell transplantation Testicular tissue grafting
9700433|NCT04450004|Experimental|Vaccine (3.75 µg) unadjuvanted|• Group 1: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine
9700434|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with CpG 1018|• Group 2: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
9700435|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with AS03|• Group 3: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
9700436|NCT04450004|Experimental|Vaccine (7.5 µg) unadjuvanted|• Group 4: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
9700437|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with CpG 1018|• Group 5: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
9700438|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with AS03|• Group 6: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
9700439|NCT04450004|Experimental|Vaccine (15 µg) unadjuvanted|• Group 7: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
9700440|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with CpG 1018|• Group 8: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
9700441|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with AS03|• Group 9: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
9778563|NCT01109602|Experimental|Arm 2: Yoga Group Plus|"Yoga Group Plus: 8 week, bi-weekly in-person yoga training focused on strength, flexibility, and balance paired with almost daily at home yoga focused on breathing and relaxation.~Yoga focused on strength, flexibility, and balance~Data for both yoga groups were combined for analyses as there were not any differences between these two groups."
9778564|NCT01109602|No Intervention|Arm 3: Wait list control group|wait-list control: will be assessed before and after 8 weeks. Will then be offered the 8 week yoga intervention.
9778565|NCT01109849|Active Comparator|weight recovery treatment- monitoring|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the monitoring arm , participants will continue on their ER stimulant 7 days a week and have their weight, height and BMI checked monthly.
9778566|NCT01109849|Active Comparator|behavior therapy|10 week basic parent training, advanced 8 week parent training course. monthly boosters, option for individual parent training sessions, school consultant assigned to each subject
9778567|NCT01109849|Experimental|ER stimulant|daily use of 12 hour extended release methylphenidate product
9778568|NCT01109849|Experimental|weight recovery treatment- caloric supplement|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the caloric supplement arm, participants will continue on their ER stimulant 7 days a week, have their weight, height and BMI checked monthly and be prescribed a 150 kcal caloric supplement to be consumed every evening.
9778569|NCT01109849|Experimental|weight recovery treatment- drug holiday|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the drug holiday arm, participants will only take their ER stimulant on school days a week and have their weight, height and BMI checked monthly.
9778570|NCT01109940|Experimental|AIN457|
9785024|NCT01240863|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
9785025|NCT01240863|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
10189413|NCT03707652|Experimental|Cohort B (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
10189414|NCT03707652|Experimental|Cohort B(oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
10189415|NCT03707639|Experimental|Experimental: Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
10189416|NCT03707626||LAD with collaterals with and without wellens sign|
9785030|NCT01240915|Experimental|Cohort 1|The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 & 2).
9785031|NCT01240915|Experimental|Cohort 2|This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
10204368|NCT02786329|Active Comparator|Sevoflurane+lidocaine|"Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.~Intervention: sevoflurane anesthesia+ lidocaine infusion"
10189417|NCT03707613|Experimental|DWT learning curve|Initial cannulation is performed with a wire-guided sphincterotome by a trainee. If the cannulation proves difficult (cannulation time >10min, cannulation attemtps >5 or inadvertent PD cannulation >1) and PD is inadvertently entered, DWT will be performed by one of the two trainees. If DWT fails within 5min or 5 attempts, a trainer will take over and continue the cannulation. To prevent PEP, all patients receive prophylactic PD stent and post-ERCP rectal indomethacin. Aggressive hydartion will be administrated at the discretion of endoscopists.
10189418|NCT03707600|Sham Comparator|Sham|The sham coil setting is designed to mimic the auditory artifact and scalp sensations evoked by the real coil without stimulating the brain.
9700442|NCT04449393|Experimental|Emdogain® FL|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation. EDTA gel will be applied for 2 minutes in the respective pockets, followed by rinsing with saline, drying and application of Emdogain® FL.
9700443|NCT04449393|Placebo Comparator|Control group|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation, followed by rinsing with saline.
9700444|NCT04442256|Other|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a monthly fashion. Observation period will be 30 minutes after injection
9700445|NCT04438525|Active Comparator|early maintenance phase|patients who reached the maintenance dose of venom immunotherapy one week (max. +3 weeks) before recruitment will be sting challenged
9700446|NCT04438525|Active Comparator|maintenance phase|patients who reached the maintenance dose of venom immunotherapy one year (+/- 2 months) before recruitment will be sting challenged
9700447|NCT04438525|Active Comparator|after stopping VIT|patients who finished venom immunotherapy two years (+/- 6 months) before recruitment (duration of VIT: at least 3 years) will be sting challenged
9700448|NCT04438525|Other|blood donors|patients with confirmed vespid venom allergy who have not undergone venom immunotherapy (blood donation necessary to perform BAT Inhibition test)
9700449|NCT04438330|Experimental|Nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
9700450|NCT04438330|Active Comparator|non-nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
9700451|NCT04438057|No Intervention|Standard of Care|Patient will receive standard of care therapy.
9700452|NCT04438057|Active Comparator|Treatment Arm|Patient will receive convalescent plasma
9700453|NCT04436692|Other|Improve dietary pattern|Nudging approach to test this methodological approach in persons with intellectual disabilitites with goal to improve dietary pattern and loss of weight
9700454|NCT04429893|Experimental|Group BM|The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.
9700455|NCT04429893|Active Comparator|Group B|The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml
9700456|NCT04428047|Experimental|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
9700457|NCT04417257|Experimental|LAU-7b|Active drug as LAU-7b capsules
9700458|NCT04417257|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
9700459|NCT04416178||Parents of children with SCD|Parent of child with HbSS, HbS/ β0thalassemia, or HbSC aged 12 months to 18 years at study initiation
9700460|NCT04416178||Adolescents with SCD|Patient aged 13-18 with HbSS, HbS/ β0thalassemia, or HbSC
9700461|NCT04410653|Experimental|Arm 1 (KRASwt PDAC)|
9700462|NCT04410653|Experimental|Arm 2 (IMA)|
9700463|NCT04410653|Experimental|Arm 3 (other)|
9700464|NCT04409353|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
9700465|NCT04409353|Active Comparator|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
9700466|NCT04409353|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
9700467|NCT04408638|Experimental|Glofit-GemOx|Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
9700468|NCT04408638|Experimental|R-GemOx|Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
9700469|NCT04406948|Experimental|MGCND00EP1|"Participants who will assigned to receive add on MGCND00EP1 will receive carrier oil containing THC and CBD in ratio 20:1, (10% of cannabidiol and 0.5 % and (-)-trans-Δ9-tetrahydrocannabinol) .~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
9778571|NCT01109979|Active Comparator|Estradiol+MPA|
9778572|NCT01109979|Active Comparator|Estradiol+DRSP|
9778573|NCT01109992|Active Comparator|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
9778574|NCT01109992|Experimental|Exercise + Regadenoson (Lexercise)|Exercise plus Regadenoson (Lexercise) Rubidium-82 Positron Emission Tomography
10189419|NCT03707600|Active Comparator|TMS|Active TMS
10189420|NCT03707561||Group 1 - IPAH and heritable PAH|Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)
10189421|NCT03707561||Group 2- PAH associated with CHD|Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)
10189422|NCT03707561||Group 3- PAH associated with CTD|Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)
10189423|NCT03707561||Group 4- portoPH|Portopulmonary hypertension
10189424|NCT03707561||group 5- PAH-HIV|Pulmonary arterial hypertension associated with HIV infection
9700470|NCT04406948|Placebo Comparator|PLACEBO|"Participants who are assigned to receive add on PLACEBO will be administered the carrier oil (without the active ingredients).~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
9700471|NCT04404153|Experimental|Active tDCS|The active tDCS will involve 30-minutes of direct current at intensity of 2 milliamperes (mA).
9700472|NCT04404153|Sham Comparator|Sham tDCS|Sham stimulation consists of the direct current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining application period.
9700473|NCT04403516|Experimental|DEXTENZA Group|Patients with Pterygium DEXTENZA Group
10189425|NCT03707561||group 6- operable CTEPH|Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
10189426|NCT03707561||group 7- non-operable CTEPH|Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
9700474|NCT04403516|Experimental|Topical Prednisolone Acetate 1% Group|Patients with Pterygium Topical Prednisolone Acetate 1% Group
9700475|NCT04403425||Emergency laparotomy, obstruction|Patients undergoing emergency laparotomy for intestinal obstruction in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
9700476|NCT04403425||Emergency laparotomy, perforation|Patients undergoing emergency laparotomy for perforated ventricle or intestine in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
9977968|NCT01367041|Experimental|Normal|Postmenopausal women without osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
9977969|NCT01367054|Experimental|Metformin|500 mg
9700479|NCT04383639|Active Comparator|1|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
9700480|NCT04383639|Experimental|2|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
9700481|NCT04383639|Experimental|3|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
9700482|NCT04367857||Prior Positive polymerase chain reaction (PCR) and Recovered|Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.
9700483|NCT04367857||Never tested, history of COVID-19 Symptoms and Recovered|Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days
9977970|NCT01367067||Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and have filled out a psychometric questionnaire
9977971|NCT01367067||No Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and did not fill out a psychometric questionnaire
9977972|NCT01367093||ICU patients admitted for severe illness|
9977973|NCT01367106|Experimental|exposed offspring|
9977974|NCT01367106|Other|controls|
10189427|NCT03707548|Experimental|Group BPT|"Six group BPT sessions (using a waiting-period comparator and pre-/post design)~A nested randomized controlled trial (RCT) is included to evaluate the short-term efficacy of smartphone-triggered bodily interventions compared with the smartphone triggered control intervention of audio-typed fairy tales."
10189428|NCT03707535|Experimental|CT-P13|
10189429|NCT03707535|Active Comparator|China-approved Remicade|
9977975|NCT01367145|Active Comparator|Omacor|
9977976|NCT01367145|Placebo Comparator|Placebo|
10189430|NCT03707509|Experimental|Camrelizumab + Gemcitabine + Cisplatin|subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
10189431|NCT03707509|Active Comparator|Placebos + Gemcitabine + Cisplatin|subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
10189432|NCT03707496||DeWinterCohort|Patients with de Winter syndrome pattern ECG
10189433|NCT03707483|Experimental|Intervention|250 μM of vitamin C will be used with the platelet rich fibrin
10189434|NCT03707483|Active Comparator|Comparator|using platelet rich fibrin alone
10189435|NCT03707470|Experimental|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
10189436|NCT03707470|Active Comparator|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 15 mmHg at both the ankle and thigh)
10189437|NCT03707470|Sham Comparator|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
10189438|NCT03707457|Experimental|Arm A: Nivolumab + anti-GITR|Patients receive nivolumab intravenously (IV) over 30 minutes and anti-GITR intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10189439|NCT03707457|Experimental|Arm B: Nivolumab + IDO1 inhibitor|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1 and IDO1 inhibitor daily by mouth. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9700484|NCT04367857||Never tested and current COVID-19 Symptoms|Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)
9700485|NCT04367857||Never tested and asymptomatic|Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker
9700486|NCT04366323|Experimental|Experimental|
9700487|NCT04366323|No Intervention|Control|
9700488|NCT04366310||capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
9700489|NCT04366245|Experimental|Experimental|
9700490|NCT04366245|Active Comparator|Comparator|
9700491|NCT04359446|Other|Stent under-expansion with NC Balloon|
9700492|NCT04359446|Other|Stent under-expansion with Laser Excimer + NC Balloon|
9700493|NCT04354493|Experimental|Baseline and Training|This group consists of a baseline and training conditions only.
9700494|NCT04354493|Experimental|Baseline, Training, and Control|This group stops training condition sooner and returns to a control to evaluate carry-over effects.
9700495|NCT04353492|Experimental|Ofatumumab|Ofatumumab 20 mg subcutaneous injections every 4 weeks, following loading of 3 doses in the first 14 days
9700496|NCT04349722|Active Comparator|Hyoscine|Participants receive intravenous bolus of 1ml (20 mg) Hyoscine
9700497|NCT04349722|Placebo Comparator|Placebo|Participants receive intravenous bolus of 1ml normal saline
9700498|NCT04338685|Experimental|RO7119929|Participants will receive RO7119929 every week in 3-week cycles. In Part A (dose-escalation on a weekly schedule) maximum tolerated dose (MTD) and/or recommended dose for expansion cohorts (RDE) will be determined. Following determination of MTD and/or RDE, treatment will commence at up to three different doses in specific expansion cohorts of participants for extended PD analysis (Part B).
9700499|NCT04334460|Active Comparator|Active (BLD-2660) Group|
9700500|NCT04334460|Placebo Comparator|Placebo Group|
9700501|NCT04332172|Placebo Comparator|General information|Control
9700502|NCT04332172|Experimental|General information + SMS|SMS refers to tailored text messaging.
9700503|NCT04332172|Experimental|Baseline brief intervention|Brief technology-delivered intervention for alcohol use during pregnancy
9700504|NCT04332172|Experimental|Baseline brief intervention + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging
9700505|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device.
9700506|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.
9700507|NCT04331769|Experimental|Device group: AccuCinch Ventricular Restoration System|Subjects in this arm will receive the AccuCinch Ventricular Restoration System
9700508|NCT04331769|Active Comparator|Control group: Guideline-Directed Medical Therapy|Subjects in this arm will receive guideline-directed medical therapy (GDMT)
9700509|NCT04328948|Experimental|Chemoradiation therapy with elective nodal irradiation|Chemoradiotherapy consists of 5-FU (1,000 mg / m2, day1-4, day29-32), CDDP (75 mg /m2, day1, 29) and radiotherapy (50.4 Gy/28Fr)
9700510|NCT04328948|Active Comparator|Chemoradiation therapy with involved field irradiation|Chemoradiotherapy consists of 5-FU (700 mg /m2, day1-4, day29-32), CDDP (70 mg /m2, day1,29) and radiotherapy (60 Gy/30Fr)
9700511|NCT04328740|Experimental|Monotherapy|TP-1454
9700512|NCT04328740|Experimental|Combination Therapy|TP-1454, ipilimumab and nivolumab
10189440|NCT03707457|Experimental|Arm C: Nivolumab + Ipilimumab|Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab intravenously (IV) over 90 minutes on Day 1. Courses repeat every 21 days for up to 4 doses. After ipilimumab is discontinued, courses of nivolumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10189441|NCT03707444||Scrambler Therapy|All participants get the same device treatment with the Scrambler Therapy device, up to 10 treatments.
10189442|NCT03707431|Experimental|Web-based CBT (WebMAP)|Receives access to WebMAP
10189443|NCT03707431|Active Comparator|Pain Education (WebED)|Receives access to WebED
9700513|NCT04327609|Experimental|SELUTION SLR™ DEB|Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
9700514|NCT04327609|Active Comparator|Control Treatment|POBA
9700515|NCT04325464|Experimental|PEAR-003A|Digital Therapeutic
9700516|NCT04321031|Placebo Comparator|Placebo|participants will receive medication for 48 weeks
9700517|NCT04321031|Experimental|PF-06865571 25 milligrams (mg) twice daily (BID)|participants will receive medication for 48 weeks
9700518|NCT04321031|Experimental|PF-06865571 75 mg BID|participants will receive medication for 48 weeks
9700519|NCT04321031|Experimental|PF-06865571 150 mg BID|participants will receive medication for 48 weeks
9700520|NCT04321031|Experimental|PF-06865571 300 mg BID|participants will receive medication for 48 weeks
9700521|NCT04321031|Experimental|PF-06865571 (150 mg BID) + PF-05221304 (5 mg BID)|participants will receive medication for 48 weeks
9700522|NCT04321031|Experimental|PF-06865771 (300 mg BID) + PF-05221304 (10 mg BID)|participants will receive medication for 48 weeks
9700523|NCT04313972|Experimental|Low-dose naltrexone|2mg low-dose naltrexone capsules
9700524|NCT04313972|Placebo Comparator|Placebo|Placebo capsules
9700525|NCT04313530|Experimental|fatigue in MSA Arm one|This arm will receive a total 10 sessions of TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
9700526|NCT04313530|Sham Comparator|fatigue in MSA Arm two|This arm will receive a total 10 sessions of sham-TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
9977977|NCT01367197|No Intervention|No intervention|Observation only
10189444|NCT03707418|Active Comparator|Bivalirudin Injection (Angiomax)|This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
9700527|NCT04310020|Experimental|Treatment (hypofractionated radiation therapy, atezolizumab)|"RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity."
9700528|NCT04309682|Experimental|crestal sinus approach technique|Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
9700529|NCT04309682|Active Comparator|lateral sinus elevation technique|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take plac
9700530|NCT04306393|Experimental|Treatment Group|Inhaled Nitric Oxide until PaO2/FiO2 >/= 300 mmHg
9700531|NCT04306393|No Intervention|Control Group|
9700532|NCT04306016|Experimental|Sensory stimulation|Participants allocated to the intervention group will receive a model-based sensory stimulation intervention, which is aimed at providing visual and auditory stimulation to ICU patients with additional support from family caregivers.
9700533|NCT04306016|No Intervention|Usual care|Participants in the control group will receive usual care routine that they are receiving or planning to receive. The registered ICU nurses will provide the same nursing care as previously, including but not limiting to the use of sedation, analgesia, spontaneous breathing trial, indwelling catheter, feeding, and bowel care.
9700534|NCT04302454|Active Comparator|Radiotherapy without hormonal therapy|Metastase-directed radiotherapy without the addition of hormonal therapy
9700535|NCT04302454|Experimental|Radiotherapy combined with hormonal therapy|Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)
10189445|NCT03707418|Active Comparator|Heparin Sodium|This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
10189446|NCT03707392|Active Comparator|Control|Standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
9700536|NCT04296292||AMBITION Trial Participants|Individuals who have been enrolled into the AMBITION trial
9700537|NCT04296292||The next-of-kin of AMBITION Trial Participants|Individuals who have provided consent for an AMBITION trial participant who had an abnormal mental status at baseline
10189447|NCT03707392|Experimental|Treatment|Ostomy care educational video combined with standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
10189448|NCT03707379||common care group|diabetic patients under common care group
10189449|NCT03707366|Experimental|FHF-T Intervention Group|9 months of 1:1 youth mentoring by graduate-student mentors; workshops; educational advocacy
9700538|NCT04296292||AMBITION Researchers|Individuals working on the AMBITION trial
9700539|NCT04293055|Experimental|Maintenance program+possibility of phone coaching|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. Some participants randomized to this condition will also receive 4 consecutive weeks of phone coaching at some point over the 1-year intervention period (this is determined by a weight-based algorithm).
9700540|NCT04293055|Active Comparator|Maintenance program only|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. No participants in this condition will receive phone coaching.
9700541|NCT04286568|Experimental|WOW Intervention|"Participants will receive blood pressure monitor and health passport to record blood pressure readings for 3 months.~Participants will receive daily text message reminders to take and record blood pressure readings.~Participants will receive health education and health care navigation. Participants will be assessed for social determinants of health. Participants will take surveys 3 times over 3 months. Participants will receive home visits or phone calls to collect data and receive health coaching."
9700542|NCT04284787|Active Comparator|Arm I (AZA, VEN)|"INDUCTION THERAPY PHASE: Patients receive azacitadine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2. Patients also receive venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY PHASE: Patients receive azacitadine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2. Patients also receive venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment per physician discretion."
10189450|NCT03707366|No Intervention|Control group|Services as usual
10189451|NCT03707353|Experimental|Group 1|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by ChAd63 ME-TRAP vaccination intravenously.
10189452|NCT03707353|Experimental|Group 2|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
10189453|NCT03707353|Experimental|Group 3|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by ChAd63 ME-TRAP vaccination intravenously.
9700543|NCT04284787|Experimental|Arm II (AZA, VEN, pembrolizumab)|"INDUCTION THERAPY PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitadine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitadine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment with azacitadine and venetoclax per physician discretion."
9700544|NCT04283409|Experimental|Motor Control Exercise|The primary goal of motor control exercises is to retrain optimal control and coordination of the spine. It uses principles of motor learning such as segmentation, simplification and task-specific practice to retrain control of trunk muscles activation, alignment and movement. The first stage of the treatment involves assessment of the postures, movement patterns and muscle activation associated with symptoms and a retraining program designed to improve activity of muscles assessed to have poor control (usually the deep trunk muscles). Participants are taught how to contract these muscles independently. During this stage additional exercises for breathing control, posture of spine and movement are performed. The second stage of the treatment involves the progression of the exercises towards functional activities, firstly using static then dynamic tasks. Education is also included.
9700545|NCT04283409|Experimental|Graded Activity|The primary goal of graded activity is to address individual modifiable contextual factors associated with the pain experience such as self-efficacy, pain-related fear, kinesiophobia and unhelpful beliefs/behaviors about back pain while at the same time addressing physical impairments such as endurance, muscle strength and balance. A primary goal of the program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. Activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Cognitive-behavioral principles are used to help patients overcome the natural anxiety associated with pain and activities.
9700546|NCT04281719|Experimental|Mobile App|Youth will be assigned to interact with a novel mobile application during a course of outpatient psychotherapy for substance use disorder(s) and co-occurring mental health disorder(s).
9700547|NCT04280965|Experimental|Quetiapine|Flexible dosing begins at 50 mg, titrating up to 100 mg at the end of week 2 with additional doses up to 400 mg per day if needed
9700548|NCT04280965|Active Comparator|Treatment As Usual (TAU)|Standard of care medications
9700549|NCT04280029|Experimental|SELUTION SLR™ DEB|
9977978|NCT01367197|Experimental|Exercise training group|Group exercise training, three times weekly high-intensity
10189454|NCT03707353|Experimental|Group 4|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by MVA ME-TRAP vaccination intravenously. 4 weeks after the last vaccine dose, all vaccinated volunteers will undergo malaria challenge by mosquito bite.
10189455|NCT03707353|No Intervention|Group 5|6 Volunteers will receive no vaccinations but will undergo malaria challenge infection by mosquito bite at the same time as groups 1-4.
10189456|NCT03707353|No Intervention|Group 6|6 Volunteers will be used as infectivity controls if any volunteers from Groups 1-4 are rechallenged 5 - 7 months after the initial CHMI.
10189457|NCT03707353|Experimental|Group A|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
10189458|NCT03707327|Experimental|Game Ready group|the participants performed cryotherapy by compression with Game Ready
10189459|NCT03707327|Experimental|Ice pack|the participants performed cryotherapy for ice pack
10189460|NCT03707314|Other|Group A: Immediate angiography|Immediate angiography with follow-on revascularisation if indicated
10189461|NCT03707314|Other|Group B: Standard of care angiography|Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)
10189462|NCT03707288|Other|Spine exercise program|"The preclinical second year medical students will be prospectively randomized into two (2) groups, a control group (Group A) and an intervention group (Group B) that will be given a standardized spine exercise program. They will be asked to complete a Questionnaire B to evaluate changes in knowledge, attitude and practice towards musculoskeletal problem of the back and neck pain after intervention; the numeric rating scale (NRS), and the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) at eight (8) weeks.~The standardized spine exercise program will be provided in a handout and given only to the intervention Group B subjects, these are basic low back exercises to be done three (3) times per week for 20mins, as well as a few very brief stretching exercises to be done during periods of sitting for greater than sixty (60) minutes."
10189463|NCT03707275|Experimental|Alexa+ Arm|
10189464|NCT03707275|Other|Standard of Care Arm|
10189465|NCT03707249|Experimental|Iron|Received a blinded single 15 mg/kg dose of iv ferric carboxymaltose (Ferinject) up to a maximum off 1g total dose 2 weeks prior to ascent to very high-altitude.
10189466|NCT03707249|Sham Comparator|Saline control|Received a blinded single dose of iv normal saline 2 weeks prior to ascent to very high-altitude.
10189467|NCT03707236|Experimental|Treatment arm|Patients in the treatment arm will have monthly office visits for weeks 0-4 and then have monthly teledermatology visits during weeks 8-20 with a final office visit at week 24. Standardized baseline photographs including 3 facial images (front, left, and right) as well as 2 truncal images of the chest and back (if affected) will be taken in the office at treatment week 0 and 24 for all patients. All patients will be required to take photos in front of a white wall to facilitate blinding.
10204369|NCT02779855|Experimental|Talimogene laherparepvec + Chemotherapy|Talimogene laherparepvec with Neoadjuvant Paclitaxel Chemotherapy treatment administration on an outpatient basis. Phase I: Dose Escalation to Determine Maximum Tolerated Dose (MTD). Phase II: Treatment at MTD.
10189468|NCT03707236|No Intervention|Control arm|Patients in the control arm will have the same series of photographs taken at each monthly visit. These patients will also be required to fill out a monthly survey assessing acne severity, quality of life, cost of attending appointment, time missed from school/work, satisfaction with treatment (only to be reviewed by study staff) and will be screened for adverse events by their provider. Every patient will be counseled about isotretinoin and contraception (if applicable) by their provider in order to adhere with iPledge requirements. All photographs will be uploaded into the patient's medical record. The physician will be required to document a progress note in the electronic medical record after each visit as per standard hospital protocol.
9700550|NCT04280029|Active Comparator|Control Treatment|"For subjects randomized to the control group (SOC) the treating physician may chose to implant a commercially available DES or alternatively may use POBA only to treat the patient. The decision should be based on the treating physicians' assessment of the best treatment option for the individual patient. However, it is expected that patients with one prior stent will receive DES and patients with two prior stents will receive POBA. Treating physicians may deviate from this if it is determined to be in the best interest of the patient, but the justification for the treatment decision must be recorded in eCRF.~Choice of DES is at the treating physician's discretion, but is limited to ZES and EES devices."
9700551|NCT04278482|Active Comparator|DHA supplement|Supplement rich in DHA form algae source
9700552|NCT04278482|Placebo Comparator|Placebo|Placebo supplement
9700553|NCT04278326|Experimental|Experimental|"Patients infected by oncogenic HPV and presented a high grade cervical dysplasia or a cervical cancer~Patients with cervical or vaginal cancer~All patients"
9700554|NCT04277442|Experimental|Treatment (nivolumab, decitabine, venetoclax)|"INDUCTION: Patients receive nivolumab IV over 30 minutes on day 15 of cycle 1 and days 1 and 15 of subsequent cycles, decitabine IV over 60 minutes on days 1-10 of induction cycle 1 (and cycles 2 and 3 if needed), and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve a CR or CRi receive nivolumab IV over 30 minutes on days 1 and 15, decitabine IV over 60 minutes on days 1-5, and venetoclax PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9700555|NCT04275232|Experimental|Allogenic Plasma Aliquots|Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.
9700556|NCT04274296||Control|Control-cohort in which no change in care is needed
9700557|NCT04274296||Advisory|Cohort in which advisory is activated
9700558|NCT04269967||Tele-rehabilitation|Patients who choose tele-rehabilitation
9700559|NCT04269967||Usual care|Patients who choose usual (rehabilitation) care
9700560|NCT04265287||Pediatric patients with severe pneumonia|Pediatric patients admitted to PICU due to severe pneumonia
9700561|NCT04265261|Placebo Comparator|Group A|Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
9700562|NCT04265261|Experimental|Group B|Participants will receive a low oral dose of RG7774 QD
9700563|NCT04265261|Experimental|Group C|Participants will receive a high oral dose of RG7774 QD
9700564|NCT04264013|Placebo Comparator|Exercise|Exercise
9700565|NCT04264013|Active Comparator|Exercise + Diet|Exercise + eggs
9700566|NCT04261738|No Intervention|Control|The first 2-hour session will be a control where participants will sit quietly (as they would in the hyperbaric chamber) and will not be allowed to consume carbohydrates unless directed to by the hyperbaric department hypoglycemia protocol.
9700567|NCT04261738|Experimental|Hyperbaric Oxygen|"The following day for the HBO2 session, subjects will be fitted for an oxygen hood and given a standard HBO2 treatment. In the chamber the pressure will increase to approximately 2-1/2 times normal atmospheric pressure (2.4 atmospheres absolute [ATA]). Once they reach the treatment pressure, subjects will breathe oxygen by placing the hood over their head and securing it in place. They will breathe oxygen for a 30-minute period, and then take the hood off for 5 minutes for an air break. They will have a total of three 30-minute oxygen periods and two 5-minute air breaks. A subject will be in the hyperbaric chamber for approximately 2 hours."
9700568|NCT04260347||Patients >80 years after approval|
9700569|NCT04260347||Patients >80 years before approval|
9700570|NCT04259359||patients who will be treated with bee venom immunotherapy|
9700571|NCT04254250||High risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
9700572|NCT04254250||Low risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
9700573|NCT04248712|Experimental|Treatment Group|Participants receive Famotidine 40 mg tab twice daily by mouth and Loratadine 10 mg tab once daily by mouth for 12 weeks.
9700574|NCT04248712|Placebo Comparator|Placebo Group|Participants receive Famotidine placebo tablet matching Famotidine orally twice daily for 12 weeks, and Loratadine placebo tablet matching Loratadine orally daily for 12 weeks.
9700575|NCT04247828|Experimental|Experimental and Generic Communication Interfaces for AAC|Receives both Experimental and Generic AAC systems to communicate. Each participant will receive both devices, with Experimental AAC presented first (Day 1) and Generic AAC presented second (Day 2; reference).
9700576|NCT04246203||Group A|Patients are allocated to group A according to preoperative presence of detectable ctDNA.
9700577|NCT04246203||Group B|Patients are allocated to group B according to preoperative absence of detectable ctDNA.
9700578|NCT04230395|Experimental|CAP (Counseling on Alcohol Problems)|The CAP intervention is an up to 4-session alcohol reduction intervention that uses a combination of Motivational Enhancement Therapy and Cognitive Behavioral Therapy. The intervention will also include 3 booster sessions.
9700579|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
9700580|NCT04227106|Experimental|EB-101|One-time surgical application of EB-101 on up to 6 chronic, RDEB wounds
10189469|NCT03707223|Experimental|experimental|"The interfaces Program"
10189470|NCT03707223|Active Comparator|control group|supported employment using the individual placement and support (IPS) model
9700581|NCT04226027|Experimental|T2.coach|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center) and are asked to use T2.coach for 6 months.
9700582|NCT04226027|No Intervention|Control|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center).
9700583|NCT04225819|Experimental|Vitamin D3 supplement|Two- 5,000 IU capsules, taken daily with a meal
9700584|NCT04225819|Placebo Comparator|Placebo|Two placebo capsules, taken daily with a meal
9700585|NCT04223401|Experimental|Prehabilitation group|Patients in the experimental group will undergo prehabilitation before the elective surgery for gastric cancer.
9700586|NCT04223401|No Intervention|Control group|Patients in the control group will not undergo prehabilitation.
9700587|NCT04214249|Experimental|Arm I (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
9700588|NCT04214249|Active Comparator|Arm II (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
9700589|NCT04213794|Experimental|Treatment (cytoreduction, HIPEC)|Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate IV over 12 hours.
9700590|NCT04212923|Experimental|Medical Dashboard based self-management intervention|Chronic kidney disease patients in the intervention group will receive the usual care plus the tailored 'Medical Dashboard' based self-management intervention.
9700591|NCT04212923|No Intervention|Usual care services|Chronic kidney disease patients in the comparison group will receive usual care consisting of personalised in- and outpatient treatment based on symptoms experienced and disease severity, as outlined in the Kidney Disease Improving Global Outcomes (KDIGO).
9700592|NCT04211480|Experimental|γ-globin reactivated autologous hematopoietic stem cells|each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells
9700593|NCT04210375|Active Comparator|JK07|Single dose of JK07 administered by intravenous infusion over 60 minutes
9700594|NCT04210375|Placebo Comparator|Matching Placebo|Single dose of placebo administered by intravenous infusion over 60 minutes
9700595|NCT04207424|Experimental|Embolization|Patients undergoing embolization of the gastro-epiploic arcade
9700596|NCT04201756|Experimental|Afatinib|
9700597|NCT04199624|Experimental|Experimental: omeprazole and ascorbic acid|
9700598|NCT04195061|Other|Cardiopulmonary exercise testing|
9700599|NCT04191122|Active Comparator|COPESS and Treatment as usual|"COPES is a brief (4 + 1 sessions, 50 minutes) psychotherapy based on psychodynamic and cognitive analytic principles that was developed to help those struggling with SH and depression. COPES is designed to be brief and accessible, and involves working collaboratively with a client to try and identify patterns or conflicts in emotional experiences and interpersonal relationships, linked to depressed mood and acts of SH. The therapist works with the client to build a shared map or understanding of these experiences. A goal of therapy is to work towards a small number of specific exits, representing helpful steps the client might make to improve their difficulties. Therapy would take place either in the participant's home or in a community setting (e.g. health centre or clinic) depending on preference.~Safety for the therapist and/or mobility for the patient will be reviewed throughout the recruitment period. Participants in the COPES arm of the trial will also receive TAU."
9700600|NCT04191122|No Intervention|Treatment as usual only|The control group will receive Treatment-as usual (TAU), defined as the standard care provided to individuals struggling with self-harm (SH) as detailed within the 'Managing SH in primary care' NICE guidelines. These include: an initial comprehensive psychosocial assessment of skills and risks; co-production of a care and risk management care plan, which should include harm reduction plans, the need for between 3 and 12 sessions of psychological intervention as well as treatment for associated mental health conditions. Primary care practices in the control arm will be asked to provide information on what constitutes TAU within their organisation. This trial may enhance TAU as researchers will provide details of NICE guidance to GP practices that may not currently be following these guidelines. We will collect data regarding the acceptability of TAU for SH offered by GPs within both treatment arms.
9700601|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 1|3 oral doses of RV3 vaccine (Bio Farma) batch 1; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
9700602|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 2|3 oral doses of RV3 vaccine (Bio Farma) batch 2; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
9700603|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 3|3 oral doses of RV3 vaccine (Bio Farma) batch 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
9700604|NCT04185545|Placebo Comparator|Immunogenicity Group - Placebo|3 oral doses of Placebo; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
9700605|NCT04185545|Experimental|Other Efficacy Group - RV3 Vaccine (Bio Farma)|3 oral doses of RV3 vaccine (Bio Farma) administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
9700606|NCT04185545|Placebo Comparator|Other Efficacy Group - Placebo|3 oral doses of Placebo administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
9977979|NCT01367210|Experimental|MARAVIROC, DARUNAVIR/r|"Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy"
9977980|NCT01367210|Sham Comparator|current ART with 3 drugs|Patients on HAART with three drugs and HIV RNA below 50 copies/mL
9700609|NCT04175106|Experimental|a phytochemical-rich blueberry variety|Single-time consumption of 150 g phytochemical-rich blueberry per participant.
9700610|NCT04175106|Experimental|a phytochemical-poor blueberry variety|Single-time consumption of 150 g phytochemical-poor blueberry per participant.
9700611|NCT04175106|Experimental|"a minimally processed blueberry-rich protein bar"|Single-time consumption of blueberry-rich protein bar matched for 150 g blueberry phytochemicals.
9977981|NCT01367223|Experimental|solution of amino acids with glutamine|Group 1 as the experimental group who will be administered a solution of amino acids supplemented with glutamine
9977982|NCT01367223|Other|amino acids solution without glutamine|Group 2:control group will be administered a solution of amino acids (Aminoven Infant® or Vamin®) not supplemented with glutamine
10189471|NCT03707210|Experimental|Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
10189472|NCT03707210|No Intervention|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
9700612|NCT04175106|Placebo Comparator|a blueberry control beverage of matched-nutritive content|Single-time consumption of control beverage matched for the macronutrient content of the blueberry-rich protein bar.
9700613|NCT04167423||Healthy|No thyroid disease in pregnancy defined as plasma TSH (thyrotropin), TPOAb (thyroperoxidase auto antibodies) or FT4 (free thyroxin) out of the ranges proposed by 2017 American Thyroid Association Guideline.
9700614|NCT04167423||hyperthyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
9700615|NCT04167423||hypothyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
9700616|NCT04167423||thyroid autoimmunity|Thyroid disease in pregnancy defined as plasma TPOAb out of the ranges proposed by 2017 American Thyroid Association Guideline.
9700617|NCT04165317|Experimental|PF-06801591 + BCG induction and maintenance|PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).
9700618|NCT04165317|Experimental|PF-06801591 + BCG induction only|PF-06801591 in combination with Bacillus Calmette Guerin (induction only).
9700619|NCT04165317|Active Comparator|BCG induction and maintenance|Bacillus Calmette Guerin (induction and maintenance).
9700620|NCT04165317|Experimental|BCG Unresponsive CIS|PF-06801591
9700621|NCT04165317|Experimental|BCG Unresponsive NMIBC|PF-06801591
9700622|NCT04164979|Experimental|Cabozantinib and Pembrolizumab|Subjects receive Cabozantinib 40mg PO daily on days 1-21 and Pembrolizumab 200mg IV on day 1 every 21 days.
9700623|NCT04159857|Active Comparator|One-hand|During LTCS, the fetal head traditionally is delivered by one-hand manual extraction (a surgeon inserts one hand into the uterus via the hysterotomy and lifts the fetal head out of maternal pelvis, subsequently significant abdominal pressure is required to squeeze the fetal head out of hysterotomy) along with application of significant abdominal/fundal pressure.
9700624|NCT04159857|Experimental|Two-hand|An innovative approach to manual head extraction, with surgeon's both hands formed as a pair of forceps, has been used by the PI of this study for years during the LTCS for head extraction in the difficult situations described above without complication, often time it was used after one hand approach failed to deliver the infant, vacuum/forceps and abdominal pressure usually was not needed in these cases.
9700625|NCT04154943|Experimental|Cemiplimab|Will receive IV infusion Q3W
9700626|NCT04148573|Active Comparator|Arm NFX88 - 1|1.05 g/day NFX88
9700627|NCT04148573|Active Comparator|Arm NFX88 - 2|2.10 g/day NFX88
9700628|NCT04148573|Active Comparator|Arm NFX88 - 3|4.20 g/day NFX88
9700629|NCT04148573|Placebo Comparator|Arm PLACEBO - 4|Placebo
9700630|NCT04138706|Placebo Comparator|Control: Placebo|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will receive a placebo for an additional 14 days (twice a day x 7 days, then once a day for 7 days).
9700631|NCT04138706|Active Comparator|Intervention: Extended vancomycin regimen|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will will receive active vancomycin for an additional 14 days (125mg twice a day x 7 days, then 125mg once a day for 7 days).
9977983|NCT01367288|Experimental|A (Neoadjuvant therapy + Zometa)|Patients will be treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : Zometa 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with Zometa 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
9700633|NCT04133324||Main group|One groupe in the study
9778575|NCT01110005|Active Comparator|D5 Lactated Ringer's solution (D5LR)|IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.
9778576|NCT01110005|Active Comparator|Lactated Ringer's solution (LR)|Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.
9778577|NCT01110135|Experimental|Treatment (chemotherapy and colony-stimulating factor)|"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until > 5 x 10^6 CD34+/kg has been collected.~."
10189473|NCT03707197|Experimental|Meditation Group|The intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basic + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
10189474|NCT03707197|No Intervention|Wait-list Control Group|Wait-list control group participants will continue their normal activities and not engage in any form of meditation during the study period
9778578|NCT01110187|Experimental|IV LCM (lacosamide)|Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
9778579|NCT01110187|Active Comparator|IV fPHT (fos-phenytoin)|Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin
9778580|NCT01110200|Active Comparator|ADVAIR DISKUS 250/50 mcg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
9977984|NCT01367288|Active Comparator|B (Neoadjuvant therapy)|Patients will be treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
9977985|NCT01367301|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.~RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16."
10189475|NCT03707171|Active Comparator|Liraglutide|12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
10189476|NCT03707171|Placebo Comparator|Placebo|12 weeks of Placebo treatment at adjusting dose Drug:Placebo
10189477|NCT03707145|Active Comparator|Professional led with online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
9700634|NCT04130555||CELLIS Rectopexy|Rectal prolapse repair by ventral rectopexy with the CELLIS Rectopexy matrix
9700635|NCT04123470|Experimental|Treatment|Delolimogene mupadenorepvec plus atezolizumab
10189478|NCT03707145|Active Comparator|Professional led without online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
9700636|NCT04120610||Healthy|Healthy cohort is an age-matched population (over 40 years old) without history of PAD or suspected PAD. Healthy cohort will receive FlowMet-R measurement, Ankle Brachial Index (ABI), and Toe Brachial Index (TBI) measurements.
10189479|NCT03707145|Experimental|Patient empowered with online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
9700637|NCT04120610||PAD|PAD cohort is all-comers to the vascular lab that are scheduled to undergo assessment for Peripheral Artery Disease (PAD) or have a planned endovascular or surgical intervention to address PAD. PAD cohort patients will receive FlowMet-R measurement in addition to their routine standard of care.
9700638|NCT04119063|Experimental|Exoskeleton Assistance|Walking with exoskeleton assistance to make walking easier.
9700639|NCT04119063|Experimental|Exoskeleton Resistance|Walking with exoskeleton resistance for functional gait training.
9700640|NCT04101292|Experimental|Fluorescence characterization|
10204370|NCT02772328|Experimental|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
9700641|NCT04099693||General Anesthesia|"All the patients will be intubated and ventilated using cisatracurium (0.15 mg/kg) as a muscle relaxant and propofol (1.5-2mg/kg) for induction. The inhalational anesthetic, sevoflurane, will be used to maintain the depth of anesthesia using 50% mix of nitrous oxide and oxygen.~Fentanyl will be used in both groups at a rate of 1-2 microgram /kg to achieve an adequate level of analgesia in both groups."
9700642|NCT04099693||Anesthetist Administered sedation for ERCP|To ensure a steady level of AAS each patient in this group will be sedated using propofol. An induction bolus of propofol (0.5 - 1 mg/kg) will be administered followed by continuous infusion with variable doses depending on the patients' age, weight, and clinical condition. In addition, fentanyl 1.5 μg/kg will be used at the anesthetist discretion.
9700643|NCT04097119|Other|Dietary supplement arm|Subjects to receive a specific dietary supplement
9700644|NCT04092842|Experimental|Group intervention: Silicone prothesis|Breast cancer conservative surgery will be performed by removing the tumor according to the usual technique and then the defect generated will be filled with a silicone prosthesis of the same size. Said prosthesis will be covered with fat and subcutaneous cellular tissue and then the skin will be closed.
9700645|NCT04092842|Active Comparator|Group control: Usual surgical technique|Breast cancer conservative surgery will be performed according to the usual surgical technique, that is, removing the tumor and covering the defect by mobilizing the breast tissue and then closing the skin.
9700646|NCT04084769|Experimental|Group 1: MenACYW Conjugate vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
9700647|NCT04084769|Experimental|Group 2: MenACYW Conjugate vaccine (Menveo Vaccine-primed)|Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
9700648|NCT04084769|Experimental|Group 3: MenACYW Conjugate vaccine + Trumenba vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).
9700649|NCT04084769|Experimental|Group 4: MenACYW Conjugate vaccine + Bexsero vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).
9700650|NCT04082754|Experimental|CSL311 Cohort A1 (SAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)
9700651|NCT04082754|Experimental|CSL311 Cohort A2 (SAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
9700652|NCT04082754|Experimental|CSL311 Cohort A3 (SAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
9700653|NCT04082754|Experimental|CSL311 Cohort A4 (SAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
9700654|NCT04082754|Experimental|CSL311 Cohort A5 (SAD Dose 5)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
10204371|NCT02772328|No Intervention|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
9700655|NCT04082754|Experimental|CSL311 Cohort A6 (SAD Dose 6)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
9977986|NCT01367314|Experimental|NVC-422 Dermal Gel, 1.5%|
9977987|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.5%|
10189480|NCT03707145|Active Comparator|Patient empowered without online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
9700656|NCT04082754|Experimental|CSL311 Cohort A7 (SAD Dose 7)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
9700657|NCT04082754|Experimental|CSL311 Cohort A8 (SAD Dose 8)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
9700658|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
9700659|NCT04082754|Experimental|CSL311 Cohort B2 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
9700660|NCT04082754|Experimental|CSL311 Cohort B3 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
9700661|NCT04082754|Experimental|CSL311 Cohort B4 (MAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
9700662|NCT04082754|Placebo Comparator|Placebo|0.9% sodium chloride solution administered intravenously
9700663|NCT04082754|Placebo Comparator|Placebo (2)|0.9% sodium chloride solution administered subcutaneously
9700664|NCT04082754|Experimental|CSL311 Cohort C1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously (SC)
9700665|NCT04082754|Experimental|CSL311 Cohort C2 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
9700666|NCT04082754|Experimental|CSL311 Cohort C3 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
9700667|NCT04082754|Experimental|CSL311 Cohort D1 (Dose 1)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously in healthy volunteers
9977988|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.1%|
9700669|NCT04074993|Experimental|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
9700670|NCT04074343|Experimental|TAS-102 and Irinotecan|Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
9700671|NCT04073043|Experimental|Intervention Group|The intervention group will have access to the web-based intervention along with telephone coaching. Participants in the intervention will receive 7 coach calls over a period of 12 weeks.
9700672|NCT04073043|No Intervention|Control Group|The control group will have access only to the web-based intervention without telephone support
9700673|NCT04071171|Active Comparator|Phoxilium®|
9700674|NCT04071171|Experimental|Biphozyl®|
9700675|NCT04069117|Active Comparator|• Study group|It contains 100 patients will undergo ovarian stimulation with letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) for 5 days starting from the first day of menstruation in combination with low dose step up stimulation with recombinant FSH starting in the third day of menstruation.
9700676|NCT04069117|No Intervention|• Control group|It contains 100 patients will undergo ovarian stimulation with low dose step up stimulation with recombinant FSH starting in the third day of menstruation
9700677|NCT04066868|Experimental|PRO active|
9700678|NCT04066868|Active Comparator|PRO not active|
9700679|NCT04065438|Experimental|LIPOSORBER® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using LIPOSORBER® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
9700680|NCT04061252|Experimental|KHK4827 210mg Q2W SC|
9700681|NCT04061252|Placebo Comparator|Placebo Q2W SC|
9700682|NCT04056078||Team Handball Players Playing with Shoulder Pain|Team Elite Handball players playing with shoulder pain i their dominated shoulder for more than 3 months.
9700683|NCT04056078||Team Handball Players playing without shoulder pain|Team Elite Handball players who never have experience shoulder pain i their dominated shoulder.
9700684|NCT04056078||Team Handball Players playing with previous shoulder pain|Team Handball players who have had shoulder pain i their dominated shoulder, but currently have been playing without shoulder pain in the previous 6 months.
9700685|NCT04053764|Experimental|crizanlizumab + standard of care|5 mg/kg by intravenous (i.v.) infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.
9700686|NCT04053764|Active Comparator|standard of care|Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.
9700687|NCT04044144|Experimental|Probiotic Dietary Supplement|Subjects will be asked to take 1 capsule per day of the dietary supplement for a period of 10 days
9700688|NCT04043936|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using behavioral health services. Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced. Participants in this condition will complete three separate 15-minute CBM-HS sessions."
9700689|NCT04043936|Sham Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a CBM task with a neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
9977989|NCT01367327|Experimental|Exercise with music|Loaded sit-to-stand exercise with music for 6 weeks
9977990|NCT01367327|Active Comparator|Exercise without music|Loaded sit-to-stand exercise without music for 6 weeks
9977991|NCT01367340|Experimental|Exercise and physical activity|
9977992|NCT01367340|Active Comparator|Exercise only|
9977993|NCT01367353|Experimental|ovarian cancer|
9977994|NCT01367366||Mediastinal malignant lymphadenopathy|
9977995|NCT01367379||Physician of internal medicine in Taipei city hospital|
9700690|NCT04043936|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
9700691|NCT04042493|Experimental|Connect for Health Program|
9700692|NCT04041232|Experimental|PBA treatment of ATF6-/- Achromatopsia|Patients will be monitored at the baseline visit, followed by a second and third visit that will be 1 and 3 months after the initial visit. Patients will complete a standard visual functioning questionnaire and undergo a complete ophthalmic evaluation at each visit. Other visual assessments will consist of color vision testing, contrast sensitivity, retinal imaging, and macular sensitivity testing using microperimetry. Full-field electroretinogram will also be performed at the baseline visit and after 1 and 3 months of PBA use. If improvement in retinal function is observed, an additional ophthalmic evaluation will be conducted after 6 months of PBA use. A blood draw will be performed at each visit to test for any indications of adverse effects from drug use.
9700693|NCT04040361|Experimental|Pembrolizumab+Ramucirumab+Surgery|Pembrolizumab and Ramucirumab will be administered simultaneously for non small cell lung cancer patients for 2 cycles before surgery.
9700694|NCT04025372|Experimental|Bicalutamide+GnRH Agonist+Radiation Therapy|"Bicalutamide is administered orally on a daily basis~GnRH Agonist as prescribed~Radiation therapy is administered starting 4-16 weeks after ADT"
9700695|NCT04025372|Experimental|Darolutamide+Radiation Therapy|"Darolutamide is administered orally twice daily~Radiation therapy is administered starting 4-16 weeks after ADT"
9700696|NCT04024228|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
9700697|NCT04024228|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
9700698|NCT04014660|Active Comparator|Probiotic group|The participants in this group are provided with a dietary supplement (capsules) containing freeze dried bacteria (active lactobacilli culture) mixed with corn starch, for daily intake (1 capsule per day).
9700699|NCT04014660|Placebo Comparator|Placebo group|The participants in this group are provided with a dietary supplement (capsules) containing corn starch only, for daily intake (1 capsule per day).
9700700|NCT04011176|Placebo Comparator|Standard treatment + placebo|Placing the microcurrent pads on the patient but not turning on the microcurrent box for 30 minutes once a week for 6 weeks
9700701|NCT04011176|Experimental|Standard treatment + Microcurrent Therapy|100-300µA microcurrent delivered for 20-300 minutes, once a week for 6 weeks
9700702|NCT04010344|Experimental|Enhanced Usual Care Group|All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
10189481|NCT03707132||Tourniquet Group|'Tourniquet: Folley catheter in the low segment of the uterus
10189482|NCT03707132||Control Group|Standard hysterectomy is performed
9700703|NCT04010344|Active Comparator|Usual Care|Patients in this arm of the study will receive usual care as determined by their providers. Usual care in the region typically involves at least one visit every 2-3 months for review of adherence to treatment, blood pressure control, and prescriptions for medication refills. Similar to the intervention group, participants will have a total of three follow-up visits which will be separate from their regular appointments during which study outcomes will be assessed.
9700704|NCT04007939||Employee population|Subject comprised of employees of Metagenics but later will be expanded to those recruited from practitioner practices
9700705|NCT04007276|Experimental|Lumify Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
9700706|NCT04007276|Sham Comparator|Control Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
9700707|NCT04005456|Other|N of 1 Tent|Personalized dietary supplements, food plans, and behavioral change support program for a broad group (both an employee population and those recruited from practitioner practices) inclusive of all study Participants and specifically generally healthy individuals, those with established disease/conditions requiring a personalized approach, those with diseases/conditions currently with low prevalence in our study population and those women currently pregnant or breastfeeding.
9700708|NCT04005456|Other|Wellness Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals characterized by minimal physical complaints and laboratory biomarkers of modest clinical significance.
9700709|NCT04005456|Other|Elevated Homocysteine Bucket|Personalized dietary supplements, food plans, and behavioral change support program for individuals from the Wellness Umbrella with elevated homocysteine level ≥ 10.4 µmol/L.
9700710|NCT04005456|Other|Dental Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with established dental disease.
9700711|NCT04005456|Other|Immune Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with autoimmune/inflammatory conditions (excluding metabolic disorders/atherosclerosis)
9700712|NCT04005456|Other|Elevated Anti-Nuclear Antibodies (ANA) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with elevated levels of antinuclear antibodies (preclinical symptomatology only).
9977996|NCT01367392|Experimental|interventional procedure|The patients undergo the required interventional procedure, biopsy or ablation
10204372|NCT02731352|Experimental|iodine-131 Refractory/Resistant Differentiated Thyroid Cancer|iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer
10204373|NCT02726659|Experimental|Celecoxib|Adjunct celecoxib in 6 week treatment
9700713|NCT04005456|Other|Autoimmune Conditions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with an established diagnosis of an autoimmune conditions (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level >1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.
10189483|NCT03707119||S4BE|"The intervention consisted of the use of Student 4 Best Evidence blog to teach EBP competence. The section S4BE about has been used to teach the EBP principles and their key steps and the section S4BE topics has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours."
9700714|NCT04005456|Other|Symptomatic Fatigue/Myalgias Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a broad employee health group with symptoms of persistent fatigue and myalgias.
9700715|NCT04005456|Other|Gastrointestinal Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health and of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
9700716|NCT04005456|Other|Irritable Bowel Syndrome (IBS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health.
9700717|NCT04005456|Other|Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
9700718|NCT04005456|Other|Wellness Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals characterized by minimal physical complaints and normal biomarkers.
9700719|NCT04005456|Other|Metabolic Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia).
9700720|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket C/S Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). C/S = crossover
9700721|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket R/I Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). R/I = randomization/inclusion
9700722|NCT04005456|Other|Ketogenic Product Development Exploratory Group|Subgroup investigation in participants (classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia) during their 8- or 12-week ketogenic program intervention phase
9700723|NCT04005456|Other|Reproductive Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of participants with conditions associated with reproductive and hormonal health (including polycystic ovary syndrome, premenstrual syndrome, endometriosis, peri-menopause and menopausal conditions, women currently pregnant or breastfeeding, testosterone deficiency and andropause/late onset hypogonadism, and prostate health).
9700724|NCT04005456|Other|Perimenopausal and Menopausal Transitions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically peri-menopause and menopausal conditions.
9700725|NCT04005456|Other|Premenstrual Syndrome Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically premenstrual syndrome.
9700726|NCT04005456|Other|Polycystic Ovary Syndrome (PCOS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with PCOS with signs/symptoms/biomarkers of both metabolic dysfunction and hormonal derangements.
9700727|NCT04005456|Other|Andropause/Late Onset Hypogonadism Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of men with conditions associated with reproductive and hormonal health specifically testosterone deficiency and andropause/late onset hypogonadism.
9700728|NCT03997266|Active Comparator|Empiric antibiotics|Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.
9700729|NCT03997266|Placebo Comparator|Placebo|Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.
9700730|NCT03996148|Active Comparator|Remifentanil, Propofol, and Desflurane|Study group A: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
9700731|NCT03996148|Active Comparator|Remifentanil, Dexmedetomidine, and Desflurane|Study group B: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
9700732|NCT03996148|Active Comparator|Remifentanil and Desflurane|Study group C (control group): no midazolam given; maintenance drugs started immediately after induction and airway is secured.
9700733|NCT03986203|Experimental|Active|Subjects in this group will receive the active treatment for each daily treatment session.
9700734|NCT03986203|Sham Comparator|Sham|Subjects in this group will receive the sham treatment for each daily treatment session.
9977997|NCT01367405|Experimental|surgical decompression|surgical decompression within 24 hours post-injury
10189484|NCT03707106|Experimental|VR based cue exposure smoking cessation|an established CBT intervention for smoking cessation supported by cue exposure in virtual reality
10189485|NCT03707106|Active Comparator|PMR supported smoking cessation|an established CBT intervention for smoking cessation supported supported by specific stress reduction (Progressive Muscle Relaxation, Jacobson)
10204374|NCT02726659|Placebo Comparator|Placebo|Adjunct placebo in 6 week treatment
10189486|NCT03707080||Prospective|"The prospective DAA-PASS cohort will include a subset of HCV RNA positive participants in the TARGET-HCC study who meet entry criteria including hepatitis C (with no prior history of DAA therapy) and newly diagnosed Barcelona Clinic Liver Cancer (BCLC) Stage A HCC.~Participants will be enrolled in the countries participating in TARGET-HCC which will include: United States (US), France, Germany, Italy, and Spain."
10189487|NCT03707080||Historical|The historical cohort will be derived from the ITA.LI.CA database, which includes data on all consecutive patients with HCC who were managed within participating centers in Italy. The historical cohort will include patients from the ITA.LI.CA database who have active HCV infection who were not treated for HCV (IFN-based or DAA-based regimens) during the followup period, with initial HCC diagnosis BCLC Stage A, and subsequent successful treatment of HCC with curative therapy.
9700735|NCT03983772|Experimental|RS10-10-10|First 2 weeks is for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 10 g RS blend. Fourth 2 weeks is 10 g RS blend.
10189488|NCT03707067|Experimental|Custom fitted compression garments|Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
10189489|NCT03707067|Sham Comparator|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
9700736|NCT03983772|Experimental|RS10-20-20|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 20 g RS blend.
10189490|NCT03707054|Experimental|Study Arm|Measurements of optic nerve diameter, Urine and plasma osmolality, Serum vasopressin.
9700737|NCT03983772|Experimental|RS10-20-30|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 30 g RS blend.
9700738|NCT03983772|Placebo Comparator|Placebo10-10-10|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g placebo. Third 2 weeks is 10 g placebo. Fourth 2 weeks is 10 g placebo.
9700739|NCT03981471|Other|Elderly without fall history|Elderly people in the community who have no fall history
9700740|NCT03981471|Other|Elderly with fall history|Elderly people in the community who have fall history
9700741|NCT03980938|Experimental|neflamapimod first|"neflamapimod in Treatment Period 1, placebo in Treatment Period 2~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food.~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food."
9700742|NCT03980938|Placebo Comparator|placebo first|"placebo in Treatment Period 1, neflamapimod in Treatment Period 2~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food."
9700743|NCT03974087|Active Comparator|MCI patients with real transcranial direct current stimulation|Patients will receive 2mA stimulation in 10 consecutive sessions.
9700744|NCT03974087|Sham Comparator|MCI patients with sham transcranial direct current stimulation|Patients will receive sham stimulation in 10 consecutive sessions.
9700745|NCT03972280|Experimental|Dose Level 1 (HS)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
9700746|NCT03972280|Experimental|Dose Level 1 (PPP)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
9700747|NCT03972280|Experimental|Dose Level 1 (Total)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
9700748|NCT03972280|Experimental|Dose Level 2 (HS)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
9700749|NCT03972280|Experimental|Dose Level 2 (PPP)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
9700750|NCT03972280|Experimental|Dose Level 2 (Total)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
9700751|NCT03957733|Experimental|Experimental arm|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and surgery. Consolidation chemotherapy will start 2-4 weeks after the end of CRT. Surgery will be performed 2-4 weeks after the last chemotherapy cycle. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).
9700752|NCT03957733|No Intervention|Standard arm|Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).
9700753|NCT03940131|Experimental|Single Arm|Panitumumab with FOLFOX6/FOLFIRI
9700754|NCT03939390|No Intervention|follicular phase stimulation|
9700755|NCT03939390|Experimental|luteal phase stimulation|
9700756|NCT03926845|Active Comparator|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|The cream contains 0.2% Isobutylamido-thiazolyl-resorcinol.
9700757|NCT03926845|Placebo Comparator|Vehicle|The cream contains no active ingredients.
9700758|NCT03923296||HCPs|Health care professional interviews (market research)
9700759|NCT03923296||Patients or caregivers|Patients or caregivers interviews
9700760|NCT03922646|Experimental|NEAT Active Experimental Group|People in the active group will receive NEAT intervention
10189491|NCT03707002|Active Comparator|scFOS|scFOS consumed at 5g/day for 6 weeks
10189492|NCT03707002|Placebo Comparator|Placebo|maltodextrin consumed at 5g/day for 6 weeks
10189493|NCT03706950||Elpida® + 2 NRTIs|Elpida® 20mg qd in the first line of therapy for HIV-1 infected patients with a background standard ART.
10189494|NCT03706937||Paramedical professionals|Paramedical professionals of the Lucien Neuwirth Cancer Institute
10189495|NCT03706924|Experimental|VM-1500FDC|VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
9700761|NCT03922646|Active Comparator|Control Group|People in the control group will receive non-essential regularly-scheduled programming (active control) coinciding with the same timeframe
9700762|NCT03918343|Other|All patients|
9700763|NCT03914300|Experimental|Treatment (cabozantinib S-malate, nivolumab, ipilimumab)|Patients receive cabozantinib S-malate PO QD on days -14 to -1 prior to cycle 1, days 1-42 of cycles 1-4 and days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1, 15, and 29 of cycles 1-4 and day 1 of subsequent cycles and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Treatment repeats every 42 days for cycles 1-4 and every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
9700764|NCT03912818|Experimental|Cohort II (durvalumab, cis-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Cisplatin 70 mg/m2 on Cycle Day 2, and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
9700765|NCT03912818|Experimental|Cohort III (Durvalumab, carbo-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Carboplatin: AUC 5 on Cycle Day 1 and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
9700766|NCT03912818|Experimental|Cohort I (durvalumab, DD MVAC)|Durvalumab (MEDI4736), at1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Dose Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin (DD MVAC), in 14 day cycles (2 weeks), Methotrexate 30 mg/m2 on Cycle Day 1, Vinblastine 3 mg/m2 on Cycle Day 2, Doxorubicin 30 mg/m2 on Cycle Day 2 and Cisplatin 70 mg/m2 on Cycle Day 2. Patients undergo cystectomy within 6 weeks.
9700767|NCT03906604|Other|Dominant hand-open Carpal Tunnel Release|Standard mini-open carpal tunnel release (standard of care) on the dominant hand.
10189496|NCT03706924|Active Comparator|Elpida® & Truvada®|Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
10189497|NCT03706872|Experimental|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care.
9700768|NCT03906604|Other|Dominant hand-Incisionless thread carpal tunnel release|Incisionless thread carpal tunnel release on the dominant hand.
9700769|NCT03906539|Placebo Comparator|Control Group|The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.
10189498|NCT03706872|No Intervention|Control Group|Provision of usual prenatal care
10189499|NCT03706859|Experimental|Tourniquet inflation pressure method 1|the pneumatic tourniquet inflation pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Unver B. et al.,: (AOP=[SBP+10]/KTP)
9700770|NCT03906539|Experimental|VCO Group|The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).
9700771|NCT03899090|Experimental|Float Pool|Floating supine in a pool for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
9700772|NCT03899090|Active Comparator|Float Chair|Floating supine in a zero-gravity chair for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
9700773|NCT03899090|Experimental|Float Pool Preferred|Floating supine in a pool for a preferred amount of time (6 total sessions, up to 2 hours/session, as frequently as they prefer within a 12-week period with a minimum of 24 hours between sessions)
9700774|NCT03897270|Experimental|Diagnostic (photoacoustic imaging of the breast)|Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.
9700775|NCT03896464|Active Comparator|Soft-tissue hamstring|All patients in the study will undergo arthroscopic-assisted, single-bundle, complete transphyseal, anatomic primary ACL reconstruction at the discretion of the surgeon, considering the individual patient's age, physeal status, and anticipated years of growth remaining to skeletal maturity. Patients in this arm will undergo soft-tissue autograft reconstruction using hamstrings (i.e. semitendinosus and/or gracilis) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
9700776|NCT03896464|Active Comparator|Quadriceps tendon|Patients in this arm will undergo soft-tissue autograft reconstruction using all-soft-tissue quadriceps (i.e. full or partial thickness) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
9778581|NCT01110200|Active Comparator|Serevent 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
9977998|NCT01367405|Active Comparator|Conservative treatment|Normal conservative treatment without surgical intervention
10189500|NCT03706859|Active Comparator|Tourniquet inflation pressure method 2|the pneumatic tourniquet inflateion pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Hong-yun Liu et al.,: (AOP = 17.986 + 3.158X1 + 0.408X2)
10189501|NCT03706846|Other|Fasting 2 hours|Fasting 2 hours
10189502|NCT03706846|Other|Fasting 6 hours|Fasting 6 hours
10189503|NCT03706820||normal rest and exercise hemodynamics|
10189504|NCT03706820||normal rest and abnormal exercise hemodynamics|
10189505|NCT03706820||resting pulmonary hypertension|
10189506|NCT03706820||abnormal wedge pressure at exercise|
10189507|NCT03706807|Experimental|Mindfulness-Based Intervention|"This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as mindfulness in breathing, body scan, mindful walking, mindful movements and 3-minutes of mindfulness and the concepts of first and second suffering and the Hi-Thanks-Bye."
10189508|NCT03706807|Active Comparator|Cognitive Stimulation|The basic workshop is considered a cognitive stimulation and the participants will receive an hour and thirty minutes class once a week during four months. The abilities learned at the workshop will be basic computer functions from development of the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks. The activities of the workshop are elaborated according to the development of each class and is participants.
9700777|NCT03891563||Sport specialists, MVPA|"AOSSM Criteria:~Participation in intensive training and/or competition in organized sports greater than 8 months per year (essentially year round)~Participation in 1 sport to the exclusion of participation in other sports (limited free play overall)~Involving prepubertal (seventh grade or roughly age 12 years) children.~AND~Activity Tracker Criteria:~Greater than 180 accumulated minutes of moderate-to-vigorous physical activity (MVPA) during participation in one sport type across one week of activity tracking~- Meets these criteria within either one or both years of follow-up"
10189509|NCT03706807|No Intervention|Naïve|It's a waiting list group which will receive no intervention.
10189510|NCT03706794|Experimental|Clinical Decision Support Tool|Tailored education provided via a smartphone application
10189511|NCT03706794|Active Comparator|Headache Education|Non-tailored education provided via a smartphone application.
10189512|NCT03706781|Experimental|Test product CTP/BNZ with mucus adhesive polymer|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) + mucus adhesive polymer is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
10189513|NCT03706781|Active Comparator|Reference product CTP/BNZ - Tantum Verde Bocca|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) Tantum Verde Bocca is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
10189514|NCT03706768|Other|Glycocalyx|degree of glycocalyx breakdown in patients with aSAH
10189515|NCT03706755|Active Comparator|A|group A: will receive 1 mcg/Kg of Norepinephrine intravenously
10189516|NCT03706755|Active Comparator|B|group B: will receive 0.5 mcg/Kg of Norepinephrine intravenously
10189517|NCT03706742|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
10189518|NCT03706742|Active Comparator|Mailed outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
10189519|NCT03706729|Experimental|Spraino intervention group|Participants will use Spraino® as a measure to prevent future lateral ankle sprains during all training sessions and games.
10189520|NCT03706716|Other|Intervention with use of decision aid in the consultation|With use of developed decision aid for pelvic organ prolapse / At the beginning of the consultation the IF will be opened within the patients electronic journal. The conversation will take its starting point from the generated IF which should define the area of interest rather for the patient.
10189521|NCT03706716|No Intervention|Control with no use of decision aid in the consultation|Without decision aid / The conversation during the consultation will follow the general standard for consultation conversations in the department.
10189522|NCT03706703|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with docetaxel/carboplatin or pemetrexed/carboplatin
10189523|NCT03706664|Other|Training of machine learning algorithm|113 MR Enterography images labelled by Radiologists will be used to develop a machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal.
10189524|NCT03706664|Other|Testing of machine learning algorithm|"113 MR Enterography images labelled by Radiologists will be used to test the accuracy of the machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal compared to Radiologists opinion.~Cross Validation analysis will be used for data analysis."
10189525|NCT03706651||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
10189526|NCT03706651||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
10189527|NCT03706638|Other|Daily|Patients randomized to this arm will take ferrous sulfate 325 mg every day.
10189528|NCT03706638|Other|Intermittent (Every other day)|Patient's randomized to this arm will take ferrous sulfate 325 mg every other day.
10189529|NCT03706625||Non-Hodgkin-Lymphoma (after transplantation)|Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
10189530|NCT03706625||Non-small cell lung cancer|Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
10189531|NCT03706625||Primary Central Nervous System Lymphoma|Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
10189532|NCT03706625||Gliomas|Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
9700778|NCT03891563||Non-sport specialist, any activity level|"AOSSM Criteria:~Participation in more than 1 sport at any physical activity level OR~Participation in none or low training and/or competition in organized sports for any period of time.~Involving prepubertal children.~AND~Activity Tracker Criteria:~Greater than or less than 180 accumulated minutes of MVPA across one week of activity tracking~- Meets these criteria during both years of follow-up"
9700779|NCT03889912|Experimental|Cemiplimab|Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion. After completion of the above, two additional cohorts (A and B) of patients will be evaluated.
9700780|NCT03887702|Experimental|Group A (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD immediately or within 42 days after initial dose of chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
9700781|NCT03887702|Experimental|Group B (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD after HBV reactivation during chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
9700782|NCT03887702|Experimental|Group C (TAF, TDF, entecavir, usual care)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD at the discretion of the physician during usual care. Treatment continues for up to 6 months after discontinuation of usual care or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
9700783|NCT03879434||Ostenil® Mini|1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.
9700784|NCT03876795|Active Comparator|Single intra-articular Bone Marrow Concentrate injection|Single intra-articular Bone Marrow Concentrate injection in the knee
10189533|NCT03706625||Non-Hodgkin-Lymphoma with HIV infection|Immune-suppressed patients (during HIV infection) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
9700785|NCT03876795|Experimental|combined Bone Marrow Concentrate injection|combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)
9700786|NCT03876262|Experimental|Annual Moxidectin|Moxidectin 8mg per oral, administered annually for 24 months
9700787|NCT03876262|Experimental|Biannual Moxidectin|Moxidectin 8mg per oral, administered biannually for 24 months
9700788|NCT03876262|Active Comparator|Annual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
9700789|NCT03876262|Experimental|Biannual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
9700790|NCT03876106|Experimental|LUT014 dose level 1|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
9700791|NCT03876106|Experimental|LUT014 dose level 2|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
9700792|NCT03876106|Experimental|LUT014 dose level 3|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
9977999|NCT01367418|Experimental|Thoracic Epidural Analgesia (TEA)|TEA is used for perioperative pain management, having been used both intra- and postoperatively, up to 48 h.
9978000|NCT01367418|Active Comparator|Patient controlled analgesia (PCA)|PCA is the standard of pain management and is usually used for up to 48 h postoperative for pain management following radical prostatectomy.
10189534|NCT03706599|Experimental|Fever therapeutic education session|Therapeutic education session on fever
9978001|NCT01367431||20 mg|Single dose 20 mg Xanthohumol
9978002|NCT01367431||60 mg|Single dose 60 mg Xanthohumol
9978003|NCT01367431||180 mg|Single dose 180 mg Xanthohumol
9978004|NCT01367470|Active Comparator|VSL#3 probiotic preparation|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) 1 sachet per day of probiotics (VSL#3) during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet before meal).
9700799|NCT03868891|Experimental|EMST150|Subjects with or without cleft palate will use the EMST150 2 times a day for 8 weeks.
9700800|NCT03867981|Experimental|Internet weight loss + possibility of brief phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive a brief period (i.e., once/week for 3 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
9700801|NCT03867981|Experimental|Internet weight loss + possibility of extended phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive an extended period (i.e., once/week for 12 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
9978005|NCT01367470|Placebo Comparator|Placebo VSL#3|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) a placebo comparable to VSL#3 during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet/day, before meal)
9978006|NCT01367483|Experimental|Arm1|MNTX active treatment
9978007|NCT01367496|Experimental|Arm 1|
9978008|NCT01367496|Experimental|Arm 2|
9978009|NCT01367496|Experimental|Arm 3|
9978010|NCT01367496|Experimental|Arm 4|
9978011|NCT01367509|Experimental|Arm 1|SC Methylnaltrexone (MNTX)
9978012|NCT01367522|Experimental|Arm 1|
9978013|NCT01367535|Experimental|Arm 1|
9978014|NCT01367535|Experimental|Arm 2|
9700802|NCT03867981|Active Comparator|Internet weight loss only|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
9978015|NCT01367535|Active Comparator|Arm 3|
10189535|NCT03706599|Placebo Comparator|Control therapeutic education session|Control therapeutic education session (on household accidents)
9700803|NCT03866564||Multi-Afflicted|Participants with multiple self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
10189536|NCT03706586|Active Comparator|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
10189537|NCT03706586|Experimental|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
10189538|NCT03706547|Experimental|anti-CD19/BCMA CAR-T cells|"Chemotherapy with a classic combination with fludarabine and cyclophosphamide;~Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients."
10189539|NCT03706534|Active Comparator|Manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored. Radiologists also make assessment decision without any intervention from artificial intelligence. 10 radiologists review manually.
9700804|NCT03866564||Un-Afflicted|Participants who report no afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
9700805|NCT03866564||Single Afflicted|Participants with one self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
9700806|NCT03865719|Other|Healthy Habits for Life Intervention|Participants will receive the Healthy Habits for Life Intervention
9700807|NCT03864731|Other|Bone conduction device - ADHEAR|Patients will receive a hearing aid (ADHEAR). Hearing assessment will be carried out. Quality of life measurement will be carried out.
9700808|NCT03864562||Black African or Caribbean|Healthy individuals of black African or Caribbean descent
9700809|NCT03864562||White European|Healthy individuals of white European descent
9700810|NCT03863509||Exclusive Smokers|Smokes Daily; >/= 5 cigarettes/day for last 6 months
9700811|NCT03863509||Exclusive E-Cig users|E-cig usage >/= 5 days/week for last 3 months
9700812|NCT03863509||Never users|< 100 cigarettes in lifetime, none for > 5 years; < 3 E-cig usage in lifetime
9700813|NCT03863353|Experimental|Education Intervention|This group will receive the scenario-tailored STOMP educational feedback
9700814|NCT03863353|No Intervention|Control|This group will receive only standard of care information.
9700815|NCT03860883|Experimental|Arm A (Wide Local Excision = 1cm Margin)|1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
9700816|NCT03860883|Active Comparator|Arm B (Wide Local Excision = 2cm Margin)|2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
9700817|NCT03852836|Other|1.5T magnetic field|For each patient who undergo a 1.5T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
9700818|NCT03852836|Other|3T magnetic field|For each patient who undergo a 3T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
9700819|NCT03846089||Retrograde reperfusion|After completion of the inferior vena cava anastomosis, the clamps were removed to allow retrograde reperfusion of the graft.
9700820|NCT03846089||Antegrade reperfusion|After completion of the inferior vena cava anastomosis, the portal vein anastomosis is completed and then the clamps were removed to allow antegrade reperfusion of the graft.
9700821|NCT03834909|Active Comparator|Standard Dose Truvada®|Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day
9700822|NCT03834909|Experimental|Pregnancy-Adjusted Truvada®|Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day
9700823|NCT03834870|Experimental|Elder adults in emergency department setting|Elder mistreatment in an Emergency Department setting.
9700824|NCT03832309|Active Comparator|Group 1|Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
9700825|NCT03832309|Other|Control Arm|Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.
9700826|NCT03819803|Experimental|Steroid refractory GI-aGvHD|"Patients with GI-aGvHD not sufficiently responding to GvHD therapy with corticosteroids.~Intervention: Fecal microbiota transplantation"
9700827|NCT03818204|Experimental|Experimental Group|"The purpose of the experimental group is to test the intervention. Participants will have their acuity measured (refraction as needed), slit lamp with Nafl & NEI scale, visual functioning questionnaire (VFQ), cognitive assessment (MOCA).The eye lid will be prepped and video recorded.The masked clinical staff will then apply the polarized magnets and perform a number of measurements to ascertain effectiveness of intervention.~-Intervention - Magnetic Levator Prosthesis (MLP)"
10189540|NCT03706534|Experimental|Review by S-Detect for Breast|The same images will be separately processed by the artificial intelligence system (S-Detect for Breast) by Samsung. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
10189541|NCT03706534|Experimental|Review with assistance of S-Detect for Breast|Second, the images will be reviewed by the radiologists with the help of artificial intelligence system, which is an interactive tool automatically providing recommendations on BIRADS descriptor choices that can be modified by the radiologists. The radiologists, after selecting all the descriptors of BIRADS, will decide the assessment categories. These decisions will be compared with the ground truths generated from the biopsy results or a 24-month follow-up (CADx).
9700828|NCT03818204|Other|Control/Normal Vision Group|"The purpose of the normal vision group is to test the experimental setup prior to enrolling ptosis patients. If the measurements of the normal vision group are found to be non-different to the experimental group, the data will be pooled.~-Intervention - Magnetic Levator Prosthesis (MLP)"
9700829|NCT03816735|Active Comparator|hyaluronic acid suppository therapy|"Women receive a vaginal suppository called Cikatridina manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria. The suppositories contain ontain hyaluronic acid, tea tree oil, tigergras extract, and aloe vera."
9700830|NCT03816735|Active Comparator|Juliet feminine laser|The fractional microablative laser with 2940 nm wavelength has a high degree of absorption in water and selectively stimulates the synthesis of sub-mucosal collagen. The erbium-doped yttrium-aluminum-garnet (Er:YAG) laser has been successfully used in the field of plastic skin rejuvenation and reconstruction. The procedure is based on photothermic treatment of connective tissue: It has been established in animal and human studies that it affects collagen remodeling resulting in tightening of the supportive tissue.
9978016|NCT01367535|Placebo Comparator|Arm 4|
9700832|NCT03816332|Experimental|Treatment (tacrolimus, prednisone, nivolumab, ipilimumab)|"Patients receive tacrolimus PO BID and prednisone PO QD. Within 28 days, patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 24 cycles (96 weeks) in the absence of disease progression or unacceptable toxicity.~Patients who experience PD or patients who have experienced allograft loss at 16 weeks receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Patients also receive tacrolimus PO BID and prednisone PO QD. Cycles repeat every 3 weeks for 4 cycles (12 weeks) in the absence of disease progression or unacceptable toxicity. Starting 6 weeks later, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 21 cycles (84 weeks) in the absence of disease progression or unacceptable toxicity."
9700833|NCT03815851|Other|Drain group|Place prophylactic drainage after surgery.
9700834|NCT03815851|Other|No-drain group|Not place prophylactic drainage after surgery.
10189542|NCT03706495|Experimental|The Group I|The Group I Postural exercise will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
10189543|NCT03706495|Experimental|The Group II|The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
10189544|NCT03706443|Active Comparator|Systane® Complete|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Complete, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
10189545|NCT03706443|Active Comparator|Systane® Ultra|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Ultra, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
10189546|NCT03706404|Experimental|Point-of-care Testing and Ultrasound pathway|
10189547|NCT03706404|No Intervention|Classical pathway|
10189548|NCT03706391||ALS and PMA Reversals|
10189549|NCT03706378|Other|Glucose Reference 1|50g glucose dissolve in 250 ml of water
10189550|NCT03706378|Other|Glucose Reference 2|50g glucose dissolve in 250 ml of water
10189551|NCT03706378|Other|Glucose Reference 3|50g glucose dissolve in 250 ml of water
10189552|NCT03706378|Experimental|Wheat Yellow Noodle|Boiled 170.6g of wheat yellow noodle
10189553|NCT03706378|Experimental|Beta-glucan Yellow Noodle|Boiled 230.4g of beta-glucan yellow noodle.
10189554|NCT03706378|Experimental|Rice Roll|Steamed 197.6g of rice roll
10189555|NCT03706378|Experimental|Rice Roll with resistant starch|Steamed 232.6g of rice roll fortified with resistant starch
10189556|NCT03706378|Experimental|Sucrose jelly|Jelly made with 25g of sucrose and 48g of wheat white bread
10189557|NCT03706378|Experimental|Isomaltulose jelly|Jelly made with 25g of isomaltulose and 48g of wheat white bread
10189558|NCT03706352|Experimental|tunneling group|Epidural Catheter Insertion and fixation by subcutaneous tunneling procedure.
10189559|NCT03706352|Active Comparator|taping group|Epidural Catheter Insertion and fixation by use of adhesive tape without tunneling.
9700835|NCT03813290|Experimental|Neuro-Technological Intervention|"Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment.~Participants will also be required to fill up some questionnaires at baseline and post-intervention visits."
9700836|NCT03810352||Patients with ITP|Patients with primary or secondary immune thrombocytopenia
9700837|NCT03809962||Ostenil® Plus|1-3 injections of sodium hyaluronate 2% (40 milligrams (mg) / 2,0 millilitres (ml)) in weekly interval.
9700838|NCT03808480|Experimental|CA and Nivolumab|"After 1 cycle of cyclophosphamide and doxorubicin (CA) induction therapy, Nivolumab 360mg flat dose will be given on day 1 with CA chemotherapy in a 21-day cycle.~After the completion of 4 cycles of CA chemotherapy, Nivolumab will be continued as a single agent at a dose of 480mg flat dose every 4 weeks until loss of clinical benefit"
9700839|NCT03802097|Experimental|A group (treatment group)|No use of antimicrobial prophylaxis
10189560|NCT03706339|Placebo Comparator|normal saline arm group|they received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
9700840|NCT03802097|Experimental|B group (control group)|Use of antimicrobial prophylaxis
9700841|NCT03795870|Active Comparator|Polymeric Tube Feeds|This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
9700842|NCT03795870|Active Comparator|Blenderized Tube Feeds|This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
9700843|NCT03795610|Experimental|Arm A: IPI-549 40 mg PO qdaily|Patients enrolled in Arm A will receive IPI-549 40 mg by mouth daily for at least 21 days
9700844|NCT03791216||Psoriasis patients to be treated only topically|
9700845|NCT03791216||Psoriasis patients with moderate-to-severe psoriasis who begin|
9700846|NCT03791216||Age-, sex- and BMI percentile-matched controls|
9700847|NCT03791216||Patients being treated with isotretinoin for acne|
9778582|NCT01110239|Experimental|remote limb preconditioning|Subjects with subarachnoid hemorrhage will undergo escalating times of limb ischemia to determine tolerability and safety. The leg will be made transiently ischemic with application of a blood pressure cuff for up to 3 cycles of 10 minutes.
9778583|NCT01110252|Active Comparator|pre-procedure|emphysema patients evaluated prior to the stem cells infusion
9778584|NCT01110252|Experimental|post-procedure|emphysema patients evaluated 30 days after the stem cells infusion
9778585|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F126)|ketoconazole 2% cream (formulation F126) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
9778586|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F012) (Nizoral)|ketoconazole 2% cream (formulation F012) (Nizoral) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
9778587|NCT01110330|Placebo Comparator|Placebo cream|Placebo cream A topical white homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
9778588|NCT01110382|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose)will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
9778589|NCT01110382|Experimental|Meropenem|Meropenem 20 mg/kg per dose (up to 1 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV meropenem only or IV meropenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
9778590|NCT01110395|Experimental|MR Spectroscopy Post-Heart Transplant|Patients post heart transplant getting heart biopsy
9778591|NCT01110408|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
9778592|NCT01110408|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be dministered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefepime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
9778593|NCT01110421|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
9778594|NCT01110421|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefipime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
9778595|NCT01110434|Experimental|Topiramate|Topiramate (200 mg daily)
9778596|NCT01110434|Placebo Comparator|Sugar pill|
9778597|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
10189561|NCT03706339|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
10189562|NCT03706339|Experimental|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
9778598|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
9778599|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
9778600|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
9778601|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
9978017|NCT01367548|Experimental|Arm 1|
9978018|NCT01367548|Placebo Comparator|Arm 2|
9700848|NCT03785028|Experimental|Experimental Arm|Only arm of this basic science study, participants will undergo working memory and attention tasks
9700849|NCT03780790|Active Comparator|Quadratus Lumborum Block|US-guided quadratus lumborum block will be performed with 0,5 ml/kg 0.25% Bupivacaine in the anterior layer of the thoracolumbar fascia between psoas major and quadratus lumborum muscles
9700850|NCT03780790|Active Comparator|Transversus Abdominis Plane Block|US- guided transversus abdominis plane block will be performed with 0,5 ml/kg 0.25% Bupivacaine into the fascial plane between internal oblique muscle and transversus abdominis muscle
9700851|NCT03780790|Active Comparator|Caudal Block|US-guided caudal epidural block will be applied to 0.7 ml/kg 0.25 % Bupivacaine up to a maximum of 20 mL
9700852|NCT03778983||Pediatric Live Transplantation Group|Children who underwent pediatric Ltx at RenJi Hospital before 12 month, and now age between 2 and 7 years;
9700853|NCT03769298|Experimental|Envarsus XR|Envarsus XR (extended release) will be administered orally, once-daily, for 6 months.
9700854|NCT03765177|Experimental|CLIC-1901|A single Intravenous infusion of CLIC-1901 will be given.
9700855|NCT03761953|Experimental|Oritavancin|Single IV infusion of 1200mg of oritavancin
10189563|NCT03706326|Experimental|Treatment with Anti-MUC1 CAR-T cells|Anti-MUC1 CAR-T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
10189564|NCT03706326|Experimental|Combination Therapy: CAR-T combining PD-1 knockout T Cells|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
10189565|NCT03706326|Experimental|Treatment with PD-1 knockout Engineered T cells|PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
9700856|NCT03751800||Women with HMB|Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain
9700857|NCT03750981|Other|A 12-week pilot intervention study introducing a high-intensi|
10189566|NCT03706300|Experimental|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited
10189567|NCT03706300|Active Comparator|Mucinex D|Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA
9700858|NCT03734315||Ostenil®|3-5 injections of sodium hyaluronate 1 % (20 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
9700859|NCT03733717|Experimental|Isatuximab|Administered intravenously every week in Cycle 1 (4 weeks) followed by every 2 weeks (Q2W) in subsequent cycles.
9700860|NCT03728595||Patients with lung disease having HAST|"Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:~venepuncture~spirometry."
10189568|NCT03706287|Experimental|Anlotinib + AP/PC|
10189569|NCT03706274|Experimental|CX-188 Escalation|
9700861|NCT03724526|Experimental|Intervention-Text messaging|Participates will receive regular 6 text messages per week for 12 months. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week. Each message will be sent on 6 of 7 randomly selected weekdays and arrived at random times the day during working hours.
9700862|NCT03724526|No Intervention|Control|Participates in control group will not receive text messages.
9700863|NCT03724136|Active Comparator|Arm 1|Intravenous Bone Marrow Stem Cell (BMSC) Fraction
9700864|NCT03724136|Active Comparator|Arm 2|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Near Infrared Light exposure .
9700865|NCT03724136|Active Comparator|Arm 3|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Intranasal topical Bone Marrow Stem Cell (BMSC) Fraction.
9700866|NCT03709888||Observation Group|Subjects will be identified from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be treated with memantine XR-pregabalin combination therapy.Patients who agree to participate will be asked to complete study questionnaires prior to the start of their CIPN treatment and once per week for six weeks during their treatment.
9700867|NCT03708965|Experimental|JR-141|"Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.~During the study, the dose of all subjects will be switched to the selected one*.~* The dose was determined to be 2.0 mg/kg/week based on the safety and efficacy data of JR-141-BR21 study."
10189570|NCT03706274|Experimental|CX-188 Alternative Dosing Schedule|
9978019|NCT01367561|Experimental|Arm 1|
9978020|NCT01367561|Experimental|Arm 2|
10189571|NCT03706261|Experimental|Offspring Cohort|Racially/ethnically diverse subjects with or without a positive family history of Alzheimer's disease (AD) will have one PET scan with 18F-MK-6240 over a 30 to 60-minute scanning period, and one PET scan with 18F-Florbetaben over a 20-minute scanning period.
10189572|NCT03706248||No recurrence|"CT scan has confirmed that subjects are without recurrence. Blood can be drawn up to 4 weeks after scan.~Effective Feb 28, 2019, this group is closed to accrual as it has reached the goal."
10189573|NCT03706248||Recurrence|CT scan has confirmed that subjects are have recurrence of their colorectal cancer. Blood can be drawn prior to any treatment for the recurrent disease.
10189574|NCT03706235||No recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging. Imaging documents no recurrence.
10189575|NCT03706235||Recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence. Imaging documents recurrence.
10189576|NCT03706222||Drug interaction of Elbasvir/Grazoprevir|Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.
10189577|NCT03706209|Experimental|150 mg MP1032 bid|3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
10189578|NCT03706209|Experimental|300 mg MP1032 bid|6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
10189579|NCT03706209|Placebo Comparator|Placebo bid|6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
10189580|NCT03706196||high incidence crohn's disease area|subjects living in high incidence crohn's disease area coming in dentist for dental extraction linked to medical indication
10189581|NCT03706196||low incidence crohn's disease area|subjects living in low incidence crohn's disease area coming in dentist for dental extractionlinked to medical indication
10189582|NCT03706183||Study Group|The IMA levels will be determined and the association of the IMA and Hearing thresholds will be evaluated.
10189583|NCT03706183||Control Group|The IMA levels will be determined.
10189584|NCT03706157|Active Comparator|Iodinate contrast|Doxorubicin solution reconstituted in 5 mL iso-osmolar ionic iodinated contrast media
10189585|NCT03706157|Active Comparator|Normal saline|Doxorubicin solution reconstituted in 5 mL normal saline
10189586|NCT03706144|Experimental|Prodigy Intervention Group|Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
10189587|NCT03706144|No Intervention|Control Group|Instruction as usual = TAU
10189588|NCT03706131|Experimental|experimental group|one session 15 minutes cervical mobilisation and home exercise
10189589|NCT03706131|No Intervention|control grup|no intervention
10189590|NCT03706118|Experimental|MRI and Neuropsychologic testing|"102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36.~102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36."
10189591|NCT03706105|Experimental|Intervention - Cardiac Rehabilitation|
10189592|NCT03706092||Before|Elderly patients > = 70 in ICU without any intervention of the pharmacists and of the geriatricians
10189593|NCT03706092||After|Elderly patients > = 70 in ICU with individualized intervention of the pharmacists and of the geriatricians
10189594|NCT03706066||PanOptix|Cataract surgery with implantation of Acrysof IQ PanOptix IOL
10204375|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.~Inclusion criteria are ability to produce sputum and having a chronic i.e. > 2 years of positive respiratory cultures, MRSA CF lung infection."
10204376|NCT02654132|Experimental|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)~Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~•Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Subjects > 75 years old:~•Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
10204377|NCT02654132|Active Comparator|Control Arm|"Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects > 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~Decadron~Dexamethasone Intensol~Dexpak~Taperpak"
10204378|NCT02646475|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
10204379|NCT02646475|Placebo Comparator|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
10204380|NCT02620033|No Intervention|Standard Care|Those assigned to the standard care group will follow the routine pre- and post-operative care for patients whose undergoing radical prostatectomy.
10204381|NCT02620033|Active Comparator|Yoga therapy group|Those assigned to the yoga therapy group will be asked to participate in yoga session three times in a week for 6 weeks prior to the scheduled surgery and then re-initiated 3 weeks after the surgery for another 6 weeks. Each session will be approximately 60 - 75 minutes. These yoga session will be held at Nydia's Yoga Therapy Studio, located in San Antonio, TX, under the guidance of certified yoga instructor, Dr. Nydia Tijerina Darby, PT, DPT, MS, who's the owner of the studio and co-investigator of this study. The yoga exercise will be tailored to patient's comfort level.
10204382|NCT02603432|Experimental|Arm A|Avelumab plus Best Supportive Care (BSC)
10204383|NCT02603432|Other|Arm B|"Best Supportive Care (BSC) alone~Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the watch and wait part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued."
10204384|NCT02602314|Experimental|Imatinib + Nilotinib|
10204385|NCT02602314|Experimental|Nilotinib|
10204386|NCT02600923|Experimental|Palbociclib + Letrozole|palbociclib and letrozole combination
10204387|NCT02597790||Group A (HIV/HCV coinfected)|
10204388|NCT02597790||Group B (HIV monoinfected)|
10204389|NCT02502318|Experimental|Lobectomy using video-thoracoscopy|
10204390|NCT02502318|Active Comparator|Lobectomy using thoracotomy|
10204391|NCT02490800|Experimental|Drug: BAL101553|Oral daily administration of BAL101553
10204392|NCT02484664|Experimental|celecoxib|Celecoxib 200mg PO QD for 6 months
10204393|NCT02464436|Experimental|human retinal progenitor cells (hRPC)|Single subretinal administration of human retinal progenitor cells (hRPC)
10204394|NCT02460900|Active Comparator|Varenicline and Standard of Care|Participants will receive varenicline and standard of care
10189595|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 3 fractions|
9700870|NCT03696043|Active Comparator|EVD placement|Catheter placement is most commonly performed via a freehand approach using external anatomical landmarks to help identify the location of the lateral ventricle within the brain without the aid of imaging. Proper identification of the ventricles on pre-procedure imaging, surgeon skill, and estimation of pathologic perturbations to the normal location of the ventricles all factor into the success of catheter placement. Multiple passes are often required. The accuracy rate from the freehand technique has been reported to range from 40 to 98 percent.
9700871|NCT03696043|Experimental|Axium Stealth Image Guidance|The novelty of this study is to investigate whether using image guidance technology can improve EVD catheter placement. Image guidance is used very commonly for EVD and shunt placement in the operating room with excellent accuracy and precision. We hypothesize that using this same workflow at the bedside will improve accuracy; decrease the number of passes needed for a successful placement, decrease the number of post-placement hemorrhagic events, and help improve the effectiveness of the catheter as well as patient outcomes.
9700872|NCT03687359||Participants with atopic dermatitis (AD)|Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enroll in the study.
9700873|NCT03682744|Experimental|anti-CEA CAR-T cells|One intraperitoneal infusion of gene-modified anti-CEA T cells are administered to patients with CEA-expressing peritoneal metastases or malignant ascites
9700874|NCT03677154|Experimental|Consolidation Therapy (Cohort A)|Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
9700875|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Monotherapy (Cohort B)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
9700876|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
9700877|NCT03677011|Other|category 1|Low responder
9700878|NCT03677011|Other|category 2|Medium Responder and High Responder
9700879|NCT03670368|Experimental|Intervention (Mentor/Mentee)|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on social relationships, coping behaviors, and healthy lifestyles.
9700880|NCT03670368|Active Comparator|Comparison group - written materials|Youth in the comparator group will receive written versions of all materials covered in the mentoring sessions.
9700881|NCT03664609||Parkinson's Disease|Subjects with Parkinson's disease, implanted with a Boston Scientific Deep Brain Stimulation System
9700882|NCT03664609||Essential Tremor|Subjects with Essential Tremor, implanted with a Boston Scientific Deep Brain Stimulation System
9700883|NCT03664609||Dystonia|Subjects with dystonia, implanted with a Boston Scientific Deep Brain Stimulation System
9700884|NCT03659136|Experimental|Xentuzumab/everolimus/exemestane|
9700885|NCT03659136|Placebo Comparator|Placebo/everolimus/exemestane|
9700886|NCT03658551||Liver cirrhosis|Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
9700887|NCT03658551||Control group|Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.
9700888|NCT03654261|Experimental|1-Day CBT Workshop - Immediate|Women assigned to the immediate workshop group will participate in the first of two workshops (9 weeks apart).
9700889|NCT03654261|Experimental|1-Day CBT Workshop - Waitlist|Women assigned to the waitlist will participate in the second of two workshops (12 weeks apart).
9700890|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
9700891|NCT03642132|Experimental|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
9700892|NCT03642132|Experimental|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
9700893|NCT03642132|Active Comparator|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
9700894|NCT03633305|Active Comparator|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
9700895|NCT03633305|Experimental|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
9700896|NCT03633305|Experimental|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
9700897|NCT03633305|Experimental|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
9700898|NCT03633305|Experimental|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
9700899|NCT03633305|No Intervention|No additional treatment|
9700900|NCT03625869|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
9700901|NCT03625869|Experimental|PICSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
9700902|NCT03622593|Experimental|A: Faricimab 6 mg Q8W|Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
9778602|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
9978021|NCT01367561|Placebo Comparator|Arm 3|
10189596|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 5 fractions|
10204395|NCT02460900|Placebo Comparator|Placebo and Standard of Care|Participants will receive placebo and standard of care
10204396|NCT02460900|Active Comparator|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
9700903|NCT03622593|Experimental|B: Faricimab 6 mg PTI|Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.
9700904|NCT03622593|Active Comparator|C: Aflibercept 2 mg Q8W|Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
9700905|NCT03622580|Experimental|A: Faricimab 6 mg Q8W|Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
9700906|NCT03622580|Experimental|B: Faricimab 6 mg PTI|Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.
9700907|NCT03622580|Active Comparator|C: Aflibercept 2 mg Q8W|Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
9700908|NCT03616717|Active Comparator|modafinil 100 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
9700909|NCT03616717|Active Comparator|modafinil 200 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
9700910|NCT03616717|Placebo Comparator|placebo|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
9700911|NCT03612154|Experimental|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
9700912|NCT03610971|Experimental|Combination Therapy + Remission Phase|"Combination therapy followed by treatment free remission (TFR) phase.~Combination Therapy: Ruxolitinib plus BCR-ABL Tyrosine Kinase Inhibitors (TKIs).~All eligible patients will begin ruxolitinib in combination with their BCR-ABL TKI on cycle 1 day 1 of the combination phase. For cycle 2 and beyond, if day 1 of a cycle is delayed, day 1 procedures should be repeated if out of the specified window and day 1 of the cycle is considered the day study drug is restarted. They will continue combination therapy for a total of 12 cycles. Each cycle will be approximately 28 days.~At the end of 12 cycles ruxolitinib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, participants will discontinue their BCR-ABL TKI and be monitored off treatment."
10189597|NCT03706014|Experimental|SIBS Program|The program condition includes 12 weekly 90-minute afterschool group sessions for siblings. Sessions are structured as psycho-educational groups and include social interactional activities, role-playing, discussion, and didactic presentation. The focus is on sibling relationship skills, cognitions, and activities. During a total of 3 family nights, parents attend with their children. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children. Family Nights promote parents' understanding of sibling relationships, review concepts, provide strategies for parental support of siblings, and teach parents skills for dealing with sibling problems. Family Nights include dinner and last 2 hours.
9700913|NCT03606213|Placebo Comparator|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
9700914|NCT03606213|Active Comparator|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
9700915|NCT03606213|Active Comparator|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
9700916|NCT03606213|Active Comparator|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
9700917|NCT03604783|Experimental|Single Arm TP-1287|TP-1287 by oral administration
9700918|NCT03594110|Experimental|Empagliflozin|
9700919|NCT03594110|Placebo Comparator|Placebo|
9778603|NCT01110499|Experimental|Part 2, AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
9978022|NCT01367574|Experimental|Arm 1|
9978023|NCT01367574|Experimental|Arm 2|
10204397|NCT02460900|Active Comparator|Positively Smoke Free and Varenicline|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
10204398|NCT02428647|Active Comparator|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
10204399|NCT02428647|Placebo Comparator|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
9700922|NCT03586479|Experimental|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
9700923|NCT03586479|Experimental|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
9700924|NCT03586479|Experimental|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
9700925|NCT03582085|Experimental|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
9700926|NCT03582085|Placebo Comparator|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
9700927|NCT03581942|Experimental|Copanlisib in combination with Ibrutinib|Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off). Phase II: (Simon two-stage design: 14 patients will be treated at the MTD (including 6 patients from the phaseIb portion) If at least 11 patients respond then an additional 19 patients will be accrued to the second stage. Patients in the phase II portion of the trial will receive sequential drug dosing. Patient will be treated in 28-day cycles. During one cycle, only one drug will be administered with a ibrutinib/copanlisib ratio of 1:2. Patients will receive Ibrutinib at 840 mg daily during cycle 1 (day 1 through day 28) (28-day cycles), then copanlisib 60mg weekly on day 1, 8, and 15 during cycle 2 and 3. Patients will then repeat the sequence.
9700928|NCT03577327||Adults with vitiligo|
9700929|NCT03577327||Healthy adults|
9700930|NCT03575208|Experimental|HBIG followed by Peginterferon alfa-2a|HBIg x 12 weeks followed by peginterferon alfa-2a 180mcg x 24 weeks
9700931|NCT03575208|Active Comparator|Peginterferon alfa-2a|Peginterferon alfa-2a 180mcg x 24 weeks
9700932|NCT03573739|Experimental|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
9700933|NCT03573739|Active Comparator|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
9700934|NCT03572634|Experimental|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
9700935|NCT03572634|Experimental|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
9700936|NCT03570177||all subject|the all population (described in eligibility criteria)
9700937|NCT03569280|Experimental|KPG-121|Safety and Antitumor Activity of KPG-121 capsules 1.5, 2.5, 5.0, 10, 20, and 30 mg/day daily for 21 days
9700938|NCT03562221|Experimental|Gluten free diet|Gluten free diet
9700939|NCT03562221|Active Comparator|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
9700940|NCT03562221|Placebo Comparator|Placebo|Placebo capsules with maize starch and without any bacteria.
9700941|NCT03562156|Experimental|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
9700942|NCT03562156|Placebo Comparator|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
9700943|NCT03547271|Experimental|Group 1|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and measles, mumps, and rubella [MMR] vaccine) at 2, 4 and 12 to 18 months of age
9978024|NCT01367574|Experimental|Arm 3|
9700944|NCT03547271|Active Comparator|Group 2|Licensed meningococcal vaccine (Nimenrix®), 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV- HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
9700945|NCT03547271|Experimental|Group 3|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
9700946|NCT03547271|Experimental|Group 4|MenACYW conjugate vaccine, 4 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4, and 12 to 18 months of age and administered alone at 6 months of age
9700947|NCT03545386|Experimental|FMT|
9700948|NCT03545386|Placebo Comparator|Placebo|
9700949|NCT03536793||Pancreatic cysts|Samples (urine, serum, whole blood and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM). Some of the cystic fluid and the whole blood sample will either be analysed at the University of Hull or a commercial laboratory for proteomic and genomic data. Collection will occur on the same day of the participants' routinely indicated procedure.
9700950|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
9978025|NCT01367587|Experimental|Arm 1|
9978026|NCT01367600|Experimental|Arm 1|
9978027|NCT01367613|Experimental|Arm 1|
10189598|NCT03706014|Placebo Comparator|Contact-Equivalent Attention Control|The Contact-Equivalent Attention Control condition includes 12 weekly 90-minute afterschool group sessions for siblings led by two co-leaders. Students work on educational games and activities. Groups begin with an icebreaker and continue with games and projects. This condition also includes 3 family nights, where parents attend with their children. Activities of the Family Nights include children showing their parents the activities they have been engaging in during the sessions. Family Nights include dinner and last 2 hours. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children; during this part, parents will break out with one group leader, and siblings will work with the other group leader.
10189599|NCT03706001|Experimental|Experimental Arm|Participants will receive psychotherapy for once a week.
10189600|NCT03706001|No Intervention|Control Arm|Participants will not receive any treatment for depression.
9778604|NCT01110499|Active Comparator|Part 2, bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.
10189601|NCT03705988|Experimental|Intervention Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted continuously from 500 μA~2mA.
10189602|NCT03705988|Sham Comparator|Sham Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted lower than 100 μA.
10189603|NCT03705975|Active Comparator|edit arms|classical physiotherapy and manual treatment. Classical physiotherapy consisting of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Manual treatment is consist of scapular mobilization, glenohumeral joint inferior and posterior mobilization. Treatment modality is implemented by physical therapist three times a week for 8 weeks.
10189604|NCT03705975|Active Comparator|edit arm/intervention cross|classical physiotherapy and proprioceptive neuromusculer fasilitation. Classical physiotherapy consist of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Scapular PNF and upper extremity PNF (flexion-abduction-external rotation) pattern. Treatment programme was implemented by physical therapist three times a week for 8 weeks.
10189605|NCT03705949|Active Comparator|Study group|Sodium Hyaluronate 0.1% drops
10189606|NCT03705949|Active Comparator|Control group|Sodium Hyaluronate 0.2% drops
10189607|NCT03705936|Sham Comparator|Sham 1Hz rTMS--5Hz rTMS|Participants will receive sham 1Hz rTMS, then immediately followed by 5Hz rTMS.
10189608|NCT03705936|Experimental|1Hz rTMS--5Hz rTMS|Participants will receive 1Hz rTMS, then immediately followed by 5Hz rTMS.
10189609|NCT03705936|Experimental|1Hz rTMS--30-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 30 minutes break, then followed by 5Hz rTMS.
9978028|NCT01367626|Active Comparator|letrozole|2.5 mg tablet
9978029|NCT01367626|Active Comparator|Fermara|2.5 mg tablet
10189610|NCT03705936|Experimental|1Hz rTMS--60-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 60 minutes break, then followed by 5Hz rTMS.
10189611|NCT03705936|Sham Comparator|Sham 5Hz rTMS--1Hz rTMS|Participants will receive sham 5Hz rTMS, then immediately followed by 1Hz rTMS.
10189612|NCT03705936|Experimental|5Hz rTMS--1Hz rTMS|Participants will receive 5Hz rTMS, then immediately followed by 1Hz rTMS.
10189613|NCT03705936|Experimental|5Hz rTMS--45-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 45 minutes break, then followed by 1Hz rTMS.
10189614|NCT03705936|Experimental|5Hz rTMS--90-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 90 minutes break, then followed by 1Hz rTMS.
10189615|NCT03705897|Other|Screening|Employ innovative methods for assessing personalized guideline-based screening in the clinic setting to evaluate guideline-based, over- and under-screening. Interventions include Computerized Risk Stratification Tool, Algorithmic Risk Stratification Tool, and Step completion assessment.
10189616|NCT03705884|Other|Cardiac Sarcoidosis|Patients with an established diagnosis of cardiac sarcoidosis.
10189617|NCT03705884|Other|Healthy volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
10189618|NCT03705871|Experimental|Differential Expansion Group|The experimental group will be comprised 24 patients treated with a rapid maxillary expansion using the expander with differential opening. The expander is composed by two screws, one posteriorly and the other anteriorly positioned on the palate.
10189619|NCT03705871|Active Comparator|Fan-Fype Expander Group|The active comparator group will be comprised by 24 patients treated with rapid maxillary expansion using the the fan-type expander. The expander is composed by one screw anteriorly positioned on the palate.
10189620|NCT03705858|Experimental|Ac-lintuzumab|Subjects with AML will receive Ac-lintuzumab.
10189621|NCT03705819|Experimental|Healthy Volunteers|In Stage 1, five healthy volunteers will receive a microdose of [11C]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes post-administration. These image sets will be used to evaluate [11C]-NOP46 biodistribution and derive dosimetry estimates.
10189622|NCT03705819|Experimental|Individuals with Focal Pain|In Stage 2, up to 30 subjects with focal pain will receive a microdose of [11C]-NOP46 and undergo PET/CT scans for up to 60 minutes in length. The results of Stage 1 will inform the scanning parameters (uptake period, scan length, reconstruction parameters, etc.) for Stage 2.
10189623|NCT03705780|Other|the short OSAS scale|In preoperative interview，distributing the short OSAS screening scales to children's parents，and the scale was completed preoperative，calculate the score of the scale
10189624|NCT03705780|Experimental|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
10189625|NCT03705754|Active Comparator|Tattoo arm|Tattoo will be placed by endoscopic submucosal injection of carbon black suspension
10189626|NCT03705754|No Intervention|Control arm|Tattoo will not be placed but case will follow standard procedure
10189627|NCT03705741|Experimental|Exercise group|Resistance exercise twice a week
10189628|NCT03705741|No Intervention|Control group|
10189629|NCT03705728|Experimental|Intravenous group|"Propofol & remifentanil administration using the closed-loop controller with the Easy-TIVA platfrom."
9700951|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis and a non-resolving pseudocyst, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing investigations for dyspepsia (normal control subgroup). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
9700952|NCT03534180|Experimental|Treatment (venetoclax, romidepsin)|Patients receive venetoclax PO QD on days 1-28 and romidepsin IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
9700953|NCT03532828|Experimental|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
9700954|NCT03532828|Experimental|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
9700955|NCT03530683|Experimental|TTI-622 Monotherapy|
9700956|NCT03530683|Experimental|Cohort A: TTI-622 + Azacitidine|
9700957|NCT03530683|Experimental|Cohort B: TTI-622 + Azacitidine and Venetoclax|
9700958|NCT03530683|Experimental|Cohort C1, C2 and C3: TTI-622 (low, intermediate and high dose) + Carfilzomib and Dexamethasone|
10189630|NCT03705728|Active Comparator|volatile anesthesia group|Sevoflurane will be administered manually according to the BIS values. Remifentanil will be administered manually using a Target Controlled Infusion pump using the Minto model.
9700959|NCT03530683|Experimental|Cohort D1 and D2: TTI-622 (low and high dose) + an anti-CD20 targeting agent|
9700960|NCT03530683|Experimental|Cohort E1 and E2: single-agent TTI-622 (low and high dose)|
9700961|NCT03525262|No Intervention|SAbR WITHOUT Neurovascular sparing|"GTV represents MR defined dominant radiographic disease, if identifiable.~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~PTV1_30Gy will not be used or created on this arm~PTV2_SAbR40Gy OR PTV2_SAbR45Gy will be generated by a 3mm expansion on the CTV. PTV2_SAbR will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
9700962|NCT03525262|Experimental|SAbR WITH Neurovascular sparing|"GTV represents MR defined dominant radiographic disease, if identifiable.~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~PTV1_30Gy represents a 3mm expansion on the CTV, excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).~PTV2_SAbR40Gy OR PTV2_SAbR45Gy will be generated by subtracting a 5mm expansion around the neurovascular elements to be spared (at least one side, left or right) from PTV1. These neurovascular structures consist of the neurovascular bundle, penile bulb, and internal pudendal arteries (see 4.1.5.2.16). PTV2 will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
9700963|NCT03509181|Experimental|CBM|Cognitive Bias Modification for Interpretation delivered via smartphone
9700964|NCT03509181|Active Comparator|Symptom Tracking|Weekly symptom monitoring smartphone app with anxiety and depression symptom scores
9700965|NCT03503695|Active Comparator|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
9700966|NCT03503695|No Intervention|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
9700967|NCT03498521|Experimental|Molecularly-Guided Therapy|Participants will be assigned to molecularly-guided therapy based on genomic profile.
9700968|NCT03498521|Active Comparator|Platinum-Based Chemotherapy|Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).
9700969|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
9700970|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010) and CSBD according to ICD-11.
10189631|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
10189632|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
10189633|NCT03705702|Active Comparator|Intervention Group (IG)|The intervention of active comparator will be education program plus behavioral intervention through physical activity counseling program combined with a monitoring-and-feedback tool.
10189634|NCT03705702|Sham Comparator|Control Group (CG)|The intervention of sham comparator will be an education program in asthma and physical activity recommendations.
9700971|NCT03494868|No Intervention|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
9700972|NCT03494868|Experimental|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
9700973|NCT03484819|Experimental|Treatment (copanlisib hydrochloride, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9700974|NCT03479606|Experimental|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
9978030|NCT01367639|Experimental|intervention|Inquiry Based Stress Reduction (IBSR) program
9700975|NCT03479606|Active Comparator|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
9700976|NCT03476135|Experimental|Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)|Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
9700977|NCT03476135|Experimental|Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)|Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
9700978|NCT03474445|Active Comparator|Control group|Volar Plate Osteosynthesis Aptus 2.5
9700979|NCT03474445|Active Comparator|Study Group|Volar Plate Osteosynthesis Inteos 2.5
9700980|NCT03471650|Experimental|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
9700981|NCT03468985|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10189635|NCT03705676|Active Comparator|Healthy controls - control condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
10189636|NCT03705676|Experimental|Healthy controls - fear condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
10189637|NCT03705676|Active Comparator|RLBP - control condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
9700982|NCT03468985|Experimental|Arm B (nivolumab, cabozantinib s-malate)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9700983|NCT03468985|Experimental|Arm C (nivolumab, cabozantinib s-malate, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9700984|NCT03468985|Experimental|Arm T (nivolumab, cabozantinib s-malate, ipilimumab)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9700985|NCT03465072|Experimental|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
9700986|NCT03444727|Experimental|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
9700987|NCT03444727|Placebo Comparator|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
9700988|NCT03444701|Experimental|E7130 (2-Week Regimen)|Part 1 (Cycle 1; 28 days): The first cohort of 3 participants will receive 25 micrograms per meters squared (μg/m^2) of E7130, on Day 1 and Day 15 as an intravenous infusion. If a drug-related Grade 2 or higher toxicity excluding clinically insignificant events is not observed in the initial cohort, dose-limiting toxicities (DLTs) will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the maximum tolerated dose (MTD) will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 2-week or in a 3-week regimen based on the evaluations in Part 1.
9700989|NCT03444701|Experimental|E7130 (3-Week Regimen)|Part 1 (Cycle 1; 21 days): On Day 1, participants will receive E7130 at (-1) a lower dose than the dose at which the first DLT was observed in the 2-week regimen. Once the MTD will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 3-week or in a 2-week regimen based on the evaluations in Part 1.
9700990|NCT03444376|Experimental|GX-188E, Keytruda|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg
9700991|NCT03444324|Experimental|BT524|Investigational Human Fibrinogen Concentrate
10189638|NCT03705676|Experimental|RLBP - fear condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
9700992|NCT03444324|Active Comparator|Fresh Frozen Plasma (FFP)/Cryoprecipitate (Cryo)|Standard of Care
9700993|NCT03437668|Experimental|Withania Somnifera Extract (WSE)|WSE 500 mg bid for 12 weeks
9700994|NCT03437668|Placebo Comparator|Placebo tablets|Placebo oral tablet bid for 12 weeks
9700995|NCT03423199|Experimental|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
9700996|NCT03423199|Active Comparator|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
9700997|NCT03422224||Good transplant function|Kidney transplant recipients without histological signs of rejection.
9700998|NCT03422224||Transplant Rejection|Kidney transplant recipinets experiencing a T cell mediated rejection episode.
9700999|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
9701000|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
9701001|NCT03416868|Experimental|Week 3 start|"For the first two weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In the following 3 weeks of voice therapy (weeks 3 through 5), patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
10189639|NCT03705676|Active Comparator|CLBP - control condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
10189640|NCT03705676|Experimental|CLBP - fear condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
10189641|NCT03705663||Women interested in HIV PrEP|Cis-gender women at high risk for HIV interested in or initiating HIV PrEP
10189642|NCT03705650|Experimental|Medicare Primary Care Provider (PCP) Patients|This is a non-randomized study of non-significant risk (NSR) that will be conducted at Northwestern's Central Dupage Hospital. Medicare patients > 65 years who are scheduled for a routine physical exam with their PCP that meet inclusion and exclusion criteria will be asked to participate in this study. Consenting patients will be scheduled for 2 back to back ultrasound scans including 5 standard 2D echocardiogram views each. The first scan will be performed by a non-ultrasound specialist using EchoGPS experimental guidance technology and the second control exam will be performed by a trained sonographer using a cleared conventional ultrasound platform.
9701002|NCT03416868|Experimental|Week 4 start|"For the first three weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy weeks 4 and 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
9701003|NCT03416868|Experimental|Week 5 start|"For the first four weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy week 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
9701004|NCT03416829|Experimental|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
9701005|NCT03416829|Experimental|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
9701006|NCT03416829|Experimental|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
9701007|NCT03416816|Experimental|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
9701008|NCT03416335|Experimental|Monotherapy Arm - Part A|Dose Escalation Drug DSP-0509
9701009|NCT03416335|Experimental|Combination arm - Part B|Dose Escalation Drug DSP-0509, Pembrolizumab
9701010|NCT03416335|Experimental|Combination arm - Part C|Dose Expansion, Drug DSP-0509, Pembrolizumab
9701011|NCT03395184|Experimental|PF-06700841 or placebo|
9701012|NCT03395184|Experimental|PF-06651600 or placebo|
9701013|NCT03393637|Experimental|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
9701014|NCT03393637|No Intervention|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
9701015|NCT03388749|Experimental|Liposomal annamycin|
9701016|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-6 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9701017|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-6 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9978031|NCT01367652|Active Comparator|Letrozole|2.5 mg tablet
9978032|NCT01367652|Active Comparator|Femara|2.5 mg tablet
9701018|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 6-12 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9701019|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 6-12 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9701020|NCT03384563|Placebo Comparator|Placebo 6-12 months|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9701021|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-3 years|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9701022|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-3 years|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9701023|NCT03384563|Placebo Comparator|Placebo 1-3 years|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
9701024|NCT03384563|Placebo Comparator|Placebo 1-6 months|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
10189643|NCT03705637|Experimental|Exparel Arm|20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.
10189644|NCT03705624|No Intervention|Standard of Care|Standard of care with passively monitored malaria incidence at health centers that receive appropriate diagnostic and clinical supplies and Seasonal Malaria Chemoprevention (SMC) for children less than 5 years of age
9701027|NCT03377049|Experimental|Acetazolamide Challenge|Participants entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
9701028|NCT03372291|Experimental|Psychological app|"Psychological intervention consist of four components~Supportive psychotherapy interventions to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance;~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social supports;~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty;~Self-care to promote positive health behaviors and enhance patients' sense of control especially as they transition from the hospital to outpatient care.~The psychological intervention will consist of four sessions (20-25 minutes each) that patients will start during their first week of admission for intensive chemotherapy and continue weekly"
9701029|NCT03372291|Active Comparator|Usual Care|"Participants receiving usual care will not have access to the psychological intervention app. -They will receive usual leukemia care with all the supportive care measures instituted by the leukemia team.~Patients in usual care will also meet with the leukemia social worker based on their request or at the discretion of the treating leukemia team"
9701030|NCT03355456|Active Comparator|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
9701031|NCT03355456|Active Comparator|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
9701032|NCT03354585|Experimental|Meditation Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
9701033|NCT03354585|Active Comparator|Meditatin Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
9701034|NCT03354585|Active Comparator|Book Listening Control Group|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 12 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
9701035|NCT03346109|Experimental|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
9701036|NCT03346109|No Intervention|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
9701037|NCT03342937|Experimental|Oxaliplatin+Capecitabine+Pembrolizumab|
9701038|NCT03333928|Active Comparator|HTD1801 500 mg BID|
9701039|NCT03333928|Active Comparator|HTD1801 1000 mg BID|
9701040|NCT03333928|Placebo Comparator|Placebo BID|
9701041|NCT03327714|Experimental|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
9978033|NCT01367678|Experimental|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
10189645|NCT03705624|Experimental|CCM|Standard of care supplemented with enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with artemether-lumefantrine (AL) according to national guidelines
9701042|NCT03327714|No Intervention|Control group|The control group consists of children who do not perform mindfulness in school.
9701043|NCT03327519|Experimental|SHUTi|Self-guided, automated, interactive, and tailored web-based program
9701044|NCT03327519|Experimental|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
9778605|NCT01110681|Experimental|Solesta|"Open label. Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) The study treatment consisted of 4 submucosal injections, 1 mL Solesta each, in the proximal part of the high pressure zone in the anal canal.~Re-treatment is allowed one month after initial treatment if the subject is still incontinent."
9778606|NCT01110707|Experimental|r-hFSH + r-hLH|
9778607|NCT01110707|Active Comparator|r-hFSH alone|
9778608|NCT01110876|Experimental|Phase I Group 1: Vorinostat + Erlotinib + Temozolomide|"Phase I 3-Drug Combination Vorinostat with Erlotinib + Temozolomide~Starting doses Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 125 mg/m^2 orally once daily on Days 1-7 and 15-21."
9778609|NCT01110876|Experimental|Phase I Group 2: Vorinostat + Erlotinib|"This Phase I arm to be activated only after completion of Part A of the Phase II trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
10189646|NCT03705624|Experimental|CCM+MSAT|Standard of Care supplemented with CCM and Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
9778610|NCT01110876|Experimental|Phase II Part A 3-Drug Combination|"Vorinostat+Erlotinib+Temozolomide where drug dosing based on the MTD identified in the Phase I portion of the study.~Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 100 mg/m^2 orally once daily on Days 1-7 and 15-21."
9778611|NCT01110876|Experimental|Phase II Part B 2-Drug Combination|"This Phase II Part B arm to be activated only after completion of Part A of the Phase I and II Part A trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
10189647|NCT03705611|No Intervention|Standard of care|Provide personalised clinic invitation slips (letters) to partners to come for HIV testing, and to access post-test services
9778612|NCT01110915|Experimental|MRI group|Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
9778613|NCT01110915|Active Comparator|Control group|Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.
9778614|NCT01111058|Experimental|Everolimus (RAD001)|Subjects will receive Everolimus 10 mg daily
9778615|NCT01111058|Experimental|Placebo|Subjects will receive double-blind placebo
9778616|NCT01111123|Active Comparator|1|Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
9778617|NCT01111123|Placebo Comparator|2|Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only
9778618|NCT01111149|Placebo Comparator|Sugar Pill|Sugar pill will be given to patients as a comparison group to the active varenicline group. In the fist week, one placebo pill will be given per patient, followed by 2 pills per day for the remaining 12 weeks of the study.
9778619|NCT01111149|Experimental|Varenicline|Varenicline has not previously been examined for its efficacy and safety in subjects with schizophrenia. Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study. This is an experimental group to be compared against both placebo and bupropion HCl.
9778620|NCT01111149|Active Comparator|Bupropion HCl|Bupropion HCl is an established smoking cessation agent and will be used to compare its efficacy and safety against varenicline. Subjects in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study.
9778621|NCT01111162|Experimental|Vaccine|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
9778622|NCT01111240||Psoriatic Arthritis|Participants with Psoriatic Arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
9778623|NCT01111292|Experimental|Arm I (inositol)|Beginning within 14 days after colonoscopy, patients receive inositol PO QD on days 1-14 and BID on days 15-90.
9778624|NCT01111292|Placebo Comparator|Arm II (placebo)|Beginning within 14 days after colonoscopy, patients receive placebo PO QD on days 1-14 and BID on days 15-90.
9778625|NCT01111318|Experimental|BI 10773|50 mg single dose
9778626|NCT01111331|Experimental|BI 10773 25 mg|1 tablet 25 mg BI 10773 qd for 5 days
9778627|NCT01111331|Experimental|BI 10773 25 mg + Warfarin 25 mg|1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
9778628|NCT01111331|Active Comparator|Warfarin 25 mg|5 tablets 5 mg warfarin single dose
9778629|NCT01111370|Experimental|CGM|continuous glucose monitoring system
9778630|NCT01111461|Experimental|Lenvatinib 24 mg|Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.
10189648|NCT03705611|Experimental|HIV self-testing only|HIV self-testing only
10189649|NCT03705611|Experimental|HIV self-testing secondary accuracy|HIV self-testing secondary accuracy
10189650|NCT03705598|Placebo Comparator|Light physical exercise|Normal walking, light intensity resistance exercise and stretching, and health education discussions.
10189651|NCT03705598|Active Comparator|Tai Chi|Joint rotations and balance games, Tai Chi walking drills and the 8 forms.
10189652|NCT03705585|Experimental|Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine prior to routine endoscopic examination. During endoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings might also be obtained.
9701045|NCT03324100||Allergic Rhinitis Patients|
10189653|NCT03705585|Experimental|Endoscopy, Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine after initial endoscopic exam and specimen collection and prior to a routine follow up endoscopic examination during which additional specimens will be collected.
9701046|NCT03324100||Healthy Controls|
10189654|NCT03705585|No Intervention|Endoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during endoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum if colonoscopy performed, duodenum if EGD performed).
10189655|NCT03705572|Active Comparator|Dietary Supplement: Phospholipid drink.|Participant in an intervention parallel group consumed a drink with added phospholipids (Lacprodan PL20).
9701047|NCT03312868|Experimental|Prospective Arm|Prospective arm with patients being treated with SBRT
9701048|NCT03309878|Experimental|Arm I (pembrolizumab, mogamulizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9701049|NCT03309878|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9701050|NCT03309332|Experimental|Device|Subjects implanted with the AMPLATZER™ PFO Occluder.
9701051|NCT03304639|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9701052|NCT03304639|Experimental|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during cycle 1.
9701053|NCT03298984|Experimental|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
9701054|NCT03295747|Experimental|180 mg|180 mg of peppermint oil
9701055|NCT03295747|Experimental|360 mg|360 mg of peppermint oil
9701056|NCT03295747|Experimental|540 mg|540 mg of peppermint oil
9701057|NCT03295552|Experimental|DC|DNA demethylating agent decitabine plus carboplatin
9701058|NCT03294954|Experimental|GINAKIT cells + cytoxan + fludara|"Cyclophosphamide and fludarabine will be administered prior to the GINAKIT cells.~Day -4: Cyclophosphamide and Fludarabine~Day -3: Cyclophosphamide and Fludarabine~Day -2: Fludarabine~Day -1: Rest~Day 0: GINAKIT cells"
9701059|NCT03290651|Experimental|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
9701060|NCT03290651|Placebo Comparator|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
9701061|NCT03283930|Experimental|Active ABMT|Active attention bias modification will be provided in addition to individual cognitive behavioral therapy
9701062|NCT03283930|Placebo Comparator|Placebo|Placebo attention bias modification will be provided in addition to individual cognitive behavioral therapy
9701063|NCT03281369|Active Comparator|1L-Control: mFOLFOX6 (Gastric Cancer)|Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
9701064|NCT03281369|Experimental|1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)|Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018.
9701065|NCT03281369|Experimental|1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)|Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018.
9701066|NCT03281369|Active Comparator|2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)|Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
9701067|NCT03281369|Experimental|2L-1: Atezo + Cobi (Gastric Cancer)|Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019.
10189656|NCT03705572|Placebo Comparator|Dietary Supplement: Placebo milk drink.|Participant in an intervention parallel group consumed a drink without added phospholipids.
10189657|NCT03705559|Experimental|Vaporized Marijuana|Participants will receive non-therapeutic, experimental doses of active or placebo. vaporized marijuana. Active marijuana/placebo will be administered once per session and will be administered via a vaporizer.
10189658|NCT03705559|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intranasally (snorting).
9701068|NCT03281369|Experimental|2L-2: Atezo + PEGPH20 (Gastric Cancer)|Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
9778631|NCT01111474|Active Comparator|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
10189659|NCT03705559|Experimental|Opioid Agonist/Marijuana Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with non-therapeutic, experimental doses of active vaporized marijuana/placebo. Opioid/placebo and marijuana/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
10189660|NCT03705533|Other|Sequence ABAB|Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10189661|NCT03705533|Other|Sequence BABA|Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
10189662|NCT03705520||Cross-Sectional|This cohort is composed of only medicated PD subjects and their spouse or 1st degree relative.
9701069|NCT03281369|Experimental|2L-3: Atezo + BL-8040 (Gastric Cancer)|Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
9701070|NCT03281369|Experimental|2L-4: Atezo + Linagliptin (Gastric Cancer)|Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
9701071|NCT03281369|Experimental|1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)|Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy.
9701072|NCT03281369|Experimental|1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy.
9701073|NCT03281369|Active Comparator|1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy.
9701074|NCT03281369|Experimental|1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)|Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy.
9701075|NCT03278509|Experimental|Oral beta-blocker treatment|Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician. Metoprolol succinate will be strongly recommended as first choice. Bisoprolol will be allowed as an alternative. Atenolol (or any other beta-blocker therapy) will not be allowed. The treating physician will be encouraged to aim for a dose of ≥ 100 mg for metoprolol succinate and ≥ 5 mg for bisoprolol. Prescribed treatment and dosing will be registered. Initiation (whether the prescribed drug is dispensed) and adherence (defined as proportion of prescribed tablets that are dispensed), and persistence (time on treatment) will also be recorded via the Drug prescription registry.
9701076|NCT03278509|No Intervention|No beta-blocker treatment|Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Patients assigned to no beta-blockade also receive best evidence-based care, without beta-blockers. For blood pressure control, other drugs than beta-blockers will be recommended as first-line treatment. Regarding later use of beta-blockade, follow up is performed in the Drug prescription registry. Patients will be asked to provide future physicians with the written information about the study when beta-blockade treatment is discussed.
9701077|NCT03266484|Active Comparator|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.~The probiotics sachets will be taken twice a day for 12 weeks."
10189663|NCT03705520||Logitundinal|This cohort is composed of only non-medicated PD subjects and their spouse or first degree relative.
10189664|NCT05177692|Active Comparator|Intervention group - Vguard|Intervention group will be fitted with a Vguard system Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
9701078|NCT03266484|Placebo Comparator|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo~The identical placebo sachets will be taken twice a day for 12 weeks."
10189665|NCT05177692|No Intervention|Control group - regular intra-ventricular drainage|Control group will be fitted with a standard system for drainage of ventricular fluid Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
10189666|NCT05177679|Experimental|Active Supplement|The active supplementation group participants will be asked to consume a daily carotenoid supplement for 9 months.
10189667|NCT05177679|Placebo Comparator|Placebo Control|The placebo control group participants will be asked to consume a placebo supplement for 9 months.
9701079|NCT03262454|Experimental|Interventions|Atezolizumab
9701080|NCT03254264|Experimental|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
9701081|NCT03254264|Active Comparator|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
9701082|NCT03244852||OCD Patients with Deep Brain Stimulators|Patients with deep brain stimulation for intractable obsessive compulsive disorder (OCD)
9978034|NCT01367678|Experimental|i-Gel|Directly measured mucosal pressures
9978035|NCT01367717|Active Comparator|Creatine Monohydrate|Each of the 25 subjects took Creatine Monohydrate.
9701083|NCT03244384|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
9701084|NCT03244384|Active Comparator|Arm B (observation)|Patients undergo observation.
10189668|NCT05177653|Experimental|GIPRA|
10189669|NCT05177653|Experimental|GLP-1RA|
9701087|NCT03226548|Experimental|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
9701088|NCT03226548|No Intervention|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
9701089|NCT03225989|Experimental|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
9701090|NCT03225625|Experimental|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
9701091|NCT03225625|Experimental|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Exoskeleton or equivalent stimulation following this treatment."
9701092|NCT03225625|Experimental|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Virtual Reality or equivalent visualization following this treatment."
9701093|NCT03216083|Experimental|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
9701094|NCT03216083|Placebo Comparator|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
9701095|NCT03196778|Experimental|Low Dose Radiation|Subjects will receive low dose body radiation for 5 weeks.
9701096|NCT03194932|Experimental|Treatment|"In Part 1, venetoclax with cytarabine will initially be given at dose level 1 and escalated based on tolerability. Idarubicin will be given only at dose level 4.~Note: Part 1 has been completed.~Two expansion cohorts will be enrolled:~Cohort A will be a group of 12 participants receiving the recommended phase 2 doses (RP2D) of venetoclax plus cytarabine.~Cohort B will be a group of 12 participants receiving the RP2D of venetoclax plus cytarabine and idarubicin.~Intrathecal Triple Therapy (ITMHA) will be given prior to cycle 1. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA beginning on day 8 until the cerebrospinal fluid becomes free of leukemia.~Cohort C: Participants will receive venetoclax PO on days 1-21, azacitidine IV on days 1-7, and cytarabine Q12H on days 8-11."
9701097|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
9701098|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
9701099|NCT03194867|Active Comparator|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
9701100|NCT03192215|Experimental|Active agent: Apixaban|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban
9701101|NCT03192215|Active Comparator|Active control: Aspirin|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin
9701102|NCT03175198||Patients with nonvalvular atrial fibrillation (NVAF)|Patients with nonvalvular atrial fibrillation (NVAF) taking daily oral dose of Prazaxa® Capsules (Dabigatran etexilate). Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg [as 2 capsules of 75 mg] twice a day (b.i.d)) or 220 mg (110 mg [as 1 capsule of 110 mg] b.i.d) for a treatment duration of 52 weeks.
9701103|NCT03164980|Experimental|Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
9701104|NCT03164980|Experimental|Arm B|"Carboplatin/PLD~Carboplatin/Gemcitabine~Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
9701105|NCT03158727|Experimental|Cx611|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each.
9701106|NCT03158727|Placebo Comparator|Placebo|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate.
9701107|NCT03149003|Experimental|Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab|
9701108|NCT03149003|Active Comparator|Arm 2: Bevacizumab|
9778632|NCT01111474|Active Comparator|Laser|3 Low intensity laser application (48 hour interval). The application of 1Joule/cm^2 was performed for eight seconds at three points along the dental neck, using the infrared wavelength (795nm)
9778633|NCT01111526|Experimental|LBH589, in Addition to Glucocorticoids|Phase I Dose Escalation, Followed by Phase II Treatment at Maximum Tolerated Dose (MTD) of LBH589, in Addition to Glucocorticoids.
9978036|NCT01367717|Active Comparator|Creatine Ethyl Ester|Each of the 25 subjects took Creatine Ethyl Ester.
9978037|NCT01367730||osteoporosis and osteopenia|Subjects will be stratified based on DXA BMD T-scores.
10189670|NCT05177653|Experimental|GIPRA + GLP-1RA|
10189671|NCT05177653|Placebo Comparator|Saline|
10189672|NCT05177627|Experimental|Fundamental of Care Framework implementation|Educational interventions related to introduction of FoC framework and taking charge of patients and their fundamental needs will be realized during theoretical, simulation and internship learning.
10189673|NCT05177627|No Intervention|No Fundamental of Care Framework implementation|the participants of no intervention group will receive the standard training as scheduled on the curriculum
10189674|NCT05177601|Active Comparator|TMS+DCS|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
10189675|NCT05177601|Active Comparator|TMS+Placebo|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
10189676|NCT05177601|Sham Comparator|shamTMS+DCS|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
10189677|NCT05177601|Placebo Comparator|shamTMS+placebo|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
10189678|NCT05177588|Experimental|Metformin|Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
10189679|NCT05177588|No Intervention|Standard of Care|Patients in the control arm will continue the SOC medications
10189680|NCT05177562||PCOS|No intervention.
10189681|NCT05177562||PCOS surgery|No intervention
10189682|NCT05177562||Surgery control|No intervention
10189683|NCT05177562||IVF PCOS|No intervention
10189684|NCT05177562||IVF control|No intervention
10189685|NCT05177562||Investigations, fertility PCOS|No intervention
10189686|NCT05177562||Investigations, fertility control|No intervention
10189687|NCT05177562||Pregnancy - gestational diabetes mellitus|No intervention
10189688|NCT05177562||Pregnancy - Intrahepatic cholestasis of pregnancy|No intervention
10189689|NCT05177562||Pregnancy - control|No intervention
10189690|NCT05177549|Experimental|on estrogen-progestin contraception|
10189691|NCT05177549|Experimental|under micro-progestational contraception|
10189692|NCT05177549|Experimental|without hormonal contraception|
10189693|NCT05177536|Experimental|Iberdomide|Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle
10189694|NCT05177523||MS patient group|Recruitment of 200 MS patients at the MS Clinic of the Department of Neurology (Neurologische Klinik und Poliklinik), University Hospital Basel (Universitätsspital Basel)
10189695|NCT05177523||control group (HC)|Recruitment of 100 healthy controls (HC) by public announcements (i.e. advertisement/flyer) on the University Hospital's and the University's notice board.
10189696|NCT05177497|Experimental|treatment arm|
10189697|NCT05177445|Experimental|Intervention group with phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction ) positive for coronavirus-19 will receive the phototherapy intervention. It consists of the introduction of the nasal probe of the phototherapy device in the nasal cavity of the patient. A mixture of ultraviolet light A, ultraviolet light B and red light will be applied between 2 and 3 minutes. The patient will receive a maximum of 10 interventions. Furthermore both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
10189698|NCT05177445|Active Comparator|Intervention group (corticosteroids + OT) without Phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
10189699|NCT05177419|Experimental|High-dose LSD|High dose of lysergic acid diethylamide
10189700|NCT05177419|Active Comparator|Low-dose LSD|Low dose of lysergic acid diethylamide
10189701|NCT05177406||Full cohort|patients newly initiating Aimovig therapy
10189702|NCT05177393||Participants with Esophageal Cancer|Participants with esophageal cancer will be administered questionnaires, and medical charts will be accessed to collect study related data.
10189703|NCT05177380|Experimental|Personalized rehabilitation program of facial involvement in systemic sclerosis|"3 sessions of 2 hours of facial rehabilitation in hospital over 2 weeks including:~Physiotherapy with facial and endo-oral massages, self-massages, active and passive exercises of the face and mouth, tongue exercises~Speech therapy with mobilization of the orofacial sphere applied to swallowing and speech difficulties~Individual workshop on the theme of dry mouth, dry mouth, swallowing disorders, and oral care~Individual therapeutic makeup workshop~A motivational interview~A patient notebook with a personalized protocol for self-rehabilitation of the face~A video tutorial for self-rehabilitation of the face Facial self-rehabilitation sessions at home"
10189704|NCT05177380|Other|Routine care|Delivery of a standard prescription for facial rehabilitation
9978038|NCT01367743|Active Comparator|epinephrine|
10189705|NCT05177341||Amputees with acceptable phantom sensation|
10189706|NCT05177341||Amputees with no phantom sensation|
10189707|NCT05177341||Control group|
9701109|NCT03147768|Experimental|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
9701110|NCT03139370|Experimental|KITE-718|"Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A."
9701111|NCT03139344|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session low-frequency exercise or high-frequency exercise.
9701112|NCT03139344|Experimental|Training study|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with high-frequency exercise.
9701113|NCT03129139|Experimental|Regimen A (monotherapy)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
9701114|NCT03129139|Experimental|Regimen B (combination)|MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
9701115|NCT03129139|Experimental|Regimen C (monotherapy in Gastric Cancer)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
9701116|NCT03126799|Active Comparator|A: Erlotinib only|"Standard therapy arm:~Erlotinib 150mg. po, qd, daily, q 3weeks"
9701117|NCT03126799|Experimental|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
9701118|NCT03113513|Active Comparator|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
9701119|NCT03113513|Active Comparator|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
9701120|NCT03099174|Experimental|Cohort A|Xentuzumab + Abemaciclib (Dose 1)
9701121|NCT03099174|Experimental|Cohort B|Xentuzumab + Abemaciclib + Letrozole (Dose 2)
9701122|NCT03099174|Experimental|Cohort C|Xentuzumab + Abemaciclib + Anastrozole (Dose 3)
9701123|NCT03099174|Experimental|Cohort D|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
9701124|NCT03099174|Experimental|Cohort E|Xentuzumab + Abemaciclib (Dose 1)
9701125|NCT03099174|Experimental|Cohort F|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
9701126|NCT03099174|Experimental|Cohort D1|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
9701127|NCT03099174|Experimental|Cohort D2|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
10189708|NCT05177328|Experimental|ShA9 dominant and placebo non-dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of ShA9 applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of placebo applied to their contralateral arm (i.e. left arm for a right handed participant).
10189709|NCT05177328|Experimental|ShA9 non-dominant and placebo dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of placebo applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of ShA9 applied to their contralateral arm (i.e. left arm for a right handed participant).
10189710|NCT05177276|Experimental|Dose Level -1|Selinexor 12mg po twice weekly (Monday & Wednesday or Tuesday & Thursday); Irinotecan 50mg/m2 IV once daily on days 1, 8 & 15
9701132|NCT03075826|Other|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
9701133|NCT03072238|Active Comparator|Placebo + Abiraterone|Participants received Placebo plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
9701134|NCT03072238|Experimental|Ipatasertib + Abiraterone|Participants received Ipatasertib plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
9701135|NCT03067636|Active Comparator|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
9701136|NCT03067636|Active Comparator|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
9701137|NCT03067636|No Intervention|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
9978039|NCT01367743|Active Comparator|norepinephrine|
9978040|NCT01367756|Experimental|1|
9978041|NCT01367756|Placebo Comparator|2|
9701138|NCT03065049|Experimental|Peer-PA+Fitbit|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
9701139|NCT03065049|Active Comparator|Fitbit Only|Participants will be given a Fitbit activity tracker along with brief advice for increasing physical activity.
9701140|NCT03065049|No Intervention|Usual Care|Participants do not receive any intervention but participate in the assessments only.
9701141|NCT03062280|Experimental|Chronocort®|Chronocort® modified release hydrocortisone
10189711|NCT05177276|Experimental|Dose Level 1|Selinexor 15mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
10189712|NCT05177276|Experimental|Dose Level 2|Selinexor 20mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 100mg/m2 IV once daily on days 1, 8 & 15.
9701144|NCT03041844|Experimental|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
10189713|NCT05177276|Experimental|Dose Level 3|Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
10189714|NCT05177276|Experimental|Dose Level 4|Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 125mg/m2 IV once daily on days 1, 8 & 15.
9701145|NCT03041844|Sham Comparator|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
9701146|NCT03038672|Active Comparator|Group I (nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
9701147|NCT03038672|Experimental|Group II (varlilumab, nivolumab)|Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.
9701148|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
9701149|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
9701150|NCT03038373||Group III|Lean Diabetics, No surgery
9701151|NCT03038373||Group IV|Lean Non Diabetics, No surgery
9701152|NCT03036007|Active Comparator|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
10189715|NCT05177237|Experimental|Endostar combined with Methylprednisolone|Endostar combined with Methylprednisolone lasts for 10 weeks
10189716|NCT05177224|Experimental|Participants with dual mobility cup|
10189717|NCT05177211|Experimental|Treatment with Fedratinib|Participants will taken Fedratinib by mouth once a day every day of each 28 day cycle.
10189718|NCT05177159||Postoperative delirium|
10189719|NCT05177159||Non postoperative delirium|
10189720|NCT05177120||FMF patients|Patients with diagnosed FMF
10189721|NCT05177107|Experimental|Group 1: Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
10189722|NCT05177107|Placebo Comparator|Group 2: Placebo|Placebo (normal saline) will be administered using the same schedule and techniques as for Group 1 (phage therapy).
10189723|NCT05177081|Experimental|Home BIA Monitoring group|Preemptive management by Body fluid monitoring system (BWA ON + App + Web)
10189724|NCT05177081|No Intervention|Control group|Usual heart failure management (Outpatient follow-up and medical treatment)
9701153|NCT03036007|Experimental|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
10189725|NCT05177068|Experimental|Experimental|fruquintinib + sintilimab + SOX (S-1 + oxaliplatin)
10189726|NCT05177029|Experimental|Part A: Lu AG06466 or Placebo|Participants will receive single dose of Lu AG06466 capsule or matching placebo orally on Day 1.
10189727|NCT05177029|Experimental|Part B: Lu AG06466 or Placebo|Participants will receive starting dose of Lu AG06466 capsule or matching placebo orally once daily from Day 1 to Day 4 followed by Lu AG06466 capsule or matching placebo at a titrated treatment dose orally once daily from Day 5 until Day 8. Participants will then receive LuAG06466 capsule or matching placebo at a higher assigned dose orally once daily from Day 9 to Day 15.
9701157|NCT03029702|Active Comparator|Usual Care|Participants will undergo standard counseling and be prescribed a treatment for their GDM. Treatments include insulin, glyburide, and metformin.
10189728|NCT05176938|Experimental|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected in the serratus intercostal space at 6 ribs midaxillary line and (20ml) in pecto-intercostal space at 2 ribs parasternal.
10189729|NCT05176938|Experimental|Ultrasound guided Erector Spinae plane Block (ESPB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the fourth thoracic segment (T4).
10189730|NCT05176938|No Intervention|General anesthesia|Patients will receive general anesthesia only without blocks.
10189731|NCT05176925|Experimental|Tislelizumab combined with sitravatinib|
10189732|NCT05176912|Experimental|Experimental Exercise Group|Reformer Pilates exercises will given for 8 weeks, 3 days in a week.
10189733|NCT05176912|No Intervention|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
10189734|NCT05176834|Experimental|B-Cure laser pro|In case of appearance of mucositis, patients will receive standard treatment as usual (rinses, painkillers, etc.). In addition, study participants will treat themselves with the B-Cure laser pro before each radiation therapy session at the clinic and will continue with daily treatment until the disappearance of the mucositis should it develop.
10189735|NCT05176821|Experimental|High-dose dual therapy group|esomeprazole 20mg qid plus amoxicillin 750mg qid were used in the high-dose dual therapy group
9701158|NCT03029702|Active Comparator|Individualized Treatment|Participants will undergo standard counseling and be matched to therapy based on their GDM mechanism. Treatments include insulin, glyburide, and metformin.
9701159|NCT03017885||Group A|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and have discontinued the drug at the time of participation in the active surveillance.
9701160|NCT03017885||Group B|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance .
9701161|NCT03017885||Group C|Patients who have been newly prescribed nintedanib & docetaxel at the time of participation in the active surveillance.
9701162|NCT03014414|Experimental|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
9701163|NCT03014414|Active Comparator|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. [The study and investigative team have no financial relationship with Weight Watchers].
9701164|NCT03012620|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
9701165|NCT03011593|Experimental|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
9701166|NCT03011541|Active Comparator|Arm 1|BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
9701167|NCT03011541|Active Comparator|Arm 2|BMSC provided retrobulbar, subtenon, intravitreal and intravenous for one or both eyes
9701168|NCT03011541|Active Comparator|Arm 3|BMSC provided either intraoptic nerve or subretinal for eye with worse vision with fellow eye receiving either retrobulbar and subtenon or retrobulbar, subtenon and intravitreal; followed by intravenous.
9701169|NCT02993731|Experimental|Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
9701170|NCT02993731|Active Comparator|Arm 2: Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
9701171|NCT02992743|Experimental|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
9701172|NCT02978859|Experimental|MGCD516|Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.
9701173|NCT02978755|Experimental|GM102 escalating doses|8 successive cohorts
9701174|NCT02978755|Experimental|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
9701175|NCT02978755|Experimental|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
9701176|NCT02975869|Active Comparator|Standard Leukemia Care|Standard Leukemia care
9701177|NCT02975869|Experimental|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
9701178|NCT02965716|Experimental|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
9701179|NCT02965703|Experimental|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity.
9701180|NCT02965703|Experimental|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity.
9701181|NCT02965703|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity.
10189736|NCT05176821|Active Comparator|Furazolidone-based quadruple therapy|furazolidone 100mg bid + amoxicillin 1000mg bid + esomeprazole 20mg bid + bismuth potassium citrate 1000mg(220mg of bismuth) bid were used in the Furazolidone-based quadruple therapy
10189737|NCT05176795||Experimental|Child under 10 years old newly diagnosed with JIA, IBD or T1DM
9701184|NCT02936752|Experimental|Treatment (entinostat, pembrolizumab)|Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.
9701185|NCT02936024|Experimental|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
9701186|NCT02936024|Other|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
10189738|NCT05176795||Active Comparator: Healthy control|Brother/sister of child with pediatric onset inflammatory disease (same age category - same environment: food, living space)
10189739|NCT05176782|Active Comparator|Group A (HTK cardioplegia)|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
10189740|NCT05176782|Active Comparator|Group B ( Cold Cardioplegia)|will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
10189741|NCT05176756|Active Comparator|Attention Control|In addition to using a wearable device, participants in this arm will receive a daily notification of their step count from the previous day. This notification serves as an 'attention control' and allows us to better isolate the impact of the gamification with social support. It may also help to reduce differential attrition across arms.
10189742|NCT05176756|Experimental|Gamification and Social Support|Participants in this arm will receive the same devices and daily messaging as control. They will also be entered into a game designed using behavioral economic principles for 6 months. This intervention has been adapted from our prior successful pilot studies. The game runs automatically and does not require any effort on the part of the participant to 'play' the game other than to strive for physical activity goals. Participants in this arm will also select a family member or friend who will serve as a support partner to encourage the participant to meet their step goals. The gamification and social support interventions will end after 6 months at which point participants will receive the same treatment as the attention control arm for the 3-month follow-up period.
10189743|NCT05176730|Experimental|Patients with hemodialysis receiving mindfulness meditation|The ABC standardized version of mindfulness meditation was used. The experimental group received 30-minute mindfulness meditation sessions 3 times a week for 5 weeks (450 minutes). An additional two-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. To ensure the consistent delivery of the intervention, the researcher recorded the intervention instructions in Arabic based on the intervention protocol and sent the audio-recorded instructions to the participants via WhatsApp or email. The audio-recorded intervention contents were validated by two psychologists and experts in meditation. The recorded intervention instructions were accessed by the participants during the sessions using their cell phones and headsets, as recommended. This method allowed for up to 3-5 participants to listen to the instructions and perform the intervention simultaneously.
10189744|NCT05176730|No Intervention|Control group|The participants in the control group were instructed to sit with their eyes closed and relaxed for 30 minutes 3 times a week for 5 weeks during hemodialysis sessions to control for the nonspecific effects of social interaction and environment. The timings of the control group sessions were similar to those of the experimental group, whereby if a given experimental group intervention lasted for 30 minutes, the control group participants would be asked to sit with their eyes closed and relax for 30 minutes also.
10189745|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence A|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 4 gram/day.
10189746|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence B|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 8 gram/day.
9701190|NCT02907372|Other|cognitive tests|
9701191|NCT02903212|Experimental|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
9701192|NCT02888067|Active Comparator|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
9701193|NCT02888067|Active Comparator|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
9701194|NCT02879695|Experimental|Treatment (blinatumomab, nivolumab, ipilimumab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year.
9701195|NCT02874131|Experimental|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
9701196|NCT02874131|Active Comparator|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
9701197|NCT02864914||Empagliflozin|Patients initiating Empagliflozin treatment within the study period
9701198|NCT02864914||DPP-4 inhibitors|Patients initiating DPP-4 inhibitor treatment within the study period
9701199|NCT02858921|Experimental|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.
9701200|NCT02858921|Experimental|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks
9701201|NCT02858921|Experimental|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
9701202|NCT02858284|Experimental|TUG Device|1 time external application - device powered on
10189747|NCT05176626|Experimental|Phentermine|Participants randomized to active treatment in LEAP will be provided with phentermine hydrochloride 8 mg scored tablets. This formulation of the drug is commercially available and marketed as Lomaira TM.
10189748|NCT05176626|Placebo Comparator|Placebo|Participants randomized to the control arm of LEAP will be provided with placebo tablets consisting of cellulose and corn starch and manufactured to have the same characteristics of the active drug, including size, shape, weight, and sensory perceptions.
10189749|NCT05176548||Group 1|Patients in whom Cardiac Amyloidosis is confirmed
9701203|NCT02858284|Sham Comparator|Sham|1 time external application - device powered off
9701207|NCT02834780|Experimental|H3B-6527 (escalation and expansion)|Hepatocellular Carcinoma
9836117|NCT02769624|Placebo Comparator|Placebo|A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.
9701208|NCT02831764|Experimental|DTG + 3TC (50 mg+300 mg|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the subject no longer derives clinical benefit, or (iv) the subject meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
9701209|NCT02831764|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
9701210|NCT02826161|Experimental|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
10189750|NCT05176548||Group 2|Patients in whom Cardiac Amyloidosis is ruled out
10189751|NCT05176535|Experimental|FertyBiotic Balance|Participants received FertyBiotic Balance one capsule a day
10189752|NCT05176444|Experimental|Music therapy intervention|Music therapy
9701211|NCT02826161|Active Comparator|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
9701212|NCT02805855|Experimental|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
9701213|NCT02805855|Experimental|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
9701214|NCT02805855|Experimental|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
9701215|NCT02805855|Experimental|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
9701216|NCT02795052|Active Comparator|Arm 1 - Intravenous BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously.
9701217|NCT02795052|Active Comparator|Arm 2- Intravenous and Intranasal BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
9701218|NCT02776306|Experimental|Mirror box therapy|The participants in the mirror box therapy arm will receive mirror box therapy for 3 weeks for upper limb rehabilitation post stroke.
9701219|NCT02776306|No Intervention|Standard treatment group|The participants will receive the standard treatment arm for 3 weeks for upper limb rehabilitation post stroke.
9701220|NCT02739087|Experimental|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
9701221|NCT02720874|Experimental|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
9701222|NCT02720874|Active Comparator|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
9701223|NCT02697474|Experimental|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
9701224|NCT02697474|Experimental|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
9701225|NCT02632344|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
9701226|NCT02627443|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9701227|NCT02619682|Experimental|Treatment (ixazomib citrate and lenalidomide)|Within 30-120 days after finishing autologous transplant, patients receive ixazomib citrate PO on days 1, 8 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-28. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients will continue to alternate between ixazomib citrate and lenalidomide every 2 courses for up to 24 months in the absence of disease progression or unacceptable toxicity.
10189753|NCT05176444|No Intervention|Control group - standard care|Standard care for residents with cognitive impairment. Staff will not receive music therapy training.
10189754|NCT05176392|Active Comparator|Active rTMS with telehealth headache management therapy|Participants receive both active rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
10189755|NCT05176392|Other|Active rTMS with telehealth headache education control|Participants receive active rTMS treatment at the left dorsolateral prefrontal cortex and headache education
10189756|NCT05176392|Other|Sham rTMS with telehealth headache management therapy|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
10189757|NCT05176392|Sham Comparator|Sham rTMS with telehealth headache education control|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and headache education
10189758|NCT05176379|Experimental|fluconazole|fluconazole tablet/pill 150 mg, single acute dose
9701230|NCT02586025|Experimental|Trastuzumab, Pertuzumab, Docetaxel|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
9701231|NCT02586025|Experimental|Trastuzumab, Placebo, Docetaxel|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
9701232|NCT02520011|Experimental|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
9701233|NCT02520011|Active Comparator|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
10189759|NCT05176379|Placebo Comparator|Placebo|250 mg pill microcrystalline Cellulose, single acute dose
10189760|NCT05176340|Experimental|Intervention group|Participants in the experimental group were provided an education program through the Care Action Module during their hospitalization period, and follow-up was conducted one and two months after discharge.
9701236|NCT02498613|Experimental|Treatment (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.
9701237|NCT02474160||Ancillary-correlative (tissue and blood procurement)|Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
9701238|NCT02453620|Experimental|Treatment (entinostat, nivolumab, ipilimumab)|Patients receive entinostat PO on days -14 and -7 and then weekly, nivolumab IV over 60 minutes on day 1 and then every 2 weeks, and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9701239|NCT02415816|Experimental|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
10189761|NCT05176340|No Intervention|Control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
9778634|NCT01111539|Experimental|Phase B: Single-blind Prospective Treatment Phase|Participants received initial dose of escitalopram 10 milligram (mg) blinded capsule (over-encapsulated tablet), orally, once daily, increased to 20 mg/day at the end of Week 1 based upon tolerability profile, for up to maximum of Week 8. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
9778635|NCT01111539|Experimental|Phase B+: Single-blind Phase B Responders|Participants with response (≥50% reduction in depressive symptom severity in Hamilton Depression Rating Scale {HAM-D17} Total Score; or a HAM-D17 Total Score of <14 at Week 8 or a Clinical Global Impression of Improvement {CGI-I} Score of <3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B, for up to maximum of Week 14, in Phase B+.
9778636|NCT01111539|Experimental|Phase C: Aripiprazole/Escitalopram Combination|Participants with incomplete response (less than 50% reduction in depressive symptom severity between Baseline and Week 8 measured by the HAM-D17 Total Score and HAM-D17 Total Score of ≥14 at Week 8 and CGI-I Score of ≥3 at Week 6 and 8) at Week 8 received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily at Week 9. Participants were up titrated to aripiprazole target dose of 12 mg/day at Week 10 (if initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on initial 6 mg/day dose), and thereafter received same dose up to maximum of Week 14. No dose increases were allowed for aripiprazole after end of Week 12, however, doses might be decreased at any visit based upon tolerability. In combination with aripiprazole, participants received escitalopram (10 or 20 mg/day blinded capsules) taken during final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments allowed for escitalopram during Phase C.
9836118|NCT02769702|Experimental|Intervention|Acthar 80 IU SC twice w eek
10189762|NCT05176327|Experimental|Intervention|Subjects will receive 2 consecutive courses of exoskeleton training with twelve 45-minute sessions, each to be completed in 6 to 8 weeks. The total period of training will be 12 to 16 weeks.
10189763|NCT05176327|Active Comparator|Control|Subjects will receive twelve 45-minute sessions of usual physiotherapy treatment, consisting of maintenance exercise in the first 6 to 8 weeks, and then one course of exoskeleton training with twelve 45-minute sessions in the following 6 to 8 weeks.
10189764|NCT05176288|Experimental|Axitinib, Avelumab and Palbociclib|"During each 28 day (+/- 3 days) study cycle, all participants will receive:~Axitinib: 2x Daily until it is determined participant must stop the drug~Palbociclib: Taken 1x time per day on days 8-28 of each cycle until it is determined participant must stop the drug.~Avelumab: Once every 2 weeks continued for up to 2 years or earlier if it is determined participant must stop the study drug"
10189765|NCT05176275|Experimental|68Ga-NOTA-RP25|Intravenous injection
10189766|NCT05176236|Experimental|Pictographic group|Participants received the pictographic handouts on tracheostomy care
10189767|NCT05176119|Active Comparator|Nalbuphine arm|0.1 mg /kg nalbuphine was given to 30 patients
10189768|NCT05176119|Active Comparator|Ketamine arm|0.25 mg /kg ketamine was given to 30 patients
10189769|NCT05176119|Placebo Comparator|Saline arm|an equivalent volume of normal saline was given to 30 patients
9701241|NCT02345265|Experimental|Treatment (olaparib and cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10189770|NCT05176106|Experimental|Intervention-Randomized Parishes|Parishes will be randomized in Masindi District to receive the intervention (i.e., an incentives package). VHTs who are active in that parish will thereby receive the incentives intervention.
9701242|NCT02315534|Experimental|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
9701243|NCT02315534|Experimental|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
9701244|NCT02311920|Experimental|Arm I (temozolomide and ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
9701245|NCT02311920|Experimental|Arm II (temozolomide and nivolumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes once every 2 weeks for 16 weeks and then once every 2 weeks for 48 weeks in the absence unacceptable toxicity.
9701246|NCT02311920|Experimental|Arm III (temozolomide, nivolumab, ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and nivolumab IV over 60 minutes once every 2 weeks for 64 weeks in the absence unacceptable toxicity.
10189771|NCT05176106|No Intervention|Control-Randomized Parishes|Non-intervention randomized parishes will be the control parishes. Active VHTs in the control parishes will not receive the incentives intervention.
10189772|NCT05176093|Active Comparator|Engensis|Active Comparator: Engensis 64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
10189773|NCT05176093|Placebo Comparator|Placebo|Placebo Comparator: Placebo 32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
9701247|NCT02311582|Experimental|Phase I: MK-3475 + MLA|-In the phase I portion of this study, MK-3475 will be given every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.
9701248|NCT02311582|Experimental|Phase II: MK-3475 Only (Arm B)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no debulking)~The phase II dose was determined during the Phase I portion of the study. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will only be performed when clinically warranted."
9701249|NCT02311582|Experimental|Phase II: MK-3475 + MLA (Arm A)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no debulking).~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~--For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
9701250|NCT02311582|Experimental|Phase II (after amendment #12): MK-3475 + MLA|"After amendment 12, all patients will be enrolled in this arm~MK-3475 will be given every 3 weeks no more than 1 week after MLA~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
9836119|NCT02769858|Experimental|Light Therapy|Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.
9978042|NCT01367769||Thrombosis|"Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.~Age and sex matched controls (volunteers)"
10189774|NCT05176067|No Intervention|drug therapy group|targeted therapy, immune, chemotherapy
10189775|NCT05176067|Experimental|drug therapy concurrent radiotherapy|drug therapy(targeted therapy, immune, chemotherapy ) combined with thoracic tumor concurrent radiotherapy
10189776|NCT05176028|Experimental|Control group|conventional physiotherapy
10189777|NCT05176028|Experimental|Intervention group|conventional physiotherapy and fascial release
10189778|NCT05176002|Experimental|Neoadjuvant Camrelizumab combined with radiotherapy group|
10204400|NCT02428647|Active Comparator|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
10204401|NCT02428647|Active Comparator|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
10204402|NCT02418689|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
9701251|NCT02310321|Experimental|Phase 1 Dose Evaluation Part|In the dose-evaluation part in Phase 1 part, subjects will receive ASP2215 at assigned single dose for determination of MTD and/or RED. Treatment of AML in this study is composed of 3 periods of therapy: remission induction (42-day cycles x 2 at maximum), consolidation (28-day cycles x 3 at maximum), and maintenance (28-day cycles x 26 at maximum). The decision of whether or not to proceed to the next dose will be made based on the occurrence of DLT during Cycle 1 of the induction period.
9701252|NCT02310321|Experimental|Phase 1 Dose Expansion Part|In the dose expansion part in Phase 1 part, subjects will receive ASP2215 at RED that has been determined in the dose-evaluation part, and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.
9701253|NCT02310321|Experimental|Phase 2 Part|Subjects will receive ASP2215 at the recommended dose established in Phase 1 part.
9701254|NCT02298959|Experimental|Treatment (pembrolizumab and ziv-aflibercept)|Patients receive pembrolizumab IV over approximately 30 minutes and ziv-aflibercept IV over 1-2 hours on day 1. Cycles repeat every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9701255|NCT02290886|Placebo Comparator|Placebo|Intravenous administration of placebo
9701256|NCT02290886|Experimental|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
9701257|NCT02290886|Experimental|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
9701258|NCT02290886|Experimental|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
9701259|NCT02279719|Experimental|BBI608 and Sorafenib|
9701260|NCT02279719|Experimental|BBI503 and Sorafenib|
9701261|NCT02279719|Active Comparator|Sorafenib|
10189779|NCT05175963||High Risk|"Nurses (auxiliary nurses, enrolled nurses and professional nurses), medical doctors (interns, medical officers, registrars and consultants) and auxiliary/para-medical staff involved in the care of patients admitted for respiratory illnesses at Chris Hani Baragwanath Academic Hospital (CHBAH). This will include staff that have been assigned to work in:~Internal Medicine: Staff working in the Ambulatory and Emergency Department, staff in the pneumonia-admission ward (ward 24), and staff in the COVID-19 confirmed case wards.~Paediatrics: Staff involved in-hospital care of patients admitted to the dedicated pneumonia ward and COVID-19 cases wards.~Intensive Care Unit: All medical staff working in the intensive care unit."
10189780|NCT05175963||Low Risk|Nursing and medical-doctor staff that are working in the neonatal high-care and intensive care unit; who are likely to be at lower risk from SARS-CoV-2 acquisition in the health-care facility compared to their peers listed in Group 1.
9701264|NCT02275221||Hepatitis B and C|Hepatitis B and C
9701265|NCT02247752|Other|Inactive carriers|
9701266|NCT02240472|No Intervention|Axillary clearance|Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis
9701267|NCT02240472|Experimental|No axillary clearance|Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis
9701268|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
9701269|NCT02235857|Experimental|Liposorber® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using Liposorber® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
9701270|NCT02230189|Experimental|Allergen challenge subjects|"Intervention: Segmental airway allergen challenge~Three types of subjects are studied in this arm:~1) Volunteers with neither asthma nor allergy (as established by skin prick testing); 2) Volunteers with allergy (as established by skin prick testing) but without asthma; and 3) Volunteers with both asthma and allergy (as established by skin prick testing)"
10189781|NCT05175963||Intermediate Risk|"A third group, with a likely intermediate risk for hospital-facility based SARS-CoV-2 infection, are:~VIDA staff involved in sample collection related to COVID-19, and laboratory personnel that will be involved in sample collection at VIDA.~Nurses and medical doctors from the Obstetrics & Gynaecology."
10189782|NCT05175963||Mixed Risk|In 2021 with an eminent 3rd wave spreading across the country an additional group will be included comprising of any person working at CHBAH even if not in direct contact with patients.
10189783|NCT05175963||TND group|Any person working at CHBAH or Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH) even if not in direct contact with patients.
10189784|NCT05175950|Experimental|Test group 1: primary vaccination completed with ChAdOx1 nCOV-19|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
9701275|NCT02192398|Active Comparator|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
9701276|NCT02192398|Active Comparator|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
9701277|NCT02192398|Placebo Comparator|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
9701278|NCT02179086|Active Comparator|Arm A1 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9836120|NCT02770014|Experimental|EGFR mutation Positive, Treatment With Erlotinib|Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
9836121|NCT02770170|Experimental|BI 655064 dose 1|
10189785|NCT05175950|Placebo Comparator|Placebo group 1: primary vaccination completed with ChAdOx1 nCOV-19|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
9701279|NCT02179086|Experimental|Arm B (photon IMRT)|"Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9701280|NCT02179086|Active Comparator|Arm A2 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9701281|NCT02179086|Experimental|Arm C (proton beam radiation therapy)|"Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9701282|NCT02178956|Experimental|BBI608 plus Paclitaxel|
9701283|NCT02178956|Placebo Comparator|Placebo plus Paclitaxel|
9701284|NCT02176902|No Intervention|Arm I (control)|Patients receive no intervention.
9701285|NCT02176902|Experimental|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low-fat diet comprising 20% Kcal from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day PO for 1 year.
9701286|NCT02167945|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.
9701287|NCT02160015|Experimental|Treatment (lenalidomide, ibrutinib, rituximab)|Patients receive rituximab IV on day 1 (up to 6 cycles), lenalidomide PO QD on days 1-21 (up to 12 cycles), and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9701288|NCT02159755|Experimental|Treatment (ibrutinib, palbociclib)|Patients receive ibrutinib PO QD on days 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9701289|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
9701290|NCT02159404||Healthy controls|
9701291|NCT02152995|Experimental|Cohort A (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients with RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.
9701292|NCT02152995|Experimental|Cohort B (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients without BRAF/RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.
9701293|NCT02152995|Experimental|Cohort C (trametinib)|Patients may continue trametinib at the doctor's discretion and do not receive iodine I-131.
9701294|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
9701295|NCT02145741|Experimental|Xentuzumab|Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)
9701296|NCT02122354|Experimental|Survey + videogame|"Hide and Seek videogame"
9701297|NCT02097420|Other|Single device arm|Mitral valve replacement
9701298|NCT02061605|Experimental|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
9701299|NCT02049632|Experimental|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
9701300|NCT02048813|Experimental|Arm A (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28. Beginning cycle 2, patients also receive rituximab IV over 4 hours on days 1 and 2 of cycle 2, and day 1 of cycles 3-7. Treatment repeats every 28 days for 7 cycles in the absence of unacceptable toxicity. In the absence of disease progression, patients may continue ibrutinib PO QD.
9836122|NCT02770170|Experimental|BI 655064 dose 2|
9836123|NCT02770170|Experimental|BI 655064 dose 3|
9836124|NCT02770170|Placebo Comparator|Placebo|
9701301|NCT02048813|Active Comparator|Arm B (rituximab, fludarabine phosphate, cyclophosphamide)|Patients receive rituximab IV over 4 hours on days 1 and 2 of cycle 1, and day 1 of cycles 2-6. Patients also receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 30 minutes on days 1-3. Treatment repeats every 28 days for 6 cycles in the absence of unacceptable toxicity.
9701302|NCT02035358|Experimental|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
9701303|NCT02030028|Other|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
10189786|NCT05175950|Experimental|Test group 2: primary vaccination completed with BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
10189787|NCT05175950|Placebo Comparator|Placebo group 2: primary vaccination completed with BNT162b2(Pfizer)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
10189788|NCT05175950|Experimental|Test group 3: primary vaccination completed with mRNA-1273(Moderna)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
10189789|NCT05175950|Placebo Comparator|Placebo group 3: primary vaccination completed with mRNA-1273(Moderna)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
10189790|NCT05175950|Experimental|Test group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
10189791|NCT05175950|Placebo Comparator|Placebo group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
10189792|NCT05175950|Experimental|Test group 5: primary vaccination completed with ChAdOx1 nCOV-19(AZ)-BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
10189793|NCT05175950|Placebo Comparator|Placebo group 5: primary vaccination completed with ChAdOx1 nCOV-19-BNT162b2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
10189794|NCT05175937||APP group|Patient wearing ICD with Bluetooth® technology and smartphone APP based remote monitoring
10189795|NCT05175937||Bedside transmitter group|Patient wearing ICD monitored remotely through a bedside transmitter
10189796|NCT05175924|Experimental|Virtual reality|In the Aquarium VR group, virtual reality headset compatible with iPhone 7 (Apple) was used to distract attention. Before use, the headsets were tested on five children for face fit and visibility of the application used. Written and verbal consent of the children and their parents was obtained to test the headsets. The children who tested the headsets were not included into the study. The headset offered a soft and comfortable experience in contact with the skin due to its leather and pad covering. It also had a wide viewing angle and an optical zoom button. Due to its noise isolation function, it did not disturb anyone or make noise.
10189797|NCT05175898||VA-ECMO|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest.
10189798|NCT05175898||ECMELLA|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella® micro-axial pump.
10189799|NCT05175885|Experimental|Experimental group|Ex vivo normothermic perfusion (EVNP) of the graft with the Ark Kidney System
10189800|NCT05175885|Active Comparator|Historical control group|Nonrandomized historical control group formed by patients transplanted without ex vivo normothermic perfusion (EVNP) in the period Sept 2015-Sept 2020, selected by retrospective matching.
10189801|NCT05175859||Early tracheostomy|Tracheostomy time before day 10 following endotracheal airway management and invasive ventilation.
10189802|NCT05175859||Late tracheostomy|Tracheostomy time after day 11 following endotracheal airway management and invasive ventilation.
10189803|NCT05175807|Experimental|Mindfulness Group_1|The intervention will be characterized by be based on Mindfulness exercises (e.g. body scan, gentle yoga, sitting, grounding and walking meditation), relaxation techniques and cognitive rehabilitation exercises. walking), relaxation techniques and cognitive rehabilitation exercises. The objective is to provide specific practical skills to learn how to deal with difficult and/or stressful situations managing emotions and intercurrent thoughts. The intervention is proposed to last for a total of 5-6 sessions lasting 45 minutes each, two sessions per week, for a three-week commitment. In addition, between sessions, reflection materials, readings or exercises will be offered. The intervention will be conducted in telemedicine by a Psychologist, who has experience in conducting these interventions and who receives regular supervision. The sessions will be conducted through special platform and audio-recorded to ensure the reliability of the data collected, prior consent.
10189804|NCT05175807|No Intervention|Waiting List Group_2|"In both groups the usual care or usual treatment, will consist of the usual daily medical examinations of the department, respiratory and motor physiotherapy sessions. The Group 2, therefore, will not be submitted to other type of treatment outside of that previewed near O.U. for the course of the first three weeks, during which they will be placed on the waiting list. Once the Once the assessment is carried out after 3 weeks, we will proceed to implement the intervention proposed to the Group 1. If the participant has already been discharged from the structure, it will still be possible to proceed with the intervention, since it is online. If the participant has already been discharged from the structure, you can still proceed with the intervention, since this is in telemedicine, in order to promote the continuity hospital-territory."
10189805|NCT05175729||Pregnant Group|First trimester pregnant group would be included and will be followed up in second, third trimesters and after pregnancy
10189806|NCT05175729||Control group|Age-, sex-matched healthy volunteers
10189807|NCT05175703|Other|the infrainguinal arteries disease group|Actual patient group with any atherosclerotic change in the infrainguinal arteries
10189808|NCT05175664||MCI|Patients suffering from mild cognitive impairment (MCI) due to Alzheimer's disease.
10189809|NCT05175664||AD|Patients diagnosed with mild to moderate Alzheimer's disease (AD)
10189810|NCT05175664||NDD|Patients under investigation of a neurodegenerative disease (NDD)
10189811|NCT05175664||DLB|Patients diagnosed with Dementia with Lewy Bodies (DLB)
10189812|NCT05175664||VaD|Patients with vascular dementia (VaD)
10189813|NCT05175664||FTD|Frontotemporal dementia (FTD)
10189814|NCT05175664||NPH|Normal pressure hydrocephalus (NPH)
9701304|NCT02024607|Experimental|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.
10189815|NCT05175664||Healthy Controls|Healthy Controls without brain disease
10189816|NCT05175651|Experimental|Subjects identified by Optum Health|10,000 individuals identified by Optum Health as likely meeting inclusion criteria by claims analysis.
9701305|NCT02024607|Experimental|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
9701306|NCT02024607|Experimental|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.
9701307|NCT02024607|Experimental|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
9701308|NCT02024607|Experimental|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
9701309|NCT02024607|Experimental|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
9701310|NCT02024607|Experimental|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
10189817|NCT05175638||Control|A total of 20 term newborn infants with a median gestational age of 40 weeks (range: 37-42 weeks) will be selected from the Gynecology and Obstetrics Hospital (Assiut University). All control infants should have an Apgar score of > 9 at 1, 5, and 10 minutes.
10189818|NCT05175638||Study group|"Thirty newborn infants born for Covid-19 positive mothers will be prospectively included in this study. The diagnosis of hypoxia will made based on Apgar score, clinical signs present during the first hours of life and acid-base status.~The following inclusion criteria will be used (all necessary): Covid-19 positive mothers, term newborn (>37 completed gestational weeks), free from severe malformations. All infants will be examined generally, systemically and neurologically at birth for clinical assessment of HIE if present and for detection of outcome of these neonates."
9701313|NCT01955499|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO on days 1-21 and ibrutinib PO on days 1-28 (days 2-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9701314|NCT01938677|Experimental|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
9701315|NCT01938677|No Intervention|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
9701316|NCT01929811|Experimental|Metformin arm|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
9701317|NCT01929811|Other|TEC|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
9701318|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 1|Combination chemotherapy and inotuzumab ozogamicin - Dose level 1 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and 0.4 mg/m2 inotuzumab ozogamicin IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9701319|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 2|Combination chemotherapy and inotuzumab ozogamicin - Dose level 2 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.6 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9836125|NCT02770248|Experimental|SIMBRINZA|Brinzolamide 1% / Brimonidine 0.2% tartrate ophthalmic suspension, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
10189819|NCT05175625|Experimental|SpikoGen COVID-19 Vaccine|
10189820|NCT05175625|Placebo Comparator|Saline Placebo|
10189821|NCT05175547|Active Comparator|Intensive blood pressure management group|Target blood pressure of 90-120mmHg (Intensive BP management group)
10189822|NCT05175547|Active Comparator|Standard blood pressure management group|Target blood pressure of 90-160mmHg (Standard BP management group)
9701320|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 3|Combination chemotherapy and inotuzumab ozogamicin - Dose level 3 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9701321|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 4|Combination chemotherapy and inotuzumab ozogamicin - Dose level 4 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9701322|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 5|Combination chemotherapy and inotuzumab ozogamicin - Dose level 5 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10189823|NCT05175521|Placebo Comparator|Eucalyptus Oil Scent|Eucalyptus oil diluted in mineral oil 1:20
9701323|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - MTD|Combination chemotherapy and inotuzumab ozogamicin - Maximum Tolerated Dose Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9701324|NCT01886859|Experimental|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up cycle of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients who have achieved CR/CRi, nodular PR, partial remission with persistent lymphocytosis, partial remission, or who have stable disease discontinue lenalidomide and continue ibrutinib.
10189824|NCT05175521|Active Comparator|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70%
9701325|NCT01856478|Experimental|afatinib|oral intake, once daily
9701326|NCT01856478|Active Comparator|methotrexate|intravenous bolus injection, once weekly
9701327|NCT01841723|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9701328|NCT01829568|Experimental|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 1 and once weekly at weeks 13, 21, 29, and 37.
9701329|NCT01818323|Experimental|Intra-tumoral T4 immunotherapy|Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy
9701330|NCT01803906||Mitochondrial disease|Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
9701331|NCT01803555|Experimental|BF Spiromax|2 inhalations of BF Spiromax at a dosage of 160/4.5 mcg and 2 inhalations of SYMBICORT placebo administered twice daily (AM and PM) during the 12-week treatment period.
9701332|NCT01803555|Active Comparator|Symbicort Turbohaler|2 inhalations of SYMBICORT TURBOHALER at a dosage of 200/6 mcg and 2 inhalations of placebo SPIROMAX administered twice daily (AM and PM) during the 12-week treatment period.
9701333|NCT01791816|Experimental|Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)|
9701334|NCT01790360|Active Comparator|Patient Navigation (PN)|Behavioral Intervention: 'Patient Navigation (PN) Intervention' participants will receive support from navigators in choosing a provider and remembering to attend appointments
9701335|NCT01790360|Experimental|Financial Incentives (FI)|Behavioral Intervention: 'Financial Incentives (FI) Intervention' participants will receive gift cards and money for attending clinic visits
9701336|NCT01786434|Experimental|Routine medication arm|Fentanyl is given routinely to all patients before the procedure
9701337|NCT01786434|Active Comparator|Fentanyl on-demand arm|Fentanyl is given during the procedure if the patient experiences pain
9701338|NCT01784159|Placebo Comparator|Placebo|Placebo 1tb / day/ 7days
9701339|NCT01784159|Active Comparator|Aspirin|Intervention aspirin 200 mg/day for 7 days
10189825|NCT05175508|Experimental|Azacytidine Combined With ARTA|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle with ATRA 20mg tid by po on days 1-21 of every cycle 28 days
9701340|NCT01782703||Control|Healthy subjects with no history of atopy (atopic dermatitis, asthma, or allergic rhinitis) from 0 months to 17 years of age that are age and sex matched to our atopic dermatitis subjects.
9701341|NCT01782703||Atopic Dermatitis|Children with atopic dermatitis from 0 months to 17 years of age.
9701342|NCT01782703||Control with Atopy history|Healthy subjects from 0 months to 17 years of age with history of asthma, food allergies, or allergic rhinitis, but no atopic dermatitis or with positive family history of atopy
10189826|NCT05175508|Experimental|Azacytidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle
10189827|NCT05175430|Active Comparator|Pretreatment with paroxetine|Pretreatment with paroxetine (10 mg daily for 1 week followed by 20 mg daily for 5 weeks, per os), followed by administration of LSD (0.1 mg, per os) on the study day
10189828|NCT05175430|Placebo Comparator|Pretreatment with placebo|Pretreatment with placebo for 6 weeks (mannitol, per os), followed by administration of LSD (0.1 mg, per os) on the study day
10204403|NCT02412735|Experimental|Rexlemestrocel-L|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with saline on Day 0 (Visit 2).
10204404|NCT02412735|Experimental|Rexlemestrocel-L + HA|Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0 (Visit 2).
9701343|NCT01776307|Experimental|BBI608 in combination with cetuximab|
9701344|NCT01776307|Experimental|BBI608 in combination with panitumumab|
9701345|NCT01776307|Experimental|BBI608 in combination with capecitabine|
9701346|NCT01771107|Experimental|Treatment (brentuximab and combination chemotherapy)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9701347|NCT01745783|Experimental|Experimental|"Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.~Dose: 1-2x10^6 cells/Kg"
9701348|NCT01745783|Placebo Comparator|Placebo Comparator|Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10^6 cells/Kg
9701349|NCT01695941|Experimental|Treatment (alisertib, bortezomib, and rituximab)|"Patients receive alisertib PO BID on days 1-7; bortezomib SC on days 1, 8, and 15; and rituximab IV on day 1. Treatment repeats every 28 days* in the absence of disease progression or unacceptable toxicity.~Note: *After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity."
9701350|NCT01681264|Active Comparator|Morphine:Placebo|
9701351|NCT01681264|Active Comparator|Morphine:Guanfacine 1mg|
9701352|NCT01681264|Active Comparator|Morphine:Guanfacine 2mg|
9701353|NCT01681264|Active Comparator|Placebo:Guanfacine 2mg|
9701354|NCT01681264|Placebo Comparator|Placebo:Placebo|
9701355|NCT01678586|Active Comparator|True Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.
9701356|NCT01678586|Sham Comparator|Sham Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.
9701357|NCT01678586|Active Comparator|Gabapentin|Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
9701358|NCT01678586|Sham Comparator|Sham Gabapentin|Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
9701359|NCT01630213|Active Comparator|Vitamin D3 + fish oil/placebo|Vitamin D3 2000 IU/day and fish oil (840 omega 3-fatty acids; Omacor)(or fish oil placebo)/day
9701360|NCT01630213|Placebo Comparator|Vitamin D3 placebo + fish oil/placebo|Vitamin D3 placebo + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo
9701361|NCT01623167|Experimental|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 6
9701362|NCT01623167|Experimental|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 3
9701363|NCT01623167|Experimental|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18months, and receive eltrombopag day 1 to month 6
9701364|NCT01623167|Experimental|Extrension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
9701365|NCT01550575||Patients eligible for SCS, RF or other treatment approaches|Patients who have previously been implanted with, or are eligible for implantation with a spinal cord stimulation system or various other treatment approaches such as RF, IDS, etc.
9701366|NCT01550575||Patients Eligible for treatment options with prior treatment|Patients who have previously been implanted with a spinal cord stimulation system or other various treatments, and have thereafter received a different form of chronic pain treatment such as a different SCS system, RF, IDS etc.
9701367|NCT01535274|Experimental|Desflurane|Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
9701368|NCT01535274|Experimental|Propofol|Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
9701369|NCT01528046|Experimental|Metformin in Combination with VIT|Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).
9701370|NCT01506206||Patients with Deep Brain Stimulators|Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
9701371|NCT01506206||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
9701372|NCT01470716|Experimental|Study arm|Neo-adjuvant Erlotinib treatment arm.
9701373|NCT01441349|Active Comparator|Control arm|IP chemotherapy arm
9701374|NCT01441349|Experimental|Treatment arm|IP chemotherapy plus simvastatin arm
9701375|NCT01394900|Experimental|CNU intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of CNU intervention
9701376|NCT01394900|Active Comparator|WP intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of general wellness promotion (WP) intervention
9701377|NCT01383915||inpatients|Youth with a clinical diagnosis of a mood disorder or psychosis spectrum disorder
9701378|NCT01327690|No Intervention|Wait List|Wait Period corresponding in length to treatment period
9701379|NCT01327690|Experimental|EFT (Emotional Freedom Techniques)|EFT group therapy sessions.
9701380|NCT01327690|Active Comparator|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
9701381|NCT01224665|Active Comparator|Arm I|therapeutic conventional surgery therapeutic standard lymphadenectomy
10189829|NCT05175378|Active Comparator|Intervention arm|In the intervention group, MS women received a personalized daily eating plan (specific meals, recipes, food portions) together with nutritional consultation on the Meditteranean dietary pattern, as well as physical activity guidelines. All essential aspects of the dietary plan e.g. daily energy expenditure, classification of physical activity based on the concept of metabolic equivalent (MET), caloric adjustment according to nutritional status, and macronutrient distribution were calculated by a Clinical Decision Support System (CDSS). Body mass index (BMI) was also calculated, as the ratio of reported weight (kg) to the square of height (m2). Co-existed health issues, such as constipation or esophageal reflux, were taken into consideration. All MS patients acquired personal login passwords that allowed them to get access to their personal CDSS account and track their progress in regards to body weight, physical activity, and healthy food choices consumption.
10189830|NCT05175378|Sham Comparator|Control arm|"Patients of the control group received general dietary advice and physical activity recommendation that was in accordance with the National Dietary Guidelines for Greek adults"
10189831|NCT05175352|Experimental|Administration of Cendakimab and Cytochrome P450 (CYP) substrates|
10189832|NCT05175313||normal people|people who don't complain of respiratory diseases will be examined by chest ultrasound and pulmonary function test.
10189833|NCT05175313||obstructive respiratory diseases|the patients who are diagnosed with either COPD or asthma.
10189834|NCT05175313||restrictive respiratory diseases|patient with either ILD
10189835|NCT05175300|Experimental|Group 1|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
10189836|NCT05175300|Active Comparator|Group 2|Prosthesis with ceramic-on-ceramic (CoC) torque.
10189837|NCT05175235|Experimental|CURATE.AI|"Participants will undergo two treatment periods: selection period and CURATE.AI modulation period. During the selection period, baseline ctDNA measurements and CT scans will be performed. Subsequently, participants will receive Standard of Care (SOC) doses of nivolumab and have their ctDNA measured at the end of the third cycle together with other SOC monitoring.~After the first ctDNA measurement and CT scan, selected patients who responded to treatment through both ctDNA and CT scan may continue into the CURATE.AI modulation period. Non-responders will receive SOC doses of nivolumab for 2 cycles before having their ctDNA measured and CT scan at the end of the 2 cycles. Subsequent responders through both ctDNA and CT scans may then continue into the CURATE.AI modulation period.~Only the dose of nivolumab will be modulated with CURATE.AI, based on measurements of the response marker (ctDNA)."
10189838|NCT05175222|Experimental|Laser|Patients receive low-level laser therapy with LightWalker laser from the first day of conditioning chemotherapy till +2 day post hematopoietic stem cell transplantation. Additionally, standard supportive care is introduced.
10189839|NCT05175222|No Intervention|Control|Patients are observed and receive standard supportive care.
10189840|NCT05175131|Experimental|Mebeverine+Simethicone combination|three times a day per os
10189841|NCT05175131|Active Comparator|mebeverine|three times a day per os
10189842|NCT05175131|Active Comparator|simethicone|80 mg (2 capsules 40 mg) three times a day per os
10189843|NCT05175105|Experimental|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
10189844|NCT05175105|Placebo Comparator|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
10189845|NCT05175105|Experimental|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the open-label extension period will receive both mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment.
10189846|NCT05175079|Experimental|Accupressure group|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
10189847|NCT05175079|Placebo Comparator|Control group|
10189848|NCT05175066|Experimental|Bisoprolol|40 patients who were given bisoprolol at a dose of 1.25 mg daily, and in the absence of clinical symptoms and heart rate above 60 and systolic blood pressure above 100, 1.25 mg was added to the therapeutic dose every 2 weeks to reach 5 mg daily.
10189849|NCT05175066|Placebo Comparator|Placebo|Two placebo tablets in similar shape and color to bisoprolol were given on a daily basis to each of the 40patients as the control group.
10189850|NCT05175027|Active Comparator|Hypochlorosis|Hypochlorosis was used as an antiseptic for the patients
10189851|NCT05175027|Active Comparator|Povidone iodine|Povidone iodine was used as an antiseptic for the patients
10189852|NCT05175014|Experimental|Single full dose of PCV 10|27 clusters randomized to receive a vaccination campaign with the full dose.
10189853|NCT05175014|Experimental|Single fractional dose of PCV10 (1/5)|27 clusters randomized to receive a vaccination campaign with the fractional dose (1/5).
10189854|NCT05175014|No Intervention|Control Group|9 clusters randomized to the control arm.
10189855|NCT05174975|Experimental|App-based Positive Psychological Intervention group|The intervention will be conducted on the app, including 2-week PPI, diabetes-related health education, physical records, and online consultation.
10189856|NCT05174975|No Intervention|control group|usual care which will educated by certificated educators in terms of self-management
10189857|NCT05174936|Experimental|PLWH intervention sessions|The PLWH in this arm will receive five 2-hour intervention sessions delivered over five weeks (one session per week) in the clinics. Two trained facilitators will deliver the materials through interactive trainings that include multimedia presentations, group discussions, role-play, personal testimonies, and/or games. The same two facilitators will deliver all five sessions within a clinic to increase group cohesion and rapport with PLWH. The goal of this intervention is to assist PLWH in identifying and developing internal and external resilience resources to aid in coping HIV stigma.
9701382|NCT01224665|Experimental|Arm II|therapeutic conventional surgery therapeutic extended lymphadenectomy
10189858|NCT05174936|Experimental|Family member intervention|The intervention sessions for family members will be similar to PLWH sessions in terms of format and content and will be led by trained facilitators. Family member intervention sessions will emphasize supporting PLWH to cope with HIV-related stigma and to improve their clinical outcomes. The goal of this intervention is to provide social support for PLWH's resilience building as well as foster resilience at the family level.
9701383|NCT01156545|Experimental|Treatment arm|BIBW 2992 plus simvastatin arm
9701384|NCT01156545|Active Comparator|control arm|BIBW 2992 arm
9701385|NCT01140516|Active Comparator|Trimethoprim|Prophylactic Antibiotics
9701386|NCT01140516|Placebo Comparator|Simple syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
9701387|NCT01119365|Experimental|Light|Sequence of bright light flashes of varying durations, interflash intervals, flash lengths, flash brightness, and flash color.
9701388|NCT01047865||pancreas-kidney transplant|pancreas-kidney transplant recipients with type 1 diabetes.
9701389|NCT01034670|Experimental|endoscopy arm|imaging performed in conjunction with the regularly scheduled endoscopy during which the newer imaging techniques will be used to detect premalignant conditions. includes wide field fluorescence, microscopy, Raman spectroscopy and/or ultrasound.
9701390|NCT00981396|Active Comparator|CBT|Cognitive Behavioral Therapy
9701391|NCT00981396|Experimental|EFT|Emotional Freedom Techniques, a novel but efficacious stress-reduction technique
9701392|NCT00977860|Other|SBRT|
9701393|NCT00966979|Other|Triathlon PKR|All subjects enrolled will receive the Triathlon PKR device.
9701394|NCT00957086|Active Comparator|Nimotuzumab|Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab
9701395|NCT00957086|Placebo Comparator|Placebo|Comprising Adjuvant Cisplatin, Concurrent RT and Placebo
10189859|NCT05174936|Experimental|Health care provider intervention|The HCP intervention curriculum consists of four 1.5-hour sessions (e.g., one per week) that will be delivered in small groups in the clinic setting by trained facilitators (e.g., health educators from Guangxi CDC). The delivery schedule and format will be flexible and individually tailored (e.g., four sessions can be given one per week or consolidated into two longer sessions). The goal of this intervention is to reduce the institutional stigmatizing attitudes and practices toward PLWH and other social identities, such as MSM, sex workers, and drug users, and improving the provider-patient relationships.
9701396|NCT00759304||PROOF cohort|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.
9701397|NCT00647387|Experimental|1|Implantation with the device
9701398|NCT00544830|Experimental|Treatment (androgen therapy, radiation therapy)|"ADT: Patients not currently on ADT receive goserelin acetate SC or leuprolide acetate via injection once every 4 or 12 weeks and bicalutamide PO QD. Treatment repeats every 12 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients already receiving ADT at the time of enrollment continue treatment until they have received 36 weeks of therapy.~RADIATION THERAPY: Patients achieving PSA normalization after initiation of androgen deprivation therapy undergo intensity-modulated radiation therapy daily for 2-7 weeks during or after completion of androgen deprivation therapy."
9701399|NCT00539981|Experimental|FluBlok (Lots A, B, C)|Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
9701400|NCT00539981|Placebo Comparator|Placebo|Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
9701401|NCT00537004||PPA (Primary Progressive Aphasia)|Individuals with primary progressive aphasia
10189860|NCT05174923||Age Range 45 to </= 60|
10189861|NCT05174923||Age Range 61 to </= 75|
10189862|NCT05174923||Age >/= 76|
10189863|NCT05174897|No Intervention|Control Group|The child for whom an intravenous catheter will be applied will be placed on a stretcher and pain and fear will be evaluated before the procedure. Afterwards, an intravenous catheter will be applied. Pain and fear scores will be evaluated during and after the procedure.
10189864|NCT05174897|Experimental|Experimental group|The child to whom an intravenous catheter will be applied is placed on a stretcher. After evaluating the pain and fear score before the procedure, emotional liberation technique (EFT) is performed for 10 minutes. followed by an intravenous catheter. Pain and fear scores are evaluated during and after the procedure.
10189865|NCT05174793|Experimental|dehydration to rehydration|subjects were rehydrated following 2% dehydration
9701402|NCT00537004||Control|Individuals with no diagnosis of any type of dementia
9701403|NCT04734418|Experimental|Remifentanil group|
9701404|NCT04734418|Active Comparator|Dexmedetomidine|
9701405|NCT04734249|Experimental|Advanced CRC|Patients with Advanced CRC were given Surufatinib Combined With Chemotherapy
9701406|NCT04734223||Group 1|The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis
9701407|NCT04734223||Group 2|The 2nd group (N=390) was obtained by subtracting the 1st group from all cases.
9701408|NCT04734223||Group 3|The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging
9701409|NCT04734223||Group 4|The 4th group (N=247) was obtained by subtracting the 3rd group from all cases.
9701410|NCT04734236|Active Comparator|New technique group|
9701411|NCT04734236|Sham Comparator|Xpert group|
9701412|NCT04734171|Placebo Comparator|Informational sheet (IS)|participant receives an informational sheet about COVID-19
9701413|NCT04734171|Active Comparator|IS + Video Solo|participants an informational sheet about COVID-19 and a 90 seconds video aimed at sensitizing participants to COVID-19 related stigma
9836126|NCT02770248|Active Comparator|Vehicle|Vehicle, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
10189866|NCT05174793|Experimental|euhydration to dehydration|subjects were dehydrated by 2% with exercise in the heat
10189867|NCT05174741|Active Comparator|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT *3 sets/session*TD Walk (10-15 minutes) * BD
9701414|NCT04734171|Active Comparator|IS + Video Friends|participants an informational sheet about COVID-19 and a 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends.
9701415|NCT04734171|No Intervention|Control|No intervention
9701416|NCT04734262|Experimental|Cohort A|Subjects will receive 70mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
9701417|NCT04734262|Experimental|Cohort B|Subjects will receive 100mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
9701418|NCT04734093||Sohag university recruited patients|
9701419|NCT04734093||Minia university recruited patients|
9701420|NCT04734093||Assuit university recruited patients|
9701421|NCT04734093||Kasr Elini recruited patients|
9701422|NCT04734093||Tanta university recruited patients|
9701423|NCT04734093||Monofia university recruited patients|
9701424|NCT04734093||Aswan university recruited patients|
9701425|NCT04734093||Ain shams university recruited patients|
9701426|NCT04734340|Experimental|EIT-guided group|Treatment based on EIT
9701427|NCT04734340|Placebo Comparator|Control group|Treatment based on ARDS-net Peep setting
9778637|NCT01111539|Experimental|Phase C: Escitalopram Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received escitalopram dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
9778638|NCT01111539|Experimental|Phase C: Aripiprazole Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily for Week 9. Participants were up titrated to the aripiprazole target dose of 12 mg/day at Week 10 (if the initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on the initial 6 mg/day dose), and thereafter received the same dose for up to maximum of Week 14. No dose increases were allowed for aripiprazole after the end of Week 12, however, doses might be decreased at any visit based upon tolerability.
9778639|NCT01111552|Active Comparator|Phase B: Single-blind Prospective Treatment Phase|Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the end of Week 1 based upon tolerability profile, plus one matching placebo capsule, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
9778640|NCT01111552|Active Comparator|Phase B+: Single-blind Phase B Responders|Participants with response at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B plus one matching placebo capsule, for an additional 6 weeks, in Phase B+.
9778641|NCT01111552|Active Comparator|Phase C: Escitalopram Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
9778642|NCT01111552|Active Comparator|Phase C: Aripiprazole Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any week, based upon tolerability.
9778643|NCT01111552|Active Comparator|Phase C: Aripiprazole/Escitalopram Combination Therapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
9778644|NCT01111604|Active Comparator|mFOLFOX-6|mFOLFOX-6
9778645|NCT01111604|Experimental|mFOLFOX-6 + Ramucirumab|mFOLFOX-6 + Ramucirumab
9778646|NCT01111604|Experimental|mFOLFOX-6 + Icrucumab|mFOLFOX-6 + Icrucumab
9778647|NCT01111825|Experimental|Temsirolimus plus Neratinib|This is an open-label, single arm, dose-escalation phase I-II study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma. Patients with trastuzumab-refractory HER2-amplified disease or triple negative disease will be enrolled in both phases of this clinical trial.
10204405|NCT02412735|Placebo Comparator|Placebo|Participants received saline solution as matching-placebo on Day 0 (Visit 2).
9778648|NCT01111838|Experimental|STA-9090|This is an open-label Phase 2 clinical study in patients with advanced colorectal cancer (CRC). Patients will be treated with 200mg/m2 of STA-9090 during a 1-hour intravenous infusion 1 time per week for three consecutive weeks followed by a 1 week dose-free interval. Patients tolerating STA-9090 will be permitted to continue treatment until disease progression.
9778649|NCT01111851|Experimental|Fosaprepitant 150 mg|Fosaprepitant 150 mg
9778650|NCT01111851|Experimental|Aprepitant 165 mg|Aprepitant 165 mg
9778651|NCT01111851|Experimental|Aprepitant 250 mg|Aprepitant 250 mg
9778652|NCT01112059|Placebo Comparator|Placebo|Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
10204406|NCT02371889|Experimental|Topiramate + Medical Management|Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit
9701428|NCT04734132|Experimental|Moringa|Six Moringa oleifera capsules (400 mg dry leaf powder /capsule) consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
9701429|NCT04734132|Placebo Comparator|Placebo|Six placebo capsules containing microcrystalline cellulose consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
9701430|NCT04734327|Experimental|Orthokine periradicular injection|Ultrasound guided injections
10189868|NCT05174741|Experimental|Aerobic Training group|"Supervised Conventional chest physiotherapy+ Aerobic training Conventional chest physiotherapy supervised (1st week) Then non supervised for 2nd to 6th week Warm-up (5 minutes) Breathing exercise and stepping Diaphragmatic Breathing exercise *15 Reps* TD~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day Cool down (5 minutes) AROM +Body stretch"
9701431|NCT04734327|Active Comparator|Orthokine epidural injection|Ultrasound guided injections
9701432|NCT04734405|Experimental|ProF-001 Group|"ProF-001 Group:~• During induction period: app. 5 g of ProF-001 for 6 days (twice daily app. 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of app. 2.5 g of ProF-001 at bedtime and 1 placebo capsule on days 1, 4, and 7 and~• During maintenance period: 2 doses of app. 2.5 g of ProF-001 per week for 22 weeks (total of 44 single doses) and 1 placebo capsule per week for 24 weeks"
9701433|NCT04734405|Active Comparator|Fluconazole Group|"Fluconazole Group:~During induction period:~1 Fluconazole 150 mg capsule on days 1, 4, and 7 and a daily dose of app. 5 g of placebo cream for 6 days (twice daily 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of 2.5 g of placebo cream at bedtime and~During maintenance period:~capsule of fluconazole 150 mg per week for 24 weeks and two doses of 2.5 g of placebo cream per week for 22 weeks (total of 44 single doses)"
9701434|NCT04734067||observational group|Patients receiving ICIs for the first time
9701435|NCT04734392||Cohort A|Historical cohort 2019 + 2020
10189869|NCT05174689|Other|EIA wih house dust mite|Patients with EIA and house-dust mite allergy and an eNO > 30 ppb
9701436|NCT04734392||Cohort B|Prospective study cohort 2020 + 2021 (TAVR implantation according new IFU)
9701437|NCT04734158||Healthy control|
9701438|NCT04734158||Diabetics with macular edema|
9701439|NCT04734158||Diabetics without macular edema|
9701440|NCT04734301|Active Comparator|Group 1: IVES (2 times in a week)|This group included the IVES in addition to all components of the BT. IVES was performed in lithotomy position via electrical stimulation device with a vaginal probe.
9701441|NCT04734301|Experimental|Group 2: IVES (5 times in a week)|This group also included the IVES in addition to all components of the BT as in Group 1. IVES performed in the same way as Group 1, except for frequency of treatment.
9701442|NCT04734054|Experimental|Rapid maxillary expansion|The rapid maxillary expansion will be conducted using bonded modified Hyrax palatal expander. The expander will be activated twice daily (0.4 mm) until an overcorrection of 2-3 mm will be gained.
9701443|NCT04734054|Active Comparator|Slow maxillary expansion|The slow maxillary expansion using a removable plate with a midline screw will be accomplished. The expander will be activated twice weekly until an overcorrection of 2-3 mm will be gained.
9701444|NCT04734353|Experimental|E5 group|Escalation in CHIP
9701445|NCT04734353|Active Comparator|T60 group|Escalation in CHIP
9701446|NCT04734314|Experimental|conventional treatment of back pain|Group A: received conventional treatment of back pain which included; TENS 20 min and hot packs 10 min .The total treatment session is 30 min three session per week for four weeks
9701447|NCT04734314|Experimental|vojta therapy|received conventional treatment of back pain in addition to Vojta therapy . The total treatment session is 40 min.
9701448|NCT04734119||Group A- same anesthesiologist|In Group A patients were evaluated preoperatively and anesthetized by the same anesthesiologist.
9701449|NCT04734119||Group B- different anesthesiologist|In Group B the preoperative assessment and actual anesthesia was performed by two different anesthesiologists
9701450|NCT04734041|Other|Integrative Medicine|Anti-inflammatory (Mediterranean) diet, as well as general behavioral and psychosocial support.
10189870|NCT05174689|Other|EIA without sensitization|Patients with EIA without allergic sensitization and an eNO < 20 ppb
9701451|NCT04733833|Experimental|Arm 1|VB-201 + standard of care
9701452|NCT04733833|Active Comparator|Arm 2|Standard of care
9701453|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and self-injection of 125ml by a volunteer (Arm I):|A volunteer layperson (research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. Then the subject will self-inject a second 125ml of TLE into his/her right anterior thigh.
9701454|NCT04733781|Active Comparator|Subcutaneous injection of 125ml by a physician and 125ml by another volunteer (Arm II):|A volunteer layperson (primary research subject), at least 16 years of age, will first receive 125ml of TLE injected subcutaneously into the left anterior thigh by a physician. The primary research subject will then receive a second 125ml of TLE injected into his/her right anterior thigh by a second adult volunteer who is at least 16 years old and not a medical professional.
9701455|NCT04733781|Active Comparator|Subcutaneous injection of 250ml by a physician into a volunteer (Arm III)|A volunteer layperson (research subject), at least 16 years old, will receive 250ml of TLE injected subcutaneously into the one anterior thigh by a physician.
9701456|NCT04733872|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
9701457|NCT04733872|Experimental|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
9701458|NCT04733690||Healthy Volunteers (Glycemic Index)|The glycemic index (GI) of the common bean product will be assessed in this cohort among 10 study participants. The GI of the product will be assessed on 3 test days over a 120 min period on each study day.
9701459|NCT04733690||Healthy Volunteers(Food Insulin Index)|The food insulin index (FII) of the common bean product will be assessed in this cohort among 10 study participants. This study will recruit 10 participants. The FII of the product will be assessed on 3 test days over a 120 min period on each study day.
9701460|NCT04733690||Type-2 diabetes (T2DM) patients|Glycemic, insulinemic and satiety responses associated with the consumption of the common bean product will be assessed in this cohort among 10 T2DM patients. Participants will attend one study visit lasting approximately 120 min.
9701461|NCT04733885|Experimental|Electrical Stimulation group|ES and lifestyle advice have been applied ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
9701462|NCT04733885|Sham Comparator|Sham Electric Stimulation group|Sham ES and lifestyle advice have been applied Sham ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
9701463|NCT04733716|Active Comparator|Total Knee Arthroplasty with using Tourniquet|A pneumatic tourniquet was used before surgery at the proximal thigh and inflated before the skin incision until skin closure in this group. The tourniquet was inflated to either 275 or 325 mmHg, depending on the patient's systolic blood pressure.
10189871|NCT05174689|Other|Healthy controls|Healthy controls without allergic sensitization or known asthma
10189872|NCT05174676|Experimental|Intervention|The participant will receive 6 therapy sessions of approximately 25 minutes each WITH the application of error enhancement.
10189873|NCT05174676|Sham Comparator|Control|The participant will receive 6 therapy sessions of approximately 25 minutes each WITHOUT the application of error enhancement.
9701464|NCT04733716|Active Comparator|Total Knee Arthroplasty without using Tourniquet|A pneumatic tourniquet was not used in this group during the total knee arthroplasty.
9701465|NCT04733794|Experimental|Surgery for Stoma Reversal|All study participants will receive stoma reversal, complete baseline questionnaire, pelvic floor training and follow up questionnaires
9701466|NCT04733859|Placebo Comparator|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
9701467|NCT04733859|Experimental|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
10204407|NCT02371889|Placebo Comparator|Placebo Pill + Medical Management|Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
9701470|NCT04733755|Experimental|Beauty Image|
9701471|NCT04733755|Placebo Comparator|Placebo Control|
9701472|NCT04733651|Active Comparator|Control arm|In this arm subjects will receive the hospital COVID-19 standard care
9701473|NCT04733651|Experimental|Isoquercetin arm|In this arm subjects will receive the hospital COVID-19 standard care + Isoquercetin
9701474|NCT04733625|Active Comparator|Intervention(Vitamin D therapy|40 patients with diabetes and vitamin D deficinecy that are Covid-19 positive. a single dose of Cholecaciferol will be administered
9701475|NCT04733625|Placebo Comparator|Placebo|16 diabetic patients with vitamin D deficiancy and COVID-19 POSITIVE
9701476|NCT04733365|Experimental|Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
9701477|NCT04733365|No Intervention|Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
9701478|NCT04733261|Active Comparator|Diaphragmatic mobility|The patient will be in supine, supported on one/two pillows under her head, and a bolster under her knees.
9701479|NCT04733261|Experimental|Chest Physiotherapy|Give passive ROM exercise to all joints of the upper and lower extremities.
9701480|NCT04733326|Experimental|Cryothrapy|5 ml Saline at low temperature (2.5°C) will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
9701481|NCT04733326|Experimental|Ketroloc tromethamine|2ml 30 mg Ketroloc tromethamine will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
9701482|NCT04733326|Placebo Comparator|Saline at room temperature|30 ml Saline at room temperature will be used as intra-canal irrigantion during single visit endodontics treatment, to study the effect on reduction of post-operative pain and expression of IL-8.
9701483|NCT04733586|Active Comparator|fascia iliaca group|
9701484|NCT04733586|Active Comparator|quadratus lumborum|
9701485|NCT04733612|Experimental|SMS Group|In addition to traditional treatment received three to four informative SMS messages per week during the 6-month period
9701486|NCT04733612|No Intervention|Control Group|Followed in accordance with the traditional treatment schedule
9701487|NCT04733378|Experimental|Peri-operative neurological monitoring|
9701488|NCT04733963|Experimental|Arm A|Maintenance therapy with Fruquintinib Plus Capecitabine
9701489|NCT04733963|Active Comparator|Arm B|Maintenance therapy with Bevacizumab Plus Capecitabine
9701490|NCT04733521|Experimental|NSCLC|
9701491|NCT04733521|Experimental|BTC|
9701492|NCT04733443|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 /45mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
9701493|NCT04733443|Active Comparator|SeQuent® Please Neo|paclitaxel released coronary balloon catheters Length: 10 / 15 / 20 / 25 / 30 / 35 / 40 mm Diameter: 2.0/2.25/2.5/2.75/3.0/3.5/4.0 mm
9701494|NCT04733508|Experimental|111In-exendin-DTPA|Injection of 111In-exendin-DTPA for subsequent localization of the tracer in excised tissue using autoradiography
9701495|NCT04733508|Experimental|exendin-IRDye800CW|Injection of exendin-4-IRDye800CW for subsequent localization of the tracer in excised tissue using fluorescence microscopy
9701496|NCT04733339||'Traditional' group|10 stroke patients
9701497|NCT04733339||'Technology-supported' group|10 stroke patients
9701498|NCT04733456||IBD Patients (UC and CD)|"Participants will complete a Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, *EQ5D-5L, *GAD-774, *PHQ-975, *PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, *Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy (*questionnaires available through the CIHR IMAGINE grant).~Stool will be collected at baseline and after 16 weeks for assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome (through the International Microbiome Center [IMC], U of C). Blood will be drawn and urine collected at baseline and after 16 weeks for inflammatory markers and metabolomic [IMC] analysis"
9701499|NCT04733482|No Intervention|Control group|Participants in the control group received usual care during adjuvant chemotherapy. The usual care consisted of written information and verbal guidance on the adverse effects of chemotherapy and related psychological reactions.
10189874|NCT05174637|Experimental|FDA018-ADC 2.5mg/kg|Subjects will receive FDA018-ADC 2.5 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
10189875|NCT05174637|Experimental|FDA018-ADC 5.0mg/kg|Subjects will receive FDA018-ADC 5.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
10189876|NCT05174637|Experimental|FDA018-ADC 7.5mg/kg|Subjects will receive FDA018-ADC 7.5 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
9701500|NCT04733482|Experimental|Cosmetic care group|Participants in the intervention group received cosmetic care in combination with usual care. The cosmetic care was a 3-hour, free-of-charge beauty activity, including face moisturizing steps, make-up, wigs, and breast prostheses wearing. It was provided by professional cosmeticians at a cosmetic training base before the patients finished half of their chemotherapy cycle.
9701501|NCT04733248|Active Comparator|Kinesiotaping group|Hot pack, Tens, stretching exercises, Kinesiotaping (I-O) and Home plan
10189877|NCT05174637|Experimental|FDA018-ADC 10.0mg/kg|Subjects will receive FDA018-ADC 10.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
10189878|NCT05174637|Experimental|FDA018-ADC 12.0mg/kg|Subjects will receive FDA018-ADC 12.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
9701502|NCT04733248|Experimental|stretching group|Hot pack, Tens, stretching exercises and Home plan
10189879|NCT05174637|Experimental|FDA018-ADC15.0mg/kg|Subjects will receive FDA018-ADC 15.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
9701503|NCT04733469|Experimental|Multimedia Psychoeducational Intervention + Enhanced Usual Care|Intervention participants receive the Multimedia Psychoeducational Intervention in addition to Enhanced Usual Care
9701504|NCT04733469|Other|Enhanced Usual Care|Control participants receive Enhanced Usual Care
9701505|NCT04733352|Experimental|proximal acupoints of knees|GB34, SP9, and EX-LE2
9701506|NCT04733352|Experimental|distal acupoints of knees|LI11, HT3, and TE10
9701507|NCT04733300|Experimental|Mindfulness-Based College - Standard Dose|MBC standard dose is a 9-week, 9 session program providing systematic and intensive training in mindfulness meditation practices. The curriculum is grounded in the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum. MBSR was adapted to the young adult life stage by: (1) Training mindfulness skills such as attention control, self-awareness and emotion regulation, using the MBSR curriculum, and (2) applying these skills to the health behaviors and priorities most relevant to young adults. Specific behaviors and priorities targeted are social relationships, sleep, stress, diet, physical activity, obesity, alcohol consumption, substance use, digital media use, and performance (e.g. athletic, artistic and academic). The intervention is administered live, online via a video conferencing platform. The standard dose class meets once a week for 2.5 hours for 9 weeks. There is also an all-day retreat that takes place around week 6 of the program.
9701508|NCT04733300|Experimental|Mindfulness-Based College - Low Dose|The MBC low-dose program is mirrored after the standard MBC program (described previously); however, instead of meeting for 2.5 hours each week, the low-dose MBC program is abbreviated to meet for 1.5 hours each week for the 9 weeks. MBC low-dose will be administered live, online via the free video conferencing platform, Zoom.
9701509|NCT04733300|Active Comparator|Health education control group|Those randomized to the health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
9701510|NCT04733313|Active Comparator|quadratus lumborum-2|
9701511|NCT04733313|Active Comparator|quadratus lumborum-3|
9701512|NCT04733235||with endometrial compaction|Participants who have endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
10189880|NCT05174637|Experimental|FDA018-ADC 18.0mg/kg|Subjects will receive FDA018-ADC 18.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
10189881|NCT05173441|Experimental|High Dose Group|Standard of care (SOC)+high dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
10204408|NCT02344420|Other|Single Arm|As it is not a randomize trial there is only one study arm. Described interventions as echocariography, six minute walk test, Quality of Life test or self assessment score should be done in all patients.
10189882|NCT05173441|Experimental|Low Dose Group|Standard of care (SOC)+low dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
9701513|NCT04733235||without endometrial compaction|Participants who have not endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
9701514|NCT04733287|Experimental|Effect of High Intensity Interval Training|"Young and older subjects will participate in single-leg, high-intensity interval training of the right knee extensors (4 intervals of 4 minutes at 80% of max aerobic power with 4 minute rest intervals between, 3x per week for 6 weeks).~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
9701515|NCT04733287|Experimental|Effect of Muscle Heat Therapy|"Young and older subjects will participate in single-leg,heat therapy training of a single leg ( quadriceps femoris, 120 minutes of shortwave diathermy to raise the muscle temperature to ~39C) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
9701516|NCT04733287|Sham Comparator|Effect of Sham Muscle Heat Therapy|"Young and older subjects will participate in a sham treatment of single-leg,heat therapy training of the right knee extensors (120 minutes with shortwave diathermy unit positioned on leg, but not turned on) 3 times a week for 6 weeks.~Muscle function and knee extensor critical power will be measured before and after the 6 weeks of treatment."
9701517|NCT04733287|Sham Comparator|Effect of Immobilization with Daily Sham Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of a sham heat therapy treatment each day. For the sham treatment, the heating device will be applied to the limb, but, unbeknownst to the participant, it will not be turned on.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
9701518|NCT04733287|Experimental|Effect of Immobilization with Daily Heat Therapy|"Young subjects (18-35 years) will undergo 2 weeks of leg immobilization while receiving 2 hours of heat therapy treatment each day. Heat therapy will consist of 120 minutes of shortwave diathermy to raise the quadriceps femoris muscle temperature to ~39C.~Muscle function and knee extensor critical power will be measured before and after the 2 weeks of leg immobilization."
9701519|NCT04733131||converted to a belatacept based immunosuppression|Belatacept: infusion on Days 1, 15, 29, 43, 57 then every 28 days. All patients received a background maintenance immunosuppressive regimen of mycophenolate mofetil or mycophenolic acid, with adjunctive corticosteroids, according to their immunosuppressive regimen at the time of enrollment.
9701520|NCT04733066||Non-treatment Group|"Quality of life assessment (SBS-QoL, SF- 36)~Nutrition status assessment (BIA, BMI)~Assessment of functional absorptive small bowel length (citrulline)~Clinical data (nutritional program, stool characteristics)"
9701521|NCT04733066||Teduglutide-treated Group|"Quality of life assessment (SBS-QoL, SF- 36)~Nutrition status assessment (BIA, BMI)~Assessment of functional absorptive small bowel length (citrulline)~Clinical data (nutritional program, stool characteristics)"
9701522|NCT04733573|Active Comparator|Occlusal appliance by Okeson with canone guidance|Occlusal appliance will be used while sleeping for 30 days.
9701523|NCT04733573|Active Comparator|Bimaxillary splint without canine guidance|Bimaxillary splint will be used while sleeping for 30 days.
9701524|NCT04733820|Experimental|Adjuvant chemotherapy group|"Participant will receive at least 2 cycles of adjuvant chemotherapy. If having any of the following factors, participant will receive additional 2 cycles of adjuvant chemotherapy per risk factor. All patients received maximum 6 cycles of postoperative chemotherapy.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 4cm before surgery."
9701525|NCT04733820|No Intervention|Control group|The participants receive no intervention.
9701526|NCT04733001|Experimental|HSG4112 Treatment Arm: Fasted|Single oral dosing of HSG4112 480 mg under fasted conditions
9701527|NCT04733001|Experimental|HSG4112 Treatment Arm: Low-Calorie Diet|Single oral dosing of HSG4112 480 mg under low-calorie (400-500 kcal with 100-125 kcal fat) diet conditions
9701528|NCT04733001|Experimental|HSG4112 Treatment Arm: High-Calorie Diet|Single oral dosing of HSG4112 480 mg under high-calorie (800-1000 kcal with 500-600 kcal fat) diet conditions
9701529|NCT04732936|Experimental|Device Usability|Device usability and safety will be evaluated.
9701530|NCT04732936|Experimental|Preliminary Efficacy|Preliminary treatment efficacy will be evaluated.
10189883|NCT05173441|Placebo Comparator|Control Group|Standard of care (SOC)+placebo (0.9% sodium chloride). Placebo will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
10189884|NCT05172492|Experimental|Endocare|
10189885|NCT05172492|Active Comparator|Digital control|
10189886|NCT05170919|Experimental|Olanzapine|
10189887|NCT05170919|Experimental|Mirtazapine|
10189888|NCT05170425||Cohort 1|
10189889|NCT05170425||Cohort 2|
10189890|NCT05170386|Experimental|study group|receive cognitive training combined with instructive conventional treatment for sleeping disorder
10189891|NCT05170386|Experimental|control group|receive instructive conventional treatment for sleeping disorder
10189892|NCT05167305||liver disease without COVID-19 infection-April-May 2019|
10189893|NCT05167305||liver disease without COVID-19 infection -April- May 2021|
10205421|NCT01413100|Experimental|Treatment (HDIT autologous PBSCT)|"STEM CELL MOBILIZATION AND PREPARATION: Patients receive filgrastim SC on mobilization days 1-4 followed by apheresis until a target dose of CD34+ cells >= 2.5 x 10^6/kg are collected. Patients difficult to mobilize with filgrastim alone receive cyclophosphamide IV or *plerixafor SC on mobilization days 1-2 and filgrastim SC on mobilization days 5-7.~HDIT CONDITIONING: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days -5 to -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5.~TRANSPLANTATION: Patients undergo autologous PBSCT on day 0.~MAINTENANCE THERAPY: Beginning 2-3 months after transplant, patients receive mycophenolate mofetil PO BID for 2 years."
10189894|NCT05166252|Experimental|Experimental group|"Installation of the study app.~At the beginning of the meal, participants press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and participants need to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the participants are instructed to take a picture with their smartphone from the meal table.~A time out from the smartphone starts, meaning that all functions of the phone are locked. The time-out is over as soon as the participant presses the stop button.~A short questionnaire about the meal is sent via App to the participating family member when the smartphone is used again.~During the whole period of the study the App tracks the smartphone behavior (i.e., frequency and duration of smartphone use and the specific applications used). Active comparator: control group"
10189895|NCT05166252|Active Comparator|Control group|Control points in time include all parts as in the experimental group except for number 3.
9701531|NCT04732923|Experimental|Experimental arm|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks~STEP 2 : monitoring at 6 months after cardiac rehabilitation program~STEP 3 : monitoring at one year after cardiac rehabilitation program"
9701532|NCT04732884|Experimental|Weight sensor with biofeedback|Activation of the feedback function of the weight-bearing sensor as mean to possibly enhance compliance to weight-bearing instructions postoperative.
9701533|NCT04732884|Experimental|Weight sensor without biofeedback|Standard patient education considering postoperative weight-bearing parameters and measurement of actual weight-bearing with the sensor.
9701534|NCT04733027|Experimental|Arm A: PEP010 as single agent|In arm A, the dose escalation phase will use accelerated titration design (ATD) for the first 4 dose levels (0.15, 0.3, 0.6, 1.2 mg/kg), followed by 3+3 design
9701535|NCT04733027|Experimental|Arm B: PEP010 in combination with paclitaxel.|In arm B, the dose escalation phase will begin with DL4 (1.2 mg/kg) and will follow a 3+3 design
9701536|NCT04733209|Experimental|Mobilization with movement|"Mobilization with movement technique and traditional physiotherapy were applied to the intervention group. For mobilization with movement technique, the patient was asked to actively flex and extend the wrist with the forearm in neutral in a sitting position on a treatment table, and the pain was asked. The painful side was determined according to the patient's statement.~In a patient whose painful side was flexion, the wrist joint was shifted manually (with the help of the web space of both hands of the therapist) to the lateral and medial at the same time while the patient actively flexed the wrist. The treatment was done 3 times a week for 4 weeks."
9701537|NCT04733209|Active Comparator|Conventional|Traditional physiotherapy techniques were applied to the intervention group. Conventional TENS type was used. Current transition time was set as 50-100 µs. TENS application is performed at a frequency of 100 Hertz for 20 minutes in amplitude that does not cause muscle contraction in the patient and creates a feeling of numbness and tingling. Continuous ultrasound type was applied with full contact technique. Ultrasound treatment was applied over the transverse carpal ligament in the wrist with circular movements towards the proximal and distal at a speed of 1-2.5 cm per second, at a dose of 1 W / cm2, for 6 minutes, with a frequency of 3 MHz. And; tendon-nerve gliding exercises, night splint, stretching and strengthening exercises applied. The treatment was done 3 times a week for 4 weeks.
9701538|NCT04732897|No Intervention|Control arm|wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)
9701539|NCT04732897|Experimental|Interventional arm|wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint
9701540|NCT04733092|Experimental|Embolization|Embolization of the inflammatory hypervascularization with a lipiodol emulsion
9701541|NCT04733196|Experimental|Essential oils|Mouthwash based on essential oils - menthol, eucalypts oil, thymol, alcohol
9701542|NCT04733196|Experimental|Essential oils in combination with clorhexidine 0,12%|Mouthwash based on essential oils - mentol, eucalypt oil, thymol, alcohol, and 0,12% chlorhexidine
9701543|NCT04733196|Placebo Comparator|Placebo mouthwash|Water, colorant, sweetener
10189896|NCT05160142|Experimental|Intervention|Participate in the DICE program, which entails culinary and diabetes educational programming delivered weekly for 10 consecutive weeks.
10189897|NCT05158855|Experimental|neutralizing antibody booster for vaccinated participants|participants after 6-month vaccinated with COVID-19 vaccine received 1 capsule of B. subtilis spore extract
10189898|NCT05157724||PLASMA|This technique consists of an endoscopic intervention, through the natural route (urethra).
10189899|NCT05157724||HOLEP|"This is a recent and difficult technique of endoscopic prostate enucleation, requiring a greater learning curve for the operators compared to PLASMA. The principle remains the same technically as the PLASMA procedure, the energy used is not electrical energy, but a laser.~Once the adenoma has been enucleated, it can only be removed by a morcellator (additional material) which can lead to complications such as bladder perforation. This is a blade that rotates in a tube that has to cut the adenoma once it has been freed from the prostate when it is in the bladder and it can happen that this blade catches on the bladder wall and causes a bladder wound or even a perforation."
10189900|NCT05156684|Experimental|placebo group|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
10189901|NCT05156684|Experimental|pentoxifylline group|Intervention group 1: received pentoxifylline (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)
10189902|NCT05156684|Experimental|Zinc group|Intervention group 2: received zinc ( Zinc Sulfate 220mg Capsules,One time daily)
10189903|NCT05156684|Experimental|pentoxifylline+ zinc group|Intervention group 3: received pentoxifylline+ zinc (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily + Zinc Sulfate 220mg Capsules,One time daily )
10189904|NCT05156034|Experimental|SRK-001- Dose 1|Participants will receive intravenous (IV) SRK-001 every 2 weeks (Q2W) for 4 doses.
10189905|NCT05156034|Experimental|SRK-001- Dose 2|Participants will receive IV SRK-001 every 4 weeks (Q4W) for 2 doses.
10189906|NCT05156034|Experimental|SRK-001- Dose 3|Participants will receive IV SRK-001 Q2W for 4 doses.
10189907|NCT05156034|Placebo Comparator|Placebo|Participants will receive IV placebo Q2W for 4 doses or Q4W for 2 doses.
10189908|NCT05155540|Active Comparator|Direct mechanical thrombectomy|Direct mechanical thrombectomy performed within 4.5 of stroke onset without giving intravenous recombinant tissue plasminogen activator.
9701544|NCT04733196|Experimental|Clorhexidine 0,20% in combination with aroma oils|Mouthwash based on 0,20% chorhexidine without alcohol in combination with aroma oils of rose and lavender
9701545|NCT04733196|Experimental|Prebiotic|Mouthwash based on prebiotic
9701546|NCT04733196|Experimental|Hydrogen peroxide|Mouthwash based on 0,8% hydrogen peroxide in combination with menthol and eucalypts oil
9701547|NCT04732741||Oral Cancer|patients diagnosed clinically and histopathologically with oral cancer who have yet to receive any treatment.
10189909|NCT05155540|Active Comparator|Bridging therapy|Mechanical thrombectomy performed within 4.5 of stroke onset after giving intravenous recombinant tissue plasminogen activator at a dose of 0.9 mg/Kg
10189910|NCT05155384|Experimental|biopsychosocial model-based treatment|Biopsychosocial model-based management will be applied including pain neuroscience education, functional exercises, and relaxation training.
9701548|NCT04732741||Premalignant lesions|patients diagnosed clinically and histopathologically with oral potentially malignant lesions who have not yet to receive treatment or had a month wash-out period from any previous treatment.
10189911|NCT05155384|Active Comparator|Conventional physiotherapy|Conventional physiotherapy will be applied including standard exercises and electrical stimulation.
10189912|NCT05154864||SBUF-SMUF|All patients underwent standard of care cardiac surgery, cardiopulmonary bypass and SBUF-SMUF with effluent removal of 30 ml/kg/hr and physiologic solution replacement of 25ml/kg/hr.
10189913|NCT05154526|Experimental|Exercise Group|Exercise Program only
10189914|NCT05154526|Active Comparator|Manual Therapy Group|Manual Therapy only
9701549|NCT04732741||Control Group|healthy individuals who will be examined clinically through conventional visual and tactile examination to ensure no oral lesions are present and through thorough medical history
9701550|NCT04732754|Placebo Comparator|Control Group (CG)|This group will receive placebo capsules to be consumed for 8 weeks daily and will not exercise;
9701551|NCT04732754|Active Comparator|Aerobic Exercise (AE)|This group will receive placebo capsules and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
9701552|NCT04732754|Experimental|Aerobic exercise + Theobroma cocoa (AETC)|This group will receive 500mg cocoa capsules to be consumed daily and will perform 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% VO2peak) for 8 weeks
9701553|NCT04732754|Experimental|Theobroma cocoa (TC)|This group will receive 500mg cocoa capsules to be consumed daily for 8 weeks.
9701554|NCT04732819|No Intervention|Usual care|Facilities in the 'usual care' arm will be offered electronic messaging and education regarding the COVID-19 vaccine. This material stems from the Centers for Disease Control and Prevention (CDC) and AMDA - The Society for Post-Acute and Long-Term Care Medicine (AMDA) resources and represents a suggested approach to reduce vaccine hesitancy in staff and residents/proxies (e.g., legally authorized representatives, powers of attorney). This electronic quality improvement (QI) material will be developed as part of a QI initiative and disseminated by the American Health Care Association (AHCA) to the SNF chains and using social media.
9701555|NCT04732819|Experimental|High touch|Facilities in the 'high touch' arm will receive the same electronic messaging and educational material as in the 'usual care' arm but will receive an additional high touch multi-pronged behavioral intervention.
9701556|NCT04732390|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
9701557|NCT04732390|Active Comparator|Group (M)|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5. .
9701558|NCT04732377|Placebo Comparator|GROUP(A) (CONTROL GROUP)|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
9701559|NCT04732377|Active Comparator|Group (D)|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
9701560|NCT04732403|No Intervention|0 degree supine position|Surgical bed will be set to a 0 degree supine position
9701561|NCT04732403|Experimental|10-20 degree angle in reverse Trendelenburg|Surgical bed will be set to a 10-20 degree angle in reverse Trendelenburg
9701562|NCT04732455|Placebo Comparator|Group Control (C)|20 adult breast cancer patients on Taxane chemo protocol will receive 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
9701563|NCT04732455|Experimental|Group lidocaine infusion (L)|20 adult breast cancer patients on Taxane chemo protocol will receive lidocaine i.v infusion (2 mg/kg) in 200ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy lidocaine (2 mg/kg) re-infused after each session. If lidocaine side effects such as circumoral numbness, twitches, metal test, tachy or bradycardia recorded at any time, lidocaine infusion will be reduced to 1mg/kg, if side effects persist, the patients will be managed accordingly as well as lidocaine infusion will be stopped and patient will be excluded from the study.
9701564|NCT04732455|Experimental|Group duloxetine (D)|20 adult breast cancer patients on chemotherapy will take oral duloxetine tablet 30 mg once per day starting from the night pre chemotherapy session until the end of cycle. If any selected patient reported neuropathic pain (DN4 > 4) during the course of chemotherapy the duloxetine dose will be adjusted to 60 mg daily till the end of the cycle. They also will receive 200 ml normal saline over forty minutes before each chemotherapy session until end of the cycle.
9701565|NCT04732611|Experimental|Pilates|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
9701566|NCT04732611|Active Comparator|Walking|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks
10189915|NCT05154526|Active Comparator|Manual Therapy and Exercise Group|Manual Therapy + exercise program
10189916|NCT05153850||Cases|Patients diagnosed with inflammatory bowel disease with the complete vaccination regimen.
10189917|NCT05153642|Experimental|Microsurgical intervention|Microsurgical intervention will be used for treatment of acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment
9701567|NCT04732585|Experimental|Patient with PFPS or ACL injury|Physiotherapy intervention Surgical intervention
10189918|NCT05153642|No Intervention|Standard treatment|Acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment - intravenous thrombolysis and/or mechanical thrombectomy
10189919|NCT05153096|Experimental|Experimental: solid tumors|"Dose-escalation stage: Patients will receive NBL-015 once every two or three weeks, starting at a dose of 1 mg/kg.~Cohort-expansion stage: Patients will receive NBL-015 at selected dose as per the results of dose-escalation stage."
9701568|NCT04732585|No Intervention|Healthy control group|The healthy control group will not do any intervention
9701569|NCT04732351||Active sentry|Cataract procedures conducted with the active Sentry handpiece
9701570|NCT04732351||Non-active sentry|Cataract procedures conducted with an handpiece different from the Active Sentry Handpiece
10189920|NCT05151380|Other|Women with CO2 laser MonaLisa Touch ® sessions|Women with 3 sessions of CO2 laser MonaLisa Touch ®
10189921|NCT05149781||patients with EH|patients with endocrine hypertension
9701571|NCT04732533|Experimental|tDCS|Active transcranial direct current stimulation (tDCS) will be administered with the goal of facilitating the excitability of the left dorsolateral prefrontal cortex (dlPFC). Electrode placement and current parameters for each electrode have been optimized using a standard brain with the goal of generating an average electric field of 0.25 V/m67 within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
9701572|NCT04732442|Experimental|Immuno-group|The immuno-group will consist of patients who, as part of preoperative nutritional support, used immunonutrition ONS (2x Impact Oral® Nestle, Switzerland per day) for 2 weeks before surgery.
9701573|NCT04732442|Sham Comparator|Control-group|The control group will consist of patients who, as part of preoperative nutritional support, used standard ONS (3x Fortimel Compact Protein® Nutricia, United Kingdom per day) for 2 weeks before surgery.
9701574|NCT04732299||Acute thrombus group|Within 14 days after onset
9701575|NCT04732299||Subacute thrombus group|During 15-30 days after onset
10189922|NCT05149781||patients with PH|patients with primary hypertension
10189923|NCT05148637|Active Comparator|Group I|anesthesia maintained by sevoflurane
9701576|NCT04732299||Chronic thrombosis group|More than 15-30 days after onset
9701577|NCT04732468|Experimental|Cohort 1- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 1, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Suspension for injection) again on day 22 (boost).
9701578|NCT04732468|Experimental|Cohort 2- hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+ N-ETSD (Oral capsule)|For subjects in cohort 2, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-S-Fusion+N-ETSD (Oral capsule) on day 22 (boost).
9701579|NCT04732468|Experimental|Cohort 3 - hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 3, hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on days 1 (prime) and on day 22 (boost).
9701580|NCT04732468|Experimental|Cohort 4 - hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule)|For subjects in cohort 4, hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) will be administered on day 1 (prime) and hAd5-SFusion+N-ETSD (Oral capsule) will be administered on days 15 (boost) and 22 (boost).
9701581|NCT04732637||COVID Positive|Individuals who have recently tested positive for COVID19 by RTPCR, with active infection.
10189924|NCT05148637|Active Comparator|Group II|anesthesia maintained by desflurane
10189925|NCT05148637|Active Comparator|Group III|anesthesia maintained by TIVA
10189926|NCT05148091|Experimental|18~59 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18~59 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
10189927|NCT05148091|Placebo Comparator|18~59 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of study adjuvant (SCT-VA02B ,0.5mL) on Day 0 and Day 28
10189928|NCT05148091|Placebo Comparator|18~59 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
10189929|NCT05148091|Experimental|≥60 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
10189930|NCT05148091|Placebo Comparator|≥60 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
10189931|NCT05148091|Placebo Comparator|≥60 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
10189932|NCT05148091|Experimental|18~59 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18~59 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
10189933|NCT05148091|Placebo Comparator|18~59 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
10189934|NCT05148091|Placebo Comparator|18~59 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
10189935|NCT05148091|Experimental|≥60 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
10205422|NCT01286038|Experimental|Eltrombopag Treatment|Phase I: Dose Escalation
10189936|NCT05148091|Placebo Comparator|≥60 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
10189937|NCT05148091|Placebo Comparator|≥60 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
10189938|NCT05147558|Experimental|Pembrolizumab With Lenvatinib|Lenvatinib (20mg once daily orally) in combination with Pembrolizumab (200mg every 3 weeks, intravenously)
10189939|NCT05147116|Experimental|Hypoxia - 15% O2|Participants will sleep in a tent for 10 nights.
9701582|NCT04732637||COVID Negative|Individuals who have recently tested negative for COVID19 by RTPCR.
9701583|NCT04732572|Experimental|Adenotonsillectomy|Within 1 to 4 weeks (30 days) of randomization, participants randomized to the adenotonsillectomy arm will undergo surgery under general anesthesia, as occurs as part of routine standard of care.
9701584|NCT04732572|Active Comparator|Watchful waiting with supportive care|Within 1 to 4 weeks after the 7-month visit, participants in the Arm 2 group will be referred for re-evaluation of surgical candidacy. Symptoms and polysomnographic findings (baseline and month 7) will be reviewed by the ENT and a decision whether to proceed with adenotonsillectomy as part of routine clinical care will be made.
9701585|NCT04732364|Placebo Comparator|Group (C) (control group):|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
9701586|NCT04732364|Active Comparator|Group (D) (Dexmetonidine group):|Patient will receive 20ml 0.25% levobupivacaine + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5..
10189940|NCT05147116|Sham Comparator|Sham - room air 21% 02|Participants will sleep in a tent for 10 nights.
10189941|NCT05146596|Experimental|LLLT group|use low level light therapy,The Dr.Tai's energy cap
9701587|NCT04732364|Active Comparator|Group (M) (magnesium slphate group):|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5..
10189942|NCT05146596|No Intervention|control group|routine care.
10189943|NCT05146440|Experimental|PM14 in monotherapy and in combination with radiotherapy in STS and other solid tumors|"Cohort A : Phase I. PM14 24-h IV 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort B: Phase I. PM14 3-h IV infusion 3 d 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort E: PM14 at RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort F: PM14 at the RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort C: Phase I: PM14 at the RP2D, 21-d cycles in combination with radiotherapy, up to PD or toxicity. Dexamethasone recommended. Radiation therapy 3Gy/f 10 d. Phase II: PM14 at RP2D with radiation therapy.~Cohort D: Phase I: PM14 at the RP2D, 3 x 21-d cycles in neoadjuvant setting, in combination with radiotherapy. Dexamethasone recommended. Radiation therapy 1.8Gy/f 25 d. Phase II: PM14 at RP2D with radiation therapy."
9701588|NCT04732598|Active Comparator|Arm A|
9701589|NCT04732598|Experimental|Arm B|
9701590|NCT04732507|Active Comparator|One to two needle passes|Receive 1-2 needle passes for needling at each trigger point
10189944|NCT05145686|Experimental|Comparing MMP-2, -8, -9 in reversible and irreversible pulpitis|The coronal pulp samples from both reversible and irreversible groups were placed in an eppendorf tube containing TriPure Reagent transport medium. The MMP-2, -8 and -9 expression levels were determined with specific primers by real time polymerase chain reaction method (RT-PCR).
9701591|NCT04732507|Active Comparator|Ten needle passes|Receive 10 needle passes for needling at each trigger point
9701592|NCT04732507|Active Comparator|Twenty needle passes|Receive 20 needle passes for needling at each trigger point
9701593|NCT04732325|Experimental|Burst / kHz / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
9701594|NCT04732325|Experimental|Burst / Sham / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
9701595|NCT04732325|Experimental|kHz / Sham / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
9701596|NCT04732325|Experimental|kHz / Burst / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
9701597|NCT04732325|Experimental|Sham / Burst / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
9701598|NCT04732325|Experimental|Sham / kHz / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
9778653|NCT01112059|Active Comparator|doxycycline|Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation
10189945|NCT05145686|Active Comparator|Comparing the clinical success of MTA and Biodientine in primary molar pulpotomy treatments|In reversible pulpitis group MTA (ProRoot MTA,white) was used in 21 teeth and Biodentine was used in the other 21 teeth for pulpotomy treatments. Final restorations were performed with stainless steel crowns in both group. At the end of 3, 6 and 9 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption.
10189946|NCT05145530|Active Comparator|Group C|selective anterior cervical discectomy and fusion (ACDF)
9778654|NCT01112228||Obese patients|Obese patients for Bariatric surgery
9701599|NCT04732338|Experimental|Study arm - Osteopathic Manipulative Therapy|"Standard of care including physical therapy, occupational therapy and over the counter medication AND OMT as described below:~Musculoskeletal examination of the cervical spine. Testing will be comprised of :~Range of motion testing involving cervical rotation, lateral side bending, flexion and extension.~Muscular palpation of the cervical paraspinals for hypertonicity of the muscles and/or tenderness.~Patient placed supine on the examination table.~Treatment sessions lasting 5-10 minutes each. OMT techniques: cervical muscle energy, myofascial release of the cervical paraspinals and a suboccipital release.~Assessment with Headache Impact Test (HIT-6) at baseline and follow-up visit and change in pain scores between baseline and post treatment."
9701600|NCT04732338|No Intervention|Control - Standard of care|Standard of care including physical therapy, occupational therapy and over the counter medication.
9701601|NCT04732169|Active Comparator|Epidiolex (cannabidiol) (CBD)|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
9701602|NCT04732169|Placebo Comparator|Placebo|During the first week after randomization, participants will receive 125mg of Epidiolex (CBD) or matching placebo taken twice daily (250mg/day). During the second week after randomization, the dosage will be increased to 250mg of Epidiolex or placebo taken twice daily (500mg/day) for one week. During the third week after randomization, the dosage will be increased to 500mg of Epidiolex (CBD) or matching placebo taken twice daily (1000mg/day). Participants will remain on 1000mg/day of Epidiolex (CBD) or matching placebo for four more weeks, at which point they will be stepped down to 500mg/day of Epidiolex (CBD) or placebo for one week, followed by 250mg/day of Epidiolex (CBD) or placebo for one week.
9701603|NCT04732026||Cases|150 infants with invasive serotype III GBS disease (isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
9701604|NCT04732026||Controls|450 infants exposed to serotype III GBS at birth - but who do not develop invasive GBS disease in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
9701605|NCT04732039|Experimental|LVAD recipients|Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients
9701606|NCT04732039|Experimental|Healthy controls|Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls.
9701607|NCT04732130|Active Comparator|Time-Restricted Feeding|Participants in the time-restricted feeding are instructed to eat ad libitum from 12:00 to 20:00 daily, and fast from 20:00 to 12:00 daily for 4 weeks.
9701608|NCT04732130|Active Comparator|Alternate Day Fasting|Participants in the alternate day fasting group are instructed to eat every second day ad libitum, but to abstain from calorie intake on fast days (100 % restriction) for 4 weeks.
9701609|NCT04732130|No Intervention|Control|Participants in the control group are instructed to maintain their habitual diet regimen.
9701610|NCT04732091||Subproject 1 - acute STEMI|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure until complete a total of 50 minutes.
9778655|NCT01112241|Experimental|albuterol-tiotropium|At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide [Spiriva®] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).
10189947|NCT05145530|Experimental|Group SNRB|US-guided selective nerve root block (SNRB) then selective anterior cervical discectomy and fusion (ACDF)
10189948|NCT05144620|Experimental|Preoperative Imaging|
10189949|NCT05144178||Mild and moderated COVID -19 patient treated out side the hospital sitting|Reviewing files of such group that had been received Sotrovimab
10189950|NCT05144061|Experimental|Single Arm|HRS2398 Tablets
10189951|NCT05143775|Experimental|new surgical plan group|The investigators use a monopolar stimulator to determine and retain the tumor margin within 5mm in the sensitive area which is posterior superior longitudinal fasciculus or posterior arcuate fasciculus.
10189952|NCT05143775|Active Comparator|traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified, those points would be retained to avoiding language function impairment after the tumor resection.
10189953|NCT05142761||Posterior component separation|Patients undergoing posterior component separation
10189954|NCT05142644||Early / growth restriction|Intrauterine growth restriction with onset before 32 weeks of gestation
10189955|NCT05142644||Late growth restriction|Intrauterine growth restriction with onset after 32 weeks of gestation
10189956|NCT05141227|Experimental|two stage ORIF|Two-stage Open reduction and internal fixation
10189957|NCT05141227|Experimental|single stage Ex. Fix|Single-stage external fixation with minimal internal fixation if needed
10189958|NCT05140837||cross-sectional study|
10189959|NCT05140837||real-world cohort study|
10189960|NCT05140252|Experimental|Breast cancer decision aid|Participants receive a breast cancer decision aid.
10205423|NCT01178814|Experimental|Revlimid|Revlimid (Lenalidomide) capsule taken orally once a day
10205424|NCT01125176|Experimental|All subjects|In Cycle -1, even numbered patients will receive oral lenalidomide daily on days 1-14 and then no treatment on days 15-28. In Cycle -1, odd numbered patients will receive oral thalidomide daily days 1-14 followed by no treatment on days 15-28. Starting with cycle 1, all patients will alternate daily thalidomide (every odd day) with daily lenalidomide (every even day) for days 1-28. Rituximab will be given on days 1, 8, 15, and 22 starting with Cycle 1, and then again every 6th cycle thereafter (cycles 7, 13, 19, etc.)
10189961|NCT05137665||Amyotrophic Lateral Sclerosis ALS|Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
10189962|NCT05137665||Healthy|Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
9701611|NCT04732091||Subproject 2 - acute STEMI initially treated with fibrinolytic|Participants with acute STEMI initially treated with fibrinolytic therapy within 12 hours will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI; High MI will continue after PCI procedure until complete a total of 50 minutes.
10189963|NCT05135988||Children in vital distress|
10189964|NCT05135988||Health care givers|Experts in vital distress care Non experts in vital distress care
10189965|NCT05133310|No Intervention|Standard Care Group|Patients will receive the standard chemotherapy regimen assigned for their treatment and, they will be followed and monitored until the end of treatment and hospitalization.
10189966|NCT05133310|Experimental|Simvastatin Treatment Group|Patients will combine the standard CALGB treatment scheme plus Simvastatin 10mg orally every 24 hours during the first 7 days of treatment and then continue with 20mg every 24 hours until the end of treatment and hospitalization.
9701612|NCT04732091||Subproject 3 - NSTEMI|Participants with NSTEMI or with high-risk unstable angina will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
9701613|NCT04732091||Subproject 4 - No reflow|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2 MI) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
9701614|NCT04732091||Subproject 6 - Pre-hospital care (ambulance)|Participants with acute STEMI routing from the ambulance to the emergency department will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
9701615|NCT04732247|Experimental|Oxytocin nasal spray|4x per day (QID) intranasal treatment with oxytocin (48 IU per dose)
9701616|NCT04732247|Placebo Comparator|Placebo nasal spray|4x per day (QID) intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
9701617|NCT04731987|Experimental|Orange juice (A)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of orange juice naturally rich in hesperidin (drink A) during 6 weeks
9701618|NCT04731987|Placebo Comparator|Control beverage (B)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (drink B)- a soft drink with sugar concentration identical to drink A - during 6 weeks
9701619|NCT04731987|Experimental|Control beverage supplemented with hesperidin formulation (B+HESP)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (identical to drink B but supplemented with hesperidin to reach level of drink A) during 6 weeks
9778656|NCT01112267|Experimental|Tramadol Hydrochloride (HCl)/acetaminophen|Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
9778657|NCT01112267|Placebo Comparator|Placebo|Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
9778658|NCT01112293|Experimental|Investigational drug infusion-for safety and effectiveness|Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment
10189967|NCT05129982|Experimental|Intervention|The reflex response will be recorded during whole-body vibration.
10189968|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Doses TBD|Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels
10189969|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300|LYT-300, Dose TBD with and without food, separated by 7-day washout
10189970|NCT05129865|Experimental|LYT-300, Dose TBD QAM every 24 h for 7 days|
10189971|NCT05129865|Placebo Comparator|Placebo QAM every 24 h for 7 days|
9701620|NCT04731961|Active Comparator|Controls|Subjects in this arm will be administered the standard injection site protocol (15 sites).
9701621|NCT04731961|Experimental|Experimental|Subjects in this arm will be administered the same amount of Botox in 5 injection sites.
10189972|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Dose TBD QAM or QHS every 24 h for 7 days|Subjects will crossover across 2 dosing periods in which they will receive LYT-300 Dose TBD QAM or QHS every 24 h for 7 days
10189973|NCT05129865|Placebo Comparator|Placebo QAM or QHS every 24 h for 7 days|Subjects will crossover across 2 dosing periods in which they will Placebo QAM or QHS every 24 h for 7 days
10189974|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Dose TBD BID every 12 h for 7 days|
10189975|NCT05129865|Placebo Comparator|Placebo BID every 12 h for 7 days|
10189976|NCT05126537||health volunteers|
10189977|NCT05126537||ICU non-sepsis patients|
10189978|NCT05126537||sepsis patients|
10189979|NCT05122559|Active Comparator|N-acetyl cysteine|N-acetyl cysteine (NAC) 1200mg t.i.d.
10189980|NCT05122559|Placebo Comparator|Placebo|Placebo 1200mg t.i.d.
10204409|NCT02272803|Experimental|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Biological: Elotuzumab (BMS-901608)~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
10204410|NCT02272803|Active Comparator|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
10204411|NCT02263209|Experimental|Bioguard Group|Randomised study to either Bioguard or control stock
10204412|NCT02263209|Active Comparator|Control Group|Randomised study to either Bioguard or control stock
10204413|NCT02257424|Other|Phase 1/2|
10204414|NCT02235142|Experimental|Localised prostat cancer and androgen deficiency|
10204415|NCT02221687|Experimental|Synbiotic formula|"Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.~Route : oral, ad libitum~Duration of product intake:~Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)"
10204416|NCT02221687|Placebo Comparator|Control formula|"Control formula : standard formula without pre and probiotic~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.~Route: oral, ad libitum~Duration of product intake:~Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Control FoF : 6 months of consumption (from 6 to 12 months of age)"
10204417|NCT02221687|No Intervention|Breast-fed group|"- Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.~Dose:~Breast milk : on demand~Route : oral, ad libitum~Duration of product intake:~Breast milk : at least 4 month (from birth until at least 4 months of age)"
10204418|NCT02186834|Experimental|Selinexor, Liposomal Doxorubicin and Dexamethasone|"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D).~After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg along with dexamethasone for 1 day. One week later, patients will receive weekly selinexor at a starting dose from 60 mg once a week to 80 mg twice a week in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone 40 mg orally weekly."
10204419|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
10204420|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
10204421|NCT02171884||Group T1|Singletons conceived naturally
10204422|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
10204423|NCT02121158|Other|1|ICD implantation in addition to Optimal Medical Therapy
10204424|NCT02121158|Active Comparator|2|Optimal Medical Therapy
10204425|NCT02111642|Experimental|Online risk calculator used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence used during preoperative counseling session.
10204426|NCT02111642|Placebo Comparator|Online risk calculator not used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence not used during preoperative counseling session.
10204427|NCT02100722|Active Comparator|FFR guided PCI|Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity (or Onyx) drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
10205425|NCT01024829|Other|Whole tumor boost|Patients in this arm will receive radiotherapy (66Gy) in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole
9701622|NCT04732234|Active Comparator|( Group A)|ultrasound guided superior hypogastric plexus block using 20 ml Bupivacaine 0.5% before skin incision.
9701623|NCT04732234|Placebo Comparator|(Group B)|ultrasound guided superior hypogastric plexus block using 20 ml normal saline 0.9% instead of bupivacaine.
9701624|NCT04732104|Experimental|intranasal spray anesthesia|intranasal lidocaine lidocaine 4% topical
9701625|NCT04732104|Active Comparator|injectable local anesthesia|gold standard infiltration local anesthesia (2% lidocaine with 1:100,000 epinephrine)
9701626|NCT04732000|Active Comparator|N-acetyl cysteine|N-acetyl cysteine will be administered as follows: A loading dose of 50 mg/kg will be started as a 1-hour infusion before surgical incision, and will be followed by a maintenance dose of 50 mg/kg administered over 4 hours.
10189981|NCT05117164|No Intervention|control group|Patients will receive enteral feeding based on the practice of the leading physician.
10189982|NCT05117164|Experimental|intervention|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
9701627|NCT04732000|Placebo Comparator|Normal Saline|Normal will be administered as follows: A normal saline infusion will administered at a rate and duration to mimic the N-acetyl cysteine administration.
9701628|NCT04731727|Experimental|Cross linking treatment for corneal thinning|Cornea will be saturated with Vitamin B2 (Riboflavin) and then treated with 365 nm wavelength ultra violet light.
9701629|NCT04732143|Experimental|Incentive Spirometry|Participants will undergo inspiratory muscle training using an incentive spirometer daily for 14 days prior to surgery.
9701630|NCT04732143|No Intervention|Standard Care|Participants will not undergo any inspiratory muscle training prior to surgery.
9701631|NCT04731636|Experimental|Intervention arm|Patients with Crawford type I-V thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
9701632|NCT04731792|Experimental|Virtual Reality group|
9701633|NCT04731792|No Intervention|control group|
9701634|NCT04731935|Experimental|tAN Therapy|tAN will be delivered at a duty cycle of for 5 minutes ON and 10 seconds OFF for a total of 120 hours (5 days) therapy duration. Stimulation intensity will be customized to the participants comfort level and within range of therapeutic effectiveness.
9701635|NCT04731740|Experimental|Pembrolizumab + Lenvatinib|"Experimental treatment:~Lenvatinib p.o. once a day, pembrolizumab 200 mg i.v. every 21 days started 21 days after start of Lenvatinib~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
9701636|NCT04731740|Experimental|Pembrolizumab + Chemotherapy|"Experimental treatment:~Investigators' choice of the Сhemotherapy, pembrolizumab 200 mg i.v. every 21 days started 21 days after the start of chemotherapy~Duration of treatment per patient:~until the end of month 36 after registration of the last patient or disease progression or toxicity (whichever occurs first)"
9978043|NCT01367782|Active Comparator|Active repetitive Transcranial Stimulation|Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
9978044|NCT01367782|Sham Comparator|Sham Stimulation|The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
9701639|NCT04731870||Nurses/Doctors|Covid-19 vaccine confidence and recommendation practices of nurses/doctors
9701640|NCT04731870||Minority populations living in rural south|Covid-19 vaccine confidence and uptake of key at-risk subgroups and tailored Covid-10 vaccine messaging for at-risk subgroups.
9701641|NCT04731805|Experimental|Moving On After Breast Cancer - Intervention Arm|Participants are randomized to the intervention arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Participants are given the patient education materials (booklet, therapeutic exercise DVD, small ball, range of motion wand). The research assistant orients the participant to the education materials and summarizes each section of the booklet. The research assistant also teaches the participant how to do the therapeutic exercises in the booklet. All participants in the intervention also receive usual care.
9701642|NCT04731805|No Intervention|Usual Care|Participants are randomized to the usual care arm after their breast cancer diagnosis (but before cancer surgery) and baseline measurements (T0) are taken. They are followed up again at 2 weeks after their breast cancer surgery (T1), and again at 3 months after surgery (T2). Usual care consists of pre-operative testing, pre-operative nursing education on care of the surgical incision and pain management followed by breast cancer surgery.
9701643|NCT04731948|Placebo Comparator|Folic Acid + Placebo|400µg Folic Acid per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
9701644|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 1|400µg Folic Acid + 2 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
10189983|NCT05109520||investigational group|Participants of the FUTURE study who switched during the study to Gla-300
10189984|NCT05109520||control group|Participants of the FUTURE study who did not switch to Insulin Gla-300
10189985|NCT05108909||mild to moderate traumatic brain injury|patients diagnosed with mild to moderate traumatic brain injury within 1 week after onset of TBI.
9701645|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 2|400µg Folic Acid + 10 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
9978045|NCT01367795||palliative tumor disease|Patients in a known palliative setting with symptoms due to tumor growth.
10189986|NCT05108909||isolated orthopaedic trauma patients|Patients with isolated orthopaedic trauma were identified and enrolled using the same process as that for patients with TBI.
10189987|NCT05108909||healthy non-injury control|Healthy non-injured controls were recruited either via a relationship with a TRACK-TBI participant or through public advertisement within TRACK-TBI institutions, and were able to provide informed consent.
10189988|NCT05102292|Experimental|HLX208|Participants receive HLX208 450mg bid po
9701646|NCT04731948|Active Comparator|Folic Acid + Vitamin B12 Dose 3|400µg Folic Acid + 50 µg Vitamin B12 per day for 16 weeks after a pre-treatment phase with 400µg FA per day for 11 weeks
9701647|NCT04731909|Experimental|Toripalimab Combined With Anlotinib, Etoposide and Platinum|Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d,d1-14,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 or Carboplatin AUC=5, d1, q3w,4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Toripalimab 240mg,d1,q3w+Anlotinib 12mg/d, was taken orally for 2 weeks and stopped for 1 week until the disease progressed.
9701648|NCT04731857||Genetic diseases|For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.
9701649|NCT04731766|Active Comparator|Citrine 5% Sodium Fluoride|It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
9701650|NCT04731766|Experimental|concocuted Nano-silver fluoride|Nano-silver fluoride (NSF) is a laboratory synthesized solution
9701651|NCT04731571||Adaptive Radiotherapy|Patients treated using adaptive radiotherapy on the Varian Ethos linear accelerator
9701652|NCT04731571||Conventional Radiotherapy|Patients treated using conventional, non-adaptive radiotherapy on the Varian Truebeam linear accelerator
9701653|NCT04731584||AVC|Patients hospitalized for TM after a proximal ischemic stroke of the middle cerebral artery and whose reperfusion is satisfactory (TICI 2b, 2c and 3). Additional blood sample will be taken during usual treatment the day of the stroke.
9701654|NCT04731584||Control|Population of control patients, consisting of patients admitted on an outpatient basis for a diagnostic cerebral arteriography.
9701655|NCT04731545|Active Comparator|thin buccal bone|
9701656|NCT04731545|Active Comparator|thick buccal bone|
9701657|NCT04731493||therapeutic Education Program|"individual and group sessions will be set up with educational workshops specialized by age group (child / adolescent / transition / adult / entourage / parents), socio-administrative workshops, etc.~The objectives will be adapted to each age group and to each patient individually."
9701658|NCT04731558|Experimental|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
9701659|NCT04731558|Other|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
9701660|NCT04731662|No Intervention|Control Group (8888888)|The Control group will have 8-hours time-in-bed, both weeknights and weekends.
9701661|NCT04731662|Experimental|Stable Short Sleep (8866666)|The short sleep group will have 6-hours time-in-bed on weeknights and 8-hours time-in-bed on weekends.
9701662|NCT04731662|Experimental|Variable short sleep group (8884846)|The short sleep group time in-bed will vary across weeknights but will maintain the same amount of total time-in bed as the stable short sleep (8866666).
9701663|NCT04731363|Experimental|Xylitol|oral xylitol, a potent artificial sweetener
9701664|NCT04731363|Experimental|Erythritol|oral erythritol, a potent artificial sweetener
9701665|NCT04731831||Patient with arthritis starting infliximab or adalimumab|Patients with Rheumatoid Artritis, Psoriatic Arthritis, Anchylosing Spondylitis starting treament with infliximab or adalimumab
9701666|NCT04731649|Experimental|Sex Education + Standard Care|The experimental arm will receive the FTT + intervention
9701667|NCT04731649|No Intervention|No Education + Standard Care|The control arm will not receive the FTT + intervention
9701668|NCT04731402|Experimental|Acupressure|Acupressure group Acupressure application will be applied twice a week, 24 times in total in 12 weeks. Each acupressure point will be massaged for 30 seconds to provide circulation before compression. After the massage, pressures will be applied consecutively for 90 seconds. The session duration for each woman will be 8 minutes in total, with 2 minutes for each point in each attempt.
10189989|NCT05100641|Experimental|AV-GBM-1|Autologous dendritic cells loaded with autologous tumor antigens cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
9701669|NCT04731402|Experimental|Laughter Yoga|Laughter Yoga group Laughter yoga sessions begin with gentle warm-up techniques that include stretching and stretching movements, songs, applause, and body movements. Therapy sessions are between 30-45 minutes.8 sessions of laughter yoga will be done once a week.
9701670|NCT04731402|Experimental|mindfulness stress reduction program|mindfulness stress reduction program mindfulness stress reduction program consists of 8 weeks. each week is 2.5 hours. each week has a different theme. There is a 6-hour silence day in the 6th week of the program.
9701671|NCT04731402|No Intervention|Control Group|INTERVENTION NOT IMPLEMENTED
9701672|NCT04731376|Experimental|Arm I (testosterone cypionate)|Patients with low testosterone levels receive testosterone cypionate IM QW for 3 months.
9701673|NCT04731376|Active Comparator|Arm II (best practice)|Patients with normal testosterone levels receive standard peri-operative care.
9701674|NCT04731285||Pressure wire based FFR|Pressure wire based FFR was reference group
9701675|NCT04731285||CT-FFR|CFD-based RuiXin-FFR was test group
9701676|NCT04731337|Active Comparator|Patient's normal canine occlusal relationship|The vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital calliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
9701677|NCT04731337|Sham Comparator|Canine occlusal relationship after full mouth rehabilitation|The vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital calliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
9701678|NCT04731350|Experimental|Shock wave(A)|subjects will recive radial extracorporeal shock wave (2000 shock/session, 10Hz and EFD 0.178 mJ/mm²) on knee joints once per week for four weeks in addition to strengthening exercise
9701679|NCT04731350|Experimental|Iontophoresis (B)|subjects will recive dexamethasone iontophoresis on knee joints once per week for four weeks in addition to strengthening exercise
9701680|NCT04731350|Other|Control (C)|stregnthening exercise;straight leg raising exercisein which the patients were positioned in the crook lying position with the unexercised limb was the flexed one then the patients were asked to contract the quadriceps muscle and elevate the limb to 45º and hold for 6 seconds, slowly lower the limb and then relax for 6 seconds, three sets of 10 repetitions were don ,Isometric quadriceps contraction (quadriceps drill) in full knee extension maintained for 5 seconds, followed by a 5-second rest; the exercise was performed for 20 repetitions per session .treatment once per week for four weeks
9701681|NCT04731506|Experimental|Family Connection|2 in-person sessions spaced one week apart & 10 IVR calls/6 months; delivers intervention to parents only
9701682|NCT04731506|No Intervention|Waitlist Standard-Care|6-month delayed start (waitlist) in the FC program; receive post-randomization standard health promotion materials available at the local health department; delivers intervention to parents only
9701683|NCT04731246|Experimental|Parkinson's disease (mild to moderate stage)|
9701684|NCT04731428|Experimental|Progressive Relaxation Exercise|In individuals with normal daily circadian rhythms, cortisol levels peak at 8:00 AM, followed by a constantly declining daily cycle throughout the day. Therefore, it is important to collect blood samples taken for the measurement of serum cortisol levels approximately at the same time. Venous blood samples (3 ml) were obtained from the upper arm at 06:45 AM to evaluate the baseline and 45 minutes after Progressive Relaxation Exercise at 08:00. Vital signs and oxygen saturation were assessed at 6:30 AM before Progressive Relaxation Exercise and at 07:20 AM 5 minutes after Progressive Relaxation Exercise. Measurements were performed in the morning on the day of surgery and on postoperative days 1, 2, and 3.
9701685|NCT04731428|No Intervention|Standard Care|In the control group, no application made during and after the surgical intervention, and routine treatment and care applied.
9701686|NCT04731532|Active Comparator|Classical respiratory physiotherapy application|Patient positions, postural drainage application tapping and trifled
9701687|NCT04731532|Active Comparator|classical respiratory physiotherapy with thoracic vibration|Thoracic Vibration: The physiotherapist places his hands open with his / her fingers on the front and side walls of the patient's chest when the elbow is at 5-10 degrees of flexion. The elbow expands the patient's chest with vibrations. Exercise can be repeated 5-10 times a day+Patient positions, postural drainage application tapping and trifled
9701688|NCT04731415|Other|Healthy pregnant women|Optical coherence tomography and Optical coherence tomography angiography using Optovue® were performed in each trimester and at 6 weeks after childbirth.
10189990|NCT05100641|Placebo Comparator|Autologous monocyte control (MC)|Autologous monocytes cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
9701689|NCT04731454|Experimental|Healthy Nordic Diet (ND)|A healthy diet meeting and exceeding the Nordic Nutrition Recommendations and with more than 80% foods from the Nordic region.
9701690|NCT04731454|Experimental|Control Diet (CD)|A control diet approximating the average depressed person's diet, i.e. of somewhat lower quality than the average Swedish diet.
9978046|NCT01367808|Placebo Comparator|Placebo|
9701692|NCT04731116|Experimental|CANNABIDIOL|CANNABIDIOL 5% 3 ml twice daily for 14 days.
9701693|NCT04731324|Experimental|ZYIL1 Capsule|six subjects will be recruited in each cohort. safety data up to day 3 will be evaluated to determine whether progression to the subsequent dose Cohort is indicated. Single dose will be administered in ascending manner starting from 25 mg.
9701694|NCT04731038|Experimental|Experimental|Anlotinib 12mg qd. po. d1-d14 q3w Toripalimab 240mg ivgtt. d1 q3w Paclitaxel 135mg/m2 ivgtt. d1 q3w Cisplatin 50mg/m2 ivgtt. d1 q3w Carboplatin AUC=5 ivgtt. d1 q3w
10189991|NCT05098340||AIS group|This group includes patients with acute ischemic stroke (AIS).
9701695|NCT04731220||Study group|Newly diagnosed as bile duct cancer
9701696|NCT04731220||Control group|No history of cancer in previous 5 years
9701697|NCT04731259|Experimental|ATR-04|The intervention is an ointment that will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
9701698|NCT04731259|Placebo Comparator|Placebo|Placebo ointment will be applied topically BID for 28 days. It will be supplied in small aluminum foil packets. Packets of study medication will be labeled with Subject Kit numbers to ensure the double-blind treatment.
9701699|NCT04731597||Cases with hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano who presented hip fracture between 2014 and 2019
9701700|NCT04731597||controls without hip fracture|Patients afiliated to a HMO Plan de Salud Hospital Italiano without hip fracture between 2014 and 2019
9701701|NCT04731090|Active Comparator|Standard antibiotic prophylaxis|IV fluoroquinolone 1 hour preoperatively and oral antibiotics were used for 24h postoperatively.
9701702|NCT04731090|Experimental|enhanced prophylaxis|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
9701703|NCT04731207|Other|Healthy pregnant women|All participants will be investigated by Optovue® in follicular phase, ovulatory phase, luteal phase of menstrual cycle. The investigation will be done between 12 PM and 1 PM at each phase. Urine pregnancy testing was done at first and last visits. LH ovulation test was performed by the participants own. if the ovulation was detected by urine strip test, the participant have to underwent the Optovue® within 48 hours.
9701704|NCT04731051|Experimental|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
9978047|NCT01367808|Active Comparator|Vorikonazole|
10189992|NCT05098340||HC group|This group includes healthy controls (HC).
10189993|NCT05097027|Experimental|Blood flow restriction recovery (Experimental I)|Active recovery program with blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
10189994|NCT05097027|Experimental|Non-Blood flow restriction recovery (Experimental II)|Active recovery program without blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
10189995|NCT05095831||Suspicion of solid neoplastic lesion|Patients with high suspicion of solid pancreas neoplasia: carcinoma, intrapapillary mucinous neoplasia (IPMN), neuroendocrine tumor, lymphoma, or intrapancreatic metastasis; based on CT/MR.
10189996|NCT05095831||Suspicion of a solid inflammatory lesion|Patients with high suspicion of solid inflammatory lesions: acute, chronic, or autoimmune pancreatitis; based on CT/MR.
9701705|NCT04731051|Active Comparator|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
9701706|NCT04731194|Experimental|performance-based financial incentive program|Village doctors in villages of the intervention group will promote policy awareness, support registration, follow-up patients, and receive financial incentives based on their performance.
9701707|NCT04731194|No Intervention|current situation|Village doctors in villages of the control group will not be contacted. The control group would serve as a natural baseline and do not receive any intervention.
9701708|NCT04730817|Experimental|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks.
9701709|NCT04730817|No Intervention|Control group|This arm will not be given any kind of treatment and will act as a passive control group.
10189997|NCT05095831||Control group|Patients without a history of any type of solid or hematologic malignancy, hepato-pancreato-biliary disease (including fatty liver and pancreas disease), tobacco/alcohol habits, or morbid obesity with bariatric surgery criteria; who require EUS evaluation (e.g., suspicious of a subepithelial lesion in the context of chronic dyspepsia).
10189998|NCT05095350|Experimental|Probiotic powder|The probiotic powder contains 10 strains from Lactobacillus and Bifidobacterium genus. Participants will orally take two sachets daily and last for 8 weeks.
10189999|NCT05095350|Placebo Comparator|Placebo powder|The placebo powder consists of maltodextrin and contains no probiotics. Participants will orally take two sachets daily and last for 8 weeks.
10190000|NCT05094115|No Intervention|Training as usual|Training as Usual for the 3rd SFAB is the U.S. Army Master Resilience Trainer (MRT). It focuses on teaching resilience skills and is one of the foundational pillars of the Comprehensive Soldier Fitness program. MRT course is intended to impart training resilience skills, designed to introduce other resilience concepts that soldiers will likely encounter through their careers. Key focus of course are (1) resilience, (2) building mental toughness, (3) identifying character strengths, and (5) strengthening relationships. The 3rd SFAB uses a a team training grounded in strengths-based leadership. The Small Team Development Consultant and Brigade Behavioral Health Provider serves as a consultant to units conducting their own resiliency training as usual. No booster sessions will be offered to Training as Usual.
10190001|NCT05094115|Active Comparator|Training as usual with psychological flexibility training|"Training as usual, with psychological flexibility training delivered during a 2-day workshop.~Day 1 provides an overview of the training and describes the posture or stance to prepare for response to challenging situations in a psychologically flexible manner.~Day 2 provides common coping strategies."
10190002|NCT05092815|Experimental|HLX208|Participants receive HLX208 450mg bid po
10190003|NCT05092802|Experimental|HLX208|
10190004|NCT05081622|Experimental|ICC-T|5 days with 9 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
10190005|NCT05081622|No Intervention|Monitoring condition|No intervention
10190006|NCT05078736|Experimental|moderate intensity intermittent training|baseline physical therapy treatment along with moderate intensity intermittent training
10190007|NCT05078736|Experimental|moderate intensity continuous training|baseline physical therapy treatment along with moderate intensity continuous training
10190008|NCT05074862|Experimental|Ketone monoester (3-OHB)|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US). Bolus of 200 mg/kg followed by a 2-hour continuous enteral infusion with a dosing of 150 mg/kg/hour (maximal total dose 50 grams). There is a 1-hour lag between the bolus and the continuous infusion.
10190009|NCT05074862|Placebo Comparator|Placebo Treatment|Maltodextrin- and fatbased placebo in isocaloric, isovolemic dose to the experimental arm.
10190010|NCT05072028|Experimental|[14C]DBPR108|Subjects will receive a single oral 100 mg (radioactivity of 150 µCi) dose of [14C]DBPR108 on Day 1.
10190011|NCT05071027|Experimental|App Medication Reminder Group|Patients in this group will receive dual antiplatelet medication reminders.
10190012|NCT05071027|No Intervention|Non-app Using Group|Patients in this group receive the same standard of care [i.e. endovascular stent-based treatment of unruptured aneurysms] as the other group, but do not receive app dual antiplatelet reminders.
10190013|NCT05069714|Experimental|MTX 1 week hold|Patients who will hold MTX for 1 week after an influenza vaccine.
10190014|NCT05069714|Active Comparator|MTX 2 week hold|Patients who will hold MTX for 2 weeks after an influenza vaccine.
10190015|NCT05069701|Experimental|Healthy volunteers|SVV test will be done.
10190016|NCT05065801|Experimental|GABRINOX|"D1, D8 and D15 GEMBRAX: Albumin bound paclitaxel 125mg / m² followed by Gemcitabine 1000mg / m² followed by 2 weeks of rest~D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over 46h at 2400mg / m² followed by 2 weeks of rest"
10190017|NCT05065801|Active Comparator|FOLFIRINOX|D1, D15, D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400mg / m², 5-fluorouracil 400mg / m² as a bolus followed by continuous administration over 46h at 2.400mg / m² followed by 2 weeks of rest.
10190018|NCT05064254|Active Comparator|Treatment as usual|All participants allocated to the control group will have access to standard care.
10190019|NCT05064254|Experimental|Mindful Adaptive Practice in Pregnancy Therapy|"Participants allocated to the intervention group will have access to treatment as usual in addition to synchronous virtual MAPP.~MAPP draws upon existing integrative principles of structured psychotherapies (mindfulness-based, cognitive, behavioural and relational psychotherapy)"
10190020|NCT05060783||Renal Call Carcinoma|Patrients with renal cancer
9701710|NCT04730973|Active Comparator|Evolocumab|Subcutaneous evolocumab 140 mg will be administered every 2 weeks on top of optimal lipid-lowering therapy
9701711|NCT04730973|Placebo Comparator|Standard|No further treatment besides optimal lipid-lowering therapy will be administered
10190021|NCT05060783||Oncocytoma|Patients with oncocytoma
10190022|NCT05060783||Healthy persons|Patients with CT scan shows no renal cancer
9701714|NCT04730986|Experimental|Intervention Arm|This is a single-arm study with all enrolled patients receiving the same ED GOAL Nursing intervention
9701715|NCT04730869|Experimental|Standard treatment in conjunction with MTP|"Standard:~Concurrent chemoradiation - Radiation (60-Gy in 30 fractions over 6 weeks or, in adults unfit for this [eg >65 years and/or poor performance status] 40-Gy in 15 fractions over 3 weeks) with daily oral temozolomide.~Adjuvant chemotherapy - Daily oral temozolomide (5 days per 4-week cycle, starting 4 weeks after completion of chemoradiation, with at least 6 cycles intended).~MTP:~If 6 weeks of chemoradiation - Two 5-day fasts (allowing water, salt, tea, coffee, and a magnesium supplement) during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet (one or two 1-hour eating windows per day, allowing oils, meats, vegetables, nuts, seeds, limited berries, and a multivitamin) between fasts.~If 3 weeks of chemoradiation - One 5-day fast during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet between fasts."
9701716|NCT04730778||CIN|"STEMI patients who develop CIN contrast induced nephropathy within 1 week from primary PCI."
9701717|NCT04730778||Control|STEMI patients who do not meet criteria of CIN through 1 week post primary PCI
9701718|NCT04731012||healthy oocyte-donation pregnancy|healthy pregnancy
9701719|NCT04731012||preeclamptic oocyte-donation pregnancy|preeclampsia
9701720|NCT04731012||healthy IVF or ICSI pregnancy|healthy pregnancy
9701721|NCT04731012||preeclamptic IVF or ICSI pregnancy|preeclampsia
10190023|NCT05057000|Experimental|Group A|DIET PROGRAM IN ADDITION TO AEROBIC EXRCISES
10190024|NCT05057000|Other|Group B|DIET PROGRAM
10190025|NCT05054569|Experimental|10-week eHealth intervention|Weekly video conference groups led by a trained facilitator
10190026|NCT05054530|Experimental|GMA106|6 different dosages will be subcutaneously injected into the abdomen.
10190027|NCT05054530|Placebo Comparator|Matching placebo|6 different dosages will be subcutaneously injected into the abdomen.
10190028|NCT05053490|Experimental|Static Stretching|Participants will perform static stretching on day 1 and dynamic stretching after the switching.
10190029|NCT05053490|Experimental|dynamic stretching|Participants will perform dynamic stretching on day 1 and static stretching after the switching.
9701722|NCT04731012||healthy spontaneous conception pregnancy|healthy pregnancy
9701723|NCT04731012||preeclamptic spontaneous conception pregnancy|preeclampsia
9701724|NCT04730960||Study Group|Healthy patients between the ages of 18 and 30 without neck problems will be included in the study.
9701725|NCT04730765||Surgical Experimental Group|Patient operated between 01/02/2021 and 30/07/2021, in elective situation of sigmoid diverticulitis
9701726|NCT04730765||Medical Control Group|Patient not operated and medically treated
9701727|NCT04730895|Experimental|Oral 13 cis retinoic acid|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
9701728|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days. All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
10190030|NCT05052307||Fully vaccinated with BNT162b2 COVID-19 vaccine|Defined as 2 doses of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
9701729|NCT04730895|Experimental|13 cis retinoic acid doses orally in combination with spike protein based vaccine|The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
9701730|NCT04730895|Experimental|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days and also, participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
9701731|NCT04730895|Sham Comparator|spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|The participants will receive two doses of 5-7.5x10^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
9701732|NCT04730752||Right Low Quadrant Pain|AIR and AAS scores will be calculated for the patients with right low quadrant pain in emergency service.
9701733|NCT04730726|Experimental|Patients with thyroid nodules|Patients with thyroid nodules that underwent or will undergo an ultrasound with FNA if indicated and if indicated will be scheduled for a (hemi)thyroidectomy
9701734|NCT04730908|Placebo Comparator|G0 - placebo|Dental gel without fluoride in the composition
9701735|NCT04730908|Sham Comparator|G1: Daily Regenerator Dentalclean Neutro (RDCN)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). NEUTRAL pH
9978048|NCT01367808|Active Comparator|Posakonazole|
9701736|NCT04730908|Active Comparator|G2: Sensodyne Repair & Protect (SRP)|1426 ppm of sodium fluoride and calcium sodium phosphosilicate 5% (NOVAMIN technology).
9701737|NCT04730908|Experimental|G3: Daily Regenerator Dentalclean Acid (RDCA)|1450 ppm F- of sodium fluoride and tetrasodium pyrophosphate (Refix technology). ACIDIC FORMULA
9701738|NCT04730908|Active Comparator|G4: Colgate Total Daily Repair (CTDR)|1450 ppm F- of as sodium fluoride, 0.30% triclosan, arginine, tetrasodium pyrophosphate.
9701739|NCT04730999|Experimental|Single Arm|"Induction phase (6 cycles, 21 days duration): carboplatin, etoposide, bevacizumab and atezolizumab.~Maintenance phase (12 cycles, 21 days duration): bevacizumab and atezolizumab"
10190031|NCT05052307||Ever vaccinated with BNT162b2 COVID-19 vaccine|defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
10190032|NCT05052307||Partially vaccinated with BNT162b2 COVID-19 vaccine|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
9701740|NCT04730830|Experimental|Only experimental arm|Only experimental arm. Patients filling out questionnaires.
10190033|NCT05052307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines other than the BNT162b2 according to the manufacturer recommendations.
10190034|NCT05052307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
9701741|NCT04730934||Healthy population|Healthy individuals aged between 18-65
9701742|NCT04730934||Chronic Low Back Pain Group|Patients aged between 18 and 65 and has at least 3 months of low back pain which started before pandemic.
9701743|NCT04730934||Fibromyalgia Group|Patients aged between 18 and 65 and has a diagnosis of fibromyalgia for at least 6 months
9701744|NCT04731181|Experimental|mobile application (little lovely dentist).|intervention mobile application simulating the dental procedure that will be done to the child
9701745|NCT04731181|No Intervention|Tell-Show-Do technique.|control behavior technique where ''tell'' is to tell the child about the procedure in non-threatening words, ''show'' is to demonstrate the procedure to the child, and ''do'' is the execution of the procedure
9701746|NCT04730700|Active Comparator|Radiofrequency ablation (RFA) with MEE|Radiofrequency ablation involves a minimally invasive procedural technique. It uses radiofrequency waves to burn the nerve causing pain. This nerve will no longer be able to send pain signals to your brain. For this study, the multi-tined expandable electrode needle will be used. This needle will result in a larger treatment area. This may result in better pain relief and longer lasting pain relief. If you undergo the radiofrequency ablation procedure you will have pain medication injected where the ablation will be done. The procedure will take about 20 mins to complete. You will be allowed to go home afterward.
9701747|NCT04730700|Active Comparator|Conventional Medical Management (CMM) Treatment Only|Your current standard of care treatment may already consist of some CMM therapies. Standard of care includes a variety of intervention types such as medication, physical therapy, home exercise programs, back brace, walking aid, and chiropractic care.
9701748|NCT04730713||Admitted to the center ICU due to neurosurgery, brain dysfunction and other neurological reasons|Aneurysmal subarachnoid hemorrhage (aSAH), traumatic brain injury (TBI), acute deficiency Blood stroke (AIS), acute cerebral hemorrhage (ICH), hypoxic ischemic encephalopathy (HIE), Sepsis-associated encephalopathy (SAE), intracranial tumor surgery; older than 18 years old, <85 Years old; patients who need lumbar puncture.
9701749|NCT04730466|Experimental|Neuropsychological rehabilitation|In the experimental group, patients will receive a 12-session neuropsychological rehabilitation protocol that will be carried out over four weeks (3 weekly sessions). The protocol and the number of sessions has been designed by neuropsychologists following the Díez-Cirarda et al. recommendations
9701750|NCT04730466|No Intervention|Control|The control group will not receive any therapy. The participants will be simply evaluated at the same time as the experimental group
9701751|NCT04730427|Experimental|GX-I7|GX-I7
10190035|NCT05052307||Fully vaccinated plus booster dose of BNT162b2 COVID-19 vaccine|Defined as fully vaccinated with available COVID-19 vaccines according to the manufacturer recommendations plus booster dose of BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
10190036|NCT05051436|Experimental|Mirabegron (M)|Drug will be administered for 12 weeks after baseline procedures.
10190037|NCT05051436|Experimental|Tadalafil (T)|Drug will be administered for 12 weeks after baseline procedures.
9701752|NCT04730427|Placebo Comparator|GX-I7 vehicle|GX-I7 vehicle
9701753|NCT04730323|Experimental|Tocilizumab Group|Tocilizumab administration protocol: Patients received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion.
9701754|NCT04730323|Active Comparator|Methylprednisolone (corticosteroid) group|Corticosteroid administration protocol: Patients received methylprednisolone 80mg/day in two divided doses as per national/local guidelines and predefined parameters of disease severity were assessed on each day.
9701755|NCT04730492||Renal Transplantation|Renal Transplantation
9701756|NCT04730492||Hernias reparation post renal transplantation|Hernias reparation post renal transplantation
9701757|NCT04730362|Active Comparator|Control group|20 patients in which a Guedel oral airway will be inserted for airway management and to conduct inhalational anesthetic through face mask fixed with harness to the head and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
9701758|NCT04730362|Active Comparator|supraglottic group|20 patients in which supraglottic airway laryngeal mask airway (LMA) will be used and then connected to anesthesia breathing circuit of MRI compatible anesthesia machine for maintenance of anesthesia of O2 and sevoflurane 2-4% .
9836127|NCT02770287|Experimental|Venus Freeze Diamond Polar treatment|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
9836128|NCT02770365|Experimental|Test Product|estradiol cream
9701759|NCT04730687|Placebo Comparator|Traditional non-surgical mechanical therapy|Mechanical instrumentation in all groups continued with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH & Co, Ltd, Stockach, Germany) until the clinician gently felt that the surface was sufficiently debrided.There is no laser application. The laser tip is placed in the peri-implant sulcus but not activated.
9701760|NCT04730687|Active Comparator|Diode laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) has been applied with the aid of a 300 µm diameter optical fiber tip (E3-9 mm) placed approximately 1 mm above the most apical part of the peri implant pocket, parallel to the implant surface. Pocket irrigation was performed with 3% hydrogen peroxide solution for 10 seconds before and after diode laser application.The fiber was moved in apico-coronal and mesial-distal directions for a total of 30 seconds during laser light emission.The laser tip was checked every 7-8 seconds and wiped with sterile saline in order to prevent a possible coagulation or temperature increase.The laser was used in continuous pulse mode, at a power of 0.8 Watt (W), an energy density of 3J / cm2 and a spot diameter of 1 mm. Pulse width and pulse interval were applied as 20 milliseconds.
9701761|NCT04730687|Active Comparator|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical debridment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) was applied in short pulse '' H '' mode, water cooled with a non-contact sweeping motion for 30 seconds parallel to the implant surface.The settings used are: 1.5 W power, 30 Hz frequency, 50% water, 40% air, 140 s pulse duration and 1 cm spot size.
9701762|NCT04730414||Age, Male, Female, ethnicity,|"The aim of the study is to be inclusive of all groups as to avoid bias. Furthermore, the study aims to determine if its formulation will encompass all skin types, genders and age groups.~Full-spectrum hemp dosage is determined to begin with 40mg - 2-3X/day = topical application; for a period of 2-3 months.~Drug: Full Spectrum hemp (0.018% THC), Topical Application Placebo = cream without hemp (Double blinded) One cream will be placed on one side of the face (R/L) and the other cream on the other side of the face."
9701763|NCT04730622||Fragility fracture|Patients undergoing a hip replacement for a fragility fracture of the femoral neck (n= 10).
9701764|NCT04730622||Osteoarthritis|Patients undergoing a hip replacement for severe osteoarthritis (n= 10).
9701765|NCT04730609|Experimental|Dexmedetomidine|IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.
9701766|NCT04730401|Experimental|High-titre CP|200mL high-titre CP on admittance
10190038|NCT05051436|Experimental|Mirabegron and Tadalafil (MT)|Both drugs will be administered for 12 weeks after baseline procedures.
9701767|NCT04730401|Active Comparator|low-titre CP|200ml low-titre CP on admittance
9701768|NCT04730401|Placebo Comparator|Placebo|200mL saline as placebo on admittance
9701769|NCT04730544|Experimental|Experimental Arm A|"Treatment for 108 weeks (one cycle = 12 weeks; 9 cycles):~Nivolumab 480 mg every 4 weeks (27 infusions) and ipilimumab 1 mg/kg every 6 weeks (18 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
9701770|NCT04730544|Active Comparator|Control Arm B|"Induction of 12 weeks (one cycle = 3 weeks; 4 cycles):~Nivolumab 240 mg and ipilimumab 1 mg/kg every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab), Maintenance of 96 weeks (one cycle = 4 weeks; 24 cycles): Nivolumab 480 mg every 4 weeks for 24 dosing cycles (24 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first)."
9701771|NCT04730531|Experimental|Treatment Arm|Local infiltration with 0.25% bupivacaine and epinephrine
9701772|NCT04730531|Placebo Comparator|Control Arm|Placebo of equal volume injectable saline
9701773|NCT04730440||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
9701774|NCT04730440||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
9701775|NCT04730557|Experimental|Weight-Loss|Participants in the weight-loss intervention arm of the study will be enrolled in an individualized 6-month intervention designed to achieve a 10% reduction of body weight relative to baseline. Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine [29]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Intervention activities include individual diet counseling, group support, goal setting, self-monitoring, stress management, and problem solving. Weekly group support and education sessions, along with daily food journaling and weekly weigh-ins, are recognized approaches for successful weight loss [30-32]. Once the weight loss goal is achieved, diets will be liberalized for weight maintenance.
9701776|NCT04730557|No Intervention|Wellness Education|Control participants will be counseled to maintain their baseline body weight and level of physical activity. They will report weights weekly and if their weight deviates from baseline they will be asked to keep daily food logs and counseled to return calorie intakes to weight maintenance level. To document diet intakes/adherence, 3-day food records will be collected at months 0, 3, and 6 and analyzed for calorie and nutrient composition. Participants will be encouraged not to change their physical activity levels from baseline and their activity will be monitored by Actigraph activity monitors worn in 7-day periods at months 0, 3, and 6. In addition, each participant will be invited to enter the weight loss intervention after completion of the health education control course.
10190039|NCT05051436|Placebo Comparator|Placebo (P)|
9836129|NCT02770365|Active Comparator|Reference Product|estradiol cream
10190040|NCT05050994|Experimental|Microwave ablation|Patients receiving microwave ablation of splenomegaly
10190041|NCT05048199|Experimental|pressure regulated volume-controlled mode of ventilation (PRVC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
10190042|NCT05048199|Active Comparator|volume-controlled mode of ventilation (VC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
10190043|NCT05044507|Sham Comparator|BQ 2.0 sham stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
10190044|NCT05044507|Active Comparator|BQ 2.0 active stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
10190045|NCT05042882|Experimental|Early enteral nutrition|Intervention group: enteral nutrition from the first postoperative night until 50% of caloric requirements are covered by oral nutrition. Enteral nutrition will start at a flow of 250 ml/12h. If tolerated, enteral nutrition will be increased to 500 ml/12h on postoperative day 1, 750 ml/12h on postoperative day 2, and 1000 ml/12h on postoperative day 3. A hypercaloric enteral nutrition will be used (Isosource Energy Fibre or similar).
10190046|NCT05042882|No Intervention|Oral nutrition|Control group: patients will receive standardized oral nutrition. The night after the operation, patients will be allowed to have free drinks. On postoperative day 1, they will receive bouillons, creams, yogurts, and drinks >2 l. On postoperative day 2, they will receive a light diet. On postoperative day 3, they will receive half portion of normal diet and on postoperative day 4 normal diet.
10190047|NCT05041842|Experimental|Tucatinib plus systemic treatment with or without hormone therapy|Addition of tucatinib (300 mg orally twice daily) to the systemic treatment (pertuzumab and trastuzumab) with or without hormone therapy
10190048|NCT05038904|Experimental|Acalabrutinib|Participants will be given acalabrutinib (four doses of 100 mg of acalabrutinib to be taken orally twice daily).
10190049|NCT05037786|Active Comparator|Powerpoint group|In the control group, there will be a face-to-face intervention of 15 minutes of education on pain explained by Verbal form with supporting Powerpoint presentation. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
10190050|NCT05037786|Experimental|Infographic group|In the intervention group, the same pain education will be carried out, explained verbally but with the support of an infographic instead of a Powerpoint. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
10190051|NCT05035277|Active Comparator|Acetylsalicylic acid|Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.
10190052|NCT05035277|Experimental|Direct oral anticoagulation (DOAC)|Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.
10190053|NCT05033717|Experimental|Group A|Tissue Flossing Technique
10190054|NCT05033717|Active Comparator|Group B|Static Stretching exercises
10190055|NCT05030597|Experimental|68Ga-DOTA-FAPI and 18F-FDG PET/CT|Investigators recruit patients whom are clinically highly suspected oral cancer or recurrence after treatment. Patients undergo 68Ga-DOTA-FAPI and 18F-FDG PET/CT imaging within one week.
10190056|NCT05028972|Experimental|Intervention: Personal Amplifier|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
10190057|NCT05028972|Other|Control: No Personal Amplifier|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
10190058|NCT05028621|Experimental|Genomic analysis|When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
10190059|NCT05026944|Experimental|Group A|Percussive massage and static stretching exercises
10190060|NCT05026944|Other|Group B|Static stretching exercises
10190061|NCT05026931|Experimental|Group A|Foam Rolling
10190062|NCT05026931|Active Comparator|Group B|Stretching exercises
10190063|NCT05023876|Experimental|IASTM group|
10190064|NCT05023876|Experimental|Control Group|
10190065|NCT05022147|Experimental|Alternating-Frequency DBS|In this single-arm study, all participants will receive all interventions in a crossover fashion.
10190066|NCT05015751||Hydrocephalus Patients|Hydrocephalus patients with an existing ventriculoperitoneal shunt and symptoms of a shunt malfunction.
10190067|NCT05003037|Experimental|Wild-type Genotype|
10190068|NCT05003037|Experimental|EGFR mutation|
10190069|NCT05003024|Active Comparator|TOF scan train of four ratio monitoring|Recovery of train of four ratio after sugammadex administration
10190070|NCT05003024|Experimental|ITF device tetanus stimulation monitoring|Recovery of tetanus 100 Hz ratio after sugamamdex administration
10190071|NCT04996771|Experimental|Surufatinib Combined With Toripalimab and Chemotherapy|
10190072|NCT04996771|Experimental|Surufatinib Combined With Chemotherapy|
10190073|NCT04994665|Active Comparator|Sleeve gastrectomy|realization of a sleeve gastrectomy alone
10190074|NCT04994665|Experimental|sleeve gastrectomy with omentopexy|realization of a sleeve gastrectomy followed by an omentopexy
10190075|NCT04993664|Experimental|Pelacarsen group (TQJ230)|The first group will receive 80 mg of pelacarsen every month subcutaneously for 6 months.
10190076|NCT04993664|Placebo Comparator|Placebo group|The first group will receive 80 mg of placebo every month subcutaneously for 6 months.
10190077|NCT04993443|Experimental|Active Comparator: Drug :LQ036|Experimental, Single and Multiple Oral escalating dose
10190078|NCT04993443|Placebo Comparator|Placebo Comparator: Matching Placebo for LQ036|Matching Placebo for LQ036: Matching Placebo
9701779|NCT04730596|Placebo Comparator|Group I (Control group)|- The patients in this group will receive normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
10190079|NCT04980846|Experimental|Intervention group|Intervention: Other: Driving under the influence of alcohol with a driving simulator
10190080|NCT04980820|Experimental|FFP2|This arm starts with a FFP2 mask and switches to a FFP3 mask.
9701780|NCT04730596|Experimental|Group II (Ketamine group)|- The patients in this group will receive ketamine at a dose of 0.3 mg/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
9701781|NCT04730596|Experimental|Group III (Dexmedetomidine group)|- The patients in this group will receive Dexmedetomidine in a dose of 0.5 ug/kg dissolved in normal saline in a labeled syringe which will be prepared by an assistant nurse not participating in the study.
9701782|NCT04730674|Experimental|post-mastectomty seroma group|female patients with established diagnosis of post-mastectomy seroma following modified radical mastectomy, were treated by local injection of tetracycline after the seroma fluid was aspirated, then a crepe bandage was applied over the mastectomy area. Then after 5 days the patient were examined again for seroma re-collection or the presence of complications. The amount of seroma aspirated in each session.
10190081|NCT04980820|Experimental|FFP3|This arm starts with a FFP3 mask and switches to a FFP2 mask.
10190082|NCT04978519|Experimental|Cryotherapy|Cryotherapy achieves a temperature averaging -40°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.
9701783|NCT04730661|No Intervention|Conventional arm|For the patients enrolled in this conventional arm, the decision of hospitalisation or discharge will be taken with usual criteria (pulsed oxygen saturation (SpO2) in room air <92% and respiratory rate> 22/min, respiratory rate> 30/min, Blood gas hypoxemia, decompensation of comorbidity, home monitoring not possible, other intercurrent pathology requiring hospitalization, several risk factors for COVID infection requiring hospitalization in intensive care (age> 65y, hypertension complicated by a cardiovascular event, chronic cardiovascular disease, unbalanced diabetes with complications, chronic respiratory disease (excluding well-controlled asthma), chronic renal failure dialysis, obesity, progressive cancer under treatment, congenital or acquired immunosuppression)
9701784|NCT04730661|Experimental|Interventional arm|For the patients enrolled in this interventional arm, the decision of hospitalisation or discharge will be taken with usual criteria and the result of Sit to Stand Test.
9701785|NCT04730518|Experimental|Yoga-based Group Therapy|"The yoga-based group therapy (YBGT) involves a four-week intervention with weekly group therapy sessions in addition to TAU. The fifty-minute session takes place with a group size of max. 10 participants and was held once a week by a psychologist who is experienced in yoga-based therapy.~A yoga session starts with breathing exercises (pranayama), followed by various exercises in standing, sitting and lying down (asanas), which are accompanied by mindful instructions from the psychologist. Every yoga session ends with a final relaxation (shavasana), which can take the form of a body scan, for example."
9701786|NCT04730518|Active Comparator|Treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
9701787|NCT04730583|Active Comparator|Kybella Injection|
9701788|NCT04730583|Active Comparator|980nm laser|
9701789|NCT04730583|Active Comparator|755nm laser|
9701790|NCT04730583|Active Comparator|Radiofrequency|
9701791|NCT04730310||Regional Anesthesia (RA)|"RA~Includes spinal, epidural, peripheral nerve block, excludes local infiltration (unlikely that any major open revascularization can be done under local)~Defined as: NSQIP Principal (ANESTHES) or additional (ANESTHES_OTHER) anesthesia technique = regional, spinal, epidural, or MAC (in NSQIP RA/Spinal/Local + MAC are coded as MAC; while this includes local + MAC, it would be unlikely that local anesthesia would be sufficient for open revascularization)"
9701792|NCT04730310||General Anesthesia (GA)|"GA~Defined as: NSQIP Principal or additional anesthesia technique = general~Since GA is selected as the principal anesthetic technique by default when multiple techniques are present, GA + RA could potentially have been coded as GA if the optional variable of additional anesthesia technique is not filled in, leading to differential misclassification of patients with GA + RA (most likely epidural and peripheral nerve block) in the GA group."
9701793|NCT04730505|Experimental|Patient App + HCP Portal (Cohort 1)|Cohort 1 is to assess how patients will use the Patient App if connected in real time with the Healthcare professional (HCP) Portal
9836130|NCT02770365|Placebo Comparator|Placebo product|Placebo cream
10190083|NCT04977232|Experimental|Escitalopram + game intervention|Escitalopram treatment and game intervention are given in combinations for 8 weeks.
10190084|NCT04977232|Active Comparator|Escitalopram|Escitalopram treatment for 8 weeks
10190085|NCT04976790|Experimental|Chinese Tuina group (CTG)|The participants in Chinese Tuina group will receive the traditional Chinese Tuina therapy on the basis of health education and home-exercise. All the treatment will cost 20-25 minutes. Patients in this group received 4 treatments over 14 days.
10190086|NCT04976790|Active Comparator|Flurbiprofen Cataplasms group (FCG)|The FCG group received flurbiprofen gel on the basis of the health education and home-exercise, twice daily, for 14 days.
10190087|NCT04973670|Experimental|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h
10190088|NCT04973670|Active Comparator|placebo|The same amount of NS containing only sivelestat sodium excipients
9701794|NCT04730505|Experimental|Patient App Alone (Cohort 2)|Cohort 2 is to assess how patients will use the Patient App where there is no connectivity to the Healthcare professional (HCP) Portal and thus no real-time data sharing with the HCP Portal
9701795|NCT04730375|Active Comparator|( Group A)|: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery
9701796|NCT04730375|Active Comparator|(Group B)|Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
9701797|NCT04730284|Experimental|Health supplements|One arm only
9701798|NCT04730245|Experimental|Microbiota modification|
9701799|NCT04730219|Experimental|Tislelizumab and Nab Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
10190089|NCT04969198|Experimental|Nicotine Patch + Nicotine Mini Lozenge|"No medication for 1 Week after Target Quit Day (TQD). Medication started 1 Week after TQD.~Patches (Nicotine): 14 mg Patches for 4 weeks postquit (Week 1-5), then 7 mg patches for 4 weeks (Week 6-9)~Mini Lozenge (Nicotine): 2 mg Mini Lozenges 5x per day (up to 20x day max) for 8 weeks post quit (Week 1-9)"
10190090|NCT04962633|Experimental|Probiotic Pasta Group|Subjects in the Probiotic Pasta group will consume 80 g per day of a probiotic pasta for 4 weeks
9701800|NCT04730297|Active Comparator|Paracetamol/codeine Group A|analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg
9701801|NCT04730297|Active Comparator|Ibuprofen Group B|analgesic group preoperative oral dose of ibuprofen 400 mg
9701802|NCT04730297|Placebo Comparator|Placebo Group C|Placebo group preoperative placebo
9778659|NCT01112358|Experimental|r-FSH + r-hLH|Lutropin alfa (r-hLH) will be administered at a daily dose of 150 International Units (IU) from the presence of at least one follicle greater than (>) 14 millimeter (mm) to complete ovarian stimulation. Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 milligrams (mg) of recombinant Human Chorionic Gonadotropin (r-hCG) will be administered subcutaneously at 12 hours after the last injection of lutropin alfa and/or follitropin alfa and analogous GnRH antagonist.
10190091|NCT04962633|Active Comparator|Control Pasta Group|Control Pasta Subjects in the Control Pasta group will consume 80 g per day of conventional pasta for 4 weeks.
9778660|NCT01112358|Active Comparator|r-FSH|Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 mg of r-hCG will be administered subcutaneously at 12 hours after the last injection of follitropin alfa and analogous GnRH antagonist.
9778661|NCT01112514|Experimental|ICG Injection|These participants underwent a colonoscopy after having an ICG injection.
9778662|NCT01112579|Experimental|Treatment|
9778663|NCT01112579|Other|Control|
9778664|NCT01112670|Experimental|ABCB1 Group 1|ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
9778665|NCT01112670|Experimental|ABCB1 Group 2|ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
9778666|NCT01112670|Experimental|ABCB1 Group 3|ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
9778667|NCT01112683|Experimental|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
9778668|NCT01112683|Placebo Comparator|Placebo|These are identically-looking pills to the ones in the Memantine Arm
9778669|NCT01112696|Other|Sensor|All subjects that wear sensors (all subjects)
9778670|NCT01112735|Experimental|ARTISS|ARTISS will be used as an adjuvant to standard of care.
9778671|NCT01112735|Other|Standard of care|Standard of care
9778672|NCT01112865|Other|Mark VII/Current pen|Subject will use Mark VII pen for 2 months followed by Current pen for 2 months
9778673|NCT01112865|Other|Current pen/Mark VII|Subject will use current Genotropin pen for 2 months followed by Mark VII pen for 2 months
9778674|NCT01112917|Experimental|VenaTech Convertible Vena Cava Filter|Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.
10190092|NCT04955314|Experimental|PA mobilizations on their main painfull vertebral segment|Patients who will be treated with PA mobilizations on their main painfull vertebral segment.
10190093|NCT04955314|Experimental|PA mobilizations on an adjacent vertebral segment from the most painful|Patients who will be treated with PA mobilizations on an adjacent vertebral segment from the most painful.
9778675|NCT01112982|Other|Febuxostat Sub-Study|"To analyze the effect of urate-lowering therapy (specifically with febuxostat [Uloric]) on the synovial pannus in the index joint of a subgroup of patients. Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric) and who have a serum urate level of > or = to 9.0, will be treated with febuxostat (Uloric) and their serum urate level will be followed at months 1, 3, 6, and 9. Magnetic Resonance Imaging (with and without gadolinium) of the same index joint will be repeated at month 9 to assess for the presence and degree of synovial pannus. Because initiation of urate-lowering therapy can induce acute attacks of gout, these subjects will also be started on colchicine as a prophylactic (and remain on colchicine for 6 months)."
9778676|NCT01112982|Other|MRI of index joint|"To analyze synovial pannus in the Magnetic Resonance Imaging (with and without gadolinium) of the index joint on Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric)."
9778677|NCT01113008|Experimental|Remote postcondtioning|Patients assigned to remote ischemic postconditioning (randomized controlled trial)
9778678|NCT01113008|Placebo Comparator|Control group|
9701803|NCT04730258|Experimental|1A: Monotherapy escalation and expansion|Dose escalation and expansion arm with CFI-400945
10190094|NCT04949399|Experimental|BOTOX|BOTOX will be injected into the platysma muscle on Day 1
10190095|NCT04949399|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1
9701804|NCT04730258|Experimental|1B: Food Effect|Food effect at the recommended phase 2 dose
9701805|NCT04730258|Experimental|2A: Combination escalation and expansion|Dose escalation and expansion arm with CFI-400945 and azacitidine
9701806|NCT04730258|Experimental|2B: Combination escalation and expansion|Dose escalation and expansion arm with CFI-400945 and decitabine
9701807|NCT04729985|No Intervention|Standard Care|A blinded CGM will be placed to review glucoses after discharge in the Standard Care arm.
9701808|NCT04729985|Active Comparator|Diabetic education and CGM monitoring|Treatment arm will get diabetic education, active CGM use with patient feedback for 14 days, active access to the PI for concerns relating to hospitalization. They will also receive a brief, 15 minute phone call from the PI on day 3-4, 6-7, 9-10 and day 14-15.
9701809|NCT04729920||subjects with neuromuscular disease|Adult subjects with neuromuscular disease, with an active prescription of MI-E for more than 3 months
9701810|NCT04729855||colorectal cancer patients|"Colorectal cancer patients( n = 74 ) from stage I-III with the following criteria:-~a. Inclusion criteria:~No sex predilection.~Age (25-65 yr).~Colorectal carcinoma confirmed by histopathological examination"
9701811|NCT04729855||Healthy controls ( n = 74)|matched as regarding age and sex as much as possible with cases.
9701812|NCT04729803|Experimental|Attention Guidance + Exposure|Participants will complete teleconferencing-based exposure trials with an attention guidance component.
9701813|NCT04729803|Active Comparator|Exposure Alone|Participants will complete teleconferencing-based exposure trials.
10190096|NCT04944368|Experimental|Vaccine candidate|
10190097|NCT04944368|Placebo Comparator|Saline placebo|
9701814|NCT04729803|Experimental|Attention Control + Exposure|Participants will complete teleconferencing-based exposure trials with an attention control component.
9701815|NCT04729894|Experimental|Safe Medication Storage Device + Education|
9701816|NCT04729894|Active Comparator|Education|
10190098|NCT04942028|Experimental|Internet-delivered exposure-based treatment|10 weeks of therapist-guided exposure-based treatment delivered via the Internet.
9701817|NCT04729881|Experimental|Conventional Rehabiliation Group|"Participants 5 days a week for 4 weeks; TENS, US and neck specific exercise program will be applied.~Conventional TENS will be applied to the participants with the CefarCompex rehab400 (New Chattanooga Compex Rehab, USA) muscle rehabilitation device. It will be applied with electrodes coated with a special adhesive material for each participant for 20 minutes at a frequency of 60-120 Hz. In the study; 4 channels and 8 electrodes will be used. Electrodes will be placed paravertebrally in the cervicothoracic space, covering the painful area. The dose of the current will be increased as the patients become accustomed to the current intensity.~Continuous Ultrasound will be applied to the participants due to chronic neck pain. It will be applied at a frequency of 1MHz and a dose of 1.5 W / cm2 for 5 minutes."
9701818|NCT04729881|Active Comparator|Spesific Exercise Group|Participants will be given a home exercise program consisting of exercises specifically applied to the neck. Participants will be asked to practice the exercises 5 days a week. The application status of the participants' home exercise program will be followed by the researcher over the phone. Participants who do not practice the home exercise program will be excluded from the study. The exercise program to be applied to the participants in the exercise group is listed below.Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise.
10190099|NCT04942028|Active Comparator|Internet-delivered standardized education and prolonged assessment|10 weeks of therapist-guided intervention based on prolonged assessment and routine care educational material delivered via the Internet.
10190100|NCT04940338|Experimental|Bromfenac|Group 1 will receive topical bromfenac (0.9 mg/mL) 2x daily, 7 days before the surgery
10190101|NCT04940338|Experimental|Dexamethasone|Group 2 will receive topical dexamethasone (1mg/mL) 3x daily before the surgery
10190102|NCT04940338|Placebo Comparator|Placebo|Group 3 will receive topical placebo (artificial tears substitute) 2x daily before the surgery
10190103|NCT04937088|Placebo Comparator|Placebo|Soy Bean Oil identical packaging as the active arm, taken once daily by mouth for 30 days.
10190104|NCT04937088|Active Comparator|Liquid ASA|Aspirin 150 mg liquid formulation (2.5%w/w) taken once daily by mouth for 30 days
10190105|NCT04934540||Patients undergoing ERBT|Patients who are diagnosed with bladder tumors and planning for ERBT.
9701819|NCT04729881|Other|Control Group|
9701820|NCT04729842|Active Comparator|Group - B , Patients who recieved Bupivacaine|30 ml of 0.5% bupivacaine was injected equally divided and injected in four nerves (musculocutaneous, median, radial and ulnar nerves)
9701821|NCT04729842|Active Comparator|Group - R , Patients who received Ropivacaine|30 ml of a solution containing 0.5% ropivacaine was equally divided and injected in the four nerves (musculocutaneous, median, radial and ulnar nerves)
9701822|NCT04730180|Active Comparator|No neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.
10190106|NCT04930874|Experimental|ICU patients with COVID-19|NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure levels (MAP, ie 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using Tissue Oxygenation Index values and mean arterial pressure values in a regression analysis and will be considered sufficient if the relative Pearson correlation coefficient is less than 0.3. Cerebral blood flow will be assessed by blood flow index determination after intravenous infusion of 5 mg indocyanine.
10190107|NCT04927390|Experimental|Mycophenolate Mofetil (MMF) Arm|Participants will receive mycophenolate mofetil (MMF) for up to 96 weeks, in addition to their background Standard of Care medication for systemic sclerosis related symptoms. They will receive 500mg twice daily over the first 4 weeks following their randomisation, and if tolerated the dose will be increased to a target dose of 1g twice daily starting from week 5 until their Final visit.
10190108|NCT04927390|No Intervention|Control Arm|Standard of Care (no immunosuppression) for systemic sclerosis related symptoms.
9701823|NCT04730180|Active Comparator|Mixed reality neuronavigation|For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.
9701824|NCT04729946|Experimental|Pure-Vu Treatment|Participants in this arm will undergo colonoscopy using the Pure-Vu cleansing device.
10190109|NCT04927325|Other|central line with a reddened exit site|A standardized set of photos will be taken of 10 central lines with an erythema at exit site (visible to the naked eye)
10190110|NCT04927325|Other|Control Group: central line without a reddened exit site|A standardized set of photos will be taken of 10 newly inserted CVC (as a control over time to evaluate the in-patient redness and the impact of irritation of a CVC)
10190111|NCT04926376|Experimental|EYE90 Microspheres Treament|Radioembolization with Eye90 Microspheres
10190112|NCT04924842||Children|Hospitalized children, 0 to 17 years of age, 30 subjects, consecutive sample survey, recruitment in quotas of five age ranges.
10190113|NCT04924842||Adults|Hospitalized adults, 18 years and above, 60 matched subjects
9701825|NCT04729998|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
9701826|NCT04729998|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.
10190114|NCT04919707|Experimental|Older Adolescent Soccer Players|10 male, 10 female soccer players, grades 11-12, age 16-18 Neurocognitive measures, physical measures, header session, MRI
10190115|NCT04919707|Experimental|Younger Adolescent Soccer Players|10 male, 10 female soccer players, grades 6-7, age 12-13 Neurocognitive measures, physical measures, header session, MRI
10190116|NCT04913961|Experimental|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study.
10190117|NCT04913961|Active Comparator|Control|The control group will get the western medicine conventional therapy with some additional tests for the study.
10190118|NCT04911361|Active Comparator|Topical loteprednol suspension in both eyes|25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.
10190119|NCT04911361|Experimental|Lower eyelid canaliculi DEXTENZA insertion (study group)|25 subjects will be randomized to receive treatment of OTX-DED
10190120|NCT04908761|Experimental|Transmuscular quadratus lumborum block group|Patients assigned to the Transmuscular Quadratus Lumborum (TQL) block group receive the Transmuscular Quadratus Lumborum block in a lateral decubitus position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
10190121|NCT04908761|Placebo Comparator|Control group|For patients assigned to the control group, 30cc of 0.9% normal saline is used for Transmuscular Quadratus Lumborum block.
10190122|NCT04906993|Experimental|camrelizumab combined with famitinib malate|
10190123|NCT04906993|Active Comparator|platinum-based chemotherapy|
9701827|NCT04729647|Other|Axillary Lymph Node Metastasis|
9701828|NCT04729556|Experimental|Sericin and chitosan cream|A flim-forming cream containing sericin and chitosan cream. Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).
9701829|NCT04729556|Active Comparator|Cavilon|"Active control is a commercial cream containing dimethicone as the substance forms a durable, thin, and transparent film. The cream is used as a moisturizer to prevent the skin against irritation, dryness, and pressure ulcers.~Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours)."
9701830|NCT04730141|Experimental|mobilization protocol|The early mobilization protocol developed by using up-to-date guidelines and expert opinions were applied to the patients in the intervention group.
9701831|NCT04730141|No Intervention|routine care|The routine mobilization follow-up approach of the intensive care unit was applied to the patients in the control group .
10190124|NCT04895072|Active Comparator|Standard group|standard injection rate will be applied
10190125|NCT04895072|Active Comparator|Long group|long injection rate will be applied
10190126|NCT04893343||Neonatal infection with antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated with antibiotics
10190127|NCT04893343||Neonatal infection without antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated without antibiotics
10190128|NCT04889716|Experimental|Cohort 1|Participants receive mosunetuzumab 60 mg for cycles 1 and 2 (although fractionated for cycle 1), and 30 mg for all subsequent cycles after standard-of-care therapy with CD19-directed CAR T-cells
10190129|NCT04889716|Experimental|Cohort 2|Participants receive obinutuzumab (1000 mg for each subject) and glofitamab after standard-of-care therapy with CD19-directed CAR T-cells. The dose of glofitamab for each subject will be 30 mg, other than for cycle 1, which will be 12.5 mg glofitamab fractionated over two weeks.
10190130|NCT04870034|Experimental|Treatment (palbociclib, binimetinib)|Patients receive palbociclib PO QD and binimetinib PO BID for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week after last dose of study medication, patients undergo surgery.
10190131|NCT04869371|Experimental|Androgen Deprivation Therapy with Docetaxel|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus docetaxel and prednisone, as per standard of care. Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks. Docetaxel (75 mg/m2 body surface area) will be administered as intravenous drip every 3 weeks for 6 cycles. Robot assisted radical prostatectomy will be followed in 2 weeks when 24-week treatment cycle is finished.
10190132|NCT04869371|Active Comparator|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robot assisted radical prostatectomy. Triptorelin Pamoate 15mg will be administered once per 12 weeks.
10190133|NCT04869124|Active Comparator|Dapagliflozin|Dapagliflozin tablet (10mg/tablet), orally, once daily for 12 weeks.
9701832|NCT04730154|Experimental|Pain Neuroscience Education (PNE) + Motivational Interviewing (MI)|Breast cancer survivors assigned to the experimental intervention will participate in 1 online PNE session followed by 3 PNE + MI sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format, allowing to individually tailor content to the patient's maladaptive beliefs and perceived injustice. After the first live session, breast cancer survivors will receive a perceived injustice-targeted PNE information leaflet that they need to read carefully at home.
9701833|NCT04730154|Active Comparator|Biomedically-focused Education|Breast cancer survivors assigned to the experimental intervention will participate in 1 online biomedically-focused education session followed by 3 biomedically-focused education sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format in order to balance nonspecific treatment effects between treatment arms, the duration, format and number of sessions as well as the didactical approach will be identical in both treatment groups. After the first live session, breast cancer survivors will receive an information leaflet from 'Kom op tegen Kanker' regarding 'Pain in and after treatment' that they need to read carefully at home.
9701834|NCT04729673|Active Comparator|Patient's normal canine occlusal relationship.|Before full mouth rehabilitation with 8 stainless steel crowns for primary molars , the vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
9778679|NCT01113385|Experimental|Galactose|Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
9836131|NCT02770521|Experimental|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
10190134|NCT04869124|Placebo Comparator|Placebo|Placebo tablet, matching Dapglilflozin, orally, once daily for 12 weeks.
10190135|NCT04868279|Experimental|Interventional Gruop|"Web-based interactive nurse support program with the intervention group will continue for 3 months, the implementation will last 6 months in total. Individuals in the intervention group will be able to access the training content by accessing the website designated for the study from devices such as computers or mobile phones.~Data collection forms will be applied to the intervention group 3 times in total, before starting the Web-based interactive nurse support program, at the end of the Web-based interactive nurse support program (in the 3rd month) and in the 6th month."
10190136|NCT04868279|No Intervention|Control Group|Web-based interactive nurse support program will not be opened to the control group, only access to data collection tools will be provided.
10190137|NCT04867070||LLDN with ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
10190138|NCT04867070||LLDN without ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
10190139|NCT04865432|Experimental|UVB treatment|The treatment group will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 4-week study where they will be exposed to their individualized titration evaluation.
10190140|NCT04862390||Normal Pregnancy|Pregnant women with no diabetes
10190141|NCT04862390||Gestational diabetes on diet alone|
10190142|NCT04862390||Gestational diabetes on diet + Metformin therapy|
10190143|NCT04860518|Experimental|IV IFN beta-1a|Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
10190144|NCT04860518|Active Comparator|IV Dexamethasone|Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.
10190145|NCT04859231|Active Comparator|Control|
10190146|NCT04859231|Experimental|Investigational|
10190147|NCT04859231|No Intervention|Mother's-own Breast Milk|
10190148|NCT04858542|Experimental|Mask-wearing healthcare workers|All participants in this arm will view the educational health modules and their subjective/objective outcomes will be measure pre/post module viewing.
10190149|NCT04845191|Experimental|Experimental: Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
10190150|NCT04845191|Experimental|Experimental: Cohort 2: hAd5-S-Fusion+N-ETSD Subcutaneous and Oral|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Oral on Day 1
10190151|NCT04843722|Experimental|Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
10190152|NCT04843722|Experimental|Cohort 2: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual on Day 1
10190153|NCT04834635|Experimental|FundoRingOAGB group|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part (and suture cruroplasty if present hiatal hernia).
10190154|NCT04834635|Active Comparator|OAGB group|laparoscopic one anastomosis gastric bypass (and suture cruroplasty if present hiatal hernia).
10190155|NCT04831021|Experimental|Patients issued from dialysis units (clinic)|
9701835|NCT04729673|Sham Comparator|Canine occlusal relation after full mouth rehabilitation|After full mouth rehabilitation with 8 stainless steel crowns for primary molars , the vertical overlap of both upper and lower primary canines shall be determined by locating the meeting tip of the cusp of the upper primary canine over the lower primary canine at the right and left sides using a sharp pencil. The distance from this point to the tip of the lower primary canine shall be determined using a digital caliper.(Shenzhen Jiabaili Electronic Commerce Co., Ltd), and the reading will be photographed by a digital camera (iPhone 11 dual 12 MP Ultra-Wide and wide camera,Apple Inc.).
10190156|NCT04828733|Experimental|Antireflux OAGB group|Antireflux laparoscopic one anastomosis gastric bypass with suture cruroplasty and the total wrapping of the fundus of the gastric excluded part.
10190157|NCT04828733|Active Comparator|Standard OAGB group|laparoscopic one anastomosis gastric bypass with only suture cruroplasty.
10190158|NCT04820426||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of neuropathic pain and its effect on the quality of life, at their admission.
9701836|NCT04729699|Experimental|Intervention group|Intervention group (n=10) received 12 physiotherapy sessions and exercises for TMJ 30-45 minutes 2 days per week.
9701837|NCT04729699|Active Comparator|Control group|Control group (n=9) was introduced with physiotherapy program in order to perform it independently at home.
9701838|NCT04729764|Experimental|GP681 Tablet 20mg|Two sentinel subjects were first enrolled in the trial (test drug: placebo=1:1). After the two sentinel subjects completed the 72h safety follow-up after the administration, it was judged that if there was no dose-limiting toxicity , Then start the trial of the remaining 6 subjects in the dose group (experimental drug: placebo = 5:1).
9701839|NCT04729764|Experimental|GP681 Tablet 40mg|10 subjects in 40mg group (including 2 placebo)
9701840|NCT04729764|Experimental|GP681 Tablet 60mg|10 subjects in 60mg group (including 2 placebo)
9701841|NCT04729764|Experimental|GP681 Tablet 80mg|10 subjects in 80mg group (including 2 placebo)
9701842|NCT04729764|Experimental|GP681 Tablet 120mg|10 subjects in 120mg group (including 2 placebo)
9701843|NCT04729660|Active Comparator|Study group|Evaluate of the Kinesio tex gold tape that applied to anterior neck localised.
9701844|NCT04729660|Sham Comparator|Sham group|Evaluate of the Kinesio tex gold tape that applied to different neck localised as no-stretched.
9701845|NCT04730102||Patients undergoing rectal washout in transanal mesorectal excision|Patients undergoing rectal washout in transanal mesorectal excision for rectal cancer.
9701846|NCT04729790|Active Comparator|Patients with RCDI will receive FMT capsules from single donor|"Capsules made with intestinal bacteria from single healthy donor~st treatment day, lyophilized product generated from single donor (90g of stool)~nd treatment day, lyophilized product generated from single donor (90g of stool)"
9701847|NCT04729790|Experimental|Patient will receive FMT capsules from three donors|"Capsules made of intestinal bacteria from three healthy donors~st treatment day, lyophilized product generated from three donors (90g of stool)~nd treatment day, lyophilized product generated from three donors (90g of stool)"
9701848|NCT04729543|Experimental|Adoptive therapy with autologous MC2 TCR T cells|"Accelerated titration phase I design and a subsequent single arm phase II study~Prior to T cell transfer (day 0), patients will be treated with valproic acid (dose 50 mg/kg/d, 7d; days -9 to day -3) and 5' azacytidine (dose 75mg/m2/d, 7d; days -9 to day -3)~Phase I: patients will be treated with one single intravenous administration of MC2 TCR T cells at 5 different escalated doses of 5x10E7, 5x10E8, 5x10E9,1.0x10E10, and the total number of cultured TCR T cells (i.e., usually 1.0-5.0 x10E10 TCR T cells). MC2 TCR T cell infusions will be supported by low dose of IL-2 administrations (s.c. 5x10E5 IU/m2 2qd for 5 days)~T cells will be processed using IL-15 and IL-21 to generate young T cells"
9701849|NCT04729868|Other|group Levo-bupivacaine|Group A (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 1ml normal saline under the guidance of ultrasound for infraclavicular brachial plexus block.
9701850|NCT04729868|Other|group levo-bupivacaine plus 50µg dexmedetomidine|Group B (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 50µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
9701851|NCT04729868|Other|group levo-bupivacaine plus 100µg dexmedetomidine|Group C (20 patients): Anesthesia will be performed with 35 ml of 0.5% levo-bupivacaine plus 100µg dexmedetomidine under the guidance of ultrasound for infraclavicular brachial plexus block.
9701852|NCT04729582|Experimental|Verum Group|Participants receive primary human muscle stem cells as one-time injection into the urethral sphincter region under visual control using cystoscopy.
9701853|NCT04729582|Placebo Comparator|Placebo group|Participants receive placebo solution as one-time injection into the external urethral sphincter region under visual control using cystoscopy.
9701854|NCT04729478|Other|Natural sleep|"Natural sleep endoscopy (NSE)~OSA patients will be endoscopically evaluated during natural sleep.~During NSE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
9701855|NCT04729478|Other|Drug-induced sleep|"Drug-induced sleep endoscopy (DISE)~OSA patients will be endoscopically evaluated during drug-induced sleep.~During DISE additional physiological measurements (flow shape analysis, acoustic analysis of snoring sounds and esophageal pressure measurements) will be carried out."
9701856|NCT04729569|Other|Tested finish line preparation|Feather edge finish line preparation (Intervention)
9701857|NCT04729569|Active Comparator|Comparator finish line preparation|Deep chamfer finish line preparation (Comparator)
9701858|NCT04729530|Active Comparator|Active|Air purifier device with standard filter cartridges installed.
10204428|NCT02100722|Active Comparator|CABG|CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
10204429|NCT02059265|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10190159|NCT04813549||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of secondary fibromyalgia and its effect on the quality of life, at their admission.
9701859|NCT04729530|Placebo Comparator|Placebo|Air purifier device with placebo (non working) filter cartridges installed.
10190160|NCT04807907|Experimental|Infant Directed Speech (IDS) Video + IDS Calendar|The participant will be shown a 3-minute video describing the value of IDS and how the participant can use IDS with their child. The participant will receive an IDS-themed wall calendar.
10190161|NCT04807907|No Intervention|Control|No intervention. The participant will receive a regular wall calendar with an image of Stanford.
9701860|NCT04729465|Active Comparator|Active Comparator|"Active Comparator: Control Patients with cardiac disaese receive general anesthesia with Propofol~Interventions:~Drug: Propofol"
9701861|NCT04729465|Experimental|Experimental|"Experimental: Bispectral Index Monitor Patients with cardiac disease receive a general anesthesia with Propofol where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Interventions:~Drug: Propofol Device: Bispectral Index Monitor"
9701862|NCT04729491|Active Comparator|Dutasteride|Dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
10190162|NCT04805489|Experimental|stress test with masks|Within the framework of this research, an additional stress test is performed. This stress test, consisting of 3 periods, will follow a cardiovascular assessment requested as part of a health check-up, a license application, for risk factor assessment.
9701863|NCT04729491|Placebo Comparator|Placebo|Placebo q.d. for 30 days or until COVID-19 remission (defined as full remission of symptoms plus viral clearance through rtPCR-SARS-CoV-2)
9701864|NCT04729322|Experimental|Arm I (FMT, pembrolizumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.~POST-COLONOSCOPIC FMT: Patients receive standard of care pembrolizumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients receive fecal microbiota transplantation capsule PO on day 1. Cycles repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
9701865|NCT04729322|Experimental|Arm II (FMT, nivolumab)|"Patients receive metronidazole PO Q8H on days -14 to -8 and then vancomycin PO Q6H and neomycin PO Q6H on days -8 to -6. Patients then undergo colonoscopic FMT on day -5.~POST-COLONOSCOPIC FMT: Patients receive standard of care nivolumab IV over 30 minutes on day 1. Patients also receive fecal microbiota transplantation capsule PO on days 1 and 8 of cycles 1-2. Beginning in cycle 4, patients receive fecal microbiota transplantation capsule PO on day 1 of every other cycle. Cycles repeat every 14 days for up to 6 months in the absence of disease progression or unacceptable toxicity."
10190163|NCT04804358|Other|Anorexic women|Anorexic women with or without history of psychological trauma will perform study procedure : sociodemographic and clinical assessments, measurement of cardiac variability and salivary cortisol changes, before, during and after the exposition test.
10190164|NCT04804293|Experimental|Operative treatment (surgical decompression) for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated at 3 and 6 months post-operatively. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. This imaging will be done before the treatment. We will repeat the imaging study at 3 and 6 months after the treatment. Each ultrasound imaging session will take about less than 10 min. The investigators do not expect any discomfort during the imaging.
10190165|NCT04804293|Experimental|Corticosteroid injection treatment for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated after 6 weeks following corticosteroid injection. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. The investigators do not expect any discomfort during the imaging.
10190166|NCT04803227|Active Comparator|Emricasan|Emricasan
10190167|NCT04803227|Placebo Comparator|Placebo|Placebo
10190168|NCT04793698|Experimental|Compassion meditation|Compassion meditation is a contemplative meditation practice that fosters compassion through contemplation of common humanity.
10190169|NCT04793698|Active Comparator|Applied relaxation|Veteran.calm is an applied relaxation program that exposes participants to a variety of relaxation strategies and their application.
10190170|NCT04788628|Experimental|Epilepsy inpatients|Epilepsy inpatients with implanted hippocampal electrodes and continuous scalp EEG monitoring
10190171|NCT04788251|Experimental|Exercise-based fall prevention intervention|To receive 7 weeks of exercise-based programme
10190172|NCT04788251|Other|Wait-list controls|To receive fall prevention resources while waiting for programme
10190173|NCT04769323|Experimental|Group 1|Group 1 use virtual reality.
10190174|NCT04769323|Experimental|Group 2|Group 2 do traditional home exercises.
10190175|NCT04769323|Experimental|Group 3|Group 3 do traditional home exercises and virtual reality.
10190176|NCT04765969||Severe COPD patients|GOLD C and D group patients
10190177|NCT04765280||Patients with chronic musculoskeletal pain|Patients with any musculoskeletal pain for at least 3 months
10190178|NCT04764331|Other|Intervention|Caps will be provided for each subjects will use the cap once daily for10-minute treatment regimen
10190179|NCT04763941||Memory consultation patient|The study will be conducted on the basis of the patient consulting in Memory Consultation, specifically with the information already collected in normal care and the MEMORA cohort.
10190180|NCT04763928|Experimental|VenDec|Patients will receive a combination of VENETOCLAX (400 mg per day orally on days 1 to 28 of 28-days courses) and DECITABINE (20 mg/sqm intravenously on days 1 to 5 of 28-days courses)
10190181|NCT04761822|Experimental|Moderna COVID-19 Vaccine|The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.
10190182|NCT04761822|Experimental|Pfizer-BioNTech COVID-19 Vaccine|The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.
10204430|NCT02046096|Experimental|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
9701866|NCT04729517|Active Comparator|Azelastine Hydrochloride|Patients that will receive azelastine hydrochloride are defined as the active control arm.
9701867|NCT04729517|Experimental|AI201901|Patients that will receive AI201901 are defined as the test arm.
9701868|NCT04729166|Experimental|Study group|The study group were provided with education with structured educational material and followed in this study, in addition to the usual care provided by healthcare professionals.
9701869|NCT04729166|No Intervention|Control group|Control group was int the usual care.
9701870|NCT04729179|Experimental|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
9701871|NCT04729179|Placebo Comparator|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
9701872|NCT04729309|Experimental|Mass Balance (MB) Cohort|Participants will receive oral [14C] RO7049389 under fasted conditions, followed by intravenous IV [13C] after a two-hour period.
9701873|NCT04729309|Experimental|Absolute Bioavailability (BA) Cohort|In Periods 1 and 2, participants will receive oral [12C] RO7049389 under fasted conditions, followed by IV [13C] RO7049389. There is a minimum 7-day washout between periods.
9701874|NCT04729283||Sigmoidectomy for sigmoid cancer|Sigmoid resection surgery for patients who suffer from sigmoid cancer
9701875|NCT04729283||Sigmoidectomy for diverticulitis|Sigmoid resection surgery for patients who suffer from symptomatic diverticulitis
9701876|NCT04729270|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
9701877|NCT04729270|Experimental|CONTROL GROUP|The intervention for this group consisted of 10 sessions with Transcutaneous Electrical Nerve Stimulation (TENS) for a month.
9701878|NCT04729244|Active Comparator|CBD(hemp oil) cream|cream 2000mg/1oz (50mg/dose) once daily dosing for a total of 4 weeks to area of most pain.Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
10190183|NCT04761822|Experimental|Placebo +Moderna COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.5 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Moderna COVID-19 Vaccine, with the first dose administered 1 month later. The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart."
10190184|NCT04761822|Experimental|Placebo+Pfizer-BioNTech COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.3 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Pfizer-BioNTech COVID-19 Vaccine, with the first dose administered 1 month later. The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart."
10190185|NCT04759066|Experimental|Experimental|Participants will wear HEALiX device
9701879|NCT04729244|Active Comparator|CBD (Hemp oil) Tincture|1500mg CBD/30ml (50mg/dose) once daily dosing for total of 4 weeks. Patients will record outcome in pain, anxiety, sleep, and report any adverse effects.
9701880|NCT04729413|Experimental|Couples Counseling Intervention|Couples in the intervention group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health, as well as three couple counseling visits (one during pregnancy and two postpartum). The couples counseling sessions will provide (1) information on key relationship topics (communication, trust and respect, love and support); (2) relationship skills exercises (role playing); and (3) the opportunity to discuss health and relationship priorities/goals of the couple.
9701881|NCT04729413|Sham Comparator|Control|Couples assigned to the control group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health. Couples will also have the opportunity after the trial is complete to opt-in to receive a condensed one-session couples counseling visit (data not to be used for study purposes but offered for ethical reasons).
9701882|NCT04729348|Experimental|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment, including evaluations and follow up visits.~PEMBROLIZUMAB daily, every 3 weeks~LENVATINIB daily every 3 weeks"
9701883|NCT04729426|Experimental|Position Group|Position group
9701884|NCT04729426|No Intervention|Control group|No Position group
9701885|NCT04729153||Chronic HCV patients previously treated by DAADs.|
9701886|NCT04729153||Chronic HCV patients not treated by DAADs yet.|
9701887|NCT04729101|Experimental|Treatment A (vonoprazan)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Vonoprazan will be administered via 20 mg oral tablet once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
10190186|NCT04752904|Experimental|ClearSight group|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem, with a finger cuff around the middle finger, and the anesthesiologist manages blood pressure based on this.
9701888|NCT04729101|Active Comparator|Treatment B (lansoprazole)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Lansoprazole will be administered via 30 mg oral capsule once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
9701889|NCT04728932|Experimental|Levosimendan|A continuous infusion of Levosimendan will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
9701890|NCT04728932|Placebo Comparator|Placebo|A continuous infusion of Placebo will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects
10190187|NCT04752904|No Intervention|Control group|The blood pressure is measured at 1-minute intervals by non-invasive blood pressure monitor using the arm cuff, and the anesthesiologist in charge manages the blood pressure based on the measured blood pressure.
10190188|NCT04749108|Experimental|Experimental: Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy performed within 4 to 6 weeks from randomization."
10190189|NCT04749108|Active Comparator|RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy) followed after 7 weeks by a proctectomy."
10190190|NCT04748224|Active Comparator|group A (bupivacaine only)|Group A will be injected with 20 ml of 0. 25% bupivacaine in each side
10190191|NCT04748224|Active Comparator|group B (bupivacaine plus dexmedetomidine)|Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA).
10190192|NCT04744116|Active Comparator|Arm 1 (ruxolitinib)|Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
10190193|NCT04744116|Experimental|Arm 2 (ruxolitinib, lower dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
10190194|NCT04744116|Experimental|Arm 3 (ruxolitinib, higher dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
10190195|NCT04742270|Experimental|SIMEOX+ respiratory physiotherapy telecare|Use the device for 3 months in addition to usual care
10190196|NCT04739969|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
10190197|NCT04739969|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
10190198|NCT04735913|Other|Fasting group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
10190199|NCT04735913|Experimental|Postprandial group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®)orally after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
9701891|NCT04728789|Experimental|Avatrombopag treatment group|Avatrombopag would be started with 20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The dosage could range from 20mg/week to 60mg/day.
10190200|NCT04724668|Other|Morning light version+ Melatonin|Morning light version and melatonin 3mg capsule (3hrs before DLMO)
10190201|NCT04724668|Other|Morning light version+ Placebo|Morning light version and placebo capsule (3hrs before DLMO)
10190202|NCT04723667|Experimental|Intervention|13-week multimodal intervention
9701892|NCT04728841|Experimental|Treatment group|Arm of GS001
9701893|NCT04728867|Active Comparator|Surgical textbook|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be a textbook chapter explaining the details for laparoscopic rectal surgery.
9701894|NCT04728867|Active Comparator|3D animation|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational animation video showing laparoscopic rectal surgery.
9701895|NCT04728867|Active Comparator|Cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be an educational cadaveric dissection video showing laparoscopic rectal surgery.
9701896|NCT04728867|Active Comparator|Both 3D animation + cadaveric video|Volunteers in four groups were given 4 weeks to review their educational material at least two times. For this group, this will be both animation and educational cadaveric dissection video showing laparoscopic rectal surgery.
9701897|NCT04728802|Active Comparator|Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
9701898|NCT04728802|Placebo Comparator|Placebo + Usual Care|Placebo + usual care as determined by care provider
9701899|NCT04728945|Experimental|lung recruitment|Standard ventilatory management with lung recruitment every 30 minutes
9701900|NCT04728945|Active Comparator|control|Standard ventilatory management
9701901|NCT04728828||In-center adult haemodialysis patients eligible and voluntary for COVID19 vaccination|
9701902|NCT04728854||Adult bullous pemphigoid patients|Patients with diagnosis of bullous pemphigoid will participate in monitoring with face to face assessment and remote telehealth visits with store and forward images captured.
9701903|NCT04728958|Experimental|Gratitude Journal|Participants will be given instructions and asked to write a gratitude journal about their week, focusing upon what they are grateful for. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
10190203|NCT04723667|Active Comparator|Active control|5-week health education programme
9701904|NCT04728958|Experimental|Gratitude Letter|Participants will be given instructions and asked to write a gratitude letter to a person in their life, for whom they are grateful for either in that week or another time in their life. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times, creating 4 different letters).
9836132|NCT02770521|Placebo Comparator|Placebo (Part A)|Placebo administered as a single SC bolus injection.
9836133|NCT02770521|Experimental|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
10190204|NCT04722848|Experimental|Ponatinib+Blinatumomab|patients will receive induction with ponatinib followed by at least 2 cycles of blinatumomab
10190205|NCT04722848|Active Comparator|Chemotherapy+Imatinib|patients will receive a combination of imatinib and chemotherapy.
10190206|NCT04722276|Active Comparator|fraction of inspired oxygen 80%|
10190207|NCT04722276|Experimental|Fraction of inspired oxygen 80% with positive end expiratory pressure|
9701905|NCT04728958|Placebo Comparator|Weekly Diary|Participants will be given instructions and asked to write a diary about their week, focusing upon both the good and the bad they have experienced that week. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
9701906|NCT04728984|Experimental|Nalfurafine Hydrochloride 5μg|Oral administration after dinner, once daily for 14 consecutive days
9701907|NCT04728984|Experimental|Nalfurafine Hydrochloride 2.5μg|Oral administration after dinner, once daily for 14 consecutive days
9701908|NCT04728984|Placebo Comparator|Placebo|Oral administration after dinner, once daily for 14 consecutive days
9701909|NCT04728971|Experimental|Micafungin Preventing Group|
9701910|NCT04728971|Active Comparator|Others Preventing Group|
9701911|NCT04728763||Cases|"Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of invasive pulmonary aspergillosis (IPA) or Chronic pulmonary aspergillosis (CPA) in current care :~Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019) or~Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)"
9701912|NCT04728763||Control Group|Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care
9701913|NCT04728724|Experimental|Group A|Anti-PD-1 monotherapy
9701914|NCT04728724|Experimental|Group B|Anti-PD-1 plus chemotherapy
9701915|NCT04728568|Experimental|Sintilimab|Sintilimab will be administered every 3 weeks Sintilimab will be administered through IV infusion
9701916|NCT04728594|No Intervention|Delayed Contact|This group will not receive an email for at least two days.
9701917|NCT04728594|Experimental|Social Proof|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also emphasizes how many fellow health care workers have been vaccinated. Seeing the behaviors of other people might encourage recipients to copy that behavior.
9701918|NCT04728594|Experimental|Reframing Side Effects and Adverse Reactions|This group will receive an email that points out that vaccine availability for employees will soon be limited. It also addresses concerns about the side effects and adverse reactions of the vaccine. Due to potentially overblown concerns about the vaccine caused by the salience of side effects in the (social) media, the email attempts to reframe the risks by explicitly noting the small possibility of being affected by serious side effects and by contrasting that to the more severe effects of COVID-19. As a result of this reframing, recipients might recalibrate their perception of risks and benefits and opt for vaccination.
9701919|NCT04728529|Experimental|USSM protocol|patient in the intervention group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to USSM protocol of fluid resuscitation.
9701920|NCT04728529|Experimental|ACCM protocol|patient in the control group receive fluid resuscitation and inotropic-vasoactive agent, if needed, in accordance to ACCM protocol of fluid resuscitation.
9701921|NCT04728542||Origine|Group of 70 subjects who will undergo a surgery with the ORIGIN PS System
9701922|NCT04728542||Vanguard|Group of 70 subjects who will undergo a surgery with the VANGUARD System
9701923|NCT04728516|Experimental|Vonoprazan-based dual eradication therapy|H. pylori eradication using a dual eradication regimen, a course of 14 days, followed up to 6 months after randomization; the treatment regimen is as follows: routine use of Vonoprazan 20mg bid + amoxicillin 1g tid, a course of 14 days .
9701924|NCT04728516|Active Comparator|Pantoprazole|To take pantoprazole 40 mg daily, followed up to 6 months after randomization.
9701925|NCT04728698|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
9701926|NCT04728698|Placebo Comparator|Placebo|Excipient
9701927|NCT04728685|Active Comparator|Group A|One-fifth of body weight traction force will be given
9701928|NCT04728685|Active Comparator|Group B|One-third of body weight traction force will be given
9701929|NCT04728685|Active Comparator|Group C|One-half of body weight traction force will be given
9701930|NCT04728607|Experimental|Participants|Individuals requiring ring removal.
9701931|NCT04728581|Placebo Comparator|Placebo|use of placebo during first 2 weeks after TKA surgery
9701932|NCT04728581|Experimental|Low dose Mirtazapine|Use of Mirtazapine 3.75mg before lights-out, allowed to increase medication to 7.5mg
9701933|NCT04728581|Experimental|Low dose Quetiapine|use of Quetiapine 3.125mg before lights-out, allowed to increase medication to 6.25mg
9701934|NCT04728555|Experimental|Game before RT start|Intervention of a digital game five days before start of RadioTherapy
9701935|NCT04728555|Experimental|Game after RT start|Intervention of a digital game three days after start of RadioTherapy
9701936|NCT04728659|Experimental|Desogestrel Group|Ovulation inhibition will be performed using Desogestrel (75 mcg) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first
9701937|NCT04728659|Active Comparator|GnRH antagonist|Ovulation inhibition will be performed using ganirelix (Orgalutran, 0.25 mg/die) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first.
9701938|NCT04728490|Experimental|Allogenic transplantation using treosulfan in conditioning regimen|"Haplo-identical transplantation using treosulfan in conditioning regimen Treosuflan, in the conditioning regimen will be administrated as followed 10 gr/m2 per day -4, -3 and -2 IV route~In combination with:~Thiotepa 5 mg/kg on day -6 Fludarabine 30 mg/m2 per day from day -5 to day -1"
9701939|NCT04729010|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
9701940|NCT04729010|Active Comparator|Randomized Subjects receive a real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
9978049|NCT01367821||Patients with obstructive jaundice|Patients with obstructive jaundice
9978050|NCT01367821||Healthy volunteers|Healthy volunteers
9978051|NCT01367873|Placebo Comparator|Placebo|
9978052|NCT01367873|Experimental|VIA-3196|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
9978053|NCT01367873|Experimental|VIA-3196 with Food|Second, single dose administered after a standard high-fat breakfast.
9978054|NCT01367873|Placebo Comparator|Placebo with Food|
10190208|NCT04718545|Active Comparator|Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a conventionally prepared recipient site and sutured to cover the mucosal recession
9978055|NCT01367899||CONSERVE® Plus hip resurfacing|Recipients/C Plus (IDE)study
9978056|NCT01367912|No Intervention|Progesterone only group|received a single daily application of vaginal progesterone gel beginning from the day of OPU and continued at least until pregnancy was ruled out by a negative serum ß-hCG measurement performed on the 14th day after embryo transfer with no E2 added
9978057|NCT01367912|Active Comparator|Progesterone+Early Estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
10190209|NCT04718545|Experimental|Modified Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a modified recipient site and sutured to cover the mucosal recession
9701948|NCT04728737|Experimental|combined swallowing and IOPI group|the patients will receive swallowing therapy and IOPI biofeedback exercise program
9701949|NCT04728737|Active Comparator|combined swallowing and NMES group|the patients will receive swallowing therapy and neuromuscular electrical stimulation
9701950|NCT04728737|No Intervention|Normal group|20 normal people will receive sonography evaluations to verify the inter-rater and intra-rater reliability of sonography, and use IOPI to assess maximal muscle strength and endurance of oropharyngeal muscles.
9701951|NCT04728672|Experimental|Experimental Group|Kinesio tape was applied and then outcome measures were noted.
9701952|NCT04728672|Placebo Comparator|Control Group|Placebo Micropore Tape was applied and then outcome measures were noted.
9701953|NCT04728386|Experimental|curcumin irrigant|final flush root canal irrigation with 5 ml curcumin solution
9701954|NCT04728386|Experimental|sodium hypochlorite|final flush root canal irrigation with 5 ml sodium hypochlorite
9701955|NCT04728464||Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Patients will be treated by Periodontally Accelerated Osteogenic Orthodontics using fixed appliances.
9701956|NCT04729127|No Intervention|Treatment as usual|The families keep receiving their treatment as usual
9701957|NCT04729127|Active Comparator|ImPACT at a dose of 1 hour/week|ImPACT at a dose of 1 hour/week over 6 months
9701958|NCT04729127|Active Comparator|ImPACT at 4 hours/week|ImPACT at 4 hours/week over 6 months.
9701959|NCT04729036||mandibular fracture group|
9701960|NCT04729088|Experimental|Test Drug|Isosorbide 0.5% gel
9701961|NCT04728503|Experimental|5-Minute Mindful Movement Video|5 minute mindful movement video watched in the exam room on an iPad
9701962|NCT04728503|Placebo Comparator|Written Educative Materials|1 page printed written educative material about mindfulness benefits read for 5 minutes in the exam room
9701963|NCT04728256|Experimental|İntervention group|A six-session antenatal care program included both music listening and laughter therapy, and was designed for those in the study group as a session every week. The program was carried out by arranging a session of music listening for one week and a laughter therapy session over the following week. Also, the notes uttered by pregnants women were discussed at the week laughter listening sessions were performed. Data from the intervention group was collected four times as pretest (after providing informed contest), first-interval measurement (fourth week of the intervention), second-interval measurement (the first month following the birth) and post-test (the third month following the birth).The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
9701964|NCT04728256|No Intervention|Control group|Mothers receiving standard antenatal care in the prenatal period, giving birth, and having a three-month-old baby constituted the control group. The Control group was created after the procedures were completed for those in the intervention group. Only the post test was applied to the control group.The data were collected through Beck depression Inventery (BDI), Edinburg postpartum depressıon scale EPDS, Brief semptom ınventory(BSI) and maternal attachment scale(MAS) evaluate overall mental health status comprehensively. All participants responded to the questionnaire prepared for the study.
9701965|NCT04729218||Familial Mediterranean Fever group|30 participants
9701966|NCT04729218||Healthy group|30 participants
9701967|NCT04729140|Active Comparator|Ivermectin plus Doxycycline|"Ivermectin 200 mcg/kg on day 1 and day 2-plus doxycycline 100 mg tablets twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
9701968|NCT04729140|Active Comparator|Ivermectin plus Placebo|"Ivermectin 200 mcg/kg on day 1 and day 2-plus placebo tablet twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin and Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
9701969|NCT04729140|Placebo Comparator|Placebo plus Placebo|"Placebo (number of tablets according to weight) plus placebo twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
9701970|NCT04728425|Active Comparator|IVIG + SCIG|This group of MG patients will start with 2g/kg of IVIG on month 1, 1 g/kg of IVIG 4 and then 8 weeks later, and within 2 weeks switch to SCIG treatment
9701971|NCT04728425|Active Comparator|SCIG alone|This group of MG patients will start with SCIG alone
10190210|NCT04716959|Experimental|Prepectoral Prosthetic Breast Reconstruction|
10190211|NCT04716959|Active Comparator|Subpectoral Prosthetic Breast Reconstruction|
10204431|NCT02046096|Experimental|Cook Celect® Vena Cava Filters|Cook Celect® Vena Cava Filters
9701972|NCT04728243|Experimental|WHO QualityRights|Mental health professionals assigned to the experimental arm will be enrolled in the WHO QualityRights online training.
9701973|NCT04728243|Placebo Comparator|WHO Coronavirus Disease of 2019 (COVID19)|Mental health professionals assigned to the control arm will be enrolled in the WHO novel coronavirus 2019 online training series.
9836134|NCT02770521|Active Comparator|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
9701974|NCT04728178|Active Comparator|study group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. When SVV value increased to 13% and over in the study group, 250 ml of crystalloid was given in the first stage, and if it continued to be 13% and over, 250 ml of colloid bolus was given. Vasoconstrictor agent was used when SVV was below 13% and MAP was below 65 mmHg.
10190212|NCT04716153|Experimental|Interventional|"Patients in the interventional arm will follow a multifactorial sensory rehabilitation program focused on smell and taste that integrates several non-drug interventions, which are part of the current recommendations: program of workshops at the technical center, hydration of the mucous membranes with daily (3 times a day) liposomal sprays (LipoSaliva® and LipoNasal) between V0 and V1, presentation of visual dishes.~The workshops will take place at the frequency of one session of 2 hours per week and will last for 3 weeks. Each session will accommodate 6 to 10 participants. The program will include 3 workshops on olfactory rehabilitation and taste rehabilitation.~Exercises (taking up the themes discussed) will be carried out at home between 2 workshops."
9701975|NCT04728178|Placebo Comparator|control group|In the control group, fluid management was set as MAP (Mean arterial pressure) 65 mmHg and above and diuresis 0.5ml/kg/hour and above. Crystalloid infusion at 7ml/kg/hour was started. They were given 250 ml of crystalloid in the first stage if the MAP was below 65 mmHg, and 250 ml of colloid bolus if the hypotensive episode continued. If hypotension persisted despite these fluid boluses, a vasoconstrictor agent was used. In addition, when the diuresis of the patients was detected at 0.5mg/kg/hr or less, 250 ml of colloid bolus was administered.
9701976|NCT04728074|Experimental|Intervention|"The ENtering Employment and SUstaining Work (ENESUW) program consists of 6 main topics which are; self-awareness, occupational self-awareness, taking responsibility, teamwork and labor division, problem identification and problem solving. The entire program adopts a very plain and easy to understand method of information transmission in order to facilitate lossless comprehension and strengthen the trust relationship between the therapists and the participants.~The ENESUW program took 8 weeks in total with twice weekly sessions, making up a total of 16 structured group sessions. The group format enabled the participants to learn through meaningful peer interactions and group activities which were supportive of the main learning goals (i.e. group work, labor division and taking responsibility) of the program. The twice weekly sessions were 45 minutes long in order to keep the participants attentive and active throughout the program."
9701977|NCT04728074|Active Comparator|control|The control group also consisted of individuals with ID. They received face to face, individual vocational based occupational therapy approaches, which were twice a week for 8 weeks (approximately 40-45 minutes)
9778680|NCT01113398|Experimental|AMG 102 with Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg prior to AMG 102, which will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg. Subjects will receive infusions every 2 weeks.
10190213|NCT04716153|Other|Control|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
9778681|NCT01113463|Experimental|TPI 287|TPI 287 Starting dose 160 mg/m^2 intravenous (IV) every 3 weeks
9778682|NCT01113502|Experimental|Phase 1 DL1|50 mg; Taken daily by mouth
9778683|NCT01113502|Experimental|Phase 1 DL 2|100 mg; Taken daily by mouth
9778684|NCT01113502|Experimental|Phase 1 DL3|200 mg; Taken daily by mouth
9778685|NCT01113502|Experimental|Phase 1 DL 4|300 mg; Taken daily by mouth
9778686|NCT01113502|Experimental|Phase 2|200 mg taken daily by mouth for 2 weeks; then 300 mg taken daily by mouth
9778687|NCT01113541|Experimental|Active treatment (switch to oral Ziprasidone)|
9778688|NCT01113580|Experimental|Adults|Healthy volunteers aged 18 to 59 years
9778689|NCT01113580|Experimental|Older Adults|Healthy volunteers aged 60 years or older
9778690|NCT01113632|Experimental|Ofatumumab 1000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks
9778691|NCT01113632|Experimental|Ofatumumab 2000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks
9778692|NCT01113710||Neupro®|Routine treatment in accordance with the local marketing authorization for Neupro® in RLS
9778693|NCT01113723|Other|CMAC Device|CMAC Intubating device time to achieve successful tracheal intubation.
9778694|NCT01113723|Active Comparator|Fiberoptic bronchoscope|Fiberoptic bronchoscope Intubating device time to achieve successful tracheal intubation.
9778695|NCT01113749|Experimental|Decision support|Structured decision aid with prompting to share information in discussion with primary treating health care providers.
9778696|NCT01113749|No Intervention|Control|Usual care
9778697|NCT01113801|Placebo Comparator|Placebo|
9778698|NCT01113801|Experimental|2 mg LY2382770|
9778699|NCT01113801|Experimental|10 mg LY2382770|
9778700|NCT01113801|Experimental|50 mg LY2382770|
9778701|NCT01113879|Experimental|Aphasia therapy with an exercise adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Aerobic exercise: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate."
9778702|NCT01113879|Placebo Comparator|Aphasia therapy with a stretching adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Stretching: Stretching will occur for 50 minutes a day, three days/week for 12 weeks."
9778703|NCT01113892|Active Comparator|EXXCEL Soft|A vascular graft comprised of extruded, expanded polytetrafluroethylene (ePTFE), indicated for use as a vascular prosthesis for replacement or bypass of diseased peripheral arteries (510(k) K962433).
9836135|NCT02770547|Active Comparator|Low Heat Thermotherapy|Low heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies low heat to the subject's leg.
10190214|NCT04716127|Experimental|Women 50 to 65 years with no regular cervical cancer screening|Women aged 50 to 65 years with no cervical smear or no gynecological examination for more than three years, attending the mobile unit for breast cancer screening in the Department of Hérault, or the Medical and Social Care Center in the Department of Aude.
9701978|NCT04728113|Experimental|Early together group|Oncological standard of care at M0, M3, M6, M9 and M12 with early introduction of supportive care every 6 weeks.
9701979|NCT04728113|Active Comparator|Control group|Oncological standard of care at M0, M3, M6, M9 and M12.
9701980|NCT04728126||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
9701981|NCT04728334|Experimental|AK117 monotherapy|AK117 monotherapy intravenous (IV) infusion - Weekly doses
9701982|NCT04728321|Experimental|AK104|AK104 15mg/kg IV every 3weeks (Q3W)
9701983|NCT04728321|Experimental|AK104 and Lenvatinib|AK104 15 mg/kg IV every 3 weeks (Q3W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
9701984|NCT04728204|Experimental|Intervention group|8 module, 8 week long internet-based intervention for reducing burden of depression
9701985|NCT04728204|No Intervention|Control group|Participants randomized to the control group will be instructed to wait until the intervention group finishes the treatment and that they will be able to use the same intervention afterwards.
9701986|NCT04728412|Experimental|patients undergoing bronchoscopy under sedation with or at risk of respiratory failure|
9701987|NCT04728399|Experimental|Experimental group|2g Soybean peptide, 3g CLA and ng protein.
9701988|NCT04728399|Placebo Comparator|Control group|2g+N protein and 3g Soybean oil.
9701989|NCT04728360|Experimental|BAT2206|"Patients who weigh ≤ 100 kg: BAT2206 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
9701990|NCT04728360|Active Comparator|Stelara (EU-sourced)|"Patients who weigh ≤ 100 kg: EU-sourced Stelara 45 mg (1 injection of 45 mg/0.5 mL) by SC injection via PFS.~Patients who weigh > 100 kg: EU-sourced Stelara 90 mg (2 injections of 45 mg/0.5 mL each) by SC injection via PFS."
10190215|NCT04714671|Experimental|Euthymics patients with history of suicide attempt (suicide attempters)|Euthymics patients with a lifetime history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
9701991|NCT04728308|Active Comparator|Experimental group|20ml of 0.5% bupivacaine is infiltrated in the subcutaneous tissue around the incision site
9701992|NCT04728308|Placebo Comparator|Placebo group|20 ml of distill water is infiltrated in the subcutaneous tissue around the incision site
9701993|NCT04728347|Experimental|ARCT-021|Participants will receive a single dose of ARCT-021 on Day 1
9701994|NCT04728347|No Intervention|Long-term follow up from ARCT-021-01|Participants will not receive intervention but will be followed for safety.
9701995|NCT04728269|Experimental|Lactibiane topic AD|Cosmetical product Lactibiane Topic AD
9701996|NCT04728269|Placebo Comparator|Placebo|Placebo made with the same base as the cosmetical product
10190216|NCT04714671|Experimental|Euthymics patients without any history of suicide attempt (affective controls)|Euthymics patients without history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
10205426|NCT01024829|Other|Boost 50% SUV area|Patients in this arm receive radiotherapy (66Gy) in 24 fractions of 2.75Gy with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET-CT scan)
9701997|NCT04728230|Experimental|Treatment (chemo-immunotherapy, radiation therapy)|See detailed description.
9701998|NCT04728035|Experimental|Dose escalation (part 1)|Patients will receive irinotecan liposome injection (CSPC) at the initial starting dose until progression or unacceptable toxicity.
9701999|NCT04728035|Experimental|Dose expansion (part 2)|Once the appropriate dose has been established in Part 1, patients will be enrolled into two expansion cohorts according to the sub-type of breast cancer.
9702000|NCT04727723||Lutathera®|Lutathera® will be administered according to the local label and according to the recommended treatment regimen in adults consisting of four equally divided doses of Lutathera® for a total of 29.6 GBq (800 mCi).
9702001|NCT04727879|Other|PMR|"Patients with PMR will be offered biopsy of the synovial membrane with puncture of synovial fluid during cortisone infiltration for analgesic purposes. In case of associated peripheric arthritis, the patient will also be offered a joint fluid sample during a cortisonic infiltration for analgesic purposes, performed as part of routine care~The study-specific examination that is not part of current practice is the synovial biopsy performed during the cortisonic infiltration procedure."
9702002|NCT04727879|Other|Control|Witnesses recruited into the orthopedic surgery department will be offered a synovial membrane biopsy during a shoulder surgery in the context of mechanical pathology.
9702003|NCT04728009|Experimental|longan and lingzhi mushroom syrup|All participants (N = 8) were asked to consume 5 mL of longan and lingzhi mushroom syrup as a sweetener daily for 12 weeks.
9702004|NCT04727671|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702005|NCT04727671|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702006|NCT04727658|Experimental|Radiosurgical thalamotomy on GammaKnife|
9702007|NCT04727892||complications after epilepsy surgery|Group A with no complication; Group B with complications
9702008|NCT04727619|Experimental|Experimental|Participants who participated in the SLEEP program.
10190217|NCT04707846|Experimental|Bright Light Therapy|Individuals will receive bright blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Bright blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total). Bright blue light treatment has been previously identified as an efficacious treatment for fatigue. It has also been shown in a number of studies that the blue wavelength of light is a key component to the shift of fatigue measures in patient reported outcomes.
10190218|NCT04707846|Active Comparator|Dim Light Therapy|Individuals will receive dim blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Dim blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total).
9702009|NCT04727619|No Intervention|Control|Participants who did not participate in the SLEEP program.
9702010|NCT04727905|Experimental|energy drink|Intake after exercise
9702011|NCT04727905|Placebo Comparator|Seasoned water|Intake after exercise
9702012|NCT04727697|Active Comparator|Standard of Care, preoperative teaching group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care.
9702013|NCT04727697|Experimental|Augmented Reality perioperative experiences group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care in addition to receiving the augmented reality (AR) perioperative experience.
9702014|NCT04727996|Experimental|Sitravatinib/Tislelizumab|All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
9702015|NCT04727918|Active Comparator|Cold biopsy forceps (CBF)|Patients will be allocated to the CBF arm after randomization (1:1)
9702016|NCT04727918|Active Comparator|Cold snare polypectomy (CSP)|Patients will be allocated to the CSP arm after randomization (1:1)
9702017|NCT04728022|Experimental|Students|Education program
9702018|NCT04727840|Other|Intervention|All 20 CKD patients will be receiving a potassium binder while consuming a tailored diet of non-potassium restricted foods
9702019|NCT04727684|Active Comparator|Agonist Group (long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702020|NCT04727684|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702021|NCT04727957||Dataset for development and testing|
9702022|NCT04727957||Dataset for external validation|
9702023|NCT04727515|Experimental|General anesthesia|Patients will receive general anesthesia
9702024|NCT04727515|Experimental|Axillary Block|Patients will receive axillary nerve block
9702025|NCT04727801||Febrile (n=50)|Febrile is defined as having sublingual temperatures of 37.5 °C or above. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
9702026|NCT04727801||Afebrile (n=50)|Afebrile is defined as having sublingual temperatures of less than 37.5 °C. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
9702027|NCT04727814||Water exchange with computer-aided detection system|Computer-aided detection system overlaid videos with water exchange colonoscopy method
9702028|NCT04727814||Air insufflation with computer-aided detection system|Computer-aided detection system overlaid videos with air insufflation colonoscopy method
9702029|NCT04727775||Complications|Evaluathion
9702030|NCT04727775||Oxygen status|Evaluathion
9702031|NCT04727775||Oxugen support|Evaluathion
9702032|NCT04727853|Experimental|irinotecan liposome injection|Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, over 90 min on Days 1 of every 14-day cycle.
10190219|NCT04707846|No Intervention|Usual Care|During usual care periods, participants will be instructed to abstain from use of AYO light therapy devices, and instructed to treat their fatigue as they normally would. Usual care will be presented in 2 periods each 2 weeks in length (4 weeks total).
10190220|NCT04704193|Experimental|Electronic Decision Aid|Participants in this arm will complete an electronic decision aid for genetic testing.
10190221|NCT04702581|Experimental|PCV alone|Administration of 6 cycles of PCV chemotherapy alone.
9702033|NCT04727606|Experimental|Open label|The study provides for a single group, which will be its own control (pre/post intervention study). Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day) for 1 month
10190222|NCT04702581|Active Comparator|RT + PCV|Radiotherapy followed by administration of PCV chemotherapy.
9702034|NCT04727346||Study Group|CBCT and DISE
9702035|NCT04727346||Control Group|DISE only
9702036|NCT04727437|Active Comparator|Control|Full dose anticoagulation treatment as standard care for at least 3 months.
9702037|NCT04727437|Experimental|Intervention|Withholding anticoagulation for Isolated Sub-Segmental Pulmonary Embolism (ISSPE) for at least 3 months.
9702038|NCT04727255|Experimental|Intervention|The intervention will be implemented through a group-based delivery format involving internal educated resilience trainers. The Engaged and Resilient training program consists of twenty weekly, short-term sessions to build resilience skills in leaders.
9702039|NCT04727255|No Intervention|Control|Participants in the (waitlist) control group will be exposed to their usual activities in the organization and will not perceive any interventions from the resilience curriculum. After the final data is collected, the control participant will be offered the opportunity to be trained by the internal trainers, educated in the research study.
9702040|NCT04727268||Group 1|"Retrospective data regarding genetic information will be collected from participants' medical records.~Deep phenotyping of participants will also be completed."
9702041|NCT04727190|Experimental|TBCB group|Specimens were obtained using 1.1 mm ultrathin cryoprobe with or without guide sheath by bronchoscope.
9702042|NCT04727190|Active Comparator|TBFB group|Specimens were obtained using 1.5 mm or 1.9 mm biopsy forceps with or without guide sheath by bronchoscope.
9702043|NCT04727320|Experimental|patient+TUDCA|
9702044|NCT04727320|Placebo Comparator|patient+placebo|
9702045|NCT04727489||Autism Spectrum Disorder|Probands with Autism Spectrum Disorder, (N=700), Diagnosis of ASD according to DSM-V criteria For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
9702046|NCT04727489||Control without Autism Spectrum Disorder|Controls without Austim Spectrum Disorder, aged 6 to 40, N=2100 (300 adultes, 300 children) Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
9702047|NCT04727489||Relatives of probands with Autism Spectrum Disorder|"Relatives of probands with Autism Spectrum Disorder (N=1200 parents, N=600 siblings, N=300 other relatives)~Without Autism Spectrum Disorder diagnosis according to DSM-V,~With Autism Spectrum Disorder diagnosis according to DSM-V, and using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders"
9702048|NCT04727489||Relatives of controls|Relatives of controls without Autism Spectrum Disorder, N=400 first degree relatives
9702049|NCT04727164|Experimental|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced melanoma and other solid tumors
9702050|NCT04727541|Experimental|Neoadjuvant therapy with Bintrafusp alfa|1200 mg of Bintrafusp alfa will be administered by intravenous infusion every 2 weeks for a total of 2 dosages (Q2W). Subsequently, the surgery will be performed.
9702051|NCT04727502|Active Comparator|( Group Duloxetine )|• Dosing and administration (Group A) Duloxetine 30 mg /day oral intake at bed time
9702052|NCT04727502|Active Comparator|(Group Pregablin )|control group Pregablin 150mg /day( 75 mg /12 hours ) oral intake.
9702053|NCT04727398|Other|Cataract patients who was scheduled for phacoemulsification|Wide-field optical coherence tomography was performed before the surgery, and then was done at 1, 3, 6 and 12 months following the phacoemulsification.
9702054|NCT04727372||Islamabad Group|Individuals residing and surveyed in Islamabad
9702055|NCT04727372||Lahore Group|Individuals residing and surveyed in Lahore
9702056|NCT04727372||Faisalabad Group|Individuals residing and surveyed in Faisalabad
9702057|NCT04727372||Bahawalpur Group|Individuals residing and surveyed in Bahawalpur
9702058|NCT04727450|Active Comparator|1. Integrated format|Integrated or Combination of ABC of A: cognitive training. B: physical training and C: Combined Cognitive and Physical Training (CCPT).
9702059|NCT04727450|Active Comparator|2. Cognitive training + Physical Training (A+B)|Intervention of A & B treatments.
9702060|NCT04727450|Active Comparator|3. Physical training + CCPT (B+C)|Intervention of B & C treatments.
10190223|NCT04693377|Active Comparator|Arm A (SBRT)|Patients undergo stereotactic body radiation therapy for 1 fraction.
10190224|NCT04693377|Experimental|Arm B (cryoablation, SBRT)|Patients undergo cryoablation. Within 10 days after cryoablation, patients undergo stereotactic body radiation therapy for 1 fraction.
10190225|NCT04693325|Experimental|Prolonged normothermic machina perfusion|Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.
10190226|NCT04693039|Experimental|FLZ-150mg|Drug：Phenlarmide；Dosage：150mg；
10190227|NCT04693039|Experimental|FLZ-300mg|Drug：Phenlarmide；Dosage：300mg；
10190228|NCT04693039|Experimental|FLZ-600mg|Drug：Phenlarmide；Dosage：600mg；
9702061|NCT04727450|Active Comparator|4. CCPT + Cognitive training (C+A)|Intervention of C & A treatments.
10190229|NCT04693039|Experimental|FLZ-900mg|Drug：Phenlarmide；Dosage：900mg；
10190230|NCT04693039|Placebo Comparator|Placebo-150mg|Drug：Placebo；Dosage：150mg；
9702062|NCT04727450|No Intervention|5. Control group|No intervention
9702063|NCT04727580|Experimental|HSK7653 10 mg|
9702064|NCT04727580|Experimental|HSK7653 25 mg|
9702065|NCT04727580|Placebo Comparator|Placebo|
9702066|NCT04727476||Children with attention deficit disorders|children aged 7-13 years who have attended a specialised outpatient clinic treating children with attention deficit disorders i in the period from 1 April 2013 to 5 November 2019.
10190231|NCT04693039|Placebo Comparator|Placebo-300mg|Drug：Placebo；Dosage：300mg；
10190232|NCT04693039|Placebo Comparator|Placebo-600mg|Drug：Placebo；Dosage：600mg；
9702067|NCT04727385|Experimental|single-arm of 3 cohorts|"These patients will be sequentially recruited in 3 cohorts :~One disc level cohort: 5 patients with only one disc to be treated; First enrolled cohort with 48 weeks of follow-up (9 visits V1-V9)~Two disc level cohort: 5 patients with 2 discs to be treated; Second enrolled cohort with 36 weeks of follow-up (8 visits, same visits except for V9)~One or two disc level cohort: 10 patients with 1 or 2 discs to be treated; Third enrolled cohort with 24 weeks of follow-up (6 visits, V1 to 7 except for V4)"
9702068|NCT04727203|Experimental|Intervention|Partcipants in this group will receive the 8 week healthy lifestyle program
9702069|NCT04727203|No Intervention|Control|Participants in this group will not receive any intervention
9702070|NCT04727294||MGUS, SMM, MM Patients or their Caregivers|"Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile.~The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility.~Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete."
9702071|NCT04727034|Active Comparator|Control group|Propofol（1.5mg/kg）
9702072|NCT04727034|Experimental|Test group 1（Remimazolam tosylate 0.15mg/kg）|Remimazolam tosylate 0.15mg/kg
9702073|NCT04727034|Experimental|Test group 2（Remimazolam tosylate 0.2mg/kg）|Remimazolam tosylate 0.2mg/kg
9702074|NCT04727112||asthma and rhinitis|Screening of patients with upper and lower airway symptoms
9702075|NCT04727112||asthma and rhintis follow-up|same Group as screened in 2000, was followed up three years later
9702076|NCT04727008|Experimental|CXCR4 modified anti-BCMA CAR T cell therapy|CAR T cell therapy
9702077|NCT04727216|Active Comparator|Continuous DRG-S Dosing|2 week stimulation program using continuous DRG-S dosing at standard stimulation parameters
10190233|NCT04693039|Placebo Comparator|Placebo-900mg|Drug：Placebo；Dosage：900mg；
10190234|NCT04691206|Other|standardized step-wise operative curriculum|"General surgery residents at Mayo Clinic will complete surveys measuring resident autonomy, performance, confidence and case complexity at baseline and postoperatively following laparoscopic cholecystectomy to serve as a pre-intervention baseline.~A standardized step-wise operative curriculum will then be implemented Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID). The effectiveness of the intervention will then be measured by comparing survey results pre and post intervention."
10190235|NCT04690218||Mastalgia|"Mastalgia group will consist of women with confirmed mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
10190236|NCT04690218||Controls|"Controls group will consist of women attending to general surgery clinic for reasons other than mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
10190237|NCT04686903|Experimental|Epiduroscopy|Epiduroscopy in patients with FBSS
10190238|NCT04686903|Experimental|Racz catheter epidural procedure|Racz catheter epidural procedure in patients with FBSS
10190239|NCT04686903|Experimental|Caudal epidural block|Caudal epidural block treatment of FBSS
10190240|NCT04684823|Experimental|Use of Patch Cap and Patch App|Subjects will use Patch Technologies to track their medication regimen compliance
10190241|NCT04682860|Placebo Comparator|Placebo|In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds
10190242|NCT04682860|Active Comparator|Hyoscine N butylbromide|In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.
9702078|NCT04727216|Experimental|1 minute on: 1 minute off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 1 minute off intermittent DRG-S dosing at standard stimulation parameters
9702079|NCT04727216|Experimental|1 minute on: 2 minutes off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 2 minutes off intermittent DRG-S dosing at standard stimulation parameters
9702080|NCT04726956||case cohort|Pancreatic ductal adenocarcinoma patient
9702081|NCT04726956||control cohort|healthy control person
9702082|NCT04726982|Experimental|Low dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
9702083|NCT04726982|Experimental|High dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
9702084|NCT04726982|Placebo Comparator|Placebo|Matching placebo tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
9702085|NCT04726644||patients|cirrhotic patients with ventral hernia
9702086|NCT04726657|Active Comparator|Premixed Insulin|Premixed Human Insulin
9702087|NCT04726657|Active Comparator|Premixed insulin|Premixed Insulin Analog
9702088|NCT04726722|Experimental|Design of the CBT treatment content|Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content
9702089|NCT04726722|Experimental|Control of support and feedback|Patient-controlled support and feedback (person-centred) vs. therapist -controlled.
9702090|NCT04726735||Patients with histologically documented normal bladder|
9702091|NCT04726735||Patients with histologically documented Non Muscle Invasive Bladder Cancer|
9702092|NCT04726735||Patients with histologically documented Muscle Invasive Bladder Cancer|
9978058|NCT01367912|Active Comparator|Progesterone+Late estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel
10190243|NCT04680936|Active Comparator|low dose dextrose arm (5% dextrose)|Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
10190244|NCT04680936|Active Comparator|high dose dextrose arm (15% dextrose)|Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
10190245|NCT04680936|Active Comparator|Isotonic saline arm (0.9% NaCl)|Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
10190246|NCT04676724|Experimental|GSK3228836 for 24 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 24 weeks, followed by up to 24 weeks of PegIFN.
9702093|NCT04727047|Active Comparator|Neuromuscular Electrical Stimulation|"Neuromuscular electrical stimulation will be applied to the calf muscles. The level of stimulation will be increased weekly from 10 to 30 mA during the first 6 weeks after surgery.~In addition, patients will follow standard therapy for Achilles tendon repair."
9702094|NCT04727047|No Intervention|Control|Patients will follow standard therapy for Achilles tendon repair.
9702095|NCT04727073|Experimental|Arm A|Experimental: Spironolactone Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was > 30 mL/min/m2 and potassium < 4.5 mmol/L.
9702096|NCT04727073|Placebo Comparator|Arm B|Placebo Comparator: Placebo Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
10190247|NCT04676724|Experimental|GSK3228836 for 12 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 12 weeks, followed by up to 24 weeks of PegIFN.
9702097|NCT04726631|Other|Basal insulin analogue and premeal rapid acting insulin|
9702098|NCT04726631|Other|Neutral Protamine Hagedorn with regular insulin|
9702099|NCT04726774|Experimental|Hypnosis group|The intervention consisted of two hypnosis sessions by a physician trained in medical hypnosis. The hypnosis group received also the usual rehabilitation program.
9702100|NCT04726774|Active Comparator|Control group|The control group follow the usual rehabilitation program which includes intensive physiotherapy for 2 weeks (i.e., focused on walking and enhancing balance exercises in group or individual and group) and patient education on the risk of falling and on prevention of falls.
9702101|NCT04726930||Intercostal nerve block with surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.~Code name: ICNB-INUS-check"
9702102|NCT04726930||Paravertebral block with surface ultrasound|Number of participants: 10 Paravertebral blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.
9702103|NCT04726930||Intercostal nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: ICNB-INUS-guide"
9702104|NCT04726930||Paravertebral nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Paravertebral blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: PVB-INUS-guide"
9978059|NCT01367925||Cruciate Substituting Tibial Insert|
10190248|NCT04674319|Experimental|Brain engagement while using compesatory modes for walking|Brain engagemnent (recruitment of attention) is measured during four walking conditions
10190249|NCT04671251|Experimental|AEVI-007|
10190250|NCT04668638|Other|Control group|Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.
10190251|NCT04668638|Other|Intervention group|Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.
10190252|NCT04667494|Experimental|Sonotherapy|All participants will undergo sonotherapy
10190253|NCT04666636|Placebo Comparator|Placebo|Participants in the group will receive placebo.
9978060|NCT01367925||Posterior Stabilized Tibial Insert|
9978061|NCT01367938||OMNI Apex Ultracongruent Knee Device|
9702105|NCT04726904|Other|Conventional lead placement|The cadaver is placed in the prone position. The exact location for insertion of the needle is defined with the conventional technique.
9702106|NCT04726839||Stroke suspicion|Patients with stroke suspicion within 24 hours of stroke's symptoms
9702107|NCT04726670||A Comparison of Pain Levels|A Comparison of Pain Levels at different time intervals according to the Irrigation Activation Protocols
9702108|NCT04726670||The evaluation of postoperative pain (Mean Rank) within the group according to time periods|The evaluation of postoperative pain (Mean Rank) within the group according to time periods
9702109|NCT04726943|Experimental|RF Energy|RF delivery targeting the atrial side of a significant residual leak in patients with acute and chronic evidence of incomplete percutaneous LAA occlusion
10190254|NCT04666636|Experimental|Mirabegron|Participants in this group will receive Mirabegron for 16 weeks.
10190255|NCT04664985|Active Comparator|Mucogyne®|The dosage during the study will be 1 Mucogyne® ovule per day at bedtime for 10 days and then 1 ovule every 2 days until the end of the 3-month follow-up.
9702110|NCT04726813|Experimental|a self-guided Internet delivered intervention|MinADHD: 7 self-help modules.
9702111|NCT04726813|Placebo Comparator|Psycho-education|One self-guided psychoeducation module
10190256|NCT04664985|No Intervention|Control|No treatment for this arm.
9702112|NCT04726683|Experimental|Dry needling|Trigger point dry needling on an active myofascial trigger point of the masseter muscle.
9702113|NCT04726683|Experimental|Injection|Trigger point injection of lidocaine on an active myofascial trigger point of the masseter muscle.
9702114|NCT04726683|Placebo Comparator|Placebo|Combines sham dry needling + sham injection.
9702115|NCT04726683|Active Comparator|Dry needling + Injection|Combines experimental dry needling and injection
9702116|NCT04727021|Experimental|Treatment A: Single oral dose of a 20 mg tablet rivaroxaban|"2-way crossover: The subjects will receive the following treatments in a randomized order:~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
9702117|NCT04727021|Experimental|Treatment B: Single oral dose of 20 mg rivaroxaban, granules|"2-way crossover: The subjects will receive the following treatments in a randomized order:~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
9702118|NCT04726787|Experimental|Bridging Radiotherapy|Disease areas requiring effective long-term control will receive full-dose radiotherapy (20-30Gy/5-15#); other areas will receive low dose (4Gy/2#)
9702119|NCT04726592|Placebo Comparator|Control arm|"placebo and standard care :~Placebo IV~Ketoprofen 100 mg IV (if nausea-vomiting)~Metoclopramide 10 mg IV(if nausea-vomiting)"
9702120|NCT04726592|Experimental|Experimental arm|"clorazepate and standard care :~Clorazepate 20 mg IV~Ketoprofen 100 mg IV (if nausea-vomiting)~Metoclopramide 10 mg IV(if nausea-vomiting)"
10190257|NCT04664946|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
9702121|NCT04726917||Patients with COPD|Patients qualified for 3-week in-hospital pulmonary rehabilitation
10190258|NCT04664933|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
9702123|NCT04726696|No Intervention|Control group|None intervention to be administered, they continue their normal routine.
9702124|NCT04726696|Experimental|Intervention group|ROLE-AP is a multifaceted program offered over a month period to participating primary care nurses and includes three interactive workshops. Each workshop will be 4 hours long.
9702125|NCT04726761||Frequent/Non-frequent|Patients randomized to this order will first have an ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night) and then a few days later have another ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours)
9702126|NCT04726761||Non-frequent/frequent|Patients randomized to this order will first have an ABPM conducted with the non-frequent measuring interval (1 time an hour during all 24 hours) and then a few days later have another ABPM conducted with the frequent measuring intervals (3 times an hour during day and 2 times an hour at night)
9702127|NCT04726319|Experimental|Intervention|In addition to usual care, patients will be asked to answer questions about any family history through the use of a questionnaire.
9702128|NCT04726319|No Intervention|Usual Care|Patients receive usual care, which consists of health care providers inquiring about and dealing with family history as they would in usual practice.
9702129|NCT04726293|Experimental|Mango beverage|Mango composite served as a frozen drink
9702130|NCT04726293|Placebo Comparator|Control beverage|Energy matched Control frozen drink
9702131|NCT04726332|Experimental|XL102 Single-Agent Dose-Escalation Cohorts|Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
9702132|NCT04726332|Experimental|XL102 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with triple-negative breast cancer (TNBC) (Cohort D), epithelial ovarian cancer (EOC) (Cohort E), hormone receptor-positive breast cancer (HR+ BC) (Cohort F), and metastatic castration-resistant prostate cancer (mCRPC) (Cohort G).
9702133|NCT04726332|Experimental|XL102 + Fulvestrant Dose-Escalation Cohorts|Subjects with HR+ BC (Cohort B) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
9702134|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts|Subjects with mCRPC (Cohort C) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
9702135|NCT04726332|Experimental|XL102 + Fulvestrant Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with HR+ BC (Cohort H).
9702136|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with mCRPC (Cohort I).
10190259|NCT04654052|Other|VerifyNow® PRUTest ≤30 (De-escalated Prasugrel Ticagrelor )|Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will be de-escalated to Clopidogrel 75 mg q.d during 11 months.
9702137|NCT04726267|Other|Glaucoma patients who was scheduled for trabeculectomy|Wide-field OCT was performed 1-2 weeks before the trabeculectomy. The OCT was done postoperatively at 1 month, 3 months, 6 months and 12 months after surgery.
9702138|NCT04726345|Experimental|Fexofenadine|Participants in this arm will receive fexofenadine 180mg once daily, in addition to standard of care pain medications (NSAIDs).
9702139|NCT04726345|Placebo Comparator|Placebo|Participants in this arm will receive placebo once daily, in addition to standard of care pain medications (NSAIDs).
9702140|NCT04726436|Experimental|Dextrose 5%|100 mL/ hour of dextrose 5% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon to assess the timing and dosing of dextrose solution effect on PONV.
9702141|NCT04726436|Experimental|Dextrose 10%|100 mL/ hour of dextrose 10% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
9702142|NCT04726436|Placebo Comparator|Saline placebo|100 mL/ hour of normal saline were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
9778704|NCT01113892|Experimental|FUSION Bioline|A synthetic vascular graft constructed of two layers. The inner layer is comprised of extruded, ePTFE. The outer layer is comprised of knit polyester textile. These two layers are fused together with a proprietary polycarbonate-urethane adhesive. The vascular graft also has a heparin coating on the graft's luminal surface. The Bioline coating is a bioactive surface coating consisting of a covalent Heparin Sodium coupled to immobilized recombinant human albumin.
10190260|NCT04654052|Other|VerifyNow® PRUTest ≤30 (Prasugrel or Ticagrelor )|Active comparator: Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will continue with these previous treatment during 11 months.
9778705|NCT01113931|Experimental|Doxycycline Hyclate 200 mg tablet|Once daily
10190261|NCT04647162|Active Comparator|medical group|Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.
9778706|NCT01113931|Active Comparator|Vibramycin 100 mg capsule|Twice daily
9778707|NCT01113983|Experimental|TAVI - TF and TA approach|Transcatheter aortic valve implantation and transfemoral/ transapical approach
9778708|NCT01114334|Active Comparator|Guideline-based Medical Management|"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.~The evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications"
9778709|NCT01114334|Experimental|Motivational Interview with GBMM|Motivational Interviewing for Depression combined with guideline-based medical management for depression
9778710|NCT01114360|Active Comparator|Melatonin|African-American subjects with mild to moderate essential hypertension will be given 8mg time release melatonin for 4 weeks. (either before or after placebo exposure).
9778711|NCT01114360|Placebo Comparator|Placebo|African-American subjects with mild to moderate essential hypertension will be given placebo for 4 weeks (either before or after exposure to melatonin)
9778712|NCT01114373|Active Comparator|Melatonin|Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
9778713|NCT01114373|Placebo Comparator|Placebo|Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.
9778714|NCT01114438|Experimental|Device|
9778715|NCT01114503|Experimental|Part A|Up to 4 cohorts of 5 patients receive dose rising treatments of otelixizumab
9778716|NCT01114503|Experimental|Part B - Otelixizumab|Parallel dosing group in Part B receive otelixizumab over 8 days at a dose decided upon results from Part A
9778717|NCT01114503|Active Comparator|Part B - Methylprednisolone|Parallel dosing group in Part B of weekly doses of methylprednisolone for 12 weeks
9778718|NCT01114516|No Intervention|control|emergent cerclage with no peri-operative antibiotics or indomethacin
9778719|NCT01114516|Experimental|indomethacin and antibiotics|perioperative antibiotics and indomethacin
9778720|NCT01114529|Experimental|Everolimus|Conversion from CNI to everolimus in combination with Myfortic and steroids
9778721|NCT01114529|Active Comparator|Calcineurin inhibitor, Prograf or Neoral|Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids
10190262|NCT04647162|Experimental|surgical group|Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.
10190263|NCT04640909|Other|CAR T Cells generation|CAR T Cells generation at baseline and after 6 and 12 months of treatment
10190264|NCT04630613||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
10190265|NCT04621786|Experimental|Experimental arm|All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
10190266|NCT04621500|Other|Open label|All enrolled subjects will receive vitamin D3 at 4,000 IU daily for approximately one year.
10190267|NCT04614467|Experimental|GCSF-mobilized autologous CD34+ cells|
10190268|NCT04614467|Placebo Comparator|Placebo|
9778722|NCT01114555|Experimental|Bevacizumab, Irinotecan and Temozolomide|This is a phase II study of the combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.
9778723|NCT01114581|Active Comparator|Guaifenesin|Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
10190269|NCT04613453|Experimental|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
10190270|NCT04613453|Active Comparator|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
10190271|NCT04610528|Experimental|U3-1402|U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
9702143|NCT04726540||Group I|
9702144|NCT04726540||Group II|
9702145|NCT04726384||Observed group|The group was monitored for physical activity levels using the SenseWear Armband device. The group was informed of the purpose of the study and asked to wear the device 24 hours a day for the next 4 days (Friday-Monday) excluding bath time, no more than 30 minutes. Patients received the device on Thursday afternoon and returned it on Tuesday. However, the days Friday-Monday were analyzed to have a record of the entire days
9702146|NCT04726449||psychiatric diagnosis|psychiatric diagnosis : patients who were given a psychiatric diagnosis at the end of the follow up
9702147|NCT04726449||somatic diagnosis|somatic diagnosis: patients who were given a somatic diagnosis at the end of the follow up
9702148|NCT04726202||Control arm|standard procedure of coding at hospital
9702149|NCT04726202||Precoding arm|Coding of the standard procedure will be reviewed and corrected
9702150|NCT04726527||Florbetapir F 18 Recipients|Participants in this arm of the study will receive a 10 mCi (370 MBq) bolus injection of florbetapir F 18 and then be scanned in a PET scanner for brain imaging.
9702151|NCT04726280|Experimental|10 ml single-shot injection|"In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
9702152|NCT04726280|Active Comparator|20 ml single-shot injection group|"In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
9702153|NCT04726488|Experimental|Periareolar Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
9702154|NCT04726488|Active Comparator|Inframammary Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
9702155|NCT04726371|Active Comparator|Generic Best Practices (GBP)|The ~200 group homes randomized into this arm will receive the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consists of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings.
9702156|NCT04726371|Experimental|Tailored Best Practices (TBP)|The ~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents.
9702157|NCT04726462|Experimental|Functional exercise group|
9702158|NCT04726462|Experimental|Posture exercises group|
9702159|NCT04726553|Experimental|Anifrolumab plus Standard of Care|Anifrolumab will be added to Standard of Care Treatments for SLE
9702160|NCT04726553|Placebo Comparator|Standard of Care|Standard of Care Treatments for SLE
9702161|NCT04726189|Active Comparator|Standard care exercises|This is the currently used treatment in the nine weeks of immobilisation with an orthosis.
9702162|NCT04726189|Experimental|Early progressive strength exercise|This exercise program initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration.
9702165|NCT04726150||Mildly of Asymptomatic COVID|Athletes with prior COVID-19 that had a mildly or asymptomatic course
9702166|NCT04726150||Moderate to Severe Symptoms, Cardiac Symptoms|Athletes with prior COVID-19 that had a moderate to severely symptomatic course, or who experience(d) cardiac symptoms
9702167|NCT04726150||Hospitalized for|Athletes that were hospitalized for COVID-19
9702168|NCT04725786|Experimental|Case group|The intervention of the research corresponds to the realization of a thoracic echography.
9702169|NCT04726046|Experimental|Antibiotic treatment group|They were Antibiotic treatment group (AG, cefotetan 1g, 1 dose/prophylactic) before surgery.
9702170|NCT04726046|No Intervention|Non-antibiotic treatment group|They were Non-antibiotics treatment such as cefotetan 1g before surgery.
9702171|NCT04725799||MESS with and without stressful stimuli|The subjects participate in meal, exercise, sleep activities alone or in combination with stressful stimuli.
9702172|NCT04725747|Experimental|Midazolam/Ketamine Melt|One Midazolam/Ketamine 3mg/50mg melt administered sublingually
9702173|NCT04725747|Active Comparator|Midazolam Melt|Midazolam 3mg melt administered sublingually
9702174|NCT04725747|Active Comparator|Ketamine Melt|Ketamine 50mg melt administered sublingually
9702175|NCT04726033|Experimental|Dose level 1 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu
9702176|NCT04726033|Experimental|Dose level 2 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 8mg of unlabelled TLX592 (mass dose of 10mg).
9702177|NCT04726033|Experimental|Dose level 3 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 18mg of unlabelled TLX592 (mass dose of 20mg).
9778724|NCT01114581|Placebo Comparator|Placebo|Given as 2 tablets
9702178|NCT04726033|Experimental|Confirmation of optimal 64Cu-TLX592 dose|"Based on the result of Groups 1-3, the optimal dose and imaging timepoints will be selected to treat 3 patients with higher tumour burden (≥10 metastatic sites and/or visceral disease as detected on a 68Ga-PSMA-11 or 18F-DCFPyl PSMA PET/CT scan).~Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 0, 8 or 18mg of unlabelled TLX592."
9702179|NCT04726020|Experimental|Intensive monitoring|Intensive phone monitoring of drug adverse events
9702180|NCT04726020|Placebo Comparator|Standard monitoring|Standard monitoring of drug adverse events
9702181|NCT04725890|Experimental|Intervention|All eligible participants will receive the DyaMX procedure.
9702182|NCT04726111|Other|Control patients|Control patients (negative serology and PCR)
9702183|NCT04726111|Other|asymptomatic patients|asymptomatic patients (PCR positive)
9702184|NCT04726111|Other|symptomatic patients|symptomatic patients (PCR positive)
9702185|NCT04726111|Other|Cured patients|cured patients who contracted the disease during pregnancy (positive serology in the 15 days preceding childbirth or history of positive PCR during pregnancy and negative PCR within 72 hours)
9702186|NCT04725773||PD DBS|Patients with Parkinson's disease and deep brain stimulation
9702187|NCT04725812|Experimental|Eculizumab|Twelve subjects in the interventional arm will receive eculizumab at an induction dose of 900mg IV weekly (q7 days) for 4 weeks followed by a dose of 1200mg IV at week 5. Thereafter, patients will receive a maintenance dose of 1200mg IV every two weeks (q14 days). The last dose of eculizumab will be given up to 48 hours post-partum, with a dose that is dependent on the dosing schedule (i.e. whether the last dose is given within the 4-week induction period or is during the maintenance phase).
9702188|NCT04726059|Sham Comparator|ABT+SHAM|The SHAM is low-intensity, ineffective stimulation verified by the absence of lower extremity skeletal muscle activation and delivered at the same anatomical location as TCSCS.
9702189|NCT04726059|Experimental|ABT+TCSCS|Therapeutic TCSCS will be delivered during ABT using an isolated bipolar constant current stimulator. Continuous TCSCS applied over the T11-T12 spinous processes at 5-40 Hz has been shown to induce stepping movements in participants with their legs in a gravity-independent position.
9702190|NCT04725981|Experimental|Arm A (test surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0 and 1 continuous suture with V-Loc 2-0
9702191|NCT04725981|Active Comparator|Arm B (control surgical technique)|Colpotomy closure technique: 3 Z-suture with PDS 0
9702192|NCT04725708|Experimental|normoxy|"Group 1(n=50) FiO2%40, PaO2<180 ve PaO2≥80mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored.~An rSO2 less than 45% triggered an alarm, the anesthesiologist timed the event, and after 60 seconds initiated an intervention protocol means; PaO2 levels were checked, PaO2> 100 mmHg was achieved, if not improved, pump blood flow, mean arterial pressure were increased, if there is still no response and hematocrit <20%, patients were scheduled for erythrocyte transfusion until the rSO2 was restored to at least 60% at both probes.In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months."
9702193|NCT04725708|Experimental|hyperoxia|Group 2(n=50) FiO2%100, PaO2≥180mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored..In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months.
9702194|NCT04726072|Experimental|Kundalini Yoga|The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises and meditation. Participants were also asked to do at-home practice for half an hour daily.
9702195|NCT04726072|Active Comparator|Psychoeducation|The psychoeducation group consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily
9702196|NCT04726085|Active Comparator|Ibuprofen|Ibuprofen 600 mg q6 hours for 24 hours- total dose of 2400mg- after emergent cerclage placement
9702197|NCT04726085|Active Comparator|Indomethacin|Indomethacin 50 mg q8 hours for 24 hours- total dose of 150mg- after emergent cerclage placement
9702198|NCT04725591|Active Comparator|Diabeloop closed-loop glucose control session with the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.~Subjects are asked to declare their meals for 4 weeks.~A remote monitoring system is provided in closed-loop session."
9702199|NCT04725591|Experimental|Diabeloop closed-loop glucose control session without the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.~Subjects are asked to not declare their meals for 4 weeks.~A remote monitoring system is provided in closed-loop session."
9702200|NCT04725487|Experimental|Standard integration program with social and health promoting intervention|Participants follow the standard integration program offered by Naestved Municipality and participate in various social and health promoting activities in addition
9702201|NCT04725487|Active Comparator|Standard integration program|Participants follow the standard integration program offered by Naestved Municipality
9702202|NCT04725500|Experimental|Auto-titrating EPAP|ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.
9702203|NCT04725682|Active Comparator|Sequence 1 (TRTR)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of TRTR.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules Treatment R (Reference): 1 × 1mg RLD tacrolimus capsules"
9702204|NCT04725682|Active Comparator|Sequence 2 (RTRT)|"Each subject is scheduled to receive each treatment twice by the end of the study in the order of RTRT.~Treatment T (Test): 1 × 1mg Test tacrolimus capsules Treatment R (Reference): 1 × 1mg RLD capsules"
9702205|NCT04725669|Other|Seroprevalence of pertussis among children and adolescents in Croatia|For all patients participating in the study one serum sample will be collected for serological analysis.
10190272|NCT04609644|No Intervention|Passive|"Passive arm participants will be sent two devices, at no cost-an Apple Watch and a Beddit Sleep Monitor. These are commercially available and have not been modified for this study. Participants will be asked to use these devices regularly throughout study Year 1. Participants can optionally continue to use devices during Year 2, if they have met requirements during Year 1 to keep study devices. To be eligible to keep devices, participants must meet pre-specified levels of adherence to study procedures.~Access to the Study App will be provided to all participants. It will be used to administer informed consent and electronic patient reported outcome (ePRO) measures, and for other study purposes. However, passive participants will not have access to the Study App features designed to support asthma self-management."
9702206|NCT04725396|Experimental|Patients undergoing PVP-assisted MR|PVP is based on CT-scan with millimetric thin slice acquisitions of the facial bone and fibulas. The surgeon defines the exact sites of the intended mandibular osteotomies. A single external subcontracted laboratory (Materialise®) produces the various cutting guides for mandibular resection, flap conformation and the preformed plates for flap osteosynthesis. Flap conformation is entirely performed at the donor site before section of the vascular pedicle (flap still vascularized).
9702207|NCT04725396|Active Comparator|Patients undergoing conventional (i.e. without PVP) MR|Flap modeling and positioning requires one or multiple cuneiform osteotomies. The bone transplant is shaped to restore the contours of the mandibular defect using preoperative imaging studies and the resection specimen. Flap conformation begins at the donor site and is generally completed at the recipient site after fibular pedicle section and before microvascular anastomosis (during ischemia time). The different bone fragments are fixed together and to the native mandible using either titanium miniplates or reconstruction plate and monocortical screws. Regardless of the material used for fixing the fibular flap to the native mandible, the use of a reconstruction plate adapted to the native mandible (or other similar techniques) prior to tumor resection is recommended to guide flap shaping and positioning, and to insure an accurate MR.
9702208|NCT04725617|Active Comparator|Health Intervention Approach 1|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
9702209|NCT04725617|Active Comparator|Health Intervention Approach 2|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
9702210|NCT04725344|Experimental|ACTIV'DOS group|ACTIV'DOS is a smartphone application of self rehabilitation. There are 7 muscular exercices. Patients going to exercices during 15 minutes per day, during 6 weeks.
9702211|NCT04725344|Experimental|Control group|This group uses a sheet of paper for self-rehabilitation exercise. The self-rehabilitation program is the same as the ACTIV'DOS group. Patients have to exercise during 15 minutes per day, during 6 weeks.
9702212|NCT04725448|Experimental|Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin|"Drugs: Toripalimab, 240mg (6ml)/bottle, ivgtt, d1, q3w, administration until PD or death, the longest use time is two years.~Drugs: Bevacizumab, 7.5mg/kg, ivgtt, d1, q3w,the longest use time is two years.~Drugs: Nab-paclitaxel, 260mg/m2,ivgtt,d1 or 130mg/m2,ivgtt,d1,8, q3w, up to six cycles.~Drugs: Carboplatin, AUC=4～5, ivgtt, d1, q3w, up to six cycles."
9702213|NCT04725526|No Intervention|usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care on site
9702214|NCT04725526|Experimental|mHealth intervention plus usual clinical practice|A group of pluripatological patients with heart failure and complex needs of health will be tratad per standard of care plus mHealth intervention on site
9702215|NCT04725578|Experimental|Telehealth Single Session Consultation|
9702216|NCT04725656|Active Comparator|Active arm, low concentration (18 mg/mL) nicotine salt e-liquids|
9702217|NCT04725656|Active Comparator|Active arm, high concentration (59 mg/mL) nicotine salt e-liquids|
9702218|NCT04725656|Other|Control group|Receive only smoking cessation counseling
9702219|NCT04725266|Experimental|family-based intervention plus routine care|This group of participants including drug abusers and their families will be receiving family-based intervention which is a well-designed intervention with group sessions and routine care provided by professional social workers in local social service center.
9702220|NCT04725266|Active Comparator|routine care|The group of participants will receive routine care which is widely used in social service providers and mainly includes individual counselling service for drug abusers.
9702221|NCT04725253|Experimental|Nicotinamide|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously. Study medication will be managed by nurses and administered daily at 7 a.m. This regimen will be continued up to 7 days after admission. The dosage of nicotinamide will be 1,5 gr per day.
9778725|NCT01114620|Experimental|Arepanrix Group|Healthy Japanese male and female adults, 65 years of age or older, who received one dose of the study vaccine Arepanrix™, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
9778726|NCT01114646|Other|Cemented Hip Hemiarthroplasty|This arm received a hemiarthroplasty with a cemented femoral prosthesis (VerSys LD/Fx, Zimmer, Warsaw, IN).
9702222|NCT04725253|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization, resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner. Study medication will be managed by nurses and administered daily at 7 a.m. (in these case placebo tablets). This regimen will be continued up to 7 days after admission.
9702223|NCT04725383|Active Comparator|amitriptyline|Subjects will receive active amitriptyline compounded into look-alike capsules to resemble placebo capsules. Dosing will be as tolerated, up to tid and maximum of 100mg/day or 1.5mg/kg/day, for 12 weeks.
9702224|NCT04725383|Placebo Comparator|placebo|Subjects in this arm will receive placebo compounded into capsules that resemble the compounded amitriptyline capsules, up to 4 capsules a day (1 qam, 1 q4pm and 2 capsules qhs), for 12 weeks.
9702225|NCT04725370||CHOP (US)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2012 to 2019 at the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
9702226|NCT04725370||SFG (Guatemala)|Children with isolated cleft lip and/or cleft palate scheduled for surgery between 2017 and 2020 with Smiles for Guatemala, Guatemala City, Guatemala.
9702227|NCT04725435|Experimental|Kangaroo care|"No Intervention: Standard care The control group will be followed by infants using nesting in the incubator. It will be followed for 60 minutes without any action or application.~Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes."
9702228|NCT04725435|Experimental|Facilitated tucking position|"No Intervention: Standard care In the Control Group, the heel stick procedure will be performed in the infants own bed as in the clinical routine.~Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position, with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
9702229|NCT04725149|Placebo Comparator|0 ml tart cherry concentrate|Still cherry-flavored beverage, similar in appearance, taste, aroma and calories to the 30 ml and 60 ml tart cherry concentrate beverages
9702230|NCT04725149|Experimental|30 ml tart cherry concentrate|"Low dose tart cherry concentrate beverage"
9702231|NCT04725149|Experimental|60 ml tart cherry concentrate|"High dose tart cherry concentrate beverage"
9702232|NCT04725409||Epilepsy patients|All participants will be patients with medically refractory epilepsy undergoing depth electrode placement for seizure localization. For this study participants will complete psychiatric questionnaires measuring depression, anxiety, obsessive compulsive disorder, and impulsivity, and EEG recordings will be collected from the depth electrodes while subjects rest quietly. Some subjects will also participate in neuro cognitive tasks while neural recordings/stimulation are performed.
9702233|NCT04725162||Epilepsy patients|Pediatric patients with focal epilepsy.
9702234|NCT04725162||Control|Age-matched controls who underwent 18F-FDG PET/CT examination for diseases outside brains.
9702235|NCT04725162||Validation|Children who underwent 18F-FDG PET/MRI to examine extracranial tumors.
9702236|NCT04725279|Experimental|Type of rehabilitation treatment|Depending on whether the cervical pain associated with vertigo in the patients associated pain radiating to the arms or not, treatment with conventional physiotherapy or electrotherapy was prescribed. In addition, both groups had a control group that performed exercises at home prescribed by a physician.
9702237|NCT04725461|Experimental|Low cost lower limb socket testing|Fabrication and testing of a low cost lower limb prosthetic socket and ensure this socket has appropriate suspension, comfort and f unction for a transtibial amputee.
9702238|NCT04725357|Experimental|Arthroscopic Labral Repair + postoperative Meloxicam|After surgery participants will receive a prescription of 20 pills of 15 mg Meloxicam
9702239|NCT04725357|Active Comparator|Arthroscopic Labral Repair without Meloxicam|After surgery participants will receive a prescription of 20 pills of 5/300 mg vicodin (hydrocodone/acetaminophen)
9702240|NCT04725422||disease modifying anti-rheumatic drug, DMARD|
9702241|NCT04725422||tumor necrosis factor inhibitor, TNFi|
9702242|NCT04725422||bisphosphonate|
9702243|NCT04725214|Experimental|Experimental|For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)
9702244|NCT04725123|Experimental|Clostridioides difficile infection|Stool of patients with Clostridioides difficile infection that will be subject to microbiome analysis. Comparisons will be done between patients with favorable and unfavorable outcome
9702245|NCT04725110|Experimental|T3 Intervention|Participants in this arm will receive the experimental intervention.
9702246|NCT04725110|Placebo Comparator|Placebo Therapy|Participants in this arm will receive placebo therapy.
9702249|NCT04725201|Experimental|Intravenous unfractionated heparin|Administration of intravenous unfractionated heparin according to the Centre hospitalier de l'Université de Montréal (CHUM) deep vein thrombosis (DVT) protocol for 5 days after vascular anastomosis. A bolus will be administered intraoperatively based on the patient's weight. Dosages will be adjusted according to the activated partial thromboplastin time (aim for an APTT of 50-70), which will be measured 6 hours after the start of the protocol and after every dosage adjustment or every morning at 6 a.m. if no adjustments were made in the last 6 hours.
9702250|NCT04725201|Sham Comparator|Control|"No administration of intravenous unfractionated heparin. These patients receive 5000 IU BID of heparin subcutaneously, as a standard post-operative protocol for all in-patients.~The control group receives sham bolus intraoperatively of normal saline and a post-operative normal saline infusion at a fixed dose through an infusion pump to mimic IV heparin infusion."
9702251|NCT04725513|Active Comparator|Physical Therapy Only|
9702252|NCT04725513|Experimental|Shockwave Therapy and Physical Therapy|
9702253|NCT04725513|Experimental|Photobiomodulation, Shockwave Therapy and Physical Therapy|
9702254|NCT04724941||REM behavior disorder +|"Individuals with REM Sleep Behavior Disorder:~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
10190273|NCT04609644|Experimental|Active|"Active arm participants will be sent the same devices, also at no cost, and asked to use them in the same manner.~Only the active arm will have access to Study App features for asthma self-management, including:~Smart nudges that may promote proactive asthma self-management~Asthma symptom and trigger tracking~Evidence-based asthma education~The ability to photograph and easily reference an asthma action plan from a healthcare provider.~A 90-day summary of self-reported asthma symptoms/triggers and device-recorded heart rate and respiratory rate. This summary can be shared with providers.~In-app viewing of active asthma medications, refills available, and phone numbers to call for refills (subject to prescription benefits).~Active participants can, but are not required to, use the Study App in Year 2. Those who choose to may keep using study devices in Year 2, provided they meet requirements to keep devices. These requirements are the same for both arms."
10190274|NCT04603482|Experimental|Self-Management|
9702255|NCT04724941||REM behavior disorder -|"Individuals without REM Sleep Behavior Disorder with increased risk for PD:~All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years."
9702256|NCT04725019|Experimental|Active tDCS + motor training|In this arm, participants will receive 20 minutes of active tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games.
9702257|NCT04725019|Experimental|Sham tDCS + motor training|In this arm, participants will receive 20 minutes of sham tDCS and motor training that involves a high number of repetitions while engaged in child-friendly games. Children receiving sham tDCS will wear the tDCS device but not receive active stimulation.
9702258|NCT04724785||patients with persistant low level HBV DNA (<10 IU/ml)|No further intervention(s) to be administered except for monitoring of HBV DNA viraemia
9702259|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) but refuse to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen. If those patients refuse to change the regimen which they are using , No further intervention(s) to be administered except for monitoring of HBV DNA viraemia until those patients change their idea
9702260|NCT04724785||patients with persistant HBV DNA (>10 IU/ml) and agree to change the regimen|All patients with CHB receiving ETV or second-line NA(LAM/ADV/LdT) treatment for more than six months to one year will receive HBV-DNA detection, and patients with HBV-DNA≥10 IU/ml will be informed and recommended to adjust the treatment regimen.They will change their regimen according one which they are using.
9702261|NCT04724707||Myocarditis|Proven or suspected myocarditis
9702262|NCT04724707||Heart failure|Heart failure (NYHA functional class II-IV) before or during hospitalization with COVID-19
9702263|NCT04724707||ACS|Combination of COVID-19 with ACS or development of ACS during hospitalization with COVID-19 or performed percutaneous coronary intervention
10190275|NCT04603482|Active Comparator|Attention Control Condition|
9702264|NCT04724707||Pulmonary embolism|Proven pulmonary embolism
9702265|NCT04724707||Arrhythmias|Hemodynamically significant arrhythmias (atrial fibrillation, high-grade ventricular premature beats, paroxysmal ventricular arrhythmias), including those associated with the QT interval prolongation
9702266|NCT04724811|Experimental|Weight-bearing as tolerated|Patients are instructed to mobilise the hip and weight-bear as tolerated
9702267|NCT04724811|Active Comparator|Touch-down weight-bearing|Patients are instructed to mobilise the hip. Touch-down weight-bearing for 6-8 weeks
10190276|NCT04602507|Experimental|Intervention|50 patients with the routine care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
9702270|NCT04724733|No Intervention|Control|The control group will receive incentives for study participation but will not be introduced to the Smoke Sense app.
9702271|NCT04724733|Experimental|Smoke Sense|
9702272|NCT04724733|Active Comparator|Smoke Sense Plus|
9702273|NCT04724889||Patients with underlying AF|Patients that will have AF detected by ILR will be compared with patients without AF.
9702274|NCT04724889||Patients without AF|Patients that will have AF detected by ILR will be compared with patients without AF.
9702275|NCT04724850||COVID-19 patients|All patients diagnosed with COVID-19 in the community of Extremadura from the beginning of the epidemic to its ending in Spain.
9702276|NCT04724915|Experimental|Robot-assisted TKA|Patients undergoing TKA with the assistance of robot technology.
9702277|NCT04724915|Active Comparator|Conventional TKA|Patients undergoing TKA with manual instrumentarium
9702278|NCT04724655|Other|control group|gastric lavage with saline and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
9702279|NCT04724655|Active Comparator|paraffin group|gastric lavage with paraffin oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
9702280|NCT04724655|Active Comparator|coconut group|gastric lavage with coconut oil and bicarbonate and standard treatment :inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
9702281|NCT04724928|No Intervention|non-metastatic MIBC on PET-CT|patients receive classical treatment with neo-adjuvant chemotherapy followed by radical cystectomy (RC) or trimodality therapy (TMT) and regular follow up
9702282|NCT04724928|Experimental|oligo-metastatic MIBC on PET-CT|patients receive classical treatment with neo-adjuvant chemotherapy followed by RC or trimodality therapy TMT and metastasis-directed therapy followed by regular follow up
9702283|NCT04724928|Experimental|poly-metastatic MIBC on PET-CT|patients receive classical treatment with neo-adjuvant chemotherapy followed by RC or trimodality therapy TMT and start of immunotherapy followed by regular follow up
9702284|NCT04724863|Experimental|Protocol|Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
9702285|NCT04724954|Experimental|Rehabilitation Therapy on Experimental Robotic Table and standard of care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited for experimental group.~The investigators will also recruit the 10 caregivers of the experimental subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
9702286|NCT04724954|Sham Comparator|Rehabilitation Therapy as part of Standard of Care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited as a control group.~The investigators will also recruit the 10 caregivers of the control subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
10190277|NCT04602507|Placebo Comparator|Control|50 patients with routine care offered in the hospital plus placebo orally (2 drops per kg) in a single dose.
9702287|NCT04724759|Experimental|Opioid-free Anesthesia|Patients in this arm will not receiving opioids but the total intravenous anesthetic during surgery. Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics.
9702288|NCT04724759|No Intervention|Standard Anesthesia|Patients in this arm will undergo the standard of care and receive opioids as part of their anesthetic regimen.
9702289|NCT04724993|Experimental|Online Aerobic Dance Exercises|In this group, aerobic dance exercises will be applied online under the supervision of a physiotherapist. And participants will record their physical activities on the Physical Activity Tracking Chart.
9702290|NCT04724993|Experimental|Physical Activity Counseling|In this group, participants will be informed online about physical activity and exercise. And they will record their physical activities on the Physical Activity Tracking Chart too.
9702291|NCT04724629|Experimental|IL-17 inhibitor (Ixekizumab)|Patients will receive study medication Ixekizumab 80 mg per week, (SC) once a week for 4 weeks or until discharge.
9702292|NCT04724629|Experimental|IL-2 (Aldesleukin)|1.5 million IU per day (SC) for 7 days or until discharge. Patients will receive study medication Aldesleukin 1.5 million IU per day (SC), for 7 days or until discharge.
9702293|NCT04724629|Experimental|Indirect IL-6 inhibitor (Colchicine)|Patients will receive study medication colchicine 0.5 mg every 8 hours for 3 days (PO), followed by 4 weeks (+/-7 days) 0.5 mg twice daily. If a dose is missed, it should not be replaced.
9702294|NCT04724629|Active Comparator|Standard of care|Standard treatment, supplementation of O2 ventilation + standard treatment of the institution, which may include Dexamethasone according to the institutional protocol.
9702295|NCT04724200||Referred from primary care for investigation of suspected heart failure|All patients recruited to the OPERA trial will have been referred from their primary care clinician for investigation of a suspected diagnosis of heart failure.
9702296|NCT04724434||Study group|Patients with positive test for SARS-CoV-2 by PCR
9702297|NCT04724434||Control group|Patients with negative SARS-CoV-2 antibody test
9702298|NCT04724486|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702299|NCT04724486|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702300|NCT04724473|Experimental|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9702301|NCT04724473|Active Comparator|RETIN-A® (Tretinoin) Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
9702302|NCT04724473|Placebo Comparator|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
10190278|NCT04601831|Experimental|Radiation Therapy to all residual FDG-avid sites*|"All patients enrolled in the trial will receive focal radiation therapy (RT) to all* residual FDG-avid sites per Lugano criteria (Lugano 4-5) as noted on day 30 post-CAR-T PET/CT scan.~*If >5 distinct sites, physician discretion will be allowed as to how many sites are treated, with recommendation that at least all symptomatic and bulky (>=7.5 cm in largest dimension) sites be treated."
10190279|NCT04598152|Experimental|Transcranial Direct Current Stimulation during fMRI|Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.
9702303|NCT04724499|Experimental|High-Intensity Intervals Training|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the exercise group (HIIT), will receive an exercise bike and have 3 weekly supervised exercise training sessions for four (4) months/16weeks.~Participants can choose to participate in the exercise sessions at home via zoom or in clinic.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post High-Intensity Intervals Training (HIIT) tests and four (4) month follow up test and receive 3 MRIs over the span of 9 months."
9702304|NCT04724499|Active Comparator|Attention Control|"Participants will be randomized into one of two groups: High-Intensity Intervals Training (HIIT) or Attention Control~Participants assigned to the Attention Control group, will receive instruction on a 16 week home-based stretching program.~Participants will have two (2) baseline tests, one (1) midpoint test, two (2) post home-based stretching program tests and receive 3 MRIs over the span of 9 months.~At the end of the 16-week home-based stretching program, participants will be provided the option to participate in the High-Intensity Intervals Training (HIIT) program."
9978062|NCT01367951|Experimental|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
10190280|NCT04595045|Experimental|patients with spastic lower limb paresis|patients with spastic lower limb paresis secondary to Multiple Sclerosis
9778727|NCT01114646|Experimental|Press-Fit Hip Hemiarthroplasty|This arm received a press-fit hemiarthroplasty (VerSys Beaded FullCoat, Zimmer, Warsaw, IN),
9778728|NCT01114672|Active Comparator|Ergocalciferol|
9778729|NCT01114672|Placebo Comparator|oral placebo|
9778730|NCT01114724|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|
9778731|NCT01114737|Experimental|Sapropterin dihydrochloride|
9778732|NCT01114737|Placebo Comparator|Tablet without active ingredient|
9778733|NCT01114828|Experimental|3.75 mg|Once-daily oral administration of OPC-41061
9778734|NCT01114828|Experimental|7.5 mg|Once-daily oral administration of OPC-41061
9778735|NCT01114880|Placebo Comparator|Placebo|Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
9778736|NCT01114880|Experimental|Adalimumab|Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
9778737|NCT01114893|Active Comparator|TRAVATAN|TRAVATAN 0.004% once daily
9778738|NCT01114893|Placebo Comparator|Travoprost Vehicle|Travoprost Vehicle
9778739|NCT01114893|Experimental|Travoprost Group A|Travoprost Group A
9778740|NCT01114893|Experimental|Travoprost Group B|Travoprost Group B
10190281|NCT04592445|Active Comparator|Axon Treatment Arm|Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
10190282|NCT04592445|Sham Comparator|Sham Control Arm|Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
10190283|NCT04585100|Experimental|Bioequivalent test of FM101 oral solution and FM101 tablet|
10190284|NCT04585100|Experimental|Phase 2a|
10190285|NCT04578314|Experimental|Relating module + Treatment as usual|Participants in this arm will receive 16 weekly sessions with Relating Therapy (RT) over 5 months in addition to their treatment as usual.
10190286|NCT04578314|Active Comparator|Treatment as usual|Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include Cognitive Behavior Therapy or psychodynamic interventions.
10190287|NCT04576000||Open-Label Group|Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.
10190288|NCT04571658||NEPTUNE Match Participants|"Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas.~NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years."
9778741|NCT01114893|Experimental|Travoprost Group C|Travoprost Group C
10190289|NCT04570943|Experimental|Gabrinox followed by stereotactic radiotherapy|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
10190290|NCT04565158||Women with bilateral salpingo-oophorectomy (BSO)|
10190291|NCT04565158||Women without bilateral salpingo-oophorectomy (BSO)|
9778742|NCT01114945|Experimental|Video-Mac|Video-Mac device used during intubation procedure
9778743|NCT01114945|Experimental|GlideScope|GlideScope device used during intubation procedure
9778744|NCT01114945|Experimental|McGrath|McGrath device used during intubation procedure
9778745|NCT01114945|Active Comparator|Direct Macintosh Laryngoscopy|Direct Macintosh Laryngoscopy (DL) used during intubation procedure
9778746|NCT01114971|Active Comparator|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or Heart Rate (HR) > 80 bpm)"
9702305|NCT04724616|No Intervention|Control Group|Participants received no specific educational program
9702306|NCT04724616|Experimental|Intervention Group|Participants received our educational program for five days, with one teaching session per day. Every teaching session will be conducted for 60 minutes in a group of up to 6 children by a trained member of our staff.
10190292|NCT04556916|Experimental|Men over 40 being suspicious of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent and performing before the 1st prostate biopsy
10190293|NCT04556916|Experimental|Men over 40 with no suspicion of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent
9702307|NCT04724538|Experimental|Healthy volunteers|CT-scans for exclusion of pneumonia. Accumulated absorbed dose calculation of volunteers' lungs after inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 833 MBq of 99mTc-pertechnetate.
9702308|NCT04724538|Experimental|Patient with COVID-19 pneumonia|Inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 4165 MBq of 99mTc-pertechnetate. CT scans a day before, 7 and 14 days after inhalation procedure. Blood tests a day before, 1, 3 and 7 days after inhalation procedure.
9702309|NCT04724538|No Intervention|Patient with COVID-19 pneumonia without intervention|Blood tests at 1, 3 and 7 days.
9702310|NCT04724187|Experimental|intrauterine misoprostol and oxytocin|there will be added effect of misoprostol to stimulate uterine contraction along with oxytocin
9702311|NCT04724187|Active Comparator|oxytocin|only oxytocin will stimulate uterine contraction
9702312|NCT04724226|Experimental|C-couple|Camrelizumab and Apatinib after Cryoablation
9702313|NCT04724343|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702314|NCT04724343|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
9702315|NCT04724382|Experimental|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
9702316|NCT04724382|Active Comparator|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
9702317|NCT04724356|Experimental|Virtual Reality Group|The Kinect based rehabilitation group received virtual reality therapy using Xbox Kinect-based games, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
9702318|NCT04724356|Experimental|Resistance exercise Group|The resistance exercise group received resistance training, in addition to complex decongestive physiotherapy. The intervention was led once per day, five days a week, over 8 weeks. All participants wearing multilayer bandage or compression stocking during training to avoid exacerbation of the lymphedema in the affected limb.
9702319|NCT04724408|Experimental|VieScope|intubation with the VieScope laryngoscope
10190294|NCT04554277|No Intervention|Control|Usual management of heart failure. The sST-2 level will be blunted.
10190295|NCT04554277|Experimental|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
9702320|NCT04724408|Active Comparator|Conventional|intubation with MacIntosh-type laryngoscope
9702321|NCT04724317|Sham Comparator|Steroid Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% added to triamcinolone 40 mg under the ultrasound guidance
9702322|NCT04724317|Active Comparator|Ozone Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by injection of 10 ml of Oxygen-Ozone mixture (15 µg/ml) under the ultrasound guidance
9702323|NCT04724317|Active Comparator|PRF Group|shoulder intra-articular injection of 5 ml of Bupivacaine 0.125% followed by pulsed radiofrequency application under the ultrasound guidance
9702324|NCT04724239|Experimental|sintilimab + chidamide + IBI305|
9702325|NCT04724239|Experimental|sintilimab + chidamide|
9702326|NCT04724213|Other|Testing of reliability / validity of new questionnaire|
9702327|NCT04724174||Pancreaticogastrostomy (PG) group|Patients underwent pancreatoduodenectomy with the PG technique
9702328|NCT04724174||Pancreaticojejunostomy (PJ) group|Patients underwent pancreatoduodenectomy with the PJ technique
10190296|NCT04552197|Experimental|Part 1: Treatment A (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.
9702329|NCT04724148|Experimental|Injecting 1~2mg/kg fentanyl intravenously.|"Measuring HVPG after the preparation of TIPS in patients with portal hypertension;~Measuring HVPG again 5 minutes later after injecting 1~2mg/kg fentanyl intravenously."
9702330|NCT04724031||One cohort|women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
10190297|NCT04552197|Experimental|Part 1: Treatment B (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.
10190298|NCT04552197|Experimental|Part 1: Treatment C (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.
9702331|NCT04723914|Experimental|Treatment group|Dual target CAR-T cell therapy
9702332|NCT04723836|Active Comparator|TT genotype active comparator group|5mg riboflavin per day from 16th gestational week
9702333|NCT04723836|Experimental|TT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
9702334|NCT04723836|Placebo Comparator|TT genotype placebo group|Placebo supplement from 16th gestational week
9702335|NCT04723836|Active Comparator|CT genotype active comparator group|5mg riboflavin per day from 16th gestational week
9702336|NCT04723836|Experimental|CT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
9702337|NCT04723836|Placebo Comparator|CT genotype placebo group|Placebo supplement from 16th gestational week
9702338|NCT04723927||Older adults|The data for motor function and gait pattern analysis was obtained.
9702339|NCT04723849|Experimental|Tretment group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
9702340|NCT04723849|Placebo Comparator|Placebo group|Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study.
9702341|NCT04723979||Exposed to recombinant FVIIa (NovoSeven®)|all women exposed to NovoSeven® during sPPH
9702342|NCT04723979||Standard of Care|Women with postpartum hemorrhage not exposed to NovoSeven®.
9702343|NCT04724135||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
9702344|NCT04723784|Experimental|Person with disability|"Initial assessment.~Implementation of AT in the daily life of participants~Application of outcome measures and analysis of the data"
9702345|NCT04723940|Active Comparator|Oral Antibiotics|Participant will receive 6 weeks of oral antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
9702346|NCT04723940|Active Comparator|Intravenous Antibiotics|Participant will receive 6 weeks of intravenous (IV) antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
9702347|NCT04724083||Fabry Disease subjects with cardiomyopathy|Patients (males and females) with confirmed Fabry disease, with clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
9702348|NCT04724083||Fabry Disease subjects without cardiomyopathy|Patients (males and females) with confirmed Fabry disease, without clinical cardiac involvement based on results of structural imaging (cardiac echocardiography and MRI).
9702349|NCT04724083||Healthy control|The control group will consist of age-and gender-matched healthy individuals.
9702350|NCT04723693||individuals With Haemophilia A and with inhibitors on emicizumab|Qualitative interviews
10190299|NCT04552197|Active Comparator|Part 1: Treatment D (JNJ-64251330)|Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.
9702351|NCT04723732|Experimental|Myrrh mouthwash|1% mouthwash of Commiphora myrrha made from resin extract. Participants will use 10 ml of the mouthwash twice daily for 14 days.
9702352|NCT04723732|Active Comparator|Chlorhexidine Mouthwash|Commercial 0.2% Chlorhexidine gluconate mouthwash (Avalon Pharma, Riyadh). Participants will use 10 ml of the mouthwash twice daily for 14 days.
9702353|NCT04723732|Placebo Comparator|Normal saline|Commercial 0.9% sodium chloride solution (Pharmaceutical solutions industry, Jeddah). Participants will use 10 ml of the mouthwash twice daily for 14 days.
9702354|NCT04723797|No Intervention|Control group|The participants in the control group will be asked to maintain their lifestyle as before the study.
9702355|NCT04723797|Experimental|Moderate-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 150min/week. This at a moderate intensity, which means a slightly increased heart rate and breathing also talking is possible.
9702356|NCT04723797|Experimental|Vigorous-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 75min/week. This at a vigorous intensity, which means increased heart rate and breathing also talking is possible.
9702357|NCT04723602|Active Comparator|cAd3-Marburg at 1 x 10^11 Particle Units (PU)|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
9702358|NCT04723602|Active Comparator|cAd3-EBO-S at 1 x 10^11 PU vaccine|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.
9702359|NCT04723589|No Intervention|Standard Arm|Participants randomized to standard care will not receive an intervention but will participate in other study procedures, which are blood collection and data collection.
9702360|NCT04723589|Experimental|Intervention Arm|Participants randomized to the intervention arm will receive standard care plus an infusion of thawed plasma, starting rate 30 ml/hour for 24 hours, increased to 50 ml/hour if deemed to be hypovolemic (low fluid volume). Only non-convalescent (COVID-antibody-free) plasma will be used.
9702361|NCT04723628|Experimental|Experimental group|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
9702362|NCT04723628|No Intervention|Control group|All data forms were then completed, and the HbA1c value was taken from the medical data. No additional procedure was performed to the control group. The research data were collected again at the end of 12 weeks.
10190300|NCT04552197|Experimental|Part 2: Treatment EF (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
10190301|NCT04552197|Experimental|Part 2: Treatment FE (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
10190302|NCT04537793|Experimental|Part A: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
9702363|NCT04723888|Experimental|alpha-ketoglutarate Group|Take alpha-ketoglutarate supplements, alpha-ketoglutarate 300mg/d mixed with food or drink, for 1 years
9702364|NCT04723888|No Intervention|Normal Control Group|Don't take alpha-ketoglutarate supplements
9702365|NCT04724096||Non-patient volunteers|5 non-patient volunteers for testing of protocol to allow for the ascertaining of good quality data prior to the scanning of patients.
9702366|NCT04724096||Patients|50 patients to be scanned with the oxygen enhanced MRI scan protocol prior to definitive curative intent therapy.
9702367|NCT04723875|Experimental|Adjuvant chemotherapy group|"Participant will receive 3 cycles of adjuvant chemotherapy if having any of the following factors；participant will receive 6 cycles of adjuvant chemotherapy if having ≥2 of the following factors.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 2cm"
9702368|NCT04723875|No Intervention|Control group|The participants receive no intervention.
9702369|NCT04723862|Experimental|Spironolactone|Prior to the first or second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
9702370|NCT04723862|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
9702371|NCT04723745||VTRACTS|We will target post-9/11 Veterans with TBI or blast exposure who self-report ongoing post-concussive neurobehavioral symptoms, but V-TRACTS will be open to all post-9/11 Veterans irrespective of any diagnoses.
9702372|NCT04723901|Experimental|Treatment group|Dual target CAR-T cell therapy
9702373|NCT04723719|Experimental|SIESTA training + treatment as usual for ADHD|We developed a cognitive behavioral therapy for sleep problems in adolescents with ADHD. This includes seven individual sessions with the adolescent and two individual sessions with the parent(s)/guardian(s). Participants receive this CBT training called SIESTA next to their treatment as usual for ADHD symptomatology (mostly ADHD-medication).
9702374|NCT04723719|Active Comparator|Treatment as usual for ADHD only|Participants continue their treatment as usual for ADHD (mostly ADHD-medication).
9702375|NCT04723550|Experimental|Telemedicine|Diabetes education and support by telemedicine
9702376|NCT04723550|Active Comparator|Usual care|Diabetes education and support in person
9702377|NCT04723654||ICU Population|Patients admitted to one of 3 ICUs at Lurie Childrens
9702378|NCT04723654||Non-ICU Population|Healthy volunteers who are under 18 years of age, whose parents consent to their participation, and who are willing to visit CAMP for a one time study visit can participate in this study.
9702379|NCT04723563|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: Four times per day Duration: until hospital discharge
9702380|NCT04723563|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: Four times per day Duration: until hospital discharge
9702381|NCT04723524|Experimental|Treatment group|150 Cases, treated with Jinhua Qinggan (JHQG) Granules
9702382|NCT04723524|Placebo Comparator|Control group|150 Cases, Placebo treated
9702383|NCT04724070||NGS and PDO/PDX establishment|
9702384|NCT04723121|Other|High risk NMIBC|Patients with primary or recurrent NMIBC for whom primary TURBT was done and intravesical BCG was administered
9702385|NCT04723472|Active Comparator|Classic bismuth quadruple treatment group|
9702386|NCT04723472|Experimental|Cefuroxime containing bismuth quadruple treatment group|
9702387|NCT04723147|Experimental|Carbidopa Levodopa followed by Placebo|Participants will receive first Carbidopa Levodopa at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day; and then placebo.
9702388|NCT04723147|Experimental|Placebo followed by Carbidopa Levodopa|Participants will receive first placebo, and then Carbidopa Levodopa (L-DOPA) at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA with a starting dose of 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day.
9702389|NCT04723342|Experimental|Blinatumomab|Consolidation therapy with Blinatumomab administration
9702390|NCT04723329|Experimental|web-based education group|Patients will be given a username and password to access the website. The change stage of the patients will be determined by the researcher with the Exercise Change Phase Short Question Form, and it will be ensured that they reach the educational content prepared according to the transtheoretic model. Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
9702391|NCT04723329|No Intervention|Control Group|In the first interview, the patients in the control group will be collected data and contact information will be obtained using the Patient Information Form, Exercise Change Phase Short Question Form, Change Processes Scale, Decision Making Balance Scale and Self-Efficacy Scale. Later, patients will be given their username and password so that they can log into the website where the scales are located in order to apply the final test. No intervention will be applied to the patients in the control group. At the end of the 6th month, the same scales will be applied on the website as a final test. At the end of the study, it is aimed to gain exercise behavior to the patients in the control group.
10190303|NCT04537793|Experimental|Part B: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.
10190304|NCT04537013|Active Comparator|Control Arm|Patients with small chondral lesions of the knee
10190305|NCT04537013|Experimental|Investigational Group|Patients with large chondral lesions of the knee
10190306|NCT04535635|Experimental|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
9702392|NCT04723420|Active Comparator|Steamroller Technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
9702393|NCT04723420|Active Comparator|Direct Technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
9702394|NCT04723459|Active Comparator|Ivermectin mask group|Contacts who will use ivermectin masks
9702395|NCT04723459|No Intervention|ordinary mask group|Contacts who will use regular masks
10190307|NCT04535635|Placebo Comparator|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
10190308|NCT04533568|Experimental|ibuprofen|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
10190309|NCT04533568|Experimental|dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
10190310|NCT04518072||Biopsy prostatic group|positive biopsy (100) negative biopsy (100)
10190311|NCT04518072||Control group|No prostate cancer (50)
10190312|NCT04511078|Experimental|Panitumumab-IRDye800|50 mg infusion of panitumumab-IRDye800 given over 60 minutes
9702396|NCT04723225|Experimental|Experimental|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided.
9702397|NCT04723225|No Intervention|Control|In control intervention group usual care will be provided.
9702398|NCT04723498|Other|Patients|male and female patients, handled on an ambulatory basis in Psychiatric University Clinics, Department of Child and Adolescent Psychiatrythe ages from 8 - 18 years during the study
9702399|NCT04723290|Experimental|Serological tests|All staff at GHdC who want to know their level of antibodies against SARS CoV-2
9702400|NCT04723511|Experimental|GPR|participants in this group receive global postural reeducation technique+ Kendall exercises
9702401|NCT04723511|Active Comparator|Kendall|Kendall exercises
9702402|NCT04723381|Experimental|Experimental|Partivipants recieved web based genital hygiene education for seven week
9702403|NCT04723381|No Intervention|Control|No intervention was applied to the women in the control group
9702404|NCT04723238|Experimental|Duloxetine Test Product|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
9702405|NCT04723238|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
9702406|NCT04723433|Experimental|"Conservative O2 Supplementation"|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
9702407|NCT04723433|Active Comparator|"Liberal O2 Supplementation"|Oxygen administration will titrated to an SpO2 > 96%.
9702408|NCT04723212||Younger healthy adults|Healthy subjects in the age group of 18-30 years old, and without history of any neurological condition
9702409|NCT04723212||Older healthy adults|Healthy subjects aged 55 years and older, and without history of any neurological condition
9702410|NCT04723407||Exposed patients|Those who had the management strategy implemented by the service during confinement
9702411|NCT04723407||Unexposed patients|Those who could not benefit from this strategy
9702412|NCT04723264|Experimental|Eating behavior activities|
9702413|NCT04723095||Observational (medical chart review)|Patients' medical records are reviewed retrospectively and prospectively. Patients are followed up by email, telephone, or U.S. mail every 4 months for up to 10 years from date of initial study enrollment. Patients, who are beyond 5 years from their initial diagnosis, are followed up by email, telephone, or U.S. mail annually.
9702414|NCT04723069|Experimental|Fuke Qianjin capsule|"Metronidazole tablets Simulant + Doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.~Fuke Qianjin Capsules and their simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet and their simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
9778747|NCT01114971|Experimental|Labetalol|"Labetalol 5 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
9836136|NCT02770547|Experimental|High Heat Thermotherapy|High heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies high heat to the subject's leg.
9702415|NCT04723069|Active Comparator|Metronidazole tablets + Doxycycline hyclate tablets|"Metronidazole tablets + Doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.~Fuke Qianjin Capsules and their simulants are taken as 2 capsules at a time, 3 times a day, orally after breakfast, lunch and dinner, respectively; Metronidazole Tablets are taken as 2 tablets (0.2 g/tablet) at a time, twice a day, at the same time as breakfast and dinner, respectively; Doxycycline Hyclate Tablet and their simulants are taken as 1 tablet (0.1 g/tablet, Doxycycline Hyclate Tablet calculated as C22H24N2O8) at a time, twice a day, at the same time as breakfast and dinner, respectively."
9702416|NCT04722900||non-GDM|
9702417|NCT04722900||GDM|
10190313|NCT04510636|Experimental|Pembrolizumab and Bendamustine|"The study drugs will be given in 3 week periods called cycles.~Pembrolizumab is available in powder form or as a liquid for infusion. Pembrolizumab at a dose of 200 mg will be given over 30 minutes, once every cycle for up to 35 cycles (approximately 24 months).~Bendamustine is available in powder form for injection. Bendamustine at a dose of 90 mg/m2 will be given over 60 minutes, on Days 1 and 2 of every cycle for up to 6 cycles."
9702418|NCT04722796|Experimental|TAVR with Supra-annular sizing strategy|"Experimental: Supra-annular sizing strategy (Hangzhou Solution).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Waist sign with less than mild contrast regurgitation: Venus A plus Valve down size and Target implant depth 0-2mm.~No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: annular sizing Venus A plus Valve with implant depth 4-6mm."
9702419|NCT04722796|Other|TAVR with Annulus based sizing strategy|"Control: Traditional sizing strategy (Annulus based sizing strategy).~Pre-dilation with balloon size (20/23/26mm Z-MED) just below the annular size.~Annular sizing Venus A plus Valve with implant depth 4-6mm."
10190314|NCT04508634|Experimental|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
10190315|NCT04508634|Active Comparator|Metformin Group|Metformin Group
9702420|NCT04722874|Active Comparator|Ortho-k|Participants will continue to use ortho-k lenses alone.
9702421|NCT04722874|Experimental|RLRL+Ortho-k|Participants will be treated with RLRL twice a day in addition to ortho-k lenses.
9702422|NCT04722822|Experimental|Providers recommending HPV vaccine at age 9-10 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 9-10 years of age.
9702423|NCT04722822|Active Comparator|Providers recommending HPV vaccine at age 11-12 years of age|Providers in this arm will routinely recommend HPV vaccine starting at 11-12 years of age.
9702424|NCT04722640|Experimental|RISAKIZUMAB|SKYRIZI
10190316|NCT04507373|Placebo Comparator|Placebo|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
10190317|NCT04507373|Active Comparator|Simvastatin 40mg|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
10190318|NCT04504435|Experimental|Participants in Cohort 1|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with 20 milligram (mg) and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
9702426|NCT04722770||Pediatric patients with possible ear infections|Pediatric patients presenting with otitis media (acute otitis media or otitis media with effusion) will be imaged with the PhotoniCare OtoSight.
9702427|NCT04722783|Experimental|ESDM and PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months PCIT-A for 8 months (see Study Protocol, Figure 2).
9702428|NCT04722783|Experimental|ESDM and active control for PCIT-A|Participants in this arm receive 2 years ESDM and after 4 months 1h-ESDM as active control instead of 1h-PCIT-A for 8 months
9702429|NCT04722783|Experimental|PCIT-A and active control for ESDM|Participants receive after 4 month PCIT-A for 8 months and early special needs education as an active control for ESDM.
9702430|NCT04722783|Active Comparator|Active control for ESDM and PCIT-A|Participants receive early special needs education as an active control for ESDM and PCIT-A.
9702431|NCT04723030|Experimental|carleilizumab in combination with apathy mesylate and chemoradiotherapy (paclitaxel (albumin-bound)|Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped.
9702432|NCT04722965|Active Comparator|Fistulotomy with marsupialization|40 patients with a simple low transsphincteric anal fistula. A fistulotomy with marsupialization is performed.
9702433|NCT04722965|Active Comparator|Fistulotomy with open wound|40 patients with a simple low transsphincteric anal fistula. A fistulotomy leaving the wound open is performed.
10190319|NCT04504435|Experimental|Participants in Cohort 2|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with dose level (DL) 5 and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
9702434|NCT04722835||Normal RV/TLC Group:|Plethysmographic RV/TLC equal or less than lower limit of normal.
9702435|NCT04722835||Abnormal RV/TLC Group:|Plethysmographic RV/TLC higher than lower limit of normal.
9702436|NCT04723004|Active Comparator|Experimental group|Toripalimab combined with Bevacizumab
9702437|NCT04723004|Active Comparator|Control group|Sorafenib
9702438|NCT04722809|Experimental|Symptomatic patients in the context of bruxism|
9702439|NCT04722627|Experimental|AT-752 250 mg single dose|AT-752 administered orally, 250 mg on Day 1
9702440|NCT04722627|Placebo Comparator|Placebo -single dose|Matching placebo administered orally on Day 1
9702441|NCT04722627|Experimental|AT-752 500 mg single dose|AT-752 administered orally, 500 mg single doses on Day 1 and Day 7
9702442|NCT04722627|Placebo Comparator|Placebo- single dose|Matching placebo administered orally on Day 1 and Day 7
10190320|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fasted then fed)|Participants will receive the selected dose level (DLX) of GSK3494245 in the fasted state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fed state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
10190321|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fed then fasted)|Participants will receive the DLX of GSK3494245 in the fed state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fasted state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
9702443|NCT04722627|Experimental|AT-752 1000 mg single dose|AT-752 administered orally, 1000 mg single dose on Day 1
9702444|NCT04722627|Placebo Comparator|Placebo - single dose|Matching placebo administered orally on Day 1
9702445|NCT04722627|Experimental|AT-752 1500 mg single dose|AT-752 administered orally, 1500 mg single dose on Day 1
9702446|NCT04722627|Placebo Comparator|Placebo: single dose|Matching placebo administered orally on Day 1
9702447|NCT04722627|Experimental|AT-752 - 1000 mg QD multiple doses|AT-752 - administered orally, 1000 mg once daily (QD) for 7 days
9702448|NCT04722627|Placebo Comparator|Placebo - Administered once daily (QD)|Matching placebo administered orally once daily (QD) for 7 days
9702449|NCT04722627|Experimental|AT-752 - 500 mg twice daily (BID)|AT-752 administered orally, 500 mg twice daily (BID) for 7 days.
9702450|NCT04722627|Placebo Comparator|Placebo - Administered twice daily (BID)|Matching placebo administered orally twice daily (BID) for 7 days.
9702451|NCT04722614|Active Comparator|Control group|Mechanically ventilated patients who will be subjected to the routine unit intervention for agitation
9702452|NCT04722614|Experimental|Music group|Mechanically ventilated patients who will listen to classic music
9702453|NCT04722614|Experimental|Essential oil group|Mechanically ventilated patients who will inhale bergamot oil
9702454|NCT04722562|Experimental|Child Pugh A|Participants with mild hepatic impairment
9702455|NCT04722562|Experimental|Child Pugh B|Participants with moderate hepatic impairment
9702456|NCT04722562|Experimental|Healthy participants|Participants with normal hepatic function
9702457|NCT04722510|Experimental|Effect of repeated TMS on aggressive impulse behavior in patients with BPD.|A protocol of 15 sessions of repeated Transcranial Magnetic Stimulation at 1 Hz on right dorsolateral prefrontal cortex.
9702458|NCT04722523|Experimental|Head and Neck Squamous Cell Cancer/HNSCC|Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
9702459|NCT04722497||Physicians and nurses|All physicians, nurses, involved in a cesarean births are included in the cohort.
9702460|NCT04722497||Patients undergoing cesarean births|All patients undergoing cesarean births
9702461|NCT04722458||Patients with Lower urinary tract sypmtoms|Patients with Lower urinary tract sypmtoms over 18 years old will be included to this study
9702462|NCT04722484|Experimental|Patients with normal creatine clearance (CLCR)|Subjects with renal impairment according to their medical history and estimated glomerular filtration rate (eGFR) at screening but had normal creatinine clearance at the pre-profile day (-01day)
9702463|NCT04722484|Experimental|Normal renal function (Healthy subjects)|Subjects with creatinine clearance at pre-profile day >80 ml/min
9702464|NCT04722484|Experimental|Mildly impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 50-80 ml/min
9702465|NCT04722484|Experimental|Moderately impaired renal function|Subjects with creatinine clearance at pre-profile day in the range of 30-<50 ml/min
9702466|NCT04722484|Experimental|Severely impaired renal function|Subjects with creatinine clearance at pre-profile day <30 ml/min
9702467|NCT04722588|No Intervention|Control period|The control period is represented by standard care procedures, which are similar in all three EDs: Patients cared for in the EDs receive treatment from ED physicians and nurses, and no pharmacists are involved in any of the EDs.
9702468|NCT04722588|Experimental|Intervention period|"During the intervention period, clinical pharmacists will be present in the EDs from 08.00 - 19.00 Monday to Friday.~The ED pharmacists will collaborate with the interdisciplinary team and perform the following tasks as appropriately as possible and by prioritized need; medication history taking, medication reconciliation, medication review, drug therapy recommendations, guidance on drug administration, medication information and counseling to patients/next of kin and health care personnel and communication about medications and changes in medication regimes. Standardized procedures, like the integrated medicines management (IMM) methodology, will be applied where possible. How, when and which task will be performed for each patient cannot be predetermined, but must be performed according to patient's needs and eventual time constraints."
9702469|NCT04722705|Experimental|combined IPL/fractional Er:YAG laser treatment site|"At baseline, three lesions were randomized to IPL / fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed all laser treatments including IPL and 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
9702470|NCT04722705|Active Comparator|fractional Er:YAG laser treatment alone site|"At baseline, three lesions were randomized to fractional Er:YAG laser combination therapy site.~Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The same dermatologist performed 2,940 nm Er:YAG fractional laser. The face was cooled after treatment with gauze soaked in ice water.~The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
9702471|NCT04722705|No Intervention|untreated control site|At baseline, three lesions were randomized to untreated control site. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment. The evaluation of scar site was conducted 3 months later after last treatment.
9702472|NCT04722328||CNS infection|
9702473|NCT04722328||Non-CNS infection|
9702474|NCT04722354|Active Comparator|ABA group|95 ug 2x/day for 14 days
10190322|NCT04501653|Experimental|Psilocybin first|Participants will receive 25 mg of psilocybin at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the control drug (methylphenidate) at their second drug exposure neuroimaging session.
10190323|NCT04501653|Active Comparator|Methylphenidate first|Participants in this group will be randomized to receive 40 mg of methylphenidate at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the active comparator (psilocybin) at their second drug exposure neuroimaging session.
9702475|NCT04722354|Placebo Comparator|Placebo group|Corn Starch 300 mg for 14 days
9702476|NCT04722380|Experimental|test group|10 infrabony defects treated surgically with Nigella Sativa oil extract Mixed with xenograft
9702477|NCT04722380|Placebo Comparator|control group|10 infrabony defects treated surgically with xenograft alone
9702478|NCT04722406||Low TGR group|Patients with low level of TGR determined by X-tile program
9702479|NCT04722406||High TGR group|Patients with high level of TGR determined by X-tile program
9778748|NCT01114971|Experimental|Esmolol|"Esmolol 10 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
9778749|NCT01114997|Active Comparator|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
9778750|NCT01114997|Active Comparator|Esmolol|Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min
9778751|NCT01114997|Experimental|Lidocaine + Esmolol (Combo)|"Performed with the administration of both drugs.~Pre-induction:~Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)~Post-induction:~Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
9778752|NCT01115101|Experimental|Oxycodon|
9778753|NCT01115101|Active Comparator|Patient controlled analgesia (PCA) device with Pritramid|
9778754|NCT01115166||Cardiac surgery|Patients subjected to open cardiac surgery with the help of extracorporal circulation.
9778755|NCT01115231||Group 1 (Control)|Case control subjects without AMD diagnosis
9778756|NCT01115231||Group 2 (Age-related Macular Degeneration)|Case (i.e., within 5 years) subjects will be recruited. Cases are defined as subjects with diagnosed AMD.
9778757|NCT01115309|Other|XprESS Balloon Device|Sinus dilation
9778758|NCT01115452|Experimental|5% KNO3 solution|Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
9778759|NCT01115452|Experimental|2.5% KNO3 solution|Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
9778760|NCT01115452|Placebo Comparator|Sterile Water|Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period.
9778761|NCT01115491|Experimental|A|
9778762|NCT01115517|Experimental|Bevacizumab|
9778763|NCT01115517|Active Comparator|Mitomycin C|
9778764|NCT01115556|Experimental|Lucentis 2.0 mg|Lucentis 2.0 mg
9778765|NCT01115556|Active Comparator|LUCENTIS 0.5 mg|
9778766|NCT01115569|Experimental|Hydrocodone Bitartrate|Open-label, all patients fulfilling the protocol Inclusion/Exclusion criteria will receive HC-CR in a flexible dosing regimen.
9778767|NCT01115582|Experimental|Cholic Acid Capsule|Manufactured cholic acid capsules
9778768|NCT01115660|Experimental|stroke education|Patients in this arm receive a telephone call by a medication coach who reviews their condition and importance of adherence to medication regimen.
9778769|NCT01115660|No Intervention|control arm|Subjects in this arm received instruction at hospital discharge and a 3-month follow-up call to collect study data.
9785032|NCT01240915|Experimental|Cohort 3|These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.
9785033|NCT01241240|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
9785034|NCT01241240|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
9785035|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 10mg|
9785036|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 20mg|
9785037|NCT01241318|Experimental|Chlorhexidine cord care|Mothers located in health facility catchment areas assigned to this arm will apply Chlorhexidine gluconate (4%) to their infants daily until three days after the cord completely separates. Bottles of chlorhexidine is provided to women during antenatal care.
9785038|NCT01241318|Active Comparator|Dry cord care|Mothers in health facility catchment areas assigned to this arm will use dry cord care - keeping their babies' umbilical stumps clean and dry - as per normal routine standard of care and in accordance with Zambia Ministry of Health policy.
9785039|NCT01241344|Active Comparator|Brincidofovir|"Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
9785040|NCT01241344|Placebo Comparator|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
9785041|NCT01241435|Experimental|LY2216684|LY2216684: A single dose of 18 milligrams (mg) administered orally in participants with normal hepatic function, mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C)
9702480|NCT04722211|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
9702481|NCT04722211|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
9702482|NCT04722393|Experimental|Pulmonary Rehabilitation Group|An 8-week comprehensive outpatient PR program including respiratory exercises, aerobic and strengthening training
9702483|NCT04722393|Other|Control Group|Respiratory exercises
9702484|NCT04722861||Primary Glaucoma|Patients with primary glaucoma diagnosed by glaucoma professionals
9702485|NCT04722861||Glaucoma Suspect Controls|Glaucoma suspect controls had a diagnosis of glaucoma suspect or ocular hypertension, and also were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
9702486|NCT04722237|Experimental|Immediate Acceptance and Commitment Therapy|Receiving 6-to-12 weekly sessions of Acceptance and Commitment Therapy immediately after allocation. Each session will be up to one hour in length.
10190324|NCT04500171|Active Comparator|English Original Assessment Tools|Short-Test of Functional Health Literacy in Adults ColoCARE Instruction Sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
10190325|NCT04500171|Active Comparator|Samoan Original Assessment Tools|Samoan Short-Test of Functional Health Literacy in Adults ColoCARE Instruction sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
9702487|NCT04722237|No Intervention|Waitlist Control|Receiving no intervention during a 12-week wait, though no restrictions will be placed on the use of other services. After the wait participants will receive 6-to-12 weekly sessions of Acceptance and Commitment Therapy. Each session will be up to one hour in length.
9702488|NCT04722471||400 mg|Treatments where 400 mg tablet presentation of micronized vaginal progesterone was used, the protocol being one vaginal tablet twice a day.
9702489|NCT04722471||200 mg|Treatments where 200 mg tablet presentation of micronized vaginal progesterone was used, the protocol being two vaginal tablets twice a day.
10190326|NCT04500171|Experimental|English Modified Assessment Tools|Short-Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
10190327|NCT04500171|Experimental|Samoan Modified Assessment Tools|Samoan Short Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
9702490|NCT04722549|Placebo Comparator|Placebo|Placebo (cellulose)
9702491|NCT04722549|Active Comparator|Butyrate|Sodium butyrate
9702492|NCT04722757|Experimental|transanal IPAA|In the experimental arm, patients will undergo transanal dissection of the distal part of the rectum. After proctectomy, an ileal pouch-anal anastomosis (IPAA) will be created. A Gelpoint Path will be used to create access through the anus. Postoperative care will occur following the hospital specific protocols.
9702493|NCT04722757|Active Comparator|transabdominal IPAA|In the control group, proctectomy will occur through abdominal dissection (laparoscopy, single port laparoscopy, robotic or open). Postoperative care will occur following the hospital specific protocols.
9702494|NCT04722367|Experimental|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
9702495|NCT04722198|Experimental|PS128|Each PS128 capsule contained >1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
9702496|NCT04722224|Experimental|Intervention: Home-based pulmonary rehabilitation|Patients will be treated for 12 weeks. The intervention consists in a strategic mixture of home visits and phone calls. The program includes exercise training and the self-management educational program Living Well with COPD.
9702497|NCT04722133|Experimental|HERZUMA+mFOLFOX|
9702498|NCT04722159||Treatment resistent hypertensives, treated with renal denervation|Patients having undergone renal denervation and fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
9702499|NCT04722159||Treatment resistent hypertensives, conservatively treated|Patients fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP >140/90 despite treatment with at least three antihypertensive drugs) with a follow up period of at least 5 years.
9702500|NCT04721873|Experimental|Intervention|
9702501|NCT04721873|Placebo Comparator|Placebo|
9702502|NCT04721899||Vitamin D- recurrent implantation failure (RIF)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
9702503|NCT04721899||Vitamin D- recurrent pregnancy loss (RPL)|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
9702504|NCT04721899||Vitamin D- infertility|All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.
9702505|NCT04721912|No Intervention|Standard of Care|Subjects in the control group will not receive any Probiotic capsules and will be advised to continue their routine prenatal self-care.
9702506|NCT04721912|Experimental|Probiotic Dietary Supplement|Participants in the intervention group will begin taking oral study Probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth. The research staff member will sequentially distribute the pre-labeled bottles of study capsules to the intervention group, one bottle of 30 Florajen Digestion probiotic capsules to women in the intervention group at the time of randomization.
9702507|NCT04721938|Other|Intervention|Systematic weight loss intervention
10190328|NCT04499963|Experimental|Open Label Arm|The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
10190329|NCT04499963|No Intervention|Healthy Control Arm|We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
10190330|NCT04493645|Active Comparator|Standard of Care (SOC)|Participants will be randomized to receive standard of care rehabilitation (SOC) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the SOC group for 24 months following completion of their assigned SOC intervention.
10190331|NCT04493645|Experimental|Foot Intensive Rehabilitation (FIRE)|Participants will be randomized to receive foot intensive rehabilitation (FIRE) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the FIRE group for 24 months following completion of their assigned SOC intervention.
10190332|NCT04481009|Experimental|YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
9702508|NCT04722315|Experimental|MAD diet group|15 adult participants with confirmed KMT2D pathogenic mutations. Baseline labs and education about Modified Atkins Diet. Then 12 weeks on a Modified Atkins Diet. Weekly urine dips for ketones and diet logs. Blood draw every 3 weeks.
9702509|NCT04722289|Experimental|Together on Diabetes|The intervention consists of five components: Recruitment of peers and peer supporters; training of peer supporters; matching peers and peer supporters; individual face-to-face meetings between peers and peer supporters; and ongoing supervision and network meetings for peer supporters.
9702510|NCT04722068|Experimental|Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial|
9702511|NCT04721964|Experimental|Intervention|All 24 participants will daily consume 6 mg iron/kg body weight for 13 weeks to correct their anaemia and increase their iron stores.
9702512|NCT04721860|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 4 weeks.
9702513|NCT04721860|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 4 weeks.
9702514|NCT04721886|Experimental|Diagnostic (CEUS)|Patients undergo ultrasound without contrast. Patients then receive Definity IV over 15 minutes and undergo CEUS.
9702515|NCT04721990|Experimental|Automatic Sound Management 3.0|Current SONNETEAS listeners, who meet the eligibility criteria, will be tested with their current listening configuration and also fit with a SONNET2EAS, programmed with Automatic Sound Management 3.0 (under the Investigational Device Exemption).
9702516|NCT04721847|Experimental|Pain Neuroscience Education|Pain Neuroscience Education (PNE) sessions. Additionally, treated with Transcutaneous Electrical Nerve Stimulation (TENS), Stretching and Strengthening exercises similar as in control group
10190333|NCT04481009|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
10190334|NCT04481009|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
10190335|NCT04477161|Experimental|Ketone Intervention|Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
9702517|NCT04721847|Active Comparator|Conventional Physical therapy|Control group will be treated by TENS, stretching and strengthening exercises.
9702518|NCT04722081|Experimental|Control Group|children received selected physical therapy exercises
9702519|NCT04722081|Experimental|Study Group|children received selected physical therapy exercises plus virtual reality training
9702520|NCT04722094||Patients with Psoriasis|All patients pertaining to the Unit of Dermatology and affected by psoriasis will be screened for the inclusion in the study
9702521|NCT04721834|Active Comparator|Low-intensity ESWT|Patient would be positioned in a supine position. Shockwaves would be delivered to the stretched penis at proximal, mid and distal penile shaft and bilateral crura of penis. (Energy: 0.1-0.25 mJ/mm2; 3000pulses per session; Frequency 3Hz) Treatment consists of 6 sessions over 5 weeks in total. It would be a twice-weekly treatment with one-week interval of resting period. Patient would be discharged home after each treatment session.
9702522|NCT04721834|Sham Comparator|Sham ESWT|Sham therapy would be given with a modified probe which no shockwave would be emitted. A working noise would still be generated which mimicked active treatment.
9702523|NCT04722107|Experimental|Single arm|Single arm
9702524|NCT04721444||Arm A - Cohort A1|Training set: Pneumonitis in the context of IO therapy and negative for infectious pneumonia (including COVID-19)
9702525|NCT04721444||Arms A and B - Cohort B1|Training set B1: IO and RT naive and pneumonia (without COVID-19)
9702526|NCT04721444||Arms A and B - Cohort B2|Training set B2: IO and RT naive and confirmed COVID-19 positive with pneumonia
9702527|NCT04721444||Arm B - Cohort A2|Training set: Pneumonitis in the context of thoracic RT and negative for infectious pneumonia (including COVID-19)
9702528|NCT04721444||Arm A - Test Cohort (Cohort C1)|Test set C1: Patients on IO and with possible toxicity versus COVID-19 or other infective pneumonitis
9702529|NCT04721444||Arm B - Test Cohort (Cohort C2)|Test set C2: Patients with pneumonitis in context of thoracic RT with possible toxicity versus COVID-19 or other infective pneumonitis.
9702530|NCT04721444||Arm C|Patients with radiotherapy planning CT scans and post-treatment surveillance CT scans at 3, 6 and 12-months post treatment
10190336|NCT04475731|Experimental|Experimental arm|"MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).~Patients will receive the study drug until disease relapse or progression."
10190337|NCT04473742|Experimental|Patients exposed to silica|
10190338|NCT04473742|Active Comparator|Patients exposed to asbestos fibres|
10190339|NCT04469491|Experimental|Inhaled IFN arm|IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; +/- dexamethasone; + appropriate O2 support)
9702531|NCT04721509|Experimental|Smartphone-based telemedicine|
9702532|NCT04721509|No Intervention|Conventional management without telemedicine|
9702533|NCT04721496|Experimental|Trained|Athletes who had at least 2 years of continuous strength training experience, and at least 6 months of training with unstable situations and device
9702534|NCT04721496|Experimental|Untrained|Athletes who had at least 2 years of continuous strength training experience, but no training experience with unstable situations and devices
9702535|NCT04721535|Experimental|DWJ1248|Camostat mesilate 200mg
9702536|NCT04721535|Placebo Comparator|Placebo|Placebo
9702537|NCT04721587|No Intervention|Standard of care|Office hysteroscopy performed as the standard of care of our Hospital
9702538|NCT04721587|Experimental|Virtual Reality|Office hysteroscopy with the use of VR environment (preprocedure and during procedure)
9702539|NCT04721639|Experimental|The experimental intervention (Sphinx Yoga Therapy)|In this group, participants will be intervened with Sphinx Yoga therapy which will take place in a conserved therapy center of Koohi Goth Hospital. This stretching exercise session will take place in the afternoon and for a duration of 10 minutes followed by 30 minutes therapy session five times per week (total 12 weeks).
9702540|NCT04721639|No Intervention|The control intervention (Usual Care)|In this Group, participants won't be receiving any intervention and provided with the usual care.
9702541|NCT04721561||Chronic stroke patients|Patients who are at least 6 months after a first unilateral stroke
10190340|NCT04469491|Active Comparator|Control Arm:|Aerosol (WFI water and routine care (+/- antibiotics;+/- dexamethasone; + appropriate O2 support).
9702542|NCT04721561||Healthy controls|Healthy subjects with no history of any neurological condition and who are in the same age group as the chronic stroke patients
10190341|NCT04459338|Placebo Comparator|Saline|Saline infused during the hyperglycemic clamp with escalating doses of glucagon
9702543|NCT04721678|Experimental|Interpersonal psychotherapy (IPT)|10 weeks of internet-administered interpersonal psychotherapy with therapist support.
9702544|NCT04721678|No Intervention|Wait-list control group|The participants in the control group will receive access to the treatment after the post-treatment assessment has been conducted.
9702545|NCT04721782||otherwise healthy, smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
9702546|NCT04721782||otherwise healthy, non-smoking, singleton pregnant women between 24- 36 weeks|Fetal liver circulation will be evaluated with doppler ultrasound, The degree of maternal smoking will be assessed by measuring urine cotinine and exhaled carbon monokside levels
9702547|NCT04721652||Hemodialysis Patients (nondiabetic)|Nondiabetic adult hemodialysis patients
9702548|NCT04721418||Cocaine Use Disorder|
9702549|NCT04721418||Healthy Control|
9702550|NCT04721574|Active Comparator|Bright light therapy|Daily exposure to a high brightness LED light box for 30 minutes as soon as possible after awakening, preferably between 7 and 8 AM in the patient's hospital room The device emits 10,000 lux of cool-white fluorescent light at 50-75 cm from the screen to the cornea with an ultraviolet filter
10190342|NCT04459338|Active Comparator|Exendin-9,39|Exendin-9,39 infused during the hyperglycemic clamp with escalating doses of glucagon
10190343|NCT04459156|Experimental|Healthy Participants|healthy control subjects
10190344|NCT04459156|Experimental|Chronic Obstructive Pulmonary Disease patients|Established diagnosis of Chronic Obstructive Pulmonary Disease
9702551|NCT04721574|Sham Comparator|Sham Therapy|Light-therapy with filters that reduced lamp output to less than 50 lux. for 30 minutes as soon as possible after awakening.
9702552|NCT04721483|Active Comparator|T3-T4 sympathicotomy|In this group, patients underwent a classical T3 and T4 sympathicotomy to treat primary palmar hyperhidrosis
9702553|NCT04721483|Experimental|T3-T4 ramicotomy|In this group, patients underwent a selective T3 and T4 gray ramicotomy
9702554|NCT04721470|Experimental|Combined therapy|Patients undergoing combined therapy
9702555|NCT04721470|Active Comparator|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
9702556|NCT04721470|Active Comparator|Microwave ablation|Patients undergoing Microwave ablation
9702557|NCT04721795|Experimental|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
9702558|NCT04721795|Active Comparator|Anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs only consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
9702559|NCT04721704|Experimental|Group A|Group A will be given Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI based triple regimen
9702560|NCT04721704|Experimental|Group B|Group B will be given Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI based triple regimen
9702561|NCT04721379|Experimental|Heartfulness Meditation Group|Participants will be guided through relaxation and meditation session with a Heartfulness trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
9702562|NCT04721379|Active Comparator|Control Group with Self Meditation|Participants will be self-guided through relaxation and meditation session without a trainer with EEG and EKG recording. After finishing the session, they fill out meditation depth questionnaire.
9778770|NCT01115673|Experimental|ACE-1000|1000 mg Acetaminophen Caplet
9702563|NCT04721366||Standard of Care (SoC)|Neonatal and pediatric participants who has been on ERT (VPRIV) will be followed up for 36 months from the time of treatment initiation as per SOC.
10190345|NCT04459156|Experimental|Healthy Young Participants|healthy young subjects with age 18-30 years old
9702564|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part1|JAB-3068+JS001 dose escalation
9702565|NCT04721223|Experimental|JAB-3068+PD1 inhibitor Part2|JAB-3068+JS001 dose expansion
9702566|NCT04721080||COPD patients with tuberculous sequelae|COPD patients with tuberculous sequelae
9702567|NCT04721080||COPD patients without tuberculosis sequela|COPD patients with tuberculous sequelae
9702568|NCT04721054|Active Comparator|group receiving thoracic epidural anesthesia|
9702569|NCT04721054|Active Comparator|group receiving thoracic general anesthesia|
9702570|NCT04721275||Sepsis on the elderly population in ED|The elderly population is defined as patients over 65 years old of age.
9702571|NCT04721275||Sepsis on the non-elderly population in ED|The non-elderly population is defined as patients aged of 18 to 64 years old.
9702572|NCT04721249|Active Comparator|Verum|
9702573|NCT04721249|Placebo Comparator|Placebo|
9702574|NCT04721093|Experimental|PBM(Photobiomodulation)|Subjects applied PBM(Color-DNA-WSF U, Color Seven; 610 nm±10nm wavelength; 3.0 mW/㎠±20%) therapy in the locations of the sternocleidomastoid muscle in the ICA area and the trapezius muscle in VA area. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
9702575|NCT04721340||Test Group|people with multiple sclerosis
9702576|NCT04721340||Control Group|healthy volunteers
9702577|NCT04721041|Experimental|Washed Microbiota Transplantation (WMT)|Patients undergo once WMT a day for three consecutive days.
9702578|NCT04721327|Experimental|Pediatric Arm|Patient ages 1-17 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
9702579|NCT04721327|Experimental|Adult Arm|Patient ages 18-90 years who are current cochlear implant (CI) users will receive CI programming in person for the first visit and remotely for the second visit.
9702580|NCT04721743||Affected Participants|Participants with Uveitis
9702581|NCT04721431|Experimental|Normal|Body mass index must to be in range limits (18.5-24.9 kg/meter square)
9702582|NCT04721431|Experimental|Overweight|Body mass index must to be in range limits (25-29.9 kg/meter square)
9702583|NCT04721431|Experimental|Obese|Body mass index must to be in range limits (30-34.9 kg/meter square)
9702584|NCT04721119|Experimental|Local Infiltration Anesthetic|This group of patients will receive the local infiltration anesthetic only.
9702585|NCT04721119|Experimental|Local Infiltration Anesthetic + Adductor Canal Block|This group of patients will receive the local infiltration anesthetic and adductor canal block combination.
9702586|NCT04721301|Experimental|Combination immunotherapy|Treatment arm with Nivolumab, Ipilimumab and Maraviroc combination treatment
9702587|NCT04720924|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through white light EGD examination with assistance of AQCS.
9702588|NCT04720924|No Intervention|Control group|Patients in control group will go through white light EGD examination without AQCS.
9702589|NCT04721210|Experimental|Frequency of 1 Hz|continuous stimulation with a frequency of 1 Hz, 2000 pulses, 10 days-daily;
9702590|NCT04721210|Experimental|Frequency of 10 Hz|continuous stimulation with a frequency of 10 Hz-10 seconds with a pause of 50 seconds, 2000 pulses, 10 days-daily;
9702591|NCT04721210|Placebo Comparator|Continuous stimulation placebo|continuous stimulation placebo
9702592|NCT04720807|Experimental|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
9702593|NCT04720768|Experimental|Dose escalation phase|"Encorafenib (tablet) 450mg PO daily~Binimetinib (tablet) 45mg PO BD~Palbociclib (tablet) variable dose PO daily for 21 consecutive days on treatment, followed by 7 consecutive days off treatment in a 28 day cycle"
9702594|NCT04720794|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
9702595|NCT04720833|Experimental|dried plum (100 g dried plum)|Participants will receive 100 g dried plum daily plus 500 mg calcium and 300 IU vitamin D daily
9702596|NCT04720833|Placebo Comparator|Calcium and vitamin D|Participants will receive 500 mg calcium and 300 IU vitamin D daily
9702597|NCT04720690||Appropriately grown for age infants|40 appropriately grown for gestational age (AGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
9702598|NCT04720690||Small for gestational age infants|40 small for gestational age (SGA) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
9702599|NCT04720690||Fetal growth restricted infants|40 fetal growth restricted (FGR) infants. 20 will be <32 weeks, and 20 will be ≥32 weeks gestational age at birth.
9702600|NCT04720859|Experimental|Patients with PHH following Roux-en-Y-gastric bypass (cases)|Patients diagnosed with PHH following Roux-en-Y-gastric bypass.
9702601|NCT04720859|No Intervention|Healthy individuals (controls)|Healthy normoweight individuals, matched by age and gender with the cases.
9702602|NCT04720989|Experimental|Bathing With Baby Cleanser|Skin cleansing products will be used in the first baths of the participants in this group.
9702603|NCT04720989|Experimental|Bathing With only Water|Only water will be used in the first baths of the participants in this group.
9702604|NCT04720885||Patients with a placental remnant in medical history|
9702605|NCT04720638|Experimental|Short fiber reinforced flowable resin composite restorations|(everX Flow, GC Europe) + (Gaenial posterior, GC Europe
9702606|NCT04720638|Active Comparator|Conventional resin composite restoration.|(Gaenial posterior, GC Europe)
9702607|NCT04720898|Experimental|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG once a week for 12 weeks.
9702608|NCT04720898|No Intervention|Control|The control group will receive its rehabilitation care.
9702609|NCT04720755|Experimental|Treatment|Participants will receive twice-weekly Li-ESWT treatments of 0.2mJ/mm² over 3 treatment sites along the dorsal penile shaft (distal, mid-shaft, proximal), 1500 shocks per treatment (500 shocks per treatment site) for a total of 3000 shocks per week, for 6 weeks (total of 18,000 shocks)
9702610|NCT04720820|Experimental|Early Supported Discharge (ESD) Group|Patients in the ESD group will be discharged to home as soon as the acute medical treatment is finished. The patients will follow a pre-planned ESD program which consists of home-based rehabilitation (at least 30 minutes of physical therapy and 30 minutes of occupational therapy per week) offered by therapists. The ESD team will also provide social/medical services as needed. The ESD program will be provided till 1 months after discharge point.
9702611|NCT04720820|Active Comparator|Conventional Rehabilitation (CR) Group|The patients in CR group will be provided with inpatient rehabilitation after the acute medical treatment is finished. The length of inpatient rehabilitation may depend on the hospital's current program. Patients will be provided with outpatient based rehabilitation program if needed after discharge.
9702612|NCT04720586|Experimental|triple procedure|lower eyelid retractors plication , transcutaneous blepharoplasty and wedge resection
9702613|NCT04720586|Active Comparator|combined procedure|lower eyelid retractors plication and transcutaneous blepharoplasty
9702614|NCT04720950|Experimental|Morning exercise|1 hour of exercise completed between 0800-1000
9702615|NCT04720950|Experimental|Evening exercise|1 hour of exercise completed between 1800-2000
9702616|NCT04720703|Experimental|Intervention Group|The Intervention Group will receive the Family-based Telehealth Intervention for the first three months of the study period. Once they have completed the intervention, there will be a two-week washout period. After the washout period, they will receive monthly newsletters, with similar information learned in the intervention, for three months until the end of the study period.
9702617|NCT04720703|Active Comparator|Wait-list Control Group|The Waitlist Control Group will receive monthly newsletters, with similar information learned in the intervention, for the first three months of the study period while the Intervention Group receives the intervention. Then, there will be a two-week washout period. After the washout period, they will receive the Family-based Telehealth Intervention for 3 months until the end of the study period.
9702618|NCT04720508||Group A (patient group)|"included 25 patients with BC admitted to department of medical Oncology, South Egypt Cancer Institute, Assiut University.~blood samples will be obtained after getting informed consent."
10190346|NCT04456400||Derivation cohort|"The derivation sub-cohort will be used to derive optimum reconstruction algorithm parameters of MSOT images.~Primary objective of the derivation cohort is to derive Multispectral Optoacoustic Tomography (MSOT) thresholds maximizing receiver operating characteristic (ROC) to distinguish endoscopic remission from active disease.~As secondary objective, performance of the Multispectral Optoacoustic Tomography (MSOT) device will be analyzed."
10190347|NCT04456400||Validation cohort|Objective of the validation cohort is to confirm the performance of Multispectral Optoacoustic Tomography (MSOT) using prescribed thresholds from the derivation cohort.
9702619|NCT04720508||Group B (control group)|included 25 controls age-matched , sex-matched and apparently healthy. blood samples will be obtained after getting informed consent .
9702620|NCT04720495|Active Comparator|One stage ridge splitting|
9702621|NCT04720495|Experimental|Two-stage ridge splitting|
9702622|NCT04720339|Experimental|Experimental arm|
9702623|NCT04720352|Sham Comparator|Sham Comparator|Sham delivers non therapeutic levels of radiofrequency and cryogen
9702624|NCT04720352|Experimental|Active Arm|Active arm delivers radiofrequency and cryogen
9702625|NCT04720365|Experimental|play-based rehabilitation|"Patients randomized in the play-based rehabilitation group will perform 2 to 3 gambling rehabilitation sessions at home using the Kinect® system linked to the Curapy.com platform for 12 months."
9702626|NCT04720365|No Intervention|routine care|"Patients randomized in the usual care group will have their usual rehabilitation care provided by their physiotherapist."
10190348|NCT04449588|Experimental|Treatment group|
10190349|NCT04449588|Experimental|Control group|
10190350|NCT04438538||Patients with Dizziness|All trial participants are within this group. All trial participants will either have a diagnosis or a suspected diagnosis of Ménière's Disease in order to take part.
10190351|NCT04427488|Experimental|Morning Chronotype (MC) Group|In the MC group, exercises were applied in the morning hours for the first 6 weeks and in the evening hours for the next 6 weeks.
9702627|NCT04720521|Experimental|OE+white light|Using white light firstly to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus.
9702628|NCT04720521|No Intervention|White light|Using White light to observe from esophagus to duodenum.
9702629|NCT04720326|Experimental|Envarsus®|Participants take prolonged-release tacrolimus tablets orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
9702630|NCT04720326|Active Comparator|Advagraf®|Participants take prolonged-release tacrolimus capsules orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
9702631|NCT04720573|Active Comparator|Group N|Neostigmine was used for the reversal of neuromuscular blockade.
9702632|NCT04720573|Active Comparator|Group S|Sugammadex was used for the reversal of neuromuscular blockade.
10190352|NCT04427488|Experimental|Evening Chronotype (EC) Group|The EC exercises were applied in the evening hours for the first 6 weeks and in the morning hours for the next 6 weeks
9702633|NCT04720742|Experimental|Experimental group|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration, and during the first 8 months, a temporary immune intervention including the combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074, which will be infused once per month.
9702634|NCT04720261|Other|Caplacizumab|All patients in the study are aTTP and needs to be treated by caplacizumab. The duration of this treatment will be evaluated through the ADAMTS 13 activity.
9702635|NCT04720287|Active Comparator|Group 1(QL group)|
9702636|NCT04720287|Active Comparator|Group 2 (CB group)|
9778771|NCT01115673|Active Comparator|ACE-650|650 mg Acetaminophen Caplet
10190353|NCT04420403|Experimental|Manual therapy plus cervical stabilization exercise group|The patients diagnosed with chronic neck pain (CNP) with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
9702639|NCT04720235|Other|Subject Self-Collection and Specimen Testing|Subjects will be provided with the Lucira COVID-19 Test Kit and collect one (1) nasal swab according to the QRI and test the sample on the Lucira COVID-19 All-In-One Test. HCP will observe subject during this process and document any observations and deviations from the QRI.
9778772|NCT01115673|Placebo Comparator|ACE-0|0 mg Acetaminophen Caplet
9778773|NCT01115738|Placebo Comparator|Placebo and 60 milligram (mg) Prasugrel|Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
10190354|NCT04420403|Active Comparator|Only manual therapy group|The patients diagnosed with CNP with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
9778774|NCT01115738|Experimental|600 mg Clopidogrel and 60 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
9778775|NCT01115738|Experimental|600 mg Clopidogrel and 30 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
9778776|NCT01115803|Experimental|Arm A: LY2584702 + Erlotinib|Participants received 50 mg LY2584702 once daily (QD )+ 150 mg Erlotinib QD, 50 mg LY2584702 twice daily (BID) + 150 mg Erlotinib QD, 100 mg LY2584702 BID + 150 mg Erlotinib QD and 75 mg LY2584702 BID + 150 mg Erlotinib QD.
10190355|NCT04416711|Active Comparator|Services As Usual|Participants assigned to the SAU condition will receive services as usual at their university, which include required programming related to heavy episodic drinking and sexually aggressive behavior either online or through new-student orientation.
10190356|NCT04416711|Experimental|Personalized Feedback and Cognitive Training|The prevention program will target heavy episodic drinking, sexually aggressive behavior, and risky sexual behavior through 2 sessions that integrate personalized feedback and cognitive training components.
10190357|NCT04398524|Experimental|single arm|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
10190358|NCT04397354|Active Comparator|Group 1|intracochlear dexamethasone application during cochlear implantation
10190359|NCT04397354|Active Comparator|Group 2|intratympanic dexamethasone application during cochlear implantation
10190360|NCT04397354|Sham Comparator|Group 3|No drugs during cochlear implantation
10190361|NCT04395586||Culture-proven infected patients|
10190362|NCT04394481|Experimental|DMD|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection Dexmedetomidine: IV injection (1µg/kg)
10190363|NCT04394481|Active Comparator|Control|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection
10190364|NCT04383431|Experimental|Standard CXL|Standard epithelium-off CXL, 30 minutes soaking time with riboflavin, 30 minutes UVA corneal irradiation continuous mode.
10190365|NCT04383431|Experimental|Accelerated CXL|Accelerated epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation continuous mode.
10190366|NCT04370847||Lung Ultrasound (LUS) Examination|Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients
10190367|NCT04367246||Affected Patients|Eligible subjects have a confirmed germline TP53 mutation or variant, OR have a family history of LFS and clinically managed as a LFS patient, OR meet LFS diagnostic criteria including Classic, Chompret, and LFL (Birch and Eeles) criteria. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a blood sample for plasma and a stool sample every six months, as well as access to their residual clinical tissues.
9778777|NCT01115803|Experimental|Arm B: LY2584702 + Everolimus|Participants received 50 mg LY2584702 QD + 10 mg Everolimus QD, 100 mg LY2584702 QD + 10 mg Everolimus QD and 50 mg LY2584702 BID + 10 mg Everolimus QD.
9778778|NCT01115855|Experimental|Eplerenone arm|Add on standard heart failure therapy
9778779|NCT01115855|Placebo Comparator|Placebo arm|Add on standard heart failure therapy
9778780|NCT01115933|Experimental|XIENCE PRIME SV EECSS|XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
9778781|NCT01115998|Experimental|Power wheelchair|
9778782|NCT01115998|Other|Control group|
9778783|NCT01116024|Experimental|3f Enable Aortic Bioprosthesis Model 6000|Single arm study
9778784|NCT01116037|Other|ATS 3f Aortic Bioprosthesis|ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
9778785|NCT01116102|Experimental|24 ga catheter, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
9778786|NCT01116102|Experimental|24 ga catheter, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
9778787|NCT01116102|Experimental|24 ga catheter, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
9702640|NCT04720313|Experimental|CART BCMA|The dose escalation phase (Part A) will include the following doses of CAR-positive (CAR+) T cells: 150×10^6, 450×10^6, 800×10^6 or 1200 ×10^6 The expansion phase (Part B) will include a dose between 450×10^6 to 800×10^6 CAR-positive (CAR+) T cells
9702641|NCT04720248||Metamizol postoperatively|Patients submitted to scheduled craniotomy receiving metamizol as analgesic medication postoperatively
9702642|NCT04720248||Paracetamol or other analgesics postoperatively|Patients submitted to scheduled craniotomy receiving paracetamol or other drugs as analgesic medication postoperatively
10190368|NCT04367246||Family Members|Biological relative of subjects with germline TP53 mutation or variant (LFS), including first degree (siblings, parents) and second degree (grandparents, aunts, uncles) relatives. Negative for germline TP53 mutation or variant. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a stool sample, as well as access to their residual clinical tissues.
10190369|NCT04367246||Household Members|Household member of subjects with germline TP53 mutation or variant (LFS), sharing a living space (apartment or free-standing home) for at least 6 months prior to study enrollment. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time stool sample.
9702643|NCT04720144||bIMI cases|"Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for:~i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD).~AND~iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days."
9702644|NCT04720144||Controls|"For each bIMI case, we will include 2 control cases fulfilling the following criteria:~i) Receiving continuous posaconazole prophylaxis for at least 7 days~ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay"
9702645|NCT04720183|Experimental|Sulfasalazine + GLPG3970|
10190370|NCT04360369|Active Comparator|Goldmann Applanation Tonometer|Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.
9702646|NCT04720131|Experimental|Camrelizumab combined with Apatinib and Capecitabine|Camrelizumab was administered 200mg iv every 3 weeks. Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle) Apatinib:A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle). The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group. The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
9702647|NCT04720300|Active Comparator|MaaS app|The Mobility-as-a-Service (MaaS) App will be provided to students in the Intervention Group and is intended to facilitate their use of alternative transportation modes such as public transit, ride-hailing, walking, biking, bike share, and e-scooter share to get to campus. The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app. This means, for instance, that a student can plan a trip that includes driving to a train station, taking the train, and then walking from the alighting train station to their final destination. The app will be white label, i.e. it will have a customized look and feel specific to the participating south Florida colleges, and it will have personalization features so that students can tailor the app to their travel patterns. Students in a cluster assigned to the MaaS group will also receive information concerning housing options. Students complete surveys
9702648|NCT04720300|Placebo Comparator|No app|Students receive no app, no housing information, students complete surveys.
9702649|NCT04720170|Other|Single Arm|This is a 26 week, single arm, single-site, Investigator-initiated, exploratory trial evaluating the efficacy of the standard of care revascularization of the lower extremity with the addition of revascularization of the lateral plantar artery and anterior pedal loop of the foot as treatment for participants with PAD, diabetic neuropathy and have a clinical diagnosis of type 1 or type 2 diabetes whose main symptoms are numbness and/or tingling of the feet with or without pain.
9702650|NCT04720014|Experimental|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training.
9702651|NCT04720027||Closurefast|Patients who were randomised to and underwent radiofrequency ablation using the Closurefast device in the original 3RF Study
9702652|NCT04720027||Radiofrequency Induced Thermal Therapy (RFITT)|Patients who were randomised to and underwent radiofrequency ablation using the RFITT device in the original 3RF Study
10190371|NCT04360369|Active Comparator|ORA G3 and ic100|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.
9702653|NCT04720027||EndoVenous Radiofrequency (EVRF)|Patients who were randomised to and underwent radiofrequency ablation using the EVRF device in the original 3RF Study
9702654|NCT04719871||with posterior vitreous detachment|patient with stage 3 or more of posterior vitreous detachment on optical coherence tomography
9702655|NCT04719871||without posterior vitreous detachment|patient with stage 2 or less of posterior vitreous detachment on optical coherence tomography
10190372|NCT04360369|Experimental|Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.
9702656|NCT04719962|Experimental|Disseminated Lyme infection|Only patients presenting with disseminated Lyme borreliosis will be part of the study.
9702657|NCT04720105|Experimental|Participants with plaque type psoriasis|Participants with plaque type psoriasis to be treated with Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion) to be applied thinly once a day on the affected areas of hands and/or feet.
10190373|NCT04358458|Experimental|Monotherapy Arm|
10190374|NCT04358458|Experimental|Combination Arm|
10190375|NCT04356430|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before robotic assisted radical prostatectomy
10190376|NCT04356430|Experimental|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robotic assisted radical prostatectomy. Goserelin 10.8 mg will be administered once per 12 weeks.
10190377|NCT04354233|Experimental|Physical activity intervention with connected devices|Women randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
9702658|NCT04720469|Experimental|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy
9702659|NCT04719923||Subjects with autism spectrum disorders|Children affected by autism spectrum disorders
9702660|NCT04719923||Healthy controls|Healthy children
9702661|NCT04720482||Comatose survivors of cardiac arrest|Adult (>18 years) patients remaining comatose during intensive care 48 hours after cardiac arrest. All patients are submitted to both clinical routine measurements: pupillometry and somatosensory evoked potentials.
9702662|NCT04720092|Experimental|Treatment A-B|Subjects received a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
9702663|NCT04720092|Experimental|Treatment B-A|Subjects received a single oral dose of 10 mg rivaroxaban oral suspension in the fasted state on Day 1 (Treatment B) during intervention period 1; and then a single oral dose of 10 mg rivaroxaban tablet in the fasted state on Day 1 (Treatment A) during intervention period 2. A wash-out of at least 7 days was maintained between the treatments.
9702664|NCT04720040|Experimental|YMS-201B|transcranial Direct Current Stimulation (tDCS) application 5 ~7 days a week for 6 weeks (total of 30~42 applications)
9702665|NCT04719975|Experimental|Mental Fatigue (Stroop) - Chair task|Participants will be performing the Chair Task (150 submaximal dynamic knee extensions at 50% of their maximal voluntary contraction (MVC)) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
9702666|NCT04719975|Placebo Comparator|Control Task (Documentary) - Chair Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Chair Task, During the whole trial EEG will be measured.
9702667|NCT04719975|Experimental|Mental Fatigue (Stroop) - Bike Task|Participants will be performing the Bike Task (a 9 min cycling task performed at 45 rpm with intensity being constant and will be 10% below VT) when mentally fatigued. A 60 minute variant of the Stroop task will be used to induce the mental fatigue. During the whole trial EEG will be measured.
9702668|NCT04719975|Placebo Comparator|Control task (Documentary) - Bike Task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content. This will be followed by the Bike Task, During the whole trial EEG will be measured.
9702669|NCT04719819||Usual pratice|Assessment of usual practices
10190378|NCT04354233|No Intervention|Standard care|Women will receive stardard care and physical activity international recommendations, without further intervention
10190379|NCT04353271|Experimental|Hydroxychloroquine|Subjects in this arm will receive the study drug
10190380|NCT04353271|Placebo Comparator|Placebo|Subjects in this arm will take placebo for 6 days
10190381|NCT05310396|Experimental|Powdered cow's milk-based infant formula containing uniquely processed whey protein|Starter and follow up formula containing combination of an HMO blend, myelin nutrient blend, and MOS
10190382|NCT05310396|Active Comparator|Powdered infant fortified cow's milk|Standard Starter and follow up formula without added HMOs or MOS containing lower levels of myelin nutrients
10190383|NCT05310383|Experimental|Patients with recurrent cervical cancer|Patients with recurrent, metastatic and persistent advanced cervical cancer
10190384|NCT05310344|Experimental|Patients with platinum-resistant recurrent epithelial ovarian cancer|
10190385|NCT05310331|Experimental|Patients with recurrent cervical cancer|Eligible patients according to inclusion and exclusion criteria.
10190386|NCT05310292|Experimental|Subjects diagnosed with IKH|10 patients, diagnosed with IKH
10190387|NCT05310292|Experimental|Healthy control subjects|10 subjects, healthy, matched for gender, BMI, age
9702670|NCT04719546||NEC Group|All Premature Neonates born in Nancy and Lyon over 10 years and presenting with Necrotizing Enterocolitis
9702671|NCT04719546||Control Group|All Premature Neonates born in Nancy and Lyon over 10 years without Necrotizing Enterocolitis throughout the neonatal period
9702672|NCT04719949|Experimental|Behavioral Activation (BA) Therapy|Participants complete four sessions of BA, 60-90 minutes per session.
9702673|NCT04719949|Active Comparator|Problem Solving Therapy (PST)|Participants complete four sessions of PST, 60-90 minutes per session.
9702674|NCT04719650|Experimental|zoledronic acid 1mg|Add 20 mL of Zoledronic acid injection (100mL : 5mg) with 80 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
9702675|NCT04719650|Experimental|zoledronic acid 2.5mg|Add 50 mL of Zoledronic acid injection (100mL : 5mg) with 50 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.
10190388|NCT05310279|Experimental|Active video gaming|Participants will engage in 6 weeks of active video gaming (AVG), 2x/week
10190389|NCT05310266|Active Comparator|Group TAP|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
10190390|NCT05310266|Active Comparator|Group QLB|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
10190391|NCT05310240||Hip arthroscopy|Patients that underwent hip arthroscopy at this department between 2013 and 2021.
10190392|NCT05310214|Experimental|Acupuncture treatment (ACP)|The experimental group will be treated with acupuncture
10190393|NCT05310214|Active Comparator|Laser acupuncture treatment (LACP)|The active comparator group will be treated with laser acupuncture
10190394|NCT05310162|Experimental|Food, fun and family|This intervention aims to change eating and screen time habits in children to decrease the amount of added sugar consumed and the time spent using recreational screens, this with guides and precise instructions given to the parents to have a healthier lifestyle.
10190395|NCT05310162|Active Comparator|Counseling|The parents will receive simple verbal instructions to reduce the consumption of added sugar and recreational screen time, giving advice on which foods to avoid and the amount of time permitted for the use of screens.
10190396|NCT05310149|Experimental|obturator group(unilalateral maxillary defect)|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
10190397|NCT05310149|No Intervention|Control group|intact side of the same patient
10190398|NCT05310136|Experimental|Nurse-guided BBTi intervention group|Participants will experience 4-week treatment period (2 in person and 2 via telephone).
9702676|NCT04719650|Experimental|zoledronic acid 5mg|Infusion 100 mL of Zoledronic acid injection (100mL : 5mg) with constant speed in 20 minutes. Administration only once.
10190399|NCT05310136|No Intervention|Control group|Participants will received sleep hygiene at the enrollment of the study and be required to maintain their usual lifestyle and medical treatment for 4 weeks.
10190400|NCT05310110|Experimental|10% lidocaine spray and cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
9702677|NCT04719650|Placebo Comparator|placebo|Infusion 100 mL of normal saline with constant speed in 20 minutes. Administration only once.
9702678|NCT04719507|Experimental|erector spinae arm|ultrasound guided erector spinae block
10190401|NCT05310110|Experimental|10% lidocaine spray and placebo of cisatracurium group|The subjects received laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1.25 mg/kg.
10190402|NCT05310110|Experimental|Placebo of lidocaine spray and cisatracurium group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous cisatracurium 0.12 mg/kg, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 1 mg/kg.
10190403|NCT05310110|Placebo Comparator|Placebo group|The subjects received normal saline spray as a substitute for laryngeal local anesthetics (10% lidocaine spray), intravenous normal saline as a substitute for cisatracurium, and propofol before laryngeal mask airway placement. The predetermined dosage of propofol for the first subject is 2 mg/kg.
10190404|NCT05310097|Experimental|Cognitive Processing Therapy + Memory Support (CPT + MS)|CPT + MS will involve the same treatment strategies as CPT while incorporating deliberate and frequent use of memory and learning support strategies. MS strategies are designed to enhance the memory of specific treatment points, defined as any insight, skill or strategy determined to be important for the patient to remember and/or implement. MS is not designed to enhance memory functioning generally, but rather improve the encoding, consolidation and retrieval of specific components of therapeutic learning.
10190405|NCT05310097|Active Comparator|Cognitive Processing Therapy (CPT)|CPT is a manualized, trauma-focused therapy for PTSD. Treatment consists of psychoeducation on the cognitive model of PTSD, identification of trauma-related stuck points (i.e. dysfunctional beliefs), and cognitive challenging techniques to help participants identify more realistic and adaptive ways of viewing their trauma, themselves, and the world.
10190406|NCT05310084|Experimental|Coadministration Group|BNT162b2 and SIIV followed by placebo a month later
10190407|NCT05310084|Experimental|Separate Administration Group|Placebo and SIIV followed by BNT162b2 a month later
10190408|NCT05310071|Experimental|Aducanumab|Participants will receive aducanumab, up to 10 milligrams per kilograms (mg/kg), monthly (once every four weeks), administered as intravenous (IV) infusion.
10190409|NCT05310071|Placebo Comparator|Placebo|Participants will receive placebo, monthly (once every four weeks), administered as IV infusion.
10190410|NCT05310058|Active Comparator|12.5 g/d of C6 ketone di-ester|Low dose of ketone di-ester.
10190411|NCT05310058|Active Comparator|25 g/d of C6 ketone di-ester|Middle dose of ketone di-ester.
10190412|NCT05310058|Active Comparator|50 g/d of C6 ketone di-ester|Highest dose of ketone di-ester.
10190413|NCT05310032|Experimental|HSG4112 800 mg Single Dose|Single oral dosing of HSG4112 800 mg
10190414|NCT05310032|Experimental|HSG4112 1200 mg Single Dose|Single oral dosing of HSG4112 1200 mg with a high-fat meal or fasting condition, with a washout period of 21 days in between each dosing
10190415|NCT05310032|Experimental|HSG4112 800 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
10190416|NCT05310032|Placebo Comparator|Placebo 800 mg Multiple Dose|Multiple oral dosing of placebo 800 mg for 14 days
10190417|NCT05310032|Experimental|HSG4112 1200 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
9702679|NCT04719507|Experimental|thoracic paravertebral arm|ultrasound guided thoracic paravertebral block.
9702680|NCT04719507|Active Comparator|drug arm|pethidine (1 mg/kg ) once
9702681|NCT04719637|Experimental|PRDS-001|Renal denervation
10190418|NCT05310032|Placebo Comparator|Placebo 1200mg Multiple Dose|Multiple oral dosing of placebo 1200 mg for 14 days
10190419|NCT05310006|Experimental|High Speed Resistance Exercise (HSRE)|Exercise sessions performed using eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s.
10190420|NCT05310006|Experimental|Traditional Resistance Exercise (TRE)|Exercise sessions were performed using four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s.
10190421|NCT05310006|No Intervention|Control Session (CS)|Participants remained seated in a comfortable chair listening to music and/or talking with study investigators for approximately 30 min.
9702682|NCT04719559|Other|Post-Thyroidectomy Hypertrophic Scar|Patients had all presented a persistent hypertrophic scar at the neck region for more than 1 year after their thyroidectomy.
10190422|NCT05309980||Without Shock Team|Before January 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device without involvment of a dedicated shock team
10190423|NCT05309980||With Shock Team|After April 2013, patients with refractory cardiogenic shock were implanted with short term mechanical circulatory device following a collegial meeting of a shock team (cardiac surgeon, cardiologist, intensivist) using a common algorythm.
10190424|NCT05309967|Placebo Comparator|LASER|Diode laser (Gallium and Aluminum Arsenide) (ArGaAl) acting on the infrared with a wavelength of 808 nm.
10190425|NCT05309967|Experimental|GLUMA|Glutaraldehyde + Hydroxyethyl methacrylate (GLUMA® Desensitizer)
10190426|NCT05309967|Placebo Comparator|PLACEBO|DISTILLED WATER
10190427|NCT05309967|Active Comparator|GLUMA AND LASER|LASER AND GLUMA® Desensitizer
10190428|NCT05309941|Experimental|Internal Cues Messaging|Participants will view a five-minute video focusing on intuitive eating principles.
9702683|NCT04719884|No Intervention|Control group|Standard perioperative anesthesia management
9785042|NCT01241448|Placebo Comparator|Placebo|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
10190429|NCT05309941|Active Comparator|External Cues Messaging|Participants will view a five-minute video focusing on traditional nutrition education principles.
10190430|NCT05309928|Experimental|Amox 1 GM|Amoxicillin 1000 mg PO
10190431|NCT05309928|Experimental|Amox 1GM + Probenecid|Amoxicillin 1000 mg PO + Probenecid 1000 mg PO
10190432|NCT05309928|Experimental|Amox 3 GM|Amoxicillin 3000 mg PO
10190433|NCT05309928|Experimental|Amox 3 GM + Probenecid|Amoxicillin 3000 mg PO + Probenecid 1000 mg PO
10190434|NCT05309915|Other|Cohort 1|Dose 3mg of STP707 (8 subjects) + placebo (2 subjects) randomized
10190435|NCT05309915|Other|Cohort 2|Dose 6mg of STP707 (8 subjects) + placebo (2 subjects) randomized
10190436|NCT05309915|Other|Cohort 3|Dose 12mg of STP707 (8 subjects) + placebo (2 subjects) randomized
10190437|NCT05309915|Other|Cohort 4|Dose 24mg of STP707 (8 subjects) + placebo (2 subjects) randomized
10190438|NCT05309889||high exposure level|Patients have a high level of exposure factors
10190439|NCT05309889||low exposure level|Patients have a low level of exposure factors
10190440|NCT05309876|Experimental|Usage of tool|Participants get access to the tool and use it regularly
10190441|NCT05309876|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease is followed via clinical registries.
10190442|NCT05309863||Residential treatment|Patients administered for residential treatment of severe obesity will be included. Patients are treated according to standard of care in a multimodal program, focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support. Residential treatment is possible for a duration of maximum 1 year.
10190443|NCT05309863||Ambulatory treatment|Patients in specific pediatric obesity care pathways will be included. Patients are treated according to standard of care in a multimodal ambulatory program focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
10190444|NCT05309837|Active Comparator|Polydextrose (PDX)|Subject consumed a daily dose of 18g polydextrose enriched drink mixtures and biscuits (12 g from the drink mixtures and 6 g from the biscuits) providing 16.2 g dietary fibre/d.
10190445|NCT05309837|Placebo Comparator|Control (CON)|Subjects consumed placebo products, where maltodextrin replaced PDX and differed only in the amount of fibre per gram (1.7 g).
10190446|NCT05309824||Atrial fibrillation|
10190447|NCT05309824||Left ventricular hypertrophy|
10190448|NCT05309824||Pulmonary hypertension|
10190449|NCT05309824||Coronary atherosclerotic heart disease|
10190450|NCT05309824||Heart failure with retained ejection fraction|
10190451|NCT05309811|Experimental|Group A|RLRL therapy with routine IOP-lowering medications in the 1st-12th weeks then crossing to only routine IOP-lowering medications in the 13th-24th weeks
10190452|NCT05309811|Experimental|Group B|Only routine IOP-lowering medications in the 1st-12th weeks then crossing to RLRL therapy with routine IOP-lowering medications in the 13th-24th weeks
10190453|NCT05309798|Experimental|Evening Fasting|Participants will undertake acute evening fasting (feeding between 8am-4pm)
10190454|NCT05309798|Experimental|Control|Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm).
10190455|NCT05309798|Experimental|Morning Fasting|Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm).
10190456|NCT05309772|Experimental|Biomarker arm|"All participants will have blood taken to test for BAT/MAT. Participants with a positive BAT/MAT will dispense from oral food challenge (OFC).~Participants with negative or inconclusive BAT/MAT will undergo OFC."
10190457|NCT05309772|Active Comparator|Standard-of-care arm|All participants in the standard-of-care arm will have blood taken to test for BAT/MAT. Regardless of the result of BAT/MAT, all participants in this arm will undergo an oral food challenge, as per the current standard-of-care.
10190458|NCT05309746||Ovarian Tissue Cryopreservation|Children faced with a fertility threatening diagnosis will be offered ovarian tissue cryopreservation. Pre-surgery assessment will be done while the child is in the hospital or in the pediatric oncology, surgery, or anesthesia clinic as an outpatient. The surgical procedure used to remove the child's ovary is called laparoscopy. It is not required for the treatment of the child's cancer or other medical condition. Laparoscopic surgery is done under general anesthesia (the child will be asleep during the surgery) in the operating room.
10190459|NCT05309707||Patients with aortic arch pathologies treated by branch stent graft systems|Patients with aortic arch pathologies treated by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
9702684|NCT04719884|Active Comparator|Study group|Perioperative extended haemodynamic monitoring of fluid loading, cardiac output and changes of peripheral vascular resistance by analysing the arterial curve was provided by non-invasive haemodynamic monitoring (LIDCO Rapid, Lidco Ltd., United Kingdom).In SG fluid optimisation was performed before pneumoperitoneum and after abdominal desuflation with actions to achieved CI, MAP and SI within 80% of baseline values.
9702685|NCT04719624|Experimental|Adaptos-Si [0.5-1 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [0.5-1 mm] (synthetic bone graft material) in combination with a gelatin sponge.
9702686|NCT04719624|Experimental|Adaptos-Si [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos-Si [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
9702687|NCT04719624|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft) in combination with a gelatin sponge.
9702688|NCT04719624|Placebo Comparator|Empty extraction socket|Post-extraction the socket filled only by clot.
9702689|NCT04719624|Experimental|Adaptos [1-2 mm]|Bone augmentation, after tooth extraction, with Adaptos [1-2 mm] (synthetic bone graft material) in combination with a gelatin sponge.
9702690|NCT04719598|Experimental|intervention group is ( internet - based group) who will receive CBT sessions|study group ( group A)
9702691|NCT04719598|No Intervention|control group ( group B)|researchers just answer their questions
9702692|NCT04719715||Cases with ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
9702693|NCT04719715||Controls with autoimmune diseases other than ANCA vasculitis|Indirect immunofluorescence (IIF) will be performed as well as myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays and evaluated
9702694|NCT04719754||Pregnant women with abnormal vaginal discharge|
9702695|NCT04719754||Pregnant women without abnormal vaginal discharge|
9702696|NCT04719780|Active Comparator|Waitlist Control Group (CBT)|Individuals in this arm (n=44) are provided with a transdiagnostic cognitive-behavioural treatment for depression and anxiety (MoodGym) that has been empirically validated after their 15-week wait period is complete.
9702697|NCT04719780|Experimental|EFIT Group|Individuals in the EFIT Group (n=44) will receive 12-15 sessions of EFIT in order to treat their symptoms of depression and anxiety.
9702698|NCT04719793|Experimental|Wharton's Jelly|Intraarticular injection of Umbilical Cord-derived Wharton's Jelly
9702699|NCT04719728||pre lingual|aided response, speech perception threshold impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
9702700|NCT04719728||post lingual|aided response, speech perception threshold speech in noise impedance telemetry electrically evoked action potential p1n1 cortical evoked potential
9702701|NCT04719845|Experimental|Endoscopic laser resection|Using CO2, diode or similar wavelenght laser the stenotic tracheal segment will be vaporized allowing a less than 20% residual stenosis. Dilatation will not be performed after laser resection for residual stenosis.
9702702|NCT04719845|Experimental|Dilatation|Using a ballon or rigid bronchoscope the stenotic tracheal segment will be dilated with or without previous radial incision with electrocautery or laser.
9702703|NCT04719767|Experimental|visual|In the visual group, a visual laryngeal mask was placed and endotracheal intubation was guided under visual conditions. The endotracheal tube was removed 10 minutes before the end of the operation, and the laryngeal mask was retained.
9702704|NCT04719767|No Intervention|Non-visual|In the non-visual group, laryngeal mask airway was inserted. After clinical judgment of good counterpoint, endotracheal intubation was inserted blindly through LMA. Endotracheal intubation was removed 10 minutes before the end of the operation, and the laryngeal mask airway was retained.
9702705|NCT04719585|Experimental|Experimental: Duloxetine group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
9702706|NCT04719585|Active Comparator|Active comparator: Opioid group|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
9702707|NCT04719572|Other|Basic treatment group|elemental calcium 600mg/ day + vitamin D 1000IU/day
9702708|NCT04719572|Active Comparator|Basic treatment+ anti-osteoporosis drug group|alendronate(70mg/week), zoledronate(5mg 1/ year), tripopeptide(20ug 1/day), denosumab(120mg/month), activated vitamin D(0.25ug 1/day), menatetrenone(15mg tid) according to the patient's condition
9702709|NCT04719572|Other|Basic treatment + non-drug treatment group|diet, exercise, rehabilitation therapy
9702710|NCT04719689|Experimental|Dry needling|Dry needling, hot pack, stretching exercises.
9702711|NCT04719689|Experimental|Dry Cupping|Dry cupping, hot pack, stretching exercises.
9702712|NCT04719416|Active Comparator|Active Treatment with Relaxation|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
9702713|NCT04719416|Active Comparator|Remission with Relaxation|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will be completing the pre-recorded relaxation audio therapy twice weekly prior to falling asleep.
10190460|NCT05309694|Other|Group 1|Paragard® T380A Intrauterine Copper Contraceptive with new inserter Non parous and parous female subjects of child bearing potential
9702714|NCT04719416|No Intervention|Active Treatment without|This subgroup comprises of patients who are currently receiving active treatment for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
9702715|NCT04719416|No Intervention|Remission without|This subgroup comprises of patients who are currently in remission for their cancer diagnosis. They will not be asked to complete any additional relaxation therapy.
9702716|NCT04719442|Experimental|BHF-LC|To test an innovative implementation strategy, four communities will be assigned to pilot test the packaged PWMI and training materials when coupled with a learning collaborative facilitation strategy and sustainability action planning process to support PWMI adoption, implementation, and sustainability (BHF-LC).
9702717|NCT04719442|Active Comparator|BHF-Program Only|Four other communities will be assigned to receive the packaged PWMI and training program only.
9702718|NCT04719429|Experimental|Cricket-derived protein beverage|Ingestion of a cricket-derived protein beverage
9702719|NCT04719429|Experimental|Beef-derived protein beverage|Ingestion of a beef-derived protein beverage
9702720|NCT04719481|Experimental|pravastatin 80mg/d|Oral administration of pravastatin at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
9702721|NCT04719481|Placebo Comparator|placebo|Oral administration of placebo at 1 h before zoledronic acid infusion, 24 h and 48 h after zoledronic acid infusion
9702722|NCT04719494|Experimental|Training Group|During the 12-training day sessions, subjects will walk on the treadmill for a total of 30 minutes. Participants will walk at a comfortable pace while we perform controlled movements to the treadmill system. Subjects will be fitted with a fall-arrest harness and assisted onto the treadmill system. In the dynamic balance training group, we will move the motion base as participants walk in order to challenge their balance.
9702723|NCT04719494|No Intervention|Control Group|Subjects who are in the control group will also walk on the treadmill, but the motion base will remain stationary. They will complete 12-training day sessions.
9702724|NCT04719364||Focus Groups|10 black, 10 Latinx, and 10 white MSM will be recuited in this focus group 'cohort'
9702725|NCT04719364||Quantitative Survey Group|Cross-sectional group of 100 black, 100 Latinx, and 100 white MSM
9702726|NCT04719468|Experimental|Intervention|
9702727|NCT04719468|No Intervention|Usual Treatment|usual treatment with the addition of joining 'Tea and Biscuit' sessions remotely
9702728|NCT04719455|Experimental|Intervention treatment experienced patients|AIMS
9702729|NCT04719455|Experimental|Intervention starting patients|AIMS
9702730|NCT04719455|Other|Control group treatment experienced patients|Regular care
9702731|NCT04719455|Other|Control group starting patients|Regular care
9702732|NCT04719676|Experimental|Core strength training using unstable surface|The experimental group will use Core strength training using unstable surface
9702733|NCT04719676|Active Comparator|The stable surface would be gym floor.|The control group will use stable surface.
9702734|NCT04719104|Experimental|Participating group of neonates|Participating group: Neonates that have had both a serum bilirubin measurement and transcutaneous measurement post phototherapy. This is a single arm study as we are only targeting one group of individuals with the intervention (transcutaneous bilirubin measurement). However, we will compare the serum bilirubin measurement to the transcutaneous measurement from the same neonate to determine if there is a clinically significant difference between the two measurements.
9702735|NCT04719091|Experimental|HA formulation Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of Experimental mouth spray. They will then be given their assigned product to use twice daily for one week
9702736|NCT04719091|Placebo Comparator|Placebo Oral Spray|The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of placebo mouth spray. They will then be given their assigned product to use twice daily for one week
9702737|NCT04719169|Experimental|Post-low pelvic colorectal anastomosis|Single armed study
9702738|NCT04719325|Experimental|Herbert screw|
9702739|NCT04719325|Active Comparator|Lag screw|
9702740|NCT04719351|Experimental|Condition 1: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9702741|NCT04719351|Experimental|Condition 2: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9702742|NCT04719351|Experimental|Condition 3: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9702743|NCT04719351|Experimental|Condition 4: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9785043|NCT01241448|Experimental|2.5 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
9702744|NCT04719351|Experimental|Condition 5: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9702745|NCT04719351|Experimental|Condition 6: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9978063|NCT01367951|No Intervention|non-operative|"Mechanical ventilation: Patients in respiratory distress will receive endotracheal intubation, and placed on mechanical ventilation. PEEP will be utilized as needed, at the discretion of the ICU and respiratory therapy team.~Other conservative means/Pulmonary toilet:Patients will receive aggressive pulmonary toilet (suctioning of ET tube as needed), chest physiotherapy (as per standard local protocol), and will have the head of the bed elevated to 30° unless contraindicated (ie unstable C-spine injury).~Pain control:Epidural catheters, intercostal nerve block, PCA, IV/PO pain medication"
9978064|NCT01367964|Experimental|ACTH treatment|Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.
9702746|NCT04719351|Experimental|Condition 7: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9702747|NCT04719351|Experimental|Condition 8: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: not included;"
9702748|NCT04719351|Experimental|Condition 9: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
10190461|NCT05309681||Study group|Female patients of the Department of Oral medicine diagnosed with burning mouth syndrome
10190462|NCT05309681||Control group|Age-matched female patients without oral lesions and without burning mouth syndrome
9702749|NCT04719351|Experimental|Condition 10: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
9702750|NCT04719351|Experimental|Condition 11: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
9702751|NCT04719351|Experimental|Condition 12: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: not included;"
9702752|NCT04719351|Experimental|Condition 13: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
9702753|NCT04719351|Experimental|Condition 14: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
9702754|NCT04719351|Experimental|Condition 15: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
9702755|NCT04719351|Experimental|Condition 16: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: no;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: not included;"
9702756|NCT04719351|Experimental|Condition 17: Positive: no; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
9702757|NCT04719351|Experimental|Condition 18: Positive: yes; Workload: no; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
9702758|NCT04719351|Experimental|Condition 19: Positive: no; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
9702759|NCT04719351|Experimental|Condition 20: Positive: yes; Workload: yes; Controllability: no; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: not included;~Behavioral prompts: included;"
9978065|NCT01367977||Ehlers-Danlos patients|Patients with diagnosed or suspected Classic or Hypermobile Ehlers-Danlos Syndrome
10190463|NCT05309668|Experimental|Selumetinib single arm|This study consists of a screening period (up to 28 days), a treatment period (25 cycles) and a long term safety follow-up for participants until they are 5 years old or commence an alternative systemic NF1-PN treatment, whichever is the earlier. Participants may continue treatment with selumetinib throughout the long term safety follow-up as long as they are considered to be receiving clinical benefit in the opinion of their Investigator. A safety follow up assessment will be performed 30 days after the last dose of study intervention for all study participants.
9702760|NCT04719351|Experimental|Condition 21: Positive: no; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
9702761|NCT04719351|Experimental|Condition 22: Positive: yes; Workload: no; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
10190464|NCT05309642|Active Comparator|ICR Arm|On 2 non-consecutive days per week, participants in the ICR (5:2 diet) group will be instructed to consume 500 kcal/day for women and 600 kcal/day for men.
10190465|NCT05309642|Placebo Comparator|Soc Arm|The SoC group will receive 80% of standard calorie (1,200-1,500 kcal/day or reducing 500-1000 kcal/day from standard calorie).
10190466|NCT05309629|Experimental|QL1706+chemotherapy|Participants received intravenous infusions of QL1706 5mg/kg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle for 4-6 cycles. On Days 2 and 3 of every 21-day cycle, etoposide 100 mg/m^2 was administered alone for 4-6 cycles. Thereafter, participants received maintenance QL1706 5mg/kg on Day 1 of every 21-day cycle until progressive disease, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
10190467|NCT05309616|Experimental|Talz|All participants receive Talz
10190468|NCT05309603|Active Comparator|Unloaded Walking|Walking on a treadmill without wearing a pack
10190469|NCT05309603|Experimental|Loaded Walking High|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the high-back
10190470|NCT05309603|Experimental|Loaded Walking Mid|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the mid-back
10190471|NCT05309551|Experimental|Powerbreathe Medic- Intervention group|Along with standard post-transplant physical therapy, the intervention group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with weekly incremental increases in respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
10190472|NCT05309551|Sham Comparator|Powerbreathe Medic - Placebo group|Along with standard post-transplant physical therapy, the placebo group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with no increase of respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
10190473|NCT05309551|No Intervention|Usual care group|Patients will only participate in standard post-transplant physical therapy.
10190474|NCT05309538|Active Comparator|Group A|Control group
10190475|NCT05309538|Experimental|group B|experimental group
10190476|NCT05309512|Experimental|KN052 single drug group|The 8 dose groups in the dose increasing period were intravenous administration of 0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg and 9mg/kg every two weeks, respectively. Based on the selected maximum tolerated dose of Q2W and in combination with the pharmacokinetic model, the sponsor would consider adding 1-2 Q3W treatment groups, with 6-12 patients in each dose group for DLT observation to explore the optimal dose regimen. The queue extension period is dose RP2D; Give it intravenously every two weeks or three weeks.
10190477|NCT05309499|Active Comparator|FCM group|The ferric carboxymaltose doses were determined using the patient's screening visit body weight measurement and haemoglobin value. Patients receives all doses during hospitalization accordance with the drug local labels.
10190478|NCT05309499|Active Comparator|Ferrous sulphate group|100 mg of ferrous sulphate is administrated 2 times per day during hospitalization and continue within next 2 month.
10190479|NCT05309499|No Intervention|Group with normal iron status|Patiants with normal iron status
10190480|NCT05309473|Experimental|Subjects Who Received Acoustic Stimulation|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive acoustic stimulation via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive acoustic stimulation via the Philips Smart Sleep device during slow-wave sleep again.
10190481|NCT05309473|Sham Comparator|Subjects Who Received Sham (no Acoustic Stimulation)|Following 40 hours of deprivation participants will sleep for approximately a four hour recovery sleep period and receive Sham (no acoustic stimulation) via the Philips SmartSleep during slow-wave sleep. They will then sleep for second night of four hour recovery sleep and receive Sham (no acoustic stimulation) via the Philips Smart Sleep device during slow-wave sleep again.
10190482|NCT05309460|Active Comparator|Nifedipine|Patients randomized to Nifedipine will be started on Nifedipine XR 30mg BID. Escalation in therapy to be determined by primary provider. Maximum dose of Nifedipine is 120mg daily. All patients will be monitored for signs and symptoms of hypotension or medication side effect- severe HA, orthostasis, syncope.
10190483|NCT05309460|Active Comparator|Labetalol|Patients randomized to Labetalol will be started on 200mg TID. Escalation in therapy to be determined by primary provider. Maximum dose is 2400mg in a day. All patients will be monitored for signs and symptoms of hypotension or medication side effect- orthostasis, syncope, bradycardia.
10190484|NCT05309447||Patients with sLSS|Patients with Symptomatic Lumbar Spinal Stenosis (n=10)
10190485|NCT05309447||Young Controls|Young healthy control subjects (n=10)
9785044|NCT01241448|Experimental|10 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
10190486|NCT05309447||Age-Matched Controls|Age-matched healthy control subjects (n=10)
10190487|NCT05309421|Experimental|EVX-01 in combination with pembrolizumab|EVX-01 is administered im. Pembrolizumab is administered according to label
10190488|NCT05309395|Experimental|Food Rx- meal plans and groceries|These households will receive grocery delivery weekly for 6 months
10190489|NCT05309395|Active Comparator|Wait-listed control|These households will not receive grocery delivery for the first 6 months, but will get them the second six months after recruitment.
10190490|NCT05309356|Active Comparator|Usual care (Control)|Routine COPD patient care.
9702762|NCT04719351|Experimental|Condition 23: Positive: no; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
9702763|NCT04719351|Experimental|Condition 24: Positive: yes; Workload: yes; Controllability: yes; Open: no; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: not included;~Behavioral prompts: included;"
9702764|NCT04719351|Experimental|Condition 25: Positive: no; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
9702765|NCT04719351|Experimental|Condition 26: Positive: yes; Workload: no; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
10190491|NCT05309356|Experimental|ACCEPT Decision Intervention|Clinical prediction model (ACCEPT)-based treatment recommendations: The ACCEPT tool will display the predicted risk of exacerbations, and the corresponding treatment recommendations to the physicians. These recommendations will be provided in a non-mandatory 'directive' format where the physician can override the recommendation, but is required to provide a justification (pre-set choices and a free text).
10190492|NCT05309343||Exposed group|Western medicine treatment with Chinese medicine treatmen
10190493|NCT05309343||Non-exposed group|Western medicine treatment
10190494|NCT05309330||Participants with CeD|Participants diagnosed with CeD will be observed prospectively for CeD symptom patterns over a 3-month period.
10190495|NCT05309317|Experimental|CAUTI-VSG|Preventing Catheter-Associated Urinary Tract Infections with a Virtual Simulation Game
10190496|NCT05309317|Active Comparator|Control group|"Training on CAUTI Prevention"
9702766|NCT04719351|Experimental|Condition 27: Positive: no; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
9702767|NCT04719351|Experimental|Condition 28: Positive: yes; Workload: yes; Controllability: no; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: not included;~Questions with open answers: included;~Behavioral prompts: included;"
10190497|NCT05309304|Experimental|3 g cefazolin|Healthy adult subjects weighing ≥120 kg. (g=grams)
10190498|NCT05309304|Active Comparator|2 g cefazolin|Healthy adult subjects weighing <120 kg. (g=grams)
9702768|NCT04719351|Experimental|Condition 29: Positive: no; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
9702769|NCT04719351|Experimental|Condition 30: Positive: yes; Workload: no; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: not included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
10190499|NCT05309265|Other|Breast cancer patients with work difficulties|Breast cancer patients with work difficulties can receive any of the three types of support, or a combination of these: information, occupational therapy and social support, in order to overcome barriers and return to work/continue to work
10204432|NCT02034422|Experimental|Specific Aim #1|Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
10204433|NCT02034422|Experimental|Specific Aim #2|Specific Aim 2: Determine the remediable effect of combined antioxidant treatment and exercise rehabilitation in the treatment of hypertension. Hypothesis: Acute antioxidant treatment administered prior to exercise in hypertensive patients will ameliorate the exaggerated EPR resulting in a normal and safe blood pressure response to exercise-based rehabilitation. This two-pronged approach (antioxidants and exercise training) will result in a safely achieved reduction in skeletal muscle afferent feedback facilitating improved exercise tolerance, improved muscle blood flow and ultimately reduced cardiovascular risk in this population.
10204434|NCT02001961||Heart failure|Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years.
10204435|NCT02001961||Control|Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast.
9702770|NCT04719351|Experimental|Condition 31: Positive: no; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: not included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
10190500|NCT05309226||Pregnant Cannabis User|"Pregnant individuals who disclose cannabis use in pregnancy~We will examine patterns of cannabis use including the type of cannabis used, amount and frequency of cannabis use during the perinatal and postpartum periods. If participant decides to stop using cannabis in pregnancy, they will not be excluded from the study."
10190501|NCT05309226||Pregnant Cannabis Non-User|Pregnant individuals who report not using cannabis in pregnancy and who have not used cannabis products for at least 3-months prior to pregnancy.
10190502|NCT05309226||Offspring of Pregnant Cannabis User|Infants born to pregnant participants who disclose cannabis use in pregnancy
10190503|NCT05309226||Offspring of Pregnant Cannabis Non-User|Infants born to pregnant participants who report no cannabis use in pregnancy
10190504|NCT05309226||Partners|Partners of pregnant participants enrolled in this study.
10190505|NCT05309213|Experimental|IM19 CAR-T cells|
10190506|NCT05309200|Placebo Comparator|OCE-205 Cohort 1|Placebo, intravenous infusion
9702771|NCT04719351|Experimental|Condition 32: Positive: yes; Workload: yes; Controllability: yes; Open: yes; Prompt: yes;|"Component list:~Questions about positive emotions: included;~Questions about workload/work environment: included;~Questions about controllability: included;~Questions with open answers: included;~Behavioral prompts: included;"
10190507|NCT05309200|Experimental|OCE-205 Cohort 2|OCE-205, 8 µg/hr, intravenous infusion
10190508|NCT05309200|Experimental|OCE-205 Cohort 3|OCE-205, 15 µg/hr, intravenous infusion
10190509|NCT05309200|Experimental|OCE-205 Cohort 4|OCE-205, 30 µg/hr, intravenous infusion
10190510|NCT05309200|Experimental|OCE-205 Cohort 5|OCE-205, 50 µg/hr, intravenous infusion
10190511|NCT05309187|Experimental|IO-202 Monotherapy (dose escalation)|Experimental: IO-202 dose escalation + pembrolizumab increasing dose levels of IO-202 with fixed dose of pembrolizumab
10190512|NCT05309187|Experimental|IO-202 + pembrolizumab combination therapy (dose expansion)|RP2D of IO-202 + pembrolizumab combination therapy in solid tumor cohorts.
10190513|NCT05309174|No Intervention|General anesthesia group|Patients received general anesthesia.
10190514|NCT05309174|Experimental|General anesthesia combined laryngeal nerve block|Group L received ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine, along with general anesthesia.
10190515|NCT05309161|Placebo Comparator|A group (placebo)|Placebo
10190516|NCT05309161|Active Comparator|B group (experimental)|Crassocephalum rabens extract
9702772|NCT04719312|Experimental|transconjunctival Y modification|
9702773|NCT04719234|Other|lung ultrasound|lung ultrasonography protocol will be applied.
9702774|NCT04719078|Other|All patients|There are no study arms. All patients obtain all imaging modalities.
9702775|NCT04719273|Experimental|Treatment (onapristone, anastrozole)|Patients receive onapristone PO BID and anastrozole PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
9702776|NCT04719403|Experimental|VIDEO|Participants receive access to video recordings of their clinic visits
9702777|NCT04719403|No Intervention|Usual Care|Participants receive usual care (UC), which is their normal clinic visit and written after-visit summary
9702778|NCT04719286|Experimental|Intervention group|The intervention is the use of the MinSafeStart mobile application. The app utilizes the Pregnancy-Unique-Quantification-of-Emesis-24 (PUQE-24) scale to categorize the women's NVP severity (e.g. mild, moderate, or severe) on a daily basis, and visualizes the fluctuations over time in a graph. Each woman will have their own personal graph based on the information they put in. They will also be able to see how their symptoms are compared to an average graph. The women will get treatment advice based on their PUQE-24 scale, e.g. dietary and lifestyle advice for mild symptoms and referral to see the doctor for moderate and severe symptoms.
9702779|NCT04719286|No Intervention|Control group|Standard care.
9702780|NCT04719026||Cases|Patients for the case study group will be recruited from those hospitalized for acute myocardial infarction on the Cardiology Ward and Coronary Care Unit at Aberdeen Royal Infirmary. All patients will be diagnosed using current clinical criteria for type-1 myocardial infarction according to the ESC guidelines10 and recruited within 3 days of admission. Recruitment of this arm is now complete.
9702781|NCT04719026||Controls|A control group of dental patients matched for age (±3 years), gender, and risk factors for CAD (hypertension, obesity, diabetes, smoking, hypercholesterolaemia and family history) but with no history of myocardial infarction will be selected at Aberdeen Dental School or from the SHARE register or via the NHS Research Scotland Primary Care Network on an invitation basis. Thr recruitment of this arm of the study is ongoing.
9785045|NCT01241448|Experimental|20 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
9785046|NCT01241461|Experimental|LY2584702|
9785047|NCT01241513|Experimental|N-acetyl-L-Cysteine|N-Acetyl-L-Cysteine
10190517|NCT05309148|Experimental|Training on eye tracker based device|Patients will undergo a primary diagnostics of cognitive functions (memory, thinking skills, language, visual-spatial and communicative functions) and an diagnostics of the visual attention index on an eye tracker-based device. Based on the results of the diagnosis, participants will be offered a scheme of correctional training and secondary diagnostics at the end of training. Correctional training on an eye tracker-based device consists, firstly, of a 10-minute exercise at the beginning of each lesson aimed at improving visual functions and attention. Patients had to follow a spontaneously moving object. Secondly, correctional training includes a block of neurorehabilitation (simple cognitive exercises similar to the tasks presented in the assessment).
10190518|NCT05309148|Active Comparator|Training with a neuropsychologist|Patients will undergo primary and secondary diagnostics on an eye tracker-based device, then participants will have a conventional correctional training with a neuropsychologist according to an individual correction plan.
9702782|NCT04718974|Experimental|"intervention  Call for life- mHealth tool with standard of care for PLHIV"|"The system has options to either use interactive voice response or short message service and the user has to make a choice, get a secret pin code which ensures privacy to end user.~The mHealth tool/system offers personalised pill reminder calls, health tip messages, clinic appointment reminders and remote symptom reporting"
9978066|NCT01367990|Experimental|Norepinephrine|
9702783|NCT04718974|No Intervention|"Standard of care usual care"|"Standard~• Care and support for people living with HIV, and the first line ART regimen is based on the Apr 2018, consolidated guidelines for prevention and treatment of HIV in Uganda (MoH, 2018), and will also follow the healthcare services package for PLHIV including the Adult Care and Treatment Package."
9702784|NCT04719299|Experimental|smart phone application|Behavior modification of patients will be done by showing them smartphone application game. The game demonstrates the use of common dental equipment like mirrors, ultrasonic scalers, handpieces and suction tips, etc. in the form of animated pictures with visual and sound effects. The dentist will play the game to show the child the dental procedure that will be performed on him later.
9702785|NCT04719299|Active Comparator|traditional behavior management technique|Using traditional behavior management techniques (Tell-Show-Do) which will be applied prior to local anesthesia administration
9702786|NCT04718883|Experimental|JWCAR029 treatment|JWCAR029 be administrated at dose level: 1 x 10^8 CAR+T cells
9702787|NCT04718792|Experimental|Psilocybin|10 patients will receive a single administration of psilocybin
9702788|NCT04719130|Experimental|Experimental Group|Will received multimodal circuit exercise group.
9702789|NCT04719130|Active Comparator|Control Group|Will received multidisciplinary lectures on pain and usual care provided by the Basic Health Units.
9702790|NCT04719260|Experimental|Nutrition Thinking®|Nutrition Thinking® approach to promote weight loss and healthy diet pattern.
9702791|NCT04719260|Active Comparator|Standard Nutritional Approach|The traditional nutritional prescriptive approach.
9702792|NCT04718805|Experimental|Treatment A|Participants will receive Treatment A (a single dose of darunavir [DRV]/cobicistat [COBI] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence AB or BA). A washout period of at least 7 days will be maintained between each treatment period.
9702793|NCT04718805|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of DRV/COBI as separate tablets under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence BA or AB). A washout period of at least 7 days will be maintained between each treatment period.
9702794|NCT04719039|Experimental|Yoga Group|Restorative Yoga intervention
9702795|NCT04719039|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
10190519|NCT05309148|Active Comparator|Training on eye tracker based device and with a neuropsychologist|Patients will undergo primary and secondary diagnostics and correctional training on an eye tracker-based device, in the same time participants will have a conventional correctional training with a neuropsychologist according to an individual correction plan.
10190520|NCT05309135|Active Comparator|Low dose Rho kinase inhibitor Y-27632 10 µM|Low dose Rho kinase inhibitor Y-27632 10 µM
9702796|NCT04718779|Experimental|Velaglucerase Alfa (VPRIV)|Participants will receive VPRIV 60 Units per kilogram (U/kg) intravenous infusion every other week for 60 minutes as per physician treatment plan up to 12 months.
10190521|NCT05309135|Active Comparator|Mid dose Rho kinase inhibitor Y-27632 50 µM|Mid dose Rho kinase inhibitor Y-27632 50 µM
9702797|NCT04718844|Experimental|1.0mg/kg - Thalassaemia|
9702798|NCT04718844|Experimental|3.0mg/kg - Thalassaemia|
9702799|NCT04718844|Experimental|6.0mg/kg - Thalassaemia|
9978067|NCT01368003|Experimental|STA9090 with Dutasteride|STA9090 with Dutasteride
9978068|NCT01368003|Experimental|STA9090|STA9090
9978069|NCT01368016|Experimental|Experimental NRT|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits.
9978070|NCT01368016|Active Comparator|Nicotine GUM|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits.
10190522|NCT05309135|Active Comparator|High dose Rho kinase inhibitor Y-27632 100 µM|High dose Rho kinase inhibitor Y-27632 100 µM
10190523|NCT05309109|Experimental|MCO-HD group|Hemodialysis sessions using the Theranova 500™ (Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg)
9702800|NCT04718844|Placebo Comparator|Placebo - Thalassaemia|
9702801|NCT04718844|Experimental|Xmg/kg - Thalassaemia|
9702802|NCT04718844|Experimental|1.0mg/kg - Myelodysplastic Syndrome|
9702803|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome|
9702804|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome|
9702805|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome|
9702806|NCT04718844|Experimental|3.0mg/kg - Thalassaemia multi dose|
9978071|NCT01368029|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
9978072|NCT01368029|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
9978073|NCT01368068|Experimental|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
9978074|NCT01368068|Active Comparator|Escitalopram|10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
9978075|NCT01368068|Placebo Comparator|Placebo|Placebo arm containing sweetener has been approved and will be used as placebo arm.
9978076|NCT01368094|Active Comparator|Standard drainage|
9978077|NCT01368094|Experimental|Short drainage|
9978078|NCT01368107|Placebo Comparator|Placebo Arm|the patients will receive Placebo before the 1st and during the 3rd CT cycle (N=6)
10190524|NCT05309109|Experimental|HF-HD group|Hemodialysis sessions using the Elisio 21H™ (Nipro Europe, Zaventen Belgium; surface area 2.1 m², ultrafiltration coefficient: 82 ml/h/mmHg)
10190525|NCT05309070|Active Comparator|Study group|female patients with primary burning mouth syndrome
10190526|NCT05309070|Placebo Comparator|Control group|female patients with primary burning mouth syndrome
10190527|NCT05309057||Studies with intermittent fasting|Studies with intermittent fasting strategies.
9702807|NCT04718844|Experimental|10.0mg/kg - Thalassaemia multi dose|
9702808|NCT04718844|Experimental|Xmg/kg - Thalassaemia multi dose|
9702809|NCT04718844|Experimental|3.0mg/kg - Myelodysplastic Syndrome multi dose|
9702810|NCT04718844|Experimental|10.0mg/kg - Myelodysplastic Syndrome multi dose|
9702811|NCT04718844|Experimental|Xmg/kg - Myelodysplastic Syndrome multi dose|
9702812|NCT04718844|Placebo Comparator|Placebo - Thalassaemia multi dose|
9702813|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome|
9702814|NCT04718844|Placebo Comparator|Placebo - Myelodysplastic Syndrome multi dose|
9702815|NCT04718831|Other|Baseline|Did not take nutritious food
9702816|NCT04718831|Experimental|General dose|Taking 6g spirulina
9702817|NCT04718831|Experimental|Double dose|Taking 12g spirulina
9702818|NCT04718948||Patients Positive for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention~The group of cases will consist of patients who meet the inclusion and exclusion criteria in the operative note for:~Transurethral Resection of Bladder Neoplasia (TURBT)~Radical Cystectomy for Bladder Neoplasia~Diagnostic ureterorenoscopy and / or laser treatment of ureteral and / or renal pelvis neoplasia~Segmental ureterectomy with or without ureteral reimplantation~Nephroureterectomy with or without bladder cuff excission"
9702819|NCT04718948||Patients Negative for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention~The control group will consist of patients who meet the inclusion and exclusion criteria in the operative note for:~Transurethral Resection of Prostate (TURP)~Other endoscopic treatments of Benign Prostatic Hyperplasia (BPH)~Open interventions of prostatic adenomectomy~Endoscopic lithotripsy interventions of bladder stones or cystotomy with removal of bladder stones~Rigid and / or flexible ureterorenoscopy for the treatment of kidney and / or ureteral stones~Placement of ureteral catheter for ureteral and / or renal stones~Bladder Neck Incision (TUIP)~Endoscopic urethrotomy"
9702820|NCT04718987|Experimental|Prostate Cancer Patients|Low- or favourable intermediate-risk prostate cancer patients
9702821|NCT04718740|Experimental|fluzoparib|"Experimental: group A Intervention: Drug: fluzoparib, caffeine, vitamin K, warfarin, omeprazole, and midazolam~Experimental: group B Intervention: Drug: fluzoparib, repaglinide and bupropion"
9702822|NCT04718753|Experimental|Mindful Breathing Group|Mindful breathing intervention which has been used in mindfulness-based interventions
9702823|NCT04718753|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
9702824|NCT04718701|Experimental|Experimental Group|Patients who failed first-line therapy with locally advanced or metastatic pancreatic cancer will be assigned to receive anlotinib plus toripalimab and nab-paclitaxel as second-line or maintenance treatment.
9702825|NCT04718610|Active Comparator|Control|Patients will receive only caner treatment. No osteopathic treatment.
9702826|NCT04718610|Experimental|Osteopathic intervention|Patients will receive cancer treatment associated with osteopathic intervention
9702827|NCT04718402|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with advanced gastric carcinoma will receive 20mg/m2Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
9702828|NCT04718363|Experimental|PNF stretching group|
9702829|NCT04718363|Experimental|Non-vibration foam rolling prior to PNF stretching group|
9702830|NCT04718363|Experimental|Vibration foam rolling prior to PNF stretching group|
9702831|NCT04718363|No Intervention|Control Group|
10190528|NCT05309031|Experimental|Immersion|This group will receive the immersion intervention
10190529|NCT05309018||Patients|
10190530|NCT05309018||medical staff|
9702832|NCT04718454||Equator attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,Equator Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
9702833|NCT04718454||ball attachment|Implant installation over epoxy resin model at the canine area on both sides following the surgical protocol of the implant placement,ball Attachment fabrication is firmly screwed to the fixture on both sides at the canine region
9702834|NCT04718532||patients|patients with retinal diseases
9702835|NCT04718688|Experimental|CO-OP intervention|CO-OP intervention
9978079|NCT01368107|Experimental|CYT107 treatment before CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and the placebo during the 3rd CT cycle (N=6)
9978080|NCT01368107|Experimental|CYT107 treatment during CT|patients will receive the placebo before the 1st CT cycle and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6)
9978081|NCT01368107|Experimental|CYT107 treatment before and during CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6).
9702839|NCT04718311|Active Comparator|Tacrolimus treatment|Apply a small amount (about 1 teaspoon) of medication to the lesions, twice a day after brushing the teeth, with a soft bristle toothbrush or with a finger (covered with a well-fitting glove).
9978082|NCT01368120|Experimental|IV Clear™|
9978083|NCT01368120|Active Comparator|Tegaderm CHG™|
10190531|NCT05309005||ABI group|The patient group consists of 100 patients with acquired brain injury (e.g. cerebrovascular incidents, anoxia, encephalitis and non-progressive brain tumors)
10190532|NCT05309005||Healthy control group|100 healthy adults will be matched to the patients with respect to age, gender and education.
10190533|NCT05308992|Other|Couples who use condom|The investigator will recruit heterosexual couples who have experience using silicone-lubricated latex condoms. All couples are required to have a backup birth control option and must be monogamous to participate in the study.
10190534|NCT05308979|Experimental|1 Injection Site|100u Botox® injected at one intradetrusor site
10190535|NCT05308979|Active Comparator|10 Injection Sites|100u Botox® injected at 10 intradetrusor sites
9702840|NCT04718311|Placebo Comparator|Anti-inflammatory mouthwash|Anti-inflammatory mouthwash In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
9702841|NCT04718376|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
9702842|NCT04718324|Experimental|e-PROMS|Patients allocated to the e-PROMS arm will fill an online version of PROMS and then respond to the e-PREMS questionnaire.
9702843|NCT04718324|Active Comparator|p-PROMS|Patients allocated to the p-PROMS arm will fill in PROMS in paper form (p-PROMS) and then respond to the p-PREMS questionnaire.
9702844|NCT04718493|Experimental|Stent|
9702845|NCT04718493|Active Comparator|Dilatation|
9702846|NCT04718298|Experimental|Inguinal hernia repair laparoscopic|recurrent inguinal hernia after open repair or bilateral hernia patients
9702847|NCT04718584|Experimental|Experimental Arms|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
9702848|NCT04718597||Open hernia repair|Patients who underwent inguinal hernia repair via an open Liechtenstein procedure
9702849|NCT04718597||Robotic assisted hernia repair|Patients who underwent inguinal hernia repair via robotic assisted laparoscopy
9978084|NCT01368120|Placebo Comparator|Vehicle Control Dressing|
9978085|NCT01368146|Experimental|IV Clear™|
9978086|NCT01368146|Active Comparator|Tegaderm CHG™|
9978087|NCT01368146|Placebo Comparator|Control Vehicle Dressing|
9978088|NCT01368159|Active Comparator|pressure centred at 25 mm Hg|
9978089|NCT01368159|Active Comparator|pressure between 20 and 36 mm Hg|
9978090|NCT01368159|Placebo Comparator|pressure between 10 and 15 mm Hg|
9978091|NCT01368172|Experimental|Physical Activity Guidelines|Participants randomized to this arm received training/guidance on following the physical activity guidelines for adults with spinal cord injury
9978092|NCT01368172|No Intervention|Control|
10190536|NCT05308966||Patient presenting MPS treated with nivolumab and ipilimumab|Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma (MPM) treated with combination of Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of their data
10190537|NCT05308953|Experimental|NVG-291 SAD|Doses will begin at the lowest dose level in Cohort 1, increasing in dose with each subsequent cohort to the highest dose level in Cohort 6 or until a maximum tolerated dose (MTD) is reached.
10190538|NCT05308953|Experimental|NVG-291 MAD|Participants will receive 1 dose daily for for 14 consecutive days. The maximum starting dose for MAD will be 2 dose levels lower than the maximum dose achieved during SAD. There will be a maximum of 3 dosing cohorts in Part 2. The maximum daily dose in Part 2 will not exceed the maximum daily dose tolerated in Part 1.
9702850|NCT04718649|Experimental|Celebrex + Joins|"The experimental group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and Joins (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only Joins (taken 3 times a day) at week 12. They will only take Joins for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
9702851|NCT04718649|Placebo Comparator|Celebrex + Placebo|"The control group will receive 12 weeks of Celebrex 200mg tab (taken once a day) and placebo (taken 3 times a day) at the clinical pharmacy at the first visit, and will be prescribed only placebo (taken 3 times a day) at week 12. They will only take Joins placebo for another 24 weeks until the 36th week.~The subject's oral medication is received at the clinical pharmacy twice at the time of first visit and at week 12. The follow-up period of the study will be 36 weeks."
9702852|NCT04718428||psoriatic arthritis|Patients with psoriatic arthritis who met the CASPAR criteria and were 18-70 years old were included. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, another rheumatological disease, systemic infection, and pregnancy were excluded.
9702853|NCT04718428||healthy controls|A gender- and age-matched healthy controls were included. They were recruited from the healthy relatives of the hospital staff. Participants with infection of the nails to be examined, loss of nails, trauma history of the nails, having the habit of nail biting, peripheral neuropathy, peripheral vascular disease, any rheumatological disease, systemic infection, and pregnancy were excluded.
9778788|NCT01116102|Experimental|24 ga catheter, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
9785048|NCT01241513|Placebo Comparator|Placebo|placebo
9785049|NCT01241539|Experimental|Dabigatran etexilate 110 mg|Capsule, oral
9785050|NCT01241539|Experimental|Dabigatran etexilate 75 mg|Capsule, oral
9978093|NCT01368198|Active Comparator|Ocular Emulsion|An Ocular Emulsion
9978094|NCT01368198|Active Comparator|OPTIVE™|An OPTIVE™
9978095|NCT01368224|Placebo Comparator|Maltodextrin|
9978096|NCT01368224|Experimental|Lactobacillus paracasei NCC 2461 (ST 11)|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
9978097|NCT01368224|Experimental|Lactobacillus paracasei+ Bifidobacterium longum|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
9978098|NCT01368237||Patients|Patients awaiting invasive coronary angiography
9978099|NCT01368250||1|Patients with native aortic stenosis undergoing TAVI
9978100|NCT01368250||2|Patients with native aortic regurgitation undergoing TAVI
9978101|NCT01368250||3|Patients with degenerative surgical bioprosthesis undergoing TAV-in-SAV
9978102|NCT01368289||Colonic Polyps|Patients who present with colonic polyps >20mm
10190539|NCT05308888|Experimental|Intervention|All patients will have to undergo an 18F-FDG PET-CT.
9702854|NCT04718506|Experimental|Exercise|Supervised exercise training
9702855|NCT04718506|Active Comparator|Controls|Non-supervised SEPAR exercise guidelines
9702856|NCT04718272|Experimental|Puncture tube group|After the operation, the traditional traditional silicone tube which placed through the surgical incision was removed in the operating room, and the small puncture tube was retained for thoracic drainage.
9702857|NCT04718272|No Intervention|Traditional tubes group|Routine thoracic drainage management measures were adopted, that is, both of the small puncture tube and traditional silicone tube were retained after surgery.
9702858|NCT04718714|Active Comparator|midazolam|postoperative ventilation and sedation with continuous intravenous infusion of midazolam only for 24 hours
9702859|NCT04718714|Active Comparator|propofol|postoperative ventilation and sedation with continuous intravenous infusion of propofol only for 24 hours
9702860|NCT04718714|Experimental|dexmedetomidine|postoperative ventilation and sedation with continuous intravenous infusion of dexmedetomidine only for 24 hours
9702861|NCT04718519||Migrant Workers|
10190540|NCT05308875|Experimental|PD1-BCMA-CART|Each subject will accept one of the following dosages of PD1-BCMA-CART cells intravenously (IV) on day 0: 0.5-2*10~6/KgBW.
9702862|NCT04718623||Sepsis group (SG)|with source of infection and SOFA Score more than or equal 2
9702863|NCT04718623||Non-Sepsis Group (NSG)|with SOFA score less than 2
9702864|NCT04718467|Experimental|adults group (aged 18-59 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
9702865|NCT04718467|Placebo Comparator|adults group (aged 18-59 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
9702866|NCT04718467|Experimental|elderly adults group (aged 60-85 years) & vaccine|three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.
9702867|NCT04718467|Placebo Comparator|elderly adults group (aged 60-85 years) & placebo|three doses of placebo at the schedule of day 0, 21, 42.
9702868|NCT04718480|Placebo Comparator|Placebo|2 x 100 mg placebo daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
9702869|NCT04718480|Experimental|Fluvoxamine|2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
9702870|NCT04718051|Experimental|Shen Pu Yang Gan Wan|Traditional Chinese Medicine
9702871|NCT04718051|Placebo Comparator|Placebo Comparator|Placebo Comparator
9702872|NCT04718233|Experimental|sildenafil citrate|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
10190541|NCT05308862|Experimental|Intervention|Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it.
9702873|NCT04718233|Placebo Comparator|placebo|placebo will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured initially and after 3 hours.
9702874|NCT04717921||Patients|Subjects with unipolar depression
9702875|NCT04717921||Healthy|Healthy Control Group
9702876|NCT04717869||ICU Patients|Adult Surgical, Cardiothoracic, and Neuro- ICU patients will be enrolled within 48 hrs of admission
9702877|NCT04717947||Short interval group|≤ 8weeks between the end of neoadjuvant therapy and surgery
9702878|NCT04717947||Intermediate interval group|> 8 and ≤ 12 weeks between the end of neoadjuvant therapy and surgery
9702879|NCT04717947||Long interval group|> 12 weeks between the end of neoadjuvant therapy and surgery
9702880|NCT04717882|No Intervention|Control arm|Patients in the control arm will receive the usual treatment
9702881|NCT04717882|Experimental|Intervention arm|After crossing over to the intervention period, attending physicians will receive medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
9702882|NCT04718064|Experimental|fingolimod with standard therapy|Patients will be treated with intravascular therapy and fingomod.
9702883|NCT04718064|Placebo Comparator|Placebo with standard therapy|Patients will be treated with intravascular therapy and placebo.
9702884|NCT04717999|Experimental|UWN2D CAR-T|
9702885|NCT04718090|Active Comparator|interscalene block|
9702886|NCT04718090|Active Comparator|PENG block|
9702887|NCT04718077|Experimental|IO dexamethasone injection|
10190542|NCT05308862|No Intervention|Control|Continue with usual care.
10190543|NCT05308849|Other|Pediatric Peritonitis|Patient (from 3 to 17 years-old) treated for appendicular peritonitis. It includes surgical treatment (appendicectomy, peritoneal toilet) and antibiotherapy according to French recommendation.
10190544|NCT05308836|Experimental|Adipose-derived messenchymal stem cell (AD-MSC)|Intervention: Intravenousling (IV) AD-MSC in 10 patients with type 1 diabetes mellitus.
10190545|NCT05308823|No Intervention|Group 1|The paients in this group will receive traditional treatment of IIH for 3 months.
9702888|NCT04718077|Active Comparator|SM dexamethasone injection.|
9702889|NCT04718259|Experimental|Group A|Will include patients who will receive bupivacaine intrathecal injection without adjuvant.
9702890|NCT04718259|Experimental|Group B|Will include patients who will receive bupivacaine and midazolam.
9702891|NCT04718246|Other|Dental Implants in hyperlipidemia patients|Implants will be placed at T0, then Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks then the impressions (indirect, closed tray echnique) shall be taken to fabricate the final crowns, then the final crowns will be fitted in place.
9702892|NCT04717960|Active Comparator|study group group (1)|the group which will undergo submucosal injection of platelet rich plasma
9785051|NCT01241539|Experimental|Dabigatran etexilate 150 mg|Capsule, oral
9702893|NCT04717960|No Intervention|comparative group group (2)|patients using the usual lines of medical treatment like nasal douching and lubricants
10190546|NCT05308823|Experimental|Group 2|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent.
10190547|NCT05308797|Active Comparator|Erector Spinae Plane Block|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
9702894|NCT04718129|Experimental|Mindfulness|App-based, coached Mindfulness Program. Nne weekly coached sessions with practice exercises between sessions.
9702895|NCT04718129|No Intervention|Control|Participants in this arm are randomly assigned to an assessment-only, no intervention control condition.
9702896|NCT04717908|Experimental|PZA sensitivity guided all oral regimen|"This regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide. Then based on molecular PZA drug sensitivity results, patients will be divided into three sub-groups.~The regimen for PZA-S patients, consisting of bedaquiline, linezolid, cycloserine and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week).~PZA-R sub-group regimen, consisting of bedaquiline, linezolid, cycloserine and clofazimine ,are given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) .~PZA-U sub-group continue the previous regimen, consisting of bedaquiline, linezolid, cycloserine , clofazimine and pyrazinamide ,until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week) ."
9702897|NCT04717986|Experimental|Intervention Group|Dapagliflozin 10 mg every 24 hours for 12 months
9702898|NCT04717986|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 12 months
9702899|NCT04718194|Experimental|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
9702900|NCT04718194|Placebo Comparator|Self-monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
9702901|NCT04718142|Experimental|vNEP with various shapes and sizes and overnight PSG|Administer vNEP therapy to study participants on the throat's anterior surface with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O. Assess participants for a reduction in Apnea-Hypopnea Index (AHI) for at least 120 minutes using polysomnography (PSG) and treatment tolerance compared to CPAP.
9702902|NCT04718207||Patient with Alzheimer disease|Patients recruited retrospectively with the available nuclear medicine listing of patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
9702903|NCT04717895|Experimental|1st Situation|Subjects included will be identified with an even selection number will begin the virtual reality session by viewing a rocking environment followed by a translation environment
9702904|NCT04717895|Active Comparator|2nd Situation|Subjects included will be identified with an odd selection number will start the virtual reality session by viewing a translation environment followed by a rocking environment
9978103|NCT01368302|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to normalize threat-related attention biases.
10190548|NCT05308797|Active Comparator|Combine Serratus Anterior Plane Block|Combine Serratus Anterior Plane block will be performed at the level of 5th costa with 30 mL of 0.25% bupivacaine (15 mL superficial serratus plane block and 15 mL deep serratus plane block) solution under ultrasound guidance before the operation.
10190549|NCT05308771|Experimental|Epidural anesthesia using VPC syringe|Epidural anesthesia detection using VPC syringe
10190550|NCT05308758|Experimental|GameHIIT intervention group|In the GameHIIT group, a specially designed game-based training program with HIIT in nature will be delivered to the participants for 8 weeks.
10190551|NCT05308758|Active Comparator|GameSE intervention group|In the GameSAE group, participants will attend a tailor-made game-based exercise training program. Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week.
10190552|NCT05308758|No Intervention|Control group|No intervention.
10190553|NCT05308745|Active Comparator|Probiotic group|Participants within this group consumed Yakult® as research product 1 bottle/day for 24 weeks (168 days).
10190554|NCT05308745|Placebo Comparator|Placebo group|Participants within this group consumed placebo as research product 1 bottle/day for 24 weeks (168 days).
10190555|NCT05308732|Experimental|Copaiba arm|It will consist of the group of patients who will use copaiba mouthwash. It will be subdivided into 6 consecutive cohorts.
10190556|NCT05308719|No Intervention|Standard Oxygen Therapy|Standard oxygen therapy arm patients will be given 30-40% inspired O2 and flow 2-6 l/min via nasal prongs or non-rebreathing mask (not humidified and not heated) post extubation. Monitoring of saturations, respiratory rate and arterial gases will happen 15 minutes post extubation and then as per local policy thereafter. If saturations < 93% then FiO2 will be increased as per respiratory escalation protocol. Standard oxygen therapy will be given for a minimum of 16 hours post extubation.
9702905|NCT04718220|Placebo Comparator|Unexposed (SARS-CoV-2 negative) cohort|Women who do not experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
9702906|NCT04718220|Active Comparator|Exposed (SARS-CoV-2 positive) cohort|Women who experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
10204436|NCT01988883|Placebo Comparator|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
9702907|NCT04717856|Other|drug users|
9702908|NCT04717843|Experimental|Patients with embolic strokes of undetermined source.|Patients over 18 years old, with embolic strokes of undetermined source, fulfilling the TOAST criteria. The intervention consists of a 4D Flow MRI.
9785052|NCT01241552|Experimental|MK-3415 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI
9978104|NCT01368302|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
9978105|NCT01368315|Experimental|CT327|Cream
9978106|NCT01368315|Placebo Comparator|Placebo|Cream (Vehicle only)
9702909|NCT04717843|Experimental|Patients with non-paroxysmal AF.|Patients over 18 years old, with non-paroxysmal AF. The intervention consists of a 4D Flow MRI.
9702910|NCT04717843|Active Comparator|Heathy volunteers|The control group will include volunteers over 45 years old with no history of cardio-vascular or neuro-vascular disease. The last will be certified by a pre inclusion protocol containing a medical consultation, a Holter ECG and a trans-thoracic echocardiography. The age of 45 was chosen to get comparable age group and set the analyses free of the age-related effect on the cardiac hemodynamic. The intervention consists of an ECG, holter ECG, Trans thoracic echocardiography ETT, Blood sample and 4D Flow MRI.
10190557|NCT05308719|Other|High-Flow Nasal Therapy|High-flow nasal therapy arm patients will be given AIVRO 2 high flow oxygen therapy machines post extubation, start at 30-40% inspired O2 and flow 30 l/min then up to 50 l/min over 5-10 min. Monitoring of saturations, respiratory rate and arterial gases will happen after 15 minutes post extubation and then as per local policy thereafter. If saturations < 93% then increase FiO2 as per respiratory escalation protocol. High flow nasal therapy will be given for a minimum of 16 hours post extubation.
10190558|NCT05308706|Experimental|Commercial Apollo System Device|The active experimental group received the commercial Apollo System device.
10190559|NCT05308706|Sham Comparator|Sham Apollo System Device|The control experimental group received a sham/placebo device that is identical to the commercial Apollo System device but uses an ultra-low (i.e., effectively zero) frequency pattern of vibrations.
10190560|NCT05308693|No Intervention|Control-Classical patient education|Before the operation, the stoma area is marked, the patient is educated with the classical method brochure
10190561|NCT05308693|Experimental|Experimental-Patient Compatible Stoma Educational Material|The stoma area is marked before the operation; A brochure is given to the patient. Practical training is given on the patient's own body with patient-compatible stoma training material.
10190562|NCT05308667|Experimental|iTBS + mCIMT group|
10190563|NCT05308667|Sham Comparator|Sham iTBS+ mCIMT group|
10190564|NCT05308667|Active Comparator|mCIMT group|
10190565|NCT05308654|Experimental|Dose Escalation ABBV-453|Participants with relapsed or refractory (R/R) multiple myeloma (MM) will receive escalating doses of ABBV-453, until the maximum tolerated dose (MTD) is determined.
9702911|NCT04717843|Experimental|ESUS and non-paroxysmal AF patients with cardiac MRI|ESUS and non-paroxysmal AF patients (fulfilling the group 1 et 2 criteria) and who had had cardiac MRI, in a retrospective way. It corresponds to retrospective inclusion of patients which had MRI in the year before the beginning of the study.
9702912|NCT04717830|Experimental|Gamezumab 1/10 therapeutic dose|1/10 therapeutic dose (5 volunteers)
10190566|NCT05308641|Active Comparator|PreviousSurgery(PrevSurg)_YES/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 4000 pulse, 20 Hz
10190567|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: 500 pulse, 2 Hz
9702913|NCT04717830|Experimental|Gamezumab 1/2 therapeutic dose|1/2 therapeutic dose (5 volunteers)
9702914|NCT04717830|Experimental|Gamezumab full therapeutic dose|therapeutic dose (10 volunteers)
9702915|NCT04717739||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
9702916|NCT04717817|Experimental|Group 1: experimental|Daily inspiratory muscle training (IMT) using an IMT Threshold device (Philips) prior to surgery
9702917|NCT04717817|Active Comparator|Group 2: comparator|Standard physiotherapy prior to surgery
9702918|NCT04717713|Experimental|steroid group|patients receiving steroid injection for preventing postoperative dysphagia
9978107|NCT01368315|Active Comparator|Active comparator|Cream
9702919|NCT04717713|Placebo Comparator|placebo group|patients receiving saline injection for comparator
9702920|NCT04717752|Experimental|Double trigger unit|HCG: 6000IU (Ovidrel: 250ug) + GnRH-a (Troprilin) 0.2mg
9702921|NCT04717752|Sham Comparator|HCG trigger unit|HCG: 6000IU (Ovidrel: 250ug)
9702922|NCT04717804|Active Comparator|AIP (Average Intensity Projection) CT (Computed Tomagraphy)|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
9702923|NCT04717804|Placebo Comparator|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
9702924|NCT04717544|Active Comparator|Intervention Arm|"Healthcare providers from clinics participating in the intervention refer existing clients to study coordinators for smoking cessation services, wherein the coordinators link clients to the smoking cessation services, which include: 1) a weekly cognitive-behavioral therapy smoking cessation (CBT) counseling group; and 2) smoking cessation medication, which include varenicline (Chantix), bupropion (Zyban) and nicotine patches, gum, and lozenges. Clients interested in these medications will meet with the prescribing clinician to help choose the best prescription option.~In addition to linking clients to the smoking cessation services, coordinators will invite clients to participate in the outcome study.~Existing clients can sign-up for these services and/or the outcome study directly with the study coordinators and do not require a healthcare provider referral."
9702925|NCT04717544|No Intervention|Treatment As Usual Arm|Existing clients can be referred to the outcome study by their healthcare providers from clinics designated as TAU or they can sign-up directly with the study coordinators.
9702926|NCT04717687|Experimental|Electrodes|Electrodes
9702927|NCT04717648||Patients with anastomotic leakage|Post operative anastomotic leakage
9702928|NCT04717648||Patients without anastomotic leakage|Post operative without anastomotic leakage
9702929|NCT04717531|Experimental|Cohort A|"2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib, epirubicin, and cyclophosphamide (THB*2-ECB*4). The cycles repeated every 21 days.~Pyrotinib: 400mg, qd, po, day 1-21; Trastuzumab: 6 mg/kg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90 mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
9978108|NCT01368315|No Intervention|No intervention|
9978109|NCT01368328|Placebo Comparator|Placebo|
9978110|NCT01368328|Active Comparator|Chromium nicotinate 50 mcg|
9978111|NCT01368328|Active Comparator|Chromium nicotinate 200 mcg|
9978112|NCT01368341|Active Comparator|Doxycycline|Doxycycline, 100 mg, tablets, b.i.d., 14 days
9978113|NCT01368341|Active Comparator|Penicillin|Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
9702930|NCT04717531|Active Comparator|Cohort B|"2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin and cyclophosphamide (THP*2-EC*4). The cycles repeated every 21 days.~Trastuzumab: 6 mg/kg, day 1; Pertuzumab: 420 mg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1."
10190568|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: no
9702931|NCT04717583|Experimental|IPL-treated side|For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits, the IPL-treated side of the face will be treated with IPL, once every 4 weeks for 3 consecutive times.
9702932|NCT04717583|No Intervention|Control side|"For each participant, the two sides of face will be randomized into an IPL-treated side and a control side. In the first 3 visits (before Week 12), the control side of face will not be treated by IPL.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
9702933|NCT04717388|Experimental|impact of tinnitus on executive cognitive functioning|
9702934|NCT04717388|Experimental|impact of tinnitus on reorganization of functional/ structural brain connectivity maps|
9702935|NCT04717609|Active Comparator|Partial Meniscectomy without Saphenous Nerve Block|Participants scheduled for partial meniscectomy will preoperatively receive 0.5% ropivacaine with epinephrine
9702936|NCT04717609|Experimental|Partial Meniscectomy with Saphenous Nerve Block|Participants scheduled for a partial meniscectomy will preoperatively receive a saphenous nerve block at the medial femoral condyle in addition to an injection of 0.5% ropivacaine with epinephrine
9702937|NCT04717661||76 healthy early pregnant women in the trial group|The pulse sound waves of three parts and five layers of each of the two hands of 76 pregnant women will be collected by Pulse Detection System of Sound Waves.
9702938|NCT04717661||76 relatively healthy non-pregnant women in the control group|The pulse sound waves of three parts and five layers of each of the two hands of 76 relatively healthy non-pregnant women will be collected by Pulse Detection System of Sound Waves.
10190569|NCT05308641|Active Comparator|PrevSurg_YES/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: YES rESWT: denied
9702939|NCT04717778|Experimental|pH milk|Group of children who were given the different types of milk and only the pH was measured
9702940|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#1|Drug: SHR0302 Ointment Twice a day (BID)
9702941|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#2|Drug: SHR0302 Ointment Twice a day (BID)
9702942|NCT04717310|Active Comparator|Active Comparator: SHR0302 Ointment Dose#3|Drug: SHR0302 Ointment Twice a day (BID)
9702943|NCT04717310|Placebo Comparator|Placebo Comparator: Placebo|Drug: Vehicle Twice a day (BID)
10190570|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_4000|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 4000 pulse, 20 Hz
10190571|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_500|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: 500 pulse, 2 Hz
10190572|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_no|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: no
10190573|NCT05308641|Active Comparator|PrevSurg_NO/rESWT_deny|Previous Surgery on degenerative pathology in lumbar spine: NO rESWT: denied
10190574|NCT05308628|Active Comparator|Post-Transplant-Liver Allograft Fibrosis|
10190575|NCT05308628|Sham Comparator|Post-Transplant-Liver Allograft regular recovery|
10190576|NCT05308615|Experimental|Active (Investigational Product)|"Investigational (Active) product:~Rhea® Health Tone (1.8 mg of Gardenia jasminoides; 1.8 mg Commiphora myrrha oil; 1.8 mg Boswellia serrata oil; 1.8 mg Daucus carota oil; 1.8 mg of Foeniculum vulgarae oil and 0.99 mg of Olea europeae oil or Olive oil as a solvent.)~Regimen:~Subjects will receive Rhea® Health Tone 2 times supplementation 1 ml a day for 84 days"
10190577|NCT05308615|Placebo Comparator|Placebo (Control Product)|"Placebo (Control Product):~Using olive oil without the active ingredients contained in the Rhea® Health Tone test product.~Regimen:~Subjects will receive Placebo 2 times supplementation 1 ml a day for 84 days"
10190578|NCT05308602|Experimental|SCTV01C|
9702944|NCT04717271|Experimental|Movement Guidance Group (MVG)|In the MVG Group, the physiotherapist will provide kinesthetic stimuli by assisting manually the participant movements.
9702945|NCT04717271|Experimental|No Movement Guidance Group (NO-MVG)|In the NO-MVG, the involvement of the physiotherapist will be restricted to guarantee the safety of the participant.
9978114|NCT01368341|Active Comparator|Amoxicillin|Amoxicillin 500 mg capsula, t.i.d., 14 days
10190579|NCT05308602|Experimental|SCTV01E|
9785053|NCT01241552|Experimental|MK-6072 + SOC|Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI
10190580|NCT05308602|Active Comparator|mRNA vaccine manufactured by Pfizer or Moderna|
10190581|NCT05308602|Active Comparator|Sinopharm inactivated COVID-19 vaccine|
10190582|NCT05308589|Experimental|Continuous Postoperative Pericardial Flushing|Continuous Postoperative Pericardial Flushing (inflow of 500 ml NaCl 0,9% flushing fluid into the pericardial cavity during the first 8 postoperative hours) executed with the Haermonics investigational device
10190583|NCT05308589|No Intervention|Control|Standard care
10190584|NCT05308576|Experimental|Cohort 1: SCTV01E|one dose of SCTV01E on D0, D28 and D180, respectively
10190585|NCT05308576|Active Comparator|Cohort 1: CoronaVac|one dose of CoronaVac on D0, D28 and D180, respectively
10190586|NCT05308576|Experimental|Cohort 2: SCTV01E|one dose of SCTV01E on D0 and D180, respectively
10190587|NCT05308576|Active Comparator|Cohort 2: Sinopharm inactivated COVID-19 vaccine|one dose of Sinopharm inactivated COVID-19 vaccine on D0 and D180, respectively
10190588|NCT05308576|Experimental|Cohort 3: SCTV01E|one dose of SCTV01E on D0 and D180, respectively
10190589|NCT05308576|Active Comparator|Cohort 3: Other approved vaccines|the same COVID-19 vaccine the participant previously vaccinated or the locally approved COVID-19 vaccine on D0 and D180, respectively
9702948|NCT04717232|Experimental|The blended learning approach to mentoring education for dental health care professionals|The blended learning approach to mentoring education for dental health care professionals will last five weeks, including four face-to-face seminars, interprofessional group work and self-reflection assignments lasting for two days. The educational content will include mentoring as a process, mentoring as a relationship, challenges of mentoring, and personal mentoring.
9702949|NCT04717232|Experimental|The interprofessional online mentoring education|The intervention group will attend mentoring competence education. The Interprofessional online mentoring educations includes videos of specialist lectures, e-learning materials, along with assignments concerning reflection skills and participant-based evaluation. The education content included the processes and interactions of mentoring, goal-oriented mentoring, along with student-based feedback and student-centered evaluation. The mentoring education can be completed in an online learning environment and participants can complete the education at their own pace within six weeks.
9702950|NCT04717232|Active Comparator|The Control group|The control group are dentists´ and dental hygienists´ who are working at health care centers on the Finnish Dental Association site, participate in student mentoring and have not received any education before.
9702951|NCT04717102|Experimental|0.75 MAC desflurane|The effects of 0.75 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
9702952|NCT04717102|Active Comparator|0.5 MAC desflurane|The effects of 0.5 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.
9702953|NCT04717050|Experimental|Progressive combine training (PCT)|"Participants will be randomly assigned to Progressive combine training (PCT) group.~Participants will have two (2) baseline tests, then begin a two phase PCT program.~Phase 1: Supervised 16-week resistance and cardiovascular exercise at a local YMCA (months 1-4) or remotely at home via Zoom~Participants will receive midpoint testing, approximately week 8.~Phase 2: Unsupervised 16-week resistance and cardiovascular exercise at a local YMCA (months 5-8) or remotely at home~Participants will receive midpoint testing, approximately two months into phase 2.~After the two (2) 16-week phases, participants will be followed for 4 months."
9702954|NCT04717050|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to Attention Control (AC) group.~Two (2) baseline tests will be performed prior to starting the program. Participants will perform 12 months of home-based stretching and have a 1x test performed during months 2, 4, 6, 8 and 10. Two (2) tests will be performed in month 12."
9702955|NCT04717037|Experimental|Study|The olive oil massage will be applied initially at 72 hrs of life then twice daily with a dose of 4ml/kg till 28 days .
9702956|NCT04717037|No Intervention|Control|Patients who are assigned to the control group will receive standard care as per unit policies.
9702957|NCT04717089||postoperative patients admitted to TMH extended post anaesthetic care in PACU|"Exclusion criteria:~Patients awaiting ICU admission in the ordinary recovery room~Patients requiring level 3 intensive care on arrival at the recovery room"
9702958|NCT04717089||Postoperative patient admitted to ICU with case matched|"Inclusion criteria:~o Based on case matched with the extended post anaesthetic care in PACU"
9702959|NCT04716842||sepsis|In intensive care patients with suspected or proven infection, if the SOFA score ≥2, the patients will be evaluated as sepsis and routine examination, monitoring and treatment will be applied.
9702960|NCT04716842||septic shock|Patients with sepsis who require vasopressor to keep mean arterial pressure above 65 mmHg and lactate> 2 mmol/l will be included in the septic shock group.
10190590|NCT05308550|Other|Phase 1|"Version 1 of the rapid test:~The clinician taking the nasopharyngeal / oropharyngeal swab for standard PCR testing for Covid-19 collected a second swab directly afterwards for the rapid RNA test. The swab was placed in a dry tube, labelled with the patient's ID, date and time of taking the sample, and was taken to the microbiology laboratory for processing.~In the laboratory, 2ml of RNase-free water was added to the tube and shaken with the swab. Twenty-five microlitres of the swab solution was transferred into a PCR tube containing the dried reagents for the rapid RNA test. This tube was then incubated for 45 minutes at 65'C, then taken out to cool down. The colour of the tube was recorded by the laboratory technician."
10190591|NCT05308550|Other|Phase 2|"Version 2 of the rapid test:~The clinician taking the nasopharyngeal / oropharyngeal swab for standard PCR testing for Covid-19 collected a second swab directly afterwards for the rapid RNA test. The swab was placed in a tube containing 1ml of normal saline (instead of a dry tube). If the patient was eligible but the standard swab had already been taken >12 hours before, we asked them for their consent to take a second standard swab alongside the swab for the rapid RNA test, to ensure that the samples were comparable.~In the laboratory, the swab was heated to 95'C for 5 minutes to inactivate the virus. Nine ml of RNase-free water was added to the tube and shaken with the swab, before transferring 25ul of the swab solution into the PCR tube containing the dried reagents. This tube was then incubated for 30 minutes at 65'C, then the colour of the tube was recorded and photographed by the laboratory technician at 30 minutes (primary reading) and 45 minutes (secondary reading)."
10190592|NCT05308537|Experimental|Mindful Compassion Care Program|The MCCP comprises six regular 1 hour and 30-minute sessions and 1 all-day class lasting 4 hours and 30 minutes.
10190593|NCT05308537|No Intervention|Waiting List|
10190594|NCT05308485||Parkinson´s disease individuals|
10190595|NCT05308485||Individuals with recent-onset parkinsonism|
10190596|NCT05308485||Healthy individuals|
10190597|NCT05308472|Placebo Comparator|Placebo|
10190598|NCT05308472|Experimental|DISC-1459 oral dose level 1|
10190599|NCT05308472|Experimental|DISC-1459 oral dose level 2|
10190600|NCT05308459|Experimental|Step 1: Allocated to start the Data Health VET intervention phase January 2022|Participants receive the Data Health VET intervention in all its steps starting in January 2022
10190601|NCT05308459|Experimental|Step 2: Allocated to start the Data Health VET intervention phase August, 2022|Participants receive the Data Health VET intervention in all its steps starting in August 2022
10190602|NCT05308381|Experimental|Fasted exercise|Fasted prior to exercise
10190603|NCT05308381|Experimental|High protein breakfast exercise|High protein breakfast consumption prior to exercise
10190604|NCT05308381|Experimental|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
10190605|NCT05308368|Experimental|Tremor Group|Individuals with either parkinson's disease or essential tremor will be recruited in this group
9702961|NCT04716842||control|It will be formed from patients who are hospitalized in the intensive care unit for a reason other than sepsis and septic shock, without suspected or proven infection.
10190606|NCT05308368|Experimental|Able Body Group|Individuals with no disorders will be recruited in this group
9702962|NCT04716998|Experimental|MesenCure treatment|"Clinical interventions:~Health questionnaire, respiratory rate, heart rate, blood pressure, RA O2 saturation, x-ray.~Blood tests: leukocyte and lymphocyte count, CRP, D-Dimer, renal and liver function, optional: cytokine levels."
9702963|NCT04716894|Experimental|BI 474121 alone|
9702964|NCT04716894|Experimental|BI 474121 + itraconazole|
9702965|NCT04717141|Experimental|Biomecanical evaluation of the selective nerve block effects|"D0 :~Information, collection of consent, inclusion,~Clinical and instrumental evaluation,~Realization of the selective nerve block,~Post-selective nerve block clinical and instrumental re-evaluation,~Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
9702966|NCT04717167|Experimental|DN group|All identified MTrPs were inserted with a sterile filiform needle (0,30mm x 40mm or 0,30mm x 75mm, depending on the muscle) that moved up- and downwards until a local twitch response was elicited. When the repeated local twitch response fade away or the subject reported too much pain, the needle was removed. After the treatment, a 15 minutes break(51) was set up and the subjects were not permitted to use a hot pack or to stretch the muscle.
10190607|NCT05308355||OFA : Opioid Free Anesthesia|Opioid-free surgery. Analgesia provided by attenuation analgesic 1, dexmedetomidine, ketamine and general anesthesia by propofol. Regional loco anesthesia is performed in the OFA group and possible in the OBA group. It's local service protocol used since 1 year.
10190608|NCT05308355||OBA : Opioid Based Anesthesia|Conventional anesthesia with Propofol and Sufentanil boli with the possibility of regional loco anesthesia.
9702967|NCT04717167|Sham Comparator|Sham needling (SN) group|The SN technique was similar to DN, except for penetrating the muscle. In this technique, the needle only penetrated the skin and was therefore impossible to provoke a local twitch response.
9702968|NCT04717063|Active Comparator|Peroxyl|"Drug: Peroxyl Mouthwash Mouthwash~Other Names:~• 1.5% HP"
9702969|NCT04717063|Placebo Comparator|placebo mouthwash|"Drug: Placebo Mouthwash Mouthwash~Other Names:~• 0.0% HP Mouthwash"
9702970|NCT04717180|Active Comparator|group I|patients who received rehabilitation using the software program for aphasia rehabilitation
9702971|NCT04717180|Active Comparator|group II|patients who received rehabilitation using the conventional therapy
9702972|NCT04717193|Experimental|Rectus Sheath Block|Participants randomized to the experimental arm will receive a bilateral rectus sheath block which is additional to the standard of care (infiltration of 5mg (2mL) 0.25% bupivacaine with epinephrine around port site incisions). For rectus sheath block, use the formula Volume (ml) = 2mg/kg x weight (kg) divided by 2.5mg/ml - 6ml to a maximum of 14ml. Maximum total dose is 2mg/kg. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
9702973|NCT04717193|Active Comparator|Local Anesthetic|Participants in the control arm will receive the standard care which is infiltration of 5mg (2mL) of 0.25% bupivacaine with epinephrine around port site incisions. Participants will be asked to rate their pain a total of 4 times for the study. Each occurrence is expected to take approximately 1-2 minutes to complete. There will be no additional follow-up required as part of the study. The 6 week follow-up visit is standard routine practice.
9702974|NCT04717206|Experimental|Plyomtric training to male badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to male badminton players.
9702975|NCT04717206|Experimental|Plyomtric training to female badmninton players|Baseline assessment will be perfomimg on first day before intervention, 4 weeks plyometric training to female badminton players.
9702976|NCT04716855||Evaluation tests|RCS cases between the ages of 19-64 (n:40) who agreed to participate were included in the study. Pain severity (Visual Analogue Scale - VAS), range of motion (Universal Goniometer), muscle test (Manual muscle test), upper extremity functional status and disability (Quick-DASH questionnaire), physical activity level (International Physical Activity Questionnaire - UFAA) ) and quality of life (Short Form-36 - SF-36) were evaluated
9702977|NCT04716829|Experimental|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG for 12 weeks.
9702978|NCT04716829|No Intervention|Control|The control group will receive its rehabilitation care.
10190609|NCT05308342|Experimental|UC-MSCs+hormone replacement group|Group A was the hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells group(test group).
10190610|NCT05308342|Active Comparator|hormone replacement group|Group B was the hormone replacement group (control group).
10190611|NCT05308316|Experimental|Impact of Sugar Content|Participants will be ask to attend 4 laboratory sessions during which they will be asked to smoke their usual brand (UB) cigarettes and then one of three study cigarettes with low, medium and high levels of sugar in separate sessions using a within-subject design with conditions counterbalanced determined by a Latin square. In each session, smokers will be asked to smoke a cigarette in a standardized manner (10 puffs,30 second interval between puffs) and 1 hour later, ad libitum. Each of the sessions will be separated by at least 48 hours but not more than 5 days.
10190612|NCT05308303||All cause OHCA|
10190613|NCT05308303||OHCA of non-cardiac origin|
9702979|NCT04716816|No Intervention|traditional treatment|received conventional analgesics.
9702980|NCT04716816|Experimental|Stripping massage|received SM twice daily in the active trigger points of the rhomboid for two weeks.
9702981|NCT04716582|Experimental|SIT group|participants will sitting 4 hours continuously.
9702982|NCT04716582|Experimental|INTERRUPT group|participants will sitting 25 minutes with 5 minutes walking per half hour,40minutes walking in total
10190614|NCT05308277|Other|Single Arm - Leo Device Monitoring|Child's respiratory impedance will be continuously recorded using the Leo device during hospital/ED stay after consent and enrollment, and then during 7 days at home after discharge. The Leo device provides no intervention, and will only monitoring chest impedance for the worn period. Oscillometry and spirometry testing and flow volume assessment using PNT will be performed during study visits with Leo device attached.
9702983|NCT04716582|Experimental|COGN group|participants will perform GED test as cognitive loading task during 4-hour sitting
9702984|NCT04716608|Active Comparator|Group 1 INT (= intervention)|"physiotherapy program with~Myofascial Release Massage (quadriceps)~Foam Rolling lower extremity~Knee Isometrics in knee extension (sitting position)~Dynamic and static stretching (quadriceps) in half knee position~Core Stability (planks)~Strengthening (calf raises, good morning,squats, squat jump)~Balance (single leg stance)"
9702985|NCT04716608|Placebo Comparator|Group 2 USC (= usual care)|"usual care treatment with~Core Stability (prone plank)~Strengthening: (Hip extension, abduction; Calf raises)~Stretching (M. rectus femoris (static) in standing position; Hamstring in sitting position)~Balance (single leg stand)"
9702986|NCT04716621|Experimental|Early intervention|Three sites received the Pain Management Support System for Primary Care (PMSS-PC) integrated into the Electronic Health Record.
9702987|NCT04716621|Other|Delayed intervention|Delayed wait-list control group. Three additional sites received the intervention 6 months after the first arm.
9702988|NCT04716556|Experimental|Standard Therapy+Convalescent Plasma|Patients will receive standard therapy + 200-300 ml of convalescent plasma for a maximum of 3 times in 5 days, according to clinical conditions.
9702989|NCT04716556|No Intervention|Standard Therapy|Patients will receive standard therapy for the treatment of SARS-CoV2 infection, according to AIFA indications
9702990|NCT04716647|Experimental|Ayurveda Intervention|Ashwagandha, Giloy and Tulsi were given in tablet form for oral administration.
9702991|NCT04716569|Experimental|intranasal Ivermectin group|Ivermectin group Patients who will receive intranasal ivermectin
9702992|NCT04716569|Other|Control group|patients who will receive regular protocol drugs
9702993|NCT04716517|Experimental|Cention N|Intervention Alkasite Restoration will be used to restore cervical carious in adult patients.
9702994|NCT04716517|Active Comparator|Resin Modified Glass Ionomer|Comparator Resin-modified glass ionomer material will be used to restore cervical carious in adult patients.
9702995|NCT04716660||Women receiving epidural analgesia for labor|
9702996|NCT04716868|Experimental|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 week.
9702997|NCT04716868|Experimental|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 gf once a day for 8 week.
9702998|NCT04716868|Experimental|Maltodextrin 10 g + Agave Fructans 5 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 week.
9702999|NCT04716868|Active Comparator|Psyllium plantago 15 g|Psyllium plantago 15 g once a day for 8 week.
9703000|NCT04716790|Experimental|Ultrasounds once a week|Patients will undergo the application of ultrasound therapy with a frequency of once a week.
9703001|NCT04716790|Experimental|Ultrasounds once every two weeks|Patients will undergo the application of ultrasound therapy with a frequency of once every two weeks.
9703002|NCT04716790|Active Comparator|Standard of care|Patients will be treated using the conventional treatment established by the protocol of the Diabetic Foot Unit of the University Podiatry Clinic of Complutense University of Madrid.
9703003|NCT04716634|Experimental|Tislelizumab + Fruquintinib|Participants with one of the tumors will be enrolled: GC,CRC and NSCLC
9703004|NCT04716751|Experimental|Toripalimab|
9703005|NCT04716777|Experimental|Brief Transdiagnostic GCBT|Participants receive Brief Transdiagnostic group cognitive-behavioral treatment. Eight weekly sessions.
9703006|NCT04716777|No Intervention|Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the Brief Transiagnostic GCBT for eight weeks.
9703007|NCT04716673|Experimental|Children (4-11y) with epilepsy|Down-phase-targeted closed-loop auditory stimulation is administered in each arm.
9703008|NCT04716673|Experimental|Teenagers (12-17y) with epilepsy|
9703009|NCT04716673|Experimental|Young adults (18-30y) with epilepsy|
9703010|NCT04716673|Experimental|Healthy children (4-11y)|
9703011|NCT04716673|Experimental|Healthy teenagers (12-17y)|
9703012|NCT04716673|Experimental|Healthy young adults (18-30y)|
9703013|NCT04716595|Experimental|morning administration|K-877 ER 0.2 mg/day morning administration (once daily)
9703014|NCT04716595|Experimental|evening administration|K-877 ER 0.2 mg/day evening administration (once daily)
10190615|NCT05308264|Experimental|Dose Escalation|"Standard 3+3 design~Experimental: Dose Expansion Phase"
9703015|NCT04716543||ILI Investigation|The suspected ILI cases will be first identified using the WHO clinical case definition of ILI and Covid 19 as either with:Acute onset of fever (> 37.5˚C axillary temperature or > 38˚C tympanic temperature) AND cough; OR Acute onset of ANY ONE OR MORE of the following signs or symptoms: Fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anosmia (loss of smell) or ageusia (loss of taste); with symptoms with onset within the last 10 days.
9703016|NCT04716686|Experimental|Niraparib as maintenance therapy for Endometrial Serous Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
9703017|NCT04716686|Experimental|Niraparib as recurrent therapy for Endometrial Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
9703018|NCT04716491|Experimental|Intervention group|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.
9703019|NCT04716491|No Intervention|Control group|Participants will not use the devices at any time of admission to the intensive care unit
9703020|NCT04716478||Patient in need of endodontic care|
9785054|NCT01241552|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI
9785055|NCT01241552|Placebo Comparator|Placebo + SOC|Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI
9703021|NCT04717258|Experimental|Main FIREFLI trial: Intervention arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) offered by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer) once randomised.
9703022|NCT04717258|No Intervention|Main FIREFLI trial: Control arm|Usual care from healthcare professionals; falls prevention leaflet; Safe and Well Visits (SWVs) by the Fire and Rescue Service (FRS) (either a firefighter, day duty safety advocate or home safety officer offered 12 months post-randomisation)
9703023|NCT04717258|Experimental|Recruitment SWAT: Self-Determination Theory informed invitation letter|The recruitment pack to take part in the FIREFLI study will include an invitation letter informed by Self-Determination Theory.
10190616|NCT05308251|Active Comparator|high ligation|High ligation of the indirect hernia sac is traditional in inguinal hernia repairs. In this arm, patients with indirect inguinal hernia undergoing open mesh herniorrhaphy will have their hernia sac was opened and high ligated.
9703024|NCT04717258|No Intervention|Recruitment SWAT: Standard invitation letter|The recruitment pack to take part in the FIREFLI study will include the University of York, York Trials Unit's standard invitation letter
9703025|NCT04717258|Experimental|Retention SWAT: Pen arm|A pen (which has the University of York logo on it) will be included with the first four-month reminder questionnaire.
9978115|NCT01368354|Active Comparator|CLTS Arm|To induce behavioural changes by confronting the community with their open defecation behaviour. This will lead to voluntary construction and use of latrines and improved hygiene behaviour. CLTS involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination.
9978116|NCT01368354|No Intervention|Control arm|
9978117|NCT01368367|Active Comparator|Intensive exercise group|
9978118|NCT01368367|Placebo Comparator|Stretch exercise only|
10190617|NCT05308251|Experimental|non-ligation|In this arm, the patients' hernia sac will be dissected high but not opened or ligated. The sac will be invaginated to the abdomen.
9703026|NCT04717258|No Intervention|Retention SWAT: No pen|No pen will be included with the four-month reminder questionnaire.
9703027|NCT04716920|Experimental|Supportive Care (Tai Chi, Fitbit, Tai4Chijoint group)|Patients attend Tai Chi exercise classes over 1 hour BIW and wear a Fitbit device for up to 12 weeks. Patients are encouraged to complete self-practice over 30 minutes and record practice times daily in a diary log form. Patients also join a Facebook private TaiChi4joint group where they receive instructional videos matching the progress of weekly classes for at-home practices and peer support in Tai Chi engagement.
9703028|NCT04716530||born before 2000|No patient treatment is associated with the study.
9703029|NCT04716530||born between 2000-2010|No patient treatment is associated with the study.
9703030|NCT04716530||born after 2010|No patient treatment is associated with the study.
9703031|NCT04717245|Active Comparator|Fractional CO2 LASER|Vaginal fractional CO2 LASER 3 sessions applications
9703032|NCT04717245|Active Comparator|Microablative fractional radiofrequency|Vaginal Microablative fractional radiofrequency 3 sessions application
9703033|NCT04717245|Active Comparator|Promestriene Vaginal|Promestriene vaginal use during 3 months
9703034|NCT04716738||Irritable Bowel Syndrome with Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
9703035|NCT04716738||Irritable Bowel Syndrome without Sexual Dysfunction|We use Rome IV criteria, scale bristol and the female sexual fuction to establish IBS and sexual dysfunction diagnosis, and SF-36 to determinated quality of life.
10190618|NCT05308212|Experimental|FLU-M Tetra w/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (with preservative) intramuscularly
10190619|NCT05308212|Experimental|FLU-M Tetra w/o/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (without preservative) intramuscularly.
10190620|NCT05308212|Active Comparator|Ultrix Quadri|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Ultrix Quadri vaccine.
9703038|NCT04716244||Gestational diabetes|Women who were diagnosed with gestational diabetes within the least year
9703039|NCT04716244||Pre-eclampsia|Women who were diagnosed with pre-eclampsia within the past year
9703040|NCT04716348|Experimental|group A|suboccipital muscle energy technique
9703041|NCT04716348|Sham Comparator|group B|sham muscle energy technique
9703042|NCT04716296|Experimental|Ketamine arm|Treatment arm consisting of patients randomized to receive a low dose of ketamine for the second stage of DBS surgery.
9703043|NCT04716296|Active Comparator|Control arm|Control arm consisting of patients randomized to receive sham control of saline during the second stage of DBS surgery.
9778789|NCT01116102|Experimental|25 ga needle, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
9778790|NCT01116102|Experimental|25 ga needle, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
9778791|NCT01116102|Experimental|25 ga needle, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
9785056|NCT01241565|Experimental|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|Single arm study, all patients will receive the study device.
9785057|NCT01241591|Experimental|CP 690,550 5 mg BID+Placebo BIW|
9785058|NCT01241591|Experimental|CP 690,550 10 mg BID+Placebo BIW|
10190621|NCT05306899|Active Comparator|Ketamine infusion|Intravenous Ketamine
10190622|NCT05306899|Placebo Comparator|Placebo infusion|
10190623|NCT05303324|Experimental|Sequence 1 (AB)|"Participants received ALXN1840 once in each Period as a single oral dose under fasted conditions as follows:~Period 1: ALXN1840 as a single EC tablet (Treatment A, reference). Period 2: ALXN1840 as three EC tablets (Treatment B, test).~Participants were discharged following the 240-hour post-dose procedures (approximately 10 days after dosing in each period) unless it was medically necessary to extend the confinement.~There was a washout period of at least 14 days between each ALXN1840 dosing."
10190624|NCT05303324|Experimental|Sequence 2 (BA)|"Participants received ALXN1840 once in each Period as a single oral dose under fasted conditions as follows:~Period 1: ALXN1840 as three EC tablets (Treatment B, test). Period 2: ALXN1840 as a single EC tablet (Treatment A, reference).~Participants were discharged following the 240-hour post-dose procedures (approximately 10 days after dosing in each period) unless it was medically necessary to extend the confinement.~There was a washout period of at least 14 days between each ALXN1840 dosing."
10190625|NCT05302128|Experimental|Cold vapor group|Cold vapor will be applied to the experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtime-un600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
10190626|NCT05302128|No Intervention|Control group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of nausea and vomiting when they come to the recovery room and at the 2nd, 6th,12th, and 24th hours after the surgery in the postoperative service.
9703044|NCT04716764||Case Group|The study will include female individuals aged 19-64 years who applied to Necmettin Erbakan University Meram Medical Faculty General Surgery and Medical Oncology Departments and were diagnosed with breast cancer for the first time and volunteering to participate in the study. Patients with breast cancer will be followed up before surgery, before chemotherapy, and in the sixth and twelfth months after starting chemotherapy.
9703045|NCT04716764||Healthy (Control) participants|The control group consists of healthy adult women who applied to the Internal Diseases (Internal Medicine) outpatient clinic of Necmettin Erbakan University Meram Medical Faculty Hospital, who are at the same age as the case group, and who have not been diagnosed with any disease by the doctor, and who are willing to participate in the study. Healthy individuals will be interviewed once. The obtained data will be compared with the preoperative data of breast cancer patients.
9978119|NCT01368380|Experimental|Psychological Intervention|
9978120|NCT01368380|No Intervention|Usual care|
9703046|NCT04716413|Experimental|Treatment|Subjects will receive dose of Dsuvia 30mcg SL (1st dose) after induction but before first incision. Post-operatively, if subject rates pain higher than 4 out of 10, subject will receive a second dose of Dsuvia 30mcg SL. If 30 minutes after second dose, subject rates pain higher than 4 out of 10, subject will receive ibuprofen 800mg IV. If 60 minutes after second dose, subject rates pain higher than 7 out of 10, subject will receive hydromorphone 0.4 mg IV.
9703047|NCT04716413|No Intervention|Control|Subjects will be receive routine standard of care.
9703048|NCT04716452|Experimental|Open Label Administration of Ceramide NanoLiposome|Ceramide NanoLiposome will be administered by Intravenous Dosing twice per week in accordance with the protocol relative to dose escalation. There is no placebo group or arm of the study.
9703049|NCT04716439||magnesium sulfate effect on IONM reading in spine surgery|one group receives magnesium other do not
9703050|NCT04716465||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 (symptomatic and asymptomatic) will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
9703051|NCT04716374||Patients with epithelial ovarian cancer|Patients with epithelial ovarian adenocarcinoma with archival tumor tissue available for analysis were identified through the Hellenic Cooperative Oncology Group (HeCOG)'s tumor repository. Patients had received treatment at HeCOG-affiliated institutions following standard international guidelines.
9703052|NCT04716205|Experimental|Mulligan's bent leg raise Technique|Mulligan's bent leg raise Technique and Static Stretching
9703053|NCT04716205|Active Comparator|Static stretching|Static Stretching
9703054|NCT04716400|Experimental|Intervention group|"Stop sexual harassment"
9703055|NCT04716400|No Intervention|Control group|No intervention
9703056|NCT04716426|Experimental|Tetracycline hydrochloride 3%|4 drops of tetracycline hydrochloride 3% (APT™ T3X) applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
9703057|NCT04716426|Placebo Comparator|Placebo|4 drops of placebo applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
9978121|NCT01368393|Experimental|Electroacupuncture|
9978122|NCT01368393|Active Comparator|Sham acupuncture|
9978123|NCT01368419|Experimental|Treatment|
9978124|NCT01368445|Active Comparator|MP03-36 Nasal Spray|azelastine hydrochloride 0.15%
9978125|NCT01368445|Active Comparator|MP03-36 and Placebo Nasal Spray|azelastine hydrochloride 0.15% and Placebo
9978126|NCT01368445|Active Comparator|Azelastine 0.1%, Nasal Spray|Azelastine 0.1%, Nasal Spray
9978127|NCT01368445|Placebo Comparator|Placebo Nasal Sapray|0mg, 2 sprays per nostril twice daily AM & PM)
9978128|NCT01368458|Experimental|Conversion to mono therapy|Conversion from 2 to 1 antipsychotic
10190627|NCT05299632||Patients with biochemical and clinical evidence of primary hyperparathyroidism|Patients who have biochemical and clinical evidence of primary hyperparathyroidism and who are scheduled for routine surgery and preoperative imaging including 99mTc-MIBI planar imaging and SPECT/CT. Subjects who enroll in the study will receive one additional F-18PSMA PET/CT imaging study. F-18 PSMA imaging study will be scheduled on the same day as of the Tc-99m MIBI scan. Since F-18 PSMA PET/CT employs 511kEv annihilation photon, the lower energy if (140 KeV) of Tc-99m MIBI will not interfere.
9703058|NCT04716218|Placebo Comparator|neutral position|The initial percentage of glottic opening (POGO) by laryngoscopy was recorded in the ramped position. Thereafter, a second POGO (laryngeal view) was scored in the neutral position and then intubation was performed.
9703059|NCT04716218|Experimental|back up head elevated position|The initial POGO was recorded in the neutral position. The second POGO was scored in the ramped position and then the trachea was intubated.
9703060|NCT04716062||subjects who underwent open-air surgery|Fifty-one (37%) out of 138 subjects underwent open-air surgery.
9703061|NCT04716062||subjects underwent laparoscopic-assisted surgery|A total of 87 (63%) out of 138 subjects underwent laparoscopic-assisted surgery.
9703062|NCT04716179|Experimental|Patients with COVID-19|Patients with confirmed COVID-19 infection
9703063|NCT04716179|Other|Healthy participants|The controlled group with healthy participants without COVID-19 infection.
9703064|NCT04716192|Experimental|Positional release technique|Positional release technique, Mayofascial release technique and ultrasound
9703065|NCT04716192|Active Comparator|Mayofascial release technique and ultrasound|Mayofascial release technique and ultrasound
9703066|NCT04716140|No Intervention|MTP1 joint with no cartillage laesion or grade I|Patients in whom no treatment of the cartilage lesions is performed: these patients have no cartilage lesion or a grade I cartilage lesion at the MTP I joint that has been found peroperatively. The degree of the cartilage lesions will be determined on the basis of the ICRS scale and an MS Hololens.
9703067|NCT04716140|No Intervention|MTP1 joint with cartillage laesion > grade I - non treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the no treatment group
9703068|NCT04716140|Experimental|MTP1 joint with cartillage laesion > grade I - treatment|Patients in whom a cartilage lesion> grade 1 is found during surgery randomised in the treatment group. They will be treated through debridement of the lesion and microfracture.
9703069|NCT04715971||Patients admitted ≤72 hours to an acute geriatric hospitalisation unit.|All patients aged ≥75 years, admitted to the acute geriatric hospitalisation units of the University Hospitals Leuven in Belgium, were consecutively screened for inclusion within 72 hours of admission in a 2 month period (between October 26 and December 18, 2015).
9703070|NCT04715854|Active Comparator|Nasal canula (flexicare)|Patients will receive oxygen by classical nasal cannula
9703071|NCT04715854|Active Comparator|Intersurgical aerosol mask with one hole closed by tape|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask partially closed (one lateral hole of the face mask closed by tape)
9703072|NCT04715854|Active Comparator|Intersurgical aerosol mask|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask
9703073|NCT04715958|Experimental|Diagnostic (CEUS, Definity)|Patients undergo CEUS and receive perflutren lipid microspheres IV over 10-15 minutes before NAC, after 10% of NAC, and after 30% of NAC
9703074|NCT04715841||group A|Group A (Study group ) : 25 adolescent females suffering patellofemoral pain syndrome were recruited from the outpatient clinic of the faculty of physical therapy delta university in addition to the medical diagnosis was confirmed by consultant orthopedist using clinical and radiographic investigations .
9703075|NCT04715841||group B|Group B (Control Group):25 adolescent females with healthy knee joints with no clinical and radiographic evidence of patellofemoral pain syndrome , were recruited from the students of the faculty of physical therapy delta university .
9703076|NCT04715659||COPD patients|
9703077|NCT04716049|Experimental|Protocol I|Powerade© Carbohydrates+Protein Cherry Juice Foam Roller Cold Water Immersion
9703078|NCT04716049|Experimental|Protocol II|Powerade@ Carbohydrates+Protein Stretching Intermittent Cold-Water Immersion
10190628|NCT05295914||Patient with chronic hepatitis B infection|Patient with chronic hepatitis B infection visited at liver and internal medicine clinic, Siriraj hospital between January 2015-2020
10190629|NCT05294354|Experimental|aerobic exercise group (AE)|35-min cycling at moderate intensity (50-60% heart rate reserve).
9703079|NCT04715763|Active Comparator|Telmisartan (80 mg)|Telmisartan 80 mg (given as two 40 mg encapsulated tablets) given orally each day x 21 days
9703080|NCT04715763|Placebo Comparator|Placebo|Two placebo capsules given orally each day x 21 days
9703081|NCT04715789|Experimental|physical therapy intervention|"core stability exercises:~Multifidus exercises~Frontal & Side Plank exercise~Pelvic floor exercises~abdominal exercises~Strengthening exercises~Bridging~straight leg raise~gluteus medius strength~gluteus maximus strengthening for about 20 min to 30 min to strength back and proximal hip control muscles"
10190630|NCT05294354|Experimental|aerobic exercise with virtual reality group (AE-VR)|35-min cycling at moderate intensity (50-60% heart rate reserve) with 3D virtual reality.
10190631|NCT05294354|Experimental|combined exercise group (CE)|This 35-min exercise combines aerobic, bodyweight exercise, and meditation.
10190632|NCT05294354|Active Comparator|control group|It has a 35-minute video about exercise science.
10190633|NCT05294172|Experimental|KL-A167+Gemcitabine+Cisplatin|subject will receive KL-A167 1200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, 4-6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day,4-6 cycles
10190634|NCT05294172|Placebo Comparator|Placebo+Gemcitabine+Cisplatin|subject will receive placebo every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, 4-6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, 4-6 cycles
10190635|NCT05293548|Experimental|NVSI-06-09 Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
10190636|NCT05293548|Active Comparator|Inactivated Vaccine Sequential Immunization Group|the subjects who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine (Vero cell) for ≥6 months
10204437|NCT01988883|Experimental|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
9703082|NCT04715789|Experimental|graded exposure and graded activity in addition to phycal therapy intervention|"Graded exposure:This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities for about 10 min before physical therapy program (strengthening)"
9703083|NCT04715607|Active Comparator|Nasopharyngeal swab, oropharyngeal swab, and salvia collection|"The participants will first be tested with nasopharyngeal swabs followed by oropharyngeal swab and saliva collection.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
9703084|NCT04715607|Active Comparator|Oropharyngeal swab, salvia collection, and nasopharyngeal swab|"The participants will first be tested with oropharyngeal swabs followed by saliva collection and nasopharyngeal swab.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
9703085|NCT04715607|Active Comparator|Salvia collection, nasopharyngeal swab, and oropharyngeal swab|"The participants will first be tested with saliva collection followed by nasopharyngeal swab and oropharyngeal swabs.~The collection material, virus transport medium and laboratory equipment for each method is the same in both arms"
9703086|NCT04715594||CONNECT DES Registrty|
9978129|NCT01368458|No Intervention|control|No change in antipsychotics
9703087|NCT04715737|Experimental|Vasopressin|Vasopressin (20IU) intranasally
9703088|NCT04715737|Experimental|Oxytocin|Oxytocin (24IU) intranasally
9978130|NCT01368471|Experimental|MGuard|MGuard stent will be deployed
9978131|NCT01368471|Active Comparator|BMS or DES|A regular bare metal stent or drug-eluting stent will be deployed
9978132|NCT01368484|Placebo Comparator|Sunflower oil|
9703089|NCT04715737|Placebo Comparator|Placebo|Placebo intranasally
9703090|NCT04715633|Experimental|PD-1 inhibitors plus VEGF inhibitors|Patients will be given 4 cycles of Camrelizumab (200mg iv every 3 weeks) plus Apatinib (250mg QD day1-14) before being evaluated for response.
9703091|NCT04715919||Patients in ICU|ICU patients with COVID-19
9703092|NCT04715919||Patients in Hospital Ward|Patients with COVID-19 in hospital wards
9978133|NCT01368484|Experimental|Docosahexanoic acid|
9703093|NCT04715802||PAAG removal + Immediate implant reconstruction|Patients who had a one-stage operation comprising gel removal and immediate breast reconstruction.
9703094|NCT04715802||PAAG removal + Delayed implant reconstruction|Patients who had a two-stage operation comprising gel removal and delayed breast reconstruction at least 3 months later. The first included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
9703095|NCT04715802||PAAG removal + No breast reconstruction|Patients who only underwent surgical PAAG removal without breast reconstruction.
9703096|NCT04715802||PAAG removal + Delayed autologous fat grafting reconstruction|Patients who underwent a two-stage operation comprising surgical PAAG removal and autologous fat injection at least 3months later. Usually, the amount of transplanted fat was 150-200mL/side. A multilayer and multi-tunnel injection method was commonly used.
10204438|NCT01988883|Experimental|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
9703097|NCT04715802||PAAG removal + breast reconstruction with implants|Patients who underwent surgical PAAG removal with immediate or delayed implant breast reconstruction.
9703098|NCT04715802||Primary breast augmentation with implants|Patients who had undergone conventional breast augmentation(BA) with implants during the study period who matched the study cohort by age(±5 years).
9978134|NCT01368510|Experimental|OCD Active CBT|Adults with obsessive-compulsive disorder (OCD) will be treated with cognitive-behavioral therapy (CBT) from the time of enrollment.
9703100|NCT04715672||copper|
9703101|NCT04715672||no-copper|
9703102|NCT04715672||normal|
9703103|NCT04715880|Active Comparator|Paravertebral Block (PVB) group|"Under complete aseptic precaution, Patient will be in lateral decubitus position a paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity.~The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour"
9785059|NCT01241591|Active Comparator|Placebo BID+Etanercept 50 mg BIW|
9785060|NCT01241591|Placebo Comparator|Placebo BID+Placebo BIW|
9785061|NCT01241604|Active Comparator|Respironics BiPAP S/T|Control Arm using Respironics BiPAP S/T
9978135|NCT01368510|Active Comparator|OCD Waitlist|Adults with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
9978136|NCT01368510|No Intervention|Healthy Control|Healthy control adults will be given no intervention.
9978137|NCT01368523|Experimental|nilotinib|
9978138|NCT01368549||Metanx®|Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.
9978139|NCT01368575|Active Comparator|subgroup B1|subgroup B1 will receive CABG combined with MV repair with annuloplasty rigid ring
9978140|NCT01368575|Active Comparator|subgroup B2|B2 - CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
9978141|NCT01368575|Active Comparator|subgroup A2|CABG combined with MV repair with remodeling annuloplasty rigid ring
9978142|NCT01368575|Active Comparator|subgroup A1|only CABG
9703104|NCT04715880|Active Comparator|Paravertebral block/Intercostal Block (PVB/ICB) group|Under complete aseptic precaution, patient will be in lateral decubitus position a paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
9703105|NCT04715698|Experimental|ICG-guided|anti-hypertensive drug selection based on physician's experience and hemodynamic profiling by measured ICG
9703106|NCT04715698|Active Comparator|Empirical|anti-hypertensive drug selection based on physician's experience only
9703107|NCT04716023||Chronic Airflow obstruction / COVID-19|Patients with either chronic airflow obstruction of COVID-19
9703108|NCT04715828||"control arm fresh"|Fresh semen treated without irradiation before cryopreservation
9703109|NCT04715828||"control arm cryopreserved"|cryopreserved semen without irradiation (n=60)
9703110|NCT04715828||acute irradiation at low dose|Pelvis scanning : acute irradiation (1 or 2 second) using low dose (n=30),
9703111|NCT04715828||long irradiation at low dose|Bone scintigraphy : long irradiation (3h) using low dose (n=30),
9703112|NCT04715828||long irradiation at medium dose|Radioactive Iodine 131 therapy (RAT) applied for thyroid cancer : long irradiation (3h) using medium dose (n=60),
9703113|NCT04715724|Experimental|Baby doll with remote controlled jaw|In this arm, participants will complete a simulation using the Newborn Oral Assessment and Latch Simulator (NORALSim), which is designed to look, feel, and weigh like a healthy human newborn. The NORALSim's jaw can be remotely operated by the user to demonstrate attachment at the breast.
9703114|NCT04715724|Active Comparator|Baby doll with hand controlled jaw|In this arm, participants will complete a simulation using a cloth baby with a puppet-style jaw which can be opened and closed by the user to demonstrate attachment at the breast.
10204439|NCT01988883|Experimental|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
9703115|NCT04715724|Active Comparator|Static baby doll|In this arm, participants will complete a simulation using a rigid, plastic baby with a static, open mouth.
9703116|NCT04715620|Experimental|niraparib|
9978143|NCT01368575|Active Comparator|subgroup B3|patients in subgroup B3 will be performed CABG and MV replacement with preservation of subvalvular apparatus
9703118|NCT04715945||Women|12,583 women recruited when non-pregnant
9978144|NCT01368601|Active Comparator|CPAP (positive airway pressure)|To evaluate if continuous positive airway pressure(CPAP) on the lung undergoing lobectomy can decrease the inflammatory response PPC (postoperative pulmonary complications).
9978145|NCT01368601|No Intervention|Control without CPAP|
9978146|NCT01368627|Experimental|Supralimus® Sirolimus-Eluting Coronary Stent|
9978147|NCT01368640||healthy adults|The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
9703119|NCT04715945||Children|3,158 liveborn singleton offspring of women recruited to the study
9703120|NCT04715711|Active Comparator|Active Cooling|Participants will be actively cooled during rest breaks
9703121|NCT04715711|Placebo Comparator|No Intervention|"Participants will participant in passive cooling where they sit in a chair during rest."
9703122|NCT04716036|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
9703123|NCT04716036|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
9703124|NCT04715776|Placebo Comparator|Pre-DM patients with placebo|Pre-Diabetes patients uptake placebo as dietary supplement
9978148|NCT01368666|Experimental|Perceval S Valve Prosthesis|Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis
9978149|NCT01368679|Experimental|Endoprothesis Scitech|"The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.~The delivery system is done by linear drive or screw diameters greater than 30mm"
9978150|NCT01368692|Active Comparator|neutral shoulder|neutral shoulder position during subclavian vein catheterization
9978151|NCT01368692|Experimental|shoulder retraction|position of shoulder retraction during subclavian vein catheterization
9978152|NCT01368705|Active Comparator|Control Group|
9978153|NCT01368705|Experimental|Intervention Group 1|
9978154|NCT01368705|Experimental|Intervention Group 2|
9978155|NCT01368718|Other|Active/Sham CPAP|
9978156|NCT01368731|No Intervention|nil prophylactic coagulation|
9978157|NCT01368731|Active Comparator|Prophylactic coagulation|
9978158|NCT01368744||OSNA Breast Cancer System|
9978159|NCT01368770|Experimental|Coronary CTA|Coronary CTA using standard protocols
9978160|NCT01368770|Active Comparator|Stress MPI SPECT|Stress-rest MPI SPECT using standard protocols
9978161|NCT01368783|Experimental|atazanavir|400 mg/day for 2 days
9978162|NCT01368783|Experimental|Atazanavir and Tenofovir|
9978163|NCT01368783|Experimental|Atazanavir and Ritonavir|
9978164|NCT01368783|Experimental|Atazanavir + tenofovir + ritonavir|
9978165|NCT01368796|Active Comparator|Trivalent Influenza vaccine subunit|The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
9978166|NCT01368796|Active Comparator|Adjuvanted Tri-valent Influenza Vaccine|The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
10204440|NCT01945775|Experimental|talazoparib|Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
10204441|NCT01945775|Active Comparator|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
9703125|NCT04715776|Experimental|Pre-DM patients with supplement|Pre-Diabetes patients uptake Brown seaweed as dietary supplement
10190637|NCT05292989|Experimental|Group 1- Personalised tailored approach|If patients are assigned to this group they will be asked to complete a frailty assessment which includes an assessment of grip strength, time to complete 5 sit-to-stands, balance test, and gait speed along with some questionnaires on comorbid medical conditions. The treating Gastroenterologist will then go through the results of the frailty assessment with the patient and based on this information will discuss the benefits and risks associated with having a surveillance colonoscopy. The patient will then decide if they would like to go ahead with a surveillance colonoscopy and the treating Gastroenterologist will provide further advice as required. The frailty assessment is intended to be done at the time of the appointment with the specialist. However, operational requirements may dictate that e.g. a telehealth delivered occasion of service is done at a separate date.
10190638|NCT05292989|Placebo Comparator|Group 2- Standard Care|Patients assigned to this group will discuss the benefits and risks associated with having a surveillance colonoscopy with the treating Gastroenterologist and will decide whether to proceed with the colonoscopy.
9703126|NCT04715776|Placebo Comparator|DM patients with placebo|Diabetes patients uptake placebo as dietary supplement.
9703127|NCT04715776|Experimental|DM patients with supplement|Diabetes patients uptake Brown seaweed as dietary supplement
9703128|NCT04715568|Experimental|Placebo then Losartan|Placebo tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, losartan tablets will be administered for the next 4 weeks.
9703129|NCT04715568|Experimental|Losartan then Placebo|Losartan tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, placebo tablets will be administered for the next 4 weeks.
9978167|NCT01368796|Active Comparator|Intradermal Tri-valent Influenza vaccine|(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
9978168|NCT01368796|Active Comparator|Trivalent Split-virion Influenza vaccine|Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
9978169|NCT01368861||control|water and normal physical comfort provided by mom
10190639|NCT05292846|Experimental|Uninterruped direct-acting oral anticoagulation|Uninterrupted direct-acting oral anticoagulation in patients undergoing trans-radial percutaneous coronary procedures
10190640|NCT05292625|Experimental|UC-MSC infusion via intravenous route|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
9703130|NCT04715555||Atrial Fibrillation|Participants with a diagnosis of atrial fibrillation (AF) who exhibited AF in previous AF screening (as part of the SAFER Programme).
9703131|NCT04715555||Non-Atrial Fibrillation|Participants without a diagnosis of atrial fibrillation (AF) who have previously undergone AF screening (as part of the SAFER Programme).
9703132|NCT04715217|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
9703133|NCT04715217|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of middle dose group will be intravenously infuse with 2.0×10^6 CAR+Tcells/kg.
9703134|NCT04715217|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of high dose group will be intravenously infuse with 5.0×10^6 CAR+Tcells/kg.
9703135|NCT04715217|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
9703136|NCT04715373|Experimental|DR-LISA|"Experimental:~Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs. A trained physician will perform LISA using Hobart method. Infants requiring FiO2 >0.8 on CPAP 8 cm H2O to maintain SpO2 88-94% by 20 minutes of life will be intubated prior to transport. After admission to the NICU, CPAP will be titrated 5-8 cm H20."
9703137|NCT04715373|Active Comparator|NICU-LISA|Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs and transported to NICU on CPAP. After admission to NICU, CPAP will be escalated every 30 minutes up to a maximum level of 7 cm H2O at which point infant would qualify for LISA if the FiO2 requirement is ≥0.3. LISA will be performed using Hobart method. Infants requiring FiO2 >0.8 to maintain SpO2 88-94% by 20 minutes of life will be intubated in the DR.
9703138|NCT04715256|Experimental|KCNQ1 mutated subjects|"This arm includes :~KCNQ1-mutated subjects with long QT Romano-Ward syndrome~KCNQ1-mutated subjects without phenotypic expression of the Romano-Ward syndrome~family relatives of a KCNQ1-mutated enrolled subject, carrying the KCNQ1 family mutation"
9703139|NCT04715256|Sham Comparator|Healthy subjects|Healthy subjects will be matched to KCNQ1 subjects. The matching factors will be age per decade (18-28 years, > 28-38 years, > 38-48 years), gender and body mass index (BMI: ≤ 24.9 kg/m2; 25-29.9 kg/m2; > 30 kg/m2).
9778792|NCT01116102|Experimental|25 ga needle, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
9778793|NCT01116401|Experimental|GnRH Agonist Injection|We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.
9703140|NCT04715412|Other|Study group|"The standard training sessions were conducted for individual patient by the transplant physician to explain rejections, infections and tumor risks, post-transplant medication. After discharge, all patients had scheduled follow-up visits at the outpatient clinic of the transplant center, where immune suppressant blood levels were measured and their dosing adjusted accordingly. Patients also had the opportunity to discuss any concern of their condition or drug therapy with the transplant physician in charge.~in addition to this standard transplant training, patients received intensified care by a dedicated clinical pharmacist combining educational and technical interventions aiming at achieving and maintaining adherence to his/her prescribed medication and improving health outcomes."
10190641|NCT05292625|Experimental|UC-MSC infusion via intrathecal route|1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication
9703141|NCT04715269|Experimental|Alprazolam Arm|0.5mg Alprazolam will be given to the patient at the time of presentation
9703142|NCT04715269|Placebo Comparator|Placebo Arm|The empty capsule will be given to the patient at the time of presentation
9703143|NCT04715139||Arthrex ProStop®|The ProStop® arthroereisis subtalar implant is intended to assist in treating the hyperpronated foot by stabilizing the subtalar joint. The main goal is to block forward, downward, medial displacement of the talus, and to help in reducing the talonavicular joint, thereby limiting excessive valgus of the hindfoot.
9703144|NCT04715425|Active Comparator|Thoracoscopic ablation|Thoracoscopic ablation
9703145|NCT04715425|Active Comparator|Catheter ablation|Catheter ablation
9703146|NCT04715152|Active Comparator|ACB group|Patients will receive ultrasound-guided (USG) ACB with levobupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline.
9703147|NCT04715152|Placebo Comparator|IA group|Patients will receive intra-articular levobupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline.
9703148|NCT04715178||Patients with suspected or confirmed pediatric solid tumors|Patients with suspected or confirmed pediatric solid tumors
9703149|NCT04715334|Experimental|Single arm study|The intervention is the Mollii suit which is fitted and programmed by the Mollii suit distributor, Inerventions and will be administered by trained physiotherapists from KKH. Participants will be involved in the Intervention phase of the study for 4 weeks with treatment duration of 60 min/ session every day.
9703150|NCT04715360|Other|Control|Only received standard medication (avigan) for severe COVID-19 management
9703151|NCT04715360|Experimental|PRP Group|received standard medication (avigan) for severe COVID-19 management and autologous activated platelet-rich plasma transfusion
9703152|NCT04715295|Experimental|Doxycyclin and Rivaroxaban|Oral Doxycyclin 200 mg daily for 7 days with or without Rivaroxaban
9703153|NCT04715295|Active Comparator|National Standard|Hydroxychloroquine 400 mg daily for 5 days in combination with Azithromycin 500 mg on day 1 and 250 mg daily from day 2 through day 5
9703154|NCT04715282|Other|Epley maneuver|The Epley maneuver was performed for all patients (both EpleyM and EpleyM&Exe groups) included in this study until nystagmus had disappeared in each position. If nystagmus/vertigo was not seen, the Epley maneuver was not performed for patients at the 1st, 3rd, and 6th week assessments.
9703155|NCT04715282|Other|Cawthorne-Cooksey exercises combined with the Epley maneuver|Additional Cawthorne-Cooksey exercises were prescribed to the EpleyM&Exe group. The physiotherapist explained and demonstrated the exercises to each patient and the patients practiced the exercises until they performed them correctly. Then the exercises were prescribed twice a day and repeated 10 times for 6 weeks as a home exercise program.
9703156|NCT04715503|Experimental|PET-IA|68Ga-DOTANOC 18F-FDG
9703157|NCT04715490|Experimental|The Multimedia Symptom Management Program Intervention|The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support.
9703158|NCT04715490|Active Comparator|Control group|Participants in the control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
9703159|NCT04715165|Active Comparator|Group I|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline.
9703160|NCT04715165|Placebo Comparator|Group II|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
9703161|NCT04715477||Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
10190642|NCT05292625|Other|control arm|standard stroke treatment and rehabilitation therapy
10190643|NCT05292599|Experimental|Supervised|All participants in this arm will receive physiotherapy treatment that includes craniocervical flexion exercise (CCFE), isometric flexion exercises (IFE), isometric extension exercises (IEE), self-resistance exercise for neck flexion and extension (RFE), self-resistance exercise for neck rotation (RRE), midscapular exercise (ME) in 2 sessions for week, 60 minutes each, for 8 weeks. CCFE will focus on the recruitment of the deep cervical flexor muscles and will be performed from lower to higher complexity. Each of the exercises will be for 3 sets of 10 repetitions with 10 seconds of isometric contraction during the 8 weeks. IFE and IEE consist of 3 sets of 8 repetitions with 6 seconds of isometric contraction, for 6 weeks. For self-resistance exercises, the patient performs RFE and RRE. These exercises will be performed with 3 sets of 8 repetitions with 6 seconds of isometric contraction during the 8 weeks. The ME will be performed in 3 sets of 8 repetitions during the 5 weeks.
10190644|NCT05292599|Active Comparator|No supervised|The participants will perform the same exercises as the supervised group. However, in this arm will be instructed to perform the same exercises as the experimental group at home, without any supervision. These instructions will be given by the physiotherapist through videos and/or photos.
9703162|NCT04714944|Placebo Comparator|Placebo|isocaloric placebo
9703163|NCT04714944|Experimental|whole fiber product|15 g for 2 weeks, followed by 30 g for 10 weeks
9703164|NCT04714931|Other|Sentinel Lymph Node|Sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
10190645|NCT05292248|Experimental|CONFIDENCE Education Intervention|Participants will attend the 5-week CONFIDENCEProgram. This program will include attending 5 group-based sessions delivered by videoconference. Each session will last approximately 1.5 hours each and will cover topics such as how to budget, accessing community resources to displace the out-of-pocket costs of caregiving, asking for help, balancing employment and caregiving, and more.
9703167|NCT04715048|Experimental|Onabotulinumtoxin A|8-10 units of Botox will be injected in the glabellar lines in one side of the face in 3 different locations. This injection will happen once.
9703168|NCT04715048|Experimental|Prabotulinumtoxin A|8-10 units of Jeuveau will be injected in the glabellar lines in the other side of the face in 3 different locations. This injection will happen once.
9703169|NCT04715061|Experimental|Cancer patients with MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition (with MRI), then randomly MICE condition and HIIT condition (with MRI).
9703170|NCT04715061|Experimental|Cancer patients without MRI|9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition, then randomly MICE condition and HIIT condition, all without MRI.
9703171|NCT04715061|Active Comparator|Healthy patients|9 healthy patients will be recruited and received 2 experimental conditions : first the rest condition (with a MRI), then HIIT condition (with MRI).
9703172|NCT04715035|Active Comparator|Conventional treatment|
9978170|NCT01368861||sucrose|sugar and normal physical comfort provided by mom
9978171|NCT01368861||physical intervention|physical intervention using the 5 S's and water
10190646|NCT05292053|Experimental|COPD subjects|COPD with or without asthma
10190647|NCT05291650|Active Comparator|glucocorticoid injection into infrapatellar fat pad|
10190648|NCT05291650|Placebo Comparator|placebo injection into infrapatellar fat pad|
10190649|NCT05291559|Experimental|Enterade (VS001)|237 mL (8 fluid oz) per os, once daily for 14 days
10190650|NCT05291559|Placebo Comparator|Placebo|237 mL (8 fluid oz) per os, once daily for 14 days
10190651|NCT05291143|Experimental|Intervention arm|This arm will get the educational video intervention
10190652|NCT05291026|No Intervention|control group|Type 2 diabetes patients, 18 years old and above, enrolled in the out-patient, diabetes clinic of the tertiary health facility, receiving only standard of care, and who gave their informed consent
9703173|NCT04715035|Experimental|Conventional treatment + eccentric exercises|
9703174|NCT04714788|Experimental|Intervention group RECAP_MyLife mobile app|Participants in the intervention group will be instructed to use the mobile app daily for four weeks.
9703175|NCT04714788|Active Comparator|Control group|Comparator will be the usual data collection method applied by the cohorts.
9703176|NCT04714801|Active Comparator|Infusion of 100 million ASC|Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors
9703177|NCT04714801|Active Comparator|Infusion of 200 million ASC|Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors
9703178|NCT04714801|Placebo Comparator|Infusion of placebo|Infusion of saline
10190653|NCT05291026|Experimental|intervention group|type 2 diabetes patients, 18 years old and above, enrolled in the out-patient diabetes clinic of the tertiary health facility, receiving standard of care in addition to a mobile phone - based health education and follow-up messaging on a frequency of once a day corresponding to how often they are expected to take their medications (that is every day), and who gave their informed consent.
10190654|NCT05290246|Experimental|Time restricted eating|daily 8 hour eating window
10190655|NCT05290246|Active Comparator|Caloric Restriction|reduction of caloric intake by 15%
9703179|NCT04714684|Experimental|fitostimoline proctogel|
9703180|NCT04714684|Experimental|fitostimoline proctogel + muscle relaxants|
9703181|NCT04714684|Experimental|muscle relaxants|
9703182|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9703183|NCT04715113|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9778794|NCT01116427|Experimental|Abatacept|Receives abatacept during first course of treatment, switching to placebo during extension phase.
9978172|NCT01368861||physical intervention and sucrose|Physical intervention using the 5 S's and sugar water
9978173|NCT01368887|Experimental|1|DPS-102
9978174|NCT01368887|Placebo Comparator|2|Vehicle
9978175|NCT01368887|Active Comparator|3|Calcipotriol Monotherapy
9978176|NCT01368887|Active Comparator|4|Nicotinamide Monotherapy
9978177|NCT01368913||Patients treated with orally disintegrating tablet|
10190656|NCT05288985|Experimental|Erector spinae plane catheter group in addition to Systemic Analgesia|
10190657|NCT05288985|Active Comparator|Systemic Analgesia Only Group|
10190658|NCT05288790|Experimental|Study Supplement|Probiotic
10190659|NCT05288790|Placebo Comparator|Study placebo|Placebo
10190660|NCT05288712|Experimental|Experimental: Training protocol with the cervical device for treatment (CDAT).|"Endurance and stabilization training program of deep cervical flexors with the cervical device for treatment.~Endurance and stabilization training program of deep cervical extensors with the cervical device for treatment."
10190661|NCT05288712|Active Comparator|Conventional training protocol:|"Endurance and stabilization training program of deep cervical flexors with conventional protocol.~Endurance and stabilization training program of deep cervical extensors with conventional protocol."
10190662|NCT05288712|No Intervention|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
10190663|NCT05288634|Experimental|Experimental|Routine maintenance and Progressive relaxation exercise practice
10190664|NCT05288634|No Intervention|Control|Routine maintenance
10204442|NCT01923662|Experimental|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
10190665|NCT05288621|Experimental|electroacupuncture at'four sacral points'|The participants in the electroacupuncture at'four sacral points'group will receive treatment that consists of 8 acupuncture sessions over an 4-week period after baseline (2 sessions in each week), each for 30 minutes. Hua Tuo brand disposable acupunctureneedles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.The device will be set at a frequency of 2.0 Hz, continuous wave and a moderate intensity the patient can tolerate. Electrostimulation will be performed for 30 min during each treatment. BL30 (Baihuanshu )(both sides and BL35 (Huiyang )(both sides), were selected as acupoints protocol.BL30 is located on either side of the sacrococcygeal joint, approximately 1 cm from the joint. BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
9703184|NCT04715113|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9703185|NCT04715113|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9703186|NCT04715009||participants use smartphone less than 4 hours per day|participants use smartphone less than 4 hours per day
9703187|NCT04715009||participants use smartphone more than 4 hours per day|participants use smartphone more than 4 hours per day
9703188|NCT04714723|Experimental|Routine education group|350-400 subjects aged 20-65 years with high metabolic risk
9703189|NCT04714723|Experimental|Programmed smartphone intervention group|350-400 subjects aged 20-65 years with high metabolic risk
9978178|NCT01368913||Patients treated with tablets|
9978179|NCT01368926|Experimental|Part 1|
9703190|NCT04714723|Experimental|Programmed smartphone plus dietitian intervention group|350-400 subjects aged 20-65 years with high metabolic risk
9703191|NCT04714762|Experimental|Intervention (eMOM GDM application)|Participants in the intervention group will use the eMOM GDM -application one week/month. The participants will also receive regular antenatal care in maternity clinics and hospitals. In addition they will meet a study nurse (measurements) three times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum).
9703192|NCT04714762|No Intervention|Control|Participants in the control group will meet a study nurse (measurements) 3 times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). They also receive regular antenatal care in maternity clinics and hospitals.
9703193|NCT04714827|Experimental|Low Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 1.0×10^6 CAR+T cells/kg.
9703194|NCT04714827|Experimental|Middle Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2.5×10^6 CAR+T cells/kg.
9703195|NCT04714827|Experimental|High Dose Group|CD19-BCMA CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5.0×10^6 CAR+T cells/kg.
9703196|NCT04714827|Experimental|Amplification Dose Group|CD19-BCMA CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 1.0-5.0×10^6 CAR+Tcells/kg.
9703197|NCT04715087|Other|Atopic dermatitis patients|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be re-applied (via patchtest) to AD patient. After reading the patch test results, skin biopsies will be performed
9978180|NCT01368926|Experimental|Part 2|
9978181|NCT01368952|Active Comparator|Pure Prone Positioning|Sleeping in prone position by pure prone positioning device, which consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
9703198|NCT04715087|Other|Healthy controls|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. After reading the patch test results, skin biopsies will be performed.
9703199|NCT04714697|Experimental|Cohort 1(post nivolumab and ipilimumab combination)|the subject who failed one prior line by nivolumab and ipilimumab
9703200|NCT04714697|Experimental|Cohort 2 (post pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, or avelumab and axitinib)|the subject who failed one prior line by PD-1/PD-L1 inhibitors in combination with VEGF TKI
9703201|NCT04714697|No Intervention|Cohort 3 (post sequential immunotherapy after VEGFR TKI)|the subject who failed the second line by immunotherapy (PD-1 antibody or PD-L1 antibody) following the first line VEGFR TKI
9703202|NCT04714658|Experimental|Immediate PTE|
9703203|NCT04714658|Other|6-month deferred PTE|
9703204|NCT04714645|Experimental|Intervention group|VR+ training
9703205|NCT04714645|Sham Comparator|Control group|VR- training
9703206|NCT04714307||Symptomatic|Molecularly diagnosed SCA3/MJD Symptomatic subjects.
9703207|NCT04714307||Non-related Controls|Controls matched with symptomatic by age and educational level.
9703208|NCT04714307||At 50% risk for SCA3/MJD group|The offspring of affected individuals with SARA<3. This group will be comprised of two subpopulations: pre-symptomatic individuals and related controls. The determination will be made upon molecular diagnosis to be done in a double-blind manner.
9703209|NCT04714268||Procedures with EndoNaut|Endovascular interventions using the EndoNaut workstation. 3D image fusion is used for overlaying arterial information on top of fluoroscopic images
9703210|NCT04714268||Procedures without EndoNaut|Control group, endovascular interventions without 3D image fusion
9978182|NCT01368952|No Intervention|Baseline|No intervention for sleep position
9978183|NCT01368978|Experimental|Test (with the InsuPatch device)|Device use
9978184|NCT01368978|No Intervention|Control (without the InsuPatch device)|
9978185|NCT01368991|Active Comparator|Kryptonite|Sternal closure with stainless steel and kryptonite
9978186|NCT01368991|Active Comparator|Conventional Closure|Sternal closure with stainless steel wires
10190666|NCT05288621|Active Comparator|conventional electroacupuncture|The participants in the conventional electroacupuncture group will select RN3 (Zhongji), CV4 (Guanyuan), and ST28 (Shuidao, both sides), KL3 (Taixi).A needle measuring 0.25×40 mm will be inserted perpendicularly to a depth of 25- 40 mm to RN3, CV4 and ST28 and 0.5 cun to KL3 to induce a local sensation (distention or sourness).Subsequently, the electrodes from the SDZ-IIB electroacupuncture device will be connected to the needles at these points, with the anode connected to ST28 and RN3, the cathode connected to ST28 and CV4. The protocol includes the same duration, frequency of sessions and the parameter setting of electroacupuncture as for the'four sacral points'treatment.
9703211|NCT04714255|Experimental|TICK-B group as Intervention group|Pediatric patients received TICK-B as a distraction in the TICK-B group Trace Image and Coloring for Kids-Book were conducted on the children undergoing the Cannulation procedure.
9703212|NCT04714255|No Intervention|Standard care provided group as control group|Pediatric patients received standard care (routine care) in the control group.
9703213|NCT04714632||Children with idiopathic scoliosis|Adolescent between 10-18y with diagnosing idiopathic scoliosis
9978187|NCT01369004|Experimental|Daily self-weighing + feedback/lessons|Participants will be instructed to weigh daily and they will receive a smart scale for daily monitoring of weighing via the website bodytrace.com. They will also receive weekly emailed lessons with content related to behavioral weight control (e.g., How to control portion sizes, How to develop an exercise routine) as well as weekly emailed feedback from a registered dietitian on their daily weighing and weight loss progress.
9703214|NCT04714632||Healthy children|Healthy children between 10-18y without any orthopedics problems
9703215|NCT04714450|No Intervention|MMST control|
9703216|NCT04714450|Experimental|MMST+|
9703217|NCT04714580|Experimental|Animal Fun Group|Baseline assessment with MABC-2; Animal Fun activity with a certified trainer (physiotherapist) for one month, three times a week, for 30 minutes; one-month follow-up assessment with MABC-2.
10190667|NCT05288608||Simple palliation|Treatment of patients who are referred for palliative radiotherapy to uncomplicated metastases.
10190668|NCT05288608||Complex palliation|Treatment of patients who require treatment to a site of previous radiation, patients undergoing concurrent systemic therapy, and those requiring a radiation dose exceeding 8 Gy.
9703218|NCT04714580|No Intervention|Control Group|Baseline assessment with MABC-2; normal curricular activity at school with the teachers; one-month follow-up assessment with MABC-2.
9703219|NCT04714606|Experimental|Sibling support group|8 session, tailored support group for siblings of children who have an ASD
9703220|NCT04714606|Active Comparator|Booklet|Control condition in which siblings of children who have an ASD will receive a tailored booklet to complete at home
9703221|NCT04714528|Active Comparator|Physical Exercise Group|45 minutes of aerobic, high intensity group training, three times per week during a 12-week period.
9703222|NCT04714528|Other|Relaxation Group|45 minutes of relaxation therapy once per week for 12 weeks.
9778795|NCT01116427|Placebo Comparator|Placebo, followed by abatacept|Receives a placebo for first course of treatment, switching to abatacept in the extension phase.
9778796|NCT01116440|Experimental|BGS649 co-administered with Levora 28™|
9778797|NCT01116440|Placebo Comparator|Placebo co-administered with Levora 28™|
9778798|NCT01116466|Experimental|ActiGait|Receiving ActiGait - implantable drop foot stimulator
9778799|NCT01116544|Experimental|AMES therapy with EMG biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of EMG activity the subject is able to generate in the hand. This study will examine whether AMES therapy combined with EMG biofeedback can restore hand opening to plegic stroke subjects.
9778800|NCT01116544|Experimental|AMES therapy with Torque biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of torque (force) the subject is able to generate in the hand during the movement. This study will examine whether AMES therapy combined with Torque biofeedback can restore hand opening to plegic stroke subjects.
9978188|NCT01369004|No Intervention|Delayed Intervention Control Group|Participants will receive the same components of the experimental group with the exception of the weekly feedback after the 6-month study period is complete.
9778801|NCT01116661|Experimental|ALA for glioma (WHO G1-IV) subjects|Up to 300 patients with diagnosed glioma (WHO G1-IV) eligible for surgery will be entered into the trial and will be given 5-Aminolevulinic Acid (ALA) orally at a dose of 20mg/kg body weight preoperatively
9978189|NCT01369017|Active Comparator|Anakinra|All subjects will undergo 2 CCRE challenges. Each subject will be given either anakinra or placebo prior to CCRE challenge
10190669|NCT05288517|No Intervention|Control Arm|Control patients received three invitations for a survey only and were blind to the L2L intervention.
9978190|NCT01369017|Placebo Comparator|Placebo|Normal saline injection
9978191|NCT01369043|Active Comparator|Vitamin E and Vitamin C|4 weeks with Vitamin E and Vitamin C supplementation with no exercise and 4 weeks of supplementation with prescribed exercise.
9778802|NCT01116687|Experimental|Treatment (RO4929097)|See detailed description.
9778803|NCT01116739|Experimental|COHS administered fluoride varnish and oral health education|Paraprofessionals, called community oral health specialists (COHS), will be trained to administer fluoride varnish and oral health education to head start children quarterly for 2 years.
9778804|NCT01116739|Active Comparator|Usual care|Usual care will include regular dental services provided by the Indian Health Service.
9778805|NCT01116882|Active Comparator|SOS|Patients randomized to the SOS arm are transferred to tertiary hospitals for their PCI procedure.
9778806|NCT01116882|Experimental|Non-SOS|Patients in the non-SOS arm are randomized to stay at the community hospitals for their PCI procedure.
9778807|NCT01116895|Active Comparator|LEO 22811 0.5 mg|LEO 22811 0.5 mg: Oral solution
9778808|NCT01116895|Active Comparator|LEO 22811 1.5 mg|LEO 22811 1.5 mg: Oral solution
9778809|NCT01116895|Active Comparator|LEO 22811 3.0 mg|LEO 22811 3.0 mg: Oral solution
10190670|NCT05288517|Active Comparator|Lock to Live Intervention Arm|Patients in the Intervention Arm received the invitation to Lock to Live, including up to 3 EHR invitation messages plus three messages to complete a follow-up survey evaluating study outcomes.
10190671|NCT05288205|Experimental|Dose escalation|
10190672|NCT05288205|Experimental|Dose expansion|
10190673|NCT05287243|Other|Inspiratory Muscle Training|involves the intervention portion of the study to improve strength of the cardiopulmonary system
10190674|NCT05286632|Experimental|KidneYou APP|"In patients randomized in Group A (intervention group) the NP program will be administered by means of App KidneYou. Each patient will select the assigned daily menu or the proposed alternatives, following instructions reported for breakfast, mid-morning snack, lunch, afternoon snack, and dinner.~Patients randomized to Group A (intervention group) will be administered the PA program by means of App KidneYou. Each patient will follow the assigned exercise program (i.e., recommended type of PA, minutes of exercise/day, number of days/week, level of intensity).~Only patients randomized to Group A (KidneYou users) will be invited by the investigator to follow stress-reducing activities. This difference between the two groups is based on the nature of the mindfulness program, consisting solely of multimedia contents."
10190675|NCT05286632|No Intervention|Standard of care control group|"In patients randomized in Group B (control group) the NP program will be administered by means of a paper diary containing the entire range of daily menu and related alternatives needed to terminate the 3-month study period.~Patients randomized to Group B (control group) will be administered the PA program by means of a paper diary containing the entire range of exercises needed to terminate the 3-month study period.~The stress reduction program is not a standard of care currently used within the treatment strategy of CKD patients, neither through face-to-face visits with a specialist, nor through multimedia content.~Patients provided with paper diary and randomized in Group B (KidneYou non-users) represent the population followed by the current standard of care and will not be provided with any multimedia content in the context of their participation in the present study."
10190676|NCT05286112|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT delivered over the course of 8, ~60 minute sessions
9703223|NCT04714489||experimental group|
9703224|NCT04714554|Experimental|Part 1: Relugolix/E2/NETA Plus Erythromycin|"Treatment Period 1: Healthy premenopausal women will receive a relugolix/E2/NETA (40 mg/1 mg/0.5 mg) alone on Day 1.~Treatment Period 2: Healthy premenopausal women will receive erythromycin on Day 1 through 12 (500 mg, QID), with co-administration of a single dose of relugolix/E2/NETA (40 mg/1 mg/0.5 mg) with the morning dose of erythromycin on Day 8."
9703225|NCT04714554|Experimental|Part 2: Relugolix Plus Erythromycin|"Treatment Period 1: Male participants will receive a single 120-mg dose of relugolix alone on Day 1.~Treatment Period 2: Male participants will receive erythromycin on Days 1 through 12 (500 mg, QID), with co-administration of a single 120-mg dose of relugolix with the morning dose of erythromycin on Day 8."
9703226|NCT04714593|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
9703227|NCT04714593|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2×10^6 CAR+T cells/kg.
9703228|NCT04714593|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5×10^6 CAR+T cells/kg.
9703229|NCT04714593|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
9978192|NCT01369043|No Intervention|Placebo|Placebos instead of the Vitamin E and Vitamin C supplements
9978193|NCT01369056|Experimental|Advanced Adherence Counseling (AdvAdh)|Please see the Intervention Description section
9703230|NCT04714242||Patients underwent anti-VEGF therapy|intravitreal Anti-VEGF therapy: Three monthly intravitreal injections
9703231|NCT04714242||Control Group|Healthy eyes without actual and previous ocular diseases
9703232|NCT04714463||Immediate breast reconstruction|Women undergoing immediate breast reconstruction due to breast cancer or a high risk for breast cancer
9703233|NCT04714463||Delayed breast reconstruction|Women undergoing delayed breast reconstruction due to breast cancer or a high risk for breast cancer
9703234|NCT04714476|Experimental|Fit test of made-to-measure garments|Healthy subjects will test made-to-measure compression garments
9703235|NCT04714229|Experimental|EuMCV4|Healthy adults received 0.5mL single intramuscular dose on Day 0.
9703236|NCT04714229|Active Comparator|Menveo|Healthy adults received 0.5mL single intramuscular dose on Day 0.
9703237|NCT04714567||Patients with severe asthma|Patients of all ages with severe asthma included in the RAG.
9703238|NCT04714515||Hydroxychloroquine and Montelukast|Group 1 was given Standard of care (SOC) + HCQ + Montelukast
9703239|NCT04714515||Montelukast|Group 2 was given Standard of care (SOC) + Montelukast
9703240|NCT04714515||Hydroxychloroquine|Group 3 was given Standard of care (SOC) + HCQ
9703241|NCT04714515||Hydroxychloroquine, Montelukast and Invermectin|Group 4 was given Standard of care (SOC) + Montelukast + HCQ and Ivermectin
9703242|NCT04714424||Participants undergoing vision exams|
9703243|NCT04714502||Infants enrolled in AAMBI1|
9703244|NCT04714294|Experimental|SAD: Each volunteer will receive 6 mg, 10mg, 20mg, 40mg(or TBD) of IP once daily for 1 day|Drug: HPP737 or placebo One 1 mg capsule and one 5mg capsule taken orally (by mouth) once daily for SAD arm 1/ Two 5mg capsule taken orally (by mouth) once daily for SAD arm 2/ Four 5mg capsule taken orally (by mouth) once daily for SAD arm 3/ Eight 5mg capsule taken orally (by mouth) once daily for SAD arm 4
9703245|NCT04714294|Experimental|MAD: Each volunteer will receive 10mg, 20mg, 40mg(or TBD) of IP once daily for 7 days|Drug: HPP737 or placebo Two 5mg capsule taken orally (by mouth) once daily for MAD arm 1/ Four 5mg capsule taken orally (by mouth) once daily for MAD arm 2/ Eight 5mg capsule taken orally (by mouth) once daily for MAD arm 3
9703246|NCT04714541|Experimental|Ketogenic Diet Adoption Followed by Ketamine Infusion|All 5 Participants Will Be Educated to Adopt a Ketogenic Diet, As Outpatient. After at Least 4 Weeks on the Diet, They Will Have A Series of Titrated Intravenous Ketamine Infusions Over A 2 Week Period
9778810|NCT01116895|Placebo Comparator|Placebo|Placebo: Oral solution
9703247|NCT04713969|Experimental|Functional dyspepsia patients before and after PPI|Pantoprazole 40mg twice daily in functional dyspepsia patients for 4 weeks
10190677|NCT05286112|Active Comparator|Health Education|Health education sessions delivered over the course of 8, ~60 minute sessions
9978194|NCT01369056|No Intervention|Control|Standard of care (including counseling regarding antiretroviral treatment adherence) received by HIV/AIDS patients at the study clinic
9978195|NCT01369082||CIT Islet Transplantation Recipients|"Subjects who received an islet-cell transplant for Type 1 Diabetes (T1D) while enrolled in one of the Clinical Islet Transplantation (CIT) parent studies and continue to have islet graft function. All subjects will continue immunosuppressive medications under CIT08. Detailed follow-up evaluations including but not limited to islet function will occur on an annual basis.~The immunosuppressive medications (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate mofetil [MMF], mycophenolic sodium) in this study are obtained by prescription unless provided by the study through the drug distributor. Generic brands are allowed, when available. Antibacterial, antifungal, and antiviral prophylaxis, insulin therapy, and other standard therapies will be provided per site-specific practices."
9978196|NCT01369121|Experimental|Xerecept|All patients will receive hCRF (XERECEPT)
9978197|NCT01369160||1|Chronic Transfusion
10190678|NCT05283252|Experimental|Guided Endodontic Micro-Surgery|Use of the 3-D printed guide in endodontic micro-surgery
10190679|NCT05283252|Placebo Comparator|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
9978198|NCT01369160||2|hydroxyurea
10204443|NCT01858922|Experimental|Rapid Early Responders|All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients with rapid early response (RER) determined by FDG-PET/CT scan after two cycles of ABVE-PC will receive two more cycles of ABVE-PC. If subsequent PET/CT scan indicates a complete response (CR), therapy will stop and regular follow-up will begin. If the subsequent PET/CT for RER patients indicates a partial response, those patients will undergo IFRT.
10204444|NCT01858922|Experimental|Slow Early Responders|"All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients determined to have a slow early response (SER) determined by PET/CT scan after two cycles of ABVE-PC will receive 2 courses of DECA. If after PET/CT, the patient has a partial or complete response, then 2 additional courses of ABVE-PC will be given. If subsequent PET/CT scan indicates PR or CR, those patients will then undergo IFRT.~If stable or progressive disease is found at either PET/CT scan, the patient will be taken off-study and follow up will begin."
10204445|NCT01844726|Experimental|GLYX-13|Single IV infusion of GLYX-13, 5mg/kg,
9978199|NCT01369160||3|matched sibling donor stem cell transplantation (MSD-SCT)
9978200|NCT01369160||4|standard comprehensive care (SCC, control)
10204446|NCT01844726|Placebo Comparator|Placebo|Single IV administration of placebo
9703248|NCT04713969|No Intervention|Healthy controls before PPI|Baseline investigations
9703249|NCT04714164|Experimental|Teletherapy Group CBT participants|Patients over the age of 65 with either a Major Depressive Disorder or Generalized Anxiety Disorder who will be participating in a Group CBT delivered by Teletherapy
9703250|NCT04714073|Experimental|Reference: BI 706321 alone|First treatment period
10204447|NCT01781637|Experimental|omalizumab group|Patients will receive omalizumab.
10204448|NCT01781637|Placebo Comparator|placebo|Patients will receive placebo.
9703251|NCT04714073|Experimental|Test: BI 706321 + Itraconazole|Second treatment period
9703252|NCT04713930|Experimental|JNJ-61393215|Participants will receive one of 3 single oral doses of JNJ-61393215 on Day 1, escalated sequentially based on the safety review in Cohorts 1, 2, and 3 up to Day 5.
9703253|NCT04713930|Active Comparator|Placebo|Participants will receive a single oral dose of placebo on Day 1 in Cohorts 1, 2, and 3 up to Day 5.
9703254|NCT04714125||Patients with COVID-19|Patients hospitalized with COVID-19 from the General Hospital of the University of Sao Paulo, Brazil.
9703255|NCT04714060|Experimental|cohort 1|2.5 mg/kg UB-621 group
9703256|NCT04714060|Experimental|cohort 2|5 mg/kg UB-621 group
9703257|NCT04714112|Experimental|preoperative group|Intravenous dexamethasone (5mg) is used when ultrasound guided ISB is performed.
9703258|NCT04714112|Active Comparator|postoperative group|Ultasound guided ISB is performed before operation and intravenous dexamethasone (5mg) is used in postoperative care unit ( PACU)
10204449|NCT01773278|Experimental|antioxidant effects on retinal function|Patients with SLOS will be treated with both cholesterol supplementation and antioxidants. Retinal function will be followed by serial electroretinogram (ERG) testing and pigmentary retinopathy will be followed by Serial Ophthalmologic exams under anesthesia
10204450|NCT01773278|Experimental|antioxidant effects on hearing|Patients with SLOS will be treated with cholesterol and antioxidant medication and their hearing will be followed by serial brainstem audiometry (ABR)
9703259|NCT04713943|Experimental|>Your< Iron Syrup|
9703260|NCT04713943|Other|Placebo|
9703261|NCT04713865||PFA slightly jailed by proximal SFA stent(100 pts)|
9703262|NCT04713865||PFA moderately jailed by proximal SFA stent(100 pts)|
9703263|NCT04713865||PFA totally jailed by proximal SFA stent (100pts)|
9703264|NCT04714008||Active gamblers in 2019/2020|Three panels of 40 000 gamblers active in 2019 and 2020, either in France or Sweden
9703265|NCT04714008||Newly registered gamblers in 2019 or 2020 (France and Sweden)|Six panels of 10 000 gamblers who newly registered either during the period of March-May 2019 or of March-May 2020, either in France or Sweden
9703266|NCT04714099|Experimental|Topical CsA|Group A received topical CsA 0.05% for 3 months
9978201|NCT01369173|Active Comparator|Mexican Menu|24 days, all foods and drinks provided, menu consists of traditional mexican meals
9978202|NCT01369173|Active Comparator|US diet|24 days, all foods and drinks provided, menu consists of foods commonly eaten in contemporary United States
9978203|NCT01369186|Active Comparator|Morphine|Vendal 5 mg i.v. bolus injection
9978204|NCT01369186|Placebo Comparator|Placebo|Sodium chloride 0.9% i.v. bolus injection
9978205|NCT01369212|Experimental|Tenofovir|Tenofovir 192 weeks
9703267|NCT04714099|Placebo Comparator|Control|Placebo group
9703268|NCT04713956|Experimental|G-CSF+DAC+BF|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
9703269|NCT04713956|Active Comparator|G-CSF+DAC+BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo- HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 to -2.
10190680|NCT05283083|Experimental|Dexmedetomidine|"Patients will receive dexmedetomidine infusion according to the protocol plus the usual care.~We will evaluate patients for inclusion in the study after 6 hours on NE infusion, given stabilization of the MAP > 65 mmHg. In the DEX group, we will commence DEX infusion at the rate of 0.2 mcg.kg-1.h-1 without a loading dose, then titrate DEX infusion to maintain the HR from 60 to 90 bpm.~Titration of the DEX infusion rate will not be more than 0.1 mcg.kg-1.h-1 every 30 minutes at any time. The maximum DEX infusion rate will be 0.7 mcg.kg-1.h-1.~We aim to continue DEX infusion for 48 hours. After 48 hours of DEX infusion, we will taper the DEX infusion over one hour.~According to our protocol, DEX infusion would trigger either STOP events or hemodynamic assessment events:"
10190681|NCT05283083|No Intervention|Usual care without dexmedetomidine infusion|The patients in this group will receive the usual care.
10190682|NCT05282940|Experimental|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
10190683|NCT05282940|Active Comparator|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the test marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
9978206|NCT01369212|Experimental|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks
9703270|NCT04714021|Experimental|Single steep arm- CO2 insufflation|PEG will be performed by single step technique and CO2 will be insufflated during the endoscopy
10190684|NCT05282316|Active Comparator|EVOO polyphenols enriched|Fifteen subjects with metabolic syndrome will be randomly enrolled each year (3 years of study planned), to the addition of 40 ml daily of healthy polyphenols enriched EVOO to their mediterranean diet for the duration of six months
10190685|NCT05282316|Placebo Comparator|EVOO standard|Fifteen subjects with metabolic syndrome will be randomly enrolled each year (3 years of study planned), to the addition of 40 ml daily of standard EVOO to their mediterranean diet for the duration of six months
10190686|NCT05279352|Experimental|Treatment Arm|FBR-002 at 4.3 EU/kg on D1 and D3 or FBR-002 at 5.7 EU/kg on D1 and D3
10190687|NCT05279352|Placebo Comparator|Placebo Arm|Two administrations of placebo at D1 and D3
10190688|NCT05278676|Experimental|Cohort A Single Dose: Dotinurad|Participants will receive dotinurad 1 milligram (mg) (1*1 mg tablet) as a single oral dose after 10-hour fasting on Day 1 in the morning.
9978207|NCT01369238|Experimental|Bee Venom Acupuncture & zaltoprofen|
10190689|NCT05278676|Experimental|Cohort B Multiple Dose: Dotinurad|Participants will receive dotinurad 4 mg (2*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning. A washout period of 3 days will be maintained after single dose on Day 1 and then participants will receive dotinurad 4 mg (2*2 mg tablets) after 10-hour fasting from Day 4 to Day 10 once daily in the morning.
9703271|NCT04714021|Active Comparator|Single steep arm- air insufflation|PEG will be performed by single step technique and air will be insufflated during the endoscopy
9703272|NCT04714021|Experimental|Pull technique arm- CO2 insufflation|PEG will be performed by pull technique and CO2 will be insufflated during the endoscopy
9703273|NCT04714021|Active Comparator|Pull technique arm- air insufflation|PEG will be performed by pull technique and air will be insufflated during the endoscopy
9703274|NCT04714177|Experimental|Edaravone Dexborneol|Edaravone Dexborneol injection
9703275|NCT04714177|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
9703276|NCT04713878|Active Comparator|Group 1|Intubated without comorbidity
9703277|NCT04713878|Active Comparator|Group 2|Intubated with comorbidity
9703278|NCT04713878|Active Comparator|Group 3|No intubated
9703279|NCT04714203||cohort|Sarcopenia assessment
9703280|NCT04713839||Participants|The participants were invited to the study, then each participant was asked to complete the self-report questionnaires.
9703281|NCT04713904|Experimental|Clormadinone Ethinyl estradiol Test Product|
9703282|NCT04713904|Active Comparator|Clormadinone Ethinyl estradiol Reference Product|
9703283|NCT04713917|Active Comparator|Gel Group|Two applications of HA gel (Mucogyne®) per week during one year.
9703284|NCT04713917|Experimental|Laser Group|Laser CO2 for vulvovaginal area during 2 sessions (15 min) at visits D0 and M6.
9703285|NCT04713917|Experimental|HA Injection Group|Injection of 1 mL of HA at D0 and M6 (DESIRIAL®).
9703286|NCT04713891|Experimental|Phase 1a: Cohort 1|KF-0210 tablet will be administered at 120 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
9703287|NCT04713891|Experimental|Phase 1a: Cohort 2|KF-0210 tablet will be administered at 240 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
9703288|NCT04713891|Experimental|Phase 1a: Cohort 3|KF-0210 tablet will be administered at 450 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
9785062|NCT01241604|Active Comparator|Respironics BiPAP Auto SV3|Treatment arm using Respironics BiPAP Auto SV3
9978208|NCT01369238|Active Comparator|zaltoprofen|
9978209|NCT01369238|Active Comparator|Bee Venom Acupuncture|
9978210|NCT01369251|Experimental|Hygiene with water and soap|
9978211|NCT01369251|Active Comparator|Usual alcohol care|
9703289|NCT04713891|Experimental|Phase 1a: Cohort 4|KF-0210 tablet will be administered at 600 mg as a single agent orally once daily (QD) continuously in cycles (1 cycle=21 days) until the disease progression, intolerance, or informed consent withdrawal.
9703290|NCT04713891|Experimental|Phase Ib, Cohort 1|KF-0210 (dose RP2D-2, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
9703291|NCT04713891|Experimental|Phase Ib, Cohort 2|KF-0210 (dose RP2D-1, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
10190690|NCT05278676|Experimental|Cohort C Single Dose: Dotinurad|Participants will receive dotinurad 10 mg (5*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning.
10190691|NCT05278611|Experimental|EP-9001A|Dose-escalation trial
10190692|NCT05278611|Placebo Comparator|Placebo|Dose-escalation trial
10190693|NCT05278221|Other|Healthy volunteers|Each healthy volunteer during Part I of the study will receive every 2 weeks a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo. All healthy volunteers will perform tests using the new software that combines Transcranial Magnetic Stimulation Combined With EEG/EMG,
10190694|NCT05278221|Other|Patients with focal epilepsy|Patients during Part II, will receive the treatment according to the treating physician's discretion, regardless of the protocol, either with Lacosamide, 300 mg p.o. or Brivaracetam, 100 mg p.o. All patients will perform tests using the new software that combines Transcranial Magnetic Stimulation Combined With EEG/EMG,
10190695|NCT05277402|Experimental|Dose escalation|ADG116 combination treatment with pembrolizumab, both drugs will be administered in each cohort.
9703292|NCT04713891|Experimental|Phase Ib, Cohort 3|KF-0210 (dose RP2D, orally once daily)+ Atezolizumab (1200 mg every 3 weeks) continuously until disease progression/recurrence or death from any cause, or serious adverse events (SAE) observed (whichever occurs earlier) for up to 2 years.
9703293|NCT04713683|Active Comparator|Amplatzer PFO Occluder|Patients randomized in this arm will be implanted with Amplatzer PFO Occluder.
9703294|NCT04713683|Active Comparator|Gore Cardioform Septal|Patients randomized in this arm will be implanted with Gore Cardioform Septal Occluder.
9703295|NCT04713800|Experimental|ZR-TiB|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR)
9703296|NCT04713800|Active Comparator|PFM-GA|Porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM)
9703297|NCT04713787|Experimental|Group A|400 mg (4 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
9703298|NCT04713787|Experimental|Group B|800 mg (8 capsules of 100 mg) of Oxfendazole administered orally as a single dose on Day 1. N=83.
9703299|NCT04713787|Active Comparator|Group C|400 mg (1 tablet of 400 mg) of Albendazole administered orally as a single dose on Day 1. N=83.
9703300|NCT04713670|Experimental|(A) T-V14|
9703301|NCT04713670|Experimental|(B) T-V7|
9703302|NCT04713670|Experimental|(C) D-V14|
9703303|NCT04713670|Experimental|(D) HD-V14|
9703304|NCT04713670|Experimental|(E) BQ-V14|
9703305|NCT04713670|Experimental|(F) RH-V14|
9703306|NCT04713670|Experimental|(G) BQ-L14|
9703307|NCT04713670|Experimental|(H) T-L14|
9703308|NCT04713644||Burst Suppression|Patients who present burst suppression after standardized propofol administration during anesthetic induction
9703309|NCT04713644||No Burst Suppression|Patients who did not present burst suppression after standardized propofol administration during anesthetic induction
9703310|NCT04713696|Experimental|Functional training|Participants received functional training
9703311|NCT04713696|Active Comparator|Routine training|Participants received routine training
9703312|NCT04713488|Experimental|Sputnik Light Vaccine|solution for intramuscular injection Composition for 1 dose (0.5 ml): Active substance: recombinant serotype 26 adenoviral particles containing the SARS-CoV-2 S protein gene, in the amount of (1.0±0.5) x 10*11 particles per dose.
9703313|NCT04713735|Placebo Comparator|Control: Placebo|Control: Placebo
9703314|NCT04713735|Experimental|Investigational: 600 mg bovine lactoferrin supplement|Investigational: 600 mg bovine lactoferrin supplement
9703315|NCT04713761|Experimental|Toripalimab|
9703316|NCT04713566|Experimental|Group A|will be using Salvadora Persica oral rinse
9703317|NCT04713566|Experimental|Group B|will be using Commercial Phenolic mouthwash.
9703318|NCT04713436||Triple antibiotic paste(TAP)|ciprofloxacin, metronidazole and minocycline
9703319|NCT04713436||Doble antibiotic paste(DAP)|ciprofloxacin and metronidazole
9703320|NCT04713436||Modified triple antibiotic paste(mTAP)|ciprofloxacin, metronidazole and cefaclor
9703321|NCT04713631|Active Comparator|Artesunate and Curcumin|Artesunate 200 mg PO once a day x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
9703322|NCT04713631|Active Comparator|Artesunate and Placebo C|Artesunate 200 mg PO once a day x 2 weeks. Placebo C x 13 weeks.
9703323|NCT04713631|Active Comparator|Curcumin and Placebo A|Placebo A x 2 weeks. Curcumin 2 gm PO once a day x 13 weeks.
9703324|NCT04713631|Placebo Comparator|Placebo A and Placebo C|Placebo A x 2 weeks. Placebo C x 13 weeks.
9703325|NCT04713254|Experimental|Lu AG06466|
9703326|NCT04713059||patients with CPS ≥ 1 or MSI-H or TMB ≥ 10Mb/MUT|
9703327|NCT04713059||patients with CPS =0 , MSS and TMB < 10Mb/mut|
9703328|NCT04713306||Participants in the Swedish Neuro Register|Participants are patients with parkinsonian symptoms
9778811|NCT01116921|Active Comparator|nCPAP Control Group|Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
9778812|NCT01116921|Experimental|LMA Group|Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
9778813|NCT01116934||PLS patients|Eight PLS patients (one female) from 6 families.
10190696|NCT05277051|Experimental|Participants receiving GSK4381562 monotherapy|
9703329|NCT04713085|Active Comparator|Sacral Nerve Stimulation|"Sacral nerve stimulation is surgically implanted within three surgeries:~Implantation of a test stimulation system for 3 weeks: A trail electrode is implanted to neuronal fibers of S3/4 on both sides as a confirmatory diagnostical step. Stimulation is conducted via an external pulse generator.~Implantation of the final electrode (tined-lead electrode). The stimulation remains to be generated externally by an external pacemaker.~Implantation of the internal pacemaker system 4 weeks after the electrode's implantation.~Stimulation parameters: Single current, frequency 15Hz, duration 210μs. Stimulation intensity is individually determined beyond the pain threshold (adjustable amplitude between 0-10mA, depending on the intraoperative response).~Start point of clinical evaluation is time of implantation of tined lead electrode.~Medical and behavioral therapy is to be continued as started before intervention and can be adjusted under neuromodulation."
9703330|NCT04713085|Active Comparator|Non-invasive Sacral Nerve Stimulation|"Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field by single current with a 15 Hz frequency for a duration of 210μs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).~Start point of clinical evaluation is start of external stimulation.~Medical and behavioral therapy is to be continued as started before intervention and can be adjusted under neuromodulation."
10190697|NCT05277051|Experimental|Participants receiving GSK4381562 plus dostarlimab|
10190698|NCT05277012|Experimental|Treatment sequence ABC|Participants will be sequentially administered with Treatment A, B then C (Treatment A: etrumadenant capsule in fasted state; Treatment B: etrumadenant tablet in fasted state; Treatment C: etrumadenant tablet in fed state). Each treatment will be separated by a washout period of 7 days.
10190699|NCT05277012|Experimental|Treatment sequence BCA|Participants will be sequentially administered with Treatment B, C then A. Each treatment will be separated by a washout period of 7 days.
9978212|NCT01369264|Experimental|True Left High Frequency|True left high frequency repetitive transcranial magnetic stimulation
9703331|NCT04713397||LLD group|Patients who have functional scoliosis due to structural LLD
10190700|NCT05277012|Experimental|Treatment sequence CAB|Participants will be sequentially administered with Treatment C, A then B. Each treatment will be separated by a washout period of 7 days.
10190701|NCT05275959|Other|Intervention|The intervention consisted of four components: a) Create supportive school and family environment, b) Health lifestyles education and related compulsory physical activities, c) Instruct and promote school physical education, d) Self-monitor obesity related behaviors. Four types of outcomes including anthropometric, behavioral, blood chemical and physical fitness were measured to assess the effectiveness of the intervention program.
10190702|NCT05275959|No Intervention|Control|health education class
10190703|NCT05275569|Experimental|True acupuncture + standard antiemetic treatment|
9703332|NCT04713397||LLD concurrent with AIS|Patients who have structural LLD concurrent with AIS
9978213|NCT01369264|Placebo Comparator|Passive sham left high frequency|Passive sham left high frequency repetitive transcranial magnetic stimulation
9984339|NCT04209621|Other|Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Duvelisib with ibrutinib will be administered for the first six 28-day (± 7) cycles followed by duvelisib alone until disease progression or intolerance. Duvelisib is an orally administered at 15 mg twice a day (dose level 1) or 25 mg twice day (dose level 2). Subjects will continue the same dose of ibrutinib prior to study enrollment for the first six 28-day cycles. Ibrutinib is an orally administered and provided as 140 mg white opaque capsules or tablets in 4 strengths: 140 mg, 280 mg, 420 mg, and 560 mg.
9984340|NCT04209465|Experimental|Phase 1 - Dose escalation|In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
9984341|NCT04209465|Experimental|Phase 2 - Dose expansion|In Part B, patients with a solid tumor harboring specific allosteric HER2 mutations or an HER2 or EGFR exon 20 insertion mutation will receive the recommended Phase 2 dose of BDTX-189. It is expected that approximately 100 participants will be enrolled in this phase 2 portion.
9984342|NCT04207983|Experimental|Treatment Arm A (Re-administration)|Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.
9984343|NCT04207983|Experimental|Treatment Arm B (Single administration)|One administration of EYS606 (135μg pEYS606/90 μL) at the baseline visit (V1).
9703333|NCT04713124|Experimental|R2C-M intervention|"R2C-M telephone intervention - Six approximately weekly sessions of R2C-M telephone-delivered intervention (50 minutes in duration), delivered by the same R2C-M Counsellor each session (a qualified clinical psychologist trained in the R2C protocol by the developer, Dr Kate Hall). Call duration will be recorded. Sessions will be digitally recorded, and an independent researcher will randomly select and rate fidelity of intervention sessions for 20% of participants.~R2C-M workbooks - Two workbooks to facilitate counsellor-delivered exercises within sessions, and between-session practice, will be mailed/emailed to participants.~Self-help booklet - (as in control group) R2C-M participants will also receive a booklet of information and self-help strategies for methamphetamine use problems."
9778814|NCT01116934||Healthy controls|Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.
9785063|NCT01241760|Experimental|001 T(q8h) / PR|Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
10190704|NCT05275569|Placebo Comparator|Sham acupuncture + standard antiemetic treatment|
10190705|NCT05275010|Active Comparator|Arm 1: PH FDC SC Administered Using a Handheld Syringe with Hypodermic Needle|
10190706|NCT05275010|Experimental|Arm 2: PH FDC SC Administered Using the On-Body Delivery System|
10190707|NCT05274958|Experimental|Initial PROM plus monthly PROM plus educational video|These patients receive usual care plus monthly PROMs and educational video(s) while on the waitlist
10190708|NCT05274958|No Intervention|Usual Care|Patients will complete the initial bundle of PROMs, then no further PROMs while they remain on the waitlist
10190709|NCT05273008||Active hockey players|Observational study on 180 Hockey players
10190710|NCT05272527|Experimental|Intervention Group|After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Within the scope of the Transition to Motherhood Program, 5-session training and phone follow-ups were made in the first week and the fourth week postpartum to the experimental group. Post-tests were applied to the experimental group at the postpartum 1st month and 4th month.
10190711|NCT05272527|No Intervention|Control Group|After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Pretest and postpartum 1st month and 4th month posttests were applied to the control group.
10190712|NCT05272046|Active Comparator|Monopolar Electrocautery tool|Patients randomized into this group will receive the standard of care monopolar tool for their POEM procedure.
10190713|NCT05272046|Experimental|Bipolar Electrocautery tool|Patients randomized into this group will receive the standard of care bipolar tool for their POEM procedure.
9703334|NCT04713124|Active Comparator|Control|"Self-help booklet - Control participants will receive (by mail/email) a booklet of information and self-help strategies for methamphetamine use problems.~Telephone check-ins + information on further support - (to control for frequency of contact across treatment arms) Participants in this group will receive 6 telephone calls from the research team (lasting maximum 5 minutes, call duration will be recorded). During these calls, participants will be asked about their use of the booklet. Whenever required, the researcher will provide participants with information on further support (e.g. DirectLine or other state/territory AOD helpline for advice or referral)."
9978214|NCT01369277|Experimental|Japanese cohort|A total of 12 Japanese healthy subjects will be allocated to receive 3 ascending single doses (100 mg, 300 mg and 750 mg) of PF-04991532 or placebo through 3 dosing periods in a randomization ratio of 3:1.
9978215|NCT01369277|Experimental|Weterner Cohort|9 western healthy subjects will be enrolled to receive 2 single ascending doses (300 mg and 750 mg) of PF-04991532 through 2 dosing periods.
9703335|NCT04713176|Experimental|DWJ1248 with Remdesivir|Camostat mesylate 200 mg, Remdesivir
9703336|NCT04713176|Placebo Comparator|Placebo with Remdesivir|Placebo, Remdesivir
9703337|NCT04713384|Experimental|Treatment|Participants will undergo 4 weeks (20 sessions) of experimental rehabilitation in their home. They will play custom therapeutic games that are intensive and adapt to their condition. Before and after the 4-week intervention participants will travel to Kessler Foundation to undergo evaluations. The therapy is designed to improve arm range, strength, endurance, as well as memory, focusing and decision making. Data will be stored on the cloud, protected and monitored by the research team.
9978216|NCT01369290||Drug 1|Venlafaxine
10190714|NCT05271799|Experimental|Participants receiving gepotidacin powder for oral suspension followed by tablet|
10190715|NCT05271799|Experimental|Participants receiving gepotidacin tablet followed by powder for oral suspension|
10190716|NCT05270759||Hospitalized patients receiving hemodiafiltration|"Adult patients hospitalized in the intensive care unit (ICU) or general ward receiving hemodiafiltration treatments as least 3 times per week with ≥1L of fluid removal per session~Exclusion criteria:~Planned hospital discharge, death, or transition to comfort care within 48 hours according to the attending physician~End of active care (awaiting hospital discharge)~Planned blood product transfusions during the session"
10190717|NCT05270460|Experimental|PCS12852 0.1mg|PCS12852 0.1mg tablet
10190718|NCT05270460|Experimental|PCS12852 0.5mg|PCS12852 0.5mg tablet
10190719|NCT05270460|Placebo Comparator|Placebo|Similar in appearance to active study drug
10190720|NCT05269368|Experimental|No wicking|Absence of Wicking after intervention
10190721|NCT05269368|Active Comparator|Control|Wicking after intervention
10190722|NCT05269004|Experimental|Ocrelizumab|Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046). Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.
10190723|NCT05266612|Experimental|3+3 design|This is an open label, single-arm trial using standard 3+3 design, in up to 24 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients.
10190724|NCT05264389||Poly-Tape Device|Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
9703338|NCT04713371|Other|Single arm. Subjects receiving treatment.|Efficacy of Cryosurgical Freezing and Multiplex Immunochemotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria.
9703339|NCT04713410|Experimental|Group A|Steroids will be given for short duration of time i-e 12 weeks
9703340|NCT04713410|Active Comparator|Group B|Steroid will be given for longer duration i-e 20 weeks
9703341|NCT04713345|Experimental|Experimental group|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
9785064|NCT01241760|Experimental|002 T(b.i.d.) / PR|Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
9978217|NCT01369290||Drug 2|Bupropion
9978218|NCT01369290||Drug 3|Escitalopram
9978219|NCT01369290||Drug 4|Duloxetine
9978220|NCT01369290||Psychotherapy|Cognitive behaviour therapy
9978221|NCT01369303|Experimental|Daily dosing|Tenofovir 1% gel will be inserted each day or evening at about the same time with the last study-sex 12 hours after the final dose
9978222|NCT01369303|Experimental|BAT24 dosing|Tenofovir 1% gel will be inserted 1 hour before and 1 hour after sex
9978223|NCT01369303|Experimental|Pericoital dosing|Tenofovir 1% gel will be inserted either 1 hour before sex OR 1 hour after sex
10190725|NCT05264363|Experimental|Intervention|The main intervention is the application of the Investigational Medical Device (VIPUN Gastric Monitoring System prototype) together with the reference device (solid state high-resolution manometry) to record intraluminal pressure. The planned procedures are identical for all subjects in this single-arm investigation.
9978224|NCT01369316|Experimental|Circumferential Submucosal Incision Resection|
9978225|NCT01369316|Active Comparator|Endoscopic Mucosal Resection|Patients randomised into this arm will receive the conventional treatment Endoscopic Mucosal Resection in which the sessile lesion is injected and snared by piecemeal technique.
9703342|NCT04713345|Sham Comparator|Control group|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
9703343|NCT04713215||Patients where MCAs are currently being used|Intervention: Patient questionnaire - Part A - patients where MCAs are currently being used
9703344|NCT04713215||Patients where an MCA was discontinued|Intervention: Patient questionnaire - Part B - patients where an MCA was discontinued
9978226|NCT01369368|Experimental|1|Azacitidine, valproic acid, all-trans retinoic acid, hydroxyurea, eventually donor leukocyte infusions
9978227|NCT01369381|Experimental|Airtraq laryngoscope|The Airtraq is an alternative indirect laryngoscope that appears to cause less cervical spine motion during intubation that conventional direct laryngoscopy (Macintosh blade)
9978228|NCT01369381|Active Comparator|Macintosh laryngoscope|This arm constitutes intubation with a conventional direct laryngoscopy with a Macintosh blade which has been shown to result in cervical spine extension, particularly in the upper cervical segments.
9703345|NCT04713215||Patients where an MCA was declined|Intervention: Patient questionnaire - Part C - patients where an MCA was declined
9703346|NCT04713215||Carers where MCAs are currently being used|Intervention: Carer questionnaire - Part A - carers where MCAs are currently being used
9703347|NCT04713215||Carers where an MCA was discontinued|Intervention: Carer questionnaire - Part B - carers where an MCA was discontinued
9703348|NCT04713215||Carers where an MCA was declined|Intervention: Carer questionnaire - Part C - carers where an MCA was declined
9703349|NCT04713228|Experimental|Pregnant with Pre-eclampsia|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
9703350|NCT04713228|Experimental|Pregnant with gestational hypertension|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
9703351|NCT04713228|Active Comparator|Pregnant without Hypertension - Control|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit is not applicable to the control group.
9703352|NCT04713111|Other|Lifestyle Intervention Group (Exercisers)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace, 2 or more times a week for a duration of 4 weeks."
9785065|NCT01241903|Experimental|Crestor|
9785066|NCT01241903|Placebo Comparator|sugar pill|
9978229|NCT01369394|Experimental|Tailored information|Individuals assigned to the experimental group will receive individually-tailored educational messages.
9978230|NCT01369394|Active Comparator|Untailored information|Individuals assigned to the control group will receive generic, untailored educational messages.
9978231|NCT01369407||Enrolled Subjects|Enrolled subjects participate for up to 2 years
9978232|NCT01369446||Women undergoing IVF treatment|
9984344|NCT04204811||Participants with Ovarian Cancer|Participants are diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian tube carcinoma)
9984345|NCT04203329||Paroxysmal A-Fib|
9984346|NCT04203329||Persistent A-Fib|
9978233|NCT01369459|Experimental|Family Counseling with MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
9978234|NCT01369459|No Intervention|Historical Control|
9978235|NCT01369472|Experimental|Dilatrend SR capsule 8mg|
9978236|NCT01369472|Experimental|Dilatrend SR capsule 16mg|
9978237|NCT01369472|Experimental|Dilatrend SR capsule 32mg|
9978238|NCT01369472|Experimental|Dilatrend SR capsule 64mg|
9978239|NCT01369472|Experimental|Dilatrend SR capsule 128mg|
9978240|NCT01369524||ICUpatient with need of fluid|age > 18 - haemodynamic monitoring - informed consent - admission on ICU
9703353|NCT04713111|Other|Lifestyle Intervention Group (Meditators)|"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation.~Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks."
9703354|NCT04713111|No Intervention|Garmin wearable arm|Existing stress and recovery participants were invited to participate in a Garmin wearable arm where they were provided a Garmin Vivoactive 4 smartwatch to wear continuously, and in particular, while they were on shift at work for a total of 4 consecutive weeks.
9703355|NCT04713111|No Intervention|Hair cortisol arm|Interested existing stress and recovery participants were invited to participate in a one time hair sample collection for cortisol analysis.
9978241|NCT01369537||adults > 65 yrs undergoing noncardiac surgery|
9978242|NCT01369550|Placebo Comparator|High-oleic sunflower oil-containing foods|Subjects will consume 3 servings of foods containing high-oleic sunflower oil plus 3x500 mg high-oleic sunflower oils softgels per day.
9978243|NCT01369550|Active Comparator|Eicosapentaenoic acid|Subjects will consume 3 x 500 mg eicosapentaenoic acid ethyl ester in softgels plus 3 servings of high-oleic sunflower oil-containing foods per day
9978244|NCT01369550|Experimental|SDA soybean oil-containing foods|Subjects in this arm will consume 3 servings of SDA soybean oil-containing foods plus 3 x 500 mg high-oleic sunflower oil softgels per day.
9978245|NCT01369576|Placebo Comparator|Placebo|Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
9978246|NCT01369576|Experimental|zopiclone|Sleep apnea OSR Medical Treatment plan ©
9978247|NCT01369602|Experimental|healthy controls|healthy subjects (creatinine clearance > 90 mL/min)
10190726|NCT05264298|Experimental|VIRTUAL Intervention (Treatment)|Participants assigned to intervention arm will have scheduled video telehealth appointments with a multidisciplinary team (Stroke provider, social worker, pharmacist) and remote telemonitoring of blood pressure with blood pressure medication adjustments biweekly as needed by pharmacists.
9978248|NCT01369602|Experimental|ESRD / severe renal insufficiency|Severe (creatinine clearance 15 to 29 mL/min) OR ESRD (creatinine clearnace <15 mL/min OR requiring dialysis)
9978249|NCT01369602|Experimental|Moderate renal impairment|Moderate (creatinine clearance = 30 to 59 mL/min)
10190727|NCT05264298|Active Comparator|Standard Care|Participants assigned to standard care will follow-up with a stroke provider within 2 weeks of discharge and primary care as per usual recommendations. Participants will monitor their blood pressure on their own and pharmacists will contact participants monthly to review blood pressure. Pharmacists will make recommendations for blood pressure medication adjustment to participant primary care provider.
10190728|NCT05260242|Experimental|Conversation|Scripted interaction
10190729|NCT05260242|No Intervention|No Conversation|Control Group
10190730|NCT05260125|Experimental|Ultrasound-guided Suprascapular Nerve Block|Ultrasound-guided Suprascapular Nerve Block
10190731|NCT05260125|Active Comparator|Anatomical Landmark-guided Suprascapular Nerve Block|Anatomical Landmark-guided Suprascapular Nerve Block
10190732|NCT05255653|Experimental|p53abn-RED trial: experimental|Adjuvant chemoradiation followed by olaparib (lynparza), 300 mg twice daily, for two years
10190733|NCT05255653|Active Comparator|p53abn-RED trial: control|Adjuvant chemoradiation
9978250|NCT01369602|Experimental|Mild renal impairment|Mild (creatinine clearance = 60 to 89 mL/min)
9978251|NCT01369628|Experimental|Arm 1|"1 arm with the 3 following dose regimens:~Regimen 1: Atacicept 25 mg weekly for 12 weeks~Regimen 2: Atacicept 75 mg weekly for 12 weeks~Regimen 3: Atacicept 150 mg weekly for 12 weeks"
9978252|NCT01369654|Experimental|Computerized decision aid|
9978253|NCT01369667|Active Comparator|vitamin D|Capsule, one taken daily
9978254|NCT01369667|Placebo Comparator|Placebo|Capsule, one taken daily
9978255|NCT01369693|Active Comparator|General Portion 1 g pouch|
9978256|NCT01369693|Active Comparator|Catch Licorice Portion 1 g pouch|
9978257|NCT01369693|Active Comparator|Catch Licorice Portion Mini 0.5 g pouch|
9978258|NCT01369693|Active Comparator|Catch Licorice Portion Dry Mini 0.3 g pouch|
9978259|NCT01369719|Experimental|Osveral|20 mg/kg oral osveral daily
9978260|NCT01369719|Active Comparator|desferal|40mg/kg desferal for 6 nights in a week subcutaneously
10190734|NCT05255653|Experimental|MMRd-GREEN trial: experimental|Adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab, 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles)
10190735|NCT05255653|Active Comparator|MMRd-GREEN trial: control|Adjuvant pelvic external beam radiotherapy
10190736|NCT05255653|Experimental|NSMP-ORANGE trial: experimental|Adjuvant pelvic external beam radiotherapy followed by oral progestagens (medroxyprogesterone acetate or megestrol acetate) for two years
10190737|NCT05255653|Active Comparator|NSMP-ORANGE trial: control|Adjuvant chemoradiation
10190738|NCT05255653|Experimental|POLEmut-BLUE|no adjuvant therapy for stage I-II disease and no adjuvant therapy or pelvic external beam radiotherapy only for stage III disease
10190739|NCT05254847|Experimental|combined treatment group|Capecitabine combined with lenvatinib and tislelizumab: Lenvatinib,8mg po. qd.Tislelizumab,200mg iv. q3w. Capecitabine 1250mg/m^2 bid.d1-d14 q3w
10190740|NCT05253911||Cohort 1|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 1st or 2nd palliative therapy line.
10190741|NCT05253911||Cohort 2|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 3rd or 4th palliative therapy line.
10190742|NCT05250115||Evaluate the effectiveness, usage and patient characteristics of real-world use of Abrocitinib|"This is a 36-month, prospective, non-interventional, multicenter study to evaluate the effectiveness, usage and patient characteristics of real-world use of Abrocitinib in patients with moderate to severe AD in a real-world setting.~Eligible patients will be followed up from the date of first Abrocitinib prescription for 12 months. Patients who are switched from the initial Abrocitinib therapy to other therapies will be further followed. Patient documentation is expected quarterly as per standard clinical practice."
10190743|NCT05250037||Screening (spirometry measurements)|Patients undergo home spirometry measurements with a portable handheld spirometer and complete questionnaires weekly, a nasal swab for viral PCR surveillance bi-weekly, and undergo blood collection and nasal and oral swabs every 3 months for up to 1 year.
10190744|NCT05249725|Experimental|Irsogladine Maleate|
9978261|NCT01369771|Experimental|Tafluprost 0.0015%|Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.
10190745|NCT05249725|Placebo Comparator|Hydrotalcite|
10190746|NCT05249699|Experimental|Positive TSPOT results with clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
10190747|NCT05249699|Placebo Comparator|Negative TSPOT results with clinical risk factors group|patients receive no additional therapy
10190748|NCT05249699|Experimental|Clinical risk factors group|patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge
10190749|NCT05246345||Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax|Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax
10190750|NCT05245812|Experimental|Treatment arm (SPrNSM)|Patients will undergo Single Port robotic Nipple Sparing Mastectomy (SPrNSM) with immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm)
10190751|NCT05244213|Experimental|Sintilimab plus chemo|3 cycles of neoadjuvant Sintilimab (200mg every 3 weeks) with nab-paclitaxel and carboplatin (nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including EGFR-TKIs for up to 1 year or till disease progression or unacceptable toxicity.
9785067|NCT01241916|Experimental|Static-progressive splint|
9785068|NCT01241916|Experimental|Dynamic Splint|
9978262|NCT01369797|No Intervention|reference|"reference group, where every patient will benefit: of the same GGA at home as those of the  specific intervention  group. The GGA results will not be supplied to the family practioner."
10190752|NCT05243745|Experimental|Test Product|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Test product is a combination toothpaste of 3% methyl vinyl ether/maleic anhydride co-polymer (PVM/MA) + 5% Potassium Nitrate (KNO3). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); Participants will be permitted to rinse with water post-brushing.
10190753|NCT05243745|Active Comparator|Comparator 1|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Comparator 1 toothpaste is containing 3% PVM/MA. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
10190754|NCT05243745|Active Comparator|Comparator 2|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Comparator 2 toothpaste is containing 5% KNO3. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
10190755|NCT05243745|Other|Negative Control|Participants will dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion. Negative control is regular fluoride toothpaste. Participants will brush their two selected 'test teeth' first, followed by the whole mouth for one timed minute, twice daily (morning and evening); participants will be permitted to rinse with water post-brushing.
10190756|NCT05241535|Experimental|Sequence 1 (starting with MT-7117 or Placebo)|"Treatment A or B (a single oral dose of MT-7117 or Placebo), Treatment C (a single oral dose of moxifloxacin), then Treatment A or B (a single oral dose of placebo or MT-7117)."
10190757|NCT05241535|Experimental|Sequence 2 (starting with MT-7117 or Placebo)|Treatment A or B (a single oral dose of placebo or MT-7117), Treatment A or B (a single oral dose of MT-7117 or Placebo), then Treatment C (a single oral dose of moxifloxacin).
10190758|NCT05241535|Experimental|Sequence 3 (starting sequence with Moxifloxacin)|Treatment C (A single oral dose of moxifloxacin), Treatment A or B (a single oral dose of placebo or MT-7117), then Treatment A or B (a single oral dose of MT-7117 or Placebo).
10190759|NCT05235880|Experimental|study group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
10190760|NCT05235880|Active Comparator|control group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
10190761|NCT05235425|Active Comparator|Standard NDPP|12-month long, calorie-restricted NDPP
10190762|NCT05235425|Experimental|Very low-carbohydrate diet (VLCD)|VLCD is an adaptation of the standard NDPP curriculum, which preserves all features with the exception of altered dietary advice.
10190763|NCT05234437|Experimental|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at 3.6mg/m2 given at a minimum of 28-day intervals.
9703356|NCT04713189|Experimental|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
9703357|NCT04713189|Experimental|Placebo|Participants in the stage I were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
9703358|NCT04713163||Health care or laboratory-based workers|Healthy individuals about to receive any approved COVID-19 vaccine
9703359|NCT04713163||Outpatients|Outpatients about to receive any approved COVID-19 vaccine
9703360|NCT04713332|Active Comparator|vitamin E|Oral intake of Vitamin E treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. Patients in the group receiving 500 IU of d-alpha-tocopherol capsules orally (3 times daily).
9978263|NCT01369797|Experimental|specific intervention|"specific intervention group, where every patient will benefit: of an GGA at home. According to the frailties or the detected morbidity, a specific plan of intervention will be established for the person. all the preventive actions will be coordinated by UPSAV."
9978264|NCT01369810||1|All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
9703361|NCT04713332|Active Comparator|Hydrogen rich water|Oral intake of HRW (2 ppm) treatment will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The group of patients receiving Hydrogen water took an amount of 250 ml orally 3 times a day.
9703362|NCT04713332|Placebo Comparator|placebo|Oral intake of placebo will be given on a daily basis in a single-blind manner one day before the first day of RT and continued for 8 weeks. The placebo group received 3 soft gel placebo capsules containing gelatin three times a day.
9703363|NCT04713007|Experimental|Group 1|Supportive Care Materials and Resources
9703364|NCT04713007|Experimental|Group A|Ted Talks/Educational videos
9703365|NCT04712981|Experimental|Intervention|HOPE intervention peer-led online community
9703366|NCT04712981|No Intervention|Control|Online community without HOPE intervention psychological components
9703367|NCT04712955|Active Comparator|Bloodflow restricted exercise|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRRE) conducted as 4 sets of bilateral knee extensions at 30% of 1RM until voluntary fatigue. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
10190764|NCT05231473|No Intervention|Standard|The participants are assigned according to the implanted and functioning program of each center. In this case, without Nurse Enhanced Recovery After Surgery Coordinator. It will be the control group. ERAS program will be working without this role.
9703368|NCT04712955|No Intervention|Non-exercise control|No intervention.
9703369|NCT04712929||Homogenous oral leukoplakia|"uniform, flat, thin, smooth/ wrinkled/corrugated surface throughout the white lesion.~Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days"
9703370|NCT04712929||Non-Homogenous oral leukoplakia|mixture of red and white lesions with a irregularly speckled/ nodular/ verrucous surface Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a mouth rinse for 2 minute and swallowed) once a day for 14 days
9703371|NCT04712929||Control group|30 healthy controls ( age and sex matched) would also be recruited from patients who are reporting for other routine dental problems.
9978265|NCT01369836|Experimental|20 mg soft gelatin capsule|
9978266|NCT01369836|Experimental|40 mg (20 mg*2) soft gelatin capsule|
9703372|NCT04712994|Experimental|PrEP Optimization Strategies|Up to 16 facilities will be assigned one of four intervention groups (4 facilities per group). One of the intervention groups is pre-identified (PrEP video counselling, HIV Self-Testing, and optimized delivery and prescription processes), however the other 4 strategies have no yet been identified but will be through other activities in the PrEPARE study.
9703373|NCT04712994|No Intervention|Comparator|Up to 4 facilities will be assigned to the comparator group.
9778815|NCT01116986|Experimental|1, Patch, Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
10190765|NCT05231473|Experimental|Nurse Coordinator|The participants are assigned according to the implanted and functioning program of each center. In this case, with Nurse Enhanced Recovery After Surgery Coordinator. It will be the intervention group. ERAS program will be working with this role.
9978267|NCT01369836|Active Comparator|Placebo|
9978268|NCT01369862|Placebo Comparator|SPGNH buffer|SPGNH buffer administration by liquid nasal spray
9978269|NCT01369862|Experimental|GHB16L2|Dose level ~7.0 log10 fTCID50/strain/person
9978270|NCT01369901|Experimental|Group A|Functional exercise
9978271|NCT01369901|Active Comparator|Group B|Stretching exercise
10190766|NCT05229640|Other|Fibroscan|One study visit for fibroscan measurement of the liver.
10190767|NCT05227079|Active Comparator|Group A (double bite forceps)|Participants in group A will proceed to have their biopsies during endoscopy taken with the conventional double bite forceps. Meaning, they will have two biopsies taken each time the forcep is passed through the endoscope. To obtain a total of six biopsies, the forceps will be passed through the endoscope a total of three times.
9978272|NCT01369940||NICHD Fetal Growth Study - Twin Gestations|"Women with dichorionic twin gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2012-2013) in this prospective cohort study.~Intervention: No intervention"
9978273|NCT01369979||Patients with chronic liver disease|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
9778816|NCT01116986|Experimental|2, Patch, Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9785069|NCT01242085|Active Comparator|control group|control group will have standard instrumentation of their knee replacement
10190768|NCT05227079|Experimental|Group B (multiple bite forceps)|Participants in group B will have their biopsies during endoscopy retrieved with the multiple bite forceps. Meaning, they will have six consecutive biopsies taken with each pass through the endoscope.
10190769|NCT05224102|Experimental|Faricimab|
10190770|NCT05223816|Experimental|Safety Run-in Cohort|10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
10190771|NCT05223816|Experimental|Cohort 2 (HCC)|21 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
10190772|NCT05223816|Experimental|Cohort 3 (ICC)|20 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days.
10190773|NCT05215119||Immediate|NC endometrial preparation will start immediately after blastocyst cryopreservation confirmation.
9984347|NCT04203329||A-Fib|
10190774|NCT05215119||Delayed|NC endometrial preparation will start on day 1 of the patient's 2nd menstruation after the oocyte retrieval cycle menstruation or in a subsequent cycle.
10190775|NCT05211414|Experimental|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
10190776|NCT05210530|Experimental|VCTX210A combination product|Up to ten (10) units will be implanted
10190777|NCT05207709|Experimental|Ribociclib + Endocrine Therapy|Ribociclib + Fulvestrant or Letrozole
10190778|NCT05207709|Experimental|Palbociclib + Endocrine Therapy|Palbociclib + Fulvestrant or Letrozole
10190779|NCT05207709|Experimental|Paclitaxel - Exploratory cohort|Additional experimental Cohort that includes patients with Basal-Like intrinsic subtype.
10190780|NCT05207306|Experimental|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA) group|Patients receiving right M-TAPA.
10190781|NCT05207306|Experimental|Subcostal transversus abdominis plane block (subcostal TAPB) group|Patients receiving right subcostal TAPB.
10190782|NCT05207111|Experimental|Revefenacin Inhalation Solution, 175 mcg/3 mL|
10190783|NCT05206994|Experimental|Close to Home Intervention|Sites receiving the intervention arm were determined prior to the initiation of the research. The rape crisis center in each community applied for funding from the California Department of Public Health to implement the Close to Home model in their community and they were accepted via a competitive application process. Close to Home (C2H) is a community mobilization model developed in Boston and adapted for California and is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms.
10190784|NCT05206994|No Intervention|Control Program|"The control program is the 4-H Youth Development Program, which is implemented across every county in California via the University of California Cooperative Extension. In 4-H programs, kids and teens complete hands-on projects in areas like health, science, agriculture and civic engagement in a positive environment where they receive guidance from adult mentors and are encouraged to take on proactive leadership roles. The model does not use community mobilization and does not address sexual violence.~Control communities were selected based on propensity score matching using sociodemographic and community-level variables related to risk for sexual violence. The closest match was recruited first, and a next-best match was used if the first match declined participation."
10190785|NCT05206942|Experimental|Doppler Ultrasound|Patients receiving standard of care immune checkpoint inhibitor are followed with the ultrasound studies at treatment baseline, 3 weeks and 6 weeks.
10190786|NCT05205746|Experimental|Intramuscular|10 8.0 EID 50/dose intramuscular
10190787|NCT05205746|Experimental|Intranasal|10 8.0 EID 50/dose intranasal
10190788|NCT05205746|Other|Intramuscular Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intramuscular After mask opening ChAdOx-1-S[recombinant]) Intramuscular
10190789|NCT05205746|Other|Intranasal Placebo|Physiological saline solution of Sodium Chloride at 0.9% Intranasal After mask opening ChAdOx-1-S[recombinant]) Intramuscular
10190790|NCT05203653|Experimental|All participants|All participants will undergo two separate testing sessions
10190791|NCT05203640|Experimental|All participants|All participants will be in a single arm that undergoes two separate interventions. These interventions will include a high repetition, low resistance protocol, and a moderate repetition, moderate intensity protocol.
10190792|NCT05202223|Experimental|Harmony at HOME|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
10190793|NCT05201287|Experimental|VIA Disc NP|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 or 2 levels, L1-S1.
10190794|NCT05201248|Experimental|Cohort 1 Part 1: Epcoritamab Monotherapy|Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
10190795|NCT05201248|Experimental|Cohort 1 Part 2: Epcoritamab Expansion|Participants will receive SC epcoritamab in 28 day cycles.
10190796|NCT05201248|Experimental|Cohort 2: Epcoritamab + RCHOP|Participants will receive SC epcoritamab in combination with [intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)] in 28 day cycles.
10190797|NCT05201248|Experimental|Cohort 3: Epcoritamab + R2|Participants will receive SC epcoritamab in combination with [intravenously (IV) infused rituximab, and oral lenalidomide (R2)] in 28 day cycles.
10190798|NCT05199688|Experimental|Cohort 1: Participants with body weight ≥10kg to <20kg|Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients
10190799|NCT05199688|Experimental|Cohort 2 Participants with body weight ≥20kg to <40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
9978274|NCT01369979||Healthy subjects|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
9978275|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® administered via AeroChamber Plus™ spacer
9978276|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™|Clenil® Modulite® administered via Volumatic™ spacer
9978277|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block
9703374|NCT04712630|Experimental|NIPSA without grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
9703375|NCT04712630|Active Comparator|NIPSA with grafting biomaterial|A single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied and the bone defect will be filled with a composite of xenograft and enamel matrix derivates. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
9703376|NCT04712552||Stereotactic robot-guided deep brain stimulation procedure|Patients requiring a stereotactic robot-guided deep brain stimulation procedure (Parkinson's disease, disabling tremor, dystonia)
10190800|NCT05199688|Experimental|Cohort 3 Participants with body weight ≥40kg|Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.
9703377|NCT04712734|Experimental|Iloperidone|
10190801|NCT05199610|Experimental|Aumolertinib|single dose oral 55mg of aumolertinib
10190802|NCT05199077|Placebo Comparator|placebo group|Topical administration of a drug-free placebo ointment daily for 28 days.
9703378|NCT04712708|Active Comparator|Control Group|Eighteen children with spastic CP will receive especially designed physical therapy program based on Neuro-Developmental treatment (NDT) approach with emphasis on exercise encourage independent standing, stretches exercises, strengthening exercises, approximation, enhancement and facilitation of gait patterning and ankle ROM exercises for one hour for 24 sessions
9785070|NCT01242085|Experimental|trumatch group|the trumatch patient will have custom instruments made from preop CT scans
9785071|NCT01242111|Experimental|BMN 110|
9785072|NCT01242176|Experimental|BI 10773 Final Formulation|one single film-coated tablet in the morning
9978278|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™ plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
9978279|NCT01370044|Experimental|Verum|Verum arm receiving Carbogen
9978280|NCT01370044|Placebo Comparator|Placebo|Placebo arm receiving oxygen
9978281|NCT01370057|Experimental|Treatment Group|Treatment with bracing
9978282|NCT01370057|No Intervention|Control Group|Watchful waiting without bracing
9978283|NCT01370070|Experimental|MK-2206|
9978284|NCT01370109||Penn Site|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks, with additional follow-up at 1 and 2 years.
10190803|NCT05199077|Active Comparator|cohort A|Topical administration of a 2.5 % GM-XANTHO ointment daily for 28 days.
10190804|NCT05199077|Active Comparator|cohort B|Topical administration of a 5 % GM-XANTHO ointment daily for 28 days.
10190805|NCT05198258|Experimental|Implementation study - experimental group|Physiotherapists in the experimental group (group A) will receive on-line theoretical education including three hours of practical training by the project leaders. The standardized theoretical education includes three 45 minutes on-line lectures. The theoretical education will be followed by three hours practical training including clinical examination in patients with neck disability and instructions how to perform the neck-specific exercises.To facilitate the implementation process, group A will receive additional support; the physiotherapists can contact the project leader via e-mail, phone, online meetings and/or outreach visits
10190806|NCT05198258|Active Comparator|Implementation study - control group|Physiotherapists in the control group (group B) will receive the same theoretical and practical training as group A but without additional support from the research group or education after the first three theoretical on-line lectures and the three hours practical education.
10190807|NCT05195762|Experimental|Patients receiving NFX-179 Gel|NFX-179 Gel 1.50% applied QD for 12 weeks
10190808|NCT05195567|Experimental|Subject glucometer measurement|
10190809|NCT05194995|Experimental|Phase 1b Dose Escalation|Dose escalation of JAB-21822 to determine maximum tolerated dose of JAB-21822 in combination with cetuximab.
10190810|NCT05194995|Experimental|Phase 2 Dose Expansion, Cohort 1|Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
10190811|NCT05194995|Experimental|Phase 2 Dose Expansion, Cohort 2|Enrollment into the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced small intestinal cancer and advanced appendiceal cancer.
10190812|NCT05194735|Experimental|TCR-T Cell Drug Product|"Phase I: Dose-escalation of TCR-T Cell Drug Product~Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study"
9703379|NCT04712708|Experimental|Study Group|ighteen children with spastic CP will receive the same program that the control group received in addition to especially designed exercises using rebound therapy (Mini Trampoline) that include push up exercise, standing, squatting, single limb squatting, kneeling position, catching and throwing a ball over head in kneeling position, catching and throwing a ball over head in standing position, kicking the ball, broad jumping with assistance, jumping in place, for 1 hour three times per week for three successive months.
9703380|NCT04712916|Experimental|Intervention group|Individualized education on medication use, appropriate diet and physical activity was given to the participants in intervention group.
10190813|NCT05194735|Experimental|TCR-T Cell Drug Product with Aldesleukin (IL-2)|"Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2)~Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study"
9703381|NCT04712916|No Intervention|Control group|Participant received usual care in the clinic. No individualized education on medication use, appropriate diet and physical activity was given to the participants.
9703382|NCT04712617||FGIDs|Patient who were diagnosed with NERD/RH, FD, IBS and their overlaps (NERD/RH-FD, NERD/RH-IBS, FD-IBS, NERD/RH-FD-IBS)
9978285|NCT01370109||Vanderbilt University Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
9978286|NCT01370109||Case Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
9978287|NCT01370109||University of Wisconsin at Madison|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
9978288|NCT01370122||Subjects exposed to radiation|
9978289|NCT01370122||Subjects not exposed to radiation|
9978290|NCT01370135|Experimental|Lucentis (Ranibizumab)|
9703383|NCT04712617||Healthy controls|Subjects who underwent GI evaluations as part of health check-up or for other problems, such as mild abdominal discomfort or pain for a relatively short period of time, but had no organic problems during GI endoscopy
9703384|NCT04712760||Transient congenital hypothyroidism|- children with congenital hypothyroidism who are no longer treated with Levothyroxine at an age of 3 years and 6 months
9703385|NCT04712760||Permanent congenital hypothyroidism|- children with congenital hypothyroidism who are still treated with Levothyroxine at an age of 3 years and 6 months
9703386|NCT04712578|Experimental|Caffeinated Pre-workout Supplement|This arm will consist of ingestion of the commercially available, caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
10190814|NCT05193916|Experimental|Chiglitazar low dose|3 tablets of drug and 1 tablet of placebo p.o. per day
10190815|NCT05193916|Experimental|Chiglitazar high dose|4 tablets p.o. per day
10190816|NCT05193916|Placebo Comparator|control group|4 placebo tablets p.o. per day
10190817|NCT05192863||Participants with CD|Participants diagnosed with moderately to severely active CD who are initiating vedolizumab intravenous (IV) induction treatment with the option to switch to vedolizumab subcutaneous (SC) treatment, as maintenance therapy in accordance with the current SmPC will be observed prospectively for 18 months.
9703387|NCT04712578|Active Comparator|Non-Caffeinated Pre-Workout Supplement|This arm will consist of ingestion of the commercially available, non-caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
9703388|NCT04712578|Placebo Comparator|Placebo|This arm will consist of a flavor-matched placebo beverage without the active components contained in the supplements administered in the other study arms.
9703389|NCT04712786||Group|27 patients, Group 1 consisted of patients with pseudophakic rhegmatogoneous retinal detachment who underwent pars plana vitrectomy and 12% perflouropropane (C3F8) gas tamponade and 20 patients Group 2 consisted of patients with epiretinal membrane or vitreous hemorrhage who underwent PPV without any tamponade
9703390|NCT04712695|Experimental|Graded Motor Imagery Group|
9703391|NCT04712695|Experimental|Mirror Visual Feedback Group|
9703392|NCT04712695|Experimental|Augmented Biofeedback Group|
9703393|NCT04712695|Sham Comparator|Diaphragmatic Breathing Group|
9703394|NCT04712773|Other|Cardiac surgery patients|Patients scheduled for elective cardiac surgery (CABG or valve surgery).
9703395|NCT04712539|Experimental|Arm I (oseltamivir, baloxavir marboxil)|Patients receive oseltamivir PO BID for up to 10 days and baloxavir marboxil PO every 72 hours for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
9703396|NCT04712539|Active Comparator|Arm II (oseltamivir)|Patients receive oseltamivir PO BID for up to 10 days in the absence of disease progression or unacceptable toxicity.
9703397|NCT04712825|Active Comparator|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions
9703398|NCT04712825|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis sessions
9703399|NCT04712799|Experimental|COPD patients|Wlaking tests before and afrer 1 spray with oxymetazoline
9978291|NCT01370148|Experimental|Subjects with severe hepatic impairment|
9978292|NCT01370148|Active Comparator|Subjects with normal hepatic function|
9978293|NCT01370161|Experimental|TIPS treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
9978294|NCT01370161|Active Comparator|Medical treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.
9978295|NCT01370187|No Intervention|Control|Control group
9703400|NCT04712500|Experimental|AND017: Fasted - Fed|Subjects were randomized to receive single dose of AND017 under fasted condition in Period 1 and under fed condition in Period 2
9703401|NCT04712500|Experimental|AND017: Fed - Fasted|Subjects were randomized to receive single dose of AND017 under fed condition in Period 1 and under fasted condition in Period 2
9978296|NCT01370187|Experimental|Montelukast|4mg Montelukast daily for 2 months
9978297|NCT01370200|Active Comparator|4% citrate|4% trisodium citrate, starting infusion rate 180 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
9978298|NCT01370200|Active Comparator|15% citrate|15% trisodium citrate, starting infusion rate 50 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
9703402|NCT04712487||Routine discectomy|Patients undergoing routine spine surgery due to degenerative disease of the spine
9703403|NCT04712435|Experimental|Experimental: N-acetylcysteine|Sachets containing N-acetylcysteine 200 mg Powder for Oral Solution administered every 8 hours (Daily dose 600 mg/day). is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
9703404|NCT04712435|Placebo Comparator|Placebo Comparator: Placebo|200mg granulated solution of matching placebo administered every 8 hours (Daily dose 600 mg/day), is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner
9703405|NCT04712526||AEON Endostapler|Stapling performed with AEON Endostapler
9703406|NCT04712513||Patients with coronary artery disease and hemodynamically stable|
9703407|NCT04712474|Experimental|In-home decluttering|Study participants receive weekly sessions of in-home decluttering for 10 weeks.
9703408|NCT04712474|No Intervention|Delayed treatment|Study participants receive weekly session of in-home decluttering after a 10 week delay.
9778817|NCT01116986|Experimental|3, Patch, Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778818|NCT01116986|Experimental|4, Patch, Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778819|NCT01116986|Experimental|5, Patch, Gum, No Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9978299|NCT01370226|Active Comparator|CBI|Computer delivered Brief Intervention
9778820|NCT01116986|Experimental|6, Patch, Gum, No Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778821|NCT01116986|Experimental|7, Patch, Gum, No Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778822|NCT01116986|Experimental|8, Patch, Gum, No Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778823|NCT01116986|Experimental|9, Patch, No Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
10190818|NCT05191472|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10190819|NCT05188729|Experimental|Part 1 LTX-315 Safety Run-in|In Part 1 of the trial, the starting total daily dose for the evaluation of LTX-315 will be 2 mg for the first subject. Subjects will receive ascending once daily doses (increasing in 1 mg increments for up to 3 days in a 7 day treatment week [≥4 days off between treatment weeks]) until the first lesion is necrosed or until the subject experiences a DLT, whichever occurs first.
9778824|NCT01116986|Experimental|10, Patch, No Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9785073|NCT01242176|Experimental|BI 10773 XX Trial Formulation 2|one single dose tablet in the morning
9978300|NCT01370226|Active Comparator|TBI|Therapist delivered Brief Intervention
9978301|NCT01370226|No Intervention|EUC|Enhanced Usual Care
9978302|NCT01370239|Experimental|Hu3S193|Single arm
9978303|NCT01370252||scope technique|
9978304|NCT01370252||open technique|
9978305|NCT01370291|Active Comparator|active Risperidone and active rTMS|active Risperidone and active rTMS for the first-episode schizophrenia patients
9978306|NCT01370291|Experimental|active rTMS and sham Risperidone|active rTMS and sham Risperidone for the first-episode schizophrenia
9978307|NCT01370291|Sham Comparator|sham rTMS and active Risperidone|sham rTMS and active Risperidone for the first-episode schizophrenia patients
9978308|NCT01370304|Experimental|active rTMS and active Venlafaxine|
9978309|NCT01370304|Experimental|active rTMS and sham Venlafaxine|
9703409|NCT04712084|No Intervention|Control group|Extubation procedure following standard of care
9703410|NCT04712084|Experimental|Pressure support group|Extubation procedure is performed with 100% of O2 but with application of positive pressure before and after extubation
9978310|NCT01370304|Sham Comparator|sham rTMS and active Venlafaxine|
9978311|NCT01370343|Experimental|PF-04991532 alone|
9703411|NCT04712162|Other|D: maintain anesthesia with desflurane|D: maintain anesthesia with Suprane® (Desflurane) at 6%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
10190820|NCT05188729|Experimental|Part 2 LTX-315 Safety Run-in|Part 2 will be initiated upon completion of Part 1 to confirm the MTD. One subject will be enrolled to receive treatment at the preliminary MTD (ie, the dose below which any DLTs occurred on Part 1). The planned dosing regimen in Week 1 of Part 2 will be an LTX 315 loading dose on Week 1/Day 1 (W1D1) at half the target dose, followed by total daily doses at the full target dose for the remaining dosing days of the treatment week (up to 3) until the lesion is necrosed
10190821|NCT05188729|Experimental|Part 3 LTX-315 Dose Expansion|Part 3 will be initiated with 2 dose cohorts of up to 20 subjects each that will be enrolled to receive LTX 315 at the confirmed MTD and the dose immediately below the MTD. Alternatively, the Safety Review Committee (SRC) may designate a lower dose for exploration of efficacy based on the results of Part 2. Subjects will receive LTX-315 until the target lesion is necrosed. Doses will be administered daily in accordance with the dosing regimen determined in Part 2.
9703412|NCT04712162|Other|S: maintain anesthesia with sevoflurane.|S: maintain anesthesia with Sevorane® (Sevoflurane) at 2%. Volatile concentration was titrated according to end-tidal MAC to maintain 0.7-1.3 MAC using end-tidal monitor of Dräger Primus anesthesia machine.
9703413|NCT04712357|Placebo Comparator|Placebo (Vitamin C)|Control placebo (Vitamin C - 500mg / day, for 10 days)
9703414|NCT04712357|Active Comparator|Tenofovir disoproxyl fumarate (TDF)|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)
9703415|NCT04712357|Active Comparator|TDF + FTC|Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)
9703416|NCT04712461|Experimental|SUPPORTS Implementation Model|The SUPPORTS implementation model will consist of a package of implementation strategies aimed at improving EBP sustainment through reducing provider burnout and turnover and improving organizational climate. The content and structure of SUPPORTS will be informed by the occupational health literature (e.g., psychoeducation about burnout, mindfulness training, or changes involvement of providers in organizational decision-making) and from a needs and context assessment.
9703417|NCT04712461|No Intervention|Implementation as Usual|Agencies in the Implementation as Usual condition will have implementation strategies tied to the implementation of EBPs that these agencies in the community are already using (i.e., the study will measure the implementation strategies being used by the agency but will not provide any additional strategies). There will be no strategies related to reducing provider burnout and turnover and improving organizational climate.
10190822|NCT05188014|Experimental|All participants|All participants will be in a single study arm.
10190823|NCT05183763|Experimental|STAR-MAP|Interactive health coaching sessions and medication reminder tools
9703418|NCT04712331|Experimental|The Study group A|they received graduated abdominal strengthening exercises for 30 min., 3 times per week for 6 weeks preoperatively.
9703419|NCT04712331|Experimental|The Study group B|they received Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
9703420|NCT04712331|Experimental|The Study group C|they received combination between graduated abdominal strengthening exercises and Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
9703421|NCT04712331|No Intervention|The Control group D|they were instructed to presume in normal activities of daily living preoperatively, without abdominal exercises or Russian stimulation.
9703422|NCT04712318|Other|ReLex Smile surgery|"The aim of this study is to investigate the effect of Relex Smile surgery to correct the residual refractive errors (myopic and hyperopic) 6 months after Trifocal IOL Implantation.~At myopic residual refraction (min -0.75 D) (100eyes) 6 months after Trifocal IOL Implantation we used Relex-Smile surgery for treatment."
9703423|NCT04712318|Other|ReLex Smile surgery-fresh corneal lenticule implantation|At hyperopic residual refraction 30 eyes 6 months after Trifocal IOL Implantation we used fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
9703424|NCT04712240|Other|Respiration rate monitor (concurrently measured with standard of care capnography)|Single group study whereupon participants will be fitted with portable respiration rate monitor around their chest for duration of surgery. Respiration rates acquired by the respiration rate monitor will be compared to capnography, which is standard of care and applied to all surgical cases
9703425|NCT04712227||difficult intubation|patients with a difficult intubation score of 5 or more
9703426|NCT04712227||easy intubation|patients with difficult intubation score less than 5
9978312|NCT01370343|Experimental|PF-04991532 + cyclosporine|
9978313|NCT01370382||Time interval|"Patients are divided according to the interval between the onset of chest pain symptoms and presentation at the hospital in an early(<4 hours) and late(> = 4 hours) group."
9978314|NCT01370395||Left ventricular function|According to the result of the echocardiographic exam, the patients will be divided into subgroups with (LV-EF>=55%) and without preserved ejection fraction (LV-EF<55%).
9978315|NCT01370434|No Intervention|VAD combination|"vincristine 0.4mg iv on D1-4~doxorubicin 9mg/m2 iv on D1-4~dexamethasone 40mg/d po on D1-4,9-12,17-20~Many physicians use vincristine, doxorubicin, and dexamethasone (VAD) for three to four months as induction therapy (Alexandrian et al, 1990). VAD produces partial response (PR) in about 50% patients, with complete response (CR) observed in 5%-10% patients (Kyle et al, 2004)."
9978316|NCT01370486|Active Comparator|melatonin|
9978317|NCT01370486|Placebo Comparator|placebo|
9978318|NCT01370551|Experimental|Gynoflor|This study consists only of this arm.
9978319|NCT01370577||1|Total 300 subjects who was diagnosed with asthma
9984348|NCT04201821|Experimental|FMT Administration|This is a single arm study in which all eligible participants will receive FMT.
9984349|NCT04199754|Experimental|Contrast Enhanced Cone Beam CT|60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.
10190824|NCT05183763|Active Comparator|Medication App and Reminder System Medication Adherence Program (MARS-MAP)|Medication reminder tools only
10190825|NCT05180734|Experimental|JS001 240mg, Q3W with XELOX regimen or SOX regimen|"JS001 240mg, will be intravenously administered once every 3 weeks, until 17 cycles XELOX regimen (oxaliplatin + capecitabine) or SOX regimen (oxaliplatin + S-1), given in one therapeutic cycle of 3 weeks for up to 8 cycles XELOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; capecitabine, 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W.~SOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; S-1 Capsules, 40-60mg, orally, twice per day, from day 1 to day 14, Q3W."
10190826|NCT05180734|Placebo Comparator|Placebo combine with chemotherapy|"XELOX regimen (oxaliplatin + capecitabine) or SOX regimen (oxaliplatin + S-1), given in one therapeutic cycle of 3 weeks for up to 8 cycles XELOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; capecitabine, 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W.~SOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; S-1 Capsules, 40-60mg, orally, twice per day, from day 1 to day 14, Q3W."
10190827|NCT05180591|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
9703427|NCT04712227||difficult mask ventilation|group 3 and 4 by han mask ventilation grouping
9703428|NCT04712227||easy mask ventilation|group 1 and 2 according to han mask ventilation grouping
9703429|NCT04712201|Experimental|En bloc|En bloc transurethral resection of the bladder
9703430|NCT04712201|Active Comparator|Conventional|Conventional transurethral resection of the bladder
9703431|NCT04712409|Active Comparator|SADI-S as a primary surgery|
9703432|NCT04712409|Active Comparator|BPD-DS as a primary surgery|
9703433|NCT04712409|Active Comparator|SADI-S as a revisional procedure|
9703434|NCT04712409|Active Comparator|BPD-DS as a revisional procedure|
9703435|NCT04712396|Experimental|Capivasertib + Itraconazole|Subjects will receive a single oral dose of capivasertib on Day 1 during treatment period 1, itraconazole on Days 3, 4, and 5 during treatment period 2, and single oral dose of capivasertib plus a dose of itraconazole on Day 6, followed by itraconazole alone on Day 7 during treatment period 3.
9703436|NCT04712370|Active Comparator|Conventional caudal block|Patients of this group will receive the conventional method (blind technique without ultrasound) of caudal block
9703437|NCT04712370|Experimental|Ultrasound-guided caudal block|Patients of this group will receive caudal block using ultrasound.
9703438|NCT04712370|Experimental|Ultrasound guided erector spinae plane Block|Patients of this group will receive ultrasound guided erector spinae plane Block at the level of the transverse process of the second lumbar vertebrae(L2) .
9703439|NCT04712266|Active Comparator|Insulin IV|calculated insulin rate
9703440|NCT04712266|Experimental|Insulin and Glucagon IV|calculated molar ratio insulin:glucagon
9703441|NCT04712279|Active Comparator|Ivermectin 0.6mg/kg/day|
9703442|NCT04712279|Active Comparator|Ivermectin 1.0mg/kg/day|
9703443|NCT04712279|Placebo Comparator|Placebo|
9703444|NCT04712344|Experimental|COVID-19 convalescent plasma|A total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 and standard treatment.
10190828|NCT05180591|Placebo Comparator|Saline Injection|2 placebo injections spaced 4 weeks apart at the beginning of the trial
10190829|NCT05180500|Active Comparator|Q-GRFT Nasal Spray|Q-Griffithsin (Q-GRFT) nasal spray (7.5mg/mL). Two metered doses of 100μL into each nostril, total of 3mg Q-GRFT per administration, administered once daily for 14 consecutive days.
9703445|NCT04712344|No Intervention|Standard treatment|Standard treatment.
9703446|NCT04712214|Experimental|Patients with brain tumours candidate for neurosurgery|Patients will be recruited following the inclusion criteria: any patient with a diagnosis of brain tumour, age ranging from 18 with no upper limit, who will agree to the operation and to take part of the present study, will be enrolled. During surgery, multispectral and/or hyper spectral acquisition of images from the surgical field will be performed. Each patient will have an average acquisition of 6 datasets. As each dataset will correspond to an image, this will be divided into many reading regions (from 10 to 20) for a total of approximatively 60 measurements per patient.
9703447|NCT04712045|Experimental|New PPE|Use of Short sleeve gown and single pair of gloves
9703448|NCT04712045|Active Comparator|Old PPE|Use of Long sleeve gown and double pairs of gloves
9703449|NCT04712188||Arcing|"10 patients with traumatic spinal cord injury using the arcing stroke pattern to propel manual wheelchair"
9703450|NCT04712188||Semicirculer|"10 patients with traumatic spinal cord injury using the semicirculer stroke pattern to propel manual wheelchair"
9703451|NCT04712188||Single loop|"10 patients with traumatic spinal cord injury using the single loop stroke pattern to propel manual wheelchair"
10190830|NCT05180500|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray. Two metered doses of 100μL into each nostril, administered once daily for 14 consecutive days.
10190831|NCT05178316|Experimental|JZP150 0.3 mg|Participants who will be randomized to receive JZP150 0.3 mg orally once daily for up to 12 weeks.
10190832|NCT05178316|Experimental|JZP150 4.0 mg|Participants who will be randomized to receive JZP150 4.0 mg orally once daily for up to 12 weeks.
9703452|NCT04712188||Double loop|"10 patients with traumatic spinal cord injury using the double loop stroke pattern to propel manual wheelchair"
9703453|NCT04712149|Experimental|intervention arm|In the intervention arm, 15 patients will receive a weekly questionnaire. Alerts will be sent to the multidisciplinary care team, who will undertake follow-up actions. In the control arm, 15 patients will receive the standard care pathway without weekly questionnaire and without automatic alerts to the care team. The standard care pathways and the care team are the same in both groups. In this pilot study, the weekly follow-up will be evaluated by a validation questionnaire, semi-structured interviews with patients and the care team, and workload registration of the care team during a six-month period.
9703454|NCT04712149|No Intervention|Control arm|
9785074|NCT01242241|Other|Non-obese|Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile
9703455|NCT04711980|Experimental|Mudan granule|"Based on the standard medical care, experimental group were treated with Mudan Granule 7g , 3 times/d.~Intervention: Drug: Mudan granule"
9703456|NCT04711980|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 7g , 3 times/d Intervention: Drug: Placebo
9703457|NCT04712032|Experimental|Image Guided Bowel Anastomosis group|ICG-guided perfusion assessment
9978320|NCT01370668|Experimental|Functional remediation|"Patients assigned to the experimental treatment will receive standard psychiatric care and will be enrolled in the neurocognitive intervention program composed of 21 sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 8-to-10 patient group conducted by 2 experienced neuropsychologists. with previous experience with bipolar patients (at least 3 years) and specific training on patients' group management."
9703458|NCT04712032|No Intervention|Conventional Bowel Anastomosis group|conventional perfusion assessment
9703459|NCT04711785|Active Comparator|Intervention|Multicomponent exercise program twice a week (2 hours per week) during six months
9703460|NCT04711785|No Intervention|Control Goup|Usual routine.
9978321|NCT01370668|Active Comparator|Psychoeducation|The group psychoeducation is a tested (Colom et al, 2003) and manualized intervention (Vieta and Colom, 2006) consisting on 21 sessions of 90 minutes, aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences and lifestyle regularity. The program will be performed in an 8-10 patient group conducted by 2 experienced psychologists with previous experience with bipolar patients and specific training on patients' group management. The structure of each session consists of a 30 to 40 minute speech on the topic of the day, followed by an exercise related to the issue (eg. drawing a life chart, writing a list of potential triggering factors) and a discussion.
9978322|NCT01370668|Active Comparator|Treatment as Usual|This arm will not receive any sort of add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
10190833|NCT05178316|Placebo Comparator|Placebo|Participants who will be randomized to receive placebo orally once daily for up to 12 weeks.
9703461|NCT04711772||DOR group|Genomic DNA will be extracted from peripheral blood leukocytes to perform whole-genome sequencing in participates with diminished ovarian reserve.
9703462|NCT04711772||Control group|Participants with normal ovarian reserve will be recruited as control group and peripheral blood leukocytes genomic DNA will be extracted to perform whole-genome sequencing.
10190834|NCT05177848|Experimental|Exclusive cigarette smokers|Exclusive cigarette smokers will be recruited and will be exposed to all of the conditions described in the intervention section.
9703463|NCT04711798||Patients receiving cardiac surgery|Patients receiving cardiac surgery will be included. All patients received a passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system, a lung recruitment maneuver (LRM) and an echographic evaluation of the right cardiac function.
10190835|NCT05177848|Experimental|Dual cigarette/ nicotine vaping product users|Dual cigarette and nicotine vaping product users will be recruited and will be exposed to all of the conditions described in the intervention section.
9703464|NCT04711746|Experimental|Previous proximal unprovoked pulmonary embolism|
9703465|NCT04711746|Active Comparator|Previous proximal provoked pulmonary embolism|
9703466|NCT04711967|Experimental|Fecal Microbiota Transplantation group|treat with FMT
10190836|NCT05177757|Experimental|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
10190837|NCT05174910|Active Comparator|With Obsidian ASG|Anastomosis treatment using standard procedure and Obsidian ASG
9703467|NCT04711967|Active Comparator|Control group|treat with traditional medicine
9703468|NCT04711759|Experimental|Sequence A: High flow nasal cannula - Standard oxygen therapy|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of standard oxygen therapy.
9703469|NCT04711759|Experimental|Sequence B: Standard oxygen therapy - High flow nasal cannula|Once participants are extubated they will receive one hour of standard oxygen therapy followed by one hour of high flow nasal cannula.
9703470|NCT04711954||ATHENA|Cohort of people living with HIV in the Netherlands
9703471|NCT04711954||LUKCY|Cohort of people living with HIV in the Lviv area, Ukraine
9703472|NCT04711694|Experimental|Early Mindfulness Intervention|The Early MBI group partake on the mindfulness intervention after first outcome assessment.
9703473|NCT04711694|Placebo Comparator|Late Mindfulness Intervention|"The Late MBI group partake on the mindfulness intervention after the second outcome assessment.~This groups is the control group for the Early MBI group.~After the second assessment, this group engage on the same intervention as the early group."
9703474|NCT04711707|Experimental|Community navigator|This group is guided through the resources and provided bi-monthly support with a community navigator
9703475|NCT04711707|Other|Self-Navigation|This group receives the social needs resources to self-navigation
9703476|NCT04711720|Experimental|Navigation|
9703477|NCT04711720|No Intervention|Control|
9703478|NCT04711889|Experimental|Ulinastatin|Ulinastatin 10 0000 Units is taken intravenously three times a day.
9703479|NCT04711889|Placebo Comparator|Saline|Same saline dose as ulinastatin is taken intravenously three times a day.
9703480|NCT04711733||Patients 6-14 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
9703481|NCT04711733||Parents of 6-14 years old patients|Individual interview + Self-report questionnaire
9785075|NCT01242241|Active Comparator|Obese children|Obese children are categorized as those with a body mass index >95th percentile
9978323|NCT01370681|Experimental|Group1|
10190838|NCT05174910|No Intervention|Without Obsidian ASG|Anastomosis treatment using standard procedure
9703482|NCT04711733||Patients 15-25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
9978324|NCT01370681|Experimental|Group2|
9978325|NCT01370707|Active Comparator|Metformin|
9978326|NCT01370707|Experimental|CJ-30001/CJ-30002|
9978327|NCT01370720|Active Comparator|Recoclix (CM&D Pharma Limited)|Recoclix: two tablets per day for 12 weeks
9703483|NCT04711733||Parents of 15-25 years old patients|Individual interview + Self-report questionnaire
9978328|NCT01370720|Placebo Comparator|Placebo|IBS patients
9978329|NCT01370746||Cross-Sectional Study Group|Cross-sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents/legal guardians of children 0-11 years versus adolescents 12-21 years
9978330|NCT01370746||Longitudinal Study Group|Subset of Cross-Sectional Study Group to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation
9978331|NCT01370759|Experimental|Colon-targeted cleaning capsule|
9978332|NCT01370772|Active Comparator|Standard R-FC arm|"Standard R-FC arm 6 cycles every 28 days~Cycle 1:~Rituximab : 375 mg/m² i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count > 25* G/L : rituximab in two equal doses at D1, D2~Cycle 2-6:~Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
9978333|NCT01370772|Experimental|DenseR-FC arm|"DenseR-FC arm =1 prephase R Dense course +6 R-FC courses~Prephase:~- Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count > 25* G/L : rituximab 250 mg D-1, D0 prephase~Cycle 1-6 (cycle 1 beginning at D22):~Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
9978334|NCT01370798|Experimental|promestriene|Children with severe hypospadias treated with promestriene 1%
9703484|NCT04711733||Patients > 25 years old|Individual interview + Self-report questionnaire + long-term follow-up medical consultation + At 1 year : Assessment of prescription's adherence
9703485|NCT04711733||Parents of > 25 years old patients|Individual interview + Self-report questionnaire
9703486|NCT04712006|Experimental|Cohort 1: JNJ-64304500|Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.
9978335|NCT01370798|Placebo Comparator|Placebo|Control group, children with severe hypospadias treated with Placebo.
9978336|NCT01370811|Placebo Comparator|OC oral solution treatment D|Placebo
9703487|NCT04712006|Experimental|Cohort 2: JNJ-64304500|Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.
9703488|NCT04712448||Healthy subjects|Donors of the Transfusion Center of Venice Healthy volunteers afferent to BioBIM
9703489|NCT04712448||Patients|Patients with chronic diseases afferent to BioBIM
9703490|NCT04711863|Experimental|Fluvoxamine|Start fluvoxamine 50 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
9703491|NCT04711863|Placebo Comparator|Placebo|Start ursodeoxycholate (UDCA) 100 mg once, then 100 mg twice daily until discharge from community treatment center or for approximately 10 days. The maintenance dose may be reduced for tolerability reasons.
9703492|NCT04711655|Experimental|(ARMA) antireflux ablation of the cardiac mucosa|The ARMA (Ablation with electrocoagulation current or by argon gas fulguration) technique will be performed in patients assigned to this treatment arm.
9703493|NCT04711655|Placebo Comparator|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
9703494|NCT04712058|Experimental|Same-day initiation with BIC/F/TAF|
9978337|NCT01370811|Experimental|OC oral solution treatment C|High dose oxybutynin and clonidine
9978338|NCT01370811|Experimental|OC oral solution treatment A|Low dose oxybutynin and clonidine
10190839|NCT05166824|Experimental|Surgical- abdominoplasty|Subjects enrolled in the surgical arm were treated with the device being placed in contact with the skin on the abdomen. The hand piece, number of passes and parameters used for the treatment were determined by the Investigator.
10190840|NCT05166824|Experimental|Women's Health|Subjects enrolled in the women's health were treated with the device in the vaginal and perineal area.
10190841|NCT05166824|Experimental|Skin Rejuvenation|The hand piece, applicator or tip was placed in contact with the skin. The entire defined treatment area was treated by delivering energy to the skin. The hand piece, number of passes and parameters used for the treatment was determined by the Investigator.
9703495|NCT04711993|No Intervention|Control group|No application will be made to the control group. However, these patients will be included in the exercise program they want after the 8-week treatment period is completed.
9703496|NCT04711993|Experimental|Aerobic exercise group|Patients in the aerobic exercise group will exercise under the supervision of the therapist.
9703497|NCT04711993|Experimental|Stretching exercise group|Patients in the stretching-mobility exercise group will do stretching exercises under the supervision of the therapist
9703498|NCT04711668|Experimental|Group Ketamin|0.5 mg / kg i.v. ketamine bolus at induction and 0.25 mg / kg / hr i.v. ketamine infusion intraoperatively
9703499|NCT04711668|Experimental|Group Lidokain|1.5 mg / kg i.v. lidocaine bolus at induction and 1.5 mg / kg / hr i.v. lidocaine infusion intraoperatively
9703500|NCT04711668|Placebo Comparator|Group Placebo|i.v. saline (in the same volume and duration like group ketamine/lidokain)
9978339|NCT01370811|Experimental|OC oral solution treatment B|Intermediate dose oxybutynin and clonidine
9703501|NCT04711941|Experimental|ToM training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to comprehend and hypothesize interpretations of the emotions and social interactions, providing discussion occasions to enhance the attribution of mental states and emotions. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
9703502|NCT04711941|Active Comparator|Non mentalistic training|ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to provide a historical and descriptive overview of cinema movies, TV news, documentaries, newspapers, and advertising. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.
10190842|NCT05166824|Experimental|Surgical- blepharoplasty|Subjects enrolled in the surgical arm were treated with the device being placed in contact with the skin on the eyelids. The hand piece, number of passes and parameters used for the treatment were determined by the Investigator.
9703503|NCT04711876||Test group with enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV +
9703504|NCT04711876||Control group with no enterovirus meningitis|Level of Cytokine in blood and CSF for Patient with RT-PCR-EV -
9978340|NCT01370824||Basal cell carcinoma|"- Population: Eligible are patients (men and women) ≥18 years of age who visit the outpatient department of dermatology of the Maastricht University Medical Centre because of a clinically suspected BCC.~- Inclusion criteria: All patients aged 18 years or older, otherwise healthy, with ≤ three primary (no previous treatment) clinically determined BCC.~- Exclusion criteria: Patients using immunosuppressive drugs. Genetic skin cancer disorders. Earlier treatments at the same site. Age under 18 years. More than 3 clinical suspected BCCs. Not capable of informed consent."
9703505|NCT04711681|Experimental|PBS1|"This group will recieve an enhanced PBS intervention."
9703506|NCT04711681|Active Comparator|PBS 2|"This group will receive standard PBS with fewer training and coaching sessions than PBS 1."
9978341|NCT01370850||Normal|Normal results from the clinical exam and free of ocular pathology.
9703507|NCT04711642|No Intervention|No intervention|Control group.
9703508|NCT04711642|Experimental|Treatment 1|Sodium hyaluronate 0.1% eyedrops (Systane ultra plus), q.i.d from day 7 to day 30 after cataract surgery.
9978342|NCT01370850||Glaucoma|Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma.
9978343|NCT01370850||Retina|Clinical exam results consistent with retina pathology.
9978344|NCT01370876|Experimental|Oxaliplatin/5-FU|
9978345|NCT01370889|Experimental|Basic Science (resveratrol)|Patients receive resveratrol PO QD for 12 weeks.
9978346|NCT01370902|Experimental|Single-dose (SD) trial part (i.v.)|
9703509|NCT04711642|Experimental|Treatment 2|Sodium hyaluronate 0.1% eyedrops (Hylo-comod), q.i.d from day 7 to day 30 after cataract surgery.
9703510|NCT04711564||Provision of olive oil emulsions in PN|Olive oil-based (Oliclinomel: 80% OO, 20% LCT provided in a complete all-in-one PN bag by Baxter) parenteral nutrition
9703511|NCT04711564||Provision of soybean emulsions in PN|Soybean-based (Kabiven: 100% LCT provided in a complete all-in-one PN bag)
9978347|NCT01370902|Experimental|Single-dose (SD) trial part (s.c.)|
9978348|NCT01370902|Experimental|Multiple-dose (MD) trial part (s.c.)|
9978349|NCT01370915|Experimental|Pregabalin|Patients receive oral placebo 150 mg 1hour prior to septal surgery, and 12 hours later
9703512|NCT04711577|Experimental|Condition 1|Track clinician-determined symptoms
9703513|NCT04711577|Experimental|Condition 2|Track clinician-determined and self-determined symptoms
9703514|NCT04711330||Patients treated with maintenance immunotherapy after concurrent chemo/RT|"Observation of response and response. The microbiome of the patients throat and stool will be analyzed before the standard treatment with IO is initiated after completion of the chemoradiation therapy.~No intervention is planned."
9703515|NCT04711291|No Intervention|Remain on IR-Tac prescribed doses every 12 hours|Patient will remain in Tacrolimus IR-Tac Arm and will complete medication adherence questionnaire monthly. They will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus Trough levels and change in tacrolimus dose levels during their routine follow up.
9703516|NCT04711291|Active Comparator|Convert to Envarsus XR once daily|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR and will complete medication adherence questionnaire. However, patients in this group will not receive any notifications from TransMedAx application. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
9703517|NCT04711291|Experimental|Convert to Envarsus XR once daily combined with TransMedAx app use|Subjects randomized to this arm will switch from IR-Tac to Envarsus XR, will receive notification by scanning a QR code through TransMedAx application and will complete medication adherence questionnaire. Research staff and PI will collect their Tacrolimus trough levels and change in tacrolimus dose during their follow up.
9703518|NCT04711304|Experimental|Wharton's Jelly|Intraarticular injection of Wharton's Jelly
9703519|NCT04711304|Active Comparator|Hyaluronic Acid|Intraarticular injection of Hyaluronic Acid
9703520|NCT04711304|Placebo Comparator|Saline|Intraarticular injection of Saline
9978350|NCT01370915|Placebo Comparator|Placebo|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
10190843|NCT05139498|Experimental|Conservative Management for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
10190844|NCT05139498|Active Comparator|Hysterectomy at time of delivery for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
10190845|NCT05131477|Experimental|KY1005 Dose Level 1|Every 4 weeks
10190846|NCT05131477|Experimental|KY1005 Dose Level 2|Every 4 weeks
10190847|NCT05131477|Experimental|KY1005 Dose Level 3|Every 4 weeks
10190848|NCT05131477|Experimental|KY1005 Dose Level 4|Every 4 weeks
9978351|NCT01370928|Experimental|Prototype colonoscope|The new colonoscope to be tested
9703521|NCT04711343|Experimental|BAT2306 injection|150mg /1ml; subcutaneous injection
9703522|NCT04711343|Active Comparator|Cosentyx (US-licensed)|150mg /1ml; subcutaneous injection
9703523|NCT04711343|Active Comparator|Cosentyx (EU-licensed)|150mg /1ml; subcutaneous injection
9703524|NCT04711395||Cataract Surgery Group|
9703525|NCT04711395||Non-surgical group|
9703526|NCT04711239||Two types of samples (TE and SCM) will be collected for all blastocysts included in the study|
9703527|NCT04711200|Experimental|Adipose derived stromal cells intravenously injected|
9703528|NCT04711499|Experimental|Fatigue Group|The trial will recruit trainee anaesthetists of ST3 grade or higher who take part in a resident night-shift rota at Nottingham University Hospitals NHS Trust. Participants will undergo baseline psychometric testing to measure baseline mood. There will be a series of questions to ascertain levels of fatigue. All participants will then be asked to perform a standardised ultrasound-guided peripheral nerve blockade task using a high fidelity bench-top phantom model. Performance in this task will be independently assessed using a previously-validated scoring tool by two raters blinded to participant group allocation.
9703529|NCT04711499|Active Comparator|Non Fatigued group|The non fatigued group will be asked to perform the same series of questions and tasks after a night at home with no work duties or commitments
9978352|NCT01370928|Active Comparator|Standard colonoscope|The standard colonoscope used world-wide today.
10190849|NCT05131477|Placebo Comparator|Placebo|Every 4 weeks
10190850|NCT05128019|Experimental|Intervention|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will offer the patients a session of unspecified length or number of consultations, to follow the conversation tool ICIT
10190851|NCT05128019|No Intervention|Control|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will however, only receive standard routine care and follow-up by their GP.
10190852|NCT05125510||Hospitalized ICU Cohort|COVID-19+ patients over age 16 who are critically ill and admitted to an ICU and/or required mechanical ventilation (MV) in participating hospitals will be invited to participate. Patients who were hospitalized prior to study start up will be invited to participate in CANCOV.
10190853|NCT05125510||Hospitalized non-ICU Cohort|COVID-19+ patients over age 16 admitted to acute care hospitals, GIM/other wards of participating hospitals will be invited to participate. Patients who were hospitalized prior to this study start up (from January 25, 2020 to study start up) will be invited to participate in this study.
10190854|NCT05125510||Non-Hospitalized Cohort|Individuals who are community dwelling, over the age of 16, are COVID-19+ and never hospitalized for their COVID-19 infection are included. These individuals may be diagnosed by participating hospital emergency rooms / in-person assessment centres / virtual clinics. In addition, we will include individuals who were diagnosed from January 25, 2020 within 6 months of study start up.
9703530|NCT04711226|Experimental|AT-1501 Single Arm|
9703531|NCT04711434|Experimental|Prevention group|Toripalimab: 240mg IV every 3 months for a year
10190855|NCT05125510||Caregiver Cohort|Up to 500 family caregivers of patients admitted to the GIM wards and ICUs of participating hospitals will be invited to participate.
10190856|NCT05125510||Antibody Negative/Presumed COVID-19 comparator cohort|Approximately 500 individuals who do not have a positive COVID-19 test (nasal swab, serological antibody assay, etc.) but who have experienced COVID-19 symptoms and have strong epidemiologic links suggesting probable COVID-19 infection (such as household or occupational contacts and close timing of their symptoms to an index case) will be invited to participate.
9703532|NCT04711434|No Intervention|Follow-up group|Routine follow-up, no intervention
9703533|NCT04711629|Experimental|Smoker COPD|Patients who continue to smoke
9703534|NCT04711629|Active Comparator|Ex-smoker COPD|Patients who quit smoking.
9703535|NCT04711616|Experimental|physical therapy intervention|
9703536|NCT04711447|Other|no-tape, experimental KT, sham KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both an experimental-KT (E-KT) and sham-KT (S-KT) condition.
10190857|NCT05122650|Experimental|10 milligram (mg) JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.
10190858|NCT05122650|Experimental|20 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.
10190859|NCT05122650|Experimental|30 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.
10190860|NCT05122650|Placebo Comparator|Placebo|Participants will receive placebo from Day 1.
9703537|NCT04711447|Other|no-tape, sham KT, experimental KT|Participants were asked to perform a repeated arm elevation task during three different taping conditions: no KT, experimental KT and sham KT. Each taping condition performed the repeated arm elevation task during two loading conditions: no load and loaded with 2.3 kilograms. All six conditions were tested during one visit with the no load condition preceding the loaded condition for each taping condition. This trial consisted of a baseline trial (no KT; N-KT) that was performed first, followed by both a sham-KT (S-KT) condition and experimental-KT (E-KT).
9703538|NCT04711460||treatment plus mindfulness comparing young vs old|Eligible participants had a diagnosis from the DSM-V that included psychotic spectrum disorders, were adults from ages 18 to 55 years, and attended a group therapy-based outpatient mental health program for at least five weeks. Scores were matched for younger vs older participants and compared.
9785076|NCT01242371|Active Comparator|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
9978353|NCT01370941|Active Comparator|Drug A: Chymosin|A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
10190861|NCT05121194|Active Comparator|ZOOM Video Conference Participants|Participants will be offered the opportunity to join one of two weekly meeting times. Participants will be sent a link to join a Zoom videoconference session at the outset of each week, allowing them to log in at their chosen timeslot. These meeting times will be arranged based on discussions with the PAC around optimal timeslots for their shift workers. Sessions will be 90 minutes in length and will be facilitated by a minimum of 2 trained clinician facilitators and 1 research assistant. The session will include a PowerPoint presentation of the CBTm material in a lecture format. Participants will be invited and encouraged to discuss, comment and ask questions of the facilitators about the material throughout the presentation. Homework will be assigned each session relating to the material that was covered. Participants will have 1 week to work through and practice the skills learned, and this homework will be discussed at the next session.
9703539|NCT04711460||treatment plus mindfulness practice and no treatment or Treatment As Usual (TAU)|"Participants in the Treatment plus mindfulness practice had Cognitive Behavioral Therapy, mindfulness education and mindfulness technique practice.~Participants in the Treatment As Usual group had Cognitive Behavioral Therapy and education about the mindfulness process, but no practice of the technique as a group. The scores of each group were compared to determine effect differences."
9703540|NCT04711486|Experimental|Contraloid acetate|"300 mg Contraloid/participant administered orally (for 28 days) as a single daily dose.~Other Name: PRI-002"
9703541|NCT04711486|Placebo Comparator|Placebo|300 mg Placebo (Microcrystalline cellulose)/participant administered orally (for 28 days) as a single daily dose.
9703542|NCT04711213|Active Comparator|Dexamethasone Dose 1|
9703543|NCT04711213|Active Comparator|Dexamethasone Dose 2|
9703544|NCT04711213|Placebo Comparator|Placebo Dose 1|
9703545|NCT04711213|Placebo Comparator|Placebo Dose 2|
9703546|NCT04711421|Experimental|Experimental: Feedback|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve feedback regrding the number of steps taken by them at the end of each day
9703547|NCT04711421|No Intervention|No Intervention: Control|Patients in this arm will wear a pedometer following gynecology and gynecology oncology surgeries until discharge. During this period, they will recieve no feedback regrding the number of steps taken by them.
9703548|NCT04711408|Experimental|Virtual reality|women allocated to undergo ultrasound for the diagnosis of endometriosis with Virtual reality System
9703549|NCT04711408|No Intervention|Standart care|women allocated to undergo ultrasound for the diagnosis of endometriosis without VR
9703550|NCT04711161|Experimental|Phase 1a: Single Arm, Open Label (GRN-300 monotherapy)|The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 as a single agent will be determined. The overall duration of Phase 1a will be approximately 9-12 months, depending on the rate of enrollment and the number of subjects enrolled.
9703551|NCT04711161|Experimental|Phase 1b: Single Arm, Open Label (GRN-300 plus paclitaxel)|"The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment, in combination with intravenously administered paclitaxel weekly x 3 during each 28-day cycle. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 in combination with paclitaxel will be determined. The overall duration of Phase 1b will be approximately 9-12 months, depending on the rate of enrollment and the number of subjects enrolled. Phase 1b will commence following determination of the MTD and RP2D of GRN-300 monotherapy in Phase 1a.~Overall duration of the study will be approximately 24 months, depending on the rate of enrollment and number of subjects enrolled."
9978354|NCT01370941|Placebo Comparator|Drug B: Placebo|B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
9978355|NCT01370954||CerefolinNAC®|Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
9978356|NCT01370967||Study formula-fed only|
9978357|NCT01370967||Human milk-fed only|
9978358|NCT01370967||Mixed-fed using study formula only|
9978359|NCT01370980||Study population|Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
9978360|NCT01371019||Women with preterm delivery|
9978361|NCT01371019||Women without preterm delivery|
9978362|NCT01371045||Acromegaly|Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.
9978363|NCT01371045||Carcinoid Syndrome|Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.
9978364|NCT01371045||Healthy Controls|
9978365|NCT01371058|Active Comparator|routine dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically； clopidogrel 75mg/d for 1year.
9978366|NCT01371058|Experimental|high maintenance clopidogrel|aspirin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 150mg/d for 1 month followed by 75mg/d for at least 1 year.
9978367|NCT01371058|Experimental|policosanol plus dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 75mg/d for at least 1 year; Policosanol 40mg/d for 6months.
10204451|NCT01773278|Experimental|Antioxidant effect on Oxysterols|Patients with SLOS will be treated with antioxidants and cholesterol. Blood oxysterol levels will be measured. Future focus will be on being able to use oxysterol levels to regulate antioxidant doses, and to determine which particular antioxidants might have the most benefit in lowering oxysterols
10204452|NCT01721850|Active Comparator|control formula|infants are fed a commercial stage 1 infant formula during the first 4 months of life, according to protocol
10204453|NCT01721850|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
9978368|NCT01371071||CIS or early relapsing-remitting MS|
9978369|NCT01371084|Experimental|Physical activity treatment group|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
9978370|NCT01371084|Placebo Comparator|Wait List Control|
9703552|NCT04711122||Role of prophylactic antibiotics in childscore A|Role of prophylaxis against infections in progression of cirrhotic patients with childscore A
9703553|NCT04710862|Active Comparator|Breathing training with a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will perform exhalation exercises through a breathing device. Homework activities will be assigned. Post-training testing sessions will also be conducted.
10190862|NCT05121194|Active Comparator|WEB Online CBTm Course Participants|Participants will receive access to the online self-guided CBTm course. The material is identical to the material taught in the facilitator-led group. Participants will receive access to the Class 1 upon joining the study at which point they can move through the material. The material is presented in a slide show format with pre-recorded audio to accompany each slide, in accordance with the material covered for in person classes. Material may be completed in a single sitting or they can choose to pause and return to it at a later time. Homework will be assigned as in Arm 1, through online forms at the end of each class. If a participant has questions, they can use a 'contact us' button, allowing questions to be sent to our research team. One week after completion of Class 1, participants will receive access to Class 2. The one-week timeframe prior to accessing the next class is used to mirror the timeline in the facilitator-led groups (Arm 1)
9703554|NCT04710862|Active Comparator|Breathing training without a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will receive training on the use of breathing techniques without a device, but with visual feedback throughout training. Homework activities will be assigned. Post-training testing sessions will also be conducted.
9703555|NCT04710771||Group-A|Patient performed prone lying position for three hours.
10190863|NCT05121194|No Intervention|WAIT participants|(WAIT) participants will be assigned to a waitlist control. These individuals will not receive any type of active intervention but will continue to receive mental health questionnaires to complete in line with the ZOOM and WEB participants at weekly intervals. These individuals will be offered a choice of videoconference CBTm or online CBTm at completion of their waitlist period (6 months).
9703556|NCT04710771||Group-B|along with Prone lying position, patients also performed alternate nostril breathing for ten minutes.
9703557|NCT04711096||Group A|TAB group formed of 65 patients
9703558|NCT04711096||Group B|"Group B : The Infiltration Group formed of 65 patients.~• This group will B wills provided with single-shot local anesthetic wound infiltration with 20 ml of 0.25% bupivacaine injected subcutaneously above and below skin incision before closure of skin."
9703559|NCT04711096||Group C|"Group C : Narcotics only group formed of 20 patients~• routine analgesic was taken only without any intervention"
9703560|NCT04710797|Experimental|No Lymphadenectomy|Comprehensive staging surgery with no Lymphadenectomy
9703561|NCT04710797|Active Comparator|Lymphadenectomy|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
9978371|NCT01371097|No Intervention|Control Group|
9978372|NCT01371097|Experimental|Treatment group|
9978373|NCT01371123||On long-term PN|
9703562|NCT04710758|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D2 lymphadenectomy for patients enrolled in this group.
9703563|NCT04710758|Active Comparator|Open total gastrectomy|The surgeon will perform OTG with D2 lymphadenectomy for patients enrolled in this group.
9703564|NCT04710927|Active Comparator|Group 1|High Viscosity GIC
9703565|NCT04710927|Experimental|Group 2|SDF and High Viscosity GIC
9703566|NCT04710927|Experimental|Group 3|SDF, Papain-Based Gel and High Viscosity GIC
9703567|NCT04711005|Experimental|SAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.1 mg/kg via slow IV infusion (40 minutes)
9703568|NCT04711005|Experimental|SAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 0.25 mg/kg via slow IV infusion (40 minutes)
9703569|NCT04711005|Experimental|SAD Cohort 3|(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes)
9703570|NCT04711005|Experimental|SAD Cohort 4|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes)
9703571|NCT04711005|Experimental|SAD Cohort 5|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes)
9703572|NCT04711005|Experimental|SAD Cohort 6|(2R,6R)-Hydroxynorketamine @ 4.0 mg/kg via slow IV infusion (40 minutes)
9703573|NCT04711005|Experimental|MAD Cohort 1|(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
9703574|NCT04711005|Experimental|MAD Cohort 2|(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
9703575|NCT04711005|Experimental|MAD Cohort 3|(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
9703576|NCT04711005|Placebo Comparator|Placebo|Control product (placebo) will be sterile saline also administered via slow IV infusion (40 minutes).
9703577|NCT04711109|Experimental|Arm A (denosumab)|Patients receive denosumab SC q6m for up to 5 years in the absence of disease progression or unacceptable toxicity.
9703578|NCT04711109|Placebo Comparator|Arm B (placebo)|Patients receive placebo SC q6m for up to 5 years in the absence of disease progression.
9703579|NCT04710914|Experimental|sedation by inhaled isoflurane|sedation by midazolam with the MIRUS device
9703580|NCT04710914|Active Comparator|sedation with intravenous midazolam|continuation of sedation with intravenous midazolam
9703581|NCT04710888|Experimental|basil extract mucoadhesive gel|10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed.
9703582|NCT04710888|Placebo Comparator|mucoadhesive placebo gel|10 patients treated by mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
9703583|NCT04710888|Sham Comparator|healthy patients|10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)
9978374|NCT01371123||Never been on TPN|
9703584|NCT04710953|Experimental|CPAP arm|In addition to standard of care, CPAP will be provided at high altitude posts where Gamow bag is not available and all patients of HAPE will be given CPAP when evacuation/descent is either not possible or delayed due to weather conditions.
9703585|NCT04710953|No Intervention|Gamow bag arm/hyperbaric chamber|Posts where Gamow bag would be available, the patients of HAPE will be given standard of care and will be asked to lie inside Gamow bag inflated at 2 Psi for several hours to simulate a descent of 1500 meters when evacuation/descent is either not possible or delayed due to weather conditions.
9703586|NCT04711044|Experimental|Study group|
9703587|NCT04710901|Active Comparator|uTECH|Approximately 165 participants will be randomly assigned to this arm and will receive the uTECH intervention over the course of 12 months.
9703588|NCT04710901|Active Comparator|Young Men's Health Project (YMHP)|Approximately 165 participants will be randomly assigned to this arm and will receive the YMHP intervention over the course of the first 3 months. Months 3-6 will be inactive, and they will be followed for a total of 12 months.
9703589|NCT04710823|Experimental|Thoracic paravertebral block|Patients will receive ultrasound-guided continuous thoracic paravertebral blockusing bupivacaine 0.25% for 4 days.
9978375|NCT01371136|Experimental|Curricular Trained|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
9703590|NCT04710823|Experimental|Serratus anterior plane block|Patients will receive ultrasound-guided continuous SAP block using bupivacaine 0.25% for 4 days.
9703591|NCT04711057|Experimental|Pulmonary Rehabilitation + Community-based PA program|After PR, the experimental group will integrate a community-based PA program.
9703592|NCT04711057|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates PA recommendations.
9703593|NCT04710849||Treatment Failure Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. Definition of systemic glucocorticoid treatment failure during hospitalization is (Reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): The following occurs from the 2nd to the 7th day after admission Situation: ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
9703594|NCT04710849||Treatment Success Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. The treatment success group was defined as not meeting any of the following conditions for failure of systemic hormone therapy during hospitalization (reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
9703595|NCT04711018||Group DL (+)|Grade III or IV laryngeal view according to Cormack-Lehane classification
9703596|NCT04711018||Group DL (-)|Grade I or II laryngeal view according to Cormack-Lehane classification
9703597|NCT04710810|Experimental|Experimental|Patients receive group and rhesus compatible UCB cells through intravenous bolus injections (4 injections at 2-week intervals) after pre-medication with Clemastine (0.025 mg/kg body weight, intravenously). One dose is 250±10 x 10⁶ viable cells per sample.
9703598|NCT04710810|No Intervention|Control|Patients receives standard therapy (applied behavioral analysis, speech therapy).
9703599|NCT04711070||Patients with sepsis|Muscle velocity recovery cycles, electromyography, nerve conduction studies, direct musclestimulation, blood test
9703600|NCT04711070||Patients with chronic renal failure|
9703601|NCT04711070||Healthy control|
9703602|NCT04710966|Experimental|debridement group|For the debridement group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic debridement will be performed.
9703603|NCT04710966|Experimental|repair group|For the repair group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic repair will be performed.
9703604|NCT04710745||Study Group|Patients in sinus rhythm without history of AF, with high risk for ischemic stroke and AF. CHA2DS2-VASc score > 2 (for females > 3) and with more than 3 specific criteria for inclusion.
9703605|NCT04710719|Active Comparator|TAC only|Participants will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
9778825|NCT01116986|Experimental|11, Patch, No Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9978376|NCT01371136|No Intervention|conventional residency training|These residents proceed through surgical residency training as usual
9978377|NCT01371149|No Intervention|Physician led ventilator set up|Patients will be set up on non-invasive ventilation as per the current gold standard physician led approach
9978378|NCT01371149|Experimental|parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
9978379|NCT01371162|Experimental|A1 Healthy Volunteers|
9978380|NCT01371162|Placebo Comparator|A2|
10190864|NCT05115123|Active Comparator|Intervention|patients scheduled for elective LC will receive 60 mg duloxetine before surgery
9978381|NCT01371162|Experimental|B1 HCV Infection|
9978382|NCT01371162|Placebo Comparator|B2|
10190865|NCT05115123|Placebo Comparator|Control|patients scheduled for elective LC will receive placebo before surgery
10190866|NCT05111756||Unit A|Staff at first phase units, receiving Braining, physical exercise
9703606|NCT04710719|Active Comparator|TAC + 5FU|Participants will be treated with adjuvant intralesional TAC and 5FU at a dose of 0.1mg TAC for every 0.9mg 5FU 7-10 days post-op then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
9703607|NCT04711031||Usual care + FLUS|At index consultation, patients will receive a FLUS examination in addition to the GP's usual care of adults presenting with symptoms of an acute LRTI.
9703608|NCT04710472|Experimental|MH|Arm MH - mobile Mentora app to monitor and track treatment side-effects, vital signs, therapeutics and daily habits;
9703609|NCT04710472|No Intervention|C|SOC
10190867|NCT05111756||Unit B|Staff at second phase units, receiving Braining, physical exercise
10190868|NCT05109494|Active Comparator|Conventional Fractionated|radiation treatments will be delivered daily, delivered over a maximum of 7 weeks from the first treatment, surgery will be within 5-14 days of completion of RT
9703610|NCT04710680||group A|
9703611|NCT04710680||group I|
9703612|NCT04710290|Experimental|Solid beverage powder|Whey portein solid beverage powder use 1 pack for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
9703613|NCT04710290|Experimental|Capsule|Capsules use 1 cap for every 10 kg of body weight.A total of 6 cap under 60 kg a day, an extra 1cap for each additional 10 kg over 60 kg. Use from the 7th day of the 2nd course of treatment for 5 months.
9703614|NCT04710290|Placebo Comparator|Placebo|placebo use 1 powder for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
9703615|NCT04710381|Experimental|IMUNOR|Study subjects in this arm will receive IMUNOR preparation as prevention against COVID-19 disease.
9778826|NCT01116986|Experimental|12, Patch, No Gum, Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778827|NCT01116986|Experimental|13, Patch, No Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778828|NCT01116986|Experimental|14, Patch, No Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778829|NCT01116986|Experimental|15, Patch, No Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9978383|NCT01371175|Experimental|Group A|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
10190869|NCT05109494|Experimental|Hypofractionated|the maximum frequency of treatment will be every day and the minimum frequency will be every other day, delivered over a maximum of 3 weeks from the first treatment, surgery will be within 5-14 days of completion of RT
10204454|NCT01721850|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
10204455|NCT01711541|Experimental|Arm I (veliparib, combination chemotherapy)|Patients receive veliparib PO BID on days 1-7, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then continue on to concomitant chemoradiotherapy.
10204456|NCT01711541|Experimental|Arm II (placebo, combination chemotherapy)|Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
9978384|NCT01371175|Experimental|Group B|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
9978385|NCT01371175|Experimental|Group C|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intradermally. Vaccine:Placebo =18/3
9978386|NCT01371175|Experimental|Group D|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
9978387|NCT01371175|Experimental|Group E|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
9978388|NCT01371175|Experimental|Group F|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
9978389|NCT01371175|Experimental|Group G|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
9703616|NCT04710446||NSTEMI Patients presenting with normal ECG|NSTEMI Patients presenting with normal ECG
9703617|NCT04710446||NSTEMI Patients presenting with isolated T wave inversion|NSTEMI Patients presenting with isolated T wave inversion
9703618|NCT04710446||NSTEMI Patients presenting with transient ST-segment elevation|NSTEMI Patients presenting with transient ST-segment elevation
9703619|NCT04710446||NSTEMI Patients presenting with resting U wave inversion|NSTEMI Patients presenting with resting U wave inversion
9978390|NCT01371175|Experimental|Groups C2/D2/E2 (Subgroups of C,D,E)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered ID, SC, or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in C2/D2/E2 = 16.
9978391|NCT01371175|Experimental|Group F2/G2 (Subgroup of F and G)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered either SC or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in F/G= 29.
9978392|NCT01371188||Controls|Healthy male volunteers, non-smokers, 20-40yo, living in the city of Mendonça, São Paulo-Brazil.
10190870|NCT05095428|Experimental|PARTS|The Program for Alleviating and Resolving Trauma and Stress (PARTS) Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
9703620|NCT04710446||NSTEMI Patients presenting with low QRS voltage|NSTEMI Patients presenting with low QRS voltage
9703621|NCT04710602||Minimally invasive|Patients who underwent surgery with a muscle sparing, minimally invasive technique for unstable chest wall after trauma.
9703622|NCT04710602||Historical control|Patients who underwent surgery with large incisions and simultaneous thoracotomy for unstable chest wall after trauma.
10190871|NCT05095428|Active Comparator|NBSR-T|The Nature Based Stress Reduction for Trauma Survivors (NBSR-T) Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
10190872|NCT05094050|Experimental|Arm 1: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the abdomen (Period 1), flank (Period 2), arm (Period 3) and thigh (Period 4).
10190873|NCT05094050|Experimental|Arm 2: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the arm (Period 1), abdomen (Period 2), thigh (Period 3) and flank (Period 4).
10190874|NCT05094050|Experimental|Arm 3: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the thigh (Period 1), arm (Period 2), flank (Period 3) and abdomen (Period 4).
9703623|NCT04710394|Active Comparator|Unimodal Olfactory Training with Conventional Odors|Participants will undergo smell training without a visual component, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
9703624|NCT04710394|Experimental|Unimodal Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training without a visual component, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
9703625|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Conventional Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and train using 4 pre-determined scents: rose, lemon, eucalyptus, and clove.
9703626|NCT04710394|Experimental|Bimodal Visual, Olfactory Training with Patient-Preferred Odors|Participants will undergo smell training while simultaneously focusing on a picture of the odor, and undergo an odor selection process in which they choose four scents to train with that they identify as important. A total of 24 scents will be included for patients to select from, including: Lemon, Orange, Grapefruit, Lime, Eucalyptus, Peppermint, Spearmint, Tea Tree, Rose, Lavender, Jasmine, Geranium, Frankincense, Cedarwood, Juniper, Sandalwood, Black Pepper, Oregano, Rosemary, Clove, Vanilla, Coffee, Cinnamon, Nutmeg.
9703627|NCT04710654|Other|Control|"Behavioural therapy~Exercise program"
10190875|NCT05094050|Experimental|Arm 4: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the flank (Period 1), thigh (Period 2), abdomen (Period 3) and arm (Period 4).
10190876|NCT05085756|Active Comparator|Guided treatment|8-week transdiagnostic CBT with written guidance from M.Sc-level students under supervision.
10190877|NCT05085756|Active Comparator|Unguided treatment|8-week transdiagnostic CBT without guidance.
9978393|NCT01371188||Sugarcane Workers|Healthy male volunteers, non-smokers, 20-40yo, sugarcane workers, living in the city of Mendonça, São Paulo-Brazil.
10190878|NCT05085756|Other|Waitlist|8-week transdiagnostic CBT without guidance, made available 6 months after recruitment.
9978394|NCT01371201|Experimental|Sunitinib|sunitinib 37.5 mg per day
9978395|NCT01371201|Placebo Comparator|Placebo|Placebo 37.5 mg per day
9978396|NCT01371214|Experimental|Group 1|PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
9978397|NCT01371214|Active Comparator|Group 2|Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
9978398|NCT01371227|Experimental|JNS002|JNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
9984350|NCT04195776|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
9703628|NCT04710654|Active Comparator|connective tissue manipulation|
9703629|NCT04710654|Active Comparator|Interferential current stimulation (100 Hz frequency)|
9978399|NCT01371253|Experimental|Nintendo Wii traning|Balance training
9703630|NCT04710654|Active Comparator|Interferential current stimulation (0-100 Hz frequency)|
9703631|NCT04710433|Active Comparator|Non-invasive Neuromodulation|"Application of non-invasive sacral nerve stimulation for 12 weeks, at least 8 hours per day.~Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field with a 15 Hz frequency for a duration of 210µs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).~Medical and behavioral therapy is to be continued as started before intervention."
9978400|NCT01371253|Placebo Comparator|EVA-soles|
9703632|NCT04710433|Other|Medical/behavioral Therapy|Patients receive an optimized conventional treatment for 12 weeks, including lifestyle changes, toilet training and weight-adjusted medication. Conventional medical options include oral laxative medication with polyethyleneglycol or rectal medication with saline enemas in possible combination with a stimulant laxative (glycerin or bisacodyl).
9703633|NCT04710420||WIfI composite 1-4|Summing the three individual WIfI components together, the WIfI composite score 1-4.
9703634|NCT04710420||WIfI composite 5-9|Summing the three individual WIfI components together, the WIfI composite score 5-9.
9703635|NCT04710589||CTV 3mm|CTV is expanded by 3mm on the basis of GTV.
9703636|NCT04710589||CTV 6mm|CTV is expanded by 6mm on the basis of GTV.
9703637|NCT04710342|Experimental|CTO proximal cap crossing|To demonstrate that CapBuster breaks the proximal cap of CTO's
9703638|NCT04710459|Active Comparator|Group 1|it included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy.
9703639|NCT04710459|No Intervention|Group 2|it included include 30 patients, they were subjected to chemoradiotherapy.
9703640|NCT04710550|Experimental|Safety/Dosimetry Cohort|
9703641|NCT04710550|Experimental|Traumatic Brain Injury|
9703642|NCT04710550|Experimental|AD/MCI|
9703643|NCT04710550|Active Comparator|Healthy Controls|
9703644|NCT04710355||Chronic pain|Failed back surgery syndrome
9703645|NCT04710329||C Vit|The patients who were admitted to the intensive care unit and received a high dose intravenous vitamin C protocol constituted the treatment group
9703646|NCT04710329||non-C Vit|The patients who were admitted to the intensive care unit but did not receive the vitamin C protocol constituted the control group
9703647|NCT04710407|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a total of five doses of TBPM-PI-HBr 600 mg orally every 8 hours.
9703648|NCT04710498|Experimental|Atezolizumab|Subjects will receive neoadjuvant atezolizumab intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 (+/- 3 days) of each 21-day cycle for a total of 3 doses prior to surgery, unless there is clinical or radiographic evidence of disease progression.
9703649|NCT04710511||Control group|Medically free children aged from 5 years to 7 years and do not practice oral habits.
9703650|NCT04710511||Oral habit practicing group|Medically free children aged from 5 years to 7 years and practicing oral habits.
9703651|NCT04710316|Experimental|Patients|- Hospitalized patients in one of the four centers in Bamako, with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures
9703652|NCT04710316|Experimental|Caregivers|"Caregivers of one of the four centers in Bamako.~Serological screening: all.~Molecular screening: with clinical signs of infection of the upper or lower respiratory tracts with fever or feeling of fever or any other signs of SARS-Cov-2 infection or who have seroconverted to SARS-CoV-2 or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures"
9703653|NCT04710251|Active Comparator|Colonoscopy with the speedometer|
9703654|NCT04710251|No Intervention|Colonoscopy without the speedometer|
9703655|NCT04710264||recombinant hFSH|Patient stimulated with recombinant hFSH
9703656|NCT04710264||recombinant hFSH : r-hLH|Patient stimulated with recombinant hFSH : r-hLH ratio 2:1
9703657|NCT04710225|Active Comparator|Group 1 (General anesthesia group)|"Upper limb fracture surgery will be performed with the aid of pneumatic tourniquet. General anesthesia will be induced with intravenous (IV) thiopental sodium and fentanyl.~Rocuronium will be used as the neuromuscular blocking agent. Endotracheal tube will be placed and anesthesia will be maintained with sevoflurane and IV fentanyl while the lungs were ventilated with O2-N2O (50-50%) to achieve an EtCO2 at 30-35 mm Hg."
9703658|NCT04710225|Active Comparator|Group 2 (Multiple injection axillary block group)|Multiple injection axillary block will be performed with the aid of a nerve stimulator. When the slight twitching of the motor response from the relevant muscles is achieved (at 0.4 mA, 2Hz, 0.1 ms) % 18-20 ml of Bupivacaine 0.5 (90-100 mg) will be injected.
9978401|NCT01371266|Active Comparator|Honey|60.7 grams daily orally times 14 days
9978402|NCT01371266|Active Comparator|CHO|50 grams daily orally times 14 days
9978403|NCT01371266|Active Comparator|High Fructose Corn Syrup|65.7 grams daily orally times 14 days
9978404|NCT01371292|Experimental|Transformational teaching condition|Teachers allocated to this condition will receive the transformational teaching intervention.
9978405|NCT01371292|Active Comparator|Standard practice control condition|Teachers allocated to this condition will not receive the transformational teaching intervention. Instead they will take part in a parallel workshop offered by their respective school board (unrelated to transformational leadership training).
9978406|NCT01371305|Experimental|BG00011|Participants will receive 8 consecutive weekly doses of BG00011
9978407|NCT01371305|Placebo Comparator|Placebo|Participants will receive 8 consecutive weekly doses of placebo.
9978408|NCT01371318|Experimental|OWEMR|Medical centers will be randomized to use the Online Wound Electronic Medical Record to enhance care of patients with diabetic foot ulcers
9984351|NCT04194047||RBC group|Patients who received RBC transfusion
10190879|NCT05079412||NIV-NAVA group|Premature infants (22 0/7 to 31 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIV-NAVA for at least 24 hours are enrolled in this arm after obtaining parents' consent.
9703659|NCT04709913|Active Comparator|Active Treatment: HU6 Planned doses of HU6; N = 32|Drug = HU6 HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
10190880|NCT05079412||NIPPV group|Premature infants (22 0/7 to 31 6/7 weeks gestation) with respiratory distress syndrome who are admitted to Mount Sinai NICU and are supported by NIPPV for at least 24 hours are enrolled in this arm after obtaining parents' consent.
10190881|NCT05077969|Experimental|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
9703660|NCT04709913|Placebo Comparator|Placebo Comparator Non-active study drug N = 8|Placebo Comparator, non-active study drug.
9703661|NCT04710069|No Intervention|Control/Usual Care|standard treatment of postoperative pain, which involves automatic prescription of a narcotic pain medication regimen after surgery,
9703662|NCT04710069|Experimental|Opt-in/POINT|An opt-in program (POINT), which requires the patient to consent to receiving a prescription for narcotics
9703663|NCT04710082|Active Comparator|Patients planned to undergo conventional 2 step trans-epithelial PTK-PRK|"Patients planned to undergo:~Epithelial removal using Phototherapeutic Keratectomy PTK as a separate step.~Laser Vision Correction using Excimer laser wavefront optimized technology."
10190882|NCT05077969|Placebo Comparator|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.
9703664|NCT04710082|Active Comparator|Patients planned to undergo the new single step trans-epithelial (StreamLight) PRK.|"Patients planned to undergo:~Epithelial removal and Excimer wavefront optimized Laser Vision Correction in a single step using the new StreamLight Technology."
9703665|NCT04709991||Procedures with EndoNaut|
9703666|NCT04709991||Procedures without Endonaut|
9978409|NCT01371318|No Intervention|Standard of Care|Medical/wound centers will be randomized to continue routine care of patients with diabetic foot ulcers
9703667|NCT04709952|Active Comparator|High real stimulation group|2mA tDCS stimulation daily (42 times) for 6 weeks
10190883|NCT05076591|Experimental|IMM2902|IMM2902 Dose escalation: 0.03, 0.1, 0.25, 0.5, 1.0, 1.5, and 2.0 mg/kg through intravenous administration weekly up to 48 weeks.
9703668|NCT04709952|Active Comparator|Low real stimulation group|1mA tDCS stimulation daily (42 times) for 6 weeks
9703669|NCT04709952|Sham Comparator|Sham stimulation group|sham stimulation daily (42 times) for 6 weeks
10190884|NCT05073302|Experimental|Treatment Group|Implantation of the Device-Less sentinel units. Ultrasound Monitoring. Islet Transplantation. Explantation of Device-Less Sentinels. Standard of Care. Concomitant Care. Post Transplant Testing and Visits. Participant Retention (nine month follow up assessment).
10190885|NCT05060679||Non-sepsis|Non-septic patients receive supportive treatment at the ICU.
10190886|NCT05060679||Sepsis|Patients receive sepsis therapy.
10190887|NCT05060679||Sepsis-related organ dysfunction|Patients receive sepsis therapy and advanced supportive treatment based on the occurrence of specific sepsis-related organ dysfunctions.
10190888|NCT05060328||Health services research (Google Translate Conversation Mode)|"Patients use Google Translate Conversation Mode translation application before and after surgery. Patients also complete survey over 10 minutes."
9703670|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, W.|If the rate of popliteal artery stenosis of patients < 50%, the patients only receive the wound treatment.
9978410|NCT01371331|Experimental|Tacrolimus granules|oral
9984352|NCT04194047||crystalloids group|Patients who received fluid resuscitation with crystalloids
9984353|NCT04193644|Active Comparator|Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax).
10190889|NCT05059509|Experimental|FB825|One dose FB825, 5mg/kg, by 1 hour IV infusion on Day 1
10190890|NCT05057897|Other|2 doses of AZD1222, 4 weeks apart|Previously unvaccinated. First dose administered on Day 1 and second dose on Day 29.
10190891|NCT05055024|Experimental|NLS-2 (mazindol extended release)|NLS-2 (mazindol extended release) administered once a day.
10190892|NCT05052502|Experimental|reactive focal mass drug administration (rfMDA)|Reactive FMDA (rfMDA) led by VMVs in response to cases in study area sub-district, in both villages and forest workers; quantitative G6PD testing for all individuals and 14-day PQ for G6PD non-deficient.
10190893|NCT05052502|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMVs; village-based RACD conducted by district staff in some areas.
9703671|NCT04709887|Other|Rate of popliteal artery stenosis < 50%, WT.|If the rate of popliteal artery stenosis of patients < 50%, the patients receive the wound treatment and tibial transverse transport surgery.
9703672|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WV.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and vascular intervention surgery.
9703673|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment and tibial transverse transport surgery.
9703674|NCT04709887|Other|Rate of popliteal artery stenosis ≥ 50%, WVT.|If the rate of popliteal artery stenosis of patients ≥ 50%, the patients receive the wound treatment, vascular intervention and tibial transverse transport surgery.
9778830|NCT01116986|Experimental|16, Patch, No Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9785077|NCT01242371|Placebo Comparator|Identical-appearing Placebo|Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
9785078|NCT01242514|Experimental|A|Oral treatment
9785079|NCT01242514|Experimental|B|Oral treatment
9703675|NCT04710121|Experimental|Intervention Arm|"The experimental group will be asked about their anxiety states with the State and Trait Anxiety Inventory, their pain conditions with the Analog Scale (VAS), and their first life findings will be measured, and the first measurement values will be recorded in the Vital Signs Follow-up Form. Virtual reality glasses will be placed on the patient's head during colonoscopy. The duration of the colonoscopy will vary between 3-10 minutes, videos with music background, park, nature and seaside walks, underwater videos, which the patient chooses, will be watched and the Vital Signs Tracking Form Second measurement values will be recorded by making measurements. Immediately after the colonoscopy procedure is completed, Visual Analogue Scale (VAS), Vital Signs Follow-up Form (measurement will be made and 3rd measurement values will be recorded. The State Anxiety Inventory will be read and the answers will be recorded."
10190894|NCT05047263|Experimental|Finerenone (BAY94-8862)|Participants will receive finerenone.
10190895|NCT05047263|Placebo Comparator|Placebo|Participants will receive placebo.
9703676|NCT04710121|No Intervention|Control Arm|No application will be made in the control group. during and after colonoscopy and routine treatment and care will be applied.
10190896|NCT05046236|Experimental|Interactive POWER rehabilitation|Participants in this group would be treated with POWER for twice a week, total 12 weeks.
9978411|NCT01371344|Experimental|Part A: Heart Transplant (Tacrolimus granules)|In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
9978412|NCT01371344|Experimental|Part A: Liver Transplant (Tacrolimus granules)|In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
9978413|NCT01371344|Experimental|Part A: Kidney Transplant (Tacrolimus granules)|In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
9978414|NCT01371344|Experimental|Part B: All Participants (Tacrolimus capsules)|In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.
9978415|NCT01371357|Experimental|TEST1|2.4 g/day of guanidinoacetic acid
9978416|NCT01371357|Experimental|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
10190897|NCT05046236|Active Comparator|Conventical physical training Group|Participants in this group would be treated with traditional exercise rehabilitation for twice a week, total 12 weeks.
9703677|NCT04709848||Pre-screening group|Individuals undergoing bone marrow transplantation Jun 2018 - July 2020
9703678|NCT04709848||Screened group|Individuals undergoing bone marrow transplantation July 2020 - July 2021
9703679|NCT04709861||Retrospective 6 week Weight-Bearing|Delayed weight-bearing 6 weeks after total ankle replacement
9703680|NCT04709861||Prospective 2 week Weight-Bearing|Early weight-bearing 2 weeks after total ankle replacement
9703681|NCT04710095|Active Comparator|Brief Alcohol Intervention|A brief intervention consisting of a 30-45 minute individual face-to-face session based on the principles of motivational interviewing.
9703682|NCT04710095|Sham Comparator|Attention-Matched Control Condition|Brief attention-matched control condition.
9703683|NCT04710173||ARDS children|children with severe ARDS
9703684|NCT04710017|Other|Tranexamic acid group|will tranexamic acid 500 mg 4 times daily in one group,
9703685|NCT04710017|Other|Medroxyprogesterone acetate|will receive 150mg of medroxyprogesterone acetate once intramuscular.
9703686|NCT04709939||Patient Participants|Adults patients who are discharged from the hospital on outpatient parenteral antibiotic therapy.
9703687|NCT04709939||Physician Participants|Infectious disease physicians who prescribe OPAT to their patients but were not involved in the study.
9703688|NCT04709965|Other|Main Study|Patients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern.
9703689|NCT04709965|Other|Faces Sub Study|Patients eligible to be recruited to the Faces Sub Study will have biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder.
9703690|NCT04710108|No Intervention|No treatment control|No treatment; no intervention (survey only)
9703691|NCT04710108|Experimental|Video|A Taste of Home video, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
9703692|NCT04710108|Experimental|Print|A Taste of Home comic book, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
9703693|NCT04710186||Male patients with PAD|The cohort was built to collect information about the role of androgen receptor, insulin receptor and Insulin-like Growth Factor 1 Receptor (IGF-IR) expression in patients with peripheral artery disease referred to Vascular Surgeon Specialist.
9703694|NCT04710043|Experimental|Part 1 group A BNT153|Monotherapy dose escalation.
9703695|NCT04710043|Experimental|Part 1 group B BNT152|Monotherapy dose escalation.
9703696|NCT04710160|Active Comparator|Novel fast setting calcium silicate ( Protooth)|In the form of powder and liquid to be mixed together to form paste.
9703697|NCT04710160|Experimental|MTA|In form of powder to be mixed with saline to form paste.
9703698|NCT04709809|Experimental|Experimental arm|Measurement RVA / IOP / with ECG gating
9978417|NCT01371357|Experimental|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
9978418|NCT01371357|Experimental|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
10190898|NCT05046236|No Intervention|Control group|Usual care
9703699|NCT04709770|Experimental|Low-volume preparation|"Low-volume preparation of 2-liters polyethylene glycol with citrate and simethicone. This formulation includes 4 large (A) and 4 small (B) sachets; the components of 2 sachets A and 2 sachets B are mixed in 1 liter of water.~Each sachet A contains:~polyethylene glycol (4000) 52.50 g;~simethicone 0.08 g;~sodium sulphate anhydrous 3.75 g.~Each sachet B contains:~sodium citrate 1.863 g;~anhydrous citric acid 0.813 g;~sodium chloride 0.73 g;~potassium chloride: 0.37 g;~acesulfame potassium 0.13 g. Participants will drink the first liter of preparation at 19.00 p.m. on the day before the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids. The second liter of preparation will be administered at 7.00 a.m. on the day of the colonoscopy, at a rate of 250 ml every 15 minutes, followed by 500 ml of clear liquids."
9703700|NCT04709770|Active Comparator|High-volume preparation|"High-volume preparation with 4-liters polyethyleneglycol with simethicone. This formulation includes 4 sachets, each dissolved in 1 liter of water.~Each sachet contains:~polyethylene glycol (4000) 58.30 g;~simethicone 0.08 g;~sodium sulphate anhydrous 5.68 g;~sodium bicarbonate 1.68 g;~sodium chloride 1.46 g;~potassium chloride 0.74 g. Participants will drink the first 2 liters of preparation at 19.00 p.m. on the day before colonoscopy, at a rate of 250 ml every 15 minutes. The remaining 2 liters of preparation will be administered at 6.00 a.m. on the day of the endoscopic procedure, at a rate of 250 ml every 15 minutes."
9703701|NCT04709731|Experimental|Total Patients|Intolerant Group Ponatinib 15 mg tablet, taken orally once daily (QD) Resistant Group Ponatinib 30 mg tablet, taken orally once daily (QD) The dose will be reduced to 15mg once daily (QD) as soon as a Complete Cytogenetic Response will be obtained. In those patients showing Major Molecular Response or better, the dose could be further reduced to 15MG every other day (EOD), due to the prolonged half-life of the drug.
9703702|NCT04709471|Experimental|Switch to low nicotine e-cigarettes|Switch to e-cigarettes containing 60% of baseline e-cigarette nicotine content.
9703703|NCT04709471|Experimental|Reduce number of e-cigarette pods|Reduce e-cigarette use to 60% of baseline number of pods per week.
9703704|NCT04709471|No Intervention|Use e-cigarettes as usual|Continue using usual nicotine e-cigarettes as usual.
9703705|NCT04709549|Active Comparator|Diabetes Prevention Program|The DPP is a behavioral obesity and diabetes prevention program run by the YMCA, over a 12-month period.
10190899|NCT05042544||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. In settings with high anticipated HCV antibody prevalence (>15%; e.g. drug treatment, prisons, needle and syringe programs), people who have previously been told they have HCV infection, or people who have previously received HCV treatment, testing will be performed using point-of-care HCV RNA testing. In settings with a low anticipated HCV antibody prevalence (<15%; e.g. mental health, homelessness), testing will be performed using point-of-care HCV antibody testing and if positive, point-of-care HCV RNA testing will be performed.
9703706|NCT04709549|Experimental|Diabetes Prevention Program + Job and Legal Services|Participants meet with service connectors to receive an individual assessment of your needs and create an individual service plan for job services and be referred to legal support services if also needed.
9703707|NCT04709406||obese patients|obese patients underwent bariatric surgery
9703708|NCT04709510|Other|AllPatients|There is only one cohort in this study. They all received the same follow up and ultrasound protocol.
9703709|NCT04709523|Experimental|i-PRF enriched bovine-derived xenograft|Patients treated with i-PRF-enriched bovine-derived xenograft + resorbable membrane
10190900|NCT05040659||Anosmic patients|Anosmic patients will be recruited from Dr. Albers Smell Clinic at MGH and through past participation in research with known anosmia and permission to recontact. All consent and testing will occur on a phone/tablet app in the participant's home.
10190901|NCT05040659||Asymptomatic participants / Healthy participants|Asymptomatic participants recruited in a hospital setting (eg. healthcare workers and household members of symptomatic patients who are potentially COVID positive). No symptoms of COVID infection at the time of enrollment. Potential or definite exposure to SARS-CoV-2 virus without symptoms of upper respiratory infection (smell loss, taste loss, fever, myalgia, cough, nasal congestion, runny nose, shortness of breath). All consent and testing will occur on a phone/tablet app in the participant's home.
10190902|NCT05040659||Symptomatic participants|Symptomatic individuals will be recruited from respiratory illness clinics to evaluate smell function in patients with either SARS-CoV2, Influenza, or Adenovirus infection. All consent and testing will occur on a phone/tablet app in the participant's home.
9703710|NCT04709523|Experimental|bovine-derived xenograft|Patients treated with bovine-derived xenograft + resorbable membrane
9703711|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/90|Stimulation delivered at 30 seconds ON and 120 seconds OFF through patient's existing spinal cord stimulator.
9703712|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/360|Stimulation delivered at 30 seconds ON and 360 seconds OFF through patient's existing spinal cord stimulator.
9703713|NCT04709588|Placebo Comparator|placebo group|subjects drank 50 ml every night for 14, 28 days
10190903|NCT05037175|Experimental|CPT-Text + Incentive|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Retention Incentive (RI). Participants will be told at baseline that they can retain their discount in subsequent months if they message with their therapist regularly."
9703714|NCT04709588|Experimental|collagen drinks|subjects drank 50 ml every night for 14, 28 days
9703715|NCT04709718||churgery of geant liver hemangioma|
9703716|NCT04709666||Endsocopic Retrograde ColangioPancreatography (ERCP)|Endsocopic Retrograde ColangioPancreatography (ERCP)
9703717|NCT04709536|Experimental|IBI306|IBI306 administered subcutaneously (SC)
9703718|NCT04709536|Placebo Comparator|Placebo|administered subcutaneously (SC)
9703719|NCT04709445|Experimental|ICG-NIRF Imaging and objective perfusion rate|Intraoperatively, ICG-NIRF imaging is used to visualize the blood supply and the rate of tissue perfusion in the area of the anastomotic site. Postoperatively, an additional ingress and egress analysis at specific regions of interest is performed.
9785080|NCT01242514|Experimental|C|Oral treatment
10190904|NCT05037175|Experimental|CPT-Text + Reminder As Usual|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
9703720|NCT04709744||SLE patients|SLE patients were presented to chest outpatient clinic and emergency hospital, Mansoura University with manifestation suggesting COVID-19 infection. Vit D was measured in serum by ELISA. Vit D was added to anti COVID-19.
9703721|NCT04709640|Experimental|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
9978419|NCT01371370|Experimental|Resistance exercise training|Lower-body exercises 3 times per wk for 12 wk
9978420|NCT01371370|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
9978421|NCT01371370|Experimental|Resistance exercise training & diet|Lower-body exercise training and diet
9978422|NCT01371370|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
9978423|NCT01371383|Experimental|omega-3 fatty acids|
10190905|NCT05037175|Active Comparator|Culturally Informed Trauma Treatment (CITT) + Incentive|"CITT will be conducted by Talkspace therapists with a specialty in PTSD culturally informed PTSD treatment.~Retention Incentive (RI). Participants will be told at baseline that they can retain their discount in subsequent months if they message with their therapist regularly."
9978424|NCT01371383|Placebo Comparator|Placebo|
9703722|NCT04709796|Experimental|Intervention group: EmbryoGlue|Embryo transfer with EmbryoGlue®
9703723|NCT04709796|Active Comparator|Control group|Conventional embryo transfer
9703724|NCT04709393|Experimental|Pre-screening|Receiving FRAX+SARC-F questionnaire pre-screening results on estimated fracture risk
9978425|NCT01371396|Other|Hispanic subjects|Subjects will identify as Hispanic ethnicity.
9978426|NCT01371396|Other|African American subjects|Subjects will self-identify as African American in origin.
9978427|NCT01371409|Experimental|active cTBS|
9703725|NCT04709393|No Intervention|Control|Not receiving FRAX+SARC-F questionnaire pre-screening preliminary results on estimated fracture risk
9703726|NCT04709692|Other|Arm 1 A (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
9703727|NCT04709692|Other|Arm 1 B (cohort 1)|Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
9978428|NCT01371409|Sham Comparator|Sham cTBS|
9978429|NCT01371422|Experimental|A1 (PVB)|PVB technique will be utilized for injection of the anaesthetic under the skin before the procedure.
9978430|NCT01371422|Placebo Comparator|A2 (Placebo)|The placebo is an inactive substance that looks identical to the test intervention but contains no active ingredients and will be administered the same as the PVB by a local skin injection, but no advancement of the needle to the paravertebral space will be made to avoid unnecessary risks.
9978431|NCT01371435||Patients prescribed PAXIL|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
9978432|NCT01371448||Patients prescribed PAXIL for long-term use|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
9978433|NCT01371461||Patients prescribed PAXIL|Patients with depression or depressed state prescribed PAXIL during study period
9978434|NCT01371474||Patients prescribed PAXIL|Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period
9978435|NCT01371487|Experimental|Treatment A|GSK1120212 Dose /Treatment 2.0 mg/Fasted
9978436|NCT01371487|Experimental|Treatment B|GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
9978437|NCT01371513||PSA level|more than 2.5ng/ml
9978438|NCT01371526|Experimental|Synacthen|active treatment
9978439|NCT01371604|Experimental|IDX184 50 mg + Peg-IFN/RBV|IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
9978440|NCT01371604|Experimental|IDX184 100 mg + Peg-IFN/RBV|IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
9978441|NCT01371617|Experimental|IPI-926|Single Arm, Phase 2 trial evaluating the safety and efficacy of IPI-926 in patients with myelofibrosis
9978442|NCT01371669||IPAH or CPEPH|Idiopathic pulmonary arterial hypertension (IPAH) or pulmonary hypertension associated with chronic post-embolic pulmonary hypertension (CPEPH)
9978443|NCT01371682|Other|Session 1|Ropinirole manufactued at Crawley will be compared to that manufactured at Aranda
9978444|NCT01371682|Other|Session 2|Ropinirole manufactured at Crawley will be compared to that manufactured at Aranda.
9978445|NCT01371760|Experimental|Intervention|The patients will undergo PTA of the extracranial cerebral veins
9978446|NCT01371760|Sham Comparator|Controls|The patients will undergo sham procedure
10190906|NCT05037175|Active Comparator|CITT+ Reminder as Usual|"CITT will be conducted by Talkspace therapists with a specialty in culturally informed PTSD treatment.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
10190907|NCT05034042|Experimental|Fezolinetant: low dose|Participants will receive low dose of fezolinetant once daily for 12 weeks.
9703728|NCT04709692|Other|Arm 2 A (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.vivax
10190908|NCT05034042|Experimental|Fezolinetant: high dose|Participants will receive high dose of fezolinetant once daily for 12 weeks.
10190909|NCT05034042|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 12 weeks.
9703729|NCT04709692|Other|Arm 2 B (cohort 2)|600 mg SJ733 administered orally once every day for three consecutive days for patients with P.falciparum
9703730|NCT04709692|Other|Arm 3 A (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
9978447|NCT01371773|Experimental|Left-sided double lumen tube|
9978448|NCT01371799|Experimental|Study drug at 4mg|GSK1034702 at 4mg
9978449|NCT01371799|Experimental|Study drug at 8mg|GSK1034702 at 8mg
9703731|NCT04709692|Other|Arm 3 B (cohort 3)|Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
9703732|NCT04709380|Experimental|Radiotherapy plus Toripalimab|Patients in the experimental group will be given local vein tumor thrombus/hepatic vein tumor thrombus +/- intrahepatic large lesions with hypofractionated intensity modulated radiotherapy (tumor area dose 40-60Gy/10-20f), concurrent with and followed by 240mg Q3W of teriprizumab within 1 week of radiotherapy.
9703733|NCT04709380|Active Comparator|Sorafenib|Patients in the control group will be treated with sorafenib (400mg, twice a day).
9703734|NCT04709185|Experimental|AVS after 1mg DST|Patients divided into AVS after 1mg DST group need to oral 1mg dexamethasone the night before AVS
9703735|NCT04709185|Placebo Comparator|AVS after placebo|Patients divided into AVS after placebo group need to oral placebo the night before AVS
9703736|NCT04709172|Experimental|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
9978450|NCT01371799|Placebo Comparator|Placebo|Placebo
9978451|NCT01371812|Experimental|Cohort 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 150mg, to 600mg, to 1200mg and 1200mg with a FDA high fat/high calorie meal, will be administered over the 13 week long study allowing adequate washout period between doses.
9978452|NCT01371812|Experimental|Cohort 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 300mg, to 900mg, and 1500mg, will be administered over the 13 week long study allowing adequate washout period between doses.
9978453|NCT01371864||Pediatric Cardiothoracic Team|This group consists of members of the cardiothoracic surgery team: The attending physician, the fellow physician, the nurses, and the physician assistants.
9978454|NCT01371864||Critical Care Team|This group consists of the nurses and physicians who work in the pediatric intensive care unit and the neonatal intensive care unit caring for patients who require cardiothoracic surgery.
9978455|NCT01371864||Subspecialty Team|This group consists of physicians and nurses from pediatric cardiology and pediatric anesthesiology who care for children who require cardiothoracic surgery.
9978456|NCT01371864||Parent|This group consists of the parent or legal guardian of the pediatric patient who requires cardiothoracic surgery.
9978457|NCT01371890||Intradialytic hypertension|Patients with systolic blood pressure increases > 10 mmHg during 4/6 hemodialysis sessions
9978458|NCT01371916||ESAT-6 positive|
9978459|NCT01371916||ESAT-6 negative|
9978460|NCT01371929||ICU patients who become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected to develop sepsis, severe sepsis, or septic shock.
9703737|NCT04709146|Other|Recovered Covid-19 patients|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
9703738|NCT04709146|Other|Healthy Control|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
9703739|NCT04709055|Experimental|Co-management arm (geriatric and surgical)|
9703740|NCT04709055|Active Comparator|Usual care|
9703741|NCT04709328|Experimental|SCTA01 low dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
9703742|NCT04709328|Experimental|SCTA01 middle dose+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
9703743|NCT04709328|Experimental|SCTA01 High dose +SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
9703744|NCT04709328|Placebo Comparator|Placebo+SOC|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
9703745|NCT04709315|Active Comparator|saline pretreatment/succinyl group (SS group).|patients receive pretreatment with 10 ml 0.9% saline over 10 minutes, and succinyl choline 1mg/ kg is the intubating muscle relaxant.
9703746|NCT04709315|Experimental|Dex pretreatment/ rocuronium group (DR group),|patients receive pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg is the intubating muscle relaxant.
9703747|NCT04709094|Experimental|Part 1: Danicopan and Warfarin|"Period 1: Participants received a single dose of warfarin.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of warfarin.~Scheduled pharmacokinetics (PK) and pharmacodynamics samples were collected, with a washout period of at least 14 days between the dose of warfarin in Period 1 and the first dose of danicopan in Period 2."
9984354|NCT04193644|Experimental|Mindfulness and Self-Compassion focussed Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax) and additionally practice mindfulness exercises and self-compassion exercises during the 60 minutes.
9984355|NCT04193644|No Intervention|TAU-Group|Participants in this group receive no intervention.
9703748|NCT04709094|Experimental|Part 2: Danicopan and Bupropion|"Period 1: Participants received a single dose of bupropion.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of bupropion.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of bupropion in Period 1 and the first dose of danicopan in Period 2."
9703749|NCT04709094|Experimental|Part 3: Danicopan and EE/NET|"Period 1: Participants received a single dose of EE/NET.~Period 2: Participants received danicopan three times daily, in addition to coadministration with a single dose of EE/NET.~Scheduled PK samples were collected, with a washout period of at least 7 days between the dose of EE/NET in Period 1 and the first dose of danicopan in Period 2."
9703750|NCT04709211|Active Comparator|Group I: Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca Block using bupivacaine 0.25%
9703751|NCT04709211|Active Comparator|Group Q: Anterior Quadratus lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using bupivacaine 0.25%
9703752|NCT04709068||COVID19+|
9703753|NCT04709289|Experimental|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
9703754|NCT04709341|Experimental|Group A|
9703755|NCT04709341|Active Comparator|Group B|
9703756|NCT04709081|Experimental|Part 1: ACH-0145228, Midazolam, and Digoxin|"Period 1: Participants received single doses of midazolam and digoxin.~Period 2: Participants received ACH-0145228 twice daily, in addition to coadministration with single doses of midazolam and digoxin.~Scheduled pharmacokinetics (PK) blood and urine samples were collected, with a washout period of at least 7 days between collection of the last PK blood sample in Period 1 and the first dose of ACH-0145228 in Period 2."
9703757|NCT04709081|Experimental|Part 2: ACH-0145228 and Itraconazole|"Period 1: Participants received a single dose of ACH-0145228.~Period 2: Participants received itraconazole once daily, in addition to coadministration with a single dose of ACH-0145228.~Scheduled PK blood samples were collected, with a washout period of at least 2 days between collection of the last PK blood sample in Period 1 and the first dose of itraconazole in Period 2."
9703758|NCT04709133|Experimental|multi-ligament knee injures|A chart review will be performed to identify patients who underwent surgical treatment for multiligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
9785081|NCT01242527|Placebo Comparator|placebo|
9785082|NCT01242527|Experimental|Epanova 2 g|
9785083|NCT01242527|Experimental|Epanova 3 g|
9785084|NCT01242527|Experimental|Epanova 4 g|
9785085|NCT01242644|Experimental|pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour;
9785086|NCT01242644|Active Comparator|saline pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
9785087|NCT01242644|Active Comparator|injectable medication only|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected and no pain pump.
9785088|NCT01242748|Experimental|Degarelix 240 mg/480 mg|
9785089|NCT01242748|Active Comparator|Goserelin acetate|
9785090|NCT01242813|Experimental|Canakinumab|This was an open-label, single treatment arm, multicenter study of monthly canakinumab 150 mg (2 mg/kg for patient ≤ 40 kg) subcutaneous injections in patients with active recurrent or chronic TRAPS.
9785091|NCT01243112|Experimental|Lidocaine w/ Epi|0.2ml 1% Lidocaine with Epinephrine (1:100,000)
9785092|NCT01243112|Experimental|Bupivacaine with epi|0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
9785093|NCT01243112|Experimental|Low dose Lido and Bupi w/ Epi|0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
9785094|NCT01243112|Experimental|High Dose Lido and Bupi with epi|0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
9785095|NCT01243151|Placebo Comparator|A|
9785096|NCT01243151|Experimental|B|
9785097|NCT01243151|Experimental|C|
9785098|NCT01243151|Experimental|D|
9785099|NCT01243151|Experimental|E|
9785100|NCT01243177|Experimental|Lacosamide|
9785101|NCT01243177|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|
9785102|NCT01243242|Experimental|METADOXINE|Eligible subjects will be randomly assigned to receive MG01CI (1,400 mg)
9785103|NCT01243242|Placebo Comparator|Placebo|Eligible subjects will be randomly assigned to receive Placebo (1,400 mg)
9785104|NCT01243268||Patients with essential hypertension|
9785105|NCT01243294|Active Comparator|SenSura|"CE marked and launched (The letters CE do not represent any specific words, though may have initially stood for Communauté Européenne (European Community) or Conformité Européenne (European Conformity). By affixing the CE marking to a product, the manufacturer declares that it meets EU safety and health and environmental requirements."
9785106|NCT01243294|Active Comparator|New ostomy appliance (SS)|SS = New ostomy appliance. Due to company confidentiality the product is just called SS and this is not short for any other names.
9785107|NCT01243320|Experimental|10ppm Oral Silver|Oral Dose of 10ppm
9785108|NCT01243320|Experimental|32ppm Oral Silver|Oral Dose of 32ppm
9785109|NCT01243333|Experimental|Diagnostic (multi-tracer PET scans)|Patients undergo Positron Emission Tomography (PET) scans with [F-18]fluorodeoxyglucose and [F-18]fluorothymidine at baseline and within 7 days of completion of 1 or 2 (if the course is less than 3 weeks) therapeutic agent courses.
9785110|NCT01243411|Experimental|AA4500|collagenase clostridium histolyticum
9785111|NCT01243424|Experimental|linagliptin|patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
9785112|NCT01243424|Active Comparator|glimepiride 1-4 mg QD|patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)
9785113|NCT01243450|Active Comparator|Active generic|Treatment of acne for 12 weeks with generic tretinoin
9785114|NCT01243450|Placebo Comparator|Placebo|Treatment of acne for 12 weeks with Placebo
9703759|NCT04709159|Active Comparator|Intervention|"Participants on this arm will use Interactive Voice Response (IVR) daily pill reminders, thrice-weekly health messages, clinic appointment reminders, remote symptom reporting service and a 24 hour toll-free number to access services. These participants will also have the option to co-register a caregiver who will also receive daily pill reminders, clinic appointment reminder, weekly health tips and remote symptom reporting service.~In addition, these participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines."
9703760|NCT04709159|No Intervention|Standard|These participants will receive the standard of care according to Uganda National Tuberculosis Treatment guidelines.
9703761|NCT04709302||COVID-19 positive, HIV-positive with ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV who are on ART
9978461|NCT01371929||ICU patients who do not become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected NOT to develop sepsis, severe sepsis, or septic shock.
9703762|NCT04709302||COVID-19 positive, HIV-positive without ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
9703763|NCT04709302||COVID-19 positive, HIV-negative|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
9703764|NCT04709276|Experimental|Neuroendocrine Prostate Cancer (NEPC) or Aggressive Variant Prostate Cancer (AVPC)|"Subjects with neuroendocrine prostate cancer (NEPC) or aggressive variant prostate cancer (AVPC) will receive a combination of nivolumab, ipilimumab, carboplatin and cabazitaxel for up to 10 cycles of 21 days each. After carboplatin and cabazitaxel are discontinued, a combination of nivolumab and ipilimumab will be administered.~Nivolumab will be administered intravenously at a dose of 360 mg every 3 weeks.~Ipilimumab will be administered intravenously at a dose of 1 mg/kg every 6 weeks.~Carboplatin will be administered intravenously at a dose of AUC 4 mg/ml per minute.~Cabazitaxel will be administered intravenously at a dose of 20 or 25 mg/m2."
9978462|NCT01371955||diabetic nephropathy group|patient with diabetic nephropathy, defined as Albuminuria > 30 mg/day or urinary Albumine/ creatinine ratio > 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
9978463|NCT01371955||diabetic retinopathy group|patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
9978464|NCT01371955||no complication group|patient without diabetic nephropathy or retinopathy
9703765|NCT04709029|Active Comparator|intravenous dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0. 5% +1 ml normal saline + intravenous 8 mg dexamethazone in 10 ml saline,to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
9703766|NCT04709029|Active Comparator|intrathecal dexamethazone group|Patients receive intrathecal 3 ml heavy bupivacaine 0.5% + 4 mg (1 ml) dexamethazone + intravenous 10 ml normal saline to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.
9978465|NCT01371968|Experimental|alfentanil|patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
9978466|NCT01372007|Experimental|Lanreotide Autogel 120mg|
9978467|NCT01372007|Placebo Comparator|Placebo|
9978468|NCT01372020|Sham Comparator|control group|
10190910|NCT05031975|Experimental|TEMIRI|"Irinotecan intravenous infusion (IV) given every 14 days in combination with oral (PO) temozolomide over days 1-5 every 28 days.~The treatment will consist of six 28-days cycles of TEMIRI."
9703767|NCT04709003||vaccinated|participants who received the Covid-19 vaccine
9703768|NCT04709003||unvaccinated|participants who didn't received the Covid-19 vaccine
9703769|NCT04708756|Experimental|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
9703770|NCT04708756|Experimental|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
9703771|NCT04708756|No Intervention|Control Group|Patients will not receive the Collabree application and will continue to receive standard care.
9703772|NCT04708795|Experimental|Verum|AP701 single dose oromucosal application
9703773|NCT04708743||CKD group|patients with CKD stage 3-5 including dialysis, followed tongue images by Automatic Tongue Diagnosis System
9703774|NCT04708743||Health group|patients who had no past history or systemic disease, CKD followed tongue images by Automatic Tongue Diagnosis System
9703775|NCT04708925||group A- conservative therpay|hypertriglyceridemia-induced acute pancreatitis patients who recieved conservative therapy
9978469|NCT01372020|Experimental|neuromuscular electrical therapy|
9978470|NCT01372033|Experimental|CBT|Use of cognitive behavioral therapy focused on social skill development and interpersonal relationships
9978471|NCT01372046|Experimental|Enhanced|A external consultant works with the team to develop skills and trains an in-house coach
9978472|NCT01372046|Experimental|Trainer|External consultant provides booster session
9978473|NCT01372046|Experimental|Standard|Receive agency training
9978474|NCT01372059|Experimental|Rhythm and music therapy|Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
9984356|NCT04193085||Spinal Muscular Atrophy (SMA)|ambulatory children and adults at least 5 years old by the time of enrollment with genetically confirmed SMA
9703776|NCT04708925||group B- plasmapharesis therapy|hypertriglyceridemia-induced acute pancreatitis patients who recieved plasmapharesis therapy
9703777|NCT04708821|Experimental|DEXTENZA|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
10190911|NCT05031897|Experimental|Radiation-Based Cohort (fludarabine, TBI, infusion)|Patients receive fludarabine IV on days -11, -10, -9, and -8, undergo TBI BID on days -10 and -9, undergo DLI on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
10190912|NCT05031897|Experimental|Chemotherapy-Based Cohort (fludarabine, melphalan, TBI)|Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo hematopoietic stem cell transplant on day 0.
9978475|NCT01372059|Active Comparator|Therapeutic riding|Therapeutic riding can be useful for individuals with neurological and muscular impairments. The goal of therapeutic riding as professional treatment is to improve neurological functioning and to achieve functional gains and enhance life skills.
9978476|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
10190913|NCT05023369|Experimental|Dexamethasone group|Patient in this group will receive administration of 9 mg dexamethasone injected in the peri-articular tissues after the bone cut for hip endoprosthesis
10190914|NCT05023369|No Intervention|Routine care|In this group only routinely performed anaesthesia protocol will be provided
10190915|NCT05023109|Experimental|GP+PD-1+Tight|"Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
10190916|NCT05021536|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
10190917|NCT05021536|Experimental|AMX0035|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
10190918|NCT05020405|Experimental|ARS with GBR and SMV|alveolar ridge splitting in combination with the use of GBR with SMV with immediate implant placement
9703778|NCT04708821|Active Comparator|Antihistamine|PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.
9703779|NCT04708821|Active Comparator|Topical Steroid|ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.
10190919|NCT05020405|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without SMV with immediate implant placement
10190920|NCT05019833|Experimental|Signals collection|Collection of sensors signals by the implanted device.
10190921|NCT05019677|Experimental|GP+PD-1+Tight|"Experimental: Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
9703780|NCT04708938|Experimental|Treatment group|High voltage electrical stimulation + exercise therapy
9703781|NCT04708938|Active Comparator|Control group|Exercise therapy
9703782|NCT04708808|Experimental|MVA case undergone music therapy|case undergone manual vacuum aspiration are randomised to receive music therapy during the procedure.
9703783|NCT04708808|No Intervention|Control|Routine Care
9703784|NCT04709562|Experimental|High Velocity Nasal Insufflation (HVNI)|Patients randomly assigned to this arm will be placed on HVNI therapy with an appropriately fitted Vapotherm Prosoft HVNI nasal cannula. Physiologic and ventilation parameters will be recorded.
9703785|NCT04709562|Active Comparator|Noninvasive Positive Pressure Ventilation (NIPPV)|Patients randomly assigned to this arm will be placed on NIPPV therapy with an appropriately fitted full face mask using a pressure support mechanical ventilator system. Physiologic and ventilation parameters will be recorded.
9703786|NCT04708769|Experimental|Smartphone App Participants (APP)|Smartphone application, diet and activity goals, online lessons, brief remote sessions with a Health Promotionist
9703787|NCT04708769|Experimental|Diabetes Prevention Program Participants (DPP)|Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist
9703788|NCT04708964|Active Comparator|Flurbiprofen|5 ml of flurbiprofen solution 0.25% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
10190922|NCT05018299|Placebo Comparator|FB704A placebo|placebo
10190923|NCT05018299|Experimental|FB704A|Anti-IL6 antibody
9703789|NCT04708964|Placebo Comparator|Placebo|5 ml of saline solution 0.9% will be administered, through the subglottic intake door of the endotracheal tube. The solution will be left in place for 1 minute
9703790|NCT04708977|Active Comparator|Group 1: Indirect Decompression|Lateral lumbar interbody fusion (LLIF), with indirect decompression
9703791|NCT04708977|Active Comparator|Group 2: Direct Decompression|Lateral lumbar interbody fusion (LLIF), with direct decompression
10190924|NCT05010785|Experimental|alveolar ridge splitting with GBR and i-PRF|alveolar ridge splitting in combination with the use of GBR with i-PRF (sticky bone) with immediate implant placement
9703792|NCT04709497|Active Comparator|viscotrabeculotomy (VT)).|
9703793|NCT04709497|Active Comparator|visco-circumferential-suture-trabeculotomy (VCST)|
9703794|NCT04709497|Active Comparator|Combined VT-Trabeculectomy with MMC (VT-Trab).|
9703795|NCT04708912||1|Mild-Moderate COVID-19
9703796|NCT04708912||2|Severe COVID-19
9703797|NCT04708912||3|Convalsent (COVID-19)
9978477|NCT01372072|Active Comparator|Humidification|Patients in this arm of the trial will receive humidification with the non-invasive ventilation.
9978478|NCT01372072|No Intervention|NIV without humidifivation|As per usual practice patients in this arm will not have humidification with their NIV
9978479|NCT01372098|Experimental|NFP + IPV intervention|The protocol for number and timing of visits will be the same for both NFP+IPVI and Standard Care, as follows: weekly for the first four visits, every other week for the remainder of the pregnancy, every week for six weeks in the postpartum and every other week until the infant is 21 months old after which it is once a month for the last three months. We recognize that the intervention might prompt the nurse and mother to alter the regular visit schedule if IPV is present.
9978480|NCT01372098|No Intervention|NFP (standard care)|"The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should assist her to evaluate threats to personal safety and make referrals as needed. There is a prompt to be mindful of client safety, and to make referrals as needed."
9978481|NCT01372124|Experimental|NOX-E36|All subjects included in this study will receive the same dose of NOX E36.
9703798|NCT04708912||4|Healthy persons
9978482|NCT01372137|Experimental|NOX-H94|Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks
9978483|NCT01372137|Placebo Comparator|Glucose 5%|Group A to Group H get NOX-H94 or Placebo
9703799|NCT04708873|Experimental|High Intensity Interval Training Group|Participants in this group will initially undergo continuous aerobic training to achieve a baseline fitness level, after which HIIT and resistance training will be employed. Warm-up period will be followed by 4 bouts of 4-minute interval treadmill running and stationary bike cycling at 80-95% of the measured HR reserve, interspersed with active recovery phase at 55-70% HRR. After this resistance exercises will be performed in a circuit fashion for strengthening the upper limbs, lower limbs and trunk. The session will be ended with a 5-7 minute cool-down period
9703800|NCT04708873|Active Comparator|Moderate Intensity Continuous Training Group|Participants in this group will also initially undergo continuous aerobic training to achieve a baseline fitness level, after which the intensity will be increased to moderate continuous training achieving 55-70% of HRR. Every session will be preceded by appropriate warm-up and end with cool down.
9978484|NCT01372163|Experimental|2 mg PF-05190457 or Placebo BID|
9978485|NCT01372163|Experimental|10 mg PF-05190457 or Placebo BID|
9703801|NCT04708899|Active Comparator|Cases|cases will receive the proposed program(the arabic version of differential processing training program)
9703802|NCT04708899|Active Comparator|control|controls will receive the computer based auditory training program (CBAT)
9703803|NCT04708717|Experimental|Stimulation Rate|
9703804|NCT04708717|Active Comparator|Electrode Location|
9978486|NCT01372163|Experimental|40 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
9978487|NCT01372163|Experimental|150 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
9978488|NCT01372163|Experimental|5 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
9978489|NCT01372163|Experimental|50 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
9978490|NCT01372163|Experimental|xxx mg PF-05190457 or Placebo|Dose and dose frequency to be determined based on emerging safety and PK data.
9978491|NCT01372176|Experimental|Early Goal-Directed Nutrition|
9978492|NCT01372176|Active Comparator|ASPEN-guidelines|
9778831|NCT01116986|Experimental|17, No Patch, Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778832|NCT01116986|Experimental|18, No Patch, Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778833|NCT01116986|Experimental|19, No Patch, Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778834|NCT01116986|Experimental|20, No Patch, Gum, Prequit, Int In-Person, Int Phone, 16Wk|How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt
9785115|NCT01243450|Active Comparator|Brand|Treatment of acne over 12 weeks with tretinoin Brand
9978493|NCT01372189||colorectal cancer|Patients with colorectal carcinoma during conventional endoscopic imaging.
9978494|NCT01372189||colorectal adenoma|Patients with colorectal adenoma during conventional endoscopic imaging.
9978495|NCT01372228|Experimental|Inherited Metabolic Disorder Patients|Recipients are treated with hematopoietic stem cell infusion from living donors
9978496|NCT01372241|Experimental|Early Intervention|This group served as the treatment group for analysis of the primary outcome.
9978497|NCT01372241|No Intervention|Delayed Intervention|This group served as a wait-list control group, eventually receiving the intervention after the treatment group completed the intervention and the primary outcomes were assessed for both groups.
9978498|NCT01372267|Experimental|CBT for pain|
10190925|NCT05010785|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without i-PRF (sticky bone) with immediate implant placement
9978499|NCT01372267|Active Comparator|Psychoeducational control group|This group is designed to be an active control which provides detailed information about substance us and chronic pain without providing any CBT or other specific therapy.
9978500|NCT01372280|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
9978501|NCT01372280|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
10190926|NCT05008965|Experimental|FB825|"FB825 will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.~FB825 will be administered as 1-hour IV- infusions every 4 weeks."
10190927|NCT05008965|Placebo Comparator|Placebo|"Placebo will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.~Placebo will be administered as 1-hour IV- infusions every 4 weeks."
9978502|NCT01372306|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's
9978503|NCT01372306|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
9703805|NCT04709679|Experimental|Constant dwell time but varying power and duration|The laser dwell time will be constant but the laser power and duration will be varied for patients
9703806|NCT04709679|Experimental|Constant power but varying dwell time and duration|The laser power will be constant but the laser dwell time and duration will be varied for patients
9703807|NCT04709679|Experimental|Constant duration but varying dwell time and power|The laser duration will be constant but the laser dwell time and power will be varied for patients
9703808|NCT04708691|Experimental|Aerobic exercise|aerobic exercise for 30 mins
9703809|NCT04708691|No Intervention|Control|sitting for 30 mins
9703810|NCT04708652||preterm children|Our previous intervention study enrolled 178 VLBW (birth body weight less than 1,500 gm) preterm children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
9703811|NCT04708652||term children|Our previous intervention study enrolled 62 term children who were born or admitted at the National Taiwan University Hospital, the Mackay Memorial Hospital and Taipei City Hospital, Branch for Women and Children in Taipei, Taiwan, during the time period of 2006 to 2008. No any intervention was conducted, just the observation.
9703812|NCT04708379|Experimental|Intervention group|Nutrition education and physical activity education.
9703813|NCT04708379|No Intervention|Control group|No specific intervention.
9978504|NCT01372319||Glaucoma Patients (OAG, Aulhorn stages II - IV)|Manifest glaucoma (OAG, Aulhorn stages II - IV) with advanced binocular visual loss, as obtained by semi-automated kinetic perimetry (SKP), no study medication
9978505|NCT01372319||Normal subjects|male+female > 18 years
10190928|NCT05003609|Active Comparator|Intervention Group|ECMO early rehabilitation is led by a senior physiotherapist who has specialised training in ECMO care and coordinates individualised early physical training from randomisation to day 28 in ICU and liaises with the patient through to hospital discharge. The early rehabilitation intervention involves physical activity, functional retraining, strengthening exercises and mobilisation based on a reproducible, physiological approach.
10190929|NCT05003609|No Intervention|Control Group|The control group will receive standard care from nursing and physiotherapy staff not involved in the early, co-ordinated rehabilitation.
10190930|NCT05002127|Experimental|Phase 2 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
10190931|NCT05002127|Active Comparator|Phase 2 - Arm B|Trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
10190932|NCT05002127|Experimental|Phase 3 - Arm A|Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
9785116|NCT01243567|Active Comparator|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
9978506|NCT01372332||Normal subjects|Age-related (+ 5 years of age) and gender-matched normal subjects.
9978507|NCT01372332||Patients with homonymous hemianopia|Patients with homonymous visual field defects
9978508|NCT01372345|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
9978509|NCT01372345|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
9978510|NCT01372358|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
9978511|NCT01372358|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
9978512|NCT01372371|Active Comparator|Vancomycin|
9978513|NCT01372371|Active Comparator|Vancomycin and Gentamycin|
9978514|NCT01372371|Active Comparator|Intravenous Antibiotic|
9978515|NCT01372423|Active Comparator|AMITIZA|Manufactured by Sucampo Pharmaceuticals (24 mcg administered for 7 days)
9978516|NCT01372423|Placebo Comparator|Placebo|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
9978517|NCT01372423|Experimental|Lubiprostone|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
9978518|NCT01372436||1|children in high-school
9978519|NCT01372436||2|children in primary school
10190933|NCT05002127|Active Comparator|Phase 3 - Arm B|Ramucirumab 8 mg/kg Q2W IV and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.
9703814|NCT04708314|Other|30 mg/kg|Golodirsen 30 mg/kg will be administered as an intravenous (IV) infusion over approximately 35 to 60 minutes once a week during the treatment period (up to 96 weeks). After the treatment period, patients can go into a safety extension period (not to exceed 48 weeks) until the patient is able to transition to commercially available drug or a separate golodirsen study.
9703815|NCT04708457|Active Comparator|Early ECMO|Early ECMO therapy for patients who have SARI and have been mechanically ventilated for 5-7 days.
9978520|NCT01372449|Active Comparator|Memantine|
9978521|NCT01372449|Placebo Comparator|Placebo|Placebo Comparator
9978522|NCT01372488|Active Comparator|Study group|Study group will be provided with suture removal instructions and suture removal kit and asked to consider removing their own sutures
9978523|NCT01372488|Placebo Comparator|Control group|Control group will be asked to have their sutures removed as they normally would (see family doctor or clinic)
10190934|NCT04999969|Experimental|AZD0171 + Durvalumab + chemotherapy|Participants will receive AZD0171 (intravenous [IV]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel).
10190935|NCT04995887||C-Section Delivery with EBL ≥ 1500 mL|Patients with ≥ 1500 mL estimated blood loss (EBL) at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
10190936|NCT04995887||C-Section Delivery with EBL < 1500 mL|Patients with < 1500 mL EBL at time of Jada insertion for cesarean delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
10190937|NCT04995887||Vaginal Delivery with EBL ≥ 1000 mL|Patients with ≥ 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
10190938|NCT04995887||Vaginal Delivery with EBL < 1000 mL|Patients with < 1000 mL EBL at time of Jada insertion for vaginal delivery; data collection will continue until a minimum of 100 patients are enrolled in each group/category or until March 31, 2022 (whichever occurs first).
10190939|NCT04992416|Experimental|SMV with ATBG around implant|SMV mixed with ATBG around immediately placed dental implants in the extraction sockets
10190940|NCT04992416|Active Comparator|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
10190941|NCT04987333|Experimental|Group 1: Chinese participants - efavaleukin alfa dose level 1|Chinese participants will receive a single dose of efavaleukin alfa at dose level 1.
9703816|NCT04708457|No Intervention|Standard Care|Patients with SARI who are already mechanically ventilated will continue to receive the standard intensive care therapies, including ECMO if required.
9703817|NCT04708405||Inflammatory bowel disease patients|Inflammatory bowel disease patients screened for Helicobacter Pylori Infection
9703818|NCT04708483|Experimental|Malignant thoracic tumoral pathology.|Patients suffering from primary malignant thoracic tumoral pathology or second line patients having had a therapy pause of at least 6 weeks.
9703819|NCT04708275|Experimental|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
9703820|NCT04708275|Active Comparator|Waitlist|PaCT after a waiting period (3 months)
9703821|NCT04708574|Experimental|Intervention|The intervention group attended a supervised exercise program for women only that presented Arabic music and traditional dance steps (the Lebanese Dabka) three times a week in the London Muslim Mosque Gym. The intervention lasted 12 weeks. There was also a nutrition education component that occurred once per week for the duration of the intervention. The lifestyle intervention group was instructed to walk 10,000 steps per day for the 12 weeks of the program. They were given instructions to take a 30-min walk on days when no formal exercise sessions were offered.
9703822|NCT04708574|Placebo Comparator|Control|The control group participants followed their typical work and leisure routines during the weeks of investigation. The women in the control group were offered the same intervention at the end of the 12 weeks.
9703823|NCT04708587|Active Comparator|dual anti-platelet therapy at least 6 months|
9703824|NCT04708587|Experimental|dual anti-platelet therapy 3months or less|
9703825|NCT04708392|Experimental|Tonic spinal cord stimulation|Patients are programmed with tonic (continuous) spinal cord stimulation for a period of four weeks.
9703826|NCT04708392|Experimental|Burst spinal cord stimulation|Patients are programmed with burst (intermittent) spinal cord stimulation for a period of four weeks.
9703827|NCT04708366|Experimental|1L PEG|Patients will be prepared with 1L-PEG-based bowel preparation.
9703828|NCT04708366|Active Comparator|2L PEG|Patients will be prepared with 2L-PEG-based bowel preparation.
9703829|NCT04708366|Active Comparator|4L PEG|Patients will be prepared with 4L-PEG-based bowel preparation.
9703830|NCT04708496|Experimental|Standard dose of Artemether lumefantrine|Dose comparison-concurrent control In this arm, Participants receiving Efavirenz400mg based ART will be randomized to standard dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
9978524|NCT01372514||suspected thromboembolic disease|Patients with thromboembolic disease according to diagnostic tests (MDTC with angiography, scintigraphy V/Q, dimer d, ecografia doppler, etc. ) required by the physician.
9984357|NCT04193085||Duchenne / Becker Muscular Dystrophy (DMD/BMD)|ambulatory children and adults ages at least 5 years old by the time of enrollment with genetically confirmed Duchenne or Becker muscular dystrophy or evidence on muscle biopsy with a clinical presentation consistent with DMD /BMD.
9984358|NCT04193085||Healthy Control|The healthy control group will be age and gender-matched to the SMA and DMD groups as best as possible
9984359|NCT04190823|Experimental|RC98|
9984360|NCT04189263|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
9984361|NCT04189263|Active Comparator|No dietary intervention|Standard of care aromatase inhibitors
9703831|NCT04708496|Experimental|Double dose Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to double dose Artemether Lumefantrine when treating uncomplicated malaria in HIV-malaria co-infected participants
9703832|NCT04708496|Experimental|5 day course of Artemether lumefantrine|Dose comparison concurrent control In this arm, Participants receiving Efavirenz based ART will be randomized to 5 day course of Artemether Lumefantrine as opposed to the standard 3day course when treating uncomplicated malaria in HIV-malaria co-infected participants
9703833|NCT04708249|Experimental|D-chiroinositol treatment|
10190942|NCT04987333|Experimental|Group 2: Chinese participants - efavaleukin alfa dose level 2|Chinese participants will receive a single dose of efavaleukin alfa at dose level 2.
10190943|NCT04987333|Experimental|Group 3: Japanese participants - efavaleukin alfa dose level 2|Japanese participants will receive a single dose of efavaleukin alfa at dose level 2.
10190944|NCT04987333|Experimental|Group 4: Caucasian participants - efavaleukin alfa dose level 2|Caucasian participants will receive a single dose of efavaleukin alfa at dose level 2.
9703834|NCT04708548||Oligodendroglioma (Grade II and III) Patients|Patients diagnosed with a WHO Grade II or III Oligodendroglioma
9703835|NCT04708236|Experimental|ORTD-1 Low dose|Arm 1: ORTD-1
9703836|NCT04708236|Experimental|ORTD-1 Mid Dose|Arm 2: ORTD-1
9978525|NCT01372527|Experimental|TopCare Intervention|"The TOP-CARE intervention will be based on a medical informatics platform that:~Identifies all patients eligible for any of the three cancer screening programs~Links patients with a specific clinician~Offers a visit-independent method for clinicians to review panels of their eligible patients~For patients due for one or more cancer screenings, clinicians will access a web-based informatics tool to:~Screen their panel based upon risk~Defer patients, document exclusions, and update the EHR~Order a screening test with patient information material based upon the patient's risk profile and automatically initiate the process of:~Informing the patient by letter of the need to schedule a test, educating the patient with respect to the benefits of cancer screening, and properly documenting the transaction in the patient's EHR, or~Referral to a patient navigator for patients most likely to benefit from this more intensive approach"
9703837|NCT04708236|Experimental|ORTD-1 High Dose|Arm 3 : ORTD-1
9984362|NCT04186663|Experimental|Advantage Arrest|38% silver diamine fluoride, topical, 1 drop, single application
9984363|NCT04180267|No Intervention|Control Group|Subject assigned to Control Group will not receive LMHFV
9703838|NCT04708236|Placebo Comparator|Vehicle Control|Arm 4: Vehicle control
10190945|NCT04987047||Prescription with pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants based on the results of pharmacogenetics analyses.
10190946|NCT04987047||Prescription without pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants left to the discretion of the clinician without pharmacogenetics assistance.
10190947|NCT04983810|Experimental|Phase I Dose escalation|"Phase I = Fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.~Phase 2 = Recommended Fadraciclib phase 2 dose and schedule administered orally in 28 day cycles."
10190948|NCT04981145|Experimental|IGU Group|
9703839|NCT04708210|Experimental|Phase Ia Dose-Escalation Stage: IBI319|
9703840|NCT04708561|Experimental|Brain-injured participants|
10190949|NCT04981145|Active Comparator|HCQ Group|
9703841|NCT04708353|Placebo Comparator|control group|the patient will receive one placebo capsule (vitamin c) once one hour before the operation.
9703842|NCT04708353|Active Comparator|Group Pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
10190950|NCT04976231||Treatment Naive|subjects who are naïve to ERT and start treatment with idursulfase
9703843|NCT04708353|Active Comparator|Group Pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
9703844|NCT04708132|Active Comparator|screw retained restorations|
9703845|NCT04708132|Other|implant-retained ball overdentures|
9703846|NCT04708522|Experimental|Breath Control|Participants in the breath control study arm will be given a breathing exercise that is to be completed in a comfortable upright seated posture. This intervention exercise will be completed daily for a period of 8 weeks.
9703847|NCT04708522|Experimental|Guided Mindfulness|Participants in the guided mindfulness study arm will be lead through a seated mindfulness exercise. This intervention exercise will be completed daily for a period of 8 weeks.
9703848|NCT04708522|Sham Comparator|Control|Participants in the control group will receive a sham intervention. The sham intervention will involve minimal instructed meditation exercise. This intervention exercise will be completed daily for a period of 8 weeks.
9703849|NCT04707989|Experimental|Ketone-Promoting Food Ingredient 1|Novel ketone-promoting food ingredient (#1) administered in a beverage once daily for 28 days.
9703850|NCT04707989|Placebo Comparator|Ketone Free Placebo|Beverage matched for appearance, volume, taste and texture to experimental arm (ketone promoting food ingredient #1) that does NOT contain a ketone ingredient. Consumed once daily for 28 days.
9703851|NCT04707989|Active Comparator|Ketone-Promoting Food Ingredient 2|Previously characterized ketone-promoting food ingredient (#2) administered in a beverage once daily for 28 days.
9703852|NCT04708197|Other|aphasic patients|post stroke aphasic patients will receive 10 sessions of high frequency rTMS 3 times per week over the damaged hemisphere without language therapy
9703853|NCT04708002|Other|First EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
10190951|NCT04976231||Treatment less than 3 years|Subjects who have received ERT for <3 years
10190952|NCT04976231||Treatment over 3 years|Subjects who have received ERT for 3 or more years
9703854|NCT04708002|Other|Early intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
9703855|NCT04708002|Other|Late intermediate EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
9978526|NCT01372527|Active Comparator|Augmented Standard Care|In augmented standard care control practices, we will implement a system that includes: 1) a population-based perspective to identify all eligible patients overdue for screening, 2) an automated, centralized process to contact selected patients by letter, 3) a result management system that automatically tracks test scheduling and completion, 4) a web-based, easily accessible tool allowing practice personnel to contact patients not completing testing, and 5) use of patient navigators for high risk patients not responding to initial outreach. In the control arm, the process of escalating the reminder intervention from a letter, to contact by phone call, to a patient navigator, will occur in a standard algorithmic fashion without provider input.
9978527|NCT01372540|Experimental|Treatment (filanesib and carfilzomib)|Patients receive filanesib IV over 1 hour on days 1, 2, 15, and 16 and carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 8 courses of therapy, patients may continue with dosing of carfilzomib on days 1, 2, 15, and 16 and filanesib as tolerated. If patient progresses on carfilzomib maintenance with administration on days 1, 2, 15, and 16 they may increase the intensity and add in days 8 and 9 dosing.
9703856|NCT04708002|Other|Last EIPCA-NH group|There are 5 nursing home in each arm (cluster), randomly selected from 3 French areas.
9703857|NCT04708184|Experimental|GLPG3970 solution|Single oral dose of GLPG3970 in fasted conditions
9703858|NCT04708184|Experimental|GLPG3970 tablet fasted|Single oral dose of GLPG3970 in fasted conditions
9703859|NCT04708184|Experimental|GLPG3970 tablet fed|Single oral dose of GLPG3970 in fed conditions
9703860|NCT04707833|Experimental|Patient infected or cured from covid19|"Patients with an acute SARS-CoV-2 infection confirmed by a positive RT-PCR, hospitalized in COVID units or in COVID resuscitations,~Nurses at the Rouen University Hospital infected with COVID 19, and cured,~Patients with a high suggestive clinic for COVID-19 infection but with negative COVID-19 RT-PCR"
9703861|NCT04707859||Cohort|"Participants consenting to the study will undergo:~a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years~Patients with suspicion of coronary stenosis detected by CCTA will after undergo:~b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)"
9703862|NCT04707950|Active Comparator|study group will be given tranexamic acid|"Participants will be divided into two groups: a study group & a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~Bleeding continues after 30 minutes~Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
9703863|NCT04707950|Placebo Comparator|Control group|The control group will not be given Tranexamic acid but only the standard management ( Oxytocin )
9703864|NCT04708093|Experimental|whole body vibration training (WBVT)|whole body vibration group
9703865|NCT04708093|No Intervention|Controlled|advised about healthy dieting
9703866|NCT04708119|Other|histopathological evaluation|angulation of impacted lower mandibular third molar and histopathological evaluation
9978528|NCT01372553||Family history risk stratification|primary care patients who receive risk stratification and clinical decision support based upon the family health history they entered in to MeTree
9978529|NCT01372579|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9703867|NCT04708028||Control|No exposure to the therapy dog.
9703868|NCT04708028||Dog Therapy|Introduced to a therapy dog and allowed to pet the dog for up to 2 minutes (timed) prior to the dental procedure.
9703869|NCT04708106|Experimental|RELX ENDS Tobacco Flavor|Switch from combustible cigarettes to RELX ENDS Tobacco Flavor for 56 days
9978530|NCT01372592||Degenerative|Patients being treated for degenerative spine conditions.
9978531|NCT01372592||Deformity|Patients being treated for a deformity spine condition.
9978532|NCT01372592||Trauma|Patients being treated for a trauma related spine condition.
9703870|NCT04708106|Experimental|RELX ENDS Menthol Flavor|Switch from combustible cigarettes to RELX ENDS Menthol Flavor for 56 days
9703871|NCT04708106|Experimental|RELX ENDS Tobacco and Menthol Flavors|Switch from combustible cigarettes to RELX ENDS Tobacco and Menthol Flavor for 56 days
9703872|NCT04708106|No Intervention|Continue-smoking|Continue smoking combustible cigarettes for 56 days
9703873|NCT04708080||Group E|patients who underwent thoracic epidural catheter for postoperative analgesia
9703874|NCT04708080||Group I|Patients who cannot be applied thoracic epidural catheter for postoperative analgesia
9703875|NCT04707807||Nightshift workers|
9703876|NCT04707807||Non-nightshift workers|
9703877|NCT04707924|Experimental|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
9703878|NCT04707924|No Intervention|Control area|No treatment performed on control areas.
10190953|NCT04973696|Experimental|Toolkit for Optimal Recovery after Orthopedic Injury - Active|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
10190954|NCT04973696|Active Comparator|Minimally Enhanced Usual Care (MEUC) - Control|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
10190955|NCT04971096|Experimental|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
10190956|NCT04971096|Experimental|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
10190957|NCT04971096|Placebo Comparator|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
10190958|NCT04971096|No Intervention|Healthy Control|No intervention
10190959|NCT04962698|Experimental|All participants|All participants will receive various types of interventions in random order. The types of interventions are the same across subjects.
10190960|NCT04961996|Experimental|Arm A: Giredestrant|
10190961|NCT04961996|Active Comparator|Arm B: Endocrine Therapy of Physician's Choice|
10190962|NCT04959812|Experimental|Sufentanil|Sufentanil (30 microgram tablet) will be administered via a sublingual pill
10190963|NCT04959812|Placebo Comparator|Placebo|Placebo will be administered via a sublingual pill
10190964|NCT04956952|Other|Enhanced External Counterpulsation (EECP)|1 hour of treatment with EECP
10190965|NCT04955444|No Intervention|Historical control group|The historical control group underwent a thyroidectomy or parathyroidectomy procedure prior to implementation of the quality improvement bundle.
10190966|NCT04955444|Experimental|Post-implementation group|The post-implementation group will have a thyroidectomy or parathyroidectomy procedure after bundle implementation and will receive care that is enhanced by the quality improvement bundle.
10190967|NCT04952610|Experimental|Etripamil NS 70 mg|Self- administration of a dose of 70 mg of etripamil. Patients will be provided with a maximum of 4 pre-filled devices at a time. If the symptoms of PSVT persist 10 minutes after the first dose of etripamil NS 70 mg, a second dose of etripamil NS 70 mg can be self-administered by the patient. A second dose of etripamil NS 70 mg should be taken not earlier than 10, and not later than 15 minutes after the first dose.
9703879|NCT04707898|Experimental|Group Single Bond Universal|Single Bond Universal adhesive system with selective-etch approach following the manufacturer's instruction
9703880|NCT04707898|Experimental|Group G-Premio Bond|G-Premio Bond Adhesive System with selective-etch approach following the manufacturer's instruction
9978533|NCT01372631|Experimental|Pressure assessment|30 patients undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled to assess the ideal pressure that should be applied when taking optical measurements.
10190968|NCT04946916|Experimental|Participant with psychiatric condition without cognitive impairment|In the psychiatric condition group without cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria.
10190969|NCT04946916|Experimental|Participant with psychiatric condition with cognitive impairment|In the psychiatric condition group with cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. To date, there are no clinical criteria for defining the dementia evolution of psychiatric disorders. The diagnosis of psychiatric disorder with cognitive involution is often made on the basis of subjective criteria or on the appreciation of health care teams. In the present study, cognitive involution will be defined by the occurrence of cognitive deterioration objectified by disturbed neuropsychological tests and the occurrence of progressive behavioral changes contrasting with the person's previous state and reported by the care team, a member of the family or by the patient himself. Cognitive involution must be accompanied by a decrease in autonomy with respect to the person's previous abilities.
10190970|NCT04946916|Experimental|Patients with biological Alzheimer's disease|Alzheimer's disease with frontal, amnestic, language, and visual presentation with typical Alzheimer CSF according to the 2011 NIA-AA diagnostic criteria.
10190971|NCT04946916|Experimental|Patient with fronto-temporal dementia|Probable or definite Fronto-temporal dementia, mostly behavioral variant of FTD (according to the diagnostic criteria for FTDb of Rascovsky, 2011) but Semantic Disease, Primary Progressive Non-Fluent Aphasia, Progressive Supra-Nuclear Palsy-DFT will be accepted if behavioral onset.
10190972|NCT04943848|Experimental|"Lead In: rHSC-DIPGVax Monotherapy"|rHSC-DIPGVax for 8 total doses
10190973|NCT04943848|Experimental|Part A: rHSC-DIPGVax in Combination with BALSTILIMAB (Anti-PD1)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 12 years or older. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB), the study will proceed to Part B."
9978534|NCT01372631|Experimental|Random and Systematic Errors|40 patients undergoing lumpectomy or mastectomy will be enrolled to assess the random and systematic errors of the miniature spectral imaging system.
9703881|NCT04707963|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
9703882|NCT04707963|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
9703883|NCT04707755|Experimental|Motor imagery technique|Motor Imagery technique Plus Conventional Physical therapy
9703884|NCT04707755|Active Comparator|Conventional Physical therapy|passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
9703885|NCT04707820|Experimental|Patient group|- Patient with an acute SARS-CoV-2 infection, confirmed by PCR or typical CT images, requiring hospitalization in a COVID unit at Rouen University Hospital.
9703886|NCT04707820|No Intervention|control group|- Rouen University Hospital staff free of any symptomatology compatible with an SARS-CoV-2 infection (fever, cough, fatigue, loss of taste, loss of smell) since February 1, 2020
9703887|NCT04708171||Awake mapping under local anesthesia|
9703888|NCT04708171||Asleep mapping under general anesthesia|
9703889|NCT04708171||Resection under general anesthesia without mapping|
9703890|NCT04707742|Experimental|Povidone-iodine 2% (Betadine© bucal 100 mg/ml)|"Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).~The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (3 mL of povidone-iodine 10% for oral use - Betadine© with 12 mL of distilled water)."
9827816|NCT02469389|Experimental|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
10190974|NCT04943848|Experimental|Part B: Dose Escalation of ZALIFRELIMAB (Anti-CTLA4)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 12 years or older. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB), the study will proceed to Part C."
10190975|NCT04943848|Experimental|Part C: Dose Expansion|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity."
10190976|NCT04941716|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-28. Patients receive acalabrutinib alone for the first three 28 day cycles. Venetoclax is added beginning with Cycle 4. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
10190977|NCT04932265|Active Comparator|Red ginseng HRG80|16 subjects will receive 200 mg of red ginseng preparation HRG80 in one capsule
10190978|NCT04932265|Experimental|Red ginseng HRG80 incorporated in gamma-cyclodextrin|16 subjects will receive 200 mg of red ginseng preparation HRG80 incorporated in gamma-cyclodextrin in two chewable tablets
10190979|NCT04928339|Experimental|PIFB intervention|bilateral PIFB with a mixture of standard 0.25% bupivacaine (15 mL) and 133 mg liposomal bupivacaine (10mL)
10190980|NCT04928339|Sham Comparator|Saline Control|bilateral PIFB with 25 mL saline only
10190981|NCT04926337||Tight fitting facemask|Preoxygenation with tight facemask, 100% oxygen.
10190982|NCT04926337||High flow nasal oxygen|Preoxygenation with high flow nasal oxygen, 100% oxygen
10190983|NCT04923594|Active Comparator|NLS-2 (mazindol extended release)|2 mg dosed orally, once daily for 1 week; followed by 3 mg dosed orally, once daily for up to 3 weeks (total of 4 weeks)
10190984|NCT04923594|Placebo Comparator|Placebo|Dosed orally, once daily for up to 4 weeks
10190985|NCT04923048|Experimental|GB261|Participants will receive GB261 via intravenous (IV) infusion as a single agent on Day 1, Day 8 and Day 15 of Cycle 1 and 2 followed by Day 1 of each cycle（21 days per cycle） afterwards until disease progression or other situations specified in the protocol, whichever comes earlier.
10190986|NCT04922333|Experimental|Bisphosphonate|Participants in this arm will receive six months of 150 mg once monthly oral risedronate
10190987|NCT04922333|Placebo Comparator|Placebo|Participants in this arm will receive six months of placebo
10190988|NCT04921995|Experimental|Experimental|"Main group: Patients will be given first line tislelizumab plus investigator's choice chemotherapy, with re-irradiation postponed or omitted.~Subgroup: For patients that progressed after exposure to another PD-1 antibody, tislelizumab rechallenge combined with either low dose SBRT or low dose gemcitabine and metronomic capecitabine is accepted as a second subgroup."
10190989|NCT04917549||Patients diagnosed with COVID-19|
10190990|NCT04912089|Experimental|Cognitive Training Low Dose|Cognitive training completed for 8 sessions
10190991|NCT04912089|Experimental|Cognitive Training High Dose|Cognitive training completed for 16 sessions
10190992|NCT04912089|No Intervention|Repeat Assessment|
9703891|NCT04707742|Experimental|Hydrogen peroxide 1% (Oximen® 3%)|Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain). The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (5 mL of hydrogen peroxide 3% - Oximen© with 10 mL of distilled water).
9703892|NCT04707742|Experimental|Clorhexidine 0,12% (Clorhexidine Dental PHB©)|"Clorhexidine 0,12% (Clorhexidine Dental PHB©) contains clorhexidine (C22H30N10Cl2).~Rinses were ready to use in their commercial formulas."
9703893|NCT04707742|Experimental|Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©)|"Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©) contains cetylpyridinium chloride (C21H38ClN).~Rinses were ready to use in their commercial formulas."
9703894|NCT04707742|Placebo Comparator|Control (Distilled Water)|Distilled water.
9703895|NCT04707560|Experimental|Heparin Wet first group|Heparin based wet suction method of EUS FNB will go first for 2 passes and then shift to dry suction method for another 2 passes.
9703896|NCT04707560|Experimental|Dry suction first group|Dry suction method of EUS FNB will go first for 2 passes and then shift to heparin base wet suction method for another 2 passes.
9703897|NCT04707547|Experimental|Radiofrequency Ablation|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy
9703898|NCT04707547|Placebo Comparator|Radiofrequency Ablation combine with Nivolumab|Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy, and improving immune systems by Nivolumab
9703899|NCT04707508|Experimental|Valsartan and metformin|
9703900|NCT04707508|Active Comparator|Metformin only|
9978535|NCT01372631|Experimental|Sensitivity and Specificity Assessment|150 patient undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled in order to determine the sensitivity and specificity of the miniature spectral imaging system.
9978536|NCT01372644|Experimental|ADH, ALH, LCIS, SOM 230|Women who meet eligibility criteria.
9978537|NCT01372657||cataract patients|cataract patients
9978538|NCT01372670|Experimental|Hydroxyzine|Hydroxyzine given TID
9978539|NCT01372670|Placebo Comparator|Sugar Pill|Placebo given 3 times per day
9978540|NCT01372683|Experimental|Test cereal 1|Oat based breakfast cereal
9703901|NCT04707443|Experimental|donor human milk|For patients who can be fed orally or through tubes after surgery, donor milk will be used to feeding for 4 weeks.
9703902|NCT04707443|Active Comparator|extensively hydrolyzed formula|For patients who can be fed orally or through tubes after surgery, extensively hydrolyzed formula will be used to feeding for 4 weeks.
9978541|NCT01372683|Experimental|Test cereal 2|2nd Oat based breakfast cereal
9978542|NCT01372683|Experimental|Leading oat based RTE cereal|3rd oat based breakfast cereal
9978543|NCT01372696|Other|Tissue sample|Patients who consent to participate in this study will have a small sample of their polyp and normal tissue sent for molecular testing.
9978544|NCT01372709||Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
9703903|NCT04707703|Experimental|SOC plus Isavuconazonium sulfate|SOC plus intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by 372mg once daily for up to 28 days
9703904|NCT04707703|Placebo Comparator|SOC plus Placebo|SOC plus intravenous placebo every 8 hours for 6 doses followed by once daily for up to 28 days
9703905|NCT04707586|No Intervention|Control|No application will be made to patients in this group. Routine patient care will be provided. After the patients who develop pain are recorded, the application will be made with a cold application bandage.
9703906|NCT04707586|Experimental|experimental group|Patients in this group will be applied cold application with cold application bandage for 20 minutes as soon as the infusion begins.
9978545|NCT01372722|Experimental|Sham then Stimulation|
9978546|NCT01372722|Experimental|Stimulation then Sham|
9703907|NCT04707729|No Intervention|Standard of care|Patients will be intubated according to both the standard of care
9703908|NCT04707729|Experimental|Standard of care + ROX algorithm|In the intervention arm, patients will be intubated according to both the standard of care and the ROX index, whichever are met first. If the patient has a ROX index below different thresholds after different time-point within the first 12 hours since randomization, the NHF support will be increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. Then, the ROX index will be recalculated in 30 minutes. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done, the ROX index will be recalculated after 30 minutes of full NHF support. Then: 1) if the ΔROX is <0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 30 minutes; and 3) if the ΔROX is >0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration.
9703909|NCT04707521|Experimental|3M tape ship-shaped combined with strap fixing method|"Cutting method of 3M adhesive tape of ship shape: cut a piece of 20cm×3cm elastic adhesive tape, fold it in half to form a rectangle of 10cm×3cm, cut 5cm straight line from the middle point of the crease, cut it at an Angle of 45°, fold and open the 3M elastic adhesive tape in half, which is the adhesive tape required for fixing. The final shape is similar to that of a ship, and it is named as 3M adhesive tape of ship shape.~Fixation method: The ship shape with 3M adhesive tape was pasted upward on the opposite cheek (near zygomatic), and the endotracheal intubation was wound around for two rounds and then glued to the near cheek (near zygomatic).Put the tooth pad next to the endotracheal intubation and wrap the tooth pad and catheter together for two turns with a short 3M adhesive tape of 12cm×1.5cm.Finally, fasten it with a lacing."
9703910|NCT04707521|No Intervention|traditional X-shaped tape and string fixing|traditional X-shaped tape and string fixing
9978547|NCT01372761|Placebo Comparator|Normal Saline|
9978548|NCT01372761|Experimental|ZGN-433|
9978549|NCT01372787||Arm I|
10190993|NCT04909645|Experimental|Clearsight (finger cuff)|
9978550|NCT01372800||volunteer|
9978551|NCT01372826|Experimental|NKTR118 Group1|Normal Renal Function
9978552|NCT01372826|Experimental|NKTR118 Group 2|Moderate Renal Function
9978553|NCT01372826|Experimental|NKTR118 Group 3|Severe Renal Impairment
9978554|NCT01372826|Experimental|NKTR118 Group 4|End-Stage Renal Disease
9978555|NCT01372839|Active Comparator|Atorvastatin|80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
9978556|NCT01372839|Other|Usual care|statin dose should not be higher than that described in exclusion criteria.
9978557|NCT01372852||T2DM patients|newly diagnosed T2DM patients and untreated with any drugs.
9978558|NCT01372852||Non-diabetic Control Group|
9978559|NCT01372865|Experimental|Mometasone|
9978560|NCT01372865|Active Comparator|Nasonex®|
9978561|NCT01372891||Patients underging PCI|
9978562|NCT01372904|Experimental|Dexamethasone|
9978563|NCT01372917||Allomax|The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction.
9978564|NCT01372930|Experimental|Etanercept|
9978565|NCT01372930|Placebo Comparator|saline|
9978566|NCT01372943|Experimental|synthetic stool|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
9978567|NCT01372956||Dyslipidemia|
9978568|NCT01372969|Experimental|Cx601|
9978569|NCT01372982|Active Comparator|Femara|
9978570|NCT01372982|Experimental|Letrozole|
9978571|NCT01373008|Experimental|Inhaled QVAR|Inhaled QVAR 100 mic via aerochamber twice daily until 3 month post discharge
9978572|NCT01373008|Placebo Comparator|Inhaled placebo|Inhaled nonmedicated MDI [metered dose inhaler] in a similarly marked aerosol chamber using the same delivery technique, obtained from the drug manufacturer
9978573|NCT01373021|Placebo Comparator|F|Fentanyl+Normal saline
9978574|NCT01373021|Experimental|D|Fentanyl+Dexmedetomidine
9703911|NCT04707690|Active Comparator|Intraurethral laser therapy|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic fluid (Cathejell ®) will be applied to the urethral meatus. Before laser therapy, an intraurethral swab will be taken before treatment in order to determine the intraurethral microbiome.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Incontinence mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2."
9984364|NCT04180267|Active Comparator|LMHFV group|Subject assigned to LMHFV group will receive LMHFV (35Hz, 0.3g, 20min/day, at least 3 times/week) for half year.
9984365|NCT04179734|Experimental|Intervention|Bremelanotide 1.75 mg - prefilled subcutaneous autoinjector containing 1.75 mg Bremelanotide in a 0.3 mL solution volume.
9703912|NCT04707690|Placebo Comparator|Intraurethral SHAM laser therapy|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
10190994|NCT04909021|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1
10190995|NCT04909021|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2
9984366|NCT04179734|Placebo Comparator|Placebo|1.75 mg equivalent - prefilled subcutaneous autoinjector containing Bremelanotide formulation without the active ingredient in a 0.3 mL solution volume.
9984367|NCT04178031|Experimental|IUD insertion group|All participants will have IUD inserted and follow up for occurance of complications
9703913|NCT04707456|No Intervention|MFM staff-level operator|
10190996|NCT04909021|Experimental|Dosage Group 3: RSV Vaccine Dosage 3 (Single-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3
10190997|NCT04909021|Experimental|Dosage Group 3a: RSV Vaccine Dosage 3 (Two-dose)|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3 followed by a second identical dose of the investigational RSV vaccine 28 days later
10190998|NCT04909021|Placebo Comparator|Placebo (Single-dose)|Participants in this arm will receive a single intranasal dose of placebo
9703914|NCT04707456|Other|MFM fellowship trainee-level operator|
9703915|NCT04707651|Experimental|Lifestyle intervention|Nutrition advices and formula diet
9703916|NCT04707599|No Intervention|OFF intervention|No reminder plus (telephone reminder from therapist) but standard test message reminder (SMS) from second admission
9703917|NCT04707599|Experimental|ON intervention|Reminder plus (telephone reminder from therapist) AND standard test message reminder (SMS) from second admission
9703918|NCT04707638||Parkinson's disease or dystonia patients|Patients with Parkinson's disease or dystonia and underwent STN DBS under general anesthesia in neurosurgery department
9703919|NCT04707716|Experimental|conometric concept (Acuris system)|single implant crown retention using friction only
9703920|NCT04707716|Active Comparator|screw retention|screw retained implant Crown fixation
9703921|NCT04707716|Active Comparator|cementation|cement retained implant Crown fixation
9703922|NCT04707378|Active Comparator|active left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC.
9703923|NCT04707378|Sham Comparator|sham left DLPFC navigated-rTMS|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of sham stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (sham) over the left DLPFC.
9703924|NCT04707365|Experimental|digestive cancers|Colorectal and pancreatobiliary cancers
9984368|NCT04177238|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no anthocyanin content
9984369|NCT04177238|Experimental|Cherry juice|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
9984370|NCT04177238|Experimental|Blueberry|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
9703925|NCT04707209|Experimental|Intravitreal Sirolimus|
9703926|NCT04707040|Experimental|Neurocognitive Exercise Program Group|The group received NEP for 10 weeks, one hour per week conducted by the same physiotherapist with 6 years of experience in this field. Children with ADHD were given home exercises for the other six days of the week without a NEP session. Home exercises were followed with an exercise diary under the control of children's parents. The home exercise program consisted of visual-motor and auditory-motor coordination tasks (daily 15 min).
9703927|NCT04707404||PEEK|Cranioplasty patients with PEEK.
9703928|NCT04707404||Titanium|Cranioplasty patients with titanium mesh.
9703929|NCT04707066|Experimental|1|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
9703930|NCT04707066|Experimental|2|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
9978575|NCT01373034|Experimental|Soy Dietary Fiber|
9978576|NCT01373034|Placebo Comparator|Rice powder|
9978577|NCT01373047|Experimental|Intrahepatic anti-CEA designer T cells|
9978578|NCT01373060|Experimental|ASP1941 group|
9978579|NCT01373060|Placebo Comparator|placebo group|
9978580|NCT01373073|Experimental|Experimental Human Milk Fortifier|Experimental human milk fortifier to be added to human milk
9978581|NCT01373073|Active Comparator|Control Human Milk Fortifier|Control human milk fortifier to be added to human milk
9978582|NCT01373099|Experimental|Static Spacer|Patients in this group will be randomized to a static, nonarticulating, antibiotic-impregnated cement spacer.
9703931|NCT04707066|Experimental|3|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
9703932|NCT04707066|Experimental|4|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
9978583|NCT01373099|Experimental|Articulating spacer|Patients in this group will be randomized to an articulating antibiotic-impregnated cement spacer.
9703933|NCT04707066|Experimental|5|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
9703934|NCT04707066|Experimental|6|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
9978584|NCT01373112|Experimental|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
9703935|NCT04707092|Experimental|Antibiotic at induction|Patients will receive one single dose of Antibiotic at induction
9703936|NCT04707092|Experimental|Antibiotic one week|Patients will receive one single dose of Antibiotic at induction, plus a 7 day treatment with oral Antibiotic
9703937|NCT04706962|Experimental|TH1902|TH1902 peptide-drug conjugate
9703938|NCT04707014|Placebo Comparator|Attention-Distraction techniques|A high-tech distraction technique (Apple®), passive and chosen by the child, either an animated video or his or her favourite music. After standard intravenous sedation, the child is taken to the operating theatre to watch his or her favourite video or music and this is maintained throughout the procedure.
9703939|NCT04707014|Experimental|HIPNOSIS GROUP|A technique of rapid conversational hypnosis, with focus on therapeutic suggestion (guiding the patient into a hypnotic trance), adapted to the child's cognitive development. Induction with hypnotic suggestion focuses and accompanies the child's body sensations and allows their active participation. After standard sedation, therapeutic suggestion is maintained throughout the surgery and in the post-hypnotic period before awakening.
9703940|NCT04707287||Breast Cancer Patients|All the patients irrespective of age, ethnicity and stage of disease will be including once the disease is confirmed after triple assessment
9703941|NCT04707105||Second Affiliated Hospital, School of Medicine, Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University
9703942|NCT04707105||Second People's Hospital of Hangzhou City, Zhejiang Province|a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province
9703943|NCT04707105||4th Affiliated Hospital, School of Medicine at Zhejiang University|a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University
9703944|NCT04707352|Experimental|Dapagliflozin|The baseline procedures will be performed on the same day of screening or within the next five working days. All the baseline procedures will be performed on the same day. The baseline procedures include biobank, clinical assessment and echocardiogram, on the same day. In the following 24 hours, the patient will initiate Dapagliflozin at the recommended dose of 10 mg daily during 6 months. Temporary discontinuation may be considered at investigator criteria as in cases of symptomatic hypotension or acute declines in renal function and after discarding other potential causes.
9703945|NCT04707079|Experimental|Duvelisib|Eligible subjects will be given duvelisib (15mg, 25mg), orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
9703946|NCT04707274||Patients group|Individuals with greater trochanteric pain syndrome and gluteal tendinopathy
9984371|NCT04176302|Active Comparator|Parkinson Holter|The neurologists in the study will receive information from the Parkinson Holter (device being studied)
9984372|NCT04176302|Active Comparator|Parkinson's diary|The neurologists in the study will receive information from a motor fluctuations diary
10190999|NCT04909021|Placebo Comparator|Placebo (Two-dose)|Participants in this arm will receive a single intranasal dose of placebo followed by a second identical dose of placebo 28 days later
10191000|NCT04905524|Other|Intervention arm|All participants received the intervention in this trial (VPNP diet and supplement recommendations).
10191001|NCT04898062|Active Comparator|CRP-apheresis|Patients randomized to this group will undergo apheresis treatments with treatments every 24 ± 12 h each lasting 4-7 hours, until the CRP value does not rise to ≥ 30 mg/l within 96 h after the last treatment
10191002|NCT04898062|No Intervention|Control|Patients randomized to this group will not undergo a apheresis treatments. They will be treated according to the current conventional treatment concept for covid-19 disease
10191003|NCT04896697|Experimental|Part 1A - XTX101 Monotherapy Dose Escalation|Part 1A Dose Escalation of XTX101 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
9984373|NCT04176302|Placebo Comparator|Traditional clinical practice|The neurologists in the study will receive no additional information other than what is obtained during the visit
10191004|NCT04896697|Experimental|Part 1B - Pharmacodynamic (PD) Dose Expansion|Part 1B XTX101 at the RP2D will be administered to further examine XTX101 as monotherapy in patients with select advanced solid tumors.
10191005|NCT04896697|Experimental|Part 1C - XTX101 Dose Escalation in Combination with Pembrolizumab|Part 1C Standard labeled dose of pembrolizumab followed by administration of escalating doses of XTX101 to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
10191006|NCT04896697|Experimental|Part 2- XTX101 and Pembrolizumab Combination Therapy|Part 2 will examine XTX101 and pembrolizumab combination therapy at the RP2D in patients with unresectable or metastatic melanoma
10191007|NCT04892173|Experimental|Arm A|NBTXR3, as an intratumoral/intranodal injection, activated by investigator's choice of RT alone or RT in combination with cetuximab. NBTXR3 is given as a single intratumoral injection as a dose of 33% of the Gross Tumor Volume
10191008|NCT04892173|Active Comparator|Arm B|Investigator's choice of RT alone or RT in combination with cetuximab
10191009|NCT04891978|Experimental|AIRQ, Asthma Checklist, and PRECISION Program|All participants in the trial will be given the behavioral interventions which include the AIRQ tool, the Asthma Checklist tool, and the PRECISION program educational resources.
10191010|NCT04887064|Experimental|Normal Hepatic Function|
10191011|NCT04887064|Experimental|Moderate Hepatic Impairment|
10191012|NCT04887064|Experimental|Severe Hepatic Impairment|
10191013|NCT04886583||Gabi Baby Band|GSC 1
10191014|NCT04886518|Active Comparator|High dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
10191015|NCT04886518|Active Comparator|Low dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning"
10191016|NCT04886518|Placebo Comparator|Placebo|"Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
10191017|NCT04885166|Experimental|Web-based simulation intervention|Participants in this condition will receive psychoeducation about stimulant medication diversion, stimulant medication misuse, and will practice navigating and resisting requests for their medication with a virtual human.
10191018|NCT04885166|Placebo Comparator|Placebo condition|Participants in this condition will learn about psychological conditions that affect college students most often (e.g., depression), causes of those conditions, and pharmacological/behavioral treatments for those conditions.
10191019|NCT04882514|Experimental|Vaccine p*17-K4S2 (25 µg/mL) Vaccine|To evaluate the safety and immunogenicity of *17-CRM197 (12.5µg) + K4S2-CRM197 (12.5µg): TOTAL 25 µg
10191020|NCT04882514|Experimental|Vaccine p*17-K4S2 (50 µg/mL) Vaccine|To evaluate the safety and immunogenicity of p*17-CRM197 (25µg) + K4S2-CRM197 (25µg): TOTAL 50 µg
10191021|NCT04882514|Experimental|Vaccine p*17-K4S2 (100 µg/mL) Vaccine|To evaluate the safety and immunogenicity *17-CRM197 (50µg) + K4S2-CRM197 (50µg): TOTAL 100 µg
10191022|NCT04882514|Experimental|J8-K4S2 (100 µg/mL ) Vaccine|To evaluate the safety and immunogenicity -CRM197 (50µg) + K4S2-CRM197 (50µg): TOTAL 100 µg
10191023|NCT04882514|Sham Comparator|Rabavert Vaccine|Comparator vaccine (RABAVERT)
10191024|NCT04880070|Experimental|Shockwave Device|The Shockwave device will be used on multiple areas of the body for the purpose of treating connective tissue.
10191025|NCT04870606|Active Comparator|GT0918+ standard of care|
10191026|NCT04870606|Placebo Comparator|placebo+ standard of care|
10191027|NCT04864626||patient with eating disorder|
10191028|NCT04862585|Active Comparator|Arm I (paclitaxel, pre-medications)|Patients continue on pre-medications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel.
10191029|NCT04862585|Experimental|Arm II (paclitaxel)|Patients discontinue premedications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel, unless patient develops a subsequent infusion HSR.
10191030|NCT04857502|Experimental|Diagnostic (99mTc-PSMA-I&S, SPECT/CT)|The first 5 patients receive an initial dose of undergo 99mTc-PSMA-I&S IV followed by 5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I&S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I&S IV before standard of care surgery.
10191031|NCT04850105||TEGSEDI-exposed cohort|This cohort consist of patients diagnosed with hATTR-PN who are receiving any dose of commercial TEGSEDI and who have provided written informed consent to be included into the study.
10191032|NCT04850105||TEGSEDI-unexposed cohort|This cohort which will consist of patients diagnosed with hATTR-PN who have not taken any dose of TEGSEDI within 25 weeks prior to enrollment and are eligible for TEGSEDI treatment per applicable product label and who have provided written informed consent to be included into the study.
10191033|NCT04847596||participants with RMS treated with ofatumumab|Relapsing MS participants receiving a full course (two doses) of a COVID-19 mRNA vaccine after starting ofatumumab 20 mg subcutaneous treatment
9703947|NCT04707053||Intraaxial lesion group|Patients with intraaxial brainstem lesions (lesions located in the brainstem) + experienced brainstem surgery in our department during the study period
10191034|NCT04844268|Experimental|Cohort 1|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 1 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
10191035|NCT04844268|Experimental|Cohort 2|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 5 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
10191036|NCT04844268|Experimental|Cohort 3|Intramuscular (IM) injection of VACCINE RNA MCTI CIMATEC HDT(HDT-301) at a dose of 25 µg. Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
10191037|NCT04844268|Placebo Comparator|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride). Participants will be randomized (4:1 ratio for active vaccine:placebo) with equal probability of receiving a schedule of two doses, of the same concentration, on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single-dose administration (group 3).
9978585|NCT01373112|Experimental|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
9978586|NCT01373125||Radiofrequency Ablation (RFA)|Participants in this group are greater than or equal to 12 months status post radiofrequency ablation (RFA).
9978587|NCT01373125||Radiofrequency Ablation Longitudinal (RFAL)|Participants in this group are part of a longitudinal portion of the study and are enrolled prior to their first radiofrequency ablation procedure and followed at 6 and 12 months after completion of RFA.
9978588|NCT01373125||Gastroesophageal Reflux Disease (GERD)|Participants in this group have been diagnosed with gastroesophageal reflux disease.
9978589|NCT01373125||Asymptomatic Controls (AC)|Participants in this group are asymptomatic controls and enrolled as part of the comparison group.
9978590|NCT01373138|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
9703948|NCT04707053||Extraaxial lesion group|Patients with extraaxial brainstem lesions (lesions close to the brainstem) + experienced brainstem surgery in our department during the study period
10191038|NCT04837937|Experimental|Condition 1|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise. All participants will complete this exercise; it will serve as the constant.
9978591|NCT01373138|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
10191039|NCT04837937|Experimental|Condition 2|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Patient [Advanced]' ' conflict negotiation/dispute resolution exercise
10191040|NCT04837937|Experimental|Condition 3|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise
9978592|NCT01373177|Active Comparator|BSID-II, then Bayley-III|Receive BSID-II testing 4-8 weeks before Bayley-III testing
9703949|NCT04706975|Active Comparator|Difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg tablet administered twice daily
9703950|NCT04706975|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
9978593|NCT01373177|Active Comparator|Bayley-III, then BSID-II|Receive Bayley-III testing 4-8 weeks before BSID-II testing
9978594|NCT01373190||Epilepsy Group|Individuals diagnosed with Partial/Focal Onset Epilepsy ICD9CM 345.4 and/or 345.5
9978595|NCT01373190||Control Group|Individuals who do not have the diagnosis of Epilepsy and have no history of seizure disorders
9978596|NCT01373216|Experimental|Exenatide|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
9703951|NCT04707118|Experimental|Thermal perfusion cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
9703952|NCT04707118|Active Comparator|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
9978597|NCT01373216|No Intervention|Control|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment
9978598|NCT01373255|Experimental|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
9978599|NCT01373255|No Intervention|No intervention|no intervention prior to cesarean
9978600|NCT01373307|Experimental|Early Intervention|Participants are nested in churches which were randomly assigned to receive the intervention first.
9978601|NCT01373307|No Intervention|Delayed Intervention|Wait-list control group. Participants are nested in churches which were randomly assigned to receive the intervention at a later date. Delayed Intervention participants receive an educational luncheon addressing stress reduction during the window of no intervention.
9978602|NCT01373320|Experimental|Early Intervention|Participants in this group are nested in churches which were randomly assigned to the treatment group.
10191041|NCT04837937|Experimental|Condition 4|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Patient [Advanced]' conflict negotiation/dispute resolution exercise
10191042|NCT04837937|Experimental|Condition 5|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise
10191043|NCT04837937|Experimental|Condition 6|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Patient [Advanced]' conflict negotiation/dispute resolution exercise
10191044|NCT04837937|Experimental|Condition 7|(1) 'Caregiver vs. Patient [Beginner]' negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise
10191045|NCT04837937|Experimental|Condition 8|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise; (4) 'Caregiver vs. Patient [Advanced]' conflict negotiation/dispute resolution exercise
9703953|NCT04707001|Active Comparator|Ultrasound monitoring group|In the ultrasound group, urinary retention is monitored, according to current practice, with an ultrasound scanner and the patient is catheterized if necessary, if residual urine exceeds 800 ml, or if the patient is symptomatic.
9978603|NCT01373320|No Intervention|Delayed Intervention|Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
10191046|NCT04836975||SCLC|Patient Diagnosed with Small Cell Lung Cancer- (extensive or limited)
10191047|NCT04836975||NSCLC|Patient diagnosed with primary stage III Non-Small cell lung Cancer
9978604|NCT01373359|Experimental|Sublingual misoprostol|400 µg powdered misoprostol administered sublingually; IM placebo
9978605|NCT01373359|Active Comparator|Oxytocin|10 IU IM oxytocin; placebo powder
9978606|NCT01373372|Experimental|Functional Dyspepsia cohort|Cohort of subjects with functional dyspepsia
9978607|NCT01373372|Other|Control cohort|Control group of subjects with no functional dyspepsia
9703954|NCT04707001|Active Comparator|Symptoms alone group|Urination is monitored by asking at regular intervals about the onset of spontaneous urination and the patient is catheterized only on a symptomatic basis.
9703955|NCT04707027|Sham Comparator|complete polypoidal regression arm|follow up monthly with color fundus photography and OCT at each visit
9703956|NCT04707027|Active Comparator|incomplete polypoidal regression arm|continue treatment with aflibercept injection (treat and extend regimen)
9703957|NCT04706845||1|No evident disease
9703958|NCT04706845||2|Metastatic Disease; Watchful Waiting: Tumors bearing NOTCH Mutation
9703959|NCT04706845||3|Metastatic Disease; Watchful Waiting: Tumors bearing Notch Wild Type
9703960|NCT04706845||4|Progressive Disease: Tumors bearing NOTCH Mutation
9703961|NCT04706845||5|Progressive Disease: Tumors bearing Notch Wild Type
9703962|NCT04706936|Experimental|Anti-BCMA CAR-T (CBG-002)|All subjects were intravenous administrated with CBG-002.
9703963|NCT04706806|Experimental|liquid vinegar|2 tablespoons (diluted in water) taken twice daily with meals
9703964|NCT04706806|Placebo Comparator|vinegar pill|1 vinegar pill taken daily
9978608|NCT01373385||Surgical|Patients receiving a surgical procedure for vesicoureteral reflux at Connecticut Children's Medical Center.
9978609|NCT01373411|Placebo Comparator|Placebo|Placebo twice daily. Study drug will be started within 48 hours of CABG.
9978610|NCT01373411|Active Comparator|ticagrelor 90 mg|Taken twice daily. Study drug will be started within 48 hours of CABG.
9978611|NCT01373424||Cervical dystonia|People diagnosed with cervical dystonia
9978612|NCT01373424||Laryngeal dystonia|People diagnosed with laryngeal dystonia
9978613|NCT01373424||Other voice disorders|People diagnosed with a voice disorder other than laryngeal dystonia - enrollment for this group is complete
9978614|NCT01373424||Craniofacial dystonia|People diagnosed with craniofacial dystonia (including blepharospasm, meige syndrome, and oromandibular dystonia)
9978615|NCT01373424||Limb dystonia|People diagnosed with limb dystonia
9978616|NCT01373424||All other isolated dystonias|People diagnosed with any isolated dystonia not listed in descriptions of other cohorts
9978617|NCT01373424||Myoclonus dystonia|People diagnosed with myoclonus dystonia
9703965|NCT04706780||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
9978618|NCT01373424||Dopa-responsive dystonia|People diagnosed with dopa-responsive dystonia
9978619|NCT01373437||Intubate|
9978620|NCT01373463|Experimental|Arm A|"Patients will be given the drugs pemetrexed and carboplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
9978621|NCT01373463|Experimental|Arm B|"Patients will be given the drugs pemetrexed and cisplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
9978622|NCT01373476|Experimental|Qideng Mingmu capsule|High dosage group,Middle dosage group,Low dosage group.
9978623|NCT01373476|Placebo Comparator|Placebo|Placebo group
9978624|NCT01373502|Experimental|DES Limus Carbostent Coronary Stent|
9978625|NCT01373502|Active Comparator|Taxus Liberté Coronary Stent|
9978626|NCT01373515|Experimental|Cohort 1; 1x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
9978627|NCT01373515|Experimental|Cohort 2; 2.5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
9978628|NCT01373515|Experimental|Cohort 3; 5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
9978629|NCT01373515|Experimental|Cohort 4; 5x10E7 DCP-001|n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001. Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
9978630|NCT01373528|Experimental|Budesonide|
9703966|NCT04706689||Unresponsive wakefulness syndrome patients (UWS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
9703967|NCT04706689||Minimally conscious patients MINUS (MCS-)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
9703968|NCT04706689||Minimally conscious patients PLUS|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
9703969|NCT04706689||Patients emerging from the minimally conscious state (EMCS)|The level of consciousness will be assessed with the Simplified Evaluation of CONsciousness Disorder (SECONDs) and the Coma Recovery Scale-Revised (CRS-R).
10191048|NCT04830345|Experimental|ATGC-100 100U|ATGC-100 will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
9703970|NCT04707339||Acute Appendicitis pre-COVID management|Audit of Acute appendicitis management in 2017-18
9703971|NCT04707339||Acute Appendicitis during COVID management|Audit of Acute appendicitis management in 2020
9703972|NCT04706728|Experimental|Playlists with Expert-Curated Music - four weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
9703973|NCT04706728|Active Comparator|Playlists with Expert-Curated Music - two weeks|Patients can choose from two expert-curated playlists with music, matching the trajectory of the ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for two weeks (the first four ECT procedures).
9703974|NCT04706728|Placebo Comparator|Playlists with Nature Sounds|Patients can choose from two expert-curated playlists with recorded sounds from nature (Rain, Waves) during ECT treatment (immediately before-, during and after the procedure). Playlists are available to the patients for four weeks (the first eight ECT procedures).
9703975|NCT04706871|Experimental|taVNS group|
9703976|NCT04706871|Placebo Comparator|tnVNS group|
9703977|NCT04706754||Prospective|Confirmed ALK, EGFR, ROS1, ERBB2 (HER2), exon 20 EGFR mutation, MET and BRAF cancer patients from across participating sites/cancer centers across Canada.
10191049|NCT04830345|Active Comparator|Botox 100U|Botox inj. will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
9703978|NCT04706637|Experimental|evogliptin|evogliptin 5 mg + metformin, oral administration once a day for 48 weeks
9703979|NCT04706637|Active Comparator|dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
9703980|NCT04706910|Experimental|18F-DOPA injection|All enrolled participants will receive an intravenous injection of the investigational 18F-DOPA radiopharmaceutical
9978631|NCT01373541|Active Comparator|InFat group|Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)
9978632|NCT01373541|Active Comparator|Control group|Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)
9978633|NCT01373541|No Intervention|Referance group|Human milk breastfeeding
9703981|NCT04706949|Experimental|Pyrotinib combined with pemetrexed plus carboplatin|
9703982|NCT04706897|Sham Comparator|Normal saline (Control) group|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1 mic/kg of IBW).
9703983|NCT04706897|Experimental|Dexmedetomidine, ketamine and lidocaine (Study) group|A loading infusion of syringe (B) containing the mixture was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
9785117|NCT01243567|Active Comparator|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
9978634|NCT01373554|Placebo Comparator|Placebo|
9978635|NCT01373554|Experimental|Oltipraz|
9978636|NCT01373567|Experimental|TINEFCON|Tablets of 700 mg.
9978637|NCT01373593|Experimental|lidocaine|lidocaine block
9978638|NCT01373593|Placebo Comparator|Placebo|
9978639|NCT01373606|Experimental|Terlipressin|
9978640|NCT01373619|Experimental|IVABRADINE, HEART FAILURE WITH NORMAL EF|Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
9978641|NCT01373632|Experimental|Firebird 2 stent group|the patients who receive Firebird 2 stent
9978642|NCT01373632|Active Comparator|Excel stent group|the patients who receive Excel stent
9978643|NCT01373645|Experimental|Yinyi stent|subjects with Yinyi stent implantation
9978644|NCT01373658|Experimental|Yinyi stent|
9978645|NCT01373684|Experimental|Peginterferon alfa-2a add on|All patients are all currently being treated with long-term NA treatment. PEG-IFN will be given in a dose of 180 μg per week s.c. for a total duration of 48 weeks starting at week 0.
9978646|NCT01373684|Active Comparator|Nucleoside analogue|All patients are all currently being treated with long-term Nucleos(t)ide analogue treatment and will continue using this medication during the duration of the study.
10191050|NCT04824989|Experimental|Sleep Health|Family receives the Sleep Health In Preschoolers parenting intervention to address toddler sleep problems.
10191051|NCT04824989|Experimental|Behavior Health|Family receives the Family Check-Up parenting intervention to address toddler behavior problems.
10191052|NCT04824989|Experimental|Choice|Family is given the opportunity to select either the Sleep Health in Preschoolers intervention to address toddler sleep problems or the Family Check-Up intervention to address toddler behavior problems.
10191053|NCT04824989|Active Comparator|Control|Family receives a safety and hygiene active control intervention.
10191054|NCT04821570||Chemotherapy (IV and oral)|
10191055|NCT04821570||Immunotherapy|
9703984|NCT04706702|Experimental|Tele-EF|Tele-EnhanceFitness
10191056|NCT04821570||Chemotherapy + Immunotherapy|
10191057|NCT04821570||Cyclin- dependent kinase (CDK) 4/6 inhibitors|
10191058|NCT04821570||Stem Cell Transplant recipients|
10191059|NCT04818216|Placebo Comparator|Placebo Group|Placebo capsules will be administered 2 capsules twice daily for 10 days
10191060|NCT04818216|Experimental|Nicotinamide Riboside Group|Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
10191061|NCT04818060||Low Risk of Motor Diagnosis|
10191062|NCT04818060||High Risk of Motor Diagnosis|
10191063|NCT04818060||Stage I or II Huntington's Disease|
10191064|NCT04818060||Healthy Controls|
10191065|NCT04816981|Experimental|EBUS-Elastography|
10191066|NCT04813276|Experimental|Serious game intervention|Participants receive the Strong Together serious game program on a tablet computer.
10191067|NCT04813276|Active Comparator|Enhanced care as usual|Participants receive a paper-based self-advocacy guide.
10191068|NCT04811027|Experimental|(CPS ≥1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
10191069|NCT04811027|Active Comparator|(CPS ≥1): Pembro|Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).
10191070|NCT04811027|Experimental|(CPS <1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
10191071|NCT04808843||Dienogest|Patients with endometriosis who have been prescribed with Dienogest.
10191072|NCT04808180|Experimental|Trial Group|Teeth from this group suffer from MIH. They will be evaluated after home oral care with BioRepair toothpaste containing microRepair®.
10191073|NCT04808180|Active Comparator|Control Group|Teeth from this group suffer from MIH. They are in the contralateral quadrants in respect to teeth from trial group. They will not be treated with the hydroxyapatite toothpaste.
10191074|NCT04806334|Experimental|4D MRI of pelvis/bladder with genomic analysis of bladder tumor|Patients with sessile appearing bladder masses who are destined to undergo transurethral resection of the bladder tumor (TURBT) and are felt by the treating physician to harbor MIBC will be enrolled. Prior to TURBT, ALL subjects will undergo axial imaging for clinical staging in the form of contrast enhanced MRI of the abdomen and pelvis (standard of care). The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI). Both the abdominal and pelvic MRI will have an official interpretation by a radiologist, thus both can be used in the care of the subject. Next, ALL subjects will undergo TURBT at which time, voided urine, blood and fresh frozen bladder tumor will be collected. Follow-up pathology will be collected.
10191075|NCT04804306||Diagnostic Test: CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis as part of the CBC-Diff ordered by ED Physician as part of the Institution's Standard of Care. Results will not be used to manage patients
10191076|NCT04802759|Active Comparator|Cohort 1: Giredestrant Monotherapy|
10191077|NCT04802759|Experimental|Cohort 1: Giredestrant + Abemaciclib|
10191078|NCT04802759|Experimental|Cohort 1: Giredestrant + Ipatasertib|
10191079|NCT04802759|Experimental|Cohort 1: Giredestrant + Inavolisib|
10191080|NCT04802759|Experimental|Cohort 1: Giredestrant + Ribociclib|
10191081|NCT04802759|Experimental|Cohort 1: Giredestrant + Everolimus|
10191082|NCT04802759|Experimental|Cohort 1: Giredestrant + Samuraciclib|
10191083|NCT04802759|Active Comparator|Cohort 2: Giredestrant + PH FDC SC|
10191084|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Abemaciclib|
10191085|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Palbociclib|
10204457|NCT01670539|Experimental|Telemonitor|"In addition to routine care, the HomMed Telemonitor wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months."
10204458|NCT01670539|No Intervention|Routine care for patients with lungCa|Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals. No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
10204459|NCT01552434|Experimental|Group I (temsirolimus, bevacizumab, cetuximab)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10204460|NCT01552434|Experimental|Group II (temsirolimus, bevacizumab, valproic acid)|Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10204461|NCT01552434|Experimental|Group III (temsirolimus, bevacizumab)|Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9785118|NCT01243580|Active Comparator|Ortho-Cyclen®|Ortho-Cyclen® is a comparator drug intervention
10191086|NCT04799054|Experimental|Part 1 Dose Escalation: TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.
10191087|NCT04799054|Experimental|Part 2 Dose Escalation: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.
9703985|NCT04706832|Other|ThorS-MagNT Treatment|Low-frequency, low-intensity repetitive magnetic stimulation bilaterally at T7-8 intravertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
9703986|NCT04706624|Active Comparator|A - High intensity Contingency management + SMS reminders|Participants who respond to the high intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
9703987|NCT04706624|Active Comparator|B - High intensity Contingency management + Matrix only|Participants who do not respond to the high intensity contingency management are randomized into the Matrix only group.
9978647|NCT01373697|Active Comparator|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
9978648|NCT01373697|Active Comparator|Ibuprofen|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
9703988|NCT04706624|Active Comparator|C - High intensity Contingency management + (Matrix + CM)|Participants who do not respond to the high intensity contingency management are randomized into the Matrix plus contingency management group.
9703989|NCT04706624|Active Comparator|D - Low intensity Contingency management + SMS reminders|Participants who respond to the low intensity contingency management (frontline intervention) receive the adaptive intervention of SMS reminders.
9978649|NCT01373710|Experimental|Trastuzumab intrathecal|
9978650|NCT01373723|Experimental|invitation letter|to participate in the screening
9703990|NCT04706624|Active Comparator|E - Low intensity Contingency management + Matrix only|Participants who do not respond to the who intensity contingency management are randomized into the Matrix only group.
9703991|NCT04706624|Active Comparator|F - Low intensity Contingency management + (Matrix+CM)|Participants who do not respond to the who intensity contingency management are randomized into the Matrix plus contingency management group.
9703992|NCT04706611|Experimental|Irritable Bowel Syndrome|Fecal Microbiota Transplantation will be performed.
9703993|NCT04706611|Experimental|Constipation|Fecal Microbiota Transplantation will be performed.
9703994|NCT04706611|Experimental|Clostridium Difficile Infection|Fecal Microbiota Transplantation will be performed.
9703995|NCT04706611|Experimental|Functional Dyspepsia|Fecal Microbiota Transplantation will be performed.
9703996|NCT04706611|Experimental|Parkinson's Disease|Fecal Microbiota Transplantation will be performed.
9978651|NCT01373723|Experimental|Invitation letter, informative leaflet and phone call reminder|to participate in the screening
9978652|NCT01373723|Experimental|Invitation letter and informative leaflet|to participate in the screening
9703997|NCT04706611|Experimental|Metabolic Syndrome|Fecal Microbiota Transplantation will be performed.
9703998|NCT04706611|Experimental|Non-Alcoholic Fatty Liver Disease|Fecal Microbiota Transplantation will be performed.
9703999|NCT04706611|Experimental|Autism Spectrum Disorder|Fecal Microbiota Transplantation will be performed.
10191088|NCT04799054|Experimental|Part 3 Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination.
10191089|NCT04788667|Experimental|Experimental Group|A health education programme using a telerehabilitation platform
10191090|NCT04788667|Active Comparator|Control Group|General recommendations using a telerehabilitation platform
9704000|NCT04706611|Experimental|Radiation Enteritis|Fecal Microbiota Transplantation will be performed.
9704001|NCT04706611|Experimental|Atopic Dermatitis|Fecal Microbiota Transplantation will be performed.
9978653|NCT01373749|Experimental|NOS|NO inhalation was performed in the first stage(<48h) of PPHN, NO inhalation was replaced by sildenafil in the second stage(>48h).
9978654|NCT01373749|Placebo Comparator|NO|NO inhalation was performed during the whole treatment procedure of PPHN. There is no other methods given to treat PPHN during the therapy course.
9704002|NCT04706611|Experimental|Food Allergic|Fecal Microbiota Transplantation will be performed.
9704003|NCT04706611|Experimental|Graft-versus-Host Disease|Fecal Microbiota Transplantation will be performed.
9704004|NCT04706611|Experimental|Obesity|Fecal Microbiota Transplantation will be performed.
9704005|NCT04706611|Experimental|Diabetes mellitus|Fecal Microbiota Transplantation will be performed.
9704006|NCT04706611|Experimental|Multi-Drug Resistant Infection|Fecal Microbiota Transplantation will be performed.
9704007|NCT04706611|Experimental|Hepatic Encephalopathy|Fecal Microbiota Transplantation will be performed.
9704008|NCT04706611|Experimental|Enteric Dysbacteriosis|Fecal Microbiota Transplantation will be performed.
9704009|NCT04706611|Experimental|Multiple Sclerosis|Fecal Microbiota Transplantation will be performed.
9978655|NCT01373762|Experimental|Exercise Videogame Bike|Families in this group will receive an interactive exercise videogame bike (ie. the Active Cycle) to keep in their home for three months.
9978656|NCT01373762|Other|Stationary Bike|Families will receive a stationary bike to keep in their home for three months. It is required that the family places the stationary bike (Active Cycle without video game controllers) in front of a television.
9978657|NCT01373775||Revisit|HF patients who revisit the emergency department before the next appointment date.
9978658|NCT01373775||Non-revisit|HF patients who follow up on the appointment date.
9978659|NCT01373801|Active Comparator|Control|
9978660|NCT01373801|Experimental|GuardaCare|
9978661|NCT01373827||MC1 Subjects|
9978662|NCT01373840||healthy controls|
9978663|NCT01373840||patients with focal dystonias|
9978664|NCT01373853|Experimental|Femtec Groupe A|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery
9704010|NCT04706611|Experimental|Pseudomembranous Enteritis|Fecal Microbiota Transplantation will be performed.
9704011|NCT04706611|Experimental|Acute Pancreatitis|Fecal Microbiota Transplantation will be performed.
9704012|NCT04706611|Experimental|Chronic Fatigue Syndrome|Fecal Microbiota Transplantation will be performed.
9704013|NCT04706611|Experimental|Acute-on-chronic Liver Failure with HBV Infection|Fecal Microbiota Transplantation will be performed.
9704014|NCT04706611|Experimental|Alcoholic Liver Disease|Fecal Microbiota Transplantation will be performed.
9704015|NCT04706611|Experimental|Anorexia|Fecal Microbiota Transplantation will be performed.
9978665|NCT01373853|Active Comparator|Manual Group B|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
9978666|NCT01373866|Experimental|Multimodal MRI-guided rTMS|
9978667|NCT01373866|Active Comparator|Conventional T3-P3 rTMS|
9978668|NCT01373879|Experimental|Group 1A|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
9978669|NCT01373879|Experimental|Group 1B|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME TRAP
9978670|NCT01373879|Experimental|Group 2A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
10191091|NCT04787250|Experimental|Arm 1, Phage Therapy with Antibiotic Treatment|Phage therapy will be administered in conjunction with antibiotic treatment.
9704016|NCT04706611|Experimental|Decompensated Cirrhosis|Fecal Microbiota Transplantation will be performed.
9704017|NCT04706611|Experimental|Henoch-Schonlein Purpura|Fecal Microbiota Transplantation will be performed.
9704018|NCT04706611|Experimental|Autoimmune Liver Disease|Fecal Microbiota Transplantation will be performed.
9704019|NCT04706611|Experimental|Systemic Lupus Erythematosus|Fecal Microbiota Transplantation will be performed.
10191092|NCT04787250|Active Comparator|Arm 2, Standard of Care|Two-stage exchange arthroplasty entails resection arthroplasty and placement of an antibiotic-loaded spacer, antibiotic therapy, an antibiotic-free observation period, and re-implantation of a new prosthesis.
10191093|NCT04785469|Experimental|Eccentric training group|
9704020|NCT04706611|Experimental|IgG4-Related Disease|Fecal Microbiota Transplantation will be performed.
9704021|NCT04706611|Experimental|Celiac Disease|Fecal Microbiota Transplantation will be performed.
9704022|NCT04706611|Experimental|Protein-losing Enteropathy|Fecal Microbiota Transplantation will be performed.
9704023|NCT04706611|Experimental|Asperger Syndrome|Fecal Microbiota Transplantation will be performed.
9704024|NCT04706611|Experimental|Rheumatoid arthritis|Fecal Microbiota Transplantation will be performed.
9704025|NCT04706611|Experimental|Ulcerative colitis|Fecal Microbiota Transplantation will be performed.
9704026|NCT04706611|Experimental|Crohn's disease|Fecal Microbiota Transplantation will be performed.
9704027|NCT04706611|Experimental|Psoriasis|Fecal Microbiota Transplantation will be performed.
9704028|NCT04706611|Experimental|Ankylosing spondylitis|Fecal Microbiota Transplantation will be performed.
9704029|NCT04706611|Experimental|Immune checkpoint inhibition-related colitis|Fecal Microbiota Transplantation will be performed.
9704030|NCT04706611|Experimental|Autoimmune enteropathy|Fecal Microbiota Transplantation will be performed.
9704031|NCT04706611|Experimental|Drug-induced diarrhea|Fecal Microbiota Transplantation will be performed.
9704032|NCT04706390||Health care workers|500-1000 health care workers prioritized for early vaccination
9704033|NCT04706390||prioritized patient populations|2000 individuals in patient populations prioritized for vaccinations
9704034|NCT04706338|Experimental|TMS treatment|Patients with TMS treatment
9704035|NCT04706455|Active Comparator|sodium hyaluronate 0.1%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then, corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.1% will be installed and biometry and corneal topography will be repeated after 5 minutes.
9704036|NCT04706455|Active Comparator|sodium hyaluronate 0.3%|First preoperative Biometry of the eye at the IOL Master® will be measured. Then,corneal topography will be measure at the Oculus pentacam®. Afterwards, sodium hyaluronate 0.3% will be installed and biometry and corneal topography will be repeated after 5 minutes.
9704037|NCT04706429|Active Comparator|Trientine|Trientine dihydrochloride 1200 mg per day. This shall be taken orally as two Cufence 200mg hard capsules two times per day. The IMP will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
9704038|NCT04706429|Placebo Comparator|Placebo|The placebo shall be taken orally as two capsules two times per day. This will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).
9704039|NCT04706572|Experimental|Patients with Golden Rhythm|Administration of an external auditory cue based on Golden Rhythm
9704040|NCT04706572|Placebo Comparator|Patients with Metronome|Administration of an external auditory cue based on metronome binary rhythm
9704041|NCT04706182|Experimental|Combined PRF and PSG|
9978671|NCT01373879|Experimental|Group 2B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
9978672|NCT01373879|Active Comparator|Group 2C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
9978673|NCT01373879|Experimental|Group 3A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
9978674|NCT01373879|Experimental|Group 3B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
9978675|NCT01373879|Active Comparator|Group 3C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
9978676|NCT01373892|Active Comparator|Surgery|Slevve vs. Roux-Y
9978677|NCT01373892|No Intervention|Healthy lean volunteers|
9978678|NCT01373905|Active Comparator|Sustained lung inflation|recruitment was done using CPAP of 30 Cm/ H2o for 30 seconds
9978679|NCT01373905|Active Comparator|Stepwise PEEP elevation|Recruitment was done using stepwise elevation of PEEP followed by determination of the alveolar collapsing pressure
9978680|NCT01373944||Stress Only SPECT MPI with Anger Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
9984374|NCT04173338|Experimental|Cabozantinib + Pemetrexed|Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
9704042|NCT04706182|Experimental|Only PRF|
9978681|NCT01373944||Stress Only SPECT MPI with SD Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
9704043|NCT04706182|Experimental|Only PSG|
9704044|NCT04706182|No Intervention|Control (no treatment)|
9704045|NCT04706312|Experimental|hAMSCs injection|hAMSCs were injected via venous in the dorsum of hand.
9704046|NCT04706494|Experimental|AlphaWave® LTheanine|
9704047|NCT04706494|Placebo Comparator|Placebo|
9704048|NCT04706169||Older adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Older adult group: over 65 years.
9704049|NCT04706169||Adults|Participants, without symptoms in the shoulder and / or cervical area (at least the last year), were assigned to the Adult groups: 20 to 64 years.
9704050|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
9978682|NCT01373957||1|Patients hospitalized and diagnosed with UA, STEMI or NSTEMI
9978683|NCT01373970|Placebo Comparator|Placebo|
10191094|NCT04785469|Active Comparator|Control group|
9704051|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE|COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
9704052|NCT04706325||COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.|COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
9704053|NCT04706585||Youth|Young people in Indonesia between the age of 15-24 who are currently attending high school or university-level education to fill in our online survey.
9704054|NCT04706130|Other|Arm1: No primaquine|Enrolled patients will only received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days)
9704055|NCT04706130|Other|Arm2: Primaquine low dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.25 mg/kg/day for 14 days (starting at day 7)
9704056|NCT04706130|Other|Arm3: Primaquine high dose|Enrolled patients will received blood stage antimalarial (artesunate at 2 mg/kg per day every 24h for 7 days) and primaquine at 0.50 mg/kg/day for 14 days (starting at day 7)
9704057|NCT04706286|Experimental|Group 1|"Period 1: Treatment A~Period 2: Treatment B"
9704058|NCT04706286|Experimental|Group 2|"Period 1: Treatment B~Period 2: Treatment A"
9704059|NCT04706546|Experimental|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
9704060|NCT04706546|Other|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9704061|NCT04706377|Active Comparator|Active treatment group|Patients were given oral dispersible tablet with 1000μg of vitamin B12 daily for 12 months.
9704062|NCT04706377|Placebo Comparator|Placebo group|Patients were given placebo tablet similar to the tablet given to the active group once a day for 12 months.
9704063|NCT04706299|Active Comparator|No Mask|Will not wear a mask
9704064|NCT04706299|Experimental|Surgical mask|Will wear a surgical nose and face covering
9704065|NCT04706234||Multiple System Atrophy|Patients diagnosed will probable or possible MSA according to the 2nd criteria for the diagnosis of MSA (Gilman 2008) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
9704066|NCT04706234||progressive supranuclear palsy|Patients diagnosed will probable or possible Progressive Supranuclear Palsy or (PSP) related 4repeat tauopathies according to the Movement Disorders Society diagnostic criteria (Höglinger 2017) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
9704067|NCT04706234||Parkinson Disease|Patients diagnosed will Parkinson's disease according to the Movement Disorders Society diagnostic criteria (Postuma 2015) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
9704068|NCT04706195|Experimental|Person-centred care|PCC in the form of a combined eHealth and structured telephone support combined with an eHealth support on top of usual care
9704069|NCT04706195|No Intervention|Usual care|Regular evidence-based treatment and care as outlined in treatment guidelines and followed as usual at their local primary care center
9704070|NCT04706078||thick-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thick-gingiva (outline if the probe cannot be seen through the gingival)
9704071|NCT04706078||thin-gingiva group|After insertion of the probe into the facial aspect of the sulcus, the peri-implant biotype can be categorized as thin-gingiva (outline of the probe can be seen through the gingival)
9704072|NCT04706052||Superficial Parotidectomy Patient|All the patients with pleomorphic adenoma irrespective of age and gender who underwent Superficial parotidectomy
9704073|NCT04706156||Vaccinated Healthcare Workers (CZ)|Czech healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
9704074|NCT04706156||Vaccinated Healthcare Workers (DE)|German healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
9704075|NCT04706156||Vaccinated Healthcare Workers (SK)|Slovak healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
9978684|NCT01373970|Active Comparator|PPI + Placebo|PPI followed by cross over to placebo
9978685|NCT01373983|Other|ziconotide|
9978686|NCT01373996||Wireless|Measuring of invasive arterial blood pressure through HMW10 Wireless System.
9978687|NCT01373996||Wired|Measuring of invasive arterial blood pressure through conventional wired technology.
9978688|NCT01374022|Experimental|ART Strategy|maximum alveolar recruitment plus PEEP titration
9978689|NCT01374022|Active Comparator|ARDSNet Strategy|standard strategy (ARDSNet)
9978690|NCT01374035|Experimental|Participating GPs|GPs working at randomly selected GP centers/offices within the region that are invited to participate and signs a written informed consent to participate. (N=30-40)
10191095|NCT04783428||Prior TIO Burosumab Clinical Trial Participants|
10191096|NCT04783428||Adults Who Have Not Participated In Prior Burosumab Clinical Trials|
10191097|NCT04783428||Pediatrics Who Have Not Participated In Prior Burosumab Clinical Trials|
9704076|NCT04706156||Vaccinated Healthcare Workers (TR)|Turkish healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
9704077|NCT04706117|Other|Canalicular obstruction|
9704078|NCT04705922|Experimental|Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]|Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
9704079|NCT04705922|Experimental|Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]|Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.
9704080|NCT04705922|Experimental|Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]|Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.
9978691|NCT01374035|No Intervention|Control group|GPs working at randomly selected GP centers/office within the region that are not invited to participate, will form the control group. (N=30-40)
9978692|NCT01374061|Active Comparator|1: Classical intubation|
9978693|NCT01374061|Experimental|2: Glidescope intubation|
9704081|NCT04706091|Experimental|Treatment --> Placebo|This group will receive suvorexant during the first 4-week phase, and placebo during the second 4-week phase.
10191098|NCT04782323|Experimental|Group A aQII-1 Investigational|
10191099|NCT04782323|Experimental|Group B aQII-3 Investigational|
9704082|NCT04706091|Experimental|Placebo --> Treatment|This group will receive placebo during the first 4-week phase, and suvorexant during the second 4-week phase.
9704083|NCT04705896|Active Comparator|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of slow low efficiency dialysis (SLED) or intermittent hemodialysis (IHD) and another 100 mL 25% Albumin fluid after 4 hours of treatment.
10191100|NCT04782323|Experimental|Group C aQII-6 Investigational|
10191101|NCT04782323|Experimental|Group D aQII-7 Investigational|
9704084|NCT04705896|Placebo Comparator|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED or IHD and another 100 mL 0.9% Normal Saline after 4 hours of treatment.
9704085|NCT04705935||Term pregnant women without labor contractions or rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample before a scheduled caesarean section.
9704086|NCT04705935||Term pregnant women with labor contractions|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample when labor contractions, but before spontaneous rupture of membranes.
9978694|NCT01374074||White GERD|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with gastroesophageal reflux disease and do not have Barrett's esophagus."
9978695|NCT01374074||African American GERD|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with gastroesophageal reflux disease and do no have Barrett's esophagus."
9978696|NCT01374074||White BE|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with Barrett's Esophagus."
9978697|NCT01374074||African American BE|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with Barrett's Esophagus."
9978698|NCT01374100|Active Comparator|Standard Exercise|See methods below - standard strength and endurance training
9978699|NCT01374100|Experimental|Qigong exercise|See methods below - medical QiGong therapy session
9978700|NCT01374113|Experimental|Group 1|Subjects with moderate renal impairment
10191102|NCT04782323|Experimental|Group E aQII-9 Investigational|
10191103|NCT04782323|Experimental|Group F aQII-10 Investigational|
10191104|NCT04782323|Experimental|Group G aQII-11 Investigational|
9704087|NCT04705935||Term pregnant women with spontaneous rupture of membranes|Term pregnant women > 37 weeks gestation with a normal pregnancy. One blood sample after spontaneous rupture of membranes, but without labor contractions.
9704088|NCT04705935||Preterm labor contractions (PLC)|One blood sample when labor contractions before 34 weeks gestation without rupture of membranes.
9704089|NCT04705935||Preterm Prelabor Rupture of the Fetal Membranes (PPROM)|One blood sample when rupture of the fetal membranes before 34 weeks gestation without labor contractions.
9704090|NCT04705935||Control group|Women with normal pregnancies. One blood sample in gestation week 25+0 to 37 matched as controls for PLC and PPROM cases.
9704091|NCT04705935||Longitudinal cohort during pregnancy|Women with normal pregnancies, where blood samples will be collected at week 12, 20, 28, 34 and 36, as well as at labor.
9978701|NCT01374113|Experimental|Group 2|Subjects with severe renal impairment
9978702|NCT01374113|Experimental|Group 3|Matched subjects with normal renal function
9978703|NCT01374126|Experimental|Azithromycin-Artesunate|
9978704|NCT01374126|Active Comparator|Control (artesunate alone)|
9978705|NCT01374139|Experimental|Cohort 1|
9978706|NCT01374139|Experimental|Cohort 2|
9978707|NCT01374152|Experimental|Perfetti|Cognitive sensory motor training method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
10191105|NCT04782323|Active Comparator|Group H QII Active Comparator|
10191106|NCT04780516||Participants Treated With Risankizumab|Participants will receive risankizumab (Skyrizi) as prescribed by the physician according to the local label.
10191107|NCT04777292|Experimental|Immediate-use|Immediate use of esTOCma mobile app. Participants will use the mobile application immediately after the baseline assessment (T0) during approximately 10 days or until app completion.
10191108|NCT04777292|Active Comparator|Delayed use|Delayed use of esTOCma mobile app. Participants will start using the app 10 days after the first assessment (T0), and immediately after the T1 assessment.
9978708|NCT01374152|No Intervention|conventional rehabilitation|conventional occupational therapy method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
9978709|NCT01374165||Low dose SANGUINATE™|"160 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
9978710|NCT01374165||High dose of SANGUINATE™|"320 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
9978711|NCT01374191|Active Comparator|onabotulinum toxin type-A|1 injection of Btx-A, or up to 4 injections of Btx-A during the 1-year study period if pain recurs
10191109|NCT04776499|Experimental|Healthy volunteers receiving propylthiouracil, riociguat, and perphenazine|Eight healthy volunteers will be included. Up to 15 healthy volunteers will be screened to reach the goal of 8 exposed volunteers. Sex is not expected to have an impact on the short-term evaluation of the potential drug-drug interactions. Therefore female and male participants will be included in an undefined proportion.
10191110|NCT04767711|Active Comparator|L. reuteri|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 30 days, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day. Oral glucocorticoid 25 mg daily for 7 days.
10191111|NCT04767711|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 30 days.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day. Oral glucocorticoid 25 mg daily for 7 days.
10191112|NCT04764188||Cohort 1|Participants starting alectinib treatment before (Arm A) or after (Arm B) study enrollment as first-line treatment will be followed up for up to 4 years.
10191113|NCT04764188||Cohort 2|Participants receiving alectinib as second-line treatment after study enrollment will be followed up for up to 2 years.
10191114|NCT04762433|Experimental|Kegel Exercise Pregnancy Training - App|The intervention arm will be given a mHealth app for two months duration with the usual antenatal follow-up.
9704092|NCT04705935||Longitudinal cohort post partum|Women with normal pregnancies, where blood samples will be collected at labor, as well as 2 days, and 4, 8 and 12 weeks after birth.
9704093|NCT04705805||Case|Patient presenting an olfactory dysfunction of any acquired aetiology that has been evolving for at least 3 months without total recovery.
9704094|NCT04705805||Control|Patient with no sense of smell problems followed up in ENT for another pathology that does not affect the sense of smell
10191115|NCT04762433|No Intervention|Waitlist control|The control (waitlist) group will continue their usual antenatal follow-up and the KEPT-app will be given after the study ends.
10204462|NCT01480154|Experimental|Treatment (Akt inhibitor MK2206, hydroxychloroquine)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on cycle 2, patients also receive hydroxychloroquine PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10204463|NCT01477008|Experimental|BiCRI|BiPhasic Cartilage Repair Implant
10204464|NCT01477008|Active Comparator|Marrow Stimulation|Microfracture or Subchondral Drilling
10204465|NCT01433315|Experimental|sleep restriction|restricted sleep during the experimental period
9704095|NCT04705948|Experimental|ketamine group|ketamine gargle (0.5 mg/kg up to 30 ml dextrose water) 15 minutes before the operation
9704096|NCT04705948|Experimental|magnesium sulfate group|magnesium sulfate gargle (20 mg/kg up to 30 mL G5%) 15 minutes before the operation.
9704097|NCT04706143||Vaccined group by live attenuated or viral vector or mRNA vaccine|Adults between 25-65 years old
9704098|NCT04706104||Propofol-Ketamine|2-3 mg/kg propofol and 1-2 mg/kg ketamine will be used for anesthesia induction
9704099|NCT04706104||Midazolam-Fentanyl|0.15 mg/kg midazolam and 10-15 mcg/kg fentanyl will be used for anesthesia induction
9704100|NCT04705831|Active Comparator|RUCONEST|IV Ruconest
9704101|NCT04705831|Placebo Comparator|Placebo|Placebo
9704102|NCT04705675|Experimental|Experimental Group|The mothers in the experimental group (152) were administered.
9704103|NCT04705675|No Intervention|Control Group|The mothers in the control group (152) were administered.
9704104|NCT04706065||GROUP 1|Group 1 (patients with PD) All participants will be subjected to thorough history taking, full clinical and neurological examination. Diagnosis of PD by using Brain Bank Criteria for diagnosis of Parkinson Disease , assessment of the severity of PD by using PDRS and evaluation of cognitive functions using MMSE.
9704105|NCT04706065||Group 2|Group 2 (controls) All participants will be subjected to thorough history taking, full clinical and neurological examination.
9704106|NCT04705688||Left Atrial Appendage Occlusion|Patients undergoing left atrial appendage occlusion.
9704107|NCT04705987|Experimental|Experimental|Colchicine 0.5 mg
9704108|NCT04705987|Placebo Comparator|Placebo|Placebo
9704109|NCT04705909|Experimental|Pitavastatin group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Pitavastatin tablets 2 mg once daily.
9704110|NCT04705909|Placebo Comparator|Placebo group|For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Placebo tablets matching pitavastatin orally once daily.
9704111|NCT04706026|Experimental|Local anesthesia|This arm will receive local anesthesia for their inguinal hernia repair.
9704112|NCT04706026|Active Comparator|General anesthesia|This arm will receive general anesthesia for their inguinal hernia repair.
9978712|NCT01374191|Placebo Comparator|placebo|saline
9978713|NCT01374191|Active Comparator|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
10204466|NCT01433315|No Intervention|normal sleep|normal sleep during the experimental period
10191116|NCT04756440|Experimental|Experimental: Intervention Group|Firstly, Pre-tests were applied to the women in the experimental group. The 4-week training program created by taking into account the cultural characteristics of the Roma; It includes the Anatomy of Female Reproductive Organs, Anatomy of the Cervix, Cancer, Cervical Cancer, Early diagnosis and its importance, Pap smear test, HPV-DNA test, Cancer Early Diagnosis, Screening and Education Center. Afterwards, music therapy will be applied to the women in the experimental group with the song written and composed by the researchers who emphasized the importance of early diagnosis. At the end of the program, a focus group discussion will be held with the participants in the experimental group regarding their educational experiences, learning experiences for cervical cancer and screening, and program outcomes. Final tests will be made 3 months after the training ends.
10191117|NCT04756440|No Intervention|No Intervention: Control Group|First, pre-tests will be applied to the women in the control group. Women in this group will not be intervened and post-tests will be made 3 months after the pre-test.
10191118|NCT04756427|Experimental|Sodium citrate 4%|All enrolled participants will received the daily sodium citrate 4% locking solution for CLABSI prophylaxis intervention and be observed prospectively for adverse events
10191119|NCT04753749|Experimental|Shortened DAPT followed by P2Y12 inhibitor monotherapy|
10191120|NCT04753749|Active Comparator|Dual Antiplatelet Therapy|
10191121|NCT04747496||NVAF patients|NVAF adult patients with one or more risk factors treated with edoxaban.
9704113|NCT04705727|Experimental|budesonide/formoterol Turbuhaler®|After randomization, patients in the experimental arm will receive budesonide/formoterol Turbuhaler® 100/6 μg, one inhalation every 5 minutes (Maximum 12 inhalations).
9704114|NCT04705727|Active Comparator|nebulisation of terbutaline|0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered. In case of an insufficient response, 3 additional doses will be administered for a maximum of 6 nebulisations.
9704115|NCT04705701|Experimental|Arm A group participants receive same day post-op dialysis|Arm A group participants receive same day post-op dialysis
9704116|NCT04705701|No Intervention|Arm B group participants receive dialysis per standard care|Arm B group participants receive dialysis per standard care
9704117|NCT04706000||Study group|endometrial polyp
9704118|NCT04706000||Control group|normal endometrium
9704119|NCT04705792|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 12 consecutive weeks.
10191122|NCT04746131|Experimental|IMM0306|IMM0306 Dose escalation: 0.1mg/kg, 0.2mg/kg, 0.4mg/kg, 0.8mg/kg,1.2mg/kg and 1.6mg/kg through intravenous administration weekly up to 52 weeks.
9704120|NCT04705610|Experimental|Radiologically Isolated Syndrome (RIS)|
9704121|NCT04705610|Experimental|Clinically Isolated Syndrome (CIS)|
9978714|NCT01374230|Experimental|E1 Tibial bearing|All patients undergoing primary total knee replacement surgery will receive a tibial bearing made of E1 polyethylene, which is the material being monitored in this study.
9978715|NCT01374256||Combination therapy|Patients with Acinetobacter baumannii bacteremia treated with combination therapy of imipenem and sulbactam
10191123|NCT04744090|Experimental|Roflumilast add-on|Eligible patients will take 500 Mcg of roflumilast once daily (up to 28 days) plus standard of care.
10191124|NCT04744090|Placebo Comparator|Placebo control|Eligible patients will take placebo plus standard of care.
10191125|NCT04742894|Experimental|Aphasia Group|
9704122|NCT04705610|Experimental|Relapsing-Remitting MS (RRMS)|
9704123|NCT04705610|Experimental|Secondary Progressive MS (SPMS)|
9704124|NCT04705610|Experimental|Primary Progressive MS (PPMS)|
9704125|NCT04705610|Experimental|Healthy volunteer|
10191126|NCT04742894|Experimental|Control Group|
9704128|NCT04705584|Active Comparator|Topical steroids|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.
9704129|NCT04705584|Experimental|Topical Cyclosporine A|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Cyclosporine A 2% Topical eye drops 2 times per day for 6 weeks.
9704130|NCT04705584|Experimental|Topical Tacrolimus|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Tacrolimus A 0.3% Topical eye drops 2 times per day for 6 weeks.
9704131|NCT04705389|Other|Case group|Intervention only includes additional blood sampling at baseline and during follow up (5 samplings).
9704132|NCT04705493||CASE GROUP|Lidco rapid examination and echo examination were done to septic shock patients then the passive leg raising test was done and fluid responder cases were given mini fluid challenge and fluid challenge
9704133|NCT04705558|Experimental|group I|Continuous aerobic exercise with ketogenic diet for three month
9704134|NCT04705558|Experimental|group II|Ketogenic diet alone for three month
9704135|NCT04705363|Experimental|Interaction with a VHA with voice|A virtual health assistant computer-generated doctor who will have a conversation with you.
9704136|NCT04705363|Active Comparator|Interaction with a VHA without voice|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide you through the interaction. No voice will accompany the photos or text.
9704137|NCT04705740||September 2013 to August 2015|5 endoscopists
9704138|NCT04705740||September 2015 to December 2017|4 endoscopists
9704139|NCT04705740||January 2018 to June 2020|3 endoscopists
9704140|NCT04705753|Experimental|Cretan IAMA (CAPeo)|All patients are to receive Cretan IAMA (CAPeo) from Day 1.
9785119|NCT01243580|Experimental|AG200-15|AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention
9978716|NCT01374256||Not combination therapy|Patients with Acinetobacter baumannii bacteremia not treated with combination therapy of imipenem and sulbactam
9978717|NCT01374295|Experimental|video|If randomized to this arm patient watches a 3 minute video
9978718|NCT01374295|Active Comparator|standard education|If randomized to this arm patient receives standard verbal education from healthcare provider.
10191127|NCT04741386||Cohort A|Patients with CKD stages 4 and 5
9978719|NCT01374308|Experimental|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
9978720|NCT01374308|Active Comparator|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
9978721|NCT01374321|Placebo Comparator|Placebo|
10191128|NCT04741386||Cohort B|Patients on hemodialysis and peritoneal dialysis
9704141|NCT04706039|Experimental|Outpatients without hospitalisation criteria|Symptomatic and asymptomatic outpatient without hospitalisation criteria presenting in a COVID-19 screening centre of the Hospices Civils de Lyon
9704142|NCT04705636|Experimental|Connected device|Connected device for three months period to support children care
9978722|NCT01374321|Experimental|TRO40303|
9978723|NCT01374347||One dose, Repeat doses|First group recives one dose Second group receives several doses
9978724|NCT01374347||One dose, several doses|15 patients will take one dose of 20 mg cialis, and will have a second brain SPECT 24 hours after cialis administration. 15 other patients (age and risk factor matched) will be prescribed 5 mg of cialis once daily for 7 days, and a second SPECT study will be performed 24 hours after the last dose.
9978725|NCT01374373|Other|Open Label|One arm open label
9978726|NCT01374386|No Intervention|Usual Physical Activity|Participants in this arm are do not have access to Exergames, only usual physical activity at the gym
9978727|NCT01374386|Experimental|Exergaming|Participants in this arm will have access to usual physical activity at the gym as well as access to Exergaming equipment (video games that require physical activity)
9704143|NCT04705857||test group|"bone reconstructive surgery with the use of Histograft bone substitute (gene-activated matrix based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) mixed with shredded autobone (in a ratio of 50/50) harvested during the surgery"
9704144|NCT04705857||control group|bone reconstructive surgery with the use of shredded bone autograft harvested from iliac crest
9704145|NCT04705337|Experimental|Levosimendan|administration of levosimendan
10191129|NCT04741386||Cohort C|Kidney Transplant Recipients
10191130|NCT04741386||Cohort D|Controls
10191131|NCT04733534|Active Comparator|Dasatinib plus Quercetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16^INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 will assess the permanence of change after completion of the trial."
9704146|NCT04705337|Placebo Comparator|Placebo|administration of placebo
9704147|NCT04705480|Experimental|Pregabalin|
9704148|NCT04705480|Experimental|Gabapentin|
9704149|NCT04705480|Active Comparator|Neither Pregabalin nor Gabapentin|
10204467|NCT01428635|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD in the absence of disease progression or unacceptable toxicity.
9704150|NCT04705506|Experimental|Gemigliptin group|The participants will receive gemigliptin 50 mg daily
9704151|NCT04705506|Placebo Comparator|Control|The control received standard care of diabetes
9704152|NCT04705441|Experimental|SMART intervention|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions over 10-12 weeks. The intervention sessions are held over Zoom.
9704153|NCT04705441|No Intervention|Waitlist|Individuals randomized to WL will continue in their usual care. After they complete their 13-week and 6-month assessments, they will begin participating in the SMART program.
9704154|NCT04705233|Experimental|Sputum chart|Use of the 5 point sputum colour chart, adapted from Bronkotest® a self-management (SM) plan and rescue pack (RP) containing 5 days supply of antibiotic and steroid treatment
9704155|NCT04705233|No Intervention|Control|Use of the plan and rescue pack alone (best usual care)
9704156|NCT04705402|Experimental|Patients randomized to receive the treatment arm of mannitol.|The mannitol solution used in the hospital contain 18% mannitol in 500ml solution. An equivocal volume of 2.8 cc / kg body weight, which will be given intravenously with the use of an Ivac pump, infused for a duration of 15 minutes through an existing peripheral intravenous access catheter within 15-30 minutes prior to renal artery reperfusion
9704157|NCT04705402|Placebo Comparator|(Control arm) Study participants will receive a 0.9% saline solution|(Control arm) Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
9704158|NCT04705519|Experimental|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel, Bevacizumab
9778835|NCT01116986|Experimental|21, No Patch, Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9785120|NCT01243593|Experimental|Treatment Group|
9785121|NCT01243593|Active Comparator|Control Group|
9978728|NCT01374399|Experimental|resistance and endurance exercise|
9978729|NCT01374399|Active Comparator|relaxation|
9978730|NCT01374412||osteoporosis|patients with benign osteoporosis
9978731|NCT01374464|Active Comparator|High Volume, High Concentration|
9978732|NCT01374464|Active Comparator|High Volume, Low Concentration|
9978733|NCT01374464|Active Comparator|Low Volume, High Concentration|
9978734|NCT01374464|Active Comparator|Low Volume, Low Concentration|
9978735|NCT01374477||Adolescent with preeclampsia|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy.
9978736|NCT01374477||Normal adolescent|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy.
9978737|NCT01374503|Experimental|ALX-0651|
9978738|NCT01374503|Placebo Comparator|Placebo|
9704159|NCT04705467|Other|Patients|Device: Gynecological brachytherapy requiring an Interstitial or ring and tandem insert involves insertion of the needle and applicators with no standard real-time image guidance. Occasionally 2-dimensional ultrasound is used, but it greatly limited by its flat nature, preventing a volumetric view of the needle pathways. Interstitial brachytherapy is done under general anesthesia. The trans-abdominal and trans-rectal standard 2D ultrasound that are used in some cases, will be expanded to 3D dimensional imaging through the use of an investigational device. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning.
10191132|NCT04733534|Active Comparator|Fisetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 to will assess the permanence of change after completion of the trial."
9704160|NCT04705428|Experimental|Group I: intervention group 1|Professional hygiene will be carried out with the application of fluoride varnish (Duraphat) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
9704161|NCT04705428|Experimental|Group II: intervention group 2|Professional hygiene will be carried out with the application of fluorine varnish (Tiefenfluoride) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
9978739|NCT01374542||Respiratory endoscopy patients|Patients undergoing respiratory endoscopy at Singapore General Hospital
9704162|NCT04705428|Experimental|Group III: intervention group 3|Professional hygiene will be carried out with the application of fluorine varnish (Fluor Protector S) and the use of fluoride paste according to the age will be recommended for oral hygiene at home.
9704163|NCT04705714|Experimental|Frankincense Extract|the anti-bacterial and antibiofilm activity of frankincense extract against Porphyromonas gingivalis clinical isolates were studied
9704164|NCT04705311|Experimental|pain neuroscience education plus rotator cuff repair rehabilitation|
9704165|NCT04705311|Active Comparator|rotator cuff repair rehabilitation|
9704166|NCT04705415|Experimental|ANA001|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned treatment as a single oral dose (1000 mg, 2000 mg, or 3000 mg of ANA001) with a standardized light meal. Each capsule is 250 mg.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned treatment twice daily (BID) or thrice daily (TID) (total daily dose is to be determined following the completion of the SAD portion of the study and will not exceed 2000 mg ANA001) with a standardized light meal for 7 consecutive days. Each capsule is 250 mg."
9704167|NCT04705415|Placebo Comparator|Matching Placebo|"For the single ascending dose (SAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) as a single dose (4, 8, or 12 capsules) with a standardized light meal.~For the multiple ascending dose (MAD) portion of the study, subjects will receive their assigned matching placebo (hydroxypropylmethylcellulose (HPMC) dose twice daily (BID) or thrice daily (TID) with a standardized light meal."
9704168|NCT04705285|Experimental|Erbium:Yag Laser|Patients allocated to the erbium:yag laser are going to undergo 2 sessions of vaginal laser, separated by one month each other.
9704169|NCT04705285|Active Comparator|Pelvic floor training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist.
9704170|NCT04705129|Experimental|zanubrutinib+Tislelizumab|Zanubrutinib 160mg Bid, D1-21, po；Tislelizumab 200mg, D1, ivgtt
9704171|NCT04705103||initial|
9704172|NCT04705103||relapse|
9704173|NCT04705103||inactive|
9704174|NCT04705194||One stage resection|Patients that are selected for a single hepatectomy of 2 segments or more.
9704175|NCT04705194||Two stage resection|Patients that are selected for a two-stage resection, where the first stage consists of either PVE or ALPPS and the second stage is a hepatectomy of 2 or more segments.
9978740|NCT01374581|Experimental|Artemether/Lumefantrine|Tablets 20 mg/120 of Artemether/Lumefantrine will be given to 124 trial patients
9978741|NCT01374581|Experimental|Artesunate/Amodiaquine|Tablets 25mg/67,5 mg of Artesunate/Amodiaquine will be given to 124 trial patients.
9704178|NCT04705220|Experimental|Nutritional Supplementation with Test Product|Subjects will receive 1 tablet of MERIVA® in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months. This treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
9704179|NCT04705220|Placebo Comparator|Control Group without Nutritional Supplementation|Subjects will receive 1 tablet of placebo in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months.
9704180|NCT04704921|Experimental|RGX-314 Dose 1|RGX-314 Dose 1 administered via subretinal delivery one time.
9704181|NCT04704921|Experimental|RGX-314 Dose 2|RGX-314 Dose 2 administered via subretinal delivery one time.
9704182|NCT04704921|Active Comparator|Control Arm|Ranibizumab administered via intravitreal injection approximately every 28 days
9704183|NCT04705207|Experimental|reflexology massage|foot reflexology massage
9704184|NCT04705207|Placebo Comparator|sham massage|traditional foot massage
9704185|NCT04704960||Lung metastases from colorectal cancer, local ablative therapy (surgery or radiation)|patients diagnosed with lung metastases from colorectal cancer and undergoing surgery or radiation for lumg metastasis
9704186|NCT04704908||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
9704187|NCT04704908||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
9978742|NCT01374581|Active Comparator|Quinine + Clindamycin|Quinine tablet 125mg + Clindamycin syrup 75mg/5ml will be given to 60 children.
9978743|NCT01374594||Healthy adults|
9978744|NCT01374594||Type 2 diabetes|
9978745|NCT01374620|Experimental|Paclitaxel Dose escalation|"A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide)~+ blood collection"
9704188|NCT04704908||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
9704189|NCT04704778|Active Comparator|Transcutaneous|Transcutaneous electrostimulation and uso of oclusal splint
9704190|NCT04704778|Active Comparator|Percutaneous|Percutaneous electrostimulation and splint
9704191|NCT04704778|Placebo Comparator|Control|Oclusal splint
9704192|NCT04704947|Experimental|nonselective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.
9704193|NCT04704947|Experimental|cardio-selective beta blocker group|Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.
9704194|NCT04704947|Placebo Comparator|Control group|Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.
10191133|NCT04733118|Experimental|Patient HER 2+ IHC 3+|Patients ≥18 years of age with previously untreated HER2-positive (HER2[+]) (Immunohistochemistry [IHC] 3+) invasive carcinoma according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and tumor size between >5 to 25 mm by breast magnetic resonance imaging (MRI) and node-negative status by clinical exam, MRI, and ultrasound. Patients must have not been previously treated with chemotherapy, anti-HER2 therapy, radiation therapy, or endocrine therapy (ET) for invasive breast cancer. Patients with metastatic disease are not eligible. In patients with suspected axillary node involvement, a negative fine needle aspiration biopsy (FNAB) will be mandatory
10191134|NCT04721977|Experimental|Tucatinib + Trastuzumab + Capecitabine|Participants will receive tucatinib plus trastuzumab plus capecitabine. Tucatinib 300 mg will be administered orally twice daily (BID). Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose thereafter, will be administered intravenously (IV) on Day 1 of each 21-day cycle. Capecitabine 1000 mg/m^2 will be administered orally BID on Days 1-14 of each 21-day cycle. Tucatinib, trastuzumab and capecitabine treatment will continue until unacceptable toxicity, disease progression, death, withdrawal of consent or study closure.
10191135|NCT04712097|Experimental|M + Len|Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
10191136|NCT04712097|Experimental|R + Len|Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 6, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
10191137|NCT04709016||male or transgender patients|of sexual orientation MSM (men having sex with men) or bi-sexual, consultant in sexual health centers
9704195|NCT04705077|Experimental|Single Dose Treatment|"Each subject will be assigned to the fixed period sequence.~Period 1: SR419 suspension in the fasted state;~Period 2: SR419 capsule in the fasted state;~Period 3: SR419 capsule in the fed state (high-fat meal)."
9704196|NCT04705077|Experimental|Repeated Dose Treatment|Each subject will receive 30 mg of SR419 capsule, once every 8 hours (Q8h), for 5 days.
9704197|NCT04705090|Experimental|YY-20394 treatment|YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.
9704198|NCT04705142|Experimental|MgSO4|"MgSO4~1st dose within 6 hours of life @250mg/kg,2nd after 24 hours of life @250mg/kg, 3rd after 48 hours of life @250mg/kg.~Monitoring and Protective measures:~Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour."
9704199|NCT04704973|Experimental|Transdiagnostic short-term psychotherapy|
9704200|NCT04705064||AI_AKI|Adults patients undergoing non-cardiac surgery
9704201|NCT04704856|Active Comparator|Interventiongroup|Interventiongroup, undergo supervised exercise for the first 6 weeks.
9704202|NCT04704856|No Intervention|Controlgroup|Controlgroup, do not undergo supervised exercise for the first 6 weeks (possibility to undergo supervised exercise after 6 weeks).
9704203|NCT04705012|Experimental|Test - increased frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
9704204|NCT04705012|Active Comparator|Control - conventional frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
9704205|NCT04704765|Experimental|The effectiveness of receiving abdominal breathing training|The patients receiving the intervention of abdominal breathing training were in the experimental group. The experimental group received the abdominal breathing training for a total of 8 weeks. During this period, they received the abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time). The control group without training.
9704206|NCT04704765|No Intervention|The effectiveness of not receiving abdominal breathing training|The control group who did not receive abdominal breathing training. The effectiveness assessment used the Beck anxiety inventory and physiological index (heart beats, breath and blood pressure), required to be completed by the control group.
9704207|NCT04704791|Experimental|Procedure arm|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
9704208|NCT04704895|Active Comparator|Arm A: Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
9704209|NCT04704895|Experimental|Arm B: Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
9978746|NCT01374620|Experimental|Cohort extension|"An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose~+ blood collection"
9978747|NCT01374633|Experimental|1:patient with severe traumatic brain|
9978748|NCT01374659||Study patients|Study patients with histologically proven DTC were studied. All patients had previously undergone total thyroidectomy and more than one session of postoperative RI therapy. After the last RI therapy session, all patients showed increasing pathological Tg levels (Tg > 9-10 ng/ml) after TSH stimulation (TSH > 30 mU/l). However, neither tumor recurrence nor metastasis could be detected in any patient by post-therapeutic [131I] scanning, neck US, or chest radiography. Patients with obvious cervical pathology or positive fine-needle aspiration cytology (FNAC) were excluded from the study. The work was approved by our Institutional Review Board and written informed consent was obtained from each patient.
9978749|NCT01374672||Correlative studies|DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.
10191138|NCT04703920|Experimental|Talozoparib in combination with Belinostat|Patients will receive Talozoparib in combination with Belinostat
10191139|NCT04699799|Experimental|record brain activity while smelling odors|Record brain activity while smelling odors
10191140|NCT04698031|Experimental|Clopidogrel|"After randomization, patients will receive clopidogrel mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
10191141|NCT04698031|Experimental|Aspirin|"After randomization, patients will receive aspirin daily for the duration of the study. The VA Research Pharmacy will dispense similar looking pills (using a dummy pill) with Arm 1 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Patients will be followed for 24 months with repeat brain MRI scans obtained at 24 months."
10191142|NCT04691869|No Intervention|Control|Patients will be randomized into a control group and study group. The control group will receive an informational discussion with the nurse-practitioner regarding steps to reduce the risk for osteoporosis, as well as an informational handout in their discharge papers.
10191143|NCT04691869|Experimental|Interventional|The study group will undergo the QUS (performed by a member of the study team) and receive the same informational discussion and handouts, with the addition of a QUS screening to take to their follow-up appointment. The QUS screening will come with a half-page description, describing the screening and what their results mean. A discussion lead by the nurse-practitioner, who is a member of the study staff, regarding the results will happen prior to discharge.
9704210|NCT04704986|Active Comparator|PVI using the Arctic Front Cryoballoon (Medtronic)|Pulmonary vein isolation using the Arctic Front Cryoballoon (Medtronic)
9704211|NCT04704986|Active Comparator|PVI using the PolarX Cryoballoon (Boston Scientific)|Pulmonary vein isolation using the PolarX Cryoballoon (Boston Scientific)
9984375|NCT04167969|Experimental|Prostate cancer patients|Patients will receive an intravenous (IV) injection of approximately 5 mCi (+/- 10%) of PSMAtargeting C' dot tracer up to 48 hours before surgery. Patients will then undergo serial preoperative PET/MR imaging to help characterize the safety, biodistribution/pharmacokinetics, and dosimetry of this agent. To assess total radioactivity in whole blood/plasma and urine samples, as well as radioactive metabolites, blood and urine samples will be collected at approximately 30 min post-injection as well as before each imaging session
9704213|NCT04704622|Active Comparator|dexmedetomidine group|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
9704214|NCT04704622|Active Comparator|ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
9704215|NCT04704622|Active Comparator|midazolam|midazolam intranasal injection,0.2 mg/kg, once, 30 min preoperative
9704216|NCT04704596|Active Comparator|dynamic lung compliance for detection of optimum PEEP|detection of optimum PEEP by measurement of the dynamic lung compliance (by the ventilator machine) after lung recruitment
9704217|NCT04704596|Active Comparator|Lung ultrasound for detection of the optimum PEEP|Lung ultrasound will be used to detect the optimum PEEP after lung recruitment
9704218|NCT04704492|Experimental|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0 , 2.
9704219|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9704220|NCT04704440|Sham Comparator|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9704221|NCT04704440|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9704222|NCT04704440|Active Comparator|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9704223|NCT04704687|Experimental|tDCS|
9704224|NCT04704687|Active Comparator|Sham|
9984376|NCT04167462|Experimental|Arm A:BMS-986165 oral administration|
9984377|NCT04167462|Placebo Comparator|Arm B: Placebo oral administration|
9984378|NCT04166942|Experimental|Normal Hepatic Function (Group 1--Control)|Matched healthy subjects with normal hepatic function
9984379|NCT04166942|Experimental|Mild Hepatic Impairment (Group 2)|Subjects with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6
9984380|NCT04166942|Experimental|Moderate Hepatic Impairment (Group 3)|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9
9984381|NCT04166942|Experimental|Severe Hepatic Impairment (Group 4)|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10 to 14
9984382|NCT04166643|Experimental|WHHIP-PLUS|"Component I: Stakeholder Group Involvement:~Component II: Environment Assessment:~Component III: Organizational Changes To Reduce Job Stress:~Component IV- Worker Health Behavior Change:"
9984383|NCT04166643|Active Comparator|Education only|Education
9984384|NCT04164901|Experimental|Vorasidenib|Vorasidenib 40 mg, continuous daily dosing.
10191144|NCT04689347|Experimental|FLIRT-bevacizumab|"Bevacizumab intravenous infusion (IV), irinotecan IV, leucovorin (LV) IV, 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU), given every 14 days, in combination with oral (PO) temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days.~The treatment will consist of an induction period of four 28-day cycles of FLIRT- bevacizumab followed by maintenance regimen of 5-FU/LV-bevacizumab administered every 14 days in combination with PO temozolomide according to dose level over days 1-5 every 28 days in patients without progressive disease at the end of the induction period."
10191145|NCT04685759|Active Comparator|In-Person Exercise Protocol (IPEP)|This group will receive exercise instruction and monitoring in-person from the certified Cancer Exercise Trainer (CET) in the gym facility at Moncrief Cancer Institute (MCI). Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
10191146|NCT04685759|Experimental|Virtual Exercise Protocol (VEP)|This group will receive exercise instruction and monitoring from the CET via telehealth sessions at home. Study participants will be scheduled for exercise sessions twice a week with the oncology exercise trainer.
10191147|NCT04683224|Placebo Comparator|Placebo Stratum 1: 18 to 59 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
10191148|NCT04683224|Experimental|UB-612 Stratum 1: 18 to 59 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
10191149|NCT04683224|Placebo Comparator|Placebo Stratum 2: ≥60 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
10191150|NCT04683224|Experimental|UB-612 Stratum 2: ≥60 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
10191151|NCT04683224|Placebo Comparator|Placebo Stratum 3: 18 to 59 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
10191152|NCT04683224|Experimental|UB-612 Stratum 3: 18 to 59 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
10191153|NCT04683224|Placebo Comparator|Placebo Stratum 4: ≥60 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
10191154|NCT04683224|Experimental|UB-612 Stratum 4: ≥60 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
10191155|NCT04679857|Experimental|UC|Total Knee Arthroplasty with an ultracongruent insert
10191156|NCT04679857|Active Comparator|PS|Total Knee Arthroplasty with posterior stabilized design
10191157|NCT04679181|Experimental|Active arm|use of telemedicine
10191158|NCT04674995||Stent|Patients with tracheal stenosis treated with stent placement via rigid bronchoscopy.
10191159|NCT04674995||Balloon dilatation|Patients with tracheal stenosis treated with balloon dilatation via laryngoscope.
10191160|NCT04672291|Experimental|Safety Cohort|A randomized (4:1) initial safety cohort of 13 patients will receive 2 cycles of drug (N=10) or placebo (N=3)
10191161|NCT04672291|Experimental|Expansion Cohort|A randomized (4:1) expansion cohort will receive 3 cycles of drug (N=24) or placebo (N=6). A total of 30 patients will be accrued.
10191162|NCT04669340|Experimental|Intervention group|"Participants in the intervention group will receive patient education through an e-learning program at home. A study nurse will introduce patients to the program and they will be asked to accomplish the program within four weeks. Furthermore, they will be encouraged to go through the program as many times as necessary and involve family and relatives if they like.~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
10191163|NCT04669340|Active Comparator|Control group|"Participants in the control group will receive conventional patient education from a nurse in the out-patient clinic within four weeks after inclusion. Relatives can take part in the conversation.~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
10191164|NCT04663932|Placebo Comparator|immediate stenting group|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
10191165|NCT04663932|Experimental|deferred stenting group|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
10191166|NCT04663750|Experimental|Arm A - Surgery with aflibercept|Surgery with aflibercept at the end of surgery, with post-operative review day 1 and week 1 (day 7)
10191167|NCT04663750|Active Comparator|Arm B - Aflibercept monotherapy|Aflibercept monotherapy commencing at baseline.
10191168|NCT04660812|Experimental|etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab|Participants will receive oral etrumadenant in combination with zimberelimab +mFOLFOX-6 +/-bevacizumab by IV infusion.
10191169|NCT04660812|Active Comparator|mFOLFOX-6 +/-bevacizumab|Participants will receive mFOLFOX-6 +/- bevacizumab by IV infusion.
10191170|NCT04660812|Active Comparator|regorafenib|Participants will receive oral regorafenib
10191171|NCT04660812|Experimental|etrumadent+ zimberelimab + AB680|Participants will receive oral etrmadenant in combination with zimberelimab +AB680 by IV infusion.
10191172|NCT04660396||Outpatients following discharge for treatment of heart failure|Daxor Corporation's commercially available Blood Volume Analyzer, BVA-100, will be performed at 5 timepoints for each patient.
10191173|NCT04659707|Experimental|COVID-19 Survivors|Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.
10191174|NCT04657367||Diabetes|Patients with diagnosed diabetes
10191175|NCT04657367||Prediabetes|Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance
10191176|NCT04657367||Normoglycemia|Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance
10204468|NCT01416935|Active Comparator|No Amiodarone|Patient will be randomized not to receive to Amiodarone post Cox-Maze procedure unless indicated.
10204469|NCT01416935|No Intervention|Amiodarone|Patients randomized to receive Amiodarone post Cox-Maze procedure which is our current standard of care.
9704225|NCT04704713|Experimental|Afamelanotide|Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
9704226|NCT04704713|Placebo Comparator|Placebo|Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.
9704227|NCT04704362|Active Comparator|Training and Supervision as Usual|Non-specialists are trained in a psychological intervention under standard conditions. No feedback from competency-based evaluations is provided to modify the training or supervision curriculum.
10191177|NCT04649151|Experimental|mRNA-1273|"Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram [ug] each), 28 days apart, on Day 1 and Day 29.~Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29.~Part 2 (Open-Label): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29."
10191178|NCT04649151|Placebo Comparator|Placebo|Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.
10191179|NCT04649151|Experimental|mRNA-1273 BD|"Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B.~Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose.~Part 2 (Open-Label): Participants will receive 1 IM injection as a BD of mRNA-1273 (50 ug) on Day 149, at least 3 months post-Dose 2."
9978750|NCT01374698|Active Comparator|Aspirin|All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
9978751|NCT01374698|No Intervention|No intervention|No intervention
9978752|NCT01374711|Placebo Comparator|placebo|LPS will be administered twice on days 1 and 7. In between placebo will be administered on days 2, 4 and 6 subcutaneously.
9978753|NCT01374711|Active Comparator|GM-CSF|LPS will be administered twice on days 1 and 7. In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
9978754|NCT01374711|Active Comparator|IFN-y|LPS will be administered twice on days 1 and 7. In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
9978755|NCT01374724|Experimental|Ban & Informational Pamphlet|Following 8.5 weeks of cessation subjects are given an informational pamphlet on tobacco cessation and relapse prevention.
9978756|NCT01374724|Experimental|Ban & Tailored Pamphlet|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force
9978757|NCT01374724|Experimental|Ban & Tailored Pamphlet & Intervention|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force. In addition they are given a face to face relapse prevention intervention.
9704228|NCT04704362|Experimental|Competency-based Training and Supervision|Non-specialists are trained and supervised in a competency-based approach in which trainers and/or supervisors are provided with the competency scores of trainees in order to modify the training and supervision content and approach as needed.
9704229|NCT04704310|Experimental|Intervention Group|Individuals acting as own control. Looking at changes pre and post intervention
9704230|NCT04704388||patients hospitalized in intensive care units for SARS-CoV-2|patients hospitalized in intensive care units for SARS-CoV-2
9704231|NCT04704388||patients hospitalized outside intensive care units|patients hospitalized outside intensive care units
9704232|NCT04704739|Experimental|GLPG1205 oral and [14C]-GLPG1205 IV|Single oral dose of GLPG1205 followed by [14C]-GLPG1205 solution for infusion
9704233|NCT04704739|Experimental|[14C]-GLPG1205 capsule|Single oral dose of GLPG1205 as solid formulation
9704234|NCT04704284|Experimental|ZTE MRI Imaging|Pediatric patients that have gotten a clinically indicated CT within a 6 week time period will receive a Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)
9704235|NCT04704570|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
9704236|NCT04704570|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
9704237|NCT04704570|Other|Remotely assessment Group-Face to Face Assessment Group|First, a remote evaluation and then a face to face evaluation will be made.
9704238|NCT04704570|Other|Face to Face Assessment Group-Remotely assessment Group|First, a facet o face evaluation and then a remote evaluation will be made.
9978758|NCT01374737|Other|dexmedetomidine, children|
9978759|NCT01374750|Active Comparator|m-TOR inhibitor free|Immunosuppressive drug
9978760|NCT01374750|Experimental|Sirolimus|Immunosuppressive drug
9978761|NCT01374763|Active Comparator|Oxycodone|Drug: prolonged-release oxycodone
9978762|NCT01374763|Active Comparator|Oxycodone/naloxone|Prolonged-release oxycodone/naloxone
9978763|NCT01374776|Experimental|intravenous iron carboxymaltose|intravenous iron carboxymaltose infusion
9978764|NCT01374789|Experimental|Arm A (GemCis + Panitumumab)|gemcitabine + cisplatin + panitumumab
9978765|NCT01374789|Active Comparator|Arm B (GemCis)|gemcitabine + cisplatin
9978766|NCT01374815|Experimental|The Online Advocate|
9978767|NCT01374828|Experimental|Ketolorac|
9978768|NCT01374841|Experimental|Stem Cell Transplant+Cyclophosphamide|patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide
9978769|NCT01374854|Experimental|Stem Cell Infusion|
9978770|NCT01374854|Active Comparator|traditional therapy control|
9978771|NCT01374880||Dyspnea cohort|Dyspnea cohort
9978772|NCT01374880||Stable chronic heart failure|Stable chronic heart failure
9978773|NCT01374880||Valvular heart disease|Valvular heart disease
9978774|NCT01374880||Ventricular assist device|Ventricular assist device
9978775|NCT01374880||Cardiac arrest|Cardiac arrest
9978776|NCT01374880||Cardiac rehabilitation|Cardiac rehabilitation
9978777|NCT01374893|Active Comparator|Exercise|
9978778|NCT01374893|Placebo Comparator|Control group|Usual care
10191180|NCT04646044|Experimental|Bempegaldesleukin IV + Standard of Care|
10191181|NCT04646044|Placebo Comparator|Placebo + Standard of Care|
9785122|NCT01243619|Experimental|FLT PET|This is a single arm trial, in which all patients receive three FDG-PET scans and three FLT-PET scans, before, during and after pre-operative chemoradiation for esophageal cancer.
10191182|NCT04643886|Experimental|Cohort with Genetic Profile A|"Subjects will have Genetic Profile A.~Intervention: Biological: GEM103."
10191183|NCT04643886|Experimental|Cohort with Genetic Profile B|"Subjects will have Genetic Profile B.~Intervention: Biological: GEM103"
10191184|NCT04634890|Other|Type 2 Diabetes|Subjects with type 2 diabetes, diagnosed within the last 3-5 years, treated with metformin only as an anti-diabetic drug
10191185|NCT04634890|Other|Prediabetes|Subjects with prediabetes, defined as impaired fasting glucose or/and impaired glucose tolerance
10191186|NCT04634890|Other|Normoglycemia|Subjects with normal fasting glucose and normal glucose tolerance
10191187|NCT04634591||Obesity - undergoing bariatric surgery|Patients with morbid obesity, treated with the bariatric surgery
10191188|NCT04634591||Obesity - without bariatric surgery treatment|Patients with morbid obesity, not treated with the bariatric surgery
10191189|NCT04634591||Non-obese|Non-obese patients - control group (without obesity and without the bariatric surgery treatment)
10191190|NCT04634136|Active Comparator|Active Substance: Full-spectrum Medical Canabis Product (HemPhar)|For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.
10191191|NCT04634136|Placebo Comparator|Placebo|For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.
10191192|NCT04630574||Patients with Huntington's disease|Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.
10191193|NCT04629508|Experimental|Part 1 : Dose Escalation of itacitinib|Participants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.
10191194|NCT04629508|Experimental|Part 2 : Dose Expansion of itacitinib|Participants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.
10191195|NCT04628962||Asthma-COPD Overlapped (aCOPD)|50 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
10191196|NCT04628962||Non-Exacerbator COPD (neCOPD)|50 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects
10191197|NCT04628962||frequent Excacerbator with Emphysema COPD (eeCOPD)|50 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects
10191198|NCT04628962||frequent Excacerbator with chronic Bronchitis COPD (ebCOPD)|50 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects
10191199|NCT04628962||Asthma patients (AST)|200 subjects affected by asthma comparable by age and sex with the other recruited subjects
10191200|NCT04628962||Healthy subjects (CTRL)|200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects
10191201|NCT04623684|Experimental|Study Group|Mydriasis with microdrops
10191202|NCT04623684|Active Comparator|Control Group|Mydriasis with standard drops
10191203|NCT04621981|Experimental|Sodium Bicarbonate Ringer's Solution|Intravenous drip, 500~1000ml per time. Infusion speed: 15ml/kg/h or according to guidelines or department routine.
10191204|NCT04621981|Active Comparator|Normal Saline|"Intravenous drip, 500~1000ml per time. Dosage depends on age、weight and symptoms.~Infusion speed: According to the department process or clinician's decision."
10191205|NCT04616339|Active Comparator|Formulation A (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
10191206|NCT04616339|Experimental|Formulation B (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation B at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
10191207|NCT04616339|Experimental|Formulation C (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation C at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
10191208|NCT04616339|Experimental|Formulation D (Cohort 1)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation D at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
10191209|NCT04616339|Active Comparator|Formulation A (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation A at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
10191210|NCT04616339|Experimental|Formulation E (Cohort 2)|Following an overnight fast of at least 10 hours, subjects received PF-06882961 (Danuglipron) 100 mg immediate release tablet as formulation E at approximately 0800 hours (±2 hours). A minimum of 72 hours between the single 100 mg doses administered in each period was employed
10191211|NCT04616196|Experimental|Dose Escalation of NKTR-255 with Cetuximab|Establish RP2D, of NKTR-255 with cetuximab.
10191212|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort A|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with HNSCC.
10191213|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort B|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with CRC.
10191214|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort C|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cSCC.
10191215|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort D|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with ASCC.
10191216|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort E|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cervical cancer.
9978779|NCT01374932|Experimental|CPAP (see below)|Adult patients with asthma who require treatment with CPAP because of OSAS (RDI> = 20 events per hour). CPAP will be administered according to SEPAR guidelines and tailored to individual characteristics
9978780|NCT01374945|No Intervention|SOC preparation and colonoscopy|
10191217|NCT04615442|Experimental|All subjects|Subjects that undergo a clinical video EEG are asked to additionally wear a wearable EEG headband for up to 2 periods of 4h during the video EEG.
10191218|NCT04614246|Experimental|BAY1817080 150 mg|Participants will receive 150 mg of BAY1817080 twice daily over a 12-week intervention period
10191219|NCT04614246|Experimental|BAY1817080 75 mg|Participants will receive 75 mg of BAY1817080 twice daily over a 12-week intervention period
10191220|NCT04614246|Experimental|BAY1817080 25 mg|Participants will receive 25 mg of BAY1817080 twice daily over a 12-week intervention period
10191221|NCT04614246|Active Comparator|Elagolix|Participants will receive 150 mg of Elagolix once daily over a 12-week intervention period
10191222|NCT04614246|Placebo Comparator|Placebo|Participants will receive placebo matching BAY1817080 twice daily over a 12-week intervention period
10191223|NCT04603807|Experimental|Entrectinib|Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
10191224|NCT04603807|Active Comparator|Crizotinib|Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
10191225|NCT04602728|Experimental|Back2Life Program|Youth with chronic SCD pain and their parents or caregivers receiving an adaptive cognitive behavioral treatment program for pain coping skills.
10191226|NCT04595370|Experimental|AZD9977 Dose A + dapagliflozin 10 mg|Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.
10191227|NCT04595370|Experimental|AZD9977 Dose B + dapagliflozin 10 mg|Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.
10191228|NCT04595370|Experimental|AZD9977 Dose C + dapagliflozin 10 mg|Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.
10191229|NCT04595370|Experimental|Dapagliflozin 10 mg|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
10191230|NCT04589845|Experimental|Cohort A: ROS1 fusion-positive tumors|Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) >/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
10191231|NCT04589845|Experimental|Cohort B: NTRK1/2/3 fusion-positive tumors|Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA >/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
10191232|NCT04589845|Experimental|Cohort C: ALK fusion-positive tumors|Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.
10191233|NCT04589845|Experimental|Cohort D: TMB-high tumors|Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged >/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged < 18 years on Day 1 of each 21-day cycle.
10191234|NCT04589845|Experimental|Cohort E: AKT1/2/3 mutant-positive tumors|Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants <35 kg, 300 mg for participants >/= 35 and <45 kg, 400 mg for those >/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
10191235|NCT04589845|Experimental|Cohort F: HER2 mutant-positive tumors|Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.
10191236|NCT04589845|Experimental|Cohort G: MDM2-amplified, TP53 wild-type tumors|"Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle.~Note: Cohort G has been closed for enrollment"
10191237|NCT04589845|Experimental|Cohort H: PIK3CA multiple mutant-positive tumors|Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.
9978781|NCT01374945|Experimental|Miniprep and Clearpath|
9978782|NCT01374984||Subjects treated with VIGIV.|"Subjects treated with VIGIV deployed from the US Strategic National Stockpile for any of the following conditions:~Eczema vaccinatum.~Progressive vaccinia.~Severe generalized vaccinia.~Vaccinia infections in individuals who have skin conditions.~Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis)."
9978783|NCT01374997|Other|patients with Fabry disease|detection of this disease in end-stage renal failure patients, transplant or hemodialysis
9978784|NCT01375023|Experimental|Anti-Thymocyte Globulin+radiotherapy|triple negative breast cancer patients treated with radiation and Anti-Thymocyte Globulin iv
9978785|NCT01375062|No Intervention|tissue from biopsies|
9704239|NCT04704297|Active Comparator|Standard Therapy (ST)|ST will consist of 975mg of Acetaminophen PO and either 30mg of Ketorolac IM or 15 mg IV. Upon discharge ST will consist of prescriptions for acetaminophen 650mg every 4 hours by mouth, Ibuprofen 400mg every 4 hours by mouth, and 10 mg of cyclobenzaprine nightly by mouth. Additionally, participants will be provided a handout going over these medications and the use of heat for low back pain and instructions on the performance of McKenzie stretching exercises for low back pain.4
9704240|NCT04704297|Active Comparator|ST plus Trigger Point Injections (TPI) with 8 mL of 0.5 percent Bupivacaine|ST plus TPI with 8 mL of 0.5 percent Bupivacaine
9704241|NCT04704297|Active Comparator|ST plus TPI with 8 mL of Normal Saline (NS)|ST plus TPI with 8 mL of Normal Saline
9704242|NCT04704414|Experimental|Validation of smartphone face scanner|Validation of smartphone face scanner in comparison to Hertel Exophthalmometer and high-definition face scanner.
9704243|NCT04704323||Experimental: Phase Ia - Dose escalation|Cohorts of 3 subjects will receive intravenous [IV] administrations of escalating doses of CAP-100.
9704244|NCT04704323||Experimental: Phase Ib - Dose expansion|Six subjects will receive intravenous [IV] administrations of CAP-100 at the Recommended Phase 2 Dose determined in Phase Ia - Dose Escalation of this trial.
9704245|NCT04704453|Experimental|Experimental arm (A): capsaicin patch|
9704246|NCT04704453|Other|Standard arm (B): amitriptyline|
9704247|NCT04704427|Experimental|Rehabilitative BCI training|The experimental group will receive brain computer interface-based lower limb function training (BCI-LLT), 30 minutes/time, 5 times/week, with a 4-week training period.. The training using the lower limb orthosis targeted the patient's ability to walk.
9978786|NCT01375088|Placebo Comparator|placebo mouth wash|10 patients swish & swallow 15 ml placebo mouth wash for at least 5 min from the first session of radiotherapy until the last session
9978787|NCT01375088|Active Comparator|propolis|10 patients swish & swallow 15 ml propolis mouth wash for at least 5 min from the first session of radiotherapy until the last session
9978788|NCT01375101|Active Comparator|quercetin|quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
9978789|NCT01375101|Placebo Comparator|placebo|placebo capsul is produced with lactose for using in placebo/ control group.
9978790|NCT01375153|Placebo Comparator|Placebo|0,9% NaCl administered as a continuous intravenous infusion during four hours.
9978791|NCT01375153|Active Comparator|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours.
9978792|NCT01375166||Diabetic retinopathy|Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
9704248|NCT04704427|Active Comparator|Traditional physical therapy protocol|The control group will only receive traditional physical therapy protocol. The traditional physical therapy protocol of lower limb conducted with the same treatment frequency, intensity and duration of treatment, including muscle strength training, balance training and walking training, etc.
9704249|NCT04704401||Patients PWV follow-up|"Patients included in the meta-analysis sleep apnea syndrome and arterial stiffness and contacted by phone for the collection of cardiovascular and metabolic events, incident cancers and deaths, through a structured questionnaire."
9704250|NCT04704635||Ischemic stroke/TIA|Patients with ischemic stroke or transient ischemic attack
9704251|NCT04704180|Experimental|Experimental Group: Facilitation Tuchking Group|The experimental group neonates received facilitated tucking under the radiant heater after birth of the NICU as well as the routine interventions.
9704252|NCT04704180|No Intervention|Control Group|The control group underwent the routine interventions of the observation unit of the NICU. The group did not receive any other intervention
9785123|NCT01243671|Experimental|Adalimumab|Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.
10191238|NCT04589845|Experimental|Cohort I: BRAF class II mutant or fusion-positive tumors|Participants with BRAF class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
9978793|NCT01375166||healthy|healthy control subjects
9978794|NCT01375179|Experimental|KRP203|"Experimental~Edit~Experimental"
9978795|NCT01375179|Placebo Comparator|Placebo|Placebo
9978796|NCT01375218|Active Comparator|Plastizote Brace|
9978797|NCT01375218|Active Comparator|Pavlik Brace|
9978798|NCT01375231|Active Comparator|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
9978799|NCT01375231|Active Comparator|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
9978800|NCT01375244|Experimental|A|Subjects received the Par formulated product.
9978801|NCT01375244|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
9978802|NCT01375257|Active Comparator|Guideline treatment with parenteral antibiotics|Guideline treatment with parenteral antibiotics
9978803|NCT01375257|Experimental|Oral treatment with antibiotics|Oral treatment with antibiotics based on resistens pattern
9978804|NCT01375270|Experimental|Glucotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose."
9978805|NCT01375270|No Intervention|Control Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding."
9978806|NCT01375270|Experimental|Lipotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids."
9978807|NCT01375283||lung cancer surgery|
9978808|NCT01375296|Experimental|SES|including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
9704253|NCT04704206|Active Comparator|Active Interactive Media Group|"AIMG children will perform active activities on the interactive tablet media. The games and applications that will be used during this intervention were selected through a search in the online application store compatible with the tablet used during the intervention (Google Play). The search term used was games for children aged 2 to 3 years and they were analyzed for the following criteria: (1) interactivity: critical thinking, active participation, decision making; (2) learning: activities that stimulate cognitive development, fine motor, receptive language, expressive and social-emotional language (see table 1 to view activities); (3) suitability: age, period of development, multiple domains and (4) results: challenging activity, not frustrating, providing feedback"
9978809|NCT01375296|Other|medicine|
9978810|NCT01375309|Active Comparator|Active|Bifidobacterium bifidum
9978811|NCT01375309|Placebo Comparator|Placebo|Dextrin without Bifidobacterium bifidum
9978812|NCT01375322|Active Comparator|Co-Diovan® Group|The starting dose of Co-Diovan® was 1 capsule (contains 1/2 tablet) (valsartan/ hydrochlorothiazide 40 mg/ 6.25 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (valsartan/ hydrochlorothiazide 160 mg/ 25.0 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
9978813|NCT01375322|Experimental|Amtrel® Group|The starting dose of Amtrel® was 1 capsule (contains 1/2 tablet) (amlodipine / benazepril hydrochloride 2.5 mg/ 5 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (amlodipine / benazepril hydrochloride 10 mg/ 20 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
9704254|NCT04704206|Active Comparator|Passive Interactive Media Group|PIMG children will go to the intervention room where they will use interactive tablet media in passive activities, such as: watching videos and children's stories that they often watch at home. This survey will be possible thanks to the questionnaire on the Use of Interactive Media where parents will list which drawings, stories and videos children use to watch.
10191239|NCT04589845|Experimental|Cohort J: BRAF class III mutant-positive tumors|Participants with BRAF class III mutant-positive tumors(adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
9704255|NCT04704167|Active Comparator|3D titanium mesh tray|3D titanium mesh tray as a method of fixation for double-barrel vascularized fibula
9704256|NCT04704167|Experimental|3D titanium miniplate|3D titanium miniplate as a method of fixation for double-barrel vascularized fibula
9704257|NCT04704258|Experimental|TAVI + Embolic protection|Subjects with severe native aortic valve stenosis who meet the clinically approved indications for aortic valve interventions such as TAVI
9704258|NCT04704245|Experimental|epidermal growth factor (EGF) containing ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
9978814|NCT01375335|Experimental|Dobutamine|
9978815|NCT01375348|Active Comparator|Remifentanil|"Investigate the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle pain induced by the tourniquet pain model~cognitive tests~recording of brain activity by use of 64 channel cap"
9978816|NCT01375348|Placebo Comparator|Placebo infusion|"To blind the study and use as comparator in the investigation of the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle induced pain by the tourniquet pain model~cognitive tests~brain activity by use of a 64 channel cap"
9978817|NCT01375361|Experimental|Inhaled Albuterol|Patients identified to have Cardiogenic Pulmonary Edema, will receive 2.5mg of Albuterol nebulizer on enrollment in the study and again at 4 hours. Patients will be monitored on telemetry in the emergency department during and after study drug administration. Although study drug administration will cease after 4 hours, we will continue to record ongoing data during the patient's hospitalization.
9978818|NCT01375361|Placebo Comparator|Inhaled Placebo.|Patients identified to have Cardiogenic Pulmonary Edema will receive 2.5mg Normal saline inhaled (Placebo) on enrollment and at 4 hours in the emergency department. Patient will be monitor on telemetry in the emergency department during and after placebo administration.
9978819|NCT01375387|Experimental|Lacosamide 100 mg, Japanese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
9978820|NCT01375387|Experimental|Lacosamide 100 mg, Chinese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
9978821|NCT01375387|Experimental|Lacosamide 200 mg, Japanese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
9978822|NCT01375387|Experimental|Lacosamide 200 mg, Chinese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
9978823|NCT01375387|Experimental|Lacosamide 400 mg, Japanese|4 Lacosamide 100 mg tablets
9978824|NCT01375387|Experimental|Lacosamide 400 mg, Chinese|4 Lacosamide 100 mg tablets
9978825|NCT01375387|Placebo Comparator|Placebo Comparator, Japanese|4 placebo tablets
9978826|NCT01375387|Placebo Comparator|Placebo Comparator, Chinese|4 placebo tablets
10191240|NCT04589845|Experimental|Cohort K: RET fusion-positive tumors|Participants with RET fusion-positive tumors will self-administer Pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).
9978827|NCT01375413|Experimental|Integrated dual task training|Integrated dual task training delivered by a physiotherapist. In this training mode walking practice will be combined with simultaneously carrying out cognitive discrimination, verbal fluency and memory tasks.
10191241|NCT04582864|Experimental|Flotetuzumab|"Will start on cycle 1 day 1 on the dose escalation ramp schedule of flotetuzumab as a continuous intravenous (IV) infusion. Patients will be initiated at 30 ng/kg/day and have their dose increased daily to a target goal of 500 ng/kg/day by day 7~Patients will continue on flotetuzumab at 500 ng/kg/day for the remaining 21 days of the 28 day cycle.~On cycle 1 day 28, patients will undergo bone marrow biopsy for assessment of disease status. Patients who have achieved a CR/CRi will proceed to a second cycle per protocol, while patients with a PR or SD or better may proceed to cycle 2 with permission of the investigator. Patients with available donor lymphocytes may receive DLI concurrently with flotetuzumab during Cycle 1 and/or Cycle 2."
10191242|NCT04579757|Experimental|Surufatinib and tislelizumab (dose escalation_Part 1)|In Part 1 (dose escalation), surufatinib and will be administered orally (PO) once daily (QD) and tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).
10191243|NCT04579757|Experimental|Surufatinib and tislelizumab (indication specific_Part 2)|In Part 2, the indication-specific expansion portion of the study, patients will receive surufatinib at the Recommended Phase 2 Dose (RP2D) dose selected in Part 1 with 200 mg tislelizumab IV, Q3W
10191244|NCT04578652|Active Comparator|MET|MET (850 mg po bid - standard of care) + Fiber placebo daily
10191245|NCT04578652|Active Comparator|FIBER|Fiber supplementation [35g fiber daily] + MET placebo po bid
10191246|NCT04578652|Experimental|FIBER + MET|Fiber supplementation [35g fiber daily] + MET 850 mg po bid
10191247|NCT04577807|Experimental|Arm 1: Lerapolturev Only|Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 weeks thereafter.
10191248|NCT04577807|Experimental|Arm 2: Lerapolturev and anti-PD-1|Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 or 4 weeks thereafter. Anti-PD-1 therapy given as per the anti-PD-1 approved package insert.
10191249|NCT04573296|Experimental|Participants using Vitadio|Participants in the intervention arm undergo a 6-month digitally administered behavioral change program Vitadio focused on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and one-on-one remote coaching. In addition, they undergo regular face-to-face medical assessment.
10191250|NCT04573296|Active Comparator|Participants assigned to conventional high-intensity lifestyle intervention program|Participants in the control group undergo a 6-month high-intensity lifestyle intervention program consisting of of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator. In addition, they undergo regular face-to-face medical assessment.
10191251|NCT04570670|Experimental|Test (BLS-11)|A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1
9778836|NCT01116986|Experimental|22, No Patch, Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
10191252|NCT04570670|Active Comparator|Reference (Tecfidera)|A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1
10191253|NCT04566484|Experimental|BBV87vaccine(BBV87 20 µg/ BBV87 40 µg)|"The test article, inactivated Chikungunya virus vaccine 'BBV87', is available in a 2 mL clear glass USP Type 1 vial that contains a single dose of 0.5 mL of the vaccine as singlehuman dose (SHD). Vials are stoppered and sealed with tear-down aluminum seals.~• Route: BBV87 vaccine will be given to participants intramuscularly in the deltoid region of the upper arm. 0.5 mL of the investigational vaccine (BBV87 20 µg/ BBV87 40 µg) will be administered."
10191254|NCT04566484|Placebo Comparator|Normal Saline|Each 0.5 ml vial of placebo will contain normal saline.The placebo will be given to participants intramuscularly in the deltoid region of the upper arm.0.5 mL of placebo will be administered.
10191255|NCT04566445|Experimental|GT005 Medium Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 Medium Dose.
10191256|NCT04566445|Experimental|GT005 High Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 High Dose.
10191257|NCT04566445|No Intervention|Untreated control|Approximately 83 subjects are planned, with subjects randomised to untreated control.
10191258|NCT04566003|Experimental|[18F]PI-2620 PET, then [18F]GTP1 PET|Participants will undergo one [18F]PI-2620 PET imaging session, then one [18F]GTP1 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18F]PI-2620 or 7mCi of [18F]GTP1.
10191259|NCT04566003|Experimental|[18F]GTP1 PET, then [18F]MK-6240|Participants will undergo one [18F]GTP1 PET imaging session, then one [18F]MK-6240 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18 F]MK-6240 or 7mCi of [18F]GTP1.
10191260|NCT04562870|Experimental|Arm S: Selinexor|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Selinexor 60 mg oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.
10191261|NCT04562870|Active Comparator|Arm PC: Physician's Choice Treatment|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Physician's choice treatment which will be administered as per clinical practice.
10191262|NCT04555239|Active Comparator|Standard of Care, Upper Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
10191263|NCT04555239|Active Comparator|Standard of Care, Lower Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
10191264|NCT04555239|Experimental|FDM, Upper Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
10191265|NCT04555239|Experimental|FDM, Lower Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
10191266|NCT04554940|Experimental|Vosoritide + Standard of Care|Standard of Care treatment for cervicomedullary compression and once daily subcutaneous injection of vosoritide at 30μg/kg (ages 0 - <2 years old) or 15 μg/kg (ages >2 years old)
10191267|NCT04554940|No Intervention|Standard of Care Alone|Institutional standard of care monitoring and treatment for cervicomedullary compression
10191268|NCT04553068|Experimental|EVO100 gel|EVO100 vaginal gel, 5 g
9704259|NCT04704245|Placebo Comparator|Vehicle ointment group|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment."
10191269|NCT04553068|Placebo Comparator|Placebo gel|Placebo vaginal gel, 5 g
9704260|NCT04704141||Infertile men with leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
9978828|NCT01375413|Active Comparator|Consecutive task training|Consecutive task gait training delivered by a physical therapist. In this training mode, walking practice will be conducted separately, focusing on the motor task only. Training of cognitive discrimination, verbal fluency and memory tasks will be done consecutively while the subjects are sitting.
9978829|NCT01375439|Other|Active search of lower genital tract infections|"Active search of lower genital tract infections~Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome."
10191270|NCT04552704|Experimental|Phase I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 with standard of care (i.e., steroids per treating physician and best supportive care) in the absence of disease progression or unacceptable toxicity.
9978830|NCT01375452|Active Comparator|Femara|
9978831|NCT01375452|Experimental|Letrozole|
9978832|NCT01375465|Other|Dior|One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.
9978833|NCT01375478||Cohort|
9978834|NCT01375504|Active Comparator|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
10191271|NCT04552704|Experimental|Phase II, Arm I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
10191272|NCT04552704|Placebo Comparator|Phase II, Arm II (placebo)|Patients receive placebo IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
10191273|NCT04550494|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy at baseline and 4 hours after talazoparib dose on day 1 of cycle 2, and an optional biopsy either at the restaging follow up or at the time of disease progression.
10191274|NCT04546581|Experimental|Intervention Group|Participants in this group will receive the investigational product and standard of care (SOC).
9704261|NCT04704141||Infertile men without leukocytes in semen and eugonadal|Standard fertility evaluation and treatments
9704262|NCT04704141||Infertile men with hypogonadism|Standard fertility evaluation and treatments, including hormone replacement therapy such as with clomiphene citrate
9704263|NCT04703881|Experimental|AYMES ActaGain|Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks will be changed / started on an equivalent prescription of 'AYMES ActaGain' for a period of 30 days.
9978835|NCT01375504|Other|Mindfulness Training Program|The mindfulness training program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
9978836|NCT01375543||Enrollees|Enrolled study participants in whom genetic sequencing was done
9978837|NCT01375582|Experimental|Drop Administration|
9978838|NCT01375621||AHS cohort|population of S. aureus asymptomatic rural Iowans
9978839|NCT01375621||Non-AHS group|symptomatic S. aureus infections in rural Iowans.
9978840|NCT01375634|Placebo Comparator|Placebo|Normal saline
9978841|NCT01375634|Experimental|Midazolam|Midazolam
9978842|NCT01375647|Experimental|Rotarix + No IPV|Randomized to receive rotarix vaccine but no IPV boost
10191275|NCT04546581|Placebo Comparator|Control Group|Participants in this group will receive a placebo and standard of care (SOC).
10191276|NCT04544436|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
10191277|NCT04544436|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
10191278|NCT04535492|Other|Colorectal Cancer Screening Recommended|The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.
9978843|NCT01375647|Experimental|Rotarix + with IPV boost|Randomized to receive both rotarix vaccine and IPV boost
9978844|NCT01375647|No Intervention|No Rotarix + No IPV|Randomized to receive neither rotarix vaccine nor IPV boost
9978845|NCT01375647|Experimental|No Rotarix + with IPV boost|Randomized to receive no rotarix vaccine but to receive IPV boost
9704264|NCT04703959||glaucomatous subjects (50)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~increase in intraocular pressure (IOP before treatment greater than 21 mmHg) with characteristic alterations of the optic nerve (pathological papillary excavation, papillary pallor, papillary atrophy) with corresponding alterations and characteristics of the visual field. The visual field should be considered reliable (European criteria (European Glaucoma Society, 1999).~Patients whose age is greater than or equal to 18 years~Male or female patients~Patients not objecting to the study~Affiliation to a social security scheme or beneficiary of such a scheme"
10191279|NCT04535492|Other|Lung Cancer Screening Recommended|The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults ages 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
10191280|NCT04535492|Other|Breast Cancer Screening Recommended|The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
10191281|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A|Single IV administration of 4D-310 Dose Level 1 - AAV NAb Titer Group A patients
9704265|NCT04703959||non glaucomatous subjects (100)|"Subjects included in the MARS database of CHU Grenoble-Alpes with available polysomnographic data and with the following ophthalmological characteristics:~no known ophthalmological pathologies, with an ophthalmological examination on telephone examination - in the 2 years preceding the polysomnographic examination - normal apart from minor refractive disorders (myopia with spherical equivalent less than -6 diopters or hyperopia with spherical equivalent less than 3 diopters).~Patients whose age is greater than or equal to 18 years~Male or female patients~Patients not objecting to the study~Affiliation to a social security scheme or beneficiary of such a scheme"
10191282|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV NAb Titer Group B|Single IV administration of 4D-310 Dose Level 1 - AAV NAb titer Group B patients
9704266|NCT04703894|Experimental|AYMES 'CARDIFF'|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'CARDIFF' for a period of 30 days.
9704267|NCT04703868|Experimental|YPI-011 10/500mg|Part A: 1 tablet administered before the breakfast during 7 days
9704268|NCT04703868|Experimental|YPI-011 20/500mg|Part B: 1 tablet administered before the breakfast during 7 days
9978846|NCT01375686||Those at Risk for Type 2 diabetes|All subjects will be at risk for diabetes based on the American Diabetes Association (ADA) Standard of Care Guidelines.
9704269|NCT04703842|Experimental|SRD-001|3E13 vg; one-time intracoronary infusion
9978847|NCT01375699|Experimental|Sildenafil + doxorubicin|"Patients receive sildenafil citrate PO QD* beginning at least 2 days prior to scheduled first dose of doxorubicin hydrochloride and continuing until 2 weeks after last scheduled dose of doxorubicin hydrochloride. Patients also receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.~NOTE: *Patients receive sildenafil citrate PO TID on days that doxorubicin hydrochloride is also administered."
9978848|NCT01375699|Active Comparator|Doxorubicin-based chemotherapy|Patients receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
9978849|NCT01375712|Active Comparator|Fermented milk|Fermented milk containing Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
10191283|NCT04519749|Experimental|4D-310 Dose Level 2 - AAV NAb Titer Group A|Single IV administration of 4D-310 Dose Level 2 - AAV NAb titer Group A patients
10191284|NCT04519749|Experimental|4D-310 Dose Level 2 - AAV NAb Titer Group B|Single IV administration of 4D-310 at Dose Level 2 in AAV NAb titer Group B patients
10191285|NCT04519749|Experimental|4D-310 Dose Expansion|Dose expansion cohort of single IV administration of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients
10191286|NCT04511702|Experimental|Pegloticase 60 Minute Infusion with methotrexate (MTX)|Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
10191287|NCT04511702|Experimental|Pegloticase 45 Minute Infusion with methotrexate (MTX)|Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
10191288|NCT04511702|Experimental|Pegloticase 30 Minute Infusion with methotrexate (MTX)|Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
10191289|NCT04508530|Experimental|Panzyga|Panzyga 10% IVIG
10191290|NCT04508530|Placebo Comparator|Placebo|Placebo
10191291|NCT04505436|Experimental|HM15211|
10191292|NCT04505436|Placebo Comparator|Placebo|
10191293|NCT04499248|Experimental|Cohort 1 -Dose A|Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
9704270|NCT04703842|Placebo Comparator|Placebo|One-time intracoronary infusion
9978850|NCT01375712|Placebo Comparator|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
9978851|NCT01375725||Coumadin (warfarin)|Subjects currently receiving coumadin (warfarin) treatment.
10191294|NCT04499248|Experimental|Cohort 1 - Dose B|Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
9978852|NCT01375738|Active Comparator|Gastroduodenostomy|Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
9704271|NCT04703985||Patients under the protocol of Enteral Nutrition|Patients put under the protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
9704272|NCT04703998|Experimental|Arthroscopic rotator cuff repair and platelet rich plasma|A standard double-row arthroscopic rotator cuff repair will be performed and at the end of the procedure 10 ml of autologous platelet-rich plasma will be placed under direct vision at the tendon-bone interface.
9978853|NCT01375738|Experimental|Roux-en Y gastrojejunostomy|Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
10191295|NCT04499248|Experimental|Cohort 2 - Dose A|AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
9704273|NCT04703998|Active Comparator|Arthroscopic rotator cuff repair|A standard double-row arthroscopic rotator cuff repair will be performed.
9704274|NCT04703907|Experimental|Intervention group|This group is constituted from patients who will receive the intervention first within 15 weeks
10191296|NCT04499248|Experimental|Cohort 2 -Dose B|AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
10191297|NCT04480736|Placebo Comparator|Placebo|Participants will receive matching placebo of JNJ-64281802 orally.
9704275|NCT04703907|No Intervention|Waiting list|This group is constituted from patients who will receive the intervention after 15 weeks
9704276|NCT04703803|Experimental|1% lidocaine injection|The intervention group will be submitted to the trigger point injection procedure with 1% lidocaine (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
9704277|NCT04703803|No Intervention|Control Group|The control group will receive usual care, defined as the treatment for pain prescribed by their assistant doctors.
10191298|NCT04480736|Experimental|JNJ-64281802 High dose|Participants will receive high dose of JNJ-64281802 orally.
10191299|NCT04480736|Experimental|JNJ-64281802 Medium dose|Participants will receive medium dose of JNJ-64281802 orally.
9704278|NCT04704128||Case group|women with primary stomatodynia
9704279|NCT04704128||Control group|women without oral disease
9704280|NCT04704063|Active Comparator|Active|Tocovid Suprabio 200mg
9704281|NCT04704063|Placebo Comparator|Placebo|Placebo
10191300|NCT04480736|Experimental|JNJ-64281802 Low dose|Participants will receive low dose of JNJ-64281802 orally.
10191301|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen X|Participants will receive dosing regimen X of JNJ-64281802 orally.
10191302|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Y|Participants will receive dosing regimen Y of JNJ-64281802 orally.
10191303|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Z|Participants will receive dosing regimen Z of JNJ-64281802 orally.
9704282|NCT04704102|Experimental|Muscle energy technique group|Use one of the muscle energy technique methods -- postisometric relaxation technique(PIR) as the intervention method.
9704283|NCT04704102|Experimental|Strain-counterstrain group|Use the Strain-counterstrain technique as the intervention method.
10191304|NCT04473625||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191305|NCT04473625||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191306|NCT04473625||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191307|NCT04473625||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191308|NCT04473625||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
9704284|NCT04704102|Sham Comparator|Control group|Use the modified Strain-counterstrain technique as the intervention method.
9704285|NCT04704089||spectrophotometer, and numerical values of tooth color in the populations studied|at the first visit Shooting with Spectrophotometer and at the second visit for all patients except control population: Tooth extraction or restorative treatment Collection of teeth or enamel debris for analysis
9704286|NCT04703972|Experimental|Bipolar Patients with connected devices|Patients with bipolar disorder provided with connected devices (wristwatch and wristband)
9704287|NCT04703751|Experimental|CIRCULATE Catheter|CIRCULATE Catheter will be used to deliver nitroglycerin and CardioCell to evaluate safety and efficacy of the device
9704288|NCT04703712|Active Comparator|Lens extraction combined with goniosynechialysis group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent phacoemulsification combined with goniosynechialysis.
9704289|NCT04703712|Active Comparator|Trabeculectomy Group|One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent trabeculectomy.
9704291|NCT04703465|Experimental|tenofovir alafenamide|tenofovir alafenamide 25mg daily for 48 weeks
9704292|NCT04703530|Experimental|Hot footbath effect on schizophrenia patient' sleep quality|Participants were randomly allocated to the experimental group. The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep, and this was repeated five times a week for four weeks. The CPSQI was used to collect the pre- and post-test data.
9704293|NCT04703530|No Intervention|Routine care on schizophrenia patient' sleep quality|Participants were randomly allocated to the control group. They were given routine care for four weeks. The CPSQI was used to collect the pre- and post-test data.
9704294|NCT04703608|Experimental|Arm 1 of Cohort 1|Index Case / Household members Ivermectin / Ivermectin (with preventative package)
9704295|NCT04703608|Experimental|Arm 2 of Cohort 1|Index Case / Household members Ivermectin / Placebo (with preventative package)
9704296|NCT04703608|Placebo Comparator|Arm 3 of Cohort 1|Index Case / Household members Placebo / Placebo (with preventative package)
9704297|NCT04703608|Experimental|Arm 1 of Cohort 2|Aspirin 150mg daily for 28 days or until hospital discharge or death (whichever is sooner)
9978854|NCT01375790|Experimental|Exercise with Whole-body vibration platform|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm). Training volume and intensity we will increase systematically over six weeks according to the overload principle.
10191309|NCT04473625||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191310|NCT04473625||Kidney/Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191311|NCT04473625||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191312|NCT04473625||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191313|NCT04473625||Pancreas|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191314|NCT04473625||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191315|NCT04473625||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
10191316|NCT04471844|Experimental|Optune® + RT + TMZ for 6 weeks|Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
10191317|NCT04471844|Active Comparator|RT +TMZ for 6 weeks|RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
10191318|NCT04468607|Experimental|Dose-Escalation Stage|Participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD).
10191319|NCT04468607|Experimental|Dose-Expansion Stage|Once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial.
9704298|NCT04703608|Placebo Comparator|Arm 2 of Cohort 2|Non identical placebo; doses as per above
9704299|NCT04703348|Other|Healthy patients|Healthy patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
9704300|NCT04703348|Other|Complex regional pain syndrome patients|Complex regional pain syndrome patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
9704301|NCT04703348|Other|Musculoskelettal disorders patients|Musculoskelettal disorders patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
10191320|NCT04466475|Experimental|Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)|Patients receive 211At-OKT10-B10 IV continuously on days -7 to -4 and melphalan via infusion on day -2. Patients then undergo PBSC transplantation on day 0.
10204470|NCT01413529|Experimental|HEART to HAART|HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
9704302|NCT04703439|Experimental|Experimental group|This group consisted of 116 participants who received a medication-taking reminder every morning at a random time between 7-8 am on WeChat app. Also, participants received a piece of educational material every five days at a random time between 8 am and 9 am regarding improving medication adherence and preventing coronary heart disease.
10204471|NCT01413529|Active Comparator|Adherence counseling|Adherence counseling with the addition of a smart phone control
10204472|NCT01351909|Experimental|Treatment (veliparib, cyclophosphamide)|Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10204473|NCT01351896|Experimental|Arm A (Concurrent PCV13 and lenalidomide)|Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on day 1 of courses 3 and 5.
10204474|NCT01351896|Experimental|Arm B (Sequential PCV13 and lenalidomide)|Patients receive PCV13 IM on days 1 and 78 (cycles 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 1 of course 4. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity.
9704303|NCT04703439|Placebo Comparator|Control group|This group consisted of 114 participants who only received a piece of educational material every five days at a random time between 8 am and 9 am. The educational materials sent to this group were general medical information, which were not specifically about improving medication adherence or preventing coronary heart disease.
9704304|NCT04703595||50 non-smoking patients with chronic cough|50 non-smoking patients aged between 30 and 99 years with chronic and / or refractory cough as the only manifestation or associated with gastroesophageal reflux
9704305|NCT04703452||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test at least 6 months before inclusion in the study.
9978855|NCT01375790|Active Comparator|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli, during a six weeks training period (3sessions/week). Training volume and intensity we will increase systematically over six weeks according to the overload principle
10191321|NCT04431830|Experimental|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery) for managing pain.
10191322|NCT04431830|No Intervention|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
10191323|NCT04421378|Experimental|Phase 1: Arm A: Selinexor+Radiation Therapy|Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.
10191324|NCT04421378|Active Comparator|Arm A Control: Temozolomide+Radiation Therapy|Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.
10191325|NCT04421378|Experimental|Phase 1: Arm B: Selinexor+Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period. Participants will continue selinexor weekly per dose level assigned until PD.
10191326|NCT04421378|Active Comparator|Arm B Control: Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.
10191327|NCT04421378|Experimental|Arm C: Selinexor+Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m^2 of lomustine or 150-200 mg/m^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
9704306|NCT04703387||Postextubation Success|
10191328|NCT04421378|Active Comparator|Arm C Control: Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 110 mg/m^2 of lomustine or 200 mg/m^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
10191329|NCT04421378|Experimental|Arm D: Selinexor+Bevacizumab|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.
9704307|NCT04703387||Postextubation Distress|
9704308|NCT04703673||Sinolpan® group|Sinolpan® group: patients suffering from rhinosinusitis and, where appropriate, from bronchitis; intake of Sinolpan® 100 mg or Sinolpan® forte 200 mg (cineol) according to the instructions for use; before and after treatment for rhinosinusitis and, where appropriate, from bronchitis, patients complete a questionnaire that contains the Rhinosinusitis Quality of Life questionnaire and Questions about the severity of bronchitis symptoms. The latter should only be answered by patients who suffer from bronchitis in addition to rhinosinusitis.
9704309|NCT04703673||Nasal spray group|Control group: patients with rhinosinusitis; Use of nasal decongestants according to the instructions for use. Before and after treatment for rhinosinusitis, patients complete a questionnaire that includes the Rhinosinusitis Quality of Life questionnaire.
9704310|NCT04703634|Experimental|erector spinae group|All blocks will be done under general anesthesia. Using a 6-10 MHz linear ultrasound (Esaote my-lab 6, Italy). With the ultrasonography device of our clinic, the side of the nephrectomy surgery will be performed with the position of the nephrectomy, and the position (lateral decubitus) is given to the patient. The thoracic 10th vertebra will be found under ultrasound guidance. After the T12 transverse protrusion is seen by sliding 3 cm laterally from the midline, 30 ml of 0.25% Bupivacaine will be injected under the erector spinae muscle above it.
9704311|NCT04703634|Placebo Comparator|placebo group|No block transaction will be applied to this group. Only postoperative analgesia methods will be used for this group as specified in the protocol.
9704312|NCT04703374|Experimental|A|Period 1: Test drug(CKD-382 formulation I) Period 2: Test drug(CKD-382 formulation II) Period 3: Reference drug(D026)
9704313|NCT04703374|Experimental|B|Period 1: Test drug(CKD-382 formulation II) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation I)
9704314|NCT04703374|Experimental|C|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation I) Period 3: Test drug(CKD-382 formulation II)
9704315|NCT04703374|Experimental|D|Period 1: Test drug(CKD-382 formulation I) Period 2: Reference drug(D026) Period 3: Test drug(CKD-382 formulation II)
9704316|NCT04703374|Experimental|E|Period 1: Test drug(CKD-382 formulation II) Period 2: Test drug(CKD-382 formulation I) Period 3: Reference drug(D026)
9704317|NCT04703374|Experimental|F|Period 1: Reference drug(D026) Period 2: Test drug(CKD-382 formulation II) Period 3: Test drug(CKD-382 formulation I)
9704318|NCT04703517|Other|Self Controlled|Patients will active as their own comparator
9978856|NCT01375803|Experimental|1|3g/day
10191330|NCT04421378|Active Comparator|Arm D Control: Bevacizumab|Participants with rGBM will receive 10 mg/kg of Bevacizumab IV infusion Q2W in each cycle in a 28 Day cycle for all cycles.
10191331|NCT04421378|Experimental|Arm E: Selinexor+TTField|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
10191332|NCT04421378|Active Comparator|Arm E Control: TTField|Participants with rGBM will receive scalp application of 200 kHz of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
10191333|NCT04410445|Experimental|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Arm A: Participants will receive bempegaldesleukin (NKTR-214) IV in combination with nivolumab every 3 weeks.
10191334|NCT04410445|Active Comparator|Nivolumab|Arm B: Participants will receive nivolumab IV alone every 4 weeks.
9704319|NCT04703478|Experimental|Single group|Implementation of a mobile application for the rehabilitation of patients with respiratory sequelae of COVID-19
9704320|NCT04703569|Experimental|Monolayer high compression elastic bandage|An elastic bandage of cotton, viscose, nylon and elastane
9704321|NCT04703569|Active Comparator|Unna boot|A wet bandage with zinc oxide
9704322|NCT04703491|Experimental|Full intervention|This group receives the full-featured intervention, including CCBT, CBM, Mindfulness, chatbot with many interactive elements.
9704323|NCT04703491|Active Comparator|Limited CCBT control group|This group receives feature-limited intervention (text-based computerized CBT)
9704324|NCT04703491|Other|Waitlist control group|This group receives waitlist control.
9704325|NCT04703660|Active Comparator|group A|This group will receive antero-posterior cervical mobilization at c5-6 grade III oscillation
9704326|NCT04703660|Active Comparator|group B|This group will receive lateral glide cervical mobilization at c5-6 grade III oscillation
9704327|NCT04703660|Active Comparator|group C|This group will receive postero-anterior cervical mobilization at c5-6 grade III oscillation
10191335|NCT04401384|Other|Diclectin plus active acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) , 2-4 tablets/day) + active acupuncture (30 min /every day).
9704328|NCT04703426|Experimental|Sargramostim (GM-CSF) + Pembrolizumab (anti-PD-1)|"Participants will receive 12 weeks of sargramostim (GM-CSF) and pembrolizumab (anti-PD-1). Participants may be pre-medicated with drugs to reduce the chance of having a sensitivity reaction to the study treatment of pembrolizumab (anti-PD-1) and sargramostim (GM-CSF).~Study cycles are 21 days in length:~Pembrolizumab (anti-PD-1) will be given by intravenous infusion once on day 1 of every 21 day cycle~Sargramostim (GM-CSF) will be self-administered by participants via a subcutaneous (below the skin) injection daily for days 1 - 14 of each 21- day cycle.~Participants will be assessed at 12 weeks for disease response/progression and further study treatment."
9704329|NCT04703686|Experimental|Obinutuzumab + RO7082859|
9704330|NCT04703283|Experimental|Lifestyle Medicine Group|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
9704331|NCT04703283|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
9704332|NCT04703218|Experimental|Patients with stroke and olfaction disorder benefiting from specific olfaction training.|
9704333|NCT04703218|No Intervention|Patients with stroke and olfactory disorder benefiting from standard post-stroke rehabilitation|
9704334|NCT04703270||Exposed|Expectant mothers with a positive nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation regardless of antibody status.
9704335|NCT04703270||Seropositive|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation but positive IgM/IgG antibodies against SARS-CoV-2.
9704336|NCT04703270||Unexposed|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation and negative IgM/IgG antibodies against SARS-CoV-2.
9704337|NCT04703257|Placebo Comparator|Control group|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
9704338|NCT04703257|Active Comparator|Intervention group|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
9704339|NCT04702854|Experimental|Experimental|Measure of cutaneous melanomas by ultrasound biomicroscopy
9704340|NCT04702906|Active Comparator|control group|All patients will continue to receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. Conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation, and antiarrhythmic agents if indicated.
9704341|NCT04702906|Active Comparator|trimetazidine group|"The trimetazidine group will receive conventional standard treatment plus Trimetazidine dihydrochloride metacardia ® (20 mg three times daily produced by Pharco-Egypt) will be administered twice every 24 hours until at least treatment is no longer needed."
9704342|NCT04702945||Registry participants|Patients presenting to participating emergency departments with suspected and or confirmed COVID-19.
9704343|NCT04703140|Experimental|nasopharyngeal swabs|One patient will have 2 nasopharyngeal for PCR and COVIDISC
9704344|NCT04702958||Torsemide|Patients enrolled in the TRANSFORM-HF study randomized to Torsemide
9704345|NCT04702958||Furosemide|Patients enrolled in the TRANSFORM-HF study randomized to Furosemide
9704346|NCT04702828||Fallers group|1.60 years to 99 years old 2. have a recent fall within two months 3.can understand and answer the questions 4.can give their informed consent
9704347|NCT04702828||Non-fallers group|1.60 years to 99 years old 2. have any fall experiences in past year 3.can understand and answer the question 4.can give their informed consent
9704348|NCT04703127|Active Comparator|Patients with lifelong premature ejaculation and non-responding to dapoxetine alone|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
9978857|NCT01375803|Experimental|2|6g/day
9704349|NCT04703127|Active Comparator|Patients with Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
9704350|NCT04702971|Experimental|patients with migraine|patient with migraine will be prescribed with flunarizine or routine clinical care per clinician's decision based on the condition of each individual patient
9704351|NCT04702971|Other|healthy control|healthy control
9704352|NCT04703088|Experimental|INTERVENTION GROUP - ONDANSETRON|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
10191336|NCT04401384|Other|Diclectin plus sham acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg), 2-4 tablets/day) + sham acupuncture (30 min /every day).
9704353|NCT04703088|Placebo Comparator|CONTROL GROUP - NORMAL SALINE|2 mL of 0.9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
9704354|NCT04703062|Experimental|Experimental group 1|physical activity counseling group + exercise group
9704355|NCT04703062|Experimental|Experimental group 2|physical activity counseling group
9704356|NCT04703023||COPD|Secretions are collected from Bronchoscopy in clinical routine in COPD patients
9704357|NCT04703023||lung healthy|Secretions are collected from Removal of endotracheal tubes after elective surgery in lung healthy patients
9704358|NCT04702841|Experimental|CAR-γδT|Infusion,iv,0.2-5 ×10^6/ kg,once.
9704359|NCT04703114|Experimental|Symptomatic|40 symptomatic patients to COVID-19 infection
9704360|NCT04703114|Experimental|Asymptomatic|40 asymptomatic patients to COVID-19 infection
9704361|NCT04702932||Patient with Monoclonal gammopathies of inflammatory significance|This group of patient will present a monoclonal gammopathy associated with inflammatory symptoms without known origin.
9704362|NCT04702932||Control group|The Control group will be healthy subject and patients with monoclonal gammopathies without inflammatory symptoms.
10191337|NCT04401384|Other|Placebo plus active acupuncture|Diclectin placebo (2-4 tablets/day) + active acupuncture (30 min / every day)
10191338|NCT04401384|Other|Placebo plus sham acupuncture|Diclectin placebo (2-4 tablets/day) + sham acupuncture (30 min /every day)
10191339|NCT04393181||recipients of hearts with impaired function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with impaired function
9704363|NCT04702867||Periodontal bone loss group|The cases with level of alveolar crest more than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
9704364|NCT04702867||Healthy group|The cases with level of alveolar crest equal to or less than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
9704365|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence A-B-C|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
10191340|NCT04393181||recipients of hearts with normal function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with normal function
10191341|NCT04390750|No Intervention|Treatment Group 1|Treatment Group 1 will receive a standard educational booklet, a clinical oral health evaluation and a smart electronic toothbrush with no instruction on oral hygiene technique. The study coordinator will download the toothbrush data for data collection. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided. The hygienist will provide basic instruction on proper use of the smart electronic toothbrush.
10191342|NCT04390750|Experimental|Treatment Group 2|Treatment Group 2 will receive a standard educational booklet, a smart electronic toothbrush, a clinical oral health evaluation with tailored instruction on oral hygiene technique and care partner coaching. The study coordinator will download the toothbrush data for data collection. The dental hygienist and interventionist will work together to fulfill the following intervention components: tailored instruction and coaching.
9704366|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence A-C-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
9704367|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-A-C|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by oral suspension dose of peposertib (Treatment C) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
9704368|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence B-C-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by oral suspension dose of peposertib (Treatment C) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
9704369|NCT04702698|Experimental|Part 1: Peposertib: Treatment Sequence C-A-B|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2, followed by single oral dose of peposertib tablet (Treatment B) on Day 15 under fed condition in period 3. There will be washout period of 7 days between each treatment period.
9978858|NCT01375803|Placebo Comparator|Placebo beverage|0g/day
10191343|NCT04390750|No Intervention|Control Group|The Control group will receive a standard educational booklet and a clinical oral health evaluation with no instruction on oral hygiene technique. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided.
10191344|NCT04369846|Experimental|Test drug group|The arm applies the test drug of GM-XANTHO
10191345|NCT04369846|Placebo Comparator|Placebo group|The arm applies the placebo
10191346|NCT04336722|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 104 weeks.
9978859|NCT01375816|Active Comparator|FOLFIRI 1 or m FOLFIRI3-Bevacizumab|"FOLFIRI 1-Bevacizumab:~Day 1 H0 : Bevacizumab 5 mg/kg, 30-90 min infusion H+1: Irinotecan 180 mg/m² in 250 ml NaCl 0.9%, 1h infusion Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) over 2h H + 3: 5-FU bolus 400 mg/m², 15 min infusion H + 3.5: 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14~modified FOLFIRI3-Bevacizumab H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H+1:Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion H+1: Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) 2-h infusion H + 3: 5-FU continuous infusion 2400 mg/m² 46-h infusion Day 3 (H+49) H0 Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion End of cycle: day 14"
9978860|NCT01375816|Experimental|FUPEP-Bevacizumab|"Day 1 H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H +1 :PEP02 80 mg/m² , 1h30 infusion. The infusion time could be reduced to 1h from cycle 2 if no acute infusion reaction has occured in cycle 1.~H +1 : Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) , 2-h infusion H +3 : 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14"
9978861|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.01 mg/kg|Participants will receive intravenous (IV) infusion of atezolizumab 0.01 milligrams per kilogram (mg/kg) every 3 weeks (q3w) until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
9978862|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.03 mg/kg|Participants will receive IV infusion of atezolizumab 0.03 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
9978863|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.1 mg/kg|Participants will receive IV infusion of atezolizumab 0.1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
10191347|NCT04336722|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 104 weeks.
10191348|NCT04333563|Active Comparator|CPAP|respiratory stressed infants getting Continuous positive airway pressure (CPAP)
9978864|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.3 mg/kg|Participants will receive IV infusion of atezolizumab 0.3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
9978865|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 1 mg/kg|Participants will receive IV infusion of atezolizumab 1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
9978866|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 3 mg/kg|Participants will receive IV infusion of atezolizumab 3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
9978867|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 10 mg/kg|Participants will receive IV infusion of atezolizumab 10 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
9978868|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 20 mg/kg|Participants will receive IV infusion of atezolizumab 20 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
9984385|NCT04164901|Placebo Comparator|Matching Placebo|Matching placebo 40 mg, continuous daily dosing. Participants who experience centrally-confirmed radiographic disease progression and who were receiving placebo will have the option to cross-over to vorasidenib, provided certain criteria are met.
10191349|NCT04333563|Experimental|respiratory stressed infants getting NIV NAVA|respiratory stressed infants getting Non-invasive neurally adjusted ventilatory assist (NIV NAVA)
10191350|NCT04329065|Experimental|Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab)|Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10204475|NCT01189786|Experimental|Cohort 2: CD34+ cells as a top off|"Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a topoff without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse."
9704370|NCT04702698|Experimental|Part 1: Peposertib Treatment Sequence C-B-A|Participants will receive oral suspension dose of peposertib (Treatment C) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2, followed by single oral dose of peposertib tablet (Treatment A) on Day 15 under fasted condition in period 3. There will be washout period of 7 days between each treatment period.
9704371|NCT04702698|Experimental|Part 2: Peposertib Treatment Sequence A-B|Participants will receive single oral dose of peposertib tablet (Treatment A) on Day 1 under fasted condition in period 1, followed by single oral dose of peposertib tablet (Treatment B) on Day 8 under fed condition in period 2. There will be washout period of 7 days between each treatment period.
9704372|NCT04702698|Experimental|Part 2: Peposertib: Treatment Sequence B-A|Participants will receive single oral dose of peposertib tablet (Treatment B) on Day 1 under fed condition in period 1, followed by single oral dose of peposertib tablet (Treatment A) on Day 8 under fasted condition in period 2. There will be washout period of 7 days between each treatment period.
9704373|NCT04702685|Experimental|Ropivacaine|Ropivacaine 0.5% - 20 ml will be administered as erector spinae plane block under ultrasound guidance
9978869|NCT01375842|Experimental|Expansion Cohort (Atezolizumab)|Participants will receive IV infusion of atezolizumab q3w up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first. The dose which result in total drug exposure less than or equal to (</=) exposures achieved at the MTD or maximum administered dose (MAD), will be selected for expansion cohort.
9978870|NCT01375855|Active Comparator|Polimeric-PES|Arm receiving polimeric stent (Taxus)
9978871|NCT01375855|Active Comparator|Non-Polimeric PES|Arm receiving non-polimeric PES (axxion)
10191351|NCT04324645||Active Symptom Monitoring via Noona|Participants will undergo a single training session on how to use the Noona software no more than 4-12 weeks before starting therapy. They can start using the software immediately after the training session. Patients will be invited to complete either the Chest Radiotherapy (if radiotherapy alone), Chemotherapy-18 (if chemoradiation therapy), or Bone Radiotherapy (if other) module at baseline, every other week throughout therapy, and during follow up for 90-days. Patients will be encouraged by the treatment team to complete the baseline symptom report prior to starting any therapy and to complete the reports during therapy and in follow up. Patients will also complete the EORTC QLQ-C30 and the NCCN Distress Thermometer at baseline (no more than 12 weeks before starting therapy), within 1 week of completing therapy, and at 90-days follow up. Patients will be encouraged to use Noona's other features beyond invited modules and PRO inventories, such as the diary during the study
10191352|NCT04313712||Participants|All study participants will be observed before and after they receive exposure to tabernanthe iboga in other countries.
9704374|NCT04702685|Placebo Comparator|Placebo|No injection. Bandage will be placed over the presumed site of injection
10191353|NCT04308681|Experimental|IPF Dose 1 + Post Treatment Follow-up or OTE|IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
9704375|NCT04702633||Confirmed diagnosis group|Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.
9704376|NCT04702633||Pre-diagnosis group|Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.
9778837|NCT01116986|Experimental|23, No Patch, Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778838|NCT01116986|Experimental|24, No Patch, Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778839|NCT01116986|Experimental|25, No Patch, No Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778840|NCT01116986|Experimental|26, No Patch, No Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778841|NCT01116986|Experimental|27, No Patch, No Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778842|NCT01116986|Experimental|28, No Patch, No Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778843|NCT01116986|Experimental|29, No Patch, No Gum, No Prequit, Min In-Person, Min Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778844|NCT01116986|Experimental|30, No Patch, No Gum, No Prequit, Min In-Person, Int Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778845|NCT01116986|Experimental|31, No Patch, No Gum, No Prequit, Int In-Person, Min Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
9778846|NCT01116986|Experimental|32, No Patch, No Gum, No Prequit, Int In-Person, Int Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
9778847|NCT01117012|Experimental|VX-770|VX-770 (ivacaftor) 150 milligram (mg) tablet orally twice daily (q12h).
9778848|NCT01117051|Placebo Comparator|placebo|placebo
9778849|NCT01117051|Active Comparator|Resolor|prucalopride
9778850|NCT01117181|Experimental|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention
9978872|NCT01375868|Experimental|Vaccine Silgard|vaccination with tetravalent antiviral vaccine, 3 doses
9704377|NCT04702672|Experimental|Type 2 diabetes|Adults with T2D. Hemoglobin A1C between 48-78 mmol/l. No use of insulin or once-weekly glucagon-like peptide-1 (GLP-1) or acarbose. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
10191354|NCT04308681|Experimental|IPF Dose 2 + Post Treatment Follow-up or OTE|
9978873|NCT01375881||001|darunavir/ritonavir plus background regimen darunavir/ritonavir oral use in naive and experienced patients at approved dosages
9978874|NCT01375894|Active Comparator|depresive patients|30 patients suffering from depression
10191355|NCT04308681|Placebo Comparator|IPF Placebo + Post Treatment Follow-up or OTE|
9704378|NCT04702672|Experimental|Non-diabetics|Adults without T2D. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
9704379|NCT04702646||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
10191356|NCT04308681|Experimental|PF-ILD Dose 1 + Post Treatment Follow-up or OTE|PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
10191357|NCT04308681|Experimental|PF-ILD Dose 2 + Post Treatment Follow-up or OTE|
10191358|NCT04308681|Placebo Comparator|PF-ILD Placebo + Post Treatment Follow-up or OTE|
10191359|NCT04303858|Experimental|RO7284755 as a Single Agent|Part 1: Dose-escalation of RO7284755 as a single agent. RO7284755 will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.
10191360|NCT04303858|Experimental|RO7284755 in Combination with Atezolizumab|Part 2: Dose-escalation of RO7284755 in combination with atezolizumab.
10191361|NCT04303858|Experimental|RO7284755 as a Single Agent and/or with Atezolizumab|Part 3: Extension of RO7284755 as a single agent and/or in combination with atezolizumab.
10191362|NCT04298307||Patients with calcified coronary artery disease|Patients with calcified coronary artery disease require an ICL using the Shockwave catheter.
10191363|NCT04289025|Active Comparator|Exercise|Personalised exercise programme is provided to the exercise group.
10191364|NCT04289025|No Intervention|No Intervention|This group of patients will receive no intervention.
10191365|NCT04276493|Experimental|Cohort 1- ZW25 + Docetaxel|ZW25 intravenous (IV) infusion followed by docetaxel IV infusion first-line therapy once every three weeks (Q3W) in female participants with metastatic breast cancer
10191366|NCT04276493|Experimental|Cohort 2- ZW25 + Tiselizumab + Chemotherapy|ZW25 intravenous (IV) infusion followed by tiselizumab IV infusion and CAPOX chemotherapy (oral capecitabine + IV oxaliplatin) first-line therapy once every three weeks (Q3W) in participants with metastatic gastric / GEJ adenocarcinoma
10191367|NCT04275310|Experimental|Microeconomic intervention|
9704380|NCT04702542|Experimental|Enteral oxygen therapy for the improvement of children with chronic gastroduodenal pathology.|Enteral oxygen therapy is prescribed for children with chronic gastroduodenal pathology during the recovery period, after inpatient treatment, for 14 days, every day, in the form of an oxygen cocktail. An oxygen cocktail is prepared on the basis of a pharmaceutical product using herbal ingredients. The patient takes a 200 ml oxygen cocktail. using a small spoon, during the daytime.
9704381|NCT04702607||contrast enhanced 4DCT|
9704382|NCT04702594|Experimental|UHR and SRH|All patients over the age of 60 present in the UHR and hospitalized in SRH with behavioral disorders in the context of a neurocognitive disorder
9704383|NCT04702503|Experimental|10% WP1220 ointment|10% WP1220 ointment topically applied 2x day for 84 days
9704384|NCT04702490|Experimental|MET409 A|MET409 Active (50mg)
10191368|NCT04275310|No Intervention|Waitlisted control|
10191369|NCT04239222|Experimental|Revo-M to Proflex XC|Transtibial amputees randomized to start with Revo-M and cross over to Proflex XC
9704385|NCT04702490|Placebo Comparator|MET409 P|MET409 Placebo (50mg)
9704386|NCT04702490|Experimental|MET409A +Open-Label Empagliflozin|MET409 Active (50mg) + Empagliflozin (10mg)
9704387|NCT04702490|Placebo Comparator|MET409P +Open-Label Empagliflozin|MET409 Placebo (50mg) + Empagliflozin (10mg)
9704388|NCT04702516|Experimental|Semaglutide|Ozempic 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
9704389|NCT04702516|Placebo Comparator|Placebo|Placebo (saline) 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
9704390|NCT04702477|Experimental|Only Arm|This is a single-arm, paired-sample pilot intervention study among participants with pre-diabetes or diabetes. Goal to integrate a MBSR intervention into a group-based, lifestyle intervention among patients with prediabetes or diabetes in the primary care setting
9704391|NCT04702373|Experimental|Passive range-of-motion|daily assisted exercise sessions lasting 15-20 minutes, conducted by trained physical therapists, for up to 21 days prior to hospital discharge, plus standard of care
9704392|NCT04702373|No Intervention|Standard of care|standard of care at study site
9978875|NCT01375894|Experimental|Schizophrenia patients|30 Schizophrenia patients
9978876|NCT01375907|Experimental|Rotavin|Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses
9978877|NCT01375920|Active Comparator|Metyrapone, daily medication|500 milligrams Metyrapone to be taken orally twice daily for 3 weeks.
9978878|NCT01375920|Placebo Comparator|placebo|a matched placebo will be given for patients to take twice daily
9978879|NCT01375933|Active Comparator|NicVAX - Phase 3 Lot|NicVAX - Phase 3 Lot
9978880|NCT01375933|Active Comparator|NicVAX - Commercial Lot|NicVAX - Commercial Lot
9978881|NCT01375972|Experimental|SP treatment|S-1 plus cisplatin combination chemotherapy
9978882|NCT01375972|Active Comparator|GP treatment|Gemcitabine plus Cisplatin combination chemotherapy
10191370|NCT04239222|Experimental|Proflex XC to Revo-M|Transtibial amputees randomized to start with Proflex XC and cross over to Revo-M
10191371|NCT04239222|Experimental|Revo-M to Taleo|Transfemoral amputees randomized to start with Revo-M and cross over to Taleo
10191372|NCT04239222|Experimental|Taleo to Revo-M|Transfemoral amputees randomized to start with Taleo and cross over to Revo-M
10191373|NCT04236245|Other|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
10191374|NCT04231513|Experimental|SAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
10191375|NCT04231513|Experimental|SAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
10191376|NCT04231513|Experimental|SAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
10191377|NCT04231513|Experimental|SAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
10191378|NCT04231513|Experimental|SAD, Cohort 5: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo as an intravenous infusion, once, on Day 1.
10191379|NCT04231513|Experimental|MAD, Cohort 1: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
10191380|NCT04231513|Experimental|MAD, Cohort 2: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
10191381|NCT04231513|Experimental|MAD, Cohort 3: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
10191382|NCT04231513|Experimental|MAD, Cohort 4: E2814 or E2814-matched Placebo|Participants will receive E2814 or E2814-matched placebo as an intravenous infusion Q4W on 3 occasions up to Day 57 of the Treatment Period.
10191383|NCT04194203|Experimental|Treatment A|Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
10191384|NCT04194203|Placebo Comparator|Treatment B|Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
10191385|NCT04155788|Experimental|Food Exposure|
10191386|NCT04151901|Experimental|Male Rehabilitation (M-REHAB)|Disuse + resistance exercise rehabilitation
10191387|NCT04151901|Experimental|Male Control (M-CON)|Disuse + ambulatory control rehabilitation
10191388|NCT04151901|Experimental|Female Rehabilitation (F-REHAB)|Disuse + resistance exercise rehabilitation
10191389|NCT04151901|Experimental|Female Control (F-CON)|Disuse + ambulatory control rehabilitation
10191390|NCT04147494|Experimental|Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes. Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a separate day (for volunteer patients only, PSMA PET/CT is optional and not required).
10191391|NCT04146051|Experimental|Phase 1b Dose-Escalation|Generalized Myasthenia Gravis
10191392|NCT04146051|Experimental|Phase IIa Expansion|Generalized Myasthenia Gravis
10191393|NCT04145635|Experimental|Aortix Device|Aortix Pump, Aortix Delivery System, Introducer Set, Aortix Control System, Aortix Retrieval System
10191394|NCT04137107|Experimental|Phase II, Arm I (duloxetine hydrochloride, placebo)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
10191395|NCT04137107|Experimental|Phase II, Arm II (duloxetine hydrochloride)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 60 mg (2 duloxetine capsules) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
10191396|NCT04137107|Placebo Comparator|Phase II, Arm III (placebo)|Patients in Phase II receive placebo (1 placebo capsule) orally (PO) once daily (QD) during week 1, placebo (2 placebo capsules) PO QD weeks 2-16, followed by placebo (1 placebo capsule) PO QD during week 17 in the absence of unacceptable toxicity.
10191397|NCT04137107|Experimental|Phase III, Arm I (duloxetine hydrochloride)|Patients in Phase III receive most promising dose of duloxetine hydrochloride from Phase II PO QD in the absence of unacceptable toxicity.
10191398|NCT04137107|Placebo Comparator|Phase III, Arm II (placebo)|Patients in Phase III receive placebo PO QD in the absence of unacceptable toxicity.
10191399|NCT04133909|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously once every 4 weeks over a treatment period of at least 52 weeks up to a maximum of 104 weeks.
10191400|NCT04133909|Experimental|Mepolizumab|Participants will receive mepolizumab subcutaneously once every 4 weeks over a treatment period of at least 52 weeks up to a maximum of 104 weeks.
10191401|NCT04127539|Experimental|Intervention|Will start a Strong & Steady group exercise programme immediately after baseline testing.
10191402|NCT04105699||Device: Blood sampling|
10191403|NCT04095039|Experimental|Hi Arm|Patients to allow blood serum phosphate levels to rise to 6.5 mg/dl or above
10191404|NCT04095039|No Intervention|Lo Arm|Patients to titrate blood serum phosphate levels to the standard <5.5mg/dl
10191405|NCT04093323|Experimental|Treatment (IFNA2, rintatolimod, celecoxib, alphaDC1 vaccine)|Patients receive recombinant interferon alpha-2 IV over 30 minutes, rintatolimod IV over 2.5 hours, and celecoxib PO BID on days 1-3. Beginning cycle 2, patients also receive alpha-type-1 polarized dendritic cells ID on day 1. Treatment repeats every 3 weeks up to 4 cycles in the absence of disease progression or unacceptable toxicity. At 12 weeks, patients with progressive disease may switch to ipilimumab with or without a PD-1/PD-L1 inhibitor and patients with a complete response CR, PR, or stable disease SD may switch to a PD-1/PD-L1 inhibitor or best alternative care.
10191406|NCT04090749|Experimental|Open Label Group|In this arm, 5 participants will be enrolled in the intervention without blinding or randomization. The intervention and study delivery will be improved based on findings from this arm.
9978883|NCT01375985|Experimental|AVI-7100|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
9978884|NCT01375985|Experimental|Placebo|Vehicle
9978885|NCT01375998||Group 1|
9704393|NCT04702048|Experimental|Aflibercept injection|Intravitreal injection of Aflibercept
9978886|NCT01376011|Experimental|healthy young|
10191407|NCT04090749|Other|Waitlist Control|The waitlist control group (n=20) will be provided written materials with community resources for caregivers during the first 16 weeks, then the intervention will begin.
10191408|NCT04090749|Experimental|Immediate Intervention|The immediate intervention group (n=20) will receive the intervention during weeks 0-16. There will be assessment at week 32 to examine maintenance on primary and secondary outcomes.
10191409|NCT04080804|Experimental|Nivolumab + Relatlimab|Nivolumab 480mg IV + Relatlimab 160mg IV D1 - optional Nivolumab 480 mg IV + Relatlimab 160mg IV D28 (D28 at clinician discretion i.e. surgery postponed)
9704394|NCT04702048|Placebo Comparator|Sham injection|Empty syringe with no needle
10191410|NCT04080804|Experimental|Nivolumab + Ipilimumab|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg D1 then Nivolumab 3 mg /kg D14 and then optional Nivolumab 3 mg/kg D28 (D28 at clinician discretion i.e., surgery postponed)
9704395|NCT04702061|Active Comparator|Group E|Patients who receive general anesthesia after erector spina plane block
9978887|NCT01376011|Experimental|healthy old|
9978888|NCT01376063|Experimental|FG-4592|
9978889|NCT01376076|Experimental|1|Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine
9978890|NCT01376076|Placebo Comparator|2A|Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35
9978891|NCT01376076|Placebo Comparator|2B|Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35
9978892|NCT01376102||BONVIVA(ibandronate)|Patients administrated ibandronate injection with postmenopausal osteoporosis
9978893|NCT01376115||Subjects administered nelarabine|Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
9978894|NCT01376128||Subjects prescribed PAXIL|Pediatric subjects with panic disorder prescribed PAXIL during study period
10191411|NCT04080804|Experimental|Nivolumab|Nivolumab 480 mg IV D1 and then optional Nivo 480 mg IV D28 (D28 clinician discretion i.e. surgery postponed)
10191412|NCT04077723|Experimental|Part I|Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).
10191413|NCT04077723|Experimental|Part II|Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
10191414|NCT04077723|Experimental|Part III|Dose-Expansion Stage: Participants with r/r follicular lymphoma (FL), r/r diffuse large B-cell lymphoma (DLBCL), and r/r MCL will receive RO7227166 administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
10191415|NCT04075266|Experimental|Cohort 1|Participants with a body weight from >/= 25 kg to < 40 kg (with at least 2 participants with a body weight from >/= 25 kg to </= 35 kg) will receive 300 milligram (mg) ocrelizumab
10191416|NCT04075266|Experimental|Cohort 2|Participants with a body weight >/= 40 kg (with at least 2 participants with a body weight >/= 40 kg but </= 50 kg) will receive 600 mg ocrelizumab
9704396|NCT04702061|Active Comparator|Group T|Patients who receive general anesthesia after thoracic epidural block
9704397|NCT04702230||post-TAE|
9704398|NCT04702230||post-TARE|
9704399|NCT04702074|Experimental|Traditional Chinese medicine granules|The experimental group will be given Bu Fei Jian Pi Hua Tan granule or Yi Qi Yang Yin Qing Fei granule based on TCM syndrome differentiation.
9978895|NCT01376141||Subjects prescribed IMIGRAN|Subjects with migraine disorders prescribed IMIGRAN during study period
9978896|NCT01376154||Subjects prescribed lamivudine tablet|Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period
9978897|NCT01376180||Subjects prescribed lamotrigine tablet|Subjects with epilepsy prescribed lamotrigine tablet during study period
9978898|NCT01376193||Subjects prescribed naratriptan tablets|Subjects with migraine headache prescribed naratriptan tablets during study period
9978899|NCT01376206||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
9978900|NCT01376219||All patients|All patients entered in the study
9978901|NCT01376232|Experimental|GSK1278863|100 mg of GSK1278863
9978902|NCT01376232|Experimental|GSK1278863 + food|100 mg of GSK1278863 given with a high fat meal
9978903|NCT01376232|Experimental|GSK1278863 + Gemfibrozil|GSK1278863A 100mg + Gemfibrozil 600mg steady state
9978904|NCT01376258||Patients adherent to 5-alpha reductase inhibitor (5ARI)|Patients with benign prostate hyperplasia (BPH) who are adherent (as measured by a medication possession ratio (MPR)) based on 3 MPR threshold values of 70%, 75% and 80%
9978905|NCT01376258||Patients who are non-adherent to 5ARI therapy|Patients with BPH who are not adherent to 5ARI therapy as measured by 3 MPR threshold values of 70%, 75%, and 80%
9978906|NCT01376271||Subjects prescribed paroxetine tablets|Subjects with SAD prescribed paroxetine tablets during study period
9978907|NCT01376284||Subjects prescribed dutasteride capsules|Subjects with BPH prescribed dutasteride capsules during study period
9978908|NCT01376323|Experimental|GSK256073 1mg bid|GSK256073 1mg capsule taken orally twice a day
9978909|NCT01376323|Experimental|GSK256073 2mg qd|GSK256073 2 x 1mg capsule taken orally once a day
9978910|NCT01376323|Experimental|GSK256073 5mg bid|GSK256073 5mg capsule taken orally twice a day
9978911|NCT01376323|Experimental|GSK256073 10mg qd|GSK256073 2 x 5mg capsule taken orally once a day
9978912|NCT01376323|Experimental|GSK256073 10mg bid|GSK256073 10mg capsule taken orally twice a day
9978913|NCT01376323|Experimental|GSK256073 20mg qd|GSK256073 2x 10mg capsule taken orally once a day
9704400|NCT04702074|Placebo Comparator|Traditional Chinese medicine granules placebo|The control group will be given Bu Fei Jian Pi Hua Tan granule placebo or Yi Qi Yang Yin Qing Fei granule placebo based on TCM syndrome differentiation.
9704401|NCT04702178|Experimental|Group A-2|COVAC-2 25 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
9704402|NCT04702178|Placebo Comparator|Group B-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
9704403|NCT04702178|Experimental|Group C-2|COVAC-2 50 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
10191417|NCT04075266|Experimental|Cohort 3 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from >/= 25 kg to < 40 kg may be enrolled and receive another dose level of ocrelizumab
10191418|NCT04075266|Experimental|Cohort 4 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight >/= 40 kg may be enrolled and receive another dose level of ocrelizumab
10191419|NCT04042701|Experimental|Part 1 (Dose Escalation)|HER2-positive breast cancer, HER2-low expressing breast cancer, HER2-expressing NSCLC, and HER2-mutant NSCLC participants who received escalating doses of DS8201a (initial dose 3.2 mg/kg Q3W) and pembrolizumab 200 mg.
10191420|NCT04042701|Experimental|HER2-positive breast cancer (Part 2 Dose Expansion)|HER2-positive breast cancer participants with prior ado-trastuzumab emtansine (T-DM1) with disease progression and who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
10191421|NCT04042701|Experimental|HER2-low breast cancer (Part 2 Dose Expansion)|HER2 low breast cancer participants with prior failed standard treatments who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
10191422|NCT04042701|Experimental|HER2-expressing NSCLC (Part 2 Dose Expansion)|HER2-expressing NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
10191423|NCT04042701|Experimental|HER2-mutant NSCLC (Part 2 Dose Expansion)|HER2-mutant NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
10191424|NCT04021290|Experimental|Participants receiving DTG/3TC FDC|Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
10191425|NCT04021290|Active Comparator|Participants receiving CAR|Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.
10191426|NCT04019405||Frailty status|Frailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.
10191427|NCT04005690|Experimental|Arm I (cobimetinib)|Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
10191428|NCT04005690|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
9978914|NCT01376323|Experimental|GSK256073 25mg bid|GSK256073 25mg capsule taken orally twice a day
9978915|NCT01376323|Experimental|GSK256073 50mg qd|GSK256073 2x 25mg capsule taken orally once a day
9704404|NCT04702178|Placebo Comparator|Group D-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
9704405|NCT04702178|Experimental|Group E-2|COVAC-2 100 µg: 8 healthy adults 18 to 54 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
9704406|NCT04702178|Placebo Comparator|Group F-2|Placebo Control: 4 healthy adults 18 to 54 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
9704407|NCT04702178|Experimental|Group G-2|COVAC-2 25 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
9704408|NCT04702178|Placebo Comparator|Group H-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
9978916|NCT01376323|Placebo Comparator|Placebo|Matching placebo capsules taken orally either once a day or twice a day
9704409|NCT04702178|Experimental|Group I-2|COVAC-2 50 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
9704410|NCT04702178|Placebo Comparator|Group J-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
9978917|NCT01376323|Active Comparator|Sitagliptin 100mg qd|Commercially available Sitagliptin 100mg capsules taken once a day
9704411|NCT04702178|Experimental|Group K-2|COVAC-2 100 µg: 8 healthy adults ≥ 55 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
9704412|NCT04702178|Placebo Comparator|Group L-2|Placebo Control: 4 healthy adults ≥ 55 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of saline placebo on Day 28.
9704413|NCT04702282||unilateral Total knee arthroplasty|Patients receiving unilateral Total knee arthroplasty
9704414|NCT04702282||simultaneous bilateral Total knee arthroplasty|Patients receiving simultaneous bilateral Total knee arthroplasty y
9778851|NCT01117181|Placebo Comparator|Placebo|matching placebo and psychosocial intervention
9978918|NCT01376336|Experimental|Safe storage device|This arm will be assigned a safe water storage device.
9978919|NCT01376336|No Intervention|Control|This arm of the trial will receive nothing until the end of the trial.
9978920|NCT01376414||Non specific upper abdominal pain|Cohort is patients who present to the Emergency Department with primary complaint of upper abdominal pain without obvious cause.
9978921|NCT01376440|Experimental|Household water treatment|household water treatment with 1.25% sodium hypochlorite
9978922|NCT01376440|No Intervention|control|"Usual practice (the use of Jerrican for water storage, which is considered as safe storage)"
10191429|NCT04005690|Experimental|Arm III (temuterkib)|Patients receive temuterkib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
9978923|NCT01376453|Experimental|Sorafenib Dose Escalation|Pre-operative Continuous 5-FU, and Sorafenib with External Radiation Therapy. Dose level -1 will only be evaluated if dose level 1 exceeds MTD. The sorafenib and infusional 5-FU will only be given Day 1-5(Monday-Friday) with radiation only.
9978924|NCT01376466||patients with acute appendicitis|Patients who have been clinically diagnosed to have acute appendicitis
9704415|NCT04702191|Experimental|Triple P (Positive Parenting Program)|Triple P - level 4 group: All 600 participants will undergo screening and a baseline assessment before randomization. Once randomized, the Triple P group (n=200) will be provided with 8-week group/individual sessions.
9704416|NCT04702191|Experimental|Circle of Security Parenting|Circle of Security - Parenting (COS-P): Once randomized to the COSP group (n=200), caregivers will be provided with an 8-week group session.
9978925|NCT01376479|Experimental|INV21 Low Dose|
9978926|NCT01376479|Experimental|INV21 High Dose|
9704417|NCT04702191|No Intervention|Treatment As Usual|Treatment as usual: Caregivers randomized to this arm (n=200) will receive either a different program, or brief services depending on the organization.
10191430|NCT04005690|Experimental|Arm IV (onvansertib)|Patients receive onvansertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
9704418|NCT04702334|Experimental|Hyaluronic acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel . This adjunctive treatment was performed at baseline and at the 3 months control.
9984386|NCT04164849|Experimental|5-ALA photopheresis|All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light or red light photopheresis. The investigators will collect mononuclear cells by connecting patient to Spectra Optia with CMNC (continuous mononuclear cell collection protocol), and these cells will include active T-lymphocytes. 5-ALA will be incubated for 1 hour to produce photoactive protoporphyrin-IX (PpIX) before light exposure.
9984387|NCT04164199|Experimental|Tislelizumab monotherapy|
9984388|NCT04164199|Experimental|Pamiparib Monotherapy|
9984389|NCT04164199|Experimental|Tislelizumab and Pamiparib Combination Therapy|
9984390|NCT04164199|Experimental|Tislelizumab and Pemetrexed Combination Therapy|
10191431|NCT03978611|Experimental|Part 1: Dose Escalation Phase|
10191432|NCT03978611|Experimental|Part 2: Dose Expansion Phase|
10191433|NCT03969212|Experimental|Baloxavir Marboxil|Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.
10191434|NCT03969212|Placebo Comparator|Placebo|Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.
10191435|NCT03968822|Experimental|Intralipid 20% IV Bolus|
10191436|NCT03968822|Placebo Comparator|Saline|
10191437|NCT03961971|Experimental|Treatment (MBG453, spartalizumab, stereotactic radiosurgery)|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10191438|NCT03942263||Newly Diagnosed and RR cHL Participants|Participants diagnosed with RR cHL at the time of enrollment and RR cHL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed cHL, or RR cHL at the time of enrolment, or RR cHL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
9704419|NCT04702334|Placebo Comparator|Lidocaine|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic. This adjunctive treatment was performed at baseline and at the 3 months control.
9984391|NCT04164199|Experimental|Tislelizumab and Capecitabine Combination Therapy|
9984392|NCT04164199|Experimental|Experimental: Pamiparib and temozolomide|
9984393|NCT04161183|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
9984394|NCT04161183|Experimental|Extracoporeal shock wave therapy|Extracoporeal shock wave therapy (shock wave probe w/ energy)
9984395|NCT04159415|Experimental|Treatment A|
9984396|NCT04159415|Experimental|Treatment B|
9984397|NCT04159272|Experimental|Mindfulness Training|The MT programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on our ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
9984398|NCT04159272|No Intervention|Control|Participants follow their regular course curriculum.
9984399|NCT04158219|Experimental|Treatment|Behavioral activation for health and depression (BA-HD)
9984400|NCT04157075|Placebo Comparator|No injection|No injection will be performed
9984401|NCT04157075|Sham Comparator|Normal Saline Injection|Normal saline will be injected into the uterosacral ligaments prior to colpotomy
9984402|NCT04157075|Active Comparator|Bupivacaine Injection|Bupivacaine will be injected into the uterosacral ligaments prior to colpotomy
10191439|NCT03942263||Newly Diagnosed and RR sALCL Participants|Participants diagnosed with RR sALCL at the time of enrollment and RR sALCL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed sALCL, or RR sALCL at the time of enrolment, or RR sALCL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
9827817|NCT02469389|Active Comparator|Health & Wellness (H&W)|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
9827818|NCT02469597|Experimental|Single Dose of Furosemide|Furosemide 1 dose
9704420|NCT04702412|Experimental|Opal patient portal|Exposure to routine use of a patient portal (Opal) through which HIV patients are expected to complete a measure on barriers to ART adherence for screening purposes, before each HIV care visit.
9704421|NCT04702321||Patient cohort|Patients with clinical data and biospecimens
9704422|NCT04702399|Experimental|GEL GROUP|Intracavitary application of an anti-adhesion hyaluronic acid gel (HYALOBARRIER® GEL ENDO)
9704423|NCT04702399|No Intervention|CONTROL GROUP|No Intervention
9704424|NCT04702035|Experimental|iNPH patients|20 patients with completed diagnostics concerning NPH, in which the indication for implantation of a VP shunt for NPH treatment was found by the responsible surgeon independently from the study.
9704425|NCT04702035|Active Comparator|Healthy volunteers|20 volunteers, matched with group 1 concerning sex and age.
9704426|NCT04702035|Active Comparator|Young healthy volunteers|20 volunteers, matched with group 1 concerning sex only and between 18 and 40 years old.
9704427|NCT04702100|Experimental|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization+conventional therapy three times per week for four week
9704428|NCT04702100|Experimental|integrated neuromuscular inhibition technique|the patients will receive integrated neuromuscular inhibition technique+ conventional therapy. three times a week for four week
9704429|NCT04702100|Active Comparator|conventional therapy|the patients will receive conventional therapy three times a week for four week
9704430|NCT04702087|Experimental|OLEP|Omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
9704431|NCT04702087|Placebo Comparator|Placebo|isocaloric formula
9704432|NCT04701970|Other|changes in the occlusal load distribution|A crossover clinical study was carried out with previously constructed and used conventional complete dentures before relining with soft denture liners and then with the same dentures after relining with soft denture liners. patients were comfortably using their relined mandibular complete dentures for at least three months and the retention and stability of the conventional dentures were assessed before second recording of occlusal parameter. The evaluation of occlusal force distribution was carried out with the aid of T-Scan device
9704433|NCT04702009|Active Comparator|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy
9704434|NCT04702009|Experimental|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy
9704435|NCT04701697|Active Comparator|active comparator：HumanAlbumin|Participants received HumanAlbumin 10g/d
9704436|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 10g|Participants received Recombinant Human Albumin Injection 10g/d
9704437|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 20g|Participants received Recombinant Human Albumin Injection 20g/d
9704438|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 30g|Participants received Recombinant Human Albumin Injection 30g/d
9704439|NCT04701879|Active Comparator|Spine decompression with core stability exercises|Interventions in experimental group includes Hot pack, Spinal decompression therapy and core stability exercises
9827819|NCT02469597|Placebo Comparator|Placebo|Normal saline 1 dose
9827820|NCT02469610|Experimental|study|In the study group the surgeon will perform an intercostal Bupivacaine block of 100ml over five intercostal spaces which include the operation cuts. The block will be done in the beginning of the surgery right after the insertion of the video camera to the pleural space.
9827821|NCT02469610|Other|control|In the control group the surgeon will perform the same intercostal block at the end of the surgery just before closing the operation cuts. this approach is used today in our department.
9827822|NCT02469623|Experimental|Dipole Density Mapping|
9836195|NCT02774343|Experimental|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
9704440|NCT04701879|Experimental|Spine decompression|Intervention includesHot pack and spinal decompression therapy ..
9704441|NCT04701723|Experimental|Cardiac Coherence Training|"The cardiac coherence training will consist in the realization during 3 months by the patient, at home :~of 6 respiratory cycles by minute (inspiration : 4,5 seconds/expiration : 5,5 seconds),~during 5 minutes,~3 times a day (morning, late morning and late afternoon)"
9704442|NCT04701775|Experimental|Lactobacillus rhamnosus GG Group|Participants received only 1x106 cfu Lactobacillus rhamnosus GG once a day for 8 weeks.
9704443|NCT04701775|Experimental|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis Group|Participants recevied a combined Lactobacillus acidophilus 1x109 cfu and Bifidobacterium animalis subsp.lactis 1x109 cfu once a day for 8 weeks.
9704444|NCT04701775|Placebo Comparator|Placebo|Those participants received placebo capsule once a day for 8 weeks.
10191440|NCT03936478|Experimental|8.2 Gy Radiation Therapy|Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
9978927|NCT01376492||001|Functioning assessment The functioning will be assessed with 2 scales (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
9978928|NCT01376492||002|Quality of sleep assessment The quality of sleep will be assessed with 2 scales (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
9978929|NCT01376505|Experimental|HER-2 Vaccine|"combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720~This escalation arm has completed. The trial has moved on to the extension arm"
10191441|NCT03926143|Experimental|Cancer patients|Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
10191442|NCT03915626|Experimental|RLD patch|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
10191443|NCT03915626|Experimental|generic patch|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
10191444|NCT03915626|Experimental|RLD patch with heat|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
10191445|NCT03915626|Experimental|generic patch with heat|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
10191446|NCT03909165|Experimental|Part A. Sugammadex 2 mg/kg|Single intravenous (IV) bolus of sugammadex at 2 mg/kg
10191447|NCT03909165|Experimental|Part A. Sugammadex 4 mg/kg|Single IV bolus of sugammadex at 4 mg/kg.
10191448|NCT03909165|Experimental|Part B. Sugammadex 2 mg/kg|Single IV bolus of sugammadex at 2 mg/kg.
10191449|NCT03909165|Experimental|Part B. Sugammadex 4 mg/kg|Single IV bolus of sugammadex at 4 mg/kg.
10191450|NCT03909165|Active Comparator|Part B. Neostigmine|Single IV bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
10191451|NCT03907046|Active Comparator|Apixaban|Apixaban dosing will be 5 mg tablet in morning and 5 mg tablet in evening. A reduced dose of 2.5 mg tablet in morning and 2.5 mg tablet in evening will be used if: (1) ≥2 of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine 1.5-2.4 mg/dL, or (2) Patient is taking a strong CYP3A4/pGP inhibitor (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin).
10191452|NCT03907046|Placebo Comparator|Aspirin|Aspirin dose will be 81 mg tablet once daily.
10191453|NCT03888105|Experimental|FL|Follicular lymphoma grade 1-3a cohort
10191454|NCT03888105|Experimental|DLBCL|Diffuse large B-cell lymphoma cohort
10191455|NCT03888105|Experimental|MCL|Mantle Cell Lymphoma cohort
9704445|NCT04701892||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
9704446|NCT04701736|No Intervention|Routine Care|Routine care consists of an oncology pharmacist counselling the patient on supportive care medications prior to the patient getting his or her prescription dispensed.
9704447|NCT04701736|Active Comparator|Intervention|The intervention group will encompass the oncology pharmacist using the computer system to print a Picture Medication Calendar for the patient and use the calendar to explain supportive medications, in addition to routine care.
9704448|NCT04701606|Experimental|Artecom® (pyronaridine-artesunate)|Artecom® is treated orally once a day for 3 consecutive days.
9704449|NCT04701606|Placebo Comparator|Placebo|Placebo is treated orally once a day for 3 consecutive days.
9704450|NCT04701554|Experimental|Qigong program|The experimental group participated in the Qigong program during 2 months, 16 sessions with a total of 16 hours.
9704451|NCT04701554|Active Comparator|Active comparator group|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
9704452|NCT04701710|Experimental|Experimental Group|"The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.~Standard biosecurity care"
9704453|NCT04701710|No Intervention|Control Group|Standard biosecurity care
9704454|NCT04701814|Active Comparator|group A (controlled group)|received passive range of motion (PROM)/ active assisted range of motion (AAROM)/ active range of motion (AROM) exercises, strengthen of rotator cuff, biceps, shoulder and scapular muscles, ultrasound (5 min. - 1.5 W/c.m2 - 1 MHZ), electrical stimulation ( interferential bipolar technique for 20 min. on shoulder joint). This treatment was repeated three times per weeks with 24 hours rest for 3 weeks.
9704455|NCT04701814|Active Comparator|group B(Study group)|All patients in group B received biomechanical scapular mobilization with movement and motor learning and traditional methods.
10191456|NCT03888105|Experimental|MZL|Marginal Zone Lymphoma cohort
10191457|NCT03888105|Experimental|Other B-NHL|Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia [WM])
10204476|NCT01189786|Experimental|Cohort 1: CD34+ Cells for transplant|Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
9978930|NCT01376505|Experimental|EXTENSION HER-2 Vaccine at OBD|"Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720 at dose level cohort 2~This extension arm is ongoing"
9978931|NCT01376518||respiratory failure|patients with respiratory failure and need of high positive end-expiratory pressure ventilation.
9978932|NCT01376531||acute renal failure|patients at intensive care unit with definition of acute renal failure and the need for continuous veno-venous hemodialysis
9978933|NCT01376544|Active Comparator|Assist control ventilation|Assist control ventilation
9978934|NCT01376544|Active Comparator|Pressure support ventilation|
9978935|NCT01376570|Experimental|Contingency Management arm|The Contingency Management arm will receive the abstinence-reinforcing contingency management intervention.
9978936|NCT01376570|Active Comparator|Control arm|The Control arm will receive the performance feedback intervention.
9704456|NCT04701567||Liver disease|
9704457|NCT04701567||Pancreatic disease|
10191458|NCT03874767|Active Comparator|10th floor south|"The unit in this arm will be assigned physical therapists plus mobility technicians in the first month and only physical therapists in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~On evaluation, a PT will assign a JH-HLM scale rating to the patient~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~The mobility technician will then see that patient daily, unless the score is <4~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
10191459|NCT03874767|Active Comparator|6th floor Round Wing|"The unit in this arm will be assigned only physical therapists in the first month and physical therapists plus mobility technicians in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~On evaluation, a PT will assign a JH-HLM scale rating to the patient~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~The mobility technician will then see that patient daily, unless the score is <4~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
10191460|NCT03867084|Experimental|Pembrolizumab|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle for up to 17 cycles.
10191461|NCT03867084|Placebo Comparator|Placebo|Participants receive IV placebo on Day 1 of each 21-day cycle for up to 17 cycles.
10191462|NCT03848715|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight; 1 infusion
10191463|NCT03848715|Placebo Comparator|Placebo|same volume of 0.9% saline
10191464|NCT03847090|Experimental|Reloxaliase|Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule
10191465|NCT03847090|Placebo Comparator|placebo|placebo capsule
9704458|NCT04701749||with atrial closure|
9704459|NCT04701749||without atrial occlusion|
10191466|NCT03843554|Placebo Comparator|Standard of Care Oral Hygiene|Standard of Care Oral Hygiene group (SOC-OH): Subjects assigned to SOC-OH will attend weekly oral care visits where they will have their teeth brushed with a soft bristled toothbrush by the interventionist. No treatment to the oral mucosa will be provided to this group as part of the intervention. Subjects will receive oral care instructions and will be asked to follow SOC oral hygiene instructions at home.
10191467|NCT03843554|Experimental|Oral Mucosal Deterging and Dental Prophylaxis (OMDP)|Oral Mucosal Deterging & Dental Prophylaxis (OMDP) protocol: Subjects assigned to OMDP will attend weekly intervention visits during which they will have their teeth cleaned and will receive the OMDP intervention as follows: subjects will receive a professional dental prophylaxis including periodontal surface debridement and deterging of the oral mucosal surfaces. Subjects will be asked to follow OMDP oral hygiene instructions at home.
10204477|NCT01046825|Other|Group A|"Completely resected stage I or completely resected abdominal stage II lesions.~Group A will include: COPAD x 2 cycles."
9704460|NCT04701528|Experimental|Voclosporin (VCS)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the experimental arm tacrolimus is switched to voclosporin 6 capsules (of 7.9 mg each) BID for a treatment period of minimal 56 days with a possible extension up to 1 year.~Safety drug monitoring will take place during the study to ensure that VCS trough levels are maintained between 30-60 ng/mL. If trough levels are not within these levels, dose adjustments will take place."
9704461|NCT04701528|Active Comparator|Tacrolimus (TAC)|"Prior to or at study entry, subjects are reduced in their standard immunosuppressive therapy to dual therapy with prednisone and tacrolimus according to current local guidelines.~In the Active comparator arm tacrolimus dosage is maintained.~Safety drug monitoring will take place during the study to ensure that TAC trough levels are maintained between 3-7 ng/ml. If trough levels are not within these levels, dose adjustments will take place."
9704462|NCT04701489|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 10 minutes for up to 7 days, in addition to standard clinical care.
9704463|NCT04701489|No Intervention|Control Group|Standard clinical care with no ultrasound stimulation.
9778852|NCT01117311|Experimental|VNB off first, then VNB on|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
9836196|NCT02774343|Placebo Comparator|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
9836197|NCT02774616|Other|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
9836198|NCT02774616|Other|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
9836199|NCT02774616|Other|Ilivia ICD and Plexa lead|Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting
9836200|NCT02774681|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab IV over 30-90 minutes every 3 weeks.
9836201|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:~Oxford Grades 1 & 2 - intra-rectal intussusception~Oxford Grades 3 & 4 - intra-anal intussusception~Oxford grade 5 - Overt Rectal Prolapse"
9836202|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
9978937|NCT01376596|Experimental|CBT-based Intervention|Contrast the impact of a CBT intervention for the treatment of social anxiety in schizophrenia with standard care (care as usual)
9978938|NCT01376596|Active Comparator|Treatment as usual|Usual care received by patients at clinic/hospital - randomized to a wait list to receive the CBT intervention at the end of the group that received the intervention immediately
10191468|NCT03842228|Experimental|Treatment (copanlisib hydrochloride, olaparib, and durvalumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 and olaparib PO BID. Beginning cycle 2, patients receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.
10191469|NCT03834220|Experimental|Debio 1347|Participants will receive Debio 1347 once daily from Day 1 to Day 28 in 28-Day cycles.
9978939|NCT01376622||Chronically Transfusion Patients|Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
9978940|NCT01376622||Controls|Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
9978941|NCT01376661||Active Surveillance/ Prostate Cancer|
9978942|NCT01376687||Pain free|No pain in the cervical spine
9978943|NCT01376687||Pain|Pain of 3 or greater on a VAS scale for the cervical spine
9978944|NCT01376713|Experimental|Ofatumumab alone|Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).
9978945|NCT01376713|Experimental|Ofatumumab plus Dacarbazine|Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.
9978946|NCT01376726|Experimental|Previous HIV Vaccine Trial Participants (Group 1)|"Participants will receive the study vaccine administered as one 0.5 mL intramuscular injection (IM) in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
9704464|NCT04701541|Other|Obese Patients undergoing Bariatric Surgery|"Obesity is a progressively growing morbid condition in the world, and given the direct relationship between body mass index (BMI) and costs, this has a major impact on economic and health policy. Obese patients undergoing bariatric surgery are at high risk for postoperative respiratory complications. In these patients, postoperative respiratory complications are related to various pathophysiological mechanisms that include: decreased lung volumes, respiratory muscle dysfunction and atelectasis. Demographic (age, gender, BMI) and clinical features of the population included: ASA, comorbidity and pre and postoperative respiratory function [PaO2/FiO2, haemogasanalysis (EGA)]. Ultrasound evaluation of DIA was performed.~T0: preoperative within 24h before surgery: DIA, haemogasanalysis; T1: Post operation: 60 min after extubation: Aldrete Score, DIA, EGA; T2: Post operation: 240 min after extubation: Aldrete, EGA."
10191470|NCT03822013|Experimental|Miglustat|"Miglustat is administered, dose is adjusted according to Body Surface Area as below:~>1.25 : 200 mg TDS 0.88-1.25 : 200mg BID 0.73-0.88 :100mg TDS 0.47-0.73 : 100mg BID <0.47 :100mg daily"
9978947|NCT01376726|Experimental|No Previous HIV Vaccine Trial (Group 2)|"Participants will receive the study vaccine administered as one 0.5 mL IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
9978948|NCT01376739||Group 1|
9978949|NCT01376752|Active Comparator|maximal cytoreductive surgery without HIPEC|The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.
9978950|NCT01376752|Experimental|maximal cytoreductive surgery with HIPEC|The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²
9978951|NCT01376765|Experimental|Cohort 1|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine received with aluminum hydroxide adjuvant (Alhydrogel®), without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 5 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine {(SARS vaccine with aluminum hydroxide adjuvant (Alhydrogel®)}; 4 subjects receive placebo.
9978952|NCT01376765|Experimental|Cohort 3|SARS vaccine with adjuvant, without adjuvant, or placebo; l in 2 intramuscular doses, 28 days apart, at 45 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant); 4 subjects receive placebo.
9978953|NCT01376765|Experimental|Cohort 2|SARS vaccine with adjuvant, without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 15 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant) 4 subjects receive placebo.
9978954|NCT01376778|Active Comparator|CMV hyperimmune globulin - Cytogam®|Infusion of Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV)
9978955|NCT01376778|Placebo Comparator|Placebo|IV 5% albumin diluted 1 to 9 with 5% Dextrose in water (D5W)
9978956|NCT01376817|Experimental|Omega 3|
9978957|NCT01376817|Active Comparator|MCT / LCT|
9978958|NCT01376830||COPD patients|
9978959|NCT01376843||Health care workers|health care workers who performed TST or Quantiferon-TB Gold In tube assay before
9978960|NCT01376856||PET/CT and surgical biopsy group|person who performed PET/CT and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer
10191471|NCT03822013|No Intervention|No Miglustat|
9704465|NCT04701398|Experimental|Multimodal intervention|supervised physical training (1-hour sessions, 24 sessions, 8 weeks) + nutritional supplementation + psychological advice
9978961|NCT01376869|Active Comparator|102mg extract 1 hops|Equivalent to 0.5g dry weight
9978962|NCT01376869|Active Comparator|410mg extract 1 hops|Equivalent to 2g dry weight
9978963|NCT01376869|Active Comparator|79mg extract 2 hops|Equivalent to 0.5g dry weight
9978964|NCT01376869|Active Comparator|316mg extract 2 hops|Equivalent to 2g dry weight
9978965|NCT01376869|Placebo Comparator|Placebo|
9978966|NCT01376882|Experimental|Acute withdrawal|Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
9978967|NCT01376882|Experimental|Acute caffeine-independent of withdrawal|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
9704466|NCT04701398|No Intervention|Standard Care|Healthy living recommendations
9704467|NCT04701463|Experimental|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement|
10191472|NCT03785925|Experimental|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Participants will receive bempegaldesleukin (NKTR-214) in combination with nivolumab.
10191473|NCT03779334|Experimental|Open-label Arm|Participants will be enrolled to receive risdiplam orally once daily at a dose selected to achieve the targeted exposure range.
10191474|NCT03735589|Experimental|Treatment (nCTLs, alpha-DC1 vaccine)|Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0, on day 0, and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects, patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.
10191475|NCT03729245|Experimental|Combination of bempegaldesleukin + nivolumab|Patients in Arm A will receive bempegaldesleukin in combination with nivolumab.
10191476|NCT03729245|Active Comparator|sunitinib or cabozantinib|Patients in Arm B will receive the Investigator's choice of either one of two treatment options.
10191477|NCT03728842||Spontaneous regression|Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
9704468|NCT04701463|Placebo Comparator|Placebo|
9704469|NCT04701580|Experimental|HD patients|At baseline and 2-year follow-up
9704470|NCT04701580|Active Comparator|Healthy controls|At baseline and 2-year follow-up
9704471|NCT04701385||NSTEMI|Patients presenting with a myocardial infarction will have blood samples taken for analysis. At the time of their angiography/angioplasty procedure they will have an OCT assessment of the culprit coronary artery to distinguish if the heart attack was caused by a plaque rupture or plaque erosion event
9704472|NCT04701385||Control|Patients undergoing planned angioplasty will have blood samples taken pre and post angioplasty to help as a control for the flow cytometry and for biomarker analysis
10191478|NCT03714711||Total hip arthroplasty|Patient who are scheduled to undergo total hip replacement.
10191479|NCT03714711||Total knee arthroplasty|Patient who are scheduled to undergo total knee replacement.
10191480|NCT03706690|Experimental|Durvalumab Therapy|Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/deterioration or confirmed radiological progression)
9704473|NCT04701307|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21 of cycles 1-4, and on days 1-42 of subsequent cycles. Patients also receive dostarlimab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-4 and every 42 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
9704474|NCT04701333|Experimental|Cabergoline|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
9978968|NCT01376882|Experimental|Chronic abstinence|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
9978969|NCT01376882|Experimental|Acute caffeine-in state of withdrawal|Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
9978970|NCT01376895|Experimental|POWER|Power is a 3 session intervention delivered through the internet in real time by a trained health educator. It focuses on reducing HIV risk. Each session last from 1 to 2 hours.
9704475|NCT04701333|Placebo Comparator|Placebo|After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
9978971|NCT01376895|Active Comparator|Power Health|Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
9704476|NCT04701125|Experimental|Study group|Players receive selective head-neck cooling after concussion
9704477|NCT04701125|No Intervention|control group|Players receive the standard sport-related concussion management
9704478|NCT04701268|Experimental|Intervention/treatment|Implantation of the Hemiverse Shoulder Prothesis
10191481|NCT03706690|Placebo Comparator|Placebo Therapy|Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)
9704479|NCT04701294|Experimental|Giomer Beautifil flow plusF03 Shofu-Japan|Giomer beautifil flow plusF03 shofu-Japan an application of flowable resin with sprg as a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the experiment.
9978972|NCT01376947||Nulliparous|Nulliparous women who were submitted to IUD device insertion
9978973|NCT01376947||Multiparous with no cesaraen section|Multiparous women with no cesarean sections that were submitted to IUD device insertion
10191482|NCT03703635|Experimental|Intracranial Angioplasty|Intracranial balloon angioplasty and aggressive medical care.
10191483|NCT03703635|No Intervention|Aggressive Medical Care|Aggressive medical care alone.
10191484|NCT03701399|Experimental|Arm 1: BHV-4157|Troriluzole 200mg PO
9978974|NCT01376947||Mulitparous with cesarean section|multiparous women with a cesarean section that were submitted to IUD insertion
10191485|NCT03701399|Placebo Comparator|Arm 2: Placebo|Placebo 200mg PO
10191486|NCT03698279|Experimental|Group 1: QIV-HD 30 μg (US: 6 months to 17 years)|Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
10191487|NCT03698279|Experimental|Group 2: QIV-HD 45 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
10191488|NCT03698279|Experimental|Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
9704480|NCT04701294|Active Comparator|Tetric N flow ivoclar vivadent-Germany|Tetric N flow ivoclar vivadent-Germany an application of flowable resin a sealant for pits and fissures on the occlusal surface of permanent first molars until the end of the comparator.
9704481|NCT04701164|Experimental|ANX005 Treatment Group - Dose 1|Participants will receive a single IV infusion of ANX005 (Dose 1) on Day 1.
9704482|NCT04701164|Experimental|ANX005 Treatment Group - Dose 2|Participants will receive a single IV infusion of ANX005 (Dose 2) on Day 1.
9978975|NCT01376960|Active Comparator|single shot popliteal fossa block|
9978976|NCT01376960|Active Comparator|ankle blocks|
9704483|NCT04701164|Placebo Comparator|Placebo Group|Participants will receive a single IV infusion of placebo on Day 1.
10191489|NCT03698279|Active Comparator|Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)|Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
10191490|NCT03698279|Experimental|Group 5: QIV-HD, 60 μg (Canada: 6 to <24 months)|Participants from Canada (aged 6 to less than [<] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
10191491|NCT03698279|Active Comparator|Group 6: Adjuvanted TIV (Canada: 6 to <24 months)|Participants from Canada (aged 6 to <24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
10191492|NCT03692403|Experimental|Quinagolide 360 µg|Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
10191493|NCT03692403|Experimental|Quinagolide 720 µg|Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
10191494|NCT03692403|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
10191495|NCT03692403|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
10191496|NCT03680274|Experimental|Vitamin C|Vitamin C: 50 mg/kg every 6 hours for 96 hours.
9704484|NCT04701047||pessary|Vaginal prolapse being treated by pessary
9704485|NCT04701047||surgery|Vaginal prolapse being treated by surgical repair
9704486|NCT04701086|Experimental|Cationorm Pro|Cationorm Pro is an ophthalmic sterile unpreserved eye drops emulsion (N=40) Posology: One Drop in each eye 4 times daily for 84 days
9704487|NCT04701086|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
9704488|NCT04701242|Active Comparator|Atorvastatin-Ezetimibe combination|Eligible patients randomized to this arm will receive combination of Atorvastatin 80mg plus Ezetimibe 10mg
10191497|NCT03680274|Placebo Comparator|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
10191498|NCT03669640|Experimental|Part A: Monotherapy|Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.
10191499|NCT03669640|Experimental|Part B: Add-On Therapy|Participants will receive a low or high dose of RO6889450 or a dose-matched placebo in addition to their usual anti-psychotic treatment(s).
10191500|NCT03660657|Experimental|Ozone Group:|Standard treatment + Ozone therapy (O3/O2)
10191501|NCT03660657|Placebo Comparator|Control Group:|Standard treatment + Oxygen (O2)
10191502|NCT03653364|Experimental|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
10191503|NCT03653247|Experimental|BIVV003|Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.
10191504|NCT03651505||Prior Burosumab Clinical Trial Participants|Patients who participated in burosumab clinical trials and continue to receive burosumab via prescription from their physician.
9704489|NCT04701242|No Intervention|Atorvastatin monotherapy|Eligible patients randomized to this arm will receive Atorvastatin 80mg as monotherapy for LDL-C reduction. They can be upgraded to combination (adding Ezetimibe 10mg) if found in follow-up that they had not achieve recommended LDL-C targets.
9704490|NCT04701320|Experimental|Glass carbomer|Nano hydroxyapatite Reinforced Glass Ionomer that results in chemical bond formation with tooth structure mimic that of enamel tissue
9704491|NCT04701320|Active Comparator|Fuji ix|Conventional Glass Ionomer cement fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics, a wear resistant, self-adhesive
9704492|NCT04701229||normal karyotype|control group
9704493|NCT04701229||del5q-RBM22neg-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22, a loss of SLU7.
9704494|NCT04701229||del5q-RBM22neg-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22 but no loss of SLU7
9704495|NCT04701229||del5q-RBM22pos-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22, but a loss in SLU7
9704496|NCT04701229||del5q-RBM22pos-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22 nor SLU7
9978977|NCT01376973||group A|Not received any oral device (Control)
9978978|NCT01376973||Group B and Group C|Group B - Used Michigan Occlusal Splint (MOS); Group C - Used Planas Oral Appliance (POA).
10191505|NCT03651505||Not from Prior Burosumab Clinical Trial|Patients may take other treatments for XLH and may start burosumab treatment at any time as prescribed by a physician.
9704497|NCT04701099||On ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl during ECMO support.
9704498|NCT04701099||Off ECMO|patients who is receiving vancomycin or meropenem or milrinone or dexmedetomidine or fentanyl after weaning off ECMO.
10191506|NCT03622424|Active Comparator|Gelesis200|Subjects on this ARM will receive Gelesis200
10191507|NCT03622424|Placebo Comparator|Placebo|Subjects on this ARM will receive a placebo device
10191508|NCT03622424|Active Comparator|Gelesis200 and Placebo|Subejcts on this ARM will receive both Gelesis200 and placebo.
10191509|NCT03621124||Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
10191510|NCT03621124||Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
10191511|NCT03609203||Patients|
10191512|NCT03609203||Controls|
10191513|NCT03605849|Experimental|Centanafadine|400 mg total daily dose
10191514|NCT03596866|Experimental|Brigatinib|Brigatinib 90 milligram (mg), tablets, orally, once daily 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
10191515|NCT03596866|Active Comparator|Alectinib|Alectinib 600 mg, capsules, orally twice daily until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
10191516|NCT03593811|Active Comparator|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
10191517|NCT03593811|Active Comparator|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
10191518|NCT03593811|Active Comparator|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
10191519|NCT03593811|Active Comparator|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
10191520|NCT03593811|Active Comparator|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 4mg or 8mg dependent upon age disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine 4mg twice a day.
10191521|NCT03588299|Experimental|BAY2599023 / (DTX201)|Adult patients with severe hemophilia A, who have been previously treated with FVIII products
10191522|NCT03572764|Experimental|CPX-351|"CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction~If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3~In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
10191523|NCT03559010|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
10191524|NCT03558191|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
10191525|NCT03551496|Experimental|DES BTK|Treatment with DES BTK
9978979|NCT01376986|Experimental|Activation|All those determined fit for service or who are granted postponement will be included in the activation intervention. The physical activation intervention will be implemented between the call-up and start of military service. The activation group utilises an ICT platform that will be developed.
9704499|NCT04700982||Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and > 3 months (Group 2).
9704500|NCT04700930|Experimental|CBD|Patients receive CBD cigarettes additionally to standard psychiatric care including neuroleptic medication
9704501|NCT04700930|No Intervention|Non-CBD|Patients recieve standard psychiatric care including neuroleptic medication
9704502|NCT04701255|Experimental|aberration-free IOL|20 human eyes with aberration-free intraocular lens Implantation after phacoemulsification cataract surgery
9704503|NCT04701255|Active Comparator|negative spherical aberration IOL|20 human eyes with negative spherical aberration intraocular lens Implantation after phacoemulsification cataract surgery
9704504|NCT04701138|Experimental|Dietary Supplement|All subjects will receive the intervention (SPM Active Supplement)
9978980|NCT01376986|No Intervention|control|no access to the activation platform
9978981|NCT01376999|Experimental|Step Down|Step Down: We begin the COS (controlled ovarian stimulation) with 150 IU of FSH-r until 7th day of stimulation. This day we make an adjustment reducing the dose if necessary.
10191526|NCT03551496|Active Comparator|Conventional PTA|Treatment with standard PTA
10191527|NCT03548961|Experimental|Neoadjuvant chemotherapy|
10191528|NCT03543098|Experimental|Early Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and early rehabilitation.
9978982|NCT01376999|Active Comparator|Step Up|Step up: We begin the COS (controlled ovarian stimulation) with 75 IU of FSH-r until 7th day of stimulation.This day we make an adjustment increasing the dose if necessary.
9978983|NCT01377025|Experimental|Sorafenib blinded Phase|400 mg Sorafenib bid until PD
9978984|NCT01377025|Placebo Comparator|Placebo blinded Phase|Two tbl. in the morning and two tbl. in teh evening until PD
9978985|NCT01377025|Experimental|Sorafenib Open Phase|400 mg Sorafenib bid until PD
10191529|NCT03543098|Experimental|Early Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and delayed rehabilitation.
9978986|NCT01377038|Active Comparator|Duloxetine|Phenotype assessment prior to and after treatement with duloxetine 20-30 mg oral daily for eight weeks.
10191530|NCT03543098|Experimental|Delayed Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and early rehabilitation.
10191531|NCT03543098|Experimental|Delayed Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and delayed rehabilitation.
10191532|NCT03543098|Experimental|Early Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only early rehabilitation.
10191533|NCT03543098|Experimental|Delayed Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only delayed rehabilitation.
10191534|NCT03533283|Experimental|Atezolizumab|Participants will receive Glofitamab in combination with Atezolizumab up to the maximum tolerated dose (MTD).
10191535|NCT03533283|Experimental|Polatuzumab Vedotin|Participants will receive Glofitamab in combination with polatuzumab vedotin up to the MTD.
10191536|NCT03533283|Experimental|Imaging Sub-study|"Participants will undergo positive-emission tomography/computed tomography (PET/CT) at screening, followed by an Imaging Cycle, to replace Cycle 1 of the main study. Eligible participants will have the option roll-over to the atezolizumab arm of the main study from Cycle 2 onwards."
10191537|NCT03526588|Experimental|Autologous umbilical cord blood|
10191538|NCT03520686|Experimental|Cohort A (Experimental)|
10191539|NCT03520686|Experimental|Cohort B (Experimental)|
10191540|NCT03520686|Experimental|Cohort C (Experimental)|
10191541|NCT03520686|Active Comparator|Cohort A (Control)|
10191542|NCT03520686|Active Comparator|Cohort B (Control)|
10191543|NCT03520686|Active Comparator|Cohort C (Control)|
10191544|NCT03517111|Experimental|Nutrition/substance use prevention|Parenting and nutrition curriculum targeting substance use prevention and diet improvement.
10191545|NCT03517111|Active Comparator|Substance use prevention only|Parenting curriculum targeting substance use prevention only.
10191546|NCT03517111|Sham Comparator|Academic success program|Control program focused only on academic success.
10191547|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the Recommended Phase 2 Dose ([RP2D], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
10191548|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
10191549|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
10191550|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
9978987|NCT01377038|Active Comparator|Diclofenac|Phenotype assessment prior to and after treatment with topical diclofenac four times daily
9978988|NCT01377051|Active Comparator|Bronchodilator|Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
9978989|NCT01377051|Placebo Comparator|Placebo|Will be administered with the same device by a third independent investigator
9978990|NCT01377064|Experimental|Physical activity group|Subjects will participant in physical activity program
9978991|NCT01377064|Active Comparator|Standard care group|This group will not receive a physical activity intervention
9978992|NCT01377077|Experimental|epidermal 1mm grafting|Epidermal skin biopsies of 1mm diameter
9978993|NCT01377077|Experimental|dermal 1mm grafting|dermal skinbiopsies of 1mm diameter
9978994|NCT01377077|Experimental|dermal 1,5mm grafting|dermal skinbiopsies of 1,5mm diameter
9978995|NCT01377077|Active Comparator|epidermal 1,5mm grafting|epidermal skinbiopsies of 1,5mm diameter
9978996|NCT01377090||SSc DU-history subgroup|Systemic sclerosis patients with history of digital ulcers
9978997|NCT01377090||SSc with No-DU-history subgroup|Systemic sclerosis patients with no history of digital ulcers
9978998|NCT01377103|Placebo Comparator|Placebo|Placebo Gel
10191551|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
9978999|NCT01377103|Active Comparator|Testosterone Supplementation|Testosterone Gel
10191552|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
10191553|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
9979000|NCT01377129|Active Comparator|Single Bundle|These patients are operated using a single bundle technique.
9979001|NCT01377129|Experimental|Double bundle|These patients are operated using a double bundle technique.
9979002|NCT01377142||Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
9704505|NCT04701151|Experimental|Intervention|"Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours.~If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm."
9704506|NCT04701151|Active Comparator|Control|The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.
10191554|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
9979003|NCT01377142||Vaginal mesh hysteropexy|Vaginal Mesh Hysteropexy using the Uphold device which includes Sacrospinous Ligament Fixation
9979004|NCT01377155|Other|Insulin determir|
9704509|NCT04701346|Experimental|Low SAA diet|Dietary intervention
9704510|NCT04701346|Active Comparator|High SAA diet|Dietary intervention
9704511|NCT04700995|Experimental|ProTaper rotary NiTi instruments|The ProTaper Universal Retreatment rotary system and ProTaper Gold rotary system were used.
9704512|NCT04700995|Experimental|Hyflex EDM rotary NiTi instruments|Hyflex EDM rotary system was used.
10191555|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
9704513|NCT04700995|Experimental|Reciproc Blue reciprocating NiTi instruments|Reciproc Blue reciprocating system was used.
9979005|NCT01377168|Placebo Comparator|Placebo pill|Daily oral placebo.
9979006|NCT01377168|Active Comparator|NTX|Daily oral naltrexone.
10191556|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
10191557|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
10191558|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
10191559|NCT03512418|Experimental|PrEPsteps|Participants receive the digital pills with Truvada, plus the PrEPsteps intervention that is programmed at the randomization study visit (Study Visit 2). Participants will use PrEPsteps and the digital pill to measure Truvada adherence for months 1-3.
10191560|NCT03512418|Active Comparator|Control|Participants receive digital pills with Truvada alone. Participants will use digital pills with Truvada for months 1-3.
10204478|NCT01046825|Other|Group B|"All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV)~Group B will include the intervention COP, COPD M3, CYM as follows:~Pre-Phase: COP~Induction: COPAD M3 x 2 cycles~Consolidation: CYM x 2 cycles."
9979007|NCT01377181||group A|the patients were accepted laparoscopic purse-string knot closing the internal hernia opening only
9979008|NCT01377181||group B|the patients were accepted the lateral umbilicus ligament covering the internal hernia opening region after the laparoscopic purse-string knot
9979009|NCT01377207|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI)
9979010|NCT01377207|Active Comparator|Male Arm|Male Gender diagnosed with ST segment Elevation Acute Myocardial Infarction (STEMI)
10204479|NCT01046825|Other|Group C|"Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal~Group C will include the intervention COP, COPADM8, CYVE as follows:~Pre-Phase: COP~Induction: COPADM8 cycle 1~Induction: COPADM8 Cycle 2~Consolidation: CYVE x 2 cycles~and Maintenance"
10204480|NCT01019356|Experimental|Rosiglitazone|Lean and obese PCOS women
10204481|NCT01019356|Active Comparator|Acarbose|Obese PCOS women
10204482|NCT01019356|No Intervention|Control|Obese and lean healthy women evaluated only at baseline
10204483|NCT00981448|Experimental|Zinc supplement|
10204484|NCT00581672||questionnaires|Black men with prostate cancer
10204485|NCT00576654|Experimental|Dose escalation (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days -1 to 14 (days 3-14 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10191561|NCT03509012|Experimental|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
10191562|NCT03509012|Experimental|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
10191563|NCT03509012|Experimental|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
10191564|NCT03509012|Experimental|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
10191565|NCT03509012|Experimental|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
10191566|NCT03509012|Experimental|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
10191567|NCT03509012|Experimental|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
10191568|NCT03509012|Experimental|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
9704514|NCT04700995|Experimental|Waveone Gold reciprocating NiTi instruments|WaveOne Gold reciprocating system was used.
9704515|NCT04701034|Active Comparator|Active treatment group|Intravenous immunoglobulin and prednisolone. See study description
10191569|NCT03487185|Experimental|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
9979011|NCT01377246|Placebo Comparator|Saline solution.|
9979012|NCT01377246|Experimental|Octrotide-LAR|
9979013|NCT01377259||1Tissue oxygenation change|Spinal anesthesia may result different changes of tissue oxygenation in blocked area ( upper extrimities ) and non-blocked area ( lower extrimities). The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for orthopedic surgery
10191570|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
10191571|NCT03484884||Thyroid cancer/nodal metastasis|Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
10191572|NCT03478930|Experimental|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
10191573|NCT03478930|Experimental|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
10191574|NCT03478930|Experimental|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
10191575|NCT03478930|Experimental|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
10191576|NCT03477539|Experimental|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT.~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
10191577|NCT03476681|Experimental|NEO-201 in combination with pembrolizumab|Subjects will receive 3 doses NEO-201 in combination with one dose of pembrolizumab in a 42 day cycle. This course will be repeated in the absence of disease progression or unacceptable toxicity.
10191578|NCT03440112|Active Comparator|Clarithromycin (Not used anymore as of 4/2020)|Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.
10191579|NCT03440112|Placebo Comparator|Placebo (Not used anymore as of 4/2020)|Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.
10191580|NCT03440112|Active Comparator|Transdermal flumazenil (added 4/2020)|Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
10191581|NCT03440112|Placebo Comparator|Placebo cream (added 4/2020)|Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
9704516|NCT04701034|Placebo Comparator|Passive treatment group|Human albumin infusion and placebotablet. See study description
9704517|NCT04701112|Experimental|His-bundle pacing first|"AV sequential His-bundle pacing (or VVI pacing if in atrial fibrillation) via temporary right atrial and His-bundle electrodes.~Then AV sequential Biventricular pacing via the patient's already implanted CRT device.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
9836203|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
9836204|NCT02774941|Active Comparator|Control|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
9704518|NCT04701112|Active Comparator|Biventricular pacing first|"AV sequential biventricular pacing (or VVI pacing if in atrial fibrillation) via the patient's already implanted CRT device. Then AV sequential or VVI His-bundle pacing via temporary right atrial and His-bundle electrodes.~Measurements of stroke volume, cardiac output, pressure in the right ventricle and pulmonary capillary wedge pressure, during rest and exercise. Simultaneous 12 lead ECG registration."
10191582|NCT03435640|Experimental|Doublet: NKTR-262 + bempegaldesleukin|"Phase 1 Doublet: NKTR-262 in escalating doses, will be combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a safe and tolerable RP2D for NKTR-262 in combination with bempegaldesleukin (Every Three Week [Q3W] fixed dose) in select tumor indications.~Phase 2 Doublet: NKTR-262 RP2D will be combined with a Q3W dose of bempegaldesleukin in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
10191583|NCT03435640|Experimental|Triplet: NKTR-262 + bempegaldesleukin + Nivolumab|"Phase 1 Triplet: The RP2D of NKTR-262 RP2D will be combined with a Q3W dose regimen of bempegaldesleukin plus nivolumab. The goal is to establish the safety and tolerability of the triplet regimen.~Phase 2 Triplet: The RP2D of NKTR-262 will be combined with a Q3W dose regimen of bempegaldesleukin plus nivolumab in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
9704519|NCT04700852|Experimental|allergic rhinitis|Puressentiel protective nasal spray
10191584|NCT03434353|Experimental|Group 1: Inarigivir Soproxil 50 mg + TAF|Viremic participants will be administered inarigivir soproxil 50 mg (2 x 25 mg capsules) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks.
10191585|NCT03434353|Experimental|Group 2: TAF|Viremic participants will be administered TAF 25 mg tablet once daily orally with food for 48 weeks.
10191586|NCT03434353|Experimental|Group 3: Inarigivir Soproxil 200 mg + TAF|Viremic participants will be administered inarigivir soproxil 200 mg (2 x 100 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks
10191587|NCT03434353|Experimental|Group 4: Inarigivir Soproxil 100 mg + commercially available NUCs|Virally suppressed participants receiving commercially available nucleoside/nucleotide (NUC) will be administered inarigivir soproxil 100 mg tablet once daily orally 1 hour before or 1 hour after a meal for 12 weeks. Participants will continue commercially available NUCs for 48 weeks.
10191588|NCT03434353|Experimental|Group 5: Inarigivir Soproxil 400 mg + TAF|Viremic participants will be administered inarigivir soproxil 400 mg (2 x 200 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed TAF 25 mg tablet once daily orally with food for 36 weeks.
10191589|NCT03434262|Experimental|A: ribociclib + gemcitabine|Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim.
10191590|NCT03434262|Experimental|B: ribociclib + trametinib|Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, [sonic hedgehog (SHH)- or WNT-activated];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.
9704520|NCT04701372||Obsessive-Compulsive Disorder|adults, adolescents, and children with obsessive-compulsive disorder
9704521|NCT04700865|Other|Examination|Continuous ECG monitoring for minimum 3 days
9979014|NCT01377259||2Tissue oxygenation change|The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for cesarean section
9704522|NCT04701008||Patients with significative post-operative pain despite|Patients with significant pain despite receiving narcotics in PACU will receive a bolus dose of IV ketamine to assess its efficacy for pain score reduction. Bolus doses are given by 10mg IV increments, to reach approximate dose of 0,25mg/kg.
9704523|NCT04700774|Experimental|mBA|Motor enhanced behavioral activation. 10 sessions.
9704524|NCT04700774|Experimental|BA|Standard behavioral activation. 10 sessions.
9704525|NCT04700774|No Intervention|Waitlist|10 week waitlist.
9704526|NCT04700826|Experimental|Direct Oral anticoagulants (DOAC)|Commence DOAC even with low or intermediate risk of stroke or thromboembolism, which could include currently licensed drugs apixaban, dabigatran, edoxaban or rivaroxaban; choice of drug and dose according to local practice guidelines
9704527|NCT04700826|No Intervention|No anticoagulant therapy (usual care)|Continuation of usual anticoagulant prescribing practice in patients with AF; e.g. according to National Institute for Health and Care Excellence (NICE), patients with AF should commence oral anticoagulation with a CHA2DS2-VASc score of 2 or above.
9979015|NCT01377285|Experimental|ARB & Pentoxifylline|angiotensin receptor blockers(ARB)and Pentoxifylline 400mg tablet (If CKD3 1# BID(Bi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
10191591|NCT03434262|Experimental|C: ribociclib + sonidegib|Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) >6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.
10191592|NCT03430973|Experimental|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
9704528|NCT04700683|Active Comparator|Noninvasive Peripheral Nerve Stimulation|NPNS device programmed to deliver active stimulation.
10191593|NCT03430973|Experimental|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
10191594|NCT03430973|Experimental|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
10191595|NCT03430973|Experimental|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
10191596|NCT03430973|Experimental|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=40) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) 12-pack of beer on passenger seat, or (2) 12-pack of sparkling water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
10191597|NCT03430973|Experimental|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
10204486|NCT00576654|Experimental|Expansion portion (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days 1-15 (days 2-15 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10204487|NCT00576654|Experimental|Intermittent dose escalation (irinotecan, ABT-888)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 3 and 10 and veliparib PO BID on days 1 to 4 and 8-11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9704529|NCT04700683|Sham Comparator|Sham control|NPNS device programmed to deliver sham stimulation.
9836205|NCT02774941|Experimental|Study|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
9836206|NCT02775240|Active Comparator|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
9836207|NCT02775240|Experimental|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
9836208|NCT02775240|Active Comparator|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
9836209|NCT02775344|Experimental|three dimension laparoscopy|This group of patients will have laparoscopic ovarian cystectomy performed using three-dimension laparoscopy. The procedure will be performed in usual manner.
9836210|NCT02775344|No Intervention|Two dimension laparoscopy|Two-dimension laparosocpy would be used in this group of patient. The procedure will be performed in usual manner.
9836211|NCT02775617|Other|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
9979016|NCT01377285|Active Comparator|ARB & Placebo|angiotensin receptor blockers(ARB) and Placebo tablet(If CKD3 1# BIDBi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
10191598|NCT03430973|Experimental|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng & Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
10191599|NCT03425838|Active Comparator|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
10191600|NCT03425838|Active Comparator|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
10191601|NCT03424018|Experimental|BMN 111|
10191602|NCT03415022|Experimental|4-week computer-based treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
10191603|NCT03415022|Experimental|8-week computer-based treatment|An 8-week (12-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks, and then once a week for the subsequent four weeks.
10191604|NCT03404960|Experimental|Arm A|Niraparib + Nivolumab
10191605|NCT03404960|Experimental|Arm B|Niraparib + Ipilimumab
10191606|NCT03401749|No Intervention|Control Group|Usual preadmission surgery instructions (shower the night before).
10191607|NCT03401749|Experimental|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
10191608|NCT03401749|Experimental|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
10191609|NCT03399773|Experimental|Treatment (chemotherapy, TBI, NLA101)|"Patients receive either regimen A or regimen B.~REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.~REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 2-4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0."
10191610|NCT03377452|Experimental|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
10191611|NCT03377452|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
10191612|NCT03367689|Experimental|Olaparib 300 mg|Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.
10191613|NCT03366467|Experimental|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
10191614|NCT03366467|Experimental|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
10191615|NCT03364244||Sildenafil|Pediatric patients receiving Revatio
10191616|NCT03351244|Experimental|BI 409306 50 mg|1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
10191617|NCT03351244|Experimental|BI 409306 25 mg|1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
10191618|NCT03351244|Placebo Comparator|Placebo|1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
10191619|NCT03344913|Active Comparator|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
10191620|NCT03344913|Active Comparator|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
9979017|NCT01377298|Experimental|Pazopanib|Single arm study, pazopanib
9979018|NCT01377311|Experimental|1|Patients suffering from unilateral limbal stem cell insufficiency. Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
9979019|NCT01377324|Experimental|Single arm|Fluoroestradiol-PET is performed at baseline, after 1 month, and 3 months
9979020|NCT01377337|Active Comparator|Sodium bicarbonate|1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
10191621|NCT03334617|Experimental|Durvalumab + olaparib|Durvalumab given in combination with olaparib .
10191622|NCT03334617|Experimental|Durvalumab + AZD9150|Durvalumab given in combination with AZD9150.
10191623|NCT03334617|Experimental|Durvalumab + AZD6738|Durvalumab given in combination with AZD6738.
10191624|NCT03334617|Experimental|Durvalumab + vistusertib|Durvalumab given in combination with Vistusertib (AZD2014).
9979021|NCT01377337|Placebo Comparator|0.9% NaCl|1 ml/kg of 0.9% NaCl (Blinded label)
10191625|NCT03334617|Experimental|Durvalumab + Oleclumab|Durvalumab given in combination with Oleclumab
10191626|NCT03334617|Experimental|durvalumab + trastuzumab deruxtecan|durvalumab given in combination with trastuzumab deruxtecan (DS-8201a)
10191627|NCT03334617|Experimental|durvalumab + cediranib|durvalumab given in combination with cediranib (AZD2171)
10191628|NCT03334617|Experimental|AZD6738 (ceralasertib) monotherapy|AZD6738 (ceralasertib) given as monotherapy
10191629|NCT03334617|Experimental|durvalumab & AZD6738 (ceralasertib)|durvalumab given in combination with AZD6738 (D15-D28)
9704530|NCT04700631|Active Comparator|healthy subject|healthy subjects : no medical history, in particular cardiovascular, without drug treatment, without proteinuria, normal BMI
10191630|NCT03323151|Experimental|Phase I: Ixazomib & Ibrutinib|Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
10191631|NCT03323151|Experimental|Phase II: Ixazomib & BTK-Naive|Patients who are BTK-Naive will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
10191632|NCT03323151|Experimental|Phase II: Ixazomib & BTK Pre-Treated (Closed 8/7/2020)|Patients previously treated with a BTK will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
10191633|NCT03318497|Experimental|Diagnostic (Interim FLT PET/CT)|"The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.~Procedure: Computed Tomography~Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
10191634|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
10191635|NCT03286114|Experimental|Pembrolizumab|
10191636|NCT03283670|Experimental|1. 25% nitrous oxide, 25% nitrogen, 25% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
10191637|NCT03283670|Experimental|2. 50% nitrous oxide, 50% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
10191638|NCT03283670|Placebo Comparator|3. Placebo gas: 50% nitrogen(inert), 50% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
9704531|NCT04700631|Experimental|CRF patients|CRF patients : eGFR estimated according to the MRDR formula less than 89 mL/min/1,73m²
9704532|NCT04700540|Experimental|Intervention Group|The PWMC and Care partner in this group will receive the SR. The project will provide a smartwatch and smartphone for the dyads in the study. All others (family, friends, etc.) will be able to download a smartphone app from an online store. Instructional material will be created to show the suggested information that can be entered into the app. Care partners and PWMC are administered surveys at baseline, 3 months and 6 months following enrollment.
9704533|NCT04700540|No Intervention|Attention Control Group|Care partners are administered surveys at baseline, 3 months and 6 months following enrollment. The attention control group will receive a contact call from one of the researchers 3-months and 6-months after enrollment. Based on our prior experience, PWMC and care partners in an attention control group will often seek information and psychosocial support during these calls. We will provide free information resources (e.g., brochures or websites of the Alzheimer's Association) at that time.
9979022|NCT01377350|Experimental|"Pneumedicares monitoring system"|"Single arm study - Pneumedicares monitoring system is used for monitoring heart failure patients"
9979023|NCT01377363||Not treatment|Locally recurrent breast carcinoma or metastatic
9979024|NCT01377376|Experimental|ARQ 197|ARQ 197 and Erlotinib
9979025|NCT01377376|Placebo Comparator|Placebo|Placebo and Erlotinib
9979026|NCT01377415|Active Comparator|bupivacaine|a continuous flow of 5 mg/ml bupivacaine 2 ml/h 48 h
10191639|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.~These patients will receive standard pain treatment until the planned surgery."
10191640|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.~These patients will receive standard pain treatment until the planned surgery."
10191641|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
10191642|NCT03239145|Experimental|Pembrolizumab + Trebananib|Part 1 Standard 3+3 Dose Escalation
10191643|NCT03239145|Experimental|Pembrolizumab + Trebananib (Melanoma)|Part 2 Dose Expansion
10191644|NCT03239145|Experimental|Pembrolizumab + Trebananib (Ovarian)|Part 2 Dose Expansion
10191645|NCT03239145|Experimental|Pembrolizumab + Trebananib (Colorectal)|Part 2 Dose Expansion
10191646|NCT03239145|Experimental|Pembrolizumab + Trebananib (Renal Cell Carcinoma)|Part 2 Dose Expansion
10191647|NCT03238326|Experimental|Rollover & De-Novo|1-4 mg/day; Start at 0.5 mg/day, titrate and maintain between 1mg/day to max of 4 mg/day
10191648|NCT03233217|Experimental|Cohort 1: QIV-HD by IM|Participants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0.
10191649|NCT03233217|Experimental|Cohort 1: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
10191650|NCT03233217|Experimental|Cohort 2: QIV-HD by IM|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0.
10191651|NCT03233217|Experimental|Cohort 2: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
10191652|NCT03233217|Active Comparator|Cohort 2: QIV-SD by SC|Participants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0.
10191653|NCT03229200|Experimental|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
9704534|NCT04700748|Other|Diffusion-weighted MRI to predict treatment response in stereotactic radiotherapy of CNS metastases.|Patients with brain metastases who will receive radiotherapy to the brain will undergo diffusion-weighted magnetic resonance imaging (MRI) at the same time as dose planning MRI is performed, after end of radiotherapy, and after 3 and 6 months after end of radiotherapy.
10191654|NCT03219567|Experimental|Normals|Normal subjects will be imaged with the OCT system to ensure the imaging range of the system.
10191655|NCT03219567|Experimental|Patients with a history of cataract surgery or high myopia|Subjects will be imaged with both the OCT system and MRI. Reconstructions of the eye from each modality will then be compared.
9704535|NCT04700670||Group 1|patients with cardiac surgery with CBP. Blood samples in the operating room, 5 to 10 minutes after neutralization of heparin by protamine
10191656|NCT03215485|Experimental|Intervention Group|"All intervention youth participants will receive three components:~Nutrition lessons~Virtual World learning environment~Newsletters"
9704536|NCT04700670||Group 2|patients who had cardiac surgery with CBP, between day 1 and day 5 after surgery.
9704537|NCT04700670||Group 3|hospitalized patients in intensive care unit, including patients on extracorporeal life support (ECLS).
9704538|NCT04700670||Group 4|patients hospitalized in a medical non-intensive care ward.
9704539|NCT04700657||15 patients affected by ocular GVHD|
9704540|NCT04700657||15 age-matched normal volunteers.|
9704541|NCT04700592|Experimental|Gabapentin group|group which receives 600 mg of Gabapentin (two tablets) one hour prior to surgery
10191657|NCT03215485|Active Comparator|Comparison|"All comparison youth participants will only receive one component:~1) Newsletters"
10191658|NCT03206047|Experimental|Cohort I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
10191659|NCT03206047|Experimental|Cohort II (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9704542|NCT04700592|Experimental|ketamine group|group which receives an injection of ketamine at a dosage of 0.15 mg/Kg before surgery incision
9704543|NCT04700488|Experimental|6D-MRI|Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.
9704544|NCT04700943||Regional awake anesthesia|"In non-intubated patients, an epidural catheter was placed at T5-T6. An anesthetic load of 0,5 mg/kg of ropivacaine was administered to reach anesthesia of the thoracic wall. Adjunctive local anesthetic infiltration of the incision site was performed by the surgeon with 2% lidocaine and 7,5% Ropivacaine. The cumulative dose of anesthetics drugs was computed as not to exceed the recommended dosage.~To improve patient comfort through the procedure, sedation with Target Controlled Infusion of propofol (using Schnider algorithm) and low dose remifentanil (0,05 mcg/kg/min) was also administered."
9704545|NCT04700943||General anesthesia|"Either epidural block or an interfascial plane block of the thoracic wall, such as serratus anterior plane block or erector spinae plane block, were performed.~Patients were then anesthetized with Propofol plus opiates (usually remifentanil) and muscle paralysis was achieved with Rocuronium."
10191660|NCT03206047|Experimental|Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine)|Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9704546|NCT04700696|Experimental|EPIC Participants|EPIC participants are 1) matched with trained peer recovery supporters with lived experience related to child welfare and substance EPIC participants are also incentivized to participate in 2) family treatment drug court (FTDC), with medications for opioid use disorders (MOUD); and 3) home-based parenting supports based on the Nurturing Parenting Program.
10191661|NCT03205358|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
10191662|NCT03205358|Active Comparator|Group 2: NIMENRIX®|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.
10191663|NCT03198078|Experimental|Brexpiprazole (OPC-34712)|2-4 mg/day; Start at 0.5 mg/day, titrate to max of 4 mg/day
10191664|NCT03198078|Active Comparator|Aripiprazole|10-20 mg/day; Start at 2 mg per day, titrate up to max of 20 mg/day
10191665|NCT03198078|Placebo Comparator|Placebo|Matching placebo, daily
10191666|NCT03194646|Experimental|A1(3/1 regimen)|2.0 mg treatment of 12 weeks, each separated by 1 bleeding break
10191667|NCT03194646|Experimental|A2(6/2 regimen)|2.0 mg treatment period of 24 weeks, each separated by 2 bleeding break
10191668|NCT03194646|Experimental|A3(3/2 regimen)|2.0 mg treatment period of 12 weeks, each separated by 2 bleeding break
9704547|NCT04700696|Active Comparator|Ohio Sobriety Treatment And Reducing Trauma (START) participants|Adapted from the evidence-based national START model (Sobriety Treatment and Recovery Teams) this intervention matches child welfare parents in need of addiction services to caseworker and family peer mentor (FPM) dyads for intensive case management services.
9704548|NCT04700696|No Intervention|Treatment as usual (TAU)|Treatment as usual includes home visits by the assigned caseworker, referrals to SUD assessment/treatment, family group decision making, and (non-incentivized) referral to FTDC.
9704549|NCT04700579||TB Cases|"n= 50 (25 HIV positive and 25 HIV negative)~Xpert MTB/RIF Ultra-confirmed TB"
9704550|NCT04700579||Healthy Household Contacts|"n= (25 HIV positive and 25 HIV negative)~Culture negative TB result"
9704551|NCT04700579||Sick controls|"n=50~Diseases: Asthma, Chronic obstructive pulmonary disease (COPD), Cancer, Bronchiectasis (including post-TB) and Pneumonia"
9704552|NCT04700566|Experimental|Injection of Renuva Allograft adipose matrix in vocal fold|Injection of Renuva Allograft Adipose matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
9704553|NCT04700553|Experimental|Conventional physical therapy intervention plus localized muscle vibration|physical therapy intervention plus localized muscle vibration
9979027|NCT01377415|Placebo Comparator|saline|saline 9 mg/ml infusion 2 ml/h 48 h
9979028|NCT01377428|Experimental|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
9979029|NCT01377428|Active Comparator|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
9704554|NCT04700553|Sham Comparator|Conventional physical therapy intervention|physical therapy intervention
9979030|NCT01377493|Placebo Comparator|placebo|
10191669|NCT03194646|Other|B(Standard of care)|Standard of care as determined by the investigators, this could be watch & wait or non-hormonal medical treatment
10191670|NCT03182426|Experimental|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
10191671|NCT03182426|Experimental|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
10191672|NCT03174535||Exposure group|The exposure group was the patients who were treated with Qilong capsules (QLC). The willingness of the patients and the objective judgment of the clinician were comprehensively considered to decide whether to use QLC for intervention. Patients who chose to use QLC for intervention would take it immediately after being deemed eligible for enrollment. The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks. QLC was produced by Jining Huaneng Pharmaceutical Factory Co., Ltd. All participants in the exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
10191673|NCT03174535||Non-exposure group|The non-exposure group was the patients who did not take QLC. All participants in the non-exposure groups received the standard level of CT provided by clinicians according to the clinical diagnosis and treatment guidelines for IS, including antiplatelet aggregation drugs, antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs.
10191674|NCT03153111|Active Comparator|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
10191675|NCT03153111|Placebo Comparator|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks.
10191676|NCT03149237|No Intervention|Standard of Care|The 12 clinics randomized to the control arm will continue to provide standard of care (SOC) EMTCT services that include: standard HoPS male engagement (male invitation to ANC services and couples HIV testing), opt-out rapid HIV testing of all pregnant women attending ANC, HIV-specific counseling and support for all women who test positive, provision of cotrimoxazole prophylaxis, and universal ART, as per option B+ guidelines.
10191677|NCT03149237|Experimental|Couples-based Services|The 12 clinics randomly assigned to the intervention arm will receive a combination of community and clinical EMTCT services, including: (1) ANC-based couples HIV testing, couples-based treatment enrollment, and clinical care for sero-concordant HIV+ expectant couples; (2) couple-centered treatment in the post-partum period at the EID clinic; (3) couples-based education and skills building during the ANC and post-partum period; and (4) treatment continuity support by expert-patient (peer) navigators selected among couples who have successfully navigated EMTCT.
10191678|NCT03138889|Experimental|Dose Optimization, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)|Cohort 1: NKTR-214 will be combined with pembrolizumab
10191679|NCT03138889|Experimental|Dose Expansion, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)|Cohort 2: NKTR-214 will be combined with pembrolizumab
10191680|NCT03138889|Experimental|Dose Expansion, Combo of NKTR-214 + Pembrolizumab (KEYTRUDA®)|Cohort 3: NKTR-214 will be combined with pembrolizumab
10191681|NCT03138889|Experimental|Dose Expansion, NKTR-214 + Pembrolizumab and either Cisplatin, or Carboplatin and Pemetrexed|Cohort 4: NKTR-214 will be dosed in combination with pembrolizumab and either cisplatin, or carboplatin and pemetrexed, per investigator discretion
10191682|NCT03138889|Experimental|Dose Expansion, NKTR-214 + Pembrolizumab and Carboplatin and either Nab-paclitaxel or Paclitaxel|Cohort 5: NKTR-214 will be dosed in combination with pembrolizumab and carboplatin and either nab-paclitaxel or paclitaxel, per investigator discretion
10191683|NCT03128411|Experimental|Bosutinib|Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
10191684|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
9778853|NCT01117311|Experimental|VNB on first, then VNB off|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
9778854|NCT01117337|No Intervention|Mesh Non Fixation Group|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed by ant means
9785124|NCT01243762|Experimental|Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg|Participants in Part 1 of the study receive dalotuzumab 7.5 mg/kg intravenously (IV) weekly + MK-0752 1800 mg orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy.
9979031|NCT01377493|Active Comparator|POs-Ca|
9979032|NCT01377493|Active Comparator|POs-Ca+F|
9979033|NCT01377506|Experimental|Lifestyle counseling|Diabetes Prevention Program Lifestyle Balance Intervention delivered by lay health educator
10191685|NCT03100539|Experimental|Therapist treated massage (TT-M)|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
9979034|NCT01377506|Active Comparator|Cognitive Training|Adaptation of SeniorWise Memory Training program for delivery by lay health educator, matched in duration and contact to the other study arm
10191686|NCT03100539|No Intervention|Wait list control (WL-C)|Participants in the waitlist control will be instructed to continue their medical care as normal and to not begin any massage treatment during the 6 months of the study. At the competition of the final 6 month outcome, participants in the control arm will be eligible to attend a caregiver training session and receive a complementary massage session from a TOMCATT study therapist.
10191687|NCT03100487|Experimental|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
9704555|NCT04700709|Experimental|RaparoBell® Tablet|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
9704556|NCT04700709|Active Comparator|Mycophenolate Mofetil Tablet/Capsule|ABO-i De novo Living Kidney transplant recipients will be randomized after Kidney transplant.
10191688|NCT03100487|Experimental|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
10191689|NCT03093064|Experimental|Patient Group: Natalizumab|Natalizumab 300mg, intravenous, once monthly, total of 3 doses
10191690|NCT03093064|Placebo Comparator|Patient Group: Placebo|Saline, intravenous, once monthly, total of 3 doses
10191691|NCT03085173|Experimental|EGFRt/19-28z/4-1BBL CAR T cells|Following enrollment, patients will undergo leukapheresis of peripheral blood for further T cell enrichment, activation and genetic modification using a retroviral vector encoding a CD19targeted CAR, the co-stimulatory ligand 4-1BBL and the EGFRt safety system (EGFRt/19-28z/4-1BBL). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. Modified T cell infusions will be administered 2-7 days following completion of the treating investigator's choice of conditioning chemotherapy. Serial sampling of blood and bone marrow will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.
9979035|NCT01377519|Active Comparator|MR Guided Focused Ultrasound|
9979036|NCT01377519|Placebo Comparator|Placebo MR Guided Focused Ultrasound|
9979037|NCT01377545|Active Comparator|Local Anesthetic Via Catheter|30mL of Lidocaine (local Anesthetic) will be injected via a perineural catheter at hour 0.
9979038|NCT01377545|Active Comparator|Local Anesthetic Via Needle|30mL of Lidocaine (local Anesthetic) will be injected via a needle at hour 0.
9979039|NCT01377558|Experimental|Aerobic endurance training intervention|Aerobic endurance training
9979040|NCT01377558|Experimental|Strength endurance training intervention|Strength endurance training
9979041|NCT01377558|Experimental|Combined training intervention|Combined aerobic endurance training and strength endurance training intervention
9979042|NCT01377558|No Intervention|Control group|control group
9979043|NCT01377571|Experimental|Rotavin2H|2 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 2-month separation between doses
9979044|NCT01377571|Experimental|Rotavin2L|2 doses of Rotavin-M1 vaccine, 106.0FFU/dose, 2-month interval between doses
9979045|NCT01377571|Experimental|Rotavin3H|3 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 1-month interval between doses
9979046|NCT01377571|Experimental|Rotavin3L|3 doses of Rotavin-M1, 106.0FFU/dose, 1-month interval between doses
9979047|NCT01377597|Experimental|ranibizumab intravitreal injection|
9704557|NCT04700761|Experimental|Group OFA (Opioid-free anesthesia)|Not using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (except a single dose of alfentanil for endotracheal intubation)
9979048|NCT01377610|Active Comparator|Buprenorphine|Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
9979049|NCT01377610|Active Comparator|Oral naltrexone|The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.
9979050|NCT01377649||Control|Age matched control subjects without PAD
9979051|NCT01377649||Patients with PAD|
9979052|NCT01377675||Usual curriculum education program|Third year internal medicine residents
9979053|NCT01377688||Diabetics with PKD|Diagnoses of diabetes type 2 with progressive kidney disease (slope of eGFR decline between -15 to -3 ml/min/1.73m2 per year, estimated by calculating an eGFR for each creatinine using the 4-variable Modification of Diet in Renal Disease Study [MDRD] equation and conducting a simple ordinary least squares regression from these values to evaluate changes over time to derive each individuals' slope of eGFR, annualized using test dates)
9979054|NCT01377779|Experimental|Intercoat treatment|women treated by Intercoat gel following hysteroscopy for retained products of conception
9979055|NCT01377779|Placebo Comparator|Control group|No additional treatment following hysteroscopy was performed
9979056|NCT01377792|Active Comparator|5 ml|
9979057|NCT01377792|Active Comparator|10 ml|
9979058|NCT01377805||Multiple Sclerosis patients|Multiple sclerosis patients
9979059|NCT01377818|Experimental|ventilation|Group program of positive pressure ventilation noninvasive
9979060|NCT01377818|Experimental|exercise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~d. 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~e. Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
9979061|NCT01377818|Experimental|exercise training and ventilation|Group of exercise training program and noninvasive positive pressure ventilation
9979062|NCT01377857|Experimental|Opt-In|Opt-in refers to a default of no test - patients must ask for the test in order to receive it. Patients are informed of the availability of rapid testing. They are tested only if they request the test.
10191692|NCT03073733|Experimental|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
10191693|NCT03073733|Other|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
10191694|NCT03073733|Experimental|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
10191695|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
10191696|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
10191697|NCT03056794||PDC Deficiency|Pyruvate Dehydrogenase Complex Deficiency Disease
10191698|NCT03025139|Active Comparator|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
10191699|NCT03025139|Active Comparator|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
10191700|NCT03025139|Active Comparator|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
10191701|NCT03013998|Experimental|BAML-16-001-S1 (Closed)|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
10191702|NCT03013998|Experimental|BAML-16-001-S2|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
10191703|NCT03013998|Experimental|BAML-16-001-S3|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
10191704|NCT03013998|Experimental|BAML-16-001-S4 (Closed)|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
10191705|NCT03013998|Experimental|BAML-16-001-S5 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
10191706|NCT03013998|Experimental|BAML-16-001-S6|The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
10191707|NCT03013998|Experimental|BAML-16-001-S9 (Closed)|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
10191708|NCT03013998|Experimental|BAML-16-001-S16 (Closed)|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
10191709|NCT03013998|Experimental|BAML-16-001-S8|This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. Initially, the combination of gilteritinib and decitabine was tested (Group 1); however, subsequently the combination of decitabine and venetoclax was shown to be a highly effective therapy for older AML patients, so the triple combination of gilteritinib in combination with decitabine and venetoclax (Group 2) is now being evaluated in this study.
10191710|NCT03013998|Experimental|BAML-16-001-S10 (Closed)|This is a phase 1b/2 clinical trial to assess the safety and efficacy of the combination of AZD5153 and venetoclax. In a phase 1b component, safety and tolerability of the combination will be assessed in relapsed/refractory AML patients ≥ 18 years of age. Following determination of the recommended Phase 2 dose (RP2D), newly diagnosed, marker negative patients age ≥ 60 will be enrolled in the phase 2 component; these patients will be treated at the previously identified RP2D for the combination. The RP2D will be the highest dose level with ≤ 1 out of 6 patients with dose limiting toxicity and defined as the maximum tolerated dose.
10191711|NCT03013998|Experimental|BAML-16-001-S14|The study is an open-label Phase 1b/2 clinical study of TP-0903 given in addition to decitabine in patients ≥ 60 years with newly diagnosed, previously untreated AML with TP53 mutations and/or complex karyotype. The Phase 1b portion of this study will use a standard 3 + 3 design with dose escalation based upon dose limiting toxicities. The maximum tolerated dose will be defined as the highest dose where at most 1 patient in 6 experiences dose-limiting toxicity, and this is generally the recommended Phase 2 dose (RP2D). Once the RP2D is determined from Phase 1b, patients will be enrolled at this dose level to initiate the Phase 2 portion of the study.
10191712|NCT03013998|Experimental|BAML-16-001-S18 (Closed)|This is an open-label Phase 1b clinical study of AZD5991 + azacitidine in patients aged ≥60 years with newly diagnosed, previously untreated, hypermethylated and marker-negative AML. The phase 1b1 study will adopt a standard 3+3 design with dose escalation based upon dose limiting toxicities. The recommended Phase 2 dose (RP2D) is defined in this study as the highest dose level where less than 2 dose limiting toxicities (DLT) are observed out of 6 patients. Once the RP2D is defined, patients will be enrolled into 2 separate cohorts (hypermethylation and marker negative group) for the phase 1b2 expansion. These 2 groups will both be treated at the RP2D determined from phase 1b1.
10191713|NCT03013998|Experimental|BAML-16-001-S17|This is an open-label Phase 1b dose escalation and expansion clinical trial to determine the safety and recommended dose of SNDX-5613 combined with azacitidine and venetoclax in newly diagnosed, untreated AML patients age ≥ 60 years who are not candidates or do not wish to pursue intensive induction therapy and who have NPM1 mutated/FLT3-ITD and FLT3-TKD wild type or MLL-rearranged disease. After determination of the recommended dose of SNDX-5613, the study will have an expansion cohort to be treated at the recommended dose in combination with azacitidine and venetoclax in the same patient population.
10191714|NCT03011671|Experimental|Acetazolamide with Temozolomide|Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
10191715|NCT03008616|Active Comparator|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
10191716|NCT03008616|Placebo Comparator|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
9979063|NCT01377857|Experimental|Opt-Out|Opt-out has a default to test - patients are informed that they will receive a rapid HIV screening test unless they decline it. Patients will be tested unless they decline.
10191717|NCT02989636|Experimental|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
10191718|NCT02989636|Experimental|Arm II (nivolumab, SRS)|Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
10191719|NCT02968264||TOF participants|Tetralogy of fallot patients at any age
10191720|NCT02947087|Active Comparator|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
10191721|NCT02947087|Placebo Comparator|Placebo|Subjects will be given Saline weekly for 4 weeks.
10191722|NCT02931695|Other|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum~ECG~circulating sex hormones levels"
10191723|NCT02931695|Other|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum~ECG~circulating sex hormones levels"
9704558|NCT04700761|Active Comparator|Group OUA (Opioid-using anesthesia)|Using opioid analgesics during laparoscopic gynecologic surgery under general anesthesia (continuous infusion of remifentanil)
9704559|NCT04700787|Experimental|Sulopenem|Sulopenem intravenous 1000 mg (single dose) on Day 1 followed by oral sulopenem etzadroxil/probenecid 500 mg/500 mg (single dose) on Day 2.
9979064|NCT01377857|Experimental|Active Choice|In the active choice treatment, there is no default; patients must actively accept or actively decline the test.
10191724|NCT02922777|Experimental|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
10191725|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
10191726|NCT02920866|Experimental|Functional Strength Integration (FSI)|Progressive strength training exercise, specific functional activity to improve pelvic stability and core muscle strength
10191727|NCT02920866|Active Comparator|Control Group (CON)|Usual care, continuing education on postsurgical precautions
10191728|NCT02885753|Experimental|Experimental arm FOLFOX with oxaliplatin intraarterial + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intraarterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
10191729|NCT02885753|Active Comparator|Reference arm FOLFOX with oxaliplatin intravenous + targeted therapy to RAS status|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
9704560|NCT04700839|Experimental|SGLT2 inhibitors group|Intervention with SGLT2 inhibitors for 3 months
9979065|NCT01377857|Experimental|$1 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
10191730|NCT02885753|Experimental|Experimental arm mFOLFIRINOX with oxaliplatin intraarterial + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intraarterially Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
10191731|NCT02885753|Active Comparator|Reference arm mFOLFIRINOX with oxaliplatin intravenous + Bevacizumab|Bevacizumab (5 mg/Kg) Oxaliplatin (85 mg/m²) intravenously Irinotecan (150 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 2400 mg/m² intravenously over 46 hours
10191732|NCT02881086|Other|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
10191733|NCT02881086|Other|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
9704561|NCT04700839|Active Comparator|metformin group|Intervention with metformin for 3 months
10191734|NCT02881086|Active Comparator|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
9704562|NCT04700475|Experimental|Laser group|Laser group composes of thirty patients who will receive low level laser three times a week, on alternate day (48h interval) Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions
10191735|NCT02881086|Experimental|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
10191736|NCT02881086|Other|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
10191737|NCT02881086|Other|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
10191738|NCT02881086|Other|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
9979066|NCT01377857|Experimental|$5 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
9979067|NCT01377857|Experimental|$10 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
9979068|NCT01377857|Experimental|Early Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
10191739|NCT02881086|Active Comparator|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
10191740|NCT02881086|Experimental|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
9979069|NCT01377857|Experimental|Late Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
9979070|NCT01377857|Experimental|FITD Questionnaire|"There will be two versions of the early questionnaire: one standard Early questionnaire, and one with an additional question: If you were offered an HIV test as part of your routine health care at no cost, would you get tested? The two questionnaires will be otherwise identical."
10191741|NCT02862171|Experimental|Dapivirine Vaginal Ring-004|Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.
10191742|NCT02848781|Experimental|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
10191743|NCT02848781|Active Comparator|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
10191744|NCT02848781|Active Comparator|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
9704563|NCT04700475|Other|Control group|control group composes of thirty patients will be treated with 15mL of a 2% citric acid solution applied as a mouth rinse for 30 sec
9704564|NCT04700436|Experimental|Test group|Subject administered with Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
9704565|NCT04700436|Active Comparator|Control group|Subject administered with Suvast tablet 10 mg (Rosuvastatin 10 mg)
9979071|NCT01377857|Experimental|Free|When offering the HIV test, study staff will inform subjects that the ED is offering HIV testing (and that the test is also free); no monetary incentive will be offered.
9979072|NCT01377870|Placebo Comparator|cell free media|15 patients with relapsing remitting multiple sclerosis who receive cell free media
10191745|NCT02841540|Experimental|H3B-8800 (RVT-2001) Dose Escalation|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
10191746|NCT02841540|Experimental|H3B-8800 (RVT-2001) MDS Expansion|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1.
9979073|NCT01377870|Experimental|mesenchymal stem cell reciepiants|Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
10191747|NCT02841540|Experimental|H3B-8800 (RVT-2001) Dose Optimization|Transfusion-dependent, lower-risk MDS subjects (very-low to intermediate risk categorization per IPSS-R) with missense mutations in SF3B1, and who have not been exposed to HMA's or lenalidomide in a prior line of therapy.
10191748|NCT02836899|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
10191749|NCT02836899|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
10191750|NCT02824575|Experimental|Arm A1-2: Paclitaxel plus Rebastinib.|"Arm A1 (Dose Escalation Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm A2 (Expansion Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
10191751|NCT02824575|Experimental|Arm B1-2: Eribulin plus Rebastinib.|"Arm B1 (Dose Escalation Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm B2 (Expansion Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
10191752|NCT02822378|Experimental|Ca2+/VitD Control|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
10191753|NCT02822378|Experimental|50g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
10191754|NCT02822378|Experimental|100g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
10191755|NCT02821000|Experimental|Pembrolizumab|Participants receive pembrolizumab 2 mg/kg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
10191756|NCT02807181|Active Comparator|Chemotherapy (Cisplatin-Gemcitabine)|Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
10191757|NCT02807181|Experimental|Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)|A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
10191758|NCT02749968|Active Comparator|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
10191759|NCT02749968|Placebo Comparator|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
10191760|NCT02740205|No Intervention|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
10191761|NCT02740205|Experimental|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
9984403|NCT04156217|Experimental|EBV-TCR-T cells|Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
9979074|NCT01377883|Sham Comparator|Standard intervention|"Preparation and information: the doctor and nurse explained the steps of the procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Memory change and positive reinforcement: medical staff present spoke to the child positively and offered prizes, among which the child could choose.~Volunteer attendance: as part of the control session, receiving no particular instructions in relation to the child's potential pain during the procedure."
9984404|NCT04155853|Active Comparator|Interposition Arthroplasty|Fascia lata interposition arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
10191762|NCT02738255|Active Comparator|Polysomnogram With Varnum First, Regular Polysomnogram Second|Varnum mouthpiece, similar to a mouth tape with central opening on the first night, then a 1-week non-treatment period, then overnight sleep study with no mouthpiece.
10191763|NCT02738255|Active Comparator|Regular Polysomnogram First, Polysomnogram With Varnum Second|Baseline sleep study without Varnum mouthpiece on the first night, then a 1-week non-treatment period, then an overnight sleep study with Varnum mouthpiece on the second night.
10191764|NCT02730546|Experimental|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
10191765|NCT02713776|Experimental|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
10191766|NCT02713776|Placebo Comparator|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
10191767|NCT02702414|Experimental|Cohort 1: Hepatocellular Carcinoma (HCC)-Prior Systemic Therapy with Sorafenib|Participants with previously systemically treated HCC received a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.
10191768|NCT02702414|Experimental|Cohort 2: HCC-Systemic Therapy Naïve|Participants with HCC who had not received treatment for systemic disease received a pembrolizumab 200 mg IV infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.
10191769|NCT02677818||experimental group|The risk of bleeding adverse reactions when FVIII below the normal level.
10191770|NCT02677818||control group|The risk of bleeding adverse reactions when FVIII in normal level.
10191771|NCT02637531|Experimental|Part A/B: IPI-549 Dose Escalation|Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
10191772|NCT02637531|Experimental|Part C: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191773|NCT02637531|Experimental|Part D: IPI-549 Monotherapy|Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.
10191774|NCT02637531|Experimental|Part D Annex: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191775|NCT02637531|Experimental|Part E: NSCLC: IPI-549 and nivolumab|Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191776|NCT02637531|Experimental|Part E: Melanoma: IPI-549 and nivolumab|Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191777|NCT02637531|Experimental|Part E: SCCHN: IPI-549 and nivolumab|Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191778|NCT02637531|Experimental|Part F: TNBC: IPI-549 and nivolumab|Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191779|NCT02637531|Experimental|Part G: ACC: IPI-549 and nivolumab|Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191780|NCT02637531|Experimental|Part G: Mesothelioma: IPI-549 and nivolumab|Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191781|NCT02637531|Experimental|Part H: High-circulating MDSCs: IPI-549 and nivolumab|Participants with high-circulating MDSCs receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
10191782|NCT02624102|Experimental|Cognitive therapy|Major depressive disorder treated with cognitive therapy (Trial Based Cognitive Therapy plus Drug).
10191783|NCT02624102|Experimental|Behavioral Therapy|Major depressive disorder treated with behavioral therapy (Behavioral Activation plus drug).
10191784|NCT02624102|Other|Antidepressants|Major depressive disorder treated only with antidepressants (Drug alone).
10191785|NCT02605616|Experimental|Active drug AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
10191786|NCT02605616|Placebo Comparator|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
10191787|NCT02573233|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
10191788|NCT02573233|Experimental|Dupilumab|Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
10191789|NCT02568267|Experimental|NTRK1/2/3-rearranged NSCLC|Oral entrectinib (RXDX-101)
10191790|NCT02568267|Experimental|ROS1-rearranged NSCLC|Oral entrectinib (RXDX-101)
10191791|NCT02568267|Experimental|ALK- or ROS1-rearranged NSCLC|"with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.)~Oral entrectinib (RXDX-101)"
10191792|NCT02568267|Experimental|NTRK/1/2/3-rearranged mCRC|Oral entrectinib (RXDX-101)
10191793|NCT02568267|Experimental|ROS1-rearranged mCRC|Oral entrectinib (RXDX-101)
10191794|NCT02568267|Experimental|ALK-rearranged mCRC|Oral entrectinib (RXDX-101)
10191795|NCT02568267|Experimental|NTRK1/2/3-rearranged other solid tumor|Oral entrectinib (RXDX-101)
10191796|NCT02568267|Experimental|ROS1-rearranged other solid tumor|Oral entrectinib (RXDX-101)
9979075|NCT01377883|Experimental|clown care|Cognitive coping: encouraging a child to cope with the challenge. Imagery: a cognitive technique used to encourage the child to cope with the pain and distress of the procedure by imagining a pleasant object or experience Empowerment: the child is made to feel empowered by controlling the actions of the clown Reflecting emotions: the clown, sensing the state of the child, plays it out in an exaggerated fashion.
9979076|NCT01377909|Experimental|statin|
9979077|NCT01377935||Patients exposed to Saxagliptin|
9979078|NCT01377935||Patients exposed to OAD in classes other than DPP4 inhibitors|OAD - Oral Antidiabetic Drug
10191797|NCT02568267|Experimental|ALK-rearranged other solid tumor|Oral entrectinib (RXDX-101)
10191798|NCT02563574|Experimental|Motivational Interviewing Group|This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.
10191799|NCT02563574|Active Comparator|Control Group|This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.
10191800|NCT02558504|Active Comparator|Oesophagectomy|While surgical reference technique for invasive cancer of the lower esophagus is the technique according to Lewis Santy, there is no consensus on the technique and surgical approaches lack of specific work in the particular case of superficial lesions . The centers will have the choice of using the technique according to Lewis Santy with gastric plasty or technique of esophagectomy without thoracotomy with lower mediastinal dissection. In the absence of consensus to date available, abdominal surgery time will be by laparotomy or laparoscopy (laparoscopic assisted technique called). In both cases, an exploratory laparoscopy for diagnostic purposes is realized to remove an extension of the disease that would indicate against-resection with curative intent. For surgery, patients will be put under antisecretory therapy proton-pump inhibitor; this at least throughout the duration of the study.
10191801|NCT02558504|Experimental|Radiofrequency ablation|"The equipment processing is:~The radiofrequency generator,~The radiofrequency balloon 360,~the radiofrequency probe 90.~The radiofrequency treatment should be carried out according to the following protocol:~The radiofrequency treatment is done within 2 months following the last endoscopic assessment.~The maximum number of sessions is 4, including 2 maximum with 360 Halo probe.~Endoscopy is performed under general anesthesia.~The removal must begin at the top 1cm above the upper pole of the lesion and must end 1cm below the lower pole of the lesion.~The patient is left fasting until morning. In case of chest pain, the patient may receive analgesics.~During the time of treatment, the patient must follow an antisecretory therapy pump inhibitor with dual proton dose orally. The patient should avoid taking aspirin or nonsteroidal anti-inflammatory drugs during the 10 days following each session."
10191802|NCT02509689|Experimental|Single Arm|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
10204488|NCT00407602|Other|Implant of Argus II Retinal Prosthesis|This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.
10204489|NCT00345345|Experimental|Alemtuzumab in patients with T cell large granular lymphocytic leukemia (T-LGL)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
10204490|NCT00169806|Other|cohort|Subjects who are scheduled to undergo a percutaneous kidney stone removal who do not have complicated comorbidities
10204491|NCT00138372||Adult Repeat Cross-Sectional study (ARCS)|This group will be enrolled from the sub-location of Kanyawegi, Kisumu District, Nyanza Province.
10204492|NCT00138372||Prospective Infant Cohort study (PIC)|will be a clinic-based study recruiting infants attending Chulaimbo Rural Health Training Center (CRHTC), Maseno Division, Kisumu District, Nyanza Province for routine immunizations.
10204493|NCT00138372||Normal volunteers|will be recruited from the CWRU/UHCMC area as well as general local community.
10204494|NCT05202730|Other|Traditional injection site and traditional local anesthetic formulation|
10204495|NCT05202730|Experimental|Traditional injection site and new local anesthetic formulation|
10204496|NCT05202730|Experimental|New injection site and traditional local anesthetic formulation|
9704566|NCT04700150|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
10204497|NCT05202730|Experimental|New injection site and new local anesthetic formulation|
10204498|NCT05202717|Experimental|PHENIX U4+|Electrical stimulation treatment for patients with urinary incontinence using a new type of pelvic floor therapy instrument
9704567|NCT04700150|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
9704568|NCT04700059|Experimental|Intervention|10 perinatal home visits
9704569|NCT04700059|No Intervention|Usual care|Routine medical care for mother and infant. Access to online resources.
9704570|NCT04700410|Experimental|Pure-Vu|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System (single arm)
9979079|NCT01377948|Other|ACT with RAGE-Control|all subjects are assigned to this arm. This is an open feasability proof of concept trail with a single experimental group with all subjects receiving the intervention being studied.
9979080|NCT01377961|Active Comparator|Arm1: Metabolic Syndrome Volunteers|
9979081|NCT01377961|Active Comparator|Arm 2:Previously Diagnosed diabetic patients|
9979082|NCT01377974|Active Comparator|Standard Treatment|Meglumine antimoniate as recommended by the Brazilian Ministry of Health
10191803|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:~detection of PUUV RNA in plasma collected at admission.~or/and detection of IgM and IgG against PUUV in serum collected at admission,~or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
9979083|NCT01377974|Experimental|Tested Intervention|Miltefosine as the tested intervention
9979084|NCT01378000||UFH,once a day|
10191804|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
10191805|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
10191806|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
10191807|NCT02425904|Experimental|Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine|"Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
9704571|NCT04700254||working condition|In order to further explore the differences among working status the data will be categorized into three different groups: suspension of work, employment and unemployment.
9704572|NCT04700254||Family status|In order to xplore the differences among the family status, the data will be categorized into the married and the singles DM patients.
10191808|NCT02425904|Experimental|LCH-related disorders + Clofarabine|"Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
10191809|NCT02420795|Experimental|Treatment (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10191810|NCT02403323|Experimental|Part 1: Etrolizumab Open-Label Extension|Participants will receive open-label treatment with etrolizumab once every 4 weeks until commercial availability in their country or sponsor's decision to terminate the study, whichever is earlier (up to approximately 10 years after the first patient is enrolled).
10191811|NCT02403323|No Intervention|Part 2: Safety Monitoring|Participants who have stopped etrolizumab treatment (either by exiting Part 1 of this study or by entering directly from Study GA29144 [NCT02394028]) will be monitored for 92 weeks for progressive multifocal leukoencephalopathy (PML) and other safety events.
10191812|NCT02402244||Observational (Project: Every Child)|Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, saliva, cerebrospinal fluid, or urine).
10191813|NCT02399995||patients following hepatectomy|
10191814|NCT02389244|Experimental|Regorafenib|"For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .~For children Age ≥10 years to <18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent."
10191815|NCT02389244|Placebo Comparator|placebo|Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
10191816|NCT02384759|Experimental|A|Aflibercept + LV5FU2
10191817|NCT02384759|Active Comparator|B|LV5FU2
10191818|NCT02384018|No Intervention|Control|Patients will receive standard islet transplantation.
10191819|NCT02384018|Experimental|autologous mesenchymal stromal cell|Patients will receive MSCs together with standard islet transplantation.
10191820|NCT02367846|Experimental|Combined Oral Contraceptive (COC)|We are testing the effects of a COC (Apri (Reclipsen); 30 µg EE, 150 µg desogestrel). On the first day of the intervention, the participants randomized to COC will begin taking the pill. One pill will be ingested orally at the same time each day for days 1-49 of the intervention. Pills ingested during days 1-21 and during days 29-49 will be active tablets. Pills ingested on days 22-28 will be tablets without active ingredients. Each participant in the COC group will ingest a pill from the first pack each day for the first 28 days then begin the second pack. If a participant is unable to collect a 24-h urine sample on day 49, she will take active tablets from the third pill pack until she has collected the 24-h urine sample.
10204499|NCT05202717|Active Comparator|Traditional pelvic floor electrical stimulation therapy instrument|Electrical stimulation treatment for patients with urinary incontinence using traditional pelvic floor therapy instrument
9979085|NCT01378000||heparin Calcium,every 12 hours|
9979086|NCT01378000||dextran,Salviae,once a day|
9979087|NCT01378000||UFH,continuous intravenous infusion,|
9984405|NCT04155853|Active Comparator|Hematoma and Distraction Arthroplasty|Hematoma and Distraction Arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
9984406|NCT04155437|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities.
9979088|NCT01378013||Elective sugery|"Patients entering into elective surgery. These will be divided into three subgroups:~A. Patients with cancer. This will include patients with malignancy of the gastrointestinal and colorectal tract (including those excised by microsurgery) cancer of the breast or solid tumours of the kidney.~B. Patients with benign diseases of the bowel requiring surgery e.g. inflammatory bowel disease C. Benign surgical conditions, usually operated on in a day surgery setting. These will specifically be of the biliary tree (gall stones) and the anterior abdominal wall (e.g. Hernia surgery)"
9979089|NCT01378013||Acute (emergency) surgery|"Patients presenting to Accident and emergency under the care of the general surgery on call team will be recruited into this study group. This study group will have the following subgroups:~A. Acute abdominal pain, as per the previous ethical clearance B. Patients with acute sepsis thought to be of surgical origin. C. Patients suffering major trauma with an Injury severity score of >15, multiple injuries, who require surgery or who have >1 organ system that is failed or who are admitted to the intensive care department."
9704573|NCT04700254||BMI status|In order to further explore BMI scale results, we divided the data obtained from the participants into normal (18.50 - 24.99 kg/m2), overweight (25-29.99 kg/m2) and obese (≥30 kg/m2), according to the international classification of the World Health Organisation (WHO).
9704574|NCT04700228|Placebo Comparator|Group C|0.25% bupivacaine at a total volume of 0.5ml/kg.
10191821|NCT02367846|Experimental|Contraceptive Vaginal Ring (CVR)|We are testing the effects of the vaginal ring (Nuva Ring; 15 µg/d EE, 120 µg/d etonogestrel). When randomized to CVR, participants will insert the contraceptive ring into their vagina . The ring will be worn during weeks 1-3, and again during weeks 5-7. During week 4, no ring will be worn to allow for withdrawal bleeding. If a participant is unable to collect a 24-h urine sample on day 49, they will insert a third ring which will remain in the vagina until she has collected a 24-h urine sample.
10191822|NCT02243878|Experimental|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
10191823|NCT02243878|Sham Comparator|Arm B (control)|"Participants will receive a sham treatment.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
9979090|NCT01378039|Other|Budesonide|patients who gave their agreement were randomised to 3 months treatment with either inhaled budesonide (400 µg BD) or placebo
10191824|NCT02240485|Experimental|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"Couple therapy: The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Treatment for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
10191825|NCT02240485|Active Comparator|Usual individual/group treatment|Usual individual/group treatment: The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
9979091|NCT01378052||urothelial carcinoma pateints|
10191826|NCT02227147|Experimental|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, formulation containing anti-oxidant
10191827|NCT02227147|Placebo Comparator|Placebo|Vehicle: formulation containing anti-oxidant
10191828|NCT02199691|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
10191829|NCT02199691|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
9979092|NCT01378052||healthy controls|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
9979093|NCT01378078|Sham Comparator|sham|patients receive sham tDCS stimulation
9979094|NCT01378078|Active Comparator|active|active transcranial direct current stimulation
9979095|NCT01378091|Experimental|Lenalidomide, Docetaxel, Prednisone|Subjects will receive this drug combination during a treatment phase and an extension phase.
9704575|NCT04700228|Active Comparator|Group BD1|0.25% bupivacaine + 1mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
9984407|NCT04155437|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities.
9984408|NCT04154423|Active Comparator|Glow! Group Prenatal Care|Group prenatal care with wrap around services.
9984409|NCT04154423|Active Comparator|Individual Prenatal Care- CPSP|Individual prenatal care with supplemental services covered by CPSP.
9984410|NCT04154371|Experimental|Single-arm or non-randomized trial|Six post-stroke patients, in the chronic recovery stage, will receive a treatment in which motor execution is promoted by virtual and augmented reality using serious gaming controlled by myoelectric pattern recognition. The aim of this treatment is to improve upper limb functionality.
9984411|NCT04154189|Experimental|Randomization Phase: Lenvatinib + Ifosfamide + Etoposide|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
9984412|NCT04154189|Active Comparator|Randomization Phase: Ifosfamide + Etoposide and Lenvatinib (Optional)|Participants with relapsed or refractory osteosarcoma will receive ifosfamide with etoposide. Participants with relapsed or refractory osteosarcoma may receive optional lenvatinib plus or minus chemotherapy (Ifosfamide and Etoposide) if disease progression is observed in study.
9984413|NCT04152824|Experimental|Leader Intervention|Leaders in the intervention group will go through the Resilience-Supportive Leadership Training (RESULT)
9984414|NCT04152824|No Intervention|Control Group|Leaders in the control group will be usual practice
9979096|NCT01378143|Experimental|OCZ103-OS, mFOLFOX6 or FOLFIRI|OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
9979097|NCT01378156|Experimental|JS7 plasmid DNA and MVA62B vaccines|All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
10191830|NCT02199691|Experimental|Group 3: MenACYW Conjugate Vaccine+Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
10191831|NCT02199691|Active Comparator|Group 4: Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
10191832|NCT02199665|Experimental|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10191833|NCT02163694|Active Comparator|Veliparib Placebo with Carboplatin and Paclitaxel|Placebo capsules for veliparib (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
10191834|NCT02163694|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
10191835|NCT02145208|Experimental|Medi-Tate iTind|TIND System
10191836|NCT02143726|Active Comparator|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10191837|NCT02143726|Experimental|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10191838|NCT02091141|Experimental|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks. This treatment arm is now closed for screening and enrollment.
10191839|NCT02091141|Experimental|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
10191840|NCT02091141|Experimental|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
10191841|NCT02091141|Experimental|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
10191842|NCT02091141|Experimental|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
10191843|NCT02091141|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
10191844|NCT02088112|Experimental|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
10191845|NCT02088112|Experimental|Expansion Arm|MEDI4736 will be combined with gefitinib
10191846|NCT02087852||kidney cancer patients receiving care at MSKCC|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
10191847|NCT02087852||relatives of patients with kidney cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
10191848|NCT02087852||healthy controls who are unrelated & do not have hx of cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
9704576|NCT04700228|Active Comparator|Group BD2|0.25% bupivacaine + 0.5mcg/kg dexmedetomidine at a total volume of 0.5ml/kg.
9785125|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-0752 1800 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-0752 1800 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
9979098|NCT01378169||SIRS patients|Every patient, without exclusion criteria, presenting with SIRS during an hospitalization in ICU.
9979099|NCT01378208|Experimental|Normal weight|Body Mass Index between 18-25 kg/m2 Age between 18-35 years male
9979100|NCT01378234|Experimental|EDPP Intervention|Receive EDPP transitional care intervention from social worker upon hospital discharge
9979101|NCT01378234|No Intervention|Usual Care|Receive usual care upon hospital discharge
9979102|NCT01378247|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in heart failure.
9979103|NCT01378247|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
9704577|NCT04700020|Other|Patients above the age of 18 years|"In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal.~MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland."
10191849|NCT02087852||high risk|Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation
10191850|NCT02086578|Experimental|Group 1|Physical examination by MD, optional Breast MRI, Breast-Q© at baseline (after permanent implant exchange, physical exam and Breast-Q© may be done after the initiation of IMRT), 12 ± 2 months and 24 ± 2 months post- IMRT. Total length of the follow-up time will be 24 ± 2 months post-IMRT. A subset of 10 left-sided patients will receive 13N-NH3 PET scans within the radiation simulation session. A CT for coronary calcium scoring and a low-dose CT for attenuation correction will also be obtained at this time. Myocardial blood flow will be measured during rest and at peak stress with 13N-NH3 as a perfusion tracer. A follow-up 13N-NH3 PET study with low-dose CT for attenuation correction will be obtained 12-18 months (± 6 months) post-IMRT.
10191851|NCT02086578|Experimental|Group 2|Physical examination by MD, optional Breast MRI, Breast-Q © at baseline (after permanent implant exchange and after IMRT), 18 ± 2 months and 30 ± 2 months post-IMRT, as these patients will undergo exchange of the temporary expander for the permanent implant approximately 4-8 months following the completion of radiation (at the discretion of the treating plastic surgeon). Total length of the follow-up time will be 30 ± 2 months post-IMRT
10191852|NCT02085148|Experimental|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
9704578|NCT04700358||Patients with Cystic Fibrosis|Patients with pulmonary Cystic Fibrosis with or without bacterial colonization
10191853|NCT02085148|Experimental|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
10191854|NCT02085148|Experimental|Dose escalation|Dose escalation phase: This phase of the study has been completed
10191855|NCT02076620|Experimental|L19TNFα + doxorubicin|"Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design:~cohort 1 --> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --> 17 μg/kg L19TNFα + doxorubicin."
10191856|NCT02046512|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
10191857|NCT02046512|Placebo Comparator|Sugar Pill|Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis
10191858|NCT02030210||cardiologists|
10191859|NCT02030210||study coordinators|
9704579|NCT04700358||Control group|Healthy age- and sex-matched controls including healthy individuals and patients with acute or chronic bacterial infections
9704580|NCT04700085|Experimental|ReMotion Knee|The ReMotion Knee (mechanical prosthetic knee type) was used during measurements
9704581|NCT04700085|No Intervention|Current prosthetic knee|The participant's current prosthetic knee was used during measurements
9827823|NCT02469701|Experimental|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.~Either cryoablation or thermal ablation may be performed as per standard institutional policies.~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
9827824|NCT02469714|Experimental|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
10191860|NCT02030210||registred nurses|
10191861|NCT02010593|Experimental|Dapivirine Vaginal Ring|Safety study of a vaginal ring containing Dapivirine in a postmenopausal female population
10191862|NCT02010593|Placebo Comparator|Placebo|The placebo VR is a flexible, platinum-catalyzed-cured matrix ring, identical to Dapivirine Ring-004, containing no active-drug
10191863|NCT01958593|Placebo Comparator|Comparator|Participants will receive placebo during each of two experimental sessions.
10191864|NCT01958593|Experimental|3,4-methylenedioxymethamphetamine|Participants will receive full-dose MDMA during each of two experimental sessions.
10191865|NCT01946074|Experimental|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
10191866|NCT01946074|Experimental|Cohort C|ABT-165 plus ABBV-181
10191867|NCT01946074|Experimental|Cohort B|ABT-165 plus FOLFIRI
10191868|NCT01946074|Experimental|Cohort A|ABT-165 plus paclitaxel
10191869|NCT01946074|Experimental|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
9827825|NCT02469714|No Intervention|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
9827826|NCT02469857|Experimental|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
9827827|NCT02469857|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, IV, single dose
10191870|NCT01934296|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
10191871|NCT01932125|Experimental|Cohort|
10191872|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
10191873|NCT01842035|Experimental|Regadenoson|"Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.~--------------------------------------------------------------------------------"
10191874|NCT01779388|Other|Bronchoscopy guided by fluoroscopy|Bronchoscopy guided by fluoroscopy followed by ENG
10191875|NCT01779388|Experimental|Bronchoscopy guided by electromagnetic navigation|Bronchoscopy guided by ENG followed by fluoroscopy
10191876|NCT01751984|Experimental|ETC-1002|ETC-1002 treatment, once daily oral
10191877|NCT01751984|Placebo Comparator|Placebo|Placebo treatment, once daily oral
10191878|NCT01732627|Experimental|Group 1: MenACYW Conjugate Vaccine|Adult participants aged greater than or equal to (≥) 56 years received a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine on Day 0.
10191879|NCT01732627|Active Comparator|Group 2: Menomune® A/C/Y/W 135 vaccine|Adult participants aged ≥56 years received a single dose of Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined (Menomune®) vaccine on Day 0.
10191880|NCT01702571|Experimental|Trastuzumab Emtansine (All Participants)|This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
10191881|NCT01702571|Experimental|Trastuzumab Emtansine (Asian Participants)|This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
10191882|NCT01581840|Experimental|5Fu-mitomycine-panitumumab + radiotherapy|5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10
10191883|NCT01578239|Experimental|177Lu-DOTA0-Tyr3-Octreotate|"30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died.~Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
10191884|NCT01578239|Active Comparator|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed."
10191885|NCT01564056|Other|Arm A: ENDOCRINE TREATMENT|HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
10191886|NCT01564056|Experimental|Arm B: CHEMOTHERAPY + ENDOCRINE TREATMENT|"HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).~CHEMOTHERAPY regimen will be chosen amongst the following ones:~TC (docetaxel + cyclophosphamide)~AC (doxorubicin + cyclophosphamide)~MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)"
10191887|NCT01556243|Experimental|Breast conservation surgery and radiation therapy|Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy.
10191888|NCT01458340|Experimental|TD-9855 Dose 1|
10191889|NCT01458340|Experimental|Placebo|
10191890|NCT01458340|Experimental|TD-9855 Dose 2|
10191891|NCT01411267|Experimental|ALL AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
10191892|NCT01411267|Experimental|AML AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
9704582|NCT04700332|Experimental|High risk prostate cancer|DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy
10191893|NCT01411267|Experimental|ALL AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
10191894|NCT01411267|Experimental|ALL AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
9979104|NCT01378260||Surgical Bypass|use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral, or popliteal artery
9704583|NCT04700332|Experimental|Biochemically recurrent prostate cancer|DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.
9704584|NCT04700306|Experimental|Sophrology|the patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology
9979105|NCT01378260||Endovascular Therapy|angioplasty and/or stent to treat lesions in the superficial femoral or popliteal artery
9979106|NCT01378260||Medical Management|"Documentation of the following in the medical record:~i. Walking/physical therapy to improve endurance was recommended; ii. For tobacco users, tobacco cessation was recommended; iii. Prescribing pentoxifylline (Trental) or cilostazol (pletal) iv. Ongoing care by physician for treatment of claudication"
9979107|NCT01378286|Experimental|artesunate/amodiaquine|"artesunate (AS) / amodiaquine (AQ) as fixed dose combination~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment"
9979108|NCT01378286|Active Comparator|chloroquine|150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment
10191895|NCT01411267|Experimental|ALL AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
10191896|NCT01411267|Experimental|ALL AC220 @ 130 mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
9979109|NCT01378312|Placebo Comparator|Placebo Arm|
9979110|NCT01378312|Active Comparator|AERAS 402 Arm|
10191897|NCT01411267|Experimental|AML AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
10191898|NCT01411267|Experimental|AML AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
10191899|NCT01411267|Experimental|AML AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
10191900|NCT01411267|Experimental|AML AC220 @ 130mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
10191901|NCT01357772|Experimental|Tamoxifen|tamoxifen at daily dose of 5 mg for a total treatment time of 3 years
10191902|NCT01357772|Placebo Comparator|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
9979111|NCT01378338||Typical reflux symptom by EGD|Total 2000 subjects who has Typical reflux symptom by EGD
9704585|NCT04700306|No Intervention|Control|the patient must make 7 visits with interviews and questionnaires
9704586|NCT04700293|Experimental|AYMES AMSTERDAM|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'AMSTERDAM' for a period of > 7 days.
9979112|NCT01378364|Experimental|AbGn-168H very low dose i.v.|subject to receive a single very low dose of AbGn-168H intravenously (i.v.) or placebo
9979113|NCT01378364|Experimental|AbGn-168H low dose i.v.|subject to receive a single low dose of AbGn-168H intravenously (i.v.) or placebo
9979114|NCT01378364|Experimental|AbGn-168H medium dose i.v.|subject to receive a single medium dose of AbGn-168H intravenously (i.v.) or placebo
9979115|NCT01378364|Experimental|AbGn-168H high dose i.v.|subject to receive a single high dose of AbGn-168H intravenously (i.v.) or placebo
10191903|NCT01336634|Experimental|Cohort A (Dabrafenib Monotherapy)|"Participants received Dabrafenib 150mg BID and continued treatment until disease progression, death, or unacceptable adverse event.~Participants receiving and adequately tolerating dabrafenib as a single agent and who continue to meet the inclusion and exclusion criteria had the option to switch to Dabrafenib (150 mg BID) and Trametinib (2 mg once daily) combination treatment within 4 weeks of radiologic disease progression with prior approval from a medical monitor."
10191904|NCT01336634|Experimental|Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E|Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.
10191905|NCT01336634|Experimental|Cohort C - Double Combination (Dabrafenib+Trametinib) naive mBRAF V600E|Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.
10191906|NCT01326832||Primoris|50 patients included in RSA cohort of total of 350 anticipated Primoris cases
9979116|NCT01378364|Experimental|AbGn-168H very low dose s.c.|subject to receive a single very low dose of AbGn-168H subcutaneously (s.c.) or placebo
9979117|NCT01378364|Experimental|AbGn-168H medium dose s.c.|subject to receive a single medium dose dose of AbGn-168H subcutaneously (s.c.) or placebo
9979118|NCT01378390|Experimental|ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million cells in case of incomplete fistula closure following week 12 assessment.
9979119|NCT01378390|Sham Comparator|Placebo|Instillation of saline solution into the fistulous tract, following identical tract preparation process as for the investigational treatment group.
9979120|NCT01378442|Experimental|high level training group|receive high frequency fitness training program(Frequency: three times a week, Duration: 40 minutes).
9979121|NCT01378442|Experimental|low level training group|will receive low frequency fitness training program(Frequency: 1-2 times a week, Duration: 40 minutes).
9704587|NCT04700397||Repeatability group 1|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 100 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
9704588|NCT04700397||Repeatability group 2|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 200 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
9979122|NCT01378442|No Intervention|control|No intervention, but maintain usual physical activities
9979123|NCT01378455|Experimental|ICHTP group|In ICHTP (interactive computerized handwriting training program) group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software
9979124|NCT01378455|Active Comparator|THTP group|The THTP (traditional handwriting training program)group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
9979125|NCT01378468||Patients with first ischemic stroke|
9979126|NCT01378481|Experimental|Treatment (vorinostat, surgery, FSRT)|Patients receive high-dose vorinostat PO at 48, 27, and 3 hours prior to surgery. Beginning 2-6 weeks later, patients receive vorinostat PO QD on days 1-3 in weeks 1-2and undergo fractionated stereotactic body radiation therapy on days 1-5 in weeks 1-2. Treatment continues in the absence of disease progression or unacceptable toxicity.
9979127|NCT01378494||HIV+|HIV+ patients that entered the 1917 Clinic at UAB as naive to ART
9979128|NCT01378507|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
9979129|NCT01378533|Experimental|AC-T（dose-dense）|AC-T(dose-dense) EPI（Pharmorubicin） CTX（cyclophosphamide） PTX（Paclitaxel） G-CSF
9979130|NCT01378533|Experimental|chemotherapy:PC|PTX（Paclitaxel） CBP（carboplatin）
9979131|NCT01378559||Penis prosthesis cohort|
10191907|NCT01323309||Individual Meaning-Centered Psychotherapy (IMCP)|
10191908|NCT01323309||standard Individual Supportive Psychotherapy (ISP)|
10191909|NCT01323309||enhanced usual care (EUC)|
10191910|NCT01312857|Experimental|Randomization to panitumumab|Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
10191911|NCT01312857|Experimental|Randomization to No Panitumumab|Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
10191912|NCT01155375|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
10191913|NCT01155375|Active Comparator|Oral Iron|Participants will receive oral iron 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
10191914|NCT00799058|Active Comparator|dapivirine gel 4789|will be applied by participants once daily for 12-weeks treatment period
10191915|NCT00799058|Active Comparator|dapivirine gel 4759|Will be applied by participants once daily for12-weeks treatment period
10191916|NCT00799058|Placebo Comparator|HEC-based placebo gel, 2.5g containing no Dapivirine|Will be applied once daily for 12-weeks treatment period
10191917|NCT00788684|Experimental|ABT-263 + rituximab|
10191918|NCT00785798|Experimental|vorinostat doxil|Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle
10191919|NCT00673010|Experimental|1|131 I-iodine (131-I), 124 I-iodine (124-I)
10191920|NCT00628095|Experimental|Active|
10191921|NCT00628095|Placebo Comparator|Placebo|
10191922|NCT00579709|Experimental|1|Thymus Tissue for Transplantation
10191923|NCT00579514|Active Comparator|1|"All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer cases and first primary controls."
10191924|NCT00579514|Placebo Comparator|2|Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.
9979132|NCT01378585|Experimental|Treatment 1|Test drug treatment: 3 x 490 mg DLBS1033 daily
10191925|NCT00566488|Experimental|Thymus and Parathyroid transplantation|Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants
10191926|NCT00490763||Active Surveillance|Patients with low-risk prostate cancer who choose to undergo active surveillance.
9704589|NCT04700397||Repeatability group 3|The patient with systolic blood pressure above 120 mmHg, who will receive a repeatability test with 200mcg, then another 300 mcg nitroglycerine injection, with a time interval of 3 minutes apart.
9979133|NCT01378585|Placebo Comparator|Treatment 2|Placebo treatment: 3 x 1 tablet daily
9704590|NCT04700397||pressure-recommended doses of NTG|The patient with systolic blood pressure above 100 mmHg, who will receive the nitroglycerine injection with the dose of recommendation, adjusted according to the blood pressure.
9979134|NCT01378611|Placebo Comparator|active control group|The active control group is stimulated with: Output current 0.25 milliampere, Pulse width 0.1 milliseconds, Frequency 1 Hz, Duty cycle: 14 sec on 60 min off (duty cycle <0.5%)
9979135|NCT01378611|Experimental|treatment group|The high stimulation group is stimulated with output current 0.25 milliampere, Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off in the treatment group the current was stepwise increased with two week intervals to the maximally tolerated output current (maximum 1.75 mA).
9979136|NCT01378624|Experimental|Bronchoscopy|
9979137|NCT01378637|Experimental|AMES Leg treatment|An investigational device flexes and extends the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the foot. The subject's task is to assist the motion of the device by pulling or pushing with the foot. Feedback of ankle torque or the electrical signal produced by the muscles (EMG) while the subject is assisting the motion is provided during the 30 treatment sessions.
9979138|NCT01378650|Experimental|Cilostazol group|Administration of Cilostazol 100mg twice a day for 4 weeks
9979139|NCT01378650|Placebo Comparator|Placebo group|placebo drug twice a day for 4 weeks.
9979140|NCT01378663||Post congenital cardiac surgery pain management|All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA.
9979141|NCT01378689|Experimental|Online video|Participants in this arm are shown a brief video (~5 minutes) after ordering a refill for their glucocorticoid use. The video includes real patients telling their own story about the possible side effects of prolonged use of glucocorticoids.
9979142|NCT01378689|No Intervention|No video|
9979143|NCT01378702|Experimental|Iscucin populi strength F, G and H|1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.
9979144|NCT01378702|Experimental|Viscum Mali e planta tota D3, D2, 2%|1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.
9979145|NCT01378702|Placebo Comparator|Placebo|1 ampoule two times a week subcutaneously
9979146|NCT01378715|Active Comparator|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
10191927|NCT00346125|Active Comparator|Preferred Standard Regimen|Subjects with soft tissue sarcoma who are receiving pegylated liposomal doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
10191928|NCT00346125|Active Comparator|Alternative Treatment Regimen|Subjects with soft tissue sarcoma who are receiving Doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
9704591|NCT04700319|Experimental|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T cell infusion on relapsed or refractory hematological malignancies of CD19 / CD20+ B cell line
9785126|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 90 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-2206 90 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
9979147|NCT01378715|No Intervention|Control|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to no-pretreatment with rosuvastatin.
9979148|NCT01378728||Patients with chronic or acute wounds.|Patients with chronic or acute wounds.
9979149|NCT01378741|Active Comparator|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
9979150|NCT01378741|Active Comparator|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
9979151|NCT01378754|Experimental|6.5 milligram per kilogram of Fospropofol (Lusedra®)|
9979152|NCT01378754|Experimental|10 milligram per kilogram of Fospropofol (Lusedra®)|
9979153|NCT01378754|Experimental|12 milligram per kilogram of Fospropofol (Lusedra®)|
9979154|NCT01378767|Active Comparator|Krill oil capsules|Two grams per day daily for 21 days
9979155|NCT01378767|Placebo Comparator|Coconut oil capsules|Two grams per day for 21 days
9979156|NCT01378780|Active Comparator|Intervention for diet, exercise|This group will receive the educational intervention for healthy diet and increased physical activity
9979157|NCT01378780|Other|Control|This group will get a skin cancer awareness educational message. At the end of the study this group will also receive the diet and exercise intervention but outcomes will not be measured after the crossover.
9984415|NCT04150497|Experimental|Dose Escalation|"Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART22 administered at the RP2D"
10191929|NCT04347603|Experimental|General Anesthesia|- General anesthesia : After pre-anesthetic preparation (25-50 mg Hydroxizine orally), the anesthesia induction will be performed by IV perfusion of Propofol 1 to 2 mg/kg, Sufentanyl for analgesia 0,2 to 0,4 µg/kg, curarisation with Atracurium 0,15 mg/kg. The anaethesia depth will be monitored by the bispectral index (BIS). Orotracheal intubation will be performed, the patient will be ventilated to controlled volume with 6-8 mL/kg of current volume based on expected body weight (PBW). The respiratory rate will be adjusted to have an ETCO2 between 35 and 45 mmHg. The anesthesia will be maintained through the Sevorane at 0.7-1 MAC, the average blood pressure will be controlled through a pressure cuff with a target between 60 and 80 mmHg. The Fio2 will be adapted to obtain saturation > 94% with 5 cmH2O PEEP.
10191930|NCT04347603|Active Comparator|Local Anesthesia|Local anesthesia at the device introduction site will be obtained by infiltration of Naropein.
10191931|NCT04340180|Experimental|Subjects with enhancing breast lesions|
10191932|NCT04339920||Chinese patients with clinical suspicious of prostate cancer|Chinese patients with clinical suspicious of prostate cancer, due to elevated serum PSA or abnormal digital rectal examination, will be recruited for the study from the Prince of Wales Hospital and North District Hospital.
10191933|NCT04338815|Experimental|Determine optimal assistance pattern|
10191934|NCT04338815|Experimental|Determine effects on endurance|
10191935|NCT04335669|Active Comparator|Arm A (Platinum-based dose dense EC):|Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
10191936|NCT04335669|Experimental|Arm B (Platinum-based with capecitabine):|Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
10191937|NCT04327999|Experimental|Preservative free artificial tears|Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
10191938|NCT04327687|Experimental|remote ischemic conditioning|remote ischemic conditioning is a physical strategy performed by an electric auto-control device with cuffs placed on bilateral arms: five cycles of 5-min inflation and 5-min deflation one or two times per day. The duration of the treatment is six months.
10191939|NCT04327687|Active Comparator|conventional therapy|conventional therapy
10191940|NCT04323189|Other|Crossover AB|Subjects in arm A will first receive placebo daily for 7 days in the first intervention followed by sitagliptin 100mg/d for 7 days in the crossover intervention.
10191941|NCT04323189|Other|Crossover BA|Subjects in arm B will first receive sitagliptin 100mg/d for 7 days in the first intervention followed by placebo for 7 days in the crossover intervention.
10191942|NCT04316130|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
10191943|NCT04316130|Active Comparator|Exercise using brochure|brochure
10191944|NCT04313153|Experimental|Vadadustat once daily|
10191945|NCT04313153|Experimental|Vadadustat three times weekly|
9979158|NCT01378793|No Intervention|Standard of Care|Participants will be asked to continue doing whatever their healthcare providers advise for their insomnia, but not to start any new treatments during the study. They will also be given a sleep hygiene handout as a standard of care. After six weeks, they will be reassessed and then provided the opportunity to engage in the web-based acupressure intervention.
10191946|NCT04313153|Active Comparator|Darbepoetin alfa|
10191947|NCT04304079|Experimental|ARssist system|The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist system used by the patient side surgeon.
10191948|NCT04297345|Experimental|hemodialysis group|"The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke.~The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers."
9984416|NCT04149704|Experimental|ACP video decision aid|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care~10 minute video decision aid: describing the goals-of-care options .~Follow telephone interview at 3 months"
10191949|NCT04297345|No Intervention|control group|The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.
10191950|NCT04282811||cohort group|Patients who have received at least one dose of venetoclax
10191951|NCT04279197|Experimental|FZHY Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~Fuzheng Huayu tablets"
10191952|NCT04279197|Placebo Comparator|Placebo Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~placebo"
10191953|NCT04278690|No Intervention|Usual Care|Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.
10191954|NCT04278690|Experimental|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.
10191955|NCT04278690|Experimental|HELPix+Tech|After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app
10191956|NCT04274426|Active Comparator|Control arm with Platinum-based chemotherapy|"Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d~Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 & d8) q21d~Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d"
9979159|NCT01378793|Active Comparator|Relaxation Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily.
9979160|NCT01378793|Active Comparator|Stimulating Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily.
9979161|NCT01378806|Experimental|Intervention|A 12-week intensive intervention on nutrition and exercise education and coping skills training (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
9979162|NCT01378845|Placebo Comparator|Prostavasin|
9979163|NCT01378845|Active Comparator|Prostavasin + Bosentan|
9979164|NCT01378871|Experimental|Anitbody Therapy|Treatment with Imtox-25 intravenously over 4 hours every other day for 4 doses. Hospital admission is required during this treatment.
9979165|NCT01378884|Experimental|Domeperidone|Patients to receive Domperidone for treatment of Gastroparesis
9979166|NCT01378910|Experimental|Change of 3rd drug to maraviroc|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
9979167|NCT01378923|Experimental|Values-based mindfulness group|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
9979168|NCT01378923|Other|Treatment as usual|has access to standard jail interventions and programs
10191957|NCT04274426|Experimental|Carboplatin + Mirvetuximab soravtansine (IMGN853)|Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.
10191958|NCT04268628||Participants with mCRPC|Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen [PSA] response).
10191959|NCT04247516|No Intervention|Standard Control Group|The standard control group (CG) will not have access to the self-regulatory (SR) intervention program.
9979169|NCT01378936|Experimental|MI plus IOC group intervention|
9979170|NCT01378936|Experimental|Motivational Interview only|
9979171|NCT01378949|Active Comparator|PsCB Group|Ultrasound-Guided Psoas Compartment Block will be used in patients for pain relief after THA
9979172|NCT01378949|Active Comparator|FICB Group|Ultrasound-Guided Fascia Iliaca Compartment Block will be used in patients for pain relief after THA
9979173|NCT01378949|Active Comparator|Patient-Controlled Analgesia|Patient-controlled analgesia will be used for pain relief after THA
9979174|NCT01379001|Experimental|Young|Young healthy controls, aged 21-35
9979175|NCT01379001|Experimental|Older|Older healthy controls, aged 65-80
9979176|NCT01379014|Experimental|Decision Aid Tool|Intervention group - receives the decision aid tool in booklet form and is introduced to it by an investigator.
9979177|NCT01379014|No Intervention|Control|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
9979178|NCT01379027|No Intervention|a treatment as usual (TAU) control condition|Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.
9979179|NCT01379027|Experimental|Pure self-help Internet CBT for depression|Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist
9979180|NCT01379027|Experimental|Guided self-help Internet CBT|Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists
9979181|NCT01379027|Experimental|Stepped-Care Internet CBT condition|This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on
9979182|NCT01379040||Cystic Fibrosis Patients|Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
9979183|NCT01379040||Control|Healthy volunteers
9979184|NCT01379053||Staphylococcus Patients|Patients suspected of having Methicillin-resistant and/or methicillin-susceptible staphylococcus aureus.
9979185|NCT01379053||Control|Healthy volunteer
9979186|NCT01379066||Tuberculosis Patients|Suspected Tuberculosis patients
9979187|NCT01379066||Control|Healthy volunteers
9979188|NCT01379079|Experimental|aspirin at bedtime|
9979189|NCT01379079|Active Comparator|aspirin on awakening|
9979190|NCT01379092|Experimental|Breast biopsy specimen imaging & comparison of image quality|Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
9979191|NCT01379105|Other|electromyography|The electrical activity of the femoral bicep muscle of the right thigh was recorded by a four channel EMG system with using superficial bipolar active electrodes (pre-amplified) with acquisition software and signal processing. The sampling frequency was 2,000 Hz, and the amplifier had a high-pass filter at 20 Hz and a low-pass filter at 500 Hz; a 12-bit analogical converter and computer completed the system
9979192|NCT01379131||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
9979193|NCT01379144|Experimental|latanoprost 75 ug|
9979194|NCT01379144|Experimental|latanoprost 100 ug|
10191960|NCT04247516|Experimental|Online-intervention group I (IGI)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration."
9979195|NCT01379144|Experimental|latanoprost 125 ug|
10191961|NCT04247516|Experimental|Online-intervention group II (IGII)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration; iii) the program includes gamification strategies with the purpose of promoting engagement in participants."
10191962|NCT04246346|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
10191963|NCT04246021|Experimental|Ferric carboxymaltose (ferrinject)|"Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.~Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion~If the needed Ferric carboxymaltose dose is > 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion"
10191964|NCT04245085|Active Comparator|Arm A|"Atezolizumab (1200 mg) Q3W, until PD~Bevacizumab (15 mg/kg), Q3W, until PD~Carboplatin (AUC5) Q3W, 4-6 cycles~Paclitaxel (175-200 mg/m2), Q3W, 4-6 cycles"
10191965|NCT04245085|Active Comparator|Arm B|"Atezolizumab (1200 mg), Q3W, until PD~Bevacizumab (15 mg/kg), Q3W, until PD~Pemetrexed (500 mg/m2), Q3W, until PD"
10191966|NCT04243070|Other|3-channel Holter ECG recording for EPS patient|Patients participating in an EPS will undergo a 3-channel Holter ECG recording in parallel to the standard 12-channel Holter ECG recording during the EPS followed by an optional 24 h observation period
10191967|NCT04243070|Other|12-channel Holter ECG recording for non-EPS patients|Patients scheduled for a follow-up for their heart disease will undergo a 12-channel Holter ECG recording while participating in a Body Motion test followed by a 24 h observation period
9979196|NCT01379144|Active Comparator|latanoprost 50 ug|
10191968|NCT04243044|Experimental|Intensity 1 (0.8x resting threshold, 30 minute duration)|Transcutaneous spinal stimulation will be applied continually at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
10191969|NCT04243044|Experimental|Intensity 2 (0.8x resting threshold, dual-site, 30 minute duration)|Transcutaneous spinal stimulation will be applied continually at 0.8x resting threshold at two sites as determined from baseline testing of posterior root muscle reflexes.
10191970|NCT04243044|Experimental|Intensity 3 (burst 0.8x rest threshold, 30 minute duration)|Transcutaneous spinal stimulation will be applied in bursts at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
10191971|NCT04243044|Experimental|Frequency 1 (30 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 30 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
9979197|NCT01379157|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days
9979198|NCT01379157|Experimental|Extended infusion arm|Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days
9979199|NCT01379170|Experimental|Type 2 diabetes, de novo hypothyrodism treatment|Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
9979200|NCT01379196|Experimental|Azithromycin PO three times weekly|Tablets Azithromycin 500 mg PO three times weekly for three months
9979201|NCT01379235|Experimental|Intervention group|Intervention group: will receive 12 weeks of pilatis exercise 3 times a week.
9979202|NCT01379235|Other|control group|The control group will be offered the same intervention (pilatis exercise) at the end of the study period.
10191972|NCT04243044|Experimental|Frequency 2 (50 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 50 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
10191973|NCT04243044|Experimental|Frequency 3 (80 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 80 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
9979203|NCT01379248|Experimental|thrombus aspiration|Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA)
9979204|NCT01379248|No Intervention|no thrombus aspiration|
9979205|NCT01379261|Active Comparator|Hypothermia treatment|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
9979206|NCT01379261|No Intervention|Standard treatment|Standard treatment
9979207|NCT01379287|Experimental|Patients with Advanced Solid Tumors|The trial was initially designed as a 3 hour IV infusion of iso-fludelone every 3 weeks with three dose-escalation stages (12 patients), however it has been amended to study iso-fludelone administered over 6 hours (+/- 30 minutes) every 3 weeks schedule.
9979208|NCT01379300|Experimental|Dabigatran|Single 150-mg dose of dabigatran etexilate
9979209|NCT01379300|Experimental|Rivaroxaban|Single 20-mg dose of rivaroxaban
9979210|NCT01379300|No Intervention|No intervention|No study drug will be administered
9979211|NCT01379313|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
9979212|NCT01379313|Experimental|1:1 group|1:1 I:E ratio group, inspiratory time : expiratory time = 1:1
9979213|NCT01379313|Experimental|2:1 group|inverse ratio group, inspiratory time : expiratory time = 2:1
9979214|NCT01379313|Active Comparator|1:2 PEEP group|I:E ratio of 1:2 with external PEEP of 5 cm H2O
9979215|NCT01379326|Experimental|Mebendazole|
9979216|NCT01379339|Experimental|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
9979217|NCT01379339|Experimental|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
9979218|NCT01379339|Experimental|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
9979219|NCT01379339|Experimental|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
9984417|NCT04149704|Active Comparator|Standard Care|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care~Receive the verbal description of the three types of care~Follow telephone interview at 3 months"
9984418|NCT04148937|Experimental|Cohort A LY3475070|LY3475070 administered orally.
10191974|NCT04239573|Experimental|Arm I (low intensity surveillance)|Patients undergo MRI or CT at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
10191975|NCT04239573|Experimental|Arm II (high intensity surveillance)|Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst > 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
10191976|NCT04239274|Experimental|Transcranial Direct Current Stimulation (tDCS)|
10191977|NCT04239274|Experimental|Transcranial Pulsed Stimulation tPCS|
10191978|NCT04239274|Sham Comparator|No Stimulation|
10191979|NCT04235855|Experimental|Endoscopic USG guided Liver biopsy|Olympus linear echo endoscope (GF -UCT 180, Olympus Ltde, Tkyo, Japan) will be used. 19 Gz EUS Acquire needle Boston ©Scientific Corp will be used for liver tissue acquisition.
10191980|NCT04235855|Active Comparator|Percutaneous Liver biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
10191981|NCT04235335|Other|Wait List Control|Participants receive intervention after 12 week delay
10191982|NCT04234945|Experimental|study|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7.
10191983|NCT04234945|Placebo Comparator|control|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7
10191984|NCT04232540|Experimental|Patients with undetectable viral load for at least 2 years|Patient and provider will view and discuss results of the MedViewer test.
10191985|NCT04232540|Experimental|Patients with detectable viral load once in past 2 years|Patient and provider will view and discuss results of the MedViewer test.
10191986|NCT04229901|Experimental|HepaStem|Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 millions of cells/kg (7 day interval)
10191987|NCT04229901|Placebo Comparator|Placebo|Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)
9704592|NCT04700384|No Intervention|Control Group|"Control Group - Baseline Training~25 Participants allocated. Individuals receive introductory information on using the simulator and the scenario. They perform 5 simple subpial tumour resections for practice and have 5 minutes per trial. After each attempt, the student takes a 5-minute break with no assessment or feedback on their performance. On their 6th attempt they have 13 minutes to perform a different realistic scenario."
9704593|NCT04700384|Experimental|Experimental Group - Virtual Operative Assistance Training|"Experimental Group - Virtual Operative Assistance Training~25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistance Training assessment of their performance and audiovisual feedback."
9704594|NCT04700384|Experimental|Experimental Group - remote-based expert Instructor Training|25 participants allocated. Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
9704595|NCT04700033|Experimental|Somatic IVR|Participants with participate in Somatic IVR protocol three times per week for four weeks.
9704596|NCT04700033|Active Comparator|Distractive IVR|Participants with participate in Distractive IVR protocol three times per week for four weeks.
10191988|NCT04222205|Active Comparator|Crossover sequence 1|"Cluster-randomization crossover sequence 1:~T-piece during odd-numbered months and inspiratory pressure augmentation during even-numbered months."
10191989|NCT04222205|Experimental|Crossover sequence 2|"Cluster-randomization crossover sequence 2:~T-piece during even-numbered months and inspiratory pressure augmentation during odd-numbered months."
10191990|NCT04221269|Active Comparator|Enhanced Treatment as Usual|Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
9704597|NCT04700033|Placebo Comparator|Control IVR|Participants with participate in Control IVR protocol three times per week for four weeks.
9704598|NCT04700241|Active Comparator|Potassium nitrate|During this experimental day, men will receive 10 mmol of potassium nitrate
10191991|NCT04221269|Experimental|Coping Long-term with Active Suicide Program for Schizophrenia|Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
10191992|NCT04220840||Study Group|All consecutive patients who underwent damage control surgery (DCS) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers
9704599|NCT04700241|Placebo Comparator|Placebo|During this experimental day, men will receive an isomolar dose of potassium chloride
9704600|NCT04699994|Experimental|FLOT therapy|
9979220|NCT01379339|Experimental|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
9979221|NCT01379352||High MELD group|Preoperative MELD score greater than 20
9979222|NCT01379352||Low MELD group|Preoperative MELD score lesser than 20
9979223|NCT01379365|Experimental|Treatment|
9979224|NCT01379391|Active Comparator|TPO|Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.
9979225|NCT01379391|No Intervention|TPO-Free Arm|No TPO intervention
10191993|NCT04220840||Control group|All consecutive patients who underwent other than DCS surgery (resection with primary anastomosis, Hartmann´s procedure, laparoscopic lavage) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers which do not apply DCS routinely.
9979226|NCT01379417|Placebo Comparator|Maltodextrin|Maltodextrin
9979227|NCT01379417|Active Comparator|Probiotic B lactis/B longum|Bifidobacterium lactis + Bifidobacterium longum
10191994|NCT04209543|Experimental|Estetrol 15 mg -Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
10191995|NCT04209543|Experimental|Estetrol 20 mg -Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
9704601|NCT04700046|Active Comparator|Mexiletine|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg)
9704602|NCT04700046|Placebo Comparator|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
9704603|NCT04699981|Experimental|Control: Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteria and not subjected to antibiotic pressure
9704604|NCT04699981|Experimental|Case: Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure|Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.
9704605|NCT04699929|Experimental|Intervention/treatment|All subject will receive YH001 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
9704606|NCT04699825|Active Comparator|study group|new-born infants born from preeclampsia mother
9704607|NCT04699825|Other|control group|new-born infants born from mothers with normal pregnancy matched with the same gestational age, sex and race
9785127|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 135 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 135 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
9979228|NCT01379417|Active Comparator|Probiotic B longum|Bifidobacterium longum
9979229|NCT01379417|Active Comparator|Probiotic B lactis|Bifidobacterium lactis
9979230|NCT01379430|Experimental|Group 1|Intramuscular arm
9979231|NCT01379430|Experimental|Group 2|Intradermal arm
9979232|NCT01379443|Active Comparator|Parental reports of their children|Parental report of family-centered processes of care (MPOC) Parent mental health Parent perceived social support
9979233|NCT01379443|No Intervention|Integration of service provider teams|Network co-alition teams were measured using the Integration of Human Services Measure, the Partnership Synergy Measure and a Network Capacity Measure were employed at the CEO level.
9979234|NCT01379456|Experimental|physiotherapy|exercises
9979235|NCT01379456|No Intervention|conventional treatment|care as usual
9984419|NCT04148937|Experimental|Cohort B LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered intravenously (IV).
9979236|NCT01379482|Experimental|Multimodal treatment|Neoadjuvant systemic chemotherapy followed by cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
9979237|NCT01379495|No Intervention|Usual Care|Burns victims will receive information according to the service routine
9979238|NCT01379495|Experimental|educational program+telephone follow up|Burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
9979239|NCT01379547|Active Comparator|Conventional Treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice
9979240|NCT01379547|Experimental|procalcitonin-guided antibiotics treatment|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.
9979241|NCT01379560|Experimental|unoprostone isopropyl (2 drop)|
9979242|NCT01379560|Experimental|unoprostone isopropyl (3 drop)|
9979243|NCT01379586|Experimental|E|ONO-4053
9979244|NCT01379586|Placebo Comparator|P|Placebo
9979245|NCT01379599|Experimental|Brief motivation intervention|Brief motivation intervention was implemented with enrollees identified with heroin and cocaine use who were allocated to the experimental group. The aim was to test the ability of a peer-delivered intervention to reduce risk of HIV and STIs related to sexual behaviors (condom use and sex while high on drugs.
9979246|NCT01379599|No Intervention|control group|Care as usual.
10191996|NCT04209543|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
10191997|NCT04209543|Experimental|Estetrol 20 mg + P4 100 mg - Safety Part|Estetrol (E4) 20 mg and Progesterone (P4) 100 mg will be administered once daily for up to 53 weeks
9704608|NCT04699643|Experimental|EVER4010001 combination with Pembrolizumab|EVER4010001 combination with Pembrolizumab, EVER4010001 started dose escalation from 40mg bid, and then to 60mg bid, 80mg bid, 100mg bid and 120 mg bid if applicable, dose escalation decision will be made by safety monitoring committee which is composed of the study team members. After phase II dose was recommended by safety monitoring committee, this dose will be applied to phase II patients. Pembrolizumab will be administered at 200mg every 3 weeks through the study.
9704609|NCT04699916|No Intervention|Control (Usual care)|Sedation will be guided with a standard protocol based on Sedation Agitation Scale already implemented in the Intensive Care Unit
9704610|NCT04699916|Experimental|EEG-based sedation protocol|Sedation will be guided using a protocol based on 2 parameters from the EEG: Suppression Rate and Spectral Edge Frequency
9704611|NCT04699747|Experimental|Multiple sclerosis|F-18 3F4AP PET Scan
10191998|NCT04203134|Experimental|Treatment Group|Patients in the randomly assigned treatment group will receive a mouthguard at first visit along with standard treatment of BMS.
10191999|NCT04203134|No Intervention|Control Group|Control group will proceed through treatment for BMS in an otherwise standard treatment protocol and will not receive a mouthguard.
10192000|NCT04192370|Experimental|Cannabidiol|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.
9704612|NCT04699747|Active Comparator|Healthy controls|F-18 3F4AP PET Scan
9704613|NCT04699903||Positive SARS-Cov-2 cohort|Positive diagnosis of COVID-19 confirmed by a positive EUA SARS-CoV-2 PCR will be stratified in three subgroups 0 - 7 days since onset of symptoms 8 - 14 days since onset of symptoms 15 -90 days since onset of symptoms
9704614|NCT04699903||Negative SARS-Cov-2 cohort|Negative diagnosis of COVID-19 confirmed by a negative, EUA SARS-CoV-2 PCR test within 0-7 days of PCR sample collection will be included in the negative cohort.
10192001|NCT04188509|Experimental|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a stick pack formulation (powder blend formulation packaged as stick packs). Participants aged ≥ 12 years and/or ≥ 40 kgs will receive a voxelotor dose of 1500 mg QD. Participants aged < 12 years and < 40 kgs will receive weight based dosing of voxelotor. The participant's weight at study entry will be used to determine the starting voxelotor dose in this study. Participants may receive study drug as long they continue to receive clinical benefit that outweighs risk as determined by the investigator and/or until the participant has access to voxelotor from an alternative source.
10192002|NCT04188028|Experimental|CYP2D6 gene score 0|CYP2D6 gene score 0: carrier of two non-functional alleles
10192003|NCT04188028|Experimental|CYP2D6 gene score ≥1|CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles
10192004|NCT04183218||Observational (cardiac monitoring)|Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
9704615|NCT04699734|Active Comparator|Xylocaine|Nerve block
9704616|NCT04699734|Placebo Comparator|Isotonic saline|Nerve block
9704617|NCT04699955|No Intervention|Assessment only Control|Participants received no intervention content. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments were delivered via an online survey.
9979247|NCT01379612||Rectal cancer patients in chemoradiation|
9979248|NCT01379638||cardiac output|Adult patients undergoing cardiac surgery with normothermic cardiopulmonary bypass
9979249|NCT01379677|Other|Single arm|This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.
9979250|NCT01379690||Control|Controls were selected from patients with diabetes on consultation during the year 2005-2010 in specialist clinic, without a previous hip fracture. There was no followup period for these patients. Instead the A1C value upon the point of consultation was used to reflect glycaemic control at the point of consultation
9979251|NCT01379690||Case|All patients with treated diabetes admitted with primary diagnosis hip fractures from 2005-2010 to Changi General Hospital was included in the study. The A1C at the point of admission was used to reflect the glycaemic control at that point in time. This was a retrospective study and there was no subsequent follow up on patients after the point of admission
10192005|NCT04179591|Experimental|Exercise|Exercises will be performed three times per week for six weeks.
10192006|NCT04179591|Experimental|Insole|Customized arch support insoles will be worn for six weeks.
10192007|NCT04179591|Experimental|Exercise plus Insole|Exercises will be performed three times per week, and customized arch support will be worn for six weeks.
10192008|NCT04168502|Experimental|Experimental arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~Maintenance with glasdegib 100 mg daily for one year or until toxicity/relapse"
10192009|NCT04168502|Active Comparator|Standard arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~clinical observation"
9979252|NCT01379729|Active Comparator|Group A|Patients with loss of long-term function after intraportal implantation
9979253|NCT01379729|Active Comparator|Group B|Patients that are candidates for islet cell transplantation
9979254|NCT01379742|Active Comparator|Iodine-125 standard 18 g needle|Rapidstrand
9979255|NCT01379742|Active Comparator|20 g needle|Thin Strand
9984420|NCT04148937|Experimental|Cohort C1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
9984421|NCT04148937|Experimental|Cohort C2 LY3475070|LY3475070 administered orally.
9984422|NCT04148937|Experimental|Cohort D1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
9984423|NCT04148937|Experimental|Cohort D2 LY3475070|LY3475070 administered orally.
9984424|NCT04148937|Experimental|Cohort E LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
9984425|NCT04144283|Experimental|NAP|The NAP group will undergo a post-learning 2-hour sleep opportunity in Experiment 1.
9984426|NCT04144283|Active Comparator|WAKE|The WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness in Experiment 1.
10192010|NCT04159740||Endometriosis - Cases|Premenopausal women with suspected endometriosis, planning to undergo laparoscopic surgery.
10192011|NCT04159740||Controls|Premenopausal women without endometriosis, planning to undergo laparoscopic surgery for non-cancer indications including elective salpingectomy, tubal ligation or surgical procedures for abnormal uterine bleeding
10192012|NCT04154800|Experimental|Part A:SAD|Single Ascending Dose
10192013|NCT04154800|Experimental|Part B: MAD|Multiple Ascending Dose
10192014|NCT04154800|Experimental|Part C: DDI|Drug-Drug Interaction
10192015|NCT04154800|Experimental|Part A (SAD) Placebo|
10192016|NCT04154800|Experimental|Part B (MAD) Placebo|
9984427|NCT04139993|Experimental|Treatment (RBX7455)|Prior to standard of care surgery, patients receive RBX7455 orally (PO) 4 days a week for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
9984428|NCT04131959|Experimental|Pharmacodynamic population|Single arm
9984429|NCT04129229|Experimental|LTR Treatment|Eligible subjects will undergo insertion of the LTR device in their tongue. Initiation of treatment will occur 7 days post insertion procedure and will be monitored over the course of 1 year.
9984430|NCT04128956|Experimental|Aspirin®|"To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy.~To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term treatment."
10192017|NCT04146441|Experimental|SonoVue|SonoVue + chemotherapy
10192018|NCT04146441|Active Comparator|control|chemotherapy
10192019|NCT04137692|Experimental|Red Blood Cell Transfusion|Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.
10192020|NCT04135300|Experimental|Arm of BBM-H901|Subjects will be dosed with single dose of BBM-H901 at 5x10·12 vg/kg via intravenous infusion.
10192021|NCT04130191||Participants with hereditary angioedema (HAE)|Participants who initiate treatment with lanadelumab according to current product labelling will be enrolled and followed for up to 24 or 36 months (depending on their enrollment date).
9984431|NCT04128956|No Intervention|Control group|Observational study of standard of care anticoagulation (rivarobaban dosis defined in the clinical routine).
9984432|NCT04125368|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities and in the community
9984433|NCT04125368|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities and in the community
9984434|NCT04125316||Asthma|Asthma patients
9984435|NCT04121559|Experimental|Intervention|A&T intervention areas: adolescent-nutrition-focused behavior change interventions delivered through government primary schools and communities
9984436|NCT04121559|No Intervention|Control|Comparison areas: standard activities at government primary schools
9984437|NCT04119544|Active Comparator|Conventional Rehabilitation|at least 4 sessions/week for 6 weeks, from 1 hour of conventional upper limb rehabilitation by an occupational therapist.
9984438|NCT04119544|Experimental|Intensive Visual Simulation|at least 4 sessions/week for 6 weeks, of 1 hour of upper limb rehabilitation including 45 minutes of conventional rehabilitation (occupational therapy) and 15 minutes of work with a medical device allowing intensive visual digital simulation.
9984439|NCT04115345|Experimental|Renal Autologous Cell Therapy (REACT®)|The dose of Renal Autologous Cell Therapy (REACT®) for subjects in the Phase 1 clinical trials (TNG-CL010 and TNG-CL011) was 3 x 106 SRC /g estimated kidney weight. The present trial does a similar dosage. The volume of REACT® to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula.
10192022|NCT04127968|Experimental|intervention group|Septic children with vitamin A deficiency who will receive vitamin A supplementation.
9979256|NCT01379807|Experimental|panitumumab + docetaxel + cisplatino|
9979257|NCT01379833||Subjects|Subjects are patients with CIDP
9979258|NCT01379833||Controls|Controls are age-matched people without CIDP
9979259|NCT01379846|Experimental|TAK-816|
9979260|NCT01379846|Active Comparator|ActHIB|
9979261|NCT01379872||Study Protocol A - IMRT Post Prostatectomy|"Prospective TROG 08.03 (RAVES) Participants~Prospective Participants (NOT participating in TROG 08.03 (RAVES))~Retrospective TROG 08.03 (RAVES) Participants~Participating in dosimetric evaluation and toxicity/QoL study~Participating in dosimetric evaluation only"
10192023|NCT04127968|Placebo Comparator|control group|Septic children with vitamin A deficiency who will receive placebo.
10192024|NCT04112693|Experimental|Esophageal biopsies during POEM|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020.~The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse."
9979262|NCT01379872||Study Protocol B - IMRT Anal Cancer|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)"
9979263|NCT01379872||Study Protocol C - IMRT Nasopharynx|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)~Post-Treatment Prospective Participants (toxicity/QoL and cost study)"
10192025|NCT04112602||Patients with MPS|In this cohort are included patients under 18 years old with MPS (all types). The objective is to be representative of the diversity of MPS, and of this evolution.
10192026|NCT04112602||Non-MPS patients|In this control group are included patients under 18 years old, with no respiratory problems, no MPS.
10192027|NCT04098497|Experimental|ACT-based microintervention delivered by mobile app|"At every time-point of the study, participants will complete self-reports of mania (as measured by the shortened YMRS), depression (as measured by the shortened SIGH-D ), medication adherence, and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
9704618|NCT04699955|Experimental|Positive Message Condition|Participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
9704619|NCT04699955|Experimental|Negative Message Condition|Participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. They provided assessments of past week protective strategy use, alcohol use, and alcohol problems. All assessments and messaging was delivered via an online survey.
9979264|NCT01379872||Study Protocol D - IGRT Intact Prostate|"Patients with prostate cancer~- A sample of 30 patients from at least 10 centres that are to be treated for intermediate risk prostate cancer will be enrolled. The sample will be selected to comprise at least 10 patients that will undergo non-IGRT, 10 that will undergo IGRT with fiducials and planar imaging, and 10 that will undergo IGRT with volumetric imaging."
9979265|NCT01379885|Active Comparator|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
9979266|NCT01379885|Experimental|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
9979267|NCT01379898|Active Comparator|Phenoxybezamine|Phenoxybenzamine (capsules 10 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
9979268|NCT01379898|Active Comparator|Doxazosin|Phenoxybenzamine (slow release tablets 4 or 8 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
9979269|NCT01379911|Active Comparator|Yogurt with added inulin|Yogurt with 6g of added inulin
9979270|NCT01379911|Placebo Comparator|Regular yogurt|Regular yogurt without added inulin
9979271|NCT01379950||periodontitis|patients diagnosed with periodontal disease
9704620|NCT04699851|Experimental|Intervention|The intervention arm are participants who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey.
9979272|NCT01379976|Placebo Comparator|CHT cisplatin containing + placebo|
9979273|NCT01379976|Experimental|CHT cisplatin containing + acetyl-L-carnitina|
9979274|NCT01380015|Placebo Comparator|Placebo Control|Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
9979275|NCT01380015|Experimental|Experimental|Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
9979276|NCT01380054||patients with pulmonary hypertension|
9979277|NCT01380067||Group A|the patients were subjected laparoscopic purse-string knot for closing the internal hernia opening
9979278|NCT01380067||Group B|the lateral umbilicus ligament was used to cover the internal hernia opening after the laparoscopic purse-string knot
10192028|NCT04097184|Active Comparator|"active tDCS group"|Patients will benefit from a series of 10 double-blind effective tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
9979279|NCT01380119|Experimental|V7|Oral pill containing heat-killed Mycobacterium vaccae
9979280|NCT01380119|Placebo Comparator|Placebo pill|Identically appearing placebo pills
9979281|NCT01380132|Experimental|Anal injection of Nasha Dx|
9979282|NCT01380158|Experimental|Pessary use during pregnancy|Device: Cup pessary
9979283|NCT01380158|No Intervention|Expectant management|Expectant Management + weekly intramuscular progesterone injections
9979284|NCT01380171||Cleft lip/palate|Patients who have had surgical intervention for cleft lip/palate since 1998 at Children's Healthcare of Atlanta at the Center for Craniofacial Disorders
10192029|NCT04097184|Sham Comparator|"sham tDCS group"|Patients will benefit from a series of 10 double-blind placebo tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
10192030|NCT04095078|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
10192031|NCT04095078|No Intervention|Control|Usual care
10192032|NCT04094792|Experimental|Intervention|For the intervention group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later). Intervention group subjects will use the Breather app twice daily, five minutes each time, for a period of 21 days.
10192033|NCT04094792|No Intervention|Control|For the control group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later).
10192034|NCT04089969|Experimental|Evaluation of Standard of care followed by CTA/FFRct|Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct
10192035|NCT04088136|Experimental|Everyday Metacognitive Memory|Training in techniques for managing memory demands in everyday life
9979285|NCT01380223|Experimental|Dose-escalation Cohort 1|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
9979286|NCT01380223|Experimental|Dose-escalation Cohort 2|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
9979287|NCT01380223|Experimental|Dose-escalation Cohort 3|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
9979288|NCT01380223|Experimental|Dose-escalation Cohort 4|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
9979289|NCT01380249|Experimental|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12 mg, 2.24 mg, 3.5 mg and 14 mg, 28 mg and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or the patient is refractory to it.
9979290|NCT01380262||Low Dose Doxycycline|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of doxycycline daily
9979291|NCT01380275|Experimental|Docetaxel and Irinotecan (DI)|"Combination chemotherapy of Docetaxel and Irinotecan (DI) in recurrent or refractory bone and soft tissue sarcomas.~Docetaxel and Irinotecan (DI) have different biologic targets, mode of action and mechanism of resistance. Preclinical studies have demonstrated an additive or synergistic effect of irinotecan and taxanes when used in combination in human.~Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1 Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8 Therapy consists of 3-week cycles comprising weekly treatment for 2 weeks (docetaxel on D1 and irinotecan on D1 and D8) followed by 1-week rest, and will be continued in the absence of disease progression or unacceptable toxicity."
9979292|NCT01380288|Active Comparator|without white matter change|
9979293|NCT01380288|Active Comparator|with white matter change group|
9979294|NCT01380301|Experimental|Miltefosine and Antimony|Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
9979295|NCT01380301|Active Comparator|Miltefosine alone|Miltefosine 1,5 to 2,5 mg x kg x d during 14 days
9979296|NCT01380314|Experimental|1|Miltefosine 150 mg x day + Imiquimod 5%
9979297|NCT01380314|Placebo Comparator|2|Miltefosine 150 mg x day + Placebo
10192036|NCT04088136|Active Comparator|Memory Strategy Control|Trains the use of memory strategies for learning new associations and concepts
10192037|NCT04071626|Experimental|Ertugliflozin Treatment Arm|Ertugliflozin 5 mg tablet once a day for 12 weeks
10192038|NCT04071626|Placebo Comparator|Placebo|Placebo tablet once a day for 12 weeks
10192039|NCT04057339|Placebo Comparator|SOC (Standard of Care)|Everyone in this arm will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
10192040|NCT04057339|Experimental|TRE + SOC|Everyone in this arm will receive standard of care nutritional behavioral counseling and will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
10192041|NCT04056962|Experimental|patients treated with Tacrolimus ointment|
10192042|NCT04051268|Experimental|Vi-DT TCV Batch 1|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1
9979298|NCT01380340|Experimental|Seniors early intervention driving group|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
10192043|NCT04051268|Experimental|Vi-DT TCV Batch 2|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2
10192044|NCT04051268|Experimental|Vi-DT TCV Batch 3|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3
10192045|NCT04051268|Active Comparator|PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)|1 dose of 0.5 ml of PQed TCV Vaccine
10192046|NCT04051268|Active Comparator|Vi Polysaccharide Vaccine (subjects 46-60 years old)|1 dose of 0.5 ml of Vi Polysaccharide Vaccine
10192047|NCT04047303|Experimental|Administration of CC-90010|During the preoperative period, all subjects will be given a course of orally administrated CC-90010 at 30 mg once daily for 4 consecutive days on Cycle 1 Day 1 to Day 4. The last CC-90010 dose (Day 4) will be administrated 6-24 hours prior to brain tumor resection. Following recovery from surgery and a minimum of 4 weeks from the first CC-90010 dose (Cycle 1 Day 1), subjects who are fit to continue study treatment my restart CC-90010 on Day 1 of Cycle 2 at 45 mg given orally once daily for 4 consecutive days followed by 24 consecutive days off (4 days on/24 days off), in each 28 day cycle.
9979299|NCT01380340|No Intervention|Matched comparison group|The subjects will be recruited from a parallel service and will be paired with similar subjects in the experimental group.
9979300|NCT01380353|Experimental|Breast Group|Diclofenac epolamine patch applied to the breast
9979301|NCT01380353|Experimental|Abdomen Group|Diclofenac epolamine patch applied to the abdomen
9979302|NCT01380405|No Intervention|without health education|the normal practices without specific intervention
10192048|NCT04045223||Epidural analgesia and fever|Group 1 will be patients with vaginal delivery and having an epidural analgesia that develop fever during delivery.
9979303|NCT01380405|Experimental|individual health education|"The study intervention is an individual education in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. The lesson included inhalation devices, explanatory leaflets"
9979304|NCT01380405|Experimental|health education group|"The study intervention is education in group in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. In addition to the necessary furniture and teaching material that will be required (slide projector, over-head-projector, projection screen, video, etc.), the physical space given over to this purpose should consist of an area in which material can be left which will be used to complete the teaching and patient information (inhalation devices, explanatory leaflets, small monographs, slides, etc.)."
9979305|NCT01380418||Study group|Obese BMI>30 18-85 years old
10192049|NCT04045223||Epidural analgesia and no fever|Group 2 will be patients with vaginal delivery and having an epidural analgesia that do not develop fever during delivery.
9979306|NCT01380431|Experimental|A|Subjects received the Par formulated product.
9979307|NCT01380431|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
9979308|NCT01380431|Active Comparator|C|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
9979309|NCT01380444|Active Comparator|1|Gamma3 Intramedullary Nails
9979310|NCT01380444|Active Comparator|2|Sliding Hip Screws
10192050|NCT04045223||No epidural analgesia|Group 3 serves as additional control group and consists of patients having no epidural analgesia and no fever.
10192051|NCT04038515|Experimental|E-liquid Order 'A'|Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
10192052|NCT04038515|Experimental|E-liquid Order 'B'|Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
9979311|NCT01380457|Experimental|A|Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions
9979312|NCT01380457|Active Comparator|B|Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.
9979313|NCT01380470||Chronic Obstructive Pulmonary Disease|Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.
9979314|NCT01380483|Experimental|A|Subjects received the Par formulated product
9979315|NCT01380483|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals formulated product.
9979316|NCT01380496|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
9979317|NCT01380496|Active Comparator|C|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
9979318|NCT01380496|Experimental|A|Subjects received the Par formulated product
9979319|NCT01380509|Experimental|A|Subjects received kali product under fasting conditions
9979320|NCT01380509|Active Comparator|B|Subjects received Searle product under fasting conditions
9979321|NCT01380522|Experimental|A|Subjects received kali product under fed conditions
9704621|NCT04699851|Active Comparator|Control|The control group will receive general recommendations about health prevention in a pandemic.
10192053|NCT04038515|Experimental|E-liquid Order 'C'|One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
9979322|NCT01380522|Active Comparator|B|Subjects received Searle product under fed conditions
9979323|NCT01380548|Placebo Comparator|Placebo|
10192054|NCT04038515|Experimental|E-liquid Order 'D'|One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
9979324|NCT01380548|Placebo Comparator|Iron alone|
9979325|NCT01380548|Experimental|Low-dose 5-aminolevulinic acid|
9979326|NCT01380548|Experimental|Medium-dose 5-aminolevulinic acid|
9704622|NCT04699968|Experimental|Treatment group A|
9979327|NCT01380548|Experimental|High-dose 5-aminolevulinic acid|
9979328|NCT01380561|Experimental|Single Arm Study|asimadoline
10192055|NCT04031508|Experimental|Omega 3|The experimental group will receive a parenteral emulsion containing soy oil, MCT, olive oil and n-3 LCPUFA in fish oil
10192056|NCT04031508|Sham Comparator|Control group|The Control group will receive a parenteral emulsion containing soy oil and MCT
9979329|NCT01380587||Acute Lymphoblastic Leukemia|We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
9979330|NCT01380600|Other|single arm; Dose escalation|Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
9979331|NCT01380613|Active Comparator|Workshop Control|Participants receive HIV/STDs risk reduction information.
9979332|NCT01380613|Experimental|Intervention Workshop|Participants learn skills to cope with depressive symptoms and stress as well as safer sex and injection skills.
10192057|NCT04024631|Other|Phenotyping|"All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.~They will also undergo a whole body DXA (intervention) during the study day."
10192058|NCT04017832|Experimental|Oral semaglutide 3 mg and placebo (sitagliptin)|Oral semaglutide tablets 3 mg and sitagliptin placebo tablets for 26 weeks
9979333|NCT01380626|Experimental|exercise training|
9979334|NCT01380652|Experimental|rehabilitation with vibration training|
9979335|NCT01380652|No Intervention|rehabilitation without vibration training|
9979336|NCT01380665|Other|There is one group of 100 patients|50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;
9979337|NCT01380678|Active Comparator|bevacizumab|intralesional bevacizumab injection
10192059|NCT04017832|Experimental|Oral semaglutide 7 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 4 weeks, after which the target dose of 7 mg is taken for 22 weeks
10192060|NCT04017832|Experimental|Oral semaglutide 14 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 8 weeks, after which the target dose of 14 mg is taken for 18 weeks
9704623|NCT04699968|Experimental|Treatment group B|
9979338|NCT01380678|Active Comparator|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
9979339|NCT01380704|Experimental|Active|
9979340|NCT01380704|Placebo Comparator|Placebo|
9979341|NCT01380717|Active Comparator|Standard treatment|Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
9979342|NCT01380717|Active Comparator|Intensive vasodilation|Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
9979343|NCT01380756|Experimental|Arm 1- Dose Escalation|The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
9979344|NCT01380756|Experimental|Arm 2- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
9979345|NCT01380795|Other|Circulating Tumor Cell|blood sample CTC monitoring and CTC EGFR/K-ras status determination
9979346|NCT01380808|Experimental|experimental arm|capecitabine and pseudomonas aeruginosa combination
9979347|NCT01380821||SPECT|Patients clinically indicated to undergo myocardial SPECT in our institution.
9979348|NCT01380847||Renal allograft nephropathy|To evaluate urine from KTRs during the first year post-transplantation to assess whether mRNA levels of genes involved in EMT/fibrogenesis can diagnose and predict CAN, and identify patients at risk of chronic allograft dysfunction
9979349|NCT01380860|Experimental|Mesh|The patients allocated to this arm of the study will have mesh (Covidien France: mono filament polyester bidimensional knit) implanted in association with their colostomy.
9979350|NCT01380860|Active Comparator|No mesh|The patients allocated to this arm of the protocol will not receive mesh implantation with their colostomy.
9979351|NCT01380873|Experimental|Group1|
9979352|NCT01380873|Experimental|Group2|
9979353|NCT01380873|Experimental|Group3|
9979354|NCT01380886|Experimental|Infant formula, alternate protein source|Experimental infant formula with alternate protein source
9979355|NCT01380886|Active Comparator|Infant formula powder|Infant formula powder
9979356|NCT01380912||breast cancer|"Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity"
9979357|NCT01380951|Experimental|telbivudine|
9979358|NCT01380964||DMD patients|DMD Patients
9979359|NCT01380964||Control patients|Control patients
9979360|NCT01380977|Experimental|Impact of Crime group intervention|
9979361|NCT01380977|Active Comparator|Treatment as usual|
9704624|NCT04699942|Active Comparator|Conventional low-flow Oxygen Delivery|
9704625|NCT04699942|Experimental|Oxygen Delivery via Revoxa Oxygen Rebreather Device|
9979362|NCT01381003|Experimental|pCCLchimGp91s lentiviral vector transduced CD34+ cells|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
9979363|NCT01381029||HIV positive|HIV positive, receiving Influenza vaccine as standard of care.
9979364|NCT01381055|Experimental|Pentoxifylline plus antimony|
9979365|NCT01381055|Placebo Comparator|Placebo plus antimony|
9979366|NCT01381081|Experimental|platelet-rich plasma intra-articular knee injections|a single intra-articular injection of PRP in knee osteoarthritis
9979367|NCT01381081|Active Comparator|Corticosteroid intra-articular knee injections|a betamethasone and bupivacaine intra-articular injection
9979368|NCT01381133|Experimental|CBOP without ACC|
9979369|NCT01381133|Experimental|CBOP with ACC|
9979370|NCT01381133|Experimental|MET/CBT 7 without ACC|
9979371|NCT01381133|Experimental|MET/CBT 7 with ACC|
9979372|NCT01381146|Experimental|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
9979373|NCT01381146|Other|TAU|treatment as usual -- participants have access to all other jail programs and services
9979374|NCT01381185|No Intervention|Standard therapy|standard dose of 100mg aspirin qd and 1x75mg Clopidogrel will be given
9979375|NCT01381185|Active Comparator|ASA/CLP increase|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd
9979376|NCT01381198|Active Comparator|Distal rectus femoris transfer|Single-event multilevel surgery with a concomitant distal rectus femoris transfer
9979377|NCT01381198|No Intervention|No distal rectus femoris transfer|Single-event multilevel surgery without distal rectus femoris transfer
9979378|NCT01381211|Active Comparator|Yttrium-90 radioembolization (90Y-RE)|
9979379|NCT01381211|Active Comparator|Transarterial chemoembolization with drug eluting beads|Transarterial chemoembolization is performed with drug eluting beads, polyvinyl alcohol-based microspheres (DC Beads, Biocompatibles) loaded with the chemotherapeutic agent doxorubicin.
9979380|NCT01381224||Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection.
10192061|NCT04017832|Experimental|Sitagliptin 100 mg and placebo (oral semaglutide)|Sitagliptin tablets and oral semaglutide placebo tablets for 26 weeks
9704626|NCT04699669|Other|Cohort 1: CBL-514 2 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
9704627|NCT04699669|Other|Cohort 2: CBL-514 10 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
9704628|NCT04699669|Other|Cohort 3: CBL-514 20 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
9704629|NCT04699669|Other|Cohort 4: CBL-514 40 mg, 1.0 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
9979381|NCT01381250|Experimental|Treatment|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
9979382|NCT01381263|Experimental|Behavioural medicine|
9979383|NCT01381263|Active Comparator|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
9979384|NCT01381276|Experimental|Cassava Treatment 1|Single meal containing bio-fortified, high carotenoid cassava without oil.
9979385|NCT01381276|Experimental|Cassava Treatment 2|Single meal containing bio-fortified, high carotenoid cassava with oil.
9979386|NCT01381276|Active Comparator|Cassava Treatment 3|Single meal containing low carotenoid cassava with oil and retinyl palmitate.
9979387|NCT01381302||Parkinson|Early onset of disease
9979388|NCT01381315|Other|Sentinel lymph node biopsy|During surgery, 1.0 mCi of technetium-99m sulfur colloid will be injected into sub-dermal subareolar aspect of the affected breast. The KUMC Nuclear Medicine Department will be responsible for performing the injection of the isotope and dilution of the isotope using saline to a final volume of 4.0 ml or less.
9979389|NCT01381315|Other|Axillary lymph node biopsy|
9979390|NCT01381328||RAL Group|HIV-1 infected patients failing to a RALTEGRAVIR-containing regimen
9979391|NCT01381341|Experimental|linifanib|
10192062|NCT04012216||The study population|Patients consulting for persistant, moderate-to-severe rhinitis and meeting eligibility criteria.
10192063|NCT04006522|Experimental|Cohort 1|Patients with Localized RCC prior to nephrectomy.
9979392|NCT01381354|Experimental|Combined intervention|Combination intervention consisting of the following: structured modified paleolithic diet, Progressive Exercise, Neuromuscular Electrical Stimulation designed to facilitate the adoption of multiple therapeutic lifestyle behaviors associated with superior health outcomes.
9979393|NCT01381367|Experimental|Vaccine|Enrolled COPD patients receiving PPSV23 pneumococcal vaccine
9979394|NCT01381367|Placebo Comparator|Normal saline|Enrolled COPD patient receiving placebo normal saline
9704630|NCT04699669|Other|Cohort 5: CBL-514 40 mg, 2 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 2 cm^2
9704631|NCT04699669|Experimental|Cohort 6: CBL-514 80 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
9704632|NCT04699669|Experimental|Cohort 7: CBL-514 160 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
9704633|NCT04699669|Experimental|Cohort 8: CBL-514 240 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
10192064|NCT04006522|Experimental|Cohort 2|Patients with Unresectable/Metastatic RCC prior to treatment with an immune checkpoint inhibitor.
9979395|NCT01381380|Other|single-arm studies|Manual therapy for one group
9979396|NCT01381393||Ibandronate|The subjects with osteoporosis in postmenopausal women
9979397|NCT01381419|Experimental|Part A, Cohort 1|In Cohort 1, four subjects (two on active and two on placebo for first dose, and then three on active and one on placebo for subsequent doses) will be included. Subjects will be dosed at least 30 minutes apart over the dosing day and only doses administered where the predicted plasma concentration will remain below those corresponding to the MABEL.
9979398|NCT01381419|Experimental|Part A, cohort 2|In Cohort 2, 10 subjects will be included (8 active : 2 placebo). Dosing will start once the previous cohort (Cohort 1) has completed the Treatment Phase. For Cohort 2 and any subsequent cohorts, dosing will take place on two different days when a new dose is administered such that no more than one subject receives the agreed ascending dose on the first dosing day. Doses may be split in up to three divided doses given 2 to 3 hours apart. Dosing for the first four sessions in each cohort will be staggered over 2 days. On the first day of each dosing session, only one subject will receive the highest dose for that dosing session and at least one subject each will receive placebo. The remaining subjects in the cohort will be dosed on the second day according to the randomisation plan.
10192065|NCT04003961||Moderate/high risk for OSA with EDS|All clinical data of the patients who has moderate/high risk for OSA with excessive daytime sleepiness (EDS) will be assessed with statistical methods.
10192066|NCT04003961||Moderate/high risk for OSA without EDS|All clinical data of the patients who has moderate/high risk for OSA without excessive daytime sleepiness(EDS) will be assessed with statistical methods.
9979399|NCT01381419|Experimental|Part B|Part B of the study will consist of a Screening Visit (up to 30 days before the dosing session), three PET scans (where possible, all three scans may be performed in one visit when subject is admitted overnight) and a Follow-up Visit. Each subject will receive an oral dose of study drug. The dose may be split in up to three divided doses given 2 to 3 hours apart.
9979400|NCT01381432||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the lung transplantation
10192067|NCT04003961||Low risk for OSA|All clinical data of the patients who has low risk for OSA will be assessed with statistical methods.
10192068|NCT04002908||In-facility Observations|Mothers and their LBW babies will be observed starting within 6 hours of birth until the baby is discharged from the health facility.
9704634|NCT04699669|Experimental|Cohort 9: CBL-514 320 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
9979401|NCT01381445|Experimental|GW870086 0.2% &amp; GW870086 2%|GW870086 0.2%, 2% &amp; placebo each applied to an identified area for 42 days.
9979402|NCT01381445|Experimental|GW870086 2% &amp; Clobetasol Propionate|GW870086 2% &amp; placebo applied to an identified area for 42 days, while Clobetasol Propionate is applied to an area for 21 days
9979403|NCT01381458||COPD patients receiving pharmacotherapy|COPD patients age 40 years and older receiving pharmacotherapy to treat their COPD and an index event of COPD hospitalization or ER visit.
9979404|NCT01381484|No Intervention|Placebo|This group received placebo gel and requested to apply periorbital area and over the face for 3 months.
9704636|NCT04699526|Experimental|Intervention|Received UPC training, school policy and climate interventions, and Unplugged prevention program
9979405|NCT01381484|Experimental|Study group|This group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.
9979406|NCT01381497||Employed migraine sufferers|Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
9704637|NCT04699526|No Intervention|Control|Only implemented Unplugged prevention program
9704638|NCT04699708||Preterm infants ≤ 32 weeks|All preterm infants ≤ 32 weeks born in two study centers receiving resuscitative measures at the time of birth either in the form of face mask ventilation or intubation.
9704639|NCT04699617|Experimental|Active arm|The active arm will include 3 days a week of training with the Dolphin 2.0 for 12 consecutive weeks. Each session will have the duration of 60 minutes.
10192069|NCT04002908||Prospective cohort study - Quantitative|Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
9704640|NCT04699617|Active Comparator|Delayed-start control arm|The delayed-start control arm will have six-weeks of physiotherapy specialized for PD (3 times/week, 60 minutes/session) and six-weeks of 3 days a week of training with the Dolphin 2.0, with sessions of 60 minutes.
9704641|NCT04699552|Experimental|2J 20 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 20Hz
10192070|NCT04002908||Prospective cohort study - Qualitative|"Research specialists at each site will be speaking to key informants (includes doctors, nurses, midwives, community health workers (CHWs), Ministry of Health (MOH) officials, supply chain & milk bank experts) who are knowledgeable about breastfeeding policy, supply chain, or milk banks. Clinicians in study health facilities who work on labor and delivery, postnatal, newborn and neonatal ICU wards. They participate in In-depth interviews. Mothers, family members and health care workers of LBW babies, as well as community leaders (including religious leaders) who are knowledgeable about infant feeding in their communities will participate in focus group discussions. Focus group discussion will take up to 2 hours. In-depth interviews will take up to 1 hour.~Mothers (6-month extension): Mothers chosen and consented for IDIs will include those currently enrolled in the prospective cohort. Additionally, their infants need to be between 9 and 12 months of age."
9979407|NCT01381510||Adherent BPH patients|Patients with benign prostatic hyperplasia (BPH) who are adherent to 5-alpha reductase inhibitor (5ARI) therapy based on a medication possession ratio (MPR). Analyses will be conducted with threshold adherence levels of 70%, 75% and 80%
10192071|NCT04002908||Retrospective Chart review|The retrospective chart review is a review of secondary data of mothers and their LBW babies who were born in the study health facilities prior to the start of the study.
9979408|NCT01381510||Non-adherent BPH patients|Patients with BPH who are not adherent to 5ARI therapy based on an MPR and threshold levels of less than 70%, less than 75% and less than 80%
10192072|NCT04002908||Donor Human Milk Readiness Assessment|"Key stakeholders in the area of newborn health who determine policy and procedures or who are directly involved with the provision of care. This includes clinicians, nurses, lactation/nutrition specialists, hospital leadership and/or Ministry of Health officials present in the study health facilities.~This is a one-time data collection exercise in the form of either: (1) a largely qualitative facility readiness assessment tool with some qualitative questions for facility staff or (2) a facility tool observing the flow of milk along with key informant interviews in the study facilities. This could take anywhere from 1hr to a day depending on the tool administered, key informants involved and size of the study facility."
9979409|NCT01381523||Study-treatment naive insured adults with migraine|Adult health care plan members with a pharmacy claim for a combination product of sumatriptan and naproxen sodium (SumaRT/Nap) and propensity score matched controls with a pharmacy claim for a single-entity triptan
10192073|NCT04002583|Experimental|Early-onset Alzheimer's disease (EOAD) subjects|Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
9979410|NCT01381523||Insured adults with migraine who switch study treatment|Adult health plan members with a pharmacy claim for SumaRT/Nap following at least one single-entity triptan pharmacy claim in the previous 6 months and propensity-score matched controls who switched from one single-entity triptan to another
9979411|NCT01381536|Experimental|GSK1550188 1mg/kg or 10mg/kg|one shot IV
9979412|NCT01381588||Post menopausal women|Post menopausal women between 50 to 80
9984440|NCT04113811|Experimental|Microwave needle thermoablation of prostate cancer|The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.
9984441|NCT04112654|Active Comparator|Conventional laparoscopy|Laparoscopy realized at the conventional pressure (12-15 mmHg) using conventional insufflator.
9984442|NCT04112654|Experimental|Low pressure laparoscopy|Laparoscopy realized at low pressure (6-8mmHg) using pressure-controlled insufflator AirSeal®
10192074|NCT03998683|Experimental|Guselkumab Group|Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.
10192075|NCT03998683|Placebo Comparator|Placebo Group|Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.
9704642|NCT04699552|Experimental|2J 40 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 40Hz
9704643|NCT04699552|Experimental|2J 60 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 60Hz
9984443|NCT04108819|Experimental|Ketogenic Diet|Participants will receive the ketogenic diet.
9984444|NCT04108026|Experimental|Immunotherapy|Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.
9984445|NCT04101253|Experimental|Interventional|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
9984446|NCT04100135|Experimental|Test Arm|Device PFO closure with the GORE® CARDIOFORM Septal Occluder
9984447|NCT04100135|Sham Comparator|Control Arm|Sham device PFO closure (PFO not closed)
10192076|NCT03998618|Experimental|Acceptance and Commitment Therapy|Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
10192077|NCT03998618|Active Comparator|Education/Support|Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
9984448|NCT04098406|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatment
10192078|NCT03994510|Other|Patients with Borderline Personality Disorder|At each visit, these patients will have an interview that will allow for a clinical evaluation, as well as completing the hetero-questionnaires and self-questionnaires
10192079|NCT03986957||Hypertensive patients|Patients with SBP: 140-159; DBP: 90-99
10192080|NCT03968172|Experimental|EBBC programme|Participants in the intervention group will receive access to evidence-based patient information (EBPI) about lifestyle factors in MS combined with a complex behaviour change programme (EBBC programme), an online tool that was developed in line with principles of patient empowerment and cognitive behavioural therapy (CBT) approaches, including acceptance and mindfulness oriented techniques.
10192081|NCT03968172|Active Comparator|Control group programme|Participants randomized to the active control group will receive access to an information platform with optimized standard care consisting of information compiled from the German Multiple Sclerosis Society (DMSG) information material to reflect current practice.
9979413|NCT01381601||Severe adverse event claims in subjects with metastatic RCC|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurence as reported in product label.
9979414|NCT01381614||Occurance of severe adverse event claims in subjects|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurance as reported in product label.
10192082|NCT03966248|Experimental|Chinese Tuina group (CTG)|The participants in CT group will receive the traditional Chinese Tuina therapy on the basis of KOA health education and home-exercise.
9704644|NCT04699591|Other|Overall Study|Receive domperidone 4 times a day, weight-dependent dose
9979415|NCT01381627|Active Comparator|Remifentanil|
9979416|NCT01381627|Experimental|Dexmedetomidine|
10192083|NCT03966248|Active Comparator|Physical Manual group (PMG)|The participants in PM group will receive the modern physical manual therapy on the basis of KOA health education and home-exercise.
9979417|NCT01381640|Active Comparator|Marketed paracetamol|Marketed formulation
10192084|NCT03957213|Experimental|Active IH + CT|Acute intermittent hypoxia will be provided to the subject by delivering 15 brief exposures (~60 seconds) of hypoxic air alternated with 15 brief exposures (~60 seconds) of room air. The amount of oxygen delivered during hypoxic exposures may range from 15%-9% fraction of inspired oxygen, compared to 21% oxygen in normal atmospheric air. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training.
10192085|NCT03957213|Sham Comparator|Sham IH + CT|A sham protocol will be administered in which 21% fraction of inspired oxygen will be delivered by the hypoxicator during hypoxic intervals, and room air will be delivered through the four-way valve during room air intervals. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training (Posit; Brain HQ).
10192086|NCT03947684|Experimental|TMS|Paired-pulse transcranial magnetic stimulation during active contraction to determine the influence of sex hormone fluctuations on cortical excitability in naturally cycling women.
10192087|NCT03946098|Experimental|iCBT for Gambling Disorder|Treatment will consist of a 1+10 module internet delivered CBT program targeting problem gambling, newly developed. A bottom-up procedure was used to develop the treatment protocol, inspired by Clark's (2004) method for developing novel CBT treatments. We developed a clinical model delineating what factors contribute to the persistence of problem gambling behavior, and aligned these with targeted treatment interventions; based on behavioral upon research on the learning and maintenance processes of gambling behavior (Ramnerö et al, in press), theoretical models of gambling and comorbidity (Blaszczynski & Nower, 2002); as well as qualitative interviews with treatment seeking gamblers with or without comorbidity.
10192088|NCT03945825|Experimental|Group 1|0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
10192089|NCT03945825|Experimental|Group 2|0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
10192090|NCT03945825|Experimental|Group 3|0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40
10192091|NCT03945825|Experimental|Group 4|0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
10192092|NCT03945825|Experimental|Group 5|0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
10192093|NCT03945825|Experimental|Group 6|0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
10192094|NCT03942419|Experimental|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser
10192095|NCT03942419|Experimental|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser
10192096|NCT03942419|Placebo Comparator|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser
10192097|NCT03937141|Experimental|ADU-S100 and pembrolizumab|All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
10192098|NCT03924479|Experimental|Breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
9979418|NCT01381640|Experimental|Experimental paracetamol formulation|Experimental formulation
9704645|NCT04699760|Placebo Comparator|Placebo|Nutritional supplement without fish oil
9979419|NCT01381653|Experimental|Motivational Interviewing|Eight 30-minute sessions utilizing Motivational Interviewing will be delivered to reduce substance use and sexual risk in a group of high risk young men who have sex with men.
9979420|NCT01381744|Experimental|Group 3: 6 mcg Flagellin/F1/V|12 subjects will receive 6 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
9979421|NCT01381744|Experimental|Group 4: 10 mcg Flagellin/F1V|12 subjects will receive 10 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
9979422|NCT01381744|Experimental|Group 2: 3 mcg Flagellin/F1/V|12 subjects will receive 3 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
9979423|NCT01381744|Experimental|Group 1: 1 mcg Flagellin/F1/V|12 subjects will receive 1 microgram (mcg) of Flagellin/F1/V or placebo on Day 0 and Day 28.
9979424|NCT01381770|Experimental|Platelet-derived repairing factors|
9979425|NCT01381783|Other|Topical anesthesia|
9979426|NCT01381796|Active Comparator|Treatment A - NP101|
10192099|NCT03924479|Sham Comparator|Sham breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
10192100|NCT03922698||Case Group|Patients who undergo surgical intervention of carotid trombo-endo-arterectomy at the Department of Vascular Surgery of the IRCCS Neuromed, with specific inclusion/exclusion criteria
10192101|NCT03908788|Experimental|Intplex test|In vitro diagnostic device
10192102|NCT03902431|No Intervention|Control|CVD risk prior to the patient and clinician training
10192103|NCT03902431|Experimental|Training|CVD risk after the patient and clinician training
10192104|NCT03902028|Experimental|Reinforced multidisciplinary follow-up|"Entrance medication reconciliation performed by a pharmacist~Patient compliance evaluation~Patient quality of life evaluation~Pharmaceutical analysis with focus on medication optimization with a specific check-list (according to ESC 2016 recommendations)~Hospitalisation discharge medication reconciliation~Patient pharmaceutic interview at the hospitalisation discharge~Transmission of informations to the general practitioner and the pharmacist's patient~Multidisciplinary consult at 1 month after hospitalisation discharge"
10192105|NCT03902028|No Intervention|Standard care|"Drug review by a paramedic or a pharmacist~Pharmaceutical analysis~Therapeutic optimisation based on the usual practices care of the cardiologic department~Writing of the prescription given on leaving hospital based on the usual care of the department~Treatments explanations and support to the patient on the usual care~Transmission of the hospitalisation report to the patient general practitioner as the usual practice~Medical consult in usual time frames (an average of 1 month after hospitalisation discharge) at the patient location of choice"
10192106|NCT03891329|Other|Acticor/Rivacor ICDs/CRT-Ds|Implant of the new Cor Family ICDs and Plexa ProMRI S DX lead (if applicable). Device measurements, pre-defined programming and Adverse Event Reporting
10192107|NCT03889418|Active Comparator|Electronic medical recorded clinical decision support|Usual care only
9979427|NCT01381796|Active Comparator|Treatment C - oral sumatriptan succinate|
9979428|NCT01381796|Experimental|Treatment B - NP101B|
9979429|NCT01381796|Experimental|Treatment D - NP101D|
10192108|NCT03889418|Active Comparator|stepped opioid collaborative care model|Usual care AND collaborative care with behavioral health integration
10192109|NCT03885765||Test group|The first 60 patients recruited.
10192110|NCT03885765||Validation group|The last 100 patients recruited.
10192111|NCT03884985|Experimental|Normal Vision|This study examines high-acuity vision, oculomotor behavior recorded using high-resolution eyetracking. Healthy participants are asked to perform different types of visual tasks, ranging from letter identification to judging facial expressions while their eye movements will be recorded with high-precision together with their behavioral performance in the task.
9979430|NCT01381809|Experimental|Epoetin alfa|Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
9704646|NCT04699760|Active Comparator|Fish oil|Nutritional supplement with fish oil
9979431|NCT01381809|Placebo Comparator|No treatment|Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
9979432|NCT01381822|Experimental|TH-302 Dose escalation|The initial dose of TH-302 will be 240 mg/m2. A Dose Level minus 1 and 2 will be built into the study in the event that subjects experience excessive toxicity at Dose Level 1. Dose escalation will continue with approximately 40% increases from the previous dose level; however lower dose increases of 20-39% may be implemented after consultation between the Investigators, Medical Monitor and Sponsor with the percent increase dependent on the current dose level and the cumulative safety data.
9979433|NCT01381835|Experimental|001|TMC435 150 mg capsule once daily for 7 days
9979434|NCT01381848|Experimental|001|Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients <8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients >=8 weeks CA.
9979435|NCT01381887|Placebo Comparator|001|Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
9979436|NCT01381887|Experimental|002|"Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
9979437|NCT01381887|Experimental|003|Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
9979438|NCT01381887|Experimental|004|"Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
9979439|NCT01381939||Induction of labor in ICP|Induction of laborin women with ICP
9979440|NCT01381939||Induction of labor in women with no ICP|No ICP
9979441|NCT01381939||ICP and spontanius delivery|
9979442|NCT01381965|Active Comparator|Eyes with macular hole|
9979443|NCT01381991|Experimental|i-scan-EGD|Examination of GE junction using conventional WL as well as i-scan mode
9979444|NCT01382004|Active Comparator|Penicillin-G-Benzathine|penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
9979445|NCT01382004|Experimental|Azithromycin|Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)
9979446|NCT01382017|Placebo Comparator|Placebo|Placebo arm
10192112|NCT03877354||Paediatric patients anaesthesia|Paediatric patients who underwent diagnostic or surgical procedure under general anaesthesia with the need for mechanical ventilation in the selected time period.
9979447|NCT01382017|Experimental|Lasosamide 200|Lacosamide 200 mg
10192113|NCT03877354||Paediatric patients intensive care|Paediatric patients admitted to the paediatric intensive care unit with the need for mechanical ventilation in the selected time period
10192114|NCT03877094|Active Comparator|Nature Virtual Reality Video|After signing the Informed Consent Form, the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy. In the end of the procedure, the patient you will receive a Ipad (specific to the study and blocked for other functions) to respond a demographic questionnaire to characterize the sample and the likerts questionnaire to measure their pain, comfort, well-being, stress and anxiety during the procedure.
10192115|NCT03877094|No Intervention|Control group|This control group will not receive an intervention.
10192116|NCT03874754|Experimental|The iHBE program group|an intervention group
10192117|NCT03874754|No Intervention|Usual Care (Control group)|A control group
10192118|NCT03873636|Experimental|Active Stimulation|Active stimulation of targeted brain regions involved in task-switching and dual-tasking.
9979448|NCT01382017|Experimental|Lacosamide 400|Lacosamide 400 mg
9979449|NCT01382017|Active Comparator|Carbamazepine 600|Carbamazepine 600 mg
10192119|NCT03873636|Sham Comparator|Sham Stimulation|Sham stimulation of targeted brain regions involved in task-switching and dual-tasking.
10192120|NCT03839745|Other|Power level 10, 15, or 20 watts|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned battery power levels
10192121|NCT03839745|Other|1 of the other 2 remaining power levels|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 remaining power levels
10192122|NCT03839745|Other|Remaining power level|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining power level
9979450|NCT01382030|Experimental|Treatment Arm|All patients receive 4 cycles of EIA chemotherapy pre- and postoperatively. There is no further observation arm. The study is non-randomized.
9979451|NCT01382043||Endeavor Segment group|
9979452|NCT01382043||Excel Segment Group|
9979453|NCT01382056|Experimental|Mixed beans (higher amount)|Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
9979454|NCT01382056|Experimental|Mixed beans (lower aomunt)|Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
9979455|NCT01382056|Active Comparator|Control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
9979456|NCT01382069|Placebo Comparator|Placebo|Placebo
9979457|NCT01382069|Experimental|Dimethandrolone Undecanoate|DMAU group with different doses 100, 200 and 400 groups
9979458|NCT01382082||subjects with breast cancer|
9979459|NCT01382082||subjects with lymphoma|
9979460|NCT01382082||subjects without cancer|
9979461|NCT01382095|Experimental|Group A|
9979462|NCT01382095|Experimental|Group B-1|
9979463|NCT01382095|Experimental|Group B-2|
9979464|NCT01382095|Experimental|Group C|
9979465|NCT01382121|Experimental|Peer modeling|Participants watch a video geared to increase confidence in ability to preform fitness test. Male participants will watch a video of a male adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of his ability. Female participants will watch a video of a female adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of her ability.
9979466|NCT01382121|Active Comparator|Control|Participants watch a video unrelated to the fitness test and self-efficacy. The video depicts healthy food and nutrition options.
9979467|NCT01382134|Placebo Comparator|Placebo group|Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
9979468|NCT01382134|Active Comparator|Aspirin group|Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
9979469|NCT01382147|Experimental|S-HAM|S-HAM (S-HAMescalated for younger patients and S-HAMbasis for elderly patients)
9979470|NCT01382147|Active Comparator|TAD-HAM (younger) or HAM-HAM (elderly)|is TAD-9 - HAM for younger patients (with 2 mandatory induction cycles) and HAM (- HAM) for the elderly patients with the second HAM cycle only applied in the case of inadequate blast clearance (> 5%) in the day 16 bone marrow aspirate
9979471|NCT01382160|Experimental|adalimumab|40 mg every two weeks, by subcutaneous way
9979472|NCT01382199|Experimental|Ven100|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
9984449|NCT04098406|Experimental|30 mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
9979473|NCT01382238|Experimental|Single arm|Subjects will have a screening visit within 30 days prior to the first dose of study drug, five treatment periods containing a single dose of study drug, followed by 48 hours of serial PK collection. In the 5 treatment periods subjects will receive DTG granule formulation 1) directly to mouth; 2) with purified water; 3) with Contrex brand water; and 4) with milk-based infant formula. They will also receive the current 50 mg tablet formulation administered with tap water. These treatments will be administered in a random order. Subjects will check out of the unit on Day 3 after the 48 hour PK sample in each period. Study periods will be separated by at least 5 days. Subjects will have a follow-up visit 5-7 days after last dose of DTG given.
9979474|NCT01382264|Experimental|CADS|
10192123|NCT03834779|Other|DOORS-CHW Intervention|"The type of intervention is behavioral.~Participants randomized to the intervention arm will meet with the Community Health Worker (CHW) and a staff member from Unlocking DOORS. The Unlocking DOORS broker will complete a needs assessment, generate an individualized re-entry plan and make referrals to providers in the extensive Unlocking DOORS network. The CHW will assist the participant in navigating these referrals, specifically with regards to HIV care, substance use treatment and mental healthcare."
10192124|NCT03834779|No Intervention|Treatment As Usual|TAU participants will receive standard of care, which involves passive referral by jail medical staff to the outpatient HIV clinic.
10192125|NCT03794089|Experimental|Brief anxiety intervention|Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management
9979475|NCT01382277|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg for 76 weeks.
10192126|NCT03794089|Active Comparator|Usual PC-MHI care|Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care
10192127|NCT03768544|Experimental|Self-help guided by a lay provider|
9979476|NCT01382316|Experimental|Making Alcoholics Anonymous Easier|Six session, group format intervention, consisting of introductory session, four core sessions (sponsorship, principles not personalities, spirituality, living sober), and return to introductory session as MAAEZ graduate
9979477|NCT01382316|Active Comparator|Usual care|Usual group sessions on education about alcohol and drug problems
9979478|NCT01382329|Experimental|Treatment group I / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22
9979479|NCT01382329|Experimental|Treatment group II / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22
10192128|NCT03768544|Other|Waiting list where participants wait for delayed treatment|
10192129|NCT03764696|No Intervention|air, the first and second stage of labor|"Patients randomized to the group will receive room air.~The therapy will continue until after delivery"
10192130|NCT03764696|Experimental|oxygen, the first and second stage of labor|"Patients randomized to the group will receive oxygen administered by high flow facemask oxygen at 10 L/min oxygen.~The therapy will continue until after delivery"
10192131|NCT03733925|Experimental|Golimumab|Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24. Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
10192132|NCT03720561||Group: Ibrutinib Treatment|Participants will not receive any intervention as a part of this study. This study will collect retrospective and prospective real-world data to describe retention rates for participants of chronic lymphocytic leukemia (CLL) receiving ibrutinib in routine Italian clinical practice over a 2-year follow-up period. Participants with CLL who have started ibrutinib treatment within 3 months before enrollment visit or in case ibrutinib was prescribed before or on the enrollment day as per routine clinical practice within the 30 days after enrollment visit will be included in the study. The primary data source for this observational study will be the medical records of each enrolled participant, as well as questionnaires concerning quality of life and treatment adherence. Data will be collected every 3 months for the first year and every 6 months for the second year during prospective period.
10192133|NCT03712527|Experimental|Platelet-Rich Plasma|
10192134|NCT03712527|Placebo Comparator|Placebo|
10192135|NCT03702751|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
10192136|NCT03702751|Active Comparator|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
10192137|NCT03689530|Experimental|Peer Support Arm.|Participants randomized to peer support will be matched with a peer supporter.
10192138|NCT03689530|Active Comparator|Enhanced Usual Care|Participants randomized to enhanced usual care will receive brief education and folder of information and resources.
10192139|NCT03689478|Experimental|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
10192140|NCT03678402|Experimental|Palarum Fall Prevention System|The Study site, the OSU Wexner Center Brain and Spine Hospital, is located on three contiguous floors with each floor being made up of two units or Pods designated East and South. Following commencement of the study, and throughout its duration, Pods assigned to the Study will only utilize the Palarum Fall Prevention System and a monitored PUP™ sock, i.e., (Patient is Up) System as the standard of care intervention for fall prevention in accordance with its operating instructions and procedures.
10192141|NCT03670628|Active Comparator|720 shockwave therapy Group|Participants in this group will receive a total of 5 daily sessions of shockwave therapy within a week. Each therapy session will consist of 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
10192142|NCT03670628|Sham Comparator|Sham shockwave therapy|Participants in this group will receive a total of 5 daily sessions of sham shockwave therapy within a week. Sham therapy will be applied to the penis and to the left and right crus (shaft near the base).
10192143|NCT03670355|Experimental|Tenofovir (TFV) Intravaginal Ring (IVR)|The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
9979480|NCT01382329|Experimental|Treatment group III / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22
10192144|NCT03670355|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
10192145|NCT03666871|Experimental|Arm 1|Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
10192146|NCT03666871|Active Comparator|Arm 2|Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
10192147|NCT03659578|Experimental|Thymosin α1|Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
10192148|NCT03641937|Experimental|INVSENSOR00011 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00011 investigational sensor.
10192149|NCT03614364|Experimental|nanoxel and herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
10192150|NCT03610750|Active Comparator|Specialty Care|Psychiatric medications and evidence-based psychotherapies to be provided at a specialty mental clinic facilitated by psychiatric technicians, the mental health specialty workforce already in place in Mozambique.
10192151|NCT03610750|Experimental|Integrated Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers.
9979481|NCT01382329|Experimental|Treatment group IV / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22
10192152|NCT03610750|Experimental|Community Clinic Stepped Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers and community health workers, respectively.
9979482|NCT01382342|Experimental|rasagiline|Participants in this arm will receive 1 mg of rasagiline daily for the six month duration of the study.
9979483|NCT01382342|Placebo Comparator|Placebo|Participants in this group will receive 1 mg of placebo daily for the six month duration of the study.
9979484|NCT01382355||Kidney transplant|
9979485|NCT01382368|Experimental|Sildenafil|
9979486|NCT01382394||Sepsis Group, Heart failure group|"The first group will include 60 patients with the diagnosis of acute decompensated heart failure.~The second group will include 60 patients with the diagnosis of sepsis."
9979487|NCT01382407||Cetuximab|All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.
9979488|NCT01382420|Active Comparator|Adrenalectomy group|patients who undergo adrenalectomy
9979489|NCT01382420|No Intervention|Control group|patients who receive conservative treatment
9979490|NCT01382433|Experimental|Chronic Cannabis Users|
9979491|NCT01382433|Experimental|Control|Neurotypical subjects
9979492|NCT01382459||type 1 DM children- intervention group|will have home visits and trainings at school
9979493|NCT01382459||type 1 DM children- control group|will receive the standard care at the clinic
9979494|NCT01382472|Experimental|Rosuvastatin|40 mg rosuvastatin pre PCI and daily during hospital stay
9979495|NCT01382472|Other|Historical data (KOMPIS)|Patients from the KOMPIS trial (n=44) will be used as historical controls. They received no statins omn the first day. Low dose simvastatin during hospital stay.
9979496|NCT01382485|Active Comparator|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
9979497|NCT01382485|Experimental|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
9979498|NCT01382498|Placebo Comparator|Placebo|Placebo tablets will be administered to the patients in Placebo arms daily for three months.
10192153|NCT03610438|Experimental|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
9979499|NCT01382498|Experimental|Calcium dobesilate|Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
9979500|NCT01382524||Stabilization system A|A commercialized stabilization dressing using a winged PIV catheter.
9979501|NCT01382524||Stabilization System B|A commercialized stabilization device using a non-winged PIV catheter
9979502|NCT01382537|Active Comparator|A|
9979503|NCT01382537|Placebo Comparator|B|
9979504|NCT01382550||VTE subjects|"subjects with a recent (<3 months) first VTE event undergoing long-lasting OAT or 12-month OAT~Exclusion criteria: missing data during the follow-up; contraindications to or lack of compliance to oral anticoagulation (OAT), lack of informed consent; history of previous VTE event; indication for continuous oral anticoagulation (e.g., an artificial heart valve or chronic atrial fibrillation); events occurring during pregnancy, malignancy, puerperium, oral contraceptive intake, hormone replacement therapy; deficiencies of Prot. C and Prot S or combined inhibitor deficiencies."
9979505|NCT01382576||PCOS patients|
10192154|NCT03610438|Experimental|Cohort 2|Cohort 2 will enroll 38 Ph- patients
10192155|NCT03608865|Experimental|experimental group|Drug:Durvalumab + tremelimumab Dose/Potency:Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental
10192156|NCT03602235|Experimental|Low dose melphalan + high dose ascorbate acid (HDAA)|"Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions.~HDAA + Melphalan:~HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5.~A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area."
9979506|NCT01382576||PCOS patients and healthy controls|There are two groups in this study. One group is PCOS patients and other group is healthy controls.
9979507|NCT01382589|Experimental|Arm A: Afamelanotide + NB-UVB|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 6 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total)
10192157|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
10192158|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
10192159|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
9979508|NCT01382589|Active Comparator|Arm B: NB-UVB alone|Subjects in this arm B will receive NB-UVB light only (administered thrice weekly, 72 treatments in total)
10192160|NCT03580083|Experimental|Dose 1; 1x10^10 GC/g brain mass of RGX-111|
10192161|NCT03580083|Experimental|Dose 2; 5x10^10 GC/g brain mass of RGX-111|
10192162|NCT03572244|Experimental|Laser-Lok|A Laser-Lok microgrooved implant will be placed.
9979509|NCT01382615||Healthy Volunteers|Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
9979510|NCT01382615||Patients with multiple myeloma|Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.
9979511|NCT01382628||Preulcerative plantar foot lesion|An area on the plantar foot, usually at the location of a bony prominence, that presents with erythema, significant hyperkeratosis, or thin, shiny skin.
9979512|NCT01382628||Plantar ulcer no history of amputation|Plantar ulceration without a history of amputation or require an amputation.
9979513|NCT01382628||Plantar ulcer and digital amputation|Plantar ulceration who will be undergoing a digital amputation.
9979514|NCT01382628||Plantar ulcer and transmet amputation|Plantar ulceration who will be undergoing a transmetatarsal amputation.
10192163|NCT03572244|Active Comparator|Machine|A machined implant will be placed.
10192164|NCT03566082||Post Approval Study|"The PAS cohort consisted of 137 subjects who were implanted with the R3 delta Ceramic Acetabular System (DoD) in the pivotal study. These patients will continue to be followed to 10 years post-operatively.~The primary endpoint for the PAS study is implant survivorship at 10 years post study procedure."
10204500|NCT05202691|Experimental|Group 1 (Physical Therapy+Magnetic Field Therapy)|"Physical Therapy Protocol plus Magnetic Field Therapy~A protocol of physical therapy treatment including:~Manual therapy techniques for inhibition of piriformis, quadratus lumbaris, and paravertebral muscles in prone position and bilaterally.~2 functional techniques applied to the sacrum in prone position.~A myofascial release of ligaments inserted to the sacrum in prone position and bilaterally.~Manual therapy technique for inhibition of psoas-iliacus muscle in supine position and bilaterally.~Stretching techniques of piriformis, gluteal and paravertebral muscles in supine position and bilaterally.~Active gluteus maximus contraction in supine position bilaterally.~To this protocol, a 15 minutes of Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany) applied to the lumbosacral region in prone position is added."
10204501|NCT05202691|Active Comparator|Group 2 (Physical Therapy)|"Physical Therapy Protocol alone:~The same Physical Therapy Treatment protocol with a sham magnetic intervention applying in the same region with a disconnected Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany) during 15 minutes."
9979515|NCT01382628||Plantar ulceration and choparts|Plantar ulceration who will be undergoing Chopart's or more proximal amputation.
9979516|NCT01382641|Other|Hoya AF-1 IOL|
9979517|NCT01382641|Other|Revital Vision|
9979518|NCT01382667||GLP-2 and symptom evaluation|Before starting and at the end of the chemotherapy, along with a blood withdrawal for GLP-2 evaluation, a GSRS (gastrointestinal symptom rate scale) questionnaire will be filled by each patient to account for GI symptoms. In addition, minor complaints such as warm sensation after chemotherapy, susceptibility to nausea under specific condition, sweating and weakness will scored by visual analog score (VAS). Lastly, the NCI-CTC score for mucositis will be performed.
9979519|NCT01382680|Active Comparator|Classic guidewires|Conventional guidewires used in combination as preferred by the investigating ERCP specialist
9979520|NCT01382680|Active Comparator|New guidewire (G240)|Primary use of the new guidewire (G240)
9979521|NCT01382693|Experimental|TimeSlips group storytelling program|
9979522|NCT01382693|Active Comparator|Standard care activity program|
10204502|NCT05202678|Other|AGN1 LOEP|Subjects treated with AGN1 LOEP in proximal femur
9979523|NCT01382706|Experimental|Treatment|Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.
9979524|NCT01382732|Experimental|Carbetocin|"Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.~Ringer's Lactate 4mL applied to a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr"
9979525|NCT01382732|Active Comparator|Oxytocin|Protocol B (oxytocin + placebo) Ringer's Lactate 11mL directly into the vein in no less than two minutes. Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
9979526|NCT01382745|Experimental|Nimotuzumab|Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
9979527|NCT01382758||Acute kidney injury|The group of patients who develop acute kidney injury as defined by the pediatric RIFLE criteria.
9979528|NCT01382758||No acute kidney injury|The patients who do not develop acute kidney injury
10192165|NCT03562767|Experimental|Group-based Cognitive Behavioral Intervention|Subjects receiving the group-based CT-CB intervention
9979529|NCT01382771|Active Comparator|Intra-articular corticosteroid injection|Intra-articular corticosteroid injection in conjunction with confirmatory anesthetic medial branch blocks
10192166|NCT03562767|Experimental|Web-based Cognitive Behavioral Intervention|Subjects receiving the web based CT-CB intervention
10192167|NCT03562767|Placebo Comparator|Usual Care|Subjects receiving usual care from their primary care providers
10192168|NCT03560193|Experimental|Chlorhexidine Group|
9979530|NCT01382771|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injections with confirmatory anesthetic medial branch blocks
9979531|NCT01382810|Active Comparator|Altaire Gel forming solution|
9979532|NCT01382810|Placebo Comparator|Refresh Tears|
9979533|NCT01382823|Experimental|Femtosecond Laser|
9979534|NCT01382836||Black inner city children with persistent asthma|
9979535|NCT01382836||Black inner city non-atopic healthy children|
9979536|NCT01382849||CAA positive microbleeders|Cerebral amyloid angiopathy (CAA) positive microbleeders
9979537|NCT01382849||probable CAA macrobleeders|
9979538|NCT01382849||CAA negative microbleeders|
9979539|NCT01382862|No Intervention|Regular Care|Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
9979540|NCT01382862|Active Comparator|Stroke Emergency Unit Mobile (STEMO)|The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
9979541|NCT01382875|No Intervention|Conventional care program|
9979542|NCT01382875|Experimental|Multi-disciplinary management program|
9979543|NCT01382888|Active Comparator|Heparin 2,400 IU /ml Cutaneous Spray|Patients are randomized to receive the active comparator heparin 2,400 IU/ml cutaneous spray for 24 weeks
9979544|NCT01382888|Placebo Comparator|Placebo Cutaneous Spray|Patients are randomized to receive placebo cutaneous spray for 24 weeks
9979545|NCT01382914|Experimental|chlorhexidine 0.12 %|
9979546|NCT01382927||General Anesthesia|
9979547|NCT01382927||Spinal Anesthesia|
9979548|NCT01382966||Single group|Maintenance hemodialysis patients of minimal 6 months of hemodialysis duration; free of malignancy, infection and autoimmune disease; age over 18 years
9979549|NCT01382979|Experimental|Alcohol education and prevention|AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen.
9979550|NCT01382979|No Intervention|Control|Control group.
9979551|NCT01382992||Early Stage|
9979552|NCT01382992||Late Stage|
9979553|NCT01383031|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
9979554|NCT01383031|Active Comparator|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC（conventional laparoscopic cholecystetomy）by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
9979555|NCT01383044|Experimental|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
9979556|NCT01383044|Active Comparator|carvedilol|carvedilol 6.25-12.5 mg per day
9979557|NCT01383057|Experimental|Femtosecond Laser|
9979558|NCT01383070|No Intervention|Lactational Conseling|The existing staff of the hospitals will be provided training in IYCF by BPNI. They will be encouraged to set up their own systems to continue counseling during the ante natal period, at delivery and during the immunization visits. The participants will be asked to come for the same schedule of visits as in the intervention group where their data will be collected.
9979559|NCT01383070|Experimental|Lactation Counseling by Cell Phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
9979560|NCT01383083||iloprost|In the adult patient group, iloprost acceptable target dose is 2.5 ug 4-6 times/day according to the patient's compliance. Because of the concern of safety and tolerability, during the first 4 weeks of treatment, patients receive 2.5 ug twice daily. After 4 weeks, this is increased to the target dose, if iloprost is well tolerated.
9979561|NCT01383122|Active Comparator|Active device|Functional pulsed electromagnetic field device
9979562|NCT01383122|Placebo Comparator|Placebo - inactive device|Inactive pulsed electromagnetic field device
9979563|NCT01383148|Experimental|Arm 1 - TG4010 + first line therapy|First-line therapy and maintenance therapy
9979564|NCT01383148|Active Comparator|Arm 2 : Placebo + first line therapy|First-line therapy and maintenance therapy
9979565|NCT01383187|Experimental|DE graft and PRP concentrate|Patients enrolled in this arm receive the innovative treatment methods consisting of application of DE graft together with PRP concentrate.
10192169|NCT03560193|Active Comparator|Povidone Iodine Group|
10192170|NCT03559699|Experimental|AG-348|Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1. This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.
10192171|NCT03557281|Experimental|Subjects receiving GSK3036656|Eligible subjects will receive sequential doses of GSK3036656 at a starting dose of 5 milligrams given orally during treatment period.
10192172|NCT03557281|Active Comparator|Subjects receiving RIFAFOUR e-275|Eligible subjects will receive RIFAFOUR e-275 tablet given daily orally as standard-of-care therapy.
9979566|NCT01383187|Active Comparator|Standard treatment group|PAtients included into this arm will receive a standard treatment for deep-burn injuries, i.e. DE graft without the application of the PRP concentrate.
9979567|NCT01383226|Other|Thoracic endosonography|Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
9979568|NCT01383239|Active Comparator|Immediate postoperative therapy|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay
9979569|NCT01383239|Active Comparator|postoperative therapy delayed for 6 weeks|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay.
9979570|NCT01383252|Experimental|Water method|Water infusion in lieu of air insufflation for screening and surveillance colonoscopy
9979571|NCT01383252|Active Comparator|Air method|Air insufflation for screening and surveillance colonoscopy
9979572|NCT01383265|Experimental|Water method and chromoendoscopy|Combined water method with chromoendoscopy using 0.008% IC solution for screening colonoscopy
10192173|NCT03557242|Other|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
10192174|NCT03557242|Other|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
9979573|NCT01383265|Active Comparator|Water method|Control method will use plain water with the water method for screening colonoscopy
9979574|NCT01383278|Experimental|Computer-directed 5 A's intervention for smoking|
10192175|NCT03557242|Other|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
10192176|NCT03540420|Experimental|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
10192177|NCT03540420|No Intervention|Observation|standard care after completed chemo-radiotherapy and non-progression
10192178|NCT03538821|Experimental|Intact cod protein from fillet|Dietary supplement: intact cod protein from fillet, 8 g protein daily for 8 weeks
10192179|NCT03538821|Experimental|Intact cod protein from residual material|Dietary supplement: intact cod protein from residual material, 8 g protein daily for 8 weeks
10192180|NCT03538821|Experimental|Control|Control group receive tablet containing fillers and no proteins
9979575|NCT01383278|Active Comparator|Screening and resource provision|
9979576|NCT01383291||Pelvic floor prolapse|Those who underwent prolift and those who underwent IVS
9984450|NCT04095104|Experimental|Phentermine & Topiramate|"Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration:~4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
9984451|NCT04095104|Placebo Comparator|Placebo Drugs|"Placebo Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration: 4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning~+~Placebo Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning~+~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
9984452|NCT04091113||Participants with Hereditary Angioedema|Participants older than 18 years that are clinically diagnosed with Hereditary Angioedema type 1/2 and experienced ≥4 HAE attacks within last 12 month before the enrollment
9984453|NCT04090502|Experimental|Grupo A. Dry needling in Trigger point|Participants will be treated in the most hyperalgesic foci within the hamstring musculature.
9984454|NCT04090502|Placebo Comparator|Grupo B. Dry needling in non-hyperalgesic areas|Participants will be treated in non-hyperalgesic areas within the hamstring muscles.
9984455|NCT04086966|Experimental|Metastatic Prostate Cancer Arm|[68Ga]PSMA-11 PET/MRI or PET/CT for guiding the radiation treatment plan in patients with known or suspected locally metastatic prostate cancer
9984456|NCT04084990|Experimental|aPAP|Nightly use of aPAP when sleeping through the date of delivery
9984457|NCT04084990|No Intervention|No aPAP|No use of aPAP (standard of care)
9984458|NCT04084678|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the individual maximum tolerated dose (maximum dose of 1400 mcg)
10192181|NCT03529344|Active Comparator|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
9984459|NCT04084678|Placebo Comparator|Placebo|Matching placebo tablets (oral)
9984460|NCT04079348|Active Comparator|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application Oasis Extracellular Matrix to their donor site wound.
9984461|NCT04079348|Active Comparator|Standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
10192182|NCT03529344|Placebo Comparator|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
10192183|NCT03517228|Experimental|total laparoscopic or robotic-assisted hysterectomy|All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.
10204503|NCT05202665|Experimental|Flouride Varnish applications (non-invasive approaches)|ClinproTM White Varnish 22600 ppm, 3M ESPE was applied in line with the manufacturer's recommendation to non-cavitated proximal caries lesion.
10204504|NCT05202665|Experimental|Resin Infiltration (micro-invasive approaches)|ICON DMG was applied in line with the manufacturer's recommendation to non-cavitated proximal caries lesion.
10204505|NCT05202652|Placebo Comparator|Control Group|The control group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing 455mg of the carrier substance (magnesium stearate)
9979577|NCT01383330|Experimental|Megace|800mg
9979578|NCT01383330|Active Comparator|DW-ES(A)|625mg
9979579|NCT01383330|Active Comparator|DW-ES(B)|625mg
10192184|NCT03516279|Experimental|Treatment (pembrolizumab, dasatinib, imatinib, nilotinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and dasatinib, imatinib mesylate, or nilotinib PO as clinically indicated per the treating physician. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients with detectable MRD after course 18 continue pembrolizumab and dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity. Patients with UMRD at any time before course 18 discontinue pembrolizumab after course 18 and continue dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity.
10192185|NCT03515083|Experimental|Experimental|"In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget.~The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully."
10192186|NCT03515083|No Intervention|Control|"Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study.~During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication."
10192187|NCT03508739|Experimental|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
10192188|NCT03508739|Experimental|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
10192189|NCT03474679|Experimental|Ibrutinib|Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
9979580|NCT01383343|Experimental|Treatment (FOLFIRI and bevacizumab)|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate PO QD or BID on days 3-6 and 10-13*. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9979581|NCT01383395|Experimental|simvastatin/cilostazol|simvastatin 40 mg on day 1 and 6, cilostazol 100 mg from day 2 to day 6
9979582|NCT01383408|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
10192190|NCT03473561|Experimental|Racecadotril plus standard treatment oral rehydration solution|Racecadotril Infants Granules for Oral Suspension 10 mg (in addition to standard treatment i.e. oral rehydration solution) Racecadotril Children Granules for Oral Suspension 30 mg (in addition to standard treatment i.e. oral rehydration solution)
10192191|NCT03459534|Experimental|Radotinib HCl|"Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
10204506|NCT05202652|Active Comparator|HealthSpan(HS) Group|The HS group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing the 455mg of the mixture of the active compounds along with the carrier.
9979583|NCT01383408|Experimental|lung cancer|patients with histologically confirmed lung cancer, but no history of other cancer
9979584|NCT01383408|Experimental|breast cancer|patients with histologically confirmed breast cancer, but no history of other cancer
9979585|NCT01383408|Experimental|ovarian cancer|patients with histologically confirmed ovarian cancer, but no history of other cancer
9979586|NCT01383460|Active Comparator|G-CSF+EPO|
9979587|NCT01383460|Placebo Comparator|Placebo|
9979588|NCT01383473||Leukemia Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
9979589|NCT01383473||Solid Tumor Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
10192192|NCT03455517|Experimental|Veritas|"Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.~Step 2. All patients will receive 6 courses of the VR combination.~Step 3. After 6 courses of VR combination:~3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
10192193|NCT03446170|Experimental|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
9704647|NCT04699331|Experimental|Individualized stimulation group|Patients receive five sessions of individualized stimulation obtained from brain image-based transcranial direct stimulation simulation. The simulator generates the electrode's location on the scalp.
9704648|NCT04699331|Active Comparator|Conventional stimulation group|Patients receive five sessions of conventional stimulation with electrodes over C3 and C4 based on the 10-20 system.
9704649|NCT04699331|Sham Comparator|Sham stimulation group|Patients receive five sessions of sham stimulation with electrodes over C3 and C4 based on the 10-20 system.
9704650|NCT04699487|Experimental|Patient receiving Photobiomodulation|
9704651|NCT04699175|Experimental|Treatment group A|
9704652|NCT04699175|Experimental|Treatment group B|
10192194|NCT03446170|Experimental|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
10192195|NCT03446170|Experimental|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
9704653|NCT04699175|Placebo Comparator|Treatment group C|
9704654|NCT04699396|Experimental|Mobilisation with Movement 1 (MWM1)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at fibula and talus. Three sets of 10 repetitions of each techniques, were administrated.
9704655|NCT04699396|Experimental|Mobilisation with Movement 2 (MWM2)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at talus and fibula (order of application inverted). Three sets of 10 repetitions of each techniques, were administrated.
9704656|NCT04699396|Placebo Comparator|Placebo|The Placebo group participants performed the same number of sets and repetitions of lean/lunge forward into dorsiflexion, without any glide application, in the same position
10192196|NCT03446170|Experimental|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
10192197|NCT03446170|No Intervention|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
9704657|NCT04699396|Experimental|Intervention|The experimental groups (MWM1 and MWM2), were later merged into a single Intervention group.
10192198|NCT03436901|Other|Testicular cancer st. II-III|MRI with DWI vs CT
10192199|NCT03433339|Experimental|Active Treatment|Thoracic anodal transcutaneous spinal direct current stimulation 2.5mA for 20 min/ three times per week for 8 weeks.
10192200|NCT03433339|Sham Comparator|Sham Treatment|Thoracic anodal transcutaneous spinal direct current sham stimulation session of 20min/ three times per week for 8 weeks.
10192201|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
10192202|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
10192203|NCT03422003|Experimental|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
9704658|NCT04699214|Experimental|Endostar combined with chemotherapy AI|"Endostar: Endostar 45mg/d, D1-5 iv, Q3W, that is, continuous intravenous pump injection for 120 hours for 5 consecutive days, one cycle. Endostar uses 15 medicines per cycle, 15 Endostar medicines and a Baxter pump per single cycle. Subjects buy and use them at their own expense every two cycles.~AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W."
9704659|NCT04699214|Active Comparator|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
9704660|NCT04699214|Placebo Comparator|Observation group|"The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator.~Patients with no disease progression (local tumor recurrence, distant metastasis, or the appearance of new lesions of the same tumor subtype) and the adverse reactions can be tolerated, continue to use the drug for 6 cycles, and cannot receive other anti-tumor treatments. In the course of medication, if the disease progresses or the researcher believes that the patient is not suitable for continuing medication, the medication will end."
9704661|NCT04699474|Experimental|Early in-bed leg cycling|
9704662|NCT04699305||ActiGraft|Whole blood clot (WBC) gel
9704663|NCT04699292||Cohort A|MLS patients managed by surgery only
9704664|NCT04699292||Cohort B|MLS patients receiving preoperative RT to a dose of 36 Gy (equivalent) followed by surgery
9704665|NCT04699292||Cohort C|MLS patients receiving preoperative RT to a dose of 50 Gy (equivalent) followed by surgery
9704666|NCT04699292||Cohort D|MLS patients receiving surgery followed by postoperative RT to a dose of 50-66 Gy (equivalent)
9704667|NCT04699292||Cohort E|MLS patients with oligometastatic and/or oligoprogressive disease receiving definitive RT to a dose of 36Gy (equivalent)
10192204|NCT03422003|Active Comparator|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23-25 fractions to the supraclavicular (with or without axillary) lymph nodes.
10204507|NCT05202639||Continuation of pregnancy|The parents who have chosen to continue pregnancy will be asked to complete a questionnaire.
9704668|NCT04699370|Experimental|cognition-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to cognition-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For Cognition- targeted exercise , all standardized physical therapy exercises will be performed in a time-contingent rather than in a symptom-contingent way ."
9704669|NCT04699370|Active Comparator|symptom-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to symptom-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For symptom- targeted exercise, All Standardized physical therapy exercises will be performed in a symptom-contingent way (Stop or adjust the exercise when it hurts)."
9704670|NCT04699318|Experimental|Single Dartos TIP|Single dartos tubularized incised plate urethroplasty
9704671|NCT04699318|Experimental|Double Dartos TIP|Double dartos tubularized incised plate urethroplasty
9704672|NCT04699448|Active Comparator|High-protein hypocaloric diet|Composition of hypocaloric diet: protein:40%,carbohydrates:30% and fat:30%.
9704673|NCT04699448|Active Comparator|High-carbohydrate hypocaloric diet|Composition of hypocaloric diet: carbohydrate 60%, protein:18% and fat:22%
9704674|NCT04699344||Pre-tissue biopsy patients|Pre-tissue biopsy patients with suspected prostate carcinoma will be the experimental group to determine the sensitivity and specificity of PROUD analysis, the result will be compared with histological results and PCA3 test.
9704675|NCT04699344||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of PROUD analysis.
9704676|NCT04699513|Experimental|P-SIMV+PS group|The reason behind using P-SIMV+PS as a conventional mode was that it is a pressure controlled mode like APRV.
9704677|NCT04699513|Experimental|APRV group|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
9704678|NCT04699409|Experimental|FAST|stroke education: FAST
9704679|NCT04699409|Experimental|STROKE 112|stroke education: STROKE 112
9704680|NCT04699227|Sham Comparator|Control group not receiving RIC|Those randomised to the control group will have the blood pressure cuff placed on the arm, but it will not be inflated.
9704681|NCT04699227|Experimental|Interventional group receiving RIC|RIC will consist of 3-4 cycles of cuff inflations to 200 mmHg for 5 min with deflation to 0 mmHg for another 5 min, which is automatically administered by the pre-programmed cuff.
9704682|NCT04698850|Active Comparator|aflibercept|Patients with RAP who will be receiving aflibercept.
9704683|NCT04698850|Experimental|brolucizumab|Patients with RAP who will be receiving brolucizumab.
9704684|NCT04698941|Experimental|Simvastatin + Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
9704685|NCT04698941|Active Comparator|Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles)
9704686|NCT04699084|Experimental|Music Group|Patients received music intervention and usual postoperative care.
9704687|NCT04699084|No Intervention|Control Group|Patients received only postoperative usual care.
9704688|NCT04698980|Other|participants selected according to their G6PD activity|"50 subjects with severe deficit G6PD activity (<30% of the median in the general population, ie 3.6U / g Hb), adults or children two years and over.~50 subjects with intermediate G6PD activity (30-80%), adults.~50 subjects with normal G6PD activity (> 80% ie> 9.6U / g Hb), adults."
10192205|NCT03419234|Experimental|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
10192206|NCT03419234|Active Comparator|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
9704689|NCT04699058||Health care workers|questionnaire and COVID antibody test
9704690|NCT04699058||Household members|questionnaire and COVID antibody test
9704691|NCT04699110|Experimental|Treatment group|Patients receiving intracoronary adrenaline
9704692|NCT04699110|Active Comparator|Control group|Patients receiving intracoronary adenosine
9704693|NCT04699097||azytromycin|children who recieved azithromycin due to COVID 19 infection
9704694|NCT04698759||Stunted subject|Children with stunted status condition based on Z score criteria
9704695|NCT04698759||Normal subject|Children with normal status condition based on Z score criteria
9704696|NCT04699279|Experimental|Statin|
9704697|NCT04699279|No Intervention|Blank|
9704698|NCT04698954|Experimental|AIMS intervention group|A nurse-delivered behavioural intervention focussing on medication adherence, physical activity, and symptom management integrated in routine clinical care. AIMS-CHF incorporates nurse-counselling and feedback from electronic monitoring of medication use (using MEMS-buttons) and physical activity (using pedometers).
10204508|NCT05202639||Medical termination of pregnancy|The parents who have chosen to terminate pregnancy will be asked to complete a questionnaire.
9704699|NCT04698954|Active Comparator|Treatment-as-usual group|Participants in the control group will receive treatment as usual. They will visit the out patient clinic each 3 or 6 months for 30 minutes.
9704700|NCT04698746|Active Comparator|Ultrasound guided pericapsular nerve group block|Injection of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline mixture between iliopubic eminentia and psoas tendon under ultrasound guidance
9704701|NCT04698746|Active Comparator|Intra-articular local anesthetic injection|At the end of the surgical case, a total of 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml isotonic saline injection intra-articularly.
9704702|NCT04698889|Active Comparator|Cow milk|Administration of natural cow whole milk
9704703|NCT04698889|Active Comparator|Human milk|Administration of natural human milk
9704704|NCT04698889|Active Comparator|Modified cow milk - low protein|Administration of modified cow milk at low protein content
9704705|NCT04698889|Active Comparator|Modified cow milk - high protein|Administration of modified cow milk at high protein content
9704706|NCT04699019||Active Runners|All participants will be required to run unshod for a combination of four prescribed speeds (walking and up to 9 mph) and three different foot strike patterns (rearfoot, midfoot, and forefoot) on level ground.
10192207|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
10192208|NCT03405311|Active Comparator|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
9704707|NCT04698785|Experimental|Regorafenib and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib and best supportive care followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
9704708|NCT04698785|Placebo Comparator|Placebo and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo and best supportive care followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
9704709|NCT04698876|Experimental|Outpatient measurement of intraocular pressure|The intervention group measures its intraocular pressure itself in their home environment for 7 days at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m. with a self-tonometer (iCareHOME).
9704710|NCT04698876|Active Comparator|Stationary measurements of intraocular pressure|The intraocular pressure of the control group is measured by means of rebound tonometry or Goldmann applanation tonometry in a clinic for minimum 24 hours at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m.
9704711|NCT04698863||high flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 4 L/min for Group High flow rate.
9704712|NCT04698863||low flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 1 L/min for Group Low flow rate.
10192209|NCT03405311|Experimental|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
10192210|NCT03396081|Experimental|PRADO-IC|
9704713|NCT04698590|Active Comparator|WFG Scleral Lenses|Scleral lenses with customized wavefront guided optics
9704714|NCT04698590|Placebo Comparator|Traditional Scleral Lenses|Scleral lenses with traditional optics
9704715|NCT04698642|Experimental|CBL-514 180 mg, 1.2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
9704716|NCT04698642|Experimental|CBL-514 240 mg, 1.6 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
9704717|NCT04698642|Experimental|CBL-514 300 mg, 2 mg/cm^2|CBL-514 will be administrated with the grid spacing of 2.5 cm^2
9704718|NCT04698720|Experimental|Muscle Relaxation with Guided Imagery|The participants in Experimental Group will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
10192211|NCT03396081|Other|Usual care|
10192212|NCT03393078|Active Comparator|Real Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
10192213|NCT03393078|Sham Comparator|Sham Stimulation|The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
10192214|NCT03383679|Experimental|Arm 1 Darolutamide|Darolutamib: 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally, continuously until disease progression
10192215|NCT03383679|Other|Arm 2 Capecitabine|"according to the 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC3) capecitabine monotherapy is one of the recommended options even in first line (Cardoso et al, 2017).~According to each center policy (minimum 1000 mg/m²) twice daily for 2 weeks followed by 1-week rest period, until progression or unacceptable toxicity"
9785128|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 150 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 150 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
9704719|NCT04698720|Experimental|Hypnosis with Guided imagery|The participants in Experimental Group will receive a four individual 45-minute sessions, every two weeks, of hypnotic intervention with guided imagery focused on ulcer healing, carried out by the Hypnotherapist on the day of the Diabetic Foot appointments.
9704720|NCT04698720|Placebo Comparator|Active Control Group|Participants in the Active Control Group will receive four individual 45-minute sessions of neutral guided imagery placebo, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
9704721|NCT04698720|No Intervention|Passive Control Group|The participants in the Passive Control Group will not receive any intervention nor placebo session.
9704722|NCT04698577|Experimental|Attention Training|"Engaged in sustained updating by mentally keeping score during an interactive game without written or verbal aids.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
9704723|NCT04698577|Active Comparator|Active Control|"Played the same interactive game as the attention training group without the requirement of mentally keeping score.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
9704724|NCT04698798|Experimental|Skeletal muscle wasting|investigating acute skeletal muscle wasting in patients infected with SARS-CoV-2 and admitted to the ICU
9704725|NCT04698655|Active Comparator|Control group|"Asked to read a single-A4 page of brief osteoarthritis information (what is osteoarthritis)"
9704726|NCT04698655|Experimental|Treatment options group|"Asked to read brief osteoarthritis information + two A4 pages of information on treatment options (osteoarthritis treatment options)"
10192216|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
9704727|NCT04698655|Experimental|Treatment options + recommendation group|Asked to read brief osteoarthritis information + information on treatment options + receive hypothetical general practitioner recommendation for exercise
9704728|NCT04698486|Active Comparator|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD~MR spectroscopy verified no steatosis"
9704729|NCT04698486|Active Comparator|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD~MR spectroscopy verified steatosis"
9704730|NCT04698473|Active Comparator|NCPAP|"Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
10192217|NCT03367299|Experimental|Chemotherapy + Blinatumomab|Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
10192218|NCT03350269|Experimental|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
10192219|NCT03350269|No Intervention|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
9704731|NCT04698473|Active Comparator|NIPPV|"Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94.~Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O."
9704732|NCT04698707||lower limb lymphedema patients|This retrospective cohort study enrolled 131 lower limb lymphedema patients including 10 patients who have received VLNT as their primary lymphedema surgery showing minimal post-VLNT improvement (Group I) and 121 patients without previous lymphatic surgery (Group II).
9704733|NCT04698616||Malignant lymphoma patients|Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.
9704734|NCT04698993|Other|Symptomatic|Collection of specimens from symptomatic COVID-19 positive participants
9704735|NCT04698993|Other|Asymptomatic|Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2
9704736|NCT04698928|Experimental|Theta burst stimulation group|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
9704737|NCT04698772||Survey Packet 1 Group|"Patients who receive Packet 1 will be in group 1, or the treatment group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2. The physician will be asked to administer a sub-dissociative dose of ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)."
9704738|NCT04698772||Survey Packet 2 Group|"Patients who receive Packet 2 will be in group 2, or the control group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2.The physician will be asked to administer morphine 4 mg IV push over 3-5 minutes for pain control."
9704739|NCT04698421||patients with rare autoimmune neurological diseases|
10192220|NCT03341806|Experimental|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
10192221|NCT03333057|Experimental|NOV03 4 times daily (QID)|Perfluorohexyloctance solution 4 times daily (QID)
10192222|NCT03333057|Experimental|NOV03 2 times daily (BID)|Perfluorohexyloctance solution 2 times daily (BID)
10192223|NCT03333057|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
10192224|NCT03333057|Placebo Comparator|Placebo 2 times daily (BID)|Saline solution (0.9% sodium chloride solution) 2 times daily (BID)
9704740|NCT04698512||Arteriovenous Fistuloplasty with MagicTouch™ Balloon|Patients above the age of 21 that have undergone AVF / AVG fistuloplasty with MagicTouch™ at Singapore General Hospital will be included in the study and followed up post-op for 12 months. Patients will be treated and followed-up following standard clinical care pathways.
9704741|NCT04698447|Experimental|Dietary Supplement blinded|20 subjects with the metabolic syndrome receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
9704742|NCT04698447|Placebo Comparator|Placebo blinded|20 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
9704743|NCT04698447|Active Comparator|Dietary Supplement open-label|20 healthy volunteers receiving natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice (1000 mg/day)
9979590|NCT01383512|Experimental|Rehabilitation robotics|Subjects will be practicing an Armeo Spring rehabilitation program in addition to their usual care (1.5h/day,5d/week) 1h/day 5d/week 4 weeks.
9979591|NCT01383512|Active Comparator|Self-rehabilitation|Subject will associated to there classical care 1 hours, 5 days per week during 4 weeks, of self rehabilitation.
9704746|NCT04698668||1|Patients with pancreatic fluid collection treated with traditional EUS-drainage
9704747|NCT04698668||2|Patients with pancreatic fluid collection treated with fusion imaging
9778855|NCT01117350|Experimental|Insulin Glargine|"Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.~The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 < FPG ≤ 100 mg/dL (3.9 < FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation."
9778856|NCT01117350|Active Comparator|Liraglutide|"Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.~The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment."
9778857|NCT01117428|Experimental|Sym004|
9778858|NCT01117454|Other|Flecainide then placebo|In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
9778859|NCT01117454|Other|Placebo then flecainide|In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.
9778860|NCT01117480||Moderate-to-severe rheumatoid arthritis|Participants with moderate-to-severe rheumatoid arthritis treated with adalimumab in routine clinical practice
10192225|NCT03328988|Experimental|Quadratus lumborum block|Single shot bilateral QLB, ropivacaine 75 mg (20 mL) per side, placed under ultrasound control, at the end of surgery. 22 patients will be allocated in this group.
9778861|NCT01117623|Experimental|Arm 1|
9778862|NCT01117623|Experimental|Arm 2|
9778863|NCT01117623|Experimental|Arm 3|
9778864|NCT01117623|Experimental|Arm 4|
9778865|NCT01117623|Experimental|Arm 5|
9778866|NCT01117623|Experimental|Arm 6|
9778867|NCT01117623|Experimental|Arm 7|
9778868|NCT01117623|Experimental|Arm 8|
9778869|NCT01117727|Experimental|Pilot Testing|
9778870|NCT01117766|Active Comparator|Active drug|
9778871|NCT01117766|Placebo Comparator|Placebo|
9778872|NCT01117792|Experimental|S-ICD System|
9778873|NCT01117857|Experimental|Duloxetine|After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.
9778874|NCT01117870|Placebo Comparator|Placebo|The needle will be continuously stimulated at a low voltage to give a sensation of PRF treatment.
10192226|NCT03328988|No Intervention|Epidural|"Epidural catheter (placed before anesthesia induction), ropivacaine 75 mg in 50 mL isotonic saline (1,5 mg/mL), induction bolus after surgery 1 mL/10 kg ideal weight and there on continuous infusion 2-8 mL/h according to analgesic need. 22 patients will be allocated in this group.~This is the current standard for postoperative pain relief in cystectomy patients in our hospital"
9778875|NCT01117870|Experimental|Pulsed Radiofrequency|PRF will be applied for 120 seconds at 42 degrees celsius.
9778876|NCT01117948|Experimental|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
9778877|NCT01117948|Placebo Comparator|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
9778878|NCT01117987|Experimental|Core imatinib|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
9778879|NCT01117987|Experimental|Core placebo|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
9778880|NCT01118052|Experimental|Treatment (EGEN-001)|Patients receive intraperitoneal EGEN-001 on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9778881|NCT01118091|Active Comparator|Arm 1-Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
9785129|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 200 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 200 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
9704748|NCT04698551||16 pregnant women and their spouses|16 pregnant women and their spouses
9704749|NCT04698733|Experimental|Experimental: BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive 2 treatments a week on nonconsecutive days for 6 weeks in the clinic with an active electrical stimulation device.
9704750|NCT04698356|Experimental|Validation of auditory-cognitive training paradigm|In order to provide maximal speech-in-noise training benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate the translated and adjusted sentences (based on the Nottingham UK PLUS training paradigm), the adaptive procedure, and the short-term memory component, in young, normal-hearing adults (18-30 years). Based on the results of this pilot study, the investigators can further optimize the sentences and procedures to be used during the training paradigm for older adults.
10192227|NCT03316872|Experimental|Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)|"Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks~SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days."
9704751|NCT04698408|Experimental|high-protein, carbohydrate-reduced diet|
9704752|NCT04698408|Active Comparator|Dutch Nutritional Guidelines|
9704753|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 40 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 40 V.
9704754|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 60 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 60 V.
9704755|NCT04698395|Experimental|HABIT-ILE|Baby HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks
9704756|NCT04698395|Active Comparator|Regular care|Usual customary care intervention during two weeks
9704757|NCT04698252|No Intervention|Systemic therapy|Patients will receive standard of care with systemic therapy alone.
9704758|NCT04698252|Experimental|Local therapy + systemic therapy|In addition to systemic therapy, patients will receive local therapy for all oligometastatic sites. Options of local therapy will be radiotherapy, radiofrequency ablation, and/ or surgery.
9704759|NCT04698226|Active Comparator|ILM peel|Patients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade.
9704760|NCT04698226|Experimental|Inverted flap|Patients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.
9704761|NCT04698083||Group1:normal SpO2(NS,n = 80) and low SpO2(LS, n = 80).|Patients with normal oxygen saturation (SpO2; ≥ 90%) who did not receive oxygen therapy and patients with low SpO2(<90%) who received nasal oxygen therapy were included in this study
9704762|NCT04698083||Group2:Rightward axis shift(Rws) and Leftward axis shift (Lws)|Both groups were divided into two main subgroups:patients with Rws and patients with leftward shift(Lws) of the QRS axis.The patient numbers were as follows: NS Rws (n=37),NS Lws(n=43),LS Rws (n=40),andLS Lws (n=40)
9704763|NCT04698278||Surgical Treatment Group|This is a prospective, single center, bilateral, non-randomized, open-label, observational clinical study. All patients will have had prior myopic Lasik and will receive a PanOptix Trifocal IOL in both eyes at the time of cataract surgery. These patients will then be followed for up to 6-months to assess their refractive predictability, quality of vision, spectacle independence, and overall patient satisfaction.
9704764|NCT04698200|Experimental|Blood pressure|Measurement of brachial, central and beat-to-beat blood pressure.
9704765|NCT04698239|Experimental|Laser application ( BEFORE/AFTER)|"All patients will receive a maximum of 13 laser pulses in each lesion. We are going to make a comparison of the before and after the treatment, it is the patient himself who checks himself.~The number of lesions will be counted before treatment and after treatment(72-hour and 1-week ) . Adverse reactions will be collected at several visits as well, during the 2 weeks that the patient is included in the study."
9704766|NCT04698213|Experimental|intermittent axitinib plus Avelumab|"All patients enrolled in the trail will receive axitinib at 5 mg BID plus avelumab at 10 mg/Kg every two weeks.~Treatment will be continued until progression of disease during the first 36 weeks of therapy. At week 36, patients achieving a tumor decrease ≥ 30% will discontinue axitinib and continue avelumab until progression of disease defined as ≥ 20% increase compared to the tumor burden measured at week 36. At disease progression, axitinib will be restarted at the same dosage used before discontinuation for at least 24 weeks if progression did not occur before. Patients who achieved again tumor decrease of ≥ 30% after 24 weeks of therapy rechallenge with axitinib and avelumab may discontinue axitinib and maintain avelumab until progression of disease in an intermittent manner."
9704767|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 40 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 1 uses 40 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
9704768|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 20 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 2 uses 20 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
9704769|NCT04698265|Experimental|CellularMatrix (a combination of platelet-rich plasma and hyaluronic acid)|CellularMatrix (RegenLab SA, Switzerland) is composed of sterile and non-pyrogenic tubes allowing the mix of Platelet Rich Plasma (PRP) with Hyaluronic Acid (HA) in the same proportion (2mL of PRP for 2mL of HA).
9704770|NCT04698265|Placebo Comparator|Normal saline|4ml of normal saline
10192228|NCT03314272|No Intervention|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:~<150 mg/dl: 0 units of insulin~150-220 mg/dl: 2 units of insulin~201-250 mg/dl: 4 units~251-300 mg/dl: 6 units~301-350 mg/dl: 8 units~351-400 mg/dl: 10 units~> 400 mg/dl: inform the MD on call"
10204509|NCT05202626||Sun Yat-Sen University Cancer Center|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Sun Yat-Sen University Cancer Center. The clinicians in Sun Yat-Sen University Cancer Center consider it necessary to perform an endoscopic image-guided biopsy.
10192229|NCT03314272|Experimental|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.~Intervention:~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (<70mg/dl) and hyperglycemic (> 200mg/dl) events will be recorded."
10192230|NCT03305016|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
10192231|NCT03301532|Experimental|Patients on a ketogenic diet|This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.
10192232|NCT03300336|Experimental|Intervention|Implementation of STRIDE program
9704771|NCT04698291||Controls|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
9704772|NCT04698291||Cases|This research aims to recruit only adult volunteers that have taken part of the Gene & Health program. We will focus on two groups: individuals presenting the polymorphisms of interest and individuals without the genetic variants in the genes of interest, which will be used as matched controls. Eligible individuals will consent to donate blood samples for this study, in addition to consent access to their medical and health records.
9704773|NCT04698317|Experimental|beta-tricalcium phosphate plus concentrated growth factors|surgery plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group).
9704774|NCT04698317|Placebo Comparator|beta tricalcium phosphate alone(control group)|surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone. (control group),
9704775|NCT04698018|Experimental|Faster aspart|Subjects will receive 2 injections of a single dose of faster aspart at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
9704776|NCT04698018|Active Comparator|NovoRapid®|Subjects will receive 2 injections of a single dose of NovoRapid® at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
9704777|NCT04698044||Healthy|Have not chronic disease
9704778|NCT04698044||Cancer|Have cancer
9704779|NCT04698044||Non-Cancer Crhronic Disease|Have non-cancer chronic disease
9704780|NCT04697953|Experimental|brolucizumab 6mg|Open label, brolucizumab 6mg, daily dosing, Treat & Extend regimen by up to 2 week intervals. Dosing intervals as per previous therapy and treatment extension intervals
9704781|NCT04697992|Experimental|group A|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
10192233|NCT03300336|No Intervention|Usual Care|Pre-implementation before STRIDE program
10192234|NCT03291067|Experimental|MT-8554 1mg|
10192235|NCT03291067|Experimental|MT-8554 5mg|
10192236|NCT03291067|Experimental|MT-8554 10mg|
10192237|NCT03291067|Placebo Comparator|Placebo|
10192238|NCT03276221|Active Comparator|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
10192239|NCT03276221|No Intervention|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
10192240|NCT03276221|No Intervention|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
10192241|NCT03273907|Experimental|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
10192242|NCT03271047|Experimental|Phase 1b / Arm 1A|binimetinib + nivolumab
10192243|NCT03271047|Experimental|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
9704782|NCT04697992|Experimental|group B|one eye was treated with tranexamic acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
9704783|NCT04698005|Experimental|Supplementation of exogenous ketones|Exogeneous ketones will be administered orally using monoester 3-OHB concentrate without added salts (25g 3-OHB in 65ml H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent). The drink will be administered over 10 mins every 3 hours, 3 times in a row.
9704784|NCT04698005|Placebo Comparator|Control group|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
9704785|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
9704786|NCT04697862|Experimental|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
9704787|NCT04697836|Experimental|ST (superficial cervical plexus block combined with Translareyngeal block)|Superficial cervical plexus block combined with Translareyngeal block Group.
9704788|NCT04697836|Active Comparator|S (superficial cervical plexus block)|Superficial cervical plexus block Group
9704789|NCT04697849|Experimental|CREST|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
9704790|NCT04697849|Active Comparator|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
10192244|NCT03271047|Experimental|Phase 2 / Arm 2A|binimetinib + nivolumab
10192245|NCT03271047|Experimental|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
10192246|NCT03262610|Experimental|Setmelanotide daily subcutaneous injection|Up to 18 weeks setmelanotide treatment.
10192247|NCT03257436|Other|Single Arm|General population who receive a Boston Scientific Resonate family of CRT-D device in accordance with its labeled indication for use.
10192248|NCT03257150|Experimental|Study Treatment|Single arm trial of irreversible electroporation using the NanoKnife system for locally advanced pancreatic ductal adenocarcinoma.
10192249|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
9704791|NCT04697914|Placebo Comparator|Control Sock|Control comercial Socks (Lurbel Tierra). These socks are designed to perform trekking.
9704792|NCT04697914|Experimental|Experimental Relief Pressure sock|Experimental Socks (Lurbel Tierra based), with a discharge element (in the own fabric and fibres of the sock).
10192250|NCT03248154|No Intervention|Immunocompetent with 2-14% TBSA|Immunocompetent with 2-14% TBSA thermal burn subjects. Does biofilm infection result in conversion of partial-thickness burn wounds to full-thickness?
10192251|NCT03248154|Experimental|Immunocompromised with >=20% TBSA|Immunocompromised patients with large thermal burn >=20% TBSA. Higher bacterial burden with biofilm infection will result in higher rates of graft loss. Does application of a wireless electroceutical dressing (Procellera) lower biofilm burden compared to burn subjects receiving standard of care therapy?
10192252|NCT03248154|No Intervention|Peripheral blood - all subjects|All subjects enrolled in arms 1 and 2. Do children have a more robust innate immune response to prevent biofilm infection?
10192253|NCT03212794|Experimental|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine or methadone treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
9704793|NCT04697680|Active Comparator|Group 1|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 1) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
9704794|NCT04697680|Active Comparator|Group 2|Subjects randomized into Group 2 will be provided with a sleep schedule each week based on an algorithm (Algorithm 2) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
10192254|NCT03212794|No Intervention|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine or methadone.
9704795|NCT04697680|Active Comparator|Group 3|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 3) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
9704796|NCT04697446||Patients from the BLU-667-1101 (ARROW) study|Patients with Non-Small Cell Lung Cancer (NSCLC) who received treatment with pralsetinib as part of the BLU-667-1101 (ARROW) study
9704797|NCT04697446||External Control Group|Patients with Non-Small Cell Lung Cancer (NSCLC) that received best available therapy
9704798|NCT04697602|Experimental|Dose titration group|Stepwise dose titration of febuxostat and low-dose colchicine
9704799|NCT04697602|Active Comparator|Standard treatment group|Fixed dose febuxostat and low-dose colchicine
9704800|NCT04697641|Experimental|Helicobacter pylori eradication therapy Group|Patients with Functional Dyspepsia receiving two week course of triple drug regimen for H pylori eradication followed by six weeks of proton pump inhibitors
9704801|NCT04697641|Active Comparator|Symptomatic treatment group|Patients with Functional Dyspepsia receiving symptomatic therapy with proton pump inhibitors or gastric prokinetics
9704802|NCT04697888|Experimental|Overall Study|Use of Omegaven for patients with parenteral nutrition associated liver disease.
9704803|NCT04697524|Experimental|Phase 1: Supportive care (GMV)|Participants will take a baseline assessment to collect socio-demographic information and complete a series of patient-reported outcome assessments (PROs) prior to their first group medical visit (GMV). The GMV intervention will take place over four weekly sessions conducted virtually. At the completion of all four weekly GMV sessions, participants will be asked to complete an exit survey. Participants in phase one will not be contacted or followed after the exit survey.
9704804|NCT04697524|Experimental|Phase 2: Refined GMV|Up to three new cohorts of participants are recruited to assess the acceptability and feasibility of the refined intervention based on the results from the Phase 1 group
9704805|NCT04697732||Adult patients age above 18 years|ASA I-IV adult patients over 18 years of age who will receive general anesthesia and are scheduled to be extubated postoperatively, who can give informed consent, have no known psychological or psychiatric problems, and who are suitable for postoperative follow-up.
9704806|NCT04697589|Experimental|SBRP 300 mg|300 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
9704807|NCT04697589|Experimental|SBRP 600 mg|600 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
9704808|NCT04697589|Placebo Comparator|Placebo|Colored maltodextrin
10192255|NCT03187860|Experimental|Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)"
10192256|NCT03187860|Experimental|Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))~Intervention: Bronchial Biopsy + ALI culture"
9704814|NCT04697784|Experimental|Subjects who receive the TREO Abdominal Stent-Graft System|Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.
9704815|NCT04697706|Active Comparator|"Study period Water"|Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.
9704816|NCT04697706|Experimental|"Study period Moonstone"|Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.
10192257|NCT03187860|Experimental|Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD~Intervention: Bronchial Biopsy + ALI culture"
10192258|NCT03187860|Experimental|Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.~Intervention: Bronchial Biopsy + ALI culture"
9704817|NCT04697771|Experimental|Study Group|First Evaluation - Fine Motor Skills Training - 8 week - 3 session per week - 40 minute per session - Second Evaluation
9704818|NCT04697771|Other|Kontrol Group|First Evaluation - 8 week waiting period - Second Evaluation - 8 week Fine Motor Skills Training
9704819|NCT04697537|Active Comparator|Ultrasound guided regional anesthesia|Patient will be given a peripheral nerve block from their treating anesthesiologist before the operation (in the OR) with an conventional ultrasound guided femoral and sciatic block of each 15 ml ropivacaine 0,5% and 0,5 ml dexmedetomidine (100µg/ml).
9704820|NCT04697537|Active Comparator|Local infiltration analgesia|Patient will be given a local infiltration analgesia from their treating surgeon during the operation (in the OR) with 60 ml ropivacaine 0,5% and 1 ml dexmedetomidine (100µg/ml).
9704821|NCT04697615||Algometry|In the test stage, pain threshold evaluations were started through the algometer in a randomized manner by two different examiners trained and experienced in the application of the test, following the same order of evaluation of the muscles (middle deltoid, upper trapezius, pectoralis major, biceps brachii , triceps, lumbar multifidus, rectus femoris, biceps femoris, tibialis anterior and soleus, bilaterally), with an interval between each assessment of five minutes in which the participants remained at rest. After the interval described, the retest stage was initiated, which had the same procedures as the test stage.
9704822|NCT04697485|Experimental|Low-Dose, Triple Polydiuretic Therapy (LDTPT)|Polydiuretic therapy will consist of bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg once daily for 4 weeks.
10192259|NCT03180554|Other|tVNS version 1|Transcutaneous vagus nerve stimulation (tVNS) version 1 will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
9704823|NCT04697745|Active Comparator|dexamethasone intrathecal|
9704824|NCT04697745|Active Comparator|dexmedetomidine intrathecal|
9704825|NCT04697875|Experimental|Normobaric hypoxia (FiO2 15%)|
9704826|NCT04697875|Sham Comparator|Placebo-ambient air (FiO2 21%)|
9704827|NCT04697511|Experimental|Midazolam and/or M2951|
9704828|NCT04697355|Experimental|Naringenin + Beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day
9704829|NCT04697277|Active Comparator|Group 1|Group 1 (Prophylactic antibiotic 30 minutes before skin incision): Antibiotic diluted in 10 ml syringe 30 minutes before skin incision and after cord clamping, 0.9% NaCl in 10 ml syringe will be administered intravenously within 15 seconds.
9704830|NCT04697277|Active Comparator|Group 2|Group 2 (prophylactic antibiotic after cord clamping): 30 minutes before the skin incision, 0.9% NaCl in a 10 ml injector and after the cord is clamped, the antibiotic diluted in a 10 ml syringe will be administered intravenously within 15 seconds.
9704831|NCT04697342|Active Comparator|NIS with pressure injury(PI) education|Clinical nurses use Nursing information system(NIS) to log in nursing records every day, and pressure injury (PI) education pops out of the NIS window for teaching
9704832|NCT04697342|Active Comparator|NIS with PI education, and microvideo|In addition to the built-in PI education in the NIS that nurses use every day, it also provides a flipped digital learning plan course unit, which can be self-study courses anytime, anywhere, without being restricted by time and space. And hold a 4-hour physical course for participants.
9704833|NCT04697342|Experimental|NIS with PI education, and workshop|In addition to the built-in PI education in the NIS that nurses use every day, an 8-hour physical course is also provided.
9704834|NCT04697316|Experimental|ADHD tDCS|
9704835|NCT04697316|Sham Comparator|ADHD Sham|
9704836|NCT04697316|Experimental|Healthy control tDCS|
9704837|NCT04697316|Sham Comparator|Healthy control Sham|
9704838|NCT04697108|Other|Proprioception Test (TRMOPL)|In the Familiarization stage (1), the TRMOPL was applied by means of a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability.
9704839|NCT04697082|Placebo Comparator|Group A|The open surgical method and a moist gauze (with saline) were applied to patients in group A
10192260|NCT03180554|Other|tVNS version 2|Transcutaneous vagus nerve stimulation (tVNS) version 2 will be delivered non-invasively via a portable take-home stimulation device which attaches to the center of the left ear lobe. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
9704840|NCT04697082|Experimental|Group B|Open surgery and then PRP application were performed on patients in group B. After the cavity was filled with PRP, the wound was covered with a dry gauze.
9704841|NCT04697082|Experimental|Group C|PRP was applied to the patients in group C after curettage of the sinus cavity. And again the wound was covered with a dry gauze.
9704842|NCT04697199|Placebo Comparator|Placebo group|patients received scaling and root planing using hand and ultrasonic instruments.
9979592|NCT01383512|Other|Healthy volunteer|20 healthy volunteer will be recruiting and using ARMEO Spring. All volunteer will repeat 5 times the same program on the medical device.
10192261|NCT03180554|Other|MNRB version 1|Motivational nondirective resonance breathing (MNRB) version 1 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a deep breathing session. Participants will practice MNRB version 1 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
9704843|NCT04697199|Active Comparator|Probiotic group|"patients received SRP and by using blunt syringe, subgingival delivery of 1ml of probiotic suspension was applied to these sites at baseline (immediately after SRP), one, two and four weeks. Periodontal dressing was applied after placement of the drug.~After placement of the drug, patients were instructed to keep away from chewing hard or sticky food, brushing near the treated areas, or using any interdental aids for 24 hours."
9704844|NCT04697303||Middle and low rectal cancer|
9704845|NCT04697056|Experimental|ANB019 Biological|humanized monoclonal antibody
9704846|NCT04697056|Placebo Comparator|placebo|solution
9704847|NCT04697433||Myotonometry|The evaluation of myotonometry will be carried out by two independent evaluators. The first evaluator will perform the test bilaterally on the middle deltoid, upper trapezius, pectoralis major, biceps brachii, rectus femoris, anterior tibialis, triceps brachii, lumbar multifidus, biceps femoris and soleus previously marked. Immediately after, the second appraiser will perform the same measurements in the same order (Inter-rater reliability). After a 15-minute interval, the retest (intra-rater reliability) will be performed following the same procedure and order as the test step.
9704848|NCT04697264|Experimental|Patients with endometrial cancer|"Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.~Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.~Blood sample will be collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 3/6 months post-surgery follow-up in clinic.~For the women undergoing chemotherapy, blood sample will be procured prior to commencing chemotherapy and after 3rd (with the blood test before the fourth cycle of chemotherapy) and 6th cycles of chemotherapy."
9704849|NCT04697420|Experimental|Group (P)|the patients were received paravertebral block to control pain postoperatively.
9704850|NCT04697420|Experimental|Group (T)|the patients were received transversus abdomins plane (TAP) block to control pain postoperatively.
10192262|NCT03180554|Other|MNRB version 2|Motivational nondirective resonance breathing (MNRB) version 2 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a paced breathing session. Participants will practice MNRB version 2 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
9704851|NCT04697147|Experimental|Intervention Group|Immediately randomized to receive the intervention for 12 weeks.
9704852|NCT04697147|No Intervention|Waitlist Control|Randomized to receive the intervention post-study.
9704853|NCT04696926||patients who underwent an aortic valve replacement|
10192263|NCT03171480|Experimental|Monoket pill|Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,
9704854|NCT04696978||PND group|patients occur neurocognitive disorders according to scores in this group
9704855|NCT04696978||NO PND group|patients do not occur neurocognitive disorders according to scores in this group
9704856|NCT04697368|Experimental|Experimental Group (EG)|The experimental group (EG), in addition to the standard treatment, will perform one session per day, each lasting 40 minutes, with the Armeo Power robotic system for upper limb rehabilitation. Each subject will perform a total of 25 ± 3 treatment sessions with a frequency of 5 times a week for 5 weeks.
9704857|NCT04697368|Active Comparator|Control Group (CG)|The control group (CG), in addition to the standard routine rehabilitation treatment, will follow 40 minutes of conventional upper limb rehabilitation. Each subject will perform a total of 25 ± 3 conventional upper limb treatment sessions with a frequency of 5 times a week for 5 weeks.
9979593|NCT01383525|Experimental|Direct Selective Trabeculoplasty|Treatment by an Direct Selective Trabeculoplasty device
9979594|NCT01383538|Experimental|FOLFIRINOX Plus IPI-926|
9979595|NCT01383551|Experimental|"Becoming Parents intervention"|"A Becoming Parents Programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
9704861|NCT04697069|Experimental|ANB019|Biological humanized monoclonal antibody
9704862|NCT04697069|Placebo Comparator|Placebo|Solution
9704863|NCT04697134|Experimental|Conscious Discipline Intervention Group|Participants in this group received one-on-one Conscious Discipline classes with a Roving Caregiver. These classes consisted of the dissemination of Conscious Discipline Skills and fun songs, games, and activities to foster connections between the infant and caregiver. Both the infant and caregiver received the intervention simultaneously.
9704864|NCT04697134|No Intervention|Control|Participants in this group did not receive the intervention.
9704865|NCT04697095|Experimental|early / intermediate AMD without neovessels and without macular atrophy|
9704866|NCT04697095|Experimental|Late exsudative AMD with neovessels|
9704867|NCT04697095|Experimental|Late AMD with macular atrophy without neovessels|
9704868|NCT04697095|Sham Comparator|Patientes with No AMD|
9704869|NCT04696887|Experimental|Tele Tai Chi|8-week Tele Tai Chi intervention
9704870|NCT04697017|Other|Multiple births (twins and triplets)|Twins and triplets who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study
10192264|NCT03171480|Placebo Comparator|Placebo pill|The pharmacy has compounded an identical appearing placebo
10204510|NCT05202626||Guangdong Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Guangdong Provincial People's Hospital. The clinicians in Guangdong Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
10192265|NCT03164655|Experimental|HAI oxaliplatin combined with I.V. FOLFIRI + target therapy|"HAI oxaliplatin 100 mg/m² on D1~I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT~modified FOLFIRI regimen without fluorouracil bolus~I.V. irinotecan 180 mg/m² D1~I.V. bolus 5-Fluorouracil (5-FU): 0~I.V. leucovorin 400 mg/m² in 2 hours D1~I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours"
9704871|NCT04697017|Other|Singletons|Singletons who had developmental anomalies such as cleft lip and palate, premature tooth loss, systemic diseases or syndromes that could influence oral health or had already undergone or were undergoing orthodontic therapy, as well as those whose family did not give consent, were excluded from the study.
9704872|NCT04696965|Experimental|Correct/recheck strategy|Patients of study arm will be asked to show how they use their two inhalers and identify errors using a device-specific checklist by research assistant. Research assistant then show the patient how to use these devices correctly and give the checklist including the steps patients did wrong. After teaching by the research assistant, patients were asked to demonstrate the correct way of wrong step(s) they made at beginning.
9704873|NCT04696965|Active Comparator|Usual verbal instruction|Patients of control arm will be asked to show how thy use their two inhalers and identify errors using specific check list by research assistant. The educational nurse will give verbal instruction.
9704874|NCT04696991|Experimental|Experimental Group|The mothers in the experimental group (70) were given the postpartum discharge education with PechaKucha Method.
9704875|NCT04696991|No Intervention|Control Group|The mothers in the control group (70) were given the routine postpartum discharge education.
9704876|NCT04696939|Experimental|Atezolizumab + Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Atezolizumab, 1200 milligrams(mg) on Day 1 of every 21-day cycle, 2 cycles; Carboplatin, 75 mg per square meter(mg/m^2) on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.~Surgery: patients will receive surgery."
9704877|NCT04696939|Active Comparator|Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Carboplatin, 75 mg/m^2 on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.~Surgery: patients will receive surgery."
9704878|NCT04696913||Pulmonary Embolism Positive|As determined by CT Pulmonary Angiogram
10192266|NCT03164655|Active Comparator|conventional systemic CT|"Response to systemic induction CT~Toxicity and duration of the systemic induction CT~RAS status~Current guidelines/standard of care"
10192267|NCT03162627|Experimental|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.~When maximum tolerated dose reached, Dose Expansion Phase begins."
10192268|NCT03162627|Experimental|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
9704879|NCT04696913||Pulmonary Embolism Negative|As determined by CT Pulmonary Angiogram
9704880|NCT04697186|Experimental|berberine , amoxicillin and rabeprazole triple therapy|Berberine 300mg three time daily for 14days, amoxicillin 1000 mg and rabeprazole 10 mg by mouth, twice daily for 14 days.
9704881|NCT04697186|Active Comparator|Bismuth-containing Quadruple Therapy|amoxicillin 1000 mg，clarithromy 500mg，rabeprazole 10 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
9704882|NCT04697121|Placebo Comparator|Placebo|
9704883|NCT04697121|Active Comparator|Combined Bergamot Phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract
9704884|NCT04697251|Other|FOT measurements|FOT measurements in newborns and small infants
9704885|NCT04697043|Experimental|systemic therapy followed by surgery|"ُThe main intervention is surgery. After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
9704886|NCT04697043|No Intervention|Systemic therapy|"After the diagnosis of primary distant metastatic breast cancer, patients will be randomly allocated into two groups: A. systemic therapy followed by surgery if the disease is not progressive; B. Systemic therapy Patient selection criteria~The eligibility criteria for the study are:~- primary distant metastatic breast cancer (M1); - an anticipated survival of at least 6 months; - a histologically proven diagnosis of the breast tumor; - a known hormonal and HER2Neu status; - TNM classification: T1-T3, resectable T4 status, and N0-N3; - performance status and comorbidity should allow surgery and/or systemic therapy; - age ≥ 18 years;- written informed consent."
9704887|NCT04696770|Experimental|Mindfulness Intervention|"Four face-to-face direct coachings on Mindfulness technique at weekly intervals. The following will be the broad theme of each coaching session~Week 1 - On the first encounter, the mothers will learn how to practice an introductory mindfulness technique to develop the awareness of any sensations felt in the body while holding their baby.~Week 2 - On the second encounter, the mothers will learn how to practice a second mindfulness technique to create positive feelings in the body while holding their baby.~During the third and fourth weekly encounters, the mothers will have a chance to ask their questions and explore further both mindfulness techniques as needed."
9704888|NCT04696770|No Intervention|Control|Standard of care will be offered to all mothers in the control group which includes kangaroo care but does not involve any mindfulness practices.
9704889|NCT04696848|Experimental|CKD-516 plus Durvalumab|Stage 1 : dose escalation durvalumab (1500 mg Q4W) plus CKD-516 at dose levels (9, 11, or 13 mg/m2) Stage 2 : durvalumab (1500 mg Q4W) plus CKD-516 at recommended phase 2 dose
9704890|NCT04696679||Very preterm children group|
9704891|NCT04696679||Control group|
10192269|NCT03162627|Experimental|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
10192270|NCT03162627|Experimental|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
9704892|NCT04696666|Experimental|Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeks|Single Group Assignment
9704893|NCT04696783|Experimental|Drug Group|Esomeprazole Magnesium Enteric-coated Tablets and lifestyle adjustment
10192271|NCT03162627|Experimental|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
10192272|NCT03160794|Experimental|[18F] DCFPyL PET/MRI|"[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.~Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery."
9704894|NCT04696783|Placebo Comparator|non-Drug Group|Only lifestyle adjustment
10192273|NCT03158285|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
9704895|NCT04696705|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 2 cycles of ex-vivo expanded allogeneic γδT cells treatments, at 14 days' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
9704896|NCT04696588|Experimental|Kinesiotherapy group|This is the group (n=59) receives treatment i.e complex set of neck exercises and massage
9704897|NCT04696588|No Intervention|Waiting List group|Individuals registered in the waiting list for receiving the treatment specified for kinesiotherapy group (n=59).These patients receive no treatment for tinnitus.
9704898|NCT04696718|Experimental|Traitement 1|Lactobacillus salivarius
10192274|NCT03158285|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
9704899|NCT04696718|Experimental|Traitement 2|Lactobacillus Rhamnosus GG
9704900|NCT04696718|Experimental|Traitement 3|Bifidobacterium lactis
9704901|NCT04696523|Active Comparator|Air/Oxygen|Control arm: air/oxygen with standard of care
9704902|NCT04696523|Experimental|xenon|Xenon arm: xenon inhalation in air/oxygen with standard of care
9704903|NCT04696796|Experimental|BasIQ-4 Surgical Knife|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with BasIQ-4 Surgical Knife according to computer generated randomization.
9704904|NCT04696796|Active Comparator|Episiotomy Scissors|Following the administration of 10 ml of 1% lidocaine, mediolateral episiotomy will be preformed with episiotomy scissors according to computer generated randomization.
9704905|NCT04696237||orthodontists|
9704906|NCT04696237||general dentists|
9704907|NCT04696237||oral and maxillofacial surgeons|
9704908|NCT04696237||plastic surgeons|
9704909|NCT04696237||cleft nurses|
9704910|NCT04696237||cleft lip and palate patients|
9704911|NCT04696237||speech therapists|
9704912|NCT04696237||ENT specialists|
10192275|NCT03158285|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
10192276|NCT03115424|Placebo Comparator|Sleeve Gastrectomy Placebo|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
10192277|NCT03115424|Active Comparator|Sleeve Gastrectomy Saxenda|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
9704913|NCT04696237||psychiatrists|
9704914|NCT04696406||Weaning failure|Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours
9704915|NCT04696406||Weaning success|Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation.
9704916|NCT04696224|Active Comparator|INTRAVENOUS|30 patients who will receive 15mg / kg of TXA intravenous in 100ml salina solution (0,9%), after anesthetic induction and before incising the skin (administered in 10 minutes). For masking purposes, these patients will also receive at the end of the surgery, and before performing the plan closure, a compress soaked in 80ml of saline solution (0.9%), which will fill all the plans of the incision, and will be kept for 5 minutes.
9704917|NCT04696224|Active Comparator|LOCAL|30 patients who, at the end of the surgery, and before the suture in layers, will receive a compress soaked in a solution of 1.5 g of tranexamic acid (six ampoules of Transamin®, Zydus Nikkho) diluted in 50 ml of saline solution (0.9 %) (total volume of 80ml), which will fill all the plans of the incision and will be maintained for 5 minutes. For masking purposes, these patients will also receive 100ml of saline solution (0.9%) after anesthetic induction and before incising the skin.
9704918|NCT04696224|Placebo Comparator|PLACEBO|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2.
9704919|NCT04696510||Chronic migraineurs|This group includes patients with chronic migraine.
9704920|NCT04696510||Control group|This group includes healthy subjects.
9704921|NCT04696510||Episodic migraineurs|This group includes patients with episodic migraine
9704922|NCT04696211|Experimental|Experimental group|The music-with-movement exercise program (MMEP) is an 8-week program. In the first 4 weeks a center-based program will be offered in the District Elderly Centers, and from week 1 to week 8 home-based and digital-based activities will be delivered via a WhatsApp group.
9704923|NCT04696211|No Intervention|Control group|The participants in the control group will continue to receive their usual care and receive a one-page pain management pamphlet.
10192278|NCT03115424|Sham Comparator|RYGB|Twenty five subjects will be recruited from the Nutrition Clinic at Mayo Clinic Rochester prior to undergoing RYGB surgery.
10192279|NCT03074240|Active Comparator|TAPB Group|Compare the instance in the TAPB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing TAPB to anesthetize the abdominal wall.
9704924|NCT04696562|Experimental|Intervention group|The intervention group is the group in which the investigors applied deep breathing exercises with triflo.
9704925|NCT04696562|No Intervention|Control group|The control group is the group that receives standard clinical care.
9704926|NCT04696432|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
10192280|NCT03074240|Active Comparator|RSB Group|Compare the instance in the RSB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing RSB to anesthetize the abdominal wall.
9704927|NCT04696601|Experimental|Olfactory test|The result of the olfactory test will be compared to the result of the RT-PCR test.
9704928|NCT04696328|Experimental|Group of subjects undergoing cell transplantation|Human (allogeneic) iPS cell derived-cardiomyocyte sheet transplantation (only once)
9704929|NCT04696627||Dural puncture|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
9704930|NCT04696627||Dural puncture with blood patch|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019 that were treated with an epidural blood patch.
9704931|NCT04696627||No dural puncture|Patients who did not have recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
9704932|NCT04696458|Experimental|EXPERIMENTAL PROBIOTIC|1 Multistrain Probiotic Capsule
9704933|NCT04696458|Placebo Comparator|Placebo|1 Identical Placebo Capsule
9778882|NCT01118091|Experimental|Arm 2 - Adoptive cell therapy|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x10^8) and the administration of high-dose aldesleukin.
9778883|NCT01118117|Experimental|Misago™ Self-Expanding Stent System|
9778884|NCT01118143|Experimental|intervention group|Tailored oral health literacy instruction
9778885|NCT01118143|No Intervention|control group|Oral health instruction not tailored to oral health literacy level
9778886|NCT01118221|Experimental|Arm 1|enroll in pulmonary rehabilitation program
9778887|NCT01118221|No Intervention|Arm 2|no structured exercise
9778888|NCT01118273|Experimental|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|
9778889|NCT01118273|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
9778890|NCT01118273|Experimental|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|
9778891|NCT01118273|Active Comparator|Naproxen Sodium 220 mg (BAYH6689)|
9778892|NCT01118273|Active Comparator|DPH 50mg|
9778893|NCT01118273|Active Comparator|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|
9778894|NCT01118299|Experimental|Device|AMPLATZER Cardiac Plug
9778895|NCT01118299|Active Comparator|Optimal Medical Therapy (control)|Warfarin Dabigatran
9778896|NCT01118312|Active Comparator|Nasal Steroid|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
9778897|NCT01118312|Placebo Comparator|Placebo|Intranasal placebo, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
9778898|NCT01118325|Experimental|AZD6140 45 mg bd|
9778899|NCT01118325|Experimental|AZD6140 90 mg bd|
9778900|NCT01118325|Active Comparator|Clopidogrel 75 mg od|
9778901|NCT01118338|Experimental|Redesigned Purevision Contact Lens|Redesigned Bausch & Lomb PureVision contact lens
9778902|NCT01118338|Active Comparator|PureVision Contact Lens|Bausch & Lomb PureVision contact lens
9778903|NCT01118351|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
9778904|NCT01118377|Experimental|Capecitabine + radiation therapy|Participants received 9 weeks of capecitabine 650 mg/m^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.
9778905|NCT01118455|Experimental|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
9778906|NCT01118455|Experimental|Anti-Epileptic Drug (AED)|This arm will supply a comparison between VNS and new AEDs which is necessary to determine an overall treatment regimen for the 30% to 40% of patients who fail to respond to 2 AEDs.
9778907|NCT01118520|Active Comparator|perindopril|ACE inhibitor blood pressure lowering agent
9778908|NCT01118520|Active Comparator|amlodipine|calcium channel blocker blood pressure lowering agent
9778909|NCT01118520|Placebo Comparator|placebo|inactive substance identical in appearance to the othe two comparators
9778910|NCT01118624|Experimental|Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin (Folotyn)|"Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
9778911|NCT01118663|Experimental|Acetadote without EDTA|Acetadote EF [Ethylenediaminetetraacetic Acid (EDTA) - Free]
9778912|NCT01118663|Active Comparator|Acetadote|Acetadote [Old formulation containing EDTA]
9778913|NCT01118715|Experimental|Compression glove|Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
9778914|NCT01118715|No Intervention|Control|Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.
9979596|NCT01383551|No Intervention|Usual prenatal education|Attend usual prenatal classes which will be provided by the midwives in the hospital.
9979597|NCT01383564|Active Comparator|CPAP group|CPAP group
10192281|NCT05276882|Experimental|hypnosis|
10192282|NCT05276882|Active Comparator|pre-surgery consultation|
9704934|NCT04696393|Experimental|Treatment Sequence 1: AB|Participants will receive Treatment A (mitapivat 100 milligram [mg] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
9704935|NCT04696393|Experimental|Treatment Sequence 1: BA|Participants will receive Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment A (mitapivat 100 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
9704936|NCT04696315||SCD subjects with positive amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with positive amyloid show the evidence of amyloid deposition in brain. They have higher risk of conversion to mild cognitive impairment and dementia compared with SCD with negative amyloid. They are also considered as preclinical AD.
9704937|NCT04696315||SCD subjects with negative amyloid|In this study, the participants are from two research centers in China and Germany. All participants will conduct amyloid PET scanning, after which they are classified into two grous (SCD with amyloid+ and SCD with amyloid-). SCD subjects with negative amyloid do not show the evidence of amyloid deposition in brain. They have lower risk of conversion to mild cognitive impairment and dementia compared with SCD with positive amyloid.
9704938|NCT04696367||Patients with acute intra-abdominal pathology|Patients admitted to hospital with acute intra-abdominal pathology
9704939|NCT04696250||Adverse Events associated with Antineoplastic and Immunomodulating Agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by anticancer drugs, with a chronology compatible with the drug toxicity
9704940|NCT04696341|Experimental|Matrix Rhythm Therapy|Group I (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound, conventional massage and Matrix Rhythm Therapy were applied. Home-based exercise program and recommendations were also given to patients.
9704941|NCT04696341|Experimental|Control|Group II (15 subjects) received 10 sessions as 5 sessions a week. Hot pack to cervical and upper thoracic regions, conventional TENS, therapeutic ultrasound and conventional massage were applied. Home-based exercise program and recommendations were also given to patients.
9704942|NCT04696302|Experimental|Focus of attention in individuals post chronic stroke during seated lateral weight shifting|Feasibility study
9704943|NCT04696302|Experimental|Focus of attention in individuals post acute stroke during seated lateral weight shifting|Feasibility study
9704944|NCT04696276|Experimental|A-ERAS|will receive ERAS pathways care
9704945|NCT04696276|No Intervention|B-nonERAS|will receive traditional non ERAS care
9704946|NCT04696536|Experimental|Group 1: Listerine Cool Mint Mouth Rinse (Marketed product)|Participants will receive Alcohol-containing Essential Oil (AEO) containing mouth rinse (Listerine Cool Mint, marketed) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
9704947|NCT04696536|Experimental|Group 2: Negative Control (5 Percent (%) Hydroalcohol Mouth Rinse)|Participants will receive negative control mouth rinse (5% Hydroalcohol mouth rinse) orally for 12 weeks. Participant will brush their teeth and rinse once daily under supervision during the week (five days) for 30 seconds with 20 milliliter (mL) of mouth rinse and brush their teeth and rinse a second time each day during the week at home. During the weekends, participants will brush twice daily in their usual manner, following rinsing with their assigned mouth rinse, unsupervised at home.
9704948|NCT04696536|Experimental|Group 3: Flossing Performed by Dental Hygienist|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Dental hygienist will floss participant's teeth at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
9704949|NCT04696536|Experimental|Group 4: Flossing under Supervision|Participants will brush their teeth and then undergo instructions on flossing technique using reach dental floss orally for 12 Weeks. Participants floss their teeth under supervision at the site once daily during the week (five days). The second brushing will be done unsupervised at home. The remaining weekend days flossing and brushing will be done unsupervised at home.
9704950|NCT04696185|Active Comparator|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg
9704951|NCT04696185|No Intervention|Standard care|No SGLT-2 inhibitor therapy with dapagliflozin
9704952|NCT04696068||Control|The patients included in this group will receive meals with the usual presentation (plastic trays) during six days. Their data will be collected at day 1 and day 6.
9704953|NCT04696068||Experimental|The patients included in this group will receive the main course in porcelain plates during six days. Their data will be collected at day 1 and day 6.
9704954|NCT04696107|Experimental|Intervention Group|Standard pharmacological treatment aimed at controlling mCNCP with four-week face to face psychoeducational intervention.
9704955|NCT04696107|No Intervention|Control Group|Standard pharmacological treatment aimed at controlling mCNCP without psychoeducational intervention.
9704956|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) with postoperative ARDS|
9704957|NCT04696172||Patients undergoing cardiopulmonary bypass (CPB) without postoperative ARDS|
9979598|NCT01383564|Placebo Comparator|non CPAP group|non CPAP group
10192283|NCT05276869||group A|from 3 to 7 years included 36 patients
10192284|NCT05276869||group B|from 8 to 16 years included 17 patients
10192285|NCT05276843|Experimental|group A|receive Qigong exercise in addition to traditional physical therapy program
10192286|NCT05276843|No Intervention|group B|receive traditional physical therapy program only
10192287|NCT05276830|Experimental|40 micrograms|Sublingual film containing 40 micrograms Dexmedetomidine
10192288|NCT05276830|Experimental|60 micrograms|Sublingual film containing 60 micrograms Dexmedetomidine
10192289|NCT05276830|Experimental|Placebo|Sublingual Placebo film
10192290|NCT05276817|Sham Comparator|Perio maint. then sham laser|
10192291|NCT05276817|Experimental|Perio maint. then medicament|
10192292|NCT05276817|Experimental|Perio maint. then diode laser 1|
9704958|NCT04695990|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given Wenyang Huoxue Decoction, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
9704959|NCT04695990|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
9704960|NCT04696016|Experimental|Skin conductance guided|Sufentanil is titrated by the intensive care team to maintain skin conductance in target
9704961|NCT04696016|Active Comparator|Standard care|Sufentanil is titrated at the discretion of the intensivist
9704962|NCT04696003|No Intervention|control|The patients with classic PPROM between 22/0-26/0 weeks' gestation with oligo/anhydramnion with standard conservative treatment (7 days Amoxicillin/Clarithromycin therapy or 7 days Amoxicillin and once Azithromycin 1 g per os, and corticosteroids like Celestan®, Essex Pharma, Munich, Germany) as RDS prophylaxis will represent the control group (DGGG Guideline AWMF 015-025, February 2019, Version 1.0). The diagnosis of the PPROM must be not early than 20/0 weeks' gestation.
9704963|NCT04696003|Active Comparator|Amnion Flush group (continuous amnioinfusion)|"In the Amnion Flush group additionally to the standard treatment the amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intra-amniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. Amnion Flush Solution (CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h (2400 ml/d) under periodic ultrasound using the standard i.v. pump. The deepest pool of amniotic ﬂuid should be stabilized by about 4 cm. The ultrasound control will be performed daily. Induction of the labour or c-section at 34/0 week of gestation or earlier if indicated."
9704964|NCT04696042||Lanreotide|Patients treated with lanreotide
9979599|NCT01383577|Experimental|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each session of treatment.
9704966|NCT04695886|Experimental|CIME intervention|Community-delivered Integrated Malaria Elimination (CIME). The CIME intervention model integrates interventions for malaria, dengue, tuberculosis, childhood diarrhoea and RDT-negative fever.
9704967|NCT04695886|No Intervention|ICMV standard of care|Integrated Community Malaria Volunteer (ICMV) model - this is the current standard of care. This model involves malaria volunteers undertaking additional screening and referral services for a range of other diseases including: dengue, lymphatic filariasis, tuberculosis, HIV/AIDS and leprosy.
9704968|NCT04695782|Experimental|Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)/44fx (1.25 Gy per fraction), two daily|
9704969|NCT04695782|Experimental|Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)/46-52 fx (1.25 per fraction) two daily|
9704970|NCT04695964|Other|ICG-NIRF Imaging and objective perfusion rate|ICG-NIRF imaging is used to visualise the blood supply and the bowel perfusion rate in the area of the pouch anastomoses. An additional ingress and egress analysis at specific regions of interest is performed. This is to get an objective method of visualisation of the blood inflow and outflow over time and thus bowel perfusion at the anastomotic site.
9704971|NCT04695912|Other|Initial activity tracker with feedback followed by control period|Initial activity tracker with feedback followed by control period
9704972|NCT04695912|Other|Initial control period followed by activity tracker with feedback|Initial control period followed by activity tracker with feedback
9704973|NCT04695730|Active Comparator|Active physical therapy|Active intervention (including both pain education and home exercises). A 60-minutes education session will be provided, concerning pain mechanisms and management and a demonstration of the exercises to perform individually at home. Home exercises will be performed daily. To support patients during the treatment, a booklet will be created. One 30-minutes booster session will be planned after 4 weeks. Patients will follow this active intervention for 8 weeks.
9704974|NCT04695730|Experimental|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
9704975|NCT04695665|Active Comparator|Cervical pain|Only patients with positive Cervical pain syndrome.
10192293|NCT05276817|Experimental|Perio maint. then diode laser 2|
10192294|NCT05276791|Active Comparator|Endoscopic submucosal dissection|
10192295|NCT05276791|Active Comparator|Endoscopic mucosal resection|
10192296|NCT05276778||People with type 2 diabetes|People diagnosed with type 2 diabetes age 18-70
10192297|NCT05276765|Experimental|CAD/CAM customized Socket Sealing Abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
10192298|NCT05276765|Active Comparator|Standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
10192299|NCT05276739|Experimental|Bright light|Participants will receive a 6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake). Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
10204511|NCT05202626||Nanfang Hospital, Southern Medical University|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Nanfang Hospital. The clinicians in Nanfang Hospital consider it necessary to perform an endoscopic image-guided biopsy.
9704976|NCT04695665|Active Comparator|Thoracic pain|Only patients with positive Thoracic pain syndrome.
9704977|NCT04695665|Active Comparator|Lumbar pain|Only patients with positive Lumbar pain syndrome.
9704978|NCT04695925|Active Comparator|osimertinib monotherapy|osimertinib 80 mg po qd.
9704979|NCT04695925|Experimental|combination of osimertinib and chemotherapy|osimertinib 80 mg po qd plus pemetrexed 500 mg/m2 and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance osimertinib and pemetrexed until disease progression
10192300|NCT05276739|Experimental|Time-restricted eating|Participants will consume 4 identical meals, as in the other groups, except that the meal window will be restricted to 6.5 hours instead of 12 hours (meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (<3 lux) throughout the 16-hour wake episode.
9704980|NCT04695951|Experimental|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
9704981|NCT04695951|Placebo Comparator|Control|A total of 35 patients treated with the study product Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
10192301|NCT05276739|Sham Comparator|Control|Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (<3 lux) throughout the 16-hour wake episode.
9704983|NCT04695938|Other|MRI|MRI examination
9704984|NCT04696120|Experimental|Study group: apixaban|apixaban 2.5mg or 5mg bid
9704985|NCT04696120|Placebo Comparator|Control group: placebo|placebo bid
9704986|NCT04695756||People who require liver transplant|We will compare the year before the beginning of the COVID-19 Pandemia with the period during the COVID-19 Pandemia.
9704987|NCT04695496|Experimental|Theta bust stimulating group|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
9704988|NCT04695821|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
9704989|NCT04695834|Active Comparator|Conservative treatment|"Patients that are randomized to the conservative arm of the trial. These patients will not be operated until primary endpoint is reached.~If necessary, cross-over can occur after primary endpoint is reached.~Conservative treatment is considered standard of care."
9704990|NCT04695834|Active Comparator|Surgical treatment|"Patients randomized to the surgical arm will be operated within 1 week after randomization (if possible within 2 days).~Neurolysis is considered standard of care."
10192302|NCT05276713||Tucidinostat-based therapy|30 mg tucidinostat was given orally(as six 5 mg tablets per day) twice a week (either, Monday and Thursday, Tuesday and Friday, or Wednesday and Saturday) for 4 consecutive weeks in a 4-week cycle.The endocrine drugs combined with tucidinostat were given based on previous treatment.Patients received tucidinostat-based treatment until disease progression or intolerable adverse events.
9704991|NCT04695535||Chemotherapy with Anlotinib|Patients received chemotherapy with Anlotinib.
9704992|NCT04695470|Experimental|Fruquintinib with Sintilimab|Patients who met the eligibility criteria took fruquintinib 5mg qd for 2 weeks on and 1 week off Q3w plus Sintilimab 200mg iv, Q3w.
9704993|NCT04695561|Experimental|Self Myofascial Relaxation|In addition to the exercises applied to the participants in the control group, the participants in this group used Foam Roller, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
10192303|NCT05276687|Experimental|Diluted betadine|
10192304|NCT05276687|Experimental|Powdered vancomycin|
10192305|NCT05276687|No Intervention|No intervention|
10192306|NCT05276674||ZNN Bactiguard Retrograde Femoral Nail|Patients implanted with a ZNN Bactiguard Retrograde Femoral Nail for fixing and stabilizing a femoral fracture or osteotomy.
10192307|NCT05276661|Experimental|"A gel (TAC/Collagen gel)"|"The A gel (TAC/Collagen gel) was applied on subjects' right face"
10192308|NCT05276661|Placebo Comparator|"B gel (placebo lotion)"|"the B gel (placebo lotion) on their left face"
10192309|NCT05276648|Experimental|ESP BLOCK|erector spina plane block applied
10192310|NCT05276648|Active Comparator|no ESP BLOCK|those who did not apply erector spina plan block
10192311|NCT05276635|Other|Control (EFT)|had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I)
10192312|NCT05276635|Active Comparator|Sleep Hygiene Education (SHE) intervention group|received a Sleep Hygiene Education (SHE) intervention
10192313|NCT05276609|Experimental|HS-20093 (Phase Ia: Dose escalation)|There are five escalating dose cohorts.
10192314|NCT05276609|Experimental|HS-20093 (Phase Ib: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
9704994|NCT04695561|Experimental|Instrument Assisted Soft Tissue Mobilization|In addition to the exercises applied to the participants in the control group, the participants in this group used Instrument Assisted Soft Tissue Mobilization, which was performed with the principle of painless movement 2 times a week for a total of 12 times a week for 6 weeks.
9704995|NCT04695561|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the hip flexors, hip extensors and iliotibial band were shown to the participants in the control group for 6 weeks every day of the week.
9704996|NCT04695613|Active Comparator|aminoacid group|patients received an IV amino acid infusion 150 ml/kg/hr starting just before and during anesthesia
9704997|NCT04695613|Active Comparator|magnesium sulfate group|patients received an IV magnesium sulphate bolus and infusion 40 mg/kg starting just before and during anesthesia
10192315|NCT05276596|Active Comparator|Control group|The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
10204512|NCT05202626||Fujian Provincial Cancer Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Fujian Provincial Cancer Hospital. The clinicians in Fujian Provincial Cancer Hospital consider it necessary to perform an endoscopic image-guided biopsy.
9704998|NCT04695522|Experimental|Group of subjects undergoing cell transplantation|
9704999|NCT04695522|Sham Comparator|Group of subjects undergoing sham operation|
9705000|NCT04695600|Experimental|Botulinum toxin arm|100 units of botulinum toxin (Botox, Allergan, CA) diluted in 2.5 mL of normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Botulinum toxin will be injected into the muscle in four aliquots into each quadrant using 23 G needle (160cm). Post procedure patient will be observed for an hour for any untoward adverse event
9705001|NCT04695600|Placebo Comparator|Placebo arm|2.5 mL of Normal saline will be injected into the cricopharyngeus muscle under direct endoscopic vision using an esophago-gastro-duodenoscope (GIF 190,Olympus). The procedure will be done under general anesthesia in the endoscopy suite as the position of the endoscope is unstable at cricopharynx and the muscle needs to be relaxed during the procedure. Pre-procedure a Ryle's tube will be placed into the stomach under endoscopic guidance which will be kept a day post procedure. Cricopharyngeus muscle will be identified as the muscle at the upper esophageal sphincter located just behind the laryngeal opening. Post procedure patient will be observed for an hour for any untoward adverse event
9705002|NCT04695717|Placebo Comparator|Vaccine|Received two doses of IVACFLU-S vaccine intramuscularly in children aged 6 months to under 9 years old and one dose of IVACFLU-S vaccine in children from 9 years old to under 18 years old adult over 60 years old
9705003|NCT04695717|Other|Placebo|Received two doses of placebo intramuscularly in children aged 6 months to under 9 years old and one dose placebo in children from 9 years old to under 18 years old adult over 60 years old
9705004|NCT04695548|Experimental|Concentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
9705005|NCT04695548|Experimental|Isometric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
9705006|NCT04695548|Experimental|Eccentric contraction exercise|After applying the dry needling technique to the upper trapezius muscle, the participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
9705007|NCT04695548|Experimental|Analytic passive stretching.|After applying the dry needling technique to the upper trapezius muscle, the patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
9705008|NCT04695743|Experimental|Intervention|Attendance at online CST groups
9705009|NCT04695743|No Intervention|Control|Treatment as usual
9705010|NCT04695483|Experimental|Corifollitropin alpha group|Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
9705011|NCT04695483|Active Comparator|FSH group|Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
9705012|NCT04695639||cohort group|A convenient sample of children with spastic hemiparetic CP of both genders will participate in this study. To avoid type II error, sample size calculation was performed prior to the study, based on data of pilot study, using G*POWER statistical software (version 3.1.9.2; Franz Faul, Universitat Kiel, Germany) [Exact tests- correlational study, α=0.05, β=0.2, and effect size = 0.4] and revealed that the appropriate sample size for this study is N=46.
9705013|NCT04695418|Placebo Comparator|Placebo|an isocaloric wheat germ-based supplement
9705014|NCT04695418|Active Comparator|Rice Germ|
9705017|NCT04695405||Treatment-Resistant Depression|Patients, who previously received intravenous ketamine, will be asked to provide genetic samples in order to assess relationships between response and genetic markers.
9705018|NCT04695574|Experimental|Volunteer young adults|Healthy young adults
9705019|NCT04695509|Experimental|moderate sedation|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with moderate propofol sedation
9705020|NCT04695509|Experimental|deep sedation|Arm Description: patients with American Society of Anesthesiologists (ASA I-II), Montreal cognitive assessment test ≥ 26, trauma surgery under regional anesthesia with deep propofol sedation
9705021|NCT04695587||TakoTsubo|Patients hospitalized with TakoTsubo syndrome according to the INTERTAK criteria
9705022|NCT04695769|Experimental|Group A: SOF/VEL/VOX with RBV|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: < or > 60 kg).~Another name: Vosevi, RBV"
9705023|NCT04695769|Active Comparator|Group B: SOF/VEL/VOX|"Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).~Another name: Vosevi"
9705024|NCT04695704|Experimental|Montelukast|10mg oral montelukast once daily for 28 days.
9705025|NCT04695704|Placebo Comparator|Placebo|oral placebo once daily for 28 days.
9705026|NCT04695197|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine, standard 3-day antimalarial treatment regimen.
9705027|NCT04695197|Experimental|Pyronaridine-artesunate|Pyronaridine-artesunate, standard 3-day antimalarial treatment regimen.
9705028|NCT04695015||Melanoma and Nevus|Patients diagnosed with melanoma or/and nevus on the skin around the eye before surgery.
9705029|NCT04695015||Basal cell carcinoma;Squamous cell carcinoma;Sebaceous gland carcinoma|Patients diagnosed with basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma before surgery.
9705030|NCT04695353|Experimental|Study group|These patients will receive telemedicine by using Telecommunication Platform videoconferences/messages.
9705031|NCT04695353|No Intervention|Control group|The patients will receive in-office clinical care
9705032|NCT04695249|Experimental|Exposure intervention|Eleven individual sessions.
9705033|NCT04695184|Other|ICG-NIRF Imaging|ICG-NIRF imaging is used intraoperatively to visualise precisely the blood supply and bowel perfusion rate in the area of ileal pouch formation and the ileal pouch-anal anastomosis.
9705034|NCT04694989|Experimental|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
9705035|NCT04694989|Experimental|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
9705036|NCT04695028||Persons with crystal related arthropathies|
9705037|NCT04695093||London (intervention)|1606 children aged 6-9 yrs old, recruited in 44 London primary schools (years 2-4) within the Central London ULEZ area
9705038|NCT04695093||Luton (comparison)|1706 children aged 6-9 yrs old, recruited in 41 Luton and Dunstable primary schools (years 2-4)
9705039|NCT04695158||COVID-19 group (Group I)|Patients diagnosed with COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatment according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020.
9705040|NCT04695158||Type II Diabetes Mellitus and COVID-19 group (Group II)|Patients diagnosed with both Type II Diabetes Mellitus and COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatments according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020 and routine treatment for Type II Diabetes Mellitus.
9705041|NCT04695158||Control group (Group III)|Healthy volunteers will be in this group. No intervention will be applied in this group.
9705042|NCT04695171||Prior Primary Large Hiatal Hernia with LINX Placement MSA|Patients who were previously implanted with the LINX device during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at 3 and 5 years to determine recurrence of hiatal hernia.
9705043|NCT04695171||Prior Primary Large Hiatal Hernia with Fundoplication|Patients who previously underwent lower esophageal sphincter reconstruction by fundoplication during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at about 3 and 5 years to determine recurrence of hiatal hernia.
9705044|NCT04695314|Experimental|Glaucoma Group|Patients with glaucoma come in and get an intraocular pressure check at baseline. They get a 5 minute foot massage and then have their intraocular pressure checked every 30 minutes over 2 hour span.
9705045|NCT04695314|Experimental|Ocular Hypertension Group A|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again."
9778915|NCT01118728|Experimental|Sarilumab|Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.
9778916|NCT01118780|Experimental|Duloxetine 30 milligrams (mg) -120 mg|
9778917|NCT01118780|Placebo Comparator|Placebo|
9778918|NCT01118845|Experimental|SyB L-0501|
10192316|NCT05276596|Experimental|Test group|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
10192317|NCT05276583||Patients with depression like symptoms|Participants in this condition must indicate that they are currently suffering from a mental health illness and score at least 20 on the Becks Depression Inventory. These participants will undergo the motivate learning task and will study images associated with high and low rewards. After 24-hours participants will be tested on their memory for those images.
10192318|NCT05276583||Healthy controls without depression like symptoms|Participants in this condition must indicate that they do not currently suffer from a mental health condition and score less than 20 on the Becks depression inventory. These participants will also undergo the motivate learning task and will study images associated with high and low rewards. After 24-hours participants will be tested on their memory for those images.
9705046|NCT04695314|Active Comparator|Ocular Hypertension Group B|"Patients with OHTN come in and get an IOP check at baseline. They get a 5 minute foot massage and then have their IOP checked every 30 minutes over 2 hour span.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received sham flat shoe insert. Patients come back in the afternoon to have their IOP checked again.~2 week washout period and then patients return. Patients come in the morning to have their IOP checked. Received raised experimental shoe insert. Patients come back in the afternoon to have their IOP checked again."
9705047|NCT04695236|Experimental|Study group|Study Group: intravascular hypothermia therapy group ZOLL Intravascular Temperature Management system, Quattro catheter will be used in study group
9705048|NCT04695236|Placebo Comparator|Control group|"Control group: Without intravascular hypothermia therapy group~ZOLL Intravascular Temperature Management system, Quattro catheter will not be used in control group"
9705049|NCT04695223|Experimental|Arsenic Trioxide|Arsenic Trioxide (0.16mg/kg,d1-5,ivgtt,28days as a duration) for injection
9705050|NCT04695002||Control group|Citizens in the control group participate in the existing course of vocational rehabilitation offered in the municipal employment department, without the use of MIRA app.
9705051|NCT04695002||MIRA group|Citizens in the MIRA group will participate in the existing course of vocational rehabilitation offered in the municipal department. In addition they will be introduced to MIRA at the beginning of the rehabilitation course, and use MIRA throughout the course of rehabilitation.
9705052|NCT04695145|Experimental|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer with special training in medical issues. The exercise will be monitored with continuous heart rate registration.~The group training session will begin with a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied."
9705053|NCT04695145|Active Comparator|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
9705054|NCT04694963||Subaute Cough|N=500
10192319|NCT05276570|Experimental|ARO-RAGE|ARO-RAGE Inhalation
10192320|NCT05276570|Placebo Comparator|Placebo|(0.9% NaCl)
9705055|NCT04694612|Placebo Comparator|Mild condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive the same quantity of Placebo.~Duration of treatment : 5 days in each group"
10192321|NCT05276557|Experimental|Indication for H. pylori testing|Walk in basis: Symptomatic patients of H. pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test (a single dose of 13C urea at 75mg in powder form, to be dissolved in potable water as the kit indicates) in addition to stool antigen test comparison.
10192322|NCT05276531|Experimental|subcutaneous progesterone|PROLUTEX® 25 mg Solution for injection, IBSA Group, Lugano, Switzerland
10192323|NCT05276531|Active Comparator|vaginal progesterone|LUTINUS® 100 mg vaginal tablets, Ferring GmbH Wittland/Kiel/Germany
10204513|NCT05202626||Hainan Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Hainan Provincial People's Hospital. The clinicians in Hainan Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
9705056|NCT04694612|Active Comparator|Moderate condition|"Study arm groups will receive a Favipiravir treatment of 1800 mg po BID on day 1, then 800 mg po BID from day 2 onwards and control groups will receive Inj Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily.~Duration of treatment : 10 days in Favipiravir group & 5 days in Remdesivir group"
9705057|NCT04694690|Experimental|RelyX U200 Automix Self Adhesive Resin Cement|Self Adhesive Resin Cement
9705058|NCT04694690|Active Comparator|G-Cem LinkForce Resin Cement|Resin Cement system used after surface treatment
9705059|NCT04694625|Experimental|Structured rehabilitation program|Structured rehabilitation program & conventional physical therapy
9705060|NCT04694625|Active Comparator|conventional physical therapy|conventional physical therapy
9705061|NCT04694573||POST-TX Covid-19 Serum Study Case|Kidney or liver-transplanted patients being hospitalized due to an infection with SARS-CoV-2
9778919|NCT01118949|Experimental|Lacosamide|
9705062|NCT04694573||POST-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection after TX; matching according to~age (18-34, 35-59, 60-75 years)~sex~type of transplantation~time after transplantation (0-180, 181-365, 366-1095, 1096-2555, >2555 days after TX)"
9705063|NCT04694573||PRE-TX Covid-19 Serum Study Case|Patients being kidney or liver-transplanted after having had an infection with SARS-CoV-2
9705064|NCT04694573||PRE-TX Covid-19 Serum Study Control|"2 matched controls without SARS-CoV-2 infection prior to TX; matching according to~age(18-34, 35-59, 60-75 years)~sex~type of transplantation"
10192324|NCT05276492|Experimental|Group 1: Dose Regimen 1|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal every other day.~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
10204514|NCT05202613||Dorage group|"HIV-1 infected patients~aged > 50 years old~naive patients receiving doravirine-based regimens~experienced patients with persistent HIV RNA < 50 copies/mLfor at least 6 months, who switched to doravirine-based regimens, because of toxicity, convenience or other reasons."
9705065|NCT04694898|Other|Control|Households in the control arm receive standard/national nutrition specific interventions, i.e. growth monitoring, vaccination, vitamin A supplementation and deworming
9705066|NCT04694898|Experimental|SURE Intervention|"Households in the intervention group with children younger than 2 years benefit from:~Interpersonal contacts to provide counselling on infant and young child feeding practices (IYCF) and nutrition-sensitive agriculture advice to mothers and fathers of children under 24 months, inclusive of pregnant women and fathers-to-be, jointly delivered by the local health and agriculture extension workers during routine household visits~Men's and women's group dialogues targeting all men and women in a given community network, facilitated also by the local health and agriculture extension workers~Media campaign to reinforce IYCF and dietary diversity messages"
10204515|NCT05202613||Control group|HIV negative subjects, matched for age and Charlson Index score (to evaluate comorbidity impact)
9705067|NCT04694599|Experimental|Early intervention|The experimental group will receive oxygen supplementation when oxygen saturation decreases according to the monitoring of wearable devices.
9705068|NCT04694599|Active Comparator|Typical|The control group will receive oxygen supplementation when oxygen saturation decreases according to typical periodical monitoring.
9705069|NCT04694729|Experimental|study group|Videoconference-based
9705070|NCT04694729|Experimental|control group|Video-based
9705071|NCT04694664||Pregnant Women|Pregnant women who are 18 years of age or older.
9705072|NCT04694664||Post-partum women|Women who have at least one child younger than 18 years of age.
9705073|NCT04694859||Symptomatic Severe Aortic Valve Stenosis|Patients >18 years old with symptomatic severe aortic valve stenosis.
9705074|NCT04694833|Experimental|Stroke patients|Stroke patients with hemiparesis and/or cognitive impairments (such as apraxia, aphasia and hemineglect)
9705075|NCT04694833|Experimental|Healthy subjects|Subjects who do not suffer from any pathology that could affect upper-limb motor function or cognition
9705076|NCT04694586|Experimental|High-dose rifampicin and pyrazinamide|"rifampicin 35 mg/kg for 4 months provided as a combination of fixed drug combination tablets (HRZE for 8 weeks and HR Week 9-16) and single drug tablets of rifampicin (R)~AND~pyrazinamide 40 mg/kg the first 2 months provided as a combination of fixed drug combination tablets (HRZE) and single drug tablets of pyrazinamide (Z)~fixed drug combination tablets are: isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 16 (total treatment duration 4 months)"
9705077|NCT04694586|No Intervention|Standardized TB treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9-26 (total treatment duration 6 months)
9705078|NCT04694703||Covid-19 group|Patients diagnosed with COVID-19 will be enrolled in this group.
9705079|NCT04694716||Covid-19 group (Group I)|Patients diagnosed with Covid-19 will be enrolled in this group.
9705080|NCT04694716||Control group (Group II)|Healthy individuals will be enrolled in this group.
9705081|NCT04694872|Experimental|a) TELEREHABILITATION BASED LSVT BIG TREATMENT GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
9705082|NCT04694872|Active Comparator|b) TELEREHABILITATION BASED FUNCTIONAL BALANCE AND MOBILITY EXERCISES GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.
9705083|NCT04694846|Experimental|Arm I (ETIP)|Patients receive nicotine replacement therapy via trans-dermal patch, gum, nasal spray, inhaler or lozenges for 12 weeks in the absence of unacceptable toxicity. Patients also receive bupropion PO QD BID or varenicline PO QD and BID for 24 weeks in the absence of unacceptable toxicity. Patients undergo 3 cessation counseling sessions in person, via telehealth or phone within 7 days of enrollment into study, 1 week after established quit date and 3 weeks after establishing quit date.
9705084|NCT04694846|Active Comparator|Arm II SOC|Participants randomly assigned to the standard treatment (ST) group will receive an in-office smoking cessation recommendation by the physician and referral to a quit line.
9705085|NCT04694677|Active Comparator|women receiving tranexamic acid|
9705086|NCT04694677|Active Comparator|women receiving misoprostol|
9705087|NCT04694742||ARDS COVID-19|Patients who meet Berlin's ARDS diagnostic criteria, with confirmed SARS-CoV-2 infection, requiring invasive mechanical ventilation.
10192325|NCT05276492|Experimental|Group 2: Dose Regimen 2|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1, day 3, day 5 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
9705088|NCT04694924||Localized and locally advanced prostate cancer|Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.
9705089|NCT04694911||Health Services Research (focus group, interview, OOCAT)|"FOCUS GROUP: Patients participate in focus group session over 60-90 minutes.~COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT.~FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference."
10192326|NCT05276492|Experimental|Group 3: Dose Regimen 3|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 and day 4 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
10192327|NCT05276492|Experimental|Group 4: Dose Regimen 4|"You will be enrolled in the study based on the study group that is open at that particular time. If you are enrolled in this group, you will receive:~- Abiraterone 500 mg and prednisone 5mg with a low-fat meal on day 1 of every week~You will take 2 pills (500 mg total) of abiraterone acetate, first thing in the morning with breakfast. The tablets should be swallowed whole and not crushed, chewed, or dissolved in water. This breakfast should be a low-fat meal (avoid high calorie foods with a high percentage of fat, such as bacon or sausage). You will be asked to document the details of the meal/taking abiraterone in a daily log.~You will also take prednisone 5 mg daily in the form of tablets taken by mouth with approximately 8 ounces of water with food. You do not have to take prednisone and abiraterone at the same time of day. If you inadvertently miss a dose of the study drug, you should take the dose the next day and record this on your Drug Diary."
9705090|NCT04694755|Placebo Comparator|Heart lung qi deficiency syndrome placebo group|Buyixinfei placebo was given.Tianjiang brand formula granules were used. One dose a day, two times orally, five days a week.
9705091|NCT04694755|Placebo Comparator|Deficiency of lung and Kidney Qi placebo group|Tonifying kidney and protecting lung prescription placebo was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
9705092|NCT04694755|Experimental|Heart lung qi deficiency syndrome drugs group|Buyixinfei formula was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
9705093|NCT04694755|Experimental|Deficiency of lung and Kidney Qi drugs group|The prescription of invigorating the kidney and protecting the lung was given. The drug was Tianjiang brand granule, one dose a day, two times orally, five days a week
9705094|NCT04694638|Experimental|HFNC and NIPPV|Combined use of prone positioning and non-invasive positive pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC)
9785130|NCT01243762|Experimental|Dalotuzumab + Ridaforolimus|Participants in Part 2 of the study receive dalotuzumab 10 mg/kg IV weekly + ridaforolimus 20 mg PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy.
10192328|NCT05276466|Other|Single arm|All subject's samples will undergo the same diagnostic test utilizing Polymerase Chain Reaction and Next-Generation DNA Sequencing
10192329|NCT05276440||General Anesthesia|
10192330|NCT05276440||Erector Spinae Plane Block|
10192331|NCT05276440||Rhomboid Block|
10192332|NCT05276427||Non clinical procedure|Completion of consent form and interview session
10192333|NCT05276375|Active Comparator|Bronchipret|Bronchipret syrup (3x 5,4 ml daily, according to summary of product characteristics) until day 14
10192334|NCT05276375|No Intervention|standard of care|no study intervention
10192335|NCT05276362||Typical Sleepers|This will be a single arm study of approximately 70 typical sleepers that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
10192336|NCT05276362||Insomnia Sleepers|This will be a single arm study of at least 25 participants with insomnia that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
10192337|NCT05276362||Obstructive Sleep Apnea Sleepers|This will be a single arm study of at least 25 participants with obstructive sleep apnea that will wear the Study Watch(es) and Actiwatch for one night in a sleep laboratory.
10192338|NCT05276323|Experimental|Medihoney Derma Cream|Intervention group: Medihoney Derma Cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
10192339|NCT05276323|Active Comparator|Hydrocortisone 1% cream|control group: Hydrocortisone 1% cream will be applied topically, twice a day, on all affected areas in the body for two weeks. Then, follow-up for two more weeks, overall participating for 4 weeks in the trial.
10192340|NCT05276310|Experimental|IMC-002|Dose escalation will follow the traditional 3+3 design.
10204516|NCT05202600||Incidental appendectomy (IA)|Group IA will include adult patients operated on for colon tumors who have data on age, sex, data on a previously diagnosed colon tumor, data on incidental appendectomy, and a PHD finding for a removed vermiform appendix.
9979600|NCT01383577|Experimental|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. The three following monthly appointments of patients of this arm are for sham hemorrhoidal ligations and final revision.
9705095|NCT04694521|Experimental|antegrade colorectal single stapler anastomosis|open Side to end antegrade colorectal anastomosis colo rectal cancers.
9705096|NCT04694521|Experimental|open end to end colorectal stapler anastomosis|open end to end colorectal single anastomosis in non-emergent colo rectal cancers.
9705097|NCT04694508|Experimental|Group A|Headphones (Disok, Alicante, España)
9705098|NCT04694508|No Intervention|Group B|Without music therapy
9705099|NCT04694937||metabolic healthy obese|Demographic, clinical laboratory and heart rate variability assesment
9705100|NCT04694937||metabolic unhealthy obese|Demographic, clinical laboratory and heart rate variability assesment
9705101|NCT04694326||Inpatients|Patients who were inpatients of units other than internal medicine services and internal medicine side-branch services
9705102|NCT04694170|Experimental|Experimental group|Patients with musculoskeletal pain in the lumbar region. Patients with typical symptoms of functional dysfunction of kidney undergo conventional physiotherapy and an alternative approach by yoga set exercising and regimen restriction according to traditional Chinese medicine.
9705103|NCT04694170|Active Comparator|control group|Patients with musculoskeletal pain in the lumbar region. Patients with kidney dysfunction symptoms treated by conventional physiotherapy only.
9705104|NCT04694183|Experimental|Camrelizumab combined with chemotherapy|The enrolled patients will be administered in two ways according to the difference between peritoneal metastasis and liver metastasis
9705105|NCT04694391||Recurrence|The period of recurrence was within 2 years after radiotherapy. Pathologic diagnosis was squamous cell carcinoma same with preradiotherapy.
9705106|NCT04694391||No recurrence|The period was more than 3 years after radiotherapy and no recurrence signs were observed.
9705107|NCT04694222|Other|Control Group|scaling and root planning (SRP) was applied.
9705108|NCT04694222|Active Comparator|LANAP Group|After scaling and polishing, three LANAP stages were performed : In the first stage, Nd:YAG laser was applied. In the second stage, full mouth SRP procedure was performed. In the third stage, Nd:YAG laser was applied again.
9705109|NCT04694222|Active Comparator|LLLT Group|after SRP Low Level Laser Therapy was performed using Nd:YAG laser.
9705110|NCT04694222|Active Comparator|LANAP+LLLT Group|after scaling both LANAP and LLLT were applied.
9705111|NCT04694313|Experimental|OPM|Two types of measurement will be compared (SQUID and OPM) with the reference that constitutes the in-depth recordings (Stereotactic-EEG or SEEG) used to precisely define the region of the brain to be resected in order to cure epileptic patients of their seizures.
9705112|NCT04694235|No Intervention|Observational cohort (control group)|In the observational cohort, pregnant mothers in the 2nd trimester (n=500) will be recruited and they will be followed up until their children are 24 months old. The control group women will receive standard intervention in the form of Ante Natal Care from village midwives (Polindes) or Puskesmas (IFA tablet, calcium tablet, nutrition counselling).
9705113|NCT04694235|Experimental|Intervention group|The intervention group women (n=153) will be provided one egg three times per week from recruitment (2nd trimester) until term along with the standard Ante Natal Care.
9705114|NCT04694482||psychiatric patients|Psychometric scales
9705115|NCT04694482||healthy controls|Psychometric scales
9705116|NCT04694352|Experimental|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side
9705117|NCT04694352|Active Comparator|Conventional|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping."
9705118|NCT04694118|Experimental|15 hemiparetic cerebral palsy,walking back group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
9705119|NCT04694118|Experimental|15 hemiparetic cerebral palsy,rebound therapy group|GMFM I or II degreed 6-15 age range hemiparetic cerebral palsy
9705120|NCT04694404|Experimental|S-1 Plus Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-10, q2w)
9705121|NCT04694365|Experimental|Normal Hepatic Function|
9705122|NCT04694365|Experimental|Mild Hepatic Impairment|
9705123|NCT04694365|Experimental|Moderate Hepatic Impairment|
9705124|NCT04694092|Experimental|Intensive rate control with landiolol|Intensive heart rate control using landiolol with the goal to achieve HR<115 during the first 2 hours.
9705125|NCT04694092|Active Comparator|Standard therapy|Standard heart rate control with therapy other than landiolol
9705126|NCT04694430||Severe exacerbation of COPD|N = 250
9705127|NCT04694430||Mild and moderate exacerbations of COPD|N = 250
9705128|NCT04694300|Experimental|Naproxen sodium|Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)
9705129|NCT04694300|Active Comparator|Acetaminophen|Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)
9778920|NCT01118962|Experimental|Lacosamide|"Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949).~Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses."
9979601|NCT01383590|Experimental|Cat-PAD|
9979602|NCT01383603|Experimental|Cat-PAD|
9979603|NCT01383629|No Intervention|No counselling|normal preoperative procedures prior to vitrectomy surgery
9979604|NCT01383629|Experimental|Preoperative counselling|Counselling to patient about what to expect during vitrectomy surgery under local anaesthesia
9979605|NCT01383642||individuals age >=70|
9705130|NCT04694417|Experimental|Compression stocking|Compression stockings are mainly used for the prevention and reduction of lower limb oedema or venous thrombosis. There are three compression classes used in health care. The compression stocking group of the study will receive CE-marked stockings within the compression class of 1 (25-40 mmHg compression). The correct size for the compression stockings will be defined by the reported circumference of the participant's ankle and calf. The participants will be given instructions to put the stockings on immediately after getting out of bed in the morning and to take them off before going to bed in the evening for the last four weeks of the study. Stockings within the mild compression class have no harmful effects on individuals when the exclusion criteria are considered. The participants will be instructed to communicate with a dedicated research assistant via e-mail or phone in case of any problems or questions.
10192341|NCT05276297|Experimental|ASO24-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
10192342|NCT05276297|Active Comparator|ASO24 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
10192343|NCT05276297|Experimental|ASO12-TI Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by GSK3528869A (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
9705131|NCT04694417|Active Comparator|Magnesium|"Magnesium is a mineral substance which regulates many biochemical reactions in the body, for example protein synthesis and the function of the muscles and nerves. It has a significant role in controlling blood sugar, blood pressure, energy generation and the formation of the bones. The recommended dietary allowance for magnesium is 420 mg for males and 320 mg for females over 50 years old. Dark green vegetables, leguminous plants, nuts, seeds and wholegrains are good sources of magnesium (11,12).~In the average Finnish diet, the recommendation is usually exceeded, and excessive amounts of magnesium in the body are extremely rare. The magnesium arm of the study will take oral tablets containing 620 mg of magnesium hydrochloride daily for the last four weeks of the study, which is equivalent to 250 mg of pure magnesium per day. The magnesium tablets for this study were manufactured and analysed by the Pharmia pharmaceutical company in Finland."
9705132|NCT04694417|Placebo Comparator|Placebo|The placebo tablets will consist of microcrystalline cellulose, magnesium stearate (anti-caking agent) and silicon dioxide. The placebo tablets were manufactured and analysed by the Pharmia pharmaceutical company in Finland. The placebo arm will receive placebo tablets to be taken daily for the last four weeks of the study. The participants will not know whether they are randomised into the magnesium arm or the placebo arm. The packaging and the appearance of the placebo and magnesium tablets are identical.
9705133|NCT04694274||group 1|patients with temporomandibular disorders
9705134|NCT04694274||group 2|healthy control
9705135|NCT04694469||Group Day|operated at 07:30 AM - 06:30 PM
9705136|NCT04694469||Group Night|operated at 06:30 PM - 07:30 AM
9705137|NCT04694209|Experimental|Fixed implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a hybrid prosthesis. a metal framework, acrylic resin denture base and acrylic resin teeth
9705138|NCT04694209|Active Comparator|Removable implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a telescopic retained overdenture, both primary and secondary copings are custom made. the secondary copings are conncetd via a metal framework
9705139|NCT04694495||volunteers from health examination center|volunteers(n = 50/center) doing gynecologial examination recruited from health examination center, who shows no symptoms and signs in reproductive tract and are potentially regarded as the healthy controls
9705140|NCT04694495||volunteers from gynecology outpatient|volunteers(n = 150/center) recruited from gynecology outpatient, who show abnormal symptoms and signs in reproductive tract and are potentially regarded as the cases with conditions in reproductive tract
9705141|NCT04694456|Experimental|Facioscapulohumeral muscular dystrophy|Adult ambulant patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1)
9705142|NCT04694079|Experimental|Group 1, CMR-guided VT ablation|"Patients randomized to Group 1, will undergo CMR-guided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
9705143|NCT04694079|Experimental|Group 2, CMR-aided VT ablation|"Patients randomized to Group 2, will undergo CMR-aided VT ablation. LGE-CMR data obtained by 1,5 or 3 T CMR and multi-detector cardiac tomography (MDCT) data obtained using a 128 slice CT scanner will be processed with ADAS-VT software (Galgo Medical, Barcelona, Spain).~Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation."
9705144|NCT04694079|Active Comparator|Group 3, Electroanatomical guided ablation|Patients assigned to Group 3, will not undergo LGE-CMR. Ablation procedure will be carried out in an electrophysiology lab by using the CARTO 3 electroanatomical mapping system (Biosense Webster, Diamond Bar, CA, USA). A ThermoCool SmartTouch SF open irrigated 3,5 mm tip radiofrequency catheter (Biosense Webster, Diamond Bar, CA, USA) will be used both for mapping and ablation.
9705145|NCT04694105|Active Comparator|dexmedetomidine|Bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
9705146|NCT04694105|Active Comparator|dexamethasone|Bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml)
9705147|NCT04694105|Placebo Comparator|control group|Bupivacaine 30 ml 0.25% was combined with 2 ml normal saline
9705148|NCT04694027|Active Comparator|group a|will receive omega 3 plus vitamin E
9705149|NCT04694027|Active Comparator|Group b|will receive vitamin E
9705150|NCT04694027|No Intervention|Group c|no intervention just reassurance and analgesics on need
9979606|NCT01383655|Experimental|Magnesium|i.v. magnesium infusion 40mg/kg in 20 min
9705152|NCT04693988|Experimental|Case management|Patient receives case management while in hospital.
9705153|NCT04693988|No Intervention|Usual Care|This control condition does not receive intervention of case management
9705154|NCT04693728|Active Comparator|Behavioral Intervention|The study intervention arm was a behavioral treatment that consisted of training resilient intrinsic self-regulation strategies to help alleviate chronic pain.
9705155|NCT04693728|No Intervention|Wait-list with no treatment|The control comparison arm consisted of a wait-list condition in which participants received no treatment during a time interval comparable to the intervention arm.
9705156|NCT04693650|Experimental|Treatment group- UHF(+RF) stimulation|Patients implanted with leads and be administered with UHF stimulation
9705157|NCT04693650|No Intervention|Control group|Patients implanted with lead receiving fake stimulation (no stimulation but same device procedure with test group)
9705158|NCT04694066|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (followup; 8 hours). The sessions will be supervised by an experienced qigong master.
10192344|NCT05276297|Active Comparator|ASO12 Group|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period, followed by non-active control (Treatment 2) study intervention administered at Days 1, 57, 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week, with the possibility to extend up to 12 weeks.
10192345|NCT05276284|Experimental|TEMPLE|Study drugs: Atezolizumab, 6-mercaptopurine and 6-thioguanine
10192346|NCT05276271||epileptic children|epileptic children who had been diagnosed with epilepsy with at least two focal seizures within a year, and treated with levetiracetam monotherapy for at least 12 months
9705159|NCT04694066|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise only, with the same duration and frequency of supervised sessions identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
9705160|NCT04693832|Experimental|5inD|All children receive routine antiemetic therapy before chemotherapy. Children in the experimental group will use the interactive mobile application (5inD) for seven days from the first day of chemotherapy. The games in this application will help distract their attention and manage their nausea and vomiting.
9705161|NCT04693832|No Intervention|Control group|All children receive routine antiemetic therapy before chemotherapy.
9705162|NCT04693871||high-flow rate group|
9705163|NCT04693871||low-flow rate group|
9705164|NCT04693858|Experimental|Child Anxiety Learning Modules (CALM)|Children randomly assigned to this condition will receive the CALM intervention.
9705165|NCT04693858|Active Comparator|Child Anxiety Learning Modules--Relaxation (CALM-R)|Children randomly assigned to this condition will receive the CALM-R intervention.
9705166|NCT04693858|No Intervention|Waitlist control|Within each nurse, 20% (1 in 5) children will be randomly assigned to wait a period of eight weeks prior to starting the intervention with their school nurse. During this period, the child is not prevented from seeing the school nurse, nor are they prevented from continuing to utilize stable doses of community treatment (i.e., therapy outside of school or medication); nurses are simply asked to provide normal support and avoid using techniques specific to CALM or CALM-R. After the 8 weeks, youth are re-evaluated and nurses begin delivering the intervention to the student.
9705167|NCT04693663|Other|ReLex Smile surgery|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was between -0.75D till -5.50D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(Viscot-Medster).
10192347|NCT05276271||healthy controls|healthy controls who was without an exposure to levetiracetam
10192348|NCT05276258|Experimental|Nerve Block Using Liposomal Bupivacaine and cryoSPHERE Ablation|The experimental group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine and the cryoSPHERE ablation of intercostal nerves during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.
10192349|NCT05276258|Active Comparator|Nerve Block Using Liposomal Bupivacaine Alone|The control group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine alone (standard approach) during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.
10192350|NCT05276245|Experimental|Program Group|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
10192351|NCT05276245|No Intervention|Waitlist control group|Participants who were randomly assigned to the waitlist control group were instructed to spend their usual half-hour lunch break in the office for consecutive 10 weekdays. Also, the waitlist control group was told to wait for at least three months before they took part in the structured protocol of nature contact.
10192352|NCT05276232|Experimental|Baseline followed by 5-10% THC Validation|
10192353|NCT05276232|Experimental|Baseline followed by 5-10% THC Verification|
9705168|NCT04693884|Experimental|High THC, Smoked|
9705169|NCT04693884|Experimental|High THC, Vaporized|
9705170|NCT04693884|Experimental|High CBD, Smoked|
9705171|NCT04693884|Experimental|High CBD, Vaporized|
10192354|NCT05276219|Active Comparator|Furosemide only|• Boluses of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
10192355|NCT05276219|Active Comparator|isosorbide dinitrate|• Boluses of 3 mg IV isosorbide dinitrate given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
10192356|NCT05276219|Active Comparator|isosorbide dinitrate + furosemide|• Boluses of both 3 mg IV isosorbide dinitrate + of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician.
10192357|NCT05276180|Experimental|Arm A) Multifactorial intervention strategy|Experimental: Multifactorial intervention strategy for safe patient handling and movement (PHM) - Arm A The multifactorial intervention strategy for care units randomized to Arm A includes: 1) Swedish guideline for PHM and digital introduction for using the guideline (two workshops for manager and implementation team) 2) Training modules (theoretical and practical - one session) 3) Risk assessment with TilThermometer (four times) and 4) Fall risk assessment using Downton Fall Risk Index (DFRI) or existing fall risk assessment instrument at the care unit (all patients) and 5) Work environment mapping with Structured Multidisciplinary Work Environment Survey (SMET) including active/personal feedback
9979607|NCT01383655|Placebo Comparator|Placebo|i.v. 0.9 % NaCl
9979608|NCT01383668|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD on days 1-28 and gold sodium thiomalate IM on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9979609|NCT01383694|Experimental|Piperine Dose 1|Piperine 1 mM
10192358|NCT05276180|Active Comparator|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
10204517|NCT05202600||Acute appendectomy (AA)|Group AA will include adult patients who have been operated due to clinical suspicion of acute appendicitis and have data on age, sex, data on the diagnosis of acute appendicitis and accompanying PHD findings of the performed appendectomy.
9979610|NCT01383694|Experimental|Piperine Dose 2|Piperine 150 microM
9705172|NCT04694040||healthy adult volunteers showing no signs of temporomandibular disorders|
9705173|NCT04693780|Experimental|Structured guide with pre-appraisal content|Once logged into the website, participants in the intervention group will navigate health information through an annotated structured guide to health evidence which is designed to inform participants where to find specific health information but it will also provide information to understand why such content is more valuable than other content. This structured annotated guide to evidence will also outline the value of pre-appraisal and will help them navigate to products produced for them. These products have been produced by the research team and include a collection of web resource ratings, evidence summaries and blog posts modelled after those developed and presented on the McMaster Optimal Aging Portal. The topics of this citizen content match the scope of the IMAGINE Network.
9705174|NCT04693780|Placebo Comparator|Listing without pre-appraisal content|Once logged into the website, participants in the control group will navigate health information through a structured one-page guide (see Appendix 1) that does not include pre-appraisal information. Instead it will list the main organizations in the field that produce citizen content with descriptions of the type of content they produce with links to their individual websites. This will be presented to participants when they login to the platform. None of the citizen content produced specifically for the study will be provided to them prior to crossing-over.
9705175|NCT04693923|Experimental|Group A (rapid fluid challenge)|Patients will receive a rapid fluid challenge (4ml/kg of crystalloids in 5 minutes using a syringe of 60 mL and a timer in the multiparameter monitor).
9705176|NCT04693923|Active Comparator|Group B (standard fluid challenge)|Patients will receive a standard fluid challenge (500 ml of crystalloids in 30 minutes).
9705177|NCT04693910|Experimental|Multimedia information group|The experimental group received a weekly multimedia hormone therapy information program for 6 weeks.
9705178|NCT04693910|No Intervention|Routine care group|The control group will receive routine care.
9705179|NCT04693897||Overactive bladder with Mirabegron|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Mirabegron 50mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
9705180|NCT04693897||Overactive bladder with Solifenacin|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Solifenacin 5mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
9705181|NCT04693897||Urinary tract infection|Urinary samples for beta-3 adrenoceptor concentration of 100 patients with urinary tract infection.
9705182|NCT04693897||Control|Urinary samples for beta-3 adrenoceptor concentration of 100 patients without lower urinary tract symptoms.
9705183|NCT04693949|Active Comparator|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
9705184|NCT04693949|Experimental|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
9705185|NCT04693793|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the Janssen test results.
9778921|NCT01118975|Experimental|Pilot Phase - Vornistat 200 to 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and escalating doses of vorinistat (200mg run-up, 300mg, and 400mg 4 days on 3 days off)
9979611|NCT01383733|Experimental|Single Arm|
9979612|NCT01383746|Experimental|1|Yttrium microsphere injection
9979613|NCT01383772|Experimental|Visual fields|One arm study. All patients will receive laser treatment following visual field testing.
9979614|NCT01383785|Active Comparator|GROUP A|Intracoronary full bolus dose of abciximab proximal to thrombus occlusion
10192359|NCT05276167|Experimental|The experimental group|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy.
10192360|NCT05276167|No Intervention|The control group|Participants in the control group will receive radical cystectomy alone.
9705186|NCT04693793|Experimental|Educational Materials and Janssen Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
9705187|NCT04693793|Experimental|Educational Materials and Janssen Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the Janssen test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
10192361|NCT05276076|Experimental|Part 1 Single Ascending Dose, Cohort 1|Cohort 1 : 1X10^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the two subjects: Begin enrollment for Cohort 2.
10192362|NCT05276076|Experimental|Part 1 Single Ascending Dose, Cohort 2|Cohort 2 : 3X10^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the two subjects: Begin enrollment for Cohort 3.
10192363|NCT05276076|Experimental|Part 1 Single Ascending Dose, Cohort 3|Cohort 3 : 5X10^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP.
9705191|NCT04693962||Partial Nephrectomy (PN)|Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.
9705192|NCT04693962||Hemicolectomy (HC)|Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.
9705193|NCT04693962||Nephrolithotomy (NL)|Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury
9705194|NCT04693611|Experimental|Intervention Group|"Participants who meet the inclusion criteria will be randomised to the CS intervention group or to the control group that will maintain their usual treatment.~Participants in the intervention group will participate in two CS sessions per 12 weeks besides their treatment as usual."
9705195|NCT04693611|No Intervention|Control Group|Participants in the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed dementia-specific medication.
9705196|NCT04694014||Emotional Intelligence Skills study among frontline HCW managing Covid19 in Busia Kenya|Researchers from Alupe University College will select study participants as follows 6 Clinical officers, 2 nurses, 1 nutritionist, 1 lab technician, 2 lab technologists, 7 members on the sub county surveillance Matayos, Teso north and Bunyala 2 from UHC office
9705197|NCT04693936|Active Comparator|Nutraceuticals|Participants will receive a combination of nutraceuticals and will be instructed to follow a Mediterranean diet
9705198|NCT04693936|No Intervention|Control|Participants will follow usual diet
9705199|NCT04693676|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
9705200|NCT04693741|Other|"Autogenous iliac bone graft group A"|The autogenous iliac bone graft will be used to fill the alveolar defect.
9705201|NCT04693741|Other|"Xenograft with PRF group B"|Xenograft with PRF will be used to fill the alveolar defect.
9705202|NCT04693845|Active Comparator|Treatment as Usual|Community Mental Health Center Next Day Appointment clinic
9705203|NCT04693845|Experimental|Experimental|Collaborative Assessment and Management of Suicidality (CAMS)
9705204|NCT04693572||Parturients undergoing repeated caesarean sectiona|
9705205|NCT04693481|Experimental|experimental group: 5 seconds for each photo|receive the intervention, which is viewing each nature photo for 5 seconds
9705206|NCT04693481|Experimental|experimental group: 15 seconds for each photo|receive the intervention, which is viewing each nature photo for 15 seconds
9705207|NCT04693481|Experimental|experimental group: 30 seconds for each photo|receive the intervention, which is viewing each nature photo for 30 seconds
9705208|NCT04693481|No Intervention|control group|not receive the intervention, which is viewing each nature photo for 0 seconds.
9705209|NCT04693494|Experimental|Intervention group|"Four training sessions (before the baby is 1 month old, at 3 months, at 6 and at 9 months old) teaching the main motor milestones to get in the next 3 months and how to help infants with the correct stimuli, positions or plays; triptychs containing the main points explained at the session and links to short videos about the given advices.~Two evaluations of motor milestones at the age of 9 and 12 months old"
9705210|NCT04693494|No Intervention|Control group|Two evaluations of motor milestones at the age of 9 and 12 months old
9705211|NCT04693273||Carpal Tunnel Release surgical patients|This is the group the investigators survey who are candidates for carpal tunnel release (CTR) surgery: patients should be 18 years or older, comprehend and read English, and patients who consent to do the survey.
10192364|NCT05276076|Experimental|Part 2 Multiple Ascending Dose, Cohort 1|Cohort 1 : two doses in total, 1X10^6 cells/kg per dose, weekly The safety of 3 subjects is evaluated for 4 week after two dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the three subjects: Begin enrollment for Cohort 2.
9705212|NCT04693169|Experimental|[Al18F]PSMA137 PET/CT imaging|All study participants will be allocated to this arm (single-arm study).Study participants will undergo [Al18F]PSMA137 PET/CT scans.
9705213|NCT04693117|Experimental|Study Group|Participants were voluntarily participated by non-probability consecutive sampling. It was a one group study with a limitation of non-randomization. The interventional group had performed interval training for 12 weeks, 3 days/week (figure 1). They sedentary conferring to activity level (≥ 30-minute, 3 days/weeks, moderate-intensity physical activity). They were not participated in any interval training program before participating in the study from six months. Written consent was taken after demonstration of the purpose, procedure, and related pros and cons. They were instructed to participate regularly in interval training.
9778922|NCT01118975|Experimental|Phase II - Vorinistat 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and vorinostat 400 mg 4 days on 3 days
9778923|NCT01118988|Experimental|Mentorship|"Subjects randomly assigned to this arm received the specified Mentorship Intervention"
9705214|NCT04693299||Study cohort|"Inclusion criteria:~Outpatient and hospitalized patients, adults, candidates for colonoscopy for any pathology, as part of the normal care process, with the need to repeat bowel preparation due to inadequate cleansing.~Exclusion criteria:~Emergency regime~Inability to obtain consent~Refusal of the patient"
9705215|NCT04693104|Experimental|PVA Hydrogel|PVA Hydrogel (Rottapharm Biotech, Monza): 2 mL prefilled syringe for intra-articular injection
9705216|NCT04693104|Active Comparator|Synvisc-One®|Synvisc-One® (Genzyme Corporation, Ridegield, New Jersey, USA): 6 mL prefilled syringe for intra-articular injection
9705217|NCT04693442||Burn patients|with the condition
9705218|NCT04693442||Control group|without the condition (blood sampling only for adults) and children undergoing general anaesthetic procedures that involve skin resections (blood sampling and excised skin)
9705219|NCT04693130|Experimental|Mindfulness-based prenatal education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
10192365|NCT05276076|Experimental|Part 2 Multiple Ascending Dose, Cohort 2|Cohort 2 : four doses in total, 1X10^6 cells/kg per dose, weekly The safety of 3 subjects is evaluated for 8 week after two dose of IP.
10192366|NCT05276063|Placebo Comparator|Placebo|Placebo Arm
9705220|NCT04693130|Experimental|Application for prenatal education|The intervention includes
9705221|NCT04693130|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
9705222|NCT04693156|Active Comparator|oblique subcostal tap block|ultrasound-guided right oblique subcostal TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl (sodium chloride) 10ml and ultrasound-guided posterior TAP block with %0.9 NaCl 30ml
9705223|NCT04693156|Active Comparator|posterior tap block|ultrasound-guided right oblique subcostal TAP block with %0.9 NaCl 30ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
9705224|NCT04693156|Active Comparator|dual tap block|ultrasound-guided right oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml and ultrasound-guided posterior TAP block with an anesthetic solution of %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml
9705225|NCT04693208|Experimental|Laser|Laser light will be applied to the surgery site after tonsils excision.
9705226|NCT04693208|No Intervention|Standard care|
10192367|NCT05276063|Active Comparator|Low Dose|Active Arm Low Dose Linsitinib
10192368|NCT05276063|Active Comparator|High Dose|Active Arm High Dose Linsitinib
10192369|NCT05276037||Study group|Milan-out, up-to-7-in, PET negative (≤1.15) HCC patients
10192370|NCT05276037||Control group|Milan-in HCC patients
10192371|NCT05275985|Experimental|68Ga-FAPI PET/CT examination|Patients with suspected pancreatic lesions underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The clinicians decided the treatment methods based on the results of 68Ga-FAPI PET/CT.
10192372|NCT05275972|Placebo Comparator|DMEK plus topical placebo|
10192373|NCT05275972|Experimental|DSO plus topical ripasudil 0.4%|
10192374|NCT05275946|Other|Treatment group|
10192375|NCT05275933|Placebo Comparator|PC+SC|Placebo Control Capsules (PC) are provided in addition to Standard Care medications
10192376|NCT05275933|Active Comparator|LH+SC|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications.
10192377|NCT05275894|Experimental|Non-surgical electrolytic cleaning|"Implant hygiene instructions and removal of the prosthesis~Local anaesthesia~Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA)~Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).~Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).~Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.~Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).~If necessary, modification and polishing of the prosthesis to make it cleanable."
9705227|NCT04693403|Experimental|High-flow oxygen nasal cannula (HFNC)|In the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier and applied continuously through large-bore bi-nasal prongs, with a gas flow rate of 40-60 liters per minute and adjusted based on the clinical response.
9705228|NCT04693403|Experimental|Continuous positive airway pressure (CPAP)|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment. CPAP will be started at 7.5 cm of water. The level will be decreased to 5 cm of water or increased to 10 cm of water as needed based on the clinical response and tolerance.
9705229|NCT04693403|Active Comparator|Standard Low flow Oxygen Arm|Patients assigned to the standard treatment group will receive oxygen delivered through a Non-rebreather face mask until endotracheal intubation, death, or fulfillment of oxygen delivery cessation criteria (an oxygen saturation by pulse oximetry (SpO2) above 92% without oxygen and a respiratory rate below 25 cycles/min).
9705230|NCT04693338|Experimental|Supportive care (ICP)|Patients completion surveys of 4 common symptoms: fatigue, hot flashes, insomnia, and sexual dysfunction and receive educational material via mobile app to help with bothersome symptoms. Patients also complete questionnaires.
9705231|NCT04693312|Experimental|Group I|scalene muscle level injection of depomedrol
9705232|NCT04693312|Experimental|Group II|Rheumboid muscle level injection of depomedrol
9705233|NCT04693195|Experimental|BLU-5937 oral tablet|Eligible participants will receive BLU-5937 BID orally for 4 weeks.
9705234|NCT04693195|Placebo Comparator|Placebo oral tablet|Eligible participants will receive matching Placebo BID orally for 4 weeks.
9705235|NCT04693559|Other|autogenous iliac bone graft (group A)|autogenous iliac bone graft will be used to fill the alveolar defect
9705236|NCT04693559|Other|Nano crystalline Hydroxyapatite (group B)|Nano crystalline Hydroxyapatite will be used to fill the alveolar defect
9705237|NCT04693520|Experimental|Active treatment|ALZ-801 265 mg tablets once daily for two weeks and twice daily thereafter
10192378|NCT05275881|Experimental|Virtual Reality headset Group|30 patients will be included in the virtual reality arm
9705238|NCT04693143|Other|Parenteral Nutrition for Critically Ill Children|Total Parenteral Nutrition for critically ill children
10192379|NCT05275881|Active Comparator|Control group with usual practices|30 patients will be included the usual practices
9705239|NCT04693091|Experimental|Senti Arm|"In stage 1 of this study (6 patients), the patient will apply the device and complete the initial patient survey; questions are around usability, comfort (including feelings of pressure), and acceptability. The Investigator will record the time taken to apply the device. A brief 30 seconds of chest sounds will be recorded from each of the nine sensors on the device in three different settings: standing up, lying down, walking around.~In stage 2 of this study (10 patients; 6 of whom would be re-recruited from the first stage), the participant will use the device at home over five days. The Investigator will assess the participant daily for any signs of pressure sores or complications from using the device (including topical allergic reactions). The participant will complete a daily survey. The participant is encouraged to remove the device and apply it at their discretion. The participant can opt-out of wearing the device at any stage."
10192380|NCT05275855|Experimental|Part A: EDI048 or Placebo|Part A is a single ascending dose study
9705240|NCT04693065||Ponseti|Patients treated by ponseti method
9705241|NCT04693078|Experimental|Intervention Arm|Consecutive patients undergoing screening or surveillance colonoscopy in whom a new polyp detection system based on deep learning will be used during the procedure.
9705242|NCT04693455|Experimental|Experimental: Cohort 1, Dose 1 of ZD03 or Placebo|Dose 1 of ZD03 or matching Placebo capsules by mouth
9705243|NCT04693455|Experimental|Experimental: Cohort 2, Dose 2 of ZD03 or Placebo|Dose 2 of ZD03 or matching Placebo capsules by mouth
9705244|NCT04693455|Experimental|Experimental: Cohort 3, Dose 3 of ZD03 or Placebo|Dose 3 of ZD03 or matching Placebo capsules by mouth
9705245|NCT04693455|Experimental|Experimental: Cohort 4, Dose 4 of ZD03 or Placebo|Dose 4 of ZD03 or matching Placebo capsules by mouth
9705246|NCT04693455|Experimental|Experimental: Cohort 5, Dose 5 of ZD03 or Placebo|Dose 5 of ZD03 or matching Placebo capsules by mouth
9705247|NCT04693455|Experimental|Experimental: Cohort 6, Dose 6 of ZD03 or Placebo|Dose 6 of ZD03 or matching Placebo capsules by mouth
9705248|NCT04693455|Experimental|Experimental: Cohort 7, Dose 7 of ZD03 or Placebo|Dose 7 of ZD03 or matching Placebo capsules by mouth
9705249|NCT04692948|Experimental|TAA6 cell injection|"Drug: TAA6 cell injection（Targeting CD276 autologous chimeric antigen receptor T cells）~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells.Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
9705250|NCT04692987|Experimental|Intervention|Participants will receive decision-aid video
10192381|NCT05275855|Experimental|Part B: EDI048 or Placebo|Part B is a multiple ascending dose study
10192382|NCT05275842|Experimental|Cognitive Processing Therapy-Lifesteps (CPT-L) [Group A]|
9705251|NCT04692987|No Intervention|Usual care|Participants will receive usual care
9705252|NCT04693052||Patients receiving mental health care prior to and during the COVID-19 pandemic|
9705253|NCT04692792|Placebo Comparator|Placebo drink|
9705254|NCT04692792|Experimental|Dai Dai flower drink|
9705255|NCT04693026|Experimental|Group A: Remdesivir + Baricitinib treatment group|"Remdesivir (Injectable solution):~A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~+~Baricitinib (oral tablet form):~Baricitinib tablets 4 mg/day for 2 to 4weeks"
9705256|NCT04693026|Active Comparator|Group B: Remdesivir + Tocilizumab treatment group|"Remdesivir (Injectable solution) A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~+~Tocilizumab (Injectable solution):~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
9705257|NCT04692935||Asian lung adenocarcinoma|Asian LUADs patients who had broad-panel next-generation sequencing (NGS) performed on their primary tumor between January 2018 and December 2019 at the department of thoracic surgery of Peking University People's Hospital
10192383|NCT05275842|Active Comparator|Lifesteps [Group B]|
10192384|NCT05275829||Control group: Face-to-Face learning of simple interrupted suturing|"The students watched a video demonstrating simple interrupted suturing, with the instructor commenting on the steps.~The students then watched the video again.~The instructor then demonstrated the procedure for the students.~The students then practiced suturing with immediate and specific feedback provided by the instructor until he and the students were satisfied with the performance."
10192385|NCT05275829||Study group: Distance learning (tele simulation) of simple interrupted suturing|"The instructor ran the interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform). The students used their personal smartphones or laptops with audio-video capabilities. The instructor ran the session through his smartphone.~The instructor shared a video demonstrating simple interrupted suturing while commenting on the steps (the same video used in the control group).~The instructor then ran the video again for the students.~The instructor then demonstrated the skill for the students by turning on his camera.~The students then practiced suturing, and periodically turned on their cameras to receive live and specific feedback from the instructor on their performance, until the instructor and the students were satisfied.~No face-to-face interactions between the students and the instructor."
10192386|NCT05275777|Experimental|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide (Phase Ib)|Intravenous ADG106 + 2 weekly doxorubicin and cyclophosphamide
9778924|NCT01118988|No Intervention|Control|Subjects randomly assigned to this control group receive treatment as usual (TAU).
9705258|NCT04692935||Caucasian lung adenocarcinoma|Caucasian LUADs patients who had targeted NGS (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) will be identified in the AACR GENIE database, which consists of 6673 primary lung adenocarcinoma samples with clinical annotations
9705259|NCT04692753||Pre-intervention|baseline data prior to training and education of health care workers. Intervention: intensive training and education of workers for maintenance of venous access devices.
9705260|NCT04692753||Post intervention|observation after training and education of health care workers
9705261|NCT04693013|Experimental|Interventional|use of virtual reality (VR)
9705262|NCT04693013|No Intervention|Control|no use of VR
9705263|NCT04692974|Experimental|Intervention Group|Participants in the intervention group will be given the wearables which they will use together with the accompanying mobile application for the period of the study (6 months). During the period of intervention, the wearable will track the physical activity of the older adults via the number of steps taken and number of hours of moderate physical work (based on heart rate). Heart rate and steps will be tracked whenever participants are wearing the watch, which is when they are awake. The watch is to be charged every night when they are sleeping. Participants will have to log down their physical activity by activating the physical activity tracker either on the watch or on the mobile application. If they did not hit the required level of physical activity, they will be sent a notification prompt through the mobile application with details of nearby workout locations as recommendation.
10192387|NCT05275777|Experimental|ADG106 combined with Paclitaxel (Phase Ib)|Intravenous ADG106 + weekly paclitaxel
10192388|NCT05275777|Experimental|ADG106 combined with dose dense Doxorubicin and Cyclophosphamide follow by Paclitaxel (Phase II)|Intravenous ADG106 combined with two weekly doxorubicin and cyclophosphamide followed intravenous ADG106 combined with weekly paclitaxel
9705264|NCT04692974|No Intervention|Control Group|For the control group, they will wear the wearables as a tracking device for the period of the study (6 months). No prompts will be given and the mobile application will only be installed but not used for this group.
9705265|NCT04692649|Experimental|PPCS|Novel intervention
9705266|NCT04692649|Active Comparator|CBS|Cross arm stretch gave to individuals
9705267|NCT04692909|Active Comparator|Active|Active dTMS
9705268|NCT04692909|Placebo Comparator|Placebo|Placebo dTMS
9705269|NCT04692571|Experimental|Study B: Limb-Absent Subject|"Ten unilateral transradial limb-absent subjects will each participate in one, half-day experimental session. Subjects will be seated and prepared in test apparatus seat (16 electrodes on the affected side, hand-wrist on the able side secured to load cells). Subjects will complete the 1-DoF and 2-DoF dynamic (force-varying) contractions (40-s duration, 0.75 Hz bandlimited, uniform random target). With 2 DoF contraction trials, hand Opn-Cls will always be one of the dimensions. The subject will then be released from the cuff and their able side not further involved in the experiment. The force feedback triangle cursor on the computer screen will be deleted such that only the target remains. Subjects will then repeat 1-DoF and 2-DoF trials in which the affected side attempts to produce hand-wrist effort that mimic movement of the target (with no feedback provided)."
9705270|NCT04692571|Experimental|Study B: Able-bodied Subjects|Ten able-bodied subjects, the electrodes will be mounted on the dominant arm for the EMG-force and EMG-target tracking trials. In addition, the non-dominant arm will also be constrained and measured in a second load cell. This load cell will not be used for feedback during the experiment, but will compare (RMS error, off-line) the dominant vs. non-dominant forces. For EMG-target tracking, the dominant hand will remain in the wrist cuff (to prevent flailing during contractions), with the screen feedback disabled. These subjects will repeat the trials with the electrodes moved to the non-dominant side. EMG-force tracking will be repeated using mirrored contractions. The three training methods (EMG-force ipsilateral, EMG-force contralateral mirrored, EMG-target on the dominant side) will be contrasted to help understand the source of errors when training with limb-absent subjects.
9705271|NCT04692545||A|patients receiving immunonutrition supply
9705272|NCT04692545||B|patients receiving standard dietary advice
9705273|NCT04692805|Experimental|EUS-guided treatment of varices|"Procedure: EUS-guided injection of coils with cyanoacrylate glue (CYA) and sclerosing agent.~First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with Coils plus CYA and sclerosing agent (Group A)."
9705274|NCT04692805|Experimental|EUS-guided partial splenic embolization + EUS-guided treatment of varices|"Procedure: EUS-guided partial splenic embolization + EUS-guided treatment of varices First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with coils plus CYA and sclerosing agent.~At the same procedure, a branch of splenic artery will be identified by EUS and implanted with coils plus CYA (Group B)."
9705275|NCT04692636||Total study cohort|Patients with dysfunctional hemodialysis vascular access referred for PTA or patients who received maintenance hemodialysis will be prospectively enrolled.
9705276|NCT04692506|Active Comparator|Low dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
10192389|NCT05275764||optic capture group|IOL optic was captured through the posterior continuous curvilinear capsulorhexis
10192390|NCT05275764||endocapsular group|IOL was placed in the bag
10192391|NCT05275699|Experimental|68Ga-FAPI-04 PET/CT and 68Ga-RGD PET/CT|All patients diagnosed with keloid underwent 68Ga-FAPI PET/CT and 68Ga-RGD PET/CT.
10192392|NCT05275660|Experimental|HFB30132A|Participants will receive HFB30132A administered across 2 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
10192393|NCT05275660|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
9705277|NCT04692506|Active Comparator|High dose: Sachet with B. longum|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
9705278|NCT04692506|Placebo Comparator|Placebo Sachet|"The IP will be self-administered by the subject. Subjects will be asked to consume the IP (1 sachet) once per day, at approximately the same time every day, for 28 days.~The sachet should be emptied in, and mixed with, a bottle of milk."
9979615|NCT01383785|Experimental|GROUP B|Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter
9979616|NCT01383785|Experimental|GROUP C|Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter
9705281|NCT04692623|Experimental|Moxfloxacin Group|In this arm 30 healthy volunteers were selected and they were given Moxifloxacin drug.
9705282|NCT04692623|Experimental|Gemifloxacin Group|In this arm 30 healthy volunteers were selected and they were given Gemifloxacin
9705283|NCT04692597|Experimental|Group 1 (LLLT)|"Group 1: Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes affected per hand.~The protocol for each group will involve one minute of LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
10192394|NCT05275634|Experimental|Standard treatment and interferential current with carrier frequency 2 KHz|Standard treatment and interferential current with carrier frequency 2 KHz will be received three times a week for four weeks.
10192395|NCT05275634|Experimental|Standard treatment and interferential current with carrier frequency 4 KHz|Standard treatment and interferential current with carrier frequency 4 KHz will be received three times a week for four weeks.
10192396|NCT05275634|Experimental|Standard treatment and interferential current with carrier frequency 8 KHz|Standard treatment and interferential current with carrier frequency 8 KHz will be received three times a week for four weeks.
10192397|NCT05275634|Placebo Comparator|Standard treatment and placebo interferential current|Standard treatment and placebo interferential current will be received three times a week for four weeks.
10192398|NCT05275621|Experimental|Subjects requiring PICC|Subjects requiring a PICC. Positioning is first tried under Virtual Reality distraction. If failure (movements or discomfort) standard procedural sedation is applied. No kind of physical restraint is allowed.
10192399|NCT05275608|Experimental|VLCKD|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~Age 25-65~BMI 30-40 mg/m2~NAFLD~DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c > 7 and < 10 %."
10192400|NCT05275608|Active Comparator|Hypocaloric Mediterranean Diet|"20 Patients recruited from our endocrinology department that will keep the same medical visits frequency and drugs and accept to be randomized to one of the two groups.~Inclusion criteria:~Age 25-65~BMI 30-40 mg/m2~NAFLD~DM2 drug-treated (metformin, SGLT2 inhibitors, GLP-1 analogues, DPPIV inhibitors, insulin) and HbA1c > 7 and < 10 %."
10192401|NCT05275595||chronic renal disease with covid|all patients who have chronic kidney disease with COVID-19 infection
10192402|NCT05275595||chronic renal disease without covid|all patients who have chronic kidney disease without COVID-19 infection
10192403|NCT05275582|Experimental|CARE-PACT|Brief (5 minute) meeting between the PACT medical provider and a behavioral health educator (in person or virtual using VA's VVC system) -followed by- 30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app 2 optional 15-minute phone calls with behavioral health educator
10192404|NCT05275582|Experimental|CARE-PCMHI|30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app 2 optional 15-minute phone calls with behavioral health educator
9705284|NCT04692597|Sham Comparator|Group 2 (LLLT Sham)|"Group 2: Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes affected per hand.~The protocol for each group will involve one minute of sham LLLT over each of the following treatment zones: dorsal fingers and thumb, dorsal metacarpals, dorsal wrist, palmar fingers and thumb, palmar metacarpals, palmar wrist for a total of 6 minutes affected on each hand. The LLLT device will be held approximately 12 inches from the skin surface."
10192405|NCT05275465|Experimental|HH-006|
10192406|NCT05275465|Placebo Comparator|Placebo|
9785131|NCT01243775|Experimental|Belotaxel plus Belloxa|Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)
9979617|NCT01383798|Placebo Comparator|Placebo|Red capsule (50 mg) lactose
9979618|NCT01383798|Experimental|Ferrous sulfate|
9979619|NCT01383811|Active Comparator|Moderate Intensity Aerobic Exercise|
9979620|NCT01383811|Other|Wait List/Usual Care|The subjects in this group will continue to receive the usual treatment that they were on at the time of enrollment through the wait list period of 12 weeks. Subsequently they will receive the 12 weeks of aerobic exercise program intervention
9979621|NCT01383824|Other|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
10192407|NCT05275452||School age children aged 9-13 years|
10192408|NCT05275452||Women of reproductive age aged 18-44 years|
10192409|NCT05275413|Experimental|family-based mHealth intervention|The expectant mothers and their family members (fathers and grandparents) in this group will receive health education and support and family support via a smartphone app.
10192410|NCT05275413|Experimental|mother-only mHealth intervention|The expectant mothers in this group will receive health education and support via a smartphone app.
10192411|NCT05275413|Active Comparator|Health education|The expectant mothers in the control group will receive health education via a smartphone app.
10192412|NCT05275348|Experimental|Tele-EF|Remote delivery of Enhance Fitness.
10192413|NCT05275348|Active Comparator|In-person EF|In-person delivery of Enhance Fitness.
9979622|NCT01383837|Experimental|STYLEnS|Multifamily Group HIV/STI Prevention intervention or Single Family Dyad (youth and a parent)
9979623|NCT01383837|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
9705285|NCT04693000|Experimental|Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|"An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.~Keratotic nodular size observation after 12 weeks"
9778925|NCT01118988|No Intervention|Mentors|"Subjects recruited to the Mentor arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone."
10192414|NCT05275322|Experimental|Treatment group|
9778926|NCT01119001|Experimental|P300 Brain Computer Interface for people with ALS|
9778927|NCT01119040|Experimental|NOTES PEG Rescue|A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.
9778928|NCT01119105|Experimental|BC-3781 dose 100mg|
9778929|NCT01119105|Experimental|BC-3781 dose 150mg|
10192415|NCT05275322|No Intervention|Waiting list group|
10192416|NCT05275309|Experimental|Children <= 6 years old|Pediatric patients under 6 years of age scheduled for surgery in the prone position
10192417|NCT05275296|Experimental|experimental group|Microport NeuroTech Intracranial Visualized Stent
10192418|NCT05275296|Active Comparator|control group|LVIS™ and LVIS™ Jr
10192419|NCT05275283|No Intervention|Control group|Applying tidal volume 7 ml/kg without PEEP
10192420|NCT05275283|Experimental|PEEP group|Applying tidal volume 7 ml/kg with 6 cmH2O of PEEP
9778930|NCT01119105|Active Comparator|Vancomycin|
9778931|NCT01119118|Experimental|1|ZD4054 + multimodal PET/MRI imaging
9778932|NCT01119131|Active Comparator|Arm 1|Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
10192421|NCT05275270|Active Comparator|Group A|patients were treated with an active gel containing oxytocin
10192422|NCT05275270|Placebo Comparator|Group B|patients were treated with placebo gel without oxytocin
10192423|NCT05275257|Experimental|Uricap group|the new incontinence device
9778933|NCT01119131|Placebo Comparator|Arm 2|Will be on placebo and 1000mg of calcium.
9778934|NCT01119222|Active Comparator|Gabapentin 1200mg|
9778935|NCT01119222|Active Comparator|Diphenhydramine 50 mg|
9778936|NCT01119222|Active Comparator|Morphine 10 mg|
9778937|NCT01119222|Placebo Comparator|Placebo formulations|
9778938|NCT01119248||Children undergoing MRI|120 children ages of 6 months and 8 years for MRI and axillary temperature before MRI and after the MRI with MRI compatible device
9778939|NCT01119287|Experimental|Maxidex|Dexamethasone 0.1% ophthalmic suspension, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
9778940|NCT01119287|Experimental|Patanol|Olopatadine hydrochloride 0.1% ophthalmic solution, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
9778941|NCT01119287|Placebo Comparator|Tears Naturale II|Inactive ingredients, used as placebo, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
9778942|NCT01119443|Other|Treatment sequence A|V4: PPX ER 1.5mg x 1 fed, V5: PPX ER 0.375mg x 4 fed, V6:: PPX ER 1.5mg x 1 fasted, V5: PPX ER 0.375mg x 4 fasted
9778943|NCT01119443|Other|Treatment sequence B|V4: PPX ER 0.375mg x 4 fed, V5: PPX ER 1.5mg x 1 fed, V6:: PPX ER 0.375mg x 4 fasted, V5: PPX ER 1.5mg x 1 fasted
9778944|NCT01119456|Experimental|IMC-RON8|A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).
9778945|NCT01119508|Experimental|Ipilimumab + Temozolomide|Induction: Ipilimumab 10 mg/kg IV over 90 minutes Day 1 + Temozolomide 200 mg/m2 PO on Days 1 - 4, every 3 weeks for 4 courses over 3 months.
9778946|NCT01119625|Experimental|Synflorix™ Commercial-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of commercial lot of Synflorix™ co-administered with Rotarix™ and Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
9778947|NCT01119625|Active Comparator|Synflorix™ Clinical-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of clinical lot of Synflorix™ + Rotarix™ co-administered with Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (clinical and commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
9778948|NCT01119703||Arm 1: Healthy, elderly participants|Healthy participants 65 years old and older.
9778949|NCT01119703||Arm 2: Healthy, young, participants|Healthy participants 25 to 40 years old.
9979624|NCT01383850|Active Comparator|NCPAP + standard air|
10192424|NCT05275257|No Intervention|Control group|the usual incontinence care
10192425|NCT05275244||Osteoarthritis Group|The patients diagnosed with single or preferential symptomatic osteoarthritis of the shoulder or hip treated with KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%), and ankle or base of the thumb treated with KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%). Each patient will be administrated three injections, one per week.
10204518|NCT05202574|Active Comparator|dexamethasone|
10204519|NCT05202574|Active Comparator|ondanestrone|
10204520|NCT05202574|Placebo Comparator|control group|
10204521|NCT05202548||Lymphadenitis TB|The group study was blocked paraffin from lymphadenitis tuberculosis patient that already confirmed diagnosis histopathological anatomy (PA histopathology)
10192426|NCT05275218|Experimental|Intervention Group|Implementation of the KDIGO bundle for at least 12 hours 1. discontinuation of all nephrotoxic drugs when possible 2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring) 3. close monitoring of serum creatinine, fluid balance and urinary output 4. avoidance of hyperglycemia 5. considerations of alternatives to radiocontrast agents 6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period 7. avoidance of hydroxyethyl starch, gelatin, and chlorid-rich solutions
9705286|NCT04692558|Experimental|HYALURONIC ACID|CAF+CTG+HA
9705287|NCT04692558|Active Comparator|WITHOUT HYALURONIC ACID|CAF+CTG
9705288|NCT04692727|Active Comparator|Exercise grup|An exercise program that includes stretching, strengthening and balance exercises accompanied by physiotherapist in the clinic will be applied to all individuals participating in the study for 6 weeks, 2 times a week (12 sessions). Each session will take approximately 40 minutes and patients will be asked to repeat the exercises at least 2 sets a day at home when they are not in the clinic (other 5 days a week). The home program will be followed by the exercise daily form.
10192427|NCT05275218|No Intervention|Control Group|"Patients in the control group will receive standard of care. According to best clinical practice, this includes the following targets (unless specific individual targets are chosen by treating physician):~mean arterial pressure (MAP): ≥ 65 mmHg~passive leg raising test (PLRT): increase of cardiac output (CO)<10%"
9705289|NCT04692727|Experimental|McConnell patellar taping grup|McConnell patellar taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group. The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
9705290|NCT04692727|Experimental|Femoral rotational taping grup|Femoral lateral rotation taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group.The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
10192428|NCT05275205|Experimental|UBX1325|
10192429|NCT05275205|Active Comparator|Aflibercept (EYLEA ®)|
9705291|NCT04692844||Patients with essential tremor treated with Propranolol|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Propranolol in the course of routine medical practice, will be included.
9705292|NCT04692844||Patients with essential tremor treated with Primidone|Patients will be recruited from the outpatient clinic for extrapyramidal disorders. Only patients with the diagnosis of ET made according to the newest consensus statement on the classification of tremors and only patients who will receive Primidone in the course of routine medical practice, will be included.
9705293|NCT04692896|Experimental|0.1% lidocaine|
9705294|NCT04692896|Experimental|0.2% lidocaine|
9705295|NCT04692896|Experimental|0.3% lidocaine|
9705296|NCT04692740|Experimental|Chlorambucil|
9705297|NCT04692857|Experimental|group 30|participants received a supra inguinal fascia iliaca compartment block with 30 ml of 0.2% ropivacaine
9705298|NCT04692857|Experimental|group 40|participants received a supra inguinal fascia iliaca compartment block with 40 ml of 0.2% ropivacaine
9705299|NCT04692857|Experimental|group 50|participants received a supra inguinal fascia iliaca compartment block with 50 ml of 0.2% ropivacaine
9705300|NCT04692610|Placebo Comparator|Group A|Postoperative Education Group received stoma education and stoma care after surgery beginning from the postoperative day-1. In the preoperative period they were informed about stoma and stoma sites were marked.
9705301|NCT04692610|Active Comparator|Group B|Pre- and Postoperative Education Group received stoma education both before surgery and on the postoperative day-1. They received stoma care postoperatively as usual. In the preoperative period they were also informed about stoma and stoma sites were marked.
9705302|NCT04692610|Experimental|Group C|Prehabilitation Group received the same protocol as Group B, however in addition they were prehabilitated with a water-filled stoma pouch (250 ml) 48 hours before surgery. These pouches were not removed until surgery, and EST nurse preoperatively taught the patients how to manage the stoma pouch with similar standards as the usual postoperative stoma-care.
9705303|NCT04692766|Experimental|RPH-104 80 mg|subjects will receive RPH-104 at a dose of 80 mg subcutaneously once every 2 weeks
9705304|NCT04692766|Placebo Comparator|Placebo|subjects will receive placebo subcutaneously once every 2 weeks
9705305|NCT04692519|Experimental|Intervention|The Duet 2.0 intervention is comprised of six training modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. Modules were translated into Spanish. Participants will watch one Duet intervention module a week and have up to 3 months to complete all 6 modules. As intervention families review the modules on their own time at home, they will receive remote coaching from an assigned interventionist and weekly module-specific fidelity/comprehension questions. Interventionists will check-in weekly via phone or video (~30-60 minutes), whichever is more convenient for the family. During the check-in, interventionists will do teach-back about the module, guide the family on how to incorporate the strategies into their daily lives, and provide feedback. Intervention participants will be scheduled for follow-up data collection at 3 months, 6 months, and pending funding, 1-year after baseline.
9778950|NCT01119716||All Enrolled Participants|Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
10192430|NCT05275192|Experimental|Videoscope-assisted periodontal regeneration minimally invasive surgery|Videoscope-assisted periodontal regeneration minimally invasive surgery - Test group
9778951|NCT01119768|Active Comparator|Esomeprazole 8 weeks treatment|20 mg q.d. (quaque die) once a day dosing for 8 weeks
9778952|NCT01119768|Active Comparator|Esomeprazole 2 Weeks Treatment|20 mg q.d. (quaque die) once a day dosing for 2 weeks
9778953|NCT01119794|Experimental|ofatumumab and bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
10192431|NCT05275192|Active Comparator|Periodontal regeneration minimally invasive surgery|Periodontal regeneration minimally invasive surgery - Control Group 1
10192432|NCT05275192|Active Comparator|Guided tissue regeneration surgery|Guided tissue regeneration - Control Group 2
10192433|NCT05275179||Posaconazole Therapeutic Drug Monitoring|Therapeutic Drug Monitoring of posaconzole is performed by measuring posaconazole concentrations in serum
9705306|NCT04692519|No Intervention|Delayed Access|Participants who are in the delayed access control group will not have to complete the modules and will be scheduled for a 3-month, 6-month, and pending funding, a 1-year follow-up calls. They will have delayed access to the modules, which means that they will receive access to the module videos at their 6-month study session and will be offered the opportunity to contact the research team with any questions.
9705307|NCT04692480|Experimental|Breastfeeding Video Education|"Participants will view a breastfeeding educational video entitled Breastfeeding in the First Hour, It's in Your Hands."
10192434|NCT05275166|Other|Patients|Patients hospitalized for rehab. HRE following induction of alcohol craving and questionnaires
9705308|NCT04692480|Other|Control|Participants will view a PDF of breastfeeding education materials available for inclusion in standard discharge paper work.
9705309|NCT04692454|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
10192435|NCT05275166|Other|Healthy Volunteers|Healthy Volunteers with non alcohol dependance. HRE following induction of alcohol craving and questionnaires
10192436|NCT05275153|Experimental|Home based cognitive rehabilitation program|The intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
9705310|NCT04692285|Active Comparator|Patients with focal dystonia treatment first placebo second|Zolpidem 5 mg single dose
9705311|NCT04692285|Placebo Comparator|Patients with focal dystonia placebo first treatment second|Placebo 5 mg single dose
10192437|NCT05275153|No Intervention|No intervention|In the control group, natural cognitive changes with the passage of time were observed.
10192438|NCT05275127||Control|Evaluation of changes of gingival crevicular fluid miRNA
9705312|NCT04692272|No Intervention|CONTROL group|The CONTROL group did not exercise.
10192439|NCT05275127||Periodontitis|Evaluation of changes of gingival crevicular fluid miRNA
10192440|NCT05275127||Cardiovascular disease|Evaluation of changes of gingival crevicular fluid miRNA
10192441|NCT05275127||Periodontitis + cardiovascular disease|Evaluation of changes of gingival crevicular fluid miRNA
10192442|NCT05275114|Experimental|Hand Tasks + M1(1mA) & aIPS(1mA) tDCS|20 minutes of Hand Taks + applying 30 minutes of M1(1mA) & aIPS(1mA) tDCS and fNIRS
10192443|NCT05275114|Active Comparator|Hand Tasks + Sham tDCS|20 minutes of Hand Tasks + 30 minutes of sham tDCS and fNIRS
10192444|NCT05275088|Experimental|Treatment|Transcatheter atrioventricular valve replacement with the Prizvalve® system
9705313|NCT04692272|Experimental|XBOX group|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
10192445|NCT05275075||Pancreatic Cancer Cohort|All eligible adenocarcinoma pancreatic cancer patients with operable cancer.
10192446|NCT05275062|Experimental|IM92 CAR-T cells|
10192447|NCT05275049|Experimental|PT+ Device|PT plus translingual stimulation device PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
10192448|NCT05275049|Active Comparator|PT + Control Device|PT plus translingual stimulation control device Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
10192449|NCT05274997|Experimental|YY-20394|Administer linperlisib (YY-20394) 80 mg (4 tablets) orally with water, once daily, in a 28-day cycle.
10192450|NCT05274984|Placebo Comparator|Group Placebo|the control group will be given the same volume of saline as the experimental group
10192451|NCT05274984|Active Comparator|Group Lidocaine|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
10192452|NCT05274945|Experimental|total neoadjuvant therapy|patients will be treated by total neoadjuvant therapy, including concurrent chemoradiotherapy in the form of radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil + Calcium leucoverin for first 4 days and last 3 days of radiotherapy or capecitabine at 825 mg\m2 twice daily. Then, after 2-3 weeks preoperative chemotherapy will be started in the form of 6 cycles of FOLFOX or CAPOX. Then, after 3-4 weeks surgery will be done.
10192453|NCT05274945|Active Comparator|standard neoadjuvant therapy|patients will be treated by standard neoadjuvant therapy , including concurrent chemoradiotherapy in the form of radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil + Calcium leucoverin for first 4 days and last 3 days of radiotherapy or capecitabine at 825 mg\m2 twice daily . Then, after 6-8 weeks surgery will be performed followed by adjuvant chemotherapy.
10192454|NCT05274906|Experimental|Controlled HEI-2015 diet with red and processed meat|
10192455|NCT05274906|Experimental|Controlled HEI-2015 diet without red and processed meat|
10192456|NCT05274893|Experimental|SYHX2011(T)-Abraxane®(R)|Patients will be administrated with SYHX2011 followed by Abraxane®
10192457|NCT05274893|Experimental|Abraxane®(R)-SYHX2011(T)|Patients will be administrated with Abraxane® followed by SYHX2011
10192458|NCT05274880|Experimental|1group|"Period 1 - A single dose of 2 tablets(CKD-393) under fed condition.~Period 2 - A single dose of 2 tablets(CKD-393) under fasting condition."
9705314|NCT04692259|Experimental|experimental arm|Single arm study. All patient who had an MRI performed before liver resection is included
9785132|NCT01243944|Experimental|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
9979625|NCT01383850|Experimental|NCPAP + Heliox|
10192459|NCT05274880|Experimental|2group|"Period 1 - A single dose of 2 tablets(CKD-393) under fasting condition.~Period 2 - A single dose of 2 tablets(CKD-393) under fed condition."
9705315|NCT04692246|Experimental|Test Group|Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
9705316|NCT04692246|Placebo Comparator|Control Group|Patients that will follow the same protocol, but using placebo irrigation and a placebo spray at home.
9705317|NCT04692142|Active Comparator|Passive online|Before L1, all students will be asked to complete a set of multiple-choice questions (MCQs), formative exam (i.e. pre-test). Following the test , the lecture will be delivered to the participants of PG using a passive online teaching format for 60 minutes (i.e., live-video streaming). After the lecture is completed, students will be asked to re-take the same pre-test exam and complete questionnaire regarding their experience with the teaching methods.
9705318|NCT04692142|Experimental|Flipped classroom|"Participants of FG will have an access to a recorded lecture. and they will be taught using an active teaching model known as flipped classroom model. In this model, participants will have 7 -day monitored remote access to the recorded L1. Similar to PG, completing the online pre-test formative exam will be preliminary requirement to access the published recorded L1.~At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately. After the lecture is completed, students will be asked to re-take the same pre-test of L1 and complete questionnaire regarding their experience with the teaching methods."
9705319|NCT04692311|Experimental|Persons with central nervous system diseases|Persons with central nervous system diseases received additional training with i-ACT during 6 weeks. After final training, a semi-structured interview was performed. And at six weeks follow-up, a final assessment took place.
9705320|NCT04692311|Other|Occupational therapists|Occupational therapists were invited to a semi-structured interview to gather information about their professional opinion regarding i-ACT.
9705321|NCT04692155|Experimental|phase 1b and phase 2|"for phase 1 B portion, Ublitixumab will be given IV at dosage 900mg from Cycle 1 Day1 till cycle 6. If investigator decides to continue the treatment as maintenance, Ublitixumab will be given IV every 8 weeks for 24 months Umbralisib (800mg) will be given orally once a day within 30 minutes of a meal from Cycle 1 Day1 till cycle 6.If investigator decides to continue the treatment as maintenance,• Umbralisib will be given at orally daily for 24 months.~Chemotherapy combination of CHOP-cyclophosphamide IV 750mg/m2 for Age <70 years, 500 mg/m2 for Age>70 years doxorubicin IV 50mg/m2for Age <70 years, 25 mg/m2 for Age>70 years , and vincristine IV 1mg/m2 (max 2mg)) are administered on Cycle 1 day 1 till Cycle 6. Prednisone 50-100mg will be given orally on days 1 through 5 of every cycle.~For Phase II portion- Once Umbralisib dose is defined in phase Ib, the study will expand to phase II portion after SMC/DSMB (Safety monitoring committee/Data Safety Monitoring Committee) agrees."
9705322|NCT04692376|Experimental|MSCs group|MSCs group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.
9705323|NCT04692376|Active Comparator|Control group|Glucocorticoids and CsA will be used for treatment.
10192460|NCT05274854|Experimental|Preconsultation Intervention|Pre-consultation intervention includes 4 arms ((a) standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing)
9705324|NCT04692441|Other|Intervention|All participants undergo the same intervention: Drinking heavy cream and undergoing MRI.
9705325|NCT04692428|Experimental|FIBSI group|ultrasound supra inguinal Fascia iliaca block
10192461|NCT05274854|Experimental|Consultation Intervention|Consultation intervention includes 2 arms (a) consultant-led outpatient clinic or b) a integrated care clinic depending on their response to the initial preconsultation intervention.
9705326|NCT04692428|Experimental|FNB group|ultrasound femoral nerve block
10192462|NCT05274841|Other|Identified support needs|Identified need of either support from a psychologist, nurse, doctor, socialworker or a combination of theese.
9705327|NCT04692116|Experimental|ExAblate Arm|ExAblate Model 4000 System for the treatment of Parkinson's disease
9705328|NCT04692337|Experimental|Ommaya Reservoir placement|Subjects undergoing surgery for a confirmed or suspected brain tumor will have an Ommaya Reservoir placed at the time of surgery.
9705329|NCT04692233|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (follow-up; 8 hours). The sessions will be supervised by an experienced qigong master. Throughout the intervention period, participants will be asked to self-practice BQ for 30 minutes twice a week from weeks 1 to 8, and then three times a week from weeks 9 to 16 (20 hours).
9705330|NCT04692233|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise without any abdominal breathing and meditation techniques. The duration and frequency of supervised sessions and self-practice will be identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
9705331|NCT04692090|Experimental|Yoga Group|Hatha yoga will be practiced twice a week for 10 weeks
9705332|NCT04692090|No Intervention|Control group|This group will not have any intervention.
9979626|NCT01383876|Active Comparator|Collar|Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
10192463|NCT05274828|Experimental|H7-Coil Deep TMS Treatment|H7-Coil Deep TMS Treatment
10192464|NCT05274672|Experimental|Patients not receiving postoperative antibiotics|Patients who will not receive prophylactic postoperative antibiotics after HoLEP.
10192465|NCT05274672|Active Comparator|Patients receiving postoperative antibiotics|Patients who will receive3 days prophylactic postoperative antibiotics after HoLEP.
10192466|NCT05274399||Hemodialysis Patients|Receiving hemodialysis treatment for at least three months
9705333|NCT04692415|Active Comparator|degludec arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IDeg-100 In phase one they received IDeg-100 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IDeg-100 to IGlar-300 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
9705334|NCT04692415|Active Comparator|glargine arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IGlar-300 In phase one they received IGlar-300 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IGlar-300 to IDeg-100 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
9705335|NCT04692168||Entire group|The group will be test prior and three months after a neurotoxic chemotherapy for gynecological cancer.
10192467|NCT05257785|Experimental|Lymfit exercise intervention|Participants randomized to the intervention group will be allocated a pre-registered Fitbit, a personalized exercise prescription designed by the kinesiologist, and 12 weeks of supervision by the kinesiologist.
10192468|NCT05257785|Other|Waitlist control|Participants will receive the exact same Lymfit exercise intervention 3 months after they consent to participate in the study.
10192469|NCT05257499|Experimental|On line debfriefing|Participants in this group will practice the skills taught as above but in the presence of the same certified instructor who will guide them throughout all the steps of HBB using a virtual platform (Webex® or Zoom®).
10192470|NCT05257499|No Intervention|In person debriefing|Participants in this group will practice the skills taught in the virtual class on the neonatal mannequin. They are expected to work as a small group of 3 to 4 at a time. They will receive coaching, debriefing and feedback from a certified instructor who will conduct the traditional in-person training with face-to-face feedback and debriefing.
10192471|NCT05256589|Experimental|SARS_CoV_2 Antigen Rapid Test|"The same group of patients participate in two arms of the study:~One arm is for obtaining performance data of the Sona Saliva C-19 Rapid self test and the comparator arm is to obtain data from the primary care route using approved RT-PCR testing."
9705336|NCT04692402|Other|open label|open label prospective feasibility trial.
9705337|NCT04692038||Treatment Group|The subjects would receive forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS
10192472|NCT05255952|Experimental|Patients|"3 cycles of electrical stimualtions will be done at the end of cardiac surgery, before end of surgery (patient closure), under anaesthesia.~Cardiac outcomes will be monitored"
10192473|NCT05255562|Active Comparator|Combined Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anterior area to the superficial serratus anterior area above the serratus anterior muscle and injected 2 ml normal saline for hydrodissection. Finally, 15 ml of 0.25% bupivacaine will be injected for the superficial serratus anterior block into the interfacial area.
10192474|NCT05255562|Active Comparator|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
10192475|NCT05255497|Experimental|Biodex Balance Group|This group performed exercises using the biodex balance system
10192476|NCT05255497|No Intervention|Control Group|This group was informed about diabetes self-management.
10192477|NCT05255471|Experimental|Olaparib|
10192478|NCT05255471|Active Comparator|Chemotherapy|
10192479|NCT05255341|Experimental|roll pedicle connective tissue graft with bovine bone|"sulcular incisions were performed on the buccal and lingual aspects of the teeth to be extracted~Atraumatic extraction was made by periotome.~After tooth extraction the soft tissue was reflected at least 4 mm beyond the alveolar crest margin and the socket was filled with bovine derived xenograft and covered with roll pedicle connective tissue graft as a barrier membrane.~This pedicle is rolled under the buccal mucosa.The palatal connective tissue pedicle graft was outlined by full thickness incision along the oblique incision line, and parallel incision given from the mesial line angle of target place and reflected coronally up to the crest of the ridge defect. then a partial thickness incision was made extending beyond the line angles of adjacent incisors and mucogingival junction, leaving the periosteum on the bone.~the pedicle graft was rolled from the apical end and secured with interrupted sutures to the labial flap."
9705338|NCT04692025|Experimental|Group 1|ASC41 one tablet, on Day 1 before meal；ASC41 one tablet, on Day 15 after meal.
9705339|NCT04692025|Experimental|Group 2|ASC41 one tablet, on Day 1 after meal；ASC41 one tablet, on Day 15 before meal.
9705340|NCT04692051|Experimental|Nab-paclitaxel + Cisplatin|Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin
10192480|NCT05255328|Experimental|MELAS|Patients with MELAS syndrome will receive 12-18g/day of glutamine
10192481|NCT05254730|Experimental|micro-macroelectrodes|Patients will be implanted with usually the novel intracerebral micro-macroelectrodes (instead of the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
10192482|NCT05254314|Experimental|Study Drug (Semaglutide)|Semaglutide 2.4mg once weekly
10192483|NCT05254314|Placebo Comparator|Placebo|Placebo 2.4mg once weekly
10204522|NCT05202535|Experimental|Aerobic exercise training|hospital-based aerobic exercise training on treadmill/cycle ergometer with the intensity of 40-70% of HR max, for 15-30 mints for 8 weeks
10204523|NCT05202535|Active Comparator|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
9705341|NCT04692051|Active Comparator|Gemcitabine + Cisplatin|Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin
9705342|NCT04691674|Experimental|Study group|Endoscopic removal of pancreatic duct stent at 4 weeks following ERCP, unless spontaneously dislodged.
9705343|NCT04691674|Placebo Comparator|Control group|Endoscopic removal of pancreatic duct stent at 2 weeks following ERCP, unless spontaneously dislodged.
9705344|NCT04691765|Experimental|100 mg SC|100 mg of Kineret (anakinra) will be administered sub-subcutaneously once a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
9705345|NCT04691765|Experimental|100 mg SC BID|100 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
9705346|NCT04691765|Experimental|200 mg SC BID|200 mg of Kineret (anakinra) will be administered sub-subcutaneously twice a day for 28 days (1 cycle) with a maximum of 7 cycles (28 weeks of treatment)
9705347|NCT04691752||COPD patients|"Adults (men or women) aged more than 40 years old~Diagnostic code in Andalusian clinical records (Diraya) in accordance with ICD-9 (Diagnostic codes 496, 492.8, 494.0, 491.20, 493.2)~Current of former smokers of at least 10 pack- years~Patient with a minimum follow up of 1 year, who have been assisted in a scheduled primary care appointment at inclusion date."
9705348|NCT04691687|No Intervention|Standard of Care (Group 1)|Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient's care.
10192484|NCT05253898|Active Comparator|Pelvic Floor Physical Therapy|"Group 1 includes a training program about correctly using pelvic floor muscles. At the first session, an educational program will be given to all women about the anatomy and function of the pelvic floor muscles. Then, the pelvic floor muscles contractions will be controlled by vaginal palpation for approximately 10 minutes.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of fast and slow pelvic floor muscles contractions in different positions, and 10 minutes of abdominal breathing, general relaxation, stretching, and cool-down exercises.~It is planned to teach contractions with internal palpation for 10 minutes before the first session to ensure that the patients' pelvic floor contractions are performed correctly. PFT treatment will be given as two sessions per week, 45 minutes, and 8 weeks as group sessions."
9705349|NCT04691687|Placebo Comparator|IV Placebo Infusion|Patients in Group 2 received IV saline infusion (20-40 ml) concentrated by the pharmacist to minimize fluid intake.The infusions were continuous over 3 hours, biweekly over a one-month period.
9705350|NCT04691687|Experimental|IV Furosemide Infusion|The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions). The infusions were continuous over 3 hours, biweekly over a one-month period.Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, SBP <80 mmHg or symptoms of presyncope).
9705351|NCT04692012|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
9705352|NCT04691908|Active Comparator|Phase III Adult-vaccine (A Sample, blind study)|Group 1 (phase III): 2400 volunteers from 18 years old and elder who will be the QazCovid-in® twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9705353|NCT04691908|Placebo Comparator|Phase III Adult-Placebo (A Sample, blind study)|Group 1 (phase III): 600 volunteers from 18 years old and elder who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9705354|NCT04691778|Active Comparator|CTO PCI using antegrade wiring strategy starting with the Gladius guidewire|Study subjects will undergo CTO PCI with primary antegrade wiring strategy starting with the Gladius guidewire. In case of failed CTO crossing with the Gladius wire, the decision on continuing antegrade wire escalation with a different wire or switching to a different CTO PCI strategy will be left to the discretion of the operator.
9705355|NCT04691778|Other|CTO PCI using standard antegrade wire escalation strategy|Control subjects will undergo CTO PCI using standard antegrade wiring strategy starting with the lower/intermediate penetration force guidewires and, if necessary, escalating up to high gram-force guidewires, but without the use of first-choice Gladius guidewire.
9705356|NCT04691726|Active Comparator|Lidocaine infusion|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 2 mg/kg IBW i.v., continuous infusion of 1% lidocaine postoperatively rate 1 mg/kg IBW i.v. for 24 hours
9705357|NCT04691726|Placebo Comparator|Saline infusion|equal volumes of placebo - 0,9% saline i.v.
9705358|NCT04691817|Experimental|Atezolizumab and Tocilizumab|Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days
9705359|NCT04691973||Access to tool|Access to the digital tool. Participants use the tool at their own in addition to usual care and do the different themes that are available. They are recommended to use it at least every other week.
9705360|NCT04691973||No access to tool|Participants are followed by their ordinary healthcare provider and are not exposed to the tool.
9705361|NCT04691947|Experimental|Low dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 3 µg/0.5 ml Vaccine Intervention Description:Two applications on Days 0 and 21
9705362|NCT04691947|Experimental|Medium dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 6 µg/0.5 ml Vaccine Intervention Description: Two applications on Days 0 and 21
9705363|NCT04691947|Placebo Comparator|Placebo|Placebo Vaccine, containing 0.9 % saline Intervention Description: Two applications on Days 0 and 21
9705364|NCT04691882|Experimental|Diaphragmatic contraction|
9705365|NCT04691882|Active Comparator|Diaphragmatic relaxation|
9705366|NCT04691570|Experimental|ANX005|Participants will receive two once-weekly doses of ANX005 at specific time points
9979627|NCT01383876|Experimental|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
9705367|NCT04691349|Experimental|Chimeric antigen receptor T cell|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells
9705368|NCT04691544|Active Comparator|Fecal microbiota transplant from donor A|One FMT delivered by enema
9705369|NCT04691544|Active Comparator|Fecal microbiota transplant from donor B|One FMT delivered by enema
9705370|NCT04691544|Active Comparator|Fecal microbiota transplant from donor C|One FMT delivered by enema
9705371|NCT04691544|Placebo Comparator|Fecal microbiota transplant from autologous feces|One FMT delivered by enema
9705372|NCT04691297|Experimental|Escape|The ESCAPE program provides 8 counseling sessions over the phone, provides nicotine replacement therapy at no cost, and education about lung screening
9705373|NCT04691297|Experimental|Standard Care|The usual care program will include 1 counseling session, nicotine replacement therapy at no cost referral and enrollment in quitworks and an educational brochure about lung cancer screening
9705374|NCT04691466||HIP_R|Patients undergoing hip replacement surgery
9705375|NCT04691466||KNEE_R|Patients undergoing knee replacement surgery
9705376|NCT04691388|Experimental|Amlotinib+Sindili|Patients will be treated with amlotinib hydrochloride combined with Sindili monoclonal antibody
9705377|NCT04691401|No Intervention|Standard WL (white light) colonoscopy|all patients receive standard colonoscopy (with high definition- HD- endoscopes) with white light (WL) in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination.
9705378|NCT04691401|Experimental|Standard colonoscopy with assistance of Artificial Intelligence (CAD-EYE (Fujifilm Co, Tokyo, Japan)|all patients receive colonoscopy examinations (with HD endoscopes) equipped with an Ai system (CAD-EYE, Fujifilm Co, Tokyo, Japan) in both insertion and withdrawal phase). This system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.All polyps identified are removed and sent for histopathology examination.
9705379|NCT04691271|Experimental|Intervention group|In addition to routine anesthesia management and surgical operations, a stellate ganglion block was performed before induction of anesthesia, and related statistical indicators were collected prospectively.
9705380|NCT04691271|No Intervention|Blank control group|In this study, a blank control was used. Routine anesthesia management and surgical operation were used without any special interventions. Only relevant statistical indicators were collected prospectively.
9705381|NCT04691323|Other|HU-Go app intervention arm|Participants will use the HU-Go app intervention arm for 12 months.
9705382|NCT04691479|Experimental|PIMAGroup|"Educational and training program using motivational interview technical.~Stratification labels: to determine the personalized intervention plan are obtained from two types of variables: personal and modulation variables. For psychological variables the Perceived Competence Evaluation Questionnaire validated in Adherence to CPAP in OSA (CEPCA) is used. Drowsiness is obtained through the administration of the Epworth Somnolence Test, and the apnoea-hypopnea index is taken from the patient's clinical history.~Segmentation: With the psychological and clinical variables, in this first visit, predictive information is obtained on how the patient's adherence will be: high adherence, moderate adherence or low adherence.~Taking this information into account, the care plan will start considering how the patient is and their situation with respect to adherence. Depending on their evolution, the care plan is adapted. For patients with low adherence, telemonitoring is used."
9705383|NCT04691479|Experimental|Control|The patients followed the standard of care, which consists of starting therapy in the hospital, where the nurse performed training in the use of CPAP equipment, mask adjustment, and safety and maintenance instructions. For follow-up, the patient was always referred to the Hospital, with a frequency established by the Spanish Society of Pulmonology and Thoracic Surgery (Day 30, Day 90 and Day 180). The follow-up procedure consisted of reviewing the CPAP hour meter and resolving any incidents that may have arisen, with the necessary corrective actions (change of mask, positive reinforcement, and explanation of specific aspects).
10192485|NCT05253898|Active Comparator|Therapeutic Yoga Training|"Group 2 program includes therapeutic yoga training. It will begin with education about the positive effects of yoga on the body and pelvic floor.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of different asanas coordinated with breathing, and 10 minutes of yogi breathing and cool-down exercises.~Also, a home exercise program will be given based on yoga sessions. Participants will receive a detailed description of the home program."
9705384|NCT04691596|Active Comparator|Control Group|One fourth of participants were assigned to the Control Group, and received a basic training with the StepUp app and were asked to contact the study team with any problems or questions they encountered during the eight-week study period. No other intervention tools or app reminders were provided to the Control Group.
9705385|NCT04691596|Experimental|Treatment Group 1|Additionally eligible to receive weekly $5 Amazon gift cards over the first four weeks of the study for performing a ≥10-minute walk (i.e. non-cue-contingent incentives)
9836212|NCT02775617|Other|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
10192486|NCT05250063|Experimental|LUM-201 (3.2 mg/kg/day)|
10192487|NCT05248139|Experimental|Single-dose antibiotic and steroid medication delivered during surgery|
10192488|NCT05248139|Active Comparator|Standard of care post-operative antibiotic and steroid drops|
9705386|NCT04691596|Experimental|Treatment Group 2|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were similarly eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any time of day (i.e. non-cue-contingent incentives)
9705387|NCT04691596|Experimental|Treatment Group 3|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit, then they were eligible weekly for $5 Amazon gift cards over the first four weeks conditional on completing a ≥10-minute walk at any the pre-specified time of their chosen contextual cue (i.e. cue-contingent incentives)
10192489|NCT05245058|Experimental|SPH5030 tablets|"Subjects will take SPH5030 tablets orally on an empty stomach once or twice a day.~Each subject will receive only one corresponding dose, and there were five dose groups: 50mg/ d, 100mg/ d, 200mg/ d, 300mg/ d and 400mg/ d."
9705388|NCT04691843|Active Comparator|Standard iron dose|Iron supplementation of 4mg/kg/day will start when infant is on full enteral feedings of 120-150mL/kg/day and at least two weeks old. Iron dosing will be adjusted for weight at weekly intervals to maintain dosing at 4mg/kg/day.
9705389|NCT04691843|Experimental|Early, high-dose iron|Iron supplementation will start at 3mg/kg/day when infant is on enteral feeds of 60mL/kg/day and at least one week old, then increased to 6mg/kg/day when enteral feeds are at 100mL/kg/day. Iron dosing will be adjusted to maintain ferritin level of 70-400ng/mL. At 36 weeks corrected age, iron supplementation will be adjusted to the dose routinely used for preterm infants.
9705390|NCT04691453|Active Comparator|QM-C Hysterectomy|QM-C Hysterectomy
9705391|NCT04691453|Experimental|QM-B Hysterectomy|QM-B Hysterectomy
9705392|NCT04691310|Active Comparator|Kinesio taping study|Kinesio tex gold tape was applied to neck localised lymphedema as stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
9705393|NCT04691310|Sham Comparator|Kinesio taping sham|Kinesio tex gold tape was applied to neck localised lymphedema as no-stretched. Kinesio tape maintained during consecutive days and also were re applied with manual lymphatic drainage therapy as 5 times first week, and afterthat 2 times for 3 weeks (total 4 weeks)
9705394|NCT04691492|Experimental|Friends-Based Motivational Interview (FMI) Group|Will participate in the Friends-Based Motivational Interview (FMI) program.
9705395|NCT04691492|No Intervention|Wait List Control|The Wait List Control group will also be offered to participate in the Friends-Based Motivational Interview Program but at a deferred date (12 weeks later).
9705396|NCT04691362|Active Comparator|Oral Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
9705397|NCT04691362|Active Comparator|Intravenous Tranexamic Acid|128 patients scheduled for primary total hip arthroplasty
9705398|NCT04691336|Experimental|PIMAGroup|All patients were summoned to the care center, being evaluated individually by a nurse, and based on the results, a care plan adapted to the specific needs and objectives was initiated. This care plan involved monitoring using different channels (face-to-face, telephone), with the main objective of monitoring the evolution of compliance, adherence and improving the quality of life of patients. The interventions that were carried out were educational and formative (using counseling communication skills), and technological (using monitoring tools in specific cases). The empowerment program was an educational session in which the nurse discussed content about dyspnea, the benefits of therapy, etc.
10192490|NCT05240950|Experimental|MRD or positive ctDNA patients to inject anti-CEA CAR-T cells|Patients with liver metastasis of colorectal cancer after R0 surgery and adjuvant chemotherapy could not clear MRD (including patients with MRD still positive after the intermediate and final evaluation of adjuvant chemotherapy, and patients with MRD positive again after the end of adjuvant chemotherapy), and no measurable lesions or tumor remnants were found on imaging after surgery.
10192491|NCT05235113|Active Comparator|Remote Exercise|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
9705399|NCT04691284|Experimental|Observational arm|Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including miR and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S rRNA gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used. Moreover, we might be able to characterized potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.
10192492|NCT05235113|Sham Comparator|In person Exercise|Subjects will perform exercises in the clinic without tele-exergaming platform twice a week.
9705400|NCT04691440|Experimental|HBOT|Hyperbaric oxygen breathing at 2.4 atm.abs for 90 minutes. The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
9705401|NCT04691258|Active Comparator|Restricted Group (RG)|Intervention with the movement technique traditional of squat exercise.
9705402|NCT04691258|Experimental|Complete Group (CG)|Intervention with the squat exercise technique prioritizing the full range of motion.
9705403|NCT04691531|Experimental|group C|After induction of general anesthesia, patients will undergo caudal block by classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
9705404|NCT04691531|Experimental|Group S|After induction of general anesthesia, patients will undergo caudal block by Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz, and Bupivacaine 1 ml/kg of 0.25% will be injected.
10192493|NCT05232734|Experimental|Oral caffeine group|Patients in this arm will receive treatment with oral caffeine
10192494|NCT05232734|Placebo Comparator|Control group|Patients in this group will receive syrup BP (placebo)
10192495|NCT05232396|Experimental|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg, single dose usage
10192496|NCT05232396|Experimental|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg, single dose usage
9705405|NCT04691245|Experimental|Intervention|Femoral access using 3D US
9705406|NCT04691245|Active Comparator|Control|Femoral access using 2D US
9705407|NCT04690920|No Intervention|Control|
10192497|NCT05232396|Experimental|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg, single dose usage
9705408|NCT04690920|Experimental|Tocilizumab|
9705409|NCT04690920|Experimental|Remdesivir|
9705410|NCT04690920|Active Comparator|Standard Treatment|
9705411|NCT04691713|Experimental|Targeting CD276 autologous chimeric antigen receptor T cells|
9705412|NCT04690933||Multicentric NAViRe cohort with biocollection|"The National Reference Center (CNR) for cytomegalovirus with the French Society for Medullary Transplantation and Cell Therapy (SFGM-TC) has set up a surveillance cohort of allografted patients (NAViRe cohort) receiving, as prevention or treatment, Anti-Cytomegalovirus (Anti-CMV) molecules, new or less recent, thus allowing the development of a new observatory evaluating in real life the potentials of these drugs in terms of efficacy, emergence of resistance, tolerance and morbidity and mortality associated with CMV infection.This work is useful to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients and allows the emergence of an real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients."
9705413|NCT04691895||Patients admitted to hospital for COVID19 disease (case group)|"The study cohort will be composed by consecutively enrolled COVID19 confirmed inpatients (case group)~Inclusion criteria:~Signed informed consent~Age ≥18 years and ≤85 years~Consecutive COVID19 confirmed patients (COVID +ve)~Ability to conform to study protocol~Exclusion criteria:~Patients under mechanical ventilation~Patients unable to report required data~Current diagnosis of cancer"
9705414|NCT04691895||Patients admitted to hospital in absence of COVID19 disease (control group)|"The study cohort will be composed by consecutively enrolled COVID19 negative patients hospitalized for other reasons (controls group)~Inclusion criteria:~Signed informed consent~Age ≥18 years and ≤85 years~Consecutive hospitalized COVID19 negative patients (COVID -ve)~Ability to conform to study protocol~Exclusion criteria:~Patients under mechanical ventilation~Patients unable to report required data~Current diagnosis of cancer"
9705415|NCT04690894|Active Comparator|Erector spinae group|the child received ultrasound-guided erector spinae muscle block in a dose of 0.4mg/kg of 0.25%bupivacaine between the 10th transverse process and erector spinae muscle
9705416|NCT04690894|Active Comparator|caudal group|child received ultrasound-guided caudal block in a dose of 2.5mg/kg of bupivacaine 0.25%
9705417|NCT04690894|No Intervention|control|child didn't received any regional block
9705418|NCT04691830|Experimental|group IA|"Preschool cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
9705419|NCT04691830|Active Comparator|group IB|preschool control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the preschool age control group.
9705420|NCT04691830|Experimental|group IIA|"School age cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
9705421|NCT04691830|Active Comparator|group IIB|School age control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the school age control group.
9705422|NCT04690972||Hepato-bilio-pancreatic surgery|Patients whom hepato-bilio-pancreatic surgery is indicated as part of the care
9705423|NCT04690972||biopsy of the hepatic parenchyma|Patients whom a biopsy of the hepatic parenchyma, one or more hepatic nodules or a loco-regional treatment is indicated as part of the care
9705424|NCT04690972||Viral chronic infection|Patients with a viral chronic liver disease
9705425|NCT04690946|Active Comparator|Cognitive Behavioral Therapy|14-18 sessions of psychotherapy according to principles of Cognitive Behavioral Therapy
9705426|NCT04690946|Active Comparator|Emotion-Focused Therapy|14-18 sessions of psychotherapy according to principles of Emotion Focused Therapy
9705427|NCT04691219|Experimental|Mulberry leaves powder plus diet control|
9705428|NCT04691219|Other|Diet control alone|
9705429|NCT04691232|Experimental|Regulatory T cells|Intravenous infusion of a single dose of 0.5x10e6, 1x10e6, 2x10e6, 5x10e6 or 10x10e6 Treg/kg body weight
9705430|NCT04691076|Experimental|Propofol/Esketamine sedation|Propofol target-controlled infusion is performed first,when the infusion concentration reaches 1.5μg/ml,esketamine 0.15mg/kg is injected intravenously;then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration, the corresponding increase of esketamine is 0.05mg/kg; the total dose of esketamine used in surgery shall not exceed 0.5mg/kg.
9705431|NCT04691076|Active Comparator|Propofol/Fentanyl sedation|Propofol target-controlled infusion is performed first.When the infusion concentration reaches 1.5μg/ml, fentanyl 0.6μg/kg is injected intravenously; then the dose is adjusted according to the depth of anesthesia and the modified observer's assessment of alert /sedation scale, and propofol target-controlled infusion for every increase of 5μg/ml in concentration,the corresponding increase of fentanyl is 0.2ug/kg; the total dose of fentanyl used in surgery shall not exceed 1.2ug/kg.
9705432|NCT04690959|Experimental|Neural gliding mobilization|Initial participant positioning for gliding will be : lying in supine, shoulder at approximately 90 of abduction, wrist in neutral, elbow at 90 flexion and head/neck neutral. From this starting position, participants actively and simultaneously will perform extension of the elbow (to 45) and ipsilateral neck flexion (to approximately 45) and then returned to 90 of elbow flexion and 45 of contralateral neck flexion while maintaining the shoulder at 90 abduction. According to Silva et al., (2014) this combination of movements was the one that promoted the greatest excursion of the median nerve (10.2 mm) . For gliding, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series was performed.
9836213|NCT02775864||Antipsychotic|Individuals initiating treatment with an antipsychotic medication
9836214|NCT02775864||Antidepressant|Individuals initiating treatment with an antidepressant medication
9705433|NCT04690959|Experimental|Neural tensioning mobilization|Tensioning will be performed with the subject lying supine. The investigator will perform the upper limb neurodynamic test as reported by Butler (2000): shoulder depression; 110 of shoulder abduction; external shoulder rotation; wrist and fingers extension; forearm supination and then elbow extension. The final test position will be defined as either i) end of joint amplitude or ii) the joint amplitude that provokes pain, paresthesia or numbness. In this case, a decrease of 5 to 10 of range of motion (elbow extension) will be allowed for symptoms to disappear and from this end position the investigator will perform repetitive movements of approximately 10 of elbow flexion/extension while maintaining the test end position for all the other joints. For tensioning, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series will be performed. After each cycle of 10 repetitions, the position will be held for 10 seconds.
9705434|NCT04690959|Sham Comparator|Control|Participants in the sham group will receive a treatment consisting of maneuvers that mimic the neural mobilization treatment but not to stress the neural tissues in the upper extremity. The sham mobilization consists of passively positioning the participants in the following consecutive positions: (1) a neutral cervical spine (0° of lateral flexion), (2) 45°of shoulder abduction without scapula depression, and (3) 45° of shoulder external rotation combined with 45° of elbow flexion with forearm pronation. This will be immediately followed by 10 cycles of passive wrist flexion/extension at a rate of approximately 6 seconds per cycle (3 seconds into extension and 3 seconds into flexion) . Upon moving from wrist flexion to extension, an initial sense of resistance will be used as a sign to alternate directions. Following the 10th cycle, a static hold will be maintained while in wrist flexion for 10 seconds.
9705435|NCT04691141|Experimental|ATG-016|5 mg QD×Days 1-5/week will be the initial dose of this study.
9705436|NCT04691063|Experimental|Treatment group A|
9705437|NCT04691063|Placebo Comparator|Treatment group B|
9705438|NCT04691024|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
9705439|NCT04691024|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
10192498|NCT05232396|Active Comparator|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg，as active comparator, single dose usage.
10192499|NCT05232136|Experimental|OH2|This arm include two doses (1x10e6, 1x10e7 CCID50/mL) of OH2 injection，the 1x10e6 CCID50/mL dose group should be delivered before the 1x10e7 CCID50/mL dose group.
9705440|NCT04691011|Other|Muscle|
9705441|NCT04691011|Other|Spinal cord|
9705442|NCT04691011|Other|Brain|
10192500|NCT05228613|Experimental|Vaccine Candidate Formula A|2 doses of vaccine candidate formula A administered with 28 days interval (0.5 mL per dose)
10192501|NCT05228613|Experimental|Vaccine Candidate Formula B|2 doses of vaccine candidate formula B administered with 28 days interval (0.5 mL per dose)
10192502|NCT05228613|Experimental|Vaccine Candidate Formula C|2 doses of vaccine candidate formula C administered with 28 days interval (0.5 mL per dose)
10192503|NCT05228613|Experimental|Vaccine Candidate Formula D|2 doses of vaccine candidate formula D administered with 28 days interval (0.5 mL per dose)
9705443|NCT04690985|Sham Comparator|Control group|The control group will be asked to continue their own daily routes. One research assistant, who will not be involved in other procedures of the study, will contact with the participants to talk about different issues except the SO related topic. The frequency of face-to-face meetings and telephone calls will be similar to the experimental group. The issues talked in the control group could be as follows but not limited: a) normal social communication topics such as greetings, recent living conditions, news in the past week; b) health consultations asked by the participants; c) avoid to mention dietary or exercise related information. An appointment of post-test will be made in the last time telephone call.
9705444|NCT04690985|Experimental|Experimental group|The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive 6 times face-to-face meetings (on week 1, 2, 3, 4, 8 and 12) and weekly telephone call. Each face-to-face meetings will last for around 1 hour, during which the reseacher will help to establish the participants' intention for dietary behavior change, then help transform the intention into detailed plan, and help monitor the execution of the plan continuously.
9836215|NCT02775864||Benzodiazepine|Individuals initiating treatment with a benzodiazepine
10192504|NCT05228613|Active Comparator|Active Control|2 doses of active control administered with 28 days interval (0.5 mL per dose)
10192505|NCT05222724|Experimental|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
10192506|NCT05222724|Active Comparator|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
10192507|NCT05221424|Experimental|Active Comparator|"MARS, PAIS-SR and Patient Information Form, containing data about the patient and the disease were applied to each patient in the experimental group during pretest. Then, the individual training was given to each patient by giving the Hypertension Training Booklet prepared in line with the Roy Adaptation Model. The training period lasted for averagely 45-50 minutes for each patient. After the training, the patients were called by phone at least once a week, every week for four weeks and reminder information was obtained and their follow-ups were made. One month after the training, post-test data were applied to the patients. In the posttest phase; MARS, PAIS-SR and the questions containing lifestyle changes were repeated and their follow-ups were then terminated."
10192508|NCT05221424|No Intervention|No Intervention|• MARS, PAIS-SR and Patient Information Form containing data about the patient and the disease were applied to each patient in the control group in the pretest. Without giving any training to the patients in the control group, only the patients were called at least once a week, every week for four weeks and their health status was examined. One month after the collection of initial data, posttest data were applied to the patients. In the posttest phase; MARS, PAIS-SR and the questions containing lifestyle changes were repeated and then their follow-ups were terminated. After the follow-up, the training prepared in line with Roy Adaptation Model was applied to the voluntary patients and the training booklet was given to them.
10192509|NCT05220059|Experimental|Polyphenol extract low dose|156mg single dose
10192510|NCT05220059|Experimental|Polyphenol extract medium dose|222mg single dose
9705445|NCT04690881|Experimental|Psychodrama group psychoteraphy|Psychodrama is not just a training but also a treatment technique where an individual is offered a potential cure, as well as improvement and awareness for his or her ongoing relationships within the group. In psychodrama, the participant is given an opportunity to re-experience of earlier incidents for a second time so that the person could be free from the impacts of that earlier experience. All of this happens simultaneously with joy, tears, laughter, and depth of feeling.Prenatal psychodrama is held by psychodrama psychotherapists in individual and group therapy sessions. In these sessions the pregnant mother encounters herself, her baby, her partner, her mother, her fear of childbirth and the moment of birth; she may act as protagonist in some scenes and in this way she closes any unfinished business from the past and rehearses the future in a safe therapeutic environment. In this study, 90-minute psychodrama practice was conducted in addition to pregnancy training for 6 weeks.
9705446|NCT04690881|No Intervention|Childbirth-antenatal education|Childbirth is one of the most significant events in a parent's life and has the potential to be an exhilarating and fulfilling experience for some or a frightening anxiety provoking experience for others. Structured antenatal classes have developed worldwide as traditional methods of information sharing have declined and expectant parents look for strategies to prepare for childbirth. In this study, routine pregnancy training was conducted for 6 weeks.
9705447|NCT04691050|Other|OrthoMta (BioMTA)|OrthoMTA was applied in primary molars without successors
9705448|NCT04691193||study and control group|The study group included patients with low back pain for less than 3 months. The control group consists of healthy volunteers.
9705449|NCT04690777|Experimental|VESTIBULAR EXERCISE|"1. The vestibular exercises were performed with the indications of a physical therapist, in sessions of about 20 minutes with 5 times per week (Monday to Friday) consisting of 5 repetitions ensuring the following were not overworked:~Head and eye movements while sitting.~Head and body movements while sitting.~Paused exercises.~Combined exercises of modifications on rungs, unstable surfaces and walking exercises."
9705450|NCT04690777|Active Comparator|MULTICOMPONENT EXERCISE|"1. A 6-week multi-component therapeutic physical exercise program was carried out. The ministerial guide and the Vivifrail consensus was followed (25, 26). There were 5 daily sessions per week (Monday to Friday), each lasting approximately 45 minutes. These sessions were conducted following the instructions of a physical therapist. VIVIFRAIL exercises are intended to be used over a progression period of up to 12 weeks, with combined exercises by days in cardiovascular aerobic balance strength and flexibility."
9705451|NCT04690608|Experimental|resistant diabetic macular edema and central retinal vein occlusion|"Prospective non randomized interventional study on 60 eyes of 40 patients with previously diagnosed macular edema secondary to type 1 or 2 diabetes mellitus will be included.~The study will be conducted from January 2021 to June 2021.~For transition to suprachoroidal injection of TAAC a diagnosis of resistant DME is required.~Cases with recent onset central retinal vein occlusion less than 2 months duration will be included"
9705452|NCT04690517|Other|Tracheal ultrasound|The patients in cardiopulmonary arrest should be performed tracheal ultrasound when tube is passed through the trachea or esophagus.
10192511|NCT05220059|Experimental|Polyphenol extract high dose|333mg single dose
9705453|NCT04690712|No Intervention|Socio-Demographic Characteristics of Students|When the socio-demographic characteristics of the students are examined according to the pre-test findings; It was seen that 27% were in the first grade, 20.9% in the second grade, and 25.7% in the third grade. When the age groups were evaluated, it was determined that 47.8% were in the 7-8 age group, 51.5% were in the 9-10 age group and 50% of them were female students and 50% were male students. It was observed that 27.6% of the students had a bad income and 59.3% had a medium level of income. When the father's education status was questioned, it was determined that 17.6% of them did not finish primary school, 55.4% of them were primary school graduates, 2.6% of them were high school graduates. On the other hand, 55% of their mothers did not complete primary school, 43.5% were primary school graduates and 1.5% were secondary school graduates
9705454|NCT04690712|Experimental|Comparison of Students' Pretest and Posttest Development Screening Average|According to the results of height and weight screening at the pre-test stage; the average height of the students is 127.0 ± 9.11; It was determined that the average weight was 26.1 ± 6.19, the average height was 130.61 ± 8.83 and the average weight was 29.92 ± 6.39 in the final test stage. A significant difference was found between pre-test and post-test screening results
9979628|NCT01383889|Other|Treading mill exercise|Pregnant women in this group will perform treadmill exercise during 20 minutes. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
10192512|NCT05220059|Placebo Comparator|Placebo|Maltodextrin single dose
10192513|NCT05219929|Active Comparator|Tetracycline First|Tetracycline for first 3 months, placebo for second 3 months.
10192514|NCT05219929|Placebo Comparator|Placebo First|Placebo for first 3 months, tetracycline for second 3 months.
10192515|NCT05219578|Experimental|RTX-224 Dose Escalation|Phase 1: RTX-224 monotherapy dose escalation in Solid Tumors, administered intravenously on Day 1 of each cycle.
10192516|NCT05219578|Experimental|RTX-224 Dose Expansion|Phase 2: RTX-224 monotherapy dose expansion in Solid Tumors, administered intravenously on Day 1 of each cycle.
10192517|NCT05218629|Experimental|Anlotinib， PD-1inhibitor|Anlotinib 8-14 mg, oral, once a day for 14 days every 3 weeks. PD-1 inhibitor (Pembrolizumab) 200mg iv day1, every 3 weeks
10192518|NCT05218603||Maintenance with V-Dara after receiving VMP-Dara as induction regimen|Maintenance with bortezomib plus daratumumab (V-Dara) after induction with bortezomib, melphalan, prednisone plus daratumumab (VMP-Dara)
10192519|NCT05218109|Experimental|tVNS + mindfulness|Transcutaneous vagus nerve stimulation plus behavioral: mindfulness
10192520|NCT05218109|Sham Comparator|Sham + mindfulness|Sham transcutaneous vagus nerve stimulation plus behavioral: mindfulness
10192521|NCT05218109|Active Comparator|Mindfulness only|
10192522|NCT05218109|Active Comparator|Control|Control number puzzle task delivered via mobile device
9979629|NCT01383889|Other|Stationary bicycle exercise|Pregnant women in this group will perform exercise using a stationary bicycle. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
9836216|NCT02775864||Mood stabilizer|Individuals initiating treatment with a mood stabilizer
10192523|NCT05216614|Experimental|Fluvoxamine|"This arm will be given the active treatment, oral fluvoxamine capsules of 25 mg each.~The first six weeks will be gradual titration (weeks 1 & 2 25mg BID, weeks 3 & 4 75mg BID, weeks 5 & 6 100mg BID).~The following six weeks will be fixed dose of 100mg TID.~The last two weeks will be a taper down (first week 50mg BID and second week 25mg BID)~There will be 14 weeks of active treatment and assessments will be conducted after completion of week 12, prior to beginning taper down period."
10192524|NCT05216614|Placebo Comparator|Placebo|"Placebo capsules that look, smell, and taste like fluvoxamine capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule BID during the first six weeks following the titration schedule and one capsule TID during the next six weeks for the fixed-dose period.~Subjects will then taper-down placebo to imitate the fluvoxamine arm for two weeks.~Assessments will be conducted at 12 weeks following completion of fixed-dose period, prior to starting taper down period."
9705455|NCT04690712|Experimental|Comparison of Pre-Test and Post-Test Screening Results of Students|In the statistical evaluation, it was found that there was no significant difference between pre-test and post-test screening results
9705456|NCT04690647|Placebo Comparator|Opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia without preoperative regional anaesthesia and dexamethasone.
9705457|NCT04690647|Experimental|Regional anaesthesia, opioid and non opioid postoperative analgesia.|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and without preoperative dexamethasone.
9705458|NCT04690647|Experimental|Regional anaesthesia, dexamethasone, opioid and non opioid postoperative analgesia|Group of patients with opioid and non opioid based postoperative analgesia with preoperative regional anaesthesia and dexamethasone.
9778954|NCT01119846|Experimental|Part A|Part A (Cohort 1) is a single-blind, randomized, placebo-controlled, 5-period crossover in which drug naïve T2DM subjects will receive escalating doses of GSK1292263 in each of 3 periods and placebo and open-label sitagliptin in the other 2 periods. The sequence will be randomized, but will maintain the low, medium and high dose order for GSK1292263.
9778955|NCT01119846|Experimental|Part B|Part B (Cohort 2) is a single-blind, randomized, 2-period study in which T2DM subjects will receive a single dose of GSK1292263, fasted or fed.
9778956|NCT01119846|Experimental|Part C|Part C (Cohort 3, optional Cohort 4) is a single-blind, randomized, placebo-controlled, 5-arm study of 14 days of dosing with GSK1292263, placebo or open-label sitagliptin. An optional Cohort 4 may be enrolled to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1292263 when dosed in a BID regimen.
9778957|NCT01119859|Experimental|Tocilizumab 8 mg/kg|Patients received 6 infusions of tocilizumab 8 mg/kg intravenously every 4 weeks and 12 injections of placebo to adalimumab subcutaneously every 2 weeks.
9778958|NCT01119859|Active Comparator|Adalimumab 40 mg|Patients received 12 injections of adalimumab 40 mg subcutaneously every 2 weeks and 6 infusions of placebo to tocilizumab intravenously every 4 weeks.
9778959|NCT01119898|Experimental|PENNSAID Gel|Diclofenac sodium 2.0% w/w
9778960|NCT01119898|Placebo Comparator|Vehicle|The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
9778961|NCT01119937|Experimental|NVA237|50µg once daily
9778962|NCT01119937|Experimental|Tiotropium|18µg once daily
9778963|NCT01119950|Experimental|NVA237 12.5 µg q.d.|NVA237 12.5 µg once daily
9778964|NCT01119950|Experimental|NVA237 25.0 µg q.d.|NVA237 25.0 µg once daily
9778965|NCT01119950|Experimental|NVA237 12.5 µg b.i.d.|NVA237 12.5 µg twice daily
9778966|NCT01119950|Experimental|NVA237 50.0 µg q.d.|NVA237 50.0 µg once daily
9778967|NCT01119950|Experimental|NVA237 25.0 µg b.i.d.|NVA237 25.0 µg twice daily
9778968|NCT01119950|Experimental|NVA237 100.0 µg q.d.|NVA237 100.0 µg once daily
9778969|NCT01119950|Experimental|NVA237 50.0 µg b.i.d.|NVA237 50.0 µg twice daily
9778970|NCT01119950|Placebo Comparator|Placebo|Placebo to NVA237 once daily
9778971|NCT01119963|Active Comparator|17-alpha hydroxyprogesterone caproate, Makena®|250 mg of 17P, Makena® intramuscular (IM) weekly.
9778972|NCT01119963|Placebo Comparator|Placebo|Castor Oil (Placebo)intramuscular (IM) weekly
9778973|NCT01120028|Experimental|Alemtuzumab/Sirolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
9778974|NCT01120028|Experimental|Alemtuzumab/Tacrolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
9778975|NCT01120028|Active Comparator|Basiliximab/Tacrolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
9778976|NCT01120028|Active Comparator|Basiliximab/Sirolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
9979630|NCT01383902|Other|dessert / chocolate|
9778977|NCT01120067|Experimental|Intensive Treatment|Intensive 3 week treatment for pain and PTSD. This includes elements of Cognitive Processing Therapy and CBT for Chronic Pain
9778978|NCT01120067|Experimental|Treatment as Usual|Treatment as Usual. Participants are eligible for all treatment services as needed except for treatment of pain or PTSD
9778979|NCT01120093|Experimental|Aclidinium bromide 100 μg bid|Aclidininum bromide 100 μg twice daily by inhalation
9778980|NCT01120093|Experimental|Aclidininum bromide 200 μg bid|Aclidininum bromide 200 μg twice daily by inhalation
9778981|NCT01120093|Experimental|Aclidininum bromide 400 μg bid|Aclidininum bromide 400 μg twice daily by inhalation
9778982|NCT01120093|Placebo Comparator|Placebo|Placebo twice-daily by inhalation
9778983|NCT01120093|Active Comparator|Formoterol 12 μg bid|Formoterol 12 μg twice daily by inhalation
9778984|NCT01120184|Experimental|Trastuzumab + Taxane (docetaxel or paclitaxel)|
9778985|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab|
9778986|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab placebo|
9785133|NCT01243944|Other|Best Available Therapy|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
9705459|NCT04690751|Experimental|Types of Cenobamate|"Treatment A: Oral Dose of cenobamate administered as a single 200 mg tablet under fasted conditions~Treatment B: Oral Dose of cenobamate administered as a single 200 mg/20 mL suspension under fasted conditions~Treatment C: Oral Dose of cenobamate administered at a single 200 mg/20 mL suspension under fed conditions"
10192525|NCT05206279|Experimental|ureteral ICG injection|There is only one arm of the study. All patients will undergo normal laparoscopy. After examining the abdominal structures for presence of endometriosis as well as performing photographic documentation, cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
9705460|NCT04690556|Active Comparator|Lucentis (ranibizumab)|Intravitreal injection
9705461|NCT04690556|Experimental|LUBT010 (proposed ranibizumab biosimilar)|Intravitreal injection
10192526|NCT05200884|Active Comparator|: A (Lidocaine 2%)|"20 children will be injected with 1 ml of lidocaine 2% with epinephrine. each one received lidocaine2% at his\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e. 20 injections will be distributed randomly to the two drugs using the randomization table"
10192527|NCT05200884|Experimental|B (Articaine 4%)|"20 children will be injected with 1 ml of Articaine 4% with epinephrine. each one received articaine 4% at his\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e.20 injections will be distributed randomly to the two drugs using the randomization table"
10204524|NCT05202496|Experimental|Experimental: oral vitamin D supplementation during orthodontic treatment|"The biological methods include using various chemicals like parathyroid hormone, thyroid hormone, prostaglandins, corticosteroids, relaxin and vitamin D.~Due to its important role in bone remodeling, vitamin D is hypothesized to play an important role in accelerating orthodontic tooth movement.~experimental group subjects with serum vitamin D levels in the range of 30-40 ng/ml are enrolled"
9705462|NCT04690634|Experimental|PCOS group|obese female patients with Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
9705463|NCT04690634|Active Comparator|control group|obese female patients without Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG)
9705464|NCT04690543|Active Comparator|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
9705465|NCT04690543|Experimental|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
9705466|NCT04690738||Post Pancreas Transplant Patients|Patients that have received a pancreas transplant (Pancreas After Kidney or Simultaneous Pancreas Kidney) from 2012 through present will have a fecal elastase stool sample collected.
9705467|NCT04690452|Experimental|Intervention condition|Intervention group that receive a standardized 8 weeks Compassion Cultivation Training from a faculty member certified CCT© instructor (https://www.compassioninstitute.com/about-us/teacher-directory/)
9705468|NCT04690452|Other|Waitlist control condition|"The participants assigned to the waitlist control will fill in the same questionnaires as the intervention group at the different time points (i.e., pre, post, 2-month and 6-month follow-ups).~Two months after finishing the intervention, will become participants of a CCT© program themselves given by the same faculty member certified CCT© teacher as for the experimental group."
9705469|NCT04690413|Experimental|Persons tested with investigational device|Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test
9705470|NCT04690205|Experimental|End of Life (EOL) Care at at Home|End of Life (EOL) Care at at Home intervention entails the following: patient-reported symptoms and home monitored vital signs and body weight with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
9705471|NCT04690725|Experimental|TQB3525 arm|3+3 design for phase I for RP2D (Recommended Phase 2 Dose) for adolescents (12-17 years old) (15mg QD or 20mg QD); phase II for efficacy exploration for another 17 patients using RP2D QD
9705472|NCT04690569||Infectious|Eligible pediatric and adult patients from ED\Urgent care and hospital admitted, with symptoms consistent with acute bacterial or viral infection.
9705473|NCT04690569||Healthy|For the purpose of establishing a normal reference range.
9705474|NCT04690270|Experimental|Sumatriptan 100 mg|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
9705475|NCT04690270|Placebo Comparator|Placebo|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
9705476|NCT04690283|Placebo Comparator|Placebo-control group|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and placebo treatment twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
9705477|NCT04690283|Experimental|Treatment group I|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Huangqi Guizhi Wuwu granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
9705478|NCT04690283|Experimental|Treatment group II|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Danggui Sini granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
9705479|NCT04690803|Active Comparator|treatment with forced-air cooling|comparing treatment with and without forced-air cooling in a comparative lower extremity model
9705480|NCT04690803|No Intervention|treatment without forced-air cooling|comparing treatment without forced-air cooling in a comparative lower extremity model
9705481|NCT04689958|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin D 5000 IU once daily (experimental group).
9705482|NCT04689958|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline
9705483|NCT04690088||Manual infusion (control) group|
9705484|NCT04690088||TCI (case) group|
9705485|NCT04690244|Experimental|Tai Chi Chuan group|"Fifteen healthy elderly subjects participated in 10 weeks of Tai Chi Chuan practice. Inclusion criteria were:~aged 60 years and older;~sedentary behavior for at least 6 months;~no previous experience of Tai Chi Chuan practice;~good physical health determined by Physical Activity Readiness Questionnaire as - confirmed by medical history;~no cognitive impairments determined by baseline Mini-Mental State Examination score of ≥ 45.~All participants were asked to not perform any sports activities while the research was ongoing."
9705486|NCT04690244|No Intervention|Control group|In the control group, fifteen subjects also had to meet the same criteria and did not perform any exercises or make changes in their daily living life.
10192528|NCT05200312|Experimental|Treatment-naive DLBCL|Treatment-naive high-risk DLBCL patients will be enrolled. R/R2-CHOP were allowed in cycle 1 due to poor physical condition or liver and renal failure caused by lymphoma progression. Patients achieving Complete Remission (CR) or Partial Remission (PR) after 2 cycles will receive another 2 cycles. Patients achieving CR or PR after 4 cycles will finish 6 cycles. Patients achieving CR after 6 cycles with double-hit/triple-hit/double-expression/median to high risk aaIPI will undergo Autologous Stem Cell Transplantation (ASCT). Other patients will be administered rituximab for another 2 cycles and then turn to follow-up. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for another 3 years. Patients achieving Stable Disease (SD) or PD (Progression Disease) after 2 or 4 cycles will quit the study. After 6 cycles, patients achieving SD or PD will quit the study and patients achieving PR will receive second-line therapy.
10192529|NCT05199753|Experimental|LM-108 Dose Escalation|
10192530|NCT05199753|Experimental|LM-108 Dose Expansion|
9705487|NCT04690166||Cancer Patients|"In outpatients clinic, the first group consists of 60 head and neck cancer patients who were treated by ours. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
9705488|NCT04690166||Healty Control|"In outpatients clinic, the control group consists of 60 patients who have not speech and hear impairments. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
9705489|NCT04690257|Experimental|TICK-B group as Intervention group|"Experimental: TICK-B group~-Pediatric patients received TICK-B as a distraction in the TICK-B group"
9705490|NCT04690257|No Intervention|Standard care provided group as control group|-Pediatric patients received standard care (routine care) in the control group.
9705491|NCT04690140|Active Comparator|modified coronally advanced tunnel technique|Initial sulcular incisions and flap separation were then carried out with tunnel knives. Dissection was extended at least 8 mm apically to the mucogingival junction and the muscle attachments were removed with curettes so that the flap could be moved in a coronal direction without tension. Interdental papillae were undermined to prepare the bed for connective tissue graft placement. Connective tissue graft was then inserted under the tunnel at the sites of recession and retracted laterally by sutures towards each end of the tunnel. After connective tissue graft positioning, the flap was gently stretched coronally to obtain passive flap closure. The exposed connective tissue was covered by connecting the adjacent flap margins with additional sutures.
9705492|NCT04690140|Active Comparator|epithelialized free gingival graft|A partial-thickness flap was elevated (blade #15c) with horizontal incisions at the cemento-enamel junction level of the adjacent teeth. Then, two vertical incisions extending to the apical were made from two ends of the horizontal incision. The epithelium in the framed region was removed with a scalpel and the underlying connective tissue was exposed. To achieve the best vascularization from the recipient site, bed preparation was completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region.
9705493|NCT04690010|Active Comparator|Ambulatory tubeless PCNL|Patients will be discharged home on the same day as surgery. No nephrostomy tube will be placed (tubeless).
10192531|NCT05199753|Experimental|LM-108 combination dose escalation|
10192532|NCT05199753|Experimental|LM-108 combination dose expansion|
10192533|NCT05199415|Experimental|HaWC Intervention|These are the buildings that are randomized to receive the intervention during the study period.
10192534|NCT05199415|No Intervention|Control|These are the buildings that are randomized to continue as normal (no intervention) during the study period.
10192535|NCT05198245||Pregnancies in women with migraine and exposure to rimegepant|
10192536|NCT05198245||Pregnancies in women with migraine exposed to other medications|Pregnancies in women with migraine exposed to other medications indicated for the treatment of migraine
10192537|NCT05198245||Pregnancies in women without migraine|
9705494|NCT04690010|Active Comparator|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days with a nephrostomy tube placed at the time of surgery that will then be removed prior to discharge.
9705495|NCT04689971|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily (experimental group).
9984462|NCT04076813||STEMI/NSTEMI|Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction
10192538|NCT05197270|Experimental|4D-150 Dose Escalation up to 4 dose levels|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
10192539|NCT05197270|Experimental|4D-150 Dose Expansion Dose 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
10192540|NCT05197270|Experimental|4D-150 Dose Expansion Dose 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
10192541|NCT05197270|Active Comparator|4D-150 Dose Expansion Control|Aflibercept at a fixed regimen will be administered.
9705496|NCT04689971|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
9705497|NCT04690075|Experimental|Intervention|To receive routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
9705498|NCT04690075|Placebo Comparator|Control|To receive routine nutrition management for 12 weeks.
9705499|NCT04689984|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and astaxanthin 6 mg tablet once daily (experimental group).
9705500|NCT04689984|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
10192542|NCT05196984|Experimental|Down Syndrome Experimental|Experimental arm within Down Syndrome participant group: exposure to active 40Hz stimulation for 30-60 minutes.
10192543|NCT05196984|Sham Comparator|Down Syndrome Sham|Sham arm within the Down Syndrome participant group: exposure to control stimulation for 30-60 minutes.
9705501|NCT04690049|Experimental|Neuromuscular resistance exercise group|Subjects will develop an innovator program consisting in the performance of exercises of increasing difficulty, with movements based on functional tests to analyze the subjects' neuromuscular capacities. Participants will attend to 80 individual, face-to-face physiotherapy sessions, including both supervised and semi-supervised monitoring. From the total, a minimum of 15 sessions will be supervised, including 6 sessions to teach and monitor the exercises, and 9 sessions to perform the tests in order to quantify the load; 37 sessions will be semi-supervised, where subjects will perform the exercises independently, but with the presence of an instructor; additionally, the remaining 28 sessions will consist in non-supervised aerobic work at a 70-80% from maximum heart rate, obtained according to the methodology of Tanaka et al.
9705502|NCT04690049|Active Comparator|Control exercise group|This program will be based on a home exercise protocol considering painful sensation and self-perceived stability as progression criteria: regarding pain management, exercises will be planned in a way that increased pain after their performance reverts to before-exercise levels prior to the next session; regarding self-perceived stability, participants will be asked to maintain a constant sensation of joint stability and control during the execution of the exercises. Participants will perform shoulder rotations (external and internal) and abduction up to 30º by using elastic bands. The resistance of the band will be adjusted by the physiotherapist so that participants perceive the exercises as demanding enough but not too unpleasant, being able to complete the 10 repetitions before taking the rest. Likewise, exercises will progress until a maximum of 90º of shoulder abduction.
9705503|NCT04690127|Experimental|Plyometric Training Group|Individuals in the plyometric training group will receive plyometric training. In this training, individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery). Except for one session that will be applied every two weeks, all other trainings will be given on the basis of telerehabilitation via distance education tools.
9705504|NCT04690127|No Intervention|Control Group|Volunteers in this group will not participate in any training.
9705505|NCT04690309|Active Comparator|Patients treated with human insulin preparations|Treatment with human regular insulin administered subcutaneously before breakfast, lunch and supper and with Neutral Protamine Hagedorn insulin (isofane insulin) administered subcutaneously before sleep.
9705506|NCT04690309|Active Comparator|Patients treated with insulin analogues|Treatment with insulin analogues lispro administered subcutaneously before breakfast, lunch and supper and with glargine administered subcutaneously before sleep.
9705507|NCT04690036|Experimental|one group|All patients encountered EBV reactivation after allo-HCT could be enrolled in this study, there was only one group of treatment.
9705508|NCT04690062|Experimental|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
10192544|NCT05196984|Experimental|Cognitively Normal Experimental|Experimental arm within the cognitively normal control participant group: exposure to active 40Hz stimulation for 30-60 minutes.
10192545|NCT05196984|Sham Comparator|Cognitively Normal Sham|Sham arm within the cognitively normal control participant group: exposure to control stimulation for 30-60 minutes.
10192546|NCT05196503|Active Comparator|Experimental group|Surgery for disc herniation and intraoperative periradicular administration of PRF
9705509|NCT04689776|Experimental|High Frequency Dual-Task Training (HF)|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-120 minutes of training.
10192547|NCT05196503|Active Comparator|Control group|Surgery for disc herniation alone (i.e. reference treatment).
10192548|NCT05195892|Experimental|Sequence 1|Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 and a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 3.
10192549|NCT05195892|Experimental|Sequence 2|Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 3.
10192550|NCT05195892|Experimental|Sequence 3|Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 3.
10192551|NCT05195892|Experimental|Sequence 4|Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A).
9705510|NCT04689776|Experimental|Low Frequency Dual-Task Training (LF)|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-120 minutes of training.
9705511|NCT04690296|Experimental|US group|a group underwent real time USG-SCV catheterization
9705512|NCT04690296|Experimental|LM group|a group in whom anatomical LM method was used
9984463|NCT04072458|Experimental|BP1002 monotherapy|L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m^2.
9705513|NCT04689737|Experimental|Experimental group|Doravirine (Pifeltro, MSD) will be added to participant's cART (100 mg once daily) for 5 days
9705514|NCT04689789||Patients with RAP|Patients with previous diagnosis of retinal angiomatous proliferation
9705515|NCT04689789||Patients with reticular pseudodrusen|Patients with previous diagnosis of reticular pseudodrusen
9705516|NCT04689789||Control group|Healthy eyes without actual and previous ocular diseases
9705517|NCT04689633|Active Comparator|Quadratus lumborum block|received bilateral ultrasound-guided Quadratus lumborum block using 20 ml bupivacaine 0.25% on each side
9705518|NCT04689633|Active Comparator|Erector spinae block|received bilateral ultrasound-guided erector spinae block using 20 ml bupivacaine 0.25% on each side
10192552|NCT05195892|Experimental|Sequence 5|Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B).
10192553|NCT05195892|Experimental|Sequence 6|Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C).
9705519|NCT04689633|No Intervention|Control|didn't received any block
9705520|NCT04689880||XLIF Decade Plate|
9705521|NCT04689867|Experimental|CBSPp|Cognitive Behavioral Suicide Prevention for psychosis is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions.
9705522|NCT04689815|Experimental|Oral arsenic trioxide-Azacitidine|12 monthly cycles of oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle).
9705523|NCT04689750||Allogeneic HSCT recipients and donors|
9705524|NCT04689841|Experimental|Vojta Therapy|In Vojta therapy, the therapist selectively presses certain areas of the body, with the patient lying prone, - supine or - lateral. These types of stimuli, in humans of any age, provoke automatically and without their own initiative, that is, without the active voluntary collaboration of the person
10192554|NCT05194111|Experimental|Arm 1: Sacubitril-valsartan|Sacubitril-valsartan administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
10192555|NCT05194111|Experimental|Arm 2: Valsartan|Valsartan administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
10192556|NCT05192694|Other|FAPI PET|Prospective single arm cohort
10192557|NCT05191420||Virtual topical discussion guide|Study will pilot test this virtual topical discussion guide by incorporating this module in myWakeHealth or myAtrium Health in 3 diverse clinics across legacy Wake Forest and legacy Atrium to assess feasibility and acceptability by clinic and by diverse patient population.
10192558|NCT05190042|Experimental|Continuous suture group|"Surgical sutures were used to completely close the post-EMR/ESD mucosal/submucosal defects.~This group was set as a experimental group."
10192559|NCT05190042|Active Comparator|Clips group|Clips were used to completely close the post-EMR/ESD mucosal/submucosal defects. This group was set as a control group.
10192560|NCT05181410|Active Comparator|Test Product|Subjects will be given the test product (Isolated Fucoidan Marine Algae Supplement) to consume for 2 weeks, come back for testing then have a one-week washout.
10192561|NCT05181410|Placebo Comparator|Placebo|Subjects will be given the placebo product to consume for 2 weeks, come back for testing then have a one-week washout.
10192562|NCT05179824||Group 1: Standard of Care (SOC) CGP|This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions. The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.
10192563|NCT05179824||Group 2: Disease or Profile Specific Cohorts|"Group 2 will consist of specific cohorts that will facilitate collection of paired clinical and molecular data done outside of the standard of care, longitudinal CGP, or narrowly defined cohorts based on mutations or treatment settings. The goal of Group 2 is to capture specific participants in specific cohorts to better understand longitudinal outcomes across institutions and standards of care.~Protocol contains complete eligibility criteria."
10192564|NCT05176691|Experimental|Treatment|All patients to receive HMPL-760 daily.
10192565|NCT05166850|Experimental|Preventive-Intervention-for-Cholera-for-7-Days (PICHA7) Mobile Health (mHealth) Program|Preventive-Intervention-for-Cholera-for-7-Days (PICHA7) mHealth program promoting handwashing with soap and water treatment for diarrhea patient households
10192566|NCT05166850|Active Comparator|Standard Arm|Standard recommendation in the Democratic Republic of the Congo for diarrhea patients upon discharge from health facilities
10192567|NCT05164666|Experimental|TAK-103 Cohort 1|TAK-103, 1 × 10^7 Chimeric antigen receptor (CAR) (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
10192568|NCT05164666|Experimental|TAK-103 Cohort 2|TAK-103, 1 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
9705525|NCT04689841|Placebo Comparator|Control Group|In the control group, a placebo intervention is administered, similar to an experimental intervention
9705526|NCT04689893|Experimental|68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT scan|Patients of Tumor-induced osteomalacia PET/CT imaging: The patients were subcutaneously injected with 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and underwent PET/CT scan 20~40min after the injection in two consecutive days.
9705527|NCT04689763|Experimental|Lifestyle Redesign Training|The participants will receive a total of 12 training sessions, and each session will contain 120 minutes of training.
9705528|NCT04689412||Cases|Children spontaneously treated with nasal resveratrol at the beginning of each upper airways infection
9705529|NCT04689412||Controls|Children spontaneously treated with nasal lavage at the beginning of each upper airways infection
9705530|NCT04689451||Perclose ProGlide|Perclose ProGlide group: use Perclose ProGlide to suture the artery
9705531|NCT04689451||Surgical Arterial Repair|Surgical Arterial Repair group : suture the artery by surgery
9705532|NCT04689425|Experimental|MNC+PRP|The combination of PRP and MNC
9705533|NCT04689425|Active Comparator|PRP|PRP alone.
9705534|NCT04689581|Experimental|Bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
9705535|NCT04689581|Experimental|Modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
9705536|NCT04689620|Experimental|HELIUM NEON LASER plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
9705537|NCT04689620|Experimental|GALLIUM ARSENIDE plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
9705538|NCT04689620|Active Comparator|regular ulcer care|dressing for the ulcer
9705539|NCT04689698|Experimental|experimental group|
9705540|NCT04689594|Experimental|CLS2702C/CLS2702D|
9705541|NCT04689555|Experimental|Novel method without manual compression|
9705542|NCT04689555|Active Comparator|Standard method with manual compression|
9705543|NCT04689607|Experimental|Mulligan Traction Straight Leg Raise (TSLR)|This technique involves sustained traction applied to the limb. Patient actively does the SLR and both the therapist and the patient note the range. Therapist now grasp patient lower leg proximal to the ankle joint and raise it off the bed to a position just short of the painful range. Therapist flexes his knees and holds the clasped leg to his (therapist's) chest. When the therapist extends his knees this will effectively apply a longitudinal traction to the leg provided the bed is low enough and the therapist is tall enough. Sustain this traction and undertake a straight leg raise as far as it will go provided there is no pain.When pain free SLR with traction is given for three times.
9705544|NCT04689607|Active Comparator|Post Isometric Relaxation technique (PIR):|The patient is placed in the supine position with the non-affected leg lying flat on the table. The knee of the affected leg is gently placed in extension, and the affected hip is then flexed. The calf of the patient is then placed on the shoulder of the practitioner The practitioner stands on the side of the affected leg. The hands of the practitioner are then placed over the upper leg, just proximal to the knee. The hip of the affected leg is then passively flexed until resistance is felt. The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance. The practitioner resists hip extension to create an isometric contraction and then, after appropriate time and breathing instructions. The patient is instructed to relax and the practitioner gently flexes the hip until the next barrier is reached. After a period of relaxation, the technique will be repeated three to four times.
9705545|NCT04689308|Experimental|Part A: Dose Escalation and Determination of RP2D|Part A: Dose Escalation and determination of RP2D, multiple dose levels of MH048 to be evaluated
9705546|NCT04689308|Experimental|Part B: Dose Expansion in Selected Relapsed/Refractory B-cell Malignancies|Part B: Selected relapsed/refractory B-NHL subjects with at least 1 prior systemic OR standard-of-care therapy.
10192569|NCT05164666|Experimental|TAK-103 Cohort 3|TAK-103, 5 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
10192570|NCT05164666|Experimental|TAK-103 Cohort 4|TAK-103, 1 × 10^9 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
10192571|NCT05156398|Active Comparator|Rimegepant / BHV3000|Rimegepant 75mg or 50mg (2 X 25mg) ODT
9705547|NCT04689217|Experimental|Group F|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml fentanyl (25 μg)
9705548|NCT04689217|Experimental|Group N|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.8 mg nalbuphine hydrochloride
9705549|NCT04689217|Placebo Comparator|Group C|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml normal saline
9705550|NCT04689178|Experimental|Invitation letter + GP reminder (Arm 1)|
9705551|NCT04689178|Active Comparator|Invitation letter (Arm 2)|
10192572|NCT05156398|Placebo Comparator|Matching Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
10192573|NCT05150587|Active Comparator|Rifaximin-Tested dose A|
10192574|NCT05150587|Active Comparator|Rifaximin-Tested dose B|
9705552|NCT04689178|No Intervention|Usual care (Arm 3)|
9705553|NCT04689438||Healthy control groups|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
9705554|NCT04689438||Gingivitis groups|Consisted of individuals with a BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.
9705555|NCT04689438||Stage III -Grade C periodontitis groups|Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4. Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.
9705556|NCT04689191|Experimental|Experimental Vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
9705557|NCT04689191|Active Comparator|Active Comparator Vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
9705558|NCT04689139|Experimental|Thoracic aorta surgery patients|Blood samples on proadrenomedullin, presepsin, NT-proBNP, Troponin I, procalcitonin are acquired
9705559|NCT04689386|Experimental|"Group I Stimulation of reflex rolling from the Vojta method"|
9705560|NCT04689386|Experimental|Group II Expiratory flow increase technique|
9705561|NCT04689386|No Intervention|Control Group|Routine intervention in the NICU with mechanical ventilation.
10192575|NCT05150587|Placebo Comparator|Placebo|
10192576|NCT05146700|Experimental|Restrictive oxygen|"- Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94% either using no supplemental oxygen, a nasal cannula, a non-rebreather mask or manual/mechanical ventilation (intubated trial participants)~and~- Only trial participants receiving an FiO2 = 0.21 can saturate >94%~Pre-oxygenation as usual prior to intubation is permitted"
10204525|NCT05202496|Active Comparator|control : Orthodontic treatment with no intervention|control group subjects with serum vitamin D levels in the range of (30-40 ng/ml) are enrolled
10204526|NCT05202457||Cirrhosis|Patients with cirrhosis undergoing urgent and elective surgery
10204527|NCT05202444|Experimental|Osteotomy using piezoelectrical device|
10204528|NCT05202444|Active Comparator|Osteotomy using surgical saw|
9705562|NCT04689113|Experimental|Intervention Group|ıntervention group After determining the women according to the research criteria, they were randomized into intervention and control groups.Firstly, Pre-tests were applied to the women in the experimental group. The Incontinence Health Belief Development Program was applied to the women in the experimental group as 5 sessions.This program includes the following topics; urinary system anatomy and physiology, urinary incontinence and risk factors, definition of kegel exercise and its place in urinary incontinence treatment, kegel exercise applied expression, health motivation. A WhatsApp group was established to remind women in the intervention group about the kegel exercise 3 times a day for 3 months to increase their self-efficacy. In addition, a facebook group was opened and posts about urinary incontinence and kegel exercises were made. Posttests were made 3 months after the training ended
9705563|NCT04689113|No Intervention|Control Group|Firstly, Pre-tests were applied to the women in the control group. No intervention was applied to this group.Posttests were made 3 months after pre-test.
9705564|NCT04689204|Experimental|Administration of CTA30X|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
9705565|NCT04689152|No Intervention|Control group|Best Supportive care
9705566|NCT04689152|Experimental|Injection group: Cellgram-LC|Within 1 month after extracting bone marrow, directly inject 7X10^7 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
9705567|NCT04689464||mild covid|
9705568|NCT04689464||moderate covid|
9705569|NCT04689464||severe covid|
9705570|NCT04689243|Experimental|ALA-PDT|
9705571|NCT04689243|Other|red light|
9705572|NCT04689321||Phase 1|Patients recruited for phase 1 will undergo a semi-structured interview to identify issues that may be relevant to include in the revised EORTC QLQ-BN20 questionnaire.
9705573|NCT04689321||Phase 3|Patients recruited for phase 3 will complete the draft questionnaire, and rate each item for relevance, and indicate the 10 most important items. Also, a semi-structured interview will be conducted including debriefing questions to determine if the questionnaire is complete and the questions are acceptable.
9705574|NCT04689126|Experimental|intervention|diagnosis and treatment plan before and after cone beam computed tomography scan
9705575|NCT04689230|Active Comparator|upper eyelid blepharoplasty|"traditional upper eyelid blepharoplasty : upper eyelid entire length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with subcuticular 6/0 vicryl suture"
9705576|NCT04689230|Experimental|small incision technique|"medial upper eyelid 4 mm length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with interrupted 6/0 vicryl sutures"
10204529|NCT05202431|Experimental|Adherence|Participants received training, telefollow-up and daily text messages for 6 months.
10204530|NCT05202431|No Intervention|Standart care|The standard follow-up applied in the dispensary for this group was performed.
9705577|NCT04689100|Experimental|Dose Escalation Cohort|"Monotherapy: Six dose levels of JMT101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of JMT101 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
9705578|NCT04689100|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
9705579|NCT04689282|Experimental|Intranasal M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). M2 were generated in vitro from peripheral blood of a parent during 7 days. Cell-free culture medium, containing M2-BFs, was collected, and aliquots of 2 mL/vial were cryopreserved.~30 children with speech disorders will receive their first doses (n=2-3) of M2-BFs in Clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose. The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment."
9705580|NCT04689165|Experimental|Experimental Vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
9705581|NCT04689165|Active Comparator|Active Comparator Vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
9705582|NCT04689269|Active Comparator|McGrath-King Vision|The participants will attempt double-lumen tube intubation using the McGrath (X-blade) laryngoscope then they will use the King Vision (channelled blade size 3) in the same order.
9705583|NCT04689269|Active Comparator|King Vision-McGrath|The participants will attempt double-lumen tube intubation using the King Vision (channelled blade size 3) then they will use the McGrath (X-blade) laryngoscope in the same order.
9705584|NCT04689087|Experimental|Second line conventional treatment|
9705585|NCT04689035|Experimental|Cohort 1|AVLX-144_dose1
9705586|NCT04689035|Experimental|Cohort 2|AVLX-144_dose2
9705587|NCT04689035|Experimental|Cohort 3|AVLX-144_dose3
9705588|NCT04689035|Experimental|Cohort 4|AVLX-144_dose4
9705589|NCT04689035|Experimental|Cohort 5|AVLX-144_dose5
9705590|NCT04689035|Experimental|Cohort 6|AVLX-144_elderly
9705591|NCT04689477||COVID-19|Hospitalized patients diagnosed with COVID-19, presenting with arterial hypoxemia.
9705592|NCT04689477||Control|Healthy subjects
9705593|NCT04689477||Non-COVID critically ill patients|Non-COVID critically ill patients admitted to the ICU.
9705594|NCT04688996||Malagasy Participants|Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
9785134|NCT01243957|Experimental|LY2216684 + fluoxetine|"LY2216684: 18 milligrams (mg) oral (po) once daily (QD) on Days 1, 2, and 3 and Days 25-27~Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)"
9705595|NCT04688996||USN Health Research Center|USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
9705596|NCT04688983|Active Comparator|Arm 1|Ponatinib plus standard induction and consolidation
9705597|NCT04688983|Active Comparator|Arm 2|Imatinib plus standard induction and consolidation (comparator arm)
9705598|NCT04688983|Experimental|Arm 3|Ponatinib plus Blinatumomab
9705599|NCT04688970||Acute stroke with affection of the upper extremity|"Subject is 18 years or above.~Subject has an acute stroke affecting one UE (FMA less than 50).~Subject or caregiver understands the study and its procedures and gives informed consent.~If the subject is not able to give informed consent:~The assumed will of the patient is to be determined by the patient's provision (if existing), the health care proxy (if existing) and/or the moral concepts expressed by the patient to close relatives.~The legal representative gives informed consent because participation is the assumed will of the patient as assessed by the aforementioned points."
10192577|NCT05146700|Active Comparator|Liberal oxygen|"- 15 L O2/min flow for non-intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the flow can be reduced to ≥12 L O2/min if the arterial oxygen saturation is ≥98%~or~- FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the FiO2 can be reduced to ≥0.6 if the arterial oxygen saturation is ≥98%"
10192578|NCT05145816|Experimental|Cohort (DL 0) for Part 1|Cohort (DL 0) for Starting Dose : Belantamab mafodotin 2.5 mg/kg on Day 1 every 6 weeks
10192579|NCT05145816|Experimental|Cohort (DL +1) for Part 1|Cohort (DL +1) for Dose Escalation: Belantamab mafodotin 2.5 mg/kg on Day 1 every 4 weeks
10192580|NCT05145816|Experimental|Cohort (DL -1) for Part 1|Cohort (DL -1) for Dose De-escalation : Belantamab mafodotin 2.5 mg/kg on Day 1 every 8 weeks
10192581|NCT05145816|Experimental|Cohort (DL -2) for Part 1|Cohort (DL -2) for Dose De-escalation: Belantamab mafodotin 1.9 mg/kg on Day 1 every 8 weeks
10192582|NCT05145816|Experimental|Cohort Dose Expansion for Part 2|Cohort Dose expansion for Part 2: Belantamab mafodotin Dose 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosage calculations.
10192583|NCT05143957|Experimental|IONIS-TMPRSS6-LRx Dose Level 1|IONIS-TMPRSS6-LRx will be administered by SC injection every 4 weeks.
10192584|NCT05143957|Experimental|IONIS-TMPRSS6-LRx Dose Level 2|IONIS-TMPRSS6-LRx will be administered by SC injection every 4 weeks
10192585|NCT05139615|Experimental|APD418 (Part A: Dose Cohort 1-5)|
10192586|NCT05139615|Experimental|APD418 (Part B: Dose Group 1 and 2)|
10192587|NCT05139615|Placebo Comparator|Placebo (Part A: Cohort 1-5 and Part B)|
10192588|NCT05134935|Active Comparator|OKL|
10192589|NCT05134935|Experimental|DIMS|
10192590|NCT05131672|Experimental|Operative reduction w/ fixation|open reduction and internal fixation (ORIF)
10192591|NCT05131672|Active Comparator|Non-operative immobilization|immobilization in a cast without reduction
10192592|NCT05127616|Experimental|Minimal Contact-Cognitive Behavior Therapy|CBT is a goal-focused, learning-based treatment that teaches practical self-management tools and strategies targeting biobehavioral factors that aggravate pelvic pain and urinary symptoms
10192593|NCT05127616|Active Comparator|Education/Support|EDU emphasizes the empowering therapeutic benefits that come from the common across empirically-validated drug or non-drug treatment such as being listened to, support, receipt of science-based information, mobilization of hope, and the establishment of a strong patient-doctor relationship working toward shared goals
9705600|NCT04689022|Other|Group І received general anesthesia (n=53)|"The sedation with constant rate infusion of 1% propofol, 1-4mg/kg/h, guided by Bispectral analysis (60-70 - for regional anesthesia and 40-60 - for the general one). 0.005% fentanyl analgesia was injected, 3-10 mkg/kg or 0.05-0.2 mkg/kg/min during induction; and 2-10 mkg/kg/h for maintaining analgesia, by periodic bolus injection 25-100 mkg or by permanent infusion.~The postoperative pain management of the I group patients was provided according to the local clinical protocol: paracetamol+/-non-steroid anti-inflammatory drugs +/-opioids.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
9705601|NCT04689022|Other|Group II received regional anesthesia: peripheral block was performed (n=73)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
9785135|NCT01244035|Experimental|Part I - Sequence ABC|Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
9785136|NCT01244035|Experimental|Part I - Sequence ACB|Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
9785137|NCT01244035|Experimental|Part I - Sequence BCA|Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
10192594|NCT05124080|Experimental|Deucravacitinib 6 mg Daily|All participants will receive 6 mg of deucravacitinib daily.
10192595|NCT05116202|Active Comparator|Cohort 1: Nivolumab + Ipilimumab|Cohort 1 participants in the nivolumab plus ipilimumab arm will receive treatment for 2 cycles (6 weeks) on Day 1 of each cycle (cycle length 21 days) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
10192596|NCT05116202|Experimental|Cohort 1: RO7247669|Cohort 1 participants in the RO7247669 arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
9785138|NCT01244035|Experimental|Part I - Sequence BAC|Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
9979631|NCT01383941||Subjects with Mild to Severe Asthma|This is an epidemiologic, multi-center, cross-sectional study to define the phenotypic characteristics of Difficult-to-Treat asthma, among children receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis.
9979632|NCT01383967|Experimental|LY2979165 Part A, Cohort 1|20 mg LY2979165 administered orally, daily for 14 days
9705602|NCT04689022|Other|Group III received regional anesthesia with sedation (n=92)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
9705603|NCT04689009|Active Comparator|SOC Group|SOC Group (or control group) will follow the standard therapy with visits twice a week. More specifically, the treatment consists of: dressing change, cleansing and eventual debridement of the lesion, the topic treatment and compression bandage.
9979633|NCT01383967|Experimental|LY2979165 Part A, Cohort 2|60 mg LY2979165 administered orally, daily for 14 days
9705604|NCT04689009|Experimental|EmoLED Group|EmoLED Group will be visited once a week. Therapy in this case includes, in addition to the standard therapy, a treatment with EmoLED device; it consists in irradiating each 5 cm diameter area of the lesion for 60 seconds, with the blue light emitted by the device. For lesions larger than 5 cm, several applications will be applied on adjacent areas, until the whole lesion is covered.
9705605|NCT04688801|Active Comparator|Chemotherapy± Radiotherapy Group|Chemotherapy± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
9979634|NCT01383967|Experimental|LY2979165 Part A, Cohort 3|100 mg LY2979165 administered, orally daily for 14 days
10192597|NCT05116202|Experimental|Cohort 1: + Atezolizumab + Tiragolumab|Cohort 1 participants in the atezolizumab plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
9979635|NCT01383967|Experimental|LY2979165 Part A, Cohort 4|150 mg LY2979165 administered orally, daily for 14 days
10192598|NCT05116202|Experimental|Cohort 1: RO7247669 + Tiragolumab|Cohort 1 participants in the RO7247669 plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
10192599|NCT05116202|Experimental|Cohort 2: RO7247669 + Tiragolumab|Cohort 2 participants in RO7247669 plus tiragolumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
10192600|NCT05108298||Intervention arm|5 domain-specific HRQOL measures
10192601|NCT05108298||Control arm|5 pre-selected HRQOL measures
10192602|NCT05107310|Experimental|Navigation group 1 ARSN|Augmented reality surgical navigation (ARSN). Pedicle screw placement using the Philips ClarifEye system combined with Philips Allura for imaging.
10192603|NCT05107310|Active Comparator|Control group 1 FH|Free hand (FH) surgical technique. Pedicle screw placement using conventional free hand technique.
10192604|NCT05107310|Experimental|Navigation group 2 IRSN|Infrared surgical navigation (IRSN). Pedicle screw placement using Brainlab Curve 1.2 combined with Medtronic o-arm for imaging.
10192605|NCT05107310|Active Comparator|Control group 2 FH|Free hand (FH) surgical technique. Pedicle screw placement using conventional free hand technique.
10192606|NCT05090566|Experimental|Sub-Study A|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
10192607|NCT05090566|Experimental|Sub-Study B|BCMA-CD3 bispecific antibody + immunomodulatory drug
10192608|NCT05077917|Experimental|Cromolyn|2mL of 1% cromolyn sodium solution delivered via nebulizer 4 times a day for 4 days followed by 4% cromolyn solution administered intranasally 4 times per day for 14 days
10192609|NCT05077917|Placebo Comparator|Placebo|2-3mL of normal saline delivered via nebulizer 4 times a day for 4 days followed by intranasal administration of normal saline 4 times per day for 14 days
10192610|NCT05075564|Experimental|Part 1 dose escalation|ES002023 doses will be escalated in patients with advanced solid tumors with approximately 30 subjects.
9705606|NCT04688801|Experimental|Chemotherapy + Immunotherapy ± Radiotherapy Group|Chemotherapy + Immunotherapy ± Radiotherapy is used as adjuvant therapy for high risk patients after surgery with or without neoadjuvant therapy.
9785139|NCT01244035|Experimental|Part I - Sequence CAB|Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
9785140|NCT01244035|Experimental|Part I - Sequence CBA|Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
9785141|NCT01244035|Experimental|Part II - Sequence DEF|Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
9979636|NCT01383967|Experimental|LY2979165 Part B, Cohort 5|Dose to be determined by safety review of doses administered in Part A, administered, orally daily for 14 days
9979637|NCT01383967|Placebo Comparator|Placebo|Administered orally, daily for 14 days in a ratio of 3:1 in each Cohort of Part A
9979638|NCT01383967|Experimental|LY2979165 Part A, Cohort 6|250 mg LY2979165 administered orally, daily for 14 days
9979639|NCT01383967|Experimental|LY2979165 Part A, Cohort 7|400 mg LY2979165 administered orally, daily for 14 days
9979640|NCT01383980|No Intervention|Control|Tube feeds are held night prior to elective surgery (standard of care)
10192611|NCT05075564|Experimental|Part 2 dose expansion|Part 2 of the study will consist of 3 expansion cohorts for pancreatic ductal adenocarcinoma (Cohort 2A), NSCLC (Cohort 2B), and colorectal adenocarcinoma (Cohort 2C) with 10 subjects per expansion cohort respectively at the recommended optimal biological dose determined in Part 1 dose escalation.
10192612|NCT05067257|Experimental|Resiniferatoxin|15 mcg, 20 mcg, or 25 mcg in 2mL injected once into the epidural space
10192613|NCT05067257|Placebo Comparator|Placebo|2mL injected once into the epidural space
10192614|NCT05067257|No Intervention|Concurrent Control|No intervention
10192615|NCT05065255||Patients|Adult subjects with neurogenic or non-neurogenic urinary tract disorders, newly initiated to ASI, and users of the SpeediCath line of catheters.
9705607|NCT04688840||study results and satisfaction with telemedicine|the investigators designed a group on WhatsApp for all patients included in the study. The questionnaires were sent on the group to be filled by the patients in addition to a request for routine x ray follow up. Also, the investigators used the group to send any announcement, schedule of routine visits and some instructions about how to answer the questionnaires. To keep the privacy of patients' informations, every patient was asked to resend the file and x- ray pictures to the surgeon private account. the investigators collected data received by all patients and reviewed all x-rays. If there was any serious complain or major radiological finding the investigators asked the patient for immediate clinical visit.
9705608|NCT04688840||study results and satisfaction with routine follow up|the investigators asked the patients to come for routine follow up visit (RV) and reevaluate them clinically and radiologically. the investigators asked patients to calculate total time needed for completion of the questionnaires, time needed for x-ray and the investigators added time needed for reviewing these files. The same was done at the RV including time of transportation
9705609|NCT04688892|Active Comparator|Intervention Group|The type of cupping therapy will be dry-cupping with moving-cupping (dynamic cupping therapy). The participants will remain in the supine position on a massage table (Posturarte® Olympic), without inclination. Cupping therapy will be performed with a plastic suction cup (5.08 cm in diameter) (K.S. Choi Corp®) and with a pistol for dosing pumps (K.S. Choi Corp®). Prior to the cupping therapy, a small amount of massage cream (ATL®) will be applied throughout the median nerve pathway in order to facilitate the sliding of the suction cup. The cupping therapy will performed with the suction cup sliding with a slow rhythm, insufflation of the suction cup with two pumps for 5 minutes along the median nerve path.
9705610|NCT04688892|No Intervention|Control Group|The participants will remain at rest in a supine position on a massage table (Posturarte® Olympic) without inclination for 5 minutes.
9705611|NCT04688879||According to the degree of occlusion, 13 patients were divided into complete and incomplete groups.|Seven patients were complete occlusion and 6 patients were incomplete occlusion and all underwent thrombolysis with intra-arterial urokinase and the outcome was analysed..
9705612|NCT04688957|Active Comparator|osteotome sinus lifting|
9705613|NCT04688957|Experimental|oseodensification sinus lifting|
9705614|NCT04688606||Two groups|"Initial diagnosis of suspected hepatocellular carcinoma;~patients undergoing liver transplantation, radical resection or ablation of liver cancer"
9705615|NCT04688736|Experimental|Placebo|Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.
10192616|NCT05057312|Experimental|Experimental arm 1|Video narrative persuasion
9705616|NCT04688736|Active Comparator|Chlorpheniramine|Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.
9705617|NCT04688619|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by receiving activities to do with their children, given to the adolescents during the scool program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
9705618|NCT04688619|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
9705619|NCT04688489|Active Comparator|Intervention|The intervention consists of a supplement of maltodextrin at training episodes combined with added dietary carbohydrates at all meals
9705620|NCT04688489|No Intervention|Control|The control receives no intervention. Standard treatment will be administered.
9705621|NCT04688567|Experimental|Patient-driven iCBT|Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment program
9705622|NCT04688567|Active Comparator|Standardized iCBT (TAU)|Patients who are randomized to the control condition undergo the usual iCBT program available for anxiety disorders for a standardized time period of 8 weeks
9705623|NCT04688853|Experimental|Single Arm, Open label|"This is a single arm, open-label, multicenter phase I study with a dose escalation and an expansion segment.~For the Dose escalation segment, 3-9 patients per dose cohort will receive:~Dose level 1: Low~Dose level 2: Medium~Dose level 3: High~For the expansion segment, additional patients may be enrolled until a maximum of 20 patients have received the recommended dose"
9705624|NCT04688723|Active Comparator|Dabigatran/Clopidogrel|Patiënt receive standard care, with dabigatran + clopidogrel 75mg once daily up to 12 months.
10192617|NCT05057312|Experimental|Experimental arm 2|Written narrative Persuasion
10192618|NCT05057312|Experimental|Experimental arm 3|Enhanced Access to HPV vaccines
10192619|NCT05057312|Experimental|Experimental arm 4|Video narrative persuasion; Enhanced Access to HPV vaccines
10192620|NCT05057312|Experimental|Experimental arm 5|Written narrative Persuasion
10192621|NCT05057312|No Intervention|Control/ active comparator Arm 6|CDC information
10192622|NCT05051735|Experimental|Paracetamol|Paracetamol P.O. 500 mg 2 tablets four times a day for 7 days
10192623|NCT05051735|Placebo Comparator|Placebo|Placebo P.O. 2 tablets four times a day for 7 days
10192624|NCT05051475|Active Comparator|radiofrequency ablation|Circumferential ablation with radiofrequency ablation will be performed for each segment of the BE starting from the proximal end with one ablation at 12J/cm2, followed by cleaning of mucosal slough with esophageal cap, patient extubation, cleaning of ablation device with wet gauze, and finally a second ablation at 12 J/cm2 (1 × 12J/cm2-clean-1 × 12 J/cm2). Focal ablations will be performed with three consecutive ablations at 12 J/cm2 without cleaning (simplified protocol).
10192625|NCT05051475|Active Comparator|hybrid argon plasma coagulation|Patients in the Hybrid argon plasma coagulation group will be treated with a single ablation per session with a power limitation of 60 W (pulsed mode (VIO® 300 D & APC 2, PULSED APC®, Effect 2). No scraping with the endoscope cap and second ablation will be performed.
10192626|NCT05046418||Hypoallergenic formula containing synbiotics|Infants (aged <13 months) with cow's milk allergy (CMA) who are prescribed a hypoallergenic formula containing synbiotics as part of usual clinical practice for the dietary management of CMA.
10192627|NCT05046288|Experimental|Group 1|Participants will participate to the 3-month cycle of virtual guided tour of the MMFA and will complete assessments at M0 and at M3
10192628|NCT05046288|No Intervention|Group 2|Participants will not participate to the 3-month cycle of virtual guided tour of the MMFA but will complete assessments at M0 and at M3
10192629|NCT05046106|Placebo Comparator|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks.
10192630|NCT05046106|Active Comparator|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
10192631|NCT05046106|Active Comparator|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks.
9705625|NCT04688723|Experimental|Dabigatran/Ticagrelor|Patiënt receive standard care, with dabigatran + ticagrelor 90mg twice daily up to 12 months.
9778987|NCT01120197|Experimental|Exercise group|"Exercise group with intervention~Subjects in the intervention group must participate in a training course consisted of 24 sessions over 3 months. The exercises include aerobic, stretching, balance and functional training, i.e. circuit exercises focus been on: the prevention of falls and fractures, improving balance and coordination, improving posture, and informing subjects about risk factors for falls and for osteoporosis and fractures. A 3-hour session of information and supervision will be hold for the intervention group by the same physiotherapist who leads the training sessions. The focus is on body awareness and ergonomic advice in specific, daily-life situations (e.g. lifting/carrying, resting positions)."
9778988|NCT01120197|Other|Control Group|"Control group with no intervention~Subjects in the control group are asked to maintain their current lifestyle. No restrictions are placed on their exercise activities. The control group is followed for the same duration as the intervention group."
9778989|NCT01120210|Experimental|Part 1 (Main Study)|3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
9778990|NCT01120210|Experimental|Part 2 (Extended Infusion Sub-Study)|1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo
9778991|NCT01120223|Experimental|LEO 80185 gel once daily application|
9778992|NCT01120236|Experimental|Arm I (androgen deprivation and cixutumumab)|Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
9778993|NCT01120236|Active Comparator|Arm II (androgen deprivation therapy)|Patients receive androgen deprivation therapy comprising bicalutamide and either goserelin acetate or leuprolide acetate as in arm I.
9778994|NCT01120275|Experimental|Treatment (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10192632|NCT05040984||solifenacin|
9778995|NCT01120379||XV-LTF cohort|
9778996|NCT01120405|Experimental|Xenon|0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
9778997|NCT01120405|Active Comparator|sevoflurane|0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)
9778998|NCT01120600|Experimental|Odanacatib 50 mg once weekly|Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
9778999|NCT01120600|Placebo Comparator|Placebo once weekly|Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
9785142|NCT01244035|Experimental|Part II - Sequence DFE|Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
10192633|NCT05040984||mirabegron|
10192634|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
9785143|NCT01244035|Experimental|Part II - Sequence EFD|Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
9785144|NCT01244035|Experimental|Part II - Sequence EDF|Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
9785145|NCT01244035|Experimental|Part II - Sequence FDE|Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
9785146|NCT01244035|Experimental|Part II -Sequence FED|Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3
9785764|NCT01259427|Active Comparator|Arm 2: Health and Wellness Group|Health and Wellness Group: The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
9785765|NCT01259440|Active Comparator|Video Teleconferencing Care|Video teleconferencing care
9785766|NCT01259440|Placebo Comparator|Usual Care|Usual Care
9785767|NCT01259466|Experimental|Cognitive Behavioral + Nicotine Patch|Cognitive Behavioral Therapy + Nicotine Replacement Patch
9785768|NCT01259466|Active Comparator|Health Education + Nicotine Patch|Health Education + Nicotine Replacement Patch
10192635|NCT05039489|Active Comparator|The schizophrenia patients with general auditory hallucinations|Drug intervention
10192636|NCT05039489|No Intervention|The healthy controls|MRI scan at baseline and no drugs treatment
10192637|NCT05039489|Experimental|Drug + cTBS intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug + cTBS intervention (the left temporoparietal cortex as the stimulation target)
10192638|NCT05039489|Active Comparator|Drug intervention: the first-episode schizophrenia patients with auditory hallucinations|Drug intervention
9705626|NCT04688645|Experimental|Balanced crystalloid solution|Balanced crystalloid solution - Plasmalyte.
9705627|NCT04688645|Active Comparator|Normal saline|0.9% sodium chloride solution.
9705628|NCT04688697|Experimental|Prepectoral Group|Prepectoral implant-based reconstruction applied for patients in this group
9705629|NCT04688697|Active Comparator|Subpectoral Group|Subpectoral implant-based reconstruction applied for patients in this group
9705630|NCT04688762||Group without the e-consult tool|standard consultation
10192639|NCT05039489|Experimental|The schizophrenia patients with medication-resistant auditory hallucinations from the fourth arm|Drug + cTBS intervention (the left cerebellum Crus II as the stimulation target)
10192640|NCT05037500|Experimental|Treatment (decitabine and cedazuridine, enzalutamide)|Patients receive decitabine and cedazuridine PO QD on either days 1-3, 1-4, or 1-5 and enzalutamide PO QD on days 1-28. Treatments repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9705631|NCT04688762||Group with the e-consult tool|The e-consult tool is a digital application developed and designed by the Center François Baclesse, This tool is a consultation support to explain the surgical management of the patient.
10192641|NCT05032092|Experimental|Adult patients with locally advanced and/or metastasized carcinoma|"Liquid biopsies of all 200 study patients will be analysed with FoundationOne®Liquid CDx.~Tissue biopsies from all study patients for whom a tissue biopsy is available will be analysed with FoundationOne® CDx and IHC (approximately 50% of the enrolled patients).~Biomarker Monitoring of study patients receiving matched therapy with AVENIO ctDNA Surveillance Kit."
9705632|NCT04688580|Experimental|XW10172|
9705633|NCT04688632|Active Comparator|Group 1a|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin <Dose A>
9705634|NCT04688632|Active Comparator|Group 1b|Day 1: Single dose of Moxifloxacin <Dose A>; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin Placebo
9705635|NCT04688632|Experimental|Group 2 - Treatment|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 7: Single daily dose of Ampreloxetine <Dose A>; Day 8 - Day 14: Single daily dose of Ampreloxetine <Dose B>; Day 15: Single dose of Moxifloxacin Placebo; Day 15: Single dose of Ampreloxetine Placebo;
9705636|NCT04688515|Experimental|Intervention group|Intervention group refers to mother-child dyads who will be participating in a nutrition program consisting of nutrition education and cooking sessions for 3 months.
9705637|NCT04688515|No Intervention|Comparison group|The comparison group will not receive any intervention but will be provided with the developed educational materials used in the program after the program has been completed.
9705638|NCT04688827|Experimental|training group 1: low-intensity resistance training|
9705639|NCT04688827|Experimental|training group 2: moderate-intensity resistance training|
9705640|NCT04688450|Experimental|Intervention group|The investigational system will be evaluated for safety and user acceptance in 20 patient-subjects and associated nurse-subjects
9705641|NCT04688437||Patients with degenerative scoliosis|
9705642|NCT04688554||Refractory Obsessive Compulsive Disorder|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical capsulotomy
9705643|NCT04688554||Refractory Pain|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
9705644|NCT04688554||Refractory Tremor|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical thalamotomy
9705645|NCT04688554||Refractory Depression|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
9705646|NCT04688359|Experimental|Intervention group|Those receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
9705647|NCT04688359|No Intervention|Control group|Those not receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
9705648|NCT04688372||Inpatient encounters with COVID-19 present-on-admission|See Study description above
9705649|NCT04688346|Placebo Comparator|Control|Saline Pellet
10192642|NCT05030467|Experimental|Intervention Arm|Providers within the clinics randomized to the intervention arm will receive a variety of EHR-based tools for eligible patients with uncontrolled hypertension.
9705650|NCT04688346|Experimental|Intervention|Racemic Epinephrine Pellet
10192643|NCT05030467|No Intervention|Control Arm|Providers within the clinics randomized to usual care will receive no EHR tools, except those currently available in clinical practice.
10192644|NCT05029518|Experimental|Treatment A: SMP-100 dissolved in water administered under fasting conditions|12 subjects，For Treatment A, SMP-100 will be dissolved in a total of 240 mL of water and administered orally to each subjects, and a hand and mouth check will be performed to ensure consumption of the medication. Subjects will be required not to wear dentures or mouth piercing at the time of dosing. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
10204531|NCT05202314|Experimental|Immunotherapy group|After clinical success of colonic stenting, regardless of the MSI state all patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
10204532|NCT05202288|Active Comparator|Single vaccination|"The control arm (vaccination alone) will serve as a comparator of vaccine response.~r-VSV-ZEBOV vaccine will be administered at inclusion (D0)"
9705651|NCT04688268||deep neuromuscular blockade|patients who underwent surgery with deep neuromuscular blockade
9705652|NCT04688281|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
9705653|NCT04688281|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
9705654|NCT04688216||MDRO|
9705655|NCT04688216||Non-MDRO|
9705656|NCT04687995|Active Comparator|Tragal preichondrium graft|Tragal perichodrium graft for endoscopic myringoplasty as a reference graft
9705657|NCT04687995|Active Comparator|pretragal ( SMAS) fascia graft|pretragal ( SMAS) fascia graft for endoscopic myringoplasty as a new graft
9785147|NCT01244061|Experimental|Varenicline|
9705658|NCT04687930|Active Comparator|Active genicular nerve block group|group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).
9705659|NCT04687930|Other|intra-articular steroid injection group|while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.
9705660|NCT04688021|Experimental|Tocilizumab cohort|Each patient receives Tocilizumab (8 mg/kg, i.v.) on day -1 added to conventional acute GVHD prophylaxis regimen (CsA+MTX+low-dose MMF+ATG) of haploidentical HSCT.
9705661|NCT04688086||Women with no personal history of breast cancer|Women who came in for a breast mammography between ages 30 and 80 years were invited to take part in the study. All the women included in the study underwent breast cancer screening first by Thermalytix, the AI-based thermal imaging test, followed by mammography.
9705662|NCT04687956|Experimental|LYMPHA|LYMPHA procedure is performed in which the lymphatic vessels drained from the arm and the axillary vein are micro-bonded to the side branches.
9705663|NCT04687956|Active Comparator|Control|No LYMPHA procedure is performed
9705664|NCT04688424|Experimental|FES + Cycling|Functional electrical stimulation cycling group
9705665|NCT04688424|Active Comparator|Cycling only|Volitional cycling group (no electrical stimulation)
9705666|NCT04688424|No Intervention|Control|control group
9705667|NCT04688190||Transcatheter Mitral Valve Implantation (TMVI)|Patients with successful TMVI screening, who underwent Transcatheter Mitral Valve Implantation subsequently. All devices may be included.
9705668|NCT04688190||Interventional mitral valve edge-to-edge repair (E2E)|Patients with TMVI screening failure, who subsequently underwent interventional mitral valve edge-to-edge repair.
9705669|NCT04688190||Mitral valve surgery (Surgery)|Patients with TMVI screening failure, who subsequently underwent mitral valve surgery (i.e., mitral valve repair or replacement).
9705670|NCT04688190||Medical therapy (OMT)|Patients with TMVI screening failure, who subsequently underwent conservative or optimal medical therapy (OMT).
9705671|NCT04687917|Active Comparator|Training, Feedback, Consultation, and Facilitation|A multilevel implementation strategy
9705672|NCT04687917|Experimental|Training, Feedback, Consultation, Facilitation, and P4P|An enhanced version of the multilevel implementation strategy
9705673|NCT04688138||ischemic stroke|Patients with ischemic stroke within 7 days of onset
9705674|NCT04687943||PELOID therapy|A total of 15 sessions of peloid therapy for 3 weeks, 5 days a week for 42 patients in the first group
9705675|NCT04687943||Kinesio tape|42 patients in group 2 will be given 2 sessions of muscle and fascia correction techniques per week, with kinesio tape application and cold application
9705676|NCT04687943||Exercise|42 patients in the third group will be given 3 sets of 10 repetitions home exercise programs for 3 weeks
9705677|NCT04688229|Experimental|Hummingbird intervention group|10 one-hour sessions of focused hand training (affected or dominant hand) using the Hummingbird device in addition to standard of care inpatient rehabilitation
9705678|NCT04688229|Active Comparator|Comparison (sham) group|10 one-hour sessions of activity focused on playing games or puzzles gaged to the ability of the subject in addition to Standard of care inpatient rehabilitation
9705679|NCT04688073|Experimental|Downhill running|Running at 60% VO2max on -15% slope for 30 min on a treadmill
9705680|NCT04688073|Experimental|Level running|Running at 60% VO2max on level surface for 30 min on a treadmill
9705681|NCT04688073|Placebo Comparator|Control|Rest 30 min
9705682|NCT04688060||fallers|stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure Patients who have fallen 1 or more times since stroke
9705683|NCT04688060||non-fallers|"stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure.~Patients who have not fallen 1 or more times since stroke"
9705684|NCT04688008|Other|Treatment sequence #1|29 of 58 subjects were given single oral dose of early phase hetrombopag olamine formulation in period 1 and late phase formulation in period 2
9705685|NCT04688008|Other|Treatment sequence #2|29 of 58 subjects were given single oral dose of late phase hetrombopag olamine formulation in period 1 and early phase formulation in period 2
9705686|NCT04688385|Experimental|Multipeptide Vaccine + XS 15|a personalizied multi-peptide vaccine in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes
9705687|NCT04687904|Active Comparator|Therapeutic education group|"The psychologist associated with the project takes care of the patient to receive a 1.5 hour therapeutic education interview (control group)."
9705688|NCT04687904|Experimental|Mindfulness meditation group|"The psychologist associated with the project takes care of the patient to receive training in mindfulness meditation twice (1.5 hours) (active group)"
9705689|NCT04687982|Experimental|mDLI infusion|"The planned number of mDLI is 3.~Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
9705690|NCT04687878|Experimental|Insulin|Regular Insulin, 20 IU twice a day, intranasally, every day for 12 weeks
9705691|NCT04687878|Placebo Comparator|Placebo|Normal saline, twice a day, intranasally, every day for 12 weeks
9705692|NCT04687839|Experimental|Healthy adult subjects|"It's a randomized intra-individual comparative study with two injured study areas (treated and untreated) for each subject.~The randomization will determine the application side on which the tested product will be applied (RIGHT or LEFT forearm).~Twice daily application on the treated area."
10192645|NCT05029518|Experimental|Treatment B: SMP-100 tablets administered under fasting conditions|12 subjects，For Treatment B, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL. No food will be allowed from at least 10 hours before dosing until at least 4 hours post-dose.
9979641|NCT01383980|Experimental|Continuous Feeding|Tube feeds are continued up until surgery. Subjects with a nasogastric tube will have their stomach contents emptied prior to surgery.
10192646|NCT05029518|Experimental|Treatment C: SMP-100 tablets administered under fed conditions|"12 subjects，For Treatment C, SMP-100 tablets will be administered to each subject with 240 mL of water and a hand and mouth check will be performed to ensure consumption of the medication. The dosing procedure must be completed within 2 minutes. In the event that subjects cannot swallow all tablets with 240 mL of water, additional water may be allowed up to a maximum total volume of 400 mL.~After a supervised fast of at least 10 hours, subjects will be served a high-fat, high-calorie meal of approximately 800 to 1000 calories (approximately 50% of total caloric content of the meal derived from fat). This test meal should derive approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. Subjects should start the meal approximately 30 minutes prior to drug administration. Subjects will be required to completely eat the meal in 30 minutes or less. No food will be allowed until at least 4 hours post-dose."
9705695|NCT04687553|Experimental|Patients with vegetative state|Patients with vegetative state were assessed by the SECONDs and CRS-R for two days.
9705696|NCT04687553|Experimental|Patients with minimally conscious state|Patients with minimally conscious state were assessed by the SECONDs and CRS-R for two days.
9705697|NCT04687566|Experimental|dextromethorphan|Dextromethorphan, 60 mg per day, once daily, for 12 weeks
9705698|NCT04687566|Experimental|memantine|Memantine, 5 mg per day, once daily, for 12 weeks
9705699|NCT04687566|Experimental|dextromethorphan and memantine|Dextromethorphan (60mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks
9705700|NCT04687566|Placebo Comparator|placebo|placebo, once daily, for 12 weeks
9705701|NCT04687579|Experimental|Umbilical hernia repair|Patients with cirrhosis undergoing umbilical hernia repair with or without preoperative optimization. See the section about interventions.
9705702|NCT04687579|Other|Watchful waiting|Patients who do not agree for operation but consent for follow-up. Patients will be followed in the whole inclusion period and can at any time change their preference if they wish to undergo surgery.
9705703|NCT04687644|Experimental|Online Education|The education program developed within the scope of the research consists of five modules. In order to use the question and answer method in education, to make the education interactive and to receive feedback, 4 separate training groups of 7 people will be formed. The training will take place on the online platform, not face to face. Midwives will be contacted by phone and / or e-mail and the researcher will give a brief information about the research after introducing himself. A social media group will be created for each training group in order to communicate, announce trainings and inform changes.
9705704|NCT04687644|Active Comparator|Control|Midwives who attend the online forms of study will complete the survey. In the survey there are demographic and their view about woman centred care question forms. There are also Patient Centred Care Competency Scale and Minnesota Job Satisfaction Questionnaire. They will complete the survey.
9705705|NCT04687748|Experimental|EMG BF Group|Pelvic floor muscle contraction will be performed via an S-EMGBF device; patients in the s-EMGBF group will receive visual and auditory feedback.
9705706|NCT04687748|Active Comparator|Control Group|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds.
9705707|NCT04687787|Experimental|Group I|This group will receive Core Stability Exercises with Application of TENS
9705708|NCT04687787|Active Comparator|Group II|This group will receive Routinely prescribed Exercises with application of TENS
9705709|NCT04687657|Experimental|cord blood transfusion|The arm that will receive the target treatment.
9705710|NCT04687722|Experimental|High Intensity Aerobic Training Group.|The experimental group will receive High Intensity Aerobic Training at 80-90% of Heart Rate Maximum calculated using karvonen rule.
9705711|NCT04687722|Active Comparator|Control Group|The control group will receive routine low Intensity aerobic Training at 40-60% of Heart Rate Maximum calculated using karvonen rule.
9705712|NCT04687735|Experimental|Intervention arm|Patients with frozen shoulders at any stage
9705713|NCT04687631|Experimental|mFOLFOXIRI plus Cetuximab|
9705714|NCT04687631|Experimental|mFOLFOXIRI plus Bevacizumab|
9705715|NCT04687813|Experimental|Single Ascending Doses 100mg|Drug: FTP-198, single dose 100mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
9705716|NCT04687813|Experimental|Single Ascending Doses 300mg(food-impact)|Drug: FTP-198, single dose 300mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet 2-X: fasting (Period 1) ; 2-Y:Postprandial (Period 1) 2-X:Postprandial (Period 2); 2-Y:fasting (Period 2)
9785148|NCT01244061|Placebo Comparator|Placebo|
10192647|NCT05027308|Experimental|Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive teduglutide 0.05 mg/kg (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous (SC) injection once daily for 24 weeks followed by no treatment period for 4 weeks. The maximum duration of treatment is approximately 18 months.
10192648|NCT05026749|Placebo Comparator|Control Group|
10192649|NCT05026749|Active Comparator|AZM 20mg/kg Treatment Group|
10192650|NCT05019950|Experimental|LABP-104 250mg|"Dose escalation in the SAD part of the study (Part A) will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either LABP-104 or placebo (ratio 5:2). LABP-104 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort (500 mg, 750 mg, 1000 mg, 1500 mg).~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either LABP-104 or placebo (ratio 5:2), once daily for seven days. LABP-104 dose levels to be evaluated in Part B will be 250 mg, 500 mg, and 1500 mg."
9705717|NCT04687813|Experimental|Single Ascending Doses 600mg|Drug: FTP-198, single dose 600mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
9705718|NCT04687670|Experimental|Intervention group(pET)|Personalized embryo transfer of a single vitrified blastocyst in a HRT cycle according to the ERA test results.
10192651|NCT05019950|Placebo Comparator|Placebo|"Dose escalation in the SAD part of the study (Part A) will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either LABP-104 or placebo (ratio 5:2). LABP-104 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort (500 mg, 750 mg, 1000 mg, 1500 mg).~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either LABP-104 or placebo (ratio 5:2), once daily for seven days. LABP-104 dose levels to be evaluated in Part B will be 250 mg, 500 mg, and 1500 mg."
10192652|NCT05017818||Treated and untreated subjects with TK2 deficiency|Two TK2 deficiency groups. (1) Subjects treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study. (2) Subjects not treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study.
9705719|NCT04687670|Active Comparator|Control group(FET)|Frozen embryo transfer of a single vitrified blastocyst in a HRT cycle according to the clinical standard practice.
9705720|NCT04687462|Experimental|Experimental|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
10192653|NCT05014698|Experimental|WGS|"at inclusion visit :~- Blood collection for whole Genome sequencing will be performed~At final visit :~the results of the WGS will be delivered to patients"
10192654|NCT05008289|Active Comparator|ACTIVE|Magnetic transcutaneous spinal cord stimulation
10192655|NCT05008289|Sham Comparator|PLACEBO|
10192656|NCT05007418|Experimental|STI-1492|Four dosing cohorts will be evaluated: Cohort 1 (1 × 10^5 donor DAR-T cells/kg); Cohort 2 (5 × 10^5 donor DAR-T cells/kg); Cohort 3 (1 × 10^6 donor DAR-T cells/kg); Cohort 4 (3 × 10^6 donor DAR-T cells/kg) where STI-1492 will be administered intravenously once.
9705721|NCT04687462|Active Comparator|Control|TKRA operation undergoing 2-mm thickness variance polyethylene insert total knee arthroplasty system (Lospa, Corentec)
9705722|NCT04687475|Experimental|Clinical Tool (Mobile Spirometry and Survey)|All subjects enrolled will be placed into the clinical tool arm. The clinical tool is comprised of a mobile application based assessment of home spirometry and a survey measuring patient reported outcomes.
10192657|NCT04995029|Experimental|Induction Phase: Rapid Induction|Participants will receive 4 mg transmucosal buprenorphine on Day 1. Participants meeting eligibility requirements will then receive 300 mg extended-release buprenorphine by subcutaneous injection at least 1 hour later and a second dose on Day 8.
10192658|NCT04995029|Experimental|Induction Phase: Standard of Care Induction|Participants will receive transmucosal buprenorphine for a minimum of 7 days per applicable product labelling information. Participants meeting eligibility requirements will receive 300 mg extended-release buprenorphine by subcutaneous injection on Day 1 and a second dose on Day 8.
9705723|NCT04687761|Experimental|AZA-Based|"Azacitidine 75 mg/m2/daily SC on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle plus Venetoclax (ramp-up) 400 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the AZA-based schedule.~AZA and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of AZA + Venetoclax + Quizartinib regimen (30 patients)."
9705724|NCT04687761|Experimental|LDAC-Based|"Low-dose subcutaneous cytarabine 20 mg/m2/daily SC, days 1 to 10 plus Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28 plus Quizartinib phase I/RP2D mg/daily oral, days 8 to 14-28.~If 1 DLT is observed among these 3 patients, additional 3 subjects will receive the level 2 dose, and it will be recommended in the absence of DLT between them. If >1 DLT occurs in these 6 level 2 patients, the dose administered in the level 1 will be the RP2D of the LDAC-based schedule.~LDAC and Venetoclax doses will remain the same in all levels and only the dose of Quizartinib will be modificated according to the following table:~Escalation-Quizartinib dose-Quizartinib duration; Level-2 -30 mg/daily-Days 8 to 14; Level-1 -30 mg/daily-Days 8 to 21; Level1-40 mg/daily-Days 8 to 28; Level2-60 mg/daily-Days 8 to 28.~In phase II, patients randomized to this arm, will receive the recommended phase 2 dose (RP2D) regimen of LDAC + Venetoclax + Quizartinib regimen (30 patients)."
9705725|NCT04687605|Experimental|Optimum duration of hypercapnia|Daily serial measurement of 2 hours under target hypercapnia of pCO2 50 - 55 mmHg by changes of respirator settings once per day
9705726|NCT04687852|Experimental|Focused Pelvic Floor Exercise with Motor ImageryTechnique Group|5 minute-Meditation Therapy 10 minute-Progressive Relaxation training ( Bernstein-Borkovec Method) 5 min - Breathing Exercises (Diaphragmatic Breathing Exercise, Pursed lip breathing Exercise) 35 min -Motor Imagery Technique Focused Pelvic Floor Exercises-MOPEXE 5 min - Meditation Therapy Twice a week for 60 minutes 12 weeks Participants will be evaluated online at the beginning of the research and at the end of the 12-week program.
9705727|NCT04687852|Active Comparator|Nonsteroidal Anti-Inflammatory Drug(NSAID) Group|Naproxen Sodium 550 mg film-coated tablet prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the pain of the patient. Treatment time; 12 weeks.
9779000|NCT01120626|Active Comparator|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
10192659|NCT04995029|Experimental|Maintenance Phase: Extended-release Buprenorphine 100 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 100 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
9785149|NCT01244126|Active Comparator|IM morphine|0.1 mg/kg morphine IM
10204533|NCT05202288|Experimental|Simoultaneous vaccination|Mabs and r-VSV-ZEBOV vaccine will be administered the same day, at inclusion (D0), one hours appart
10192660|NCT04995029|Experimental|Maintenance Phase: Extended-release Buprenorphine 300 mg|Participants eligible to continue treatment will be randomized at Week 6 to receive maintenance doses of 300 mg extended-release buprenorphine by subcutaneous injection every 4 weeks for a total of up to 8 maintenance injections (Weeks 6 to 34).
10192661|NCT04992338|Experimental|Intervention group - CarpeDiem app|Participants will receive at their home the activity tracker of Fitbit brand, model Inspire HR 2, as well as instructions to download and use the CarpeDiem application and the Fitbit application in their mobile phones and synchronize the bracelet. The intervention consists of detecting unhealthy user behaviors and, through contextualized and personalized recommendations and strategies based on gamification, modifying said behaviors and motivating individuals to maintain this modification over time in order to prevent illnesses associated with bad habits. The intervention is performed through the CarpeDiem application, participants will be able to answer follow-up questionnaires, carry out missions designed to improve their eating habits, monitor their physical activity and sleep.
10192662|NCT04992338|No Intervention|Control group - Activity tracker + general recommendations|"Participants will receive the Fitbit activity tracker, model Inspire HR 2. They will also receive instructions to download the Fitbit application from their mobile phone and synchronize the bracelet. Additionally, this group will receive general recommendations on healthy lifestyle habits through standardized documents that contain general guidelines, such as: Get in the habit of going to sleep and always waking up at the same time, even on weekends."
10192663|NCT04992247|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
10192664|NCT04992247|Placebo Comparator|Placebo|Excipient
10192665|NCT04986189|Other|Invitation to have a low dose CT thorax|All participants are invited to undergo a low dose CT thorax
10192666|NCT04985409|Experimental|Feedback|Participants in the intervention arm will receive a Fitbit upon admission and will receive feedback from the activity tracker and the in-room TV screen as demonstrated by the Study Navigator. Study participants in this arm will be engaging with their physicians around achievement of daily step goals by viewing the in-room TV display of their daily step counts on rounds.
10192667|NCT04985409|No Intervention|Control|Subjects in the control arm will receive a Fitbit upon admission for their transplant but neither the physician, nurse, nor patient will receive any feedback from the device. They will be blinded to any data capture by their activity monitor. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods to encourage ambulation.
10192668|NCT04977375|Experimental|Pembrolizumab with stereotactic radiation therapy and surgical resection|
10192669|NCT04973254|Experimental|Cohort 1- HIV injection at a community-based site|CAB-RPV LA administered to patients in an alternative community-based site
10192670|NCT04973254|Active Comparator|Cohort 2- HIV injection at a HIV clinic|CAB-RPV LA administered to patients in the HIV clinic
10192671|NCT04973254|Active Comparator|Cohort 3- Standard of care for HIV|Individuals who share characteristics of cohort 1 and are engaged in standard of care
10192672|NCT04967105||elderly patients following liver resection|elderly patients (aged ≥60 years) scheduled for any type of liver resection due to benign or malignant hepatobiliary diseases
10192673|NCT04958031|Experimental|CVL-871 1.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 1.0 milligrams (mg) until Day 85 during the treatment period.
10192674|NCT04958031|Experimental|CVL-871 3.0 mg|Participants will receive CVL-871 tablets orally QD up to the maximum dose of 3.0 milligrams (mg) until Day 85 during the treatment period.
10192675|NCT04958031|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-871 tablets orally QD until Day 85 during the treatment period.
10192676|NCT04951544|Experimental|Intervention Group|This arm will start the intervention using LetSync app v1.0 from T1 to T4, baseline/Month 0 to Month 14.
10192677|NCT04951544|Active Comparator|Waitlist-Control Group|This arm will wait to begin the intervention using the LetSync app v2.0 from T3 to T4, Month 8 to Month 14.
10192678|NCT04949269|Experimental|Part A|
10192679|NCT04949269|Experimental|Part B|
10192680|NCT04949269|Experimental|Part C|
10192681|NCT04949269|Experimental|Part D|
10192682|NCT04943302|Experimental|Isatuximab + bendamustine|Bendamustine will be administered by IV at a dose of 70mg/m2 on cycle days 1 and 8 for up to 6 cycles. Isatuximab will be administered by IV at a dose of 10mg/kg on cycle 1 days 1, 8, 15, and 22; cycle 2-6 days 1,8; and cycle 7-12 day 1.
10192683|NCT04942717||Aim 1|For the survey component, recruitment will focus on patients who have not participated in a semi-structured interview as part of the Aim 1 research. For Aim 1, we will seek to recruit approximately 36 patients and 12 family members for the initial key informant interviews, 20 patients for the followup survey, and 10 for the English/backtranslated-English side-by-side comparison.
10192684|NCT04942717||Aim 2|"Patients who provide consent during Months 9-11 (i.e., first three months of Control Period of pilot trial) will be in the control group, with follow-up for outcomes data collection occurring during Months 12-14. Patients who provide consent during Months 16-18 (after implementation of the intervention at the end of Month 15) will be in the intervention group and will be followed for three more months (Months 19-21) for outcomes data collection. We will enroll a total of 130 patients (65 in control period, 65 in intervention period) during the pilot trial across the two trial sites, SBH and Jacobi, to reflect, as much as possible, the relative patient numbers and the demographic composition of the sites. During the intervention period, family who accompany patients to clinic and are included (patient option to include one family member) in the CONVO values discussions will be approached (in person or via video conferencing platform or telephone) for participation at the clinic."
10192685|NCT04938271|Experimental|Healables Wearable Microcurrent Electroceutical HEAL-122 with e-Textile Sports Sleeve|Subjects activate electroceutical at home for 60 minutes (+/- 20 minutes) daily, 5 times per week, for 4 weeks
10192686|NCT04931342|Experimental|Ipatasertib + Paclitaxel (PIK3CA/AKT1/PTEN-altered tumors)|Participants in the Ipatasertib + Paclitaxel arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
10192687|NCT04931342|Experimental|Cobimetinib (BRAF/NRAS/KRAS/NF1-altered tumors)|Participants in the Cobimetinib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
9705728|NCT04687852|Other|Diosmin Group|Diosmin (90%) 500 mg film-coated tablets prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the patient's pain. Treatment time; 12 weeks.
9705729|NCT04687852|Experimental|Acupressure Group|"4 acupuncture points will be applied twice a day for 12 weeks. These points are; LI4, CV4, CV6, SP6~."
9705730|NCT04687852|No Intervention|Control Group|Participants will not be treated.
9705731|NCT04687514|Experimental|Phase a (V1a-Ev2a): Dulaglutide first- Phase b (V1b-Ev2b) Placebo second|Dulaglutide is injected via pen s.c. once a week. The titration scale will be 1x 1.5mg in 0.5 ml in the first week and 2x 1.5 mg in 2x 0.5 ml once weekly for 3 further weeks. Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
10192688|NCT04931342|Experimental|Trastuzumab Emtansine (ERBB2-amplified/mutant tumors)|Participants in the Trastuzumab Emtansine arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
10192689|NCT04931342|Experimental|Atezolizumab + Bevacizumab (Non-matched)|Participants in the Atezolizumab + Bevacizumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
10192690|NCT04925947|Experimental|KN046|KN046 will be given intravenously every 2 weeks.
10192691|NCT04922866||elderly patients following hepatectomy|elderly patients (aged ≥65 years) scheduled for any type of liver resection
10192692|NCT04921683|Experimental|Treatment LIFUP|LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone to minimize bone absorption and refraction. Accurate aiming will be ensured using the Brain Sight neuronavigation device, customized for tracking our LIFUP transducer. Following LIFUP, the patient will undergo a second EEG session, except for the EEG cap being fit to the patient's head prior to the LIFUP session so that, as soon as LIFUP administration is complete, the EEG paradigm can be promptly administered. The patient will then be allowed to rest (~1h).The patient will then be administered a second dose of tracer in order to undergo a second PET measurement. Finally, at the end-of-day, the clinical coordinator will collect an Adverse Event Questionnaire and will fit the PSG device for night monitoring.
10192693|NCT04920383|Experimental|Dose Escalation and Expansion|ALPN-202 + Pembrolizumab
10192694|NCT04914793|No Intervention|Reference phase|"At the start (month 0), a point prevalence surveys (PPS) on hospital antimicrobial use are performed (more details on conduct of PPS are given in following section) to collect baseline data before introducing paper-based guidelines.~All medical doctors of each participating hospital are asked to complete an AMS knowledge survey and pre-prescribing guidelines survey after PPS is conducted. Then, paper-based prescribing guidelines in both adult and paediatric versions (one adult guideline and one paediatric guideline) are distributed to all doctors at participating hospitals, followed by guideline introductory session of the guidelines. After introduction of the paper-based guidelines, all six hospitals are formally included in the reference period."
10192695|NCT04914793|Experimental|Intervention phase|"Antimicrobial Prescribing guidelines mobile phone application (MicroGuide) Both paediatric and adult antimicrobial prescribing guidelines are transferred to MicroGuide; which is a medical guideline application. MicroGuide is an offline application, free-of-charge for the individual users. The app can monitor the number of users and which guidelines are being accessed. The app is installed to the personal smart phones of local physicians by the PI. Both mobile app and paper guidelines will be available in Lao languages.~Antimicrobial stewardship (AMS) training AMS training sessions are given to prescribers in participating hospitals when they firstly enter to the intervention phase. This session is given alongside an introduction of mobile phone app prescribing guideline. The training focus on good practices of antimicrobial prescription. Providing training after introducing treatment guidelines is not routine practice in many hospitals in Laos."
10192696|NCT04912245|Other|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
10192697|NCT04911673|Experimental|Music group|"Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song was composed by Juan Martin Saavedra.~In the first month, music group was filled the State Anxiety Inventory (SAI) between 10 and 20th of the menstruation that SAI consists of 20 statements that ask people to describe how they generally feel. In the second month, pain scores were measured on the first day of menstruation using a visual analogue scale (VAS) of 10 cm (0 no pain at all, and 10 the worst possible pain) and Trait Anxiety Inventory (TAI) was filled to assess the anxiety.In the third month, after the participants were listening the music in three days before menstruation and the first day of menstruation (during four days), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety."
10192698|NCT04911673|Experimental|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them. In the first month, chocolate group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation.In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety.In the third month, after the participants were eating 40 mg of dark chocolate per day in three days before menstruation and the first day of menstruation (during four days/total 160 mg), pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
9705732|NCT04687514|Experimental|Phase a (V1a-Ev2a): Placebo first- Phase b (V1b-Ev2b) Dulaglutide second|The Placebo will be injected via syringe and contains 0.5ml (only first injection) or 2x0.5ml (second to fourth injection) of 0.9% sodium chloride (0.9% NaCl). Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
9779001|NCT01120626|Placebo Comparator|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
9785150|NCT01244126|Active Comparator|IV morphine|0.1 mg/kg morphine IV
9785151|NCT01244126|Active Comparator|fentanyl IN|Intranasal fentanyl 2 mcg/kg IN
10192699|NCT04911673|No Intervention|Control group|Control group had no intervention. In the first month, control group was filled the SAI to assess state anxiety between 10 and 20th of the menstruation. In the second month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the trait anxiety. In the third month, pain scores were measured on the first day of menstruation using VAS and TAI was filled to assess the anxiety.
10192700|NCT04902976|Active Comparator|CPC+Zn|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride associated with 0.28% zinc lactate solution.
10192701|NCT04902976|Active Comparator|CPC|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride solution.
10192702|NCT04902976|Placebo Comparator|Negative Control|patients submitted to mouth rinse with distilled water.
10192703|NCT04902066|Experimental|Cognitive Behavioural Virtual Reality Therapy (CBT-VR)|The CBT-VR consists of traditional CBT with the augmentation of virtual reality exposure. The virtual reality exposure comprises four virtual social environments (a bus, café, street, and supermarket). These are daily social situations that generally elicit paranoid thinking in patients with a schizophrenia spectrum disorder. While virtually engaging in these distressing situations, the therapist will facilitate a CBT dialogue aimed at generating alternative (i.e. non-threatening) thinking, diminishing safety behaviours (e.g. social isolation), and building up new coping strategies. This is expected to alleviate distress, anxiety, and improve daily social functioning. Preliminary findings reveal this virtual reality program to be well-tolerated and highly effective in reducing paranoia and anxiety in psychosis. Patients will be offered 10 individual sessions.
10192704|NCT04902066|Active Comparator|Traditional Cognitive Behavioural Therapy|The treatment in the CBT group will follow the core principles of CBT used for psychotic disorders. The CBT treatment facilitates an individualised, problem-oriented approach, and uses key CBT techniques such as developing a problem and goal list, normalising psychotic-like experiences, evaluation of appraisals, and removing or diminishing safety behaviour. Patients will be offered 10 individual sessions.
10192705|NCT04900428|Experimental|COVI-DROPS|10 mg or 20 mg of COVI-DROPS administered intranasally
10192706|NCT04900428|Placebo Comparator|Placebo|1 mL administered intranasally
10192707|NCT04899102|Experimental|Time-Restricted, Intermittent Fasting Group|Special type of diet for 6 weeks, called time-restricted, intermittent fasting.
10192708|NCT04894370|Experimental|Experimental|"Phase 1: Radiotherapy (8 Gy on target lesions)~Phase 2: Combination immunotherapy and mDCF regimen mDCF regimen every 2 weeks for 8 cycles~Docetaxel (40 mg/m², day 1),~Cisplatin (40 mg/m², day 1)~5-FU (1200 mg/m²/day for 2 days) Spartalizumab: 400 mg intravenous will be administrated every 4 weeks~Phase 3 : Multimodal treatment of residual disease The multimodal treatment is recommended in oligometastatic anal cancer. The support by ablative treatment (surgery, hypofractionnated radiotherapy or by radiofrequency) improve survival.~In absence of progression disease:~Ablative treatment: surgery, hypofractionnated radiotherapy or by radiofrequency of residual metastases~and Chemo-radiotherapy (CRT) for local disease~Phase 4: Maintenance treatment with Spartalizumab 400 mg intravenous every 4 weeks for 12 months from enrolment maximum"
10192709|NCT04893915|Experimental|Lead In Cohort Recipient: Cytokine-induced memory-like NK cells|"Fludarabine and cyclophosphamide beginning on Day -6.~NK cell product will be infused on Day 0.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.~NK cell product will be infused into the recipient on Day +14.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.~In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.~Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
10192710|NCT04893915|Experimental|Phase II Recipient: Cytokine-induced memory-like NK cells|"Fludarabine and cyclophosphamide beginning on Day -6.~NK cell product will be infused on Day 0.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.~NK cell product will be infused into the recipient on Day +14.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.~Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.~Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
10192711|NCT04893915|Experimental|Donor|"The allogeneic donor will undergo non-mobilized large volume (20-L) leukapheresis on Day -1.~On Day +13 the allogeneic donor will again undergo non-mobilized large volume (20-L) leukapheresis"
10192712|NCT04879043|Experimental|HDP-101|"Participants will receive HDP-101 intravenously at one dose every 3 weeks (21 day cycle) until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal.~During the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered."
10192713|NCT04867187|Experimental|rTMS active and active mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.
10192714|NCT04867187|Sham Comparator|rTMS active and sham mirror-based therapy using virtual reality|The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.
10192715|NCT04864249|Experimental|SNOO Responsive Bassinet|Will receive and be instructed on the use of the SNOO responsive bassinet for their newborn + the current standard of care of safe sleep education in the postpartum period
10192716|NCT04864249|Active Comparator|Usual Care|Will receive the current standard of care of safe sleep education in the postpartum period
9785152|NCT01244191|Experimental|Tivantinib and erlotinib|Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day
9785153|NCT01244191|Active Comparator|Placebo and erlotinib|Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day
10192717|NCT04860765||TPVR|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
10192718|NCT04850170|Experimental|Experimental group|"The first ten subjects will be enrolled in a pilot study. The following sixty subjects will be separated randomly to experimental group and control group.~The first ten subjects and the experimental group will be arranged manual therapy and rehabilitation for six months."
10192719|NCT04850170|Active Comparator|Control group|The control group will be arranged rehabilitation.
10192720|NCT04847778|Active Comparator|Masked arm|"Participants will be instructed on the correct installation and use of the Insulclock device and app on masked mode for recording insulin bolus information.~Participants do not receive any other information and will not have access to the Insulclock 360 application from the Internet.~Participants will keep administering insulin treatment as usual."
10192721|NCT04847778|Active Comparator|Active arm|"Participants will receive detailed instructions on using the Insuclock 360 app and Insulclock device~Participants will be instructed and motivated for full use of all system functions: alarms, messages to the caregivers and investigation team."
10192722|NCT04846647||Unexplained hypophosphatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
10192723|NCT04837976||Individuals with Parkinson's Disease|
10192724|NCT04837976||Supportive individuals|For example carers, family members or any other individual providing regular support or care to the person with Parkinson's.
10192725|NCT04837976||Healthcare Professionals|
10192726|NCT04837716|Experimental|Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)|"INDUCTION THERAPY: Patients receive ensartinib PO QD on days 1-21, carboplatin IV over 15-60 minutes on day 1, pemetrexed IV over 10 minutes on day 1 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ensartinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
10192727|NCT04825470|Experimental|Liver Transplantation|
10192728|NCT04824820|Experimental|Vibrator|Participants will be using commercially available genital vibrator for at least 5 minutes and/or reaching an orgasm three times a week for 3-4 months.
10192729|NCT04822181|Experimental|Semaglutide OW (once weekly )|Semaglutide administrated subcutaneously once weekly
10192730|NCT04822181|Placebo Comparator|Placebo|Placebo administrated subcutaneously once weekly
10192731|NCT04819191|Experimental|SHARING Choices|"Components of SHARING Choices include:~A letter from the clinic introducing an initiative to prepare persons and families for Advance Care Planning (ACP); Access to a facilitator trained to lead ACP discussions; Patient-family agenda-setting to align perspectives about the role of family and stimulate discussion about ACP; Facilitated registration to the patient portal (for patient and family) as desired; Education & resources about Alzheimer's Disease and Related Dementias (ADRD) for clinic staff."
10192732|NCT04819191|No Intervention|Usual care|Usual care
10204534|NCT05202288|Experimental|Early vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 3 weeks later
10204535|NCT05202288|Experimental|Intermediate vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 6 weeks later
10204536|NCT05202288|Experimental|Late vaccination|Mabs are administered at inclusion (D0) and r-VSV-ZEBOV vaccine 12 weeks later
10204537|NCT05202275|Experimental|OPA regimen|All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5.
10204538|NCT05202236|Experimental|selective FGFR1-3 inhibitor|
10204539|NCT05202171|Experimental|Exercise group|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
10204540|NCT05202171|Active Comparator|Standard treatment group|Standard treatment group will be given preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks.
10204541|NCT05201989||Atrial fibrillation|Subjects with symptomatic paroxysmal atrial fibrillation scheduled for AF ablation at Örebro University hospital
10204542|NCT05201989||Control|Sex and age-matched subjects without AF
10204543|NCT05201976|Active Comparator|Intervention|Virtual cardiac rehab program delivered through the CardaHealth platform.
10204544|NCT05201976|Active Comparator|Control|Clinically ordered standard of care cardiac rehab program (in-person).
10204545|NCT05201963|No Intervention|Group 1 control group|Control group will recive only IV Opioids
10204546|NCT05201963|Experimental|Group 2 ((Serratus Anterior Plane Block SAPB))|Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25%
10204547|NCT05201963|Experimental|Group 3 ((Erector Spinae Plane Block ESB))|Patients will receive Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%.
10204548|NCT05201924|Experimental|Bedtime routine|A bedtime routine intervention handbook and check list, including bedtime brushing, limited sugar consumption around bedtime, reading books instead of using screen devices before bed, setting a regular bedtime, turning off the light, and reaching a 9 to 12-hour sleep duration
10204549|NCT05201924|Active Comparator|control group|healthy lifestyle checklist
10204550|NCT05201859|Experimental|Adjuvant Sintilimab Plus Capecitabine|Lead-in Phase: Sintilimab (200mg, D1, D14 for 2 cycles); Adjuvant Phase: Sintilimab ( 200mg D1, every three weeks, a total of 24 weeks, 8 cycles) + Capecitabine ( 1000 mg/m2, BID, D1-14 every three weeks, a total of 24 weeks, 8 cycles).
10204551|NCT05201859|Active Comparator|Adjuvant Capecitabine|Capecitabine 1000 mg/m2, BID, D1-14, every three weeks, a total of 24 weeks, 8 cycles.
10204552|NCT05201833||Telephone Assessment Battery|TRACK-TBI participants may complete up to three annual telephone calls to assess outcome status. These assessments will determine eligibility for the in-person study visit.
10192733|NCT04817189|Experimental|NEPA (300mg netupitant/0.5mg palonosetron) + Dexamethasone 8 mg|"Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Dexamethasone (8 mg) will be administered on Day 1 of each cycle."
10192734|NCT04817189|Active Comparator|Standard of care + Dexamethasone 8 mg|"Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy and one of the 5-HT3-RAs recommended by European Society for Medical Oncology (ESMO) and Multinational Association of Supportive Care in Cancer (MASCC) guidelines (standard of care), i.e. either:~Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)"
10192735|NCT04813601|Experimental|Robot Asissted Gait Training|The rehabilitation sessions will be carried out by a physiotherapist trained in rehabilitation with the ATLAS 2030 exoskeleton and will also have the technical supervision of personnel specialised in the handling of the laboratory and the robotic device.
10192736|NCT04804566||ERT User- Did Not Switch to Galafold|ERT users with mutation amenable to Galafold who did not switch
10192737|NCT04804566||ERT User- Switched and Stayed on Galafold|ERT users with the mutation amenable to Galafold who switched and stayed on Galafold
10192738|NCT04804566||No Previous Therapy- Started Galafold and Stayed On|Those naïve to therapy with the mutation amenable to Galafold who went on and stayed on Galafold
10192739|NCT04804566||No Previous Therapy- No Current Therapy|Those who were naïve to therapy with the mutation amenable to Galafold and have never been on any therapy.
10192740|NCT04804566||ERT Users- Switched and Discontinued Galafold|Participants who are ERT users with an amenable mutation who switched to and later discontinued Galafold
10192741|NCT04804566||No Previous Therapy- Started Galafold and Discontinued|Participants who are naïve to therapy with an amenable mutation, went on Galafold, and discontinued
10192742|NCT04804514|Experimental|KH001|
10192743|NCT04804514|Placebo Comparator|Placebo|
10192744|NCT04801316|Other|Part 1: Video training|"Participants will undergo the following procedures:~Community instructors (involved in the training itself):~Attend a video-facilitated training~Be assessed for competency level of class execution before and after the video-facilitated training~Might need to conduct or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)~Might need to participate in one interview/discussion which will last up to 2 hours~Community-dwelling older adult or community providers (individuals involved in the programme implementation but not the training itself):~Attend or observe 2 video-facilitated SF exercise classes (about 1 hour each time) over the course of 2 weeks (1 class per week)~Participate in one interview/discussion which will last up to 2 hours"
10192745|NCT04801316|Experimental|Part 2: Exercise Intervention|"Participants will participate in 6 months of exercises, and be provided with education and advice on how to reduce their risk of falls.~The exercises are divided into 2 phases:~The Steady Feet (SF) exercise programme phase. A twice-weekly tailored structured group exercise class will be conducted for 3 months with community instructors and exercise video.~A 3 months maintenance exercise phase. A once-weekly structured community group exercise class."
10192746|NCT04801316|No Intervention|Part 2: Control|Participants will be provided with the usual education and advice on how to reduce their risk of falls.
10192747|NCT04798716|Experimental|Escalating Dose First Cohort|"First Cohort:~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 2 x 10^9 exosomes"
10192748|NCT04798716|Experimental|Escalating Dose Second Cohort|"Second Cohort:~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 4 x 10^9 exosomes."
10192749|NCT04798716|Experimental|Escalating Dose Third Cohort|Five patients will receive a treatment dose of 8 X 10^9 exosomes every other day for a period of 5 days, with a minimum of 24 hours between doses recorded.
10192750|NCT04798716|Placebo Comparator|Treatment Dose Fourth Cohort Randomized control ratio 1:3|"Fourth Cohort:~Randomized Cohort Up to 40 patients may be enrolled in this phase of the trial. For those receiving the placebo (~25%), 3 doses will be given over the 5 day period, dispensed from identical vials with physician and patient blinded. The full dose of 8 X 10^9 exosomes will be given to 75% of the patients in 3 doses over the course of 5 days, with one dose occurring every other day."
10192751|NCT04784390|Active Comparator|Patching|Patching of the sound eye (fellow eye) - patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
10192752|NCT04784390|Experimental|Binocular video games|Binocular video games - patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
10192753|NCT04784234|Active Comparator|GlaucoCetin Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
10192754|NCT04784234|Placebo Comparator|Placebo Peripheral Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
10192755|NCT04784234|Active Comparator|GlaucoCetin Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
10192756|NCT04784234|Placebo Comparator|Placebo Central Group|Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
10192757|NCT04783714|Experimental|Active Group|"Active treatment comprises of 3 soft gel capsules daily (with food) of Swisse Nutra+ Cholesterol Balance, a novel combination nutraceutical containing bergamot juice extract, artichoke leaf extract, hydroxytyrosol and plant sterols, totaling a daily dose of 375 mg bergamot juice extract, 150 mg artichoke leaf extract, 50 mg hydroxytyrosol and 1.8 g sunflower phytosterols.~Each capsule contains 125mg of bergamot juice extract, 50mg artichoke leaf extract, 16.67mg hydroxytyrosol and 600mg plant sterols.~The intervention will be administered for 4 months (112 days)."
10192758|NCT04783714|Placebo Comparator|Placebo|3 soft gel capsules of matching placebo daily (total daily dose of 696 mg palm olein and 232 mg olive oil).
10192759|NCT04782830|Experimental|placebo|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
10192760|NCT04782830|Active Comparator|Standard treatment|Either midodrine or atomoxetine at their regular dose.
10192761|NCT04781426||HIV-negative MSM/TG|Oral pre-exposure prophylaxis (PrEP) will be offered to HIV negative MSM, TG identified to be at substantial risk for HIV infection and those motivated to take daily PrEP.
9779002|NCT01120639|Experimental|Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
10192762|NCT04780802|Other|Ballloon catheter|Balloon-assisted transarterial therapy will be performed in the first treatment session only
10192763|NCT04776941|Experimental|Arm I (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief positive messages and write essays about their experiences over 30 minutes (non-stop) QW for 3 weeks.
10192764|NCT04776941|Active Comparator|Arm II (questionnaires, messages, writing)|Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief neutral messages and write essays about neutral topics over 30 minutes (non-stop) QW for 3 weeks.
10192765|NCT04767906|Other|Cabozantinib|Enrolled patients start with 60mg of Cabozantinib. The maximum duration of treatment is 336 days. The dose can be adjusted by the physician to 40mg or 20mg.
10192766|NCT04766970|Active Comparator|Standardized assessment|
10192767|NCT04766970|Experimental|Telehealth assessment|
10192768|NCT04765865||Baseline (Years 1-2)|Participants(n=3060) will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a baseline STEPs survey(n=2160) , 24-hour and spot urine assessments(n=450) , and 24-hour dietary recall assessment(n=450) .
10192769|NCT04765865||Interim (Year 3-4)|Participants(n=2610) will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a baseline STEPs survey(n=2160) and 24-hour and spot urine assessments(n=450).
10192770|NCT04765865||Final (Years 5-6)|Participants(n=3060) will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a baseline STEPs survey(n=2160) , 24-hour and spot urine assessments(n=450) , and 24-hour dietary recall assessment(n=450) .
10192771|NCT04757688|Experimental|Cardiac radioablation (CRA)|CRA delivered via linear accelerator (stereotactic body radiotherapy) to the suspected arrhythmogenic substrate to a dose of 25 Gy in 1 fraction.
10192772|NCT04752501|Experimental|Psychologically Informed Video Series|"This 3 part educational video series will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it); Simple methods of cognitive restructuring; and how to respond to activity-related pain."
10192773|NCT04752501|Active Comparator|Biomedical Education Video Series|Participants in the control (biomedical education) group will watch a series videos on the iPad equal in length to the psychologically informed video series. The control video will discuss basic anatomy of the knee and provide no psychosocial education or positive reinforcement about their condition, basic strengthening exercises and proper lower extremity mechanics
10192774|NCT04751630|Experimental|Therapeutic Exercise group|The study participants corresponding to the Therapeutic Exercise (ET) intervention group will follow the prescriptions given to them by their primary care physician. In addition, and as the main part of the intervention, they will undergo a six-week ET program with two sessions per week, for a total of 12 sessions. Full participation in 10 sessions will be necessary to be included in the ET group during the statistical analysis. Each session will be one hour long. The sessions will be given and supervised by a physiotherapist expert in therapeutic exercise prescription through the online modality.
10192775|NCT04751630|No Intervention|Control group|Study participants in the control group will follow the prescriptions given to them by their primary care physician and will receive a weekly call to assess their recovery. At the end of the study follow-up, when their participation in the study as a control group ends, participants in this group will be offered to participate in the structured ET program to be carried out by the ET group. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of the research.
10192776|NCT04749693||Patient with HbA1c >= 8% despite the use of insulin pump and frequent glycemic control|only group included in the study
10192777|NCT04745702|Other|Low-Calorie Control Group|The control group will receive for 2 calorie-restricted balanced meals per day, consisting of a portion of meat, a portion of vegetables, a portion of medium to high GI carbohydrates and prepared with refined corn oil. The control meals will be devoid of any whole legumes and will contain minimal amounts of spices. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
10204553|NCT05201833||Comprehensive Assessment Battery (CAB)|Participants who demonstrate decision-making capacity will be asked to complete the Comprehensive Assessment Battery (CAB). The CAB in-person is comprised of measures of cognition (i.e. attention, memory, information processing speed, executive functions), mood (i.e., depression, anxiety), social participation, subjective well-being, post-traumatic stress, interviews, global functional status measures, and a COVID-19 questionnaire.
10192778|NCT04745702|Active Comparator|Low-Calorie Treatment Group|The treatment group will receive for 2 calorie-restricted (isocaloric with control group) meals per day containing 100 g cooked whole legumes (amounting to a total of 200 g cooked legumes, approximately 1 cup of cooked legumes)and/or certain meat analogues (textured vegetable [soy] proteins), and/or a portion of vegetables, low GI, wholegrain carbohydrates for their starch sources (rice/noodles/pasta), added spices (dried spice powder) at dietary and culinary acceptable doses and blended vegetable oil. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
10192779|NCT04745143|Experimental|NMDAE|An NMDA enhancer
10192780|NCT04745143|Placebo Comparator|Placebo|Placebo
10192781|NCT04740931|Experimental|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
10192782|NCT04740931|Active Comparator|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
9705733|NCT04687618|Experimental|Automatic control of FiO2|Infants randomized to this arm will be monitored using automatic oxygen control system on the High Flow Nasal Cannula. When infants oxygen saturation are out of the target range the OAM module on HFNC will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation in the target range.
10192783|NCT04731077|Other|Avenir Complete Femoral Stem|All enrolled subjects receive the study implant
10192784|NCT04730856|Active Comparator|Tinzaparin 4500 UI/day|Procedure: Tinzaparin 4500 UI/day SC until hospital discharge.
10192785|NCT04730856|Active Comparator|Tinzaparin 100 UI/Kg/day|Procedure: Tinzaparin 100 UI/Kg/day SC until hospital discharge.
10192786|NCT04730856|Active Comparator|Tinzaparin 175 UI/Kg/day|Procedure: Tinzaparin 175 UI/Kg/day SC until hospital discharge.
10192787|NCT04728048|Experimental|Dural puncture epidural (group DPE)|"The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA). In group DPE, a single dural puncture with confirmation of free-flow CSF will be performed. If there is no free-flow CSF return through the spinal needle, the epidural catheter will be threaded 4-5cm in the epidural space and the patient will still be assigned to the DPE group, as per intent-to-treat protocol."
10192788|NCT04728048|Active Comparator|Standard epidural (group EPL)|The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA).In Group EPL, no dural puncture will be performed and the catheter will be threaded 4-5cm in the epidural space.
10192789|NCT04723173|Experimental|Experimental device: Noise reduction on|The noise reduction is activated. The feature shall support the hearing aid user in noisy situation and shall reduce the listening effort in these special situations.
10192790|NCT04723173|Active Comparator|Experimental device: Noise reduction off|To compare the advantage of the special noise reduction feature the tests will be done additionally with the deactivated feature.
10192791|NCT04718675|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of KB-0742.
10192792|NCT04718675|Experimental|Part 2: Cohort Expansion|"Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) in Part 1, the following expansion cohorts will be enrolled:~Cohort A: Relapsed or refractory (R/R) solid tumors with evidence of MYC amplication/overexpression.~Cohort B: Relapsed or refractory (R/R) soft tissue sarcomas with evidence of transcription factor dysregulation."
10192793|NCT04707534|Experimental|Dexamethasone 20 mg|Dexamethasone 20 mg daily for 5 days, followed by dexamethasone 10 mg daily for 5 days
10192794|NCT04707534|Active Comparator|Dexamethasone 6 mg|Dexamethasone 6 mg daily for 10 days
10192795|NCT04704804||Prostate cancer|Man with cancer and localized (non-metastatic) prostate cancer
10192796|NCT04704804||Brain cancer|Male or Female with a brain tumor (primitive)
10192797|NCT04697823|Active Comparator|study group|Patients receiving an embryo transfer in hyaluronan-enriched transfer medium
10192798|NCT04697823|No Intervention|control group|Patients receiving an embryo transfer in conventional culture medium
10192799|NCT04696861|Experimental|IDEAS for Hope Intervention|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
10192800|NCT04696861|Active Comparator|Enhanced Standard of Care with Safety Planning|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
10192801|NCT04691856|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
9979642|NCT01384006||Control|standard pancreas allograft recipients
10192802|NCT04691856|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
10192803|NCT04691856|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
10192804|NCT04682457||Late Onset|Participants diagnosed with Type 1 diabetes at over 30 years of age.
10192805|NCT04682457||18 to 30|Participants diagnosed with Type 1 diabetes between 18 and 30 years of age
10192806|NCT04675775|Experimental|Medically-tailored meals|Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than 2000 grams a day).
10192807|NCT04671966|Experimental|Fasting only|To acutely elevate myocardial triglyceride content, subjects will be asked to abstain from eating for 2 days (reproducibly causes a significant and physiological increase in myocardial fat deposition, transiently). Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
10192808|NCT04671966|Experimental|LBNP Only|Subjects undergo lower body negative pressure at 40 mmHg.
10192809|NCT04671966|Experimental|Estrogen add back with GnRHant|Subjects are given estradiol patch.
10192810|NCT04671966|Experimental|Placebo add back with GnRHant|Subjects are given placebo patch.
10192811|NCT04666688|Experimental|Part 1 dose escalation|LYT-200 in metastatic solid tumors
10192812|NCT04666688|Experimental|Part 2 dose expansion|LYT-200 in select metastatic solid tumors, eg., pancreatic cancer, cholangiocarcinoma
10192813|NCT04653220|Other|Control 1|Glucose 25g
10192814|NCT04653220|Other|Control 2|Glucose 25g
10192815|NCT04653220|Experimental|Standard Crokao|Commercially available snack bar
10192816|NCT04653220|Experimental|Low sugar variant 1|Low sugar snack bar with sticky rice
10192817|NCT04653220|Experimental|Low sugar variant 2|Low sugar snack bar with promitor
10192818|NCT04653220|Experimental|Low sugar variant 3|Low sugar snack bar with inulin
10192819|NCT04653220|Experimental|Low sugar variant 4|Low sugar snack bar with yellow soy
10192820|NCT04653220|Experimental|Low sugar variant 5|Low sugar snack bar with rice syrup
10192821|NCT04649021|Experimental|BNT162b2 18-85 years of age|
10192822|NCT04649021|Placebo Comparator|Placebo 18-85 years of age|
10192823|NCT04648709||asymptomatic patients|asymptomatic patients with PCR-positive PCR
10192824|NCT04648709||mild symptoms patients|patients with mild symptoms and PCR positive
10192825|NCT04648709||seriously symptomatic patients|seriously symptomatic patients with PCR positive
10192826|NCT04648709||patients in resuscitation|patients in resuscitation with positive PCR
10192827|NCT04648709||heathly volunteer|heathly volunteer as control
10192828|NCT04647617|Experimental|Quantitative Weight-bearing|Experimental wearing 0.5 kg quantitative sandbag 12~15 Repetitions/set X 5 set X 3day. Weight adjustment: After the first month of intervention, if the experimental can perform for more than 20 repetitions/set , we will asked to increase the weight of the sandbag to 1 kg until the end of the experiment
10192829|NCT04647617|Placebo Comparator|Control group|They are keep their normal live style
10192830|NCT04647032|Experimental|Theta Stimulation Group|This group will receive 6 Hz (theta) stimulation
10192831|NCT04647032|Active Comparator|Delta Stimulation Group|This group will receive 1 Hz (delta) stimulation
10192832|NCT04646499|Experimental|Gamma Stimulation Group|This group will receive gamma stimulation
10192833|NCT04641637|Other|Selective catheterization of segmental or more peripheral arteries in TACE|From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders.
10192834|NCT04632459|Experimental|pembrolizumab plus ramucirumab|"Ramucirumab 8mg/kg on q2W~Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles"
10192835|NCT04630717|Active Comparator|control group|normal discussion before general anesthesia induction
9979643|NCT01384006||Study|recipients of extended donor criteria pancreas allografts
10192836|NCT04630717|Active Comparator|Hypnosis group|hypnosis session before general anesthesia induction
10192837|NCT04630249|Experimental|Listening to Women|This group will receive text-message based SBIRT with phone based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, other drugs including prescription medication), and domestic violence.
10192838|NCT04630249|No Intervention|Treatment as Usual|This group will receive in-person screening and referral to treatment assessment. The same screening tools are used to assess substance abuse and mental health problems in LTW and TAU groups.
10192839|NCT04626921|Experimental|Active treatment with 30 mg of CNM-Au8|Highly pure elemental Au nanocrystals are suspended in deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) concentrated up to 0.5 mg/mL (500 ppm) Au.
10192840|NCT04599036|Experimental|Feasibility|To explore if the feasibility of adding an EMG controlled device to the acute rehabilitation for stroke subjects with severe arm deficit.
10192841|NCT04596163|Active Comparator|Intervention|Ultrasound guided Regional block using 0.25% levobupivacaine (local anaesthetic agent) 20ml (50mg) on each side of the sternum over 1-2 minutes after general anaesthesia before surgery.
10192842|NCT04596163|Placebo Comparator|Control|Ultrasound guided Regional block using 20ml of 0.9% normal saline on each side of the sternum after general anaesthesia before surgery.
10192843|NCT04593901|Other|Video and App Review|Single arm study in which home healthcare workers review and provide feedback on scripts and/or videos and on the usefulness, usability, and desirability of an interactive app in an iterative, participatory manner.
10192844|NCT04590430|Experimental|HFB30132A|Participants will receive HFB30132A administered across 3 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
10192845|NCT04590430|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
10192846|NCT04587661|Active Comparator|off-the-shelf digital CBT|standard implementation strategy that has no content or references to SCD, chronic pain, or the unique challenges facing minority groups
9705734|NCT04687618|Active Comparator|Manual Control of FiO2|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
10192847|NCT04587661|Experimental|adapted digital CBT|has content or references to SCD, chronic pain, and the unique challenges facing minority groups
10192848|NCT04586556|Experimental|Artificial intelligence for real-time detection and monitoring of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information on the detection of polyps, follow-up and prediction of pathology. The full-length colonoscopy videos will be annotated for the exact time of the identification of the anatomical landmarks, polyps, also for polyp- and procedural-related characteristics.
9705735|NCT04687384|Experimental|Robotic-assisted surgery|Patients undergoing robotic-assisted colectomy for colonic neoplasm
9705736|NCT04687384|Active Comparator|Laparoscopy|Patients undergoing conventional laparoscopic colectomy for colonic neoplasm
9705737|NCT04687293|Experimental|HUBER|"HUBER is an isometric strengthening device. It consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed.~Intervention will consist of 2 sessions of HUBER per week. Each session lasts approximatively 30 minutes. The intervention is 8 weeks long."
9705738|NCT04687293|No Intervention|Control|The control group will not received any intervention except usual care.
9705739|NCT04687241|Experimental|Almonertinib|
9705740|NCT04687241|Placebo Comparator|Placebo Almonertinib|
9705741|NCT04687332|Experimental|plasma exchange|patients were treated with plasma exchange
9705742|NCT04687332|Experimental|immunadsorption|patients were treated with immunadsorption
9705743|NCT04687488|Other|Fluorescein|"Fluorescein dye and ultraviolet (UV) light are used to assess the aerosol contamination during endonasal investigations. We will dilute medical fluorescein vials (FLUORESCEINE 10% Faure; SERB, 40 Avenue George V, 75008 Paris, France) to a concentration of 1% fluorescein in 10ml of normal saline solution. Next, we swab the nasal cavity with a compress soaked (15 droplets with a pipette) in fluorescein and we apply 5 droplets into the nasal cavity and nasopharynx at the beginning of the investigation.~After coating the nose with fluorescein, the patient will wear a surgical nose-mouth mask and will be positioned in the bed used for HRiM or MII-pH probe insertion. As the MII-pH probe is removed 24h after placement of the probe, prior to this activity the same fluorescein application method (fluorescein drops and a cotton swab) will be used."
9705744|NCT04687826||Pancreaticoduodenectomy in 2015|Patients who underwent pancreaticoduodenectomy in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique. Most of the patients spent the first postoperative night in ICU where the monitoring of urine output and fluid balance are more specific than in a normal ward.
10192849|NCT04581382|Experimental|Treatment (radiation therapy, plasma exchange, immunotherapy)|Patients undergo radiation therapy daily on days 1-5 (weekdays). Patients then undergo therapeutic plasma exchange over 1-2 hours on days 4-6 or 5-7. Beginning on day 7, patients receive pembrolizumab IV or nivolumab IV. Treatment with pembrolizumab continues every 3 weeks or treatment with nivolumab continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
9705745|NCT04687826||Pancreaticoduodenectomy in 2017|Patients who underwent pancreaticoduodenectomy in 2017 got liberal intraoperative fluid therapy and most of the patients spent the first postoperative night in a regular ward.
9705746|NCT04687397||Disorders of consciousness|Patients diagnosed as either in a Vegetative State or in a Minimally Conscious State
9705747|NCT04687410|Active Comparator|FNA|
9705748|NCT04687410|Experimental|FNB|
9705749|NCT04687345||Propeller Flap|The propeller flap is based on a perforator that serves as a pivot joint, allowing the flap to rotate up to 180°. It provides the advantages of greater freedom of movement and versatility in flap design.
9705750|NCT04687345||Rotation Flap|The rotation flap is primarily supplied by the perforator artery accompanied by the random supply from the skin base. It is also associated with a lower venous congestion risk.
9705751|NCT04687423|Experimental|Experimental: phase I dose exploration|FCN-011 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
9705752|NCT04687449|Active Comparator|Active Comparator: Curcumin therapy added to standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
9785154|NCT01244243|Experimental|Active therapy|All subjects receive the same active robotic therapy, there is no placebo arm, as a key goal of this study is to define predictors of response to active treatment.
10192850|NCT04579679|Experimental|Surufatinib|"Cohorts A, B, and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1~Cohort D:~Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1"
10192851|NCT04577352|Experimental|Vatiquinone|Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if ˂12 years of age and weighing ˂25 kilograms (kg) or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 72 weeks during the placebo-controlled phase and for 24 weeks during the open-label extension phase.
10192852|NCT04577352|Placebo Comparator|Placebo|Participants will receive placebo matching to vatiquinone (per age and weight) orally TID for 72 weeks during the placebo-controlled phase and vatiquinone at a dose of either 200 mg orally TID if ˂12 years of age and weighing ˂25 kg or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 24 weeks during the open-label extension phase.
10192853|NCT04572126|Experimental|Mindfulness Group|Participants in the mindfulness group will receive mindfulness based instructions.
10192854|NCT04572126|Active Comparator|Control Group|Participants in the control group will receive instructions to cope with cravings how they normally would.
9705753|NCT04687449|Active Comparator|Active Comparator: Placebo with Standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
9705754|NCT04687202||Patients developing CA|Including patients developing intraoperative cardiac arrest during transcatheter aortic valve implantation from January 2014 to May 2019
9705755|NCT04687189|Experimental|Women with a known history of submucosal fibroids|
9705756|NCT04687189|Experimental|Women recruited from a general population subject to I/E criteria|
9705757|NCT04687306||Females|15 females
9705758|NCT04687306||Males|15 Males
9705759|NCT04687111|Active Comparator|Control|Valsartan 40mg bid titrated to maximum dose of 160mg bid
9705760|NCT04687111|Experimental|Intervention|Sacubitril/Valsartan 50mg bid titrated to maximum dose of 200mg bid
9705761|NCT04686890|Active Comparator|postoperative opiod (morphine) consumption|patient-controlled analgesia (15 minutes. lock time, 2 ml bolus= total 1 mg morphine intravenously, limited to maximum 4 bolus / per hour )
9705762|NCT04686890|Active Comparator|peroperative continuous opioid (remifentanil) consumption|continuous remifentanil infusion was given during the whole procedure
9705763|NCT04686890|Active Comparator|postoperative numerated rating scale|at the 1, 3, 6, 12 and 24 th hour postoperatively - numerated rating scale score was evaluated and recoded as 0= no pain (better), 10: unbearable pain (worse)
9705764|NCT04687176|Experimental|Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)|"Induction: Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and Ascorbic acid 1g daily for 42 days Consolidation: ral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles.~Maintenance: Oral Arsenic trioxide 10mg daily, ATRA (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 2 weeks every 8 weeks for a total of 2 years (i.e. for 12 cycles in total)."
9705765|NCT04686877|Experimental|STAPLE group|For patients in STAPLE group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided aspiration followed by urokinase clot irrigation (every 12 h for up to 5 days or until reduction of ICH to ≤10 mL). CT will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset. On the 1st, 3rd, 5th, and 7th day of post-operation, patients will be re-examined using CT. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
9705766|NCT04686877|No Intervention|Conservative treatment group|We used the 2015 ASA/AHA and 2020 Chinese multidisciplinary expert consensus recommendations for treatment of spontaneous intracerebral hemorrhage, including a standard approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacological treatment of intracranial mass effect. Patients allocated to the standard medical care group had follow-up CT scans and other monitoring assessments on the same schedule as those in the STAPLE group. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
9705767|NCT04686955|Experimental|Group A|Group A will receive Xiao-Xian-Gui-Fu-Tang three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 6 weeks. Post-follow-up will be 4 weeks later.
9705768|NCT04686955|Placebo Comparator|Group B|Group B will receive a placebo three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the Xiao-Xian-Gui-Fu-Tang for another 6 weeks. Post-follow-up will be 4 weeks later.
9705769|NCT04687150|Active Comparator|The study group|The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit
9705770|NCT04687150|Placebo Comparator|The control group|The control group will be given colored water at same timepoints
9705771|NCT04687163|Experimental|OXA 130|Patients received sorafenib or lenvatinib Plus HAIC of 130 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
10192855|NCT04567667|Experimental|Group 1|
10192856|NCT04567667|Experimental|Group 2|
10192857|NCT04552470|Placebo Comparator|Placebo|
10192858|NCT04552470|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
9705772|NCT04687163|Active Comparator|OXA 85|Patients received sorafenib or lenvatinib Plus HAIC of 85 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
9705773|NCT04686981||mesenteric artery thromboembolism patients without intestinal necrosis|After laparoscopic exploration, If there is no intestinal necrosis, minimally invasive intravascular thrombus aspiration treatment will be performed,
10192859|NCT04552470|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
10192860|NCT04552470|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
10192861|NCT04544410|Experimental|Tildacerfont Group|Tildacerfont administered daily via oral tablet for 76 weeks at dose level 1.
9705774|NCT04686981||mesenteric artery thromboembolism patients with intestinal necrosis|After laparoscopic exploration, If intestinal necrosis occurs, open surgery, mesenteric artery embolectomy and necrotic bowel resection, intestine fistula will be performed.
9705775|NCT04686851|Experimental|Intervention|Comprehensive Geriatric Assessment and follow-up as add on to standard oncologic care
9705776|NCT04686851|No Intervention|Control|standard oncologic care according to national guidelines
9705777|NCT04686994|Experimental|ASC41|ASC41 two tablets, once daily, from Day 1 to Day 28.
9705778|NCT04686994|Placebo Comparator|ASC41 placebo|ASC41 placebo two tablets, once daily, from Day 1 to Day 28.
9705779|NCT04686812|Experimental|Worksite health promotion program|Participants had a baseline health risk assessment (HRA) after which they were invited to participate in a workplace health promotion program. The intervention lasted six months and included the following components: nutrition counseling, physical activity, and stress management. HRAs were performed 6 and 12 months after intervention onset.
9705780|NCT04686812|No Intervention|Control|Participants only had a baseline and follow-up health risk assessments at 6 and 12 months.
9705781|NCT04686929|Experimental|Cohort 1|The participants in Cohort 1 will receive a lower dose of abatacept s.c as maintenance
9705782|NCT04686929|Experimental|Cohort 2|The participants in Cohort 2 will receive a higher dose of abatacept s.c as maintenance
9705783|NCT04687124|Active Comparator|Fish oil|dietary counselling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
9705784|NCT04687124|Placebo Comparator|standard care|The departmental usual procedure with the possibility of requiring of a dietician when needed
9705785|NCT04686968|Experimental|Greenhouse group|Patients underwent greenhouse technique：The high-strength suture was passed through the tendon using Mason-Allen method, and then Crimson duvet procedure was performed on the foot print area from the articular surface of the humeral head to the apex of the greater tubercle. Immediately after this procedure, a lateral row anchor was used.
9705786|NCT04686968|Active Comparator|Vent group|The three-line anchor suture method is the same as before, the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
9705787|NCT04686942||Before sonazoid|US detection liver metastases before sonazoid
9705788|NCT04686942||After sonazoid|US detection liver metastases after sonazoid
9705789|NCT04687085|Placebo Comparator|Neutral Content|Participants will listen to a 10 minute neutral content recording just prior to epidural catheter placement.
9705790|NCT04687085|Experimental|Mindful Meditation|Participants will listen to a 10 minute mindful meditation recording just prior to epidural catheter placement.
9705791|NCT04687098|Other|Risk-adapted postremission treatment.|Induction (idarubicin, cytarabine), first consolidation (high dose cytarabine), risk- stratification: allogeneic matched related or unrelated donor transplant vs. consolidation courses.
9705792|NCT04686695|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation|
9705793|NCT04686916|Experimental|IP2018_dose 1|IP2018_dose1
9705794|NCT04686916|Experimental|IP2018_dose 2|IP2018_dose2
9705795|NCT04686916|Placebo Comparator|Placebo|Placebo
9705796|NCT04686747||Esophageal Cancer|
9705797|NCT04686747||Gastric Cancer|
9705798|NCT04686747||Pancreatic Cancer|
9705799|NCT04686747||Colorectal Cancer|
9779003|NCT01120639|Experimental|Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
9779004|NCT01120639|Experimental|Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
9779005|NCT01120639|Experimental|Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
9779006|NCT01120691|Experimental|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
9779007|NCT01120691|Active Comparator|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
9779008|NCT01120691|Active Comparator|open-label tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
9779009|NCT01120704|Experimental|1, 26Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779010|NCT01120704|Experimental|2, 26Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779011|NCT01120704|Experimental|3, 26Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779012|NCT01120704|Experimental|4, 26Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9705800|NCT04686760|Experimental|Nitroglycerin solution|
9705801|NCT04686760|No Intervention|standard solution|
9705802|NCT04686721||Patients at risk of developing tracheal stenosis after prolonged intubation or tracheostomy|Patients older than 18 years of age who underwent either prolonged intubation or tracheostomy will be enrolled. A minimum of 2 months follow-up from hospital discharge is required. Patients tested negative for SARS-CoV-2 will be used as a control group
9705803|NCT04686539|Experimental|Recipients of CBD oil|Patients receiving Cannabidiol oil drops, administered sublingual, 3 times a day, while hospitalized. Dosing and administration frequency would be assessed bi-daily by the medical staff.
9705804|NCT04686539|Placebo Comparator|Recipients of Placebo|Patients receiving placebo oil, administered sublingual, 3 times a day, while hospitalized.
9705805|NCT04686448|Active Comparator|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
10192862|NCT04544410|Placebo Comparator|Placebo|Placebo administered daily via oral tablet for 24 weeks.
9705806|NCT04686448|Active Comparator|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
9705807|NCT04686825|Experimental|T1|DA-8010 2.5 mg (Fasting)
10192863|NCT04541225|Experimental|Phase 1 Dose Escalation|NUV-422 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.
10192864|NCT04541225|Experimental|Phase 2 Dose Expansion|NUV-422 will be administered at the recommended Phase 2 dose (RP2D).
10192865|NCT04541225|Experimental|Phase 1 Surgical Substudy for Recurrent Glioblastoma|"For subjects with pre-planned surgery per standard of care:~NUV-422 will be administered before surgery for the experimental group~No study treatment will be administered before surgery for the control group.~All patients will be offered NUV-422 post surgery and recovery, if deemed eligible."
10192866|NCT04540445||Concussed Cohort|The concussed cohort will consist of children ages 5-17 diagnosed with a concussion within 72 hours following injury and recruited from a pediatric emergency department.
10192867|NCT04540445||Healthy Matched Controls|The healthy matched control cohort consists of children 5-17, who are age and gender matched to concussed subjects who will be recruited from affiliated pediatric primary care and adolescent clinics.
9705808|NCT04686825|Experimental|T2|DA-8010 2.5 mg (Fed)
9705809|NCT04686825|Experimental|T3|DA-8010 5 mg (Fasting)
9705810|NCT04686825|Experimental|T4|DA-8010 5 mg (Fed)
9705811|NCT04686578||Fibromyalgia group|Diagnosed as Fibromyalgia according to American College of Rheumatology Fibromyalgia 2018 classification criteria over 1 year, and disease activity was stabil with the same drug at least 3 months.
10192868|NCT04540302|Experimental|AVF Peripheral study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
10192869|NCT04540302|Other|AVF Peripheral control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
10192870|NCT04540302|Experimental|AVG Anastomosis|All subjects in this single arm cohort will receive treatment with the WRAPSODY Endovascular Stent Graft
10192871|NCT04540302|Experimental|AVF/AVG Central study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
10192872|NCT04540302|Other|AVF/AVG Central control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
10192873|NCT04534218|Experimental|Experimental|"REGORAFENIB:~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.~METRONOMIC CHEMOTHERAPIES:~Capecitabine: 625mg/m²/orally twice daily continuously for 6 months~Cyclophosphamide: 50 mg per os, daily, for 6 months~ASPIRIN:~75 mg orally and daily until progression"
10192874|NCT04531215|Active Comparator|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
10192875|NCT04531215|Active Comparator|ultrasound guided erector spinae|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
9705812|NCT04686578||Control Group|The participants who have no physicological or severe musculoskeletal, rheumatologic diseases.
10192876|NCT04528082|Experimental|Apremilast|Participants will receive apremilast orally in the double-blind 12 week treatment phase. Then the participants will continue to receive apremilast in the active 40 weeks treatment phase.
9705813|NCT04686552|Experimental|cinnamon|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served with 6 g of ground cinnamon.
9705814|NCT04686552|No Intervention|control|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served without 6 g of ground cinnamon
9705815|NCT04686617|No Intervention|No-force group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction on one side and the other side was used as the premolar tooth control group. Oral B HummingBird device (Procter&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks. At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
9779013|NCT01120704|Experimental|5, 26Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9705816|NCT04686617|Active Comparator|Force Group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction to one side and the other side was used as the premolar tooth control group. As in no-force group, same device procedure was used for the application of vibration. Self-ligating Speed (Strite Industries, Cambridge, Ontario, Canada) tubes and brackets with 0.022×0.026 inch slots were bonded to the buccal surfaces of the right and left first molar teeth and first premolar teeth.150g of buccally directed forces, producing by a 0.017×0.025-in beta-titanium-molybdenum alloy (3M Unitek, Monrovia, Calif) cantilever spring, were applied to premolar teeth on both side.The force magnitude was measured with a strain gauge (Dentaurum). At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
9705817|NCT04686708||Pre-pandemic period|Patients managed in the pre-pandemic period
9705818|NCT04686708||Pandemic period|Patients managed in the pandemic period
9705819|NCT04686656|Active Comparator|nasal oxygen supplementation group|supplemental oxygen will be administered with nasal cannula
9705820|NCT04686656|Active Comparator|buccal oxygen supplementation group|supplemental oxygen will be administered with Ring-Adair-Elwyn (RAE) tube
9705821|NCT04686513||Obese young adult|
9705822|NCT04686513||Non Obese young adult|
9705823|NCT04686474|Experimental|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment will be used twice daily for 12 weeks
9705824|NCT04686604|Experimental|Electron Health Record-based Provider Alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
10192877|NCT04528082|Placebo Comparator|Placebo to Apremilast|Participants will receive the matching placebo orally in the double-blind 12 week treatment phase. Then the participants will receive apremilast in the active 40 weeks treatment phase.
9705825|NCT04686604|No Intervention|Usual Care|Providers will not receive an alert and will proceed with usual care.
9705826|NCT04686643|Experimental|Treatment|AGSAVI
9705827|NCT04686643|Active Comparator|Reference|AGLS
9705828|NCT04686630||Single group|Only observational study
9705829|NCT04686344|Active Comparator|Hypertonic saline continuous infusion Group|will receive Hypertonic saline continuous infusion
9705830|NCT04686344|Active Comparator|Hypertonic saline intermittent boluses Group|will receive Hypertonic saline intermittent boluses for 48 hours
9705831|NCT04686500|Other|Deep Inspiration Breath-hold (DIBH) Respiratory Motion|DIBH qualified patient will experience one high-resolution CT scan as SOC and additional 3 low resolution/lower dose CT scans to further investigate inter-DIBH patient surface and tumor position stability and repeatability
9705832|NCT04686669|Experimental|Subjects receiving treatment sequence ABC|Subjects will receive treatment sequence ABC on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
9705833|NCT04686669|Experimental|Subjects receiving treatment sequence BCA|Subjects will receive treatment sequence BCA on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
9705834|NCT04686669|Experimental|Subjects receiving treatment sequence CAB|Subjects will receive treatment sequence CAB on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
9705835|NCT04686669|Experimental|Subjects receiving treatment sequence ACB|Subjects will receive treatment sequence ACB on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
9705836|NCT04686669|Experimental|Subjects receiving treatment sequence BAC|Subjects will receive treatment sequence BAC on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
9705837|NCT04686669|Experimental|Subjects receiving treatment sequence CBA|Subjects will receive treatment sequence CBA on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
9705838|NCT04686396|Experimental|Interpositional Group|Demineralized bone matrix
9705839|NCT04686396|No Intervention|Control|Without demineralized bone matrix
9705840|NCT04686591|Experimental|AZD9977|"In Period 1, one 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capsules) and one 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL).~In Period 2, one 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)."
10192878|NCT04509791|Placebo Comparator|placebo|placebo arm
10192879|NCT04509791|Active Comparator|2.5 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
9705841|NCT04686357|Experimental|Intervention group (mET)|Microbiome-driven embryo transfer of a single vitrified blastocyst in an HRT cycle according to the EMMA/ALICE test results.
9705842|NCT04686357|Active Comparator|Control group (FET)|Frozen embryo transfer of a single vitrified blastocyst in an HRT cycle according to the clinical standard practice.
9705843|NCT04686461|Experimental|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment dose- twice daily for 12 weeks
9705844|NCT04686162|Experimental|Group using the smartphone application bae|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months.
9705845|NCT04685954|Experimental|Bulk-Fill|Filtek™ Bulk Fill Posterior, 3M ESPE, St. Paul MN, USA (FB)
9705846|NCT04685954|Experimental|Incremental|Filtek Ultimate Universal, 3M ESPE, St. Paul MN, USA (FU)
9705847|NCT04686370|Active Comparator|sandblasted acid-etched implants|implant will be installed intraforaminal
10192880|NCT04509791|Active Comparator|1.5 mg ATG/kg|the next two cohorts of 12 participants will be randomised to placebo, 2.5 mg/Kg, and 2 specified middle ATG total doses in a 1:1:1:1 allocation ratio
10192881|NCT04509791|Active Comparator|0.5 mg ATG/kg|The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg and a single selected middle ATG total dose in a 1:1:1 allocation ratio
10192882|NCT04509791|Active Comparator|0.1 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
10192883|NCT04506463|Experimental|Arm A|MM-II 1 ml
10192884|NCT04506463|Experimental|Arm B|MM-II 3 ml
10192885|NCT04506463|Experimental|Arm C|MM-II 6 ml
10192886|NCT04506463|Placebo Comparator|Arm 4|Placebo 1ml
10192887|NCT04506463|Placebo Comparator|Arm 5|Placebo 3ml
10192888|NCT04506463|Placebo Comparator|Arm 6|Placebo 6ml
10192889|NCT04492605|Placebo Comparator|Placebo|Placebo
9705848|NCT04686370|Experimental|laser treated implants|implant will be installed intraforaminal
9705849|NCT04686006||Graves disease|
9705850|NCT04685980||Failed spinal anaesthesia group|Failed spinal anaesthesia: failure of anaesthetic level of blockade both sensory and motor blockage, and consequently receive general anaesthesia
9705851|NCT04685980||Control Group|Patient receiving spinal anaesthesia and successfully finish the cesarean section
9705852|NCT04686071|Experimental|PNF method|
9705853|NCT04686071|Other|standard rehabilitation|
9705854|NCT04686084|Experimental|CT scan|CT scan (MDCT, standard of care) and DE-CBCT (Investigational)
9705855|NCT04686019|Experimental|Intervention group|"2 x IMT (5-10 min) 2 times a day 7 days a week for 3 weeks with or without supervision~Log-book~Conventional neurorehabilitation"
9705856|NCT04686019|Active Comparator|Control group|Conventional neurorehabilitation
9705857|NCT04686058|Active Comparator|TCI propofol|Target controlled infusion propofol titrated by the investigator intra-procedure, based on the Modified Observer's Assessment of Alertness and Sedation Scale
10192890|NCT04492605|Experimental|TCI378 Probiotics|TCI378 Probiotics
10192891|NCT04492605|Experimental|TCI507 Probiotics|TCI507 Probiotics
10192892|NCT04469907|Experimental|Treatment - AZD9977|There are 4 cohorts in this arm based on renal function (mild, moderate, severe, and normal). Each cohort will have 8 participants.
10192893|NCT04457336|Experimental|Tildacerfont Group 1|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1
10192894|NCT04457336|Experimental|Tildacerfont Group 2|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2
10192895|NCT04457336|Experimental|Tildacerfont Group 3|Tildacerfont administered daily via oral tablet for 70 weeks at dose level 3
10192896|NCT04457336|Placebo Comparator|Placebo|Placebo administered daily via oral tablet for 12 weeks.
10192897|NCT04401059|Experimental|Elemene plus First or Third generation EGFR-TKIs|Elemene Injectable Emulsion sequentially with Elemene Oral Emulsion plus First -generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib) or Third-generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib).
10192898|NCT04401059|Active Comparator|First or third generation EGFR-TKIs only|First-generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib) or third-generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib).
9705858|NCT04686058|Active Comparator|PCS propofol|Patient-controlled sedation titrated by the patient to comfort level
9705859|NCT04686058|Active Comparator|midazolam and pethidine|Midazolam and pethidine bolus doses administered by the investigator based on clinical parameters and observation
9705860|NCT04685967|Experimental|Glass-ionomer|Equia Forte HT, GC, Tokyo, Japan (EHT)
9705861|NCT04685967|Experimental|Bulk-Fill|SonicFill2, Orange, CA, USA (SBF)
9705862|NCT04685915|Experimental|Ibrutinib + Copanlisib|"During 28 day study treatment cycle, participants will:~Take Ibrutinib daily at predetermined dose for as long as there are no serious side effects and disease progression~Receive intravenous infusion of Copanlisib at a predetermined dose days 1, 8 and 15 for cycles 1-6."
9705863|NCT04685928|Experimental|MRI arm|MRI prostate with contrast, followed by MRI-guided biopsy under local anaesthesia only if MRI show suspicious lesion. Men with non-suspicious MRI will not receive a biopsy.
9705864|NCT04685928|Active Comparator|TP-arm Systematic biopsy|24-core Systematic transperineal prostate biopsy under local anaesthesia
9705865|NCT04686149||Neo CCRT+Neo CTx +/- cystectomy|Patients receive neoadjuvant CCRT and neoadjuvant CTx. Radical cystectomy is performed depending on pathologic response. The patients showing clinical complete response after neoadjuvant CCRT and initially stage T2N0M0 are not treated with neoadjuvant chemotherapy.
9705866|NCT04686123|Experimental|Group A|Group A performed active Stretching of Pectoralis Minor (PMi) muscle along with the strengthening of Lower Trapezius muscle under the supervision of a physiotherapist
9705867|NCT04686123|Active Comparator|Group B|Group B performed active Stretching of the Pectoralis Minor (PMi) muscle only under the supervision of a physiotherapist.
9705868|NCT04686110|Other|Patients Amyotrophic Lateral Sclerosis|
9705869|NCT04686110|Other|Control subjects|
9705870|NCT04686214|Experimental|study group|
9705871|NCT04686214|No Intervention|control group|
9705872|NCT04686032|Experimental|Advanced Rehab Group|The experimental group will receive early physical therapy interventions including patient education, ambulation, in-bed exercises, deep breathing exercises, connective tissue manipulation and TENS during the first 3 post-operative days following abdominal hysterectomy
10192899|NCT04331236|Experimental|Patient and Caregiver Intervention|Patient and Caregivers receive both cognitive behavioral intervention and yoga interventions each week, for 7 weeks.
10192900|NCT04304534|Experimental|BAY 2433334 high dose|
10192901|NCT04304534|Experimental|BAY 2433334 medium dose|
10192902|NCT04304534|Experimental|BAY 2433334 low dose|
10192903|NCT04304534|Placebo Comparator|BAY2433334 matching placebo|
9705873|NCT04686032|Active Comparator|Early ambulation Group|Participants of this group will receive patient education and early ambulation during the first 3 post-operative days following abdominal hysterectomy
9705874|NCT04686253||PFO patients with CS or/and TIA|PFO patients with CS or/and TIA (transcatheter closure of PFO was performed).
10192904|NCT04301765|Experimental|testosterone 1.62% gel|Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
9705875|NCT04686253||PFO patients with migraine|PFO patients with migraine (transcatheter closure of PFO was performed).
9705876|NCT04686253||PFO patients without symptom|PFO patients without symptom (5-year follow-up).
9705877|NCT04686201|Experimental|intervention group|
9705878|NCT04686201|No Intervention|control group|
9705879|NCT04686097|Experimental|experimental group (electrocoagulation)|Participants in the experimental group will receive ultrasound-guided puncture of coagulation incompetent perforator veins.
9705880|NCT04686097|Active Comparator|control group (sclerotherapy)|Participants in the control group will receive an ultrasound-guided sclerosing agent injected.
9705881|NCT04685798|Experimental|DWI MRI|-The patients will undergo an optimized research neck DWI MRI, up to 3 weeks post-treatment and then a standard-of-care 3-month post-treatment FDG PET/CT examination.
9705882|NCT04685512|Experimental|TDF / FTC|2 tablets on Day-1 then 1 tablet/day for 6 days
9705883|NCT04685512|No Intervention|usual care|Standard of Care
9705884|NCT04685642|No Intervention|non-drug|
10192905|NCT04301765|Placebo Comparator|placebo gel|The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
10192906|NCT04296799|Experimental|Single Ascending Dose|The study will consist of 6 cohorts (1 cohort per dose level) of 8 subjects (6 subjects receiving the study drug and 2 receiving matching placebo), for a total of 48 subjects.
10192907|NCT04296799|Experimental|Multiple Ascending Dose|The study will consist of 3 cohorts (1 cohort per dose level) of 8 subjects. Six subjects will receive study drug and 2 subjects will receive matching placebo, daily for 14 consecutive days, for a total of 24 subjects (18 study drug; 6 placebo).
10192908|NCT04280328|Experimental|Ciforadenant in combination with daratumumab|Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg.
10192909|NCT04251884|Experimental|Receiving the pudendal nerve block|
10192910|NCT04251884|Active Comparator|Not receiving the pudendal nerve block|
10192911|NCT04209660|Experimental|recurrent/metastatic adenoid cystic carcinoma (R/M ACC)|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
10192912|NCT04209660|Experimental|recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
10192913|NCT04196569||trifocal intraocular lens|
10192914|NCT04196283|Experimental|Arm 1: ABBV-368 + Tilsotolimod|Participants will be administered ABBV-368 and Tilsotolimod at various timepoints as described in the protocol.
10192915|NCT04196283|Experimental|Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel|Participants will be administered ABBV-368, Tilsotolimod and Nab-paclitaxel at various timepoints as described in the protocol.
10192916|NCT04196283|Experimental|Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181|Participants will be administered ABBV-368, Tilsotolimod, Nab-paclitaxel and ABBV-181 at various timepoints as described in the protocol.
10192917|NCT04188405|Experimental|Treatment (ponatinib, venetoclax, decitabine)|See Detailed Description.
10192918|NCT04175613|Experimental|Patients treated with Apremilast|Subjects with a weight between 20 kg to < 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
10192919|NCT04168580|No Intervention|OA- Older Athlete|Older adults who are regularly engaged in endurance exercise
10192920|NCT04168580|Active Comparator|OS- Older Sedentary|Older adults who are sedentary
10192921|NCT04165109||Trial Ready Cohort|Non-demented adults with Down syndrome (DS)
10192922|NCT04090411|Experimental|450 mg|PF-06480605
10192923|NCT04090411|Experimental|150 mg|PF-06480605
10192924|NCT04090411|Experimental|50 mg|PF-06480605
9705885|NCT04685642|Active Comparator|Aspirin|
9705886|NCT04685642|Active Comparator|Statin|
9705887|NCT04685564|Experimental|RBD1016 experiment group|Subjects in experiment groups will receive a single subcutaneous injection of RBD1016.
9705888|NCT04685564|Placebo Comparator|placebo gruop|Subjects in placebo groups will receive a single subcutaneous injection of placebo.
9705889|NCT04685434||pediatric patients diagnosed with rheumatic diseases.|The Shriners Hospital for Children Upper Extremity Evaluation, the Jebsen-Taylor Hand Function Test, and the Childhood Health Assessment Questionnaire will be administered in children with rheumatic diseases. The Shriners Hospital for Children Upper Extremity Evaluation will be administered two weeks after the first examination and the results will be compared.
9705890|NCT04685889|Active Comparator|Icon Group|Icon® resin infiltration treatment was performed on 58 permanent central teeth with MIH and evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
9705891|NCT04685889|No Intervention|Control Group|No treatment was performed on healthy teeth. However, similar to the treated teeth, 58 healthy permanent central teeth of the same individuals were evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
10192925|NCT04090411|Placebo Comparator|0 mg|
10192926|NCT04057677|Experimental|Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. We are examining the effects of a recovery exercise program for older adults with pre-diabetes and type 2 diabetes. Following 10 days of bed rest and during the first 4 weeks of recovery, participants will perform a combination of aerobic and resistance exercise training.
9705892|NCT04685733||Group 1|Comparison of blood pressure, LVET and CO/SV measures with respective Gold Standards
9705893|NCT04685733||Group 2|Comparison of blood pressure and HRV measures with respective Gold Standards
9705894|NCT04685733||Group 3|Comparison of blood pressure and CO/SV measures with respective Gold Standards
9705895|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
9705896|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 0 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
9705897|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
9705898|NCT04685603|Experimental|Experimental: AV-COVID-19 (0.1 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
9705899|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
9705900|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
10192927|NCT04057677|Experimental|Non-Exercise Recovery|Older males and females with pre-diabetes or type 2 diabetes. Participants in the ambulatory recovery group will not receive any exercise intervention or advice on exercise following 10 days of bed rest. Rather these participants will return to their regular daily routine that they engaged in prior to the bed rest intervention.
10192928|NCT04000360|Experimental|High-Intensity Exercise Group|Mild to moderate Parkinson's disease patients: The exercise group will be asked to cycle 3x/week for 12 months on a Peloton bicycle which will be delivered to their home.
10192929|NCT04000360|No Intervention|Usual and Customary Care Group|Mild to moderate Parkinson's disease patients, receiving no exercise intervention through the research. They will continue to receive usual and customary care for their Parkinson's disease during the 12 month period.
9705901|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
9705902|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
9705903|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
9705904|NCT04685447|Experimental|Expanded Hemodialysis|Hemodialysis modality performed by using a medium cut-off membrane
9705905|NCT04685447|Experimental|Protein-leaking hemodialysis|Hemodialysis modality performed by using a membrane with accentuated absorption capacities.
9705906|NCT04685824|Active Comparator|Biofeedback Training|"Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total).~30 min daily reading at home for 4 weeks."
10192930|NCT03995199||Furlow group|All cleft palate patients surgically treated with a modified Furlow technique since January 2012
10192931|NCT03995199||Furlow + Sommerlad group|All cleft palate patients surgically treated with a modified Furlow technique in combination with an intravelar veloplasty by Sommerlad
10192932|NCT03891953|Experimental|DKY709|DKY709 monotherapy
10192933|NCT03891953|Experimental|DKY709 + PDR001|Combination therapy with DKY709 and PDR001
10192934|NCT03870672|Active Comparator|CCFES + rTMS facilitating cHMC|"This rTMS paradigm is the New Approach. Facilitation of the intact hemisphere target (cHMC) will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
10192935|NCT03870672|Active Comparator|CCFES + rTMS facilitating iM1|"This rTMS paradigm is the Conventional Approach.Facilitation of M1 will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
10192936|NCT03870672|Sham Comparator|CCFES + Sham rTMS|"This rTMS paradigm is the Sham Approach. Immediately after sham rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
10192937|NCT03861143|Experimental|BT-11 low-dose (500 mg)|Oral
9705907|NCT04685824|Experimental|Biofeedback Training + Immersive VR|"Biofeedback training (BFT) [1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks], 1 session per week for 4 weeks (4 sessions total).~30 min daily reading at home for 4 weeks~Immersive virtual-reality stimulation (IVR) [1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks], 1 session every 2 days for 4 weeks (14 sessions total)."
9705908|NCT04685837|Experimental|Tele-rehabilitation group|The participants randomly assigned to the tele-rehabilitation group will use a computer application to know and execute the exercise protocol. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the application works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
9779014|NCT01120704|Experimental|6, 26Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
10192938|NCT03861143|Experimental|BT-11 high-dose (1,000 mg)|Oral
9705909|NCT04685837|Experimental|Face to face group|Participants randomly assigned to the face-to-face group will use the physical therapy clinic to do the exercises controlled by the principal investigator. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the protocol works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
9705910|NCT04685499|Experimental|Telomelysin (OBP-301)|All patients will receive intratumoral injection(s) with OBP-301. If tolerated and no progression is observed, up to twelve injections may be given in each patient.
9705911|NCT04685694|No Intervention|Expectant|No medication is assigned.
9705912|NCT04685694|Experimental|Medical|SL 800 mcg Misoprostol
9705913|NCT04685720|Experimental|Inhaled NO delivered using LungFit|Inhaled Nitric Oxide in doses up to 250 ppm
9705914|NCT04685538|Experimental|Chloroprocaine 3%|All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.
10192939|NCT03861143|Placebo Comparator|Placebo|Oral
10204554|NCT05201833||Abbreviated Assessment Battery (AAB)|Participants who do not have decision-making capacity will be asked to complete a modified assessment battery, called the Abbreviated Assessment Battery (AAB). The AAB in-person assessment will administer the Speech Intelligibility, GOAT, and CAP and/or CRS-R to study participants.
9705915|NCT04685538|Active Comparator|Tetracaine 0.5%|All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.
9705916|NCT04685707|Active Comparator|Active-Sedentary Control|
9705917|NCT04685707|Experimental|Active-Sedentary Experimental|
9705918|NCT04685551|Experimental|Survivorship Management among African American and Latinx Cancer Dyads|"This arm will implement a one group pre-test and posttest design to improve health outcomes of African American and Latinx cancer survivors and caregivers in collaboration with health professional students trained as Cancer Survivorship and Caregiver Leaders Aimed for Minority Populations (CSC LAMPs)."
9705919|NCT04685460|Experimental|3D-printed bolus|
9705920|NCT04685460|No Intervention|Conventional bolus|
9705921|NCT04685395|Active Comparator|Benzydamine hydrochloride|"group I ( benzdymine HCL ); subject will be instructed to use Benzydamine hydrochloride gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dose :5 ml every time dosage form ; mouth wash"
9705922|NCT04685395|Active Comparator|Rebamipide|"group II ( rebamipide) :subject will be instructed to use Rebamipide gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dosage form ; mouth wash"
9705923|NCT04685148|Experimental|Intervention|Estradiol patches (200 μg per day) 0-3 weeks postpartum.
9705924|NCT04685148|Placebo Comparator|Placebo|Placebo patches (Coloplast Comfeel) for 0-3 weeks postpartum
9705925|NCT04685096||Asian skin|Twice-daily application for 55 Days
9705926|NCT04685096||African-American skin|Twice-daily application for 55 Days
9705927|NCT04685161|Experimental|Surgical extrusion|Novel and alternative treatment option for horizontal crown root fractured maxillary incisors
9705928|NCT04685161|Active Comparator|Fibre post|Treatment modality normally used for crown-root fractured tooth
9705929|NCT04685330||Adult patients undergoing an ultrasound-guided procedure|Adult patients undergoing an ultrasound-guided procedure, such as paracentesis, thoracentesis, or biopsy
10204555|NCT05201820|No Intervention|Standard of care|Epidural analgesia
10204556|NCT05201820|Experimental|Cryoanalgesia|Cryoanalgesia
9705930|NCT04685252|Experimental|Pre-Partum and Post-Partum (BL) NCC3001|One stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
10204557|NCT05201677|Experimental|High myopia with axial length between 26 mm and 28 mm|The patients' axial length is between 26 mm and 28 mm
10204558|NCT05201677|Experimental|High myopia with axial length more than 28 mm|The patients' axial length is more than 28 mm
10204559|NCT05201625|Active Comparator|control group|Healthy control group
10204560|NCT05201625|Active Comparator|ICU COVID 19 patients|ICU COVID 19 patients
10204561|NCT05201625|Active Comparator|non-ICU covid 19 patients|non-ICU covid 19 patients
10204562|NCT05201599|Experimental|Flexible ureteroscope with intelligent control of renal pelvic pressure(FURL-ICP)|Patients will be placed in supine lithotomy position with 60-90° oblique on the affected side upward. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The pressure sensory and suctioning channels are connected to the irrigation and suctioning platform.
10204563|NCT05201599|No Intervention|Traditional flexible ureteroscope(f-URL)|Each procedure is completed under general anesthesia in lithotomy position. A semi-rigid ureteroscopy is used to place a 0.032-inch guidewire. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The irrigation and suctioning platform will be not used. A 7.5 Fr flexible ureteroscopy is used to break the stone with a holmium laser (fiber diameter 200 µm). A basket is used to remove the stone fragments. A 4-6Fr ureteral stent is left for 2 weeks after the operation. Stone composition is analyzed. If the UAS is failed to be placed, ureteral stent will be placed for 2 weeks and a second stage traditional f-URL will be performed.
10204564|NCT05201586|Active Comparator|Conditional cash transfer|Investigators will randomize 15 patients into this intervention arm. All participants will undergo a semi-structured patient interview about how social needs impact health and self-perceptions of health at the time of enrollment and again in 6 months. All participants will receive a CCT after the first interview.
10204565|NCT05201586|Active Comparator|Control|Investigators will randomize 15 patients into this control arm. All participants will undergo a semi-structured patient interview about how social needs impact health and self-perceptions of health at the time of enrollment and again in 6 months.
10204566|NCT05201573||Subjects historically treated with DIAM|Subjects randomized to the DIAM arm and treated with the DIAM™ Spinal Stabilization System in the IDE study OR randomized to the Control arm and crossed over to receive treatment with the DIAM™ Spinal Stabilization System in the IDE study
10192940|NCT03800134|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy|"Durvalumab (MEDI4736) in concurrence with platinum-based chemotherapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:~carboplatin/paclitaxel~cisplatin/gemcitabine~pemetrexed/cisplatin~pemetrexed/carboplatin"
9705931|NCT04685252|Placebo Comparator|Placebo Control|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.
9705932|NCT04685252|Experimental|Post-Partum (BL) NCC3001 (Crossover Arm)|One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily for 3 months during pre-partum, followed with switch to one stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily for 3 months post-partum.
10192941|NCT03800134|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy|"Placebo in concurrence with platinum-based chemotherapy.~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:~carboplatin/paclitaxel~cisplatin/gemcitabine~pemetrexed/cisplatin~pemetrexed/carboplatin"
9705933|NCT04685018||HC|Mentally and medically healthy adults between 18 and 60 years, free from any current or previous medical or psychiatric condition.
9705934|NCT04685018||OCD|Adults between 18 and 60 years, with a diagnosis of Obsessive-Compulsive Disorder and medication-free or with stable medication regimen for at least 3 weeks prior to the study.
9705935|NCT04685031|Experimental|nitroglycerin|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
9705936|NCT04685031|Experimental|clobetasol|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
9705937|NCT04685031|No Intervention|routine|routine nursing care
9705938|NCT04685291|Active Comparator|Group 1: Control|Systemic conventional pain management. Adult patients with acute fractures of the clavicle, who are scheduled to have internal fixation of the fracture within the next 24 hours receive oral and intravenous pain management.
9705939|NCT04685291|Active Comparator|Group 2: Nerve Block|Adult patients with acute fractures of the clavicle, who are scheduled for an internal fixation of the fracture within the next 24 hours will receive an ultrasound-guided block of the supraclavicular nerves using a maximum of 3 ml of a long-acting local anesthetic. The injection is carried out directly in the emergency department following a sonographic or radiological diagnosis.
9705940|NCT04685005|Experimental|Wake up|Drinking regular formula of Wake Up
10192942|NCT03761446|Experimental|Older adults with pre-diabetes or type 2 Diabetes|Male and female older adults between the ages 65-80 with pre-diabetes or type 2 diabetes
9705941|NCT04685005|Active Comparator|Caffeine|Drinking 100mg of Caffeine
9705942|NCT04685005|Placebo Comparator|Placebo|Drinking Placebo (only water with sugar)
9705943|NCT04685005|Experimental|Wake up Double Dose|Drinking formula of Wake Up with double doses of guarana, green tea, elderberry and Fruit-up
9705944|NCT04685005|Experimental|Wake up tripple dose|Drinking formula of Wake Up with tripple doses of guarana, green tea, elderberry and Fruit-up
9705945|NCT04684966|Experimental|Experimental group (EG)|"Randomized intervention in the NMES (GE) group:~Patients in the NMES group will receive, in addition to conventional rehabilitation, combined quadriceps femoris and triceps surae NMES.~Detail of the NMES :~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (possibility of 16 electrodes).~One device per lower limb of each patient is necessary: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~Stimulation frequency: 50hz.~Pulse duration: 400 μs.~Contraction time: 6 seconds.~Rest time: 6 seconds.~The intensity must generate a visible muscular contraction and must be well supported. by the patient.~The voluntary contraction accompanies the electrical stimulation.~Surface electrode 50 × 50 mm."
9705946|NCT04684966|Sham Comparator|Control group (CG)|"Patients in the control group (GC) will receive, in addition to the classical rehabilitation, the combined sham NMES of the quadriceps femoris and triceps surae.~Detail of the NMES :~It is carried out 5 times a week for 4 weeks, supervised by a physiotherapist.~The device used will be the same as in the EG group.~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (16 electrodes can be used).~One device per lower limb of each patient is required: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~Stimulation frequency: 5hz.~Pulse duration: 100 μs.~Contraction time: 6 seconds.~Rest time: 6 seconds.~The intensity must generate a visible muscle contraction and must be well supported by the patient.~The voluntary contraction accompanies the electrical stimulation.~Surface electrode 50 × 50 mm."
9705947|NCT04685109|Experimental|Alocross|Cross-linked HA 0.2% + Aloe Vera 0.1% solution (N=40) Posology: One Drop in each eye 4 times daily for 84 days
9705948|NCT04685109|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
9705949|NCT04684836||Synchronous telemedicine alone|
9705950|NCT04684836||Telemedicine-supplemented in-person care|
9705951|NCT04684836||In-person care alone|
9705952|NCT04684732||Apixaban dose concordant to leaflet|Patients who were prescribed apixaban dose concordant to apixaban leaflet approved by Thai FDA
9705953|NCT04684732||Apixaban dose discordant to leaflet|Patients who were prescribed apixaban dose discordant to apixaban leaflet approved by Thai FDA
9705954|NCT04684888|Active Comparator|Visumax Femto-flap|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. Refractive surgery was planned for both eyes and they chose the Visumax Femto-LASIK after a complete explanation of all the possible complications, costs, and differences. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
9705955|NCT04684888|Active Comparator|Sub Bowman's keratomileusis (SBK )-Flap group|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. They chose LASIK with mechanical SBK microkeratome surgical approach to be their refractive surgery for both eyes after all the possible complications, costs and differences had been explained clearly. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
9705956|NCT04685044|Other|Healthy Volunteers|BrainPET insert
9705957|NCT04684927|Experimental|MID-C treatment|Follow-up measurements during 5 years post MIC-C system implantationin order to evaluate safety and efficacy parameters.
9705958|NCT04685083||Patients with Depression in consolidation phase|
9705959|NCT04685083||Patients with Depression in acute onset|
9705960|NCT04685083||Healthy subjects|
9705961|NCT04684797|Experimental|Intervention group|Each participant will undergo two sessions, consisting of performing the virtual T-maze task, scalp-EEG recording and/or intracranial video-EEG recording.
9705962|NCT04684992|Experimental|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
9705963|NCT04684771|Active Comparator|MYOSTIM®|MYOSTIM® 2 bars/day during 12 weeks MYOSTIM® as a food bar. Active ingredient: Pomegranate extract, L-leucine, Creatine, D3 Vitamin, Proteins IP Status: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
9705964|NCT04684771|Placebo Comparator|PLACEBO|PLACEBO 2 bars/day during 12 weeks
9705965|NCT04684784|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
9705966|NCT04684784|Placebo Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
10192943|NCT03761446|Experimental|Older adults without pre-diabetes or Type 2 Diabetes|Male and female older adults between the ages 65-80 without pre-diabetes or type 2 diabetes
9705967|NCT04684680|Experimental|zamzam water|patient will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
9705968|NCT04684680|Active Comparator|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
9705969|NCT04684693|Experimental|Laser Group|
9705970|NCT04684693|Active Comparator|Control Group|
9779015|NCT01120704|Experimental|7, 26Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779016|NCT01120704|Experimental|8, 26Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779017|NCT01120704|Experimental|9, 26Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
10192944|NCT03755414|Experimental|Pilot Study: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~Stem cell transplantation on Day 0~Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
10204567|NCT05201560|Experimental|Butorphanol tartrate|Butorphanol tartrate on the patients with mechanical ventilation
10204568|NCT05201560|Active Comparator|fentanyl|fentanyl on the patients with mechanical ventilation
9779018|NCT01120704|Experimental|10, 26Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779019|NCT01120704|Experimental|11, 26Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779020|NCT01120704|Experimental|12, 26Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9785155|NCT01244425|Experimental|FS VH S/D 500 s-apr|Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
10192945|NCT03755414|Experimental|Expansion Phase: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~Stem cell transplantation on Day 0~Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
9979644|NCT01384032|Experimental|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
10192946|NCT03708003|Experimental|venetoclax + ibrutinib|Ibrutinib lead-in followed by venetoclax plus ibrutinib administered until cycle 31. The combination treatment will be continued as maintenance treatment or stopped depending on MRD-neg CR/CRi status.
10192947|NCT03699930|Active Comparator|tDCS + speech therapy|Participants will receive 20 minutes of anodal tDCS paired with speech and language therapy over five consecutive days.
10192948|NCT03699930|Sham Comparator|sham + speech therapy|Participants will receive 20 minutes of sham tDCS paired with speech and language therapy over five consecutive days.
10192949|NCT03699865|Experimental|Purple|Participants will receive cigarettes with intermediate or very low nicotine content in purple packaging
10192950|NCT03699865|Experimental|White|Participants will receive cigarettes with intermediate or very low nicotine content in white packaging
10192951|NCT03699865|Experimental|Black|Participants will receive cigarettes with intermediate or very low nicotine content in black packaging
10192952|NCT03694405|Experimental|Group 1A|3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)
10192953|NCT03694405|Experimental|Group 1B|3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
10192954|NCT03694405|Experimental|Group 1C|3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
10192955|NCT03694405|Experimental|Group 2A|2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)
10192956|NCT03694405|Experimental|Group 2B|2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
10192957|NCT03694405|Experimental|Group 2C|2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
10192958|NCT03694405|Experimental|Group 3A|1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)
10192959|NCT03694405|Experimental|Group 3B|1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)
10192960|NCT03694405|Experimental|Group 3C|1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)
10192961|NCT03692208|Experimental|Intervention|Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
10192962|NCT03692208|Active Comparator|Delayed Intervention/Control|Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.
10192963|NCT03683823|Experimental|Attention guidance|In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
10192964|NCT03683823|Active Comparator|Control intervention|"Participants will complete two intervention sessions within one week. The intervention will use a manualized protocol.~On the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.~Participants will then have 5 minutes to plan and outline a speech based on a topic given to them. All participants will receive the same topic. Participants will not be allowed to use the outline during the public speaking exposure trials.~Participants will then give six speeches that are each 3 minutes long on the same topic. Participants will give all the speeches in the immersive 360º-video environment.~Between speeches participants will have a 1-minute break."
10192965|NCT03678506|Experimental|Positive D-Dimer|At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.
10192966|NCT03678506|No Intervention|Negative D-Dimer|Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.
10192967|NCT03677596|Experimental|Dose Level 2|Inotuzumab ozogamicin at starting dose 1.2 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
10192968|NCT03677596|Active Comparator|Dose Level 1|Inotuzumab ozogamicin at starting dose 1.8 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
10192969|NCT03662841|Other|ACE for HCC of size >10cm|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
9705971|NCT04684667|Other|Propranolol Therapy|This arm will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.
9705972|NCT04684940|Experimental|Valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg in Active Inhibitor Population (Part A) and Prior Inhibitor Population (Part B).
9705973|NCT04684433||Surgical intervention|Patients who had a surgical procedure since the start of the lockdown in Belgium due to the COVID19 pandemic (16 of March 2020 to the 12 of April 2020.
9705974|NCT04684342|Experimental|cirrhotic ICU Patients|about 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.
9705975|NCT04684381|Experimental|L-glutamine|Pharmacokinetic characteristics of L-glutamine
9705976|NCT04684316|No Intervention|Care-as-usual: all consult physician|All employees at risk are invited to attend screening. Upon arrival, several biometrics are measured (weight, length, Body Mass Index, blood pressure), along with spirometries, a vision test, and a blood and urine test. The OP then investigates the general health status and systems of the employee, which includes an anamnesis with questions about new health burdens or changes in occupational risks, follow-up questions on previous complaints, medical advice, referral to a healthcare provider, or booking another appointment with an occupational health specialist. After the PHS, a (employee-unique) link to an online questionnaire is sent by email to gather information on final (health, health care use, absenteeism and presenteeism) and intermediary (health literacy, help-seeking behaviour) outcomes.
9705977|NCT04684316|Experimental|Intervention: Electronic survey with selective consultations|In the intervention group, all employees at risk receive a (employee-unique) link to an online health screening questionnaire by email. Dependent upon their answers, 20% of the employees (i.e. the 20% of the employees that mostly need contact with the OP) are referred to the occupational physician for a discussion of the results. The OP then gives medical advice, refers to a healthcare provider (e.g. general practitioner or specialist), or books a (follow-up) appointment with an occupational health specialist (OP, occupational nurse, etc.).
9705978|NCT04684186||Endovascular fiducial marker insertion|Fiducial markers are inserted and released near the tumor through femoral puncture. A catheter is led through the venous system to the right heart and from there through the heart into the pulmonary arteries.
9705979|NCT04684186||Bronchoscopic fiducial marker insertion|Fiducial markers are inserted and released near the tumor into the bronchi using an endoscopic route
9705980|NCT04684641|Experimental|Phage therapy|Participants will be randomized to receive 3mL phage therapy, nebulized daily for 7 days.
9705981|NCT04684641|Active Comparator|Placebo|Participants will be randomized to receive the 3mL placebo, nebulized daily for 7 days.
9705982|NCT04684628|Experimental|Biochemical Reoccurrence|"Patients with biochemical reoccurrence (post-prostatectomy or post radical radiotherapy) or patients with biochemical relapse with rising PSA in spite of taking hormone treatment (this situation is characterized as non-metastatic castration resistant prostate cancer M0CRPC) and compare it to bone scan and CT in 2 groups:~PSA >= 0.2 ng/mL and <= 0.5 ng/mL or PSA > 0.5 ng/ml"
9705983|NCT04684628|Experimental|High Risk Prostate Cancer|Patients with high risk prostate cancer who have not received any definitive treatment. These high-risk patients are defined using the D'Amico Classification System: Those with a PSA of more than 20, or a Gleason score equal to or greater than 8, or have a clinical stage greater than T2c.
9705984|NCT04684264|Experimental|Pharmacist-directed collaborative practice|Participants will be referred to a pharmacist-directed collaborative practice for heart failure prevention.
9705985|NCT04684264|No Intervention|Usual care|Participants will receive usual care with their primary care physician.
9705986|NCT04684537|Active Comparator|Shockwave group|each subject will receive extracorporeal shockwave therapy
9705987|NCT04684537|Active Comparator|Injection group|each subject will receive ultrasound-guided piriformis corticosteroid injection
9779021|NCT01120704|Experimental|13, 26Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9705988|NCT04684251|Experimental|Treatment arm|The treatment arm will undergo the intervention with embolisation of their hemorrhoidal arteries. The embolisation will be performed using a standard right femoral puncture and after inserting a 5 Fr introducer sheath. The inferior mesenteric artery will be catheterised using a Simmons catheter (radiofocus-Terumo). The superior rectal arteries will be then catheterized with a rapid transit microcatheter Progreat microcatheter (Radiofocus-Terumo) and embolised with coils. The treatment will include the use of fluoroscopy for which the radiation protection department of Oxford University Hospitals NHS Foundation Trust has been consulted. The technical success of the procedure will be assessed fluoroscopically by achieving stasis of blood flow distally to the site of the embolization. CE marked coils will be used for the embolisation of the arteries feeding the haemorrhoids.
9705989|NCT04684459|Experimental|CAR-T cell therapy|Dual-targeting HER2 and PD-L1 CAR-T cell therapy
9705990|NCT04684446|Experimental|Arm 1|AZD1222 on Day 1 followed by rAd26-S on Day 29
9705991|NCT04684446|Experimental|Arm 2|rAd26-S on Day 1 followed by AZD1222 on Day 29
9705992|NCT04684355|No Intervention|Standard-of-care group|Participants in this group received their colonoscopic and pathological diagnosis simultaneously at next clinical visit, which arranged in 1 to 2 weeks later.
9705993|NCT04684355|Experimental|Intervention group|Participants in this group received their colonoscopic diagnosis right after they awake from general anesthesia, and then received pathological diagnosis at next clinical visit, which arranged in 1 to 2 weeks later.
9705994|NCT04684290|Active Comparator|Alcohol Septal Ablation|
9705995|NCT04684290|Active Comparator|Surgical Septal Myectomy|
9705996|NCT04684407|Active Comparator|calcium hydroxide|calcium hydroxide powder is mixed with normal saline and placed as intra-canal medication
9705997|NCT04684407|Experimental|Triple antibiotic paste|"Triple antibiotic paste (TAP)- combination of metronidazole,ciprofloxacin and minocycline mixed in a ratio of 1:1:1 .~TAP paste is combined with propylene glycol and placed as intra canal medication."
9705998|NCT04684472|Experimental|Modified anti-CD19 CAR T cell therapy|CAR T cell therapy
9705999|NCT04684199|Active Comparator|Melatonin|"Melatonin~All participants will receive a 5 mg. dose of melatonin before bed for a period of two weeks during study period."
9706000|NCT04684199|Placebo Comparator|Placebo|"Placebo~All participants will receive a placebo comparative in substance, color, and flavor, before bed for two weeks during the study."
9706001|NCT04684225|Experimental|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
9706002|NCT04684225|Experimental|Home-exercises|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied by their own at home for 3 sessions per week.
9706003|NCT04684225|No Intervention|Control|They will have no intervention for 8 weeks. After the period, they will do home exercises.
10192970|NCT03651401||Subacromial impingement syndrome|Participants were assessed for SME, pain (rest, activity, night, measurement), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
10192971|NCT03651401||partial rotator cuff tears|Participants were assessed for SME, pain (rest, activity, night, measurement), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
10192972|NCT03651401||age gender matched healthy controls|Participants were assessed for SME, shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
10192973|NCT03648489|Active Comparator|Arm 1: Weekly paclitaxel alone|Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
10192974|NCT03648489|Experimental|Arm 2: Weekly paclitaxel plus TAK228|"Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria~TAK228, oral capsule 4mg on days 2-4, 9-11, 16-18 and 23-25 of a 28 day cycle i.e. in concurrence with paclitaxel. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria"
10192975|NCT03646812|Other|Glucose Reference 1|50g of glucose dissolved in 250ml of water to be consumed.
10192976|NCT03646812|Other|Glucose Reference 2|50g of glucose dissolved in 250ml of water to be consumed.
10192977|NCT03646812|Other|Glucose Reference 3|50g of glucose dissolved in 250ml of water to be consumed.
10192978|NCT03646812|Experimental|Semolina Penne|70g of semolina penne boiled in 1 Litre of water for 11 minutes. Drained and consume immediately.
10192979|NCT03646812|Experimental|Wholegrain Penne|76g of wholegrain penne boiled in 1 Litre of water for 9 minutes. Drained and consume immediately.
10192980|NCT03646812|Experimental|Semolina Spaghetti|71g of semolina spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
10192981|NCT03646812|Experimental|Wholegrain Spaghetti|76g of wholegrain spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
10192982|NCT03646812|Experimental|Jasmine rice|63g of rice cook with 150g of water. Served and consume immediately.
10192983|NCT03646812|Experimental|Asian Noodles|92.4g of Asian Noodles cook in boiling water for 45 seconds. Drained and consume immediately
10192984|NCT03641677|Experimental|EVLP|
10192985|NCT03641677|Active Comparator|Control|
10192986|NCT03637660|Active Comparator|1|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly on Day 1, n=280
10192987|NCT03637660|Experimental|2|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly weekly for three successive weeks, n=280
10192988|NCT03636074||Hearth-valve surgery|
10192989|NCT03636074||Hearth bypass surgery|
10192990|NCT03630354|Experimental|Arm I (supervised exercise together)|Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting remotely for 6 months.
10192991|NCT03630354|Experimental|Arm II (supervised exercise separately)|Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting remotely for 6 months.
9706014|NCT04684550|Placebo Comparator|Placebo|Health personnel who work in places of greater risk (hospitals and primary level consultation) with conventional protection elements added to the application of 2 nasal puff every 8 hours of a nasal spray containing 0.9% SSN (placebo) and gargles (SSN 0.9%).
9706015|NCT04684550|Experimental|Experimental|Health personnel who work in higher risk places (hospitals and primary level consultation) with conventional protection elements added to the application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
9706016|NCT04684277|Experimental|antidepressant treatment|recieve antidepressant treatment
9706017|NCT04684277|Experimental|antidepressant treatment combined with Internet-based interventions|recieve antidepressant treatment combined with Internet-based interventions
9706018|NCT04684303|Experimental|Lumbar medial branch RF neurotomy|Procedure lumbar medial branch RF neurotomy By raising the temperature of the tip of the electrode to 85 C for 120 seconds. RF generator. Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be > 4 )
9706019|NCT04684303|Experimental|Lumbar medial branch cryoablation|"Procedure lumbar medial branch cryoablation Decreasing the temperature of the electrode to - 85 C for 120 seconds in two cycles.~Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be =/> 4 )"
9706020|NCT04684498|Experimental|Tamiflu (Oseltamivir Phosphate Capsules)|Standardized STEMI treatment + oseltamivir phosphate capsule (75mg, 2 times/day, 7days, oral)
9706021|NCT04684498|Other|no intervention|Standardized STEMI treatment + no intervention
9706022|NCT04684173||Term infants|The inclusion criteria for term infants are: gestational age 37-42 weeks, birth weight >2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
10192992|NCT03630354|Experimental|Arm III (unsupervised exercise separately)|Survivors and partners undergo 2 training sessions remotely over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.
9706023|NCT04684173||Preterm infants|The inclusion criteria for preterm infants are: gestational age <37 weeks, birth weight <2,500 grams, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
9706024|NCT04683913|Experimental|Immediate Intervention: Telerehabilitation|Immediate entry into the gait modification intervention delivered using teleconferencing methods
9706025|NCT04683913|Experimental|Delayed Intervention: Telerehabilitation|Delayed (6 weeks) entry into the gait modification intervention delivered using teleconferencing methods
9706026|NCT04683874|Experimental|3D printed tray|3D printed tray
9706027|NCT04684004||TTC patients with hyperglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by higher blood glucose values at admission, and so defined as hyperglycemics.
10192993|NCT03622073|Experimental|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
10192994|NCT03622073|Active Comparator|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
10192995|NCT03621254|Experimental|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
10192996|NCT03621254|Active Comparator|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (< 90-100 milliampere, patient dependent)
9706028|NCT04684004||TTC patients with normoglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by normal blood glucose values at admission, and so defined as normoglycemics.
10192997|NCT03612258|Experimental|Functional Magnetic Resonance Imaging|
10192998|NCT03590691|Active Comparator|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
10192999|NCT03590691|Experimental|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.~PLUS~Three selected enhancements integrated into routine clinical care:~expanded community health worker services;~home blood pressure self-monitoring; and~a storytelling intervention."
10193000|NCT03589794|Experimental|Group 1|10 subjects receive 10 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
9706029|NCT04683809|Experimental|Exercise group|Patients in this group will attend telerehabilitation sessions.
10193001|NCT03589794|Experimental|Group 2|10 subjects receive 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
10193002|NCT03589794|Experimental|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85.
10193003|NCT03589794|Experimental|Group 4|9 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
10193004|NCT03589794|Experimental|Group 4B|10 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
9706030|NCT04683809|No Intervention|Control group|Patients in this arm will be subject to routine follow up.
9706031|NCT04684095|No Intervention|routine follow-up group|only according to the routine follow-up frequency to the center visit.
9706032|NCT04684095|Experimental|ePRO group|ePRO group : self-evaluation in ePRO mode was accepted, and the patients were visited in the center according to the routine follow-up frequency.
9706033|NCT04683965|Experimental|Pemetrexed + TAS-102 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ TAS-102, capsule, 35mg/m2, bid,po, d1~5, d8~12 + Bevacizumab 5 mg/kg d1, d14; Repeated every 4 weeks
9706034|NCT04683861|Experimental|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
9706035|NCT04683822|Experimental|Exercise group|Patients who receive telerehabilitaton
9706036|NCT04683822|No Intervention|Control|Patients with routine care
10193005|NCT03589794|Experimental|Group 5|10 subjects receive 10 mcg or 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 1, 2, and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, subjects will receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ). Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
9706037|NCT04683835||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
9706038|NCT04684108|Experimental|SG301|Study treatment: SG301 administered every week via intravenous infusion
9706039|NCT04684043||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
9706040|NCT04684056||Riva-control group|Routine concentration of Rivaroxaban (Peak)
9706041|NCT04684056||Riva-High group|High concentration of Rivaroxaban (Peak)
9706042|NCT04684056||Riva-Low group|low concentration of Rivaroxaban (Peak)
9706043|NCT04684056||Dabi-control group|Routine concentration of Dabigatran(Peak)
9706044|NCT04684056||Dabi-High group|High concentration of Dabigatran(Peak)
9706045|NCT04684056||Dabi-low group|low concentration of Dabigatran(Peak)
9706046|NCT04684056||Edo-control group|Routine concentration of Edoxaban(Peak)
9706047|NCT04684056||Edo-high group|High concentration of Edoxaban(Peak)
9706048|NCT04684056||Edo-low group|low concentration of Edoxaban(Peak)
9706049|NCT04683926|Experimental|Desmetramadol 10 mg, fasted|While fasting a single oral dose of 10 mg desmetramadol under.
9706050|NCT04683926|Experimental|Desmetramadol 20 mg, fasted|While fasting a single oral dose of 20 mg desmetramadol.
9706051|NCT04683926|Experimental|Desmetramadol 30 mg , fasted|While fasting a single oral dose of 30 mg desmetramadol.
9706052|NCT04683926|Experimental|Desmetramadol 30 mg , fed|After feeding a single oral dose of 30 mg desmetramadol.
9706053|NCT04684030|Experimental|CGMS group|Using continuous glucose monitoring system(CGMS) group
9706054|NCT04684030|Active Comparator|SMBG group|Self-monitoring of blood glucose group (conventional fingerpricking method)
10193006|NCT03589794|Other|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain.
10193007|NCT03576586|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
9706057|NCT04684134||experimental group|patients with colorectal polyps
9706058|NCT04684134||control group|patients without intestinal diseases
9706059|NCT04684082||Single Group Assignment|Patients will receive colonic irrigation as bowel preparation prior to colonoscopy.
9706060|NCT04683887|Experimental|Tape application|
10193008|NCT03576586|Placebo Comparator|Control|Attention placebo control (cognitive task for same amount of time) plus usual care in the maternity department
10193009|NCT03570333|Experimental|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
10193010|NCT03570333|Experimental|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
9706061|NCT04683887|No Intervention|No tape application|
9706062|NCT04684160|Active Comparator|Fixed-bearing group|
9706063|NCT04684160|Experimental|Mobile-bearing group|
9706064|NCT04683770||HR + / HER2 - advanced breast cancer|
9706065|NCT04684069|Active Comparator|syringe free long axis in-plane|
9706066|NCT04684069|Sham Comparator|Short axis out-of-plane|
9706067|NCT04684017|Experimental|Anlotinib plus etoposide and carboplatin|Etoposide and carboplatin plus anlotinib for 4 cycles and anlotinib as maintenance therapy
9706068|NCT04683458||Paclitaxel-coated devices|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any drug-coated medical device (e.g., drug-eluting stent, drug-coated balloon).
9706069|NCT04683458||Controlls|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any medical device except drug-coated techniques (e.g., drug-eluting stent, drug-coated balloon).
9706070|NCT04683796|Experimental|100% APRP|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
9706071|NCT04683796|Active Comparator|100% AS|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
9706072|NCT04683952|Experimental|Rehabilitation with HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
9706073|NCT04683952|Active Comparator|Control Group rehabilitation without HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
9706074|NCT04683497|Experimental|CE-IOUS|Patients with pancreatic cancer undergoing surgery with the performance of CE-IOUS
9706075|NCT04683731|Active Comparator|Group 1|Patients view decision aid without personalized message and whose providers do not receive the personalized message.
9706076|NCT04683731|Experimental|Group 2|Patients view decision aid with personalized message and whose providers do not receive the personalized message.
9706077|NCT04683731|Experimental|Group 3|Patient view decision aid without the personalized message and whose providers receive the personalized message.
10193011|NCT03553095|Active Comparator|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
9706078|NCT04683731|Experimental|Group 4|Patients view decision aid with the personalized message and whose providers receive the personalized message.
9706079|NCT04683653|Experimental|Hypofractionated Radiation Treatment (Dose-Finding Arm)|All study participants in this arm will receive hypofractionated whole pelvic radiation treatment for a shortened time period of 3-5 weeks. The goal of this arm is to establish a safe and tolerable dose of shortened (hypofractionated) pelvic radiation treatment for study participants. Once a safe and tolerable dose is established for this shortened form of radiation treatment, participants who meet criteria for the second phase of this study will participate in an expansion cohort that will explore the efficacy (how effective shortened/hypofractionated radiation treatment is for treating endometrial cancer).
9706080|NCT04683653|Experimental|Expansion Cohort (Efficacy Arm)|"Participants in this arm will test how effective hypofractionated/shortened whole radiation treatment is (efficacy) at the dose established in the first phase of this study by following up with their doctors to report their current health status and symptoms during clinical visits. Participants will return for routine clinical follow-up approximately 1 month following radiation, then at 3 months following radiation, then every 3 months for the next 2 years following treatment."
9706081|NCT04683640|Experimental|Daily Oral GABA|You will take, by mouth, 2 pills of GABA (500 mg) (Capsule 250mg) daily at home for 4 weeks
9706082|NCT04683640|Placebo Comparator|Daily Placebo|You will take, by mouth, 2 pills of Placebo daily at home for 4 weeks
9706083|NCT04683445||HR+/HER2- advanced breast cancer|Efficacy and Safety of Eribulin in the Treatment of HR+/HER2- Advanced Breast Cancer
9706084|NCT04683445||HER2+ advanced breast cancer|Efficacy and Safety of Eribulin and anti-HER2 Targeted therapy in the Treatment of HER2+ advanced breast cancer
9706085|NCT04683445||triple negative advanced breast cancer|Efficacy and Safety of Eribulin and Immunotherapy in the Treatment of triple negative advanced breast cancer
9706086|NCT04683523|Experimental|Anaerobic exercise training|
9706087|NCT04683523|Active Comparator|Aerobic exercise training|
10193012|NCT03553095|Active Comparator|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
10193013|NCT03553095|Active Comparator|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
9706090|NCT04683536||control group|Patients underwent TUR-BT under spinal anesthesia
9706091|NCT04683536||Study group|Patients underwent TUR-BT under spinal anesthesia combined with ultrasound guided obturator nerve blockade
9706092|NCT04683705||patients without shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the asymptomatic shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
9706093|NCT04683705||patients with shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the painful shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
9706094|NCT04683562|Other|Normal pregnancy group|
9706095|NCT04683562|Other|Placenta accreta group|
9706096|NCT04683419|Experimental|Patients with pleural effusion of Undetermined etiology|Patients with undiagnosed exudative pleural effusion will undergo modified pleural cryobiopsies and conventional pleural forceps biopsies in the same settings
9706097|NCT04683744||Healthcare system leadership, providers, and staff|Leadership, providers, and staff at the study team's affiliated health systems.
9706098|NCT04683744||Patients receiving primary care at the study team's affiliated health systems|Patients who had a least one primary care visit during the past 24 months at the study team's affiliated health care systems.
9706099|NCT04683406|Experimental|ZSP1273 600 mg + Oseltamivir Placebo BID|Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
9706100|NCT04683406|Active Comparator|Oseltamivir 75mg + ZSP1273 Placebo|Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days
9706101|NCT04683406|Placebo Comparator|Placebo Comparator|Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days
9706102|NCT04683328|Experimental|SCTA01 Group|SCTA01+Best Supportive Care
9706103|NCT04683328|Placebo Comparator|Placebo Group|Placebo+Best Supportive Care
9706104|NCT04683341|Experimental|Arm A - initial TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and HBV NUC treatment naïve or experienced (except prior TAF) will receive initial treatment (Arm A) with TAF 25 mg/day.
9706105|NCT04683341|Experimental|Arm B - switch to TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and currently under HBV NUC treatment (except TAF) with HBV DNA < 20 IU/mL within 6 months prior screening will switch (Arm B) to TAF 25 mg/day
9706106|NCT04683315|Experimental|Subtype diagnosis and classification: Basal|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Upon diagnosis, patients categorized as basal will receive two months of the Gemcitabine/Nab-paclitaxel Treatment Regimen.
10193014|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
9706107|NCT04683315|Experimental|Subtype diagnosis and classification: Classical|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Patients in the classical group will receive two months of the mFOLFIRINOX Treatment Regimen.
9706108|NCT04683315|Experimental|Basal Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
9706109|NCT04683315|Experimental|Classical Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
9706110|NCT04683315|Experimental|Basal Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
9706111|NCT04683315|Experimental|Classical Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
9706112|NCT04683315|Experimental|Basal Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
9706113|NCT04683315|Experimental|Classical Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
9706114|NCT04683302|Active Comparator|control|conventional 2D guided internal jugular vein catheterization
9706115|NCT04683302|Experimental|intervention|3D biplanar guided internal jugular vein catheterization
9706116|NCT04683263|Active Comparator|Intervention|Fisiocrem®, a topical cream composed of the natural ingredients Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
9706117|NCT04683263|Placebo Comparator|Placebo|topical cream with similar characteristics and aspect, without active ingredients.
9706118|NCT04683198|Experimental|Experimental: camrelizumab +apatinib+ Carboplatin + Etoposide|Induced stage：camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1 ; maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
9706119|NCT04683016||Periodontitis patients|Patients with a diagnosis of periodontitis, irrespective of its stage and grade.
9706120|NCT04683042|Active Comparator|TENS with PT|TENS with PT group: The TENS with PT group will receive usual PT care and following enrollment, during the second PT visit, participants will receive TENS units and instruction on use of the TENS units. TENS will be applied to the upper and lower back with butterfly electrodes using the following parameters: mixed frequency (2-125Hz), strong but comfortable intensity, variable pulse duration from 100-250 microseconds. TENS to be applied when the patient is active and doing exercises at home and during PT sessions for 30 minutes at least 2 hours per day. The TENS with PT group will complete TENS use to the end of the study at 6 months.
9706121|NCT04683042|Other|No TENS with PT|The No TENS group will receive usual PT care until the primary endpoint timeframe of 60 days. After completion of the research homework at 60 days, TENS units will be mailed to the participants and a study team member will complete virtual TENS instruction. The no TENS group will complete TENS to the end of the study at 6 months.
9706122|NCT04683276|Active Comparator|small flap medium-sized macular hole (SFMM)|small flap (1-2 disc-diameter) was performed in medium sized macular hole (250-400 um)
9706123|NCT04683276|Active Comparator|large flap medium-sized macular hole (LFMM)|large flap (3-4 disc-diameter) was performed in medium sized macular hole (250-400 um)
9706124|NCT04683276|Active Comparator|small flap large-sized macular hole (SFLM)|small flap (1-2 disc-diameter) was performed in Large sized macular hole (>400 um)
9706125|NCT04683276|Active Comparator|large flap Large-sized macular hole (LFLM)|large flap (3-4 disc-diameter) was performed in large sized macular hole (>400 um)
10193015|NCT03541447|Experimental|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
9706126|NCT04683471|Experimental|Neuromodulation|Neuromodulation
9706127|NCT04683471|Sham Comparator|Sham|Sham
9706128|NCT04683484|Experimental|Low dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
9706129|NCT04683484|Experimental|Middle dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
9706130|NCT04683484|Experimental|High dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
9706131|NCT04683484|Placebo Comparator|Placebo|Intramuscular injection, two doses given 28 days apart
9706132|NCT04683367|Experimental|clinical hernia|developing clinical hernia
9706133|NCT04683107|Experimental|Eccentric protocol|
9706134|NCT04683107|Experimental|Isometric protocol|
9706135|NCT04683081||Foley catheter group|pregnant women who were applied Foley catheter for cervical ripening
9706136|NCT04683081||Cook balloon catheter group|pregnant women who were applied Cook balloon catheter for cervical ripening
9706137|NCT04683081||Modified double-balloon Foley catheter group|pregnant women who were applied modified double-balloon Foley catheter for cervical ripening
9706138|NCT04683289|Experimental|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy
9706139|NCT04683289|Active Comparator|viscotrabeculotomy|Viscotrabeculotomy
10193016|NCT03541447|Experimental|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
10193017|NCT03536559|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
10193018|NCT03536559|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
10193019|NCT03536559|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
10193020|NCT03523806|Experimental|Solution-Focused Coaching Group|Half of the participants (n=15) will be assigned a coach and receive coaching 8 times for up to 1 hour over 6 months. The first session will take place in the home and subsequent session will take place online using an online meeting tool.
10193021|NCT03523806|No Intervention|Control Group|Half of the participants (n=15) will not be receiving coaching
10193022|NCT03515551|Experimental|Phase 1: Dose Escalation|Four fixed-dose, dose escalation cohorts (Cohorts 1 to 4) and 3 intrapatient dose escalation cohorts (Cohorts 5 to 7) to establish the MTD/RP2D of IMCnyeso.
10193023|NCT03515551|Experimental|Phase 2: Dose Expansion|Three planned cohorts treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso. Phase 2 was not initiated and data were not collected.
10193024|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
10193025|NCT03484364|Experimental|Intervention Group|The ENACTS intervention is four peer-facilitated educational classes delivered over 8 weeks focused on hypertension self-management.
9706140|NCT04683172|Experimental|Active tDCS|Active tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
10193026|NCT03484364|No Intervention|Waitlist Group|Usual care and $50 in groceries every other week for 8 weeks.
10193027|NCT03469492|Active Comparator|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
9706141|NCT04683172|Sham Comparator|Sham tDCS|Sham tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
9706142|NCT04683159|No Intervention|Control|No intervention, only routine pre-operative drops
9706143|NCT04683159|Experimental|Brimonidine 0.15%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.15% in the operating eye
9706144|NCT04683159|Experimental|Brimonidine 0.025%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.025% in the operating eye
9706145|NCT04683146|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propranolol- 1 60% as control.
9706146|NCT04683146|Active Comparator|Hand antisepsis with solution of alcohol, chlorhexidine digluconate and potassium sorbate|Effectiveness of pre-surgical hand washing in reducing bacterial load using a solution of alcohol, chlorhexidine digluconate and potassium sorbate
9706147|NCT04683133|Other|Single arm|Optical coherence tomography evaluation of coronary arteries with intermediate to severe stenosis.
9706148|NCT04683185|Experimental|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
9706149|NCT04683185|Experimental|Cohort 3: E6742 400 mg or Placebo|Participants will receive E6742 400 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
9706150|NCT04683185|Experimental|Cohort 1: E6742 100 milligram (mg) or Placebo|Participants will receive E6742 100 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
9706151|NCT04683237|Other|MA alone|enrolled patients will receive megestrol acetate 160mg po qd
9706152|NCT04683237|Experimental|MA+liraglutide|enrolled patients will receive megestrol acetate 160mg po qd plus liraglutide (1.8mg/d or the max tolerable dosage)
9706153|NCT04683120|Experimental|Single Arm Study|This is a single arm study, which will involve all patients qualifying for Breast Conservation Therapy as a part of their breast cancer management excluding patients undergoing neoadjuvant therapy for inoperable disease.
9706154|NCT04683679|Experimental|Arm A|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT + olaparib
9706155|NCT04683679|Experimental|Arm B|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT only
10193028|NCT03469492|Active Comparator|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
10193029|NCT03461900|Experimental|Minifluid challenge|100 ml of 4% Albumin will be deliver to assess fluid responsiveness
10193030|NCT03461900|Experimental|Control|Patient will be treated as defined by most recent surviving sepsis campaign guidelines
9706156|NCT04683354|Experimental|Dose Escalation|There are 3 cohorts for the dose escalation study. Six subjects each cohort will receive oral administration of HL-085 capsules at three daily dose levels (12 mg, 18 mg and 24 mg). Three subjects of each cohort will receive TID and 3 subjects will receive BID dose regimen. Dose escalation can occur after 6 patients have completed 28 days of treatment and no or 1 DLT is identified.
10193031|NCT03448978|Experimental|Descartes-08 plus fludarabine/cyclophosphamide pretreat|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
10193032|NCT03448692|Experimental|PF-06730512 Cohort 1|Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
10193033|NCT03448692|Experimental|PF-06730512 Cohort 2|Subjects in cohort 2 will receive dose 2 IV infusion.
10193034|NCT03448692|Experimental|PF-06730512 Cohort 3 (optional)|Subjects in cohort 3 will receive dose 3 IV infusion.
10193035|NCT03441126||Multicenter Quality Improvement program|Locally developed and reliably implemented ICU Quality Improvement program to reduce blood culture use.
9706157|NCT04682964|Experimental|Nebulizer inhalation bacteriophage therapy|To study the effects of bacteriophage therapy on acute tonsillitis in children and adolescents in an outpatient setting.
10193036|NCT03439891|Experimental|Part 1: Dose Escalation (CLOSED TO ENROLLMENT)|Participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dose.
9706158|NCT04682938||adrenal incidentalomas in Chinese community adults|Patients aged over 18 years with adrenal incidentaloma (the maximum diameter of tumor ≥ 10 mm) were found by low-dose chest CT in physical examination center.
9779022|NCT01120704|Experimental|14, 26Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779023|NCT01120704|Experimental|15, 26Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779024|NCT01120704|Experimental|16, 26Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779025|NCT01120704|Experimental|17, 8Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779026|NCT01120704|Experimental|18, 8Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779027|NCT01120704|Experimental|19, 8Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779028|NCT01120704|Experimental|20, 8Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779029|NCT01120704|Experimental|21, 8Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779030|NCT01120704|Experimental|22, 8Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779031|NCT01120704|Experimental|23, 8Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779032|NCT01120704|Experimental|24, 8Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779033|NCT01120704|Experimental|25, 8Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779034|NCT01120704|Experimental|26, 8Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779035|NCT01120704|Experimental|27, 8Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9785156|NCT01244425|Active Comparator|Manual compression - Control|A dry surgical gauze swab will be used to apply by hand an even light pressure onto the oozing resection surface of the liver. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
9785157|NCT01244451|Experimental|Bendofa|Bendamustine + Ofatumumab
10193037|NCT03439891|Experimental|Part 2: Child Pugh B Expansion (sorafenib, nivolumab)|Participants receive sorafenib on days 1-28, and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9706159|NCT04682808|Experimental|Dose Escalation and Expansion|FCN-338 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL , until the maximum tolerated dose or recommended dose is reached. Followed by up to 43 patients enrolled in the expansion cohort at the recommended dose.
9706160|NCT04682782|Experimental|Esketamine|Participants randomized to this arm will receive Esketamine (1 mg/ml) infused at 0.1 mg/kg/hour (0.1 ml/kg/h) throughout the operation
9706161|NCT04682782|Placebo Comparator|Saline|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the operation
10193038|NCT03439033|Experimental|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
10193039|NCT03439033|Experimental|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
9706162|NCT04682678|Sham Comparator|OFF STIM|without stimulation
9706163|NCT04682678|Active Comparator|ON STIM|stimulation with the most effective parameters
9706164|NCT04682665||Experimental|Patients randomized to the experimental arm of the EMT2 trial, receiving Icosapent Ethyl (EPA-EE) according to the EMT2 protocol.
9706165|NCT04682665||Placebo comparator|Patients randomized to the placebo comparator arm of the EMT2 trial, receiving placebo capsules according to the EMT2 protocol.
9706166|NCT04682925|Experimental|skin care arm of where evidence-based practices in the implementation guide|Participants in this arm will be given evidence-based skin care interventions, which are included in the guidelines to prevent medical device-related pressure injuries, and are implemented by the researcher nurse. After the nasogastric tube is inserted by the patient's physician.
10193040|NCT03439033|Experimental|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
10193041|NCT03414372|Experimental|Tough Talks Online|Participants will use Tough Talks Online
10193042|NCT03414372|Experimental|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
9706167|NCT04682925|Experimental|hydrocolloid (Convatec Granuflex-extra thin) dressing|Patients in this arm will be applied a translucent hydrocolloid cover, which is compatible with the sensitive skin structure, can be applied to all body surfaces and nasal mucosa, and allows the underlying mucosa and skin to be observed after the nasogastric tube is inserted by the patient's physician. This cover will be applied to the nasal mucosa and nasal wing under the nasogastric tube.
9706168|NCT04682925|Other|control|Participants in the control group will be given no intervention , these patients will receive the routine clinical care(dressing change and nasal skin cleaning once a day) applied in the intensive care unit.
9706169|NCT04682613|Experimental|"Prevention Program young In Favor of Myself, active teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers will also participate by delivering planned activities to do with their pupils in addition to each week's topic, parallel to the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
9706170|NCT04682613|Active Comparator|"Prevention Program young In Favor of Myself, passive teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers won't participate in the program, they will only be present in the classroom during the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
9706171|NCT04682691|Sham Comparator|Group (C)|who will receive flavored water in total volume 15 ml at two hours preoperative.
9706172|NCT04682691|Active Comparator|Group (M)|will be receive 10 ml of oral metoclopramide (10mg)
9706173|NCT04682691|Active Comparator|Group (E)|will receive 10 ml of oral Erythromycin (400mg)
9706174|NCT04682756||CNN model|Electronic health information of NSTEMI and UA patients in two chest pain centers from 2017 to 2019 was collected，After manual labeling, the characteristics of patient admission records were selected, and through the construction of one-dimensional convolution (CNN) model. Taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
9706175|NCT04682756||XG boost|Through the construction of XG boost model,taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
10193043|NCT03414372|Placebo Comparator|Standard of Care|Participants will receive the standard of care (SOC).
10193044|NCT03405740|Active Comparator|Remote Patient Management|Patients will be followed by remote monitoring only.
10193045|NCT03405740|Placebo Comparator|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
10193046|NCT03396874|Experimental|68Ga-PSMA|PET/CT imaging
10193047|NCT03385265|Experimental|DIPPer Academy|Parents randomized to this group will participate in the DIPPer Academy curriculum.
10193048|NCT03385265|Active Comparator|Standard of Care Control|Parents randomized to this group will receive care as usual from their child's diabetes provider
9706176|NCT04682795|Experimental|Needle-free injector group|To evaluate the efficacy and safety of the needle-free injector in T2DM
10193049|NCT03383575|Experimental|Arm I (enasidenib, azacitidine)|Patients who are HMA-naive receive enasidenib PO QD on days 1-28 and azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10193050|NCT03383575|Experimental|Arm II (enasidenib)|Patients relapsed and/or refractory to HMA therapy receive enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9706177|NCT04682795|Active Comparator|Insulin pen group|To evaluate the efficacy and safety of the insulin pen in T2DM
9706178|NCT04682418|Experimental|xvision Spine|
9706179|NCT04682444|Experimental|Group 1 - Active Treatment|Patient who were randomized into Group 1 ingested Amizon tablets 0.5 g (2 tablets) after a meal, 3 times a day, for 7 days; each tablet contains 0.25 g of enisamium iodide.
9706180|NCT04682444|Placebo Comparator|Group 2 - Placebo|Patient who were randomized into Group 2 ingested placebo tablets after a meal, at the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
9706181|NCT04682392|Active Comparator|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|This group will use Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction for rehab.
9706182|NCT04682392|Active Comparator|Non Delfi PTS Personalized Tourniquet System for Blood Flow Restriction Group|Standard post operative ACL rehab without Blood flow restriction
9706183|NCT04682899|Experimental|PCT-guided antibiotic therapy (PCT group)|Participants in the PCT group will complete a PCT test within 2 hours after randomization and the results will be sent back to the clinician by laboratory through the internal network of the hospital. The prescribing clinician will use the results of the PCT to help guide their antibiotic prescription decision. The detailed recommendations are as follows: if PCT<0.1ng/ml，strongly discouraged；if PCT (0.1-0.25ng/ml) and no sputum purulence, discouraged; if PCT (0.1-0.25ng/ml) and sputum purulence, Recommended; PCT>0.25 ng/ml, Strongly recommended.
9706184|NCT04682899|Active Comparator|Guideline-guided antibiotic therapy (guideline group)|Participants in the guideline group will also need to complete a PCT test within 2 hours after randomization, however, the laboratory will save the results and do not sent back to the clinician. The clinician will make an antibiotic prescribing decision on the basis of the recommendations of GOLD guideline. The guideline recommend the following patients to receive antibiotic therapy. Patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).
9706185|NCT04682431|Experimental|Part A: PY159 Single agent dose level 1|PY159 dose level 1 IV administration, Q3 weekly until consent withdrawal, intolerable toxicity or investigator decision.
9706186|NCT04682431|Experimental|Part A: PY159 Single agent dose level 2|PY159 dose level 2
9706187|NCT04682431|Experimental|Part A: PY159 single agent dose level 3|PY159 dose level 3
9706188|NCT04682431|Experimental|Part A: PY159 single agent dose level 4|PY159 dose level 4
9706189|NCT04682431|Experimental|Part A: PY159 single agent dose level 5|PY159 dose level 5
9706190|NCT04682431|Experimental|Part A: PY159 single agent dose level 6|PY159 dose level 6
10193051|NCT03378102|Experimental|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|"Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. The donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion and infused within 4 hours as a bolus on day 0.~Subjects will receive virus-specific, antigen selected T cells within a targeted range of 1 x 10^3- 2 x 10^5 per kg of recipient weight."
10193052|NCT03371719|Placebo Comparator|Arm 1 (Radiation Therapy + Placebo)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or unacceptable toxicity.
9706191|NCT04682431|Experimental|Part A: PY159 single agent dose level 7|PY159 dose level 7
9706192|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 1|PY159 dose level 1 in combination with pembrolizumab
9706193|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 2|PY159 dose level 2 in combination with pembrolizumab
9706194|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 3|PY159 dose level 3 in combination with pembrolizumab
9706195|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 4|PY159 dose level 4 in combination with pembrolizumab
9706196|NCT04682431|Experimental|Part A: PY159/Pembrolizumab Combination dose level 5|PY159 dose level 5 in combination with pembrolizumab
9706197|NCT04682431|Experimental|PY159 Part B: Single agent dose expansion cohort(s)|PY159 Single agent dose expansion cohort(s)
9706198|NCT04682431|Experimental|PY159 Part B: PY159/Pembrolizumab Combination dose expansion cohort(s)|PY159 in combination with pembrolizumab dose expansion cohort(s)
9706199|NCT04682717||PI group|A cut-off value of baseline PI below which hypotension at 5 min post induction could be predicted will be the primary outcome, while positive and negative predictive values at 15 minutes will be secondary outcomes.
9706200|NCT04682535||Cohort 1|Spousal/partner family caregivers to persons living with dementia. Participants will complete 14-days of surveys about their relationships, social interactions, as well as health and health behaviors. A subsample of n=15 may volunteer to provide diurnal saliva samples.
9706201|NCT04682561|Experimental|Supportive Trauma Exposure Preparation (STEP) Program|Nurses or personal support workers at Unity Health Toronto - Providence Healthcare will undergo the STEP Program Psychotherapy
9706202|NCT04682327||Responder group|"After the 4 cycles of anti-PD-1/PD-L1 mAbs treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Responders are defined as complete remission, partial remission, or stable disease."
9706203|NCT04682327||Nonresponder group|"After the 4 cycles of anti-PD-1/PD-L1 treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Nonresponders are defined as disease progression."
9706204|NCT04682379||AIS with Proprioceptive Defect|AIS subjects possessing statistically significant difference on testing outcomes compared with healthy controls.
9706205|NCT04682379||AIS without Proprioceptive Defect|AIS subjects with similar testing results compared with healthy controls.
9785158|NCT01244477|Experimental|CPT-C|Participants in group CPT-C
9979645|NCT01384032|Experimental|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
9979646|NCT01384032|Experimental|High saturated fat plus DHA diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
9706208|NCT04682275|Other|Female Group|Females with periodontal disease (71 subjects with gingivitis, 100 subjects with periodontitis)
9706209|NCT04682275|No Intervention|Male Group|males with periodontal disease (72 subjects with gingivitis, 96 subjects with periodontitis)
9706210|NCT04681937|Experimental|Hyaluronic Acid + Physical Therapy|4 ml hyaluronic acid (subacromial)
9706211|NCT04681937|Experimental|Platelet-Rich-Plasma (PRP) + Physical Therapy|4 ml platelet-rich-plasma (subacromial)
9706212|NCT04681937|Experimental|Steroid + Physical Therapy|methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) (subacromial)
9706213|NCT04681937|Experimental|Placebo (serum saline) + Physical Therapy|4 ml serum saline (subacromial)
9706214|NCT04682002|Experimental|OMT + multidisciplinary path|Patients in the experimental group will follow the obstetrician's and multidisciplinary path which provides osteopathic treatments, mindfulness, yoga, clinical nutrition, coaching and usual obstetric care.
9706215|NCT04682002|Other|Usual care|Patients in control group will continue the routine obstetrical care as established by international guidelines
9706216|NCT04682028|Other|experiment group|Nurses provide web-based continuous care to patients.
9706217|NCT04682028|Other|contral group|Nurses provide the routine care to patients.
9706218|NCT04682171|Experimental|Low level Laser Therapy|Low Level Laser Therapy and Conventional Exercise therapy
9706219|NCT04682171|Active Comparator|Conventional ExerciseTherapy|Conventional ExerciseTherapy
9706220|NCT04682067|Experimental|Contingency Management|Participants in the contingency management (CM) treatment arm will receive the usual care (UC) treatment program offered at the Tobacco Treatment Research Program (TTRP) and will be eligible to earn gift cards at each weekly visit on their quit date up until four weeks post-quit for proof of abstinence. They will earn $20 in gift cards for quitting on the specified quit day (i.e., one week after the orientation visit), and this amount will increase by $5 with each successive weekly abstinent visit (i.e., up to $40 in gift cards at 4 weeks post-quit; up to $150 total).
9706221|NCT04682067|Placebo Comparator|Usual Care|Participants in the usual care (UC) group will receive the standard smoking cessation treatment offered at the Health Promotion Research Center's Tobacco Treatment Research Program (TTRP) at the University of Oklahoma. This includes at least 4 treatment sessions of counseling and the opportunity to use nicotine replacement therapy or medications.
9706222|NCT04682080|Active Comparator|Needle-free injection group|In needle-free injection techniques, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using the Comfort-In system. Pain intensity and anxiety levels of patients were measured.
9706223|NCT04682080|Active Comparator|Dental injection group|In the conventional dental-injection method, 4% articaine with 1/100.000 epinephrine (Ultracaine DS forte) was injected using a 27G, 50-mm, disposable syringe with a needle. Pain intensity and anxiety levels of patients were measured.
9706224|NCT04682249|Experimental|Systemic Chemotheray, Apatinib plus Sintilimab|
10193053|NCT03371719|Experimental|Arm 2 (Radiation Therapy + Apalutamide)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
10193054|NCT03362099|No Intervention|Group Varenicline|Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
10193055|NCT03362099|Active Comparator|Group Genetic|"The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs.~Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve."
10193056|NCT03343483|Experimental|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
10193057|NCT03343483|Active Comparator|Life Review|Self-guided program of life review for 12 months.
9706225|NCT04681989|Experimental|MOVE-ABC intervention arm|"MOVE-ABC interventional group participants receive usual care plus the MOVE-ABC education instruction and materials. After the participant completes the baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~instructions on the education materials by a research staff member~a range of motion wand~a small ball~MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment. The follow-up phone calls are expected to take 20 - 30 minutes each time. During these follow-ups research staff will review material, and answer any questions the participant may have. All documentation of phone calls and questions asked by participants during these reviews will be captured in REDCap."
9785159|NCT01244477|No Intervention|Treatment-as-Usual|Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).
10193058|NCT03340896|Active Comparator|TPF followed by radiotherapy|"Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy~Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
9706226|NCT04681989|No Intervention|Control/Usual Care arm|Control group participants will be measured at baseline and at 1 month follow-up. They receive usual care. Usual care does not include specialized, physical therapy-based education on recovery from breast cancer.
9706227|NCT04682184|Experimental|Wearable Biosensor Patch Device + Propranolol|Participants will wear the biosensor patch device followed by propranolol administered orally in one of three study periods.
9706228|NCT04682184|Experimental|Wearable Biosensor Patch Device + Pseudoephedrine|Participants will wear the biosensor patch device followed by pseudoephedrine administered orally in one of three study periods.
9979647|NCT01384045|No Intervention|Usual Care|Patients continue to receive usual diabetes care without outreach by health promotions staff.
10193059|NCT03340896|Experimental|Cisplatin and radiotherapy|"Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy~. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
10204569|NCT05201534|Experimental|Integrative Symbolic Non-Symbolic (iSNS) Training|Integrative symbolic non-symbolic (iSNS) training: Over a period of 8 weeks, participants will complete activities that progressively strengthen the mapping of symbolic numerical representations to non-symbolic numerical quantities and enhance fluency in symbolic numerical skills.
9706229|NCT04682184|Experimental|Wearable Biosensor Patch Device (Alone)|Participants will wear biosensor patch device (alone) during one of three study periods.
9706230|NCT04682054|Experimental|surgically-removed eye tissue|
9706231|NCT04682210|Experimental|Arm A|sintilimab 200mg + bevacizumab 7.5mg/kg IV Q3W
9706232|NCT04682210|No Intervention|Arm B|Active surveillance
9706233|NCT04682119|Experimental|LY3526318 (Part A)|LY3526318 administered orally as single ascending doses.
9706234|NCT04682119|Experimental|LY3526318 (Part B)|LY3526318 administered orally as multiple doses.
9706235|NCT04682119|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
9706236|NCT04682119|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
9706237|NCT04682015|Experimental|Intervention|The intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.
9706238|NCT04682015|No Intervention|Control|Control group will receive usual care and follow up in hospitals and community health centers.
9706241|NCT04682262|Experimental|Cervical dilatation|Patients receive cervical dilatation up to 10 millimeter Hegar dilator under general anaesthesia. Patient undergo standard hysteroscopy operation.
9706242|NCT04682262|No Intervention|Expectant|Patients are scheduled for follow-up.
9706243|NCT04681820||flumatinib|flumatinib 600mg QD, fasting administration
9706244|NCT04681820||nilotinib|nilotinib 400mg BID, fasting administration
9706245|NCT04681885|Experimental|Tapered bristles A|
9706246|NCT04681885|Active Comparator|Tapered bristles B|
9706247|NCT04681885|Active Comparator|End rounded bristles|
9706248|NCT04681911|Experimental|Inetetamab Combined With Pyrotinib and Chemotherapy|"Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.~Pyrotinib: 400mg, oral, every day.~Chemotherapy: the choice of physicians，as the following regimens:~Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle Carboplatin, AUC = 6, 3-week cycle Albumin paclitaxel, 100 mg/m2, weekly Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle"
9706249|NCT04681924|Experimental|Low carb diet|Low carb diet (n=54)
9706250|NCT04681924|Experimental|Low fat diet|Low fat diet (n=40)
9706251|NCT04681976|Experimental|Intervention group|Intervention Group participants will perform a 3-month telematic dance program based on choreographic work, 2 times per week
9706252|NCT04681976|No Intervention|Control group|Control group will follow their daily routine without added exercise
9706253|NCT04682041|Experimental|EnteraGam + standard of care|Subjects will receive EnteraGam® (oral nutritional therapy) + standard of care for COVID-19 for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
9706254|NCT04682041|Other|Control (standard of care)|Subjects will receive standard of care for COVID-19 alone for 2 weeks. Total study duration (including the screening phase) will be approximately 4 weeks.
9706255|NCT04681703|Experimental|Intervention group|In addition to usual care: a 1-h educational and training program conducted by the family nurse (FN) in a dedicated room of the ambulatory care centers. During the program, the nurse instructed patients on how to self-measure blood pressure (BP) using the BP self-measurement device and on the importance of adequate device maintenance. The intervention was carried out by the FN on a daily basis during outpatient visits of the participants to the general practitioner (GP).
9706256|NCT04681703|No Intervention|Conrol group|Management of hypertensive patients, usual care: verbal and written instructions during which the family nurse (FN) or general practitioner (GP) advised the patient to follow the recommendations regarding correct HBPM. A written summary of the recommendations was given to all participants by the GP or FN at the end of the training program.
9706257|NCT04681469|Experimental|Single Arm Treatment|"For all patient's population:~Niraparib 200 mg/day: day -49 to day -21;~Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~Niraparib 200 mg/day: day -21 to day -7~Dostarlimab 500 mg iv: day -7~Radiological assessment (day -1, ± 3 days),~Surgery (original margin) at day 0 (±3 days)~Standard postoperative (chemo)radiotherapy according to pathologic report;~Maintenance Niraparib, 200 mg/day for 6 months~Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
9785160|NCT01244490|Experimental|Extended-release Guanfacine Hydrochloride|
9785161|NCT01244490|Other|Atomoxetine Hydrochloride|Active Reference
9706258|NCT04681495|Other|Usability of Bullying Prevention Online Application|This intervention has a single arm. It consists of conducting focus groups and usability testing of a bullying prevention online application for middle-school-aged students.
9706259|NCT04681716|Active Comparator|ELDOA GROUP|ELDOA position was instructed to this group
9706260|NCT04681716|Experimental|CONVENTIONAL PHYSIOTHERAPY|Hot pack,TENS and mobalization was given in this group
9706261|NCT04681547|Experimental|Genicular nerve block|An ultrasound-assisted genicular nerve block will be performed. 4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves.
9706262|NCT04681547|Active Comparator|Local infiltration Analgesia|Administration of ropivacaine 0.2% 150 ml will be performed.
9706263|NCT04681378|Active Comparator|Classical double layer closure|a holding Vicryl 1-0 was placed in the in the left corner to stabilize and define the demarcation of the suture line. A continuous unlocked stitch beginning at the right corner was used, closing the whole thickness of the uterine wall, including the decidual layer. The second unlocked stitch was performed by Vicryl 1-0 in a lateral -lateral (horizontal) position, adapting the first layer. Up to three additional single sutures were added for hemostasis if required.
9706264|NCT04681378|Active Comparator|Turan technique|beginning in one corner, the incision is closed using Vicryl 1-0 stitch. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously in the form of a purse string closure. With this technique, the original string is returned to the starting point and tied with a knot. Following the double layered purse-string closure, the aperture left in the middle of the uterine incision is closed with one separate figure of eight suture
9706265|NCT04681378|Active Comparator|Double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
9706266|NCT04681391||anodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During anodal tDCS, the anode was placed over right temporoparietal junction, and the cathode was placed over left supraorbital area.
9706267|NCT04681391||cathodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During cathodal tDCS, the cathode was placed over right temporoparietal junction, and the anode was placed over left supraorbital area.
9706268|NCT04681391||sham (as a control condition)|same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds.
9979648|NCT01384045|Experimental|Arm 1-Health Promotoin Outreach|Active outreach by health promotion staff to send diabetes report card and schedule services including laboratory testing and visits.
9706269|NCT04681573|Other|Single ARM|Only one arm
9706270|NCT04681612||MINOCA|Patients hospitalised with MINOCA according to the recently published consensus document of ESC after cardiac MRI confirmation.
9706271|NCT04681638|Experimental|Plasma|Pathogen-Reduced Plasma resuscitation
9706272|NCT04681638|Active Comparator|Crystalloid|Standardized crystalloid resuscitation
9979649|NCT01384058|Active Comparator|Ezetimibe 10mg/d|intake of ezetimibe 10mg per day for six weeks after wash-out
9979650|NCT01384058|Active Comparator|Simvastatin 20 mg per day|intake of simvastatin 20 mg per day for six weeks after wash-out
9979651|NCT01384058|Active Comparator|Ezetimibe 10 mg/d and Simvastatin 20mg/d|intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out
9979652|NCT01384071|Experimental|Unstable shoes (MBT)|MBT shoes (Masai Barefoot Technology, Switzerland)
9979653|NCT01384071|Sham Comparator|Stable shoes (Adidas)|Adidas stable shoes (Adidas Bigroar2)
9706273|NCT04681521|Experimental|HOT THERAPY:GROUP A|Hot Compress Group
9706274|NCT04681521|Experimental|COLD THERAPY:GROUP B|Cold Compress Group
9706275|NCT04681521|Placebo Comparator|PLACEBO: GROUP C|Inoperative compress Group
9706276|NCT04681599|No Intervention|Nebulization without filter or scavenger|Subject will use a standard nebulizer
9706277|NCT04681599|Experimental|Nebulization with a filter or scavenger|Subject will use a nebulizer with a filter placed at the other end of nebulizer mouthpice or a scavenger outside the nebulizer mask
9706278|NCT04681599|No Intervention|High-flow nasal cannula|Subject will use high-flow nasal cannula at 40 L/min
9785162|NCT01244490|Placebo Comparator|Placebo|
9979654|NCT01384084|Experimental|POP repair plus mini-sling|Patients affected by urogenital prolapse and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy plus anti-incontinence procedure (mini-sling).
9979655|NCT01384084|Active Comparator|pelvic organ prolapse repair|Patients affected by urogenital prolapsed and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy alone.
9979656|NCT01384097||Conventional care|patients treated by conventional haemodynamic care intraoperatively
9979657|NCT01384097||Haemodynamic algorithm|patients treated within a goal-directed haemodynamic algorithm intraoperatively
9979658|NCT01384110|Experimental|Brown Seaweed Lemon Tea|Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose
9979659|NCT01384110|Placebo Comparator|Placebo lemon tea|Single administration of placebo lemon tea containing 50 g of sucrose
9979660|NCT01384136||High risk pregnancy|
9979661|NCT01384136||"|Control - Normal low risk pregnancies"|
9979662|NCT01384149|Active Comparator|standart slt|gonioscopic selective laser trabeculoplasty
9979663|NCT01384149|Experimental|external slt|perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots
10204570|NCT05201534|Active Comparator|Active Control Intervention (Working Memory Training)|Active control intervention: Over a period of 8 weeks, participants will complete activities that enhance short-term storage and maintenance of visuospatial or verbal information, including an adapted Cogmed Working Memory Training program.
9706279|NCT04681599|Experimental|High-flow nasal cannula with a scavenger face tent|Subject will use high-flow nasal cannula at 40 L/min, with a scavenger face tent
9706280|NCT04681599|Active Comparator|High-flow nasal cannula with a surgical mask|Subject will use high-flow nasal cannula at 40 L/min, with a surgical mask over nasal cannula
9706281|NCT04681586|Experimental|Bright white light|
9706282|NCT04681586|Placebo Comparator|Dim red light|
9706283|NCT04681833|Experimental|Cohort 1: BARS13 low repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29.
9706284|NCT04681833|Placebo Comparator|Cohort 1: BARS13 placebo low repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
9706285|NCT04681833|Experimental|Cohort 2: BARS13 high repeat dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29.
9706286|NCT04681833|Placebo Comparator|Cohort 2: BARS13 placebo high repeat dose|Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.
9706287|NCT04681833|Experimental|Cohort 3: BARS13 high repeat multiple dose|Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57.
9706288|NCT04681833|Placebo Comparator|Cohort 3: BARS13 placebo high repeat multiple dose|Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57.
9706289|NCT04681508|Experimental|All patients|All patients undergo chest CT without contrast enhancement and chest X-ray. Blood and urine sampling from patients subsequently undergoing emergency laparoscopy or laparotomy. Otherwise standard care
9706290|NCT04681300||Patients with atopic Prurigo nodularis , non-atopic Prurigo nodularis or atopic dermatitis|
9706291|NCT04681300||Patients with plastic surgery interventions|
9706292|NCT04681235|Experimental|Training Group|Training Group recieved 10 sessions on VR (Grail Motekforce, Netherlands) during two weeks. One session lasted 40 minuties.
9706293|NCT04681222||LFCN|Patients received LFCN + PENG blocks
9706294|NCT04681222||Wound Infiltration|Patients received wound infiltration + PENG blocks
9706295|NCT04681326|Experimental|Biological prosthesis|The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia to allow the positioning of the transfix stitches necessary to the mesh fixation. Successively the retro-muscular rectum muscles plane will be prepared by the separation of the rectum muscles from the posterior rectum-muscles fascia. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched placed at the cardinal and inter-cardinal points. The prosthesis will be placed with a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt (JP) 10 suction drain will be placed under the prosthesis. A JP 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate- reabsorbable-time suture. Another JP 10 suction drain will be placed over the anterior fascia. No subcutaneous suture. Skin stapler or interrupted stitches will be used to close.
9706296|NCT04681326|No Intervention|Standard of care|Normal abdominal wall closure
9706297|NCT04681664|Experimental|50 % fat diet|In the high fat group the subjects were assigned to the diet containing in average 50 % fat, 25 % proteins and 25 % carbohydrates for four weeks.
9706298|NCT04681209|Experimental|DRT-Condition|This is the experimental group that engaged in the DRT-based intervention activity.
9706299|NCT04681209|Active Comparator|Empathy-Condition|This is the experimental group that engaged in the empathy-based intervention activity.
10204571|NCT05201495|Experimental|Treatment|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
9706300|NCT04681274||patient with hepatocellular carcinoma|Phenotype signature database building Image features extraction and clustering
9706301|NCT04680884|Experimental|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
9706302|NCT04680884|Experimental|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
9706303|NCT04680884|Experimental|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
9706304|NCT04680884|Other|Best standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
9706305|NCT04680962|Experimental|MabionCD20 / MabionCD20|Patients receive one or two treatment courses of MabionCD20, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
9706306|NCT04680962|Active Comparator|EU-Rituximab / EU-Rituximab|Patients receive one or two treatment courses of MabThera®, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
9706307|NCT04680962|Active Comparator|US-Rituximab / MabionCD20|Patients receive a single treatment course of Rituxan®, consisting of two 1000 mg i.v. infusions at Day 1 and Day 15. After 24 weeks of follow-up, all patients eligible for re-treatment, are switched to receive a single treatment course of MabionCD20, consisting of two 1000 mg i.v. infusions at Week 24 and Week 26.
9979664|NCT01384162|Experimental|sNN0029, ICV infusion|
9979665|NCT01384175|Active Comparator|intravenous analgesia|Patients received postoperative analgesia by intravenous fentanyl 10 µg/ml 3-8 mL/h.
9706308|NCT04681027|Active Comparator|Pediatric Age Groups: 7 to ≤12 years|Participants expected to require ATC opioids for an extended period of time
9979666|NCT01384175|Active Comparator|epiduaral infusion|Patients received epidural analgesia intraoperatively with ropivacaine 0.75% 1 mg/kg and fentanyl 1 µg/kg followed by continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL postoperatively.
9706309|NCT04681027|Active Comparator|Pediatric Age Groups: 13 to ≤17 years|Participants expected to require ATC opioids for an extended period of time
9706310|NCT04681040||UrBMC19 Group (International Cooperative Group)|The examination of urine for mild pre-diagnosed COVID-19 cases are conducted to evaluate the risk classification and detect the effectiveness of early intervention by COVID-19 treatment such as dexamethasone, chloroquine, remdesivir, ivermectin, actemra, and so forth within the period of 14 days after starting the intervention.
9706311|NCT04681287|Experimental|inetetamab and PD-1 inhibitor combined with chemotherapy.|
9706312|NCT04681053|Active Comparator|Group (A) received both oral and inhaled ivermectin in addition to the standard of care.|use oral and inhaled ivermectin
9706313|NCT04681053|Active Comparator|B) received oral ivermectin in addition to the standard of care|receive oral ivermectin
9706314|NCT04681053|Active Comparator|c) received inhaled ivermectin in addition to the standard of care|received inhaled ivermectin
9706315|NCT04681053|No Intervention|Group (d) received the current standard of care only|received standard of care only
9706316|NCT04681131|Experimental|CAB-AXL-ADC (BA3011)|CAB-AXL-ADC (BA3011) alone
9706317|NCT04681131|Experimental|CAB-AXL-ADC (BA3011)+PD-1 inhibitor|CAB-AXL-ADC (BA3011) with PD-1 inhibitor
9706318|NCT04681001|Experimental|Coldamaris pro|One puff per nostril three puffs into mouth
9706319|NCT04681001|Placebo Comparator|Coldamaris sine|One puff per nostril three puffs into mouth
9706320|NCT04680923|Experimental|CPPLAI|Group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline in patients scheduled for laparoscopic sleeve gastrectomy.
9706321|NCT04680923|Placebo Comparator|Placebo|Group 2 (placebo) (n= 58) will receive intraoperative combined periportal and preperitoneal sterile water 40 ml in patients scheduled for laparoscopic sleeve gastrectomy.
9706322|NCT04680949|Placebo Comparator|Placebo|Patients receiving standard-of-care (SOC) and placebo. Placebo is injected subcutaneously once daily for 10 days
9706323|NCT04680949|Experimental|Anakinra|Patients receiving SOC and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
9706324|NCT04680806|Experimental|Er,Cr:YSGG laser 2780 nm|Group A was treated by an Er,Cr:YSGG laser 2780 nm cylindrical tip (tip 600 μm, 45 millijoule /pulse, average power 2.25 W, frequency 50 Hz, pulse duration 60 µs, energy density 43 J/cm2, water 50%, and air 40%). The procedure was performed completely without anesthesia with the laser tip at angulation ~30° and distance of ~1 mm from the gingival tissue. The laser tip was advancing in scanning movement from in the cervical-apical direction in all pigmented areas. The following settings was used to achieve hemostasis in case of the bleeding was present (tip 600 μm, 30 millijoule /pulse, average power 1.5 W, frequency 50 Hz, pulse duration 700 µs, energy density 28.7 J/cm2, water 10%, and air 20%).
9706325|NCT04680806|Experimental|Diode laser 940 nm|Group B was treated with diode 940 nm Laser. The procedure was performed with a pencil-sized handpiece containing a 400 µm lasing fiber (400 μm initiated tip, average power 0.8 watts, Pulsed mode, Duty cycle 20%, Pulse duration 10 μs, energy density 636.9 J/cm2 per second, no water or air). Infiltration anesthesia was injected for B group . The laser tip was placed in angle ~30° with the gingival surface. Short light paint brush strokes were used in the cervical-apical direction in all pigmented areas.
9706326|NCT04680871||Normal Temperature Subjects|"Subjects will sit for 20 to 30 minutes. The subject may be covered with a blanket. At the end of the wait period, a homogeneous temperature will be taken from both thermometers. The subjects will be disconnected from the devices and excused.~The study is expected to take 30 minutes to an hour for each normal temperature subject."
9706327|NCT04680871||Induced Febrile Subjects|"Heating of the body will be created using multiple heating devices. A vapor barrier will cover the entire body of the subject from the base of the neck down, including the feet. The purpose of the vapor barrier is to prevent evaporative cooling during the heating period. Subjects will then sit in an infrared sauna. Electric heating pads will be placed on the back, torso, and/or feet. Finally, a nylon cape will be placed over the body from the base of the neck to the floor and a head covering will be placed on the head. (See Figure 2 for reference)~During the Warming period (approximately 90 minutes) the sublingual temperature will be raised to a minimum of 99.5°F (as determined by the Reference Clinical Thermometer). A febrile temperature will be recorded from both thermometers."
9706328|NCT04680819||Compared with given anatolian propolis group and do not use anatolian propolis group|According to the spectrophotometic analysis report of this anatolian group, there should be a minimum phenolic 106.0 mg gae per ml and 73.1 mg ke flavonoid content in each ml and a total content of 253.9 mg te / ml.
9706329|NCT04680832|Experimental|ILD patients|Patients diagnosed with one of the most prevalent fibrotic ILDs: IPF, CHP, CTD-ILD, iNSIP, IPAF, and unclassifiable ILD (defined as unclassifiable disease at the time of the first MDT).
9706330|NCT04680858|No Intervention|Standard Communication|Endoscopic procedures performed by skilled endoscopic team with standard communication (no headset)
9979667|NCT01384175|Active Comparator|patient-controlled epidural analgesia|In addition to epidural anesthesia and epidural infusion, postoperatively patients received patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
9979668|NCT01384188|Experimental|E1|ONO-5334
9979669|NCT01384188|Experimental|E2|ONO-5334
9979670|NCT01384201||Confocal Laser Endomicroscopy|OGD by Confocal Endomicroscopy
9979671|NCT01384201||White light endoscopy|OGD by whitelight endoscopy
9979672|NCT01384214|Experimental|1|botulinum toxin Type A
9979673|NCT01384227|Experimental|Proflavine Hemisulfate|
9979674|NCT01384240|Experimental|Proflavine Hemisulfate|
9706331|NCT04680858|Experimental|DECT enhanced Communication|Endoscopic procedures performed by skilled endoscopic team with enhanced communication tools ( DECT headset)
9706332|NCT04680767|Experimental|[¹⁴C]-LY3502970|A single dose of LY3502970 and [¹⁴C]-LY3502970 administered orally.
9706333|NCT04680494|Experimental|Rest|Participants rest quietly for 30 minutes, sitting on a chair. They may read magazines not involving motion-related elements
9706334|NCT04680494|Experimental|Moderate intensity exercise|Participants cycle on a cycle ergometer during 30 minutes at 65% of their maximal cardiac frequency
9706335|NCT04680494|Experimental|High intensity exercise|Participants cycle on a cycle ergometer during 15 minutes at 75% of their maximal cardiac frequency. This session also includes 3 minutes of warm-up and three minutes of cool down at 50% of their maximal cardiac frequency
9779036|NCT01120704|Experimental|28, 8Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779037|NCT01120704|Experimental|29, 8Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779038|NCT01120704|Experimental|30, 8Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779039|NCT01120704|Experimental|31, 8Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
9779040|NCT01120704|Experimental|32, 8Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
9779041|NCT01120717|Experimental|QVA149|110µg/50µg capsule for oral inhalation, once daily, delivered by a single dose dry powder inhaler (SDDPI)
9779042|NCT01120717|Placebo Comparator|Placebo|Placebo to match QVA149, capsules for inhalation once daily, delivered by an SDDPI
9779043|NCT01120756|Experimental|Goal-oriented attentional self-regulation training|Goal-oriented attentional self-regulation training (GOALS).
9779044|NCT01120756|Active Comparator|Brain Health Education|Brain Health Education (EDU)
9779045|NCT01120782|Active Comparator|etafilcon A toric new lens/etafilcon A toric lens|The lens worn first is a new etafilcon A toric contact lens and the lens worn second is a marketed etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
9779046|NCT01120782|Active Comparator|etafilcon A toric lens/etafilcon A toric new lens|The lens worn first is a marketed etafilcon A toric contact lens and the lens worn second is a new etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
9779047|NCT01120808|Experimental|All Participants|Participants were registered competitors in RacingThePlanet 6 stage 7 day 155mile (250km) ultramarathon.
9779048|NCT01120834|Experimental|all subjects|
9779049|NCT01120899|Experimental|Minocycline|
9779050|NCT01120990|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
9779051|NCT01121146|Active Comparator|Crosslinked Marathon polyethylene|
9779052|NCT01121146|Active Comparator|Standard Enduron polyethylene|
9779053|NCT01121172||obese|obese subjects according to International Obesity Task Force criteria
9779054|NCT01121172||lean|
9779055|NCT01121185|Experimental|MBL-HCV1|
9779056|NCT01121185|Placebo Comparator|0.9% sodium chloride|
9779057|NCT01121211|Active Comparator|Testosterone|Testosterone x 24 weeks
9779058|NCT01121211|Placebo Comparator|Placebo|Placebo x 24 weeks
9779059|NCT01121224|Active Comparator|BMS Group|Patients who receive a bare metal stent in the saphenous vein graft target lesion(s).
9779060|NCT01121224|Experimental|DES Group|Patients who receive a drug-eluting stent in the saphenous vein graft target lesion(s).
9779061|NCT01121250|Experimental|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
9779062|NCT01121250|Active Comparator|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
9706336|NCT04680520|Experimental|Best practice skin care advice booklet plus emollient (Doublebase Gel® or Diprobase Cream®)|Use of emollient (Doublebase Gel® or Diprobase Cream®) plus best practice skin care advice. The advice is given in the form of a booklet containing advice on skin care. This will contain information on avoiding soap etc. It will also explain how to apply the emollient i.e. in the direction of the hair, all over the child's skin daily for the first year of life. Intervention group will receive both emollients and parents are asked to choose their preferred.
9706337|NCT04680520|Active Comparator|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
9706338|NCT04680429|Experimental|RP7214, Single and multiple doses|"In Part 1 up to 3 cohorts with single ascending doses of RP7214 at 100 mg QD, 200 mg QD and 400 mg QD.~In Part 2 up to 2 cohorts with multiple ascending doses of RP7214 at 200 mg BID, 400 mg BID."
9706339|NCT04680429|Placebo Comparator|Placebo, Single and multiple doses|In Part 1 up to 3 cohorts and in Part 2 up to 2 cohorts with matching placebo to RP7214 tablet
9706340|NCT04680754|Experimental|Experimental Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to patients in experimental group after thyroidectomy. A brochure was developed in line with the literature on head-neck stretching exercises. Since the patients came to the clinic on surgery day, the exercises were examined by the patient on the first postoperative day. The patient was asked to perform the exercises 3 times a day, in the morning, noon and evening for a month, provided that each movement was 5 times. Then, the Patient and Observer Scar Rating Scale (POSAS)  was applied.~The pain level of the patient on postoperative day 1 was evaluated using VAS. For further evaluations, the patient was called by phone at the 1st week and 1st month. Neck pain and discomfort status was evaluated with the Neck Pain and Disability Scale (NPAD), and then the scar appearances with the Patient and Observer Scar Assessment Scale by requesting neck photographs at the 1st week and 1st month."
9706341|NCT04680754|No Intervention|Control Arm|"Routine nursing care (use of analgesics, IV fluid therapy and wound care) was applied to the control group after thyroidectomy. Follow-up of the patients with the scales applied in the experimental group were also performed to the control group at the same intervals. After thyroidectomy, patients were called by phone in the 1st week and 1st month. Neck pain and discomfort scale and Patient and Observer Scar Rating Scale were applied again in both phone calls. Photographs of the scar appearance at the 1st week and the 1st month were requested from the patients."
9706342|NCT04680624|Other|Single Group|
9706343|NCT04680845|Experimental|Self-affirmation|"Participants will be asked to complete a standard questionnaire including:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will… …think about the things I value about myself~remember things that I have succeeded in~think about what I stand for~think about things that are important to me~If…______________________________________________________________________"
9706344|NCT04680845|No Intervention|Control|Participants will be asked to complete a standard questionnaire.
9706345|NCT04680650|Experimental|Group DS|Anesthesia was maintained with sevoflurane and target-controlled infusion of remifentanil in the group DS
9706346|NCT04680650|Active Comparator|Group DP|Anesthesia was maintained with propofol and target-controlled infusion of remifentanil in the group DP
10204572|NCT05201482|Experimental|25 patients aged 8-16 years with moderate or severe visual impairment|25 patients aged 8-16 years with moderate or severe visual impairment will test the impact of a head-mounted augmented reality low vision aid (SightPlus) on vision and quality of life
9706348|NCT04680611||Patients with severe eosinophilic asthma Phase 1|Patients with severe eosinophilic asthma on Nucala(R) treatment
9706349|NCT04680611||Patients with severe eosinophilic asthma Phase 2|Patients with severe eosinophilic asthma to start Nucala(R) treatment
9706350|NCT04680611||Partners of patients with severe eosinophilic asthma Phase 2|Partners of patients with severe eosinophilic asthma to start Nucala(R) treatment
9706351|NCT04680611||Phase 3: Patients with severe eosinophilic asthma from Phase 2|A sub-group of patients who participate in Phase 2
9706352|NCT04680611||Phase 3: Partners of patients in Phase 3|Partners of the sub-group of patients who participate in Phase 3
9706353|NCT04680663||Non-severe complications group|where the non-complicated patients is the patients running the normal postoperative course of surgery and without any need for intervention
9706354|NCT04680663||severe complications group|any deviation from the normal post-operative course
9706355|NCT04680715|Experimental|Per-Operative Radiotherapy technique by Papillon +TM|Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM
9706356|NCT04680572|Active Comparator|Bipolar hemiarthroplasty group|
9706357|NCT04680572|Active Comparator|Dual mobility cups total hip replacement group|
9706358|NCT04680689||Fuse-Heart -SG 01|Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries.
9706359|NCT04680689||Fuse-Heart -SG 02|Study subjects surviving an acute myocardial infarction, revascularized or not.
9706360|NCT04680728||patient|Patient admitted to intensive care for less than 24 hours.
9706361|NCT04680702|Experimental|Metabolic Syndrome and Sims Score|
9706362|NCT04680442|Active Comparator|Control Group|Recommendations for continuing or holding trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) for the control group are guided by an adaptation of the 2008 Canadian recommendations.
9706363|NCT04680442|Experimental|Intervention Group|The intervention group will continue to receive trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in the setting of asymptomatic decline in LVEF up to an LVEF of 40% as outlined in the criteria listed in Table 3. For reasons of practicality, in the intervention group, the first dose of trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) after randomization can be administered up to 3 weeks late. This will allow time for the participant to be reviewed by a cardiologist and to receive ACE-I/angiotensin receptor blocker and/or beta-blocker, and for dose titration.
9779063|NCT01121250|No Intervention|Usual Care|Participants do not receive any services.
10204573|NCT05201417|No Intervention|control group A|patients continue their usual HIV management no intervention
9706364|NCT04680468|Experimental|Belantamab mafodotin|Patients receive Belantamab mafodotin 2.5 mg/kg by intravenous infusion on day -42 relative to autologous stem cell infusion (day 0), on day +60, and every 90 days thereafter, for up to 2 years following ASCT.
9706365|NCT04680559|Experimental|MCBI Group|Training in mindfulness and compassion (MCBI) is facilitated in eight weekly sessions of 2 hours. With a didactic format, through theory, class discussions, and guided meditation practices.
9706366|NCT04680559|Active Comparator|Active-Wait List Group|Completion of a record during these 8 weeks. Active work of introspection about one's own sensations, thoughts, distractions, judgments, etc. in therapy sessions. Registered after each session.
10193060|NCT03340064|Experimental|Levetiracetam|"Subjects aged 1 month to <6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to <4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day.~At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months or by LEV 20 mg/kg/day for subjects aged 6 months to <4 years at 2-week intervals to 0 mg/kg/day."
10193061|NCT03330249|Experimental|Split Cisplatin and radiotherapy|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy
10193062|NCT03330249|Active Comparator|Cisplatin and radiotherapy|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy
9706367|NCT04680221|Active Comparator|Treatment|The transversus abdominis plane block is a procedure involving injection of a local anesthetic solution into the abdominal plane between the internal oblique muscle and the transversus abdominis muscle. In our institution, this is done under ultrasound guidance which is the current standard to improve efficacy and limit complications. Liposomal bupivacaine uses an innovative technology consisting of lipid-based particles containing active pharmaceutical agent (bupivacaine) which extends the duration of the medication through a process of gradual release for metabolism.This drug delivery technology extends the duration of action to up to 96 hours when given at a dose of 266 mg liposomal bupivacaine admixed with 30 ml of bupivacaine 0.25% and 30 ml of saline. Forty ml of solution is deposited on the left side of the abdomen and 40 ml on the right.
9706368|NCT04680221|Placebo Comparator|Control|The transversus abdominis plane block will be performed under ultrasound guidance with deposition of 80 ml of saline (40 ml on either side).
9706369|NCT04680234|Active Comparator|Cryotherapy group|Patients underwent superficial cryotherapy using dimethyl ether and propane (DMEP) at -57C very 2 weeks for maximum six sessions
9706370|NCT04680234|Active Comparator|Microneedling group|Patients underwent microneedling 2 weeks for maximum six sessions
9706371|NCT04680351|Experimental|phrenic stimulation|
9706372|NCT04680104||Cohort A|Infusion of Na-Lev plus 5-FU (unique administration by one 48h-infusional pump)
9706373|NCT04680104||Cohort B|Infusion of Ca-Lev followed by infusion of 5-FU (two separated administrations by using one plastic bag followed by one 48h-infusional pump)
9706374|NCT04680377||Participants receiving standard of care durvalumab|Prior to receiving treatment participants will have samples taken from three different sources to test the microbiome bacteria to determine if it will help predict toxicity to the treatment
9706375|NCT04680091|Experimental|Efavirenz 600 mg + Pyrotinib 400 mg|
9706376|NCT04680091|Active Comparator|Pyrotinib 400 mg|
9706377|NCT04680364|Experimental|participants|to analyze the effects of 6-month ballroom dance (3 times/wk) on physical fitness and reaction time in twenty-four experienced older adults
9706378|NCT04680143|Experimental|Systemic erythropoietin injections|The study included 10 patients diagnosed as post papilledemic optic atrophy
9706379|NCT04680273|Experimental|Part 1: [14C]-GDC-9545|Participants will be enrolled to receive a single dose of Carbon-14 labelled [14C]-GDC-9545.
9706380|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BCD|Participants will be randomly allocated to one of two treatment sequences (BCD for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
9706381|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BDC|Participants will be randomly allocated to one of two treatment sequences (BDC for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
9706382|NCT04680247|Active Comparator|VA-LCP|Osteosynthesis with a VA-LCP system
9706383|NCT04680247|Active Comparator|NCB-PT|Osteosynthesis with a NCB-PT system
9706384|NCT04679922|Active Comparator|Peri Implant mucosal thickness connective tissue graft|
9706385|NCT04679922|Experimental|Peri Implant mucosal thickness fascia lata graft|
9706386|NCT04680000|Active Comparator|Standard BCBT-CP|Brief Cognitive Behavior Therapy for Chronic Pain (BCBT-CP) is a seven-module intervention for chronic pain based on the efficacious specialty-care, ten-session version of this treatment called Cognitive Behavioral Therapy for Chronic Pain (CBT-CP).
9706387|NCT04680000|Experimental|Standard BCBT-CP with Telephone Booster|"Participants will receive standard BCBT-CP as described in the Standard BCBT-CP arm. They will also receive telephone or video teleconference booster contacts as follows:~BCBT-CP Booster Contacts are intended to refresh BCBT-CP content without introducing new skills. To accomplish this, Booster Contacts are manualized (see appended Booster Protocol form) to cover assessment of pain since last contact, review of most recent BCBT-CP module(s) and reminder about the next BCBT-CP appointment (if one is scheduled)."
9706388|NCT04680169|Active Comparator|Group A: Bronchoscopic intubation using AuraGain LMA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using AuraGain
10193063|NCT03328026|Experimental|INCMGA00012, SV-BR-1-GM combination|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 with cycles every 3 weeks
9706389|NCT04680169|Active Comparator|Group B: Bronchoscopic intubation with I-gel SGA as conduit|A group of 50 patients randomly allocated to bronchoscopic intubation using I-gel
9706390|NCT04680013||Cognitive Control|Participants in this group are cognitively intact.
9706391|NCT04680013||Mild Cognitive Impairment|Participants in this group have mild cognitive impairment.
9706392|NCT04680013||Dementia Group|Participants in this group have dementia.
9706393|NCT04680208||Planned ICU admission|Cases who were planned for postoperative ICU admission at the time of preanesthetic check up
9706394|NCT04680208||Unplanned ICU admission|Cases who got admitted to ICU postoperatively without anticipation
9706395|NCT04680078|Active Comparator|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop. The sutures are removed 1 week after the surgery.
9706396|NCT04680078|Active Comparator|Conventional Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop.
9706397|NCT04679948|Experimental|Period 1 with reference treatment alone|
9706398|NCT04679948|Experimental|Period 2 with reference and test treatment|
9706399|NCT04679883|Experimental|GLH8NDE 5% and GLH8NDE Placebo|Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo
9706400|NCT04679883|Experimental|GLH8NDE 5%|Total 6 times 1 drop of GLH8NDE 5%
9706401|NCT04679883|Placebo Comparator|GLH8NDE Placebo|Total 6 times 1 drop of GLH8NDE Placebo
9706402|NCT04680338|Active Comparator|Cardiac magnetic resonance imaging|Cardiac magnetic resonance (CMR) stress perfusion imaging with feedback of clinically actionable findings
9706403|NCT04680338|No Intervention|Control|No intervention, following the natural course of coronary atherosclerosis
9706404|NCT04680182|Experimental|Study group|Wound drain is kept until until a scheduled visit three weeks after the surgery unless the drain produced less than 30 ml/day for two consecutive days, in which case it could be removed earlier.
9706405|NCT04680182|Active Comparator|Control group|When the drain produces less than 100 mL over 24 hours, the self-suction bulb is removed and the drain is shortened and drained into a colostomy bag placed around the site of drain insertion. A request is filed with the community nursing system to have a visiting nurse to pull out the drain 1-2 cm per day.
9706406|NCT04679987||paroxysmal Af|
9706407|NCT04679987||no paroxysmal Af|
9706408|NCT04680325|Placebo Comparator|Placebo juice|
9706409|NCT04680325|Active Comparator|Cranberry juice|
9706410|NCT04679974|Experimental|MBCT treatment|Melodic-based communication treatment
9706411|NCT04680286|Placebo Comparator|Placebo|A 5 ml syringe with saline will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
9706412|NCT04680286|Experimental|Methadone|A 5 ml syringe with 1 mg/ml of methadone will be prepared and study drug will be administered as intravenous bolus dose (0.1 mg/kg). The study drug will be administered at induction of anesthesia.
9706413|NCT04679896|Experimental|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
9706414|NCT04679896|Other|Local autograft|
9706415|NCT04679831|Experimental|Ujiplus® porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
9706416|NCT04679831|Active Comparator|Praziquantel 400mg|Arm receiving the approved Praziquantel treatment of 400mg once with plain porridge daily (without papaya seeds)
9706417|NCT04679844|Experimental|MagnetOs Putty|"Interventions~Procedure: Instrumented posterolateral spine fusion~Device; MagnetOs Putty"
9706418|NCT04679844|Active Comparator|Autograft Bone|"Interventions~Procedure: Instrumented posterolateral spine fusion~Device: Autologous bone graft"
9706419|NCT04679766|Experimental|Patients with non-restorable tooth in maxillary bi-cuspid region with labial/buccal plate dehiscence|
9706420|NCT04679753|Active Comparator|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)
9706421|NCT04679753|Active Comparator|Brainsway DTMS with High Frequency Stimulation (HF)|Brainsway DTMS with High Frequency Stimulation (HF)
10204574|NCT05201417|Other|intervention group B|patients continue their usual HIV management, patients will benefit from an adapted physical activity program for 12 weeks
9706422|NCT04679714|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
9706423|NCT04679649|Experimental|Trial A - Intervention Group (manual mobilisation)|Participants will continue to receive routine care and 13 sessions of manual spinal mobilisation will be administered over a 6 months period to compare routine care vs routine care plus manual spine mobilisation physiotherapy.
9706424|NCT04679649|No Intervention|Trial A - Control Group (routine care)|Participants in control group will continue to receive routine care, and routine care measurements for axial spondyloarthritis will be taken at baseline, 3 months and 6 months plus follow up.
9706425|NCT04679636|Experimental|Experimental group|receive biofeedback training for heart rate variability for eight weeks
9706426|NCT04679636|No Intervention|Control group|receive conventional treatment
9706427|NCT04679662|Experimental|Single-arm study of PLAR Implant and Delivery System to treat severe mitral regurgitation|All enrolled patients will receive the study device
9706428|NCT04679675|Active Comparator|Usual Care|
9706429|NCT04679675|Active Comparator|Education|
9706430|NCT04679675|Active Comparator|Direct Mail|
9706431|NCT04679675|Active Comparator|Opt-in|
9706432|NCT04679545|Experimental|CBD|Subject will receive a 28-day supply of 20 mg CBD sublingual tablets to be taken 3 times a day for 28 days.
9706433|NCT04679545|Placebo Comparator|Placebo Control|A placebo sublingual tablet to be taken three times a day for 28 days.
9706434|NCT04679558|Active Comparator|Comparator|Preventive protocol
9706435|NCT04679558|Experimental|Intervention|Adding chlorhexidine to the preventive protocol
9706436|NCT04679701||Recruited Amputees|The amputee participants will be recruited over the course of 6 months. Once a patient is recruited and has given consent, they will be fitted with a prosthesis using the Confidence Socket technology and be administered an initial survey. A follow-up meeting for one month after the fitting is scheduled. At the follow-up appointment adjustments to the prosthesis are made as needed and the patient is administered another survey.
9706437|NCT04679493|Experimental|XC7 100 mg single|Cohort 1 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 100 mg (3 subjects) or placebo (1 subject, see placebo single arm)
9706438|NCT04679493|Experimental|XC7 200 mg single|Cohort 2 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 200 mg (3 subjects) or placebo (1 subject, see placebo single arm)
9706439|NCT04679493|Placebo Comparator|Placebo single|Placebo comparator arm will consist of 2 subjects (1 subject from Сohorts 1 and 2)
9706440|NCT04679493|Experimental|XC7 200 mg multiple|Cohort 3 - 6 subjects will be randomized in a 6:2 ratio to be treated either XC7 200 mg (6 subjects) or placebo (1 subject, see placebo multiple arm)
9706441|NCT04679493|Placebo Comparator|Placebo multiple|Placebo comparator arm will consist of 2 subjects from cohort 3
9706442|NCT04679389|Experimental|Acetazolamide|Acetazolamide administered via capsule or liquid suspension. Capsule would be 250 mg oral capsules encapsulated by gelatin capsule and filled with lactose to match placebo. Liquid suspension would be 25 mg/mL oral suspension but adding 125 mg Acetazolamide tablets to suspending agent Ora-blend
9706443|NCT04679389|Placebo Comparator|Placebo|Placebo administered via capsule or liquid suspension. Capsule would be a gelatin capsule filled with lactose powder to match Acetazolamide. Liquid suspension would be Ora-blend.
9706444|NCT04679298||Apixaban|N=20
9706445|NCT04679298||Edoxaban|N=20
9706446|NCT04679298||Dabigatran|N=20
9706447|NCT04679298||Rivaroxaban|N=20
9706448|NCT04680195|Experimental|Thalidomide treatment Group|"Induction period:~Thalidomide tablets: 50-100 mg/d, qn, po.~Maintenance period:~Thalidomide tablets: 50-75 mg/d qn, po."
9706449|NCT04679532|Other|Validation. Gx sweat collection patch|Left ventral forearm placement using Epicore Biosystems Gx patch
9706450|NCT04679532|Other|Validation. Reference sweat collection patch|Right ventral forearm placement using a well-established methodology as published in peer-reviewed journals
9706451|NCT04679454|Experimental|Preoperative Radiation Treatment|
9706452|NCT04679441|Active Comparator|Healthy individuals Skills training only|These participants will receive CFSAT training only (n = 60). They will train for 24 hours over 12 weeks.
9706453|NCT04679441|Experimental|MCI, Skills training only|These participants will receive 24 hours of CFSAT training over 12 weeks following the same training protocol as the NC sample.
9706454|NCT04679441|Experimental|MCI, Combined treatment|Participants assigned to this condition will initially train for 3 weeks @ 60 minutes twice per week on CT (Posit Science). Participants will train 90 minutes on Double Decision and 30 minutes on Hawkeye. They can train on Hawkeye in 15- minute increments and intersperse it within the Double Decision training. They will then train CFSAT for 9 weeks at the recommended dosage. Each task will be trained twice before advancing to the next task
9706455|NCT04679597||total neoadjuvant therapy|Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery.
9706456|NCT04679597||standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
9706457|NCT04679259|Experimental|Cardiac surgical patients|
9706458|NCT04679571|Experimental|Targeted Albumin with Standard Medical Treatment|Patients with serum albumin <3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks
9706459|NCT04679571|Active Comparator|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year"
9706460|NCT04679519|Active Comparator|Control|Control group that was not given a supplement.
9706461|NCT04679519|Experimental|BCAA|Supplement group that was given Branched Chain Amino Acids (BCAA).
9706462|NCT04679519|Experimental|Leucine|Supplement group that was given Leucine.
9706463|NCT04679519|Experimental|HMB|Supplement group that was given β-Hydroxy β-methylbutyric acid (HMB)
9706464|NCT04679584||Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, SUEP).
9706465|NCT04679584||High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (POP, SUEP).
9779064|NCT01121263||Angiogram Review Group|All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
10193064|NCT03328026|Experimental|INCMGA00012, Epacadostat 600 mg BID, SV-BR-1-GM combination|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 and epacadostat 600 mg BID with cycles every 3 weeks
10193065|NCT03328026|Experimental|INCMGA00012, Epacadostat, SV-BR-1-GM combination expansion|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 and epacadostat (dose to be determined) with cycles every 3 weeks
9706466|NCT04679584||Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)|Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, POP).
10193066|NCT03316807|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
9706467|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV
9706468|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV
10193067|NCT03316807|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
10193068|NCT03304379|Experimental|Dosing regimen 1|
10193069|NCT03304379|Experimental|Dosing regimen 2|
9706469|NCT04679350|Experimental|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo
9706470|NCT04679350|Placebo Comparator|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)
9706471|NCT04679792||operated|Patients Under 18 years of age who are operated for Chiari Malformation on the basis of routine neurosurgical assessment.
9706472|NCT04679792||non operated|Patients Under 18 years of age who are not operated for Chiari Malformation on the basis of routine neurosurgical assessment.
9706473|NCT04679415|Experimental|Standard of care + hzVSF-v13 200 mg at D1, hzVSF-v13 100mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
9706474|NCT04679415|Experimental|Standard of care + hzVSF-v13 400 mg at D1, hzVSF-v13 200mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
9706475|NCT04679415|Placebo Comparator|Standard of care + 3 doses of the placebo (normal saline) IV|Drug: Placebo (Normal saline solution) Dosage form: 0.9% NaCl Solution Frequency Frequency: Dose at Day 1, 3, 7 Other names: 0.9% Normal saline
9706476|NCT04679363|Experimental|Active release technique group|Active release technique group (ART group) will receive Oscillatory mobilization with active release technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
9706477|NCT04679363|Experimental|Post isometric relaxation group|Post isometric relaxation group (PIR group) will receive Oscillatory mobilization with post isometric relaxation technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
9706478|NCT04679480|Experimental|Intervention|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion at the trial site and administered as a flat 350mg dose in 100ml sodium chloride 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
9706479|NCT04679246|Experimental|General Intervention|The strategies will be implemented in the three intervention elementary schools. The schools were conveniently chosen for the size of the student population. In addition to having a sufficient population, it was important that the authorities of each school site agreed to participate.
9706480|NCT04679246|Experimental|Subsample intervention|A group will be randomly selected from each school grade from the intervention schools, and within each chosen group 12 children will be randomly selected per group (48 children in total per school).
9706481|NCT04679246|No Intervention|Control|Three primary schools were selected from a close locality (Villa Corona, Jalisco). This was chosen because it is similar in relation to the social, economic, and geographical context to the locality of intervention. The schools were selected for the similarity in the size of the student population of the intervention schools.
9706482|NCT04679779|Experimental|control group|receive occupational therapy program
9706483|NCT04679779|Experimental|study group|receive wii virtual reality
9706484|NCT04679129|Experimental|Single Ascending Dose-ASC42|ASC42 tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
9706485|NCT04679129|Experimental|Multiple Ascending Dose-ASC42|ASC42 tablet, Dose 1，Dose 2，Dose 3，q.d.×14 days
9706486|NCT04679129|Placebo Comparator|Single Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
9706487|NCT04679129|Placebo Comparator|Multiple Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，q.d.×14 days
9706488|NCT04679077|Other|Cytocam-IDF Imaging|All patients will undergo the same interventional test.
10193070|NCT03304379|Experimental|Dosing regimen 3|
10193071|NCT03304379|Experimental|Dosing regimen 4|
10193072|NCT03268499|Active Comparator|Lipiodol-cisplatin suspension|
10193073|NCT03268499|Active Comparator|Lipiodol-cisplatin emulsion|
10193074|NCT03255070|Experimental|ARX788 Phase 1a (Dose Escalation)|ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.
10204575|NCT05201352|Experimental|Experimental arm|trifluridine/tipiracil + XB2001
10204576|NCT05201352|Placebo Comparator|Control arm|trifluridine/tipiracil + placebo
9706489|NCT04679051|Experimental|8 hours time in bed|Participants will be asked to spend 8 hours time in bed with the aim of achieving one week of normal sleep duration (7 to 8 hours).
9706490|NCT04679051|Experimental|11 hours time in bed|Participants will be asked to spend 11 hours time in bed with the aim of achieving one week of long duration sleep as defined as 9+ hours of sleep.
9706491|NCT04678986||ER2 participants|all participants of ER2 database will be included in the analysis
10193075|NCT03255070|Experimental|ARX788 Phase 1b (Dose Expansion)|ARX788 will be administered every 3 weeks (Q3W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
9706492|NCT04679376|Experimental|Group 1|Atorvastatin (40 mg daily)
9706493|NCT04679376|Placebo Comparator|Group 2|
9706494|NCT04679220|Active Comparator|Non-heated Resin Composite group|Patients received Non-heated nanofilled resin composite on one side of the mouth
9706495|NCT04679220|Placebo Comparator|Preheated Resin Composite group|Patients received preheated nanofilled resin composite on the other side of the mouth
9706496|NCT04678869|Experimental|Cirprofloxacin prophylaxis|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
9706497|NCT04678869|Active Comparator|Standard of care|standard of care
9706498|NCT04679142||Adult patients starting a treatment with Baclocur®|Baclofen(Baclocur®) 10mg, 20mg, 30mg, 40mg.
9706499|NCT04678934||Bicuspid aortic valve subgroup|For analysis in Bicuspid aortic valve population.
9706500|NCT04679090|Experimental|Participant|Participants will answer a series of questionnaires, wear a physical activity tracker (pedometer) and do functional tests (six minute walk test, chair stand test, balance, back scratch, sit and reach, leg strength and hand strength) pre and post.
9706501|NCT04679064|Active Comparator|Phisician's choice of standard chemotherapy|"Chemotherapy at physician's choice between Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 Gemcitabine 1000 mg/mq d 1,8,15 q 28 Topotecan 1.25 mg/mq day 1-5 q 21~+/- Bevacizumab at defined scehedule"
9706502|NCT04679064|Experimental|Niraparib+Dostarlimab|Dostarlimab 500 mg q 3W for the fist 4 cycles, 1000 mg q 6W thereafter + Niraparib 300 mg or 200 mg if platelet count <150,000 /μL and/or body weight <77kg QD po q 28
9779065|NCT01121263||Therapeutic Intervention Group|"Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR~Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents"
9779066|NCT01121393|Experimental|Arm A BIBW 2992|Patients receive a tablet of BIBW 2992 daily until progression or unacceptable toxicity
9779067|NCT01121393|Active Comparator|Arm B Chemotherapy|Patients receive Gemcitabine and Cisplatin, maximum is 6 courses
9779068|NCT01121406|Experimental|BI 6727|Patients receive BI 6727 infusion every 3 weeks
10193076|NCT03220945|No Intervention|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
10193077|NCT03220945|Experimental|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
10193078|NCT03196518|Experimental|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
9779069|NCT01121406|Active Comparator|Cytotoxic|At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin
9779070|NCT01121484|Experimental|desvenlafaxine succinate sustained-release|
9779071|NCT01121484|Placebo Comparator|Placebo|
9779072|NCT01121536|Experimental|Armodafinil 150-200 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. At the discretion of the investigator, the dosage of armodafinil may be increased to 200 mg/day on day 6 or thereafter, and reduced to 150mg/day if the higher dose is not well tolerated. Treatment was administered for six months.
9779073|NCT01121549||Aromasin|All patients included in the study
9779074|NCT01121562|Experimental|Sunitinib arm|
9779075|NCT01121575|Experimental|Arm 1|PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
9779076|NCT01121575|Experimental|Arm 2|PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
9779077|NCT01121666|Active Comparator|Gonal-f® (Follitropin alfa)|
9779078|NCT01121666|Experimental|AFOLIA-150 (Follitropin alfa)|
9779079|NCT01121757|Experimental|Azacitidine followed by Lenalidomide|"Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.~Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1."
9779080|NCT01121757|Experimental|Lenalidomide followed by Azacitidine|"Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.~Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a."
9779081|NCT01121900|Experimental|Trazodone HCl OAD|OAD: Once A Day
9779082|NCT01121900|Active Comparator|Trazodone HCl (Apotex Corp.)|
9779083|NCT01121913|Experimental|Trazodone Contramid® OAD (test product 1)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
9779084|NCT01121913|Experimental|Trazodone Contramid® OAD(test product 2)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
9779085|NCT01121913|Active Comparator|Triticco®|
9779086|NCT01121913|Active Comparator|Desyrel®|
9779087|NCT01121926|Experimental|Trazodone HCl OAD|OAD: Once A Day
9706503|NCT04678804|Experimental|Matrix Graft Group|patients treated with Porcine Derived Volume Stable Matrix
9706504|NCT04678804|Other|Autogenous ctg group|patients treated with autologous tissue
9706505|NCT04679103|Experimental|Eculisumab (JSC GENERIUM, Russia)|Eculizumab
9706506|NCT04678960|No Intervention|Standard Reentry Practice|Youth/safe adult participants only receive assessments (baseline assessment while youth are at the facility; 3, 6, 12, 18 months follow-up assessments after youth are released from the facility).
9706507|NCT04678960|Experimental|TBRI Group Training only|"Youth/safe adult dyads participate in 8 TBRI caregiver modules (caregivers only), 8 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After the youth's release, they would receive phone support (only when requested by the caregiver or youth)."
9706508|NCT04678960|Experimental|TBRI Group Training + TBRI In-Home Structured Coaching|"Youth/safe adult dyads participate in 8 TBRI caregiver modules (caregivers only), 8 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads in which they meet 4 times (once monthly) over the first 4 months following release."
9706509|NCT04678960|Experimental|TBRI Group Training + TBRI In-Home Responsive Coaching|"Youth/safe adult dyads participate in 8 TBRI caregiver modules (caregivers only), 8 youth modules (youth only), and 4 Nurture Groups (caregiver and youth joint role-play activities) prior to youth's release.~After youth's release, trained TCU TBRI Practitioners provide coaching sessions to youth/safe adult dyads. They meet a minimum of 2 times during the first 2 months after release. Starting from Month 3, TBRI Practitioners would provide additional coaching when requested or when a research assistant (RA) identifies a need for additional coaching sessions."
10193079|NCT03169894|Experimental|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
10193080|NCT03162536|Experimental|Phase 1: Dose Escalation and Determination of RP2D|Phase I: Dose Escalation and determination of RP2D, multiple dose levels of nemtabrutinib to be evaluated (Up to approximately 22 months).
10193081|NCT03162536|Experimental|Phase 2: Expansion Cohort A|Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) participants with at least 2 prior systemic therapies and previously treated with a covalent Bruton's tyrosine kinase inhibitor (BTKi) who must have a documented BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until progressive disease (PD), unacceptable adverse events (AEs), or discontinuation at investigator's discretion (up to approximately 40 months).
9706510|NCT04679116|Other|Laparoscopic|laparoscopic inguinal hernia repair, TAPP
9706511|NCT04679116|Other|Open|open inguinal hernia repair
9706512|NCT04678713|Experimental|Fat rich diet|Participants consuming 3 days of fat rich diet
10193082|NCT03162536|Experimental|Phase 2: Expansion Cohort B|R/R CLL/SLL participants who have failed or were intolerant to a BTKi with documentation of the absence of BTK mutation on C481 residue receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
9706513|NCT04678713|Experimental|Carbohydrate rich diet|Participants consuming 3 days of carbohydrate rich diet
9706514|NCT04678921|Experimental|Dose Level 1|1mg/kg Q1W
9706515|NCT04678921|Experimental|Dose Level 2|3 mg/kg Q1W
9706516|NCT04678921|Experimental|Dose Level 3|10mg/kg Q1W
10193083|NCT03162536|Experimental|Phase 2: Expansion Cohort C|Richter's transformation (RT) participants who have failed at least one prior therapy receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
10204577|NCT05201339|Active Comparator|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
9706517|NCT04678921|Experimental|Dose Level 4|15 mg/kg Q1W
9706518|NCT04678830|Placebo Comparator|Placebo|
9706519|NCT04678830|Experimental|700mg Leronlimab|
9706520|NCT04678752|Active Comparator|Standard of Care|Each primary care provider will administer weight loss care per their standard practice.
9706521|NCT04678752|Experimental|PATHWEIGH|A weight management care path that support primary care both through the EHR and training for the clinicians.
9706522|NCT04678778|Experimental|Combined, simultaneous physical and cognitive activity|The combined physical and cognitive activity VR arm will participate in our customized spatial navigation program that increases difficulty and length per trial over time. As described in the Game Design section, each session will consist of 5 trials. The first trial will be a long-delay free recall condition from the previous day's path. The next 4 trials will consist of learning, cued recall, and free recall. This VR-based spatial navigation program has been tested in our feasibility trial for safety and tolerability in older adults.
9706523|NCT04678791|Experimental|Nimotuzumab+ chemoradiotherapy|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy.
9706524|NCT04678791|Active Comparator|Chemoradiotherapy|Patients receive cisplatin and undergo external-beam radiation and brachytherapy
9706525|NCT04678700|Experimental|Experimental groupe|"Intervention; 10 sessions telematics. Before starting and at the end of the respiratory physiotherapy program, the patient complete an online form which includes a quality of life questionnaire, an effort dyspnea questionnaire and an anxiety questionnaire.~The intervention of the following study follow the recommendations of chest physiotherapy in the management of the patient post covid-19 (1)(17).~Pre-session; respiratory frequency, dyspnea, oxigenation level are taken. Breathing techniques;~Abdominal-diaphragmatic breathing(1)(16). (10 times).~Costal expansion exercises with flexion and abduction of the upper limbs. (10 times)(1).~Self-passive stretching of the ribcage and neck muscles, accessory to inspiration(25)(26).~Jacobson's progressive relaxation(27). Post-session, respiratory frequency and the Borg's dyspnea index/ oxigenation level."
9779088|NCT01121926|Active Comparator|Trazodone HCl (Apotex Corp.)|
9779089|NCT01121939|Experimental|1|combination of bevacizumab, pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers
9706526|NCT04678700|Other|control groupe|The control group will complete the same questionnaires before and after the intervention, which will give us an idea of whether our intervention has had any improvement. In order for all patients to be able to receive the therapy if they want to. The control group will be on the waiting list to perform the sessions.
9706527|NCT04678739|Experimental|Group A: Remdesivir + Tocilizumab treatment group|"Drug: Remdesivir Injectable solution Tocilizumab Injectable solution A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
9706528|NCT04678739|No Intervention|Group B: Control group|Treatment as given without Remdesivir and Tocilizumab.
9706529|NCT04679155|Experimental|eTRE|participants allocated to this group will be required to eat only between 0800h and 1600h.
9706530|NCT04679155|Active Comparator|lTRE|participants allocated to this group will be required to eat only between 1200h and 2000h
9706531|NCT04678609|Experimental|Open kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
9706532|NCT04678609|Experimental|Closed kinetic chain exercise|In the OKC exercise group, participants will be taught by a physiotherapist about open kinetic chain exercises. Then, they will do the exercises at their home for eight weeks, with three session per week. The physiotherapist will contact the participants to monitor their adherence to the intervention. A diary is also provided to monitor their progress, pain level and any adverse events related to the intervention.
9706533|NCT04678609|No Intervention|Control|The untreated control group will receive patient's usual care of local government hospital which includes information about clinical manifestations, risk factors, diagnosis, treatment and nursing care for knee OA. Control group did not receive any home exercises guidance.
9706534|NCT04678622||Classic Orthrosis|Group of patients who they will wear the usual splint indicated by the servicio physicians
9706535|NCT04678622||3D Orthrosis|Group of patients who they will wear the personalized splint designed by the company OPTIMUS 3D.
9706536|NCT04678635|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. The stimulation will happen simultaneously to aerobic exercises for 20 minutes. Total number of stimulation associated with aerobic exercise sessions: 16
9706537|NCT04678635|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session. However, the patients will do aerobic exercises for 20 minutes. Total number of sham-stimulation associated with aerobic exercise sessions: 16
9706538|NCT04678596|Active Comparator|EonAligner|Patients in the EonAligner group were given a single thickness and hardness aligner and were asked to use the same it for 3 weeks.
9706539|NCT04678596|Active Comparator|Clearfix|In the Clearfix group, the patients were given three different thickness and hardness aligner and they were asked to use each aligner for one week from soft to hard.
9706540|NCT04678388|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
9706541|NCT04678388|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
9706542|NCT04678388|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
9706543|NCT04678388|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
9706544|NCT04678388|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
9706545|NCT04678388|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
9706546|NCT04678323|Active Comparator|Phentermine Plus Lifestyle Therapy|Participants in this arm will receive 15 mg p.o.q.day of phentermine plus lifestyle therapy for 52 weeks.
9706547|NCT04678323|Placebo Comparator|Placebo Plus Lifestyle Therapy|Participants in this arm will receive a matching placebo plus lifestyle therapy for 52 weeks.
9706548|NCT04678544|Experimental|Intervention Group|Before the chemotherapy, patients in intervention group will use cooling cap 30 minutes before chemotherapy. Once chemotherapy drug be ready, patients will receive chemotherapy. After the chemotherapy, patients go to the cooling cap area (room) and wear the cooling cap additional 20 minute for Taxane and 90 minute for other drugs, respectively.
9706549|NCT04678544|No Intervention|Controlled Group|chemotherapy with usual care
9706550|NCT04678349|Experimental|PHGG|Patient who met inclusion criteria and consented during intervention period will be assigned as PHGG group. Surgical medical officer will obtain consent from eligible subject. After consented, subjects will be assessed weight and PG-SGA during admission. They will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar once allowed orally. Staff nurse in charged will monitor compliance of subject on the PHGG. Daily stoma output & consistency will be recorded and daily energy protein intake will be assessed by dietitian in charged. Renal profile will be taken daily as routine procedure for patients with ileostomy.
9706551|NCT04678349|Other|CG|Historical records of patients with ileostomy under conventional care from January 2016 to June 2019 (before started on PHGG) will be assessed and traced retrospectively from the medical system. Data will be recorded in data collection sheet.
9706552|NCT04678492|Experimental|High-dose esomeprazole and amoxicillin dual therapy|Esomeprazole 40 mg and amoxicillin 1000 mg by mouth，three time daily for 14 days
9706553|NCT04678492|Active Comparator|Bismuth-containing quadruple therapy|Tetracycline 500mg three time daily for 14 days，furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
9706554|NCT04678375||Retinal diseases diagnosed by artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
9706555|NCT04678297|Experimental|Physical activity + emotion regulation group|
9706556|NCT04678297|Active Comparator|Physical activity control group|
9706557|NCT04678505|Experimental|Panel A: Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of 100 mg MK-3402 via intravenous (IV) infusion on Day 1
9706558|NCT04678505|Experimental|Panel B: Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1
9706559|NCT04678505|Experimental|Panel C: Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1
9706560|NCT04678505|Experimental|Panel D: Healthy Participants|Healthy Matched Control will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1
9706561|NCT04678505|Experimental|Panel E: End-Stage Renal Disease (ESRD) Undergoing Hemodialysis|Participants with ESRD undergoing HD will receive a single dose of 100 mg MK-3402 via IV infusion before HD on Day 1 of Period 1 and after HD on Day 1 of Period 2. There will be at least a 6-day washout period before dosing in Period 2.
9706562|NCT04678518|Active Comparator|SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group I (SIRS)
9706563|NCT04678518|Placebo Comparator|NON-SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group II (Non-SIRS)
9706564|NCT04678570|Experimental|Intervention Group-1|White Noise intervention and standard care, procedures will be applied.
9706565|NCT04678570|Experimental|Intervention Group- 2|The swaddling method and standard care, procedures will be applied.
9706566|NCT04678570|Experimental|Intervention Group- 3|White Noise, swaddling method, and standard care, procedures will be applied.
9706567|NCT04678570|No Intervention|No Intervention Group|Standard care and procedures to be applied.
9706568|NCT04678531|Experimental|Swabs containing tea tree oil and chamomile oil|The swabs will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
9706569|NCT04678531|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks
9706570|NCT04678453|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once every three weeks (Q3W) for four cycles.
9706571|NCT04678453|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered Q3W for four cycles.
9706572|NCT04678453|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered Q3W for four cycles.
9706573|NCT04678453|Experimental|Cohort 4 - SNK01 at Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D)|SNK01 (at MTD/RP2D) administered Q3W for four cycles.
9706574|NCT04678167|Experimental|Boarding ring glasses|"Realization of the following examinations WITH Boarding ring glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
9706575|NCT04678167|Placebo Comparator|Placebo glasses|"Realization of the following examinations WITH Placebo glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
9706576|NCT04678167|Other|No glasses|"Realization of the following examinations WITHOUT glasses :~caloric tests,~measurement of the speed of Nystagmus,~angle of deviation in Fukuda,~Alexander's degree of nystagmus,~EHTEV and EEV questionnaires,~anxiety VAS"
9706577|NCT04678258|Active Comparator|Group 1: MVG ablation|Group 1 - MVG: high-resolution mapping and maximum voltage guided stepwise CTI ablation (stepwise voltage guided approach (SVG)).
9706578|NCT04678258|Active Comparator|Group 2 - control: linear ablation|Group 2 - control: conventional bipolar mapping and conventional linear CTI ablation.
9706579|NCT04678245|Experimental|Immediate Above the Influence-Vaping Intervention|School receives Above the Influence-Vaping (ATI-V) prevention program training after baseline assessment. Training and intervention continue over two school years (approximately 18 months). Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade).
9706580|NCT04678245|Active Comparator|Delayed Above the Influence-Vaping Intervention|Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade). ATI-V prevention program training after 4th assessment - after 28 months.
9706581|NCT04678011||Personalized surveillance and intervention protocol|
9706582|NCT04678063|Experimental|Asthmatic subjects allergic to cat|Group A will be randomized into 2 subgroups of 10 subjects: group A1 and A2. Both subgroupes will be exposed to placebo on exposure 1 then Subgroup A1 will be exposed to dose A on exposure 2 and dose B on exposure 3. Subgroup A2 will be exposed to dose B on exposure 2 and dose A on exposure 3. Dose A and B correspond to different Allergen concentration in the EEC.
9706583|NCT04678063|Active Comparator|Asthmatic allergic subjects not sensitized to cat|Group B will be exposed to placebo at exposure 1, and then at exposure 2, the concentration of cat allergens corresponding to the dose that achieved the main objective (Dose A or B).
9706584|NCT04678973|Experimental|Intervention|Participants in the intervention group will receive a 4 week program delivered via text message. Week 1 will include psychoeducation delivered via brief readings and video. Weeks 2-4 will include daily guided mindfulness practice focusing on self-compassion and weight and body image concerns.
9706585|NCT04678973|No Intervention|Wait-list control|Participants in the control group will receive no study content during the 4 week intervention period. They will receive access to intervention content (text messages, audio files) after completing end-of-treatment surveys 4 weeks after randomization.
9706586|NCT04679194|Experimental|Mana 312|"Mana 312 is administered intravenously (IV) within 30 minutes in either an inpatient or outpatient setting; either a central or peripheral IV line may be used. Each cycle of administration of Mana 312 will be 28 days.~Subjects not experiencing dose-limiting toxicity (DLT) following their initial dose may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses"
9706587|NCT04679025||Diabetes with postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
9706588|NCT04679025||Diabetes without postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
9706589|NCT04679025||No diabetes with postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
9706590|NCT04679025||No diabetes and no postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
9706591|NCT04678154|Active Comparator|Control|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
9706592|NCT04678154|Experimental|Treatment|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
9706593|NCT04678076|Experimental|ketoprofen 25mg/5ml oral gel stick pack|Single dose of ketoprofen 25mg/5ml oral gel stick pack will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
9706594|NCT04678076|Active Comparator|OKi 80 mg granules for oral solution (bipartite sachet)|Single dose of half sachet containing 40 mg of ketoprofen lysine salt (corresponding to 25 mg as ketoprofen) will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
9706595|NCT04678115|Experimental|MLP first, KTFS second|Participants in this arm will receive the MLP in the first period of the crossover and the KTFS in the second period.
9706596|NCT04678115|Experimental|KTFS first, MLP second|Participants in this arm will receive the KTFS in the first period of the crossover and the MLP in the second period.
9979675|NCT01384253|Experimental|Phase I: Dose escalation|In preparation for the study, patients screened and eligible will have a peritoneal catheter placed and the evening prior to the injection of the labeled antibody will receive furosemide. Herceptin will be administered IV followed by a single IP infusion of ²¹²Pb-TCMC-Trastuzumab. Serial sampling of blood, urine, and dosimetry will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antitumor effects.
10193084|NCT03162536|Experimental|Phase 2: Expansion Cohort D|Follicular Lymphoma (FL) participants who have failed at least 2 prior systemic therapies and are histology grade 1, 2, or 3A receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
10193085|NCT03162536|Experimental|Phase 2: Expansion Cohort E|Mantle Cell Lymphoma (MCL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
9979676|NCT01384266||Subjects undergoing Cataract Surgery|Subjects undergoing routine cataract surgery
9706599|NCT04678687|Other|COVID-19 group|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
9706600|NCT04678128|Active Comparator|Dance4Healing control group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will not have a dance buddy.
9779090|NCT01122030|Experimental|Cohort 1|In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
9979677|NCT01384279|Experimental|metformin, topiramate|
9979678|NCT01384318||Cuffed ETT|Patients intubated with cuffed endotracheal tubes.
10193086|NCT03162536|Experimental|Phase 2: Expansion Cohort F|Marginal Zone Lymphoma (MZL) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
10193087|NCT03162536|Experimental|Phase 2: Expansion Cohort G|High-grade B-cell lymphoma (BCL) participants who have failed at least 2 prior systemic therapies and have known MYC and BCL2 and/or BCL6 translocations confirmed by flourescence in situ hybridization (FISH) or overexpression by immunohistochemistry (IHC) receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
10193088|NCT03162536|Experimental|Phase 2: Expansion Cohort H|Waldenström macroglobulinemia (WM) participants who have failed at least 2 prior systemic therapies receive up to 65 mg of nemtabrutinib per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
10193089|NCT03162536|Experimental|Phase 2: Expansion Food Effect Cohort I|B-cell Non-Hodgkin's lymphoma (NHL), CLL/SLL and WM participants receive up to 65 mg of nemtabrutinib fasted (1 hour prior to or 2 hours after meal) and non-fasted per day orally in each cycle (Cycle length = 28 days) until PD, unacceptable AEs, or discontinuation at investigator's discretion (up to approximately 40 months).
10193090|NCT03138538|Experimental|M8891 7 mg|Participant received M8891 at dose of 7 milligrams (mg) orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
10204578|NCT05201339|Experimental|Head-neck rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
9706601|NCT04678128|Experimental|Dance4Healing Buddy Group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will have a dance buddy.
10193091|NCT03138538|Experimental|M8891 12 mg|Participant received M8891 at dose of 12 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
10193092|NCT03138538|Experimental|M8891 20 mg|Participant received M8891 at dose of 20 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
9706603|NCT04678102|Experimental|Cohort 1 (PHI-101 40mg/day)|In the starting dose cohort 1 subject will be administered 40mg/day PHI-101 and will be assessed for DLT ('single subject cohort'), and until an ADR ≥ [CTCAE version 5.0] grade 2 occurs, higher doses will be explored in single subject cohorts in a stepwise fashion. If an ADR ≥ [CTCAE version 5.0] grade 2 occurs, the accelerated 3+3 design will be immediately switched to the standard 3+3 scheme.
9706604|NCT04678102|Experimental|Cohort 2 (PHI-101 80mg/day)|In cohort 2, the subject will be administered 80mg/day PHI-101.
9706605|NCT04678102|Experimental|Cohort 3 (PHI-101 120mg/day)|In cohort 3, the subject will be administered 120mg/day PHI-101.
9706606|NCT04678102|Experimental|Cohort 4 (PHI-101 160mg/day)|In cohort 4, the subject will be administered 160mg/day PHI-101.
9706607|NCT04678102|Experimental|Cohort 5 (PHI-101 200mg/day)|In cohort 5, the subject will be administered 200mg/day PHI-101.
10193093|NCT03138538|Experimental|M8891 35 mg|Participant received M8891 at dose of 35 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
9706608|NCT04678102|Experimental|Cohort 6 (PHI-101 240mg/day)|In cohort 6, the subject will be administered 240mg/day PHI-101.
9706609|NCT04678050|Active Comparator|group I received ketamine/propofol (ketofol) solution|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
9706610|NCT04678050|Active Comparator|group II received the Dex solution (4 µg/mL|A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h.
9706611|NCT04678674|Experimental|bone defect surgery|augmentation on insufficient alveolar ridges with autologous teeth will be performed (wisdom tooth or periodontally compromised tooth)
9706612|NCT04678661|Experimental|My Dose Coach (Insulin Dosing Support App)|"Phase 1 Titration: Patients receive insulin therapy education from diabetes educator (DE). Plus, DE trains patients to use My Dose Coach (MDC) for titration guidance according to an algorithm prepared by endocrinology provider (EP). Patients are asked to return for a 3-month (mo) follow-up clinic visit. Patients who successfully reach glycemic target are invited to Phase 2.~Phase 2 Maintenance: At 3-mo clinic visit, an EP or DE trains patients the MDC Maintenance Module to support proper insulin dosing. Patients are asked to return for follow-up clinic visits at mo 6. Patients are surveyed (0, 3, 6 mo) to assess changes in behavioral and psychosocial factors that influence diabetes self-management and MDC acceptability."
9706613|NCT04678661|Active Comparator|Usual Care Group|A retrospective comparative group will be selected from eligible patients who previously were treated at the University of Pittsburgh Medical Center (UPMC) Diabetes Outpatient Clinics following standard insulin therapy education. Patients in the usual care group will be identified using data available in the electronic medical record system. Propensity score matching will be used to pair intervention and usual care participants.
9706614|NCT04677933|Experimental|Arm A|Patients will receive 5 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
9706615|NCT04677933|Experimental|Arm B|Patients will receive 10 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
9706616|NCT04677933|Experimental|Arm C|Patients will receive Diluent placebo BIW for 15 days (Day 1, 4, 8, 11 and 15) Mode of Administration: Subcutaneous injection
9706617|NCT04677985|Experimental|Menthol based topical analgesic|Menthol based topical analgesic was applied to a variety of upper and lower body muscles and tendons.
10193094|NCT03138538|Experimental|M8891 60 mg|Participant received M8891 at dose of 60 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
10193095|NCT03138538|Experimental|M8891 80 mg|Participant received M8891 at dose of 80 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
9706618|NCT04677985|Placebo Comparator|Placebo|Placebo (cream that smelled like menthol) was applied to a variety of upper and lower body muscles and tendons.
9706619|NCT04677998||Personalized surveillance and intervention protocol|
9706620|NCT04678219|Experimental|Low-Protein/Vegan/Low-Sulfur Diet|This is a specific diet that is both vegan and low in protein. The vegan diet eliminates all animal products, (including meats, eggs, dairy products) and animal by-products such as honey.
9706621|NCT04678219|Experimental|Specific Carbohydrate Diet|"The Specific Carbohydrate Diet emphasizes consumption of specific carbohydrates that require minimal digestion. Therefore, it eliminates most carbohydrates, including grains, starches, dairy and sugars.~The idea behind this diet is that it reshapes the microbiome of the intestines. The diet restricts the intake of certain carbohydrates that may increase the growth of bad bacteria possibly contributing to inflammation. By restricting the amount of these carbohydrates in the microbiome, the diet aims to reduce their activity in the gut and reduce inflammation."
9706622|NCT04678037|Active Comparator|Group A (PROs assessment every 2 weeks)|
9706623|NCT04678037|Active Comparator|Group A (PROs assessment every 4 weeks)|
10193096|NCT03135990|Experimental|CBT + VR|Cognitive Behavioral Therapy with Virtual Reality technology.
9706624|NCT04677868|Experimental|MTX and corticosteroid|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
9706625|NCT04677894||Group Direct Laringoscopy|Group DL: Group of patients intubated using a Macintoch blade laryngoscope.
9706626|NCT04677894||Group Videolaringoscopy|Group VL: Group of patients intubated using a McGrath video laryngoscope.
9706627|NCT04677764|Experimental|Wii Fit Group|Received Standard of care and Wii Fit protocol consisted of strength, balance, and aerobic programs that were performed on the Wii Fit balance board (Nintendo Inc., Kyoto, Japan). For muscle strengthening exercise, lunges, single-leg extensions, sideways leg lifts, single leg twists, and rowing squats were performed. For exercise that enhances balancing sense, the soccer heading, ski slalom, penguin, table tilt, and balance bubble games were used. Aerobic games as hula hoop, super hula hoop and basic step.
9706628|NCT04677764|Other|Standard of care group|On discharge from the hospital, patients in the SOC group were given instructions on how to perform physical therapy and occupational therapy exercises after discharge. After education, patients could perform the physical therapy and occupational therapy exercises either at their own home or a gym.
9706629|NCT04677686||Pre-implementation phase (October 2018 - September 2019)|"During this time period, 137 patients underwent colorectal surgery. Only basic measures for preventing SSI were performed:~Hair was removed in the operating field with a clipper instead of shaving hair.~Blood glucose was monitored only during the operation.~Antibiotic prophylaxis was applied 60 minutes before the operation.~The application of an antibiotic prophylaxis was repeated if the operation lasted longer than 4 hours.~Measures of warming were only applied during the operation and in the recovery room.~Instruments and gloves were changed after finishing the anastomosis."
9706630|NCT04677686||Implementation phase (October 2019 - September 2020)|"During this phase, additional measures have been introduced:~Implementation of wound protectors during colorectal surgery.~Colorectal operations were only performed with the support of an experienced consultant surgeon."
9706631|NCT04677686||Post-implementation phase (October 2020 - September 2021)|"During this phase, additional measures are implemented.~Close monitoring of blood glucose. During the stay in the recovery room and for 48 hours post-operative, blood glucose is monitored closely. Moreover, if blood glucose is higher than 9 mmol/l, the patient will be treated with insulin. This measure is applied to diabetic as well as to non-diabetic-patients.~The measures of warming will be intensified. First of all, during the operation and during the stay in the recovery room patients will be placed on warming mattresses. Moreover, a warming towel will be placed on the operating field directly after the operation.~The patients will be asked to take a shower the night before surgery. In case of an emergency operation, patients will be asked to wash the axilla, trunk, genitalia, groins and umbilicus"
9706632|NCT04677790|Active Comparator|"Very short arm (12 months)"|Very short arm (12 months): 3 months between every step. Step by step gradual introduction of egg containing food products during 12 months, unless next step can not be taken.
9706633|NCT04677790|Active Comparator|"Short arm (20 months)"|Short arm (20 months): 5 months between every step. Step by step gradual introduction of egg containing food products during 20 months, unless next step can not be taken.
9706634|NCT04677556|Other|Severe acute bronchiolitis|Infants under 6 months admitted in Pediatric Intensive Care Unit for a severe acute bronchiolitis needing NIV (modified Woof clinical asthma score (WCAS) >4 and/or hypercapnic acidosis (pH<7,3 and/or pCO2>50mmHg)
9706635|NCT04677673|Experimental|NAC PLUS SURGERY|Patients receive three cycles of the modified dose of TGO plus oxaliplatin before curative gastrectomy.
9706636|NCT04677673|Active Comparator|SURGERY FIRST|Patients undergo curative gastrectomy without any prior chemotherapy.
9706637|NCT04678180|Experimental|Virtual tic training|A combination of treatment using virtual tic training and training at the hospital. In total nine sessions using a combined training of HRT and ERP. In four of the nine sessions (session 3, 5, 6, 7) training is performed as a virtual training. All sessions last 60 minutes
9706638|NCT04678180|Experimental|Video tic training|A combination of treatment using self-instructive videos and training at the hospital. In total nine sessions using a combined training of HRT and ERP. Four of the nine sessions are completed at the hospital (session 1 and 2 are combined 120 minutes, session 4: 60 minutes, session 8: 60 minutes and session 9: 60 minutes). For all sessions, self-instructive videos have been recorded instructing the child and their families how they should perform the training
9706639|NCT04677634|Other|Tolerability Arm|This is a single arm study. All subjects will receive the test material. The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily for 30 days.
9706640|NCT04678362|Experimental|Talazoparib+avelumab|"Talazoparib will be administered at the daily dose of 1 mg given orally in a 28-day cycle, except for patients with mild renal impairment (Creatinine clearance 30-59 mL/min) who will receive 0.75 mg per day.~Avelumab will be administered by intravenous (I.V.) route over 60 minutes at the dose of 800 mg on D1 and D15, in a 28-day cycle."
9706641|NCT04677855|Experimental|PCUR-101 Dose Escalation|PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
9706642|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 1|PCUR-101 dosed orally once per day in 28 day cycles
9706643|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 2|PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
9706644|NCT04677855|Experimental|PCUR-101 Dose Expansion Cohort 3|PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles
9706645|NCT04677582|Experimental|Intervention Group|The intervention group will receive weekly education sessions about nutrition, exercise, and behavioral health.
9706646|NCT04677699||Birth Cohort|Newborns less than 8 months old and born in the state of Washington.
9706647|NCT04677699||Kids Cohort|Children ages 4-7 years and born in the state of Washington.
9706648|NCT04677881|Placebo Comparator|Wholegrain bread with yeast|The control group will be given min. 5 slices of bread baked with yeast per day.
10204579|NCT05201326|Experimental|Treatment arm|irinotecan + bevacizumab + Re-radiotherapy
9706649|NCT04677881|Experimental|Wholegrain bread with sourdough|The experimental group will be given min. 5 slices of bread baked with sourdough per day.
9706650|NCT04677530|Experimental|Part 1: JNJ-40411813 or Matching Placebo|Participants will receive a single oral dose of JNJ-40411813 or a matching placebo in Cohorts 1, 2, and 3.
9706651|NCT04677530|Experimental|Part 2: JNJ-40411813|Participants will receive a single oral dose of JNJ-40411813 in Cohort 4.
10193097|NCT03126292|Experimental|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
10193098|NCT03126292|Active Comparator|Handout|Families in the control group will receive handouts regarding child safety
9706652|NCT04677530|Experimental|Part 3: JNJ-40411813 or Matching Placebo|Participants will receive a multiple oral dose of JNJ-40411813 or a matching placebo in Cohort 5 and optional Cohort 6.
10193099|NCT03122522|Experimental|ipilimumab and nivolumab|Pts will receive 2 doses of ipilimumab 3mg/kg + nivolumab 1mg/kg every 3 weeks. Week 6, if pts have achieved a favorable antitumor effect by RECIST will begin maintenance nivolumab alone at 480mg every 4 weeks for 2 doses (week 6 & week 10) & repeat response assessments at week 12. If pts don't achieve a favorable antitumor effect at week 6, pt will get 2 additional doses of ipilimumab + nivolumab every 3 weeks & then will be assessed for response at week 12. If pts haven't achieved a favorable antitumor effect by week 12, if felt in the best interest for the pt as determined by the PI, pts may continue getting additional doses of ipilimumab + nivolumab with response reassessments after every 2 doses. Maintenance nivolumab will continued until unacceptable toxicity or confirmed disease progression. If pts have had an initial clinical benefit from therapy & subsequently experience progressive disease at any time, reinduction with combination ipilimuma+ nivolumab will be allowed.
9706653|NCT04677452|Experimental|JWCAR129|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JWCAR129
9706654|NCT04677309||Lung resection less than lobectomy|participants scheduled for lung resection that is less than lobectomy
9706655|NCT04677309||Lung resection equal to or greater than lobectomy|participants scheduled for lung resection that is equal to or greater than lobectomy
9706656|NCT04677153|Experimental|Test and Treat plus Peer Mentors Intervention Arm|Participants offered 8 weeks of glecaprevir/pibrentasvir (GLE/PIB) at OTP plus peer support.
10193100|NCT03112928|Experimental|Phantom Motor Execution (PME)|Phantom motor execution is decoded via myoelectric pattern recognition and promoted via serious gaming in virtual and augmented reality.
10193101|NCT03112928|Active Comparator|Phantom Motor Imagery (PMI)|Use the same device and visual stimulation as PME, with the difference that participants imagine to perform, rather than execute phantom movements. Myoelectric activity is used to monitor that the subjects do not produce muscular contractions but only imagine the movements.
10193102|NCT03110978|Experimental|Arm I (stereotactic body radiation therapy)|Patients undergo stereotactic body radiation therapy over 1-2 weeks.
9706657|NCT04677153|Active Comparator|Standard of Care Referral Arm|Participants referred to offsite (non-OTP) location for HCV treatment.
9706658|NCT04677400|Experimental|Experimental Group|Participants in the Experimental group start the MBA intervention immediately (Time 0; T0).
9706659|NCT04677400|Active Comparator|Waiting-list group|Participants in the waiting-list group start the MBA intervention at Time 1 (T1; 15 days after the Experimental group).
9706660|NCT04677296|Experimental|VS002A|Amino acid based ORS/medical food (VS002A). Initial treatment dosing with VS002A will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
9706661|NCT04677296|Active Comparator|Standard WHO-ORS|Standard WHO-ORS. Initial treatment dosing with WHO-ORS will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
10193103|NCT03110978|Experimental|Arm II (stereotactic body radiation therapy, nivolumab)|Patients undergo stereotactic body radiation therapy over 1-2 weeks. Beginning within 36 hours before or after the first fraction of stereotactic body radiation therapy, patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 4 weeks for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
10193104|NCT03085056|Experimental|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
9706662|NCT04677335|Experimental|Nutraceutical|Nutraceutical capsules taken once daily for 12 weeks
9706663|NCT04677335|Placebo Comparator|Control|Placebo capsules taken once daily for 12 weeks
9706664|NCT04676919|Experimental|pulsed mode phonophoresis group|Phonophoresis therapy with pulsed mode ultrasound.
9706665|NCT04676919|Experimental|continuous mode phonophoresis group|Phonophoresis therapy with continuous mode ultrasound.
10204580|NCT05201313|Experimental|lidocaine spray|nebulization 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
9706666|NCT04676919|Sham Comparator|sham group|Sham ultrasound
9706667|NCT04676893|Experimental|Reference-Test|
9706668|NCT04676893|Experimental|Test-Reference|
10204581|NCT05201313|Active Comparator|mepivacaine infiltration|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
9706672|NCT04676880|Experimental|Intervention arm - Left atrial appendage occlusion (with Watchman FLX or Amplatzer Amulet device)|Patients randomized to the intervention arm will receive left atrial appendage occlusion. In order to prevent device-related thrombus, they will use dual antiplatelet therapy (acetylsalicylzuur + clopidogrel) for three months and single antiplatelet therapy (acetylsalicylzuur) until at least 12 months after the procedure.
9706673|NCT04676880|No Intervention|Control arm - no or usual care|The patients in the control arm will stay on optimal treatment as decided by the referring physician (antiplatelet therapy or nothing).
9779091|NCT01122030|Experimental|Cohort 2|In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
9779092|NCT01122030|Experimental|Cohort 3|In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
10193105|NCT03083808|Experimental|Pembrolizumab 200mg IV every 21 days|Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m^2 IV D1 and D8 every three weeks, docetaxel 75mg/m^2 IV D1 every three weeks, or pemetrexed 500mg/m^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
9706674|NCT04677361|Experimental|MILs™ in Combination with Pembrolizumab|"Each patient will have their bone marrow collected, MILs produced, and the patient will be dosed with all of the MILs produced for that individual patient. The minimum requirement for treatment is 2 x 108 cells. The MILs™ must be administered via a central catheter which could either be a PICC line, port or central line.~Subjects will be treated with MILs™ and pembrolizumab (200 mg Q3W) combination. MILs™ will be administered on Day 0 and pembrolizumab administered on Day 1. Pembrolizumab will be administered as a 30 minute IV infusion with a window of -5 minutes and +10 minutes is permitted."
9706675|NCT04677010|No Intervention|Run-in period, patients with cerebral palsy or muscular dystrophy|10 weeks of no exercise
9706676|NCT04677010|Active Comparator|Exercise period, patients with cerebral palsy or muscular dystrophy|10 weeks of exercise
9706677|NCT04677023|Other|Admira fusion X--tra® bulk|The special ORMOCER® compound molecules in Admira Fusion x-tra reduce the volume shrinkage to an extremely low level (1.25 % by volume) in conjunction with very low shrinkage stress (3.87 MPa). Admira Fusion x-tra is the bulk fill version of Admira Fusion. This means that this restorative material can be applied in layers of up to 4 mm and then reliably cured. This makes placing posterior restorations particularly quick and economical. The universal shade U further simplifies handling, as it provides aesthetic results by adapting, chameleon-like, to the surrounding dental substance
9706678|NCT04677023|Other|GrandioSO x-tra® bulk|a nano-hybrid composite which is in a class of its own. It is distinguished by outstanding handling and excellent physical properties, modelled on the natural tooth.its the packable bulk fill material for the highest standards in durability and aesthetics.GrandioSO x-tra has outstanding surface hardness, at 223 MHV, which is closer to natural tooth enamel, compared with other bulk fill composites. Because of this, GrandioSO x-tra ensures restorations which are abrasionresistant and dimensionally stable over the long term. In addition to the surface hardness, reliable curing is very important when larger increments are used. Here as well, GrandioSO x-tra achieves an outstanding result and, at the 219 MHV measured at a depth of 4 mm, it even significantly exceeds the values measured for other bulk fill composites at the surface.
9706679|NCT04677127|Experimental|Intervention|The intervention group was given training based on the health belief model with groups of 10-12-13 people every week for 6 weeks in the Family Health Center, followed by telephone counseling in the following 6 weeks and follow-up for 12 weeks.
9706680|NCT04677127|No Intervention|Control|Patients in the control group were assessed at the first interview and the last interview, received routine health care, and no intervention was performed during the research.
9706681|NCT04676958|Placebo Comparator|Placebo|380 mg capsule/day micro-crystalline cellulose
9706682|NCT04676958|Active Comparator|Vitamin K2|380 mg capsule/day micro-crystalline cellulose including 240ug/day Vitamin K2
10204582|NCT05201274|Experimental|Baduanjin sequential therapy|
9706683|NCT04677114|Experimental|Outpatient Parenteral Antibiotic Therapy (OPAT)|Patients with opioid use disorder (OUD) and severe, injection-related infections (SIRI) will be treated with buprenorphine and be discharged with outpatient parenteral antibiotic therapy (OPAT).
9706684|NCT04677114|Active Comparator|Treatment as Usual (TAU)|Patients with OUD and severe, injection-related infections (SIRI) will receive usual care.
9706685|NCT04677075||mastectomy group|patients with breast cancer and eligible for mastectomy
9706686|NCT04677101||Subjects with NASH documented by liver biopsy|One hundred subjects with NASH documented by liver biopsy and no evidence of another form of liver disease with a BMI ≥30 and ≤55 kg/m2.
9706687|NCT04677101||Healhy Donor|Fifty subjects with normal liver who underwent laparoscopic elective cholecystectomy, but otherwise in healthy conditions, will be used as controls.
9706688|NCT04677088|Experimental|HBV/ TCR T cell infusion|Autologous T cells with HBV antigen-specific TCR
9706689|NCT04677062|Experimental|GV-328|"The treatment should be carried out for 4 days. Children between 3 and 6 years old had to consume 4 pills a day, children between 7 and 10 years old 5 pills, and children between 11 and 13 years old up to 6 pills. The patient had to slowly thin the tablet in the mouth, maintaining direct contact with the area to be treated.~The study consisted of 2 visits, one initial and one final. In the initial visit , the documentation (informed consent) and the treatment were delivered. During this visit, baseline assessments of pain level, functional limitation, marginal mucosal edema, and lesion size were recorded. In addition, a photograph of the area to be treated was taken. Parents were also given a chart, in which they had to record the intensity of pain daily using the Wong-Baker face scale."
9779093|NCT01122030|Experimental|Cohort 4|In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
9779094|NCT01122030|Experimental|Cohort 5|In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
9779095|NCT01122030|Experimental|Cohort 6|In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
9779096|NCT01122108|Active Comparator|Cholestyramine 12 grams|Cholestyramine 12 grams
10204583|NCT05201274|Active Comparator|Aerobic exercise|
10204584|NCT05201261||Ultrasound-guided group|Adult patients with American Society of Anesthesiologists physical status I/II/III scheduled to undergo elective Lower limb surgery under spinal anesthesia were considered for eligibility.
10204585|NCT05201131||Rezum procedure|
10204586|NCT05201118|Experimental|CT103A combined with Selinexor|All subjects will be assigned to two Selinexor dose groups of 20 mg/week and 40 mg/week after receiving a single dose infusion of CT103A.
9706690|NCT04677049|Experimental|Niacin|"Niacin controlled release technology (CRT):~Niacin CRT™ is to be started 7 days before concurrent Radiation Therapy (RT)- Temozolomide (TMZ) treatment.~Chemo/Radiation Therapy:~For all patients, regardless of the phase of the study, concurrent RT and TMZ for 6 weeks followed by 6-12 cycles of monthly TMZ will be given.~Concurrent Temozolomide:~TMZ will be administered from the first to the last day of RT at 75 mg/m2 orally (PO) for a maximum of 49 days.~Monthly Temozolomide:~Cycles of chemotherapy Day 1 to Day 5 every 28 days will start 28 days (+/- 2 days) after the end of RT-TMZ. First cycle of TMZ is administered at 150 mg/m2 Day 1-Day 5 by mouth (PO) and increased to 200 mg/m2 Day 1-Day 5 PO from cycle 2 onwards if well tolerated. While 6 cycles are standard of care, the Neuro-Oncologist may continue up to 12 cycles if clinically appropriate."
10193106|NCT03070366|Active Comparator|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:~PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)~PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
10193107|NCT03070366|Experimental|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
9706691|NCT04676984|Other|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
9706692|NCT04677192|Experimental|Microwave Ablation Combined with Chemotherapy|All patients will receive microwave ablation of oligohepatic metastasis and chemotherapy according to NCCN guidelines,and the efficacy was evaluated every 8 weeks until the disease progressed or the patient could not tolerate it.
9779097|NCT01122108|Active Comparator|Colesevelam HCl|Colesevelam HCl, 4 grams
9779098|NCT01122160|Placebo Comparator|placebo|Placebo with berries (blackberries + strawberries)
9779099|NCT01122160|Experimental|omeprazole|Prilosec (omeprazole) 20.6 mg tablet with berries (blackberries + strawberries)
9779100|NCT01122173|Experimental|Robotic catheter manipulation, Ablation|To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
10193108|NCT03055026|Experimental|Rivaroxaban|Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
10193109|NCT03055026|Placebo Comparator|Placebo|Orally administered, OD for 3 weeks (extended prophylaxis)
10193110|NCT03025269||Relapsing MS patients treated with Ocrelizumab|30 patients diagnosed with relapsing forms of multiple sclerosis and newly beginning treatment with Ocrelizumab according to neurologists' orders
9779101|NCT01122238|Experimental|1, Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
9779102|NCT01122238|Experimental|2, Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9779103|NCT01122238|Experimental|3, Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
9779104|NCT01122238|Experimental|4, Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9779105|NCT01122238|Experimental|5, Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
9779106|NCT01122238|Experimental|6, Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9779107|NCT01122238|Experimental|7, Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
9779108|NCT01122238|Experimental|8, Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9779109|NCT01122238|Experimental|9, No Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
9779110|NCT01122238|Experimental|10, No Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9706693|NCT04677036||TUH Staff|Staff within Tallaght University Hospital - anonymised
9706694|NCT04677036||ASIT Members|Members of the Association of Surgeons in Training - anonymised
10193111|NCT03001024|Experimental|Implementation of WayToServe Español|The experimental design to be employed in the trial evaluation of WayToServe Español (WTS-E) in this direct-to-Phase II project is a two-arm randomized field trial design (WTS-E vs. Usual and Customary [UC] training) with three assessment points (pretest - immediate post-test - 9 month follow-up).This constitutes a 2 (level of RBS training intervention) x 3 (level of time assessment) mixed factorial design. Spanish dominant onsite and off-site licensed alcohol premises will be the unit of analysis, stratified by type of premise (onsite vs. off-site sales) and state (New Mexico vs. Texas).
10193112|NCT03001024|Active Comparator|Usual and Customary RBS Training|The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
9706695|NCT04676945||untreated control group|NO MDS disease modifying therapy
9706696|NCT04676945||treated patients|ANY MDS disease modifying therapy
10193113|NCT02999087|Active Comparator|Arm A Patient FIT|"Lead-in phase (Day-8) : no treatment~Concomitant radiotherapy phase : Radiotherapy by IMRT + cisplatin 100mg/m2~Maintenance phase : no treatment until follow-up phase"
10193114|NCT02999087|Experimental|Arm B Patient FIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase : Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
9706697|NCT04676971|Experimental|100 mg hzVSF-v13 IV + SOC|100 mg hzVSF-v13 IV + SOC
9706698|NCT04676971|Experimental|200 mg hzVSF-v13 IV + SOC|200 mg hzVSF-v13 IV + SOC
9706699|NCT04676971|Placebo Comparator|Placebo (saline) IV + SOC|Placebo (saline) IV + SOC
9706700|NCT04676867|Active Comparator|900 mg dose|Patients will receive Dalcetrapib 900 mg for 10 days
9706701|NCT04676867|Active Comparator|1800 mg dose|Patients will receive Dalcetrapib 1800 mg for 10 days
10204587|NCT05201079|Experimental|MBK-01|Participants will receive MBK-01 capsules of fecal microbiota coming from healthy donors (49 patients).
9706702|NCT04676867|Active Comparator|3600 mg dose|Patients will receive Dalcetrapib 3600 mg for 10 days
9706703|NCT04676867|Placebo Comparator|Placebo tablets|Patients will receive Placebo for 10 days
9706704|NCT04676997|Experimental|Camrelizumab+Chemotherapy|Participants receive Camrelizumab d1,15 (Q2W) + nab-paclitaxel d1,8,15(QW 3/4) x 4 cycles, followed by Camrelizumab Q2W + epirubicin + cyclophosphamide Q2W x 4 cycles as neoadjuvant therapy prior to surgery
9706705|NCT04677270|Experimental|Traditional interface|Digital problem solving tool with a simple textbased graphical interface
9706706|NCT04677270|Experimental|Advanced interface|Digital problem solving tool with an advanced graphical interface and automatic functions
9706707|NCT04676841||Hemiarthroplasty|Hip fracture patients operated with hemiarthroplasty
9706708|NCT04676750|Experimental|MBSR|receives 8-week MBSR course
9706709|NCT04676750|No Intervention|control|receives intervention after experiment finishes
9706710|NCT04676763|Experimental|Substance P challenge in Part 1|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 1 will include a single challenge visit.
9706711|NCT04676763|Experimental|Substance P challenge in Part 2|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 2 will include two challenge visits.
9706712|NCT04676828|Experimental|SPECT functional avoidance treatment|SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.
9706713|NCT04676828|No Intervention|Standard treatment|CT-based radiation therapy given over 5- 6.5 weeks.
9706714|NCT04676815||NBI PATIENT|Diagnostic Test: NBI in combination with electronic bronchoscope
9706715|NCT04676815||Non-NBI PATIENT|Diagnostic Test: Electronic bronchoscope without NBI
9706716|NCT04676685|Experimental|Part A, Cohort 1: E2730 20 Milligram (mg) or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 20 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
9706717|NCT04676685|Experimental|Part A, Cohort 2: E2730 40 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 40 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
9706718|NCT04676685|Experimental|Part A, Cohort 3: E2730 60 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 60 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
9706719|NCT04676685|Experimental|Part A, Cohort 4: E2730 80 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 80 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
9706720|NCT04676685|Experimental|Part B, E2730 80 mg: Fasted + Fed|Participants will receive a single treatment of E2730 (80 mg capsule) in fasted condition on Day 1 treatment period 1 followed by E2730 80 mg capsule in fed condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
9706721|NCT04676685|Experimental|Part B, E2730 80 mg: Fed + Fasted|Participants will receive a single treatment of E2730 80 mg capsule in fed condition on Day 1 of treatment period 1 followed by E2730 80 mg capsule in fasted condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
9779111|NCT01122238|Experimental|11, No Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
9706722|NCT04676620||CK surgery|Conductive keratoplasty (CK) had shown to be a safe and effective procedure for the treatment of low to moderate hypeopia. It had been approved by the U.S. Food and Drug Administration (FDA) to treat presbyope in early 2004. CK appeals to both surgeons and patients as it avoids the need for flap creation, the use of high intraocular pressure (IOP), or tissue ablation.
9706723|NCT04676620||LASIK surgery|LASIK surgery is femtosecond laser assisted conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
9706724|NCT04676568|Active Comparator|extravesical VVF repair|
9706725|NCT04676568|Active Comparator|Transvesical VVF repair|
9706726|NCT04676789|Experimental|Intervention/treatment|Patients will receive sintilimab,200mg,ivdrip,day1; pegaspargase,2,500 unit/m2 deep intramuscular injection at three different sites,day 1, every 3 weeks for 4 cycles before radiation.Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent sintilimab of 200mg and pegaspargase,2,500 unit/m2 will be administered every 3 weeks for 2 cycles during IMRT for patients who do not achieve complete remission to previous induction therapy. After radiotherapy or CCRT, patients achieving CR with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.
9706727|NCT04676581||Aeromonas infection|
9706728|NCT04676581||No infected|
9706729|NCT04676581||bacterial infection|
9706730|NCT04676503|Experimental|Test Arm - Biovaginil 480 mg capsules|All patients will be treated with 1 capsule/day of BIOVAGINIL for two treatment cycles of 14 days each.
9706731|NCT04676529|Experimental|PXS-5505, Dose Level 1, Escalation Phase (Cohort A)|Patients will receive PXS-5505 dose level 1, twice daily for a period of 4 weeks.
9706732|NCT04676529|Experimental|PXS-5505, Dose Level 2, Escalation Phase (Cohort B)|Patients will receive PXS-5505 dose level 2, twice daily for a period of 4 weeks.
9706733|NCT04676529|Experimental|PXS-5505, Dose Level 3, Escalation Phase (Cohort C)|Patients will receive PXS-5505 dose level 3, twice daily for a period of 4 weeks.
9979679|NCT01384331|Active Comparator|Group 1 Marvelon ,placebo|"7 days daily intake of oral capsule containing Marvelon ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules containing starch for 21 day treatment Cycle"
9979680|NCT01384331|Active Comparator|Marvelon|"21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~for one cycle of 21 days"
9979681|NCT01384331|Active Comparator|NuvaRing|21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days Treatment will be for 21 days
9979682|NCT01384331|Placebo Comparator|Starch capsule|21 days daily oral placebo capsules Treatment will be for one 21 day cycle
9979683|NCT01384344|Active Comparator|witness|no mnesic complaint
9979684|NCT01384344|Experimental|Alzheimer disease with apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA with apathy
9979685|NCT01384344|Experimental|Alzheimer's disease without apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA without apathy
9979686|NCT01384357||ultrasound,lymphadenopathy|
9979687|NCT01384370||AHPV positive and negative subjects|
10204588|NCT05201079|Active Comparator|Fidaxomicin|Participants will receive Fidaxomicin (49 patients).
9979688|NCT01384396|Experimental|KW-3357|
9979689|NCT01384409|Experimental|KW-3357|
9979690|NCT01384422|Experimental|GLPG0634 100 mg bid oral capsules|
9979691|NCT01384422|Experimental|GLPG0634 200 mg qd oral capsules|
9979692|NCT01384422|Placebo Comparator|Placebo oral capsules|
9979693|NCT01384435|Experimental|KPS-0373, lowest dose|
9979694|NCT01384435|Experimental|KPS-0373, 2nd lowest dose|
9979695|NCT01384435|Experimental|KPS-0373, 2nd highest dose|
9706734|NCT04676529|Experimental|PXS-5505, Expansion Phase|All patients will receive PXS-5505 at the selected twice daily dose for a period of 24 weeks, or until progressive disease, unacceptable toxicity, dose-limiting toxicity or withdrawal of consent.
9706735|NCT04676295|Experimental|PE intervention|A 12-month lifestyle intervention program to improve mothers and their children blood pressure and CVD risk profile.
9706736|NCT04676295|No Intervention|PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
9706737|NCT04676295|No Intervention|Non-PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
9706738|NCT04676269|Sham Comparator|Amnion only|Amnion bilayer as a scaffold to overlay the endometrium, with minor curettage prior to stick the scaffold.
9979696|NCT01384435|Experimental|KPS-0373, highest dose|
9979697|NCT01384435|Placebo Comparator|Placebo|
9979698|NCT01384448|Experimental|Initial Stress Echocardiography|
9979699|NCT01384448|Experimental|Initial Coronary CT Angiography|
9979700|NCT01384461||Cohort|
9979701|NCT01384474||CRM training of surgical teams|CRM : Crew resource Management
9979702|NCT01384474||No CRM training of surgical teams|CRM : Crew resource Management
9979703|NCT01384487||Normal Eyes|Eyes without disease
9979704|NCT01384487||Eyes with Glaucoma|
9979705|NCT01384487||Eyes with Retinal Disease|
9979706|NCT01384487||Eyes with Corneal Disease|Including post keratorefractive surgery
9979707|NCT01384500|Experimental|Saline in tube cuff|Use of sterile saline to inflate tracheal tube cuff
9979708|NCT01384500|No Intervention|Air in tube cuff|No intervention (control) - patient cohort, using air to inflate tracheal tube cuff.
9979709|NCT01384513|Experimental|Treatment (Allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28."
9706739|NCT04676269|Experimental|Amnion- self endometrium stem cells (EnSC)|Amnion bilayer as a scaffold, seeded with endometrium stem cells to regenerate the thin endometrium.
9706740|NCT04676269|Experimental|Amnion- amnion epithelial stem cells (AESC)|Amnion bilayer as a scaffold, seeded with amnion epithelial stem cells to regenerate the thin endometrium.
9706741|NCT04676269|Experimental|Amnion- co culture self EnSC - AESC|Amnion bilayer as a scaffold, seeded with co-culture of endometrium stem cells and amnion epithelial stem cells to regenerate the thin endometrium.
9706742|NCT04676360|Experimental|(BELANTAMAB MAFODOTIN|"Belantamab mafodotin will be administered intravenously on day 1 of a 21-day cycle.~Treatment is intended to be administered on an outpatient basis."
9706743|NCT04676659|Experimental|Group 1 (rhTNK-tPA 0.10 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.10 mg/kg IV bolus over 5-10 seconds.
9706744|NCT04676659|Experimental|Group 2 (rhTNK-tPA 0.25 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.25 mg/kg IV bolus over 5-10 seconds.
9706745|NCT04676659|Experimental|Group 3 (rhTNK-tPA 0.32 mg/kg)|Dissolve one vial of rhTNK-tPA in 3 ml sterile water for injection to prepare a solution of 5.33 mg/ml. Calculate the required volume according to the body weight of the subject, then measure the required volume. Administer as a single 0.32 mg/kg IV bolus over 5-10 seconds.
9706746|NCT04676659|Active Comparator|Group 4 (rt-PA 0.9 mg/kg)|10% of rt-PA 0.9 mg/kg administered as an initial IV bolus followed by the remaining 90% as an IV infusion over the next 1 hour.
9706747|NCT04676516|Experimental|Experimental Arm|Participants randomized to treatment with GSK3326595 will be requested to take 15 +/- 3 days of the medication at the dose of 200 mg orally daily (2 capsules of 100 mg) prior to their breast cancer surgery or repeat biopsy. GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
9706748|NCT04676516|No Intervention|No Intervention Arm|Participants will receive no treatment for 15 +/- 3 days prior to breast surgery. There is no placebo in this trial.
9706749|NCT04676542|Experimental|One group taking part in 2 separate conditions|The proposed research design will be utilizing a randomized cross over repeated measures design. Subjects will take part in two separate conditions: 1) One hour of a beginning martial art class (EP), and 2) One hour walk at 4.0 mph pace (IP).
9706750|NCT04676373|Experimental|Alglucosidase Alfa|A dose of 20 mg/kg body weight once every 2 weeks for a minimum of 52 weeks
9706751|NCT04676204||Cladribine|Participants with MS commencing cladribine disease modifying treatment as clinically prescribed.
9706752|NCT04676204||Dimethyl Fumarate|Participants with MS commencing dimethyl fumarate disease modifying treatment as clinically prescribed.
9706753|NCT04676204||Fingolimod|Participants with MS commencing fingolimod disease modifying treatment as clinically prescribed.
9706754|NCT04676204||Teriflunomide|Participants with MS commencing teriflunomide disease modifying treatment as clinically prescribed.
9706755|NCT04676217|Active Comparator|FDP|Face down positioning
9706756|NCT04676217|Experimental|NSP|"No positioning named non-supine positioning. Participants are to avoid recumbent positioning."
9706757|NCT04676776|Experimental|Missed period pill regimen|1.5 mg levonorgestrel given on day 1 200 mg mifepristone given on day 3
9706758|NCT04676464||ultra- sound|ultra- sound assessment of their quadriceps muscle layer thickness (QMLT)
9706759|NCT04676230|Experimental|Experimental group|caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
9706760|NCT04676230|Active Comparator|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
9706761|NCT04676139|Experimental|Fluoxetine|patients will undergo maintenance therapy selective serotonin reuptake inhibitors, fluoxetine, 10 mg capsules once daily for 12 weeks
9706762|NCT04676139|Placebo Comparator|Placebo|patients will undergo maintenance therapy Placebo for 12 weeks
9706763|NCT04676243|Experimental|Quizartinib plus standard of care (SOC)|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Quizartinib
9706764|NCT04676243|Active Comparator|Physician's choice|Physician's choice (usually Daunorubicin/ Cytarabine or Idarubicin/Cytarabine and Midostaurin)
9706765|NCT04676256|Experimental|Early Vitrectomy|Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis
9706766|NCT04676256|Active Comparator|Comparator|"Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed.~Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up"
9706767|NCT04676438||Patients receiving surgery breast surgery for cancer at National Institute of Oncology|No intervention will be administered
9706768|NCT04676165|Experimental|SAM Group|At discharge from hospital, patients (and/or caregivers) will receive access to Smart About Meds (SAM), a medication management mobile application that has been developed by the McGill Clinical and Health Informatics (MCHI) Research Group.
9979710|NCT01384526||history of hormone therapy|
9979711|NCT01384526||no history of hormone therapy|
9706769|NCT04676165|No Intervention|Usual Care Group|At discharge from hospital, patients will be provided with a written discharge prescription to be filled at their community pharmacy, and may or may not receive written or verbal instructions about changes made to therapy.
9706770|NCT04676061|Placebo Comparator|Control Group|Placebo to Norethindrone acetate (NTA)
9706771|NCT04676061|Active Comparator|Treatment Group|Norethindrone acetate (NTA)
9706772|NCT04676035|Experimental|SHR3680+ Midazolam, Warfarin, Omeprazole, VitaminK1|administrate Midazolam, Warfarin, Omeprazole, VitaminK1 on Day1 and Day22, SHR3680 on day 6-27.
9979712|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
9706773|NCT04675944|Experimental|BIA 5-1058 / treprostinil|Three treatment periods separated by a washout period of at least 10 days
9706774|NCT04676074|No Intervention|control group|the participant will not do any exercise program but just they will take the routine medication.
9706775|NCT04676074|Experimental|study group|will receive normal routine medication with the treatment program of moderate intensity upper limb ergometer for 15 minute with frequency three times per week for four weeks.
9706776|NCT04675879|Experimental|Velpau bandage (Group 1)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with velpau bandage.
9706777|NCT04675879|Experimental|Shoulder arm sling (Group 2)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with shoulder arm sling.
9706778|NCT04675879|Experimental|Padded shoulder arm sling (Group 3)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with padded shoulder arm sling with 30 degree abduction.
9706779|NCT04676113||Pediatric Patients with Sickle Disease who are overweight/obese|Pediatric Patients age 10-19 years diagnosed with Sickle cell disease who have a BMI of >85%ile.
9706780|NCT04676113||Pediatric Patients with Sickle Cell Disease who are underweight/normal weight|Pediatric Patients age 10-19 years diagnosed with Sickle Cell disease who have a BMI<85%ile.
9706781|NCT04675905||PACORUS-D Main cohort|Eligibility, Endpoints as described above
9706782|NCT04675905||PACORUS-D Delirium-Subcohort|Eligibility: patients aged >= 65 years undergoing noncardiac nonneurosurgical procedures (definition see above); Endpoints as described above; additional explanatory variable: postoperative Delirium detected by CAM on postoperative day 1 and 2
9706783|NCT04675658|Active Comparator|Classroom Intervention|"Physical activity support is provided by integrating daily structured activities in the classroom delivered by physical activity leaders through a video conferencing platform in partnership with the classroom teacher. Activities last about 10 minutes or less and have the flexibility of being integrated with academic lessons or serving as a break from academics.~The activities are simple and get kids moving in place. The activities will be delivered by a research staff member via video conferencing (using the schools preferred platform). A combination of live activities led by the research team and pre-recorded videos will be used (see example below). If live videos do not work for the teacher, they will have the option to only use the pre-recorded videos or receive a list of resources to promote CBPA in their classrooms."
9706784|NCT04675658|Experimental|Classroom Intervention plus family support|"Same components as the Classroom Intervention Arm plus the following:~Family Component: A newsletter will be sent to parents or guardians once every two weeks over the semester and posted on the study website. The newsletters include physical activity information related to safety/protection, skills building, motivation, overcoming barriers, and goal setting and monitoring (all newsletters are included as an appendix). As part of the program, children also receive a Garmin wearable physical activity monitor. Parents or guardians will receive text messages with behavior change messages based on the Garmin data (text message content is included as an appendix). Text messages also contain links to website materials.~Texts will be sent out using the Twilio platform."
9706785|NCT04675697|Experimental|Anlotinib+EP|
9706786|NCT04675671||Pregabalin group (Group P)|Group pregabalin patients will be received 75 mg of pregabalin twice daily for 2 days before surgery
9706787|NCT04675671||Control group (Group C)|The Control group will be received plasebo capsule mg at the same point in time
9706788|NCT04675593|Experimental|iTAB-CV + Self Monitoring|Receives iTAB-CV intervention plus self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
9706789|NCT04675593|Active Comparator|Self Monitoring|Receives self-monitoring (SM), blood pressure home monitoring, eCAP, and weekly mood rating
9706790|NCT04675593|Experimental|iTAB-CV + Self Monitoring - High Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the high intensity booster group will start off receiving 1 reminder per day and taper down to 1 reminder per week over 2 months, in addition to self monitoring.
9706791|NCT04675593|Experimental|iTAB-CV + Self Monitoring - Low Intensity Booster|Following the 4-month assessment, subjects in the iTAB-CV group will be re-randomized to receive either a high intensity booster or low intensity booster. Those in the low intensity booster group will receive 1 reminder per week for 2 months, in addition to self monitoring.
9706792|NCT04676126|Experimental|Experimental|Subjects in the experimental arm will consume 1.5 Tbsp (22.2 mL) of a commercial macular pigment-containing medical food (liquid) once per day and use a carbonic anhydrase inhibitor topical eye drop (2% dorzolamide ophthalmic solution) three times per day in both eyes for 3 months.
9706793|NCT04676126|Placebo Comparator|Placebo|Subjects in the placebo arm will consume 1.5 Tbsp (22.2 mL) of a placebo liquid which resembles the commercial macular pigment-containing medical food (liquid) in taste once per day and use a lubricating eye drop (0.5% sodium + 0.9% glycerin ophthalmic solution) three times per day in both eyes for 3 months.
9706794|NCT04675619|Experimental|Oral pirfenidone|Pirfenidone will be administered orally in 267 mg capsules taken with food. The dose will be titrated over 2 weeks from one capsule three times a day during Week 1 to two capsules three times a day during Week 2 then maintenance dose (three capsules three times a day Week 3.
9706795|NCT04675619|Experimental|Standard care|Standard care
10193115|NCT02999087|Experimental|Arm C Patient UNFIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
10193116|NCT02999087|Active Comparator|Arm D Patient UNFIT|"Lead-in phase (Day-8): Cetuximab 400mg/m2~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2~Maintenance phase : no treatment until follow-up phase"
10193117|NCT02998385|Active Comparator|Radiotherapy|"Arm A~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC."
10193118|NCT02998385|Experimental|Radiotherapy + concomitant cisplatin|"Arm B Concomitant systemic treatment with cisplatin + radiotherapy~According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC"
10193119|NCT02994758|Other|Personalised medicine arm|"This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care."
10193120|NCT02987543|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
10193121|NCT02987543|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary."
9706796|NCT04676087|Experimental|Treatment (mogamulizumab, ECP)|"INDUCTION (WEEKS 1-7): Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, and 36 in the absence of disease progression progression and unacceptable toxicity. Patients also undergo extracorporeal photopheresis on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression and unacceptable toxicity.~TREATMENT (CYCLES 1-12): Patients receive mogamulizumab IV over 60 minutes on days 1 and 15, and undergo extracorporeal photopheresis on days 1 and 15 of cycles 1-6, then day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression and unacceptable toxicity.~MAINTENANCE (CYCLES 13+): Patients with clinical benefit may continue extracorporeal photopheresis on day 1. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity."
9706797|NCT04675892|Active Comparator|A1 pulley group|A1 pulley division only
9706798|NCT04675892|Experimental|A1 pulley + FDS group|Combination of A1 pulley division and excision of one or both slips of the flexor digitorum superficialis tendon
9706799|NCT04675762|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
9706800|NCT04675762|Placebo Comparator|Placebo with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with placebo.
9706801|NCT04675645|Other|HU-Go app intervention arm|Participants will use HU-Go app intervention arm for a total of 12 weeks.
9706802|NCT04675684|Experimental|Recovery-group|"The recovery group consists of:~Physical, mental and social health education, advice and feedback from a health investigator.~Daily self-monitoring about their mood and health in an app, Monsenso.~Intersectoral collaboration between 1) Mental Health Centre Copenhagen Rigshospitalet, IAOC 2) Centre for Research and Education in General Practice, University of Copenhagen 2) Centre for Social Medicine at Frederiksberg Hospital, 3) Competence Centre for Rehabilitation and Recovery, Mental Health Centre Ballerup, and 5) Private Practicing Psychiatrists."
9706803|NCT04675684|No Intervention|Control-group|The control group consists of usual treatment at their General Practitioner and / or Private Practicing Psychiatrist.
9706804|NCT04675710|Experimental|Treatment (dabrafenib, trametinib, pembrolizumab)|Patients receive 21-day cycles of dabrafenib 150 mg orally (PO) twice daily from Days 1-21, trametinib 2mg PO once daily from Days 1-21, and pembrolizumab 200mg intravenously (IV) on Day 1 of each cycle.
9706805|NCT04675606|Active Comparator|Low fiber diet|Patients in this arm will receive low fiber diet starting postoperative day 1. This is currently the standard protocol at our institution.
9706806|NCT04675606|Experimental|Regular diet|Patients in this arm will receive regular diet starting postoperative day 1. This will be the experimental arm.
9706807|NCT04675736|Experimental|brushing force|
9706808|NCT04675528|Experimental|Fasting treatment|
9706809|NCT04675528|Experimental|Fed treatment|
9706810|NCT04675983|Experimental|Sintilimab + Ramucirumab|Ramucirumab on days 1 and 8 in combination with Sintilimab on day 1 of each 21-day cycle until disease progression, intolerable toxicity or other criteria for treatment discontinuation
9706811|NCT04675983|Active Comparator|Cisplatin+ 5-fluorouracil/Oxaliplatin+capecitabine|Cisplatin on day 1 in combination with 5-fluorouracil, continuous pumping for 24 hours a day on days 1 to 5 of each 21-day cycle. (FP regimen) or Oxaliplatin on day 1 in combination with capecitabine on days 1 to 14 of each 21-day cycle. (XELOX regimen)
10193122|NCT02982902|Experimental|CMV specific adoptive t-cells|This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
10193123|NCT02958150|Experimental|Dexmedetomidine|Dexmedetomidine according to the stablished protocol
10193124|NCT02958150|Active Comparator|Standard Clinical Practice|The physician in charge will decide the treatment to be administered (if deemed necessary) in accordance with the protocol established at the department
9706812|NCT04675437|Experimental|Frail patients (CABG, HF or mini-AVR)|12-weeks cardiac exercise program (3 sessions per week) consisting of aerobic exercises (ergometer, treadmill and arm ergometer).
9706813|NCT04675242|Experimental|NCX 4251|NCX 4251 Ophthalmic Suspension
9706814|NCT04675242|Placebo Comparator|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension
9706815|NCT04675359|Active Comparator|Enzymatic digestion group|A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue
9706816|NCT04675359|Active Comparator|Mechanical fragmentation group|A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint
9706817|NCT04675203||Normal tooth eruption|
9706818|NCT04675281||Critically-ill adult patients who died in the Intensive Care Unit from a documented COVID-19|
9706819|NCT04675463|Other|Budesonide/Glycopyrronium/Formoterol arm|52 weeks treatment
9706820|NCT04675463|Other|Glycopyrronium/Formoterol arm|52 weeks treatment
9706821|NCT04675112|Experimental|group A genetically informed intervention|Group A patients are offered a genetically based approach to tinnitus management that includes a genetic test and at least three office based treatment sessions. A rationally-designed personalized management plan based on the genetic results is based on four single nucleotide polymorphisms (SNPs) of the dopamine and serotonin pathways, namely COMT rs4680, HTR2A rs7997012, HTR2A rs6311, and TPH2 rs4570625, that have been associated with behavioral or cognitive responses
9706822|NCT04675112|Other|group B control|In Group B, treatments are offered randomly taking care to offer CBT to equal number of patients as in Group A. In both groups, during the first visit, patients are offered a simple, few-minute tinnitus update and advice, relevant to their educational level and are being suggested that an average of 4 sessions are required over a period of approx. 4 months for making tinnitus noise less or not bothersome
10193125|NCT02955290|Experimental|Phase I (CIMAvax, nivolumab)|"LOADING PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.~MAINTENANCE PHASE I: Patients who do not experience a DLT receive CIMAvax every 4 weeks and nivolumab every 2 weeks."
10193126|NCT02955290|Experimental|Phase II Study A and B (CIMAvax, nivolumab)|PHASE II STUDY A and B: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for nivolumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients in Study A with antibody titer >= 1:4000 at the end of the loading phase may receive CIMAvax IM every 8 or 12 weeks during the maintenance phase.
10193127|NCT02955290|Experimental|Phase II Study C (CIMAvax, pembrolizumab)|PHASE II STUDY C: Patients with PD-L1 expression >= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 2 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
9706823|NCT04675502|Experimental|Supervised Exercise Group|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In this loading program; respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes is taken. Stretching exercises are done during the cooling period. This group was included in an exercise program 2 days a week, 45-90 minutes, for 12 weeks, accompanied by a specialist physiotherapist to the pulmonary rehabilitation unit in the chest diseases ward.
9706824|NCT04675502|Experimental|Home Exercise Group|For patients to do at home (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), sitting and standing exhaustion, and brisk walking to reach 60-85% of the person's maximum heart rate.)), exercises is taught. Patients were asked to do the exercises at home for 45-90 minutes, 2 days a week, for 12 weeks. Participants of the control group are contacted every two weeks via communication methods such as e-mail, message and telephone conversation.Exercise diary is given to all patients and is taken from them at the end of the study.
9706825|NCT04675255|Active Comparator|Immediate switch|Immediate switch
9706826|NCT04675255|Active Comparator|Delayed switch|Delayed switch
9706827|NCT04675164|Active Comparator|LAISS group|Viable immotile testicular sperms will be selected before ICSI using laser assisted immotile sperm selection (study group).
9706828|NCT04675164|Active Comparator|HOST group|Viable immotile testicular sperms will be selected before ICSI using hypo-osmotic swelling test (control group).
9706829|NCT04675177|Active Comparator|Polidocanol foam sclerotherapy|Patients submitted to polidocanol foam sclerotherapy
9706830|NCT04675177|Active Comparator|Doppler-guided hemorrhoidal artery ligation|Patients submitted to doppler-guided hemorrhoidal artery ligation
9706831|NCT04675450|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
9706832|NCT04675450|Active Comparator|NBP|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
9706833|NCT04675268|Experimental|7 night home oximetry|Patients will undergo 7 nights home monitoring with oximetry.
9706834|NCT04675190||Case|Cases will be patients in the department of surgery above 18 years with ultrasound findings of gall stone disease.
9706835|NCT04675190||Control|Controls will be patients in the department of surgery above 18 years with ultrasound findings showing evidence of no gallstones
9779112|NCT01122238|Experimental|12, No Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9779113|NCT01122238|Experimental|13, No Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
10193128|NCT02955290|Experimental|Phase II Study D (CIMAvax, pembrolizumab)|PHASE II STUDY D: Patients with PD-L1 expression < 50% after 4 cycles of induction chemotherapy with pembrolizumab, receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
10193129|NCT02955134|Experimental|Chinese medicine prescription|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in experimental group use the traditional Chinese medicine application prescription.
10193130|NCT02955134|Placebo Comparator|placebo|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
10193131|NCT02953977|Experimental|Diabetes Intervention|Diabetes Prevention Program
10193132|NCT02953977|Other|Delayed Intervention|Diabetes Prevention Program
10193133|NCT02935205|Experimental|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
10193134|NCT02919306|Experimental|Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 * 10^10 viral particles [vp]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10^8 Plaque-forming unit [pfu]) at Week 24 and 48.
10193135|NCT02919306|Placebo Comparator|Placebo|0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.
10193136|NCT02870530|Experimental|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
10193137|NCT02868970|Other|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, Meningococcal ACWY vaccine, Tdap, Herpes Zoster vaccine and Travel Health vaccines (Hepatitis A, Hepatitis B, Typhoid Fever).
9706836|NCT04675086|Experimental|Aralast NP + Antiviral Treatment + Standard of Care|"The investigational product is alpha1-proteinase inhibitor, administered as a loading dose of 120mg/kg/body weight intravenous infusion on the first day, and then 60mg/kg/BW intravenous infusion on Days 3, 5, 7 and 9. Booster infusion of 120 mg/kg/BWon Day 17.~The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
9706837|NCT04675086|Active Comparator|Antiviral Treatment + Standard of Care|"The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
9706838|NCT04675372|Experimental|Group 1|Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)
10193138|NCT02861183|Experimental|OVT (Sodium Hyaluronate)|Sodium hyaluronate is supplied as a 2 mL unit dose in a 3 mL glass syringe.
9706839|NCT04675372|Active Comparator|Group 2|Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam
9706840|NCT04675216||Posterior fossa lesion|This group will be integrated by patients with posterior fossa lesion that likely to rise the posterior fossa intracranial pressure
9706841|NCT04675216||Post-operative posterior fosa surgical patients|This group will be integrated by patients operated for posterior fossa lesions in which we will try to find out what range of posterior fossa pressure is to be expected in this situation
9706842|NCT04675398|Active Comparator|Open-loop deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving open-loop deep brain stimulation.
9706843|NCT04675398|Active Comparator|Randomized deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation at random time points.
10193139|NCT02861183|Placebo Comparator|Saline|0.9% sterile saline is supplied as a 2 mL unit dose in a 3 mL glass syringe.
10193140|NCT02847949|Experimental|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Spectrum sponsored IGN002 study, IGN002-101.
10193141|NCT02822924|Other|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
10204589|NCT05201066|Experimental|Sabatolimab + azacitidine|Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w
10204590|NCT05201066|Experimental|sabatolimab + decitabine|Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v.
10204591|NCT05201066|Experimental|sabatolimab + venetoclax + azacitidine|Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w
10204592|NCT05201066|Experimental|sabatolimab + spartalizumab + decitabine|Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w.
10204593|NCT05201066|Experimental|sabatolimab + HMA|"Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w~HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine."
10193142|NCT02822716|Other|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
9706844|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb movement|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of contralateral limb movement.
9706845|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb rest|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of no movement for contralateral limb.
9706846|NCT04675567|Active Comparator|Safety-Net Intervention|
9706847|NCT04675567|No Intervention|Treatment as Usual|
9706848|NCT04675073|Experimental|ABLATE arm|Ventricular tachycardia substrate ablation intending to: i) eliminate all the potential arrhythmogenic substrate, aiming for complete electrical isolation/elimination of all the electrograms with delayed components or showing hidden slow conduction properties, and ii) non-inducibility or ventricular tachycardias at the end of the procedure. Standard medical treatment will also be given for these patients.
9706849|NCT04675073|No Intervention|NO-TREAT arm|Only standard medical treatment will be offered for these patients.
10193143|NCT02807805|Experimental|Treatment (abiraterone acetate, niclosamide, prednisone)|Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
10193144|NCT02780414||Study Cohort|A group of at least 1,541 pregnant women with NO Pre-E diagnosis
10193145|NCT02780414||Positive Pre-E Control|A group of at least 250 pregnant women diagnosed with Pre-E
9706850|NCT04674956|Experimental|Treatment arm|Regimens：anti-PD1 antibody and AG regimens.
9706851|NCT04674956|Placebo Comparator|Control arm|Regimens：Placebo and AG regimens.
10193146|NCT02764268|Experimental|Apatinib|
9706852|NCT04675021|Experimental|AZD6094 (Savolitinib) D5084C00010|All volunteers will receive either a single dose or two doses of AZD6094 (Savolitinib) D5084C00010
9706853|NCT04675047||healthy control|healthy control
9706854|NCT04674657||caspofungin|Adult critically ill patients on ECMO receiving caspofungin therapy
9706855|NCT04674657||posaconazole|Adult critically ill patients on ECMO receiving posaconazole therapy
9706856|NCT04674735|Experimental|APSLXR|
9706857|NCT04674722|Experimental|Injection of 99mTc-NM-02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99mTc-NM-02 (99mTc labeled anti-HER2 sdAb) in a single dose injection.
9706858|NCT04674722|Experimental|Injection of 188Re-NM-02|Ten breast cancer patients recruited to the study will be administered 66 MBq/kg of 188Re-NM-02 (188Re labeled anti-HER2 sdAb) in a single dose injection.
9706859|NCT04674930|No Intervention|Control group|Pharmacological management
9706860|NCT04674930|Experimental|Exercise group|"Aerobic training: The target training zone was set at 40-60% of the peak heart rate, as determined in the baseline 6min walk test (6MWT), with a rating of 11-13 on the Borg rating of perceived Exertion scale.~Resistance Training: This training was prescribed at 70% of one repetition maximum (RM). Patients were instructed to train a variety of upper and lower body muscle groups (e.g., latissimus, deltoid, biceps, quadriceps, and gastrocnemius muscles), using Thera-band"
9706861|NCT04674865|Active Comparator|Conventional treatment protocol group|Standardized treatment protocol including chest physical therapy as well as limb physical therapy and functional mobility was addressed.
9706862|NCT04674865|Experimental|ANB group|2 sessions per day was added to the standardized treatment protocol
9706863|NCT04674943|No Intervention|Control group|No physical therapy intervention was given. Only pharmacological treatment was provided.
9706864|NCT04674943|Experimental|Breathing exercise group|1. Pursed lip breathing 15 reps x 3 sets) 2: Diaphragmatic breathing (15 reps x 3 sets) 3:Lateral costal breathing 15 reps x 3 sets)
10193147|NCT02763189|Active Comparator|Control|Control group will study the learning material independently. 'Self-study'.
10193148|NCT02763189|Experimental|Mentored|Mentored group will study the learning materials and then receive expert mentoring
9706865|NCT04674917|Experimental|Group A|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
9706866|NCT04674917|Experimental|Group B|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
9706867|NCT04674917|Other|Group C|Hot pack , TENS, Mobilization, Exercise therapy
9779114|NCT01122238|Experimental|14, No Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9779115|NCT01122238|Experimental|15, No Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
9779116|NCT01122238|Experimental|16, No Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
9779117|NCT01122264|Experimental|Tadalafil on demand|10 milligrams (mg) or 20 mg on demand
9779118|NCT01122264|Experimental|Tadalafil once a day|5 mg or 2.5 mg once a day
9779119|NCT01122264|Active Comparator|Sildenafil Citrate|50 mg, 100 mg, or 25 mg on demand
10193149|NCT02753452|Active Comparator|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
9779120|NCT01122316|Experimental|Metformin|
9779121|NCT01122394|Experimental|Tailored Intervention (TI)|Tailored intervention based on the transtheoretical model
9779122|NCT01122394|Placebo Comparator|Attention Placebo (AP)|Attention Placebo
9706868|NCT04674891|Active Comparator|baseline physical therapy treatment|baseline physical therapy treatment ,Control group- Group A
9706869|NCT04674891|Experimental|Cervical Stabilization exercises|baseline physical therapy treatment along with Cervical Stabilization exercises- Experimental Group- Group B
9706870|NCT04674878|Experimental|MET group|METs for accessory muscles of respiration including sternocleidomastoid, scalenes and trapezius given thrice a week for 8 weeks.
9706871|NCT04674878|Active Comparator|Breathing exercise group|Diaphragmatic breathing, pursed lip breathing and diaphragmatic breathing with resistance given thrice a week for 8 weeks.
9706872|NCT04674696|Experimental|Experimental|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
9706873|NCT04674904|Experimental|Group A|Dry Needling
10193150|NCT02753452|Active Comparator|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
10193151|NCT02753452|No Intervention|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
9706874|NCT04674904|Active Comparator|Group B|Hot pack , TENS , Stretching
9706875|NCT04675060|Experimental|Cohort 1|TQ-B3139 capsules administered single dose of 600 mg under fasted conditions in day 1 followed by single dose of 600 mg with a high-fat meal in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
9706876|NCT04675060|Experimental|Cohort 2|TQ-B3139 capsules administered single dose of 600 mg with a high-fat meal in day 1 followed by single dose of 600 mg under fasted conditions in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.
9706877|NCT04674982|Experimental|Vibration Group|In the vibration group, a vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz) was applied to the middle/side area through which the sural nerve passes immediately below the knee of the extremity from which heel blood was to be collected approximately 30 seconds prior to commencement of the heel lance procedure. The vibration was continued throughout the heel lance procedure unless there was redness, swelling, bruising or a change in the skin integrity in the area to which the vibration was applied, and the vibration was stopped once the procedure was over.
9706878|NCT04674982|No Intervention|Control Group|No interventions were made on the newborns in the control group during the heel lance procedure.
9706879|NCT04675008|Experimental|Study arm|Dacomitinib
9706880|NCT04674839|Experimental|MS-20|8 ml/day for 8 weeks
9706881|NCT04674839|Other|Placebo|8 ml/day for 8 weeks
9706882|NCT04674644|Other|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals|Dental professionals
9706883|NCT04674709|Placebo Comparator|Safety of Oleander 4X HPUS|: To evaluate the clinical safety of OLEANDER 4X HPUS in healthy volunteers relative to the control arm (placebo group).
9706884|NCT04674709|Experimental|Pharmacokinetics evaluation of Oleander 4X HPUS|To evaluate the pharmacokinetics of OLEANDER 4X HPUS versus placebo.
9706885|NCT04674566|Experimental|Cohort 1|COR-101 low dose
9706886|NCT04674566|Experimental|Cohort 2|COR-101 mid dose 1
9706887|NCT04674566|Experimental|Cohort 3|COR-101 mid dose 2
9706888|NCT04674566|Experimental|Cohort 4|COR-101 high dose
9706889|NCT04674488|Experimental|TILs intervention|
9706890|NCT04674605||ocular myasthenia gravis|
9706891|NCT04674605||generalized myasthenia gravis|
9706892|NCT04674423|Experimental|TAF Treatment|TAF treatment for 144 weeks and followed for 48 weeks after 144-week TAF treatment
9706893|NCT04674423|No Intervention|Observation arm|Observation for 144 weeks
9706894|NCT04674332|Experimental|long acting insulin|
9706895|NCT04674332|Active Comparator|multiple dose regimen|
9706896|NCT04674449|Active Comparator|Intervention Group - Stratified Medicine|All randomised participants will receive stratified medicine. The subjects will undergo functional coronary angiography involving guidewire-based coronary function tests (interventional diagnostic procedure, IDP) as an adjunct to invasive coronary angiography. The IDP results will be disclosed to the catheter laboratory clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and IDP findings.
9779123|NCT01122446|Placebo Comparator|Placebo comparator|Two doses of placebo day 1 and 30
9779124|NCT01122446|Active Comparator|Alum-GAD (Diamyd)|20 microgram Diamyd day 1 and 30
9779125|NCT01122576|Experimental|Crystalens AO|Eligible subjects to undergo small incision cataract surgery and were implanted with the Crystalens AO bilaterally.
9779126|NCT01122576|Active Comparator|ReSTOR|Eligible subjects to undergo small incision cataract surgery and were implanted with the ReSTOR IOL bilaterally.
9779127|NCT01122576|Active Comparator|Tecnis Multifocal IOL|Eligible subjects to undergo small incision cataract surgery and were implanted with the Tecnis Multifocal IOL bilaterally.
10193152|NCT02753452|No Intervention|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
10193153|NCT02744677|Experimental|TPVR - Main Cohort|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
10193154|NCT02744677|Experimental|TPVR - THV Registry|Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.
10193155|NCT02740608|Other|Liver transplantation|All Participants will receive liver transplantation using the OrganOx metra device
10193156|NCT02714322|Experimental|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
10193157|NCT02714322|Active Comparator|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
9706897|NCT04674449|Sham Comparator|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also receive the IDP at time of the angiogram. The results of the IDP will be concealed from the catheter laboratory clinician who will be blinded. The cardiac physiologist / clinical scientist will remain unblinded for the purpose of data recording and quality assurance. The sham procedure is intended to be the same as in the Intervention Group. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and IDP findings.
9706898|NCT04674176|Experimental|Rifaxamin (R)|Patients in the experimental group will receive additional instructions to take 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet. The experimental group will be provided the required doses of Rifaximin at the initial weigh-in and office visit.
9706899|NCT04674176|No Intervention|Control|Participants in the control group will undergo no intervention and will only be asked to follow an Intermittent fasting diet.
10193158|NCT02700945|Active Comparator|Reveal LINQ™ Insertable Cardiac Monitor|Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
10193159|NCT02700945|No Intervention|Control Arm|Subjects randomized to the control arm will be followed per site specific standard of care.
9706900|NCT04674254|Active Comparator|Anti-vascular endothelial growth factor agent|Intravitreal injections of 1.25 mg/0.05 ml of Bevacizumab every 4 weeks through 12- week visit then pro re nata to complete 12 months according to Protocol S.
9706901|NCT04674254|Active Comparator|Targeted retinal photocoagulation|Targeted retinal photocoagulation guided by fundus fluorescein angiography will be administered after topical anesthesia, directed to areas of nonperfused peripheral retina plus a 1-disc area margin using the Mainster lens. Subsequent treatments if needed will be delivered at 3 monthly intervals for a minimum follow-up of 12 months. The extent of the laser applied will be determined based on areas of nonperfusion identified by fundus fluorescein angiography.
10193160|NCT02700035|Experimental|BZDDD Prevention Program Intervention|We employed an experimental randomized block (RB) design; blocked on reservation where 157 were assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention, we completed a pre-test with families in the experimental group. Following the program, we completed a post-test and a 6-month youth follow-up.
10193161|NCT02700035|No Intervention|BZDDD Prevention Program Control|We employed a randomized block (RB) design; blocked on reservation, 147 families were randomly assigned to the control condition. We completed a post-test and a 6-month youth follow-up.
10193162|NCT02683200|Experimental|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
10193163|NCT02659514|Experimental|Cohort 1: Poziotinib 24 mg|Participants received poziotinib 24 milligrams (mg), administered as three 8 mg tablets, orally, once daily (QD) on an intermittent dosing schedule of 14 days on treatment followed by 7 days off treatment, in a 21-day cycle until disease progression, death, intolerable adverse events (AEs) or for up to a maximum of 24 months, whichever occurs first.
9706902|NCT04674254|Active Comparator|Standard pan-retinal photocoagulation|"Standard pan-retinal photocoagulation will be performed at baseline and then every 3 months thereafter if needed, for a minimum follow-up period of 12 months.~PRP will be performed at two consecutive sessions with adherence to the guidelines of the Early Treatment Diabetic Retinopathy Study Group. Following topical anesthesia, 1000 to 1200 laser spots will be applied to the retina at each session with a 532 nm frequency doubled Nd-YAG laser (VISULAS, Carl Zeiss, Germany) using a spot size of 300-500 μm. PRP will be applied in all 4 retina quadrants.~The Mainster lens will be used. Retreatment will be done according to the Diabetic Retinopathy Clinical Research network protocol S classification for patients with stable, worsening, or with failure of regression of neovascularization."
10193164|NCT02659514|Experimental|Cohort 2: Poziotinib 16 mg|Participants received poziotinib 16 mg, administered as two 8 mg tablets, orally, QD, on a continuous dosing schedule in a 21-day cycle until disease progression, death, intolerable AEs or for up to a maximum of 24 months, whichever occurs first.
9706903|NCT04674527|Experimental|experimental group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.And elemene injectable emulsion will be given for 80 -120 ml/day in each 14-day cycle or 21-day cycle.
9706904|NCT04674527|Experimental|contral group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
9706905|NCT04674540||Sedation and Analgesia Implementation Status Group|To investigate the implementation status of sedation and analgesia in ICU critical patients.
9706906|NCT04674501||Thoracic irradiation|A cohort of cancer patients who receive thoracic irradiation. Patients with any type of malignancy, such as lung cancer, breast cancer, esophageal cancer, or thymoma, are eligible as long as the patients undergo thoracic irradiation.
9706907|NCT04674215|Experimental|intervention group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.~The patients in the intervention group were given a planned in-bed turning and mobilization training in the patient's room by the researcher one day before the surgery. This training included explaining the importance of postoperative mobility, demonstrating the correct in-bed turning and mobilization steps through pictures with the Illustrated In-Bed Turning and Mobilization Training Material, answering questions (if any), and finally, simulating postoperative in-bed turning and the first mobilization using the role-playing technique in collaboration with the patient."
9779128|NCT01122680|Experimental|Treatment A|patients inhale 2 puffs (dose of 1.25 mcg) once daily in the evening via Respimat inhaler
10204594|NCT05201053||Mild acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
10193165|NCT02615275|Experimental|Supportive Care (bioelectrical impedance analysis, RT)|Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.
9706908|NCT04674215|Other|control group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.~Patients in the control group received routine clinical care. This care included the provision of verbal information to the patient at different times by the primary physician and/or nurse about postoperative in-bed turning and mobilization and answering questions if any."
9706909|NCT04674592||Tibial fracture|Patients with a traumatic tibial fracture and without acute compartment syndrome.
9706910|NCT04674592||Tibial fracture complicated by acute compartment syndrome|Patients with a tibial fracture and acute compartment syndrome of fractured leg.
9706911|NCT04674592||Acute compartment syndrome without fracture|Patients with acute compartment syndrome but without a fracture.
9706912|NCT04674202||Pharmaceutical interview|This group will benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
9706913|NCT04674202||No pharmaceutical interview|This group will not benefit from a pharmaceutical interview, accordingly with the common practice in the department in which they are treated.
9706914|NCT04673760|Experimental|Arm 1:Highly structured specialized palliative home care|"Specialized palliative home care teams provide ambulant palliative care following the PROAKTIV approach. This approach, including additional to usual care:~Creating and systematically updating of a palliative care plan (including advance directives).~Regular palliative assessment of the care situation. Updating general practitioner and home care nurses about the care situation. Specialized palliative care educational material and support."
9706915|NCT04673760|Other|Arm 2: Normally structured specialized palliative home care|Specialized palliative home care teams provide ambulant palliative care as usual
9706916|NCT04673760|No Intervention|Arm 3: No care of specialized palliative home care teams at study inclusion|No care of specialized palliative home care teams at study inclusion
9706917|NCT04673877|Experimental|Bier Block Group|Subjects will receive antibiotic Vancomycin from a Bier Block (injected into an arm vein with a tourniquet up to keep antibiotics in the arm). Samples will be collected from bone and tissue that is normally removed during surgery.
9706918|NCT04673877|Active Comparator|Systemic Intravenous IV Group|Subjects will receive antibiotic Vancomycin through intravenous administration. Samples will be collected from bone and tissue that is normally removed during during surgery.
9706919|NCT04673903|Experimental|Intervention group|"The intervention group will be instructed to include the Copenhagen adduction exercise into their warm up before training session (3 times per week) during one season (6 months).~The Copenhagen adduction exercise is a body-weight exercise which mainly works the groin and hip adductor. It has a large eccentric component, meaning the muscles are working whilst lengthening."
9706920|NCT04673903|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
9706921|NCT04673838|Experimental|Lower Extremity Sensory Training + Bobath Therapy|Intervention Group will have Lower extremity sensory training and Bobath Therapy.
10193166|NCT02607813|Experimental|Dose escalation LXH254|
10193167|NCT02607813|Experimental|Dose expansion LXH254: Group 1|
10193168|NCT02607813|Experimental|Dose expansion LXH254: Group 2|
10193169|NCT02607813|Experimental|Dose expansion LXH254: Group 3|
10193170|NCT02607813|Experimental|Dose expansion: LXH254 + PDR001|
10193171|NCT02607813|Experimental|Dose escalation LXH254 + PDR001|
10193172|NCT02553473|Active Comparator|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
9706922|NCT04673838|Active Comparator|Bobath Therapy|Control Group will have only Bobath Therapy. Bobath approach will be applied for 4 weeks, 3 days a week and 12 sessions in total.
9706923|NCT04673968|Active Comparator|prehabilitation (P)|inhospital exercise training 5 times/week, 5~6 weeks during nCRT (neoadjuvant chemoraiotherapy); home exercise 5 times/week, 5~6 weeks, between completion of nCRT and before surgery
9706924|NCT04673968|No Intervention|control group (C)|no prehabilitation
9706925|NCT04674046|Experimental|Nonoperative treatment if deltoid ligament is intact|AirCast Air-stirrup (DJO Global) functional orthosis for 6 weeks.
9706926|NCT04674046|Experimental|Operative treatment if deltoid ligament is ruptured|Open reduction, internal fixation of the fibular fracture using plate and screws.
9706927|NCT04673916|Active Comparator|Clobetasol treatment|The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied [11]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
9779129|NCT01122680|Experimental|Treatment C|patients inhale 2 puffs (dose of 5 mcg) once daily in the evening via Respimat inhaler
10193173|NCT02553473|Placebo Comparator|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
10193174|NCT02522507|Experimental|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
10193175|NCT02522507|No Intervention|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
10193176|NCT02519270|Experimental|Dose Escalation Stage/ Expansion Stage|"The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.~In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles."
10204595|NCT05201053||moderately severe acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
9706928|NCT04673916|Active Comparator|Anti-inflammatory mouthwash|In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
9706929|NCT04673929||patients with HNC recurrence treated with TORS|Report of disease-free survival at 2 years for patients with HNC recurrence treated with TORS
9706930|NCT04674072|Experimental|Intervention group|The intervention group will be instructed to include the reverse Nordic curl exercise into their warm up 15 to 20 mins before training session (3 times per week) during one season (6 months).
9706931|NCT04674072|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions
9706932|NCT04674150|Sham Comparator|Non-AR Group|Patients allocated to the control group will be able to interact with the iPad and visualize objects and decals in the walls but not able to initiate the AR technology. In other terms, patients in this group will be provided with the same iPad to the AR group patients with the only exception that the AR technology will be off and will only see objects through the device camera in normal reality.
10193177|NCT02507596|Experimental|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
9706933|NCT04674150|Active Comparator|AR Group|Patients randomized to the AR group will be able to use the iPad and SpellBound app to initiate the AR experiences in the game.
9706934|NCT04673747|Experimental|Group 1 (Total Hip Arthroplasty with intraoperative manual correction)|Patients will undergo total hip arthroplasty with intraoperative manual correction of Iliosacral displacement of the sacroiliac joint
10193178|NCT02507596|Sham Comparator|Open flap debridement|an open periodontal flap without adding bone graft.
10193179|NCT02472912|Experimental|Treatment A|Single Injection of 40mg / 0.8 mL BMO-2
10193180|NCT02472912|Active Comparator|Treatment B|Single Injection of 40mg / 0.8 mL EU-Humira
10193181|NCT02472912|Active Comparator|Treatment C|Single Injection of 40mg / 0.8 mL US-Humira
10193182|NCT02467582|Experimental|Aspirin 100 mg|Asprin 100 mg daily for maximum 3 years standard chemo if indicated
10193183|NCT02467582|Active Comparator|Placebo|Placebo daily for maximum 3 years standard chemo if indicated
10193184|NCT02445885|Experimental|Acute PCI|Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours
10193185|NCT02445885|Active Comparator|Subacute PCI|Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours
10193186|NCT02435173|Experimental|Part I: CDZ173|Participants consecutively received CDZ173 10 mg twice a day (b.i.d.) from Day 1 to Day 28, CDZ173 30 mg b.i.d. from Day 29 to Day 56 and CDZ173 70 mg b.i.d. from Day 57 to Day 84.
10193187|NCT02435173|Experimental|Part II: CDZ173|Participants received CDZ173 70 mg b.i.d. from Day 1 to Day 85.
10193188|NCT02435173|Placebo Comparator|Part II: Placebo|Participants received Placebo b.i.d. from Day 1 to Day 85.
10193189|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
10193190|NCT02390245|Experimental|Phase 1: Telemedicine Screening Participants|Participants across the Philadelphia, PA region were invited to participate in free eye screenings at primary care physician offices or health centers. Screenings included images of optic nerve and macula using non-contact, autofocus, hand-held fundus cameras (Volk Optical, Mentor, Ohio, USA) and measuring Intraocular Pressure (IOP) in millimeters of mercury (mm Hg) with non-contact rebound tonometers TA01I (ICare, Helsinki, Finland).
10193191|NCT02390245|Experimental|Phases 2 and 3: Enhanced Intervention Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Enhanced Intervention Group and were referred to a general ophthalmologist for follow-up eye care. Patient navigation and a social worker and referred to a general ophthalmologist close to the current health center or primary care physician office where they received the non dilated eye exam. Prior to all follow-up visits, patients in the Enhanced Intervention Group were provided a scheduled appointment and received a personal phone call reminding them to attend. Patients received necessary interpretation services and educational materials.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
10193192|NCT02390245|Experimental|Phases 2 and 3: Usual Care Group|"From eye screening results (visit 1), Phase 2 includes participants requiring further evaluation received comprehensive eye exam to confirm diagnosis (visit 2). Following confirmation diagnosis, patients were randomized to the Usual Care Group and were referred to a general ophthalmologist for follow-up eye care. These patients were scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team was able to track outcomes. This group represents a realistic choice currently available for patients. Practice patterns vary depending on the resources, staff time, and services available within each local ophthalmology practice.~Phase 3. Includes following this group over a 5 year period for adherence to eye care."
10193193|NCT02356458|Experimental|Ibrutinib & Bortezomib|Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
10193194|NCT02349971|Experimental|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
10193195|NCT02346825|Experimental|Intensive Plus Cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
10193196|NCT02346825|Experimental|Intensive Plus Splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
9706935|NCT04673747|Active Comparator|Group 2 (Total hip Arthroplasty: standard method)|Patients will undergo total hip arthroplasty according to the standard method
9706936|NCT04674098||Usual Care|Every patient who is admitted or transferred to the target unit during both the baseline and intervention phases of the study will be approached by a member of the research staff to be a subject in the study. The patient will be informed of the overall study objectives and be requested to provide informed consent to participate. The patient's involvement in the study will include having the research staff access and extract relevant outcome variables collected from their electronic health record (EHR) (AEs, admissions to the ICU, hospital length of stay and activation of the rapid response team) as a result of their hospital stay.
9706937|NCT04674098||Intervention|If the patient provides consent during the intervention phase, the BAS technology will passively monitor their vital signs generated by the Philips vital sign monitor by relaying their deidentified vital signs data to the CLU, proprietary Cloud server, and subsequently Lumori® on a study-issued cell phone of the RN who is primarily responsible for the patient's care. Patient's admitted or transferred to the targeted unit will NOT be excluded from being approached to participate in the study.
9706938|NCT04673981|Experimental|patient treated for a oral cavity and oropharynx cancer|questionnaire and tests to evaluate neuropathic pain
9706939|NCT04673799|Experimental|MV088|MV088 injection (60mg) by subcutaneous injection once on the first day
9706940|NCT04673799|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day
9706941|NCT04673812|Active Comparator|Bupivacaine-Fentanyl Spinal Anaesthesia|
9706942|NCT04673812|Active Comparator|Bupivacaine-Fentanyl-Naloxone Spinal Anaesthesia|
9706943|NCT04674137|Experimental|XC8 100 mg|XC8 100 mg orally
9706944|NCT04674137|Placebo Comparator|Placebo|Placebo orally
9706945|NCT04673864|Experimental|Sequence 1|"Period 1: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 3: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
9706946|NCT04673864|Experimental|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 2: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 4: D012, D326, D337- A single oral dose of 3 tablets under fasting condition"
9706947|NCT04673474|Experimental|Arm A|Hemay022 Period 1, Fasted control → Period 2, Fed control
9706948|NCT04673474|Experimental|Arm B|Hemay022 Period 1, Fed control → Period 2, Fasted control
9706949|NCT04673461|Experimental|STA363 containing 90 mg (60 mg/mL) lactic acid|"STA363 containing 90 mg (60 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
9706950|NCT04673461|Experimental|STA363 containing 180 mg (120 mg/mL) lactic acid|"STA363 containing 180 mg (120 mg/mL) lactic acid will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
9706951|NCT04673461|Placebo Comparator|Placebo|"Placebo will be injected into the center of up to two intervertebral discs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.~Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period."
9706952|NCT04673526|Experimental|Intersphincteric resection|After a laparoscopic TME (total mesorectal excision) is carried out down to the elevator ani plane and the anorectal junction, the intersphincteric plane is dissected, opening the space between puborectalis muscle and interior sphincter. Margin of resection is at least 1 cm below the lower margin of the tumor. Rectal excision is completed with transanal circumferential dissection and after specimen extraction through the anus, a colo-anal hand sewn anastomosis is fashioned.
9706953|NCT04673526|Active Comparator|Abdomen-perineal procedures|After identification of the elevator ani plane, the descendent colon is transected with a linear stapler and a terminal stoma is fashioned. Then, a circumferential incision is made around anal orifice and perineal dissection is performed circumferentially to the pelvic cavity. Perineal defect is repaired performing mono-lateral or bilateral inferior gluteal flap.
9706954|NCT04673565|No Intervention|Control|Control groups that undergo standard audiological care
9706955|NCT04673565|Experimental|Treatment|Treatment groups that undergo motivational interviewing with audiological care
9706956|NCT04673513|Active Comparator|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy will be provided as described in Beck et al. (1979) and Beck (2011), with adaptations for the treatment of comorbid personality disorders as described in Beck et al. (2015).
9706957|NCT04673513|Active Comparator|Cognitive Behavioral Therapy - Skill enhanced (CBT-SE)|This condition includes a variation of CBT (as provided in the other condition) with special emphasis on helping clients to develop the skills of CBT.
9706958|NCT04673500|Experimental|Propofol-lidocaine through large vein|Eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the antecubital fossa and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
9706959|NCT04673500|Placebo Comparator|Propofol-lidocaine through small vein|Another eighty patients randomly assigned in this arm received a 20 gauge intravenous catheter at the dorsum of hand and a mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given for induction of general anesthesia.
9706960|NCT04673695|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)~Period 2: Test drug(CKD-344 60 mg)"
9706961|NCT04673695|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)~Period 2: Reference drug(Lixiana 60 mg)"
9706962|NCT04673435|Experimental|Permeaderm as temporary coverage|A: temporary coverage with PermeaDerm until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
9706963|NCT04673435|Active Comparator|FHCA as temporary coverage|B: temporary coverage with FHCA until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
9706964|NCT04673435|Experimental|Permeaderm over widely meshed autograft|C: temporary coverage of widely meshed autograft with PermeaDerm until healing occurs and PermeaDerm can remove
9706965|NCT04673435|Active Comparator|FHCA over widely meshed autograft|D: temporary coverage of widely meshed autograft with FHCA until healing occurs
9706966|NCT04673539||Single group|Instrument validation in stroke patients
9706967|NCT04673604|Placebo Comparator|Triple preservative-free therapy with placebo in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use placebo (artificial tears) in the evening (21:00) for 6 months. At the end of this period patients will be crossed over to the other therapy (cyclosporine 0.1% in the evening)
9706968|NCT04673604|Active Comparator|Triple preservative-free therapy with cyclosporine 0.1% in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use cyclosporine 0.1% drops in the evening (21:00) for 6 months. At the end of this period all patients will be crossed over to the other therapy (placebo in the evening)
9706969|NCT04673578|Experimental|Celecoxib|Celecoxib 50 mg orally twice daily (if weight 10-25 kg) or 100 mg orally twice daily (if weight > 25 kg) for 12 weeks. Used as adjunct to treatment-as-usual.
9706970|NCT04673578|Placebo Comparator|Placebo (microcrystalline cellulose)|Placebo capsules identical to celecoxib. One capsule orally twice daily for 12 weeks. Used as adjunct to treatment-as-usual.
9706971|NCT04673708|Other|Hashim Talib Hashim|It is a video with +18 different contents to know the effect of much video than the others.
9706972|NCT04673708|Experimental|Mustafa Ahmed Ramadhan|Is is an assessment of the vital signs among the participants and the change with the showing of videos.
9706973|NCT04673396|Experimental|Tolerance test|The design is based on 3+3 dose escalation: three subjects were enrolled in each dose group, administered once a day for 2 weeks, and were observed for 7 days after withdrawal. If dose-limiting toxicity (DLT) was not observed, the dose was incresed to the next dose group. If dose-limiting toxicity (DLT) was found in 2 or more patients in a given dose group, the climbing test was terminated and the dose was reduced by 1 dose. If there were only three subjects, three more subjects were observed, so that the MTD dose group had at least six evaluable subjects.If DLT occurs in 1 patient in a given dose group, 3 more subjects should be added to that dose group. If DLT occurs in 1 or more of these 3 subjects, the climb will be stopped and the dose group will be reduced by 1 dose group. If there are only 3 subjects, 3 more subjects will be observed, so that at least 6 patients in the MTD dose group can be evaluated.
9706974|NCT04673396|Experimental|Pharmacokinetic studies|At the same time of tolerance test, blood PK sampling was performed. At the end of the tolerance test in each group, on the premise of good safety, and after evaluation by the researchers, additional cases were selected from the three dose groups (low, medium and high) for pharmacokinetic study, so as to ensure that at least 8 patients could be evaluated for PK in each group.
10193197|NCT02346825|Experimental|Intensive no Constraint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks but will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
10193198|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
10193199|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
10193200|NCT02254278|Experimental|IMRT 6 weeks + cisplatin|IMRT 6 weeks with concurrent cisplatin
10193201|NCT02254278|Experimental|IMRT 5 weeks|IMRT 5 weeks
10193202|NCT02134392|Experimental|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
10193203|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
10193204|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
10193205|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
10193206|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
10193207|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
10193208|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
10193209|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
10193210|NCT02104921||Healthy volunteers|
10193211|NCT02047097||dimethyl fumarate (DMF)|Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care
10193212|NCT01974609|Experimental|Narcotic|Hydrocodone + acetaminophen 4 times per day 1 week after surgery
10193213|NCT01974609|Active Comparator|non-narcotic|ibuprofen + acetaminophen 4 times per day 1 week after surgery
10193214|NCT01868373|Other|microbiota transplantation|Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
10193215|NCT01850524|Active Comparator|IXAZOMIB|"IXAZOMIB 4.0 mg capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40 mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
10193216|NCT01850524|Placebo Comparator|Placebo|"IXAZOMIB matching-placebo capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib placebo-matching capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
9706975|NCT04673396|Active Comparator|Comparative Study|It is planned to select the 20mg dose of norcantharidin sodium for injection to carry out pharmacokinetic study of 8 cases. The specific research design will be formulated after the tolerance and pharmacokinetic test of norcantharidin lipid microsphere injection is completed.
10193217|NCT01758081|Active Comparator|vitamin D + fish oil|vitamin D3 + Omacor
10193218|NCT01758081|Active Comparator|vitamin D + fish oil placebo|vitamin D3 + fish oil placebo
10193219|NCT01758081|Active Comparator|vitamin D placebo + fish oil|vitamin D placebo + Omacor
9706976|NCT04673669|Experimental|Single group|measuring the strength of the tendon of the posterior tibial muscle in healthy subjects with a hand-held dynamometer by two examiners and with an isometric dynamometer
9706977|NCT04673318|No Intervention|Control|Course of recovery with standard of care.
9706978|NCT04673318|Active Comparator|Exercise training|low resistance velocity based exercise training ~40 min, 3 times a week at home for 8 weeks
10193220|NCT01758081|Placebo Comparator|vitamin D placebo + fish oil placebo|vitamin D placebo + fish oil placebo
9706979|NCT04673318|Experimental|heat therapy|heat therapy (~40C skin temperature) with a leg garment 5 times a week for 40-55 min for 8 weeks
9706980|NCT04673682|Experimental|Group 1|"Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)~Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)"
9706981|NCT04673682|Experimental|Group 2|"Treatment B: Test drug(CKD-845(Testosterone) 1 vial, once, i.m. inj.)~Treatment A: Reference drug(D309(Testosterone) 1 vial, once, i.m. inj.)"
9706982|NCT04673370|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
9706983|NCT04673370|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
10193221|NCT01673867|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
9706984|NCT04673305|Experimental|Arm 1|patients ≥ 70 years, whith haematological malignancy, who need to start a treatment within 3 months
9706985|NCT04673643|Experimental|taVNS|Transcutaneous Auricular Vagus Nerve Stimulation
9706986|NCT04673344|No Intervention|Partial Rotator Cuff Repair|Routine partial rotator cuff repair
9706987|NCT04673344|Active Comparator|Partial Rotator Cuff Repair with Regeneten Scaffold|Routine partial rotator cuff repair with the addition of the Regeneten scaffolding patch
9706988|NCT04672928|Experimental|IBI318 in combination with paclitaxel|
9706989|NCT04673097|Experimental|Group 1|
9706990|NCT04673097|Active Comparator|Group 2|
9706991|NCT04673097|Active Comparator|Group 3|
9706992|NCT04673110||Anastomotic leakage group|9 patients developed anastomotic leakage (8%) in a median of 8 days (range: 5-9) median CRP level postoperative day 4:164mg/dL
9706993|NCT04673110||no Anastomotic leakage group|117 patients (92%) median CRP level postoperative day 4: 64mg/dL
9706994|NCT04672954|Active Comparator|BI 474121|
9706995|NCT04672954|Placebo Comparator|Placebo|
9706996|NCT04672993|Experimental|Urine Collection Device for Men|Test of Urine Collection Device for Men for 7 (+/- 3/0 days).
9706997|NCT04673201|Active Comparator|Viscotrabeculotomy group|Management of medically uncontrolled steroid induced glaucoma by viscotrabeculomy technique
9706998|NCT04673201|Active Comparator|"Trabeculectomy with MMC group"|Management of medically uncontrolled steroid induced glaucoma by trabeculotomy with MMC
9706999|NCT04673045|Active Comparator|Active neuromuscular electrical stimulation|This group will receive active NMES delivered the electrical current through electrodes inserted in saline-soaked sponges.
9707000|NCT04673045|Sham Comparator|Sham neuromuscular electrical stimulation|This group will receive sham NMES
9707001|NCT04673227||Contact with active TB/ LTBI|After a close contact with bacteriologically confirmed TB suspicion for LTBI with an evidence of previous BCG vaccination status TB confirmed with TST (TST ≥ 5 mm or BCG unvaccinated or TST ≥ 15 mm for BCG vaccinated) 20 children and adolescents 20 adults
9707002|NCT04673227||Active TB group|Active TB group with positive microbial culture and pathological chest radiography or chest CT 20 children and adolescents 20 adults
9707003|NCT04673227||Contact with active TB/ negative|After a close contact with bacteriologically confirmed TB no evidence of TB in TST or IGRA test for 3 months 20 children and adolescents 20 adults
10193222|NCT01673867|Active Comparator|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
10193223|NCT01665573|Active Comparator|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
10193224|NCT01665573|Placebo Comparator|Placebo|Placebo
10204596|NCT05201053||severe acute pancreatitis|Groups are defined by the Revised Atlanta classification. Anticipated 60% mild, 30% moderate and 10% severe patients
9707004|NCT04673071|Active Comparator|Thread Embedding Acupuncture (TEA)|TEA once a month for 4 months + AEDs
9707005|NCT04673071|Sham Comparator|Sham-TEA (STEA)|STEA once a month for 4 months + AEDs
9707006|NCT04673162|Experimental|A SOC plus MP|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Methylprednisolone 1gr daily iv on days 1,2,3
10193225|NCT01341626|Experimental|Treatment Foster Care Oregon (TFCO)|Youth are placed individually in well-trained and supervised foster homes. Basic components include: (a) daily telephone contact with TFCO parents using the Parent Daily Report; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation.
9707007|NCT04673162|Active Comparator|B SOC plus Pb|Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Placebo
9707008|NCT04673253|Active Comparator|Passive leg raise|group for passive leg raise
9707009|NCT04673253|Placebo Comparator|Control|
10193226|NCT01341626|Active Comparator|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%).
9707010|NCT04673214|Experimental|Triple therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, will be every 24 hours for 2 days and Rivaroxaban tablets of 10 mg will take 1 every 24 hours for 10 days
9707011|NCT04673214|Active Comparator|Double therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half a tablet orally every 24 for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.
9707012|NCT04672863|No Intervention|Standard of Care Group|Subjects will participate in a standardized Transplant Nutrition class between day 21-40 as per institutional protocol and will be counseled as per the Mayo Clinic standard of care vis a vis dietary intervention, standard aerobic and resistance exercise recommendations (consistent with AASLD guidelines) and other lifestyle interventions.
9707013|NCT04672863|Experimental|Behavioral: Structured Modified Mediterranean Diet|Subjects will participate in a one-on-one counselling session with a dietician, as opposed to attending the standardized Transplant Nutrition class. Counselling will be provided on the elements of the modified Mediterranean diet which emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt, moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats.
9707014|NCT04672655|Experimental|ONBOARD Intervention Group|Those randomized to the ONBOARD condition will receive the intervention which consists of four 60-minute sessions with study interventionist. Each session will be scheduled two weeks apart from each other.
9707015|NCT04672655|No Intervention|CGM Only Group|Those randomized to the CGM Only group will not receive the ONBOARD intervention during their 12-month participation in the study. There will only receive 12 weeks of CGM supplies and provide A1Cs, data downloads, and survey responses during various time points in the study.
9707016|NCT04672642|Experimental|SpyGlass DS after endoscopic treatment|
9707017|NCT04672720|Experimental|Adding l-carnitine to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. In the experimental group, the women will receive 3 tablet of L-carnitine daily (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) from day 2 of the previous menstrual cycle until pregnancy test day.
9707018|NCT04672720|Placebo Comparator|Adding placebo to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. The patients in the control group will receive 3 placebo tablets in similar way for 8 weeks.
9707019|NCT04672694|Active Comparator|VNB (vagus nerve block)|Vagus nerve block
9707020|NCT04672694|Placebo Comparator|Control|No vagus nerve block
9707021|NCT04672473|Experimental|Treatment|DAC combined with Ag-CTL
9707022|NCT04672551|No Intervention|Waitlist control group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. No intervention or any other procedure will be conducted during the study period of 36 weeks. Afterwards these subjects will be offered an EMDR therapy as provided in the intervention.
9707023|NCT04672551|Experimental|Intervention group|The intervention group consists of 30 patients diagnosed with PTSD induced by ACS. Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
9707024|NCT04672616|Experimental|Group psychotherapy|Weekly group meeting w/psychotherapist: All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or problems the group members have
9707025|NCT04672590||Cases|Patients admitted to a study hospital meeting criteria for confirmed or probable acute new-onset neurological disease and confirmed or probable COVID-19.
9707026|NCT04672590||Controls|Patients admitted to a study hospital meeting criteria for confirmed or probable COVID-19, without confirmed or probable acute new-onset neurological disease.
9707027|NCT04672603|Experimental|Complete Preservation of Denonvilliers Fascia|Complete preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
9707028|NCT04672603|No Intervention|Partial Preservation of Denonvilliers Fascia|Partial preservation of Denonvilliers fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for mid-low rectal cancer patients.
9707029|NCT04672837|Experimental|Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
9707030|NCT04672837|Active Comparator|Stretching Group|"A protocol of Stretching at home. 3-5 sessions twice a day. Each stretch will be maintain10 to 30 seconds. Each session 15 will take no less than 15 minutes. 7 days a week.~Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
9707031|NCT04672759||Cohort 1|Cohort 1 will include patients with unresectable stage III non-small cell lung cancer. Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
10204597|NCT05200936|Placebo Comparator|Arm 1- Placebo|A total of 26 patients will receive a placebo identical in appearance to the investigational medicinal product (IMP) administered orally twice weekly (e.g., Tuesday/Friday) for 6 weeks.
9707032|NCT04672759||Cohort 2|Cohort 2 will enroll patients with histologically or cytologically confirmed NSCLC or SCLC who will or have received chemotherapy/radiotherapy at the physician's discretion.
9707033|NCT04672499|Experimental|Cohort 1: Miricorilant 900 mg (Regimen A1)|Participants will receive a single oral dose of miricorilant 900 mg (3 X 300 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
9707034|NCT04672499|Experimental|Cohort 1: Miricorilant 300 mg (Regimen A2)|Participants will receive a single oral dose of miricorilant 300 mg (2 X 150 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
9707035|NCT04672499|Experimental|Cohort 2: Miricorilant (Regimen B1 and B2)|Participants will receive a single oral dose of miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
9707036|NCT04672499|Placebo Comparator|Cohort 2: Placebo (Regimen B1 and B2)|Participants will receive a single oral dose of placebo matching miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
9707037|NCT04672499|Experimental|Cohort 3: Miricorilant (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
9707038|NCT04672499|Placebo Comparator|Cohort 3: Placebo (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of placebo matching miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and placebo matching miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
9707039|NCT04672811|Experimental|App/Sensor Intervention|All subjects will be enrolled into the same experimental group for the duration of the study
9707040|NCT04672525|Active Comparator|RIFAMPICIN|Patient with staphylococcal PJI, treated with DAIR strategy, and randomized in the control group will receive rifampicin in association with another antibiotic except rifabutin, as-per recommendations for 12 weeks.
9707041|NCT04672525|Experimental|RIFABUTIN|Patient with staphylococcal PJI treated with DAIR strategy, and randomized in the experimental group, will receive rifabutin in association with another antibiotic except rifampicin, as-per recommendations for 12 weeks.
9707042|NCT04672577||Arboviral infection or malaria positive cohort|
9707043|NCT04672707|Experimental|Group A|Bromhexine Hydrochloride Tablet, 32 mg, 8 mg 4 tablets, three times a day, for 2 days
9707044|NCT04672707|Experimental|Group B|Bromhexine Hydrochloride Tablet, 48 mg, 8 mg 6 tablets, three times a day, continuous service within 2 days
9707045|NCT04672707|Experimental|Group C|Bromhexine Hydrochloride Tablet, 64 mg ,8 mg spec 8 tablets ,3 times daily ,2 days in succession)
9707046|NCT04672707|Experimental|Group D|Bromhexine Hydrochloride Tablets, 80 mg ,8 mg Standard preparation 10 tablets ,3 times a day ,2 day
9707047|NCT04672746|Experimental|Brief MI interaction via instant communication|The interaction communication using brief motivational interviewing will be applied via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
9707048|NCT04672746|Placebo Comparator|General health information|"The subjects will receive general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
9707049|NCT04672785||Patients who underwent a posterior fossa craniectomy for a cerebellar hematoma|
9707050|NCT04672447|Experimental|L-Citrulline + Glutathione|Citrulline: 2 grams/day, Glutathione: 200mg/day for 4 weeks
9707051|NCT04672447|Experimental|L-Citrulline|Citrulline: 6 grams/day
9707052|NCT04672447|Placebo Comparator|Placebo|Maltodextrin: 6 grams/day
9707053|NCT04672408|Active Comparator|His bundle pacing|Pacing programmed from the His bundle lead
9707054|NCT04672408|Placebo Comparator|Right ventricular pacing|Pacing programmed from the right ventricular lead
9707055|NCT04672421|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after laparoscopic surgery
9707056|NCT04672421|Sham Comparator|Placebo|laparoscopic surgery
9707057|NCT04672096|Experimental|Neuronoff BASMATI Injectrode|Subjects will be provided with the placement of an Injectrode insert. The maximal placement duration will be 28 days.
9707058|NCT04672148||A|Patient who died in the 30 days after receiving mechanical thrombectomy, no matter the mortality cause
9707059|NCT04672148||B|Non-30-day-mortality group after receiving mechanical thrombectomy
10193227|NCT01182727|Experimental|salsalate|Salsalate will be administered in two divided doses of 2grams in the morning and 2 grams in the evening. Salsalate will be administered for 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until a tolerated dose or a minimum dose of 2 grams per day is reached.
10193228|NCT01059188|Experimental|Cetuximab, Cisplatin, Docetaxel, Radiotherapy and Surgery|
10193229|NCT01033552|Experimental|Transplant in Epidermolysis Bullosa|
10193230|NCT00877500|Experimental|Group I (ixabepilone)|Participants receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10193231|NCT00877500|Active Comparator|Group II (standard of care)|Participants receive standard of care for 18 weeks.
10193232|NCT00624715|Active Comparator|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint"
10193233|NCT00624715|Placebo Comparator|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
10193234|NCT00455104||National Registry|To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
10193235|NCT00335777|Experimental|Migranal treatment first treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
10193236|NCT00335777|Experimental|Migranal second treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
10193237|NCT00159588|Active Comparator|Prophylaxis from the start|Use of preventive drugs from the start without abrupt withdrawal
10193238|NCT00159588|Other|Abrupt withdrawal|Device: Abrupt withdrawal. Standard out-patients detoxication program including telephone call after 2 weeks and rescue medicine up to 2 days/week
10193239|NCT00159588|Other|Controls|Active control: No instruction for abrupt withdrawal or prophylactic treatment. The controls finished the study period after 5 months observation, and were then offered the optimal type of treatment
10193240|NCT03060473|Experimental|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
10193241|NCT03060473|Active Comparator|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
10193242|NCT03051217|Placebo Comparator|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
10193243|NCT03051217|Experimental|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
10193244|NCT03051217|Experimental|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
10193245|NCT03025542|Experimental|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
10193246|NCT03025542|Experimental|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
10193247|NCT03017573|Experimental|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
10193248|NCT03008382|Other|Double-Blind Randomized Drug|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
10193249|NCT03008382|Other|Double-Blind Randomized Placebo|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
10193250|NCT02992080|Other|Cystic fibrosis Patients|
10193251|NCT02992080|Other|Patients without fibrosis cystic|
10193252|NCT02992080|Other|Cystic fibrosis Patients (secondary use of samples)|
10193253|NCT02988401|Experimental|Intranasal insulin 20 international units|Subjects will administer 20 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
10193254|NCT02988401|Experimental|Intranasal insulin 10 international units|Subjects will administer 10 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
10204598|NCT05200936|Experimental|Arm 2- MM-120|A total of 26 patients will receive 20 μg of MM-120 administered orally twice weekly for 6 weeks.
10193255|NCT02988401|Placebo Comparator|Intranasal saline|Subjects will administer a sterile diluent containing inactive ingredients in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
10193256|NCT02987530|Experimental|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
9707060|NCT04672174|Other|Effect of hearing loss on dementia|Effect of hearing loss on dementia, collected with a standardized questionnaire
9707061|NCT04672031|No Intervention|Control Arm|Patients in the control arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the control arm will be defined as follows: fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL (i.e. conventional targets). Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
10193257|NCT02987530|Active Comparator|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
9707062|NCT04672031|Experimental|Interventional Arm|Patients in the experimental arm will be instructed to check blood sugars seven times per day: fasting, pre-prandial, and 1 hour after each meal. The glycemic targets for the intervention arm will be defined as follows: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL. Patients who do not achieve glycemic goals with diet and exercise will be started on medical therapy (metformin or insulin) at the discretion of a maternal-fetal medicine subspecialist and endocrinologist.
9707063|NCT04672200|Experimental|Intervention arm|This group will receive the weekly group exercise which will be delivered online initially, and in the community clubs once they are allowed to reconvene according to government guidance. The duration of the intervention is 12 weeks.
9707064|NCT04672265|Experimental|Mother tongue and Norwegian|Written material related to screening sent to the invitee in two languages.
9707065|NCT04672265|No Intervention|Norwegian|Written material related to screening sent to the invitee in Norwegian only.
9707066|NCT04672356|Experimental|Phase Ia: IBI939 in combination with Sintilimab|IBI939 10mg/kg combination with Sintilimab
9707067|NCT04672356|Experimental|Phase Ia:IBI939 in combination with Sintilimab|IBI939 20mg/kg combination with Sintilimab
9707068|NCT04672369|Experimental|IBI939 in combination with Sintilimab|
9707069|NCT04672369|Active Comparator|sintilimab|
9707070|NCT04672213|No Intervention|No TXA|No preoperative, intraoperative, or postoperative tranexamic acid will be given
9707071|NCT04672213|Experimental|IV TXA|1g IV TXA bolus will be given at the time of incision intraoperatively
9707072|NCT04672213|Experimental|Pre-Oral TXA|Three 650 mg tablets of oral TXA 2 hours prior to incision
9707073|NCT04672213|Experimental|Full Oral TXA|Three 650 mg tablets of oral TXA 2 hours prior to incision and three 650 mg tablets of oral TXA given each day for three days postoperatively (while in the hospital as an inpatient).
9707074|NCT04672317|Experimental|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
9707075|NCT04672239|Experimental|SiS|"Participants will be onboarded (remotely) to the smartphone app Smiling instead of Smoking (SiS), and will be asked to use it for 7 weeks while they quit smoking."
9707076|NCT04672239|Active Comparator|QG|"Participants will be onboarded (remotely) to the smartphone app QuitGuide (QG), and will be asked to use it for 7 weeks while they quit smoking."
9707077|NCT04672239|Other|CTA|"Participants will be onboarded (remotely) to the NCI brochure Clearing the Air (CTA), and will be asked to use it for 7 weeks while they quit smoking."
9707078|NCT04672278|Experimental|Group A|
9707079|NCT04672278|Experimental|Group B|
9707080|NCT04672070|Active Comparator|Selective Caries Removal|The patient will be treated with Selective Caries Removal (SCR)
9707081|NCT04672070|Active Comparator|Pulpotomy|The patient will be treated with full coronal Pulpotomy.
9707082|NCT04672330|Experimental|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) prior to radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 1 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
9707083|NCT04672018|Experimental|Treatment group|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
9707084|NCT04672018|Active Comparator|Control group|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
9707085|NCT04672057|Active Comparator|Right hemiparetics|right-sided affected hemiparetic individuals
9707086|NCT04672057|Active Comparator|Left hemiparetics|left-sided affected hemiparetic individuals
9707087|NCT04672057|Active Comparator|Control|healthy individuals
9779130|NCT01122680|Placebo Comparator|Placebo|patients inhale 2 puffs of placebo matching tiotropium once daily in the evening via Respimat inhaler
9779131|NCT01122680|Experimental|Treatment B|patients inhale 2 puffs (dose of 2.5 mcg) once daily in the evening via Respimat inhaler
9779132|NCT01122849|Experimental|Prototype Nasal Dilator|Prototype Nasal Dilator
9779133|NCT01122849|Active Comparator|Marketed Nasal Strip|Marketed Nasal Strip
9779134|NCT01122849|Placebo Comparator|Placebo Nasal Strip|Placebo
9779135|NCT01122862|Active Comparator|0.12% Chlorhexidine Mouthrinse|Commercially available 0.12% Chlorhexidine mouthrinse
9779136|NCT01122862|Active Comparator|Cosmetic mouthrinse|Commercially available cosmetic mouthrinse
9707088|NCT04672005|Experimental|Treatment Regimen: mFOLFIRINOX + mGnabP|"All study participants will receive the following treatment:~mFOLFIRINOX (28-day cycle)~Day 1 and Day 15:~Oxaliplatin 85 mg/m2 2-hour intravenous infusion followed by leucovorin 400 mg/m2 2-hour infusions with the addition of irinotecan 150 mg/m2 as a 90 minute infusion. 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours will follow irinotecan.~Day 3 and Day 17:~Pegylated-Granulocyte Colony Stimulating Facotr (peg-GCSF) 6 mg subcutaneous injection following disconnection of 5-FU infusion, first cycle and then per investigator discretion.~Biweekly mGnabP (28-day cycle)~Day 1 and Day 15:~Nab-paclitaxel 125 mg/m2 infused over 30 minutes, immediately followed by Gemcitabine 1200 mg/m2 intravenously infused at the rate of 10mg/m2/min (over 120 minutes).~Patients will receive one month of each regimen, alternately monthly until progression of disease."
9707089|NCT04671992|Active Comparator|Ultrasound Guided Out of-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding horizontal)
9707090|NCT04671992|Active Comparator|Ultrasound Guided In-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding vbertical)
9707091|NCT04671758||AR TAVI|The population consists in patients with severe symptomatic AR on native aortic valve who are candidates for surgical aortic valve replacement but who are deemed inoperable by the heart team due to technical issues (i.e., porcelain aorta, previous coronary artery bypass grafting,…), extreme left ventricular dysfunction or comorbidities (liver cirrhosis, severe chronic obstructive pulmonary disease…).
9707092|NCT04671732||Fenestrated endovascular aortic aneurysm repair (FEVAR)|
9707093|NCT04671732||Open repair (OR)|
9707094|NCT04671888|Experimental|COPD patients|
9707095|NCT04671784||Enlarged mediastinal or abdominal|Consecutive patients with enlarged mediastinal or abdominal detected by cross-sectional imaging and confirmed at EUS will be enrolled.
9707096|NCT04671745||Expérimental|patient receiving care with interactive music
9707097|NCT04671745||Control|patient receiving care without interactive music
9707098|NCT04671914|Active Comparator|Hyaluronic acid gel after D&C|After abortion in the II trimester, we provide D&C and after the procedure, we apply in uterine cavity Hyaluronic acid gel.
9707099|NCT04671914|Active Comparator|Only D&C|After abortion, in the II trimester, we provide only D&C.
9707100|NCT04671849|Experimental|adult patients_Dose 1|
9707101|NCT04671849|Experimental|adult patients_Dose 2|
9707102|NCT04671849|Experimental|adult patients_Dose 3|
10193258|NCT02986620||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
10193259|NCT02965690|Active Comparator|Zimmer Biomet NexGen CR|Patients receive a Zimmer Biomet NexGen Total Knee Replacement
10193260|NCT02965690|Active Comparator|Medacta International GMK Sphere|Patients receive a Medacta International, GMK Sphere Total Knee Replacement
9707103|NCT04671849|Experimental|adult patients_Dose 4|
9707104|NCT04671849|Experimental|adult patients_Dose 5|
9707105|NCT04671849|Experimental|adult patients_Dose 6|
9707106|NCT04671849|Experimental|adult patients_Dose 7|
9707107|NCT04671849|Experimental|adult patients_Dose 8|
9707108|NCT04671862|Experimental|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~1 Treatment pre radiotherapy~3 treatments weekly during radiotherapy"
9707109|NCT04671836|Experimental|Lorazepam first|This arm comprises of participants who were randomized to receive lorazepam 1 mg prior to the first MRI scan and then placebo on the second MRI scan a week later.
9707110|NCT04671836|Placebo Comparator|Placebo first|This arm comprises of participants who were randomized to receive placebo prior to the first MRI scan and then lorazepam 1 mg orally prior to the second MRI scan a week later.
9707111|NCT04671537|Experimental|Study group (preloading with crystalloid fluid - isotonic solution)|Preloading with crystalloid fluid (isotonic solution) at 10 ml/kg of ideal body weight
10193261|NCT02964182|Experimental|Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks."
10193262|NCT02964182|Experimental|Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks."
10193263|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
10193264|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
10193265|NCT02938689|Experimental|Lumbar extension exercise|Exercise education based on Mckenzie lumbar extension exercise for 4 weeks
10193266|NCT02938689|Active Comparator|Lumbar flextion exercise|Exercise education based on Wilillams lumbar flexion exercise for 4 weeks
10204599|NCT05200910||Patient|Patients whose ventricular septal defect closed percutaneously.
10204600|NCT05200910||Control|Healthy children
10204601|NCT05200897|Experimental|Amyloid positive mild cognitive impairment+ BDNF met carrier|Transdermal trigeminal electrical modulation for 3 months
9707112|NCT04671537|No Intervention|Control group (not preloading)|no preloading
9707113|NCT04671771|Experimental|Experimental: InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
9707114|NCT04671459|Experimental|TTFields and SRS based on MRI or FET-PET|All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.
9779137|NCT01122862|Placebo Comparator|Sterile Water|Sterile Water
9779138|NCT01122901|Experimental|Group A (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9779139|NCT01122901|Experimental|Group B (gamma-secretase inhibitor RO4929097, surgery)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days -6 to -1. Patients undergo surgical resection on day 0. Within 30 days after surgical resection, patients receive gamma-secretase inhibitor RO4929097 as in group A.
10193267|NCT02929069|Experimental|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
10193268|NCT02929069|Active Comparator|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
10193269|NCT02929069|Active Comparator|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
10193270|NCT02909868|Experimental|RV location|All included subjects will undergo the PV loop test with 'BackBeat PHC' ON and OFF
9707115|NCT04671940||Retrospective Cohort|"Patients who have previously had radiotherapy and then have had their local residual/recurrent disease managed with salvage TORS at the Royal Marsden Hospital will be eligible for inclusion. They will be informed of the RECUT+ study by a member of their usual care team at RMH during their routine outpatient appointments for follow up of their H&N cancer.~Potential participants will be asked to consent to provide blood/saliva sample for germline DNA and for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis. Where patients have returned to their referring institution and are no longer under active regular follow up at RMH, a research pack will be sent to the patient via post and email. This pack will contain the Cover Letter, the Participant Information Sheet and the Informed Consent Form. It will also contain a saliva collection tube, buccal swab, blood tubes and instructions for how to provide blood/saliva samples."
9707116|NCT04671940||Prospective Cohort|Patients who have previously had radiotherapy and then are due to have their local residual/recurrent disease managed with salvage transoral robotic surgery at the Royal Marsden Hospital (RMH) will be approached prior to their salvage surgery at a routine outpatient appointment. They will be asked to consent to provide blood/saliva sample for germline DNA pre and post operatively. They will also be asked for permission for their original tumour biopsy sample and their residual/recurrent resection to undergo DNA analysis
9707117|NCT04671680||Pregnant women with suspected placenta accreta|Pregnant women undergoing cesarean delivery with suspected placenta accreta spectrum.
9707118|NCT04671472|Experimental|Aceneuramic acid tablets|Aceneuramic acid tablets 6 g/day, divided 3 times a day for 48 weeks
10204602|NCT05200897|Experimental|Amyloid positive mild cognitive impairment+ BDNF Val/Val|Transdermal trigeminal electrical modulation for 3 months
10204603|NCT05200897|Experimental|Amyloid negative mild cognitive impairment+ BDNF met carrier|Transdermal trigeminal electrical modulation for 3 months
9707119|NCT04671472|Placebo Comparator|Aceneuramic acid placebo tablets|Matching placebo 3 times a day for 48 weeks
9707120|NCT04671498||Ancillary-correlative (biospecimen collection) (Breast Cancer patients)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
9707121|NCT04671498||Ancillary-correlative (biospecimen collection) (Volunteer)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
10204604|NCT05200897|Experimental|Amyloid negative mild cognitive impairment+ BDNF Val/Val|Transdermal trigeminal electrical modulation for 3 months
9707122|NCT04671407|Active Comparator|CONTROL|40ml of hypersal saline (3% NaCl) will be administered to bladder the after the surgery
9707123|NCT04671407|Placebo Comparator|PLACEBO|40ml of normal saline (0.9% NaCl) will be administered to bladder the after the surgery
9707124|NCT04671641|Experimental|Endovenous Radiofrequency Ablation Closure System|
9707125|NCT04671641|Active Comparator|ClosureFast™ Radiofrequency Ablation System|
9707126|NCT04671589|Experimental|Meropenem|Meropenem 1 gram intravenous every 8 hours
9707127|NCT04671589|Placebo Comparator|Placebo|Placebo intravenous every 8 hours
9707128|NCT04671628|Experimental|Relaxing music|
9707129|NCT04671628|No Intervention|Control|
9707130|NCT04671563|Experimental|Viproof Film Coated Tablets 300mg|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
9707131|NCT04671563|Active Comparator|Viread Tablets|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
9707132|NCT04671186|Experimental|Probiotic group|Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) throughout the study
9707133|NCT04671186|Placebo Comparator|Placebo Group|Placebo group is to receive placebo oral capsule daily throughout the study.
9707134|NCT04671368|Experimental|Artificial Intelligence|A deep learning based artificial intelligence diagnostic system(DOI:10.1093/neuonc/noaa163)
9707135|NCT04671368|Active Comparator|Practicing Pathologists|One pathologist who has at least 5 years of experience
9707136|NCT04671368|Other|Gold Standard|A committee composed of two expert pathologists who has at least 10 years of experience and one expert pathologist who has at least 15 years of experience
9707137|NCT04671238||Patient for SPECT/CT scan|Patients referred for SPECT/CT scan of the spine as part of a vertebroplasty workup and selected retrospectively.
9707138|NCT04671329|Other|Affirm Contrast Biopsy|Women 40 years of age or older recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities
9779140|NCT01122927|Experimental|Phase 1 and Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
9779141|NCT01123070|Experimental|TL011|TL011 infusions
9779142|NCT01123070|Active Comparator|MabThera|MabThera infusions
9779143|NCT01123083|Experimental|otelixizumab|otelixizumab
9779144|NCT01123083|Placebo Comparator|placebo|placebo
9779145|NCT01123148|Other|Tilt testing|
10193271|NCT02889809|Experimental|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
10193272|NCT02889809|Placebo Comparator|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
10193273|NCT02884648|Experimental|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
9779146|NCT01123161|Active Comparator|Group1: IV t-PA and normothermia|IV tpa and normothermia
10193274|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:~The study coordinator will provide the decision aid for the parent/clinician dyad.~The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.~The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.~The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.~The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
10193275|NCT02872558|Other|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
10193276|NCT02849587|Placebo Comparator|Placebo Cannabis|Subjects will smoke cannabis with placebo THC (.02%) ad libitum
10193277|NCT02849587|Experimental|Cannabis with 5.9% THC|Subjects will smoke cannabis cigarettes with 5.9% THC ad libitum
10193278|NCT02849587|Experimental|Cannabis with 13.4% THC|Subjects will smoke cannabis cigarettes with 13.4% THC ad libitum
10193279|NCT02839551|Experimental|Simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
10193280|NCT02837445|Active Comparator|Treatment|Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
10193281|NCT02837445|Placebo Comparator|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
10193282|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
10193283|NCT02835443|Experimental|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
10193284|NCT02823730||Synergy Stent Cohort|Retrospective registry of 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
10193285|NCT02823730||Xience V Cohort|500 patients that are propensity matched to the 500 patients that underwent PCI with a Synergy stent, eligible for similar time points of follow-up following the PCI.
10193286|NCT02818023|Experimental|Pembrolizumab plus vemurafenib and Cobimetinib|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
10193287|NCT02815540|Other|Observational|This study looks at participants already receiving CBD from the state of MN. We are not providing the CBD. We are looking at heart function with ECGs and Holter monitoring before and after CBD is taken by the participant. We are also looking at dysautonomia signs and symptoms and seizure frequency before and after CBD is taken by the participant.
10193288|NCT02814708|Experimental|Dose Group 1|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 1
10193289|NCT02814708|Experimental|Dose Group 2|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 2
10193290|NCT02814708|Experimental|Dose Group 3|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 3
10193291|NCT02814708|Experimental|Dose Group 4|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 1
10193292|NCT02814708|Experimental|Dose Group 5|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 2
9779147|NCT01123161|Active Comparator|Group 2 : IV t-PA and hypothermia and anti-shivering treatment|IV tpa and hypothermia and anti-shivering treatment
9779148|NCT01123200|Other|Brain Computer Interface In-Home Use|
10193293|NCT02814708|Experimental|Dose Group 6|rTSST-1 Variant Candidate Vaccine 100 µg Number of Immunizations: 3
10193294|NCT02814708|Placebo Comparator|Dose Group 7|Al(OH)3 Adjuvant, 1mg Number of Immunizations: 3
10193295|NCT02808572|Experimental|Cardiovascular risk evaluation|Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
9779149|NCT01123356|Experimental|Oratumumab and Lenalidomide|"Single arm, non randomized study~Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.~Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.~Treatment to be administered for up to 6 cycles"
9779150|NCT01123382|Experimental|IM Electrical Stimulation (IM ES)|The IM ES Group will receive electrical stimulation treatment for three weeks (6 hrs daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
9779151|NCT01123382|Active Comparator|Usual Care (UC)|The Usual Care Group will receive outpatient therapy for four weeks, coupled with prescribed daily home exercises.
9779152|NCT01123395|Experimental|Colcrys® (colchicine USP) 0.6 mg intact tablet|One Colcrys® (colchicine USP) 0.6 mg intact tablet taken by mouth
9779153|NCT01123395|Experimental|Colcrys® 0.6 mg tab in apple juice|One Colcrys® 0.6 mg tablet crushed and dissolved in apple juice
9779154|NCT01123512|Experimental|Kiva VCF Treatment System|
9779155|NCT01123512|Active Comparator|Balloon Kyphoplasty|
10193296|NCT02785224||Vasopressin Steroids Epinephrine (VSE)|Patients with in-hospital cardiac arrest treated with vasopressin, methylprednisolone, and epinephrine during cardiopulmonary resuscitation, and also with stress-dose hydrocortisone for postresuscitation shock.
10193297|NCT02785224||Control|Patients with in-hospital cardiac arrest treated with normal saline placebo, normal saline placebo, and epinephrine during cardiopulmonary resuscitation, and also with normal saline placebo for postresuscitation shock.
10193298|NCT02781883|Experimental|Untreated AML|BP1001 in combination with Ventoclax plus decitabine
10193299|NCT02781883|Experimental|Refractory/Relapsed AML|BP1001 in combination with Ventoclax plus decitabine
10193300|NCT02781883|Experimental|Refractory/Relapsed AML (ventoclax-intolerant or resistant)|BP1001 + decitabine combination in patients who are resistant or intolerant of venetoclax-based treatment, or considered not optimal candidates for a venetoclax-based therapy.
10193301|NCT02781727|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
10193302|NCT02781727|Active Comparator|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
10193303|NCT02780583|Placebo Comparator|placebo|methylprednisolone intravenously, placebo shots every 6 hours
10193304|NCT02780583|Experimental|anakinra (Kineret)|methylprednisolone intravenously, anakinra shots every 6 hours
10193305|NCT02778204|Experimental|Cohort 1 Stratum 1A|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; without in utero exposure to maternal efavirenz.
10193306|NCT02778204|Experimental|Cohort 1 Stratum 1B|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; with in utero exposure to maternal efavirenz.
10193307|NCT02778204|Experimental|Cohort 2 Stratum 2A|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; without in utero or breast milk exposure to maternal efavirenz.
10193308|NCT02778204|Experimental|Cohort 2 Stratum 2B|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; with in utero and breast milk exposure to maternal efavirenz
10193309|NCT02750865|No Intervention|Control Usual Care|In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
10193310|NCT02750865|Experimental|Embodied Conversational Agent (ECA)|In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
10193311|NCT02745002|Experimental|navigated bronchoscopy|
10193312|NCT02743364|Experimental|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
10193313|NCT02743364|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
10193314|NCT02725853|Experimental|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
10193315|NCT02725853|Active Comparator|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
10193316|NCT02725853|Sham Comparator|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
10193317|NCT02701907|Other|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
10193318|NCT02701907|Other|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
10193319|NCT02701907|Other|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
10193320|NCT02701907|Other|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
10193321|NCT02701907|Other|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
10193322|NCT02701907|Other|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
9707139|NCT04671277|Experimental|Chewing of breads|"6 samples (2x3 full factorial design with 2 white sandwich bread types (a regular gluten-containing (GC) and a gluten-free version (GF)) and 3 spread conditions (no spread, butter and mayonnaise)) were evaluated in two sessions of 30 min each. The first session was designed for video recording and the second session for the evaluation of texture attributes and collection of food bolus.~Bread samples were served as two stacked cylinders resembling the consumption of a sandwich (diameter: 3.5 cm, approximate total height: 2.4 cm) (Figure 1). Due to differences in bread density, the average weight of two stacked cylinders was 5.1 ± 0.2 and 5.7 ± 0.4 for GC and GF breads, respectively. Butter and mayonnaise were added to breads at approximately 12% w/w."
9707140|NCT04671446||Severe eosinophilic asthma and/or EGPA|
9707141|NCT04671446||Other respiratory conditions|Milder asthma, other vasculitides, eosinophilic COPD, and/or eosinophilic oesophagitis
9707142|NCT04671446||Healthy controls|
9707143|NCT04671290||Control|Carbapenem (imipenem, or meropenem, or ertapenem) as first-line therapy or after receiving up to 72 hours of other antibiotics (including aminoglycosides).
9707144|NCT04671290||Cases|Temocillin above 50% of the time of effective antibiotic therapy duration. Temocillin had to be given as first-line therapy or after receiving a maximum of 5 days of other antibiotics (including carbapenems and aminoglycosides).
9707145|NCT04671134|Experimental|Biomimetic remineralizing agent|
9707146|NCT04671134|Active Comparator|Resin modified glass ionomer varnish|
9707147|NCT04671160||1|Group treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
9707148|NCT04671160||2|Group treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
9707149|NCT04671160||3|Group not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.
9707150|NCT04671160||4|Group not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
9707151|NCT04671264|Experimental|VC group|"Vibrating capsule (VC) was proposed and applied for the patent by professor Liao Zhuan from Changhai Hospital, developed and manufactured by the Ankon Medical Technology Co., Ltd. The system consisted of a vibrating capsule and an external configuration device (ECD). It's 26.7 mm in length, 11.8 mm in diameter and 4.5 + 0.5 g in weight.~Each VC has its own semiconductor chip with serial number in order to be recognized and controlled by ECD. VC can be stopped by ECD or mobile-phone application. There was a bidirectional radio frequency communication signal between VC and ECD. In addition, an application (APP) named VCP can be connected to ECD through smart phone to select mode and debug specific parameters for VC. The capsule can be activated by ECD, and then the vibration mode can be controlled by a configurator or an smartphone application."
9707152|NCT04671264|Placebo Comparator|Control group|The Intervention of control group were similar to VC group except the capsule function. Sham capsule we used in control group which had no function of vibrating.
9707153|NCT04671394|Experimental|Test (FMUD + DLIG)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by irrigation with indocyanine green solution and diode laser irradiation.
9707154|NCT04671394|Sham Comparator|Control (FMUD + ST)|Periodontal pockets are treated by ultrasonic debridement and, after 7 and 28 days, by sham therapy.
9707155|NCT04671303|Experimental|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
9707156|NCT04671420|Experimental|HLX01|
9707157|NCT04671420|Active Comparator|EU-sourced rituximab (Mabthera®)|
9707158|NCT04671511|Experimental|Targeted Axillary Dissection|Ultrasound of the axilla preoperative. Clipped biopsy proven positive node. I125 radioactive seed before surgery. Sentinel node biopsy using Tc99 +/- blue dye. Targeted Axillary Node Dissection performed at surgery
9707159|NCT04671108|Experimental|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
9707160|NCT04671108|Active Comparator|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
9707161|NCT04670978|Experimental|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxel, 260mg/m2，ivdrip，D1，once every three weeks bevacizumab biosimilar, 10mg/kg，ivdrip，D1, once every three weeks
9707162|NCT04671147||Skull tong femoral traction|
9707163|NCT04671147||Cotrell longitudinal traction|
9707164|NCT04670926|Experimental|TruGraf - Group 1:|Patients randomized to Group 1 will receive serial TruGraf testing at months 3, 4, 5, 6, 7, 8, 9, and 12. Results will be available in real-time and used by the physician to guide management of immunosuppression.
9707165|NCT04670926|Active Comparator|CPMC Standard of Care - Group 2:|Patients randomized to Group 2 or CPMC Standard of Care Group patients will have current standard of care laboratory assessments.
9779156|NCT01123642||Group 1|Operation Enduring Freedom and Operation Iraqi Freedom Veterans
9707166|NCT04670952|Experimental|Low Pressure Laparoscopic Cholecystectomy|"LPLC refers to Low Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 10mmHg."
9707167|NCT04670952|Other|Standard Pressure Laparoscopic Cholecystectomy|"This is taken as the control group. SPLC refers to Standard Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 14 mmHg."
9707168|NCT04671056|Experimental|MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet|MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days
9707169|NCT04670861|Experimental|experimental group|Upper extremity Biodex balance training program three times/week for eight weeks in addition to regular weightlifting training exercises
9707170|NCT04670861|Active Comparator|control group|regular weightlifting training exercises
9707171|NCT04670887|Active Comparator|Immediate surgery|Patients undergo excision of a renal mass by partial or radical nephrectomy and will be followed by UISS risk classification.
9707172|NCT04670887|Active Comparator|Active surveillance|Patients enter active surveillance protocol. Delayed surgery on active surveillance will be recommended if progression from Bosniak 3 to 4 or a solid mass is noted on imaging by radiologist
9707173|NCT04671121|Active Comparator|Grup LP (n = 31)|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
9707174|NCT04671121|Active Comparator|Grup SP (n = 31)|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
9707175|NCT04671316|Experimental|T1T2R|"Period I: T1, DA-5209 60mg without water Period II: T2, DA-5209 60mg with 150mL water Period III: R, Lixiana 60mg with 150mL water"
9707176|NCT04671316|Experimental|T1RT2|"Period I: T1, DA-5209 60mg without water Period II: R, Lixiana 60mg with 150mL water Period III: T2, DA-5209 60mg with 150mL water"
9707177|NCT04671316|Experimental|RT1T2|"Period I: R, Lixiana 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: T2, DA-5209 60mg with 150mL water"
9707178|NCT04671316|Experimental|RT2T1|"Period I: R, Lixiana 60mg with 150mL water Period II: T2, DA-5209 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
9707179|NCT04671316|Experimental|T2RT1|"Period I: T2, DA-5209 60mg with 150mL water Period II: R, Lixiana 60mg with 150mL water Period III: T1, DA-5209 60mg without water"
9707180|NCT04671316|Experimental|T2T1R|"Period I: T2, DA-5209 60mg with 150mL water Period II: T1, DA-5209 60mg without water Period III: R, Lixiana 60mg with 150mL water"
9707181|NCT04670653|Experimental|MAGNÓLIA|Two applications in each nostril, once a day.
9707182|NCT04670653|Active Comparator|MOMETASONE FUROATE|Two applications in each nostril, once a day.
9707183|NCT04671225|Experimental|Intervention - Psychoeducation at the referral hospital|Intervention: Manual-structured group psychoeducation.
9707184|NCT04671225|Other|Waiting list - at the referral hospital|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
9707185|NCT04670614|Other|Nerve Block Procedure|Supra-orbital and Infra-orbital peripheral nerve blocks with 0.5% ropivicaine
9707186|NCT04670614|Sham Comparator|Placebo sham control|sham control 0.9% Normal Saline
9707187|NCT04670692|Experimental|5G-MCE examination|There will be 20 volunteers assigned to the 5G-MCE system group. These patients will accept the magnetically controlled capsule examination in Yinchuan. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the assistant in Yinchuan. Then, the assistant activated the capsule with the capsule locator. The patient is instructed to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. After the capsule entering into the stomach, the examination will be performed through the 5G-MCE system by the endoscopist (W.Z.), with experience of more than 1000 cases of MCE operation, in Shanghai.
9707188|NCT04670692|Active Comparator|MCE examination|There will be 20 volunteers assigned to the MCE system group as comparator group. After an overnight fasting and drinking 800-1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of the endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient is instructed to assume the left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist (W.Z.) face to face, subject continue the examination of stomach and duodenum.
9707189|NCT04670601|Experimental|Flurbiprofen 8.75 mg|Flurbiprofen 8.75 mg lemon and honey flavour lozenge
9707190|NCT04670601|Active Comparator|Strepfen 8.75 mg|Strepfen 8.75 mg lemon and honey lozenge
9707191|NCT04670913|Experimental|Camrelizumab plus Apatinib|Camrelizumab, 200mg, q3w, iv and Apatinib, 250mg, qd, po
9707192|NCT04670588||Locally advanced rectal cancer patients|Patients with LARC undergoing TNT.
9707193|NCT04671069|Experimental|MGL-3196 100 mg tablet plus Clopidogrel 75 mg tablet|
9707194|NCT04670835||Case Group (unic)|"Group/Cohort Label :~Users of Emergency Call Centers Users of French territory 'Region Pays de la Loire'~Group/Cohort Description:~All Users calling through the five Emergency Medical Centers of the French Pays de la Loire region (5 areas of the region are : Loire-Atlantique, Maine-et-Loire, Mayenne, Sarthe, Vendée).~In each Emergency Medical Center, an advanced telephone system automatically keeps track of all inbound calls.~Average annual number of incoming calls for the 5 Emergency Medical Center of Pays de la Loire region is 1,6 million."
9779157|NCT01123655|Experimental|Arm 1|"The study will have 3 treatment arms each with 10-12 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 2 treatment arms (30 micrograms APL A12 or placebo). Each of the 2 treatments will be given for 16 weeks.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
10193323|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 40mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
10193324|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 600mg + Cobi 40mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
9707195|NCT04670796|Experimental|HLX02|patient receive one dose of HLX02
9707196|NCT04670796|Active Comparator|EU-sourced Trastuzumab (Herceptin®)|patient receive one dose of EU-sourced Trastuzumab (Herceptin®)
10193325|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 800mg + Cobi 40mg)|Participants received Venetoclax 800mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
9707197|NCT04670796|Active Comparator|US-licensed Trastuzumab (Herceptin®)|patient receive one dose of US-licensed Trastuzumab (Herceptin®)
9707198|NCT04670809|Experimental|Clevidipine Butyrate Injection|
9707199|NCT04670809|Active Comparator|Ncardipine Hydrochloride Injection|
9707200|NCT04670575||Vivity|Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.
9707201|NCT04670718|Experimental|OCT probe|The examination of gastrointestinal tract resected specimen with the use of the OCT probe
9707202|NCT04670666|Experimental|MADALENA|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association, oral;~1 tablet empagliflozin + linagliptin association placebo, oral;~1 tablet metformin placebo, oral."
9707203|NCT04670666|Active Comparator|Metformin + empagliflozin + linagliptin|"The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association placebo, oral;~1 tablet empagliflozin + linagliptin association, oral;~1 tablet metformin, oral."
9707204|NCT04670939|Experimental|SPT|
9707205|NCT04670900|Active Comparator|Operative|Patients will be operated according to Orthopedic Trauma Association (OTA) principles with either tension band wiring or plate fixation with an anatomical precontoured plate.
9707206|NCT04670900|Experimental|Non-operative|Patients will be offered a plaster cast for 1-2 weeks
9707207|NCT04670523|Other|Test group|Test group: The patients of the study group are getting their chest tube removed according to the investigators' current airleak protocol (Flow <20 mL/ min on digital suction device) but already in the operating room immediately following wound closure (Postoperative day 0 (POD0)). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
9707208|NCT04670523|Other|Control group|In the control group, the chest tube gets removed according to the investigators' traditional standard protocol not earlier than on postoperative day 1 (POD1).
9707209|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 2.0 ng/mL|
9707210|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 4.0 ng/mL|
9707211|NCT04670536||PASS LP implants|Patient suffering from a spinal degenerative disease and who is operated with PASS LP
9707212|NCT04670536||PASS Degen implants|Patient suffering from a spinal degenerative disease and who is operated with PASS DEGEN
9707213|NCT04670536||PASS Tulip PRIME implants|Patient suffering from a spinal degenerative disease and who is operated with PASS TULIP PRIME
9707214|NCT04670536||PASS Tulip GENESIS implants|Patient suffering from a deformity and who is operated with PASS TULIP GENESIS implant(s)
9707215|NCT04670549|Other|Pre and post implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase patients with hip and knee OA will receive OA care more in line with the treatment recommendations."
9707216|NCT04670627||Seasonal Allergic Rhinitics|"Non-smoking males and females aged 18-70 years, inclusive with history of Seasonal Allergic Rhinitis defined by:~Sensitization to at least one seasonal aeroallergen via skin prick testing (wheal =3 mm than negative control), AND History of physician-diagnosed seasonal allergic rhinitis, OR Symptoms consistent with seasonal allergic rhinitis, such as runny nose, nasal congestion, sneezing, or nasal pruritis."
9707217|NCT04670627||Control|Non-smoking males and females aged 18-70 years, inclusive with no history of physician-diagnosed allergic rhinitis and no history of seasonal runny nose, nasal congestion, sneezing or nasal pruritis. Negative results to a panel of aeroallergens via skin prick testing.
9707218|NCT04670341|Experimental|chewing tapioca pearls in the bubble tea drinks|In the first week, the subjects drink as much as 100 ml of bubble tea over a span of 5 minutes once a day for 3 days
9707219|NCT04670341|Placebo Comparator|drink tea without chewing tapioca pearls|In the second week, the subjects drink tea without tapioca pearls as much as 100 ml for 5 minutes per day for 3 days.
9707220|NCT04670211||Tooth-borne distractor|Maxillary distraction with the use of a tooth-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
9707221|NCT04670211||Bone-borne distractor|Maxillary distraction with the use of a bone-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
9707222|NCT04670211||Hybrid distractor|Maxillary distraction with the use of a hybrid distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
9707223|NCT04670432|Experimental|Treatment group|Hydroxyethylrutoside oral tablet twice daily for 8 weeks starting at the time of randomization, in addition to usual care.
9707224|NCT04670432|No Intervention|Control group|Usual care, consisting of anticoagulant treatment and elastic compression therapy for full study duration.
9707225|NCT04670510|Experimental|Aerobic Exercise|The Aerobic Exercise (AE) condition will involve 150-minutes of moderate-intensity AE per week for 6-months and will involve a graded decline in supervision. Supervised AE will occur in groups, though each participant's AE prescription will be personalized based on baseline exercise capacity, as assessed by a maximal cardiopulmonary fitness test. Supervised AE sessions will involve the treadmill, elliptical, and/or bike, and routines will be varied to promote adherence. Supervised AE sessions will gradually increase to 50-minutes per session; however, participants will be encouraged to engage in home-based AE sessions according to their own preference of length and frequency in order to achieve 150 minutes of AE per week.
10193326|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 60mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 60mg daily on Days 1-21 of each 28-day treatment cycle.
10193327|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 400mg + Ida 200mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
10193328|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 600mg + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 150mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
10193329|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 600mg + Ida 200mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
9707226|NCT04670510|Active Comparator|Social Engagement|The Social Engagement (SE) condition will be designed to control for the social component of the AE intervention (i.e., supervised on-site sessions with professional staff, frequent phone contact from study staff). A variety of enjoyable group-based activities will be scheduled throughout the 6-month period (e.g., movie club, cooking, cultural perspectives on aging), with a gradual decline in frequency of meetings. This condition will involve twice weekly, 1-hour-long on-site meetings for the first 6-weeks of the intervention, weekly group meetings during weeks 7-12, and bi-weekly meetings during weeks 13-26 (grand total of 25 sessions).
9707227|NCT04670328||Covid-19 disease severity|Mild, moderate, severe and critical disease
10193330|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 400mg + Ida 400mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 400mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
10193331|NCT02670044|Experimental|Dose Optimisation: Arm B (Ven 600mg (Day 1 to 21) + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-21 of each 28 day treatment cycle and Idasanutlin 150mg daily on Days 1-5 of each 28 day treatment cycle.
10193332|NCT02648997|Experimental|Cohort 1 (original cohort): Nivolumab Monotherapy|Nivolumab monotherapy (240 mg every 2 weeks)
10193333|NCT02648997|Experimental|Cohort 2: Nivolumab in Combination with Ipilimumab|"External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy)~Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks)~Followed by Nivolumab monotherapy (480 mg every 4 weeks)."
9707228|NCT04670276|Experimental|Experimental arm|Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction
9707229|NCT04670315||Single Group|Scale validation in stroke patients
9707230|NCT04670367|Placebo Comparator|Arm A: usual care|routine usual care
9707231|NCT04670367|Experimental|Arm B: walk|walk 30mins per day, 5 days per week.
9707232|NCT04670367|Experimental|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
9707233|NCT04670367|Experimental|Arm D: Baduanjin plus walk|walk 30mins then Baduanjin 12 mins per day, 5 days per week.
9707234|NCT04670289|Experimental|Treatment|TenoMiR intralesional injection
9707235|NCT04670289|Placebo Comparator|Placebo|0.9% saline intralesional injection
9707236|NCT04670497|Active Comparator|ultrasound guided lumbar plexus block|patients were recieved lumbar plexus block ultrasound guided by shamrock technique using 0.5% bupavacaine in a dose 0.3ml/kg
9707237|NCT04670497|Active Comparator|ultrasound guided Fascia iliaca block|patients were received fascia iliaca block ultrasound guided using 0.5% bupoavacaine in a dose 0.3ml\kg
9707238|NCT04670302|Active Comparator|Control group (Tendon repair)|The control group will undergo tendon repair procedure only (without augmentation)
9707239|NCT04670302|Experimental|Experimental group (Tendon repair augmented with AAdMSC-HAM composite)|The experimental group will undergo tendon repair procedure augmented with AAdMSC-HAM composite
9707240|NCT04670107|Experimental|combination group|
9707241|NCT04670458||CA group|Patients with In-Hospital Cardiac Arrest
9707242|NCT04670458||CONTROL group|Patients without In-Hospital Cardiac Arrest
9707243|NCT04670445|Experimental|Refine Intervention and Study Procedure|"Small open pilot (n=10) to refine the intervention and study procedures.~The study will involve three surveys (one before first infusion, one after, and one six weeks later).~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team."
9707244|NCT04670445|Experimental|Educational Video and QPL List|"Randomized into Intervention Arm~The study will involve three surveys (one before first infusion, one after, and one six weeks later).~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team.~Audio Recorded Conversation with oncologist"
9707245|NCT04670445|Active Comparator|Usual Care|"Randomized into Usual Care Arm~The control group will have three surveys (one before first infusion, one after, and one six weeks later)~Audio Recorded Conversation with oncologist"
9707246|NCT04670094||Covid19 infection related patients|"Patients over the age of 18 hospitalized for SARS-CoV-2 up to end of June 2020 in the San Gerardo Hospital and other centers will be included.~Patients are followed until discharge from hospital or death."
9707247|NCT04670120|Experimental|First group|Pyfazimine 100mg group, 12 cases.
9707248|NCT04670120|Experimental|Second group|Pyfazimine 200mg group, 12 cases.
9707249|NCT04670120|Experimental|Third group|Pyfazimine 300mg group, 12 cases.
9707250|NCT04670120|Active Comparator|Forth group|Pyrazinamide 1500mg group, 10 cases.
9707251|NCT04670120|Active Comparator|Fifth group|Pyfazimine 200mg + Pyrazinamide 1500mg group, 10 cases.
9707252|NCT04670406|Experimental|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
9707253|NCT04670250||newly diagnosed patients with ulcerative colitis|patients who are newly diagnosed to have ulcerative colitis who are above 18 years old,not pregnant and not known to have cancer colon
10193334|NCT02639780||healthy young female|
10193335|NCT02639780||healthy young male|
10193336|NCT02639780||healthy older female|
10193337|NCT02639780||healthy older male|
10193338|NCT02639780||obese older female|
10193339|NCT02639780||obese older male|
10193340|NCT02564380|Experimental|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
10193341|NCT02564380|Placebo Comparator|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
10193342|NCT02560298|Experimental|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
9707254|NCT04670419||HEV gt 3 clade abchijklm|patients infected with HEV gt 3 clade abchijklm
9707255|NCT04670419||HEV gt 3 clade efg|patients infected with HEV gt 3 clade efg
9707256|NCT04670185|Experimental|Internet-based parent training|Five weeks of therapist-guided online delivered parents training
9707257|NCT04670185|No Intervention|Waitlist|Five weeks of waitlist
9707258|NCT04670224|Experimental|QLB technique|
9707259|NCT04670224|Active Comparator|Intravenous anesthesia without QLB|
9707260|NCT04670003||users|users of web-application
9707261|NCT04670172||Chronic rhinosinusitis patients|Adult chronic rhinosinusitis patients capable of using a mobile application.
10193343|NCT02560298|Experimental|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
10193344|NCT02547493|Active Comparator|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
10193345|NCT02547493|Active Comparator|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.~Abatacept started on frst day."
10193346|NCT02545517|Experimental|Conv-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 and JE primary series regimen on days 1 and 29 in the parent study V49_23 were enrolled in the Conv-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
10193347|NCT02545517|Experimental|Acc-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1, 4 and 8 and JE primary series regimen on days 1 and 8 in the parent study V49_23 were enrolled in the Acc-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
10193348|NCT02545517|Experimental|Conv-R Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 in the parent study V49_23 were enrolled into the Conv-R Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
9707262|NCT04669873|Active Comparator|Active Comparator: Standard|Whole breast Radiotherapy, 40 Gray (40Gy) fractions
9707263|NCT04669873|Experimental|Experimental 1: Hypofractionated radiotherapy|Whole breast Radiotherapy, 26 Gray (26Gy) in 5 fractions
9707264|NCT04669873|Experimental|Experimental 2: Accelerated Partial Breast Irradiation|Partial Breast Irradiation 26 Gray (26Gy) to the tumor bed in 5 fractions.
9707265|NCT04669821|Experimental|HSK3486|
9707266|NCT04669821|Active Comparator|Propofol|
9707267|NCT04670081|Placebo Comparator|Nicotinamide|1st dose: 100 mg Nicotinamide (Vitamin B3) - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
9707268|NCT04670081|Experimental|Psilocybin (low-dose)|1st dose: 5 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
9707269|NCT04670081|Experimental|Psilocybin (high-dose)|"1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 5 mg Psilocybin~1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin"
9707270|NCT04670016||Patient/Caregiver dyad diagnosed with DIPG|"All of these criteria must be met for a patient to be eligible for this study:~Patient aged >2 and <21 years treated with a repeat course of radiation for DIPG~Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).~Enrollment within 14 days of starting re-irradiation (RT2).~Patients with malignant transformation of the first tumour are eligible.~There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.~The patient is treated at a site where the study is approved by the local ethics board~Consent, and, if applicable, assent, has been obtained according to institutional standards"
9779158|NCT01123655|Experimental|Arm 2|"The next group will receive a higher dose (50 micrograms) and/or placebo (Block 2).~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
9779159|NCT01123655|Experimental|Arm 3|"Block 3 (Arm 3) will include placebo and both doses of APL/A12 to ensure 10-12 patients are enrolled in each arm ( total of approximately 32 subjects) so we will have 24 subjects who complete the 16 weeks of study treatment. Arms 2 and 3 will run simultaneously.~Intervention: Drug treatment will be stopped or interrupted if indicated."
9779160|NCT01123889|Active Comparator|control|corticosteroid injection into subacromial space
10193349|NCT02537613|Experimental|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
10193350|NCT02537613|Experimental|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
10193351|NCT02537613|Experimental|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
10193352|NCT02525432|Experimental|Autologous BMMNC Infusion|Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
10193353|NCT02525432|Placebo Comparator|Placebo Infusion|"Subjects randomized to the placebo control group will undergo a sham bone marrow harvest."
10193354|NCT02501226|Other|Control group|Treatment as usual
10193355|NCT02501226|Experimental|Interventional group|ENVIE psychoeducational program
10193356|NCT02496611|Placebo Comparator|Weight Loss Maintenance without Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve ≥5% BMI reduction. A selection of these participants are then randomized to receive treatment with placebo.
10193357|NCT02496611|Active Comparator|Weight Loss Maintenance with Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve a >/= 5% BMI reduction. A selection of these participants are then randomized to receive treatment with GLP-1RA.
10204605|NCT05200858|Active Comparator|Active Group (AG)|Active group (AG). The AG (n=20) will be undergoing TENS therapy with an active device during 4 weeks. To deliver TENS, a band strap with hydrogel pads will be placed around the calf muscle of one lower-extremity alternating to the other side in a weekly basis.
10204606|NCT05200858|Placebo Comparator|Placebo Group (PG)|Placebo Group (PG) The PG (n=20) will be undergoing TENS therapy with a sham device as described in the AG. The sham device is identical to the active device in all respects except that it stimulates for 6 minutes during each therapy session instead of 60 minutes, and is therefore 10% of the dose.
10204607|NCT05200845|Experimental|Conditioned Stimulus+ (CS+) and High Fat Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose first. They will also undergo the high fat meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucralose and the high carbohydrate test meal session.
10204608|NCT05200845|Experimental|Conditioned Stimulus+ (CS+) and High Carbohydrate Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose first. They will also undergo the high carbohydrate meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucralose and the high fat test meal session.
10204609|NCT05200845|Experimental|Conditioned Stimulus- (CS-) and High Fat Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucralose first. They will also undergo the high fat meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucrose and the high carbohydrate test meal session.
10204610|NCT05200845|Experimental|Conditioned Stimulus- (CS-) and High Carbohydrate Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucralose first. They will also undergo the high carbohydrate meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucrose and the high fat test meal session.
10204611|NCT05200819||COVID 19 Patients|Patients who have survived COVID-19 infection, including those included in the Michigan Medicine COVID-19 Cohort (M2C2) will be eligible to participate.
10204612|NCT05200806|Other|Intervention|Pre-Op Enhanced Recovery After Surgery (ERAS): Gabapentin (900mg capsule), Acetaminophen (1,000mg tablet), Dexamethasone (8mg IV), Granisetron (1mg IV), Morphine (0.15mg Intrathecal) Intraoperatively: Appropriate medications administered at discretion of the treating anesthesiologist during colectomy, with Ketamine use encouraged if not contraindicated. Post-Op (PACU, Onward during inpatient stay): Acetaminophen (Oral) (650mg, q4hrs), Gabapentin (300mg, q6hours), Methocarbamol (750mg, QID), 5% Lidocaine Patch (q12hrs PRN) One time rescue dose (Hydromorphone, Morphine, Oxycodone) available for breakthrough pain during hospital stay (differs from traditional ERAS protocol where medications can be administered as needed). If one-time rescue dose is needed, the covering physician will be notified and can choose to order an appropriate narcotic regimen for remainder of patient's hospitalization. All patients are discharged with a narcotics prescription that they can choose to fill.
10204613|NCT05200793|Active Comparator|Metformin arm (control group)|Patients will receive Metformin (1500 mg orally/day) for 12 weeks .
10204614|NCT05200793|Active Comparator|Empagliflozin arm|Patients will receive Empagliflozin (25 mg orally/day) for 12 weeks.
10204615|NCT05200793|Active Comparator|Linagliptin arm|Patients will receive Linagliptin (10 mg orally/day) for 12 weeks
10204616|NCT05200767||COVID-19|Adults (18-65 yo) hospitalized for COVID-19 (coronavirus disease 2019)
10204617|NCT05200741|Experimental|Test Product|DelNS1-2019-nCoV-RBD-OPT1 virus titre at not less than 6.3 lg CCID50/dose, 2 doses 3 weeks apart, intranasal administration
10204618|NCT05200741|Placebo Comparator|Reference Product|Matching placebo, 2 doses 3 weeks apart, intranasal administration
10204619|NCT05200728|Experimental|SIM1910-09|"This trial includes of 2 parts, Part A-single ascending doses and Part B- multiple ascending doses.~Part A, there are 4 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~Part B, there are 3 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
10204620|NCT05200728|Placebo Comparator|Placebo|"This trial Includes of 2 parts, Part A-single ascending dose and Part B- multiple ascending dose.~Part A, there are 4 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~Part B, there are 3 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
10204621|NCT05200715||Patients affected by autoinflammatory diseases|
10204622|NCT05200702|Experimental|Knee-hip Powered Soft Exoskeleton|Patients and healthy subjects will use a Knee-hip Powered Soft Exoskeleton to perform different standardised tasks
10204623|NCT05200702|No Intervention|No assistance device|Patients and healthy subjects will perform different standardised tasks without Knee-hip Powered Soft Exoskeleton
10204624|NCT05200689|Experimental|Thoracotomy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, alongside the KT protocol.
10204625|NCT05200689|Experimental|Thoracoscopy, KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, alongside the KT protocol.
10204626|NCT05200689|No Intervention|Thoracotomy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracotomy protocol, without the KT protocol.
10193358|NCT02476097|Placebo Comparator|Sudden discontinuation|placebo for 7 days
10193359|NCT02476097|Active Comparator|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
9707271|NCT04670016||Patient/Caregiver dyad with re-RT for a recurrent brain tumour|"All of these criteria must be met for a patient to be eligible for this study:~Patient aged >2 and <21 years treated with a repeat course of radiation for a recurrent or progressive brain tumour (stratum 2).~Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).~Enrollment within 14 days of starting re-irradiation (RT2).~Patients with malignant transformation of the first tumour are eligible.~There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.~The patient is treated at a site where the study is approved by the local ethics board~Consent, and, if applicable, assent, has been obtained according to institutional standards"
9707272|NCT04669756|Experimental|A|ovariopexy for 2 days
9707273|NCT04669756|Experimental|B|ovariopexy for 4 days
9707274|NCT04669756|Experimental|C|ovariopexy for 6 days
9707275|NCT04669756|Placebo Comparator|D|Placebo Operation for 2 days
9707276|NCT04669743|Experimental|Study Population|Subjects will be recruited and consented following screening. Subjects will be characterized into cohorts based on presence of COPD and smoking status. All subjects enrolled will be undergoing the same interventions: 1st Bronchoscopy (3 wks pre-exposure), Ozone Exposure, 2nd Bronchoscopy (1 day post-exposure), 3rd Bronchoscopy (5 days post-exposure). Ozone exposure will take place in an exposure chamber.
9707277|NCT04669795|Placebo Comparator|Group 1|Placebo was given to ten patients during consolidation period ( 2 capsule daily for 6 months during consolidation period)
9707278|NCT04669795|Experimental|Group 2|Cissus quadrangularis in form of capsules given to ten patients ( 2 capsule daily for 6 months during consolidation period)
9707279|NCT04670029|No Intervention|Standard|
9707280|NCT04670029|Experimental|APA|"During the first 3 cures, 3 APA sessions will be offered per week:~2 sessions of anaerobic type of 1 hour with muscle strengthening, stretching, flexibility and balance, supervised in the room,~1 aerobic type exercise session of 1.5 hours (Nordic walking: outdoors) or a 3rd indoor session if not possible,~+ home exercise book if the patient so wishes with record the time in minutes per session and the intensity felt and the modalities of the exercises carried out.~During the 5 remaining cycles, 3 APA sessions will be offered per week:~1 session of 1 hour in an anaerobic exercise room (muscle strengthening, stretching, flexibility, balance) supervised,~1 session of anaerobic exercise per week in autonomy at home (with exercise book),~1 or more session per week of one hour of walking or cycling independently at home (aerobic effort) with declaration in the logbook of the intensity of exertion felt and the time in minutes per session."
9707281|NCT04669951|Experimental|uPAR expression|Immunohistochemistry
9707282|NCT04670055|Experimental|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
9707283|NCT04669847|Experimental|Study Group|Patients who performed Trunk-oriented exercise program and conventional exercise program
9707284|NCT04669847|Experimental|Control Group|Patients who performed a conventional exercise program
9707285|NCT04669964||High-Risk For Dehydration|Patients with an Ileostomy output of >1L at discharge.
9707286|NCT04669977|Experimental|Auxiliary|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. They are expected to finish the mulberry juice in 10 to 11 days. Measurements of clinical symptoms and blood sampling are conducted on day 1 of every other week for 5 weeks. If clinical measurements or blood extractions fail or miss, a substitute assessment or blood sample will be obtained on day 2 or day 3. The research period for these participants is 29 days (4 weeks). The checkpoints are arranged because patients with oxaliplatin treatment visit the clinic every two weeks, and patients with paclitaxel treatment visit the clinic every week. For patients having docetaxel therapy, the research period is 43 days (6 weeks) because docetaxel is administered every three weeks.
9707287|NCT04669977|No Intervention|Non-auxiliary|For the non-auxiliary group (control group), patients are informed of their allocation results and they will not consume mulberry juice during the research period but will receive the mulberry juice after the research period.
9707288|NCT04669938||Patients hospitalized for COVID-19|
9707289|NCT04669717|Active Comparator|Amoxicilline and Metronidazole for 7 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 7 days~Systemic antibiotics after sub gingival mechanical debridement"
9707290|NCT04669717|Active Comparator|Amoxicilline and Metronidazole for 3 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 3 days~Systemic antibiotics after sub gingival mechanical debridement"
9707291|NCT04669717|Active Comparator|Azithromycine for 3 days|"Drug: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH~1/d 500mg for 3 days~Systemic antibiotics after sub gingival mechanical debridement"
9707292|NCT04669782|Experimental|Patients with osteoporosis treated with teriparatide + Vitamin K|Patients will have to take teriparatide (standard of care) + Vitamin K (MK7) at the dosage of 375 microg / day
9707293|NCT04669782|Active Comparator|Patients with osteoporosis treated with teriparatide|Patients will have to take teriparatide (standard of care)
10193360|NCT02459392|Other|Epiduroscopy mechanical lysis - failed back surgery syndrome|Epiduroscopy only mechanical lysis
10193361|NCT02459392|Experimental|Epiduroscopy combination - failed back surgery syndrome|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
10193362|NCT02459392|Other|Epiduroscopy mechanical lysis - chronic low back pain without previous spine surgery|Epiduroscopy only mechanical lysis
10193363|NCT02459392|Experimental|Epiduroscopy combination - chronic low back pain without previous spine surgery|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
10193364|NCT02417272|Experimental|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
10193365|NCT02417272|Experimental|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
9707294|NCT04669782|No Intervention|Controls|Subject without osteoporosis, no treatment will be administered.
9707295|NCT04669730|Placebo Comparator|Arm A: usual care|Routine usual care
9707296|NCT04669730|Active Comparator|Arm B: walk|Walk 30mins per day, 5 days per week.
9707297|NCT04669730|Active Comparator|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
9707298|NCT04669730|Experimental|Arm D: Baduanjin plus walk|Walk 30mins then Baduanjin 12 mins per day, 5 days per week.
9707299|NCT04669392|Experimental|70% Ethanol|Using 70% Ethanol Alcohol as a root canal irrigating solution before obturating the lower primary second molar with Metapex
9707300|NCT04669392|No Intervention|Normal Saline|Irrigating the canals with Normal Saline before obturating the lower primary second molar with Metapex
9707301|NCT04669418||Group 1|70 children with cancer and a positive blood culture.
9707302|NCT04669418||Group 2|50 children with cancer and no positive blood culture.
9707303|NCT04669535|Experimental|AXO-AAV-GM2|AXO-AAV-GM2 infusion
9707304|NCT04669496|Experimental|Neoadjuvant treatment|"Gemox chemotherapy D1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.~Lenvatinib (8mg/d) for 9 weeks of continuous use.~Toripalimab (240 mg, once every 3 weeks), used 3 times in a row. All patients undergoing resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses."
9707305|NCT04669496|No Intervention|Traditional group|No anti-tumor drug treatment before surgery. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, a total of 8 courses.
9707306|NCT04669509||Group 1|Patients with normal ALT, AST and total bilirubin values
9707307|NCT04669509||Group 2|Patients whose ALT, AST or total bilirubin levels are up to 3 times upper limit of normal
9707308|NCT04669509||Group 3|Patients whose ALT, AST or total bilirubin levels are increased more than 3 times upper limit of normal
9707309|NCT04669457|Experimental|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
9707310|NCT04669457|Active Comparator|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
9707311|NCT04669769||shaving|patients with DIE and shaving
9707312|NCT04669769||disc resection|patients with DIE and Disc resection
10193366|NCT02413736|Experimental|Imatinib|Imatinib 400 mg/day for 24 months.
10193367|NCT02413736|No Intervention|No imatinib|No further imatinib.
10193368|NCT02394964||Systemic Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
9707313|NCT04669769||segmental resection|patients with DIE and segmental resection
9707314|NCT04669769||multifocal|patients with multifocal DIE having more than one bowel procedure
9707315|NCT04669652|No Intervention|ICSI|Traditional microinjection (ICSI) is performed on oocytes.
9707316|NCT04669652|Experimental|Piezo-ICSI|Microinjection (ICSI) is performed using the Piezo-ICSI technique.
9707317|NCT04669626|Other|Group 2|Wound cleansing with NaCl (natrium chlorid) solution 0.9%
9707318|NCT04669626|Experimental|Group 1|Wound cleansing with Octenilin®
9707319|NCT04669470|Active Comparator|Group with adjustable IGB|
9707320|NCT04669470|Active Comparator|Group with nin-adjustable IGB|
9707321|NCT04669431|Experimental|Xbox kinect Training|X Box Games include Tennis Playing, Joy riding, Rally ball.
9707322|NCT04669431|Active Comparator|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living
9707323|NCT04669262|Experimental|Part 1: BGB-DXP604|Part 1A: Single low dose of BGB-DXP604 or placebo Part 1B: Single high dose of BGB-DXP604 or placebo
9707324|NCT04669262|Experimental|Part 2 : BGB-DXP604 + BGB-DXP593|Single dose of BGB-DXP593 followed by a single dose of BGB-DXP604 or placebo
9707325|NCT04669223|Other|Seldinger chest drain 14F|Patients with seldinger chest drain 14F inserted
9707326|NCT04669223|Active Comparator|Seldinger chest drain 8F|Patients with seldinger chest drain 8F inserted
9707327|NCT04669405|Active Comparator|HILT group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving high intensity laser therapy.
9707328|NCT04669405|Other|Control group|Patients with hemiplegic shoulder pain with partial thickness rotator cuff receiving exercise.
9707329|NCT04669613|Experimental|Patients|
9707330|NCT04669483||Intervention group (post-interruption)|Patients receive evidence-based informed consent forms for total knee arthroplasty and related anaesthesia procedures
9707331|NCT04669483||Control group (pre-interruption)|Patients receive standard consent forms (of the study centre) for total knee arthroplasty and related anaesthesia procedures
9707332|NCT04669158|Experimental|Idebenone|Participants will take Idebenone 200 mg for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
9707333|NCT04669158|Placebo Comparator|Placebo|Participants will take Placebo for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.
9707334|NCT04669171|Experimental|Cohort 1|Safety Lead-In, Dose-Finding, Cohort, with a 3-by-3 design of EO2463 for 6 weeks followed by addition of lenalidomide week 7 and rituximab week 19 (depending on response). Four to 18 evaluable (previously treated) patients with Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) will be Included based on safety findings
9779161|NCT01123889|Experimental|experimental|patients will receive an injection of platelet rich plasma into the subacromial space
10193369|NCT02394964||Subacute Cutaneous Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
10193370|NCT02394964||Control|Blood, stool, and swab samples will be collected for comparison to each disease group
9979713|NCT01384552|Active Comparator|Normal Weight, Restrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
10193371|NCT02394964||Cutaneous T-Cell Lymphoma|Blood and swab samples will be collected for comparison to each disease group
10193372|NCT02394964||Autoimmune Disorders|Blood, stool, and swab samples will be collected for comparison to each disease group
10193373|NCT02361125|Experimental|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
10193374|NCT02359084|Experimental|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
10193375|NCT02359084|Active Comparator|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
10193376|NCT02338921|Active Comparator|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor~Sitagliptin"
10193377|NCT02338921|Active Comparator|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors~Dapagliflozin"
10193378|NCT02338921|Active Comparator|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist~Lobeglitazone"
10193379|NCT02326116|Experimental|Group 1|Trachael Traction Exercises
10193380|NCT02326116|Placebo Comparator|Group 2|Trachael Massage
10193381|NCT02320994||stroke patients|post-rehabilitation stroke patients
10193382|NCT02312401|Experimental|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 & 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
10193383|NCT02312193||Case|Hypertensive subjects
10193384|NCT02312193||Control|Normotensive subjects
10193385|NCT02245308|Experimental|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
10193386|NCT02245308|Active Comparator|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
10193387|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 1 (brentuximab 1.2mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.2mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
10193388|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 2 (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
10193389|NCT02227199|Experimental|Phase II: Dose Expansion (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
10193390|NCT02177695|Experimental|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
10193391|NCT02177695|Experimental|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
10193392|NCT02167022|Experimental|Intense Physiotherapy (Group 1)|30 minutes each of physical and occupational therapy each weekday for 12 weeks (intense physiotherapy) followed by the same therapies administered once a week for 36 weeks (the current standard of care).
10193393|NCT02167022|Experimental|Delayed Intense Physiotherapy (Group 2)|30 minutes each of physical and occupational therapy once a week for 36 weeks (the current standard of care) followed by the same therapies administered each weekday for 12 weeks (intense physiotherapy).
9707335|NCT04669171|Experimental|Cohort 2|15 Previously untreated patients with FL Or MZL. Evaluation of EO2463 monotherapy at the established dose in Cohort 1
9707336|NCT04669171|Experimental|Cohort 3|15 Previously untreated patients with FL or MZL. Evaluation of EO2463 at the established dose in cohort 1 as monotherapy for 6 weeks and in combination with rituximab from week 7
9707337|NCT04669171|Experimental|Cohort 4|15 Previously treated patients with FL Or MZL. Evaluation of EO2463 at the established dose in Cohort 1 in combination with lenalidomide and with addition of rituximab from week 19 onwards (depending on response)
9707338|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins
9707339|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and placebo|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and placebo
9707340|NCT04669119|Placebo Comparator|Placebo|Patients treated post-operatively for 30 days with placebo
9707341|NCT04669093|Experimental|Placebo|All participants will participate in two sessions, one with a placebo suggestion that matches the participant's motivational style, and one with placebo suggestion that does not match their motivational style, in a pseudo-random order.
9707342|NCT04669093|Experimental|Control|Each session will also include a control phase, in which the same cream will be applied, and participants will be instructed that the cream has no analgesic effects.
9707343|NCT04669145|Experimental|Continuous Regional Anesthesia Lower Limb Surgery|Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks A catheter will be placed for the given block for 48 hours. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
9707344|NCT04669145|Experimental|Single Shot Regional Anesthesia Lower Limb Surgery|"Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks. These blocks will be given via a single dose or single shot. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia."
9707345|NCT04669145|Experimental|Continuous Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
9707346|NCT04669145|Experimental|Single Shot Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
9707347|NCT04669080|Other|Cost navigation training intervention|
9707348|NCT04669353|Active Comparator|Platelet Rich Plasma|In the operating room before the start of each procedure, approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate. After closure of the fascia and prior to skin closure, PRP was directly applied to the subcutaneous tissue of the wound site by using a sterile syringe.
9707349|NCT04669353|No Intervention|control group|In the control group (group II), the patients did not receive topical treatment and the subcutaneous tissue was cleaned with normal saline before skin closure
9707350|NCT04669275|Experimental|telephone counseling|People receiving telephone counselling.
9707351|NCT04669275|Experimental|telephone counselin|People receiving telephone counselling.
9707352|NCT04668976|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
9707353|NCT04668911||Controls tested PCR (-) for COVID-19|
9707354|NCT04668911||Tested PCR (+) for COVID-19, Mild - not admitted to the hospital|
9707355|NCT04668911||Tested PCR (+) for COVID-19, Severe - admitted to ICU (Intensive Care Unit)|
9707356|NCT04668807|Experimental|Connected Medical Device|"SMART ANGEL Intra-hospital System 's Connected Medical Device (DMC) measuring physiological parameters in the operating room"
9707357|NCT04668807|Active Comparator|Traditional system|Traditional wired transmission system between the sensor and the data processing device in the operating room
9707358|NCT04669366||Patients in Sweden with metastatic renal cell carcinoma|The cohort of patients with metastatic renal cell carcinoma in Sweden
9707359|NCT04669197|Other|Treatment|Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine
9707360|NCT04669106||Healthy group|90 research subjects coming from mothers who had healthy children
9707361|NCT04669106||Stunting group|90 research subjects came from mothers who had stunted children or other nutritional disorders
9707362|NCT04668703|Experimental|combined cataract surgery and intravitreal Conbercept injection|Subjects will receive conbercept injections at a dose of 0.5 mg/eye at the conclusion of cataract surgery.
9707363|NCT04668703|No Intervention|cataract surgery alone|Subjects will undergo cataract surgery by phacoemulsification and intraocular lens implantation.
9707364|NCT04668989|Experimental|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week then cross-over to the control lenses for one week.
9707365|NCT04668989|Active Comparator|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week then cross-over to the test lenses for one week.
9707366|NCT04669327||Normal|normal subjects
9707367|NCT04669327||Scoliosis|subjects with moderate idiopathic scoliosis
9707368|NCT04668833|Experimental|Treatment (Autologous Lymphocyte Infusions)|The purpose of this study is to determine the safety and preliminary efficacy of un-manipulated autologous lymphocyte infusion (ALI) using the patient's own lymphocytes collected using apheresis, and infused after the completion of radiation/chemoradiation.
10193394|NCT02145403|Experimental|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
10193395|NCT02134574||hematologic malignancy|hematologic malignancy with a sampling of blood
10193396|NCT02105636|Experimental|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
10193397|NCT02105636|Active Comparator|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression~OR~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression~OR~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
10193398|NCT02091245|Experimental|KPT-330|KPT-330 will be administered twice a week on Days 1 and 3 for four weeks. Starting dose 30 mg/m2.In the dose-escalation cohort, three patients will initially be enrolled at each dose level and will be monitored for a DLT during the 28-day treatment cycle before dose escalation may occur.
10193399|NCT02038946|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity
10193400|NCT02016872|Experimental|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
10193401|NCT02016599||Initial cohort|Initial cohort used to develop a series of multivariate clinical deterioration indices using monitoring modalities and biospecimen collection
10193402|NCT02016599||Validation cohort|Separate cohort of infants used to validate the clinical deterioration indices using monitoring modalities and biospecimen collection
9707369|NCT04668963|Experimental|INTENSIVE MIRROR THERAPY|The intensive therapy group participants received 5 Mirror Therapy (+physiotherapy) sessions /week for 6 weeks, which makes a total of 30 sessions.
10193403|NCT01988571|Active Comparator|Arm 1 - Atorvastatin|One 40 mg Atorvastatin tablet each morning by mouth for 24 months
10193404|NCT01988571|Placebo Comparator|Arm 2 - Placebo|One placebo tablet each morning by mouth for 24 months.
10193405|NCT01979367|Experimental|Anodyne|To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)
10193406|NCT01973452|Experimental|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
10193407|NCT01973452|Placebo Comparator|Placebo|continuous infusion of 0.4 mcg/kg/hr
10193408|NCT01863550|Experimental|Arm A (bortezomib, lenalidomide, dexamethasone)|Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
10193409|NCT01863550|Experimental|Arm B (carfilzomib, lenalidomide, dexamethasone)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
10193410|NCT01863550|Experimental|Arm C (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
10193411|NCT01863550|Experimental|Arm D (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
10193412|NCT01824875|Experimental|Arm A (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
10193413|NCT01824875|Experimental|Arm B (temozolomide and capecitabine)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
10193414|NCT01792583||Prospective Cohort|Prospective is defined per protocol: prospective data of pregnancy exposure are data acquired prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation at prenatal examination (e.g. fetal ultrasound, serum markers).
10193415|NCT01792583||Retrospective Cohort|Retrospective is defined per protocol: retrospective data of pregnancy exposure are data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation on prenatal test.
9707370|NCT04668963|Active Comparator|SPACED OVER TIME MIRROR THERAPY|The conventional therapy group received the same number of sessions but more spaced in time, consisting in 3 Mirror Therapy (+physiotherapy) sessions/week for 10 weeks.
10193416|NCT01755975|Experimental|Romidepsin and Lenalidomide|This will be a multicentered, open label, phase Ib/IIa trial of romidepsin and lenalidomide in patients with relapsed or refractory lymphomas or multiple myeloma. Lenalidomide will be provided in accordance with the Celgene Corporation's Revlimid REMS® program. Per standard Revlimid REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, and all research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS® program. Only enough lenalidomide for one cycle of therapy will be supplied to the patient each cycle.
10204627|NCT05200689|No Intervention|Thoracoscopy, Non-KT|Patients in this group will undergo the same analgesia protocol as other groups. They will undergo the thoracoscopy protocol, without the KT protocol.
10204628|NCT05200663|Experimental|"Tamoxifen"|Group A patients will receive tab tamoxifen 10 mg twice a day for total of six months.
9707371|NCT04668898||LRRK2 Parkinson Disease|Individuals with LRRK2-related Parkinson Disease
9707372|NCT04668898||GBA Parkinson Disease|Individuals with GBA-related Parkinson Disease
9707373|NCT04668898||Idiopathic Parkinson Disease|Individuals with Idiopathic (without any known genetic cause) Parkinson Disease
9707374|NCT04668898||LRRK2 non-manifesting carriers|Individuals without Parkinson Disease who have a LRRK2 mutation
9707375|NCT04668898||GBA non-manifesting carriers|Individuals without Parkinson Disease who have a GBA mutation
9707376|NCT04668898||Healthy control|Individuals without a personal or family history (1st or 2nd degree) of a neurodegenerative disease
9707377|NCT04668859|Active Comparator|Midodrine Arm|Patients will receive the drug Midodrine
9707378|NCT04668859|Placebo Comparator|Placebo Arm|Patients will receive placebo.
9779162|NCT01123928|Experimental|Counseling|Subjects will be asked to watch a 5-10 min video and participate in a 10-15 min pre-operative counseling session with a trained nurse. Subjects will also participate in a 5 min post-operative counseling session.
9779163|NCT01123928|No Intervention|Non-counseling|
9979714|NCT01384552|Active Comparator|Normal Weight, Restrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
9979715|NCT01384552|Active Comparator|Overweight, Unrestrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
9779164|NCT01123941|Experimental|NVGH Vi-CRM197 conjugate vaccine|
9779165|NCT01123941|Active Comparator|Vi-polysaccharide vaccine|
9779166|NCT01123980|Experimental|BIAsp 30|0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
9779167|NCT01123980|Active Comparator|Insulin glargine|0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
9779168|NCT01124006|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
9779169|NCT01124006|Placebo Comparator|Water for injection|Sterile water for injection
9779170|NCT01124045|Experimental|DUREZOL|Difluprednate ophthalmic emulsion, 0.05%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
9779171|NCT01124045|Active Comparator|PRED FORTE|Prednisolone acetate ophthalmic suspension, 1.0%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
9779172|NCT01124097|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
9779173|NCT01124097|Experimental|Eslicarbazepine acetate 1200 mg QD|
9779174|NCT01124097|Experimental|Eslicarbazepine acetate 1600 mg QD|
9779175|NCT01124097|Placebo Comparator|Placebo|
9779176|NCT01124149|Experimental|MMX mesalamine/ mesalazine|
9779177|NCT01124162|Experimental|Generic Test Product|Losartan 100mg Tablets
9779178|NCT01124162|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
9779179|NCT01124175|Experimental|Generic Test Product|Losartan 100 mg Tablets
9979716|NCT01384552|Active Comparator|Overweight, Unrestrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
9979717|NCT01384552|Active Comparator|Overweight, Restrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
9779180|NCT01124175|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
9779181|NCT01124188|Experimental|Study Intervention Arm|Higher-dose venlafaxine and Problem Solving Therapy for Depression and Pain (PST-DP)
9779182|NCT01124188|Active Comparator|Active Control|Higher-dose venlafaxine and supportive management (SM)
9779183|NCT01124292|Experimental|Able-bodied subject with piercing|Able-bodied subjects who already have tongue piercing.
9779184|NCT01124292|Experimental|Able-bodied subject without piercing|Able-bodied subjects who willing to receive a tongue piercing for this study.
9779185|NCT01124292|Experimental|Subjects with spinal cord injury|Persons with mobility limitations requiring power wheel chair, able to move tongue, able to follow simple commands, and have some experience with computers. All participants willingly received a mid-line tongue piercing.
9979718|NCT01384552|Active Comparator|Overweight, Restrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
9979719|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
9979720|NCT01384565|Active Comparator|G-CSF+EPO|
9979721|NCT01384565|Placebo Comparator|Placebo|
9979722|NCT01384578|Experimental|pentoxiphylline and Vitamin E|
9979723|NCT01384578|Active Comparator|Vitamin E|
9707379|NCT04668612|Active Comparator|Standard-bolus|Standard boluses for all meal
9707380|NCT04668612|Experimental|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m
9707381|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2019|
9707382|NCT04668937||Children who came to the Nancy's Pediatric emergencies during the study period in 2020|
9707383|NCT04668625|Experimental|Experimental group|Participate in a massive musical event
9707384|NCT04668625|No Intervention|Control Group|Not participate in a massive musical event
9707385|NCT04668755|Active Comparator|Charcot Restraint Orthotic Walker 3d printed sole|the group fit with Charcot Restraint Orthotic Walker 3d printed sole for 12 week. the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
9707386|NCT04668755|Active Comparator|Generic Charcot Restraint orthotic walker|the group fit with Generic Charcot Restraint Orthotic Walker for 12 week.the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
9707387|NCT04668508|Experimental|anlotinib combined with radiation|
9707388|NCT04668924|Experimental|Epi-on PiXL in high oxygen|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
9979724|NCT01384617|Experimental|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
9979725|NCT01384617|Active Comparator|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
9979726|NCT01384643|Experimental|Propofol group|
9979727|NCT01384643|Placebo Comparator|Control group|
10193417|NCT01737827|Experimental|INC280|The protocol consists of two independent parts (Dose-Determining Part and Dose Expansion Part). Approximately 6 patients will be treated with INC280 300 mg twice a day in the Dose-Determining Part. Approximately 50 patients will be treated with INC280 in the Dose Expansion Part. The dose for the Expansion Part can be lower, equal or higher than in the Dose-Determining Part will be determined after the Dose Determining Part at the dose decision analysis.
9979728|NCT01384656|Experimental|GIK group|
9979729|NCT01384656|Placebo Comparator|Control group|
9979730|NCT01384669||Group 1|papillary thyroid microcarcinoma without lymph node metastasis
10193418|NCT01715285|Experimental|Abiraterone acetate + Prednisone + ADT|Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) along with 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.
10193419|NCT01715285|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants will receive placebo matched to abiraterone acetate and prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.
9707389|NCT04668456|Placebo Comparator|Group C (control group)|Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
9707390|NCT04668456|Active Comparator|Group SD (subtenon dexmedetomiine)|Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
9707391|NCT04668456|Active Comparator|Group ID (iv dexmedetomidine)|Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block.
9707392|NCT04668417|Active Comparator|Reminders with direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with a link enabling direct scheduling
9707393|NCT04668417|Active Comparator|Reminders with no direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with no direct scheduling link
9707394|NCT04668573|Experimental|Trunk exercise group|Participants received trunk exercise for 30 minutes per session, twice a week for 12 weeks.
9707395|NCT04668573|No Intervention|Control group|Participants remained their regular activities.
9707396|NCT04668430|Other|patients|"Patients for whom orthopedic surgery is indicated and planned among :~Tibial valgus osteotomy~Supra-malleolar osteotomy~Hallux osteotomy for hallux valgus~Total knee arthroplasty~Total ankle arthroplasty~Ankle arthrodesis~Hallux arthrodesis~Rear foot torque arthrodesis~Inverted shoulder prosthesis~Anterior lumbar interbody arthrodesis"
9707397|NCT04668651||diabetic|diabetic patients
9979731|NCT01384669||Group 2|papillary thyroid microcarcinoma with lateral lymph node metastasis
9979732|NCT01384682|No Intervention|No change|continue their current cART regimen
9979733|NCT01384682|Active Comparator|Replace N(t)RTI drugs with Maraviroc|Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
9979734|NCT01384682|Active Comparator|Replace PI/r drugs with Maraviroc|Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.
9979735|NCT01384695|Experimental|Fluorescein|Confocal imaging using contrast agent fluorescein
9979736|NCT01384695|Experimental|Proflavine hemisulfate|confocal imaging using contrast agent proflavine
9979737|NCT01384708|Experimental|treatment|imaging with proflavine
9979738|NCT01384747|Experimental|Fimasartan|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
9979739|NCT01384747|Placebo Comparator|Placebo|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
9707398|NCT04668651||non diabetic|non-diabetic patients
9707399|NCT04668482|Experimental|SCS off|SCS is switched off
9707400|NCT04668482|Experimental|SCS on|SCS is switched on
9707401|NCT04668690|Experimental|Experimental: Mitoxantrone Hydrochloride Liposome Injection|Patients with relapsed/refractory PTCL will receive Mitoxantrone Hydrochloride Liposome Injection every 28 days (a cycle) for a maximum of 8 cycles. The dose of Mitoxantrone Hydrochloride Liposome Injection is 20 mg/m2.
9707402|NCT04668690|Active Comparator|Active Comparator: Chidamide|Patients with relapsed/refractory PTCL will receive Chidamide 30 mg p.o., twice per week until disease progression.
9707403|NCT04668534|Experimental|Treatment group 1|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
9707404|NCT04668534|Experimental|Treatment group 2|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
9707405|NCT04668534|Active Comparator|Control group|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left earlobe. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
9707406|NCT04668339|Experimental|Study Group 1, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
9707407|NCT04668339|Experimental|Study Group 2, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
9707408|NCT04668339|Experimental|Study Group 3, Younger Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
9979740|NCT01384812|Placebo Comparator|Isoton sodium chloride|
9979741|NCT01384812|Active Comparator|Prostin E2 (dinoprostone)|
9979742|NCT01384825||MS|Subjects with Multiple Sclerosis
9979743|NCT01384825||HC|Healthy Controls
9979744|NCT01384825||OND|"Subjects with Other Neurodegenerative Diseases, including both other non-inflammatory neurodegenerative diseases (OND) and other inflammatory neurodegenerative diseases (ONDi)"
9979745|NCT01384838|Other|Counseling|Patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
9979746|NCT01384838|Experimental|Controlled physical activity|"All patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.~Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable, unobserved exercise program at home."
10193420|NCT01702883|No Intervention|Control|Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.
10193421|NCT01702883|Experimental|Intervention Group A|Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.
9707409|NCT04668339|Placebo Comparator|Study Group 4, Younger Adult Participants|Participants will receive one of Placebo (Saline) on Day 0, one dose of Placebo on Day 28, and one dose of Placebo on Day 208
9707410|NCT04668339|Experimental|Study Group 1, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
9707411|NCT04668339|Experimental|Study Group 2, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
9707412|NCT04668339|Experimental|Study Group 3, Older Adult Participants|Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
9707413|NCT04668339|Placebo Comparator|Study Group 4, Older Adult Participants|Participants will receive one dose of Placebo (saline) on Day 0, a second dose of Placebo on Day 28 and a third dose of Placebo on Day 208
9707414|NCT04668469|Experimental|Ivermectin plus standard care in Mild/Moderate COVID-19 (Group I)|100 patients with Mild/Moderate COVID-19 (Coronavirus disease) infection received a 4-days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard of care as issued by Egyptian protocol of COVID-19 treatment.
9979747|NCT01384851|Experimental|Next Generation Emulsion|Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
9979748|NCT01384851|Active Comparator|Refresh Dry Eye Therapy|A preserved multi-dose formulation for use in treating dry eye symptomatology. The key ingredients are Castor oil, Polysorbate 80, Carbomer 1342 and Glycerin. Refresh Dry Eye Therapy® Lubricant Eye Drops contains emulsified castor oil, which enhances the natural oily superficial tear layer on the ocular surface. By stabilizing and supplementing the lipid layer, castor oil may retard evaporation of surface moisture.
10204629|NCT05200663|Active Comparator|"Tamoxifen and Antioxidant"|Group B patients will receive tab tamoxifen 10 mg twice a day and cap. vit E 400mg once a day for total of six months.
10204630|NCT05200637|Active Comparator|Orsiro|Two-stent DK-crush technique with Orsiro
9707415|NCT04668469|Active Comparator|hydroxychlorquine plus standard care in Mild/Moderate COVID-19 (Group II)|100 patients with mild/moderate COVID-19 infection received hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care.
9707416|NCT04668469|Experimental|Ivermectin plus standard care and steroids in Sever COIVD-19 (Group III)|100 patients with severe COVID-19 infection received a 4 days course of Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast plus standard care and steroids
9707417|NCT04668469|Active Comparator|hydroxychlorquine plus standard care and steroids in Sever COVID-19 (Group IV)|100 patients with Severe COVID-19 infection received hydroxychlorquine (400 mg every 12 hours for one day followed by 200 mg every 12 hours for 9days) plus standard care and steroids
9707418|NCT04668469|Experimental|Ivermectin plus personal protective measures in COVID-19 prophylaxis (Group V)|100 health care and or household contacts received a prophylactic dose of ivermectin 400 micrograms/kg single oral dose before breakfast to be repeated after one week in addition to Personal Protective Measures ( (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
9707419|NCT04668469|Active Comparator|Personal protective measures in COVID-19 prophylaxis (Group VI)|100 health care and or household contacts received only Personal Protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, Masks, respiratory etiquette, and self-isolation)
9707420|NCT04668521||COHORT A|Women with a pelvic mass, symptomatic or asymptomatic.
9707421|NCT04668521||COHORT B|Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
9707422|NCT04668521||COHORT C|Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
9707423|NCT04668495||Cangrelor Group|This is the study cohort that the blood sample will be obtained from. There are no interventions
9707424|NCT04668547|Experimental|Interventional arm|Single arm, no comparison
9707425|NCT04668560|Experimental|Intervention|Course intervention, six weeks wellbeing course
9707426|NCT04668560|No Intervention|Control|Follow-up as usual
9707427|NCT04668729|No Intervention|Control group|20 people will be included in the control group. 3 measurements will be taken one week apart in total. Measurements will consist of maximum isometric muscle strength, lumbar range of motion, balance performance, and pain intensity. And it will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD) and Modified Schober test, flamingo balance test, and visual analog scale.
9979749|NCT01384851|Active Comparator|Refresh Contacts|Solution contains carboxymethylcellulose sodium (carmellose), sodium chloride, boric acid, sodium borate, potassium chloride, calcium chloride, magnesium chloride, Purite®, sodium hydroxide, and purified water. This product is registered as a CE Mark medical device. Refresh Contacts Comfort drops providing soothing relief from tired, dry eyes. Although intended for contact lens wearers, the primary indication is for relief of dry eyes as is being studied in this investigation.
9979750|NCT01384864|Experimental|treatment|fluorescent imaging with proflavine
10193422|NCT01702883|Experimental|Intervention Group B|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.
10193423|NCT01702883|Experimental|Intervention Group C|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.
10193424|NCT01670409|Experimental|SMART combined with PF chemotherpay|SMART-base IMRT with concurrent and adjuvant chemotherapy(cisplatin and 5-fluorouracil)
10193425|NCT01570465||All patients enrolled in the GIMEMA AML1310 study.|"All patients enrolled in the GIMEMA AML1310 study;~Signed written informed consent according to ICH/EU/GCP and national local laws."
9979751|NCT01384890|Experimental|VMAT with CBCT|Volumetric modulated arc therapy (VMAT) with cone-beam computed tomography position (CBCT) verification
9979752|NCT01384890|Active Comparator|VMAT with kV-ray|Volumetric modulation arc therapy (VMAT) with kV-ray position verification
9979753|NCT01384903|Experimental|KW-3357|
9979754|NCT01384903|Active Comparator|Plasma-derived antithrombin|
10193426|NCT01526135|Active Comparator|Arm A GEMCITABINE|Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
10193427|NCT01526135|Experimental|Arm B mFOLFIRINOX|"Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
10193428|NCT01475110||Study cohort group|"Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.~Adult pts treated with Nilotinib as second line therapy after Dasatinib."
10193429|NCT01468246||Young Women|Young women with newly diagnosed breast cancer
10193430|NCT01415752|Experimental|Arm A|Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm E.
10193431|NCT01415752|Experimental|Arm B|Patients receive induction therapy comprising bortezomib IV subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm F.
10204631|NCT05200637|Active Comparator|Xience|Two-stent DK-crush technique with Xience
10204632|NCT05200637|Other|Single stent|Provisional one-stent strategy with any drug-eluting stent
9779186|NCT01124305|Active Comparator|Traditional Instrumentation|Control group: Cases performed with traditional surgical instruments
9707428|NCT04668729|Experimental|Chiropractic group|20 people will be included in the experimental group. Lumbal chiropractic HVLA (High Velocity, Low amplitude: HVLA) spinal manipulation and sacroiliac joint chiropractic HVLA manipulation will be applied 3 times in total with a weekly interval. The maximum isometric muscle strength before and immediately after the application, lumbar joint range of motion, balance performance, and pain intensity will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD), and Modified Schober test, flamingo balance test, and visual analog scale.
9707429|NCT04668378|Experimental|Time restricted eating (TRE) - two month|partecipants underwent 2 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
9707430|NCT04668378|Active Comparator|Normal Diet (ND) - two month|partecipants underwent 2 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
9707431|NCT04668378|Experimental|Time restricted eating (TRE) - twelve month|partecipants underwent 12 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
9707432|NCT04668378|Active Comparator|Normal Diet (ND) - twelve month|partecipants underwent 12 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
9707433|NCT04668352|Experimental|Dactolisib 10mg once daily|
9707434|NCT04668352|Placebo Comparator|Placebo|
9707435|NCT04668404||COVID-19 positive patient with ARDS|All patients with COVID-19 diagnosed with RT-PCR.
9707436|NCT04668222|Experimental|Deficiency of Qi and Yang (QYang-group)|Participants will receive Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
9707437|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yang (PQYang-group)|The placebo is made of 5% Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
9707438|NCT04668222|Experimental|Deficiency of Qi and Yin (QYin-group)|Participants will receive Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
10193432|NCT01415752|Experimental|Arm C|Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm G.
9707439|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yin (PQYin-group)|The placebo is made of 5% Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
9707440|NCT04668300|Experimental|Treatment (oleclumab, durvalumab)|Patients receive oleclumab IV over 1 hour every 2 weeks for 5 doses, then every 4 weeks thereafter. Patients also receive durvalumab IV over 1 hour every 4 weeks. Cycle repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9707441|NCT04668287|Other|Increasing Self-Esteem|All participants will be included in working groups.
9707442|NCT04668274|Experimental|Initial Dose|First Low dose, initially 200 mg resveratrol as JOTROL
9707443|NCT04668274|Experimental|Second (ascending) dose|Second (presumed) intermediate dose estimated at 500 mg resveratrol as JOTROL
9979755|NCT01384916|Experimental|Yoga|
9979756|NCT01384916|Active Comparator|Health education|
9979757|NCT01384929||ICU patients|All patients present in the ICU on the selected days
9979758|NCT01384942|Experimental|Meaning-Based Bereavement Group|
9979759|NCT01384942|Active Comparator|Conventional Bereavement Group|
9979760|NCT01384955||exercise|subjects diagnosed and treated in the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between 1983 and 1994, with scoliosis - specific exercise program
9979761|NCT01384955||control|age and condition - matched subjects, who were diagnosed at the same time, in the same clinic, and by the same physician, and prescribed the same method of physiotherapy, but did not start the exercise treatment
9979762|NCT01384968|Experimental|Beetroot juice|beetroot juice (170 mL, 8 mmol nitrate)
9979763|NCT01384968|Placebo Comparator|Nitrate-depleted beetroot juice|140 mL ...0 nitrate. Beetroot juice
9979764|NCT01384981|Active Comparator|pulmonary rehabilitation with NIV|Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
9979765|NCT01384981|Sham Comparator|pulmonary rehabilitation without NIV|Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
9979766|NCT01384994|Experimental|FOLFOX + Panitumumab|
9707444|NCT04668274|Experimental|Third (ascending) dose|Third (presumed) and highest dose estimated at 1000 mg resveratrol as JOTROL
9707445|NCT04668274|Experimental|Highest dose level (above) with a concomitant food evaluation|Third (presumed) and highest dose estimated at 1000 mg resveratrol as JOTROL administered in conjunction with a food effect evaluation
9707446|NCT04668261||Neurosurgical patients|"• Neurosurgical diseases with the potential to alter blood flow to the brain:~Cerebrovascular disease~Brain tumors~Normal Pressure Hydrocephalus"
9707447|NCT04668261||Healthy subjects|"Male and Female subjects >18 years of age~Written Informed Consent by the participant after information about the project. Foreign speaking healthy subjects should be accompanied by a person with sufficient German language proficiency to act as a translator"
9707448|NCT04668196||High-flow nasal cannula treatment|
9707449|NCT04668196||Continuous positive airway pressure (CPAP) treatment|
9707450|NCT04668196||Noninvasive ventilation treatment|
9979767|NCT01384994|Active Comparator|FOLFOX|
9979768|NCT01385020|Experimental|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects
9979769|NCT01385046|Experimental|physical activity and nutrition|
9979770|NCT01385059|Experimental|Arm I (neoadjuvant enzyme inhibitor and prostatectomy)|Patients receive axitinib PO BID on days 1-28. Patients then undergo prostatectomy and pelvic lymph node dissection. Treatment continues in the absence of disease progression or unacceptable toxicity.
10193433|NCT01415752|Experimental|Arm D|Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
10193434|NCT01415752|Experimental|Arm E|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
10193435|NCT01415752|Experimental|Arm F|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
10193436|NCT01415752|Experimental|Arm G|Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
10193437|NCT01415752|Experimental|Arm H|Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
10193438|NCT01398852|Experimental|CXL Treatment|All eyes to be treated with riboflavin and UV light
10193439|NCT01332266|Active Comparator|Active Comparator; Phase 1b: Cohort 1,2,and 3|"Phase 1b:~Cohort 1; 200 mg E7050 + 250 mg/m2 cetuximab Cohort 2; 300 mg E7050 + 250 mg/m2 cetuximab Cohort 3; 400mg E7050 + 250mg/m2 cetuximab~Phase 2: Arm 1; MTD E7050 + 250 mg cetuximab Arm 2; 250 mg cetuximab~Interventions: Drug cetuximab"
10193440|NCT01332266|Active Comparator|Phase 2|"Phase 2:~Arm 1; MTD E7050 + 250 mg/m2 cetuximab Arm 2; 250 mg/m2 cetuximab"
10193441|NCT01325805|Experimental|Structured Weight Loss|Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
10193442|NCT01325805|Active Comparator|Routine Weight Loss Counseling|Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.
10193443|NCT01264549|Experimental|PCT guided arm|
10193444|NCT01264549|No Intervention|Control|Standard treatment
10193445|NCT01261728|Experimental|Gemcitabine and Cisplatin|This is a Phase II Study of Gemcitabine and Cisplatin (GC) as neoadjuvant chemotherapy in patients with upper tract high-grade urothelial carcinoma who are candidates for radical nephroureterectomy or distal ureterectomy.
10193446|NCT01222754|Experimental|1|Radiation with Lenalidomide
10193447|NCT01209000||FSGS/MCD Cohort (Cohort A)|"Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
10193448|NCT01209000||MN Cohort (Cohort A)|"Membranous Nephropathy (MN) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
10193449|NCT01209000||Other glomerulopathies cohort|"Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
10193450|NCT01209000||cNEPTUNE (Cohort B)|Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.
10193451|NCT01150890|Placebo Comparator|Placebo|Participants received placebo intravenously at baseline and week 4.
10193452|NCT01150890|Experimental|Brodalumab 210 mg|Participants received 210 mg brodalumab intravenously at baseline and week 4.
10193453|NCT01150890|Experimental|Brodalumab 350 mg|Participants received 350 mg brodalumab intravenously at baseline and week 4.
10193454|NCT01150890|Experimental|Brodalumab 700 mg|Participants received 700 mg brodalumab intravenously at baseline and week 4.
10193455|NCT01143779|Experimental|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
10193456|NCT01140867|Experimental|1|
10193457|NCT01137773|Experimental|Intensive IV Insulin|Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
10193458|NCT01137773|Active Comparator|Conventional Insulin Treatment|Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl
10193459|NCT01127256|Experimental|1|
10193460|NCT01127256|Active Comparator|2|
10193461|NCT01079728||ischemic stroke patients|patients with an ischemic stroke in the anterior (ACA, MCA) and posterior flow area (PCA, BA) of any severity in the last 36h
10193462|NCT01004861|Experimental|PLX3397|
10193463|NCT00978458|Active Comparator|Arm I|Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
10193464|NCT00978458|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
10193465|NCT00912223|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
10193466|NCT00589654||1|
10193467|NCT00572481|Other|Sentinel Lymph Node Biopsy Only|Axillary Reverse Mapping
10193468|NCT00572481|Other|Full Axillary Lymph Node Dissection|Axillary Reverse Mapping
10193469|NCT00482833|Experimental|ARM A - ATO/ATRA|
10193470|NCT00482833|Active Comparator|ARM B - ATRA|
10193471|NCT00381381|Experimental|1|
10193472|NCT00381121||Kidney disease cohort|Individuals with a clinically indicated biopsy are recruited and/or surplus tissue that remains from past clinical interventions is obtained.
10193473|NCT00352573||Normal Volunteers|Adults over 21 years old
10193474|NCT00102648|Experimental|Treatment (temozolomide and lonafarnib)|Patients receive temozolomide PO QD on days 1-7 and 15-21 and lonafarnib PO BID on days 8-14 and 22-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
10193475|NCT00038675|Experimental|Imatinib|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily.
10204633|NCT05200624|Active Comparator|Active laser|Application of the active 2RT sub threshold laser
9707451|NCT04668027|Experimental|chronic airway disease group|Before the test, patients with FEV1/FVC≥0.7 are divided into the provocation test group, patients with FEV1/FVC <0.7 are divided into the dilation test group.
9707452|NCT04667988|Experimental|RA patients|newly diagnosed RA will started therapy with conventional synthetic DMARDs (including methotrexate)
9707453|NCT04667988|Experimental|control|JAK2 mutation assesment by PCR
9707454|NCT04668053|Active Comparator|Traditional training protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills
9707455|NCT04668053|Experimental|Hip flexor resistance protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills and hip flexors resistance protocol
9707456|NCT04668131|Experimental|Artificial tears|
9979771|NCT01385059|Active Comparator|Arm II (surgery)|Patients undergo prostatectomy and pelvic lymph node dissection at 5-6 weeks after biopsy confirmation of prostate cancer.
9707457|NCT04668131|Active Comparator|Acupuncture|
9707458|NCT04668183||Pudendal Nerve Block|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
9707459|NCT04668183||Dorsal Penile Nerve Block|Ultrasound (US) guided dorsal penile nerve block with in plane technique was done. Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
9707460|NCT04667936||moderate to severe COVID-19 ARDS|patients with an oxygenation index <200 under intubation anesthesia and mechanical ventilation.
9707461|NCT04667975|Experimental|Part 1(Dose escalation)|"Part 1: 3 or 6 subjects are enrolled, per each dose group in a traditional 3+3 design.~Begin with the starting dose determined by the non-clinical study and increase the dose according to the dose levels. If DLT does not occur in the 3 subjects when they have completed the 1st cycle at each dose level, increase the dose to the next level. Dose escalation proceeds until the maximum tolerated dose (MTD) is reached.~Dose-limiting toxicity (DLT) is evaluated following the completion of dosing for the 1st cycle of all subjects enrolled in each dose group in order to determine whether to proceed to the next level. Following completion of the DLT evaluation of the planned dose level in this study, the SRC reviews the outcome of the evaluation and determines whether to set additional dosing or proceed to PART 2 (Dose expansion)."
9707462|NCT04667975|Experimental|Part 2(Dose expansion)|"Part 2: The primary objective of Part 2 is to evaluate the efficacy of CKD-702 by identifying the ORR after administering the RP2D of CKD-702 determined in Part 1. Along with this, to determine the CKD-702 effective patient group, the patient groups were classified into several cohorts based on non-clinical study results.~Therefore, in Part 2, the RP2D determined in Part 1 is administered until the occurrence of an adverse event causing PD occurrence, death or treatment discontinuation, and tumor response is evaluated based on RECIST version 1.1."
9707463|NCT04668079|Experimental|Modified cross body stretch|modified cross body stretch
9707464|NCT04668079|Experimental|Modified sleeper stretch|modified sleeper stretch
9707465|NCT04668118|Experimental|Diquafosol group|The treatment period is 12 weeks. The day after subjects who meet the inclusion criteria undergo baseline examination is the day starting the medication. Dosing frequency was six times daily for 3% Diquafosol Ophthalmic Solution. The follow-up time points are 2, 4, 8, 12 weeks, and no other medication is required on the follow-up day.
9707466|NCT04667767|Experimental|Intervention|"In addition to the national standard outpatient treatment for uncomplicated severe acute malnutrition, caregivers of participants will receive a WASH kit containing a plastic container, a supply of Aquatabs® (effervescent chlorine tablets), and training in their use and associated hygiene practices."
9707467|NCT04667767|Active Comparator|Control|National standard outpatient treatment for uncomplicated severe acute malnutrition
9707468|NCT04667754|Experimental|10 week ICBT|CBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
9707469|NCT04667728|Experimental|intervention group (IGr)|The IGr participants wore a professional continuous glucose monitoring (CGM) sensor (iPro™2) during the first six days of the study. Following this period, IGr participants had a medical consultation for the CGM results and treatment adjustments. Additionally, they received a personalized diet plan from a dietitian. After three months, the IGr participants again wore the CGM sensor for one week. These participants also followed the regular institutional Comprehensive Diabetes Care program care plan.
9707470|NCT04667728|No Intervention|control group (CGr)|The control group followed the regular institutional Comprehensive Diabetes Care program care plan.
9707471|NCT04668040|Experimental|Muscle energy technique|Muscle energy technique applied in the lower cross syndrome muscle pattern.
9707472|NCT04668040|Active Comparator|Stretching|Stretching technique applied in the lower cross syndrome muscle pattern.
9779187|NCT01124305|Experimental|Customized Patient Instrumentation|Experimental group: Cases performed with custom instruments specifically made for each patient using pre-op CT scans.
9979772|NCT01385072|Experimental|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
9979773|NCT01385085||No natural sunlight|one group works in a basement with no natural sunlight
9707473|NCT04667793|Experimental|Thymoma|"Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Carboplatin AUC 5, Amycin 50mg/m2, Cyclophosphamide 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines."
9707474|NCT04667793|Experimental|Thymic carcinoma|"Neoadjuvant treatment stage: Toripalimab 240mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Cisplatin 50mg/m2, Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: the patients who did not receive 4 cycle therapy will receive 1-2 cycles therapy up to 4 cycles in total, the following therapy is according to the NCCN guidelines."
9707475|NCT04667663|Experimental|CPD-DARA|"Drug: Daratumumab Other Name: Darzalex~Drug: Cyclophosphamide~Drug: Pomalidomide Other Name: Pomalyst/ Imnovid~Drug: Dexamethasone"
9707476|NCT04667598|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given modified Wenxin Tang granules, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
9707477|NCT04667598|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
9707478|NCT04667676|Experimental|TENS Therapy Group|patients received acupoint TENS
9707479|NCT04667676|Sham Comparator|Control group|patients received shame acupoint TENS
9707480|NCT04667871||Eyes for cataract surgery|Eyes for cataract surgery
9707481|NCT04667871||Eyes without cataract surgery|Eyes without cataract surgery
9707482|NCT04667962||Hospital service change|This group is composed of caregivers who changed hospital service during COVID-19 health crisis.
9707483|NCT04667962||No hospital service change|This group is composed of caregivers who have not changed hospital service during COVID-19 health crisis.
9707484|NCT04667832||abnormal ABI|those patients with ankle brachial index ( ABI) less than 0.9
9707485|NCT04667832||normal ABI|Those patients with ankle brachial index more than 0.9
9707486|NCT04667910|Experimental|601 1.25mg|
9707487|NCT04667910|Experimental|Ranibizuman 0.5 mg|
9707488|NCT04667897|Experimental|601 1.25mg|
9707489|NCT04667897|Experimental|Ranibizuman 0.5 mg|
9707490|NCT04667611||Mild|
9707491|NCT04667611||Moderate|
9707492|NCT04667611||Severe|
9707493|NCT04667819|Experimental|sodium hyaluronate|Sodium hyaluronate has become a novel and effective eye drop for the treatment of the dry eye. However, we design a special method of usage of sodium hyaluronate in dry eye patients.
9707494|NCT04667624|Active Comparator|Reference|TWYNSTA Tablet 80/5mg(Telmisartan/Amlodipine)
9707495|NCT04667624|Experimental|Test|LodienT Tablet 80/2.5mg(Telmisartan/S-amlodipine)
9707496|NCT04668105|Experimental|High volume nordic hamstring exercise|High volume Nordic hamstring exercise
9707497|NCT04668105|Experimental|Low volume Nordic Hamstring exercise|Low volume Nordic Hamstring exercise
9707498|NCT04667715|Active Comparator|Exablate Test Arm|Subjects will undergo ExAblate BBBD prior to their standard of care tumor removal
9707499|NCT04667715|No Intervention|Control Test Arm|Subjects will undergo their standard of care tumor removal
9707500|NCT04667286|Experimental|Oxygen and Prone Position (PP)|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96% plus PP for a minimum of 10 hrs a day
9707501|NCT04667286|Active Comparator|Oxygen|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96%
9707502|NCT04667351|Active Comparator|5-fu 2400|
9707503|NCT04667351|Experimental|5-fu 1200|
9707504|NCT04667273|Experimental|Exercise Training (ET) + Neuromuscular Electrical Stimulation (NMES) group|volunteer patients with Subacromial Impingement Syndrome
9707505|NCT04667273|Other|Exercise Training (ET) group|volunteer patients with Subacromial Impingement Syndrome
9707506|NCT04667364|No Intervention|Group MED|A group of participants that receives treatment as usual that consists of medicinal treatment, prescribed by a specialist doctor (Carsten Kock-Jensen, MD) from the CRPS clinic and will be monitored using patients' medicinal records.
9707507|NCT04667364|Experimental|Group TENS|A group of participants that receives transcutaneous electrical nerve stimulation (TENS) which is an inexpensive, noninvasive and safe treatment for pain.
9707508|NCT04667455|No Intervention|Control subjects|Infants and Children with no evidence of congenital heart disease based on echocardiography and standard ECG assessment
9707509|NCT04667455|Active Comparator|Congenital heart disease subjects|Infants and Children with evidence of predefined congenital heart disease lesions based on echocardiography and standard ECG assessment
9707510|NCT04667533|Experimental|Desidustat tablet|
9707511|NCT04667429|Experimental|Food effect|HEC83518 40mg will be administered fasted, or with high-fat meal for once.
9707512|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 20mg|HEC83518 20mg will be administered before sleep for 15 days .
9707513|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 40mg|HEC83518 40mg will be administered before sleep for 15 days .
9707514|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 80mg|HEC83518 80mg will be administered before sleep for 15 days .
9707515|NCT04667429|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo will be administered before sleep for 15 days .
9707516|NCT04667520|Experimental|LPA+Fitbit|Participants in this group receive a Lifestyle Physical Activity intervention and are provided with a Fitbit to collect activity data
9707517|NCT04667520|Active Comparator|Fitbit Only|Participants in this group are provided with a Fitbit to collect activity data
9707518|NCT04667390|Active Comparator|total knee arthroplasty using the active robotic system|total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
9707519|NCT04667390|Active Comparator|total knee arthroplasty using computer navigation|Primary total knee arthroplasty using computer navigation and intraoperation control system
9707520|NCT04667390|Active Comparator|total knee arthroplasty using the standard manual tekhnik|Primary total knee arthroplasty using the standard recommended set of instruments
9707521|NCT04667546|Other|Patient having urinary tract infection|Patients with a confirmed urinary tract infection in accordance with the GPIP (french Pediatric Infectious Disease Group) definition and inclusion criteria.
9707522|NCT04667182||Combined Diabetes Management Data|Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.
9979774|NCT01385085||Low level of Natural Sunlight|the second group work in offices with unopenable windows.
9707524|NCT04667169|Experimental|Laser Haemorrhoidoplasty|A stab incision was made at the ano-cutaneous junction and the anodermis was tunneled with artery forceps to the pedicle of the haemorrhoids. The laser catheter was introduced submucosally towards the pedicle guided by a visible beam to ascertain the exact location of the laser fibre. This was then followed by about six pulsed laser energy delivered at five mm interval, while gradually withdrawing the laser catheter.
9707525|NCT04667169|Experimental|Haemorrhoidal Artery Ligation|In addition to the delivery of laser energy as per the procedure described above, each identified pedicle was ligated with a suture, without Doppler guidance.
9707526|NCT04667507|Experimental|Dextenza (Group A)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 1-3 days prior to cataract surgery
9707527|NCT04667507|Experimental|Dextenza (Group B)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 6-8 days prior to surgery
9707528|NCT04667507|Experimental|Dextenza (Group C)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 13-15 days prior to surgery
9707529|NCT04667507|Experimental|Dextenza (Group D)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 19-23days prior to surgery
9707530|NCT04667507|Experimental|Dextenza (Group E)|Dextenza (dexamethasone ophthalmic insert 0.4mg) 26-31 days prior to surgery
9707531|NCT04667507|No Intervention|Control|Will not receive Dextenza (dexamethasone ophthalmic insert 0.4mg)
9707532|NCT04667221|Experimental|Anodal transcranial direct current stimulation|Patients will be bilaterally stimulated with anodal tDCS at the parietal cortex (Broadman Area 7).
9707533|NCT04667221|Experimental|Cathodal transcranial direct current stimulation|Patients will be bilaterally stimulated with cathodal tDCS at the parietal cortex (Broadman Area 7).
9707534|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for anodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Broadman Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
9979775|NCT01385085||High level of Natural Sunlight|The third group works outdoors.
9979776|NCT01385111|Active Comparator|Arm A|EBUS centered
9979777|NCT01385111|Experimental|Arm B|EUS centered
9707535|NCT04667221|Sham Comparator|Sham transcranial direct current stimulation for cathodal group|Patients will be bilaterally stimulated with sham tDCS at the parietal cortex (Broadman Area 7). As a consequence of the crossover design, both experimental arms receive sham stimulation.
9707536|NCT04667299|Experimental|BMT group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid and metronidazole 0.4 g qid for 14 days
9707537|NCT04667299|Active Comparator|BMQ group|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and amoxicillin 1 g bid for 14 days
9707538|NCT04666792|Other|PrEP for HIV-1 uninfected for women accessing family planning|Women accessing family planning will be assessed for HIV risk and PrEP eligibility. If eligible and willing to initiate PrEP, they will be provided PrEP in accordance with national guidelines as part of their standard of care at the family planning clinic.
9707539|NCT04666896|Experimental|Evidence-based tailored care (group A)|Patients who were randomized to group A received a tailored exercise program, with exercises developed based on recent hEDS/HSD research data.
9707540|NCT04666896|Active Comparator|Evidence-based standard care (group B)|This exercise program was composed in order to reflect evidence-based standard care, in a telerehabilitation format.
9707541|NCT04666844||Survey|Clinicians will be asked to provide responses to the two surprise questions for each of their PD patients.
9707542|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 10 mg, plus metformin XR|
9707543|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein 5 mg, plus metformin XR|
9707544|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 10 mg, plus metformin XR|
9707545|NCT04667143|Experimental|Retagliptin placebo, Henagliflozein 5 mg, plus metformin XR|
9707546|NCT04667143|Experimental|Retagliptin 100 mg, Henagliflozein placebo, plus metformin XR|
9707547|NCT04666948|Active Comparator|Standard of Care Vancomycin treatment|Vancomycin standard-of-care dosing and therapeutic drug monitoring, according to institutional guidelines during 30 day study period
9979778|NCT01385124|Experimental|Oral Cannabidiol|Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.
9979779|NCT01385163|No Intervention|Control - VSLA|the wait control sample for the economic intervention
9979780|NCT01385163|Other|Control - Mental Health|treatment as usual based on standard psychosocial services in the area
9979781|NCT01385163|Experimental|Voluntary Savings/Loans Assoc|
9979782|NCT01385163|Experimental|Cognitive Processing Therapy|
9979783|NCT01385215|Placebo Comparator|Placebo|
9979784|NCT01385215|Placebo Comparator|Nasal Aerosol Immunization|
9979785|NCT01385215|Placebo Comparator|Nasal Droplet Immunization|
9979786|NCT01385215|Placebo Comparator|Intramuscular Immunization|
9979787|NCT01385228|Experimental|"Dose Level Xa"|once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
9979788|NCT01385228|Experimental|"Dose Level Xb"|once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
9979789|NCT01385241|Experimental|Received video intervention|The group of women who received an Ipod Touch with the video loaded onto it and told to view it at least once a week for the first 4 weeks, and as often as desired in weeks 5-12.
10193476|NCT05179863||Patient population|Children, adolescents, and adults with a high suspicion, or a confirmed diagnosis of a rare disease who are treated or living in Switzerland.
10193477|NCT05179759|Experimental|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
10193478|NCT05179759|Active Comparator|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
10204634|NCT05200624|Sham Comparator|Sham laser|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant)
10204635|NCT05200611||Fecal Immunochemical Test|People in this group with positive fecal immunochemical test results were further examined by colonoscopy.
10204636|NCT05200169|Experimental|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
10204637|NCT05198531|Experimental|TQB2858 Injection combining with other drugs|"Combination 1 is TQB2858 Injection and Anlotinib Hydrochloride Capsules. Combination 2 is TQB2858 Injection, Gemcitabine Hydrochloride Injection and Cisplatin Injection for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment.~Combination 3 is TQB2858 Injection, Gemcitabine Hydrochloride Injection, Cisplatin Injection and Anlotinib Hydrochloride Capsules for 4-6 cycles of induction chemotherapy, then using TQB2858 Injection and Anlotinib Hydrochloride Capsules for maintenance treatment."
10204638|NCT05195112|Experimental|MT921|"Injection volume/interval: 0.2mL/1.0cm~Number of Injection: Maximum 50 times~Concentration per unit area: 3mg/cm2"
10204639|NCT05195112|Placebo Comparator|Placebo|"Injection volume/interval: 0.2mL/1.0cm~Number of Injection: Maximum 50 times~Concentration per unit area: 0mg/cm2"
10204640|NCT05188989|Experimental|TPN171H 2.5mg group|
10204641|NCT05188989|Experimental|TPN171H 5mg group|
10204642|NCT05188989|Experimental|TPN171H 10mg group|
10204643|NCT05188989|Placebo Comparator|Placebo group|
9707548|NCT04666948|Experimental|vancomycin model-informed precision dosing|Area Under the Concentration (AUC)-time curve/MIC-based model-informed precision dosing of vancomycin using a CE labelled dosing calculator during 30 day study period
9707549|NCT04666831|Experimental|AMI and CBT Intervention|Participants will receive four weekly sessions of individual therapy (60 minutes) with a graduate student therapist over videoconferencing technology or telephone. The intervention combines Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT) techniques for food addiction. Participants will complete questionnaires at baseline, postintervention or 1-month postbaseline, and 2- and 4-months postbaseline.
9707550|NCT04666831|No Intervention|Waitlist Control|Participants will complete questionnaires at baseline, 1-month postbaseline, and 2- and 4-months postbaseline (at timepoints comparable to the intervention arm). They will not receive any intervention during this time. Following the 3-month waitlist, they will cross over into the same procedure as the intervention arm.
10193479|NCT05179759|Experimental|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
9707551|NCT04666870||axis length|1007 healthy students with moderate to high myopia (SE ≤ -4.00D) and 894 without myopia (-0.50D ≤ spherical power ≤ +2.00D) were enrolled.
9707552|NCT04666870||gender|male were 54.29% (N=1032), and female were 45.71% (N=869)
9707553|NCT04666987||Xultophy®|Participants are patients with Type 2 Diabetes (T2D) treated with Xultophy® (IDegLira) in a real-world setting in Italy
10193480|NCT05179759|Active Comparator|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
10193481|NCT05179759|Experimental|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
9707554|NCT04666883||Splenic flexure cancer patients|Splenic flexure cancer patients
9707555|NCT04666805||Drug Group|Endocrine therapy drugs include selective estrogen receptor modulators (Tamoxifen, Toremifene) and aromatase inhibitors (Anastrozole, Letrozole, Exemestane), which have been widely used in the adjuvant treatment of hormone receptor positive breast cancer.
9707556|NCT04667117|Experimental|Cohort 1|RMS patients receiving a 2020-2021 inactivated influenza vaccine at least two weeks prior to ofatumumab start
9707557|NCT04667117|Experimental|Cohort 2|RMS patients receiving a 2020-2021 inactived influenza vaccine at least 4 weeks after ofatumumab start.
9707558|NCT04667117|Experimental|Cohort 3|RMS patients currently on iDMT receiving a 2020-2021 an inactivated influenza vaccine
9707559|NCT04666766|Active Comparator|Traumatic intracranial hemorrhage|Patients with traumatic intracranial hemorrhage diagnosed by Computerized Tomography of the head
9707560|NCT04666766|Active Comparator|Trauma without traumatic intracranial hemorrhage|Patients with trauma to the head but traumatic intracranial hemorrhage ruled out by Computerized tomography of the head
9707561|NCT04666766|Active Comparator|Healthy age-matched volunteers|Healthy age-matched volunteers with no previous trauma to the head within the past two weeks.
9707562|NCT04666935|Experimental|Intervention group|The intervention group will be instructed to include the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program as a warm up before training session (3 times per week) during one season (6 months).
9707563|NCT04666935|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
9707564|NCT04667091|Experimental|Experimental|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Positional Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
9707565|NCT04667091|Active Comparator|Comparator|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Myofascial Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
9779188|NCT01124370|Experimental|Treatment|All enrolled subjects will undergo attempted system implantation and therapeutic assessment. Subjects' baseline assessment values will serve as control parameters for the therapy evaluation.
9779189|NCT01124422|Experimental|fluticasone propionate/salmeterol DISKUS 250/50 + tiotropium|This is the active DISKUS (that is, containing fluticasone propionate/salmeterol combination) + open-label tiotropium
9779190|NCT01124422|Placebo Comparator|placebo DISKUS + tiotropium|This is the DISKUS and excipient minus the active ingredient (which is fluticasone propionate/salmeterol combination) + open-label tiotropium
9779191|NCT01124448|Experimental|Lactobacillus salivarius PS2|Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
9779192|NCT01124448|Active Comparator|Lactobacillus salivarius PS2B|Lactating women without mastitis (n=15)
9779193|NCT01124604|Experimental|Tapentadol Hydrochloride|
9779194|NCT01124604|Placebo Comparator|Placebo|
9779195|NCT01124617|Experimental|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
9779196|NCT01124617|Placebo Comparator|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
9779197|NCT01124643|Experimental|Replagal 0.2 mg/kg EOW|Intravenous, 0.2mg/kg EOW
9707566|NCT04667052|Experimental|JNJ 64304500: Reference|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 reference formulation.
9707567|NCT04667052|Experimental|JNJ 64304500: Test|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 test formulation.
9979790|NCT01385241|No Intervention|Did not receive video|This group does not receive the video intervention during the study period, and will complete surveys at baseline, 30 days and 90 days for comparison to the intervention group.
9979791|NCT01385254||siblings and mothers of Very Low Birth Weight infants|50 older siblings (closest in age) and mothers of very low birthweight (VLBW) infants, born at <33 weeks gestation and <1500 grams at birth
9707568|NCT04667130|Experimental|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Providing information about the possibilities of physiotherapy, Computer Kinesiology, psychotherapy, Motor progam activating therapy, aerobic exercise
9707569|NCT04666974|Experimental|Phase 3: iCBT + Treatment As Usual|CWs in the iCBT group, will be assigned to one the six therapy modules, based on their gender and diagnosis (i.e. Female/Male * GAD, MDD or PTSD). Each CW will be assigned a specific clinician (a trained psychiatrist/psychologist/ social worker) who would be their care liaison through the study. Each week, the clinician would send one session of the 12-session curriculum to the CW on a pre-determined day of the week. Each weekly session consists of 20-30 slides followed by a homework assignment. It usually takes 40-60 minutes for a participant to complete one weekly session which they have to complete by a specific day of the week. The clinician will review the CW's assignments and provide feedback on their performance. The clinician feedback is structured and takes approximately 15 minutes to complete. The clinician will then send the content for the next session along with the feedback.
9707570|NCT04666974|No Intervention|Phase 3: Treatment as Usual|Participants will complete clincally validated questionnaires to measure symptoms while continuing with their regular daily activities and treatments (if any) (i.e., exercise, diet, medications, etc.)
9707571|NCT04666974|Experimental|Phase 4: iCBT + Treatment as Usual|Participants will be randomly assigned to this group and take part in the iCBT module program from phase 3.
9707572|NCT04666974|Active Comparator|Phase 4: In-Person CBT + Treatment as Usual|Participants will be randomly assigned to this group and complete in-person CBT with similar content, homework, and feedback as in the iCBT + TAU group. All in-person CBT will be delivered by a trained professional and each session will take approximately 60-75 minutes.
9707573|NCT04666818||Self Monitoring Blood Glucose (SMBG)|Women used self-monitoring of blood glucose= Control group (CG)
9707574|NCT04666818||Flash Glucose Monitoring (FGM)|Women used flash glucose monitoring= FGM group (FG)
9979792|NCT01385254||siblings and mothers of healthy infants|50 siblings (closest in age) and mothers of healthy, full-term infants (between 38-42 weeks gestation and lacking medical conditions that require a hospital stay past the mother's discharge date)
9979793|NCT01385267||Diamniotic twin gestations|
9979794|NCT01385319|Active Comparator|bare metal stent|
9979795|NCT01385319|Experimental|Endeavor sprint stent|
9979796|NCT01385332|Active Comparator|Early luteal phase -COH-|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the early luteal phase.
9979797|NCT01385332|Active Comparator|Late folicular phase - COH -|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the late follicular phase.
9979798|NCT01385345|Active Comparator|Vitamin D3 high dose|200,000 units (time 0) followed by (100,000 units) at months 1.5, 3 and 5. Participants will also have daily 1,000 units per day to mirror the control arm and maintain double blinding.
9979799|NCT01385345|Placebo Comparator|Vitamin D3|Participants will have a placebo liquid (to mirror the active arm high dose Vitamin D3) and also have daily 1,000 units Vitamin D3.
9979800|NCT01385358|Experimental|Thoracoscopically Assisted Surgical Ablation|This arm will have an index thoracoscopically assisted surgical ablation.
9979801|NCT01385358|Active Comparator|Catheter Ablation|This is an active comparator arm where study subjects will undergo conventional catheter ablation.
9979802|NCT01385384|Other|NeuRx|
9979803|NCT01385397|Experimental|Preceptorship and virtual community|
10193482|NCT05179759|Active Comparator|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
10193483|NCT05179759|Experimental|Tealeaf - Year 4: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
10193484|NCT05179759|Active Comparator|Enhanced Usual Care - Year 4: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
10193485|NCT05179746|Active Comparator|With electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
9979804|NCT01385410|Active Comparator|CPS, cell phone based peer support|Cell phone base peer mother support for continued exclusive breastfeeding
9979805|NCT01385410|Active Comparator|PSG, group meeting based peer support|Group based peer Cell phone base peer mother support for continued exclusive breastfeeding
9707575|NCT04666779||No access|Group not accessing chiropractic care
10193486|NCT05179746|Placebo Comparator|Without electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
10193487|NCT05179733|Experimental|ZR2|six courses of zanubrutinib, rituximab and lenalidomide
10193488|NCT05179733|Active Comparator|R-miniCHOP|six courses of rituximab combined with low-dose CHOP
10193489|NCT05179720|Experimental|puncture stent-assisted transperineal prostate biopsy|This group of patients underwent puncture stent-assisted transperineal prostate biopsy.
10193490|NCT05179720|Active Comparator|transperineal free-hand biopsy|This group of patients underwent perineal free-hand biopsy
10193491|NCT05179694|Experimental|Local Anaesthetic Transperineal Prostate Biopsy (LATP)|"LATP prostate biopsy performed with an average of 12 biopsy cores in 6 sectors depending on prostate size, plus typically 4 target cores per MRI lesion, using an ultrasound probe-mounted LATP needle guidance device (e.g. the Precision-Point access system, or BK UA1232, or any other which is used in a virtually identical fashion)."
10193492|NCT05179694|Active Comparator|Transrrectal Ultrasound-guided Prostate Biopsy (TRUS)|TRUS prostate biopsy performed according to each hospital's standard practice, with an average of 12 biopsy cores, in two sectors with additional target pots (typically 4 target cores per MRI lesion).
10193493|NCT05179681||patients with non-intubated thoracic surgery|
10193494|NCT05179642||Control group|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group."
10193495|NCT05179642||Tool OPTIM-EHPAD|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
10193496|NCT05179616||Heart Failure Patients|Patients suffering from symptoms of right heart failure due to high-grade tricuspid regurgitation
10193497|NCT05179590||General anesthesia Group|
10193498|NCT05179577|Active Comparator|40mg Arbaclofen Extended-Release|Extended-release oral tablet, twice daily dosing
10193499|NCT05179577|Placebo Comparator|Placebo|Extended-release oral tablet, twice daily dosing
9707576|NCT04666779||Access to care|Group with access to care in a 6 months period. Differences in the degree of access, measured in ranges of numbers of visits, will be used as independent variable within this group.
10193500|NCT05179564|Experimental|iohexol plasma clearance|"a weight-dependent dose of iohexol will be injected as an intravenous bolus in 100 patients~2,5 -9kg = 1ml; 10-19kg = 2ml; 20-29kg = 3ml; 30-39kg = 4ml; ≥ 40kg = 5ml"
10193501|NCT05179538|Experimental|Single Arm Treatment|Cued picture naming therapy will be delivered to all participants. There will be four cohorts of participants based on BDNF and ApoE genotypes.
10193502|NCT05179525|Experimental|Risperidone ISM® 100 mg|Subjects will receive 4 mg oral risperidone once daily for 7 days. After the 1 week oral risperidone regimen subjects will be administered 100 mg risperidone ISM as an injectable into the gluteal muscle. A total of 4 doses of intramuscular (IM) 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. Each dose will be separated by 4 weeks.
10193503|NCT05179512||Tiotropium|Reference group
10193504|NCT05179512||Salmeterol/Fluticasone|Exposure group
10193505|NCT05179473||Acute stroke patients|12 weekly evaluations starting within the first week post-stroke. Follow-up assessment at week 16. MRI at week 6.
10193506|NCT05179408|Experimental|Telerehabilitation|Telerehabilitation intervention consisting of exercise training, education, and behavioral support
10193507|NCT05179408|No Intervention|Control|No intervention arm, with assessment of functional and patient-reported outcomes only
10193508|NCT05179395|Experimental|Brasthesis|All five participants will wear Brasthesis for 4-weeks
10193509|NCT05179356|Active Comparator|Dapagliflozin 10 mg once daily|Dapagliflozin 10 mg (Farxiga 10 mg) given once daily for three months
10193510|NCT05179356|Placebo Comparator|Matching placebo|Placebo given once daily for three months
10193511|NCT05179317|Experimental|QL1706+chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1706 5mg/kg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6)
10193512|NCT05179291|Experimental|Buzzy Group|In this group external cold and vibration-Buzzy was applied to the children during phlebotomy.
10193513|NCT05179291|Experimental|Virtual Realitiy-VR Group|In this group Virtual Realitiy-VR was applied to the children during phlebotomy.
10193514|NCT05179291|No Intervention|Control Group|In this group, children received routine phlebotomy procedure
10193515|NCT05179278|Experimental|Intervention Group: pre-surgical consultation with nurse follow-up|
10193516|NCT05179278|No Intervention|Control Group: pre-surgical consultation without nurse follow-up|
10193517|NCT05179265|Placebo Comparator|Control group|0.45 g/bottle，50 mL
9707577|NCT04666857|No Intervention|standard care|Control subject will receive standard care of treatment
9707578|NCT04666857|Experimental|intervention group|intervention group will receive early intervention
9707579|NCT04666922|Experimental|BI 765080 treatment group|BI 765080
9707580|NCT04666922|Placebo Comparator|Placebo group|Placebo
10193518|NCT05179265|Experimental|test group|10 g/bottle (20%, 50 mL)
10193519|NCT05179252|Experimental|SFI intervention group|shenfu injection used during surgery, day one and two after surgery, 50ml,iv drop.
10193520|NCT05179252|Sham Comparator|Control group|same volume of normal saline used during surgery, day one and two after surgery, 50ml,iv drop.
9707581|NCT04666753||ImmunoFormulation cohort|"Patients treated* with IMUNO TF® with a combination of nutraceuticals.~*Without restrictions on the adjuvant treatment received."
9707582|NCT04666753||Control cohort|"Control cohort: patients not treated* with IMUNO TF® with a combination of nutraceuticals.~*Without restrictions on the adjuvant treatment received."
9707583|NCT04666597||Modified CariesCare International management intervention group|
10193521|NCT05179213|Experimental|Azacytidine combined with chidamide|Patients in the experimental arm will received azacytidine plus chidamide treatment. This regimen was repeated every 28 days.
10193522|NCT05179187|Experimental|Parkinson disease patients|Participants diagnosed with Parkinson's disease
10193523|NCT05179187|Active Comparator|Healthy adults|Healthy adult age-matched controls
10193524|NCT05179174||patients with uveal melanoma|51 patients with a diagnosed with uveal melanoma; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, diseases kidney, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
10193525|NCT05179174||healthy controls|51 age sex matched controls, patients with diagnosed with cataracts; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, kidney diseases, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
10193526|NCT05179161|Experimental|Prone crawl position|Patients are placed in the prone crawl position for whole breast irradiation and are treated with 15 x 2,67 Gy (± boost treatment if required as per international guidelines)
10193527|NCT05179148|Experimental|intervention|The arm will receive motivational interviewing
10193528|NCT05179122|Experimental|Surgical drain|In this arm participants a surgical drain (Redon type) will be inserted above the abdominal fascia prior to suture of the subcutaneous tissue and of the skin
10193529|NCT05179122|No Intervention|Control|In this arm the subcutaneous tissue and the skin of the surgical wound will be sutured without insertion of any type of drain
10193530|NCT05179109|Experimental|Robot-assisted laparoscopy|Surgery for deep endometriosis using robot-assisted laparoscopy.
10193531|NCT05179109|Active Comparator|Conventional laparoscopy|Surgery for deep endometriosis using conventional laparoscopy.
10204644|NCT05186207||observation group|those who need clinical intervention before or after pregnancy, the experts shall formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process. And they should be confirmed intrauterine pregnancy within the study period.
10204645|NCT05186207||control group|those who need not clinical intervention before or after pregnancy, pregnancy was prepared under the clinical and health care guidance provided by experts, and intrauterine pregnancy was confirmed within the study period.
10204646|NCT05184192|Experimental|Gabapentin|"This arm will be given the active treatment, oral Letco (gabapentin) gelatin capsules of 300mg each.~Up to the first four weeks will be a titration period (week 1 300mg TID, week 2 600mg TID, week 3 900mg TID, week 4 1,200mg TID) as tolerated. If intolerable adverse reactions occur, the dosage will be decreased to prior tolerable dose (e.g., if 900mg TID is intolerable, dose will be decreased to 600mg TID).~The following eight weeks will be fixed dose, the highest tolerable dose from the titration period.~Up to two weeks will be a taper down tailored to the maximum dose the participant reached during the titration and fixed periods.~A maximum 14 weeks will mark the end of active treatment. Follow-up assessments will be conducted 4 weeks after completion of the taper-down period."
10204647|NCT05184192|Placebo Comparator|Placebo|"Placebo gelatin capsules that look, smell, and taste like gabapentin capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule TID the first week, the second week two capsules TID, the third week three capsules TID, and fourth week four capsules TID as tolerated. If intolerable, the dose will be decreased to prior tolerable dose.~The next eight weeks will be a fixed amount of placebo based on the highest tolerable amount from the titration period.~Subjects will then taper-down placebo to imitate the gabapentin arm for maximum two weeks based on highest dose achieved during study.~4 weeks after completion of taper-down, follow-up assessments will be conducted."
10204648|NCT05181982||Intervention Group|Patients being treated at the FIT hospital (Pfalzklinikum) between January 2020 and December 2023
10204649|NCT05181982||Control group|Patients being treated in standard care (control hospitals) in the German federal state Rheinland-Pfalz
10204650|NCT05181371|Active Comparator|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive programmed intermittent bolus of local anaesthetic: 20mls 0.125% levobupivacaine every two hours.
10204651|NCT05181371|Active Comparator|Ultrasound Guided ESP Block with Continuous Infusion (CI)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive a continuous infusion local anaesthetic: 0.125% levobupivacaine at an infusion rate of 10 ml/hr.
10204652|NCT05181280|Experimental|Intervention|"Treatment: Standardized body image messaging targeting mothers. Following a similar model that has been used in previous studies testing the effect of traditional media exposure on body image and disordered eating behaviour, participants randomized to the treatment condition will have 1 exposure session per day over 5 days. Each exposure session will consist of 15 social media body message posts. Body image messaging targeting mothers will consist of mothers with ideal postpartum bodies and captions trending over the past 24 months."
10204653|NCT05181280|Placebo Comparator|Control|Control: Standardized infant feeding tips messaging. Participants randomized to the control will have 1 exposure session/day over 5 days. Each exposure will consist of 15 social media posts on infant feeding tips.
9707584|NCT04666675|Experimental|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A once daily (QD).
9707585|NCT04666675|Experimental|Upadacitinib Dose B|Participants will receive Upadacitinib Dose B QD.
9707586|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose A|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose A QD.
9979806|NCT01385410|No Intervention|Control|Current standard of care and support (national health system)
10193532|NCT05179096|Experimental|Mindfulness|Participants in the experimental group will undergo an 8-week mindfulness training program with weekly 60-minute group sessions
9707587|NCT04666675|Experimental|Placebo for Upadacitinib Followed by Upadacitinib Dose B|Participants will receive placebo for Upadacitinib followed by Upadacitinib Dose B QD.
9707588|NCT04666701|Experimental|Escócia association|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Escócia association, oral~1 dragee Placebo Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual"
9707589|NCT04666701|Active Comparator|Ketorolac|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 tablet Ketorolac, sublingual~1 tablet Placebo Escócia association, oral~1 dragee Placebo Scopolamine, oral"
9707590|NCT04666701|Active Comparator|Scopolamine|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:~1 dragee Scopolamine, oral~1 tablet Placebo Ketorolac, sublingual~1 tablet Placebo Escócia association, oral"
9707591|NCT04666506||VR as distraction during a medical procedure|Paediatric outpatients undergoing a medical procedure, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a distraction method during a potentially painful or scary procedure (e.g., vaccination, wound care, venipuncture,...).
9707592|NCT04666506||VR as relaxation method during a hospital stay|Paediatric inpatients, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a relaxation method during a potentially stressful hospital stay (e.g., patients with psychosomatic complaints, patients with eating disorders,...).
9707593|NCT04666376|Other|Vitrified ovarian tissue|Ovarian tissue will be vitrified and warmed by Ova kit type M protocol.
9707594|NCT04666623|Active Comparator|intranasal esketamine (56mg)|
9707595|NCT04666623|Placebo Comparator|placebo|
9707596|NCT04666337|Active Comparator|Group B (bupivacaine group)|patients received 20 ml bupivacaine 0.5% plus normal saline (2ml)
9707597|NCT04666337|Active Comparator|Group F (fentanyl group)|patients received 20 ml bupivacaine 0.5% plus fentanyl (100µg-2 ml)
9707598|NCT04666337|Active Comparator|Group T (tramadol group)|patients received 20 ml bupivacaine 0.5% plus tramadol (100mg-2 ml)
9707599|NCT04666480|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
9707600|NCT04666714|Experimental|Praga formulation|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Placebo pregabalin tablet, oral Night: Placebo pregabalin tablet, oral plus Praga formulation,oral"
9707601|NCT04666714|Active Comparator|Pregabalin|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Pregabalin tablet, oral Night: Pregabalin tablet plus, oral placebo Praga formulation, oral"
9707602|NCT04666363|Experimental|Lavender oil|On the first day (before intervention), the intensity of needle insertion-related pain was measured. The experimental group inhaled lavender essence (12 consecutive hemodialysis seasons).
9707603|NCT04666363|No Intervention|Control group|The patients will not smell lavender oil.
9707604|NCT04666415|Experimental|Osteopathic treatment + as-usual treatment|"Osteopathic treatment: a protocol of 5 sessions of osteopathic treatment that have a 25 minutes duration and are spaced of around one week between two sessions.~As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers."
9707605|NCT04666415|No Intervention|As-usual treatment|As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers.
9707606|NCT04666324|Active Comparator|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
9707607|NCT04666324|Experimental|Multilac Baby|Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
9707608|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 500 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 500 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
9707609|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 750 IU/m ² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 750 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)
9707610|NCT04666649|Experimental|Cohort 400mg of Venetoclax, 1000 IU/m² of Pegcrisantaspase|The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m² of Pegcrisantaspase in an IV every 14 days ( per cycle)
9707611|NCT04666649|Experimental|Cohort 600mg Venetoclax, 1000 IU/m ² of Pegcrisantaspase|The subject will take 600mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m ² of Pegcrisantaspase in an IV every 14 days ( Per cycle)
9785163|NCT01244503|Experimental|Sodium Octanoate Breath Test|Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.
9979807|NCT01385423|Experimental|IL-15 Patients with AML|Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)
10193533|NCT05179096|No Intervention|Control|The control group will follow routine daily school activities
10193534|NCT05179083|Experimental|High-impact Exercise|
10193535|NCT05179083|Active Comparator|Low-impact Exercise|
9707612|NCT04666493|Experimental|Facing Your Fears - Open label|All participants in the study will receive 12 weekly sessions of Facing Your Fears intervention, each lasting approximately 1 to 1.5 hour. Each session involves a component with all the parents and children (30-45 minutes) and a separate time with all the parents only (30-45 minutes). Additionally, there will be two check-in calls (30 minutes each) with the families after weeks 7 and 9 of the program.
9707613|NCT04666220||Renal cell carcinoma (RCC)|"For all series, clinical and epidemiological features will be recorded, all available histological slides will be reviewed and, on the primary tumor slides, histological characteristics will be re-assessed.~Whenever multiple samples of tumors would be present, those having the tumor-surrounding tissue interface will be selected and stained with CD34 antibody.~VETC will be evaluated independently by, at least, two pathologists, blinded to clinical data. VETC will be recorded as positive or negative, being VETC defined as CD34 unequivocal immunoreactivity of a continuous lining of endothelial cells around tumor clusters. VETC will be considered alternative to the common capillary pattern, consisting in small circular or linear blood vessels."
9707614|NCT04666220||Adrenal carcinoma|see (RCC)
10193536|NCT05179070|Experimental|UpTitration|the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively
9707615|NCT04666233|Experimental|Resuscitation with PPE for prevention of SARS-Cov-2 infection|
9707616|NCT04666233|Active Comparator|Resuscitation without PPE for prevention of SARS-Cov-2 infection|
9707617|NCT04666051|Experimental|Fibrin glue|A fibrin glue was applied to the lymphadenectomy bed before wound closure and insertion of a drain.
9707618|NCT04666051|No Intervention|Control|Lymphadenctomy wound was closed after insertion of a drain,
9707619|NCT04666142|Active Comparator|Individual Characteristics of the Individuals in the Experimental and Control Groups|The personal characteristics of the individuals included in the study were examined.
9707620|NCT04666142|Active Comparator|Disease Characteristics of the Individuals in Experimental and Control Groups|The intensive care experience of the individuals included in the study, their status of receiving respiratory support, and the reason for staying in the intensive care unit were explained.
9707621|NCT04666142|Active Comparator|Distribution of Findings Regarding Sleep Activity of the Individuals in Both Groups|The personal characteristics of the individuals in the experimental and control groups regarding sleep were examined.
9707622|NCT04666142|Active Comparator|Comparison of the Individuals in the experimental and control groups after 24 hours of sleep|The effect of light after 24 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
9707623|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 24 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 24 hours after their admission to the ICU.
9707624|NCT04666142|Active Comparator|Comparison of the Sleep Times of the Individuals in Both Groups 48 Hours After Intensive Care|The effect of light after 48 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
9707625|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 48 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 48 hours after their admission to the ICU.
9707626|NCT04666142|Active Comparator|Distribution of Total Sleep Times of the Individuals in the Experimental and Control Groups|The sleep times of the individuals in both groups were compared
9707627|NCT04666155|Experimental|Intermittent Colon Exoperistalsis|ICE Treatment with Mowoot device. 20min dayly for 12 weeks
9707628|NCT04666155|Active Comparator|Standard-of-Care|Standard-of-care for chronic constipation for 12 weeks.
9707629|NCT04665869|Experimental|Combined balance and brisk walking training|Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session 2. Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session 3. Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)
9707630|NCT04665869|Active Comparator|Flexibility and strengthening exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~Participants practice own flexibility and strengthening exercise 2-3 times/week (to aim at 150 min of exercise per week)"
9707631|NCT04666168|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
9707632|NCT04666090|Experimental|Carillizumab|"Preoperative neoadjuvant therapy for 2-3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.~Carillizumab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death."
9707633|NCT04665908|Other|PT-led triage|Patients are assessed by PT
9707634|NCT04665908|Other|Standard care|The patiens are assessed by a orthopedic surgeon
9785164|NCT01244516|Other|galyfilcon A|Subjects that were randomized to receive the galyfilcon A lens with a base curve of 8.30 throughout the entire course of the study.
10193537|NCT05179070|Active Comparator|Control|And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
9785165|NCT01244516|Other|lotrafilcon B|Subjects that were randomized to wear lotrafilcon B lens throughout the course of the study.
9979808|NCT01385436||HPV HSIL cervical carcinoma|
9979809|NCT01385449|Experimental|interscalene block|interscalene block
10193538|NCT05179044|Experimental|Guardian knee brace group|Patients undergoing elective Total knee arthroplasty (TKA) by surgeons from NYU Langone with the presence of a pre-operative knee flexion contracture greater than 5 degrees and willingness to participate in our institution's outpatient rehabilitation and physical therapy. Those randomized to this group will be fitted with a Guardian Rehabilitator Brace.
9979810|NCT01385449|Experimental|interscalene catheter|interscalene catheter
9979811|NCT01385475|Experimental|Control|
9707635|NCT04666025||Observational (biospecimen collection, medical chart review)|"DONORS: Prior to HCT, sibling donors (MRD and haplo) undergo a nasopharyngeal swab per standard of care for SARS-Cov-2 testing. For MUD donors, initial testing may consist of a questionnaire. All donors undergo collection of blood and saliva at the time of granulocyte-colony stimulating factor (G-CSF). Donors' medical charts are also reviewed.~RECIPIENTS: Patients undergo a nasopharyngeal swab for SARS-Cov-2 testing at 30, 60, 90, 120 days post-HCT, and afterwards as deemed necessary by the treating physician. Patients also undergo the collection of blood and saliva specimens at days 30, 60, 90, 120, 150, and 180 post-HCT. Recipients' medical charts are also reviewed."
9707636|NCT04665895|Experimental|Test Product|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
9707637|NCT04665895|Active Comparator|Reference Product|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
9707638|NCT04665895|Placebo Comparator|Placebo|Placebo
10193539|NCT05179044|No Intervention|No Guardian brace used group|Patients undergoing elective Total knee arthroplasty (TKA) by surgeons from NYU Langone with the presence of a pre-operative knee flexion contracture greater than 5 degrees and willingness to participate in our institution's outpatient rehabilitation and physical therapy as part of standard of care.
10193540|NCT05179018||SLE patients group|The study will include 50 patients suffering from SLE, all patients with SLE should fulfill 2012 SLICC criteria
9707639|NCT04666012|Experimental|Group 1: low dose|Subject will receive single dose of AdCLD-CoV19(2.5x10^10VP) as intramuscular injection.
9707640|NCT04666012|Experimental|Group 2: middle dose|Subject will receive single dose of AdCLD-CoV19(5.0x10^10VP) as intramuscular injection.
9707641|NCT04666012|Experimental|Group 3: high dose|Subject will receive single dose of AdCLD-CoV19(1.0x10^11VP) as intramuscular injection.
9707642|NCT04666012|Experimental|Group 4: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
9707643|NCT04666012|Experimental|Group 5: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
9707644|NCT04665986|Experimental|NHP|Navelbine, Herceptin, Pertuzumab
9707645|NCT04665986|Active Comparator|THP|Docetaxel, Herceptin, Pertuzumab
9707646|NCT04666194|Active Comparator|Cold forceps|4-6mm polyps were removed with cold forceps
10193541|NCT05179018||Healthy control group|Control group of 40 healthy volunteers with age and gender-matched with SLE patients.
10193542|NCT05179005||RibFix Advantage|Underwent surgical stabilization of rib fractures
10193543|NCT05178992|Experimental|Socially Assistive Robot Activity|Participants will attend two sessions per week and interact with the robot. Four weeks with a humanoid robot and four weeks with a dog robot. Participants can continue to join other activities held within the facility.
10193544|NCT05178992|Active Comparator|Usual Activity Program|Participants will attend at least two sessions per week at activities held within the facility. They will not be exposed to the robot activities.
10193545|NCT05178979|Experimental|Intervention|The intervention arm will receive up to 4 sessions of training. Trained intervention facilitator experienced in health professional trainings will lead the training. The intervention content delivered is aimed to increase HIV providers' knowledge, motivation, skills, and empathy to: 1) equitably deliver ART program guidelines (i.e., quality of care) and 2) provide gender sensitive counseling to address ART patients' gendered barriers to HIV care engagement, increasing patient satisfaction, retention, and ART adherence, and reducing gender disparities in HIV outcomes.
10193546|NCT05178979|No Intervention|Control|The control arm will receive no training.
10193547|NCT05178966|Experimental|Bp OneDay programm|The BP One-Day program is based on a single day of psychoeducation .
10193548|NCT05178966|No Intervention|Waiting List|Patients assigned in control group will be placed in waiting list and will benefit from the program after their participation to this study. During study participation, they will receive treatment as usual.
10193549|NCT05178953|Experimental|pentoxifylline group|"Group 1: Patients receiving pentoxifylline (TRENTAL 400 mg tablets, OSPS; 400 mg, twice daily) Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients.~These volunteers receive two pentoxifylline tablets(400 mg) daily for 3 month, (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)~Other names:~Trental"
10193550|NCT05178953|Experimental|Zinc Sulfate group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate tablet(229 mg) daily for 3 month,(Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
10193551|NCT05178953|Experimental|pentoxifylline+ zinc group|"Infertile men referred to an infertility treatment center who have had unprotected sex for at least one year have not had normal fertility in their partner. These men are all married. According to WHO criteria, sperm motility abnormalities are observed in these patients. Candidates receive one zinc sulfate(220mg) tablet+ two pentoxifylline tablets(400 mg) daily for 3 month (TRENTAL 400 mg modified release tablets, OSPS; 400 mg +Zinc Sulfate 220mg Capsules)~Other Names:~zinc sulfate"
10193552|NCT05178914|Experimental|The interventional group|"Patients are defined by the disclosure of the IMR value. The pre-PCI IMR is used to guide therapy.~For patients with pre-PCI IMR ≥ 25 will benefit from intensified coronary artery disease treatment to manage the microcirculatory damage according to the recommendations and consensus of European experts.~For patients with a pre-PCI IMR < 25 will benefit from de-escalade therapeutic adaptation."
10193553|NCT05178914|Sham Comparator|The control group|The control group is defined as follows: the pre-PCI IMR has been performed but its result is not undisclosed (sham procedure) ; patients will receive standard medical treatment according to the physician's preference.
10193554|NCT05178875||NDNS participants|Random participants from all the UK (including England, Scotland, Wales and North Ireland)
10193555|NCT05178862|Experimental|IV echinocandin followed by oral ibrexafungerp (SCY-078)|
10193556|NCT05178862|Active Comparator|IV echinocandin followed by oral fluconazole|
9707647|NCT04666194|Active Comparator|Cold snare|4-6mm polyps were removed with cold snare
9707648|NCT04666194|Active Comparator|Hot snare|4-6mm polyps were removed with hot snare
9707649|NCT04666103|Experimental|Thyroid lobectomy with intraoperative thermal ablation|"Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection. After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
9707650|NCT04666103|No Intervention|Thyroid lobectomy|Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection.
9707651|NCT04666077|Experimental|Home-based MT through Supervised, Supported Singing (H3S)|Treatment arm 1
10193557|NCT05178836|Experimental|F520+F007|"Treatment period：~F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 14-day cycle for 8 cycles.~F520 (200mg) administered intravenously (IV) on Day 2 of each 14-day cycle for cycle 1.~F520 (200mg) administered intravenously (IV) on Day 1 of each 14-day cycle for cycle 2 to 8.~Maintenance period：~F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 56-day cycle for 10 cycles.~F520 (200mg) administered intravenously (IV) on Day 1/15/29/43 of each 56-day cycle for 10 cycles."
9707652|NCT04666077|Experimental|H3S and IMT|Treatment arm 2 received both Home-based Supervised, Supported Singing (H3S) and Individualized Music Therapy (IMT)
9707653|NCT04666077|Placebo Comparator|Attention Control (AtCon)|Comparison condition with comparable attention
9707654|NCT04666116|No Intervention|COVID-19 patients no dietary administration|Only medication agreed by the hospital committee
9707655|NCT04666116|Experimental|COVID-19 patients with dietary administration|Medication agreed by the hospital committee and nutritional supplement.
9707656|NCT04665882|Experimental|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
9707657|NCT04665882|No Intervention|Standard axillary lymph node dissection|Standard axillary lymph node dissection was performed with complete resection of Berg's levels I and II.
9707658|NCT04665830|Active Comparator|Group 1|Evolocumab group, patients who are receiving this therapy for 12 months.
9707659|NCT04665830|Placebo Comparator|Group 2|The Statin group includes patients who are maintained on statin therapy.
9707660|NCT04665804|Experimental|Experimental Group A (Creatine Supplementation)|
9707661|NCT04665804|Experimental|Experimental Group B (Glucosamine and Chondroitin sulfate Supplementation)|
9707662|NCT04665791|Experimental|Challenge|Challenge participants will be inoculated intranasally with reconstituted, previously lyophilised Neisseria lactamica (LyoNlac). The initial dose will be 10^5 colony forming units and will be escalated to a maximum of 10^7 colony forming units to find the dose which successfully colonises at least 70% of volunteers.
9707663|NCT04665674||Pulmonary Langerhans cell histiocytosis (PLCH)|All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses
9707664|NCT04665661|Experimental|High-intensity aerobic training (HIAT)|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
9707665|NCT04665661|Active Comparator|Wait-list control (WLC)|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
9707666|NCT04665583||Prehabilitation|All study patients will receive preoperative optimization with a standardized prehabilitation protocol prior to any intervention.
9707667|NCT04665531|Experimental|Group A - Erector Spinae Catheter group|"Patients in the experimental group will receive the erector spinae catheter prior the surgery and will be administered local anesthetics for 48 hours post-operatively.~Anesthetic regimen: initial bolus of 20ml 0.5% levobupivacaine before the end of surgery. Then continually ropivacaine 0,2% 5ml/h with intermittent boluses 15ml ropivacaine 0,2% every 4h.~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
10193558|NCT05178810|Experimental|FAB122|
10193559|NCT05178810|Placebo Comparator|Placebo|
10193560|NCT05178758|Experimental|Virtual Reality (VR) Rehabilitation Training|Patients in the VR group will receive VR rehabilitation training in the hospital. The content of the training is the same as the control group. The only difference is that participants in the intervention group will use VR as a training platform. The VR system will include the training materials and tasks required for the patients to perform in the 3D environment. Demographic, clinical data and treatment costs will be collected before and after the rehabilitation training.
9707668|NCT04665531|Active Comparator|Group B - Intercostal block|"Patients will receive standard treatment, i.e. the multi-level intercostal block administered at the end of the surgery by the surgeon. They will receive 20ml 0,5% levobupivacaine on 6 levels of the thoracic wall according to the operative wound level.~Both groups will receive multimodal analgetic treatment consisting of a patient-controlled (PCA) pump with opioid analgetics and a peripherally acting analgetic metamizol on a regular basis. The PCA pump will be set to intermittent boluses of 3mg piritramide with a lock-out time 15 min and a maximal number of 6 boluses /3 hours. Patients will receive metamizol 2,5g/12hours i.v. on the day of surgery and 500-1000mg / 6 hours orally on the first and second post-operative day."
9707669|NCT04665765|Experimental|Treatment (PolaR-ICE)|"SALVAGE THERAPY: Patients receive polatuzumab vedotin IV on day 1, rituximab IV on day 1, etoposide IV on days 1-3, carboplatin IV on day 2, and ifosfamide IV on day 2 or days 1-3. Treatment repeats every 21 days for up to 2-3 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response or stable disease by C2D15 may receive 1 additional cycle of PolaR-ICE IV.~CONSOLIDATION THERAPY: Within 30-60 days after ASCT, patients receive polatuzumab vedotin IV on day 1. Treatment repeats every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity."
9785166|NCT01244516|Other|comfilcon A|Subjects that were randomized to wear comfilcon A lens throughout the course of the study.
9707670|NCT04665505|Experimental|ICU Staff|The study group is composed of ICU care providers at the Ottawa Hospital Civic campus and the Montfort Hospital, including intensivists, fellows, nurses and allied health professionals. The study site participant breakdown is approximately 58 TOH staff respondents and 15 Montfort respondents.
9707671|NCT04665778||high risk of hospitalization|
9707672|NCT04665778||not high risk of hospitalization|
9707673|NCT04665609|Experimental|Anlotinib and TQB2450 solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Oral anlotinib (12 mg/d) will be administered and its cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks. The treatment continues until disease progression or treatment intolerance. Anlotinib and TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
9707674|NCT04665609|Active Comparator|TQB2450 Solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks.TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
9707675|NCT04665466||Group A|QFR≤0.80 vessels with PCI strategy and low PPG index
10193561|NCT05178758|No Intervention|Control - Conventional Rehabilitation Training|Patients in the control group will receive conventional rehabilitation training currently provided in the hospital. An instructor will assign each participant for training. Demographic, clinical data, and treatment costs will be collected before and after completing the rehabilitation training
10193562|NCT05178745||Cohort 1|Patients with metastatic colorectal cancer and liver metastases treated with FOLFIRI plus aflibercept after failure of an oxaliplatin-based regimen
9707676|NCT04665466||Group B|QFR≤0.80 vessels with PCI strategy and high PPG index
9707677|NCT04665466||Group C|QFR≤0.80 vessels with conservative strategy
9707678|NCT04665635|Active Comparator|Rectosigmoid resection|
9707679|NCT04665635|Active Comparator|Rectosigmoid seromuscular tumor shaving|
9707680|NCT04665544|Experimental|Early-stage endometrial cancer patients|"Histologically proven endometrial cancer (any tumour type).~Apparent early-stage endometrial cancer with intermediate or high risk prognostic factors (deep myometrial invasion or G2/G3 disease or non- endometrioid histological type), no evidence of bulky or suspicious pelvic/para-aortic lymph nodes or distant metastases on preoperative conventional imaging studies; minimum requirement for clinical staging includes expert US or pelvic MRI for local staging and abdominal US or abdominal CT scan or PET CT for distant staging.~Performance status ECOG: 0-1.~Age ≥18, ≤85.~History of second primary cancer only if more than 5 years with no evidence of disease.~Approved and signed informed consent"
9707681|NCT04665453|Experimental|Melatonin peroral|0,1mg/kg melatonin will be given in the form of a syrup to the participant before EEG and vital functions monitoring
9707682|NCT04665453|Experimental|Dexmedetomidine intranasally|3 mcg/kg of dexmedetomidine in the form of a nasal spray will be given to the participant before EEG and vital functions monitoring
9707683|NCT04665453|Experimental|Dexmedetomidine sublingually|3 mcg/kg of dexmedetomidine will be given to the participant sublingually before EEG and vital functions monitoring
9707684|NCT04665492||SCI with CNP|People with subacute spinal cord injury and no chronic pain
9707685|NCT04665492||SCI no CNP|People with subacute spinal cord injury with central neuropathic pain
9707686|NCT04665492||Able bodied|Able bodied people with no chronic pain
9707687|NCT04665375|Experimental|DOR/3TC/TDF|100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)
9707688|NCT04665518|Experimental|Acupressure group|The following applications will be made 10 minutes before the patients in the acupressure group. Hands are washed before applying acupressure. Before acupressure is applied, the patient is allowed to sit in a comfortable position on the sofa in the single blood collection room. Before starting the acupressure application, the arm is rubbed from fingertips to the elbow to relax, and press the acupressure points (Large Intestine Meridian 4th Point [LI 4], Large Intestine Meridian 11th Point [LI 11], and Heart Meridian 7th Point [HT 7]). application is carried out. 2 minutes to each acupressure point. pressure (3 to 5 kg of pressure) is applied. Only one acupressure session is given to each patient, and each acupressure session lasts 10 minutes. Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
9707689|NCT04665518|No Intervention|Control group|Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
9707690|NCT04665427|Other|Patient in whom a bilioenteric anastomosis is performed for any etiology.|Patient in whom a bilioenteric anastomosis is performed for any etiology..
9707691|NCT04665323||People living with FOP|
9707692|NCT04665323||Parent or legal guardian primary caregivers|
9707693|NCT04665323||Parent or legal guardian|
9707694|NCT04665323||Siblings|
9707695|NCT04665297|Experimental|Intervention arm|Subjects from intervention clusters will receive the GMCD intervention, delivered in monthly visits to the home by frontline health workers, for 24 months. 0-12 months represents the primary effectiveness study, and 12-24 months a secondary maintenance study.
9707696|NCT04665297|No Intervention|Control Arm|Subjects in control clusters will continue to receive usual care from their frontline health workers. After 12 months (primary effectiveness study) control will cross into the intervention for months 12-24.
9707697|NCT04665362|Experimental|M1-c6v1 combined with SHR-1210 and Apatinib|Single-arm
9707698|NCT04665648|Experimental|Treatment arm|Patients who received intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
9707699|NCT04665648|Placebo Comparator|Placebo arm|Patients who received intravenous placebo before and after reperfusion with primary primary percutaneous coronary intervention
10193563|NCT05178732|Experimental|Protein and early|Ingestion of 20g of protein during early phase of the menstrual cycle.
10193564|NCT05178732|Experimental|Protein and late|Ingestion of 20g of protein during late phase of the menstrual cycle.
10193565|NCT05178732|Experimental|Protein-polyphenol and early|Ingestion of 6g of a blend of protein and polyphenol during the early phase of the menstrual cycle.
10193566|NCT05178732|Experimental|Protein-polyphenol and late|Ingestion of 6g of a blend of protein and polyphenol during the late phase of the menstrual cycle.
9707700|NCT04665349|Experimental|Pre-op|Nutricia Pre-op, 400 milliliters, per os
9707701|NCT04665349|No Intervention|Control|No intervention
9707702|NCT04665401|Active Comparator|Standard MERIT|24 sessions of Metacognition Reflection and Insight Therapy
9707703|NCT04665401|Experimental|Tailored MERIT|24 sessions of personalized Metacognition Reflection and Insight Therapy (sessions personalized using real-world interactions)
9707704|NCT04665219|Active Comparator|Control group|Only receive a standard message.
10193567|NCT05178719|Experimental|PMA-zeolite|All subjects receive the substance 3 times per day in a measuring spoon as powder
10193568|NCT05178693|Experimental|Treatment|
10193569|NCT05178680|Experimental|relaxation session combining music and soft light|
10193570|NCT05178680|No Intervention|usual rest session|
10193571|NCT05178667|Experimental|High dose|4 capsules with 1.6g of active product per day: 2 at breakfast and 2 at dinner
10193572|NCT05178667|Active Comparator|Low dose|4 capsules with 0.8g of active product per day: 2 at breakfast and 2 at dinner
10193573|NCT05178667|Placebo Comparator|Placebo|4 placebo capsules (maltodextrin) per day: 2 at breakfast and 2 at dinner
10193574|NCT05178641|Experimental|Ninjamas Pyjama Pant, Then Participant's Overnight Current Standard of Care|For the first 3 weeks participants use Ninjamas Pyjama Pants, then for the next 3 weeks they switch to the Overnight Current Standard of Care.
10193575|NCT05178641|Experimental|Participant's Overnight Current Standard of Care, Then Ninjamas Pyjama Pant|For the first 3 weeks participants use their Overnight Current Standard of Care, then for the next 3 weeks they switch to Ninjamas Pyjama Pants.
10193576|NCT05178615|Experimental|Education group|Preoperative education
9707705|NCT04665219|Experimental|Test group|Receive HBM-based messages.
9707706|NCT04665232||Patients affected by autoimmune diseases|Infertile patients suffering from autoimmune diseases to be subjected to IVF in which the luteal phase has been supplemented with 25 mg /die of aqueous subcutaneous progesterone
9707707|NCT04665102||No pathology|
9707708|NCT04665102||Pathology|
9707709|NCT04665141||Standard of care|Patients with severe asthma being treated with non-biological standard therapies, mainly systemic corticosteroids.
10193577|NCT05178615|No Intervention|control|Traditionally care
9707710|NCT04665141||Biological therapies|Patients with severe asthma being treated with omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab.
9707711|NCT04665440|Other|Voice only then distraction|First intervention: mother's voice without tactile stimuli Second intervention: mother's voice with tactile stimuli
9707712|NCT04665440|Other|Distraction then voice only|First intervention: mother's voice with tactile stimuli Second intervention: mother's voice without tactile stimuli
9707713|NCT04665063|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
9707714|NCT04665076|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
9707715|NCT04665050|Experimental|pPCV|Participants receive a single dose of pPCV on Day 1.
9707716|NCT04665050|Active Comparator|PNEUMOVAX™23|Participants receive a single dose of PNEUMOVAX™23 on Day 1.
9707717|NCT04665180|Experimental|Primary knee arthroplasty|Questionnaires
9707718|NCT04665167|Active Comparator|Body image exposure|Guided non-judgmental exposure, 40 minutes total
10193578|NCT05178602|Experimental|The experimental group|Routine treatment, and tai Chi exercise,5 times a week
10193579|NCT05178602|No Intervention|The control group|Routine treatment, and cardiac rehabilitation is not mandatory
9979812|NCT01385488|Experimental|self-monitoring|participants will use bioelectrical impedance to self-monitor arm volume at home
9707719|NCT04665167|Active Comparator|Self-compassion|8 Short self-compassion meditations, 40 minutes total
9707720|NCT04665193|Experimental|Abbott Panbio test device|WestJet passengers departing from YVR screened for COVID-19 using Abbott Panbio test device
9979813|NCT01385488|No Intervention|completion of forms|participants will complete self-report forms
9707721|NCT04665011||Clinically stable adults, including heart failure patients visiting an outpatient clinic|Observational to compare simultaneous pulse tracings from PPG and non-invasive blood pressure monitors in capturing the pulse responses to a Valsalva maneuver.
9707722|NCT04665284|Experimental|Empagliflozin|
9979814|NCT01385501|No Intervention|routine care|
9979815|NCT01385501|Experimental|Educational intervention group|
9979816|NCT01385514||company A-Training Base No.1|
9707723|NCT04665284|Active Comparator|Usual Care Group|
9707724|NCT04665271|Experimental|Immediate Treatment - Zemedy App|Participants will be given immediate access to the Zemedy app for IBS.
9707725|NCT04665271|Active Comparator|Active Control - Education and Relaxation Training App|Participants will be given access to a education and relaxation training app. After 8 weeks they will then be crossed over to the Zemedy app.
9979817|NCT01385514||company A-Training Base No.2|
9979818|NCT01385514||company A-Training Base No.3|
9979819|NCT01385527|Experimental|Weekly Internet survey w medication|Weekly survey via email plus topical triamcinolone
9979820|NCT01385527|Active Comparator|Topical triamcinolone only|Standard of care
9979821|NCT01385540||Task-based fMRI|
9979822|NCT01385553|Active Comparator|Individual Drug Counseling|
9979823|NCT01385553|Experimental|Fathers for Change|
9979824|NCT01385605||female patients|ICSI treatment because of male subfertility
9979825|NCT01385618||high responder|females with >15 follicles or E2>3000 after treatment with gonadotropins
9979826|NCT01385618||low responder|patients with <3 follicles or no response to treatment with gonadotropins
9979827|NCT01385618||control|females with an indication for treatment because of male subfertility
10193580|NCT05178563|Experimental|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
10193581|NCT05178563|Sham Comparator|; IPT+Placebo|This experimental arm consist of performing IPT in randomly assigning patients to receive sham use of photodynamic therapy(PDT).
10193582|NCT05178524|Experimental|Bifico Group|Continued administration during perioperative period
10193583|NCT05178524|No Intervention|Control Group|No intervention
10193584|NCT05178511|Experimental|hydrochloric acid ensartinib|Ensatinib 225mg daily, QD, until progression or intolerance
9707728|NCT04665310|Active Comparator|Group 1 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
9707729|NCT04665310|Active Comparator|Group 1 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
9707730|NCT04665310|Active Comparator|Group 1 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
9707731|NCT04665310|Active Comparator|Group 2 - Low-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 2 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 8-10 mg/mL Month 1 to Month 3: 6-8 mg/mL"
9707732|NCT04665310|Active Comparator|Group 2 - Moderate-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 3 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 10-12 mg/mL Month 1 to Month 3: 8-10 mg/mL"
10193585|NCT05178498||Observational (physical exam, questionnaire)|Patients complete physical measurements every 6 months and complete questionnaires annually for 5 years. Patients are followed up annually in years 5-10.
10193586|NCT05178420|Experimental|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
10193587|NCT05178420|No Intervention|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
9707733|NCT04665310|Active Comparator|Group 2 - High-Intensity|"All patients will receive standard induction immunosuppression according to institution protocol. TAC will be started when clinically appropriate according to institution protocol.~TAC dosing will be 4 mg twice daily to be reduced by 20% after week 1 and start Envarsus XR once daily.~Target Tacrolimus Trough Concentrations:~Week 0 to Week 4: 12-14 mg/mL Month 1 to Month 3: 10-12 mg/mL"
9707734|NCT04664920||Intervention|Exergame intervention arm.
9707735|NCT04664803|Experimental|Cefecin Tab.|Cefecin Tab./Placebo to Omnicef Cap.
9707736|NCT04664803|Active Comparator|Omnicef Cap.|Omnicef Cap./Placebo to Cefecin Tab.
9707737|NCT04664673|Experimental|HABIT-ILE|HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks adapted for adults stroke survivors
9707738|NCT04664673|Active Comparator|Regular care|Usual customary treatment for adults stroke survivors during two weeks
9707739|NCT04664660||Patients with previous histologic diagnosis of endometriosis|
9707740|NCT04664660||Patient without endometriosis|
9707741|NCT04664725|Experimental|SHR3680+ Repaglinide, Bupropion|"Experimental: Repaglinide, Bupropion and SHR3680~Repaglinide and Bupropion QD on Day 1 and Day 21, SHR3680 240 mg once daily (QD) from Study Day 6 - 26"
9779198|NCT01124734|Experimental|Course 1 Cycle 1 and Cycle 2|"Course 1 Cycle 1: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.~Course 1 Cycle 2: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days."
10193588|NCT05178407|Experimental|Multiple micronutrient-fortified bouillon cube|"10-gram shrimp-flavoured bouillon cube, fortified with 6 micronutrients~Enrolled participants will receive a household bouillon ration for use in daily cooking (ad lib). Bouillon rations will be replenished every 2 weeks for the study duration of 38 weeks (non-pregnant, non-lactating women 15-49 y and children 2-5 y) or 12 weeks (lactating women 15-49 y and 4-18 mo postpartum)."
10193589|NCT05178407|Placebo Comparator|Control bouillon cube (iodine only)|"10-gram shrimp-flavoured bouillon cube, fortified with iodine~Enrolled participants will receive a household bouillon ration for use in daily cooking (ad lib). Bouillon rations will be replenished every 2 weeks for the study duration of 38 weeks (non-pregnant, non-lactating women 15-49 y and children 2-5 y) or 12 weeks (lactating women 15-49 y and 4-18 mo postpartum)."
10193590|NCT05178394|Experimental|Male recreational weightlifters|
10193591|NCT05178381|Experimental|Target: frontal pole; Order: frontal pole first|In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the frontal pole stimulation in the first TMS session and vertex stimulation in the second TMS session.
10193592|NCT05178381|Experimental|Target: frontal pole; Order: vertex first|In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the vertex stimulation in the first TMS session and frontal pole stimulation in the second TMS session.
10193593|NCT05178381|Experimental|Target: IFG; Order: IFG first|In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive IFG stimulation in the first TMS session and vertex stimulation in the second TMS session.
10193594|NCT05178381|Experimental|Target: IFG; Order: vertex first|In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive vertex stimulation in the first TMS session and IFG stimulation in the second TMS session.
10193595|NCT05178368||Early aortic valve replacement|Asymptomatic severe aortic stenosis patients randomised to early aortic valve replacement
9779199|NCT01124786|Experimental|CO-1.01|
9779200|NCT01124786|Active Comparator|gemcitabine|
9707742|NCT04664751||Patients scheduled for general surgery with anesthesia|Patients scheduled for general surgery with anesthesia, receiving Nil-per-Oral order.
9707743|NCT04664829|Experimental|Bexarotene and Capecitabine|
9707744|NCT04664699|Other|Plethysmographic Variability Index group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the PVI group
9707745|NCT04664699|Other|Standard monitoring group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the standard monitoring group
9707746|NCT04664764|Active Comparator|degludec arm|Group A received insulin degludec,
9707747|NCT04664764|Active Comparator|glargine arm|group B received insulin glargine
9707748|NCT04664764|Active Comparator|NPH group|Group C received NPH insulin
9707749|NCT04664907|Experimental|Patients suffering from post traumatic stress disorder|
9707750|NCT04664686|Active Comparator|AF catheter ablation|
10193596|NCT05178368||Standard care|Asymptomatic severe aortic stenosis patients randomised to 'watchful waiting' until symptom onset.
9707751|NCT04664686|Active Comparator|AV node ablation|
9707752|NCT04664712|Active Comparator|shock wave|
9707753|NCT04664712|Active Comparator|shock wave and tendon supplement|
9707754|NCT04664790|Active Comparator|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week.
9707755|NCT04664790|Active Comparator|Cognitive training|Neuropsychologist guided cognitive training.
9707756|NCT04664374||Mood Disorder|Based on screening questions administered on-line as part of the enrollment process, participants will be divided into two groups: (i) those who screen positive for a history of mood disorders and (ii) all other participants. All outcome measures apply only to the mood disorder group.
9707757|NCT04664374||Other|see above
9707758|NCT04664504|Active Comparator|Group CRT|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
9707759|NCT04664504|Experimental|Group SCRT|Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
9707760|NCT04664504|Experimental|Group es-SCRT|Local dose increase of Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
9707761|NCT04664647||Patients with CCPD|"Inclusion criteria：~Criteria for central nervous system involvement: T2 high-signal intensity lesions in the brain, or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities.~Criteria for peripheral nervous system involvement: conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS). In the present study, it was compulsory for at least two nerves between the median, ulnar, tibial and peroneal nerves to have abnormal findings indicating demyelination.~Exclusion criterion:~Secondary demyelinating diseases or changes."
9707762|NCT04664439|Experimental|CT-FFR|The CCTA images of the patients in this group will be analyzed and the FFR values of the lesions will be measured using the indicated software. ICA will be determined according to the value of CTFFR.
9707763|NCT04664439|No Intervention|direct ICA|The patients will be submitted to undergoing ICA procedure according to the decision of the investigators.
9707764|NCT04664296||Children|Hospitalized children, 0 to 17 years of age, 25 subjects, consecutive sample survey
9707765|NCT04664296||Adults|Hospitalized adults, 18 years and above, 50 matched subjects
9707766|NCT04664426||Renal transplant recipients|Renal transplant recipients will undergo examination according to the amTCNS, QST (thermal threshold testing), and NCS (amplitude, velocity and distal latency of measurements at the sural sensory nerve, ulnar sensory nerve, peroneal motor nerve, tibial motor nerve and ulnar motor nerve, soleus H reflex will be measured).
10193597|NCT05178303|Experimental|Cirrhosis|Experimental benefits in resistance to cirrhosis were observed in all patients who had previously received certain components of the treatment for cirrhosis SB-1121(1) for various therapeutic purposes.
9707767|NCT04664595|Sham Comparator|Group SP|The Supreme™ group
9707768|NCT04664595|Active Comparator|Group PS|The ProSeal™ group
9707769|NCT04664595|Active Comparator|Group IG|The I-gel™ group
9707770|NCT04664595|Active Comparator|Group LT|The Laryngeal Tube Suction IITM group
9707771|NCT04664569||Cohort of bacterial meningitis in children|
9707772|NCT04665024|Active Comparator|Group 1|"G1 included patients undergoing planned surgery who performed chest physiotherapy at home in two weeks period before the surgical operation pre and postoperative chest physiotherapy was performed in G1.~The chest physiotherapy included the following steps~Snipping through the nose several times, then breathe out through the mouth~Taking a deep breath through the nose, hold the air in, push it down in the stomach, than back to the chest, and in the end breath out through the mouth~Put both hands on the shoulders. Lift the elbows to the sides and take a deep breath through the nose, then lower them, breathe out through the mouth. This procedure was done for the other side as well.~Put both hands on your hips. Lift your right arm to the side, turn backwards with it and take a deep breath through the nose, then turn back, put your hand back to the hip and breathe out through the mouth.This procedure was done for the other side as well"
9707773|NCT04665024|Active Comparator|Group 2|"G2 included patients who patients undergoing planned surgery but did not perform preoperative chest physiotherapy at home.only postoperative chest physiotherapy made in G2.~The patient was seen on the first day after surgery in the intensive care unit and was asked if he had performed breathing exercises at home before surgery and then re-evaluation of both groups with respect to respiratory functions and oxygen saturation values from the first day until the seventh after surgery. Also, a daily chest physical therapy program was introduced in accordance with the hospital's policy until the patient's discharge.~Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy mentioned above but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.~The exercises were repeated 10 times and performed 3-4 times per day."
9707774|NCT04664842|Experimental|Manual Therapy Group|
9707775|NCT04664842|Sham Comparator|Manual Control Group|
9707776|NCT04664842|Experimental|Breathing Training Group|
9707777|NCT04664842|Sham Comparator|General Exercise Control Group|
9707778|NCT04664842|Experimental|Manual Therapy Combined Breathing Training Group|
9707779|NCT04664556||Cohort of invasive pneumococcal disease in children|
9707780|NCT04664491|Experimental|Standardized management|Patients will be managed according to recommendations in GOLD guideline and China's guidelines for COPD care.
9707781|NCT04664491|Other|Usual care|Patients will undergo usual care according to current clinical practice in study sites.
9707782|NCT04664543|Active Comparator|3 days of low residue diet|Currently participants in the colorectal cancer screening program follow a 3 days low residue diet before colonoscopy. This is the active comparator arm of this study.
9707783|NCT04664543|Experimental|Free diet|Participants assigned to this arm are NOT instructed to follow any kind of restriction in the diet before colonoscopy.
9707784|NCT04664530|Placebo Comparator|Control group|
9707785|NCT04664530|Experimental|Treatment group|
9707786|NCT04664816|Experimental|n-3PUFAs group|These patients will receive omega-3 plus (1200 mg) orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
9707787|NCT04664816|Placebo Comparator|Control group|These patients will receive placebo orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
9707788|NCT04664361|Experimental|NMN 250|NMN tablet (250 mg)
9707789|NCT04664361|Experimental|NMN 500|NMN tablet (500 mg)
9707790|NCT04664361|Placebo Comparator|Placebo|NMN-free placebo tablet.
9707791|NCT04664283|Experimental|DCB group by OCT guided|
9707792|NCT04664283|Active Comparator|DES group by OCT guided|
9707793|NCT04664517|Active Comparator|FIN (Flexible intramedullary nail)|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
9707794|NCT04664517|Active Comparator|Long arm cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
9707795|NCT04664517|Other|Patient Choice FIN|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
10193598|NCT05178303|Experimental|"Cirrhosis/Hcc stable"|Experimental benefits in resistance to cirrhosis/Hcc were observed in all patients who had previously received certain components of the treatment for cirrhosis SB-1121(2) for various therapeutic purposes.
10193599|NCT05178290|Experimental|CHILD testing|One child and parent dyad will be tested for COVID-19 using the ASU saliva test as part of back-to-ECE safely programming. All sites will receive this condition.
10193600|NCT05178290|Experimental|CHILD+ personnel testing|This arm receives the CHILD condition plus ECE site personnel are screened biweekly for COVID-19 using the ASU saliva test.
9707796|NCT04664517|Other|Patient Choice cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
9707797|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (extension of the lumbar spine)|
10193601|NCT05178290|Experimental|SAGE garden|The SAGE arm is a garden-based curriculum that emphasizes outdoor learning opportunities such as active games, songs, and garden-activities. About half of the original 40 sites (roughly evenly divided by CHILD and CHILD+) will receive this in year one, and the remaining sites will receive this condition in year two.
10193602|NCT05178290|Sham Comparator|Wait list|Those in the wait list condition will receive SAGE in year two.
10193603|NCT05178251||Control group without Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2018 to December 14, 2018 and from March 17, 2019 to December 14, 2019
9707798|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (lumbar spine in neutral positioning)|
9707799|NCT04664400|Experimental|Main arm|
9707800|NCT04664153|Experimental|atopic dermatitis - PF-07038124 ointment|
9707801|NCT04664153|Placebo Comparator|atopic dermatitis - vehicle ointment|
9707802|NCT04664153|Experimental|plaque psoriasis - PF-07038124 ointment|
9707803|NCT04664153|Experimental|plaque psoriasis - vehicle ointment|
10193604|NCT05178251||Test group with Covid 19 pandemic|- Patients who underwent an appendectomy from March 17, 2020 to December 14, 2020
10193605|NCT05178238||Patients with high viral load of SARS-CoV-2 in feces|
9707804|NCT04664114|Experimental|Experimental group|Both the evaluation of the fetus and the ultrasound for visual purposes took 15-20 minutes in total. These pregnant women were asked to bring their mobile phones with them during delivery. When the birth of the pregnant woman started, she was hospitalized by the third researcher. The follow-up and deliveries during the labor were carried out by the 3rd and 4th researchers. With an application installed on the pregnant woman's phone, these two-dimensional images were transformed into three-dimensional images and the pregnant women were watched consecutively with the VR Box 3D virtual reality glasses. In cases where the program was not compatible with the phone of the pregnant woman, the researcher was watched by the midwife. The total image viewing time was recorded.
9707805|NCT04664114|No Intervention|Control Group|Only one pregnant woman was included in the study at the same time in order to avoid any interruption in the follow-up of the pregnant women. VAS was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale and the Perinatal Anxiety Screening Scale were applied.
9707806|NCT04664322||NIV/HFNC|patients receiving non-invasive ventilation than high flow nasal canulae oxygen therapy
10193606|NCT05178238||Patients with low viral load of SARS-CoV-2 in feces|
10193607|NCT05178186|Other|Thyroid carcinoma|Patients with thyroid carcinoma submitted to thyroidectomy
10193608|NCT05178160|Active Comparator|Group A|All the patients undergo to helmet-CPAP setting PEEP at 10 cmH2O and performing a blood gas analysis after 2 hours
10193609|NCT05178160|Experimental|Group B|All the patients undergo to helmet-CPAP. PEEP was increased from 5 to 7.5 and 10 cmH20 in 30-minute steps during which lung ultrasound and blood gas analyses were repeated. The best PEEP was setted as the PEEP value before the appearance of lung pulse and with a PaO2/FiO2 levels stable or major than 20% in comparison to the basal value
10193610|NCT05178147|Experimental|Volunteers|Volunteers having compression bandages applied to their legs.
10193611|NCT05178121|Experimental|Project WISE eLearning Training in Suicide Safety Planning|
9707807|NCT04664322||HFNC/NIV|patients receiving high flow nasal canulae oxygen therapy than non-invasive ventilation
9707808|NCT04664192||Lung transplant Recipients|Biobank registry for Lung transplant recipients
9707809|NCT04664335||endometriosis cases|endometriosis laparoscopically removed / child wish
9707810|NCT04664335||controls|endometriosis laparoscopically excluded / child wish
9707811|NCT04664010|Experimental|moderate COVID-19 group|patients with moderate COVID-19 receiving western medicine treatment
9707812|NCT04664010|Experimental|severe COVID-19 group|patients with severe COVID-19 receiving western medicine treatment
9707813|NCT04664010|Experimental|moderate COVID-19 with traditional Chinese medicine group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
9707814|NCT04664010|Experimental|moderate COVID-19 with combination therapy group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
9707815|NCT04664010|Experimental|severe COVID-19 with traditional Chinese medicine group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
9707816|NCT04664010|Experimental|severe COVID-19 with combination therapy group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
9707817|NCT04664127||Combination therapy (Kagocel + Valacyclovir: n=25)|Therapy according to routine practice (including Kagocel). Groups will be splitted during the final data analysis.
9707818|NCT04664127||Monotherapy by Valacyclovir (n=20)|Therapy according to routine practice. Groups will be splitted during the final data analysis.
9707819|NCT04664062|Active Comparator|Home|This induction arm is asynchronous and unobserved. The home induction is done primarily by the participant in their home or current residence. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. Home induction is initiated by the participant at a time and place (other than the practice) determined by the participant. The participant determines when to stop taking opioids, begins withdrawal, monitors symptoms, administers the SOWS, and determines when to take first dose of medication, per the instructions and protocol provided. The clinic team does not observe or have contact with the participant while the participant undergoes these steps or takes the first dose. The participant continues this process for additional doses. Follow-up contact with clinic team may occur after the first or second day, typically within a week.
9707820|NCT04664062|Active Comparator|Office|This induction arm is synchronous and observed by the clinical team. The participant receives instruction from clinic team at an in-person or telehealth visit. On a pre-determined day, the participant stops taking opioids and comes to office with mild to moderate withdrawal. The clinic team monitors the participant, assesses symptoms, administers COWS to determine time of first dose of medication, and administers first dose with the participant. The clinic team observes and has in-person contact with the participant. Office induction includes the observed administration of the first dose, followed by observation and evaluation 30-60 minutes after the first dose. After 30-60 minutes of observation, the clinic team and participant decide whether to administer the second dose in the office or for the participant to leave the clinic to administer subsequent doses. On rare occasions, a second dose may not be needed (if the participant has a low COWS score after just one dose).
9779201|NCT01124838|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
9979828|NCT01385631|Placebo Comparator|Atorvastatin plus Placebo|50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
10193612|NCT05178108|Other|healthy individuals|
10193613|NCT05178095|Experimental|AI|Colonoscopy with AI
10193614|NCT05178095|Placebo Comparator|No AI|Colonoscopy without AI
10193615|NCT05178082|Experimental|VPP group|"VPP is composed by six modules of 3-6 minutes each, which can be delivered through a link to be watched online. A research nurse will inform patients how to access the videos and the patients will watch by themselves. The modules are described in the following.~Module 1: Chronic pain concepts - what pain is and difference between acute and chronic pain.~Module 2: Treatment of chronic pain - treatment goals and interdisciplinary intervention components.~Module 3: Pain at work - strategies to adapt. Module 4: Treatment of complex chronic pain conditions - self-management, physiotherapy and psychological support, complementary treatments and free choice of hospital/referral.~Module 5: Help yourself - social support, physical and leisure activities, diet and sleep.~Module 6: Family - support from relatives and relatives co-affected by your pain."
10193616|NCT05178082|Experimental|ERP group|Single educational session with two main components: didactics and skills acquisition. Patients learn how to identify catastrophizing in the moment, and how to self-treat it by acquiring skills and developing a plan to apply the learned skills to decrease physiological hyperarousal - diaphragmatic breathing and progressive muscle relaxation. Participants also acquire skills that improve the regulation of cognition and emotion and develop a plan for implementing these skills in daily life to use behaviors that modulate attention and counteract helplessness (Darnall BD et al. From Catastrophizing to Recovery: a pilot study of a single-session treatment for pain catastrophizing. J Pain Res 2014;7:219-26. ). Session lasts 130 minutes and can be delivered by a nurse certified in the ERP.
10193617|NCT05178082|No Intervention|Control group|This group will receive no intervention, but patients will be assessed regarding the same variables collected in the other two arms.
10193618|NCT05178043|Experimental|GT90001+Nivolumab|
10193619|NCT05178030||GALLOP-11|Patients with a proven KIT exon 11 mutated GIST covered by our in-house designed ddPCR assay.
9707821|NCT04664062|Active Comparator|Telehealth|This induction arm is synchronous via phone or video contact and observed. The participant receives instruction on induction process from clinic team at an in-person or telehealth visit. The participant undergoes the same process as an office induction but from a location other than the clinic. Like an office induction, the participant has regular contact with someone from the practice team on Day 1 of induction. Prior to initiating the first dose, the participant has contact by phone or video with the clinic team to assess symptoms and determine level of withdrawal (using COWS or SOWS). The administration of the first dose of medication is determine by the clinic team during phone or video contact, and the clinic team is in contact with the participant by phone or video when the first dose is taken. This process continues through the second and possible third dose. The participant is re-assessed via video or phone regularly by clinic staff and prescriber throughout this process.
10193620|NCT05178004||Non-IgE-mediated CMPA|Infants with mild, moderate and severe non-IgE-mediated cow's milk protein allergy
9707822|NCT04664257|Experimental|e-CBT|All e-CBT sessions will be administered through OPTT and will consist of approximately 30 slides per week. The content and format of each weekly online session will be designed to mirror in-person CBT for the treatment of BAD-II. Participants will complete the module and submit the assigned homework to their clinician through OPTT where the clinician will be able to provide personalized feedback. These pre-designed engaging and multimedia modules will be able to streamline the therapy process, helping care providers save time on repeating similar materials to all patients and focusing on delivering personalized feedback to each patient. The slides will highlight a different topic each week and include general information, an overview of skills, and homework that is to be completed within that week. All weekly sessions have an estimated completion time of 50 minutes. During the 12 weeks, both groups will continue with their TAU.
9707823|NCT04664257|No Intervention|Treatment as Usual|Participants will continue with treatment as usual and any lifestyle activities (diet, exercise, medication, etc.)
9707824|NCT04664270|Experimental|e-Psychotherapy|Group will receive 8-week online program including CBT in combination with mindfulness and problem-based therapy in addition to treatment as usual. The content will reflect challenges cancer and palliative patients face through the course of treatment and developed into interactive and engaging therapy modules. All online sessions and interactions will occur through a secure online platform. Pre-designed therapy modules are assigned to the patients, accessible to them at any time throughout the week. Each module consists of approximately 30 slides, which take 45-50 minutes to complete. Each module highlights a different topic and includes general information, an overview of skills, and homework that is to be completed within that week. This homework can be directly submitted through the platform to the clinician who will then provide personalized feed-back to the patient. The average time spent per week by a clinician with a particular patient is about 15 minutes.
9707825|NCT04664270|No Intervention|Treatment as Usual|The control group will receive treatment as usual in the first 8 weeks; if still significantly symptomatic (less than 50% response to treatment from baseline), they will then be offered the 8-week e-psychotherapy program. They will be instructed to continue with any lifestyle activities (i.e., diet, exercise, medication, etc.)
9707826|NCT04664049||NRICM101|Subjects who confirmed, suspected or prevented infected of COVID 19 disease and received dietary supplement NRICM101
9707827|NCT04664036||NAFLD + type 1 diabetes|type 1 diabetes patient with NAFLD on screening
9707828|NCT04664036||noNAFLD + type 1 diabetes|type 1 diabetes patient without NAFLD on screening
9707829|NCT04663828|Other|Structured counseling|Patients will receive a structured counseling therapy
9707830|NCT04663828|Other|Hearing Aids|Patients will receive hearing aids support
9707831|NCT04663828|Other|Cognitive behavioral therapy|Patients will receive cognitive behavioral therapy
9707832|NCT04663828|Other|Sound therapy|Patients will follow a sound therapy program
9707833|NCT04663828|Other|Combination of sound therapy and cognitive behavioral therapy|Patients will receive a combination of sound therapy and cognitive behavioral therapy
9707834|NCT04663828|Other|Combination of hearing aids and cognitive behavioral therapy|Patients will receive a combination of hearing aids and cognitive behavioral therapy
9707835|NCT04663828|Other|Combination of hearing aids and structured counseling|Patients will receive a combination of hearing aids and structured counseling
9707836|NCT04663828|Other|Combination of structured counseling and sound therapy|Patients will receive a combination of structured counseling and sound therapy
10193621|NCT05178004||IgE-mediated CMPA|Infants with IgE-mediated CMPA
10193622|NCT05178004||Healthy|Healthy infants who have never shown signs of cow's milk protein allergy
10193623|NCT05178004||Non allergic gastrointestinal conditions|Infants with suspected cow's milk allergic at enrolment and ruled out following Oral Food Challenge
10193624|NCT05177978|Experimental|Phosphatidylserine|100 mg elemental phosphatidylserine
10193625|NCT05177978|Placebo Comparator|Placebo|Placebo comparator
10193626|NCT05177952|Experimental|Blood Flow Restriction|The BFR group will complete 1 set of 30 (1 x 30) at 30% of their 1 repetition maximum for leg press, leg extension, leg curl, chest press, seated row, and shoulder press completed on exercise machines with 2 minutes between exercises.
10193627|NCT05177952|Active Comparator|Standard of Care|The standard of care group will complete 1 set of 8-12 repetitions at 60-80% of their 1 repetition maximum for leg press, leg extension, leg curl, chest press, seated row, and shoulder press completed on exercise machines with 2 minutes between exercises.
10193628|NCT05177926|Other|antiviral prophylaxis with Tenofovir Alafenamide Fumarate (TAF)|All participants will receive oral Tenofovir Alafenamide Fumarate 25mg, daily, at gestational 27-29 week until delivery.
10193629|NCT05177887|Experimental|Traumacel PULVIS|Traumacel PULVIS will be poured into the bleeding area directly or using an applicator Traumacel ENDO Applicator.
10193630|NCT05177874|Experimental|Traumacel FAM Trium|Randomized application haemostatic agent Traumacel FAM Trium in the bleeding site.
9707837|NCT04663828|Other|Combination of hearing aids and sound therapy|Patients will receive a combination of hearing and sound therapy
10193631|NCT05177874|Active Comparator|Surgicel Fibrillar|Randomized application of haemostatic agent Surgicel Fibrillar in the bleeding site.
10193632|NCT05177809||RFC1|Participants with genetically confirmed RFC1 repeat expansion disease (ORPHA: 504476; OMIM 102579) will be recruited. Target sample size for the RFC1 cohort is 100 participants.
9707838|NCT04663828|Other|Combination of cognitive behavioral therapy and sound therapy|Patients will receive a combination of cognitive behavioral therapy and sound therapy
9707839|NCT04664088|Experimental|Acupuncture group|Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions).
9707840|NCT04664088|Active Comparator|Medication group|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks.
10193633|NCT05177809||Unrelated healthy controls|Unrelated healthy controls Healthy controls may undergo the same study procedures as the RFC1 cohort. Target sample size for the control cohort is 50.
9707841|NCT04664218|Experimental|patients with Peritoneal carcinomatosis|Peritoneal carcinomatosis (PC) is a well-known sequel of multiple abdominal malignancies either arising from the gastro-intestinal tract or of gynaecologic origin. On occurrence, PC is mostly considered as a very bad prognostic sign hence it affects the overall survival with very poor response to systemic chemotherapy.
10193634|NCT05177783|Experimental|Tuune|Participants complete the Tuune contraceptive decision aid health questionnaire.
10193635|NCT05177783|Active Comparator|Control|Participants complete a standard physician intake health questionnaire.
10193636|NCT05177744||allergic (Zagreb, urban)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Zagreb (urban)"
9707842|NCT04664231||Children with JIA|Children with JIA coming to clinic
9707843|NCT04664231||Healthy Children|Healthy Children in the school
9707844|NCT04664387||patients with myocardial bridge|patients who underwent coronary angiography and was diagnosed as myocardial bridge
9707845|NCT04664387||patients without myocardial bridge|patients who underwent coronary angiography and was diagnosed as without myocardial bridge
9707846|NCT04663763|Experimental|Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy|"A total of 40 patients receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 4 cycles of CAPOX chemotherapy.~Interventions:~Shor-course radiotherapy: 25Gy/5Fx;~Induction immunotherapy: Sintilimab 200mg ivgtt d1 q3w x 4 cycles;~Concurrent Chemotherapy: Oxaliplatin: 130mg/m2 d1 q3w + Capecitabine: 1000mg/m2 d1-14 q3w x 4 cycles;"
9707847|NCT04663854|Experimental|Trehalose|Trehalose Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks.
9707848|NCT04663854|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks.
9707849|NCT04663880|Experimental|Asthmatic subjects allergic to house dust mite|24 subjects were randomized in a doubleblinded manner into six subgroups. All were exposed first to placebo then in cross over to three different Der p1 concentrations, respectively 15, 25, and 46 ng/m3.
9707850|NCT04663880|Active Comparator|Asthmatic subjects not allergic to house dust mite|13 subjects were exposed first to placebo then to Der p1 concentration of 25 ng/m3.
9707851|NCT04664244|Experimental|All eligible patients|All eligible patients enrolled
9707852|NCT04663815|Other|AB arm|Animal-assisted activity intervention on 2nd day of hospitalization, control intervention on the 4th day of hospitalization.
9707853|NCT04663815|Other|BA arm|Control intervention on 2nd day of hospitalization, animal-assisted activity intervention on the 4th day of hospitalization.
9707854|NCT04663919|Active Comparator|Anorexia Nervosa|Patients diagnosed with Anorexia Nervosa, having a BMI of <18, being followed up and treated in the Psychiatry Eating Disorders Polyclinic and endocrinology outpatient clinics, and who have approximately 10% weight gain during the treatment process
9707855|NCT04663919|Active Comparator|Morbidly Obese|Patients with a BMI> 40 diagnosed with Morbid Obesity and who lost approximately 10% of their weight by performing obesity surgery (gastric bypass or sleeve gastrectomy)
9707856|NCT04663919|No Intervention|Healthy Volunteer|Volunteers with normal BMI and without any additional chronic disease
10193637|NCT05177744||healthy subjects (Zagreb, urban)|"Healthy subjects that will be recruited from continental region in Croatia - Zagreb (urban).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
10193638|NCT05177744||allergic (Slavonia, urban and rural)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from continental region in Croatia - Slavonia (urban and rural)"
10193639|NCT05177744||healthy subjects (Slavonia, urban and rural)|"Healthy subjects that will be recruited from continental region in Croatia -(Slavonia, urban and rural).~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
10193640|NCT05177744||allergic Mediterranean region (urban and rural population)|"Participants will be selected based on proven sensitization to at least one food allergen (preferentially but not only to seafood) with a diagnosis of at least one allergic disease (i.e. allergic asthma, allergic rhinitis, atopic dermatitis and/or food allergy) for at least a year.~Subjects will be recruited from mediterranean region in Croatia - urban and rural"
9707857|NCT04663906||Isotretinoin|Test population, prescribed oral isotretinoin between March and October 2020.
9707858|NCT04663906||Control|Background age-matched population, not prescribed oral isotretinoin during March to October 2020
9707859|NCT04663607|No Intervention|Control|Participants will receive paper-based health education as part of standard of care
9707860|NCT04663607|Experimental|App|Participants will receive health education via a mobile app, PretermConnect
9707861|NCT04663594|Experimental|Ways of Being online Experience|Ways of Being (WoB) every day for three days
9707862|NCT04663594|Other|Ashmolean Website|The Ashmolean Website every day for three days
9707863|NCT04663789|Experimental|Staple line plus reinforcement|In this experimental group, a lock stitch will be placed after transecting the pancreas with stapler.
9707864|NCT04663789|Other|staple line with no reinforcement|In this control group, no additional reinforcement is used after transecting the pancreas with stapler.
9707865|NCT04663646|Experimental|Intervention Group|
10193641|NCT05177744||healthy subjects Mediterranean region (urban and rural population)|"Healthy subjects that will be recruited from mediterranean region in Croatia -urban and rural.~Negative history of allergic diseases, as well as other severe chronic diseases, including malignant, autoimmune, or mental illnesses."
10193642|NCT05161468|Active Comparator|Lidocaine|50 Subjects will be randomized to this group and will receive a lidocaine injection in their ACJ.
10193643|NCT05161468|Active Comparator|Corticosteroid|50 Subjects will be randomized to this group and will receive a corticosteroid injection in their ACJ.
9707866|NCT04663646|Placebo Comparator|Control Group|
9707867|NCT04663685|Experimental|Single Arm|This is the only arm in the study. All participants will be allocated to this arm, where they will receive an 8-week remotely-delivered exercise and nutrition program.
9707868|NCT04663802|Active Comparator|Default order set|This arm will have the default order set implementation strategy
9707869|NCT04663802|Active Comparator|Physician-targeted accountable justification|This arm will have the physician-targeted accountable justification implementation strategy
9707870|NCT04663802|Active Comparator|Default order set + physician-targeted accountable justification|This arm will have the default order set and physician-targeted accountable justification
9707871|NCT04663802|Placebo Comparator|Standard of Care|This arm will have no interventions and standard of care practices will be in place.
9707872|NCT04663802|Active Comparator|Physician-targeted accountable justification + RT-targeted accountable justification|This arm will have the default order set and respiratory therapist-targeted accountable justification
9707873|NCT04663529||CLADE|contact lens wearers with DED
9707874|NCT04663529||non-CLADE|DED without contact lens wear
9707875|NCT04663529||NC|normal control
9707876|NCT04663581|Experimental|Left Sided Colonoscopy|Left Sided starting position in colonoscopy
9707877|NCT04663581|Active Comparator|Right sided Colonoscopy|Right Sided starting position in colonoscopy
9707878|NCT04663698|Experimental|Healthy|Lung-healthy subjects, randomized lung function testing
10193644|NCT05161468|Active Comparator|Platelet Rich Plasma (PRP)|50 Subjects will be randomized to this group and will receive a PRP injection in their ACJ.
10193645|NCT05160324|Active Comparator|Axillary dissection (standard treatment)|"Axillary dissection in women with sentinel lymph node metastases.~(removal of at least 10 lymph nodes recommended)"
10193646|NCT05160324|Experimental|Preservation of axillary lymph nodes|Omission of Axillary dissection in women with sentinel lymph node metastases.
9707879|NCT04663698|Experimental|Patient 1|COPD patients, randomized lung function testing
9707880|NCT04663698|Experimental|Patient 2|COPD patients, randomized lung function testing
9707881|NCT04663698|Experimental|Patient 3|COPD patients, randomized lung function testing
9707882|NCT04663698|Experimental|Patient 4|COPD patients, randomized lung function testing
9707883|NCT04663360|Experimental|Intervention|Intervention to be administered: Adverse Drug Reactions (ADRe) Profile. asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
9707884|NCT04663360|No Intervention|Control|Usual clinical care.
9707885|NCT04663425||Sleeve gastrectomy operation|Outcome of patients that underwent sleeve gastrectomy with BMI greater than 60.
9707886|NCT04663425||Gastric bypass operation|Outcome of patients that underwent gastric bypass with BMI greater than 60.
10193647|NCT05160155|Active Comparator|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area. The block will be terminated.
10204654|NCT05180903|Experimental|Bulk Fill resin composite restorations reinforced by ultra high molecular weight polyethylene.|Bulk Fill resin composite restorations (X-tra base & GrandioSO, Voco, Cuxhaven, Germany) reinforced by ultra high molecular weight polyethylene. (Ribbond THM, Ribbond Inc, Seattle, WA, USA)
9707887|NCT04663425||Gastric Band operation|Outcome of patients that underwent gastric banding with BMI greater than 60.
9707888|NCT04663633|Experimental|Core stability training|"The EG performed an 8-week core stability training, consisting in 30 min of core stability and plyometric exercises 3 days per week, 24 sessions in total.~The CST sessions were conducted in a gym suitable for RG practise and the safety of the participants will be maintained. The equipment necessary for the training was provided to the participants.~The coaches are RG professionals with national coach level in RG and volunteered to lead the specific CST designed by a RG national coach and an expert core stability physiotherapist.~Before each session EG and CG performed a 15 min warm up. The load of the session was calculated by the RPE (rate of perceived exertion). And was modulated in order to maintain 7-8 intensity."
9707889|NCT04663633|No Intervention|Traditional RG training|The CG performed the traditional training while the EG carried out the CST. The training load was calculated to be 7-8 RPE in order that both groups (EG and CG) undergo an equivalent intensity and training load.
9707890|NCT04664023||Patients with severe SARS-CoV-2 infection|Patients with severe SARS-CoV-2 infection hospitalised in intensive care unit
9707891|NCT04664023||Patients with intermediate SARS-CoV-2 infection|Patients with intermediate SARS-CoV-2 infection hospitalised in infectious and tropical diseases department
9707892|NCT04664023||Little symptomatic patients with SARS-CoV-2 infection|Little symptomatic ambulatory patients with SARS-CoV-2 infection
9707893|NCT04664023||Patients with SARS-CoV-2 infection hospitalised in geriatry department|Patients with SARS-CoV-2 infection hospitalised in geriatry department to study influence of age on the studied mechanisms
9707894|NCT04664023||Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects above 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
9707895|NCT04664023||Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine|Subjects below 65 years wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine
9707896|NCT04663659||diabetic group|Patients over the age of 18 with diabetes mellitus in intensive care unit
9707897|NCT04663659||non-diabetic group|Patients over the age of 18 without diabetes mellitus in intensive care unit
9707898|NCT04663451||Toxic Nodule|Hyperthyroid patients with underlying toxic nodule
9707899|NCT04663451||Toxic multinodular goiter|Hyperthyroid patients with underlying toxic multinodular goiter
9707900|NCT04663971||Crohn's disease|Patients with Crohn's disease.
9707901|NCT04663971||Ulcerative colitis|Patients with Ulcerative colitis
9707902|NCT04663477||Trained nurse-completed CRS|
9707903|NCT04663477||Patient-completed CRS|
9707904|NCT04663438||Arm A|200/Atezolizumab combined with EC regimen Atezolizumab:1200 mg Q3w
9707905|NCT04663438||Arm B|100/Atezolizumab combined with chemotherapy Atezolizumab:1200mg Q3w
9707906|NCT04663412|Experimental|Patients FIGO IB stage|Vulvar Cancer IB stage
9707907|NCT04663516|Experimental|experimental|exercise through video game (Wii)
9707908|NCT04663516|No Intervention|control|children in this group will be given advice about the importance of exercising
9707909|NCT04663490||simple acute diverticulitis|Ninety-one percent (n=295) were categorized as simple acute diverticulitis
9707910|NCT04663490||complicated acute diverticulitis|9% (n=30) presented were categorized as complicated acute diverticulitis
9707911|NCT04663568|Other|Levonorgestrel-releasing intrauterine system|
9707912|NCT04663672|Experimental|Exposure Therapy + Exposure Scent Cue During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of the exposure scent.
9707913|NCT04663672|Placebo Comparator|Exposure Therapy + Novel Scent During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of a novel scent.
9707914|NCT04663672|Sham Comparator|Exposure Therapy + No-Scent Control During Sleep|Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of an odorless control vehicle.
9707915|NCT04663737|Experimental|Group A|Group A will receive the best supportive care and/or recommended standard of care (at this point no standard of care drugs are recommended by CDC for patients with moderate COVID-19) in combination with the study drug Silmitasertib
9707916|NCT04663737|Active Comparator|Group B|Group B (control) that will receive the same care as the Group A but without Silmitasertib
9707917|NCT04663295|Experimental|Subjects with Type 1 diabetes wearing HCL pump system|Subjects 14-75 years of age who have been diagnosed with Type 1 diabetes.
9707918|NCT04663542|Experimental|0-week immobilization|0-week brace immobilization after the surgery will be conducted.
9707919|NCT04663542|Experimental|2-week immobilization|2-week brace immobilization after the surgery will be conducted.
9707920|NCT04663542|Other|4-week immobilization|4-week brace immobilization after the surgery will be conducted.
9707921|NCT04663542|Other|6-week immobilization|6-week brace immobilization after the surgery will be conducted.
9707922|NCT04663048|Experimental|Protocol A|PiXL treatment with pulsed UV illumination (1.0 sec on /0.8 sec off) in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 10 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
9707923|NCT04663048|Active Comparator|Protocol B|PiXL treatment with pulsed (0.5 sec on / 1 sec off) UV illumination in high oxygen in a central ring-shaped 3.5-mm zone of the cornea and total illumination time of 16:40 min. The area consist of three rings with a central 1.5-mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring.
9707924|NCT04663061|Experimental|High intensity medical weight loss (HIWL)|Participants randomized to the HIWL treatment group will be placed on a meal replacement-based weight loss protocol. Participants will consume a minimum of 80 grams of protein daily in 4-5 servings of meal replacement. Participants will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-24, caloric prescriptions will be between 1100 to 1600 calories a day, using a combination of meal replacements and food, for continued weight loss. Beyond week 25, caloric intake will be individually tailored to achieve continued gradual weight loss or maintenance of body weight based on individual weight loss goals. We will recommend continued use of at least 1 serving of meal replacement per day for maintenance of weight loss.
9707925|NCT04663061|Active Comparator|Diabetes self-management education (DSME)|"The DSME intervention will be administered and delivered at the Wake Forest Baptist Health Diabetes Center, located next to the Weight Management Center, by a team of certified diabetes educators, nurses, and nutritionists in group and individual settings.~The diabetes education program is accredited by the American Diabetes Association in recognition of meeting national standards for diabetes self-management education. The goal of the program is to provide participants with information to make informed decisions about how to best integrate diabetes management strategies into their daily lives. Assessment, planning, implementation, and evaluation are the basic components of the diabetes education process."
9707926|NCT04663061|Experimental|High intensity medical weight loss (HIWL) plus continuous glucose monitoring (CGM)|Participants randomized to the HIWL + CGM treatment group will be placed on a meal replacement-based weight loss protocol as described in the HIWL arm. In addition, the participants in this arm will receive a supply of continuous glucose monitors to use throughout the trial. The CGM we provide will give the patient instant feedback on blood glucose levels and be readable using a mobile phone device or an associated CGM reader. The data from the CGM will be integrated into the Carium app and used to help guide the patient's actions based on defined care pathways.
9707927|NCT04663009||Mechanical chest compression|Patients recieving LDB CPR
10193648|NCT05160155|Active Comparator|Intercostal Block|The USG probe will be placed at the level of the posterior axillary line and the broken ribs. The ribs, external intercostal muscle, and internal intercostal muscle structures will be imaged. 3 ml of 0.25% bupivacaine will be injected into the subcostal area. This 3 ml 0.25% bupivacaine injection will be administered for each broken rib. The block will be terminated.
10193649|NCT05160129|Experimental|Circuit-selective DBS|People suffering from severe obsessive-compulsive disorder (OCD)
9707928|NCT04663009||Manual chest compressions|Patients recieving manual CPR
9707929|NCT04662983|Experimental|Experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions.
9707930|NCT04663126|Experimental|Treatment group|Patients diagnosed with advanced melanoma (stage III-IV) will receive IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m before the first cycle of clinically scheduled anti-PD-1 immunotherapy.
9707931|NCT04663139|Experimental|normal weight healthy adult volunteers receiving Xla1|one capsule Xla1 given once daily
9707932|NCT04663139|Experimental|overweight and class 1 obese adult patients receiving Xla1|one capsule Xla1 given once daily
10193650|NCT05158933|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
9707933|NCT04663139|Placebo Comparator|overweight and class 1 obese adult patients receiving placebo|one capsule placebo given once daily
9707934|NCT04663269|Other|Control|Standard Care Protocol - peritubal block standard local analgesic administration in the form of a peritubal block
10193651|NCT05158491|Active Comparator|180 mg/mm2|Subjects will be dosed at 180 mg/mm2 level.
10193652|NCT05158491|Active Comparator|220 mg/mm2|Subjects will be dosed at 220 mg/mm2 level.
10193653|NCT05158491|Active Comparator|260 mg/mm2|Subjects will be dosed at 260 mg/mm2 level.
10193654|NCT05158491|Active Comparator|300 mg/mm2|Subjects will be dosed at 300 mg/mm2 level.
10193655|NCT05158127|Experimental|Treatment Group (AlloRx)|intravenous infusion and intralesional injection of 100 million cells
10193656|NCT05158114|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
9707935|NCT04663269|Experimental|ANES Block|Patients randomized to the erector spinae block (Group 2) will have the block placed in the preoperative area by the anesthesia team. 0-4 mg midazolam and/or 0-100 mcg of fentanyl may be provided prior to and in order to place the block itself. The local anesthetic will diffuse to involve the dorsal and ventral rami of the spinal nerves, achieving a sensory block of the affected area. The erector spinae block analgesic will be administered by the anesthesia team. The analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone.
9707936|NCT04663022||Child with cochlear implant|15 childs with coclear implant but without autism spectrum disorder
9707937|NCT04663022||Child with cochlear implant and autism spectrum disorder|15 childs with coclear implant and with autism spectrum disorder
9707938|NCT04662996|Experimental|1- Chemotherapy|Intervention : one blood sample is done before beginning chemotherapy as a first treatment line for a metastatic castration resistant prostate cancer
9707939|NCT04662996|Experimental|2- Novel Hormonal Agent|Intervention : one blood sample is done before beginning a novel hormonal agent (abiraterone, enzalutamide) as a first treatment line for a metastatic castration resistant prostate cancer
9707940|NCT04663204|Experimental|Sparsentan|Sparsentan will be administered once daily, starting at a dose of 200 mg (two 100 mg oral capsules) for the first 2 weeks of the study. Patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg (one 400 mg tablet). Patients who do not tolerate the target dose will have their dose reduced back to 200 or 100 mg/day; throughout the study, patients will be maintained on the maximum allowed dose of sparsentan they can tolerate. All patients will be treated with sparsentan for a total of 110 weeks.
9707941|NCT04662957|Experimental|Probiotic preparation|Multi-strain probiotic mixture. The daily dose was five billion (2 capsules/day).
9707942|NCT04662957|Placebo Comparator|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture (2 capsules/day).
9779202|NCT01124838|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
10193657|NCT05158101|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10193658|NCT05157607|Experimental|Family Connections Protocol for Relatives of Patients with SBD.|"The intervention lasts three months and includes 12 sessions with a weekly two-hour group format. The FC program is divided into six modules:~Module 1: Up-to-date information and research on suicide (Epidemiology, frequency, Risk factors, protective factors).~Module 2: Psychoeducation on the development of suicide, explanatory theories, available treatments, comorbidity.~Module 3: Emotional regulation skills, skills of acceptance, validation, approach, awareness, and to decrease emotional reactivity.~Module 4: Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~Module 5: Communication skills and effective self-expression. Module 6: Problem management and making safe plans for crisis management."
9707943|NCT04663165|Other|Flap surgery alone|Access flap
9707944|NCT04663165|Other|Flap surgery with adjunctive EMD|Access flap and adjunctive enamel matrix derivative
10193659|NCT05157607|Active Comparator|Treatment as Usual Optimized Protocol (TAU-O).|"Family members in this condition will continue to receive their treatment as usual in their care center of reference. In addition, we will optimize the treatment based on the recommendations of the international guidelines for the treatment of suicide. There will be one three-hour session in group format with the following component:~Module 1: Updated information and research on suicide (Epidemiology, frequency, Risk factors, protective factors). Psychoeducation on the development of Suicide, Explanatory theories. Available treatments, and comorbidity."
9707945|NCT04663100|Experimental|Pharmacist Coordinated care Oncology Model|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and community pharmacists.
9707946|NCT04663256|Experimental|Cognitive Stimulation Group|This group receives physical training based on exercises for cognitive stimulation.
9707947|NCT04663256|No Intervention|Control Group|This group does not receive any treatment.
9707948|NCT04663243|Experimental|Quasi experimental study|Before intervention and after intervention comparison
10193660|NCT05157568|Active Comparator|Control (C)|Participants will receive a exercise prescription and a home exercise plan. It will specify how many days per week they should exercise and will indicate how hard they should be working using their heart rate and rating of perceived exertion (RPE) as a guide. They will attend 8 onsite rehabilitation classes at the University of Ottawa Heart Institute (1 class per week for 8 weeks). These classes will be led by a specially trained instructor who will teach and encourage self-monitoring of heart rate and RPE. The class will include a warm-up, 30 minutes of aerobic exercise and a 15 min cool-down, including strength exercises and stretches. Following each class there will be a short mini-education session highlighting a variety of topics on how to manage risk factors. Patients will have access to onsite classes for nutrition and stress management. Participants will receive access to 8 additional educational videos that highlight topics such as exercise safety, goal setting and nutrition.
9707949|NCT04663074||IVUS Group|Patients treated by BEVAR/CHEVAR/FEVAR due to a thoracoabdominal aneurysm.
9707950|NCT04663191||Full VATS|
9707951|NCT04663191||VATS with conversion|
9707952|NCT04663191||Thoracotomy upfront|
9707953|NCT04663035|Experimental|Ablation Plus Tislelizumab|Patients in this arm will receive ablation followed by tislelizumab, which will be started within 3-7 days after ablation until disease progression or intolerable toxicity, for 12 months.
9707954|NCT04663035|Active Comparator|Ablation Alone|Patients in this group will receive ablation therapy and then enter the follow-up phase.
9707955|NCT04663178|Experimental|Warm Salt Water Foot Bath Group|"In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale (PFS) were applied to the patients. A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to patients.~Each patient received iodine salt and a liquid thermometer to measure the temperature of the water. The patients were asked 1 day after the treatment to apply warm salt water bath of 41-42ºC once a day for 20 minutes for 7 days.~Subsequently, the fatigue level of the patients was evaluated 30 minutes after having a warm saltwater foot bath and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. In the last interview PFS was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
9707956|NCT04663178|No Intervention|Control Group|"A training booklet about chemotherapy-induced fatigue~In the first interview Patient Identification Form, Fatigue Severity and Piper Fatigue Scale were applied to the patients.~A training booklet about chemotherapy-induced fatigue containing the definition, causes, ad development process of chemotherapy-induced fatigue and effective coping approaches were delivered to experimental group.~Subsequently, the fatigue level of the patients was evaluated and recorded by questioning via calling them with phone every day and using the Visual Fatigue Scale for 7 days. The patients were evaluated in the evening. In the last interview conducted with the patient on the 7th day, Piper's Fatigue Scale was used to evaluate the effect level of fatigue on the quality of life and the assessment process was completed."
9707957|NCT04662775|Experimental|Intervention group|This group received the multi-component physical activity intervention (physical activity programme, weekly behaviour change support calls, non-reply text messages)
9707958|NCT04662775|No Intervention|Waitlist control|Participants in the wait-list control group were asked to continue their usual PA habits and received no additional contact from the research team outside of data collection points. Following post-intervention data collection, control group participants were invited to participate in the same intervention as described above.
9707959|NCT04662788|Experimental|Administration of NK cells/Combined Monoclonal Antibodies|
9707960|NCT04662762|Experimental|nursing intervention group|An educational interview by trained nurses was performed at three months in patients allocated to the intervention group. The visit was carried out at the hospital. Family and caregivers were also asked to attend this visit for instruction. For patients unable to move, the nursing team went to their home to perform the intervention, or it was conducted by phone. The duration of this interview was approximately 40 minutes and was focused on some measures and recommendations to improve or maintain adherence. Then, there is a reminder call at 6 months.
9707961|NCT04662762|No Intervention|Usual care group|The patient is followed up and regular visits
9707962|NCT04662814|Experimental|shock wave|shock wave for primary dysmenorrhea for study group along side to dietary modification
9707963|NCT04662814|Active Comparator|dietary modification|dietary modification for primary dysmenorrhea for control group
9707964|NCT04662749||concave group|the group whose level of sinus floor is lower than both of the adjacent teeth
9707965|NCT04662749||angle group|the group whose level of sinus floor is lower than one of the adjacent teeth and higher than the other one of the adjacent teeth
10204655|NCT05180903|Active Comparator|Bulk Fill resin composite restorations|Bulk Fill resin composite restorations (X-tra base & GrandioSO, Voco, Cuxhaven, Germany)
10204656|NCT05180214|Active Comparator|bupivacaine|
10204657|NCT05180214|Active Comparator|bupivacaine and ketorolac|
9707966|NCT04662749||flat group|the group whose level of sinus floor is similar to both of the adjacent teeth
9707967|NCT04662827|Experimental|Palmithylethanolamid|Probands receive PEA 3xday for 28 days, 8 weeks wash out will follow, then they receive placebo for 28 days
9707968|NCT04662827|Placebo Comparator|placebo|Probands receive placebo 3xday for 28 days, 8 weeks washout will follow, then they receive PEA for 28 days
9707969|NCT04662736||patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|
9707970|NCT04662840|Sham Comparator|Sham procedure|"The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. A script detailing the procedure verbally will be followed by the interventionalists to waste time, but the only actual medical act that will be done is freezing of the skin around the knee (as for nerve ablation procedure) and at the groin (as for embolization procedure). Dressings will be applied at the knee and groin area."
9707971|NCT04662840|Active Comparator|Geniculate artery embolization|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee (as for the ablation procedure) and at the groin and in this group a geniculate artery embolization will be performed via an intraarterial access and use of embolization microspheres injected into the hypervascular arteries feeding the knee joint. Dressings will be applied at the knee and groin area.
9707972|NCT04662840|Active Comparator|Geniculate nerve ablation|The patient will be placed on the procedural table as for the other arms. They will be blinded to what is occuring around them. They will undergo a similar script than everyone one else with freezing of the skin around the knee and at the groin (as for the embolization procedure) and in this group a geniculate nerve ablation will be performed by advancing a radiofrequency ablation (RFA) needle at three locations alongside the tibia and femur where the nerves course and ablation performed. Dressings will be applied at the knee and groin area.
10204658|NCT05180188|No Intervention|Placebo periode|In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health.
10204659|NCT05180188|Experimental|Exercise periode|In the second period, participants will perform regular moderate-intensity exercise 3 times/week.
10204660|NCT05179668|Experimental|Intervention arm|Hemodialysis patients receiving empagliflozin 10 mg once daily
9707973|NCT04662554|Experimental|Novel PET Camera|Patients already undergoing a PET/CT scan for HNC will afterwards undergo a PET scan with the proposed device, thus no additional radioactivity is needed as part of this study.
9707974|NCT04662866|Active Comparator|Metformin|Metformin 500 mg x 1, morning, for 2 weeks, then Metformin 500 mg x 2, morning and evening for 10 weeks.
9707975|NCT04662866|Active Comparator|Empagliflozin|Empagliflozin 10 mg x 1, morning, for 2 weeks, then Empagliflozin 10 mg morning + Placebo evening for 10 weeks.
9707976|NCT04662866|Active Comparator|Linagliptin|Linagliptin 5 mg x 1, morning, for 2 weeks, then Linagliptin 5 mg morning + Placebo evening for 10 weeks.
9707977|NCT04662866|Active Comparator|Pioglitazone|Pioglitazone 30 mg x 1, morning, for 2 weeks, then Pioglitazone 30 mg morning + Placebo evening for 10 weeks.
9707978|NCT04662853||Patients with positive results in the fecal occult blood test.|Patients with positive results in the fecal occult blood test in the Program for Early Detection of Colon and Rectal Cancer, undergone by the Consejeria de Salud de la Junta de Andalucia (Spain), were invited to participate in the CCR-microbiome study. This program is screening Andalusian population aged between 50 and 69 years old for colo-rectal cancer presence by fecal occult blood test, and further colonoscopy when positive for this test. Patients included in CCR-microbiome study were recruited between January 2017 and March 2020, at the Reina Sofia University Hospital (Cordoba, Spain) with the consumption of antibiotic within the previous month as exclusion criteria.
9707979|NCT04662398|Active Comparator|Case (Testes shocker device)|The shocker will be used in delivering the current gradually on the testes and penis to improve the blood flow and stimulates the sexual activity among males.
9707980|NCT04662398|Sham Comparator|Control (non testes shocker device)|These groups will not given the shocks, shame device will be used instead and then compare the two results.
9707981|NCT04662671|Experimental|RD-X19 Device|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
9707982|NCT04662671|Sham Comparator|Sham|
9707983|NCT04662476|Active Comparator|Vitamin D supplement|331 children will each received 60,000IU of vitamin D once a month for 3 months.
9707984|NCT04662476|Active Comparator|Intervention|The intervention arm will receive vitamin D3.
9707985|NCT04662606|No Intervention|Fasting-group|
9707986|NCT04662606|Experimental|Fed-group|
9707987|NCT04662437||Covid-19 Patient Group|10 ml of venous blood was taken from the forearm venous vein from people in the Covid-19 Patient Group, and the level of parathyroid hormone, calcium, phosphorus, alkaline phosphatase was measured from this blood.
9707988|NCT04662437||Healthy Control Group|10 ml of venous blood will be taken from the forearm venous vein from the healthy control group and the parathyroid hormone, calcium, phosphorus, alkaline phosphatase level will be measured from this blood.
9707989|NCT04662541|Experimental|Mobile Integrated Health (MIH)|Patients with urgent medical needs are seen and treated in the home by trained community paramedics. The community paramedics perform a standardized assessment, including a physical examination, vital signs, home safety evaluation, and medication reconciliation. During the MIH encounter, the emergency medicine physician at each site is contacted via telemedicine. Physicians can access clinical notes, discharge summaries, and medication lists via the institutional EHR. Adjustments to outpatient medications can be e-prescribed and follow-up appointments can be scheduled with primary care clinicians.
9707990|NCT04662541|Active Comparator|Transitions of care coordinator (TOCC)|Patients receive a follow-up phone calls for a nurse coordinator within 48-72 hours of hospital discharge. Phone calls include clinical/social needs assessment with escalation to primary care team, emergency care, or social work as needed; patient education; and reminder about follow-up appointments.
10204661|NCT05179668|Placebo Comparator|Placebo|Hemodialysis patients receiving placebo oral tablet once daily
10193661|NCT05157568|Active Comparator|Exercise Streaming (ES)|"Participants will complete 1 live virtual class per week for 8-weeks. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the instructor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rates and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. They will be encouraged to access them on demand throughout the week. In addition participants will have access to the same 8 pre-recorded educational videos that the control group will receive. Topics include; exercise safety, goal setting, nutrition, stress management, medication information, risk factor awareness and transition planning."
9707991|NCT04662567|Active Comparator|Oral acetaminophen group|the subjects in this group will receive 1000 mg oral acetaminophen 30-45min prior to oocyte retrieval
10204662|NCT05179343|Experimental|Active arm|Participants in this arm will receive the active AffeX-CT device.
9707992|NCT04662567|Active Comparator|IV acetaminophen group|the subjects in this group will receive 1000 mg IV acetaminophen formulation intraoperatively
9707993|NCT04662580|Experimental|ARX517 Part 1 (Dose Escalation)|Subjects will be administered ascending dose levels of ARX517 via intravenous (IV) infusion every 3 weeks. Subjects will be enrolled into escalating dose levels during the Dose Escalation period of the study.
9707994|NCT04662580|Experimental|ARX517 Part 2 (Dose Expansion)|Subjects will be administered maximum dose levels of ARX517 via intravenous (IV) infusion every 3 weeks. Subjects will receive the maximum tolerated dose during the Dose Expansion period of the study.
9707995|NCT04662528|Placebo Comparator|Placebo|
9707996|NCT04662528|Experimental|MAT9001 (omega-3-pentaenoic acid)|
9707997|NCT04662658|Other|Visit 1 UVA|"Visit 1 will last approximately 4 hours, and will include consenting, collection of data, questionnaires, and procedures as follows:~Informed consent~Demographic data~Smoking history~Medical history review~Medication review~Limited physical exam~6-minute walk test~St. George's Respiratory Questionnaire (SGRQ)~Baseline dyspnea index (BDI)~Chronic respiratory questionnaire (CRQ)~PFTs including:~Pre-bronchodilator spirometry/ post bronchodilator spirometry.~Body plethysmography (static lung volumes)~Carbon monoxide diffusion capacity (DLCO)~Collection of peripheral blood (20mL), exhaled breath condensate (EBC), and urine~Hyperpolarized xenon-129 MRI (HXeMRI) if all eligibility criteria are met"
9707998|NCT04662658|Other|Visit 2 Duke University|"Visit 2 will last about 3 hours, and will occur within 2-12 weeks of Visit 1. The purpose of this study visit is to obtain a measure of basic test-retest variability on 6 e-cigarette users and 6 control subjects. Participants will be selected based on age and sex matching needs at the time of enrollment.~During Visit 2, changes in health since Visit 1 will be assessed. In addition, the following will be done in accordance with the parent protocol:~The standard MR compatibility screening form will be completed.~Spirometry will be performed before and after MR imaging.~A limited physical exam~Female subjects who could be pregnant will take a urine pregnancy test prior to imaging.~Xenon MRI will be performed~In addition to the above, the following will be completed:~Carbon monoxide diffusion capacity (DLCO)~Peripheral blood (20mL) and urine"
9707999|NCT04662333|Active Comparator|Crestal sinus lift|Implant site preparation with detachment of Schneiderian membrane and subsequent implant placement. The corresponding healing abutment is made up of PEEK (poly-ether-ether-ketone)
9708000|NCT04662333|Experimental|Crestal sinus lift with adjunctive xenograft|Implant site preparation with detachment of Schneiderian membrane. After that, collagen membrane plus xenogenic bone substitute will be placed into the site before implant placement. The corresponding healing abutment is made up of titanium.
9708001|NCT04662593|Experimental|Intervention Group|"The intervention group participates in a 17-week whole health program including:~Weekly, small group online meetings with a health coach;~Supportive social media including a private Facebook group and selective text messaging;~Exposure to community tree planting and stewardship (through live streaming or in-person if COVID-19 public health guidance at the time, permits."
9708002|NCT04662593|No Intervention|Control Group|The control group participates only in questionnaire data collection at baseline, 4 months, and 6 months as well as daily weighing. Control group participants will be offered 3 web-based seminars (webinars) highlighting the effective lifestyle approaches demonstrated in the study and intervention group health education materials. The webinars and materials will be provided after the 6-month data collection which concludes the study.
9708003|NCT04662424|Experimental|MUSIC|music in labor
9708004|NCT04662424|No Intervention|control|no music during labor
9708005|NCT04662645|Experimental|Supportive care (embedded palliative care)|Participants and caregivers undergo embedded palliative care comprising symptom management (physical and psychological), advanced directives and goals of care discussion, caregiver support, and referral for adjunctive supportive services as needed at each clinic visit.
9708006|NCT04662346|Other|patients undergoing robotic pancreatoduodenectomy|patients have pancreatic neoplasm and undergoing robotic pancreatoduodenectomy
9708007|NCT04662385|Experimental|aloe vera toothpaste group|a recently available aloe vera toothpaste for gingival care, offers a completely improved approach for treatment of gingivitis. aloe vera toothpaste was certified as an antibacterial .This innovative toothgel is made using stabilized aloe vera gel from Forever's own plantations and can help you fight plaque as part of a regular brushing routine.
9708008|NCT04662385|Active Comparator|colegate total toothpaste group|Active Ingredient: Stannous fluoride 0.454% (0.15% w/v fluoride ion) Purposes: Anticavity, Antigingivitis, Antisensitivity. Inactive ingredients: Zinc phosphate, Water, Sorbitol, Hydrated silica, Glycerin, PEG-12, Tetras
9708009|NCT04662372||Patients|Patients
9979829|NCT01385631|Experimental|Atorvastatin plus Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
9979830|NCT01385657|Experimental|Placebo|Placebo (for Dupilumab) as a single subcutaneous (SC) injection on Day 1, 8, 15, and 22
9979831|NCT01385657|Experimental|Dupilumab 150 mg|Dupilumab 150 mg as a single SC injection on Day 1, 8, 15, and 22
9979832|NCT01385657|Experimental|Dupilumab 300 mg|Dupilumab 300 mg as a single SC injection on Day 1, 8, 15, and 22
10204663|NCT05179343|Sham Comparator|Sham arm|Participants in this arm will receive the sham (inactive) AffeX-CT device.
9708010|NCT04662229|Experimental|Experimental: 10 hz stimulatión|Eco-guided percutaneous electrical stimulation application of low frequency electrical current at 10 hz, 240 microsecond, over the median and ulnar nerve in the arm, for 1 minute on each nerve. The intensity of the current will reach the excitomotor threshold, causing visible but comfortable contractions.
9708011|NCT04662229|Sham Comparator|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and a sound will be applied.
9708012|NCT04662177|Experimental|Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies|The group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by continuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression.
9708013|NCT04662177|No Intervention|Group 2: Standard anaesthesia with propofol and electrophysiological studies|The group 2 receive standard anaesthesia management.
9708014|NCT04661943|Experimental|Arm A|Chidamide Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
9708015|NCT04661969||1|Foreign Substance disseminated to both lower extremities and buttocks
9708016|NCT04661969||2|Foreign Substance isolated to buttocks with moderate to severe skin changes
9708017|NCT04661969||3|Foreign substance isolated to lower legs with mild skin changes and superficial ulcerations
9708018|NCT04661969||4|Foreign substance isolated to lower legs with moderate to severe skin changes and/or ulceration
9708019|NCT04662164|Placebo Comparator|placebo|control
9708020|NCT04662164|Active Comparator|4.2mg hepalatide|low dose
9708021|NCT04662164|Active Comparator|6.3mg hepalatide|middle dose
9708022|NCT04662164|Active Comparator|8.4mg hepalatide|high dose
9708023|NCT04661982||Observational (long term follow-up)|Patients undergo long term follow-up and complete questionnaires.
9708024|NCT04662125|Active Comparator|group A|Group A (conservative treatment): Patients will receive good hydration, recumbent positioning, three tablets per day (combined paracetamol and caffeine tablet) for three days and stool softener.
9708025|NCT04662125|Active Comparator|group B|Group B (oral prednisolone): Patients will receive three tablets per day (one oral tablet prednisolone 20 mg plus two tablets of vitamins to maintain blinding) for three days.
10204664|NCT05179135|Active Comparator|Control|Standardized meal, without exercise
9708026|NCT04662125|Active Comparator|group C|Group C (oral pregabalin): Patients will receive three tablets per day (oral tablet pregabalin 100 mg) for three days.
9708027|NCT04662242|Experimental|low serum selenium with selenium supplement|Patients having low serum selenium with selenium supplement given
9708028|NCT04662242|Placebo Comparator|low serum selenium with placebo supplement|Patients having low serum selenium with placebo given
9708029|NCT04662242|Active Comparator|non-low serum selenium with selenium supplement|Patients having normal serum selenium with selenium supplement given
9708030|NCT04662242|Placebo Comparator|non-low serum selenium with placebo supplement|Patients having normal serum selenium with placebo given
9708031|NCT04662112|Experimental|NASOX|Liposomal irinotecan+S-1+oxaliplatin
9708032|NCT04662216|Active Comparator|control group|Scaling and root planing
9708033|NCT04662216|Experimental|test group|"scaling and root planing + Perisolv +Hyadent BG gels."
9708034|NCT04661891|Experimental|Healthy Participants|The investigators will look at muscle activity of healthy participants from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
9708035|NCT04661891|Experimental|Clinical Participants|The investigators will look at muscle activity of participants post-stroke from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
9708036|NCT04662047||Adults and children living in the 11 principal cities of Cataluña, Spain.|Adults and children living in the 11 principal cities of Cataluña, Spain: Barcelona, Hospitalet de Llobregat, Tarrasa, Badalona, Sabadell, Lérida, Tarragona, Mataró, Santa Coloma de Gramanet, Reus, Girona.
9708037|NCT04662021|Experimental|Exercise group|
9708038|NCT04662021|Experimental|Cognitive therapy group|
9708039|NCT04661904|Experimental|cTBS group|Patients randomly assigned to cTBS group will receive 12 sessions cTBS for total four days after surgery.
9708040|NCT04661904|Sham Comparator|sham group|Patients randomly assigned to sham group will receive 12 sessions sham stimulation for total four days after surgery.
9708041|NCT04661917|Experimental|BAY2327949|Participants will receive 60 mg of BAY2327949 (2 tablets of 30 mg) once daily for 28 days.
10204665|NCT05179135|Experimental|Low-intensity walking|
10204666|NCT05179135|Experimental|Moderate-intensity cycling (MOD)|
10204667|NCT05179135|Experimental|High-intensity interval exercise (HIIT)|
10204668|NCT05179135|Experimental|Intermittent high-intensity exercise (IHE)|
9708042|NCT04661917|Placebo Comparator|Placebo|Participants will receive matching placebo once daily for 28 days.
9708043|NCT04661865|Other|Control group|Routine care only They will receive routine antenatal care that included iron supplementation with follow up of hemoglobin level
9708044|NCT04661865|Experimental|Intervention group|They will receive the Heath Information Package Program (HIP program)
9708045|NCT04661618|Active Comparator|GT|12 weeks of progressive training in the first phase and 12 weeks of maintenance training in the second phase.
9708046|NCT04661618|Other|Control|"No intervention for the first phase and will be active comparator in the second phase.~No intervention for the first 12 weeks (first phase) and 12 weeks of progressive training in the second phase."
9708047|NCT04661553|Experimental|Group1: patients with a low risk of premature birth|Asymptomatic patient receiving usual follow-up in the maternity ward.
9779203|NCT01124864|Experimental|EGFR mutant patients|Patients with EGFR activating mutation tumors (Note: These patients must have progressed on one prior EGFR TKI containing regimen unless they have documented T790M activating mutation). Patients received AUY922 at 70 mg/m^2 weekly infusions.
10204669|NCT05177172|Placebo Comparator|Control|White wheat flour bread
9708048|NCT04661553|Experimental|Group2: patients with a high risk of premature birth|Symptomatic patients with cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm. Asymptomatic patients with a history of premature delivery or late miscarriage and cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm.
9708049|NCT04661683|Experimental|Peripheral Endothelial Function|Brachial artery flow-mediated dilation will be used to measure endothelial function
9708050|NCT04661683|Experimental|Central Arterial Stiffness|Pulse wave velocity will be used to measure arterial stiffness.
9708051|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by articulating paper|In this group the final occlusal correction will be performed with the patient in supine position using 20 um thick articulating paper and articulating foil 8 um thick. The patient will be asked to tap 3 times on the articulating paper and occlusal correction will be done using carbide laboratory bur and rubber cone till uniform contact on all teeth is achieved in centric relation which is illustrated on the splint by a series of uniformly appearing articulating paper dots. Then the patient will be asked to make protrusive and right and left excursions to ensure smooth anterior guidance and posterior disocclusion.
9708052|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by T-scan|"In this group the same adjustment sequence will be done using T Scan III (software version 8.0) computerized occlusal analysis, a new patient file will be opened, the patient's biological data will be entered, and the T Scan dental arch size is customized to fit the patients arch anatomy. The patient will be asked to clench to record occlusal force and areas that needs adjustment will be grinded using the paper marks as the guideline and carbide laboratory bur till bilateral force balance achieved and the center of force (COF) icon sits close to the midline.~Mandibular excursions are then adjusted in a similar fashion. Contacts rather than anterior and canine guidance will be eliminated till achieving anterior guidance and posterior disocclusion in time less than 0.5 seconds."
10193662|NCT05157568|Active Comparator|Exercise Streaming + Equipment (ES+E)|"Participants will receive an indoor bicycle and an exercise band (delivered and set up in their home). Participants will complete 1 live class per week for 8 weeks. Their exercise prescription will be based on a stress test. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the exercise supervisor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rate and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. Participants will be encouraged to access them throughout the week. Participants will have access to the same 8 pre-recorded educational videos that the control and exercise streaming groups will receive."
9708053|NCT04661826|Experimental|Oncofid-P-B|Oncofid-P-B will be administered once a week for 6 weeks in the first treatment phase and once a month for 6 months followed by other 6 months in the second maintenance phase
9708054|NCT04661800|Other|Test de bâton de Sniff|Cohorte
9708055|NCT04661501|Active Comparator|AlloDerm group|Device for immediate implant based breast reconstruction.
9708056|NCT04661501|Active Comparator|AlloMax group|Device for immediate implant based breast reconstruction.
9708057|NCT04661501|Active Comparator|DermACELL group|Device for immediate implant based breast reconstruction.
9708058|NCT04661501|Active Comparator|Flex HD group|Device for immediate implant based breast reconstruction.
9708059|NCT04661644|Experimental|Test Group 1 (Low Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, which is divided into 1 cc pre-filled syringes and administered in 20 divided doses to 15-20 parts of the muscle in divided doses along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia so that the entire diluted solution is administered.
9708060|NCT04661644|Experimental|Test Group 2 (High Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, then administered to 15-20 parts of the muscle along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia.
9708061|NCT04661709|Experimental|Wen Xin granule|Patients are given Wen Xin granule by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
9708062|NCT04661709|Placebo Comparator|WXG placebo|Patients are given Wen Xin granule placebo by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
10193663|NCT05157464|Experimental|Losartan Group|
10193664|NCT05157464|No Intervention|Control Group|No additional steps in management are required for the control arm of the study.
9708063|NCT04661527|Experimental|Sarilumab arm|
9708064|NCT04661488||Children and adolescence|
9708065|NCT04661696|Experimental|single-arm|Paclitaxel (albumin-bound) 130 mg/m2, i.v., d1, 8; Carboplatin AUC 5, i.v. d1; repeat every 21days, 6 cycles.
9708066|NCT04661657||COVID-19|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have tested positive or have been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
9779204|NCT01124864|Experimental|Kras mutant patients|Patients with KRAS mutant tumors. Patients received AUY922 at 70 mg/m^2 weekly infusions.
9779205|NCT01124864|Experimental|EGFR and Kras wild type patients|Patients exhibiting both mutations were stratified to the KRAS mutation stratum. Patients received AUY922 at 70 mg/m^2 weekly infusions.
9708067|NCT04661657||Control|Non-prisoner and non-pregnant subjects, without prior cardiac disease, who have never tested positive and/or has never been hospitalized due to COVID-19 infection. Subjects will be undergo a physical exam, blood draw to asses serological biomarkers. Subjects will also undergo an transthoracic echocardiogram (TTE) and a clariscan-enhanced cardiovascular magnetic resonance imaging (CMR) using a gadolinium based contrast agent (GBCA).
10193665|NCT05157100|Experimental|Ingrezza|Participants will receive Ingrezza orally once daily for 12 weeks.
10193666|NCT05157035|Experimental|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
10204670|NCT05177172|Experimental|High betaglucans|White wheat flour bread included beta glucans with the highest amounts in this study
9708068|NCT04661475|Experimental|Dexmedetomidine adjunctive to ECT arm|
9708069|NCT04661475|Placebo Comparator|Normal Saline adjunctive to ECT arm|
9708070|NCT04661774|Other|Sham massage before reflexology massage (RP)|Sham massage (MS) comparator will be realised before RP.
9708071|NCT04661774|Other|Reflexology massage (RP) before Sham massage|RP will be realized before Sham massage.
9708072|NCT04661449|Experimental|Lifestyle Intervention|every 3 months within 1 year.
9708073|NCT04661449|No Intervention|control group|Regular follow-up every 6 months within 1 year.
9708074|NCT04661852|Experimental|CABOZANTINIB WITH TOPOTECAN-CYCLOPHOSPHAMIDE|"Participants will be accrued to dose levels in cohorts of 3 using the 3 + 3 design with a combination of cabozantinib, topotecan and cyclophosphamide.~Each study treatment cycle lasts 21 days.~Participants may receive up to 17 cycles.~Participants will be assigned a specific dose and schedule of the study drugs determined when enrolled in the study."
9708075|NCT04661046|Experimental|TCM Syndrome Types|Traditional Chinese Medicine
9708076|NCT04661098|Experimental|Postpubertal patients with imperforate hymen|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
9708077|NCT04661189|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
9708078|NCT04661189|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
9708079|NCT04661345||Septic group|The septic group is composed of patients with prosthetic joint infection mediated by coagulase-negative Staphylococci (CoNS)
9708080|NCT04661345||Aseptic group|The aseptic group is composed of patients with implant failure unrelated to infection.
9708081|NCT04661254|Other|Lymphapheresis|Blood is drawn from one of the patient's two arms and passes through a separation circuit. After removing the white blood cells, it is reinjected into the other arm.
9708082|NCT04661371|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
9708083|NCT04661371|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
9708084|NCT04661319|Experimental|video editing training group|"- inclusion criteria~trainees in general surgery~No experience of laparoscopic cholecystectomy~Less than 5 experiences of laparoscopic surgery~Uncomplicated symptomatic gallstone disease~The experimental group received video editing training"
9708085|NCT04661319|Experimental|traditional training group|"- inclusion criteria~trainees in general surgery~No experience of laparoscopic cholecystectomy~Less than 5 experiences of laparoscopic surgery~Uncomplicated symptomatic gallstone disease~The control group received tradtional training"
9708086|NCT04661332||Endoscopic retrograde cholangio-pancreatography|Endoscopic retrograde cholangio-pancreatography procedure
9708087|NCT04661397|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
9708088|NCT04661397|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COBI] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
9708089|NCT04661111|Experimental|Hymovis ONE Arm|Hymovis® ONE (32 mg/4 ml) intra-articular mono injection. Patients will be followed during 12 months including 6 visits.
9708090|NCT04661020|Experimental|Administration of CD19 CAR T-cells|
9708091|NCT04660773|Active Comparator|NB UVB phototherapy|(20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months.
9708092|NCT04660773|Active Comparator|pregabalin|20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.
9708093|NCT04660630|Experimental|Precision group|The subjects were tested for gene, and the corresponding therapeutic drugs were selected according to the results of gene detection. Regular follow-up was conducted according to the study design to evaluate the efficacy and adverse reactions.
9708094|NCT04660630|Active Comparator|Experience group|The subjects were treated with drugs selected by doctors according to their experience. Follow up was performed at the same frequency as the precision group to evaluate the efficacy and adverse reactions.
9979833|NCT01385683|Active Comparator|Arm A|Dabigatran then dabigatran and clarithromycin
9708095|NCT04660630|No Intervention|Observation group|The subjects did not accept any intervention, including follow-up, especially regular evaluation of efficacy and adverse reactions.
9708096|NCT04660708|Experimental|Pregnant women|"Physical assessment for women 20-34 weeks gestation including evaluating pain, back and hip range of motion, strength of hip and abdominal muscles, diastasis recti, and strength, amount of scar tissue from previous pregnancies / deliveries, level of muscle overactivity, and the extent of any prolapse of pelvic floor muscles.~Treatment: internal and external myofascial release of the pelvic floor muscles, pelvic floor stretching, and instruction diaphragmatic breathing and exercises for postpartum recovery to perform at home. Exercises include: Pelvic floor stretching: happy baby stretch, deep squat, butterfly stretch; Belly breathing; transverse abdominis contraction, transverse abdominis march, bridge, shoulder blade; Instruction and education on perineal massage and posture."
9708097|NCT04660669|Other|ESDM 15h|This arm receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center.
9708098|NCT04660669|Other|ESDM 8h + MOOC|This arm receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.
9708099|NCT04660916||isotretinoin|The patients aged 18-45 that were planned to begin treatment with isotretinoin for acne
9708100|NCT04660916||control|Healthy volunteers aged 18-45 without any diseases/drugs affecting the nail
9779206|NCT01124864|Experimental|Patients with EML4-ALK translocation|Patients with NSCLC who have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase. ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain. Patients received AUY922 at 70 mg/m^2 weekly infusions.
9779207|NCT01124864|Experimental|Modified EGFR mutant patients|The modified EGFR stratum was defined as patients less heavily pretreated who had received one or two lines of prior therapy, with a documented response to a EGFR tyrosine kinase inhibitor (TKI) (complete response (CR), partial response (PR) or stable disease (SD) for ≥ 6 months), unless the patient had de novo resistance to EGFR TKI. Patients received AUY922 at 70 mg/m^2 weekly infusions.
9779208|NCT01124916|Active Comparator|Laparoscopic Abdominal Sacrocolpopexy (LASC)|Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC)
9779209|NCT01124916|Experimental|Robotic Assisted Laparoscopic (RASC)|Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
9779210|NCT01124955|Active Comparator|Intervention Group|Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.
9779211|NCT01124955|Placebo Comparator|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
9779212|NCT01125046|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
9779213|NCT01125098||PRO-CT group: Experimental|COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.
10204671|NCT05177172|Experimental|Low beta glucans|White wheat flour bread included beta glucans with the lowest amounts in this study
9779214|NCT01125098||Standard group: No intervention|COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
9779215|NCT01125163|Active Comparator|multivitamin with iron|daily oral multivitamin providing 2mg/kg of iron
9779216|NCT01125163|Placebo Comparator|multivitamin without iron|daily oral multivitamin without iron
9779217|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg)|
9779218|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg)|
9779219|NCT01125189|Placebo Comparator|Placebo plus peg-interferon alfa-2a and ribavirin|
9779220|NCT01125202|Experimental|SCT-based behavioral intervention|Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary counseling intervention based on Social Cognitive Theory. Dietary counseling is paired with Personal Digital Assistant-based dietary self-monitoring.
9779221|NCT01125202|Active Comparator|Attention control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
9779222|NCT01125293|Experimental|Phase I Stage A Level 1|"Combination of everolimus & rituximab for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
9779223|NCT01125293|Experimental|Phase I Stage A Level 2|"Combination of everolimus & rituximab for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
9779224|NCT01125293|Experimental|Phase I Stage B Level 1|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle (1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
10193667|NCT05157035|No Intervention|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
10193668|NCT05157009|Other|Immediate implant placement without reconstruction|Immediate implant placement after tooth extraction
10193669|NCT05157009|Other|Immediate implant placement with reconstruction|Immediate implant placement and simultaneous bone reconstruction after tooth extraction
10193670|NCT05156905|Experimental|Cirmtuzumab + Docetaxel|There is only one treatment arm on this study. The combination of cirmtuzumab + docetaxel will be administered on one treatment arm. Treatment will cirmtuzumab will be administered initially as a loading dose alone on days 1, 15, and 29 of cycle 1. Following the loading, cirmtuzumab will be given on Day 1 of every 21-day cycle starting on Cycle 2 to up to Cycle 7 corresponding with concurrent docetaxel administration. Following discontinuation or completion of docetaxel, treatment with cirmtuzumab will be continued Day 1 of every 28 cycle until disease progression, toxicity or study withdrawal. Docetaxel will be administered on day 1 of every 21-day cycle starting Cycle 2 for up to 6 cycles.
10193671|NCT05155722|Experimental|Single group|First Phase: dose escalation study. It was divided into three dose groups: 100mg, 300mg and 600mg. The safety, tolerance and pharmacokinetics of BAT1308 injection were explored according to the 3+3 dose increasing mode. It is expected that 12-18 cases will be included in the group. Second Phase: dose expansion study. After the completion of dose increment, 300mg tolerated doses were selected for extended research on advanced non-small cell lung cancer, advanced hepatocellular carcinoma and cervical cancer (80-130 cases), so as to provide recommended doses for subsequent clinical trials.
10193672|NCT05155657|Experimental|Low dose umbilical cord mesenchymal stem cells (UCMSCs)|
10193673|NCT05155657|Experimental|Medium dose UCMSCs|
10193674|NCT05155657|Experimental|High dose UCMSCs|
10193675|NCT05153044|Other|sickle cell children group|sickle cell children group
10193676|NCT05153044|Other|sickle cell adult group|sickle cell adult group
10193677|NCT05153044|Other|control children group|control children group
10193678|NCT05153044|No Intervention|Vaccinated patients|Vaccinated patients
10193679|NCT05152381|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10193680|NCT05152368|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10193681|NCT05152290|Experimental|Treatment Group (AlloRx)|intravenous infusion and intrathecal injection (total of 100 million cells)
10193682|NCT05147987|Experimental|Intervention Group|Will be provided a discreet, hands-free, wearable breast pump with an associated App
10193683|NCT05147987|No Intervention|Standard care group|Will be provided a standard mechanical breast pump with no associated App.
10193684|NCT05147766|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10193685|NCT05147701|Experimental|Treatment Group (AlloRx)|intravenous and sub-tenon delivery (total dose of 100 million cells)
10193686|NCT05146466|Other|E-MATVR (intervention)|
10193687|NCT05146466|Other|E-MATEE (control)|
10193688|NCT05145582|Experimental|Unguided, Transdiagnostic ICBT Tailored for PSP|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD.
10193689|NCT05145582|Experimental|Unguided, Transdiagnostic ICBT Tailored for PSP + Online Discussion Forum|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD plus a built-in online discussion forum.
10193690|NCT05142280|Experimental|Active choice|This intervention contains information and an assignment to foster an active choice regarding coping with an increased CVD risk. Participants will be presented a hypothetical 'heart age' of 16 years older than their actual age. They will be asked to imagine that this heart age really applies to them. Next, participants will receive information about the meaning of the risk, including its causes and potential consequences, and about four coping strategies: changing one's lifestyle; taking medication; doing both; or changing nothing. The pros and cons of each strategy will be presented, followed by a value-clarification exercise.
10193691|NCT05142280|Other|Control|The control group will receive online information and advice that resembles GP's usual care. The information contains a hypothetical CVD risk: a risk of 31% to get CVD within 10 years. They will be asked to imagine that this risk really applies to them. Participants will read about an imaginary GP who advices to change one's lifestyle (i.e., quitting smoking; healthy diet; more physical activity), and to use medication to decrease the risk.
10193692|NCT05137834|Experimental|"Exercise with a peanut ball."|"The rehabilitation program consists of mobility- and functional training exercises with a peanut ball."
10193693|NCT05137834|Active Comparator|"Exercise without peanut ball"|"The rehabilitation program consists of standard mobility- and functional training exercises without a peanut ball."
10193694|NCT05135910|Experimental|HSG|Hallux terbinafine subungual gel
10193695|NCT05121714|Other|Evaluation of CYP1A2 inhibition and induction potential by ABX464|Using a fixed-sequence crossover study design, the Pharmacokinetics (PK) of caffeine (50 milligrams (mg) single oral dose) will be evaluated in the absence and presence of ABX464 (50 mg once daily for 14 days) in 24 healthy subjects. Caffeine will be administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.
10193696|NCT05121714|Other|Evaluation of ABX464 as a substrate for CYP1A2|Using a fixed-sequence crossover study design, the PK of ABX464 (50 mg single oral dose) will be evaluated in the absence and presence of fluvoxamine (100 mg once daily for 10 days) in 36 healthy subjects. ABX464 will be administered on Day 1 in the absence of fluvoxamine and on Day 11 simultaneously with fluvoxamine following 10 days of once daily dosing of fluvoxamine to evaluate whether ABX464 is a substrate for CYP1A2
10193697|NCT05121675|Experimental|App with behavioral economics + financial incentives|NeuroFlow uses behavioral economics reminders, gamification, and fun, motivating messages to encourage use. It also includes financial incentives so users can earn redeemable points accrued for activity completion for gift cards at popular outlets (e.g., 1000 points which is the maximum per month = $10 gift card).
9708101|NCT04660877|Experimental|Cheddar chese|Once enrolled, participants will either ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
9708102|NCT04660877|Active Comparator|Milk|Once enrolled, participants will ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
9708103|NCT04660851|Experimental|Coached|10 weeks of diet coaching
9708104|NCT04660851|No Intervention|Not-coached|No coaching provided
9708105|NCT04660786|Active Comparator|intralesional injection of triamcinolone acetonide|5mg/ml) using sterile saline for dilution every 4 weeks for 3 sessions
9708106|NCT04660786|Active Comparator|intralesional injection of vitamin D|(2.5 mg/mL) every 4 weeks for 3 sessions
9708107|NCT04660955||Patients|Patients who had ACL reconstruction
9708108|NCT04660955||Controls|Controls who have no previous knee injury or surgery, no diagnosis of osteoarthritis
9708109|NCT04660981|Experimental|İntervention Group|"The women in the intervention group were individually provided with Training Program on Fear of Childbirth Based on Motivational Interview Method once a week, four sessions in total."
9708110|NCT04660981|No Intervention|Control Group|No interventions were made for those in the control group other than routine hospital practices.
9708111|NCT04660825|Experimental|High intensity resistance band exercise|Randomly assigned as exercise group, exercise intervention. This will be a progressive exercise programme with the aim being to participate three times per week, one in a group session and two in-home sessions.
9708112|NCT04660825|Experimental|Non resistance band exercise|Randomly assigned non-exercise group
9708113|NCT04660682|Experimental|Modified static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the modified cross-body stretching position. Additionally, they will receive standard physiotherapy program.
9708114|NCT04660682|Experimental|Traditional static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the traditional standing cross-body stretching position. Additionally, they will receive standard physiotherapy program.
9708115|NCT04660682|Active Comparator|Control Group|The participants in this group will receive sham stretching and standard physiotherapy.
9708116|NCT04660942||Control|Healthy child
9708117|NCT04660942||Experimental|Patients with developmental delay
9708118|NCT04660994||Therapeutic education|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
9708119|NCT04660994||Therapeutic education and Yapouni educational game|Children with disordered breathing requiring CPAP or NIV and followed-up by the pediatric non-invasive ventilation and sleep unit of Necker-Enfants Malades hospital.
9708120|NCT04660734|Experimental|3D printing group|"Group 1 (G1) consisted of 20 patients who underwent preoperative molding of the osteosynthesis plate on a 3D printed model of the pelvis. A preoperative scan of the healthy hemi-pelvis was used to create the 3D-printed model for patients in G1 according to the following three-step methodology: 1) A scanographic acquisition of images was performed using a multi-strip scanner in thin sections. These images were recorded as digital images in the standard medical format of digital imaging and communications ; 2) A digital, 3D model of the pelvis in the stereolithography format was created to digitally treat the 2D images. The individualization of the healthy hemi-pelvis, to which a mirror effect was applied allowed for the creation of a symmetrical 3D image, as hemi-pelvises are globally symmetrical. 3) A 3D printer was used to create a physical, 3D-printed model of the affected hemi-pelvis using polylactic acid."
9708121|NCT04660734|Experimental|conventional technique group|Group 2 (G2 or control group) included 23 patients who underwent surgery using the conventional technique.The patients in the control group (G2) underwent surgery following the conventional procedure based on radiographic and CT images with 3D reconstructions.
9708122|NCT04660903|Experimental|Intervention|One arm study - the intervention arm is the only actual
9708123|NCT04660695||Group 1|Patients included will undergo an EUS-guided gastroenterostomy with a 15x10mm or a 20x10mm lumen apposing metal Stent (Axios, Boston Scientific, Mass).
9708124|NCT04660643|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
9708125|NCT04660643|Placebo Comparator|Placebo|Placebo administered SC
9708126|NCT04660604|Experimental|Graston Technique® Group|Participants were asked to warm up at a speed that they felt comfortable for 5 minutes at a gentle tempo with an ergometer. Time was followed by a stopwatch. Participants who completed warm-up were taken to GT® application. Application was implemented by a GT® certified therapist with 13 years of experience in orthopedic rehabilitation. Intervention dosage was determined as 2 times a week, 12 sessions over 6 weeks. GMed muscle was scanned between crista iliaca and trochanter major, and a fascial release was applied. Each session lasted 5 minutes. At the end of sessions, iliotibial band stretching exercises (30 seconds, 3 repetitions) was given to the treated side. Application protocol has been determined with reference to GT® manual
9708127|NCT04660604|No Intervention|Control Group|Control group is followed up for 6 weeks without intervention.
9708128|NCT04660578|Experimental|Single Group|A.Chohan continuous squeezing suture (ACCSS); An Obstetrical procedure using half circle 40mm round body polyglactin 910 suture #1 (Vicryl plus by Ethicon®), for controlling hemorrhage from the lower uterine segment, in patients with placenta previa / accreta for the prevention of hysterectomy at cesarean section.
9708129|NCT04660266|Other|all cohort|
9708130|NCT04660513||Morbid obesity|BMI 32.5 kg/m2 and above
9708131|NCT04660513||Non-obese healthy controls|BMI below 25 kg/m2
9708132|NCT04660591|Active Comparator|standard femoral stem|standard length femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
9708133|NCT04660591|Active Comparator|long femoral stem|long femoral stem arthroplasty applied for patients with proximal femoral metastasis either impending or pathological fracture
10193698|NCT05121675|Active Comparator|App with behavioral economics incentives only|NeuroFlow uses behavioral economics reminders, gamification, and fun, motivating messages to encourage use. including points accrued for activity completion. This version of the app does not have financial incentives.
10193699|NCT05118750|Experimental|ALTO-300|ALTO-300 tablet PO; daily dosing 8 weeks
10193700|NCT05117710|Active Comparator|Ebselen|The intervention will be 7-10 days administration of ebselen 600 mg twice daily taken orally. Ebselen has been manufactured to Good Manufacturing Practice (GMP) standards and will be provided by Sound Pharmaceuticals Inc. in 200 mg capsules.
10193701|NCT05117710|Placebo Comparator|Placebo|The intervention will be 7-10 days administration of placebo 600 mg twice daily taken orally.Identical placebo capsules have been manufactured and formulated in the same facilities as the active treatment.
10193702|NCT05114785||HFpEF group|Suspected HFpEF group: 80 patients will be recruited with history of dyspnoea, LV ejection fraction ≥ 50%, raised NTproBNP
9708134|NCT04660552|Experimental|CognilumTM|During the study participants will be wearing the photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
10193703|NCT05114785||Control group|20 patients with suspected CAD but with no dyspnoea and normal echocardiogram.
10193704|NCT05111236|Active Comparator|RPT Group|"Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies. This whole regimen will be practiced fives times a week for a period of twelve weeks.~Other Names:~• Routine Physical Therapy"
9708135|NCT04660552|Placebo Comparator|Placebo condition|During the study participants will be wearing the photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
9708136|NCT04660253|Experimental|LTP Plus Dads|Participants in this group will receive 10 sessions of LTP plus dads
10193705|NCT05111236|Experimental|Massage Group|"Traditional massage of thirty minutes duration ( five minutes of massage will be provided to all four limbs, front and back of trunk area) prior to routine physical therapy. Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies.~Other Names:~• Routine physical therapy and Traditional massage"
9708137|NCT04660461|Experimental|1. Randomized placebo-controlled, parallel-group study, crossover-design|
9708138|NCT04660461|Experimental|2. Randomized placebo-controlled, parallel-group study, crossover-design|
9708139|NCT04660305|Experimental|AT278|Single subcutaneous injection 0.3U/kg
9708140|NCT04660305|Active Comparator|NovoRapid|Single subcutaneous injection 0.3U/kg
9979834|NCT01385683|Active Comparator|Arm B|Clarithromycin and dabigatran and dabigatran
9708143|NCT04660318|Experimental|Experimental: remote photoplethysmography for physiological parameters Monitor Readings|
9708144|NCT04660318|Other|Control: rstandard acquisition system for physiological parameters Monitor Readings|
9708145|NCT04660292|Experimental|Study Group|The study group was treated with Maitland mobilization and manipulation techniques including postero-anterior Maitland mobilization for C1-C2, Maitland lateral PA glide for C3-C6 and Maitland thrust manipulation for cervico-thoracic junction. Frequency of mobilization was 2 days a week for 4 weeks. While intensity of mobilization was grade 3 and 4 based on the Maitland concept.13 Time of oscillations was 2 or 3 oscillations in a second for 1 to 2 minutes.
9708146|NCT04660292|Active Comparator|Control Group|While placebo treatment with conventional physiotherapy (active exercises-10 repetitions in all direction in pain free range, isometrics 5-10 seconds brief but maximum contraction each held for 5-16 seconds for flexors, extensors, side flexors and rotators)14 without gliding, oscillations and thrust were recommended for the control group.The placebo group was treated with baseline treatment including TENS 10 minutes and moist hot packs in sitting position for 15 minutes on cervical region in with head resting on table with a pillow.
9708147|NCT04660435||Women with ER+/Her2 negative metastatic breast cancer|Patients with ER+/HER2-negative metastatic breast cancer candidate to first-line treatment with a CDK4/6 inhibitor and an aromatase inhibitor as per standard clinical practice
9708148|NCT04660409|Other|Child Pugh A|
9708149|NCT04660409|Other|Child Pugh B|
9708150|NCT04660409|Other|Child Pugh C|
9708151|NCT04660409|Other|HCC|
9708152|NCT04660409|Other|Healthy|
9708153|NCT04660474||Early reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT<24 hours were assigned to Early reperfusion group.
9708154|NCT04660474||Intermediate reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT ranging from 24 hours to 7days were assigned to Intermediate reperfusion group.
9708155|NCT04660474||Late reperfusion group|All patients hospitalized and diagnosed as STEMI according to the 4th universal definition of myocardial infarction underwent coronary angiography and PCI treatment. Patients with SO2RT>7days were assigned to Late reperfusion group.
9708156|NCT04660565|Experimental|Glucocorticoid monotherapy Group|Patients treated with single glucocorticoid
9708157|NCT04660565|Experimental|Combination therapy Group|Patients treated with Belimumab and glucocorticoid
9708158|NCT04660188|Experimental|Multidisciplinary collaborative care arm|Post-treatment clinical follow-up visits will be staggered between the oncologist and a dedicated PCP. A patient navigator will be assigned to each study participant to conduct follow-up sessions over the phone regularly at an approximate interval of 3 months.
9708159|NCT04660188|No Intervention|Attentional control arm|BCS will receive follow-up care by their oncologists and any other healthcare providers under existing usual care practices at NCCS.
9708160|NCT04660383|Experimental|IMT 50|"IMT intervention: IMT50 - 50% of the maximum inspiratory pressure (MIP), using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
9708161|NCT04660383|Experimental|IMT 30|"IMT intervention: IMT30 - 30% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
9708162|NCT04660383|Sham Comparator|IMT 10|"IMT intervention: IMT10 - 10% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
9708163|NCT04660370|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
9708164|NCT04660370|Experimental|Sequence 2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
9708165|NCT04660162|Experimental|Arm-1: Laser speckle contrast imaging|(Perimed AB, Järfälla, Sweden)
9708166|NCT04660162|Experimental|Arm-2: Laser Doppler perfusion imaging|(Moor Instruments, Devon, UK)
9708167|NCT04660136|Experimental|CEUS|
9708168|NCT04659889||Patients with clinical features of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are currently displaying symptoms of long Covid
9708169|NCT04659889||Patients with no symptoms of Long Covid|Patients who have had COVID-19 (PCR proven and/or clinical features of COVID-19) who are not displaying symptoms of long Covid
9708170|NCT04660110|Active Comparator|Intervention arm|A single dose/round of IPT with DP (40mg/320mg tabs, Fosun Pharmaceuticals)
10193706|NCT05110937||Sepsis|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
9708171|NCT04660110|No Intervention|Standard of care|Health information, no study drugs
9708172|NCT04659733|Experimental|Anlotinib hydrochloride|
9708173|NCT04659954|Experimental|Application O'DIDE|The subjects will use the application O'DIDE during 8 weeks
9708174|NCT04659928|Experimental|High volume evacuation (HVE) suction only and hydrogen peroxide|
9708175|NCT04659928|Experimental|HVE suction and extraoral vacuum aspirator (EVA) and hydrogen peroxide|
9708176|NCT04659928|Experimental|HVE suction and external evacuation device (EED) and hydrogen peroxide|
9708177|NCT04659837|Active Comparator|Inhibitory Control Training|Active Inhibitory Control Training vs. Sham Inhibitory Control Training
9708178|NCT04659837|Other|Gameification|Gameified elements added vs. No gameified elements added
9708179|NCT04659720|Active Comparator|summers' osteotome technique for closed sinus lift|Implant stability will be evaluated after closed sinus lift using summer's osteotome technique in posterior edentulous maxilla
9708180|NCT04659720|Active Comparator|Patient satisfaction evaluation after closed sinus lifting using summers' osteotome technique|"Will be assessed numerically using a patient satisfaction chart .~Time of assessment: immediately after surgery"
9708181|NCT04659967|Experimental|Pre/Post Training (Within subject)|Participants will complete a baseline questionnaire followed by immediate virtual training, and complete a post-training questionnaire. Participants will also be asked to complete a questionnaire 1-month, 3-months, and 6-months post-training.
9708182|NCT04660006||Control|Patients undergoing uneventful cataract surgery with no retinal vascular disease.
9708183|NCT04660006||Diabetic Retinopathy (DR)|Patients with non-proliferative diabetic retinopathy with no diabetic macular edema treatment in the 6 months prior to uneventful cataract surgery.
9979835|NCT01385709||Sertraline|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that sertraline is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking either sertraline on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
9979836|NCT01385709||Lithium|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that lithium is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking lithium on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
9708184|NCT04660006||Diabetic Macular Edema (DME)|Patients with diabetic macular edema undergoing active Anti-VEGF treatment (within the last 3 months) undergoing uneventful cataract surgery.
9708185|NCT04659824||Healthy|
9708186|NCT04659915|Experimental|Metformin + Prednison|"During one of the study periods, subjects receive Metformin 500 mg tablets p.o. for seven days (starting with a dose of 500 mg /d, then the dose will be increased by 500 mg the next days until 2000 mg /d is achieved).~Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days."
9708187|NCT04659915|Placebo Comparator|Placebo + Prednison|During the other study period, subjects receive the same dose of placebo tablets p.o instead of metformin. Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days.
10193707|NCT05110937||Healthy Controls|"Blood Collection.~The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable."
9708188|NCT04659759||COVID-19 Positive|Patients diagnosed with COVID-19 during pregnancy or while breastfeeding
9708189|NCT04659759||COVID-19 vaccine|Patients who receive COVID-19 vaccine during pregnancy or while breastfeeding
9708190|NCT04659759||Controls|Reproductive age women exposed to COVID-19 vaccine
9708191|NCT04659759||Pregnant Control|Pregnant women who delivered at TJUH, COVID negative
9708192|NCT04660019|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
9708193|NCT04660019|Placebo Comparator|sham acupuncture|Auricular points sticker
9708194|NCT04659980|Active Comparator|hilotherapy|
9708195|NCT04659980|Active Comparator|frozen gloves|
9708196|NCT04660058||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
9708197|NCT04660058||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
9708198|NCT04660058||gastric cancer|patients with gastric cancer according to histopathological results
9708199|NCT04660123|Experimental|Quadruple therapy with colloidal bismuth pectin granules|colloidal bismuth pectin granules 150 mg, Selection of 2 antibiotics and 1 proton pump inhibitor based on China's fifth national consensus report on the management of H. pylori infection.All medication is taken orally, twice a day.
9708200|NCT04660084|Other|Ultra-rapid molecular point-of-care testing|Extended and more rapid diagnostics on microbiological specimens and an active feedback to treating staff with results.
9708201|NCT04660084|No Intervention|Standard of care|Standard collection of microbiological specimens and standard reply to treating staff.
9708202|NCT04659785|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
9708203|NCT04659850|Other|Group 1|Group 1 participants in the young 18 - 30 age group
9708204|NCT04659850|Other|Group 2|Group 2 participants in the older 55 - 75 age group
9708205|NCT04659902|Placebo Comparator|CON|Participants will ingest a drink containing a control protein only
10193708|NCT05107219|Experimental|Arm I (plecanatide, EGD)|Patients receive a single dose of plecanatide (3 mg) PO 60-120 minutes prior to standard of care EGD.
10193709|NCT05107219|Experimental|Arm II (linaclotide, EGD)|Patients receive a single dose of linaclotide (145 mcg) PO 60-120 minutes prior to standard of care EGD.
10193710|NCT05107219|Active Comparator|Arm III (EGD)|Patients undergo standard of care EGD.
10193711|NCT05097885|Experimental|Sub Acute (12 week) Whole Body Training|
10193712|NCT05097729|Experimental|Stimulation Modality 1|Repetitive TMS will be applied at 100% resting motor threshold intensity to a region of interest located in the parietal cortex, that will be determined based on its connectivity with the hippocampus.
10193713|NCT05097729|Sham Comparator|Stimulation Modality 2|Parameters will be identical to the modality 1, except that the coil will be flipped over.
10193714|NCT05097729|Active Comparator|Stimulation Modality 3|The stimulation will be delivered over the motor cortex contralateral to the predominant painful region, i.e., right motor cortex stimulation if left knee pain. The stimulation intensity will be set at 80% of the resting motor threshold.
9708206|NCT04659902|Active Comparator|CON-C|Participants will ingest a drink containing a control protein plus Capolac® (9547 mg to provide 2500mg of calcium)
9708207|NCT04659902|Active Comparator|PRO|Participants will ingest a drink containing an aggregate protein only
9708208|NCT04659902|Active Comparator|PRO-C|Participants will ingest a drink containing an aggregate protein plus Capolac® (9547 mg to provide 2500mg of calcium)
9708209|NCT04659876||Grup S (Survivors)|Survivors in ICU follow-up
9708210|NCT04659876||Grup NS (Nonsurvivors)|Patients who died in ICU follow-up
10193715|NCT05080621|Experimental|Escalation|"Escalation Phase: Increasing doses of ripretinib in combination with increase doses of binimetinib in patients with advanced GIST who have progressed on at least imatinib or are intolerant to imatinib and are ripretinib naïve in repeated 28-day cycles.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
10193716|NCT05080621|Experimental|Expansion|"Ripretinib in combination with binimetinib at the recommended Phase 2 dose (RP2D) in patients with advanced GIST who have progressed on imatinib or are intolerant to imatinib and are naïve.~Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent"
9708211|NCT04659447|Experimental|Platelet-Rich Plasma|Four semitendinosus tendons and gracilis tendons are prepared. 4 ml platelet-rich plasma is completely absorbed by a gelatin sponge and fixed in the center of the four tendons. 4-0 absorbable line is used for fixation.Then we use conventional surgical techniques to reconstruct the ACL.
9708212|NCT04659447|No Intervention|control group|We performed conventional surgical techniques to reconstruction without using platelet-rich plasma.
9708213|NCT04659460|Experimental|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
9708214|NCT04659460|Sham Comparator|Sham Remote Ischemic Conditioning|RIC sham interventions will be applied to the upper extremity for a total of 20 cumulative minutes. For sham, inflation will occur.
10193717|NCT05070351|Experimental|PPI deprescribing arm|Patients taking a PPI (at least 20 mg omeprazole equivalent daily) will be instructed to stop taking their PPI.
10193718|NCT05070351|No Intervention|PPI continuation arm|Patients will be instructed to continue taking their PPI (at least 20 mg omeprazole equivalent daily) as usual.
10193719|NCT05070143|Experimental|Brief education|"Participants will be randomly allocated to the Brief Education condition or one of the five treatment conditions (see below).~In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time."
10193720|NCT05070143|Experimental|Treatment condition|All participants will receive the Brief Education intervention described above. Then, participants will be randomly allocated to one of the following conditions for habit formation.
10193721|NCT05068388|Placebo Comparator|Placebo|oral capsule
10193722|NCT05068388|Experimental|1 mg (Z)-endoxifen|oral capsule
9708215|NCT04659395|Other|Emergency nurses|Emergency nurses who are trained in an one-day course
9708216|NCT04659434|Experimental|treatment group|Sintilimab 200mg ivdrip Q3W; Rituximab 375mg/m2 ivdrip; Gemcitabine 1000mg ivdrip; Oxaliplatin 100mg/m2 ivdrip
10193723|NCT05068388|Experimental|2 mg (Z)-endoxifen|oral capsule
10193724|NCT05064007|Experimental|1|this group will be exposed to condition A first, then B, and C
9708219|NCT04659356||Patients admitted in Intensive Care Units|All patients admitted in our ICU since august were enrolled in our study, after they have been informed and given their consent for their participation in this observational study.
9708220|NCT04659525|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
9708221|NCT04659525|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
9708222|NCT04659330|Other|Intervention group|All patients underwent intervention
9708223|NCT04659343||Cohort 1|Patients treated for metastatic renal cell carcinoma in Denmark over a 2-year period.
9708224|NCT04659486|Experimental|Exercise training|A 12 weeks parallel-group randomized controlled trial will be performed, in which covid-19 survivors adolescents will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength and aerobic exercises
9708225|NCT04659486|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
9979837|NCT01385735|Placebo Comparator|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
9979838|NCT01385735|Active Comparator|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
10193725|NCT05064007|Experimental|2|this group will be exposed to condition B first, then C, and A
10193726|NCT05064007|Experimental|3|this group will be exposed to condition C first, then A, and B
9708226|NCT04659551|Experimental|Arm 1|Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses plus exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) started concomitantly to anthracycline based chemotherapy, to be continued until surgery.
10193727|NCT05062707||AYA cancer patients|Patients aged 18-39 years, with a first histological and/or cytological diagnosis of a haematological or solid malignancy, scheduled to start systemic therapy with curative intent.
10193728|NCT05060315||De Novo Cohort|Patients new to parenteral prostacyclin-class therapy.
9708227|NCT04659668|Experimental|MMG-23-04-2019|MMG-23-04-2019 is composed by sodium hyaluronate at concentration of 2% (20 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent, in aqueous solution at physiological pH. The filler of 1ml is administered once or twice depending on the individual necessity.
9708228|NCT04659694|Other|Single arm study|This study only contains one arm
9708229|NCT04659681|Active Comparator|PVI Guided Fluid Therapy|Patients will receive PVI guided fluids during surgery PVI to be maintained below 12% if PVI >12 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 Lung zones in both lungs to measure total number of B-lines.
9708230|NCT04659681|Active Comparator|CVP Guided Fluid Therapy|Patients will receive Standard CVP Guided Fluids , CVP maintained between 10-16 cms H20 , if CVP< 10 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 zones in both lungs to measure total number of B-lines.
9708231|NCT04659577|Experimental|internet based CBT|all patients will be offered active treatment via internet based CBT
9708232|NCT04659616|Experimental|Treatment (cytarabine, daunorubicin, pemigatinib)|"INDUCTION: Patients receive cytarabine IV on days 1-7, daunorubicin IV on days 1-3, and pemigatinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients with hematologic count recovery (assessed between days 25-42) after induction proceed to consolidation therapy.~CONSOLIDATION: Patients receive high dose cytarabine IV BID on days 1, 3, and 5, and pemigatinib PO QD on days 8-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression of unacceptable toxicity."
9708233|NCT04659499|Experimental|Nab-paclitaxel in combination with pyrotinib treatment group|Nab-paclitaxel 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib 240mg daily for one year
10193729|NCT05060315||Transition Cohort|Patients who are currently receiving SC Remodulin therapy via a previous generation infusion pump.
10193730|NCT05057676|Experimental|Intervention Autoimmune Intervention Mastery Course (AIM) online course|This arm will begin the intervention immediately after randomization
10193731|NCT05057676|Other|Delayed Autoimmune Intervention Mastery Course|This is the control arm.
10193732|NCT05056506|Active Comparator|Endoscopic papillary large balloon dilation group|Endoscopic papillary large balloon dilation to extract bile duct stones
9708234|NCT04659642|Active Comparator|dexmedetomidine group (group A)|will receive Dexmedetomidine 1ug/kg body weight IV diluted to 100ml normal saline (NS) over 15 minutes.
9708235|NCT04659642|Active Comparator|Fentanyl group (group B)|will receive Fentanyl 1 ug/kg body weight IV diluted to 100 ml normal saline (NS) over 15 minutes.
9708236|NCT04659642|Active Comparator|Both Dexmedetomidine and fentanyl group (group C)|will receive both Dexmedetomidine 1ug/kg body weight mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes.
9708237|NCT04659304|Active Comparator|Cohort 1|Single Intravenous (IV) dose of Allocetra-OTS with 5x10^9 cells
10193733|NCT05056506|Experimental|Endoscopic papillary Large balloon dilation combined with limited endoscopic sphincterotomy group|Endoscopic papillary large balloon dilation combined with limited endoscopic sphincterotomy to extract bile duct stones
10193734|NCT05043870|Experimental|infliximab and immunosuppressives therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1.5-2.5mg/kg per day or methotrexate 10-25 mg/m2 week
9708238|NCT04659304|Active Comparator|Cohort 2|Single Intravenous (IV) dose of Allocetra-OTS with 10x10^9 cells
10193735|NCT05043870|Active Comparator|infliximab therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
9708239|NCT04659304|Active Comparator|Cohort 3|Two IV doses of Allocetra-OTS with 10x10^9 cells in each dose
9708240|NCT04659564|Other|Breast-cancer related lymphedema (BCRL)|
9708241|NCT04659655|Other|surgical aortic valve replacement|n=20 patients with aortic valve pathology and indication for surgical aortic valve replacement
9708242|NCT04659655|Other|surgical mitral valve replacement|n=10 patients with mitral valve pathology and indication for surgical mitral valve replacement
10193736|NCT05035303|Active Comparator|Nor-Epinephrine (NE)-Group|The PCNL tract is infiltrated by Nor-Epinephrine before its dilatation.
10193737|NCT05035303|Placebo Comparator|S-Group|The PCNL tract is infiltrated by Normal Saline before its dilatation.
10204672|NCT05177172|Experimental|Low beta glucans + low polar lipids|White wheat flour bread included a combination of the lowest amounts of beta glucans and polar lipids
10204673|NCT05177172|Experimental|low polar lipids|White wheat flour bread included polar lipids
9708243|NCT04659278|Placebo Comparator|Group 1 Placebo|Placebo Isolate Placebo (Hemp seed oil and peppermint flavoring)
9708244|NCT04659278|Active Comparator|Group 2 Isolate Comparator|Isolate Placebo Isolate (CBD no terpenes Hemp seed oil [slightly lower concentration of CBD ratio])
9708245|NCT04659278|Placebo Comparator|Group 3 Placebo Comparator|Placebo OMD Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
9708246|NCT04659278|Experimental|Group 4 Experimental Placebo|OMD Placebo Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)
9979839|NCT01385761||Laryngeal Mask airway (LMA)|children weighing 20 to 30 kg
9979840|NCT01385761||Intubating Laryngeal Airway (ILA-SP)|Children weighing 20-30 kg
10204674|NCT05176613|Experimental|HF-rTMS and ML|High frequency Repetitive Transcranial Magnetic Stimulation and Motor Learning(Experimental group)
10204675|NCT05176613|Sham Comparator|Sham-rTMS and ML|Sham Repetitive Transcranial Magnetic Stimulation and Motor Learning
9708247|NCT04659213|Experimental|Interventional Group|Placement of a luminal esophageal temperature probe (LET) and insertion of esolution esophageal retractor. In the intervention group, esolution will be utilized to deviate the esophagus during RF catheter ablation
9708248|NCT04659213|No Intervention|Control Group|Placement of a luminal esophageal temperature probe (LET) during RF ablation
10193738|NCT05030688|Active Comparator|Group FICB = Fascia iliaca compartment block|FICB will be performed with a suprainguinal approach under US guidance. The probe will be placed sagittally to view the ilium and iliacus muscle. The probe will be moved medially and inferiorly along the inguinal ligament to view the femoral artery. The probe will then be moved superiorly and laterally along the inguinal ligament towards the anterior superior iliac crest to reach the lateral aspect of the femoral nerve. The deep circumflex artery will be visualized 1-2 cm cephalad to the inguinal ligament and superficial to the iliac fascia. The needle will be inserted with in-plane method 2-4 cm caudal to the inguinal ligament to reach below the fascia ilica. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
10204676|NCT05174273|No Intervention|Participants with a confirmed diagnosis of MDD receiving TAU|Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will continue to receive their usual anti-depressant.
9708249|NCT04659200||Covid Disease Patient Group|Researchers evaluated serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies in patients hospitalized for COVID-19 infection. The researchers evaluated the results of white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in Covid-9 patients.
9708250|NCT04659200||Covid-Free Control Group|Researchers evaluated the results of serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in the non-patient control group.
9708251|NCT04659265|Active Comparator|No suspected diagnosis (control group)|Participants receive the information that the pre-treating physician thought that the patient is suffering from a medical emergency (no diagnosis).
9708252|NCT04659265|Active Comparator|Correct suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from an acute myocardial infarction (correct diagnosis).
9708253|NCT04659265|Active Comparator|Wrong suspected diagnosis|Participants receive the information that the pre-treating physician thought that the patient is suffering from a pulmonary embolism (wrong diagnosis).
9708254|NCT04659187||All hospitalized COVID-19 patients|All consecutive hospitalized patients, tested positive for SARS-CoV-2 at 45 Asklepios hospitals in Germany
9708255|NCT04659187||Subgroup: Detailed cohort of 7 hospitals|Cohort of 7 hospitals with detailed data set
9708256|NCT04659187||Subgroup with cardiovascular events|Definition: Patients hospitalized to COVID-19, who developed a cardiovascular event, defined as (1) cardiopulmonary resuscitation in cardiac arrest, (2) cardiogenic shock, (3) acute coronary artery syndrome, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), (4) acute myocarditis, (5) denovo cardiac arrhythmia, (6) arterial or venous thrombosis, (7) pulmonary artery embolism, (8) worsening of prior or new onset heart failure, (9) ischemic stroke
9708257|NCT04659187||Subgroup with oncological patients|Definition: Patients hospitalized to COVID-19 with prior or preexisting oncological disease
9708258|NCT04659187||Subgroup with critical ill COVID-19 patients|Definition: Patients hospitalized to COVID-19 with intensive care treatment
9708259|NCT04659239|Experimental|Investigational Vaccine|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) according to the immunization schedule of D0, D14.
9708260|NCT04659239|Placebo Comparator|Placebo|Participants will receive 2 doses of the placebo according to the immunization schedule of D0, D14.
9708261|NCT04659109|Experimental|glenzocimab 1000 mg|
9708262|NCT04659109|Placebo Comparator|Placebo|
9708263|NCT04658901|Experimental|test group|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) made by Acotec Scientific Co.,Ltd.
9708264|NCT04658901|Active Comparator|control group|use the ClosureRFG™ and ClosureFast™ made by Medtronic Inc.
9708265|NCT04659070|Experimental|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
9708266|NCT04659070|Active Comparator|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
9708267|NCT04659070|Active Comparator|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
9708268|NCT04658927|Experimental|Dexamethosone intracanalicular insert|All 30 eyes will undergo iLUX MGD Treatment System for the treatment of evaporative DED secondary to MGD. Patients will have their most symptomatic eye selected to receive the dexamethasone intracanalicular insert at the day of the iLUX MGD Treatment System (study eye).
9708269|NCT04658927|Active Comparator|Group 1: Prednisolone actetate 1%|15 fellow eye will undergo iLux and receive topical prednisolone acetate 1% on a 4,3,2,1 taper for 30 days.
9708270|NCT04658927|Sham Comparator|Group 2: Sham dilation|"15 fellow eye will undergo ILux and receive punctal sham dilation (control eye)."
9708271|NCT04659018||patient|individual performing a screening colonoscopy
9708272|NCT04658979|Experimental|Intervention group|
9779225|NCT01125293|Experimental|Phase I Stage B Level 2|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
9785167|NCT01244529|Other|galy A Plus/ galy A / seno A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
10193739|NCT05030688|Active Comparator|Group PENG|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
9708273|NCT04658966||cases|Women with a history of pre-eclampsia
10193740|NCT05029960|Experimental|Experimental|Brivaracetam at a dose of 50 mg twice daily for 6 months
10193741|NCT05029011||Patients of the Sleep Disorders Laboratory|Monitoring vital signs
9708274|NCT04658966||controls|Women with no history of hypertensive disorder during pregnancy
9708275|NCT04659057|Active Comparator|Group L|Lidocaine group; 45 randomly assigned patients.
9708276|NCT04659057|Active Comparator|Group D|Demedetomidine group; 45 randomly assigned patients.
9708277|NCT04659057|Active Comparator|Group DL|Combined lidocaine and dexmedetomidine group. 45 randomly assigned patients.
9708278|NCT04659057|Placebo Comparator|Group C|Control group; 45 randomly assigned patients.
10193742|NCT05026996|Experimental|Mild hepatic impairment patients|Participants with mild hepatic impairment
10193743|NCT05026996|Experimental|Healthy participants|Matched healthy participants with normal hepatic function
9708279|NCT04659226|Experimental|Episodic or chronic migraine|Women starting treatment with erenumab according to clinical indication
9708280|NCT04658836|Experimental|Triamcinolone application|Patients will recieve intratympanic triamcinolone acetonide 24h before vestibular schwannoma surgery
9708281|NCT04658914|No Intervention|rotarix only|Rotarix will be administered at 6 and 10 weeks of age following the national Expanded Program for Immunization (EPI) schedule. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
9708282|NCT04658914|Experimental|P2 VP8 only|Parenteral P2-VP8 subunit vaccine will be administered at 6, 10 and 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
9708283|NCT04658914|Experimental|Rotarix + 1 dose P2-VP8|Rotarix will be administered at 6 and 10 weeks of age, followed by parenteral P2-VP8 subunit vaccine at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
9708284|NCT04658914|Experimental|Rotarix + 3 doses P2-VP8|Rotarix and parenteral P2-VP8 subunit vaccine will be coadministered at 6 and 10 weeks of age, with an additional dose of P2-VP8 subunit vaccine administered at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
9708285|NCT04658875|Experimental|Spirulina maxima supplementation and exercise group|Supplementation with Spirulina maxima (4.5 g/d) with a systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
9708286|NCT04658875|Experimental|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) without exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
9708287|NCT04658875|Experimental|Exercise group|Systematic physical exercise program during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
9708288|NCT04658875|Active Comparator|Control group|No systematic physical exercise program and No supplementation during 12 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 12 more weeks. During the 26 weeks of study duration every participant will have a personal isoenergetic diet.
9708289|NCT04658745|Experimental|iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
10193744|NCT05025865|Placebo Comparator|HA35 Placebo Group|12 study participants will be given a placebo capsule to take once per day in the morning with breakfast for 3 days.
10193745|NCT05025865|Active Comparator|HA35 Treatment Group|12 study participants will be given an HA35 capsule to take once per day in the morning with breakfast for 3 days.
9708290|NCT04658745|Sham Comparator|Sham iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere, but with a sham coil (i.e., sham iTBS). After the sham stimulation, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
9785168|NCT01244529|Other|galy A Plus / seno A / galy A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
10193746|NCT05024890|Experimental|WASH in Schools programme|Schools in the intervention group will receive the Splash WASH in Schools programme (Project WISE) during the study period (2021/2022 academic year), including sanitation, water storage and filtration, drinking water and handwashing stations, and hygiene and menstrual health education.
10193747|NCT05024890|No Intervention|Control|Schools in the control group will receive no intervention during the study period (2021/2022 academic year), but will be on a waitlist to receive the Project WISE intervention after the end of the study period (2022/2023 academic year or later).
10193748|NCT05023161||Patient having a fetus with intra-uterine growth restriction diagnosis below the 3rd percentile|
10193749|NCT05018858|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10193750|NCT05018845|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10193751|NCT05018832|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10193752|NCT05018819|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
10193753|NCT05018767|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
10193754|NCT05018481|Placebo Comparator|HA35 Placebo Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a placebo to take once a day with breakfast.
10193755|NCT05018481|Active Comparator|HA35 Treatment Group|24 study participants will receive the standard of care treatment for AH and a 90-day supply of a HA35 to take once a day with breakfast.
9708291|NCT04658745|Sham Comparator|iTBS to the ipsilesional primary motor cortex plus sham mirror therapy|"iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time, but with a covered mirror (e.g., sham mirror therapy).~In the sham mirror therapy condition, the mirror is covered by a cloth and the participant is instructed to move both arms while looking at a cross mark on the covered mirror and imaging the analogous movements of the affected arm. The movement practice will involve 5 table-top tasks (same as mirror therapy) and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes."
9708292|NCT04658524||Chonic kidney disease stages 3, 4 and 5|Patients with stage chronic kidney disease stages 3, 4 and 5. CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO): a) stage 3A: eGFR 45 and 59 ml/min/1.73m2; b) stage 3B: eGFR between 30 and 44 ml/min/1.73m2; c) stage 4: eGFR between 15 and 29 ml/min/1.73 m2
9708293|NCT04658511|Experimental|Participants|Patients diagnosed with cubital tunnel syndrome who are being scheduled for a primary endoscopic cubital tunnel release by the principle investigator will be recruited
9708294|NCT04658446|Experimental|Augmented Reality-Assisted Bonding|The quadrant of the upper arch that shall use the AR-assisted bonding method. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
9708295|NCT04658446|Active Comparator|Digitally-Asssited Indirect Bonding|The quadrant of the upper arch that shall use the digitally-assisted bonding method utilizing a 3D printed tray. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
9708296|NCT04658407||all patients diagnosed with a severe hepatic failure|Retrospective cohort using only data already entered in the Health data warehouse of the APHP (Public Paris Hospital)
9708297|NCT04658459||Results at short term follow up|Functional and Radiological results at short-term follow up (one year at least)
9708298|NCT04658459||Results at middle term follow up|Functional and Radiological results at the last follow up of the patient (2 years at least)
9708299|NCT04658485|Active Comparator|Active tDCS|
9708300|NCT04658485|Placebo Comparator|Sham tDCS|
9708301|NCT04658719|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
9708302|NCT04658719|Active Comparator|Standard Care|Foley catheter, uncoated
10193756|NCT05016817|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
9708303|NCT04658680|Experimental|BCG available at first health facility contact|Infants living in catchment areas of HFs randomized to opening of BCG vial if just 1 eligible child is present.
9708304|NCT04658680|No Intervention|Usual availability of BCG at health facilities|Infants living in catchment areas of HFs randomized to BCG availability according to the per usual restricted vial opening policy aiming at reducing vaccine wastage. This entails that BCG vaccination is commonly only available on specific predefined days where a BCG vial will only be opened if several children are present.
9708305|NCT04658589|Experimental|Laparoscopic distal gastrectomy|Laparoscopic distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
9708306|NCT04658589|Active Comparator|Open distal gastrectomy|Open distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
9708307|NCT04658394|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.
9979841|NCT01385774|Active Comparator|Intervention group: Angioplasty|Angioplasty with or without stent of the iliac artery
10193757|NCT05016804|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
10193758|NCT05012410|Experimental|Immediate treatment group with High-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive telephone and email prompts.
10193759|NCT05012410|Experimental|Immediate treatment group with Low-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive email prompts only.
10193760|NCT05012410|Experimental|Waitlist Control after three months with high-Intensity prompts|After three months, caregivers will receive WeCareAdvisor and telephone and email prompts.
9708308|NCT04658394|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
9708309|NCT04658732|Experimental|Alprazolam (A group)|patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer.
10193761|NCT05012410|Experimental|Waitlist Control after three months with Low-Intensity Prompts|After three months, caregivers will receive WeCareAdvisor and email prompts only.
9708310|NCT04658732|Experimental|Gabapentin (G group)|patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer.
9708311|NCT04658732|Experimental|Dexmedetomidine (D group)|Dexmedetomidine 0.25 µg/kg loading dose will be infused intravenously over 10 minutes through syringe pump before surgery in the control group (Prepared using Precedex vial 200mcg/2ml manufactured by Hospira Inc, Highway 301,Rocky Mount,NC 278001 USA)
9708312|NCT04658537|Active Comparator|Standard Arm|8 Gy / 1 Fraction
9708313|NCT04658537|Experimental|Single Fraction Dose Escalation|8Gy Planning Target Volume / 12Gy Clinical Target Volume +/- 14Gy Gross Tumour Volume / 1 fraction
9708314|NCT04658615|Other|group with rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
9708315|NCT04658615|Other|group without rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
9708316|NCT04658706|Sham Comparator|Control|a physical activity prescription to be performed autonomously
9708317|NCT04658706|Experimental|Prehabilitation|They will receive a supervised exercise programat least 2 weeks before starting the conventional chemoradiotherapy treatment and concomitant
9708318|NCT04658706|Experimental|Rehabilitation|They will receive a supervised exercise programat 12 weeks after the first radiotherapy session, once standard treatment has finished
9708319|NCT04658420|Experimental|Ketamine|One group will receive IV ketamine 0.5mg/kg infused over forty minutes
9708320|NCT04658420|Experimental|Ketamine + Music|One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music
9708321|NCT04658420|Experimental|Music|One hour of pre-planned music without ketamine
9708322|NCT04658420|No Intervention|Treatment as usual|No music nor ketamine given
9708323|NCT04658563|Experimental|Group 1: Yoga|High-density HY training; average 90-110 minutes, 2 sessions per week under the supervision of the physiotherapist, once a week as a home program, will be applied for a total of 8 weeks to the first group.
9708324|NCT04658563|No Intervention|Group 2: Control|Individuals in the second group will not included in any exercise training program
9708325|NCT04658550||Remote Weight Loss Behaviour Modification Program with Meal Replacements|This is the prospective study group who will receive 26-weeks of weight loss and maintenance counselling in a remote setting and a low-calorie meal replacement as part of their usual care.
9708326|NCT04658550||In Person Weight Bahaviour Modification Program with Meal Replacements|This is the retrospective study group who received 26-weeks of weight loss and maintenance counselling in person and a low-calorie meal replacement as part of their usual care.
9708327|NCT04658602|Active Comparator|Direct composite restoration|Bulk-fill composite (Filtek bulk flow, 3M Espe ) will be used and covered using a nanohybrid copmosite (filtek XT, 3M Espe )
9708328|NCT04658602|Active Comparator|Preformed metal crowns|Preformed stainless-steal crowns cemented by glass ionomer lutting cement (ketac cem. 3M Espe )
9708329|NCT04658355|Active Comparator|Povidone-Iodine|Povidone-iodine to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
9708330|NCT04658355|Experimental|Chlorhexidine Gluconate|Chlorhexidine gluconate to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
9708331|NCT04658264|Experimental|Treatment Arm|The Treatment group shall receive 2 Kg of the composite flour every week, sufficient for 21 chapattis, and shall eat chapattis made from this flour instead of their usual wheat flour chapattis. The participants shall continue to receive the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study.
9708332|NCT04658264|No Intervention|Control Group|This group shall receive only the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study. They will continue to eat their usual diet as before their enrollment. They shall however receive usual counseling on lifestyle modifications including diet
9708333|NCT04658316||20-39Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
9708334|NCT04658316||40-59Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
9708335|NCT04658316||60-79Years-old Male|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
9708336|NCT04658316||20-39Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
9708337|NCT04658316||40-59Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
9708338|NCT04658316||60-79Years-old Female|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure.
9708339|NCT04658160|No Intervention|Control|None- normal care
9708340|NCT04658160|Experimental|Intervention/Tracking|This group will have access to the longitudinal tracking and intervention platform for Medicare Advantage patients. Members of this group's care team will have access to the longitudinal data on the platform and will be able to intervene if any red flags emerge (i.e. if a patient displays signs of depression on a patient reported outcome measure/survey)
9708341|NCT04658082|Other|Non invasive glucose monitor|Single arm. All subjects will have glucose levels measured both by non invasive glucometer and by core lab
9708342|NCT04657913|Experimental|cold water spray group|application of cold water in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
9708343|NCT04657913|Experimental|cold saline spray group|application of cold 0.9% SF (saline) in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
9708344|NCT04657913|No Intervention|control group|no intervention
9708345|NCT04658238||Dry eye disease|Patients with dry eye disease
9708346|NCT04658238||Healthy controls|Healthy controls without dry eye disease
9708347|NCT04657874|Active Comparator|Bromelain and Escin|
9708348|NCT04657874|Placebo Comparator|Placebo|
9708349|NCT04657900||All eligible patients|Observational cohort using anonymized patient-level primary care data linked to secondary administrative data; CPRD-GOLD and CPRD-AURUM.
9708350|NCT04657978||Substrate guided intervention arm|Participants recruited to the study will undergo High Density Wave Solution™ guided substrate mapping of the left atrium. Ablation will thereafter be performed to comprise wide area circumferential ablation of the pulmonary veins in pairs, followed by ablation of low voltage zones in the left atrium.
9708351|NCT04657965|Experimental|Administration of LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
9708352|NCT04658134|Experimental|Glycine supplementation|Glycine supplementation
10193762|NCT05011149|Experimental|Selective early medical treatment (SMART) strategy|"Infants who are randomized to experimental group will follow the SMART treatment protocol, which includes echocardiographic screening every 72 hours to categorize PDA disease severity by combining clinical and echocardiographic features. At any evaluation if patients are found to have a severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness, they will receive pharmacotherapy aimed at PDA closure (The PDA severity has been divided into mild, moderate or severe based on pre-defined clinical and echocardiographic criteria)."
10193763|NCT05011149|No Intervention|Early conservative management strategy|Infants randomized to this arm will not undergo any further echocardiographic assessment or pharmacological treatment of the PDA regardless of the clinical signs. If the infant gets an echocardiographic assessment for a reason different than PDA assessment (such as hypotension or oxygenation failure) and a PDA is incidentally noted that fits the treatment criteria, the infant will not be initiated on pharmacotherapy. After 7 days of age, decision on PDA assessment and treatment will be at the discretion of the treating physician.
10193764|NCT05007470|Experimental|Probiotic|VSL#3
9708353|NCT04658004|Experimental|Administration of NKG2D CAR T-cells|
10193765|NCT05007470|Placebo Comparator|Pacebo|
10193766|NCT05006092|Experimental|surveillance endoscopy with CADe support|
10193767|NCT05006092|No Intervention|conventional surveillance endoscopy|
10193768|NCT05003960|Experimental|Treatment Group|One intravenous infusion of 100 million cells
10193769|NCT05003947|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
10193770|NCT05003934|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
10193771|NCT05003921|Experimental|Treatment Group|three intrathecal injections of 50 million cells at two-month intervals.
10193772|NCT05003908|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
9708354|NCT04658069||One Cohort receiving routine hemodialysis therapy without any specific interventions|all HD patients enrolled in this study
10193773|NCT05003388|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
10193774|NCT05000463|Active Comparator|ozone group|Ozone injection under ultrasound guidance in addition to the medical treatment
10193775|NCT05000463|Other|control group|receive the medical treatment only. The medical treatment includes optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin
10193776|NCT04996043|Placebo Comparator|Placebo drink|
10193777|NCT04996043|Experimental|Collagen Peptide Drink|
10193778|NCT04995978|Experimental|Pioglitazone|
10193779|NCT04995978|Placebo Comparator|placebo|
9708355|NCT04658212|Experimental|3D LCBDE group|
9708356|NCT04658212|Active Comparator|ERCP group|
9708357|NCT04658043|Experimental|ASD Intervention Group|Participants in the ASD intervention group will receive training to help children improve socioemotional functioning.
9708358|NCT04658043|No Intervention|Wait List Control Group|Participants in this group will be placed on the wait list and receive the ASD intervention training 2 months after the other groups
9708359|NCT04657848|Experimental|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
9708360|NCT04657861|Experimental|Administration of APRIL CAR T-cells|Each subject receive APRIL CAR T-cells by intravenous infusion
9979842|NCT01385774|Active Comparator|Control: Supervised Exercise Therapy|Supervised exercise therapy by a physiotherapist
10193780|NCT04993534|Experimental|Psychological First Aid + Stepped-care intervention (DWM/PM+)|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~The treatment group will receive the stepped-care program consisting of DWM (step 1) and Problem Management Plus (PM+).~The DWM program has been developed by WHO and collaborators working in the humanitarian field. DWM was designed to be relevant for large segments of adversity-affected populations: it is intended to be transdiagnostic, and easily adaptable to different cultures and languages.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques that are empirically supported."
9708361|NCT04657939|Active Comparator|Liraglutide-Pioglitazone|Participants randomised to receive liraglutide treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with pioglitazone.
9708362|NCT04657939|Active Comparator|Pioglitazone-Liraglutide|Participants randomised to receive pioglitazone treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with liraglutide.
9708363|NCT04658030|Experimental|VR 360 video surgery preparation|Preparing pediatric patients for surgery with a newly developed VR 360 degree video. Maximum 30 minutes, one time.
9979843|NCT01385800|Placebo Comparator|Placebo|Intradermal injection, 1 x 8 administrations 2 weeks apart
9708364|NCT04658030|Active Comparator|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
9708365|NCT04658017|Experimental|GARNET device|All enrolled subjects will receive treatment with the GARNET device.
9708366|NCT04658121||Senior Living Facilities|Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
9708367|NCT04658121||Outpatient Healthcare Facilities|Adults attending outpatient healthcare in neighborhoods of selected research sites
9708368|NCT04658121||General Communities|Adults and children (>2 months of age) in neighborhoods of selected research sites
9708369|NCT04658225|Active Comparator|Solution 1|0.12% chlorhexidine
9708370|NCT04658225|Placebo Comparator|Solution 2|Saline solution
9708371|NCT04657952|Active Comparator|Standard medical Treatment (paracetamol)|Patients will receive paracetamol 1 gm every 6 hours daily intravenously for a day.
9708372|NCT04657952|Experimental|Sphenopalatine block|Patients will receive sphenopalatine block
9708373|NCT04658056||WATER AQUABEAM Robotic System cohort|WATER Study subjects previously-treated with Aquablation of the prostate with the AQUABEAM Robotic System for lower urinary tract symptoms associated with BPH.
9708374|NCT04658056||WATER TURPS cohort|WATER Study subjects previously-treated with standard transurethral resection of the prostate (TURP) for lower urinary tract symptoms associated with BPH.
9708375|NCT04658251||Patients with an intronic variant unknown in a gene implicated in cone disorders.|
9708376|NCT04657705|Experimental|High power ablation|High power ablation parameters (50-55 W)
9708377|NCT04657705|Active Comparator|Standard ablation power|Standard ablation power parameters (40-45 W)
9708378|NCT04657614|Experimental|Neutral Alignment Group|A straight pylon with the ankle at neutral.
9708379|NCT04657614|Experimental|Anterior Alignment Group|An anteriorly displaced pylon with ankle dorsiflexion at 5 degrees.
9708380|NCT04657614|Experimental|Posterior Alignment Group|A posteriorly displaced pylon with 5 degrees of plantarflexion at the ankle.
9708381|NCT04657744|Experimental|A test|Test drug (Sphingomod ) 1 capsule contains 0.5 mg Fingolimod
9708382|NCT04657744|Active Comparator|B reference|Reference drug (Gilenya) 1 capsule contains 0.5 mg Fingolimod
9708383|NCT04657627|Experimental|PACE plus calorie information intervention group|PACE plus calorie information intervention group will receive PACE plus calorie information of discretionary foods via social media posts.
9708384|NCT04657627|Active Comparator|Calorie-only information comparator group|Calorie-only information comparator group will receive calorie-only information of discretionary foods via social media posts.
9708385|NCT04657536|Experimental|TRF group|the group who treated with temperature controlled radiofrequency
9708386|NCT04657536|Active Comparator|Estriol group|the group who treated with promestriene vaginal soft capsules
9708387|NCT04657471|Experimental|revised HOMe-CoV|Revised HOME-CoV
9708388|NCT04657419||Participant|Patient or health professional coming to the Bordeaux University Hospital screening center for COVID-19 screening
9708389|NCT04657549|Active Comparator|Tonsillectomy|Patients will undergo tonsillectomy under general anesthesia within three weeks after enrollment.
9708390|NCT04657549|Active Comparator|Tonsillotomy|Patients will undergo tonsillotomy under general anesthesia within three weeks after enrollment.
9708391|NCT04657549|No Intervention|Watchful waiting|Patients will be closely monitored for the 5-6 months monitoring period.
9708392|NCT04657393|Active Comparator|Alternative Ventilation Rate|ventilation is performed at 20 breaths/min
9979844|NCT01385800|Experimental|ToleroMune Grass Dose 1|Intradermal injection 1 x 8 administrations 2 weeks apart
9708393|NCT04657393|Active Comparator|Conventional Ventilation Rate|ventilation is performed at 10 breaths/min
9708394|NCT04657588|Experimental|Anal insert|This group will be asked to use anal inserts to help manage their faecal incontinence during the treatment period
9708395|NCT04657588|Sham Comparator|Care as usual|This group will be asked to continue with their care as usual (e.g. incontinence pads)
9708396|NCT04657354|Active Comparator|Fast track|Study subjects in Fast Track arm will get an MRI done on the same day. If the MRI shows concordant findings of herniated disc, the subject will be referred to a spine surgeon to be seen within one week. If the surgeon and subject decide on discectomy, the surgery is scheduled within the same week. Total timespan from first interview to surgery will be no longer than 2 weeks.
9708397|NCT04657354|No Intervention|Usual care|"Study subjects in Usual Care will be treated following the Danish National Guidelines in which a conservative approach for the first 4-6 weeks with focus on pain relief by pain-relief medication, exercises and encouragement to resume normal activities as much as possible. Patients in this arm will be scheduled 2 and 4 week follow-up appointments as per national guidelines.~If the symptoms have not resolved after this period, then a referral to a multidisciplinary spine care department is made. However, if symptoms are still present at 8-12 weeks first then a referral for a spine surgeon assesment can be done."
9708398|NCT04657445||home-quarantined patients|home-quarantined patients
9708399|NCT04657445||inhospitalized patients|inhospitalized patients
9708402|NCT04657718|Other|All subjects|The KODEX-EPD system will be used in combination with leads to image during all procedures.
9708403|NCT04657497|Experimental|FOY-305 group|Camostat Mesilate tablets 600 mg will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
9708404|NCT04657497|Placebo Comparator|Placebo group|Placebo tablets will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
9708405|NCT04657510||Proximal femur fracture AND COVID-19|Surgical treatment of femur fracture
9708406|NCT04657510||Proximal femur fracture NO COVID|Surgical treatment of femur fracture
9708407|NCT04657484|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 2 weeks, 10 mg/day for 2 weeks
9708408|NCT04657484|Active Comparator|Low dose prednisolone|A dose of 10 mg/day of prednisolone will be administered for 6 weeks
9708409|NCT04657250|Experimental|Smoking cessation + quitline linkage text messages|Text messaging for smoking cessation + text messages with proactive linkage to quitline
9708410|NCT04657250|Placebo Comparator|Passive quitline referral|Single text message with contact information for the Quitline
9708411|NCT04657237|No Intervention|control group|all patients will receive general anesthesia and will receive intravenous paracetamol (1 g) before skin closure and then given every 6 hrs in the 1st postoperative day
9979845|NCT01385800|Experimental|ToleroMune Grass Dose 2|Intradermal injection 1 x 8 administrations 2 weeks apart
9708412|NCT04657237|Active Comparator|TPVB group|Patients will receive total volume (20 ml) 0.25% bubivicaine divided equally at each level of T4 and T6 at thoracic paravertebral space then they will recive general anesthesia.
9708413|NCT04657757|Experimental|Intraoral apparatus|intraoral apparatus in which two platelets of each of the 8 materials (Esteticor Lumina PF; Esteticor Lumina PF - after Lactic acid storage; Pagalinor 2; Esteticor Economic; Pekkton ivory - untreated; Pekkton ivory - rough; Oralloy; Machined Titan Zirconia (TiZr) alloy) are to be examined. Examination is a crystal violet OD595 staining (10 minutes). The color absorbed by the bacteria is then dissolved with a 30% acetic acid and measured spectrophotometrically at 595 nm. The plaque formed on the material surface is removed immediately after removal from the oral cavity and analyzed by determination of Colony Forming Unit (CFU) number.
9708414|NCT04657601||Treatment Group|Patients undergo polypectomy facilitated by the study device.
10193781|NCT04993534|Other|Psychological First Aid + usual care|"All participants will be offered individual Psychological First Aid (PFA), a WHO developed support strategy that involves humane, supportive and practical help for individuals suffering from serious humanitarian crises.~In addition, both the groups will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation."
9708415|NCT04656977|Active Comparator|VR+TAU|Participants will participate first to a VR-based intervention and then to the TAU condition. The TAU condition is a homogenous standard program proposed by the Centre d'études et de recherché en intervention familiale (CERIF) at Université du Québec en Outaouais (UQO) based on group counseling offered to women and men who experienced a perinatal loss.
9708416|NCT04656977|Active Comparator|TAU+VR|Participants will be invited first to participate to the TAU condition and then to the VR-based intervention.
9708417|NCT04656834||Hand incision closure type 1|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: buried monocryl sutures and skin glue
9708418|NCT04656834||Hand incision closure type 2|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: simple nylon sutures
9708419|NCT04656990|Experimental|Gross motor and social-emotional integrated intervention group|Participants will receive a nine-month intervention which focuses on gross motor skills, physical activity, and social-emotional skills.
9708420|NCT04656990|No Intervention|Control|Participants will receive the center's everyday business as usual curriculum.
9708421|NCT04657042||Healthy|Healthy volunteers from the local community
9708422|NCT04657042||Liver cancer|Patients undergoing radiotherapy for liver cancer
9708423|NCT04657042||Lung cancer|Patients undergoing radiotherapy for lung cancer
9708424|NCT04656912||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
9708425|NCT04657107|Placebo Comparator|Saline group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous normal saline before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
9708426|NCT04657107|Experimental|K1 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.2mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
10193782|NCT04990531|Experimental|Covid-19 subjects|Childrens and adolescent with PCR-proven previous SARS-CoV-2 infection
10193783|NCT04990531|Active Comparator|Healthy controls|Healthy controls negative for previous SARS-CoV-2 infection
9708427|NCT04657107|Experimental|K2 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.3mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
9708428|NCT04657133|Experimental|Intervention group|Subjects in the intervention group will receive remote ischemic conditioning and standard background medical treatment.
10204677|NCT05174273|Active Comparator|Participants with a confirmed diagnosis MDD who will receive FMT + TAU|Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will be assigned to receive FMT provided by healthy donors.
10204678|NCT05174273|No Intervention|Participants with a confirmed diagnosis of MDD + IBS assigned to continue with TAU|
10204679|NCT05174273|Active Comparator|Participants with a confirmed diagnosis of MDD + IBS assigned to receive FMT + TAU|
9979846|NCT01385800|Experimental|ToleroMune Grass Dose 3|Intradermal injection 1 x 8 administrations 2 weeks apart
9708429|NCT04657133|Placebo Comparator|Sham group|Subjects in the placebo group will receive sham remote ischemic conditioning and standard background medical treatment alone.
9708430|NCT04657055|Experimental|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
9708431|NCT04656886|Experimental|Ketalar|0.5mg/kg of ketalar (ketamine). Single, intravenous, steady state infusion over 40min.
9708432|NCT04656886|Placebo Comparator|Saline|Single, intravenous, steady state infusion over 40min.
9708433|NCT04656860|Experimental|Juice Plus+|Participants will consume 6 capsules daily consisting of a combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend and Juice Plus+ Berry Blend. Participants will consume supplements for 24-months.
9708434|NCT04656860|Placebo Comparator|Placebo|Participants will consume 6 capsules daily consisting of microcrystalline cellulose, rice starch, vegetarian capsule (cellulose), and magnesium stearate. Participants in this condition will receive 1-year of supplements after the study is completed.
9708435|NCT04657029|Experimental|Treadmill condition|The intervention condition consisted of a single session of moderate-high intensity aerobic exercise (65% of heart rate reserve) for 30 minutes walking on a standard treadmill. The single treadmill session included a progressive increase in intensity to reach the target heart rate (approx. 5 mins) as well as a cooling down period (approx. 5 mins). The warm-up and cool-down were included as part of the total 30 minutes of walking exercise. Target heart rates were calculated using the Karvonen method [25] with levels adjusted for those taking heart rate lowering medications (i.e. beta blockers), following methods previously published in post stroke populations [26, 27]. Participants were asked to self-rate their intensity of exercise every 10 minutes verbally using BORG's 6-20 scale rating of perceived exertion [28]. Participants were instructed to walk at a pace that resulted in a rating between 11 (fairly light) and 14 (somewhat hard) on the scale.
9708436|NCT04657029|Other|Control condition|The control condition involved an equivalent time period (30 minutes) of seated resting where participants were provided with an education session about the impact and effects of stroke by the same research assistant.
9708437|NCT04657172|Experimental|Pilocarpine 1% Solution|1% pilocarpine ophthalmic solution administered with the Optejet dispenser
10193784|NCT04986397|Experimental|Cold Therapy & Standard Post Operative Analgesia|Patients in the cryotherapy group will have the ice water in their cryotherapy device maintained continuously for 2 days from initial application as this is the reported time of average patient disability and children typically return to school by post-operative day 3. The device will not be placed directly on the skin to minimize tissue damage. An additional protective barrier pad included with the cold therapy device will provide a barrier between the skin and the cooling device. This allows for continuous cooling at a higher target skin temperature. Aside from the cryotherapy, all surgical treatment will be standard of care.
9708438|NCT04657172|Experimental|Pilocarpine 2% Solution|2% pilocarpine ophthalmic solution administered with the Optejet dispenser
9708439|NCT04657172|Placebo Comparator|Placebo Solution|Placebo ophthalmic solution administered with the Optejet dispenser
9708440|NCT04657185||Before OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place but without OR PathTrac feedback optimization.
10193785|NCT04986397|Active Comparator|Standard Post Operative Analgesia|
10193786|NCT04985331|Experimental|W-GenZD|W-GenZD is powered by natural language processing and machine learning techniques, the brief, self-guided intervention draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT-A) and some elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile medical application is designed to be targeted, relevant, tailored, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.
9708441|NCT04657185||After OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place AND OR PathTrac feedback optimization.
9779226|NCT01125293|Experimental|Phase I Dose Expansion|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
9779227|NCT01125293|Experimental|Phase II|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
9779228|NCT01125358|Experimental|10 milligrams (mg) LY2140023|
9779229|NCT01125358|Experimental|80 mg LY2140023|
9779230|NCT01125358|Experimental|160 mg LY2140023|
9779231|NCT01125358|Placebo Comparator|Placebo|
10193787|NCT04985331|No Intervention|Psychoeducation Control|The control for this study is the scheduled delivery of digital psychoeducational files (PDFs). The PDFs were selected to provide information on depression, anxiety and stress, as well as outline common coping skills.
10193788|NCT04983602|No Intervention|Usual care Control group|The usual care control group receives conventional care in the Emergency Department (ED) or Acute Medical Assessment Unit (AMAU)The comparison group will receive routine care as would be usual in the ED or AMAU. Currently there is no dedicated team to perform CGA in the ED and AMAU at UHL with ad hoc allied health assessment available only at the discretion of the referring ED doctor or medical team. This process will be continued during the study and will be documented. The participants in this group will under baseline data collection prior to randomisation and follow up.
10204680|NCT05174273|No Intervention|Participants with a confirmed diagnosis IBS only receiving TAU|
9779232|NCT05308199|Experimental|experimental|thoracic manipulation group
9779233|NCT05308199|Active Comparator|control|MET group
9779234|NCT05308173||Surgical Aortic Valve Replacement|Surgically replaced aortic valve. Patients with planned concomitant bypass grafting other valvular interventions, arrhythmia ablation, or left atrial appendage occlusion were excluded. Any tissue or mechanical valve implantation in an aortic position with sternotomy or minimal access was included.
10193789|NCT04983602|Experimental|Comprehensive Geriatric assessment arm|The intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team (consisting of a geriatric specialist registrar, specialist geriatric nurse, senior pharmacist, senior physiotherapist, senior occupational therapist, and senior medical social worker) in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED.
10193790|NCT04983602|Experimental|EDPLUS arm|The ED PLUS intervention will comprise initially of a detailed interdisciplinary assessment and intervention by one or more members of the dedicated geriatric team. The team in both ED and AMAU will assess all participants in the intervention group and perform CGA. Potential participants will be approached regarding trial recruitment post ED triage thereby ensuring rapid assessment shortly after hospital arrival by the teams in both AMAU and in ED. Additionally the participants in this arm will undergo a 6 week physiotherapy led intervention in the community involving 3 home visits and weekly telephone support. The intervention will involved assessment of the patients function in terms of strength, balance and mobility. Following assessment the intervention will be aimed at addressing deficits in the function of the participants, review of their medical management by a geriatrician trainee and focusing on self management of their own program.
9708442|NCT04657159||2010-2016|Patients treated 2010-2016
9708443|NCT04657159||2017-2019|Patients treated 2017-2019
9708444|NCT04656821|Active Comparator|Control Group|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.
9708445|NCT04656821|Experimental|Erector Spinae Block (ESB) group|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
9708446|NCT04656821|Experimental|Thoracic Paravertebral Block group|Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography
9708447|NCT04656808|Experimental|Guilt focused intervention|Following literature on factors associated with guilt experiences in caregivers (Gonyea et al., 2008; Gallego-Alberto et al., 2019; Losada et al., 2014; Prunty & Foli, 2019; Romero-Moreno et al., 2014; Spillers et al., 2008) and previous intervention studies testing an Acceptance and Commitment Therapy intervention for dementia family caregivers (Losada et al., 2015; Márquez-González et al., 2020), a guilt focused intervention was specifically designed for caregivers who experienced high levels of guilt and emotional distress. The program is based on CBT (Márquez-González et al., 2007) and Acceptance and Commitment Therapy (ACT) approaches (Losada et al., 2005; Márquez-González et al., 2010), combined with techniques of Compassion-Focused Therapy (CFT; Gilbert, 2009), which were adapted to work with guilt experienced by family dementia caregivers.
9708448|NCT04656808|Active Comparator|Cognitive behavioral therapy|Following the cognitive behavioral model adapted to caregiving (Losada et al., 2006) and considering other previous CBT intervention studies with dementia caregivers (Gallagher-Thompson et al., 2003), a CBT intervention developed and tested for dementia family caregivers (Márquez-González et al., 2007) was used for this study. Specifically, this intervention consists of different components that are described in more detail in Losada et al. (2011) and Márquez-González et al. (2007): a) a cognitive restructuring module aimed at modifying caregivers' dysfunctional thoughts about caregiving into other, more appropriate thoughts which promote the use of more adaptive coping strategies for caregivers; b) increasing pleasant activities or behavioral activation; c) asking for help skills; and d) relaxation techniques for reducing physiological activation.
9708449|NCT04656483|Experimental|Telemedicine Video Feedback Arm|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
9708450|NCT04656483|Active Comparator|Psychoeducational booklet arm|Mothers assigned to condition B will receive an informative booklet addressing the same themes discussed in the experimental intervention (i.e., responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant or specific parenting challenges.
9708451|NCT04656457|Active Comparator|resistance exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting) three times daily and five times per week. The 1 repetition maximum (1RM) is measured at baseline and following the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last 6 weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. Time of exercise equal time of rest
9779235|NCT05308173||Transcutaneous Aortic Valve Implantation|Transfemoral aortic valve implantation. Patients with a planned concomitant percutaneous coronary intervention were excluded
9779236|NCT05308160|Active Comparator|Dapagliflozin|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
9779237|NCT05308160|Placebo Comparator|Non-used drug|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease.
9779238|NCT05308147|Other|Arm 1 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
10193791|NCT04981665|Experimental|Postoperative TACE + Tislelizumab 200mg IV Q3W|TACE will be performed after curative resection (4±1w) once and then Tislelizumab Injection will be initiated after TACE (5±2d). Tislelizumab will be administered every three weeks, until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 17 cycles of Tislelizumab.
10193792|NCT04958577||Wing A (Ada WRA)|Patients in this group will be filling out the Ada assessment themselves and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
10193793|NCT04958577||Wing B (Ada HDA)|Patients in this group will be asked questions from the Ada assessment by a health care practitioner and then heading to a normal consultation by first the usual care doctor and then the study-provided physician.
9708452|NCT04656457|Active Comparator|aerobic exercise|Aerobic training (AT) program of submaximal intensity will include a 45-minute session five times per week under the supervision of the researcher. Aerobic exercise will consist of three phases: warm-up, training and cool down. At the beginning of exercise session, subjects will have a ten-minute warm-up. The warm up protocol will be slowly running on treadmill. Then, the warm-up phase will be followed by the training phase. At baseline, the training phase will be commenced with two 30- minute running on treadmill at 50% of their maximal heart rate (MHR) in the first week and increased to 70% MHR by the final week of training. By the end of exercise session, subjects will have a five-minute cool down. The cool down protocol will be slowly running on treadmill. The vital measures such as HR and blood pressure was monitored before patient left the department (Dimeo et al.,2016), maximum heart rate will be calculated using the formula: (HR Max =220- age)
9708453|NCT04656587|Other|Standard Therapy (Control)|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
9708454|NCT04656587|Experimental|Standard Therapy plus BPAP|Application of BPAP along with standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
9708455|NCT04656509|Experimental|4-s sprint inertial load training|Participants trained three times a week for eight weeks following the training program consisting of 30 bouts of 4s all-out cycling on an inertial-load ergometer with progressively decreasing recovery time (30 to 24 to 15s).
9708456|NCT04656743|Experimental|intra-articular injection group|will receive ultrasound guided intraarticular injection consisting of 20 mL of 0.25% bupivacaine before surgical procedure. The surgical procedure will be started 30 min after intraarticular injection.
9708457|NCT04656743|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% before surgical procedure. The surgical procedure will be started 30 min after genicular nerve block.
9708458|NCT04656613|Experimental|Vaccine|a study group of 750 subjects receiving the Gam-COVID-Vac combined vector vaccine against the SARS-СoV-2-induced coronavirus infection
9708459|NCT04656613|Placebo Comparator|Placebo|a reference group of 250 subjects receiving placebo
10193794|NCT04957498|Active Comparator|FBT|Family Based Treatment (FBT) includes up to 15 session (50-60 minutes) with a trained therapist.
9708460|NCT04656782||Expert panelists|Expert panelists will be recruited from EORTC Imaging Group, EORTC GI Group, ESOI and ESGAR and will actively participate in the imaging survey rounds.
9708461|NCT04656782||Facilitators|The two central facilitators will moderate and guide the survey rounds. Blinded results will be forwarded to the expert panelists by the facilitators. Further Survey rounds will be adapted by the facilitators according to the previous answers given by the panelists.
9708462|NCT04656626|Experimental|COVID19 Frontline Health Care Providers recieving mindfulness intervention|This arm will receive mindfulness audios (randomized and double blinded)
9708463|NCT04656626|Placebo Comparator|COVID19 Frontline Health Care Providers receiving progressive muscle relaxation|This arm will receive progressive muscle relaxation audios (randomized and double blinded)
9708464|NCT04656535|Experimental|AB122 + AB154 Safety Cohort (Cohort A)|Eligible patients will be sequentially enrolled to receive intravenous AB154 combined with AB122 (N=6). AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat).
9779239|NCT05308147|Other|Arm 2 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9779240|NCT05308147|Other|Arm 3 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
10193795|NCT04957498|Experimental|FBT-GSH|Family Based Treatment Guided Self-Help (FBT-GSH) includes an online website with educational videos, readings, discussion groups, and journals. Parents assigned to this arm will have up to 12 coaching sessions (20-30 minutes) with a trained therapist.
10193796|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 1|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 750 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.~A single cycle of consolidation may last between 4-8 weeks in duration."
10193797|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 2|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 1,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine(every 21 days ( per cycle).~A single cycle of consolidation may last between 4-8 weeks in duration."
10204681|NCT05174273|No Intervention|Healthy Controls|Data from healthy comparison (HC) participants will be drawn from another completed research study. Healthy comparison participants who will best match the patient population enrolled in the current trial and who consented to data sharing will be selected.
9708465|NCT04656535|Experimental|AB154 Surgical Cohort (Cohort B1)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B1 (N=10): AB154 single agent (10 mg/kg) + placebo~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
9708466|NCT04656535|Experimental|AB122 Surgical Cohort (Cohort B2)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B2 (N=10): AB122 single agent (240 mg) + placebo~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
9708467|NCT04656535|Experimental|AB154 + AB122 Surgical Cohort (Cohort B3)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B3 (N=10): AB154 (10 mg/kg) +AB122 (240 mg)~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
9708468|NCT04656535|Experimental|Placebo Surgical Cohort (Cohort B4)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B4 (N=10): Two placebo infusions~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
9708469|NCT04656444||phone call to emergency department|
9708470|NCT04656769||PERI group|
9708471|NCT04656769||EV group|
9708472|NCT04656704|Experimental|Hyaluronidase 200mg monthly|Hyaluronidase 200mg monthly (Weeks 0, 4, 8, 12, 16, 20); for six doses; a 6-month treatment course with follow-up 1 month after
9708473|NCT04656574|Experimental|Experimental Group|Experimental group received the course explaining vaginal delivery for the first timethat used simulation-based training.
9708474|NCT04656574|No Intervention|Control Group|Control group received the course explaining vaginal delivery for the first time
9708475|NCT04656756|Experimental|Experimental Group|The mothers in the experimental group (60) were administered.
9708476|NCT04656756|No Intervention|Control Group|The mothers in the control group (60) were given the routine care.
9708477|NCT04656548||HydroPICC|Cohort who received the HydroPICC
9708478|NCT04656548||Standard of Care|Cohort who received something different than HydroPICC
9708479|NCT04656665|Experimental|75mg|Take 75mg of aspirin daily in tihis group
9708480|NCT04656665|Active Comparator|100mg|Take 100mg of aspirin daily in this group
9708481|NCT04656665|No Intervention|blank|Not taking aspirin in this group
9708482|NCT04656431|Experimental|Hyperpolarized pyruvate (13C) Single Image (Cohort 1)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) and undergo MRI at baseline
9708483|NCT04656431|Experimental|Hyperpolarized pyruvate (13C) Multiple Images (Cohort 2)|"Newly diagnosed PCNSL participants with planned treatment of standard high-dose methotrexate,temozolomide plus rituximab (MT-R) regimen~Images using 13C will be performed both at baseline and after three cycles of standard induction chemotherapy. Participants in Cohort 2 will also have option to undergo an additional imaging at a later time if their cancer progresses."
9708484|NCT04656405|Experimental|Online real-time CPR training program|Online real-time quality measurement and feedback video-based CPR training will be provided to participants
9708485|NCT04656405|Active Comparator|Online real-time CPR training without quality measurement program|Online real-time feedback video-based CPR training without quality measurement will be provided to participants
9708486|NCT04656405|Placebo Comparator|Conventional CPR training program|Conventional CPR training will be provided to participants
9708487|NCT04656288|Experimental|Formula A under fasted conditions - Part 1|
9708488|NCT04656288|Experimental|Formula B under fasted conditions - Part 1|
9708489|NCT04656288|Experimental|Formula B under fasted conditions - Part 2|
9708490|NCT04656288|Experimental|Formula C under fasted conditions - Part 2|
9708491|NCT04656288|Experimental|Formula D under fasted conditions - Part 2|
9708492|NCT04656288|Experimental|Formula B under fed conditions - Part 2|
9708493|NCT04656327||Non interventional group|Community-dwelling elders dependent for care
9708494|NCT04656314||Healthy participants aged 18 to 40|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
9708495|NCT04656314||Healthy participants aged 60 and above|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
9708496|NCT04656340|Active Comparator|Standard rehabilitative care (SC)|Twice weekly physical therapy, occupational therapy and pain psychoeducation
9708497|NCT04656340|Experimental|Complementary and Integrative Health (CIH) therapies in addition to Standard rehabilitate care (SC)|Twice weekly chiropractic, acupuncture, yoga and foam roller instruction, in addition to SC
9708498|NCT04656145|Experimental|Chlorhexidine Gluconate Gel Dressing|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
9708499|NCT04656145|No Intervention|Standard of Care|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to received standard drain care - gauze (no intervention).
9708500|NCT04656041|Experimental|FOLFOX/ nal-IRI|"Treatment will be administered on an outpatient basis.~FOLFOX with nal-IRI for eight two-week cycles (16 weeks total)~Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks~Surgery"
9708501|NCT04656392|Other|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
9708502|NCT04655989|Experimental|Routine first|Group A subjects will be assigned to 4 weeks of routine dialysis (control group) followed by 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group).
9708503|NCT04655989|Experimental|Investigational first|Group B subjects will be assigned to 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group) followed by 4 weeks of routine dialysis (control group).
9708504|NCT04655989|Other|VARRM sub-study|Following completion of the initial 8-week treatment, subject's were eligible to participate in the sub-study, VARRM. The total participation time for the VARRM sub-study was approximately 1.5 weeks.
9708505|NCT04656106||Ryzodeg|Patients treated with any basal-insulin or premix-insulin for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg®.
9708506|NCT04656002|Experimental|Paclitaxel, Ramucirumab + TEW-7197|"Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours~-Paclitaxel, Ramucirumab Intravenous (IV) Ramucirumab injection, provided as a single-use 500-mg/50-mL vial containing 10 mg/mL of product in histidine buffer, with disease progression, toxicity requiring discontinuation, or without interruption for any reason. After diluting to 8 mg/kg every 2 weeks, IV It is administered by infusion.~Paclitaxel is administered at a dose of 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle, with disease progression, toxicity requiring discontinuation, or without interruption for any reason."
9708507|NCT04656119||patients without irAEs or patients with good efficacy|
9708508|NCT04656119||patients with irAEs or patients with poor efficacy|
9708509|NCT04656262|Experimental|Metronomic cyclophosphamide|Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks. Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.
9708510|NCT04656262|Active Comparator|Doxorubicin|Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.
9708511|NCT04656093|Experimental|Intervention|"Intervention group - Cognitive Restructuring, Motivational Interviewing, and Multi-Medication Adherence.~The pilot intervention is comprised of three educational sessions for individual study patients, conducted by interventionist with a master's degree in psychology with cognitive behavioral therapy training. The topics addressed in the sessions are as follows:~Review of COPD medication inhaler technique, psychoeducation on maladaptive beliefs and emotional response."
9708512|NCT04656093|Active Comparator|Control|Control group - Supportive counseling for comorbidity management
9708513|NCT04656184|Experimental|KINERET|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature <38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
9708514|NCT04656184|Active Comparator|Intravenous Immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
9708515|NCT04655937|No Intervention|non-randomised no treatment arm|Participants who do not opt in to group support will only provide self-report data on their wellbeing and quality of life every 3 months for up to 12 months. Data collected through online survey platforms using validated questionnaires
9708516|NCT04655937|Experimental|randomised invite Acceptance and Commitment Therapy (ACT) Group|Only those who opt in to invites for group support will be randomised. Randomisation will occur once sufficient numbers have been recruited and in a 2:1 ratio (intervention: attention control). Participants in this arm will be invited to 8 weekly ACT-informed therapy sessions involving core values identification, mindfulness practices and committed action plans. There will be homework in between sessions.
9708517|NCT04655937|Active Comparator|randomised invite Social Support Group|Only those who opt in to invites for group support will be randomised. Randomisation will occur once sufficient numbers have been recruited and in a 2:1 ratio (intervention: attention control). Participants in this arm will be invited to 8 weekly group sessions involving social support activities. There will be homework in between sessions.
9708518|NCT04656197||Patients with dry eye disease|
9708519|NCT04656197||Healthy controls|
9708520|NCT04656366||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
9708521|NCT04656366||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
9708522|NCT04656249|Experimental|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing <60 kg and 12mg/d to those ≥60 kg.
9708523|NCT04656132|Experimental|Participants with cardiovascular disease or cardiovascular disease risk factors|Population We will recruit 59 males and females age > 18 being seen in the NYU Langone Center for Prevention of Cardiovascular Disease (4F). Participants have cardiovascular disease or cardiovascular disease risk factors.
9979847|NCT01385813||Pregnant women who develop preeclampsia|pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
9979848|NCT01385826|Experimental|adalimumab|Anti-tumor necrosis factor alpha monoclonal antibody
9979849|NCT01385826|Placebo Comparator|placebo|placebo
9979850|NCT01385839|Experimental|alopecia areata|pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle
9979851|NCT01385852|Active Comparator|Longitudinal U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, LONGITUDINAL ULTRASOUND
9979852|NCT01385852|Active Comparator|Torsional U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, TORSIONAL ULTRASOUND
9708524|NCT04656171|Experimental|Minor patients with Fanconi anemia|MRI of hands and forearm, neuropsychological and neuromotor tests
9708525|NCT04656171|Active Comparator|Minor controls|MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation
9708526|NCT04655859||severe early childhood caries|
9708527|NCT04655859||healthy children|
9708528|NCT04655872|Experimental|[14C]TPN171H|
9708529|NCT04655846|Active Comparator|Control group|Usual manage during prenatal control program
9708530|NCT04655846|Experimental|Intervention group|Educational intervention towards the maintenance of exclusive breastfeeding in the first six months in first pregnant adolescents enrolled in the prenatal control program
9708531|NCT04655898|Experimental|Administration of [14C]CC-90001|A single oral dose of [14C]CC-90001, containing approximately 100 μCi of radioactivity, will be administered on Day1 under fasted conditions.
9708532|NCT04655911||ABO-101|Participants from prior interventional trials involving the administration of ABO-101.
9708533|NCT04655534|Experimental|IMW Group|Patients who performed inspiratory muscle warm-up (IMW) before inspiratory muscle training (IMT)
9708534|NCT04655534|Experimental|Standart IMT Group|Patients who performed standard inspiratory muscle training (IMT) without inspiratory muscle warm-up (IMW) protocol
9708535|NCT04655677|Experimental|Autologous EXP039 administered by intravenous (IV) infusion|Autologous EXP039 administered by intravenous (IV) infusion
9708536|NCT04655560||Women living with HIV|
9708537|NCT04655742|Experimental|single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
9708538|NCT04655625|Experimental|Group A (AG-0302-COVID19)|
9708539|NCT04655625|Placebo Comparator|Group A (Placebo)|
9708540|NCT04655625|Experimental|Group B (AG-0302-COVID19)|
9708541|NCT04655625|Placebo Comparator|Group B (Placebo)|
9708542|NCT04655482|Experimental|Treatment arm|"Patients treated with aflibercept (2.0ml/0.05cc) using treat-and-extend regimen.~Three monthly loading injections followed by proactive treatment using treat-and-extend regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
9708543|NCT04655495|Experimental|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
9708544|NCT04655495|Active Comparator|Balanced gluten free diet|Balanced gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients.
9708545|NCT04655807|Experimental|Group 1- Standard of Care (SOC) Biological Therapy: Adalimumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo subcutaneous (SC) injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to adalimumab or its biosimilar as SOC therapy.
9708546|NCT04655807|Experimental|Group 2: SOC Biological Therapy: Ustekinumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo SC injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to ustekinumab as SOC therapy.
9708547|NCT04655651||Frailty|patients with a FRAIL Scale of 3 to 5
9708548|NCT04655651||Non-frailty|patients with a FRAIL Scale of 0 to 2
9708549|NCT04655664|Experimental|Treatment Group|Men and women aged 18-60 years, not currently experiencing chronic pain, kidney problems, liver problems, or other hormone disorders
9708550|NCT04655664|Active Comparator|Regularly Group|Subjects who consumed vitamin D supplements regularly, were pregnant, or were breastfeeding.
9708551|NCT04655417|Experimental|INTERVENTION GROUP|SINGLE ARM OF PATIENTS WHO WILL RECEIVE SAME TREATMENT
9708552|NCT04655508|Experimental|Seretide|"For children between 6 to 11 years (< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
9708553|NCT04655508|Placebo Comparator|placebo|For children between 6 to 11 years (< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
9708554|NCT04655703|Experimental|Cohort 1|Cohort 1- Study group-Home discharge. Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
9708555|NCT04655703|No Intervention|Cohort 2|Cohort 2- Control group-Home discharge. Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
9708556|NCT04655703|Experimental|Cohort 3|Cohort 3- Study group-Transfer to an inpatient rehabilitation center. Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.
9708557|NCT04655703|No Intervention|Cohort 4|Cohort 4- Control group-Transfer to an inpatient rehabilitation center. Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.
9708558|NCT04655768|Active Comparator|Operative Arm|Radius fractures C1/C2 treated by palmar plate fixation
9708559|NCT04655768|No Intervention|Conservative Arm|Radius Fractures C1/C2 treated by cast fixation
9708560|NCT04655781|Experimental|N-T group|ILM was peeled off from nasal retina to temporal retina.
9979853|NCT01385852|Active Comparator|Longitudinal U/S - high fluidic|ASPIRATION FLOW RATE - 40 CC/MIN, BOTTLE HEIGHT - 110 CMS, LONGITUDINAL ULTRASOUND
9979854|NCT01385865|Experimental|Mulberry leaf extract|
9979855|NCT01385865|Placebo Comparator|Placebo|
9979856|NCT01385878|Active Comparator|Phacoemulsification with 1.8mm incision|Microcoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
9979857|NCT01385878|Active Comparator|Phacoemulsification with 2.2mm incisi|Microcoaxial phacoemulsificaiton will be performed through 2.2mm incision
9708561|NCT04655781|Experimental|T-N group|ILM was peeled off from temporal retina to nasal retina
9708562|NCT04655794||had >= grade 2 adverse reactions|
9708563|NCT04655794||had <2 frade 2 adverse reactions|
9708564|NCT04655430|Experimental|3-second SDF application|3-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708565|NCT04655430|Experimental|5-second SDF application|5-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708566|NCT04655430|Experimental|10-second SDF application|10-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708567|NCT04655430|Experimental|15-second SDF application|15-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708568|NCT04655430|Experimental|30-second SDF application|30-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708569|NCT04655430|Experimental|45-second SDF application|45-second application time of silver diamine fluoride (38% SDF) in arresting tooth decay (dental caries) in the primary teeth of preschool children.
9708570|NCT04655430|Experimental|60-second SDF application|60-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708571|NCT04655430|Experimental|120-second SDF application|120-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708572|NCT04655430|Experimental|180-second application time|180-second application time of silver diamine fluoride (38% SDF) in arresting dental caries in the primary teeth of preschool children.
9708573|NCT04655443||Control Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that maintained sinus rhythm will be assigned to Control."
9708574|NCT04655443||Afib Group|"Patients will be scheduled for an electrocardiogram thirty days after their electrical cardioversion. Based on the electrocardiogram result, patients that developed persistent atrial fibrillation will be assigned to Afib."
9708575|NCT04655339|Experimental|Group-1|Bilateral abdominal Lap-TAP block injection near incision site with 0.25% Bupivacaine HCl (30cc) with 30ml being injected bilaterally. Remaining residual is injected into port incision sites.
9708576|NCT04655339|Experimental|Group-2|Bilateral abdominal Lap-TAP liposomal Bupivacaine (Exparel®) injection with 133mg (20ml) Exparel® plus bupivacaine 0.25% (30ml), plus 10ml of normal saline for a total volume of 60ml, injecting 30ml each side.
9708577|NCT04655339|No Intervention|Group-3|
9708578|NCT04655105|Experimental|Truanatomy rotary file|use of tru anatomy rotary files root canal instrumentation followed by post operative pain evaluation
9708579|NCT04655105|Experimental|hyflex EDM rotary file|use of hyflex EDM rotary files root canal instrumentation followed by post operative pain evaluation
9708580|NCT04655105|Experimental|edge endo reciprocating rotary file|use of edge endo reciprocating rotary files root canal instrumentation followed by post operative pain evaluation
9708581|NCT04655105|Active Comparator|protaper gold rotary file|use of protaper gold rotary files root canal instrumentation followed by post operative pain evaluation
9979858|NCT01385891|Experimental|children with advanced leukemia|
9979859|NCT01385930|Experimental|Lifestyle counseling|Lifestyle counseling
9708582|NCT04655170|Experimental|Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin 175 μg once per day and Formoterol 20 μg twice per day via jet nebulizer for 7 days or until discharge if prior to day 7.
9979860|NCT01385930|No Intervention|Control group|Control group
9708583|NCT04655170|Active Comparator|Group 2: Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of Care|Albuterol and Ipratropium every 6 hours nebulized over the 7-day treatment period or until discharge if prior to day 7.
9708584|NCT04655209|Experimental|M1-Seq group|
9708585|NCT04655209|Experimental|PMC-Seq group|
9708586|NCT04655209|Sham Comparator|MT with sham tDCS|
9708587|NCT04655183|Experimental|Part 1A (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight < 77 kilograms (kg) or baseline platelet count < 150, 000 per cubic millimeter will be included in this Part. Dose escalation of M4344 administered along with niraparib.
9708588|NCT04655183|Experimental|Part 1B (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight > =77 kilograms (kg) and baseline platelet count >=150, 000 per cubic millimeter will be included in this Part. M4344 will be administered at a dose and schedule that was determined as the recommended dose for expansion (RDE) in Part 1A. Dose of niraparib will be escalated to the next higher dose level.
9708589|NCT04655183|Experimental|Part 2 (Dose expansion): PARPi resistant, Niraparib plus M4344|Participants with Poly(ADP-ribose) polymerase inhibitor (PARPi) resistant, germline breast cancer 1/2 mutated (gBRCA1/2m) human epidermal growth factor receptor 2 (HER2) negative advanced Breast Cancer (aBC) will receive the combination of niraparib and M4344 at the RDE which was determined in Part 1.
9979861|NCT01385943||Skin Cancer|Patients from dermatology practices throughout Europe that have a skin lesion or tumor requiring a biopsy for diagnosis.
9979862|NCT01385956|Experimental|SOM 230 LAR and Gemcitabine|"Combination Therapy: Dose escalation of SOM 230 LAR and standard treatment with gemcitabine. Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period.~SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month."
9979863|NCT01385969||Standard Practice|
9979864|NCT01385969||Syringe recoil|
9979865|NCT01385969||Pressure Transducer|
9708590|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive niraparib as a single agent.
9708591|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib plus M4344|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive the combination of niraparib and M4344 at the RDE as determined in Part 1 of this study.
9708592|NCT04655040|Experimental|Caffeine and Ritlecitinib|"In Period 1 Day 1, participants will be dosed with a single oral administration of caffeine 100 milligram (mg) tablet.~In Period 2 Day 1 to Day 7, participants will be dosed with a single oral administration of ritlecitinib 200 milligram (mg) tablet. On Day 8, participants will be dosed with caffeine 100 milligram (mg) tablet within 5 minutes after administration of a 200 milligram (mg) dose of ritlecitinib on the morning of Day 8. Dosing with oral 200 milligram (mg) ritlecitinib QD will continue until Day 9."
9708593|NCT04655196|Experimental|Internet-based self-help + weekly feedback by a coach|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text, audio and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly feedback by a coach.
9708594|NCT04655196|Experimental|Internet-based self-help + weekly automated messages|Internet-based self-help on the basis of CBT-interventions, mindfulness and self-compassion to address cognitions, emotions and behavior related to loneliness. The self-help program consists of nine text-, audio- and video-based sessions, various exercises (e.g., breathing meditation, diaries) and tasks. Participants receive weekly automated messages in order to increase motivation.
9708595|NCT04655196|No Intervention|Waiting control group|
9708596|NCT04655131|Active Comparator|Protein consumption : 0 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate
9708597|NCT04655131|Experimental|Protein consumption : 12.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate
9708598|NCT04655131|Experimental|Protein consumption : 25 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate
9708599|NCT04655131|Experimental|Protein consumption :37.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate
9708600|NCT04655131|Experimental|Protein consumption : 50 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate
9708601|NCT04655131|Experimental|Protein consumption : 62.5 gm|Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate
9708602|NCT04655053|Active Comparator|Goal intention condition|"Participants in this condition are asked to form the goal condition: I will walk as fast as I can for as long as I can"
9708603|NCT04655053|Experimental|Implementation intention (behavior initiation) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if I do the task, then I will walk as much as I can!)"
9708604|NCT04655053|Experimental|Implementation intention (goal preference management) condition|"Participants in this condition are asked to form the same goal intention ( I will walk as fast as I can for as long as I can) and add the if-then plan (and if at this moment I prefer not to walk because of my pain (or fatigue; depending on person), then I will accept that I have this difficulty and I will walk as much as I can!)"
9708605|NCT04655014|Experimental|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
9979866|NCT01385982|Other|Actionable Test Results|"Creating standardized policies and procedures around actionable test results (ATR) management, and implementing them network-wide:~Defining the levels of severity and urgency for clinically significant test results~Network-wide policy for test result follow-up by the responsible providers, documentation and escalation processes to assure timely communication.~Standardized policies for the time frames and nature of communication of test result alerts.~Establish criteria for appropriate ATR management by the responsible provider.~Feedback performance including provider, practice and service report cards"
9979867|NCT01386021||Prior recipients of allografts for CABG|
9979868|NCT01386034|Experimental|Citrulline/Placebo|
9979869|NCT01386034|Experimental|Placebo/Citrulline|
9979870|NCT01386047|Experimental|iCPR randomized providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. The iCPR tool will automatically trigger for providers randomized into the iCPR intervention arm when they initiated an encounter for a patient that meets the criteria for possible evaluation of Strep Pharyngitis or Pneumonia.
9979871|NCT01386047|No Intervention|Control providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. These providers will conduct visits for Strep Pharyngitis and Pneumonia in their manner (usual care).
9708608|NCT04655599|Experimental|Olorinab, Then Placebo|Participants will first receive olorinab, followed by a washout period, and they then will receive placebo.
9708609|NCT04655599|Placebo Comparator|Placebo, Then Olorinab|Participants will first receive placebo, followed by a washout period, and they then will receive olorinab.
9708610|NCT04655274||RayOne Trifocal intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of RayOne Trifocal (Rayner IOL, Ltd.) intraocular lenses
9708611|NCT04655274||AcrySof IQ PanOptix intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of AcrySof IQ PanOptix (Alcon Laboratories, Inc.) intraocular lenses
9708612|NCT04654936|Experimental|MIND diet with support|This intervention group are to follow the MIND diet guidelines for 12 weeks with the support of a 12 week online theory driven website and resources
9708613|NCT04654936|Experimental|MIND diet no support|This group are to follow the MIND diet guidelines with no website support
9708614|NCT04654936|No Intervention|Control|The group follow usual diet
9708615|NCT04655235||patients with schizophrenia|200 patients with a DSM 5- diagnosis of schizophrenia
9708616|NCT04655235||healthy relatives of patients with schizophrenia|200 healthy relatives of the patients with schizophrenia
9708617|NCT04655235||healthy control subjects|healthy control subjects without relatives with mental disorders
9708618|NCT04654962||patients receiving preoperative analgesic management with anesthetic block|This cohort includes all patients that received preoperative anesthetic block for hip fracture surgery as main analgesic management during the study period.
9708619|NCT04654962||patients receiving conventional preoperative analgesic management|This cohort includes all patients that received conventional preoperative analgesic management (oral, intravenous or intramuscular medication) for hip fracture surgery as main analgesic management during the study period.
9708620|NCT04654884|Active Comparator|Group 1|The participants in group 1 will receive AA as an adjunctive therapy to TaU (i.e. individual counseling therapy, psycho therapy, pharmacological therapy) during 8 weeks.
9708621|NCT04654884|No Intervention|Group 2|Group 2, the control group, will receive TaU and will, just like goup 1, have a follow-up after 8 weeks.
9708622|NCT04654949|Experimental|Horticultural Therapy|The Horticultural Therapy group receives 30 minutes of horticultural therapy activities using mobile horticulture kits conducted by therapists or therapy assistants to engage participants at their bedside.
9708623|NCT04654949|No Intervention|Existing Care|The existing Care group receives 30 minutes of routine ward-based engagement leisure activities (e.g. watching television, reading newspapers, etc).
9708624|NCT04654871|Experimental|Experimental Group|
9708625|NCT04654871|Experimental|Active Comparator Group|
9708626|NCT04654793|Experimental|Intervention group|Robot assisted inclined bed treatment and FES
9708627|NCT04654793|Active Comparator|Control group|conventional inclined bed treatment
9708628|NCT04654494||Chron's disease patients with colorectal cancer|This group of patients with Chron's disease have been diagnosed with colorectal cancer and treated surgically
9708629|NCT04654858|Active Comparator|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used after infiltration or block anaesthesia for affected molar, following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
9708630|NCT04654858|Active Comparator|Performed metal crowns|PMCs (3M Espe, Seefeld, Germany) will be placed after infiltration or block anaesthesia for affected molar, followed by removal of carious dentin and enamel, Tooth preparation for fitting the crown, The correct size of crown will be chosen, and then Cemented with glass ionomer luting cement (KetacCem, 3M Espe).
9708631|NCT04654520|Experimental|Drug therapy combined with radiotherapy for primary tumor omitted CTV|"IMRT (omitted CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~IMRT (omitted CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
9708632|NCT04654520|No Intervention|Drug therapy combined with radiotherapy for primary tumor with CTV|"IMRT (with CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~IMRT ((with CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
9779241|NCT05308147|Other|Arm 4 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9779242|NCT05308147|Other|Arm 5 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9779243|NCT05308147|Other|Arm 6 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9779244|NCT05308121||Group: Pregnant women (first pregnancy)|This group will consist of women in the first trimester of pregnancy. Pregnant women will be evaluated 3 times in total, each measurement being in a different trimester.
9779245|NCT05308108||Children with Obstructive Sleepapnea|
9779246|NCT05308069|Other|Single vision contact lens|Subjects will wear a single vision soft contact lens during the study visit
9779247|NCT05308069|Other|Multifocal contact lens|Subjects will wear a multifocal soft contact lens during the study visit
9779248|NCT05308056||ECT-patients|Patients receiving routine ECT.
9779249|NCT05308043||Retinoblastoma patients|Retinoblastoma patients who undergo standard medical care in Beijing Tongren Hospital. The anonymous image of these patients will be prospectively collected and labelled by senior ophthalmologists.
9779250|NCT05308017|Active Comparator|Richard Wolf 24F Laser scope|
9779251|NCT05308017|Active Comparator|Karl Storz 28F Laser scope|
9785169|NCT01244529|Other|galy A / galy A Plus / seno A|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
9979872|NCT01386060|Experimental|Mindfulness Meditation Training|Participants receive the 6-week meditation training intervention between the 1st and 2nd study visits.
10193798|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 3|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High- dose Cytarabine.~The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 1,500 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine.~A single cycle of consolidation may last between 4-8 weeks in duration."
9708633|NCT04654624|Experimental|Silver Diamine Fluoride|
9708634|NCT04654624|Active Comparator|Atraumatic Restorative Treatment|
9708635|NCT04654572|Experimental|burned group|burned patients
9708636|NCT04654572|Experimental|control group|sedentary people
9708637|NCT04654585|Experimental|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
9708638|NCT04654585|Active Comparator|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
9708639|NCT04654611|Other|Treatment group|The intervention will be preservative free tafluprost 0.0015% topical ophthalmic solution given once daily for the study duration.
9708640|NCT04654598|Other|BPA level|BPA (bisphenol A) in urine, blood and follicle fluid samples
9708641|NCT04654416||Steroids|Dexamethasone 6mg intravenous OD for seven to ten days
9708642|NCT04654416||Colchicine|Patients treated with colchicine at a dose of 0.5 mg every 12 hours for 7 to 14 days.
9708643|NCT04654481|Active Comparator|Standard Care Plus Monitoring|All subjects will be monitored via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
9708644|NCT04654481|Experimental|Standard Care Plus Monitoring and HCFWO|In addition to home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments, subject will receive an Afflovest device for home use.
9708645|NCT04654637|Experimental|Arm A|fix model of cycle exercise(online supervise) and routine nutrition consult
9708646|NCT04654637|Experimental|Arm B|fix model of cycle exercise(online supervise) and online nutrition consult
9708647|NCT04654637|Experimental|Arm C|individualize cycle exercise(online supervise) and routine nutrition consult
9708648|NCT04654637|Experimental|Arm D|individualize cycle exercise(online supervise) and online nutrition consult
9708649|NCT04654728|Active Comparator|ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using ePTFE vascular grafts
9708650|NCT04654728|Other|Dacron graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
9708651|NCT04654403|Experimental|Camrelizumab|Camrelizumab (200 mg every 2 weeks),Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years)
9708652|NCT04654403|Active Comparator|Camrelizumab plus chemotherapy|Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
9708653|NCT04654819|No Intervention|Control group|This group made anesthesia application on patients without training on simulators.
9708654|NCT04654819|Experimental|Study group|This group made anesthesia application on patients after training on simulators.
9708655|NCT04654559|Other|Unobtrusive data collection|
9708656|NCT04654780|Experimental|tax on purchases|"exposed to high-price purchases of high in foods, including sugary drinks."
9708657|NCT04654780|Experimental|subsidies on purchases|exposed to purchases with prices that consider subsidies in fruits and vegetables.
9708658|NCT04654780|Placebo Comparator|Control|It will not be subjected to any intervention and therefore will buy with current or market prices.
9708659|NCT04654715||Localized prostate cancer treatment induced rectourethral fistula|Every patient over 18 years old operated for closure of a rectourethral fistula with gracilis flap interposition after localized prostatic cancer treatment (Radiotherapy, surgery, cryotherapy and HIFU).
9708660|NCT04654767||COPD-PH group|Patients with confirmed COPD and pulmonary hypertension
9708661|NCT04654767||IPF-PH|Patients with confirmed pulmonary fibrosis and pulmonary hypertension
9708662|NCT04654767||Control group|Control group without diagnosed COPD, IPF, or pulmonary hypertension
9708663|NCT04654442||Cases|30 cases will be recruited : Patient diagnosed by RT-PCR for a COVID19 at Grenoble University Hospital
9708664|NCT04654442||Controls|30 controls will be recruited : Patient suspected for a COVID-19 but negative by RT-PCR for a COVID19 at Grenoble University Hospital
9708665|NCT04654754|Experimental|high-flow high humidity oxygen device with tracheostomy adapter|This device provides high-flow gas to tracheostomy patients with heat and humidification. A special adapter is used to connect the tracheostomy tube and circuit.
9979873|NCT01386060|No Intervention|Waitlist Control|Participants receive no intervention between the 1st and 2nd study visits. They receive the training between the 2nd and 3rd study visits only.
9708666|NCT04654754|Active Comparator|large-volume nebulizer (cool aerosol) with trach collar|This device is the conventional device that is commonly utilized to provide humidification for spontaneous breathing patients with tracheostomy.
9708667|NCT04654754|Placebo Comparator|Venturi-adapter with trach collar|This device did not provide any humidification but only oxygen
9979874|NCT01386073|Active Comparator|FreshKote|
9708668|NCT04654754|Experimental|large-volume nebulizer (cool aerosol) with T-piece and a filter|this device is added with a filter, in order to reduce aerosol particle concentrations in the surrounding environment
9708669|NCT04654754|Experimental|high-flow high humidity device with a scavenger or a surgical mask|this device is added with a scavenger or a surgical mask over the adapter, in order to reduce aerosol particle concentrations in the surrounding environment
9708670|NCT04654390|Experimental|DWP16001 Amg, Dapagiflozin Bmg placebo|Tablets, Orally, Once daily
9708671|NCT04654390|Active Comparator|DWP16001 Amg placebo, Dapagliflozin Bmg|Tablets, Orally, Once daily
9708672|NCT04654741|Experimental|Progestin Primed ovarian stimulation Group|progestin 10 mg daily during ovarian stimulation
9708673|NCT04654741|Active Comparator|GnRH antagonist|GnRH antagonist 0.25 mg daily during ovarian stimulation
9708674|NCT04654377|Experimental|Personalised education|"Greetings~Recording clinical/imaging data.~Questionnaires administration.~Explaining the disease and possible outcome in the context of clinical/lab/imaging data.~Answering specific queries from patients and care givers."
9708675|NCT04654377|No Intervention|Standard communication|"Greetings~Recording clinical/imaging data.~Administration of questionnaire.~Addressing general queries from patients and care givers."
9979875|NCT01386073|Placebo Comparator|Systane|
9979876|NCT01386086|Experimental|Aripiprazole|aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
9708676|NCT04654286|Active Comparator|Control group (Nerve transfer procedure)|Patient will receive nerve transfer procedure without augmentation
9708677|NCT04654286|Experimental|Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)|Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation
9979877|NCT01386099|Experimental|PSN821|
9979878|NCT01386099|Placebo Comparator|Placebo|
9979879|NCT01386112|Experimental|EUR-1100 1.5 mg|
9979880|NCT01386112|Experimental|EUR-1100 3.0 mg|
9979881|NCT01386112|Placebo Comparator|placebo|
9979882|NCT01386138|Experimental|RBT+WHIC|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups. The four WHC modules were incorporated into the RBT sessions.
9708678|NCT04654234||Total-body PET/CT (uExplorer)|Patients with locally advanced NSCLC will receive total-body PET/CT (uExplorer) scans before, during and after the treatment
9708679|NCT04654338|Experimental|Intervention Arm|
9708680|NCT04653974|Active Comparator|Needle-free injection group|In needle-free injection techniques, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using the Comfort-In system.
9708681|NCT04653974|Active Comparator|Dental injection group|In the conventional dental-injection method, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using a 27G, 40-mm, disposable syringe with a needle.
9708682|NCT04654299||standard PD (ST-PD)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and standard hepaticojejunostomy
9708683|NCT04654299||PD with external biliary stent(PD-BS)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and hepaticojejunostomy with external biliary stent for externalization of bile fluid
9708684|NCT04654247|Sham Comparator|Control group|Endoscopists in control group were informed standard quality indicators requirements and the corresponding references during informed consent.
9708685|NCT04654247|Experimental|Feedback group|Endoscopists in feedback group were informed standard quality indicators requirements and the corresponding references during informed consent. In addition to the quality requirements, endoscopists randomized to feedback group received customized quality reports feedback from Endo.Adm weekly.
9708686|NCT04653987||Puncture angle : ≤30 (group I) >30 (group II)|The patients will be divided into two groups based on the puncture angle: ≤30° group and >30° group. The two groups will be retrospectively analyzed for technical success, fluoroscopy time and complications.
9708687|NCT04653987||Technical Parameters of all Interventions|Peripheral bile duct diameter, central bile duct diameter, number of punctures, type of drainage and total fluoroscopy time will be noted.
9708688|NCT04654091|Experimental|Cryoteraphy with liquid nitrogen|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
9708689|NCT04654091|Experimental|Nitric-zinc complex|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
9708690|NCT04654208||HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)|Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)
9708691|NCT04654208||HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant|Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)
9708692|NCT04654156||Pathological group|Patients with pulmonary embolism on thoracic CT angiography
9708693|NCT04654156||Healthy group|Patients without pulmonary embolism on thoracic CT angiography
9708694|NCT04654078|Experimental|Group 1|Group 1
9708695|NCT04654078|Experimental|Group 2|Group 2
9708696|NCT04654078|Experimental|Group 3|Group 3
9708697|NCT04654078|Experimental|Group 4|Group 4
9708698|NCT04654078|Experimental|Group 5|Group 5
9708699|NCT04654078|Experimental|Group 6|Group 6
9708700|NCT04654065|Experimental|IN-C004|IN-C004
9708701|NCT04654221||Male, BMI <= 24.9|Male subjects with a BMI of less than or equal to 24.9
9708702|NCT04654221||Female, BMI <= 24.9|Female subjects with a BMI of less than or equal to 24.9
9708703|NCT04654221||Male, BMI 25-29|Male subjects with a BMI of 25 to 29
9708704|NCT04654221||Female, BMI 25-29|Female subjects with a BMI of 25 to 29
9708705|NCT04654221||Male, BMI >29|Male subjects with a BMI of greater than 29
9708706|NCT04654221||Female, BMI >29|Female subjects with a BMI of greater than 29
9708707|NCT04654169|Experimental|The IAI and SSNB group|Ultrasound-guided IAI and SSNB are planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
9708708|NCT04654169|Active Comparator|The only-IAI group|Ultrasound-guided IAI is planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
9708709|NCT04654104||Healthy never smokers|Clinical evaluation of immune check points expression. A prospective study
9708710|NCT04654104||Smokers with normal lung function|evaluation of immune check points expression
9708711|NCT04654104||Lung cancer|evaluation of immune check points expression
9708712|NCT04654104||COPD|evaluation of immune check points expression
9708713|NCT04654000|Experimental|Rheopheresis group|"In addition to the standards of care, the experimental group will carry out the rheopheresis in two stages:~Stage 1: induction treatment: 3 apheresis sessions during the first week (w0; i.e. between D1 and D7) and then 2 apheresis sessions each week for 3 weeks (from w1 to w3; i.e. between D8 and D28) ;~Step 2: maintenance treatment with 1 apheresis session per week until the 11th week (i.e. between D29 and D84)."
9708714|NCT04654000|Sham Comparator|Sham-apheresis group|In addition to the standards of care, the comparator group will carry out Sham-apheresis sessions according to the same scheme as the rheopheresis sessions of the experimental group.
9708715|NCT04654260|Experimental|Behavioral Therapy for Irritability in Autism (BTIA)|BTIA consists of 15 ninety-minute weekly sessions that will be conducted with the teens and their parents by experienced therapists using a structured, detailed manual.
9708716|NCT04654260|Active Comparator|Psychoeducation and Supportive Therapy (PST)|PST consist of 15 weekly, ninety-minute sessions focused on learning about and discussing issues of diagnosis, treatment and educational services with an experienced therapist could be helpful to children on the autism spectrum and their families.
10193799|NCT04953780|Experimental|Calaspargase pegol-mknl dose level 4|"Induction Phase (It usually lasts 29 days):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take Idarubicin 12 mg/m2 for three doses in an IV after the first, third, and fifth High-dose Cytarabine.~The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine every 21 days ( per cycle).~Consolidation Phase ( One cycle of consolidation lasts 4-8 weeks):~The subject will take Cytarabine 3000 mg/m2 in an IV every 12 hours on days 1, 3, 5 for 6 doses.~The subject will take a dose of 2,000 U/m2 of Calaspargase pegol-mknl in an IV after the last (6th) dose of High-dose Cytarabine per cycle.~A single cycle of consolidation may last between 4-8 weeks in duration."
10193800|NCT04950426|Experimental|Treatment with reconsolidation therapy|Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet
10193801|NCT04950322|Experimental|Treatment group A|
9979883|NCT01386138|Active Comparator|Psycho-education|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups.
9708721|NCT04654182|Experimental|Log reduction in bacterial count|Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period. Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.
9708722|NCT04653935|Experimental|Full app with all app components|Users receive app that contains all intervention components including: Symptom and Lifestyle information, Energy management, Goal Setting, Managing Difficult Times, Assertiveness and Communication Skills.
9708723|NCT04653935|Active Comparator|Control minimal app with information component only|Users receive app that contains only Symptom and Lifestyle information, and cannot see other intervention components.
9979884|NCT01386151|Active Comparator|Study drug|Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
10193802|NCT04950322|Placebo Comparator|Treatment group B|
9979885|NCT01386151|Placebo Comparator|Placebo|Saline will be used as a placebo comparator
9979886|NCT01386164|Experimental|Gardasil®|
10193803|NCT04939636|Active Comparator|Vitamin D3 capsules 4000IU/100µg|Get Vitamin D3 capsules 4000IU/100µg.
9979887|NCT01386164|Experimental|Cervarix®|
9979888|NCT01386177|Experimental|doxazosin, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9979889|NCT01386190|Experimental|Exercise Group|Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.
9979890|NCT01386190|Active Comparator|Control|Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
9979891|NCT01386203||Lung Cancer|
9979892|NCT01386203||Lung Cancer after therapy|
9979893|NCT01386203||COPD controls|
9979894|NCT01386216|Experimental|Bone Marrow Cell Concentrate|Bone Marrow Cell Concentrate Prepared Using the Magellan System
10193804|NCT04939636|Active Comparator|Vitamin D3 capsules 600IU/15µg|Get Vitamin D3 capsules 600IU/15µg.
10193805|NCT04929548|Experimental|ECPy-THP Programs|Epirubicin 100 mg/m2, iv cyclophosphamide 600 mg/m2, iv + Pyrotinib 400 mg/d, po 4-week treatment, sequential docetaxel 80 mg/m2, iv + trastuzumab 6 mg/kg (first dose 8 mg/kg), iv + patuximab 420 mg (first dose 840 mg), iv ,po 4 weeks of treatment
10193806|NCT04921722|Experimental|Topical use of sirolimus|Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
10193807|NCT04921722|Active Comparator|Oral use of sirolimus|Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
10193808|NCT04914351|Experimental|Dose Escalation|"Cohort 1: 0.03 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 2: 0.3 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Accelerated dose escalation: One patient will be enrolled. Cohort 3: 1 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 4: 2 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 5: 4 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort.~Cohort 6: 10 mg/kg Q2W HY-0102 ivgtt Duration: 26w DLT observation period: 28 days Standard 3+3 Dose escalation: Three patients will be enrolled for each dose cohort."
10193809|NCT04907045|Experimental|Standard Implementation Plus Health Coaching|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
10193810|NCT04907045|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinic in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
10193811|NCT04904718|Experimental|DreaMed Advisor Pro tool used for insulin optimization|
10193812|NCT04895449|Experimental|≥ 1 x 10E7 IU (low dose) in seronegative subjects|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
10193813|NCT04895449|Experimental|≥ 5 x 10E7 IU (middle dose) in seronegative subjects|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
9708725|NCT04653870|Experimental|cyriax manipulation|cyriax manipulation have three types of classes, rotation, extension and anti-deviation, which is further divided into subclasses. On the inferior level of lumber spine L4-L5 and L5-S1rotation intervention of manipulation are capable of having striking effects of decreasing herniation. First of all we have to perform the simple 'stretch' on lumber spine, which is being the little rotation pressure applied on the body. The patient position of the body is in side lying with the effected side upward so that the outside part of the joint are separated easily on the involved side. After that, whenever it is essential by making use of femur as a rigid bar or support, this maneuver is go along with powerful rotation technique.
9708726|NCT04653870|Experimental|lumber decompresion|Spinal decompression therapy has been developed a treatment without surgery for the prolapsed disc and deteriorative spinal disc disease one of the considerable reason for low back pain. This noninvasive interventional treatment for herniated disc and deteriorative disc diseases operated on the principle of remarkably decreasing the pressure on the disc between vertebras.
9708727|NCT04654026||CAA Group|Patients with cardiovascular and cerebrovascular disease with cerebral amyloidosis
9708728|NCT04654026||None CAA Group|Patients with cardio-cerebrovascular disease without cerebral amyloid vascular disease
9708729|NCT04654325|Other|Patients attending to the COVID19 screening facility|Patients will have both nasopharyngeal and conjunctival swab for SARS-CV-2 genome detection using PCR. Study will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. These results will be corelated to symptoms of disease assessed with a stan
9708730|NCT04653909|Experimental|Case|A patient who was diagnosed with the calfan syndrome
9708731|NCT04653727||Online survey with 3.000 participants using mobile website technology|
9708732|NCT04653831|Other|Standard of Care - Control|Standard of care (Soc) according to current guidelines and the discretion of treating physician.
9708733|NCT04653831|Experimental|Pirfenidone Treatment|"In addition to SoC, Pirfenidone 2,403 mg administered orally or per nasogastric tube as 801mg TID, for 4 weeks.~Pirfenidone dose will be 2,403mg daily, from day one of admission to the ICU, titrated over 3 days:~Day 1 - 801mg x 1/d (801mg) Day 2 - 801mg x 2/d (1,602 mg) Day 3 - 801mg x 3/d (2,403 mg) Feeding and medication delivery will be upon the discretion of the treating physician according to tolerability. Powdered 801mg tablets will be administered through the nasogastric tube: Each tablet will be crushed and dissolved in 20cc of water. The nasogastric tube will be flushed afterwards to avoid obstruction..~If the patient is able to swallow and the nasogastric tube is removed, pirfenidone will continue to be delivered orally."
9708734|NCT04653519|Experimental|Virtually guided minimally invasive preparation|
9708735|NCT04653506|Experimental|Paracetamol group|Women who were treated with a double-blind mechanism in an envelope containing paracetamol pills (1000 mg)
9708736|NCT04653506|Experimental|Ibuprofen group|Women who were treated with a double-blind mechanism in an envelope containing Ibuprofen pills (400 mg)
9708737|NCT04653948||Cohort Study|Women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age seeking antenatal care at Kawempe National Referral Hospital in their first and second trimesters of pregnancy will be invited to participate in the study until a sample size of at least 4000 women is achieved. They will be followed-up along with their liveborn infants until a minimum of 14 weeks post-delivery.
9708738|NCT04653948||EMR Cohort|Anonymised data from the entire maternal and infant population that attend Kawempe Hospital for antenatal and/or delivery +/- post-partum care during the two-year study period will be analysed to describe maternal, obstetric and neonatal outcomes.
9708739|NCT04653532|Experimental|mHealth Technology|Participants in this group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
9708740|NCT04653532|Active Comparator|Exercise Counselling|Participants in this group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular contact with an exercise specialist.
9708741|NCT04653701||Patients with hepatocellular carcinoma treated with TAMDEM® 100 micron and SEQURE® microcatheter|Patients included in this study and with chemoembolization indications will be superselective embolized using TAMDEM® 100 micron preloaded particles (Doxorubicin) and SEQURE® microcatheter combination (SYNERGIC EFFECT). Objective tumoral response and 30 days-complications (Safety) are primary outcomes.
9708742|NCT04653857||High-level athlete who had a recent COVID 19 infection, symptomatic or not|High-level athlete who had a recent COVID 19 infection, symptomatic or not
9708743|NCT04653753|Experimental|Orthosis Group|Use of kneeSOFT500 device
9708744|NCT04653753|No Intervention|Control Group|No use of the device
9708745|NCT04653623|Experimental|Tranexamic acid before high tibial osteotomy|"Interventions~Procedure/Surgery: High tibial osteotomy~Drugs: Tranexamic acid"
9979895|NCT01386229|Active Comparator|Ketamine|
9979896|NCT01386229|Active Comparator|Etomidate|
9979897|NCT01386242|Experimental|The first group|Recombinant anti-tumor and anti-virus protein for injection, twice per week
9979898|NCT01386242|Experimental|The second group|Recombinant anti-tumor and anti-virus protein for injection, three times per week
9979899|NCT01386242|Placebo Comparator|Placebo group|Saline Injection, three times per week
9979900|NCT01386242|Experimental|The third group|High dose of recombinant anti-tumor and anti-virus protein for injection, three times per week
9979901|NCT01386255|Active Comparator|baclofen|Baclofen suspension
9979902|NCT01386255|Placebo Comparator|placebo|Identical palcebo suspension
9979903|NCT01386268||Group 1|
9979904|NCT01386281||Group 1|Drug (incl. Placebo)
9979905|NCT01386294|Experimental|Tenofovir 1% vaginal gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
10193814|NCT04895449|Experimental|≥ 1 x 10E8 IU (high dose)in seronegative subjects|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
9708746|NCT04653623|Active Comparator|High tibial osteotomy only|"Interventions~- Procedure/Surgery: High tibial osteotomy"
9708747|NCT04653649|Experimental|HSP-CAR30 (anti-CD30 CAR T cells)|"Phase I:~Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.~Phase IIa:~Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy."
9708748|NCT04653662|Experimental|Treatment group|Treatment group arm. Open label. Only 1 arm study
10193815|NCT04895449|Experimental|≥ 1 x 10E7 IU (low dose)|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
9708749|NCT04653766|Experimental|Ir-CPI - Dose 1|Participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
9708750|NCT04653766|Experimental|Ir-CPI - Dose 2|Participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
9708751|NCT04653766|Experimental|Ir-CPI - Dose 3|Participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
9708752|NCT04653766|Experimental|Ir-CPI - Dose 4|Participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
9708753|NCT04653766|Placebo Comparator|Placebo|Participants received a single intravenous dose of placebo during 6 hours
9708754|NCT04653792|Experimental|Pregabalin|Participants received Pregabalin 75mg capsule twice daily from preoperative day to 1 week postoperative
9708755|NCT04653792|Placebo Comparator|Pregabalin Placebo|Participants received Pregabalin placebo capsule matching Pregabalin twice daily from preoperative day to 1 week postoperative
9708756|NCT04653779|Experimental|Group A|Patients receive Evogliptin 5mg/Metformin 1000mg once a day
9708757|NCT04653558||definite LNB|patients with definite early Lyme neuroborreliosis
9708758|NCT04653558||possible LNB|patients with possible early Lyme neuroborreliosis
9708759|NCT04653493|Experimental|CD19 CAR-T cells|Pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukemia (R/R B-ALL)
9708760|NCT04653441|Experimental|Child-only Intervention|The children in this arm will receive only child intervention curriculum (peer group activities). The child intervention includes 20 hours of facilitator-guided programming delivered in 10 sessions in a peer-group setting and aims to increase resilience by developing a number of skills including positive thinking, emotional regulation, coping, and problem solving.
9708761|NCT04653441|Experimental|Child+Caregiver Intervention|The children in this arm will receive child intervention and their caregivers will receive the caregiver intervention, At the caregiver level, caregivers receive 10 hours of facilitator-guided programming delivered in five sessions that aims to increase positive parenting skills and build the capacity of the caregiver to engage in self-care and seek support.
9708762|NCT04653441|Experimental|Child+Caregiver+Community Intervention|The children in this arm will received child intervention; their family will receive caregiver intervention and community-based intervention. At the community level, trained community advocates (e.g., teachers, village nurses) conduct monthly home visits and organize a series of community-based activities over a period of two years to promote cohesion and strength within local communities and to increase community support for affected families.
9708763|NCT04653441|No Intervention|Attention Control|Children and caregivers who do not receive any intervention activities
9708764|NCT04653415|Active Comparator|Study Group|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
9708765|NCT04653415|Placebo Comparator|Controls group|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - saline solution.
9708766|NCT04653259|Experimental|Intervention Group|The INT group will meet with their health coach over the phone or video chat. The health coach will orient them to the LyfeMD, app and ensure the participant has received a nutrition plan in the app. They will be asked to complete the app assessment tools to design a personalized nutrition, physical activity and yoga and meditation program. They will set goals in each area they are interested in implementing. The health coach will then follow-up by phone, video or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach will use the following schedule to discuss app related content: First visit nutrition content; second visit behaviour change tools; third visit Yoga, meditation and breathing plans, and; the fourth visit the physical activity plans. The health coach will also be available to answer questions when required using email. Goal attainment will be collected weekly within the app.
9708767|NCT04653259|No Intervention|Conventional Management Group|The CM group (n=22) will receive conventional care as well as a similar health coaching schedule as the intervention group. The health coach will meet the patient over the phone or video chat to outline their role over the next 3 months and to provide general nutrition guidelines using Canada's Food Guide and Alberta Health Services online resources. The health coach will then follow-up by phone, video chat or email 2 weeks after the initial meeting, then monthly with the patient for 2 more months (total of 4 meetings). The health coach session topics will be the same as the intervention group. For example, the second visit will provide online resources from Alberta Health Services focused on promoting behaviour change, the third visit will orient the patient to Alberta Health Services focused online stress management tools and the final visit will share online versions of the Canadian guidelines for physical activity and sedentary time.
9708768|NCT04653168|Experimental|LY3041658 Low Dose|LY3041658 administered by subcutaneous (SC) injection.
9708769|NCT04653168|Experimental|LY3041658 High Dose|LY3041658 administered by SC injection.
10193816|NCT04895449|Experimental|≥ 5 x 10E7 IU (middle dose)|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
10193817|NCT04895449|Experimental|≥ 1 x 10E8 IU (high dose)|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
10193818|NCT04893954|Other|Obese patients|
10193819|NCT04859842|Active Comparator|Pulse Electromagnetic Field Group|Pulse Electromagnetic Field Therapy (PEMF) will be applied to patients' low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to PEMF therapy.
10193820|NCT04859842|Active Comparator|Interferential Current Group|Interferential current will be applied to patients' low back pain region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to Interferential current.
9708770|NCT04653090||Varus group|Radiographic stem axis was assessed on standard anteroposterior hip radiographs performed at the 3-month follow-up visit. Alignment was evaluated as described by Reina et al., by the angular deviation of the anatomic femoral axis and the stem axis. The 3 degrees minimal-value was considered to be the threshold defining a varus stem.
9708771|NCT04653090||Neutral group|Alignment between anatomic femoral axis ans stem axis was less than 3°.
9708772|NCT04653194|Experimental|Biktarvy treatment|First-line HIV treatment of Biktarvy OD for 48 weeks
9708773|NCT04653194|Active Comparator|Symtuza treatment|First-line HIV treatment of Symtuza OD for 48 weeks
9708774|NCT04653064|Experimental|Placebo Cream first|"Each participant will undergo thermal pain tasks after being administered a treatment cream to one of eight body sites."
9708775|NCT04653064|Experimental|Control Cream first|"Each participant will undergo thermal pain tasks after being administered a control cream to one of eight body sites."
9708776|NCT04653311|Experimental|Endomina procedure + lifestyle intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. This group will also receive the medical standard treatment defined as lifestyle intervention.
9708777|NCT04653311|No Intervention|Lifestyle intervention|The group will receive the medical standard treatment defined as lifestyle therapy combining diet (mediterranean diet) with increased physical activity
9708778|NCT04653246|Experimental|Isa-RVD|"The main study consists of 4 phases a) 28-day screening phase; b) an induction phase inclusive of two 42-day induction treatment cycles: Isatuximab (IV), Bortezomib (SQ). Lenalidomide (PO), Dexamethasone; c) Followed by stem cell mobilization (at the discretion of the Principal Investigator [PI]);d) Participants will proceed with either autologous stem cell transplant or two additional induction cycles.~- Induction will be followed by a maintenance phase that continues until disease progression."
9708779|NCT04653272||Experimental|"Patients aged 16 to 40 years with ACL anterior cruciate ligament rupture, meniscal injury, patella instability or dislocation (Young Adult group),~Patients over 55 years of age with gonarthrosis (Senior adults group)."
9708780|NCT04653272||Control|"a group of young (16 to 40 years old)~senior (over 55 years old) adult controls~Everybody free of knee pathology."
9708781|NCT04653155|Experimental|Treatment arm|Participants in the treatment group will show significant improvement on insomnia symptoms after intervention compared to those in the waitlist control group.
9708782|NCT04653155|No Intervention|Waitlist control|Participants in the waitlist control group will show little improvement on insomnia symptoms after the treatment period of the treatment group.
9708783|NCT04653337|Active Comparator|Robot-assisted rTMS and Antidepressants|Patients with suicidal ideation and depression will receive antidepressants combined with robot-assisted rTMS.
9708784|NCT04653337|Active Comparator|Conventional rTMS and Antidepressants|Patients with suicidal ideation and depression will receive antidepressants combined with conventional rTMS.
9708785|NCT04653337|Sham Comparator|Sham rTMS and Antidepressants|Patients with suicidal ideation and depression will receive antidepressants combined with sham rTMS.
9708786|NCT04653012|Experimental|Macro-microelectrode implantation|Implantation of macro-micro electrodes of the Adtech Benkhe-Fried type in epileptic patients who are undergoing evaluation with intracranial EEG electrodes
9708787|NCT04653129|Experimental|Group (A): Primary nerve repair with autologous fat graft|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope with autologous fat grafting around site of repair
9708788|NCT04653129|Active Comparator|Group (B): Standard primary nerve repair|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope without fat grafting.
9708789|NCT04653376||Chronic tonsillitis|Patients with tonsil sizes grade 1 and 2, and tonsillectomy indications included frequently recurrent tonsillary infection, sore throat, and malodorous mouth problems were accepted as the chronic tonsillitis group.
9708790|NCT04653376||Tonsillar hypertrophy|Patients with tonsil size grades 3 and 4 and tonsillectomy indications included obstructive symptoms such as snoring, open mouth breathing, difficulty in breathing, and swallowing problems were accepted as the tonsillar hypertrophy group.
9708791|NCT04653025|Experimental|Test group|Test group patients received an immediate implant with provisional restoration, bone augmentation and soft tissue grafting
9708792|NCT04653025|Experimental|Control group|Patients in the control group received soft tissue grafting after tooth extraction and an implant with bone augmentation after 6 weeks of healing.
10193821|NCT04859842|Sham Comparator|Sham Group|Sham electrodes will be placed on the low back region. Also, patients will receive a conventional therapy program consisting of hotpack, ultrasound, and transcutaneous electrical stimulation in addition to sham therapy.
9708793|NCT04653077|Experimental|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
9708794|NCT04652934|Experimental|Intervention group|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
9979906|NCT01386294|Placebo Comparator|Universal placebo gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
9708795|NCT04652934|Sham Comparator|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
9708796|NCT04653103||Patients with obesity|Subjects with different classes of obesity
9708797|NCT04653233|Experimental|Intervention|After the theoretical lesson, the students in the experimental group were taken to the laboratory room where the 3D Systems Touch Haptic Simulator is located. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option. Since the preparation of the material in the full teaching method in the simulator takes a long time, these steps were removed to show similarity with the control group. The skill practice option for an average of 5-10 minutes where all steps of the Checklist for Teaching Urinary Catheterization Skill can be applied was used. Urinary catheterization with 3D Systems Touch Haptic Simulator was explained by 1 researcher who was responsible for the Fundamentals of Nursing course.
9708798|NCT04653233|No Intervention|Control|"After the theoretical lesson, the control group was taken to Fundamentals of Nursing Skill Laboratory. 1 researcher, who is responsible for the Fundamentals of Nursing, was explained on the Simple Urinary Catheterization Model by applying the steps of Checklist for Teaching Urinary Catheterization Skills. The students were allowed to ask questions and the questions asked were answered. Then all the students in the control group were taken to an empty class. The two researchers prepared the necessary materials for the urinary catheterization skill practice in the same way in separate rooms. The doors were closed to keep the environment calm during the application. One student was taken to each laboratory rooms in order not to be affected by each other. While the student was practicing, both researchers filled in the Checklist for Teaching Urinary Catheterization Skills. Satisfaction Questionnaire was given to the student who completed the application and asked to fill it."
9708799|NCT04652999|Experimental|Muscle Relaxation with Guided Imagery|The participants in Experimental Group will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
9708800|NCT04652999|Placebo Comparator|Active Control Group|Participants in the Active Control Group will receive four individual 45-minute sessions of neutral guided imagery placebo, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
9708801|NCT04652999|No Intervention|Passive Control Group|The participants in the Passive Control Group will not receive any intervention nor placebo session.
9779252|NCT05307991||Index PrEP participants|This group includes persons 15 years and older who are started on PrEP at the STI clinic. Participants in this group will be followed for 6 months, with follow-up visits at 1, 3, and 6 months, and will be asked to refer sexual partners from the preceding 6 months as well as any new sexual partners throughout the study period. They will also receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
9779253|NCT05307991||Non-PrEP participants|This group includes persons who are eligible to receive PrEP but who decline initiation at their index visit to the STI clinic. These participants will be followed for 6 months, with follow-up visits at 3 and 6 months, and receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. However, at any time during the follow-up period these persons can choose to initiate PrEP. This would not change their follow-up frequency nor their assigned group, and they would continue to be followed for 6 months from the date of initial enrollment. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
9979907|NCT01386320|Active Comparator|Ultrasound guided ankle block|Subjects in this arm will be given an ultrasound guided ankle block prior to foot surgery.
9979908|NCT01386320|Active Comparator|Medial forefoot block|Subjects in this arm will be given a nerve-stimulator guided forefoot block prior to anaesthesia and forefoot surgery
9979909|NCT01386333|Experimental|Oxytocin 24IU|Oxytocin 24 IU administered intranasally twice daily for 1 week
9979910|NCT01386333|Experimental|Oxytocin 48 IU|48 IU of intranasal oxytocin administered twice daily for 1 week
9979911|NCT01386333|Experimental|72 IU oxytocin|72 IU of intranasal oxytocin administered twice daily for 1 week
9979912|NCT01386333|Placebo Comparator|Saline nasal spray|
9979913|NCT01386346|Experimental|All subjects|"Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.~Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2"
9979914|NCT01386359||Adult de novo EBV-seropositive kidney-transplant recipients|Adult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
9979915|NCT01386372|Experimental|Tolvaptan|
9979916|NCT01386372|Active Comparator|standard therapy|
10193822|NCT04843852|Experimental|Intervention - vaccination|"HEPLISAV-B is available in pre-filled, single-dose 0.5 mL vials. Each dose contains 20 μg of HBsAg and 3,000 μg of 1018 adjuvant. HEPLISAV-B is administered as an intramuscular injection in the deltoid region.~Study subjects randomized to the vaccine group will receive a total of 2 injections, each administered at least 4 weeks apart - the same dosing schedule recommended for hepatitis B prevention.~Once enrolled, participants will have study visits on days 0 (first injection), 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196."
9708802|NCT04652817|Experimental|MMI-22-04-2019|Sodium hyaluronate at a concentration of 2.5% (25 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent administered once or twice depending on the individual necessity.
9708803|NCT04652830|Active Comparator|Naprapathy training|Training program for three months
9708804|NCT04652830|Placebo Comparator|Control group|No change of daily routines
9708805|NCT04652921|Experimental|Creatine-guanidinoacetic acid|2 grams of creatine and 2 grams of GAA Administered one dose two times per day on an empty stomach in the morning and at the evening
9708806|NCT04652921|Placebo Comparator|Inulin|4 grams of inulin Administered one dose two times per day on an empty stomach in the morning and at the evening
9708807|NCT04652635|Active Comparator|Nail plate removal, nail bed repair|Participants will undergo nail plate removal and nail bed repair, and follow up at clinic visits at 1 week, 3 months, and 6 months
9708808|NCT04652635|No Intervention|Observation|Participants will follow up at clinic visits at 1 week, 3 months, and 6 months
9708809|NCT04652869|Experimental|Mindfulness Training|Mindfulness training
9708810|NCT04652869|Experimental|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
9708811|NCT04652869|Experimental|Mindfulness + tDCS|Mindfulness training with transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
9708812|NCT04652752|Experimental|CONNETTIVINA HI TECH patch|CONNETTIVINA HI TECH patch will be applied to eligible patients. CONNETTIVINA HI TECH will be renewed every two day, according with general principles of wound management
9979917|NCT01386411||Women with Breast Cancer|The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
9979918|NCT01386541|Active Comparator|BYK324677|"Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)~Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)~Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)~In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.~Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.~Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner."
9979919|NCT01386541|Placebo Comparator|Placebo|
9984464|NCT04067622|Other|Exersides restraints first|Patients in this arm will wear the novel Exersides restraint during hours 1-4 on Day 1, then switched to soft wrist restrains during hours 5-8. On Day 2, patients in this arm will will wear soft wrist restraints during hours 1-4, and Exersides during hours 5-8. They will then wear Exersides during study days 3-6.
10193823|NCT04843852|No Intervention|No vaccination|Participants randomized to the control group will have study visits on days 0, 14, 28, 56, and 196 with phone call follow ups on days 7, 35, and 393. Research blood samples will be collected at days 0, 14, 28, 56, 196.
10193824|NCT04826276|Experimental|All Subjects|"for the abstinence intervention, 12+ hours after smoking will be assessed before assessments following smoking as normal~For the satiated intervention, smoking as normal will be assessed first before assessments following 12+ hours of abstinence from smoking"
10193825|NCT04825288|Active Comparator|Arm 1|"XB2001 + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 1 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: XB2001 MTD as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-Fluorouracil 2400mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
10193826|NCT04825288|Placebo Comparator|Arm 2|"Placebo + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 2 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: Placebo as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
9708813|NCT04652908|Experimental|Treatment with PMSC-ECM|One-time administration of PMSC-ECM during the course of in utero fetal myelomeningocele surgery will be administered
9708814|NCT04652908|Other|non-PMSC untreated contemporaneous cohort|Contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort).
9708815|NCT04652674|Experimental|Group I|Patients who will undergo telemedicine visit approximately 1 week postoperatively, then an in-person clinic visit approximately 4 weeks postoperatively
9708816|NCT04652674|Active Comparator|Group II|Patients who will undergo in-person clinic visit approximately 1 week postoperatively, then a telemedicine visit approximately 4 weeks postoperatively
9708817|NCT04652648|Active Comparator|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID for 10 days
9708818|NCT04652648|No Intervention|Control|No Intervention
9708819|NCT04652713|Experimental|High protein breakfast|Participants will be served a dairy-based protein-rich breakfast meal.
9708820|NCT04652713|Experimental|High carbohydrate breakfast|Participants will be served a carbohydrate-rich breakfast meal
9708821|NCT04652713|Experimental|No breakfast|Participants will be served no breakfast
9708822|NCT04652739|Experimental|Lycopene|
9708823|NCT04652739|Active Comparator|Corticosteroids|
9708824|NCT04652661|Experimental|Dexmedetomidine Group|30 children will be sedated with 2 μg/kg intranasal dexmedetomidine
9708825|NCT04652661|Active Comparator|Midazolam Group|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
9708826|NCT04652765|No Intervention|Standard of care (SOC)|SARS-CoV-2 positive participants will receive SOC therapy alone.
9708827|NCT04652765|Active Comparator|SOC plus camostat and bicalutamide|SARS-CoV-2 positive participants will receive SOC therapy as well as camostat and bicalutamide for 7 days.
9708828|NCT04652531|Experimental|Treatment|In the treatment arm, the lesion will be treated with EV for 3 weeks once a week
9708829|NCT04652531|Sham Comparator|Internal control|The contralateral ulcer will be treated with a standard dressing and an elastic-compression bandage for 3 weeks.
10193827|NCT04809701|Experimental|Configuration A first|Subjects receive the test of Configuration A first and Configuration B second.
10193828|NCT04809701|Experimental|Configuration B first|Subjects receive the test of Configuration B first and Configuration A second.
10193829|NCT04782661|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive an oral solution of JNJ-70075200 or placebo in single ascending doses on Day 1 in cohorts 1, 2, 3, 4, 5a and 6 under fasted condition. Participants in cohort 5a will additionally receive the same study intervention under fed condition (Cohort 5b) after a washout period of at least 7 days.
10193830|NCT04782661|Experimental|Part 2: Multiple Ascending Dose (MAD)|After assessment of safety, tolerability and pharmacokinetics data in Part 1, participants will receive an oral solution of JNJ-70075200 or placebo twice daily in Cohorts 1 to 6 for 14 days under fasted/fed condition.
9708830|NCT04652427|Experimental|Use Dexmedetomidine Hydrochloride to maintain a sedative|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
9708831|NCT04652427|Placebo Comparator|Sedative were maintained with a 0.9% sodium chloride injection|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
9708832|NCT04652388|Experimental|Nutritional counseling|Children with autism spectrum disorders to whom administer nutritional counseling
9708833|NCT04652388|No Intervention|Controls|No intervention
9708834|NCT04652492|Experimental|Tislelizumab in combination with cTACE|Tislelizumab in combination with on-demanded cTACE
9708835|NCT04652440|Experimental|Radiofrequency ablation combined with PD-1 monoclonal antibody|Patients who meet the inclusion criteria will receive PD-1 treatment after primary radiofrequency ablation.
9708836|NCT04652791||Wangbi Capsule|Patients who are taking Wangbi Capsule for the treatment.
9708837|NCT04652791||Other drugs|Patients who are not taking Wangbi Capsule for the treatment.
9708838|NCT04652362|Experimental|Growth Mindset Intervention|
9708839|NCT04652362|Active Comparator|Supportive Therapy Intervention|
9708840|NCT04652271||Patients undergoing pancreatic surgery|Patients undergoing any type of pancreatic surgery.
9708841|NCT04652232|Active Comparator|Treated group|This group will receive the RV3466F lotion and a neutral shampoo
9708842|NCT04652232|Other|Control group|This group will receive a neutral shampoo
9708843|NCT04652284|Active Comparator|Rifabutin full dose|oral amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd 14 days
9708844|NCT04652284|Active Comparator|Rifabutin low dose|oral amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd 14 days
9708845|NCT04652284|Active Comparator|Standard of Care|Standard of care in previously untreated patients will consist of concomitant treatment (oral amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole 40 mg all given twice daily for 14 days). In previously treated patients standard of care will consist of bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment where available
10193831|NCT04782661|Experimental|Part 3: Single-dose Oral Solid Formulation (Optional)|Participants will receive oral dose of JNJ-70075200 on Day 1 in Cohort 1 under fasted condition. Part 3 will start after obtaining a formal regulatory/ethical approval.
9979920|NCT01386567|Experimental|Androxal|Androxal (enclomiphene citrate)12.5 mg or 25 mg
9708846|NCT04652336|Active Comparator|LSG|This group will receive standard laparoscopic sleeve gastrectomy
9979921|NCT01386567|Active Comparator|Testim (topical testosterone)|
10193832|NCT04781972|Experimental|Methylphenidate first|Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week.
10193833|NCT04781972|Placebo Comparator|Placebo first|Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week.
10193834|NCT04765852|Experimental|Experimental Group 1|High dose probiotic supplement and maltodextrin as the excipient
9708847|NCT04652336|Experimental|LSG with LTC|This group will receive LSG along with the novel LTC procedure
9708848|NCT04652323||Control|Twenty-one empty polyethylene tubes remained empty to bewere used as in the control group.
9708849|NCT04652323||ProRoot MTA|ProRoot White MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
9979922|NCT01386580|Experimental|2B3-101 Single Agent Dose Escalation|Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
9984465|NCT04067622|Other|Traditional restraints first|Patients in this arm will wear soft wrist restraints during hours 1-4 on Day 1; they will then be switched to the novel Exersides restraint during hours 5-8. On Day 2, patients in this arm will will wear Exersides during hours 1-4, and soft wrist restraints during hours 5-8. They will then wear soft wrist restraints during study days 3-6.
9984466|NCT04067284|Active Comparator|Education|Nutrition education on dietary diversity.
10193835|NCT04765852|Experimental|Experimental Group 2|Low dose probiotic supplement and maltodextrin as the excipient
9708850|NCT04652323||Medcem MTA|Medcem MTA mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
9708851|NCT04652323||Medcem Pure Portland Cement|Medcem Pure Portland Cement mixed according to the manufacturer's' instructions were filled placed into sterile p olyethylene tubules (internal diameter: 1.3 mm internal diameter, x external diameter: 1.6 mm external diameter, x length: 5.0 mm length) sterilized with ethylene oxide gas, as specified by ISO , with using a sterile Llentulo.
9708852|NCT04652349|Experimental|HGP1910|
9708853|NCT04652349|Experimental|HCP1903|
9708854|NCT04652349|Active Comparator|HGP1909|
10193836|NCT04765852|Placebo Comparator|Control Group|Placebo supplement containing only maltodextrin but having the same appearance as the probiotic supplements
9708855|NCT04652349|Active Comparator|HGP1911|
9708856|NCT04652297|Experimental|HS-10356 single dose|Single oral dose of HS-10356 ascending dose
9708857|NCT04652297|Placebo Comparator|placebo single dose|Single oral dose of placebo ascending doses
9708858|NCT04652297|Experimental|HS-10356 multiple doses|Multiple oral doses of HS-10356 ascending doses
9708859|NCT04652297|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo ascending doses
9708860|NCT04651959|Experimental|AVICOD then AVIGAN|Participants first received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state. After a washout period of 24 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
9708861|NCT04651959|Experimental|AVIGAN then AVICOD|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 24 hours, they then received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state.
9708862|NCT04651881|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
9708863|NCT04651881|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
9708864|NCT04651881|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
9708865|NCT04651881|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
9708866|NCT04651881|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
9708867|NCT04651881|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
9708868|NCT04652024|No Intervention|CONTROL GROUP|Girls in the control group received pelvic floor muscle exercise (kegel exercise) daily in the outpatient clinic 12 weeks.
10193837|NCT04756570|Active Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose Mini-Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale (SSQOL) assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
10193838|NCT04756570|Active Comparator|Robotic 1|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
10193839|NCT04756570|Active Comparator|Robotic 2|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Modified Ashworth Scale (MAS), Barthel Index, The Modified Rankin Scale, Berg Balance Scale , &-min walk test, and Stroke-Specific Quality of Life Scale assessments will be applied just before the rehabilitation program, after the application and at the end of 6 weeks
10193840|NCT04748146|Other|Intervention and Control group|Each patient will receive electrical and sham stimulation, meaning that each patient will act as their own control.
10193841|NCT04745845|Experimental|Noradrenalin|treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
10193842|NCT04741503|Experimental|Breast Cancer Screening Decision Support Tool|-After randomization, participants will complete pre-questionnaires, review the Breast Cancer Screening Decision support tool, and then complete the post-questionnaire.
10193843|NCT04741503|Active Comparator|Standard Breast Cancer Screening Education|-After randomization, participants will complete pre-questionnaires, review the standard breast cancer screening education from the NCI, and then complete the post-questionnaire.
10193844|NCT04740294|Experimental|Magnesium Sulfate|The patient will receive a bolus of 50mg/kg MgSO4 over twenty minutes.
10193845|NCT04740294|Placebo Comparator|Placebo|The patient will receive a bolus of Normal Saline over twenty minutes.
10193846|NCT04735627|Experimental|Levodopameter|During the single study visit, participants will receive either: 1) two separate doses of oral levodopa in a dose equivalent to their home regimen with one dose of carbidopa in a 1:10 ratio and one dose of carbidopa in a 1:4 ratio (carbidopa:levodopa) ratio; or will receive 2) one dose of oral carbidopa 100mg followed by intravenous levodopa in 1.2mg/kg dose. levodopa The Levodopameter microneedle sensor device will serially measure interstitial fluid levodopa levels and blood will be simultaneously collected from an intravenous line for high-performance liquid chromotography analysis of plasma levodopa levels.
10193847|NCT04730349|Experimental|A1W Dosing schema|
9708869|NCT04652024|Experimental|STUDY GROUP|Girls in the study group received the same physical therapy program given to the control group in addition to anorectal biofeedback for six sessions per week. in addition to kegel exercise
9785170|NCT01244529|Other|galy A / seno A / galy A Plus|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
9984467|NCT04067284|Experimental|Yogurt|A combination of similar education plus daily supplementation of homemade yogurt
9984468|NCT04067284|Active Comparator|Control|Control group.
9708870|NCT04651907|Experimental|acupuncture group|The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3mm×30mm. The needle placed for the real acupuncture group will be the same needle size as 0.3mm×30mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
9708871|NCT04651907|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
9708872|NCT04651907|No Intervention|waitlist-controlled group|As an waitlist control group, no acupuncture will be performed.
9708873|NCT04652011||Patients with chronic pelvic pain|Patients with chronic pelvic pain and a benign gynecologic disease associated, referring to our Unit, medically or surgically treated from 2010 to 2019
9708874|NCT04651868|Experimental|CCK + GLP-2|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
9708875|NCT04651868|Experimental|CCK + placebo|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg^-1 × min^-1) and a 210 mins intravenous infusion with isotonic NaCl
9708876|NCT04651868|Experimental|Placebo + GLP-2|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with GLP-2 (10 pmol × kg^-1 × min^-1)
9708877|NCT04651868|Experimental|Placebo + placebo|A 180 mins intravenous infusion with isotonic NaCl and a 210 mins intravenous infusion with isotonic NaCl
9708878|NCT04652180|Experimental|Robot-assisted thoracic approach in Ivor Lewis esophagectomy|Robot-assisted thoracic approach in Ivor Lewis esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
9708879|NCT04652180|Active Comparator|Open transthoracic approach in Ivor Lewis esophagectomy|Traditional open transthoracic esophagectomy with gastric conduit formation. Abdominal approach will be performed by laparoscopy.
9708880|NCT04652258|Other|Treatment arm|"The patients will be administered Tocilizmab (Actemra) at the following dosage :~First dose: 8mg/kg, max. 800mg iv. during 60min~If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose"
9708881|NCT04652141|Active Comparator|AsthmaTuner field tests|Trail treatment with AsthmaTuner up to 3 months. Objective asthma criteria: Positive reversibility test, FEV1 >12% and 200 ml or positive periodic variability PEF/FEV1 >20%. Treatment recommendation is prescribed individually by treating physician.
9708882|NCT04652141|No Intervention|Traditional trial treatment|Treatment recommendation is prescribed individually to patient by treating physician. The treatment plan is transferred to patient on printed paper and/or oral communication.
9708883|NCT04651933||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
9708884|NCT04651933||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
9708885|NCT04652310|Active Comparator|Extended-Short Nail|Implantation of TFNA extended-short nail (235 mm)
9708886|NCT04652310|Active Comparator|Long nail|Implantation of TFNA long nail (260-480 mm)
9708887|NCT04652128|Experimental|zoledronate|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
9708888|NCT04652128|Placebo Comparator|saline|Subject will receive a single infusion of physiological saline 100mL intravenously.
9708889|NCT04652115|Experimental|Defibrotide|Defibrotide IV
9708890|NCT04652076|Other|Arm A: Standard Chemotherapy alone (Paclitaxel + Carboplatin)|Standard Chemotherapy will be adminitred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
9708891|NCT04652076|Other|Arm B: Experimental double combination [Standard Chemotherapy +NP137]|Experimental double combination [Standard Chemotherapy +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
9708892|NCT04652076|Other|Arm C: Experimental double combination [Pembrolizumab +NP137]|Experimental double combination [Pembrolizumab +NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
9708893|NCT04652076|Other|Arm D: Experimental triple therapeutical combination [Pembrolizumab+ Standard Chemotherapy + NP137]|Experimental triple combination [Pembrolizumab+ Standard Chemotherapy + NP137] will be administred in 2 independant cohorts: Endometrial carcinoma or Cervix Carcinoma
10193848|NCT04730349|Experimental|A1F Dosing schema|
9708894|NCT04651842||HOMA IR high|classified based on equal tertile of HOMA IR level into 3 equal groups ( high>6.6)
9708895|NCT04651842||HOMA IR intermediate|classified based on equal tertile of HOMA IR level into 3 equal groups ( intermediate 4.6-6.6, )
9708896|NCT04651842||HOMA IR low|classified based on equal tertile of HOMA IR level into 3 equal groups (low ≤ 4.6, )
10193849|NCT04730349|Experimental|A2W Dosing schema|
10193850|NCT04730349|Experimental|A2F Dosing schema|
9708897|NCT04652154|Other|Control|Control group is recieving treatment as ususal
9708898|NCT04652154|Experimental|Intervention group|The intervention group getting the new assessment by a complementary professional team
9708899|NCT04652089|Experimental|Experimental arm: Simvastatin|Simvastatin 20mg capsule once a day for 7 days
9708900|NCT04652089|Placebo Comparator|Control arm: Placebo|Placebo capsule once a day for 7 days
9708901|NCT04651855|Experimental|Treatment arm|It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture.
9708902|NCT04651647||Bone graft group|The bone graft group (n=19) who underwent open nailing with open bone graft for aseptic subtrochanteric nonunion
10193851|NCT04730349|Experimental|Part B: Cohort B1 Neuroblastoma|
10193852|NCT04730349|Experimental|Part B: Cohort B2 Ewing sarcoma|
10193853|NCT04730349|Experimental|Part B: Cohort B3 Rhabdomyosarcoma|
10193854|NCT04730349|Experimental|Part B: Cohort B4 Miscellaneous solid tumors|
10193855|NCT04730349|Experimental|Part B: Cohort B5 NHL/leukemia|
9708903|NCT04651647||Non bone graft group|The non-BG group (n=18) who underwent closed reamed nailing without bone graft for aseptic subtrochanteric nonunion
9708904|NCT04651582|Experimental|Cognitive Training|20 hours of computerized brain exercises
9708905|NCT04651582|Active Comparator|Cognitively Stimulating Activities|20 hours of computerized brain exercises
9708906|NCT04651686|Experimental|Bronchial artery protection|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
9708907|NCT04651504|Experimental|Primary Care Clinics|"Southern Illinois Healthcare System will contact the site management and ask for participation in the study~Eligible providers and staff will be identified by clinic management. The research coordinator will work with the clinic to schedule a virtual site visit(s). The study team will interview providers and staff at the beginning and/or end of each active intervention period to assess knowledge and attitudes about CRC screening and follow-up processes, the Consolidated Framework for Implementation Research (CFIR) constructs such as role clarity within the clinical team, and satisfaction with the intervention and implementation. Post-implementation surveys will also ask about work-arounds and adaptations of the intervention tools and perceived efficacy."
9708908|NCT04651517|Experimental|Study arm|Subjects undergoing procedures with the XACT ACE Robotic system.
9708909|NCT04651530|Active Comparator|Phaco|Cataract surgery only
9708910|NCT04651530|Experimental|Phaco+ECP|Cataract surgery combined with endoscopic cyclophotocoagulation
9708911|NCT04651491||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel)
9708912|NCT04651699|Experimental|Active Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes at 2 milli amps.
9708913|NCT04651699|Sham Comparator|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current (s-tDCS) will be applied over the Primary Motor Cortex during 10 sessions of 20 minutes.
9708914|NCT04651738|Experimental|Study group|All eligible participants consenting to participate the study.
9708915|NCT04651595|Experimental|Caudal|
9708916|NCT04651595|Active Comparator|Control|
9708917|NCT04651478|Experimental|Action Observation+Motor Imagery through BCI|"Action Observation+Motor Imagery through a Brain-Computer Interface training paradigm in Virtual Reality using the NeuRow platform during 10 sessions of 20 minutes, divided in 4 series of 5 minutes."
9708918|NCT04651478|Placebo Comparator|Action Observation through non-related with movement illustrations|Control Action Observation protocol of non-related with movement illustrations during 10 sessions of 20 minutes, divided in 4 series of 5 minutes.
9708919|NCT04651751|No Intervention|Control|No Intervention: Control Participants exercised on their own without receiving any instructions.
9708920|NCT04651751|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
9708921|NCT04651816|Active Comparator|Control PSH DPP only|This group will be enrolled the PSH DPP program. There will be two cohorts for this arm.
9708922|NCT04651816|Experimental|Treatment 1 Financial Incentives A|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
9708923|NCT04651816|Experimental|Treatment 2 Financial Incentives B|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
9708924|NCT04651816|Experimental|Treatment 3 Motivational Text Messaging|This group will receive text messages with motivational messages while participating in the PSH DPP program. There will be two cohorts for this arm.
9708925|NCT04651556|Active Comparator|Parenteral Analgesia|receive ordinary analgesics via intravenous route as paracetamol (7.5- 10 mg/kg) and ketorolac (0.5 mg/kg).
10193856|NCT04730349|Experimental|Part B: Cohort B6 High-grade glioma|
10193857|NCT04730349|Experimental|Part B: Cohort B7 Medulloblastoma and Embryonal Tumors|
9708926|NCT04651556|Active Comparator|Intraperitoneal instillation|receive (Magnesium sulphate 40 mg/kg and bupivacaine 4mg/kg) in 30 ml of isotonic 0.9%N.S intra peritoneal at the end of surgery.
9708927|NCT04651764|Experimental|Robotically assisted transanal endoluminal resection of rectal lesion|
9708928|NCT04651803||Traumatic brain injury patients|Traumatic brain injury patients admitted in intensive care unit.
9708929|NCT04651621|Experimental|Open label active cTBS|Four consecutive days with 40s cTBS, 100% MT over the SMA, five times a day with 50 minutes between stimulations
9708930|NCT04651621|Experimental|active cTBS|One test session with 40s active cTBS, 100% MT, over the SMA in the initial double blind cross-over phase
9708931|NCT04651621|Sham Comparator|Sham cTBS|One test session with 40s sham cTBS, 100% MT, over the SMA in the initial double blind cross-over phase with a special sham coil that diverts the magnetic field to be only superficial
9708932|NCT04651790|Active Comparator|Vaccine 0-14|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
9708933|NCT04651790|Experimental|Vaccine 0-28|Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
9708934|NCT04651608|Experimental|manuel acupressure|In this group, manual acupress was applied to children receiving chemotherapy with moderate and high emetogenic effects.
9708935|NCT04651608|Experimental|sea-band acupressure|In this group, sea-band acupressure was applied to children receiving chemotherapy with moderate and high emetogenic effects.
9708936|NCT04651465|Experimental|Tuning in to Kids parenting program|Intervention groups receive the Tuning in to Kids parenting program
9708937|NCT04651465|No Intervention|Business as usual|"control groups have business as usual, and then get offered the intervention program after one year follow-up assessment."
9708938|NCT04651426|Placebo Comparator|Placebo|The Placebo is a Patch identical to the F3 and F4 patches in aesthetics but without any biomineral, therefore with no reflectance ability.
10193858|NCT04730349|Experimental|Part B: Cohort B8 Ependymoma|
10193859|NCT04730349|Experimental|Part B: Cohort B9 Miscellaneous brain tumors|
9708939|NCT04651426|Active Comparator|F3 Patch|The F3 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum 2 m x kg
10193860|NCT04728646|Experimental|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
10193861|NCT04728646|Other|Dissolvable intracanalicular plug|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
10193862|NCT04723277|Experimental|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
10193863|NCT04723277|Active Comparator|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
10193864|NCT04723277|Experimental|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
10193865|NCT04723277|Active Comparator|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
9708940|NCT04651426|Active Comparator|F4 Patch|The F4 is a patch made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on with a refringency spectrum of 4 m x kg
9708941|NCT04651452|Active Comparator|Value Affirmation|Participants in the value affirmation condition will complete six writing prompts regarding their personal values over the course of six months. For example, participants will be given a list of values and will be asked to rate them in order of importance within their own lives and write about a time when their top value was particularly important. Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
9708942|NCT04651452|Active Comparator|Reflective Journaling|Participants in the reflective journaling condition will complete six writing prompts over the course of six months. However, the reflective journaling condition will be writing about values that are not important to them and discuss why they could be important to others. In other tasks, they will write about aspects of daily life (e.g. morning routine). Participants will write for about ten minutes each session. The intervention tasks will be completed on a secure, online website that each individual participant will be emailed a link to. Participants can also receive paper copies via postal mail if they prefer.
9708943|NCT04651777|Experimental|Participants with poorly controlled moderate to severe asthma|Participants with poorly controlled moderate to severe asthma will be evaluated during and after a six week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements.
9708944|NCT04651413||Covid-19 Ct Value|All patients enrolled onto the ISARIC COVID-19 trial at The University Hospitals of North Midlands NHS Trust between the period 1st February 2020 to 1st July 2020 will be included in this study, provided that a laboratory cycle threshold (Ct) value is available.
9708945|NCT04651335|Active Comparator|Concentric|uses an afferent virtual reality program
9708946|NCT04651335|Active Comparator|Eccentric|uses an efferent virtual reality program
9708947|NCT04651322|Experimental|Training group|
10193866|NCT04723277|Experimental|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
9708948|NCT04651322|Other|Control group|
9708949|NCT04651023|Placebo Comparator|control group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (0g NnEx) per day with or after meals.
9708950|NCT04651023|Experimental|low concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (1g NnEx) per day with or after meals.
9708951|NCT04651023|Experimental|high concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (2g NnEx) per day with or after meals.
9708952|NCT04651062|Experimental|endocuff|all patients having performed a screeningscolonoscopy and being randomized to colonoscopy with the use of endocuff
9708953|NCT04651062|Active Comparator|no cuff|all patients participating in a screeningscolonoscopy being randomized to colonoscopy without the use of endocuff
9708954|NCT04651101||vitamin D deficient|those patient with vitamin D level below 30 ng/dl
9708955|NCT04651101||non vitamin D deficient|those patient with vitamin D above 30 ng/dl
9708956|NCT04651231|Active Comparator|tight flap technique group (forty patients-group A)|in this arm forty patients did tight flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to close the apex of triangular scleral flap tightly and two releasable stitches were used at the sides of triangular scleral flap.
9708957|NCT04651231|Experimental|loose flap technique (securing sutures) group (forty patients-group B).|in this arm forty patients did loose flap technique for punch trabeculectomy. At 12 o'clock 10/0 nylon monofilament stitch was used to secure the edges of the flap at the apex of and two-four releasable stitches were used at the sides of triangular scleral flap in group B.
9708958|NCT04651049||Propranolol treatment group|
9708959|NCT04651205|No Intervention|Untreated|This control group will be untreated for 8 weeks as to be a controlled group. Then all participants in the control group will be randomised again to either Mg-B1 or B1-Mg groups for another 8 weeks (delayed-start intervention).
9708960|NCT04651205|Experimental|Mg-B1 early start|Participants in the Mg-B1 are the 'early start' group where they will receive 400 mg of Mg per day for 4 weeks then add on 100 mg of B1 per day for another 4 weeks, a total duration of 8 weeks (MgB1).
9708961|NCT04651205|Experimental|B1-Mg early start|Participants in the B1-Mg are the 'early start' group where they will receive 100 mg of B1 per day for 4 weeks then add on 400 mg of Mg per day for another 4 weeks, a total duration of 8 weeks (B1Mg).
9708962|NCT04651283|Experimental|Adaptive seating equipment group|Study group who received the same selected program for hand function on adaptive swiss ball seating
9708963|NCT04651283|Active Comparator|Traditional seat group|Control group who received a specially selected physical therapy program for hand function on a standard chair seating.
9708964|NCT04651114|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
9708965|NCT04650958|Active Comparator|STN DBS stimulation group|In the STN DBS stimulation group, patients will receive a continuous DBS stimulation for 3 months and the first default parameters applied will be monopolar setting (0.5 V under threshold that causes side effects, 135 Hz, 90 µs, at one of the two dorsal contacts). If the default parameters are found not suitable for an individual patient due to unexpected reasons, an alternative method will be applied (e.g., decreased voltage) to try to maintain full compliance with the scheduled study.
9708966|NCT04650958|Sham Comparator|Sham stimulation group|In the sham stimulation group, the programming will also start within 1 week after the surgery, but at each follow-up the DBS system will be turned off after the parameter is adjusted to the threshold that causes side effects without continuous stimulation. After the 3-month double-blind period the patients can choose to set on the DBS system again and receive regular continuous stimulation treatment.
9708967|NCT04651309|Other|Ultrasound group|Labor progress assessed by US, avoiding digital exams as much as possible;
10193867|NCT04723277|Active Comparator|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
10193868|NCT04708886|Experimental|Females with Chronic SCI|12-month treatment with monthly subcutaneous romosozumab injections (210 mg), followed by 12-month treatment with weekly oral alendronate tablets (70 mg)
9708968|NCT04651309|No Intervention|Control group|Labor progress assessed according to the regular protocol
10193869|NCT04706923|Experimental|BCV 0.2mg/kg BIW|BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
9708969|NCT04650997|Experimental|Combined|12 weeks eccentric exercise combined with 6 sessions of extracorporeal shockwave therapy in the initial 6 weeks
9708970|NCT04650997|Sham Comparator|Exercise|12 weeks eccentric exercise combined with 6 sessions of sham extracorporeal shockwave therapy in the initial 6 weeks
9708971|NCT04650971|Experimental|"Vaccine UniFluVec 6.7 log EID50/dose"|"Cohort 1 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 6.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
9708972|NCT04650971|Experimental|"Vaccine UniFluVec 7.7 log EID50/dose"|"Cohort 2 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 7.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
9708973|NCT04650971|Placebo Comparator|Placebo|Placebo comparator arm consists of 20 subjects (10 subject in each Сohort).
9979923|NCT01386580|Experimental|2B3-101 in combination with trastuzumab|HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
9979924|NCT01386580|Experimental|2B3-101 solid tumor expansion|Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
9708974|NCT04651140|Active Comparator|Tremor group|Participants in the tremor group have tremor as the main clinical manifestation
9708975|NCT04651140|Active Comparator|Stiff group|Participants in the tremor group have stiff as the main clinical manifestation
9979925|NCT01386580|Experimental|2B3-101 glioma expansion|Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
9708976|NCT04651127|Experimental|Toripalimab + Chidamide Arm|
9708977|NCT04650776|Experimental|High heat strain|participants exercised at 75% of their heart rate maximum (HR max) and wore light athletic clothing (t-shirt and shorts)
10193870|NCT04706923|Experimental|BCV 0.3mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
10193871|NCT04706923|Experimental|BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
9708978|NCT04650776|Experimental|Low heat strain|participants exercised at 50% HR max, wearing protective firefighter clothing (jacket and trousers)
9708979|NCT04650724|Experimental|T cell infusion agent targeting BCMA chimeric antigen receptor|
9708980|NCT04650867||Patients with Crohn's disease|Patients diagnosed or with suspected Crohn's disease.
9708981|NCT04650867||Patients with Ulcerative colitis|Patients diagnosed or with suspected Ulcerative colitis
10193872|NCT04706923|Experimental|BCV 0.4 mg/kg QW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 for a minimum of 4 weeks.
9708982|NCT04650867||Patients with unclassified inflammatory bowel disease (U-IBD)|Patients diagnosed or with suspected unclassified inflammatory bowel disease (U-IBD)
9708983|NCT04650906|Experimental|Intervention group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
9708984|NCT04650906|No Intervention|Control group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
9779254|NCT05307991||Partner participants|This group is made up of named/referred partners from the Group 1 (Index PrEP participant) who are eligible for and agree to start PrEP. They will receive identical intervention to that of the Group 1, specifically: this group will be followed for 6 months, with follow-up visits at 1, 3, and 6 months, and will be asked to refer sexual partners from the preceding 6 months as well as any new sexual partners throughout the study period. They will also receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
9779255|NCT05307991||Providers|This group is made up providers involved in the provision of PrEP or other related services including STI management, HIV testing or counseling, or assisted partner notification (aPN). Examples include: clinicians, nurses, HIV testing/aPN counselors, registration staff, community tracers, and clinic management who provide clinical or aPN services. These participants will be asked to complete a survey responding to acceptability, feasibility, and appropriateness of the enhanced PrEP implementation strategy as an integrated strategy within the STI clinic. They will also participate in in-depth interviews. These activities will be completed at baseline and approximately 6 months thereafter.
9779256|NCT05307978|Experimental|Cohort 1|Participants will receive a single dose of 5 mg of ALXN1910 IV or Placebo IV.
9779257|NCT05307978|Experimental|Cohort 2|Participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
9779258|NCT05307978|Experimental|Cohort 3|Participant will receive a single dose of 15 mg of ALXN1910 IV or Placebo IV.
9779259|NCT05307978|Experimental|Cohort 4|Japanese participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
9779260|NCT05307978|Experimental|Cohort 5|Participants will receive a single dose of 45 mg of ALXN1910 SC or Placebo SC.
9779261|NCT05307978|Experimental|Cohort 6|Participants will receive a single dose of 135 mg of ALXN1910 SC or Placebo SC.
9779262|NCT05307965|Active Comparator|Standalone Percutaneous Coronary Intervention|Participants will have standard of care treatment. They will undergo PCI with devices and techniques driven by clinical decision making at the patient level and institutional level, and carried out in accordance with the Oxford University Hospitals NHS Foundation Trust department guidelines.
9779263|NCT05307965|Active Comparator|Percutaneous Coronary Intervention and Thrombus Aspiration|Participants will have standard of care treatment with manual thrombectomy catheter and PCI. They will undergo PCI with devices and techniques driven by clinical decision making at the patient level and institutional level, and carried out in accordance with the Oxford University Hospitals NHS Foundation Trust department guidelines.
9779264|NCT05307965|Experimental|Percutaneous Coronary Intervention and Retriever Thrombectomy|Participants randomised to the stent-retriever thrombectomy arm of the RETRIEVE AMI trial will undergo stent-retriever thrombectomy with the SolitaireTM X Revascularisation Device.
9779265|NCT05307952|Other|Better-performing|"Those of the participants who show a speech recognition percentage above 70% will undergo testing in order to provide a ceiling error profile for comparison during statistical analysis."
9779266|NCT05307952|Experimental|Poorer-performing|Those of the participants who show a speech recognition percentage below 70% will undergo two interventions: the first adjusting the fitting of their cochlear implant, and the second providing them with a personalized, self-administered training program.
9779267|NCT05307926|Experimental|PD-1 based therapy group|"The experimental group was given PD-1 inhibitors or PD-1 inhibitors combined with lenvatinib therapy after the operation.~Usage of PD-1 inhibitors: starting from 1 month after the operation, 200mg was given intravenously every 21 days, for a total of nine times.~Usage of lenvatinib: starting from 1 month after the operation, 8mg was taken orally, once a day, for one year."
9779268|NCT05307926|Other|Control group-TACE based|The control group was given 1-2 times TACE(Transarterial chemoembolization) after the operation.
10193873|NCT04706403|Experimental|Message 1|"Participants were randomized to receive version #1 of 5 different versions of a message from a physician regarding the COVID-19 vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 1, this statement was followed by a participatory-style recommendation (What do you think?)"
10193874|NCT04706403|Experimental|Message 2|"Participants were randomized to receive version #2 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 2, this statement was followed by a comparison of the COVID-19 vaccine to the flu shot and an explicit recommendation (I recommend that you get it)."
9979926|NCT01386593|Other|(A) Baseline|
9979927|NCT01386593|Other|(B) Inhibition|
9779271|NCT05307874|Experimental|ICT01 + LDSC IL-2|ICT01 IV on Day 1 of every 21-day cycle. Low Dose SC IL-2 is administered Days 1-5 of cycles 1/2/3 only.
9779272|NCT05307861|Active Comparator|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
9779273|NCT05307861|Active Comparator|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
9779274|NCT05307848||Female patients with bipolar disorder without medication|
9979928|NCT01386593|Other|(C) Induction|
9979929|NCT01386619|Experimental|NK cell DLI|
9708985|NCT04650750|Experimental|Xiao-Feng-San; Shian-Fang-Hwa-Ming-Yiin|Xiao-Feng-San 2g+ Shian Fang Hwa Ming Yiin 2g; twice a day for two months
9708986|NCT04650750|Placebo Comparator|Placebo|Similar placebo 4g twice a day for two months
9708987|NCT04650802|Experimental|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
9708988|NCT04651036|Experimental|Pegfilgrastim biosimilar product|QL0605 subcutaneously at a dose of 6 mg/0.6 mL.
9708989|NCT04651036|Active Comparator|US Neulasta|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
10193875|NCT04706403|Experimental|Message 3|"Participants were randomized to receive version #3 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 3, this statement was followed by a statement that millions of people have already received the COVID-19 vaccine and an explicit recommendation (I recommend that you get it)."
10193876|NCT04706403|Experimental|Message 4|"Participants were randomized to receive version #4 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 4, this statement was followed by an acknowledgment of concerns and reassurance that the physician personally reviewed the safety data and an explicit recommendation (I recommend that you get it)."
9708990|NCT04650893|Placebo Comparator|Control|no steroid or non steroidal anti-inflammatory
9708991|NCT04650893|Active Comparator|Ketorolac|one time dose of 30mg of IV Ketorolac at time of closure
9708992|NCT04650893|Active Comparator|dexamethasone|one time dose of 10mg of IV dexamethasone at the time of closure
9708993|NCT04650841|Experimental|Naloxone Group|Participants will receive 4mg naloxone nasal spray.
10193877|NCT04706403|Experimental|Message 5|"Participants were randomized to receive version #5 of 5 different versions of a message from a physician regarding vaccination. All messages included a statement that the vaccine is very safe and very effective. In Message 5, this statement was followed by an emphasis on protecting others an explicit recommendation (I recommend that you get it)."
9708994|NCT04650841|Experimental|Saline Group|Participants will receive saline in the nasal spray.
9708995|NCT04650919|Experimental|Experimental arm|
9708996|NCT04650711|Experimental|Study group|All eligible participants as one group accept P16INK4A testing, with cytology and/or hrHPV assay.
9708997|NCT04650880|Active Comparator|Vitamin D|Vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000 IU once every 2 weeks for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
9708998|NCT04650880|Placebo Comparator|Placebo|Placebo tablets with same external appearance for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
9708999|NCT04650451|Experimental|HER2-targeted dual-switch CAR-T cells|Subjects will receive one dose of BPX-603 on Day 1, followed by rimiducid IV infusion weekly (as tolerated) starting on Day 8 and continued until treatment discontinuation criteria are met.
10193878|NCT04686383|Experimental|Cohort 1: 20 mg CAL056 mesylate|Patients will receive oral dose of 20 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
10193879|NCT04686383|Experimental|Cohort 2: 40 mg CAL056 mesylate|Patients will receive oral dose of 40 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
10193880|NCT04686383|Experimental|Cohort 3: 80 mg CAL056 mesylate|Patients will receive oral dose of 80 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
10193881|NCT04686383|Experimental|Cohort 4: 120 mg CAL056 mesylate|Patients will receive oral dose of 120 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
10193882|NCT04686383|Experimental|Cohort 5: 160 mg CAL056 mesylate|Patients will receive oral dose of 160 mg CAL056 mesylate once daily under fasting condition in the morning for 28 days during each cycle.
10193883|NCT04686175|Experimental|INZ-701|The study design is a MAD 3+3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly.
10193884|NCT04684654|Experimental|Part A (SAD)|Single Ascending Dose (SAD)
9709000|NCT04650438|Experimental|High-creativity|Here participants are allocated to the high-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
9709001|NCT04650438|Experimental|Low-creativity|Here participants are allocated to the low-creativity group. Resting state EEG will be measured pre- and post-TMS and participants' creative performance will be measured by means of a creativity test battery.
9709002|NCT04650828||Experimental:person with TDF+LDT|TDF combined with LDT for 12 months
9709003|NCT04650828||Active comparator:person with TDF|TDF monotherapy was continued for 12 months
9709004|NCT04650594|Experimental|case group|Patients with knee bone malignancy
9709005|NCT04650360|Experimental|Postoperative Intervention Educational Program|The intervention group will receive an educational program during admission. The health educational program will consist of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics will be addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls
9709006|NCT04650360|No Intervention|Control|The patients in the control group will not receive any educational program. These patients will be treated according to routine protocols
9709007|NCT04650555|Experimental|Single Ascending Dose Cohort 1|500 mg BIO 300 Oral Powder administered as a single dose
9709008|NCT04650555|Experimental|Single Ascending Dose Cohort 2|1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
9779275|NCT05307848||Female patients with bipolar disorder after stable prescription for ≥6 months|
9709009|NCT04650555|Experimental|Single Ascending Dose Cohort 3|2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
9709010|NCT04650555|Experimental|Single Ascending Dose Cohort 4|Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3
9709011|NCT04650555|Experimental|Multiple Single Dose Cohort 5|Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days
9709012|NCT04650737|Active Comparator|Group A (single shot,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine ;ultrasound guided ESPB
9709013|NCT04650737|Active Comparator|Group B (continous infusion,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs;ESPB
9709014|NCT04650542|Experimental|HBI-3000 alone (Period 1) followed by HBI-3000 with Paroxetine (Period 2)|"HBI-3000: 350 mg, 50 mL intravenous infusion (IV) over 30 minutes on Day 1 of Period 1 and approximately 15 days later on Day 1 of Period 2~Paroxetine: 20 mg dose twice a day on Days 1 and 2 of Period 2, and once a day on Days 3 through 7 inclusive of Period 2"
9709015|NCT04650685|Experimental|The novel Salvadora persica toothbrush|The novel toothbrush is under Al-Abyad Miswak brand that will be supplied by Insight Prestige Sdn Bhd. Participants are expected to use this oral hygiene tool for 3 weeks.
9709016|NCT04650685|Experimental|The Salvadora persica (miswak) chewing sticks|The chewing sticks are under the brand of Al-Khair. They will be prepared into equal length of 15 cm with uniform diameter of 1.0-1.5 cm and are sealed in airtight plastic bags. Participants are expected to use this oral hygiene tool for 3 weeks.
9709017|NCT04650685|Other|Standard toothbrush and toothpaste (control)|Participants will be given straight-handle soft-bristle Oral-B™ standard toothbrush and Colgate® fluoride tooth. Participants are expected to use this oral hygiene tool for 3 weeks.
9709018|NCT04650334|Other|Perinatal Collaborative Care|Experimental: Perinatal Collaborative Care in Can Tho, Vietnam This is an active treatment arm consisting of 3 health centers receiving training in collaborative care and enrollment of a total of 100 perinatal patients into collaborative care.
9709019|NCT04650477|Active Comparator|Fixated in the EP position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the extension-pronation (EP) position
9709020|NCT04650477|No Intervention|Fixated in the neutral position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the neutral position (elbow 90 degrees flexed and hands positioned with the thump pointing up
9709021|NCT04650503||Patients with eosinophilic asthma at baseline|Patients showing ≥3% sputum eosinophils at baseline
9709022|NCT04650503||Patients with non eosinophilic asthma at baseline|Patients showing <3% sputum eosinophils at baseline
9709023|NCT04650620|Experimental|Plenhyage® thin|Plenhyage® thin for the treatment of mild wrinkles;
9709024|NCT04650620|Experimental|Plenhyage® medium|Plenhyage® medium for the treatment of moderate wrinkles;
9709025|NCT04650620|Experimental|Plenhyage® strong|Plenhyage® strong for improving the skin tones and irregularities (atrophies) of the skin surface in neck, abdomen, thighs and buttocks
9709026|NCT04650386|No Intervention|Treatment As Usual (TAU)|Participants assigned to the TAU condition will be scheduled for buprenorphine medication management appointments and will receive OBOT at the FQHC and adjunctive psychosocial treatment as typically provided at the FQHC. The team will continue to meet with the patient during subsequent MAT visits on a decreasing frequency, with some slight site-specific variation. The schedule of MAT visits generally includes 3 clinic visits during the week of induction, 1-2 visits per week until the patient is stabilized, and monthly thereafter. Behavioral health clinicians provide support to the patient, discuss UDS results, assist with strategic problem-solving around recovery and adjustment to sobriety, and monitor the patient's engagement in MAT.
9709027|NCT04650386|Experimental|Adaptive Intervention|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
9709028|NCT04650425|Experimental|Intervention group|Each participant will undergo one or two sessions, consisting of cognitive tasks, video-EEG recording and administering of questionnaires.
9709029|NCT04650412|Experimental|Intervention|Bundle of comorbidities care
9709030|NCT04650412|No Intervention|Control|Standard care
9709031|NCT04650516|Experimental|Endocare treatment|Patients will receive the treatment on a dedicated virtual reality headset to display the Endocare® application, with high quality headphones
9709032|NCT04650516|Active Comparator|Digital control treatment|Patients will receive the digital control on a dedicated tablet to display the digital control, with high quality headphones
9709033|NCT04650373||Surgical management|Underwent bariatric surgery
9709034|NCT04650373||Non-surgical management|Patients treated medically
9709035|NCT04650308|Active Comparator|Healthy group|healthy men and women aged 20-60 years old.
9709036|NCT04650308|Active Comparator|Non-healthy group|pregnant women, nursing mothers, impaired kidney and liver function, chronic disease, or other metabolic disorders.
9709037|NCT04650191||Mild COVID-19 infection|Patients with confirmed COVID-19 infection who remained asymptomatic and/or never hospitalized.
9709038|NCT04650191||Moderate COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in general ward in the hospital.
10193885|NCT04684654|Placebo Comparator|Part A (SAD) Placebo|
9709039|NCT04650191||Severe COVID-19 infection|Patients with confirmed COVID-19 infection who got admitted in intensive care unit and/or did not survive.
9709040|NCT04650763|No Intervention|Control Group|Dental implant was placed in these patients following full protocol of immediate implant placement.
9779276|NCT05307848||Age and BMI-matched healthy controls|
10193886|NCT04684654|Experimental|Part B (MAD)|Multiple Ascending Dose (MAD)
10193887|NCT04684654|Placebo Comparator|Part B (MAD) Placebo|
10193888|NCT04684654|Experimental|Part C (pSS)|Primary Sjögren's Syndrome (pSS)
10193889|NCT04684654|Placebo Comparator|Part C (pSS) Placebo|
9709041|NCT04650763|Experimental|PRP Group|In this group Platelet Rich Plasma (PRP) was injected in soft tissue over surgical site.
9709042|NCT04650269|Experimental|Rapid ART group|Patients will receive HIV care including Biktarvy for 6 months at the syringe services program followed by 6 months of standard of care at a traditional clinic.
9709043|NCT04650256|Experimental|CAM arm|Participants will be given the CAM intervention during scheduled, standard of care radiotherapy (up to 6 weeks) and 8-12 weeks (weeks 14-18) after radiotherapy.
9709044|NCT04650243|Experimental|ursodeoxycholic acid 250mg bid|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally twice a day.
9709045|NCT04650243|Experimental|ursodeoxycholic acid 250mg qd|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally once a day.
9709046|NCT04650243|Active Comparator|ursodeoxycholic acid standard dosage|Patients will receive standard dosage of ursodeoxycholic acid 250mg orally three times a day.
9709047|NCT04650321|Experimental|Home infusion of ocrelizumab|Patients will receive infusion of ocrelizumab at home, instead of at clinic.
9709048|NCT04650347|Experimental|internal urethrotomy using Holmium laser representing group|In group 1, a three hundred micron laser fiber was used to conduct the laser energy. holmium laser pulse energy of approximately 1 joule was used that was generated from a Holmium laser Quanta device and total power of 15 watts. the laser fiber was aimed directly to the midline at 12 o'clock position to start the procedure and cut the fibrous tissue till access to a wide lumen.
9709049|NCT04650347|Active Comparator|internal urethrotomy with Sachs cold knife|In group B, Sache cold knife internal urethrotomy was used with the same technique as Holmium laser internal urethrotomy at the same site to mechanically cut instead of the laser fiber.
9709050|NCT04650230|Active Comparator|high flow nasal cannula (HFNC)|Participants in the HFNC group received heated and humidified gas flow with the Fisher & Paykel Healthcare HFNC system. The flow rate was usually started at the maximum flow rate for the size of cannula and a constant flow temperature of 37 °C.The flow rate will be progressively decreased when inspired fraction of oxygen (FiO2) was inferior to 30 percent (%).
9709051|NCT04650230|Active Comparator|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)|Participants in the CPAP/NPPV group received for first CPAP using a neonatal ventilator. The recommended starting pressure for CPAP was +6 centimeter of water (cmH2O). Positive continuous pressure could be increased to a maximum of +8 cmH2O. Optimal positive end expiratory pressure (PEEP) was what could maintain SpO2 at 94 per cent using the lowest fraction of inspired oxygen. PEEP will be decreased progressively of 1cmH2O every 6 hours from the optimal PEEP when FiO2 was inferior to 30% and there is no increase of work of breath.
9709052|NCT04649983|Experimental|Arm 1|Patients will be be treated with CD19 and CD22 CAR-T cells
9709053|NCT04649970||malignant uropathy|Antegrade double-J stent
9709054|NCT04649749||Patients - bionic hand acquired|3 adult patients who acquired a bionic hand at the Medical University of Vienna after a traumatic brachial plexus lesion.
9709055|NCT04649749||Patients - bionic hand not yet acquired|3 patients eligible for the bionic hand prior to a possible amputation.
9709056|NCT04649749||Control subjects|Ten control subjects will be included for comparison.
9709057|NCT04649957||Cohort Observation|"Study investigators will identify eligible participants within 72 hours of expected discharge from hospital. Eligibility will be determined using the criteria outlined in section 5.1 which incorporates the Post-COVID-19 Functional Status (PCFS) Scale, a tool which has been developed and endorsed by the European Respiratory Society to measure functional status over time following COVID-19 infection. Patients graded 2, 3 or 4 on the PCFS will be eligible for participation. Eligible patients will be provided with a detailed explanation of the study including the provision of written information (PIS). Patients will be given time to consider participation in the research study before being approached again by the research team.~If the patient expresses an interest in study participation the research team will invite participants to a baseline data collection session that will be held at the University of Derby (Kedleston Road campus) in the days following discharge."
9709058|NCT04650100|Experimental|PENG group|For the PENG group, the ultrasound-guided PENG block (20 ml of Ropivacaine 4.75 mg/ml) is performed before the surgery.
9709059|NCT04650100|No Intervention|Control group|No additional intervention, only standard care
9709060|NCT04649892|Experimental|Naltrexone|A 12 week Naltrexone flexible dose administration plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
9709061|NCT04649892|Placebo Comparator|Placebo|A 12 week placebo matching tablets plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
9709062|NCT04649762||Control|Group 1 includes patients with anxiety consulting a doctor not practicing hypnosis
9709063|NCT04649762||TAC|Group 2 includes patients with anxiety consulting a doctor practicing hypnosis
9709064|NCT04650139||successful CTO|
9709065|NCT04650139||non- successful CTO|
9709066|NCT04649853||Acute Wounds|Patient with either traumatic or surgical wounds
9979930|NCT01386658|Experimental|Icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
10193890|NCT04683991|Experimental|treatment group 1|At the same time of implant implantation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
9709067|NCT04649853||Chronic Wounds|Patient with chronic wounds either peripheral vascular disease related or surgical/traumatic wound
9979931|NCT01386671|Experimental|Metformin glycinate|Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.
9709068|NCT04649853||Pressure Injuries Present on Admission|Patient admitted with one or more pressure injury of any stage on admission
9709069|NCT04649853||At Risk for Pressure Injury|Patient admitted with risk for pressure injury and has no pressure injuries at time of admission. Identified as at risk for based on mobility.
9709070|NCT04650126|Experimental|ATM001|Escalating dose levels of ATM001 administered as single dose in healthy subjects
9709071|NCT04650126|Placebo Comparator|ATM001 Placebo|Escalating dose levels of ATM001 Placebo administered as single dose in healthy subjects
9709072|NCT04649827||COVID-19|Patients with confirmed COVID-19 by RT-PCR or serological test
9779277|NCT05307835|Experimental|Personalized neoantigen vaccines|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
9779278|NCT05307835|No Intervention|control group|observe
9709073|NCT04650048|Active Comparator|Active tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
9709074|NCT04650048|Placebo Comparator|Sham tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
9979932|NCT01386671|Active Comparator|Metformin Hydrochloride|Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.
9709075|NCT04650113|Experimental|group A|placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude ) 9.The pellet will be remove, and the pulp chamber filled with MTA. 10.The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement
9709076|NCT04650113|Active Comparator|group B|"Pre-operative radiograph showing all roots and their apices.~Local anesthesia will be administered and a rubber dam will take place ,that ensure good isolation of the treated teeth.~Removal of caries~Pulp chambers will access using a no.330 bur in a high-speed hand piece with water coolant.~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece~Pulp amputation will perform using a spoon excavator.~Hemorrhage control will obtain within 5 minutes using sterile cotton pellets placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude )~The pellet will be remove, and the pulp chamber will be filled with MTA.~The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement.~The periapical radiographic will be taken at this baseline visit ."
9709077|NCT04650022||TPCIV-ABAO|TPCIV-ABAO
9709078|NCT04650061|Experimental|PIMA Group|"MEntA: Educational & Training Program~Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~Identification of Care plan and Schedule next visits~Follow-up D21-D90-D120-D180 depending of the care plan, through the channel that belong for each care plan"
9979933|NCT01386684||Patients with Prostate Cancer|Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
9709079|NCT04650061|Active Comparator|Control|"Training program~Schedule next visits~Follow-up D21-D90-D120-D180 using the same process: visit at home or phone."
9709080|NCT04649996||Pandemic period|patients admitted in hospital for acute appendicitis
9709081|NCT04649996||control period|patients admitted in hospital for acute appendicitis
9709082|NCT04649801|No Intervention|conventional|
9709083|NCT04649801|Active Comparator|interventional|
9709084|NCT04649723|Experimental|Rifampicin 600 mg + SHR1459 Tablets 200 mg|
9709085|NCT04649723|Active Comparator|SHR1459 tablets 200 mg|
9709086|NCT04649658||Prone position|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to prone position
9709087|NCT04649658||Standard care|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to standard care
9709088|NCT04649541|Active Comparator|Single intravenous doses of MRX-8|Single escalating doses of MRX-8
9709089|NCT04649541|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-8
9709090|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 7 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 7 days.
9709091|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 7 days|Multiple intravenous doses of placebo every 12 hours for 7 days to match MRX-8.
9709092|NCT04649541|Active Comparator|Multiple intravenous doses of MRX-8 for 14 days|Multiple ascending intravenous doses of MRX-8 every 12 hours for 14 days.
9709093|NCT04649541|Placebo Comparator|Multiple intravenous doses of placebo for 14 days|Multiple intravenous doses of placebo every 12 hours for 14 days to match MRX-8.
9709094|NCT04649684|Experimental|Conventional robot-assisted gait training group|they got conventional robot-assisted gait training, guidance force given equally to both limbs
9709095|NCT04649684|Experimental|Lower CIMT robot-assisted gait training group|they got robot-assisted gait training based on CIMT concept
9979934|NCT01386710|Experimental|Arm 2|Drug: Bevacizumab and Carboplatin
9709096|NCT04649424|Experimental|CanSwab - 1st|CanSwab will be swabbed first
9979935|NCT01386710|Experimental|Arm 1|Drug: Bevacizumab and Carboplatin
9979936|NCT01386723||Discontinuation of eltrombopag|ITP subjects who have discontinued the use of eltrombopag
9979937|NCT01386736|Active Comparator|Vitamin D|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
9979938|NCT01386736|Placebo Comparator|Placebo|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
9979939|NCT01386749|No Intervention|Control|
10193891|NCT04683991|Experimental|treatment group 2|During the second stage operation, autologous tissue is transplanted into the recipient area by using Subepithelial connective tissue graft.
10193892|NCT04680156||EN3835|Previously treated with EN3835 in EN3835-210 or the pivotal phase 3 studies
10193893|NCT04680156||Placebo|Previously treated Placebo in EN3835-210 or the pivotal phase 3 studies
10193894|NCT04678648|Experimental|RSC-1255 Treatment|Single Arm Study. All study participants receive RSC-1255.
9709097|NCT04649424|Experimental|CanSwab - 2nd|CanSwab will be swabbed second.
9709098|NCT04649528|Experimental|Supervised HIIT|Exercise intervention, 20 supervised by healthcare professional
9709099|NCT04649528|Experimental|APP HIIT|Exercise intervention, 20 self-monitored assisted by a mobilephone application
9979940|NCT01386749|Experimental|Treatment|receive 6 months LMHFV
9979941|NCT01386762|Experimental|Exercise intervention|6 months of intense multimodal training.
9979942|NCT01386775||HED Affected Males|
9979943|NCT01386775||Controls|
9979944|NCT01386801||People with Diabetes Mellitus Type II|500 subjects will have T2D
9979945|NCT01386801||Healthy|500 persons who do not have T2D, hypertension or hypercholesterol
9979946|NCT01386827|Active Comparator|A) primary immunization with MB-JEV|Volunteers immunized with MB-JEV
10193895|NCT04674826|Experimental|TR (Test-Reference)|Treatment period 1: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T) Treatment period 2: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R)
10193896|NCT04674826|Experimental|RT (Reference-Test)|Treatment period 1: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R) Treatment period 2: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T)
10193897|NCT04671043|Experimental|CAF+lowCHO|A drink containing caffeine and 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
9709104|NCT04649554|Experimental|Experimental: ExAblate 4000 System|Exablate treatment on Neuropathic Pain
9709105|NCT04649645|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
9709106|NCT04649645|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS.
9709107|NCT04649645|Active Comparator|Control Arm (Arm C)|Participant continues to not smoking or using of any nicotine/tobacco products.
9709108|NCT04649619|Other|Single-arm-study|Prospective clinical trial with intentional sample selection that aims to describe the results of the gastric Bypass surgery modified by De Melo, for the purpose of endoscopic access to the excluded remaining stomach, as well as to monitor the clinical conditions of comorbidities and the quality of life of the patient.
9709109|NCT04649411|Experimental|Ferric citrate|Participants aged 12 to <18 years and 6 to <12 years will receive ferric citrate for 24 weeks at a starting dose based on body weight categories.
9709110|NCT04649411|Active Comparator|Standard of care|Participants aged 12 to <18 years and 6 to <12 years will receive standard of care treatment for 24 weeks.
9709111|NCT04649606||Experimental|Eligible subjects will undergo repeated observations to evaluate the Meibomian gland appearance
9709112|NCT04649229|Experimental|placebo, aprepitant, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
9709113|NCT04649229|Experimental|placebo, aprepitant, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
9709114|NCT04649229|Experimental|aprepitant, placebo, placebo, aprepitant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
9709115|NCT04649229|Experimental|aprepitant, placebo, aprepitant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and aprepitant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive aprepitant and placebo, respectively.
9709116|NCT04649697|Experimental|Rebamipide|The enrolled subjects will be treated with Rebamipide in orabase for 2 weeks or until complete healing.
9709117|NCT04649697|Experimental|Nanoparticulated Rebamipide|The enrolled subjects will be treated with nanoparticulated Rebamipide in orabase for 2 weeks or until complete healing.
9709118|NCT04649697|Active Comparator|Clobetasol|The enrolled subjects will be treated with Clobetasol in orabase for 2 weeks or until complete healing.
9709119|NCT04649372|Other|EndoVE endosCopic Treatment for Oesophageal and Gastric canceR|The patient will be placed under General Anaesthetic or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged. There will be a telephone follow up after 2 days, 7 days, 4 weeks and 8 weeks. The patient will be requested to attend the clinic for a 12-week follow up for clinical review.
9709120|NCT04649502|Experimental|Metformin combined with doxycycline|
9709121|NCT04649502|Placebo Comparator|Doxycyline combined with placebo|
9709122|NCT04649437|Other|Symptomatic patients|Subjects with symptoms of atrial fibrillation i.e. AF-6 sum score 30 points or more.
10193898|NCT04671043|Active Comparator|10g CHO|A drink containing 10 g rapid-acting carbohydrate (glucose) dissolved in 200 mL of tap water
10193899|NCT04671043|Placebo Comparator|placebo|A drink containing an artificial sweetener (aspartame) dissolved in 200 mL of tap water
10193900|NCT04664738|Experimental|10 % PEP only|Cohort 1: Subjects will receive 10% PEP to the skin graft donor wound.
10193901|NCT04664738|Experimental|20% PEP only|Cohort 2: Subjects will receive 20% PEP to the skin graft donor wound
10193902|NCT04664738|Experimental|10% PEP and TISSEEL|Cohort 3: Subjects will receive 10% PEP and TISSEEL to the skin graft donor wound.
10193903|NCT04664738|Experimental|20% PEP and TISSEEL|Cohort 4: Subjects will receive 20% PEP and TISSEEL to the skin graft donor wound.
10193904|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, Future, and Risk"
10193905|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Future"
10193906|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Risk"
9709123|NCT04649437|Other|Asymptomatic patients|Subjects with no symptoms of atrial fibrillation i.e. AF-6 sum score = 0.
9709124|NCT04649125|Active Comparator|standard|standard radiotherapy 5 fractions
9709125|NCT04649125|Experimental|single fraction dose escalation|8Gy to Planned Target Volume, 12Gy to Clinical Target Volume +/- 14Gy to Gross Target Volume
9709126|NCT04649463|Active Comparator|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
9709127|NCT04649463|Sham Comparator|Concealed ABPM results|ABPM results were not used in the decision making for adjustments in antihypertensive medication at follow up visit.
9709128|NCT04649281|Other|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
9709129|NCT04649450|Experimental|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days (post-operative day 1, 2 and 3) at the neurosurgical ward they will receive music twice a day for 30 minutes. All participants will further receive standard of clinical care.
9709130|NCT04649450|No Intervention|Standard of clinical care|Standard of clinical care.
9709131|NCT04649398||oral nimodipine|60mg of nimodipine is orally administered every 4 h,
9709132|NCT04649398||intra-venous nimodipine|nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4
9979947|NCT01386827|Active Comparator|Primary and booster MBJEV vaccinations|Booster immunization with MB-JEV of vaccinees primed with MB-JEV
9709133|NCT04649398||intra-arterial nimodipine|during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes
9709134|NCT04649307|Other|MI-CBT|The treatment will be based on the AF treatment developed by the research group and further be developed and adapted during the course the study, based on the clinical presentation of the MI patients and their response to the CBT interventions detailed below. The MI-specific CBT will consist of 8 weekly face-to face digital video sessions with home assignments that can be reviewed and reported in the research groups secure platform. CBT for MI primarily targets two processes of disability; cardiac anxiety, and depressive inactivity
9709135|NCT04649346||SGA type 1|Observe the function of SGA type 1
9709136|NCT04649346||SGA type 2|Observe the function of SGA type 2
9709137|NCT04649255|Experimental|Lava LES|
9709138|NCT04649190||TAVI|
9709139|NCT04649268|Active Comparator|Optokinetic stimulation treatment with visual motion DVDs|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with visual motion DVDs
9709140|NCT04649268|Experimental|Optokinetic stimulation treatment with Virtual Reality|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with Virtual Reality environments delivered with headset (e.g. Oculus Quest headset)
9709141|NCT04649216|Experimental|Mass Balance|Subjects will receive a single oral dose of [14C]PCO371 Oral Solution.
9709142|NCT04649216|Experimental|Absolute Bioavailability and Mass Balance|Subjects will receive a single oral dose of PCO371 capsules, followed by a single IV infusion of [14C]PCO371 over 10 min, starting 2 h post-oral dose.
9709143|NCT04649320||cancer patients|adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms
9709144|NCT04649086|Experimental|Eccentric group|The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation and will be adapted according to the pain felt at the end of the session.
9709145|NCT04649086|Active Comparator|Concentric group|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
9709146|NCT04649164|Other|Focus group participants|"Subjects participating in focus groups will be either:~caregiver mentees in our previous peer mentoring study~peer mentors and completed 16 weeks of mentoring in our previous peer mentoring study~current family caregivers of community-dwelling LBD patients in the Chicago area.~The investigators will conduct virtual focus groups using a password-protected videoconference platform. The informed consent process will take place online prior to the focus group. Focus groups will be led by a qualified neuropsychologist using open-ended questions. The aim of these groups is to revise and improve upon our previous peer mentor program's curriculum. Participants will be presented with the previous program's curriculum and a variety of proposed educational resources for inclusion in the revised curriculum. The investigators will obtain participants' feedback. Focus groups will be recorded and transcribed."
9709147|NCT04649164|Other|Peer mentors|Mentors will attend one 6-7 hour virtual training session. Study expectations and logistics will be reviewed with each potential mentor prior to the training session via phone. Informed consent process will take place online via REDCap prior to the training session. Baseline data will be collected via online surveys. Next, mentors will receive training regarding topics including active listening, mentoring, goal-and boundary-setting, an overview of LBD, risk factors for hospitalization, impact on caregiver, practical approaches to symptom management, and caregiving issues. The study team will present the PERSEVERE curriculum and accompanying handbook. The team will solicit questions and lead roleplay conversations. Finally mentors will complete post-training assessments. Once all caregiver mentees (Arm 3) are recruited, the mentors will contact their mentees once weekly by phone for 16 weeks to deliver the PERSEVERE curriculum.
9979948|NCT01386827|Active Comparator|C) primary immunizations with Ixiaro|Primary immunization with Ixiaro 2 dose
9709148|NCT04649164|Experimental|Caregiver mentees|Once Aim 2 is complete and mentors have been trained, caregiver mentees will be matched with mentors by relationship to LBD patient, then by sex and age, as much as possible. The study team will contact mentees once a match is available for them. The mentee will complete baseline primary and secondary outcome assessments online via REDCap, including: mastery and loneliness scales, Short Zarit Burden Interview, Hospital Anxiety and Depression Scale. The team will provide the mentor's contact information and send the PERSEVERE handbook. Mentoring pairs will begin the 16-week peer mentor program. Pairs will be expected to speak for >15-30 minutes weekly, and to review that week's PERSEVERE topics in the handbook before or during each call to facilitate meaningful conversations. Mentors and mentees will complete online study diaries every 2 weeks. Upon completion of the 16-week mentor program, mentors and mentees will be sent a link to complete postmentoring assessments online.
9709149|NCT04648891|Other|Control|Patients will receive laryngeal injection of Botox via a transcricothyroid approach without additional anesthesia
9709150|NCT04648891|Experimental|Lidocaine|Patients will receive laryngeal injection of Botox via a transcricothyroid approach following subcutaneous injection of 0.5cc 2% lidocaine in 1:100,000 epinephrine (done approximately 2 minutes before Botox injection)
10193907|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Scenarios"
10193908|NCT04661566|Experimental|Education+Narratives+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Future, and Risk"
10193909|NCT04661566|Experimental|Education+Narratives+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Future"
9709151|NCT04648891|Experimental|Vibrating Wand|Patients will receive laryngeal injection of Botox via a transcricothyroid approach while a vibrating instrument is held adjacent to cricothyroid space
9709152|NCT04648969|Experimental|Experimental: kisspeptin, GnRH|• Intravenous administration of kisspeptin 112-121; 20 boluses in a 40-hour period. Intravenous administration of GnRH; one bolus.
9709153|NCT04648800|No Intervention|Group I|with positive RT23 test reading, not randomised and not vaccinated against tuberculosis
9709154|NCT04648800|Active Comparator|Group II|with negative RT23 test reading, receiving BCG-10 Vaccine
9709155|NCT04648800|Placebo Comparator|Group III|with negative RT23 test reading, receiving placebo
9709156|NCT04648956||Knee/Hip osteoarthritis|Patients referred for physical therapy rehabilitation
9779279|NCT05307822|Experimental|Cohort 1: Menthol with HTP device (20020064)|Subjects will self-assign to one of three menthol flavor variants of non-combusted cigarette products based on their self-reported flavor usage history.
9779280|NCT05307822|Experimental|Cohort 2: Non-Menthol with HTP device (20020064)|Subjects will self-assign to a non-menthol flavor variant of a non-combusted cigarette product based on their self-reported flavor usage history.
9779281|NCT05307809|Experimental|Psoriasis|
10193910|NCT04661566|Experimental|Education+Narratives+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Risk"
10193911|NCT04661566|Experimental|Education+Narratives+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Skills"
9779282|NCT05307809|Experimental|Psoriatic arthritis|
10193912|NCT04661566|Experimental|Education+Narratives+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives. Scenarios, Future, and Risk"
9779283|NCT05307809|Active Comparator|Controls|
9779284|NCT05307796|Experimental|Semantic Feature Analysis plus metacognitive strategy training|Participants attend three treatment sessions per week for eight weeks. Treatment sessions include: strategy education (participants learn about anomia, circumlocution, and circumlocution's purpose), Semantic Feature Analysis plus strategy application (participants build self-awareness and practice circumlocution), and strategy debriefing (participants reflect and receive feedback on their performance, and generate scenarios in which they could use the strategy in everyday life).
10193913|NCT04661566|Experimental|Education+Narratives+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Future"
9779285|NCT05307770|Experimental|Immediate Release Melatonin, Then Extended Release Melatonin|Subjects will receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks.
9779286|NCT05307770|Experimental|Extended Release Melatonin, Then Immediate Release Melatonin|Subjects will receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks.
9779287|NCT05307744|Experimental|PS128|Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.
10193914|NCT04661566|Experimental|Education+Narratives+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Risk"
9779288|NCT05307744|Placebo Comparator|Placebo|Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.
9779289|NCT05307744|No Intervention|Normal control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
9779290|NCT05307731|Experimental|Fingoland group|The patients of this group were treated with Fingolimod 0.5mg per day, in addition to guideline based treatment.
9779291|NCT05307731|Active Comparator|Control group|The patients of this group were treated with diabetes drugs based on guideline
10193915|NCT04661566|Experimental|Education+Narratives+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Scenarios"
10193916|NCT04661566|Experimental|Education+Narratives+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Future, and Risk"
9709157|NCT04648865|Experimental|LY3537031|LY3537031 administered subcutaneously (SC).
9709158|NCT04648865|Placebo Comparator|Placebo|Placebo administered SC.
9709159|NCT04648839||Benralizumab|Patients that received at least one dose of benralizumab according to routine clinical practice
9709160|NCT04648995|Other|High energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
9709161|NCT04648995|Other|Low energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
9709162|NCT04648735|Experimental|Drivers with cognitive impairments|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
9709163|NCT04648735|Active Comparator|drivers with normal cognition|The participants firstly completed a questionnaire of driving history and perceived driving competence, followed with a clinical physical and cognitive-perceptual assessment battery conducted by an occupational therapist to note any potential deficits that might affect driving performance. The participants, on a separate visit, completed three practice runs of a closed-circuit standardized course that included 8 driving maneuvers, followed by an on-road driving in the community fir 30 minutes.
9709164|NCT04648943|Active Comparator|Patients undergoing Ex-Press mini shunt insertion|Patients in this arm had the Ex-Press mini shunt inserted in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
9709165|NCT04648943|Active Comparator|Patients undergoing trabeculectomy|Patients in this arm had standard trabeculectomy in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
9709166|NCT04648657||acute hypoxemic respiratory failure patients|Mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) with P/F ratio < 300 with at least PEEP 5 cmH2O)
9709167|NCT04648813|Experimental|tiotropium bromide monohydrate (Spiriva Respimat)|
9709168|NCT04648813|Placebo Comparator|matching placebo|
9709169|NCT04648722||Left-side hemithyroidectomy|Patients who received a hemithyroidectomy of the left thyroid lobe since 1994
9709170|NCT04648722||Right-side hemithyroidectomy|Patients who received a hemithyroidectomy of the right thyroid lobe since 1994
9709171|NCT04648761|Experimental|OPTIMAL group|This group will have their anti IL 5 biologics titrated by OPTIMAL algorithm
9709172|NCT04648761|No Intervention|Control group|This group will continue their treatment with anti IL 5 biologics unchanged
9709173|NCT04648488|Experimental|Early mobilisation|Patients will start unloaded exercise treatment 3 days after surgery. They will remove the plaster 5 times every day to perform range of motion exercises.
9709174|NCT04648488|Active Comparator|Standard treatment|Patients will have a plaster 3 weeks after surgery and after that start with exercise treatment.
9709175|NCT04648670|Experimental|Group intervention|"The experimental group consists of 101 participants have been subdivided into two groups of 25/26 that perform the same intervention but on a different day of the week.~The two subgroups have received 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~."
9709176|NCT04648670|No Intervention|Group Control|The control group consists of 100 participants. The no intervention group did not receive any type of intervention
9709177|NCT04648774|Active Comparator|Active serratus anterior plane (SAP) block with Ropivacaine 0.2%|
9709178|NCT04648774|Placebo Comparator|Placebo serratus anterior plane (SAP) block with normal saline|
9709179|NCT04648514|Active Comparator|Using of bone osteotomes for closed sinus lifting|Using of summers' osteotome technique by bone osteotomes for closed sinus lifting then evaluation the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement in posterior edentulous maxilla .
9709180|NCT04648514|Active Comparator|Patient satisfaction evaluation after using bone osteotomes|Evaluation of patient satisfaction numerically will be done after using summers' osteotome technique by bone osteotomes for closed sinus lifting in posterior edentulous maxilla
9709181|NCT04648358|Active Comparator|Control group|The control group will receive scalp nerve blocks with 0.5% bupivacaine, plus normal saline with epinephrine at 1:200,000
9979949|NCT01386827|Active Comparator|S) Ixiaro booster to MBJEV primed|Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV
9984469|NCT04061564|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be administered vagal nerve stimulation to each ear (20 minutes in total)
10193917|NCT04661566|Experimental|Education+Narratives+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Future"
10193918|NCT04661566|Experimental|Education+Narratives+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Risk"
10193919|NCT04661566|Experimental|Education+Narratives|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives"
10193920|NCT04661566|Experimental|Education+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, Future, and Risk"
10193921|NCT04661566|Experimental|Education+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Future"
10193922|NCT04661566|Experimental|Education+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Risk"
9709182|NCT04648358|Experimental|DEX4mg group|DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine, plus 4 mg dexamethasone with epinephrine at 1:200,000.
9709183|NCT04648397|Experimental|Short chewing|Subjects consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a short chewing protocol.
9709184|NCT04648397|Experimental|Long chewing|Subjects will consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a long chewing protocol.
9709185|NCT04648384|Experimental|Protein Supplementation and Resistance exercise|Protein supplementation composed of 20 gram of whey protein or casein in different proportions (80:20) and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
9709186|NCT04648384|Placebo Comparator|Placebo Supplementation|Placebo supplementation composed of 20 gram of Maltodextrin and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
9709187|NCT04648384|Experimental|Resistance Training|Resistance Exercise will be performed before supplementation and is composed by 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise.
9709188|NCT04648423|Experimental|sodium oxybate|Sodium oxybate solution for oral administration (175 mg/mL). Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
9709189|NCT04648423|Placebo Comparator|placebo|Placebo solution for oral administration. Dose (body weight ≤ 65 kg): 19.0 mL daily, in 3 administrations, for 6 months Dose (body weight > 65 kg): 22.5 mL daily, in 3 administrations, for 6 months
9709190|NCT04648410||Members of European Society of Intensive Care|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
9709191|NCT04648644||Study population|All patients undergoing emergency abdominal surgery for infection or occlusion and treated with bowel resection with or without anastomosis; intestinal bypass or adhesiolysis
9709192|NCT04648592|Experimental|Intervention|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral salt supplements (9 grams) to achieve an overall daily sodium intake of 200 mmol.
9709193|NCT04648592|Placebo Comparator|Control|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral placebo supplements to achieve an overall daily sodium intake of 50 mmol.
9709194|NCT04648917|Experimental|Arm A|In Arm A: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval (weight >50kg, 200mg per time, weight < or =50kg, 100mg per time)
9709195|NCT04648917|Placebo Comparator|Arm B|In Arm B: 40 patients will receive the placebo tablets: 100-200mg, tid, po, 2 weeks treated then 1 week black interval.
10193923|NCT04661566|Experimental|Education+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Scenarios"
10193924|NCT04661566|Experimental|Education+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Future, and Risk"
9709196|NCT04648618||OSA + DME +|Patients with OSA and DME
9709197|NCT04648618||OSA - DME +|Patients with DME, but no evidence of OSA
9709198|NCT04648345|Experimental|Erector spinal plane block group (ESPB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block will be performed in the ESPB group.
9709199|NCT04648345|Active Comparator|Vertebral side block group (VSB group)|After induction of general anesthesia, pre-operative ultrasound-guided bilateral vertebral side block will be performed in the VSB group.
9709200|NCT04648345|Placebo Comparator|Local block group （LB group）|Local block will be performed at the surgical incisions after the surgery under general anesthesia.
9709201|NCT04648605|Experimental|Questionary|Questionary for all parents
9709202|NCT04648631|Experimental|ABWG|The participants in this group will be receiving the ABWG daily for 4 consecutive weeks.
9984470|NCT04061564|Sham Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be administered sham stimulation to each ear (20 minutes in total)
9984471|NCT04060342|Experimental|Phase 1: Regimen A - GB1275 monotherapy|GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).
10193925|NCT04661566|Experimental|Education+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills Future"
10193926|NCT04661566|Experimental|Education+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Risk"
9709203|NCT04648137|Experimental|Patients with central diabetes insipidus|
9709204|NCT04648137|Experimental|Healthy volunteers|
9709205|NCT04648475|Experimental|Arm 1|CD19 and CD22 targeted CAR-T cells treat
9709206|NCT04648332|Experimental|Group 1|Patients in group 1 underwent catheterization of the lumbar plexus from the posterior access on admission to the hospital and began analgesia with bupivacaine 0.125% 6-8 ml / h. Intraoperative anaesthesia was provided with a bupivacaine bolus of 0.5% 200 mg in a lumbar catheter and a sciatic nerve block with 1.5% 450 mg of lidocaine. Postoperative analgesia was provided by an elongated lumbar plexus block with bupivacaine 0.125% 6-8 ml / h.
9709207|NCT04648332|No Intervention|Group 2|Patients in group 2 underwent intraoperative spinal anaesthesia at the level of L3-L4 with hyperbaric bupivacaine at a dose of 10-15 mg.
9709208|NCT04648332|No Intervention|Group 3|Group 3 patients underwent general inhalation anaesthesia with sevoflurane with a constant infusion of fentanyl for analgesia.
9709209|NCT04648020|Placebo Comparator|Placebo|Placebo Mucoadhesive Buccal Tablet given daily during chemoradiotherapy
10193927|NCT04661566|Experimental|Education+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills"
10193928|NCT04661566|Experimental|Education+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios, Future, and Risk"
9709210|NCT04648020|Experimental|Clonidine HCl Mucoadhesive Buccal Tablet (MBT)|Clonidine HCl MBT given daily during chemoradiotherapy
9709211|NCT04648254|Experimental|Dose escalation (Q702)|Participants will receive escalating doses of Q702
10193929|NCT04661566|Experimental|Education+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Future"
10193930|NCT04661566|Experimental|Education+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Risk"
9709212|NCT04647981||Xpert® Bladder Test|A urine sample is collected before cystoscopy.
9709213|NCT04648566|Placebo Comparator|IIU control group|
9709214|NCT04648566|Active Comparator|IIU PBMC group|
9709215|NCT04648566|Placebo Comparator|FIV control group|
9709216|NCT04648566|Active Comparator|FIV PBMC group|
9709217|NCT04648566|Active Comparator|RIF group|
9709218|NCT04647994||Covid-19 HC patients|Pregnant women hospitalized with symptoms and diagnosis of SARS-CoV-2 at HC-FMUSP.
9709219|NCT04647994||Delivery patients|Asymptomatic pregnant women that tested SARS-CoV-2 serology (positive or negative serology) at the delivery time at Universitarian Hospital HU-USP and HC-FMUSP.
9709220|NCT04647994||Prenatal patients|Pregnant women that performs prenatal care in Universitarian Hospital HU-USP or HC-FMUSP with diagnosis of SARS-CoV-2.
10193931|NCT04661566|Experimental|Education+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios"
10193932|NCT04661566|Experimental|Education+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future and Risk"
10193933|NCT04661566|Experimental|Education+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future"
10193934|NCT04661566|Experimental|Education+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Risk"
9709221|NCT04647994||Negative serology patients|Pregnant women that performs prenatal care with symptoms and tested serology/swab negative for SARS-CoV-2.
9709222|NCT04648280|Experimental|Fostemsavir|Fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
9709223|NCT04648007||Control|10 patients with no personal or family problems with gambling as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
9709224|NCT04648007||Moderate Gamblers|10 patients with moderate gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
9709225|NCT04648007||Severe Gamblers|10 patients with severe gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
9709226|NCT04648072|Experimental|Periarticular Injection + Adductor Canal Block (Local Anesthestic)|"The experimental arm with receive both the periarticular injection and the adductor canal block.~The periarticular injection will be performed by the surgeon and will consist of 100 mL of injectate being distributed in the following manner: 30 mL to the posterior capsule, 10 mL to the medial collateral ligament, 10mL to the lateral collateral ligament (ensuring not to infiltrate common peroneal nerve), 20mL to the quadriceps and anterior capsule, and 30 mL to the subcutaneous tissue. The periarticular injection will consist of 250 mg of ropivacaine, 30 mg of ketorolac, and 0.5 mg of epinephrine.~The adductor canal block will be completed by the anesthesiologist after spinal anesthesia has been initiated, but before the surgery commences. The block will be completed using an aseptic technique under dynamic, in-plane US guidance. 20 mL of injectate consisting of 100mg of ropivicaine and 50 mcg of epinephrine will be injected around the hyperechoic saphenous nerve."
9709227|NCT04648072|Placebo Comparator|Periarticular Injection + Adductor Canal Block (Normal Saline)|"The control arm with receive a periarticular injection and a sham adductor canal block.~The periarticular injection will be carried out in the same manner as described for the experimental group. The technical aspects of the sham adductor canal block will be the same as for the experimental arm; however, the injectate will consist of 20 mL of normal saline."
9709228|NCT04648046|Experimental|Low Dose CAR-T Cells Only|Participants will NOT undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
9709229|NCT04648046|Experimental|Conditioning + Low Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
9709230|NCT04648046|Experimental|Conditioning + High Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused into the participant. ART will be interrupted immediately after infusion.
9709231|NCT04648267|Active Comparator|Control group|Patients who have the cast and bolster on for standard 5 days after their radial forearm free flap and 7 days after their fibula free falp
9709232|NCT04648267|Experimental|Experimental group|Patients who have the cast and bolster on for 10-14 days
9709233|NCT04648176|Active Comparator|HoLEP|Conventional laser
9709234|NCT04648176|Experimental|m-HoLEP|Moses technology
9709235|NCT04647968|Other|Primary closure of tracheo-cutaneous fistula|This group will undergo a protocoled primary closure of their tracheotomy.
9709236|NCT04647968|Other|Secondary closure of tracheo-cutaneous fistula|This group will undergo a protocoled secondary closure of their tracheotomy.
9709237|NCT04648098|Experimental|Experimental: Intervention group|Discharge training and telephone counseling
9709238|NCT04648098|No Intervention|No Intervention: Control Group|Routine care
9709239|NCT04647890|Experimental|FT011 200mg|200mg once daily for 12 weeks
10193935|NCT04661566|Experimental|Education|Participants will receive a version of the Mission Wellness app (intervention) that only includes the static educational component.
9709240|NCT04647890|Experimental|FT011 400mg|400mg once daily for 12 weeks
9709241|NCT04647890|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
9709242|NCT04647955|Experimental|Itopride|Oral dose of itopride 100 mg three times daily before the meal for 8 weeks
9709243|NCT04647955|Placebo Comparator|Placebo|Oral dose of placebo three times daily before the meal for 8 weeks
9709244|NCT04647942||Meniscectomy|Patients who underwent a meniscectomy
9709245|NCT04647747|Other|Self measurement of peripheral saturation|Participant will be equipped with a pulse oximeter and perform saturation measurements.
9709246|NCT04647734|Experimental|High intensity interval training|The experimental group will on top of standard care undergo a 12 weeks supervised exercise high intensity interval exercise training on an ergometer bike three times a week for 38 minutes. The specific intervals will be determined from our ongoing pilot study (NCT04549337)
9709247|NCT04647734|Active Comparator|Control group|This group will be allocated to standard care and therefore no supervised exercise regimen.
9709248|NCT04647669|Placebo Comparator|Local Standard of Care|Local Standard of Care
9709249|NCT04647669|Active Comparator|Remdesivir|Remdesivir (daily infusion for 10 days)
9709250|NCT04647669|Active Comparator|Acalabrutinib|Acalabrutinib (orally twice daily for 10 days)
9709251|NCT04647669|Active Comparator|Interferon|Interferon β1a(daily injection for 6 days).
9709252|NCT04647799||forward head position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes in forward head position while Children will sit on chair with their feet on the ground without any tension, the upper limbs are rested in a table then, the angle between the line passing horizontally from the spinous process of C7 and the line passing between the tragus and spinous process of C7 will be measured by goniometer and goniometer pro application to evaluate the craniovertebral angle recording, we will fix the craniovertebral angle between 40.7° and 43.2°(severe FHP )
9709253|NCT04647799||neutral position|nerve conduction velocity and f-wave applied to median , ulnar and radial nerve before and after 10,20 and 30 minutes while Children will sit on chair with their feet on the ground with head in anatomical position, the upper are rested in a table and used both hand on touch screen of mobile phone
9709254|NCT04648150|Experimental|VERUM|An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months
9709255|NCT04648150|Sham Comparator|SHAM|An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.
9709256|NCT04647812|Experimental|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology
9709257|NCT04647812|Experimental|Conventional rehabilitation|Traditional multidisciplinary rehabilitation
9709258|NCT04647851|Experimental|Remote exercise intervention Down syndrome|Intervention: The program we will be using is specifically developed for individuals with Down syndrome based on the Mann Method PT Principles. The MMPT Principles TM focus on a progressive program of therapeutic activity (cardiovascular activity), therapeutic exercise (foundational strengthening and hip strengthening activities), and neuromuscular rehabilitation (visual/vestibular and balance activities) to address the unique needs of individuals with Down syndrome. This program has been developed and successfully implemented in Down syndrome activity centers across the country. This program will be offered through Zoom. Intensity will be submaximal for both data collection and during the exercise sessions, and recorded with Polar heart rate monitors.
9709259|NCT04647929|Experimental|PRESERFLO MicroShunt|Patients will undergo Santen PRESERFLO MicroShunt implantation with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
9709260|NCT04647929|Active Comparator|Trabeculectomy|Patients will undergo trabeculectomy with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
9709261|NCT04647877|Experimental|Phenytoin 10 percent cream|Phenytoin 10 percent cream, 2 to 4 times daily application, 2 weeks long
9709262|NCT04647877|Experimental|Phenytoin 20 percent cream|Phenytoin 20 percent cream, 2 to 4 times daily application, 2 weeks long
9709263|NCT04647877|Placebo Comparator|Placebo cream|Placebo cream, 2 to 4 times daily application, 2 weeks long
9709264|NCT04647838|Experimental|NSCLC|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
9709265|NCT04647838|Experimental|Other cancers|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
9709266|NCT04647448||Healthy volunteers|Participants with no known cardiovascular disease
9709267|NCT04647448||Chest pain|Patients with symptoms of chest pain, undergoing elective coronary artery CT
9709268|NCT04647370|Active Comparator|Remote ischemic preconditioning|
9709269|NCT04647370|Sham Comparator|Sham remote ischemic preconditioning|
9709270|NCT04647773|Experimental|HSK16149 20mg BID|
9709271|NCT04647773|Experimental|HSK16149 40mg BID|
9709272|NCT04647773|Experimental|HSK16149 60mg BID|
9709273|NCT04647773|Experimental|HSK16149 80mg BID|
9709274|NCT04647773|Active Comparator|Pregabalin 150mg BID|
9709275|NCT04647773|Placebo Comparator|Placebo BID|
9709276|NCT04647864||Group 1|Edwards Sapien 3 and Edwards Sapien 3 Ultra
9709277|NCT04647864||Group 2|Medtronic Corevalve Evolut R and Medtronic Corevalve Evolut PRO
9709278|NCT04647864||Group 3|Boston Scientific Acurate neo and Boston Scientific Acurate neo2
9709279|NCT04647864||Group 4|St. Jude Medical Portico
9709280|NCT04647461|Experimental|BRIDIN-T Eye drops 0.15%(Non preservative)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
9709281|NCT04647461|Active Comparator|ALPHAGAN-P Eye drops 0.15%(Preservatives)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
9709282|NCT04647422|Experimental|AUD patients|Alcohol Use Disorder patients
9709283|NCT04647422|Experimental|AUD controls|Healthy control participants matched to group 1
10193936|NCT04650568|Experimental|Mesenchymal Stem Cell Recipient|Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.
9709284|NCT04647422|Experimental|First-degree relatives|Healthy first-degree relatives of AUD patients
9709285|NCT04647422|Experimental|First-degree controls|Healthy control participants matched to group 3
9709286|NCT04647695|Experimental|IFN-beta 1b and remdesivir|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
9709287|NCT04647695|Active Comparator|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
9709288|NCT04647357|Experimental|SHR-1316|
9709289|NCT04647630||CAP|community acquired pneumonia
9709290|NCT04647318|Experimental|Compassion focused imagery, relaxation imagery and control task|Participants engage in three tasks (compassion focused imagery, relaxation imagery and control task), three or four times every three days.
9709291|NCT04647305|Experimental|Closed face shield + Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial, as well as one closed face shield. Additionally, each participant will receive an educational intervention (video).
9709292|NCT04647305|Active Comparator|Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial. Additionally, each participant will receive an educational intervention (video).
9709293|NCT04647578||Child with IBD|
9709294|NCT04647578||Healthy child witnesses|
9709295|NCT04647552||hydrocortisone|The patients with septic shock who required a noradrenaline infusion rate above 0.5µg/kg
9709296|NCT04647552||control|The patients with septic shock who needed a noradrenaline infusion rate of up to 0.5µg/kg/min to maintain MAP>65 mmHg
9709297|NCT04647344|Experimental|Nonsquamous NSCLC|
9709298|NCT04647344|Experimental|Squamous NSCLC|
9709299|NCT04647149|Experimental|Early Time-Restricted Eating|8-hour eating window between 08:00 and 16:00
9709300|NCT04647149|Experimental|Delayed Time-Restricted Eating|8-hour eating window between 12:00 and 20:00
9709301|NCT04647149|Experimental|Control|12-hour eating window between 08:00 and 20:00
9709302|NCT04647279||Normal control group|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
9709303|NCT04647279||Osteopenia|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
9709304|NCT04647279||Osteoporosis|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
9709305|NCT04647136|Active Comparator|Fertility Health Screening|Clinic-based fertility health screening and counselling
9709306|NCT04647136|Active Comparator|Fertility Awareness Tools|Online intervention to provide fertility education and behavioural nudge for optimal reproductive timing.
10193937|NCT04650568|Placebo Comparator|Control Sham Incision|Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care.
9709307|NCT04647136|No Intervention|Control|No intervention but exposed to usual information from the media on fertility and family benefits (no different from general population).
9709308|NCT04646954|Experimental|Study group|All eligible participants are included in the study group
9709309|NCT04647019|Experimental|Blueberry powder|
10193938|NCT04647604|Active Comparator|Omega|Omegaven® (2 mL/kg/day, equivalent to 6 g Docosahexaenoic Acid (DHA)+Eicosapentaenoic Acid (EPA) in a 70 kg individual) once daily for 5 days
10193939|NCT04647604|Placebo Comparator|Sodium chloride (NaCl)|2 mL/kg/day) once daily for 5 days
10193940|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
10193941|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
9709310|NCT04647019|Experimental|Placebo powder|
9709311|NCT04647201||Control|Non-sepsis and non-GI adults
9709312|NCT04647201||Sepsis patients without GI|Patients who meet the criteria of sepsis3.0 with AGI grade I or less
9709313|NCT04647201||Sepsis patients with GI|Patients who meet the criteria of sepsis3.0 with AGI grade II or above
9709314|NCT04646980|Experimental|Biobran/MGN-3|This arm consisted from 20 males and 20 females. Biobran/MGN-3 was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
9709315|NCT04646980|Placebo Comparator|Placebo|This arm consisted from 20 males and 20 females. Placebo, with the same appearance and taste, was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
9709316|NCT04646863|Experimental|group A|consists of 20 patients received a multiwave locked system laser
9709317|NCT04646863|Experimental|group B|consists of 20 patients received Pilates exercises
9709318|NCT04646863|Experimental|group C|consists of 20 patients received a multiwave locked system laser and Pilates exercises
9709319|NCT04647071|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
9709320|NCT04647071|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
9709321|NCT04647292|Experimental|Target systolic blood pressure 115-125 mmHg|Recommended target SBP 115-125 millimetres of mercury (mmHg).
9709322|NCT04647292|Active Comparator|Target systolic blood pressure 130-139 mmHg|Target SBP 130-139 mmHg (per American Stroke Association, European Stroke Organisation guidelines).
9709323|NCT04647097|Active Comparator|Standard intervention plus repeated intervention|Patients randomized to the standard intervention plus repeated intervention arm
10193942|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES recieve prompting Text messages,
10193943|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages, and financial Incentives to attend yoga classes
10193944|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
10193945|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes and One-on-One individual sessions with a Yoga Instructor
9709324|NCT04647097|Active Comparator|Standard intervention only|Patients randomized to the standard intervention only arm
9709325|NCT04647045|Active Comparator|IBS-C group|77 constipation-predominant IBS were given three bottles of 125 ml cultured milk drink daily for 30 days
9709326|NCT04647045|Other|Non-IBS group|88 non-IBS subjects (healthy individuals) were given similar probiotics for 30 days.
9709327|NCT04647188||Urology group|Includes patients undergoing prostatectomy (n=100)
9709328|NCT04647188||Colorectal group|Includes patients undergoing anterior rectal resection (n=100)
9709329|NCT04647188||Thoracic group|Includes patients undergoing lobectomy (n=100)
9709330|NCT04647188||Gynaecological group|Includes patients undergoing hysterectomy (n=100)
9709331|NCT04647188||HpB group|Includes pancreatic tumour resection patients (n=50)
9709332|NCT04647188||Ear, Nose & Throat group|Includes patients undergoing tongue base mucosectomy (n=50)
9709333|NCT04647123||Hopeless teeth|The teeth that can not be treated periodontally and who are desperate for extraction will be included in this group.
9709334|NCT04647123||Periodontitis|Teeth diagnosed with periodontitis will be included in this group.
9709335|NCT04647123||Gingivitis|Teeth diagnosed with gingivitis will be included in this group.
9709336|NCT04647123||Healthy|Teeth diagnosed with helthy will be included in this group.
9709337|NCT04647006|Other|Conventional Thyroidectomy|Conventional Thyroidectomy
9709338|NCT04647006|Active Comparator|Transoral endoscopic thyroidectomy vestibular approach|Transoral endoscopic thyroidectomy vestibular approach
9709339|NCT04646941||T2DM with OSA|Type 2 diabetes patients with obstructive sleep apnea
9709340|NCT04646941||T2DM without OSA|Type 2 diabetes patients without obstructive sleep apnea
9709341|NCT04646876|Active Comparator|intervention arm ( Group A )|"including 30 patients Group A was given magnesium Sulphate~Administration regimen of Mgso4 was as following:~Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs."
9709342|NCT04646876|Placebo Comparator|Placebo arm (Group B )|including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate
9709343|NCT04646915||Patients with CuRC undergoing day surgery|Patients with CuRC undergoing laparoscopic colectomy or anterior resection in day surgery center.
9709344|NCT04647110||Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients|
9709345|NCT04646824|Experimental|ahead|A110 mg QD and platinum-based chemotherapy. A 110 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by A 110mg daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Dose may be reduced to allow for the management of IP related toxicity.
9709346|NCT04646733|Experimental|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet.
9709347|NCT04646733|Active Comparator|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water.
9709348|NCT04646720||Neck pain patients|Patients with neck pain evaluated with new technologies and face-to-face
9709349|NCT04646707|Experimental|Study group|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
9709350|NCT04646707|Placebo Comparator|Placebo Group|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
9779292|NCT05307718||The basic cohort|The subjects with the newly indicated indication for use: NOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins
9779293|NCT05307718||Cases|"Cases will be subjects who have observed ADRs during follow-up: bleeding that meets the criteria of major or non-major, clinically relevant bleeding (for anticoagulants and platelet aggregation inhibitors); muscle or liver lesions (for statins); any other serious ADR."
9779294|NCT05307718||Controls|Controls will be subjects in whom no ADRs were observed during the study
10193946|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages and One-on-One individual sessions with a Yoga Instructor
10193947|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive financial Incentives to attend yoga classes, prompting Text messages and One-on-One individual sessions with a Yoga Instructor
10193948|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos
9709351|NCT04646759|Experimental|Fulvestrant Combined With Pyrotinib|Fulvestrant, 500 mg, was injected intramuscularly on D1, D15, D28, D28, once every 28 days； Pyrotinib, 400mg, orally administered daily.
9709352|NCT04646759|Active Comparator|Capecitabine Combined With Pyrotinib|Capecitabine, 1000mg / m^2, twice daily; Pyrotinib, 400mg, orally administered daily.
9709353|NCT04646629|Experimental|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment"
9709354|NCT04646629|Sham Comparator|sham electroacupuncture treatment|"sham electroacupuncture treatment participants in the control group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
9709355|NCT04646811|Experimental|Tricuspid valve|tricuspid valve percutaneous repair strategy with clip for the tricuspid valve
9709356|NCT04646811|Other|Best medical treatment|
9709357|NCT04646798|Active Comparator|Hemi Arthroplasty (HA) of the elbow.|Hemi Arthroplasty (HA) of the elbow, where the surgeon replaces the bottom of the humerus bone at the elbow.
9709358|NCT04646798|Active Comparator|Total Elbow Arthroplasty (TEA).|Total Elbow Arthroplasty (TEA), where the surgeon fits a new elbow joint replacing damaged parts of the humerus bone and forearm bone that it joins onto.
9709359|NCT04646668|Active Comparator|E-Cigarette then Heat not burn.|We will use a 1:1 fashion randomization to product order (combustible cigarette, e-cigarette, heat-not-burn device.
9709360|NCT04646668|Active Comparator|Heat not burn then E-Cigarette|We will use a 1:1 fashion randomization to product order combustible cigarette, heat-not-burn device, e-cigarette.
9709361|NCT04646538|Experimental|X3 group|
9709362|NCT04646460|Experimental|Observed Success - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
9709363|NCT04646460|Experimental|Observed Failure - Experienced Failure|"This participant group (N=30) will witness a failed placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
10193949|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive financial Incentives to attend yoga classes and Personal Practice Videos
9709364|NCT04646460|Experimental|Observed Success - Experienced Failure|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
9709365|NCT04646460|Experimental|Observed Failure - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
9709366|NCT04646694|Experimental|Study Group 1|Patient will receive Ketamine at a dose of 30 mg every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Ketamine for three days or nine doses total.
9709367|NCT04646694|Placebo Comparator|Study group 2|Patient will receive Placebo at a matching dose every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Placebo for three days or nine doses total.
9709368|NCT04646512|Active Comparator|Taurine group and exercise|Intervention with taurine supplementation and physical training.
9709369|NCT04646512|Placebo Comparator|Placebo group and exercise|Intervention with placebo supplementation and physical training.
9709370|NCT04646577|Active Comparator|Active|
9709371|NCT04646577|Sham Comparator|Sham|
9709372|NCT04646382|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
9709373|NCT04646382|Experimental|Intervention|Garlic concentrated extract. Onion concentrated extract. Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
9709374|NCT04646434|Experimental|Supportive Care (brain and muscle monitoring, questionnaire)|Patients perform standard of care Kegel exercises while undergoing brain and muscle activity monitoring by EEG and EMG, respectively, before surgery, 6 weeks after surgery, and at 3, 6, and 12 months after surgery. Patients complete questionnaires over 5-10 minutes about urinary function
9709375|NCT04646486|Experimental|Intervention - Video debriefing|Baseline period (year 1): Standard practice. Intervention period (year 2-3): All teams will be assigned to video debriefing.
9779301|NCT05307692|Experimental|Seltorexant|Participants will receive single oral dose of seltorexant 20 milligrams (mg) tablet once daily from Day 1 to Day 42.
9779302|NCT05307692|Placebo Comparator|Placebo|Participants will receive single oral dose of matching placebo tablet once daily from Day 1 to Day 42.
9779303|NCT05307679|Experimental|Basmisanil|Participants will receive oral basmisanil twice daily (BID) on the first day of treatment, then three times per day (TID) until the end of the trial on Day 365.
10193950|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos and prompting Text messages
9709376|NCT04646616|Experimental|Community popular opinion leader (POL)|After successful completion of the new COVID-19 training module, POLs will reach out to members of their social networks to model and diffuse social norms to reduce the risk of COVID-19 infection and transmission, screen for symptoms and counsel regarding COVID-19, SAVAME syndemic factors, and refer at-risk or affected individuals to appropriate community services (e.g. free COVID-19 testing and treatment, mental health services, substance use services, violence prevention, support groups, etc.). As in other POL based interventions and pragmatic trials, POLs be asked to follow up with their community contacts to monitor their situation and provide additional support, but there will be flexibility with the frequency and number of follow up contacts depending on their needs identified and the preferences of the community contact. POLs will be continually supported by the research team via face-to-face biweekly booster sessions (if COVID-19 situation requires it) or by zoom.
9709377|NCT04646785|Experimental|Mindfulness-based cognitive therapy (MBCT) added to treatment as usual|Patients in the MBCT arm will in addition to their treatment as usual be invited to participate in MBCT.
9709378|NCT04646785|Active Comparator|Treatment as usual (TAU)|Patients in this arm will receive treatment as usual.
9709379|NCT04646421||Motivational intervention - clients reached|Gamblers successfully reached with the motivational telephone intervention.
9709380|NCT04646421||Control group: clients not reached for the motivational intervention|Clients aimed to be reached for the same intervention, but who were not reached and therefore were not exposed to the intervention.
10193951|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages and financial Incentives to attend yoga classes
10193952|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
9709381|NCT04646421||Prospective intervention group|Clients subject to the prospective study part (target N 200), who are successfully reached by the intervention from November, 2020, and who provide informed consent to the web survey study. Studied as a cohort without control group, but with the pre-intervention situation as their own control condition.
9709382|NCT04646746|Experimental|100 g of 100% wheat bread|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
9709383|NCT04646746|Experimental|Nude barley 50%|"Intake of 250 ml of tap water and 100 g of bread baked with 50% nude barley flour and 50% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
9709384|NCT04646746|Experimental|Nude barley 75%|"Intake of 250 ml of tapwater and 100 g of bread baked with 75% nude barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
9709385|NCT04646746|Experimental|Gen-modified high-amylose barley|"Intake of 250 ml of tap water and 100 g of bread baked with 50% gene-modified high-amylose barley and 50% wheat. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~The gene-modified barley is produced by researchers at Aarhus and Copenhagen Universities as published in 'Carciofi M, et al., Concerted suppression of all starch branching enzyme genes in barley produces amylose-only starch granules. BMC Plant Biol. 2012 Nov 21;12:223. doi: 10.1186/1471-2229-12-223' The wheat flour is standard commercial available flour."
9709386|NCT04646408||Participants with CKD|Recruitment is from a cohort of HIV positive individuals of African ancestry with Chronic Kidney Disease CKD defined as eGFR <60 mL/min/1.73m2, and/or albumin/creatinine ratio >30 mg/mmol or protein/creatinine ratio >50 mg/mmol Anticipated n=75
9709387|NCT04646408||Participants with diabetes|"Recruitment is from a cohort of HIV positive individuals of African ancestry with diabetes. Diabetes is defined as being on diabetic medications or HbA1c >48 mmol/mol.~Anticipated n=75"
9709388|NCT04646408||Participants with ischaemic heart disease/stroke|Recruitment is from a cohort of HIV positive individuals of African ancestry with previous ischaemic heart disease or stroke Anticipated n=50
9709389|NCT04646408||No CKD/DM/CVD cohort|"Recruitment is from a cohort of HIV positive individuals of African ancestry who do not have CKD, diabetes or prior ischaemic heart disease/stroke.~Anticipated n=200"
9709390|NCT04646317|Experimental|Dexmedetomidine|Dexmedetomidine infusion four 50 ml syringes containing 1 microgram per ml dexmedetomidine
9709391|NCT04646317|Placebo Comparator|normaL SALINE 0.9%|Four 50 ml syringes of .9 % Normal SALINE
9709392|NCT04646161||prostaglandins before iud insertion group|this group will receive 200 mcg prostaglandins in form of misoprostol 2 hrs before mirena iud insertion
10193953|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages but DOES receive financial Incentives to attend yoga classes, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
10193954|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive prompting Text messages, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
9709393|NCT04646161||placebo group|this group will receive placebo tablet before mirena iud insertion
10193955|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
10193956|NCT04629911|Experimental|HFNO arm|Patients will receive HFNO therapy during laryngomicrosurgery.
9709394|NCT04646018|Experimental|Lumbar Manipulation Group|Group that receives experimental lumbar non-thrust manipulation
9709395|NCT04646018|Sham Comparator|Sham Manipulation Group|Group that receives sham lumbar non-thrust manipulation
9709396|NCT04646135|Experimental|Sequence 1|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.2 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
10193957|NCT04626362|Experimental|Experimental: Cranberry juice consumption|Participants will be provided cranberry juice to consume for 21 days
9709397|NCT04646135|Experimental|Sequence 2|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.2 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.03 mg/kg/hour LZ"
9709398|NCT04646135|Experimental|Sequence 3|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.3 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
9709399|NCT04646174|Experimental|Multi-component Behavioral Treatment|This treatment consists of nine weekly phone-based individual treatment sessions, 45-60 minutes each, delivered by a trained study therapist.
10193958|NCT04626362|Experimental|Placebo juice consumption|Participants will be provided placebo juice to consume for 21 days
10204682|NCT05174182|Experimental|A novel treatment approach|"The experimental intervention were first comprised and tested in a large cohort of 10-14-year-old adolescents with a similar condition (patellofemoral pain) and was associated with a successful outcome after 12 weeks.~Afterwards, the intervention was changed slightly to target adolescents with Osgood Schlatter and then pilot-tested in a cohort of 51 participants. In this cohort, most participants needed more time to progress through exercises and sport, and the investigators have therefore piloted extending the intervention further in the clinic, with more success on these aspects.~The experimental intervention will contain an active approach with self-management of load and progressive exercise therapy throughout the treatment course, delivered through 4 one-on-one visits lasting approximately 20 minutes (at months 0, 1, 2, 3) with a physiotherapist and an accompanying leaflet with written and illustrated exercise description, and advice and information."
9709400|NCT04646174|Experimental|Self-guided Treatment|This treatment consists of self-help materials from the American Lung Association that address evidence-based smoking cessation and self-management strategies.
9709401|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants in the objective feedback group will receive a report that compares their performance in Set 1 to that of the staff surgeons' using the target interval as a reference. Participants receiving objective feedback will then complete Sets 2 and 3 knowing what factors to improve upon.
9709402|NCT04646304|No Intervention|No Feedback|Participants receiving no feedback will complete all sets with no intervention.
9709403|NCT04646291||Heterosexual Females with a Male partner|This cohort consists of heterosexual females with a male partner who have used the Mosie Baby Kit for insemination during at least one cycle
9709404|NCT04646291||Females in LGBTQ Relationships|This cohort consists of females in LGBTQ Relationships who have used the Mosie Baby Kit for insemination during at least one cycle.
9709405|NCT04646291||Solo parent|This generally will be a female without a partner who has used the Mosie Baby Kit for insemination during at least one cycle. However, it might also be a male who is using a surrogate female.
9709406|NCT04645914|No Intervention|No smokers|Healthy subjects who do not consume any nicotine products
9709407|NCT04645914|Experimental|Smokers/Vapers|Healthy subjects who consume nicotine products
9709408|NCT04645888|Active Comparator|Articaine|"All surgeries were performed by the same surgeon and monitored by the same person. 4 % articaine with 1:200.000 epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
9709409|NCT04645888|Active Comparator|Bupivacaine|"All surgeries were performed by the same surgeon and monitored by the same person. % 0.5 bupivacaine without epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
9709410|NCT04645797|Experimental|APR003 Dose Escalation|This portion of the study will evaluate the safety and pharmacokinetics of a range of APR003 doses administered once a week for 21 days in subjects with advance colorectal cancer (CRC) with metastases to the liver and to determine the RP2D.
9709411|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using Inferior pedicle|Wise pattern reduction mammaplasty using Inferior pedicle
9709412|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using superomedial pedicle|
9709413|NCT04646096|Experimental|Mako THA 4.0 group|Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
9709414|NCT04645992|Active Comparator|study group|study group will receive only one session of yoga eye exercise for 20 minutes followed by transcutaneous electrical nerve stimulation by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
9709415|NCT04645992|Sham Comparator|control group|control group will be treated with the same protocol as the study group but with the unit of transcutaneous electrical nerve stimulation is off .
10193959|NCT04600180||Palliative treatment with immunotherapy|
10193960|NCT04595305|Other|Treatment Arm - Standard of Care|Implantation of CRT-P or CRT-D for a clinical indication as per standard of care.
10193961|NCT04594408|No Intervention|No epinephrine or TXA|No intervention given.
10193962|NCT04594408|Active Comparator|Epinephrine in irrigation fluid|Epinephrine intervention used.
10193963|NCT04594408|Experimental|Intravenous TXA|Tranexamic acid intervention used.
10193964|NCT04594408|Experimental|Epinephrine and TXA|Epinephrine and tranexamic acid intervention used.
9984472|NCT04060342|Experimental|Phase 1: Regimen B - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab dose escalation and expansion:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
9984473|NCT04060342|Experimental|Phase 1: Regimen C - GB1275 with Standard of Care (SOC)|"GB1275 with SOC dose escalation:~GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)"
9709418|NCT04646447|Experimental|L-serine treatment|All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.
9709419|NCT04646057|Experimental|Treatment Arm|
9709420|NCT04646057|No Intervention|Historical Control Arm|
9709421|NCT04645836|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
9709422|NCT04645836|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
9709423|NCT04646278|Experimental|Hyperemic stimuli|Hyperemic stimuli of coronary flow by adenosine or nicorandil injection
9709424|NCT04645849||"Cohort A or End of treatment"|16 patients recruited at the end of breast cancer treatment and followed during 9 months
9709425|NCT04645849||"Cohort B or Diagnosis"|Patients recruited at breast cancer before any treatment: one blood sample to provide comparative values.
9709426|NCT04646109|No Intervention|Control Group|"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with PCR positivity in respiratory tract samples were included into the study. They were randomized to the control and study group, respectively. Hydroxychloroquine, favipiravir and azithromycin (HFA) standard treatment protocol were given to the control group as recommended in the COVID-19 (SARS-CoV-2 Infection) Guide prepared by the Republic of Turkey Ministry of Health."
9709427|NCT04646109|Experimental|Study Group|In addition to HFA treatment, ivermectin 200 micrograms/kg/day (9mg between 36-50 kg, 12mg between 51-65 kg, 15mg between 66-79 kg and 200 micrograms/kg in > 80 kg) in the form of a solution prepared for enteral use was added (HFA+I) to the treatment protocol of the study group's for five days. Blood sample was taken with the first dose of ivermectin and haplotype analysis was performed in ABCB1 and CYP3A4 genes in the whole study group.
9709428|NCT04645901|Experimental|SYHA1805|Part 1: Subjects will receive a single dose of oral SYHA1805 tablets. Part 2: Subjects will receive single ascending doses of SYHA1805 tablets. Part 3: Subjects will receive a single dose SYHA1805 tablets in a fasted state and a single dose of SYHA1805 tablets after a high-fat, high-calorie meal, with sequence determined by randomization.
9709429|NCT04645901|Placebo Comparator|Placebo|Subjects will receive the matching placebo tablets.
9709430|NCT04646265|Experimental|periodontal treatment|non-surgical root debridement
9709431|NCT04645927|Placebo Comparator|Placebo control beverage group|The placebo will be provided in the same unmarked plain packages and contain the same constituents, but without flax (control packages contain oat fiber and milk). For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
9709432|NCT04645927|Experimental|Experimental flax beverage group|Flax beverage (30 gr daily, oral) is presented in liquid form in plain unmarked packages. For 180 days (6 months) participants will consume 2 servings of 330 ml of flax beverage (treatment group; 30 gms flax/day beverage) per day.
9709433|NCT04645940|Experimental|Fed/Fasted|fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
9709434|NCT04645940|Experimental|Fasted/Fed|fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
10193965|NCT04581681|Experimental|Group CBT for Perinatal Anxiety|Using cognitive-behavioural therapy principles, this group therapy is intended to treat perinatal anxiety.
10193966|NCT04581681|Active Comparator|Waitlist Control|This is a control condition in which patients are randomly assigned to the waitlist control condition before receiving the treatment.
10193967|NCT04580446|Experimental|Hypofractionated radiotherapy with concurrent chemotherapy (weekly cisplatin 40 mg/m2)|"Level 0: 46.5 Gy in 15 fractions, 5 fractions/week~Level -1: 52 Gy in 20 fractions, 5 fractions/week"
10193968|NCT04580134|Experimental|Biotype 1 - Clozapine (B1C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
9709435|NCT04646187|Experimental|Intervention group|In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.
9709436|NCT04646187|No Intervention|Control group|Unchanged dosing interval. Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.
9709437|NCT04645875|Experimental|Sit regimen|Participants will be instructed to restrict walking and standing to ≤1 h/day each (total ≤2 h/day ) and the remainder of the waking day will be seated apart from visiting the toilet.
9709438|NCT04645875|Experimental|SitLess regimen|Participants will be instructed to substitute a minimum of 5h/day of sitting with ≥2 h of light-intensity physical activity and ≥3 h of standing. Participants will be advised to rise from the seated position for 2-5 min every 30 min to engage in standing /light-intensity physical activities to interrupt their sitting.
9709439|NCT04645615|Experimental|CURE AF|
10193969|NCT04580134|Placebo Comparator|Biotype 1 - Risperidone (B1R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
10193970|NCT04580134|Active Comparator|Biotype 2 - Clozapine (B2C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
9709440|NCT04645537||FinACAF cohort|The study cohort consists of all patients with AF diagnosis (ICD-10 I48) living in Finland during 1.1.2004-31.12.2018. The study cohort is obtained from data of Finnish national registries. Patients with permanent residence in Finland less than 12 months prior to index date and patients with age below 18 years at index date are excluded from the study.
9709441|NCT04645628|Experimental|All subjects will have an MRI examination|
9709442|NCT04645589||Myfortic|Oral administration
9709443|NCT04645654|Experimental|Hypnosis|3 sessions of script-based hypnosis (analgesic suggestions) + recordings provided for self-hypnosis
9709444|NCT04645654|No Intervention|Standard of care|Standard of care ERAS based optimized multimodal analgesia, without any complementary medicine
9709445|NCT04645459|Experimental|low phosphorus meal group (LP group)|The proteins of the low phosphorus meal had been removed by an average 20 -30% of the phosphorus through boiling the meats before cooking process.
9709446|NCT04645459|Placebo Comparator|control group|The boiling method did not process for the control meals.
9709447|NCT04645758|Active Comparator|Dry Needling Group or (DN)|Dry needling for 5 mins on the flexor group of muscles of dominant forearm.
9709448|NCT04645758|Active Comparator|Extra corporeal Shockwave therapy Group or (ESWT)|Delivering of Shock wave pulses of 1250 at the energy intensity of 0.58 mj/mm2 on the flexor group of muscles of dominant forearm
9709449|NCT04645563||Whatsapp Group|"This group includes 54 patients who have consulted via whatsapp. The ID physician will be consulted for all the subjects once laboratory results and CT reports were complete. All the consultations were performed with the same smartphone, and every Whatsapp consultation held since the very beginning of the pandemic was evaluated.~In this type of consultation, Thorax CT images of the patient were turned into a video of approximately 30-35 seconds, and during this video recording, the patient's clinical condition and laboratory results were also transferred to the ID physician. The ID physician, on the other hand, will state his/her admission-discharge decision via Whatsapp as hospitalization or discharge. Eventually the consultation result will be recorded in the patient's folder. The moment the video was sent will be recorded as the beginning of the patient's consultation period and response time to whatsapp video will be saved as consultation response time."
9709450|NCT04645563||Bedside Consultation Group|"This group includes 90 patients who have consulted bedside. The patients that has problems which are concerning multiple consultation will be excluded.~The ED physician wrote a consultation note over the hospital information system by specifying the patient's clinical status, history and laboratory parameters. A physician will be consulted for all the eligible subjects after their laboratory results and CT reports were complete. The ID physician examined the subjects at the bedside within 30 minutes (the legal response time in Turkey) of seeing the consultation request. Consultation response time will be saved as time between entering consultation information through the system to completion of the consultation note Although the consultant ID physicians will be informed via Whatsapp, they held the consultation at the bedside for the subjects they deemed appropriate."
9709451|NCT04645446|Experimental|Pro-ocular™ 1% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.7 mg of progesterone
9709452|NCT04645446|Experimental|Pro-ocular™ 0.5% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.35 mg of progesterone
9709453|NCT04645446|Placebo Comparator|Placebo topical gel|Multidose formulation identical in appearance to Experimental Products despensing unit doses of 0.07 g of topical gel containing 0 mg of progesterone
9709454|NCT04645472||CT-Ultrasound group|
9709455|NCT04645524|Experimental|AD182|Oral capsule administered before bed
9709456|NCT04645524|Experimental|AD504|Oral capsule administered before bed
9709457|NCT04645524|Placebo Comparator|Placebo|Oral capsule administered before bed
9709458|NCT04645485|Experimental|Experimental arm|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).
9709459|NCT04645680|Experimental|Arm I (isocaloric high-fiber diet)|Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.
9709460|NCT04645680|Active Comparator|Arm II (isocaloric diet)|Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.
9709461|NCT04645511|Experimental|Chronic sinusitis: Balloon sinuplasty|30 patients with chronic maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
9709462|NCT04645511|Sham Comparator|Chronic sinusitis: Placebo|30 patients with chronic maxillary sinusitis that are randomized to be treated with sham surgery.
9709463|NCT04645511|Experimental|Recurrent sinusitis: Balloon sinuplasty|30 patients with recurrent maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
9709464|NCT04645511|Sham Comparator|Recurrent sinusitis: Placebo|30 patients with recurrent maxillary sinusitis that are randomized to be treated with sham surgery.
9709465|NCT04645745|Experimental|myo-inositol plus alpha-lactalbumin|Patients were treated with 2 g myo-inositol, 50 mg alpha-LA and 200 mcg of Folic Acid twice a day for 6 months. Controls were the same patients at baseline (t0)
9709466|NCT04645641|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
9709467|NCT04645433||Favipiravir therapy|Favipiravir was advised to all patients with severe pneumonia and progressing pneumonia findings or worsening clinical manifestations except pregnant, breast feeding, postpartum woman. PCR results were not waited to start favipiravir in this group of patients and continued if it would be negative but tomography findings were consistent with COVID-19. Loading dose was 1600 mg twice a day. Maintenance dose was 600 mg per 12 hours for four days.
9709468|NCT04645433||Lopinavir-ritonavir therapy|Lopinavir-ritonavir therapy was used in selected ICU patients before widespread availability of favipiravir (23 March 2020) and/or if favipiravir was contraindicated. Combination of lopinavir 200 mg-ritonavir 50 mg tablet was the given form. It was given as double tablets twice daily for 10-14 days. Patients were accepted as under favipiravir therapy if they had incomplete course of lopinavir-ritonavir therapy (less than 5 days) and followed by favipiravir for 5 days.
9709469|NCT04645420|Experimental|Apremilast|"15 PsA patients with active disease and naïve to conventional synthetic and biologic disease modifying anti-rheumatic drugs.~Treatment with apremilast orally in the whole group (n = 15). Escalating dose the first Week (10 mg once day1, 10 mg bid day2, 10 mg-20 mg day3, 20 mg bid day4, 20 mg-30 mg day5, 30 mg bid on day6), and 30 mg bid from day7 until week24."
9709470|NCT04645407|Experimental|FZHY Group|conventional therapy plus Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time.)
9709471|NCT04645407|No Intervention|Control Group|conventional therapy
9709472|NCT04645381||Participants with RA|
9709473|NCT04645277||Patients with MRI using two dimensional reconstruction|
9709474|NCT04645277||Patients with MRI using three dimensional reconstruction|
9709475|NCT04645043|Experimental|US_Eso|US application on the participant
9709476|NCT04645056|Experimental|Intervention group|"a. Intervention Group: Neck stretching and movement~The patient starts the stretching exercises the morning after surgery with instructions from a trained professional at the department. The patient is informed that the stretching exercises will not affect the surgical wound. The patient is instructed in performing five repetitions of each of the following nine exercises three times each day in four weeks:~Relax shoulders and neck sufficiently~Look down - Stretching and movement~Look to each side - movement~Lower the head to each side - stretching~Lower the head diagonally to each side - stretching~Small nod movements~Lift the shoulders - movement~Roll the shoulders - movement~Lift the arms - movement~The first stretching session is observed by the instructor who gives feedback and correct the exercises, if necessary. Furthermore, the patient is given a training brochure."
9709477|NCT04645056|No Intervention|Control group|b. Control group The patients in the control group are not instructed in any intervention but are answering completely similar questionnaires as the intervention group.
9709478|NCT04645238|Active Comparator|Static Hamstring Stretching|Static Hamstring Stretching
9709479|NCT04645238|Active Comparator|PNF Stretching|PNF Hamstring Stretching (Hold-Relax)
9709480|NCT04645095|Active Comparator|Conventional TENS|Frequency:80 Hz, duration:100 μs
9709481|NCT04645095|Active Comparator|Burst TENS|Frequency:100 Hz, fr mod: 0, 200 µs, 2 Bps Hz
9709482|NCT04645095|Active Comparator|Modulated TENS|Frequency:80 Hz, fr mod: 50%, Amplitude mode: 40%, duration: 200 µs
9709483|NCT04645004|Other|Aspirin|81mg aspirin daily
9709484|NCT04645303|Experimental|Hyaluronic acid|1mL of hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1-pulley.
9709485|NCT04645303|Active Comparator|Triamcinolone acetonide|1 mL of Triamcinolone acetonide 10mg/ml infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1 pulley.
9709486|NCT04645355|Experimental|New-onset guttate psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
9709487|NCT04645355|Experimental|Chronic plaque psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
9709488|NCT04645368||Longidaze|80 subjects Longidaze® (bovhyaluronidase azoxymer), lyophilisate for solution for injection
9709489|NCT04645368||Dynamic control|80 subjects Patients not receiving active therapy
9709490|NCT04644978||Trainees and specialists in child and adult psychiatry|"The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in the participating European countries on the basis of his / her own declaration. Responders could provide their consent by choosing I agree on the website, after reading the information leaflet and the informed consent form."
9709491|NCT04644614|Active Comparator|Group 1: Magnetic Stimulation|Patients will be instructed to sit in a magnetic coil chair. Magnetic flux is generated in this field. This current stimulates the nerve or muscle of the pelvic floor. To administer MS, a stimulation amplitude of 200 μs and a repetition of 10 Hz for 10 minutes, 2 minutes rest in between, 50 Hz for 10 minutes (20 minutes total), 5 seconds on / 5 seconds off, in accordance with device literature will be adjusted to produce maximum stimuli with the cycle. During each treatment session, the device will be adjusted to receive patients the current intensity gradually increasing, reaching the maximum stimulation intensity.
9709492|NCT04644614|Sham Comparator|Group 2: Sham Magnetic Stimulation|"The Sham MS treatment program will be the same as active MS in terms of duration, frequency, current duration, current intensity and general patient experience. The same magnetic chair will be used for both groups. Sham therapy application will be applied by the coordinator of the study by placing a thin deflector lead / aluminum coated plate on the magnetic coil of the magnetic chair that prevents the magnetic flux from penetrating into the patient.~During both applications, the patients will be exposed to the same sound, vibration sensation and lighting of the device."
9709493|NCT04644939|Experimental|Interventional group|Patients will receive bowel preparation instructions in a conventional way in addition to a telephone call for education purposes one day prior to procedure
9709494|NCT04644939|Placebo Comparator|Conventional group|Patients will receive bowel preparation instructions in a conventional way
9709495|NCT04644835|Experimental|LESW group|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
9709496|NCT04644835|Sham Comparator|Control group|This group of patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
9709497|NCT04644848|Experimental|Pre-sentinel node biopsy ultrasonographical tattooing|Preoperative ultrasonographical tattooing of the suspicious lymph nodes. Sentinel Lymph Node Biopsy (SLNB),
10193971|NCT04580134|Placebo Comparator|Biotype 2 - Risperidone (B2R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day
10193972|NCT04567420|Experimental|Arm A|Palbociclib/Fulvestrant Combination
10193973|NCT04567420|Active Comparator|Arm B|Adjuvant Therapy
10193974|NCT04555811|Experimental|FT596 + Rituximab Dose Level 1: 9x10^7 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
9709498|NCT04644861|Other|Elders aged 70|Program of adapted physical activity
9709499|NCT04644887|Experimental|Healthy diet CC genotype|The participants will follow the intervention diet during the 12-week intervention period.
9709500|NCT04644887|Active Comparator|Control diet CC genotype|The participants will follow the control diet during the 12-week intervention period.
9709501|NCT04644887|Experimental|Healthy diet GG genotype|The participants will follow the intervention diet during the 12-week intervention period.
9709502|NCT04644887|Active Comparator|Control diet GG genotype|The participants will follow the control diet during the 12-week intervention period.
9709503|NCT04644965||Abdominal Wall Defect|patients born with an abdominal wall defect
9709504|NCT04644965||Control Group|age and sex matched Control Group
9709505|NCT04644679|Active Comparator|48-hr|48-hr electrocardiographic monitoring
9709506|NCT04644679|Experimental|7-day|7-day electrocardiographic monitoring
9709507|NCT04644627|Experimental|Single arm|Each patient serves as its own control: one half is treated with the study treatment in addition to standard wound therapy, the other half receives standard wound therapy only.
9709508|NCT04644926|Experimental|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is performed at inclusion and repeated 12 h and 24 h later.
9709509|NCT04644640|Active Comparator|Telerehabilitation|
9709510|NCT04644640|Active Comparator|In-Person Rehabilitation|
9709511|NCT04644692||Case group: patients with heart failure with preserved ejection fraction|
9709512|NCT04644692||Control Group:Never diagnosed with either preserved or altered ejection fraction heart failure.|Non dyspnoeic patients with no history of Heart failure.
9709513|NCT04644757|Experimental|Treatment|
9779304|NCT05307679|Placebo Comparator|Placebo|Participants will receive oral placebo BID on the first day of treatment, then TID until the end of the trial on Day 365.
9779305|NCT05307627||Long-term (>5 years) LDN users|Participants who have been using LDN for over 5 years
9984474|NCT04060342|Experimental|Phase 2: Cohort 1 - GB1275 with SOC|"GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:~GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI."
9709514|NCT04644588||Children being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and hand function using postural zone software to assess scapular alignment and pediatric arm function test toassess upper limb function .
9709515|NCT04644510||Lung ultrasonography group|Patient which benefited from a Lung ultrasonography during the medical consultation
9709516|NCT04644874||Older cancer patients|All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,
9709517|NCT04644718|Experimental|Anodal-tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with real tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
9709518|NCT04644718|Sham Comparator|sham tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with sham tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
9709519|NCT04644900|Active Comparator|the Mouthwash group|Patients in the mouthwash group received 15 ml of honeysuckle antibacterial mouthwash and vomited it out after 2 minutes
9709520|NCT04644900|Active Comparator|the gum group|patients in group gum chewed one piece of herbal sugar-free gum for 2 minutes and then spat it out.
9709521|NCT04644822|Experimental|[18F]PSMA-1007 Injection|A single dose of 3 - 4 MBq/kg Body Weight (up to a maximum of 400 MBq) of [18F]PSMA-1007 Injection will be administered followed by PET/CT imaging. (Patients on ADT treatment will receive the second dose approximately 6 months after the first dose)
9709522|NCT04644731||Pediatric patients who require fluid removal|Pediatric patients who require fluid removal with the Aquadex™ System per local standard of care
9709523|NCT04644562|Experimental|patients undergoing Lower Limb vascular Surgery|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
9709524|NCT04644341||COVID survivors|Individuals who were infected by CPVID-19 and recovered.
9709525|NCT04644263||Validity and reliability|
9709526|NCT04644302||non-COVID sepsis|Patients admitted to ICU with sepsis of non-COVID origin
9709527|NCT04644302||COVID sepsis|Patients admitted to ICU with sepsis of COVID origin
9709528|NCT04644432|Experimental|A - for patients with a DNA mutation that match a targeted treatment|"Listed below are the possible study drugs and dosages:~Erlotinib 150 mg once a day for 4 weeks.~Osimertinib 80 mg once a day for 4 weeks.~Alectinib 600 mg twice a day for 4 weeks~Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks~Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week~Olaparib 400 mg twice a day for 4 weeks~Pembrolizumab iv infusion 2 mg/kg every 3rd week~Cabozantinib 60 mg once a day for 4 weeks~Crizotinib 250 mg twice a day for 4 weeks~Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week~Imatinib 400 mg once a day for 4 weeks~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
9709529|NCT04644432|Experimental|B - for patients with an angiogen profile|"Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
9709530|NCT04644432|Experimental|C - for patients with an immune profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
9984475|NCT04060342|Experimental|Phase 2: Cohort 2 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
9984476|NCT04060342|Experimental|Phase 2: Cohort 3 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
10193975|NCT04555811|Experimental|FT596 + Rituximab Dose Level 2: 3x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
9709531|NCT04644432|Experimental|D - for patients that have neither mutations nor an immune- or angiogen profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
9709532|NCT04644484|Experimental|Experimental Group: SYN023+Rabies Vaccine|"SYN023:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form: 6mg/2mL, liquid, Dosage: 0.3 mg/kg of SYN023 Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
9709533|NCT04644484|Active Comparator|Control Group: HRIG+Rabie Vaccine|"HRIG:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible Dosage form: 100 IU/mL, liquid, Dosage: 20 IU/kg Frequency/duration: at Day 1~Rabies vaccine :~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
9709534|NCT04644133||Healthy|Subjects without bowel issues will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
9779306|NCT05307627||intermediate-term (1-5 years) LDN users|Participants who have been using LDN for at least 1 year, but shorter than 5 years.
9779307|NCT05307627||short-term (<12 months) LDN users|Participants who have been using LDN for less than a year. This group will serve as the control group.
9984477|NCT04059549|Active Comparator|A-CHESS|Patients randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
9709535|NCT04644133||Constipation|Subjects diagnosed with constipation will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
9709536|NCT04644133||Fecal Incontinence|Subjects diagnosed with fecal incontinence will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
9709537|NCT04644354||Group A - Advanced Preterm Labor (aPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions 4 or more in 20 minutes and cervical dilatation at 2 cm and above
9709538|NCT04644354||Group B - Threatened Preterm Labor (tPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions less then 4 in 20 minutes and cervical dilatation less then 2 cm
9709539|NCT04644250|Experimental|Arm1|Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.
9709540|NCT04644224|Experimental|Group I (coaching session, navigation session, support group)|Parents/caregivers whose churches are randomized to Group I, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
9709541|NCT04644224|Experimental|Group II (coaching session, navigation session, support group)|Families whose churches are randomized to Group II, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
9709542|NCT04644224|Active Comparator|Group III (educational handbook)|Families whose churches are randomized to Group III, receive an educational handbook on cancer prevention.
9709543|NCT04644211|Experimental|Ruxolitinib Stage 1|"In stage 1, participants will be divided into two cohorts:~Very low, Low, and Intermediate-risk ETpatients with significant symptom burden and Low-risk PV patients with significant symptom burden~Study cycles are 28 days long, participants in both cohorts will receive:~Ruxolitinib 2x daily for 6 study cycles."
9709544|NCT04644211|Experimental|Ruxolitinib Stage 2|"Stage 2 will commence based on 3 or more participants in Stage 1 showing a predetermined positive response to Ruxolitinib.~In stage 2, participants will be divided into two cohorts:~Very low, Low, and Intermediate-risk ET patients with significant symptom burden and Low-risk PV patients with significant symptom burden~Study cycles are 28 days long, participants in both cohorts will receive:~Ruxolitinib 2x daily for 6 study cycles."
9709545|NCT04644445|No Intervention|Control|Standard bariatric clear liquid diet to be started 4 hours after surgery
10193976|NCT04555811|Experimental|FT596 + Rituximab Dose Level 3: 9x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
10193977|NCT04552665||Adults|Patients who have cardiac arrhythmia
10193978|NCT04545424|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
10193979|NCT04545424|Active Comparator|Usual Temperature Management|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
10193980|NCT04543383|Experimental|Part 1: Group 1|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: ABC1, BC1A, C1AB, BAC1, C1BA and AC1B in period 1, period 2 and period 3 respectively where, Treatment A= Dose 1 of JNJ-70033093 +Dose 3 of 4F-PCC; Treatment B=Dose 2 of JNJ-70033093+Dose 3 of 4F-PCC; Treatment C1=Dose 2 of JNJ-70033093+Placebo with a washout period of 14 days to 21 days between Day 1 of each study period.
10193981|NCT04543383|Experimental|Part 1: Group 2|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: ABC2, BC2A, C2AB, BAC2, C2BA and AC2B in period 1, period 2 and period 3 respectively where, Treatment A= Dose 1 of JNJ-70033093 +Dose 3 of 4F-PCC; Treatment B=Dose 2 of JNJ-70033093+Dose 3 of 4F-PCC; Treatment C2=Dose 1 of JNJ-70033093+Placebo with a washout period of 14 days to 21 days between Day 1 of each study period.
10193982|NCT04543383|Experimental|Part 2: Group 1|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and IV injection of Recombinant Human Factor VIIa (rFVIIa) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: DEF1, EF1D, F1DE, EDF1, F1ED and DF1E in period 1, period 2 and period 3 respectively where, Treatment D=Dose 1 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment E=Dose 2 of JNJ-3093+Dose 4 of rFVIIa; Treatment F1=Dose 2 of JNJ-70033093+Placebo with a washout period of 4 days between Day 1 of each study period.
9709546|NCT04644445|Experimental|Intervention|Bariatric full liquid diet (clear liquid diet + protein shakes) to be started 4 hours after surgery
9709547|NCT04644380|Experimental|Treatment Group|During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5 days vaginal incubation
10193983|NCT04543383|Experimental|Part 2: Group 2|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and IV injection of the reversal agent Recombinant Human Factor VIIa (rFVIIa) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: DEF2, EF2D, F2DE, EDF2, F2ED and DF2E in period 1, period 2 and period 3 respectively where, Treatment D=Dose 1 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment E=Dose 2 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment F2=Dose 1 of JNJ-70033093 +Placebo with a washout period of 4 days between Day 1 of each study period.
10193984|NCT04542031|Other|Survey|Survey to be distributed at 6 and 12 months
9709548|NCT04644419|No Intervention|Control|Patients in the control arm will receive standard of care.
10193985|NCT04540107|Experimental|Group I (MRI, MRSI)|Patients undergo MRI and MRSI scans over 1 hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
10193986|NCT04540107|Experimental|Group II (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)|Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon C 13 pyruvate IV over less than 1 minute and undergo MRSI scan at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
9709549|NCT04644419|Experimental|Palliative And supportive Care inTervention (ACT)|This ancillary study does not include intervention development component. The detail intervention can be found in the parent study protocol (NCT04570709).
9709550|NCT04644081|Experimental|LTP+CaCBT|The LTP+CaCBT intervention will consist of a total of 12 (social distancing) group training sessions (60-90 minutes) and will deliver two sessions on a weekly basis for six weeks.
10193987|NCT04535102|Experimental|Polatuzumab + BR (minimum 3 cycles)|Patients will be treated with a minimum of 3 cycles up to a maximum six cycles to optimize response prior to ASCT (stem cell transplant) per investigator discretion
10193988|NCT04531969|Active Comparator|Inpatient group|Spa therapy,HP application, deep heater application, and TENS.
9709551|NCT04644081|Active Comparator|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of counselling services).
9709552|NCT04644146||SEVERE|Patients affected by SARS-CoV2 infection with severe lung dysfunction needing oxygen complementation and critical care supports - criteria 18-70yr old and without any comorbidities
9709553|NCT04644146||CONTROL|Patients affected by SARS-CoV2, as shown by PCR and/or antigen testing diagnosis and without any or minor clinical expression
9709554|NCT04643925|Experimental|hCG priming|"Control cycle: A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy.~Study cycle: hCG priming by Ovitrelle 260 IE once daily for 8 weeks followed by a standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by a single blastocyst transfer at day 5."
9709555|NCT04644185|Experimental|SCTA01 Low Dose+BSC|SCTA01in a lower dose+best supportive care
9709556|NCT04644185|Experimental|SCTA01 High Dose+BSC|SCTA01in a higher dose+best supportive care
9709557|NCT04644185|Active Comparator|Placebo+BSC|SCTA01 excipients+best supportive care
9709558|NCT04643938||Two spontaneous abortions|No intervention
9709559|NCT04643938||three spontaneous abortions|No intervention
9709560|NCT04643938||Four or more spontaneous abortions|No intervention
9709561|NCT04644120|Experimental|Part A: Group 1: ABBV-47D11 Dose A|Participants will receive ABBV-47D11 Dose A on Day 1.
9709562|NCT04644120|Placebo Comparator|Part A: Group 1: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
9709563|NCT04644120|Experimental|Part A: Group 2: ABBV-47D11 Dose B|Participants will receive ABBV-47D11 Dose B on Day 1.
9709564|NCT04644120|Placebo Comparator|Part A: Group 2: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
9709565|NCT04644120|Experimental|Part A: Group 3: ABBV-47D11 Dose C|Participants will receive ABBV-47D11 Dose C on Day 1.
9709566|NCT04644120|Placebo Comparator|Part A: Group 3: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
9709567|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A|Participants will receive ABBV-2B04 Dose A on Day 1.
9709568|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A + ABBV-47D11|Participants will receive ABBV-2B04 Dose A in combination with ABBV-47D11 on Day 1.
9709569|NCT04644120|Placebo Comparator|Part B: Group 1: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
9709570|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B|Participants will receive ABBV-2B04 Dose B on Day 1.
9709571|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B + ABBV-47D11|Participants will receive ABBV-2B04 Dose B in combination with ABBV-47D11 on Day 1.
9709572|NCT04644120|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
9709573|NCT04643964|Experimental|Entrée: Cognitive Skills|
9709574|NCT04643964|Experimental|Entrée: Behavioral Skills|
9709575|NCT04643964|Experimental|Entrée: Interpersonal Skills|
9709576|NCT04643964|Experimental|Sampler Skills|
9709577|NCT04643964|No Intervention|Control|Participants are not given videos to watch until their involvement in the study ends.
9709578|NCT04644198|Active Comparator|Convalescent Plasma Treatment|Convalescent Plasma
9709579|NCT04644198|No Intervention|Control|Standard of care
9709580|NCT04643977|Experimental|mesohyal ARGIBENONE|Name of the investigation medical device: mesohyal ARGIBENONE Code of the MD for the purpose of the clinical investigation: mARG-01-17 GMDN code: 59131 mARG-01-17 is a dermal filler recommended for cutaneous filling, facial wrinkle improvement and general condition of the skin, which is administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging.
9709581|NCT04643795|Experimental|40 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
9709582|NCT04643795|Experimental|60 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
9709583|NCT04643795|Experimental|80 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
9709584|NCT04643795|Experimental|100 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
9709585|NCT04643756|Active Comparator|Conventional Physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound. Procedure/Device: Conventional Physiotherapy Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm2 and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
9709586|NCT04643756|Active Comparator|Conventional Physiotherapy + Kinesiotaping|Kinesiotaping application in addition to classical electrotherapy method consisting of tens, hotpack and ultrasound.It will be applied to reduce pain, increase proprioception and awareness. Kinesiotaping will be re-applicated every day. Space taping will be applied to the waist area. Space taping creates a vacuum effect on the skin, loosening the adhesions in the tissue layers. With this lifting effect, it creates a space under the skin, causing an increase in circulation and a decrease in pain. Four pieces of I-tape will be used for taping. The middle point of the first tape will be attached with maximum tension. The ends of the tape will be tensionless. The second tape will also be applied at a 90 degree angle. The third and fourth tapes will be taped at an angle of 45 degrees.
9709587|NCT04643873|Experimental|Experimental group 1|physical activity counseiling +pilates exercise group
10193989|NCT04531969|Active Comparator|Outpatient group|Spa therapy,HP application, deep heater application, and TENS.
9709588|NCT04643873|Experimental|Experimental group 2|only physical activity counseiling group
9709589|NCT04643873|No Intervention|Control Group|only followed by family physician
9709590|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.05mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.05mcg/kg iv q 12h, for 10 days, starting within 6h of birth
9709591|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
9709592|NCT04643821|Experimental|NAC 40mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 40mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
9709593|NCT04643912|Experimental|Injured wrist or ankle|"Child with trauma needing wrist or ankle x-ray:~Will receive vibration analysis blinded to x-ray findings."
9709594|NCT04643990||LDT Combined with TDF for Treatment|The patients take one tablet of LDTand one tablet of TDF every night and continue to 12 months.
9709595|NCT04643990||Only TAF treatment.|The patients take one tablet of TAF every night and continue to 12 months.
9709596|NCT04644016|Experimental|Participants with non-malignant and malignant hematologic disorders|Participants with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
9709597|NCT04643730|Experimental|Reflexology Group|Foot Reflexology was applied to the babies before heel lancing
9709598|NCT04643730|Experimental|Acupressure Group|Acupressure was applied to the babies before heel lancing
9709599|NCT04643730|Active Comparator|Control Group|No pre-application was made to the babies in the control group as a routine procedure
9709600|NCT04643743||Subjects who did receive POLYPATCH® for vascular angioplasty|Subjects who did receive POLYPATCH® at least one year ago for vascular angioplasty. 2 main sub-populations will be studied depending on location of surgery (carotid and femoral) but data will be collected for all subjects who did receive POLYPATCH.
9709601|NCT04643717||intensive care patients|
9709602|NCT04643496||Patients requiring ileocolic resection for Crohn disease.|All consecutive patients requiring an ileocolic resection for Crohn disease, between January 2010 and March 2020 at the Digestive Surgery Units of CHU Montpellier.
9709603|NCT04643522||Before COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed before the diagnosis of COVID-19.
9709604|NCT04643522||After COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed after the diagnosis of COVID-19.
9709605|NCT04643509||cardiac surgery|patients benefiting from pulmonary arterial catheter monitoring after cardiac surgery
9709606|NCT04643678|Active Comparator|Anakinra Group|Anakinra + Standard of Care
10193990|NCT04529720||acellular pertussis vaccine|Antibody persistence at 5 years after a single dose vaccination of acellular pertussis vaccines (Pertagen;Boostagen;Adacel)
10193991|NCT04528069|Experimental|PanOptix Toric Trifocal IOL|PanOptix Toric Trifocal IOL implanted in the capsular bag in the posterior chamber following cataract surgery and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
10193992|NCT04522284|Experimental|CURATE.AI|"- Cohort 1: Capecitabine in solid tumours. In this cohort, participants will receive the treatment in three-week cycles. Only the dose of capecitabine will be modulated with CURATE.AI, based on measurements of the tumour marker (CEA/CA19-9). CT scans for radiological assessment will be performed according to standard of care, usually after every 2 to 3 cycles of chemotherapy for Cohort 1 only.~Cohort 2: Ibrutinib in Waldenström macroglobulinaemia In this cohort, participants will receive the treatment in four-week cycles. The total cumulative dose of Ibrutinib will be modulated with CURATE.AI, based on measurements of the tumour marker (IgM paraprotein)."
9709607|NCT04643678|Other|Standard of Care Group|Standard of Care Alone
9709608|NCT04643899|No Intervention|Control group|Patients benefiting only from the usual nutritional rehabilitation program G1a: diabetic patients G1b: non-diabetic patients
9709609|NCT04643899|Experimental|Electrostimulation group|Patients benefiting from the usual program AND muscle electrostimulation sessions G2a: diabetic patients G2b: non-diabetic patients
9709610|NCT04643704||FPIES|100 patients
9709611|NCT04643704||IgE mediated food allergy|100 patients
9709612|NCT04643704||Celiac disease|100 patients
9709613|NCT04643704||Control group|100 patients
9779308|NCT05307614|Experimental|Moksi® 400mg Tablet of Abbott|Healthy subjects were orally administered a single dose of Moksi® 400mg Tablet (Moxifloxacin) under fasting condition
9709614|NCT04643847|Experimental|Stereotactic radiosurgery with Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions
9709615|NCT04643691|Experimental|losartan / spironolactone|Losartan 50 mg and Spironolactone 25 mg pillules oral use
9709616|NCT04643691|No Intervention|usual care|Usual care of COVID-19 infection in intensive care
9709617|NCT04643665||No grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having not a grade 3 Pulmonary graft dysfunction at postoperative day 3
9709618|NCT04643665||Grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having a grade 3 Pulmonary graft dysfunction at postoperative day 3
9709619|NCT04643652|No Intervention|Control|Usual Care
10193993|NCT04521127|Active Comparator|Kinesio Taping Group|Kinesio taping will be applied to trapezius muscle
9709620|NCT04643652|Experimental|Intervention|Implementation of a Noise Reduction Bundle
9709621|NCT04643639|Experimental|Active|
10193994|NCT04521127|Active Comparator|Dry needling Group|Dry needling will be applied to trigger point on trapezius muscle
9709622|NCT04643639|No Intervention|Control|
9709623|NCT04643626|Experimental|IG|artificial intelligence dietary application, iDSA, will be introduced and installed. Explanation on the function and application of iDSA will be given. Daily energy and macro-nutrients requirement target will bed set. The daily energy and macronutrients requirement target is secured by password. Subjects will record their daily dietary intake (food with cooking method and portion size) and nutrition impact symptoms via smartphone application at least 3 times a week. Subjects able to keep track their intake at home. During follow up session, subjects show the iDSA diet intake summary records to Researcher for further assessment.
9709624|NCT04643626|No Intervention|CG|CG will receive conventional dietitian care includes nutrition care process using conventional 24 hours diet recall method for dietary assessment
9709625|NCT04643613|Experimental|PCNF|Totally 42 cancer patients with poor nutritional status under nasogastric (NG) tube feeding was recruited and administered with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks (84 days).
9709626|NCT04643600|Active Comparator|Smokers|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients who are smokers will have recorded : the age of onset of smoking, the year of smoking experience and the average number of cigarettes smoked per day. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
9709627|NCT04643600|Active Comparator|Non - smokers|All patients will be maesured: body weight, height, BMI (body mass index), waist circumference, pulse (cp), saturation (SpO2), blood pressure, respiratory index and thoracic spine mobility index measured. All patients will do a 6-minute walk test and test on a bicycle erogometer. The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
9709628|NCT04643561|Experimental|intervention|5 patients will recieve 5 days treatment with Travelan, blood samples will be taken prior and after intervention
9709629|NCT04643392||Patients with Lipedema|Participants who were diagnosed with upper extremity lipedema by a lymphologist.
9709630|NCT04643483|Experimental|Certolizumab pegol low dose arm|"Participants randomized to certolizumab pegol (CZP) who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 100 mg CZP subcutaneously (sc) every 2 weeks (Q2W).~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by placebo and a maintenance dose of 200 mg CZP sc Q2W."
9709631|NCT04643483|Experimental|Certolizumab pegol high dose arm|"Participants randomized to CZP who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 200 mg CZP sc Q2W.~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 300 mg CZP sc Q2W."
9709632|NCT04643483|Active Comparator|Adalimumab reference arm|"Participants randomized to adalimumab who weigh ≥17 kg to <40 kg will receive a loading dose of 80 mg at Week 0 and 40 mg at Week 2, followed by a maintenance dose of 20 mg sc Q2W.~Participants randomized to Adalimumab who weigh ≥40 kg will receive a loading dose of 160 mg at Week 0 and 80 mg at Week 2, 40 mg and placebo at week 4 followed by a maintenance dose of 40 mg sc and placebo Q2W."
9709633|NCT04643236|Experimental|periodontal health educational group (test)|25 subjects diagnosed with gingivitis received periodontal health education session
9709634|NCT04643236|Active Comparator|oral hygiene motivation group (control)|25 subjects diagnosed with gingivitis received standard oral hygiene motivation session
9709635|NCT04643340||active group 1|This group will train the insular cortex by real-time fMRI
9709636|NCT04643340||active group 2|This group will train the visual cortex by real-time fMRI
10193995|NCT04521127|No Intervention|Control Group|Control group will not receive any additional intervention
10193996|NCT04513353|Experimental|Digital Healthcare System Rehabilitation|
10193997|NCT04513353|Active Comparator|Conventional Rehabilitation|
10193998|NCT04513327|Experimental|Digital Healthcare System Rehabilitation|
10193999|NCT04513327|Active Comparator|Conventional Rehabilitation|
10194000|NCT04512248|Experimental|Quit and Stay Quit Monday Model|
10194001|NCT04512248|No Intervention|Usual Care|
10194002|NCT04511377|Experimental|Digital Healthcare System Rehabilitation|Rehabilitation using Uincare Homeplus
10194003|NCT04511377|Active Comparator|Conventional Rehabilitation|Rehabilitation using Brochure
9709637|NCT04643340||sham|This group will only train the insula by a particular strategy
9709638|NCT04643262||Intraoperative morbidity and mortality|Intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.
9709639|NCT04643262||peri-operative morbidity and mortality (<30 days)|Perioperative complications (<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.
9709640|NCT04643262||Post-operative morbidity and mortality (>30 days)|Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment
10194004|NCT04507555|Experimental|Intervention|
9709641|NCT04643327|Experimental|Active arm|125mg Levetiracetam capsules taken twice daily (morning and evening) for 14 days
9709642|NCT04643327|Placebo Comparator|Placebo arm|125mg maize starch-based placebo capsules taken twice daily (morning and evening) for 14 days
9709643|NCT04643275|Experimental|Non-invasive lipolysis of the upper arms|The treatment administration phase consists of four (4) treatment visits, delivered 5- 10 - days apart. Each therapy session will last 30 minutes. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
9709644|NCT04643041|Experimental|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3W) therapy and start watch and wait.
9709645|NCT04642963|Experimental|Cardiac Radiosurgery|Patients with ventricular tachycardia will undergo a non-invasive cardiac radiosurgery using one fraction of 25 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
9709646|NCT04643132|Placebo Comparator|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
9709647|NCT04643132|Active Comparator|S-ketamine at low dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
9709648|NCT04643132|Active Comparator|S-ketamine at high dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
9709649|NCT04643171|Experimental|Exercised group|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
9709650|NCT04643171|Active Comparator|group of electroacupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6, 5 times per week, for 12 week
9709651|NCT04643145|Active Comparator|Ureteral catheter|This group will receive ureteral catheter for 2 days after the procedure
9709652|NCT04643145|Active Comparator|Indwelling double J stent|This group will receive indwelling double J stent for 2-4 weeks after the procedure
9709653|NCT04642924|Experimental|Locally Advanced Rectal Cancer|Patients included with locally advanced rectal cancer SGM-101 10mg, 3-5 days prior to surgery
9979950|NCT01386840|No Intervention|Severe Pneumonia - Hospital Management|"Those randomized to hospital management will be monitored by health personnel for at least 48 hours for clinical deterioration and parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, Clinical deterioration, Other signs eg. comorbid conditions, Assessment of adherence, Adverse event.~Mothers, whose children are discharged after 48 hours, will be counseled to continue with oral treatment prescribed for a period of 7 days and will be advised to return to healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card"
9984478|NCT04059549|Experimental|PartnerCHESS|Patients randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
9984479|NCT04057131||Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
10194005|NCT04507555|Active Comparator|Standard Care|
10194006|NCT04507555|No Intervention|Observational|
10194007|NCT04506814|Active Comparator|Endocardial PVI|Endocardial complete PVI
10194008|NCT04506814|Experimental|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip
10194009|NCT04505891|No Intervention|Usual care|
10194010|NCT04505891|Active Comparator|Education alone|
10194011|NCT04505891|Active Comparator|Education and follow-up|
10194012|NCT04502914|Experimental|The experimental group|The experimental group will consist of wounds treated with the open-to-air strategy.
9709654|NCT04642924|Experimental|Recurrent rectal cancer|Patients included with (locally) recurrent rectal cancer SGM-101 10mg, 3-5 days prior to surgery
9709655|NCT04643028|Other|Home exercise|The exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
9709656|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions. Sixty seconds of rest will be given between sets.
9709657|NCT04643028|Other|Cervical stabilization|In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
9709658|NCT04643119|Active Comparator|Cruciate-Retaining Insert|
10194013|NCT04502914|Other|The control group|The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.
10194014|NCT04486391|Experimental|Tislelizumab|Tislelizumab monotherapy for up to 45 months
10194015|NCT04486391|Experimental|Salvage chemotherapy|Salvage chemotherapy for up to 45 months
10194016|NCT04470011||Patients who initiated HIV treatment|
10194017|NCT04470011||Service providers at study facilities|
10194018|NCT04468399||Patients who initiated HIV treatment|
10194019|NCT04468399||Service providers at study facilities|
9709659|NCT04643119|Experimental|Medial-Congruent Insert|
10194020|NCT04449250|Active Comparator|CTx-1301 Fasted|Subjects will receive CTx-1301 in a fasted state.
9709660|NCT04643301|Experimental|Adding Liraglutide to current treatment program|Adding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.
10194021|NCT04449250|Active Comparator|CTx-1301 Fed|Subjects will receive CTx-1301 in a fed state (high fat meal).
10194022|NCT04445558|Experimental|Membrane PEPA®|Patient will use the membrane PEPA® for the dialysis
10194023|NCT04445558|Active Comparator|Standard membrane of dialysis|Patient will use a standard membrane for the dialysis
10194024|NCT04428216|Active Comparator|Group RIB = Rhomboid intercostal block group|In group RIB, RIB block will be performed with patients in the lateral decubitus position. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injected into the fascial plane.
10194025|NCT04428216|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
10194026|NCT04423237||Severe Iron Overload (SIO)|Children affected by Severe Iron Overload who received DEFERASIROX
9709661|NCT04642937|Experimental|hP1A8|Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
9709662|NCT04642989|Sham Comparator|Healthy Control + Sham Treatment|Healthy participants who received the sham treatment
9709663|NCT04642989|Active Comparator|Healthy Control + Facial Effleurage|Healthy participants who received the Facial Effleurage treatment
10194027|NCT04423237||Severe Iron Overload + Ductopenia (SIO+D)|Children affected by Severe Iron Overload + Ductopenia who received DEFERASIROX
9709664|NCT04642989|Active Comparator|Acute Rhinosinusitis + Antibiotics|Sick participants who received the recommended antibiotics
9709665|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment|Sick participants who received the sham treatment
9709666|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage|Sick participants who received the Facial Effleurage treatment
9709667|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment + Antibiotics|Sick participants who received the recommended antibiotics and the sham treatment
10194028|NCT04413266|Active Comparator|Curcumin for CKD|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
10194029|NCT04413266|Placebo Comparator|Placebo for CKD|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
10194030|NCT04409795|Other|HLA+ Group|Participants who are high-risk HLA-DR3 and/or DR4 (+); monogenic variant (+) with rare exome variant ensemble learner (REVEL) score>0.75; and both glutamic acid decarboxylase (GAD65) and islet antigen (IA2) autoantibody (-)
10194031|NCT04409795|Other|HLA- Group|Participants who are high-risk HLA-DR3 and DR4 (-); with known or yet unknown monogenic variants with REVEL score>0.75; and either GAD65 and IA2 autoantibody (-), or autoantibody (+) with titers close to the cutoff
9709668|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage + Antibiotics|Sick participants who received the recommended antibiotics and the Facial Effleurage treatment
9709669|NCT04643197|Experimental|Experimental arm|Abdominal fascia will be closed with barbed suture.
9709670|NCT04643197|Active Comparator|Control|Abdominal fascia will be closed with non-barbed suture.
9709671|NCT04643288|Experimental|OFD control group|open flap debridement for periodontal intrabony defects
9709672|NCT04643288|Experimental|n-HA bone graft intervention group|Nanocrystalline Hydroxyapatite (n-HA) bone graft substitute was added to periodontal intrabony defects
9709673|NCT04643054|Experimental|Ovotransferrin|Dietary Supplement: Ovotransferrin
9709674|NCT04643054|No Intervention|Standard of care|Standard of care
9779309|NCT05307614|Active Comparator|Avelox® 400mg Tablet of Bayer|Healthy subjects were orally administered a single dose of Avelox® 400mg Tablet (Moxifloxacin) under fasting condition.
9779310|NCT05307575||Post-COVID syndrome (PCS) Severe COVID-19|Severe COVID-19 with PCS with cognitive complains
9779311|NCT05307575||Post-COVID syndrome (PCS) Mild COVID-19|Mild COVID-19 with PCS with cognitive complains
9779312|NCT05307575||Controls|Healthy adult controls
10194032|NCT04389333|Experimental|Non-contact MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination. In order to simplify the examination procedure, the data recorder was put on the examination bed. The patient lay down after swallowing the capsule under the remote guidance of the endoscopist.
10194033|NCT04389333|Active Comparator|MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of an endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient was instructed to assume the supine or left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist face to face, the subject turned over on the bed to complete the examination.
10194034|NCT04378179||HFpEF|HF patients with preserved ejection fraction (HFpEF)
10194035|NCT04378179||HFrEF|HF patients with reduced ejection fraction (HFrEF)
10194036|NCT04378179||PH|Patients with Pulmonary hypertension (PH)
10194037|NCT04378179||Control|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria.
10194038|NCT04378179||Controls with suspected CAD|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria, and may have a diagnosis of Coronary Artery Disease (CAD) or may be suspected to have CAD.
9709675|NCT04643067|Active Comparator|0.15mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
10194039|NCT04377919|Active Comparator|Cranberry|Administration of 2 capsules with 500mg (Miralys Ltda) of cranberry extract per day, for 8 weeks
10194040|NCT04377919|Placebo Comparator|Placebo|Administration of 2 capsules with 500mg of maize starch per day, for 8 weeks
10194041|NCT04375553|Active Comparator|Exercise group|Intradialytic aerobic exercise, 3 times a week, for 12 weeks.
10194042|NCT04375553|No Intervention|Non-exercise group|Without intradialytic aerobic exercise for 12 weeks.
10194043|NCT04375033|Experimental|Sublingual Arm|"The sublingual buprenorphine contains naloxone in a ratio of 4:1 and will be prescribed. Consistent with the SAMHSA TIP 40 guidelines 75, before SL-BUP/NLX is prescribed, participants will be evaluated for recent (within 24 hours) drug use and associated symptoms.~The randomization dose will be determined based on the maintenance dose identified during the induction period, with a target dose of 16-24mg that is standard practice. While the target dose is 16-24mg, doses may go as low as 8mg as occasionally patients prefer lower doses. SL-BUP/NLX will be prescribed at the randomization visit (28-day supply), then every 4 weeks until week 48."
10194044|NCT04375033|Experimental|Injectable Arm|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit. The target dose is 300mg, there is the option to use 100mg dose. The final study dose of injectable buprenorphine will be given at Week 48.
10194045|NCT04367740||Serum Antibodies|Blood samples to be obtained assess for IgG antibodies against SARS-CoV2
10194046|NCT04362709||Postoperative complications|
9709676|NCT04643067|Active Comparator|0.6mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
9709677|NCT04643067|Active Comparator|2mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
9709678|NCT04643067|Placebo Comparator|Placebo arm|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
9709679|NCT04643210|Experimental|F2F MoB EI and access to MoB Digital Platform (MoB DP) group|"The design of the face-to-face Management of my Bipolarity educational intervention (F2F MoB EI) will rely on the Colom & Vieta model, Cognitive- Behavioural techniques and the results of the relevant literature review and data acquired in the qualitative research of bipolar disease patients' educational needs. A textbook will be devised explaining in detail the step-by-step process and the techniques of the experimental educational method of the MoB F2F EI.~This group will also receive the technology-based intervetion, which regards access to the MoB DP. This is an ecosystem where the participants will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile."
9779313|NCT05307562|Active Comparator|Training program|Global intervallic exercise using cyclometer and analytical strength exercises
9779314|NCT05307562|Experimental|Training program + Inspiratory muscle traioning (IMT)|Global intervallic exercise using cyclometer and analytical strength exercises + inspiratory muscles training
9779315|NCT05307549||Post-COVID patients|Adults survivors from severe COVID-19
9779316|NCT05307549||Controls|Healthy adult controls
10194047|NCT04362709||No postoperative complications|
10194048|NCT04325321|Other|Stress reactivity|Stress reactivity test
10194049|NCT04325204|Experimental|Caregivers|Caregivers of a person living with dementia will participate in the Faith-HAT intervention for 12 weeks.
10194050|NCT04325204|Experimental|Persons living with dementia|Persons living with dementia will participate in the Faith-HAT intervention for 12 weeks.
10194051|NCT04320511||Patients with SARS-COV 2|Patients with SARS-COV 2 undergoing CT-V
10194052|NCT04308759|Experimental|Group I (Quitbot)|Participants participate in the Quitbot program which involves prompted, focused conversations for 42 days. Therapy description withheld to protect the integrity of the study.
10194053|NCT04308759|Active Comparator|Group II (Texting)|Participants participate in texting program over 42 days where they receive messages to support quitting smoking. Therapy description withheld to protect the integrity of the study.
9709680|NCT04643210|Active Comparator|The MoB DP group|This group will receive the technology-based intervention, which regards access to the MoB DP. The structure of the MoB DP has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
9709681|NCT04643093|Active Comparator|Pitavastatin|Pitavastatin
9709682|NCT04643093|Active Comparator|Ezetimibe|Ezetimibe
9709683|NCT04643093|Experimental|1PC111|1PC111
9709684|NCT04643314|Experimental|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
9709685|NCT04643314|No Intervention|Traditional intraoperative teaching|"Subjects randomized to this group will undergo their usual residency training.~The recordings of the 5 submitted consecutive laparoscopic cholecystectomy procedures performed by the participant as the primary operator will be stored. However participants in this arm of the study will not have access to the uploaded videos until the end of the study."
9709686|NCT04643223|Active Comparator|Kinesio tape with tension|The intervention group will receive the elastic bandage - kinesio tape with tension between seventy to ninety percent on the selected hypertrophic scar. The application of kinesio tape follows a protocol, which involves the cleaning of the selected scar with liquid soap, drying, alcohol application for sebum removal, scar measurement and marking of the therapeutic zone and anchors. Following the application of the kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the Vancouver assessments and collections of scarring material for the histopathology will be carried out, in the time intervals corresponding to the beginning of the study intervention / entry (time 0), 45 days and 90 days after being eligible, to agree to participate in the study study and intervention.
9709687|NCT04643223|Sham Comparator|Kinesio tape without tension|The controlled sham group will receive the application of kinesio tape without tension will follow the same protocol above, including the three moments of evaluation, beginning of the intervention (time 0), 45 days and 90 days, after the beginning of the intervention.
9709688|NCT04642898|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
9709689|NCT04642898|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
10194054|NCT04301180|Experimental|Experimental|"The experimental group conducted 10 weekly sessions, with an approximate duration of 45 minutes per session, which consisted of the presentation of food education content while conducting an orchard with seasonal vegetables. Simple recipes were also described in which these vegetables were included to be made at home, along with information on children's books that dealt with the topic of food and were available in the public library.~All children in the experimental groups were given written instructions so that they could perform at their home, together with their parents, the manipulative activities suggested each week. All these contents were common for all the participants in the study. Session material was renewed weekly."
9709690|NCT04642898|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
9709691|NCT04642898|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
9709692|NCT04642898|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
9984480|NCT04056299|Active Comparator|AR201 powder|Subjects were randomized to active arm of AIME01 and administered AR201 in escalating doses for approximately 6 months, followed by a maintenance dose for approximately 12 weeks
9984481|NCT04056299|Placebo Comparator|Placebo powder|Subjects were randomized to placebo arm of AIME01 and administered placebo for approximately 6 months, followed by maintenance placebo for approximately 12 weeks.
10194055|NCT04301180|No Intervention|Control|"The control group received the usual training corresponding to the contents of the human body module that is currently taught in each center."
10194056|NCT04297605|Experimental|Experimental 1: pembrolizumab and Pemetrexed|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Pemetrexed 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)"
10194057|NCT04297605|Experimental|Experimental 2: pembrolizumab and Nab-paclitaxel|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days~Pembrolizumab 200 mg and Nab-paclitaxel 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles followed by pembrolizumab alone"
10194058|NCT04292197|Experimental|18-MC SAD Study|In Part 1, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice in 1 day.
10194059|NCT04292197|Experimental|18-MC MAD Study|In Part 2, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice a day for 7 consecutive days.
9709693|NCT04642898|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
10194060|NCT04289116|Experimental|We Test|Each participant or couple will receive MI-CST + observation of ACT videos + CHTC. Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
10194061|NCT04289116|Active Comparator|Individual HIV Testing and Counseling|Individual HIV Testing and Counseling (IHTC). Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
9709694|NCT04643106|Experimental|Hemostatic agent group|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.
9709695|NCT04643106|Active Comparator|Suturing group|During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.
9709696|NCT04643080|No Intervention|Control|Subjects were asked to avoid consuming fermented foods for 12 weeks.
9709697|NCT04643080|Experimental|Yogurt|Subjects were asked to consume 6 oz. of yogurt daily for 12 weeks.
9709698|NCT04642872|Experimental|infant cimt|
10194062|NCT04274517|Experimental|Sterile Water|
10194063|NCT04274517|Experimental|3.5% betadine|
9709699|NCT04642872|Active Comparator|Infant BIT|
9709700|NCT04642872|Active Comparator|Infant CIMT/BIT|
9709701|NCT04642872|Active Comparator|Conventional Therapy|
9709702|NCT04642846|Experimental|one application of SDF|
9709703|NCT04642846|Experimental|two application of SDF one month apart|
9709704|NCT04642859|Experimental|Dyslexia|Students with dyslexia before and after the intervention
9709705|NCT04642703||COVID-19 ventilated patients subjected to tracheostomy|Patients who receive percutaneous or surgical tracheostomy due to prolonged mechanical ventilation. The indication is made by an experts team and based on national guidelines
9709706|NCT04642703||COVID-19 ventilated patients without tracheostomy|Patients supported with mechanical ventilation by 10 days or more in who an experts team of physicians decided do not perform a tracheostomy
9709707|NCT04642781||healthy children aged 8-13years (schoolgrade 2-5)|Primary school children are asked to read a German text presented on a laptop screen
9779317|NCT05307536|Experimental|Autologous BMMNCs infusion combined with educational intervention|"Bone marrows are harvested from the patients' iliac depended on the patients' body weight as follows: 8 ml/kg for patients under 10 kg; [80 ml + (body weight in kg - 10) × 7 ml] for patients above 10 kg. Mononuclear cells from collected bone marrow are infused intrathecally through a space between muber verterbrea 4th and 5th. Two transplantations will be conducted with an interval of 6 months. The educational intervention will be developed based on Early Start Denver Model for 6 months after the first infusion.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), Clinical Global Impression (CGI). In addition, Health - related quality of life (HRQoL) in patients will be evaluated at baseline, 2 months, 6 months and 12 months with those in control group (educational intervention only) using Pediatric quality of Life Inventory (PedsQL)"
9779318|NCT05307536|Active Comparator|Educational intervention alone (the controlled group)|"The educational intervention will be developed based on Early Start Denver Model for 6 months after the first infusion.~Evaluation: The efficacy outcomes will be measured using the CARS, Vineland Adaptive Behavior Scales - second Edition (VABS), Autism Behavior Checklists (ABC), Clinical Global Impression (CGI). In addition, Health - related quality of life (HRQoL) in patients will be evaluated at baseline, 2 months, 6 months and 12 months with those in control group (educational intervention only) using Pediatric quality of Life Inventory (PedsQL)"
9779319|NCT05307523|Experimental|Enriched Environment Play With Harness Support|Enriched environment play, movement, and exploration for children with Down Syndrome while using a portable partial body weight support harness to facilitate movement and exploration.
10194064|NCT04274517|Experimental|0.05% chlorhexidine gluconate|
10194065|NCT04272671|Experimental|Educational Intervention Arm|The intervention arm will receive educational material that enhances the standard of care for deprescribing opioids and BZDs.
10194066|NCT04272671|No Intervention|Ususal Care (Control Arm)|Control group will receive standard of care
10194067|NCT04262024|Active Comparator|Cabergoline with health education by a nurse|Women with hyperprolactiemia scheduled for cabergoline therapy 0.5 mg twice weekly for one month plus health education by a nurse.
10194068|NCT04262024|Active Comparator|cabergoline without health education by a nurse|Women with hyperprolactiemia scheduled for cabergoline therapy 0.5 mg twice weekly for one month without health education by a nurse.
10194069|NCT04238299||Main study cohort|Patients with CKD recruited from specialist nephrology clinics
9779320|NCT05307523|Active Comparator|Enriched Environment Play Without Harness Support|Enriched environment play, movement, and exploration without additional partial body weight support provided.
9984482|NCT04055389|Experimental|AT-III treatment|
9984483|NCT04055389|Placebo Comparator|Placebo|
10194070|NCT04226911|Experimental|Sweeteners and sweetness enhancers (S&SEs)|Healthy diet < 10 energy % (E%) sugar, foods and drinks with S&SEs allowed.
10194071|NCT04226911|Active Comparator|Sugar group|Healthy diet, < 10 E% sugar, foods and drinks with S&SEs not allowed.
10194072|NCT04222426|Experimental|89Zr-atezolizumab PET scan|All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. The 89Zr-atezolizumab PET scan will be performed 4 days after tracer injection. Procedures within the ImaGelato study will be completed after the two 89Zr-atezolizumab PET scans, but patients will continue treatment with carboplatin combined with atezolizumab in the GELATO trial.
10194073|NCT04220814|Experimental|Patients|
10194074|NCT04220814|Other|Healthy Volunteer|
10194075|NCT04213820|Active Comparator|Treatment as usual|Participants will receive treatment as usual at the eating disorder unit at the Child and adolescent psychiatric clinic and at the Psychiatric clinic during 4 weeks.
10194076|NCT04213820|Experimental|TMS and body image intervention|Participants will receive TMS and a body image intervention daily 5 times/week during 4 weeks
10194077|NCT04213820|Sham Comparator|sham TMS and body image intervention|Participants will receive sham TMS and a body image intervention Daily 5 times/week during 4 weeks
9709708|NCT04642664|Experimental|Apatinib plus Camrelizumab|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
9709709|NCT04642625||wound infiltration analgesia|25 patients who underwent wound infiltration analgesia
9709710|NCT04642625||ultrasound-guided bilateral erector spina plan block analgesia|25 patients who underwent ultrasound-guided bilateral erector spina plan block analgesia
9709711|NCT04642625||wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia both together|25 patients who underwent wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia
9709712|NCT04642716|Other|Salivary free amino acids profile observation|Saliva samples of periodontitis patients and healthy controls were collected. The AA analysis of the saliva was performed by LC-MS/MS by using the Thermo Scientific TSQ Quantum Access MAX (Thermo Scientific, Schaumburg, IL, USA) .
9709713|NCT04642729|Other|ReLex Smile surgery|The myopic lenticule after Relex Smile surgery is put into BBS solution for 10 min. Under topical anesthesia, Using VisuMax Femtosecond Laser.
9709714|NCT04642729|Other|fresh corneal lenticule implantation|Using VisuMax Femtosecond Laser we make intrastromal pocket incision 2-3 mm in periphery of cornea (Because the macular dystrophy is in the center more progressive) and 150 µm deep to put fresh corneal lenticule. After one month using VisuMax we create a flap using autologous serum with purpose to remove more dead keratocytes and adding live keratocytes with aim to regenerate the metabolism of cornea.
9709715|NCT04642807|Active Comparator|"Group 1 Long-arm full cast and routine follow-up"|Patients assigned to Group 1 will be placed in a long arm cast, at 90-100 degrees in neutral rotation. A referral will then be made to the orthopedic department and the patient reviewed at week 3 with cast removal, clinical assessment and radiographic assessment as determined by the normal practice at the local center.
9709716|NCT04642807|Experimental|"Group 2 Long-arm soft cast and no clinical or radiographic follow-up"|"Patients assigned to group 2 will be placed in a long arm cast at 90-100 degrees in neutral rotation. They will be given verbal and written information on the injury, when and how to remove the cast and contact details if there are any concerns.~Since they will not be attending clinical follow-up, an email or telephone survey will be undertaken at 3 weeks and after 6 months. The survey will inquire initially about pain, unplanned returns to the Family Physician and hospital, complications, parent/patient satisfaction and a standardized patient reported outcome score will be taken. Please see attached documentation for the itemized survey questions. The 6 month follow-up will include photographs and an illustrated guide will be given to the families on how to obtain pictures of maximal flexion, extension and the child's carrying angle (attached). Measurements of range of motion from photographs are considered comparable to clinical assessment of range of motion"
9709717|NCT04642742||Plant sterol chewable|
9709718|NCT04642586|Experimental|Hypertensive participants|diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure;
9709719|NCT04642586|Experimental|Normotensive participants|absence of HTA confirmed by Ambulatory Blood Pressure Measure
9709720|NCT04642612||Treatment Arm|Patients ages 18-85 years old presenting with orthopedic shoulder surgery with indication to receive preoperative insertion of interscalene nerve block.
9709721|NCT04642521||Iron deficiency anaemia|Preoperatively, participants who are iron deficient with or without anaemia will receive intravenous iron (Monofer) as per ProPBM protocol.
9709722|NCT04642521||No iron deficiency anaemia|Patient in this group will not be given intravenous iron.
9709723|NCT04642755||Group 1|LTBI+ and severe to moderate malnutrition
10194078|NCT04206995||Evaluation of odour capturing techniques|To evaluate two odour capturing techniques to compare VOC profiles of cancerous and healthy skin cancer.
10194079|NCT04203303||Observational|Observational
10194080|NCT04202757|Active Comparator|Young Fresh Frozen Plasma (yFFP)|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
9709724|NCT04642755||Group 2|LTBI+ and uncontrolled DM
9709725|NCT04642755||Group 3|LTBI+ and helminth infection
9709726|NCT04642755||Group 4|LTBI+ with more than one of the above conditions (severe to moderate malnutrition, DM, helminth infection)
9709727|NCT04642755||Group 5|"Healthy LTBI+ controls who are negative for all of the above conditions (severe to moderate malnutrition, DM, helminth infection)"
9709728|NCT04642755||Group 6|Healthy LTBI negative controls with none of the above conditions (severe to moderate malnutrition, DM, helminth infection).
9709729|NCT04642599|Experimental|Chronic Cerebellar Stroke|Participants with a chronic cerebellar stroke
10194081|NCT04202757|Placebo Comparator|Saline|0.1% riboflavin in normal saline
10194082|NCT04200196|Experimental|"Fabrique à histoire"|"Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the fabrique à histoire (Lunii(R)) arm in addition to the routine anaesthetic cream patch."
10194083|NCT04200196|Active Comparator|Usual care|Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the habitual care arm in addition to the routine anaesthetic cream patch.
10194084|NCT04195204|Experimental|Tropisetron|Patients allocated to this arm will receive intravenous Tropisetron (5mg) before anesthesia induction and once daily for 7 days after surgery.
10194085|NCT04195204|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of normal saline before anesthesia and once daily for 7 days after surgery.
9709730|NCT04642599|Active Comparator|Healthy Individuals (Controls)|healthy participants
9709731|NCT04642547|Experimental|Combination therapy with Lenvatinib and Gefitinib|First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight > 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight > 60Kg). Route of administration: Oral.
9709732|NCT04642768|Experimental|3-Hydroxybutyrate treatment|KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus
9709733|NCT04642768|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
10194086|NCT04183894|Experimental|Personalized Intervention Based on Network|Participants will receive personalized interventions based on their personalized network.
10194087|NCT04183101|Experimental|Aliskiren treatment|Patients will be randomized to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for 6 months. After 6 months the patients will be switched to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for the coming 2,5 years.
10194088|NCT04183101|Active Comparator|Enalapril treatment|Patients will be randomized to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for 6 months. After 6 months the patients will be switched to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for the coming 2,5 years.
9709734|NCT04642495||Human subjects aged 4 and above|Human volunteers aged 4 and above.
9709735|NCT04642248|Active Comparator|Non-intervention|This group will have the analysis and their data will be used to determine risk factors for developing running injuries.
9709736|NCT04642248|Experimental|Intervention|This group will get a personalized program based off of 3D and movement analysis results to judge the ability to reduce musculoskeletal injuries.
9709737|NCT04642261|Experimental|Empagliflozin group|Empagliflozin 10mg daily for 52 weeks
9709738|NCT04642261|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks
9709739|NCT04642417|Experimental|Experimental|intervention give experience dietary fiber literacy
9709740|NCT04642417|No Intervention|No Intervention|give standard education
9709741|NCT04642456|Other|Control group|"Healthy subjects or volunteers~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis EOS stereoradiographic full body exam"
9709742|NCT04642456|Other|ASD group|"Patient group with ASD~Intervention:~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis 2 EOS stereoradiographic full body exam Balance Assesment Scale 2 Trunk strength measurement with EMG 2"
9709743|NCT04642339|Experimental|Vaccine Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2 infection
9709744|NCT04642339|Placebo Comparator|Placebo|Placebo
9709745|NCT04642300|Active Comparator|Holmich Protocol|Treatment will be administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions
9709746|NCT04642300|Active Comparator|Myofascial Release Technique|Treatment wiil be given twice a week as individual treatment by the physiotherapist. The duration of treatment is about 30 min.
9709747|NCT04642391||RAI|Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol <9mcg/dL.
9709748|NCT04642391||Non-RAI|Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol >= 9mcg/dL.
9709749|NCT04642313|Placebo Comparator|PLACEBO group|Placebo treatment: starch tablets (250 mg)
9709750|NCT04642313|Experimental|Magnesium group|Magnesium group: Magnesium gluconate (250 mg)
9709751|NCT04642313|Experimental|Potassium group|Potassium group: Potassium chloride (250 mg)
9709752|NCT04642313|Experimental|Magnesium + Potassium group|Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)
9709753|NCT04642482|Experimental|Synbiotic|"A fine powder to be taken orally consists of~Viable cell 1,0 x 10^9 Colony Forming Unit of :~Lactobacillus plantarum 8,55 mg~Streptococcus thermophilus 8,55 mg~Bifidobacterium bifidum 2,55 mg~Fructooligosaccharide 480 mg~Additional components : isomalt, xylitol"
9709754|NCT04642482|Active Comparator|Placebo|A powder of 5 gram maltodextrin is given as active comparator, taken orally.
9709755|NCT04642508|Other|Prepectoral Reconstruction|Women with breast cancer or with high risk for breast cancer in whom a sparing mastectomy and prepectoral reconstruction was performed
9709756|NCT04642066|Experimental|Active Group|Healthy volunteers were followed during the 5-month CWI exposition under standard conditions (three times per week 7-10 min). Neoprene equipment was not allowed; volunteers with followed weight or muscle mass changes over 5% were excluded
9709757|NCT04642066|Sham Comparator|Sham control|Control without CWI exposition
9709758|NCT04642235|Experimental|Nature Nook|Nature Nook builds on our prior work with a standard vacant lot greening intervention involving: removing trash, grading the land, planting new grass and trees, installing a low wooden perimeter fence, and regular maintenance. This greening intervention was designed as a blight removal strategy. People in this arm receive no intervention.
9709759|NCT04642235|Experimental|Nature Coach|The Nature Coach intervention, developed in a prior study (NCT04146025), will be delivered to people in their homes. Participants will live in the blocks immediately surrounding the study vacant lots randomized to this arm. The lots in this arm receive no intervention.
9709760|NCT04642235|Experimental|Nature Nook + Nature Coach|This is a combined arm: a place-based intervention (Nature Nook) and a person-based intervention (Nature Coach).
9709761|NCT04642235|No Intervention|Control|The study lots randomly selected for this arm, as well as the participants living near them, receive no intervention.
9709762|NCT04642209||Aggregometry|surgical timing will be guided by the results obtained by aggregometry
10194089|NCT04170374||Patients who initiated HIV treatment|
10194090|NCT04170374||Service providers at study facilities|
10194091|NCT04151966||Cardioversion Group|Subjects scheduled to undergo direct current cardioversion (DCCV) as part of the clinical plan of care
10194092|NCT04151953||Subjects with cardiac implantable electronic device (CIED)|Subjects with previously implanted cardiac implantable electronic device (CIED) who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
10194093|NCT04142320|Experimental|Closed-loop rTMS|Closed-loop rTMS will be delivered to determine the target engagement compared to open-loop rTMS. Closed loop rTMS will be applied for two consecutive days for 30 minutes to determine dose response. Closed- loop rTMS will be delivered using neuro-navigation based on participants' own MRI images. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
10194094|NCT04142320|Active Comparator|Open-loop rTMS|A series of open-loop rTMS protocols will be delivered to determine the most effective standard and individualized rTMS. Active rTMS will be delivered using neuro-navigation based on participants' own MRI images. For each clinically-utilized rTMS protocol (1Hz, 5Hz, 10Hz, 20Hz), 3000 pulses will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
10194095|NCT04142320|Placebo Comparator|Sham rTMS|Sham rTMS will be delivered for two consecutive sessions to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
10194096|NCT04133012|Other|Single Arm|Single arm composed by 34 HIV-1 infected male subjects
9709763|NCT04642222|Experimental|APOLO-Teens Intervention Group (APOLO-Teens group)|In addition to the Treatment As Usual for pediatric obesity offered in Portuguese public hospitals, participants in this group receive the APOLO-Teens web-based intervention. It comprises three key components: 1) a manualized psychoeducational intervention implemented via Facebook® private groups, including cognitive-behavioral therapy strategies; 2) A weekly self-monitoring system (the APOLO-Teens web application) with automatic feedback messages assessing hours of physical activity, sedentary time, and consumption of fruits and vegetables; and 3) Monthly chat sessions.
9709764|NCT04642222|Active Comparator|Treatment As Usual (TAU) Control Group (TAU control group)|Treatment As Usual control group receives the standard intervention for pediatric obesity offered in Portuguese public hospitals. It comprises pediatric or/and nutritional appointments, usually a 30-minute appointment every 3 months. These appointments usually include a physical examination (weight, height) and personalized dietary/lifestyle recommendations. The Treatment As Usual intervention is common to the APOLO-Teens group and TAU control groups.
9709765|NCT04642131|Experimental|Personalized insoles|Personalized insoles without supplementation
9709766|NCT04642131|Experimental|Caffeine supplementation|Standard insoles with caffeine supplementation (3mg/kg)
9709767|NCT04642131|Placebo Comparator|Control condition|Standard insoles without supplementation
9709768|NCT04642560||Usual practice|Any child hospitalized in Pediatric or Neonatal ICU and receiving systemic (intravascular, intramuscular or oral) antibiotic treatment for an episode of suspected or proven community-acquired or nosocomial bacterial infection
9709769|NCT04642443|Active Comparator|Intracranial Hemorrhage|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~A molded plastic headpiece containing the antenna array~An intermediate control unit that contains:~a. The driving electronics for the array of antennae~A processing control unit that contains:~A spectrum analyzer~The operating software that controls the device function and data acquisition, processing and archiving.~The user interface for inputting patient information and displaying the output of the data"
9709770|NCT04642443|Active Comparator|Traumatic Brain Injury|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:~A molded plastic headpiece containing the antenna array~An intermediate control unit that contains:~a. The driving electronics for the array of antennae~A processing control unit that contains:~A spectrum analyzer~The operating software that controls the device function and data acquisition, processing and archiving.~The user interface for inputting patient information and displaying the output of the data"
9709771|NCT04642326|Experimental|Test Group: experimental - UVC Therapy applied|Test: Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy
9709772|NCT04642326|No Intervention|Control Group|Control: Antiviral + Antimalarial + Antibiotic Treatment
9709773|NCT04642157|Experimental|ELIOS group|In addition to receiving the same generic mental health resources as in the control group, the participants of the ELIOS arm will benefit from the intervention of the ELIOS team.
9709774|NCT04642157|Other|control group|Participants of the control arm will receive generic professional help contacts.
9709775|NCT04642118|Experimental|Pulmonary recruitment maneuver 30 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 30 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
9709776|NCT04642118|Active Comparator|Pulmonary recruitment maneuver 40 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 40 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
9709777|NCT04642118|No Intervention|Control|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will not be received any positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist."
9709778|NCT04642105|Experimental|Hospital-based study|The investigators will select 15 patients with refractory focal epilepsy who are admitted to the videoEEG room for longterm videoEEG recording as part of a presurgical evaluation. The Sensor-Dot and Plug 'n Patch recordings will be compared with the gold-standard videoEEG recordings.
9709779|NCT04642105|Experimental|Home-based study|The investigators will select 30 patients with refractory focal epilepsy, 15 patients with refractory idiopathic generalized epilepsy and 15 patients with frequent tonic-clonic seizures, i.e. a group at increased risk for sudden unexpected death in epilepsy (SUDEP).
9709780|NCT04641897|Other|Sequence A|Sequence A: Low RR for 12 hours - High RR for 12 hours
9709781|NCT04641897|Other|Sequence B|Sequence B: High RR for 12 hours - Low RR for 12 hours.
9709782|NCT04641923|Experimental|Seprafilm|Antiadhesion barrier applied
10194097|NCT04126551||Lean, healthy control|Lean, healthy control subjects. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
9709783|NCT04641923|No Intervention|No seprafilm|No barrier applied
9709784|NCT04642040|Experimental|Pulmonary Rehabilitation|Patients are included in a personalized pulmonary telerehabilitation program consisting of patient education, respiratory and peripheral muscle training, and breathing strategies for 4 weeks. In the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. Patients will also receive instructional exercise videos for these 3 days.
9709785|NCT04642001|Other|Group G1|Photon Laser III-DMC (without radiation emission) + My First- Colgate
9709786|NCT04642001|Experimental|Group G2|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rápido Alívio/GSK
9709787|NCT04642001|Experimental|Group G3|Photon Laser III-DMC (with irradiation emission) + My First- Colgate
9709788|NCT04642001|Experimental|Group G4|Photon Laser III-DMC (with irradiation emission) + Sensodyne® Rápido Alívio/GSK
9709789|NCT04642144|Experimental|Yerba mate and carbohydrate|Consumption of yerba mate infusion and carbohydrate-based meal.
9709790|NCT04642144|Active Comparator|Yerba mate and fasting|Consumption of yerba mate infusion and stay in a fasting state.
9709791|NCT04642144|Active Comparator|Carbohydrate and water|Carbohydrate meal consumption and water intake.
9709792|NCT04641754|Experimental|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
9709793|NCT04641845|Experimental|Heel height increases|All participants consecutively walked with four heel height conditions (0 millimeter, 3 millimeter, 5 millimeter and 8 millimeter). The order of the heel height conditions was randomized.
9709794|NCT04641676|Other|Foundation medicine NGS in parallel with local NGS|The patient will have in parallel FMI NGS test and Local reimbursed NGS test.
9709795|NCT04641676|Other|Foundation Medicine NGS|The patient will have only FMI NGS test.
9709796|NCT04641676|Experimental|LB Foundation Medicine NGS test|The patient do not have enough biopsy material or have tumor not accessible for a biopsy will have a liquid biopsy Foundation Medicine test.
9709797|NCT04641663|Experimental|100 RDD|100% of recommended daily dose (RDD) of the MORNING tablet dose (5 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
9709798|NCT04641663|Experimental|80 RDD|80% of recommended daily dose of the MORNING tablet dose (4 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
9709799|NCT04641663|Experimental|60 RDD|60% of recommended daily dose of the MORNING tablet dose (3 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
9709800|NCT04642092|Experimental|PsicAP protocol|The treatment of the experimental group will be according to the PsicAP protocol: seven sessions of a psychological treatment based on transdiagnostic approaches, collaborative interventions, group-sessions, and evidence-based psychological techniques derived from cognitive behavioral therapy.
9709801|NCT04642092|Active Comparator|Conventional treatment|The control group will have seven sessions based on the typical psychological services that currently are offered in the Dominican Primary Care Units.
9709802|NCT04641780||Rexulti Tablets|Target is 300 patients in the Philippines diagnosed with Schizophrenia and Major Depressive Disorder
9709803|NCT04641832|Experimental|Chronic cannabis use and subconcussive head impacts|"Group: Chronic cannabis users Criteria: self-reported chronic THC use (average use once per week but not dependent). Urine cannabis test must show positive.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
9709804|NCT04641832|Active Comparator|Non-cannabis use and subconcussive head impacts|"Group: Non cannabis users Criteria: self-reported none THC use. Urine cannabis test must show negative.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
9709805|NCT04641624||Premature ovarian insufficiency (POI)|"POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotrophins and low estradiol.~The study population will be consisted of 45 women with POI as study group."
9709806|NCT04641624||Control group|45 patients with normal healthy women as control group.
9709807|NCT04641546|Experimental|Occupation-Based Intervention + Therapeutic Exercise Intervention Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of 30 minutes therapeutic exercise followed by 30 minutes of occupation-based intervention.
9709808|NCT04641546|Experimental|Therapeutic Exercise Control Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of therapeutic exercise only.
10194098|NCT04126551||Overweight/obese nondiabetic|Overweight/Obese nondiabetic subjects. Overweight and obesity will be defined using the standard body mass index cutoffs. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
10194099|NCT04126551||Type 2 diabetes|Participants with type 2 diabetes will be diagnosed accordingly to ADA criteria. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
9709809|NCT04641585|Experimental|Patients affected by Brugada Syndrome 1|Patients with spontaneous or drug-induced Brugada Syndrome 1
9709810|NCT04641585|Active Comparator|Controls|Patients with no condition associated with spontaneous or drug-induced Brugada Syndrome 1
9709811|NCT04641793|Experimental|SCI|
10194100|NCT04117295|Experimental|Treatment|Subjects implanted with the Carmat TAH
10194101|NCT04110522|Experimental|Intervention with Direct Access to Rheumatologist|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation
9709812|NCT04641793|Experimental|STROKE|
9709813|NCT04641793|Experimental|UNIMPAIRED|
9709814|NCT04641689|Active Comparator|Desk Only|Participants will receive a height-adjustable desk to use in their home work environment.
9709815|NCT04641689|Active Comparator|Program Only|Participants will receive 12 weeks of online content to support reductions in sedentary behavior while working from home. Content will be based on social cognitive theory.
9709816|NCT04641689|Experimental|Desk + Program|Participants will receive a height-adjustable desk to use in their home work environment AND 12 weeks of online content to support reductions in sedentary behavior while working from home.
9709817|NCT04641689|No Intervention|Waitlist Control|Participants will receive the intervention (desk + program) after all follow-up data have been collected.
9709818|NCT04641572|No Intervention|Supine position|group A ( control ) will follow the hospital routine positions either supine or lateral during labor
9709819|NCT04641572|Experimental|Upright position|Group B (intervention) will follow the Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions. Then the researcher will register the time ( minutes/hours) that will be taken and which will be more preferable by the participant.
9709820|NCT04641468|Other|Mediana 010 or 001 left main bifurcation lesion|DCB alone combined with retracted DES implantation if necessary (d-p-d strategy)
9709821|NCT04641533|Experimental|L-PRF + DPSC|Mandibular third molars were extracted and DPSC with L-PRF placed into the socket.
9709822|NCT04641533|Active Comparator|L-PRF|Mandibular third molars were extracted and L-PRF placed into the socket
9709823|NCT04641429|Experimental|Qigong|Participants in the experimental group receive Qigong exercise training.
9709824|NCT04641429|Active Comparator|stretching|Participants in the control group receive stretching exercise training.
9709825|NCT04641806||Lymphoma cases|Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. Past history of B-cell NHL in remission, active surveillance or during first-line or second-line treatment Affiliated with a social security, consenting to the study
9709826|NCT04641806||Controls|"Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. No past history of lymphoma .~Affiliated with a social security, consenting to the study"
9709827|NCT04641611|Active Comparator|Cavoatrial cannulation|Cannulation of the atrium with 2-stage venous cannula.
9709828|NCT04641611|Experimental|Bicaval cannulation|"Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. No slush added. This technique is used in Right heart procedure (Pulmonic and tricuspid valve) and mitral valve procedures.~This technique is not routinely used in CABG operations."
9709829|NCT04641494|Placebo Comparator|Placebo|28 subject received 2 capsules 3times a day for 12 weeks Each capsule contain 1gm (High Oleic Acid Safflower oils)
9709830|NCT04641494|Active Comparator|CLA group|Participants received 2 capsules3 times a day for 12 weeks Each capsule is 1 gm and it provided 0.75 gm CLA in a 50:50 mixture
9709831|NCT04641741||Control|Healthy adults
9709832|NCT04641741||Severe eosinophilic asthma|Severe uncontrolled asthma according to ERS/ATS criteria and persistent eosinophilia in blood (>300 cells/μL)
9709833|NCT04641598|Experimental|Endometrial scratch|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The cervix will be grasped with a single tooth tenaculum and an endometrial biopsy pipelle inserted into the uterine cavity to the depth of the uterine fundus. Suction will be applied and the pipelle will be completely withdrawn in a single pass. All instruments will be removed from the vagina after hemostasis is ensured.
9709834|NCT04641598|Sham Comparator|Sham procedure|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The motions of grasping the cervix with a single tooth tenaculum and inserting the biopsy pipelle will be simulated, but not actually performed. All instruments will then be removed from the vagina.
9709835|NCT04641416||Noninvasive pump monitoring|All patients with the HeartMate 3 system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria will be included.
9709836|NCT04641364|Placebo Comparator|Control: placebo|Subjects received 0.9% sodium chloride injection.
10194102|NCT04110522|Experimental|Intervention with Standard of Care Referral|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist
10194103|NCT04110522|No Intervention|Control|Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire
10194104|NCT04104555|Active Comparator|Usual supportive care - exercises and footwear advice|"OSTRICH main trial:~Participants will be offered an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
9709837|NCT04641364|Active Comparator|Control: Human Serum Albumin(HSA)|Subjects received Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
9709838|NCT04641364|Experimental|Experimental:recombinant human albumin|Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study. For the multiple dose study, subjects received recombinant Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
9709839|NCT04641377|Experimental|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
9709840|NCT04641377|Active Comparator|Health education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
9709841|NCT04641481|Experimental|Study vaccine|BBV152B (6µg-Algel-IMDG)
9709842|NCT04641481|Placebo Comparator|Placebo|Phosphate buffered saline with Alum (without antigen)
9709843|NCT04641455|Experimental|A mucolytic solution|mucolytic solution - 100 ml of water + 600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long), 320 mg of simethicone (8 ml of Espumisan sir. 40 mg / ml)administered 20-30 minutes prior to upper endoscopy
9709844|NCT04641455|Active Comparator|B mucolytic solution|mucolytic solution-100 ml water + 400 mg N-acetylcysteine (2 tablets 200 mg ACC long), 20 mg simethicone (0.5 ml Espumisan sir. 40 mg / ml) administered 20-30 minutes prior to upper endoscopy
9709845|NCT04641455|Placebo Comparator|C Water|100 ml of water 20-30 minutes prior to upper endoscopy
9709846|NCT04641455|No Intervention|D No intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
9709847|NCT04641104|Experimental|Thiamine|Patients in this arm will receive a solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9%.
9709848|NCT04641104|Placebo Comparator|Placebo|Patients in this arm will receive a solution of 100 ml of NaCl 0.9% alone.
9709849|NCT04641039|Active Comparator|Anterior annulus removal|In these patients the anterior portion of the annulus fibrosus will be removed when inserting a complete lumbar disc prosthesis
9709850|NCT04641039|Active Comparator|Anterior annulus replacement|In these group of patients the anterior portion of the annulus fibrosus will be opened up in to flaps hinged lateraly and replaced once the complete lumbar disc prosthesis is inserted
9709851|NCT04641013||People with HIV over the age of 55 years|
9709852|NCT04641013||People without HIV over the age of 55 years|
9709853|NCT04641130|Experimental|Exposure to birch pollen|"Step 1: dose validation 16 subjects are exposed for 2 consecutive days (D1 + D2), to the same aerial concentration of Bet v1.~The main objective is achieved if the Abelson score is ≥ 5 on J1 or J2. If the main objective is achieved for the 60 ng/m3 concentration, 8 responder subjects will directly perform step 2.~If the main objective is not achieved for the 60 ng/m3 concentration, the subjects will be exposed between 7 to 10 days after exposure 1, to an allergen concentration of 120 ng/m3 (Exposure 2: D1 + D2).~Step 2: reproducibility Once the allergen concentration has been determined (step 1), 8 of the responder subjects from step 1 are exposed again to this same concentration, during 2 additional exposures (Exposure 3: D1 + D2 and Exposure 4: D1 + D2), at least 7 days apart.~A wash-out period of at least 7 days is observed between step 1 and 2. The duration of allergen exposure will be a maximum of 4 hours for all exposures."
9709854|NCT04641325|Experimental|Exercise Intervention Group|Group of up to 20 patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
9709855|NCT04641117|Experimental|Exercise|Six months of power training
9709856|NCT04641078|Experimental|Arm A|SBRT + 6 months of darolutamide (600 mg b.i.d.)
9709857|NCT04641078|Other|Arm B|SBRT only
9709858|NCT04641338|Experimental|Intervention group|
9709859|NCT04641338|Active Comparator|Control group|
9709860|NCT04641065|Experimental|Music Intervention Group|The music intervention group will be listened to Traditional Turkish Military music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
9709861|NCT04641065|No Intervention|No Intervention Group|The control group patients will receive standard care only
9709862|NCT04641052|Experimental|Music Intervention Group|The music intervention group will be listened to the music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
9709863|NCT04641052|No Intervention|No Intervention Group|The control group patients will receive standard care only
9709864|NCT04641026|Active Comparator|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
9709865|NCT04641026|Active Comparator|Deuterium oxide-labeled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
9709866|NCT04641026|Placebo Comparator|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
9709867|NCT04641026|Placebo Comparator|Deuterium oxide-labeled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
9709868|NCT04641390||Casos|altered vaginal microbiome resistant to drug treatment
9709869|NCT04641390||Controles|Altered vaginal microbiome not resistant to drug treatment
9709870|NCT04641390||semen donors|The semen donors included in the present work will be men between 18 and 35 years old who are included in the donation program of Instituto Bernabeu after having passed a series of physical, psychological, analytical, genetic and serological evaluations and are considered suitable for donation as established by Royal Decree-Law 9/2014. Likewise, donors are subjected to a series of seminal quality evaluations and seminal freeze-thaw tests in order to guarantee their fertile potential. In this way, the donors who are part of the Instituto Bernabeu donation program also comply with current legal regulations with a strict evaluation to be considered the gold standard of potentially fertile semen. In addition, it will be necessary for them to provide a signed informed consent accepting their participation in the study.
9709871|NCT04641234||Cohort 1|Adult Belgian patients diagnosed with neovascular age-related macular degeneration (nAMD) with treatment-naïve study eye.
9709872|NCT04641351|Experimental|corticosteroid|"Triamcinolone extended release (32 mg) administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.~Knee injury and Osteoarthritis Outcome Score (KOOS) pain at 6 and 12 months~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months~3D bone shape from MRI Osteoarthritis Knee Score (MOAKS) using statistical shape modeling at 3 and 12 months~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
9709873|NCT04641351|Placebo Comparator|Placebo|"Normal saline of 5 mL administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.~KOOS pain at 6 and 12 months~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months~3D bone shape from MRI using statistical shape modeling at 3 and 12 months~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
9709874|NCT04641299|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection.
9709875|NCT04641299|Experimental|AZD8233 high dose|AZD8233 high dose for subcutaneous injection.
9709876|NCT04641299|Experimental|AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
9709877|NCT04641299|Experimental|AZD8233 low dose|AZD8233 low does for subcutaneous injection.
9709878|NCT04641286||Stroke|Individuals admitted to the Hyper Acute Stroke Unit.
9709879|NCT04641182||Prone position|Prone position per institutional protocol and as indicated by the treating physician
9709880|NCT04641182||No prone position|The control group will not be in prone position
9709881|NCT04641403|No Intervention|Group 1 (Standard IV analgesia group (SA), n=40):|In this group, the block will be administered with normal saline (NS) and all port sites will be infiltrated with NS.
9709882|NCT04641403|Active Comparator|Group 2 (Local analgesia group (LA), n=40):|In this group, the block wiil be administered with NS and local anesthetic will be administered to the port sites.
9709883|NCT04641403|Experimental|Group 3 (two qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, right sided two-quadrant block will be performed using bupivacaine.
9709884|NCT04641403|Experimental|roup 4 (Four qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, bilateral four-quadrant block will be performed using bupivacaine.
9984484|NCT04054648|Active Comparator|Bedtime Antihypertensive Medications|The LTC facility's pharmacist will switch all once daily antihypertensive medications, one at a time as tolerated, to bedtime. Blood pressure lowering medications taken more than once per day are left alone.
9709885|NCT04641247|Experimental|Participants receiving niraparib|Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
9709886|NCT04641169|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
9709887|NCT04640896|Sham Comparator|Lidocaine skin wheal|They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
9709888|NCT04640896|Active Comparator|Trigger point injection with normal saline|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
9709889|NCT04640896|Experimental|Trigger point injection with bupivacaine|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine HCl + intra- and postoperative standardized analgesia regimen
9984485|NCT04054648|No Intervention|Morning Antihypertensive Medications|No change to blood pressure medication timing is made. By default, most patients are using once daily antihypertensive medications in the morning at baseline.
10194105|NCT04104555|Experimental|Prefabricated, off-the-shelf orthoses|"OSTRICH main trial:~A pair of prefabricated, off-the-shelf orthoses (i.e. mass produced to a generic shape but can be adapted by a clinician) plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
10194106|NCT04104555|Experimental|Signposting to multimedia|OSTRICH 'signposting to multimedia' Study within a trial (SWAT) Participants will be given signposting to multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
10194107|NCT04104555|Experimental|Multimedia|OSTRICH ' signposting to multimedia' Study within a trial (SWAT) Participants will be given signposting to multimedia trial information resources.
9709890|NCT04640883|Experimental|Sprints during low-intensity cycling|
9709891|NCT04640883|Active Comparator|Low-intensity cycling|
9709892|NCT04640766|Experimental|Participants with ADHD|
9709893|NCT04640740|Experimental|anterolateral approach (ALA)|anterolateral surgical approach of total hip arthroplasty
9709894|NCT04640740|Experimental|posterior approach (PA)|posterior surgical approach of total hip arthroplasty.
9709895|NCT04640649|Experimental|Prediction Algorithm|Patients in the test arm will have a screening visit, then will come for two follow-up visits, at 3 months (if the algorithm determines high-risk of conversion within 3 months) and 6 months.
9709896|NCT04640649|No Intervention|Control|Patients in the control arm will have a screening visit, then will come for one follow-up visit, at 6 months (standard care) only.
9709897|NCT04640805|No Intervention|Control group (standard fortification)|Pasteurized Donor Human Milk (PDHM) will be fortified as per unit protocols, at 1 packet of Human Milk Fortifier (Similac) to every 25ml PDHM at a feed volume of 80ml/kg/day
9709898|NCT04640805|Experimental|Intervention group (modified targeted fortification)|Pasteurized Donor Human Milk (PDHM) will be analyzed using the Miris Human Milk Analyzer, and PDHM with a fat content of 3.8g/dL or higher will be selected. Additional protein will be added using liquid protein fortifier (Similac) at 1ml to every 25ml PDHM to give an additional 0.67g/dL protein.
9709899|NCT04640831|Experimental|GH001 dose A|
9709900|NCT04640831|Experimental|GH001 dose B|
9709901|NCT04640831|Experimental|GH001 dose C|
9709902|NCT04640831|Experimental|GH001 dose D|
9709903|NCT04640831|Experimental|GH001 Individualized Dosing|
9709904|NCT04640662|Experimental|Platelet-Rich plasma|2 ml PRP using commercial kit- YCell Biokit
10194108|NCT04104555|No Intervention|no signposting to multimedia|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will not be given a pen or signposting to multimedia trial information resources in the participant information sheet, when sent to the OSTRICH recruitment pack.
10194109|NCT04104555|Experimental|Birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a standard birthday card on or shortly before their birthday to encourage completion of questionnaires..
9709905|NCT04640662|Active Comparator|Prolotherapy|2 ml 16.5% Dextrose solution
9709906|NCT04640844|Experimental|patients hospitalized|for surgery of the aorta and / or arteries of the lower limbs.
9709907|NCT04640519|Experimental|TASC Intervention|TASC patients will receive a BP monitoring kit and electronic tablet and tailored infographics, and attend 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
9709908|NCT04640519|Active Comparator|TASC Control|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
9709909|NCT04640610||Adenoidectomy / tonsillectomy|Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the centers of the study.
9709910|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 1|"TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
9709911|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 2|"TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
9709912|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 1|"TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
9709913|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 2|"TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
9709914|NCT04640532|Experimental|Cohort 3 (JAKi Intolerant MF)|KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
9709915|NCT04640558||Group 1. Latent Myofascial Trigger Point Group|24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.
9709916|NCT04640558||Group 2. Non-Latent Myofascial Trigger Point Group|24 participants who don't have latent myofascial trigger point.
9709917|NCT04640480|Experimental|Cohort 1|Dosage 1
9709918|NCT04640480|Experimental|Cohort 2|Dosage 2
9709919|NCT04640480|Experimental|Cohort 3|Dosage 3
10194110|NCT04104555|Experimental|Birthday card informed by nudge theory|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a birthday card informed by nudge theory to encourage completion of questionnaires.
10194111|NCT04104555|No Intervention|No birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will not be sent a birthday card during the trial.
10194112|NCT04103931|No Intervention|Usual Care|Participants will receive usual care and will not get the decision aid to review.
10194113|NCT04103931|Experimental|Patient Decision Aid|"Participants in this arm will receive the patient decision aid, titled Treatment Choices for Aortic Stenosis to review."
10194114|NCT04101903|Experimental|Diagnostic Aid|The experimental group will use the trial diagnostic aid for all 6-week infant hip checks
9709920|NCT04640480|Experimental|Cohort 4|Dosage 4
9709921|NCT04640480|Experimental|Cohort 5|Dosage 5
9709922|NCT04640480|Experimental|Cohort 6|Dosage 6
9709923|NCT04640389||Urban|Urban adolescents living in Moshi District, Tanzania, who are between 10-14 years of age.
9709924|NCT04640389||Rural|Rural adolescents living in Kilosa District, Tanzania, who are between 10-14 years of age.
9709925|NCT04640467||Pregnant women|Women with uncomplicated singleton pregnancy who are planning a vaginal delivery, gestational age from 36 ± 0/7 weeks until onset of active labor (cervical dilatation ≤ 4cm) and cephalic presentation
9709926|NCT04640207|Experimental|Facial skin treatment|Facial skin treatment using the Alma Hybrid system.
9709927|NCT04640233|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)
9709928|NCT04640233|Placebo Comparator|Control Group|Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21
9709929|NCT04640181|Active Comparator|Adaptive Dosing: Enoxaparin|"Low 40mg subcutaneous (SQ) daily, or~Intermediate 40mg SQ q12 hours, or~Therapeutic 1mg/kg SQ q12 hours"
9709930|NCT04640181|Active Comparator|Adaptive Dosing: Rivaroxaban|"Low 10mg po daily~Intermediate 10mg po daily~Therapeutic 20mg po daily"
9709931|NCT04640441|No Intervention|Control group|Participants in the control group received usual care.
9709932|NCT04640441|Experimental|Sit-to-stand care group|Intervention was provided once daily by trained nurses for a maximum of 14 days or until hospital discharge or death.
9709933|NCT04640051||LAAO group|Patients scheduled for LAAO with Amplatzer Amulet (Abbott) and for whom a 3D in silico simulation by FEops HEARTguide is available and reviewed before implantation
9709934|NCT04640116|Experimental|TIPS combined with microwave ablation|
9709935|NCT04640129|Active Comparator|TDF group|tenofovir 300mg taken orally per day.
9709936|NCT04640129|Experimental|peg-IFN-α plus TDF group|peg-IFN-α 180ug given subcutaneous injection per week combined with tenofovir 300mg taken orally per day .
9709937|NCT04640324|No Intervention|NAFLD wild type control group|Consisted of not treated NAFLD wild type patients
9984486|NCT04053049|Active Comparator|High fat/ Semi-solid|Subject will receive a high fat/semi-solid meal.
9709938|NCT04640324|Active Comparator|NAFLD wild type treated group|Consisted of NAFLD wild type patients treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
9709939|NCT04640324|Experimental|NAFLD mutated treated group|Consisted of NAFLD patients carrying at least one mutation among PNPLA3, TM6SF2, MBOAT7 genes, treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
9709940|NCT04640103||adjuvant therapy|Patients who received immunotherapy in adjuvant treatment stage only
9709941|NCT04640103||neoadjuvant therapy|Patients who received immunotherapy in neoadjuvant treatment stage and achieved R0 resection
9709942|NCT04640311|Experimental|Part A: Daprodustat Dissolution 1/Dissolution 2/Reference|
9709943|NCT04640311|Experimental|Part A: Daprodustat Dissolution 2/Reference/Dissolution 1|
9709944|NCT04640311|Experimental|Part A: Daprodustat Reference/Dissolution 1/Dissolution 2|
9709945|NCT04640311|Experimental|Part B: Daprodustat Process 1/ Process 2|
9709946|NCT04640311|Experimental|Part B: Daprodustat Process 2/ Process 1|
9709947|NCT04640285|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS Tobacco Flavor Period 2 - RELX ENDS Menthol Flavor Period 3 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 4 - Usual Brand Cigarette
9709948|NCT04640285|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS Menthol Flavor Period 2 - Usual Brand Cigarette Period 3 - RELX ENDS Tobacco Flavor Period 4 - Nicorette White Ice Mint Nicotine Polacrilex Gum
9709949|NCT04640285|Experimental|Product Use Sequence 3|Period 1 - Usual Brand Cigarette Period 2 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 3 - RELX ENDS Menthol Flavor Period 4 - RELX ENDS Tobacco Flavor
9709950|NCT04640285|Experimental|Product Use Sequence 4|Period 1 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 2 - RELX ENDS Tobacco Flavor Period 3 - Usual Brand Cigarette Period 4 - RELX ENDS Menthol Flavor
9709951|NCT04639921|Experimental|active - placebo|intake of socalled gluten bars two daily for seven days, followed by one week wash-out, and then placebo bars for seven days
9709952|NCT04639921|Placebo Comparator|placebo - active|intake of placebo bars two daily, followoed by wash-out for one week, and gluten bars (experimental) for seven days.
9709953|NCT04639869|Experimental|Phenyramydol then Cabral|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
9709954|NCT04639869|Active Comparator|Cabral then Phenyramydol|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
9709955|NCT04639869|Experimental|Phenyramydol then Cabral Replicate|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
9709956|NCT04639869|Active Comparator|Cabral then Phenyramydol Replicate|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
9709957|NCT04639934||Breast cancer patients|Breast cancer patients being seen at SingHealth
9709958|NCT04640090|Experimental|Smartphone app|All participants in this single-arm study will receive two months of subsidized, full access to the smartphone wellness application.
9709959|NCT04639908||barriers|find out what are the barriers
9984487|NCT04053049|Active Comparator|High carbohydrate/ Semi-solid|Subject will receive a high carbohydrate/semi-solid meal.
9984488|NCT04053049|Active Comparator|High fat/ solid|Subject will receive a high fat/solid meal.
9984489|NCT04053049|Active Comparator|High carbohydrate/ solid|Subject will receive a high carbohydrate/solid meal.
9709960|NCT04639908||facilitators|find out what are the facilitators
9709961|NCT04640064||Patient with type 1 diabetes|Children younger than 17 years with a diagnosis of type 1 diabetes prior to 2018 will be included.
9709962|NCT04640337|Experimental|Group E1: IPE applied, participants believe they are receiving IPE.|IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
9709963|NCT04640337|Placebo Comparator|Group E2: IPE applied, participants believe they are receiving placebo.|IPE will be applied following the standard protocol for PT. Subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
9709964|NCT04640337|Placebo Comparator|Group P1: IPE not applied, participants believe they are receiving IPE.|The needle will be inserted under the skin but the current will not be passing through. The subjects will see a shame video on the ultrasound screen so they will believe that the IPE is being performed.
9709965|NCT04640337|Placebo Comparator|Group P2: IPE not applied, participants believe they are receiving placebo.|The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
9709966|NCT04639895|Experimental|Virtual Reality|Standard treatment protocol and 12 sessions (30 minutes each) of personalized cognitive activities in a virtual city environment (Reh@City).
9709967|NCT04639895|Experimental|Paper and Pencil|Standard treatment protocol and 12 sessions (30 minutes each) of personalized paper-and-pencil cognitive activities,using the Task Generator tool.
9709968|NCT04639895|Active Comparator|Control Group|The standard treatment protocol.
9709969|NCT04639791||Severe asthma patients|on step 4& 5 of GINA treatment
9709970|NCT04639739|Experimental|anti-CD19 CAR NK cells|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
9709971|NCT04639700|Experimental|Psycho-educational intervention|All participants will receive receive 4 individual sessions with an interventionist in addition to the standard post-hospital HSCT information for patient follow-up care as provided by the patient's oncologist
9709972|NCT04639817||Levofloxacin targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.
9709973|NCT04639817||TMP/SMX targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.
9709974|NCT04639882|Experimental|Control-Remote-$0|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure remotely~are compensated $0 for completing the baseline and intervention procedure"
9709975|NCT04639882|Experimental|Control-Remote-$30|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure remotely~are compensated $30 for completing the baseline and intervention procedure"
9709976|NCT04639882|Experimental|Control-InPerson-$0|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure in the research lab~are compensated $0 for completing the baseline and intervention procedure"
9709977|NCT04639882|Experimental|Control-InPerson-$30|"In this condition, Participants:~receive attention control feedback~complete the baseline and intervention procedure in the research lab~are compensated $30 for completing the baseline and intervention procedure"
9709978|NCT04639882|Experimental|PNF-Remote-$0|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure remotely~are compensated $0 for completing the baseline and intervention procedure"
9709979|NCT04639882|Experimental|PNF-Remote-$30|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure remotely~are compensated $30 for completing the baseline and intervention procedure"
9709980|NCT04639882|Experimental|PNF-Inperson-$0|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure in the research lab~are compensated $0 for completing the baseline and intervention procedure"
9709981|NCT04639882|Experimental|PNF-Inperson-$30|"In this condition, Participants:~receive personalized normative feedback~complete the baseline and intervention procedure in the research lab~are compensated $30 for completing the baseline and intervention procedure"
9709982|NCT04639596|Experimental|MBTS|It will consist of four hours of sailing and mindfulness training at the Jordanelle Reservoir. Boats and skippers will be provided by Park City Sailing Association, a non-profit community organization.
9709983|NCT04639596|Experimental|SRT|SRT will occur on four separate occasions during the summer of 2019. SRT will consist of 4 hours of bowling at a community bowling alley.
9709984|NCT04639804|Active Comparator|Tegoprazan 50 mg|Multiple doses of tegoprazan alone once daily (QD) for 7 days
9709985|NCT04639804|Active Comparator|NSAIDs|Multiple doses of NSAIDs alone twice daily (BID) for 7 days
9709986|NCT04639804|Active Comparator|Tegoprazan 50 mg + NSAIDs|Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days
9709987|NCT04639856|Active Comparator|on-pump CABG|CABG using Cardiopulmonary Bypass Machine
9709988|NCT04639856|Active Comparator|off-pump CABG|CABG without Cardiopulmonary Bypass Machine
9709989|NCT04639570|Experimental|KneuroKnits group|Participants in the KneuroKnits group
9709990|NCT04639557|Experimental|Virtual Intervention|Mothers in this group will participate in 16, once per week, scheduled 2-hour virtual group therapy sessions through Zoom for Healthcare. These sessions will include both visual media (e.g., presentations, recorded examples of skills), and discussions. A technician will be present in the virtual group therapy session to manage the technical component. These sessions will be supplemented with a 1-hour drop-in session moderated by a facilitator each week in which participants will be able to clarify topics for that week, discuss the material in more depth, and/or connect with other participants to share about the skill practice.
9979951|NCT01386840|Experimental|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
9709991|NCT04639557|Experimental|Therapy Intervention Pre-recorded|Mothers in this group will have access to short pre-recorded videos of the presentations with facilitator commentary (i.e., 10-12 minutes) with additional video material as warranted each week (e.g., recorded examples of skill practice) for a maximum of 30-minutes of material per week. This arm will also have a 1-hour drop-in session each week with a group facilitator to moderate homework check-ins and discussion of the material.
9709992|NCT04639687|Experimental|Immediate intervention|If randomized to this group, household of child and participating caregiver receives 12 weekly deliveries of vegetables plus added whole grains, along with text messages containing links to cooking instruction videos
9709993|NCT04639687|Other|Wait list control (delayed intervention)|If randomized to this group, participants do not get any intervention activities for the first 12 weeks, and their outcome data at V2 contribute as controls. For ethical reasons, this low-income population ultimately gets the intervention (food)later, and data after they receive the intervention contributes to follow-up data only.
9709994|NCT04639349|Experimental|Exercised group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
9709995|NCT04639349|Other|control group|The control group will not be trained
9709996|NCT04639544|Placebo Comparator|Control group|Volunteers will take 1 capsule per day with maltodextrin for 6 months
9709997|NCT04639544|Experimental|Probiotic group|Volunteers will take 1 capsule per day with the Lactobacillus strain for 6 months
9709998|NCT04639362|Experimental|Intensification|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
9709999|NCT04639362|Experimental|Observation|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
9710000|NCT04639232|Placebo Comparator|Control group|Volunteers will take 6 capsules per day for 28 days a capsule containing maltodextrin.
9710001|NCT04639232|Experimental|Prob-milk|Volunteers will take 6 capsules per day for 28 days a capsule containing the probiotics combination.
9710002|NCT04639232|Experimental|Voluntas-Prob|Volunteers will take 6 capsules per day for 28 days a capsule containing the combination of plant extracts and the inactivated probiotic strain
9710003|NCT04639583|Experimental|Observational Arm|Any infant consented to participate in the study will have the NIRS applied for the first 96 hours of life. It will be the goal to apply the NIRS sensors in the first 12 hours of life. All infants will have the same treatment if in the study, but clinicians will not be able to see the data obtained so that there is no clinical interpretation during this time.
9710004|NCT04639609|Experimental|Group 1 : Patients|
9710005|NCT04639609|Other|Group 2 : healthy volunteers|
9710006|NCT04639674|Experimental|AST-120|"sachet Three times a day. (2g/pack*3pack/box)~1 month"
9710007|NCT04639674|No Intervention|Control|No intervention
9710008|NCT04639323||Overall eligible participants|Eligible participants whose varix size will be measured by endoscopists and endoscopic ruler will receive standard esophagogastroduodenoscopy
9710009|NCT04639401|Experimental|persons with Multiple Sclerosis|
9710010|NCT04639401|Placebo Comparator|Healthy controls|
9710011|NCT04639284||Combinational therapy|Participants who receive systemic treatment with an anti-angiogenic agent, including sorafenib, lenvatinib, apatinib, and bevacizumab, in combination with an anti-PD-1/PD-L1 antibody, including pembrolizumab, nivolumab, sintilimab, toripalimab, camrelizumab, tislelizumab, and atezolizumab.
9710012|NCT04639726|Active Comparator|Whey Protein|
9710013|NCT04639726|Placebo Comparator|Placebo|
9979952|NCT01386853|Experimental|Pitavastatin|
9979953|NCT01386853|Active Comparator|Atorvastatin|
9979954|NCT01386866|Experimental|A|
9979955|NCT01386879|Experimental|TaperGuard Evac ETT|Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
9710014|NCT04639297|Experimental|NeuroVision® IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
9710015|NCT04639297|Active Comparator|Conventional hospital based IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
9710016|NCT04639440||Obese or overweight patients|
9710017|NCT04639440||Patients without overweight|
9710018|NCT04639765|No Intervention|No video|This condition involves no video presentation.
9710019|NCT04639765|Experimental|CBT without Personalization|Video provides information about cognitive behavioral therapy.
9710020|NCT04639765|Experimental|CBT with Personalization|Video provides information about cognitive behavioral therapy and describes how treatment can be personalized.
9710021|NCT04639765|Experimental|ADM without Personalization|Video provides information about antidepressant medications.
9710022|NCT04639765|Experimental|ADM with Personalization|Video provides information about antidepressant medications and describes how treatment can be personalized.
9710023|NCT04639765|Experimental|Combined Treatment without Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications.
9710024|NCT04639765|Experimental|Combined Treatment with Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications and describes how treatment can be personalized.
9710025|NCT04639271|Experimental|Pyrotinib Plus Trastuzumab And Abraxane|Pyrotinib Plus Trastuzumab And Abraxane
9710026|NCT04639375|Experimental|Vaccinated with polio vaccine (IPV)|All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States
9710027|NCT04639492|Experimental|MBS oral solution|fermented soybean extract-MBS
9710028|NCT04639453||Stroke|Individuals with post-stroke hemiparesis in subacute phase will be included in the study.
10194115|NCT04101903|No Intervention|Standard of Care|The control group will assess infants according to standard practice, during the 6-week hip check. This group will receive a leaflet about the national best practice recommendation for this check.
9710029|NCT04639180|Experimental|Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))|Drug: Camrelizumab; Drug: Rivoceranib (Apatinib)
9710030|NCT04639180|No Intervention|Control group (Active surveillance)|
9710031|NCT04639076|Active Comparator|Behavioral Weight Loss Group|Participants in this arm will receive a standard behavioral weight loss approach that recommends a calorie deficit based on starting weight, a standard activity minute goal progression based on baseline activity and standard behavioral weekly counseling.
9710032|NCT04639076|Experimental|Personalized Behavioral Weight Loss Group|Participants in this arm will receive a personalized weight loss approach that recommends either a low carbohydrate or low fat calorie reduced diet; personalized activity plan with either daily or weekly bout-related goals; and eating frequency of either 3 times per day or 5-6 times per day.
9710033|NCT04639154|Placebo Comparator|control group|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of NaCl 0.9% will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB
9710034|NCT04639154|Active Comparator|tramadol 50|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 50 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
9710035|NCT04639154|Active Comparator|tramadol 100|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 100 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
9710036|NCT04638985|Experimental|group 1 (sIPV+DTaP+MMR)|150 subjects; simultaneously administration of sIPV+DTaP+MMR as booster immunization at the age of 18 months old, 0.5 ml each, respectively
9710037|NCT04638985|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
9710038|NCT04638985|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
9710039|NCT04638985|Active Comparator|group 4 (MMR)|150 subjects; vaccination of 0.5 ml MMR as booster immunization at the age of 18 months old
9710040|NCT04638907||Observational study group|Consenting adult male patients undergoing elective robot-assisted prostatectomy. No further selection or randomisation. Enrollment as availability for the study.
9710041|NCT04639128|No Intervention|No-Device|No placement of an adductor canal catheter
9710042|NCT04639128|Experimental|Device|Placement of an adductor canal catheter
9710043|NCT04638816|Experimental|Restylane Volyme|Hyaluronic Acid
9710044|NCT04638816|Experimental|Restylane Lyft Lidocaine|Hyaluronic Acid
9710045|NCT04638855|Experimental|Medicurtain®|Treat Medicurtain 5ml prefilled syringe after hysteroscopy surgery
9710046|NCT04638855|Sham Comparator|Placebo|No device after hysteroscopy surgery
9710047|NCT04639037|Active Comparator|Manual adjustment of vasopressor|Fluid and vasopressor will be managed as standard practice guided by the EV1000 monitoring device (manually infusion of both fluid and vasopressors) Objective being to maintain MAP within a target MAP range of 80-90 mmHg (fluid will be optimized and stroke volume index will be maintained within normal values)
9710048|NCT04639037|Experimental|Automated adjustment of vasopressor|Fluid will be managed using the EV1000 monitoring in order to optimize stroke volume index and vasopressor will be automatically deliver by a closed-loop system to maintain the MAP within the target range of 80-90 mmHg
9710049|NCT04638738||Pre-implementation|Pre-implementation of digital alerting sensor systems
9710050|NCT04638738||Post-implementation|Implementation of digital alerting sensor systems
9710051|NCT04639167|Experimental|Paths to everyday life (PEER)|The Paths to everyday life (PEER) intervention added to service as usual (SAU) consists of a 10-week group course and an opportunity of individual companionship to persons with mental vulnerability and mental health difficulties. The 10 week group sessions is facilitated by two volunteer peers with their own lived experiences with mental vulnerability.
9710052|NCT04639167|No Intervention|Service as usual (SAU)|Participants who will be allocated to the control group of the trial will receive service as usual (SAU) by their social security officer, or no specific service if the participant has been referred to the trial by self-referral. Participants who are referred to the trial via §82 in the municipality, can receive other §82 offers depending on the individual municipality.
10194116|NCT04088981|Active Comparator|Low-fat, vegan diet|For a 22-week period, participants will be asked to follow a low-fat vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
9710053|NCT04639193|Experimental|Placebo, then Dual-Therapy, then Single/Triple-Therapy|"Subjects will start with a 3-day PLACEBO regimen:~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day EXPERIMENTAL DUAL-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
9710054|NCT04639193|Experimental|Dual-Therapy, then Placebo, then Single/Triple-Therapy|"Subjects will start with a 3-day EXPERIMENTAL DUAL-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day PLACEBO regimen:~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
9710055|NCT04638712|Other|Group 1 without trastuzumab|
9710056|NCT04638712|Other|Group 2 with trastuzumab|
9710057|NCT04638972||Tactile Sense Method|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
9710058|NCT04638972||Radiographic Method (digital periapical radiography)|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
9710059|NCT04638972||Ipex® EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
9710060|NCT04638972||Propex® pixi EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
9710061|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and PFC|
9710062|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and sham rTMS over PFC|
9710063|NCT04638777|Sham Comparator|Sham rTMS over M1 and PFC|
9710064|NCT04638933||OSA patients|Patients with proven OSA (apnea-hypopnea index ≥20/h, ESS >10, age ≥18 years) and initiation of CPAP treatment
9710065|NCT04638556||Normal|A healthy, disease-free population.
9710066|NCT04638556||T2DM|T2DM group was simple type 2 diabetes mellitus.
9710067|NCT04638556||DPN|The screening criteria for T2DM patients with DPN are as follows: 1. Clear history of type 2 diabetes mellitus. 2. Neuropathy at or after the diagnosis of diabetes. 3. The clinical symptoms and signs were consistent with those of DPN. Clinical symptoms include: numbness or sensation; tingling or tingling; pain; abnormal sensitivity or tenderness after touching. 4. Examination: A. abnormal temperature sense; B. 10 g nylon thread examination, foot sensation decreased or disappeared; C. abnormal vibration sense; D. ankle reflex disappeared; e. two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement). 5. Nerve injury caused by other diseases or drugs was excluded. Two of the above five items were abnormal, or clinical symptoms + 1 item were abnormal.
9710068|NCT04638790|Experimental|Early favorable HL|HL without adverse prognostic factors
9710069|NCT04638790|Experimental|Early unfavorable HL|Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)
9710070|NCT04638790|Experimental|Advanced stages HL|(age less than 50 years)
9710071|NCT04638868|Experimental|Isolation of circulating tumor cells|Both portal venous and peripheral blood will be obtained from the patient and subjected to analysis for pancreatic cancer circulating tumor cells
9710072|NCT04639115|Experimental|Ozanimod in subjects with mild hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with mild hepatic impairment
10194117|NCT04088981|Active Comparator|Portion-controlled diet|For a 22-week period, participants will be asked to follow a portion-controlled diet which will include individualized diet plans that reduce daily energy intake by 500 kcal for overweight participants, and keep carbohydrate intake reasonably stable over time. It will derive 50% of total energy from carbohydrates, 20% from protein, and less than 30% from fat (≤7% saturated fat), with less than 200 mg/day of cholesterol/day.
9710073|NCT04639115|Experimental|Ozanimod in subjects with moderate hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with moderate hepatic impairment
9710074|NCT04639115|Experimental|Ozanimod in healthy subjects|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in healthy subjects
10194118|NCT04084626|Experimental|PD-1 antibody|PD-1 antibody and lenalidomide administered in 2 week cycles for 6 cycles.
10194119|NCT04083534|Experimental|REGN5459|Cohorts of multiple REGN5459 dose levels
10194120|NCT04082533|Active Comparator|Stiffness Intravenous Hydrocortisone|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
9710075|NCT04639063||Cesarean sectioned|All females who treated in our hospital by Cesarean section operation during two-years-period
10194121|NCT04082533|Placebo Comparator|Stiffness Intravenous Placebo|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
9710076|NCT04639063||Complicated with Abdominal wall endometriosis|All the surgically excised endometrioma cases during the same time period
9710077|NCT04638582|Experimental|Neoadjuvant pembrolizumab + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
9710078|NCT04638582|Experimental|Neoadjuvant pembrolizumab and chemotherapy + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles in combination with standard of care histology-specific chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
9710079|NCT04638764|Active Comparator|Aerobic interval training with high loads resistance training|"Patient to be randomised into combined aerobic training with high loads resistance training group."
9710080|NCT04638764|Active Comparator|Aerobic interval training with low loads resistance training|"Patient to be randomised into combined aerobic training with low loads resistance training group."
9710081|NCT04638764|Active Comparator|Aerobic interval training|"Patient to be randomised into aerobic training training group."
9710082|NCT04638959||GC|patients diagnosed with GC
9710083|NCT04638959||HC|patients diagnosed with chronic gastritis by histopathology
9710084|NCT04638751||NSCLC|Stage 3 or stage 4 non-small cell lung cancer patients, being administered checkpoint inhibitor therapy for the first time. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
9710085|NCT04638751||Triple-negative breast cancer|Stage 3 or stage 4 metastatic triple-negative breast cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
9710086|NCT04638751||Colorectal cancer|Stage 3 or stage 4 colorectal cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
9710087|NCT04638751||Pancreatic cancer|Stage 3 or stage 4 pancreatic cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
9710088|NCT04638530|Other|Residents|All residents will participate in the activity
9785171|NCT01244529|Other|seno A / galy A / glay A Plus|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
9979956|NCT01386879|Experimental|Teleflex ISIS ETT|Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
10194122|NCT04082533|Active Comparator|Non-stiff Intravenous Hydrocortisone|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
9710089|NCT04638595||Normative|50 neurotypical pediatric subjects
9710090|NCT04638517|Active Comparator|Danazol|800mg daily in two divided doses orally for 12 months. In subjects who have difficulty tolerating danazol / placebo, the dose will be reduced by 200mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200mg/day dose reductions will be allowed until a tolerated dose is achieved. Background antifibrotic therapy is allowed.
9710091|NCT04638517|Placebo Comparator|Placebo|Matching placebo capsules.
9710092|NCT04638361||No laryngeal mobility disorder post cardiac surgery|No Follow up, no questionnaires and no nasofibroscopic control.
9710093|NCT04638361||Laryngeal mobility disorder post cardiac surgery|During a follow-up consultation, questionnaires will be offered to assess the child's quality of life.
9710094|NCT04638322|Experimental|HIFT Group|This group receives physical training based on exercises of high intensity interval functional training.
9710095|NCT04638322|No Intervention|No intervention group|This group does not receive any treatment.
9710096|NCT04638348|Experimental|New Biofeedback|Women allocated to the new biofeedback group will be instructed to attach the biofeedback device to their underpants and then perform pelvic floor muscle training.
9710097|NCT04638348|Active Comparator|Conventional Biofeedback|Women allocated to the conventional biofeedback group will undergo pelvic floor muscle training with the conventional biofeedback probe inserted in the vagina
9710098|NCT04638348|Active Comparator|Control group|The control group will perform pelvic floor muscle training without any biofeedback device.
9710099|NCT04638387|Experimental|PB125|Twice daily oral administration of 1 capsule of PB125 (Pathways Bioscience). Treatment will last 12 weeks.
9710100|NCT04638387|Placebo Comparator|Placebo|Twice daily oral administration of 1 capsule of rice flour placebo (Pathways Bioscience). Treatment will last 12 weeks. Because of pandemic restricting study time frame, enrollment will favor the experimental arm in this pilot study
9710101|NCT04638335||travelers over the age of 60|blood sample taken to test the presence of Anti-HAV antibodies
9710102|NCT04638335||travelers having lived in a tropical country for more than 5 years|blood sample taken to test the presence of Anti-HAV antibodies
10194123|NCT04082533|Placebo Comparator|Non-stiff Intravenous placebo|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
9710103|NCT04638400|Active Comparator|Simvastatin|Obese subjects with elevated cholesterol
10194124|NCT04081337|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
9979957|NCT01386879|Active Comparator|Standard ETT|Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)
10194125|NCT04081337|Placebo Comparator|Placebo|Placebo administered SC.
10194126|NCT04078568|Active Comparator|the standard group|"IVIG 2g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
10194127|NCT04078568|Experimental|the standard+prednisolone group|"IVIG 2g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued."
10194128|NCT04059406|Experimental|IONIS TMPRSS6-LRx|A single injection of IONIS TMPRSS6-LRx at multiple dose levels, administered subcutaneously every 4 weeks
10194129|NCT04046497|Experimental|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
9710104|NCT04638400|Active Comparator|Ezetimibe|Obese subjects with elevated cholesterol
9710105|NCT04638608|Other|EMBRACE (Relatives)|Feasibility test of a new palliative rehabilitation blended learning program for relatives of people with ALS/cognitive impairments
9710106|NCT04638608|Other|EMBRACE (Health care providers)|Feasibility test of a new palliative rehabilitation blended learning program health care providers helping people with ALS/cognitive impairments
9710107|NCT04638179||HF-PAC|(1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.
9710108|NCT04638179||HF-non PAC|(2)The control group received traditional health education in general care and routine health care.
9979958|NCT01386892||Healthy Volunteer|Healthy Volunteer without lung disease
10194130|NCT04046497|Active Comparator|Usual Care|Usual care provided at CSC clinic
10194131|NCT04019002|Experimental|Cohort 1: Newly Diagnosed- Standard Treatment|"This arm is for patients with histologically proven newly diagnosed glioblastoma who will undergo standard treatment with radiation therapy (RT) and temozolomide (TMZ).~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at two time points: before receiving standard treatment with RT/TMZ and at the first post-radiation follow-up scan (8 weeks later)."
10194132|NCT04019002|Experimental|Cohort 2: Recurrent- Standard Surgical Resection|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will receive surgical resection for the recurrence.~Patients will receive one injection of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at one time point: before surgery."
9710109|NCT04638127|Experimental|PREEMIE PROGRESS|PREEMIE PROGRESS is an innovative, video-based intervention that applies evidence-based family management theories to better equip parents to meet the chronic, complex healthcare needs of their preterm infant.
9710110|NCT04638127|Active Comparator|Attention Control|"To maintain their attention, control parents will view Welcome Videos that explain hand hygiene, visitor IDs, parking, etc. on their mobile devices."
9710111|NCT04638543|Experimental|ABP-671|The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing.
9710112|NCT04638543|Placebo Comparator|Placebo|
9710113|NCT04638504||11-14 weeks of normal pregnancy.|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
10194133|NCT04019002|Experimental|Cohort 3: Recurrent- Standard Treatment|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will undergo standard treatment for the recurrence.~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at three time points: prior to treatment (baseline), approximately 7-14 days after the initiation of treatment, and 6-8 weeks after the initiation of treatment."
10194134|NCT04016454|Experimental|Intervention group|No handover of anesthesia care
9710114|NCT04638504||11-14 week obese pregnant|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
9710115|NCT04638504||24-28 week normal pregnant|24-28. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery, and maternal uterine artery dopes will be examined ultrasonographically.
10194135|NCT04016454|No Intervention|Control group|Complete handover of anesthesia care
9710116|NCT04638504||24w-28w obese normal pregnant|24w-28w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
9710117|NCT04638504||37w -40w normal pregant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
9710118|NCT04638504||37-40 w obese normal pregnant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
9710119|NCT04637984|Experimental|Implementation Group|Predictions will be provided to the rehabilitation team and discussed with the patient and their family. Patients will receive a multidisciplinary rehabilitation according to their individual needs.
9710120|NCT04637984|No Intervention|Control Group|This group will not received any information on the PREP2
9710121|NCT04638101|Experimental|Intervention group (RCT)|Participants from the intervention group participated in the mindfulness-based intervention between Time 1 and Time 2.
9710122|NCT04638101|Experimental|Waiting group (RCT)|Participants from the waiting group took part in the mindfulness-based intervention between Time 2 and Time 3.
9710123|NCT04638491|Experimental|single-arm|PM01183-Dose Escalation
9710124|NCT04638049|Active Comparator|Prostate (Bed) only RadioTherapy (PBRT)|Primary, adjuvant or salvage RT of the prostate (bed) without RT of the pelvic nodal regions in the small pelvis, according to local hospital guidelines and protocols.
9710125|NCT04638049|Active Comparator|Whole Pelvis RadioTherapy (WPRT)|Primary, adjuvant or salvage RT of the pelvic nodal regions in the small pelvis with possible additional RT of the prostate (bed), according to local hospital guidelines and protocols.
9710126|NCT04638140||Healthy hip population|
9710127|NCT04638140||Hip defect population|
9710128|NCT04638114|Experimental|CAM lesion|Mini-Open DAA Hip Arthroscopy
9710129|NCT04638114|Other|PINCER impingement|Mini-Open DAA Hip Arthroscopy
9710130|NCT04638296||Physicians|surgeons, anesthesiologists, and surgical residents
9710131|NCT04638296||Nurses|OR Nurses
9710132|NCT04638439|Experimental|P1101 + Nivolumab + Entecavir|
9710133|NCT04638075|No Intervention|Group A Bottle Supplementation|Group A will supplement using the bottle. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the bottle per standard of care. The mother will breastfeed for up to 25 minutes and then will offer a bottle to supplement breastfeeding for at least 5 minutes. Time at the breast and with the bottle might vary based on the neonate's ability to stay awake at the breast and to sustain a latch at the breast. The type of supplementation will be either Expressed Breast Milk (EBM), Donor Human Milk (DHM), formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of bottle use will be determined by the neonate's physician. The mother will return the neonate to their crib then pump and hand express after feeding sessions per the IBCLC's recommendation. The mother will document each feeding session in the feeding log provided at the bedside.
9785172|NCT01244529|Other|seno A / galy A Plus / galy A|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A -subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
9785173|NCT01244633|Experimental|Ecopipam|Active treatment
10194136|NCT04009005|No Intervention|Usual care|Participants will receive usual care from their treating neurologist
10194137|NCT04009005|Experimental|Therapeutic Lifestyle|Participants will be trained via videos from a three day in-person seminar that teaches the public about the use of a therapeutic diet and lifestyle to reduce multiple sclerosis related fatigue and improve quality of life.
10194138|NCT04000035|Experimental|Health in work|The interdisciplinary Health in work intervention consists of three information sessions over the course of one year, with work place processes in between. In the meetings, structured health information about musculoskeletal- and mental disorders is given and put in the context of working and the specific workplace. It is an integrated intervention where information is given together by both healthcare- and NAV-personnel.
10194139|NCT04000035|Active Comparator|Regular work place measures|Regular work place measures offered by NAV workplace service. Those are interventions given by NAV personnel without healthcare involvement and can be varying.
10194140|NCT03987126|Active Comparator|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)"
9710134|NCT04638075|Experimental|Group B SNS Supplementation|Group B will supplement using the SNS. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the SNS per standard of care. The mother will assemble the SNS, place it clamped and in position at the nipple prior to breastfeeding (see SNS instructions for use). The mother will initiate breastfeeding for up to 5 minutes and then unclamp the SNS to begin supplementation for up to 25 minutes. The SNS will contain either EBM, DHM, formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of SNS use will be determined by the neonate's physician. The mother will pump and hand express after feeding sessions per the IBCLC's recommendation. Them mother will document each feeding session in the feeding log provided at the bedside.
9710135|NCT04638244|Experimental|BOMI Group (Intervention Group)|Listening to an expert-selected, theory-guided and self-chosen song each day actively in a personalized and focused way (Brief Online Music Intervention: BOMI) for 3 months
9710136|NCT04638244|Active Comparator|POM Group (Control Group)|Receiving psychoeducational online message (POM) (for focused reading for 5 minutes) daily for 3 months
9710137|NCT04637997|Other|Study group 1|Wearing of compression stockings class I between Investigation day 28 to 56. Wearing of compression stockings class II between Investigation day 56 to 84.
9710138|NCT04637997|Other|Study group 2|Wearing of compression stockings class II between Investigation day 28 to 56. Wearing of compression stockings class I between Investigation day 56 to 84.
9710139|NCT04637971|Experimental|Coaching|The present intervention is a structured, group-based coaching program that is facilitating an active process of change through the identification of achievable personal goals, the formulation of action plans, the provision of constructive feedback, and progressive monitoring of goal attainment.
9710140|NCT04637971|Active Comparator|Self-help tips plus telephone support|Self-help tips including stress coping methods. Our project staff will contact the subject to encourage her to make use of the tips we sent her.
9710141|NCT04638192|Experimental|subject-specific tACS|Constant current (1mA) will be applied for 20min at subject-specific stimulation frequency and latency
9710142|NCT04638192|Experimental|standard tACS|Constant current (1mA) will be applied for 20min at 20Hz with a fixed 25ms latency
9710143|NCT04638192|Sham Comparator|Sham tACS|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect
9710144|NCT04638452|Other|Epidemiology|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test Passing self and hetero questionnaires of temotion felt and perceived.
9710145|NCT04638010|Experimental|Cancer control navigation (CNN) plus General referral (usual care)|"Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.~Additionally, Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only."
9710146|NCT04638010|Active Comparator|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
9710147|NCT04638270|Experimental|anti-CD19 FasT CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.~3×10^5 /KG 6×10^5 /KG 1×10^6/KG"
9710148|NCT04637789|Other|controlled group|
9710149|NCT04637789|Experimental|experimental group|
9710150|NCT04638166|Experimental|Mineral water group|The mineral water group were instructed to consume 1.25L of a commercially supplied bicarbonate rich mineral water per day at meal times, supplemented by other fluid intake up to 2.5 - 3L/day.
9710151|NCT04638166|Active Comparator|Plain water group|The plain water group consumed only plain water up to 2.5 - 3L/day.
9710152|NCT04637802|Active Comparator|Pre-operative and Post-operative Education intervention|This arm receives access to Patient Education intervention in the pre- and post-operative phases.
9710153|NCT04637802|Experimental|Pre-operative CBT intervention (SurgeryPal), Post-operative Education intervention|This arm receives access to CBT intervention in the pre-operative phase and Patient Education in the post-operative phase.
9710154|NCT04637802|Experimental|Pre-operative Education intervention, Post-operative CBT intervention (SurgeryPal)|This arm receives access to Patient Education intervention during the pre-operative period and CBT intervention during the post-operative period.
9710155|NCT04637802|Experimental|Pre-operative and Post-operative CBT intervention (SurgeryPal)|This arm receives access to CBT intervention during the pre-operative and post-operative period.
9710156|NCT04638218|Experimental|Augmented Reality|The system provides visual and audio feedback which makes the rehabilitation training process more relaxing, interesting and convenient to guide the patients performing appropriate upper-limb, lower-limb exercises and balance training.
9710157|NCT04638036|Experimental|NIR endoscopy and surgery with cetuximab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, cetuximab-IRDye800CW will be administered to a total of 15 patients with proven locally advanced rectal cancer
9710158|NCT04637685|Active Comparator|Standard pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 70mmHg
9710159|NCT04637685|Active Comparator|Low or physiological pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 30mmHg
9710160|NCT04638257|Experimental|Lactobacilli|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14 Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
10194141|NCT03987126|Placebo Comparator|Placebo|"10 g sachet, self-administered for 3 months.~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
9710161|NCT04638257|Placebo Comparator|Placebo|Receives placebo
9710162|NCT04638426|Experimental|Treatment A|HL237 tab. 200mg/day
10194142|NCT03985371|Experimental|Drops Used|
10194143|NCT03979365|Active Comparator|Tacrolimus twice-daily|Subjects assigned to this arm will take tacrolimus two times daily by mouth, at the clinically prescribed dose.
9979959|NCT01386918|Experimental|Low frequency left (LFL) sided rTMS|LFL rTMS was administered at an intensity of 115% resting motor threshold at 1HZ for 20 minutes. The treatment targeted the left temporoparietal cortex (TPC).
10194144|NCT03979365|Active Comparator|Envarsus XR|Subjects assigned to this arm will take Envarsus XR one time daily by mouth, at the clinically prescribed dose.
10194145|NCT03962465|Experimental|3-drug re-induction regimen with inotuzumab|"One cycle of a 3-drug regimen comprised of standard doses of prednisone, vincristine, and daunorubicin with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
9710163|NCT04638426|Experimental|Treatment B|HL237 tab. 400mg/day
9710164|NCT04638426|Experimental|Treatment C|HL237 tab. 800mg/day
9710165|NCT04638426|Placebo Comparator|Placebo|Placebo of HL237 tab.
9710166|NCT04637906|Experimental|L-arginine|Bioarginina®, 2 orally administered vials per day
9710167|NCT04637906|Placebo Comparator|Placebo|2 orally administered vials per day of Bioarginina® without L-arginine
9710168|NCT04637737|Experimental|Training group|
9710169|NCT04637737|Other|Control group|
9710170|NCT04637750|Experimental|Educational intervention|Randomised GPs will receive the low cost informative intervention composed by a practitioner-focused letter plus leaflet for patients
9710171|NCT04637750|No Intervention|Control group|GPs not receiving any informative intervention
9710172|NCT04637633|Experimental|Cyclosporine A|All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
9710173|NCT04637919|Experimental|IN-B001 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
9710174|NCT04637919|Experimental|IN-B001 CVA16 B dose|Inactivated CVA16 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
9710175|NCT04637919|Experimental|IN-B001 Bivalent C dose|Inactivated EV71/CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
9710176|NCT04637867|Other|RT-PCR confirmed COVID-19 patients|RT-PCR confirmed patients included in the NOSO-COR study are invited six and 12 months after the initial infection to provide blood (41.5mL in total), salivary and nasopharyngeal samples and to complete a questionnaire. Each visit is expected to take about one hour.
9710177|NCT04637958||pain|THA
9710178|NCT04637958||no pain|THA
9710179|NCT04637828|Experimental|GNS561 plus standard of care|All patients in this Arm will be treated with 200mg oral capsule of GNS561, once a day, for 10 days and with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
9710180|NCT04637828|No Intervention|standard of care|All patients in this Arm will be treated with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
9710181|NCT04637854|Experimental|Operating Microscope.|"Surgical technique is the same used for extraction of the lower third molar. Patients will be enrolled (baseline) whenever sign their written informed consent to participate to the study, after having read and understand the informative pamphlet.~The intervention will be performed under local anesthesia (mepivacaine 20 mg/ml with adrenaline 1:100000) and by the use of microscope.~At the end of the surgical procedure, all patients will receive a 100mg Nimesulide cpr and apply the ice pack on the cheek.~At the end of each procedure will give post-operative instructions for all patients and prescribe an antiseptic therapy with chlorhexidine coll. 0.2% 3 times/ day for 10 days from the day following the intervention and anti-inflammatory therapy Nimesulide 100 mg cpr to take up to 2 times / day for up to 4 days.~Each patients will be recalled for follow-up visits at 7 days."
9710182|NCT04637854|Active Comparator|Surgical Loupes with coaxial illumination.|The same as above but the intervention will be performed with the use of surgical loupes
9710183|NCT04637854|Active Comparator|Naked Eye.|The same as above but the intervention will be performed at naked eyes
9710184|NCT04637659||Healthy non-treated teeth|Healthy teeth being treated for restorative or prosthodontics reasons
9710185|NCT04637659||Healthy treated teeth|Teeth being retreated for restorative or prosthodontics reasons
9710186|NCT04637659||Irreversible pulpitis|Teeth being treated because of a poor pulpal status
9710187|NCT04637659||Post-treatment apical periodontitis|Teeth being retreated due to the presence of an apical lesion
9710188|NCT04637659||Necrosis|Teeth being treated because of pulpal necrosis
9710189|NCT04637503|Experimental|effectiveness of CAR-T cells targeting GD2, PSMA and CD276|Gene-modified T cells are designed to kill tumor cells through specific recognition of GD2, PSMA and CD276. This study will evaluate the side effects and effective doses of GD2, PSMA and CD276 CAR-T cells in treating refractory and recurrent NB
9710190|NCT04637711|Experimental|Specific surgical Intervention|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery
9710191|NCT04637711|No Intervention|Extensive lesion excision|
9710192|NCT04637451|Experimental|Gingival Unit Graft|For test group, gingival recessions were treated with gingival unit graft.
9710193|NCT04637451|Other|Connective Tissue Graft|For Control group, gingival recessions were treated with connective tissue graft.
10194146|NCT03962465|Experimental|4-drug re-induction regimen with inotuzumab|"One cycle of a 4-drug regimen comprised of standard doses of prednisone, vincristine, daunorubicin, and pegaspargase with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
9710194|NCT04637399||Ulcerative Colitis|Participants diagnoses with Ulcerative Colitis.
9710195|NCT04637399||Crohn's Disease|Participants diagnosed with Crohn's Disease.
9710196|NCT04637568||Maxillary Deficiency|59 CT scans of patients with maxillary deficiency requiring Le Fort osteotomy
9710197|NCT04637568||Control|61 CT scans of healthy patients
9710198|NCT04637581|Experimental|Wraparound|Wraparound is a 12-month intervention including a family-centered discovery process to identify values, needs, and strengths to help the family be successful in reaching family functioning and parental recovery goals; weekly or twice weekly family meetings with the Wraparound coordinator; intensive care coordination among systems and providers (substance use disorder, mental health, schools, pediatrics, homeless shelters, etc.); and bi-monthly family-centered team meetings (including the family's natural and professional supports) to discuss strategies, progress and continued needs. Wraparound coordinators (2) work with up to 10 families at a time and receive extensive training (including observation) and supervision by expert trainers at University of New Hampshire.
9710199|NCT04637581|No Intervention|treatment-as-usual|"The treatment-as-usual group will receive a packet of local services and referral contacts and treatment as usual as directed by any healthcare providers working with the family. The project team will contact treatment-as-usual families on a monthly basis to confirm any services the family may be receiving, provide reminders of scheduled assessment dates, and give small incentives ($10 gift card) when families report changes in contact information to reduce risk for loss to follow-up."
9710200|NCT04637412|Experimental|Control label|"Participant will see a QR code and footnote saying, Scan the QR code for more menu information. The label will be applied to all menu items displayed."
9710201|NCT04637412|Experimental|Icon plus text added sugars label|Participant will see a label containing an icon plus text label with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 18 variations of icons and text in this arm.
9710202|NCT04637412|Experimental|Icon only added sugars label|Participant will see a label containing an icon only with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 6 variations of icons in this arm.
9710203|NCT04637308|Experimental|Succinylated gelatin|The patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day.
9710204|NCT04637308|No Intervention|Control|Observation.
9710205|NCT04637646||children with MPS|
9710206|NCT04637542|Experimental|Control Group (Traditional)|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Anatomy Laboratory. The laboratory consists of three application rooms, one control room and one analysis room. The Anatomy of the Organs Forming the Genital System was explained using an anatomical model of the genital system organs by a researcher responsible for the human anatomy course. Students were given time until the end of the lesson to work on the models. During this time, their questions were answered. At the end, all of the students were given a State Inventory by the researcher and asked to fill it in. Students were then asked to use textbooks and atlases to study for the Knowledge Test (post-test) which took place three days later."
9779321|NCT05307484|Experimental|Serious game group|Participants in the intervention group installed a mobile application, 'Sam's Mozzie Adventure'. This is a locally designed serious game which was co-created between SingHealth Polyclinics and AI Innovation Labs (AI2 Labs) Private Limited, specifically for this study. The principal investigator reviewed existing publicly available information on dengue prevention, including those on the National Environmental Agency (NEA) 'Stop Dengue' website, and provided the relevant content and pedagogical knowledge to the team of app developers from AI2 Labs. After creating the syllabus, the developers deployed their technological knowledge to integrate the dengue prevention information into the serious game. The participants were instructed to complete playing this serious game within 2 weeks.
9979960|NCT01386918|Experimental|Priming stimulation|Priming stimulation was administered as follows: 10 minutes of 6 Hz at 90% resting motor threshold (RMT) administered to the left temporoparietal cortex followed by 10 minutes of 1 Hz stimulation at 115% RMT.
9979961|NCT01386918|Sham Comparator|Sham Control|Sham stimulation was applied with identical parameters to those for the LFL condition but with the coil angled at 90 degrees off the scalp in a single wing tilt position.
10194147|NCT03953898|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10194148|NCT03953742|Experimental|CPI-200|"Dose Escalation Group: CPI-200 will be administered via intravenous infusion once every 3 weeks for up to 7 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
10194149|NCT03948035|Experimental|E-KRd/ Arm A|Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide
10194150|NCT03948035|Active Comparator|KRd/ Arm B|Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide
9979962|NCT01386931||Cytopathologist present during EUS-FNA|"Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
9710207|NCT04637542|Experimental|Experimental Group (Mobile)|"Application in Experimental Group: After the theoretical lesson, students in the experimental group were taken to an empty classroom. The mobile application was installed on the smartphones of the students in the experimental group by the researchers and they were told not to share it with anyone until the end of the study. At the end of the study, the mobile application was also installed on the phones of the students in the control group due to ethical sensitivity. Anatomy of Organs Forming the Genital System was explained on the mobile application containing the genital system organs. The students were allowed to ask questions and the questions were answered. Afterwards, all students in the experimental group were given a State Inventory by the researcher and asked to fill it in. Students were then asked to study using the genitalsystem.apk mobile application until the Knowledge Test (post-test) which took place three days later."
9710208|NCT04637516|Active Comparator|Programme Version 60 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 60 sec"
9710209|NCT04637516|Placebo Comparator|Programme Version 300 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 300 sec"
9710210|NCT04637464|Experimental|Experimental group|"Discontinuation of empirical antibiotics, despite neutrophil count below 0.5x10⁹ cells/L, after 48 hours of apyrexia and clinical stability.~A child is considered clinically stable when there is resolution of all symptoms and signs of infection, and normalization of vital signs including heart rate, respiratory rate, oxygen saturation, blood pressure, and daily diuresis."
9710211|NCT04637464|No Intervention|Control group|Discontinuation of antibiotics when neutrophil count is equal to or above 0.5x10⁹ cells/L, and the child is afebrile and clinical stable OR the child has received 10 days of antibiotics and have been afebrile and clinically stable for 7 days
9710212|NCT04637477|Experimental|Virtual ELM|
9710213|NCT04637152|No Intervention|Group A: Usual recommended therapy|Antihypertensive regimen based on the usual recommended (optimized) therapy.
9710214|NCT04637152|Experimental|Group B: Sacubitril/Valsartan|Suspension of ACE inhibitors - for at least 36h of the last dose - or ARB. Initial dosage: Sacubitril/valsartan 49mg/51mg, 1 tablet twice daily. Target dose (after two weeks): 97mg/103 mg, 1 tablet twice daily.
9710215|NCT04637191|Experimental|MentalPlus®|This group performed the task in the digital game for 25 minutes and later will be evaluated with standardized and validated neuropsychological tests for the studied population.
9710216|NCT04637347|Other|IP-ISV|In plane infraclavicular subclavian vein catheterization
9710217|NCT04637347|Other|IP-SSV|In plane supraclavicular subclavian vein catetherization
9710218|NCT04637607|Experimental|Ear-Acupressure Group|The subjects will receive true auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive sham auricular acupoints stimulation.
9710219|NCT04637607|Sham Comparator|Sham-Acupressure Group|The subjects will receive sham auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive true auricular acupoints stimulation. (Crossover)
9710220|NCT04637113||All patients admitted to the PICU meeting eligible criteria|This is a non-interventional study.
9710221|NCT04637100|Experimental|Experimental|The patient will utilize their personal mobile or tablet device to play a pre-selected set of problem-solving games for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
9710222|NCT04637100|Active Comparator|Control|The patient will utilize their personal mobile or tablet device to watch a pre-selected set of stroke-related educational videos for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
9710223|NCT04637490|Experimental|patellar resurfacing|patellar resurfacing in TKA
9710224|NCT04637490|No Intervention|non-resurfacing|non-resurfacing TKA
9710225|NCT04637386||Group A (inevitable/incomplete abortion):|Includes 15 patients with severe vaginal bleeding or part of the product of conception pass through the cervix, cx opened, and -ve fetal pulse.
9710226|NCT04637386||Group B (with vaginal bleeding during cerclage placement):|Includes 15 patients with vaginal bleeding during cerclage
9710227|NCT04637269|Experimental|BCMA CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
9710228|NCT04637373|Experimental|the group|Women aged 18-40 years who admit to the gynecology emergency department at our institution with early miscarriage up to 12 weeks and 6 days of gestation, and choose surgical evacuation over medical treatment, are having Hysteroscopy assisted suction curettage as detailed previously. retained products of conception found at the end of the procedure, and intrauterine adhesions found on follow up are compared to the data in the literature.
9979963|NCT01386931||Cytopathologist absent during EUS-FNA|"In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
10194151|NCT03943914|Experimental|"An early NIV strategy associated with HFNC-O2"|
10194152|NCT03943914|Active Comparator|"A late NIV strategy associated with COT"|
10194153|NCT03941080||GIMICC|Adult patients with newly diagnosed metastasized or irresectable CRC with an indication for standard palliative systemic anti-tumor treatment.
10194154|NCT03940066|Other|Monitoring group|
10194155|NCT03940066|Other|Standard Care|
9710229|NCT04636918|Other|Single arm|Ikervis (cyclosporine 0.1%), emulsion, one drop into both eyes, once at night.
9710230|NCT04637178|Experimental|Resistance training added to endurance training|Participants (elite cyclists) will conduct heavy-load resistance training twice a week in addition to their habitual endurance training for ten weeks
9710231|NCT04637178|Other|Endurance training|Participants (elite cyclists) will conduct habitual endurance training-only for ten weeks
9710232|NCT04637022||3D laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 3D laparoscopic camera
9710233|NCT04637022||4k laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 4k laparoscopic camera
9710234|NCT04637204||Subgroup 1|Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.
9710235|NCT04637204||Subgroup 2|Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.
9710236|NCT04637204||Subgroup 3|Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)
10194156|NCT03930966|Experimental|PDEQ, PCL-5 and demographic survey|State of the patient evaluated with questionnaires to make the connection between peri-traumatic dissociation and the occurrence of post-traumatic stress disorder
10194157|NCT03930381|Experimental|Intervention Arm|This group will download the ASTHMAXcel application and use it for the duration of the study
9710237|NCT04637204||Subgroup 4|Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)
9710238|NCT04637035|Experimental|Supportive Oncology Care at Home|"Participants will receive the Supportive Oncology Care at Home program for 14 days following their discharge from the hospital.~The Supportive Oncology Care at Home intervention consists of three key components:~Daily monitoring of patient-reported symptoms, vital signs, and body weight.~Medically Home care based on algorithmic changes in patients' daily symptoms, vital signs, and body weight.~Structured communication with the oncology team regarding care delivered to ensure continuity of care."
9710239|NCT04637217||Control|
9710240|NCT04637217||Diabetes mellitus without Diabetic Retinopathy|
9710241|NCT04637217||Diabetes mellitus with Diabetic Retinopathy|
9710242|NCT04636957|Experimental|ciprofloxacin 0.3% plus fluocinolone acetonide 0.025%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h , morning and evening) for 7 consecutive days.
9710243|NCT04636957|Active Comparator|ciprofloxacin 0.3%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h, morning and evening) for 7 consecutive days
9710244|NCT04637126||mechanically ventilated and sedated patients with sinus rhythm|all mechanically ventilated and sedated patients with sinus rhythm hospitalized in our ICU and fitted with an hemodynamic monitoring by thermodilution technique due to hemodynamic failure
9710245|NCT04637087|Experimental|Atrial Fibrillation Risk Estimation Tool|For eligible patients presenting with an acute ischemic stroke, a clinical atrial fibrillation risk estimation tool will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the stroke neurologist caring for the patient when they first open the patient's chart. The neurologist may accept the automatically generated atrial fibrillation risk score displayed in the BPA, may modify some of the inputs of the score based on the patient's personal medical history and re-calculate, or may choose to dismiss the BPA.
9710246|NCT04637438|Active Comparator|Fecal Microbiota Transplantation|
9710247|NCT04637438|Placebo Comparator|Plasebo|
9710248|NCT04637061||REC4T study patients|Rectal adenocarcinoma or polyp with indication for resection and primary colo-rectal mechanical anastomosis using a circular stapler with/or without protective ostomy undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery (see Inclusion/Exclusion Criteria)
9979964|NCT01386957||Study group|children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.
9979965|NCT01386996|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
9710251|NCT04637282|Experimental|PLX-200|This is randomized, placebo-controlled comparator study of PLX-200 in patients with CLN3 disease.
9710252|NCT04637282|Placebo Comparator|Placebo|This is randomized comparator study of PLX-200 vs. placebo in a 2:1 ratio in patients with CLN3 disease.
9710253|NCT04636996|Experimental|artificial intelligence assisted follow-up group|artificial intelligence assisted follow-up group
9710254|NCT04636996|Placebo Comparator|Control group|Control group
9710255|NCT04637009|Experimental|Part 1 (dose escalation)|Oral administration of TAS1553 once daily at specific time points.
10194158|NCT03930381|No Intervention|Usual Care Arm|This group will just receive normal provider care
9710256|NCT04637009|Experimental|Part 2 (dose expansion)|Oral administration of TAS1553 once daily at specific time points.
9979966|NCT01386996|Active Comparator|Charcoal and Symbicort Turbuhaler|
10194159|NCT03920462|Other|Programme of intelligent electric bike for health (single arm)|All volunteers will realise the programme of intelligent electric bike for health with connected vests.
10194160|NCT03918577|Experimental|right cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their right external ear canal, with before and after measures of OCRD symptom severity and insight.
9979967|NCT01386996|Experimental|Budesonide/formoterol Easyhaler|
9979968|NCT01386996|Active Comparator|Symbicort Turbuhaler|
9710257|NCT04637360|Experimental|Cinacalcet treatment|hyperparathyroid dialysis patients using cinacalcet and active vitamin D for 6 months
9710258|NCT04637360|Experimental|traditional therapy active vitamin D|hyperparathyroid dialysis patients using traditional therapy active vitamin D without use cinacalcet for 6 months.
9710259|NCT04637139|Experimental|Group 1|VBR 300 mg solution containing 2 µCi [14C]VBR
9710260|NCT04636892|Experimental|Severe aortic stenosis|"Patients with echocardiographic evidence of severe aortic stenosis as defined by:~Aortic Vmax ≥4 m/s or mean ΔP ≥40 mmHg AVA ≤1.0 cm2"
9710261|NCT04636892|Experimental|Severe mitral regurgitation|"Patients with echocardiographic evidence of severe mitral regurgitation as defined by:~Central jet MR >40% LA or holosystolic eccentric jet MR~Vena contracta ≥0.7 cm~Regurgitant volume ≥60 mL~Regurgitant fraction ≥50%~ERO ≥0.40 cm2~Angiographic grade 3 to 4+"
9710262|NCT04636892|Experimental|Heart Failure with Reduced EF <35%|Patients with echocardiographic evidence of left ventricular ejection fraction of < or = to 35%
9710263|NCT04636892|Experimental|Pulmonary Hypertension|Patients with echocardiographic evidence of a mean pulmonary artery pressure (mPAP; supine and at rest) >20mmHg
9710264|NCT04636892|Experimental|Suspected coronary artery disease|Patients with plan to undergo elective left heart diagnostic catheterization for the assessment of coronary artery disease
9710265|NCT04636866||Gastric ulcer|
9710266|NCT04636866||Duodenal ulcer|
10194161|NCT03918577|Experimental|left cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their left external ear canal, with before and after measures of OCRD symptom severity and insight.
10194162|NCT03900533|Experimental|Adjunctive group emotion regulation skills training|Participants will receive a 7 week group emotion regulation skills training together with parents adjacent to treatment as usual provided by the child- and adolescent psychiatric clinic
10194163|NCT03900533|Active Comparator|Treatment as usual (TAU)|Participants will receive treatment as usual for 7 weeks as provided by the child- and adolescent psychiatric clinic
10194164|NCT03898648|Experimental|Depressed patients with history of suicide attempt|Depressed patients with a lifetime history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
10194165|NCT03898648|Experimental|Depressed patients without any history of suicide attempt|Depressed patients without history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
9710267|NCT04636632|Experimental|Weekly Arm|fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during concurrent chemoradiotherapy
9710268|NCT04636632|Active Comparator|Triweekly Arm|fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during concurrent chemoradiotherapy
9710269|NCT04636710|Experimental|Sentinal Node Identification|"Within standard of care treatment for inflammatory breast cancer, participants will undergo a series of Lymphoscintigraphies: an imaging procedure to determine where their lymphatic system drains from their breast.~Prior to neoadjuvant chemotherapy~Day before surgery~These two imaging studies will be compared and the information used during participant's surgery to perform the sentinel node biopsy procedure.~During surgery participants will have a blue dye injected to affected breast to map drainage and identify sentinal nodes. The sentinal nodes will be removed first, followed by standard of care procedure to remove all axillary lymph nodes.~After surgery, a small amount of tissue from the tumor removed during surgery will be evaluated.~Participants will complete a Lymphedema Questionnaire after each Lymphoscintigraphy then every 6 months for 2 years post surgery."
9710270|NCT04636671|Experimental|Methylprednisolone|"A. On day 1, loading dose of methylprednisolone (MP) 80 mg IV in 30 minutes, promptly followed by continuous infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~B. From day 2 to day 8: infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.~C. From day 9 and beyond:~If not intubated patient and PaO2/FiO2 > 200, taper to MP 20 mg IV in 30 minutes three times a day for 3 days, then MP 20 mg IV twice daily for 3 days, then MP 20 mg IV once daily for 2 days, then switch to MP 16 mg/day PO for 2 days, then MP 8mg/day PO for 2 days, then MP 4mg/day PO for 2 days;~If intubated patient or PaO2/FiO2 <= 200 with at least 5 cmH2O CPAP, continue infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h until PaO2/FiO2 > 200 then taper as in a)"
9710271|NCT04636671|Active Comparator|Dexamethasone|"A. Dexamethasone (DM) 6 mg IV in 30 minutes or PO from day 1 to day 10 or until hospital discharge (if sooner).~B. After day 10 study treatment is interrupted."
9710272|NCT04636580|Experimental|anxious parent|Parents were divided into two groups anxious and non-anxious.
9710273|NCT04636580|Experimental|non-anxious parent|Parents were divided into two groups anxious and non-anxious.
9779322|NCT05307484|Active Comparator|Dengue prevention website group|The control group accessed the NEA 'Stop Dengue' website which contained dengue prevention information in the forms of online articles, posters and video. The participants were instructed to complete reading the online resources within 2 weeks.
9779323|NCT05307471||neuropathic pain|This study will be proposed to patients undergoing thoracotomy or thoracoscopy for partial or total lung resection in the service of Thoracic Surgery of Centre Jean Perrin (Prof. M. Filaire), the objective is to recruit 120 patients (for 100 evaluable patients) over a period of 18 months of inclusion
9779324|NCT05307458||Buprenorphine Microdosing|Participants transitioning to buprenorphine from methadone using a microdosing protocol.
9779325|NCT05307445|Active Comparator|peri-implant mucositis treated with standard of care-professional mechanical debridement|patients with peri-implant mucositis are treated with standard of care, i.e. professional mechanical debridement
9779326|NCT05307445|Experimental|peri-implant mucositis treated with photobiomodulation in addition to standard treatment|patients with peri-implant mucositis are treated with photobiomodulation in addition to standard treatment
10194166|NCT03874299||Kidney Transplant Receipients|
9779327|NCT05307406|Experimental|XAB05|Single ascending dose from 0.25 mg/kg up to 20mg/kg IV infusion
9779328|NCT05307406|Placebo Comparator|Placebo|Single IV infusion
9779329|NCT05307393|No Intervention|A|
9779330|NCT05307393|Experimental|B|Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement.
9779331|NCT05307393|Experimental|C|Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
10194167|NCT03871556|Experimental|Experimental Group|
9710274|NCT04636541|Experimental|Goal Management Training|GMT modules were adapted for French-speaking patients with PD-MCI. Each session was reduced from nine 90-120-minute sessions (original GMT) to five 60-90-minute sessions, one session per week, in order to avoid fatigue. As for original GMT, participants were given exercises between sessions (mindfulness exercises and metacognitive reflections). In original-GMT, some information is repeated several times, but not in Adapted-GMT. Exercises demanding motor dexterity, such as card distribution, were removed. Adapted-GMT included information on PD-MCI and executive dysfunction (some psychoeducation). In addition, Adapted-GMT modules were administered individually with an iPad, as opposed to a power-point group presentation in original-GMT. A workbook was handed to participants, as in previous studies.
9710275|NCT04636541|Active Comparator|Psychoeducation sessions coupled mindfulness exercises|Five modules were designed as a discussion with patients and caregivers about various PD symptoms: module I-brain and motor symptoms; module II-autonomic symptoms; module III- psychological symptoms; module IV-brain and cognition; and module V-cognitive impairments in PD. Patients were handed the information book about the five modules at the beginning of the study. The objective was to improve their understanding of their condition and to discuss other components that could affect their cognitive abilities. After the 40-60-minute informative part, mindfulness exercises were offered for 20-30 minutes per session. Participants were not invited to practice exercises between sessions, but 3/6 participants reported they did.
10194168|NCT03861390|Active Comparator|Prednisone, then Placebo|
9710276|NCT04636567|Experimental|Nerindocianine for injection|One Arm: Nerindocianine for Injection (0.055 mg/kg body weight); solution, intravenous, one time administration during surgery.
9710277|NCT04636606|Active Comparator|Home Exercise|Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.
9710278|NCT04636606|Active Comparator|Manual Therapy Combined with Home Exercise|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
10194169|NCT03861390|Placebo Comparator|Placebo, then Prednisone|
9710279|NCT04636606|Active Comparator|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|"Orofacial Myofunctional therapy includes stretching the tongue muscles, tongue rotation exercises, isometric and isotonic strengthening of the tongue, special maneuver, effortful swallow exercise, strengthening exercise of hyoidal muscles.~Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
9710280|NCT04636476|Other|Modified Nesbit technique followed by dorsal dartos flap|Modified Nesbit technique to correct penile curvature followed by dorsal dartos flap to correct penile torsion
9710281|NCT04636645|Active Comparator|Normal Treadmill|After completion of the baseline evaluation, Group A participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. For each session, 20% support will be given to participants
9710282|NCT04636645|Experimental|Anti-gravity treadmill with lower limb positive pressure|Group B participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
9710283|NCT04636645|Experimental|Anti-gravity treadmill with without lower limb positive pressure|Group C participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
9710284|NCT04636658|Active Comparator|Incentive spirometer training|Incentive spirometer training
9710285|NCT04636658|Experimental|diaphragmatic resistance exercises|Incentive spirometer training with diaphragm breathing with resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient
9710286|NCT04636463|Experimental|Hand Surgery with Music|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) while listing to music
9779332|NCT05307380||patients with pain|patients with acute postoperative or post-traumatic pain or chronic pain
9979969|NCT01387048|Experimental|Skinoren gel 15 %, topical|primary treatment 12 weeks with Skinoren gel®, followed by maintenance therapy with Skinoren gel® for another 24 weeks,
9979970|NCT01387048|Active Comparator|Differin Gel 0.1%|primary 12 weeks therapy with Differin gel®, followed by maintenance therapy with Differin gel® for another 24 weeks.
10194170|NCT03861078|Active Comparator|Own brand cigarette use|During each session, participants will complete a 10-puff, directed product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
10194171|NCT03861078|Experimental|ECIG 15 mg nicotine, sweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
10194172|NCT03861078|Experimental|ECIG 15 mg nicotine, unsweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
9710287|NCT04636463|No Intervention|Hand Surgery without Music (Control Group)|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) without listening to music
10194173|NCT03861078|Experimental|ECIG 0 mg nicotine, sweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
10194174|NCT03861078|Experimental|ECIG 0 mg nicotine, unsweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
10194175|NCT03849443|Placebo Comparator|Group 1 PLACEBO|
9710288|NCT04636762|Experimental|Treatment (etoposide, cisplatin, carboplatin, radiation, Atezolizumab)|Participants receive EC/EP chemotherapy combined with Atezolizumab for 2 cycles, and the efficacy is evaluated 2 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy with EC/EP(2 cycles) + Atezolizumab will be initiated. After concurrent chemoradiotherapy+ Atezolizumab, Atezolizumab was maintained until PD or intolerance or for at most 2 years. Participants with brain metastases will receiveradiotherapy forbrain metastases during the first 2 cycles of chemotherapy.
9710289|NCT04636736||HIV POLISH (PL)|HIV infected people with polish nationality, who most probably acquired infection in Poland
9710290|NCT04636736||HIV MIGRANTS (M)|HIV infected people, originating from outside of Poland, where they were diagnosed with HIV infection
9710291|NCT04636788|Other|pancreatic cancer group|"pancreatic cancer, anticipated participants: 68~other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34"
9710292|NCT04636749|Active Comparator|Erbium laser|Treatment with Erbium laser
9710293|NCT04636749|Sham Comparator|Sham laser|Treatment with sham laser
9710294|NCT04636723||CSS Patients|HNC patients presenting chronic systemic symptoms
9710295|NCT04636723||Healthy Controls|Non-clinical controls
9710296|NCT04636489|Experimental|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 8 weeks followed by comprehensive physical and clinical examinations.
9710297|NCT04636489|Placebo Comparator|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 8 weeks followed by comprehensive physical and clinical examinations.
9710298|NCT04636827|Experimental|group 1 (sIPV+DTaP+HepA)|150 subjects; simultaneously administration of sIPV+DTaP+HepA as booster immunization at the age of 18 months old, 0.5 ml each, respectively
9710299|NCT04636827|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
9979971|NCT01387048|Experimental|Skinoren|primary 12 weeks therapy with Skinoren gel®, followed by observation only for another 24 weeks,
10194176|NCT03849443|Experimental|Group 2 IV TXA|
9710300|NCT04636827|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
9710301|NCT04636827|Active Comparator|group 4 (HepA)|150 subjects; vaccination of 0.5 ml HepA as booster immunization at the age of 18 months old
9710302|NCT04636528|Experimental|Digital Rehabilitation|Home-based 8-week rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist
9710303|NCT04636528|Active Comparator|Conventional Rehabilitation|Outpatient clinic-based 8 week rehabilitation program with face-to-face PT sessions
9979972|NCT01387061|Experimental|hepatic resection|
9979973|NCT01387087|Experimental|Group A|Lowest dose, all males, fasting
10194177|NCT03849443|Experimental|Group 3 Pre-Oral TXA|
10194178|NCT03849443|Experimental|Group 4 Full Oral TXA|
9710304|NCT04636515|Experimental|Single Arm|
9710305|NCT04636593|Experimental|Induction group|If the lung V20 of initial radiation plan is equal to or more than 28%, then the patient will receive 2 months almonertinib before concurrent thoracic radiotherapy
9710306|NCT04636593|Experimental|Concurrent group|If the lung V20 of initial radiation plan is less than 28%, then the patient will receive concurrent thoracic radiotherapy with almonertinib.
9710307|NCT04636684|Experimental|patients undergoing surgical valve replacement for degenerative aortic stenosis|
9710308|NCT04636814|Experimental|CHF6001 1600µg|
9710309|NCT04636814|Experimental|CHF6001 3200µg|
9710310|NCT04636814|Placebo Comparator|Placebo|
9710311|NCT04636814|Active Comparator|Roflumilast|
9710312|NCT04636450|Active Comparator|Adult manual instrumentation|Primary mandibular molars who are treated with a manual pulpectomy and a K-file system.
9710313|NCT04636450|Experimental|Pediatric manual instrumentation|Primary mandibular molars treated with a manual pulpectomy and a Kedo-SH system.
9710314|NCT04636450|Active Comparator|Adult rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system.
9710315|NCT04636450|Experimental|Pediatric rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a Kedo-S system
9710316|NCT04636775||Immunotherapy naïve NSCLC patients|Microbiome in immunotherapy naïve NSCLC patients receiving PD-1/L1 blockade
9710317|NCT04636424|Experimental|spastic diplegic group|assessment of the speed and weight distribution during gait
9710318|NCT04636424|Experimental|hemiplegic group|assessment of the speed and weight distribution during gait
9710319|NCT04636372|Experimental|Intense pulsed light therapy group|
9710320|NCT04636372|Experimental|Hot compress massage group|
9710321|NCT04636372|Experimental|Intense pulsed light therapy and hot compress massage group|
9779333|NCT05307367|Experimental|WP1-3|WP1+2: no intervention WP3: exercise training as intervention
9979974|NCT01387087|Experimental|Group B|Second lowest dose, all males, fasting
9979975|NCT01387087|Experimental|Group C|Third lowest dose, all males, fasting
9979976|NCT01387087|Experimental|Group D|Middle dose, all males, fasting
9979977|NCT01387087|Experimental|Group E|Third lowest dose, all females, fasting
9710322|NCT04636398|Experimental|MESSAGE mHealth group intervention|Participants in the one arm will be exposed to the mHealth group intervention. As this is a pilot developmental study, the participants will be exposed to various strategies for information delivery (live presentation at a scheduled time versus voice recording accessible at any time), discussion facilitation (heavily managed with request to speak vs. natural discussion participation), and text communication management (moderator-facilitated vs. group-led).
10194179|NCT03842033|Other|PEAKmAAP|"The Pulmonary Education and Asthma Knowledge mobile asthma action plan (PEAKmAAP) group will use a mobile app that will help manage asthma. Participants will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. mAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification."
9710323|NCT04636164|Experimental|DNN group|using deep neural networks for skin lesion diagnosis
9710324|NCT04636164|No Intervention|Control group|conventional diagnosis
9710325|NCT04636346||COMPASS (Psychoeducational / Behavioral Program)|Group Acceptance and Commitment Therapy program as part of clinical service for cancer patients
9710326|NCT04636125|Other|Revision Total Shoulder Arthroplasty|Routine cultures are taken at the time of surgery. All patients are seen by an Infectious Disease Specialist and placed on 2 weeks oral doxycycline 100 mg (or alternative based on allergy or sensitivity) pending culture results.
9710327|NCT04636242|Experimental|Group 1: Phototherapy Group|patient will be instructed to apply 5-aminolevulinic acid HCL topical solution to their shoulder prior to their surgery. 16 minutes before skin incision a blue light will be applied to the area of the shoulder where the 5-ALA was administered
9710328|NCT04636242|Active Comparator|Group 2: Control Group|patient will undergo standard of care surgery
10194180|NCT03842033|Other|PEAKmAAP-Data Sharing (DS)|PEAKmAAP with Data Sharing (PEAKmAAP-DS) group will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. PEAKmAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification. The primary care provided (PCP) will receive monthly reports to help them know how the participant's asthma symptoms are over time.
9710329|NCT04636411|Experimental|Intervention group|This group group will receive oral magnesium supplementation (250 mg of elemental magnesium daily for three months) plus the standard care for diabetic patients
9710330|NCT04636411|Active Comparator|Control group|This group will receive the standard care for diabetic patients
9710331|NCT04636099|Experimental|CTA Group|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
9710332|NCT04636099|No Intervention|Non-CTA Group|The CTA group was routinely peformed upper abdomen enhenced without CT Angiography before surgery
9710333|NCT04636268|Experimental|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
9710334|NCT04636112||control group|Patients hospitalized and diagnosed as non-AMI during the same time period were matched. All patients underwent coronary angiography and CAD was defined as at least one main coronary artery with > 50% narrowing of luminal diameter.
9710335|NCT04636112||AMI group|Patients were diagnosed as MI when a cardiac biomarker (preferably cardiac troponin) rose or fell at least one value in its 99th percentile upper reference limit and at least one of the following criteria was met, including ischemic symptoms, electrocardiogram (ECG) changes of new ischemia, pathologic Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, identification of an intracoronary thrombus by angiography or autopsy.
9710336|NCT04636255|Experimental|Exercise training group|Patients in the experimental group, under clinic follow up will perform combined exercise training for 16 weeks
9710337|NCT04636255|Sham Comparator|Control Group|Patients will be only clinically followed up. They will not perform exercise training.
9710338|NCT04636294||COVID-19 suspected by symptoms, after high-risk contact or after a borderline PCR result.|
9710339|NCT04636359|Experimental|Long term course of migraine patient without aura|Patients in this group have the history of migraine without aura more than 5 years.
9710340|NCT04636359|Experimental|Short term course of migraine patient without aura|Patients in this group have the history of migraine without aura equal or less than 5 years.
9979978|NCT01387087|Experimental|Group F|Third highest dose, all males, fasting then fed
9710342|NCT04635878||Sepsis group|patients suffering from sepsis hospitalized in intensive care unit
9710343|NCT04635878||Control group|patients without infection hospitalized in intensive care unit
9710344|NCT04635813||Group 1 - COVID group|Patients that underwent surgery during COVID-19 pandemic
9710345|NCT04635813||Group 2 - control group|Patients that underwent surgery during 2019
9710346|NCT04635722|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
9710347|NCT04635891||MOVE FSHD Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits will occur per standard of care and are anticipated to occur at least once a year.
9710348|NCT04635774|Active Comparator|Treatment Group|The treatment group will receive 40 IU via four activations of an intranasal spray.
9710349|NCT04635774|Placebo Comparator|Placebo Group|The placebo group will receive four activations of an intranasal spray containing placebo (normal saline).
9979979|NCT01387087|Experimental|Group G|Second highest dose, all males, fasting
9710350|NCT04635852|Experimental|Fentanyl|Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet)
10194181|NCT03842033|Other|Nutrition Map (NutriMap) Usual Care|Participants in this arm will use a smartphone application that sends daily non-asthma-related reminder for attention control. Participants will be asked to log their daily fruits and vegetables eaten. Participants will answer survey questions about their asthma and symptoms management.
9710351|NCT04635852|Active Comparator|Immediate release morphine|Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration)
9710352|NCT04635657||Meningioma Group|This group will include all patients in the study, regardless of location (frontal or temporal lobe) or surgical approach (endoscopic endonasal or craniotomy). Fifty patients will be included in the cohort
9710353|NCT04635618|Experimental|Intervention I: Cognitive Behavioral Brief-Telepsychotherapy|Four sessions of cognitive-behavioral therapy (CBT) conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content and content related to CBT technique.
9710354|NCT04635618|Experimental|Intervention II: Brief Interpersonal Telepsychotherapy|Four sessions of interpersonal therapy (IPT) conducted by video call by a psychologist, accompanied by the sending of 2 to 3 minute videos with psychoeducational content and content related to the ITP technique.
9710355|NCT04635618|Active Comparator|Active Comparator: Telepsychoeducation group|One single session of psychoeducation conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content for 4 weeks.
9710356|NCT04635982|Placebo Comparator|Placebo Group|With regard to the Kinesiotape technique, 2 I-shaped tapes were placed at the quadriceps, following the same direction of the muscle fibres and with no tension. At the gluteus, 2 I-shaped tapes were applied following the same direction of the muscle fibres and with no tension.
9710357|NCT04635982|Experimental|Experimental Group|In rectus femoris, origin was under the anterosuperior iliac spines, and taping finished with a Y-shape pattern under the patella. After that, an I-shaped KT was applied over vastus medialis and vastus lateralis muscles in both quadriceps. Finally, subjects were taped with a Y-shaped KT at the gluteus maximus muscles. Tape tension was between 25% and 50%.
9710358|NCT04635982|No Intervention|Control Group|It has not done any intervention in this group.
9710359|NCT04635956|Experimental|Study group|Patients will accept therapy consisting of platinum/etoposide/bevacizumab/camrelizumab
9710360|NCT04635917|Experimental|Personalized diet - Black adults|Young Black adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
9710361|NCT04635917|Experimental|Personalized diet - White adults|Young White adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
9710362|NCT04635917|Other|Conventional dietary advice- Black adults|Young Black adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
9710363|NCT04635917|Other|Conventional dietary advice- White adults|Young White adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
9710364|NCT04635865|Experimental|3D-printed patient-specific plate group|3D-printed patient-specific plate will be used for reconstruction in this patient group
9710365|NCT04635865|Active Comparator|Conventional plate group|conventional commercial plates will be used for reconstruction in this patient group
9710366|NCT04635839|Active Comparator|Standard Dosing|Standard dose of unfractionated heparin
9710367|NCT04635839|Active Comparator|Gestational Age-Based Dosing|Dose of unfractionated heparin based on trimester of pregnancy
9710368|NCT04635696|Experimental|Ethyl Chloride|Ethyl Chloride topical anesthetic mist will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
9710369|NCT04635696|Placebo Comparator|Tissue culture grade water|Tissue culture grade water (Nature's Tears Eyemist) will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
9710370|NCT04635709|Experimental|behavioral therapy|applying biofeedback training on the pelvic floor muscles
9710371|NCT04635709|Experimental|interferential therapy (IF)|Interferential current was applied to the body using four surface electrodes placed on the lower abdomen and lower buttocks.
9710372|NCT04635527|Experimental|IBI318 combined with conventional TACE (cTACE)|
9710373|NCT04635527|Placebo Comparator|Placebo combined with conventional TACE (cTACE)|
9710374|NCT04635280|Experimental|Closed-loop automatic insulin delivery system|Adults type 1 diabetic patients equiped with a closed-loop automatic insulin delivery system (or artificial pancreas)
9710375|NCT04635475|No Intervention|Control Group|Consented parents of a concussed high school student who will receive CDC Head's UP Concussion Guidelines during a five week program. 75 Participants.
9710376|NCT04635475|Experimental|Intervention Group|Consented parents of a concussed high school student who will receive the CDC Head's Up Concussion Guidelines and intervention RTL Student Protocol during a five week program. 75 Participants.
9710377|NCT04635488||Trainning group|70% of the whole participants would be randomly divided into the training group to build the predicition model.
9710378|NCT04635488||validation group|30% of the whole participant would be divided into the validation group to validate the model
9710379|NCT04635514||Study group of 32 subjects|"Thirty-two women who presented with symptomatic lateral vaginal prolapse (deep dyspareunia, sensation of vaginal fulness, and heaviness) composed the study's group.~The surgical lateral vaginal reconstruction (lateral colporrhaphy) of the lateral vaginal wall was administered."
9710380|NCT04635345|Experimental|Vibrator Therapy + dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel) plus an external vibrator.
10194182|NCT03836378|Experimental|Deep Cleaning and Intervention|One side of the participant's mouth will receive a deep cleaning in addition to the placement of a BioXclude™ membrane in the deep pocket sites. The participant will then be followed for 9 months with routine care.
9710381|NCT04635345|Active Comparator|Dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel).
9710382|NCT04635501|Experimental|ABS 5.6.7|Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device
9710383|NCT04635358|Experimental|Intervention|Setting up hypnosis sessions, psychological and nutritional assistance.
9710384|NCT04635267||patients with ARDS|
9710385|NCT04635176|Placebo Comparator|Sham iPACK block|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia+ sham iPACK block with 20 mL of normal saline.
9710386|NCT04635176|Active Comparator|Real IPACK block.|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia + real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
9710387|NCT04635202|Experimental|group A|patients (n=30) in this group will receive 16 weeks of elliptical training on elliptical trainer, 3 times per week. the training will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
9710388|NCT04635202|Other|Group B (control group)|patients (n=30) in this group will receive general advises on maintaining physical activities
9710389|NCT04635566|Active Comparator|Mebeverine|Mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
9710390|NCT04635566|Placebo Comparator|Placebo|Placebo one time/day at the evening.
9710391|NCT04635293|Active Comparator|patients who were administered levosimendan at a dose of 0.1µg/Kg/min for 24 hours prior to surgery|
9710392|NCT04635293|Placebo Comparator|patients who were not administered levosimendan prior to surgery|
9710393|NCT04635306|Experimental|Low Nitrogen GEBT test meal|GEBT test meal containing low %N content (below 7%)
9710394|NCT04635436||Pathologic group|At least 20 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled.
9710395|NCT04635215||Participants|There are not multiple groups in this study
9710396|NCT04635462|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
9710397|NCT04635462|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
9710398|NCT04635332|Experimental|Intervention|In the intervention arm, participants will be exposed to the developed intervention materials and face to face group sessions.
9710399|NCT04635332|Active Comparator|Control arm|In the control arm, participants will only be given the developed intervention materials. Face to face group sessions will not be held for the control arm.
9710400|NCT04635540|Experimental|Interventional Arm|The Interventional Arm will receive the educational brochure and complete the study tasks and questionnaires.
9710401|NCT04635319||18-40 years old of both sexes|patient from 18 to 40 years old seeking orthodontic treatment
9710402|NCT04635150|Experimental|Post-intervention parents and staff|An educational intervention for the multidisciplinary staff of a neonatal intensive care unit.
9710403|NCT04635046||Patients with tears to their peroneal tendons|Patients with pain over their peroneal tendons clinically, with a verified injury to either of the two tendons on MRI, where we might expect a tendon transfer of the peroneus longus, or extirpation of the peroneus longus, during surgery.
9710404|NCT04635007|Experimental|Group 1: Tranexamic acid group|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
9710405|NCT04635007|Experimental|Group 2: Misoprostol group|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
9710406|NCT04635072|Experimental|Stabilised Whole Rice Bran (SWRB)|"Patients with mild AD will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, one time per day.~Patients with moderate disease will be instructed to use SWRB as a cleanser as above. In addition, they will also use SWRB as an emollient after constituting it into a paste as in instructions, apply at night and leave it overnight."
9779334|NCT05307354|Experimental|Nerve Mobilization Group|Tibial nerve mobilization in addition to foot-ankle joint range of motion exercises
9779335|NCT05307354|Active Comparator|Control group|Only joint range of motion exercises
9979980|NCT01387087|Experimental|Group H|Highest dose, all males, fasting
9979981|NCT01387087|Experimental|Group I|Second highest dose, all females, fasting
10194183|NCT03836378|No Intervention|Deep Cleaning Only|One side of the participant's mouth will receive deep cleaning (scaling and root planning) only. The participant will then be followed for 9 months with routine care.
10194184|NCT03833284|Experimental|Participant Barriers to TVU Screening|Patients with a history of pre-term birth will be identified through a review of their medical history. Patients will then be asked to complete a survey assessing their knowledge of transvaginal ultrasound screening. Patients will then be asked to attend in-person or online workshops designed to increase patient knowledge of TVU screening guidelines and benefits. Finally, patients will complete exit surveys to determine whether their attitudes and beliefs towards screening have changed over time.
10194185|NCT03833284|Experimental|Provider Barriers to TVU Screening|Obstetric and Gynecologic Providers will be identified based on prior working relationships with the University of Kentucky outreach programs. Chosen providers will be asked to complete a survey assessing their attitudes towards TVU screening. Following completion, providers will be asked to attend either in-person or online workshops designed to increase provider knowledge of TVU screening guidelines and benefits. Finally, providers will complete exit surveys to determine whether their attitudes and beliefs toward screening have changed over time.
9710407|NCT04634994|Experimental|[F-18]SDM-8 tracer|Subjects will be administered standardized questionnaires for cognitive testing/other co-morbidities. They will undergo PET Scan and 3T Brain MRI. For PET Scan, an intra-arterial catheter will be inserted into the radial artery for [F-18]SDM-8 metabolite blood sampling by a trained anesthesiologist. Allen's test will be performed prior to insertion of the intra-arterial catheter. If arterial line can't be established to obtain metabolite samples, a venous line will be placed. In addition, an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer. Radiopharmaceutical will be injected as a bolus (approximately 5mCi for [F-18]SDM-8 followed by 5 mL of saline). The PET session will last up to 120 min. A head support apparatus will be used to minimize head motion. Brain PET data acquisition will begin at the moment of radiotracer injection. For MRI, several pulse sequences will be performed, no IV contrast will be used.
9710408|NCT04635033||Intervention|2 hours of reduced FiO2 (11-15%) in the inspired air, 2-3x/week, 3 months
9710409|NCT04634955|Active Comparator|S1 transforaminal injection with oboique view|S1 transforaminal injection with oblique fluoroscopic view
9710410|NCT04634955|Active Comparator|S1 transforaminal injection with AP view|S1 transforaminal injection with anteroposterior fluoroscopic view
9710411|NCT04635124|Active Comparator|1: Dog visit with a dog, no additional activity (D)|The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. Apart from the visitor, an observer is present.
9710412|NCT04635124|Experimental|2: Dog visit with an additional activity (DA)|"The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. During the visit, the visitor offers the resident to participate in an activity that involves interacting with the dog.~Apart from the visitor, an observer is present."
9710413|NCT04635124|Active Comparator|3: Visit without dog, with an additional activity (A)|"The nursing home resident receives 12 10-minute visits in their own room. During the visit, the visitor offers the resident to participate in an activity.~Apart from the visitor, an observer is present, but no dog is present.."
9710414|NCT04634929||bariatric surgery participants|participants with obesity planning to undergo bariatric surgery
9710415|NCT04634929||conservative diet participants|participants with obesity planning to controlled conservative behavioral weight loss program
9710416|NCT04635059|Experimental|Pacritinib|Pacritinib is an oral drug.
9710417|NCT04635020|Experimental|Stable glaucoma iStent|Cataract surgery combined with iStent inject
9710418|NCT04635020|Experimental|Stable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
9710419|NCT04635020|Active Comparator|Stable glaucoma|Cataract surgery
9710420|NCT04635020|Experimental|Unstable glaucoma iStent|Cataract surgery combined with iStent inject
9710421|NCT04635020|Experimental|Unstable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
9710422|NCT04634968|Experimental|intervention group|The interactive Brief MI-based text message communication via instant messaging apps (e.g., WhatsApp, WeChat) will be applied in the intervention group. The chatting function of WhatsApp and WeChat will be used as the intervention platform. The intervention will start on the first day after the participants join the follow-up group. The whole interactive text-communication intervention lasts for 1 month. The frequency of message communication will be at least twice a week. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
9710423|NCT04634968|Placebo Comparator|control group|The participants in the control group will receive general health communication twice every week via SMS. The communication lasts for 1 month. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
9710424|NCT04634942|Experimental|Cold Spray Group|Cold spray group injection process step; In addition to the IM injection procedure steps, Cryos cold spray was applied to patients in this group after skin cleansing. Cryos cold spray sprayed 3 puffs from a distance of 20 cm to the skin, and the injection process was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
9779336|NCT05307341|Active Comparator|Treatment|One dose of sufentanil 30 mcg sublingual will be given pre-operatively when entering the operating room and one dose post-operatively in the PACU in addition to standard of care pain management.
9979982|NCT01387087|Placebo Comparator|Placebo Group A|all male, fasting
10194186|NCT03823014|Experimental|External Erectile Prosthesis|Study participants will be recruited as couples (transgender man + sexual partner.) Couples will use an external erectile prosthesis (Elator) over the course of 1 month and keep track of their experiences. 20 men and their partners will be enrolled.
10194187|NCT03810417|Active Comparator|Digifab|Digifab intravenous
10194188|NCT03810417|Placebo Comparator|Placebo|saline intravenous
10194189|NCT03808987|Experimental|CHW+CPP brief prenatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
9710425|NCT04634942|Experimental|ShotBlocker Group|ShotBlocker group injection process step; In addition to the IM injection procedure steps, after cleansing the skin of the patients in this group, the protruding part of the ShotBlocker was placed in contact with the skin. ShotBlocker was pressed firmly against the skin and the injection was made through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
9710426|NCT04634942|No Intervention|Control Group|Control group injection process step; The individuals in this group were injected by following the routine IM injection procedure steps. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
9710427|NCT04634942|Placebo Comparator|Cold Spray Placebo Group|Cold spray placebo group injection procedure step; In addition to the IM injection procedure steps, the patients in this group were treated with tap water in a cold spray bottle after cleansing the skin. After spraying 3 puffs of tap water in a placebo bottle at a distance of 20 cm to the skin, the injection was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
9710428|NCT04634942|Placebo Comparator|ShotBlocker Placebo Group|ShotBlocker placebo group injection procedure step; In addition to the IM injection procedure steps, in patients in this group, the non-protruding part of the ShotBlocker was placed in contact with the skin after skin cleaning. ShotBlocker was pressed firmly against the skin and the injection was applied through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed.
9710429|NCT04635085|Experimental|Empowerment-based Cognitive behavioral therapy for insomnia for MCI (intervention)|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups.
9710430|NCT04635085|No Intervention|Social Activities provided by the community centers (active control)|The control group will not receive any structured cognitive training or sleep promoting interventions during the study period. The participants in the control group will continue to participate in the social activities offered by the elderly community centers. They have access to the newspapers, board games and computer facility in the centers. Upon completion of collecting all evaluation data for both groups at the three different time points, the empowerment-based CBT-I will be offered to participants in the control group.
9710431|NCT04635189|Active Comparator|Experimental Arm: Cycle 1-4 All subjects|"Subjects will be treated with the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
9710432|NCT04635189|Experimental|Experimental Arm: Cycle 5+ Partial Response or Better|"Subjects will be treated the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams/kilograms daily days 1-21 out of a 28 day cycle"
9710433|NCT04635189|Active Comparator|Experimental Arm: Cycle 5+ Less than Partial Response|"Subjects will be treated the following:~Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks~Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle~Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab"
10194190|NCT03808987|Experimental|CHW+CPP brief postnatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning postnatally, in addition to services from a Community Health Worker (CHW)
10194191|NCT03808987|Experimental|CHW+CPP 12 months|Participants will receive Child-Parent Psychotherapy (CPP) for 12 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
9710434|NCT04634916|Experimental|EndoAVF|
10194192|NCT03808987|Experimental|CHW only|Participants will receive services from a Community Health Worker (CHW) without Child-Parent Psychotherapy (CPP)
9710435|NCT04635137|Experimental|Ablation and Cementoplasty|All patients undergoing thermal ablation and cementoplasty procedure for one or more painful bone lesion
9710436|NCT04634903|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
9779337|NCT05307341|No Intervention|Control|A multimodal approach to analgesia will be used in all subjects in the perioperative setting and will be used in both the control and treatment groups. Intraoperative dosing of opioids will be based on the anesthesiologist's clinical judgement related to the pain and hemodynamic response to surgical stimuli and on an as needed basis in the PACU. Administration of opioids in the PACU will be in response to moderate-to-severe pain.
10194193|NCT03808311|Experimental|Intensive BP treatment arm|Participants in the intensive BP treatment arm will be treated to a systolic BP target of <120 mmHg.
10194194|NCT03808311|Other|Standard BP treatment arm|Participants in the standard BP treatment arm will be treated to a systolic BP target of <140 mmHg.
9779338|NCT05307328|Experimental|SPI-62|Active drug by mouth each morning for up to 12 weeks
9779339|NCT05307328|Placebo Comparator|Placebo|Placebo by mouth each morning for up to 12 weeks
10194195|NCT03803969|Other|ConfirmRx (Insertable Cardiac Monitor)|This is a single arm study where in patients with an approved indication for a cardiac monitor will receive a ConfirmRx Device.
10194196|NCT03796767|Experimental|Arm A (radiation therapy)|Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.
10194197|NCT03796767|Experimental|Arm B (salvage oligometastasectomy)|Patients with nodal metastases undergo salvage oligometastasectomy.
9710437|NCT04634903|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
9710438|NCT04634903|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
9710439|NCT04634864|Active Comparator|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation
9710440|NCT04634864|Sham Comparator|sham tDCS|40 minutes of 0mA intensity. the session starts with a ramp up to 2mA, but machine is switched off after 2 minutes of stimulation.
9779340|NCT05307315|Experimental|music|"The state/trait anxiety inventory and surgery-specific anxiety inventory will be administered to the experimental group before the surgery. Then they will listen to Turkish Classical Music for 30 minutes.~The scales will be applied again 15 minutes after the music ends."
9779341|NCT05307315|No Intervention|control|The state/trait anxiety inventory and surgery-specific anxiety scale will be administered to the control group before surgery. The same scales will be applied again 45 minutes after the scales are applied.
9779342|NCT05307302||Adolescent basketball players|Adolescent basketball players between the ages of 13-18 playing in basketball teams
9779343|NCT05307276|Other|Healthy volunteers|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular
9779344|NCT05307263|Active Comparator|Atherectomy plus DCB|
9779345|NCT05307263|Active Comparator|DCB|
9779346|NCT05307250|Experimental|Treatment Arm 1|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE
9779347|NCT05307250|Experimental|Treatment Arm 2|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)
9779348|NCT05307250|Other|Control Arm|Bolstered Standard of Care (BSOC)
9779349|NCT05307224|Experimental|intervention group|In the experimental group, patients will receive both routine care and mandala painting. Experimental group will paint mandala for 30 minutes/day in the evening for six consecutive days.
9779350|NCT05307224|No Intervention|control group|The control group will receive the usual care.
9779351|NCT05307211|Active Comparator|GROUP 1 (CIESI Only)|Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). Staying active will be the only recommendation, and no exercise prescription will be provided.
9779352|NCT05307211|Experimental|GROUP 2 (CIESI plus NECK STABILIZATION EXERCISES)|After the interlaminar epidural steroid injection, the patients will be taken to an exercise program in the physical therapy unit, in the company of a physiotherapist, within 24 hours, within 72 hours at the latest.
9779353|NCT05307211|Experimental|GROUP 3 ( CIESI plus NECK and SCAPULAR STABILIZATION EXERCISES)|After the interlaminar epidural steroid injection, the patients will be taken to an exercise program in the physical therapy unit, in the company of a physiotherapist, within 24 hours, within 72 hours at the latest.
10194198|NCT03796767|Experimental|Arm C (salvage oligometastasectomy, radiation therapy)|Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
9779354|NCT05307146|Experimental|micro/macro electrode|
9779355|NCT05307120|Experimental|Intervention|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on Android smartphones that enables continuous monitoring of nutrition (via food diary), physical activity (via activity tracker Fitbit and self-reported activities) and blood glucose values (via Freestyle libre 2 sensors). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
9779356|NCT05307107|Experimental|Intervention group (IG)|Participants are educators working in health and social care education receiving 8 week-SHINE.
9779357|NCT05307107|No Intervention|Control group (CG)|Participants are educators working in health and social care education without the program continuing their normal daily routines receiving SHINE for their voluntary use after this study (waitlist).
9779358|NCT05307094|Experimental|Intervention first|Participants will first be randomly assigned to a parent-mediated social communication intervention. At month 3 participants' social communication will be evaluated. Participants who present with delayed social communication skills will be randomly assigned to 2 additional treatment options: continue, or add video feedback. Participants who do not present with social communication delays will reduce intervention to a weekly phone call.
9779359|NCT05307094|Active Comparator|Developmental monitoring first|Participants will first be assigned to receive monthly monitoring of social communication development. At month 3 participants' social communication will be evaluated. Participants who present with delayed social communication skills will be randomly assigned to 2 additional treatment options: continue, or add video feedback. Participants who do not present with social communication delays will continue to receive developmental monitoring.
9979983|NCT01387087|Placebo Comparator|Placebo Group B|all male, fasting then fed
9710441|NCT04634812|Experimental|[14C]-KBP-5074|
9710442|NCT04634838|Other|MedCu Antibacterial Wound Dressings with Copper Oxide|Wound dressings impregnated with copper oxide microparticles will be applied in wounds treated with antibacterial wound dressings with silver that their sizes were not reduced by at least 50% during three weeks of treatment.
9710443|NCT04634981||Group general anesthesia (G)|patients will positioned with pelvic wedge on operating table and preoxygenated. Then rapid sequence induction with precalculated doses of propofol (2 mg/kg) and rocuronium (0.9 mg/kg) will followed by endotracheal intubation. After delivery of the baby, fentanyl will be administered. Later, anesthesia will be maintained with isoflurane (1%).
9710444|NCT04634981||Group Spinal anesthesia (S)|all parturients will co-loaded with 500 ml of colloid solution. In the left lateral position, the patients' back will be cleaned with povidone iodine. In the meantime, the spinal anesthetic drug and local anesthetic drug will be prepared. After wiping povidone iodine with alcohol, a rapid single shot of 2.5 ml of 0.5% hyperbaric bupivacaine will be administered intrathecally using 22 G spinal needle. Oxygen will be administered using simple face mask till the delivery of the baby.
9710445|NCT04634656|Active Comparator|Group L|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery.
9710446|NCT04634656|Placebo Comparator|Group C|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery.
9710447|NCT04634708||Pediatric patients on EXCOR VAD support|
9710448|NCT04634448|Other|Interval appendectomy|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
9710449|NCT04634448|Other|Follow-up MRI|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
9710450|NCT04634500|Experimental|Study group|DWP16001 A mg, Dapagliflozin placebo
9710451|NCT04634500|Active Comparator|Control group|DWP16001 A mg placebo, Dapagliflozin
9979984|NCT01387087|Placebo Comparator|Placebo Group C|all female, fasting
9979985|NCT01387100|Experimental|Physical Therapist/Occupational Therapist Intervention|This group will be assigned a physical therapist or occupational therapist to meet with followed by 2 phone consultations.
9710454|NCT04634721|Active Comparator|Laparoscopic TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
9710455|NCT04634721|Active Comparator|Ultrasaund TAP block|injecting bupivacaine in transversus abdominis plane to block the somatic nerves
9710456|NCT04634721|No Intervention|no TAP block|no TAP block would be done
9710457|NCT04634565|Experimental|PF-06651600|PF-06651600 200 milligrams(mg) once daily for 10 days
9710458|NCT04634669|Experimental|AXS-05 (dextromethorphan-bupropion)|
9710459|NCT04634422|Experimental|Plasma Exchange and convalescent Plasma|2 plasma exchange procedures within 24 hours and in addition 2 bags of CCP (equalling 600 ml CCP) infused at the end of the 2nd procedure.
9710460|NCT04634422|No Intervention|Control without intervention|Standard care without the use of PLEX or convalescent plasma.
9710461|NCT04634474|Experimental|Pain on Endotracheal Suction|Before and after endotracheal aspiration, the pain of the patient will be evaluated according to the DAS and VAS scale. VAS scores will be compared with DAÖ scores. Aspiration process will be applied to all patients by the same nurse. According to the DAQ, the pain will be assessed by a volunteer nurse who is not a researcher.
9710462|NCT04634396|Other|Experimental TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACICS. Participants will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1 hour sessions by a trained interventionalist
10194199|NCT03781362|Experimental|CPI-100 Monotherapy|"Dose Escalation Groups:~CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
9710463|NCT04634292||Children with cerebral palsy 7-9 years|21 children
9710464|NCT04634292||Children with cerebral palsy 10-12 years|21 children
9710465|NCT04634292||Healthy children 7-9 years|21 children
9710466|NCT04634292||Healthy children 10-12 years|21 children
9710467|NCT04634370|Experimental|Intervention|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
9710468|NCT04633954|Experimental|Brimonidine Group|Patients in this arm receive an extra drop of brimonidine in addition to routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
9710469|NCT04633954|No Intervention|Control Group|Patients in this arm only receive routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
9710470|NCT04634058|Experimental|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 antibody combined with CTLA-4 antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
9710471|NCT04633915||Dialysis|Patients with CKD stage 5, treated with maintenance hemodialysis
9710472|NCT04633915||Healthy|Volunteers who are not dialysis-dependent
9710473|NCT04634214||COVID 19 positive patients without diabetes|COVID 19 positive patients without diabetes
9710474|NCT04634214||COVID 19 positive patients with diabetes|COVID 19 positive patients with diabetes
9710475|NCT04634032||Hernia|Patients planned to undergo routine indirect inguinal hernia repair procedure
9710476|NCT04634032||Control|Patients planned to undergo routine circumcision procedure
9710477|NCT04634084|Experimental|Experimental group|
9710478|NCT04634084|Active Comparator|Control Group|
9710479|NCT04633980|Experimental|Experimental group|
10194200|NCT03781362|Experimental|CPI-100 Combination with Capecitabine|CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)
9710480|NCT04633902|Experimental|Olaparib + Pembrolizumab|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration including mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCA, FANCD2, MRN11A, PALB2, RAD50, RAD51, RAD54B.
9710481|NCT04634188||Meningioma Group|"This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
9710482|NCT04634188||Glioma Group|"This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor.~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
9710483|NCT04634188||Brain Metastasis Group|This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
9710484|NCT04634097|Experimental|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
9710485|NCT04634097|Other|Standard group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
9710486|NCT04633941||Post Bariatric Surgery|Post Bariatric Surgery more than 6 month. Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
9710487|NCT04633941||Medical Weight Management|Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
9710488|NCT04634305||Total elbow arthroplasty|Total elbow arthroplasty, all indications combined
10194201|NCT03772652||Peri-implantitis|Subjects who were diagnosed with peri-implantitis and received treatment at least five years ago at the Graduate Periodontics Clinic at University of Michigan with sufficient baseline data. Soft tissue measurements (observation) of the implant will be completed.
10194202|NCT03761680|Experimental|MEDPass Group|Allocation of ONS in the MEDPass mode
10194203|NCT03761680|Active Comparator|Control Group|Patients receive ONS between meals or at their request as usual
10194204|NCT03746041|Experimental|abaloparatide and bevacizumab treatment|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days. In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
10194205|NCT03745118|Other|Monitoring Device|Subjects will be asked to wear up to 4 different noninvasive seizure detection devices including EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv
10194206|NCT03731572|Experimental|Power Training|Hip abductor-adductor resistance exercises at 75% maximum strength and maximum execution speed, 3, 1-hour training sessions per week for 12 weeks.
10194207|NCT03731572|Active Comparator|Strength Training|Hip muscle abductor-adductor resistance exercises at maximum strength at reduced execution speed (2s concentric/3s eccentric), 3, 1-hour training sessions per week for 12 weeks.
10194208|NCT03713125|Active Comparator|Reading Tutoring Intervention|20 hours of one-on-one reading tutoring administered over 6 weeks
10194209|NCT03713125|No Intervention|Business as Usual|Instruction as usual within schools
10194210|NCT03712124|Experimental|CNSA-001|Participants will receive CNSA-001 20 mg/kg/day (10 mg/kg twice daily [BID]) as an oral suspension for 14 days.
10194211|NCT03712124|Placebo Comparator|Placebo|Participants will receive placebo matching to CNSA-001 BID for 14 days.
10194212|NCT03708094||molecular diagnosis confirmed|Whole exome sequencing is applied to children and the molecular diagnosis was identified before renal transplantation.
10194213|NCT03708094||molecular diagnosis unconfirmed|Whole exome sequencing is applied to children and the molecular diagnosis was not identified before renal transplantation.
10194214|NCT03705923|Experimental|Bariatric surgery|Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.
10194215|NCT03694028|Experimental|Limb Loading|This group will be exposed to a sudden unilateral lowering of the supporting surface to induce lateral weight transfer of the paretic limb.
10194216|NCT03694028|Active Comparator|Conventional Training|This group will practice weight shifting and step training that focuses on the paretic limb.
10194217|NCT03689582|Experimental|68Ga-PSMA|PET/CT imaging with 68Ga-PSMA
10194218|NCT03687528||Patient with minor head injury trauma|The emergency protocol for antiplatelet inhibitors treated patient with head injury trauma and meeting others NICE criteria involves a clinical exam followed by a CT-scanner.
9710489|NCT04634006|Active Comparator|active tDCS 1|Anodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the cathode will be placed over the the vertex (Cz), using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
9710490|NCT04634006|Active Comparator|active tDCS 2|Anodal tDCS will be applied over the right IFG (1/3 of the distance between F8 and C6) according to the 10-20 EEG electrode systems and the cathode will be placed posterior to left mastoid, using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
9710491|NCT04634006|Sham Comparator|sham tDCS|Anodal tDCS will be applied over the left DLPFC (N=13) or right IFG (N=12) according to the 10-20 EEG electrode systems and the cathode will be placed over vertex or posterior to left mastoid, respectively, using square saline-soaked sponge pads 25 cm2. Sham stimulation will be maintained for 19 min without current flow by increasing current for 30 s followed by a decrease for 30 s.
9710492|NCT04633876|Active Comparator|Control group|The subjects allocated to this group receive some results from baseline measurements (as do subjects in the intervention) but do not receive lifestyle counselling
9710493|NCT04633876|Experimental|Individual coaching|These subjects receive individual counselling during the study.
10194219|NCT03660280|Experimental|Probiotics|
10194220|NCT03660280|Placebo Comparator|Placebo|
10194221|NCT03631654|Placebo Comparator|Control|
9710494|NCT04633876|Experimental|Group coaching|These subjects receive individual counselling during the study.
9710495|NCT04633850||Before implementation|Perineural bupivacaine without adjuvants.
10194222|NCT03631654|Experimental|Intervention|
10194223|NCT03597568|Experimental|Resveratrol|Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening
10194224|NCT03597568|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
10194225|NCT03591770|Experimental|UC patients on tofacitinib monotherapy|Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
10194226|NCT03591770|Active Comparator|UC patients on anti-TNF monotherapy|Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
9710496|NCT04633850||After implementation|Perineural bupivacaine with intravenous dexamethasone.
9710497|NCT04633785||wrist BP|
9710498|NCT04633746||sepsis with AKI|Patients admitted with the diagnosis of sepsis associated with elevation of renal function tests
9710499|NCT04633746||Sepsis without AKI|Patients admitted with the diagnosis of sepsis with no elevation of renal function tests
9710500|NCT04633629||Patients with acute heart failure|Patients hospitalized for acute heart failure in medical department.
9710501|NCT04633382|Experimental|Conducting research of enhanced recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~Refusal from complete starvation. Carbohydrate drink 2 hours before surgery.~Refusal of cleansing enemas.~Refusal of premedication. NSAIDs 30 minutes before surgery~Prevention of thromboembolic complications~Multimodal analgesia: epidural catheter, paracetamol.~Minimally invasive access.~Prevention of hypothermia~Targeted infusion therapy.~Failure or limited time use of drainages: gastric, intra-abdominal, bile duct drainage.~Early activation of the patient.~Early enteral nutrition.~Prevention of nausea and vomiting."
9710502|NCT04633382|Placebo Comparator|Conducting research of traditional recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~Fasting for 2 days~Use of cleansing enemas. Bowel preparation~Premedication~Prevention of thromboembolic complications~Without multimodal analgesia~Traditional access.~Prevention of hypothermia~Targeted infusion therapy.~Use of drains: gastric, intra-abdominal, bile duct drainage.~Activation of patients within 2 days.~Enteral nutrition after 2 days after surgery.~Without the use of metoclopramide"
9710503|NCT04633720|Experimental|Evaluation of intratidal compliance|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg~Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg~Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg~Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
9710504|NCT04633499|Active Comparator|dmPFC tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the dmPFC while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
9710505|NCT04633499|Experimental|rTPJ tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the rTPJ while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
9710506|NCT04633499|Active Comparator|Social cognition tasks in younger participants|Participants will conduct two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking but without tDCS stimulation.
10194227|NCT03591770|Active Comparator|UC patients on anti-TNF and a thiopurine|Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
10194228|NCT03591770|Active Comparator|UC pts. on aminosalicylates or off immunomodulatory therapy|Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.
10194229|NCT03590041|Active Comparator|Standardized SMA|The standardized SMA model includes the same TTIM curriculum as in the patient-driven model, but it is delivered in a standardized way (order of and time spent on topics are set) across all participating practices.
10194230|NCT03590041|Active Comparator|Patient-driven SMA|In the patient-driven SMA model, patients receive the same TTIM curriculum, but patients at each practice are able to set the order of the curriculum and dictate how long to spend on each topic.
9710507|NCT04633733|Experimental|Single arm|"This single arm is conducted in fixed-sequence(Treatment A ->(washout period) -> Treatment B -> Treatment C -> Maintenance treatment).~Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days"
9710508|NCT04633668|Experimental|CBT-p|cognitive behavioral therapy, Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
9710509|NCT04633668|Active Comparator|Self-monitoring|Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
9710510|NCT04633616|Experimental|Tailored Delivery of Education|Communication will be tailored as the mode of weblink delivery will be customized to patient preference.
9710511|NCT04633616|Placebo Comparator|Non-tailored Delivery of Education|Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy.
9710512|NCT04633577|Experimental|Group Lidocaine|20 eligible patients are received 1.5mg/kg 1%lidocaine intravenously over 30-60s. Then, 4mg/kg/h lidocaine infused intravenously until end of procedure.
9710513|NCT04633577|Placebo Comparator|Group Control|2020 eligible patients are received equal 0.9% normal saline.
10194231|NCT03579680|Experimental|ADT ORDER CHECK ATTESTATION (OR)|"Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but has a strong evidence-base for changing provider behavior. Study staff will place a health factor in the EMR of patients whose clinic visits study staff have confirmed to be targets for ADT de-implementation. This health factor combined with a low PSA level will trigger the ADT Order Check Attestation Intervention (Or) when the provider places an order for ADT."
9710514|NCT04633343|Experimental|Small Volume Breath Group|Small volume breath and fast breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation
9710515|NCT04633343|Experimental|Large Volume Breath Group|Large volume breath and slow breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation.
9710516|NCT04633473|Experimental|SIBTime|50 primary parents will be assessed at enrollment, then provided the SIBTime technology and exposed to the learning routines for 4 weeks, and then re-assessed at 4 weeks (after treatment completion).
9710517|NCT04633590|Experimental|home-based exergaming|The home-based exergame intervention will take place in an unsupervised place of the participant's choosing. Participants will be provided with all of the equipment and receive training on how to use the system
9710518|NCT04633590|Active Comparator|gym-based training|As suggested in the American Diabetes Association (ADA) position statement on exercise and diabetes (Colberg et al., 2016) the aim of this session will be to create an individualised exercise programme tailored to the specific needs of each participant. Participants will be given a specific gym induction with a gym instructor at a dedicated gymnasium in the Bern area (Migros Fitnessclub). During this session the training will be adapted to the participants needs. As suggested in the ADA position statement on exercise and diabetes the aim of the program will be for the participants to engage in at least 150 min of moderate to vigorous intensity exercise (defined as a HR of 50-70% HRmax) or 75 min of vigorous intensity (defined as a HR of 70-85% HRmax) or interval training per week by the end of the program. Participants will be encouraged to train 3 times per week. Participants will also be advised of the benefits of resistance training.
9710519|NCT04633603||All patients|There is no pre-specified group or subgroup of participant(s) assigned to receive the specific intervention(s) (or no intervention) according to the protocol. All patients get the same possibility to register their data and follow management advice.
9710520|NCT04633655||Patients who are receiving a neurotoxic chemotherapy|"List of neurotoxic drugs eligible for enrolment~Platinum drugs~Taxanes~Vinca alkaloids~Epothilones~Proteasome inhibitors~Thalidomide~Vedotin-based drugs~checkpoint inhibitors~Any combination of the aforementioned drugs"
9710521|NCT04633694|Experimental|Insect protein|The participants are are given insect protein
9710522|NCT04633694|Experimental|Pea protein|The participants are are given pea protein
9710523|NCT04633694|Experimental|Whey protein|The participants are are given whey protein
9710524|NCT04633798|Experimental|IPL/Lipiflow|the group in which patients treated with IPL combined with lipiflow
9710525|NCT04633798|Active Comparator|IPL/MGX|the group in which patients treated with IPL combined with meibomian gland massage
9710526|NCT04633642|Experimental|Ultrasound Group (UAW group)|UAW debridement was performed using an UAW SONOCA 185 device (Söring GmbH, Germany). The UAW device generates an ultrasound low frequency of 25kHz and is equipped with three UAW instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth, which ranges from superficial to deep. The UAW instrument piezoelectrically transforms the electrical energy delivered from the UAW device into mechanical oscillations in the sonotrode tip. For most wounds in the UAW group, a two-minute treatment with 40% intensity was performed by holding the sonotrode in contact mode, holding it perpendicular to the wound bed and moving it across in an up-and-down pattern.
9710527|NCT04633642|Active Comparator|Surgical group|"All debridement procedures were performed by the same surgeon (J.L.M.), who is specialist in diabetic foot surgery with more than 20 years of experience.~Surgical debridement involved removal of all necrotic and devitalized tissue that was incompatible with healing, as well as surrounding callus."
9710528|NCT04633707|Experimental|Adjunctive morning BLT group|treat participants with adjunctive BLT in the morning
9710529|NCT04633707|Experimental|Adjunctive afternoon BLT group|treat participants with adjunctive BLT in the afternoon
9710530|NCT04633707|Placebo Comparator|Adjunctive placebo therapy group|treat participants with adjunctive dim red light in the afternoon
9710531|NCT04633525|Experimental|Optimum Cup Orientation|
9710532|NCT04633395|Experimental|Music before bedtime|Participants will be listening to music before bedtime for a duration of up to 1 hour each night, in a total treatment period of 4 weeks. Participants will also receive the sleep hygiene guidelines, and be told to follow these.
10194232|NCT03579680|Experimental|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior. Study staff will enter a pre-populated CPRS progress note 1 business day prior to target clinic visit. The note includes talking points for the provider to help with a discussion with the Veteran. It can be edited and cosigned by the provider, giving a quick and simple way to document the discussion. The progress note template asks providers to indicate whether patient prefers to continue or discontinue ADT. Appropriate use of the indication will be tracked for fidelity.
9710533|NCT04633395|Active Comparator|Sleep hygiene|Participants will be given sleep hygiene guidelines, and be asked to follow these during the total treatment period of 4 weeks.
10194233|NCT03567096|Active Comparator|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
9710534|NCT04633408|Experimental|Intervention|The investigators will recruit 15 Latino caregivers for each study arm (total sample size of 30). The sample size was based on a rule of thumb of 12 to 15 participants per group for pilot studies. This group will have access to the app.
9710535|NCT04633408|No Intervention|Control|12 to 15 participants, will not have access to the app.
9710536|NCT04633330|Experimental|Study Arm|AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
9710537|NCT04633330|Placebo Comparator|Control Arm|Simulation of AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
9710538|NCT04633317|Experimental|Group A Regimen|Randomized 80 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium generated by a pneumatic nebulizer or a vibrating mesh nebulizer every 12 hours for 7-10 days
9710539|NCT04633317|No Intervention|Group B Regimen|Randomized 40 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium intravenous every 12 hours for 7-10 days
9710540|NCT04633304|Other|AVF|Single arm study using primary and secondary end points as comperators between subjects.
9710541|NCT04633551|Experimental|Intervention|Participants in this arm will receive a commercially available anti-inflammatory supplement.
9710542|NCT04633551|No Intervention|Control|Participants in this arm will not receive a commercially available anti-inflammatory supplement.
9710543|NCT04633512|Experimental|ActivSight Group|Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=26) Patients undergoing cholecystectomy with ActivSight (n=14)
9710544|NCT04633187|Experimental|EDP-938|
9710545|NCT04633187|Placebo Comparator|Placebo|
9710546|NCT04633265|Experimental|ECG-I Mapping and Ablation of drivers|ECG-I Mapping will be performed and drivers will be ablated as directed by ECG-I.
9710547|NCT04633083|Other|Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbosacral level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbosacral level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
9710548|NCT04633083|Other|No Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbar level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbar level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
9710549|NCT04632901||Testing of Visual Acuity (VA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
9710550|NCT04632901||Testing of Critical Visual Acuity (CVA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
9710551|NCT04633096|Experimental|tailored feedback|Using a randomized-controlled study design one third of the participants will receive individually tailored feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
9710552|NCT04633096|Experimental|standardized feedback|Using a randomized-controlled study design one third of the participants will receive a standard feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
9710553|NCT04633096|No Intervention|no feedback|Using a randomized-controlled study design one third of the participants will not receive any feedback.
9710554|NCT04633213|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
9710555|NCT04633213|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
9710556|NCT04633018|Experimental|Patient-centered asthma intervention feasibility|Investigate the effect of the patient-centered asthma intervention using the AsthmaMD app on school days missed and medication adherence.
9710557|NCT04633018|Experimental|Wait list control|Control group with usual care (not using app).
9710558|NCT04632875|Experimental|Loving-Kindness Meditation|4-week guided Loving-Kindness Meditation training (administered online).
9710559|NCT04632875|Experimental|Relaxation Meditation|4-week guided Relaxation Meditation training (administered online).
9710560|NCT04633057|Experimental|TJ101|TJ101 1.2 mg/kg once a week for 52weeks
9710561|NCT04633057|Active Comparator|NordiFlex|NordiFlex Injection 0.034 mg/kg once a day for 52 weeks
9710562|NCT04633109||normal weight|Normal weight adults with BMI ranging from 18.5-24.9; men and women; age range 18-69years; written informed consent
9710563|NCT04633109||obese|Subjects with obesity as defined by BMI >= 30; men and women; age range 18-69 years; written informed consent
9710564|NCT04633044|Placebo Comparator|Placebo|400 mg of lactose daily for 12 weeks
9710565|NCT04633044|Experimental|Supplement|400 mg of betaine daily for 12 weeks
9710566|NCT04632849|Experimental|GEM + CGM|A self-directed lifestyle intervention for controlling Type 2 Diabetes
9710567|NCT04632979|Experimental|Backward runners|Training protocol patients
9710568|NCT04633031||Group 1|Cheneau brace
10194234|NCT03567096|Experimental|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
10194235|NCT03558737|Active Comparator|Nasal high-frequency jet ventilation (nHFJV)|
9710569|NCT04633031||Group 2|Boston brace
9710570|NCT04632862|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
9710571|NCT04632862|Placebo Comparator|DWP16001 Amg Placebo|DWP16001 Amg Placebo, Tablets, Orally, Once daily
9710572|NCT04633122|Experimental|Ripretinib|50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle.
9710573|NCT04633122|Active Comparator|Sunitinib|12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break.
9710574|NCT04633174|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38oC, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
9710575|NCT04632914|Experimental|trunk stabilizing exercise|trunk stabilizing exercises three times/week for four weeks
9710576|NCT04632914|Active Comparator|cardiac rehabilitation programe|cardiac rehabilitation program three times/week for four weeks
9710577|NCT04633135|No Intervention|Control|Households enrolled in the control arm of the study did not receive either improved cookstove
9710578|NCT04633135|Experimental|Gyapa/Gyapa|Households enrolled in the Gyapa/Gyapa arm of the study received two Gyapa stoves for free
9710579|NCT04633135|Experimental|Gyapa/Philips|Households enrolled in the Gyapa/Philips arm of the study received one Gyapa stove and one Philips stove for free
9710580|NCT04633135|Experimental|Philips/Philips|Households enrolled in the Philips/Philips arm of the study received two Philips stoves for free
9710581|NCT04632693|Experimental|CAF with SCTG and vitamin C|Coronally advanced flap with subepithelial connective tissue graft and vitamin C.
9710582|NCT04632693|Active Comparator|CAF with SCTG|Coronally advanced flap with subepithelial connective tissue graft.
9710583|NCT04632836||NIV participant (non invasive-ventilation participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
9710584|NCT04632836||CPAP participant (continuous positive airway pressure participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
9710585|NCT04632836||LTOT participant (long term oxygen therapy participant)|"From patient:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~equipment data (type, indication, parameters, observance, usage data),~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)~From partner:~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
9710586|NCT04632602|Other|patients in prone position followed by dorsal decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
9710587|NCT04632602|Other|dorsal decubitus followed by prone decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
9710588|NCT04632589|Experimental|Losartan|6 weeks of daily (50mg/day) oral losartan potassium tablet
9710589|NCT04632589|Placebo Comparator|Placebo|6 weeks of daily oral placebo tablet
9710590|NCT04632745|Other|Cast Group|participant with distal radius fracture will be treated with short arm fiberglass cast
9710591|NCT04632745|Other|Splint Group|participant with distal radius fracture will be treated with short arm velcro wrist splint
9710592|NCT04632758|Experimental|WX-0593 Tablets|Eligible patients with ALK+ NSCLC will receive WX-0593 tablets without food until documented disease progression or unacceptable toxicity. 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
10194236|NCT03558737|Active Comparator|Nasal intermittent positive pressure ventilation (NIPPV)|
10194237|NCT03557749||Immune and Microbial Reconstitution|
10194238|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
10194239|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
9710593|NCT04632758|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID without food until documented disease progression or unacceptable toxicity.
9710594|NCT04632823|Experimental|Comprehensive non-pharmacological program intervention|The experimental group receives usual diabetes care plus 24 weeks of the comprehensive non-pharmacological program intervention.
10194240|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
10194241|NCT03557749||Immune Response Triggered by Relapse|
10194242|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
10194243|NCT03557749||Allogeneic Related Donor Samples|
9710595|NCT04632823|No Intervention|Usual diabetes care|This group is control, the patients receive usual diabetes care routines.
9710596|NCT04632719|Experimental|Covid-19 Study Group|The Study Group will be the group that was remiss for COVID-19 and has some of the mentioned comorbidities as asthma, cardiovascular disease, cancer even if controlled by drugs or treatments.
9710597|NCT04632719|Active Comparator|Covid-19 Control Group|The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen cognitive functions' impairment after the remission of the symptoms of COVID-19.
9710598|NCT04632784|Experimental|Artiflex Presbyopic|About 125 - 140 subjects will receive the Artiflex Presbyopic lens bilaterally and will be followed for a period of 3 years.
9710599|NCT04632342|Experimental|Experimental group 1|HL301 1,200mg/day
9710600|NCT04632342|Experimental|Experimental group 2|HL301 1,800mg/day
10194244|NCT03557749||Cellular Therapy Products|
9710601|NCT04632342|Placebo Comparator|Control group|Placebo
9710602|NCT04632407|Experimental|"Flax milk"|"A total of 30 women will receive flax (FLX) milk on a daily basis for a total of 4 months. The FLX milk will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3."
9710603|NCT04632407|Experimental|"Oat fibre milk"|"A total of 30 women will receive the oat fiber milk on a daily basis for a total of 4 months. The oat fibre milk will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water."
9779360|NCT05307068||Grade B-C stage III-IV periodontitis group|"Grade B: Moderate Moderate bone loss is observed compared to biofilm and % Root Bone Loss/age 0.25 to 1.0 is determined as grade B.~Stage III: Severe Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4.~Grade C: Rapid Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.~Stage IV:Advanced Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≥5. Need for complex rehabilition due to: Masticatory dysfunction, Secondary occlusal trauma(tooth mobility degree ≥2) Severe ridge defect,Bite collapse, drifting, flaring. Less than 20 remaining teeth (10 opposing pairs)"
9779361|NCT05307068||Healthy control group|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
9779362|NCT05307055|Experimental|Group A|double-blinded randomization into theta burst stimulation followed by baseline stimulation
9779363|NCT05307055|Experimental|Group B|double blinded randomization into baseline stimulation followed by theta burst stimulation
9779364|NCT05307042||2012-cohort|
9779365|NCT05307029||Group A edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 4 implants
9779366|NCT05307029||Group B edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 6 implants
9779367|NCT05307016||MAP patients|All pregnancies complicated with any degree of Placenta previa anterior, posterior or centralis undergoing pre-labor CS at gestational age (36+0 to 40+0)
9779368|NCT05306990|Active Comparator|Atorvastatin|Atorvastatin tablets Dosage and frequency: 40mg orally once daily
9779369|NCT05306990|Active Comparator|Rosuvastatin|Rosuvastatin tablets Dosage and frequency: 20mg orally once daily
9779370|NCT05306964|Active Comparator|Restrictive UFnet Strategy|Fluid removal will be titrated to keep net ultrafiltration rate between 0.5-1.5 mL/kg/h
9779371|NCT05306964|Active Comparator|Liberal UFnet Strategy|Fluid removal will be titrated to keep net ultrafiltration rate between 2.0-5.0 mL/kg/h
9779372|NCT05306938|Experimental|Intervention|Adolescents in this arm will receive the Adolescent Wellness Visit intervention.
9779373|NCT05306938|No Intervention|Control|Adolescents in this arm will not receive the Adolescent Wellness Visit intervention.
9779374|NCT05306925|No Intervention|Standard parenteral nutrition|These infants will form the control group and will receive standard parenteral nutrition. They will be sub-stratified into gestational brackets - preterm (born <30 weeks) and term/near term.
9779375|NCT05306925|Experimental|Arginine supplementation|These infants will form the intervention group and will receive parenteral nutrition with additional arginine (up to 18% of amino acid make-up) for up to 14 days post-op. They will be sub-stratified into gestational brackets - preterm (born <30 weeks) and term/near term.
9779376|NCT05306912|Experimental|blood sampling|blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma
9779377|NCT05306860||Grade B-C stage III-IV periodontitis group|"Grade B-C stage III-IV periodontitis group Grade B: Moderate Moderate bone loss is observed compared to biofilm and % Root Bone Loss/age 0.25 to 1.0 is determined as grade B.~Stage III: Severe Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4.~Grade C: Rapid Rapid bone loss is observed compared to biofilm and % Root Bone Loss/age >1.0 is determined as grade C.~Stage IV:Advanced Consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≥5. Need for complex rehabilition due to: Masticatory dysfunction, Secondary occlusal trauma(tooth mobility degree ≥2) Severe ridge defect,Bite collapse, drifting, flaring. Less than 20 remaining teeth (10 opposing pairs)"
10194245|NCT03543787|Active Comparator|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
10194246|NCT03543787|No Intervention|Non intervention group|2014 - 2018 MoH referral protocol
9710604|NCT04632563||Member of BioResource|Any BioResource member who consents to take part in the study and completes the study questionnaire.
9710605|NCT04632303|Experimental|Early Palliative Care|Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.
9710606|NCT04632303|No Intervention|Standard Care Arm|Palliative care visit only upon request from attending oncologist(s) or patient/family.
9710607|NCT04632641|Experimental|Perclose ProGlide Suture-Mediated Closure System (SMC) - SMALL-BORE PROCEDURES|Perclose ProGlide Suture-Mediated Closure System (SMC) will be used as closure strategy for venous access sites using sheath sizes less than or equal to 13F.
9710608|NCT04632641|Active Comparator|Figure 8 Suture - SMALL-BORE PROCEDURES|Figure 8 suture will be used as a closure technique for venous access sites using sheath sizes less than or equal to 13F.
9710609|NCT04632641|Active Comparator|Manual Compression - SMALL-BORE PROCEDURES|Manual compression will be used as a closure technique for venous access sites using sheath sizes less than or equal to 13F.
9710610|NCT04632641|Experimental|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|Perclose ProGlide Suture-Mediated Closure System (SMC) will be used as closure strategy for venous access sites using sheath sizes greater than 13F.
9710611|NCT04632641|Active Comparator|Figure 8 Suture - LARGE-BORE PROCEDURES|Figure 8 suture will be used as a closure technique for venous access sites using sheath sizes greater than 13F.
9710612|NCT04632368|Active Comparator|Transcendental Meditation Intervention Arm|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to a randomized group of eligible HCPs ( N=40)providing care during COVID-19 pandemic.
9710613|NCT04632368|No Intervention|Treatment as usual(TAU) Control Arm|Control group consists of eligible HCPs who are randomized to control group(N=40) and would not receive any intervention. At the end of 3 month study period, control group participants would be eligible for TM training.
9710614|NCT04632277|Placebo Comparator|Placebo|"A tap water,"
9710615|NCT04632277|Experimental|Expermental recieve low MG|Low Mg bottle water (50mg/l)
9710616|NCT04632277|Experimental|Expermental recieve high MG|high Mg bottle water (100 mg/l)
9710617|NCT04632628|Experimental|NiteCAPP: Online Cognitive Behavioral Therapy for Insomnia|This is a pilot trial with one treatment condition (CBT-I).
9710618|NCT04632316|Experimental|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
9710619|NCT04632680|Experimental|PVI followed by targeting of drivers|Patients will undergo intra-procedural mapping using the ECG-I. The pulmonary veins will be isolated. Drivers will then be targeted as guided by the ECG-I system aiming for termination of AF.
9710620|NCT04632524|Active Comparator|MgSO4|Group (Mg So4) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery.
9710621|NCT04632524|Placebo Comparator|Placebo|Group (P) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse
9710622|NCT04632537|Active Comparator|TICE BCG (for intravesical use, Merck) BCG LIVE|Participants randomized to the BCG arm will receive Tice® BCG (for intravesical use) BCG LIVE is a live freeze-dried vaccine made from an attenuated strain of Mycobacterium bovis. The freeze-dried vaccine will be delivered in vials, each containing 1 to 8 x108 colony forming units (CFU). Tice® BCG (for intravesical use) BCG LIVE will be reconstituted in ~5 mL of preservative-free saline, as needed for yielding 2- x107 CFU/ mL. [34] Administration of 0.1 mL will contain 2x106 CFU, which accounts for approximately 0.1 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally. A sterile tuberculin 1mL syringe and sterile fine short needle (25 or 26 gauge with 3/8-3/4 length), will be used for each injection. The injection should be made slowly after inserting the needle ~2 mm into the superficial layer of the dermis of the upper arm (usually deltoid area), to make a symmetrical superficial bleb.
9710623|NCT04632537|Placebo Comparator|placebo vaccine|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
9710624|NCT04632472|Active Comparator|Active fixation bipolar lead|Left ventricular bipolar pacemaker lead, fixated by a side helix
9710625|NCT04632472|Placebo Comparator|Passive fixation quadripolar lead|Left ventricular quadripolar passive fixation pacemaker lead
9710626|NCT04632511|Other|Obese group|Metabolome measurements on feces and urine.
9710627|NCT04632511|Other|Children with overweight, not yet obese|Metabolome measurements on feces and urine.
9710628|NCT04632511|Other|Normal-weight control group|Metabolome measurements on feces and urine.
9710629|NCT04632394||Cases|Patients with scar-dependent ventricular tachycardia, requiring ablation. These patients will have satisfied the inclusion/exclusion criteria and be put forward for VT ablation. They will undergo the previously described study protocol, including generation of a computational model of the heart from their cardiac MRI and a VT ablation where we will study the points of interest generated from the MRI model in detail.
9710630|NCT04632667|Active Comparator|Comparison School Group|
9710631|NCT04632667|Experimental|Intervention School Group|
9710632|NCT04632433|Experimental|single arm|Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.
9710633|NCT04632550|Active Comparator|Circumferential pulmonary vein isolation(CPVI) group|
9710634|NCT04632550|Experimental|Posterior box isolation(POBI) group|
9710635|NCT04632550|Experimental|POBI+Anterior linear ablation(AL) group|
10194247|NCT03535740|Experimental|Brigatinib 90 mg/180 mg with Optional Dose Escalation to 240 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity. Participants who experienced progression on the 180 mg dose and had not experienced toxicities greater than Grade 2 had the option to receive brigatinib 240 mg QD based on investigator's discretion, up to 20 months from start of enrollment until data cut-off: 30 September 2020. Participants who experienced progression on any doses but judged as still benefiting from the study treatment by the investigator may continue to use the current dose, up to study end.
10194248|NCT03532555|Active Comparator|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
9710636|NCT04632251|Other|Familiarisation|The first 2 patients per site (N = 10 in total) are considered to be sufficient to enable further familiarisation with the procedure and use of the probe in addition to the usability work and training that the sites did prior to the start of this study.
9710637|NCT04632797|Active Comparator|Cryocompression|Patients in this group receive cryocompression for the hands.
10194249|NCT03532555|Placebo Comparator|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
10194250|NCT03526354|Experimental|Experimental|Brexpiprazole 4mg daily for 12 weeks
10194251|NCT03526354|Active Comparator|Treatment as Usual|Stay on current antipsychotic medication for 12 weeks
10194252|NCT03511599|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
10194253|NCT03511599|Active Comparator|Placebo|Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
10194254|NCT03511131|Other|QSE Resp (Only follow)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to no additional treatment, and then followed for the rest of the study.
9710638|NCT04632797|Active Comparator|Cryotherapy|Patients in this group receive cryotherapy for the hands.
9710639|NCT04632420||Women with child birth|Women attending chronic pain clinic who have previously experienced childbirth
9710640|NCT04632420||Women without childbirth|Women attending chronic pain clinic who have not previously experienced childbirth
9710641|NCT04632238|No Intervention|Control|
9710642|NCT04632238|Experimental|Metrics-driven quality improvement (MDQI) intervention|
9710643|NCT04632212|Experimental|1|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (ON)
9710644|NCT04632212|Experimental|2|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (OFF)
9710645|NCT04632212|Experimental|3|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (ON)
9710646|NCT04632212|Experimental|4|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (OFF)
9710647|NCT04632212|Experimental|5|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (ON)
9710648|NCT04632212|Experimental|6|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (OFF)
9710649|NCT04632212|Experimental|7|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (ON)
9710650|NCT04632212|Experimental|8|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
9710651|NCT04632212|Experimental|9|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (ON)
9710652|NCT04632212|Experimental|10|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (OFF)
9710653|NCT04632212|Experimental|11|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (ON)
9710654|NCT04632212|Experimental|12|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (OFF)
9710655|NCT04632212|Experimental|13|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (ON)
9710656|NCT04632212|Experimental|14|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (OFF)
9710657|NCT04632212|Experimental|15|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (ON)
9710658|NCT04632212|No Intervention|16|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
9710659|NCT04632147|Experimental|Pranayama Group|Participants in this group will apply a 45-minute training program at home, consisting of 5 minutes of Ujjayi pranayama, 5 minutes of Nadi-Shodhana pranayama and 5 minutes of Sukha pranayama, 7 days a week for 8 weeks, 3 times a day. In addition, they will perform a 15-minute session 3 day a week for 8 weeks, under the online supervision of a physiotherapist. The training program will last 8 weeks.
9710660|NCT04632147|No Intervention|Control Group|No intervention will be made to this group.
9710661|NCT04632108|Experimental|ASKB589 Injection|Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.
9710662|NCT04632095|Active Comparator|Sternotomy AVR|Aortic valve replacement due to sternotomy
9710663|NCT04632095|Active Comparator|Mini AVR|Aortic valve replacement due to parasternal right anterior mini-thoracotomy
9710664|NCT04632082|Experimental|Intervention: Telepsychoeducation with personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology. The intervention is complemented by the sending of 4 videos of 2 to 3 minutes, with psychoeducational content, sent each week by the therapist.
9710665|NCT04632082|Active Comparator|Comparator: Telepsychoeducation without personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology.
9710666|NCT04632160|Experimental|Treatment|Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
10194255|NCT03511131|Other|QSE Resp (KIU at 6-month)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to receive Keep It Up (KIU), and then followed for the rest of the study.
9710667|NCT04632134|Experimental|Transcutaneous vagal nerve stimulation (tVNS)|"After positioning the tVNS electrodes in the right ear but without delivering tVNS (Sham tVNS), above mentioned signals will be recorded for 10 minutes while supine, for 15 minutes during 75° head-up tilt.~The same protocol will be performed during active tVNS.~The tVNS will be performed while 15 minutes in supine position and during 75°head-up Tilt.~Thereafter, every patient will be provided with a Nemos© device and electrodes for home daily stimulation. Daily stimulation will consist of 4 hours of stimulation organized as 4 sessions each lasting 1 hour, to be applied at the patient's convenience."
9710668|NCT04632121||Group A|will receive standard treatment + 20 mg nicorandil prior to PPCI, and then maintained on 20 mg b.i.d for 3 months .
10194256|NCT03511131|Other|QSE Non-Resp, KIU-Control Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), responded to KIU-Control at month-6, and then were followed for the rest of the study.
9710669|NCT04632121||Group B|will be given standard treatment, without nicorandil loading or maintainance.
9710670|NCT04631952|Experimental|Online exercise|SMS messages on encouraging active lifestyle plus an online exercise video
9710671|NCT04631952|Active Comparator|SMS message|SMS messages on encouraging active lifestyle
9710672|NCT04632030|Active Comparator|Control|The tobacco power wall and number of products appears in a typical format: large power wall with a large number of products (defined here as three large cabinets)
9710673|NCT04632030|Experimental|Small|The tobacco power wall and number of tobacco products appear in their smallest format: small power wall with a small number of products displayed (defined here as one large cabinet)
9710674|NCT04632030|Experimental|Medium|The tobacco power wall and number of tobacco products appear in a format sized between the control and small conditions: a medium sized power wall with a medium number of products displayed (defined here as two large cabinets).
9710675|NCT04632199|Experimental|111In-IPN01087 Low dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a low mass dose of IPN01087
9710676|NCT04632199|Experimental|111In-IPN01087 High dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a high mass dose of IPN01087
9710677|NCT04631835|Experimental|HS-10352|There are five escalating dose cohorts
9710678|NCT04631744|Experimental|Cabozantinib Arm|
9710679|NCT04631874|Experimental|Sequence A(RT)|Reference drug (Champix) -> washout -> test drug (CDFF0318)
9710680|NCT04631874|Experimental|Sequence B(TR)|Test drug (CDFF0318) -> washout -> reference drug (Champix)
9710681|NCT04631887|Experimental|Intervention Arm: Doing What Matters in Times of Stress: An Illustrated Guide|The intervention arm will receive the assigned intervention for five weeks. They will receive the intervention materials and will be called by psychologists three times (at the beginning, middle and end) during the intervention.
9710682|NCT04631887|No Intervention|Control Arm: Wait List|The control arm has no intervention. The participants in the control arm will receive the intervention after the post-assessments are completed.
9710683|NCT04631822|Active Comparator|Dexamethasone, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 4 mg dexamethasone."
9710684|NCT04631822|Active Comparator|Dexmedetomedine, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 0.5 Mg/kg dexmedetomidine."
9710685|NCT04631679||Group A: anemic patients with iron treatment|For Group A anemic patients (hemoglobin levels below 13g/dL in men and 12g/dL in women) with iron deficiency (transferrin saturation below 20% or ferritin serum level below 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or a combination of both) and are treated with a single intravenous dose of 500 milligrams of ferric carboxymaltose in 100ml 0,9% sodium chloride solution as iron supplementation directly (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
9710686|NCT04631679||Group B: non-anemic patients without iron treatment|For Group B, non-anemic patients (hemoglobin levels above 13g/dL in men and 12g/dL in women) without iron deficiency (transferrin saturation above 20%, ferritin serum levels above 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or both combined) and are not treated with iron supplementation.
9779378|NCT05306860||Healthy control group|Consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss.
9785174|NCT01244711|Experimental|Quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
10194257|NCT03511131|Other|QSE Non-Resp, KIU-Control Non-Resp, KIU|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Keep It Up (KIU). After KIU, they were followed for the rest of the study.
10194258|NCT03511131|Other|QSE Non-Resp, KIU Control Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Young Men's Health Project (YMHP). After YMHP, they were followed for the rest of the study.
9710687|NCT04632186|Experimental|Intervention|"3 sessions with 3 different interventions 1) Transcutaneous electric nerve stimulation (TENS)- at the shoulder according to current best evidence and practice 2) EXOPULSE Mollii suits- local stimulation at the shoulder, 3) EXOPULSE Mollii suit- according to current best experienced practice~The order in which the participants´ receive the different treatments will be randomized.~Each session lasts for approximately 2.5 hours (approximately 60 min for assessment, 30 min for settings and adjustments and 60 min for treatment)"
9710688|NCT04632043|Active Comparator|Early intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will undergo intubation.
9710689|NCT04632043|Active Comparator|Delayed intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.
9710690|NCT04631978||Underweight|Comprehensive ophthalmologic examination
9710691|NCT04631978||Control|Comprehensive ophthalmologic examination
9710692|NCT04631614|Experimental|Manual therapy plus muscle strengthening exercises|The procedures to be performed with participants in the experimental group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) two ankle manual therapy techniques - [a] passive calf muscle stretching and [b] ankle joint mobilization; (3) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
9710693|NCT04631614|Active Comparator|Muscle strengthening exercises|The procedures to be performed with participants in the control group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
9710694|NCT04631627|Active Comparator|aspirin group|aspirin,tablet,100/150mg per day,(BMI<30 100mg/d，BMI≥30 150mg/d)，from pregnancy weeks<16 to 35 weeks or the day of delivery.
9710695|NCT04631627|Sham Comparator|control group|with no intervention
9710696|NCT04632017||pPROM|Singleton pregnancies admitted for pPROM to the Obstetrics ward
9710697|NCT04632017||Control group|Healthy pregnant women matched for gestational age
9710698|NCT04631770|Experimental|Mediastinal lymph node dissection group|A
9979986|NCT01387100|No Intervention|Control|This is the control group. This group will not receive the vocational rehabilitation intervention from an occupational or physical therapist. They will receive written information regarding job accommodations and disability advocacy.
9979987|NCT01387113||Acute ischemic stroke patients|All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
9979988|NCT01387126|Experimental|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
9979989|NCT01387126|No Intervention|Weight management program|
9979990|NCT01387152||Very low dose stress test protocol|Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
9710699|NCT04631770|Active Comparator|Mediastinal lymph node non-dissection group|B
9710700|NCT04631991||Non-pathological high myopia|Comprehensive ophthalmologic examination
9710701|NCT04631991||Control|Comprehensive ophthalmologic examination
9710702|NCT04632004|Other|Questionnaire survey|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
9710703|NCT04631757|Experimental|Camrelizumab plus Chemoradiotherapy|Patients with initial unresectable proximal gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive camrelizumab 200mg q3w, SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14, Q3w), and intensity modulated radiotherapy for tumors and high-risk lymphatic drainage areas (45Gy/25d). Resectable patients after conversion therapy will receive D2 resection.
9710704|NCT04631354|Experimental|Sequence A|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S-770108 inhaler at a target peak inspiratory flow rate (PIFR) of 15 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 30 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
9710705|NCT04631354|Experimental|Sequence B|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S- 770108 inhaler at a target PIFR of 30 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 15 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
9710706|NCT04631419|Experimental|Maxillary flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 maxillary arches (experimental side) before canine retraction.
9710707|NCT04631419|Active Comparator|Maxillary control group|Canine retraction will be done on the other side without Laser corticotomy .
9785175|NCT01244724|Experimental|Lexapro|escitalopram 10 mg or 20 mg/d
9979991|NCT01387165||Patients|males and females between 18 and 75 years of age who been diagnosed with T2DM as defined by the American Diabetes Association
9710708|NCT04631419|Experimental|Mandibular flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 mandibular arches (experimental side) before canine retraction.
9710709|NCT04631419|Active Comparator|Mandibular control group|Canine retraction will be done on the other side without Laser corticotomy .
9710710|NCT04631406|Experimental|Neural Stem cells injected intracerebrally|Subject cohorts will be treated with increasing doses of Neural Stem Cells injected intracerebrally using a traditional 3+3 trial design
9710711|NCT04631497||Healthcare workers|The study will cover employees of the Intensive Care Unit - nurses and doctors working with patients with COVID-19 infection. Test takers will be over the age of 18 and under the age of 70, female and male.
9979992|NCT01387191||Subjects prescribed epoprostenol|Subjects with pulmonary arterial hypertension prescribed epoprostenol injection during study period
9710713|NCT04631653|Experimental|Verisee|Screening diabetic retinopathy using Verisee software
9710714|NCT04631315|Experimental|Intervention|Difluprednate Ophthalmic Emulsion 0.05%
9710715|NCT04631315|Active Comparator|Comparator|Prednisolone Acetate 1% - Phenylephrine 0.12% Ophthalmic Suspension
9710716|NCT04631341|Experimental|Melatonin Group|Take melatonin supplements
9710717|NCT04631341|No Intervention|Normal Control Group|Don't take melatonin supplements
9710718|NCT04631666|Experimental|Group 1A (uninfected) - 2.5 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 2.5 mg/kg
9710719|NCT04631666|Experimental|Group 1B (uninfected) - 10 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 10 mg/kg
9710720|NCT04631666|Experimental|Group 1C (uninfected) - 40 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
9710721|NCT04631666|Experimental|Group 1D (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose higher than 40 mg/kg
9710722|NCT04631666|Experimental|Group 2C (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
9710723|NCT04631666|Experimental|Group 2D (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will be randomized 2:1 to receive an intravenous infusion of DZIF-10c at a dose of 40 mg/kg or placebo
9710724|NCT04631575|Experimental|Healthy participants|Intervention: Drug: SHR6390 single dose
9710725|NCT04631575|Experimental|Mild liver impairment|Intervention: Drug: SHR6390 single dose
9710726|NCT04631575|Experimental|Moderate liver impairment|Intervention: Drug: SHR6390 single dose
9710727|NCT04631484|Experimental|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Patients will receive treatment with the study drug, 20 ml twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days;patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
9710728|NCT04631484|Placebo Comparator|Placebo|Patients will receive 20 ml placebo (0.9% sodium chloride solution) twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days; patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
9979993|NCT01387204|Experimental|Single-Dose, 2 mg [14C]GSK1120212|A single 2 mg (2 mg/10mL) oral dose of [14C]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
9710729|NCT04631237||Focus Groups|N=52
9710730|NCT04631237||Cognitive Interviews|N=24
9710731|NCT04631237||Survey|N=600
9710732|NCT04631289||metformin/non-metformin group|"Preadmission metformin exposure was defined as a record of metformin usage in Medications on admission in MIMIC-III.~Metformin group included non-AKI type 2 diabetes patients with preadmission metformin exposure.~Non-metformin group included non-AKI type 2 diabetes patients without preadmission metformin exposure."
9710733|NCT04631328|Experimental|Intervention|Growing Together program
9710734|NCT04631328|No Intervention|Control|
9710735|NCT04631250|Experimental|Right: daylight illumination|The right side of the face was treated using daylight PDT
9710736|NCT04631250|Experimental|Left face: conventional illumination with red light|The left side was treated with conventional PDT.
9710737|NCT04631159|Experimental|Mobile app group|They are required to wear fitness watches to record steps ,patients will need to download and use the Health2Sync app and report blood glucose data weekly, and be monitored and advised by medical personnel.
9710738|NCT04631159|Placebo Comparator|Control group|they are required to wear fitness watches to record steps ,patients will be asked to self-manage and there is no intervention during the tracking process.
9710739|NCT04631068|Active Comparator|Santen xact Mono-EDoF ME4 Intraocular Lens (IOL)|"The Monofocal Extended Depth of Focus (Mono-EDoF) posterior chamber foldable intraocular lens is ultraviolet and blue-light absorbing designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens. The diffractive technology of the IOL allows most of the light to converge in one focal point thereby providing high quality of distance vision and continuous focus to intermediate vision while minimizing the effects of unwanted visual disturbances. The visual quality is expected to be similar to monofocal IOLs.~Surgery to implant the Mono-EDoF ME4 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
9710740|NCT04631068|Placebo Comparator|J&J TECNIS ZCB00 Intraocular Lens (IOL)|"The TECNIS 1-Piece Intraocular Lens (IOL), Model ZCB00, is a standard monofocal ultraviolet light absorbing posterior chamber IOL, which is designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens.~Surgery to implant the TECNIS ZCB00 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
9710741|NCT04631055|Experimental|DCB group|use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.
10194259|NCT03511131|Other|QSE Non-Resp, KIU Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), responded to KIU at month-6, and then were followed for the rest of the study.
10194260|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into no treatment/just follow for the rest of the study.
10194261|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into Young Men's Health Project. After YMHP, they were followed for the rest of the study.
10194262|NCT03503318|Placebo Comparator|Placebo|Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
9710742|NCT04631055|Active Comparator|Stent group|use the Intracranial Stent System made by MicroPort.
9710743|NCT04631263|Experimental|Treatment Group|
9710744|NCT04631263|No Intervention|Control Group|
9710745|NCT04631146||Camrelizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
10194263|NCT03503318|Experimental|TV-46000 q1m|Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
9710746|NCT04631276|Experimental|Single evaluation of H3 receptor occupancy|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 2.5, 25 mg TS-091 prior to an evaluation of H3 recepto occupancy
9710747|NCT04631276|Experimental|Multiple evaluations of H3 receptor occupancy|Subjects received single-dose of 5, 12.5, 25 mg TS-091 prior to Multiple evaluations of H3 recepto occupancy
9710748|NCT04631094|Experimental|Group 1|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken
9710749|NCT04631094|Experimental|Group 2|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.
9710750|NCT04631094|Experimental|Group 3|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken
9710751|NCT04631094|Experimental|Group 4|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.
9710752|NCT04631094|No Intervention|Group 5|The group that will undergo standard hospital blood collection procedure.
9710753|NCT04630899|Experimental|Active Joint Mobilization|
9710754|NCT04630899|Experimental|Passive Joint Mobilization|
9984490|NCT04052997|Experimental|Camidanlumab Tesirine|Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.
9710757|NCT04631107|Experimental|AD109 dose1|
9710758|NCT04631107|Experimental|AD109 dose2|
9710759|NCT04631107|Placebo Comparator|Placebo|
9710760|NCT04631198|No Intervention|No Intervention: GROUP CONTROL|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, expiratory flow acceleration, fractional inspiration in times, diaphragmatic breaths and aspiration when required
9710761|NCT04631198|Experimental|Active Comparator: INTERVENTION GROUP|The patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
9710762|NCT04631133||Participants with low-back pain and degenerative lesions of grade II, III, IV (Pfirmann MRI class.)|"Participants with low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification) in the following clinical applications:~Massive herniated disc in young adults~Recurrent herniated disc or herniated disc accompanying an L5 sacralization transitional anomaly, treated by discectomy~Degenerative disc disease at a segment adjacent to a fusion~Degenerative lesions with or without Modic 1~Lumbar canal stenosis treated by decompression"
9710763|NCT04630951|Experimental|Strength training based on low loads with blood flow restriction (Experimental group I)|"Squat~Single Deadlift~Back Squat"
9710764|NCT04630951|Experimental|Strenght training based on high loads (Experimental group II)|"Squat~Single Deadlift~Back Squat"
9710765|NCT04630691||Control|Patients with HbA1c around 6,0
9710766|NCT04630691||T2DM|Patients with HbA1c above 6,5
9710767|NCT04630912|Experimental|Acceptance and Commitment Therapy|12 weekly, 90 minute ACT sessions with person with dementia (with a review at week 6)
9710768|NCT04630821|Experimental|Treatment with Dilute Sodium Hypochlorite solution|Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.
10194264|NCT03503318|Experimental|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
10194265|NCT03480724|Active Comparator|Google Cardboard VRA|This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
10194266|NCT03480724|Active Comparator|Oculus Rift VRA|This group of subjects will receive VRA with Oculus Rift
10194267|NCT03480724|No Intervention|Control|This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group
10194268|NCT03477916|Other|Control (Placebo FMT and cellulose)|
9710769|NCT04630795||3D printed insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest, while the Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
9710770|NCT04631081|Active Comparator|Occlusive dressing group|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film according. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing
9710771|NCT04631081|Active Comparator|Surgical group|In surgical group, coverage with a bipedicled palmar island flap will be performed ambulatory, either on admission if patients are directly oriented to the Hand Surgery department, or within 48h of initial visit for patients addressed from the Emergency department. The flap group will be evaluated on admission, at 48h, and 6 weeks.
9710772|NCT04630743|Other|Cognitive and Behavioral Intervention|Non-pharmacological strategies for the Management of episodic breathlessness
9710773|NCT04630782||Aim 1|"The investigators will compare PET-MRI imaging and stool biomarkers between patients with VEDOSS/early SSc (n=40) and those with late SSc (n=20) not on immunosuppressive treatment.~Participants will undergo a PET-MRI scan once at baseline."
9710774|NCT04630782||Aim 2|"In early SSc patients (n=35), the investigators will determine change in biomarker levels from pre-treatment baseline to 6 months (primary end-point) and 12-months (secondary end-point) following MMF treatment.~Participants will undergo PET-MRI scans at baseline, 6-month and 12-month."
9710775|NCT04630782||Exploratory aim|"In patients with VEDOSS/early SSc (n=15) not on immunosuppressive treatment, the investigators will characterize imaging and stool biomarker changes over one year.~Participants will undergo PET-MRI scans at baseline and 12-month."
9710776|NCT04630873|Active Comparator|LOW-HIGH VOLUME|Initially a low volume of the drug (100IU botulinum toxin diluted in 2 ml) after a safe washout period of 6 months the same patients will be injected with a high volume (100IU botulinum toxin in 4 ml) of the drug.
9710777|NCT04630873|Experimental|HIGH-LOW VOLUME|initially a high volume of the drug (100IU botulinum toxin diluted in 4 ml) after a safe washout period of 6 months the same patients will be injected with a low volume (100IU botulinum toxin in 2 ml) of the drug.
9710778|NCT04630860|Experimental|56mg dose group|
9710779|NCT04630860|Experimental|84mg dose group|
9710780|NCT04630860|Experimental|112mg dose group|
9710781|NCT04630704||Non vascular repeatibility|This cohort of patients with palpable pulses will be used to test inter- and intra- observer variability for the Pedra system
9710782|NCT04630704||Non vascular physiology|This cohort of patients with palpable pulses will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
9710783|NCT04630704||CLTI physiology|This cohort of patients with CLTI will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
9710784|NCT04631185|Active Comparator|SPD (Arm A)|Single pre-operative dose of intravenous antibiotics with intraoperative redosing (SPD): Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
9710785|NCT04631185|Experimental|WPO (Arm B)|The patients assigned to this arm will receive same pre-op and intraoperative antibiotics similar to SPD (Arm A). In addition, patients in this group will receive one week of post-operative antibiotics (WPO). The post-operative antibiotic will be a first generation Cephalosporin of their surgeon's choice.
9710786|NCT04630678|Experimental|Virtual Reality Group|"The first group was received conventional physiotherapy and virtual reality therapy for 60 minutes.~The conventional physiotherapy interventions, including joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles and special for the needs of the child, was applied to both groups. The virtual reality group received that simulate daily life and contain individual scenarios by using the USE-IT system for thirty minutes. USE-IT (Most Rehabilitation, Ankara, Turkey) is a 2D non-immersive virtual reality system that plays games on a 50-inches touchscreen. The children played the matching, plumber, plumber, math, and car wash games in accordance with their reaching map results. The treatment were given three times a week for eight weeks."
9710787|NCT04630678|Active Comparator|Activity Training (Control) Group|The second group was received conventional physiotherapy and, activity training which the same movement patterns with virtual reality games for 60 minutes. The children in the activity training group received unilateral, bilateral, and bimanual activity training that supported manual skills for thirty minutes. Similar activity patterns were presented to the virtual reality group and activity training (control) group. The treatment were given three times a week for eight weeks.
9710788|NCT04630522|Experimental|JMT103- 120 mg SC Q4W|Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.
9710789|NCT04630522|Experimental|JMT103- 120 mg SC Q8W|Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.
9710790|NCT04630522|Experimental|JMT103- 180 mg SC Q8W|Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.
9710791|NCT04630444|Experimental|Intervention Group|30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).
9979994|NCT01387217|Experimental|Part A|Part A will be used to confirm the prediction of GSK2018682 PK, assess its effects on lymphocytes, and monitor its safety profile in a single cohort (Cohort 1). Cohort 1 will consist of 4 subjects and explore 4 doses of GSK2018682 in 4 study sessions. In each session, three subjects will receive GSK2018682 and one subject will receive placebo. Thus, when the cohort completes, each subject will receive placebo and 3 doses of GSK2018682.
9710792|NCT04630457|Active Comparator|Meridium-RoFT|order of existing prosthesis-Meridium prosthesis-RoFT prosthesis
9710793|NCT04630457|Active Comparator|RoFT-Meridium|order of existing prosthesis-RoFT prosthesis-Meridium prosthesis
9779379|NCT05306847|Experimental|Experimental arm|"Sintilimab will be given intravenously at a dose of 200mg every 21 days. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.~Tumor evaluation will be conducted after treatment of the tested regimen every 2 cycles. Subsequent treatment will be determined based on the evaluation results: If the patients are not suitable for radical surgery, but the result of efficacy evaluation is CR, PR, or SD, they can continue to receive the tested regimen. If the patients are still not suitable for radical surgery after 6 cycles of the tested regimen, the standard first-line or immunotherapy after chemoradiotherapy or radiotherapy will be given. If patients are eligible for radical surgery, surgery will be performed within 4 weeks after completion of the last tested regimen."
9779380|NCT05306834|Active Comparator|Minimal cSVD patient group|little or no white matter hyperintensities
9779381|NCT05306834|Active Comparator|Extensive cSVD patient group|moderate to severe white matter hyperintensities
9779382|NCT05306821|Experimental|Implementation of an electronic tool for risk stratification and thromboprophylaxis prescription|
9779383|NCT05306821|Experimental|Implementation of educative sessions and pocket cards for thromboprophylaxis|
9779384|NCT05306808|Experimental|center-based exercise|Participants in intervention group will attend a program combining 24 sessions of physiotherapy and 10 sessions of educational class over 12 weeks.
9779385|NCT05306808|No Intervention|exercise on his/her own|Participants in control group will be asked to exercise on their own, they will only attend 10 sessions of educational class over 12 weeks.
9779386|NCT05306769||Group 1|"HIV positive~≥18 years old~Currently registered to receive care under Harrison Wing (and thus potential candidates for Harrison Wing clinical studies)~Has ≥ 1 demographic identified to be underrepresented as specified in 'trial statistics'~Able and willing to provide written or witnessed informed consent to participate"
9779387|NCT05306769||Group 2|"HIV positive~≥18 years old~Currently registered to receive care under Harrison Wing~Currently participating in any clinical study in which Harrison Wing is the/ a participating centre1~Able and willing to provide written or witnessed informed consent to participate"
9779388|NCT05306756|Active Comparator|Fetal Blood Sampling (FBS)|"Fetal capillary blood samples will be collected in heparinised glass tubes and analysed in the delivery suite using the locally available gas analyser. The result of the first technically reliable sample will be interpreted and acted upon according to the protocol, taking account of the clinical circumstances and the stage of labour:~pH ≥7.25 normal, continue and if indicated repeat in 60 minutes; pH 7.21-7.24 borderline, repeat in 30 minutes; pH ≤ 7.20 abnormal, deliver."
9779389|NCT05306756|Active Comparator|digital Fetal Scalp Stimulation (dFSS)|"The examiner will stimulate the fetal scalp digitally with the index and middle finger over a period of 30 seconds.The CTG will be observed over a 5 to 10 minutes interval after the dFSS and if a fetal heart rate acceleration (>15 bpm for 15 seconds) and/or an episode of normal fetal heart rate variability (5-25 bpm) is observed the dFSS test will be considered normal. If there is no fetal heart rate acceleration and no episode of normal variability the dFSS should be interpreted as abnormal in the same way as an abnormal FBS result. If there is uncertainty whether the criteria for a normal dFSS have been fully met it can be repeated in 30 minutes as with a borderline pH result.~Acceleration/normal variability normal, if indicated repeat in 60 min; Acceleration/variability uncertain borderline, repeat in 30 minutes; No Acceleration/reduced variability abnormal, deliver."
9779390|NCT05306743|Experimental|CONQUEST Intervention Arm|Intervention arm clusters will receive the CONQUEST quality improvement program.
9779391|NCT05306743|Other|Delayed Intervention Arm|The CONQUEST quality improvement program will be rolled-out to the delayed intervention practices at the end of the outcome evaluation period.
9779392|NCT05306730|Experimental|FOCUS group|"Group of patients with chest pain undergoing FOCUS ( Focused Cardiac Ultrasound ).~Patients with odd registration number."
9779393|NCT05306730|Active Comparator|Non-FOCUS group|Patients with even registration number.
9779394|NCT05306717||Epidemiology|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year.
9785176|NCT01244893|Other|Acuvue Advance Plus prePQ/Acuvue Advance Plus postPQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification will be worn first and Acuvue AdvancePlus silicone hydrogel contact lens manufactured after process qualification will be worn second.
10194269|NCT03477916|Experimental|FMT only (FMT followed by cellulose)|
10194270|NCT03477916|Other|Prebiotic only (Placebo FMT and prebiotic fiber)|
10194271|NCT03477916|Experimental|FMT + prebiotic fiber|
10194272|NCT03477019|Experimental|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
10194273|NCT03477019|Other|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
10194274|NCT03477019|Experimental|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
10194275|NCT03477019|Other|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
10194276|NCT03444714|Experimental|RiMO-301+Radiotherapy|3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
9710794|NCT04630379|Experimental|Group A (visit with neuro-oncologist)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months to address concerns that are identified via the survey and the domain of concern identified by patient and caregiver.
9710795|NCT04630379|Experimental|Group B (visit with neuro-oncologist and palliative care team)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist and palliative care team monthly for 6 months to address concerns that are identified by the survey and domains of concerns. Caregivers also attend support sessions led by a social worker monthly for 6 months.
9710796|NCT04630379|Active Comparator|Group C (visit with neuro-oncologist, palliative care team)|Patients and primary caregiver complete quality of life portion of the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months and address important concerns that come up on the survey. Patients may also receive palliative care consultation as deemed appropriate by the neuro-oncologist.
9710797|NCT04630405|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
10194277|NCT03441282||ASA Patients I|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A normal healthy patient Healthy, non-smoking, no or minimal alcohol use"
10194278|NCT03441282||ASA Patients III|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA < 60 weeks, history (>3 months) of MI, CVA, TIA, or CAD/stents."
9710798|NCT04630405|Active Comparator|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
9710799|NCT04630548|Active Comparator|post placental IUD insertion|Following placental delivery, uterine cavity will be examined to exclude the presence of malformations or fibroids. Uterus will be stabilized by grasping it at fundus and the copper IUD (CuT 380 IUD) will be placed (within 10 minutes following the placental delivery) through the uterine wall incision high up in the uterine fundus (either by hand or using its applicator).
9710800|NCT04630548|Active Comparator|post puerperal IUD insertion|IUD will be inserted 6 - 8 weeks following caesarean delivery (during the post puerperal visit).
9710801|NCT04630470|Placebo Comparator|The placebo control group|Each patient received the massage therapy with baby oil on both lower leg areas for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
9710802|NCT04630470|Experimental|The study group|Each patient received the massage therapy with lavender oil on both lower legs for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
9710803|NCT04630535||Obstructive Sleep Apnea|Pacient with OSA (AHI≥5) undergoing aorto-bifemoral bypass
9710804|NCT04630535||Without Obstructive Sleep Apnea|Patinets without OSA undergoing aorto-bifemoral bypass
9710805|NCT04630340|Active Comparator|STEADES-2 (Intervention) arm|"Subjects in the intervention arm will fill up the questionnaire embedded in the STEADES app and be inducted to the use of STEADES-2 device by the CRC. The CRC will assist to download the STEADES app into the subject's smartphone; demonstrate the use of the app and the procedure for the serious games; and linkage to the virtual coach. The subject will use the STEADES-2 device to assess their smoking status and play the game according to the stipulations in the protocol. The STEADES-2 app provides a portal for the subject to interact with the assigned virtual coach and for motivation messages to be delivered to them. The primary outcome is total smoking cessation as measured by~exhaled breath carbon monoxide using the STEADES-2 device and~urine cotinine level which indicates the nicotine from the cigarette smoking The secondary outcome is the score using the System Usability Scale (SUS) to assess the use and experience in using the STEADES-2 system"
9710806|NCT04630340|No Intervention|Usual Care|"In the control arm, the subjects will be enrolled into the existing smoking cessation program at the respective polyclinic, which covers smoking cessation advice, together with an exhaled breath analyzed using a commercially available eCO measurement device by a trained nurse counsellor. They will complete a questionnaire and their smoking status will be re-assessed at 12 weeks after their enrolment. The primary outcome is total smoking cessation at the end of the study:~as measured by the exhaled breath carbon monoxide level determined by the STEADES-2 device and~urine cotinine levels which is a marker of nicotine level from smoking"
9710807|NCT04630665|Other|thin buccal bone|immediate implant placement in thin buccal bone wall socket
9710808|NCT04630665|Other|≥1 buccal bone|immediate implant placement in 1 mm or more buccal bone thickness socket
9710809|NCT04630314||Consecutive patients treated with covered stents post PCI CAP|
9710810|NCT04630327||Breast Cancer Patients|Breast cancer patients with no history of previously diagnosed depression or anxiety and who have been referred to or have been receiving treatment at Almaty Oncology Center
9710811|NCT04630366|Experimental|NST-1024|NST-1024 capsules given once daily for up to 14 days
10194279|NCT03432741|Experimental|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy.
10194280|NCT03420833|Experimental|CRT-On first, then CRT-Off|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed on in the first intervention period, and after six months the CRT function will be turned off in the second intervention period.
9710812|NCT04630366|Placebo Comparator|Placebo|Matching placebo capsules to NST-1024 given once daily for up to 14 days
10194281|NCT03420833|Experimental|CRT-Off first, then CRT-On|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed off in the first intervention period, and after six months the CRT function will be turned on in the second intervention period.
10194282|NCT03410706||Rivaroxaban|Anticoagulation with rivaroxaban
9710813|NCT04630600|Other|Control|Normal waiting room
9710814|NCT04630600|Experimental|Intervention#1|Waiting room with partially-equipped aquarium (without fish)
9710815|NCT04630600|Experimental|Intervention#2|Waiting room with fully-equipped aquarium (with fish)
9710816|NCT04630418|Experimental|NanoSilk Cosmo|Participants will receive a 30 mL jar of NanoSilk Cosmo
9710817|NCT04630288||Clopidogrel|Clopidogrel is a prodrug that requires metabolic activation in two stepsby hepatic CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Consequently, due to the irreversible binding to the P2Y12 receptor,platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days) and recovery of normal platelet function occurs at a rate consistent with the normal platelet turnover. Clopidogrel was approved by the European Commission on 15 July 1998 for the secondary prevention of atherothrombotic events in adult patients with ACS.
9710818|NCT04630288||Ticagrelor|Ticagrelor is a nucleoside analogue member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective and reversible ADP- receptor antagonist acting on the platelet P2Y12 receptor. This prevents the binding of ADP to the receptor which attenuates plateletactivation and aggregation.The drug was approved by the European Commission on December 3, 2010, for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
9710819|NCT04630626||Simplify Disc|Extended follow-up of IDE Subjects treated with the Simplify Cervical Artificial Disc during IDE G140154
9710820|NCT04630587|Experimental|Indirect restorations|For the indirect technique, the cavities are prepared according to the common principles for inlays/onlays. Digital impressions are taken of each tooth with a digital impression system (3Shape TRIOS® Intraoral Scanner).The dentist, utilizing the scanner's CAD SW, designs the 3D restoration. The design is imported from the scanner SW into the Rayo 3DToothFill SW to manufacture the mould and the restoration. After printing the mould, it is transferred to the Rayo robot which manufactures the restoration by casting filling material layers in the mould. The automated filling and curing procedures in the Rayo 3DToothFill robot are directed by Rayo 3DToothFill SW. After the manufacturing process is finished, the dentist cements the finished restoration into the cavity with a dual-cure resin cement (G-CEM LinkAce®).The indirect fillings are manufactured chair-side from the same composite material as in the direct technique.
9710821|NCT04630587|Active Comparator|Direct restorations|The direct composite restorations are performed based on normal treatment practices. For both direct and indirect restorations, commercially available short-fibre reinforced composite material (everX Flow, GC) is used for core material (replacing dentin) and flowable composite material (G-ænial® Universal Injectable, GC) for surface (replacing enamel), according the manufacturer´s instructions. The occlusion and articulation are checked and adjusted, and the restoration is finished with polishing instruments.
9710822|NCT04630392|Experimental|Intervention Group|There are two intervention groups: treadmill walking only, whole-body vibration plus treadmill walking.
9710823|NCT04630171|Experimental|Group 1: VerTouch for labor epidural or spinal anesthesia procedure|VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
9710824|NCT04630171|Active Comparator|Group 2: Ultrasound (US) for labor epidural or spinal anesthesia procedure|Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
9710825|NCT04630171|Active Comparator|Group 3: Control group, palpation for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
9710826|NCT04630171|Experimental|Group 4: VerTouch for lumbar puncture procedure|VerTouch utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
9710827|NCT04630171|Active Comparator|Group 5: Ultrasound (US) for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
10194283|NCT03408366|Experimental|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
10194284|NCT03406715|Experimental|Combination Immunotherapy Plus Vaccine|Combination immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC). Induction Immunotherapy, followed by Maintenance Immunotherapy and potentially Retreatment. During retreatment, participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone every three weeks for a maximum of one additional year.
10194285|NCT03399175|Other|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
10194286|NCT03394846|Experimental|Test of Existing MI Products|We will test the impact of three widely available MI products (GoNoodle, Take10, ABC for Fitness) on students' physical activity with 60 elementary classroom teachers.
9710828|NCT04630171|Active Comparator|Group 6: Control group, palpation for lumbar puncture procedure|Control group, palpation utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
9710829|NCT04630639|Experimental|Validation Arm|Participants will wear the Sparkle device (test device) while instrumented with an esophageal manometry catheter (reference standard) to record respiratory effort.
9710830|NCT04630080|Experimental|Scalp Cooling|
9710831|NCT04630041|Experimental|Social Needs Assessment|Patients in the Emergency Department will complete a social needs assessment screener that may refer them to 211 services
9710832|NCT04629885|Experimental|Oxytocin 400 IU|1mL Oxytocin 400 IU vaginal gel once daily for 12 weeks
9710833|NCT04629885|Placebo Comparator|Placebo|1mL Placebo vaginal gel once daily for 12 weeks
9710834|NCT04630015||Observational (surveys)|Patients complete surveys over 5-10 minutes at baseline (i.e. before participating in the program), and at 9 and 15 weeks follow up on the impact of COVID-19 on survivorship. Patients also complete a survey assessing how patients rate telehealth classes in the Survivorship Wellness program.
9710835|NCT04630236|Other|Ultrasound|
9710836|NCT04630223||intrauterine growth retardation|Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
9710837|NCT04630223||healthy fetuses|Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
9979995|NCT01387217|Experimental|Part B|Part B will explore doses to refine the dose-response curve of GSK2018682 on lymphocyte suppression, as allowed by stopping criteria, in 1 or 2 cohorts of up to 15 subjects (Cohort 2 and Cohort 3). In Part B, up to six single ascending doses of GSK2018682 and one dose of placebo will be investigated in up to 8 sessions.
9979996|NCT01387243||60 mg Orlistat|Purchased by consumer
9979997|NCT01387256|Other|mifepristone+misoprostol|200 mg mifepristone + 800 mcg buccal misoprostol
9979998|NCT01387256|Experimental|buccal misoprostol|2 doses of 800 mcg buccal misoprostol
9979999|NCT01387295|Experimental|chemotherapy|
9980000|NCT01387308|Experimental|A|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
9980001|NCT01387308|Sham Comparator|B|Fostamatinib 50 mg tablet x 3 (Phase 3 batch)
9980002|NCT01387308|Experimental|C|Fostamatinib 100 mg tablet (new formulation)
9980003|NCT01387308|Experimental|D|Fostamatinib 150 mg tablet (new formulation)
9980004|NCT01387308|Experimental|E|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
9980005|NCT01387321|Experimental|BYL719|
10194287|NCT03383133|Experimental|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
9710838|NCT04629989|Active Comparator|Low-flow nasal cannula|The standard oxygen delivery system (low-flow nasal cannula) is worn by the patient, without the DTM or the SM
9710839|NCT04629989|Experimental|Double-Trunk Mask|The Double-Trunk Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
9710840|NCT04629989|Experimental|Surgical Mask|The Surgical Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
9980006|NCT01387334|Experimental|Resistance Exercise Training Program|
9980007|NCT01387360|Experimental|Supracor|Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
9980008|NCT01387373|Experimental|chemotherapy|
9980009|NCT01387399|Experimental|Cisplatin as HIPEC|Phase I dose escalating study of cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
9980010|NCT01387412||Genital warts|Those with and without ano-genital warts
9980011|NCT01387425|Active Comparator|varenicline|varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
9980012|NCT01387425|Placebo Comparator|control group|
9980013|NCT01387477|Experimental|Lactate|infusion of 66 mmol of lactate
9980014|NCT01387477|Active Comparator|glucose|infusion of 33 mmol of glucose
9980015|NCT01387490|Experimental|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
9980016|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
9980017|NCT01387503|Experimental|Group 1 - Transplant strategy|Patients randomized to Group 1 will be enlisted for liver transplantation and will undergo liver transplantation within 8 months unless oncological (i.e. extrahepatic disease) or medical (i.e. cardiac insufficiency) will occur
9980018|NCT01387503|No Intervention|Group 2 - Non-transplant strategy|Patients randomized to Group 2 will continue to receive treatments according to their stage of disease, or will undergo only strict follow-up should a complete response after downstaging treatments have been achieved
9980019|NCT01387555|Experimental|Arm A|Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
9980020|NCT01387555|Other|Arm B|Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
9980021|NCT01387568|Active Comparator|group L|Lidocaine group
9980022|NCT01387568|Placebo Comparator|group P|Placebo group
9984491|NCT04052828|Experimental|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
9710842|NCT04630093|Experimental|Panel-based pharmacogenetic genotyping|All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.
9710843|NCT04629976|Experimental|NCO-48 Fumarate 4 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
9710844|NCT04629976|Experimental|NCO-48 Fumarate 20 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
9710845|NCT04629976|Active Comparator|Tenofovir alafenamide 25 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
9710846|NCT04630210|Experimental|A: Letrozole|Letrozole 2.5 mg/day oral until surgery
9710847|NCT04630210|Experimental|B: Letrozole + atezolizumab|Letrozole 2.5 mg/day oral until surgery and Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
9710848|NCT04630210|Experimental|C: Atezolizumab|Atezolizumab 840 mg IV single-dose 14 days (+/- 4 days) before surgery
9710849|NCT04630210|No Intervention|D: Observation|Observation until surgery
9710850|NCT04629924|Experimental|sleeper one|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).~Osteocentral anesthesia performed with the SleeperOne® 5 system (Dental Hi Tec) loaded with Articaine 1/200000 carpule."
9710851|NCT04629924|Active Comparator|conventional technique|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).~Anaesthesia using a conventional technique, i.e. a metal syringe loaded with Articaine 1/200000 carpule."
9710852|NCT04629755|Experimental|Intervention|The intervention was delivered via a series of daily text messages to mobile phones. Participants first were delivered an introductory text message at 6:00 pm on Day 7 of the study. This message alerted the participants to expect their first suggestion via text message at 8:00 am the following morning. For the next 14 days (Days 8 - 22), participants received one of 14 suggestions in random order. The specific daily suggestions varied in length and complexity: The simplest ones included text messages and a brief audiofile delivered via text; the more complex suggestions included text messages and a link to a web-page, which included text or embedded audiofiles describing why a suggestion was being made, how to engage in the suggested practice, and audiotaped exchanges between members of the production team describing what it was like to try the practices themselves. Some suggestions were supplemented with additional reminder and check-in text messages at noon and 4:00 pm.
9710853|NCT04629755|No Intervention|Control|Assessment only.
9710854|NCT04629794|Active Comparator|Demineralized Bone Matrix|
9710855|NCT04629794|Active Comparator|Bone Morphogenic Protein|
9710856|NCT04630132||Frailty Group|"The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:~Decreased grip strength~Self-reported exhaustion~Unintentional weight loss of more than 4.5 kg over the past year~Slow walking speed~Low physical activity"
9710857|NCT04630132||Non-Frailty Group|"The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:~Decreased grip strength~Self-reported exhaustion~Unintentional weight loss of more than 4.5 kg over the past year~Slow walking speed~Low physical activity"
9710858|NCT04630184|Experimental|Virtual reality and exercice|This group will receive the exposure intervention in virtual reality and physical activity during 12 weeks
10194288|NCT03381729|Experimental|Dose A|Intrathecal administration 6.0 X 10^13 vg of onasemnogene abeparvovec-xioi
9710859|NCT04630184|Placebo Comparator|Placebo and exercice|This group will receive the placebo intervention (relaxation) and physical activity during 12 weeks
9710860|NCT04630184|No Intervention|waiting list|This group will receive no intervention during 12 weeks, then will be randomized in the experimental or placebo group
9710861|NCT04630119||Study group of female homemakers with chronic neck pain|All female patients aged between 18-55 years with chronic neck pain (pain lasting for more than 3months) who were homemakers were included in the study. All participants reported the presence of pain in the preceding one week
9710862|NCT04629768|Other|Duodenal EMR + PuraStat|PuraStat will be applied to the defect after duodenal EMR of the lesion
9710863|NCT04629521|Experimental|CyPass Micro-Stent|CyPass Micro-Stent placed in the angle of the eye at the conclusion of cataract surgery (COMPASS trial)
9710864|NCT04629859|Experimental|study arm|dento skeletal class III patients will undergo a mandibular setback surgery and maxillary advancement
9710865|NCT04629859|Experimental|controlled arm|dento skeletal class III patients will undergo a mandibular setback surgery
9710866|NCT04629495|Active Comparator|RAPA (rapamycin) treatment group|Subjects will receive active drug
9710867|NCT04629495|Placebo Comparator|Placebo group|Subjects will receive placebo
9710868|NCT04629807|Active Comparator|Demineralized Bone Matrix (DBM)|
9710869|NCT04629807|Active Comparator|Cellular Bone Matrix (CBM)|
9710870|NCT04629846|Experimental|Trastuzumab Plus（+） QL1209 + Docetaxel|Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
9710871|NCT04629846|Active Comparator|Trastuzumab Plus（+） Pertuzumab + Docetaxel|Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery
9710872|NCT04629573|Active Comparator|Group 1|Epidural Anesthesia
9710873|NCT04629573|Active Comparator|Group 2|General Anesthesia
9710874|NCT04629690|No Intervention|Control Arm|The control group will obtain usual medical care in the Emergency Department and Acute Medical Assessment Unit
9710875|NCT04629690|Experimental|SOLAR arm|The SOLAR arm will obtain a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.
9710876|NCT04629469|Experimental|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
9710877|NCT04629677||Cohort A (questionnaire, medical record review)|Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.
9710878|NCT04629677||Cohort B (medical record review)|Patients' medical records are reviewed retrospectively.
9710879|NCT04629586||Individuals diagnosed with type 1 diabetes|"T1D Exchange Registry is currently looking for participants:~Of all ages, genders, races, and ethnic groups~Living in the United States~Diagnosed with type 1 diabetes~Currently taking insulin or have had a pancreatic or islet cell transplant"
9710880|NCT04629742|Experimental|Seawater Pizza|Administration of a seawater pizza
10194289|NCT03381729|Experimental|Dose B|Intrathecal administration 1.2 X 10^14 vg of onasemnogene abeparvovec-xioi
10194290|NCT03381729|Experimental|Dose C|Intrathecal administration 2.4 X 10^14 vg of onasemnogene abeparvovec-xioi
10194291|NCT03340532|Placebo Comparator|Sleep hygiene video|Participants will watch a sleep hygiene video
10194292|NCT03340532|Experimental|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
10194293|NCT03340532|Experimental|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
10194294|NCT03334149|Experimental|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
9710881|NCT04629742|Active Comparator|Standard Pizza|Administration of a Standard pizza
9710882|NCT04629638||covid -19 positive pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth.
9710883|NCT04629638||covid -19 negative pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-negative pregnant women in the 3rd month after birth.
9710884|NCT04629560|Experimental|Miracle Fruit Arm|Patient will be randomly assigned, by a computer generated randomization, to receive one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures.
9710885|NCT04629560|No Intervention|Control Arm (supportive measures only)|standard of care supportive measures
9710886|NCT04629456|Experimental|group 1|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
9710887|NCT04629456|Experimental|Group 2|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion(24).
9710888|NCT04629482||Children with attention deficit hyperactivity disorder with developmental delays|Children with attention deficit hyperactivity disorder with developmental delays
9710889|NCT04629482||Children with typical development|Children with typical development
9710890|NCT04629261|Experimental|Users with no incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will not receive a discount fee for enrollment.
9710891|NCT04629261|Experimental|Users with incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will do receive a discount fee for enrollment.
9710892|NCT04629261|No Intervention|Non-users|Participants with an age range similar to the intervention groups, who work or lives nearby ECOBICI's bicycle station, that are not enrolled in the ECOBICI program or in a health related program (ex. reducing weight).
9710893|NCT04629612|Experimental|Regional anesthesia|Regional block applied according to surgical area
9710894|NCT04629612|No Intervention|No Regional anesthesia|No regional anesthesia applied
9710895|NCT04629287|Experimental|KPCXM18 for injection|KPCXM18 ，freeze-dried powder,single and multiple ascending doses, Intravenous route
9710896|NCT04629287|Placebo Comparator|Placebo|Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route
10194295|NCT03334149|No Intervention|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
10194296|NCT03241121|Experimental|Time restricted feeding|For those in the intervention phase (Part 2)
9710897|NCT04629352|Experimental|Verum Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
9710898|NCT04629352|Placebo Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Sham-tDCS, no current will be delivered beyond initial ramp-up time.
9710899|NCT04629105|Active Comparator|Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.
9710900|NCT04629105|Placebo Comparator|Cohort (SARS-CoV-2): Arm 2 (Placebo)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.
9710901|NCT04629105|Active Comparator|Cohort 2 (Flu): Arm 3 (LMSCs)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.
9710902|NCT04629105|Placebo Comparator|Cohort 2 (Flu): Arm 4 (Placebo)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo.
9710903|NCT04629144|Experimental|Belimumab|Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.
9710904|NCT04629144|Placebo Comparator|Placebo|Placebo of Belimumab administered subcutaneously weekly from week 0 to week 24.
9710905|NCT04629391|Active Comparator|Anatomic TSA|The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis
9710906|NCT04629391|Experimental|RTSA|The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis
9710907|NCT04629209|Experimental|Arm A: ONC201 with Surgical Resection in Glioblastoma|Patients must be eligible for salvage surgical resection as deemed by the site Investigator. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
9710908|NCT04629209|Experimental|Arm B: ONC201 in Glioblastoma|Unequivocal evidence of recurrence (progressive disease) on contrast-enhanced brain CT or MRI as defined by RANO criteria, or have documented recurrent glioma on diagnostic biopsy. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
9710909|NCT04629365|Experimental|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
10194297|NCT03241121|Active Comparator|Regular dietary advices|For those in the intervention phase (Part 2)
10194298|NCT03241056|Experimental|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
10194299|NCT03241056|Active Comparator|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
10194300|NCT03229083|Experimental|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
10194301|NCT03223883|Experimental|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
9710910|NCT04629365|Active Comparator|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
9710911|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^11 live cells)|HV subjects receive SYNB8802 (1 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
10194302|NCT03223883|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
9710912|NCT04629170|Experimental|MAD HV: SYNB8802 (3 x 10^11 live cells)|HV subjects receive SYNB8802 (3 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
9710913|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^12 live cells)|HV subjects receive SYNB8802 (1 x 10^12 live cells) TID for 5 days in the MAD study (Part 1).
10194303|NCT03187535|Experimental|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
10194304|NCT03187535|Sham Comparator|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
10194305|NCT03153514|Experimental|Obinutuzumab|"Obinutuzumab i.v.~Cycle 1: in the peri-transplant and transplantation phase~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
9710914|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 1)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
9710915|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 2)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
9710916|NCT04629170|Placebo Comparator|MAD HV: Placebo|HV subjects receive placebo TID for 5 days in the MAD study (Part 1).
9710917|NCT04629170|Other|Crossover Arm 1: SYNB8802 crossover to Placebo|In Part 2 subjects will be randomized (1:1) to receive SYNB8802 TID for 6 days and then, following a washout period, receive Placebo TID for 6 days.
9710918|NCT04629170|Other|Crossover Arm 2: Placebo crossover to SYNB8802|In Part 2 subjects will be randomized (1:1) to receive Placebo TID for 6 days and then, following a washout period, receive SYNB8802 TID for 6 days.
9710919|NCT04629235|Active Comparator|24 hours of bedrest|- 24 hours of bedrest
9710920|NCT04629235|Experimental|Intervention group|- Wonder around after 8 hours of bedrest
10194306|NCT03126266|Experimental|Patients receiving re-irradiation|Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
10194307|NCT03125642|Experimental|BEAM: NHL & HL|BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
9710921|NCT04629326|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans
9710922|NCT04629404|Experimental|LY03003|
9710923|NCT04629404|Placebo Comparator|Placebo|
9710924|NCT04629131|Experimental|Cohort 1 TNM002 10 μg/kg/Placebo|Sentinel dosing will be conducted for Cohort 1. Two participants will be dosed (1 with TNM002, 1 with placebo) at least 72 hours prior to subsequent dosing. The remaining participants will only be dosed if no significant safety signals are identified in the sentinel participants. In total, eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
10194308|NCT03125642|Experimental|CBV: HL|Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
10194309|NCT03125642|Experimental|CY/TBI|Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
9710925|NCT04629131|Experimental|Cohort 2 TNM002 35 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
9710926|NCT04629131|Experimental|Cohort 3 TNM002 100 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
9710927|NCT04629131|Experimental|Cohort 4 TNM002 250 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
9710928|NCT04629196|Experimental|IV Weight-Based Induction Dose|
9710929|NCT04629196|Active Comparator|Standard Subcutaenous Dose|
9710930|NCT04629001||with Covid-19 infection|
9710931|NCT04629001||without Covid-19 infection|
9710932|NCT04629313||periodontal disease group|"Gingivitis: BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.~SI Periodontitis: interdental AL of 1-2 mm, PD≤4 mm and no tooth loss SII Periodontitis: interdental AL of 3-4 mm, PD≤5 mm and no tooth loss SIII Periodontitis: interdental AL ≥5 mm, PD≥6 mm SIV Periodontitis: interdental AL ≥5 mm teeth, radiographic bone lose extending to middle or apical third of the root,"
9710933|NCT04629313||periodontal healthy group|consisted of individuals with clinically healthy gingiva
9710934|NCT04629040|Experimental|Intervention|
9710935|NCT04629040|Placebo Comparator|Control|
9710936|NCT04628819|Experimental|Babybiane Imedia|Patients receive Babybiane Imedia once daily during seven days.
9710937|NCT04628819|Placebo Comparator|Placebo|Patients receive a placebo with the same consistency and taste as the Babybiane Imedia once daily during seven days.
9710938|NCT04628884|Active Comparator|Protamine dosing according the total heparin administrated|The protamine dose will be calculated according to the total heparin administered including the heparin dose add during the pump purge, 1 mg of protamine for each 100 IU of heparin
9710939|NCT04628884|Experimental|Protamine dosing according the residual heparin determined by a pharmacokinetic model|The protamine dose will be calculated according to the residual heparin estimated before the separation of the cardiopulmonary bypass using a pharmacokinetic model, 1 mg of protamine for each 100 IU of residual heparin
9710940|NCT04629157|Experimental|All patients|All patients entering the study will undergo paired testing of a lateral flow device using an anterior nasal swab and an RT-PCR using a nose and throat swab.
9980023|NCT01387633|Experimental|Educational intervention through telephone contact|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
9710941|NCT04628728||Current referral letters|One letter will be chosen from the selection of current referral letters (of average quality according to the results of the study mentioned above). Any data that would allow identification of the respective patient (i.e. name, date of birth, social insurance number, address) will be anonymised (not blackened in order not to disturb fluent reading).
10194310|NCT03106415|Experimental|Treatment (binimetinib, pembrolizumab)|Patients receive binimetinib PO BID on days 1-14 of cycle 1 and on days 1-21 of cycle 2 and subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycle 1 equals 14 days. Cycles 2 and beyond repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9710942|NCT04628728||New referral letters|The other one will be a corrected version of the first letter according to the ELGA (Elektronische Gesundheitsakte) requirements and the identified needs of patients and stakeholders (see Previous Work 1).
9710943|NCT04628910|Active Comparator|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
9710944|NCT04628910|Experimental|Simulated Flotation Therapy|Participants will utilize the Zerobody dry flotation therapy.
9710945|NCT04629118||Selution SLR™ 018 Drug Eluting Balloon|Subjects will undergo fistuloplasty with the study device - Selution SLR™ 018 Drug Eluting Balloon
9710946|NCT04628923|Experimental|QLB|"With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.~The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively."
9710947|NCT04628702|Experimental|Intervention group|receives tablet-training
9710948|NCT04628702|No Intervention|Control group|no training
9710949|NCT04628715|Experimental|Supervised RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The main goal during this intervention is to breath at resonance frequency which is slower than the usual breathing frequency. Participants will be guided towards this lower breathing frequency by using appropriate breathing techniques and the provision of a breathing pacer during the supervised sessions. During home practice, the participants will be provided with an application which will visualise a breathing pacer at their resonance frequency. At the third session, participants will no longer receive a breathing pacer but are instructed to breath in phase with their heart rate which is visualised on the computer screen instead of the breathing pacer.
9710950|NCT04628715|Sham Comparator|Supervised sham RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The sham-control treatment will follow the same steps as outlined in the supervised intervention arm. However, the participants in this control group will not receive any information regarding their own heart rate and they will not practice at their resonance frequency. Instead, a default mode will be shown during the sessions and in their application for home practice.
10194311|NCT03103971|Experimental|Treatment (leukapheresis, chemotherapy, huJCAR014)|Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
9710951|NCT04628715|Experimental|Non-supervised RSA biofeedback|1 short guided session (30 minutes) and daily practice (20 minutes; 4 bouts of 5 minutes) for 5 weeks. The biofeedback protocol will be provided by an application, similar to the supervised protocol but without guidance throughout the sessions, except for the first session. During this first session, the information will be provided about the application and the heart rate sensor (Polar band) which will detect changes in heart rate during the training. In addition, the resonance frequency of the participant will be determined so they can practice breathing at this frequency for the next 5 weeks.
9710952|NCT04628715|No Intervention|No intervention|No intervention is given.
9710953|NCT04628780|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07209960 at escalating dose levels
9710954|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1
9710955|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 2 (RCC)|Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1
9710956|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 3 (UC)|Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1
9710957|NCT04628611|Active Comparator|Video laryngoscopy Group (V) using Storz c-mac laryngoscope|video laryngoscope without a channel used for endotracheal intubation, the device used to obtain a view of the larynx, and the endotracheal tube is passed through the vocal cords independent of the device. The device is connected to the monitor via connecting cable
9710958|NCT04628611|Active Comparator|The flexible intubating laryngoscopy Group (F) using Storz flexible intubation video endoscope set|The flexible intubating scope is used to locate the vocal cords and acts as a stylet for the endotracheal tube once the scope is placed into the trachea.This device consists of a flexible insertion cord that contains a small camera at the tip, used to transmit images to camera head. The cord includes a channel for a light source, a working channel for suction or administration of oxygen or local anesthetic, and a cable that allows the operator to flex the tip of the scope. The cord attaches to a handle with a light source,camera head control lever for flexion/extension of the tip, and a working channel port. The device is connected to the monitor via connecting table
9710959|NCT04628975|Experimental|with transillumination|The nurses will use the Transillumination method for a period P1. Then these same nurses will use the control method (without transillumination) for a period P2.
9980024|NCT01387633|Active Comparator|Educational intervention group|Educational intervention group for people with diabetes through Diabetes Conversation Maps.
9980025|NCT01387646|Other|Control Group|Participants in the control arm will be interviewed at baseline, be given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and will receive abuse and enhanced clinical counseling
10194312|NCT03098394|Experimental|Rapid Turnaround Test|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
10194313|NCT03098394|Active Comparator|Usual Care|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.
9710960|NCT04628975|No Intervention|without transillumination (control method)|The nurses will use the control method for a period P1. Then these same nurses will use the Transillumination method for a period P2.
9710961|NCT04628559|Active Comparator|Dexmedetomine|Patients recieving Dexmedetomidine.
9710962|NCT04628559|Active Comparator|Ketamine|Patients recieving Ketamine.
9710963|NCT04628559|Placebo Comparator|Placebo|Patients recieving Saline.
9710964|NCT04628845|Placebo Comparator|SRP and endontic treatment without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals without using laser 940nm.
9710965|NCT04628845|Active Comparator|SRP and endodontic treatment with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
9710966|NCT04628806||HSP70CTC|Isolation of circulating tumor cells by HSP70
9710967|NCT04628793|Experimental|Cohort 1|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
9710968|NCT04628793|Experimental|Cohort 2|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
9710969|NCT04628793|Experimental|Cohort 3|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
9710970|NCT04628689|Active Comparator|Group 0.25% bupivacaine|30 ml 0.25% bupivacaine
9710971|NCT04628689|Active Comparator|Group 0.375% bupivacaine|0.375% bupivacaine
9710972|NCT04628416|Experimental|Experimental arm|
9710973|NCT04628416|Other|Control|
9710974|NCT04628676|Experimental|TXA group|tranexamic acid added to irrigation solution
9710975|NCT04628676|Experimental|EPN group|epinephrine added to irrigation solution
9710976|NCT04628312|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
9980026|NCT01387659|Experimental|Transplant recipients|All subjects receive identical drug treatment
9980027|NCT01387711|Experimental|ingenol mebutate|PEP gel 0.05% once daily exposure
9710977|NCT04628390|Experimental|Experimental|The low-power therapeutic diode laser will be applied with a wavelength 810nm ± 15nm, output power 0-2 W CW / 0-4.8 W peak power (pulse mode), for a time of 20 seconds per centimeter at lo along the buccal surface of the root of the upper and lower teeth.
9980028|NCT01387750|Placebo Comparator|Mentholated Cream|
9980029|NCT01387750|Active Comparator|Mentholated Cream with OGT|
9980030|NCT01387776||study group|patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
9980031|NCT01387802||Non-Biologic arm|Patients that have not responded to the current treatment with an NSAID (Nonsteroidal Anti-Inflammatory Drug) and/or non - biologic DMARD (Disease-Modifying Anti Rheumatic Drug) for peripheral joint involvement and switch to or addition of another NSAID /DMARDS
9710978|NCT04628390|Placebo Comparator|Placebo|A simulation of the application of therapeutic laser will be carried out as a placebo effect, for a time of 20 seconds per centimeter along the vestibular surface of the root of the upper and lower teeth.
9710979|NCT04628325|Experimental|high dose furosemide plus HSS|Patients treated high dose furosemide plus HSS
9710980|NCT04628325|Active Comparator|high dose furosemide alone|Patients treated high dose furosemide alone
9779395|NCT05306691|Experimental|Bio-smart Light Cured Protective Shield with bioactive S-PRG filler technology (PRG Barrier Coat)|Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas
9779396|NCT05306691|Active Comparator|5% NaF varnish (Proflourid Varnish VOCO America Inc.).|The gold standard remineralizing agent recommended by the guidelines
9779397|NCT05306678|Experimental|Prolonged sitting|Prolonged sitting
9779398|NCT05306678|Experimental|Breaking sitting|Breaking prolonged sitting
9980032|NCT01387802||Biologic arm|Patients that have not responded to the current treatment with non biologic DMARDS (Disease-Modifying Anti Rheumatic Drug) /NSAID (Nonsteroidal Anti-Inflammatory Drug) and switch to or addition of adalimumab
10194314|NCT03086616|Experimental|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-8 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
9710981|NCT04628468|Experimental|Possibility to use the mobile application without a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and no predefined traditional physiotherapy.
9710982|NCT04628468|Experimental|Possibility to use the mobile application with a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and a predefined number of traditional physiotherapy sessions
9710983|NCT04628468|No Intervention|Usual care|Rehabilitation after hip or knee arthroplasty without the use of a mobile application.
9710984|NCT04628455|Other|Inversion and Snaring|needlescopic inversion, snaring, and excision of the hernia sac using two Suture Grasper Sevice of Mediflex Company and a home made snare
9710985|NCT04628403|No Intervention|control|
9710986|NCT04628403|Experimental|shock waves|
9710987|NCT04628403|Experimental|massage|
9710988|NCT04628403|Experimental|lasertherapy|
9710989|NCT04628520|Sham Comparator|Maintenance|Oral hygiene instruction and periodontal maintenance
9710990|NCT04628520|Active Comparator|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
9710991|NCT04628520|Active Comparator|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
9710992|NCT04628351|Experimental|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
9710993|NCT04628351|No Intervention|Control Group|Routine patient training was given to the patients in the control group by a nurse working in the clinic.
9710994|NCT04628286|Placebo Comparator|Sham Laser|Placebo laser application in plantar fascia
9710995|NCT04628286|Experimental|Experimental group Myofascial Induction|Myofascial Induction technique application in plantar fascia
9710996|NCT04628741|Active Comparator|Dynamic Coaching Model|The Dynamic Coaching Model is an established treatment approach that entails training college students with executive function impairments (e.g., those with a history of traumatic brain injury) to rely on their own executive functions in order to problem solve and reason in real-life situations requiring them to do so (e.g., taking college classes).
9710997|NCT04628741|Experimental|Apprenticeship Approach for College Students|The Apprenticeship Approach is a novel treatment approach that incorporates explicit education about: (a) traumatic brain injury definition; (b) traumatic brain injury symptomatology; and (c) individuals who may be able to provide assistance to the individual with traumatic brain injury into the existing Dynamic Coaching Model.
9710998|NCT04628598|Experimental|Home visiting pregnant women|The pregnant women in the experimental group will be given education and care with home visits.
9710999|NCT04628598|No Intervention|Control Group|Home visits will not be made to the control group, only the primary care antenatal care will be followed.
9711000|NCT04628247|Experimental|Study group|They will receive the same traditional physical therapy exercise program in addition to gait training on spring gravity bar for one hour
9711001|NCT04628234||Patients with an onco-hematologic solid tumor in palliative care|
9711002|NCT04628637||Control Group|"Inclusion Criterias are consisted of; Not to have known acute, subacute or chronic disease history, Not to suffer from any infection in the last fortnight, Not to be on a particular medication, Presenting to the ED with reasons other than infectious complaints, and Giving their written consent to participate in the study.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease"
9711003|NCT04628637||Covid-19 (-) Pneumonia Group|Inclusion Criterias are consisted of; Presenting to the Covid-19 outpatient policlinic of the ED with pneumonia symptoms To have CT imagings were not compatible with Covid-19 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria To have nasopharyngeal swab samples taken in the ED were negative for PCR, and To give their informed consent to participate in the study. Exclusion Criteria The exclusion criteria consisted of diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative
9711004|NCT04628637||Covid-19 Infection Group|"This cohort included the patients InculUsion Criteria Presenting Whose CT imagings were normal in accordance with the RSNAEC criteria and whose PCR tests were positive To have Covid-19 PCR tests were positive as a result of contact tracing, Presenting to the ED for further examination.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative."
9711005|NCT04628533|Experimental|Four Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 16 weeks in a well-established behavioral weight loss program.
9711006|NCT04628533|Active Comparator|Six Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 24 weeks in a well-established behavioral weight loss program.
9711007|NCT04628299|Placebo Comparator|Sham Laser|A non-emission laser will be applied in plantar fascia
9711008|NCT04628299|Experimental|Experimental group Myofascial Induction|Myofascial Induction in plantar fascia
9711009|NCT04628624|Placebo Comparator|Placebo group|Placebo - capsulated, colour matched potato starch (~450mg per capsule) - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
9711010|NCT04628624|Experimental|Green tea 1|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
10194315|NCT03079401|Experimental|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
9711011|NCT04628624|Experimental|Green tea 2|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG + 150mg quercitin and 150mg alpha lipoic acid - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
9711012|NCT04628377||Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (JACC Cardiovascular Intervention 2020;13:1155-67), which evaluated invasive physiologic indices from culprit and non-culprit vessels of acute myocardial infarction patients. From the study cohort, 31 STEMI patients who underwent IMR measurement in culprit vessel after successful revascularization will be analyzed. In these patients, diagnostic accuracy of angiography-derived IMR will be compared with invasive IMR.
9711013|NCT04628377||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the culprit vessel after successful revascularization. Those patients have follow-up data after 10 years from index procedure. This cohort is STEMI subgroup derived from Institutional registry of Samsung Medical Center, whose results were previously published (JACC Cardiovascular Intervention. 2019 Apr 8;12(7):607-620.) Among 490 STEMI patients from the overall study cohorts, 309 patients with available angiograms and who were suitable for angiographic FFR and IMR measurement will be analyzed. Primary clinical outcome will be cardiac death at 10 years from index procedure. Secondary outcome will be any myocardial infarction, ischemia-driven revascularization, definite or probable stent thrombosis, congestive heart failure admission at 10 years from index procedure.
9711014|NCT04628273||radiolucent stone group|
9711015|NCT04628273||radiopaque stone group|
9711016|NCT04628208||Negative for COVID-19|Subject determined to be negative for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
9711017|NCT04628208||Positive for COVID-19|Subject determined to be positive for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
9711018|NCT04628156||Outpatients in Cerebral Palsy Greece - Open Door|Outpatients with a diagnosis of cerebral palsy
9711019|NCT04627961|Experimental|Patient|Patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease
10194316|NCT03079401|No Intervention|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
10194317|NCT03079297|Experimental|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
9711020|NCT04628000||Vitamin D deficiency and COVID19|Vitamin D deficiency and COVID19
9711021|NCT04628052|Experimental|Music|
9711022|NCT04628052|No Intervention|No-Music|
9711023|NCT04628026|Experimental|1|standard chemotherapy in combination with venetoclax
9711024|NCT04628026|Placebo Comparator|2|standard chemotherapy in combination with placebo
9711025|NCT04627870|Experimental|DCB group|use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis
9711026|NCT04627870|Active Comparator|PTA group|use PTA balloon to treat intracranial in-stent restenosis
9711027|NCT04627844|Placebo Comparator|Delayed Feeds|"Patients will receive tube feeds beginning at 6 hours after PEG tube placement. This is our institutions current practice~Intervention Type: Dietary"
9711028|NCT04627844|Experimental|Immediate Feeds|"Patients will receive tube feeds beginning immediately after PEG tube placement.~Intervention Type: Dietary"
9711029|NCT04628143|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
9711030|NCT04628143|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
9711031|NCT04628104||COVID-19 patients presented with myocardial infarction|
9711032|NCT04628104||Non-COVID-19 patients presented with myocardial infarction|
9711033|NCT04628117|No Intervention|Control|Nutritional counselling by individualized nutritional plan for 8 weeks.
9711034|NCT04628117|Experimental|Oral nutritional supplementation|Nutritional counselling by individualized nutritional plan plus oral nutritional supplementation for renal disease (237 mls per day) for 8 weeks.
9711035|NCT04628013|Experimental|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied for a single treatment in Aim 1 and after a washout period, will be applied 3x/week for 2-weeks (6 sessions) for Aim 2.
9711036|NCT04628169||group A|group A : placental tissue of 30 patients with placenta accreta
9711037|NCT04628169||group B|group B : placental tissue of 20 normal pregnancy as a control group
9711038|NCT04627792|Other|Waitlist Group|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
9711039|NCT04628091|Experimental|Test group|Test group is composed of 20 women of reproductive age devoid of any pathology coming to the hospital for a salpingectomy for contraceptive purposes or for a total hysterectomy.
9711040|NCT04627883|Other|Group 1:2|Patients in the control group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2.
10194318|NCT03079297|Placebo Comparator|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
9711041|NCT04627883|Other|Group 2:1|Patients in the IRV group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1.
9711042|NCT04627857|Active Comparator|Arm 1: Manual toothbrush|
9711043|NCT04627857|Experimental|Arm 2: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
9711044|NCT04627857|Experimental|Arm 3: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
9711045|NCT04627857|Experimental|Arm 4: Sonic toothbrush (Philips Sonicare ProtectiveClean) and water flosser|
9711046|NCT04627987||Main study|Patients with severe, symptomatic aortic stenosis will be recruited and followed up with primary outcome of heart failure death and hospitalisation (n=192). Of these, 170 will have an implantable cardiac monitor placed to detect presence and burden of non-sustained VT.
9711047|NCT04627909||Group under Robot treatment|Interaction with the Humanoid Robot for 15 minutes
9711048|NCT04627909||Group involved with medical personnel|Interaction with medical personnel for 15 minutes
9711049|NCT04627909||Control group|Exclusive interaction with the caregiver for 15 minutes
9711050|NCT04627935||COPD patients|Patients with a diagnosis of COPD aged over 60 years
9980033|NCT01387828|Active Comparator|Laparoscopy|Includes all patient underwent intervention with a laparoscopic approach, even if converted to open surgery during intervention
9980034|NCT01387828|Active Comparator|Open surgery|Includes all the patients underwent intervention with a laparotomic approach; it does not include patient underwent laparoscopic approach and then converted in laparotomy.
10194319|NCT03059472|Experimental|Group 1 (Intervention)|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
9711051|NCT04627701|Experimental|ClearRing Device|
9980035|NCT01387841|Experimental|Yoga group|Yoga intervention with standard antiemetic care
9980036|NCT01387841|Active Comparator|PMRT/Jacobsons Relaxation training|25 minutes of progressive muscle relaxation training will be given to this group with standard antiemetic care
9980037|NCT01387841|No Intervention|Standard antiemetic care|Standard antiemetic care only
9980038|NCT01387867|Experimental|Strength training|Strength training three times weekly, i.e.supervised strength training twice weekly and un-supervised strength training once weekly for 4 months.
9980039|NCT01387867|Experimental|Nordic Walking|Nordic walking three times weekly, i.e.Nordic walking twice weekly and un-supervised Nordic walking once weekly for 4 months.
9980040|NCT01387867|Active Comparator|Unsupervised home based exercise|The home based unsupervised exercise comprised exercises recommended by the Danish Arthritis Association.
10194320|NCT03059472|Experimental|Group 2 (Delayed intervention)|Delayed intervention participants will participate in the same activities as Group 1 but 6 months after Group 1.
10194321|NCT03045289|Experimental|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
10194322|NCT03045289|No Intervention|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
9779399|NCT05306639|Experimental|Spinal magnetic stimulation|Spinal magnetic stimulation group will receive repetitive spinal magnetic stimulation sessions for a total of 12 sessions. Using the Neuro-MS/D machine, circular coil will be used to stimulate S2,3 and 4 sacral roots. The outer rim of the coil will be positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2) Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 15 Hz, burst length = 10 seconds, inter-burst interval = 30 seconds with a total of 1500 pulses
10194323|NCT03007030|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10194324|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
9785177|NCT01244893|Other|Acuvue Advance Plus postPQ/Acuvue Advance Plus prePQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification worn first and Acuvue Advance Plus silicone hydrogel contact lens manufactured after process qualification worn second.
9980041|NCT01387880|Experimental|Cetuximab, everolimus, irinotecan|
9980042|NCT01387880|Active Comparator|Cetuximab, everolimus and Irinotecan.|"Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.~Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus."
9980043|NCT01387893|Experimental|Immediate & Delayed Instruction|Male patients with mild to moderate lower urinary tract symptoms will alternately be assigned to either immediate intervention or delayed intervention groups. Statistical assessments will be performed to establish comparability of baseline characteristics in the two groups.
9980044|NCT01387906|Experimental|Topical bimatoprost for eyebrows|Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
9980045|NCT01387919|Experimental|1|healthy young and lean men
9980046|NCT01387945|No Intervention|HBPM only|
9980047|NCT01387945|Experimental|HBPM+website+patient navigator|
9980048|NCT01387958|Experimental|LCQ908|
9980049|NCT01387958|Placebo Comparator|Placebo|
9980050|NCT01387971||ocular surface disorders|various ocular surface disorders
9980051|NCT01387984||Type 2 diabetes mellitus|
9980052|NCT01387997|Experimental|1|
9980053|NCT01388010|Experimental|1 = Test product|Arm 1 - Intervention 1 (probiotics)
9980054|NCT01388010|Other|2 = Control product|Arm 2 - Intervention 2 (control)
9980055|NCT01388023|Active Comparator|smellx|test group- SmellX palatal patch with the herbal formula
9980056|NCT01388023|Placebo Comparator|smellx palatal patch|negative control group- SmellX palatal patch with out the herbal formula
9711052|NCT04627805|No Intervention|Phase 2: Usual Care|The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
9711053|NCT04627805|Experimental|Phase 3: MyPath Pilot|Following completion of the usual care arm, the investogators will enroll a second group of 33 women with SUDs to participate in the MyPath intervention arm. Participants will complete the same pre-visit survey as the usual care group. In addition, they will be provided a website link to navigate through the online MyPath tool. Following completion of MyPath, participants will receive a summary page that they will be encouraged to use as a guide when discussing their reproductive health with their substance use treatment provider at their next scheduled therapy visit. After the visit, they will complete the post-visit survey. In addition to satisfaction with reproductive health services, the intervention group will be asked specific questions about their perception of the MyPath tool.
9711054|NCT04627779|Experimental|Male Group|
9711055|NCT04627779|Active Comparator|Female Group|
9711056|NCT04627571||Patient Population|Patients diagnosed with neurotrophic keratopathy.
9711057|NCT04627584|Active Comparator|MW33 injection-1200mg|
9711058|NCT04627584|Active Comparator|MW33 injection-2400mg|
9711059|NCT04627584|Placebo Comparator|Placebo|
9711060|NCT04627519|No Intervention|SoC alone|Standard of Care alone (days 1 to 9)
9711061|NCT04627519|Experimental|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after meal (every 12 hours) for 9 days to be provided together with Standard of Care.
10194325|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
9711062|NCT04627532|Experimental|Treatment|PF-07304814 assignment
9711063|NCT04627532|Placebo Comparator|Placebo|Placebo assigned
9711064|NCT04627636|Experimental|study group|which treated with MTrPs release combined with shockwave therapy and conventional program
9711065|NCT04627636|Experimental|control group|which treated with conventional physical therapy program
9980057|NCT01388023|Active Comparator|chlorhexidine|poositive control group-mouth wash with chlorhexidine 0.125%
9980058|NCT01388023|Active Comparator|listerine|listerine mouth wash
10194326|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
10194327|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
10194328|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
10194329|NCT02993146|Experimental|Treatment (ropidoxuridine, WBRT)|Patients receive ropidoxuridine PO QD on days 1-28 and undergo WBRT daily for not more than 5 days per week beginning on day 8 for a total of 15 fractions in the absence of disease progression or unacceptable toxicity.
10194330|NCT02991144|Experimental|Dose 1: 2.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
9711066|NCT04627467|Experimental|Chloroquine 150mg base|Volunteers received chloroquine tablets orally at days 0, 15, 30, 45, 60 and 75.
9711067|NCT04627766|Experimental|Monitored children|PICU Children that will be monitored with the device
9711068|NCT04627506|No Intervention|Control Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design.~Standardized anesthesia and surgical management will be conducted according to routine institutional practice."
9980059|NCT01388036|Experimental|esmolol infusion|infusion of esmolol during rest and exercise
9980060|NCT01388049|Experimental|virus detection|
9980061|NCT01388062|Experimental|virus detection|
9980062|NCT01388075|Experimental|Rifampicin|Consecutive treatments with rifampicin and placebo
9980063|NCT01388088|Active Comparator|Spironolactone|Increases the level of potassium
9980064|NCT01388088|Active Comparator|Amiloride|Increases the level of potassium
9980065|NCT01388088|Placebo Comparator|Placebo|
9980066|NCT01388101|Experimental|LECT2 detection|single-arm study: Electrosensing antibody probing system(e-AB sensor)
9980067|NCT01388114|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
9980068|NCT01388140||psychiatric inpatients, regardless of clinical diagnoses|
9980069|NCT01388153|Experimental|Arm 1|
9980070|NCT01388153|Experimental|Arm 2|
9980071|NCT01388153|Active Comparator|Arm 3|
10194331|NCT02991144|Experimental|Dose 2: 6.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
10194332|NCT02991144|Experimental|Dose 3: 1.0 × 10^13 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
9711069|NCT04627506|Experimental|Study Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
9711070|NCT04627688|Active Comparator|Standard dietary advices|
9711071|NCT04627688|Experimental|Time restricted feeding|
10194333|NCT02991144|Experimental|Dosing Process Optimization at Optical Biological Dose (OBD)|Oral prednisone (or prednisolone), 60 mg tapered over 9 weeks, initiated before dosing with DTX301. DTX301 (scAAV8OTC; optimal biologic dose) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
10194334|NCT02986789|No Intervention|Control Group|Clinicians will be performing blood transfusions using hospital standard of care procedures.
10194335|NCT02986789|Experimental|Evaluation Group|Clinicians will be guiding blood transfusions using SpHb with In vivo feature as a trigger for laboratory blood draws and PVi to inform fluid administration decisions in addition to hospital standard of care procedures.
9711072|NCT04627727|Experimental|low FODMAP diet|
9711073|NCT04627623||Screened arm|"6000 peoples (3x2000) in all ages randomly selected from the general population of three towns (Katowice, Sosnowiec, Gliwice).~From all invited is collected a venous blood samples (5ml) to assay IgM and IgG antibodies."
9711074|NCT04627480|Experimental|Experiment Arm|Active Fisher Wallace device for full 8 weeks
9711075|NCT04627480|Sham Comparator|Sham Arm|Sham Fisher Wallace device for 4 weeks, then cross over at 4 weeks to active device.
9711076|NCT04627740|Experimental|CART treatment|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
9711077|NCT04627363|Experimental|HAIC plus Bevacizumab and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 240 mg intravenously every 3 weeks. Bevacizumab 15 mg/kg intravenously every 3 weeks.
9711078|NCT04627155|Experimental|7mg dose group|
9711079|NCT04627155|Experimental|14mg dose group|
9711080|NCT04627207|Experimental|Reference-Reference-Test|Sequence 1
9711081|NCT04627207|Experimental|Reference-Test-Reference|Sequence 2
9711082|NCT04627207|Experimental|Test-Reference-Reference|Sequence 3
9711083|NCT04627350||LDCT|Single arm - all patients undergo low-dose CT (LDCT) examination of lungs
9711084|NCT04627337|Experimental|Saccharomyces boulardii (1 capsule of 250 ug BID) + Dietary advice|Patients received 1 capsule of Saccharomyces boulardii 250 ug BID plus dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
9980072|NCT01388179|Active Comparator|Real rTMS treatment|low-frequency rTMS to the left DLPFC (Dorsa-Lateral Pre-Frontal Cortex) prior to high-frequency deep rTMS to the FFA (Fusi-Form Area) through the STS(Superior Temporal Sulcus).
10194336|NCT02974907|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
10194337|NCT02974907|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
10194338|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 1b Dose Escalation|Participants with B-cell non-Hodgkin's lymphoma will receive 1 mg/kg magrolimab priming dose on Day 1 of Cycle 1 followed by weekly maintenance doses of 10, 20, 30, or 45 mg/kg on Days 8, 15, 22 for Cycle 1 and Days 1, 8, 15, and 22 for each cycle to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose and schedule (RP2DS) in combination with rituxumab 375 mg/m^2. Cycle length is 28 days.
10194339|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Indolent Lymphoma|Participants with indolent lymphoma will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
10194340|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma|Participants with diffuse large B-cell lymphoma (DLBCL) will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
10194341|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive 1 mg/kg magrolimab priming dose on Day 1 for Cyle 1 followed by maintenance doses of 30 or 45 mg/kg on Days 8, 11, 15, 22, and 29 for Cycle 1, every week for Cycle 2, and every 2 weeks for each cycle to determine maximum tolerated dose (MTD) + rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2. Cycle length is 28 days.
10194342|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive magrolimab at a dose determined from Phase 1b Safety Dose-Escalation Phase in combination with rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2.
10194343|NCT02937376|Experimental|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
10194344|NCT02937376|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
10194345|NCT02927691|Experimental|Immediate Treatment|Participants will begin treatment immediately following baseline testing.
10194346|NCT02927691|Other|Delayed Treatment|Following baseline testing, participants will receive no treatment for five weeks, then begin treatment immediately following a second baseline testing session.
9711085|NCT04627337|Active Comparator|Dietary advice without medication|Patients received dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
9711086|NCT04627090||LCH Patients|Adult patients with LCH, diagnosed starting from January 2001
9711087|NCT04627324|Experimental|The smart toothbrush and smart mirror (STM) system toothbrushing instruction (TBI)|Participants received using the STM system TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
9711088|NCT04627324|Active Comparator|conventional toothbrushing instruction (TBI)|Participants received using conventional TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
9711089|NCT04627194||Mild and asymptomatic COVID-19 patients|Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.
9711090|NCT04627194||Moderate severity COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia] at the time of hospitalization.
9711091|NCT04627194||Severe-to-critical COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) < 90% on room air] or for critical COVID-19 disease presentation [including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium] at the time of hospitalization.
9711092|NCT04627194||COVID-19 survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who survived.
9711093|NCT04627194||COVID-19 non-survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.
9711094|NCT04627376|No Intervention|Control|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires.
9711095|NCT04627376|Experimental|Intervention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
9711096|NCT04627454|Experimental|dynamic cervical implant|dynamic cervical implant in treatment of cervical disc disease
9711097|NCT04627454|Experimental|discectomy|insertion of dynamic cervical implant post cervical discectomy single level
9711098|NCT04627402|Experimental|Injection combo agents|Intravitreous injection of triamcinolone acetonide (TA) and conbercept.
9711099|NCT04627402|Active Comparator|Injection single agent|Intravitreous injection of conbercept only.
9711100|NCT04627116|Experimental|Tecarfarin 10mg|
9711101|NCT04627116|Experimental|Tecarfarin 20mg|
9711102|NCT04627116|Experimental|Tecarfarin 30mg|
10194347|NCT02921789|Active Comparator|Standard of Care (SOC) Regimen|Participants received SOC regimen (basiliximab induction, MMF, Tacrolimus, Methylprednisone, Prednisolone). Basiliximab 20 milligrams (mg) administered by intravenous injection prior to transplantation or intra- operatively before revascularisation as induction therapy and 20mg on day 3 or 4 or 5 post-transplant. MMF 1 gram (g) administered orally or intravenously twice daily until 12 months post transplant. Tacrolimus 0.1 milligram per kilogram per day (mg/kg/day) (two equally divided doses at 0.05 mg/kg/day every 12 hours with a target trough level of 4 - 11 nanogram per milliliter (ng/mL) administered orally within 48 hours post-transplant until 12 months post transplant. Methylprednisone 500, 250, 125 and 60mg administered orally or intravenously on days 0, 1, 2 and 3 respectively and continue through 12 months post transplant. Prednisolone administered orally by tapered doses of 20-30 mg on days 4-14, 10-20mg on days 15-28, 5-10mg on days 29 through 12 months post transplant.
10205427|NCT00882050|Experimental|Exentatide 0.27 ng/kg/min|"Exenatide to be infused by intravenous method at 0.27 ng/kg/min (0.066 pmol/kg/min) over 3-6 hours.~Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
9711103|NCT04627116|Experimental|Tecarfarin 40mg|
9711104|NCT04627298|Active Comparator|Video Game|This arm tests use of video game to help preteens in the decision to pursue HPV vaccination. Participants in the intervention group are asked to play the Land of Secret Gardens game and complete 3 tasks: (1) play a shield game with blue spikey virus balls, (2) find hidden objects in 4 different garden sheds, and (3) create a potion (vaccine). Participants in the intervention arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance, the Physical/Emotional/Narrative Presence Scale (PENS) to gauge preteens' immersion in the game, and game play experience.
9711105|NCT04627298|No Intervention|No Video Game|This arm does not test the video game. Participants in the comparison arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance.
9711106|NCT04627220||group 1|Group 1: Pressure of arterial oxygen> 200 mmHg during the coronary surgery
9711107|NCT04627220||group 2|Group 2: Pressure of arterial oxygen<200 mmHg and >80 mmHg during the coronary surgery
9711108|NCT04627233|Placebo Comparator|No intervention:control group|
9711109|NCT04627233|Experimental|Experimental:Intervention group|
9711110|NCT04627259||patient|patients with thumb pain or functional problems
10194348|NCT02921789|Experimental|Bleselumab Regimen|Participants received bleselumab regimen (basiliximab induction, bleselumab, Tacrolimus, Methylprednisone, Prednisolone). Basiliximab 20mg administered by intravenous injection prior to transplantation or intra - operatively before revascularisation as induction therapy and 20mg on day 3 or 4 or 5 post-transplant. Bleselumab 200mg administered by intravenous infusion on day 0, 7, 14, 28, 42, 56, 70, 90 and once per month until month 12. Tacrolimus 0.1 mg/kg/day (two equally divided doses at 0.05 mg/kg/day every 12 hours with a target trough level of 4 - 11 ng/mL) administered orally within 48 hours post transplant until 12 months post transplant. Methylprednisone 500, 250, 125 and 60mg administered orally or intravenously on days 0, 1, 2 and 3 respectively and continue through 12 months post transplant. Prednisolone administered orally by tapered doses of 20-30 mg on days 4-14, 10-20mg on days 15-28, 5-10mg on days 29 through 12 months post transplant.
10194349|NCT02918500|No Intervention|Placebo|Participants will receive 3 weeks of inactive NRT patches.
10194350|NCT02918500|Active Comparator|Active|Participants will receive 3 weeks of active NRT patches
10194351|NCT02903940|Experimental|CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
9711111|NCT04626908|Experimental|Administration of GC022F CAR-T cells|Each subject receive GC022F CAR T-cells by intravenous infusion
9711112|NCT04627051|Experimental|Dysfunction AV graft|Dysfunctional AV graft stenosis treated with atherectomy and drug coated balloon angioplasty
9711113|NCT04626895|Other|Scalp Cooling|Patients who be will using the scalp cooling device during chemotherapy will be enrolled in tis arm
9711114|NCT04626895|No Intervention|Non Scalp-Cooling|Patients who do not use scalp cooling device during chemotherapy will be enrolled in this arm.
9711115|NCT04627181|Experimental|FCM + placebo|"Ferric carboxymaltose: Single dose, 500 mg~Placebo: Single dose"
9711116|NCT04627181|Experimental|B12 + placebo|"Hydroxycobalamine: Single dose, 1000 mcg~Placebo: Single dose"
9711117|NCT04627181|Experimental|FCM +B12|"Ferric carboxymaltose: Single dose, 500 mg~Hydroxycobalamine: Single dose, 1000 mcg"
9711118|NCT04627181|Placebo Comparator|Placebo + placebo|"Placebo: Single dose~Placebo: Single dose"
9711119|NCT04626817|Active Comparator|Isotretinoin receiving group|Isotretinoin receiving group for acne vulgaris
9711120|NCT04626817|Placebo Comparator|Local treatment receiving group|Local treatment receiving group for acne vulgaris
10204683|NCT05174182|Active Comparator|Usual care|The investigators have performed a step-wise mixed-methods sub-study to investigate current standard of care in the most common settings in Denmark (Sports Physiotherapists mainly from private primary practice, and Orthopedic Surgeons caring for these patients, invited from all public secondary care orthopedic departments in Denmark). Results were then combined with reports from patients seen in the clinic (n=34) who were questioned in detail on what modalities and advice they had previously received. The results were mostly compatible with the recent international survey of clinicians treating Osgood-Schlatter. With the findings from this process the investigators have developed a patient-aimed leaflet, which will contain vignettes and elaborations of the multimodal approaches included in the standardized usual care package, which will be implemented through four visits (at months 0, 1, 2, 3) with a physiotherapist (mirroring the plan of care of the experimental group).
9711121|NCT04627272|Experimental|AutoDX and Gold Standard|A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera
9711122|NCT04626739|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) non-Hodgkin lymphoma
9711123|NCT04627129|Experimental|SHR2554+Itraconazole|SHR2554 50 mg QD on Day 1 and Day 8, Itraconazole 200 mg once daily (QD) from Study Day 4 - 12
9711124|NCT04626999|Active Comparator|Synovial fluid COMP|Knee joint fluid is aspirated for ELISA COMP examination
9711125|NCT04626999|Active Comparator|MRI T2 Mapping|Affected knee is subjected to an MRI T2 mapping examination to see the condition of cartilage
9711126|NCT04626999|Active Comparator|Instability Examination|Lachmant Test, Pivot shift test and Rolimeter Measurement
9711127|NCT04626856|Experimental|Low dosage in adults|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
9711128|NCT04626856|Experimental|Medium dosage in adults|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
9711129|NCT04626856|Experimental|High dosage in adults|High dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
9711130|NCT04626856|Experimental|Low dosage in adolescents|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
9711131|NCT04626856|Experimental|Medium dosage in adolescents|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
9711132|NCT04626856|Experimental|High dosage in adolescents|High dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
9711133|NCT04626856|Experimental|Low dosage in infants (7-71 months old)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
9711134|NCT04626856|Experimental|Medium dosage in infants (7-71 months old)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
9711135|NCT04626856|Experimental|High dosage in infants (7-71 months old)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
9711136|NCT04626856|Experimental|Low dosage in infants (2-6 months old, two-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
9711137|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, two-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
10194352|NCT02903381|Experimental|Nivolumab, Lenalidomide, Dexamethasone|"A treatment cycle is defined as 28 consecutive days.~Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
10194353|NCT02896257|Other|Proactive patient-tailored electronic consult (E-consult)|Primary care clinicians receive patient-tailored guideline concordant treatment recommendations, including orders and rationale to discontinue inhaled corticosteroids.
10194354|NCT02896257|No Intervention|Usual care|Standard practice (usual care). Primary care providers treat their patients as usual.
10194355|NCT02866279|Experimental|Postplacental|contraceptive implant placed within 30 minutes of placental delivery
10194356|NCT02866279|Experimental|Immediate Postpartum|Contraceptive Implant placed 1-3 days postpartum
10194357|NCT02866279|Active Comparator|Delayed|Contraceptive Implant placed 6 or more weeks postpartum
10194358|NCT02863718|No Intervention|Watch & wait|Watch & wait
10194359|NCT02863718|Placebo Comparator|Placebo 420 mg/d|Placebo 420mg/d
10194360|NCT02863718|Active Comparator|Ibrutinib 420mg/d|Ibrutinib 420mg/d
10194361|NCT02810990|Experimental|Bosutinib treatment|
10194362|NCT02774265|Active Comparator|VTE prophylaxis with Enoxaparin 30mg BID|The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
10194363|NCT02774265|Active Comparator|VTE prophylaxis with Aspirin 81mg BID|The group receiving VTE prophylaxis with ASA 81mg PO BID
10194364|NCT02767973|Experimental|Woodsmoke Exposure|
10194365|NCT02736617|Experimental|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
10194366|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
10194367|NCT02712515||Parkinson's disease and dystonia|Participants in this group with Parkinson's disease and/or dystonia will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
10194368|NCT02697279|Active Comparator|Traditional Incision and Drainage|Treatment of a simple cutaneous abscess with traditional incision and drainage with or without packing, decision made at the discretion of the provider.
10194369|NCT02697279|Experimental|Loop drainage|Treatment of a simple cutaneous abscess with incision and drainage using the loop drainage technique.
10194370|NCT02695992|Active Comparator|Metoprolol|Metoprolol, extended release tablets. 100 mg daily
10194371|NCT02695992|Active Comparator|Diltiazem|Diltiazem, extended release tablets. 360 mg daily
10194372|NCT02667418|Other|Fidaxomicin|Standard 10-day fidaxomicin treatment for Clostridium difficile
10194373|NCT02667418|Other|Vancomycin T/P|Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile
10194374|NCT02667418|Other|Vancomycin|Standard 10-day vancomycin treatment for Clostridium difficile
10194375|NCT02652468|Experimental|Peripheral Blood Stem Cell Transplant|"PREPARATIVE REGIMEN: Participants receive fludarabine phosphate IV over approximately 30 minutes on days -5 to -2, and mesna IV over 24 hours and cyclophosphamide IV over approximately 2 hours on days -5 and -4. Participants also undergo total nodal irradiation on day -1.~TRANSPLANT: Participants undergo T-Cell Receptor (TCR) alpha-beta/CD19 depleted hematopoietic stem cell transplant on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg participant body weight (BW), patients may receive a second graft on day 1.~GVHD PROPHYLAXIS: Participants receive mycophenolate mofetil orally twice a day (PO BID) on days -1 to 30, tacrolimus PO or IV on days 2-180 with a taper beginning on day 90 (given only if graft TCR alpha-beta+ cell content is over 1 x 10^5 cells/kg ideal BW of the patient), and rituximab IV on day 2 (given only if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the participant)."
10194376|NCT02618551|Experimental|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
10194377|NCT02616705||IgG4-related sclerosing cholangitis|Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
10194378|NCT02616705||Controls|cholangiocarcinoma, PSC, and other patients with biliary strictures
10194379|NCT02590328||Screened patients|SCID screening: some drops of blood are placed on a second Guthrie card when current screening is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
10194380|NCT02582489|Experimental|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
10194381|NCT02582489|Placebo Comparator|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
10194382|NCT02579265|Experimental|Smoflipid 20%|"Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
9980073|NCT01388179|Sham Comparator|Sham rTMS treatment|Sham coil which simulate the real coil action
10194383|NCT02579265|Active Comparator|Intralipid® 20%|"Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
10194384|NCT02525029|Experimental|1: High-Risk aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.~Individual patient dose reductions: If a patient has toxicity that meets the definition of dose limiting, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 7. Assess response at day 7:~If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.~If no response, the patient will be taken off study treatment."
10204684|NCT05171218|Experimental|Music & Auditory Beat Stimulation|Participants listened to calm music with theta auditory beat stimulation for 24 minutes
9711138|NCT04626856|Experimental|High dosage in infants (2-6 months old, two-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
9711139|NCT04626856|Experimental|Low dosage in infants (2-6 months old, three-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
9711140|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, three-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
9711141|NCT04626856|Experimental|High dosage in infants (2-6 months old, three-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
9711142|NCT04626856|Placebo Comparator|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
9711143|NCT04626856|Placebo Comparator|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
9711144|NCT04626960||Patient|OAB patients
9711145|NCT04626960||Control|Healthy
9711146|NCT04626830|Experimental|Mobile Application Intervention|Participants in the intervention group will receive 6 months the mobile application (OKTED) for improving symptoms and adherence to oral anticancer agents. The mobile application will consist of three modules. The first module will include OAA-specific information, a calendar in which start/end dates can be record, and a medication reminder. The second module will include information about common and urgent symptoms and recommendations for the management of these symptoms. The last module will comprise a question and answer section.
9711147|NCT04626830|No Intervention|Standard Care|Participants in the control group will receive standard oncology care only.
9711148|NCT04626700|Experimental|iNAP|
9711149|NCT04626700|Active Comparator|CPAP|
9711150|NCT04626934|Active Comparator|control group|Patients in the control group will recieve conventional occupational therapy treatment: 3 weeks of all together 12 sessions, 45 minutes each.
9711151|NCT04626934|Experimental|Intervention group|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
9711152|NCT04626687|Experimental|test DCB group|use the DCB made by Acotec Scientific
9711153|NCT04626687|Active Comparator|RESTORE DCB group|use the DCB made by CARDIONOVUM GmbH
9711154|NCT04626778|Active Comparator|Peroxyl|1.5% Hydrogen Peroxide mouthwash
9711155|NCT04626778|Placebo Comparator|placebo mouthwash|0.0% Hydrogen peroxide mouthwash
9711156|NCT04626765|Experimental|volunteer|The child's parents or legal guardians voluntarily signed the informed consent form, and the child himself/herself met the enter criteria for the diagnosis of patients with acute B-lymphoblastic leukemia (B-ALL) expressing specific target antigens
9711157|NCT04627077||SIC drug therapy patients|Patients with a cancer diagnosis currently being treated at SIC clinic
9711158|NCT04626648|No Intervention|Surgery without intraoperative pause|Surgical procedure without pause
10204685|NCT05171218|Active Comparator|Music Alone|Participants listened to calm music for 24 minutes
10204686|NCT05171218|Active Comparator|Auditory Beat Stimulation|Participants listened to theta auditory beat stimulation for 24 minutes
10204687|NCT05171218|Sham Comparator|Pink Noise|Participants listened to pink noise for 24 minutes
10204688|NCT05170893|Experimental|Intervention group|Oral Coenzyme Q10 capsules daily for 12 weeks.
9711159|NCT04626648|Experimental|Surgery with intraoperative pause|Three-minute long intraoperative pause, including a sugar-containing drink
9711160|NCT04626557||Women with astma|At the 7th -14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
9711161|NCT04626557||Women without asthma|At the 7th - 14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
9711162|NCT04626973|Experimental|Intensive-targeting group|
9711163|NCT04626973|Active Comparator|Conventional-targeting group|
9779400|NCT05306639|Experimental|Neuromodulation|Neuromodulation group will receive 12 sessions of bilateral transcutaneous posterior tibial neuromodulation using (Myomed 632®, Enraf Nonius, Delft, Netherlands) machine, the active rubber surface was placed behind the medial malleolus and the reference electrode was placed 10 cm proximal. Adjustment of the electric current was as follows: continuous current, pulse duration 200 ms, frequency 20 Hz; each session lasts for 30 min. The current intensity was adjusted according to the tolerance of the patient or until the big toe curls into plantar flexion
9785178|NCT01244906|Experimental|Reduced Intensity Allogeneic Stem Cell Transplantation|All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
9785179|NCT01244984|Experimental|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
9785180|NCT01244984|Experimental|Fluticasone Furoate|Inhaled corticosteroid
9711164|NCT04626752|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) Multiple Myeloma (MM)
9711165|NCT04626726|Experimental|Volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with acute B lymphocytic leukemia expressing specific target antigens
9711166|NCT04626609||EoE group|Patients with confirmed eosinophilic esophagitis
10194385|NCT02525029|Experimental|2a: Steroid-Dependent aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 14. Assess response at day 14:~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.~If no response, the patient will be taken off study treatment"
10194386|NCT02525029|Experimental|2b: Steroid-Refractory aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 14. Assess response at day 14:~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.~If no response, the patient will be taken off study treatment"
10194387|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
9711167|NCT04626609||GERD group|Patients with gastro-esophageal reﬂux disease
9711168|NCT04626609||Control group|Individuals with no esophageal disease
9711169|NCT04626531|Experimental|Intervention Group|After the pre-tests (Self-Care Activities, Self-Efficacy, Quality of Life) , the patients were given web based education and containing information and recommendations on self-management strategies for three months.
9711170|NCT04626531|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
9711171|NCT04626622||ARVI and influenza prophylaxis with Kagocel (n=50)|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
9711172|NCT04626622||ARVI and influenza prophylaxis without any antiviral medicines (n=25)|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
9711173|NCT04626661||Health volunteers|The study population will consist, initially, of healthy volunteers. This group was chosen to perform measurements on, to eliminate the effect of critical illness and interventions on the critically ill patients and to better explore the effect of time-since-application of the 5-aminolevulinic acid-patches.
9711174|NCT04626661||Patients admitted to the ICU after neurosurgery|This study population will consist of patients undergoing elective neurosurgery with planned postoperative recovery of at least 24 hours in the intensive care unit or medium care unit. Leiden University Medical Center is a neurosurgical center in which a wide variety of surgeries including tumor resection in the posterior cranial fossa (including vestibular schwannoma) are performed. Clinical experience has shown that this cohort of patients are in general, hemodynamically the most stable patients and receive the least amount of interventions compared to other cohorts of patients in the intensive care unit and medium care unit. For these reasons, the cohort of elective neurosurgical patients would be ideal to investigate the reason of the increased between- and within-subject variability of mitochondrial oxygen tension in the intensive care unit and medium care unit setting.
9711175|NCT04626570|Experimental|Cognitive and Behavioural Therapy plus Management as usual|12 sessions of CBT during 18 weeks AND management of obesity with nutritional and dietary treatment as usual
9711176|NCT04626570|No Intervention|Management as usual|management of obesity with nutritional and dietary treatment as usual
9711177|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fed condition|Single dose of 30 mg ferric maltol capsule in a fed condition
9711178|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fasted condition|Single dose of 30 mg ferric maltol capsule in a fasted condition
9711179|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fed condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition
9711180|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fasted condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition
9711181|NCT04626453|Experimental|sedentary older adults with Type 2 Diabetes|Sedentary older adults with Type 2 Diabetes as the intervention group will do a 2-month home exercise.
9711182|NCT04626453|No Intervention|Active older adults with Type 2 Diabetes|Active older adults with Type 2 Diabetes will not do exercise.
9711183|NCT04626453|No Intervention|Healthy older adults|Healthy older adults will not do exercise.
9711184|NCT04626440||Group 1|Group 1 [(A) subjects who are planning to receive surgery (mastectomy or BCS) as the first-line treatment for BC and followed by adjuvant therapy, or (B) subjects with BC recurrence at screening, who had received surgery for primary BC within 3 years prior to screening, and with primary tumor FFPE tissues available]
9711185|NCT04626440||Group 2|subjects who are planning to receive neoadjuvant therapy as the first-line treatment for BC and followed by surgery
9711186|NCT04626440||Group 3|Group 3-1 (subjects diagnosed with de novo and treatment naïve stage IV BC); or Group 3-2 [(A) stage IV subjects with BC recurrence beyond 3 years after surgery (mastectomy or BCS) or stage IV subjects who had received or are currently receiving treatments for BC].
9711187|NCT04626401|Placebo Comparator|Control diet during immobilisation|A 2 day controlled dietary intervention.
9711188|NCT04626401|Experimental|Branched chain amino acid restricted diet during immobilisation|A 2 day branched chain amino acid restricted dietary intervention.
9711189|NCT04626492||F0|Normal control group
10194388|NCT02489539|Experimental|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
10194389|NCT02489539|Experimental|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
10194390|NCT02484391|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
10194391|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
10194392|NCT02427698|Active Comparator|cyrolipolysis|
10194393|NCT02427698|Active Comparator|cryolipolysis plus subcision|
10194394|NCT02398825|Experimental|Ponatinib|
10194395|NCT02393248|Experimental|Dose Escalation|"Open-label dose escalation with an accelerated titration design based on observing each dose level for a period of 21 days.~Dose Expansion~Combination therapy:~Gemcitabine + Cisplatin + Pemigatinib~Pembrolizumab + Pemigatinib~Docetaxel + Pemigatinib~Trastuzumab + Pemigatinib~INCMGA00012 + Pemigatinib"
10194396|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
10194397|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
10194398|NCT02318654|Active Comparator|Ice Pack|
10194399|NCT02318654|Active Comparator|Topical EMLA cream|
10194400|NCT02307656|Other|Atazanavir and Cobicistat|"Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)~Stage 2:Taste Optimization using API (flavours and sweeteners)~Stage 3:Prototypes of the API - containing clinical trial materials"
10194401|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
10194402|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
10194403|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
10194404|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
10194405|NCT02216864|Experimental|Multiple Subcision|Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart.
10194406|NCT02216864|No Intervention|Control|Subjects will receive no intervention control on the other side of the face.
10194407|NCT02216838|Experimental|botulinum toxin A|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
9711190|NCT04626492||F1|Grade 1 of liver fibrosis
10194408|NCT02216838|Placebo Comparator|Saline Control|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
10194409|NCT02133248||kidney recipient waitlist|Subjects on waitlist for Kidney transplant who are sensitized
10194410|NCT02133248||chronic antibody mediated rejection|Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection
10194411|NCT02133248||control|Normal subjects-no kidney transplant or chronic rejection
10194412|NCT02090114|Experimental|Cohort A:Post-enzalutamide|Men with castration-resistant prostate cancer who have progressed on enzalutamide will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with enzalutamide 160 mg by mouth daily.
10194413|NCT02090114|Experimental|Cohort B: Post-abiraterone|Men with castration-resistant prostate cancer who have progressed on abiraterone will be enrolled to this cohort. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with abiraterone 1000 mg by mouth daily.
10194414|NCT02090114|Experimental|Cohort C: Castration Only|Men with metastatic prostate cancer who have only received first line hormone therapy with LHRH agonist alone or LHRH agonist plus an anti-androgen. Patients who have developed castrate resistance to first line therapy and have then received second line hormone therapy of any kind (including flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, enzalutamide, ARN-509 and investigational anti-androgens) are not eligible for enrollment in this cohort.
10194415|NCT02090114|Experimental|Cohort D: Mutation|Men with metastatic prostate cancer who have castrate resistant prostate cancer with inactivating somatic or germline mutations in the genes TP53, RB1 or PTEN identified using clinical grade sequencing of tumor tissue performed by qualified laboratory. Patients must have mutations in ≥2 of these genes to be eligible. Eligible patients must have progressed on first line hormone therapy with LHRH agonist alone and must have received at least one but not more than two second generation androgen ablative therapy (i.e. Abiraterone, Enzalutamide or Apalutamide).
9711191|NCT04626492||F2|Grade 2 of liver fibrosis
9711192|NCT04626492||F3|Grade 3 of liver fibrosis
9711193|NCT04626492||F4|Hepatic cirrhosis
9711194|NCT04626375|Placebo Comparator|Placebo|Placebo (2 vials per os without active substance every 12 hours)
10194416|NCT02031250|Active Comparator|Control Arm|Standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
10194417|NCT02031250|Experimental|Boost Arm|Boost radiation to hypoperfused/low-diffusion volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
10194418|NCT02019004|Active Comparator|Onabotulinum Toxin A|One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.
10194419|NCT02019004|Active Comparator|Incobotulinum Toxin A|The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.
10204689|NCT05170893|Placebo Comparator|Control group|Oral capsules similar to the intervention daily for 12 weeks.
9711195|NCT04626375|Active Comparator|Bioarginine|Bioarginine (2 vials per os of 1.66 g every 12 hours)
10194420|NCT02015351|Experimental|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.~Immunosuppression: cyclosporine and/or azathioprine"
10194421|NCT02013167|Experimental|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
10194422|NCT02013167|Active Comparator|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months."
10194423|NCT02004522|Experimental|Duvelisib|Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules
10194424|NCT02004522|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
9711196|NCT04626245|Experimental|Mindfulness training|Phone-delivered mindfulness training
9711197|NCT04626245|Other|Treatment as usual|Prenatal care
9711198|NCT04626310|Experimental|Dialectical behavior therapy - emotion regulation skills training|Dialectical behavior therapy - emotion regulation skills training
9711199|NCT04626310|Experimental|Dialectical behavior therapy - interpersonal effectiveness skills training|Dialectical behavior therapy - interpersonal effectiveness skills training
9711200|NCT04626310|Active Comparator|Non-skills-oriented interpersonal psychotherapy group|Non-skills-oriented interpersonal psychotherapy group
9711201|NCT04626167|Experimental|Intervention group|Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or construction.
9711202|NCT04626089|Experimental|Metformin glycinate|620 mg bid (PO) plus standard treatment for 14 days
10194425|NCT02000427|Experimental|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
9711203|NCT04626089|Placebo Comparator|Placebo|Placebo tablets bid (PO) plus standard treatment for 14 days
10194426|NCT01996436|Active Comparator|Nicardipine|Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty
9711204|NCT04626193|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline,Levofloxacien,tinadizole
9711205|NCT04626193|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole,amoxicilline
9711206|NCT04626284|Experimental|Donors After Circulatory Determined death|Recipients receiving an organ from donors after circulatory determined death
9711207|NCT04626336||Patients who undergo a cystectomy|Patients who undergo a cystectomy for cancer or not, since 2010 to 2020
9711208|NCT04626076||Aga Khan University|Pakistan
9711209|NCT04626076||Wits Reproductive Health Institute|South Africa
10194427|NCT01996436|Active Comparator|Verapamil|Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty
9711210|NCT04626076||African Medical and Research Foundation- Uganda|Uganda
9711211|NCT04626076||African Medical and Research Foundation- Kenya|Kenya
9711212|NCT04626076||African Medical and Research Foundation- Zambia|Zambia
9711213|NCT04626076||African Medical and Research Foundation- Senegal|Senegal
10204690|NCT05167721|Active Comparator|Arm 1|25 million mesenchymal stem cells administered intrathecally every 3 months for 4 injections
9711214|NCT04626076||World Mosquito Program|Indonesia
9711215|NCT04626076||54Gene|Nigeria
9711216|NCT04626076||African Institute of Biomedical Science & Technology|Zimbabwe
9711217|NCT04626232|Experimental|N SLEEVE|Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
9711218|NCT04626232|Other|SLEEVE|The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
9711219|NCT04626180|Active Comparator|Regular Extubation|
9711220|NCT04626180|Experimental|Pre Extubation Manual Hyperinflation|
9711221|NCT04626323|Experimental|RYGB (intervention arm)|Thirty (30) obese patients with DKD will undergo gastric bypass. Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA. The surgical procedure will consist of a laparoscopic surgery performed by an experienced surgeon (approximately 6000 bariatric surgeries), who is accredited as surgeon of excellence by the Brazilian Society of Bariatric and Metabolic Surgery and Surgical Review and Surgical Review Corporation program since 2009.
9980074|NCT01388192||Receiving pancreaticoduodenectomy|
9980075|NCT01388205|Experimental|Family-based Intervention Arm|
9980076|NCT01388205|No Intervention|Control|
10194428|NCT01996436|Active Comparator|Nicardipine + Verapamil + Nitroglycerin|Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty
10194429|NCT01981850|Experimental|Stage 1: Cohort 1 Weekly|Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
10194430|NCT01981850|Experimental|Stage 1: Cohort 1 Every 4 Weeks|Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
10194431|NCT01981850|Experimental|Stage 1: Cohort 2 Weekly|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
10194432|NCT01981850|Experimental|Stage 1: Cohort 2 Every 4 Weeks|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
10194433|NCT01981850|Experimental|Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
10194434|NCT01981850|Experimental|Stage 2: Cohort 2 3mg/kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
10194435|NCT01981850|Experimental|Stage 2: Cohort 3 10mg /kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
10194436|NCT01976247|Active Comparator|Noninvasive Cryolipolysis Device|The Zeltiq System is a noninvasive (not breaking the skin) device that reduces fat by freezing fat cells until they break apart.
10194437|NCT01976247|Active Comparator|High Intensity Focused Ultrasound Device|The LipoSonix System is a noninvasive ultrasound device, which can be used to selectively target and destroy fat tissue located deep under the skin.
10194438|NCT01957332|Experimental|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET. On the same day or the day after 18F-FES injection 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
10194439|NCT01923636|Other|detection of CMV|Cohort of neonates less than 1 month with congenital CMV infection at birth objectified by the detection of CMV in a urine sample, in saliva or blood (fresh or Guthrie card) obtained in the first 10 days life
10194440|NCT01860456||CML Imatinib/Nilotinib|Patients affected by chronic myeloid leukemia and treated with imatinib or nilotinib
10194441|NCT01807182|Experimental|Treatment (TIL, combination chemotherapy, aldesleukin)|Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
10194442|NCT01804816|Experimental|Acupuncture|10 standardized verum acupuncture (VA) sessions twice a week, over 5 weeks. The 5 weeks of acupuncture were scheduled after the period of no acupuncture for each subject.
10194443|NCT01804816|Placebo Comparator|No Acupuncture|"No acupuncture treatment or other study intervention over 5 weeks. All subjects had a 5 week period of no acupuncture prior to the 5 weeks of acupuncture sessions."
10194444|NCT01796509|Experimental|multidisciplinary follow-up|
10194445|NCT01796509|No Intervention|no follow-up|
10194446|NCT01761890||CML patients|
10194447|NCT01749709|Experimental|Instrumental music listening|Daily music listening
10194448|NCT01749709|Experimental|Vocal music listening|Daily music listening
10194449|NCT01749709|Active Comparator|Audiobook listening (control)|Daily audiobook listening
10194450|NCT01722916|Experimental|Dose of Hyaluronidase|
10194451|NCT01722851||Cohort 1|All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy
10194452|NCT01722851||Cohort 2|All breast cancer patients who present with metastatic disease, disease recurrence or progression, who are commencing up-front chemotherapy ± hormonal therapy
10194453|NCT01722851||Cohort 3|All breast cancer patient who present with metastatic disease who are commencing hormonal therapy only.
10194454|NCT01703949|Experimental|Arm A (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10194455|NCT01703949|Experimental|Arm B (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10194456|NCT01696513|Experimental|Subcision & Suction|Standard treatment for acne scars followed by suction.
10194457|NCT01696513|Active Comparator|Subcision|Standard treatment for acne scars only
10194458|NCT01688076|Experimental|Muscle contractions|Under supervision by study personnel, subjects be asked to make active muscle contractions for one hour after Botox injections. Subjects will return for follow-up visits.
10194459|NCT01688076|Active Comparator|No muscle contractions|Patients will be asked to not perform muscle contractions following Botox injections.
10204691|NCT05167721|Active Comparator|Arm 2|25 million mesenchymal stem cells administered intrathecally every 6 months for 2 injections (placebo injections at 3 month and 9 month timepoints)
10204692|NCT05167721|Placebo Comparator|Arm 3|Placebo (lactated Ringer's) administered intrathecally every 3 months for 4 injections
9980077|NCT01388218||Arm 1 - Daily+Clinical|Order of assessment: Daily PRO + Clinical visit PRO
10194460|NCT01688063||Part A: 3 Arms|Subjects will be recruited and enrolled to fill one of three Arms. The first Arm will include 25 subjects who are scheduled to receive resurfacing or tightening procedures AS STANDARD OF CARE (CO2 resurfacing or tightening procedure (1 treatment), radiofrequency (2 tx), Fraxel ( 2 tx), or PDL. These subjects will have baseline elasticity measurements recorded on their face and right forearm before their procedures, and follow up measurements will be repeated 3 months following their last treatment. The second Arm will include 25 subjects who are not scheduled to receive any cosmetic procedures but who agree to return for repeated measurements 3 months following the first. Baseline elasticity measurements will be recorded from subjects' face and right forearm and subjects will return in 3 months for follow-up measurements. The third Arm will include the remaining 50 subjects; these subjects will have the elasticity measurements performed only once on their face and forearm.
10204693|NCT05166135||Acute Myeloid Leukemia|Patients ≥18 years old at diagnosis, with de novo AML diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for AML within the study period.
9711222|NCT04626323|Active Comparator|BMT (control arm).|Thirty (30) obese patients with DKD will undergo best medical treatment for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA.
9711223|NCT04626154|Active Comparator|Respiratory insufficiency or distress|Patients demonstrating respiratory insufficiency or distress.
9711224|NCT04626154|Sham Comparator|No respiratory insufficiency or distress.|Patients NOT demonstrating respiratory insufficiency or distress.
9711225|NCT04626258|Active Comparator|Active comparator: Fluconazol|Once a month one capsule Fluconazol 150 mg
9711226|NCT04626258|Experimental|L-Mesitran|The first month every day apply L-mesitran, the next five months apply L-mesitran every week on the vagina
9711227|NCT04626102|No Intervention|Enrollment|"Participants were recruited by using a convenience sampling method. Potential participants were reached through lecturers and professors who are teaching classes at different universities in Istanbul, Turkey.~Participants were asked to fill out a questionnaire package covering Demographic Information Form, Eating Disorders Examination Questionnaire (EDEQ), Eating Attitudes Test - 40 (EAT-40), Body Image Satisfaction Questionnaire (BISQ), and Sociocultural Attitudes towards Appearance Questionnaire-4-Revised (SATAQ-4R). Filling out the questionnaire package took approximately 25-minutes."
9711228|NCT04626102|Experimental|Intervention Period|"Participants were randomly assigned to one of these conditions:~Experimental condition: Healthy Eating Attitudes and Behaviours Group Program - 6 weekly sessions, each session was about 45-minutes to 60-minutes~Active control condition: Eating Disorders and Body Dissatisfaction: A Group Work - single session about 1.5 hours to 2 hours~Wait-list control condition: Participants in this condition were informed that they will be asked to fill out questionnaires that sent to them, and at the end of 6 months, they will be invited to participate in Healthy Eating Attitudes and Behaviours Group Program."
9711229|NCT04626219|Experimental|1|Period of 12 hours where participants eat regulated meals
9711230|NCT04626219|Experimental|2|Period of 12 hours where participants do not eat anything
9711231|NCT04626206||Imaging to asess treatment response post-SRS|"There will be only one group. All recruited patients will have 3 scans, the multi-parametric MRI, contrast-clearance analysis MRI (TRAMs) and 18F-choline-PET/CT.~This is a non interventional study. Only the results of the contrast-clearance analysis MRI (TRAMs) will be used to make clinical decisions (as this is the current standard of care at the recruiting site). The multi-parametric MRI and 18F-choline PET/CT will be treated as research scans."
9711232|NCT04626037|Experimental|All Participants in Group Zoom Sessions|During each session, the mother-child dyads will meet with Nurture Science program staff virtually. The entire procedure will be done on Zoom or in person depending on school opening. All mother-child pairs will then be asked to interact, with the child sitting on the mother's lap face-to-face. The rest of the session may continue with: (1) Reading Cuddle and Calm Book (2) Mutual Mother and Child Emotional Exchange Prompts (3) Mothers Support Circle to identify and engage members of the mother's family in helping the dyad with emotional connection (4) Mommy Baby Book (5) Bottle of Emotions (6) Plans for continuing the work in the family. Returning mothers will be asked how they have progressed using the Cuddle and Calm and mutual narrative over the week and what their experience with their child after the session has been.
9711233|NCT04626063|Active Comparator|Isolated non-steroid anti-inflammatory drug group|A isolated NSAIDs group received 400 mg etodolac twice a day for 10 days in treatment of acute low back pain.
9711234|NCT04626063|Experimental|Non-steroid anti-inflammatory drug plus magnesium group|This group received 400 mg etodolac twice a day and 365 mg magnesium oral supplementation once a day for 10 days in treatment of acute low back pain.
9711235|NCT04626063|Active Comparator|Non-steroid anti-inflammatory drug plus paracetamol group.|This group 400 mg etodolac twice a day and 500 mg paracetamol twice a day for 10 days in treatment of acute low back pain.
9711236|NCT04626011|Active Comparator|Group One|Participants receiving full mouth disinfection and extractions in one stage.
9711237|NCT04626011|Active Comparator|Group Two|Participants receiving full mouth disinfection at stage one and extractions at stage two after 7 days.
9711238|NCT04625998|Experimental|Intervention|Elementary schools and Head Start centers in the intervention catchment areas implemented (1) an enhanced Coordinated Approach To Child Health (CATCH) program for elementary schools using the CATCH Coordination Guide (Enhanced CATCH Elementary School Program), and (2) CATCH Early Childhood program for Head Start Centers.
9711239|NCT04625998|No Intervention|Comparison|Elementary schools and Head Start centers in the comparison catchment area used their regular school and early care and education (ECE) nutrition and physical activity programs. Elementary schools were required by law to implement a coordinated school health program.
9711240|NCT04625790|Experimental|Study group|After randomization, this group will take 10 sessions of 1-Hz low frequency rTMS will be applied to the inferior frontal gyrus of the right frontal lobe for 20 minutes during the stroke treatment process before 10 days of speech therapy. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
9980078|NCT01388218||Arm 2 - Clinical+Daily|Order of assessment: Clinical visit PRO + Daily PRO
9711241|NCT04625790|Placebo Comparator|Control group|This group will take 10 sessions of sham rTMS for 20 minutes during the stroke treatment process before 10 days of speech therapy. The sham therapy will consist of positioning the coil on the cranium at the same spot, but without a magnetic stimulation, only with the device open and the sounds will be audible. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
9711242|NCT04625985|Experimental|Metformin glycinate|620 mg bid (PO) for 14 days plus standard treatment
10194461|NCT01688063||Part B|The study population in the second cohort will consist of 250 subjects who have a surgical scar >2 cm in length. Subjects enrolled will have three elasticity measurements performed in one study visit. Elasticity will be measured directly in the center of the scar, 3cm perpendicular to the center of the scar, and 3cm in line from one end of the scar (Appendix 2).
9711243|NCT04625985|Placebo Comparator|Placebo|Placebo tablet bid (PO) for 14 days plus standard treatment
9711244|NCT04625712|Experimental|Group A (experimental arm, surgery intervention)|Cholecystectomy within the first week after a mild acute biliary pancreatitis.
9711245|NCT04625712|Active Comparator|Group B (active comparator, surgery intervention)|Cholecystectomy four weeks later a mild acute biliary pancreatitis.
10194462|NCT01652235|Experimental|Endovascular|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
9711246|NCT04625816|Experimental|Arthroscopic shoulder surgery patients|
9711247|NCT04625842|Experimental|Patient focus group|Patients who received radiation treatment
10194463|NCT01572207|Experimental|Immediate Exercise|Subjects assigned to the immediate group will be prescribed a home exercise program during the first meeting. During the 12 week training period, the subject will read pamphlets (sent by mail) once to twice a month about developing skills to manage MS symptoms and motivational pamphlets about physical activity. In addition, the subject will have a phone conversation every two to three weeks with research staff to discuss the progress of the exercise program and to complete a short survey about his/her physical activity level.
9711248|NCT04625842|Experimental|Family focus group|Family of patients who received radiation treatment
9711249|NCT04625894|Experimental|Treatment Arm|Patients with oligometastatic gastrointestinal cancer will receive multisite SABR, followed by Camrelizumab within one week from completion of radiation. Camrelizumab for injection at 200 mg, d1, q2w, 14-day cycle will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
9711250|NCT04625686||Inpatient Treatment|Inpatient psychiatric treatment
9711251|NCT04625686||OCIC Treatment|In-person outpatient crisis intervention
9711252|NCT04625686||Telehealth Therapy Treatment|Virtual outpatient therapy
9711253|NCT04625686||No Show Group|Participant who do not attend recommended treatment
9711254|NCT04625855|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr
9711255|NCT04625751||T2DM +CAN|
9711256|NCT04625751||T2DM -CAN|
9711257|NCT04625751||Healthy control|
9711258|NCT04625868|Experimental|Soft tissue surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
9711259|NCT04625868|No Intervention|Soft tissue surgery - no video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
9711260|NCT04625868|Experimental|Bone/joint surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
10194464|NCT01572207|Experimental|Delayed exercise|Subjects assigned to the delayed group will be asked to begin the same home exercise program 12 weeks following the first meeting. During the 12 week training period, the subject will receive pamphlets, have phone conversations with research staff, and complete physical activity surveys as described above.
9711261|NCT04625868|No Intervention|Bone/joint surgery - no video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
9711262|NCT04625907|Experimental|Phase 1b Dose finding: VHR induction - IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2.~Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
9711263|NCT04625907|Active Comparator|CT1A: VHR induction - IVADO|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4"
9711264|NCT04625907|Experimental|CT1A: VHR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
9711265|NCT04625907|Active Comparator|CT1B: HR Induction IVA|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
9711266|NCT04625907|Experimental|CT1B: HR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
9711267|NCT04625907|Experimental|RT1A: Preoperative Radiotherapy|To be given either 41.4 Gy or 50.4 Gy prior to surgery
9711268|NCT04625907|Active Comparator|RT1A: Post operative radiotherapy|To be given either 41.4 Gy or 50.4 Gy following surgery
10194465|NCT01556776|Experimental|Lenalidomide|lenalidomide maintenance following firstline treatment with FCR, BR, FR, or FC(if Rituximab is contraindicated)
10194466|NCT01556776|Placebo Comparator|Placebo|placebo
9711269|NCT04625907|Experimental|RT1B: Radiotherapy for resectable disease: dose escalated|To receive 50.4 Gy
9711270|NCT04625907|Active Comparator|RT1B: Radiotherapy for resectable disease: standard dose|To receive 41.4 Gy
9711271|NCT04625907|Experimental|RT1C: Radiotherapy for unresectable disease: dose escalated|To receive 59.4 Gy
9711272|NCT04625907|Active Comparator|RT1C: Radiotherapy for unresectable disease: standard dose|To receive 50.4 Gy
9711273|NCT04625907|Experimental|RT2: Radiotherapy to primary tumour and involved lymph nodes|Radiotherapy to the primary tumour and involved regional lymph nodes only
9711274|NCT04625907|Experimental|RT2: Radiotherapy to all metastatic sites|Radiotherapy given to all metastatic sites
9711275|NCT04625907|Experimental|CT2A: VHR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
9711276|NCT04625907|No Intervention|CT2A: Maintenance -Stop treatment|To stop treatment at the point of randomisation
9711277|NCT04625907|Experimental|CT2B: HR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
10194467|NCT01550315|Active Comparator|High Sodium - POTS & Controls|Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation.
10194468|NCT01550315|Other|Low Sodium Diet (POTS & Controls)|"Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.~Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation."
9711278|NCT04625907|No Intervention|CT2B: HR Maintenance - Stop Treatment|To stop treatment at the point of randomisation
9711279|NCT04625907|Active Comparator|Relpased Chemotherapy - VIR|Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5
9711280|NCT04625907|Experimental|Relapsed Chemotherapy - VIRT|Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 given orally on days 1-5
9711281|NCT04625920|Experimental|Virtual reality|women allocated to undergo hysteroscopy with Vr System
9711282|NCT04625920|Experimental|Standart care|women allocated to undergo hysteroscopy without VR
9711283|NCT04625699|Experimental|durvalumab+ tremelimumab|durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
9711284|NCT04625959|Active Comparator|Base BT|16 weekly sessions of behavioral therapy.
9711285|NCT04625959|Experimental|Base BT + Distress Tolerance|16 weekly sessions of behavioral therapy with distress tolerance components of MABTs.
9711286|NCT04625959|Experimental|Base BT + Emotion Regulation|16 weekly sessions of behavioral therapy with emotion regulation components of MABTs.
9711287|NCT04625959|Experimental|Base BT + Mindful Awareness|16 weekly sessions of behavioral therapy with mindful awareness components of MABTs.
9711288|NCT04625959|Experimental|Base BT + Values|16 weekly sessions of behavioral therapy with values components of MABTs.
9711289|NCT04625959|Experimental|Base BT + Distress Tolerance and Emotion Modulation|16 weekly sessions of behavioral therapy with emotion regulation and distress tolerance components of MABTs.
9711290|NCT04625959|Experimental|Base BT + Distress Tolerance and Mindful Awareness|16 weekly sessions of behavioral therapy with distress tolerance and mindful awareness components of MABTs.
9711291|NCT04625959|Experimental|Base BT + Distress Tolerance and Values|16 weekly sessions of behavioral therapy with distress tolerance and values components of MABTs.
9711292|NCT04625959|Experimental|Base BT + Emotion Modulation and Mindful Awareness|16 weekly sessions of behavioral therapy with emotion regulation and mindful awareness components of MABTs.
9711293|NCT04625959|Experimental|Base BT + Mindful Awareness and Values|16 weekly sessions of behavioral therapy with values and mindful awareness components of MABTs.
9711294|NCT04625959|Experimental|Base BT + Emotion Modulation and Values|16 weekly sessions of behavioral therapy with emotion regulation and values components of MABTs.
9711295|NCT04625959|Experimental|Base BT + EM, DT, MA|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and distress tolerance components of MABTs.
10194469|NCT01535963||cutaneous surgery|Patients undergoing cutaneous surgery
9711296|NCT04625959|Experimental|Base BT + DT, ER, and V|16 weekly sessions of behavioral therapy with emotion regulation, distress tolerance, and values components of MABTs.
9711297|NCT04625959|Experimental|Base BT + DT, MA, and V|16 weekly sessions of behavioral therapy with distress tolerance, mindful awareness, and values components of MABTs.
9711298|NCT04625959|Experimental|Base BT + ER, MA, and V|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and values components of MABTs.
9711299|NCT04625959|Experimental|Base BT + ER, MA, V, DT|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, distress tolerance, and values components of MABTs.
9711300|NCT04625881|Active Comparator|Active product|A powder containing 20 g of apple derived fiber will be consumed daily
9711301|NCT04625881|Placebo Comparator|Placebo|A rice derived placebo devoid of fiber and aromatized with apple fragancy will be provided
9711302|NCT04625660|Experimental|Single Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
9711303|NCT04625608|Other|Standard care|Participants in this arm shall receive 3.6 ml/kg of water a minimum of 1 hour prior to the induction of general anaesthesia. This is standard practice in the 2 participating institutions.
9711304|NCT04625608|Experimental|Paracetamol arm|Participants in this arm shall receive 3 ml/kg of water plus 15 mg/kg of oral paracetamol suspension a minimum of 1 hour prior to the induction of general anaesthesia.
9711305|NCT04625582|Experimental|Face-to-face intervention|90 trainees at Vigo Family Medicine and Community Nursing Training Unit
9711306|NCT04625582|Experimental|Online intervention|70 trainees at Aragón Family Medicine and Community Nursing Training Unit
9711307|NCT04625582|No Intervention|Usual training|180 trainees at Balearic Islands Family Medicine and Community Nursing Training Unit
10194470|NCT01529983|Experimental|Fractional photothermolysis|Fractional photothermolysis (FP) for treatment of photo- damaged skin is an FDA-approved method for treating facial rhytids. Fractionated treatment with 1550-nm laser is a safe, nonsurgical method for improvement of periorbital rhytides, photodamage, and scarring
10194471|NCT01529983|Active Comparator|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
9711308|NCT04625595|Experimental|350 mg BID (700 mg total daily dose) of active drug or placebo|Low dose, drug IMT-002
9711309|NCT04625595|Experimental|1050 mg QD (1050 mg total daily dose) of active drug or placebo|Moderate dose, drug IMT-002
9711310|NCT04625595|Experimental|700 mg BID (1400 mg total daily dose) of active drug or placebo|Moderate to high dose, drug IMT-002
10194472|NCT01519960|Experimental|A Pegasys|
9711311|NCT04625595|Experimental|1050 mg BID (2100 mg total daily dose) of active drug or placebo|High dose, drug IMT-002
9711312|NCT04625556||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
10194473|NCT01519960|No Intervention|B Untreated Control|
10194474|NCT01519960|Experimental|C Fibrosis non-randomized|
10194475|NCT01519960|Experimental|Switch|
10194476|NCT01372566|Experimental|Platelet Rich Plasma|Concentrated blood platelets from subject will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2).
10194477|NCT01372566|Placebo Comparator|Sterile Saline|Sterile saline will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2)that has not been injected with PRP.
10194478|NCT01186640|Experimental|FCM-A followed by A-maintenance|First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
10194479|NCT01112306|Experimental|1|ACT-293987, twice daily
10194480|NCT00974415|Experimental|treatment|CO2 treatment
10194481|NCT00974415|Sham Comparator|sham|sham treatment
10194482|NCT00832325||1 individual interviews|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in an individual interview at their convenience.
10194483|NCT00832325||2 Focus Groups|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in a focus group at their convenience.
9711313|NCT04625556||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
9711314|NCT04625556||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
10194484|NCT00832325||3 Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews scheduled at their convenience.
10194485|NCT00823654||Premenopausal Women with Early Stage Breast Cancer|
10194486|NCT00823654||Unaffected High Risk Women with BRCA mutations|
10194487|NCT00688376|Experimental|1|
10194488|NCT00688376|Placebo Comparator|2|
10194489|NCT00604201|Experimental|Co-infusion of UCB and Haploidentical CD34+ cells|Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)
10194490|NCT00492349|Experimental|1|Varenicline
9711315|NCT04625556||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
9711316|NCT04625231|Experimental|Shared-Decision Making Tool Group|
9711317|NCT04625231|No Intervention|Standard of Care Group|
9711318|NCT04625283|Experimental|Ketamine|Participants in this arm will receive intraoperative ketamine bolus (0.5mg/kg) followed by continuous infusion 5 mcg/kg/min and also will receive postoperative ketamine infusion (2.5 mg/kg/min, up to 100kg max) for 48 hours.
9711319|NCT04625283|Placebo Comparator|Saline|Participants in this arm will receive an equivalent volume of intraoperative saline bolus followed by continuous saline infusion and also will receive postoperative saline infusion for 48 hours.
9711320|NCT04625491||Location on lower limb|Proximal (thigh) Medium (leg) Distal (ankle and foot)
10194491|NCT00492349|Placebo Comparator|2|Placebo
10194492|NCT00340015||AARP|Members of the AARP, aged 50-71 years, and who resided in one of six states
10194493|NCT00160771||Joint Motion Analysis|Joint motion will be recorded for analysis.
10194494|NCT00121108|Placebo Comparator|Placebo|Participants will receive IM dose of placebo matched to motavizumab every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
10194495|NCT00121108|Active Comparator|Motavizumab|Participants will receive IM dose of motavizumab 15 milligram/Kilogram (mg/kg) every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
10194496|NCT00003102|Experimental|Cohort 1 50cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
9711321|NCT04625335|Experimental|Group 1: Intervention First|Adult, healthy volunteers will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test. Following the crossover, these participants will then complete the Cold Pressor Test without prior massage.
9711322|NCT04625335|Experimental|Group 2: Intervention Last|Adult, healthy volunteers will complete the Cold Pressor Test without prior massage. After crossover, they will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test.
9711323|NCT04625348|Experimental|residents|daily care of 40 residents will be provided on the Ultracore Repose® mattress
9711324|NCT04625244|No Intervention|Group 1: In-person therapy|Standard of care, in-person therapy with a Certified Hand Therapist (CHT)
9711325|NCT04625244|Experimental|Group 2: Home therapy program|Participants will be sent video links to three therapy videos demonstrating postoperative recovery exercises, starting 4 weeks after surgery.
9711326|NCT04625322|No Intervention|Referral to outpatient specialty for HCV care|Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
9711327|NCT04625322|Experimental|Receive HCV care during inpatient admission by a hospitalist|CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred. An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive. Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay. At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
9711328|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（pilot trial arm）|Healthy subjects receive single dose of tablets HEC122505MsOH
9711329|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）|Healthy subjects receive single dose of HEC122505MsOH or matching placebo
9711330|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
9711331|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
9711332|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
9711333|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
9711334|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
9711335|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
9711336|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
9711337|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
9711338|NCT04625439|Experimental|Personality Feedback|The intervention arm will read about the Five-Factor model and receive a feedback report with individualized personality results and self-management recommendations.
10194497|NCT00003102|Experimental|Cohort 2 75cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
10194498|NCT00003102|Experimental|Cohort 3 100cGy radiation|"On day 1, patients received a single dose of 131I-cG250 (5 mCi/5 mg) administered as an intravenous infusion over 10 minutes.~Therapeutic doses of 131I-cG250 were administered the following week as fractionated outpatient doses, starting with 30 millicurie (mCi)/5 mg 131I-cG250. Subsequent doses of 131I-cG250 were administered at 2-3 day intervals with the total amount of 131I-cG250 administered based on the calculated clearance of the initial dose administered on day 1. Whole body activity was maintained at no more than 30 mCi iodine-131.~In the absence of disease progression and after recovery from toxicity, patients could be re-treated beginning 8 weeks after the last treatment of the initial series, for a total of not more than 3 treatments."
10204694|NCT05166135||Relapsed/Refractory Acute Lymphoid Leukemia|Patients ≥18 years old at diagnosis, with R/R ALL diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for R/R ALL within the study period.
10204695|NCT05158374|No Intervention|Control|No medication, 6 weeks
9711339|NCT04625439|No Intervention|No-feedback Control|The control arm will read about the Five-Factor model but will not receive feedback or their personality results until after the study.
9711340|NCT04625543|Experimental|intervention group|Neoadjuvant immunotherapy (PD-1) plus concurrent chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
9711341|NCT04625543|Active Comparator|controll group|Neoadjuvant chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
10194499|NCT05181891|Experimental|(CM+TAU) Contingency Management + Treatment as Usual|Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. Participants in CM+TAU will receive reinforcement for submitting urine samples that test negative for recent alcohol use.
10194500|NCT05181891|Active Comparator|(NC+TAU) No Contingency + Treatment as Usual|Varenicline (VC) will be supplied in .5 mg tablets once per week during the active treatment period. During the first week of treatment (Week 3) participants will be instructed to take .5 mg once per day for days 1-3, and 0.5 mg twice per day for days 4-7. The investigators will maintain a target dose of 1mg twice per day for the remaining active treatment period. Additionally, participants will also receive Take Control counseling via video. NC+TAU will receive reinforcement for submitting any urine sample, regardless of test results.
9711342|NCT04625309|Experimental|Sport|This group will be made up of subjects with a spinal cord injury that are actively participating in adaptive sports teams.
9711343|NCT04625309|No Intervention|No sport|This group will be made up of subjects with a spinal cord injury that are not actively participating in any sports team.
9711344|NCT04625387|Experimental|Dry Needle plus exercise|Group A received Dry Needling along with exercise having 25 individuals. Treatment lasted four weeks duration, twice a week.
9711345|NCT04625387|Experimental|Dry Needling alone|Group B received Dry Needling alone having 25 individuals. Treatment lasted four weeks duration, twice a week.
9711346|NCT04625452|Experimental|BBCC+5A's+GS|Brief behavior change counseling using 5A's + Guiding style (from motivational interviewing) + Printed education materials ( at baseline, 12 weeks, 24 weeks)
10194501|NCT05181852|Experimental|IP2015_dose 1|Active
10194502|NCT05181852|Experimental|IP2015_dose 2|Active
10194503|NCT05181852|Placebo Comparator|Placebo|Placebo
9711347|NCT04625452|No Intervention|Normal care|They will receive the normal care: simple advice on changing lifestyle risk factors + medications for diabetes or hypertension ( at baseline, 12 weeks, 24 weeks)
9711348|NCT04625426|Experimental|3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant|"Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).~The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer."
9711349|NCT04625426|Experimental|Conveen EasiCleanse and Conveen Critic Barrier|Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.
9711350|NCT04625426|Active Comparator|Soap and water / Incontinence wipes and Conveen Critic Barrier|Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.
9711351|NCT04625400|Experimental|post intubation tracheal stenosis patients|all ICU patients who were mechanically ventilated will be assessed for the possibility of presence of tracheal stenosis using spirometery and dyspnea will be assessed using (mMRC) score, chest X-ray to assess the location of tracheal stenosis and finally flexible bronchoscopy to confirm the presence of stenosis and identify the proper management.
9711352|NCT04625075||Healthy Volunteer|Age and sex matched healthy volunteer
9711353|NCT04625075||COVID-19 with myocardial injury|Patients hospitalised with severe COVID-19 infection and evidence of myocardial. Involvement: elevation of plasma cardiac troponin concentration (>99th centile of the upper reference limit), abnormalities on electrocardiography or abnormal echocardiography. Some patients will have suspected myocarditis or takotsubo cardiomyopathy. We will identify subgroups of interest who have left/right ventricular systolic dysfunction ± regional wall motion abnormalities, on echocardiography.
9711354|NCT04625075||COVID-19 without myocardial injury|Patients hospitalised with severe COVID-19 infection but without known elevation of plasma cardiac troponin concentration, clinically significant ECG abnormalities or an abnormal echocardiogram.
9711355|NCT04625179|Experimental|Melatonin and hyaluronic acid and sinus membrane elevation|melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement
9711356|NCT04625179|Active Comparator|sinus membrane elevation without any materials|no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.
9711357|NCT04625010|Experimental|Group 2 (Swaddling group)|Swaddling group: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
9980079|NCT01388231|Active Comparator|Manualized CBT Group|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients after receiving structured clinical training on the treatment of social phobia based on the Clark and Wells (1995) model.
10194504|NCT05181852|Active Comparator|Pregabalin|Comparator
10194505|NCT05181813|Experimental|Group 1: Ginge-Cal group:|primary molars were filled by creamy mixture pulpectomy paste of Gingerols and Calcium Hydroxide.
10194506|NCT05181813|Active Comparator|Group 2: Metapex group|primary molars were filled by a ready-made injectable creamy mixture pulpectomy paste of Metapex
10194507|NCT05181800||FIRMAGON Cohort|
10194508|NCT05181774||Bleeding|After one-year follow-up, AF patients with anticoagulation-related bleeding complications were enrolled in this group.
10204696|NCT05158374|Active Comparator|Aspirin 24 Hours|24 Hours Aspirin
9711358|NCT04625010|Experimental|Group 3 (Maternal Holding group)|Maternal holding group: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
9711359|NCT04625010|No Intervention|Group 1|In the control group, the heel stick procedures were conducted using the standard method and the neonates received no interventions during the procedures.
9711360|NCT04625127|Experimental|Aim 2: Efficacy of the GaitBetter to improve motor-cognitive function of chronic stroke survivors|The investigators propose a single-arm, non-randomized study to test the hypothesis that the GaitBetter training is effective in improving gait and cognition in individuals with chronic stroke. This design was chosen given the expected stability of functional recovery in this population.
9711361|NCT04625127|Experimental|Aim 3: Efficacy of the GaitBetter to improve rehabilitation outcomes in sub-acute stroke survivors|The investigators propose a randomized, controlled study to evaluate the effects of using the GaitBetter system in patients with subacute stroke on recovery trajectory.
9711362|NCT04624893||Pola BR/R|Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.
9711363|NCT04624958|Experimental|zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance|"Part A (Zanubrutinib and Rituximab): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve CR.~PART B (Consolidation chemotherapy of R-DHAOx): Patients receive R-DHAOx regimen every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Elderly patients (> 65 years old) and patients who achieved CR and minimal residual disease negative after PART B receive zanubrutinb maintenance therapy. Young patients (<65 years old) who achieved CR but minimal residual disease positive after PART B can receive autologous stem cell transplantation and then zanubrutinb maintenance therapy. Patients with PD, SD or PR after PART B quit the trial.~ZANUBRUTINB MAINTENANCE: Patients receive zanubrutinib every day for up to one year."
9711364|NCT04624984|Experimental|PD-1 Inhibitor or PD-1 Inhibitor with GVD|"All patients receive PD-1 Inhibitor on day 1. Treatment cycles repeat every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR or PR receive PD-1 Inhibitor for another 3 cycles. Patients with PD or SD receive PD-1 Inhibitor plus GVD (gemcitabine, vinorelbine and doxorubicin liposome) regimen every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients with PET/CT confirmed CR after 6 cycles of PD-1 Inhibitor treatment can receive radiotherapy or ASCT, which is determined by investigators. Patients with PR receive 2-4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with PD or SD receive 4 cycles of PD-1 Inhibitor plus GVD regimen.~Patients with confirmed CR or PR after PD-1 Inhibitor plus GVD regimen can receive radiotherapy or ASCT, which is determined by investigators. Patients with PD or SD quit the trial."
9711365|NCT04624906|Experimental|Single arm intervention|"100 mg Acalabrutinib (ACP-196) oral capsules twice daily for 1 year~Bendamustine and rituximab will be given for 6 x 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)."
9980080|NCT01388231|Active Comparator|CBT Group -Treatment as Usual|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients, while receiving no structured training in the treatment of social phobia.
9711367|NCT04625192|Experimental|Sinus lifting with trephine osteotomy|
9711368|NCT04625114|Experimental|Camostat|camostat 100mg 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
9711369|NCT04625114|Placebo Comparator|Placebo|Placebo 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
9711370|NCT04624789||GM1-Gangliosidosis - Sialidosis|"Confirmed diagnosis of:~GM1-Gangliosidosis Morquio B Variant~Sialidosis~Galactosialidosis"
9711371|NCT04624789||GM2-Gangliosidoses|"Confirmed diagnosis of:~Tay-Sachs Disease, incl. B1-Variante~Sandhoff Disease~GM2-Activator-Deficiency"
9711372|NCT04624880||Participants with HIP previously measured|This cohort of patients will have their genetics analyzed and compared to their HIP scores.
9711373|NCT04624880||Participants without HIP measured|This cohort of patients from the control group of the knee replacement trial (who did not have their HIP measured) will have their genetics, pain, and opioid use analyzed, and compared to the genetics, pain, and opioid use of the hypnosis group from that trial.
9984492|NCT04050540|Experimental|dPEP Intervention Arm|Participants assigned to dPEP will be instructed to take doxycycline 200 mg (two 100mg capsules) orally within 24 hours and up to 72 hours after each condomless sex act
9984493|NCT04050540|No Intervention|Standard of Care Arm|Participants assigned to Standard of Care
9984494|NCT04046471|Other|Individual In-Person|
9984495|NCT04046471|Other|Group Remote|
9984496|NCT04045405|Experimental|CDR132L|
10194509|NCT05181774||Non-bleeding|After one-year follow-up, AF patients without anticoagulation-related bleeding complications were enrolled in this group.
10194510|NCT05181735|Experimental|Arm A (Luspatercept alone)|"Patients will receive Luspatercept (at the selected dose according to part A) subcutaneously on day 1 of each 21 day cycle (every three weeks).~Doses schedules Part A :~Level 1 : 1.75mg/kg~Level -1 : 1.33mg/kg~Level -2 : 0.8mg/kg"
9984497|NCT04045405|Placebo Comparator|Saline|
9984498|NCT04044794|Active Comparator|Standard Care|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a monetary gift of $60 that can be used to purchase health-promoting supplies to support weight management.
9984499|NCT04044794|Experimental|Daily Self-Weighing|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a commercially available wireless scale. Participants will be instructed to weigh daily and view their weight on the scale's digital display.
10204697|NCT05158374|Active Comparator|Aspirin 7 Days|7 Days Aspirin
10204698|NCT05158374|Active Comparator|Aspirin 28 Days|28 Days Aspirin
10204699|NCT05158374|Active Comparator|Aspirin 6 Weeks|6 Weeks Aspirin
10204700|NCT05158374|Active Comparator|Metformin 24 Hours|24 Hours Metformin
9711374|NCT04624932|Experimental|Risk Reframing (RR) Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: reflecting on their own childhood play activities; what they got out of these experiences; outdoor play activities of the children at their center; what they do to promote children's outdoor play; what gets in the way in promoting children outdoor play.~Chapter 2: imagining themselves in six video segments where they must decide how to communicate with parents; and, whether they allow children to engage in rough and tumble play, play at heights, play with tools, play at speed/mud play, and resolve conflicts amongst themselves~Chapter 3: reflecting on their barriers and things that helped them promote and support the children's outdoor play at their center. Participants to assess whether there is anything they want to change to set a realistic goal, outlining steps for attaining that goal."
9711375|NCT04624932|Sham Comparator|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play.~It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety."
10194511|NCT05181735|Experimental|Arm B (Luspatercept + EPREX)|"Patients will receive Luspatercept (at the selected dose according to part A) subcutaneously on day 1 of each 21 day cycle (every three weeks) AND Epoetin alfa: At the selected dose (in part A) per week, subcutaneously, every week~Doses schedules Part A :~Level -2 : Luspatercept 0.8 mg/kg + EPREX 30000 UI~Level -1 : Luspatercept 1.33 mg/kg + EPREX 30000 UI~Level 1 : Luspatercept 1.75mg/kg + EPREX 30000 UI~Level 2 : Luspatercept 1.75mg/kg + EPREX 60000 UI"
9711376|NCT04624581|Experimental|Patient with fibromyalgia syndrome|250 patients with fibromyalgia syndrome (according to American College of Rheumatology 2016) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate the distribution of gene polymorphism.
9711377|NCT04624581|Sham Comparator|Healthy subjects|50 healthy matched volunteers (age, sex and menopausal status for women) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate distribution of gene polymorphism
9711378|NCT04624841|Experimental|ICG group|"Participants receive an intravenous injection of 0.05 mg/kg of ICG 45 minutes preoperatively.~A Pinpoint Endoscopic Fluorescence System (Novadac Technologies Inc., Canada) for ICG Fluorescence Observation with the easy switchable white light-fluorescent mode is used.~Before dividing any tubular structure, the fluorescence imaging mode is routinely used again, and fluorescent angiography is performed by re-injecting the same dose of ICG as initially used.~After the division of the cystic duct and artery, the fluorescence imaging mode is applied again to check for bile leakage."
9711379|NCT04624841|No Intervention|No ICG Group|No ICG is administered after randomization of the patient to a control group and hence will not produce any enhancement of the image on A Pinpoint Endoscopic Fluorescence System for ICG Fluorescence Observation. This will continue as a routine Laparoscopic cholecystectomy without fluorescent imaging enhancement.
9711380|NCT04624867|Experimental|HP-1050 patch|HP-1050 and Xulane will be administered simultaneously.
9711381|NCT04624633|Experimental|Cohort 1-Relapsed Disease|"Participants with relapsed disease~Treatment with Acalabrutinib & Umbralisib beginning C1D1,~Ublituximab beginning C7D1~Assessment of treatment response~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
9711382|NCT04624633|Experimental|Cohort 2-Treatment Naive|"Participants with previously untreated disease~Treatment with Acalabrutinib & Umbralisib beginning C1D1,~Ublituximab beginning C7D1~Assessment of treatment response~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
9711383|NCT04624750|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
9711384|NCT04624763|Experimental|LBBP group|In this arm, a left bundle branch pacing(LBBP) lead is attempted to be placed.
9711385|NCT04624763|Active Comparator|RVP group|In this arm, a right ventricular pacing(RVP) lead are placed.
9779401|NCT05306626|Experimental|The BEAM program group|The BEAM Program is delivered via mobile application and weekly group telehealth sessions. BEAM includes approximately 20 minutes of weekly asynchronous video modules on parenting and mental health. Mental Health videos will provide information and emotion-regulation strategies that draw from the Unified Protocol, an evidence-based treatment for depression and anxiety disorders. Self-compassion and effective communication will also be central focuses of the mental health content. Supportive parenting videos will provide parents with emotion-focused parenting strategies and help parents understand and respond to their children's challenging emotions and behaviours. The weekly group telehealth sessions will allow participants to discuss content and ask questions, with the purpose of increasing a sense of community and social support. The online community forum will provide a space for participants to reflect on their learned skills and connect with other participants in the program.
9779402|NCT05306626|No Intervention|Treatment as usual group|The treatment as usual (TAU) control arm of the study is designed to account for the potential effects of time on depression symptoms.
9779403|NCT05306613|Experimental|Prolonged sitting|Participants sat on a chair during the trial.
9779404|NCT05306613|Experimental|Breaking sitting|Participants walked regularly during the trial.
9779405|NCT05306587||Multiple Myeloma|40 patients with Multiple Myeloma in Department of Hematology at Odense University Hospital, Denmark
9779406|NCT05306574|Experimental|Telitacicept 160 mg|Telitacicept 160 mg + SOC
9779407|NCT05306574|Experimental|Telitacicept 240 mg|Telitacicept 160 mg + SOC
10194512|NCT05181696||COVID-19 pneumonia patients|Patients treated at the University Hospital Osijek Respiratory Center with pneumonia caused by SARS-CoV2
10194513|NCT05181631|Experimental|Biobanking|"If the patient consents, two tubes of blood will be collected for biobanking, at the same time as routine tubes will be collected.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in the biological resources center of Avicenne hospital ."
9711386|NCT04624516|Experimental|Intervention group|The group received training in self-structured foot exercise and they were encouraged to do self-structure foot exercise 3 times a week. They received usual care
9711387|NCT04624516|No Intervention|Control Group|the group received usual care
9711388|NCT04624828|Experimental|Stereotactic body radiation treatment (SBRT)|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
9711389|NCT04624607|Experimental|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive transspinal stimulation over the thoracolumbar region and non-invasive brain stimulation during assisted stepping.
9711390|NCT04624607|Experimental|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive brain stimulation and non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping.
10194514|NCT05181605|No Intervention|No Intervention: No intervention - standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated per standard of care on site (surgical resection and adjuvant therapy)
10194515|NCT05181605|Experimental|Experimental: Neoadyuvant therapy plus standard of care|A group of patients with pancreatic carcinoma plus risk factors will be treated with neoadjuvant therapy before surgical resection and adjuvant therapy
10194516|NCT05181592|Experimental|Luspatercept (single arm)|open-label, single-arm
10194517|NCT05181579|Experimental|Manuel therapy and exercise group|Patients in the manual therapy group will receive 3 to 5 sessions of sacroiliac joint manipulation once a week, depending on the treatment response. And home exercises will be given and told. Each patient will do exercise 4 days a week for 4 weeks.
10194518|NCT05181579|Experimental|Sacroiliac injection and exercise group|"To patients in the injection group corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine)will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy).~And home exercises will be given and told. Each patient will do exercise 4 days a week for 4 weeks."
10194519|NCT05181566|Experimental|Modular dual mobility group|A group of patients who underwent total hip replacement arthroplasty using a modular dual mobility cup
10194520|NCT05181566|Active Comparator|Conventional group|A group of patients who underwent total hip replacement arthroplasty using a conventional acetabular cup
10194521|NCT05181514|Placebo Comparator|Normal Saline|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of normal saline
10194522|NCT05181514|Experimental|20% Intralipid|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of Intralipid 20%.
10194523|NCT05181501|Experimental|CT103A in Newly Diagnosed Subjects With High-risk Multiple Myeloma|Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection（CT103A）will be infused at 1.0 x 10^6 CAR+ T cells/kg in newly diagnosed subjects with high-risk multiple myeloma
10194524|NCT05181488|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
10204701|NCT05158374|Active Comparator|Metformin 7 Days|7 Days Metformin
10204702|NCT05158374|Active Comparator|Metformin 28 Days|28 Days Metformin
10204703|NCT05158374|Active Comparator|Metformin 6 Weeks|6 Weeks Metformin
10204704|NCT05158374|Active Comparator|Aspirin & Metformin 24 Hours|24 Hours Aspirin & Metformin
10204705|NCT05158374|Active Comparator|Aspirin & Metformin 7 Days|7 Days Aspirin & Metformin
10204706|NCT05158374|Active Comparator|Aspirin & Metformin 28 Days|28 Days Aspirin & Metformin
10204707|NCT05158374|Active Comparator|Aspirin & Metformin 6 Weeks|6 Weeks Aspirin & Metformin
10204708|NCT05148533|Experimental|TJ1133 Injection|
10204709|NCT05147896|Active Comparator|Interventional Arm|Beside metformin and sulphonyl urea treatment, the active, interventional arm, will be receiving Semaglutide Oral Tablets as per protocol, 3 mg for the first month, 7 mg in the second month and 14 mg form the third month onwards.
10204710|NCT05147896|No Intervention|Comparative Arm|This group will not be receiving the additional therapy besides metformin and sulphonyl urea treatment. After 6 months a revaluation of glycemic control will be performed, if needed, rescue therapy with basal insulin will be implemented.
10204711|NCT05143541||AEON Endostapler|Stapling performed with AEON Endostapler
9711391|NCT04624802|Experimental|maternal exercise training group|Pregnant women in experimental group are invited to participate in 16 exercise weekly classes for 40 min including 15 min aerobic exercise，10 min relaxation exercise, and 15 min aerobic exercise, from week 16 to week 32 of gestation, and receive antenatal care and examination regularly.
9711392|NCT04624802|No Intervention|antenatal care group|Pregnant women in antenatal care group receive antenatal care and examination regularly.
9711393|NCT04624711|Experimental|Eribulin Mesylate Combined With Anlotinib|Patients receive eribulin mesylate plus anlotinib.
9779408|NCT05306574|Placebo Comparator|Placebo|Placebo + SOC
10204712|NCT05131542||Down Syndrome|Children with down syndrome
10204713|NCT05130255|Experimental|GD2-SADA:177Lu-DOTA Complex|"GD2-SADA IV. infusion followed by 177Lu-DOTA IV. infusion (The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA ).~1 treatment cycle in Part A, 2 treatment cycles in Part B and up to 5 treatment cycles in Part C"
10204714|NCT05127005|Experimental|Trapeziectomy|Trapeziectomy
10204715|NCT05127005|Sham Comparator|Sham surgery|Sham surgery
10204716|NCT05127005|Other|Non-randomized observational arm|Non-randomized observational arm (trapeziectomy, not blinded)
10204717|NCT05125913||COVID-19 group|Patients with CKD stage 3-5, on dialysis or kidney transplanted patients with confirmed SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR), at minimum 2 weeks after the confirmed test.
10204718|NCT05125913||non-COVID-19 group|CKD stage 3-5, dialysis or kidney transplantation matched patients without confirmed SARS-CoV-2 infection
9711394|NCT04624594|Experimental|Artificial Intelligence (AI) Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the AI group then performed 10 more practice repetitions with real-time audiovisual feedback from the app followed by one minute of rest. The AI's design provided one piece of feedback, if necessary, with a vocal statement and on-screen video per repetition (e.g. when a participant performed a squat repetition with their neck flexed downward, AI suggested keeping their head up with on-screen instruction). Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
9711395|NCT04624594|Active Comparator|Physical Therapist Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the PT group (n=15) also performed 10 practice repetitions with one piece of feedback per repetition, if necessary, from the PT followed by one minute of rest. Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
9711396|NCT04624672|Placebo Comparator|Control Arm|Once weekly injection of placebo 4-6 months at prescribed dose
9711397|NCT04624672|Active Comparator|Test Arm|Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose
9711398|NCT04624542||group 1|Thirty individuals diagnosed with unilateral chronic PFPS from both genders and age between 18-35 years who will be referred from an orthopedic surgeon.
9711399|NCT04624542||control group|-30 healthy active individuals ranging from 18-36 yrs as a controlled group
9711400|NCT04624477||Active Surveillance|Patients under active surveillance choose to not have immediate thyroid surgery. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if received). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
9711401|NCT04624477||Immediate Thyroid Surgery (total or partial thyroidectomy)|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
9711402|NCT04624490|Experimental|Hyperpolarized 129Xe|Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.
9711403|NCT04624464||Cohort 1: VRE negative at admission|"150 patients meeting the following inclusion criteria:~≥ 18 years~Patients with malignant primary disease and current inpatient admission to a normal ward with expected inpatient stay of at least 15 days~High risk of exposure to antibiotics during the stay~Written informed consent of the patient after clarification has been given~Exclusion criteria:~Already known current or documented past colonisation or infection by VRE~Simultaneous participation in other studies is only an exclusion criterion if the other study explicitly excludes participation in observational studies or if the other study complicates the interpretation of the endpoints of AEGON (e.g. double-blind study on antibiotic use)."
9711404|NCT04624464||Cohort 2: VRE positive at admission|"A total 20 known VREf-positive patients meeting the following inclusion criteria:~Intestinal VREf colonization already known at the time of admission (e.g. based on examinations during previous stays or in external facilities)~Accommodation in a single room or alternatively multi-bed room with single occupancy on standard wards~Expected stay of at least 7 days"
9711405|NCT04624295|Active Comparator|Early Antiplatelet Therapy|
9711406|NCT04624295|Placebo Comparator|Non-Early Antiplatelet Therapy|
9711407|NCT04624399|Experimental|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
9711408|NCT04624256|Experimental|Treatment (radiotherapy, genomic DNA testing)|Patients undergo SBRT per standard of care, then undergo collection of cheek swab and blood samples for the analysis of germline biomarkers. Afterwards, patients and their physicians engage in discussion about which form of radiotherapy to proceed with. Based on the decision, patients predicted to be at low risk of toxicity with SBRT continue to receive SBRT over 14 days while patients predicted to be at high risk of toxicity with SBRT will be counseled to undergo either conventionally fractionated radiotherapy over 63-70 days, moderate hypofractionated radiotherapy over 28-35 days, or may opt to still receive SBRT over 14 days per standard of care.
9711409|NCT04624282||Patients with chronic superficial gastritis|Patients with chronic superficial gastritis
9711410|NCT04624282||Patients with chronic atrophic gastritis|Patients with chronic atrophic gastritis
9711411|NCT04624282||Patients with gastric carcinoma|Patients with gastric carcinoma
9711412|NCT04624178|Experimental|Rucaparib in combination with Nivolumab|"One treatment cycle will consist of 28 days. Patients will receive rucaparib at 600 mg, orally, twice daily, continuously for 28 days. They will receive 480mg of nivolumab intravenously on day 1 of every four-week cycle. This is the recommended phase II dose of the combination therapy. Re-staging scans will be performed every 8 weeks.~Treatment will be repeated until the patient develops progressive disease or unacceptable toxicity or for a maximum duration of 26 cycles as long as patients are receiving benefit from treatment, have not had disease progression, met any criteria for study withdrawal and are tolerating therapy."
9711413|NCT04624269|Experimental|Hydroxychloroquine sulfate Tablets|drug:Hydroxychloroquine sulfate Tablets,0.1mg bid po
9711414|NCT04624269|Placebo Comparator|placebo|drug:placebo,0.1mg bid po
10194525|NCT05181475|Experimental|Sodium Oligomannate Capsules (GV-971)|The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening
9980081|NCT01388244|Active Comparator|Screening|Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
9779409|NCT05306561|Experimental|Arm 1|Single arm trial
9711419|NCT04624373||Identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
9711420|NCT04624373||Non identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
9711421|NCT04624347|Experimental|Acess to Videos and Movement curves|with caregivers' access to videos and movement curves (4 days)
9711422|NCT04624347|No Intervention|No Acess to Video and Movement curves|without caregivers' access to videos and movement (4 days)
9711423|NCT04624321|Experimental|Access to tool|Access to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.
10194526|NCT05181397|Experimental|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab. No Intervention: control, participants in control group will receive regular treatment.
10194527|NCT05181397|No Intervention|Control|Participants in control group will receive regular treatment.
10194528|NCT05181319||bronchopulmonary dysplasia group|infants diagnosed with bronchopulmonary dysplasia
9711424|NCT04624321|Placebo Comparator|Usual care|They are followed by their ordinary healthcare provider.
9711425|NCT04624360|Experimental|Study Drug A|Dexamethasone 8mg intravenous administration stat dose post clamping of the umbilical cord
9711426|NCT04624360|Placebo Comparator|Study Drug B|Normal saline 2cc intravenous stat dose administered after clamping of the umbilical cord
9711427|NCT04624438|Experimental|Electromyostimulation - EMS|Experimental group comprised of healthy young adults that undergoes unilateral isometric training using electromyostimulation over quadriceps femoris
9711428|NCT04624438|Experimental|Voluntary activation - VOLUNTARY|Experimental group comprised of healthy young adults that undergoes unilateral isometric training based on voluntary activation of quadriceps femoris
9711429|NCT04624438|Experimental|Combination of EMS and VOLUNTARY - COMBINED|Experimental group comprised of healthy young adults that undergoes unilateral isometric training that combines electromyostimulation and voluntary activation of quadriceps femoris.
9711430|NCT04624438|No Intervention|Control group - CONTROL|Group of healthy young adults who received no intervention.
9711431|NCT04624048||University population|Survey to analyze the impact of COVID-19.
9711432|NCT04623957|Experimental|ForgTin|Patients randomized into group 1 will receive the ForgTin Medical Device for a duration of 3 months.
9711433|NCT04623957|No Intervention|No intervention|Patients randomized into group 2 will receive no device for a duration of 3 months.
9711434|NCT04624074|Experimental|Teen Marijuana Checkup - adapted|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
9711435|NCT04623918|Experimental|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
9711436|NCT04623918|Active Comparator|Control rice|Control rice (C4)
9711437|NCT04624139|Experimental|Intervention, group 1|Combined intervention of stress reducing I-CBT and physiotherapy.
9711438|NCT04624139|Active Comparator|Active control group, group 2|Physiotherapy only
9711439|NCT04624126|Experimental|3D-Erect arm|Participants will be asked to use the 3D-printed penile device during their intercourse with partners.
9711440|NCT04624308|Experimental|TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab|TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or >75%PR. If not, operation is suggested.
9711441|NCT04624425|Experimental|Segmental breathing exercises|Segmental breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
9711442|NCT04624425|Active Comparator|Buteyko breathing exercises|Buteyko breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
9711443|NCT04623879||F508del homozygous adult CF patients|F508del homozygous adult CF patients who commenced treatment with LUM-IVA
9711444|NCT04624035|Active Comparator|Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.|Implantation of ICL (V4c with central hole) for treatment of myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
9711445|NCT04624035|Active Comparator|Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults|Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
9711446|NCT04624386||Postmenopausal/Study|Women older than 45 years of age and who have not had any menstruation for the past 12 months are considered as having entered menopause. These women are included in this group.
9711447|NCT04624386||Premenopausal/Control|Healthy women who are still having regular menstruations are included in this group
9711448|NCT04623970|Experimental|Propofol sedation group|Patients in this experimental group received propofol sedation agent.
9711449|NCT04623970|Experimental|Ketofol 1:3 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:3 mixture.
10194529|NCT05181319||no bronchopulmonary dysplasia|infants not diagnosed with bronchopulmonary dysplasia
10194530|NCT05181306||Robotic surgery|
10194531|NCT05181306||Laparoscopic surgery|
10204719|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fasted (Without Food)|Oral Dose
10204720|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fed (With food)|Oral Dose
9711450|NCT04623970|Experimental|Ketofol 1:4 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:4 mixture.
9711451|NCT04624113|Experimental|Phase I: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend on dose level assigned~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
9711452|NCT04624113|Experimental|Phase 2: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend of recommended phase 2 determined in Phase I portion of study.~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
9711453|NCT04624191|Experimental|Intervention Group|Intervention group participants will be asked to measure their oxygen saturation on a daily basis.
9711454|NCT04624191|No Intervention|Control Group|Usual Care
9711455|NCT04624061|Experimental|Intervention|"The integrated HIV/HTN care model with the following components;~Training and capacity building on the INTEGRATED HIV/HTN model and NCD care~Integrated HIV/HTN care delivery model by promoting HTN screening and care in HIV clinics.~HMIS enhancements through mentorship and coaching on the use of NCD registers and NCD patient cards and HTN data capture in the (Electronic Medical Record) EMR system.~SMS and/or WhatsApp for data coordination and communication among providers, District Health officers (DHOs) and study team (Mentors) to strengthen feedback."
10194532|NCT05181293|Experimental|Experimental|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
9711456|NCT04624061|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV and Hypertension care visits at the health facilities include;a) Provision of BP machines b)Provision of NCD register and NCD patient card and ; c) Following MOH treatment guidelines
10194533|NCT05181293|No Intervention|No Intervention|In addition to routine health services, teenage mothers will receive the BabyThrive app after the intervention is completed. They will learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive also will demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of baby to facilitate growth monitoring.
10194534|NCT05181267|Experimental|Intermittent fasting|Three weeks of alternate-day fasting.
10194535|NCT05181267|No Intervention|Western diet|Three weeks of normal Western diet (no restrictions).
10194536|NCT05181254|Experimental|Health dialogue|Patients > 18 years old seeking primary care for mental illness (depression, anxiety, sleep disorders or stress related problems) will be followed at 12 and 24 months from baseline in a first assessment, and after 5 and 10 years with follow-up in national registers in a later phase. The patient will fill out a web-based questionnaire about lifestyle habits before the visit to the health center and will be called for blood sampling and measurement of blood pressure and BMI. A nurse with special training in the Health Dialogue then meets the patient and provides individually tailored advice based on the patient's unique conditions and the risk profile on the Health Dialogue, such as help with smoking cessation, physical activity on prescription (PaR-S), contact with a dietitian, physiotherapist. A continued contact with a psychologist or physician will be planned if necessary
10194537|NCT05181241|Experimental|Group No. 1 (n=6) Dimolegin - 20 mg|Group No. 1 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 1 and 2 received Dimolegin (DD217) once at a dose of 20 mg
10194538|NCT05181241|Experimental|Group No. 2 (n=6) Dimolegin - 40 mg|Group No. 2 (n=6) consisted of 2 cohorts with 3 volunteers per each. Volunteers of Cohorts 3 and 4 received Dimolegin (DD217) once at a dose of 40 mg
10194539|NCT05181241|Experimental|Group No. 3 (n=12) Dimolegin - 60 mg|Group No. 3 (n=12) consisted of 3 cohorts. Cohorts 5 and 6 included 3 volunteers per each, and Cohort 7 included 6 volunteers. All Group 3 volunteers received Dimolegin (DD217) once at a dose of 60 mg
10194540|NCT05181228|Experimental|Intervention Group (Web-based family-centered empowerment program intervention)|Intervention group participants will receive the web-based family-centered empowerment intervention for 10 weeks.
10194541|NCT05181228|No Intervention|Control Group|No intervention was applied to the control group.
10194542|NCT05181215|Experimental|Bafiertam|190 mg (2 x 95 mg) delayed-release capsules
10194543|NCT05181215|Active Comparator|Vumerity|462 mg (2 x 231 mg) delayed-release capsules
10194544|NCT05181202||Hypersensitivity reaction group|The patients get hypersensitivity after Pegylated liposomal doxorubicin injection.
10194545|NCT05181202||None hypersensitivity reaction group|The patients do not get hypersensitivity after Pegylated liposomal doxorubicin injection.
10194546|NCT05181189|Experimental|DAOIB+Omega-3|
10194547|NCT05181189|Placebo Comparator|DAOIB+Placebo|
10194548|NCT05181150|Experimental|Meal test|
10194549|NCT05181150|Experimental|GIP, Glucose-dependent insulinotropic polypeptide|
10194550|NCT05181150|Experimental|GLP-2, Glucagon-like-peptide-2|
9711457|NCT04624100||All consecutive patients with primary ventral or incisional hernia|
9980082|NCT01388244|Other|Control|Control arm - Fracture risk assessment by FRAX without any intervention
10194551|NCT05181150|Experimental|GIP + GLP-2|
10194552|NCT05181150|Placebo Comparator|Placebo (saline)|
10194553|NCT05181137|Experimental|Part 1 Active Experimental: SHR0302 Dose#1|SHR0302 Oral tablets taken once daily (QD) for 8 weeks SHR0302 Oral tablets taken once daily (QD)
10194554|NCT05181137|Placebo Comparator|Part 1 Placebo Comparator: Placebo|Placebo Oral tablets taken once daily (QD) for 8 weeks
10194555|NCT05181137|Experimental|Part 2 Active Experimental: SHR0302 Dose#2|SHR0302 Oral tablets taken once daily (QD) for 44 weeks
10194556|NCT05181137|Placebo Comparator|Part 2 Placebo Comparator: Placebo|Placebo Comparator: Maintenance Treatment Placebo Comparator: Placebo
9711458|NCT04624412|Experimental|Continuous Aerobic Moderate Intensity Exercise|(Treadmill walking exercise) 50% - 70% of max Heart Rate (HR) (3-6 METS)
9711459|NCT04624412|Experimental|Continuous Aerobic (Mild intensity Exercise)|(Treadmill walking exercise) 30% -50 % of max HR (1-3 METS)
9711460|NCT04624152|Experimental|Normobaric Hypoxia|"Large weather balloons will be filled with a normobaric hypoxic inspirate (FiO2 = 0.15) produced by a nitrogen generator (CAT 12; Colorado Altitude Training, Boulder, CO) to simulate an altitude of 2600 m (8500 ft). Participants breathed this inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
9711461|NCT04624152|Placebo Comparator|Normobaric Normoxia|"Large weather balloons will be filled with room air (FiO2 = 0.21). Participants breathed this normobaric normoxic inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
9711462|NCT04623892|Experimental|TQB2618|TQB2618 administered intravenously (IV) on Day 1 of each 21-day.
9711463|NCT04624217|Experimental|SHR-1701|SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel
9711464|NCT04623866|Active Comparator|Huaiqihuang Group|Huaiqihuang granules 60g/1.73m2 bid 24 weeks
9711465|NCT04623866|Active Comparator|Valsartan group|Valsartan granules 80mg/1.73m2 based qd 24 weeks
9711466|NCT04623606|No Intervention|Prospective Control (Untreated) and historical controls|Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database
9711467|NCT04623606|Experimental|Treatment|Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.
10194557|NCT05181137|Experimental|Part 3 Active Experimental: SHR0302 Dose#2|SHR0302 Oral tablets taken once daily (QD) for 26 weeks
10194558|NCT05181111|Experimental|Monitoring Group|wearable sensor, besides usual care monitoring
9711468|NCT04623658||Sacrococcygeal teratoma|Fetuses and infants diagnosed with sacrococcygeal teratoma and cared for between 2007 and 2017 in the main Parisian fetal medicine and pediatric surgery units: Necker-Enfants Malades Hospital, Antoine Béclère Hospital, Armand Trousseau Hospital, Robert Debré Hospital and Le Kremlin-Bicêtre Hospital.
9711469|NCT04623619|Experimental|Acetyl L-Carnitine|Acetyl L-Carnitine
9711470|NCT04623619|No Intervention|Standard of care|Standard of care
9711471|NCT04623645|Experimental|ultrasound group|patient using ultrasound technique.probe will be placed over submandibular area, the thyrohoid muscle and thyrohyoid membrane will be identified between greater horn fo hyoid bone and thyroid cartilage , 3 ml of lignocaine will be placed on space between thim and the procedure will repeated on contra lateral side.
9711472|NCT04623645|Active Comparator|anatomical blind group|patient using anatomical land mark technique, internal branch of superior laryngeal nerve will be blocked slightly anterior to greater horn of hyoid bone . by 3 ml lignocaine . the procdure will be repeated on contra lateral side .
9711473|NCT04623762|No Intervention|Control group|yoga was not done
9711474|NCT04623762|Experimental|Experimental group|yoga was done
9711475|NCT04623749|Active Comparator|Percutaneous US guided FNAC in pancreatic masses|
9711476|NCT04623749|Active Comparator|EUS guided FNAC in pancreatic masses|
9711477|NCT04623580||Inguinal or femoral hernia repair|All consecutive inguinal or femoral hernia repair (primary or mesh)
9711478|NCT04623632|Active Comparator|Bupivacaine|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique; syringes contained bupivacaine 0.25% 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
9711479|NCT04623632|Placebo Comparator|Placebo|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique syringes contained either normal saline 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
9711480|NCT04623723|Sham Comparator|Perio Slim (PS)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with PS (DS-016A, EMS® Piezon, Switzerland) scaler tip
9711481|NCT04623723|Active Comparator|Conventional scaler tip|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with conventional (FS-407, EMS® Piezon, Switzerland) scaler tip
9711482|NCT04623840|Experimental|Exercised group|.(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
10194559|NCT05181111|Other|Usual Care group|usual care monitoring
10194560|NCT05181098||Robotic-guided surgery group|Any pediatric, adolescent or adult patient undergoing robotic-guided spine surgery, ages 12-80.
10194561|NCT05181085|Active Comparator|NST 6179|double blind, single ascending and multiple ascending dose, sequential group design
10194562|NCT05181085|Placebo Comparator|Placebo|matched placebo arm
10194563|NCT05181072|Experimental|Enhanced in-person peer-motivation|This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
10194564|NCT05181072|Experimental|Virtual peer-motivation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual.
10194565|NCT05181072|No Intervention|Self-help/Control|The participants in the control group will receive the services already in place, including a brief motivation enhancement session.
9711483|NCT04623840|Active Comparator|non-exercised group|(n=30) will be sedentary obese men with ED. All participants will receive only five milligrams of tadalafil, one time per day, for eight weeks.
9711484|NCT04623788||Myocarditis|Twenty patients with acute myocarditis will be recruited if the diagnosis has been made by a cardiologist based on clinical, biochemical, electrographic and imaging data. This reflects the diagnostic criteria set out by the European Society of Cardiology (ESC) Task force 2013.
9711485|NCT04623788||Takotsubo Cardiomyopathy|Twenty patients with takotsubo cardiomyopathy will be recruited. The diagnosis will be made according to the Mayo clinic and the European Society of Cardiology (ESC) Heart Failure Association criteria, including a normal coronary angiogram, typical appearances on cardiac imaging including ventriculography, and no evidence of fibrosis on cardiac magnetic resonance imaging.
9711486|NCT04623788||Reversible Ischaemia|Forty patients who have undergone stress echocardiography or magnetic resonance imaging; twenty with positive (areas of reversible akinesis/hypokinesis during pharmacological stress), and twenty with a negative stress result (no reversible wall motion abnormalities during pharmacological stress) as per international guidelines. They will be matched for age and sex.
9711487|NCT04623788||Healthy Volunteer|Twenty healthy volunteers of comparable age and sex to the other cohorts.
9711488|NCT04623710|Experimental|Cohort 1: Severe Impaired Renal Function|Participants will receive ALXN2050.
9711489|NCT04623710|Experimental|Cohort 2: Moderate Impaired Renal Function|Participants will receive ALXN2050.
9711490|NCT04623710|Experimental|Cohort 3: Mild Impaired Renal Function|Participants will receive ALXN2050.
9711491|NCT04623710|Experimental|Cohort 4: Healthy Control|Participants will receive ALXN2050.
9711492|NCT04623528||Pericarditis patients with constrictive physiology|Patients with pericarditis and signs of constrictive physiology (increased ventricular coupling)
9711493|NCT04623528||Pericarditis patients without constrictive physiology|Patients with pericarditis but without signs of constrictive physiology (normal ventricular coupling)
9711494|NCT04623528||Dilated cardiomyopathy patients with biventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular and right ventricular ejection fraction less than 35%
9711495|NCT04623528||Dilated cardiomyopathy patients with preserved right ventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular ejection fraction less than 35%, and right ventricular function >45%
9711496|NCT04623528||Patients with pulmonary arterial hypertension|Cohort of patients with pulmonary hypertension, either idiopathic or secondary to pulmonary emboli
9711497|NCT04623528||Control group|Cohort of subjects with no evidence of pericarditis, pulmonary hypertension, dilated cardiomyopathy and normal findings at cardiovascular magnetic resonance imaging
9711498|NCT04623463|Other|Exercise intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
9711499|NCT04623814|Experimental|Food effect|HEC113995 20mg will be administered fasted, with regular meal or with high-fat meal for once.
9711500|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 10mg|HEC113995 10mg will be administered fasted for 10 days
9711501|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 20mg|HEC113995 20mg will be administered with food for 10 days
9711502|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 40mg|HEC113995 40mg will be administered with food for 10 days
9711503|NCT04623814|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo arms will be administered fasted or with food for 10 days
9711504|NCT04623476|Experimental|Pathophysiological Excision for Chron's disease|Consecutive patients (>18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD
9711505|NCT04623450|Experimental|High Carbohydrate Meal|A smoothie including maltodextrin and low-fat strawberry yoghurt - 289 kcal, 61g carbohydrate, 6.7g protein, 1.9g fat.
9711506|NCT04623450|Experimental|High Fat Meal|A smoothie including double cream and low-fat strawberry yoghurt - 312 kcal, 13.3g carbohydrate, 7g protein, 25.5g fat.
9711507|NCT04623450|Experimental|High Protein Meal|A smoothie including whey protein and low-fat strawberry yoghurt - 307 kcal, 13.6g carbohydrate, 57g protein, 2.7g fat.
9711508|NCT04623515||Surgery Only Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
9711509|NCT04623515||Surgery and Radiation Therapy Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
10204721|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 2 x 7.5 and 2 x 5.0 mg tablets, Fasted (Without Food)|Oral Dose
9711510|NCT04623294||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
9711511|NCT04623294||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
9711512|NCT04623294||Deep coma patients for HLH Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
10194566|NCT05181046|Active Comparator|Standard eyedrops of 0.5% timolol maleate|Participants randomized to this arm will receive one standard drop of 0.5% timolol maleate in each eye.
9711513|NCT04623294||Deep coma patients for LHL Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
9711514|NCT04623294||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
9711515|NCT04623294||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
9711516|NCT04623060|Experimental|Intervention|3 sessions/week for 6 weeks
9711517|NCT04623151|Experimental|Online leaflet in narrative format|
9711518|NCT04623151|Active Comparator|Online leaflet in non-narrative format|
9711519|NCT04623151|No Intervention|No leaflet (control)|
9711520|NCT04623073||Patients who underwent DAA THA|Patients who underwent DAA THA by a single surgeon who routinely documents the distance from the should of the stem to the upper end of the EO footprint
9711521|NCT04623164|No Intervention|1 Group (Control)|ten students with healthy periodontium
9711522|NCT04623164|Experimental|2 Group|ten patients receiving standard non-surgical periodontal treatment (NSPT)
9711523|NCT04623164|Experimental|3 Group|ten patients receiving standard non-surgical periodontal treatment NSPT + 28-day chronotherapy with complex phytoadaptogens (CFA)
9711524|NCT04623307||Brain damage patients|Brain damage patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
9711525|NCT04623307||Brain edema patients|Brain edema patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
9711526|NCT04623307||Healthy subjects|Healthy subjects were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
9711527|NCT04623255|No Intervention|STANDARD OF CARE|Standard patient care for severe COVID-19
9711528|NCT04623255|Active Comparator|Plasma exchange|Standard patient care for severe COVID-19 with. plasma exchange daily for 5 days x 3 courses as required
9711529|NCT04623086|Experimental|Insulin Glargine and Insulin Degludec|Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
9711530|NCT04623086|Placebo Comparator|Insulin Degludec and placebo|Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
9711531|NCT04623229|Experimental|MCS|
9711532|NCT04623229|Experimental|ReLACS Early|
9711533|NCT04623229|Experimental|ReLACS Standard|
9711534|NCT04623203||children with migraine|Children that were diagnosed at the neurology clinic with migraine at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
9711535|NCT04623203||children with TTH|children that were diagnosed at the neurology clinic with TTH at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
9711536|NCT04623359|Experimental|Patients|Patient with constipation will have a high resolution manometry
9711537|NCT04623359|Other|Healthy volunteers|Healthy volunteers will have a high resolution manometry
9711538|NCT04623281||Observational group|Observational group of 10 haemodialysis patients following usual care for 3 weeks.
9711539|NCT04623411|Experimental|Intervention Group|Neonatal resuscitation training with classical method and serious game simulation method
9711540|NCT04623411|Experimental|Control Group|Neonatal resuscitation training with classical method.
9711541|NCT04623268||Adult offspring|Adult female and male offspring to AAA patients 45-80 years of age at inclusion Children to detected AAA patients. Found in the Multigeneration registry
10194567|NCT05181046|Experimental|Nanodropper-mediated microdrops of 0.5% timolol maleate|Participants randomized to this arm will receive one microdrop of 0.5% timolol maleate in each eye. Microdrops will be dispensed from bottles with installed Nanodropper adaptors.
10194568|NCT05181033|Active Comparator|Control arm|intramuscular (IM) fulvestrant 500mg on day 1 and day 15 during cycle 1, then day 1 only from cycle 2 onwards of every 4-weekly cycle
10194569|NCT05181033|Experimental|Experimental arm|oral (PO) letrozole 2.5mg daily plus lenvatinib 14mg daily
9711542|NCT04623268||Control group|Matched women and men, without parents with AAA. Matched in the Swedish Multigeneration registry
10194570|NCT05181020|Experimental|Maternal Voice Exposure|Infants enrolled will be exposed to maternal voice for 20 min immediately prior to being offered oral feedings. This exposure will be conducted 2 times a day until infant starts taking all enteral feeds orally.
10194571|NCT05181007|Active Comparator|MFA|mefanamic acid
10194572|NCT05181007|Active Comparator|VPA|valproate
10194573|NCT05180994|Experimental|Topical infliximab following PKP surgery|Additionally to standard post-operative regimen, patients who will be undergoing their first PKP surgery and who meet all inclusion and no exclusion criteria will be included in the experimental group. These patients will administer topical infliximab four times per day for 3 months.
10194574|NCT05180994|Active Comparator|No topical infliximab following PKP surgery|Patients who will be undergoing their first PKP surgery, but who are not qualified to receive infliximab or who refuse to receive infliximab, will be included in the control group. These patients will only administer the standard post-operative regimen following their PKP surgery and will not administer topical infliximab. They will be followed with the same follow-up schedule, questionnaires, examinations and non-invasive tests (excluding lab work) as patients in the interventional group.
10204722|NCT05116553|Active Comparator|SDT (MI)|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews.
10204723|NCT05116553|Experimental|SDT (MI) + CA|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews; moreover they will use an APP with a CA (Conversational Agent), an Artificial Intelligence.
9711543|NCT04623112|Other|FC Deactivated|Frequency Compression feature on hearing aids is deactivated for 4 weeks
9711544|NCT04623112|Experimental|FC activated & set to default|Frequency compression feature activated on hearing aids and set to default software settings for 4 weeks.
9711545|NCT04623112|Experimental|FC activated and set to hearing loss|Frequency Compression feature activated on hearing aids and set to hearing loss cut-off for 4 weeks
9711546|NCT04623333|Experimental|TQB2450 injection|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
9711547|NCT04623385|Active Comparator|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
9711548|NCT04623385|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
9711549|NCT04623346||Weber B-type Ankle fractures in prepandemic period|Patients with AO Weber B-type ankle fracture in prepandemic period
9711550|NCT04623346||Weber B-type Ankle fractures in pandemic period|Patients with AO Weber B-type ankle fracture in pandemic period
9711551|NCT04623346||Wrist fractures in prepandemic period|Patients with extraarticular distal radius fracture in prepandemic period
9711552|NCT04623346||Wrist fractures in pandemic period|Patients with extraarticular distal radius fracture in pandemic period
9711553|NCT04623346||Proximal humerus fractures in prepandemic period|Patients with 2-part,3-part and 4-part fractures in prepandemic period
9711554|NCT04623346||Proximal humerus fractures in pandemic period|Patients with 2-part,3-part and 4-part fractures in pandemic period
9711555|NCT04623125|Experimental|Spaced Repetition|Two weeks (10 sessions) of online picture-naming training with 60 words.
9711556|NCT04623021|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
9711557|NCT04623021|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
9711558|NCT04623034|Experimental|400 mg MSI-195 - SAD|400 mg MSI-195 (within Stage 1, single ascending dose)
9711559|NCT04623034|Experimental|800 mg MSI-195 - SAD|800 mg MSI-195 (within Stage 1, single ascending dose)
9711560|NCT04623034|Experimental|1600 mg MSI-195 -SAD|1600 mg MSI-195 (within Stage 1, single ascending dose)
9711561|NCT04623034|Experimental|800 mg MSI-195 - fasted|800 mg MSI-195 fed (within Stage 2, cross-over comparison)
9711562|NCT04623034|Experimental|1600 mg SAM-e Complete TM - fasted|1600 mg SAM-e Complete (within Stage 2, cross-over comparison)
9711563|NCT04623034|Experimental|800 mg MSI-195 - fed|800 mg MSI-195- fed (within Stage 2, fed arm)
9711564|NCT04622748||COVID-19|Recovered COVID-19 patients in Wuhan
9711565|NCT04622748||Healthy Control|Uninfected people in Wuhan
9711566|NCT04622696||Prospective - Performance Cohort|Subjects will undergo an ultrasound-guided breast biopsy procedure with placement of HydroMARK Breast Biopsy Site Marker per site standard of care and will return to the office at 6-12 weeks post-implant for ultrasound imaging to evaluate device visibility.
9711567|NCT04622696||Retrospective - Safety Cohort|Device-related adverse events will be collected via retrospective medical chart review for a minimum of 90 days post-HydroMARK Breast Biopsy Site Marker implant (unless the subject was exited according to the medical records due to the implant being removed/explanted or subject death).
9711568|NCT04622800|Other|Individuals applied with proprioceptive neuromuscular fasilition techniques|No exercise intervention was made.
9711569|NCT04622618|Active Comparator|G 300|The patients will receive 300 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
9711570|NCT04622618|Active Comparator|G 600|The patients will receive 600 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
9711571|NCT04622618|Active Comparator|G 900|The patients will receive 900 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
9711572|NCT04622865|Experimental|Masitinib plus Isoquercetin plus Best Supportive Care|"Patients will receive oral masitinib dose of 3 mg/kg/day for 4 days then 4.5 mg/kg/day.~The dose of isoquercetin will be 1 g/day by oral route. Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs."
9711573|NCT04622865|Active Comparator|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs.
9711574|NCT04622995||Exposed|Patients prescribed opiate replacement therapy plus a benzodiazepine.
9711575|NCT04622995||Unexposed|Patients prescribed opiate replacement therapy with no benzodiazepine prescribing.
9711576|NCT04622852||Group A: ALPS-PHP device|Patients operated with angular stable plate for displaced PHF with an ALPS plate
9711577|NCT04622852||Group B: Philos device|Patients operated with angular stable plate for displaced PHF with a Philos plate
9980083|NCT01388257|Experimental|Surgery|Seton drain removal is associated with proctological surgery.
9711578|NCT04622826|Experimental|sequential immune plasma infused patients|immune covid 19 plasma infusion
9779410|NCT05306522|Experimental|Telerehabitation Group|Patients will undergo telerehabilitation based spinal stabilization exercise 3 days per week for 6 weeks.
9779411|NCT05306522|Experimental|Face to face Group|Patients will undergo spinal stabilization exercise 3 days per week for 6 weeks.
9779412|NCT05306509|Experimental|Nurse-initiated conversations for early integration of palliative care (NiCE)|Participants will receive nurse-initiated conversations facilitating early integration of palliative care in pediatric oncology.
9779413|NCT05306509|Other|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
9779414|NCT05306457|Experimental|CNS10-NPC-GDNF - Group A|Unilateral, Motor Cortex, 0.25x10^6 cells in 10 µL/site, 21 sites (5.25x10^6 total cells) - Motor cortex corresponding to the non-dominant hand
9779415|NCT05306457|Experimental|CNS10-NPC-GDNF - Group B|Unilateral, Motor Cortex, 0.5x10^6 cells in 10 µL/site, 21 sites (10.5x10^6 total cells) - Motor cortex corresponding to the non-dominant hand
9980084|NCT01388257|Other|Simple seton drain removal|
9711579|NCT04622878|Other|acute lower limb ischemia patients|patients with no palpable pulsations or audible signals in the lower limb
9711580|NCT04622722|Active Comparator|Group A|Group A: Drinking Nutren Diabetes provides energy at 360 kcal per 360 ml
10194575|NCT05180968|Experimental|Nabilone 0.5mg|Subjects will receive nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
9711581|NCT04622722|Placebo Comparator|Group B|Group B: Having Isocaloric diet provide 360 kcal.
9711582|NCT04622709|Experimental|Study drug administration: furosemide|Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant.
9711583|NCT04622969|Experimental|Intervention|Provide the 15-week Healthy Child Development Program intervention
9711584|NCT04622969|No Intervention|Wait list control|
9711585|NCT04622956|Experimental|Experimental|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present. Filgrastim will be administered from day +5 until neutrophil recovery to ≥ 1,000/mcL for 3 days.
9711586|NCT04622956|No Intervention|Control Group|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and mycophenolate mofetil (15 mg/kg/dose p.o. t.i.d. initiated on day +5). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present.
9711587|NCT04622891|Experimental|clarithromycin|clarithromycin group
9711588|NCT04622891|Active Comparator|Azithromycin|azithromycin group
9711589|NCT04622891|Placebo Comparator|control|control group
9711590|NCT04622631||PRRT positive|patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans
9711591|NCT04622631||PRRT negative|no response to PRRT treatment
9711592|NCT04622566|Experimental|Lenvatinib and Pembrolizumab in Resectable mucosal Melanoma.|
9711593|NCT04622787||Tuscany, Italy|Infants at risk of Cerebral Palsy in Tuscany, Italy
9711594|NCT04622787||Infants at risk of Cerebral Palsy in Georgia|Infants at risk of Cerebral Palsy in Georgia
9711595|NCT04622787||Sri-Lanka|Infants at risk of Cerebral Palsy in Sri-Lanka
9711596|NCT04622787||Denmark|Infants at risk of Cerebral Palsy in Denmark
9711597|NCT04622787||Infants at risk of Cerebral Palsy in the Netherlands|the Netherlands
9711598|NCT04622787||remote Queensland, Australia|Infants at risk of Cerebral Palsy in remote Queensland, Australia
9711599|NCT04622787||Medical professionals|Medical/healthcare providers from all involved geographic locations that work with infants at risk or with diagnosis of cerebral palsy will be provided opportunities for the participation in face-to-face and/or e-learning platform trainings on the the international early detection guidelines.
9711600|NCT04622813|Placebo Comparator|Placebo group|
9711601|NCT04622813|Experimental|Multimodal group|
9711602|NCT04622579|Experimental|lenalidomide combined with rituximab|Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.
9711603|NCT04622592|Experimental|Vaccine (30 µg/strain) adjuvanted with AS03|Treatment group 2: 30 µg/strain QVLP vaccine adjuvanted with AS03
9711604|NCT04622592|Active Comparator|Vaccine (30 µg/strain) unadjuvanted|Treatment group 4: 30 µg/strain QVLP vaccine unadjuvanted
9711605|NCT04622592|Active Comparator|Vaccine (60 µg/strain) Fluzone HD Quad|Treatment group 5: 60 µg/strain Fluzone HD Quad vaccine
9711606|NCT04622670|Experimental|Group I (yoga group)|Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over 5-10 minutes and receive a yoga manual and DVD during and after CRT.
9711607|NCT04622670|Active Comparator|Group II (wait list control)|Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
9711608|NCT04622917|Active Comparator|Methylprednisolone|Depo-Medrol (Methylprednisolone) 40 milligrams/milliliter, 2 milliliters as a single dosage
9711609|NCT04622917|Placebo Comparator|Sodium Chloride (NaCl)|NaCl 0,9 milligrams/milliliter, 2 milliliters as a single dosage
9711610|NCT04622982|Experimental|All participants|Obese subjects with BMI >= 30 and with one or more of metabolic comorbidities (type 2 diabetes mellitus, dyslipidemia, high blood pressure, hyperuricemia, and others).
9711611|NCT04622488|Active Comparator|Diclofenac Potassium|In the form of insitu gel can be applied as solution or suspension that undergoes gelation after administration.
9711612|NCT04622488|Experimental|Calcium Hydroxide|
9711613|NCT04622462||Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia|"No evidence of dysplasia~Mild dysplasia~Moderate dysplasia~Severe dysplasia"
9711614|NCT04622761|No Intervention|control|Immediate surgery (radical prostatectomy) (standard care)
9779416|NCT05306457|Experimental|CNS10-NPC-GDNF - Group C|Unilateral Motor Cortex, 0.5x10^6 cells in 10 µL/site, 21 sites (10.5x10^6 total cells) - Motor cortex corresponding to the dominant hand
9711615|NCT04622761|Experimental|treatment|"14 days prior to starting Cabazitaxel patients will take 50mg Bicalutamide once daily for 21 days.~7 days prior to starting Cabazitaxel patients will be given 3 months LHRH treatment via injection. The entire dose will be administered via one injection 7 days prior to starting Cabazitaxel. This may be either leuprorelin or goserelin acetate and should be given as per local practice.~At least 30 minutes prior to each administration of Cabazitaxel, patients will be administered IV premedication consisting of:~50mg Ranitidine 10mg Chlorphenamine 8mg Dexamethasone Daily from Day 1 until end of Cabazitaxel treatment patients will take 10mg Prednisolone once daily from Day 1 until end of Cabazitaxel treatment Day 1 of each cycle - Patients will receive Cabazitaxel 25 mg/m2 intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles."
9711616|NCT04622306|Active Comparator|Control|Commercial Natural Rubber Latex Male Condom
9711617|NCT04622306|Experimental|Polyurethane Condom A|Polyurethane Condom A (002)
9711618|NCT04622306|Experimental|Polyurethane Condom B|Polyurethane Condom B (001)
10194576|NCT05180968|Placebo Comparator|Oral placebo|Subjects will receive placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
10194577|NCT05180929|Experimental|Dual-M1 tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
10194578|NCT05180929|Experimental|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
10194579|NCT05180929|Sham Comparator|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
10194580|NCT05180916|Active Comparator|Brivaracetam + Transcutaneous vagal nerve stimulation|Start of Brivaracetam (treatment as usual), combined with tVNS in the first 3 months of treatment
10194581|NCT05180916|No Intervention|Brivaracetam|Start of Brivaracetam (treatment as usual)
10194582|NCT05180877||Intermittent& mild persistent asthma|According to asthma severity assessment, this group included asthmatic pregnant females patients with intermittent asthma and mild persistent asthma
10194583|NCT05180877||Moderate& severe persistent asthma|According to asthma severity assessment, this group included asthmatic pregnant females patients with Moderate& severe persistent asthma
10194584|NCT05180864|Active Comparator|Complete omentectomy|Gastrectomy with complete omentectomy
10194585|NCT05180864|Experimental|Omentum presevation|Gastrectomy with preservation of the omentum distal to the gastroepiploic vessels
10194586|NCT05180838||BioSticker|This cohort will place BioStickers at least 3 days prior to completion of standard of care therapy and discharge home post therapy.
10194587|NCT05180825|Experimental|Trametinib experimental arm|the experimental arm will be Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
10194588|NCT05180825|Active Comparator|Vinblastine control arm|the control arm will be the weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
10194589|NCT05180799|Experimental|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
10194590|NCT05180799|Experimental|Combination Therapy|Conditionally active biologic (CAB) antibody that binds to CTLA-4 with PD-1 inhibitor
10194591|NCT05180760|Active Comparator|Smartphone app arm|Use the dedicated smartphone app for NAFLD patients
10194592|NCT05180760|Other|Standard of care|Standard of care
10194593|NCT05180747|Other|Burst group|Patients received two physical therapy sessions weekly for 6 weeks.
10194594|NCT05180747|Other|Spaced Group|Patients received one physical therapy sessions every 2 weeks for 6 months.
10194595|NCT05180721|Experimental|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
10204724|NCT05102500||Retrospective Chart Review Patients|The PI will conduct a retrospective chart review of breast cancer, colorectal cancer, and pancreatic cancer patients to better understand the patient, disease, and treatment characteristics that play a role in second opinion retention rates.
10204725|NCT05102500||Semi-structure Interview Patients|The PI will conduct semi-structured interviews with breast cancer, colorectal cancer and pancreatic cancer patients to better understand the decision-making process that goes into continued care with their primary or second opinion physician.
9711619|NCT04622293|Experimental|Solriamfetol|Those who are receiving solriamfetol will receive 37.5 mg, 75 mg, or 150 mg. Patients will begin at a 75 mg dose and then after three days titrate up or down as needed, determined by consultation visits with primary investigator. Solriamfetol will be taken orally.
9711620|NCT04622293|Placebo Comparator|Placebo|Those who are not receiving solriamfetol will receive the placebo drug, which will be encapsulated in matching capsules to reduce any bias or speculation with participants.
9980085|NCT01388270|Active Comparator|Evodial|a pre-heparin-coated hemodialysis filter
9711623|NCT04622202|Active Comparator|pregabalin|oral capsule pregabalin 150 mg.
9711624|NCT04622202|Placebo Comparator|multivitamin|oral multivitamin capsule.
9711625|NCT04622475|Experimental|Treatment|Fecal Microbiota Transplant (FMT) Capsule
9711626|NCT04622371|Experimental|moderate exercises group|Patients received 30 minutes of aerobic exercise at 40-60% of maximum heart rate
9711627|NCT04622371|Experimental|Light exercises group|Patients treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
9711628|NCT04622358|Experimental|AD-214-02/Rabeprazole|Period 1 : Test Drug(AD-214-02) Period 2 : Reference Drug(Rabeprazole)
9711629|NCT04622358|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole) Period 2 : Test Drug(AD-214-02)
9711630|NCT04622540|Experimental|Experimental group|Application of external biliary drainage
9711631|NCT04622540|No Intervention|Control group|Conventional duct-to-duct anastomosis (with or without internal stent)
9711632|NCT04622397|Active Comparator|Group T (tranexamic acid),n=15|Group T: tranexamic acid 10 mg/kg will be injected locally
10194596|NCT05180695|Experimental|extension part : Soft-tissue sarcomas with MDM2 amplification|"The aim of each extension cohort is to provide preliminary evidence of anti-tumor activity while refining toxicity data, and to gain insight progressive disease activity and exploratory biological analyses. A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with MDM2 amplification . Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
10194597|NCT05180695|Experimental|extension part : Soft-tissue sarcomas with no MDM2 amplification|"A maximum of 14 patients patients will be enrolled in this cohort  Soft-tissue sarcomas with no MDM2 amplification. Both study drugs (pazopanib and HDM201) will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
10194598|NCT05180682|Experimental|Supervised|This group training was supervised by the health care provider.
10194599|NCT05180682|Active Comparator|Non-Supervised|This group was non-supervised.
10194600|NCT05180656|Experimental|Yoga Intervention Group|All participants will be assigned to the yoga intervention group (single arm).
9711633|NCT04622397|Placebo Comparator|Group S (saline) (n=15)|Group S saline will be injected
9711634|NCT04622384||ICU patients|Patients who are treated with dialysis as CRRT and planned to undergo dialysis weaning.
9711635|NCT04622215|Other|ICIQ questionnaire|
9711636|NCT04622189|Experimental|Action observation training for the upper limb rehabilitation|Neurorehabilitation training for the upper limb using AOT consists of watching videos related to every day actions. The subjects will be asked to reproduce, as accurately as possible, the actions proposed by the system, that will record their execution. In order to keep high motivation and participation in activities, simple games of skill will also be created that will involve the patient on both the motor and cognitive side. The training program includes 250 videos of every day transitive and intransitive actions: 20 consecutive sessions of 1 hour, five times a week over four weeks.
9711637|NCT04622137|No Intervention|Arm sling only group (group S)|Participants used only arm sling for clavicula fracture
9711638|NCT04622137|Active Comparator|Arm sling with kinesiotaping therapy group (group K).|Participants used arm sling and the investigators applied kinesiotheraphy for clavicula fracture
9711639|NCT04622111|Experimental|CPL207280|"PART A: 8 cohorts are to receive single dose of IMP.Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
9711640|NCT04622111|Placebo Comparator|Placebo|PART B: 2 Participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
9711641|NCT04622111|Experimental|CPL207280 120 mg + Metformin 750 mg|1 cohort (total of 12 participants) are to receive single dose of IMP in fed and fasted state, IMP with metformin and metformin alone to assess the effect of food and metformin on bioavailability of CPL207280. There is to be one week wash-out between four treatments periods for this cohort.
9711642|NCT04622449||Chronic liver disease with anemia|All patients with anemia as diagnosed by WHO criteria in patients with liver disease of any etiology.
9711643|NCT04622241|Experimental|Eave Tubes - Traditional House|Installation of eave tubes in traditional homes.
9711644|NCT04622241|Experimental|Eave Tubes - Modern House|Installation of eave tubes in modern homes.
9711645|NCT04622241|Experimental|Eave Ribbons - Traditional House|Installation of eave ribbons in traditional homes.
9711646|NCT04622241|Experimental|Eave Ribbons - Modern House|Installation of eave ribbons in modern homes.
9711647|NCT04622241|Experimental|Full House Screening - Traditional House|Installation of full house screening, includes screening eaves and windows, in traditional homes.
9711648|NCT04622241|Experimental|Full House Screening - Modern House|Installation of full house screening, includes screening eaves and windows, in modern homes.
9711649|NCT04622241|Experimental|Partial House Screening - Traditional House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in traditional homes.
9711650|NCT04622241|Experimental|Partial House Screening - Modern House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in modern homes.
9711651|NCT04622241|No Intervention|Control - Traditional House|Control group with no intervention in traditional homes
9711652|NCT04622241|No Intervention|Control - Modern House|Control group with no intervention in modern homes.
9711653|NCT04622514|Experimental|people-centered integrated care|
9711654|NCT04622514|Active Comparator|usual care|
9711655|NCT04622423||PDAC liver-MTS|Adult patients with clinical /radiological diagnosis/suspicious of PDAC metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) from liver resection/metastasectomy or core liver biopsy.
9711656|NCT04622423||CRC liver-MTS|Adult patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver with indication to surgical resection (upfront or after neoadjuvant therapy).
10204726|NCT05094011|Experimental|Single Arm Study|Autologous MitoCell Transplantation in Subjects with Idiopathic Parkinson's Disease
9711657|NCT04622423||Primary non-MTS PDAC|Adult patients with clinical/radiological diagnosis of primary non-metastatic PDAC, candidates for surgical resection with radical intent of the primary tumor (upfront surgery or after neoadjuvant therapy). These patients will be monitored for early diagnosis of metachronous hepatic PDAC MTS by follow up testing.
9711658|NCT04622423||Healthy volunteers|Negative control for the clinical study.
9711659|NCT04622098||patients with SEL|"Any patient with detected sub-epithelial lesion during upper endoscopy either symptomatized or accidently discovered.~Patients diagnosed by EUS, CT scan or surgically removed lesions."
9711660|NCT04622072|Experimental|Experimental group|For dose escalation phase, subjects are enrolled for different doses of the experimental drug.
9711661|NCT04621851||Retrospective cohort|Patients who discontinued before the opening of this study will contribute to the retrospective cohort.
9711662|NCT04621851||Prospective cohort|Patients who will discontinue after it will contribute to the prospective cohort.
9711663|NCT04621851||Retrospective/Prospective cohort|Patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts.
9711664|NCT04621708|Experimental|Left DLPFC iTBS rTMS|
9711665|NCT04621734|Active Comparator|Nasal bridle to secure feeding tube|The nasal bridle will be used to secure the nasoenteric feeding tube.
9711666|NCT04621734|Placebo Comparator|Adhesive Tape use to secure feeding tube|Adhesive tape will be used as standard of care to secure the nasoenteric feeding tube.
9711667|NCT04622059|Experimental|acoustic stimulation|Fetuses in the group A (n=105) received an acoustic stimulation
9711668|NCT04622059|No Intervention|no acoustic stimulation|Fetuses in the group B (n=105) no intervention was performed
9711669|NCT04621760|Experimental|HIV Prevention DST Intervention|Participants in this arm will receive the HIV prevention DST intervention and will receive the intervention immediately before their provider visit.
9711670|NCT04621760|Active Comparator|Standard Counseling|Participants in this arm will receive usual care.
9711671|NCT04621929|Experimental|Allocated to intervention/treatment|Daily phentermine/topiramate x 18 months
9711672|NCT04621929|Active Comparator|Allocated to pragmatic control|Remain on their current regimen
9711673|NCT04621994|Active Comparator|Steri Strips Arm|
9711674|NCT04621994|Experimental|Dermabond Arm|
9711675|NCT04621773||PGS(Preimplantation Genetic Screening)|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via preimplantation genetic screening procedure
9711676|NCT04621773||SP(spontaneous pregnancy )|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via spontaneous pregnancy.
9711677|NCT04622046|Experimental|ALXN2060|Participants will receive ALXN2060.
9711678|NCT04622020||Adult patients with chronic neck pain (> 3 months) following whiplash injury|Cervical plexus block with local anaesthesia followed by Cervical Plexus block with depot steroids
9711679|NCT04621903|Experimental|Ayurveda|
9711680|NCT04621942|Experimental|Training group|12 women after mastectomy. Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Moreover, women from training group participated in rehabilitation gymnastics twice a week.
9711681|NCT04621942|Active Comparator|Control group|12 women after mastectomy. All women participated in rehabilitation gymnastics twice a week.
9711682|NCT04621721|Experimental|Intervention Group|The intervention will consist of a 16-week, home-based gait/balance training and progressive resistance exercises for lower extremities using resistance power bands. Participants will be given the home-based gait/balance training and progressive resistance exercise training access via a link or by DVD, and the resistance training band, and wide, firm foam surface. The intervention group will begin with light warm-up and stretching activity then a 10 minute each of gait/balance and 10 minutes of resistive (strength) training components. The program begins with light stretching to address any range of motion limitations that may affect ability to maintain balance and postural stability, and consisted of hamstring quadricep, gastroc, and soleus stretches. During stretching exercises, participants held each stretch for 10-15 seconds, repeating each stretch 2-3 times for each lower extremity. Stretching exercises do not change during the intervention.
9711683|NCT04621721|Active Comparator|Attention Control Group|The Attention Control group will receive an educational intervention via a journal in which to record their clinic appointments, and standardized American Cancer Society pamphlets which have been adjusted to fit within the journal binding for easy reference. At each data collection encounter, the intervention research assistant will discuss the information in each pamphlet, allowing time for questions related to the material. The educational materials consist of 1) Emotions and Breast Cancer; 2) Body Image and Sexuality After Breast Cancer; 3) Follow up Care After Breast Cancer Treatment; 4) Nutrition and Cancer. Sessions last approximately 45-60 minutes and occur at the same intervals as the intervention group and will precede data collection. Attention Control group participants will receive telephone calls every other week which will entail a social visit and reminder of data collection/attention intervention appointments to further equalize contact.
9711684|NCT04622033|Experimental|Brodalumab 210mg|
9711685|NCT04621695|Other|Rubber band ligation|Rubber band ligation is performed by a suction device that allows a rubber band to be applied at the base of the haemorrhoid via a proctoscope. Maximal suction force used is 40 mmHg. A maximum of 3-4 bands are used per session. This rubber band constricts the blood supply causing it to become ischaemic before being sloughed approximately 1-2 weeks later. The resultant fibrosis reduces any element of haemorrhoidal prolapse that may have been present. No sedation is required for this day-care procedure. Patients are asked to administer an enema 2 hours prior to the procedure.
9711686|NCT04621695|Other|Hemorrhoidectomy|"There are two main excisional procedures currently carried out: open (Milligan and Morgan) and closed (Ferguson). Both have the intention of excising the haemorrhoidal cushions. The procedure is performed under either general or spinal anaesthesia in a day-care setting.~Patients were asked to administer an enema 2 hours prior to the procedure."
9980086|NCT01388270|No Intervention|170 H|Conventional filter
9980087|NCT01388296||Morbidly obese patients|BMI 40-50 k/m2
9980088|NCT01388296||Morbidly obese|BMI 50-60 k/m2
9711687|NCT04621799|Experimental|Fibrin Group|Experimental: Non-Autologuos Fibrin (NAF) Subjects in the NAF arm received an injection of non-autologous fibrin
10194601|NCT05180643|Experimental|non-fluctuating patients or with minor fluctuations (Group A)|Patient without fluctuation or with minor motor fluctuations (rated 0 or 1 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)
10194602|NCT05180643|Experimental|patients with mild to moderate fluctuations (Group B).|Patient without fluctuation or with minor to moderate motor fluctuations (rated 2 or 3 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)
9711688|NCT04621656||Type 2 Diabetes|Individuals that have been previously diagnosed with Type 2 Diabetes. Those with Fasting Blood Glucose levels 126 mg/dL in two separate tests and/or HbA1C values greater than 6.5%. Individuals may take Metformin, SGLT2 inhibitors, of GLP-1 therapeutics. Not including those using Insulin therapeutics.
10194603|NCT05180630|Experimental|Study Group|Group will be fit using three different hearing aid couplings. Each participant will be supplying a rating of sound quality for each condition.
9711689|NCT04621656||Pre-Diabetes|Individuals that have been previously diagnosed with Pre-Diabetes. This group may include individuals with pre-diabetes that may be unaware of their condition. HbA1C values between 5.7% and 6.4%.
9711690|NCT04621656||Healthy|Individuals that have not been previously diagnosed with Metabolic Syndromes including Type 2 Diabetes, obesity, or increased levels of blood sugar. HbA1C values below 5.7%.
9980089|NCT01388296||Morbidly obeses|BMI 60-70 k/m2
9980090|NCT01388309||Cohort|
10194604|NCT05180617|Experimental|Individual music therapy (IMT)|"After baseline measures, each Participant will receive 6 x 1 weekly hour of music therapy. During music therapy the participants will be interacting both musically and verbally with the therapist.~Participants will be provided with both acoustic and electronic instruments with which they will be able to improvise with the therapist. In addition, IMT participants will be provided with the opportunity to compose and write songs, take part in preferred music lyric analysis, sing and discuss/talk with the therapist.~During session 2 and 5 EEG hyperscanning of therapist and patient will be applied.~All 5 IMT participants will do the same pre-post intervention test battery."
10194605|NCT05180617|Experimental|Group music therapy (GMT)|"During 6 x 1 weekly hour of GMT, 5 participants will be invited to take part in a range of group music making activities.~Participants will be provided with both acoustic and electronic instruments with which they will be able to improvise within the group setting. In addition, GMT participants will be provided with the opportunity to compose and write songs as a group, take part in preferred music lyric analysis, sing and take part in group discussions.~All 5 GMT participants will do the same pre-post intervention test battery."
10194606|NCT05180617|No Intervention|Control Group|"CG will receive standard treatment, which includes key work sessions, other group work programmes and clinical support (e.g. prescribing).~All 5 CG participants will do the same pre-post intervention test battery."
10194607|NCT05180604|Experimental|experience learning programs of eHealth care|Patients in the experimental group received 6 sections of activities.
10194608|NCT05180604|No Intervention|Usual care|Patients in control group received usual care
10194609|NCT05180578|Experimental|Tolerability of goat milk consumption in patients with EOE triggered by milk allergy|Elimination of cow milk from diet . Goat milk containing diet.
10194610|NCT05180565|Experimental|Colovac|Patients receive Colovac device during colorectal surgery
10194611|NCT05180552|Experimental|Experimental|Participants will wear HEALiX Device while intubated and sedated in the critical care setting
10194612|NCT05180552|Active Comparator|Control|Participants will wear wrist restraints while intubated and sedated in the critical care setting
10194613|NCT05180539|Experimental|SPLASH Intervention Condition|
10194614|NCT05180539|Other|Diet and Physical Activity Condition|
10194615|NCT05180526|Experimental|Experimental|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
10194616|NCT05180513|Other|Teleconference Mindfulness Intervention Group|MBSR training program that has been adapted for use via Zoom teleconferencing and for cultural relevancy
10194617|NCT05180513|Other|Smartphone App Mindfulness Intervention Group|MBSR training program that has been adapted for use via smartphone app and for cultural relevancy
10194618|NCT05180513|No Intervention|Waitlist Control Group|No intervention; control group
10194619|NCT05180487|Experimental|FCU Online + Coach|Parents in this arm will receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching will focus on Wellness and Self-Care, Parenting and Substance Use, Positive Parenting, Proactive Parenting, and Supervision and Limit Setting.
10194620|NCT05180487|No Intervention|Waitlist Control|Parents in this arm will initially serve as the control group but will receive access to the FCU Online website and telehealth coaching after completing four waves of data collection (baseline, 3-mo, 6-mo, and 12-mo follow-up).
10194621|NCT05180461|Experimental|Part 0 Pilot group emodepside 15mg Once a day (OD) 1 day|emodepside tablets 15 milligrams once a day for 1 day
10194622|NCT05180461|Experimental|Part 1 emodepside 30mg OD 1 day|emodepside tablets 30 milligrams once a day for 1 day
9980091|NCT01388322|Experimental|Enoxaparin|Subcutaneous administration of one dose daily of enoxaparin
9980092|NCT01388322|No Intervention|expectant management|Usual management
10194623|NCT05180461|Experimental|Part 1 emodepside 15mg OD 7 days|emodepside tablets 15 milligrams once a day for 7 days
10194624|NCT05180461|Experimental|Part 1 emodepside 15mg OD 14 days|emodepside tablets 15 milligrams once a day for 14 days
10194625|NCT05180461|Experimental|Part 1 emodepside 15mg twice a day (BID) 10 days|emodepside tablets 15 milligrams twice a day for 10 days
10194626|NCT05180461|Placebo Comparator|Part 1 placebo|matching placebo of emodepside tablets
10194627|NCT05180461|Experimental|Part 2 emodepside dose regimen A|emodepside tablets, dose regimen A selected from regimens tested in Part 1
10194628|NCT05180461|Experimental|Part 2 emodepside dose regimen B|emodepside tablets, dose regimen B selected from regimens tested in Part 1
10194629|NCT05180461|Active Comparator|Part 2 ivermectin|ivermectin, single oral dose of 150 micrograms per kilogram by weight
9711691|NCT04621370|Active Comparator|Arm A|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~Short course radiotherapy (25Gy delivered in 5 fractions) starting on day 1~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy and continuing for 6 cycles in total~Assessment of response will be at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
9711692|NCT04621370|Active Comparator|Arm B|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~Long course chemoradiotherapy (50Gy to boost volume, 45Gy to elective volume delivered in 25 fractions) starting on day 1~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy for 4 cycles~Assessment of response at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
9711693|NCT04621643|Experimental|digital cognitive behavioral therapy (dCBT-I)|
9711694|NCT04621643|Active Comparator|Patient education about sleep (PE)|
9711695|NCT04621578|Experimental|Transcutaneous electrical acupoint stimulation arm|Patients will be given TEAS treatment at the maximum tolerable intensity at a frequency of 2 Hertz (Hz) after surgery in postanesthesia care unit (PACU), and after returning to the ward.
9711696|NCT04621578|Sham Comparator|Sham stimulation arm|Patients will use the same device, same stimulation site, and be treated at the same time points, but the lead of the device was damaged. Therefore, although the patients can see the stimulator running, there is actually no current passing through.
9711697|NCT04621591|Experimental|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care EGD procedure performed using the Saneso 360° gastroscope. Immediately thereafter Patients will then have an EGD procedure using a standard Gastroscope (Olympus GIF 180) performed by a second endoscopist.
9711698|NCT04621461|Placebo Comparator|Experimental Arm #1|Placebo
10194630|NCT05180435|Experimental|Family Meals|Have at least 5 dinners per week.
9711699|NCT04621461|Experimental|Experimental Arm #2|Zinc sulfate
9711700|NCT04621487|Active Comparator|concomitant|Concomitant therapy consists of 14 days pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg all twice daily.
9711701|NCT04621487|Active Comparator|tailored|Tailored therapy consists of 14 days antibiotic therapy according to H. Pylori strains antibiotic sensitivity test together with pantoprazole 40 mg twice daily.
9711702|NCT04621565|Experimental|Hydrocortisone withholding group|Patients receive no hydrocortisone
9711703|NCT04621565|Active Comparator|Hydrocortisone group|Patients receive routine hydrocortisone
9711704|NCT04621617|Active Comparator|Albumin + Midodrine + SMT|Human albumin plus oral midodrine
9711705|NCT04621617|Active Comparator|Albumin + SMT|Human albumin plus placebo of midodrine
9711706|NCT04621617|Placebo Comparator|SMT|standard medical therapy plus placebo of midodrine
9711707|NCT04621669|Experimental|digoxin, Rosuvastatin calcium,SHR3680|
9711708|NCT04621669|Experimental|metformin hydrochloride ,SHR3680|
9711709|NCT04621409|Experimental|liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
9711710|NCT04621409|Placebo Comparator|Placebo|IV infusion of saline, approximately 5 hours
9711711|NCT04621266|Experimental|Home-based peer support intervention|Participants will receive intervention on top of standard usual care.
9711712|NCT04621266|No Intervention|Standard usual care|Participants will receive standard usual care.
9711713|NCT04621318|Experimental|SB16|SB16 (proposed denosumab biosimilar)
9711714|NCT04621318|Active Comparator|EU Prolia|EU sourced Prolia (denosumab)
9711715|NCT04621318|Active Comparator|US Prolia|US sourced Prolia (denosumab)
9711716|NCT04621396||Next Generation Cohort|We will follow the children from mothers who either have T2D, GDM, or are controls.
9711717|NCT04621227|Other|Period 1|Participants will receive the following treatments in this sequence : (i)Rosuvastatin alone (one dose of 10 mg), (ii) Midazolam alone (one dose of 2mg), (iii) PF 06882961 alone (120 mg twice daily), (iv) PF 06882961 (120 mg twice daily) + Rosuvastatin (one dose of 10mg), (v) PF 06882961 (120 mg) + Midazolam (one dose of 2 mg), (vi) PF 06882961 (200 mg) alone, (vii) PF 06882961 (200 mg) + Rosuvastatin (one dose of 10 mg), (viii) PF 06882961 (200 mg)+ Midazolam (one dose of 2 mg) in the study.
9711718|NCT04621448|Experimental|Immediate Start|The Immediate Start group will participate in the 12-week Moving Together program after completing the baseline assessment. Moving Together is a gentle, live-streaming, group movement program designed specifically for people with memory loss (PWML) and caregivers (CG) to do together. It is based on the in-person Preventing Loss of Independence through Exercise (PLIÉ) and Paired PLIÉ programs. The program combines physical movements to help maintain daily function with mindful body awareness exercises and social interactions to provide a comprehensive, multi-domain program.
9711719|NCT04621448|Experimental|Delayed Start|A Delayed Start group will be encouraged to continue with their usual daily activities during the first 12 weeks of the study and will begin the Moving Together program after completing the mid-point assessment.
9980093|NCT01388348|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
10194631|NCT05180435|Active Comparator|Standard|Consume the recommended amounts of fruits and vegetables.
10194632|NCT05180396||Cases with the diagnosis of Heart Failure (Acute and Chronic)|Application of a questionnaire consisting of different questions to patients.
10194633|NCT05180370||Outpatient or inpatient diagnosed with Heart Failure at least 6 months ago|ADAPTATION HF is a prospective, observational, cross-sectional, multicenter, survey-based study. Patients who applied to the cardiology outpatient clinic with a preliminary diagnosis of HF or were hospitalized for HF and had a diagnosis of HF for at least 6 months will be included in the study.
10194634|NCT05180279|Experimental|Sleep Lab|
10204727|NCT05093413|Experimental|Fully slept first; Sleep deprived second|Participants will be fully slept during the first experimental visit and sleep deprived during the second experimental visit
9711720|NCT04621383|Experimental|whey protein plus collagen group|Participants received a dose of 30 grams of whey protein plus 20 grams of collagen seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
9711721|NCT04621383|Placebo Comparator|whey protein plus maltodextrin group|Participants received a dose of 30 grams of whey protein plus 20 grams of maltodextrin seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
9711722|NCT04621513|Experimental|Collaborative Care Model of TCM and WM|Traditional Chinese Medicine(TCM):laser acupuncture and massage education. Western Medicine (WM):intra-nasal corticosteroid with singulair
9711723|NCT04621513|Active Comparator|Western medicine|Western Medicine (WM):intra-nasal corticosteroid with singulair
9711724|NCT04621188|Experimental|Lorlatinib|100 mg once daily
9711725|NCT04621539||Infected without an SMO|Defined as an acute infection not associated with admission to the intensive care unit (ICU), mechanical ventilation, or the use of vasopressors.
9711726|NCT04621539||Infected with an SMO|defined as an acute infection associated with intensive care unit (ICU) admission, mechanical ventilation, or vasopressor use.
9711727|NCT04621305|Placebo Comparator|group P (Placebo group)|Patients were assigned to group P (Placebo group) using a computer-generated random number table
9711728|NCT04621305|Experimental|group B (Bolus group)|Patients were assigned to group B (Bolus group) using a computer-generated random number table
9711729|NCT04621305|Experimental|group C (continuous infusion group)|Patients were assigned to group C (continuous infusion group) using a computer-generated random number table
9711730|NCT04621149|Placebo Comparator|placebo|1 liter of filtered water
9711731|NCT04621149|Active Comparator|chlorine dioxide aqueous solution (AS)|1 liter of filtered water with AS
9711732|NCT04621149|Active Comparator|placebo with zinc acetate (ZA)|1 liter of filtered water with ZA
9711733|NCT04621149|Active Comparator|AS with ZA|1 liter of filtered water with AS and ZA
9711734|NCT04621149|Active Comparator|placebo with famotidine, lactoferrin and green tea extract (FLG)|1 liter of filtered water with FLG
9711735|NCT04621149|Active Comparator|AS with FLG|1 liter of filtered water with AS and FLG
9711736|NCT04621149|Active Comparator|placebo with ZA and FLG|1 liter of filtered water with ZA and FLG
9711737|NCT04621149|Active Comparator|AS with ZA and FLG|1 liter of filtered water with AS, ZA, and FLG
9711738|NCT04620954|Experimental|Intervention|
9711739|NCT04621032||OSA +|Patients with visceral obesity and newly diagnosed Obstructive Sleep Apnea (during the study)
9711740|NCT04621032||OSA -|Patients with visceral obesity in whom Obstructive Sleep Apnea diagnosis have been excluded (during the study)
9711741|NCT04621214||Group-A|Group A were performing their duties on visual triage
9711742|NCT04621214||Group-B|Group A were performing their duties on Audio-visual triage
9711743|NCT04621097|Experimental|pulsed electro magnetic field|30 patients will receive the physical therapy program in form of low frequency pulsed electro magnetic field application. with frequency 15hz, and low intensity with flux density of 20 Gauss (2mT), in pulse duration 200 usec , pulsed rectangular pulses for 60 min is applied to the dorsal surface of lower leg , ankle and foot in addition to their regular medications prescribed , 3 times per week for 8 week
9711744|NCT04621097|Experimental|Treadmilltraining|"In this group, 30 patient will receive the physical therapy program in form of supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .~At first , a 5 minutes- warm up period will be allowed, it will include stretching exercises for calf muscles , hamstrings and quadriceps (i.e. each for at least 10 -15 seconds) . Patients should start with walking on the treadmill at a comfortable speed, and should not stop at the onset of leg pain but instead , he/she would continue until moderate pain is reached. At this point, he/she has to rest until pain completely subsides, then walking is resumed again . The intensity of exercise will be determined by claudication pain scale, and should not exceed the score of 4 on this scale. The exercise can be progressed if the patient can walk continuously for 10 minutes without the need to stop."
9711745|NCT04621097|Placebo Comparator|medications|It includes 20 patients who will not receive any physiotherapy intervention. They will receive medical treatment only and will act as a control group.
9711746|NCT04621253|Active Comparator|Ciprofloxacin|Day 1: 750 mg ciprofloxacin capsule in the morning and evening Day 2: 750 mg ciprofloxacin capsule in the morning and evening Day 3: 750 mg ciprofloxacin capsule in the morning and evening Day 4: Study day, 750 mg ciprofloxacin 1h prior to 1000 mg metamizole.
9711747|NCT04621253|Active Comparator|Fluconazole|Day 1: 400 mg fluconazole in the morning, placebo capsule in the evening Day 2: 200 mg fluconazole in the morning, placebo capsule in the evening Day 3: 200 mg fluconazole in the morning, placebo capsule in the evening Day 4: Study day, 200 mg fluconazole 1h prior to 1000 mg metamizole.
9711748|NCT04621253|Placebo Comparator|Placebo|Day 1: placebo capsule in the morning and evening Day 2: placebo capsule in the morning and evening Day 3: placebo capsule in the morning and evening Day 4: Study day, placebo capsule 1h prior to 1000 mg metamizole.
9980094|NCT01388374|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the Primary Out of Hours Emergency Service.
10194635|NCT05180266|Experimental|Therapeutic Touch Group|In order to examine the effects of therapeutic touch on menopausal symptoms, sleep and quality of life, women will be given therapeutic touch for 15 minutes, once a week for four weeks.Therapeutic touchis a form of descriptive treatment that lasts approximately 15-20 minutes, in which hands are used on or near the body to correct abnormalities in the person's energy field and to achieve healing, and the energy in the universe is transferred from the practitioner's hands to the applied individual.
10194636|NCT05180266|Experimental|Music Listening Group|The women were asked to listen to the relaxation music included in the relaxation exercises CD prepared by the Turkish Psychological Association every day for four weeks in a comfortable environment at home for 30 minutes before bedtime.
9711749|NCT04621058|Experimental|D VITAMIN GROUP|"The administration of vitamin D will be carried out using the following treatment scheme:~If vitamin D deficiency (< 30 ng/ml) treatment with 2 capsules of 0.266 mg If vitamin D deficiency (< 40 ng/ml): treatment with 1 capsule of 0.266 mg~Blood levels of vitamin D will be determined on day 1, 4, 7 and 14. Based on the results from day 14, a new determination is recommended 4 weeks after starting treatment with the primary care physician who will decide whether to continue or interrupt the treatment. This phase will be carried out outside of the study.~In addition, the product should only be administered, if blood calcium and phosphorus levels are within normal limits, as well as if the creatinuria/calciuria ratio is within normal ranges."
9711750|NCT04621058|Placebo Comparator|PLACEBO GROUP|The procedure will be the same as in the experimental group but instead of the active component, patients will take placebo capsules exactly the same as above but without the active component.
9711751|NCT04620980||Cases|"Participants will be assessed for disease progression: Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence.~Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
9711752|NCT04620980||controls|"Participants will be assessed for the presence of disease. Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
10194637|NCT05180266|Other|Control Group|No action will be taken on the control group for four weeks.
10194638|NCT05180253|Other|Healthy Subjects|
9711753|NCT04621110|Experimental|intranasal dexmedetomidine and fentanyl|Dexmedetomidine (precedex®) and fentanyl will be administered by intranasal routes, seeing if both sedative (dexmedetomidine) and analgesic (fentanyl) can give enough sedation for procedure
9711754|NCT04621110|Active Comparator|intravenous ketamine and midazolam|ketamine (ketalar®) and midazolam intravenous will be using to compare the efficiency of intranasal drugs
9711755|NCT04621136|Experimental|Ripasudil eye drops|Ripasudil eye drops
10194639|NCT05180162|Experimental|Cohort 1: Liver Fibrosis|Patients with liver fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
9711757|NCT04621006||UC group|Patients with active ulcerative colitis
9779417|NCT05306431|Experimental|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant. It is non-corrosive, non-toxic and acts by disrupting cell membrane integrity. PHMB 0.2% has been recently used as a root canal irrigant in vitro and has shown promising results of antimicrobial effectiveness of > 99.9% for both PHMB and Sodium hypochlorite
9779418|NCT05306431|Experimental|Sodium Hypochloride|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter.
9779419|NCT05306405|Active Comparator|vaginal misoprostol|only vaginal misoprostol 25 μg tablets will be applied for induction of laour
9779420|NCT05306405|Active Comparator|combined vaginal misoprostol and estradiol|vaginal misoprostol 25 μg (Vagiprost) tablets with vaginal estradiol 150 ml cream will be applied for induction of laour
9779421|NCT05306392|Experimental|Moderate Hypothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of moderate hypothermia during 48 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
9779422|NCT05306392|Sham Comparator|Control - Normothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
9779423|NCT05306366|Experimental|[11C]-Lu AF90103|Participants will receive [11C]-Lu AF90103 via an intravenous bolus injection on Day 1.
9779424|NCT05306353|Placebo Comparator|VIB4920 Placebo with TNFi|Participants will receive VIB4920 placebo in a blinded fashion intravenously at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period VIB4920 placebo consists of 0.9% normal saline in 250mL bags.
9779425|NCT05306353|Experimental|VIB4920 with TNFi|Participants will receive VIB4920 in a blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period
10194640|NCT05180162|Experimental|Cohort 2: Pulmonary Fibrosis|Patients with pulmonary fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
10194641|NCT05180162|Experimental|Cohort 3: Myocardial Fibrosis|Patients with myocardial fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
10194642|NCT05180084|Experimental|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
10194643|NCT05180084|No Intervention|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
10194644|NCT05180071|Experimental|TEMA elbow arthroplasty|
10204728|NCT05093413|Experimental|Sleep deprived first; Fully slept second|Participants will be sleep deprived during the first experimental visit and fully slept during the second experimental visit
10204729|NCT05091892|Experimental|Water Group|Neurodevelopmental treatment
10204730|NCT05091892|Experimental|Land Group|Lonqitudinal, transversal and compined rotation in a hydrotherapy programm
10204731|NCT05085314|Experimental|Ngenuity digital 3D microscope|
9711758|NCT04621175|Active Comparator|EAA+W & Carbohydrate: Balance (BAL) first, then Deficit (DEF)|Participants will consume an essential amino acid plus whey (EAA+W) beverage with added Carbohydrate during energy balance (BAL) first, then again during energy deficit (DEF).
9711759|NCT04621175|Active Comparator|EAA+W & Carbohydrate: DEF first, then BAL|Participants will consume an essential amino acid plus whey beverage with added Carbohydrate during energy deficit first, then again during energy balance.
9711760|NCT04621175|Active Comparator|EAA+W & EAA: BAL first, then DEF|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy balance first, then again during energy deficit.
9711761|NCT04621175|Active Comparator|EAA+W & EAA: DEF first, then BAL|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy deficit first, then again during energy balance.
9711762|NCT04621162|Experimental|Positive Expectations (initial)|
10194645|NCT05179941|Experimental|patients requiring a shoulder arthroplasty|Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an FDA approved imaging system.
9711763|NCT04621162|Experimental|Negative Expectations (initial)|
9711764|NCT04621162|Placebo Comparator|Neutral Expectations (initial)|
10194646|NCT05179889|Experimental|Arm A|FOLFOXIRI
9711765|NCT04621162|Experimental|Positive Expectations (during intervention)|
9711766|NCT04621162|Experimental|Negative Expectations (during intervention)|
10194647|NCT05179889|Active Comparator|Arm B|mFOLFOX 6
9711767|NCT04621162|Placebo Comparator|Neutral Expectations (during intervention)|
9980095|NCT01388374|Experimental|Nurse Practitioners Care|Medical care provided by the Nurse Practitioner at the Primary Out of Hours Emergency Service.
9980096|NCT01388387|Experimental|Tacrolimus pharmacokinetics|
10194648|NCT05173298||intervention|atezolizumab + bevacizumab
10194649|NCT05168917|Other|Ulcerative colitis in clinical and endoscopic remission|Patients with established diagnosis of ulcerative colitis (UC) in clinical and endoscopic remission defined as clinical score = 0 at enrollment with no endoscopy flare up may participate to follow up. Proctosigmoidoscopy to document endoscopic remission has to be foreseen. The patients' inclusion/exclusion criteria are based on the established diagnostic procedures for the UC, i.e. colonoscopy at the time of diagnosis, endoscopic evidence of remission and clinical significant findings.
10194650|NCT05164302|Experimental|Group A: LO1 point (Tooth)|Participant received auricular acupuncture and sham acupuncture at LO1 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
10194651|NCT05164302|Experimental|Group B: LO3 point (Jaw)|Participant received auricular acupuncture and sham acupuncture at LO3 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
10194652|NCT05160662|No Intervention|Women with BMI>=35 (2019-2020)|Pregnant women with BMI>=35 delivered at the hospital 2019-2020
10194653|NCT05160662|Experimental|Women with BMI>=35 (2021-2023)|Pregnant women with BMI>=35 delivered at the hospital 2021-2023
10194654|NCT05160272|Experimental|AP-325 Treatment|AP-325, film-coated tablet, 50mg once daily
10194655|NCT05160272|Placebo Comparator|Placebo Treatment|Placebo matching AP-325 film-coated tablet, once daily
10194656|NCT05160025|Other|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
10194657|NCT05159804||Carotid plaque length|Patients underwent coronary angiography and carotid ultrasonography simultaneously
10194658|NCT05159037|Experimental|Active GC-MRT Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will have been trained with prior to a stressful speech task.
10194659|NCT05159037|Placebo Comparator|Control Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will not have been trained with but ranked as highly liked prior to a stressful speech task.
10194660|NCT05158946|Experimental|Intervention Group|Participants in the intervention group received Future Oriented Group Training in addition to their treatment as usual.
10194661|NCT05158946|No Intervention|Control Group|Participants in the control group received their treatment as usual.
9711768|NCT04620928|Experimental|Concept Retrieval|Patients will be given behavioral intervention, and their brain activity recorded.
9711769|NCT04621357|Experimental|Patient with intracerebral haemorrhage|Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.
9711770|NCT04621123|Experimental|Experimental group|Subjects randomized to convalescent anti-SARS-CoV-2 MBT plasma plus SMT will receive one infusion of 200 to 300 ml of ABO-compatible convalescent plasma obtained from a convalescent donor.
9711771|NCT04621123|Placebo Comparator|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300 ml of sterile saline solution 0.9%.
9711772|NCT04621331|Experimental|Roxadustat|Starting doses of 20, 50, 70 or 100 mg based on weight.
9980097|NCT01388400|Experimental|Conventional intervention for upper limb reaching|Reaching or holding cones, cups, etc. in all planes with and without gravity or loading
9980098|NCT01388400|Experimental|VR treatment|The Virtual Reality (VR) therapy group received the treatment in the GestureTek VR environment which focused on reaching movements of the affected upper limb using virtual games and a virtual supermarket.
9980099|NCT01388413|Experimental|Weekly Oral Cyclic Antibiotic programme|
9980100|NCT01388413|No Intervention|Classic care|
9980101|NCT01388426|Experimental|7eye( Panoptx)™ Moisture chamber glasses|7eye( Panoptx)™
9711773|NCT04621240|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
9711774|NCT04620902||Dementia|Dementia
9711775|NCT04620902||MCI|Mild cognitive impairment
10194662|NCT05156814|Experimental|Fixed-dose Combination (FDC) estradiol / dydrogesterone|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
10194663|NCT05156814|Active Comparator|Combination therapy with estradiol and dydrogesterone|Duphaston®, 10 mg and Divigel, 0.1%
9711776|NCT04620902||SCD|Subjective cognitive decline
9711777|NCT04620902||HC|Cognitively healthy control
9711778|NCT04620967|Experimental|Iasp-Fiasp|First period: Insulin pump with Iasp Second period: Insulin pump with Fiasp
9711779|NCT04620967|Experimental|Fiasp-Iasp|First period: Insulin pump with Fiasp Second period: Insulin pump with Iasp
9711780|NCT04620889||PVP|Bypass or reconstruction of diseased or occluded blood vessels
9711781|NCT04620889||AV Access|Arteriovenous shunting for blood access.
9711782|NCT04620785|Experimental|methylene blue/IPL|"will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session.~This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions."
9711783|NCT04620785|Experimental|IPL|will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions.
9711784|NCT04620785|Placebo Comparator|saline|will undergo intralesional saline.
9711785|NCT04620720|No Intervention|control group|routuine analgesics wil be given
9711786|NCT04620720|Experimental|intervention group|patient will receive cap gabapentin 1200 mg 2 hours before surgery
9711787|NCT04620590|Experimental|Treatment Arm|Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
10194664|NCT05156814|Active Comparator|non-hormonal therapy|Cimicifuga racemosa rhizomatum extract (Klimadynon®)
10194665|NCT05156723|Experimental|Group 1: Subunit recombinant vaccine for the prevention of coronavirus infection|5 volunteers have been vaccinated with a single dose (Stage I)
10194666|NCT05156723|Experimental|Group 2: Subunit recombinant vaccine for the prevention of coronavirus infection|15 volunteers have been vaccinated with a single dose (Stage I)
10194667|NCT05156723|Experimental|Group 3: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers will be vaccinated with the coronavirus vaccine intramuscularly twice (Stage II)
10194668|NCT05156723|Experimental|Group 4: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers have been vaccinated with a single dose of the coronavirus vaccine intramuscularly and then treated with a single dose of placebo (Stage II)
9711788|NCT04620655|Experimental|RD13-01 cell infusion|
9711789|NCT04620642||Registry group|Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research
9711790|NCT04620876|Experimental|Bimodal and coaxial high resolution imaging of the retina|Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT)
9711791|NCT04620564||Patients|
9711792|NCT04620564||Relatives|
9711793|NCT04620811|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive up to 18 monthly doses (3mg/kg) of lirentelimab (AK002)
9711794|NCT04620408|Experimental|Group A|The subjects in group A did not have breakfast at D1, then were given an SHR4640 tablet. The subjects in group A had a high-fat breakfast on D8. After eating 30min, the subjects in group A were given SHR4640 tablet.
9711795|NCT04620408|Experimental|Group B|Group B had high-fat breakfast on D1, no breakfast on D8, and the rest was the same as group A.
9711796|NCT04620525||Participants with the relevant condition|Participants with the relevant condition
9711797|NCT04620525||Healthy controls|Healthy controls
9711798|NCT04620603|Experimental|LDR + Nivolumab|Participants will receive one treatment of brachytherapy on treatment day 1 (LDRD1). After a minimum of 7 days but no more than 30 days to allow antigenic release, participants will then begin immunotherapy treatment with Nivolumab at the standard FDA approved dose of 480mg given on the first day of every 28 day cycle. Participants can receive up to 12 doses of Nivolumab.
9711799|NCT04620837|Experimental|Treatment Arm|Tislelizumab：200mg Q3W IV Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.
9711800|NCT04620538||Controls|Healthy Controls with or without risk factors for Chronic Liver Disease (i.e. patients referred due to concerns re: liver disease but found to have no evidence of chronic liver disease following assessment)
9711801|NCT04620538||Fibrosis|Patients with evidence of Liver Fibrosis on the basis of current diagnostic techniques / expert opinion.
9711802|NCT04620538||Compensated Cirrhosis|Patients with evidence of Compensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
9711803|NCT04620538||Decompensated Cirrhosis|Patients with evidence of Decompensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
9711804|NCT04620538||Hepatocellular Carcinoma|Patients with evidence of Hepatocellular Carcinoma on the basis of current diagnostic techniques / expert opinion.
9711805|NCT04620616|Experimental|Product Use Sequence 1|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - RELX ENDS menthol flavor Period 3 - Usual Brand ENDS"
9711806|NCT04620616|Experimental|Product Use Sequence 2|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS tobacco flavor"
9711807|NCT04620616|Experimental|Product Use Sequence 3|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS tobacco flavor Period 3 - RELX ENDS menthol flavor"
9711808|NCT04620616|Experimental|Product Use Sequence 4|"Products use sequence:~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS menthol flavor Period 3 - RELX ENDS tobacco flavor"
9711809|NCT04620616|Experimental|Product Use Sequence 5|"Products use sequence:~Period 1 - RELX ENDS tobacco flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS menthol flavor"
9711810|NCT04620616|Experimental|Product Use Sequence 6|"Products use sequence:~Period 1 - RELX ENDS menthol flavor Period 2 - RELX ENDS tobacco flavor Period 3 - Usual Brand ENDS"
10194669|NCT05156723|Placebo Comparator|Group 5: Placebo|45 volunteers have been vaccinated with placebo intramuscularly twice (Stage II)
10194670|NCT05154734|Experimental|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
9711811|NCT04620824||Trial Participants|"Overall Description of Trial Participants: The spleen organ samples included in this project will be from patients undergoing elective surgery for a lesion in the pancreas in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.~Inclusion Criteria: The samples included in this project will be from patients undergoing elective surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of spleen samples from radical surgery are adult age and presence of splenic tissue in the discarded material after hepato-pancreato-biliary surgery.~Exclusion Criteria: The main exclusion criterion is acute invasive bacterial and viral infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
9711812|NCT04620694||Radial artery cannulation|Patients whom radial artery was cannulated at the beginning of the surgery.
9711813|NCT04620694||Aortic cannulation (brachial or femoral artery)|"Patients whom femoral or brachial artery was cannulated at the beginning of the surgery.~Active comparator"
9711814|NCT04620629||control group|Late premature and term babies without any disease
9711815|NCT04620629||probiotic group|Babies whose probiotic support is started and continues because they cannot receive breast milk, and whose antibiotic treatment is started in the neonatal period.
9711816|NCT04620629||antibiotic group|Babies who receives antibiotic treatment in the neonatal period and does not receive probiotic support before.
9711817|NCT04620395|No Intervention|Joint tap|Joint tap and aspiration of synovial fluid
10194671|NCT05153733|Experimental|RIFRAM implant|RIFRAM implant
10194672|NCT05152888|Experimental|Evolocumab|Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the intervention.
9711818|NCT04620395|Experimental|Punch biopsy|Punch biopsy of a prosthetic joint and extraction of 5-7 biopsies from the synovial membrane
9711819|NCT04620447|Active Comparator|Mindfulness Meditation|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 7~Final number of participants: 118~Mindfulness Meditation intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
9711820|NCT04620447|Active Comparator|Cognitive Behavior Therapy|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 19~Final number of participants: 102~Cognitive Behavior Therapy intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
9779426|NCT05306353|Experimental|VIB4920 without TNFi|Participants will stop TNFi after randomization to this arm, and receive VIB4920 in an evaluator-blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 while maintaining all other background disease-modifying RA therapy (e.g., methotrexate, hydroxychloroquine, etc.) through the study period. This arm is evaluator blinded (not aware of treatment status), with the participant aware of treatment status but evaluator is not, due to not using a TNFi placebo for this study
10194673|NCT05152823|Experimental|Single Intrathecal Delivery|
10194674|NCT05152251||Study Group|Down Syndrome
10194675|NCT05152251||Control Group|Typically Developing Children
10194676|NCT05152017|Experimental|Flu-M Quadro with preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine with a preservative
10194677|NCT05152017|Experimental|Flu-M Quadro without preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine without a preservative
10194678|NCT05152017|Placebo Comparator|Placebo|25 volunteers were vaccinated with a Placebo
10194679|NCT05151406|Active Comparator|medical students|5th year undergraduate medical students
10194680|NCT05151406|Active Comparator|nursing students|4th year undergraduate nursing students
10194681|NCT05147519||Step 1|Step 1 will enroll participants aged 15-55 years who are vulnerable to contracting HIV. They will be evaluated every 12 weeks for HIV and other sexually transmitted infections (STIs).
10194682|NCT05147519||Step 2|Participants who are diagnosed with HIV will proceed to Step 2, with evaluation of viral load and other HIV-related tests every four weeks for 12 weeks and then every 12 weeks for a total of 48 weeks.
10194683|NCT05147519||Step 3|Participants who achieve and maintain viral suppression in Step 2 will proceed to Step 3 for continued HIV monitoring every 24 weeks to document maintenance of viral suppression and maintain engagement with the study site for potential future recruitment into interventional studies, including clinical trials of novel strategies to achieve HIV remission.
10194684|NCT05144360|Experimental|Atenas association|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Atenas, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan + amlodipine placebo, oral."
10204732|NCT05085314|Active Comparator|Conventional microscope|
10204733|NCT05084326||Mohamedabosena|
10194685|NCT05144360|Active Comparator|Empagliflozin + telmisartan + amlodipine|"The patient must take 3 tablets once a day, as follows:~1 tablet Atenas placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan + amlodipine, oral."
10194686|NCT05143606|Experimental|3D printed simulator|"The participants in this arm will undergo two self-directed training sessions on a custom-made 3D-printed airway simulator. The participants will use a standard intubating fiberoptic bronchoscope to practice fiberoptic-assisted nasal intubation.~The sessions will be one week apart. Each session is 30 minutes per participant."
10194687|NCT05143606|Experimental|Virtual reality software|"The participants in this arm will practice fiberoptic-assisted nasal intubation using the free virtual reality software (AirwayEX) on their mobile phones or computer tablets. Two practice sessions are required by the investigators. The sessions will be one week apart. Each session is 30 minutes per participant.~The participants in this arm will have the opportunity to practice on the software as often as they feel necessary. All the additional practice data will be recorded."
10194688|NCT05142735|Experimental|Experimental|N-Acetylcysteine 2000 mg (4 x 500-mg tablets) orally every morning for 8 weeks
10194689|NCT05142735|Placebo Comparator|Placebo Comparator|N-Acetylcysteine Placebo tablet matching N-Acetylcysteine orally every morning for 8 weeks
10194690|NCT05142111|Experimental|Sexual therapy|In the sessions a series of questions will be proposed to the subject, who will be free to answer or not, being able to express questions in turn. The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions.
10194691|NCT05142111|Active Comparator|Mindfulness|"During the mindfulness treatment the subjects will be subjected to sessions in which they will be invited to relax, to become aware of the present moment, of their body, through exercises that involve breathing, attention, and visualization of the body.~The sessions will last about 45 minutes, and will be held once a week, for a total of 6 sessions."
10194692|NCT05140694|Experimental|Empagliflozin|Empagliflozin 10mg p.o. once daily (available to control over ~25mg)
10194693|NCT05140694|Experimental|Dulaglutide|Dulaglutide 0.75mg s.c. once weekly (available to control over ~1.5mg)
10194694|NCT05140694|Experimental|Empagliflozin and Dulagludie|Empagliflozin 10mg p.o. once daily and dulaglutide 0.75mg s.c. once weekly
10194695|NCT05138705|Experimental|Outcome|Quadrivalent influenza vaccine Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
10194696|NCT05135312|Other|Etanercept|50mg etanercept subcutaneously twice weekly for 3 months, followed by once weekly for another 3 months for a total duration of 6 months or 24 weeks.
10194697|NCT05134480|Active Comparator|Cornea from donor with diabetes|Participant will be assigned a cornea recovered from a donor with diabetes.
10194698|NCT05134480|Active Comparator|Cornea from donor without diabetes|Participant will be assigned a cornea recovered from a donor without diabetes.
10194699|NCT05132244|Experimental|Intensive Glucose Intervention|Participants will receive standard anti-hyperglycemic treatment as guided by an endocrinologist using a combination of data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Treatment will aim to maintain glucose levels between 4 and 10 mmol/L. Participants will have real-time access to their glucose data via the CGM.
10194700|NCT05132244|Other|Standard Care|Participants will receive standard anti-hyperglycemic treatment only if blood glucose level is above 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a CGM but will not be able to view their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
10194701|NCT05126979|Experimental|Flu-M (without a preservative)|15 volunteers were treated with the Flu-M inactivated split influenza vaccine without a preservative
10194702|NCT05126979|Experimental|Flu-M (with a preservative)|15 volunteers were treated with the Flu-M inactivated split influenza vaccine with a preservative
10194703|NCT05126979|Placebo Comparator|Placebo|15 volunteers were treated with a placebo
9779427|NCT05306314||TREATAPROST 0 mL( BID- 10mL*2) PO|Treataprost 10 mL ( 5 mL 2*1- PO ) 42 days Generic Name : Treatarost Advance Dosage Form: Suspension, vials of 250 mL Dosage : 250 mL Frequency : 2*1 (BID) Duration: 42 days (6 weeks) Administration:Oral administration before meals 30 minutes as 20 mL(10mL*2)
10194704|NCT05120999||Dominant hand|Application of either TetraGraph or TOFScan device on dominant hand
10194705|NCT05120999||Non-Dominant hand|Application of either TetraGraph or TOFScan device on non-dominant hand
10194706|NCT05120661|Experimental|Carbohydrate-rich food product (to be determined)|This is a nutritional product, such as bread or cake, containing 50 gram carbohydrates.
10194707|NCT05120661|Experimental|Another carbohydrate-rich food product (to be determined)|This is a nutritional product, such as bread or cake, containing 50 gram carbohydrates.
10194708|NCT05116787|Experimental|BCX9930 monotherapy|"In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions~In Part 2, all participants receive open-label BCX9930 monotherapy"
10194709|NCT05116787|Placebo Comparator|Placebo|In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions
10204734|NCT05078190||Doxorubicin|Patients treated with doxorubicin (Adriamycin) for breast cancer
10204735|NCT05078190||Trastuzumab|Patients treated with trastuzumab (Herceptin) for breast cancer
10204736|NCT05078190||Doxorubicin and Trastuzumab|Patients treated with both doxorubicin (Adriamycin) and trastuzumab (Herceptin) for breast cancer
10204737|NCT05074121|Experimental|NAC|Group receiving intervention/study drug NAC
10204738|NCT05074121|Placebo Comparator|Placebo|Group receiving placebo
10204739|NCT05073393|Experimental|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
10204740|NCT05073393|Placebo Comparator|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 28 days (14 days with sugar stress followed by 14 days without sugar stress).
10204741|NCT05070286||Young people with MS and NMOSD|"Young people aged 10-25 years, who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-structured interviews."
9984500|NCT04044729|Active Comparator|Cannabidiol|"Drug: Cannabidiol An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~CBD"
9711821|NCT04620447|Active Comparator|Novel 'Intelligent Virtual Reality Therapy System' (IVRTS)|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 10~Final number of participants: 115~Novel 'Intelligent Virtual Reality Therapy System' (IVRTS) was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
9711822|NCT04620447|No Intervention|Control Group|"A 7-week intervention course (In this case, no intervention) was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 0~Final number of participants: 125~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
9711823|NCT04620863|Experimental|tDCS group|Patients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels.
9711824|NCT04620863|Sham Comparator|Sham Group|The stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
9711825|NCT04620473|Experimental|Anlotinib+Capeox|neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox
9711826|NCT04620473|Active Comparator|Capeox|neoadjuvant treatment with Capeox
9711827|NCT04620486|Experimental|Active Best Practice Alert|Care providers taking care of these patients will receive a Best Practice Alert (BPA) in the electronic medical record (EMR) one hour before an antibiotic expires with no subsequent doses ordered. The BPA will prompt the care provider to re-order the antibiotic and give information on recommended dosage and frequency based on indication and patient characteristics.
9711828|NCT04620486|No Intervention|Inactive Best Practice Alert|The Best Practice Alert described in the Experimental Arm will not be active for patients in this arm. Care providers will proceed with usual care.
9711829|NCT04620499|Experimental|Experimental|EEG-guided drug prescription
9711830|NCT04620499|No Intervention|Control|Will receive EEG, but drugs will be prescribed as usual
9711831|NCT04620772|Experimental|Cyclophosphamide arm|Participants randomized to the cyclophosphamide arm will be administered 750 mg/m2 body weight (rounded off to the nearest 50 mg above the calculated value) of cyclophosphamide diluted in normal saline every month (Total 6 months) along with equal dose of mesna 50% administered prior to infusion and 50% after the infusion of cyclophosphamide
9711832|NCT04620772|Other|Placebo arm|Participants randomized to the placebo group will be given similar quantity of normal saline and mesna as described above
9711833|NCT04620421|Experimental|Training group (Rhythm-based multitask training)|Randomized to participate in the rhythm-based multitask training intervention
9711834|NCT04620421|No Intervention|Control group (Continuation of regular activity schedule)|Randomized to the control group who is encouraged to continue their regular everyday routines, which may include self-administrated training exercises.
9711835|NCT04620577||Antibiotic group|Infusion of ceftriaxone sodium needle (2g, solvent 100ml normal saline) within 1h before and 12h after PTCD.
9711836|NCT04620577||No-antibiotic group|Infusion of Normal saline within 1h before and 12h after PTCD.
9711837|NCT04620850|Experimental|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time) Acupressure at below knee the point ai locate about4 finger spcae below patella on the lateral side of tibia bone
9711838|NCT04620850|No Intervention|No acupressure|Standard post-operative care
9711839|NCT04620460|Active Comparator|LIFUS-left DLPFC|20 patients will be treated with active LIFUS for 3 weeks on the left DLPFC.
9711840|NCT04620460|Sham Comparator|LIFUS-SHAM|20 patients will be treated with sham LIFUS for 3 weeks on the left DLPFC.
9711841|NCT04620018|Active Comparator|Pre and post op Antibiotic|subjects received prophylactic antibiotic orally (Amoxicillin 2mg ,1 hour before surgery) and post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
9711842|NCT04620018|Active Comparator|Pre-op antibiotic|subjects received only prophylactic antibiotic (Amoxicillin 2mg ,1 hour before surgery)
9711843|NCT04620018|Active Comparator|Post-op antibiotic|subjects received post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
9711844|NCT04620031|Experimental|HSK3486|
9711845|NCT04620031|Active Comparator|Propofol|
9711846|NCT04620083|No Intervention|Control Group|For the control group, the participants received conventional therapy which included group activities for reality orientation, reminiscence therapy and activities organized by occupational therapists one hour a day, five days a week.
9711847|NCT04620083|Experimental|Experimental 3-day Normal Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 3 days per week.
9711848|NCT04620083|Experimental|Experimental 5-day Intensive Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 5 days per week. For consistency, Day 1 and 3 of the 3-day protocol were replicated as Day 4 and Day 5 of the 5-day protocol.
9984501|NCT04044729|Placebo Comparator|Placebo|"Drug: Placebos An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.~Other Names:~placebo"
9984502|NCT04040946|Other|TEMP-TDM with MIBI|Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET
9711849|NCT04620044|Experimental|Kaledo Game|Kaledo game, which is a board game, has been developed to inform children about healthy eating. The aim of this game is to teach children calorie balance through the calorie values of foods. Kaledo game gives children the opportunity to stay motivated and have fun. While children are having fun, they also gain the knowledge necessary for healthy eating behavior change. The game is played with 2-4 people. A game session takes 15-30 minutes Children in the playgroup played 15-30 minutes (1 round) Kaledo game every week for 12 weeks.
9711850|NCT04620044|Experimental|Education|"The students in the training group were trained for 20 minutes once a week for 12 weeks. Training subjects were prepared in line with health belief model components.~The following subjects were included in the training content. What is obesity?Risk factors for obesity, Characteristics of obese individuals, What is a healthy diet?Relationship between unhealthy nutrition and obesity, The consequences of unhealthy diet Health problems caused by obesity, What should be done to prevent and control obesity. How should nutrition be to lose weight? Positive results which show up with weight loss, Barriers to a healthy diet, Ways to reduce and eliminate barriers How to take action to lose weight?, Benefits of weight loss, Success stories in the fight against obesity, How are eating habits changed?, How can we achieve self-efficacy to change eating habits?"
9711851|NCT04620044|Experimental|Control|There was no intervention in the control group.
9711852|NCT04620070|No Intervention|Conventional|In the Netherlands, out-of-hospital cardiac arrest (OHCA) is managed by paramedics. In this study, in the conventional arm, OHCA is managed by a physician of the Helicopter Emergency Medical Services (HEMS), but without the possibility of prehospital ECPR.
9711853|NCT04620070|Experimental|Intervention group|OHCA managed by the physician of the HEMS team, but with the possibility of prehospital ECPR.
9711854|NCT04620109|Placebo Comparator|SDE Placebo|Subjects will receive placebo (drops without drug).
9711855|NCT04620109|Active Comparator|SDE 0.03 mg/eye|Actual dose is 0.03 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 0.5 mg/mL for 1 time.
9711856|NCT04620109|Active Comparator|SDE 0.06 mg/eye|Actual dose is 0.06 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 1.0 mg/mL for 1 time.
10194710|NCT05116774|Experimental|BCX9930 monotherapy|"In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor~In Part 2, all subjects receive BCX9930 monotherapy"
9711857|NCT04620109|Active Comparator|SDE 0.12 mg/eye|Actual dose is 0.12 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 2.0 mg/mL for 1 time.
9711858|NCT04620109|Active Comparator|SDE 0.24 mg/eye|Actual dose is 0.24 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 4 mg/mL for 1 time.
9984503|NCT04040946|Other|F18-choline PET|Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy
10194711|NCT05116774|Active Comparator|Continued C5 inhibitor therapy|In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor
10194712|NCT05112302||Virtual reality|
10194713|NCT05109104|Experimental|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
10194714|NCT05109104|Experimental|CAP Herbal Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Herbal Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
10194715|NCT05109104|Experimental|CAP Mountain Berry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Mountain Berry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
10194716|NCT05109104|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
10194717|NCT05100277||Single arm|All patients will have the test
10194718|NCT05089123|Experimental|Flu-M|160 volunteers were vaccinated with the Flu-M inactivated split influenza vaccine with a preservative
10194719|NCT05089123|Active Comparator|Ultrix|160 volunteers were vaccinated with the Ultrix (Inactivated split influenza vaccine)
10194720|NCT05077501|Experimental|ACD856|
10194721|NCT05077501|Placebo Comparator|Placebo|
10194722|NCT05064332|Experimental|OC only|Subjects will receive a single dose of an oral contraceptive during the first period of the study
10194723|NCT05064332|Experimental|PF-06650833 + OC|Subjects will receive PF-06650833 every day for 11 days and a single dose of an oral contraceptive on day 10.
10194724|NCT05057546|Experimental|Premenopausal Group: GnRH antagonist|Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection.
10194725|NCT05048979|Experimental|Exercise|Prospective pre-post pilot study design. (N=54)
10194726|NCT05048979|No Intervention|No exercise|Prospective cohort study design. (N=100)
10194727|NCT05046067|Experimental|Diagnostic (CT)|Patients undergo 4 CT scans during standard of care surgery.
10194728|NCT05039190|Active Comparator|Experimental: HBM9161 (680mg )|HBM9161 680mg; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
10194729|NCT05039190|Placebo Comparator|Placebo Comparator: Placebo|Placebo; First treatment period: Subcutaneous injection, QW for 6 doses; Second treatment period: Subcutaneous injection, QW for 6 doses
10194730|NCT05035927|Experimental|Open Label Oral Psilocybin|
10194731|NCT05034029|Experimental|Metformin|Metformin hydrochloride sustained release tablet will administer orally in escalating doses to reduce side-effects and maintain masking: 0.5 g/day for the first two weeks, 1 g/day for the next 2 weeks, and then 2 g/day until the end of the study if tolerated. If the subject cannot tolerate the maximum dose (2 g/day), take their maximum tolerable dose. In case of adverse reaction, the researchers can determine whether the subject needs to reduce or stop the drug based on their discretion.
10194732|NCT05034029|Placebo Comparator|Placebo|Placebo will administer the same as the experimental drug.
10204742|NCT05070286||Parents of young people with MS and NMOSD|"Parents of young people aged 10-25 who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-Structured Interviews"
10194733|NCT05033288||Observational (questionnaires, medical record review)|Patients complete quality of life questionnaires over 20 minutes at baseline (before any therapy), 2-4 and 5-9 months after completion of therapy, and then annually for up to 5 years. Patients' medical records are also reviewed.
10194734|NCT05010213|No Intervention|Control group|There will be no intervention to the control group.
10194735|NCT05010213|Experimental|Experimental group|The experimental group will be given training based on the roy adaptation model.
10194736|NCT05002075|No Intervention|Usual care arm|Participants in the usual control group will receive standard of care per their providers' discretion.
10194737|NCT05002075|Experimental|m-health cardiac rehabilitation intervention arm|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program
10194738|NCT05000177|Other|Experimental group: Non-specific chronic neck pain group|Subjects with non-specific chronic neck pain will be included to perform 30-minute computer typing task and assess neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation.
10194739|NCT05000177|Other|Control group: Healthy subjects group|Healthy subjects will be included to compare the differences in neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with non-specific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
10194740|NCT05000177|Other|Pilot study: Healthy subjects group|Healthy subjects will be included to test reliability of single-pulse and paired-pulse TMS, including its associated neurophysiological measurements, and also to test reliability of Liberty electromagnetic tracing system and surface electromyography. Subjects in this group will received the same assessment as the NCNP group.
10194741|NCT04998864||Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2.0 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
9711859|NCT04620109|Active Comparator|RDE 0.06 mg/eye|The actual dosage is 0.06 mg/eye given 4 times a day for a maximum daily dosage of 0.24mg (60μL KDR2-2 eyedrops concentration of 1.0 mg/mL), which will continues for 6 days plus 1 administration of 0.06 mg/eye in the morning of Day 7. That cohort only started after safety proof from SDE 0.24 mg/eye cohort.
9711860|NCT04620109|Active Comparator|RDE 0.12 mg/eye|The actual dosage is 0.12 mg/eye given 4 times a day for a maximum daily dosage of 0.48mg (60μL KDR2-2 eyedrops concentration of 2.0 mg/mL), which will continues for 6 days plus 1 administration of 0.12 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
9711861|NCT04620109|Active Comparator|RDE 0.24 mg/eye|The actual dosage is 0.24 mg/eye given 4 times a day for a maximum daily dosage of 0.96mg (60μL KDR2-2 eyedrops concentration of 4.0 mg/mL), which will continues for 6 days plus 1 administration of 0.24 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
9711862|NCT04620109|Placebo Comparator|RDE Placebo|Subjects will receive placebo (drops without drug).
9711863|NCT04620200|Experimental|ARM A|2 courses of nivolumab 3 mg/kg in week 0 and 2 prior to standard of care
9711864|NCT04620200|Experimental|ARM B|2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care
9711865|NCT04620135|Experimental|Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle|1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.
10194742|NCT04982770|Experimental|Intervention|The participants have to read ethical guidelines before they are asked to complete the questionnaire of the Oxford Utilitarianism Scale and exposed to medical triage dilemmas.
10194743|NCT04982770|No Intervention|No intervention|The participants do not have to read ethical guidelines before they are asked to complete the questionnaire of the Oxford Utilitarianism Scale and exposed to medical triage dilemmas.
10194744|NCT04966325|Experimental|Treatment T (Therapeutic dose)|Single oral dose of 200 mg LC350189 (1 × 200 mg tablet) and 2 × placebo tablets.
10194745|NCT04966325|Experimental|Treatment ST (Supratherapeutic dose)|Single oral dose of 600 mg LC350189 (3 × 200 mg tablets).
10194746|NCT04966325|Placebo Comparator|Treatment P (Placebo)|Single oral dose of 3 × placebo tablets.
10194747|NCT04966325|Active Comparator|Treatment M (positive control)|Single oral dose of moxifloxacin 400 mg (1 × 400 mg tablet; open label)
10194748|NCT04963972|Experimental|Arm I (Lucid Lane)|Patients participate in the Lucid Lane therapy program including working with a mental health therapist on mindfulness, CBT, group therapy, and mind-body therapies for 3-9 months or until the tapering off period is complete.
10194749|NCT04963972|Active Comparator|Arm II (standard of care)|Patients receive standard of care post-surgical opioid education.
10194750|NCT04963179|Experimental|Womed Leaf|IUA prevention: The novel intrauterine barrier film (Womed Leaf) is inserted immediately after completion of the hysteroscopic adhesiolysis
10194751|NCT04963179|No Intervention|Control|No IUA prevention - no placebo after adhesiolysis
10194752|NCT04962139|Experimental|ON101 Cream plus Standard of Care|ON101 cream will be applied twice daily for up to 20 weeks to the Target Ulcer. The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.
10194753|NCT04962139|Placebo Comparator|Vehicle Cream plus Standard of Care|"Vehicle cream will be applied twice daily for up to 20 weeks to the Target Ulcer.~The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary."
10194754|NCT04943367|Active Comparator|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
10194755|NCT04943367|Placebo Comparator|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
10194756|NCT04938414||subarachnoid hemorrhage|Patients with subarachnoid hemorrhage
10194757|NCT04938414||Control|patients with non-neurological diseases
10204743|NCT05070286||Clinicians|Health care practitioners from medical, nursing and AHP backgrounds with at least two years' experience in NMOSD and MS.
9711866|NCT04620135|Active Comparator|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|1 drop ripasudil twice dairy in the morning and evening in each eye.
10194758|NCT04938024|Experimental|People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
10194759|NCT04938024|Experimental|People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)|Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
10194760|NCT04938024|Active Comparator|People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
10194761|NCT04936984|Experimental|Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
10194762|NCT04936984|Experimental|Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
10194763|NCT04936984|Experimental|Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
9711867|NCT04620161|Experimental|Pradigastat Tablets 20mg|The patients in this arm will receive one tablet a day of Pradigastat 20mg and one tablet a day of Pradigastat 40mg matching placebo
9711868|NCT04620161|Experimental|Pradigastat Tablets 40mg|The patients in this arm will receive one tablet a day of Pradigastat 40mg and one tablet a day of Pradigastat 20mg matching placebo
9711869|NCT04620161|Placebo Comparator|Placebo|The patients in this arm will receive one tablet a day of Pradigastat 20mg matching placebo and one tablet a day of Pradigastat 40mg matching placebo
9711870|NCT04620265|Experimental|Treadmill training 100%|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
9711871|NCT04620265|Experimental|Treadmill training 75%|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
9711872|NCT04620265|Experimental|Treadmill training 50%|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
9711873|NCT04620265|Experimental|Treadmill training 25%|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
9711874|NCT04620265|Sham Comparator|Conventional program|This group received the conventional exercise program only.
9711875|NCT04620174|Other|Custom-made zirconia crowns Group|Ten decayed primary molars will be restored with custom-made zirconia crowns.
9711876|NCT04620174|Other|Prefabricated zirconia crowns Group|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
9711877|NCT04620174|Other|Control Group|Twenty intact contralateral teeth will be evaluated as the controls (10 molars will be the controls for custom-made ZrCs and 10 molars will be the controls for prefabricated ZrCs).
9711878|NCT04620343|Active Comparator|Phase 1, Group 1|"Patients are provided with basic information and breathing advice with biofeedback (IBA).~This is the reference treatment against which the other methods will be measured."
9711879|NCT04620343|Experimental|Phase 1, Group 2|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT)
9711880|NCT04620343|Experimental|Phase 1, Group 3|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with speech therapy
9711881|NCT04620343|Experimental|Phase 1, Group 4|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT) and speech therapy
9711882|NCT04620343|No Intervention|Phase 2, Group 1|Groups 2,3,4 in Phase 1 Wait for therapy effect
9711883|NCT04620343|Experimental|Phase 2, Group 2|If patients from Phase 1, Group 1 (reference treatment) have unchanged CLE-scoring, they are treated with inspiratory muscle training (IMT) and speech therapy.
9711884|NCT04620343|Experimental|Phase 3, Group 1|Treated with Surgery, supraglottoplasty - full procedure
10194764|NCT04936984|Experimental|Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
10194765|NCT04907877|Experimental|Probiotic|NordBiotic ImmunoVir, a mixute of bidido- and lactobacteria administered in a dose of 5 billion once a day for X-30 plus 28 days of the disease
9711885|NCT04620343|Experimental|Phase 3, Group 2|Treated with Surgery, supraglottoplasty mini-invasive procedure
9711886|NCT04620343|No Intervention|Phase3, Group 3|Non-surgery control group
9711887|NCT04620122|Experimental|intervention group|Progressive Muscle Relaxation Training and Music Therapy are applied to the intervention group.
9711888|NCT04620122|No Intervention|control group|No intervention is applied to the control group.
9711889|NCT04620317|Active Comparator|Synbiotic|The product contained three clinically studied active ingredients namely inulin-oligofructose (prebiotic; derived from chicory root), at least 6 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01 (probiotic) and 4 B CFU of Bifidobacterium lactis BB12 (probiotic) per sachet.
9711890|NCT04620317|Placebo Comparator|Placebo|Placebo contains only maltodextrin without any active ingredients, equally same in physical form, freeze-dried white powder with characteristic odor and water soluble as the synbiotic supplement.
9711891|NCT04620291|Experimental|Cohort A|250 mg UB-421 SC: ART-treated subjects
9711892|NCT04620291|Experimental|Cohort B|500 mg UB-421 SC: ART-treated subjects
10194766|NCT04907877|Placebo Comparator|Placebo|Maltodextrine administered once a day for X-30 plus 28 days of the disease
9711893|NCT04620291|Experimental|Cohort C|700 mg UB-421 SC: ART-treated subjects
9711894|NCT04620291|Experimental|Cohort D|500 mg UB-421 SC: Treatment naive subjects
9711895|NCT04620291|Experimental|Cohort E|700 mg UB-421 SC: Treatment naive subjects
9711896|NCT04620304|Experimental|Cohort A|receive 4 weekly fixed doses of UB-421 SC at 250 mg
9711897|NCT04620304|Experimental|Cohort B|receive 4 weekly fixed doses of UB-421 SC at 500 mg
9711898|NCT04620304|Experimental|Cohort C|receive 4 weekly fixed doses of UB-421 SC at 700 mg
10194767|NCT04902365|Active Comparator|Patients group 1|This group will regulate a brain region by real-time functional magnetic resonance imaging that is centrally involved in the visual snow syndrome
10194768|NCT04902365|Placebo Comparator|Patients group 2|This group will regulate a brain region by real-time functional magnetic resonance imaging that is not centrally involved in the visual snow syndrome
9711899|NCT04620226|No Intervention|Conventional Serum Testing|Participants will be screened by conventional HCV antibody (anti-HCV) serology and if screen positive, a second sample will be collected and tested for HCV RNA using a standard commercial assay.
9711900|NCT04620226|Experimental|Rapid Point-of-Care Testing|Participants will be screened using the OraQuick® Rapid Anti-HCV Point-of-Care Test (OraSure) and if screen positive, an additional whole blood sample will be collected and tested for HCV RNA using Xpert® HCV RNA (Cepheid) point-of-care testing and confirmed using a standard commercial assay.
9711901|NCT04620213|Experimental|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
9711902|NCT04620213|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
10194769|NCT04902144|Experimental|Screening (medical records, coaching)|"PHASE I: Patients' medical data are collected.~PHASE II: Patients complete questionnaires and their medical data is collected. SCCA subject matter experts and OMC providers review patients' medical data at bi-monthly virtual conferences. OMC providers receive coaching from SCCA subject matter experts for guidance on providing genetic counseling and testing to their patients."
9711903|NCT04620148|Experimental|TAK-242|Patients will be administered TAK-242 as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
9711904|NCT04620148|Placebo Comparator|Placebo|Patients will be administered placebo as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
9711905|NCT04619940|Experimental|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
9711906|NCT04619940|Active Comparator|Standard goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
9711907|NCT04619641|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
9711908|NCT04619641|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
9711909|NCT04619641|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
9711910|NCT04619615|Experimental|Asynchronous self-directed digital training|A digital training program platform that delivers an interactive case-based modular curriculum covering evidence-based psychotherapy principles and IPT-specific principles and strategies with homework will take roughly 13 hours to complete, with 4.5 hours of online learning, and an additional 7.5 hours of reading and homework assignments. The reading and homework includes viewing captioned videotaped role plays and completing self-directed lesson plans. The digital curriculum leverages audio, video, and visual content, and is self-directed - for completion within a 2-week period. Residents can access this content through a smartphone, tablet or computer at their own pace, revisit modules and digital content as needed, and access a curated list of additional resources to supplement their learning.
9711911|NCT04619615|Active Comparator|Synchronous large group online workshop|This condition will reflect training as usual. Training will involve the same content contained in the asynchronous self-directed digital training platform, except delivered over a one day (4.5 hours of online instruction) workshop; and residents will be required to do the same reading and homework of lesson plans and viewing of the on-line videotaped role plays (an additional ~7.5 hours in total).
9711912|NCT04619654|Experimental|Cataract Surgery with concurrent MIGS|
9711913|NCT04619823|Other|Patient infected by arboviruses|
9711914|NCT04619901||Parents only|
9711915|NCT04619901||Children and Parents|
9711916|NCT04619758|Experimental|Emollient Group|Mothers of the neonates in group A will be advised massage with sunflower oil.
9711917|NCT04619758|No Intervention|Non-Emollient Group|Mothers of the neonates in group B will be advised massage without any emollient.
10194770|NCT04901416|Experimental|Experimental Arm|"Lymphodepleting (LD) chemotherapy will be administered daily for 3 days to all subjects prior to DVX201. Lymphodepleting chemotherapy will consist of the following:~Cyclophosphamide 300 mg/m2 IV over 30 to 60 minutes daily x 3 (day -5 to day - 3)~Fludarabine 30 mg/m2 IV over 30 minutes daily x 3 (day -5 to day -3)~Patients will receive DVX201 at one of 3 prespecified doses infused on day 0 and 7 (± 1 day) for 1 cycle."
10194771|NCT04898153|Experimental|aXess|Patients will be implanted with the Xeltis hemodialysis access graft (aXess)
9711918|NCT04619784|Experimental|Treatment Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Patients will receive 12 sessions of pilates. Patients will be evaluated before treatment, after treatment, at the 3rd and 6th months.
9711919|NCT04619784|Other|Control Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Their routine medical treatments were continued
10194772|NCT04897776|Experimental|Therapeutic Thalamic Stimulation|Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at a therapeutic level established based on the physician's evaluation and patient specific parameters established at a previous visit. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.
9980102|NCT01388439||Oseltamivir exposure|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital experienced respiratory decompensation and tested positive for influenza virus type A by fluorescent antibody stain performed on a nasopharyngeal swab. This infant received treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared a primary medical team, nursing care, respiratory therapist, physical therapist, or occupational therapist with the influenza A positive infant. Prophylaxis was deemed necessary by the attending neonatologist after consultation with the Infectious Diseases Division of the Department of Pediatrics at the Washington University School of Medicine.
9711920|NCT04619732|Experimental|Marginal Kidneys|"Transplant patients receiving kidneys from deceased marginal donors: aged >= 60, or >= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease.~Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians.~The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days."
9711921|NCT04619771|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
9711922|NCT04619888||HeartLogic cohort|Patients implanted with a defibrillator enabling HeartLogic
9711923|NCT04619667|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
9711924|NCT04619667|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
9711925|NCT04619667|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
9984504|NCT04037527|Experimental|Neoadjuvant Chemotherapy Plus Radiation Therapy|Up to 6 cycles (once a week) of chemotherapy with a 3+3 dose escalating plan (from 100 mg to 300 mg for Gemcitabine; 10 mg to 25 mg for Docetaxel) along with radiation (five days a week) for up to 6 weeks.
10194773|NCT04897776|Sham Comparator|Non-Therapeutic Thalamic Stimulation|Four months post implant, the neurostimulator device will provide patients with hippocampal stimulation for all seizures. For seizures longer than five seconds, thalamic stimulation will be administered at below therapeutic threshold to control for implant and placebo effects. This will occur in half of the seizures the patient experiences and will be randomly assigned during this phase of the study.
10194774|NCT04886050|Active Comparator|LC350189 Formulation A (Tablet)|Each subject will be administered a single LC350189 200mg (QD) Tablet on Day 1 and Day 5, respectively.
10194775|NCT04886050|Active Comparator|LC350189 Formulation B (Capsule)|Each subject will be administered two LC350189 100mg (QD) Capsules (2 x 100-mg capsules) on Day 1 or Day 5, respectively.
10194776|NCT04885036|Active Comparator|Treatment As Usual|This group will receive treatment as usual within the family unit
10194777|NCT04885036|Experimental|EFST intervention|This group will receive an EFST stand alone treatment consisting of a two days EFST course and 6 individual parental guidance sessions
9980103|NCT01388452|Experimental|Point of Care HIV RNA PCR|Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for point of care RNA PCR testing, number the sample, and transport it to the central laboratory for processing. Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an inpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end.
10194778|NCT04884698|Experimental|Phrenic nerve stimulation with Stimit Activator|
10194779|NCT04879355|Experimental|Spinal needle|Fine needle aspiration from thyroid nodules using af spinal needle.
9711926|NCT04619914|Experimental|Group A (clomiphene citrate & estradiol group)|included 35 anovulatory PCO patients who received clomiphene citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14
9711927|NCT04619914|Experimental|Group B (Letrozole group)|included 35 anovulatory PCO patients who received letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 5 mg daily from cycle day 3 to day 7.
9711928|NCT04619849|Experimental|palmaris longus and carpal tunnel|EMG measurements of median and ulnar nerves will be made in patients with palmaris longus muscle.
9711929|NCT04619628|Placebo Comparator|Saline|Normal saline
9711930|NCT04619628|Experimental|Low dose cohort 1|COVI-VAC, single dose
9711931|NCT04619628|Experimental|Medium dose cohort 1|COVI-VAC, single dose
9711932|NCT04619628|Experimental|High dose cohort 1|COVI-VAC, single dose
9711933|NCT04619628|Experimental|Low dose cohort 2|COVI-VAC, two doses 28 days apart
9711934|NCT04619628|Experimental|Medium dose cohort 2|COVI-VAC, two doses 28 days apart
9711935|NCT04619628|Experimental|High dose cohort 2|COVI-VAC, two doses 28 days apart
9711936|NCT04619810|Other|Intervention arm|quasi-experimental pre-post study
10194780|NCT04879355|Active Comparator|Conventional fine needle|Fine needle aspiration from thyroid nodules using af conventional fine needle, which is traditionally used.
10194781|NCT04870788|Experimental|Group I (mindfulness program)|Patients and their partners participate in mindfulness program over 60 minutes consisting of meeting with a mindfulness coach to build awareness of thoughts, emotions, feelings, and sensations QW for 4 weeks.
10194782|NCT04870788|Active Comparator|Group II (mindfulness waitlist)|Patients and their partners participate in mindfulness program as in Group I beginning 12 weeks after starting the study
9711937|NCT04619719|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen Therapy (HBOT) + Standard of Care (SOC) as defined by current best practice treatments for COVID-19
9711938|NCT04619719|No Intervention|Standard of Care|Standard of Care (SOC) as defined by current best practice treatments for COVID-19
9711939|NCT04619875|Other|Lactulose|
9711940|NCT04619875|Other|KB5|
9711941|NCT04619875|Other|SG1|
9711942|NCT04619862|Experimental|Medication|"Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.~The starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: < 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day."
9711943|NCT04619862|Placebo Comparator|Placebo|Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.
9711944|NCT04619277||Ulsan Medical Center|Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center, Ulsan, South Korea
9711945|NCT04619277||Queen Elizabeth Hospital|Cardiology Department and Clinical Research Center, Queen Elizabeth Hospital II, Kota Kinabalu, Malaysia
9711946|NCT04619277||Pecking University Shougand Hospital|Department of Cardiology, Peking University Shougang Hospital, Peking, China
9711947|NCT04619277||Ulsan University Hospital|Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
9984505|NCT04035434|Experimental|CTX110|Administered by IV infusion following lymphodepleting chemotherapy.
10194783|NCT04867382|Experimental|Intervention|PCCs in clinics randomized to Opioid Wizard will be randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. Both arms will receive a case-based training on how to use the Opioid Wizard tool. The intervention arm will receive an online training that includes patient narratives and videos and person-first language.
9711948|NCT04619277||Kangwon National University School of Medicine|Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea
9711949|NCT04619277||Korea University Guro Hospital|Cardiovascular Center, Department of Cardiology, Korea University Guro Hospital, Seoul, South Korea
9711950|NCT04619459|Experimental|Newborns receiving Kangaroo Mother Care (KMC)|The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. At Minute 5, the newborns' Apgar scores were assessed and recorded during KMC. The newborn's examination and injections (Hepatitis-B and K vit) were postponed until the first breastfeeding took place. A pediatrician performed a detailed examination of the newborns under the radiant infant warmer after the first breastfeeding. Following the examination, the newborn was positioned on the mother's breast for KMC. During this KMC, the newborn was administered 1 mg K vitamin in the right leg and 0.5 ml Hepatitis-B vaccine in the left leg via intramuscular injections. The KMC session was continued for 3 hours. Care attempt of mothers such as episiotomy repair was taken that the position of KMC.
9711951|NCT04619459|No Intervention|Newborns receiving standard postpartum care (SPC):|He received the standard care of the hospital. KMC not applied.
9984506|NCT04028843|No Intervention|WIC Nutrition|Participants will receive weight management advice and care through the standard Women, Infants, and Children program. They will also receive weekly health information related to pregnancy, birth, and infant health through a closed Facebook group.
10194784|NCT04867382|Placebo Comparator|Comparison training|PCCs in clinics randomized to Opioid Wizard will be randomized 1:1 to the intervention or comparison training, stratified by clinic and waiver status. Both arms will receive a case-based training on how to use the Opioid Wizard tool.
9711952|NCT04619290|Experimental|Methylene blue treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
9711953|NCT04619290|Active Comparator|Conventionally treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
9711954|NCT04619303|Experimental|Dexamethasone Implant|Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.
9711955|NCT04619303|Active Comparator|Bevacizumab|Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.
10194785|NCT04856046||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood samples at 4-6 weeks prior to surgery/ablation and at 12 weeks, 6, 12, 18 and 24 months after surgery/ablation. Patients' previously collected tissue samples are analyzed. Patients' medical records are also reviewed at baseline, 4-6 weeks prior to surgery/ablation, 12 weeks, 6, 12, 18 and 24 months after surgery/ablation, and then every 6 months for 3 years.
10194786|NCT04855526|Experimental|Occasional Users - High THC and High CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC high CBD marijuana at the study visit
10194787|NCT04855526|Experimental|Occasional Users - High THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC and no CBD marijuana at the study visit
9711956|NCT04619264|Experimental|Papacarie-Duo|
10194788|NCT04855526|Experimental|Occasional Users - No THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of marijuana that contains no THC or CBD
9711957|NCT04619264|Active Comparator|Atraumatic Restorative Treatment|
9711958|NCT04619537|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
9711959|NCT04619446||Removable Twin Block appliance group|Patient to be treated with removable twin block appliance that are known Class II skeletal and dental subjects.
9711960|NCT04619446||Fixed Functional Appliance AdvanSync group|Patients to be treated with fixed functional appliance, AdvanSync (Molar-to-Molar) Class II Corrector
9711961|NCT04619563|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
9711962|NCT04619329|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using Lobaplatin and GSMs (150-350μm, 350-560μm, 560-710μm or 710-1000μm), patients will receive surgical resection 15-30 days later, as specified per protocol.
9711963|NCT04619329|Active Comparator|Surgical Resection Group|Patients will receive surgical resection, as specified per protocol.
9711964|NCT04619238||no urinary incontinence|patients without UI
9711965|NCT04619238||stress urinary incontinence|patients with SUI
9711966|NCT04619238||overactive bladder|patients with OAB
9711967|NCT04619238||mix urinary incontinence|patients with MUI
9711968|NCT04619238||Urge|patients with urge incontinence
9711969|NCT04619316|Other|BRAF wild type|In BRAF wild type patients trametinib 2mg (1-0-0) is applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
9711970|NCT04619316|Other|BRAF V600E Mutation|In BRAF wild type patients trametinib 2mg (1-0-0) and dabrafenib 75mg (2-0-2) are applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
9711971|NCT04619394|No Intervention|Control Group (CG)|Control Group (CG): Formed by those pregnant women who do not perform any physical exercise, only the basic and instrumental activities of daily life (ABVD and AIVD respectively) and intensity of the physical labor load of very light to moderate. The period from 10-12 SG to 37-41 SG.
9711972|NCT04619394|Active Comparator|Experimental Group 1 (GE1)|Experimental Group 1 (GE1): Created for pregnant women who carry out their own program of each monitor in the different sports centers and public and private swimming pools in the South of the Autonomous Community of Galicia. These own programs will all have the same format: initial warm-up phase, main part of indicated and personalized exercises for pregnancies and final phase with a return to calm.
9711973|NCT04619394|Active Comparator|Experimental Group 2 (GE2)|Experimental Group 2 (GE2): In this third and last group, we incorporated the AIPAP program into the exclusive programs of each monitor in the various public and private sports centers and swimming pools in the South of the Autonomous Community of Galicia. The researcher trained in this method, together with the monitors who voluntarily wish to do so, will translate said format and program into their sessions.
9711974|NCT04619212|Other|Standard of Care|Standard of Care
9711975|NCT04619212|Other|new device|new device
9711976|NCT04619251|Experimental|SRD part, active drug, poor metabolizers|
9711977|NCT04619251|Experimental|SRD part, active drug, extensive metabolizers|
9711978|NCT04619251|Placebo Comparator|SRD and MD part, placebo|
9711979|NCT04619251|Experimental|DDI part, poor metabolizers|DDI part will be initiated after SRD part
9711980|NCT04619251|Experimental|MD part, active drug, poor metabolizers|
9711981|NCT04619550|Other|Exercise intensity|Jogging or walking at RPE 9, 11, 13, and 15
9711982|NCT04619381||African Americans with Coronary Artery Disease|African Americans with Coronary Artery Disease and currently taking clopidogrel
9711983|NCT04619407||teacher|"Employed in a school in Mecklenburg-Vorpommern~Age between 18 to 67 years~Willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
10194789|NCT04842552|Active Comparator|Hydralazine hydrochloride 25mg|Hydralazine hydrochloride (25mg tablets) every eight hours (TDS)
10194790|NCT04842552|Placebo Comparator|Placebo|Placebo tablets (identical in shape to the active comparator) every eight hours (TDS)
10194791|NCT04838106||Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency with confirmed COVID-19 between 1st January to 1st July 2020.
10194792|NCT04838106||Non Covid19|Patients admitted to an adult (16 years or over), general ICU in England or Wales as an emergency without confirmed COVID-19 between 1st July 2016 and 1st July 2020.
10194793|NCT04837352||Multiple sclerosis patients|Patients with multiple sclerosis over 18 years old who have already started a long-term treatment and consent to participate to the study
9711984|NCT04619407||pupils|"Attending school in Mecklenburg-Vorpommern~Age between 6 to 17 years~Agreement to participate~Legal representative willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
9711985|NCT04619407||childcare educators|"Employed in a kindergarten in Mecklenburg-Vorpommern~Age between 18 to 67 years~Willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
9711986|NCT04619407||preschoolers|"Attending kindergarten in Mecklenburg-Vorpommern~Age between 3 to 6 years~Agreement to participate~Legal representative willing and able to provide informed consent~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
9711987|NCT04619498|Experimental|PediAppRREST app|The teams assigned to the PediAppRREST arm will manage the simulated scenario of pediatric cardiac arrest using the new PediAppRREST tablet app as a cognitive aid.
9711988|NCT04619498|Active Comparator|CtrlPALS+|The teams assigned to the CtrlPALS+ arm will manage the simulated scenario of pediatric cardiac arrest using the American Heart Association Pediatric Advanced Life Support (AHA-PALS) pocket reference card.
9711989|NCT04619498|No Intervention|CtrlPALS-|The teams assigned to the CtrlPALS- arm will manage the simulated scenario of pediatric cardiac arrest using no PALS-related cognitive aids.
9779428|NCT05306314||Antibiotic Treatment (1*1) PO + NSAID (PRN) PO ya da SUPP|"Levolon 500 mg ( 1*1 -PO) 28 daANTIBIOTIC TREATMENT Levolon 500 mg ( 1*1 - PO) 28 days (4 weeks) Dosage Form:Film-coated tablet Dosage : 500 mg Frequency : 1*1 Duration: 28 days (4 weeks) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals.~NSAID Diclomec 75 mg ( PRN- PO )- 28 days (4 weeks) Dosage Form:Tablet Dosage : 75 mg Frequency : PRN Duration: 28 days (4 weeks as per needed) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals."
9779429|NCT05306301|Experimental|Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia|"In the run-in phase, patients will receive a dosage of 15 mg of ICLUSIG (ponatinib). If there are no toxicities observed, 30 mg of ponatinib will be administered in the remaining patients. MRD of patients will be evaluated on weeks 4, 10, 16, and 22. If a donor is available, MRD-positive patients will proceed to an allogeneic transplant after cycle 3. If there is no donor available, they'll continue treatment with 5 additional consolidation/reinduction blocks, followed by 24 28-day cycles of maintenance.~Induction/consolidation cycles are administered at 28 (cycles 1-2) and 21(cycles 2-8) day intervals."
9779430|NCT05306288||Individuals with elevated-risk lung cancer (screening population)|
9779431|NCT05306262|Active Comparator|hypnotic trance|Hypnosis session of comfort for 20 minutes
9779432|NCT05306262|Experimental|hypnotic trance + catalepsy|Catalepsy + Hypnosis session of comfort for 20 minutes
9779433|NCT05306249|Experimental|CBD LGP 50 group|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
9779434|NCT05306249|Placebo Comparator|Control group|Patients will receive the MCT oil placebo without CBD until the end of week 12.
9779435|NCT05306236|Experimental|LLL therapy and postural correction ex (study group)|study group will be treated by low level laser therapy and postural correction exercises
9779436|NCT05306236|Experimental|postural correction ex (control group)|control group will be treated by postural correction exercises only
9779437|NCT05306223|Experimental|Bedaquiline-containing Short-course Regimen (SCR)|Participants will receive an oral dose of bedaquiline 400 milligrams (mg) once daily for first 2 weeks followed by bedaquiline 200 mg thrice a week for 22 weeks (with at least 48 hours between doses) in combination with oral doses of levofloxacin (LFX) up to 1000 mg (weight-based), cycloserine (CS) up to 750 mg (weight-based), clofazimine (CFZ) 100 mg daily for 40 weeks and linezolid [LZD] 600 mg daily for at least 24 weeks . If a participant is still sputum culture-positive for Mycobacterium tuberculosis by Week 16, bedaquiline treatment will be extended from Week 24 to Week 40.
9779438|NCT05306223|Experimental|Non-bedaquiline-containing Short-course Regimen (SCR)|Participants will receive oral doses of LFX up to 1000 mg (weight-based), CS up to 750 mg (weight-based), CFZ 100 mg, Pyrazinamide (PZA) up to 2000 mg (weight-based), Protionamide (PTO) up to 800 mg (weight-based) daily for first 16 weeks and LZD 600 mg daily for at least 24 weeks.
9779439|NCT05306197|Experimental|Gaze-Contingent Feedback Training (toward threat)|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
9785772|NCT01259492|Placebo Comparator|Placebo|Period 1- Placebo controlled Period 2 - The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose (40, 60 or 80 mg). In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
10194794|NCT04832841||SARS-CoV-2 naive|Kidney transplant recipients without previous SARS-CoV-2 infection verified by absence of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
10194795|NCT04832841||SARS-Cov-2 exposed|Kidney transplant recipients with previous SARS-CoV-2 exposition verified by positivity of RT-PCR test in national database who receive SARS-CoV-2 mRNA vaccine after transplantation.
9711990|NCT04618965|Placebo Comparator|Control (Placebo) group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
9711991|NCT04618965|Experimental|Intrathecal dexmedetomidine group|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
9711992|NCT04618965|Experimental|Intravenous dexmedetomidine group|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
9711993|NCT04619017|Experimental|Segmental allergen challenge|Allergic individuals with and without asthma will be enrolled.
9711994|NCT04618835||Emergency presentations|Patients discharged after a presentation to practitioners in the community, primary and secondary care.
9711995|NCT04618926||intubating Laryngeal Tube Suction Disposable|intubating Laryngeal Tube Suction Disposable Airway control
9711996|NCT04618926||intubating laryngeal Tube suction Disposable|intubating laryngeal Tube Suction Disposable
10194796|NCT04832841||Waiting list|Kidney transplant recipients who were vaccinated on waiting list (a) SARS-CoV-2 naive (b) SARS-Cov-2 exposed
10194797|NCT04819555||adult patients with ALS|incident population of ALS patients followed in the FILSLAN centres.
10194798|NCT04818944|Experimental|Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))|Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
10194799|NCT04818944|Placebo Comparator|Placebo Arm|Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
10194800|NCT04812951|No Intervention|young control|25 patients < 65 years old without any prophylactic anti-inflammatory preoperative treatment
9711999|NCT04618861||Control Group|"This cohort involved the volunteers who had no known acute, subacute or chronic disease history, who did not suffer from any infection in the last fortnight, who were not on a particular medication, who presented to the ED with reasons other than infectious complaints, and who gave their written consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
10194801|NCT04812951|No Intervention|control|25 patients > 75 years old without any prophylactic anti-inflammatory preoperative treatment
10194802|NCT04812951|Experimental|Study group|25 patients > 75 years old with prophylactic anti-inflammatory preoperative treatment
9712000|NCT04618861||CT (+), PCR (-) Covid-19 Suspected Pneumonia Group|"This group consisted of patients who applied to the emergency department with symptoms of Covid-19, whose thorax CT according to RSNAEC criteria showed typical Covid-19 pneumonia findings, but whose RT-PCR test was negative in the swab sample taken in the emergency room.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
9712001|NCT04618861||CT (+), Covid-19 Pneumonia Group|"This cohort consisted of the patients (a) who applied to the emergency department with SARS-CoV-2 symptoms and was diagnosed with SARS-CoV-2 infection according to WHO guideline (13) (b) whose CT imagings were compatible with SARS-CoV-2 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria (14), (c) whose nasopharyngeal swab samples taken in the ED were positive for RT-PCR, and (d) who gave their informed consent to participate in the study.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
9785181|NCT01245049|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
10194803|NCT04812951|Active Comparator|Vehicle group|25 patients > 75 years old with vehicle preoperative treatment
10194804|NCT04804800|No Intervention|Control group|The patients benefit from the care recommended by the HAS. They benefit from psychological interviews, psychiatric follow-up, dietetic follow-up, family interviews and therapy. Body therapies (physiotherapy, massage, fascia therapy, psychomotor skills, dance therapy, etc.) may also take place. Patients will also benefit from relaxation and body scan.
10194805|NCT04804800|Experimental|Experimental group 1 : Virtual Reality|The patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan (1 hour).
10194806|NCT04804800|Experimental|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|The patients benefit from the care recommended by the HAS, the virtual reality and the multisensory remediation programs, and also the body scan.
9712002|NCT04618861||CT (-), PCR (+) Covid-19 infection group|"This cohort included the patients (a) who presented to the Covid-19 outpatient polyclinic of the ED with pneumonia symptoms, (b) whose CT imaging's were compatible with Covid-19 pneumonia in accordance with the RSNAEC criteria and whose PCR tests were positive, (c) whose SARS-CoV-2 PCR tests were positive as a result of contact tracing, and (d) who presented to the ED for further examination.~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
9712003|NCT04618978|Other|PSG and actigraphy device evaluations|All patients will be evaluated and diagnosed according to the records by Gold standard for PLMs diagnosis and also by the actigraphy devices recording.
9712004|NCT04618848||Adult Oncology Patients|Adult oncology patients
9712005|NCT04619030|Experimental|Augmented Reality Leaflet|Patient Leaflet with Augmented reality component
9712006|NCT04619030|Active Comparator|Traditional Leaflet|Traditional leaflet without Augmented Reality component
9712007|NCT04619095|Experimental|Psyllium|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
9712008|NCT04619095|Placebo Comparator|Placebo|For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
10194807|NCT04785677|Experimental|Comprehensive Trauma-Based Reentry Program|Participants will complete up to19 session comprehensive trauma-based reentry program.
9712009|NCT04618939|Experimental|BR-TD-1001|Randomized subjects were assigned to receive a single dose of BR-TD-1001
9712010|NCT04618939|Active Comparator|Td-pur inj|Randomized subjects were assigned to receive a single dose of Td-pur inj
10194808|NCT04785677|No Intervention|Treatment as usual (TAU)|Participants will be receive all reentry services normally eligible to receive by the state or the community to which they are released.
10194809|NCT04772313|Experimental|Pegloticase plus Methotrexate (MTX)|Pegloticase (8mg) intravenous (IV every two weeks). Methotrexate (15 or 25 mg weekly) subcutaneous (SC).
9712012|NCT04619147||Patients without invasive fungal infections (IFI)|This will be our control cohort. Most of the patients would have been on posaconazole prophylaxis.
9712013|NCT04619147||Patients with invasive fungal infections (IFI)|This will be the group that we will be interested in. IFI would be diagnosed based on EORTC/ MSG definitions, and most of them would have been on posaconazole prophylaxis. Underlying risk factors of acquiring IFI in this cohort of patients will be compared with that of the control cohort.
9712014|NCT04618913||VTE and history of cancer|VTE and history of cancer
9712015|NCT04618913||VTE and active cancer|VTE and active cancer
9712016|NCT04618809|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire, which evaluates the approach to older mGC patients at each site.~Phase 2 - Providers participate in an hour-long didactic session and begin enrolling eligible metastatic gastric cancer (mGC) patients. Enrolled mGC patients complete a comprehensive geriatric assessment (CGA). Providers complete the treatment plan and review of geriatric assessment questionnaires, which also includes an evaluation of their overall view of the utility of the geriatric assessment.~Phase 3 - Follow-up chart reviews (2-3 months post intervention) are completed to assess for actual implementation of recommended interventions identified by the geriatric assessment."
9712017|NCT04618887||Meige sydrome patients|
9712018|NCT04619342|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using epirubicin and GSMs (150-350μm or 350-560μm), patients that meet certain criteria will receive surgical resection of PVTT, as specified per protocol.
9712019|NCT04619342|Active Comparator|GSMs-TACE Group|Patients will receive TACE using epirubicin and GSMs (150-350μm or 350-560μm), as specified per protocol.
9712020|NCT04618900|Experimental|Osteotome-mediated sinus floor elevation with Bio-Oss collagen|Sinus floor elevation with a grafting material (Bio-Oss collagen)
10194810|NCT04765722|Experimental|Mepolizumab arm|Mepolizumab Dosage form: 1ml pre-filled syringe Dosage: 100mg Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
9712021|NCT04618900|Placebo Comparator|Osteotome-mediated sinus floor elevation with no grafting material|Sinus floor elevation with no grafting material
9712022|NCT04619043|Experimental|Ankle Orthotic|The participant will wear two different ankle orthotics, their currently prescribed orthotic and the experimental orthotic.
9712023|NCT04619134|Experimental|NCSR Program|Non Pain Contingent Spinal Rehabilitation
9712024|NCT04619134|Active Comparator|Conventional Physical therapy|Conventional Physical Therapy
9712025|NCT04618952|Active Comparator|treatment|patients received calcium D
9712026|NCT04618952|Placebo Comparator|control|patients received placebo
9712027|NCT04619433|Experimental|Treatment group A|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
9712028|NCT04619433|Placebo Comparator|Treatment group B|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
9712029|NCT04619160|Active Comparator|propofol|
9712030|NCT04619160|Active Comparator|sevoflurane|
9712031|NCT04619069|Active Comparator|Arm 1: Standard of Care|Intermittent Hormone treatment (minimum of 8 months)
9712032|NCT04619069|Experimental|Arm 2: SBRT to mets|"Intermittent Hormone treatment (minimum of 8 months)~+ SBRT to all sites of metastatic disease"
9712033|NCT04618991|Experimental|Adult patients with SAHOS for whom maxillary transversal surgery|Adult patients with SAHOS for whom maxillary transversal surgery is recommended.
9712034|NCT04618822|Experimental|Teaching involving whole-body movements|
9712035|NCT04618822|Experimental|Teaching involving hand movements|i.e. arms and hands
9712036|NCT04618822|Active Comparator|teaching involving minimal motor movements|i.e. seated on a chair using paper and pencil
9712037|NCT04619173|Experimental|Thoracic manipulation|additional thoracic manipulation along with hotpack, transcutaneous electrical nerve stimulation ,serratus anterior,pectoralis major,minor, posterior capsular stretches..
9712038|NCT04619173|Active Comparator|Conventional Physical Therapy Program|hot pack transcutaneous electrical nerve stimulation, serratus,anterior,pectoralis major, minor, posterior capsular stretches.
9712039|NCT04618783|Experimental|Low-dosage experimental group|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
10194811|NCT04765722|Placebo Comparator|Placebo arm|Normal Saline (0.09% normal saline) Dosage form: 1ml pre-filled syringe Dosage: n/a Frequency: 3 doses at days 0, 28, 56 and 84 Duration: 12 weeks
10194812|NCT04756401|Experimental|Treatment (carfilzomib, daratumumab, dexamethasone, selinexor)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10194813|NCT04733898|Experimental|Social games|Participants in the social games group will be given access to an app with games that are either adaptations of well-known games or newly developed games, all designed to be played with just text messages and photos. A game is essentially a chat group with the people you invited to play that specific game with. Participants can play with their own network of family and friends, as well as other people in the same condition.
10194814|NCT04733898|Active Comparator|Non-personal games|Participants in the active control group will be given access to an app that offers 'non-personal games'. The portal will contain a subset of the social games, which have been adapted for non-personal play. This means that all aspects that make the games personal are removed and discouraged. The games that remain can still be played with others (family/friends and others in the same condition), but are designed not to elicit personal interaction. Participants are asked to play the games at least twice a week, but may play as often as they like.
10204744|NCT05069012|Active Comparator|50 micrograms|Patients in this arm will receive 50 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
9712040|NCT04618783|Experimental|Medium-dosage experimental group|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
9712041|NCT04618783|Experimental|High-dosage experimental group|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
9712042|NCT04618783|Active Comparator|Control wIPV group|Three doses of control wIPV, vaccinated within one-month interval between doses
9712043|NCT04618783|Active Comparator|Control sIPV group|Three doses of control sIPV, vaccinated within one-month interval between doses
9712044|NCT04618757|Experimental|Hedonic Reward|Participants' reward for meeting monthly step targets is in the form of reimbursements of up to $50 for expenses on hedonic activities of their choice
9712045|NCT04618757|Experimental|Cash Reward|Participants' reward for meeting monthly step targets is in the form of $50 cash disbursements
9712046|NCT04618666|Experimental|laparoscopic and open appendectomy|comparative study between laparoscopic and open appendectomy
9712047|NCT04618640|Experimental|DTaP-IPV combination vaccine|DTaP-IPV 0.5ml IM boosting
9712048|NCT04618354||LADA group|The patient was diagnosed with late-onset autoimmune diabetes (LADA).
9712049|NCT04618354||T2DM group|The patient was diagnosed with type 2 diabetes (T2DM).
9712050|NCT04618354||T1DM group|The patient was diagnosed with type 1 diabetes (T1DM).
9712051|NCT04618380||Bilateral trifocal implantation|Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia
9712052|NCT04618380||Myopic monovision|The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)
9712053|NCT04618380||Hybrid monovision|Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one
9712054|NCT04618380||Premium monovision|Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.
9712055|NCT04618497|Experimental|Inhalational methoxyflurane (Penthrox)|
9712056|NCT04618497|Active Comparator|Intramuscular ketorolac|
9712057|NCT04618445||Undergraduate students|prevalence of TMD among undergraduate students
9712058|NCT04618510|Experimental|SEED 1-dayPure EDOF soft contact lens|The participant will be requested to wear the daily disposable lens 8-10 hours per day and replaced daily. All participants will be followed for 12 months (followup visit schedule; 3 months, 6 months, 12 months) post-contact lens wear.
9712059|NCT04618510|Sham Comparator|Single vision spectacle lens|The participant will be requested to wear the spectacle lens daily. All participants will be followed for 12 months (follow up visit schedule; 3 months, 6 months, 12 months) post spectacle lens wear.
9712060|NCT04618367|Experimental|HAIC plus Lenvatinib and Sintilimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 200 mg intravenously every 3 weeks.
9712061|NCT04618718|Experimental|Intervention|ProtEmbo device will be used as distal protection device in subjects undergoing TAVR
9712062|NCT04618653||Early AA Attenders with Alcohol Use Disorder|observational study that includes three fixed assessments (Baseline, 3, and 6-month). Subset of participants will also provide daily EMA data.
9712063|NCT04618575|Experimental|Ursodeoxycholic acid combined with total glucosides of paeony|
9712064|NCT04618575|Other|Ursodeoxycholic acid only|
9712065|NCT04618549|Active Comparator|Direct anterior approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by direct anterior approach, using a regular OR table, without hip hyperextension.
9712066|NCT04618549|Active Comparator|Mini Posterior Approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a mini posterior approach.
9712067|NCT04618549|Active Comparator|Lateral approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a lateral (Hardinge) approach.
9712068|NCT04618588|Experimental|"Sinus elevation using Low Window Sinus Lift technique"|
9712069|NCT04618484|Experimental|Biomodulation|6-weeks post-operative cryo-, photo- and electro-biomodulation protocol after repair
9712070|NCT04618484|No Intervention|Control|standard rehabilitation after repair
9712071|NCT04618536|Experimental|Inorganic sunscreen|
9712072|NCT04618536|Experimental|Organic sunscreen|
9712073|NCT04618601|Active Comparator|High-dose spironolactone|Participants in this arm will receive high doses of per os spironolactone, defined as doses ≥100 mg daily, on top of standard of care treatment for acute heart failure
9712074|NCT04618601|No Intervention|Standard of care|Participants in this arm will standard of care treatment for acute heart failure, which may include per os spironolactone at a maximum dose of 50 mg daily
9712075|NCT04618562|Experimental|Revival Active Program|Revival Program included supervised play group, twice a week followed by home practice.
10194815|NCT04733898|No Intervention|Passive control|The passive control group will be given access to an app that contains no games. Similar to the other groups, the portal is used to complete the questionnaires. Use of other games, (gaming) apps or social media platforms is allowed in this group, as in the other groups. The only restriction they will not have access to the games offered in the social games and active control groups.
10194816|NCT04733495|Experimental|Supportive care (resistance exercise, counseling)|Patients undergo personalized resistance exercises over 1 hour daily. Patients receive dietary counseling over 60 minutes at week 1 and then over 15-30 minutes weekly for up to 6 weeks. Patients also receive group-based behavioral counseling BIW in weeks 1-8, QW in weeks 9-12, and then twice a month in weeks 13-24.
10194817|NCT04727086|Experimental|Medication (BP1.3656)|Participants will receive BP1.3656 in tablet form once daily at a dose of 30 µg/day for the first 4 days, followed by 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
9712076|NCT04618679||18F-FDOPA PET|Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.
10194818|NCT04727086|Placebo Comparator|Placebo pills|Participants will receive matching placebo pills for 14 days.
10194819|NCT04721158|Other|CGM Arm|Children with type 2 diabetes will wear a continuous glucose monitor for 10 days.
10194820|NCT04716972||Online Survey|Online survey
10194821|NCT04716972||Interviews|Interviews
10194822|NCT04714736|Active Comparator|DyeVert group|Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be handled by the DyeVert TM system.
9712077|NCT04618159|Other|Helipyl|helipyl wil be given to 10 children with asymptomatical helicobacter pylori infection
9712078|NCT04618120|Experimental|Virtual Reality-based Exercise Group|"Virtual reality-based exercises, breathing exercises and patient education on general considerations.~Virtual reality-based exercises were done using the Microsoft Xbox 360 Kinect system. Among the 'Kinect Sports' games, especially tennis, table tennis, boxing and bowling games including upper extremity movements were selected. These games require all-directional and repetitive motion of the shoulder and elbow joint. Patients played the games using the operated / affected side arms. Between games, the patient was rested in a chair. In the meantime, deep breathing exercises were done.~The patients participated in virtual reality-based exercises 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). Each exercise session was set to last 30-40 minutes in total."
9712079|NCT04618120|Experimental|Exercise Group|"Stretching exercises, range of motion exercises, posture exercises, breathing exercises and patient education on general considerations.~11 different exercises consisting of shoulder range of motion in all directions, stretching exercises, posture exercises and breathing exercises were performed in the presence of a physiotherapist.The patients participated in this exercise program 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). One session of the exercises was completed in an average of 30-40 minutes. The same exercises were repeated in each session."
9712080|NCT04618120|No Intervention|Control Group|Only patient education on general considerations.
9712081|NCT04618185||p.Phe508del homozygous genotype|People with CF with 2 copies of p.Phe508del and previously eligible for Symkevi (Tezacaftor/Ivacaftor)
9712082|NCT04618185||p.Phe508del heterozygous genotype|People with CF with 1 copy of p.Phe508del and not previously eligible for any CFTR modulator
9712083|NCT04618172|Experimental|Exercising group|This group practises 30 minute long aerobic exercises twice a week besides filling out the questionnaires.
9712084|NCT04618172|No Intervention|Control group|This group fills out the questionnaires without practising 30 minute long aerobic exercises twice a week.
9712085|NCT04618094|Experimental|High intensity interval group|
9712086|NCT04618094|Active Comparator|Moderate continous intensity group|
9712087|NCT04618094|No Intervention|non-exercising group|
9712088|NCT04618263|Experimental|GATE-101, 5 mg IV, Single Dose|GATE-101, 5 mg IV, Single Dose, with follow up of 28 days
9712089|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose|GATE-101, 15 mg IV, Single Dose, with follow up of 28 days
9712090|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose|GATE-101, 50 mg IV, Single Dose, with follow up of 28 days
9712091|NCT04618263|Experimental|GATE-101, 150 mg IV, Single Dose|GATE-101, 150 mg IV, Single Dose, with follow up of 28 days
9712092|NCT04618263|Experimental|GATE-101, 450 mg IV, Single Dose|GATE-101, 450 mg IV, Single Dose, with follow up of 28 days
9712093|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose, Lumbar Catheter|GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
9712094|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose, Lumbar Catheter|GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
10204745|NCT05069012|Active Comparator|150 micrograms|Patients in this arm will receive 150 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
9712095|NCT04618263|Experimental|GATE-101 5 mg IV, Five Daily Doses|GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose
9712096|NCT04618263|Experimental|GATE-101 15 mg IV, Five Daily Doses|GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose
9712097|NCT04618263|Experimental|GATE-101 150 mg IV, Five Daily Doses|GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose
9712098|NCT04618263|Placebo Comparator|Placebo Comparator, Single Dose|Placebo Comparator, Single Dose, with follow up for 28 days
10194823|NCT04714736|Sham Comparator|Control group|"Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions and modulated according to the left ventricular end diastolic pressure (LVEDP). During the PCI the CM injection will be carried out by a conventional manual injection syringe. Strategies for limiting CM volume are:~angiograms will be performed with injection of contrast using a 3-cm 3 syringe; this provides strict control of CM delivery by limiting the volume of contrast that can be administered in a single injection;~catheters with sideholes will be strictly avoided during percutaneous intervention;~when exchanging catheters, unused contrast is withdrawn from the catheter lumen (e.g., by back-bleeding through an opened ''Y''-connector or by aspirating residual contrast from the catheter using a syringe)~''tests'' with ''puffs'' of CM are discouraged."
10194824|NCT04708860|Experimental|Prolonged Nightly Fasting Plus Exercise|"Participants will be grouped into two cohorts determined by whether they receive palbociclib or alpelisib as part of their breast cancer treatment and then receive a 12 week prolonged nightly fasting plus exercise program consisting of:~Prolonged overnight fasting: Not consume any calorie-containing food/drinks after 8pm, waiting a minimum of 13 hours after their last meal of the day before eating the next day, target goal of fasting at least 6 days a week, daily record of first and last meals~Exercise Program: Coach provided at-home, personalized exercise regimen with target goal of 120 minutes of moderate-intensity aerobic activity each week as well as two 30-45-minute virtual strength training classes per week, receive fitbit for exercise and heart rate monitoring, weekly telephone-based support sessions with coach."
10204746|NCT05069012|Active Comparator|250 micrograms|Patients in this arm will receive 250 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
9712099|NCT04618263|Placebo Comparator|Placebo Comparator, Five Daily Doses|Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose
9712100|NCT04618276|Experimental|Arm A (MAL group)|"Skin swab for culture in the groin for baseline~PDT with 5% topical methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX~Skin swab for culture~Skin antisepsis~Skin swab for culture"
9712101|NCT04618276|Experimental|Arm B (Methylene Blue group)|"Skin swab for culture in the groin for baseline~PDT with 0.01% methylene blue based photosensitizer (NF-031)~Skin swab for culture~Skin antisepsis~Skin swab for culture"
9712102|NCT04618276|No Intervention|Control group|"Skin swab for culture in the groin for baseline~NO PDT~Skin antisepsis~Skin swab for culture"
9712103|NCT04618029|Experimental|Treatment Group|"Home Assessment and Modification A two-component individualized home hazards management program will be provided for each participant in the intervention group according to the results of the HOME FAST. Basic home safety strategies and basic modifications are developed and will be prescribed for this study according to the HOME FAST assessment (weeks et al. 2010)~Education Education on optimization of functional performance in the home will be provided via pamphlets on fall prevention, including energy conservation techniques (Chumbler et al., 2010), ergonomics (Edwards et al., 2019) and task simplification techniques (Wesson et al., 2013) will be provided. These techniques will also be provided for participants' caregivers."
9712104|NCT04618029|No Intervention|Controlled Group|1. Standard Care The standard care defined for this study is any care that are provided from the respective hospital. This will include common therapies and interventions for stroke rehabilitation in general.
9712105|NCT04618107|Experimental|Wide awake surgery|Wide awake local anaesthesia was used as mode of aneasthesia for tendon repair surgery. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
9712106|NCT04618107|Active Comparator|General anaesthesia|Tendon repair surgeries were performed under general anaesthesia. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
9712107|NCT04618042|Experimental|FX06|
9712108|NCT04618042|Placebo Comparator|Placebo|
9712109|NCT04618224||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language~30 patients with low vision (LVG) with adequate literacy of written Greek language~These patients are tested on the digital reading test DDART."
9712110|NCT04618224||Study group|The same patients as those in the control group (NVG, LVG) are tested on the online version of the Greek digital reading test DDART (wDDART).
9712111|NCT04618146|Placebo Comparator|Group C|given intrathecal bupivacaine 12.5 mg.
9712112|NCT04618146|Active Comparator|Group M25|given intrathecal bupivacaine 12.5mg + morphine 25 microgram.
9712113|NCT04618146|Active Comparator|Group M50|given intrathecal bupivacaine 12.5mg + morphine 50 microgram.
9712114|NCT04618003||Athletes with Spinal Cord Injury|Group of athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
9712115|NCT04618003||Non-athletes with spinal cord injury|Group of non-athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
9712116|NCT04618003||Able-bodied control group|Group of non-athletes able-bodied control subjects that was assessed at rest and during a physical activity in virtual reality.
9712117|NCT04618250|Experimental|Coordinated, co-produced health care|
9712118|NCT04618250|No Intervention|Care as usual|Care as usual
9712119|NCT04618289|Experimental|Vitamin D Group|The vitamin D3-fortified fruit juice supplement that will be used is vitamin D3 cholecalciferol (4000 IU, 100 mcg, Fiatec Biosystem Sdn Bhd, Selangor, Malaysia).
9712120|NCT04618289|Placebo Comparator|Placebo Group|The matching placebo will be also custom-produced and will be produced in the same manner, without the active ingredients by the same company. The placebo produced will match with vitamin D3 in terms of appearance, size, colour and taste to achieve the double-blind design.
9712121|NCT04618328|Experimental|ATRA treatment group|ATRA is given at a daily dose of 10 mg twice daily orally for 12 weeks
9712122|NCT04617951|Experimental|Ishige Okamurae extracts group|This group takes Ishige Okamurae extracts for 12 weeks.
10194825|NCT04707625|Other|Aflibercept|All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.
9712123|NCT04617951|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
9712124|NCT04617782|Experimental|Treatment A|5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
10194826|NCT04698525|Active Comparator|Valproate group|This is a well know antiepileptic drug with efficacy as a preventive tic treatment in episodic migraine
10194827|NCT04698525|Active Comparator|Memantine|This is a possible preventive treatment in episodic migraine
9712125|NCT04617782|Experimental|Treatment B|10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
9712126|NCT04617782|Active Comparator|Treatment C|10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks
10194828|NCT04696146|Experimental|Berinert|Berinert 500 units
9712127|NCT04617834||Quality Surveillance Data|For this quality surveillance study, data will be collected retrospectively through electronic health record (EHR) queries for all eligible patients treated for acute cardiovascular symptoms by one of the study sites.
9712128|NCT04617691|Experimental|Group 1: Guselkumab PFS-U|Participants will receive single intravenous (IV) guselkumab formulation using UltraSafe Plus Passive Needle Guards (PFS-U) to create the IV solution.
9712129|NCT04617691|Experimental|Group 2: Guselkumab FVP|Participants will receive single IV guselkumab formulation using Final Vialed Product (FVP) to create the IV solution.
9712130|NCT04617704|Experimental|Experimental:GC012F treatment|BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10^5/kg cells will be administered at Day 0
9712131|NCT04618081||Participants with FL or MZL|Patients who have been diagnosed with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with revlimid and rituximab for the first time.
9712132|NCT04617873|Experimental|Deep bain stimulation and Spinal cord stimulation therapy|The patients in this group will receive bilateral STN-DBS and SCS stimulation
9712133|NCT04617665|Other|One-handed mask ventilation|For the one-handed mask ventilation, only one hand can be used to achieve the face mask seal. The left thumb and index finger form a ''C,'' providing anterior pressure over the mask, while the third, fourth, and fifth fingers form an ''E'' to lift the jaw.
10194829|NCT04696146|Placebo Comparator|Placebo|Normal Saline in identical volume to Berinert
10194830|NCT04694157||Treatment group|The treatment group will receive cardiac shock wave therapy. The CSWT entire treatment will period last 3 months with 9 sessions. CSWT will administered in the first week, followed by a 3-week non-treatment interval.
9712134|NCT04617665|Other|Two-handed mask ventilation|For the two-handed mask ventilation, the provider's thumb and thenar eminence of each hand are held parallel, adjacent to the mask connector, and depress each side of the mask. The second through fifth digits wrap around and elevate the mandible to draw it anteriorly into the mask establishing both a jaw-thrust and chin-lift maneuver when appropriate.
9712135|NCT04617938|Experimental|TACUNA|Randomized participants will attend 3 virtual TACUNA workshops, focused on behavioral, physical, and spiritual domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use. They will also attend a wellness gathering, focused on healthy social networks and engaging in traditional practices.
9712136|NCT04617938|Active Comparator|Opioid education|Randomized participants will attend 1 virtual opioid education workshop, focused on behavioral and physical domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use.
10194831|NCT04693390|Experimental|Acupuncture|The acupuncture will be applied at points LI4, ST36, HT7, in association with auriculotherapy point Master Cerebral, immediately after induction of anesthesia for 20 minutes
10194832|NCT04693390|No Intervention|Standard care group|The patients will follow the standard procedure
10194833|NCT04684875||Long-Term Study Subjects|All subjects who were treated with the Aerin Medical InSeca/RhinAer Stylus in the 50-subject TP668 interventional study, who consent to continue to provide quality of life data.
10194834|NCT04673149|Experimental|GLS-5310 0.6mg [Group 1a]|0.6mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
10194835|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8.
10194836|NCT04673149|Experimental|GLS-5310 1.2mg [Group 1c]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 12.
10194837|NCT04673149|Placebo Comparator|Placebo [Group 2a]|Placebo will be intradermally administered on Day 0 and Week 8 (or Week 12).
9712137|NCT04617613|Active Comparator|Standard triple therapy|Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.
10194838|NCT04673149|Experimental|GLS-5310 1.2mg [Group 2b]|1.2mg of GLS-5310 will be intradermally administered on Day 0 and Week 8 (or Week 12).
10194839|NCT04665973|Experimental|Oral semi-structured interview|The oral semi-structured interview uses the principles of motivational interviewing (partnership with the patient, no judgment, altruism, evocation) and follow the content of the booklet used in the control group.
10194840|NCT04665973|Active Comparator|Booklet|The information booklet was designed by the physiotherapists at Cliniques universitaires Saint-Luc and is specifically dedicated to raise patient's awareness about the benefits of physical activity (PA) in the context of cancer.
9712138|NCT04617613|Experimental|Quadruple therapy group|Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.
10204747|NCT05065398|Experimental|HLX208|
10204748|NCT05065008|Experimental|Cranberry juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) of cranberry juice daily for 3 weeks.
10204749|NCT05065008|Experimental|Apple juice consumption|Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) apple juice with matching sugar and calories daily for 3 weeks.
10194841|NCT04663464|Experimental|abaloparatide-SC (Period 1) followed by abaloparatide-sMTS (Period 2)|Abaloparatide-SC injection (Period 1) followed by abaloparatide-sMTS application (Period 2). Abaloparatide-SC is a drug-device combination product consisting of abaloparatide, an active synthetic peptide analog of parathyroid hormone related peptide (PTHrP), administered to the periumbilical region via an injection pen. Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide.
10194842|NCT04663464|Experimental|Abaloparatide-sMTS (Period 1) followed by abaloparatide-SC (Period 2)|Abaloparatide-sMTS (Period 1) application followed by Abaloparatide-SC injection (Period 2).
10194843|NCT04661839|Experimental|COVID-HIGIV Dose Level 1|Eligible subjects will be randomized to receive a single IV infusion of COVID-HIGIV dose level 1.
9712139|NCT04617925|Experimental|belantamab mafodotin|Belantamab mafodotin will be administered as an IV infusion at a dose of 2.5 mg/kg every six weeks until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of eight doses (approximately 12 months), according to the response adapted modifications
9712140|NCT04617626|Other|Azithromycin|All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.
9712141|NCT04617899|Experimental|Novasight IVUS/OCT|A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter
9712142|NCT04617652|Active Comparator|Group M|Magnesium group
9712143|NCT04617652|Placebo Comparator|Group C|Control group
9712144|NCT04617730|Active Comparator|Control arm|
9712145|NCT04617730|Experimental|Interventional arm|
9712146|NCT04617405||Type A|Healthy normal-weight pregnant women
9712147|NCT04617405||Type B|Pregnant women with gestational diabetes diagnosed at early screening (before gestational week 20)
9712148|NCT04617405||Type C|Pregnant women with type 2 diabetes
9712149|NCT04617405||Type D|Healthy overweight pregnant women
9712150|NCT04617678|Active Comparator|Prospective Prehabilitation|Prospectively enrolling patients into a prehabilitation program for head and neck cancer.
9712151|NCT04617678|No Intervention|Prospective Control|Prospectively enrolling patients to a control arm with no intervention.
9712152|NCT04617600|Active Comparator|Mineral trioxide aggregate (MTA)|Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)
9712153|NCT04617600|Experimental|TheraCal PT|Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)
9712154|NCT04617795|Experimental|Basal-Bolus (Group A)|"2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with simplified bolus~6-month optional extension using Automated Mode"
9712155|NCT04617795|Experimental|Basal (Group B)|"2 weeks standard therapy - using basal injection only and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 Continuous Glucose Monitor (CGM) - with fixed basal rate, no bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR~If % time in range 70-180 mg/dL during Automated Mode is >50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus~6-month optional extension using Automated Mode"
9712156|NCT04617561|Active Comparator|Ursodeoxycholic Acid group|Ursodeoxycholic Acid 13-15mg/kg/d
9712157|NCT04617561|Experimental|Ursodeoxycholic Acid+Low Dose Glucocorticoid group|Ursodeoxycholic Acid 13-15mg/kg/d+Methylprednisolone 12mg/d in induction period and 2-4mg/d in maintenance period
9712158|NCT04617483|Experimental|Aged 26-45, Commercial Scale|Commercial scale inactivated SARS-CoV-2 vaccine in adults aged 26-45 years.
9712159|NCT04617483|Experimental|Aged 18-59, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in adults aged 18-59 years.
9712160|NCT04617483|Experimental|Aged ≥60, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in elderly aged above 60 years.
9712161|NCT04617288|Experimental|Mean and standard deviations of age and height between group A and B|100 subjects with a mean age of 30.82±6.75 (group A, 31.42±6.67; group B, 30.82±6.82) ranging from 20 to 45 years, with a mean height of 165.52±7.85 (group A, 164.92±7.79; group B, 166.12±7.87) centimeters
9712162|NCT04617288|Experimental|Between group comparison of VAS, NDI and ROM|VAS, NDI and Neck ROM between two groups were compared at pretest (0 day) and posttest (end of two weeks)
9712163|NCT04617197|Experimental|Variable-frequency combination 1|Non disclosure
9712164|NCT04617197|Active Comparator|Variable-frequency combination 2|Non disclosure
9712165|NCT04617197|Placebo Comparator|Control (Placebo)|Non-disclosure
9712166|NCT04617249|Active Comparator|Giving median anesthesia|
9712167|NCT04617249|Active Comparator|Giving paramedian anesthesia|
9712168|NCT04617223|Other|Treatment|
9712169|NCT04617509|Experimental|Part I GS-248 Formulation A|Formulation A given in fasting state.
9712170|NCT04617509|Active Comparator|Part I GS-248 Formulation B|Formulation B given in fasting state.
9712171|NCT04617509|Other|Part II GS-248 Formulation A or B|Formulation A or B given in fed condition
9712172|NCT04617210||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
10194844|NCT04661839|Experimental|COVID-HIGIV Dose Level 2|Eligible subjects will be randomized to receive a single IV infusion of COVID-HIGIV dose level 2.
10194845|NCT04661839|Experimental|COVID-HIGIV Dose Level 3|Eligible subjects will be randomized to receive a single IV infusion of COVID-HIGIV dose level 3.
10194846|NCT04661839|Placebo Comparator|Dose Placebo (saline)|Eligible subjects will be randomized to receive a single IV infusion of saline placebo.
9712173|NCT04617769|Placebo Comparator|Psychoeducation alone (PSYED)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors.
9712174|NCT04617769|Active Comparator|Psychoeducation followed by exposure (PSYED+EXP)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated.
10194847|NCT04661813|Experimental|EXTRA-CVD Virtual Care|"An adapted version of a Nurse-led intervention to EXtend the HIV TReatment CascAde for CardioVascular Disease prevention (EXTRA-CVD)."
10194848|NCT04650282|Experimental|Lidocaine in SphenoCath device|One treatment will be given.
9712175|NCT04617769|Experimental|Psychoeducation & exposure/Antagonistic Actions (PSYED+EXP+AA)|"The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated. Antagonistic action strategies during exposure to the trauma-videoclips will include (a) adopting an open posture; (b) eating a palatable snack; (c) smiling; and (d) wishing on high levels of emotional distress (e.g., come on distress hit me with your best shot). The participant will engage in all of the four antagonistic actions for the six exposure trials."
9712176|NCT04617171|Experimental|Benralizumab|Benralizumab 30 mg given in the form of subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
9712177|NCT04617171|Placebo Comparator|Placebo|Normal Saline given subcutaneously every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
9712178|NCT04617431|Experimental|Intervention group|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
9712179|NCT04617431|No Intervention|Control group|"The participants of control group had a wearable device and could upload their dietary diary to the health management platform every day. But no LINE group was created, and no reminding."
9712180|NCT04617314|Experimental|RC108|Participants will be allocated to one of the following dose groups: 0.1, 0.3, 0.9, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC108-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
9712181|NCT04617418||subjects with refractory focal epilepsy with a seizure frequency|The investigators will include 100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month, and ask them to keep a seizure diary and use the TapCounter app for three months.
9712182|NCT04617392|Active Comparator|controlled group|25 patients after bariatric-metabolic surgery without controlled postprocedural training
9712183|NCT04617392|Experimental|active group|25 patients after bariatric-metabolic surgery with controlled postprocedural training
9712184|NCT04617340|No Intervention|Usual care group|No pharmacist will be actively involved in the medication review, counseling or discharge and post-discharge procedure. In both groups the best possible preadmission drug list will be compiled for inpatients within 72 hours after admission to the geriatric ward. If potentially dangerous or life-threatening drug errors are observed in the usual care group, this will be communicated to the treating physician
9712185|NCT04617340|Experimental|Intervention group|"The clinical pharmacist-collaborative service in the intervention group comprises six steps based on the clinical pharmacy intervention proposal of Van der Linden et al (Drugs Aging 2020).~The first three steps focus on optimizing the drug therapy of geriatric inpatients. The remaining steps target a safe transition from the hospital to the community."
9712186|NCT04617262|Experimental|Remote Problem Management Plus|Five individual sessions of low-intensity psychological intervention
10194849|NCT04650282|Placebo Comparator|Saline Solution in SphenoCath device|One treatment will be given.
10194850|NCT04639466|Experimental|Phase I Arm I (COH04S1)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
10194851|NCT04639466|Active Comparator|Phase I Arm II (COH04S1, placebo)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and placebo IM in the non-dominant upper arm on day 28 in the absence of unacceptable toxicity.
10194852|NCT04639466|Placebo Comparator|Phase I Arm III (placebo)|Participants receive placebo IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
10194853|NCT04639466|Experimental|Phase II Arm I (low dose COH04S1 booster)|Participants receive low dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
10194854|NCT04639466|Experimental|Phase II Arm II (high dose COH04S1 booster)|Participants receive high dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
9712187|NCT04617184||Inflammatory Bowel Disease|any patient with IBD will be included in the registry
9712188|NCT04617236|Experimental|Cultivando la Salud Educational Intervention|After completing eligibility and baseline surveys, Lay health workers delivered an educational intervention for breast and cervical cancer screening. This educational session was delivered in participants' home and lasted between 1-2 hours. Follow-up data was collected 4-6 months post educational session.
10194855|NCT04633837|No Intervention|Group 1 Control|Group 1 will undergo standard arthroscopic shoulder surgery without the ECM injection.
9712189|NCT04617236|No Intervention|Control|No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 4-6 months post-baseline survey.
9712190|NCT04617496|Experimental|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features that encourage a higher level of speech performance.
9712191|NCT04617496|Active Comparator|Control group|Health education
9712192|NCT04617301||Group 1. Internal root resorption (IRR)|Internal root resorption is the progressive destruction of intraradicular dentin and dentinal tubules along the middle and apical thirds of the canal walls as a result of clastic activities. It is seen as a radiolucent area around the pulpal cavity, usually of incisors and mandibular molars. The various etiological factors suggested for internal root resorption include traumatic injury; infection and orthodontic treatment.
9712193|NCT04617301||Group 2. external cervical resorption (ECR)|"Cementum is considered to protect the underlying root dentin from being resorbed. It is broadly accepted that damage to or deficiency of this protective cementum layer below the epithelial attachment exposes the root surface to osteoclasts, which then resorb the dentin.~Clinical sign; Located in cervical region of tooth Pink spot might be noted by patient/dentist Tooth usually responds positively to vitality tests unless there is pulpal involvement (in very advanced cases) Spontaneous and profuse bleeding on probing Sharp, thinned out edges around the resorptive cavity"
9712194|NCT04617301||Grup 3. external replacement resorption (ERR)|external replacement resorption also known as trauma-induced resorption - and this resorption may occur in teeth that also have external inflammatory resorption. This review will not discuss external replacement resorption in detail but it will be mentioned where relevant as both types of resorption may occur in some cases. This is because replacement resorption is a consequence of the same injuries that typically cause external inflammatory resorption - such as intrusion and avulsion where there is significant damage to the external root surface during the injury, as well as sometimes during the repositioning/ replantation of the tooth.
9712195|NCT04616989|Experimental|Psycho-education intervention arm|Participants will receive psycho-education materials
9712196|NCT04616989|Active Comparator|Comparator arm|Participants will receive COVID-19 leaflets
9712197|NCT04617054|Experimental|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106|
9712198|NCT04617132||Online Mindfulness Group|Families with PPDA receiving evidence-based MBCT/MBSR intervention
9712199|NCT04617327|Experimental|Experimental : Short Course Pre-operative RadiothErapy|"As part of the planning process, you need to undergo a CT Simulation.It is special type of CT scan used to measure and design the radiation fields to precisely target the tumor.It is done at the Radiation Oncology Department at the MUHC. Some patients may be asked to also undergo an MRI Simulation, and the CT simulation. You may asked to provide a blood sample to ensure good kidney function prior to the CT and MRI scans. Both CT and MRI simulations are considered standard of care.~Once the simulation studies are done, there is about a 2 week waiting period for radiation planning prior to starting the radiation treatments.~The hypofractionation technique will be delivering five fractions (one fraction delivered every 2nd day) of 7 Gy daily of external beam radiotherapy (EBRT) over a period of one and half weeks for a total of 35 Gy. The treatment should last approximately 30 minutes. Once treatments are done, there is a 4 to 6 week wait for surgery."
9712200|NCT04617119|Experimental|Conventional physical therapy treatment and IMT|"The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.~In addition, the patient will receive inspiratory muscle training (IMT) by using a threshold IMT device. Patient will ask to use the device twice daily. In each time, patient will perform 3 sets of 10 breaths with 1-minute rest between sets.~Exercise intensity will start with 10 % of pre-measured maximal inspiratory pressure.~Once the patient successfully completed 30 breath twice a day, the exercise load will increase 5% more in the subsequent training session.~This treatment protocol will perform daily for 2 weeks."
9712201|NCT04617119|Active Comparator|Conventional physical therapy|The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
9712202|NCT04616976||convalescent plasma therapy group|the patients received convalescent plasma therapy
9712203|NCT04616976||Control group|the patients with similar situation without convalescent plasma therapy
9712204|NCT04617106|Active Comparator|Conventional Palpation group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using the conventional palpation method.
9712205|NCT04617106|Active Comparator|DNTP group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using USG-guided dynamic needle tip positioning method.
9712206|NCT04616781|Active Comparator|Ketone ester with alcohol consumption|Drink a single dose of ketone ester 1.9 kcal/kg, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
9712207|NCT04616781|Placebo Comparator|Isocaloric dextrose placebo drink with alcohol consumption|Drink a single dose of Isocaloric dextrose placebo drink, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
9712208|NCT04617145|Active Comparator|Aerobic exercise group|Included 30 patients who underwent aerobic training with 50 %-60% of maximum heart rate in the form of cycling by Bicycle ergometer for eight weeks, three sessions/week.
10194856|NCT04633837|Active Comparator|Group 2: ECM Injectable graft|Group 2 will undergo arthroscopic shoulder surgery and receive 2cc of the injectable extracellular matrix injection placed into the glenohumeral joint space via a transtendon approach at the end of the surgery
10194857|NCT04633005|Experimental|Polypill Arm|Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include metoprolol succinate (a beta-blocker), empagliflozin (an SGLT2-inhibitor), and spironolactone (a mineralocorticoid antagonist). Three dose formulations of the pill, varied in metoprolol succinate dose, will be available for up-titration of the beta-blocker dose per ACC/AHA/HFSA guidelines.
9712209|NCT04617145|Active Comparator|Resistive exercise group|Included 30 patients who underwent a resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Sessions were conducted three sessions/week for eight weeks.
9712210|NCT04616742|Experimental|[14C]SHR6390|
9712211|NCT04616911|Active Comparator|Rerouting seton|Placement of seton with rerouting of the fistula tract around the internal anal sphincter
9712212|NCT04616911|Active Comparator|LIFT|Ligation of the intersphincteric fistula tract
10194858|NCT04633005|Active Comparator|Control Arm|Patients will receive GDMT as usually prescribed by their provider. All of the individual components will be available at low- or no-cost to participants as individual pill formulations.
9712213|NCT04616794|Experimental|Cognitive Engagement Group|Participants eligible to enter this group must show low cognitive engagement in cognitively stimulating activities, defined as a score < 22 on the Cognitive Activity Questionnaire (CAQ)
9712214|NCT04616794|Experimental|Physical Activity Group|Participants eligible to enter this group must have a low level of physical activity defined as less than 600 MET-min/week (~150 minutes/week) of moderate to vigorous physical activity (MVPA), measured using the International Physical Activity Questionnaire - short form (IPAQ-SF)
10194859|NCT04624945||SICU cohort|150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. Frequency of blood sampling will be stipulated atday 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples.
9712215|NCT04616794|Experimental|Diet Group|Participants eligible to enter this group must have a low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian Mediterranean Diet Scale (MDS).
10194860|NCT04623398|Experimental|Lithium|"Li+ is an FDA (NDA: 016834) and ANSM (AMM 3400931376339) approved drug. There are two lithium salts that are marketed in France, Teralithe LI (cp 250mg) and Teralithe LP (cp 400mg).~The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials."
10194861|NCT04623398|Placebo Comparator|Placebo|"Capsules containing lactose monohydrate in all points resembling the capsules of active ingredients.~Capsules of pla62.5 mg, pla125 mg and pla250 mg (pla=placebo)"
9712216|NCT04616794|Experimental|Multi-modal Group|Participants eligible to enter this group must be eligible for at least two of the three single-arm conditions.
9712217|NCT04616638|Experimental|RT-POWER Intervention|Six familiarization sessions and 20 RT-POWER sessions.
9712218|NCT04616638|Active Comparator|Control Intervention|Six control familiarization sessions and 20 traditional RT sessions.
9712219|NCT04616872|Experimental|Methotrexate-LDE|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
9712220|NCT04616872|Placebo Comparator|Placebo-LDE|Lipid nanoparticle (LDE)
9712221|NCT04616729|Experimental|GnRH agonist Depot form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix or Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 3.75 mg Depot form will be used for final oocyte maturation. Ganirelix/Cetrorelix 0.25mg daily (in the morning) will resume for 7 days from the evening of the day of oocyte retrieval onwards. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval.
10194862|NCT04619225|Experimental|Group 1: Dominant Hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and routine clinical monitor on non-dominant hand
9712222|NCT04616729|Active Comparator|GnRH agonist Daily form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix/Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 0.2 mg Daily form will be used for final oocyte maturation. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval. The first administration of Triptorelin 3.75mg depot will be scheduled on the first day of the menstrual cycle after oocyte retrieval. To prevent the flare-up produced by the GnRH agonist, daily doses of 0.25mg of Ganirelix/Cetrorelix will be given for seven days.
9712223|NCT04616703||BMI < 25 kg/m2|Those with NFAT and BMI < 25 kg/m2.
9712224|NCT04616703||BMI 25-30 kg/m2|Those with NFAT and BMI 25-30 kg/m2.
9712225|NCT04616703||BMI > 30 kg/m2|Those with NFAT and BMI > 30 kg/m2.
9712226|NCT04617015|Experimental|Ipratropium bromide|All subjects will receive ipratropium bromide HFA and will have spirometry performed before and after ipratropium.
9712227|NCT04617028|Experimental|Jaktinib|Participants will receive Jaktinib plus placebo to match Hydroxycarbamide.
9712228|NCT04617028|Active Comparator|Hydroxycarbamide|Participants will receive Hydroxycarbamide plus placebo to match Jaktinib.
10194863|NCT04619225|Experimental|Group 2: Non-Dominant Hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and routine clinical monitor on dominant hand
10194864|NCT04596657|Experimental|Intervention|
10194865|NCT04596657|No Intervention|Control|
10194866|NCT04588051|Experimental|Cabozantinib|
10194867|NCT04560777|Experimental|experimental arm|CO-OP intervention
10194868|NCT04560296|Experimental|Community-based E-Health Program|The intervention group will consist of 80 participants who will engage in Community-based E-Health Program.
10194869|NCT04560296|Active Comparator|usual self-management and follow up with doctors/nurse|The participants will receive the usual self-management and follow up with doctors/nurse as planned.
9712229|NCT04616859|Experimental|Alcohol and Energy Drink (AmED)|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml"
9712230|NCT04616859|Active Comparator|Alcohol and Energy drink Placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)"
9712231|NCT04616859|Active Comparator|Alcohol placebo and Energy drink|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL"
9712232|NCT04616859|Placebo Comparator|Alcohol placebo and Energy drink placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL"
9712233|NCT04616755|Active Comparator|Bonded retainer 13-23|This group have bonded retainer behind six front teeth in the maxilla to keep front teeth stable.
9712234|NCT04616755|Active Comparator|Bonded retainer 12-22|This group have bonded retainer behind four front teeth in the maxilla to keep front teeth stable.
9712235|NCT04616755|Active Comparator|Vacuum-formed retainer|This group have Vacuum-formed retainer covering all erupted teeth in maxilla to keep front teeth stable
9712236|NCT04616937|Active Comparator|Galacto-oligosaccharides (GOS) Group|Daily dose of GOS over 4 weeks
9712237|NCT04616937|Placebo Comparator|Placebo group|Daily dose of maltodextrin over 4 weeks
9712238|NCT04616716|Experimental|1|"Drug:FMTN fasted in P1,low-fat diet in P2,high-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after low-fat diet in period 2,FMTN administration after high-fat diet in period 3"
9980104|NCT01388452|No Intervention|Standard of Care|"Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for dried blood spot DNA PCR testing, number the sample, and transport it to the central laboratory for processing. If the patient is PD positive then the patient will be offered ART initiation prior to hospital discharge.~Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an outpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end."
9980105|NCT01388465|Experimental|Mobile phone text message Intervention|Daily assessments with feedback about (1) filling prescription and (2) number of doses taken
9980106|NCT01388465|No Intervention|Control|No TM queries or feedback
9980107|NCT01388504|Experimental|sodium nitrite|
9980108|NCT01388504|Placebo Comparator|placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes
9980109|NCT01388517|Active Comparator|Calcitriol|Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions
9980110|NCT01388517|Active Comparator|Tacrolimus|Treatment for the relief of hypopigmented pityriasis alba lesions
10194870|NCT04557124|Experimental|USS|social cognitive training
10194871|NCT04557124|Active Comparator|MovingForward|problem solving training
10194872|NCT04550546|Experimental|Nystatin treatment|Participants will be given 1-week supply of nystatin suspension (6ml 600,000 U/mL) and be instructed to rinse the mouth with nystatin for 1 minute and spit out the suspension, at a frequency of four times a day, for a duration of 1 week. Participants will be instructed to spit the suspension after the oral rinse and do not swallow the suspension, and they will be instructed to avoid eating, drinking and brushing their teeth for 30 minutes.
10194873|NCT04547257|Experimental|Treatment|Extracorporeal therapy with Seraph 100 blood filter
10194874|NCT04547257|No Intervention|Control|patients receive antibiotics only as standard of care
10194875|NCT04540718|No Intervention|Control|Participants in this group continues with their sedentary behavior
9712239|NCT04616716|Experimental|2|"Drug:FMTN high-fat diet in P1,fasted in P2,low-fat diet in P3~FMTN administration after high-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after low-fat diet in period 3"
9712240|NCT04616716|Experimental|3|"Drug:FMTN low-fat diet in P1,high-fat diet P2,fasted in P3~FMTN administration after low-fat diet in period 1,FMTN administration after high-fat diet in period 2,FMTN administration in fasted condition in period 3"
9712241|NCT04616716|Experimental|4|"Drug:FMTN fasted in P1,high-fat diet P2,low-fat diet in P3~FMTN administration in fasted condition in period 1,FMTN administration after high-fat diet in period 2,FMTN administration after low-fat diet in period 3"
9712242|NCT04616716|Experimental|5|"Drug:FMTN low-fat diet in P1,fasted P2,high-fat diet in P3~FMTN administration after low-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after high-fat diet in period 3"
9712243|NCT04616716|Experimental|6|"Drug:FMTN high-fat diet in P1,low-fat diet P2,fasted in P3~FMTN administration after high-fat diet in period 1,FMTN administration after low-fat diet in period 2,FMTN administration in fasted condition in period 3"
9712244|NCT04616586|Experimental|Arm A|Drug - Siltuximab
9980111|NCT01388517|Placebo Comparator|Petrolatum|Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions
9980112|NCT01388556|Experimental|Tango|Twice weekly tango dance classes for 12 months.
9980113|NCT01388556|No Intervention|Control Group|
10194876|NCT04540718|Active Comparator|Exercise only|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and will sit in the exercise laboratory for 15 minutes whilst the experimental group uses the sauna.
9712245|NCT04616586|Other|Arm B|Comparator - Normal Saline
9980114|NCT01388582|Active Comparator|Combined oral contraceptive|10 women will receive COC during breastfeeding
9980115|NCT01388582|Active Comparator|Levonorgestrel intrauterine system|10 women will receive a LNG-IUS during breastfeeding
9712246|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System|
9712247|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery using OMNI surgical System|
9712248|NCT04616573|Active Comparator|iStent Inject implantation|
9712249|NCT04616521|Experimental|Asymmetric DBS group|In this arm, a one-staged combined unilateral STN and contralateral GPi DBS will be implanted into PD patients. For postural instability and gait difficulty (PIGD)-dominant patients, the GPi in the side contralateral to the leg with longer step length will be targeted. For tremor-dominant (TD) patients, the STN in the side contralateral to the body side that mostly affected will be targeted. For PD patients of mixed type, the choice of target will depend on the judgement of a multidisciplinary team based on clinical features.
9712250|NCT04616469|Active Comparator|Root canal treatment using RaCe rotary system|Canal shaping using RaCe rotary system powered with endodontic motor with real time torque monitoring capacity
9712251|NCT04616469|Experimental|Root canal treatment using TruNatomy rotary system|Canal shaping using TruNatomy rotary system powered with endodontic motor with real time torque monitoring capacity
9712252|NCT04616508|Experimental|Behavioral testing|
9712253|NCT04616261|Experimental|SET-HIGH|High volume speed endurance training
9712254|NCT04616261|Experimental|SET-LOW|Low volume speed endurance training
9712255|NCT04616222||CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery
9712256|NCT04616222||Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery
9712257|NCT04616313||c-cigarette never users|Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.
9712258|NCT04616313||former or current c-cigarette users|Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.
9712259|NCT04616313||never smokers|Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.
9712260|NCT04616495||Liver transplanted patients|
9712261|NCT04616092|Experimental|FERINJECT Group|Patients with FERINJECT injection
9712262|NCT04616092|No Intervention|Observation Group|Patients without FERINJECT injection
9980116|NCT01388582|Active Comparator|Implanon|10 women will receive Implanon during breastfeeding
9980117|NCT01388582|Active Comparator|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding
9980118|NCT01388595|Active Comparator|Fluticasone Proprionate|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
9980119|NCT01388595|Active Comparator|Salmeterol|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
9980120|NCT01388595|Placebo Comparator|placebo|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
9980121|NCT01388608||RA patients receiving etanercept|Patients with active rheumatoid arthritis (RA) who are eligible to a treatment with etanercept.
9980122|NCT01388621|Experimental|Experimental arm (A):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
9980123|NCT01388621|Active Comparator|Standard arm (B):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
9712265|NCT04616482||Digital therapeutic carbohydrate restriction (TCR) program|The intervention involves 12 weeks of online/app-based behaviour change coaching. Each week the participant focuses on a different aspect of healthy eating habits designed to cut sugar and refined carbohydrates while encouraging and providing resources for lower-carbohydrate food options. Education is done through short videos and information sheets. Participants set goals and complete worksheets/tasks based on their individual goals.
9712266|NCT04616209|Experimental|PB103 (donor-derived NK cells) infusion|Cohort 1: 0.5×10^9，Cohort 2:1×10^9 or Cohort 3: 1.5×10^9 cells
9712267|NCT04616404|Active Comparator|Intervention Group|
9712268|NCT04616404|Placebo Comparator|Control Group|
9712269|NCT04616157|Experimental|ICBT-I|The ICBT-I treatment program is a web-based intervention consisting of six chapters/sessions that adolescents go through during six consecutive weeks.The program starts with psychoeducation regarding sleep disorders and the rationale for a cognitive behavioral intervention. The main focus for the treatment is behavioral interventions, mainly sleep restriction and stimulus control. The intervention also addresses problem solving, maintenance of treatment gains, relapse prevention and relaxation techniques. Caregivers will not actively participate in the treatment. During the treatment phase participants will be in contact with a therapist through standardized forms in the program.
9712270|NCT04616053|Experimental|Intervention group|IMPACT intervention
9712271|NCT04616053|No Intervention|Control group|Usual care
9712272|NCT04616287|Experimental|dementia with Lewy bodies|
9712273|NCT04616287|Active Comparator|Alzheimer disease|
9712274|NCT04616287|Sham Comparator|healthy elderly subjects|
9712275|NCT04616391|No Intervention|MDI group:|The patient continues MDI treatment as per routine procedures
9980124|NCT01388634||Study cohort|Patients with prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
9980125|NCT01388634||control group|Patients without prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
9980126|NCT01388660|Experimental|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin
9712276|NCT04616391|Experimental|AHCL group|The patient will use MiniMed 780G AHCL system
9712277|NCT04616430|Placebo Comparator|Control|Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
9712278|NCT04616430|Active Comparator|Topical Endoxifen 10mg/breast/day|10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
10194877|NCT04540718|Experimental|Exercise and sauna|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and incorporates sauna bathing (heat therapy) immediately after exercise.
10194878|NCT04537715|Experimental|Part 1: Tazemetostat and Itraconazole Drug Interaction Cycle 1|Subjects may discontinue from the study after completion of Cycle 1 or can continue (Cycle 2+ onwards) Tazemetostat treatment at the recommended therapeutic dose (oral 800 mg Tazemetostat twice daily [12 hours apart]) in 28 day cycles. Safety and tolerability will be assessed throughout the subject's participation.
9712279|NCT04616430|Active Comparator|Topical Endoxifen 20mg/breast/day|20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
9712280|NCT04615975|Experimental|Intervention|Patients will receive 21 days of a very low carbohydrate mediterranean ketogenic diet with phytoextracts and 7 days of a low carbohydrate diet
9712281|NCT04616144|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal lenticule implantation as allogenic implant that will be taken from myopic patients to implant in hyperopic patients with high astigmatism using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity (far, intermediate, near vision) and secondary objective to stabilize(decrease) high astigmatism by reducing K values. Fresh corneal lenticule implantation as allogenic implant that we took from myopic patients (-5.0D) to implant in hyperopic patients (+4.0 D +3.0cyl) according to high K2 values. The stromal pocket diameter was 8 mm, 4mm super incision and 130-µm cap thickness.
9712282|NCT04616040||unresectable locally advanced/recurrent or metastatic esophageal cancer|
9712283|NCT04615897|Experimental|Experimental aging|The subjects received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
9712284|NCT04615897|No Intervention|Control Aging|The subjects doesn´t received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
9712285|NCT04615884|Experimental|Chinese herbs formula: Shu Yu Wan|Participants will receive Shu Yu Wan capsules, to take 3 times daily for 6 weeks.
9712286|NCT04615884|Placebo Comparator|Placebo|Participants will receive capsules to take 3 times daily for 6 weeks.
9712287|NCT04616118|Experimental|Phone|Participants randomized to this arm will receive usual care via telephone only
9712288|NCT04616118|Experimental|Video|Participants randomized to this arm will receive usual care via video call
10194879|NCT04537715|Experimental|Part 2:Tazemetostat and Rifampin Drug Interaction Cycle 1|Subjects may discontinue from the study after completion of Cycle 1 or can continue (Cycle 2+ onwards) Tazemetostat treatment at the recommended therapeutic dose (800 mg Tazemetostat twice daily [12 hours apart]), in 28 day cycles. Safety and tolerability will be assessed throughout the subject's participation.
10194880|NCT04529395|Experimental|Aromatherapy group|
10194881|NCT04529395|Active Comparator|Control group|
10194882|NCT04523181|Active Comparator|Antroquinonol with SOC|Antroquinonol in a dose of 100 mg (1 capsule) administered twice daily (BID) orally, for 14 days.
10194883|NCT04523181|Placebo Comparator|Placebo with SOC|placebo (1 capsule) administered twice daily (BID) orally, for 14 days.
10194884|NCT04523129|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
10194885|NCT04523129|Placebo Comparator|Vehicle Ophthalmic solution|Vehicle only
9712289|NCT04615741|Experimental|Trauma Informed Yoga|Participants will receive 8 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
9712290|NCT04615741|Experimental|Trauma Informed Psychotherapy|Participants will receive 8 x 90 min group-based psychotherapy sessions, delivered synchronously over Zoom.
9712291|NCT04615741|No Intervention|Control|These participants will not receive an intervention.
9712292|NCT04615910|Experimental|Verapamil|Patients treated with Verapamil within the Ver-A-T1D trial
9712293|NCT04615910|Placebo Comparator|Placebo|Patients treated with placebo within the Ver-A-T1D trial
9712294|NCT04615962|Experimental|SNG100|Combination of low potency steroid with hydrating and moisturizing agents
9712295|NCT04615962|Active Comparator|Hydrocortisone|This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).
9712296|NCT04615962|Active Comparator|Mometasone furoate|This medication is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.
9712297|NCT04615793|No Intervention|CONTROL GROUP|The control group will receive flexibility exercises and strength training focusing on the trunk and lower limb muscles, postural control exercise in different positions and different surfaces and general endurance training . Control group will receive intervention in the form of five minutes warm up followed by 12 minutes of walking at their comfortable pace and concluded with a five minutes cool down
9712298|NCT04615793|Experimental|EXPERMINTAL GROUP|The experimental group will obtain Pilate exercises, consist of strengthening,stretching and coordinated exercises on lower and trunk muscle
9712299|NCT04615637|Experimental|Sensors|All subjects will follow the same experimental procedure: a recording using classical MEG followed by a recording in the same condition with the OPM He4 prototype.
9712300|NCT04615663||face-to-face patients|During this visit, the investigator will complete the SMI score.
9712301|NCT04615663||Email patients|this visit at M0 + 7d will correspond to the emailing of the Mc_QoL and Burden_MCD questionnaires completed by the patient.
9712302|NCT04615767|Experimental|D-chiro-inositol|Volunteers are orally administered with 1 g D-chiro-inositol per day (two doses in capsules of 500 mg each, one in the morning and the other one in the evening) for thirty days
10194886|NCT04520932|Experimental|RFA treatment efficacy|PNETs ablation by radiofrequency treatment (1 to 3 sessions)
10204750|NCT05064098||Pre-Surgical Breast Cancer Patients|Adult female patients newly diagnosed with stage 0-III breast cancer seen as a surgical consultation from 06/01/2019 to present.
10194887|NCT04503525||COVID 19 hospitalized patients|COVID 19 infected patients admitted in conventional hospitalization for less than 72 hours
9712303|NCT04615780|Experimental|mouthwash with green tea group|The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily.
9712304|NCT04615780|Placebo Comparator|mouthwash with tap water group|The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
10194888|NCT04501432||Cardiac Rehabilitation|Participants will be recruited from a group of patients who regularly attended group-based cardiac rehabilitation exercise training at the study site until COVID-19 restrictions (national lockdown) came into force on 16th March 2020.
9712305|NCT04615702||application of recent guidelines in the management of acute biliary pancreatitis|all patients subjected to the following: Confirmation of the diagnosis of acute pancreatitis, Diagnosis of the cause either biliary or not, Severity scoring and Evidence based management regarding Initial management, Intervention as indicated, Prevention of recurrence and Follow up
9712306|NCT04616001|Experimental|IVIG|IVIG 0.5gram/kg IVPB using actual body weight daily x 4 days
9712307|NCT04615988||Participants being treated with immunotherapy|Participants who are to receive standard of care immunotherapy targeting PD-1 or PDL1 as treatment for malignancy
10194889|NCT04499131|Experimental|I: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and vaginal natural micronized progesterone 400mg/12h
10194890|NCT04499131|Experimental|II: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/24h
10194891|NCT04499131|Experimental|III: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/12h
10194892|NCT04499131|Experimental|IV: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and a combination of subcutaneous natural progesterone 25mg/24h + vaginal natural micronized progesterone 400mg/24h
10194893|NCT04499131|Experimental|V: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and intramuscular natural progesterone 50mg/24h
10194894|NCT04499131|Active Comparator|Natural menstrual cycle|Natural menstrual cycle (without any exogenous steroid hormone Treatment)
10194895|NCT04483791|Other|DynamX Novolimus Eluting Coronary Bioadaptor System|DynamX use in de novo coronary artery lesions
10194896|NCT04482569|Experimental|Single Ascending Dose Study|Six XNW4107 doses ( 50-1250 mg ), each administered as a single dose with 60-minute IV infusion
10194897|NCT04482569|Experimental|Multiple Ascending Dose Study|Three XNW4107 doses (167-500 mg), each administered as 60-minute IV infusion every 6 hours for 7 days
10194898|NCT04482569|Experimental|Multiple Dose Study of XNW4107 +Imipenem/Cilastatin|500 mg XNW4107 co-administered with imipenem/cilastatin as 60-minute IV infusion every 6 hours for 14 days
10194899|NCT04482556|Other|Q-NRG+ Indirect Calorimetry Device|Q-NRG+ device will be compared to current V(max) device in each enrolled patient in subsequent, alternating fashion.
10194900|NCT04482556|Other|V(max) Encore Indirect Calorimetry Device|V(max) Encore device, currently institution's standard device, will be compared to Q-NRG+ device in each enrolled patient in subsequent, alternating fashion.
10194901|NCT04469595|Active Comparator|ILUVIEN Arm|Intravitreal ILUVIEN
9712308|NCT04615598|Experimental|Action observation group|
9712309|NCT04615598|Placebo Comparator|Placebo group|
9712310|NCT04615585|Experimental|Aloe Vera + Scaling and root planing|
9712311|NCT04615585|Active Comparator|Scaling and root planing|
9712312|NCT04615611|Experimental|salbutamol|salbutamol, 800 microgram from metered dose inhaler
9712313|NCT04615611|Placebo Comparator|placebo|placebo
9712314|NCT04615507|Experimental|Test/Control/Control|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Test/Control/Control)
9712315|NCT04615507|Experimental|Control/Test/Test|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Control/Test/Test)
9712316|NCT04615728||pre-COVID cohort|Patients recruited from 1st November 2019 to 9th March 2020
9712317|NCT04615728||COVID cohort|Patients recruited from 10th March 2020 to 5th July 2020
9712318|NCT04615468|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
9712319|NCT04615481|Experimental|Elliptical Training Group|Total 30 minutes of elliptical cross training, including warm up, progressive elliptical training and cool down.
9712320|NCT04615481|Experimental|Ergo-metric Training Group|Total 30 minutes of ergometric training
9712321|NCT04615546|Experimental|Remote Phase: PBH Patients|Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days.
9980127|NCT01388660|Active Comparator|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)
10194902|NCT04469595|Active Comparator|Aflibercept Arm|Intravitreal aflibercept
10194903|NCT04454684|Experimental|AN-R: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
10194904|NCT04454684|Experimental|BED: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
10194905|NCT04454684|Experimental|Caregivers: Psychotherapy|Psychotherapy alone
10194906|NCT04454424|Experimental|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
10194907|NCT04454424|Experimental|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
10194908|NCT04454424|Experimental|Arm C: Child-Pugh C|Participants with severely impaired hepatic function (Child-Pugh C)
10204751|NCT05064098||Breast Cancer Survivors|Breast Cancer Survivors
9712322|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. May include participants from the Remote Phase or newly enrolled participants.
9712323|NCT04615546|No Intervention|In-Clinic Phase: Surgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
10194909|NCT04454424|Experimental|Arm D: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
10194910|NCT04454424|Experimental|Arm E: Normal hepatic (Matched to C)|Participants with normal hepatic function matched to Arm C
10194911|NCT04453293|Experimental|BCG vaccine|Freeze-dried Glutamate Bacillus Calmette-Guérin (BCG) (Tokyo 172) vaccine
10194912|NCT04453293|Placebo Comparator|Placebo|Vaccine diluent [sodium glutamate]
10194913|NCT04440462|Experimental|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
10194914|NCT04440462|Active Comparator|Sterile water|2 ml of sterile water
10194915|NCT04379063||Canadian physicians during COVID-19 pandemic|Any physician who is practicing in Canada during the COVID-19 pandemic, whether they hold a full, provisional, or post-graduate in-training license.
10194916|NCT04364269|Experimental|VIT-2763 Once a day (QD)|"Participants will be assigned to receive VIT-2763 once a day (QD) in a total daily dose of 60 mg or 120 mg depending on their body weight.~The study medication (VIT-2763 and/or matching placebo) will be administered for all participants twice a day to maintain the blind."
10194917|NCT04364269|Experimental|VIT-2763 Twice a day (BID)|Participants will be assigned to receive VIT-2763 Twice a day (BID) in a total daily dose of 60 mg or 120 mg depending on their body weight.
10194918|NCT04364269|Placebo Comparator|Placebo|Participants will be assigned to receive Placebo, Twice a day.
10194919|NCT04352140|Experimental|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand
10194920|NCT04352140|Experimental|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand
10194921|NCT04352127|Experimental|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and routine clinical monitor on non-dominant hand
10194922|NCT04352127|Experimental|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and routine clinical monitor on dominant hand
10194923|NCT04338828|Experimental|Treatment Group|Inhaled nitric oxide
10194924|NCT04338828|Placebo Comparator|Control Group|Inhaled supplemental oxygen
10194925|NCT04337021|Active Comparator|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving-related stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
10204752|NCT05056779|Experimental|Nemolizumab|
10204753|NCT05056779|Experimental|Placebo|
10204754|NCT05055596|Experimental|Gentle Movement|
10204755|NCT05055596|Active Comparator|Health Coaching|
9712324|NCT04615546|No Intervention|In-Clinic Phase: Nonsurgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
9712325|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients with indwelling gastrostomy tube|Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed.
9712326|NCT04615858|Active Comparator|Genepro Generation 3|1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
9712327|NCT04615858|Active Comparator|Whey Protein|1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
9712328|NCT04615559|Experimental|contrast enhanced ultrasound|CEUS will be performed at one month post-op, six months post-op and at one year.
9712329|NCT04615416|Experimental|Emotion Regulation Training via Telehealth|All participants will receive 9 sessions of Emotion Regulation Training delivered via telehealth. These individualized therapy sessions are 1-hour in length and occur semi-weekly over the course of four weeks.
9712330|NCT04615403|Experimental|Implantation and Exchange|Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.
9712331|NCT04615195||children between 8 and 15 years old|answer to the CRIES 13 questionnaire
9712332|NCT04615351|Active Comparator|Metformin|Metformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose
9712333|NCT04615351|No Intervention|Routine Care|Discharge information about maintaining a healthy diet
9712334|NCT04615026||COVID 19 patients|all patients with positive SARS-CoV 2 swap
9712335|NCT04615234||Experimental: Treated with Genetic Test Guide (TGTG)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder guided with the pharmacogenomic test (PGs)
9712336|NCT04615234||Control: Treated as Usual (TAU)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder.
9980128|NCT01388673|Experimental|ACE Stapler procedure|ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy
9712337|NCT04615013|Experimental|Treatment (NBTXR3, IMRT, chemotherapy)|Patients receive NBTXR3 IT or IN on day 1. Beginning day 15, patients undergo IMRT 5 days per week for 6 weeks for a total of 28 fractions, in the absence of disease progression or unacceptable toxicity. Concurrent with IMRT, patients receive a chemotherapy regimen consisting of either fluorouracil and oxaliplatin with or without leucovorin, oxaliplatin and capecitabine, docetaxel and fluorouracil with or without leucovorin, docetaxel and paclitaxel, or carboplatin and paclitaxel per physician discretion.
9712338|NCT04615156|Experimental|Evaluation for adverse events from 18F-2-fluoro-2-deoxy-D-glucose produced by a new manufacturer|
10204756|NCT05049343|Experimental|SAGE-904 then Placebo|SAGE-904 in combination with ketamine, followed by a washout period, followed by placebo in combination with ketamine.
9779440|NCT05306197|Active Comparator|Active Comparator: RT-Based Attention Bias Modification (toward threat)|"A dot-probe task of 160 trials. Trials begins with a fixation cross (+), on which the participant is asked to focus (500ms). Then two face stimuli (one angry one neutral) are presented above and below the fixation cross (500ms). After the stimuli disappear, a target probe (right- or left-pointing arrowhead) appears in place of one of the face stimuli. The participant is asked to indicate which target probe was presented using a predetermined key. The target probe will remain on the screen until response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the threat location (angry face). Thus, over multiple trials, learning is expected to occurs such that the threatening face predicts the location of the target probe, thereby achieving the desired change in attention pattern."
9779441|NCT05306197|Placebo Comparator|Non-Contingent Feedback Training|This condition is also based on the eye-tracking task (see Experimental Arm) with a fundamental change - The music chosen by the soldier will play continuously without any reinforcement for looking at threat or neutral faces.
9785182|NCT01245049|Active Comparator|REPEVAX GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
9785183|NCT01245062|Experimental|GSK1120212|MEK inhibitor
9785184|NCT01245062|Active Comparator|Chemotherapy|Investigator Choice of DTIC or paclitaxel
9785185|NCT01245062|Experimental|Crossover|MEK inhibitor after documented progression on Chemotherapy Arm
9785186|NCT01245101|Experimental|Raltegravir and then Observation|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
9785187|NCT01245101|Active Comparator|Observation and then Raltegravir|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
9785188|NCT01245140|Active Comparator|Active|to receive study drug (alitretinoin, 20 patients)
9785189|NCT01245140|Placebo Comparator|Placebo|to receive placebo (dummy drug, 10 patients)
9785190|NCT01245270|Experimental|Bilberry capsule first, then control cap|"Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
9785191|NCT01245270|Experimental|Control capsule first, then bilberry cap|"Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
9785192|NCT01245283|Active Comparator|Wait-list Non-exercise Control (CON)|Subjects will continue to participate in their normal activities and clinical care during the four month study period if assigned to this group.
9785193|NCT01245283|Active Comparator|Concentric Focused RX (CRX)|Training protocol for 1 set of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
9785773|NCT01259596|Active Comparator|Cognitive behavioral therapy|Cognitive-behavioral therapy consists of psychoeducation, relaxation techniques, cognitive therapy, problem-solving, thought stopping, behavioral activation, exposure, coping with pain, sleep, and relapse prevention
9980129|NCT01388686||INABBRA|Participating intensive care units of hospitals in the INABBRA alliance.
10204757|NCT05049343|Placebo Comparator|Placebo then SAGE-904|Placebo in combination with ketamine, followed by a washout period, followed by SAGE-904 in combination with ketamine.
10204758|NCT05041322|Placebo Comparator|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
10204759|NCT05041322|Active Comparator|Buspirone|"Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.~Other Names:~Buspar"
9712339|NCT04615312|Experimental|a CDK4 / 6 inhibitor and a MEK inhibitor|Participants will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment
9712340|NCT04614961||Patients with overweight, obesity or after bariatric surgery|Patients with overweight, obesity or after bariatric surgery
9712341|NCT04615169|Experimental|multi-component cognitive intervention using simulated everyday tasks (MCI-SET)|the 12-week intervention, 2 hours weekly session of MCI-SET.
10194926|NCT04337021|No Intervention|Usual Care|CGs in this arm will be contacted telephonically once by a CM. After a brief needs assessment, the CM will provide contact information for appropriate VA (e.g., local CSP clinicians) and non-VA community resources/services. CGs will be sent brochures for the national VA CSP. Information on both the program's website (which includes links to training, education, resources, and outreach programs for CGs) and the national CG hotline number will be included in the mailed packet. After this initial contact, CGs in this group will only be contacted again 4 and 9 months after baseline for administration of follow-up research assessments. CGs will be encouraged to seek medical, psychological, social support, and social services that are available to them through VAMCs or any other non-VA/community source. CGs in the SOS group will be offered similar information.
10204760|NCT05031624|Experimental|CDX-0159|Subjects will receive a single dose of CDX-0159
9712342|NCT04615260|Other|Single arm subject is own control|Posterolateral fusion is bilateral, patients will receive the Nanobone graft on the right side of their spine and the local bone graft on their left side.
9712343|NCT04614883|Other|Asymptomatic patients or Healthy volunteers|Patient with no symptom of COVID-19 infection but for whom a PCR test needs to be done because he has been in contact with a COVID-19 positive person
9712344|NCT04614883|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
9712345|NCT04614883|Other|Symptomatic patients with negative PCR but with seroconversion within 4 to 8 weeks|Patients with symptoms of COVID-19 and whose PCR result is negative at inclusion but presents a seroconversion within 4 to 8 weeks post inclusion
9712346|NCT04614831||Psoriasis and Psoriatic Arthritis|The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis
9712347|NCT04614844|Experimental|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
9712348|NCT04614844|Active Comparator|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
9712349|NCT04615221|Other|Graft recipient|During each of the visits carried out with a cervical biopsy as part of the uterine transplant project, samples will be taken.
9712350|NCT04615221|Other|Living donor|The donors will benefit from a blood sample and a sample of the vaginal microbiota during the transplant under general anesthesia or after it during a consultation scheduled as part of the uterine transplant protocol.
9712351|NCT04615221|Other|Witness|10 non-menopausal control patients will each have a cervical biopsy (at different times of the cycle) and a smear, samples of the vaginal microbiota and a blood sample. Among the 10 controls, 4 patients will have to undergo a hysterectomy for which multiple staged biopsies and samples uterine microbiota will be produced.
9712352|NCT04615052|Experimental|Exercise group|
9712353|NCT04615052|No Intervention|Control group|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
9712354|NCT04615130|Experimental|Intervention|Patients will undergo 6 weeks of outpatient rehabilitation.
9712355|NCT04615130|No Intervention|Control|Patients will receive no intervention throughout the 6 weeks period.
10204761|NCT05031624|Placebo Comparator|Normal Saline|Subjects will receive a single dose of normal saline
9712356|NCT04615078|Experimental|"Telemonitoring group"|Medical Telemonitoring in Non-Invasive Ventilation
9712357|NCT04615078|No Intervention|"Standard of Care group"|Standard medical follow-up: standard home Non-Invasive Ventilation service, with transmission of their ventilator data without analysis leading to alerts
9712358|NCT04614896|Experimental|Ultrasound for measuring DOI in tongue tumors|All patients included with tongue carcinoma
9712359|NCT04614857|Experimental|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
9712360|NCT04614727|Experimental|polymeric nano calcium fluoride containing varnish, NANO SEAL.|
9712361|NCT04614727|Other|Casein Phosphopeptide Amorphous Calcium Phosphate Containing Fluoride Varnish,MI varnish|CPP-ACP with 5%NaF
9712362|NCT04614792|Experimental|active treatment|open label experimental treatment
9712363|NCT04614818||pulmonary lymphoepithelioma-like carcinoma|The primary site of lymphoepithelioma-like carcinoma locates in the lungs.
9712364|NCT04614818||lymphoepithelioma-like carcinoma of thymus|The primary site of lymphoepithelioma-like carcinoma locates in the thymus.
9712365|NCT04614818||lymphoepithelioma-like carcinoma of salivary glands|The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.
9712366|NCT04614818||lymphoepithelioma-like carcinoma of stomach|The primary site of lymphoepithelioma-like carcinoma locates in the stomach.
9712367|NCT04614818||lymphoepithelioma-like carcinoma of esophagus|The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.
9712368|NCT04614818||lymphoepithelioma-like carcinoma of liver|The primary site of lymphoepithelioma-like carcinoma locates in the liver.
9712369|NCT04614818||lymphoepithelioma-like carcinoma of ovaries|The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.
9712370|NCT04614818||lymphoepithelioma-like carcinoma of cervix|The primary site of lymphoepithelioma-like carcinoma locates in the cervix.
9712371|NCT04614818||lymphoepithelioma-like carcinoma of tonsil|The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.
9712372|NCT04614415|Experimental|Treatment group|group 1 will be treated with autocrosslinked Hyaluronic acid
9712373|NCT04614415|Placebo Comparator|control group|group 2 treated with placebo (isotonic saline solution).
9980130|NCT01388699||migraine group|female migraineurs with aura
9712374|NCT04614376||Control Group|The control group participants have not been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
9712375|NCT04614376||Case Group|The case group participants have been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
9712376|NCT04614636|Experimental|FT538 Monotherapy|FT538 monotherapy in subjects with r/r AML
9712377|NCT04614636|Experimental|FT538 in Combination with Daratumumab|FT538 in combination with daratumumab in subjects with r/r MM
9712378|NCT04614636|Experimental|FT538 in Combination with Elotuzumab|FT538 in combination with elotuzumab in subjects with r/r MM
9712379|NCT04614623|No Intervention|Current Diabetes Management Continued|Continued Insulin Delivery Method and Current Clinic Care of Diabetes
9712380|NCT04614623|Experimental|Video Conferencing+Current Insulin Delivery|Patients continue current insulin delivery modality but receive enhanced clinical management support via video conferencing link by diabetes coordinator
9712381|NCT04614623|Experimental|AHCL pump without Video Conferencing|Patients switch to use of an Advanced Hybrid Closed Loop pump without Video Conferencing standard support
9712382|NCT04614623|Experimental|AHCL pump+Video Conferencing|Patients will use Advanced Hybrid Closed Loop pump with enhanced clinical support via video conferencing
9712383|NCT04614389|Other|CEUS and SWE|CEUS & SWE
9712384|NCT04614610|Active Comparator|Lidocaine|Lidocaine 1.5mg/kg (Max: 200mg) in dextrose 5% 100mL over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
9712385|NCT04614610|Placebo Comparator|Placebo|Dextrose 5% 100mL (placebo) over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
9712386|NCT04614688|Experimental|Patient Education Group|Patients in this group will undergo the standard physician-led informed consent process and then be provided with an interactive patient education platform for hysteroscopy on a tablet available in the clinic for up to one hour of time. After the patient has explored the patient education platform, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
9712387|NCT04614688|No Intervention|Standard Consent Group|Patients in this group will undergo the standard physician-led informed consent process only. After they have consented to the surgery, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
9712388|NCT04614519|Active Comparator|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
9712389|NCT04614519|Experimental|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
9712390|NCT04614584|Experimental|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
9712391|NCT04614584|Placebo Comparator|Placebo|Placebo 30 mg PO Daily x 4 days
9712392|NCT04614675|Active Comparator|Transarticular lateral release (TALR)|TALR The first toe is pulled distally for access into the lateral aspect of first MTPJ. A No.15 beaver blade is advanced from the medial incision laterally to divide the lateral capsule vertically and adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
9980131|NCT01388699||control group|healthy women without headache syndrome
9980132|NCT01388712|Placebo Comparator|Placebo|
10194927|NCT04331288|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.
9712393|NCT04614675|Active Comparator|Percutaneous lateral release (PCLR)|PCLR A 0.5 cm stab wound is made at lateral aspect of first MTPJ. A No. 15 beaver blade is advanced into the lateral side of MTPJ with a quarter of the blade inside the joint and verified with fluoroscope. The blade is turned laterally to face the adductor hallucis tendon. The adductor tendon is divided with lateral movement of the blade and varus manipulation of proximal phalanx. A click is heard as adequate release of adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
9712394|NCT04614311|Active Comparator|Intervention|Intra-articular corticosteroid injections into active joints
9712395|NCT04614311|No Intervention|Comparator|No intra-articular injections
9712396|NCT04614285|Experimental|Partial excavation|The treatment will be performed after applying local anesthetic according to individual needs. The intervention group will receive partial removal of the carious lesion; In the inner part of the lesion, the caries removal will be limited to reach leathery or slightly soft dentin by probing. The restorations will be placed according to evidence based methods and the material used according to the operators material of choice.
9712397|NCT04614285|Active Comparator|Complete excavation|The treatment will be performed after applying local anesthetic according to individual needs. The control group will receive the same treatment procedure as the intervention group, but the excavation procedure will include total removal of the carious tissue. The total caries removal will be ensured with hardness on probing and the visual examination. Photographs will be used as benchmark.
9980133|NCT01388712|Active Comparator|Probiotics|Lactobacillus reuteri DSM 17938
9980134|NCT01388725||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
9980135|NCT01388725||Sepsis|SIRS + infection
9980136|NCT01388738|Active Comparator|cerebrolysin|IV
9980137|NCT01388738|Active Comparator|L-Alpha glycerylphosphorylcholine|IV
9980138|NCT01388738|Active Comparator|citicoline|IV and per os
9980139|NCT01388751|No Intervention|no night splinting|
9980140|NCT01388751|Active Comparator|night splinting|Night Splinting for 4 weeks after removal of initial cast
9980141|NCT01388764|Experimental|L-arginine|
9980142|NCT01388829|Experimental|formulation comparison|formulation comparison
10194928|NCT04325958|Placebo Comparator|Placebo cannabis|Participants will drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC)
9712398|NCT04614298|Experimental|KHK4827 210 mg SC (Subcutaneous)|Single SC administration
9712399|NCT04614298|Placebo Comparator|Placebo SC|Single SC administration
9712400|NCT04613986|No Intervention|Standard|Standard of care according to our current in house SOP
9712401|NCT04613986|Experimental|Treatment|Standard of care according to our current in house SOP + Therapeutic Plasmaexchange (d1, 3, 5)
9712402|NCT04614051|Experimental|Cellgram-DC|Cellgram-DC is injected Subcutaneous injection near the upper arm lymph nodes
9712403|NCT04614259|Experimental|intravenous analgesia|
9712404|NCT04614259|Experimental|infraorbital nerve block|
9712405|NCT04613908|Active Comparator|standard care or usual rehabilitation|It will consist of the usual treatment performed by the intensive care physiotherapist, it will be applied every day that the study lasts.
9712406|NCT04613908|Experimental|neuro muscular electro stimulation|They received 5 sessions per week (except weekends) of neuromuscular electrostimulation of 30 minutes duration. Also, every day that the study is carried out in the morning and in the afternoon, the subjects will receive the usual treatment performed by the intensive care physiotherapist.
9712407|NCT04613908|Experimental|early mobilization protocol|Throughout the duration of the study, an early mobilization protocol will be applied to apply a specific treatment based on different levels of treatment for each subject of the group; It differs from the usual procedure in protocolized progression according to the objectives reached by the patient, unlike the usual treatment, where the progression is in accordance with the clinical criteria of the treatment professional.
9712408|NCT04613921||Group 1|patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)
9712409|NCT04613921||Group 2|patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD > 20) at the time of listing (n=500)
9712410|NCT04613921||Group 3|patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)
9712411|NCT04613947|Active Comparator|Control|The group with standard (written and verbal) information without multiple intelligence test
9712412|NCT04613947|Experimental|Visual/Spatial:|The group with higher visual intelligence according to the multiple intelligence test results and watch video. Also, will given with a written informed consent document
9712413|NCT04613947|Experimental|Verbal/Linguistic|The group with higher verbal/linguistic intelligence according to the multiple intelligence test results and verbally informed in detail about the operation. lso, will given with a written informed consent document
9712414|NCT04613947|Experimental|Bodily/Kinesthetic|The group with higher bodily/kinesthetic intelligence according to the multiple intelligence test results and informed with a dental model. lso, will given with a written informed consent document
9712415|NCT04614077||A( saline)|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
9712416|NCT04614077||B specific solution|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
9712417|NCT04614025|Experimental|PLX-PAD Treatment|"PLX-PAD 300 million cells (20 million/mL) administered via 15 IM injections (1 mL each).~Single administration in addition to best standard medical care."
10194929|NCT04325958|Experimental|Active cannabis|Participants will drive the simulator before and after smoking an active cannabis cigarette (12.5% THC)
10194930|NCT04313361||Smokers or Recent Smoking Quitters who Have lung Surgery|The enrolled eligible participants, that is smokers or recent smoking quitters, will be assessed for the current smoking status and smoking cessation attempts during the perioperative period, to describe postoperative complications (PCs) including postoperative pulmonary complications (PPCs) following a lung surgery, and to describe the smoking cessation methods and services participants received from their health care professionals (HCPs) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (COPD), a pulmonary lesion (example nodule, ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in China.
10194931|NCT04302558|Experimental|Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while the blood flow to the leg is reduced by a blood flow restriction cuff.
10194932|NCT04302558|Sham Comparator|SHAM Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while a blood flow restriction cuff is applied but inflation pressure will be limited
10204762|NCT05028673|Experimental|Lu AG06466 Capsule, Fasted State|Participants will receive 1 capsule of Lu AG06466 in a fasted state.
9712418|NCT04614025|No Intervention|Control Group|Best standard medical care
9712419|NCT04614181|Experimental|Carbohydrate and protein loading|Nestle Resource drink
9712420|NCT04614181|Active Comparator|Usual care|Usual fracture care as determined by clinical team
9712421|NCT04614012|Experimental|hyperimmune plasma|treated with hyperimmune plasma
9712422|NCT04614194|Experimental|Arm A: Abemaciclib + Letrozole|Patient will take twice daily abemaciclib and daily letrozole (Arm A) for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
9712423|NCT04614194|Experimental|Arm B: Letrozole|Patient will take daily letrozole only (Arm B) according to treatment arm for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
9712424|NCT04614155|Experimental|Screening (questionnaire, health education, self-collection)|Participants complete questionnaires, take part in a health education session, and receive HPV self-collection kit.
9712425|NCT04613960|Active Comparator|Magnesium arm|patients randomized to magnesium therapy at a fixed daily dose of 64 mmol reconstituted in 0.9% saline via continuous intravenous infusion for 14 days after hemorrhage onset, or until discharge or death if it occurred.
9712426|NCT04613960|Placebo Comparator|Placebo arm|patients randomized to placebo therapy with 0.9% saline (without active component) via same protocol.
9712427|NCT04614272|Experimental|active prayer group|the active prayer group will mediate over an active type of prayer
9712428|NCT04614272|Experimental|passive prayer group|the passive prayer group will mediate over a passive type of prayer
9712429|NCT04614272|Sham Comparator|control group|the control group will read a poem
9712430|NCT04614129|Experimental|Low-Dose CT|Low Dose CT Scan of the Chest
9712431|NCT04614090||99 warfarin patients|warfarin patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture. All patients on warfarin were reversed if necessary to INR≤1.5 before surgery using vitamin K and/or four-factor prothrombin complex concentrate (PCC)
9712432|NCT04614090||99 patients without anticoagulants|As a 1:1 ratio control group matched for age, gender and surgical implant. All patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture.
9712433|NCT04613895|Experimental|fed state group|just after a meal
9712434|NCT04613895|Experimental|fasted state group|before a meal
9712435|NCT04613999|Other|Single Arm|Subjects will receive regimens 50 mcg, 100 mcg and 150 mcg in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
10194933|NCT04283500|Experimental|BUP treatment arm|Subjects will be given BUP 32mg in 2 doses, and observed for at least 90 minutes after the 2nd dose. The whole process will take a total of about 3-4 hours including the consenting process. Subjects will be asked questions and be examined repeatedly. Subjects will have 4 in-person visits and a phone call in addition to review of medical records.
9712436|NCT04613609|Placebo Comparator|Placebo|E-cigarette containing no nicotine.
9712437|NCT04613609|Active Comparator|Nicotine|E-cigarette containing nicotine
9712438|NCT04613531||Participants with PD|patients with clinically diagnosed Parkinson's disease
9712439|NCT04613531||Participants without PD|participants clinically diagnosed without Parkinsons' Disease
9712440|NCT04613687|Experimental|URGOBD001|Compression bandage
9712441|NCT04613700|Active Comparator|Secretin|
9712442|NCT04613700|Placebo Comparator|Placebo|
9712443|NCT04613752|Experimental|experimental group|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
9712444|NCT04613583||SAFeR Fetuses|Different maternal lifestyle factors: smoking, BMI, social deprivation, alcohol use, medicines. Depends on specific subproject analyses.
9712445|NCT04613635|Experimental|Stratafix|
10194934|NCT04277507|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
10204763|NCT05028673|Experimental|Lu AG06466 Tablet, Fasted State|Participants will receive 1 tablet of Lu AG06466 in a fasted state.
10204764|NCT05028673|Experimental|Lu AG06466 Tablet, Fed State|Participants will receive 1 tablet of Lu AG06466 in a fed state (high-fat meal).
9712446|NCT04613635|Active Comparator|Vicryl|
9712447|NCT04613544||Atrial Fibrillation|Atrial fibrillation diagnosed patients.
9712448|NCT04613778|Experimental|Laser acupuncture|Laser acupuncture with knee-chest position
9712449|NCT04613778|No Intervention|No intervention|usual care with knee-chest position
9712450|NCT04613856|Active Comparator|Current Best Practice - 237 mL water bolus|
9712451|NCT04613856|Experimental|New Intervention - 500 mL water bolus|
9712452|NCT04613765||Non-migrants|"53 non-migrant patients will be enrolled. Non-migrants will be defined as the group of native-born persons with a Belgian nationality or with a foreign nationality but with both parents native-born."
9712453|NCT04613765||Migrants|"60 migrant patients will be enrolled. This group will include both First Generation (FG) migrants defined as the group of foreign-born persons and Second Generation (SG) migrants defined as people native-born but with either a foreign nationality or with one or both parents foreign-born."
9712454|NCT04613869|Experimental|High-dose esketamine group|After the operation, 5 mg esketamine was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 45mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/kg , Background dose 2ug/kg/h, single dose 4ug/kg/time
9712455|NCT04613869|Experimental|Low-dose esketamine group|After the operation, esketamine 2.5mg was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 22.5mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/ kg, background dose 2ug/kg/h, single dose 4ug/kg/time
9712456|NCT04613869|Placebo Comparator|Control group|PCIA formula: 6mg of hydromorphone + 10mg of tropisetron into 100ml of 0.9% sodium chloride injection, the first dose is 20ug/kg, the background dose is 2ug/kg/h, and the single dose is 4ug/kg/time.
9712457|NCT04613726|Placebo Comparator|IV 10 ml normal saline|Control group consisted of patients receiving IV 10 ml normal saline.
9712458|NCT04613726|Active Comparator|IV 8 mg ondansetron in 10 ml of normal saline|This group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline,
9712459|NCT04613726|Active Comparator|IV 3 mg granisetron in 10 ml of normal saline|This group consisted of receiving IV 3 mg granisetron diluted in 10 ml of normal saline.
9712460|NCT04613713|Experimental|Somatocognitive physiotherapy|Somatocognitive therapy is a multi-modal physiotherapy intervention utilized for women with longstanding chronic pelvic pain and provoked vestibulodynia developed at the beginning of the 2000s as a collaboration between the department of psychosomatic medicine, Oslo University Hospital (OUH) and department of physiotherapy (OsloMet)
9712461|NCT04613713|Active Comparator|Treatment as usual|The participants randomized to the treatment as usual group will follow available treatment options based on the current recommendations from Vulva clinic at Oslo University Hospital, a center that is specialized in treatment of vulvar conditions.
9712462|NCT04613557|Experimental|CYAD-211|Infusion post preconditioning non-myeloablative chemotherapy
9712463|NCT04613804|Experimental|Toripalimab group|Toripalimab 240mg ivgtt Q21d
9712464|NCT04613258|Active Comparator|SCAR Porridge Group|There were 22 subjects in the intervention group (I) who received 50 g of SCAR porridge once per day, along with dietary counseling.
9712465|NCT04613258|Active Comparator|Counseling Group|21 subjects in the control group (C) who only received dietary counseling
9712466|NCT04613102|Experimental|interventional arm, phase 2|"All participant of phase 2 will receive CBD cream for their chronic wound treatment.~This is an open-label part of the study."
9712467|NCT04613102|Experimental|Interventional arm, phase 3|"Each participants of the phase 3 will receive the active study medication (AVCN583601) during the entire study treatment period on the one of his body sides, and placebo cream - on the other body side simultaneously (left/right). So, each participant will be his own control.~The research support pharmacy will randomize, which side of the body participant should apply CBD cream on, and provide two jars with the study medications, labeled accordingly ( Left /Right)."
9712468|NCT04613193|Active Comparator|Strict BP intervention group|SBP < 120 mmHg and a reduction in SBP of >= 15 mmHg
9712469|NCT04613193|Other|Conventional BP control group|In patients < 75 years: SBP = 135 mmHg In patients >/= 75 years: SBP = 145 mmHg
9712470|NCT04613167|Experimental|Alirocumab|The first group of patients will receive 150 mg of alirocumab every two weeks subcutaneously for 6 months
9712471|NCT04613167|Experimental|Evolocumab|the second group of patients will receive evolocumab 140 mg every two weeks subcutaneously for 6 months
9712472|NCT04613167|Experimental|Control group|Control group will be included in the treatment after 6 months. During this time, the control group will not receive treatment with alirocumab or evolocumab, only standard guidelines-based treatment
9712473|NCT04613141|Sham Comparator|Mobility-plus|"Mobility-plus is a pseudo placebo comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease."
9712474|NCT04613141|Experimental|WalkingTall-PD|WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
9980143|NCT01388842|Placebo Comparator|Placebo|Controls will receive small pulses of placebo study drug via the INOpulse delivery system. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
10194935|NCT04253782|Experimental|Team Intervention Arm|Recovery coaches and trained health educators will team together and meet with participants (remotely/electronically and/or by phone or in person, when appropriate) at least twice and for a maximum of 7 times. This includes access to mediation, trained mental healthcare providers, and educational resources.
9712477|NCT04613245||Patient with asthma|
9712478|NCT04613271|Experimental|Group 1|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
9712479|NCT04613271|Active Comparator|Group 2|Administration Group 2: Azithromycin 500 mg once a day for 5 days.
9712480|NCT04613206|Experimental|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.7 mL HD-IIV (60µg of each influenza antigen) 28-42 days apart
9712481|NCT04613206|Experimental|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.5 mL SD-IIV (15µg of each influenza antigen) 28-42 days apart
9712482|NCT04613206|Experimental|One Dose High Dose Quadrivalent Inactivated Influenza Vaccine|one dose of 0.7 mL HD-IIV (60µg of each influenza antigen) followed by placebo 28-42 days later
9712483|NCT04613232|Experimental|Apple Watch|The research intervention is continuously monitoring of heart rate and physical activity (minimum 12h/day) with a smartwatch which is connected to a smartphone.
9712484|NCT04613284|Experimental|Endostar combined Radiation|
9712485|NCT04613310|Other|Saliva and nasopharyngeal swabs|One patient will have 4 swabs taken, 2 saliva for PCR and RDT, 2 nasopharyngeal for PCR and RDT
9712486|NCT04613024|Experimental|Experiment|Topamax randomized group
9712487|NCT04613024|Active Comparator|Control|Gabapentin randomized group
9712488|NCT04612998|Sham Comparator|Comparator group|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
9712489|NCT04612998|Active Comparator|Active control group|Active control group consisted of patients performing CSEA in the sitting position.
9712490|NCT04613401||VAD-patients with Telemonitoring|
9712491|NCT04613076|Experimental|"Me cuido y me siento mejor"|Patients in the primary care clinics assigned to the intervention will receive eight sessions of a computer-assisted, psycho-educational intervention delivered by trained therapists; structured telephone calls by social worker to monitor clinical progress and treatment adherence; usual medical care for chronic diseases; and access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles. Study therapists will receive biweekly and monthly supervision by psychologist and psychiatrist, respectively. A monthly meeting will be held between the PCC team and a member of the research team to ensure continuity of care.
9712492|NCT04613076|Active Comparator|Enhanced Usual Treatment|The patients in the primary care clinics assigned to the comparator will receive the usual treatment for depression and their physical conditions -all the guaranteed interventions for people with depression, hypertension, and/or diabetes in primary care, according to the Clinical Guidelines for the Treatment of Depression- and their associated basket of health benefits included in the Regime of Explicit Health Care Guarantees. They will have access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles.
9712493|NCT04613037|Experimental|Treatment arm|Fecal Microbial Transplantation in adults with Atopic Dermatitis
9712494|NCT04612920|Experimental|Study Group|Participants will receive ibuprofen 800mg every eight hours and acetaminophen 1000mg every eight hours, given at the same time, along with oxycodone five mg every six hours PRN for breakthrough pain.
9779442|NCT05306184||ECT group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving ECT as treatment
10204765|NCT05028673|Experimental|Lu AG06466 Tablet + Antacid, Fasted State|Participants will receive 1 tablet of Lu AG06466 dosed in combination with antacid in a fasted state.
9712495|NCT04612920|No Intervention|Standard Group|Participants will receive current OU standard of care therapy which includes ibuprofen 800mg every eight hours as needed (PRN), acetaminophen 1000mg every eight hours PRN, and oxycodone five mg every six hours PRN.
9712496|NCT04612907|Active Comparator|Moderate hypo-fractionation|Radiotherapy to the prostate delivered in 3Gy fractions x 19
9712497|NCT04612907|Experimental|Ultra hypo-fractionation|Radiotherapy to the prostate delivered in 6.1Gy fractions x 6
9779443|NCT05306184||TCA group|110 participants with primary diagnosis of moderate to severe major depressive disorder receiving medication (TCA) as treatment
9779444|NCT05305508|Placebo Comparator|placebo|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
9779445|NCT05305508|Experimental|Calcium Dobesilate|The CaD (Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
9779446|NCT05304546|Experimental|Single Arm MK3475, encorafenib and binimetinib|Intravenous pembrolizumab 400 mg Q6W + oral encorafenib 450 mg QD + oral binimetinib 45mg BID, for the first 4 weeks of the study. Starting week 5, monotherapy pembrolizumab 400 mg Q6W.
10194936|NCT04241549|Experimental|Part 1 (Dose Finding): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
10194937|NCT04241549|Experimental|Part 2 (Dose Expansion): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) will receive cusatuzumab intravenously (IV) at the recommended Phase 2 dose (RP2D) determined in Part 1 in combination with azacitidine subcutaneously (SC) or IV.
9779447|NCT05303909|Experimental|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg (rounded up to the nearest 10mg) diluted in 100mls of 0.9% normal saline infused over 30 minutes via a peripheral vein
9779448|NCT05303909|Placebo Comparator|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein
9779449|NCT05303116||Control|Patients with COVID who are NOT experiencing altered mental status
9779450|NCT05303116||COVID patients|COVID patients who are experiencing confusion,
9779451|NCT05302310||Older adults (1A)|All older adults visiting/contacting the Information and Advice Center
10194938|NCT04225026|Experimental|GC4419|
10194939|NCT04217135|Active Comparator|conventional treatment|This group will receive conventional evidence-based medications with up-titration to maximal tolerable dose. The evidence-based medications include angiotensin converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist, ivabradine and entresto. Which evidence-based medications will be started first depends on the decision of in-charge doctors without strict regulation. However, all evidence-based medications should be up-titrated to maximal tolerable dose. (Excuse me! Up-titration of evidence-based medications in heart failure isn't multiple intervention. Those medications should be prescribed in each heart failure case if no contraindication was noted.)
10194940|NCT04217135|Active Comparator|high-dose hydralazine group|another group will receive low-dose hydralazine initially with rapid up-titration, if no adverse effect including hypotension with worsening low cardiac output sign, skin rash and joint pain occurred. Since the half-life of hydralazine is around 4-6 hours and 3-5 half-life achieves the steady blood concentration, up-titration of hydralazine will be done per 1-2 days. For example, initial dose of hydralazine would be 25 mg tid and the dose would be 50 mg bid next day if no adverse effect occurred. Following this rule, one week is enough to reach high-dose hydralazine with daily dose of 300-400 mg.
9779452|NCT05302310||Older adults (1B)|These older adults will receive the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center
9779453|NCT05302310||Older adults (1C)|This group corresponds to a nested sample of older adults who will receive the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center and will participate in interviews with the research team.
9779454|NCT05302310||Informal caregivers (2)|The informal caregivers of older adults receiving the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center will participate in interviews with the research team.
9779455|NCT05302310||IAC nurse and social worker (3)|The nurse and the social worker who provide the integrated care (intervention) in the Information and Advice Center will participate in bi-weekly meetings with the research team
9779456|NCT05302310||External collaborators (4)|The external collaborators who are involved in the care of the participating older adults and have collaborated with the nurse and the social worker of the Information and Advice Center will complete a survey sent by mail or e-mail.
9779457|NCT05299866|Experimental|S-ketamine group|The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.
9779458|NCT05299866|Placebo Comparator|Control group|The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.
9779459|NCT05298943|Other|Subjects with 4 walking situations|
9779460|NCT05296460|Experimental|dapsone gel and trichloroacetic acid|trichloroacetic acid peeling on right side of face and dapsone gel on left side
9779461|NCT05292521|Experimental|Group A (QOL fact sheet)|Patients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).
9779462|NCT05292521|Active Comparator|Group B (usual care)|Patients receive usual care during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT.
9779463|NCT05291442|No Intervention|control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
9785194|NCT01245283|Active Comparator|Eccentric Focused RX (ERX)|"The Human Dynamics Laboratory features prototype equipment that increases resistance loads during the eccentric phase of the contraction while assistance is provided by the machine during the concentric phase. One set of each exercise - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press."
9712498|NCT04613115||Group A|patients without uremia and variant arteries
10194941|NCT04205838|Experimental|Prevention (anakinra, CAR T-cell therapy)|Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS >= grade 3 receive anakinra SC every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity.
10194942|NCT04189419|Experimental|SCM-AGH|"Ingredient: Allogeneic human bone marrow derived mesenchymal stem cells~Dose: 1x10^6 cells/Kg"
10194943|NCT04189419|Placebo Comparator|Placebo|IV infusion.
9712499|NCT04613115||Group B|patients without uremia, but with variant arteries
9712500|NCT04613115||Group C|patients with uremia ,without variant arteries
9712501|NCT04613115||Group D|patients with uremia and variant arteries
9712502|NCT04613427||Unruptured intracranial aneurysm|Patients admitted at Haukeland University Hospital in the study period for treatment of UIA.
9712503|NCT04613427||Aneurysmal subarachnoid hemorrhage|Patients admitted at Haukeland University Hospital in the study period for treatment of aSAH.
9712504|NCT04612985|Experimental|Procedures with XACT Robotic System|Device: XACT Robotic System The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous lung procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
9712505|NCT04612972|Experimental|Investigational vaccine 1. Wuhan|Inactivated SARS-CoV-2 vaccine (Vero cell); 200WU/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
9712506|NCT04612972|Experimental|Investigational vaccine 2. Beijing|Inactivated SARS-CoV-2 vaccine (Vero cell); 4μg/dose for per human use, 0.5 mL/ dose; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
9712507|NCT04612972|Placebo Comparator|Placebo/Aluminum Adjuvant of Inactivated SARS CoV|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine; Active Ingredient: None; Virus Contents: None; Adjuvant: aluminum hydroxide; Specification: 0.5 mL/ dose, 0.5mL for per human use; Intramuscular injection; Two doses: one dose/21-28 days; 4000 participants per arm
9712508|NCT04612842|Experimental|Motivational Interviewing (MI) goup|The MI experimental group will receive all the same measurements as the control group, and in addition, receive MI-based communication about fall prevention at eight occasions during the 12-month period. MI is an evidence-based communication approach for various health behavior change.
10194944|NCT04182451|Experimental|Meso Wound Matrix and Standard of Care|This is a single arm study
10194945|NCT04178603|Experimental|Acute Exercise Trial|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise. Glucose metabolism is investigated before exercise (basal), during exercise and for 120 min of recovery.
10194946|NCT04178603|Experimental|Insulin Sensitivity post Exercise|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action is investigated by a 120 min euglycemic-hyperinsulinemic euglycemic clamp.
10194947|NCT04171375|Experimental|trans-spinal Electrical Stimulation (tsES)|
9712509|NCT04612842|No Intervention|Control group|The control group participants will only receive study measurements at baseline, 3-, 6-, and 12-months after the benchmark STEADI clinic visit.
9712510|NCT04613180|Placebo Comparator|Group I (control group)|40 patients with obstructive bronchitis who received placebo
9712511|NCT04613180|Active Comparator|Group II|40 patients who received oral montelukast sodium oral, at a dosage of 0.2-0.4 mg/kg/day
9712512|NCT04612894|Experimental|Neoadjuvant Camrelizumab + Apatinib|Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.
9712513|NCT04612881||fitostimoline vaginal pessaries|
9712514|NCT04613414|Experimental|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
9712515|NCT04613414|No Intervention|Usual Care|Scheduled for sleep physician appointment approximately 6 months after home sleep apnea test/triage
9712516|NCT04612959|Experimental|Psychosexual care|The psychosexual caring program will be conducted online psychoeducation as a group intervention. The program includes four sessions with home assignments and home readings papers.
9712517|NCT04612959|No Intervention|Standard care|Standard care includes the information given by the nurse about the treatment methods to be applied once.
9712518|NCT04612777|Experimental|Opening Doors to Recovery|Participants will receive services from the team of three ODR navigators: one professional social worker, one navigator who is a family member of someone with SMI, and one peer navigator with lived experience.
9712519|NCT04612777|Active Comparator|Intensive Case Management or Case Management|Participants randomized to the control group will either receive standard services of Intensive Case Management or Case Management, depending on the services that are available in their county.
9712520|NCT04612933|Experimental|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
10194948|NCT04170972|Experimental|Exercise and vivo insulin stimulation in TBC1D4 gene-variants|Acute exercise and in vivo insulin stimulation in homozygote carriers of a p.ARg684T TBC1D4 gene-variant.
10194949|NCT04170972|Experimental|Exercise and vivo insulin stimulation in matched controls|Acute exercise and in vivo stimulation in none carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant.
10194950|NCT04154904|Experimental|Aerobic exercise|
10194951|NCT04154904|Experimental|Resistance exercise|
9712521|NCT04612933|No Intervention|No intervention|"All appointments, scheduled and non-scheduled are by face-face communication with the health care professionals.~Patients will receive their usual treatment."
9712522|NCT04612634|Experimental|Research Group 1|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
9712523|NCT04612634|Active Comparator|Research Group 2|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
9712524|NCT04612634|Active Comparator|Research Group 3|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
9712525|NCT04612803||IBS-D + dermatographism|IBS-D patients with dermatographism. Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
9712526|NCT04612556||late-onset severe eosinophilic asthma and fixed obstruction|Patients with late-onset severe eosinophilic asthma and fixed obstruction will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
9712527|NCT04612686||Frail|"At screening participants will be classed as frail if their Electronic Frailty Index score is >0.24 and if their Clinical Frailty Scale score is 6. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 3 or more frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as frail.~All participants will receive the same assessment procedures."
9712528|NCT04612686||Pre-frail|"At the point of screening, participants will be classed as pre-frail if their Electronic Frailty Index score is 0.13-0.24 and if their Clinical Frailty Scale score is 4-5. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 1 or 2 frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as pre-frail.~All participants will receive the same assessment procedures."
10194952|NCT04154904|Experimental|High intensity interval exercise|
9712529|NCT04612686||Non-frail|"At the point of screening, participants will be classed as non-frail if their Electronic Frailty Index score is 0-0.12 and if their Clinical Frailty Scale score is 1-2. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting no frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as non-frail.~All participants will receive the same assessment procedures."
9712530|NCT04612595||Group A|Group A are males with CKD stage 1-2.
9712531|NCT04612595||Group B|Group B are males with CKD stage 3-4.
9712532|NCT04612595||Group C|Group C are females with CKD stage 1-2.
9712533|NCT04612595||Group D|Group D are females with CKD stage 3-4.
9712534|NCT04612647|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)-[Parents and Children-Workshop Group]. In addition to the workshops, this group and the home-based group will receive information (activity booklets) and physical education (physical activity)-related equipment.
9712535|NCT04612647|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops, but they will receive the same information (activity booklets) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
9712536|NCT04612647|No Intervention|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks and 3 months after the completion of the 12-week period. Immediately following the follow-up test (3 months after the intervention), participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
9712537|NCT04612543|Active Comparator|Genial Posterior Composite with Polyethylene fiber|The enamel and dentin were conditioned with bonding procedure.After bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus - Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
9712538|NCT04612543|Active Comparator|Genial Posterior Composite|The enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
9712539|NCT04612491||Pre-operative Consultation|
9712540|NCT04612491||No consultation|
9712541|NCT04612699|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+ Placebo 75mg Bid
9712542|NCT04612699|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 50mg*2 Bid
9712543|NCT04612699|Experimental|Jaktinib 100mg Bid|Jaktinib 50mg*2 Bid+ Placebo 75mg Bid
9712544|NCT04612699|Placebo Comparator|Placebo|Placebo 50mg*2 Bid+ Placebo 75mg Bid
9712545|NCT04612465|Experimental|ASC (test arm)|(Autologous Adipose-derived Mesenchymal Stem Cells)
9712546|NCT04612465|Placebo Comparator|Fibringlue|Standard comparator
9712547|NCT04612582|Experimental|Group1|Group1 is the AL amyloidosis patients who have bortezomib-thalidomide-dexamethason-based regimens for their treatment.
9712548|NCT04612582|Experimental|Group2|Group2 is the AL amyloidosis patients who have bortezomib-cyclophosphamide-dexamethason-based regimens for their treatment.
9712549|NCT04612530|Active Comparator|Arm A: Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will start with the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
10194953|NCT04144348|Experimental|mRNA-1653, Adult participants|Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
9712550|NCT04612530|Experimental|Arm B: IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will first receive (an incomplete) IRE of the primary pancreatic tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
9712551|NCT04612530|Experimental|Arm C: CpG + IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), a toll-like receptor ligand (CpG) will be administered into the primary pancreatic tumor. A week later, the patient will receive (an incomplete) IRE of the primary tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
10194954|NCT04144348|Experimental|mRNA-1653 Pediatric participants|Participants will receive 1 of 2 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
10194955|NCT04144348|Placebo Comparator|Placebo, Adult participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
9712552|NCT04612673|Experimental|Treatment|Participants received Sintilimab, 200mg, iv, d1, Q3W,and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
9712553|NCT04612829|Experimental|Intervention- Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic 1 Lozenge after every 2 hours, 5 times a day. Mode of Administration: Oral Duration of Treatment: 5 days
9712554|NCT04612855||Painful post-traumatic trigeminal nerve injuries|Patients presenting with painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
9712555|NCT04612855||Non-painful post-traumatic trigeminal nerve injuries|Patients presenting with non-painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
9712556|NCT04612855||Temporary nerve injuries|Patients with a trigeminal nerve injury with symptom resolution within 3 months after data of trauma.
9712557|NCT04612855||Persistent nerve injuries|Patients with a trigeminal nerve injury and complaints persisting longer than 3 months after the trauma.
10194956|NCT04144348|Placebo Comparator|Placebo, Pediatric participants|Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
10194957|NCT04140942|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual, participants will participate in Virtual Reality Job Interview Training.
10194958|NCT04140942|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but not limited to vocational skill training, and social skill training.
10194959|NCT04133623|Experimental|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
9980144|NCT01388842|Experimental|inhaled nitric oxide|Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air using an INOpulse delivery system for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
10194960|NCT04133623|Active Comparator|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
10194961|NCT04095793|Experimental|ampreloxetine|Participants will receive a single, oral, daily dose of active drug (TD-9855) for 182 weeks.
9712558|NCT04612426|Experimental|Brain-computer Interface-Pedaling Training System|
9712559|NCT04612426|Sham Comparator|Traditional Pedaling Training System|Patients wear the same EEG equipment that only collect data, but not guide training.
9712560|NCT04612439|Experimental|VABB Elite 10G|Vacuum-assisted Elite 10G
10194962|NCT04076020|Experimental|Intervention arm|Receive the relational agent and the AliveCor Kardia for use for 120 days. Participants are directed to use these interventions daily.
10194963|NCT04076020|Active Comparator|Usual care arm|"Receive a brochure on atrial fibrillation that is published by the American Heart Association and a smartphone with the WebMD application.~Participants are directed to use the WebMD application as often as they would like."
9712561|NCT04612439|Active Comparator|BARD 14G CNB|BARD 14G Core needle
10194964|NCT04075994|Experimental|Intervention arm|Receive the relational agent coupled with the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
10194965|NCT04075994|Active Comparator|Usual care arm|Receive a brochure on atrial fibrillation, the WebMD app and the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
10194966|NCT04073238|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
10194967|NCT04073238|Experimental|Repeated low-level red-light therapy|Single vision lens & repeated low-level red-light therapy
10194968|NCT04071704||Patients|Patients who have been or are being treated for sarcoma.
10194969|NCT04071704||Health care professionals|Health care professionals with extensive experience in sarcoma care (medical oncologists, radiation oncologists, surgical oncologists, orthopaedic surgeons, nurse specialists, psychologists, physiotherapists)
10194970|NCT04064411|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide
9712562|NCT04612712|Experimental|Donafenib+ KN046|Donafenib 50mg BID/100 mg BID/200 mg BID orally + KN046 5mg/kg Q3W iv
9712563|NCT04612504|Experimental|Part 1 Cohort 1: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 1, SynOV1.1 will be administered at 3×10^11 VP by IT injection, Q3W.
9980145|NCT01388855|Experimental|Cholecalciferol|Patients were given two cholecalciferol tablets (10,000 IU each) daily for 30 days.
9712564|NCT04612504|Experimental|Part 1 Cohort 2: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 2, SynOV1.1 will be administered at 1×10^12 VP by IT injection, Q3W.
9712565|NCT04612504|Experimental|Part 1 Cohort3: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 3, SynOV1.1 will be administered at 3×10^12 VP by IT injection, Q3W.
9980146|NCT01388855|Placebo Comparator|Placebo|Patients were given two cholecalciferol placebo tablets daily for 30 days.
9712566|NCT04612504|Experimental|Part 2 Cohort 1: SynOV1.1 in combination with Atezolizumab dose escalation|"Recommended dose for combination study (RDCS) of SynOV1.1will be established based on results from Part 1.~SynOV1.1 will be administered intratumorally at 0.5 × RDCS every 3 weeks up to 6 doses. Atezolizumab will be administered at the dose of 1200 mg in 3-week cycles."
9712567|NCT04612504|Experimental|Part 2 Cohort 2: SynOV1.1 in combination with Atezolizumab dose escalation|"Recommended dose for combination study (RDCS) of SynOV1.1will be established based on results from Part 1.~SynOV1.1will be administered intratumorally at RDCS every 3 weeks up to 6 doses. Atezolizumab will be administered at the dose of 1200 mg in 3-week cycles."
9712568|NCT04612504|Experimental|Dose expansion|In dose expansion study, Atezolizumab will be administered intravenously at the dose of 1200 mg and SynOV1.1 will be administered by IT injection every 3 weeks for up to 6 cycles.
9712569|NCT04612517|Experimental|ZP7570|Four ascending doses of ZP7570
9712570|NCT04612517|Placebo Comparator|Placebo|Corresponding volume of placebo
9712571|NCT04612660|Experimental|Specific Education and Dynamic Group|"Motivational group education specifically focused on cervical cancer prevention;~Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;~Engaging community bilingual physicians in cervical cancer screening and referral;~Patient navigation assistance."
9712572|NCT04612660|Active Comparator|General Health Education|Comparison group participants received general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
9712573|NCT04612413|Placebo Comparator|Cohort 1|375 ml Ringer's lactate solution
9712574|NCT04612413|Experimental|Cohort 2|Single IV dose of Allocetra-OTS contain 5x10^9 cells
9712575|NCT04612413|Experimental|Cohort 3|Single IV dose of Allocetra-OTS contain 10x10^9 cells
9712576|NCT04612413|Experimental|Cohort 4|Single or two IV doses of Allocetra-OTS contain 10x10^9 cells in each dose
9712577|NCT04612309||Treated|Patient with colorectal cancer already treated with immunotherapy
9712578|NCT04612127|Experimental|Experimental group - Spinach|"Consumption for 90 days of spinach extract (1000mg)~Four capsules will be consumed per day, two with breakfast and two with lunch."
9712579|NCT04612127|Placebo Comparator|control group Placebo (sucrose)|Four capsules will be consumed per day, two with breakfast and two with lunch.
9712580|NCT04612179||All Comer Patients|All-comer patients (≥80 years) affected by acute coronary syn-drome (NSTE-ACS), stabile angina, or silent angina, who qualify for percutaneous coronary intervention (PCI) according to ESC-treatment guidelines and physicians' clinical routine estimation.
9712581|NCT04612114||Possible OSA|Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.)
9712582|NCT04612140|Experimental|Radiosurgery|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
9712583|NCT04612140|Active Comparator|Repeated catheter ablation|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
9712584|NCT04612257|Experimental|Insulin alone closed-loop|Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
9712585|NCT04612166|Experimental|Intervention|Patients will receive a medication action plan approved by themselves and their primary care providers to reduce their medications. They will also receive check in calls and follow ups from study health coaches to monitor their progress. During health coaching sessions motivational interviewing techniques and patient empowerment strategies will be used by trained health coaches.
9712586|NCT04612166|No Intervention|Control|Will participate in assessments for the study (baseline and 6 month follow up) and will complete 24 months of falls calendars. No intervention will be given to this group, but standard practices of care delivered by the MercyOneSM Health Network.
9712587|NCT04612270|Experimental|Participants for blood collection|The blood samples of all participants will be treated equally according to the study protocol. No intervention in-vivo.
9712588|NCT04612361||non impaired sleep group|about 200-250 patients
9712589|NCT04612361||insomnia group|about 200 patients
9712590|NCT04612361||sleep deprived group|about 200-250 patients
9712591|NCT04612192|Experimental|Active light|active blue-enriched bright light
9712592|NCT04612192|Placebo Comparator|Placebo light|dim red placebo light
9712593|NCT04612062|Experimental|Healthy Subjects (Part A)|
9712594|NCT04612062|Experimental|Atopic Dermatitis (Part B)|
9712595|NCT04611906||Stroke patient|Patients who have acute cerebral ischemic symptoms attributed by cSVD can be recruited into this study. Eligible patients will be screened by Neurologists based on the inclusion and exclusion criteria. The time window for recruitment of the patient is 4 weeks from the qualifying stroke.
9712596|NCT04611958|Experimental|Bupivacaine arm|Participants undergoing ERCP as part of routine clinical care will be consented for this study.
9712597|NCT04611893||Ischemic stroke patient|Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic
9712598|NCT04612205|Experimental|group A|females complain from SUI treated by TECAR and pelvic floor exercises
9980147|NCT01388868|Active Comparator|TOF count guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by No. of response to TOF stimulation
9712599|NCT04612205|Active Comparator|group B|females treated by pelvic floor exercises only
9712600|NCT04612036||Journey II Bi-Cruciate Stabilized|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL resected
10194971|NCT04064411|Active Comparator|abaloparatide-SC|A combination product consisting of the drug abaloparatide in a single-patient-use prefilled pen that delivers 80 μg of abaloparatide as a SC injection
10194972|NCT04063085|Experimental|PROTAHERE group|The PROTAHERE group received intra-pelvic PROTAHERE Absorbable Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
10194973|NCT04063085|Active Comparator|Hyalobarrier group|The Hyalobarrier group received intra-pelvic Hyalobarrier Gel during the scheduled pelvic surgery and be followed for 24 months.
10194974|NCT04063085|Sham Comparator|No treatment group|The no treatment group did not receive any anti-adhesion agent during the scheduled pelvic surgery and be followed for 24 months.
10194975|NCT04063085|Active Comparator|Seprafilm group|The Seprafilm group received intra-pelvic Seprafilm Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
10194976|NCT04063085|Active Comparator|Interceed group|The Interceed group received intra-pelvic Gynecare Interceed (TC7) Absorbale Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
9712601|NCT04612036||Journey II Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with only the ACL resected (therefore PCL retained)
9712602|NCT04612036||Journey II Bi-Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL retained
10194977|NCT04057937|Experimental|Placebo then Apremilast 30mg BID|Participants received matched placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
10194978|NCT04057937|Experimental|Apremilast 30 mg BID then Apremilast 30 mg BID|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
10194979|NCT04042831|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
10194980|NCT04040920|Experimental|Ozone therapy|Ozone application before pits and fissure sealants
10194981|NCT04040920|Active Comparator|Pits and fissure sealants|
10194982|NCT04040907|Active Comparator|XNW3009|
10194983|NCT04040907|Placebo Comparator|XNW3009 placebo|
9712603|NCT04612088|Experimental|Bariatric Multivitamin|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
9712604|NCT04612088|No Intervention|Waitlist|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
9712605|NCT04611984|Experimental|Piezocision|Piezocision was performed on the mesial and distal side of the maxillary right canine tooth which was served as the piezocision group. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
9712606|NCT04611984|Active Comparator|Control|Maxillary left canine served as the control group and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
9712607|NCT04612023|Active Comparator|1 mL NyDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 1 mL NyDYN injection.
9712608|NCT04612023|Active Comparator|2 mL NuDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL NyDYN injection.
9712609|NCT04612023|Placebo Comparator|Placebo of Sterile Saline|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL dose of sterile saline.
9712610|NCT04611867|Experimental|Intervention Arm|"The intervention will be comprised of providing patients with supportive application with integrated PRO consisting of:~Weekly self-reporting of PRO-CTCAE with integrated preparation questionnaire available for staff~Daily monitoring of self-reporting by study staff~Intervention if required based on self-reporting~Reports to oncologists (at consultation)~Information module about treatment, side effects and contact information"
9712611|NCT04611867|No Intervention|Standard Arm|"Standard care for patients will be included in no-intervention arm will consist of the standard procedures at Herlev Hospital, Department of Oncology for monitoring and documenting symptoms, which will be typical of oncology practice. Symptoms will be discussed and documented in the medical record during clinical encounters between patients and their oncologists. Patients will be encouraged to initiate telephone contact between visits for concerning symptoms, i.e. call early and often."
9712612|NCT04611737|Experimental|Experimental group|The researcher interviews with participants for 3 times.
9712613|NCT04611737|No Intervention|Control group|The participants receive usual care.
9712614|NCT04611997|Experimental|Group A|Laparoscopic gastrectomy group with the use of near-infrared imaging (ICG group)
9712615|NCT04611997|Placebo Comparator|Group B|Laparoscopic gastrectomy group without the use of near-infrared imaging (Non-ICG group)
9712616|NCT04611646|Experimental|Heat-suit training|Low-intensity endurance training with heat suit
9712617|NCT04611646|Other|Non-heat-suit training|Low-intensity endurance training without heat suit
10194984|NCT04033003|Experimental|Group ANC|Intervention groups consist of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
10194985|NCT04033003|No Intervention|Stand ANC|Individual standard antenatal care delivered at health facilities in Ghana
10194986|NCT04017962|Experimental|Hematopoietic cell transplantation/HCT|"Participants will be hematopoietic cell transplantation (HCT) recipients with a history of CMV infection. INTERVENTIONAL COHORT: Patients receive letermovir PO QD (or IV over 1 hour for patients unable to receive PO) for 14 weeks in the absence of disease progression or unacceptable toxicity.~OBSERVATIONAL COHORT: Patients undergo collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180."
10194987|NCT03979391|Experimental|Children with CIS or RIS|The detection of supernumerary oligoclonal bands (OCBs) in tears will be performed
9712618|NCT04611854|Active Comparator|ICBT for alcohol misuse: Guidance|In this arm, participants will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
9712619|NCT04611854|Experimental|ICBT for alcohol misuse: Self-Guidance|Participants who select this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol each week and measures of depression and anxiety administered at the beginning of week 5. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation).
10194988|NCT03978702|Experimental|Indication for pancreatectomy|Blood sampling at different time points before and after pancreatectomy
9712620|NCT04611555||CI users|
9712621|NCT04611971|Active Comparator|Active Arm: Benlysta + Candin|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously.
9712622|NCT04611971|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta.
10194989|NCT03975530|Experimental|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it. At 6 months postpartum, and upon completion of the intervention, participants in the treatment group will be asked to participate in brief semi-structured phone interviews.
10194990|NCT03975530|Active Comparator|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
10194991|NCT03937128|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
9712623|NCT04611724|Experimental|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
9712624|NCT04611581||PD patients with apathy|PD patients with apathy according to the diagnostic criteria by Robert et al. 2018
10194992|NCT03937128|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
10194993|NCT03934632|Active Comparator|Postabsorptive|Saline infusion to mimic postabsorptive circulating amino acid concentrations
10194994|NCT03934632|Active Comparator|Postprandial|Amino acid infusion to mimic postprandial circulating amino acid concentrations
10194995|NCT03912532|Experimental|NGM282 Dose 1|Administered by subcutaneous injection
10194996|NCT03912532|Experimental|NGM282 Dose 2|Administered by subcutaneous injection
10194997|NCT03912532|Experimental|NGM282 Dose 3|Administered by subcutaneous injection
10194998|NCT03912532|Placebo Comparator|Placebo|Administered by subcutaneous injection
10194999|NCT03907826|Experimental|PD-1 antibody plus chemoradiotherapy|Patients randomized to this arm will receive three cycles of PD-1 antibody (JS001, 240mg every three weeks) combined with GP chemotherapy, then receive IMRT and PD-1 antibody maintenance for eight cycles.
10195000|NCT03907826|Active Comparator|Chemoradiotherapy|Patients randomized to this arm will receive three cycles of GP chemotherapy, then receive IMRT alone.
10195001|NCT03906240|No Intervention|No intervention|Veterans will access the online portal and complete session measures, but will not be presented with any intervention content (i.e., videos, journaling exercise, and goal setting exercise)
10195002|NCT03906240|Experimental|Moral Elevation Intervention|Moral Elevation Intervention (described in intervention section).
9712625|NCT04611581||PD patients with impulse control disorder|PD patients with a) at least one item >2 or b) at least two items >1 on the hyperdopaminergic subscale of the Ardouin Scale of Behaviour in Parkinson's Disease
9712626|NCT04611581||PD patients without any relevant neuropsychiatric symptoms|PD patients with a score <2 on each item of the Ardouin Scale of Behaviour in Parkinson's Disease
9712627|NCT04611815|Active Comparator|Robotic-assisted total knee arthroplasty|Patients undergoing robotic-assisted total knee arthroplasty with use of Journey II BCS implants
9712628|NCT04611815|Active Comparator|Conventional total knee arthroplasty|Patients undergoing conventional total knee arthroplasty with use of Journey II BCS implants
9712629|NCT04611386||rivaroxaban group|20 rivaroxaban using patients
9712630|NCT04611386||apixaban group|20 apixaban using patients
10195003|NCT03905889|Experimental|Experimental Abemaciclib and Sunitinib|For the dose escalation phase, Subjects will receive a 21-day cycle of continuous oral daily Sunitinib in combination with Abemaciclib every 12 hours for 14 days followed by 7 days off. Using a traditional 3 x 3 study design assessing dose limiting toxicity, if the initial prescribed dosing of these 2 medications (Dose Level 1) is tolerated by the first 3 subjects, the study will pause for a 30 day time period between cohorts to assess toxicity. If no dose limiting toxicity is identified, the next cohort of 3 new subjects will be treated at the next higher dose level (Dose Level 2). If the original cohort treated at Dose Level 1 do not tolerate the combination of medications, the medication regimen will be modified to a lower dose (Dose Level - 1). A dose expansion phase is included which will evaluate the combination of Abemaciclib in combination with Sunitinib when given at the maximum tolerated dose as determined from the from dose escalation phase.
10195004|NCT03901950|Experimental|XNW7201|
10195005|NCT03873272|Active Comparator|Cryotherapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
10195006|NCT03873272|Active Comparator|Compression Therapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
10195007|NCT03873272|Placebo Comparator|Control arm (Loose glove/sock)|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
10195008|NCT03860168|Other|PICU Up! pre- and post-implementation|Each unit will begin in the baseline, usual care phase and then be randomized to implement the PICU Up! program during a set time period, followed by the post-implementation phase.
10195009|NCT03852576|Experimental|Esophagus sprayed with KSP/QRH dimer|Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe
9712631|NCT04611386||edoxaban group|20 edoxaban using patients
9712632|NCT04611386||control group|5 control group patients
9712633|NCT04611828|Experimental|Philips SmartSleep Device|"Participants will be instructed to sleep wearing the SmartSleep device at home for eight weeks, which will include three (3) two-week periods, one each of the following (in randomized order):~continuous fixed interval (ITI): SmartSleep will provide 1 Hz, inter-tone interval stimulation continuous during deep sleep opportunities~block: SmartSleep will provide 5s ON versus 5s OFF,1Hz inter-tone interval stimulation~in-phase adjustable: SmartSleep will provide constant stimulation with tones timed to be delivered during each upstate of the slow wave~Between periods 1 and 2 and between periods 2 and 3, subjects will undergo one week of sham condition during which SmartSleep will record EEG during sleep using a no-volume sham stimulation"
9712634|NCT04611399|Experimental|VR Group|"The treatment for the participants allocated to the VR Group consists of three home-sessions of approximately 30 minutes each, conducted over two weeks (three per week). In each session, participants will be asked to try for about 15 minutes MIND-VR. Subsequently, they will try the virtual relaxation content The Secret Garden."
10195010|NCT03849820|Active Comparator|Robotic-assisted partial nephrectomy|da Vinci surgical robotic assisted partial nephrectomy
10195011|NCT03849820|Active Comparator|Open partial nephrectomy|Open partial nephrectomy surgery
10195012|NCT03847311|Placebo Comparator|Placebos|Subjects will receive sugar pill.
10195013|NCT03847311|Active Comparator|Sulfasalazine|Subjects will receive the active drug.
9712635|NCT04611399|Active Comparator|Non-VR Group|"Participants assigned to this condition will receive the same training protocol of the VR Group without virtual reality. Both psychoeducation and relaxation will be presented on a computer screen. In particular, psychoeducation will be offered through textual material on stress and anxiety, based on content presented within MIND-VR. Relaxation will be induced by watching a non-immersive video of The Secret Garden. In each session, participants will be asked to sit at a desk in front of their PC, in which they will read a presentation on psychoeducational material for 15 minutes, and then they will watch the relaxation video for the next 10 minutes."
9712636|NCT04611399|No Intervention|Waiting List Group|The WL Group will undergo pre- and post-protocol tests without undergoing any treatment.
9712637|NCT04611620||Breast Cancer and Colorectal Cancer Survivors|The purpose of this study is to explore the factors related with cognitive concerns and other symptoms in breast and colorectal cancer survivors.
9712638|NCT04611659|Active Comparator|Information Only|Women in both the control and treatment conditions will complete a baseline survey that includes the Mini-International Neuropsychiatric Interview (MINI),34 a contraceptive use survey,35 and the WHO Quality of Life-Brief (WHO-QOL-B).36 Women in the control group will be provided a color brochure with easy-to-read information about the advantages of LARC. Via this brochure, control group women will be provided no-cost options and corresponding referral information for receiving LARC.
9785195|NCT01245374|Experimental|Nordiflex Norditropin®|Individually adjusted dose administered with Norditropin NordiFlex® for 6 weeks. Dosage depended on age, weight, etiologies and according to the summary of product characteristics (SPC)
9785196|NCT01245387||Macugen|
9785197|NCT01245413|Active Comparator|SenSura Adhesive (device)|Sensura is a commercially available adhesive, that is designed to collect output from a stoma.
10195014|NCT03829657|Experimental|ampreloxetine (Open Label (OL))|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 16 weeks.
10195015|NCT03829657|Experimental|ampreloxetine|After completing the OL, participants randomized to ampreloxetine will receive single, oral, daily dose of active drug for a further 6 weeks.
9712639|NCT04611659|Experimental|Motivational Interviewing and Educational Training (MIET)|Women randomized to the treatment group will complete the baseline survey and receive the same brochure; however, they also will receive structured education regarding unintended pregnancies among women using opioids, potential complications associated with opioid, alcohol, and other drug use, and education on contraceptive use (with an emphasis on LARC). This structured education will be coupled with a brief, initial MI conversation. The interventionist will receive respective patients' MINI for opioids,37 contraceptive survey, and WHO-QOL-B from the research coordinator, and the answers to the survey forms will expedite the conversation around each woman's contraceptive desires.
9712640|NCT04611438|Experimental|CBD|The patient would be on cannabidiol for 24 weeks and would go through laboratory, electroencephalography, and neuropsychological tests before, during, and after intervention.
10195016|NCT03829657|Placebo Comparator|Placebo|After completing the OL, participants randomized to Placebo will receive single, oral, daily dose of placebo for 6 weeks.
9712641|NCT04611698|Experimental|Immediate loading group|Visit 1 Implant surgery + Device loading Baseline Visit 2 Followup examination 2 weeks (2/+ 5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
9712642|NCT04611698|Experimental|2-week loading group|Visit 1 Implant surgery Baseline Visit 2 Device loading 2 weeks (2/+5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
9712643|NCT04611711|Other|decitabine＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine (10mg ivgttqd, d1-5) combined with TQB2450 injection (1200mg ivgtt, d5)
9712644|NCT04611711|Other|decitabine + anlotinib ＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine and Anlotinib (decitabine 10mg ivgtt qd, d1-5; Anlotinib 8mg po.qd, d5-18) combined with TQB2450 injection (1200mg ivgtt, d5), using the traditional 3+3 experimental design (First enroll 3 subjects. If 1 case of DLT is observed, 3 more subjects need to be added to the same dose group to further evaluate the toxicity) to observe DLT to evaluate MTD. The trial starts from the 8mg dose of Anlotinib Start.
9712645|NCT04611685|Experimental|NSAIDs|Parecoxib (iv.) for once & Loxoprofen (po.) for routine use during the first 3 postop. days.
9712646|NCT04611685|Active Comparator|Tramadol|Tramadol (im.) for once & Tramcontin (po.) for routine use during the first 3 postop. days.
9712647|NCT04611932|Experimental|Reference-Reference-Test|
9712648|NCT04611932|Experimental|Reference-Test-Reference|
9712649|NCT04611932|Experimental|Test-Reference-Reference|
9712650|NCT04611672||Patients with stroke|Patients with stroke of all subtypes, with and without different Kind of Lysis therapy
9712651|NCT04611672||Controls|Healthy controls of all Ages above 18 years
9712652|NCT04611412||1 group|Group I consisted of 17 people (16.83%) with a uniform type of obesity
9712653|NCT04611412||2 group|Group II included 38 children with AO, and 20 of them had normal BLOOD pressure
9712654|NCT04611594|Experimental|Fluid restriction|Prescription to ingest approximately 20 ml / kg of ideal weight.
9712655|NCT04611594|No Intervention|Control|Prescription to ingest approximately 30 ml / kg of ideal weight, considered a normal amount of daily water intake.
9712656|NCT04611360|Experimental|Anodal Transcranial Direct Current Stimulation Group|Anodal Transcranial Direct Current Stimulation and Conventional training exercises
9712657|NCT04611360|Active Comparator|Conventional Training Exercises Group|Conventional Training Exercises : Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk
9712658|NCT04611373|Experimental|A|Acetazolamide tablet 25mg/ tablet, 2 tablets a day; Levamisole 25mg/ tablet, 6 tablets/day continuous medication; Continue treatment until the disease progresses
9712659|NCT04611503|Experimental|Subretinal injection of rAAV.hPDE6A|Single subretinal injection of rAAV.hPDE6A
9712660|NCT04611334|Experimental|experimental group|HRV biofeedback
9712661|NCT04611334|No Intervention|control group|routine care
9712662|NCT04611451|Experimental|whole body vibration group|Patients in the WBV exercise group; 24 sessions of TVT exercise 3 days a week (with at least 1 day of rest between each session) was performed under the supervision of a physician for a total of 8 weeks. Patients in the WBV exercise group were also shown a classic lumbar home exercise program and they were asked to apply for 8 weeks
10195017|NCT03823989|Experimental|Promitil 1.25 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.25 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
10204766|NCT05023512|Experimental|Message 1|Participants will be randomized to receive version #1 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
9712663|NCT04611451|Active Comparator|exercise|The second group (control) only received classical lumbar home exercise program.
9712664|NCT04611464||Single-group cross-sectional cohort|"Patients who have previously received off-label prescriptions of misoprostol for lumbar spinal stenosis for any duration and who are willing to provide verbal and informed consent.~Once enrolled, patients will complete the Swiss Lumbar Spinal Stenosis Questionnaire (SSSQ) as well as the Oswestry Disability Index (ODI). The SSSQ will elicit patients' responses specifically related to their usage of misoprostol for lumbar spinal stenosis.~Then their walking tolerance will be assessed by having them walk along a measured walkway of up to 500 feet to determine the onset of their neurogenic claudication symptoms at a certain distance, their claudication distance.~Prescription information on dosage and frequency of misoprostol use, and any reported side effects with use of this medication, and any cessation or stoppage of use of this medication will all be recorded."
9712665|NCT04611347|Active Comparator|Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only ) for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
9785198|NCT01245413|Experimental|Athena adhesive|Athena = new test adhesive. The Athena baseplate is intended for collecting output from a stoma.
9785199|NCT01245439|Experimental|1|
9785200|NCT01245595|Active Comparator|Aminophylline|Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
9712666|NCT04611347|Active Comparator|Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD)for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
9712667|NCT04611256|Experimental|MSC transfusion|
9712668|NCT04611256|Active Comparator|Control|
9712669|NCT04611776|Experimental|Arm A: Atezolizumab + platinum-doublet followed by atezolizumab maintenance|
9712670|NCT04611776|Placebo Comparator|Arm B: Placebo + platinum-doublet followed by placebo maintenance|
10195018|NCT03823989|Experimental|Promitil 1.5 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.5 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
10204767|NCT05023512|Experimental|Message 2|Participants will be randomized to receive version #2 of 2 different versions of a message from the Massachusetts Department of Public Health regarding the COVID-19 vaccination.
9712671|NCT04611308||cases|
9712672|NCT04611308||controls|
9779464|NCT05291442|Experimental|Intervention group|"To integrate Family System Care and Theme Care Action Module to improve resilience, family function, self-efficacy, and quality of life for stroke patients and their caregivers.~First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
9779465|NCT05289960|Other|patients eligible for weaning by spontaneous breathing trial|
9779466|NCT05289960|Other|non invasive ventilation after weaning|
9779467|NCT05289856|Experimental|combination of Avelumab and Cabozantinib|800 mg Avelumab every 2 weeks and 40 mg Cabozantinib daily
9779468|NCT05289622|Experimental|Polyurethane expandable valve stent implant surgery|Valve stent implantation will be performed under general anesthesia with transesophageal echocardiography monitoring, with thoracotomy approach median and circulation aid extracorporeal.
9779469|NCT05289583||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
9779470|NCT05289362|Experimental|Treating pancreatic duct stones by using baskets|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the basket will be used to remove the stones first, and the balloon will replace the basket after 15 minutes to remove any remaining stones. Finally, the effect of the basket will be evaluated.
9779471|NCT05289362|Active Comparator|Treating pancreatic duct stones by using balloons|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, Endoscopic Sphincterotomy or Endoscopic Papillary Balloon Dilatation will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, the balloon will be used to remove the stones first, and the basket will replace the balloon after 15 minutes to remove any remaining stones. Finally, the effect of the balloon will be evaluated.
9779472|NCT05289167|Experimental|Participants with hematological malignancies|Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will receive a combination of cyclophosphamide, known commercially as Cytoxan®, abatacept, known as Orecia® and bortezomib commercially known as Velcade®, to reduce the rate of graft-versus-host disease (GvHD). These medications will be given for GvHD prevention during the transplant process.
9779473|NCT05289154|Experimental|self- applied acupressure plus Qigong plus advice literature|"daily 20 min of self- applied acupressure over 8 weeks on acupuncture points Yintang, LI4, Pe6, ST36, SP6 and depending on further symptoms plus DU23/24 in hyposmia, LU7 in dyspnoea, GB34 in pain conditions, GB20 in headache OR Anmian in sleeping disorders.~The 16 sessions of 45 min Qigong course over 8 weeks will contain live online guided exercises with breathing, stretching and tapping of meridians and exercises such as the crane exercise."
9779474|NCT05289154|Active Comparator|advice literature|advice literature contains naturopathic remedies such as application of massage-oils, use of herbal teas, meditation techniques, breathing exercises for reconvalescence after COVID19.
9779475|NCT05289141||Patients treated by high flow nasal oxygen therapy (Optiflow™)|
9779476|NCT05289141||Patients treated by other non-invasive ventilation or high concentration oxygen masks|
9779477|NCT05288894||Repaired Tetralogy of Fallot|A patient affected by Tetralogy of Fallot (right ventricle outflow obstruction, right ventricle hypertrophy, ventricular septal defect, aortic overriding of the ventricular defect) that already underwent cardiac surgery for the correction.
9779478|NCT05288478|Active Comparator|Group A|First 6 weeks they will use the mouthrinse 5 times a day, following 4 week washout period.
9779479|NCT05288478|Active Comparator|Group A, second period|"After the washout period, the next 6 weeks the will use the mouthrinse twice a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
9779480|NCT05288478|Active Comparator|Group B|First 6 weeks they will use the mouthrinse twice a day, following 4 week washout period
9779481|NCT05288478|Active Comparator|Group B, second period|"After the washout period, the next 6 weeks they will use the mouthrinse 5 times a day.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."
9785201|NCT01245595|Placebo Comparator|Placebo|Normal Saline Placebo
9712673|NCT04611321|Experimental|Phase Ib/II|Patients with advanced CSCC. IBI318 administered intravenously every 2 weeks.
9712674|NCT04610931|Experimental|Cybertherapy|use of cybertherapy (6 sessions) in addition to cognitive behavioral therapy (6 sessions) + pharmacological treatment
9712675|NCT04610931|Active Comparator|Treatment as usual|Treatment as usual is a cognitive behavioral therapy (6 sessions) + pharmacological treatment
9712676|NCT04611061||ARVI and influenza prophylaxis with Kagocel|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.~Group of patients receiving Kagocel for prevention of ARVI and influenza"
9712677|NCT04611061||ARVI and influenza prophylaxis without any antiviral medicines|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
9712678|NCT04610983|Experimental|Control|Control 2 * Gel Encapsulated Algal Oil Capsules (each containing 200mg DHA) Total dose of 400mg DHA.
9712679|NCT04610983|Experimental|Treatment 1 - Semi-Solid food matrix|Vegetable encapsulated algal oil integrated with a semi-solid food product (soup) to deliver 400 mg DHA.
9712680|NCT04610983|Experimental|Treatment 2 - Solid food matrix|Vegetable encapsulated algal oil integrated with a solid food product (extruded snack) to deliver 400 mg DHA.
9712681|NCT04611282|Experimental|Microsurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using microsurgery technique.
9712682|NCT04611282|Active Comparator|Macrosurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using macrosurgery technique.
9712683|NCT04611009|Experimental|motor training|intervention: motor training
9712684|NCT04611009|Active Comparator|awareness training|intervention: mindfulness exercises
9712685|NCT04611048|Experimental|Main study|Several electrophysiological and behavioural tests will be performed to properly diagnose the patients/check that the healthy controls do not suffer of neuropathy.
9712686|NCT04610957|Experimental|The 1st group|included eighty (80) women receiving Clomiphene citrate (CC) in the form of (Clomid 50 mg tablet, Sanofi Aventis, France) at dose (100 mg/day in two divided doses, starting from day 3 to day 7 of the cycle), plus Phytoestrogens (Isoflavonoids) in the form of (RosaFem 800 mg tablet, DeluxLab, Egypt) at dose (1600 mg/day in two divided doses (each dose one tablet), starting from day 3 to day 12 of the cycle
9712687|NCT04610957|Experimental|The 2nd group|included eighty (80) women receiving Clomiphene citrate only, at dose (100 mg/day, starting from day 3 to day 7 of the cycle).
9712688|NCT04611113|Experimental|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
9712689|NCT04611113|Active Comparator|Control nutritional support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
9712690|NCT04611269||Adult, patients with COVID-19 admitted to the ICU requiring mechanical ventilation|"This is a prospective cohort study including patients >18 years RT-PCR positive for SARS Cov-2 admitted to the ICU that require mechanical ventilation. Epidemiological data, comorbidities, previous signs of symptoms of COVID-19. On admission, severity of disease scores, laboratory management data, blood gases and acid-base chemistry,respiratory and mechanical ventilation management,and complications (Development of ARDS, septic shock, acute kidney injury, thromboembolic events, infections and septic shock, will be recorded. If patients die, causes of death will be recorded.Treatments administered by attending physicians will be registered.~Dates of hospital and ICU admission, of death and/or discharge will be recorded.~No intervention will be administered. Follow-up will continue until death or ICU/hospital discharge"
9712691|NCT04611126|Other|Without Ipilimumab|"At Step 1, 6 patients will be treated without Ipilimumab pre tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2.~Depending on the safety and feasibility on step 2, 6 more patients can be included at step 1."
9712692|NCT04611126|Other|With Ipilimumab|"At Step 2, 6 patients will be included. Ipilimumab 3 mg/kg will be administered 2-6 weeks pre tumor harvest.~If no additional SAE/SAR compared to the previous completed pilot study at CCIT-DK is observed additional 6 patients can be included at Step 2. If on the other hand Step 2is not found safe additional 6 patients can be included at Step 1"
9712693|NCT04611178||CIV-ABAO|CIV-ABAO
10195019|NCT03823989|Experimental|Promitil 1.8 mg/kg|two treatment cycles, intravenous infusion of Promitil at a dosage of 1.8 mg/kg delivered at 21 days interval (confirmatory cohort) and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
10195020|NCT03818737|Experimental|Bone Marrow Derived MSCs|Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).
9712694|NCT04611152|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
9712695|NCT04611152|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
9712696|NCT04611165|Experimental|single|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~Prescription dose to PTVs as according to the following schema:~PTV1: 30 - 50 Gy /10 fx, 5Gy fraction dose, 5 days/week (The prescribed dose to PTV will be decided by physician depending on the dose-volume histogram (DVH) constraints of the normal tissues, such as liver, bowel, etc. The detail of DVH constraints of normal tissues are summarized in the following table) PTV2: 30 Gy /10 fx, 3Gy fraction dose, 5 days/week"
10195021|NCT03818737|Experimental|Adipose-derived MSCs|Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).
10195022|NCT03818737|Experimental|Umbilical Cord Tissue (UCT) MSCs|Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.
9712697|NCT04610879|Active Comparator|Carbamazepine plus sleep intervention|
9712698|NCT04610879|Active Comparator|Carbamazepine plus standard care|
9712699|NCT04610879|Active Comparator|Levetiracetam plus sleep intervention|
9712700|NCT04610879|Active Comparator|Levetiracetam plus standard care|
9712701|NCT04610879|Active Comparator|No AED plus sleep intervention|
9712702|NCT04610879|No Intervention|No AED plus standard care|
9712703|NCT04610905|No Intervention|Control group|This group will be asked to maintain their daily routine.
9712704|NCT04610905|Experimental|Reducing sedentary behavior|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours.
9712705|NCT04610905|Experimental|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. Additionnaly they need to be active in periods of at least 10 minutes.
9712706|NCT04610697|Experimental|Cognitive Remediation|"Participants in the cognitive remediation condition will complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
9712707|NCT04610697|Active Comparator|Active control|"Participants in the active control condition will also complete computerised exercises followed by bridging discussions delivered using tele-heath.~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
9712708|NCT04610814||Blood products during transport|Administration of appropriate blood products during transport
9712709|NCT04610814||Standard of Care|Receiving standard prehospital air medical care
9712710|NCT04610580|Experimental|Crossover ALXN1840 Sequence 1|Participants will first receive a single dose of ALXN1840 test formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 reference formulation on Day 1 of Period 2.
9712711|NCT04610580|Experimental|Crossover ALXN1840 Sequence 2|Participants will first receive a single dose of ALXN1840 reference formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 test formulation on Day 1 of Period 2.
9712712|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 1|Participants will receive a single dose of ALXN1840.
9980148|NCT01388868|Experimental|T1/T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T1 twitch height as compared with control (T0)
9980149|NCT01388868|Experimental|T2/ T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T2 twitch height as compared with baseline (T0)
9980150|NCT01388881|Experimental|Music Education|Music education classes take place three times a week, 50 minutes each. These interventional classrooms will make available keyboard and blockflute.
9980151|NCT01388881|No Intervention|Non-intervention|In this arm, children will be not encourage practicing musical activities and will not have musical classes.
9980152|NCT01388959|Experimental|Single arm|
9712713|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 2|Participants will receive a single dose of ALXN1840.
9712714|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 3|Participants will receive a single dose of ALXN1840.
9712715|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 4|Participants will receive a single dose of ALXN1840.
9712716|NCT04610801|No Intervention|No treatment|No treatment given
9980153|NCT01389024|Experimental|Hydroxyurea|treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or ANC <4000
9980154|NCT01389024|Placebo Comparator|Placebo|Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day
9980155|NCT01389037|Experimental|Health Literacy-focused Self-help|
9980156|NCT01389037|Placebo Comparator|Delayed intervention control|
9980157|NCT01389063|Active Comparator|Arm A|HAART of subjects in arm A will be intensified with maraviroc during week 1-8.
9980158|NCT01389063|Active Comparator|Arm B|HAART of subjects enrolled in arm B will be intensified with maraviroc during week 9-16
9980159|NCT01389089|No Intervention|Control group|The Control group received ice gel packs and elevation to reduce edema.
9712717|NCT04610801|Experimental|Treatment|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nosetrils, every 6 hours
9712718|NCT04610801|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nosetrils, every 6 hours
9712719|NCT04610619||RYR1 related malignant hyperthermia/rhabdomyolysis|
9712720|NCT04611243||COVID survivors|
9712721|NCT04611243||Vaccination with CoronaVac vaccine|
9712722|NCT04611243||Vaccination with BionTech vaccine|
9980160|NCT01389089|Experimental|Multi-layer compression bandage|A multi-layer compression bandage was applied to the lower limb and foot of the patient to reduce edema. Additionally, the limb was constantly elevated.
9980161|NCT01389089|Experimental|A-V Impulse compression|An A-V Impulse compression device was used to reduce edema.
9980162|NCT01389115||Liver Cirrhosis|Patient with liver cirrhosis undergoing liver transplant
9980163|NCT01389115||Liver donors|Subjects eligible for organ explant
9980164|NCT01389115||Healthy controls|
9980165|NCT01389141||mid-reproductive age|
9980166|NCT01389141||late reproductive age-1|
9980167|NCT01389141||late reproductive age-2|
9980168|NCT01389154|Experimental|Patients recommended for a lung biopsy.|Patients with a positive diagnosis of a peripheral, less than 3.0 centimeter lung lesion, recommended for bronchoscopic biopsy are eligible to be consented into the study.
9980169|NCT01389167|Experimental|Vivitrol + BDRC|
9980170|NCT01389167|Experimental|Vivitrol + Medical Management|
9980171|NCT01389167|Experimental|Naltrexone (oral)+BDRC|
9980172|NCT01389167|Experimental|Naltrexone (oral) + Medical Management|
9980173|NCT01389180|Experimental|BDRC|
9980174|NCT01389180|Experimental|EC|
9980175|NCT01389180|Other|TAU|
9980176|NCT01389193|Experimental|Ibudilast|
9980177|NCT01389193|Placebo Comparator|Placebo|
9712723|NCT04611243||third dose vaccination with CoronaVac vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
9712724|NCT04611243||third dose vaccination with BionTech vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
9712725|NCT04610970|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
9712726|NCT04610606|Experimental|Multimodal intervention (MM)|Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization (diet + mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids) and relaxation strategies.
9712727|NCT04610606|No Intervention|Standard of care (SOC)|Education on benefits of physical activity and healthy diet, with no specific information.
9712728|NCT04610567|Experimental|MTX-LDE phase 1|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
9712729|NCT04610567|Experimental|MTX-LDE phase 2|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
9712730|NCT04610567|Placebo Comparator|Placebo-LDE phase 2|Lipid nanoparticle (LDE)
9712731|NCT04610541|Experimental|Remdesivir-HU|"Day 1 - single loading dose of remdesivir-HU 200 mg given by intravenous infusion~• Day 2 onwards - 100 mg given once daily by intravenous infusion."
9712732|NCT04610424|Experimental|Cooperative Parent Mediated Therapy|"Cooperative Parent Mediated Therapy (CPMT) is a targeted parent-mediated intervention focused on the ASD core symptoms (Bearss et al., 2015). CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions (Schreibman et al., 2016). The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction. An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals (Valeri et al., 2019)."
9712733|NCT04610424|Active Comparator|Control|Control group
9712734|NCT04610437|Active Comparator|intramedullary reabsorbable fixation system PLLA.|Arthrodesis interphalangeal with intramedullary reabsorbable fixation system PLLA.
9712735|NCT04610437|Placebo Comparator|K-wire|Arthrodesis interphalangeal with kirschner wire
9712736|NCT04610463|Other|Standard|Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
9712737|NCT04610359|Experimental|Stem cell group|Interstitial cystitis patients who receive submucosal injection of hESC-MSCs
10195023|NCT03818737|Active Comparator|Corticosteroid Injection|Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint.
10195024|NCT03810781||Cervical Spondylotic Myelopathy (CSM)|Degenerative cervical myelopathy, encapsulates a cascade of events leading to significant degenerative changes in discs, formation of osteophytes, facet hypertrophy, calcification of the posterior longitudinal ligament and ligamentous flavum with resultant canal stenosis and segmental instability.
10195025|NCT03807401|Active Comparator|Classical prismatic adaptation|Classical prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
9712738|NCT04610450|Experimental|RCI-BE-10|Robot assisted cochlear implant surgery.
9712739|NCT04610294||Aerus air sterilization|Aerus air sterilization system will be used in an operating room, in addition to routine room air filtration
9712740|NCT04610294||Conventional air handling|Only routine room air filtration will be used in an operation room.
9712741|NCT04610281|No Intervention|Control|"Wards without the Inner Garden biofeedback tool"
9712742|NCT04610281|Experimental|Inner Garden|"Wards with the Inner Garden biofeedback tool"
10195026|NCT03807401|Experimental|Virtual prismatic adaptation|virtual prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
10195027|NCT03807401|Experimental|Imaged prismatic adaptation|Imaged prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
9712743|NCT04610385||ileal conduit|
9712744|NCT04610385||cutaneous ureterostomy|
9712745|NCT04610320|Experimental|Daratumumab-SC Injection|"Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
9712746|NCT04610255|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
9712747|NCT04610255|Experimental|Dynamic myofascial release|Experimental group was given Dynamic myofascial release along with the cervical isometrics and muscle stretching
9712748|NCT04610333|Experimental|School teacher training|"Teacher training programme:~MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.~Four-day residental course~3 x 2 seminar days~Modified MBSR programme delivered to the students:~- 1hour group session once a week in 10 weeks taught by the educated teachers on class"
9712749|NCT04610333|No Intervention|Usual practice|
9712750|NCT04610268|Experimental|tDCS group|The anode of tDCS is placed on the occipital lobe and the cathode on the frontal lobe, or the anode of tDCS is placed on the left temporal lobe and the cathode on the right temporal lobe.
9779482|NCT05284500||Pediatric cardiac surgery patients|Patients undergoing pediatric cardiac surgery with cardiopulmonary bypass between 2008 and 2018 at our institution.
9712751|NCT04610073|Experimental|Interactive multimedia training|the intervention group 1 completed the pretest knowledge, attitude, and behavior questionnaire. Then, interactive multimedia was made available to this group. The questionnaire was completed again by the group, one week after completion of training, and then one month afterward.
10195028|NCT03800758|Experimental|Expressive Helping writing|"Writing sessions 1-3: Participants complete one 20-minute expressive writing session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute peer support writing session about 1 week after completion of writing session 3."
9712752|NCT04610073|Experimental|illustrated booklet|First, the intervention group 2 completed the pretest knowledge, attitude, and behavior questionnaire. Then, illustrated booklet was made available to this group. The questionnaire was completed again by the group one week after completion of training, and then one month afterward.
9712753|NCT04610073|Experimental|No Intervention|In the control group, no intervention was performed. Only before the intervention, one week and one month after the intervention, they completed the knowledge, attitude and behavior questionnaires.
9712754|NCT04610008||APON|Retrospective review of routine clinical images from patients with an acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
10195029|NCT03800758|Active Comparator|Factual Writing|"Writing sessions 1-3: Participants complete one 20-minute factual session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute factual writing session about 1 week after completion of writing session 3."
10195030|NCT03798093|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
9712755|NCT04610008||No APON control|Retrospective review of routine clinical images from patients with NO acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
9712756|NCT04610190|Experimental|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
9712757|NCT04609956|Experimental|virtual reality|Experimental arm is a virtual reality headphones
9712758|NCT04609956|Other|standard|Control arm is a usual practice (hydroxyzine + patient music with headphones)
9712759|NCT04610164|Experimental|Group 1: TXA group|Patient will receive 1 gram intravenous TXA prior to surgery
9712760|NCT04610164|No Intervention|Group 2: Control Group|Patient will not receive TXA prior to surgery
9712761|NCT04610307|Placebo Comparator|control group|patients receiving 1 % plain xylocaine
9712762|NCT04610307|Experimental|intervention group|patients receiving buffered 1 % xylocaine
9712763|NCT04610216||Bilateral users: two implant systems|For bilateral CI users two Naida CI M sound processors (one per ear) will be used during the study.
9712764|NCT04610216||Bimodal users: hearing aid contralateral|For bimodal subjects there will be one Naida CI M sound processor on the implanted ear as well as one hearing aid on the contralateral ear.
9712765|NCT04610229|Experimental|Treated with hypofractionation|1
9712766|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation S|"Experimental equine Imunoglobulins antiSARSCov Formuation S"
9712767|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation M|"Experimental equine Imunoglobulins antiSARSCov Formuation M"
9712768|NCT04610489|Other|Study Population|All subjects will undergo bilateral mid-turbinate swabs for COVID Antigen (Quidel Sofia SARS Antigen Fluorescent Immunoassay (FIA)) as well as bilateral rt-PCR testing (Quest SARS-CoV-2 rRT-PCR).
9712769|NCT04609995|No Intervention|No financial incentive|No financial incentives will be provided for completing a PrEP evaluation
9712770|NCT04609995|Active Comparator|Fixed incentive|A fixed incentive ($25 Amazon.com gift card) will be provided for completing a PrEP evaluation
9712771|NCT04609995|Active Comparator|Lottery incentive|An entry into a lottery for a 20% chance to win a $100 Amazon.com gift card will be provided for completing a PrEP evaluation
9712772|NCT04610021|No Intervention|Control|Control group: autologous bone + bench bone
9712773|NCT04610021|Experimental|i-Factor|I-Factor group: autologous bone + bench bone + i-Factor™ bone graft
9712774|NCT04610086||False positive FIT|Participants in the colorectal cancer screening program, with a positive FIT and with a normal colonoscopy
9712775|NCT04610086||Polyps|Participants in the colorectal cancer screening program, with a positive FIT and diagnosed of colorectal polyps in the colonoscopy
9712776|NCT04610086||Colorectal cancer|Participants in the colorectal cancer screening program, with a positive FIT diagnosed by colorectal cancer
9712777|NCT04610203|Placebo Comparator|Glucose|Glucose - 50 g
9712778|NCT04610203|Experimental|Nutralys S85 Plus 25 g|Nutralys S85 Plus Pea Protein 25 g + 50 g Glucose
9712779|NCT04610203|Experimental|Nutralys S85 Plus 50 g|Nutralys S85 Plus Pea Protein 50 g + 50 g Glucose
9712780|NCT04610060|Experimental|Power walking group|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018)."
9779483|NCT05283486|Experimental|Cohort 1: MYMD1 600mg|Subjects randomly assigned to the MYMD1 600mg cohort
10195031|NCT03798093|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
10195032|NCT03774121|Experimental|CRYO|Subjected to Cryoneurolysis treatment and Neuromuscular training (GLA:D).
9712781|NCT04610060|Active Comparator|Standardised outpatient cardiac rehabilitation group|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018).
9712782|NCT04610398|Active Comparator|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
9712783|NCT04610398|Placebo Comparator|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
9712784|NCT04609969|Experimental|Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
9712785|NCT04610151|Experimental|Guided Imagery|Guided Imagery Intervention:The pretest data of the patients with a pain score of 4 or higher according to VAS were collected. Afterwards, the experiment group patients were applied guided imagery.
9712786|NCT04610151|No Intervention|No-Reflexology Application , control group.|No intervention was applied on the control group patients.
9712787|NCT04610125|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
9712788|NCT04610242|Experimental|Experimental group|Patients undergo diagnostic tests before the initial infusion of rituximab, including skin prick tests, intradermal tests, and challenge tests successively. If the skin test shows a positive result, the patient will receive desensitization procedure, and if the skin test is negative, the challenge test will be done, meaning normal infusion of rituximab according to manufacturer instructions. All the HSRs in the process of desensitization or normal infusion will be recorded. Peripheral blood will be drawn from all the subjects during their infusion to investigate the mechanism of HSRs to rituximab.
9712789|NCT04609917||trainee group|Patients with native papilla who underwent selective biliary cannulation with trainee involvement
9712790|NCT04609917||non-trainee group|Patients with native papilla who underwent selective biliary cannulation without trainee involvement
9712791|NCT04610034|Experimental|"Resilient Caregivers"|Intervention program
9712792|NCT04610034|Other|Control group|Care as usual
9712793|NCT04609982|Experimental|wearing ear plugs|
9712794|NCT04609982|No Intervention|Not wearing ear drops|
10195033|NCT03774121|Sham Comparator|SHAM|Subjected to similar procedures as CRYO, but without freezing temperatures. Subjected to Neuromuscular training (GLA:D).
10195034|NCT03770130|Experimental|Dexmedetomidine treatment group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an initial loading dose of dexmedetomidine of 1μg/kg over 10 min after the induction of anaesthesia followed by a continuous infusion of 0.5μg/kg/h until the end of surgery.
10195035|NCT03770130|Placebo Comparator|Control group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an equal volume initial loading dose of 0.9% saline over 10 min after the induction of anaesthesia followed by an equal volume continuous infusion until the end of surgery.
10195036|NCT03747939|Experimental|Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD|Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
10195037|NCT03747939|Placebo Comparator|Placebo|Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.
10195038|NCT03727971|Active Comparator|omalizumab arm|The treatment is initiated with one injection with weight and serum-Immunoglobulin E balanced omalizumab one time per cyclus
10195039|NCT03727971|Placebo Comparator|placebo arm|Participants will be administered placebo (NaCl), one time per cyclus
10195040|NCT03704025|Active Comparator|Current guidelines rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by diary.
10195041|NCT03704025|Experimental|Mobile device guided rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by virtual augmented reality glasses or by mobile device.
9712795|NCT04609865|Experimental|Lidocaine 2%|The lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours,and then 0.6mg/kg/h for 14 days or until extubation.
9779484|NCT05283486|Placebo Comparator|Cohort 1: Placebo 600mg|Subjects assigned to the 600mg placebo group
9779485|NCT05283486|Experimental|Cohort 2: MYMD1 750mg|Subjects randomly assigned to the MYMD1 750 cohort
9712796|NCT04609865|Placebo Comparator|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
9712797|NCT04609813|Experimental|Cytology sample collection|A nurse who has received related operation training uses the Shikang No. 1 collection device to collect cytology samples.
9712798|NCT04610099|Active Comparator|Standard SG|100 patients undergo a standard sleeve gastrectomy
9712799|NCT04610099|Experimental|Banded SG|100 patients undergo a banded sleeve gastrectomy
9712800|NCT04609748|Active Comparator|The group that received nimesulide|
9712801|NCT04609748|Experimental|The group that received CBD Oil|
10195042|NCT03685760|Experimental|Reiki|Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
9712803|NCT04609722|Experimental|intervention group|Solution-Focused Support Program will apply to the participants.
9712804|NCT04609722|No Intervention|control group|No intervention will be applied to the parents in the control group.
9712805|NCT04609631|Experimental|Tai Chi (5 times/week)|5 sessions of Tai Chi per week for 12 weeks
9712806|NCT04609631|Experimental|Tai Chi (3 times/week)|3 sessions of Tai Chi per week for 12 weeks
9712807|NCT04609631|Experimental|Tai Chi (1 time/week)|1 session of Tai Chi per week for 12 weeks
9712808|NCT04609631|Active Comparator|cognitive behavior therapy (CBT)|1 session of CBT per week for 12 weeks
9712809|NCT04609631|No Intervention|Waiting-list|Participants will maintain their routine treatment and life style for 12 weeks.
9712810|NCT04609683|Experimental|Hydrostasis group|"50 study subjects scheduled for an EP procedure will have AleriTM sensors on subject's bicep, forearm, or wrist, to start data collection.~Measurements will be made from the subject for a period of approximately 1 hours prior to the EP procedure. . Measurements will continue as patient is moved to the operating room. Once the EP procedure is complete, the subject will be transferred from the operating room to a hospital room, where they will stay overnight. Measurements will be made for 3-5hours post-operation.Detailed analysis will investigate how does AleriTM data correlate with known measures such as saline volume/rate, urine production volume, USG, Blood osmolality and body weight;"
9712811|NCT04609449|Experimental|Long biliopancreatic limb|Patients submitted to long biliopancreatic limb Roux-en-Y gastric bypass.
9712812|NCT04609449|Active Comparator|Standard biliopancreatic limb|Patients submitted to standard Roux-en-Y gastric bypass.
9712813|NCT04609618|Experimental|Obstructive Sleep Apnea patients|Appscent device will discharge odor during the in lab night sleep
9712814|NCT04609592|Experimental|Lutathera|2 cycles of 177Lu Dotatate, followed by cytoreductive surgery, followed by additional 177Lu Dotatate (up to 2 cycles) for residual disease as determined by 68Ga DOTA TATE PET/CT
9712815|NCT04609761|Experimental|IVIG treatment|Single-arm open-label
9712816|NCT04609540||Pyrotinib and Trastuzumab group|Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
9712817|NCT04609839||Patient admitted to intensive care unit for COVID-19|
9712818|NCT04609488||COVID|
9712819|NCT04609488||non-COVID|
9712820|NCT04609605|Experimental|patients with acute pulmonary embolism|speckle tracking echocardiography for patient with acute pulmonary embolism
9712821|NCT04609475|Experimental|Osseodensification technique|
9712822|NCT04609475|Active Comparator|Motor driven expanders' technique|
9712823|NCT04609462|Active Comparator|Conventional oxygen therapy (COT) group|Oxygen therapy will be delivered by conventional nasal cannula / prongs, venturi mask, or mask with reservoir, with flows between 3 and 15 liters / minute, to ensure SpO2 ≥ 92%.
9712824|NCT04609462|Experimental|High-flow nasal cannula (HFNC) group|Breathing support with High-Flow oxygen therapy, flow will be initiated between 50 and 60 liters / minute. FiO2 60% to 100% with the objective of reaching SpO2 ≥ 92%. Adequate wetting of the system should be ensured according to the recommendations of the HFNC device manufacturer. FiO2 may be decreased gradually according to the patient's individual condition, trying to maintain SpO2 ≥ 92%.
9712825|NCT04609319||Cohort 1|
9712826|NCT04609306|Experimental|Subjects getting 3% H2O2 applied to the incision|For the experimental cohort, a lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes. Following the 3 minutes, the sponge will be removed, the wound will be flushed with 100 mL of normal saline, and the exposed dermis will be swabbed and sent for culture.
9712827|NCT04609306|No Intervention|Subjects not getting 3% H2O2 applied to the incision|In the control cohort, the dermis will be swabbed and sent for culture immediately after the skin incision is made and the knife is removed from the field.
10195043|NCT03685760|Sham Comparator|Sham Reiki|Sham Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily sham Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
9712829|NCT04609254|Experimental|First Group|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
9712830|NCT04609254|Experimental|Second Group|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
9712831|NCT04609254|Experimental|Third group|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
10195044|NCT03685760|No Intervention|Usual Care|Twice per day, 30 minutes apart, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data. Usual care will also involve a 5-day period.
10195045|NCT03677791|Experimental|Virtual 360° intervention|counselling in the virtual 360° environment and also counselling in accordance with current practice
10195046|NCT03677791|Active Comparator|Control group|counselling in accordance with current practice
10195047|NCT03664934|Experimental|Patients, Neck-specific exercises|Patients before and after neck-specific exercises, subgroup to NCT01528579 with additional measures
10195048|NCT03664934|No Intervention|Healthy controls|Healthy controls, no treatment
9712832|NCT04609553|Active Comparator|Usual care including ROR|Literacy promotion is a pediatric standard of care. Participants in this group will receive usual care that includes ROR, a primary care literacy promotion intervention.
9712833|NCT04609553|Experimental|ROR plus text messages|In addition to ROR, participants will receive three text messages per week, plus one interactive follow-up message per month, for the study period with scheduled breaks.
9712834|NCT04609553|Experimental|ROR plus text messages plus connection to community resources|In addition to ROR and text messages, participants will be referred to a county-based single point of entry system for referrals to community resources. This system simplifies access to poverty-reducing resources by creating a centralized access point, maintaining an updated data base of resources with existing capacity to support families, and providing case management.
9712835|NCT04609293||Camrelizumab+apatinib+Hypofractionated radiation therapy|"Camrelizumab:200mg every 2 weeks for 1 years or until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Apatinib:250mg everyday until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Radiation: one week following completion of the second immunotherapy, hypofractionated radiotherapy with marginal dose of 50Gy/2Gy/25f and tumor center dose of local hyperfraction increase 24-32Gy/8-12Gy/3-4f will be performed 3-5 times. The routine radiotherapy will be started at the same time as the third immunotherapy and 25 times routine radiotherapy will be completed before the fifth or sixth immunotherapy."
9712836|NCT04609358|Experimental|Intervention group|The patients' nutrition were supported according the the algorithm of the enteral nutrition.
9712837|NCT04609358|No Intervention|Control group|The patients' nutrition were supported according the prescription of the physicians and dietician in our hospital.
9712838|NCT04609267|Experimental|Paper Baseline|Half of the participants will complete the PHQ-9 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa.
9712839|NCT04609267|Experimental|Mirror Baseline|Half of the participants will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa at their first appointment. At their second appointment 1-month later, they will will complete the PHQ-9 in the traditional paper format.
9712840|NCT04609202|Experimental|Nurse led person centred care|Participants in the nurse led, person centred care arm will receive person centred follow up after hospitalization for atrial fibrillation. The person centred care and usual care routines are provided by nurses.
9712841|NCT04609202|Active Comparator|Usual care|Participants in the usual care arm will receive care as usual, ie follow up by doctors after hospitalization for atrial fibrillation.
9712842|NCT04609189|Experimental|Pearlium®/EffectiCal®|
9712843|NCT04609189|Active Comparator|Calcium Carbonate/Vitamin D3|
9779486|NCT05283486|Placebo Comparator|Cohort 2: Placebo 750mg|Subjects assigned to the 750mg placebo group
9779487|NCT05283486|Experimental|Cohort 3: MYMD1 900mg|Subjects randomly assigned to the MYMD1 900mg cohort
9779488|NCT05283486|Placebo Comparator|Cohort 3: Placebo 900mg|Subjects assigned to the 900mg placebo group
9779489|NCT05283486|Active Comparator|Cohort 4: MYMD1 1050mg|Subjects randomly assigned to the MYMD1 1050mg cohort
9779490|NCT05283486|Placebo Comparator|Cohort 4: Placebo group 1050mg|Subjects assigned to the 1050mg placebo group
9779491|NCT05280080|Active Comparator|Regular Task|Knee extensions.
9779492|NCT05280080|Experimental|Dual Task|Knee extensions while also doing a self-regulated mathematical dual-task.
9779493|NCT05274932|Active Comparator|Placebo|Knee extensions with 30% 1RM and no occlusion pressure.
9779494|NCT05274932|Experimental|BFR at 40% AOP|Knee extensions with 30% 1RM and BFR at 40% AOP.
9779495|NCT05274932|Experimental|BFR at 80% AOP|Knee extensions with 30% 1RM and BFR at 80% AOP.
9779496|NCT05273320|Experimental|Open Label|"Titration: Nabilone p.o., increased in 0.25 mg increments every 2 days to a maximum of 1 mg b.i.d.~Open label: Nabilone p.o. at maximum dose tolerated for 28 days Tapering: Nabilone p.o. decreased in 0.25 decrements per day"
9779497|NCT05272683|Experimental|GLPG3667 + itraconazole|
9779498|NCT05272657|Experimental|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
9779499|NCT05272657|Experimental|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
9779500|NCT05272397|Active Comparator|Drug Session|"In this arm of the study participants receive the drug (Methylphenidate - 20mg), administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
9779501|NCT05272397|Placebo Comparator|Placebo Session|"In this arm of the study participants receive the a placebo, administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
9779502|NCT05272397|Other|Intake Session|In this arm of the study participants are screened for suitability to participate in the experiment based on specified inclusion and exclusion criteria. They also complete some baseline tasks to assess working memory capacity, impulsiveness, and subjective mood.
9779503|NCT05272007||Acute cholecystitis|
9779504|NCT05271994||Endoscopic biliary drainage|Patients with distal malignant biliary obstruction, who need endoscopic biliary drainage
9779505|NCT05269810|Experimental|Group 1|SA001 Low dose
9779506|NCT05269810|Experimental|Group 2|SA001 Mid dose
9779507|NCT05269810|Experimental|Group 3|SA001 High dose
9779508|NCT05269810|Placebo Comparator|Placebo|Placebo
9779509|NCT05269628|Experimental|Cannabidiol (CBD)|"Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining days of treatment.~PLUS Placebo Tetrahydrocannabinol (TCH) capsules which contain no active ingredients. Matching placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol."
9712844|NCT04609059|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
9712845|NCT04609059|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
9712846|NCT04609176|Experimental|Camrelizumab+Apatinib+SOX|Participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
9712847|NCT04609176|Experimental|Camrelizumab+Apatinib|Participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
9712848|NCT04609241|Experimental|Administration of CD79b CAR-T Cell|
9712849|NCT04609371|Experimental|self-care tools|"Arms Assigned Interventions Experimental: self-care tools~The tools are adapted from those successfully deployed in the DIRECTsc depression self-care project focusing on patients with depressive symptoms, but abbreviated to meet the needs of the proposed short-term intervention for a broader sample of patients to include those with anxiety symptoms and with minimal symptoms. Tools will include individual chapters of the Antidepressant Skills Workbook; the mood monitoring tool; a workbook on managing worry; relaxation audio files and information on exercise and healthy eating. In view of the short duration of the intervention (8 weeks), a maximum of 2 tools will be sent to each participant.~An algorithm will determine which self-care tools, matched to the specific mental health symptoms reported by participants, will be sent to the participants."
9712850|NCT04609371|Experimental|coaching|Participants will receive the algorithm-determined self-care tools, matched to the specific mental health symptoms reported by participants as in the first arm. They will ALSO be offered up to 3 coach calls. Coaching by a trained lay coach will be structured and guided by a manual. Trained lay coaches will call participants in the week following delivery of the toolkit to guide them through the self-care toolkit over an 8-week period. Coaches will contact participants a maximum of 3 times, with calls expected to average 15-20 minutes. Call content will be guided by a structured coaching manual adapted from those used in the team's previous two RCTs of the self-care materials. The coaches will follow structured agendas, keep records of all contacts.
9712851|NCT04609397|Experimental|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.
9712852|NCT04609397|Experimental|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.
9712853|NCT04609397|Placebo Comparator|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.
9712854|NCT04609384||Prior to installation of device|Health care workers who perform the surgical rub prior to installation of the device that should increase the time spend on surgical rub.
9980178|NCT01389206||Standard of care|Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
9980179|NCT01389219|No Intervention|Control|Control arm
9980180|NCT01389219|Other|Intervention clusters|Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
9980181|NCT01389271||Group 1|
9980182|NCT01389297|Active Comparator|Face-to-face SMART Recovery meetings|Participants in this arm will be asked to attend face-to-face SMART Recovery meetings.
9980183|NCT01389297|Experimental|Overcoming Addictions web app|Participants in this condition will use the Overcoming Addictions web application and not attend face-to-face SMART Recovery meetings.
9980184|NCT01389297|Experimental|Web app + meetings|Participants in this condition will be asked to use both the Overcoming Addictions web application and attend face-to-face SMART Recovery meetings.
9980185|NCT01389310||HIV-infected children <18 yrs old - exposed to Atazanavir|
9980186|NCT01389336||Add-on Ayurveda - Group|In the Āyurveda add-on-group 20 patients will receive individualized treatment according to the Āyurveda diagnosis which may include manual treatments, massages, dietary advice, specific consideration of selected food items, āyurvedic lifestyle & yoga posture advice and daily self-applied massage on top of standard care.
9980187|NCT01389336||Standard Care|20 Patients will receive the individually adjusted complex conventional standard care according to the current AWMF-guidelines including physiotherapy, occupational therapy, specific pain therapy and psychotherapy.
10195049|NCT03657628|Experimental|Physical activity|"The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program.~Will receive social/behavioral support~Will receive research staff contact time to encourage them to increase their physical activity level~The participants will be given the option of a third supervised session each week"
10195050|NCT03643705|Experimental|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
9712855|NCT04609384||Post device installation|Health care workers who perform the surgical rub following installation of the device that should increase the time spend on surgical rub.
9712856|NCT04609150||Multiple myeloma patients with vertebral fractures|Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events
9980188|NCT01389349|Experimental|Acupuncture|
9712857|NCT04609098|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a low dose of 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg. Tafenoquine (TQ) on the first date of DP treatment.
9712858|NCT04609098|Experimental|DP with 0.415mg/kg Tafenoquine (TQ)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.415mg/kg Tafenoquine (TQ) on the first date of DP treatment.
9712859|NCT04609098|Experimental|DP with 0.83 mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.83mg/kg Tafenoquine (TQ) on the first date of DP treatment.
9712860|NCT04609098|Experimental|DP with 1.66mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and single dose of 1.66mg/kg Tafenoquine (TQ) on the first date of DP treatment.
9712861|NCT04608721||Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI).
9712862|NCT04608747|Experimental|Intervention arm|After an overnight fast, participants subjected to baseline measurements and blood and urine collection and then consumed an amount of 50 g of tahini. Blood and urine collection and other measurements were repeated 4 h postprandially.
9712863|NCT04608734|Experimental|Buccal midazolam|
10195051|NCT03643705|Active Comparator|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
9712864|NCT04608734|Active Comparator|Intranasal midazolam|
9712865|NCT04608864|Experimental|varicocelectomy arm|The varicocelectomy procedure will be performed three months before ICSI for men with with male-factor infertility and were diagnosed clinically with varicocele
9712866|NCT04608864|No Intervention|Control (No varicocelectomy) arm|Couples with male-factor infertility and males were diagnosed clinically with varicocele will undergo ICSI
9712867|NCT04609033|Active Comparator|bupivacaine group|
9712868|NCT04609033|Active Comparator|bupivacaine + morphine|
10195052|NCT03640286|Active Comparator|VeSTAL - active device|The VeSTAL device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
10204768|NCT05020678|Experimental|NKX019 - CAR NK cell therapy|All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 weekly doses of NKX019 on Day 0, 7, and 14 of a 28-day cycle.
9712869|NCT04609033|Active Comparator|bupivacaine + morphine + ketamine|
9712870|NCT04609033|Placebo Comparator|isotonic saline|
9712871|NCT04608838|Experimental|JTR-161|
9712872|NCT04608838|Placebo Comparator|Placebo|
9712873|NCT04608981|Experimental|Prednisolone premedication|Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
9712874|NCT04608981|Experimental|Diclofenac potassium premedication|Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
9712875|NCT04608981|Placebo Comparator|Placebo|Placebo tablet 1 hour before starting endodontic treatment.
9712876|NCT04608929|Experimental|Intervention|The arm where the Kegel exercise focused intervention is applied
9712877|NCT04608929|Experimental|Control|The arm where home follow-up and scale evaluations are made
9712878|NCT04608890||Long-standing T1D patients|Patients with long-standing type 1 diabetes
9712879|NCT04608890||Healthy volunteers|Healthy volunteers
9712880|NCT04608851|Experimental|Nissle group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral suspension containing 10 E8 CFU/ml of E coli Nissle. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
9712881|NCT04608851|Placebo Comparator|Control group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
9712882|NCT04608708||Group 1. Periapical Cemento-Osseous Dysplasia|In Periapical Cemento-Osseous Dysplasia , the lower anterior teeth are usually affected. In these lesions, normal bone is replaced by fibrous tissue that contains amorphous vascularised calcifications. In the early stage, it can mimic a periapical lesion, but it is usually associated with vital teeth, without any clinical complaint, and it requires no intervention. Histopathologically, the lesion is similar to fibrous dysplasia and ossifying fibroma.
9712883|NCT04608708||Group 2. Focal Cemento-Osseous Dysplasia|It occurs in a single area of the posterior teeth. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
9712884|NCT04608708||Grup 3. Florid Cemento-Osseous Dysplasia|When the lesions involve two or more quadrants of the jaw, it is defined as Florid Cemento-Osseous Dysplasia. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
9712885|NCT04608669|Other|Temperature comparison|
9712886|NCT04608669|Active Comparator|No change|
9980189|NCT01389349|Sham Comparator|Sham Control|
9712887|NCT04608942|Experimental|Jett Plasma Medical Lift Application|In the study group, the plasma jet will be applied to the superior and inferior eyelid margin in both eyes.
9712888|NCT04608942|Active Comparator|Mechanical Debridement|In the control group, the mechanical debridement of the superior and inferior eyelid margin with a scalpel blade will be performed.
9712889|NCT04609007|Active Comparator|Treatment as usual|The TAU condition consists of a single session of regular help-line telephone counselling
9712890|NCT04609007|Experimental|Cognitive behavioral therapy|The experimental condition consists of a single session of regular help-line telephone counselling plus four therapist guided online CBT sessions.
9980190|NCT01389362|Active Comparator|Chinese Herbal Medicine|2 sachets of Chinese Herbal Medicine to be taken daily
9712891|NCT04608565|Other|Remote biomonitoring sensor device|250 readings for a power of 80% and to detect a 5% difference in measurements with 95% confidence interval from mothers and newborns was ascertained. Once 3 probes were strapped (radiant warmer, RBM device and multichannel), a waiting period of 10 minutes for temperature stabilization was given. First RBM device & multichannel probe provided readings continuously (every few seconds); Then radiant warmer probe and manual thermometer readings were taken every 15 minutes for 5 timings: 0, 15, 30, 45 and 60 minutes. Participant safety for newborns was ensured following routine appropriate care protocols.
9712892|NCT04608604|Active Comparator|Physiotherapy 1|
9712893|NCT04608604|Active Comparator|Physiotherapy 2|
9712894|NCT04608448|Active Comparator|Topical Rapamycin|Ointment is applied to a color coded area on the subject forearm daily.
9712895|NCT04608448|Placebo Comparator|Placebo|Placebo ointment is applied to a color coded area on the subject forearm daily.
9712896|NCT04608461|Experimental|pumpkin seeds extract containing cream|Intervention-pumpkin seeds extract containing cream, dose-twice daily for 12 weeks
9712897|NCT04608474|Experimental|Evolocumab only|This arm includes subjects who are treated using Evolocumab.
9712898|NCT04608474|Experimental|Evolocumab plus statin|This arm includes subjects who are treated using a combination of Evolocumab and a statin-based drug.
9712899|NCT04608760|Active Comparator|Meksibel|Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure
10195053|NCT03640286|Sham Comparator|Sham device|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
10195054|NCT03631940|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
10195055|NCT03631940|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
9712900|NCT04608760|Active Comparator|Indometacin|Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure
9712901|NCT04608760|Active Comparator|Meloksicam|Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure
9712902|NCT04608760|Active Comparator|Oktride|Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure
9712903|NCT04608370|Experimental|Active tPBM session group|Participants in the active tPBM group will take active tPBM session, which include 12 minutes active tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
9712904|NCT04608370|Active Comparator|Sham tPBM session group|Participants in the sham tPBM group will take sham tPBM session, which include 12 minutes sham tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
9712905|NCT04608422|Experimental|Electrical stimulation|The patients will receive neuromuscular electrical stimulation on quadriceps muscle and sensory stimulation in the anatomical region of the kidneys.
9712906|NCT04608422|No Intervention|Control|The patients only will be evaluated and reassessed.
9712907|NCT04608656|Experimental|Intervention arm 1: Livestock feed only|Households in villages assigned to intervention arm 1 will receive a pre-defined amount of feed to maintain two tropical livestock units for a total of 60 days during the dry season (when animals would be moved away in search of pastures).
9712908|NCT04608656|Experimental|Intervention arm 2: 1. Provision of Livestock feeds, 2. Nutrition counselling|Households recruited into intervention arm two will receive livestock feeds similar to intervention arm 1 and will be enrolled in a nutritional education and counselling program through Infant and Young Child Nutrition (IYCF) feeding program and household food utilization. The IYCF program through the Baby Friendly Community Initiative (BFCI) will include the promotion of exclusive breastfeeding in the first six months, continued breastfeeding up to the age of two years, adequate complementary feeding, hygiene promotion and the uptake of child health services including immunization, treatment of illness, moderate and severe acute malnutrition and micro-nutrient supplementation.
9712909|NCT04608656|No Intervention|Control arm|The households recruited under this arm will receive none of the two study interventions. These households will receive identical assessment and data collection like other study households in the study. Their access to support through other interventions will be monitored. Households within the control arm will receive nutritional counselling and education given outside of the project. This is mainly at health facilities when mothers present for antenatal care or visit health facilities seeking healthcare. On some occasions in places where community health volunteers are present, nutritional counselling and education may be provided at the community level. The study instruments have been designed to collect information at the household level if such nutritional counselling and education has been provided.
9712910|NCT04608526||Group 1|Patients without deep dentin caries / apical rarefying osteitis
9712911|NCT04608526||Group 2|Patients with deep dentin caries / apical rarefying osteitis on the right or left sides
9712912|NCT04608526||Group 3|Patients with deep dentin caries / apical rarefying osteitis on either the right and left side
9980191|NCT01389362|Placebo Comparator|Placebo arm|2 sachets to be taken daily
10195056|NCT03622879|Experimental|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
10195057|NCT03622879|Placebo Comparator|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
9712913|NCT04608305|Experimental|phase I - Group Ia, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0
9712914|NCT04608305|Experimental|phase I - Group Ib, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0
9712915|NCT04608305|Experimental|phase I - Group Ic, Prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0
9712916|NCT04608305|Experimental|phase I - Group Id, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
9712917|NCT04608305|Experimental|phase II - Group IIa, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
9712918|NCT04608305|Experimental|Phase II - Group IIb, Prime, low dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
9712919|NCT04608305|Experimental|phase II - Group IIc, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
9712920|NCT04608305|Experimental|phase II - Group IId, Prime, medium dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
9712921|NCT04608305|Experimental|Phase II - Group IIe, prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
9712922|NCT04608305|Experimental|Phase II - Group IIf, Prime, high dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
9712923|NCT04608305|Experimental|phase II - Group IIg, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
9712924|NCT04608305|Experimental|phase II - Group IIh, prime-boost, low dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
9712925|NCT04608305|Experimental|phase II - Group IIi, prime-boost, medium dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
9712926|NCT04608305|Experimental|phase II - Group IIj, prime-boost, medium dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
9712927|NCT04608305|Experimental|phase II - Group IIk, prime-boost, high dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
9712928|NCT04608305|Experimental|phase II - Group IIl, prime-boost, high dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
9712929|NCT04608305|Experimental|phase II - Group IIm, prime-boost, top dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
9712930|NCT04608305|Experimental|phase II - Group IIn, prime-boost, top dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
9712931|NCT04608539|Experimental|Intravenous iron group|Single-dose intravenous infusion of 20 mg/kg body weight ferric derisomaltose/iron isomaltoside 1000 (MonoFer®)
9712932|NCT04608539|Active Comparator|Oral iron group|Oral therapy with 100 mg oral ferrous sulfate twice daily
9980192|NCT01389375|Experimental|FemoSeal®|Device: FemoSeal®
9980193|NCT01389375|Experimental|ExoSeal®|Device: ExoSeal®
9712935|NCT04608253||All enrolled subjects received an 11C-choline PET/CT prior to enrollment.|Patients with biochemically proven primary hyperparathyroidism who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging
9712936|NCT04608214|Experimental|Alisporivir|Administration of alisporivir and standard of care (SOC)
9712937|NCT04608214|Active Comparator|Standard of care (SOC)|Locally accepted regimen protocols for patient care
9712938|NCT04608396|Experimental|AXS-05|
9712939|NCT04608396|Placebo Comparator|Placebo|
9712940|NCT04608292|Active Comparator|Single-voxel MRS|MRS
9712941|NCT04608292|Active Comparator|Multi-voxel MRSI|MRSI
9712942|NCT04608292|Active Comparator|Magnetization Transfer Imaging|MTI
9712943|NCT04608292|Active Comparator|Single-voxel MRS + ClearMate(TM)|MRS+CM
9712944|NCT04608292|Active Comparator|Multi-voxel MRSI + ClearMate(TM)|MRSI+CM
9712945|NCT04608292|Active Comparator|Magnetization Transfer Imaging + ClearMate(TM)|MTI+CM
9712946|NCT04608292|Active Comparator|Single-voxel MRS + CM + Blood Sampling|MRS+CM+B
9712947|NCT04608292|Active Comparator|Multi-voxel MRSI + CM + Blood Sampling|MRSI+CM+B
9712948|NCT04608292|Active Comparator|Magnetization Transfer Imaging + CM + Blood Sampling|MTI+CM+B
9712949|NCT04608500|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
9712950|NCT04608500|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
9712951|NCT04608162|Active Comparator|Group I|Group one received PEMF and exercise (PEMF+EX)
10195058|NCT03622879|Placebo Comparator|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
10195059|NCT03622879|Sham Comparator|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
10195060|NCT03621956|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
9712952|NCT04608162|Placebo Comparator|Group II|Group two received placebo PEMF and exercise (PPEMF+EX)
9712953|NCT04608162|Active Comparator|Group III|Group three will be treated by PEMF alone (PEMF)
9712954|NCT04608071||M group|In M group, patients underwent modified post-pyloric feeding tube bedside placement
9712955|NCT04608071||C group|In C group, patients underwent conventional Corpak protocol
10195061|NCT03621956|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
10195062|NCT03593018|Experimental|Oral Azacitidine|Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
10195063|NCT03593018|Active Comparator|Investigator's choice therapy|Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
9712956|NCT04608071||EM group|In EM group, patients received standard electromagnetic guided tube placement.
9712957|NCT04608175|Experimental|Acupuncture group|"The experimental group will receive the standard treatment administered in these cases (analgesic regimen and nursing care procedures), in addition to the following acupuncture therapy.~In the first visit (preoperative), the anamnesis and energy diagnosis of each patient will be carried out following the practices of Traditional Chinese Medicine (TCM) to design a personalized treatment based on the patient's medical history. A treatment of approximately 10 to 12 acupuncture points will be designed considering the TCM diagnosis and medical history of each patient. Both TCM diagnosis and the points used will be reassessed in each session. The points belonging to the upper extremity of the affected breast will be treated on the contralateral side, taking care not to insert any needle in the limb on the affected side. No points in the operated region will be used."
9712958|NCT04608175|No Intervention|Control group|The control group will only receive standard care procedures (analgesic regimen and nursing care procedures), although they will have the same follow up visits as the patients in the intervention group to facilitate analysis of the study variables.
9712959|NCT04608084|Experimental|Treatment group|Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops
9712960|NCT04608110|Experimental|Azacitidine + Cedazuridine|"Drug: Azacitidine Tablets for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration~Drug: Cedazuridine Tablets for oral administration"
9980194|NCT01389375|Active Comparator|Manual compression|Other: Manual compression
9980195|NCT01389388|Experimental|Rosuvastatin intervention|Patients > 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient <70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
10195064|NCT03566732||Bereaved relatives|Bereaved relatives after cancer deaths in hospitals
10195065|NCT03563742|Experimental|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
10195066|NCT03548428|Experimental|A|SBRT + Atezolizumab
10195067|NCT03548428|Active Comparator|B|SBRT
10195068|NCT03521310|Experimental|Skin-to-skin Contact group|Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
10195069|NCT03521310|Active Comparator|Conventional care group|Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.
10195070|NCT03517969|Active Comparator|Arm A (docetaxel, carboplatin)|Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.
10195071|NCT03517969|Experimental|Arm B (carboplatin, berzosertib)|Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10195072|NCT03514134|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
10195073|NCT03514134|Active Comparator|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
10195074|NCT03497780||ACL Tear|Patients with ACL tears
10195075|NCT03497780||Healthy Subjects|Healthy subjects
9712961|NCT04607967|No Intervention|"Conventional oxygen-therapy (study group CO)"|"Patients randomized in the Coventional Oxygen group will be treated according to the national and international recommandations with a conventional oxygen-therapy device (nasal cannula or nasal-oral mask).~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
9712962|NCT04607967|Experimental|"High Flow Nasal Oxygen (study group HNFO)"|"Patients randomized in the HNFO group will be treated according to the CE Certification with the high flow nasal oxygen device.~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
9712963|NCT04608097|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
9712964|NCT04608097|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
9712965|NCT04608227||Third trimester pregnant women undergoing ceasarean section|
9712966|NCT04608123||DBS Patients with NFS|Patients with PD treated with STN DBS between 2016 and 2019 who underwent NFS testing in pre and post-op conditions
9712967|NCT04607772|Experimental|Arm A: Selinexor with Bendamustine and Rituximab (S-BR))|Participants will receive a dose of 40 or 60 or 80 milligrams (mg) of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an intravenous (IV) dose of bendamustine 90 milligram per square meter (mg/m^2) on Days 1 and 2 and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
9712968|NCT04607772|Experimental|Arm B: Selinexor with Polatuzumab Vedotin and Rituximab (S-PR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 milligram per kilogram (mg/kg) and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
9712969|NCT04607772|Experimental|Arm C: Selinexor, Polatuzumab Vedotin, Bendamustine, Rituximab (S-PBR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 3, and 8 for Cycle 1 to 6 (each cycle consists of 21 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 mg/kg and IV dose of rituximab 375 mg/m^2 on Day 1, and IV dose of bendamustine 90 mg/m^2 on Days 1 and 2 during primary treatment for Cycle 1 to 6.
9712970|NCT04607772|Experimental|Arm D: Selinexor, Rituximab, Gemcitabine, Oxaliplatin (S-R-GemOx)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1 and 3 for Cycle 1 to 6 (each cycle consists of 14 days) during primary treatment and 60 mg on Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2, IV dose of gemcitabine 1000 mg/m^2, and Oxaliplatin IV dose of 100 mg/m^2 on Day 1 during primary treatment for Cycle 1 to 6.
9712971|NCT04607772|Experimental|Arm E: Selinexor with Ibrutinib and Rituximab (S-IR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-4) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg once daily on Day 1 to 28 during primary treatment for Cycle 1 to 6. Participants will also receive ibrutinib oral dose of 420 mg once daily at all dose levels during continuous treatment.
9712972|NCT04607772|Experimental|Arm F: Selinexor with Lenalidomide and Rituximab (S-LR)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment for Cycle 1 to 6. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 at all dose levels during the continuous treatment.
9712973|NCT04607772|Experimental|Arm G: Selinexor with Lenalidomide and Tafasitamab (S-LT)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 12 during primary treatment and 40 (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). During the primary treatment, participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, and tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg on Days 1 and 15 for all dose levels during the continuous treatment.
9779510|NCT05269628|Active Comparator|Tetrahydrocannabinol (THC)|"The drug dose will be 2.5 mg b.i.d. during the first seven days of active treatment, and 5 mg b.i.d. for the following days of active treatment.~PLUS Placebo CBD (A matching placebo oral solution to Epidiolex® will be used that consists of all of the excipients in the active solution without the cannabidiol component). The placebo will be dosed in the same schedule and manner as active Epidiolex®."
9779511|NCT05269628|Active Comparator|CBD + THC|
9980196|NCT01389401||reflux laryngitis group pre-treatment|adults with clinical suspicion of Reflux Laryngitis confirmed by 24-hour double probe esophageal monitoring who have not made use of any treatment in the past 15 days.
9980197|NCT01389401||study group - post treatment|adults with reflux laryngitis after 16 weeks of treatment with proton pump inhibitor (omeprazole 40 mg twice a day)and dietary/lifestyle changes that present improvement in symptoms and video laryngoscopic signs of chronic laryngitis
9980198|NCT01389401||control group|healthy controls paired by gender and age that do not present symptoms and videolaryngoscopic signs suggestive of reflux laryngitis
10195076|NCT03493425|Active Comparator|Arm A (surgery, IMRT, cisplatin, carboplatin)|Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
10195077|NCT03493425|Experimental|Arm B (docetaxel, cisplatin, carboplatin, surgery, IMRT)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV or carboplatin IV weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
10195078|NCT03477396|Experimental|Treatment (ribociclib, aromatase inhibitor)|Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10195079|NCT03455439||Rivaroxaban|Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion
10195080|NCT03428828|Experimental|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
10195081|NCT03428828|Active Comparator|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
10195082|NCT03420521|Other|Nivolumab plus Ipilimumab|Nivolumab-240 mg IV over 60 minutes Q2W Ipilimumab 1mg/kg IV over 30 minutes Q6W
10195083|NCT03387813|Experimental|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
10195084|NCT03387813|Experimental|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
9712974|NCT04607772|Experimental|Arm H: Selinexor with Venetoclax (S-V)|Participants will receive 40 or 60 or 80 mg of selinexor oral tablets on Days 1, 8 and 15 for Cycle 1 to 6 of primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2-5) during continuous treatment (28 days per cycle). Participants who received 40 and 60 mg of selinexor during primary treatment will also receive oral dose of venetoclax 200 mg on Days 1 to 7 then 400 mg on Days 8 to 28 for Cycle 1; 400 mg daily for Cycle 2 to 6. Participants who received 60 and 80 mg of selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7 then 600 mg on Days 8 to 28 for Cycle 1; 600 mg daily for Cycle 2 to 6. Participants who received 80 mg selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7, then 600 mg from Days 8 to 14, then 800 mg from Day 15 to 28 for Cycle 1; 800 mg daily for Cycle 2 to 6. Participants during continuous treatment will also receive venetoclax 400 mg orally daily.
10195085|NCT03387813|Experimental|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
9712975|NCT04607902|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
9779512|NCT05269628|Placebo Comparator|Placebo CBD + Placebo THC|
9779513|NCT05265377|Experimental|STELO Exoskeleton|9 treatment sessions will be performed with the Stelo exoskeleton.
9779514|NCT05254418|Experimental|dulagutide arm|Patient will receive 1.5 mg injections per week for 12 weeks.
9779515|NCT05243953|Experimental|Levcromakalim|A time- and volume-controlled infusion pump is used to administer levcromakalim by intravenous infusion over 20 minutes.
10195086|NCT03386214|Experimental|Arm 1: Starting Dose - 5 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
10195087|NCT03386214|Experimental|Arm 2: Dose Level 2 - 10 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
10195088|NCT03386214|Experimental|Arm 3: Dose Level 3 - 20 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
10195089|NCT03375697|Experimental|SAD (Part 1): Healthy Subjects|In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
10195090|NCT03375697|Experimental|MAD (Part 2): Subjects With Alzheimer's Disease (AD)|In Part 2, multiple ascending IV doses of JNJ-63733657 or placebo will be evaluated at three dose levels in sequential cohorts in subjects with prodromal or mild AD; 3 doses will be administered over a period of 8 weeks (Day 1, Day 29, Day 57). The starting dose will be decided based on the data from Part 1. Escalations will be done based on safety and tolerability similar to Part 1. Doses will not exceed those tested in Part 1. Here, MAD indicates multiple ascending dose.
10195091|NCT03373188|Active Comparator|Arm I (surgery)|Patients undergo surgery.
10195092|NCT03373188|Experimental|Arm II (VX15/2503, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
9712976|NCT04607902|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
9712977|NCT04607902|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
9712978|NCT04607811|No Intervention|Control arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will complete study surveys at baseline and the end of the 8 week intervention.
9712979|NCT04607811|Experimental|Gamification arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will have a weekly step goal they are encouraged to meet. Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
9712980|NCT04608006||Vaginal Delivery|Delivered both twins vaginally
9712981|NCT04608006||C-Section Delivery|Delivered both twins by Cesarean Section
10195093|NCT03373188|Experimental|Arm III (VX15/2503, ipilimumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
10195094|NCT03373188|Experimental|Arm IV (VX15/2503, nivolumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
9712982|NCT04608006||Vaginal/C-Section Delivery|Delivery first twin vaginally and second twin By C-Section.
9712983|NCT04608058|Experimental|Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, asynchronous Diabetes self-management training, using digital storytelling was made available to this group. Post-test data were collected 3 months after the pretest."
9712984|NCT04608058|Experimental|No Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, the control group received the clinics' routine training. Post-test data were collected 3 months after the pretest."
9712985|NCT04608032|Experimental|Ecological Cognitive training program for schizophrenia spectrum disorder [ECo-Sz]|to inform the patient about cognitive impairments and their repercussions ; to train the patient in problem-solving skills through exercices ; to implement strategies in daily life. Duration : two month. Frequency : Two one hour individual sessions and one hour of at-home training per week. Modalities : pen and papers exercices (tools (token, cards, maps and chessboard). Modules : Psychoeducation, Attention, Memory, Executive functions, Social cognition and metacognition, Functional impairments
9712986|NCT04608032|Active Comparator|[THoR] Recovery-Oriented Therapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' and functional impact, social skills, motivation and the regulation of sleep and daily activities
9712987|NCT04607707||Postmenopausal Women|Participants who sign an informed consent will be asked to complete study questionnaires at a single visit that coincides with a normal healthcare visit. No other study procedures will be performed.
9712988|NCT04607759|Experimental|Experimental group (cucumber)|"Consumption for 90 days of cucumber extract (20mg/day)~Two capsules a day orally for 90 days."
9712989|NCT04607759|Placebo Comparator|control group Placebo (sucrose)|Two capsules a day orally for 90 days.
9712990|NCT04607824||Duchenne Muscular Dystrophy group|Forty-five male subjects were included in the Duchenne Muscular Dystrophy (DMD) group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer.
9712991|NCT04607824||Typical Development group|Forty-five male subjects were included in the healthy Typical Development (TD) control group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer
9712992|NCT04607915|Experimental|Intervention for TECC Model|
9712993|NCT04607733|Experimental|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS)
9712994|NCT04607733|Experimental|Mirikizumab - Autoinjector|Mirikizumab administered by subcutaneous injection (SC) via an autoinjector (AI)
9712995|NCT04607863||Low back pain|Patients with low back pain
9712996|NCT04607863||No low back pain|No low back pain patients
10195095|NCT03369665|Experimental|Mavenclad®|
10195096|NCT03312465||AS Domelock System Subjects|Subjects that receive the Anatomical Shoulder Domelock System
10195097|NCT03303339|Experimental|Phase 1b: Onvansertib + low-dose cytarabine|Onvansertib, administered in escalating doses orally Day 1 through Day 5 every 28 days (1 cycle) in combination with cytarabine, which will be administered in all cohorts as 20 mg/m^2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle). Onvansertib administration, in combination with cytarabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days. Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
10195098|NCT03303339|Experimental|Phase 1b: Onvansertib + decitabine|Onvansertib will be administered in escalating doses orally, Day 1 through Day 5 every 28 days (1 cycle) in combination with decitabine, administered consistently in all cohorts as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle). Onvansertib administration, in combination with decitabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days (Day 1 through Day 5). Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
10195099|NCT03303339|Experimental|Phase 2: Onvansertib + decitabine|Onvansertib recommended phase 2 dose, orally Day 1 through Day 5 every 28 days (1 cycle) and decitabine, administered consistently as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle), with treatment modifications or delays based on return of hematopoietic function to baseline or Grade ≤1 toxicity for optimal subject management.
10195100|NCT03288337||Hidradenitis Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
10195101|NCT03220178|Experimental|CANKADO active|CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
9712997|NCT04607798|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments.
9712998|NCT04607720|Experimental|the artificial-EUS-FNA group|the first two passes were made without the AI-assisted diagnosis system guidance during EUS-FNA, and then two passes were made under guidance from the AI-assisted diagnosis system
9712999|NCT04607720|Experimental|the AI-EUS-FNA group|the first two passes were made with the AI-assisted diagnosis system guidance and then another two manual passes without the AI-assisted diagnosis system guidance.
9713000|NCT04607785|Active Comparator|Miswak mouthwash group|Miswak sticks were bought from local markets, Baghdad, Iraq, washed with cold water and dried then crushed into powder. Later,7 grams of the miswak powder weighted and added to 350 ml of distilled water (D.W.) in a conical flask for 24 hours. Finally, the solution then filtered and stored in tightly closed bottles in a cool place.9
9713001|NCT04607785|Other|Chlorhexidine mouthwash group|0.12% chlorhexidine gluconate mouthwash for seven days
9713002|NCT04607694|Experimental|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
9713003|NCT04607694|Active Comparator|Photon radiotherapy|Photon radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
9713004|NCT04607629|Experimental|Genolar® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
9713005|NCT04607629|Active Comparator|Xolair® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
9713006|NCT04607603|Experimental|Cannabidiol|In the Cannabidiol (CBD) arm CBD will be titrated up to 600 mg per die (titration 1 week) in capsules (3 daily doses) and maintained at 600mg per die (3 daily doses) for 7 weeks
9713007|NCT04607603|Placebo Comparator|Placebo|In the placebo arm the placebo comparator will be administered in capsules in 3 daily doses
9713008|NCT04607564|Experimental|No comparison pilot group|Attendance at ten Ntombi Vimbela workshops running for a total 35 hours over six weeks.
9713009|NCT04607590||Group I (DY)|Patients and their partners attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy.
9713010|NCT04607590||Group II (PY)|Patients attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy. Once data collection is completed, partners will be offered intervention materials, and encouraged to attend yoga classes at the Integrative Medicine Clinic.
9713011|NCT04607590||Group III (WLC)|Patients and their partners receive usual care. Once data collection is completed, couples may participate in the DY or PY program of their choice over 60 minutes each. Partners are also offered intervention materials along with five 60 minute optional yoga sessions.
9713012|NCT04607473|Experimental|ABUS|ABUS is performed by experienced technicians using a GE inveniaTM. Each breast is imaged in three views with an automated 15.4-cm 14-6-MHz linear- array transducer, which acquires up to 1000 two-dimensional images in the transverse plane, imaging the breast in three parts: the central (anteroposterior), lateral, and medial portions of the breast. To ensure inclusion of all breast tissue, particularly in participants with very large breasts, additional views are obtained as deemed necessary by the technician to cover the entirety of the breast.
9713013|NCT04607499||Pregnant women|Pregnant women without intervention
9713014|NCT04607447|Active Comparator|Atorvastatin plus Dexamethasone tablets|
9713015|NCT04607447|Experimental|drugs+low intracranial pressure strategy treatment|Drugs means treatment with Atorvastatin plus Dexamethasone tablets
9713016|NCT04607512|Experimental|Telaglenastat|800 mg telaglenastat (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
9713017|NCT04607512|Placebo Comparator|Telaglenastat Placebo|800 mg placebo (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
9713018|NCT04607512|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin (1 x 400 mg tablet) administered on the morning of Day 4
9713019|NCT04607486||CVA and spasticity|Adults with first-ever chronic CVA and leg spasticity
9713020|NCT04607486||CVA without spasticity|Control group
9713021|NCT04607486||healthy subjects|Control group
9713022|NCT04607551|Experimental|Prone positionning|
9713023|NCT04607551|Active Comparator|Supine position|
9713024|NCT04607213|Active Comparator|Advancement-rotation approach|
9713025|NCT04607213|Experimental|Straight-line approach|
9713026|NCT04607304|Experimental|ABCA2 GIRMS|Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized
9713027|NCT04607330|Experimental|High protein liquid|A ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.
9713028|NCT04607525|Experimental|Group D|Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline
9713029|NCT04607525|Placebo Comparator|Group C|Patients received equal volume and rate of normal saline as Group D.
9713030|NCT04607239|Experimental|Telemonitoring|"In addition to the usual care, this group benefits from a weekly telephone call by the Clinical Research Associate (CRA) for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~This group will also benefit from a monthly call by the attending physician for treatment titration and side effects check."
10195102|NCT03220178|Other|CANKADO inform|CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
9713031|NCT04607239|Other|Conventional|"This group will benefit form the usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.~The usual care includes attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician."
9713032|NCT04607187||Normals, Dupuytren's subjects with and without treatment|Ultrasound analysis of patient receiving treatment for Dupuytren's
9713033|NCT04607655|Experimental|Oral GB1211, 100 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
9713034|NCT04607655|Experimental|Oral GB1211, 10 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
9713035|NCT04607655|Placebo Comparator|Oral GB1211, Placebo, twice a day|Placebo is administered as inhalation once a day
9713036|NCT04607343|Experimental|Assigned Interventions|Patients will undergo a conventional flexible nasopharyngeal laryngoscopy in which the degree of obstruction and the laryngopharyngeal sensitivity during wakefulness will be determined. Electrostimulation will be applied at different submandibular points with increasing intensity until the contraction of the dilation muscles of the airway or until the patient cannot tolerate the electrostimulation. The presence of contraction of stimulated muscles will be determined by external and endoscopic inspection.
9713037|NCT04607395||pre-operative radiographs of deep carious lesion|
9713038|NCT04607382||Low-dose estrogen progestin products (LEP)|The patients in the LEP cohort should not have taken LEP in the last 2 months before the enrollment in the study, and will take LEP during the study period.
9713039|NCT04607382||Non-LEP|Those patients in the Non-LEP cohort should not have taken LEP in the last 2 months before the enrollment and will take NSAIDs and/or Chinese medicine (CM) during the study period.
10195103|NCT03174314|Experimental|50 visually impaired|50 visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
9713040|NCT04607265||Ventricular tachycardia (VT) group|NICM patients admitted for a VT ablation with a pre-operative cardiac- MRI.
9713041|NCT04607265||Control group|NICM patients without ventricular arrhythmia and a previous cardiac-MRI. The matching with the VT group was based on the age of the patients, the mean LVEF, the time between the initial diagnosis and the MRI examination, and the origin of the NICM.
9713042|NCT04607642|Experimental|A BMX-001|Patients will receive standard of care radiation therapy plus Cisplatin. BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
9713043|NCT04607642|Placebo Comparator|B Placebo|Patients will receive standard of care radiation therapy plus Cisplatin. Placebo will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
9713044|NCT04607278|Experimental|Probiotic|Oral probiotic supplementation (Pro-Probiotic) was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
9713045|NCT04607278|Active Comparator|Prebiotic|The prebiotic (Inulin) was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
9713046|NCT04607278|Placebo Comparator|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
9713047|NCT04607291|Experimental|Health services research (Witness CARES services) Intervention|Patients who are not prepared for a colonoscopy or stool test receive educational materials, messages, and videos electronically or by mail with information about colorectal screening and are followed up by phone within 2 weeks. Patients desiring colonoscopy, receive navigators assistance with obtaining the screening (e.g.,determining gastrointestinal doctor, scheduling appointment, prep materials and process, transportation, escort). Patients desiring a stool test, receive navigators assistance by facilitating fecal tests.
9779516|NCT05243953|Placebo Comparator|Placebo (isotonic saline)|A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
9779517|NCT05237999|Experimental|Intervention: KopOpOuders-PTSD|KopOpOuders-PTSD is a blended care (i.e., partially online and partially in person) intervention that addresses the enhancing of protective factors within the family setting (reducing negative parental self-perceptions; parent-child interaction quality, social support, child adaptive functioning/coping, and child understanding of the parent's illness) from a combination of transdiagnostic and PTSD-specific perspectives. It consists of 8 sessions (5 online self-help modules, 3 in-person sessions with a professional) to be completed in a maximum period of 9 weeks.
9779518|NCT05237999|No Intervention|Control: No intervention|The control group receives no parenting intervention during their participation.
9713048|NCT04606966|Experimental|Therapeutic Horseback Riding|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual. Participants will have an assigned horse and volunteer(s) Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table for five minutes, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for two minutes while watching a 1-minute sand timer, then, participants will then don their riding helmets and enter the riding arena. Each week after conclusion of the THR intervention, participants will again sit with their group at an art table for 20 minutes followed by doing another saliva sample.
9713049|NCT04606966|Active Comparator|Barn Activity|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor. Participants will have one assigned volunteer and will have no contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse in for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table for five minutes, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for two minutes while watching a 1-minute sand timer. Each week after conclusion of the BA intervention, participants will again sit with their group at an art table for 20 minutes followed by doing another saliva sample
9713050|NCT04606966|No Intervention|Waitlist|Those assigned to the waitlist group will not have any horse-related intervention during a 10-week waiting period. Following this waiting period and the completion of post assessments, participants in this condition will begin a Hybrid group (see Hybrid Arm)
10195104|NCT03174314|Active Comparator|50 healthy controls|50 healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
10195105|NCT03139227|Experimental|Supportive Care (celery-banana bread)|Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
9713051|NCT04606966|Experimental|Hybrid|Participants who complete the Waitlist Arm and post assessments, will begin a Hybrid group that will consist of a 5- week one hour Barn Activity (BA) group condition that consists of a small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor. Participants will have one assigned volunteer and will have no contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse in for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM. After the first 5 weeks of BA, participants will then complete 5-weeks of Therapeutic Horseback Riding small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual. Participants will have an assigned horse and volunteer(s) Group times will be between 1:00-5:00 PM.
9713052|NCT04607057|Experimental|experimental group (Arm A)|"Preparation of parenteral nutrition (PN): Among winuf(1820cc for central vein, 1,450cc for peripheral vein), smofkabaven(986cc for central vein, 1206cc for peripheral vein), and nutriplex(1875cc for central vein, 1,250cc for peripheral vein) Amount of PN: Total energy expenditure (TEE) of the patients will be calculated with Harris-Benedict Equation, activity factor, and stress factor. The amount of calorie from oral intake will be subtracted from TEE then the remainder will be provided through PN.~Route of PN Injection: PICC (percutaneously-inserted central catheter) will be secured for PN for the central vein. PN for the peripheral vein will be injected directly through peripheral superficial vein.~Day0 : fasting(NPO) + crystalloid fluid~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~POD#2 : Semifluid diet (SFD) + crystalloid fluid~POD#3 : Semifluid diet (SFD) + PN~POD#4-7: Soft blended diet (SBD) + PN"
9713053|NCT04607057|No Intervention|control group (Arm B)|"Day0 : fasting(NPO) + crystalloid fluid~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~POD#2 : Semifluid diet (SFD) + dextrose 5% water~POD#3 : Semifluid diet (SFD) + dextrose 5% water~POD#4-7: Soft blended diet (SBD)"
9713054|NCT04607070||Stroke patient|This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018.
9713055|NCT04606927|Active Comparator|Natriuresis guided treatment|
9713056|NCT04606927|No Intervention|Standard of care|
9713057|NCT04606758|Active Comparator|PCNL under fluoroscopic control|
10195106|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
9713058|NCT04606758|Active Comparator|PCNL under ultrasound control|
9713059|NCT04607031||ischemic stroke patients|20 patients with ischemic stroke, onset within 24 hours, NIHSS≥8
9713060|NCT04606953|Experimental|Attention Process Training (APT-II)|Patients in the experimental group receive the APT-II training program (Attention Process Training) individually with a psychologist for 8 weeks (2 sessions/week). The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to each patient's profile in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains towards the most problematic daily activities in order to reduce the impact of the patients' cognitive problems in their daily lives.
9713061|NCT04606953|No Intervention|Standard care|Patients in the control group receive standard routine care.
9713062|NCT04606914|Experimental|neoadjuvant chemotherapy regimen|"IV Carboplatin AUC 5 (Q21 days) 7 cycles (first cycle is Carbo alone, dosing for C1D1 will be provider's choice)~IV Mirvetuximab 6 mg/kg (adjusted ideal body weight) day 1 (Q21 days) 6 cycles (starting with cycle #2)"
10195107|NCT03133156|Experimental|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
10195108|NCT03133156|Experimental|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
10195109|NCT03133156|Experimental|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
9713063|NCT04607083||Patients with at least one diminutive rectosigmoid polyp|"Consecutive adult (>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.~Exclusion criteria:~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~patients with inadequate bowel preparation~patients in which caecal intubation was not achieved or scheduled for partial examinations~polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment~patients undergoing urgent colonoscopy."
9713064|NCT04607018|Active Comparator|Chronic intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product already before the study started (since 28 days before or even longer)
9713065|NCT04607018|Active Comparator|Naive intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product only since the first day of the study
9713066|NCT04606836|Experimental|Prospective Cases|These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).
10195110|NCT03133156|Experimental|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
10195111|NCT03122301|Active Comparator|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
10195112|NCT03122301|Sham Comparator|Saline|Saline injection
10195113|NCT03085147|Experimental|Fluorescent PARPi Binding Imaging Agent PARPi-FL|In the phase I of the study, increasing concentrations of PARPi-FL will be used in up to 12 patients with OSCC to determine concentration that results in the highest contrast between tumor and normal mucosa. Dose escalation will be performed in groups of three patients until image contrast decreases, side effects are noted or the concentration of PARPi-FL exceeds 1μM. Imaging will be performed in the Department of Surgery during a presurgical visit including clinical examination of the oral cavity. In the phase II part of the study the concentration of PARPi-FL determined in phase I will be used to image 18 patients with OSCC on the day of surgery. Imaging findings will be correlated with histopathologic findings in the surgically resected specimens.
10195114|NCT03077594|Other|Successfully ablated patients|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy.
10195115|NCT03077594|Other|Successfully ablated patients - VLE|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy. Volumetric laser endomicroscopy (VLE) will be done.
10195116|NCT03034356|Experimental|Levetiracetam, Then Placebo|4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
10195117|NCT03034356|Experimental|Placebo, Then Levetiracetam|4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
10195118|NCT03032510|Experimental|Eravacycline (Intravenous)/Levofloxacin (Oral)|
10195119|NCT03032510|Active Comparator|Ertapenem (Intravenous)/Levofloxacin (Oral)|
10195120|NCT03029000|Experimental|Tbo-filgrastim (GRANIX)|"Participants will receive tbo-filgrastim 10 mcg/kg of body weight, subcutaneously on the morning of Days 1 to 5.~The actual dose of tbo-filgrastim administered to each, individual participant will be calculated at baseline according to his or her body weight and that specific dose (10 mcg/kg of body weight) for each, individual participant will remain the same for all consecutive daily doses.~If the collection goal will not meet after the first apheresis on Day 5, tbo-filgrastim 10 mcg/kg of body weight will be administered subcutaneously for up to 3 additional days (Days 6 to 8) followed by daily apheresis to reach the cumulative collection goal."
10195121|NCT03022708|Experimental|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~In addition, the PV conduit can be used for the following indications:~replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).~Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
10195122|NCT03022292|Experimental|IAI Treatment|Intravitreal injection of aflibercept 2 mg/0.05 ml at baseline, week 4, week 8, week 16, week 24, week 36, and week 48. Additional injections can be administered during the remaining visits on an as needed basis per Primary Investigator (PI) discretion based on the presence of any intraretinal or subretinal fluid on OCT, heme visualized on examination, reduction of BCVA by 5 or more ETDRS letters, or evidence of either increased area, density, or activity of the brush border of the neovascularization on OCT-angiography. There will be a minimum of 21 days between subsequent injections. Each subject will therefore receive a minimum of 7 injections and up to a maximum of 13 injections throughout the study period.
10195123|NCT03012100|Experimental|Arm I (FRalpha peptide vaccine, sargramostim)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of cycle 1 only. Starting cycle 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
10195124|NCT03012100|Placebo Comparator|Arm II (placebo, sargramostim)|Patients receive cyclophosphamide as in Arm I. Starting cycle 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
9713067|NCT04606836|No Intervention|Retrospective Controls|Controls will be gathered retrospectively from chart reviews where patient did not receive a intercostal nerve blocker bilaterally.
9713068|NCT04606719|Other|Blood Clot|It is induced through apical foramen by penetrating the periapical area by stainless steel file size 30 to fill the root canal system by growth factors also to be considered as scaffold
9713069|NCT04606719|Active Comparator|Standard PRF|Standard Platelet-rich fibrin will be prepared by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 3000 rpm for 10 min. After centrifugation, three layers will formed in the test tube-base layer of RBCs, top layer of a-cellular plasma, and a PRF clot in the middle. This clot will then pressed between two gauze pieces to form a membrane.
9713070|NCT04606719|Experimental|Advanced PRF|A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
9713071|NCT04606940||IO-KIN|Patients with a histological or cytological confirmed recurrent, metastatic or advanced HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or unknown origin (but being treated as HNSCC). Patients who are going to receive at least one dose of anti-PD1 antibody (nivolumab or pembrolizumab).
10195125|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
10195126|NCT02994368||Primary Cohort|No intervention
10195127|NCT02994368||Expansion Cohort|No intervention
10195128|NCT02973997|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
10195129|NCT02968602|Experimental|Minocycline|Participants will take 50 mg minocycline capsules twice daily for 1 week, then take 100 mg capsules twice daily for 1 week.
10195130|NCT02968602|Placebo Comparator|Placebo|Participants will take capsules that match active drug, but contain no active ingredients, twice daily for week 1, and then will take capsules that match active drug, but contain no active ingredients, twice daily for week 2.
10195131|NCT02966691|Active Comparator|Patients 'sick'|"The patients of this arm have a clinical signs of bladder cancer with :~a positive result of bladder endoscopy~or an negative endoscopy and a positive result of the conventional cytology~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice .This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized"
10195132|NCT02966691|Active Comparator|Patients 'healthy'|"The patients of this arm have no suspicion of bladder cancer with negative results of their bladder endoscopy and conventional cytology.~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
10195133|NCT02966691|Active Comparator|Patients 'monitoring'|"The patients of this arm have a history of bladder cancer, but the results of their follow up examinations (cytologic and endoscopic) are negative (no tumor).~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
10195134|NCT02963285||0 to 6 months|
10195135|NCT02963285||7 months to less than 1 year|
10195136|NCT02963285||1 to less than 2 years|
10195137|NCT02963285||2 to less than 6 years|
9713072|NCT04606862|Experimental|Investigational Arm|The patients enrolled into the investigational arm at each participating hospital will be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis.
9713073|NCT04606862|No Intervention|Control Arm|The patients enrolled into the control group of each participating hospital will not be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis. These patients will be monitored according to each institution's standard sepsis screening practices.
9713074|NCT04606615||Adults: AD + FA|Adults: atopic dermatitis and food allergy to peanut
9713075|NCT04606615||Adults: AD - FA|Adults: atopic dermatitis and no food allergy
9713076|NCT04606615||Adults: NC|Adults: Normal Control
9713077|NCT04606615||Children: AD+ Peanut|Children: atopic dermatitis and food allergy to peanut
9713078|NCT04606615||Children: AD + Milk|atopic dermatitis and food allergy to milk
9713079|NCT04606615||Children: AD + Egg|atopic dermatitis and food allergy to egg
9713080|NCT04606615||Children: AD only|atopic dermatitis and no food allergy
9713081|NCT04606615||Children: NC|Normal Control
9713084|NCT04606589|No Intervention|Standard-of-care|The standard-of-care arm will receive intermittent monitoring of pulse rate and blood oxygen saturation with a conventional pulse oximeter. Temperature and respiratory rate will also be monitored intermittently with a digital thermometer and manual counting of breaths respectively.
9713085|NCT04606589|Experimental|neoGuard vital signs monitor|The intervention group will receive continuous vital signs monitoring of pulse rate, blood oxygen saturation, temperature and respiratory rate with the neoGuard device.
9713086|NCT04606849|Other|Physician Survey|A modified version of a previously validated REDCap questionnaire will be administered to Instacare clinicians in the cluster where ePNa-CheXED was deployed via email at 6 months after ePNa-CheXED implementation. Our questionnaire includes questions on respondent demographics and Likert-style questions about respondents' experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components
9785202|NCT01245647|Placebo Comparator|Sugar Pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
10195138|NCT02963285||6 to 12 years|
9713087|NCT04606849|Other|Adapt ePNa-CheXED for InstaCares|"Adapt ePNa-CheXED for Instacares and after in silico testing, pilot it among super user clinicians during Instacare shifts and assess its usability. ePNa needs adaptation for more limited patient data available in Instacare clinics, calibration of severity measures for lower observed mortality, and a chest imaging prompt in patients with pneumonia signs and symptoms. ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion)."
9713088|NCT04606563|Experimental|Losartan|Patients will initially receive 25 mg oral losartan, increased to 50 mg after 24 hours and then increased to a max dose of 100 mg after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at 25 or 50 mg.
9713089|NCT04606563|No Intervention|Usual Care Control|Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country
9713090|NCT04606810|Active Comparator|Arm1, Participants received the multidisciplinary educational intervention at baseline|Participants in arm1 received the usual care plus the multidisciplinary educational intervention consisting of an educational DVD followed by a teleconference at baseline.
9713091|NCT04606810|Other|Arm2, Participants in arm2 received the educational intervention after 3 months|Participants in group 2 first received usual care, and after 3 months were offered the multidisciplinary educational intervention.
9713092|NCT04606979|Experimental|Parkinson Disease - Group 1a - Active tDCS first|Half of the subjects with PD will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive sham (placebo) tDCS.
9713093|NCT04606979|Sham Comparator|Parkinson Disease - Group 1b - Sham tDCS first|Half of the subjects with PD will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive active (anodal, real) tDCS.
9713094|NCT04606979|Experimental|Healthy Controls - Group 2a - Active tDCS first|Half of the healthy controls will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive sham (placebo) tDCS.
9713095|NCT04606979|Sham Comparator|Healthy Controls - Group 2b - Sham tDCS first|Half of the healthy controls will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive active (anodal, real) tDCS.
9713096|NCT04606888|Experimental|Transcutaneous electrical acupoint stimulation group|Transcutaneous electrical acupoint stimulation group patients received Transcutaneous electrical acupoint stimulation (Neiguan [PC6], Yintang [GV 29], Zusanli [ST36]) for 30 min before the induction of anaesthesia until the end of the surgery and the night before operation, the first, second and third night after operation 30 min once a day with an altered frequency 2/100 Hz, disperse-dense waves, adjusted electricity intensity which was less than 10 mA.
9713097|NCT04606888|No Intervention|Control group|In Control group, except the electronic stimulation was not applied, the treatment was the same as the Transcutaneous electrical acupoint stimulation group.
9713098|NCT04606537|Experimental|Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)|
9713099|NCT04606537|Experimental|Cohort 2 (Effects of CYP3A4 induction on KBP-5074)|
9713100|NCT04606641|Experimental|Goal specific functional tasks with mirror therapy):|"The session will be performed thrice in a week for total of 4 weeks. Each session will last for 20 minutes. Mirror therapy procedure and functional tasks will be explained to the patient before the start of treatment.~In this group, a mirror will be placed in the sagittal plane of the patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror"
9713101|NCT04606641|Active Comparator|Goal specific functional tasks without mirror therapy|"Session will be performed thrice in a week for total 4 weeks. Each session will last for 20 minutes.~The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks as mentioned in the table below Functional tasks will be same in both groups"
9713102|NCT04606524||study group|25 postmenopausal females will be included in this study
10195139|NCT02962973|Experimental|Carmat TAH|The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.
9713103|NCT04606524||control group|25 premenopausal females will be included in this tudy
9713104|NCT04606654|Experimental|Handgrip strength training with Blood flow restriction|"Three sessions per week will be given to individual subject. and training will be with Blood flow restriction.~Subjects will be followed for two weeks for;~Hand grip strength~Forearm circumference"
9713105|NCT04606654|Active Comparator|Handgrip strength training without Blood flow restriction|"Three sessions per week will be given to individual subject and training will be without Blood flow restriction.~Subjects will be followed for two weeks for;~Hand grip strength~Forearm circumference"
9779519|NCT05233761|Experimental|Defined CBD|Defined CBD will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that contain a total of 300 mg CBD and 8 mg terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks.
9785203|NCT01245647|Active Comparator|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
10195140|NCT02946047|Experimental|Ixazomib 1 mg|Cohort A: Patients will receive ixazomib 1mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
10195141|NCT02946047|Experimental|Ixazomib 2 mg|Cohort B: Patients will receive ixazomib 2mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
10195142|NCT02946047|Experimental|Ixazomib 3 mg|Cohort C: Patients will receive ixazomib 3 mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
9713106|NCT04606667|Experimental|Multi component program|"The intervention lasted 16 weeks, with the evaluations carried out at baseline, after 8 weeks and at the end.~The multi-component exercise program took place in day centers or collective residences. It was supervised by physiotherapists. The classes took place 3 times a week, at the same hour and on alternate days, for 45-60 minutes, for a total of 48 sessions. The program consisted on a warm-up (5 min) with exercises and walking, a balance and strength training (35-40 min) with exercises repeated 3 times and held for 15 seconds flexibility / relaxation (5 to 10 mins) periods. The strength training is performed with the resistance of the body weight or accessible and low cost equipment, with two series of 10 to 15 repetitions, after maximum resistance was calculated.~The flexibility and cooling training consists of 3 repetitions maintained for 15 seconds."
9713107|NCT04606680|Experimental|Heat application group|Participants will receive heat application at acupoints plus lifestyle modification. Participants will receive heat application treatment once every other day, 3 times per week, for 4 consecutive weeks.
9713108|NCT04606680|Experimental|Medicated plaster group|Participants will receive medicated plaster at acupoints plus lifestyle modification. Participants will receive medicated plaster at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
9713109|NCT04606680|Experimental|Herb-partitioned moxibustion group|Participants will receive herb-partitioned moxibustion at acupoints plus lifestyle modification. Participants will receive herb-partitioned moxibustion at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
9713110|NCT04606875||Control Group|Subjects will have no personal or family psychiatric history and no suicide attempts.
9713111|NCT04606875||Patients with Suicidal Ideation and Low Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
9713112|NCT04606875||Patients with Suicidal Ideation and High Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
9713113|NCT04606511|Other|Breast cancer patients with lymphedema|
9713114|NCT04606511|Other|Breast cancer patients without lymphedema|
9713115|NCT04606550|Experimental|Vaginal Laser HR+|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
9713116|NCT04606550|Active Comparator|Vaginal Estrogen HR-|The women in the vaginal estrogen group will be prescribed and asked to administer: Conjugated estrogen cream (Premarin®): 0.5 g of cream intravaginally daily (using applicator or fingertip) for two weeks (fourteen days) then 0.5 g twice weekly for 24 ± 2 additional weeks.
9713117|NCT04606550|Active Comparator|Vaginal Laser HR-|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
9713118|NCT04606485|Placebo Comparator|Placebo group|"Since acupressure administration was reported to have placebo effects, a placebo group was used to investigate the true effect of acupressure use. The application of placebo may consist of moderate pressure on an incorrect acupuncture point or a light touch on a real acupuncture point. This will allow us to determine the contribution of the placebo effect resulting from direct human contact and interaction in the light touch group.~At postoperative 0, 4, and 8 hours, a light touch was applied to the ST25 (Stomach Meridian 25th point), CV12 (Conception Vessel Meridian 12th point), TH6 (Triple Heater Meridian 6th point) and HT7 (Shenmen point points) for one second. No patients experienced pain or a feeling of pressure."
9713119|NCT04606485|Experimental|Experimental group|"As invasive acupuncture may cause hematoma and the wristband method of non-invasive acupressure may cause patient discomfort, itching, swelling of the wrist, and skin destruction, manual acupressure was applied in this study to reduce the risk of complications to a minimum.~The frequency and duration of the application of acupressure was decided from a scan of literature and expert opinion. The first acupressure session was applied in the first postoperative hour immediately after routine treatment and care of the patients who came to the ward from the recovery unit. Acupressure by applying pressure with the thumbs for a total of 12 mins, as 3 mins at each of the ST25, CV12, TH6 and HT7 acupuncture points, was performed at 0, 4 and 8 hours postoperatively. The acupuncture points were determined using the measurements of the patient's own fingers."
9713120|NCT04606277||Young Adult|
9713121|NCT04606368|Experimental|Interventional cohort|Each subject will serve as their own control. Left side of lower jaw and submental area is control side. Right side of subject's lower jaw and submentum area will receive treatment.
9713122|NCT04606199|Experimental|Mindfulness-based intervention|Participants will be randomly assigned to an app-based intervention that includes brief (<5 min) audio-guided mindfulness and compassion-based practices.
9980199|NCT01389414|Experimental|Arm A- p-Gemox|"Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once Q2W.~GEMOX chemotherapy will be administered after the administration of panitumumab once Q2W.~Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle."
10195143|NCT02946047|Experimental|Ixazomib 4 mg|Cohort D: Patients will receive ixazomib 4mg 3 times monthly for 12 weeks, then weekly for 12 weeks.
10195144|NCT02926924|Active Comparator|Wound Vac|Wound vac
10195145|NCT02926924|Active Comparator|Standard Dressing|Standard Dressing
10195146|NCT02912104|Experimental|hAECs transplantation|To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of POF patients
10195147|NCT02878044|Experimental|Implementation Arm|
10195148|NCT02860000|Experimental|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
9713123|NCT04606199|No Intervention|No intervention|Participants will continue their normal activities and not practice any form of mindfulness mediation at the time of app-notification.
10195149|NCT02860000|Experimental|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10195150|NCT02832648|Experimental|selenase 200mcg|selenium as selenase 200mcg once daily, oral
9713124|NCT04606134|Experimental|Experimental|
9713125|NCT04606134|Placebo Comparator|Control|
9713126|NCT04606147|Experimental|Group 1 ((Serratus Anterior Plane Block SAPB)) N=3o|Patients received Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
9713127|NCT04606147|Experimental|Group 2 ((Erector Spinae Plane Block ESPB)) N=3o|Patients received Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
9713128|NCT04606472|Experimental|Study treatment|Participants receive SI-B003 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
9713129|NCT04606043|Experimental|Sandblasting|The enamel surfaces will be subjected to sandblasting prior to acid etching
9713130|NCT04606043|Active Comparator|Acid Etching Alone|Acid etching will be applied alone before the rebounding procedures
9713131|NCT04606173|Experimental|Standard Practice plus TEACH|Primary care teamlets will receive standard organizational education and support regarding suicide prevention and also engage in Team Education for Adopting Changes in Healthcare (TEACH) huddles.
9713132|NCT04606173|No Intervention|Standard Practice|Standard Practice condition will involve the current evidence-based support included in web-based provider-trainings and electronic medical record reminders/templates that are standard within an organization
9713133|NCT04606212|Experimental|Losartan group|
9713134|NCT04606212|Placebo Comparator|Placebo group|
9713135|NCT04606251|Experimental|Arm 1: Exercise Group|This group will consist of the subjects taken for 6 weeks of exercise.
9713136|NCT04606251|No Intervention|Arm 2: Control Group|This group will consist of the subjects who did not receive any intervention for 6 weeks and were evaluated before and after 6 weeks.
9713137|NCT04606433|Experimental|Study treatment|Patients receive GNC-038 as intravenous infusion for one cycle. Participants with no intolerable AEs could continue for another three cycles. Participants with a clinical benefit after four cycles' treatment could also receive additional treatment for another four cycles at the same dose level.
9713138|NCT04606329|Experimental|LuminoMark inj.|Injection LuminoMark inj. 0.2mL once in this study.
9713139|NCT04606329|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
9713140|NCT04606420|Experimental|Experimental (Intervention) Group|These patients will receive the comprehensive lifestyle medicine intervention from day 1 through the end of the study. They will be tested at baseline, after 20 weeks, and after 40 weeks. There may be subsequent testing after 2 years.
9713141|NCT04606420|No Intervention|Control (Non-Intervention) Group|"These patients will be asked to continue their current diet and lifestyle without making any changes for 20 weeks. They will be tested at baseline and after 20 weeks. Then, they will cross over and receive the same lifestyle medicine intervention for 20 weeks and will be tested again after 20 weeks of the intervention and also after 40 weeks of the intervention. There may be subsequent testing after 2 years."
9713142|NCT04606186|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
9713143|NCT04606186|Placebo Comparator|Placebo-lozenges (BioGaia)|
9713144|NCT04606056||Patients who underwent contrast enhanced CT scans|
9713145|NCT04606225|Experimental|Losartan group|Drug: Losartan
9713146|NCT04606225|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
9713147|NCT04606082|Experimental|Group 1|Granulocyte Colony Stimulated Factor was intrauterine injected once at ovum pick up day
9713148|NCT04606082|Active Comparator|Group 2|500 IU Human Chorionic Gonadotropins was injected intrauterine once at ovum pick up day
10195151|NCT02832648|Experimental|selenase 50mcg|selenium as selenase 50mcg once daily, oral
10195152|NCT02832648|Placebo Comparator|placebo|matched placebo, once daily, oral
10195153|NCT02830165|Experimental|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
10195154|NCT02821013|Active Comparator|Arm 1: Intermittent PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
10195155|NCT02821013|Active Comparator|Arm 2: Continuous PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
10195156|NCT02784704|Experimental|Eravacycline|
9713149|NCT04606108|Experimental|Experimental|camrelizumab in combination with Liposome doxorubicin and Ifosfamide intervention
9713150|NCT04606303|Experimental|Toripalimab Combined With Platinum-containing Dual-agent.|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer.
9713151|NCT04606238|No Intervention|Group without DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
9713152|NCT04606238|Other|Group with DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
9713153|NCT04606017||Vitamain D|This group of patients were supplemented with 125IU/d Vitamin D
10195157|NCT02784704|Active Comparator|Meropenem|
10195158|NCT05241587|Experimental|The chewing gum group|"Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010). Therefore, this group of patients was allowed to chew xylitol gum for 10 minutes, five times a day for six weeks."
10195159|NCT05241587|Experimental|The mouth spray group|The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request.
10195160|NCT05241574|Experimental|radiotherapy dose escalation|Additional two fractions of endorectal high dose rate iridium brachytherapy boost, 10 Gy each.
10195161|NCT05241574|Experimental|chemotherapy dose escalation|Additional three cycles of consolidation chemotherapy consisted of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4).
9713154|NCT04606017||Control|The other group did not receive the supplementation of 125IU/d Vitamin D
9713155|NCT04605770|Experimental|pemetrexed+cisplatin|Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.
9713156|NCT04605757||Patients with acute respiratory failure due to SARS-COV-2|Patients admitted to hospital with acute respiratory failure due to SARS-COV-2 infection causing pneumonia
9713157|NCT04605705||Group 1|NIRS values will be recorded during the surgery and until 24 hours postoperatively. No intervention will be done.
9713158|NCT04605705||Group 2|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
9713159|NCT04605848|Experimental|BAT group|"Patients will be divided in two groups for statistical analysis:~patients with detectable BAT by PET-CT (BAT+)~patients with no detectable BAT by PET-CT (BAT-)"
9713160|NCT04605835||Main group|484 children with congenital obstructive uropathies
9713161|NCT04605887|Active Comparator|treatment group|Ang 1-7 subcutaneously 500 mcg/kg /day
9713162|NCT04605887|Placebo Comparator|control group|NaCl 0.9% subcutaneously 2.0 cc once a day
9713163|NCT04605952||SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020|As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days
9713164|NCT04605809|Experimental|combined motor and cognitive training|The combined motor and cognitive training group will undertake physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training.
9713165|NCT04605809|Active Comparator|motor training alone|The motor training alone group will train the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group.
9713166|NCT04605809|Active Comparator|cognitive training alone|The cognitive training alone group will train the same set of cognitive training while sitting as the combined motor and cognitive training group.
9713167|NCT04605809|No Intervention|no intervention control group.|No intervention control group will maintain habit and daily activity.
9713168|NCT04606004|Experimental|Experimental (standard of care + stool application)|In addition to standard of care, they will apply stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time.
9713169|NCT04606004|Active Comparator|Control group (standard of care)|Will follow standard of care for skin care pre-operatively. They will not be applying ostomy stool output to the skin but can apply an OTC skin barrier such as Aquaphor, Desitin, or Vitamin A&D if the patient is experiencing skin redness from urine incontinence.
9713170|NCT04605900|Experimental|Standard Footwear (SF)|Intervention: plantar orthoses, education on foot self-care and appropriate standard footwear.
9713171|NCT04605900|Experimental|Orthopedic Footwear (OF)|Intervention: plantar orthoses, education on foot self-care and orthopedic footwear.
9713172|NCT04605926|Experimental|EQ001|EQ001 administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
9713173|NCT04605926|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
9713174|NCT04605666|Experimental|CAR-T group|
9713175|NCT04605627||Chronic coronary syndrome|50 patients with chronic coronary disease
9713176|NCT04605627||Non ST segment-elevation myocardial infarction|75 patients with non ST-elevation myocardial infarction
9713177|NCT04605627||ST-elevation myocardial infarction|75 patients with ST segment-elevation myocardial infarction
9713178|NCT04605640|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
9713179|NCT04605562|Experimental|IC+CCRT with palbociclib|If patients were non-Immune Subtype.
9713180|NCT04605562|Experimental|IC+CCRT with galunisertib and PD-1 blocking antibody|If patients were Evaded Immune Subtype.
9713181|NCT04605562|Experimental|IC+CCRT with PD-1 blocking antibody|If patients were Active Immune Subtype.
9713182|NCT04605523||Patients with Ataxia Telangiectasia|
9713183|NCT04605523||Healthy controls|
9713184|NCT04605601|Experimental|Study Group|
9713185|NCT04605601|Other|Control Group|
9713186|NCT04605419|Experimental|Calcium electroporation|Calcium chloride
9785774|NCT01259596|Active Comparator|Nondirective supportive therapy|Nondirective supportive therapy consists of providing a warm and accepting environment in which a person can reflect on their experiences, thoughts, and feelings
10195162|NCT05241548|Experimental|Intervention Group|Ridge augmentation of horizontally deficient alveolar ridge in aesthetic zone by BMAC on PCL scaffold
10195163|NCT05241509|Experimental|Group I (test)|included twenty patients treated with SRP and intrapocket application of 2% lemongrass oil gel.
9713187|NCT04605367|Experimental|100% PP, a-TDCS|"After the pre-test:~repetition of the correct sequence as many times as possible (12 blocks of 30s).~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
9713188|NCT04605367|Experimental|100% PP, sham TDCS|"After the pre-test :~physical repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
9713189|NCT04605367|Experimental|100% MP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test:~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm².)"
10195164|NCT05241509|Placebo Comparator|Group II (control)|included twenty treated with SRP and intrapocket application of placebo gel.
9713190|NCT04605367|Experimental|100% MP, sham TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
9713191|NCT04605367|Experimental|50% MP and 50% PP, a-TDCS|"After the pre-test :~mental repetition of the correct sequence as many times as possible, during 6 blocks of 30s. Then physical repetition of the correct sequence as many times as possible, during 6 blocks of 30s.~After the post-test : they will receive the real stimulation. Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
9713192|NCT04605367|Experimental|50% MP and 50% PP, sham TDCS|For both tasks, the training modalities are the same. After the pre-test, this group will have to mentally repeat the correct sequence as many times as possible, during 6 blocks of 30s. Then they will have to physically repeat the correct sequence as many times as possible, during 6 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the sham stimulation. The sham stimulation will be consisted of a gradual increase in current for 30 seconds until 1mA, immediately followed by gradual decrease for 30 s until 0mA.
9713193|NCT04605367|No Intervention|No practice, No stimulation|After the pre-test, this group will read an article for 12 minutes. After this training, they will perform the post-test. Immediately after this, they will read another article during 15 minutes.
9713194|NCT04605276||Pre-biopsy cohort|"Male patients of age ≥18 suspected for prostate cancer who are scheduled for systematic and/or targeted biopsy after mpMRI examination.~No intervention study"
9713195|NCT04605276||Pre-radical prostatectomy cohort|Male patients of age ≥18 diagnosed with prostate cancer who are scheduled for radical prostatectomy
9713196|NCT04605588|Active Comparator|Active Study Drug|5 day dosing of Nitazoxanide, Ribavirin & Hydroxychloroquine sulfate
10195165|NCT05241431|Active Comparator|Intervention group|10 mg (oral) SGLT-2 inhibitor once daily
10195166|NCT05241431|Placebo Comparator|Control group|Placebo tablet encapsulated as the active treatment.
9713197|NCT04605588|Placebo Comparator|Placebo|5 day dosing of placebo
9713198|NCT04605458|Experimental|Contingency Management|
9713199|NCT04605458|Active Comparator|Standard Care|
10195167|NCT05241418||Patients with congenital heart disease undergoing a cardiac MRI with Gadolinium|Patients with congenital heart disease who are undergoing a clinically-ordered cardiac MRI and as part of that MRI the contrast agent, Gadolinium, will be administered.
10195168|NCT05241405|Experimental|Qiseng|200 mg/capsule of P. quinquefolius extract, i.e. 30 mg of ginsenosides, associated with 30 mg of vitamin C extracted from Camu Camu berry
10195169|NCT05241405|Placebo Comparator|Placebo|neutral microgranules of Qiseng® excipients without P. quinquefolius or Camu Camu extract
10195170|NCT05241392|Experimental|CAR-T cell therapy|"Dose-escalation phase:~A 3+3 dose-escalation design is used to determine MTD & R2PD. Anti-B7-H3 autologous CAR-T cells were given biweekly to patients at the following doses for each cycle, and 4 cycles as one course. Dose1: 3 patients at a dose of 20 million cells for each cycle. Dose 2: 3 patients at a dose of 60 million cells for each cycle. Dose 3: 3 patients at a dose of 150 million cells for each cycle. Dose 4: 3 patients at a dose of 450 million cells for each cycle. Dose 5: 3 patients at a dose of 900 million cells for each cycle.~R2PD confirmation phase:~Determine the R2PD based on the results from the previous dose-escalation study; Treat another 12 patients with anti-B7-H3 autologous CAR-T cells biweekly at the R2PD to further confirm the safety of R2PD.~At each dose phase, if the patients show tolerate and response to the treatment, these patients would receive several courses of treatment at PI's discretion."
10195171|NCT05241379|Experimental|Amber UI Therapy|Participants will undergo surgical implantation of the Amber UI System incorporating 2 electrode leads connected to a single IPG
10195172|NCT05241327|Active Comparator|Active|Beetroot Juice (Nitrate, 400 mg)
10195173|NCT05241327|Placebo Comparator|Placebo|Beetroot Juice (Nitrate, 0 mg)
10195174|NCT05241314|Experimental|Phase 1 Youth Focus Group|Intervention adaptation and Community Health Worker Interventionist (CHWI) training through the delivery of the intervention to an adolescent focus group. CHWI from WellShare International will lead the recruitment of adolescent youth from the existing cohort of families and up to two Zoom focus groups will be held.
9713200|NCT04605289|Experimental|Group I (study group)|Scaling and root planing + intra-pocket application of 2% Cymbopogon citratus (lemon-grass) gel
9713201|NCT04605289|Placebo Comparator|Group II (control group)|Scaling and root planing +intra-pocket application of placebo gel
9713202|NCT04605536|Other|Intervention|Give explanations about conventional capsule endoscopy and watch animation videos
9713203|NCT04605536|Other|Control|Give explanations about conventional capsule endoscopy
9713204|NCT04605575|Experimental|Pyrotinib plus vinorelbine|
9713205|NCT04605393|Experimental|Placebo/THC|Oral placebo followed by inhalation of cannabis containing THC.
9713206|NCT04605393|Experimental|CBD/THC|Oral CBD 1000mg followed by inhalation of cannabis containing THC.
9713207|NCT04605263|Active Comparator|STN DBS|Subjects will receive traditional bilateral STN devices and stimulation.
9713208|NCT04605263|Experimental|STN-PPN DBS|Patients will be implanted with both bilateral STN and bilateral PPN devices. These patients will undergo a crossover between 3 and 15 months post-op in which they will double-blindly receive PPN stimulation for six months and have stimulation turned off for six months. All patients will receive stimulation from 0-3 months post-op (mapping visits occur in this window) and from 15-27 months.
9713209|NCT04605146|Experimental|Tele-monitoring group|"In the experimental group, in addition to routine practice, each patient will benefit of a tele-monitoring of one year, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.~50 patients are expected in this arm."
9713210|NCT04605146|No Intervention|Control group|"In the control group, patients will have a routine follow-up as per institutional practice, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.~50 patients are expected in this arm."
9713211|NCT04605133||ARDS|Patients with mild or severe ARDS necessitating of prone position during mechanical ventilation
9713212|NCT04605198|Experimental|Modified Mindfulness-based Stress Reduction|
10195175|NCT05241314|Experimental|Phase 2 Youth|One randomly selected index youth per participating Karen family. Community health worker interventionists (CHWI) will deliver 7 weeks of home-based intervention with optional post-intervention focus groups to examine the feasibility of the community-based participatory research approach and intervention delivery by CHWIs.
9713213|NCT04605198|Active Comparator|Health Promotion Attention Control|
10195176|NCT05241314|Experimental|Phase 2 Caregivers/Adults|Maternal and paternal caregivers (if present) of participating Karen family. Community health worker interventionists (CHWI) will deliver 7 weeks of home-based intervention with optional post-intervention focus groups to examine the feasibility of the community-based participatory research approach and intervention delivery by CHWIs.
10195177|NCT05241314|Experimental|Phase 1 Community Leadership Board (CLB)|Intervention adaptation and community health worker interventionist (CHWI) training through the delivery of the intervention to Community Leadership Board (CLB) members. The CLB will be made up of 4-7 Karen professionals representing prominent local organizations supporting Karen refugees in resettlement. Representatives will have lived cultural and historical expertise as well as professional expertise supporting the resettled community from mental health and social services perspectives. The expertise of the board ensures culturally centered preparations for intervention dissemination. The CLB will take an active role in the adaptation of the intervention.
9713216|NCT04605224||Culinary class (intervention group)|The culinary class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
9713217|NCT04605224||Social studies class (control group)|The social studies class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
9713218|NCT04605250|Other|Adults undergoing abdominal surgery with laparotomy|Respiratory variability before and after abdominal surgery
9713219|NCT04605445|Experimental|1 visit endodontics|Root canal treatment is performed in one visit.
9713220|NCT04605445|Active Comparator|2 visits endodontics|Root canal treatment is performed in two visits.
9713221|NCT04605302|Experimental|Single Arm Tandem Study|Patients are assigned to swallow a magnetically controlled capsule first then undergo standard gastroscopy
10195178|NCT05241275|Experimental|Progressive Pulmonary Fibrosis|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis patients receiving approved treatments.
9713222|NCT04605471||PMS I study|"'PMS I' was conducted in contrast-enhanced X-ray examination between June 1999 and November 2003 in 27 countries in Europe, Africa and Asia and comprised 74,717 patients of which 2,172 were children and 32,103 were elderly patients.~Ref. Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol. 2008;49(8):902-11."
9713223|NCT04605471||IMAGE study|"'IMAGE' consists of 44,835 patients with contrast-enhanced X-ray examination and was conducted in 21 European and Asian countries from February 2008 to September 2009, 1,451 patients were children, and 15,654 were elderly patients.~Ref. Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon ST, Zhang SX, et al. Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE). Acta Radiol. 2012;53(2):179-86."
9713224|NCT04605471||TRUST study|"'TRUST' assessed the safety and tolerability of Ultravist in patients undergoing cardiac catheterization. It was conducted from August 2010 to September 2011 in China and included 17,513 patients of which 12 were children and 8,918 were elderly patients.~Ref. Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, et al. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Int J Cardiovasc Imaging. 2015;31(7):1281-91."
10195179|NCT05241262|Experimental|Active drug (NAC)|Participants will receive NAC for 3 months.
9713225|NCT04605471||Ultravist in CT study|"'Ultravist in CT' was performed with focus on contrast-enhanced CT examination between November 2006 and December 2008 and included 15,168 patients in Germany, Iran, Romania and Saudi Arabia. A total of 417 patients were children, 7,453 were elderly patients.~Ref. Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014;55(6):707-14."
9713226|NCT04605510|Experimental|Intervention Group|24 female participants with non-specific neck pain included in the mobilization group will undergo detailed manual cervical examination. In the evaluation, the most painful segment with dysfunction will be selected and mobilization application and algometric measurements will be performed on this segment. Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied in 3 sets, 30 seconds, to the segment with the detected dysfunction.
9713227|NCT04605510|No Intervention|Healthy Control Group|Healthy volunteer participants included in the control group will only be applied an evaluation protocol and blood samples will be taken without any application.
9713228|NCT04605068|Active Comparator|Transverse preputial island flap (Duckett's technique)|72 patients (Group I) with penoscrotal hypospadias with chordee
9713229|NCT04605068|Active Comparator|Double-faced preputial flap (DFPF)|72 patients (Group II) with penoscrotal hypospadias with chordee
9713230|NCT04605107|Experimental|A test|Epifasi 5000 I.U. Ampoules
9713231|NCT04605107|Active Comparator|B reference|Pregnyl 5000 I.U. Ampoules
9779520|NCT05233761|Placebo Comparator|Placebo|The placebo control will be administered as two small capsules that will be taken orally with a glass of water one hour before bedtime that do not contain any CBD or terpenes. Participants will take the treatment on a minimum of four nights per week, over a total of four-weeks. The Placebo capsules will look and smell identical to the Defined CBD capsules.
9779521|NCT05230771|Experimental|Palliative surgery after translational therapy|After randomization, patients received palliative surgery after translational therapy
9779522|NCT05230771|Active Comparator|Chemotherapy alone|After randomization, patients received chemotherapy alone
9779523|NCT05230537|Experimental|Iptacopan (LNP023)|Iptacopan (LNP023) oral use capsules
9779524|NCT05230537|Placebo Comparator|Placebo|Placebo matched to study drug, oral use capsules
9779525|NCT05228990|Experimental|Warm acupuncture - observation group|"Sequence A: Participants will receive warm acupuncture for 20 minutes twice a week for eight weeks.~Sequence B: Patients will be observed without any intervention for eight weeks."
9779526|NCT05228990|Experimental|Observation - warm acupuncture group|Sequence A: Patients will be observed without any intervention for eight weeks. Sequence B: Participants will receive warm acupuncture for 20 minutes twice a week for eight weeks.
9779527|NCT05227742|Placebo Comparator|Placebo (0 mg psilocybin)|Participants in this arm will receive 0 mg of psilocybin once per week for 5 weeks.
9779528|NCT05227742|Experimental|1 mg psilocybin|Participants in this arm will receive 1 mg psilocybin once per week for 5 weeks.
9779529|NCT05227742|Experimental|2.5 mg psilocybin|Participants in this arm will receive 2.5 mg psilocybin once per week for 5 weeks.
9779530|NCT05227742|Experimental|5 mg psilocybin|Participants in this arm will receive 5 mg psilocybin once per week for 5 weeks.
9779531|NCT05225038|Active Comparator|Control Arm (Standard of Care)|Participants will receive the current standard preoperative education and counseling. Participants will receive information regarding exercise and nutrition from a member of the surgical team. Participants will meet with a behavioral medicine specialist for additional education regarding factors affecting postoperative stress and relaxation techniques. Participants who are actively smoking will be counseled regarding smoking cessation and offered a referral to smoking cessation resources.
9779532|NCT05225038|Experimental|Intervention Arm (Prehabilitation)|"Participants in the intervention arm will receive all of the standard of care, as listed above, as well as individualized exercise and nutritional prehabilitation regimens.~During the data analysis, participants will be subdivided into treatment groups, upfront surgical resection versus neoadjuvant chemotherapy, in order to determine whether length of prehabilitation affected outcomes and distinguish any possible effect of chemotherapy toxicity."
9779533|NCT05223335|Experimental|Genotype-Guided Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 LOF allele within one week of DAPT initiation. In this group, subjects identified as CYP2C19*2 or*3 LOF allele carrier will be given prasugrel or ticagrelor monotherapy.
9779534|NCT05223335|Active Comparator|Conventional Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 LOF allele within one week of DAPT initiation. In this group, subjects identified as CYp2C19*2 or*3 LOF allele non-carriers will continue with clopidogrel monotherapy.
9779535|NCT05221307|Experimental|1/Children with cerebral palsy|Modified Pilates Exercises (MPEs) will be applied 3 days a week, 45 minutes a day for 8 weeks.
9779536|NCT05221307|Active Comparator|2/children with cerebral palsy|Traditional Neurodevelopmental Therapy (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks.
9779537|NCT05218096|Experimental|ALXN2050: 180 mg|Participants will receive ALXN2050.
9779538|NCT05218096|Experimental|ALXN2050: 120 mg|Participants will receive ALXN2050.
9779539|NCT05218096|Placebo Comparator|Placebo|Participants will receive placebo followed by ALXN2050.
9779540|NCT05217199||1/High risk of Infants|1/Term preterm infants with birth to 3 months of prenatal, postnatal and natal risk who stayed in the NICU for >2 weeks for any reason and were corrected after discharge
9779541|NCT05217199||2/Healty control infants|2/Healthy term infants
9779542|NCT05215067|Experimental|AK104 plus Docetaxel|AK104 RP2D + Docetaxel 75mg/m^2 every 3 weeks until progressive disease or unacceptable toxicity.
9779543|NCT05214833|Experimental|Real neurofeedback|The first arm will receive real neurofeedback.
9779544|NCT05214833|Sham Comparator|Sham neurofeedback|The second arm will receive sham neurofeedback.
9779545|NCT05213715||1/Children with diparetic cerebral palsy|1/Children with diparetic cerebral palsy
9779546|NCT05213715||2/Children with hemiparetic cerebral palsy|2/Children with hemiparetic cerebral palsy
9779547|NCT05213715||3/healty peer aged children|3/healty peer aged children
9779548|NCT05213663||1/parents of the children with cerebral palsy|parents of the children with cerebral palsy will be evaluated about the awereness of their children's disease, physical and socal activities and physiotherapy and rehabilitation
9779549|NCT05211739|Other|LID205255, then Biofinity Toric|Lehfilcon A toric contact lenses worn first, followed by comfilcon A toric contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
9779550|NCT05211739|Other|Biofinity Toric, then LID205255|Comfilcon A toric contact lenses worn first, followed by lehfilcon A toric contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) during waking hours for at least 5 days per week, with up to 10-12 hours wear time per day over a 30-day period. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
9779551|NCT05210634|Placebo Comparator|Group 1: Placebo|Single oral administration of 4 ml of Placebo MCT oil
9713232|NCT04605185|Experimental|Donafenib/JS001/TACE|Donafenib and JS001 Combined With TACE
9713233|NCT04605731|Experimental|Treatment (durvalumab, tremelimumab)|Patients undergo standard of care radioembolization with Yttrium-90 SIR-spheres intra-arterially over 60-90 minutes on day -14. Patients then receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on day 1. Cycles with durvalumab repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
10195180|NCT05241249|Experimental|Bethanechol|Patients with borderline resectable pancreatic cancer and no contraindication to bethanechol therapy will receive bethanechol on day 1 and continue until 2 days prior to scheduled surgery for a minimum of 2 months.
10195181|NCT05241223|Sham Comparator|Control group|This group will receive an education program which will cover information regarding asthma, physical activity and sedentary behavior.
9713234|NCT04604977|Other|Mindfulness by Smartphone|an approach that is alternative to current practice, particularly as far as reducing face-to-face hospital visits taking advantage of facilities offered by new technologies, besides including innovative and emerging treatment choices, namely a behavioural approach base on mindfulness
9713235|NCT04605341|Active Comparator|group one|patient with metacarpal fracture that will use minipate for fixation
9713236|NCT04605341|Active Comparator|gruop two|patient with metacarpal fracture that will use buried k wires for fixation
9713237|NCT04605653|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
9713238|NCT04605016|Experimental|Hydrophilic surface implants|
9713239|NCT04605016|Active Comparator|Hydrophobic surface implants|
9713240|NCT04605042|Experimental|WET First group|COOK ECHO-HD 22-C EchoTip Procore needle biopsy in WS-SNP-WS-SNP sequence
9713241|NCT04605042|Experimental|STANDARD first group|COOK ECHO-HD 22-C EchoTip Procore needle in SNP-WS-SNP-WS sequence
9713242|NCT04604938|Experimental|Losartan group|Drug: Losartan
9713243|NCT04604938|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
9713244|NCT04605120|Experimental|Allogeinic Bone Paste|Supercritical CO2 viral-inactivated allogeinic bone paste derived from human living donor femoral heads
9713245|NCT04605029||Critically Ill patients|No Intervention
9713246|NCT04605003|Active Comparator|Conventional Autoclave|The conventional autoclave is the gold standard of sterilising all medical equipments.
9713247|NCT04605003|Active Comparator|Novel rig-S|A novel devise used with the high level disinfectant
9713248|NCT04604899|Experimental|Retreated subjects|Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
9713249|NCT04604626||Population 1|Adults and children with severe obesity ie (BMI> 35 kg / m² for adults and Z BMI score> 3DS for age and sex for children) and / or eating disorders with genetic diagnosis as part of care.
9713250|NCT04604626||Population 2|Adults and children with obesity and / or eating disorders hypothalamic lesion (craniopharyngioma example).
9713251|NCT04604587|Experimental|amyloid PET、T807 PET|PET/CT
9713252|NCT04604613||Ancillary-Correlative (biospecimen collection, node mapping)|Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.
9713253|NCT04604756|Experimental|Losartan group|Drug: Losartan
9713254|NCT04604756|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
9713255|NCT04604717|Experimental|Pulmonary rehabilitation|8 weeks of pulmonary rehabilitation (twice weekly training) Exercise and education sessions accompanied by home exercise program
9713256|NCT04604717|No Intervention|Control group|Usual medical treatment for 8 week period
10195182|NCT05241223|Experimental|Experimental group|In addition to the educational program, this group will receive weekly individual and/or group online sessions for 12 weeks of motivation-based on behavior change intervention to promote physical activity and reduce sedentary behavior, based on both self-determination theory and transtheoretical model. They will also receive a pedometer with specific strategies related to it.
9713257|NCT04604964||Patients undergoing recto-sigmoid resection plus anastomosis|Patients undergoing recto-sigmoid resection and concurrent anastomosis during debulking surgery (primary or interval debunking surgery) for advanced epithelial ovarian cancer.
9713258|NCT04604873|No Intervention|No hospital one day care|No hospital one day care
9713259|NCT04604873|Other|Hospital one day care|Hospital one day care
9713260|NCT04604834|Experimental|PFAT first|1 eyedrop of PFAT every 2 hours in study eye.
9713261|NCT04604834|Experimental|APRP first|1 eyedrop of APRP every 2 hours in study eye.
9713262|NCT04604834|Experimental|APRP+PFAT first|1 eyedrop of PFAT and APRP every 2 hours in study eye.
9713263|NCT04604886|Experimental|Passive Leg Raising|Passive leg raising (PLR) test is used to predict fluid responsiveness, which is performed by raising the legs of the patient to 45°. Cardiac output will be collected from both PAC and LiDCO before and after PLR.
9713264|NCT04604886|Experimental|Dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
9713265|NCT04604847|Other|Total knee arthroplasty|patient operated for a total knee arthroplasty
9713266|NCT04604600|Experimental|amyloid PET、T807 PET|PET/CT
9713267|NCT04604678|Experimental|Treatment with Metformin and LDN|Patients will be treated with 1500 mg/day of metformin and 4.5 mg/day of LDN for a total of 4 weeks.
9713268|NCT04604678|No Intervention|Regular health care comparison group|Patients will receive regular health care and will serve as a control group.
10195183|NCT05241210|Experimental|Testing of degree of mucosal inspection|AI provides real-time feedback related to circumferential views during endoscope removal
9713269|NCT04604483|Experimental|PTNS|Treatment with PTNS for chronic anal fissure, treatment to be given for 30 minutes during 10 consecutive work Days.
9713270|NCT04604769||Daily routine, control group|ICU medical staff were asked about their stress and causes of stress during their daily professional life.
9713271|NCT04604769||During Covid-19|ICU medical staff were asked about their stress and causes of stress in their daily professional life during COVID-19 crisis.
9713272|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,3,4,intravenous (IV) microdose and placebo (Sequence A)|In Part A, participants will receive dose levels (DLs) 1, 3, 4, IV microdose of GSK3915393, and placebo in a pre-determined sequence (Sequence A). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data.
9713273|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,4,IV microdose and placebo (Sequence B)|"In Part A, participants will receive dose levels 1, 2, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence B).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
9713274|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,3,IV microdose and placebo (Sequence C)|"In Part A, participants will receive dose levels 1, 2, 3, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence C).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
9713275|NCT04604795|Experimental|Part A:GSK3915393 DLs 2,3,4,IV microdose and placebo (Sequence D)|"In Part A, participants will receive dose levels 2, 3, 4, IV microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence D).~There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and PK data."
9713276|NCT04604795|Experimental|Part B: Cohort 1: Participants receiving GSK3915393 DL X|Participants will receive GSK3915393 dose level X twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A.
9713277|NCT04604795|Placebo Comparator|Part B: Cohort 1: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level X during Part B of the study.
9713278|NCT04604795|Experimental|Part B: Cohort 2: Participants receiving GSK3915393 DL Y|Participants will receive GSK3915393 dose level Y twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
9713279|NCT04604795|Placebo Comparator|Part B: Cohort 2: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Y twice daily during Part B of the study
9713280|NCT04604795|Experimental|Part B: Cohort 3: Participants receiving GSK3915393 DL Z|Participants will receive GSK3915393 dose level Z twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.
9713281|NCT04604795|Placebo Comparator|Part B: Cohort 3: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Z twice daily during Part B of the study.
9713282|NCT04604795|Experimental|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+water/GSK3915393+GFJ/GSK3915393+ITZ (Sequence A)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and itraconazole (ITZ) in period 2. Participants will then receive oral GSK3915393 plus water in period 3, oral GSK3915393 plus grape fruit juice (GFJ) in period 4 and oral GSK3915393 plus ITZ in period 5.
9713283|NCT04604795|Experimental|Part C: GSK3915393 IV/GSK3915393 IV+ITZ/GSK3915393+GFJ/GSK3915393+water/GSK3915393+ITZ (Sequence B)|Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and ITZ in period 2. Participants will then receive oral GSK3915393 plus GFJ in period 3, oral GSK3915393 plus water in period 4 and oral GSK3915393 plus ITZ in period 5.
9779552|NCT05210634|Active Comparator|Group 2: 12.5 mg THCv (CHI-915)|Single oral administration of 12.5 mg THCv in MCT oil
10195184|NCT05241210|Experimental|Testing of clearing of fecal debris|AI provides real-time feedback related to removal of remaining fecal debris
10195185|NCT05241197|Experimental|Low load training with blood flow restriction (LL-BFR) group.|All participants in this arm will use a BFR tourniquet system during the execution of two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 20% 1 repetition maximum (RM), being progressively increased by 5% every four weeks. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. For each exercise, each participant will perform four sets with 30 repetitions the first set and 15 repetitions in the subsequent three sets, counting a total of 75 repetitions. All exercises will be performed in full range of motion (full plantar flexion to full dorsal flexion), with an interset rest period of 1 minute. Three minutes rest was provided between exercises.
10195186|NCT05241197|Active Comparator|High load training (HLT) group.|The HLT group will performed the same exercises than the BFR group, however with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions. Dynamic strength testing will be implemented to re-evaluate the current strength level and adequately adjust the load, using the PowerLift app, which was validated by Balsalobre-Fernandez in 2017. All exercises will be performed in full range of motion, with an interset rest period of 1 minute and a rest period between exercises of 3 minutes.
10195187|NCT05241171|Experimental|Fitbit plus Feedback Intervention|Participants who were randomized to the provider-feedback intervention arm received goal setting, and feedback graphs and charts,
10195188|NCT05241171|Active Comparator|Fitbit alone|Participants in self-managed control group were provided access to the Fitbit website or app but did not receive any feedback on their activity level from the study team.
10195189|NCT05241145|Experimental|IVMED-6Wk|In Group 1 (IVMED-6Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 6 weeks and were followed for an additional 20 weeks without treatment (total 26 weeks)
10195190|NCT05241145|Experimental|IVMED-16Wk|In Group 2 (IVMED-16Wk), patients instilled IVMED-80 eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
9713284|NCT04604574|Other|Pre/Post-Intervention|Patients who receive the novel IHSS intervention will be compared to historical controls who received the abstinence-based treatment model.
9713285|NCT04604704|Experimental|Treatment with LDN and NAD+|LDN will be used at a dosage of 4.5 mg/day, which will be taken orally in the form of tablets. NAD+ will be administered using the IontoPatch iontophoresis patch containing 400 mg of NAD+ solution which is worn on the skin for 4-6 hours once per week.
9713286|NCT04604639||Out-of-hospital cardiac arrest|Patients suffering an out-of-hospital cardiac arrest to who the ambulance service was requested to attend.
9713287|NCT04604730|Experimental|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
9713288|NCT04604730|Active Comparator|Anastomosis with protective stoma|Anastomosis with protective stoma
9713289|NCT04604509|Experimental|Group I (varenicline, counseling)|Participants receive varenicline PO daily or BID for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
9713290|NCT04604509|Experimental|Group II (NRT, counseling)|Participants receive NRT consisting of a patch, lozenges, or gum daily for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
10195191|NCT05241145|Placebo Comparator|Placebo|In Group 3 (Placebo), patients instilled IVMED-80 vehicle solution eye drops into their study eye twice a day for 16 weeks and were followed for an additional 10 weeks without treatment (total 26 weeks)
10195192|NCT05241132|Experimental|BMCUP treated with Tislelizumab and chemotherapy|"Patients with bone metastases from cancer of unknown primary (BMCUP) diagnosed according to the criteria defined in the 2015 European Society of Medical Oncology (ESMO) clinical Practice Guidelines and with bone metastases confirmed by imaging and histology that cannot be completely resected~Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
9713291|NCT04604509|Experimental|Group III (varenicline or NRT, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 additional weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
9713292|NCT04604509|Experimental|Group IV (varenicline or NRT, counseling)|Participants switch to a different therapy and receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
9713293|NCT04604509|Experimental|Group V (higher dose varenicline or NRT, counseling)|Participants receive a higher dose and continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
9713294|NCT04604509|Experimental|Group VI (varenicline or NRT, bupropion, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive bupropion PO daily for 6 weeks and behavioral smoking cessation counseling.
10195193|NCT05241119|Experimental|SLNB Group|undergo fluorescence SLNB
10195194|NCT05241119|Experimental|pALND Group|undergo low axillary lymph node dissection with ICBN as the boundary
10195195|NCT05241119|Experimental|ALND Group|undergo ALND
10195196|NCT05241106|Experimental|HYML-122 treatment|HYML-122 tablets, 200mg spec, 28 days for each cycle. The first eligible three enrolled subjects will be administrated with 600mg bid dose regimen for 28 consecutive days ( 1 treatment cycle). The Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of these three subjects and make decision whether the regimen need to be adjusted (increasing/decreasing administration dosing or adjusting dosing frequency).
9713295|NCT04604509|Experimental|Group VII (varenicline and NRT, counseling)|Participants receive varenicline as in Group I and NRT as in Group II for 6 weeks. Participants also receive behavioral smoking cessation counseling.
9713296|NCT04604535|Active Comparator|Concentrated beetroot juice|70mL of concentrated beetroot juice with 400mg nitrate
9713297|NCT04604535|Placebo Comparator|Placebo|70mL of concentrated beetroot juice with <0.01mmol/L nitrate
9713298|NCT04604392|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
9713299|NCT04604392|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
9713300|NCT04604392|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
9713301|NCT04604366|Active Comparator|vaginal mesoprostol|Vaginal dose---800 microgram 3 hourly two doses
9713302|NCT04604366|Experimental|sublingual mesoprostol|Sub lingual 600 microgram 3 hourly two doses
9713303|NCT04604314|Experimental|Endocrown Onlay Restoration|Endocrown onlay preparation = Buccal and lingual walls are intact with an occlusal-gingival height at least equal to half the original crown height of the tooth. Remaining buccal and lingual walls maintain a thickness ≥ 2.0 mm.
9713304|NCT04604314|Experimental|Endocrown Shoulder Restorations|Endocrown shoulder preparation = Buccal and/or lingual walls are less than half the original occlusal-gingival height of the tooth or the buccal or lingual surfaces were previously prepared axially due to a prior restoration.
9713305|NCT04604327|Active Comparator|Prophylactic bemiparin (3,500 IU/day)|Bemiparin 3,500 IU daily for 10 days
9713306|NCT04604327|Experimental|Full therapeutic bemiparin (weight adjusted)|Bemiparin at full therapeutic dose, adjusted to body weight, for 10 days
9713307|NCT04604470||Standard treatment|Chemotherapy Chemoradiotherapy Radiotherapy Immunotherapy Or a combination of above
9713308|NCT04604470||ImmunoSABR treatment|"SABR combined immunotherapy~Radiotherapy combined immunotherapy"
9713309|NCT04604431|Experimental|Intervention (CDS Tool Integrated)|Pediatric clinicians in this arm will receive the iREACH CDS tool and education on the PPA Guidelines to support adherence to the Guidelines.
9713310|NCT04604431|No Intervention|Control (No CDS Tool Integrated)|No study procedures will be implemented in the control practices, and their pediatric clinicians will not receive extra PPA Guidelines education, nor will any EHR modifications be made in their practices to support adherence to PPA Guidelines.
9713311|NCT04604457|No Intervention|Standard of Care|Palliative care specialists would not reach out to primary care providers. Palliative care needs would be met via existing mechanisms.
10195197|NCT05241093|Experimental|HYML-122 plus cytarabine|"The first three eligible enrolled patients will be treated with initial dosing of HYML-122 400mg bid daily and cytarabine 100mg/m2 intravenously by using 3+3 escalating design to explore RP2D. the Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of the phase 1 subjects and establish the combined regimen recommended dose. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgement of the investigator, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria, whichever occurs first."
10195198|NCT05241067|Placebo Comparator|Normal saline|Placebo (Dose: equal volume saline) + Standard of care
9713312|NCT04604457|Experimental|Predictive Model|Palliative care specialists review recommendations from the predictive model and contact a patient's primary care provider (PCP) when appropriate to recommend a palliative care consult.
9713313|NCT04604301|Experimental|Crown, 1.0mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.0 mm delivered with a conventional Calcium Aluminate Ionomer cement
9713314|NCT04604301|Experimental|Crown, 1.5mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.5 mm delivered with a conventional Calcium Aluminate Ionomer cement
9713315|NCT04604301|Experimental|Crown, 1.0mm thickness, dual cure resin cement|occlusal thickness of 1.0 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
9713316|NCT04604301|Experimental|Crown, 1.5mm thickness, dual cure resin cement|occlusal thickness of 1.5 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
9713317|NCT04604171|Experimental|Action Observation Training|Conventional treatment for 60 mins plus Action Observation Training for 30 mins
9713318|NCT04604171|Active Comparator|Task Oriented Training|Conventional treatment for 60 mins plus Task Oriented Training for 30 mins
9713319|NCT04604145|Other|Positive NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a positive NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
9713320|NCT04604145|Other|Negative NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a negative NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
10195199|NCT05241067|Active Comparator|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
9713321|NCT04604223|Experimental|Pioglitazone|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total.
10195200|NCT05241054|Active Comparator|Bupivacaine|Patients will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
9713322|NCT04604223|Placebo Comparator|Placebo|Placebo tablets at 45 mg/day will be given for 10 days, after 10 days, the tablets will be reduced to 30 mg/day. The treatment will be continued for 4 weeks (28 days) total.
9713323|NCT04604028|Experimental|Lenalidomide and low-dose cyclophosphamide|Oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide [Leavdo®] 15 mg daily, day 1 to day 21; cyclophosphamide [Endoxan] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days
9713324|NCT04604041||Relapsing-remmitting MS group treated with corticosteroids|"Clinical testing~Neurophysiological examination (TMS, EMNG)~Psychomotor examination~Neuropsychological evaluation~Flow cytometry~ELISA"
9713325|NCT04604041||Relapsing-remmitting MS group treated with immunomodulation|1. Clinical testing 2. Neurophysiological examination (TMS, EMNG) 4. Neuropsychological evaluation 5. Flow cytometry
9713326|NCT04604041||Healthy control group|5. Flow cytometry
9713327|NCT04604054|Experimental|Group 1|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Granulocyte Colony Stimulating Factor as a treatment.
9713328|NCT04604054|Active Comparator|Group 2|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Human Chorionic Gonadotropin as a treatment.
9713329|NCT04603885|Experimental|Aerobic exercise group|Aerobic exercise will be measured with a Polar United fitness watch. Heart rate during exercise will be measured using a Polar United fitness watch, which has been validated for monitoring moderate and high intensity physical activity.
9713330|NCT04603885|Placebo Comparator|Attention control group|The time-equivalent, stretching movements will serve as the placebo exercise condition in this proposed study. Previous research has shown that stretching could reduce attrition and patient dissatisfaction and better ensure allocation concealment. Following baseline measures, a student will demonstrate the use of a Polar United fitness watch and stretching movements via zoom from week 3 to week 5. Starting on week 3, participants will perform the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise.
9713331|NCT04603768|Experimental|Theraband exercises|Group A: baseline physical therapy treatment along with theraband exercises
9713332|NCT04603768|Experimental|Co-contraction exercises|Group B: baseline physical therapy treatment along with co-contraction exercises
9713333|NCT04603768|Experimental|isometric exercises|Group C: baseline physical therapy treatment along with isometric exercises
9779553|NCT05210634|Active Comparator|Group 3: 25 mg THCv (CHI-915)|Single oral administration of 25 mg THCv in MCT oil
10195201|NCT05241054|Active Comparator|Nitroglycerine|Patients will receive an infusion of Nitroglycerine (TNG) (0.2-1μg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65 mmHg.
10195202|NCT05241041|Experimental|[1st year]Auricular Acupressure Experimental Group 1|auricular acupressure
10195203|NCT05241041|No Intervention|[1st year]Control Group 1|education material
10195204|NCT05241041|No Intervention|[1st year]Normal Group|Non-gamblers
10195205|NCT05241041|Experimental|[2nd&3rd year]Auricular Acupressure Experimental Group 2|auricular acupressure + group counseling
10195206|NCT05241041|Placebo Comparator|[2nd&3rd year]Placebo Group|placebo acupressure + group counseling
10195207|NCT05241041|No Intervention|[2nd&3rd year]Control Group 2|education material
10195208|NCT05241028|Experimental|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
9713334|NCT04603963|No Intervention|group control|alternate exercises: in one day breathing exercises, active or with a load of large muscle groups (according to tolerance) with a maximum limit of 2 kg, sedation out of bed, walking. On another day aerobic exercise with cycle ergometer limited to 30 minutes.
9713335|NCT04603963|Experimental|intervention group|He received the same intervention as the control group, associating respiratory muscle training 1 time a day with power breathe 3 series of 10 repetitions (started with 30% of the Pimax value) with readjusted load every 7 days.
9713336|NCT04603989|Experimental|HNC042|HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route
9713337|NCT04603989|Placebo Comparator|Placebo|Placebo, multiple ascending doses, Intravenous route
10195209|NCT05241015|Active Comparator|Control Group|Patients in this group will receive standard physiotherapy program used for PD will be applied, 3 times a week for 8 weeks.
9713338|NCT04604002|Experimental|Subjects with Normal Eyes|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects without ophthalmic pathology
9713339|NCT04604002|Experimental|Subjects with Pathology|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects with retinal vascular pathology
9713340|NCT04603729|Active Comparator|group 1 dexamethasone|participants will receive dexamethasone 8mg/day Intravenous for 5 days
9713341|NCT04603729|Active Comparator|group 2 methylprednisolone|participants will receive methylprednisolone 1mg/kg/day intravenous for 5 days
9713342|NCT04604080||single group|Respondents will be given survey form, filled and will be collected back
10195210|NCT05241015|Experimental|Exercises Group|In addition to standard physiotherapy programme, patients in this group will also receive sensorimotor training.
9713343|NCT04603976|Experimental|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
9713344|NCT04603833|Experimental|SHR3680+Docetaxel|
9713345|NCT04603833|Active Comparator|SHR3680|
9713346|NCT04603833|Active Comparator|Docetaxel|
9713347|NCT04603716|Experimental|Eccentric Muscle Energy Technique|conventional physical therapy Along with eccentric muscle energy technique
9713348|NCT04603716|Experimental|concentric muscle energy technique|Conventional physical therapy along with concentric muscle energy technique
9713349|NCT04603781|Active Comparator|CBD-Isolate 300 mg.|Nightly administration of 300 mg. of CBD-Isolate for 28 consecutive days
9713350|NCT04603781|Active Comparator|Full-Spectrum CBD Oil 300 mg.|Nightly administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
9713351|NCT04603781|Active Comparator|Broad-Spectrum CBD oil 300 mg.|Nightly administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days
9713352|NCT04603781|Placebo Comparator|Placebo Oil|Nightly administration of 300 mg. of Placebo Oil for 28 consecutive days
9713353|NCT04603859|Experimental|Elective induction of labour|Elective induction of labour at 39 gestational weeks and 0 to 3 days.
9713354|NCT04603859|No Intervention|Expectant management|Awaiting spontaneous labor.
9713355|NCT04603703|Experimental|HVLAT Manipulation|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics, HVLAT
9713356|NCT04603703|Active Comparator|Conventional physical therapy|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics
9713357|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells and dasatinib|Dose levels of CAR-T cells are based on clinical trials of similar foreign products. Meanwhile, dasatinib would be combined as the following regimens: 1) Dasatinib preconditioning CAR-T cells during the manufacturing; 2) Dasatinib for the intervention of cytokine release storm after CAR-T cell infusion; 3) Dasatinib for the intervention of neurotoxicities after CAR-T cell infusion; 4) Dasatinib for the phase of CAR-T cell decreasing.
9713358|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells|Dose levels of CAR-T cells are based on clinical trials of similar foreign products.
9713359|NCT04603924|Experimental|ANA001|Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
9713360|NCT04603924|Placebo Comparator|Matching Placebo|Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
10195211|NCT05240963|Experimental|PEEK implant|Temporal PEEK implant to prevent temporal hollowing after temporalis muscle transfer
10204769|NCT05013736||Infants|Pre-term and term born infants with corrected gestational age between term age and 24 months with radiologically-confirmed acute unilateral or bilateral brain lesions, including perinatal stroke, neonatal hemorrhagic or thrombotic stroke, involving the motor cortex and/or subcortical structures, and intracranial hemorrhage, involving the motor cortex and/or subcortical white matter, or periventricular leukomalacia. Parents/legal guardians able to attend study visits at the University of Wisconsin-Madison.
10204770|NCT05006417|Experimental|Participants with R-CECS|Botox to be injected under standard palpatory technique into the affected lower leg compartment.
9713361|NCT04603937|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
9713362|NCT04603937|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
9713363|NCT04603794|Active Comparator|1% Hydrogen Peroxide Mouth Rinse|30 second oral rinse with 1% Hydrogen Peroxide
9713364|NCT04603794|Active Comparator|0.12% Chlorhexidine Gluconate Mouth Rinse|30 second oral rinse with 0.12% Chlorhexidine Gluconate
9713365|NCT04603794|Active Comparator|0.5% Povidone Iodine Mouth Rinse|30 second oral rinse with 0.5% Povidone Iodine Mouth wash
9713366|NCT04603794|Placebo Comparator|0.9% Normal Saline Mouth Rinse|30 second oral rinse with 0.9% Normal Saline
9713367|NCT04603950|Experimental|study group|The first 20 patients received Continue Adductor Canal Block + Infiltration between the Popliteal Artery and Capsule of the Knee
10195212|NCT05240924|Experimental|Exposure and Response Prevention (ERP)|ERP will be based upon the Treatments That Work series, which contains both a provider manual and client workbook. Sessions will last 90 minutes and occur weekly for 16 sessions. All ERP treatment will be delivered via VTH. Participants will receive instructions on accessing the VTH platform and take part in a brief practice run connecting to the VTH appointment with guidance from an RA. ERP treatment content includes psychoeducation about OCD, assessment of OCD symptoms, the rationale for treatment, construction of a hierarchy or a list of feared or avoided situations, and in-session in-vivo and imaginal exposures. Weekly homework assignments will include self-monitoring, reading chapters about the treatment, and practicing exposures daily. All therapy sessions will be audio-recorded. Although sessions are expected to occur weekly, accounting for delays due to scheduling, holidays, and missed appointments, the investigators will allow up to 6 months to complete the treatment.
9713368|NCT04603950|Sham Comparator|control group|The second 20 patients received Continue Adductor Canal Block alone
9713369|NCT04603664||study group|blood sampling and measduring of serum NGAL and cystatin c on admission and after 48 hours and creatinine every day
9713370|NCT04603534|Experimental|Intervention group|
9713371|NCT04603638|Active Comparator|magnesium|participations will be given intravenous magnesium.
9713372|NCT04603638|Placebo Comparator|control|participations will be given intravenous isotonic.
9713373|NCT04603378|Other|KB195|
9713374|NCT04603378|Other|Polydextrose|
9713375|NCT04603378|Other|Pullulan|
9713376|NCT04603378|Other|Maltodextrin|
9713377|NCT04603352|Experimental|Intervention group: Hip Helpers home program|Participants in the intervention group will be given a custom pair of Hip Helpers® to use at home. Parents will begin the Hip Helpers® home program upon study entry and stop the program once the child is able to pull to stand independently. The Hip Helpers® home program protocol, which consists of using the orthotic garment twice daily for 30 minutes each time, will be given to the parents and supervised by the physical therapist. The Hip Helpers® should be donned when the child is actively playing, and not used sleep or when child is inactive.
9713378|NCT04603352|No Intervention|Control group: No additional home program|Participants assigned to the control group will continue with their usual care.
9713379|NCT04603508|Experimental|Berlim 25/10|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
9713380|NCT04603508|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/10 association placebo, oral;~1 tablet empagliflozin , oral;~1 tablet rosuvastatin calcium, oral."
9713381|NCT04603625|Experimental|sitting position centering femoral heads|sitting position centering femoral heads according to Lespargot diagram
9713382|NCT04603625|Active Comparator|Usual postural management|sitting with the trunk aligned and hips abducted to facilitate activities of daily living
9713383|NCT04603573|Experimental|(intervention)|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
9713384|NCT04603573|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
9713385|NCT04603469||Trisomy 21 patients|Children <18 years old requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3
9713386|NCT04603235|Experimental|Intervention|This is a quasi-experimental study
9713387|NCT04603313||Experimental group|12 departments in mainland France covered by the tele-advice system open to general practitioners
9713388|NCT04603313||Control group|84 departments in mainland France not covered by the tele-advice system.
9713389|NCT04603599||benign endometrial changes|
9713390|NCT04603599||endometrial hyperplasia|
9713391|NCT04603599||endometrial cancer|
9713392|NCT04603443|Experimental|BCAA 20g/daily|Branched Chain Amino Acids, 10g BID x 12 weeks
9713393|NCT04603443|Experimental|BCAA 40g/daily|Branched Chain Amino Acids, 20g BID x 12 weeks
9713394|NCT04603443|Experimental|BCAA 60 g/daily|Branched Chain Amino Acids, 30g BID x 12 weeks
9713395|NCT04603443|Placebo Comparator|Placebo 60 g/daily|Protein without BCAA, 30g BID x 12 weeks
9713396|NCT04603612|Other|NMIBC patients|Patients with diagnosed bladder tumors seen the urology department (Urology and Nephrology Center, Mansoura University, Egypt) will be assessed for eligibility to the study and inclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study and will be provided with an informed consent form. Study participants will be enrolled, and the appropriate scheduled procedures will be performed.
9713397|NCT04603040|Experimental|Experimental group|Experimental group:ToripalimabTreatment
9713398|NCT04603222|Experimental|Treatment Group|Group treating blepharitis with SUMMIT BRUSH and Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
9713399|NCT04603222|Active Comparator|Control Group|Group treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
9713400|NCT04603430||Physical Therapy Students|Students will be participating in a focus group and completing a survey.
9713401|NCT04603430||Senior STEPS Participants|Seniors will be participating in a focus group, completing a survey, and researchers will be conducting a retrospective chart review on relevant documented health outcomes of the STEPS program.
9713402|NCT04603092|Experimental|Disadvantaged women in primary setting receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This group will receive the digital health literacy intervention.
9713403|NCT04603092|No Intervention|Disadvantaged women in primary setting not receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This control group will not receive the digital health literacy intervention.
9713404|NCT04603053|Experimental|CBot-A Group|Participants randomly assigned to this arm will receive access to CBot-A app.
9713405|NCT04603053|No Intervention|Wait List Group|Participants randomly assigned to this arm will be offered the intervention after the completion of the trial.
9713406|NCT04603339|Experimental|Intervention Arm|Single arm trial, all participants will receive the intervention
9713407|NCT04603261||eGFR <30 mL/min/1.73m2|Patients with eGFR <30 mL/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+.
9713408|NCT04603261||eGFR 30-59 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
9713409|NCT04603261||eGFR >=60 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
9713410|NCT04603456|Experimental|Probiotic Group|consisted of 15 cases who received probiotics only. A drug called Lacteol fort (Rameda Company) . A sachet was taken once daily for three months. Each sachet contains 10 billions lactobacilli.
9713411|NCT04603456|Experimental|SLIT Group|included 15 children who received SLIT for 6 months. Standardized Timothy Grass Pollen (Phleum pratense)
9713412|NCT04603456|Experimental|Combined treatment Group|included 15 children who received probiotics and SLIT. A drug called Lacteol fort was administered A sachet was taken once daily for 3 months . Standardized Timothy Grass Pollen was taken for 6 months
9713413|NCT04603118|Other|The patients with Idiopathic intracranial hypertension (IIH)|33 patients who applied to the neurology clinic with the pre-diagnosis of IIH were performed lumbar puncture. 25 of them diagnosed with IIH. Optic nerve sheath diameter was measured by optic ultrasonography from both eyes before and after the LP.
9713414|NCT04603118|Other|Control group|In the control group, optic nerve sheath diameter was measured from both eyes by optic ultrasonography.
9713415|NCT04603586|Experimental|Arm A|SBRT with BED 60-70Gy combined with Gemcitabine + albumin-bound paclitaxel
9713416|NCT04603586|Experimental|Arm B|SBRT with BED >70Gy combined with Gemcitabine + albumin-bound paclitaxel
9713417|NCT04603079|Experimental|Currently practicing nurses who will receive intervention|An intervention for COVID-19 preventive protocols will be delivered to the nurses in the experiment group.
9713418|NCT04603079|No Intervention|Currently practicing nurses who will not receive intervention|No intervention for COVID-19 preventive protocols will be delivered to the nurses in the control group.
10195213|NCT05240924|Other|Control Condition|Participants randomized to the control condition will receive 16 weekly sessions of stress management training via video telehealth. This control condition was chosen because it is expected to provide the therapeutic alliance and common factors associated with therapy generally and some specific effects in anxiety reduction.
9713419|NCT04603131|Experimental|BBV87 - 10 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths (10, 20 and 30 mcg) administered intramuscularly on Day 0, 29 and 57
9713420|NCT04603131|Placebo Comparator|Placebo|Placebo administered intramuscularly on Day 0, 29 and 57
10195214|NCT05240911|Experimental|Poisson regression model dosing scheme|daily levothyroxine dose=e[2.02+0.01(W)-0.0037(A )-0.098(F)-0.01(B)+0.007(T)+0.108(I)-0.014(M), where W is the weight of the patient (Kg), A is the age of the patient (years), and F is the gender (for women 1, male is 0), B represents the patient's body mass index (BMI), T represents the preoperative TSH level, I represents whether the patient takes iron preparations (1, if not 0), M represents whether the patient takes multivitamins/minerals (1, if not 0).
10195215|NCT05240911|Active Comparator|weight-based dosing scheme|daily levothyroxine dose=1.6 μg /kg/d
9713421|NCT04603131|Experimental|BBV87 -30 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
9713422|NCT04603131|Experimental|BBV87 -20 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
9779554|NCT05210634|Active Comparator|Group 4: 50 mg THCv (CHI-915)|Single oral administration of 50 mg THCv in MCT oil
9779555|NCT05210634|Active Comparator|Group 5: 100 mg THCv (CHI-915)|Single oral administration of 100 mg THCv in MCT oil
9779556|NCT05210634|Active Comparator|Group 6: 200 mg THCv (CHI-915)|Single oral administration of 200 mg THCv in MCT oil
9779557|NCT05207384|Active Comparator|Ozone (O2-O3) group|Ultrasound (US)-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
9779558|NCT05207384|Other|Corticosteroid group|US-guided injection will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
9713423|NCT04603196||Patients with Multiple Sclerosis with obstructive sleep apnea|Patients with Multiple Sclerosis with obstructive sleep apnea
9713424|NCT04603196||Patients with MS without obstructive sleep apnea|Patients with MS without obstructive sleep apnea
9713425|NCT04603066|Experimental|Ondansetron + Tariquidar|
10195216|NCT05240885||Controls|"Study subjects that are eligible based on inclusion/exclusion criteria~Screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~Study day(s): may include combinations of stable tracer infusions and with blood draws, cognitive and muscle performance testing"
10195217|NCT05240859||Geleli|RA patients treated with Geleli
9713426|NCT04603066|Placebo Comparator|Ondansetron + Placebo|
9713427|NCT04603105||Single Study Cohort|Patients will be recruited from the main study after being determined to having COVID-19 and Cancer
9713428|NCT04603209||IORT|All participants who plan to undergo partial mastectomy for treatment of early stage breast cancer will be considered for eligibility for IORT. Patient with single breast cancer less than 3cm in disease span, clinical negative axillary node will be offered the option of having IORT. If IORT is delivered following surgical resection of the tumor they will be followed in this registry for short and long term outcomes.
9713429|NCT04602988||Patients admitted to an inpatient hospital unit|Patients admitted to an inpatient hospital unit will receive EEG based monitoring of mental status
9713430|NCT04602962||Fertility preservation performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
9713431|NCT04602962||Fertility preservation not performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
9713432|NCT04603014|Experimental|Interdialytic peritoneal ultrafiltration|Will receive incremental interdialytic peritoneal ultrafiltration with a 10% dextrose solution, twice a week for three consecutive weeks
9713433|NCT04602754|Experimental|BERLIM 25/20|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
9713434|NCT04602754|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association placebo, oral;~1 tablet empagliflozin, oral;~1 tablet rosuvastatin calcium, oral."
9713435|NCT04602871|Experimental|COVID 19 Positive patients|Patients with COVID-19, qPCR for SARS-CoV-2 confirmed
9713436|NCT04602871|Other|Healthy subjects|COVID-19 Negative subjects
9713437|NCT04602767|Experimental|Vasopressin|Low dose vasopressin as first line vasopressor in cardiac surgery.
10195218|NCT05240846|Experimental|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
10195219|NCT05240846|Experimental|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on Ultrasound assistance paramedian spinal.
10195220|NCT05240833|Experimental|VExUS-Guided Arm|VExUS results will be available for the treating physician. Patients will be treated according to current clinical practice. The use of diuretic and diuretic dosage will depend on treating physician's criteria.
9713438|NCT04602767|Experimental|Phenylepherine|Low dose phenylephrine as first line vasopressor in cardiac surgery
9713439|NCT04602780||CI users|
9713440|NCT04602897|Experimental|cough group|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
10195221|NCT05240820|Placebo Comparator|Vicryl+Prolene|wound closure using polyglactin 910 (Vicryl®, Ethicon, Johnson and Johnson Ltd., NJ, USA) and polypropylene (Prolene®, Ethicon)
9713441|NCT04602897|No Intervention|control|the control group received no pain management at all during different steps of IUD insertion
9713442|NCT04602676|Experimental|Diarrheal Assessment with DEP, then diarrheal assessment|Participants will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application.
9713443|NCT04602676|Experimental|Diarrheal Assessment, then Diarrheal assessment with DEP|Participants will go through a 4 week period where clinicians will use a rehydration calculator. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm.
9713444|NCT04602741|Experimental|A4i Intervention|"App4Independence (A4i)~Experimental: A4i Intervention App4Independence (A4i) The study intervention is the digital health platform A4i. A4i operates on the individual's own phone with or without data.~Specific A4i functionality includes:~Addressing social isolation and cognitive challenges through personalized prompts, scheduling of activities, and connections to a range of resources.~Fostering illness self-management through evidence-informed content.~A peer-peer engagement platform that facilitates strategy/tip sharing between users (anonymous and moderated).~Daily wellness and goal attainment check-ins.~An ambient sound detector with an oscilloscope-type indicator that assists individuals with auditory hallucinations separate hallucinations from real sounds.~Passively collected data on phone use as a proxy for sleep.~A provider dashboard. Both control and experimental condition participants will be receiving standard outpatient care (TAU)."
9713445|NCT04602741|No Intervention|Treatment As Usual|Treatment as usual participants will be recieving outpatient mental health care through the standard supports (most typically, case management and psychiatric support) that are available in a large, Canadian, urban centre.
9713446|NCT04602663|Experimental|follow up every week|Variceal Band ligation every week.
9713447|NCT04602663|Experimental|follow up every 2 weeks|Variceal Band ligation every 2 weeks
9713448|NCT04602663|Experimental|follow up every 3 weeks|Variceal Band ligation every 3 weeks
9713449|NCT04602663|Experimental|follow up every 4 weeks|Variceal Band ligation every 4 weeks
10195222|NCT05240820|Active Comparator|PDS+Dermabond|wound closure using polydioxanone (StratafixTM Spiral PDS® Plus) and combination of 2-octyl cyanoacrylate and polyester mesh (Dermabond Prineo®)
10195223|NCT05240755|No Intervention|Standard of Care|Opioid standard of care: Tramadol 50 mg PO PRN #30, Hydrocodone/Acetaminophen 5/325 PO PRN #30
10195224|NCT05240755|Experimental|Cannabidiol Oil 100 mg|CBD 100 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
9713450|NCT04602832|Experimental|ENHANCE Treatment Group|The ENHANCE program was tailored to address the current health and well-being challenges faced by individuals living in the COVID-19 pandemic. The contents of each week will focus on a new evidenced-based principle that has been shown in research to decrease negative thinking and emotions, as well as increase positive thinking, emotions, and overall physical and mental health and well-being. Each week participants will focus on the skills and methods of implementing happiness and well-being into their daily routine.
9713451|NCT04602832|No Intervention|Wait-List Control Group|Over the course of the study, participants will be asked to refrain from accessing the ENHANCE program materials to ensure the integrity of the research design. At the end of the study duration, participants will receive the full ENHANCE program.
10195225|NCT05240755|Experimental|Cannabidiol Oil 200 mg|CBD 200 mg PO liquid suspension QD starting 30 days prior and finishing 30 days post-op
10195226|NCT05240716|Experimental|FES program|
10195227|NCT05240703|Experimental|Stabilization splint group|The patients in the splint group were treated with a stabilization splint and received counseling and instructions for masticatory muscle exercises
10195228|NCT05240703|No Intervention|Control group|The controls received only counseling and instructions for masticatory muscles exercises.
10195229|NCT05240690|Experimental|Umbilical Cord Blood Derived MAK Immune Cells|
10195230|NCT05240625|Experimental|Computer-aided colonoscopy|The subject will receive the standard colonoscopy procedure simultaneously with a computer-aided detection (CADe) analysis software designed to automatically detect and highlight potential polyps on colonoscopy images in a real-time manner during colonoscopy procedures.
10195231|NCT05240625|Active Comparator|Standard colonoscopy|The subject will receive the standard colonoscopy procedure.
10195232|NCT05240599|Experimental|Shaker|"Shaker exercises consist of isotonic and isometric contractions of the neck flexor muscles. Participants will be asked to lie on their back with their knees straight. Participants will first wait for 60 seconds by lifting their head and looking at their feet. He will repeat the movement three times in total, resting for 60 seconds in between. Then, the participants will raise their heads again, look at the toes, and put their head back on the bed without waiting. By repeating this movement 30 times in total, the exercise program will be completed.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components to be performed once, in 3 sets of 10 repetitions per day."
10195233|NCT05240599|Experimental|Chin Tuck Against Resistance|"In this exercise, participants have to place an inflatable ball with a diameter of 12 cm between their chin and sternum. This exercise has two subcomponents, isotonic and isometric. In the isometric component, individuals must compress the ball with maximum force between their chin and sternum, hold for 60 seconds, and rest for 60 seconds. One should repeat this isometric component 3 times. In the isotonic parameter, on the other hand, the participants must slowly squeeze the ball between their chin and sternum 30 times with the maximum force they can do. Participants will perform the exercise in an upright sitting position on a back-supported chair.~Individuals will perform this exercise, which consists of isometric components to be repeated 3 times and isotonic components to be performed once, in 3 sets of 10 repetitions per day."
10195234|NCT05240599|Experimental|Chin Closure Against Resistance|This exercise will be performed in the form of closing the chin against the manual resistance to be given from the tip of the mandible, starting from the maximum voluntary mouth opening. In this way, eccentric contact will be created as the suprahyoid muscles will move from the shortest position to the longest position with resistance. Participants will perform the exercise by maintaining the upright posture in the upright sitting position on the back-supported chair.
10195235|NCT05240573|Experimental|SKI App|
9713452|NCT04602910|Experimental|the phases of planning and acting|Each part of the website page was assessed for comprehensibility and usability by patients. Health care providers were asked to assess the acceptability of the website. A 5-point Likert scale was used for patient and health care provider ratings for each item. If the score were less than 3, then we would modify the website content based on the user feedback from patients and health care providers
9713453|NCT04602923|Experimental|XEN Gel Stent implantation|Participants suffering from glaucoma who are candidates for XEN Gel Stent implantation
9713454|NCT04602923|Experimental|Trabeculectomy|Participants suffering from glaucoma who are candidates for trabeculectomy
9713455|NCT04602923|Experimental|GDD implantation|Participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)
9713456|NCT04602819|Experimental|Experimental|
9785775|NCT01259713|Experimental|Liposomal amphotericin B|Liposomal amphotericin B 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
10195236|NCT05240573|Active Comparator|CMUH Dialysis Care App|
10195237|NCT05240560|Experimental|BP1.3656|1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day
10195238|NCT05240560|Placebo Comparator|Placebo|1 tablet of matching placebo per day
10195239|NCT05240547|Experimental|Spinal manipulation|Spinal manipulative therapy will be delivered to the cervical spine (segments including occiput-atlas to C7-D1) according to the chiropractors' evaluation during each visit. During each session, one or two segments will be manipulated using a high-velocity low-amplitude thrust manipulation (a joint cavitation will be expected, if not, the thrust can repeated once) applied to the segments with the highest motion restriction, as determined by the chiropractor by static and motion palpation of the cervical spine.
10195240|NCT05240547|Placebo Comparator|Placebo|Sham manipulation will be delivered to the cervical spine (segments including occiput-atlas to C7-D1) according to the chiropractors' evaluation during each visit. During each session, one or two segments will receive a sham manipulation applied to the segments with the highest motion restriction, as determined by the chiropractor by static and motion palpation of the cervical spine. The sham manipulation will consist in a identical contact to the real manipulation, except the thrust will be delivered towards the table, away from the target segment and with the intention to lower the cervical drop piece of the table, which will substitute the joint cavitation noise.
10195241|NCT05240521|Other|ARM A: GA-AT0119 / Placebo|Cross-over Study
10195242|NCT05240521|Other|ARM B: Placebo / GA-AT0119|Cross-over Study
9713457|NCT04602715|Experimental|MET-2 20 g|Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
9713458|NCT04602715|Placebo Comparator|Placebo|Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
9713459|NCT04602585|Experimental|Experimental|After discharge, the program manager will link the participants with a VHT nearest to them. The participants (randomized to the intervention arm) will be informed during the consent procedure that they will undergo 6 psycho-education sessions (1 per month) together with a family member at the participant's residence. The VHTs and participants will meet and schedule appointments for the next engagements. This shall be done on a case by case basis. Some psycho-education sessions could take place in the patient's residence, others in the nearest public space (school or church or mosque compounds). The investigators will document where the majority of these sessions happen. This will help the investigators document feasibility. The PI and RAs will sit in some of the sessions during the pilot phase of data collection to ensure fidelity to the manual.
9713460|NCT04602585|Placebo Comparator|Usual care arm|Participants will receive usual care
9713461|NCT04602403|Placebo Comparator|placebo group|people who given placebo to become agroup of comparison with the other group
10195243|NCT05240495|Experimental|Internet-based Cognitive-behavioural therapy group (n=61)|TThe generic iCBT program was based on contemporary CBT techniques adapted for stress-related disorders, and recovery from work training inspired by Hahn et al. [2011]. The iCBT consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week. In the first module (introduction), the participants received information about the outline of the program, stress physiology and defined individual treatment goals. During the second week participants were introduced to different recovery techniques and applied relaxation. The third and fourth week contained exercises related to behavioral activation, work-home balance, and values-based action skills. Between weeks five and ten, participants were able to choose between different exposure-based exercises. In addition, participants with insomnia could choose to focus on sleep management.
10195244|NCT05240495|Experimental|Internet-based Work-focused Cognitive-behavioural therapy group (n=61)|The internet-based and work-focused cognitive-behavioral therapy (W-iCBT) consisted of the generic treatment for stress-related disorders (iCBT), plus components focusing on work and return-to-work. These sections were integrated and represented in each of the ten modules. Work-focused CBT is built on the same conceptual framework as regular CBT. For example, CBT principles are used to change the appraisal of work stressors, change the dysfunctional behaviour, or increase health promoting behaviours. The CBT principal, exposure, is given special attention. Gradual exposure can help individuals develop more effective coping skills when dealing with work-related stressors (e.g., assertiveness) and stimulate gradual return to the work setting for individuals on a long-term sick leave [27].
9713462|NCT04602403|Active Comparator|tamsulosin group|people who given tamsulosin to know the effect on ureteroscopy and compare with the control group
9713463|NCT04602416||Control (Health)|The control had two sessions: the Introduction and another on Health. The health sessions were based on topics used by United States Peace Corps medical officers training volunteers about how to stay healthy in Tanzania: nutrition, worms, HIV/AIDS, and first aid.
9713464|NCT04602416||Entrepreneurship|The sessions for this arm were six: the two sessions of the Control arm, plus Sources of Capital, Marketing, Saving and Investing Profit, and Writing a Business Plan. Each session lasted one day.
9713465|NCT04602416||Beekeeping|The Beekeeping arm had six sessions: the two sessions of the Control arm, plus Beginning Beekeeping, Environment-Forests-Bees, Building a Beehive, and Harvesting.
9713466|NCT04602416||All Interventions|This arm was 10 sessions, and included all sessions of the Control, Entrepreneurship, and Beekeeping
9713467|NCT04602455|Experimental|Heartfulness Group|Participants were asked to practice relaxation tools for 15 minutes a day using the calendar and HeartBot app, and participate in once a week webinar for 30 minutes during the four weeks. UCLA Loneliness scale was recorded prior to the start of the study and at its end after the duration of 4 weeks. The score was reviewed to see the changes in the loneliness scale.
9713468|NCT04602455|No Intervention|Control Group|The control group had no change in their daily routines.
9713469|NCT04602364||Miga-Fab patients|Miga-Fab is a French prospective, observational cohort study of patients with Fabry disease treated with migalastat
9713470|NCT04602520||Dying patients|"Behavioral: Focused end of life conversations to promote connections among patients, family members and clinicians.~All eligible dying patients and families in the 3 participating acute care wards are invited to participate in wish elicitation and implementation. For clinician interviews, criterion sampling will be used, based on involvement in the care of enrolled dying patients. We will use qualitative and quantitative methods to collect and analyze data. Quantitative data will include characteristics of patients, families and clinicians. Qualitative data will be based on interviews. Pending the pandemic burden, and the status of their grief, family members of deceased patients may be invited for an interview later months after the death of their loved one."
9713471|NCT04602637||P1|
9713472|NCT04602637||P2|
9713473|NCT04602637||P3|
9713474|NCT04602442|Experimental|EXO-1|Participants (n=30) in this group will receive standard therapy and exosomes of the first type.
9713475|NCT04602442|Experimental|EXO-2|Participants (n=30) in this group will receive standard therapy and exosomes of the second type.
9713476|NCT04602442|Placebo Comparator|Placebo|Participants (n=30) in this group will receive standard therapy and inhalation placebo solution.
9713477|NCT04602572||Non-surgical group.|Patients will be offered a standardized program comprised of individual consultations by a trained nurse every 3 months over 2 years, participation in a lifestyle course with 13 group sessions focusing on healthy diet and physical activity, and pharmacotherapy.
9713478|NCT04602572||Surgical group|After completing the systematic work-up and the lifestyle course, eligible subjects will be offered bariatric surgery. The surgical procedure will be chosen at the surgeon's discretion taking into consideration the target weight, comorbidities, risk of complications, the patient's ability to cope with side effects and complications, and the patient's motivation.
9713479|NCT04602689|Experimental|Fibrin glue group|Spread Fibrin glue(Greenplast Q™) at iatrogenic ulcer after gastric ESD
9713480|NCT04602689|No Intervention|Control group|No intervention after gastric ESD
9713481|NCT04602468|Other|Standard group|The standard testing group will be available for both age cohorts with sites having a predefined recruitment cap for each testing group. The standard testing will involve the following assessments; sweat chloride, LCI, height/weight/BMI, FEV1, airway sampling (micro), FeNO, liver function testing, liver ultrasound, liver examination, stool collection, blood collection, abdominal symptom score, CFQ-R, pharmacy records medication pick up rate, adherence questionnaires, MEMs caps and antibiotic use.
9713482|NCT04602468|Other|Advanced group|In addition to all elements of the standard testing group, the advanced testing group will undergo: Ultra-low dose spirometry-controlled CT scanning, sputum collection and nasal lavage collection. This will be available for both age cohorts with sites having a predefined recruitment cap for each testing group.
9713483|NCT04602260||Prospective Cohort|The prospective cohort will assess patients upon admission to general internal medicine, at hospital discharge, and at 3, 6, 9, and 12-month follow-up.
9713484|NCT04602260||Retrospective Cohort|The retrospective cohort will assess patients at 3, 6, 9, and 12-months after being discharged from the hospital.
9713485|NCT04602273||High Risk MDS|New diagnosed patients treated with Azacitidine 75 mg/sqm SC QD on a 28 days based cycles (both 7-0-0 and 5-0-2 regimens are allowed) until disease progression, unacceptable toxicity, death or investigator decision
9713486|NCT04602247|Experimental|SIC|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe.
9713487|NCT04602247|Experimental|SIC + AA combined|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe given with 40 mg Ascorbic Acid
9713488|NCT04602247|Active Comparator|FeSO4|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe
9713489|NCT04602247|Active Comparator|FeSO4 + AA combined|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe along with 40 mg Ascorbic Acid
9713490|NCT04602247|Experimental|EP + FeSO4 combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe
9713491|NCT04602247|Experimental|EP + FeSO4 + AA combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe along with 40 mg of Ascorbic Acid
9713492|NCT04601896||Live patients admitted for Refractory Cardiac Arrest with ECMO|
9713493|NCT04601896||Live patients quality of life admitted for Refractory Cardiac Arrest without ECMO|
9713494|NCT04602026|Active Comparator|Arm I (best practice)|Non-frail patients receive standard of care.
9713495|NCT04602026|Active Comparator|Arm II (best practice)|Frail patients receive standard of care.
9713496|NCT04602026|Experimental|Arm III (physical therapy consultation, exercise intervention)|Frail patients undergo a physical therapy consultation and complete home exercises 3 days per week.
9713497|NCT04602234|Experimental|LUS group|
9713498|NCT04602234|No Intervention|No LUS group|
9713499|NCT04601948|Experimental|Intervention|Participants will receive a Fitbit activity monitor and access to the mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
9713500|NCT04602130|Experimental|Massage|Massages were performed starting from the face, focused on the newborns forehead, and then around the eyes and cheeks with gentle touches. Then, newborns' chest area and the upper and lower extremities were massaged. Finally, newborns'were placed prone position and the back was massaged. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
9713501|NCT04602130|Experimental|Sponge Bathing|In the sponge bathing group, the newborns' eyes, faces (outward from the midline), around the ear and the back of the ear were wiped from the inside out with cotton wipes and dried. Then, the chest area and arms, abdomen and back, legs and feet, respectively, were wiped and dried. Finally, the genital area was cleaned, before diapering the newborn. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form
9713502|NCT04602130|Experimental|Tub bathing|In the tub bathing group, before being immersed in the tub, the newborns' faces and heads were cleaned outwards from the midline and dried. Then, the neck, chest, arms, back, legs and genital area were soaped, before the full body was rinsed and dried. Finally, umbilical cord care was performed, and the baby was diapered. Nurses recorded the newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
9713503|NCT04602130|No Intervention|Control|The newborns in the control group did not undergo any intervention other than standard clinical practices. All physiological measurements (pulse, respiration, oxygen saturation and body temperature) were performed by nurses and recorded on the Newborn Follow-up Form.
9713504|NCT04602143|Experimental|Testosterone gel 4 weeks|Patients with low ovarian reserve received 4-week TTG application before controlled ovarian hyperstimulation.
9713505|NCT04602143|Experimental|Testosterone gel 6 weeks|Patients with low ovarian reserve received 6-week TTG application before controlled ovarian hyperstimulation.
10195245|NCT05240495|No Intervention|Wait-list control group (n=60)|Wait-list control group received equal and parallell assessment and eligibility procedure as the two experimental konditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
10195246|NCT05240469|No Intervention|Standard sperm selection|In the control group the oocytes will be injected with sperm that is selected by embryologists using conventional methods in the IVF lab.
10195247|NCT05240469|Experimental|Automated sperm selection|The only intervention is the additional sperm selection step using software immediately prior to ICSI.
9713506|NCT04602143|No Intervention|Control group|Patients with low ovarian reserve received no medication before controlled ovarian hyperstimulation.
10195248|NCT05240456|Experimental|Intervention|This arm will receive standard behavioral therapy plus Mirabegron with adjusted-dose regimen (25-50 mg), patients of 20-40 kg will receive 25-50 mg once a day; patients >40 kg will receive 50 mg once a day, for three months.
10195249|NCT05240456|Active Comparator|Control|This arm will receive will receive standard behavioral therapy plus Solifenacin with a daily dosage of (2.5-10 mg/kg), for three months.
9713507|NCT04601961|Active Comparator|SEVO Group|Patients in SEVO group will be anaesthetized by inhalational anaesthesia using sevoflurane.
9713508|NCT04601961|Experimental|TIVA group|The patients in TIVA group will be anaesthetized using total intravenous propofol.
10195250|NCT05240443|Experimental|Bariatric Surgery + Medical Management for Chronic Kidney Disease|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
10195251|NCT05240443|Active Comparator|Medical Management for Chronic Kidney Disease|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of <140/90 mmHg (<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein <2mmol/L for the treatment of CKD.
10195252|NCT05240430||stem cell application; Group I disease 0-7. days,|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group I disease 0-7. days,
10195253|NCT05240430||stem cell application; Group II; 8-14 days of the disease. days|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group II; 8-14 days of the disease. days
10195254|NCT05240430||stem cell application; Group III; those applied on the 15th day and after.|In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group III; It will be divided into 3 groups as those applied on the 15th day and after.
10195255|NCT05240417|Experimental|Study group|"Pontic-shield will be performed as ridge preservation technique."
10195256|NCT05240417|Active Comparator|Positive control (ridge preservation)|Deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction.
10195257|NCT05240417|No Intervention|Negative control (fresh socket)|No intervention will be performed after tooth extraction. Blood clot will be maintained after extraction.
10195258|NCT05240404|Other|Arm A|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation alone.
10195259|NCT05240404|Experimental|Arm B|Patients with recurrent hepatocellular carcinoma would be treated with curative-intent ablation and adjuvant immunotherapy with toripalimab.
9713509|NCT04602052|Active Comparator|Medical arm|Those who choose medical abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48 hours later for admission and misoprostol administration.
9713510|NCT04602052|Experimental|Surgical arm|Those who chose surgical abortion are given mifepristone 200 mg with or without laminaria and appointed to return the next day for surgical abortion.
9713511|NCT04602065|Experimental|Previously received anti-PD1/PD-L1 antibodies|Patients previously received anti-PD1/PD-L1 antibodies, except for those were primarily refractory to them.
9713512|NCT04602065|Experimental|Patients previously never received anti-PD1/PD-L1 antibodies|Patients previously never received anti-PD1/PD-L1 antibodies.
9713513|NCT04602169|Active Comparator|PVI only group|Patients allocated to this group will receive PV re-isolation alone
9713514|NCT04602169|Active Comparator|PVI + SVC group|Patients allocated to this group will receive PV re-isolation with SVC isolation.
10195260|NCT05240391|Active Comparator|Arm receiving 20% Human Albumin|20% Human albumin given intravenously over 4 hours
10195261|NCT05240391|Experimental|Arm receiving Midodrine|Tablet Midodrine 2.5 mg - 3 tablets thrice daily orally starting just before paracentesis
10195262|NCT05240352|Experimental|active tDCS|
10195263|NCT05240352|Sham Comparator|sham tDCS|
10195264|NCT05240339||PD participants with minor phenomena|
10195265|NCT05240313|Experimental|keepin' it REAL (kiR)|The standard keepin' it REAL intervention, adapted for an online format. This includes 10 one-hour small group sessions focused on helping youth to develop drug refusal skills and improve decision making, risk assessment, and emotion regulation. Additionally, short videos highlight various aspects of the program (refuse, explain, avoid, leave). All materials are available in Spanish and English.
10195266|NCT05240313|Experimental|kiR + aggression|The standard keepin' it REAL intervention, adapted for an online format, plus content on interpersonal aggression
10195267|NCT05240313|Active Comparator|Stress Management|A single session focused on stress management skills.
10195268|NCT05240300|Experimental|BX005-A|twice daily topical application x 8 weeks
10195269|NCT05240300|Placebo Comparator|Vehicle|twice daily topical application x 8 weeks
10195270|NCT05240274|Active Comparator|Metformin|metformin 500mg OD
10195271|NCT05240274|Placebo Comparator|Placebo|placebo 500mg OD
10195272|NCT05240261|Other|ESRAD on regular haemodialysis|30 ESRD Patients with sleep < 6 hours on regular haemodialysis . Before and after taking medications for 3 month.
10195273|NCT05240261|Other|CKD patients (predialydsis)|30 CKD Patients (predialysis) with sleep < 6 hours . Before and after taking medications for 3 month.
10195274|NCT05240222|Experimental|Theory-informed pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and subsequent follow-up consultation. The content of SC-PIES was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
9827828|NCT02469870|Experimental|Autism Parent Trainer (APT)|Practiced Routines was a facilitated program. It was organized into four modules that included a total of seven videos ranging from 3-13 minutes each. The topics overlapped with those in the TR program, but included more explicit information on function-based strategies, as well as mindfulness practice. Participants were assigned six fillable forms, and provided supplemental data collection tools. Additional resources focused on mindfulness and PBS within family routines. Eighteen brief guided audio meditations were available to participants via the Practiced MindTM mobile application. The meditations focused on bringing the parents' awareness to both internal and external experiences and helping them act intentionally.
9827829|NCT02469870|Active Comparator|Teaching Routines (Control|Teaching Routines was entirely self-directed. The program included eight modules with videos for each ranging 3 - 5 minutes in duration. The topics were antecedent-behavior-consequence method, creating task analyses, antecedent-based strategies, communication, reinforcement, teaching methods, and overcoming obstacles. Participants were assigned six activities using fillable forms and provided additional resources including examples, a glossary of terms, and a list of websites. No feedback was given to the parents apart from the automated completion responses. The participants were given access to the TR LMS for the duration of the study, but post and follow-up assessments were completed at 6 and 10 weeks (i.e., same as the PR condition).
9827830|NCT02469896|Placebo Comparator|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
9827831|NCT02469896|Active Comparator|Active drug|14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
9827832|NCT02469961|Experimental|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
9827833|NCT02469961|Active Comparator|Propofol|Participants will receive an interscalene block and be sedated with propofol
10195275|NCT05240222|Sham Comparator|Active control|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
10195276|NCT05240209|Experimental|Education (Intervention) Group|In the pretest phase of the research;Education group, those who signed the Informed Voluntary Consent Form and agreed to participate in the research will fill out the questionnaire.Data collection will take approximately 20-25 minutes.Afterwards,the researcher will give training to the training group about skin cancer,skin self-examination and sun protection behaviors.The tutorials are planned as a PowerPoint demonstration.The duration of the trainings is planned to take approximately 40minutes.The content of the training was prepared in line with the literature review.As a method;It will be in the form of narration,question and answer,brainstorming.Materials used in education;Colorfulbrochures on the subject will be given to reinforce the slide show and post-training information.A follow-up period of four months will be expected after the training given.At the end of the follow-up period,the training group will have to fill out the post-test questionnaires during the post-test phase.
10195277|NCT05240209|No Intervention|Control Group|Control Group: In the pre-test phase of the study; control group parents, those who signed the Informed Consent Form and agreed to participate in the study will fill out the questionnaire. Data collection will take approximately 20-25 minutes. During the follow-up period (120 days), no intervention will be made on the control group. At the end of the follow-up period (120 days), the control group will have to fill out the post-test questionnaires during the post-test phase. Participants will be reminded of the purpose of the research. Approval of the Informed Consent Form will be received. Completing the post-test questionnaires will take approximately 20-25 minutes. A brochure training material will be distributed to the parents of the control group, in line with the principle of equality, immediately after the completion of the post-tests.
10195278|NCT05240131|Experimental|Part A - GB1211 200 mg and 400 mg BID in combination with atezolizumab.|Part A of the study, open-label sentinel dosing will be undertaken to assess safety and tolerability of GB1211 at 200 mg and 400 mg BID in combination with atezolizumab.
9980200|NCT01389414|Active Comparator|Arm B-GEMOX|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
9980201|NCT01389427|Experimental|Torisel 15 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg
10195279|NCT05240131|Experimental|Part B - GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab|Part B of the study, GB1211 (200 or 400 mg BID to be selected from part A) in addition to atezolizumab, for 12 weeks
10195280|NCT05240131|Experimental|Part C - Extension of GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab|"Extension of GB1211 in addition to atezolizumab until part B has been unblinded.~Extension of placebo in addition to atezolizumab until part B has been unblinded"
10195281|NCT05240118||HFmrEF Group|"HFmrEF (Heart failure with mildly reduced ejection fraction): ESC Guideline heart failure 2021: patients with LVEF 41-49%.~non-cardiac events group versus cardiac events (cardiac death or heart failure-related rehospitalization) group"
10195282|NCT05240105||Departments for Psychosomatic Medicine at University Clinics|no study interventions, observational group
10195283|NCT05240105||Clinics specialized in Psychosomatic Medicine|no study interventions, observational group
10195284|NCT05240105||Departments for Psychosomatic Medicine at general hospitals|no study interventions, observational group
10195285|NCT05240105||Departments for Psychosomatic Medicine at psychiatric hospitals|no study interventions, observational group
10195286|NCT05240092|Experimental|Haptonomy Group|A home visit was made to the experimental group, and haptonomy was applied for at least 30 minutes, once a week, for 7 weeks (with the researcher for 3 weeks, with the husband by providing the training brochure and video that will help the practice for the next 4 weeks).
10195287|NCT05240092|No Intervention|Standard of care Group|The control group did not receive any treatment.
10195288|NCT05240079|Experimental|Patients|
10195289|NCT05240053|Active Comparator|group (1)|Group 1: included 25 patients who were subjected to enhance recovery program after laparoscopic colorectal surgery .
10195290|NCT05240053|No Intervention|group (2)|Group 2: included 25 patients who were subjected to traditional way
9827835|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended Release Capsules, 10 mg. Active drug, administered once
9827836|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended Release Capsules, 15 mg. Active drug, administered once
9827837|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended Release Capsules, 20 mg. Active drug, administered once
9827838|NCT02470312||CRT|Patients who are undergoing CRT implantation utilizing MediGuide system and tools
9827839|NCT02470312||EP|Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools
9827840|NCT02470390|Active Comparator|Nasal fentanyl|"nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.~Will be administered on either study day 1 or 3 per protocol and randomization."
10195291|NCT05240027|Other|Middle, High and College students within the Dallas-Fort Worth area that may Vape|The program will be going to middle school, high school, and college campuses in the Dallas-Fort Worth (DFW) area to speak with students about vaping. The program will be implemented by community outreach, as the students will be presented with information about vaping and the resources necessary to prevent or stop vaping.
10195292|NCT05239988||COVID-19 patients treated with Remdesivir|Patients suffering from SARS-CoV-2 and treated with Remdesivir admitted to Internal Medicine Unit
10195293|NCT05239975|Experimental|SCTV01C|
10195294|NCT05239975|Active Comparator|Comirnaty|
10195295|NCT05239949|Experimental|Hypopressive exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of hypopressive exercises (HE). A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform HE in an upright position. For this maneuver, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage. Four sets of 10 repetitions with a 3-minute interval between each set will be performed."
10195296|NCT05239949|Experimental|Pelvic floor muscle exercises and electrical muscle stimulation (EMS)|"Women included in this group underwent 24 sessions during 8 weeks (3 days/ week). Treatment will be given for 50 minutes in each session. Electrical muscle stimulation (EMS) will be applied in prone lying before every session of pelvic floor muscle exercises. A device will use for muscle stimulation at 7Hz for 15 minutes. The intensity of current will gradually increase from zero to a minimum that can be tolerated by the patient. Two electrodes will place medially to the ischial tuberosity and the remaining two will place on the sacral area.~After a 2-minute interval, the patient will be asked to perform pelvic floor muscle exercises in a sitting position. The patient is instructed to hold each contraction for 6 seconds, with three to four contractions added on the top. Four sets of 10 repetitions with a 2-minute interval between each set will be performed."
10195297|NCT05239923|Experimental|generation of neutralizing antibody for unvaccinated participants|participants received vaccine 1 capsule of 1×10^10 CFU of B. subtilis spore at day 0, 14, and 28 respectively.
10195298|NCT05239897|Experimental|postoperative delirium|We will use Confusion Assessment Method (CAM) to determine the incidence of postoperative delirium in participants twice per day. We will use the Memorial Delirium Assessment Scale(MDAS)and Mini-mental state examination(MMSE) to examine postoperative delirium severity.
10195299|NCT05239884|Experimental|Product usage order EFDGCHBA|Subjects will use each of the 8 products (EFDGCHBA) during an evaluation period, followed by a 4 hour Test Session
10195300|NCT05239884|Experimental|Product usage order HAGBFCED|Subjects will use each of the 8 products (HAGBFCED) during an evaluation period, followed by a 4 hour Test Session
10195301|NCT05239884|Experimental|Product usage order CDBEAFHG|Subjects will use each of the 8 products (CDBEAFHG) during an evaluation period, followed by a 4 hour Test Session
10195302|NCT05239884|Experimental|Product usage order DECFBGAH|Subjects will use each of the 8 products (DECFBGAH) during an evaluation period, followed by a 4 hour Test Session
10195303|NCT05239884|Experimental|Product usage order FGEHDACB|Subjects will use each of the 8 products (FGEHDACB) during an evaluation period, followed by a 4 hour Test Session
10195304|NCT05239884|Experimental|Product usage order BCADHEGF|Subjects will use each of the 8 products (BCADHEGF) during an evaluation period, followed by a 4 hour Test Session
10195305|NCT05239884|Experimental|Product usage order ABHCGDFE|Subjects will use each of the 8 products (ABHCGDFE) during an evaluation period, followed by a 4 hour Test Session
10195306|NCT05239884|Experimental|Product usage order GHFAEBDC|Subjects will use each of the 8 products (GHFAEBDC) during an evaluation period, followed by a 4 hour Test Session
10195307|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-1)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
9827841|NCT02470390|Active Comparator|Sub-Lingual fentanyl|"sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.~Will be administered on either study day 1 or 3 per protocol and randomization."
9827842|NCT02470390|Active Comparator|IV fentanyl|"IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.~Will be administered on study day 5 per protocol."
9827843|NCT02470403|Experimental|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
9827844|NCT02470403|Placebo Comparator|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
9827845|NCT02470403|Experimental|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
9827846|NCT02470403|Experimental|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
10195308|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-2)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
9713515|NCT04602208||Focal HIFU for primary localized prostate cancer|Between November 2009 and December 2016, at Edouard Herriot Hospital (Lyon, France), 146 consecutive patients were treated with focal HIFU for primary localized prostate cancer. Focal therapy was offered for low or intermediate risk disease (inclusion criteria: one tumor localized by systematic and targeted biopsies based on MRI findings, Gleason ≤7). Treatment failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death.
9713516|NCT04601974|Experimental|lentiviral gene therapy treatment (Intervention Arm)|Patients will receive a single dose of lentiviral gene therapy treatment administered once intracranially
9713517|NCT04601922||Emergency Medicine Consultants|
9713518|NCT04601922||General Practitioners|
9713519|NCT04601922||Acute care nursing staff|
9713520|NCT04601922||Patients presenting with suspected cardiac chest pain|
9713521|NCT04602013|Experimental|Immunotherapy combined with chemoradiotherapy|"Immunotherapy combined with chemoradiotherapy~Sintilimab Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W.~Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)~Radiotherapy The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week)."
9713522|NCT04602039|Experimental|People without Diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
9713523|NCT04602039|Experimental|Participants with Pre-diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
9713524|NCT04602039|Experimental|Participants with Type 2 diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
9713525|NCT04601636|Active Comparator|Active Prewarming group (PW group)|Group randomized to receive at least 30 minutes of active prewarming before induction of anesthesia, combined to active warming intraoperatively.
9713526|NCT04601636|Placebo Comparator|Control group (C group)|Group randomized to receive the standard care : passive prewarming before induction of anesthesia combined to active warming intraoperatively.
9713527|NCT04601519||Patients-type 1 diabetes|Participants are recruited by e-mail, among the users of the libreview platform (Abbott), who are followed up for type 1 diabetes at the CHU Grenoble Alpes (France), to participate in an anonymous online questionnaire and to allow their glycemic data extracted from the libreview platform to be used for the research.
10195309|NCT05239845|Active Comparator|Investigational Supplement 1 (INV-3)|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
10195310|NCT05239845|Placebo Comparator|Control|The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.
10195311|NCT05239819|Experimental|Intervention group|We conducted a fully engaged inspiratory muscle training (IMT) program. The exercise group received the intervention threshold IMT from preoperative to postoperative undergoing upper abdominal surgery. The IMT was started before 3 weeks of operation and surveyed in the followed 4 weeks.
10195312|NCT05239819|Active Comparator|Usual care group|The Usual care group will receive regulated education.
10195313|NCT05239780|Experimental|Participants with depression|Participants with depression to undergo brain stimulation
9713528|NCT04601688|Experimental|BRVO: Bevacizumab and intravitreal Dexamethasone|Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
9713529|NCT04601688|Active Comparator|BRVO: Bevacizumab|Participants with BRVO will receive Bevacizumab only.
10195314|NCT05239702|Experimental|Crohn Disease|
10195315|NCT05239702|Experimental|Ulcerative Colitis|
10195316|NCT05239702|Experimental|Dermatomyositis|
10195317|NCT05239702|Experimental|Still Disease|
9713530|NCT04601532|Active Comparator|Silver sulfadiazine|Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average.
9779559|NCT05205486|Experimental|Cefazolin 3gm Injection|Study drug will be administrated as an infusion over 30 minutes starting approximately 0.5 hours before surgery begins and following institutional guidelines on Day 1 (day of surgery). All subjects will have five (5) individual whole blood samples (4 mL each) collected for the estimation of cefazolin concentration in plasma at the following times after the start of the infusion: 0.5 (+/-10 min) end of infusion, 1 h (+/-15 min), 2 h (+/-15 min), 4 h (+/-15 min), and 8 h (+/-15 min).
10195318|NCT05239702|Experimental|Autoimmune Diseases|
10195319|NCT05239689|Experimental|Treatment of CD38-positive Hematological Malignancies|Administration of CD38 CAR T-cells A dose levels of 2-8*10E6/kg are administrated for each subject.
10195320|NCT05239676|Experimental|Treatment of Lymphoma|Refractory and relapsed malignant lymphoma
10195321|NCT05239650|Experimental|A：1L treatment|HLX07 * 1000 mg+HLX10* 200mg +mFOLFOX6, IV, Q2W
10195322|NCT05239650|Experimental|B：≥2L treatment|HLX07 *1000 mg monotherapy,IV, Q2W
10195323|NCT05239611|No Intervention|Usual care|Participants will receive usual standard of care
9713531|NCT04601532|Experimental|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
9713532|NCT04601701|Experimental|CRVO: Bevacizumab and intravitreal Dexamethasone.|Participants with CRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
9713533|NCT04601701|Active Comparator|CRVO: Bevacizumab|Participants with CRVO will receive a combination of Bevacizumab only.
9713534|NCT04601662|Experimental|Corticision|Patients in this group will be subjected to corticision to accelerate orthodontic movement
9713535|NCT04601662|Active Comparator|Traditional treatment|Patients in this group will undergo normal traditional treatment without any acceleration method.
9713536|NCT04601610|Experimental|Cohort 1|Subjects who have not received first-line system treatment previously;
9713537|NCT04601610|Experimental|Cohort 2|Subjects who have received at least first-line system treatment
9713538|NCT04601675|Experimental|Diabetic ME: Ranibizumab and intravitreal Dexamethasone|Participants with diabetic macular edema will receive a combination of Ranibizumab and intravitreal Dexamethasone
9713539|NCT04601675|Active Comparator|Diabetic ME: Ranibizumab|Participants with diabetic macular edema (ME) will receive Ranibizumab only.
10195324|NCT05239611|Active Comparator|exercise coaching|Participants will receive weekly coaching intervention
9713540|NCT04601649|Experimental|Intervention|Participants will take part in the PrEP Talk intervention sessions.
9713541|NCT04601649|No Intervention|Control|Participants will receive standard care.
9713542|NCT04601493|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
9713543|NCT04601493|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
9713544|NCT04601493|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
9713545|NCT04601493|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
9713546|NCT04601428|Experimental|Investigational Arm|
9713547|NCT04601545|Experimental|VR therapy group|Pulmonary rehabilitation supplemented by VR therapy
9713548|NCT04601545|Active Comparator|Active Control Group|Pulmonary rehabilitation supplemented by Schultz Autogenic Training
9713549|NCT04601727||Rectal cancer patients|
9713550|NCT04601766|Experimental|Group A|
9713551|NCT04601766|Experimental|Group B|
9713552|NCT04601506|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
9713553|NCT04601506|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
9713554|NCT04601506|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
9713555|NCT04601506|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
9713556|NCT04601480|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
9713557|NCT04601480|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
9713558|NCT04601480|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
9713559|NCT04601480|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
9713560|NCT04601415||GP Referrals|Patients with HF referred by GP to echo department
9713561|NCT04601415||Echo patients|Non-selected patients attending echo department in hospital
9713562|NCT04601402|Experimental|GEN-001 with avelumab|"Dose Escalation Cohort includes patients with advanced or metastatic solid tumors who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination) will be enrolled. 3 or 6 patients will be enrolled per escalating or de-escalating dose levels.~Dose Expansion Cohort includes patients with advanced or metastatic NSCLC, SCCHN, and UC who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)will be enrolled."
9713563|NCT04601441|Other|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
9779560|NCT05204134|Experimental|Control-IQ Technology with Algorithm Derived Initial Profile Settings and Regular Updates|After CGM run-in, participants will begin use of Control-IQ technology with algorithm derived initial insulin delivery settings, then have regular settings updates from the algorithm through 13 weeks of use.
9779561|NCT05202210||patients with Noonan syndrome|extra sample of blood and urine will be collected and stored for research utilisation
9779562|NCT05198349|Experimental|M1069|
9827847|NCT02470403|Placebo Comparator|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
10195325|NCT05239559||bubble CPAP arm|"Oxygen will be delivered by Bubble CPAP device, which will have three components:~Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~A nasal interface connecting the child's airway with the circuit: short nasal prongs are generally used to deliver nasal CPAP. They must be carefully fitted to minimize leakage of air (otherwise, CPAP will not be achieved) .~An expiratory arm with the distal end submerged in water to generate end-expiratory pressure: in bubble CPAP, the positive pressure is maintained by placing the far end of the expiratory tubing in water. The pressure is adjusted by altering the depth of the tube under the surface of the water."
10195326|NCT05239546|Experimental|Neoadjuvant Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 3 doses pre-operatively
9713564|NCT04601792|Experimental|Individualized Decoction|"It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For subjects with lung and spleen qi deficiency syndrome, the investigators added Radix Codonopsis Pilosulae, Pericarpium Citri Reticulatae, and Atractylodes Macrocephala Koidz. The investigators can adjust the individualized decoction in accordance with the change in the patient's condition throughout the whole study duration.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
9713565|NCT04601792|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
10195327|NCT05239520||People affected by FSHD|Participants with a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound.
9713566|NCT04601792|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
9713567|NCT04601467|Experimental|AZD5718|Patients will receive once daily oral dose of AZD5718 for 12 months
9713568|NCT04601467|Placebo Comparator|Placebo|Patients will receive once daily oral dose of placebo matched to AZD5718 for 12 months
9713569|NCT04601363||Patients with Personalized SpineRods|The patient is being treated with the patient-specific rod with a surgery date planned
10195328|NCT05239520||Age matched control group|Participants without a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound
9713570|NCT04601363||Patient with other hardware|Patients with other hardware not patient-specific
9713571|NCT04601324|Active Comparator|Dymista (Azelastine hydrochloride and fluticasone propionate)|Participants will receive standard of care, which includes twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride and 50 mcg of fluticasone propionate per spray) separated by 12 hours.
9713572|NCT04601324|Experimental|Fluticasone Propionate and Rupatadine|Participants will administer fluticasone propionate nasal spray once daily (2 sprays in each nostril, 50 mcg fluticasone propionate per spray)and 1 tablet of Rupatadine (10mg) once daily in the morning.
9713573|NCT04601129||patients|undergoing a minimally invasive nephrectomy, eligible to an Enhanced Recovery After Surgery Program.
9713574|NCT04601038|Other|MCI|Individuals with mild cognitive impairment due to Alzheimer's disease
9713575|NCT04601038|Other|Cognitively Normal|Individuals who are cognitively normal but who are at risk for Alzheimer's disease
9713576|NCT04601025|Experimental|Yoghurt|
9713577|NCT04601025|Experimental|Chickpea+Yoghurt|
9713578|NCT04601025|Experimental|Oat+Yoghurt|
9713579|NCT04600999|Experimental|Group Avigan|Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.
9713580|NCT04600999|No Intervention|Group Control|Supportive care (symptomatic therapy)
9713581|NCT04600986|Experimental|New oocyte triggering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl) and in addition a repeat dose of 0.1 mg s.c triptorelin (decapeptyl) will prescribed 12 h following the first dose.
9713582|NCT04600986|Other|Routine oocyte trigering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl), 35 h prior to oocyte retrieval.
9713583|NCT04601142||glucocorticoid sensitive (GS) group|
9713584|NCT04601142||glucocorticoid resistance (GR) group|
9713585|NCT04601012||Patients with COVID19|The patients with previous diagnosis of COVID19
9713586|NCT04601012||Control subjects|Healthy subjects without actual and previous ocular diseases
9713587|NCT04601259|Experimental|Orkla corn plaster with Salicylic acid|
9713588|NCT04601259|Active Comparator|Orkla corn protector without salicylic acid|
9713589|NCT04601272||Breast Cancer Screening|Women between the ages of 35-55 when they received a decision aid for breast cancer screening with no prior diagnosis of breast cancer. These people will see items only pertaining to breast cancer screening.
9713590|NCT04601272||Colon Cancer Screening|Men and women between the ages of 45-75 when they received a decision aid for colon cancer screening with no prior diagnosis of colon cancer. These people will see items only pertaining to colon cancer screening.
9713591|NCT04601272||Prostate Cancer Screening|Men between the ages of 45-74 when they received a decision aid for prostate cancer screening with no prior diagnosis of prostate cancer. These people will see items only pertaining to prostate cancer screening.
10195329|NCT05239481|Experimental|intervention|Before the examination, the nurse chose the appropriate colonoscopy position size sheet according to the patient's age and body size and spread it on the examination bed; instructed the patient to lie in the designated area according to the body size.Description: ① take off your shoes; ② follow the bed chart; ③ fade your pants to your knees.
10195330|NCT05239481|Placebo Comparator|control|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient, the following: ① please remove the shoes; ② please sit on the end of the bed mattress; ③ please lie to the left side; ④ please put the head close to the pillow; ⑤ please fade the pants to the knee; ⑥ please put the knee close to the abdomen.
10195331|NCT05239429|Experimental|Transcendental Meditation Technique|Participants are trained on the use of the Transcendental Meditation Technique. They will perform the technique twice a day for 20-minutes per session.
10195332|NCT05239429|No Intervention|Lifestyle-as-usual (control)|There is no change to the participants daily schedule and lifestyle.
10195333|NCT05236517|Experimental|Semaglutide|
10195334|NCT05236517|Placebo Comparator|Placebo|
9713592|NCT04601272||Lung Cancer Screening|Men and Women between the ages of 50-80 when they received a decision aid for lung cancer screening with no prior diagnosis of lung cancer. These people will see items only pertaining to lung cancer screening.
10195335|NCT05229809|Experimental|Yiqi Wenyang Jiedu prescription Group|
10195336|NCT05229809|Placebo Comparator|Simulation agent of Yiqi Wenyang Jiedu prescription Group|
9713593|NCT04601298||AUS|
9713594|NCT04601298||FLUS|
10195337|NCT05229692|Experimental|NEUBIE|"Experimental group will receive rehabilitation training with the NEUBIE for 6 weeks post-operative. Training will occur at Neufit 2x a week from week 1-5, and will be administered by NeuFit clinic staff. Exercises and ability to complete exercises will be recorded by NeuFit staff in standardized clinic evaluation forms.~Participants will undergo will undergo both active muscle tests and body analysis tests.~Measurements will be taken at The Piazza Center by clinic staff prior to surgery at 2,4,6,8, and 12 weeks post-operative. Measurements will be used to demonstrate milestones of functional recovery, comparable between subjects by weeks achieved."
10195338|NCT05229692|No Intervention|Control|"Control group will receive current post-operative standard of care for abdominoplasty, which includes using an abdominal binder, rest and minimal activity for 6 weeks.~Participants will undergo both active muscle tests and body analysis tests. Measurements will be taken at The Piazza Center by clinic staff prior to surgery at 2,4,6,8, and 12 weeks post-operative. Measurements will be used to demonstrate milestones of functional recovery, comparable between subjects by weeks achieved."
9713595|NCT04601233|Experimental|Treatment open label arm|Open-label feasibility study to determine the effects of testosterone (Xyosted 75mg subcutaneous once per week for 3 months) on erectile function in male Multiple Sclerosis patients with low testosterone.
9713596|NCT04601389|Experimental|"GNR-044 (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
9713597|NCT04601389|Active Comparator|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
9713598|NCT04601077|Active Comparator|Nitric Oxide|Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
9713599|NCT04601077|Placebo Comparator|Placebo|Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
9713600|NCT04601207|Experimental|Solutech™- TC10|10.0mg THC, 12.2 mg CBD liquid emulsion product given orally once in-clinic
9713601|NCT04601207|Active Comparator|MCT-diluted Cannabis Product|10.0mg THC, 12.2 mg CBD liquid MCT-diluted oil product given orally once in-clinic
10195339|NCT05224895||General Anesthesia in Trendelenburg position for robotic prostatectomy|
10195340|NCT05221463|Experimental|Educational group|Video-assisted breastfeeding training was given to the educational group.
10195341|NCT05221463|Other|Control group|Only the hospital's routine general breastfeeding training was given to the control group, and no other intervention was made.
10195342|NCT05219214||Chinese medicine group|
10195343|NCT05218850|Experimental|open label intervention arm|Butyrate enemas will be administered once daily for twelve weeks.
10195344|NCT05218811|Experimental|Treatment group|Patients underwent Cryotheapy assisted partial nephrectomy
10195345|NCT05218785||Botulinum toxin A injection|Patients will receive a total of 3 -three - injections of 75 IU Botulinum Toxin A in the proximal medial gastrocnemius muscle. Treatments will be performed by a specialist in neurology as a Ultra-Sound guided injection into the proximal medial gastrocnemius muscle Injections will be administered at baseline, 3 months and 6 months.
9713602|NCT04601181|Experimental|ThisCART22 cells injection|In this arm，allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
9713603|NCT04600713|Experimental|PT-X and IMT|Physiotherapist-led exercise-based cardiac rehabilitation (PT-X) and inspiratory muscle training (IMT).
9713604|NCT04600713|No Intervention|Control|The participants in the control group will be offered PT-X at the end of the control period.
9713605|NCT04600830|Experimental|Dry Needling Group|Dry needling will be applied to the myofascial trigger points of the gastrocnemius muscle. With the dry needle (0.3 x 40 mm. Myofib, Toledo, Spain). Thus, insert the needle until you get the first twitch response. Once the first twitch response is obtained, the needle will move about 2-3 mm vertically quickly. Twenty-five insertions without leaving the skin. The approximate frequency of 1 Hz for 25 to 30 seconds.
9713606|NCT04600830|Active Comparator|Foam Roller Group|The myofascial self-release technique with the FR Black Roll PRO (Bottighogen, Switzerland). The subject will move his body in the same direction as the muscle fibers, using his hands to propel and get the roller to slide back and forth. The device will only be applied at the muscular level, avoid the area of the Achilles tendon. It will be repeated on the contralateral leg. A total of three 60-second steps is executed on each leg and a 30-second break between both.
9713607|NCT04600843|Experimental|Physical therapy with Patient education|Treated with proper physical therapy treatment protocol according to patient presenting condition and patient education manual
9713608|NCT04600843|Experimental|Physical Therapy without patient Education|Treated with proper physical therapy treatment protocol according to patient presenting condition
9713609|NCT04600739||AVD Patients|Patients suffering from aortic valve stenosis receiving replacement of the diseased valve using a TAVI procedure.
9779563|NCT05197959|No Intervention|Group A-Control|Participants in this arm will not experience any intervention during a 4 week period of time. Participants will experience their standard medical care.
9779564|NCT05197959|Experimental|Group B-rTMS and sensorimotor training|Repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. Immediately following rTMS, participants will perform sensorimotor training. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
9785776|NCT01259713|Placebo Comparator|Placebo|Placebo to match liposomal amphotericin B twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
10195346|NCT05218473|Experimental|Prolonged ECG monitoring group|Patients receive 14-day continuous electrocardiography patch monitoring
9713610|NCT04600869|Experimental|Nursing Group|Nurses in the control group accepted the other non-fertility (standard) nursing training for the intervention, whereas those in the experimental group accepted the oncofertility training. Based on research ethics and design, a standard education course was held for the control group after completing data collection in the nursing experimental group. We began to recruit patients into the patient experimental group after all nurses completed their educational courses.
9713611|NCT04600908||Non-physician staff|All non-physician staff who have had commuting accidents
9713612|NCT04600934|Active Comparator|Standard POBA (plain old balloon angioplasty)|The first 50 patients will be pre-treated with standard POBA
10195347|NCT05218473|Active Comparator|Conventional procedure group|Patients received serial 12-lead electrocardiograms once daily for five days or 24-hour Holter monitoring
10195348|NCT05218005|No Intervention|Observation|Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.
10195349|NCT05218005|Experimental|Active-testing|Those admitted between 6-18 months of the study meeting the inclusion criteria. Saliva samples will be collected for DNA testing.
10195350|NCT05217017|Experimental|Chronic pain|Fear-avoidance components scale
10195351|NCT05216627||PSOM staff, trainees, or faculty who participate in the point of care testing|The cohort will be offered access to a self-administered saliva-based viral test is a small funnel and a tube in which participants will put their saliva into. When they are ready to self-collect their saliva sample, they will be instructed to not eat or drink for 30 minutes prior to collecting their saliva and to collect saliva in an isolated room. We will evaluate the implementation of this viral test.
10195352|NCT05216107||Hospital Universitario de Álava, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
10195353|NCT05216107||Hospital Universitario de Basurto, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
10195354|NCT05216107||Hospital Universitario de Cruces, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
10195355|NCT05216107||Hospital Universitario de Donostia, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
10195356|NCT05216107||Hospital San Pedro (Logroño), Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
10195357|NCT05216107||Hospital of Navarra, Spain|large hospitals (>200 beds) with wards admitting older surgical patients where (a) electronic medical records are available, (b) have staff committed to recruiting a minimum of 100 participants with complete follow-up, and (c) give consent for the Lead statistician in Spain to access de-identified data for aggregated analysis.
10195358|NCT05215587|No Intervention|Medical Therapy|Patients will be treated with optimal medical therapy, i.e., antihypertensives, pulse-rate regulators, and pain medication.
10195359|NCT05215587|Active Comparator|Stent Therapy|Patients will be treated with both optimal medical therapy, in addition to placement of a thoracic endovascular aortic repair stent graft.
9713613|NCT04600934|Experimental|Shockwave|The second 50 patients will be treated primarily with Shockwave
9713614|NCT04600947|Experimental|LP002|Participants will receive LP002 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W) for up to 24 months.
9713615|NCT04600635||patients with a medical history of obesity|Patients included are subject who entered a structured program of care for their obesity, with or without bariatric surgery.
9713616|NCT04600752|Experimental|Participants receiving Augmentin (ES)-600|Eligible participants will receive Augmentin (ES)-600 at 90/6.4 mg/kg/day administered in two divided doses, every 12 hours with food for 10 days.
9713617|NCT04600817|Experimental|TJ107|
9713618|NCT04600817|Placebo Comparator|TJ107Placebo|
9713619|NCT04600596||Roux-en-Y gastric bypass patients|Severely obese non-diabetic adult female patients scheduled for RYGB.
9713620|NCT04600596||Obese (BMI ≥ 35) controls|Severely obese non-diabetic adult female patients not undergoing surgery.
9713621|NCT04600596||Lean (BMI ≤ 25) controls|Lean healthy non-diabetic adult females.
9713622|NCT04600778|Placebo Comparator|placebo|twice daily
9713623|NCT04600778|Experimental|Cavosonstat 5 mg|twice daily
9713624|NCT04600778|Experimental|Cavosonstat 10 mg|twice daily
9713625|NCT04600778|Experimental|Cavosonstat 25 mg|twice daily
9713626|NCT04600622|Experimental|Intervention Arm|Participants will receive Rural Diabetes One-Day Education and Care program (R-D1D). A one time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
9713627|NCT04600622|Active Comparator|Active Comparator|Participants will receive diabetes education materials.
9713628|NCT04600765|Active Comparator|Diet Before|Typical diet contaminated with Bisphenol A. Patient assigned to this arm will consume a typical American diet as defined by USDA.
9713629|NCT04600765|Active Comparator|Diet After|Bisphenol A reduced. Patient assigned to this arm will consume a diet analogous to atypical American diet as defined by USDA, but with known Bisphenol A sources reduced or eliminated.
9713630|NCT04601116|Active Comparator|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg tablets per day for 2 years
9713631|NCT04601116|Placebo Comparator|Placebo|Placebo tablets 1 per day for 2 years.
9713632|NCT04600583|Active Comparator|Alignment according to Functional Alignment philosophy|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System aligned according to Functional Alignment philosophy. This method of implant alignment is defined by a patient's native joint line as well as the soft tissue envelope. Triathlon Total Knee System components will be positioned relative to intra-operative soft tissue laxity assessment. A mobile application (KneeBalancer) will be used to assist surgeon decision making during the dynamic joint balancing surgical step.
9713633|NCT04600583|Active Comparator|Alignment to the patient's natural Mechanical axis|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System neutrally aligned to the Mechanical axis. More specifically, the femoral component and tibial component are aligned 0° to the mechanical axis of each respective limb. Femoral component rotation is fixed to the trans-epicondylar axis. Soft tissue releases are performed at the discretion of the surgeon to achieve balance and full range of motion.
9713634|NCT04600700||CDSS weaning group|This group will be exposed to the CDSS to inform inotrope weaning
10195360|NCT05213182|Experimental|Intervention|The intervention arm (n=104 adolescent mothers) participated in the 12 in-person peer support group sessions and completed sociodemographic, base-, mid-, and end-line surveys.
10195361|NCT05213182|No Intervention|Control|The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys.
10195362|NCT05211752||Healthy young athletes (Eye-Tracker®T2 + e-VOG)|Subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
10195363|NCT05211752||Healthy young athletes (e-VOG + Eye-Tracker®T2)|Subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
10195364|NCT05211596|Other|Single Intervention Arm (Main Intervention)|Main Intervention
10195365|NCT05210959||Preterm or term born infants|Premature or term born infants between the aged 3-18 months were recruited in this study.
10195366|NCT05210816|Experimental|ACT|''Acceptance and Commitment Therapy (ACT) Based Intervention Program was applied to the intervention group.
9713635|NCT04600687|Experimental|Intervention Arm|Participants will be enrolled in a single arm with a cross over design. Each participant will receive both placebo tablets about 30 minutes apart. Questionnaires will be completed prior to and after each placebo tablet is swallowed.
10195367|NCT05210816|No Intervention|Control|Only data collection was carried out. No attempt was made by the researcher during the study.
10195368|NCT05209893|Experimental|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
9713636|NCT04600661|Experimental|control group (Traditional therapy group)|control group (Traditional therapy group) (n=21): patients will receive traditional training exercises (high load resistance training
10195369|NCT05209893|Active Comparator|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
10195370|NCT05209867|Experimental|CBD Intervention|Participants will self-administer CBD daily for 2 months.
10195371|NCT05209360|Experimental|Arm 1|Testing Order: NoCDO, CDO, Lateral, Medial
9713637|NCT04600661|Experimental|Experimental group I (BFR training group)|Experimental group I (BFR training group) (n=21): patients will receive LLRT with BFR.
9713638|NCT04600661|Experimental|Experimental group II (Neuromuscular training group)|Experimental group II (Neuromuscular training group) (n=21): patients will receive neuromuscular training exercises
9713639|NCT04600726||older adults with known mild NCD|Older adults with known mild neuro-cognitive disorders
9713640|NCT04600726||older adults with non-communicable diseases|older adults with non-communicable diseases such as diabetics, hypertension and chronic obstructive airway diseases
9713641|NCT04600726||Older adults with healthy condition|Older adults who are free from neuro-cognitive disorders and non-communicable diseases
9713642|NCT04600648|Active Comparator|Weight loss with bariatric surgery|Patients scheduled to undergo bariatric surgery will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
9713643|NCT04600648|Active Comparator|Weight Loss|Patients to receive lifestyle weight loss treatment will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
9713644|NCT04600505|Experimental|Treatment Sequence ABC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment B; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
9713645|NCT04600505|Experimental|Treatment Sequence BCA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment C; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
9713646|NCT04600505|Experimental|Treatment Sequence CAB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment A; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
9713647|NCT04600505|Experimental|Treatment Sequence ACB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment C; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
9785777|NCT01259726|Placebo Comparator|Placebo|
9785778|NCT01259726|Experimental|VP20621 Low Dose and Placebo|
10195372|NCT05209360|Experimental|Arm 2|Testing Order: NoCDO, CDO, Medial, Lateral
10195373|NCT05209360|Experimental|Arm 3|Testing Order: NoCDO, Medial, CDO, Lateral
10195374|NCT05209360|Experimental|Arm 4|Testing Order: NoCDO, Medial, Lateral, CDO
10195375|NCT05209360|Experimental|Arm 5|Testing Order: NoCDO, Lateral, Medial, CDO
10195376|NCT05209360|Experimental|Arm 6|Testing Order: NoCDO, Lateral, CDO, Medial
10195377|NCT05209360|Experimental|Arm 7|Testing Order: CDO, NoCDO, Medial, Lateral
10195378|NCT05209360|Experimental|Arm 8|Testing Order: CDO, NoCDO, Lateral, Medial
10195379|NCT05209360|Experimental|Arm 9|Testing Order: CDO, Medial, NoCDO, Lateral
10195380|NCT05209360|Experimental|Arm 10|Testing Order: CDO, Medial, Lateral, NoCDO
9713648|NCT04600505|Experimental|Treatment Sequence BAC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment A; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
9713649|NCT04600505|Experimental|Treatment Sequence CBA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment B; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
10195381|NCT05209360|Experimental|Arm 11|Testing Order: CDO, Lateral, Medial, NoCDO
10195382|NCT05209360|Experimental|Arm 12|Testing Order: CDO, Lateral, NoCDO, Medial
10195383|NCT05209360|Experimental|Arm 13|Testing Order: Medial, NoCDO, Lateral, CDO
10195384|NCT05209360|Experimental|Arm 14|Testing Order: Medial, NoCDO, CDO, Lateral
10195385|NCT05209360|Experimental|Arm 15|Testing Order: Medial, CDO, NoCDO, Lateral
10195386|NCT05209360|Experimental|Arm 16|Testing Order: Medial, CDO, Lateral, NoCDO
9713650|NCT04600479|Experimental|prevalence and follow-up of HCV positive patients|"Cross-sectional assessment of prevalence : evaluation of the prevalence of HCV, HBV and HIV viral infections~Cohort follow-up of HCV positive patients : evaluation of care pathway and barriers to care for hepatitis C"
9785779|NCT01259726|Experimental|VP20621 High Dose and Placebo|
10195387|NCT05209360|Experimental|Arm 17|Testing Order: Medial, Lateral, CDO, NoCDO
10195388|NCT05209360|Experimental|Arm 18|Testing Order: Medial, Lateral, NoCDO, CDO
10195389|NCT05209360|Experimental|Arm 19|Testing Order: Lateral, NoCDO, CDO, Medial
10195390|NCT05209360|Experimental|Arm 20|Testing Order: Lateral, NoCDO, Medial, CDO
10195391|NCT05209360|Experimental|Arm 21|Testing Order: Lateral, CDO, Medial, NoCDO
10195392|NCT05209360|Experimental|Arm 22|Testing Order: Lateral, CDO, NoCDO, Medial
10195393|NCT05209360|Experimental|Arm 23|Testing Order: Lateral, Medial, NoCDO, CDO
10195394|NCT05209360|Experimental|Arm 24|Testing Order: Lateral, Medial, CDO, NoCDO
10195395|NCT05208723|Experimental|Stress and emotion management|A locally adapted self-help guidebook originally developed by the World Health Organization (WHO), 'Doing what matters in times of stress' for managing disruptive emotions and psychological distress, will be delivered to female entrepreneurs at their residence, followed by 5-6 phone calls from a trained mental health helper to reinforce the materials over a 6-week period. The intervention is intended to help people manage their psychological distress associated with a range of adversities but is not intended for participants with severe mental health problems such as psychosis or imminent risk of suicide.
9980202|NCT01389427|Experimental|Torisel 25 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg
9980203|NCT01389427|Experimental|Torisel 50 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg
9980204|NCT01389427|Experimental|Torisel 75 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg
9980205|NCT01389440|Experimental|Gemcitabine, Erlotinib and radiotherapy|Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
10195396|NCT05208723|No Intervention|Control group|No intervention. May receive intervention post study if findings are indicative of any benefit.
10195397|NCT05208619|Active Comparator|thoracic epidural analgesia|A thoracic epidural catheter is placed before induction of general anaesthesia. Sufentanil 10 µg and Ropivacaine are applied via the catheter.
10195398|NCT05208619|Active Comparator|paravertebral block|A single-shot paravertebral block (Ropivacaine 0,5%) is placed before induction of general anaesthesia.
10195399|NCT05207397||Healthy Control|Lactate clamp: The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. The investigator will then administer priming doses of 57.5 mg [3-13C]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of [3-13C]lactate at 10 mg/min and D2-glucose at 2 mg/min. Along with the continuous isotope infusion the investigator will begin infusion of the Na-lactate at approximately 2.6mg/kg·min. Based upon readings from blood samples during the infusion, this rate will be adjusted as needed to maintain the target lactate concentration of approximately 4mM. Blood samples will be drawn at 10, 20, 30, 45, 60, 75, 90 and 120 minutes, while breath samples will be collected at 60, 75, 90 and 120 minutes.
10195400|NCT05207397||Mild Cognitive Impairment|Lactate clamp: The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. The investigator will then administer priming doses of 57.5 mg [3-13C]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of [3-13C]lactate at 10 mg/min and D2-glucose at 2 mg/min. Along with the continuous isotope infusion the investigator will begin infusion of the Na-lactate at approximately 2.6mg/kg·min. Based upon readings from blood samples during the infusion, this rate will be adjusted as needed to maintain the target lactate concentration of approximately 4mM. Blood samples will be drawn at 10, 20, 30, 45, 60, 75, 90 and 120 minutes, while breath samples will be collected at 60, 75, 90 and 120 minutes.
10195401|NCT05207202|Active Comparator|EIT-PEEP strategy|Patients will receive PEEP titrated by EIT with a stepwise decrease PEEP trial
10195402|NCT05207202|Active Comparator|ARDSNet-PEEP strategy|PEEP will be set according to the low FiO2-PEEP table to keep the oxygenation goals: SpO2 between 88% and 95%, and PaO2 between 55mmHg and 80mmHg.
10195403|NCT05207046||Patients with spinal cord injury|Patients treated with mechanical ventilation after a traumatic spine lesion with spinal cord injury
10195404|NCT05207046||Patients with NO spinal cord injury|Patients treated with mechanical ventilation after a traumatic spine lesion with NO spinal cord injury
10195405|NCT05206162|Active Comparator|continuous theta burst stimulation|cTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s.
10195406|NCT05206162|Active Comparator|intermittent theta burst stimulation|iTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in an intermittent train of 190s for iTBS, with repeated cycles of 2s stimulation and 8s pause.
9827848|NCT02470429|Experimental|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
10195407|NCT05206162|Sham Comparator|sham stimulation|Sham stimulation over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s using a plastic spacer (25mm thickness) between coil and scalp, preventing effective cortical stimulation.
10195408|NCT05205889|Experimental|Mobile based values intervention for people with chronic pain|
10195409|NCT05204823|Experimental|Experimental Product 1|Consumption of 221.24 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
10195410|NCT05204823|Experimental|Experimental Product 2|Consumption of 282.81 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
10195411|NCT05204823|Experimental|Experimental Product 3|Consumption of 589,62 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
10195412|NCT05204823|Experimental|Experimental Product 4|Consumption of 573,39 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
10195413|NCT05204823|Active Comparator|Control product|Consumption of 25g of glucose. Subjects will take this amount only on the day of the visit that they are to consume this product.
9827849|NCT02470429|Active Comparator|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
9827850|NCT02470494|Experimental|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
9827851|NCT02470585|Active Comparator|Placebo + Carboplatin + Paclitaxel -> Placebo|Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
10195414|NCT05202470|Experimental|Telehealth Education (TE)|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
10195415|NCT05202470|Active Comparator|Conventional Education (CE)|Paper-based education forms will be given to the patients in the first group. Face-to-face conventional diabetes education will be carried out.
10195416|NCT05197868|Active Comparator|Intubation with traditional laryngoscope|Participants will be required to intubate the manikin by using a traditional laryngoscope
10195417|NCT05197868|Experimental|Intubation with a straight blade video laryngoscope|Participants will be required to intubate the manikin by using a straight blade video laryngoscope
10195418|NCT05197868|Experimental|Intubation with hyper-angulated video laryngoscope|Participants will be required to intubate the manikin by using a hyper-angulated video laryngoscope
10195419|NCT05195723|Experimental|WP1122|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose [SAD]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose [MAD]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
10195420|NCT05195723|Placebo Comparator|Placebo|"Each study group consists of 10 volunteers randomized in a 4:1 ratio to receive WP1122 or placebo. In the first part of the study (Single Ascending Dose [SAD]) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, one time orally. A total of up to 40 volunteers will be enrolled into the SAD portion of the study.~The second part of the study (Multiple Ascending Dose [MAD]) will begin when the third group in the SAD part of the study has completed dosing. In this part of the study (MAD) in each group (up to 4), 8 volunteers will receive WP1122 and 2 volunteers will receive placebo, 2 times per day (12 hours apart) orally for 7 days. A total of up to 40 volunteers will be enrolled into the MAD portion of the study.~Up to 80 volunteers will be enrolled into the study entirely."
10195421|NCT05195229|Experimental|Arm 1|Aim: To estimate the viral load in aerosols generated from children with COVID-19 infection, and to compare the viral load contained in aerosols from children with aerosols from adults
10195422|NCT05193981||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
10195423|NCT05190770|Experimental|Triamcinolone + Oleogel-S10|25 participants will be randomized to triamcinolone 0.1% cream once every morning and topical Oleogel-S10 gel once prior to bedtime for a 3 week period.
10195424|NCT05190770|Placebo Comparator|Triamcinolone + Placebo|25 patients with breast cancer will be randomized to triamcinolone 0.1% cream once every morning (QAM) and vehicle gel once prior to bedtime for a 3 week period.
10195425|NCT05188027|Experimental|All participants|All participants will take part in all three testing conditions
10195426|NCT05186623||Patients with confirmed ulcerative colitis|Patients with confirmed ulcerative colitis, who are going to receive vedolizumab therapy (n=100: development cohort n=70 and validation cohort n=30), ustekinumab therapy (n=100: development cohort n=70 and validation cohort n=30), or tofacitinib therapy (n=100: development cohort n=70 and validation cohort n=30), will be enrolled.
10195427|NCT05184231||Patient cohort|
10195428|NCT05184231||Physician cohort|
10195429|NCT05178771|Experimental|test site|The test site will receive ScRp in addition to PRF
10195430|NCT05178771|No Intervention|control sites|The control site will be treated by ScRp only
9827852|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Placebo|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
10195431|NCT05173818|Experimental|HBO at 1.5 Atmosphere absolute|Participants in this group will be exposed to hyperbaric oxygen at 1.5 atmosphere absolute (ATA) for 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
9827853|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Veliparib|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles.
9827854|NCT02470741|Experimental|Letrozole|Oral letrozole 2.5mg/day
9827855|NCT02470741|Placebo Comparator|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
10195432|NCT05173818|Sham Comparator|Sham control initially at 1.2 then changed to 1.0 ATA|Participants in this group will be exposed to hyperbaric oxygen at 1.2 atmosphere absolute (ATA) during the first 5 to 7 minutes and the chamber pressure will be reduced to 1.0 ATA for the remaining 53 - 57 minutes for a total of 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
10195433|NCT05173077||Colorectal cancer patients|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
10195434|NCT05173077||Control group patients without colorectal cancer|Patients without colorectal malignant disease according to data obtained in colonoscopy
10195435|NCT05173077||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
10195436|NCT05173077||Colorectal cancer patients undergoing surgery|Patients with histologically confirmed colorectal cancer (adenocarcinoma) planned for surgical management
10195437|NCT05173077||Patients with polyps undergoing polypectomy|Patients with colon polyps that will perform polypectomy
9827856|NCT02470754|Active Comparator|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
9827857|NCT02470754|Active Comparator|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
9827858|NCT02470806|Experimental|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
9827859|NCT02470806|Active Comparator|tNPWT System|Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
9827860|NCT02470910|Experimental|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
9827861|NCT02470949|Experimental|Low Social Status|Low Social Status Condition in Monopoly Game.
9827862|NCT02470949|Experimental|High Social Status|High Social Status Condition in Monopoly Game
10195438|NCT05168163|Experimental|Arm A (atezolizumab, cabozantinib or lenvatinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10195439|NCT05168163|Active Comparator|Arm B (cabozantinib or lenvatinib)|Patients receive cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10195440|NCT05167955|Experimental|Experimental Randomized controlled waitlist|n=20 (will receive Mindfulness-based cognitive intervention)
10195441|NCT05167955|Other|Waitlist Randomized controlled waitlist|waitlist Randomized controlled waitlist n=20 (will not receive Mindfulness-based cognitive intervention for 1 month)
10195442|NCT05167253|Experimental|UB-612 100 μg, 0.5 mL|All subjects will be enrolled to receive one dose of 100 μg UB-612 vaccine
10195443|NCT05163730|Other|Panbio™ COVID-19/ Flu A&B Rapid Panel|"One nasal swab sample will be collected from both nostrils by operators and will be used to perform the Panbio™ COVID-19/ Flu A&B Rapid Panel test either in a laboratory or in a non-laboratory setting (e.g. GP centre or hospital clinic). Each Panbio™ COVID-19/ Flu A&B Rapid Panel result will be photographed by the observer at the time of test interpretation.~Nasopharyngeal samples will be collected and used for RT-PCR testing as per local procedures.~Nasal samples must always be collected prior to the Nasopharyngeal sampling."
10204771|NCT05006248|Active Comparator|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, at the end of the 7th training session, and at the end of the 12th training session.
10204772|NCT05006248|Experimental|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, at the end of the 7th training session, and at the end of the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
10204773|NCT05006248|Experimental|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions.Clinical assessments will be performed at baseline, at the end of the 7th training session, and at the end of the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
10204774|NCT04996368|Active Comparator|low dose (10mg/kg)|The dose of tranexamic acid varies widely ranging from 10mg/kg to 100mg/kg. We are comparing 10mg/kg to conventional 30mg/kg dose. The result of this study will help us to review our current practice.
9713651|NCT04600453|Experimental|Training group|"Multicomponent exercise group (intervention): The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day (morning and evening).~The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RMcombined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital."
10195444|NCT05157594||All patients|A fasting blood sample will be taken on the day of the beginning and the day of the end of the radiotherapy and during the adjuvant chemotherapy (every 3 cycles). A follow-up will be performed for 9 months, with a blood sample taken every three months on the day of the follow-up MRI.
10195445|NCT05155735||Replantation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was replanted.
9713652|NCT04600453|No Intervention|Usual care group|Usual care
9713653|NCT04600557|Experimental|Self-compassion only|Describing a shameful experience using a self-compassionate prompt and receiving no verbal responses from confederates
9713654|NCT04600557|Experimental|Compassion from others only|Describing a shameful experience using a neutral prompt and receiving compassionate responses from confederates
9713655|NCT04600557|Experimental|Self-compassion plus compassion from others|Both describing a shameful experience using a self-compassionate prompt and receiving compassionate responses from confederates
10195446|NCT05155735||Revision Amputation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was not replanted.
10195447|NCT05147636|Experimental|PEEP|
10195448|NCT05147636|Active Comparator|Aspiration|
10195449|NCT05141539|Experimental|Rehabilitation assessment software|This arm applies the developed rehabilitation assessment software by using two web cameras placed in the front and the side of the subject. The subject sits between two cameras. The observer asks the subject to move the head in each direction, to open the mouth, and to move the tongue. The software will measure CROM, mouth opening, and tongue movement.
10195450|NCT05141539|Experimental|video-fluoroscopic swallowing and FOIS.|This arm applies video-fluoroscopic swallowing (VFSS) and functional oral intake scale (FOIS) to measure the direct, dynamic view of oral, pharyngeal, and upper esophageal function during swallowing with food and liquid mixed with barium, and the functional intake of dysphagic patients, respectively.
9713656|NCT04600557|Active Comparator|Sharing-only control|Describing a shameful experience using a neutral prompt and receiving no verbal responses from confederates
9713657|NCT04600349|Experimental|Identity Oriented Psychotrauma Therapy (IOPT)|35 participants will be randomly allocated to the IOPT group. They will attend 10 groups of IOPT every two weeks and they will work 10 Intentions. The groups will be conducted by clinicians or psychotherapists specialized in IOPT. IOPT represents a group treatment developed by Franz Ruppert 20 years ago. It is an effective therapeutic intervention, offering access to less conscious aspects of our psyche, with the help of other persons, named 'representatives.' The method is based on the theory of multigenerational psychotraumatology developed by Ruppert. Although it is very often and widely used all over the world, it has not previously been the subject of randomized controlled trials (RCT), and therefore, its potential efficacy is unknown. In the current study, we want to test this new intervention model on autoimmune thyroiditis.
9713658|NCT04600349|Active Comparator|Treatment as Usual|35 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
9713659|NCT04600167|Experimental|Isoniazid and Rifapentine (INH-RPT)|Participants in intervention arm will receive an oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
9713660|NCT04600167|Placebo Comparator|Control|Participants in the control arm will receive placebo once weekly for 12 weeks.
9713661|NCT04600245|Experimental|M-FAM|Will undergo the procedure with assistance from the M-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
9713662|NCT04600245|Experimental|CARTOSOUND-FAM|Will undergo the procedure with assistance from the CARTOSOUND-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
9713663|NCT04600310|Other|Study Arm 1 Conventional Prep/Control|The preoperative preparation for the control group will use ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) that will be applied to the skin using a sponge-on-a-stick method; this solution is widely recognized as optimal. After the alcohol-based solution has evaporated (no less than 3 minutes), the patient extremity is draped for surgery.
9713664|NCT04600310|Other|Study Arm 2 ULTRAPREP Group/Intervention Arm|ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) will be poured into the ULTRAPREP bag which will be placed on the patient's extremity while in the holding area; it will be removed only after scrub time of 3 minutes is complete and the patient has been transferred to the OR, anesthetized, and positioned. The patient is draped only after the solution has evaporated (no less than 3 minutes).
9713665|NCT04600284|Experimental|Sequence 1|Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102
9713666|NCT04600284|Experimental|Sequence 2|Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102
9713667|NCT04600284|Experimental|Sequence 3|Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102
9713668|NCT04600284|Experimental|Sequence 4|Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101
9713669|NCT04600284|Experimental|Sequence 5|Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102
9713670|NCT04600284|Experimental|Sequence 6|Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101
9713671|NCT04600232|Experimental|Diagnosis arm|Urine TB-LAM, sputum smear, Gene Xpert, mycobacterial culture
9713672|NCT04600193|Experimental|Phosphate modified diet with organic phosphate|
9713673|NCT04600193|Experimental|Phosphate modified diet with inorganic phosphate|
9785780|NCT01259726|Experimental|VP20621 High Dose|
9827863|NCT02471014||Obese Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
10195451|NCT05134714|Experimental|Group 1(study group): CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
9827864|NCT02471014||Normal Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
9827865|NCT02471183|Experimental|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
9827866|NCT02471313|Experimental|[18F] FMISO PET scan|Patients with primary hepatic malignancy who underwent [18F] FMISO PET Scan following transarterial chemoembolization (TACE) procedure
10195452|NCT05134714|Active Comparator|Group 2(control): Conventional metal band and loop space maintainer|Stainless steel band and loop space maintainer will be made. Stainless steel appropriate band will be selected according to the size of the abutment teeth then design of the loop will be obtained, then will be send to the laboratory for soldering.
10195453|NCT05134259|Active Comparator|Study Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy in addition to repetitive transcranial magnetic stimulation sessions for 4 weeks.
10195454|NCT05134259|No Intervention|Control Group|The children in this group will receive traditional treatment of hemiplegic CP including medical treatment and physiotherapy for 4 weeks.
10195455|NCT05133362|Active Comparator|Standard Care with Ekso Group|Participants in the SCG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. For each participant, an individualized plan of care consistent with evidence-based practice standards will be provided based on rehabilitation goals. The interventions during each treatment session will include forward gait training with EksoNR, neuromuscular movement-related tasks, mobility tasks, and interventions using products and technology, and education for caregivers, family, and friends.
10195456|NCT05133362|Experimental|Standard Care with Ekso and Backward Walking Group|Participants in the SCBWG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. Once a week, each participant will receive standard care as described in the standard care with Ekso group.Once a week, each participant will receive backward walking training with EksoNR during their treatment session.
10195457|NCT05127473|Experimental|Dose level 1|All participants will receive a single dose of Mim8
10195458|NCT05127473|Experimental|Dose level 2|All participants will receive a single dose of Mim8
10195459|NCT05127473|Experimental|Dose level 3|All participants will receive a single dose of Mim8
10195460|NCT05127473|Experimental|Dose level 4|All participants will receive a single dose of Mim8
10195461|NCT05127473|Experimental|Dose level 5|All participants will receive a single dose of Mim8
10195462|NCT05127473|Experimental|Dose level 6|All participants will receive a single dose of Mim8
9827867|NCT02471326|Experimental|HIV Positive Subjects|VRC-HIVMAB060-00-AB (VRC01) given in HIV-infected Adults (age 18-65 years) on cART with suppressed viremia
10195463|NCT05127473|Experimental|Dose level 7|All participants will receive a single dose of Mim8
10195464|NCT05127473|Experimental|Dose level 8|All participants will receive a single dose of Mim8
10195465|NCT05127473|Experimental|Dose level 9|All participants will receive a single dose of Mim8
10195466|NCT05127473|Experimental|Dose level 10|All participants will receive a single dose of Mim8
10195467|NCT05127473|Experimental|Dose level 11|All participants will receive a single dose of Mim8
10195468|NCT05127473|Experimental|Dose level 12|All participants will receive a single dose of Mim8
10195469|NCT05123729|Experimental|Crowdsourced campaign package|The intervention will be developed through a crowdsourcing process, including an open call for submissions.
10195470|NCT05123729|Active Comparator|Standard information|The control will be the provision of standard information (e.g., view standard informational videos promoting the adoption of health-protective behaviors and COVID-19 testing).
10195471|NCT05122975|Experimental|S48168 (ARM210) once daily for 28 days|Oral dose of S48168 (ARM210) once daily on top of standard of care regimen for 28 days.
10195472|NCT05122975|Placebo Comparator|Matching Placebo once daily for 28 days|Oral dose of placebo once daily on top of standard of care regimen for 28 days.
10195473|NCT05120284|Active Comparator|Pre-Surgical Dichloroacetate (DCA)|Study medication begins in subjects randomized to preoperative DCA. GSTZ1 haplotype status will stratify subjects into 1 of 2 dose regimens. EGT carriers will receive 12.5 mg/kg/12 hr DCA. EGT noncarriers will receive 6.25 mg/kg/12 hr DCA.
10195474|NCT05120284|Active Comparator|No Pre-Surgical Dichloroacetate (DCA)|Subject randomized to start DCA after surgery will do so 12-24 hours postoperatively, depending on their ability to safely receive medication.
10195475|NCT05118724|Experimental|Atezolizumab 840mg|Atezolizumab 840mg i.v. (q2w) for a total of 12 cycles (24 doses)
10195476|NCT05118724|Experimental|Atezolizumab 840mg plus IMM-101|Atezolizumab 840mg i.v. (q2w) for a total of 12 cycles (24 doses) One initial dose of IMM-101 intradermally at 1.0 mg 14 ±2 days before start of atezolizumab treatment, followed by 12 treatment cycles Q4W: IMM-101 intradermally at a dose of 0.5 mg (q2w) for 1 cycle (2 doses), followed by 0.5 mg intradermally for 11 cycles (11 doses)
10195477|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 1mg/kg(Q3W until progressive disease)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
9713674|NCT04600401|Experimental|Participants integrate the Mentis Plus+ program|Mentis Plus+ Program was developed based in The Multifactorial Model of Positive Mental Health and its construction resulted from a systematic literature review and validation through focus group. The duration of the Mentis Plus+ program depends on the number of the six factors to be worked on. The Mentis Plus+ lasts at least 7 weeks (1 session per week, lasting 1 hour) and can work individually or in groups (2-12 people). There will be 2 initial sessions of 1 hour each and 3 sessions for each factor to work with duration of 1 hour. Still, a final session and a follow-up session (3-6 months after the program) will be held.
9713675|NCT04600401|No Intervention|Participants on a waiting list (Control Group)|Participants in the control group were told they were on a waiting list for 3-6 months, as a minimum, before they integrate the Mentis Plus+ program. Given the preventive nature of this study, a waiting list control group won't bring risks or damages to participants
9713676|NCT04600362|Experimental|Dupilumab|Patients randomized to this arm will receive two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by single 300 mg injection of Dupilumab every 2 weeks (q2w) from week 2 to week 16.
10195478|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 1mg/kg(Q3W*4cycles)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W*4cycles,and then Sintilimab 200 mg IV, Q3W single until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
10195479|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 1mg/kg(Q6W)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q6W+ Sintilimab 200 mg IV, Q3Wuntil progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
10195480|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 0.5mg/kg in combination with Sintilimab|The test group will be treated with IBI310 0.5mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
10195481|NCT05115357|No Intervention|Intravenous analgesia group|Patients will receive systemic intravenous analgesia only.
9713677|NCT04600362|Placebo Comparator|Placebo|Patients randomized to this arm will receive identically matching doses of placebo. Two subcutaneous injections of placebo as a loading dose (to mimic the experimental Dupilumab arm) on Day 1 followed by a single injection q2w from Week 2 to Week 16.
9827868|NCT02471404|Active Comparator|Dapagliflozin+metformin|Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
9827869|NCT02471404|Active Comparator|Dapagliflozin+saxagliptin+metformin|Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
9713678|NCT04600297|Experimental|3D printed resin composite posterior FDP|Three units posterior fixed dental prosthesis made with 3D printed resin composite material
10195482|NCT05115357|Experimental|Pecto-Intercostal Fascial Block (PIFB) group|Patients will receive PIFB on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.
9713679|NCT04600427|Experimental|Epidural anesthesia|The patient will be positioned appropriately and the T11-12 (if not accessible we will accept 1-2 spaces above or below) interspace landmarked using established ultrasound guidance techniques. The patient's back will be prepped and draped in a sterile fashion. An epidural catheter will be inserted into the T11-12 interspace with a midline or paramedian approach using a 17G Tuohy needle. Plain preservative free bupivicaine 0.25% will be the local anesthetic used. After a 2-3 mL test dose to rule out intrathecal catheter positioning, a loading dose of 5-8 mL will be administered over 5-10 minutes to further rule out intravascular positioning of the catheter. Successful epidural placement will be defined by catheter insertion and confirmed by sensory blockade assessed by ice or pin prick testing. When correct positioning is confirmed, a continuous infusion of 3 mL per hour of bupivacaine 0.25% plain solution will begin.
9713680|NCT04600271||Study Group|Patients over the age of 18 and who undergone major elective non-cardiac abdominal surgery.
9713681|NCT04600440|Experimental|Plasma treatment|Convalescent plasma 200 ml daily during three days
9713682|NCT04600440|No Intervention|No plasma|Best conventional treatment
9713683|NCT04600024||Piriformis syndrome group|Patients who were diagnosed as PS by diagnostic injection with ultrasound guidance
9713684|NCT04600024||Age and sex match control group|Patients who were excluded from the diagnosis of PS and had anteroposterior (AP) direct radiographic imaging
9713685|NCT04600089|Placebo Comparator|Standard of Care|Participants in this group will receive standard of care as well as a saline infusion during the study period.
9713686|NCT04600089|Experimental|Sub-Dissociative Ketamine|Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.
9713687|NCT04600206||Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor or stage III lung or ovarian tumor) from diagnosis to terminal stages
9713688|NCT04600206||Caregivers|Adult informal caregivers of patients who are diagnosed with stage IV solid tumors or stage III lung or ovarian tumors
9713689|NCT04600414|Active Comparator|Collaborative Care for Mental Health Disorders|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for mental health disorders.
9713690|NCT04600414|Experimental|Collaborative Care for Opioid Use Disorder|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for opioid use disorder.
9713691|NCT04599959|Experimental|Overall (Swab/Saliva)|
9713692|NCT04600011|Other|TELEREHABILITATION ARM|ARM 1: The TELEREHABILITATION ARM where participants receive the full originally-intended protocol that includes one initial in-person PT/OT evaluation, four virtual PT/OT visits, and one final in-person (or virtual, if in-person is not possible) PT/OT evaluation. The study duration for Arm 1 is about 10 weeks of the primary intervention as described with 3- and 6-month follow-up calls. The mobile virtual platform for Arm 1 is comprised of a tablet on a height-adjustable rotating tablet floor stand with a gooseneck and wheels.
9713693|NCT04600011|Other|VIRTUAL HOME SAFETY EVALUATIONS (HSE)-ONLY ARM|ARM 2: The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
9713694|NCT04599907|Experimental|Roll-In Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
9713695|NCT04599907|Experimental|Randomized Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
9713696|NCT04599907|Sham Comparator|Randomized Cohort: Sham Patch|Subjects will undergo identical procedure with an inactive sham device
10195483|NCT05115357|Experimental|Transversus Thoracis Muscle Plane Block (TTP) group|Patients will receive TTP on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.
10195484|NCT05107739|Experimental|Safety Run In|Patients with gynecological malignancies
10195485|NCT05107739|Experimental|EOC|Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma
9713697|NCT04600115|Experimental|MRI vs.PET with/without Cardiac disease|Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging
9713698|NCT04599998||COVID-19 inpatients|Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic
9713699|NCT04599920|Active Comparator|Red meat supplementation providing 25% of protein intake|A diet supplemented with 760 g of cooked and boneless red meat per week, corresponding the average consumption of red meat in Finnish men.
9713700|NCT04599920|Experimental|Red meat mostly replaced with legume-based foods|A diet supplemented with legume-based foods providing 20% of protein intake and with 200 g per week of red meat providing 5% of protein intake.
9713701|NCT04600492|Active Comparator|Active Comparator: Active drug group Riociguat|Riociguat 0.5mg、1.0mg、2.5mg
9713702|NCT04600492|Placebo Comparator|Placebo group|Placebo 0.5mg、1.0mg、2.5mg
9713703|NCT04600076|Experimental|BabyCenter site and the community group|
9713704|NCT04600063|Other|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
9713705|NCT04600063|Experimental|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
9713706|NCT04600037|Active Comparator|Group 1|Patients received pregabalin (target dose 300 mg/day) and exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
9713707|NCT04600037|No Intervention|Group 2|Patients received exercise therapy alone (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
10195486|NCT05107739|Experimental|Cervical|Recurrent, metastatic, or persistent cervical carcinoma
10195487|NCT05107739|Experimental|Endometrial|Advanced or recurrent endometrial cancer
10195488|NCT05106283|Active Comparator|Deep Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
10195489|NCT05106283|Active Comparator|Deep and Superficial Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 10 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anteror area to superficial serratus anteror area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 10 ml of 0.25% bupivacaine will be injected for superficial serratus anetrior block into the interfacial area.
10195490|NCT05099666|Experimental|Lurbinectedin + Doxorubicin Phase I|"The phase 1b trial will follow a standard 3+3 design. Upon determination of the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lurbinectedin plus doxorubicin. A treatment cycle will be defined as 21 consecutive days. Treatment will be administered on an outpatient basis~Lurbinectedin~Doxorubicin"
9713708|NCT04600102||GROUP 1|Healthy able-bodied individuals with no history of lower extremity trauma.
9713709|NCT04600102||GROUP 2|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
9713710|NCT04600050|Active Comparator|Control group: stroke patients with education|
9713711|NCT04600050|Experimental|Experimental: stroke patients with exercise|
9713712|NCT04599946|Experimental|Experimental formula|Infant and follow-on goat milk formula
9713713|NCT04599946|Active Comparator|Control formula|Infant and follow-on cow milk formula
10195491|NCT05099666|Experimental|Lurbinectedin + Doxorubicin at RP2D|"The randomized two arm phase 2 trial will begin following the determination of the RP2D for lurbinectedin and doxorubicin.~Participants will be randomized 1:1 to enroll to either Arm 1 or Arm 2~Participants enrolled to Arm 1 will receive Lurbinectedin with Doxorubicin at the RP2D defined during the phase 1b portion of the trial."
10195492|NCT05099666|Active Comparator|Doxorubicin Monotherapy|"The randomized two arm phase 2 trial will begin following the determination of the RP2D for lurbinectedin and doxorubicin.~Participants will be randomized 1:1 to enroll to either Arm 1 or Arm 2~Participants enrolled to Arm 2 will receive Doxorubicin at the standard dose of 75 mg/m2"
9713714|NCT04599894|Sham Comparator|control group|Oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
10195493|NCT05099588||Infants treated for ROP|
10195494|NCT05099016|Experimental|Joint Effort (mobile application)|The Joint Effort mobile application aims to support young adults into taking action on their cannabis use. Based on the Theory of Planned Behaviour, the content focuses on intention, attitude and perceived behavioral control. Various intervention methods and strategies are used to address these determinants (e.g., personalized feedback, persuasive communication, self-observation and activation of intention). The objectives includes: to allow the individual to become aware (or more aware) of their cannabis use, to support the individual's decision-making process of taking action on their cannabis use, to guide and support the establishment and sustainability of an action plan. An optional logbook-type feature (weekly journal of cannabis use) allows personalized monitoring and data collection throughout the course of the intervention.
10195495|NCT05099016|Active Comparator|Brief normative feedback and standard information|The comparator is composed of a a brief normative feedback regarding last month frequency of cannabis use and basic reliable non personalized information on lower-risk cannabis use (official public websites).
10195496|NCT05097586|Experimental|active tDCS|2mA of direct current delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
10195497|NCT05097586|Sham Comparator|control|Sham stimulation where the current is turned off after 30 seconds in a slow ramp down, delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
10195498|NCT05096377||ESP block group|Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
10195499|NCT05093959|Active Comparator|Metformin|20 weeks of metformin 1500 mg daily. Metformin is a widely used medication with an excellent safety profile. Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks. An extended release formulation will be used which improves compliance and reduces GI side effects.
10195500|NCT05093959|Placebo Comparator|Placebo|20 weeks of placebo 1500 mg daily. Placebo is a biologically inert substance placed in capsules to match appearance of active intervention (metformin). Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks.
10195501|NCT05089669|Experimental|interactive e-book|The experimental group will read an interactive e-book for 90 minutes to learn nasogastric tube feeding.
10195502|NCT05089669|Active Comparator|comparison group|The comparison group will read a paper textbook for 90 minutes to learn nasogastric tube feeding.
10195503|NCT05079906|Other|Main study arm|All subjects will have their SFA lesion assessed with FFR measurement.
10195504|NCT05079906|Other|Sub-study|Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
10195505|NCT05074979|Other|control group|While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
10195506|NCT05074979|Experimental|home exercise program group|this group will implement COVID 19 home exercise program.
10195507|NCT05074979|Experimental|telerehabilitation group|this group will implement COVID 19 telerehabilitation program.
10204775|NCT04996368|Active Comparator|high dose or conventional group (30mg/kg)|dose 30mg/kg regularly use in our center as a prophylaxis for prevention of bleeding before open heart surgery
9713715|NCT04599894|Experimental|study group|Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before operation; oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
9713716|NCT04599803|Experimental|Participants diagnosed with Obstructive Sleep Apnea|This will be a single arm study of participants that are diagnosed with Obstructive Sleep Apnea (OSA) during the study. Upon confirmation of OSA and prescription of positive airway pressure (PAP) therapy, the participant will begin using the Verily Sleep Apnea (VSA) app to supplement PAP treatment.
9713717|NCT04600518||Low risk|good prognosis with surgery only and adjuvant chemotherapy patients
9713718|NCT04600518||Intermediate risk|moderate prognosis
9713719|NCT04600518||High risk|poor prognosis
9713720|NCT04599985|Experimental|Star excursion balance training (SEBT)|Received star excursion balance training (SEBT) program. Performed 3-trials in all 8 directions of the SEBT grid.
9713721|NCT04599985|Active Comparator|Simplified star excursion balance training (SSEBT)|Received simplified star excursion balance training (SSEBT) program. Performed 3-trials in all 3 directions of SSEBT grid.
9713722|NCT04599842|No Intervention|GROUP SA|Group SA was categorized as the group which spinal anaesthesia alone (SA) was performed
9713723|NCT04599842|Active Comparator|GROUP SA+ESP|Group SA+ESP was categorized as group which SA+ESP block was performed.
10195508|NCT05073107|Experimental|Test: With Dental Monitoring|"Dental Monitoring (DM) Kit + 2-month DM subscription~Required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~Day 0 (To be taken at the clinic)~Day 7 (To be taken in the evening after brushing teeth)~Day 14 (To be taken in the evening after brushing teeth)~Day 21(To be taken in the evening after brushing teeth)~Day 28 (To be taken before study Visit 2)~There is a window period of +1 day for the intra-oral videos."
10195509|NCT05073107|No Intervention|Control: Without Dental Monitoring|No DM Kit
9713724|NCT04599881|Experimental|PTR-01 3 mg/kg|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg every other week for a total of 7 doses.
9713725|NCT04599478|Experimental|Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
9713726|NCT04599478|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and placebo. Placebo will be inactive and taken daily in pill form.
9713727|NCT04599478|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication taken daily in pill form.
10195510|NCT05070455|Experimental|Asceniv|Asceniv™ will be given as an intravenous infusion at the same dose, or higher dose where medically appropriate, as the subject's previous IV Immunoglobulin G treatment (300-800 mg/kg) every 21 or 28 days.
10195511|NCT05068570|Experimental|EXPERMINTAL GROUP|start with cycle at a pace of 15-25 cycles per minute without resistance and end with cycle 45cycles per minute
10195512|NCT05068570|No Intervention|CONTROL GROUP|selected respiratory exercise program
10195513|NCT05067101|Experimental|Capsule Sparing Cystectomy|Patients undergoing transurethral resection and enucleation of the prostate before laparoscopic cystectomy
9713728|NCT04599478|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
9713729|NCT04599543|Experimental|Administration of IL3 CAR T-cells|
9713730|NCT04599582|Active Comparator|SP-CL|
9713731|NCT04599582|Active Comparator|Corail|
9713732|NCT04599738|Placebo Comparator|Wheat muffin|Muffin made with 100% wheat flour
9713733|NCT04599738|Experimental|Finger millet grain muffin|Muffin made with 50% wheat flour and 50% finger millet crushed grain
9713734|NCT04599530|Other|Biomechanical|All experimental tasks will be evaluated on biomechanical outcome measures
9713735|NCT04599530|Other|Psychological|All experimental tasks will be evaluated on psychological outcome measures
9713736|NCT04599530|Other|Physiological|All experimental tasks will be evaluated on biomechanical outcome measures
9713737|NCT04599530|Other|Performance|All experimental tasks will be evaluated on biomechanical outcome measures
9713738|NCT04599621||patients with unstable angina|This group included patients with frequent anginal attacks, with a burdened history and comorbid conditions.
9713739|NCT04599673|Experimental|AMNIOGEN|Intraoperative1 kit of AMNIOGEN injection into shoulder joint after RCT repair.
9713740|NCT04599673|Placebo Comparator|Normal saline|Intraoperative 10 ml of normal saline injection into shoulder joint after RCT repair.
9713741|NCT04599595||Multiple Scerosis (MS) Group|This group will be composed by 150 MS patients who, consecutively, from the start of the study, will refer to the MS clinic of the Neurology Unit of the Ferrara University Hospital, Italy. The first 50 patients with a PACQoL score ≥ 32 will be asked to be willing to enter the next phase of the study that continues at the Coloproctological Outpatient Clinic of Ferrara University Hospital, Italy with an appointment provided by the neurologist with a pre-established schedule (with written consent).
9713742|NCT04599686|Active Comparator|ADT|Evaluating men with oligometastatic prostate cancer lesions randomized to ADT.
9713743|NCT04599686|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
9713744|NCT04599764|Active Comparator|Anodal Stimulation|Participants will receive anodal tDCS daily for two weeks
10195514|NCT05067101|Placebo Comparator|Conventional Radical Cystoprostatectomy|Patients undergoing conventional radical cystoprostatectomy
10195515|NCT05058313|Experimental|Postmenopausal patients|
10195516|NCT05056532||patients|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
10195517|NCT05056532||Control group|Maximal mouth pressure will be evaluated for determine respiratory muscle strength, m. pectoralis, m. serratus anterior, m. sternocloideumasteoideus and quadriceps muscles strengths will be measured to evaluate accessory respiratory muscle strength, London chest activity of daily living scale will be done for assessment of dyspnea and six minute walk test will be used for determination of functionally capacity
10195518|NCT05054985|Experimental|Intervention arm|Patients with thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
10195519|NCT05054400|Other|F18 Fluciclovine|"radioactive imaging agent help researchers better see how the disease is responding to laser interstitial thermal therapy (LITT)"
10195520|NCT05052684|Experimental|Leaflex™ Performer|
10195521|NCT05052398|Experimental|Part 1: PSP NEURO SERUM|The first part, will consist of a single arm in which all patients will receive PSP NEURO SERUM in their hands three times a day for 28 days. Each application will consist of 1 g of PSP NEURO SERUM.
10195522|NCT05051605||Vaccinated group|Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.
10195523|NCT05050292|Experimental|Experimental Group|"Activities are designed to target specific cognitive skills (attention, perception, inhibition).~An internal algorithm of the cognitive stimulation platform will adjust the activities' difficulty depending on the participant's performance, always demanding a maximum cognitive effort."
9713745|NCT04599764|Active Comparator|Anodal tDCS with Cognitive training|Participants will receive anoale tDCS daily and cognitive training for two weeks
9713746|NCT04599764|Sham Comparator|sham stimulation|Participants will receive cathodal tDCS daily for two weeks
10195524|NCT05050292|Active Comparator|Control Group|"Painting and artistic activities not designed to target specific cognitive skills.~The internal algorithm will be deactivated, so the cognitive stimulation activities will be of constant difficulty throughout the intervention."
10195525|NCT05045794|Experimental|Hypothermic oxygenated perfusion (HOPE)|Ex-vivo donor liver preservation using static cold storage followed by HOPE using the VitaSmart Liver Machine
10195526|NCT05045794|Other|Static cold storage|Ex-vivo donor liver preservation using static cold storage only
10195527|NCT05045612|Experimental|Intervention|Stop antibiotic therapy as instituted by admitting physician
10195528|NCT05045612|No Intervention|Control|Continue antibiotic therapy at the discretion of the treating physician (no change in ongoing treatment)
10195529|NCT05045430|Experimental|Assigned Intervention|Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silver II Non-Woven Dressing
10195530|NCT05040087|Active Comparator|USE OF DIABETES Rx GUIDED LARGELY BY HbA1c LEVELS|Extended-release [ER] metformin will be added if HbA1c is ≥7.0% after 3 months; if already used and maximized, pioglitazone will be begun. Other Rx will be added each time HbA1c reaches ≥7.5%. The sequence of Rx will be the same as in intensive Rx subjects; those using insulin will also do prebreakfast SMBG, aiming for glucose <100 mg/dl.
10195531|NCT05040087|Experimental|USE OF DIABETES Rx GUIDED BY SELF-MONITORED BLOOD GLUCOSE (SMBG)|"Guidance by SMBG:~Glucose goals: We will aim for <100 mg/dl premeal (2), <130 postmeal.~Monitoring will include pre-breakfast 2x/wk, and a 5-point profile 1x/wk (before and 1.5-2.5 hr after breakfast, before lunch, before supper, and bedtime).~Added Rx will be used if SMBG is >goal ≥3x in 2 consecutive weeks after ≥4 weeks of MOVE! and/or the previous Rx [e.g., any 3 of the 7 goals (<100 mg/dl premeal, <130 post)]. Metformin ER will be given first (if not already on it), and increased to 2000 mg/day if there are no side effects. (If metformin is not tolerated, it will be stopped and the second Rx will become the first Rx and given instead. If other Rx are not tolerated, the next Rx will be used. The second Rx will be the TZD pioglitazone, followed by the GLP-1 RA semaglutide, then the SGLT-2 inhibitor empagliflozin. If still above goal, glargine insulin will be added, titrated to keep fasting glucose <100 mg/dl."
10195532|NCT05039593|Experimental|first group|The patients in the first group will be given oral care with 0.12% chlorhexidine twice a day.
10195533|NCT05039593|Experimental|second group|The patients in the second group will be given oral care with 0.12% chlorhexidine 3 times a day.
10195534|NCT05039593|Experimental|third group|The patients in the third group will be given oral care with 0.12% chlorhexidine 4 times a day.
10195535|NCT05038852|Other|Group 1 smartphone applications|app is designed to help you learn relaxation skills
10195536|NCT05038852|Other|Group 2 smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
10195537|NCT05035290|Experimental|Negative pressure ventilation|Negative pressure application after extubation
10195538|NCT05035290|No Intervention|Standard approach|Standard approach - oxygentherapy based on patients need
10195539|NCT05031741|Experimental|Telemedicine|Teens who are randomly assigned a telemedicine card will have exposure to a pretend telemedicine visit equipped with an iPad and telehealth provider on the other end. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care through telemedicine from their own home or private space.
10195540|NCT05031741|Experimental|In-person Mobile Unit|Teens who are randomly assigned a in-person mobile unit card will have exposure to a pretend mobile unit visit equipped with a healthcare provider. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care on the mobile unit.
10195541|NCT05028413|No Intervention|Participants Blinded to BrAC reading (Control)|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will complete a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive and be blinded to their breath alcohol readings with the BACtrack Mobile Pro device.
10195542|NCT05028413|Experimental|Participants Aware of their BrAC reading|Participants randomized to this arm will consume three weight-based doses of alcohol with a target BAC of 0.10 and comple breathalyzer measurements every 20 minutes until a BAC of 0.03 is reached. They will be shown their breath alcohol readings with the BACtrack Mobile Pro device before completing a visual analog scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
10195543|NCT05022719|Experimental|PillCam Colon2 procedure with MB-MMX|PillCam Colon2 procedure with MB-MMX
9713747|NCT04599452|Experimental|10 patients with recurrent refractory elderly AML were treated|The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
9713748|NCT04599829||Orthosis Group 1|Use of AnkleSTRONG100 device
9713749|NCT04599829||Control Group 1|Control Group of the AnkleSTRONG100 Orthosis Group - No use of the device
9713750|NCT04599829||Orthosis Group 2|Use of AnkleSTRONG500 device
9713751|NCT04599829||Control Group 2|Control Group of the AnkleSTRONG500 Orthosis Group - No use of the device
9713752|NCT04599829||Orthosis Group 3|Use of AnkleSTRONG900 device
9713753|NCT04599829||Control Group 3|Control Group of the AnkleSTRONG900 Orthosis Group - No use of the device
9713754|NCT04599439||High arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass > 5.15 g will be considered at highest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
9713755|NCT04599439||Low arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass < 5.15 g will be considered at lowest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
9779565|NCT05197959|Experimental|Group C-Sensorimotor training|Participants will perform sensorimotor training intervention. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
9713756|NCT04599699|Experimental|1|"Simultaneously integrated boost or sequential integrated boost~Simultaneously integrated boost Prostate tumor: starting dose 8.7 Gy per fraction in 5 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy.~Sequential integrated boost Prostate tumor: starting dose 7.25 Gy per fraction in 6 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy."
10195544|NCT05013294|Experimental|Intervention|The intervention group will receive a total of 43 text messages. Text messages were developed using the Behavior Chang Wheel (BCW) through a systematic process linked to specific behavior change techniques. The text messages will provide practical information or guidance to influence selection and eating healthy diet for type 2 diabetes care. The text messages were either loss- or gain-framed to increase influence on behavioral decisions. Additionally, the participants will receive a text message to rate their ability on selection of food and eating of healthy diet based on the messages received in the month. The combination of the one-way and two-way messages in this group are designed to increase engagement of the participants.
10195545|NCT05013294|Placebo Comparator|Control Arm|The control group will continue receiving standard care in the hospitals. The control group shall also receive a reminder text messages one day prior the routine clinic appointment. The clinic appointment dates shall be derived from the hospital where the participant receives routine diabetes care.
10195546|NCT05012917|Other|Patient/Proxy-SSPedi Administered First|"Parent/child dyads will complete self-report SSPedi/mini-SSPedi and proxy-SSPedi as the first period and then co-SSPedi as a second period."
10195547|NCT05012917|Other|Co-SSPedi Administered First|"Parent/child dyads will complete co-SSPedi as the first period and then self-report SSPedi/mini-SSPedi and proxy-SSPedi as a second period."
10195548|NCT05011929|Experimental|online CBT-I with support (individualized feedback and reminders)|The mobile-APP based CBT-I consists of 6 weekly session. The treatment is structured and based on the well-established CBT elements for treating insomnia. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention. reminders and individualized feedback regarding the behavioral strategies will be sent to the participant every week.
10195549|NCT05011929|Active Comparator|online CBT-I without support|same as the experimental arm but without reminders and individualized feedback
10195550|NCT05010824|Experimental|Intervention group|The intervention will involve three consultation sessions and four follow-up phone calls with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
10195551|NCT05010824|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
10195552|NCT05010473|Experimental|Neurotypical Human Participants|Native speakers of Chinese and native speakers of English
10195553|NCT05005247|Experimental|GBS-NN/NN2|Single dose 0.5 millilitre (mL) intramuscular injection of GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
9713757|NCT04599244|Experimental|emergency pulpotomy|intervention arm
10195554|NCT05003440|Experimental|NNC0385-0434 15 mg|15 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
10195555|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 15 mg)|Oral placebo will be administered once-daily over 10 consecutive days
10195556|NCT05003440|Experimental|NNC0385-0434 40 mg|40 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
10195557|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 40 mg)|Oral placebo will be administered once-daily over 10 consecutive days
10195558|NCT05003440|Experimental|NNC0385-0434 100 mg|100 mg oral NNC0385-0434 will be administered once-daily over 10 consecutive days
9713758|NCT04599244|Active Comparator|complete pulp extirpation|control arm
9713759|NCT04599114|Experimental|VIRTUES Arm|Patients in the VIRTUES arm will be offered enrollment into the virtual atrial fibrillation care platform.
9713760|NCT04599283|Active Comparator|Symptomatic|"You have to be a male patient.~You must have a smartphone (iPhone or Android).~You are at least 35 years old and have already been diagnosed with BPH or Overactive Bladder (OAB) condition OR you are presenting at least one of the following BPH / OAB symptoms:~1. Frequent or urgent need to urinate 2. Increased frequency of urination at night (nocturia) 3. Difficulty starting urination 4. Weak urine stream or a stream that stops and starts 5. Dribbling at the end of urination 6. Inability to completely empty the bladder 7. Experience urge incontinence - the involuntary loss of urine immediately following an urgent need to urinate"
9713761|NCT04599283|Active Comparator|Asymptmatic|"You have to be a male patient.~You must have a smartphone (iPhone or Android).~You are at least 18 years old and have not been diagnosed with BPH or OAB, and you are not presenting any of the above symptoms."
9713762|NCT04599426|Experimental|Test Group|10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.
9713763|NCT04599322|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
9713764|NCT04599296|Active Comparator|Hip Brace|This group will be assigned to wear a hip brace post surgery.
9713765|NCT04599296|No Intervention|No Intervention|This group will not be assigned a hip brace after surgery.
9713766|NCT04599075|Experimental|Intravenous Insulin Infusion|Patients will be randomized to discontinuation of the CSII pump intrapartum and initiation of IV insulin infusion per hospital protocol.
9713767|NCT04599075|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Patients will be randomized to continuation of their CSII pump intrapartum and will be managed in accordance with the CSII hospital protocol.
9713768|NCT04599348|Experimental|Active Ginseng treatment|People with CFS or Fibromyalgia will receive HRG 80 Red GInseng
9779566|NCT05196243||Study Group|Study on the genomic and molecular pathological characteristics of gastrointestinal mucosal lesions
9779567|NCT05196243||Control Group|Study on the genomic and molecular pathological characteristics of normal gastrointestinal mucosa
9779568|NCT05195268|Active Comparator|Group 1 - PVI + PWI|These patients will receive pulmonary vein isolation and posterior wall isolation.
10195559|NCT05003440|Placebo Comparator|Placebo (NNC0385-0434 100 mg)|Oral placebo will be administered once-daily over 10 consecutive days
10195560|NCT05002218|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
10195561|NCT05002218|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge.
10195562|NCT04984239|Other|Acceptance and Commitment Therapy adapted for aphasia|There is only a single study arm, in which the adapted intervention will be developed using a successive cohort design.
10195563|NCT04984083|Experimental|Group I|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
10195564|NCT04984083|No Intervention|Group II|patients will not take vitamin k before cesarean section
10195565|NCT04980560||VAC cohort|Subjects who will take COVID-19 vaccines
10195566|NCT04980560||CON cohort|Subjects who are COVID-19 survivors
10195567|NCT04979078|Experimental|Experimental group|The experimental group receives 9 sessions of photobiomodulation therapy (3x/week for 3 weeks).
10195568|NCT04976777|Experimental|Updated Dexamethasone Posterior Segment Drug Delivery System|Dexamethasone Posterior Segment Drug Delivery System implant will be administered into the study eye during a single treatment.
10195569|NCT04976777|Active Comparator|Approved Dexamethasone Posterior Segment Drug Delivery System|Dexamethasone Posterior Segment Drug Delivery System implant will be administered into the study eye during a single treatment.
10195570|NCT04971954|Experimental|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
10195571|NCT04971954|Placebo Comparator|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
10195572|NCT04965077|Experimental|MIL97|
10195573|NCT04959006|Placebo Comparator|Placebo group|Placebo drink - oral bolus (25ml) - colour/taste matched (prune juice/cola/tonic water, 1:1:1 ratio).
10195574|NCT04959006|Experimental|Antioxidant supplement|Experimental condition -oral bolus (25ml) olive extract drink(https://www.oliphenolia.it/uk/)
9713769|NCT04599361||Patients with CHD|"outpatient cardiology practices, hospitals with a cardiology department and hospitals with a cardiology and heart surgery department (n=20) in Germany Patients with chronic coronary heart disease and 2- or 3-vessel or main-vessel disease who are being treated at one of the recruitment sites with a promptly planned intervention for myocardial revascularization who are insured with pre-specified German health insurance companies (BARMER or TK)~Patients will receive questionnaires."
9713770|NCT04599374||high TSH and high FT4|patients with high TSH and high FT4
9713771|NCT04599374||high TSH and low FT4|patients with high TSH and low FT4
9713772|NCT04599374||high TSH and high FT3|patients with high TSH and high FT3
9713773|NCT04599374||high TSH and low FT3|patients with high TSH and low FT3
9713774|NCT04599205|Experimental|Microneedling group A|"Patients will be subjected to the following:~Combined laser (power=3.6 mJ) and topical tranexamic acid (TXA) (one finger unit) gel on the right half of the face.~Combined microneedling (by dermapen) and topical TXA gel only on the left half. Self application of topical TXA gel (2 finger units) on both sides on daily base."
9713775|NCT04599205|Experimental|Laser group B|"Patients will be subjected to the following:~Combined laser(power=3.6 mJ) and topical TXA gel (one finger unit) on the right half.~Laser (power=3.6 mJ) only on the left one."
9713776|NCT04599205|Experimental|Gel group C|patients will be subjected to: Daily application of topical TXA gel (2 finger units) on both face sides.
9713777|NCT04599179||Group 1|Patients underwent placement of a self-expandable metal stent (SEMS)
9713778|NCT04599179||Group 2|Patients underwent to stomach-partitioning gastrojejunostomy
9713779|NCT04599127|Experimental|Mobilization with movement|Mobilization with movement on the shoulder abduction and external rotation
9713780|NCT04599127|Placebo Comparator|Conventional physical therapy|Postural correction exercise and muscle strengthening of the rotator cuff muscle and surrounding muscle on the subacromial region
9713781|NCT04599140|Experimental|Treatment (SX-682, nivolumab)|"MONOTHERAPY STAGE: Patients receive SX-682 orally PO BID on days 1-21 in the absence of disease progression or unacceptable toxicity.~COMBINATION STAGE: Patients receive SX-682 PO BID on days 1-56 and nivolumab IV over 30 minutes on days 1 and 29. Treatment repeat every 56 days weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9713782|NCT04599023||MS patients including CIS|Patients with a diagnosis of MS, including Clinically Isolated Syndrome (CIS), who have the ability to understand the audio and visual instructions for the MSPT modules and whose visual function that does not preclude an ability to see the screen of the MSPT tool.
9713783|NCT04599387|Active Comparator|Supervised Exercise arm|
9713784|NCT04599387|Placebo Comparator|Usual care arm|
9713785|NCT04598880|Experimental|Pleinvue|Subjects receive polyethylene glycol + ascorbate (PEG1A) as laxative treatment for colonoscopy preparation.
9713786|NCT04598880|Experimental|Citrafleet|Subjects receive sodium picosulfate + magnesium citrate (PSCM) as laxative treatment for colonoscopy preparation.
9779569|NCT05195268|Other|Group 2 - PVI only|These patients will receive pulmonary vein isolation only.
9713787|NCT04598672|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
9713788|NCT04598737|Experimental|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
10195575|NCT04951778|Experimental|Participants with R/R AML and R/R HR-MDS - Part A|Part A (Dose Escalation) of the study will enroll R/R AML (Relapsed or Refractory Acute Myeloid Leukemia) and R/R HR-MDS (Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes) participants and will evaluate the safety and tolerability of escalating doses of CC-91633, administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
10195576|NCT04951778|Experimental|Participants with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML participants.
10195577|NCT04951778|Experimental|Participants with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R HR-MDS participants.
10195578|NCT04950803|Active Comparator|Active arm|Subjects will take microbiome immunity formula (SIM01) daily for 3 months
10195579|NCT04950803|Placebo Comparator|Placebo arm|Subjects will take active vitamin daily for 3 months
10195580|NCT04946552|Active Comparator|Individuals with normal BMI|(BMI 18-25 kg/m2)
10195581|NCT04946552|Active Comparator|Individuals with obesity|(BMI 30-40 kg/m2)
10195582|NCT04942470|Experimental|Experimental:Intervention Arm|For the experimental group patients, sponges prepared by impregnating cream containing Aloe Vera and Propolis will be sterilized in the sterilization device. If any contamination occurs in the wound area of the patient (in the presence of feces, discharge), the product is applied to the wound bed after cleaning the wound with 0.9% isotonic sodium chloride washing solution. And the effects of the product on the wound will be monitored. The solution will be applied 2 times a day for the first 10 days. The second 10 days will be applied daily 1x1. Application results will be recorded and wound healing status will be monitored. In order to prevent and maintain pressure injury, the experimental group patients will be given an in-bed position every 2 hours. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure, etc.), necessary treatment and care is performed.
10195583|NCT04942470|No Intervention|No Intervention:Control Arm|In control group patients, if any pollution occurs in the wound area (feces, discharge) in the sterile dressing performed in the morning and evening at 10-22 hours, the wound area will be cleaned with the help of 0.9% isotonic sodium chloride washing solution and the clinical routine application of the pressure injury of the hospital will be carried out according to the physician's order. In patients in the control group, the results of the application will be recorded and wound healing status will be observed. An in-bed position will be given every 2 hours for the prevention and care of pressure injury patients of the control group patients. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure and other), the necessary treatment and care will be performed.
10195584|NCT04941391|Experimental|Paroxysmal atrial fibrillation|Subjects schedule for a de novo ablation of paroxysmal atrial fibrillation
10195585|NCT04941391|Experimental|Persistent atrial fibrillation|Subjects schedule for a de novo ablation of persistent atrial fibrillation
10195586|NCT04937790|Experimental|Core stabilization group (CSG)|This arm consists core stabilization exercises including abdominal hallowing, supine bride, bride dog, side plank, curl-up and modified push up exercise. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
9713789|NCT04598737|Experimental|Lithium disilicate|Lithium disilicate laminate veneer treatment
9713790|NCT04598646|Experimental|Cario-Oncology Rehabilitation (CORE)|"CORE consists of exercise therapy, CVD risk factor management for the first 6 months and behavioural support for 2 years.~Exercise therapy: Staff will prescribe and deliver a standardized, yet individually tailored (based on CPET results), aerobic exercise programs consisting of two days of supervised, facility-based high-intensity interval training (HIIT) and one day of supervised home-based moderate-intensity continuous training (MICT) per week. Exercise HRs and durations will be monitored using an accurate commercially available wrist-worn HR monitor and PA tracker (e.g., Apple watch).~CVD risk factor management: CVD risk factors will be assessed and treated according to Canadian guidelines.~Behavioural support: All participants will receive a planned sequence of educational and instructional material via email and ongoing PAYA-CS tailored education and peer support during the follow-up period using a peer support online system."
9713791|NCT04598646|Active Comparator|Support|The Support group will receive the behavioural support only. The timing and nature of all education, information, and Young@Heart-based peer support provided to Support participants will be identical to what is provided to CORE participants. The key difference in the long-term behavioural support strategy between CORE and Support participants is how weekly exercise goals are defined. Unlike the CORE participants who will be encouraged to use the PAI Score, Support participants will be given the challenge of meeting and maintaining the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).
9713792|NCT04598646|Active Comparator|Passive Behavioural Support (PBS) Groups|All PBS cohort participants will receive the same wrist-worn HR monitor and PA tracker as the CORE and Support participants. However, PBS participants will be blindly randomized to one of two passive behavioural support interventions (PBS1 and PBS2). PBS1 participants will be asked to download the same PAI Health application as CORE participants and will similarly be given the challenge of meeting and maintaining a weekly PAI Score ≥100 throughout the 18-month follow-up period. PBS2 participants will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week). PBS participants will not receive any additional interventions and will be followed up with and reassessed at 12- and 24-months.
9713793|NCT04598932||1: Normal Controls|Patients with normal corneas without any prior surgery to serve as the control group
9713794|NCT04598932||2 Keratoconus|Patients with various stages of keratoconus
9713795|NCT04598932||3: LASIK|Patients with normal corneas who are undergoing laser in situ keratomileusis (LASIK)
10195587|NCT04937790|Experimental|Wobble board group ( WBG)|This arm consists balance training exercises which performed on computerized wobble board for primarily lower limb and anti- gravity muscle. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
10195588|NCT04937790|No Intervention|Control group (CG)|This arm was planned as a control group. Therefore, any intervention will not be performed. Patients in this arm going to participate only one session of patient education at the beginning of the program
10195589|NCT04935736|Experimental|CORTISOMOL SP|Zinc oxide/Eugenol-type sealer containing 1% Prednisolone Acetate. The sealer is used in combination with gutta percha points for the permanent obturation of root canals.
10195590|NCT04935736|Active Comparator|SEALITE REGULAR|The Zinc oxide/Eugenol-type sealer is used in combination with gutta percha points for the permanent obturation of root canals.
10195591|NCT04933383|Experimental|AQ001S 0.125 mg/ml|AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.
10195592|NCT04933383|Active Comparator|budesonide inhalation suspension 0.125 mg/ml|Budesonide 0.125 mg/ml is a budesonide inhalation suspension administered by nebulization once daily.
9713796|NCT04598932||Group 4: PRK|Patients with normal corneas who are undergoing photorefractive keratectomy (PRK)
9713797|NCT04598932||5: SMILE|Patients with normal corneas who are undergoing small incision lenticular extraction (SMILE)
9713798|NCT04598932||6: CXL|Patients with keratoconus who are undergoing corneal cross-linking (CXL)
9713799|NCT04598958|Experimental|IMPROVE|A cluster of 6 health facilities are to receive the IMPROVE Intervention. The IMPROVE intervention includes: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees with particular attention to HIV-positive women to minimize loss to follow-up.
9713800|NCT04598958|No Intervention|Standard of care|A cluster of 6 health facilities receive Standard of Care. Routine health facility services offering the national standard of care for pregnant and breastfeeding women in Lesotho
9980206|NCT01389453|Active Comparator|stem cell transplatation|All experimental group patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
10195593|NCT04926571||Dexamethasone versus non-users of corticosteroids|
9713803|NCT04598971||Cystitis|Patients with lower UTI will be included in this group
9713804|NCT04598971||Pyelonephritis|Patients with higher UTI will be included in this group
9713805|NCT04598854|Experimental|Treatment group|The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
9713806|NCT04598854|Sham Comparator|Control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
9713807|NCT04598945|Experimental|Adults|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
9713808|NCT04598945|Experimental|Children|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
9713809|NCT04598906|Experimental|Virtual environment rehabilitation - Paper-pencil rehabilitation|The participants in this arm completes Virtual environment rehabilitation as the first condition and then crossover to Paper-pencil rehabilitation.
9713810|NCT04598906|Experimental|Paper-pencil rehabilitation - Virtual environment rehabilitation|The participants in this arm completes Paper-pencil rehabilitation as the first condition and then crossover to Virtual environment rehabilitation.
9713811|NCT04598867|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner for 32 weeks.
10195594|NCT04926571||Dexamethasone versus non-users of dexamethasone|
10195595|NCT04926571||Dexamethasone versus methylprednisolone active comparator|
10195596|NCT04915742|Experimental|exercises and thetahealing|
10195597|NCT04915742|Active Comparator|exercises|
9713812|NCT04598867|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, and dinner for 8 weeks.
9713813|NCT04598867|Active Comparator|Afobazol 30 mg/day|Patients assigned to the Afobazol 30 mg/day group will receive 1 tablet of Afobazol (10 mg) before breakfast, before lunch and before dinner for 8 weeks.
9713814|NCT04598997||600 patients involved in the prospective study|These patients will be contacted by telephone follow-up, offered participation in the study and sent the information and non-opposition letter. In case of refusal, data will not be used.
10195598|NCT04914507|Other|Anterior Vertebral Body Tethering|The subject is will receive anterior vertebral body tethering surgery, as clinically indicated, after all pre-operative assessments are complete.
9713815|NCT04598997||1000 patients involved in a non-human study|To train the algorithm to recognize images in the context of STEMI revascularization, 1000 normal coronary angiograms performed in a stable disease context will also be identified.
10195599|NCT04910360||ICU patients with severe COVID-19 pneumonia|Without using any intervention, this group has been included in the study to research certain genetic dispositions determining the severity of the COVID-19 pneumonia
10195600|NCT04910360||Random population|This group has been included as a control group to compare the genetic predisposition of ICU patients with severe COVID-19 pneumonia with the normal population.
10195601|NCT04908735|Experimental|Ruxolitinib Treatment|
10195602|NCT04905082|Active Comparator|Arm I (usual care)|Patients receive education pamphlet about WES and have their genomics test results returned by their clinician in a typical manner.
10195603|NCT04905082|Experimental|Arm II (genomics test results, HOPE-Genomics)|Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available.
9713816|NCT04599062|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy~Talimogene Laherparepvec Dose Levels:~Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly~Dose -1 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed every 2 weeks"
9713817|NCT04598763|Other|classic group|"the classic group receives classic olfactory rehabilitation using 4 scents most used in the literature (rose, eucalyptus, lemon, clove)"
10195604|NCT04905082|Experimental|Arm III (HOPE-Genomics, genomics test results)|Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool.
10195605|NCT04904562|Active Comparator|Treatment|Angiotensin II administered as an intravenous (IV) infusion will be increased every 5 minutes by 5-10ng/kg/min increments up to 80ng/kg/min
10195606|NCT04904562|Placebo Comparator|Control|Intravenous (IV) infusion (saline)
9713818|NCT04598763|Other|intensive|"the intensive group receiving olfactory rehabilitation using 8 scents (rose, eucalyptus, lemon, cloves, strawberries, cut grass, lavender, spruce)."
9713819|NCT04598984||Low levels of serum adipokines|
9713820|NCT04598984||High levels of serum adipokines|
9713821|NCT04599231|Experimental|Study group|"The investigators would perform the following tests preoperatively on the study subjects.~Hospital Anxiety and Depression Scale (HADS)~Amsterdam Preoperative Anxiety and Information Scale (APAIS)~Coping and Adaptation Processing Scale-Short Form (CAPS-SF)~Quality of Recovery -15 (QOR-15)"
10195607|NCT04904354|Experimental|Paroxysmal atrial fibrillation|Subjects schedule for a de novo ablation of paroxysmal atrial fibrillation
10195608|NCT04904354|Experimental|Persistent atrial fibrillation|Subjects schedule for a de novo ablation of persistent atrial fibrillation
10195609|NCT04900454|Experimental|DVX201 infusion|"Subjects will enroll and the MTD and/or the recommended phase 2 dose of DVX201 will be determined utilizing a modified 3+3 enrollment schema.~This study will enroll a minimum 3 subjects who each receive a single dose of DVX201 and who are evaluable for toxicities at each dose level. Depending on the occurrence of DLTs and the number of dose levels evaluated, additional subjects may be enrolled (approximately 3-15 additional subjects). All subjects will be followed for 28 days post infusion of DVX201."
9713822|NCT04598711|Experimental|Remote Limb Ischemic Conditioning (RLIC)|"RLIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 200 mmHg on the more involved thigh. RLIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RLIC is performed on visits 1-14.~Interventions:~Behavioral: RLIC~Behavioral: Muscle power training~Behavioral: Balance training~Behavioral: Treadmill training"
9713823|NCT04598711|Sham Comparator|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved thigh. Sham involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. Sham conditioning is performed on visits 1-14.~Interventions:~Behavioral: RLIC~Behavioral: Muscle power training~Behavioral: Balance training~Behavioral: Treadmill training"
9713824|NCT04599153|Experimental|High initial|At the one month follow-up, the shunt is adjusted into a high opening pressure (2.5), which is crossed over to 1.0 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
9713825|NCT04599153|Experimental|Low initial|At the one month follow-up, the shunt is adjusted into a low opening pressure (1.0), which is crossed over to 2.5 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
9713826|NCT04598568||balanSys UNI knee prosthesis|Participants treated with a balanSys® UNI knee prosthesis
9713827|NCT04598542|Experimental|TA injection followed by LOR injection|IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.
9713828|NCT04598542|Experimental|LOR injection followed by TA injection|IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.
9713829|NCT04598581|Active Comparator|Low Dose Radiation Therapy (LD-RT)|
9713830|NCT04598581|Sham Comparator|Sham irradiation|
9713831|NCT04598529|Active Comparator|A2 milk|A2 milk, organic, 200ml, twice daily
9713832|NCT04598529|Placebo Comparator|Conventional milk|Pasteurized semi-skimmed milk, organic, 200ml, twice daily
9713833|NCT04598633|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
9713834|NCT04598633|Placebo Comparator|Placebo-lozenges (BioGaia)|
9713835|NCT04598503||cases|All the babies admitted to the hospital with congenital anomalies during this period were included
9713836|NCT04598503||control|newborns without congenital anomalies
9713837|NCT04598490|Experimental|Healed extraction site|Old Extraction Space
9713838|NCT04598490|Experimental|unhealed extraction site|Recent Extraction space
9713839|NCT04598256||Children who underwent endoscopic procedures|"Children between the ages of 1-18 who were underwent endoscopic procedures~Patients who can be questioned about COVID-19 infection before and on the 7th and 14th days after the procedure~Patients who volunteered to study"
9713840|NCT04598594|Experimental|Nicotine patch|
10195610|NCT04892355|Experimental|Conventional Syringe Irrigation Group|During the final irrigation procedure, a 30 - G side vented needle was placed 2 mm shorter than the working length and was applied without agitation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
9713841|NCT04598594|Placebo Comparator|Placebo patch|
9713842|NCT04598373||IDT patients|Allocated to an IDT program
9713843|NCT04598373||Non-IDT patients|Not allocated to an IDT program
9713844|NCT04598100|Active Comparator|FOCUS-EC|"FOCUS-EC provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping, including emotional regulation, problem solving, goal setting, communication, and management of deployment & combat stress reminders, which foster parent-child and family cohesion. The intervention is delivered in six 90-minute sessions in the family home. Each session is structured with a check-in, review of the previous week's home activity, primary activity and discussion, selection of a new home activity, and a closing check-out. The family learns and practices the skills during the sessions, commits to practicing the skills during the week, and reports on their experiences the following session so that skills can be reinforced and adjustments made. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family deployment and reintegration timeline and 2) enhancing parent-child interactions."
9713845|NCT04598100|No Intervention|Web-Based Family Education|Families in the WB condition will be provided access to online educational materials covering topics such as typical child development, effects of early childhood separations, common child reactions to family stress, and the importance of self-care. CDM families in this condition will also have access to the standard services that are available to OEF/OIF/OND veterans through the VHA system, TriCare, and California Department of Veterans Affairs.
9713846|NCT04598191|Placebo Comparator|Control group|Participants in this group are administered inhaled normal saline.
9713847|NCT04598191|Experimental|iloprost group|Participants in this group are administered inhaled iloprost.
9713848|NCT04598607|Experimental|Hypidone Hydrochloride 60mg|30mg(10mg×3) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
10195611|NCT04892355|Experimental|Xp Endo Finisher Group|Xp Endo Finisher file was used with VDW Silver (VDW) endomotor at 800 rpm speed and 1 Ncm torque according to the manufacturer's instructions. The Xp Endo Finisher file was placed in the canal, 2 mm shorter than the working length, and was used with slow movements of 7-8 mm amplitude in the canal during activation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
10195612|NCT04892355|Experimental|EDDY Group|An EDDY tip of size 25/04 was used for sonic activation. The EDDY was placed in the duct 2 mm shorter than the working length and the activation process was performed with slow movements with an amplitude of 2-4 mm. In the irrigation process, 5 mL of 2.5% NaOCI was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
10195613|NCT04892355|Experimental|Endoactivator Group|Medium Endoactivator tip of 25 / .04 size was used for irrigation activation. Medium type was placed in the canal 2 mm shorter than the working length and activation was performed by making short strokes of 2-3 mm. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
9713849|NCT04598607|Experimental|Hypidone Hydrochloride 80mg|40mg(10mg×4) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
10195614|NCT04891354|Experimental|The experimental arm PDNO in increasing doses|The Investigational medicinal product, PDNO is given intravenously, in part 2 the doses is increased twice.
9713850|NCT04598607|Experimental|Hypidone Hydrochloride 100mg|50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
9713851|NCT04598607|Placebo Comparator|Placebo 60mg|3 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
9713852|NCT04598607|Placebo Comparator|Placebo 80mg|4 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
9713853|NCT04598607|Placebo Comparator|Placebo 100mg|5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
9713854|NCT04598178||Taiwan Cohort|For normative Taiwan people, cognitive function will be assessed by the Taiwan version of questionnaire Qmci (Qmci-TW) on Day 0, Day 2, Day 180.
9713855|NCT04598334||COVID-19 positive by RT-PCR|specified number of COVID-19 positive patients will be followed up from admission to outcome (discharge/death/referral). Blood samples will be tested at different time points; cytokines and stool microbiota will be tested at the end of the study and we will analyze the study findings.
10195615|NCT04891354|Placebo Comparator|Placebo|The placebo comparator, NaCl is given intravenously, before the PDNO is given.
10195616|NCT04885491|Experimental|Treatment arm|Observational period with placebo treatment and then experimental treatment
10195617|NCT04885491|Placebo Comparator|Observational period (placebo)|Starting with observational period with placebo treatment
10195618|NCT04883983|Active Comparator|Pain Medication as Standardly Prescribed|Patients will receive pain medication as standardly prescribed. Refills at the 2 week followup will be provided as per the standard treatment protocol.
10195619|NCT04883983|Experimental|Open Label Placebo|Initial post-op pain medication will be prescribed. On 2 week followup, refill request will be filled with an open label placebo.
10195620|NCT04881630|Active Comparator|Standard Care (SC)|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
9713856|NCT04598243|Experimental|Treatment of CFS/FMS with the nutritional combination|
9713857|NCT04598399|Experimental|MBRP program:|
9713858|NCT04598399|Active Comparator|Standard care|
9713859|NCT04598113|Active Comparator|Effective Traction/Sham Traction|Group of patients treated firstly with Effective Traction then with Sham Traction
9713860|NCT04598113|Sham Comparator|Sham Traction/Effective Traction|Group of patients treated firstly with Sham Traction then with Effective Traction
9713861|NCT04598074|Experimental|Opioid Package Prototype (OPP)|Oxycodone 5mg tablets dispensed in the Opioid Package Prototype (OPP) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
9713862|NCT04598074|Active Comparator|Usual Care (standard amber vial)|Oxycodone 5mg tablets dispensed in the standard amber vial (usual care) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
9713863|NCT04598308||patients undergoing invasive assessment of the microcirculation|All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator. There are no specific exclusion criteria other than contraindications for physiologic measurements in general.
9713864|NCT04598412||Mexican sample|Aged >60 years (n = 187)
9713865|NCT04598412||German sample|Aged >75 years (n = 97)
9713866|NCT04598412||Northamerican sample|Aged >60 years (n = 200)
9713867|NCT04598412||British sample|Aged >70 years (n = 38)
9713868|NCT04598438|Experimental|Music intervention treatment group|Participants attending the music behavioral early intervention program
9713869|NCT04598438|Active Comparator|Arts and crafts active control group|Participants attending the arts and crafts developmental enhancement program
9713870|NCT04598295|Experimental|microbial consortia (DS-01)|DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
9713871|NCT04598295|Placebo Comparator|placebo|Placebo capsules for DS-01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
9713872|NCT04598126|Active Comparator|Traditional physical therapy|Traditional physical therapy
10195621|NCT04881630|Experimental|Contingency Management (CM)|CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
9713873|NCT04598126|Experimental|patient education manual +traditional physical therapy|Patient education manual +traditional physical therapy
9713874|NCT04598425|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
9713875|NCT04598282|Placebo Comparator|Control Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID (four times daily) for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
9713876|NCT04598282|Active Comparator|Treatment Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion). The treatment arm will also receive the placement of PROKERA SLIM for 5-7 days. A second PROKERA SLIM may be applied based on investigator's discretion. For patients with bilateral involvement only the worse eye will be enrolled for the treatment arm.
9713877|NCT04598230|Active Comparator|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy and one of three study medications (fluoxetine, sertraline, or escitalopram).
9713878|NCT04598230|Active Comparator|Cognitive behavioral therapy (CBT)|Participants randomized to this arm will receive cognitive behavioral therapy (CBT) only
9713879|NCT04598347||Pregnant women diagnosed with SARS-CoV-2|Pregnant women diagnosed with SARS-CoV-2 infection(by PCR on nasopharyngeal aspirate or serology)that have an indication to perform an invasive technique(chorionic biopsy or amniocentesis) along thegestation.The sample size will depend on the duration of theSARS-CoV-2 pandemic.Initially we propose a study period of 18months in which we would have an approximate total of 225pregnant women with indication of invasive technique.It is planned to conduct a PCR study for SARS-CoV-2 in amniotic fluid or chorionic villi to thosepregnant women diagnosed with SARS-CoV-2 infection(approximately 5% of the total pregnant womenwith indication of invasive technique (11-12 pregnant women)).This determination is made as part of theroutine clinical practice in the context of the study of screening for perinatal infections
9713880|NCT04598464|Experimental|Exercise group|The home-based training program
9713881|NCT04598464|No Intervention|control group|All patients participated in a one-session educational program conducted by the investigators at each clinic.
9713882|NCT04598061||Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery|Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery
9713883|NCT04598048||EMMACE 3|Participants who were recruited to the EMMACE 3 study and have agreed to contact for further research.
9713884|NCT04598022||vegan|subjects having a vegan nutrition pattern for at least the last 3 months
9713885|NCT04598022||vegetarian|subjects having a vegetarian nutrition pattern for at least the last 3 months
9713886|NCT04598022||omnivores|subjects having a omnivore nutrition pattern for at least the last 3 months
9713887|NCT04598035||Primary Group|Patients with chronic low back pain that candidates them for surgical implant of a SCS device, and received a permanent SCS device.
9713888|NCT04598035||Control Group|Patients with chronic low back pain that are candidates for a surgical implant of a SCS device and do not receive a permanent SCS device after trial leads are placed.
9713889|NCT04597905||CD Participants|Participants diagnosed with CD from the 7 participating countries will take part in survey to collect data regarding their preferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
9713890|NCT04597905||UC Participants|Participants diagnosed with UC from the 7 participating countries will take part in survey to collect data regarding theirpreferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
9827870|NCT02471404|Active Comparator|Glimepiride+metformin|Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
10195622|NCT04874168|Active Comparator|In the TAP group (Group A )|"after completion of surgery, bilateral ultrasound-guided TAP block was performed .~Description of the intervention: a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used ;A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
9980207|NCT01389453|No Intervention|control|The control group gives injection through intravenous and lumbar puncture ways separately in the corresponding time, but the transplantation matter is physiological saline not the stem cell.
9713891|NCT04597970|Experimental|cTACE-HAIC(oxaliplatin and raltitrexed)|Patients receive cTACE+HAIC (oxaliplatin, raltitrexed) treatment, 6-8 weeks as a cycle
9713892|NCT04597814||interstitial lung disease patients|interstitial lung disease patients who need lung transplantation
9713893|NCT04597814||non- interstitial lung disease patients|non- interstitial lung disease patients who need thoracic surgery to remove pneumatocele
9713894|NCT04597762|Experimental|right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the right eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the left eye
9713895|NCT04597762|Experimental|left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the left eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the right eye
9713896|NCT04597840|Experimental|biosynthetic mesh group|Patient will undergo incisional hernia repair with biosynthetic mesh reinforcement. Based on the discretion of the surgeon, two types of biosynthetic mesh from different brand can be used: the Phasix mesh from BARD or the BioA mesh from GORE. These two biosynthetic meshes are resorbable, which means they are gradually absorbed by the body.
9713897|NCT04597840|Other|standard of repair group|Patient will undergo incisional hernia repair according to the standard of repair, which is simple suture or mesh reinforcement (using synthetic or biological meshes).
9713898|NCT04597749|Experimental|Concurrent PSG, HSAT, and Screener App Test|Participants will undergo a single night baseline PSG test with concurrent HSAT tests as well as non-contact screening mobile apps through a smartphone.
9713899|NCT04597866||CRPS|
9713900|NCT04597788|Experimental|Protein supplemented very low calorie diet program|The lifestyle intervention using protein supplemented very low calorie meals will be implemented with individual counseling sessions for 12 months. Initial intensive weight loss stage will be delivered during the first 4 month period with total meal replacement to partial meal replacement using protein supplemented very low calorie meals. During the weight loss maintenance stage, regular intermittent very low calorie meal replacement one week per month will be delivered for the entire period. Mobile counseling will be offered to help patients achieve weight loss as well as weight loss maintenance.
9713901|NCT04597788|Active Comparator|Conventional low calorie diet program|The conventional low calorie diet program will be offered to participants assigned to control group using educational material and individual counseling sessions for 12 months. Mobile counseling will be also offered for weight loss and weight loss maintenance.
9713902|NCT04597827||Semantic dementia|Diagnosis of semantic dementia (revised criteria Moreaud et al., 2008; based on Neary et al., 1998)
9713903|NCT04597827||Alzheimer's disease|NIAAA 2011 criteria
9713904|NCT04597827||Control|MMSE above 27, no neurological or psychiatric disorder
9713905|NCT04597879||Severe traumatic brain injury|
9713906|NCT04597879||Severe trauma without brain trauma|
9713907|NCT04597879||Healthy controls|
9713908|NCT04597645|Experimental|Elastic band (EB)|EB group participants who are attending sheltered employment will received Elastic Thera band training program two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainer) over 16 weeks for a total of 32 sessions.
9713909|NCT04597645|No Intervention|Control group (CG)|Control group participants will receive usual care.
9713910|NCT04597801|Experimental|Fluorescein sodium|A single dose of fluorescein sodium is applied before brain tumor resection. 20-40 minutes prior to the planned tumor resection, a bolus of 5 mg per kg body weight is administered intravenously, staining tumor tissue with fluorescent dye to visualize tumor cells.
9713911|NCT04597619|No Intervention|Pre-Implementation Cohort|Cohort undergoing PCNL prior to implementation of the novel nonopioid pathway
9713912|NCT04597619|Experimental|Implementation Cohort|Cohort undergoing PCNL with implementation of the novel nonopioid pathway
9713913|NCT04597983|Experimental|2S-hesperidin|This group took 500 mg (capsules) per day at breakfast of 2S-hesperidin (Cardiose®) for 8 weeks
9713914|NCT04597983|Placebo Comparator|Placebo|This group took 500 mg of microcellulose (capsules) per day at breakfast for 8 weeks
9713915|NCT04597931|Experimental|SC Romosozumab 210 mg/monthly|SC Romosozumab 210 mg/monthly
9713916|NCT04597931|Active Comparator|IV Zoledronic acid 5 mg|IV Zoledronic acid 5 mg
9713917|NCT04597541|Experimental|1|AK112
10195623|NCT04874168|Active Comparator|In the infiltration group (Group B )|at the end of surgery, 40 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (20 mL in each of the upper and lower sides) by the obstetrician before skin closure.
10195624|NCT04874168|Placebo Comparator|In placebo group (Group C )|routine analgesic was administered and recorded .
9713918|NCT04597957|Experimental|Fresh Rx Intervention group|The Fresh Rx intervention group will receive up to 8 visits to the community based farmers market with $10 incentive for fruits and vegetables at each visit.
9713919|NCT04597957|Active Comparator|Diabetic Standard of Care Control group|Diabetic standard of care control group will receive no incentive for the community based farmers market.
9713920|NCT04597723|Experimental|80% oxygen|80% oxygen given group
9713921|NCT04597723|Experimental|60% oxygen|60% oxygen given group
9980208|NCT01389466|Experimental|MG1109 - Step 1|
9980209|NCT01389466|Placebo Comparator|Normal Saline - Step 1|
9713922|NCT04597723|No Intervention|routine hospital care|The patients in this group received routine hospital care.
9713923|NCT04597567|Active Comparator|Metal removal|
9713924|NCT04597567|No Intervention|Metal retention|
9713925|NCT04597515|Experimental|Robot Reduction|The project consists in removing a breast disc at the base, causing a circular sagging skin cut of 2 to 3 cm .
9713926|NCT04597736|Experimental|cohort|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
10195625|NCT04868318|Experimental|VHP(very-high protein) group|In VHP(very-high protein) group, we will provide pre-digested formula of 37% protein to the experimental group for at least 3 days to up to 7 days.
9713927|NCT04597775|Experimental|Arm 1 hydroxychloroquine 800mg day 1 and hydroxychloroquine 400mg day 2-5|hydroxychloroquine 800mg (400mg twice daily) given orally on day 1, (loading dose) hydroxychloroquine. Then 400mg (200mg 2 tablets) on day 2,3, 4 and 5.
9713928|NCT04597775|Active Comparator|Arm 2 hydroxychloroquine 400mg day 1 and hydroxychloroquine 200mg day 2-5|hydroxychloroquine 400mg (200mg twice daily) Given orally first day (loading dose), then 200mg once daily on day 2,3, 4 and 5.
9713929|NCT04597775|No Intervention|No Intervention|No Intervention- SARS-CoV-2 surveillance Standard control measures in the country of interest such as self isolation, good personal hygiene and good nutrition.
9713930|NCT04597216|Other|unique arm|there is only 1 arm in this study (all the participants will undergo the same diagnosis procedure)
9713931|NCT04597281|Experimental|Mediterranean lifestyle|Mediterranean lifestyle, including dietary advice and physical activity advice. In addition, families receive extra-virgin olive oil and fish and two sessions of physical activity per week, for free.
9713932|NCT04597281|No Intervention|Usual care|General care by their pediatricians.
9713933|NCT04597294|Experimental|Perioperative FLOT + prophylactic HIPEC + surgery|After 4 doses of preoperative FLOT chemotherapy diagnostic laparoscopy will be performed - patients without distant metastases will be randomised, in those randomised to experimental arm HIPEC with irinotecan will be performed (a dose of 300 mg/m2 body surface area will be administered over 45 minutes at a temperature of 42 degrees Celsius)
9713934|NCT04597294|Active Comparator|Perioperative FLOT + surgery|Standard treatment regimen for advanced gastric cancer
9713935|NCT04597424|Experimental|doxycycline and Bexsero® vaccine|-doxycycline will be taken by participants as PEP (prophylaxy post exposition) and participants will received Meningococcal B vaccine (Bexsero®) at D0 and M2
9713936|NCT04597424|Experimental|doxycycline|-doxycycline will be taken by participants as PEP (prophylaxy post exposition)
9713937|NCT04597424|Experimental|Bexsero® vaccine|-Meningococcal B vaccine (Bexsero®) at D0 and M2
9713938|NCT04597424|No Intervention|No treatment|-no doxycycline and no Bexsero® vaccine
9713939|NCT04597255|Experimental|Holographic optical coherence tomography|Healthy phakic participants
9713940|NCT04597398||Group A|A total of 39 patients underwent the procedure prior to June 2019
9713941|NCT04597398||Group B|11 patients underwent the procedure as of June 2019
10195626|NCT04868318|Active Comparator|SHP(standard-high protein) group|SHP(standard-high protein) group is the control group, standard-high protein formula (16% of energy) would be given to the control group for at least 3 days to up to 7 days.
10195627|NCT04859257||Disease Group|Cohort 1 (Disease Group) of the study will collect blood and urine samples from participants who are either diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific inclusion criteria.
10195628|NCT04859257||Control Group|Cohort 2 (Control Group) of the study will collect blood and urine samples from participants who have NOT been diagnosed with Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) or experience symptoms of profound fatigue based on the cohort specific exclusion criteria.
10195629|NCT04857242|Experimental|apnea test, recruitment manoeuvre|"Continuous electric impedance tomography (EIT) recording. Recording of initial vital parameters and arterial blood gas results. Adjusment of PaCO2 between 38-42 mmHg, 10 minutes of preoxygenation with FiO2 of 1.0 then disconnection of the patient from the ventilator.~Continuous administration of 6 L/min O2 flow via a catheter into the tracheal tube.~Arterial blood gas sampling and recording of vital parameters in every second minutes. Detection of any spontaneous respiratory movement by the apnoe test investigator or by EIT signals.~Reconnection with respirator if there is any sign of spontaneous breathing effort or if there is no spontaneous breathing effort and the PaCO2 is over 60 mmHg. Recording of vital parameters.~Recruitment manoeuvre (PEEP 20 cmH2O, pressure control 20 cmH20 for 40 minutes) then set up of the initial ventilator parameters.~Terminal arterial blood gas results and vital parameters 5 minutes following the end of the recruitment manoeuvre."
9713942|NCT04597229|Active Comparator|Instant multigrain|Oral instant multigrain supplement
10204776|NCT04980521|Placebo Comparator|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
9713943|NCT04597229|No Intervention|Standard care|Standard care without oral instant multigrain supplement
9713944|NCT04597489||Angiography + FFR|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
9713945|NCT04597489||Angiography only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
9713946|NCT04597489||Subgroup ACS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with ACS."
9713947|NCT04597489||Subgroup CCS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.~This subgroup consists of patients presenting with CCS."
9713948|NCT04597489||Subgroup revascularization|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing revascularization after an angiography (with or without FFR) during the index hospital stay."
9980210|NCT01389466|Experimental|MG1109 - Step 2|
9713949|NCT04597489||Subgroup optimal medical therapy|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.~This subgroup consists of patients undergoing optimal medical therapy after an angiography (with or without FFR) during the index hospital stay."
10195630|NCT04851522|Experimental|Di-Dak-Sol + White Petrolatum|"Participants will receive Di-Dak-Sol (dilute bleach compresses) prior to receiving radiation. This will continue throughout their radiation therapy and for one week after.~Participants will also be asked to apply white petrolatum ointment 2x daily throughout treatment: once after radiation and once in the evening.~Participants will be provided with a log and asked to document information (dates/times of application) about the study treatment ."
10204777|NCT04980521|Experimental|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA.
9713950|NCT04597463|Experimental|Endometrial injury|Endometrial injury before the embryo transfer of a frozen cycle
9713951|NCT04597502|Placebo Comparator|Oral Placebo, Topical Placebo|Oral Placebo, Topical Placebo on both forearms and dorsal hands
9713952|NCT04597502|Experimental|Oral Placebo, Topical TC|Oral Placebo, Topical TC on both forearms and dorsal hands
9713953|NCT04597502|Experimental|Oral TC, Topical Placebo|Oral TC, Topical Placebo on both forearms and dorsal hands
9713954|NCT04597502|Experimental|Oral TC, Topical TC|Oral TC, Topical TC on both forearms and dorsal hands
9713955|NCT04597606||Cohort|"All patients will be performed a basal test that consist on continuous cyclergometer exercise, under constant load, with spontaneous breathing, after that the same exercise protocol performed will be carried out under non-invasive ventilation (NIV test). Parameters will be titrated previosuly.~Finally the patient will perform the same exercise at a constant load under high flow oxygen therapy ( HFNC test)."
9713956|NCT04597177|Active Comparator|ST-IMRT|standard parotid sparing IMRT
9713957|NCT04597177|Experimental|SW-IMRT|swallowing sparing IMRT
9713958|NCT04597385||Long-term Follow-Up|No intervention.
9713959|NCT04597203|Experimental|split face - left side|
9713960|NCT04597203|Active Comparator|split face - right side|
9713961|NCT04597190|Active Comparator|SSRI Then Augmentation by WET|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment augmented by Written Exposure Therapy (WET) delivered by an integrated behavioral health consultant.
9713962|NCT04597190|Active Comparator|SSRI Then Switch to SNRI|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment switched to the SNRI (serotonin-norepinephrine reuptake Inhibitor) venlafaxine.
9713963|NCT04597190|Active Comparator|WET Then Switch to SSRI|Integrated behavioral health consultants will deliver WET. Patients who do not respond to treatment by four months will be switched to one of three SSRIs (sertraline, fluoxetine or paroxetine).
9713964|NCT04597112|Experimental|Myofascial Release Group|Intervention group, who received conventional therapy and myofascial release therapy.All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. In the intervention group, the myofascial release technique will be applied to the wrist flexors and extensors, elbow flexors and extensors, pectoralis, supraspinatus, infraspinatus, trapezius muscles, starting from the fingers after the conventional treatment, 3 days a week for 4 weeks.
9713965|NCT04597112|Active Comparator|Exercise Group|The control group will consist of patients who received conventional therapy and exercise therapy. All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. After conventional treatment, a program consisting of neck extension, lateral flexion and rotation range of motion, stretching of the trapezius muscles and strengthening of the neck extensor muscles will be applied to the control group in the presence of a physiotherapist 3 days a week for 4 weeks.
9779570|NCT05191251||Full-term pregnant women with HEMSTOP|"Full-term pregnant women who have given birth vaginally or by cesarean section. Patients for whom a HEMSTOP questionnaire could be carried out in prepartum, during the pre-delivery anesthesia consultation.~Patients who received follow-up during pregnancy as recommended. Age over 18"
9779571|NCT05190640|Experimental|Intervention arm|The dietary supplement (Asystems) is designed, and marketed commercially to be taken in servings of one gummy: one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies.
9779572|NCT05188469|Experimental|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
9779573|NCT05188469|Experimental|EG-COVID-001|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
9779574|NCT05187767||Malignant GGOs|Patients with histologically proven malignant pulmonary ground glass opacities (GGOs)
9779575|NCT05187767||Benign GGOs|Patients with histologically or radiologically proven benign pulmonary ground glass opacities (GGOs)
9779576|NCT05185778||parasitic infected individuals received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who received COVID-19 vaccines of any type
9779577|NCT05185778||parasitic infected individuals not received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who don't receive COVID-19 vaccines of any type
9779578|NCT05184569|Experimental|Verdiperstat|Verdiperstat 2 tablets twice daily (600mg total daily) by mouth for 24 weeks.
9779579|NCT05184569|Placebo Comparator|Placebo|Placebo 2 tablets twice daily by mouth for 24 weeks.
9980211|NCT01389479|Experimental|Fluviral Group|
10204778|NCT04976452|Experimental|Group 1|Group 1 will include first year Physical Therapy students who will be trained for Blood Pressure (BP) measurement using a brief powerpoint lecture, completion of an interactive BP measurement module from the American Medical Association which includes a quiz assessment and certificate of completion, and a competency examination during the lab portion of class.
9713966|NCT04596852|Experimental|Healthy children|
9713967|NCT04596852|Experimental|Children with cerebral palsy|
9713968|NCT04596826|Experimental|healthy subjects|
9713969|NCT04596826|Experimental|glaucoma patients|
9713970|NCT04596826|Placebo Comparator|healthy volunteers|
9713971|NCT04596826|Placebo Comparator|Glaucoma patients|
9713972|NCT04596904|Experimental|Lavender oil group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
9713973|NCT04596904|Placebo Comparator|Distilled water group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
9713974|NCT04596787||Non-Obese Patients (Group NO: body mass index (BMI) <30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
9713975|NCT04596787||Obese Patients (Group O: body mass index (BMI) ≥30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
9713976|NCT04597034|Experimental|AN69 Oxiris|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
9713977|NCT04597034|Active Comparator|AN69 Standard|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
9713978|NCT04596774||Group 1|Group 1 patients were applied traditional approach. Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
9713979|NCT04596774||Group 2|Group 2 received Enhanced Recovery After Surgery (ERAS) approach. Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
9713980|NCT04596748|Placebo Comparator|Placebo|Participants will be taking a placebo supplement that they will be taking by mouth once per day.
9713981|NCT04596748|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day.
9713982|NCT04596800|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
9713983|NCT04596800|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
9713984|NCT04597060|Experimental|Split Keloid - first side|
9713985|NCT04597060|Experimental|Split Keloid - second side|
9713986|NCT04596813|No Intervention|standard of care|
9713987|NCT04596813|Active Comparator|standard of care and treatment with the Cytosorb® device|
9713988|NCT04596761|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
9713989|NCT04596761|Experimental|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
9713990|NCT04596956|Experimental|sodium bicarbonate Ringer injection|
9713991|NCT04596956|Active Comparator|Ringer lactate solution|
9713992|NCT04597047|Other|All Patients:|Capillary and Venous Blood Collections
9713993|NCT04597008|Active Comparator|Control|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
9713994|NCT04597008|Experimental|Treatment|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
9713995|NCT04597073|No Intervention|Healthy|included individuals with probing depth (PD) ≤3mm, no sites with attachment loss, and no radiographic evidence of alveolar bone resorption. They exhibited no sign of inflammation (GI=0).
9713996|NCT04597073|Experimental|Gingivitis|had varying degrees of gingival inflammation (GI≥1), PD≤3mm with no clinical attachment loss or with no alveolar bone destruction.
9713997|NCT04597073|Experimental|Chronic Periodontitis|was defined as those who were with PD ≥ 4mm, clinical attachment loss (CAL) ≥ 2mm, and who had bone loss affecting >30% of the existing teeth on clinical and radiographic examination.
9713998|NCT04596969|Experimental|SFD Tapioca 20g|20g soluble fiber dextrin derived from tapioca
9713999|NCT04596969|Experimental|SFD Tapioca 40g|40g soluble fiber dextrin derived from tapioca
9714000|NCT04596969|Experimental|SFD corn 20g|40g soluble fiber dextrin derived from corn
9714001|NCT04596969|Experimental|SFD corn 40g|
10195631|NCT04851119|Experimental|Treatment (tegavivint)|Tegavivint will be administered IV over 4 hours on days 1, 8, and 15 of each cycle. Administer D5W flush after completion of each tegavivint infusion. A cycle of therapy is considered to be 28 days. A cycle may be repeated for a total of 26 cycles, up to a total duration of therapy of approximately 24 months. Drug doses should be adjusted based on the weight (height and BSA will also be captured) measured within 7 days prior to the beginning of each cycle. The starting dose will be 5 mg/kg with dose levels for subsequent cohorts increasing to 6.5 mg/kg and 8 mg/kg if excessive toxicity does not occur. If the MTD has been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 4 mg/kg.
10195632|NCT04850365|Other|Abdominal sacral hysteropexy|The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.
10195633|NCT04850365|Other|Vaginal sacrospinous hysteropexy|"This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion.~The outcomes will be obtained as follow;"
9714002|NCT04596969|Placebo Comparator|Control|Maltodextrin
9714003|NCT04596722|Active Comparator|Assigned Interventions|oral active pomella taken by mouth once per day
9714004|NCT04596722|Placebo Comparator|Placebo|oral placebo taken by mouth once per day
9714005|NCT04596839|Experimental|Remdesivir with Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
9714006|NCT04596839|Other|Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy.
9714007|NCT04597099|Experimental|Flutamide|Prior to the first or second admission (randomly determined), subjects will be pretreated for 4 weeks with Flutamide (250 mg twice daily)
9714008|NCT04597099|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
9714009|NCT04596709|Active Comparator|Vitalose|dissolved in water
9714010|NCT04596709|Active Comparator|isomaltulose|dissolved in water
9714011|NCT04596709|Placebo Comparator|sucrose|dissolved in water
9714012|NCT04596709|Placebo Comparator|glucose|dissolved in water
9714013|NCT04596696|Other|Single arm Rotavac|Single arm Open Label study without comparator
9714014|NCT04596358||Healtcare workers|Women who work as nurses or doctors in public hospitals of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
9714015|NCT04596358||Non-Healthcare workers|Women who perform technical and managerial professions in a public administration body of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
9714016|NCT04596683|Experimental|Interested in SDS NSM or SSM|Patients interested same day discharge after NSM or SSM that do not have conditions that would exclude them. Based on discharge outcome after surgery, will be split into SDS group and Admit group.
9714017|NCT04596423||A|Extended fetal heart examination
9714018|NCT04596423||B|Modified extended heart examination
9714019|NCT04596423||C|Sief_Twist sign only examination
9714020|NCT04596618|Active Comparator|Forearm Cooling|Participants will be actively cooled during rest breaks.
9714021|NCT04596618|No Intervention|No Forearm Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
9714022|NCT04596462|Experimental|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
9714023|NCT04596527|Experimental|18F-FMPP PET MPI (following off-study 13N-ammonia PET MPI)|"Imaging Procedure: 18F-FMPP PET Day 1: All subjects will receive rest and stress IV boluses of 18F-FMPP injections in a large peripheral vein. The dosages of 18F-FMPP Injection administered at rest and during stress conditions are 2.5 mCi and 6.0 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor.~Imaging Procedure: 13N-Ammonia PET All subjects will receive 2 IV boluses of 13N-ammonia Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of 13N-ammonia Injection administered at rest and during stress conditions is 20mCi and 20 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor."
9714024|NCT04596332||Group A|Patients with the initial central venous pressure(CVP1) <8 mm Hg
9714025|NCT04596332||Group B|Patients with 8≤CVP1≤12mm Hg
9714026|NCT04596332||Group C|Patients with CVP1>12 mm Hg
9714027|NCT04596410|Experimental|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
9714028|NCT04596410|Active Comparator|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day
9714029|NCT04596514|Experimental|Intervention group - REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
9714030|NCT04596514|Active Comparator|Control group - ACLS|Advanced cardiovascular life support as described in the guidelines
9714031|NCT04596384|Experimental|Group I (telemonitoring program, actigraph, TapCloud)|Before surgery, patients complete a functional and nutritional assessment. The home environment of patients will also be assessed. Based on findings, patients undergo personalized prehabilitation. Patients also wear an actigraph throughout the study to measure and record daily steps taken and sedentary time. Patients use the TapCloud app on a smart device (phone, tablet) or home computer to collect, track, and report their symptoms. Based on patient input in the TapCloud app, a real-time alert is sent to an RN when predetermined thresholds are met. RNs then contact the patient via the TapCloud app and further phone calls if necessary. Patients, caregivers and surgeons may also participate in a focus group in-person, via telephone, or videoconferencing.
9779580|NCT05183048|Experimental|[89Zr]panitumumab-PET/MRI patients|All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.
9779581|NCT05182320||OrthoPath|
9779582|NCT05182320||Control|
9779583|NCT05181995|Experimental|50 mg NYX-783 QD|50 mg NYX-783 QD
9779584|NCT05181995|Placebo Comparator|Placebo|Placebo QD
9980212|NCT01389479|Active Comparator|Fluzone Group|
9980213|NCT01389492|Other|frozen meat|250 g of frozen meat meal for 4 days
9980214|NCT01389492|Other|frozen meat and wine|250 g of frozen meat and red wine for 4 days
9980215|NCT01389492|Other|fresh meat|250 g of fresh meat meal
9980216|NCT01389492|Other|fresh meat and wine|250 g of fresh meat meal
9980217|NCT01389505|Active Comparator|Panretinal photocoagulation|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
9980218|NCT01389505|Experimental|Bevacizumab + Panretinal Photocoagulation (PRP)|Group 2: Bevacizumab intravitreous injections plus PRP
9980219|NCT01389518|Active Comparator|Paracetamol,Chlorpheniramin,Phenylephrin|
9980220|NCT01389518|Placebo Comparator|Placebo|
9980221|NCT01389531|Other|Stents|All recruited patients will be receiving a stent during a rigid bronchoscopy procedure.
10195634|NCT04847440|Experimental|ATI-2173 and Viread|ATI-2173 + Tenofovir disoproxil fumarate (Viread)
10195635|NCT04847440|Active Comparator|Placebo and Viread|ATI-2173 Placebo + Tenofovir disoproxil fumarate
10195636|NCT04847440|Experimental|ATI-2173, Viread and AB-729|ATI-2173 + Tenofovir disoproxil fumarate (Viread) + AB-729
10195637|NCT04847440|Active Comparator|Placebo, Viread and AB-729 Placebo|ATI-2173 Placebo + Tenofovir disoproxil fumarate (Viread) + AB-729 Placebo
9666303|NCT04598919|Active Comparator|Saracatinab|saracatinib 125 mg once daily by mouth for 24 weeks
9666304|NCT04598919|Placebo Comparator|Placebo|matching placebo once daily by mouth for 24 weeks
9666305|NCT04597437|Experimental|Zanamivir|In the treatment group, participants will receive 600 mg for adults and 12 mg/kg in children intravenously every twelve hours for 5 days adjusted for renal function.
9666306|NCT04597437|Placebo Comparator|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
9666307|NCT04594356||Patients with COVID-19 infection|"As part of this research, existing clinical data of patients infected with COVID-19 is collected from the patients' computerized medical records.~During the hospitalization of the patients, in addition to the clinical and laboratory data collected, the dosage of IL-6, apparently playing a central role in the worsening of the symptoms of COVID-19, was performed. The remainder of the contents of the tube used to perform this assay will allow further research by assaying the DNA-myeloperoxidase (DNA-MPO) complexes. These complexes reflect a phenomenon called netosis, most likely involved in the widespread inflammation that patients have suffered from."
9666308|NCT04593498||ESVEA|ESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
9666309|NCT04593498||Non-ESVEA|Participants not meeting inclusion criteria
9666310|NCT04591249|Other|Usual postoperative care|Participants randomized to usual care group will receive postoperative care as determined by their treating surgeon.
9666311|NCT04591249|Experimental|Usual postoperative care + Physical activity intervention|Participants randomized to the physical activity intervention group will receive usual postoperative care as determined by their treating surgeon and novel physical activity intervention.
9666312|NCT04590118|Experimental|Experimental: it-hMSC|Single intravenous infusion of 0.5×10^6, 1×10^6, 2×10^6 it-hMSC/kg
9666313|NCT04590118|Placebo Comparator|Placebo-controlled: Placebo|Single intravenous infusion of 1 ml/kg placebo
9666314|NCT04587674|Other|Spinal Cord Stimulation|
9666315|NCT04587583|Active Comparator|WeCareAdvisor|immediate use of the WeCareAdvisor tool for a 1 month period
9666316|NCT04587583|Active Comparator|WeCareAdvisor after 1 month|after a wait period of 1 month, use of the WeCareAdvisor tool for a 1 month period
9666321|NCT04582799|Active Comparator|Standard of Care (NIV)|Patients in the control group will be treated with non-invasive ventilation only.
9666322|NCT04582799|Experimental|Extracorporeal CO2 Removal (NIV+ECCO2R)|Patients in the treatment group will be treated with non-invasive ventilation combined with Extracorporeal CO2 Removal.
9666323|NCT04582500||patients undergoing CTC receiving iohexol|Patients will be recruited from a pool scheduled to undergo screening or diagnostic CTC for clinical purposes. They will be given 50 ml of Iohexol as a oral contrast
9666324|NCT04581811|Experimental|Prolonged Proning Arm|Patients will receive 24 hours in the prone position followed by 8 hours in the supine position for the duration of the study
9666325|NCT04581811|Active Comparator|Traditional Proning Arm|Patients will receive standard 16 hour prone positioning followed by 8 hours in the supine position for the duration of the study
9666326|NCT04579952|Experimental|Intervention Group|The IG will receive a 20 minute program of active tDCS (2mA intensity, anode placed on primary motor cortex controlateral to the TKA, cathode placed on controlateral supraorbital region) followed by a 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
9666327|NCT04579952|Placebo Comparator|Control Group|The CG will receive a 20 minute program of sham tDCS (15 seconds of activation and then no stimulation, same position of IG) followed by the same 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
9666328|NCT04577066|Experimental|Group 1 (GA2)|Volunteers will be exposed to GA2-infected mosquito bites.
9666329|NCT04577066|Active Comparator|Group 2 (GA1)|Volunteers will be exposed to the GA1-infected mosquito bites.
9666330|NCT04577066|Placebo Comparator|Group 3 (Placebo)|Volunteers will be exposed to uninfected mosquito bites.
9666331|NCT04576494|Experimental|5q-SMA type 2 and type 3 adults|5q-SMA type 2 and type 3 adults
9666332|NCT04574609|No Intervention|no hypnotherapy|"A control group of patients receiving the usual management for PAC and chemotherapy sessions."
9666333|NCT04574609|Experimental|hypnotherapy|"A hypnotherapy group of patients benefiting from hypnotherapy sessions prior to PAC and chemotherapy cures in addition to the usual management."
9666334|NCT04573036|Experimental|HRS4800 tablets cohort 1|Part 1 - HRS4800 Single Ascending Dose
9666335|NCT04573036|Experimental|HRS4800 tablets cohort 2|Part 1 - HRS4800 Single Ascending Dose
9666336|NCT04573036|Experimental|HRS4800 tablets cohort 3|Part 1 - HRS4800 Single Ascending Dose
9666337|NCT04573036|Experimental|HRS4800 tablets cohort 4|Part 1 - HRS4800 Single Ascending Dose
10195638|NCT04844736|Other|Radiology Treatment Planning/Review|After patient consultation and enrollment, the patient will undergo routine CT simulation to initiate the radiation treatment planning process. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes. If the initial radiology review reflects concern for inadequate target volume delineation, the case will be flagged for multidisciplinary discussion between the radiation oncologist and radiologist.
10204779|NCT04976452|No Intervention|Group 2|Group 2 consists of second year PT students who only had a powerpoint lecture on Blood Pressure measurement that was done virtually with no lab component or American Medical Association interactive module training.
10204780|NCT04973852|Experimental|Exoskeleton|5 sessions of overground ambulation with wearable exoskeleton where heart rate is monitored over each session.
9714032|NCT04596384|Active Comparator|Group II (surgeon-only perioperative care program)|Patients and their families meet with the surgeon at least once before surgery. After surgery, patients are managed daily during post-operative care. Patients may receive a referral for functional and nutritional prehabilitation at the discretion of the surgeon/surgical team. Patients and their families receive instructions to follow the standard procedures for reporting problems between clinic visits, including contacting their surgical team if symptoms become severe and physical function worsens; and the use of the hospital call line to report problems. Patients, caregivers and surgeons may receive the opportunity to participate in focus group in-person, via telephone, or videoconferencing.
9714033|NCT04596605|Experimental|T2309|4 capsules daily for 12 weeks
9714034|NCT04596605|Active Comparator|Nutrof Total|2 capsules daily for 12 weeks
9714035|NCT04596488|Experimental|Efavirenz 400mg+TDF+3TC|Combined antiretroviral therapy(cART) consisting of three regimens such as efavirenz, tenofovir and lamivudine is an effective measure for the treatment of HIV-1 infection.Efavirenz 600mg daily was approved by the US Food and Drug Administration in 1998. In this single-arm research, patients were treated with a reduced 400mg dose of efavirenz combined with tenofovir 300mg and lamivudine 300mg once a day. This treatment had to be maintained indefinitely due to the existence of HIV reservoir.
9714036|NCT04596449|Experimental|healthy volunteers|
10204781|NCT04968210||Pulmonary arterial hypertension (PAH)|Patients that have been clinically diagnosed with pulmonary arterial hypertension and fall under the category of WHO group 1 PAH.
9714037|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients before radiotherapy|"Cancer patients who have not undergone radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.~Interventions:~Drug: 68Ga-ICAM-1pep Device: PET/CT"
9714038|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients after radiotherapy|"Cancer patients post-radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.~Interventions:~Drug: 68Ga-ICAM-1pep Device: PET/CT"
9714039|NCT04596644|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
10204782|NCT04957160||Cohort 1|
9714040|NCT04596553|Active Comparator|Essential Amino Acid|Participants will consume 1 dose of: 15 g crystalline essential amino acid supplement (Pure Encapsulation Essential Aminos 180) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
9714041|NCT04596553|Active Comparator|Collagen Peptide|Participants will consume 1 dose of: 15g collagen peptide (Gelita TENDOFORTE) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
9714042|NCT04596553|Placebo Comparator|Maltodextrin Placebo|Participants will consume 1 dose of:15 g maltodextrin (Canadian Protein Maltodextrin) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
9714043|NCT04596566|Other|CD-TDI|Therapeutic diet Intervention ( CD-TDI )Group : Patients receiving CD-TDI will be offered patient-centered counseling for 12 weeks by a Registered Dietitian (RD) trained in the CD-TDI protocol with the goals of (a) identification and treatment of malnutrition if present, (b) targeted treatment of macro- and micronutrient deficiencies using whole foods;(c) increasing adherence to CD-TDI (d) multivitamin adherence and (e) reduced exposure to dietary antigens (e.g., maltodextrin, carrageenan, other food additives). They will receive a5 face-to-face appointment every 3 weeks with the study RD, and all other weekly appointments, which are 8 in number will be completed by phone.
9714044|NCT04596566|No Intervention|Conventional management|Conventional Management (Control) Group: CM patients will meet with the RD at baseline, week 7 and week 13 to complete their 24HR food recall twice on different days of the week, followed by a phone few days after the visit to complete the second part of the recall. They will be advised to follow their habitual diet and will be offered the dietary intervention at 14 weeks if they are still experiencing a disease flare
9714045|NCT04596306||UNDER 70 Y-O|
10204783|NCT04957160||Cohort 2|
10204784|NCT04941755|Experimental|Sequence AB|
9714046|NCT04596306||OVER 70 Y-O|
9714047|NCT04596397|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
9714048|NCT04596397|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.
9714049|NCT04596280||Hinchey Classification|
9714050|NCT04596280||AAST classification|
9714051|NCT04596280||WSES classfication|
10204785|NCT04941755|Experimental|Sequence BA|
10204786|NCT04931641|Experimental|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g galacto-oligosaccharides|
10204787|NCT04931641|Placebo Comparator|50 mg oral iron as ferrous fumarate (FeFum) with 7.5 g maltodextrin|
10204788|NCT04927923|Active Comparator|hope-focused motivational interview-experimental group|"Volunteering to participate in research~Being over the age of 18~Being able to read and write"
10204789|NCT04927923|No Intervention|control group|"Volunteering to participate in research~Being over the age of 18~Being able to read and write"
10204790|NCT04925934|Experimental|VIB7734 SC (dosing interval 1)|
10204791|NCT04925934|Experimental|VIB7734 SC (dosing interval 2)|
9714052|NCT04596254|Other|Juice Intake|
9714053|NCT04595942|Active Comparator|Midodrine|10 mg midodrine three times a day
9714054|NCT04595942|Active Comparator|Fludrocortisone|0.1 mg fludrocortisone two times a day
10195639|NCT04844034|Active Comparator|Active treatment|High-EPA multinutrient supplement.
10195640|NCT04844034|Placebo Comparator|Placebo|Inert oil mix.
9714055|NCT04595942|Other|Lifestyle modification|Education, salt and water intake, counter-pressure maneuvers
9714056|NCT04596267|Experimental|Pitolisant|Subjects will take an 8.9 mg dose (two 4.45 mg pills) of pitolisant once per day on day 1 through 4. On day 5, 8.9 mg will be taken in front of staff prior to an alcohol self administration trial.
9714057|NCT04596267|Placebo Comparator|Placebo|Subjects will take an placebo once per day on day 1 through 4. On day 5, a placebo will be taken in front of staff prior to an alcohol self administration trial.
9714058|NCT04595916|Experimental|Polyene Phosphatidylcholine|
9714059|NCT04595916|Active Comparator|Magnesium Isoglycyrrhizinate|
9714060|NCT04595929|Experimental|PIPAC group|"Staging laparoscopy + peritoneal lavage.~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~Radical gastrectomy with D2 - lymph node dissection.~Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².~Adjuvant chemotherapy according to indications."
9714061|NCT04595929|Active Comparator|Control group|"Staging laparoscopy + peritoneal lavage.~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.~Radical gastrectomy with D2 - lymph node dissection.~Adjuvant chemotherapy according to indications."
9714062|NCT04596085|Active Comparator|Investigational product|Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy
9714063|NCT04596085|Placebo Comparator|Placebo|Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy
9714064|NCT04596007|Experimental|HEC83518 tablets|There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
9714065|NCT04596007|Placebo Comparator|placebo tablets|There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
9714066|NCT04595812|Active Comparator|Misoprostol group|receive two tablets of 200µg misoprostol (Pfizer Limited, United Kingdom) administered into the posterior fornix of the vagina 1 hour before the onset of surgery
9714067|NCT04595812|Active Comparator|Oxytocin group|After induction of general anaesthesia and immediately prior to the operation, an infusion of 30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h will be started during myomectomy.
10195641|NCT04835441|Experimental|ALPN-101|
9714068|NCT04595812|Experimental|Carbetocin group|receive 100 μg IV Carbetocin (1ml) [Pabal, Ferring (UK)] in 5 ml saline over 1 minute just before skin incision
9714069|NCT04595812|Active Comparator|pericervical tourniquet group|pericervical tourniquet using a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision.
9714070|NCT04596046|Active Comparator|Group S (systemic-peroral steroid)|Medication of oral methylprednisolonewas administered to the patients following the adjustment based on the severity of the lesion and regarding the clinic. The prednisolone dose was 0.5 mg/kg/day in patients with painful, small (<5.0 cm) unilateral lesions whereas in multiple, bilateral lesions with the diameter of ≥5 cm or for those who had significant cutaneous ulceration, the prednisolone dose was specified as 1 mg/kg/day
9714071|NCT04596046|Experimental|Group L (local-intralesional steroid)|Triamcinolone acetonidewas administered to the patients through injecting inside the lesion. The practice was based on the dose of TCA administered in acute and chronic inflammatory skin lesions. If the lesion is single-focused and small (<5.0 cm), 20mg / mL TCA was injected and if the lesion is multifocal or large (>5.0 cm) then 40mg / mL TCA was injected into the lesion with the guidance of ultrasonography
9714072|NCT04596020|Experimental|Blood Flow Restriction Group|This group will perform 2 lower extremity exercises (sitting unilateral knee extension, standing unilateral knee curl) under occlusion (i.e., BFR) for 4 sets (30/15/15/15 reps) each followed by 2 shoulder exercises (scaption and sidelying external rotation) 3 sets x 15 reps each. Exercises will be performed at 30% of 1RM.
9714073|NCT04596020|Active Comparator|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
9714074|NCT04595981|Experimental|Chemo-embolization|Intra-arterial Cisplatin suspension 150-300 mg is infused into the tumor pedicle(s)
9779585|NCT05180890|Placebo Comparator|Placebo|Placebo infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in Treatment Period 1, 2, or 3.
10195642|NCT04835441|Placebo Comparator|Placebo|
10195643|NCT04834024|Experimental|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|
10195644|NCT04834024|Active Comparator|lenalinomide|
10195645|NCT04831515|Experimental|Lens A|"daily disposable soft contact lens - test lens~Subjects will be randomized to wear test lenses for one week and then cross-over to control lenses for one week."
10195646|NCT04831515|Active Comparator|Lens B|"daily disposable soft contact lens - control lens~Subjects will be randomized to wear control lenses for one week and then cross-over to test lenses for one week."
9779586|NCT05180890|Experimental|Danavorexton LD|Danavorexton LD regimen, infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
9779587|NCT05180890|Experimental|Danavorexton HD|Danavorexton HD regimen, infusion, intravenously, administered overnight for approximately 10-hours on Days 1 to 2 in each Treatment Period 1, 2, or 3.
9779588|NCT05179772|Experimental|Olanzapine|Everyone in the study is being given Olanzapine (open label)
9779589|NCT05177510|Experimental|Mifepristone and standard of care|Mifepristone 300mg once only and standard of care
9779590|NCT05177510|Placebo Comparator|Placebo|Placebo 300mg once only and standard of care
9980222|NCT01389544|Experimental|Single Arm|
9980223|NCT01389570|Experimental|Acupressure wrist band|The group receiving acupressure wrist band
10195647|NCT04826302|Experimental|Myofascial treatment|4 sessions of myofascial intervention, 40 minutes per session, 1 session per week
9714075|NCT04595903|Experimental|Hemopurifier®|The Hemopurifier® will be placed within the extracorporeal circuit, all connections secured, treatment will utilize a blood pump at an initial flow rate of 100mL/min. The blood flow rate is to be increased gradually in a stepwise fashion over the first minutes of treatment to a maximum blood flow rate of 200mL/min. The circuit must be continually monitored for blood leaks and blood clotting within the filter. If the treatment is halted before 4 hours, another filter may be connected, and the treatment may be restarted with a goal of achieving a minimum of 4 hours of therapy. If the filter shows signs of clotting or blood leaks, the treatment must be paused, the blood will be returned to the patient and a new filter will be placed into the extracorporeal circuit. The therapy will be resumed with consideration of altering the level of anticoagulation.
9714076|NCT04596176|No Intervention|Business As Usual|Families who were involved in the child welfare services
9714077|NCT04596176|Active Comparator|Intensive Supportive Housing for Families|Families who were randomly assigned in this group
9714078|NCT04596176|Active Comparator|Program Supportive Housing for Families|Families who were randomly assigned in this group
9714079|NCT04595877|Experimental|Dipyrone group|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
9714080|NCT04595877|Placebo Comparator|Placebo group|The placebo will be matched to the study drug for, color, and size. Placebo will be administered in a single dose in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
9714081|NCT04596241|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.
9714082|NCT04595955|Experimental|Intervention group|This arm uses the CMyLife platform for at least 6 months
9714083|NCT04595955|No Intervention|Control group|This arm does not use the CMyLife platform
9714084|NCT04596137|Experimental|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
9714085|NCT04595890|Experimental|Intervention Group|Injection of Autologous Nucleated Cells
9714086|NCT04595825|Experimental|CM-101|
9714087|NCT04595825|Placebo Comparator|Placebo|
9714088|NCT04595838|Experimental|Arm A:Best supportive oral care and Chemo Mouthpiece|Patients will receive best supportive oral care along with using the Chemo Mouthpiece device
9714089|NCT04595838|Other|Arm B Best supportive oral care only|Patients will receive best supportive oral care only.
9714090|NCT04595617|Experimental|Patients with diagnosis of Glanzmann Thrombastenia (GT)|Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months
9714091|NCT04595500||GERD|
9714092|NCT04595500||Control|
9714093|NCT04595539|Experimental|Simultaneous interventions|In this condition, both interventions are proposed simultaneously. Condition 1 is spread over 5 weeks with 5 weekly laboratory sessions of 2-hours (one hour of BATD and one hour of ATT separated by a break). A 30-minutes ATT sessions at home were prescribed between sessions for a total of 5 laboratory ATT sessions and 5 at home ATT sessions.
9714094|NCT04595539|Experimental|Sequential interventions|In this condition, the interventions are introduced sequentially. Condition 2 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 4 with of one hour of ATT followed by one hour of BATD separated by a break). A six 30-minutes ATT sessions were prescribed between the first 4 sessions of ATT for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
9714095|NCT04595539|Experimental|Sequential interventions in reverse order|In this condition, the interventions are introduced sequentially in the reverse order than the condition 2. Condition 3 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 5 with of one hour of BATD followed by one hour of ATT separated by a break). A six 30-minutes ATT sessions were prescribed between the 4 last sessions for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
9714096|NCT04595682|Experimental|Study Participants|Participants in this group will track their menstrual cycle, provide daily saliva samples, and undergo two rounds of alcohol sensitivity testing (with both placebo and alcohol).
9714097|NCT04595695|Experimental|Transparent Mask|Surgeons will be provided a transparent mask for use during in-person clinic visits with a new patient. Otherwise, visits will be conducted as per usual and the patient will be surveyed immediately after the visit.
9714098|NCT04595695|Active Comparator|Covered Mask|Surgeons will be instructed to wear a typical, covered mask for the in-person clinic visit with a new patient. The visit will be conducted as it typically would, and the patient will be surveyed immediately after the visit.
9714099|NCT04595708|Experimental|Intervention - Calls|Participants randomized to the intervention will receive a call of between 5 - 10 minutes in length each by a consistent caller, five times a week, Monday through Friday for 4 consecutive weeks to check in on them. After the first week of calls, subjects in the intervention arm will be asked if the frequency of calls is acceptable or if they would like to reduce the call frequency, potentially to a minimum of twice per week.
9714100|NCT04595708|No Intervention|Control - No calls|Participants randomized to a control group will not receive the intervention calls. The control group will receive calls from a member of the research team at the beginning of the study to collect baseline survey data and at the post-4-week period to collect post-study survey data.
9714101|NCT04595643|Experimental|Specialized dysphagia treatment|Dysphagia treatment is provided by occupational therapists specialized in dysphagia.
9714102|NCT04595669|Experimental|Personalised advice|
9714103|NCT04595604|Experimental|Trimodal prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~Physical status (walking, respiratory training) Nutrition (nutritional supplements) Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
9714104|NCT04595604|Active Comparator|ERAS + nutritional prehabilitation|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
9714105|NCT04595552|Experimental|Study group|Children with cochlear implant were given Auditory training and language therapy
9980224|NCT01389583|Experimental|AUY922|AUY922
10195648|NCT04826302|Sham Comparator|Sham myofascial treatment|4 sessions of sham myofascial intervention, 40 minutes per session, 1 session per week
10195649|NCT04821141|Experimental|Bazedoxifene plus conjugated estrogens immediately|BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing immediately.
10195650|NCT04821141|Other|Bazedoxifene plus conjugated estrogens wait list|No intervention for initial 6 months (wait list), then BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing 6 months after enrollment. Optional on the part of subject.
10195651|NCT04790058||Physicians using CSRS practice recommendation to treat syncope patients in ED.|During the control period, there will be no interventions. The intervention is the knowledge translation of the CSRS practice recommendations. The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g. troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. The ED physician or non-ED physician performing consultation on the patient can apply all the components of the practice recommendation and decide disposition of the patients who are eligible to be studied.
9666338|NCT04573036|Experimental|HRS4800 tablets cohort 5|Part 2 - HRS4800 Food Effect
9666339|NCT04573036|Placebo Comparator|Placebo tablets|
9666340|NCT04568811|Experimental|Adenovirus Type-5 Vectored COVID-19 Vaccine|
9666341|NCT04568798|Active Comparator|Sana Device|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
9666342|NCT04568798|Sham Comparator|Sana Sham Device|The sham treatment device is designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
9666343|NCT04568564|Experimental|Telerehabilitation Group (TG)|Patients diagnosed with lung cancer and underwent thoracotomy
9666344|NCT04568564|Active Comparator|Control group (CG)|Patients diagnosed with lung cancer and underwent thoracotomy
9666345|NCT04568434|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
9666346|NCT04568434|Placebo Comparator|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
9666347|NCT04567121|Other|Intensive intervention group|intensive life-style and care intervention
9666348|NCT04567121|Other|Standard intervention group|standard life-style and care intervention
9666349|NCT04566991|Experimental|Deferoxamine lower dose|Deferoxamine 32 Milligram Per Kilogram (mg/kg)
9666350|NCT04566991|Experimental|Deferoxamine higher dose|Deferoxamine 48 mg/kg
9666351|NCT04566991|Placebo Comparator|Placebo|normal saline
9666352|NCT04566978|Experimental|Cohort 1|Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK
9666353|NCT04566978|Experimental|Cohort 2|Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
9666354|NCT04566978|Experimental|Cohort 3|Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
9666355|NCT04566978|Experimental|Cohort 4|Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
9666356|NCT04564014|Experimental|ISSS Intervention|The intervention group will receive 5 weekly ISSS sessions in addition to the information about mental health, depression, anxiety and available treatment and community resources also recived by the control group.
9666357|NCT04564014|Active Comparator|Wait-list control group|Members will receive information about mental health, depression, anxiety and available treatment and community resources but not ISSS during the intervention period.
9666358|NCT04562376|Experimental|Group A|The program consists of high-intensity resistance training for 60 minutes twice a week for group A during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group A will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
9666359|NCT04562376|Active Comparator|Group B|The program consists of high-intensity resistance training for 60 minutes once a week for group B during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group B will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
9666360|NCT04561713|Experimental|Attention Deficit Hyperactivity Disorder (ADHD)|Children aged 8 to 12 diagnosed with ADHD
9666361|NCT04561713|Sham Comparator|Control|Control group of healthy ADHD children matched in age, gender and laterality to children in ADHD group
9666362|NCT04561661|Active Comparator|Conservative treatment|Fracture treated with closed reduction, custom made orthosis and early mobilization.
9666363|NCT04561661|Active Comparator|Surgery|Fractures treated with closed reduction, percutaneous pinning (k-wires) and plaster.
9666364|NCT04560998|Experimental|Semaglutide|Semaglutide given in addition to standard-of-care treatment
9666365|NCT04560998|Placebo Comparator|Placebo (semaglutide)|Placebo given in addition to standard-of-care treatment
9666366|NCT04560595|Experimental|Caffeine Reduction Manual, Immediate Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the immediate treatment group will receive the guide immediately after screening."
9714106|NCT04595578|Active Comparator|Cerebellar rTMS + Physical therapy|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
9714107|NCT04595578|Sham Comparator|Sham stimulation + Physical therapy|Sham stimulation was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator. Sham stimulation was delivered to the cerebellum for 5 seconds at 55 second intervals in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
9714108|NCT04595435||Cohort A- Preoperative Prospective|Subjects are eligible to receive IORT and have agreed to participate in the study prior to any intervention.
9714109|NCT04595435||Cohort B- Postoperative Prospective|Subjects who have had IORT performed within the previous 6 month who agree to participate.
9714110|NCT04595448||Patients|Patients suffering from moderate tricuspid valve regurgitation
9714111|NCT04595448||Controls|Cardiovascular healthy, age, gender and weight matched controls.
9714112|NCT04595461|Placebo Comparator|Control|Standard of care patient education with verbal and written education
9714113|NCT04595461|Experimental|Video Group|Patient education supplemented with four short youtube videos regarding chronic rhinosinusitis and endoscopic sinus surgery
9714114|NCT04595227||Normal Subjects|Healthy eyes had intraocular pressure of less than 22 mmHg with no history of increased intraocular pressure and normal standard automated perimetry (SAP) results.
9714115|NCT04595227||Suspect Glaucoma|Eyes with suspect glaucoma were defined as those with suspicious neuroretinal rim thinning or retinal nerve fiber layer (RNFL) defects on masked stereophotographic assessment, without repeatable abnormal SAP results. Eyes with suspect glaucoma also included those with intraocular pressure (IOP) > 21 mm Hg but with healthy-appearing optic discs and without repeatable abnormal SAP results
9714116|NCT04595227||Primary Open Angle Glaucoma, early stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -0.01dB≤MD≤-6.00dB)
9714117|NCT04595227||Primary Open Angle Glaucoma, moderate stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -6.01≤MD≤-12.00dB)
9714118|NCT04595227||Primary Open Angle Glaucoma, advanced stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -12.00≤MD≤-20.00dB)
9714119|NCT04595383|No Intervention|Control|Usual care and usual communication with health professional
9714120|NCT04595383|Experimental|Intervention|They will be trained to use the ti.care platform and will be able to use it as a communication channel for any questions or clarification they require during the time elapsed between routine control visits. This platform will be a complement to the visits, but in no case will it replace them or be used as a diagnostic or therapeutic method. The platform does not have any treatment algorithm and only aims to facilitate communication between the patient at home and the health professional, both the doctor and the nurse educator. It will be used in a preventive and advisory manner for the patient for follow-up. In no case it will be used for emergencies. Daily during working hours from Monday to Friday, health professionals will review patient requests and respond to them.
10195652|NCT04789954|Experimental|AryoSeven 10 μg/kg|Single dose, intravenously
10195653|NCT04789954|Experimental|AryoSeven 30 μg/kg|Single dose, intravenously
9714121|NCT04595526|Active Comparator|Tracheal suction|Uses the local standard procedure of tracheal suction to obtain secretions from the lower respiratory tract
9827871|NCT02471521|Experimental|Neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with after rocuronium administration in children while continuous gastric auscultation and abdominal sonography are performed.
9980225|NCT01389609|Experimental|A|Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
10195654|NCT04789954|Experimental|AryoSeven 90 μg/kg|Single dose, intravenously
10195655|NCT04789954|Experimental|AryoSeven 270 μg/kg|Single dose, intravenously
10195656|NCT04789954|Active Comparator|NovoSeven 30 μg/kg|Single dose, intravenously
10195657|NCT04788017|Active Comparator|ziresovir|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
10204792|NCT04925934|Placebo Comparator|Placebo SC (dosing interval 3)|
10204793|NCT04923763||Tongue_examination|The general public will be invited for tongue examination. The data will be used to establish the automatic tongue video analysis system.
9714122|NCT04595526|Experimental|Forced expiratory technique and induced sputum|This procedure is without suction. The patient's attempts to deliver a sputum sample after forced exhalation and coughing technique. Regardless of the result the patient then receives hypertonic saline by an inhalation mask to induce the sputum. If the patient cannot deliver a sample, tracheal suction will be performed in order to obtain a specimen for the analyses.
9714123|NCT04595253|Experimental|acupressure|After recruitment, participants will be randomized to receive acupressure or control group. In the acupressure group, participants will receive acupressure treatment.
9714124|NCT04595253|No Intervention|routine care|After recruitment, participants will be randomized to receive acupressure or control group. In the control group, participants will receive routine care, including routine pain control.
9714125|NCT04595487|Experimental|left ventricular septal pacing|Implantation of a pacemaker with the ventricular lead delivered transvenously through the interventricular septum (IVS) to the left ventricular (LV) septum.
9714126|NCT04595487|Active Comparator|right ventricular pacing|Implantation of a pacemaker with the ventricular lead placed in the RV.
9714127|NCT04595318|Active Comparator|Standard clinical care|Four weeks of medication-assisted treatment (MAT) with standard clinical care (SCC). MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
9714128|NCT04595318|Active Comparator|Standard clinical care and varenicline|Four weeks of MAT with standard clinical care plus varenicline therapy (SCC and VT). Varenicline therapy included a one-month supply of standard doses: 0.5mg for the first three days, 0.5mg twice a day for the following four days, and 1 mg twice a day for the remaining 21 days. MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
9714129|NCT04595331|No Intervention|Treatment Group in pivotal study|followed for long-term safety and effectiveness with no additional treatment
9714130|NCT04595331|Experimental|Control Group in the pivotal study|receiving treatment in the extension study
9714131|NCT04595591|Active Comparator|Group Ⅰ|titration dosing speeds of propofol at 2mg/kg/min
9714132|NCT04595591|Active Comparator|Group Ⅱ|titration dosing speeds of propofol at 1mg/kg/min
9714133|NCT04595591|Active Comparator|Group III|titration dosing speeds of propofol at 0.5mg/kg/min
9714134|NCT04595409|Experimental|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive subcutaneous injections of FYB202 as detailed in the protocol.
9714135|NCT04595409|Active Comparator|Stelara® (Ustekinumab)|Patients will receive subcutaneous injections of Stelara® as detailed in the protocol.
9714136|NCT04595149|Other|Immunotherapy|Adding bintrafusp alfa (a combined TGF-β en PDL-1 inhibitor) to definitive chemoradiation with Paclitaxel and Carboplatin
9714137|NCT04595071|No Intervention|Standard Control|Use of standard two-site myoelectric control of multi-articulating hand.
9714138|NCT04595071|Experimental|Voice Recognition Control|Use of voice recognition control in addition to standard two-site myoelectric control of a multi-articulating hand.
9714139|NCT04595344|Active Comparator|Diagnostic cystoscopy , Binaural beat group|patients listened to binaural beats
9714140|NCT04595344|Active Comparator|Diagnostic cystoscopy, Classical music group|patients listened to classical music
9714141|NCT04595344|Placebo Comparator|Diagnostic cystoscopy , Placebo group|patients no audio only headphones
9714142|NCT04595344|Active Comparator|Ureteral stent removal, Binaural beat group|patients listened to binaural beats
9714143|NCT04595344|Active Comparator|Ureteral stent removal ,Classical music group|patients listened to classical music
9714144|NCT04595344|Placebo Comparator|Ureteral stent removal, Placebo group|patients no audio only headphones
9779591|NCT05168514|Experimental|Massage|"Massage begins with the patting (eflorage) maneuver. Massage is continued with petrissage, bearing, friction and percussion maneuvers.~Maneuvers are performed for 3-5 minutes. A patting motion is performed between maneuvers and at the end of the massage. During the massage, it is observed whether the integrity of the skin is impaired or in terms of redness."
9779592|NCT05163990|Experimental|TEAS group|10 minutes before intraspinal anesthesia, bilateral Neiguan points and Zusanli points are given dense wave transcutaneous acupoint electrical stimulation with the frequency of 10/50Hz. The intensity is based on the maximum tolerance of the participant, and the stimulation last until 30 minutes after subarachnoid administration.
9779593|NCT05163990|No Intervention|Control group|Electrodes are connected at bilateral Neiguan points and Zusanli points 10 minutes before intraspinal anesthesia, but no transcutaneous acupoint electrical stimulation is given, the duration is the same as that of the TEAS group.
9779594|NCT05160987|Experimental|Remimazolam Group|The patients are administered with sedation of remimazolam and analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drug before enrollment, patient would be administered with a bolus of remimazolam with 0.1-0.3mg/kg intravenously in 1 minute for the first time. And maintenance dose is 0.25-0.1mg/kg/h, meanwhile the dose of remimazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
9779595|NCT05160987|Placebo Comparator|Midazolam Group|The patients are administered with sedation of midazolam analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drugs before enrollment, patients would be administered with a bolus of midazolam with 0.01-0.05mg/kg intravenously in 1 minute for the first time. And the maintenance dose is 0.02-0.1mg/kg/h, meanwhile the dose of midazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
9827872|NCT02471521|Active Comparator|Non-neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed without rocuronium in children while continuous gastric auscultation and abdominal sonography are performed.
10195658|NCT04788017|Placebo Comparator|placebo|"The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast.~Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:~If administered 60 mL as the study drug dose, follow with approximately 180 mL water.~If administered 120 mL as the study drug dose, follow with approximately 120 mL water.~If administered 180 mL as the study drug dose, follow with approximately 60 mL water."
9714145|NCT04595136|Experimental|COVID19-0001-USR|Group 1 Patients with SARS-COV-2 (COVID19) positive test will receive Investigational Drug administer by nebulization ( COVID-19-0001-USR) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
10195659|NCT04780828||GROUP I|Group I will include cases classified as normal weight (healthy) with a body mass index of 18.5-24.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined for this group will be made. Since this group was not considered as obese, it was determined as the control group.
9714146|NCT04595136|Placebo Comparator|Normal Saline|Group 2 of patients with positive tests intervention SARS-COV-2 (COVID19) with placebo (i.e., normal saline 0.9% NS) plus standard baseline treatment for covid provided by Primary care provider ( Azithromycin, dexamethasone, and/or anticoagulants) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
9714147|NCT04595279|Experimental|Smoking sessions|This is the single arm that will go through cigarette smoking sessions
9714148|NCT04595162|Experimental|CAR-T treatment group|The patients will receive one dose of GC019F.
9714149|NCT04595019|Active Comparator|5 fraction|MRI-guided radiotherapy, 36.25 Gray (Gy) in 5 fractions (boost to 40 Gy over tumour/prostate CTV) over 10 days.
9714150|NCT04595019|Experimental|2 fraction|MRI-guided radiotherapy, 24 Gy in 2 fractions (boost to 27 Gy over tumour/prostate CTV) over 8 days.
9714151|NCT04594954|Experimental|Diet + Exercise + FMT|
9714152|NCT04594954|Active Comparator|Diet+Exercise|
9714153|NCT04595084|Experimental|MBCT-R + CHA-MW|Mindfulness-Based Cognitive Therapy (MBCT) is an effective group intervention for depression and anxiety that combines mindfulness training with elements of cognitive therapy. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
9714154|NCT04595084|Active Comparator|iCBT (MoodGym) + CHA-MW|MoodGym is a form of iCBT, which an evidence-based online program for depression, anxiety, stress and general psychological well-being. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
9714155|NCT04595084|Active Comparator|CHA-MW|Participants randomized to the CHA-MW arm will only receive CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
9714156|NCT04595006|Experimental|Cold Stimulation (CS)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.
9714157|NCT04595006|Experimental|Browning Nutraceutical (BN)|Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
9714158|NCT04595006|Experimental|Cold Stimulation and Browning Nutraceutical (CSBN)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
9714159|NCT04595058|Active Comparator|EUSDB-LAMS|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent . Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.~EUSDB-LAMS (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent)"
9714160|NCT04595058|Experimental|EUSDB-LAMS-Pigtail|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stents without coaxial plastic stent. Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.~In this arm, a double pigtail through the lumen apposing metal stent will be inserted as an axis-orienting stent.~EUSDB-LAMS-Pigtial (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent through LAMS)"
9714161|NCT04594876|Other|Flouroscopic guidance Cervical Epidural injection|Group (P) flouroscopic guidance cervical epidural injection
9714162|NCT04594876|Other|Flouroscopic guidance cervical facet injection|Group (F) Flouroscopic guidance cervical facet injection
9714163|NCT04594928|Experimental|GLPG3667 Dose A|Daily doses of GLPG3667 for 4 weeks.
9714164|NCT04594928|Experimental|GLPG3667 Dose B|Daily doses of GLPG3667 for 4 weeks.
9714165|NCT04594928|Placebo Comparator|Placebo|Placebo to match will be administered as capsules for daily oral use.
9714166|NCT04594850|No Intervention|Placebo-Control group|Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.
9714167|NCT04594850|Experimental|Injection group: Cellgram-ED|Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand.
9714168|NCT04594889|Experimental|Sirolimus|Sirolimus eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
9714169|NCT04594889|Active Comparator|Paclitaxel|Paclkitaxel eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
9714170|NCT04594863||cachexia|patients suffering from cachexia recently
9714171|NCT04594863||no cachexia|patients are not suffering from cachexia recently
9714172|NCT04594460|Experimental|experimental Group|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
9714173|NCT04594460|Active Comparator|Control Group|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
9714174|NCT04594668|No Intervention|Standard treatment|Standard intensive care
9714175|NCT04594668|Active Comparator|Senicapoc|Senicapoc
9714176|NCT04594759|Experimental|Treatment Group|
9714177|NCT04594915||Study Group|Patients diagnosed with AF who are currently using Edoxaban for stroke prevention in Turkey.
9714178|NCT04594577|Experimental|Fluispotter|Fluispotter automated blood sampling system
9714179|NCT04594447|Other|Physica KR|Subject that receive Physica Kinematic Retaining total Knee replacement system
9714180|NCT04594447|Other|Physica CR|Subject that receive Physica Cruciate Retaining total Knee replacement system
9714181|NCT04594772|Experimental|Neoadjuvant therapy|All patients will receive Neoadjuvant therapy.
10195660|NCT04780828||GROUP II|Group II will include cases classified as overweight and having a body mass index of 25.0-29.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
10195661|NCT04780828||GROUP III|Group III will include cases classified as class I obese, with a body mass index of 30.0-34.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
9714182|NCT04594720||Thyroid cancers|Enrolled study population have papillary thyroid cancers and benign thyroid tumors
9980226|NCT01389609|Experimental|B|Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
9980227|NCT01389609|Experimental|C|Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
9714185|NCT04594629|Sham Comparator|nitroglycerine group|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
9714186|NCT04594629|Active Comparator|PGI2 group|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres.
9714187|NCT04594161|Active Comparator|Percutaneous Nephrostomy|drainage of the kidney by means of a percutaneous Nephrostomy
9714188|NCT04594161|Active Comparator|Double J catheter|drainage of the kidney by means of a double J catheter
9714189|NCT04594148|Experimental|Weight-shift training|The experimental group will receive a single session of 10x 2.5min of weight-shift training with the VR Wasp Game
9714190|NCT04594148|No Intervention|Passive control|The passive control group will not receive any form of training. Instead, they will relax for 25min (i.e. talking with the researcher and/or reading a magazine)
9714191|NCT04594395||Healthy volunteers|Any adult aged 18 to 65 years of age living in Phnom Penh that is sufficiently healthy and willing to undergo fingerstick by the mobile unit for SARS-CoV-2 ELISA assays.
9714192|NCT04594395||Household contacts|Adult relatives of the healthy volunteers.
9714193|NCT04594018|Experimental|FINLÂNDIA|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride placebo, oral, once a day.~1 mL Finlândia hair lotion, topical, twice a day."
9714194|NCT04594018|Active Comparator|Minoxidil + finasteride|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride, oral, once a day.~1 mL minoxidil hair lotion, topical, twice a day."
9714195|NCT04594473|No Intervention|Standard of Care (SOC)|Participants randomized to SOC will be instructed to continue their typical lifestyle activity.
9714196|NCT04594473|Experimental|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|Participants randomized to CORE will be instructed to follow the clinical algorithm for this study. An in-clinic assessment consisting of two questionnaires will be used to identify the appropriate pathway for triage. Participants will be triaged into one of three pathways: Physical Medicine & Rehabilitation, Personal Optimism With Exercise Recovery, or Exercise Self-Management.
9714197|NCT04594083|Experimental|Palm Stimulator|The Palm Stimulator was placed in the palm of the child's active hand 20 seconds before the injection. It ensured by researcher that the apparatus was held tightly in the child's palm throughout the procedure. The apparatus was taken back from the child after completing the injection process.
9714198|NCT04594083|Experimental|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
9714199|NCT04594083|No Intervention|Control|The routine IM injection was applied to the children in the control group.
9714200|NCT04594265|Experimental|Ketone Monoester|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
9714201|NCT04594265|Placebo Comparator|Placebo Treatment|Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
9714202|NCT04594265|Active Comparator|Ketone Monoester in presence of low-dose insulin clamp|Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
9714203|NCT04594005|Experimental|abemaciclib+paclitaxel|
9714204|NCT04594330|Active Comparator|Group 1 - 30 COVID-19 patients aged ≥ 18 years old receiving the investigational drug|Group 1 - 30 COVID-19 patients receiving standard therapy and the investigational drug (Virgin Coconut Oil)
10195662|NCT04780828||GROUP IV|Group IV will include cases classified as class II obese, with a body mass index of 35.0-39.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
10195663|NCT04780828||GROUP V|Group V will include cases classified as class III (morbid) obese, with a body mass index of 40 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
9714205|NCT04594330|Placebo Comparator|Group 2 - 30 COVID-19 patients aged ≥ 18 years old receiving placebo|Group 2 - 30 COVID-19 patients receiving standard therapy and placebo
9714206|NCT04594187|Experimental|Group I (immunotherapy, radiation therapy)|Within 12 weeks of SLNB, patients start nodal radiation therapy (30 Gy in 5 treatments over 2-2.5 weeks). Immunotherapy planned to begin at any time after SLNB.
9714207|NCT04594187|Active Comparator|Group II (immunotherapy)|Patients planned to undergo immunotherapy.
9980228|NCT01389622|Experimental|Arm 1: NADA points and digital pressure|Arm 1: NADA points and digital pressure with urge.
10195664|NCT04778436|Experimental|T7082|After inclusion, the patients will consume an association of 4 food supplements including Nutrof Total.
10195665|NCT04774484|Experimental|All subjects will be in one arm|Both Lean and Obese, End-Stage Renal Disease (ESRD) patients and normal volunteers will be in one arm, that will receive the High Intensity Interval Training intervention.
9714208|NCT04594226|Experimental|EA combined with medication group|Patients in this group will receive electroacupuncture combined with gabapentin.
9714209|NCT04594226|Active Comparator|Medication group|Participants in this group will only receive gabapentin.
9714210|NCT04594044|Experimental|Individual HRT and ERP|Individual treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
9714211|NCT04594044|Experimental|Group HRT and ERP|Group treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
9714212|NCT04594057|Active Comparator|Early Start|Begin 6 weeks of gaze and postural stability training 10-14 days following surgery.
9714213|NCT04594057|Experimental|Delayed Start|Begin 6 weeks of gaze and postural stability training 6 weeks following surgery.
9714214|NCT04594135|Experimental|anti-CD5 CAR T cells|Experimental: anti-CD5 CAR T cells Dose escalation phase: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells with an escalation approach, 1e6 to 5e6 CAR-T cells/kg
9714215|NCT04594122|No Intervention|Control|No intervention in this group
9714216|NCT04594122|Experimental|Intervention|Hygiene package, training, branding, and certification
9714217|NCT04594252|Experimental|ALXN1840|Participants will be administered repeat doses of ALXN1840 30 milligrams (mg) for 15 days.
9714218|NCT04594343|Experimental|Disulfiram|
9714219|NCT04594343|Placebo Comparator|Placebo|
9714220|NCT04594304|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports upon survey completion, and their PCP will receive automatic supports in the EMR to assess and treat the patient's alcohol and/or tobacco use. In cases where a patient does not have risky alcohol and tobacco use, a personalized eToolkit based on their physical activity levels will be administered, and their PCP will receive automatic supports in the EMR to facilitate physical activity discussions. Intervention arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and a 3 months follow-up e-survey following their appointment. Resources will be automatically produced for the patient and PCP following completion of the baseline e-survey.
9714221|NCT04594304|No Intervention|Usual care|The control arm will not receive intervention materials. Control arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and 3 months follow-up e-survey following their appointment.
9714222|NCT04594070|Active Comparator|Daily iron supplementation|Oral ferrous sulfate, 325 mg, take once daily
9714223|NCT04594070|Experimental|Alternate day iron supplementation|Oral ferrous sulfated, 650mg, taken once daily every other day
9714224|NCT04594174||Responders|
9714225|NCT04594174||Non responders|
9714226|NCT04594317|Experimental|low level laser therapy|970 ± 15-nm diode laser (Biolase Epic X, Biolase, Irvine, California, USA)will be activated at 0.5 W and 10 Hz at a distance of approximately 10 mm to the tissue around the apex of the root. A circular movement will be performed during application. Pulse duration will be 0.5 s, and pulse pause will be 50%. Total application time will be30 s for the tooth. For this application, a 200-μm optical tip will be used.
9714227|NCT04594317|Active Comparator|Calcium hydroxide intracanal medication|calcium hydroxide paste (Metapaste, Meta Biomed Co., Ltd, Korea) will be inserted in the canal using disposable plastic tip and placed at a distance 1 or 2 mm less than the working length.
9714228|NCT04594109|Active Comparator|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
9714229|NCT04594109|Experimental|Tailored Counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
9714230|NCT04593992|Experimental|HTEMS|High-tone external muscle stimulation 5 times within a week for 12 weeks
9714231|NCT04593992|Placebo Comparator|Placebo|Placebo stimulation 5 times within a week for 12 weeks
9714232|NCT04593966||Pediatric AVM|"AVM patients' age under 18-years-old who underwent intervention in investigators' institution.~Patients' lesions were located in eloquent and confirmed by image."
9714233|NCT04593966||Adult AVM|"AVM patients' age over 18-years-old who underwent intervention in investigators' institution.~Patients' lesions were located in eloquent and confirmed by image."
9714234|NCT04594031|Experimental|ECT-001-CB|"An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant.~Patients will receive standard supportive care and GVHD prophylaxis"
9714235|NCT04593849|Active Comparator|group A (Ru-Yih-Jin- Huang-Saan group)|Herbal medicine(Ru-Yih-Jin- Huang-Saan) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
9714236|NCT04593849|Experimental|group B (Wan-Yin-Gao-Jia-Jean-Wey group)|Herbal medicine (Wan-Yin-Gao-Jia-Jean-Wey) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
9714237|NCT04593849|Placebo Comparator|placebo group( topical agent without therapeutic effects)|topical agent without therapeutic effects will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
9714238|NCT04593849|No Intervention|control group|only oral analgesics will be applied to patients
9714239|NCT04593888|No Intervention|No intervention|The group will be followed without any intervention, with regular visits at the research clinic.
9714240|NCT04593888|Experimental|Gluten reduced diet|"Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten.~The group will be followed with regular visits at the research clinic."
9714241|NCT04593589|Experimental|Transplantation|Submandibular Gland Stem Cell Transplantation
9714242|NCT04593797||Patients undergoing major upper abdominal surgery|major open upper abdominal surgery eg pancreatic, liver surgery
9714243|NCT04593706|Active Comparator|keloids|each patient will be injection by all 4 steroids for comparison patients with 4 or more keloids will be injection with each steroid for different keloid
9714244|NCT04593706|Active Comparator|hypertrophic scars|each patient will be injection by all 4 steroids for comparison patients with a 11 cm hypertrophic scar will be injected by all 4 steroids along the scar with a 1 cm distance between each steroid
9714245|NCT04593719|Experimental|Experiment|Lactation management model is applied to the experimental group.
9714246|NCT04593719|No Intervention|Control|Lactation management model is not applied to the control group.
9714247|NCT04593667|Other|Full Inflation|100% TR Band inflation relative to recommended inflation with 15-18 cc air injected in TR band bladder
9714248|NCT04593667|Other|Mid Inflation|75% TR Band inflation relative to recommended inflation with 11-14 cc air injected in TR band bladder
9714249|NCT04593667|Other|Low Inflation|50% TR Band inflation relative to recommended inflation with 8-9 cc air injected in TR band bladder
9714250|NCT04593602|Experimental|Early Mobilization Intervention|The bedside nurse determines the prehospital Level of Function based on patient and family report and current Level of Function based on nursing mobility assessment. Each Level of Function has 3 primary activities designed to promote the patient to the next level. The nurse leads mobility activities based on the patient's current Level of Function once per shift, twice daily (AM+PM). If a patient is able to complete each of the 3 activities, the nurse on the subsequent shift will assess whether the Level of Function can be advanced. Physiotherapy consultation is available if required, although not obligatory. Patients are encouraged to spend as much time in the chair and ambulatory as possible.
9714251|NCT04593602|Active Comparator|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
9714252|NCT04593576|Experimental|Structured physical activity/outdoor sports.|Out door sports and structured physical activity protocol will be administered on children with Autism.
9714253|NCT04593576|Active Comparator|Intensive table teaching control group|Control group will only be exposed to intensive table teaching instead of physical activity protocol.
9714254|NCT04593836|Experimental|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
9714255|NCT04593836|Placebo Comparator|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
9714256|NCT04593654||low dose thromboprophylaxis|Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin
9714257|NCT04593654||medium dose thromboprophylaxis|Daily dose of >4500 IU but <175 IU/kg of body weight tinzaparin or >5000 IU but <200 IU/kg of body weight dalteparin
9714258|NCT04593654||high dose thromboprophylaxis|Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin
9714259|NCT04593693|Other|Invia Motion Endure NPWT system|Use of Negative Pressure Wound Thearpy
9980229|NCT01389622|Experimental|Arm 2: random points + digital pressure with urge|Arm 2 (20 participants): random points + digital pressure with urge
9980230|NCT01389622|No Intervention|Arm 3 (20 participants): NO acupressure, only advice + support|
9714260|NCT04593615|Experimental|Group A|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
9714261|NCT04593615|Placebo Comparator|Group B|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
9714262|NCT04593355||HCV|
9714263|NCT04593368|Experimental|FMT|
9714264|NCT04593212||Septic Shock Survivors|
9714265|NCT04593212||Septic Shock Non-Survivors|
9714266|NCT04593238|Experimental|Double antibiotic paste intra-canal medication group (n=25)|500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.
9714267|NCT04593238|Active Comparator|Calcium hydroxide intra-canal medication group (n=25)|Calcium hydroxide paste (Metapaste) placed inside the root canal for 1 week
9714268|NCT04593316||Exertional heatstroke group|Patients presenting or having presented exertional heatstroke.
9714269|NCT04593316||Control group|Healthy people who never experienced exertional heatstroke.
9714270|NCT04593407|Active Comparator|Endoscopic Mucosal Resection (EMR):|Piecemeal EMR is a conventional endoscopic resection technique. A submucosal injection of a large volume of a solution (normal saline or other) with or without dilute epinephrine (1/10,000) with or without indigo carmine is performed. Then, sequential piecemeal resection is performed with use of a combination of stiff-type snares. At the end of the procedure when macroscopically visible adenoma has been totally resected, a snare tip soft coagulation (STSC) of the margin of the scar is performed to eliminate non visible residual neoplastic tissue. This procedure is quicker and safer than ESD but led to more recurrent disease (around 20% with the standard technique but recently reduced to 5% after the introduction of STSC)
9714271|NCT04593407|Experimental|: Endoscopic Submucosal Dissection (ESD):|ESD is a newer resection technique that allows en bloc resection for large LSLs. A submucosal injection is also needed but, in this case, different endo-knives are used to achieve the resection instead of diathermic snares. The en bloc resection allows a more precise pathological analysis and the risk of recurrence is lower (<2%) when margins are tumor-free.
9714272|NCT04593524|Active Comparator|Treatment Group|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
9714273|NCT04593524|Active Comparator|Counseling Group|24 participants which only receives nutritional counseling for 28 days
9980231|NCT01389635||Abdominoplasty patients|All patients who underwent abdominoplasty at our institution without concurrent operations
9980232|NCT01389648|Experimental|Pre Operative|Pre operative chest physiotherapy treatment
9980233|NCT01389648|No Intervention|usual care|
9714274|NCT04593381|Experimental|SBRT treatment|Intervention: Radiation: SBRT
9714275|NCT04593472|Experimental|SHARE|"SHARE components include: 1) a letter from the practice introducing the initiative, 2) access to a designated person (medical assistant, social worker, nurse, or lay person) trained to lead advance care planning discussions, 3) person-family agenda-setting to align perspectives about the role of the caregiver and stimulate discussion about goals of care, and 4) education about communication and available resources, including a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor, a blank easy to complete advance directive, and facilitated registration to the patient portal (for patient and caregiver participants) to extend electronic interactions and information access to family."
9714276|NCT04593472|Placebo Comparator|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
9714277|NCT04593329|Experimental|TIRADENTES|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet Tiradentes association, oral;~1 capsule tramadol placebo, oral;~1 tablet dipyrone placebo, oral."
9714278|NCT04593329|Active Comparator|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet dipyrone, oral;~1 tablet Tiradentes association placebo, oral;~1 capsule tramadol placebo, oral."
9714279|NCT04593329|Active Comparator|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 capsule tramadol, oral;~1 tablet dipyrone placebo, oral;~1 tablet Tiradentes association placebo, oral."
9714280|NCT04593433|Experimental|Intervention|Group with the virtual museum guided tours
9714281|NCT04593446|Experimental|Oral Sulfate Tablet(ORA·FANGⓇ)|Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery
9714282|NCT04593446|Active Comparator|Sodium Picosulfate Solution(PicosolutionⓇ)|Subjects who are randomized into experimental arm will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery
9980234|NCT01389661|Experimental|MSV treatment|MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
9980235|NCT01389674|Experimental|2D-strain echo|After myocard vitality diagnostics with MRI follows a stress echocardiography to determine the LV volumes and EF. The received Data are compare with the MRI-Data(reference)to identify the ideal strain-parameters and Cut-Off-Result for an intraprocedural vitality diagnostic of the different films (endocardial, myocardial and epicardial).
9714285|NCT04593511|Experimental|Formulation 1|a single dose of LY03009 F1
9714286|NCT04593511|Experimental|Formulation 2|a single dose of LY03009 F2
9714287|NCT04593511|Experimental|Formulation 3|a single dose of LY03009 F3
9714288|NCT04593511|Experimental|Formulation 4|a single dose of LY03009 F4
9714289|NCT04593160|Experimental|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
9714290|NCT04593160|Experimental|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
9714291|NCT04593160|Placebo Comparator|Placebo|Preoperative single dose of placebo
9714292|NCT04593186|Experimental|Trans-oral magnifying endoscopy with NBI|Transoral magnifying endoscopy with High Definition Upper Endoscope with Narrow Band Imaging enhancement (Olympus GIF-H290Z)
9714293|NCT04593485|Experimental|Cohort 1|patients with postoperative recurrence of malignant melanoma of the female genital tract requiring adjuvant therapy, Camrelizumab for injection
9714294|NCT04593485|Experimental|Cohort 2|patients with metastatic or unresectable malignant melanoma of the female genital tract, Camrelizumab for injection
9714295|NCT04593108||Letrozole misoprostol|"Group (A):~A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
9714296|NCT04593108||Misoprostol,placebo|"Group (B):~A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
9714297|NCT04592965|Experimental|Clinical and neuropsychological examinations|Participants will be assessed by means of validated and lab-tailored clinical scales, alongside with semi-structured interviews, to assess the status of the disease (PD), amongst others, such as cognitive capabilities.
9714298|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation|Participants will manipulate a patented robotic system designed to induce the PH and other accompanying bodily illusions. At the end, participants will report on various subjective experiences, by answering a structured questionnaire.
9714299|NCT04592965|Experimental|Resting-state fMRI acquistion|We will acquire resting-state data in the MRI scanner for all the participants. Respiration and heart beat rate data will also be acquired.
9980236|NCT01389687|Experimental|Study Group|
9980237|NCT01389713|Active Comparator|High doses|Administration of high doses of gonadotrophins to stimulate ovarian follicular growth
9980238|NCT01389713|Experimental|Clomid|Administration of Clomiphene Citrate to obtain ovarian follicular growth
9980239|NCT01389726|Experimental|Behavioral Parenting Training|Triple-P Parenting Training Program (group level)
9980240|NCT01389726|Experimental|Cognitive Behavioral Therapy|CBT group-level intervention (Designed by Larry Thompson & Dolores Gallagher Thompson)
9714300|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation (MRI)|All healthy participants, and all patients who are deemed capable of performing the robotic manipulation task in the MRI scanner, will take part on this arm. Participants will perform a robotic manipulation task, with a patented robotic system, capable of inducing the PH and other accompanying bodily illusions in the MRI scanner. At the end participants will report on the various subjective experiences, by answering a structured questionnaire.
9714301|NCT04593082||Pediatric MS Subjects|Subjects with pediatric MS will undergo fasting lab work, non-contrasted MRI, DEXA scan, and surveys.
9714302|NCT04593082||Healthy controls|Non-MS pediatric control subjects who will undergo fasting lab work, DEXA scan, and surveys for comparison to control group.
9714303|NCT04592952|Experimental|Single-Arm|"Provocation Phase: Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.~Open-Label Treatment Phase: Erenumab packed in a SureClick® Autoinjector Pen (AI)"
9714304|NCT04592796||Nursing-home residents|Older adults in a nursing-home who report a self-perception of poor sleep quality
10195666|NCT04767776|Experimental|Arm A|"Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)"
9714306|NCT04592900|Experimental|the control group|the control group Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and balance training exercises and gait training in open environment.
9714307|NCT04592900|Experimental|the virtual reality group|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
9714308|NCT04592900|Experimental|the Biodex Balance Training group|Group 3 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
9714309|NCT04593069|Other|COVID-19 patients|Neurocognitive impairment in COVID-19 patients
9714310|NCT04593030||Warfarin|Reference group
9714311|NCT04593030||Apixaban|Exposure group
9714312|NCT04592926|Experimental|Accuro ultrasound|
9714313|NCT04592926|Sham Comparator|Control|
9779596|NCT05160935|Experimental|Coronary Angiography Training Manual|It is the form prepared by the researchers in line with the literature information and the opinion of the specialist physician was taken. It contains information about coronary artery disease, what to do before coronary angiography procedure and what kind of situations await individuals after the procedure.
9779597|NCT05157113|Active Comparator|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
9779598|NCT05157113|Active Comparator|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
9779599|NCT05154136|Experimental|Etrumadenant then Etrumadenant + Itraconazole|"Participants will receive the Treatment A (etrumadenant) followed by Treatment B (etrumadenant + itraconazole).~A washout period of 5 days will be maintained between the two treatments."
9779600|NCT05152446|Experimental|Infusion management scheme|To implement infusion management scheme, then observe the continuous changes.
9779601|NCT05150197|Experimental|Patient (pathology) group|This group will perform both the standard of care Humphrey Visual Field (HVF) and the VisuALL Virtual Reality Visual Field.
9779602|NCT05150197|Other|Control group|This group will only perform the VisuALL Virtual Reality Visual Field.
9779603|NCT05144984|Experimental|2.4 mg semaglutide + 2.4 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
9779604|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
9779605|NCT05144984|Experimental|2.4 mg semaglutide + 7.2 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
9779606|NCT05144984|Experimental|2.4 mg semaglutide + 12.0 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
9779607|NCT05144984|Experimental|2.4 mg semaglutide + 21.6 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
9779608|NCT05144984|Experimental|NNC0480-0389 + placebo (semaglutide)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide)
9779609|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
9779610|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
9779611|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
9779612|NCT05144984|Experimental|Semaglutide 2.4 mg + placebo (NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide.
9779613|NCT05142046||Pediatric cardiac surgery|The group consists of all the children who undergo cardiac surgery in our institution from 2008 to 2018. The age limit was from birth to 16 years old.
9779614|NCT05132088|Experimental|oral semaglutide 50 mg once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
9714314|NCT04592588|Experimental|Common Elements Toolbox (COMET)|The Common Elements Toolbox is an online intervention consisting of modules from empirically supported treatments for common mental health problems.
9714315|NCT04592588|Sham Comparator|Wait-list control condition|
9714316|NCT04593004|Experimental|Teledermatology|
9714317|NCT04593004|Active Comparator|Face-to-face consultation|
9714318|NCT04592978|Experimental|Pain-Alcohol Personalized Feedback Intervention|
9714319|NCT04592978|Active Comparator|Control Personalized Feedback Intervention|
9714320|NCT04592601|Experimental|S.L.I.M.M.S. Procedure|Prospective collection of data on the safety and efficacy of the S.L.I.M.M.S. Procedure
9714321|NCT04592705|Experimental|Therapeutic plasma exchange|
9714322|NCT04592718|Experimental|Slow deep breathing plus breath counting|Participants in this group will do a daily 5-min slow deep breathing exercise (6 breaths/minute) and will also count their breaths
9714323|NCT04592718|Active Comparator|Normal-paced breathing plus breath counting|Participants in this group will do a daily 5-min normal-paced breathing (15 breaths/minute) and will also count their breaths
10195667|NCT04767776|Experimental|Arm B|"Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)"
9714324|NCT04592718|No Intervention|Control|Participants in this group will serve as a control and will not do any breathing exercises or breath counting.
9714325|NCT04592822|Experimental|Treatment T|30 minutes after the start of a standard breakfast, subjects will take one straw of WD-1602 Dabigatran Etexilate Mesylate Granules (150 mg) in 100 mL water as oral administration.
9714326|NCT04592822|Active Comparator|Treatment R|30 minutes after the start of a standard breakfast, subjects will receive a single Pradaxa® 150 mg capsule swallowed with 240 mL water as oral administration.
9714327|NCT04592679|Experimental|FES-C|
9714328|NCT04592679|Active Comparator|Standard|
9714329|NCT04592757|Experimental|Subacute stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
9714330|NCT04592757|Experimental|Chronic stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
9714331|NCT04593017|Experimental|Active Probiotic|Probiotic contain active microorganism
9714332|NCT04593017|Placebo Comparator|Placebo Probiotic|Probiotic with no active microorganism
9714333|NCT04592744|Experimental|Intervention|Patients assigned to the study group will receive Ang 2 infusion in addition to standard vasopressor regimen. Ang 2 is currently approved at UCLA as a second line vasopressor and will be used as such for the purposes of our study. Hemodynamic goals will be established at the beginning of the case by the anesthesiology and surgical teams. Ang 2 will be started as a second vasopressor once the norepinephrine dose has reached 0.05mcg/kg/min. Ang 2 will be initiated at a starting dose of 5ng/kg/min. That dose will be up titrated one time to 10ng/kg/min as vasopressor requirements escalate. Once a patient is on the 10ng/kg/min dose of ang 2, no additional up titration will be performed. Hemodynamic management will continue throughout the case with titration of other vasopressors as needed. Ang 2 will be continued throughout the intraoperative period but will be weaned off prior to leaving the operating room.
9714334|NCT04592744|Active Comparator|Control|Patients assigned to the control group will undergo intraoperative management with a standard vasopressor regimen composed of norepinephrine, vasopressin and epinephrine based on hemodynamic goals established by the surgical and anesthesia teams prior to surgery.
9980241|NCT01389726|Active Comparator|Psychosocial-Informational Support|Standard of Care informational support group
9714336|NCT04592614|Experimental|High dose|CTM-NS participants receiving monthly virtual group meetings for 2 years (24 meetings total)
9714337|NCT04592614|Experimental|Low dose|CTM-NS participants receiving quarterly virtual group meetings for 2 years (8 meetings total)
9714338|NCT04592627||Simulated home environment visit with the dyad participants|The cohort consists of six stroke survivor-informal caregiver (e.g., spouse or family member) dyads. Individual dyads will participate in the simulated home environment visit while the investigative team collects the data.
9714339|NCT04592770|Experimental|The experimental intervention (walk):|In this group, the nature walk will take place in a conserved and by far the largest recreational area of Karachi city. The safari park covering an area of 148 acres (0.60 km2), It has a zoo, geared with woodland, mountain viewing, safari tracks, as well as two natural lakes. The experiment will take place in the afternoon on a 5 km marked area. The duration of the stretching exercise sessions will be of 10 minutes followed by 50 minutes' walk session five times per week (total 12 weeks). participants will be asked to walk at moderate pace.
9714340|NCT04592770|Placebo Comparator|The control intervention (sit & relax):|Subjects will undergo 12 weeks of nature therapy that includes exposure to natural landscapes. The duration of the sessions will be 60 minutes five times per week. The subjects will be asked to sit and relax in the evening, in the same recreational area which is used for the experimental group.
9714341|NCT04592666|Experimental|Combinational therapy|
9714342|NCT04592666|Active Comparator|Single TKI|
9714343|NCT04592640|Experimental|Uremic Calciphylaxis Patients|Human amniotic mesenchymal stem cells (hAMSCs)
9714344|NCT04593056||Warfarin|Reference group
9714345|NCT04593056||Rivaroxaban|Exposure group
9714346|NCT04592939|Other|Group 1: immediate weight bearing|
9714347|NCT04592939|Other|Group 2: 6 week toe touch weight bearing|
9714348|NCT04592549|Experimental|Cohort 1: Low dose IM injection of active drug or placebo|"Subjects in cohort 1 will receive a low dose IM injection of either active drug or placebo.~Cohort 1 will dose 8 subjects to active drug and 2 subject to placebo"
9779615|NCT05132088|Placebo Comparator|oral semaglutide placebo once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
10195668|NCT04767776|Experimental|Arm C|"Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 6 milligram of activated charcoal ~Washout period (6 days)"
9714349|NCT04592549|Experimental|Cohort 2: High dose IM injection of active drug or placebo|"Subjects in cohort 2 will receive a high dose IM injection of either active drug or placebo.~Cohort 2 will dose 8 subjects to active drug and 2 subject to placebo."
9714350|NCT04592549|Experimental|Cohort 3: High Dose IM injection of active drug or placebo|"Subjects in cohort 3 will receive a high dose IM injection of either active drug or placebo.~Cohort 3 will dose 8 subjects to active drug and 2 subject to placebo"
9714351|NCT04592549|Experimental|Cohort 4: High Dose IM injection of active drug or placebo|"Subjects in cohort 4 will receive a high dose IM injection of either active drug or placebo.~Cohort 4 will dose 8 subjects to active drug and 2 subject to placebo"
9714352|NCT04592653|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via Intravenous (IV) infusion given daily for 5 consecutive days followed by an off-treatment period. Starting on Cycle 3, Day 1 of each cycle, Pembrolizumab will be administered via IV infusion followed by IV infusion of ALKS 4230.
9714353|NCT04592835|Experimental|Cohort 1 (288mg)|72 mg/0.3 mL x 4 injection sites
10195669|NCT04767776|Experimental|Arm D|"Period  rivaroxaban and 24 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 50 milligram of activated charcoal ~Washout period (6 days)~Period  rivaroxaban and 12 milligram of activated charcoal ~Washout period (6 days)"
10195670|NCT04765956|Experimental|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
9714354|NCT04592835|Experimental|Cohort 2 (576 mg)|144 mg/0.6 mL x 4 injection sites
9714355|NCT04592835|Experimental|Cohort 3 (960 mg)|216 mg/1.0 mL x 4 injection sites
9714356|NCT04593043||Warfarin|Reference group
9714357|NCT04593043||Dabigatran|Exposure group
9714358|NCT04592328||Patients planned for elective open cardiac surgery|
9714359|NCT04592211|Experimental|olaparib+pembrolizumab+paclitaxel|
10195671|NCT04761523|Active Comparator|Reduced fat arm|Daily calorie intake will be composed of 15% fat, 65% carbohydrates, 20% proteins
9714360|NCT04592263||Group 1 - Qualitative phase|4 focus groups and 6 semi-structured interviews.
9714361|NCT04592263||Group 2 - Quantitative phase|Pilot study of the tools developed from phase 1.
9714362|NCT04592159|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Each spray delivers 100 microliters (μL) of nabiximols.
9714363|NCT04592159|Placebo Comparator|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 8 weeks.
9714364|NCT04592393|Experimental|Abbreviated PB MRI|Short and Focused non-contrast MRI for surveillance
9714365|NCT04592302||Smoking Cessation Group|participants are required to cease smoking for 4 weeks prior to and 2 weeks after TJA without any nicotine replacement (any other smoking cessation aids the patient chooses will be allowed)
9714366|NCT04592302||Smoker Group 2|participants who are allowed to continue smoking and using nicotine in any form at their own discretion during the perioperative period
9714367|NCT04592419|Experimental|KSI-301 (Arm A)|"Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 to Week 44.~In the Extension Phase, participants randomized to KSI-301 (5 mg) in the Primary Study will continue to receive KSI-301 (5 mg) based on protocol-defined disease activity criteria."
9714368|NCT04592419|Active Comparator|Aflibercept (Arm B)|"Intravitreal injection of aflibercept (2 mg) once every 4 through Week 20 followed by an individualized dosing regimen of Intravitreal injection of Aflibercept (2 mg) once every 4 weeks from Week 24 to Week 44.~In the Extension Phase, participants randomized to aflibercept in the Primary Study will cross over to treatment with KSI-301 (5 mg). They will receive their first dose of KSI-301 (5 mg) at Week 48 and will receive additional treatment with KSI-301 (5 mg) based on protocol-defined disease activity criteria."
9714369|NCT04592146|Active Comparator|Control group|Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.
9714370|NCT04592146|Experimental|Intervention group|"Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person.~As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected."
9714371|NCT04592276|Experimental|PS128|Each PS128 capsule contained 3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg .
9714372|NCT04592276|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
10195672|NCT04761523|Active Comparator|Standard healthy diet arm|Daily calorie intake will be composed of 30% fat, 50% carbohydrates and 20% proteins.
10195673|NCT04756765|Experimental|Talazoparib Arm|Talazoparib 1 mg/day for 24 cycles (28 days per cycle), continuing until withdrawn or discontinued, eg, until RECIST 1.1 progression or unacceptable toxicity.
9714373|NCT04592315|Experimental|1|Dose 5 mg
9714374|NCT04592315|Experimental|2|Dose 10 mg
9714375|NCT04592315|Experimental|3|Dose 20 mg
9714376|NCT04592315|Experimental|4|Dose 40 mg
9714377|NCT04592315|Experimental|5|Dose 60 mg
9714378|NCT04592315|Experimental|6|Dose 80 mg
10195674|NCT04753970|Experimental|Cilostazol|Cilostazol 100mg BID
10195675|NCT04753970|No Intervention|No intervention|
10195676|NCT04752488|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
10195677|NCT04752488|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
10195678|NCT04749017|Experimental|Experimental group|Avena Sativa L. consumption of 900 mg for 60 days.
10195679|NCT04749017|Placebo Comparator|Control group|Identically appearing placebo capsules consumed for 60 days.
9714379|NCT04592380|Experimental|Stage 1: Clevidipine (double-blinded)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Clevidipine will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter per the Food and Drug Administration (FDA) approved clevidipine label, to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
9714380|NCT04592380|Placebo Comparator|Stage 1: Placebo (double-blinded)|Placebo will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Placebo will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter according to the same dosing instructions as for clevidipine to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
9714381|NCT04592380|Experimental|Stage 2: Clevidipine (open-label)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in an open-label fashion intravenously to all patients randomized to the clevidipine arm in Stage 2, following the same dosing instructions as in the clevidipine arm in Stage 1. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
9714382|NCT04592380|Active Comparator|Stage 2: Standard of Care (open-label)|For patients randomized to SOC, the infusion must be continuous, administered per the institution's treatment practice, and dose titration must be performed to a maximum allowed or maximum tolerated dose to achieve target SBP. If treatment with an alternative IV anti-hypertensive agent is required, the patient will be transitioned to an alternative IV antihypertensive agent according to the institutional standard of care.
9714383|NCT04592523||All Participants|Participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who initiate treatment for the first time with brigatinib in a routine clinical practical setting will be observed prospectively for up to 24 month-surveillance period.
9714384|NCT04592497|Experimental|QDOT|will undergo the AF ablation procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system
9714385|NCT04592497|Active Comparator|standard|will undergo the AF ablation procedure with assistance standard Thermocool Smartouch SF system
10195680|NCT04744051|Active Comparator|50 million cell infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
9714386|NCT04592198|Experimental|A (Buccal 0.25 Mg)|Palonosetron HCl Buccal Film 0.25 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
9714387|NCT04592198|Experimental|B (Buccal 0.5 Mg)|Palonosetron HCl Buccal Film 0.5 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
9714388|NCT04592198|Active Comparator|C (IV Injection 0.25 Mg)|IV palonosetron 0.25 Mg (ALOXI®) and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
9714389|NCT04592471||Orthosis Group 1|Use of kneeMID500 device
9714390|NCT04592471||Control Group 1|Control Group of the kneeMID500 Orthosis Group - No use of the device
9714391|NCT04592471||Orthosis Group 2|Use of kneeSTRONG700 device
9714392|NCT04592471||Control Group 2|Control Group of the kneeSTRONG700 Orthosis Group - No use of the device
9714393|NCT04592458|Experimental|Experimental|10 transfusion dependent β-thalassemia major subjects who are 8-16 years older will be transplanted with β-globin restored autologous hematopoietic stem cells that are modified with lentiviral vector LentiHBBT87Q encoding the human β-globin gene.
9714394|NCT04592172|Experimental|Bedtime Routine Education|50 families will be randomly assigned to receive the bedtime routine intervention, 3 Cs for Bedtime ZZZs delivered by research assistants at the 12-month and 15-month well-child visits, in additional to receiving usual clinical care. The intervention will take approximately 30-45 minutes to implement at each study visit. Research assistants will be trained and supervised by board-certified Behavioral Sleep Medicine providers. This intervention focuses on developing an individualized bedtime routine, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling, based on parent's preferences. Families will receive appropriate materials for their bedtime routine, including a CuddleBright kit, bedtime books, toothbrush/toothpaste, and the created bedtime chart to take home.
9714395|NCT04592172|No Intervention|Control group|50 families will be randomly assigned to control group (usual care).
9779616|NCT05128955|Active Comparator|Active Comparator: Splenic artery embolization with vascular embolic coils|Device: Splenic artery embolization with vascular embolic coils
10195681|NCT04744051|Active Comparator|150 million cell infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
10195682|NCT04744051|Active Comparator|300 million cell infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
9714396|NCT04592432|Experimental|SIGN@L-A followed by SIGN@L-B|"Participants in this arm will have access to the prototype SIGN@L-A of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-B."
10195683|NCT04744051|Placebo Comparator|Placebo|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
9714397|NCT04592432|Experimental|SIGN@L-B followed by SIGN@L-A|"Participants in this arm will have access to the prototype SIGN@L-B of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-A."
9714398|NCT04592354|Active Comparator|Oxaloacetate Therapeutic Arm|"Anhydrous Enol-Oxaloacetate~A 500 mg oxaloacetate capsule taken by mouth twice a day~Planned study duration is 6 weeks with an interim assessment at the end of 2 weeks and final assessment at 6 weeks"
9714399|NCT04592354|Placebo Comparator|Placebo Arm|"Rice Flour~A 500 mg rice flour capsule taken by mouth twice a day"
10195684|NCT04740775|Experimental|LiquiBand Exceed|Surgical wound closure using the LiquiBand Exceed Topical Skin Adhesive
10195685|NCT04734977|Experimental|HILT+exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
10195686|NCT04734977|Sham Comparator|Sham HILT+exercise|Sham therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
9714400|NCT04591990|Experimental|AVP + placebo hydrocortisone|REVERPLEG® 40 IU/2mL+ Placebo of hydrocortisone.
9714401|NCT04591990|Experimental|placebo AVP + hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
10195687|NCT04734977|Active Comparator|Exercise only|Exercise program was applied in five sessions a week for four weeks, with a total of 20 sessions a day.
9714402|NCT04591990|Experimental|AVP + hydrocortisone|REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
9714403|NCT04591990|Experimental|placebo AVP + placebo hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + placebo of hydrocortisone
9714404|NCT04592068||Retinal multi-diseases diagnosed by DL algorithm|
9714405|NCT04592068||Retinal multi-diseases diagnosed by expert panel|
9714406|NCT04591899|Experimental|CAD/CAM SS|
9714407|NCT04591899|Active Comparator|Conventionally manufactured SS|
9714408|NCT04592120|Experimental|Coalition Check-Up|The 4-step Coalition Check-Up technical assistance process provides proactive data-driven continuous quality improvement cycles. Step 1 assesses critical dimensions of the coalition's capacity and program implementation. A coalition profile based on assessment data is reviewed in step 2. Here the technical assistance provider works with the coalition to consider several dimensions of coalition capacity and program implementation, celebrating strengths and prioritizing weaknesses. Once priorities are set, the technical assistance provider uses structured action planning in step 3 to help coalition members establish consensus on how to improve prioritized weaknesses. In step 4, technical assistance providers review and support progress on action plan implementation with the coalition. Efforts are evaluated a year after the initial assessment in a continuous quality improvement cycle.
9714409|NCT04592120|No Intervention|Technical assistance as usual|Coalitions in the comparison condition will receive a feedback report but no additional support from technical assistance providers beyond what is already available to them.
9714410|NCT04592081|Experimental|DEXTENZA placed within the upper canaliculus|Dextenza placed within the upper canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
9714411|NCT04592081|Active Comparator|DEXTENZA placed within the lower canaliculus|Dextenza placed within the lower canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
9714412|NCT04591873||Critical patients in the emergency department|
9714413|NCT04591938|Other|Single arm|Fantom Encore Bioresorbable scaffold implantation
9714414|NCT04591704||Diabetic groups|COVID-19 patients with diabetes mellitus
9714415|NCT04591704||Control groups|COVID-19 patients without diabetes mellitus
9714416|NCT04591756|Active Comparator|N95 Filtering Facepiece Respirator|Subjects will wear the model of filtering facepiece respirator that they are currently approved to wear
9714417|NCT04591756|Active Comparator|Elastomeric Half-Mask Respirator with P100 filters|Subjects will wear the model of elastomeric half mask respirator that they are currently approved to wear.
9714418|NCT04591795|Experimental|100 mg SHT extract|Drug: Sahastara remedy alcoholic extract comparison with diclofenac
9714419|NCT04591795|Experimental|25 mg dicolfenac|Drug: diclofenac comparison with diclofenac
9714420|NCT04591743|Experimental|Experimental group|
9714421|NCT04591743|Placebo Comparator|Placebo group|
9714422|NCT04591639|Other|Patients with heart failure without type 2 diabetes|60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
9714423|NCT04591639|Other|Patients with heart failure with type 2 diabetes|60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
9714424|NCT04592016|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
9714425|NCT04592016|Experimental|Pivotal Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 20 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
9714426|NCT04592029|Experimental|TACE-Sin-Bev|TACE combined with sintilimab and bevacizumab.
9714427|NCT04591977|Experimental|Self-Sampling Kit|Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
9714428|NCT04591964|Active Comparator|baseline|standard medical therapy + using of mobile application + improving therapy
9714429|NCT04591964|No Intervention|Control|standard medical therapy
9714430|NCT04592042|Experimental|Feel-Good-Group|Pre-post assessment of feasibility and putative efficacy of an emotion-oriented cognitive-behavioral group intervention over 8 sessions and four weeks.
9714431|NCT04591951|Active Comparator|I2-ART Group|I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
9714432|NCT04591951|Placebo Comparator|Control Group|"The caregivers in the control group will receive usual care."
9714433|NCT04591769|Experimental|Group T(Tapered- shaped)|Tracheal intubation using TaperedGuard Tracheal Tube
9714434|NCT04591769|Active Comparator|Group C(Cylindrical-shaped)|Tracheal intubation using Hi-Contour Tracheal Tube
9714435|NCT04592094|Experimental|Blueback® Physio|Classic protocole with the use of Blueback® Physio during physiotherapy sessions, , and using the Blueback® Physio in the active mode (patient and physiotherapists see the biofeedback in real time)during the tests required by the protocol of the study.
9714436|NCT04592094|No Intervention|Standard Care|Classic protocole without the use of Blueback® Physio during physiotherapy sessions, and using the Blueback® Physio in the blind mode during the tests required by the protocol of the study
9714437|NCT04591782|Experimental|PomJuice (PJ)|8 oz of PJ
9714438|NCT04591782|Active Comparator|Sugar Water|8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
9714439|NCT04591782|Other|Water|8 oz of water
9714440|NCT04591652|Experimental|99mTc-MIRC208 SPECT/CT scan|The cancer patients will be injected with14.8 MBq/kg body weight, and 2h later, SPECT/CT scan will be performed.
9714441|NCT04591730||Type I maternity|Fathers who experienced a first childbirth in a type I maternity in Lorraine.
9714442|NCT04591730||Type II maternity|Fathers who experienced a first childbirth in a type II maternity in Lorraine.
9714443|NCT04591730||Type III maternity|Fathers who experienced a first childbirth in a type III maternity in Lorraine.
9714444|NCT04591847|Experimental|Vitamin D supplemented group|Vitamin D2 20000 IU 1 tab oral weekly start at GA 18 -22 weeks until delivery
9714445|NCT04591847|Experimental|Placebo group|Placebo drug (Appearance same as Vitamin D2) 1 tab oral weekly start at GA 18 -22 weeks until delivery
9714446|NCT04591548||Endometriosis|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
9714447|NCT04591548||Primary infertility|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
9714448|NCT04591678||SMA nusinersen adult cohort|"The nusinersen treatment will be given as standard of care. The treatment (which is NOT research, but the standard care) will be given by an injection into the cerebrospinal fluid (fluid in your spine) through a needle inserted into your lower back. Participants will receive a 12 mg (5 mL) dose during each administration/injection, which will occur on the following days: 1 (baseline), 15, 29, and 60. Following the 60 day treatment, participants will receive treatment every 4 months (6, 10, 14 etc.).~After the 60 day, 6 month, 10 month, 14 month, 18 month and 22 month treatments the study team will see each participant afterwards to collect information to evaluate your general health, function and response to the treatment for the study."
9714449|NCT04592133||Scoliosis Patients|
9714450|NCT04592133||Control Group|
9714451|NCT04591535|Experimental|WD-1603 (tablet strength 1) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 1) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
10195688|NCT04727242|Experimental|Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine|"Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine followed by postoperative systemic chemotherapy with dacarbazine. Conceptually, HIPEC will be administered as a 60 minute heated intraperitoneal infusion (ie, intraperitoneal wash or lavage).~HIPEC: Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.~Systemic adjuvant chemotherapy starting 30 days ± 14 days post surgery. Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles"
10195689|NCT04724447|Experimental|Valganciclovir|900 milligrams (mg) valganciclovir (VGCV) to be taken orally once per day for 8 weeks.
10195690|NCT04724447|Placebo Comparator|Placebo|Placebo equivalent of 900 milligrams (mg) VGCV to be taken orally once per day for 8 weeks.
9714452|NCT04591535|Experimental|WD-1603 (tablet strength 2) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 2) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
10195691|NCT04718922|Experimental|Experimental Arm|Mouthrinse with 100 ml 0.12% chlorhexidine for 1 min
10195692|NCT04718922|No Intervention|Control Arm|No mouthrinse
9714453|NCT04591535|Experimental|WD-1603 (tablet strength 3) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 3) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
9714454|NCT04591535|Experimental|WD-1603 (tablet strength 4) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 4) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
9714455|NCT04591613|Other|Standardized clinical and paraclinical follow-up|"Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format.~All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.~Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.~Total serum, plasma and naso-paaryngeal samples will be collected."
9714456|NCT04591496|Experimental|SmartFeeding4Kids|SmartFeeding4Kids: information about children's healthy diet and effective parental feeding practices, with a behavioral intervention (5 sessions plus 2 brief booster sessions online intervention)
9714457|NCT04591496|Active Comparator|SmartFeeding4Kids Health|Psychoeducational condition: information about children's healthy diet and effective parental feeding practices (5 sessions plus 2 brief booster sessions online intervention)
9714458|NCT04591444|Active Comparator|ClinproTM White Varnish|"Application of ClinproTM White Varnish containing sodium fluoride (5%) and Tricalcium phosphate (TCP).~A technology that allows calcium and phosphate ions to coexist with fluoride ions separately, forming a more resistant mineral on the tooth surface (3M ESPE Clinpro White Varnish; 3M ESPE Clinpro 5000)."
9714459|NCT04591444|Active Comparator|ClinproTM XT Varnish|"Application of ClinproTM XT Varnish, a resin-modified glass ionomer sealant.~Creates a protective layer on exposed dentin, which is durable and has the ability to release fluoride, calcium and phosphate into the surroundings. (3M ESPE Clinpro XT Varnish)."
9714460|NCT04591444|Placebo Comparator|Placebo Group|Participants who were part of the placebo group continuously used only the conventional toothpaste provided in the oral hygiene kit during the initial four weeks of the research and received a simulated treatment.
9714461|NCT04591457|Experimental|Insulin Glargine Sansulin|Drug product Insulin Glargine, Sansulin Log-G 100 IU/mL (PT. Sanbe Farma)
9714462|NCT04591457|Active Comparator|Insulin Glargine Lantus|Drug product Insulin Glargine, Pen Injector [Lantus] 100 IU/mL (PT. Sanofi-Aventis)
9714463|NCT04591574|Other|Intervention Group|All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital.
9714464|NCT04591574|Active Comparator|Usual care group|Current usual care transfusion practice, namely single RBC transfusions when Hb 70g/L or less (or modified according to clinician decision) to achieve target Hb 70-90g/L. HB measured at least weekly in hospital
10195693|NCT04710732|Active Comparator|Control|Peri-operative VTE prophylaxis with a standard once-daily dose of enoxaparin 40 mg and anti-embolic stockings
10195694|NCT04710732|Experimental|Experimental|Peri-operative VTE prophylaxis with an escalated twice-daily dose of enoxaparin 30 mg and anti-embolic stockings
9714465|NCT04591470||General population|
9714466|NCT04591470||Pazients undergone inguinal hernia correction|
9714467|NCT04591587|Active Comparator|Smile Group|Twenty patients (20) underwent SMILE surgery (first group)
9714468|NCT04591587|Active Comparator|Lenticule Group|Twenty patients (20) underwent lenticule implantation (second group)
9714469|NCT04591522|Experimental|FMT group|Patients were carried by fecal microbiota transplantation which described in detail that fecal bacteria are extracted from the faeces of healthy people and poured into the intestines of patients.
10195695|NCT04709601|Experimental|Group 1 - Patients with negative and positive urine culture|
10195696|NCT04697667|Experimental|Group I|Each subject in this group will receive a combined treatment protocol consisting of three PRP injections to knee joint and supervised exercise program.
10195697|NCT04697667|Active Comparator|Group II|Each subject in this group will receive a treatment of supervised exercise program.
10195698|NCT04697667|Active Comparator|Group III|Each subject in this group will receive a treatment of three PRP injections to knee joint.
10195699|NCT04694287||Volume flow group|The study will include consecutive patients undergoing standard fluoroscopically-guided percutaneous balloon angioplasty due to dysfunctional AVF. Intraprocedural volume flow measurements will be obtained just prior to the procedure and after final balloon dilation.
9714470|NCT04591522|No Intervention|control group|
10195700|NCT04691661|Placebo Comparator|Placebo: Dose escalation|Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
10195701|NCT04691661|Experimental|Radotinib HCl: Dose escalation|"Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.~The inclusion of subjects in the next dose level will be decided by the sponsor in consultation with a Data Monitoring Committee (DMC)."
9714471|NCT04591236|Experimental|Gait training with brain stimulation|Treadmill gait training and transcranial direct current stimulation (tDCS) on the leg motor areas
9714472|NCT04591236|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
9714473|NCT04591314|Experimental|Neurofeedback participants|All the participants studied.
9714474|NCT04591327||general anesthesia|
9714475|NCT04591327||spinal anesthesia|
9714476|NCT04591132|Experimental|kinematic analysis|each patient with a diagnosis of parkinsonism, ataxia, chorea, dystonia or tremor will be asked to perform some motor tasks routinely used in clinical evaluation wearing inertial sensors.
9714477|NCT04591171|Experimental|n-of-1 trial guided clinical decision making|
10195702|NCT04689529|Experimental|Breast cancer patients undergoing mastectomy after neoadjuvant chemotherapy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) after receiving neoadjuvant chemotherapy
10195703|NCT04689529|Active Comparator|Breast cancer patients without neoadjuvant chemotherapy and undergoing mastectomy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) even in patients who did not receive neoadjuvant chemotherapy as a control group.
9714478|NCT04591340||test group|all the patients treated with HSCT are with nutrition risk, so they will be all included to accept nutrition therapy.
9714479|NCT04591288|Experimental|FES + Treadmill|Functional Electrical stimulation walking group.
10195704|NCT04688294|Experimental|Sacubitril/valsartan|Group 30 patients will undergo treatment with sacubitril/valsartan combination according to guideline-directed medical therapy.
10195705|NCT04688294|Active Comparator|Valsartan|Group 30 patients will undergo treatment with valsartan according to guideline-directed medical therapy.
9714480|NCT04591288|Active Comparator|Treadmill only|Treadmill walking group (no electrical stimulation).
9714481|NCT04591288|No Intervention|Control|"Control group.~After control period of 12 weeks, they are randomized into FES + Treadmill or Treadmill group."
9714482|NCT04591418|Active Comparator|Rotary handpieces|
9714483|NCT04591418|Experimental|Er:YAG laser|
9714484|NCT04591275|Experimental|CMAB807|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
9714485|NCT04591275|Active Comparator|Prolia®|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
9714486|NCT04591145||Observational group|Patients received bowel preparation and colonoscopy. The withdrawal phase video was saved and their lesions detection was record.
9714487|NCT04591093|Active Comparator|CI with FineHearing with 10 more apical electrodes activated then 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated first during 1 month then FineHearing Strategy with 10 more basal electrodes activated during 1 month
10195706|NCT04679402|Experimental|Respiratory Muscle Training Breathing Low Dose Carbon Monoxide|Carbon monoxide 200 ppm in air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe the experimental gas through a mouthpiece with nose-clip in place.
9714488|NCT04591093|Active Comparator|CI with FineHearing with 10 more basal electrodes activated then 10 more apical electrodes activated|Cochlear implant with FineHearing Strategy with 10 more basal electrodes activated first during 1 month then FineHearing Strategy with 10 more apical electrodes activated during 1 month
9779617|NCT05128955|Active Comparator|Active Comparator: Splenic artery embolization with vascular embolic plugs|Active Comparator: Splenic artery embolization with vascular embolic plugs
9779618|NCT05124184||PAD Cohort|Patient was treated for peripheral arterial disease or peripheral arterial aneurysm requiring bypass treated with GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
9779619|NCT05124184||AAA Cohort|Patient underwent simultaneous or staged aortic aneurysm repair (open surgical AAA or TAAA) involving a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft
9779620|NCT05124184||Dialysis Access Cohort|Patient required the creation of a vascular access graft for hemodialysis secondary to a diagnosis of End-Stage Renal Disease using a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
9779621|NCT05122585|Experimental|Prospective MagTrace patients|All prospective patients will receive a MagSeed in the diagnosed breast cancer tumor. In addition, they will receive MagTrace to detect the sentinel lymph node during surgery. Since this is an experimental study, the patients will also be injected with the golden standard of Technetium tracer.
9779622|NCT05117554|Experimental|AB521 Dose 1|"Participants will receive Dose 1 of AB521 orally with water under fasting conditions."
9779623|NCT05117554|Experimental|AB521 Dose 2|"Participants will receive Dose 2 of AB521 orally with water under fasting conditions."
9779624|NCT05117554|Experimental|AB521 Dose 3|"Participants will receive Dose 3 of AB521 orally with water under fasting conditions."
9779625|NCT05117554|Experimental|AB521 Dose 4|"Participants will receive Dose 4 of AB521 orally with water under fasting conditions."
9779626|NCT05117554|Placebo Comparator|Placebo|Participants will receive matching placebo orally with water under fasting conditions.
10195707|NCT04679402|Sham Comparator|Respiratory Muscle Training Breathing Air|Air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe air through a mouthpiece with nose-clip in place.
10195708|NCT04675515|No Intervention|Usual Tobacco Treatment|All individuals who are identified as tobacco users are offered tobacco treatment which includes proactive, as needed, contacts via in person, telehealth or telephone visits. for tobacco treatment, pharmacotherapy as indicated, and Quitline and SmokefreeTXT referrals
10195709|NCT04675515|Experimental|Intensive Tobacco Treatment|"Patients who consent to study participation will meet with a tobacco treatment specialist in-person initially, then biweekly via telephone or telehealth or face-to-face (or more frequently as needed). They will receive tobacco treatment counseling and support from certified tobacco treatment specialist, which may include pharmacotherapy as indicated. At enrollment, participants will undergo carbon monoxide testing using a carbon monoxide monitor. At baseline, participants will complete the Fagerström Test for Nicotine Dependence, and the Cancer Patient Tobacco Use Questionnaire (C-TUQ).~These tobacco related survey measures will be completed at 3 additional time points: 30 days, 3 months and 6 months."
9714489|NCT04591600|Experimental|Ivermectin-Doxycycline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
9714490|NCT04591600|Active Comparator|Control|Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.
9714491|NCT04591301|Experimental|HEC113995 PA•H2O 2.5mg|Healthy subjects are given HEC113995 PA•H2O 2.5 mg in a single dose.
9714492|NCT04591301|Active Comparator|HEC113995 PA•H2O 5mg|Healthy subjects are given HEC113995 PA•H2O 5 mg in a single dose.
9714493|NCT04591301|Active Comparator|HEC113995 PA•H2O 10mg|Healthy subjects are given HEC113995 PA•H2O 10 mg in a single dose.
9714494|NCT04591301|Active Comparator|HEC113995 PA•H2O 20mg|Healthy subjects are given HEC113995 PA•H2O 20 mg in a single dose.
9714495|NCT04591301|Active Comparator|HEC113995 PA•H2O 40mg|Healthy subjects are given HEC113995 PA•H2O 40 mg in a single dose.
9714496|NCT04591301|Active Comparator|HEC113995 PA•H2O 60mg|Healthy subjects are given HEC113995 PA•H2O 60 mg in a single dose.
9714497|NCT04591301|Active Comparator|HEC113995 PA•H2O 80mg|Healthy subjects are given HEC113995 PA•H2O 80 mg in a single dose.
9714498|NCT04591301|Placebo Comparator|placebo|Healthy subjects are given placebo in a single dose.
9714499|NCT04591262|Experimental|PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV|PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.
9714500|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
9714501|NCT04591405|Placebo Comparator|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
9714502|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
9714503|NCT04591405|Placebo Comparator|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
9714504|NCT04591158|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
9714505|NCT04591210|No Intervention|No Treatment (Standard of Care)|Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.
9714506|NCT04591210|Experimental|ACEi treatment|The physician will initiate any ACE inhibitor and dose at their discretion.
9714507|NCT04591210|Experimental|ARB treatment|The physician will initiate any ARB and dose at their discretion.
9714508|NCT04591223|Experimental|TAU + six weekly sessions of competency-based module (CbM)|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider as well as a well-designed, one on one structural physical workout module to be offered by a licensed senior physical trainer in public sports ground or gymnasium.
9714509|NCT04591223|No Intervention|TAU|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider.
9714510|NCT04591379|Experimental|Intervention arm|
9714511|NCT04590989|Experimental|Personalized Plan (PP)|"Each subject in the PP group will be allocated to one of five clusters based on their metabolic and genetic health biomarkers from samples of urine, plasma, serum, and saliva. 58 biomarkers will be included to characterize the 5 metabolic clusters/processes in the PREVENTOMICS platform: 1) oxidative stress; 2) inflammation; 3) carbohydrate metabolism; 4) lipid metabolism; 5) microbiota-generated metabolites. Eurecat Nutrition Team has prepared a list of recommended food items to increase and food to exclude/limit from the diet for each cluster. The list will be adopted by Simple Feast in creating five different menus that will encompass the 12 meals/week of breakfasts and dinners for the five different metabolic clusters. Additionally, subjects will receive personalized actionable Do's push notifications by ONMI. The messages are personalized based on user reports from the behavioral questionnaire at V2 in addition to inputs from the nutritional recommendations of food to increase."
10195710|NCT04674384|Active Comparator|Intermittent Low Energy Diet (ILED)|
10195711|NCT04674384|Active Comparator|Continuous Low Energy Diet (CLED)|
10195712|NCT04672460|Experimental|Sequence 1|Participants receive Treatment B for 28 days, followed by Treatment A for 21 days, followed by Treatment C for 21 days.
10195713|NCT04672460|Experimental|Sequence 2|Participants receive Treatment A for 28 days, followed by Treatment B for 21 days, followed by Treatment C for 21 days.
9714512|NCT04590989|Placebo Comparator|Control Group|"Dietary intervention:~The second group of 50 subjects will receive meals from Simple Feast, after integrating their metabolic profile and other blood biomarkers by PREVENTOMICS, which are based on the national dietary guidelines.~Behavioral intervention:~Subjects will also receive nudges, after filling out ONMI's behavioral questionnaire at V2, but that will not be personalized (i.e. basic information that is available online from NHS and WHO)."
9714513|NCT04591184|Experimental|Active Covigenix VAX-001|Dose-ranging, 2 dose levels. 24 subjects receiving active i.m. vaccine
9714514|NCT04591184|Placebo Comparator|Placebo|Placebo injection. 12 subjects receiving placebo
9714515|NCT04590742|Placebo Comparator|Group 1|Placebo Tablet
9714516|NCT04590742|Active Comparator|Group 2|Melatonin (6mg)
10195714|NCT04671875|Experimental|MIL93|
9714517|NCT04590976||Healthcare Professionals (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
9714518|NCT04590976||Stage 1 (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
9714519|NCT04590976||Stage 2 (n = 10)|"Intervention: Single, Think Aloud Interview Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed."
9714520|NCT04590976||Stage 3 (n = 300)|Intervention: Single, Discrete Choice Experiment Questionnaire at Enrollment Visit
9714521|NCT04590599|Experimental|Placebo+Sintilimab|
9714522|NCT04590599|Experimental|IBI310+Sintilimab|
9714523|NCT04590729|Experimental|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
9714524|NCT04590729|Experimental|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 15 minutes for 3 hours to match the total exercise duration in the first protocol.
9714525|NCT04590729|No Intervention|Sitting|Sitting control.
9714526|NCT04590638|Active Comparator|Tumescent with adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution containing adrenaline.
9714527|NCT04590638|Active Comparator|Tumescent without adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution not containing adrenaline.
9714528|NCT04590950||Single-group study|Severe haemophilia B patients substituted with eftrenonacog-alfa
9714529|NCT04590898||significant peri-device leakage after LAA occlusion|Peri-device leakage closure after left atrial appendage occlusion
9714530|NCT04590846|Experimental|Constipation Health Education|"Health education leaflets are distributed once a week, and students are asked to bring it back to their parents to read. The activity of seeing leaflets, accumulating points, and redeeming prizes is adopted. a reply slip is designed in the weekly health education content, containing 3-5 test questions. Parents need to complete the answers and sign after reading the health education content. Those who have a high degree of correctness and fully paid in within 4 weeks will receive additional points. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. The points of the parent health education receipt and the points of the children will be combined and calculated, and the weight will be set according to the total number of points for the draw."
9714531|NCT04590846|Active Comparator|General Health Course|"In order to correctly evaluate the effectiveness of health education intervention, only the parents of the experimental group will receive the health education leaflet during the intervention period. However, after the end of the trial, an electronic file of parental health education in the control group will be provided. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. After the children's points are counted, a lottery will be drawn based on the total number of points. Since the experimental group and the control group have different benchmarks for points, the lottery will be drawn separately from each school. During the lottery process, the time will be announced in advance, and the number will be randomly selected by the computer in a live broadcast method."
9714532|NCT04590677||Group 1|Pregnant women at 36 weeks gestational age, who are not expected to have risk factors for preterm birth, n=150.
9714533|NCT04590677||Group 2|Pregnant women who have presented with signs and symptoms of threatened preterm labour (e.g. ruptured membranes, contractions, bleeding), at or after 24 weeks gestation, n=50.
9714534|NCT04590807|Active Comparator|Posterior spinal fusion with pedicle screws|
9714535|NCT04590807|Active Comparator|Anterior vertebral body tethering|
9714536|NCT04590859||Penile block|Patients undergoing procedure with penile block
9714537|NCT04590859||caudal block|Patients undergoing procedure with caudal block
9714538|NCT04590755|Experimental|Interactive father-child sessions and use of website|Intervention group will receive the Run Daddy Run intervention.
9714539|NCT04590755|No Intervention|No intervention (no interactive father-child sessions and use of website)|Intervention group will not receive the Run Daddy Run intervention.
10195715|NCT04669028|Experimental|NE3107|Hard gelatin capsule containing 20 mg micronized NE3107 drug substance blended with common excipients for oral formulations
10195716|NCT04669028|Placebo Comparator|placebo|Hard gelatin capsule containing only common excipients for oral formulations
10195717|NCT04666558|No Intervention|Standard Care|The standard of care response to COVID. Educational materials will be provided to patients via email. The package will include a combination of personalized exercises, and nutrition information for healthy eating. Participants will also receive a Garmin watch to track their activity over the intervention.
9714540|NCT04590703||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
9714541|NCT04590703||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
9714542|NCT04590937|Experimental|Reference|
9714543|NCT04590937|Experimental|BI 730357|
9714544|NCT04590768|Experimental|Fermotein™|daily lunch with 11 grams of Fermotein™ dry powder, mixed in bread, soup or a burger
9714545|NCT04590768|Active Comparator|Matched control products|daily lunch with a control bread matched in macronutrient content. Control meat alternative burgers and soup from the local supermarket.
10195718|NCT04666558|Experimental|App-Based, Personnel-Light Care|"An app-based, personnel-light approach to virtual care with a focus on support through group-based interactions with the Trainers, Dietitians and other participants. The patient's personalized 12-week home based exercise program will be enabled in the app after a baseline exercise specialist appointment. The 10-week nutrition program will be enabled at week 3 after a virtual dietitian assessment in week 2 (~1 hour). The home programs will auto-progress. Participants will also receive a Garmin watch to track their activity over the intervention."
10195719|NCT04666558|Experimental|App-Based, Personnel-Intensive Care|"An app-based, personnel-intensive approach to virtual care with support through a combination of group-based interactions with Trainers, Dietitians and other participants, as well as one-on-one support with Exercise Trainers and Dietitians. In addition to Group 2 features, patient interaction with Trainers will be via live group classes AND 1-to-1 sessions: up to seven 1-to-1 consultations with an exercise specialist and three 1-to-1 consultations with a dietitian to review progress and goals and make any necessary modifications to programming. Participants will also receive a Garmin watch to track their activity over the intervention."
9714546|NCT04590885|Other|Couple Communication and Support|CCST includes components to assist couples in communicating effectively, decreasing avoidance of important cancer-related issues, and providing each other with support. It includes training in skills for sharing one's thoughts and feelings and listening to one's partner and responding in a supportive manner, and joint problem solving. Participants will be asked to participate inactivities at home between sessions to strengthen skills acquisition.
9714547|NCT04590885|Other|Healthy Lifestyle Informaion|Healthy Lifestyle Information provides couples with health information relevant to cancer in a supportive environment. Sessions focus on the following topics: fatigue, sleep disturbance, nutrition, physical activity, survivorship care plans, and palliative care. Patients and partners are invited to discuss their experiences around the session topics with the therapist and ask questions about the information presented.
9714548|NCT04590820|Experimental|Tazemetostat + Rituxan|"Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1.~Rituximab will be administered by either Subcutaneous injection or IV infusion on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles."
9714549|NCT04590911|Experimental|CEP intervention|Cognitive Enrichment Program (CEP) : tailored for individuals who sustain a TBI in later adulthood. The CEP is a 12-week multimodal intervention structured into three modules designed to simultaneously address cognitive problems resulting from TBI, as well as age-related cognitive issues in the following domains: self-awareness, attention and memory, and executive functions.
9714550|NCT04590911|No Intervention|Usual care|Usual care : interventions within a holistic interdisciplinary rehabilitation program focused on resuming daily activities and social roles, if needed, as determined by treating physician; does not include any form of cognitive rehabilitation.
9714551|NCT04590573|Experimental|CBCT|Cognitive behavioural couple therapy (CBCT), 5-session
9714552|NCT04590573|Experimental|EFCT|Emotion focused couple therapy (EFCT), 5-session
9714553|NCT04590573|Active Comparator|Control|Social activity wait-list groups (Control), 5-session
9714554|NCT04590612|Active Comparator|Carbidopa-Levodopa|Patients will be randomized to any of the 2 arms. In Levodopa/carbidopa arm, patients will be taking Carbidopa-Levodopa (25-100mg) three times a day for the duration of the study.
9714555|NCT04590612|Experimental|Citalopram|Patients will be randomized to any of the 2 arms. In Citalopram arm, patients will be taking Citalopram (20mg) daily for the duration of the study.
9779627|NCT05115942|Experimental|Hydronidone group|Patients were given three capsules of hydronidone three times a day for 52 weeks.
10195720|NCT04663997|Experimental|177 Lu-PSMA-617|
10195721|NCT04663997|Active Comparator|Docetaxel|
9779628|NCT05115942|Placebo Comparator|The placebo group|Patients were given three capsules of placebo three times a day for 52 weeks.
9779629|NCT05108246|Experimental|Dual-Task Training|
9779630|NCT05108246|No Intervention|Control|
9779631|NCT05106296|Experimental|Treatment Regimen|Patients will be treated with the 4-drug chemo-immunotherapy regimen. Cycles are a minimum of 28 days, and maximum treatment duration is 12 cycles.
10195722|NCT04658693|Experimental|Multi contact electrode implant|"Ten subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
10195723|NCT04655300||Group 1|
10195724|NCT04655300||Group 2|
10195725|NCT04655300||Group 3|
10195726|NCT04655300||Group 4|
10195727|NCT04655300||Group 5|
10195728|NCT04655300||Group 6|
10195729|NCT04655001|Experimental|MORPH|Participants engage in 12 weeks of group and 1-on-1 coaching meant to promote physical activity throughout the day and caloric restriction. Participants engage with a custom smartphone application, use a smart scale and physical activity monitor, and meet using video conference software. At the end of 12 weeks, participants are provided with tools to continue meeting virtually on their own if desired, and will be followed for an additional 12-week maintenance phase.
10195730|NCT04655001|No Intervention|Control|This condition receives the wearable activity monitor and simply asked to use it and continue in their daily lives for 24 weeks.
10195731|NCT04651348|Experimental|MIL95|
10195732|NCT04649099|Experimental|Leaflex™ Performer|
10195733|NCT04646603|Experimental|MRG-001|Multiple SC dose of 0.0066 mL/kg MRG-001 (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
9714556|NCT04590625|Experimental|Group1|"Neoadjuvant therapy:~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~Neoadjuvant therapy is 3-4 cycles.After Neoadjuvant therapy will received interval cytoreductive surgery.~Adjuvant therapy:~After interval cytoreductive surgery,patients will received adjuvant therapy same as neoadjuvant therapy.~Adjuvant therapy is 3 cycles~maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
9714557|NCT04590625|Experimental|Group2|"1.Adjuvant therapy:~After primary cytoreductive surgery,patients will received adjuvant therapy:~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.~Adjuvant therapy is 3 cycles 3.maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
9714558|NCT04590560|No Intervention|1-year screening interval|Women will follow the normal screening program (they will be invited to screen every year)
10195734|NCT04646603|Placebo Comparator|Placebo|Single SC dose of 0.0066 mL/kg Sterile Injectable Saline (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
10195735|NCT04639089|Experimental|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure
9714559|NCT04590560|Experimental|2-year screening interval|Women will be invited to screen every two years
9714560|NCT04590560|Experimental|3-tailored screening interval|the screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C)
10195736|NCT04639089|Placebo Comparator|We will apply 10cm saline on the sternal edge before sternal closure|We will apply 10cm saline on the sternal edge before sternal closure
9714561|NCT04590378||Covid-19 Patients with Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
9714562|NCT04590378||Covid-19 Patients without Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.
9714563|NCT04590469|Experimental|WHELD training/virtual coaching programme supported with digital resources|WHELD training/virtual coaching programme supported with digital resources
10195737|NCT04636086|Experimental|Test treatment|Test Treatment: Ampoule for enteral use containing 25,000 IU/mL of cholecalciferol taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
10195738|NCT04636086|Placebo Comparator|Placebo treatment|Placebo Treatment: Ampoule of placebo for enteral use containing excipient only taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
9714564|NCT04590469|No Intervention|Treatment as Usual|Usual Best practice
9714565|NCT04590339|Active Comparator|Repositioning the bone window|Computer guided inferior alveolar nerve lateralization and implant placement with subsequent repositioning of the osteotomized bone window.
9714566|NCT04590339|Active Comparator|Augmentation using sticky bone|Computer guided inferior alveolar nerve lateralization and implant placement with grafting around the implant using sticky bone
9714567|NCT04590261|Other|group 1|Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment
9714568|NCT04590261|Other|Group 2|Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, > 5 L/mn Oxygen treatment
9714569|NCT04590261|Other|Group 3|Physician examination in the Pneumology ward, Cochin Hospital
10195739|NCT04631718||MRI based abdominal QSM|Participants with known or suspected iron overload with past serum ferritin >500 will be recruited in this study.
10195740|NCT04629430|Experimental|Prebiotic diet|2 servings a day of pre-biotics every day from start of conditioning regimen for HSCT through 100 days following HSCT
9714570|NCT04590261|Other|Group 4|Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital
9714571|NCT04590287||Patients after ischemic stroke|The analysis included the presence of CVD risk factors in patients after ischemic stroke durning in the early rehabilitation.
9714572|NCT04590287||Patients after hemorrhagic stroke|The analysis included the presence of CVD risk factors in patients after hemorrhagic stroke durning in the early rehabilitation.
9714573|NCT04590313|Active Comparator|Arthrodesis|MTPJ I Arthrodesis
9714574|NCT04590313|No Intervention|Watchful waiting|No intervention, patient information leaflet
9714575|NCT04590183|Experimental|The experimental group|
9714576|NCT04590183|Sham Comparator|The control group|
9714577|NCT04590456|Experimental|Placebo group|
9714578|NCT04590456|Experimental|PEMF group|
9714579|NCT04590352||Index case and household contacts|"nasophryngeal and throat swab at day 0.~collection of mucosal lining fluid: day 0, 7, 14, 28 for index case and day 0, 3, 6, 28 for household contacts.~fingerprick at day 28 (optional).~daily record of symptoms from day 0-28."
9714580|NCT04590508|Experimental|Xanthohumol|Participants will take capsules containing 24 mg of xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
9714581|NCT04590508|Placebo Comparator|Placebo|Participants will receive capsules filled with a rice protein vehicle by mouth once daily with the first daily meal.
9714582|NCT04590482|Experimental|letrozole then misoprostol|description:letrozole 2.5 mg each 12hours for 2 days at home followed by misoprostol 800mcg vaginally at hospital repeated after 4 hours if needed
9714583|NCT04590482|Placebo Comparator|placebo then misoprostol|Description:placebo each 12 hours for 2days at home followed by 800mcg misoprostol vaginally at hospital and repeat dose after 4 hours if needed
9714584|NCT04590391|Other|Visual and Auditory Breathing-swallowing Coordinated Training device|
9714585|NCT04590196|Experimental|treatment|
9714586|NCT04590196|Placebo Comparator|control|
9714587|NCT04590157|Experimental|study group|received pelvic floor muscle training in addition to laser acupuncture on neurogenic acupoints
10195741|NCT04628585||Subjects with sickle-cell disease|Subjects treated with ex vivo gene therapy drug products in a bluebird bio-sponsored study who agree to participate in this long-term follow-up study
9714588|NCT04590157|Experimental|control group|received pelvic floor muscle training
10195742|NCT04625634|Experimental|Consecutive work|Subjects will complete 2 consecutive days of simulated firefighting tasks in the heat. The simulated work consists of 20 minutes of simulated structural work in a hot environment, followed by 20 minutes of seated rest in a temperate room, mimicking a typical recovery period in structural firefighting. Subjects then re-enter the environmental chamber and complete 23 minutes of simulated overhaul work in a temperate environment.
10195743|NCT04623099|Other|Standard dosing|Patients randomized to standard dosing (std) will initiate escitalopram at 5 mg daily and will then increase to 20 mg/day at week 4.
9714589|NCT04589871|Experimental|Group A|Group A received a taping technique in addition to the supervised exercises protocol
9714590|NCT04589871|Active Comparator|Group B|Group B received supervised exercises protocol only
9714591|NCT04589780||Posture Assessment|Posture will be assessed with New York Posture Rating Chart (NYPR) originally published in 1958
9714592|NCT04589780||Sagittal spinal alignment and mobility|Sagittal spinal alignment and mobility will be measured using the Spinal Mouse (IdiagAG Mülistrasse 18 CH-8320 Fehraltorf, Switzerland), a computer-aided, non-invasive device.
9714593|NCT04589780||Injury risk assessment|Injury risk will be evaluated with Functional Movement Screen (FMS) test battery. A previous systematic review has demonstrated acceptable reliability for the FMS
9714594|NCT04589858|Active Comparator|Group A|Received a supervised exercise protocol including both strengthening and stretching exercises for specific muscle groups.
9714595|NCT04589858|Experimental|Group B|Received manual therapies including both myofascial mobilization and manipulation technique in addition to a supervised exercise protocol.
9714596|NCT04589884||Parathyroid disease|
9714597|NCT04589884||Thyroid disease|
9714598|NCT04589884||Liver tumors and metastases|
9714599|NCT04589884||Digestive tumors|
9714600|NCT04589884||Digestive perfusion|
9714601|NCT04589923||Group 1 - participants expected to have abnormal oxygen saturation|Within each study session, participants will have their oxygen saturation, heart rate and respiratory rate measured three times using standard of care equipment and methods. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's primary and secondary objectives only. The app does not return any measurements to the user or participant.
9714602|NCT04589923||Group 2 - participants expected to have abnormal blood pressure|Within each study session, participants will have their blood pressure and respiratory rate measured three times using standard of care equipment. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's secondary objectives only. The app does not return any measurements to the user or participant.
9714603|NCT04589806|Experimental|2-stage ridge splitting with simultaneous implant placement|
9714604|NCT04589936|Experimental|COVID-19|Non-ventilated patients with COVID-19
9714605|NCT04589936|Active Comparator|Pneumonia control|Patients with pneumonia unrelated to COVID-19 requiring supplemental O2.
9714606|NCT04589910|Other|Ultra-sound arm|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
9714607|NCT04589949|Experimental|ConvP|300 mL convalescent plasma with a minimum of neutralizing antibodies
9714608|NCT04589949|Active Comparator|FFP|300 mL Fresh Frozen plasma
9714609|NCT04589819|Active Comparator|Teriparatide|Study participants will be randomized into either the study medication arm or a placebo arm. The study medication Forteo (teriparatide [rDNA origin] injection) (El-Lilly, Indiana, USA), will be administered via an blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20mg dose of the medication daily via self-injection.
9714610|NCT04589819|Placebo Comparator|Placebo|The placebo will be administered in a replica, blinded, injection pen in the same fashion. The study participant will self-administer the medication after being given a teaching session on medication administration by the study nurse.
9714611|NCT04590053|Experimental|COVID-19|Up to 24 subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
9714612|NCT04589988|Experimental|REBIL- Intervention arm|Participants in this arm will receive the Removing Environmental Barriers to Independent Living (REBIL) intervention.
9714613|NCT04589988|Sham Comparator|Waitlist Attentional control|Participants in this arm will receive a sham intervention until the 6 month follow-up visit. At that point participants in this arm will receive the full REBIL intervention.
9714614|NCT04589793|No Intervention|Control|Conventional treatment
9714615|NCT04589793|Active Comparator|Intervention|Motivational interview
9714616|NCT04590040|Placebo Comparator|Toothpaste 1|Toothpaste 1 containing 0% nano-hydroxyapatite (HAP) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
9714617|NCT04590040|Active Comparator|Toothpaste 2|Toothpaste 2 containing 15% nano-HAP will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
9779632|NCT05106244|Experimental|family self-nursing mode|
9779633|NCT05106244|No Intervention|hospital nursing mode|
9714618|NCT04590040|Active Comparator|Toothpaste 3|Toothpaste 3 containing 5% potassium nitrate (KNO3) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
9714619|NCT04590066|No Intervention|Holdout control|Participants will only receive the standard pharmacy messaging.
9714620|NCT04590066|Experimental|Unpacking Risks Treatment|Participants will be asked to think about the risks of catching the flu this flu season and to respond with the location they are most likely to catch the flu out of a list of given options (e.g. at work, at home).
9714621|NCT04590066|Experimental|Unpacking Risks Control|Participants will be asked to think about the risks of catching the flu this flu season and to respond to confirm that they have received the message.
9714622|NCT04590066|Experimental|Active Commitment Treatment|"Participants receive a gain framed notification that they are eligible for a flu shot. In addition, participants are told Many people find it helpful to make a plan to get their shot and are asked to commit by texting back I will get a flu shot. Depending on their response, participants receive a general reminder or a commitment reminder 3 days later."
9714623|NCT04590066|Experimental|Active Commitment Control|Participants receive a gain framed notification that they are eligible for a flu shot. Participants receive a general reminder 3 days later.
9714624|NCT04590066|Experimental|Self-Generated Social Norms Treatment|Participants will first receive a message enjoining them to consider 2 peers who would want them to vaccinate. Then they will be asked to do those peers a favor by getting a vaccine at their next opportunity. They will receive a reminder 3 days later.
9714625|NCT04590066|Experimental|Self-Generated Social Norms Control|articipants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
9714626|NCT04590066|Experimental|Foot-in-the-Door Treatment|Participants will first receive a message enjoining them to encourage someone else to receive a flu vaccine this year. They will then be given a message that they might copy-paste to forward to friends, thereby lowering the effort costs of messaging others. They will receive a reminder 3 days later.
9714627|NCT04590066|Experimental|Foot-in-the-Door Control|Participants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
9714628|NCT04590066|Experimental|Prosocial Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (i.e., protecting loved ones; preserving scarce resources).
9714629|NCT04590066|Experimental|Self-Oriented Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot.
9714630|NCT04590066|Experimental|Prosocial + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (e.g., protecting loved ones; preserving scarce resources). The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
9714631|NCT04590066|Experimental|Self-Oriented + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
9714632|NCT04590066|Experimental|Dynamic + Static Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before and how many Americans got their flu shot last year.
9714633|NCT04590066|Experimental|Dynamic Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before.
9714634|NCT04590066|Experimental|Dynamic Norms Control|Participants will only receive a text message encouraging them to get a flu shot. They will not receive any norm information.
9714635|NCT04590066|Experimental|Sharing Humor|Participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
9714636|NCT04590066|Experimental|Humor Placebo|Participants will receive a text message encouraging them to get the flu shot. This message will include the same joke but participants will not be encouraged to share it.
9714637|NCT04590066|Experimental|No Humor Condition|Participants will receive a text message encouraging them to get the flu shot.
9714638|NCT04590066|Experimental|Connecting the Past Self to the Future Self Treatment|"Participants will receive a text message prompt to recall the negative experience of getting sick. When asked, Do you wish you could have avoided getting sick by getting a simple shot?, participants will have the chance to respond Y for yes or N for no. Regardless of their response, they will be prompted with a second text message to connect their past experience with present-day opportunities for preventative care (getting a flu shot) to protect the future self from the flu."
9714639|NCT04590066|Experimental|Connecting the Past Self to the Future Self Control|In the first text message, participants will receive a simple text message encouragement to receive a flu shot. In the second text message, they will receive a reminder of the appointment time and provider name.
9714640|NCT04590066|Experimental|Reverse Inference Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are healthier, wealthier, and more educated.
9714641|NCT04590066|Experimental|Reverse Inference Control Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are less likely to get the flu.
9714642|NCT04590131|Experimental|Hubrid revaskularization|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.
9714643|NCT04590131|Active Comparator|Endovascular treatment|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
9779634|NCT05105503||Adults with AVFs currently in the process of maturing|Adults with ESRD who currently have a maturing AVF that has not yet been cannulated
10195744|NCT04623099|Experimental|Pharmacogenetically-guided escitalopram dosing|Patients randomized to PGx-guided treatment, escitalopram titration will be based on CYP2C19 phenotype and predicted escitalopram exposure. In poor metabolizers (PM), escitalopram will be initiated at 5 mg daily and increased to 10 mg daily at week 4.
9980242|NCT01389739|Experimental|Exposed to the intervention|Patients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
9980243|NCT01389739|No Intervention|Usual care|
10195745|NCT04615455|Experimental|Adipose tissue-derived mesenchymal stem cells (ASCs)|One transconjunctival injection of allogeneic ASCs into the LG in one eye.
9714644|NCT04590092|No Intervention|Control|Study Participants who do not receive a pessary. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and will continue to have standard antenatal care with their maternity provider.
9714645|NCT04590092|Experimental|Pessary|Study Participants who are fitted with a pessary for urinary incontinence. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and pessary use in pregnancy. They will continue to have standard antenatal care with their maternity provider.
10195746|NCT04615455|Placebo Comparator|Placebo (vehicle, Cryostor CS10)|One transconjunctival injection of Cryostor CS10 into the LG in one eye.
10195747|NCT04613843|Active Comparator|Water stirring|
10195748|NCT04613843|Experimental|No water stirring|
10195749|NCT04613661||Researcher 1|The first researcher assessing elbow, wrist, and ankle spasticity, respectively
9714646|NCT04590105|Experimental|App Subject|"Users who were assigned to use a smartphone app downloaded a free app from the iOS App or Google Play stores titled SB Colonoscopy Prep. The app informed subjects about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite."
9714647|NCT04590105|Active Comparator|Written Instruction Subjects|Subjects in the control group were given a three-page document that described the procedure and instructed users on how to take the preparation medications. The written instructions had a list of frequently asked questions about colonoscopies and the URL of a website where users could view the animated video that was included in the app. The written instructions also contained the time and date of the procedure. All subjects were instructed to arrive one hour before their scheduled procedure.
9714648|NCT04589715|Experimental|electroacupuncture group|patients will receive electroacupuncture at 3 acupoints(Bladder meridian of foot-taiyang 33 and 35#BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 4 weeks, then 3 times/week for 4 weeks, and then once/week for 4 weeks(24 times in total in 3 months), and be followed up for 6 months after treatment. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 ×40 mm at SP 6. Standardized electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6.
9714649|NCT04589715|Sham Comparator|sham electroacupuncture group|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz.
9714650|NCT04589702||females with isolated patellofemoral arthritis|those with anterior knee pain
9714651|NCT04589702||healthy females|those without anterior knee pain
9714652|NCT04589728||Study group|All patients being observed during the study duration.
10195750|NCT04613661||Researcher 2|The second researcher assessing elbow, wrist, and ankle spasticity, respectively
10195751|NCT04606355||PDI Check & Conventional|Autostereoscopic, dynamic forced choice game (ie on Nintendo 3DS) and Rosenbaum or HOTV near card, Ishihara color plates, Innova Rabin color test, Titmus Stereo test
10195752|NCT04602156|Experimental|Group T|Patients will be randomized to undergo PC catheter placement (8-French) using the trocar method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
10195753|NCT04602156|Active Comparator|Group S|Patients will be randomized to undergo PC catheter placement (8-French) using the Sellinger method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
10195754|NCT04584320||Premature neonates with necrotizing enterocolitis|
9714653|NCT04589741|Experimental|toripalimab combined with CAV / IE regimen|toripalimab combined with CAV / IE regimen in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
9779635|NCT05104853|Experimental|4 mg/Kg CNP-104|200 mL intravenous infusion on Day 1 and Day 8: 4 mg/Kg CNP-104
9779636|NCT05104853|Experimental|8 mg/Kg CNP-104|200 mL intravenous infusion on Day 1 and Day 8: 8 mg/Kg CNP-104
9779637|NCT05104853|Placebo Comparator|Placebo|200 mL intravenous infusion on Day 1 and Day 8: Placebo
9980244|NCT01389778|Experimental|Metformin|Subjects treated with metformin.
9980245|NCT01389791|No Intervention|Roc|Patients in this group receive neither MgSO4 nor priming dose of rocuronium.
10195755|NCT04584320||Premature neonates without necrotizing enterocolitis|
9779638|NCT05103943|Experimental|SPECT MPI (myocardial perfusion imaging) Group|the SPECT MPI protocol will be modified to evaluated MBF and MFR. This modification will result in no added radiation; the radiopharmaceutical dose will still be the same compared to a standard MPI protocol.
9980246|NCT01389791|Active Comparator|priming|patients in this group receive 0.06mg/kg of rocuronium before 0.54mg/kg of rocuronium.
9980247|NCT01389791|Experimental|Mg&priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
9980248|NCT01389791|Active Comparator|MgSO4|Patients in this group receive intravenous MgSO4 before administration of rocuronium.
9980249|NCT01389804||Pediatric Solid Organ Transplant|Parents of pediatric solid organ transplant recipients
10195756|NCT04581018|Active Comparator|Health supplements + standard care|28 days of health supplements (Synbiotic) daily plus standard care
10195757|NCT04581018|No Intervention|Standard care|No intervention
10195758|NCT04575324|Experimental|Intervention Arm|Participants will receive the telemedicine linkage intervention.
9714654|NCT04589689|Experimental|Intervention Group|The intervention group will participated in the The Insul-In This Together intervention, which consists of 6 weekly 30-minute online family sessions to discuss topics related to diabetes distress and parent-teen communication. Sessions include structured education, discussions, and skill-building activities related to parental involvement, parental monitoring, and parent-adolescent conflict. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week follow-ups (after every 2 sessions for the intervention group and later the control group). Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
10195759|NCT04575324|No Intervention|Control Arm|Participants will receive a standard referral to an in-person MOUD treatment appointment, which typically occurs within 24-72 hours. They also receive a bus pass to cover transportation (both directions), as well as an appointment reminder card.
9714655|NCT04589689|Experimental|Waitlisted Control Group|The waitlisted control group will receive the same intervention as the intervention group, but at the 6-month follow-up mark. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week from baseline. Participants will be asked to provide A1C test results that will be collected via chart review or from participants sharing their test results at baseline, 6-month, and 12-month follow-up.
9714656|NCT04589442|Active Comparator|Standard of Care Dermal Graft|Standard of care cryopreserved cadaveric split thickness skin grafts
9714657|NCT04589442|Experimental|Standard of Care Dermal Graft - Microsurfaced|Microsurfaced cryopreserved cadaveric split thickness skin grafts
9714658|NCT04589429|Active Comparator|MN group|intrathecal morphine 300 micrograms+2mg nalbuphine
9714659|NCT04589429|Placebo Comparator|M group|intrathecal morphine 300 micrograms
9714660|NCT04589481|Experimental|candy intake|
9714661|NCT04589416|Active Comparator|Single Bond 2|Single Bond 2 is a traditional etch and rinse adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
9714662|NCT04589416|Active Comparator|Clearfil SE Bond|Clearfil SE bond is traditional two step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
9714663|NCT04589416|Active Comparator|Tri-S Bond|Tri-S bond is traditional one step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
9714664|NCT04589364|Experimental|abobotulinum toxin A|"Abobotulinum Toxin Type A (Dysport) dose was investigated:~dose: 100 units ( various units each site depend on clinical )"
9714665|NCT04589364|Experimental|neubotulinum toxin A|"Neubotulinum Toxin Type A (Neuronox) dose was investigated:~dose: 33.33 units ( various units each site depend on clinical )"
9714666|NCT04589403|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo will be 50 mL normal saline (Sodium Chloride), USP sterile solution administered by IV infusion over 30 minutes.
9714667|NCT04589403|Experimental|OPT101|The starting dose for the Phase 1a study is 0.16 mg/kg, which is 35-fold lower than the dog NOAEL (10mg/kg), on a mg/m2 basis. The dosing frequency for the MAD study was selected based on dosing performed in the supporting animal model studies. For an additional safety factor, the dose and volume infusion rates for the 0.16 mg/kg dose in humans will be 67-fold and 14-fold lower than the dogs dosed at 10mg/kg/min and mL/kg/min basis, respectively. For both Phase 1a and 1b, OPT101 will be administered by a slow IV infusion over 30 minutes.
9714668|NCT04589520|Experimental|HeartBot Group|The HeartBot group downloaded the app and used it daily for 21 days based on a calendar that provided them with step by step outlines of the tools for each day.
9714669|NCT04589520|No Intervention|Control Group|The control group did not download the app and experienced no change to their daily routines.
9714670|NCT04589390|Other|Selexipag|Selexipag will be up titrated for a period that will last 12 weeks (Phase 2). The initial dose will be 200 mcg of selexipag every 12 hours, with weekly dose increases of 200 mcg, up to the maximum dose of 1600 mcg every 12 hours or until the classic side effects of the prostacyclin pathway drugs (headache, mandibular pain), among others) arise. The dose will then be reduced by 200 mcg per dose, and this will be the maximum dose considered for that particular patient, maintained in Phase 3 (16 weeks).
9714671|NCT04589312|Active Comparator|Pregnant women not living with HIV, Td vaccine|
9714672|NCT04589312|Experimental|Pregnant women not living with HIV, Tdap vaccine|
10195760|NCT04563611|No Intervention|Muscle strength|Participants hamstring muscle strengths will be evaluated with ISOMED 2000 isokinetic dynamometer
10195761|NCT04563611|No Intervention|Hamstring Flexibility|In this study, Individuals' evaluations of hamstring flexibility will be assessed by the active knee extension test (ICC: 0.96) with maximum hip flexion.
10195762|NCT04563611|No Intervention|Cognitive Function|The lower (reaction time and visual-perceptual ability) and upper level (working memory, inhibitory control, and cognitive flexibility) cognitive functions of the individuals participating in the study will be evaluated with the computer assisted CNSVS test battery
10195763|NCT04563611|No Intervention|Injury risk|Injury risk analysis of individuals will be made using the strength differences between the two sides, H: Q ratios (conventional and functional ratio) and functional movement screen (FMS), which will be obtained from the isokinetic measurement results.
10195764|NCT04563611|Experimental|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. The hands and arms will be positioned on the chest and held by the physical therapist at the heels of the individuals. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed
10195765|NCT04563611|Experimental|Supine Sliding Leg Curls|The persons will be started to exercise in the hook position, with hands-on their back, with their knees next to the body, in a flexion position of approximately 60 °. Participants will be asked to first build a bridge, then maintain this position and slowly slide the slippery apparatus under their feet to bring their knees to full extension.
10195766|NCT04563611|Experimental|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
10195767|NCT04563611|No Intervention|Agility|Agility performances of individuals will be evaluated with the Agility T-test.
10195768|NCT04563247||Asymptomatic frontline HCWs for COVID 19|All healthcare workers who worked in high exposure areas of hospital dealing with COVID 19.
9714673|NCT04589312|Active Comparator|Pregnant women living with HIV, Td vaccine|
9714674|NCT04589312|Experimental|Pregnant women living with HIV, Tdap vaccine|
9714675|NCT04589455|Experimental|hennep extract|A hennep extract administered in soft gel capsules in a fasted state
9714676|NCT04589455|Experimental|hennep extract + high fat meal|A hennep extract administered in soft gel capsules in a fed state
9714677|NCT04589546|Experimental|Vitamin B3|
9714678|NCT04589546|Placebo Comparator|Placebo|
9980250|NCT01389830||Older Latinos With Cancer|Monthly Telephone Survey of Cohort with stage III or greater of breast, colorectal, or prostate cancer up until 12 months.
9714680|NCT04589572|Experimental|XLIF - group|
9714681|NCT04589572|Active Comparator|PLIF - Group|
9714682|NCT04589559|Experimental|Intervention: Heart Rate Variability Biofeedback|Participants in this intervention group complete at-home heart rate variability biofeedback (HRVB) training using a wrist-worn heart rate monitor and a smartphone app. They complete at least 10 minutes per day of HRVB training on at least 5 days per week for 3 weeks.
9714683|NCT04589494|Active Comparator|tramadol group|tramadol hydrochloride 100 mg three times daily
9714684|NCT04589494|Active Comparator|morphine group|morphine 30 mg twise times daily
9714685|NCT04589325|Experimental|Ixekizumab|
9714686|NCT04589325|Placebo Comparator|Placebo|
9714687|NCT04589299|Active Comparator|Patients treated with immunoglobulin intravenously (IVIG)|Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
9714688|NCT04589299|Active Comparator|Patients treated with immunoglobulin subcutaneously (SCIG)|Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
9714689|NCT04589000|Experimental|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
9714690|NCT04589000|No Intervention|control|No accupressure will be applied. Milk will be expressed for a total of 15 minutes, 1 time on the post-op 0th day, 2 times on the post-op 1st day and once on the post-op 2nd day for a total of 15 minutes and will be recorded in the milk measurement table.
9714691|NCT04589338|Experimental|Endurance training group|
9714692|NCT04589338|Experimental|Resistance training group|
9714693|NCT04589338|No Intervention|Control group|
9714694|NCT04589026|Active Comparator|Active Arm: Candin + Consentyx|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Cosentyx injection subcutaneously.
9714695|NCT04589026|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% NaCl, and no Cosentyx.
9714696|NCT04588922|Experimental|GFH009|
9779639|NCT05100823|Experimental|Nasal cells sampling and/or rectal biospy|"Depending of the patient' genotype, specific ONB-CFTR (50 nM) will be incubated at the apical face of in vitro epithelium, alone and in combination with CFTR modulators. Efficacy of ONB will be compared to a condition with oligonucleotide control incubation.~Rectal biopsies from volunteer patients were stored as a bio-bank of organoids."
9779640|NCT05098925|Experimental|Intervention|Study of Thermoregulatory Processes in Ultra-endurance Runners in a Hot and Humid Environment
9779641|NCT05098379|Experimental|Tele-Rehabilitation Home Exercise Program|Subjects will participate in an 8-week customized home exercise program with weekly virtual exercise coaching sessions.
9779642|NCT05091437||Retrospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in the past; more preciously from March 2020 to the study initiation date. [ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and < 3 cm) for subject inclusion].
9779643|NCT05091437||Prospective|All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in imaging exams in routine clinical practice, prior to 30 days of informed consent given [ Fleischner Society 2017 guidelines for nodules size and definition (≥ 6 mm and < 3 cm)) for subject inclusion]. Subjects identified from different sources (Nodules identified incidentally and in lung cancer screening programs) will be considered.
9779644|NCT05088863|Other|Implementation of health claim|Participants will have 2 weeks to incorporate 40g of flaxseed per day into their diet
9779645|NCT05088148||Group 1: FGR group|Estimated fetal weight <10th percentile
10195769|NCT04559464|Other|AeriSeal and Zephyr Valve Treatment|"Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-).~Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR)."
9779646|NCT05088148||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
9980251|NCT01389830||Older Latinos Without Cancer|Single Telephone Survey of Cohort without a history of cancer.
10195770|NCT04553731|Experimental|The mHealth-based program|The experimental group used the mHealth app and a wearable activity tracker (WAT) on managing and preventing excessive GWG among overweight and obese women during pregnancy
10195771|NCT04553731|No Intervention|The standard antenatal treatments with no mHealth-based elements|controls received standard antenatal treatments with no mHealth-based elements
10195772|NCT04552080|Active Comparator|Test: Amoxicillin|
10195773|NCT04552080|Placebo Comparator|Comparator: Placebo|
9714697|NCT04589143|Experimental|Experience group|In this group,participants take agomelatine at a dose of 25-50 mg/d for 8 weeks.
9714698|NCT04589143|Placebo Comparator|Contral group|In this group,participants take a placebo at a dose of 25-50 mg/d for 8 weeks.
9714699|NCT04589130|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets.
9714700|NCT04589130|Placebo Comparator|Placebo|Group given placebo
9714701|NCT04588883|Experimental|Intervention Arm|Patients, adults and adolescents, will be recruited from patient registries at 7 government operated HIV clinics in Meru County, Kenya. Patients will complete validated questionnaires at baseline, 1.5 year and 3 years into a novel adaptation of a community empowerment program. The program utilizes savings- and internal-lending/group-based microfinance process to facilitate exchange of savings amongst patients and adolescent guardians. A byproduct of this process is the development of social capital, which will be used to facilitate education, peer learning, and collective problem solving to improve determinants of well-being and clinical adherence among participants. Expected outcomes include improved viral suppression, ART adherence, clinical attendance, and mental health.
9714702|NCT04589182|Experimental|Verum|Patients will receive all-night auditory stimulation during sleep over 3 nights using a portable, safe, in-home device (MSHL-SleepBand). This device records biosignals (EEG) and precisely plays tones (between 45-65 dB, maximum 80 dB) targetted to the up-phase of sleep slow waves.
9714703|NCT04589182|Sham Comparator|Sham|Patients will receive all-night sham stimulation over 3 nights, i.e. the wearable stimulation device will be applied (EEG will be recorded), but no tones will be played.
9714704|NCT04588896|Experimental|CGM+LMP|Continuous glucose monitoring (CGM) for 8 weeks in conjunction with lifestyle modification
9714705|NCT04588896|Other|LMP only|Lifestyle modification only
9714706|NCT04589234|Experimental|Saltikva with FOLFIRINOX|30 patients will be enrolled to receive standard of care FOLFIRINOX with oral Salmonella-IL2 (Dose 10-9) every 2 weeks for 2 years
9714707|NCT04589234|Experimental|Saltikva with Gemcitabine/Abraxane|30 patients will be enrolled to receive standard of care Gemcitabine/Abraxane with oral Salmonella-IL2 (Dose: 10-9) every 3 weeks for 2 years
9714708|NCT04588961|Active Comparator|Control group|Patients undergoing trapeziectomy with suspensionplasty for primary basal thumb osteoarthritis
9714709|NCT04588961|Active Comparator|Study group|Patients undergoing joint alloplasty using prothesis for primary basal thumb osteoarthritis
9714710|NCT04588974||Screening|Sixty-five cirrhotic patients with portal hypertensive symptoms (such as platelets count less than 100,000) will be enrolled to evaluate for the presence and stage of esophageal varices by using a magnetic-assisted capsule endoscope system with or without 3D image processing.
9714711|NCT04588974||Follow-up|Thirty-five cirrhotic patients with a history of endoscopy-confirmed esophageal varices will be included for the follow-up examination by using the magnetic-assisted capsule endoscope system with or without 3D images.
9714712|NCT04588974||Control|Another 40 volunteers with GI symptoms but no known gastrointestinal disease will be enrolled as the control group.
9714713|NCT04589078||Interficial Intelligence|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
9714714|NCT04588935|No Intervention|Group 1|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated
9714715|NCT04588935|Active Comparator|Group 2|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and perindopril
9714716|NCT04588987|Experimental|Neoadjuvant group|Patients need to treat with PD-1 and apatinib before surgery. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
9714717|NCT04588987|Experimental|Adjuvant group|Before surgery, patients no need to treat with PD-1 and apatinib. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
9714718|NCT04589104|Experimental|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~Week 1: Writing to expressive difficult emotions~Week 2: Writing to release & integrate difficult emotions~Week 3: Writing to nurture gratitude~Week 4: Writing to enhance strengths & resources~Week 5: Writing to cultivate positive meaning & savor goodness~Week 6: Writing to invite insight, perspective, & growth"
9714719|NCT04588844|Experimental|Growth Hormone group|Growth Hormone pretreatment for 6 weeks before ovarian stimulation
9714720|NCT04588844|No Intervention|Control group|No pretreatment before ovarian stimulation
10195774|NCT04551131|Experimental|Frontline Arm|"Safety Phase:~Patients with newly diagnosed HLH will receive ruxolitinib PO or NGT, dexamethasone, PO or IV and etoposide IV.~Expansion Phase:~Patients with newly diagnosed HLH treatment will begin with ruxolitinib PO or NGT at the MTD dose. Dexamethasone will be administered PO or IV. Etoposide IV will be added based on disease response."
10195775|NCT04551131|Experimental|Salvage Arm|Patients with relapsed/refractory HLH will receive ruxolitinib PO or NGT and dexamethasone PO or IV. Etoposide IV will be added based on disease response.
10195776|NCT04545346|No Intervention|Wait-listed control|Participants continue care as usual. All all medications must be kept constant during the study period, unless medically necessary.
10195777|NCT04545346|Experimental|Low Glutamate diet|Participants are put on the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
10195778|NCT04532515|Experimental|Seal G / Seal-G MIST|"Seal-G Surgical Sealant [Seal-G]- will be applied on colonic anastomosis created by extra-corporal approach.~Seal-G MIST System [Seal-G MIST]- will be applied on colonic anastomosis created by intra-corporal approach."
10195779|NCT04531020||Patients at PACU|Patients undergoing elective surgical or diagnostic intervention admitted to PACU after postanaesthesia recovery
9714721|NCT04588714|Experimental|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|"RENEW is a 12-week program in which participants are paired with a peer mentor who serves as their health coach throughout the intervention period. The website serves as the program workbook to help promote skill practice and attainment in areas like goal setting, pacing, relaxation, etc."
9714722|NCT04589169||Positive cohort|Patients who develop delirium
9714723|NCT04589169||Experimental control group|Patients who do not develop delirium
9980252|NCT01389843||All consecutive hospitalized adult patients|"All consecutive hospitalized adult patients who have 1 and (2 and/or 3)~Symptom and/or sign of heart failure~Lung congestion~Objective finding of LV systolic dysfunction (LVEF), or structural heart disease."
9980253|NCT01389869|Experimental|Tears|Emotional tears of female volunteers while watching sad video clips
9714726|NCT04588532|Experimental|doxepin|"Drug: Doxepin + BAM8-22 Doxepin will be applied for 1.5 hrs followed by the application of BAM8-22. 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Histamine Doxepin will be applied for 1.5 hrs followed by the application of Histamine. 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Cowhage Doxepin will be applied for 1.5 hrs followed by the application of cowhage. 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Placebo Doxepin will be applied for 1.5 hrs followed by the application of placebo. 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
9714727|NCT04588532|Experimental|itch|"Drug: BAM8-22 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Histamine 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Cowhage 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop~Drug: Placebo 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
9714728|NCT04588454|Experimental|18F-PSMA-1007 PET/CT|
9714729|NCT04588558|Experimental|Flywheel exercise|The term isoinertial is derived from the words iso (same) and inertial (resistance), which define the primary concept of the isoinertial system in a terminology or that expresses both the concentric and eccentric phases of the same muscle contraction. Isoinertial refers to resistance used in exercise training, maintaining a constant inertia throughout the range of motion, a constant resistance in all respects, and facilitating maximum muscle strength. All participants received home exercise for 8 weeks.
9714730|NCT04588558|Active Comparator|Electrotherapy modality|"Electrotherapy modalities especially transcutaneous electrical nerve stimulation (TENS) and ultrasound is used to treat OA.~All participants received home exercise for 8 weeks."
9714731|NCT04588558|Active Comparator|Home exercise|All participants received home exercise three times a week for 8 weeks. Home exercises are structured with squats. The exercise program includes stretching exercises and strengthening (isometric and isotonic) exercises.
9714732|NCT04588831|Experimental|Pre-fabricated|
9714733|NCT04588831|Experimental|Mouth-formed|
9714734|NCT04588831|Experimental|Custom-fitted|
9714735|NCT04588636|Active Comparator|Behavioral and self-care therapy control group|Subjects received verbal and written information on the etiology and prognosis of TMDs. In addition, advice on habits and behavior changes, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
9714736|NCT04588636|Active Comparator|Rigid occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a rigid occlusal splint
9714737|NCT04588636|Active Comparator|Soft occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a soft occlusal splint
9714738|NCT04588636|Placebo Comparator|Non-occlusive splint group|Subjects in this group received behavioral and self-care therapy, in combination with a non-occlusive splint
9714739|NCT04588779|Experimental|Graston|Ultrasound, Graston technique, piriformis stretching, home plan (hip abductor and extensor strengthening)
9714740|NCT04588779|Active Comparator|Manual myofascial release|Ultrasound, Manual myofascial release, piriformis stretching, home plan (hip abductor and extensor strengthening)
9714741|NCT04588415|Experimental|Virtual Support Group Arm|Those with severe symptoms (indicated by an ICG-r score >25) will be notified that their symptoms are considered to be severe, with a suggestion to attend the virtual support groups. A recent meta-analysis of psychological interventions for grief found higher effect sizes in studies of participants who were >6 months post-loss, and those with higher baseline symptom levels. However, no participant in our study will be randomized to any treatment assignment, and the decision to attend the VSG will be left to the family members.
9980254|NCT01389869|Placebo Comparator|Saline|Saline collected after being trickled down women's skin below eyes like tears
9714742|NCT04588415|No Intervention|Non-Virtual Support Group Arm|Family members that choose not to participate in the Virtual Support Group will be part of this non-intervention arm
9714743|NCT04588649|Other|THK-5351|Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the tau protein Pharmacological category：Radio pharmaceutical
9714744|NCT04588649|Other|AV-45|Name: [18F]AV-45, (E)-4-(2-(6-(2-(2-(2-[18F]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the β- amyloid protein Pharmacological category：Radio pharmaceutical
9714745|NCT04588792|Experimental|Inhaled Furosemide|40 mg furosemide per dose, given by nebulization (4 mL of 10 mg/mL furosemide in 0.9% saline solution) over 30 mins four times daily (Q6H) for up to 28 days
9714746|NCT04588792|Placebo Comparator|Nebulized Saline|Placebo, given by nebulization (4 mL of 0.9% saline solution) over 30 mins four times daily (Q.I.D.) for up to 28 days
9980255|NCT01389869|Placebo Comparator|Fasting|Their own overnight fasting plasma of male volunteers
9714747|NCT04588740|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
9980256|NCT01389869|Experimental|Prandial|Their own postprandial plasma of male volunteers
10195780|NCT04530890|Experimental|One arm only|Only one arm with blood samples
9714748|NCT04588740|Placebo Comparator|Placebo|The placebo beet root juice is made by the same company (BEET IT, James White Drinks, Ipswich, UK) and contains no inorganic nitrate.
9714749|NCT04588701||persons with anal fistulas|all persons with anal fistulas treated by a single surgeon over 22 years
9714750|NCT04588623|Active Comparator|Omnibiotic Stress Repair (OBSR)|After randomisation, patients will receive a box with one sachet containing 3g of OBSR for each day.
9714751|NCT04588623|Placebo Comparator|Placebo|After randomisation, patients will receive an identical box with one sachet containing 3g of Placebo for each day.
9714752|NCT04588441|Experimental|Adenosine|Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer
9714753|NCT04588753|Active Comparator|Active Isolated Stretch|active isolated stretching, strengthening exercises
9714754|NCT04588753|Active Comparator|Post Facilitation Stretch|Post Facilitation Stretching, strengthening exercises
9714755|NCT04588662||Uveal Melanoma|Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent
9714756|NCT04588766||constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
9714757|NCT04588766||control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
9714758|NCT04588688|Experimental|Mifepristone|Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.
9714759|NCT04588571|Experimental|Endovascular treatment|Patients (n=55) with recanalization of the femoral-popliteal arterial segment (TASC II, type D) above the knee with a biomimetic braided nitinol stent.
9714760|NCT04588571|Active Comparator|Open surgery|Patients (n=55) with femoropopliteal proximal bypass with a prolonged atherosclerotic lesion of the femoropopliteal arterial segment (TASC II, type D).
9714761|NCT04588467|Active Comparator|Conservative group|Conservative treatment included dietary modification (intake of at lest 3 liters of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application (Lidocaine 2.5%+Prilocaine 2.5%, 2g twice a day) for 10 days
9714762|NCT04588467|Experimental|Surgical group|Thrombectomy and local excision of external hemorrhoids were performed with the patient in the lithotomy position under local infiltrative anesthesia with UltracainDS 1:200000 1.7ml
9714763|NCT04588805||Colorectal Cancer Patients|
9714764|NCT04588389|Active Comparator|Group 1 Standard of Care|Group I will receive the standard of care multimodal pharmacological management.
9714765|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block II|Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.
9714766|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block III|Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.
9980257|NCT01389895|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
9980258|NCT01389895|Placebo Comparator|AMG 557 Placebo|All will receive placebo on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
9980259|NCT01389908|Experimental|schizophrenia|schizophrenia or schizoaffective patients
9980260|NCT01389921|Experimental|healthy testpersons|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
9980261|NCT01389921|Experimental|patients with non-neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
9980262|NCT01389921|Other|patients with neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome
9714767|NCT04588376|Experimental|Clinician-level and clinic-level monthly feedback|Group of 22 clinics to receive clinician-level and clinic-level monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
9714768|NCT04588376|Active Comparator|Clinic-level only monthly feedback|Group of 17 clinics to receive clinic-level only monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
9714769|NCT04588233|Experimental|Administration of Melatonin|
9980263|NCT01389934|Placebo Comparator|Control|Women of this group be infused saline 2 ml / h for 48h.
9980264|NCT01389934|Experimental|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.
10195781|NCT04524403|Experimental|Miricorlilant - 600 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 600 mg miricorilant once daily for 26 weeks.
10195782|NCT04524403|Experimental|Miricorlilant - 900 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 900 mg miricorilant once daily for 26 weeks.
10195783|NCT04524403|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive placebo once daily for 26 weeks.
10195784|NCT04519515|Experimental|Treatment With Juvederm Vollure Right|Injection of Juvederm Vollure on one half of the face, placebo on the other side
10195785|NCT04519515|Experimental|Treatment Juvederm Vollure Left|Injection of Juvederm Vollure on one half of the face, placebo on the other side
9714770|NCT04588233|Placebo Comparator|Administration of Placebo|
9714771|NCT04588220||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
10195786|NCT04518254|Experimental|Tyrosine - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure
10195787|NCT04518254|Experimental|Tyrosine - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure
9714772|NCT04588220||Control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
9714773|NCT04588194|Experimental|Romiplostim, Rituximab, Dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21, Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21 and Dexamethasone 40 mg IV/PO days 1-4.
10195788|NCT04518254|Experimental|Placebo - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure
10195789|NCT04518254|Experimental|Placebo - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure
9714774|NCT04588090|Experimental|Experimental group|The concurrent 3 weeks treatment group（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing 3 weeks chemotherapy）
9714775|NCT04588090|Placebo Comparator|Standard chemoradiation group|Standard chemoradiation（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing weekly chemotherapy）
9714776|NCT04588181|Experimental|CBT 6 sessions|
9714777|NCT04588181|Active Comparator|CBT 12 sessions|
9714778|NCT04588285|Experimental|Ambroxol|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
9714779|NCT04588285|Experimental|Placebo|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
9714780|NCT04588064|Experimental|18F-FDG PET/CT scan|Each subject receives a single intravenous injection of 18F-FDG, and undergo PET/CT imaging within the specified time.
9714781|NCT04588038|Experimental|Treatment (efineptakin alfa)|Patients receive one dose of efineptakin alfa IM.
9714782|NCT04587973|Active Comparator|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml) plus dexmedetomidine 1 mcg/kg
9714783|NCT04587973|Active Comparator|Group Ropivacaine|Plain ropivacaine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml)
9714784|NCT04587973|Placebo Comparator|Group Control|Control group - Preoperative bilateral erector spinae plane block with N/S 0,9% (40 ml)
9714785|NCT04588103|No Intervention|Control|Participants will be asked to maintain their regular physical activity habits for the duration of the 8-week intervention period.
9714786|NCT04588103|Experimental|Heat therapy|Participants will be asked to undergo 45 minutes of lower limb hot water immersion (42 degrees C) 3 times per week for 8 weeks.
9714787|NCT04588103|Experimental|Exercise training|Participants will be asked to undergo 45 minutes of moderate-intensity cycling exercise (~40-59% VO2 reserve) 3 times per week for 8 weeks.
9714788|NCT04588103|Experimental|Combined training|Participants will be asked to undergo 90 minutes of moderate-intensity cycling exercise and lower limb hot water immersion sequentially 3 times per week for 8 weeks.
9714789|NCT04587921|Experimental|Patients monitored with oximeter|The first 45 patients will be monitored but the results will not be displayed. The second half of the patients the oximeter will have their monitoring data available online in the ward.
9714790|NCT04588116|Experimental|The web- based occupational therapy intervention SEE|The web-based intervention starts with eight educational modules focusing on engagement in activities and strategies to support an active life. The modules, that is delivered on a secure national health platform, include short education videos followed by self-reflections and digital assignments supporting the change process. The occupational therapist provides feedback after each assignment and, also, meet the patients for face- to- face online guiding sessions at three times during these first two- three weeks of the intervention. Thereafter, an individually tailored activity plan with goals and activity-based strategies are established. During the change process, the patients receive continued support from the occupational therapist until the goals are achieved.
9714791|NCT04587986|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of BTL-703 will be applied over the umbilicus. The active group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
9980265|NCT01389947||Extracorporeal circulation|Patients who have coronary artery bypass graft performed under extracorporeal circulation
10195790|NCT04514692|Experimental|Phase I -Dose finding, Cohort 1|Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days
10195791|NCT04514692|Experimental|Phase I -Dose finding, Cohort 2|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days
10195792|NCT04514692|Experimental|Phase I -Dose finding, Cohort 3|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day
10195793|NCT04514692|Experimental|Phase II-G-CSF|Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.
9980266|NCT01389947||Heart beating group|Patients who have a coronary artery bypass graft without extracorporeal circulation
9714792|NCT04587986|Sham Comparator|Sham control|The treatment administration phase will also consist of three (3) treatments, delivered once a week. The sham group will receive a treatment with the intensities of the magnetic field and radiofrequency energy set to 5% of the maximum device output.
9714793|NCT04588077|Experimental|Cirrhosis, 3-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
9714794|NCT04588077|Active Comparator|Cirrhosis, 2-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
9714795|NCT04588077|Experimental|Non cirrhosis, 3-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
9714796|NCT04588077|Active Comparator|Non cirrhosis, 2-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.
9714797|NCT04587856|Other|Biological evaluation|evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.
9714798|NCT04588012|Experimental|Online self-help the OurRelationship.dk program|Couples in the intervention condition will receive the full OurRelationship program including the three modules, the Observe, the Understand, and the Respond module. The program takes 6-8 hours to complete the program after the randomization. The second coach call will take place after the Observe phase. The third coach call will take place after the Understand phase. The fourth coach call will take place after the Respond phase.
9714799|NCT04588012|Active Comparator|"Off line self-help the book Pas på Parforholdet"|"Couples in the active control group receive two copies of the book Pas på parforholdet, når kærligheden er kommet for at blive [Take care of your relationship when love is here to stay] by Mattias Stølen Due (2016). This book includes general research based knowledge on maintaining a healthy relationship as well as questions and exercises for couples to do on their own. To support couples in an activate self-help approach, a sheet with guidelines on using the book will help couples plan their reading and couple conversations. Regular questionnaires will be sent to couples in the control group (matched timely to the questionnaires received by the intervention group). As such, the active control condition will mirror the benefit that couples are likely to get from using well-chosen, solid literature with the addition of any benefit that the research participation (filling in questionnaire) will generate."
9714800|NCT04588324|Experimental|Phase 1 Dose-Escalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
9714801|NCT04588324|Experimental|Phase 2 Dose-Expansion|SHR2150 RP2D will be combined with chemotherapy plus PD-1 or CD47 antibody in 3-week treatment cycles.
9714802|NCT04588142|Experimental|Experimental group|Participants are randomized to receive probiotics for 6 weeks
9714803|NCT04588142|Placebo Comparator|Placebo group|Participants are randomized to receive placebo for 6 weeks
9714804|NCT04588155||Chronic Low-Back Pain|Subjects diagnosed with Chronic Low-Back Pain in rehabilitation program: functional assessment (with temporal and kinematic analysis) and clinical assessment.
9714805|NCT04588155||Healthy|Healthy subjects: functional assessment (with temporal and kinematic analysis)
9714806|NCT04587843|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets
9714807|NCT04587843|Placebo Comparator|Placebo|Group given placebo
9714808|NCT04587895|Experimental|MI Intervention|The VITAAL exergame intervention for MI includes 36 training sessions with three sessions per week, each lasting around 45 minutes (30 minutes real training time) resulting in 12 weeks of training (two weeks of break/holiday allowed). A training session includes an individually calculated amount of strength, cognitive-motor and balance training, which remains the same over the 12 week intervention period.
9714809|NCT04587895|Active Comparator|MI Control|"Participants of the MI control group are instructed to do a non-individualized conventional training including 15 minutes walking exercise (in nature or on treadmill) and additional 15 minutes of strength, balance, and cognitive-motor exercises (at the therapy centre or at home). The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu). The participants will receive a training booklet with the exercises. In total there are three different training programs which are divided according to their level of difficulty. Participants are instructed to start with the first level for four weeks and then go on to the next level for another 4 weeks. The control group training in this study includes 36 training session with three sessions per week, each lasting around 45 minutes resulting in 12 weeks of training (two weeks of break/holiday allowed)."
9714810|NCT04587895|Experimental|UI Intervention|For the incontinent women in this study, the VITAAL exergame intervention will last over 12 weeks and consists of three parts 1) VITAAL exergame (2 sessions/week) lasting 45 minutes each (30 minutes real training time) at the physio centre, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home.
9714811|NCT04587895|Active Comparator|UI Control|The control group training will last over 12 weeks. The training sessions will be divided in three parts 1) 30 minutes of brisk walking (2 sessions/week, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home. The PFM training booklet will be based on two studies that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises. The PFMT program will consist of 4 PFM exercises and will be divided into three phases allowing for the gradual progression in treatment (from first to third month), with gradual increase in difficult exercises in terms of duration, repetition and position. Each phase will last four weeks.
9980267|NCT01389986|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
9714814|NCT04587908|Experimental|TAS-205|
9714815|NCT04587908|Placebo Comparator|Placebo|
9714816|NCT04588311|Active Comparator|Erythropoietin (EPO)|Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.
10204794|NCT04922801||Neuroendocrine Toumours|"Patients will undergo 177LU-Dotatate Neoruendocrine Tumours MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~Post-treatment patient-led self-monitoring.~Complete a feedback questionnaire relating to the use of self radiation monitoring."
9714817|NCT04588311|Placebo Comparator|Placebo|Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.
9714818|NCT04587960|Active Comparator|Primary closure of Cesarean wound|Immediate closure of skin incision where healing occurs by primary intention
9714819|NCT04587960|Experimental|Delayed primary closure of Cesarean wound|Delayed closure of skin incision following regular wound dressing for 2 to 3 days.
9714820|NCT04588168|Experimental|Experimental: Chemotherapy + mpMRI + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Immediate mpMRI /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Immediate Multiparametric MRI Procedure: Cystectomy and Lymphadenectomy"
9714821|NCT04588168|Experimental|Experimental: Chemotherapy + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Cystectomy and Lymphadenectomy / Postoperative pathology~Drug: Chemotherapy Procedure: Cystectomy and Lymphadenectomy"
9714822|NCT04587817||Camrelizumab+Hypofractionated radiation therapy|"Camrelizumab: 200mg every 2 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Hypofractionated Radiotherapy(SABR): tumor center dose of 24-32Gy/8Gy/3-4f and surrounding important organs at risk ≤3.0Gy will be performed when one week following completion of the first immunotherapy. And the routine radiotherapy will be started with reaching a radical cure dose for the tumor margin. Generally, the radiotherapy will end before the fourth immunotherapy."
9714823|NCT04587804|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|simultaneous treatment by repetitive pulse magnetic stimulation and radiofrequency energy for toning of abdomen and reduction of subcutaneous fat
9714824|NCT04587778|Experimental|Esketamine ((S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan."
9714825|NCT04587778|Experimental|Racemic ketamine ((R,S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan."
9714826|NCT04587765|Experimental|Extra sports group|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
9714827|NCT04587765|No Intervention|Conventional group|The group follows the schedule of school teaching programme. Students arrange their own after-school time after school.
9714828|NCT04587531|Active Comparator|Active CES Therapy|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
9714829|NCT04587531|Sham Comparator|Sham CES Therapy|Group receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
9714830|NCT04587492||Children with SMA|All children with SMA are eligible for the study
9714831|NCT04587401|Experimental|normotensive patients|Cerebral perfusion of normotensive patients who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
9714832|NCT04587401|Experimental|patients with high blood pressure diagnosis|Cerebral perfusion of patients with high blood pressure diagnosis who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
9714833|NCT04587401|Experimental|patients who do not know they are hypertensive but actual blood pressure is high|cerebral perfusion of patients who do not have high blood pressure diagnosis but actual preoperative blood pressure is higher than normal levels will be measured by transcranial doppler ultrasonography during lumbar surgery
9714834|NCT04587414|Experimental|eHealth + counselling contacts|6-month eHealth physical activity intervention complemented by face-to-face and telephone counselling contacts on physical activity..
9714835|NCT04587414|Experimental|eHealth|6-month eHealth physical activity intervention
9714836|NCT04587414|Other|Usual care|Usual care of type 2 diabetics within the primary health care setting.
9714837|NCT04587739|Experimental|Experimental group|
9714838|NCT04587505|Active Comparator|Epidural anesthesia and analgesia|Epidural catheter insertion: Th 12- L 1 or Th 11 - Th 12 using the midline approach. Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml). Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml).
9714839|NCT04587505|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
9714840|NCT04587544|Experimental|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
9714841|NCT04587544|No Intervention|No Intervention|The participants would not receive Cold Water Intervention. However, they are allowed to received the usual care
9714842|NCT04587557|Experimental|ASD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for children with Autism Spectrum Disorder
10195794|NCT04508855||Cancer patients with atrial fibrillation|"All patients will be assigned to receive subcutaneous LMWH in therapeutic doses~More specifically the regimens will be as follows:~Tinzaparin 175 units/Kg once daily; Enoxaparin 1unit/kg twice daily; Fondaparinux <50 kg, 5 mg SC once daily, 50-100 kg, 7.5 mg SC once daily, >100 kg, 10 mg SC once daily; Bemiparin 115 IU/kg once daily; <50kg, 5000IU, 50-70kg, 7.500 IU, >70kg, 10000IU Nadroparin: Patients weighing 40 to 100 kg: SC, 171 anti-factor Xa IU per kg of body weight once a day; patients weighing over 100 kg will not receive nadroparin because a treatment dosage has not been established; Dalteparin: 200 units IU/kg SC daily for 30 days, then 150 units IU/Kg SC daily Dose adjustments will occur only in case of renal insufficiency according to the medicine's SPC The treatment with the LMWH will last at least during the period of active antineoplastic therapy of cancer patients"
10195795|NCT04499950|Experimental|SLOW-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose <5%, designated slow responders, will continue BWL and initiate Contrave (SLOW-BWL). The SLOW-BWL arm will receive at least 16 weeks of Contrave [as per the Food and Drug Administration (FDA) recommended administration] starting at week 9 and discontinue if ≥5% weight loss is not achieved at month 6.
10195796|NCT04499950|Active Comparator|FAST-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose ≥5%, designated fast responders, will continue with BWL alone (FAST-BWL)
10195797|NCT04496349|Experimental|APG-115 monotherapy|APG-115 will be given alone
10195798|NCT04496349|Experimental|APG-115 + APG-2575 combination|APG-115 is given in combination with APG-2575
10195799|NCT04495621|Experimental|MEN1611|MEN1611 + Cetuximab
9714843|NCT04587557|Active Comparator|ASD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for children with Autism Spectrum Disorder
9714844|NCT04587557|Experimental|TD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for typically developed children
9714845|NCT04587557|Active Comparator|TD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for typically developed children
9714846|NCT04587609|No Intervention|Control - Standard UBI|Participants will continue to be monitored as a part of their standard UBI and receive educational material about distracted driving in the enrollment period
10195800|NCT04490850|Experimental|Participants|Blood sample
10195801|NCT04486677|Other|Caring Cards Group|Group of Veteran card-makers.
10195802|NCT04486677|Other|Caring Cards Recipients|Group of Veteran card-recipients.
10195803|NCT04482140||Genta-Foil resorb|Genta-Foil resorb® is a transparent collagen foil that forms a temporary barrier between the functional structures during the critical phase of wound healing. As a result, the ability of the tissue layers to slide against each other is retained. The absorbability of equine collagen means the foil can be left in place and does not require removal. The addition of the antibiotic Gentamicin is for self-protection since collagen implants are prone to bacterial contamination.
10195804|NCT04463394|Experimental|Vasopressin|Participants undergoing cardiac catheterization
10204795|NCT04922801||Thyroid Cancer|"Patients will undergo 131I-Thyroid cancer MRT in accordance with existing protocols at GSTTFT. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~Post-treatment patient-led self-monitoring.~Complete a feedback questionnaire relating to the use of self radiation monitoring."
9714847|NCT04587609|Other|Free Phone mount|Participants in this arm will be monitored through standard UBI, receive educational material about distracted driving in the enrollment period, and free phone mounts
9714848|NCT04587609|Other|Commitment + Habit tips|Participants in this arm will receive educational material about distracted driving during the enrollment period, be sent a free phone mount with installation instructions, sign a personalized commitment contract to reduce their phone use, set personal phone use reduction goals, and be sent personalized habit tips framed to help them reduce their handheld phone use while driving;
9714849|NCT04587609|Other|Habit Formation + Social Gamification|Participants in this arm will will receive all treatments assigned to arm 3, plus social gamification feedback, where each week participants are told if they've reach their weekly handheld phone use while driving reduction goal, and receive or lose points based on whether or not they met their goal. Based on their points participants can either move up or down a level. Each week the participants will also be sent a leader board of their ranking within their group.
9714850|NCT04587609|Other|All + Contest Financial Incentive|Participants in this arm will receive all of the treatments of arm 4 plus be entered into a financial incentive contest where they can either finish in the highest level and split the prize money amongst all participants that reached that level, and the safest driver (driver ranked #1 on the leader board of their group) will receive a small weekly financial prize.
9714851|NCT04587362||Psoriatic Arthritis|Subjects newly diagnosed with psoriatic arthritis (< 5 years), confirmed by a rheumatologist and fulfilling the CASPAR criteria.
9714852|NCT04587362||Psoriasis without musculoskeletal symptoms|Patients with dermatologist confirmed psoriasis, without any history of Psoriatic Arthritis, and musculoskeletal symptoms.
9714853|NCT04587362||Non-Inflammatory Rheumatic conditions|Patients with non-inflammatory rheumatic conditions such as osteoarthritis, non-specific back pain, soft tissue rheumatism, degenerative tendinopathy and fibromyalgia. Patients with present or past history of psoriasis, psoriatic arthritis, known or suspected rheumatic inflammatory conditions (e.g. rheumatoid arthritis, spondyloarthritis and gout), and/or inflammatory bowel disease will be excluded.
9714854|NCT04587596||Clinical staff|All clinical staff employed at one surgery in Middlesbrough, UK who wish to participate
9980268|NCT01389986|No Intervention|Conventional|Conventional postoperative feeding schedule
9714855|NCT04587700||Non-marijuana user|Has never consumed marijuana or has abstained for at least the past 12 months
9714856|NCT04587700||Chronic Marijuana User|Has used marijuana in any form at least once a week for the past 3 months
10195805|NCT04458766|Experimental|Interventions|"All subjects in this trial will receive the following interventions:~Pre-Intervention (Days 0-14): Subjects given access to Wellth application reminders, no incentives provided. A virtual check in with the study team will occur at the end of the pre-intervention period (14 days).~Intervention (Days 15-74): Subjects will use Wellth app for 60 days, with incentives provided at the 30- and 60-day mark. At the end of the intervention period (Day 60), the subject will attend a clinic visit with the medical provider and a fasting lipid panel and MMAS will also be collected at this time.~Post-intervention (Days 74-134): Subjects will continue to use the Wellth app and receive reminders, but with no incentives provided, for 60 days. A clinic visit, fasting lipid profile, and MMAS will also be collected following the post-intervention period."
10195806|NCT04454476|Experimental|Trametinib treatment|
9714857|NCT04587726|Experimental|Edutainment Body Image Video 100%|Behavioural: Girl's room video - watching 100% of the video
9714858|NCT04587726|Experimental|Edutainment Body Image Video 50%|Behavioural: Girl's room video - watching 50% of the video
9714859|NCT04587726|Experimental|Edutainment Body Image Video 25%|Behavioural: Girl's room video - watching 25% of the video
9714860|NCT04587726|Active Comparator|Control Video 100%|"Chicken Girl's Episode - 100%~Appearance neutral episode matched for target audience and video length"
9714861|NCT04587726|Active Comparator|Control Video 50%|"Chicken Girl's Episode - 50%~Appearance neutral episode matched for target audience and video length"
9714862|NCT04587726|Active Comparator|Control Video 25%|"Chicken Girl's Episode - 25%~Appearance neutral episode matched for target audience and video length"
9714863|NCT04587713|Experimental|Part A, Sequence 1|"Part A, Sequence 1 = Treatment (Tx) C, Tx A, Tx C, Tx A~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout between treatments"
9714864|NCT04587713|Experimental|Part A, Sequence 2|"Part A, Sequence 2: Tx D, Tx B, Tx D, Tx B~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
9714865|NCT04587713|Experimental|Part A, Sequence 3|"Part A, Sequence 3: Tx C, Tx A, Tx D, Tx B~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
9714866|NCT04587713|Experimental|Part A, Sequence 4|"Part A, Sequence 4: Tx D, Tx B, Tx C, Tx A~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
9714867|NCT04587713|Experimental|Part A, Sequence 5|"Part A, Sequence 5: Tx A, Tx C, Tx A, Tx C~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
9714868|NCT04587713|Experimental|Part A, Sequence 6|"Part A, Sequence 6: Tx B, Tx D, Tx B, Tx D~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
9714869|NCT04587713|Experimental|Part A, Sequence 7|"Part A, Sequence 7: Tx A, Tx C, Tx B, Tx D~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
9714870|NCT04587713|Experimental|Part A, Sequence 8|"Part A, Sequence 8: Tx B, Tx D, Tx A, Tx C~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
9714871|NCT04587713|Experimental|Part B,Treatment A|Single oral dose of Treatment A on Day 1
9714872|NCT04587349|Active Comparator|Exercise+FU 2/week|Post stroke group that received 2 years of intensive therapy. (2/week)
9714873|NCT04587349|Active Comparator|Exercise+FU 3/week|Post stroke group that received 2 years of intensive therapy. (3/week)
9714874|NCT04587349|Active Comparator|physiotherapy|Post stroke group that received 2 years of traditional physiotherapy. (3/week)
9714875|NCT04587349|No Intervention|Exercise+FU - controll|He did not receive treatment after 4 weeks of intensive care. it functions only as a control group.
9714876|NCT04587050||Cohort 1|Women with perinatally acquired HIV aged 18 or over who are sexually active
9714877|NCT04587050||Cohort 2|Women with perinatally acquired HIV aged 18 or over who are not sexually active
9714878|NCT04587063|Active Comparator|Standard Email|"The standard of care email is the same as one used in prior outreach efforts at the health system, emphasizing reduced cost for medications and convenience."
9714879|NCT04587063|Experimental|Email with Healthcare Cost Savings|The email emphasizes future reductions in healthcare costs due to increased adherence with mail-order pharmacy, in addition to mentioning reduced prices for medications. It also uses fear appeals by stating the risk of hospital stays and how mail-order pharmacy could be an easily-achievable way to avoid this negative consequence.
9714880|NCT04587063|Experimental|Email with Endorsement|The email is a letter from a doctor at the health system's health plan--who may been seen as a trusted source of information--encouraging the benefits of using a mail-order pharmacy.
9714881|NCT04587063|Experimental|Email with Comparison Table|The email includes a table comparing the benefits and drawbacks of mail-order and chain pharmacies, which appeals to their sense of agency and allows them to make the choice that best suits them.
9714882|NCT04587063|No Intervention|No Contact|Members do not receive an email.
9714883|NCT04587102|Active Comparator|whole body viberation :group A|will receive low vibrational training in the form of whole body vibration for 8 weeks
9714884|NCT04587102|Active Comparator|control group (B)|control
9714885|NCT04587258||Breast Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using mammograms.
9714886|NCT04587258||Colorectal Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using colonoscopies
9714887|NCT04586998|Experimental|"Exhaled drug monitor Edmon"|Comparison between propofol in exhaled breath and blood plasma
9714888|NCT04586959|Experimental|Surgery With UM (Arm MAN UA)|Subjects that undergo a MIS approach with a uterine manipulator (experimental arm)
9714889|NCT04586959|Active Comparator|Surgery Without UM (Arm Control)|Subjects that undergo a MIS approach without a uterine manipulator (control arm)
9714890|NCT04586933|Active Comparator|Omega-3|"0,9 gram omega-3/capsule x 4 = 3,6 gram omega-3 daily~It will be investigated whether diet optimization followed with supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used"
9714891|NCT04586933|Placebo Comparator|Placebo capsules|Soya oil
9714892|NCT04587167|Experimental|HPV ECHO|Clinics randomly assigned to this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. The intervention has a curriculum of 10 sessions focused on the evidence-based Announcement Approach. Sessions will be 60 minutes in duration and held every other weekly for 4 months at regularly scheduled times.
9714893|NCT04587167|Experimental|HPV ECHO+|Clinics randomly assigned to this arm will receive the HPV ECHO intervention plus a systems communication strategy to deliver recall notices to parents who initially decline HPV vaccination. This arm includes 12 primary care clinics in Pennsylvania.
9714894|NCT04587167|No Intervention|Control|Clinics randomly assigned to this arm will receive no ECHO interventions. This arm includes 12 primary care clinics in Pennsylvania.
9714895|NCT04587180||Patients with cutting-through|Patients who had cutting-through during the lateral knotless anchor fixation.
9714896|NCT04587180||Patients without cutting-through|Patients who didn't have cutting-through during the lateral knotless anchor fixation.
9714897|NCT04587089|Experimental|Conventional Treatment + Guedes-Pinto Paste Group|In this group, the conventional endodontic treatment will be made, the canals will be irrigated and filled with Guedes-Pinto paste.
9714898|NCT04587089|Experimental|Irrigation + Guedes-Pinto Paste Group|In this group,the canals will be irrigated and filled with Guedes-Pinto paste.
9714899|NCT04587089|Experimental|Irrigation + aPDT + Guedes-Pinto Paste Group|In this group, the canals will be irrigated, antimicrobial photodynamic therapy will be performed and the canals will be filled with Guedes-Pinto paste.
9714900|NCT04587219|Experimental|Gam COVID Vac Vaccine|the test drug will be administered according to the prime-boost scheme: the introduction of component 1 (Ad26) will be carried out on the 1st day, and component 2(Ad5)- on the 21st day of the study.
9714901|NCT04587011|Experimental|T1|Tegoprazan A mg or placebo
9714902|NCT04587011|Experimental|T2|Tegoprazan B mg or placebo
9714903|NCT04587011|Experimental|T3|Tegoprazan C mg or placebo
9714904|NCT04587011|Experimental|T4|Tegoprazan D mg or placebo
9714905|NCT04587141|Experimental|Sucrosomial iron|One or two capsules/die of sucrosomial iron will be assumed by the participant, depending on hemoglobin (Hb) concentration and participant body weight, for 8 weeks. Each capsule contains 30 mg of iron.
9714906|NCT04587141|Active Comparator|Ferric gluconate|Ferric gluconate will be administered by iv infusion, 125 mg of elemental iron once or twice weekly for 4 or 8 weeks depending on Hb concentration and patient body weight.
9714907|NCT04587141|Active Comparator|Ferric carboxymaltose|Two or three iv infusions of 500-1000 mg of elemental iron will be given as ferric carboxymaltose, over a 4 week period. Dosage and number of infusions will be established depending on Hb concentration and patient body weight.
9714908|NCT04587206|Experimental|Experimental: Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
9714909|NCT04587206|Experimental|Experimental: Sequence2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
9714910|NCT04587115|Placebo Comparator|Oxycodone|This arm will be considered the control arm, containing oxycodone as the placebo.
9714911|NCT04587115|Experimental|Oxycodone and Risperidone|Administration of oxycodone plus risperidone in a single capsule
9714912|NCT04587115|Experimental|Oxycodone and Ziprasidone|Administration of oxycodone and risperidone in a single capsule
9714913|NCT04586894||Patients|
9714914|NCT04587037|Experimental|Fascia lata group|
9714915|NCT04587037|Experimental|Dermal allograft group|
9714916|NCT04586868|Experimental|A psychotic disorder|Patients, age 13-18 years old, diagnosed with a psychotic disorder (WHO ICD-10 )
9714917|NCT04586569|No Intervention|Standard Education|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham.
9714918|NCT04586569|Experimental|Pediatric Interactive Relational Agent (PIRA)|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham and will be given access to an interactive, online educational tool for use prior to surgery. This Pediatric Interactive Relational Agent (PIRA) will be able to be accessed as many times as the family would like prior to surgery.
9714919|NCT04586816|Placebo Comparator|vehicle only-placebo|Vehicle cream base containing no maple leaf extract to be applied twice daily to the face
9714920|NCT04586816|Experimental|1% red maple leaf extract|lotion preparation with 1% red maple leaf extract to be applied twice daily to the face
9714921|NCT04586816|Experimental|5% red maple leaf extract|lotion preparation with 5% red maple leaf extract to be applied twice daily to the face
9714922|NCT04586543|Experimental|Selegiline+ Docetaxel|Selegiline and plus Docetaxel
9714923|NCT04586543|Active Comparator|Docetaxel|Docetaxel
9714924|NCT04586725|Active Comparator|Encouragement every minute|Patients will be randomised to six tests at one week apart
9714925|NCT04586725|Active Comparator|Encouragement every two minutes|Patients will be randomised to six tests at one week apart
9779647|NCT05085704||Adolescents and adults with Glut1 deficiency|"Adolescents and adults with previously documented diagnosis of Glut1 Deficiency with diagnosis genetically confirmed or confirmed by PET scan of the brain.~Ages 16 to 65~Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included."
9779648|NCT05085704||Normal healthy adolescents and adults|"Adolescents or adults in good general health.~Ages 16 to 65.~Persons with dental fillings, dental crowns, and short (max. 4 cm) dental retainer wires can be included."
9779649|NCT05083143||COVID-19 Testicular Cancer|Patients diagnosed with testicular cancer in the COVID-19 period
9714926|NCT04586686|Other|Group 1: right ovarian biopsy|Patients in group 1 will undergo a laparoscopy for an ovarian biopsy from the right ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
9714927|NCT04586686|Other|Group 2: left ovarian biopsy|Patients in group 2 will undergo a laparoscopy for an ovarian biopsy from the left ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
9714928|NCT04586595|Experimental|Intervention arm|GP trainees in this arm will receive the REVISiT intervention which will involve having their prescribing reviewed and feedback provided, at two time points (approximately 100 prescriptions at each time point) separated by approximately a 3-month time period.
9714929|NCT04586595|No Intervention|Control arm|GP trainees in this arm will continue with training as usual and will have their prescribing (approximately 200 prescriptions) reviewed once but representing two time points - separated by an approximate 3-month time period. Feedback will occur at one time point, to cover the review for the 200 prescriptions.
9714930|NCT04586517|Experimental|Intervention group|Participants will receive supervised heavy-load resistance training twice a week during treatment with chemotherapy (approximately 16-weeks). After end of chemotherapy, participants will be encouraged to continue the training program and are provided with 12-month membership at a local gym.
10195807|NCT04454411|Experimental|Buprenorphine|Participants assigned to treatment with extended-release buprenorphine
10195808|NCT04454411|Active Comparator|Naltrexone|Participants assigned to treatment with extended-release naltrexone
10195809|NCT04447846|Experimental|Cannabidiol/ Epidiolex|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 24 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of cognitive impairments in patients with Sturge-Weber syndrome.
10195810|NCT04446143|Other|Application of mindfulness meditation prior to UDS|Those in the mindfulness medication group will listen to an audio-taped mediation, which takes 10 mins to complete.
9714931|NCT04586517|Active Comparator|Control group|Participants will be encouraged to continue with their usual activities during chemotherapy and not start resistance training (approximately 16-weeks). After end of chemotherapy participants will be offered to attend a 2-week introduction to the strength-training program and provided with a 12-month membership at a local gym.
9714932|NCT04586504|Experimental|0.2 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.2 mg/kg.
9714933|NCT04586504|Experimental|0.3 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.3 mg/kg.
10195811|NCT04446143|Active Comparator|No meditation prior to UDS|The control group will be seated in a quiet empty room where they wait for 10 min.
9714934|NCT04586504|Experimental|0.4 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.4 mg/kg.
9714935|NCT04586504|Experimental|0.5 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.5 mg/kg.
10195812|NCT04441281|Active Comparator|Single-tooth tenaculum (Pozzi forceps)|In the control arm, a single-tooth tenaculum, Pozzi forceps, used during routine IUD insertion, is employed to hold and stabilize the cervix.
9714936|NCT04586842|Experimental|Community-based Occupational Therapy|Experimental study group that will receive a domiciliary and community-based occupational therapy on mental health, developed on the basis of the Model Of Human Occupation.
9714937|NCT04586842|Active Comparator|Standard community-based intervention|Control group of the study that will receive community-based interventions, public or private level (e.g. community nursing, social education and/or psychology).
10195813|NCT04441281|Experimental|AspivixTM cervical vacuum tenaculum|In the experimental arm, the investigational AspivixTM cervical vacuum tenaculum is employed to hold and stabilize the cervix.
9714938|NCT04586803|Experimental|A|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
10195814|NCT04440761||Troponin rise/ diagnosis of MINOCA|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients diagnosed with MINOCA among all patients with coronary artery disease.
10204796|NCT04922801||Hyperthyrodism|"Patients will undergo 131I-Hyperthyroidism MRT in accordance with existing protocols at GSTTFT. Patients will have one whole-body scan at 24 hr post MRT which will not involve any additional radiation. In addition, all MRT patients will be asked to undertake the following non-invasive procedures.~Post-treatment gamma camera (Planar Whole Body & SPECT/CT) imaging to estimate disease/ target tissue and whole-body dose for Neuroendocrine and thyroid cancer MRT.~Post-treatment gamma camera planar Whole Body imaging for hyperthyroidism MRT.~Post-treatment patient-led self-monitoring.~Complete a feedback questionnaire relating to the use of self radiation monitoring."
10204797|NCT04911023||Patients operated by fissurectomy|
10204798|NCT04911023||Patients operated by fissurectomy with anoplasty|
10204799|NCT04898959||Group 1|Lower extremity amputees
9714939|NCT04586803|Experimental|B|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
9714940|NCT04586803|Experimental|C|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
9714941|NCT04586803|Experimental|D|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
9714942|NCT04586803|Experimental|E|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
9714943|NCT04586803|Experimental|F|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
9714944|NCT04586608|Active Comparator|active comparator|
9714945|NCT04586608|Other|soybean oil-based IVFE|soybean oil-based IVFE
9714946|NCT04586790|Experimental|midodrine group|midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine
9714947|NCT04586790|Experimental|minirin group|the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin
9714948|NCT04586790|Experimental|control group|the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
9714949|NCT04586777|Experimental|Anodal tvDCS|20 minutes of anodal tvDCS will be applied over the spine at 2.5mA.
9714950|NCT04586777|Experimental|Cathodal tvDCS|20 minutes of cathodal tvDCS will be applied over the spine at 2.5mA.
9714951|NCT04586777|Sham Comparator|Sham tvDCS|20 minutes of sham tvDCS will be applied over the spine.
10195815|NCT04436133|Experimental|vaccine group|
9714952|NCT04587284||Patients with robot-assisted laparoscopic radical prostatectomy|
9714953|NCT04587284||Patients with open retropubic radical prostatectomy|
9714954|NCT04587284||Patients with laparoscopic radical prostatectomy|
9714955|NCT04586738|Other|Non-resorbable uveoscleral implant associated with absorbable collagen matrix|non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix
9714956|NCT04586738|Other|Isolated absorbable collagen matrix implant|non-perforating deep sclerectomy surgery with isolated absorbable collagen matrix implant
10195816|NCT04436133|Active Comparator|Positive control group|
10195817|NCT04430218|Experimental|iSens|3 months trial with the iSens system
9714957|NCT04586855||Healthy persons|Noninvasive ventilation and Cough Assist
10195818|NCT04430218|No Intervention|State of the Art Prosthesis|3 months trial with their own prosthesis.
9714958|NCT04586829|Active Comparator|Conventional diet|Conventional diet. (50% carbohydrate, 30% lipids, 20% protein). Current dietary recommendations from official guidelines will be reinforced.
10195819|NCT04427605||ketamine group|ketamine intravenous infusion in pediatric patients refractory to conventional analgesic-sedative strategy lasted more than 12 hours (dose range 10-50 mcg/Kg/min)
9714959|NCT04586829|Experimental|Ketogenic diet|Tailored ketogenic diet. Participants will be allowed to chose their meals as long as they consume less than 50gr of carbohydrates per day.
10195820|NCT04426539||Amyloid PET-Positive|Those for whom a beta amyloid PET scan is consistent with underlying AD as causing or contributing to cognitive impairment
10195821|NCT04426539||Amyloid PET-Negative|Those for whom a beta amyloid PET scan has ruled out AD (i.e. not consistent with underlying AD as causing or contributing to cognitive impairment)
10195822|NCT04424602|Experimental|cyclophosphamide|participants will receive intra venous cyclophosphamide 500mg once every two weeks for 6months.
10195823|NCT04424602|Active Comparator|mycophenolate|participants will receive oral mycophenolat 2 to 3mg/kg for 6 months.
9714960|NCT04586582||ST-segment resolution <40.15%|ST-segment resolution <40.15%
9714961|NCT04586582||ST-segment resolution >40.15%|ST-segment resolution >40.15%
9714962|NCT04586491|Experimental|Study group/ Oral care protocol with saline solution|All patients took oral care protocol in the unit with saline solution
9714963|NCT04586491|Experimental|Control group/ Oral care protocol with sodium bicarbonate solution|All patients took oral care protocol in the unit with sodium bicarbonate solution
9714964|NCT04586465|Experimental|Neoadjuvant ICI combination with chemotherapy for stage Ⅱ-Ⅲ NSCLC|Eligible patients with clinical stage Ⅱ-Ⅲ NSCLC will receive dynamic PET-CT before and after 3 cycles neoadjuvant pembrolizumab plus chemotherapy, then patients receive surgical resection. Changes in tumor size were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Net uptake rate constant of FDG-Ki value based on dynamic PET will be calculated to evaluate Ki changes before and after treatment. Pathological tumor response were evaluated according to IASLC recommendations. Dynamic PET will be compared with RECIST whether it can better predict the pathological tumor response and disease free survival.
9779650|NCT05083143||PreCOVID-19 Testicular Cancer|Patients diagnosed with testicular cancer before the COVID-19 period
9779651|NCT05080673|Experimental|Arm 1|5-Year and 10-Year Surveillance Colonoscopy after Qualifying Colonoscopy
10195824|NCT04403737|No Intervention|Usual Care|Patients in the control arm will have a Rothman Index calculated but this will not be visible to providers.
10195825|NCT04403737|Experimental|Intervention|Patients in the intervention arm will have a Rothman Index calculated and will be visible to providers. Providers will be given a set of clinician-specific recommended-use protocols that they will be encouraged to follow based on the RI thresholds achieved by patients.
10195826|NCT04398329|Experimental|Phase 1b (Cohort 1)|Fixed dose of HTX-034.
10195827|NCT04398329|Experimental|Phase 1b (Cohort 2)|Individualized dose of HTX-034.
10195828|NCT04398329|Experimental|Phase 2 (Expansion): Low Dose|Fixed dose of HTX-034.
10195829|NCT04398329|Experimental|Phase 2 (Expansion): High Dose|Individualized dose of HTX-034.
10195830|NCT04398329|Active Comparator|Phase 1b and Phase 2|Bupivacaine HCl.
10195831|NCT04391855|Experimental|Tramadol with ropivacaine|Tramadol 2mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
9714965|NCT04586218|Active Comparator|Manual control of vasopressor infusion|"Vasopressor will be manually titrated by intensive care unit nurses in charge of the patients to maintain mean arterial pressure > 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
9714966|NCT04586218|Experimental|Computer guided vasopressor infusion|"Vasopressor will be titrated automatically by the closed-loop system to maintain mean arterial pressure > 65 mmHg.~Fluid administration consists in optimization of stroke volume (assisted fluid management) during the postoperative period"
9714967|NCT04586140||Patients with COVID-19 infection|This study will be carried out on patient data usually collected as part of their care. The patients were infected with COVID-19 and hospitalized between 03/25/2020 and 05/07/2020, and who benefited from GAREC's intervention.
9714968|NCT04586140||Nursing staff AND GAREC Members|This study also concerns data collected in the context of semi-structured interviews with health professionals, in a prospective manner. These are caregivers who are members of GARED or who called on GAREC between 25/03/2020 and 07/05/2020.
9714969|NCT04586283|Experimental|Maternal Prone Position|Participants will initially be assessed in left-lateral position for 20 minutes. Participants will then be asked to lie in a prone position for 30 minutes supported by a specially designed pillow. Participants will then return to a left-lateral position for 20 minutes.
9714970|NCT04586335|Experimental|CYH33 in Combination with Olaparib|CYH33 in Combination with Olaparib; 20 mg CYH33 QD in combination with olaparib 300 mg BID. Two additional dose levels of CYH33 at 30 mg QD and CYH33 at 40 mg QD in combination with olaparib 300 mg BID will be evaluated.
9714971|NCT04586127|Experimental|Adolescents and Young Adults Needs Assessment & Service Bridge (AYA NA-SB)|Subjects will complete 2 online surveys over the course of 1 month; each should take about 15 minutes to complete.
9714972|NCT04586088|Experimental|Apatinib plus Camrelizumab arm|Subjects receive apatinib plus camrelizumab
9714973|NCT04586309|Experimental|Early TM Training|This group will receive training in Transcendental Meditation and will complete assessments at baseline, 1 month and 3 months.(3 assessments in total).
9714974|NCT04586309|Active Comparator|Delayed TM training|This arm will complete the baseline, 1 month and 3 month assessments and then will receive the TM training, followed by additional 1 month and 3 month post-training assessments (5 in total)
9714975|NCT04586257|Experimental|Group I|patients in this group will receive Erector spinae plane block after induction of general anesthesia.
9714976|NCT04586257|Experimental|Group II|patients in this group will receive thoracolumbar interfascial plane block after induction of general anesthesia
9714977|NCT04586192|Experimental|COMET|Participants receive modules focused on cognitive restructuring, gratitude, behavioral activation and self-compassion. Participants were randomized to receive 3 of the 4 possible modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.Participants in the intervention condition were randomized to receive descriptions of the four modules at the beginning of the intervention that were phrased to focus on building and improving strengths (positive) or reducing negative emotions and behaviors (negative).
9714978|NCT04586192|Sham Comparator|Self-Awareness Control|Participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
9714979|NCT04586192|No Intervention|Waitlist|Participants filled out all pre-test and post-test measures without having access to COMET of the active control exercises. Participants in this condition will receive access to COMET at the end of the study.
9714980|NCT04586179|Active Comparator|Aerobic (treadmill) Exercise|Participants will wear a heart rate monitor and complete the Buffalo Concussion Treadmill Test
9714981|NCT04586179|Experimental|Dynamic Exercise|Participants will wear a heart rate monitor and complete a dynamic exertion assessment that incorporates directional changes that incrementally increases in exercise intensity
9714982|NCT04586114||Early corticosteroid|Corticosteroid treatment within first seven days after ICU admission
9714983|NCT04586114||Late corticosteroid|Corticosteroid treatment later than seventh day's after ICU admission
9714984|NCT04586114||No corticosteroid|No corticosteroid treatment during ICU stay
9714985|NCT04586101|Experimental|Training intervention|
9714986|NCT04586101|No Intervention|Control interverntion|
9714987|NCT04586374||Control Group|Transported patients with full monitoring (including an arterial line), without inotropic/vasoactive support.
9714988|NCT04586374||Study Group|Transported patients with full monitoring and vasoactive/inotropic support being delivered by a syringe driver.
9714989|NCT04586452|Experimental|AAA Group (Aim 3A)|40 (20 men; 20 women) participants with a diagnosis of AAA (40-80 years) will undergo a PET/CT scan prior to their scheduled surgical repair of their condition. The radiotracer, 64Cu-DOTA-ECL1i, will be injected to detect CCR2+ inflammatory cells. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
9714990|NCT04586452|Experimental|Non-AAA Group|10 (5 men; 5 women) participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard of care. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
9714991|NCT04586452|Other|Ex Vivo Human AAA Specimens (Aim 2A)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens.
9714992|NCT04586452|Other|Radiotracer and CCR2 (Aim 2B)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair.
9714993|NCT04586452|Experimental|AAA Group (Aim 3B-Reproducibility)|20 (10 men; 10 women) will receive a second PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
9714994|NCT04586166|Experimental|RP Sling Group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure
9714995|NCT04586166|Experimental|SIS Group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure
9714996|NCT04586348|Experimental|Low Iodine Supplement|Iodine (potassium iodide) 20 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
9714997|NCT04586348|Active Comparator|Standard Iodine Supplement|Iodine (potassium iodide) 200 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
9714998|NCT04586361|Experimental|Experimental group 1|Intraoperative1 kit of Platelet-rich plasma(PRP) injection into knee joint after anterior cruciate ligament (ACL) reconstruction.
10195832|NCT04391855|Experimental|Dexmedetomidine with ropivacaine|Dexmedetomidine 1μg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
9714999|NCT04586361|Experimental|Experimental group 2|Intraoperative1 kit of PRP+Hyaluronic acid(HA) injection into knee joint after ACL reconstruction.
9715000|NCT04586361|Placebo Comparator|Experimental group 3|Intraoperative 20 ml normal saline injection into knee joint after ACL reconstruction.
9715001|NCT04586439|Experimental|Panel A: JNJ-73763989|Participants will receive single subcutaneous (SC) injection of low dose of JNJ-73763989 on Day 1.
9715002|NCT04586439|Experimental|Panel B: J NJ-73763989|Participants will receive single SC injection of high dose of JNJ-73763989 on Day 1.
9715003|NCT04585997|Active Comparator|Mepolizumab|Mepolizumab
9715004|NCT04585997|Active Comparator|Omalizumab|Omalizumab
9715005|NCT04585945||Group 1 (Cases)|Patients that test positive for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
9715006|NCT04585945||Group 2 (Control)|Historic group of patients delivering prior to the COVID-19 pandemic.
9715007|NCT04585737|Experimental|Treatment group 1|Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food.
9715008|NCT04585737|Active Comparator|Treatment group 2|Treatment Group 2 (n=74): Stay on baseline regimen consisting of FDC of B/F/TAF (50mg/200mg/ 25mg) (taken as prescribed) without regard to food.
9715009|NCT04585750|Experimental|Phase 1 Dose Escalation|Multiple dose levels of PC14586 will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D).
9715010|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort A|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort A participants will have advanced solid tumors harboring a p53 Y220C mutation who meet all eligibility criteria and have measureable disease per RECIST 1.1.
9715011|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort B|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort B participants will have advanced solid tumors harboring a p53 Y220C mutation who do not meet all eligibility criteria (e.g. have a primary central nervous system (CNS) tumor) and do not have measurable disease per RECIST 1.1.
9715012|NCT04585802||Suicide Attempters (1)|patients with a suicide attempt
9715013|NCT04585802||Suicide Ideators (2)|patients with suicidal ideation
9715014|NCT04585802||Control Group (3)|patients without suicide attempt and without suicide ideation
9715015|NCT04585867|Active Comparator|Liposomal bupivacaine|Exparel (266mg) given by surgeon just prior to sternal closure
9715016|NCT04585867|Active Comparator|Bupivacaine|40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure
9715017|NCT04585841|Experimental|Intervention group|Cancer patients receiving cannabidiol
9715018|NCT04585841|No Intervention|Control group|Cancer patients not receiving cannabidiol
9980269|NCT01389999||Chronic back pain patients|Patients who have had back pain for at least three months.
9980270|NCT01390012|Active Comparator|Dexamethasone oral|
9715021|NCT04585880|Experimental|Virtual Collaborative Care Clinic|The Virtual Collaborative Care Clinic arm participants use a home blood pressure monitor and routine blood pressure measurements will be uploaded to a dashboard monitored by clinical pharmacists. Blood pressure will be managed aggressively by the clinical pharmacists in coordination with Primary Care Physicians.
9980271|NCT01390012|Active Comparator|Dexamethasone intravenous|
9980272|NCT01390025|Experimental|TCN-032|
10195833|NCT04391855|Experimental|Magnesium with ropivacaine|Magnesium sulfate 10 mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
10195834|NCT04391855|Placebo Comparator|Placebo with ropivacaine|Ropivacaine (10mg/ml) 100mg with 5ml isotonic saline for wound infiltration
10195835|NCT04381897|Experimental|Group A: NAC 1800mg then Placebo|NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
9715022|NCT04585880|No Intervention|Control Intervention|The control intervention will consist of providing the participant with educational material and a home blood pressure monitor. The patients in the control group will not have support from Virtual Collaborative Care Clinic pharmacists. Routine blood pressure measures using their device will not be collected via the dashboard and will not be available for pharmacist review. Participants will continue to see their physicians for their usual care for blood pressure management.
9715023|NCT04585932|Active Comparator|Group I (apalutamide, leuprolide, degarelix)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
9980273|NCT01390025|Placebo Comparator|Placebo|
9980274|NCT01390051|Active Comparator|Innohep|Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
10195836|NCT04381897|Experimental|Group B: Placebo then NAC 1800mg|NAC Placebo-matching solution, orally every 8 hours, for 8 weeks, followed by a 2-week wash-out period, followed by NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
9715024|NCT04585932|Experimental|Group II (apalutamide, leuprolide, degarelix, RT)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo RT between cycles 4-7 in the absence of disease progression or unacceptable toxicity.
9715025|NCT04585776|Experimental|LY900014 + Insulin Degludec|LY9000014 and insulin degludec given subcutaneously (SC).
9715026|NCT04585971||Subjects|Cerebral blood flow of a subject is measured using three methods in both common carotid and vertebral arteries. 1) Phase-contrast MR 2) Doppler sonography 3) Signal Intensity Gradient (SIG) To determine whether there is a correlation between the measured values, the correlation coefficient is calculated and analyzed.
9715027|NCT04585828|Experimental|Bili Cocoon|The infants will be treated with phototherapy using a double sided fiber optic pad called Bili Cocoon with an irradiance of 30 uW/cm2/nm from both sides.
9715028|NCT04585828|Active Comparator|Conventional blue light|The infants will be treated with blue light from above at 30 Uw/cm2/nm which is the standard treatment.
9715029|NCT04585763|Experimental|Single Arm|
9715030|NCT04585672|Other|Healthy and Cirrhosis|Ammonia infusion with and without ammonia targeting
9715031|NCT04585711|Other|Optimal dosing|Obese children (≥ 2 year old) and adults with juvenile idiopathic arthritis (JIA) or Rheumatoid Arthritis (RA) who are starting etanercept as part of their routine medical care.
9715032|NCT04585893|Experimental|Single Arm Rituximab|"The safety and efficacy of first-line rituximab will be assessed through a risk-stratified rituximab-based Multicentric Castleman disease (MCD) The planned sample size is 27 adult patients accrued at a rate of 10 patients annually.~High-risk patients (defined as patients with ECOG performance status >2 or hemoglobin <8 g/dL) will receive four weekly doses of rituximab (375 mg/m2) and etoposide (100 mg/m2).~Low-risk patients will receive the same dose of rituximab (four weekly doses at 375 mg/m2) alone."
9715033|NCT04585698||headache patients|
9715034|NCT04585698||healthy subjects|
9715035|NCT04586036|Experimental|young healthy adults|Gait measured by Vicon Nexus System
9980275|NCT01390051|No Intervention|no treatment|
9980276|NCT01390103||Assessment following the hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
9980277|NCT01390116|Placebo Comparator|Sugar pill|looks like and is given in the same way as the experimental treatment but contains no active ingredient
9980278|NCT01390116|Experimental|AGE|Encapsulated aged garlic extract, 4 capsules per day, 2.56 g/day
9980279|NCT01390129|Experimental|Control|
9980280|NCT01390129|Active Comparator|Remote ischemic preconditioning|
10195837|NCT04375072|Experimental|active tDCS paired with active MBM,|
10195838|NCT04375072|Active Comparator|sham tDCS paired with active MBM|
10195839|NCT04375072|Active Comparator|active tDCS paired with sham MBM|
10195840|NCT04375072|Sham Comparator|sham tDCS paired with sham MBM|
10195841|NCT04373915|No Intervention|Standard Bedside Rounding|
9715036|NCT04586036|Experimental|young adults with chronic ankle joint instability|Gait measured by Vicon Nexus System
9715037|NCT04585607|Experimental|Expanded hemodialysis (HDx)|HDx therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
9715038|NCT04585607|Active Comparator|Conventional hemodialysis|Conventional hemodialysis therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
9715039|NCT04585490|Experimental|Cohort 1 minimal residual disease positive (MRD+)|Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy [carboplatin/pemetrexed] and durvalumab (1500 mg IV every 21 days, for 1 year), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks.Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.
9715040|NCT04585490|Experimental|Cohort 2 minimal residual disease negative (MRD )|Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab(10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.
9779652|NCT05080673|Experimental|Arm 2|10-Year Surveillance Colonoscopy after Qualifying Colonoscopy
9980281|NCT01390142|Experimental|Control|
9980282|NCT01390142|Active Comparator|RIPer|Remote ischemic preconditioning
9980283|NCT01390142|Active Comparator|RIPer + IPost|Remote ischemic preconditioning and Local ischemic postconditioning
9980284|NCT01390155||1|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left anterior descending coronary artery.
9715041|NCT04585555||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay.
10195842|NCT04373915|Experimental|Remote Bedside Rounding|Parents of infants on one care team will have the opportunity to participate in rounds via secure remote video software.
10195843|NCT04373759||Unexpected in-intensive care unit cardiac arrest patients|ICUCA Patients admitted in intensive care unit for a confirmed COVID-19 and presenting an unexpected in-intensive care unit cardiac arrest
9715042|NCT04585334|Experimental|Arm A Tricortin|Tricortin 1000 by intramuscular route
9715043|NCT04585334|Active Comparator|Arm B Itami|Itami Diclofenac sodium medicated plaster by topical application
9715044|NCT04585334|Placebo Comparator|Arm C Placebo|Placebo
9715045|NCT04585503|Experimental|Central nervous system monitoring|Each 20 patients will be implanted with subdural or intra cortical electrodes
9715046|NCT04585542|Experimental|Polyethylene glycol 3350 (MiraLax)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~One study arm is the nonspecific laxative MiraLax (one dose of 17g). Since constipation can contribute to hyperkalemia, this arm will study the effect of treating constipation instead of direct cation exchange for potassium in the gut."
9715047|NCT04585542|Experimental|Sodium polystyrene sulfonate (Kayexalate)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
9715048|NCT04585542|Experimental|Patiromer (Veltassa)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
9715049|NCT04585542|Experimental|Sodium zirconium cyclosilicate (Lokelma)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
9715050|NCT04585347|Experimental|Regimen A|ALZ-801 171 mg tablet, fasting, once
9715051|NCT04585347|Experimental|Regimen B|ALZ-801 205 mg tablet, fasting, once
9715052|NCT04585347|Experimental|Regimen C|ALZ-801 205 mg tablet, after food once
9715053|NCT04585347|Experimental|Regimen D|ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once
9715054|NCT04585412|Experimental|Palonosetron (Stothu®)|Stothu® Solution for Injection 0.25 mg/5 mL
9715055|NCT04585412|Active Comparator|Palonosetron (Aloxi®)|Aloxi® Solution for Injection 0.25 mg/5mL
9715056|NCT04585594|Experimental|Mi Propio Camino (MPC; My Own Way)|Participants will complete the MPC intervention alongside usual care for hypertension
9715057|NCT04585594|Active Comparator|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|Participants will complete the HCP intervention alongside usual care for hypertension.
9715058|NCT04585282|Experimental|intervention group|The study group was treated with intensive cognitive behavioral therapy for insomnia.
9715059|NCT04585282|Active Comparator|control group|The control group was treated with traditional cognitive behavioral therapy for insomnia.
9715060|NCT04585633||Low Risk|no complication develop within 30 days after the operation and high GOS value
9715061|NCT04585633||High Risk|"complication or complications develop within 30 days after the operation and low GOS value~Complications:~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~İntracranial hypertension requiring post op surgical drainage,~Status epilepticus or seizures,~The need for tracheal intubation or use of mechanical ventilation after surgery,~Decrease in GKS,~Unmanageable agitation that requires restriction or sedation,~Need for respiratory failure and oxygen therapy,~Unexpected serious motor deficit~Died"
9715062|NCT04585438|Experimental|Single trans-mucosal bio-adhesive disc containing Diclofenac Potassium|Premedication 1 hour before starting endodontic treatment.
9715063|NCT04585438|Placebo Comparator|Placebo Control|Premedication 1 hour before starting endodontic treatment. Identically-appearing trans-mucosal bio-adhesive disc (Does not contain medication)
9715064|NCT04585516||Patient with suspected colorectal cancer|All patients that were admitted to the department of surgery with suspected colorectal cancer between January 2016 and December 2018 (n=459).
9715065|NCT04585516||Patients admitted according to the standardized course of care for colorectal cancer|All patients that were admitted to the endoscopy department according to the standardized course of care for colorectal cancer between September 2016 and December 2018 (n=1271).
9715066|NCT04585516||Patients < 50 years that were admitted for gastroscopy|All patients younger than 50 years that were admitted to the endoscopy department for a gastroscopy between jan 2018 and April 2019 (n= 1915)
9715067|NCT04585516||Patients >80 years that were admitted for colonoscopy|All patients older than 80 years that were admitted to the endoscopy department for a colonoscopy between Sept 2016 and Jan 2019 (n= 981)
10195844|NCT04373759||In-hospital cardiac arrest patients|IHCA Patients admitted in intensive care unit for an in-hospital cardiac arrest with a confirmed Covid-19
10195845|NCT04373759||Out-of-hospital cardiac arrest|OHCA Patients admitted in intensive care unit for an out-hospital cardiac arrest with a confirmed Covid-19
10195846|NCT04371380|Experimental|OLI phase followed by Injection phase|Participants will be administered cabotegravir at a dose of 30 mg plus rilpivirine dose of 25 mg once daily with meal on Day 1 to Day 28 in OLI phase. There will be 10 to 14 days wash out period after OLI. This will be followed by an injection phase, wherein participants will receive 600 mg cabotegravir long acting given as one 3 milliliter (mL) IM injection plus 900 mg rilpivirine long acting given as one 3 mL IM injection on Day 1.
10204800|NCT04894266|Other|Standard of Care|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital.
9715068|NCT04585659|Experimental|Qigong Intervention|60-90 minute community qigong classes, once per week plus at least 10 minutes of home practice
9715069|NCT04585659|No Intervention|Wait-List Control|Participants asked not to do any qigong, yoga or taichi for 10 weeks. Participants have the option to cross-over to the experimental arm after 10 weeks of no intervention.
9715070|NCT04585321|Other|T-R|"Part 1 (QD) and part 2 (BID):~Period 1: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.~Period 2: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac."
9715071|NCT04585321|Other|R-T|"Part 1 (QD) and part 2 (BID):~Period 1: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.~Period 2: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster."
9980285|NCT01390155||2|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left circumflex artery.
9715073|NCT04585243|Experimental|Self-Sampling Kit|Participants will be mailed a Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
9715074|NCT04585360||Patient with Behcet disease|adult patient with Behcet's disease followed regularly in the internal medicine department of Bicetre
9715075|NCT04585165||Risk of HIV acquisition|Individuals reporting behavioral risk of HIV acquisition.
9715076|NCT04585386|Experimental|ATLAS|"Medical device named ATLAS which is an active corset (rigid lumbar restraint) and connected."
9715077|NCT04585386|Active Comparator|Standard lumbar support belt|Standard lumbar support belt : LombaSkin® or Lombogib®
9779653|NCT05079776||Children aged 0-18 months of age|Children aged 0-18 months of age with no structural abnormalities of the lower limbs or orthopedic conditions
9779654|NCT05076539|Other|Geospatial|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery)
9779655|NCT05076357|Experimental|Only diet group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein) during 8 weeks. Follow up with a registered dietitian.
9779656|NCT05076357|Experimental|Only cold exposure group|No dietary intervention. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during 90 min.
9779657|NCT05076357|Experimental|Combined diet + cold exposure group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein). Follow up with a registered dietitian. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during during 90 min.
9980286|NCT01390155||3|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the proximal right coronary artery.
9980287|NCT01390155||4|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the target vessel.
9980288|NCT01390168|Experimental|tailored internet-administrated CBT|Behavioral: tailored internet-administrated CBT
9980289|NCT01390168|Active Comparator|waitlist|waitlist
9980290|NCT01390194||subjects with an underlying liver disease|(1)underlying liver disease; (2) have a lesion on a prior imaging study; (3) must be prior standard MR
10195847|NCT04360837|Experimental|PEEP incremental-decremental alveolar recruitment|"installing EIT belt over the chest at the level of the 5th intercostal space and adjustment of the default recruitment settings in pressure control ventilation mode: pressure control 15 cmH20, PEEP 10 cmH2O, fraction of inspired oxygen (FiO2) and respiratory rate according to the discretion of the attending physician, recording basal parameters~implementation of recruitment:~increment phase: increasing PEEP by 3 cmH2O in every two minutes from 10 cmH2O until top of PEEP 25 cmH2O~decrement phase: decreasing PEEP by 3 cmH20 in every two minutes from 25 cmH20 until the basal PEEP 10 cmH20~end inspiratory hold manoeuvre at every PEEP level~recording closing parameters~Repeating the above detailed intervention once daily as long as the patient is controlled ventilation."
10195848|NCT04358419||PA proven/probable/possible|15 patients with proven, probable or possible PA
9980291|NCT01390207|Experimental|16mm follicles|
10195849|NCT04358419||PA suspected, not confirmed|15 patients as the PA patients, but where the diagnosis of PA is rejected.
10195850|NCT04358419||Healthy controls (PA)|15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.
10195851|NCT04358419||Pneumocystis pneumonia positive|Four patients with confirmed pneumocystis pneumonia
9980292|NCT01390285|Experimental|TENS|
10195852|NCT04358419||Pneumocystis pneumonia negative|If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.
9779658|NCT05075720|Experimental|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with sodium nitrate as an additive.
9779659|NCT05075720|Experimental|Meat without added nitrate|Pork sausages, prepared by a commercial butcher, equivalent in weight to the meat plus nitrate intervention. Nitrate is not an allowed additive in sausages.
9779660|NCT05073497|Experimental|Experimental Group|One minute before the procedure the children in the experimental group will start to play with finger puppets under the direction of the researcher. The researcher will continue to distract the child's attention during the procedure with finger puppets.
9980293|NCT01390285|Sham Comparator|Sham TENS|
9980294|NCT01390311|Active Comparator|Control Cohort|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~No Azacitidine will be given"
9980295|NCT01390311|Experimental|Cohort 1 (Starting Dose)|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 45 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
9715078|NCT04585425|Other|Control|Treatment as usual including sleep hygiene advice
9715079|NCT04585425|Experimental|Intervention|Treatment as usual (sleep hygiene advice) and bedtime music listening
9715080|NCT04585373|Experimental|(24 hours)|kinesio-tapping along with conventional therapy
9980296|NCT01390311|Experimental|Cohort 2|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 75 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
9980297|NCT01390324|Experimental|Fixed-dose combination of naratriptan+naproxen|Fixed-dose combination of naratriptan+naproxen
9980298|NCT01390324|Active Comparator|Naratriptan|Naratriptan
9980299|NCT01390324|Active Comparator|Naproxen|Naproxen
9980300|NCT01390337|Experimental|AC220|
9980301|NCT01390350|Placebo Comparator|Placebo|
9980302|NCT01390350|Experimental|Canakinumab|
9980303|NCT01390363|No Intervention|control|This study arm will receive usual clinical care, but no specific intervention will be made to inform the parent or adolescent that the adolescents is overdue for a routine vaccine.
9980304|NCT01390363|Experimental|Parent Only Group|Parent Only Phone Call
9980305|NCT01390363|Experimental|Parent and Adolescent Group|Parent and Adolescent Phone Call
9980306|NCT01390376|Experimental|BE 1|DAAOI-1 1g
9980307|NCT01390376|Experimental|BE 2|DAAOI-1 2g
9980308|NCT01390376|Placebo Comparator|starch pill|
9980309|NCT01390454|Experimental|Tennis elbow patients|These patients have tennis elbow, according to stated inclusion criteria.
9980310|NCT01390454|Active Comparator|Healthy volunteers|Healthy volunteers are selected and paired according to age, sex, socio-professional category and left- or right-handedness.
9980311|NCT01390480|Placebo Comparator|Placebo|peanut oil
9980312|NCT01390480|Active Comparator|Vitamin D (Oleovit®)|cholecalciferol
9980313|NCT01390493|Experimental|neurofeedback, alpha power|
10195853|NCT04358419||Healthy controls (pneumocystis pneumonia)|Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.
10195854|NCT04344431|Experimental|HBO group|
10195855|NCT04344431|No Intervention|Non-HBO group|
10195856|NCT04343989|Experimental|Clazakizumab 25 mg|
10195857|NCT04343989|Experimental|Clazakizumab 12.5 mg|
10195858|NCT04343989|Placebo Comparator|Placebo|
10195859|NCT04333784||exercise with BFR|Patients with rotator cuff tendinopathy will perform the exercises with a pneumatic cuff and blood flow restricted.
10195860|NCT04333784||Control|Patients with rotator cuff tendinopathy will perform the exercises without a pneumatic cuff.
10195861|NCT04330703||Cases|Children and adolescents referred for their first visit to the outpatient clinic at the Child and Adolescent Psychiatry Department (BUGL) (n=15) will be invited to participate.
10195862|NCT04330703||Contol|Age and sex-matched child from the same postal area (n=15).
10195863|NCT04330703||Syblings|Same parent siblings close in age to the study subjects (cases only) (+3y) (n=x)
10195864|NCT04328129|Experimental|Primary case|Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)
10195865|NCT04328129|Experimental|Family contact|Subject who lived in the household of the primary case while the primary case was symptomatic
10195866|NCT04324944|Experimental|Collaborative Decision Skills Training|Collaborative Decision Skills Training (CDST) is the intervention group (experimental arm).
10195867|NCT04324944|Active Comparator|Money Management|Money Management is the active control arm.
10195868|NCT04321928|Other|Group A|General health education arm.
10195869|NCT04321928|Other|Group B|Personalized health education arm.
10195870|NCT04297618|Experimental|Xiidra treatment|Each participant will use the same study drops, Xiidra, over the course of the 12-week study.
10195871|NCT04296357||IVF children|Children born from in-vitro fertilization
10195872|NCT04296357||IVM children|Children born from in-vitro maturation
10195873|NCT04291196|Experimental|Immersive Virtual Reality|Patients will be immersed in the ECT experience using VR-ECT 360o video (VR-ECT).
10195874|NCT04291196|Other|Standard Treatment|Patients will receive standard preparation for their ECT session.
10195875|NCT04281251|Experimental|ERAT arm|This is the treatment arm where endoscopic therapy of acute appendicitis would be performed
10195876|NCT04266665|Active Comparator|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
10195877|NCT04266665|Placebo Comparator|Normal saline|Normal saline (NaCl 0.9%) administration will start 10 minutes after anesthesia induction and maintained throughout the surgical procedure.
10195878|NCT04264182|Experimental|Ultra-conservative ICD programming|Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones
10195879|NCT04264182|No Intervention|Standard programming (physician discretion)|Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD
10195880|NCT04262791|Experimental|Healthy Volunteers|Healthy participants will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2.
10195881|NCT04262791|Experimental|Participants With Atopic Dermatitis (AD)|Participants with AD will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2. Participants will also be monitored at home via wrist actigraphy, sleep headband when available in the outpatient setting for 7 consecutive nights.
10195882|NCT04261972||CHARM|Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).
10195883|NCT04259749|Active Comparator|Status Quo|The StoreLab power wall will display all tobacco products.
10195884|NCT04259749|Experimental|Flavors Banned|The StoreLab will display tobacco products without characterizing flavors, but will allow mint and menthol products to be displayed.
9715081|NCT04585373|Experimental|(48hours)|kinesio-tapping along with conventional therapy
10195885|NCT04259749|Experimental|Flavors and Menthol Banned|The StoreLab will display only tobacco products without characterizing flavors; mint and menthol will not be displayed.
10195886|NCT04253834|Active Comparator|Incentive Spirometer Control Arm|Participants assigned to use the incentive spirometer after surgery.
9715082|NCT04585373|Experimental|(72 hours)|kinesio-tapping along with conventional therapy
9715083|NCT04585230|Active Comparator|Group 1: (CBD + MO cohort)|Roll on stick containing CBD and mineral oils (CBD + MO cohort)
9715084|NCT04585230|Active Comparator|Group 2: (MO cohort)|Roll on stick containing mineral oils only (MO cohort)
9715085|NCT04585230|Active Comparator|Group 3: (CBD Cohort)|Roll on stick containing CBD only (CBD cohort)
9715086|NCT04585230|Placebo Comparator|Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)|Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)
9715087|NCT04585048|No Intervention|waiting list|waiting list
9715088|NCT04585048|Experimental|treatment|treatment with the Integrated Behavioral Therapy fo Selective Mutism
10195887|NCT04253834|Experimental|GO2 Mouthpiece|Participants assigned to use the Bidirectional Oxygenation Valve (GO2 Mouthpiece) after surgery.
10195888|NCT04250636|Experimental|Study Participants|HIV-infected individuals, off ART, and with plasma HIV-1 RNA levels between 500 and 100,000 copies/ml by standard assays. Study participants will receive a single intravenous infusion of 3BNC117-LS and a single infusion of 10-1074-LS. The antibodies will be administered sequentially and dosed at 30 mg/kg.
10195889|NCT04246996|Active Comparator|Gentamicin Arm|At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
10195890|NCT04246996|Sham Comparator|Control Arm|If the patient is randomized to no instillation, at the end of the surgery but prior to awakening from anesthesia, the surgeon will clamp the catheter and label the catheter with the clamping time. The purpose of clamping the catheter for subjects receiving usual care will be to ensure patients are masked to study arm assignment if they wake up and notice their catheter. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
10195891|NCT04245748|Active Comparator|Escitalopram|Adaptively randomized, double-blind treatment with escitalopram for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with escitalopram or citalopram for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
10195892|NCT04245748|Active Comparator|Duloxetine|Adaptively randomized, double-blind treatment with duloxetine for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with duloxetine for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
10195893|NCT04245436|Active Comparator|Duloxetine|Patients randomized to duloxetine, treatment will be initiated at 30 mg qAM through Week 4 (V5) (consistent with the registration trial for duloxetine in pediatric patients with generalized anxiety disorder). Then, duloxetine will be increased to 60 mg qAM at Week 4 (V5) and will be continued at this dose until Week 6 (V6) or the end of the acute phase of the study. Beginning at Week 6 (V6), duloxetine may be increased to 90 mg daily and at Week 8 (V7), may be increased to 120 mg daily.
10195894|NCT04245436|Active Comparator|Escitalopram|Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.
10195895|NCT04231058|Experimental|Transcutaneous Electrical Nerve Stimulation (TENS)|15 experimental subjects treated withTENS and Pulmonary Rehabilitation
10195896|NCT04231058|No Intervention|Rehabilitation|15 experimental subjects treated with Pulmonary Rehabilitation only
10195897|NCT04227379|Experimental|DD-TXT|Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g. nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
10195898|NCT04227379|Active Comparator|DSE|"The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care. Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from the content of the workbook but shortened to fit the 160-character limit of a text message. There will be no customizable or interactive content for the DSE arm."
10195899|NCT04221997|Experimental|sertraline|90 patients will be randomized to sertraline
10195900|NCT04221997|Placebo Comparator|Placebo|30 patient will be randomized to placebo
10195901|NCT04221997|No Intervention|Healthy Control|30 healthy comparison subjects will be followed over the course of 12 weeks
10195902|NCT04177914|Active Comparator|ETV+CPC|Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus
10195903|NCT04177914|Active Comparator|Ventriculoperitoneal Shunt|Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus
10195904|NCT04161989|Other|Group I (omega-3 fatty acids group)|received omega 3 (Omega 3 plus, SEDICO, Egypt); once daily from 28-30 weeks till delivery. The omega 3 plus capsule contains 1000 mg Fish Oil plus 100 mg Wheat Germ Oil is a natural source of Vitamin E.
9715089|NCT04584840|No Intervention|Group 1 (non-surgical treatment)|"Soft diet.~Suspension of the use of prostheses or intraoral devices.~Oral hygiene guidelines.~Topical antiseptics: in the form of mouthrinses with 0.12% chlorhexidine after every meal and clorhexidine gel over the exposed bone or fistula.~Systemic antibiotics: for patients in stage 2 in which active acute infection is detected with Amoxicillin/Clavulanic Acid 875/125 mg every 8 hours for 2 weeks. Those allergic to penicillin will receive clindamycin 300 mg every 8 hours for 2 weeks or Levofloxacin 500 mg / day for 2 weeks. Systemic antibiotic treatment can be prolonged indefinitely until infection and symptoms are controlled."
9715090|NCT04584840|Experimental|Group 2 (surgical treatment)|"Same guidelines of conservative treatment plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment:~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~Secure a two layered waterproof closure without tension (simple or with local flaps).~Samples will be sent for Pathological and microbiological analysis.~Stitches removal after two weeks~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
9715091|NCT04584931|Experimental|Treatment of gingival recession with colored composite|Composite restoration will be applied to the gingival recession defect
9715092|NCT04584931|Active Comparator|Treatment of gingival recession with coronally advanced flap|coronally advanced flap at the gingival defect
9715093|NCT04585139|Other|Phase 1 -- Introduction to Dexcom G6 CGM|A 2 week run-in wear period of blinded CGM followed by 12 weeks of wear of a Commercially available CGM
9715094|NCT04585139|Active Comparator|Phase 2 -- Comparison of an Updated G6 Transmitter to Commercial Dexcom G6 CGM|1 group will wear a Commercially available CGM for 12 weeks while the 2 group will wear an Updated CGM for 12 weeks.
9715095|NCT04584996||Pancreatic cancer|Patients being evaluated at MDT for suspected Pancreatic Ductal Adenocarcinoma (PDAC), via radiological test (e.g. endoscopic ultrasound (EUS), endoscopic retrograde cholangiography (ERCP), cross-sectional imaging), serum tumour marker (i.e. CA 19-9), or other diagnostic procedure
9715096|NCT04584996||Control|Patients diagnosed and/or due to undergo surgery for benign pathology (e.g. gallstones, chronic pancreatitis, etc); or patients with a diagnosis of a pre-malignant lesion (e.g. pancreatic intraductal papillary mucinous neoplasm); Pancreatic Neuroendocrine Tumour, or a Biliary Tract Cancer (i.e. cholangiocarcinoma; gallbladder cancer; ampullary cancer)
9715097|NCT04584944||Healthy adult men|Healthy young men, 20- 44 years old
9715098|NCT04584944||Healthy adult women|Healthy young women, 20- 44 years old
9715099|NCT04585113||People with hand OA awaiting surgery|Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible. All IP joints in the hands are eligible (thus both IP, PIP and DIP) if in- and exclusion criteria are fulfilled.
9715100|NCT04584827||complication positive (up to 30 days after surgery)|"Complications:~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~İntracranial hypertension requiring post op surgical drainage,~Status epilepticus or seizures,~The need for tracheal intubation or use of mechanical ventilation after surgery,~Decrease in GKS,~Unmanageable agitation that requires restriction or sedation,~Need for respiratory failure and oxygen therapy,~Unexpected serious motor deficit~Died"
9715101|NCT04584827||complication negative (up to 30 days after surgery)|No complications are seen within 30 days and the patient is healthy
9715102|NCT04584879|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
9715103|NCT04584879|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
9715104|NCT04584879|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
9715105|NCT04584879|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
9715106|NCT04584879|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
9715107|NCT04584879|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
9715108|NCT04585152|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells) How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~Where: in Hospital When and how much: once; diluted in 1000 ml of normal saline."
9779661|NCT05073497|No Intervention|Control Group|No intervention will perform to reduce pain in the control group.
9779662|NCT05072964|Other|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
10195905|NCT04161989|Other|Group II (vaginal progesterone plus omega-3 group)|received vaginal progesterone (Prontogest 400 mg vaginal suppository, Marcyrl Pharmaceutical Industries, Egypt) and omega 3 once daily from 28-30 weeks till delivery.
10195906|NCT04130828|Experimental|Thrice-weekly group|Ferrous fumarate 200 mg PO PC Thrice-weekly
10195907|NCT04130828|Active Comparator|Thrice-daily group|Ferrous fumarate 200 mg PO PC Thrice-daily
10195908|NCT04095403|Experimental|Tarp assisted cooling|Whole body cooling in a small amount of 20'C water.
9715109|NCT04585152|Active Comparator|Mycophenolate mofetil|"Drug Name: Mycophenolate Mofetil (MMF)~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis Procedures: MMF 1,200 mg/m2 orally divided in 2 daily doses"
9715110|NCT04584983|Active Comparator|usual prescribed intralipid (UL) regimen|
9715111|NCT04584983|Experimental|restricted prescribed intralipid (RL) regimen|
9715112|NCT04584957|Active Comparator|VAC therapy|Prophylactic ciNPWT therapy positioning YES. Patients enrolled for placement of the device over a closed incision immediately post-operatively.
9715113|NCT04584957|No Intervention|Standard Closure|Prophylactic ciNPWT therapy positioning NO. Patients enrolled for standard laparotomic closure without ciNPWT positioning
9715114|NCT04585126|No Intervention|General anesthesia without intermediate cervical block|General anesthesia performed by the anesthesiologist
9715115|NCT04585126|Active Comparator|General anesthesia with intermediate cervical block|General anesthesia performed by the anesthesiologist associated with an echoguided intermediate cervical block (bilateral in total thyroidectomy, unilateral in partial thyroidectomy) : 10 to 30cc of ropivacaine (2 to 3,75 %)
9715116|NCT04585022|Active Comparator|Magnum|A metal-on-metal large diameter head total hip arthroplasty
9715117|NCT04585022|Active Comparator|Recap|A metal-on-metal hip resurfacing arthroplasty
9715118|NCT04584814|Active Comparator|Babies born Preterm|Preterm babies, healthy at the time of the study , free of neonatal diseases and/or sequelae or malformations or genetic diseases
9715119|NCT04584814|Active Comparator|Newborn born at term|Term healthy babies, without respiratory and/or cardiovascular malformations or genetic diseases
9715120|NCT04584775|Experimental|Traditional Chinese Medicine plus Standard Care|Participants in this group will receive standard Palliative Care and will additionally see a practitioner of Traditional Chinese Medicine. No strict protocol for the actual intervention exists (pragmatic approach). The participants will at least receive acupuncture and/or chinese herbal medicine. The standard care will include any established medical intervention according to currently available guidelines in palliative care.
9715121|NCT04584775|Other|Standard Care|The standard care will include any established medical intervention according to currently available guidelines in palliative care.
9715122|NCT04584762|Sham Comparator|Sham treatment|"The AVPI device software is set in sham mode which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
9715123|NCT04584762|Experimental|Active Treatment|"The AVPI device software is set in active mode which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
9715124|NCT04584450||1|COVID-19 survivors.
9715125|NCT04584515|Experimental|IMP4297 40 mg|Sequential treatments of IMP4297 alone, followed by Itraconazole + IMP4297, with a washout period in between.
9715126|NCT04584515|Experimental|IMP4297 100 mg|Sequential treatments of IMP4297 alone, followed by Rifampin + IMP4297, with a washout period in between.
9715127|NCT04584476|Experimental|SCR group|underwent superior capsular reconstruction
9715128|NCT04584476|Other|Partial group|underwent partial rotator cuff repair
9715129|NCT04584580|Active Comparator|Therapeutic dose low-molecular-weight heparin (LMWH)|Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours
10195909|NCT04095403|Sham Comparator|Passive cooling|Supine lying
10195910|NCT04073394|Other|Diet Intervention|
10195911|NCT03991182|Experimental|Community-based parenting group|The community-based parenting group will include 39 health zones and 585 caregiver-child dyads
10195912|NCT03991182|Active Comparator|Control group|The control group will include 39 health zones and 585 caregiver-child dyads
10195913|NCT03953703|Experimental|Experimental: Levocarnitine, Placebo|1000 mg of levocarnitine twice per day for six weeks, a two week washout period, 1000 mg of placebo twice per day for 6 weeks
10195914|NCT03953703|Experimental|Experimental: Placebo, Levocarnitine|1000 mg of placebo twice per day for six weeks, a two week washout period, 1000 mg of levocarnitine twice per day for 6 weeks
9715130|NCT04584580|Experimental|D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy|"from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH~D-Dimer level Body Weight LMWH dose~<1 mg/dl <100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD >150kg Enoxaparin 60mg BD~1-3 mg/ dl <100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD >150kg Enoxaparin 120mg BD~>3 mg/ dl Enoxaparin 80mg BD"
9715131|NCT04584645|Experimental|cardiovascular disorders digital intervention arm (CVD-I)|Individuals with cardiovascular disease who receive a targeted digital intervention aimed at increasing influenza vaccination
9715132|NCT04584645|No Intervention|cardiovascular disorders without digital intervention arm|Individuals with cardiovascular disease who receive no intervention
9715133|NCT04584437|Other|Vitality Therapy|"i. 500 to 1000 cubic centimeters of micro-clustered, hydrogen rich alkaline Vital Water.~ii. Irradiation in infrared sauna for 60 minutes at high fever temperature. iii. Supplementation - Multivitamins and Minerals."
9715134|NCT04584593|Other|SARV-Cov|Men will give semen, saliva, urine and blood specimens
9715135|NCT04584749|Experimental|LIDOCAINE|"2% lidocaine will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
9779663|NCT05071196|Experimental|Facilitated Vegan Diet|The facilitated vegan participants will self-prepare and consume 2 vegan meal kits per day for 4 weeks
10195915|NCT03922893||Proband|First individual in a family to consent to this protocol
10195916|NCT03922893||Family Member Participants|Family members of the proband will be approached to consent to this protocol
10195917|NCT03881059|Placebo Comparator|Part A: Placebo|
10195918|NCT03881059|Experimental|Part A: BMS-986165 Dose A|
10195919|NCT03881059|Experimental|Part A: BMS-986165 Dose B|
10195920|NCT03881059|Experimental|Part B: Ustekinumab + BMS-986165 Placebo|
10195921|NCT03881059|Experimental|Part B: BMS-986165 Dose A + Ustekinumab Placebo|
10195922|NCT03881059|Experimental|Part B: BMS-986165 Dose B + Ustekinumab Placebo|
9715136|NCT04584749|Placebo Comparator|PLACEBO|"0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction . After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine/placebo.~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing Physiological Serum as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
9715137|NCT04584710|Experimental|10 mg daily RTB101|"RTB101~TORC1 inhibitor"
9715138|NCT04584710|Placebo Comparator|Placebo|Placebo
9715139|NCT04584541|Other|case|Index cases (RA and SpA patients under immunosuppressive treatments)
9715140|NCT04584541|Other|controls|Members of index cases family cluster infected with the same viral strain
9715141|NCT04584398|Experimental|Intervention|The intervention group (A) will perform respiratory muscle training and steam inhalation with WellO2 device for 30 days.
9715142|NCT04584398|No Intervention|Control|The control group (B) will continue on their conventional treatment without respiratory muscle training or steam inhalation with WellO2. After 30 days, the group B performs the same 30-day intervention with the WellO2 device (test) as the group A.
9715143|NCT04584671||Mild COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of mild COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
9715144|NCT04584671||Severe COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of severe COVID-19 infection, including at least 50 participants who were hospitalized with COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
9715145|NCT04584385||Childhood epilepsy|Children with refractory tonic, myoclonic or atonic seizures
9715146|NCT04584697|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
9715147|NCT04584697|Placebo Comparator|Placebo|A single injection of placebo will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
9715148|NCT04584736|Experimental|Livalo 2mg, Ezetrol 10mg|Pitavastatin 2mg, Ezetimibe 10mg
9715149|NCT04584736|Active Comparator|Livalo 2mg|Pitavastatin 2mg
9715150|NCT04584736|Experimental|Livalo 4mg, Ezetrol 10mg|Pitavastatin 4mg, Ezetimibe 10mg
9715151|NCT04584736|Active Comparator|Livalo 4mg|Pitavastatin 4mg
9715152|NCT04584177|Experimental|Arm-hand BOOST + Control|First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program
9715153|NCT04584177|Experimental|Control + Arm-hand BOOST|First 4 weeks control program, afterwards 4 weeks arm-hand boost program
9715154|NCT04584359|Experimental|HVLA techiniques (G1)|Performed with thrust (also known as HVLA) in the sacroiliac joint and T10-L2 level
9715155|NCT04584359|Experimental|Global osteopathic protocol (G2)|Several elements were emphasized - myofascial, bone, and visceral.
9715156|NCT04584359|Experimental|Pelvic floor muscle training (G3)|Muscle Training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes.
9715157|NCT04584359|No Intervention|Control group (G4)|No intervention and was simply evaluated and re-evaluated.
9715158|NCT04584125|Experimental|Ex vivo cross linking of donor corneal tissue|The donor corneal tissue used in the penetrating keratoplasty procedures will previously undergo ex vivo crosslinking.
9715159|NCT04584216|Experimental|Steam Eye Mask With Acupoints Stimulation|"The Steam Eye Mask with acupoints stimulation (SEM with acupoints stimulation), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~Also, on the eyebrow have the acupoints made by nonwoven fabric can use hands to massage.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes and use hands to massage the acupoints on the eyebrows for the first 3 minutes."
9715160|NCT04584216|Active Comparator|Steam Eye Mask|"The Steam Eye Mask (SEM), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes."
9715161|NCT04584268|Experimental|mindfulness|3 30 minute in person interventions as well as promotion and involvement of self-guided meditations on the Insight Timer smart phone application
9715162|NCT04584268|Active Comparator|control|standard medical resident education
9715163|NCT04584333|Experimental|INTERVENTION|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established.
9715164|NCT04584333|No Intervention|NO INTERVENTION|Group 2 (non-intervention group): you will receive the usual information regarding the characteristics of your injuries and the role of tobacco and alcohol in their evolution and the importance of abandoning these habits.
10195923|NCT03878277|Experimental|Cold Brew Coffee|6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.
10195924|NCT03864211|Active Comparator|Toripalimab monotherapy|Toripalimab is administrated intravenously (240mg, Q3W) continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
9779664|NCT05071196|Active Comparator|Standard Omnivorous Diet|The standard omnivorous arm will self-prepare and consume 2 non-vegan meal kits per day for 4 weeks
10195925|NCT03864211|Experimental|Thermal ablation plus toripalimab|One to five target lesions will be ablated completely. Toripalimab therapy will be initiated on day 3 or day 14 after ablation ((240mg, Q3W) ). Toripalimab is administrated continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
9715165|NCT04584060||Conventional|Fatsing for at least 6 hours pre-operative, No restriction of IV fluids and traditional analgesia including opiates. Post-operative Ambulation-as per patients' own request, Removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge.
9715166|NCT04584060||ERAS|Preoperative information, education and counselling, If possible, Clear fluids are allowed up to 2 h and solids up to 6 h prior to induction of anaesthesia, Short acting anesthetic agents,avoid opioid agents, Post operative nausea and vomiting prophylaxis, Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off, Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward, Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube, Removal of urinary catheter-after weaning from the effect of general anesthesia and drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
10195926|NCT03840967|Other|Niraparib|
9715167|NCT04584307|Experimental|Elotuzumab + Pomalidomide|Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
9715168|NCT04584151|No Intervention|standard of care|Peri operative analgesia by opioid
9715169|NCT04584151|Experimental|Continuous regiona analgesia|Peri operative algesia by continuous bilateral ESP catheters
9715170|NCT04584047|Experimental|Intervention group|This arm has blood collected either at the time of CVS.
9715171|NCT04584021||Stress study participants|Adults who reported stress problems derived from work
9715172|NCT04584242|Experimental|Pioglitazone|
9715173|NCT04584242|Experimental|Evogliptin|
9715174|NCT04584034|Active Comparator|Salbutamol|Salbutamol inhalation 4x200ug daily for 7 days, delivered using a Babyhaler
9715175|NCT04584034|Placebo Comparator|Placebo|Placebo 4 x 2 inhalations daily for 7 days, delivered using a Babyhaler
9715176|NCT04584229||question not suitable for study|question not suitable for study
9715177|NCT04584073|Active Comparator|Adenoidectomy|Adenoidectomy
9715178|NCT04584073|Active Comparator|Adenoidectomy and Myringotomy|Adenoidectomy and Myringotomy
9715179|NCT04584073|Active Comparator|Adenoidectomy,Myringotomy and Tympanostomy tube application|Adenoidectomy and Myringotomy and Tympanostomy tube application
9715180|NCT04584008|Experimental|Matched Targeted Agent|Matched Targeted Agent
9715181|NCT04584008|Active Comparator|Unmatched Therapy|Unmatched Therapy
9715182|NCT04584372|Active Comparator|High-nitrate (HI-NI) intervention|The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.
9715183|NCT04584372|Placebo Comparator|Low-nitrate (LO-NI) intervention|The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.
9715184|NCT04583722|Other|AX oleoresin|Raw AX oleoresin, 15 mg AX (in 4 pululan capsules)
9715185|NCT04583722|Experimental|AX-olive oil-PP emulsion|Microencapsulated AX (1%:2%:3% (AXO:OO:PP, %w/v ratio) + 0.15% maltodextrin). 15 mg AX (in 4 pululan capsules)
9715186|NCT04583670||30 general practitioners, who will use ultrasound during their consultations|
9715187|NCT04583696|Experimental|Walnut Consumption of Healthy Volunteers|
9715188|NCT04583813|Active Comparator|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
9715189|NCT04583813|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 24 months
9715190|NCT04583865||teleconsultation|Patient with teleconsultation of pre-anesthesia
9715191|NCT04583852|Experimental|brightening micro-needle patch|apply brightening micro-needle patch to one of the two assigned spots on the face according to the instructions on the package
9715192|NCT04583852|Placebo Comparator|Placebo|apply placebo micro-needle patch to another one of the two assigned spots on the face according to the instructions on the package
9715193|NCT04583930||Patients with Haemophilia A|"Patients suffering from moderate to severe haemophilia A~Age ≥ 18-years~Treatment with FVIII prophylaxis~Submitted written informed consent"
9715194|NCT04583826|Experimental|CAVA|20 participants will wear the CAVA device, and a consumer-grade sleep monitoring device, and undergo polysomnography, for one night. 40 participants will wear the CAVA device and undergo polysomnography for two nights
10195927|NCT03837860|Active Comparator|Oxycodone/Placebo|Each study participant will receive all three study interventions in random order.In this arm, the participant receives oxycodone or placebo
10195928|NCT03837860|Active Comparator|Oxycodone/Risperidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or risperidone
10195929|NCT03837860|Active Comparator|Oxycodone/Ziprasidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or ziprasidone
9715195|NCT04583904||Adults - inpatient|
9715196|NCT04583904||Adults- ambulatory|
9715197|NCT04583904||Children|
9715198|NCT04583657|Placebo Comparator|Control|"Consumption of two classical eggs per day during three months. The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%."
9779665|NCT05070715||Group 1: FGR group|Estimated fetal weight <10th percentile
9779666|NCT05070715||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
9779667|NCT05068791|Experimental|Psilocybin|Participants in the Psilocybin condition will receive .36 mg/kg of psilocybin.
9980314|NCT01390506|Active Comparator|Sodium-selenite infusion|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
10195930|NCT03817853|Experimental|Obinutuzumab+Chemotherapy|Participants received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone [CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone [CVP - 21-day cycle]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator is free to choose the chemotherapy for each patient. Obinutuzumab and chemotherapy is administered during induction phase and obinutuzumab monotherapy is administered during maintenance phase.
10195931|NCT03816891|Experimental|Phase 2a - Vixarelimab 360 mg SC QW|Vixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
10195932|NCT03816891|Placebo Comparator|Phase 2a - Placebo SC QW|Placebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
9715199|NCT04583657|Experimental|Test|Consumption of two test eggs per day during three months. These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%, total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
9715200|NCT04583683|Active Comparator|Intensive lifestyle modification: Very low calorie diet|Patients will undergo a very low calorie diet
9715201|NCT04583683|Active Comparator|Metabolic Surgery|Patients will undergo metabolic surgery
10195933|NCT03816891|Experimental|Phase 2b - Vixarelimab 540 mg SC Q4W (DBL)|Vixarelimab 540 mg SC, every 4 weeks for 16 weeks during Double Blind Period
9715202|NCT04583644|Experimental|Device - FETO|Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery and removal of balloon using the BALT GOLDBAL2 balloon and BALTACCIBDPE100 catheter.
9715203|NCT04583631||Chronic adenoiditis|Patients with hypertrophy and those out of hypertrophy were determined and those who had purulant rhinorrhea signs and rate of adenoids-choana below 50% were categorized that chronic adenoiditis.
9715204|NCT04583631||Adenoid hypertrophy|Patients who have snoring and those whose adenoid choana rate is greater than 50% were categorized that adenoid hypertrophy group.
10195934|NCT03816891|Experimental|Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL)|Vixarelimab 360 mg SC, every 4 weeks for 16 weeks during Double Blind Period
10195935|NCT03816891|Experimental|Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL)|Vixarelimab 120 mg SC, every 4 weeks for 16 weeks during Double Blind Period
10195936|NCT03816891|Placebo Comparator|Phase 2b - Placebo SC, Q4W (DBL)|Placebo SC, every 4 weeks for 16 weeks during Double Blind Period
9715205|NCT04583605||PREVENA|A vacuum wound closure therapy like PREVENA is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
9715206|NCT04583605||NON PREVENA|A conventional wound closure is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
9715207|NCT04583397|Experimental|Experimental: WiFi - Sham|first intervention WiFi, second intervention sham
9715208|NCT04583397|Experimental|Experimental: Sham - WiFi|first Intervention sham, second Intervention WiFi
9715209|NCT04583436|Experimental|Endovascular recanalization|"Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.~n=45"
9715210|NCT04583436|Active Comparator|Open surgery|"Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.~n=45"
9715211|NCT04583566||COVID-19 Severe Symptoms|Patients with severe symptoms need oxygen and ventilation.
9715212|NCT04583566||COVID-19 Mild Symptoms|Patients with moderate symptoms, like normal flu symptoms. They do not need oxygen or ventilation
9715213|NCT04583566||Control Healthy|Healthy group with out any infection or symptoms.
10195937|NCT03816891|Experimental|Phase 2b - Vixarelimab 360 mg SC, Q2W (OLE)|Vixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension
9715214|NCT04583410|Experimental|Nicotine patch|
9715215|NCT04583410|Placebo Comparator|Placebo patch|
9715216|NCT04583449|Experimental|Outcome imagery|Outcome imagery condition participants will be asked to visualize themselves successfully wearing a face covering in all required public places/situations over coming week, and to imagine how they would feel. The importance of imagining distinctive relevant visual imagery linked to having successfully routinely worn face covering will be underscored in this passage. Outcome imagery participants will then be asked to write in a free-text box how they would feel having successfully worn a face covering in required public places/situations over the week ahead.
9779668|NCT05068791|Active Comparator|Active Placebo|Participants in the Active Placebo condition will receive 2.6 mg/kg of dextromethorphan (DXM).
9779669|NCT05065216|Experimental|DM199|DM199 administered by a single intravenous (IV) dose followed by a subcutaneous (SC) dose within 12 hours and then 2 times a week till Day 22.
9779670|NCT05065216|Placebo Comparator|Placebo|Placebo administered by a single intravenous (IV) dose followed by a subcutaneous (SC) dose within 12 hours and then 2 times a week till Day 22.
10195938|NCT03805230||Cohort A|all patients admitted to participating hospitals during 7 consecutive days
10195939|NCT03805230||Cohort B|30 sequential patients with a single additional inclusion criterion
10195940|NCT03784755|Active Comparator|Arm 1 (standard of care)|"Standard systemic therapy~+ Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden"
10195941|NCT03784755|Experimental|Arm 2 (standard systemic therapy + ablative therapy))|"Local Ablative therapy to all sites of disease (including untreated prostate primary)~+ Standard systemic therapy"
9662419|NCT04243759|Experimental|Standard App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
9662420|NCT04243759|Experimental|Experimental, Feedback App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
9662421|NCT04237844||no BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，infants without BPD
9662422|NCT04237844||classic BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth, the condition is not relieved, FiO2 lasts >25%
9662423|NCT04237844||BPD after RDS|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth. FiO2<23% within 7 days, and the condition is aggravated to FiO2>25%.
9662424|NCT04237844||Delayed BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There is no RDS performance after birth, FiO2 lasts <25%
9662425|NCT04237844||Early, lethal BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，Some infants who die before 36 weeks PMA (between 14 days of postnatal age and 36 weeks) due to persistent parenchymal lung disease and respiratory failure that can not be attributable to other neonatalmorbidities
9662426|NCT04229914|Other|stroke patients|Assessment
9662427|NCT04227028|Experimental|Treatment (brigatinib, bevacizumab)|Patients receive brigatinib PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Patients also receive bevacizumab IV on day 8 of cycle 1 and day 1 of subsequent cycles. Starting cycle 2, cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9662428|NCT04207086|Experimental|6 wk pembrolizumab & lenvatinib, surgery, 46 wk pembrolizumab|Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks.
9662429|NCT04202549|Experimental|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy
9662430|NCT04202458|Experimental|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA
9662433|NCT04184453|Experimental|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patient.
9662434|NCT04160507||Healthy black adults 50 and over|Healthy black adults age 50 and over with no known history of kidney disease will be recruited as controls in this study.
9662435|NCT04160507||black adult cases with non-diabetic nephropathy|black adult cases with non-diabetic nephropathy
9662436|NCT04160078|Experimental|Mindfulness Intervention Arm|A stress reduction plus sleep education intervention to improve sleep health
9662437|NCT04152486|Experimental|Intervention arm|The vaccine Ad26.ZEBOV (5x10^10 viral particles (vp)) will be given as the first dose and the vaccine MVA-BN-Filo (1x10^8 infectious units (Inf U)) will be given as the second dose 56 (-14 day +28 day) days later.
9662438|NCT04123886|Experimental|SCB-313|
9662439|NCT04101643|Experimental|Evolocumab group|Eligible patients receive subcutaneous injections of evolocumab 420 mg
9662440|NCT04082455|Experimental|carbon ion radiotherapy|carbon ion radiotherapy
9662441|NCT04062799||Study cohort|
9662442|NCT04061941||Stimulant Users|Stimulant users that fulfill SCID-5 clinician version definition for assessment on stimulant use disorder under DSM-5
9662443|NCT04059159|Experimental|Connected Catheter Users|
9662444|NCT04058392|Experimental|Camu Camu|Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
9662445|NCT04047771|Experimental|SCB-313|
9662446|NCT04014751||Symptom Monitoring Cohort|This cohort will include up to1,050 cancer patients being seen at regional Northwestern Medicine (NM) cancer centers for their cancer care. Patients who have recently completed an on-line, EHR-integrated patient-reported symptom and needs assessment as part of their regular care will be invited to complete a survey at baseline, 6- and 12-months targeting the assessment of their symptoms, healthcare experiences and utilization. Patients may also be invited to participate in a one-time interview or focus group designed to help study investigators better understand the value of the symptom and needs assessment from the patient perspective.
9662447|NCT04010747|Experimental|Motivational Interviewing for Loved Ones (MILO)|"MILO consists of four sessions of coaching in communication skills called motivational interviewing. Participants meet with a trainer/therapist for each session. At the first session, participants learn about the ideas behind motivational interviewing. In the second session, participants practice motivational interviewing skills. In the third and fourth sessions, the participant and therapist discuss the participant's efforts to communicate with their loved one using MI skills. Participants will also be offered direct assistance with a referral to mental health treatment for their loved one."
9666367|NCT04560595|Experimental|Caffeine Reduction Manual, Delayed Treatment Group|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use. Those in the delayed treatment group will receive the guide seven weeks after screening."
9715217|NCT04583449|Experimental|Process imagery|Process imagery condition participants will be asked to visualize the kinds of strategies involved in successfully wearing a face covering in all required public places/situations over the coming week. The importance of imagining distinctive relevant visual imagery linked to having effective strategies involved in successfully wearing a face covering in required public places/situations over the week ahead will be underscored in this passage. Process imagery participants will then be asked to write in a free-text box about the kinds of strategies that would be involved in successfully wearing a face covering in all required public places/situations over the coming week.
9715218|NCT04583449|Experimental|Combined imagery (outcome imagery and process imagery)|A third experimental condition will receive both outcome and process imagery exercises to read and complete in sequential order.
10195942|NCT03755934|Experimental|Dose Level 1|MEDI7352
10195943|NCT03755934|Experimental|Dose Level 2|MEDI7352
9715219|NCT04583449|No Intervention|Public health message|A fourth condition will involve viewing a UK Government public health message (HM Government, 2020) circulated on social media as an image concerning the importance of wearing face covering while in public places.
9715220|NCT04583267|Experimental|PrEP|
9715221|NCT04583111|Experimental|Domperidone group|Patients in Domperidone group took 10mg of domperidone 30min before PEG.
9715222|NCT04583111|Experimental|Sulpiride group|Patients in Sulpiride group took 100mg of sulpiride 30min before PEG.
9715223|NCT04583111|No Intervention|Control group|Patients in Control group followed the regular routine of 3L split-dose of PEG.
9715224|NCT04583241||BJI group|"Patients with an BJI on material (prosthesis or other implant) infected by Streptococcus aureus* Patients are follow-up during two years after surgery.~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
9715225|NCT04583241||Control Group With material|"Patients with mechanical problems on implanted equipment (control cohort), without infection* Patient of this group are follow-up until surgery.~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
9715226|NCT04583241||Group osteomyelitis|"Patients with chronic hematogenous osteomyelitis* Patient of this group are follow-up until surgery.~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
9715227|NCT04583241||Control Group with cruciate ligament surgery|Patients having cruciate ligament surgery Patient of this group are follow-up until surgery.
9715228|NCT04583098||carbapenem-resistant Enterobacteriaceae|
9715229|NCT04583098||vancomycin-resistant Enterococci|
9715230|NCT04583345||Hypertensive|Diagnosis of hypertension
9715231|NCT04583345||Healthy|Healthy blood pressure level and absence of any chronic disease
9715232|NCT04583228|Experimental|Sequence 1|Random allocation to HLX71 1 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
9715233|NCT04583228|Experimental|Sequence 2|Random allocation to HLX71 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
9715234|NCT04583228|Experimental|Sequence 3|Random allocation to HLX71 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
10195944|NCT03755934|Experimental|Dose Level 3|MEDI7352
10195945|NCT03755934|Placebo Comparator|Placebo|Placebo
10195946|NCT03755934|Experimental|Dose Level 4|MEDI7352
9715235|NCT04583228|Experimental|Sequence 4|Random allocation to HLX71 15 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
9715236|NCT04583202|Placebo Comparator|Placebo exposure|All patients undergo 2 placebo exposures
9715237|NCT04583202|Experimental|Birch Pollen Exposure|All patients undergo 4 allergen exposures
9715238|NCT04583293||COVID AKI|Participants who were admitted to the hospital with COVID-19 and developed AKI during their hospital stay.
9715239|NCT04583293||COVID non-AKI|Participants who were admitted to the hospital with COVID-19 and did not develop AKI during their hospital stay.
9715240|NCT04583371|No Intervention|GROUP CONTROL|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the control group, patients will be ventilated for 1 minute with 100% inspired oxygen (FiO2), followed by three aspirations for 15 seconds and with an interval of 30 seconds."
9715241|NCT04583371|Active Comparator|INTERVENTION GROUP|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.~In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the supine position, the headboard elevated to 30º in assisted pressure-controlled ventilatory mode, increasing 10 cmH2O in inspiratory pressure and in assisted ventilation mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, with Ppeak not exceeding 40 cmH2O and drive pressure not exceeding 15 cmH2O in both ventilation modes, and then a new aspiration in the same way as the control group."
9715242|NCT04583332|Other|Rhymes, Individual Items in Rhymes, Objects|Existing method Post intervention
9980315|NCT01390506|Placebo Comparator|Placebo|0.9% sodium chloride
10195947|NCT03704805|Experimental|Problem-Solving Therapy|Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.
10195948|NCT03704805|Active Comparator|Enhanced Standard of Care|Participants in the control group receive enhanced standard of care.
9715243|NCT04583124|Experimental|ATENTO-B|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed before the begining of medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
9715244|NCT04583124|Active Comparator|ATENTO-T|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed throughout medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
9715245|NCT04582968|Experimental|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Fractionated stereotactic radiotherapy(FSRT) or whole brain radiation therapy (WBRT) Drug: Pyrotinib combined with capecitabine pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
10195949|NCT03698123|Experimental|Dietary Modification|On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
9715246|NCT04583085||CP + CHD group|This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.
9715247|NCT04583085||CP group|25 patients with chronic periodontitis who were systemically healthy were selected
9715248|NCT04583085||HP group|25 patients who were systemically and periodontally healthy, were considered as HP group.
9715249|NCT04583046|Placebo Comparator|placebo|normal saline inhalation group
9715250|NCT04583046|Experimental|iloprost group|iloprost inhalation group
9715251|NCT04583189|Other|Test rapid antigenic and Test RT-PCR|
9715252|NCT04583137|Experimental|Buffered lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution combined with bicarbonate 8.4% in a 1:10 ratio.
9715253|NCT04583137|Experimental|Plain lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution.
9715254|NCT04582877|Other|FFR Measurement in Intermediate-Grade Coronary Stenosis|Participants with intermediate-grade coronary stenosis undergo measurement of fractional flow reserve using the test article (Zurich Pressure Guidewire System) and predicate article (Abbott PressureWire System).
9715255|NCT04583215|Active Comparator|Active PAS|After completing the N-back and PAS-EEG at Visit 3, MCI participants randomized to the active condition will receive a 10-session course of PAS (Visits 4-13), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
9715256|NCT04583215|Sham Comparator|PAS-Control (PAS-C)|After completing the N-back and PAS-EEG at Visit 3, MCI participants randomized to the sham condition will receive a 10-session course of PAS-C (Visits 4-13), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
9715257|NCT04583215|No Intervention|Healthy Control|Healthy Controls will complete screening and baseline N-Back and PAS-EEG. They will not complete the 10-session course of PAS or follow-up assessments.
9715258|NCT04583020|Experimental|Neoadjuvant PD-1 inhibitor|Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.
9715259|NCT04582994||Young participants|"30 young participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:~Day 1. Beta tACS (22Hz)~Day 2. Alpha tACS (10 Hz)~Day 3. Sham tACS"
9715260|NCT04582994||Old participants|"30 old participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:~Day 1. Beta tACS (22Hz)~Day 2. Alpha tACS (10 Hz)~Day 3. Sham tACS"
9715261|NCT04583059|Experimental|Taping Group|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lower end of the shank. Second step involved application of the stirrup. During this step, the foot was held in neutral, and the tape applied to pass from the medial side of the ankle, under the foot just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. The second step was repeated to apply the second stirrup. Both ends of the stirrups were firmly attached to the anchor tape applied during the first step and this attachment was reinforced with a locking tape during the third and final step by once again applying the tape circumferentially just above the malleolar level at the lower end of the shank. Taping was applied by a physical therapist according to the health association requirements
9779671|NCT05059262|Experimental|Part 1/Part 2 - vimseltinib/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) vimseltinib for 24 weeks in Part 1 and continue on 30 mg biw vimseltinib in Part 2
9779672|NCT05059262|Placebo Comparator|Part 1/Part 2 - placebo/vimseltinib|Participants receive blinded treatment of 30 mg twice a week (biw) matching placebo for 24 weeks in Part 1 and have option to receive 30 mg biw vimseltinib in Part 2
9779673|NCT05055258|Experimental|300 mg KVD824|300 mg KVD824 twice a day for 12 weeks
9980316|NCT01390519||Afinitor|Afinitor
9980317|NCT01390558||Persons with Down Syndrome who use orthotics|Orthotic users
9980318|NCT01390558||Persons with Down Syndrome who do not use orthotics|Non orthotic users
9980319|NCT01390636||ED-DMT1 and ED/only|Eating Disorder and Type 1 Diabetes and only an Eating Disorder
10195950|NCT03697629|Experimental|Daratumumab|Increased infusion rate daratumumab monotherapy
10195951|NCT03696810|Other|• Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
9715262|NCT04583059|Experimental|Bandaging Group|Standard 10 cm width elastic bandage was used. The elastic bandage was wrapped around the ankle joint to form an 8-figure shape starting from the forefoot. Then, the bandage was taken diagonally upwards, steeply enough to go well above the heel. Then, the bandage was taken around the lower calf area to form an anchor. Then its diagonally taken down across the midfoot. Again the bandage was wrapped around the forefoot and going diagonally up to finish off around the lower calf, leaving the heel open. During the bandage application process, the therapiest didn't stretch the bandage, because bandage does note need to be stretched during the application, as the bandage becomes naturally tight when its layers wraped over each others. the participant was asked to wear his/her sport shoes over the bandage during the measurement procedures.
9715263|NCT04582942|Placebo Comparator|PEG (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will only be PEG.
9715264|NCT04582942|Experimental|PEG+lactulose (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will be PEG combined with lactulose.
9715265|NCT04582955|Experimental|Arm A|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
9715266|NCT04582929|Experimental|50 unit of Neubotulinum Toxin Type A (Neuronox)|50 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
9715267|NCT04582929|Experimental|100 unit of Neubotulinum Toxin Type A (Neuronox)|100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
9715268|NCT04582838||Spontaneous breathing ICU non-COVID|"Spontaneously breathing non-COVID-19 critically ill patients with sinus rhythm.~Inclusion and exclusion criterion are listed elsewhere."
9715269|NCT04582838||Spontaneous breathing ICU COVID|"Spontaneously breathing COVID-19 critically ill patients with sinus rhythm.~Inclusion and exclusion criterion are listed elsewhere."
9715270|NCT04582552||Ovarian cancer patients treated with PARP inhibitors|PARP inhibitors therapy until disease progression
9715271|NCT04583033|Experimental|Cognitive Behavioral Therapy (CBT) Group|Participants will receive CBT intervention bi-weekly for total of six (6) sessions.
9715272|NCT04583033|No Intervention|Control Group|Participants will not receive any intervention as part of the study.
9715273|NCT04582708|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after abdominal surgery.
9715274|NCT04582695|Active Comparator|Written Exposure Therapy|
9715275|NCT04582695|Experimental|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|
9715276|NCT04582565|Active Comparator|Control group|Control group will have standard of care, consisting of verbal and written information on lymphoedema prevention and standard access to breast care nurse.
9715277|NCT04582565|Experimental|Combination product|Decongestive lymphatic therapy (DLT). DLT group will involve manual lymphatic drainage with a trained manual lymphatic drainage therapist.
9715278|NCT04582747||Major abdominal Surgery patients|Major Abdominal Surgery Patients
9715279|NCT04582630||Omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
9715280|NCT04582630||Control (standart)|Standart medical nutrition therapy
9715281|NCT04582851||Postgraduate students|prevalence of TMD among postgraduate students.
9715282|NCT04582812|Experimental|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training|
9715283|NCT04582812|Active Comparator|Isolated high-intensity inspiratory muscle training|
9715284|NCT04582604|Experimental|Ruxolitinib combined with Decitabine|Ruxolitinib and Decitabine conditioning regimen All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Decitabine. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), decitabine (20 mg/m2/day, days -15 to -10), cytarabine (4 g/m2/day, days -10 to -9 (for unrelated donors or haploidentical donors; and 4 g/m2/day, days -9 for sibling donors)), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4);carmustine(BCNU)(250mg/m2/day, day -3),
10195952|NCT03694392||Flublok Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.
9715285|NCT04582656|Experimental|Targeted microwave ablation|Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion
9715286|NCT04582786|Active Comparator|Standard group|Standard treatment (morphine) administered according to usual practice
9715287|NCT04582786|Experimental|Test group: Infusion with bolus|STR-324 or morphine HCl infusion started with a initial bolus
9715288|NCT04582786|Experimental|Test group: Infusion without bolus|STR-324 or morphine HCl infusion started without a initial bolus
9715289|NCT04582760|Experimental|early mobilization Arm|In addition to conventional bedside physical therapy, the mobilization program will be administered for 30 mins per session, two sessions per day, 7 days per week, until the patients are discharged from the ICU.
9715290|NCT04582760|No Intervention|non-early mobilization Arm|Conventional bedside physical therapy will be administered for 30 mins per session, one session per day, 5 days per week (only on working days), until the patients are discharged from the ICU.
9715291|NCT04582721|Active Comparator|CON-SCS with subcutaneous stimulation|7 days Conventional Spinal Cord Stimulation with subcutaneous stimulation
9715292|NCT04582721|Active Comparator|HF-SCS|7 days High Frequency Spinal Cord Stimulation
10195953|NCT03694392||SD-IIV Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).
10195954|NCT03677830|Active Comparator|Intravenous Acetaminophen|Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; >39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
10195955|NCT03677830|Placebo Comparator|Intravenous Placebo|Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
9666368|NCT04554472||Study group|Patients with a distal radius fracture requiring surgery who meet the exclusion and inclusion criteria
9666369|NCT04553237||Patients over 90 years old|
9666370|NCT04553237||Patients between 70 and 89 years of age.|
9666371|NCT04549402|Experimental|Mirror Therapy group|The intervention will consist of the visualization of movement through the Mirror Therapy VR® application, broadcast on a mobile device and visualized with virtual reality glasses. The knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (walking and feeding, respectively).
9666372|NCT04549402|Active Comparator|Video group|The intervention will consist of the visualization of movement through the reproduction of an immersive 360º video broadcast on a mobile device and viewed with virtual reality glasses. Knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively).
9666373|NCT04549402|No Intervention|Control group|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
9666374|NCT04548063|Experimental|6,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 6,000 words.
9666375|NCT04548063|Experimental|4,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 4,000 words.
9666376|NCT04548063|Experimental|2,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 2,000 words.
9666377|NCT04546971|Active Comparator|Brief intervention|A brief alcohol intervention lasting about 10 minutes, delivered after the baseline assessments.
9666378|NCT04546971|Experimental|Brief Intervention plus Telehealth Counseling|A brief alcohol intervention followed by referral to a telehealth counseling protocol including 5 sessions of counseling based on Motivational Interviewing and delivered by videoconferencing. Telehealth counseling extends for up to two years and also includes a text messaging intervention to encourage reductions in drinking.
9666379|NCT04546074|Experimental|Treatment|
9666380|NCT04545606|Experimental|In-person CBT for insomnia in children with autism|In-person cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted at the Thompson Center. In-person treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
9666381|NCT04545606|Experimental|Remote CBT for insomnia in children with autism|Remote/videoconferenced cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
9666382|NCT04545606|Experimental|Remote behavioral SHARE for insomnia in children with autism|Remote/videoconferenced behavioral sleep hygiene and related education (SHARE) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep and related health related concerns/interests.
9666383|NCT04545411|Active Comparator|Treatment A|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 35mg in 1mL solution REMD-477
9666384|NCT04545411|Placebo Comparator|Treatment B|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 1mL solution Placebo
9666387|NCT04542642|Active Comparator|reSET-O|Prescription Digital therapeutic
9666388|NCT04542642|Experimental|PEAR-008|Investigational Digital Therapeutic
9666389|NCT04541121|Experimental|3D printed model|Mother is given 3D printed model of fetus' face
9666390|NCT04541121|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
9666547|NCT04452825|Experimental|Social Work and Supportive Counseling (SWSC)|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
9715293|NCT04582721|Active Comparator|Combination Therapy|7 days a combination of CON-SCS with subcutaneous stimulation and HF-SCS
9715294|NCT04582526|Experimental|Intervention arm|BMS program
9715295|NCT04582513||Pre-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed according to current hospital standard without a standardized checklist.
9715296|NCT04582513||Post-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed after implementation of the AnCHor-CHecklist, a standardized checklist based on the SBAR concept.
9715297|NCT04582487|Other|Biological evaluation|A combined approach of Drug Sensitivity and Resistance Profiling (DSRP) and molecular-cytogenetic findings is used in order to prioritize compounds for tailored therapies.
9715298|NCT04582474|Experimental|Dengue module and rapid diagnostic tests|
9715299|NCT04582175||group A|patients who received complete revascularization by angioplasty during the PPCI
9715300|NCT04582175||Group B|patients who underwent complete revascularization by angioplasty in a staged procedure
9715301|NCT04582123|Other|comparison of two cross pin fixation methods|Fixation of supracondylar humerus fractures with 2 crossed pins and 3 crossed pins are compared in terms of Flynn's criteria
9715302|NCT04582084||Autoimmune Arthritis|Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings
9715303|NCT04582071|Experimental|Arm 1 (Psychotherapy, Intervention arm)|Subjects undergoing a 3 step IPAA will receive the four sessions of psychotherapy preceding and following their first surgery only, and receive an additional set of questionnaires again after their third surgery.
9715304|NCT04582071|No Intervention|Arm 2 (Non-Therapy, Control Arm)|Subjects will receive questionnaires which will be administered remotely via telemedicine if patient and psychologist/ research team member are unable to meet in person.
9715305|NCT04582110||Patients with Beta Thalassemia|Patients with previous diagnosis of Beta Thalassemia
9715306|NCT04582110||Control Group|Healthy fellow eyes without actual and previous ocular trauma
9715307|NCT04582227||The ETT group|Oral endotracheal intubation via direct laryngoscopy will be performed. The ETT cuff will be inflated to 25 cmH2O using a manometer.
10195956|NCT03661840|Experimental|Acceptance and Commitment Therapy|Participants will receive both the ACT intervention and medication management that is given as usual treatment.
10195957|NCT03661840|Active Comparator|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management.
10195958|NCT03642951|Active Comparator|Active Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device."
10195959|NCT03642951|Sham Comparator|Sham Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device.~Note: While the device looks and is operated the same as the active device, subjects in this group will be stimulated with the placebo device so no active stimulation will be given."
10195960|NCT03632135|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
10195961|NCT03632135|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
9715308|NCT04582227||The LMA group|The Ambu aura-i LMA size will be chosen and inserted using the recommended single-handed rotational technique. Subsequently, a manometer was used to inflate the cuff to 60 cm H2O.
9715309|NCT04582162|Experimental|Unsplinted implants|
9715310|NCT04582162|Active Comparator|Splinted implants|
9980320|NCT01390662|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 24 weeks.
9980321|NCT01390662|Placebo Comparator|placebo|one tablet of sugar pill per day for 24 weeks.
9980322|NCT01390688||Type 2 Diabetes|80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI > 18.5 kg/m2 fatsing plasma glucose < 12 mmol/l
10195962|NCT03630328|Experimental|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
10195963|NCT03630328|Placebo Comparator|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
10195964|NCT03628235||Early stage HDGECs|CAG length ≥ 40; DCL = 4, TFC ≥ 11
10195965|NCT03628235||Middle stage HDGECs|CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
10195966|NCT03628235||Late stage HDGECs|CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6
9666548|NCT04451785|Active Comparator|Healthy individuals|20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.
9666549|NCT04451785|Experimental|Patients with hereditary spherocytosis|60 patients with hereditary spherocytosis will be included in this study.
9666550|NCT04451187|Experimental|Treatment Sequence CADB|Participants will receive placebo once daily (OD) at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment C) in Period 1 followed by Dose 1 of seltorexant tablets and placebo OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment A) in Period 2 followed by Dose 2 of seltorexant tablets OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment D) in Period 3 followed by zopiclone on Day 1 and Day 8 and placebo from Day 2 to Day 7 OD at bedtime (Treatment B) in Period 4. There will be a washout period of 5 to 21 days between each period.
9666551|NCT04451187|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3 followed by Treatment D in Period 4. There will be a washout period of 5 to 21 days between each period.
9666552|NCT04451187|Experimental|Treatment Sequence BDAC|Participants will receive Treatment B in Period 1 followed by Treatment D in Period 2 followed by Treatment A in Period 3 followed by Treatment C in Period 4. There will be a washout period of 5 to 21 days between each period.
9666553|NCT04451187|Experimental|Treatment Sequence DCBA|Participants will receive Treatment D in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3 followed by Treatment A in Period 4. There will be a washout period of 5 to 21 days between each period.
9666554|NCT04450550|Active Comparator|Active|
9666555|NCT04450550|Sham Comparator|Sham|
9666556|NCT04448886|Experimental|Sacituzumab Govitecan + Pembrolizumab|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits. Each Cycle =21 Days~Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle~Pembrolizumab (iv) fixed dose administered once per cycle"
9666557|NCT04448886|Experimental|Sacituzumab Govitecan|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.~- Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle"
9666558|NCT04448886|Experimental|Retreatment|Participants who have attained a confirmed complete response (CR) who have been treated for at least 24 weeks on protocol therapy and had at least three cycles (with pembrolizumab and sacituzumab govitecan (Arm A) or sacituzumab govitecan alone (Arm B)) beyond the date when the initial CR was declared may be eligible for additional sacituzumab govitecan and/or pembrolizumab therapy if they progress after stopping study treatment. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the subject meets protocol-specified conditions.
9666559|NCT04448262||G1 Asthma|Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
9666560|NCT04448262||G2 Diabetes|Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
9666561|NCT04448262||G3 Asthma plus diabetes|Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
9666562|NCT04446845|Experimental|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|"A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp & Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)"
9666563|NCT04446845|Active Comparator|Conventional Stimulation (Elonva+rFSH) in follicular phase|A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG
9666564|NCT04446117|Experimental|Experimental Arm|Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w
9666565|NCT04446117|Active Comparator|Control Arm|Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization
9666566|NCT04443855|Active Comparator|Water quality|90 clusters, approx. 720 newborns
9666567|NCT04443855|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
9666568|NCT04443855|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
9666569|NCT04443855|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
9666570|NCT04443855|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
9666571|NCT04443855|Active Comparator|Nutrition+ Combined WASH|90 clusters, approx. 720 newborns
9666572|NCT04443855|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
9666573|NCT04442503|Experimental|SAGE-217|Participants will receive SAGE-217 capsules, once daily for 14 days.
9666574|NCT04442503|Placebo Comparator|Placebo|Participants will receive SAGE-217 matched-placebo capsules, once daily for 14 days.
9666575|NCT04441047|Experimental|Vaccination|ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14
9666576|NCT04440735|Experimental|DSP107 monotherapy|DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. The study will include up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
10195967|NCT03628235||Companions of early stage HDGECs|
9715311|NCT04582396|Experimental|Stellate Ganglion Block + Psychoeducation|For the active SGB arm, 7 to 8 mL of ropivacaine, 0.5%, will be injected around and into the site of the ganglion once before the hospital discharge. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
9715312|NCT04582396|Placebo Comparator|Normal saline injection + Psychoeducation|For the sham procedure, 1 to 2 mL of preservative-free normal saline will be injected into deep musculature in the neck. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
9715313|NCT04582214|Experimental|OLE Therapy with The MetaNeb® System|Subjects in the active treatment group will receive OLE therapy with The MetaNeb® System following the labeled instructions for the device.
9715314|NCT04582214|No Intervention|Control Group|The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.
9715315|NCT04582422|Experimental|Touch Therapy|"The main purpose is to provide Touch Therapy intervention measures, the degree of fear of dental treatment for preschool children.~Use the chip chip tool (PCT) to ask the children's degree of fear of dental treatment. The control group uses questionnaires to ask the caregiver's age, social and economic status, education, past dental experience, etc. In the intervention group, the questionnaire was used to ask the caregiver's age, socioeconomic status, education, past dental experience, etc. During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation , Ask the children how scared they are after seeing a doctor,"
9715316|NCT04582422|No Intervention|dental education|The Chip Chip Tool (PCT) asked the children how scared they were about dental visits. The control group used questionnaires to ask the caregiver 's age, socioeconomic status, education, past dental experience, etc. before the visit to provide routine dental care, provide dental health education, how to use toothbrush Dental floss education,
9715317|NCT04582305|Active Comparator|Bleomycin jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.
9715318|NCT04582305|Placebo Comparator|Placebo jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.
9715319|NCT04582136|Experimental|Sirolimus plus SOC|Sirolimus plus standard therapy (SOC) for SLE; Generic name: sirolimus (0.5mg capsule); Dosage: 1.5mg/day; Administration route: Oral
9715320|NCT04582136|Placebo Comparator|Placebo plus SOC|Placebo plus standard therapy (SOC) for SLE; Drug: Placebo comparator plus SOC; Administration route: Oral
9715321|NCT04582357|Experimental|Exercise arm|This arm is the only arm of the study, every patient is included in this arm, the patients will follow the physical activity program
9715322|NCT04582331||COVID-19 positive|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 positive status is confirmed by diagnostic testing and clinical diagnosis.
9715323|NCT04582331||COVID-19 negative, symptomatic|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 negative status is confirmed by diagnostic testing and clinical diagnosis.
9715324|NCT04582331||Normal Healthy Volunteers|Asymptomatic healthy participants recruited from hospital staff or co-living family members, or co-living family member of a COVID-19 positive study participant.
9715325|NCT04582279|Experimental|Receiving Ultrasound|Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
9715326|NCT04582253||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values >47.0D, inferior- superior(I-S) asymmetry measured to be > 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
9715327|NCT04582253||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
9715328|NCT04582253||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
10195968|NCT03628235||Companions of middle stage HDGECs|
10195969|NCT03628235||Companions of late stage HDGECs|
10204801|NCT04894266|Experimental|Standard of Care plus apabetalone|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital. For the apabetalone cohort, treatment will be administered BID with meals.
10195970|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
10195971|NCT03602079|Experimental|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
10195972|NCT03602079|Experimental|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
9715329|NCT04582058|No Intervention|Control Group (CG)|Control Group (CG): Standard of care, normally follow up, without mobile health
9715330|NCT04582058|Experimental|Interventional Group (IG)|Interventional Group (IG): Mobile Health to patients with an orientation about daily activities and protocol of physical exercise
9715331|NCT04582045||low risk, silver impregnated|low risk, silver impregnated
9715332|NCT04582045||low risk, border bandage|low risk, border bandage
9715333|NCT04582045||high-risk, silver impregnated|high-risk, silver impregnated
9715334|NCT04582045||high-risk, wound vacuum|high-risk, wound vacuum
9715335|NCT04582032|Active Comparator|Dexketoprofen group,|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in dexketoprofen group were administered intravenous dexketoprofen (50 mg/2ml) and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
9715336|NCT04582032|Other|Saline group|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in control group were administered intravenous 2 ml of saline and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
10195973|NCT03602079|Experimental|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
10195974|NCT03602079|Experimental|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
10195975|NCT03602079|Experimental|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
10195976|NCT03585764|Experimental|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
9715337|NCT04582097|Experimental|Ramipril|Ramipril, 2.5 mg daily, administered orally for 16 weeks
9715338|NCT04582097|Placebo Comparator|Placebo|Placebo, matched for the interventional drug, administered orally, daily for 16 weeks
9715339|NCT04582019|Active Comparator|Patients with polyurethane DJ stent|Polyurethane DJ stent, 6Fr. The stent will be removed using flexible cystoscopy.
9715340|NCT04582019|Active Comparator|Patients with polyurethane DJ stent with magnet|Polyurethane DJ stent with magnet (Blackstar, Urotech), 7Fr. The stent will be removed under ultrasound control using a magnetic retriever
10195977|NCT03585764|Experimental|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
10195978|NCT03585764|Experimental|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
10195979|NCT03585764|Experimental|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
10195980|NCT03583697|Experimental|Active BMN111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111 daily
10195981|NCT03583697|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
10195982|NCT03582137|Experimental|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
10195983|NCT03582137|Placebo Comparator|placebo|Placebo oral solution
10204802|NCT04889274|Experimental|Part A: Male healthy volunteers|
9715341|NCT04581915|Experimental|Interventional|Participants to receive Triazavirin 250mg po 8 hourly for 5 days
9715342|NCT04581915|Placebo Comparator|Control|Participants to receive placebo po 8 hourly for 5 days
9715343|NCT04581954|Active Comparator|Standard of care|
9715344|NCT04581954|Active Comparator|Fostamatinib|
9715345|NCT04581954|Active Comparator|Ruxolitinib|
9715346|NCT04581876|Experimental|raltitrexed for injection + nab-paclitaxel|Patients receive raltitrexed 2mg/m2 (iv, 15min) and nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
9715347|NCT04581902|Experimental|Morning rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
9779674|NCT05055258|Experimental|600 mg KVD824|Two 300 mg KVD824 tablets twice a day for 12 weeks
9779675|NCT05055258|Experimental|900 mg KVD824|Three 300 mg KVD824 tablets twice a day for 12 weeks
9715348|NCT04581902|Experimental|Afternoon rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
10195984|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.~Blood bag (volume of blood: from 450 to 500 mL)."
10195985|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
9980323|NCT01390688||Impaired glucose tolerance|40 individuals with impaired glucose tolerance. age 40 -65 years, BMI > 18. 5 kg/m2
9715349|NCT04581707||Kyphoplasty Single Balloon Catheter Allevo|
9715350|NCT04581707||Quattroplasty Double Balloon Catheter Stop'n GO|
9715351|NCT04581772|Experimental|Cohort A|
9715352|NCT04581772|Experimental|Cohort B|
9715353|NCT04581772|Experimental|Cohort C|
9715354|NCT04581616|Active Comparator|ICNB group|After patient was turned to lateral decubitus position, local anesthetics is injected around incision site and ICNB is performed once after surgeon geys into chest cavity.
9715355|NCT04581616|Experimental|ESPB group|After patient was turned to lateral decubitus position, ESPB is performed via ultrasound guided technique before sound incision.
9715356|NCT04581993|Experimental|Intervention|Pregnant and lactating women (PLW) will receive Super Cereal - wheat soya blend with sugar and children aged 6-23 months will receive lipid-based nutrient supplement-medium quantity (LNS-MQ). Social and behavior change communication (SBCC), community mobilization, referrals, identification of model families, food demonstrations, local recipe) ration/beneficiary entitlement cards will be provided for easy verification and tracking during delivery of intervention.
9715357|NCT04581993|No Intervention|Control|Control districts will receive routine health care services available in the study area.
9715358|NCT04581668|Other|Neurally adjusted ventilatory assist first|Ventilation in NAVA mode then ventilation in conventional mode
9715359|NCT04581668|Other|Conventional ventilation first|Ventilation in conventional mode then ventilation in NAVA mode
9715360|NCT04582006||LSG|Patients undergoing laparoscopic sleeve gastrectomy.
9715361|NCT04582006||LRYGB|Patients undergoing laparoscopic Roux-en-Y gastric bypass.
9715362|NCT04581590|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training + cognitive training.
9715363|NCT04581590|Sham Comparator|Sham group|In the group G2 will be administered: tDCS active + dual-task motor training
9715364|NCT04581720|Experimental|Participants|The participants will be applied AMG and EMG on each arm of both arms when they finish routine monitoring before the induction of general anesthesia. After the participants being unconscious, we will find each participant's supramaximal current before injecting the neuromuscular blocking agents. During the operation, when the TOF count reaches 4 again and the height of T1 reaches 50% of baseline, we perform TOF tests using 4 currents (Supramaximal current, 0.7×supramaximal current, 0.5×supramaximal current, 0.3×supramaximal current), three times for respective current to figure out that low current can show the same level of TOF ratio as the supramaximal current. When the operation ends and the T1 reaches 100% of baseline, we perform TOF tests with 4 currents again. In the postanesthesia care unit, we use EMG only and perform TOF tests with 4 currents again. The participants can feel pain by the stimulants during the tests, so if they refuse the tests, we stop the tests and record it.
9715365|NCT04581941||Patients with essential tremor|Patients with essential tremor who have clinically been deemed candidates for DBS (Deep Brain Stimulation) surgery. Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses. This intervention is not part of the study. The investigators are going to recruit patients who receive the Medtronic Percept device, which allows for brain signal recordings (this feature is FDA approved). The investigators will be conducting an observational study using this device to collect data that the subjects receive as standard of care.
9715366|NCT04581577||Adult patients with neuromuscular or neurological disorders|Telephone questionnaires administered directly to patients over 16 years of age with neuromuscular or neurological disorders
9715367|NCT04581577||Parents of paediatric patients with neuromuscular or neurological disorders|Telephone questionnaires administered to the parents of patients over 16 years of age with neuromuscular or neurological disorders
9715368|NCT04581434|Experimental|Trauma-Focused Therapy|Patients randomized to Trauma Focused Therapy will receive either Prolonged Exposure (PE) or Cognitive Processing Therapy (CPT). According to standard VA practice, assignment will be determined according to which trauma-focused therapy the assigned provider is verified to provide; if the assigned therapist is verified in both PE and CPT, the provider will decide which treatment to deliver. PE and CPT are both recommended as frontline treatments by all published PTSD guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted.
9715369|NCT04581434|Experimental|Non-Trauma-Focused Therapy|"Those randomized to non-trauma-focused therapy will receive present centered therapy (PCT). Originally designed as a strong comparator for psychotherapy research that included the components of good therapy, PCT is now a bona-fide PTSD treatment suggested at the second tier in multiple clinical practice guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted."
9715370|NCT04581785|Experimental|Dose Level 1 Part A|3 year-olds to12 year-olds
9715371|NCT04581785|Experimental|Dose Level 1 Part B|6 month to 2 year-olds
9980324|NCT01390688||Normal glucose tolerance|80 Individuals without type 2 diabetes Age 40-65 years, BMI >18.5 kg/m2.
9980325|NCT01390701|Experimental|transcutaneous electr. nerve stimulation|
10204803|NCT04889274|Experimental|Part A: Female healthy volunteers|
9980326|NCT01390701|Active Comparator|felodipin|
9980327|NCT01390714|Experimental|1|
9715372|NCT04581785|Experimental|Dose Level 2 Part A|3 year-olds to12 year-olds
9715373|NCT04581785|Experimental|Dose Level 2 Part B|6 month to 2 year-olds
9715374|NCT04581694|Experimental|TAVI without contrast|
9715375|NCT04581746|Other|experimental arm|questionnaire and follow-up visit
9715376|NCT04581447|Experimental|Metformin + Standard care|"The pharmacological treatment (Metformin) will start at dose of 850 mg once daily and, at one month, increased to 850 mg twice daily. The dosage will be adjusted if necessary because of gastrointestinal symptoms and information on dose change during follow-up will be collected Adherence to study medications will be assessed by pills count and plasmatic dosage (Metformin group).~All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups."
9715377|NCT04581447|Other|Standard Care|All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.
9715378|NCT04581525|Experimental|tDCS of DLPFC|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left dorsolateral prefrontal cortex (DLPFC). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
9715379|NCT04581525|Experimental|tDCS of M1|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left primary motor cortex (M1). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
9715380|NCT04581525|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Subjects will undergo stimulation once a day for 10 consecutive weekdays.
9715381|NCT04581564|Experimental|Rhythm intervention|
9715382|NCT04581564|Active Comparator|Non-rhythm intervention|
9715383|NCT04581603|Active Comparator|TOP + CBT-I|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Cognitive Behavioral Therapy for Insomnia (CBT-I) and TOP for the next 8 weeks.
9715384|NCT04581603|Placebo Comparator|TOP + SHE|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Sleep Hygiene Education (SHE) and TOP for the next 8 weeks.
9715385|NCT04581304|Experimental|Bio-Oss Collagen|Transcrestal approach sinus augmentation using Geistlich Bio-Oss Collagen®.
10195986|NCT03547999|Active Comparator|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
10195987|NCT03547999|Experimental|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
9715386|NCT04581304|Active Comparator|Bio-Oss Granules|Transcrestal approach sinus augmentation using Geistlich Bio-Oss®.
9715387|NCT04581551|Experimental|Stroke group|"SWE for 6 shoulder muscles will be performed by 2 assessors in randomised order.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
10195988|NCT03528694|Experimental|Durvalumab plus BCG (induction + maintenance)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
10195989|NCT03528694|Experimental|Durvalumab plus BCG (induction only)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
10195990|NCT03528694|Active Comparator|BCG treatment (Standard of care therapy)|Bacillus Calmette-Guerrin (BCG) standard of care treatment
9715388|NCT04581551|Active Comparator|Healthy controls|"SWE for 6 shoulder muscles will be performed by 1 assessors.~m. supraspinatus~m. infraspinatus~m. rhomboideus major~m. deltoideus~m. pectoralis major~m. pectoralis minor"
9715389|NCT04581889||Children|Children from1 to 18 years, enrolled in kindergartens, primary, or secondary school located in city of Tübingen, Germany.
9715390|NCT04581889||Adult comparator|Adults of unknown status of previous SARSCoV-2 infection.
9715391|NCT04581889||Adult validation|Adults who report a history of SARS-CoV-2 infections between 1. February 2020 and the time point of sampling.
9715392|NCT04581226|Experimental|Lung ultrasound|Sonographic assessments including the lung consolidation score, B-line score and Lung aeration score will be recorded 1min. after intubation, at end of surgery and 2h postoperatively.
9779676|NCT05055258|Placebo Comparator|Placebo to KVD824|One, two or three placebo tablets to be taken twice a day for 12 weeks
10195991|NCT03526848|Experimental|Group 1|HIV infected participants on ART will undergo analytical treatment interruption 2 days after the first infusion of 3BNC117 and 10-1074, and will receive 6 additional infusions of both antibodies at weeks 2, 4, 8, 12, 16 and 20 (Part A). Participants will remain off ART until week 38, if viral suppression is maintained (Part B).
10204804|NCT04889274|Active Comparator|Part B: Nitrate-rich beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) containing ~5mmol of inorganic nitrate
9715393|NCT04581408|Experimental|Orkambi|"Generic name: Lumacaftor/Ivacaftor~Dosage form: tablet~Dosage: each tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor~Frequency: two tablets twice a day."
9715394|NCT04581291|Experimental|Intervention group|
9715395|NCT04581291|Experimental|Control group|
9715396|NCT04581356|Experimental|voxelotor|Voxelotor 1500mg daily orally
9715397|NCT04581486|Experimental|OMI intervention|Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
9715398|NCT04581486|Other|Control intervention (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
9715399|NCT04581759|Experimental|RIPC|Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after endovascular treatment while in-hospital.
9715400|NCT04581759|Sham Comparator|foundational treatment group (FT)|Patients in the FT group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs, during the study period without remote ischemic postconditioning after endovascular treatment.
10195992|NCT03526848|Experimental|Group 2|HIV infected participants on ART will remain on ART and will be administered seven infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16 and 20 (Part A). Analytical treatment interruption will begin at week 26 until week 38, if viral suppression is maintained (Part B).
10195993|NCT03517852|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).
9715401|NCT04581421|Experimental|High Carb first|
9715402|NCT04581421|Experimental|Low Carb first|
10195994|NCT03501381|Active Comparator|High Dose Interleukin 2|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
10195995|NCT03501381|Experimental|High Dose Interleukin 2 plus Entinostat|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
10195996|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
9779680|NCT05046873|Experimental|NNC0480-0389 + semaglutide(co-formulation)and placebo|Sequence A: The participants will be administered a single subcutanous (s.c.) dose of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as a co-formulation by a single injection and a placebo injection
9779681|NCT05046873|Active Comparator|NNC0480-0389 + semaglutide (separate injections)|Sequence B: The participants will be administered 0.5 mg semaglutide and 5 mg NNC0480 0389 as an subcutaneus injection (s.c) on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as two separate injections.
9779682|NCT05045807|Experimental|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with sodium nitrate as an additive.
9980328|NCT01390714|Experimental|2|
9980329|NCT01390727|Placebo Comparator|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
10195997|NCT03476213|Experimental|Group TCI|induction and anesthesia will be held by using target-controll infusion
10195998|NCT03476213|Active Comparator|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
10195999|NCT03472833|Experimental|High-dose|"Intervention with high dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days."
9779683|NCT05045807|Experimental|Meat with added nitrate plus vegetables|"The same intervention as of Arm meat with added nitrate consumed together with mixed vegetables."
9779684|NCT05042648|No Intervention|Control group (Group A)|Group A will receive no intervention
9779685|NCT05042648|Experimental|Buprenorphine group (Group B)|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest.
9779686|NCT05036603|No Intervention|1/routin medical care and neonatal intensive care unit's daily care|Group 1 (n=20) routine medical treatment for newborns on mechanical ventilator respiratory support and CPAP; Appropriate antibiotics given according to the needs of the baby, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care will be provided.
9980330|NCT01390727|Active Comparator|Device-guided breathing|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
10196000|NCT03472833|Active Comparator|Standard-dose|"Intervention with standard dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days."
10196001|NCT03453385|No Intervention|Control|Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
10196002|NCT03453385|Experimental|Sampling|Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
10196003|NCT03450629|Experimental|PDP-716|
10196004|NCT03450629|Active Comparator|Brimonidine Tartrate Ophthalmic Solution|
9715403|NCT04581265|Experimental|nab-PTX, ifosfamide and cisplatin|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.
9715404|NCT04580966|Experimental|Inquiry Based Stress Reduction (IBSR) workshop|Participants of this group received an IBSR intervention workshop.
9980331|NCT01390740||Echocardiography|patients with echocardiography
9715405|NCT04580966|No Intervention|Control group|Participants of this group did not take a part in the workshop.
9715406|NCT04580875|Active Comparator|Minimally invasive surgery (laparoscopy, laparoscopic-assisted procedures)|This study will be conducted out at 3 pediatric surgery tertiary centers (Al-Azhar University hospitals in Cairo, Prince Mohammed bin Abdulaziz Hospital in Riyadh and Maternity & Children's Hospital in Bisha) on patients aged from 1-14 years presenting to the ER by stable penetrating abdominal trauma with significant clinical/radiologic findings, in the period from April 2017 to March 2022. Responders to initial resuscitation will be managed by minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures). All patients enrolled in the study will give a written informed consent even for possible conversion to laparotomy if necessary.
9715407|NCT04580875|Active Comparator|Conservative management|patients aged from 1-14 years presenting to the ER by penetrating abdominal trauma with imsignificant findings will be managed conservatively.
9715408|NCT04580849|Experimental|telerehabilitation with dance (Parkinson's)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
9715409|NCT04580849|Active Comparator|telerehabilitation with dance (Healthy controls)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
9715410|NCT04580901|Experimental|Group interpersonal psychotherapy|Group IPT consists of 12 weeks of virtually-delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions, with the first 12 sessions taking place twice weekly (acute phase) for 6 weeks and the last 3 sessions occurring every other week (maintenance phase) for 6 weeks.
9715411|NCT04580901|No Intervention|Usual care|Usual care refers to any care that the women wish to access, and there are no limits on the women in either group. It may include, but is not limited to, the family physician, obstetrician, and/or midwife, participation in regional standard perinatal depression programming, private therapy, online therapies, medication, etc.
9715412|NCT04580927|Experimental|Randomized to breastfeeding self-efficacy enhancing intervention with nurse|Participants receiving breastfeeding self-efficacy enhancing nurse-led intervention plus postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
9715413|NCT04580927|No Intervention|Randomized to usual postpartum care|Participants receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
9715414|NCT04580927|No Intervention|Non-randomized observational arm|Participants who are not planning to breastfeed receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
9715415|NCT04581031|Other|Wearable monitors - Isansys Patient Status Engine|All patients will wear the continuous vital sign monitoring sensors.
9715416|NCT04580823|No Intervention|Control|Fasting without exogenous ketone salt supplement
9980332|NCT01390753|No Intervention|Preterm formula|
10196005|NCT03448718|Experimental|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
9715417|NCT04580823|Experimental|Fasting with exogenous ketone salt supplement|Fasting with exogenous ketone salt supplement
9715418|NCT04580823|Experimental|Post-Prandial with exogenous ketone salt supplement|Post-Prandial with exogenous ketone salt supplement
9715419|NCT04581239|Active Comparator|Active neural mobilization|Therapist supervised active neural mobilization of sciatic nerve in lumber radiculopathy patients
9715420|NCT04581239|Experimental|passive neural mobilization|Therapist done passicive neural mobilization of sciatic nerve in lumber radiculopathy patients
9715421|NCT04581083||Volunteer participants|Samples of volunteer participants will be collected after informed consent and classified as symptomatic, asymptomatic and negative.
9715422|NCT04581109|Experimental|Patients with metastatic prostate cancer|
9980333|NCT01390753|Active Comparator|Donor milk + preterm formula|Human milk from a donor bank
9980334|NCT01390753|No Intervention|Breastfeeding + formula|
9980335|NCT01390753|No Intervention|Breasfeeding|
9715423|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR1_fed|Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4
9715424|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR1_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4
9715425|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR1_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4
9980336|NCT01390766||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the liver transplantation
9980337|NCT01390792||Subjects prescribed zanamivir|Subjects prescribed zanamivir during study period
9980338|NCT01390805||Subjects with recurrent genital herpes|
9980339|NCT01390831|Experimental|Catheter, Renal Denervation, Ablation|Catheter-based renal denervation and maintenance of anti-hypertensive medications
9980340|NCT01390831|No Intervention|anti-hypertensive medications|Maintenance of anti-hypertensive medications
9980341|NCT01390883||Patients prescribed fondaparinux|Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments prescribed fondaparinux during study period
9715426|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR2_fed|Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
9980342|NCT01390896||Patients prescribed fondaparinux|Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism
9715427|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR2_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4
9715428|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR2_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
9980343|NCT01390922||Subjects prescribed botulinum injection|Subjects prescribed botulinum injection
9980344|NCT01390935||systolic heart failure|EF under 45%
9980345|NCT01390974||Patients treated for ACS|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel or clopidogrel therapy.
9980346|NCT01391026|No Intervention|Usual care|
9980347|NCT01391026|Experimental|Enhanced patient-centered care|Patients will be evaluated and treated in the advanced illness management clinic
9715429|NCT04580797|Experimental|PF-06700841 MR3 (Dose A) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition
9715430|NCT04580797|Experimental|PF-06700841 MR3 (Dose B) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition
9715431|NCT04580797|Experimental|PF-06700841 MR3 (Dose C) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition
9715432|NCT04581005|Experimental|Supervised Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.~This group will receive a supervised, in-hospital training."
9715433|NCT04581005|Experimental|Home-based Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.~This group will receive a home-based training."
9715434|NCT04580862|Experimental|group 1 Non-surgical endodontic retreatment in single visit|Single visit treatments have gained more popularity. Completing the treatment in a single appointment has many advantages including reduction in treatment time and cost, lower risk of micro leakage and recontamination of root canals between appointments
9980348|NCT01391039|Experimental|Contrast perfusion and elastography arm|Intravenous injection of microbubble contrast agent and elastography
9715435|NCT04580862|Active Comparator|group 2 Non-surgical endodontic retreatment in Two-visit|Two-visit endodontic treatment with intra-canal medication was traditionally found to be effective in decreasing the number of flare-up in all retreatment cases and in reducing postoperative pain of previously symptomatic teeth
9715436|NCT04580836|Experimental|Treatment (MRI-guided SBRT)|Patients undergo an MRI scan to check the status and location of the disease, including the motion of the tumor during breathing. Two weeks after MRI, patients undergo SBRT over 1-2 hours on 3 non-consecutive weekdays in the absence of disease progression or unacceptable toxicity.
9715437|NCT04581174|Experimental|1st degree of hypertrophy according to Camacho|Patients with 1st degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
9715438|NCT04581174|Experimental|2nd degree of hypertrophy according to Camacho|Patients with 2nd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
9715439|NCT04581174|Experimental|3rd degree of hypertrophy according to Camacho|Patients with 3rd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
9715440|NCT04581174|Experimental|4th degree of hypertrophy according to Camacho|Patients with 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
9715441|NCT04581161|Experimental|Life2000® Ventilator|Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device.
9715442|NCT04581161|No Intervention|Control Group|Subjects in the control group will be identified from the population of patients previously admitted to the study site with COVID-19 infection who required non-invasive oxygen therapy with HFNC but were not treated with NIV therapy. Subject data will be collected retrospectively from the medical record.
9715443|NCT04580758|Active Comparator|Fractional laser with PRP fluid|Fractional CO2 laser then the PRP is injected afterwards
9715444|NCT04580758|Active Comparator|Fractional laser with PRP gel|Fractional CO2 laser then the PRP gel is injected afterwards
9715445|NCT04580641||Subjects with migraine|No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.
9715446|NCT04580589||Adverse Drug Reaction on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience major bleeding or clinically relevant non-major bleeding per International Society of Thrombosis and Haemostasis criteria. This is an observational study, so there will be no intervention.
9715447|NCT04580589||Treatment Failure on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience treatment failure (e.g., recurrent MI, systemic embolism, ischemic stroke, etc.). This is an observational study, so there will be no intervention.
9715448|NCT04580589||Case Control|Participants on Direct Oral Anti-coagulants (DOACs) who experience neither major bleeding or treatment failure.
9715449|NCT04580550|Other|Axial length variability|Aim of this study is to evaluate the magnitude of changes in pre and postoperative measurements of AL.
9715450|NCT04580563|Experimental|Experimental group|"The experimental group will receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.~OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized volume; pathogen free. OctaplasLG® should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
9715451|NCT04580563|Placebo Comparator|Control group|The control group will receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.
9715452|NCT04580576||Female group|Pediatric female patients undergoing hematopoietic stem cell transplantation
9715453|NCT04580576||Male group|Pediatric male patients undergoing hematopoietic stem cell transplantation
9715454|NCT04580732|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
9715455|NCT04580732|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
9715456|NCT04580745|Experimental|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
9715457|NCT04580745|Experimental|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
9715458|NCT04581122|Experimental|Selective lymphadenectomy|
9715459|NCT04581122|No Intervention|Systematic lymph node dissection|
9715460|NCT04580784|Experimental|Hypofractionation|Hypofractionated whole breast radiotherapy using a dose of 28.5 Gy over 5 fractions with once weekly fractions.
9715461|NCT04580719||Patiente|Patients aged 18 to 50, presenting menstrual cycles, consulting in the obstetrics and gynecology department of the University Hospital of Reims whatever the reason for consultation can participate in the study after signing the consent of no opposition. Participation in the study will not change the patient's medical management.
9715462|NCT04581135||COVID-19 Lung|COVID-19 survivors in Switzerland
9715463|NCT04580329|Experimental|NMES group|
9715464|NCT04580329|Experimental|control group|
9715465|NCT04580524|Active Comparator|Phasix Mesh|Phasix mesh will be used in the repair of the hernia
9715466|NCT04580524|Active Comparator|Current Care|The hernia will be repaired with either synthetic mesh or suture repair, as determined by the operating surgeon.
9715467|NCT04580264|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
9715468|NCT04580355|Experimental|FMUD + Placebos|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
9715469|NCT04580355|Active Comparator|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
9715470|NCT04580251||Magnetic marker Magseed|Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.
9715471|NCT04580251||Iodine seed 125I marker|Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
9715472|NCT04580251||Carbon suspension|Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
9715473|NCT04580316|Experimental|Experimental group|75 children were managed during intervention using Parental Active Presence.
9715474|NCT04580316|Placebo Comparator|control group|75 children were managed with passive parent presence.
9715475|NCT04580238|Experimental|Treatment Arm|The treatment group will consist of 40 patients randomly allocated to receiving Botox according to the treatment regime.
9715476|NCT04580238|Active Comparator|Control|The control group will consist of 40 patients randomly allocated to Non-Botox, standard of care treatments, to a total study population of 80 patients.
9715477|NCT04580342|Experimental|Ivabradine group|
9715478|NCT04580342|Experimental|propranolol group|
9715479|NCT04580472|Placebo Comparator|Placebo - leg|If randomized to placebo group, 4 placebo capsules will be administered PO 30 minutes prior to incision in the leg group.
9715480|NCT04580472|Experimental|Antibiotic- leg|The administration time of the oral antibiotics will be 30 minutes prior to incision in the leg group. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered
9715481|NCT04580472|Placebo Comparator|Placebo- nose|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the nose.
9715482|NCT04580472|Experimental|Antibiotic- nose|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the nose. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
9715483|NCT04580472|Placebo Comparator|Placebo- ear|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the ear.
9715484|NCT04580472|Experimental|Antibiotic- ear|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the ear. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
9715485|NCT04580394|Experimental|AD109|Oral capsule administered before sleep
9715486|NCT04580394|Active Comparator|Atomoxetine|Oral capsule administered before sleep
9715487|NCT04580394|Active Comparator|R-oxybutynin|Oral capsule administered before sleep
9715488|NCT04580394|Placebo Comparator|Placebo|Oral capsule administered before sleep
9715489|NCT04580420|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
9715490|NCT04580433|Experimental|Time-Restricted Feeding|Participants will receive 16:8 TRF.
9715491|NCT04580108||Patients with systemic lupus erythematosus|Patients with systemic lupus erythematosus enrolled in the PLUS cohort between 2007 and 2010
9715492|NCT04580173||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
9715493|NCT04580173||0 < SYNTAX score <=22|Low SYNTAX group
9715494|NCT04580173||23<=SYNTAX score<=32|Intermediate SYNTAX group
9715495|NCT04580173||SYNTAX score>=33|High SYNTAX group
9715496|NCT04580069|Experimental|Lymphatic drainage|Patients subjected to manual lymphatic drainage
9715497|NCT04580069|Experimental|Connective tissue|Patients subjected to connective tissue massage
9715498|NCT04580069|Active Comparator|control group|Subjects hat followed standard rehabilitative treatment
9785781|NCT01259856|Experimental|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
9785782|NCT01259856|Active Comparator|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
9785783|NCT01259869|Experimental|PX-866|
9785784|NCT01260142|Experimental|Arm 1|
9785785|NCT01260142|Experimental|Arm 2|
9785786|NCT01260142|Experimental|Arm 3|
9715499|NCT04580082|Experimental|Mindfulness lessons|"There are 14 lessons in total, each lasting approximately 20 minutes. Participants will be asked to listen to one lesson per day for 14 consecutive days, but to allow for possible missed days, they will have up to 25 days to complete as many of these 14 lessons as they can. The lessons will be delivered via the internet, and participants can use a variety of devices (e.g. smartphone, desktop computer, laptop computer, tablet) to access them. While the lessons cannot be downloaded, they are available for streaming anytime and anywhere there is an internet connection. Participants are welcome to revisit any lesson they have listened to previously, but are not allowed to skip ahead to other lessons until they have completed all preceding lessons. This is done because the lessons build on one another, which means that skipping lessons makes continued participation difficult. We will be able to track each participant's usage pattern and will analyze differences across users."
9715500|NCT04580082|Other|Delayed-start Mindfulness Lessons|"The control group will not receive the intervention until the intervention group has completed lesson listening. During this waiting period, they will receive periodic emails letting them know that their turn to listen to lessons is coming soon.~Once available, the control group will have 25 days to listen to the 14 lessons."
10196006|NCT03447340|Experimental|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
9715501|NCT04579965|Other|combined contraceptive pills|treat patients with isthmocele with oral contraceptive pills
9715502|NCT04579965|Other|Misotac|treat patients with isthmocele with misotac.
9715503|NCT04580199|Active Comparator|total thyroidectomy|excision of thyroid gland
9715504|NCT04580199|Active Comparator|hemi thyroidectomy|excision half of thyroid gland
9715505|NCT04580199|Active Comparator|ethanol ingection|ingection of ethanol into thyroid nodule under guidance of ultrasound
9715506|NCT04580199|Active Comparator|monopolar radiofrequency|using radiofrequency for ablation of thyroid nodule
9715507|NCT04580199|Active Comparator|laser photocaugulation|using laser for ablation of thyroid nodule
9715508|NCT04579887|Experimental|Brain changes triggered by PH induction in Parkinson's disease|Clinical and neuropsychological evaluations + Sensorimotor task for PH-induction
9715509|NCT04579991|Active Comparator|Active Group|Apply small amount of topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
9715510|NCT04579991|Placebo Comparator|Placebo Group|Apply small amount of topical emulgel-only on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
9715511|NCT04580030||hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
9715512|NCT04580030||no hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
10196007|NCT03447340|Active Comparator|Cafeteria only|Receives only cafeteria intervention
9715513|NCT04580498|Experimental|Treatment group A|SHR-1701+Paclitaxel+carboplatin
9715514|NCT04580498|Experimental|Treatment group B|SHR-1701
9715515|NCT04579913||iTind subjects|Patient who participated previously in the MT-03 study in the iTind arm
9715516|NCT04579796|Experimental|women with first trimester missed abortion|
9715517|NCT04579822||Pregnant women vaccinated with a QIV|Women aged 20-44 years who had received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
9715518|NCT04579822||Pregnant women unvaccinated with a QIV|Women aged 20-44 years who had not received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
9715519|NCT04579926|Experimental|Pinpoint App|Tablet and smartphone application.
9715520|NCT04579861||High human development|Countries classified as very high and high human development as per the United Nations development programme.
9715521|NCT04579861||Low and medium human development|Countries classified as low and medium human development as per the United Nations development programme.
9715522|NCT04579978||Subjects with advanced solid tumors starting immunotherapy|Subjects with advanced solid tumors planned to initiate standard of care immune checkpoint inhibitors
9715523|NCT04579978||Subjects with advanced solid tumors receiving ICIs|Subjects with advanced solid tumors already receiving standard of care immune checkpoint inhibitors
10196008|NCT03445858|Experimental|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
9715524|NCT04580056||Incision Group|Women following IVF treatment with donor oocytes who underwent during hysteroscopy fundus endometrial scratching by incision, before embryo transfer.
9715525|NCT04580056||No incision Group|Women following IVF treatment with donor oocytes who underwent office hysteroscopy without fundus endometrial scratching by incision, before embryo transfer.
9715526|NCT04579874|Experimental|LIVERFASt validation|blood draw for LIVERFASt
9715527|NCT04580277|Experimental|Chronic pouchitis|This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks
9715528|NCT04580147|Experimental|Intervention (serial IAI)|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
9715529|NCT04580147|Sham Comparator|Control|Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (+/-7 days) and at post-operative day 60 (+/-7 days)
10196009|NCT03442413|Experimental|2-[18F]-FA PET/CT|Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
10196010|NCT03423524|Experimental|Arm: Investigational Device|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. consisting of hydrophobic material"
10196011|NCT03396042||Group 1|5 Patient target, ages 3 to 5 yr, with visual acuity Light Perception (LP) to <=20/200
10196012|NCT03396042||Group 2|5 Patient target, ages 3 to 5 yr, with visual acuity >20/200 to <=20/50
10196013|NCT03396042||Group 3|5 Patient target, ages 6 to 11 yr, with visual acuity LP to <=20/200
10196014|NCT03396042||Group 4|5 Patient target, ages 6 to 11 yr, with visual acuity >20/200 to <=20/50
10196015|NCT03396042||Group 5|5 Patient target, ages 12 to 17 yr, with visual acuity LP to <=20/200
10196016|NCT03396042||Group 6|5 Patient target, ages 12 to 17 yr, with visual acuity >20/200 to <=20/50
9715530|NCT04579809|Active Comparator|children below six years|children below sex years both genders
9715531|NCT04579809|Active Comparator|cooperative children|repair of the tendos by modified kessler
9715532|NCT04579770|Placebo Comparator|Placebo|Only carbohydrates will be provided
9715533|NCT04579770|Experimental|Ketone ester|Ketone ester with carbohydrates will be provided
9715534|NCT04579770|Experimental|Ketone ester + bicarbonate|Ketone ester with bicarbonate and carbohydrates will be provided
9715535|NCT04579770|Experimental|Bicarbonate|Bicarbonate and carbohydrates will be provided
9715536|NCT04579497|Experimental|38° C footbath|Footbath with warm water at a constant temperature of 38° C
9715537|NCT04579497|Experimental|40° C footbath|Footbath with warm water at a constant temperature of 40° C
9715538|NCT04579497|Experimental|42° C footbath|Footbath with warm water at a constant temperature of 42° C
9715539|NCT04579497|Experimental|Rising temperature footbath|Footbath with warm water rising from 38° C to 42° C
9715540|NCT04579562||COVID-19 positive AKI|
9715541|NCT04579562||COVID-19 positive no AKI|
9715542|NCT04579562||COVID negative AKI|
9715543|NCT04579536|Experimental|Study group|This is the study group; it will consist of 84 first permanent molars. These molars will be sealed using light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA). reapplication will be done after 3,6, 12, and 18 months.
9715544|NCT04579536|Other|Control group|This group will consist of 84 first permanent molars. These molars will receive 5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA). These molars will serve as a control group. reapplication will be done after 3,6, 12, and 18 months.
9715545|NCT04579445||TAVI patients|Consecutive, severe aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI) (there will be a retrospective part: documentation of 30 patients who underwent TAVI; and a prospective part enrolling 50 patients undergoing TAVI)
9715546|NCT04579458||COVID-19 Positive|COVID-19 positive in nasopharyngeal swabs and tears or saliva.
9715547|NCT04579471||Transplanted patients|All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven
9715548|NCT04579471||Transplanted patients with past SARS-CoV-2 infection|Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity
9715549|NCT04579471||Transplanted patients without past SARS-CoV-2 infection|100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection
9715550|NCT04579588||COVID-19 participants|
10196017|NCT03396042||Group 7|5 Patient target, ages 18yr and older, with visual acuity LP to <=20/200
10196018|NCT03396042||Group 8|5 Patient target, ages 18yr and older, with visual acuity >20/200 to <=20/50
10196019|NCT03386500|Other|Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|One arm includes all enrolled patients.
10196020|NCT03385655|Experimental|WEE-1 inhibitor|
10196021|NCT03385655|Experimental|cMET inhibitor|
10196022|NCT03385655|Experimental|novel non-steroidal androgen receptor (AR) antagonist|
9715551|NCT04579588||Control participants|
9715552|NCT04579601||ERAS group|We recruited 50 patients throughout 2018 and 2019, patients undergoing thoracic surgery within an ERAS program
9715553|NCT04579601||Standard group|A group of 50 patients selected randomly prior the implementation of the ERAS program, in 2016.
9715554|NCT04579614|Active Comparator|Organizational Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own, and with the organizational target. These updates and targets are sent bi-weekly."
9715555|NCT04579614|Experimental|Achievable Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a static and achievable target based on their previous year's flu vaccination success rate."
9715556|NCT04579614|Experimental|Variable|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a variable target that will fluctuate bi-weekly, based on their previous bi-weekly flu vaccination success rate."
9715557|NCT04579627||Hospital Doctors|Hospital doctors working at Royal Cornwall Hospital during the COVID-19 pandemic
9785787|NCT01260181|Experimental|Erlotinib|Participants will receive erlotinib 150 millgrams (mg) orally daily until disease progression.
9785788|NCT01260194|Experimental|1|
10196023|NCT03385655|Experimental|CFI400945 PLK4 inhibitor|
10196024|NCT03385655|Experimental|Ipatasertib AKT inhibitor|
10196025|NCT03385655|Experimental|Durvalumab and Tremelimumab immunotherapy|
10196026|NCT03385655|Experimental|Carboplatin platinum based chemotherapy|
10196027|NCT03379727|Experimental|Midostaurin|Induction phase - D8 to D28 in combination with standard of care (7+3 or 5+2 chemotherapy) up to 2 cycles Consolidation phase - D8 to D28 in combination with cytarabine up to 4 cycles Maintenance phase - D1 to D28 up to 12 cycles
10196028|NCT03368833||Caudal block|Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
10196029|NCT03368833||Control|Patients who do not receive a caudal block.
9715558|NCT04579731||Fecal Impaction (LUTD-FI)|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those with 50% of symptom improvement were assumed to have a significant improvement attributable to the development of Lower Urinary Tract Dysfunction- Fecal Impaction (LUTD-FI).
9715559|NCT04579731||Lower Urinary Tract Dysfunction Not Related to Fecal Impaction|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those without symptom improvement place into lower urinary tract dysfunction not related to fecal impaction (LUTD-FI). They serve as a control group.
10196030|NCT03367403|Experimental|Donanemab Monotherapy (Donanemab-M)|Participants received 700 milligram (mg) donanemab intravenously (IV) every 4 weeks (Q4W) x 3 doses, then 1400 mg donanemab IV Q4W for up to 72 weeks.
10196031|NCT03367403|Placebo Comparator|Placebo|Participants received placebo IV Q4W for up to 72 weeks.
10196032|NCT03367403|Experimental|Donanemab in Combination With LY3202626 (Donanemab-C)|"Participants received 700 mg donanemab IV Q4W x 3 doses, then 1400 mg donanemab IV Q4W in combination with 12 mg of LY3202626 orally for up to 72 weeks.~As per protocol amendment (d) approved on Oct 9, 2018, donanemab in combination with LY3202626 (donanemab-C) arm discontinued as there was a low probability of identifying a statistically significant effect of 12mg of LY3202626 slowing cognitive decline."
10204805|NCT04889274|Placebo Comparator|Part B: Nitrate-deplete beetroot juice|Dietary Supplement: Concentrate beetroot Juice (70 ml) which is nitrate-depleted
10204806|NCT04878627|Experimental|Cannabidiol (CBD)|"Days 1 to 7: Patients will receive CBD 2.5 mg/kg in divided doses BID for 7 days. Days 8 to 14: Patients will receive an increase dose of 7.5 mg/kg of CBD in divided doses.~Days 15 to 21: Patients will receive an increased dose of 12.5 mg/kg CBD, in divided doses. If patients experience dose limiting side-effects, they ill be maintained on the lowest tolerated dose."
10204807|NCT04878627|Placebo Comparator|Placebo|Days 1 to 7: Patients will receive placebo in divided doses BID for 7 days. Days 8 to 14: Patients will continue to receive placebo in divided doses. Days 15 to 21: Patients will receive continue to receive placebo in divided doses.
9715560|NCT04579718||Eclipse|
9715561|NCT04579718||Zeus Cloud TPS V1.0|
9715562|NCT04579419|Experimental|Sodium Bicarbonate|
9715563|NCT04579419|Placebo Comparator|Normal Saline|
10204808|NCT04874207|Experimental|Patients|Patients
10204809|NCT04872426|Experimental|Low intensity exercise|70% of maximal leg work load capacity
9715564|NCT04579354|No Intervention|Standardized Anaesthesia briefing|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia. This corresponds to the current procedure before an operation.
9715565|NCT04579354|Experimental|Virtual reality (VR) tour|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia.Subsequently, the patients are shown a virtual tour of the operation using VR glasses. This includes the way through the clinic to the operating theatre: Admission -> inpatient preparation for the operation -> administration of premedication -> way to the operating theater -> OP preparation (holding) -> safe surgery
9715566|NCT04579705|Experimental|Group I (Brushed-1 minute)|Surgical hand scrubbing will be performed in 1 minute using a brush.
9715567|NCT04579705|No Intervention|Group II (Brushless-1 minute)|Surgical hand scrubbing will be performed in 1 minute without using a brush.
9715568|NCT04579705|Experimental|Group III (Brushed-2 minutes)|Surgical hand scrubbing will be performed in 2 minute using a brush.
9715569|NCT04579705|No Intervention|Group IV (Brushless-2 minutes)|Surgical hand scrubbing will be performed in 2 minute without using a brush.
9715570|NCT04579341|Active Comparator|probiotics arm|probiotics administered in addition to insulin regimen
9715571|NCT04579341|No Intervention|control|regular insulin regimen
9715572|NCT04579185|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
9715573|NCT04579068|Experimental|Screening and Brief Intervention of Problematic Alcohol Use|We plan to test the feasibility and effectiveness of the delivery of the peer-based SBIRT using the RAPS4-QF screening tool with CDU students. Furthermore, we will compare delivery by AAPLs' race/ethnicity, drinking status (abstainer vs. non-abstainer), and adverse life experiences. Following the screening by AAPLs, we expect a 30% detection of problematic alcohol use (i.e. high episodic drinking [HED] or AUD) and at-risk alcohol use. Participants that screen positive will receive brief motivational interviewing and referral to treatment and will be contacted 6 months following the SBIRT to assess their drinking behaviors. We expect that participants will decrease their alcohol consumption or drinking risk at the 6-month follow up.
9715574|NCT04579055|Experimental|1-min STS test: chair seat height adjusted to 90° knee flexion|In this experimental condition, the patient performs the 1-minute sit to stand test on an individually adjusted seat height of 90° knee joint flexion.
9715575|NCT04579055|Active Comparator|1-min STS test: chair seat height standardized of 46cm|In this experimental condition, the patient performs the 1-minute sit to stand test on a standard height chair of 46cm.
9715576|NCT04579263|Experimental|Patient with diabetes mellitus type 1 (T1DM)|Treatment by transplantation of fecal microbiota
9715577|NCT04579263|Experimental|Patient with diabetes mellitus type 2 (T2DM)|Treatment by transplantation of fecal microbiota
9715578|NCT04579302|Experimental|serratus anterior block|serratus anterior block with 20 ml bupivacaine
9715579|NCT04579302|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
9715580|NCT04579302|Sham Comparator|control group|sham block with 20 ml saline
9715581|NCT04579328|Experimental|Lessons with Growth Mats|Participants, clustered by neighbor groups, will be given lessons on stunting. During the lessons the trainers will use the growth mats to demonstrate their points. In these villages, village-wide events will expose the full community to the messages in combination to the mats.
9980349|NCT01391052|Active Comparator|Norethindrone acetate pretreatment|This arm will receive two cycles of norethindrone acetate before LVN IUS insertion.
9715582|NCT04579328|No Intervention|Lessons without Mats|Participants, clustered by neighbor groups, will be given lessons on stunting without the aid of the growth mats. In these villages, village-wide events will expose the full community to the messages without the aid of the mats.
9715583|NCT04578938|Experimental|Ketamine + Cognitive Training|
9715584|NCT04578938|Sham Comparator|Ketamine + Sham Training|
9715585|NCT04578938|Active Comparator|No-infusion (TAU) + Cognitive Training|
9715586|NCT04578938|Sham Comparator|No-infusion (TAU) + Sham Training|
9715587|NCT04578860|Active Comparator|Treatment as usual|Usual treatment of sleep disorders consist of adequate sleep hygiene entails the behaviors, practices, rituals, and habits.
9715588|NCT04578860|Experimental|Music Intervention|Using the app Music Care
9715589|NCT04578860|Placebo Comparator|White Noise|Using an app producing white noise (like rain, storm, fan, wind...)
9715590|NCT04578795|Experimental|Pt underwent single use flexible ureteroscopy|Patients with renal stones who will operated by single use flexible ureteroscopy
9715591|NCT04579276|Experimental|"surgical method"|
9715592|NCT04579276|Active Comparator|"anesthetic method"|
9715593|NCT04578782|Experimental|BOTOX|155 UI of Botox were injected according to the approved PREEMPT protocol (the only FDA-approved injection pattern for chronic migraine), in 31 sites. From visit 5, the PREEMPT 'follow-the-pain' paradigm was applied in patients falling in the 'non-responder' or 'partial responder' classes after the first BoNT-A injection, with the possibility to increase the doses up to 195 UI in maximum 39 sites. The injections were every 3 months for 4 cycles
9779687|NCT05036603|Experimental|2/active chest physiotherapy in modified drainage positions|Group 2 (n=20) newborns on mechanical ventilator respiratory support and CPAP; A single session of active chest physiotherapy (CP) will be applied using modified drainage positions (avoiding the trendelenburg position, excessive position change and avoiding hand contact in babies younger than 30 weeks or who are sensitive to position change). Active CP in various modified drainage positions; It will consist of percussion and vibration methods with proprioceptive replacement stimulations. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
9779688|NCT05036603|Experimental|3/active chest physiotherapy in prone positions|Group 3 (n=20) newborns on mechanical ventilator respiratory support and CPAP; a single session of active chest physiotherapy treatment to be applied only in the prone position; Starting with proprioceptive stimulation, percussion and vibration methods will be applied. After these methods, aspiration will be performed and a suitable position will be given to the lobe that is desired to be ventilated. In addition, these patients will be given routine medical treatment consisting of appropriate antibiotics, enteral-parenteral nutrition, oral or nebulizer drugs for softening the secretion, vitamin supplements and routine nursing care.
9779689|NCT05036395|Experimental|The neonates evaluated by the routine assessment protocol and AI-assisted cEEG Diagnostic tool|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol and AI assisted cEEG diagnostic tool in real time during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
9779690|NCT05036395|Active Comparator|The neonates evaluated by the routine assessment protocol|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
9779691|NCT05023720||Regorafenib group|Patients were given only regorafenib orally
9779692|NCT05023720||Joint group|The patient was treated with regorafenib orally and in combination with other medications
9779693|NCT05023486|Experimental|NP-G2-044 Monotherapy|NP-G2-044 capsule PO QD for each 28-day cycle
9779694|NCT05023486|Experimental|NP-G2-044 Combination Therapy With Anti-PD-(L)1 Therapy|NP-G2-044 capsule PO QD for each 28-day cycle, Anti-PD-(L)1 Therapy per standard of care, at a dose and frequency in accordance with the package insert
9779695|NCT05019404|Experimental|Functional anterior temporal lobectomy (FATL)|FATL via minicraniotomy is a new surgical approach, consisting of amygdalohippocampectomy and the lateral temporal lobotomy.
9779696|NCT05019404|Active Comparator|Anterior temporal lobectomy (ATL)|ATL via large frontotemporal craniotomy is a conventional surgical approach, consisting of amygdalohippocampectomy and en bloc resection of the lateral temporal lobe.
9779697|NCT05014737||Patients with low risk of PONV|
9779698|NCT05014737||Patients with high risk of PONV|
9779699|NCT05010590|Active Comparator|Romosozumab and denosumab|
9779700|NCT05010590|Active Comparator|Romosozumab|
10196033|NCT03348150|Experimental|Gastrecomy + Cytoreductive surgery + HIPEC|
9779701|NCT05004467|Experimental|Mobilization with movement technique|"The therapist applies supported pressure on right and left side and articular planes. Meanwhile, the patient executes active movements and the therapist is trying to find the specifies cervical joint to get partial or total painful relief or movements with restrictions.~If the therapist couldn´t relief or remove pain or restriction with the pressure permorfem, he will readjust pressure and slide in differents planes of motion. It is necessary achieve that aim.~After that, the patient stay in sit down raised position on a stool, with his back in contact with the wall.~Hip, knee and ankle of the patient suppor a certain position: 90º of flexion which will be checked with a conventional goniometer. His hands are on the thighs. The treatment lasts 5 minutes."
9779702|NCT05004467|Sham Comparator|Placebo technique|Placebo manual technique is performed similar to experimental group technique but no slides are performed. The therapist simply embraces cervical region with boths hands, avoiding any pressure or any painfully caoture.
9779703|NCT05004025|Experimental|TTF Plus Chemotherapy|Novacure Optune with Opdivo and Yervoy
9779704|NCT05001945|Placebo Comparator|Placebo|Placebo tablet(s) by mouth once or twice daily.
9715594|NCT04578990|Experimental|Walking intervention group|It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.
9715595|NCT04578990|Experimental|Strength intervention group|The training program consists of performing a training program with resistance exercises for 36-72 weeks.
9715596|NCT04578990|Experimental|Concurrent intervention group|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli.
9715597|NCT04578990|No Intervention|Control group|It will receive standard advice consisting of the recommendation to perform aerobic exercise at the lower limbs level.
9715598|NCT04579107|Other|Contrast Enhanced Mammography|All included women go through a Contrast Enhanced Mammography added to the standard of care examinations.
9715599|NCT04579133|Experimental|durvalumab plus olaparib|Durvalumab 1500 mg IV week 0, 3, 6 plus Olaparib tablets will be given orally on a continuous dosing schedule 300 mg BID OR 200 mg BID (if glomerular filtration rate [GFR] 31 to 50 mL/min) to complete 9 weeks of treatment.
9715600|NCT04579133|Experimental|durvalumab alone|Durvalumab 1500 mg IV week 0, 3, 6 to complete 9 weeks of treatment
9715601|NCT04578847|Experimental|The TKI dose reduction|Imatinib, nilotinib, dasatinib or bosutinib; the two stage of TKI dose reduction phase for 12 months (6 months and 6 months, respectively).
10196034|NCT03348150|No Intervention|palliative systemic chemotherapy|
9715602|NCT04578912|Active Comparator|CBIT + rTMS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with 1 Hz repetitive Transcranial Magnetic Stimulation (rTMS).
9715603|NCT04578912|Active Comparator|CBIT + cTBS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with continuous Theta Burst Stimulation (cTBS).
9715604|NCT04578912|Sham Comparator|CBIT + Sham|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with either a cTBS or rTMS sham treatment.
9715605|NCT04578899|Active Comparator|Transvertebral magnetic stimulation (Experimental group)|Experimental intervention will receive non-invasive transvertebral magnetic stimulation of the sacral spine roots (level S2-S3).
9715606|NCT04578899|Placebo Comparator|Transvertebral magnetic stimulation (Control group)|"Control group will receive an equivalent number of stimulation sessions using the placebo option."
9715607|NCT04578951||Patients receiving a prosthesis from the FHK® range|
9715608|NCT04578704|Experimental|Vacuum formed retainer group|It will be constructed following manufacturer's instructions for the thickness.
9715609|NCT04578704|Experimental|Fixed bonded retainer group|fixed bonded wire will be bonded on individual tooth extended distal to extraction space that were previously closed by fixed appliances treatment.
9715610|NCT04578704|Experimental|Vacuum formed retainer and fixed bonded retainer|Double regime retainer that will be consisted of bonded retainer and vacuum formed retainer for upper and lower arch.
9715611|NCT04579003|Experimental|Mobilization|Mobilization, heat application, ultrasound, TENS
9715612|NCT04579003|Active Comparator|Mobilization with movement|Mobilization with movement, heat application, ultrasound, TENS
9715613|NCT04578678||Apathy Group|Patients diagnosed with apathy
9715614|NCT04578678||Dysarthria Group|Patients diagnosed with dysarthria
9715615|NCT04578678||No Apathy and Dysarthria Group|Patients diagnosed with neither apathy nor dysarthria
9715616|NCT04578678||Apathy and Dysarthria Group|Patients diagnosed with apathy as well as dysarthria
9715617|NCT04578717|Experimental|Air-abrasion + Etch & rinse adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by etch&rinse adhesive application using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
9715618|NCT04578717|Experimental|Air-abrasion + Self-etch adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by self-etch adhesive application which was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
9715619|NCT04578717|Experimental|Etch & rinse adhesive|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
9715620|NCT04578717|Experimental|Self-etch adhesive|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
9715621|NCT04578665|Experimental|Healthy Participants Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
9715622|NCT04578665|Experimental|Healthy Participants Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
9715623|NCT04578665|Experimental|Clinical Populations Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
9715624|NCT04578665|Experimental|Clinical Populations Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
9715625|NCT04578353|Experimental|AquaPass System|Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.
9715626|NCT04578431|Experimental|Intervention groups|The participants will be given a beverage containing four artificial sweeteners (intervention) at baseline
9715627|NCT04578418|Active Comparator|Collagen + heavy slow resistance group|Daily collagen supplementation + heavy slow resistance training three times weekly for 12 weeks.
10204810|NCT04872426|Experimental|High intensity exercise|70% and 95% of maximal work load capacity (alternately every 5 min)
10196035|NCT03331250|Experimental|Eribulin|"Eribulin administered twice per cycle intravenously~Each cycle contains 21 days~Dosing is per the FDA label for other cancers"
10196036|NCT03326492||Patients bitten by a snake|"Any patient over 5 years old going to a participating center for curative care following a snake bite.~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient."
10196037|NCT03286426|Experimental|Vision/Eye Screening|Image of back of each eye along with color vision and visual acuity assessment if able.
9715628|NCT04578418|Experimental|Placebo + heavy slow resistance group|Daily placebo supplementation + heavy slow resistance training three times weekly for 12 weeks.
9715629|NCT04578457|Active Comparator|Hearing Aid without NR(0) enabled|Hearing Aid without Noise Reduction (NR 0) enabled serves as reference condition.
9715630|NCT04578457|Experimental|Hearing Aid with NR (1)|Hearing Aid with Noise Reduction I (NR) enabled.
9715631|NCT04578457|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
9715632|NCT04578457|Experimental|Hearing Aid with NR(3)|Hearing Aid with Noise Reduction III (NR) enabled.
9715633|NCT04578626|Experimental|dry needling group|Dry needling treatment on right or left side of the face (depending on randomization)
9715634|NCT04578626|No Intervention|control group|No treatment on left or right side of the face (depending on randomization)
9715635|NCT04578366|Experimental|Shockwavetherapy Group/Experimental group|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
9715636|NCT04578366|Active Comparator|Conventional Group|Conventional therapy hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
9715637|NCT04578561||Prophylactic mesh|Patients who received a prophylactic mesh after emergency surgery due to high risk of incisional hernia.
9715638|NCT04578561||Suture|Patients who's laparotomies closure was using only suture without any abdominal wall reinforcement
9715639|NCT04578587|Active Comparator|Rater 1|Rater 1
9715640|NCT04578587|Active Comparator|Rater 2|Rater 2
9715641|NCT04578483||PCA group|Patients receiving patient-controlled analgesia (PCA) will be allocated to PCA group.
9715642|NCT04578483||ERDS group|Patients receiving one dose of extended-release dinalbuphine sebacate (ERDS) by ultrasound-guided muscle injection will be allocated to ERDS group.
9715643|NCT04578483||PRN group|Patients receiving analgesics other than ERDS and PCA will be allocated to PRN group.
9715644|NCT04578470|No Intervention|Group C|Patients with replete VitaminD levels (≥30ng/ml) will be serving as a control in group C. Group C will not receive any Vitamin D intervention for the entire 12- month study period but will receive dietary interventions.
9715645|NCT04578470|Experimental|Group A|Group A will be prescribed Vitamin D supplementation in the form of daily 2000 IU cholecalciferol (two tablets)for 13 weeks, and daily1000 IU cholecalciferol(1tablet) for another 13 weeks and then treatment will be discontinued but dietary interventions will continue across the 12-month study period.
9715646|NCT04578470|Placebo Comparator|Group B|Group B will be prescribed placebo of Vitamin D with two tablets daily for 13 weeks then 1 tablet daily for13 weeks then no treatment for 26 weeks but dietary interventions will continue across the 12-month study period.
9715647|NCT04578405|Active Comparator|Extracorporeal anastomosis|
9715648|NCT04578405|Experimental|Intracorporeal anastomosis|
9715649|NCT04578327|Experimental|Aim 1|Data from Specific Aim 1 will be used to test the following hypotheses: H1a. The body-powered prosthetic devices are embodied more than passive and myoelectric prosthetic devices. H1b. Passive cosmetic devices are embodied less than actuated cosmetic devices (agency). H1c. Body-powered terminal devices are embodied less than myoelectric terminal devices (agency).
9715650|NCT04578327|Experimental|Aim 3|Data from Specific Aim 3 will be used to test the following hypotheses: H3a. The maximum number of channels elicits more embodiment than the minimum number. H3b. The sensory feedback from passive spatial locations of the hand increases the embodiment compared to sensory feedback just from the grasping spatial locations.
9715651|NCT04578496|Experimental|Afamelanotide|
9715652|NCT04578574|Experimental|BI-TDCS Stimulation Group|Participants in this group will receive the BI and TDCS interventions for 10 sessions over two weeks.
9715653|NCT04578574|Sham Comparator|BI-TDCS (Sham) Stimulation Group|Participants in this group will receive the BI and TDCS (Sham) interventions for 10 sessions over two weeks.
9715654|NCT04578821|Experimental|Deney group|"Education Program:The education program consists of theoretical didactic education, case discussion, film and video screening in class, Web-based laboratory work, SSI practice, poster preparation and awareness activities for a total of 12 weeks and 2 hours per week (24 hours per week).~Theoretical didactic education, film screening, video screening, Web-based laboratory work, Social Security Institution study, poster preparation, poster presentation at University Campus."
9715655|NCT04578821|No Intervention|Kontrol group|The control group participated in the courses and practices included in the routine curriculum.
9715656|NCT04578769|Active Comparator|conventional myotomy|conventional myotomy for achalasia type I, II and III
9715657|NCT04578769|Experimental|short myotomy|modified myotomy (short myotomy) for achalasia type I and II
9715658|NCT04578769|Experimental|full-thickness myotomy|modified myotomy (full-thickness myotomy) for achalasia type I and II
9715659|NCT04578769|Experimental|tailored myotomy|modified myotomy (tailored myotomy) for achalasia type III
9715660|NCT04578691|Experimental|"Anatase Spine Surgery Navigation System"|"Using Anatase Spine Surgery Navigation System in pedicle screw placement in spine surgery"
9715661|NCT04578691|Active Comparator|Medtronic Stealthstation S7 Treatment Guidance System|Using Medtronic Stealthstation S7 Treatment Guidance System in pedicle screw placement in spine surgery
9715662|NCT04579016|Active Comparator|Standard care|Standard care
9715663|NCT04579016|Experimental|PAIGE2 intervention|One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.
9715664|NCT04578301||Surgery|Patients with and without liver cirrhosis undergoing surgery.
9666577|NCT04440735|Experimental|DSP107 in combination with atezolizumab|DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion.
9980350|NCT01391052|Other|No pretreatment|LVN IUS is placed without norethindrone acetate pretreatment.
9980351|NCT01391065|Other|1|The study arm will undergo baseline multifunctional PET and MRI scans, before brachytherapy and at follow up
9980352|NCT01391078|Experimental|Sensimed Triggerfish|
9980353|NCT01391078|Active Comparator|Goldmann Applanation Tonometry/Perkins Tonometry|
9980354|NCT01391091|Active Comparator|Patients without history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
9980355|NCT01391091|Active Comparator|Patients with history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
9666580|NCT04439643||Development / training|Selected by stratified partitioning
9666581|NCT04439643||Sequestered / test|Selected by stratified partitioning
9666584|NCT04430452|Experimental|Arm I (hypofractionated RT, durvalumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9666585|NCT04430452|Experimental|Arm II (hypofractionated RT, durvalumab, tremelimumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with durvalumab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who complete the first dose of tremelimumab and demonstrate clinical benefit based upon radiographic tumor regression and/or other clinical response without progression for at least 6 cycles or 6 months on treatment, whichever is shorter, and subsequently have evidence of progressive disease during the durvalumab monotherapy portion may receive a repeat dose of tremelimumab at the next scheduled cycle of treatment with durvalumab per physician discretion.
9666586|NCT04428008|Experimental|Active arm|1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks
9666587|NCT04428008|No Intervention|Control arm|Standard care
9666588|NCT04427150|Experimental|Auditory Training Group|12 hours of psychoacoustic training over 8 weeks
9666589|NCT04427150|Active Comparator|Other Training Group|12 hours of non-psychoacoustic training over 8 weeks
9666590|NCT04427150|No Intervention|TD Group|
9666591|NCT04424745|Active Comparator|Attention Bias Modification Training with real tDCS|
9666592|NCT04424745|Placebo Comparator|Attention Bias Modification Training with sham tDCS|
9666593|NCT04421365|Active Comparator|Active neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using active EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected to be effective for symptom improvement.
9666594|NCT04421365|Sham Comparator|Sham neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using sham EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected not to be effective for symptom improvement.
9666595|NCT04418271|Experimental|Prehabilitation|Prefrail and frail patients receive prehabilitation (new form of care)
9666596|NCT04418271|No Intervention|Standard of Care|Prefrail and frail patients receive no prehabilitation, but receive standard of care
9666597|NCT04417634|Experimental|RFR: resting full-cycle ratio|RFR will be used to drive PCI
9666598|NCT04417634|Active Comparator|FFR: fractional flow reserve|FFR will be used to drive PCI
9666599|NCT04409340||Training cohort|"All patients enrolled will undergo:~Magnetic Resonance Viscoelastography~Quantitative ultrasound (QUS)"
9666600|NCT04409340||Validation cohort|"All patients enrolled will undergo:~• Quantitative ultrasound (QUS)"
9666601|NCT04408560|Active Comparator|Groupe A with homéopathic treatment|Conventional treatment : paracetamol (drug analgesic class1) + Homeopathic drug : Rhus toxicodendron 9 CH et Ruta graveolens 5 CH
9666602|NCT04408560|Sham Comparator|Groupe B without homeopathic treatment|Conventional treatment : paracetamol (drug analgesic class1)
9666603|NCT04407585||Covid-19 Symptom Study app-user|UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
9666604|NCT04398914|Experimental|Pyrotinib, trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: pyrotinib, trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).~After surgery：~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.~if tpCR: chemotherapy 0-4 cycles according to physician's choice, followed with pertuzumab and trastuzumab up to 1 year total."
9666605|NCT04398914|Active Comparator|Trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).~After surgery：~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.~if tpCR: chemotherapy 0-4 cycles according to physician's choice; followed with pertuzumab and trastuzumab up to 1 year total."
9666606|NCT04398134|Experimental|ABI-H2158 plus ETV|ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
9666607|NCT04398134|Placebo Comparator|Placebo plus ETV|Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
9666608|NCT04396613|Active Comparator|Running Subcuticular Suture|
9666609|NCT04396613|Active Comparator|Interrupted Vertical Mattress Suture|
9666610|NCT04396613|Active Comparator|Staple Closure Techniques|
9666611|NCT04390399|Active Comparator|Cohort A Control Treatment Arm|SBRT + gemcitabine + nab-paclitaxel
9666612|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 1|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin HCl + N-803
9715665|NCT04578288|Active Comparator|Standard Blood Pressure management|The standard blood pressure management is maintenance of intraprocedural pre-recanalization SBP between 140-180 mmHg for all patients who receive endovascular thrombectomy for acute ischemic stroke in anterior circulation.
9715666|NCT04578288|Experimental|Individualized Blood Pressure management|The study intervention would be maintaining the intraprocedural pre-recanalization blood pressure in individualized SBP target ranges depending on the systolic blood pressure of the patient at presentation (=baseline SBP or bSBP).
9715667|NCT04578171||Study population|Subjects with severe asthma treated with mepolizumab
10196038|NCT03272217|Experimental|Arm A - Atezolizumab + Bevacizumab|Patients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
10196039|NCT03270956|Experimental|Renal Autologous Cell Therapy (REACT®)|Renal Autologous Cell Therapy (REACT®) Treatment - Patients will receive their first treatment of 2 injections of REACT® as soon as REACT® product is made available.
9715668|NCT04578223||Study group|Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i.
9715669|NCT04578223||Control group|Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only.
9715670|NCT04578262|Experimental|Epley Manoeuvre|Epley manoeuvre in participants with Multiple Sclerosis who suffer from benign paroxysmal positional vertigo. Only one administration.
9715671|NCT04578262|Sham Comparator|Sham Manoeuvre|The second group will received a sham manoeuvre. However after the experimental intervention ends, this groups will also receive Epley manoeuvre.
9715672|NCT04577950|Experimental|Arm with procedure: identification of lymphatic drainage of the uterus following 3 sites injections|A radiocolloid (Nanocoll® marked with Technetium 99), a fluorochrome (ICG) and a blue dye (Bleu Patenté®) will be injected in submucosal tissue to see the differences in lymphatic drainage between three different injection sites. Indeed, ICG will be injected under the endometrium, whereas Nanocoll® will be injected in the cervix and Bleu Patenté® in the uterine isthmus, at the transition between the cervix and the uterine corpus.
9715673|NCT04577963|Experimental|Part 1|Approximately 6-12 patients will be enrolled to receive fruquintinib in combination with tilelizumab and assessed for DLTs during the 28-day DLT observation period
9715674|NCT04577963|Experimental|Part 2|"Approximately 60 patients with TNBC will be enrolled, up to 30 patients in each cohort. Patients will be enrolled to one of the following two cohorts:~Cohort A (TNBC, IO-Treated): Patients must have advanced TNBC who have progressed on at least one cytotoxic therapy in the metastatic setting. Patients must have also received prior therapy with an immune checkpoint inhibitor.~Cohort B (TNBC, IO-Naïve): Patients must have advanced TNBC who have progressed on at least one cytotoxic therapy in the metastatic setting. Patients must not have received prior therapy with an immune checkpoint inhibitor."
9715675|NCT04578041|Experimental|Arm 1: TRPMS + Aerobic Physical Activity Program|
9715676|NCT04578041|Active Comparator|Arm 2: TRPMS + Adaptive Cognitive Training|
9715677|NCT04577924||Road traffic injury victims|"All RTI patients presenting to ED within 24 hours of injury is included in the study..~Individual's not consenting to be part of the study or withdrawing consent later on would be excluded. We also would exclude cases where pre-hospital care provider could not be traced or where reliable data patient could not be collected even after repeated interview."
9715678|NCT04578067|Experimental|Intervention|culturally tailored intervention package on changes in lifestyle-habits
9715679|NCT04578067|No Intervention|Control|
9715680|NCT04577937|Experimental|PSG in LAM patients|Patients affected by LAM underwent whole-night PSG
9715681|NCT04578236|Experimental|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
9715682|NCT04578236|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
9715683|NCT04578119|No Intervention|Conventional Intubating Technique|'Conventional technique' means that endotracheal intubation is performed with the videolayngoscope blade lifting up the epiglottis.
9715684|NCT04578119|Experimental|Sliding Intubating Technique|'Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
9715685|NCT04578184|Other|Epithelial thickness map evaluation in keratoconus patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
9715686|NCT04578184|Other|Epithelial thickness map evaluation in healthy cornea patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
10196040|NCT03260023|Experimental|TG4001/Avelumab|
10196041|NCT03260023|Experimental|Avelumab|Applicable for Phase II part 2.
10196042|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
10204811|NCT04872426|Experimental|Low intensity exercise + intermittent ischemia-reperfusion|70% of maximal leg work load capacity with intermittent ischemia (25 seconds every 2 min)
9715687|NCT04578158|Active Comparator|Standard of care|This arm will receive the standard COVID-19 care as per the hospital physician guidelines.
9715688|NCT04578158|Experimental|Quercetin Phytosome|This arm will receive standard COVID-19 care + Quercetin Phytosome
9715689|NCT04578210|Experimental|Arm A: allogeneic T memory cells|patients will receive memory T cells
9715690|NCT04578210|Experimental|Arm B: allogeneic NK cells|patients will receive NK cells
9779705|NCT05001945|Experimental|Dose 1|MLS-101 tablet(s) by mouth once or twice daily.
9779706|NCT05001945|Experimental|Dose 2|MLS-101 tablet(s) by mouth once or twice daily.
9779707|NCT05001945|Experimental|Dose 3|MLS-101 tablet(s) by mouth once or twice daily.
9715691|NCT04578145|Other|Female sex workers (FSW)|Female sex workers (FSWs) community is the only group which has implemented the study intervention. This group has been underlined as the one of key affected populations (KAPs) that hold an increasing number of HIV incidence and prevalence recently in Indonesia even though it is approximately 226,791 FSWs by 2016 and around 5,254,065 clients access their services per year (MoH, 2017). The condition will be worst because the transmission definitely will continue to clients' sexual partner and moreover, their babies if their HIV status has not been known earlier. It means that lowering the transmission of HIV infection for FSWs, it will simultaneously lower its transmission to their sexual partners and furthermore their babies.
9715692|NCT04578132||Genitourinary cancer patients that suffered COVID-19|Patients diagnosed with genitourinary cancer (urothelial, kidney, prostate and germ) that suffered from COVID-19 infection prior to cancer treatment, during treatment, or after treatment.
9715693|NCT04577872|Experimental|Supine group (n=22)|The 22 participants with lower muscle strength (under 60 microvolt) comprised the supine group.
9715694|NCT04577872|Experimental|Sitting group (n=19)|The 19 participants with higher muscle strength (over 60 microvolt) formed the sitting group.
9715695|NCT04577872|No Intervention|Control group (n=14)|The control group comprised 7 individuals with lower muscle strength (under 60 microvolt) and 7 with higher muscle strength (over 60 microvolt)
9715696|NCT04577846|Active Comparator|Intervention Arm|The intervention arm will be administered, either Cefazolin iv every 8 hours while NPO or cefalexin 500 mg q8 hours per oral if tolerating a diet.
10196043|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
9715697|NCT04577846|Placebo Comparator|Control|Controls will be provided with initially IV placebo while NPO and then with a placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
9715698|NCT04577625|Active Comparator|L. reuteri Low Dose|L. reuteri will be delivered in a capsule at a low dose including Vitamin D3. Administration twice daily.
9715699|NCT04577625|Active Comparator|L. reuteri High Dose|L. reuteri will be delivered in a capsule at a high dose including Vitamin D3. Administration twice daily.
9715700|NCT04577625|Placebo Comparator|Placebo|The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.
9715701|NCT04577885|Experimental|experimental group|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
9715702|NCT04577859|Active Comparator|Study group|Those randomized to the study group will receive the esophageal cooling device- the ensoETM probe, during AF ablation treatment, under general anaesthetic. The cooling device is set to 4 degrees covering ablation of the left atrial posterior wall.
9715703|NCT04577859|Active Comparator|Control group|Those randomized to the control group will receive standard of care, which is an esophageal temperature monitoring probe during their AF ablation procedure, under general anaesthetic. The esophageal temperature probe is sited close to the level of ablation (the probe should be at the esophageal level where, opposite this, the ablation catheter is at, in the endocardial aspect of the posterior left atrium).
9715704|NCT04577716||Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have developed an endoleak
9715705|NCT04577716||No Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have not developed an endoleak
9715706|NCT04577716||Pre-EVAR Group|Participants who have an abdominal aortic aneurysm and who are undergoing an Endovascular Aneurysm Repair as standard of care
9715707|NCT04577573|Active Comparator|No cognitive feedback|Perform task without cognitive feedback.
9715708|NCT04577573|Active Comparator|Intermediate feedback.|Perform task with intermediate feedback.
9715709|NCT04577573|Experimental|Enhanced feedback|Perform task with virtual reality and/or haptic feedback.
9715710|NCT04577664|Active Comparator|TT group|
9715711|NCT04577664|Active Comparator|ST group|
9715712|NCT04577768|Experimental|HD-tDCS 2 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 2 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
9715713|NCT04577768|Experimental|HD-tDCS 1.5 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 1.5 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
9715714|NCT04577768|Sham Comparator|Control|Single session of 20-min of sham HD-tDCS. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
9715715|NCT04577703|Experimental|CT053PTSA (dose escalation)|"Patients were treated in 5 dose cohorts of 15 mg, 30 mg, 60 mg, 100 mg, and 150 mg QD capsules.~Patients receive treatment with CT053PTSA once on Cycle 0 Day 1 following a 7-day treatment-free withdrawal period to observe the safety and pharmacokinetic of CT053PTSA.~After that, Patients receive treatment with CT053PTSA per orally, beginning on Cycle 1 Day 1 for 28 day following a 7-day treatment-free withdrawal period to observe efficacy of CT053PTSA and determine to continue taking medicine or not. Each cycle had 28 days."
9715716|NCT04577586||Water|Patients who ingested only water as an oral contrast
9715717|NCT04577586||Milk|Patients who ingested milk as an oral contrast
9715718|NCT04577586||Mannitol|Patients who ingested mannitol as an oral contrast
9715719|NCT04577781|Experimental|GLPG3970|Participants will receive GLPG3970 solution, orally, once daily for 6 weeks.
9715720|NCT04577781|Placebo Comparator|Placebo|Participants will receive placebo solution, orally, once daily for 6 weeks.
9715721|NCT04577794|Experimental|GLPG3970|Participants will receive GLPG3970 solution, orally, once daily for 6 weeks
9715722|NCT04577794|Placebo Comparator|Placebo|Participants will receive placebo solution, orally, once daily for 6 weeks.
9715723|NCT04577469|Experimental|500 mg sulfadoxine / 25 mg pyrimethamine tablet|500 mg sulfadoxine / 25 mg pyrimethamine tablet will be administered once.
9715724|NCT04577469|Active Comparator|G-COSPE® tablets|G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) will be administered once.
9715725|NCT04577508|Experimental|Functional Remediation|Functional Remediation
10196044|NCT03232931|Experimental|Multisensory Intervention|Preterm infants in the NICU who are randomized to receive a multisensory intervention, in addition to the standard of care. The multisensory intervention uses recordings of the parents' voices and nurturing touch administered in the NICU during 12 to 23 sessions of standardized, therapist-administered, auditory-tactile stimulation, dispersed over a 2 to 3 week period. The intervention includes 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
9715726|NCT04577508|Other|Control|Treatment as usual
9715727|NCT04577612|Experimental|Group 1|150 mg CBD
9715728|NCT04577612|Experimental|Group 2|300 mg CBD
9715729|NCT04577612|Experimental|Group 3|600 mg CBD
9715730|NCT04577612|Placebo Comparator|Group 4|Placebo MCT oil
9715731|NCT04577534|Experimental|Tocilizumab (TCZ)|Participants will receive one infusion of iv TCZ (according to weight of patient)
9715732|NCT04577534|No Intervention|standard of care (no TCZ)|Participants will receive standard of care
9715733|NCT04577560|Experimental|MII with PB biopsy|Five selected MII will undergo sequential polar biopsy; on day 0 [PB1] (36-42 hours post trigger injection) and if fertilization occurred on day 1 [PB2] (17-20 hours post ICSI). On day 5, 6 or 7, the resulting blastocyst will be biopsied.
9715734|NCT04577560|Experimental|MII with no PB biopsy|MII will not go under polar body biopsy. On day 5, 6 or 7, the resulting blastocyst will be biopsied.
9715735|NCT04577339||Adult patients with acute abdominal conditions|"All adult patients >=16years of age on all general adult wards (excluding maternity) between 2013 and 2020 with the following inclusion and exclusion criteria:~Inclusion criteria:~Must have an acute intestinal condition, based on their ICD-10 codes and OPSC-4 codes~Must be >= 16 years of age at the time of admission~Have at least one full set of vital signs recorded on the day of admission~Have at least one full set of routine blood tests recorded on the day of admission~Exclusion criteria:~Maternity admissions during/after pregnancy~Patients admitted or undergoing abdominal surgery for a second time or more"
9715736|NCT04577222|Experimental|Adipose Flap|Covering neurovascular bundle with fat
9715737|NCT04577222|No Intervention|Control|No adipose flap
9715738|NCT04577443|Active Comparator|Adenosine|
9715739|NCT04577443|Placebo Comparator|Saline|
9715740|NCT04577092|Active Comparator|Motor-Cognitive|"In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.~In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed."
9715741|NCT04577092|Active Comparator|Motor-Motor|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion. In cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
9715742|NCT04577378|Active Comparator|13 cis retinoic acid doses orally|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
9715743|NCT04577378|Sham Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
9715744|NCT04577378|No Intervention|control|No intervention
9715745|NCT04577170||Fabry disease|
9715746|NCT04577170||Healthy|age and sex matched
9715747|NCT04577287|Experimental|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the supraorbital area of affected hemisphere, Cathodal on the motor are (M1) of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
9715748|NCT04577287|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor are (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
9715749|NCT04577417||ADHD|Adolescents, male or female, ages 13-19, diagnosed with ADHD, all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and under treatment with a stimulant medication with the same drug and dosage for at least 12 months before their study participation date
9715750|NCT04577417||Control|Adolescents, male or female, ages 13-19, with normal health status and development
9779708|NCT04996641|Experimental|Intervention|Root canal treatment and crown restoration
10196045|NCT03232931|Other|Standard of Care|Preterm infants in the NICU who are randomized to receive the standard of care. The standard care for preterm infants in the NICU currently follows medical protocols of skin-to-skin holding and exposure to recordings of parent's voice.
10196046|NCT03227458|Active Comparator|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
10196047|NCT03227458|Active Comparator|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
10196048|NCT03227458|Active Comparator|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
9666613|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 2|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
9666614|NCT04390399|Active Comparator|Cohort B Control Treatment Arm|Irinotecan liposome + 5-FU/leucovorin
9666615|NCT04390399|Experimental|Cohort B Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
9666616|NCT04390399|Experimental|Cohort C Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin + N-803 + PD-L1 t-haNK
9666617|NCT04390113|Placebo Comparator|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
9666618|NCT04390113|Experimental|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
9666619|NCT04388163|Experimental|Gentian Violet Treatment|A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.
9666620|NCT04387448|Experimental|GFB-887 multiple ascending dose (MAD) active|GFB-887 active once-daily dosing
9666621|NCT04387448|Placebo Comparator|GFB-887 MAD placebo|GFB-887 placebo once-daily dosing
9666622|NCT04386798|Other|survey application to mothers|In the neonatal intensive care, the information form, postpartum specific anxiety scale, and neonatal intensive care unit parent-father stress scale will be filled in for the mothers who have a baby.
9666623|NCT04386590|Sham Comparator|'Sham' manual therapy plus Pulmonary Rehabilitation (PR)|Treadmill walking, upper body exercise machine, light weight training and bicycle. These exercises are supervised. In addition to the standard exercise therapy, all participants will undergo a 20-minute session consisting of discussion with the patient and 11 minutes of detuned ultrasound, which has been used in previous studies to account for time and attention for the patient. The detuned ultrasound procedure is to apply the ultrasound gel and turn the machine on, but set the intensity at zero (0) W/cm2
9666624|NCT04386590|Experimental|Manual therapy plus Pulmonary Rehabilitation (CMT+|Manual therapy is made up of gentle Effleurage and cross-fibre friction massage applied to the muscles of the posterior chest wall. Manual Therapy consists of two separate manipulations (Grade V mobilization). Each manipulation involves the delivery of a high-velocity low amplitude (HVLA) posterior to anterior force directed at the inter-vertebral, costo-vertebral and costo-transverse joints. The first manipulation is delivered at the level of the upper/middle thoracic spine while the second is at the level of the middle/lower thoracic spine. In addition to the MT, the participant will also undergo Pulmonary Rehab as previously described.
9666625|NCT04386330|Experimental|Narrative Exposure Therapy|Firefighters will receive distance-delivered NET administered by a paraprofessional.
9666626|NCT04385927|Experimental|Immediate e-NET Group|Parents of neurodiverse children with PTSI will receive e-NET immediately after the baseline survey
9666627|NCT04385927|Experimental|Wait List Control Group|Parents of neurodiverse children with PTSI will receive e-NET 3 months after the baseline survey
9666628|NCT04384146|Experimental|Quad Shot Radiation|In this trial, patients with centrally located lung tumors will be treated with up to 3 cycles of Quad Shot Radiation. Radiation treatment will be given within 1 week of administration of chemotherapy. Quad Shot radiation will involve: 3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break. The first group of patients will be treated with 2 cycles of quad shot radiation, followed by a 3-month observation period post-RT to allow a complete evaluation of acute toxicity. The next group of patients will be treated with either 1 cycle or 3 cycles of quad shot radiation. The minimum accrual is 4 patients with an expected accrual of 16 patients. Twenty additional patients will be recruited to an expansion cohort.
9666629|NCT04382664|Experimental|UV1 vaccination + nivolumab and ipilimumab|UV1 vaccination + nivolumab and ipilimumab
9666630|NCT04382664|Active Comparator|Nivolumab and ipilimumab|nivolumab and ipilimumab
9666631|NCT04382612|Other|HARPOON MVRS|Subjects who were treated with the HARPOON MVRS.
9666632|NCT04381533|Experimental|I-A-CRA|Internet-delivered Adolescent Community Reinforcement Approach: The treatment program consists of 8 extensive treatment modules delivered over 10 weeks with continuous therapist support and guidance. There are two separate treatments for the young adult and the caregiver/significant other.
9666633|NCT04381533|Active Comparator|Psychoeducation alcohol use|Psychoeducation focusing on alcohol use: This support program provides 8 brief modules of psychoeducation (alcohol information) over 10 weeks. Participants receive no therapist guidance/support but have the possibility of asking questions to a therapist. There are two separate programs for the young adult and the caregiver/significant other.
9666634|NCT04379089||Children <18|"Infants, children, and young adults age < 18 years~Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)"
9666635|NCT04373811||Principal cohort|"Quality of life, autonomy and survival will be assessed at one year on 50 patients.~Safety of early mobilization in post-ICU setting and Medical Reasearch Council (MRC) sum score will be assessed during hospitalization."
9666636|NCT04373811||Lung cohort|Lung Ultrasound will be carried out on the first 38 patients of the principal cohort.
9666637|NCT04373811||Muscle cohort|Muscle Ultrasound will be carried out on the first 27 patients of the principal cohort.
9666638|NCT04373343|Other|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
10196049|NCT03215524|Experimental|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
9715751|NCT04577053|Experimental|PEMF Therapy|Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
9715752|NCT04577053|No Intervention|Control|Control group will not receive treatment.
9715753|NCT04577326|Experimental|Engineered Autologous T Cells|Following eligibility screening and enrollment, patients will undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMCs), to enable generation of M28z1XXPD1DNR. Following successful M28z1XXPD1DNR CAR T-cell manufacturing, patients will be reevaluated for eligibility. A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m2 will be administered 2-7 days before the infusion. A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. All patients will be monitored in the hospital for a minimum of 48 h following the administration of CAR T cells.
9715754|NCT04577027|Experimental|vitiligo patients|Thirty Patients complaining of generalized non segmental vitiligo will be recruited in this study. They will be chosen from the attendants of the out-patient clinics of Dermatology, Assiut university hospital. six patches will be selected in each patient.
9715755|NCT04577196||Briefing supported by the trauma dashboard|During the entire chain of transmission (from the initial phone call to the end of the briefing to the trauma team) the trauma leader will be provided with a trauma dashboard to synthesize and disseminate the available information about the arriving patient.
9715756|NCT04577196||Briefing without the trauma dashboard|The transmission chain will not be supported by any specific tool.
9715757|NCT04577300|Experimental|Dual Implantation|Two NT-501 devices will be implanted in the study eye.
9715758|NCT04577300|Experimental|Single Implantation|One NT-501 device will be implanted in the study eye.
9715759|NCT04577300|Sham Comparator|Sham Implantation|No NT-501 devices will be implanted in the study eye.
9715760|NCT04577118|Other|iotaSOFT Insertion System|The iotaSOFT Insertion System is a surgical device that aids the surgeon in implanting cochlear electrode arrays by controlling the speed and distance of implant insertion. All subjects enrolled in the trial will have the iotaSOFT Insertion System used during surgery.
9715761|NCT04577261||FNS Participants|Participants who will undergo surgery to treat a fractured femoral neck using the FNS (Femoral Neck System)
9715762|NCT04577144||Individuals who participated in the RECOVER study|Individuals who enrolled in the Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery (RECOVER) study. Individuals who received at least one injection in a SUBLOCADE Phase III program were eligible to participate in the original study.
9715763|NCT04577040||1|Tadalafil in moderate puts
9715764|NCT04577040||2|Tadalafil in severe puts
9715765|NCT04577040||3|Tadalafil with sildosin in moderate luts
9715766|NCT04577040||4|Tadalafil with sildosin in severe luts
9715767|NCT04577079||IPMF Screened|Patient screened and assessed by intelligent patient flow management system.
9715768|NCT04577131|Experimental|With check-ins|Daily blood pressure monitoring with weekly check-ins
9715769|NCT04577131|No Intervention|Without check-ins|Daily blood pressure monitoring without weekly check-ins
9779709|NCT04991779||The neonates with suspected seizures or high risk of seizures|The neonates with suspected seizures or high risk of seizures are monitored by continuous electroencephalogram (cEEG) at least 12 hours since admission. The cEEG will be interpreted by AI-assisted cEEG diagnostic tool at the end of cEEG monitoring. At the same time, the same cEEG will be manually reported according the reference standard.
9779710|NCT04989816|Experimental|T-DXd arm|T-DXd monotherapy
9779711|NCT04988386|Experimental|AG10|Open-label study all participants will receive AG10 during this study.
9779712|NCT04987320|Experimental|Olpasiran Dose A|Participants will be administered Olpasiran dose A as a subcutaneous injection.
9779713|NCT04987320|Experimental|Olpasiran Dose B|Participants will be administered Olpasiran dose B as a subcutaneous injection.
9779714|NCT04983771||Expert in ultrasound-guided regional anaesthesia|"At least 15 UGRA experts, member of a relevant professional society (e.g., RA-UK, ESRA, ASRA) and meeting at least 3 of the following criteria) will be recruited from centres in the UK.~Completed advanced training in UGRA or have >10 years of independent practice in UGRA~Hold a qualification related to UGRA (e.g., EDRA, higher degree or equivalent)~Regularly delivers direct clinical care using UGRA, including for 'awake' surgery where indicated~Regularly teaches UGRA in the course of their clinical work, including advanced techniques (Plan B/C/D blocks) where indicated"
9779715|NCT04977362|Experimental|ERAS protocol (intervention group)|The innovative care process in the intervention group is characterized by an interdisciplinary approach according to the previously established enhanced recovery after surgery protocol. This process aims at improving the clinical outcome after cardiac surgery, increasing patient satisfaction and quality of life, enabling early professional reentry and participation, and optimizing the cost-effectiveness of service provision. In addition, intersectoral barriers are being broken down in order to establish an interdisciplinary and cross-sectoral overall care process for patients with heart valve surgery as a new form of care in the future.
9715770|NCT04577235|Experimental|Survivors group|Lung ultrasound score and computed tomography score were evaluated in the surviving group
9715771|NCT04577235|Experimental|Non survivors group|Lung ultrasound score and computed tomography score were evaluated in the non surviving group
9715772|NCT04576975|Experimental|Ketamine|This group will receive a bolus dose of Ketamine [Ketamine HCL - Sterop, Belgium] (0.3 mg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which Ketamine infusion (500 mg vial diluted over 50 cc infusion syringe, concentration 10 mg/ml) will start with rate of 0.3 mg/kg/hr till 10 Minutes before the end of the surgery
9715773|NCT04576975|Experimental|Dexmedetomidine|This group will receive a bolus dose of Dexmedetomidine [Precedex® -Hospira, USA] (0.5 µcg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which, the Dexmedetomidine infusion (200 µcg vial diluted over 50 cc infusion syringe, concentration 4 µcg/ml) will start with rate of 0.5 µcg/kg/hr till 10 Minutes before the end of the surgery
9715774|NCT04576975|Placebo Comparator|Normal Saline 0.9%|This group will receive a bolus dose of NS 0.9% over 10 minutes by 20 ml syringe infused before induction. After which, NS 0.9% (50 ml over 50 cc syringe) will be infused.
9715775|NCT04577430|Experimental|Loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 0.5 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the operation finished.
9715776|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the surgery finished.
9715777|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 1 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 1 μg/kg per hour during the operation until 0.5 h before the surgery finished.
9715778|NCT04577430|Placebo Comparator|Normal saline|
9980356|NCT01391104|Experimental|Sildenalfil|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
9980357|NCT01391104|Placebo Comparator|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
9980358|NCT01391117|Experimental|010|TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
9980359|NCT01391117|Experimental|001|TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
9980360|NCT01391117|Placebo Comparator|002|placebo. panel 1: 2 participants receive placebo at a q24h regimen.
9980361|NCT01391117|Experimental|003|TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
9980362|NCT01391117|Placebo Comparator|004|placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
9980363|NCT01391117|Experimental|005|TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
9980364|NCT01391117|Placebo Comparator|006|placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
9980365|NCT01391117|Experimental|007|TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
9980366|NCT01391117|Placebo Comparator|008|placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
9980367|NCT01391117|Placebo Comparator|009|placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
9980368|NCT01391156|Experimental|Minoxidil|
9980369|NCT01391156|Active Comparator|MinoxidilFinasteride|
9980370|NCT01391169|Active Comparator|1sup group|enforcement of the anastomoses with seromuscular flap
9980371|NCT01391169|Placebo Comparator|2nd group|primary anastomosis without enforcement
9980372|NCT01391182|Active Comparator|EACA arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
9980373|NCT01391182|Placebo Comparator|Placebo arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
9980374|NCT01391195|Experimental|Laser therapy and aerobic capacity|Effects of low level laser therapy on aerobic capacity of young women submitted to endurance training
9980375|NCT01391208|No Intervention|peptide application|
9980376|NCT01391221|Experimental|Duloxetine treatment|Subjects with major depression will be entered into the trial and treated with open label duloxetine
9980377|NCT01391234|Experimental|STAT RT planning and delivery workflow|single arm
9980378|NCT01391247||healthy age machted controls|
9980379|NCT01391247||normal tension glaucoma patients|
9980380|NCT01391247||primary open angle glaucoma patients|
10196050|NCT03215524|Experimental|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
9980381|NCT01391260|Experimental|Radiotherapy Combined With Gefitinib|
10196051|NCT03204721|Active Comparator|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
10196052|NCT03204721|No Intervention|Controll|No procedure
10196053|NCT03200457|Experimental|Patients with hepatic iron overload or steatosis|Each patient (80) will have two MRI exams on the same day: one performed in common practice on a 1.5 Tesla device and the other on a 3 Tesla device.
10196054|NCT03198039|Experimental|Group 1|Meditation twice daily for at least two weeks prior to surgery and for four weeks after surgery
9666666|NCT04345757|No Intervention|Standard instructions|Standard instructions: activity restrictions, including no strenuous exercise, sexual intercourse, or lifting objects greater than 25 pounds for 6 weeks or until evaluation at the 6 week postpartum visit
9666667|NCT04345757|Experimental|Study Group|Study group: Structured 10 week exercise protocol
9666914|NCT04122625|Experimental|Debio 1143 + Nivolumab|Part A: Participants will receive Debio 1143 at a starting dose of 150 milligrams (mg) orally once daily on Days 1-10 and Days 15-24 every 4 weeks (q4w) along with nivolumab at a flat dose of 240 mg intravenously (IV) on Days 1 and 15 of a 28-day cycle, participants may be switched to 480 mg IV on Day 1 q4w, exclusively upon investigator request with the sponsor agreement. Part B: Participants will receive Debio 1143 at RP2D established in Part A in combination with nivolumab as per standard care.
9666915|NCT04121897|Experimental|TEMPO|The Therapist Education and Massage for Parent-Infant Outcomes program (TEMPO) is a structured, therapist-led physical therapy program. TEMPO trains and supports parents to deliver physical therapy interventions including massage and developmental play during hospitalization and in the home setting.
9666916|NCT04120467|Experimental|Dance|Dance Standard rehabilitation post-stroke
9666917|NCT04120467|Active Comparator|Control|Standard rehabilitation post-stroke
9666918|NCT04119804||septic loosening|Septic loosening of primary hip implants according to the 2014 CDC criteria (as routinely performed in the clinical setting), adding another major and necessary criterion: at least 3 positive intraoperative tissue samples (same micro-organism).
9666919|NCT04119804||aseptic loosening|aseptic loosening of primary hip implants not meeting the CDC 2014 criteria
9666920|NCT04118270|Experimental|AFib 2gether(TM) App|Patients with known Atrial Fibrillation will be assigned to download and use an app targeted at determining stroke risk and increasing knowledge of Atrial Fibrillation and stroke risk along with treatment options and will use this information to facilitate a discussion with their cardiovascular provider.
9666921|NCT04116593|Experimental|Intervention|
9666922|NCT04116593|No Intervention|Control|
9666923|NCT04116099||Conservative care alone|Conservative care alone which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
9666924|NCT04116099||Flexitouch Plus and conservative care|Flexitouch Plus and conservative care which includes Flexitouch Plus treatment as well as conservative care measures which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
9666925|NCT04114695||Non-CKD (eGFR >60 ml/min/1.73 m2)|Patients with renal function considered normal for age (eGFR >60 ml/min/1.73 m2) without proteinuria or structural kidney disease.
9666926|NCT04114695||CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)|Patients with CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)
9666927|NCT04114695||CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)|Patients with CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)
9666928|NCT04114695||CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)|Patients with CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)
9666929|NCT04114695||CKD stage 5 (eGFR <15 ml/min/1,73 m2)|Patients with CKD stage 5 (eGFR <15 ml/min/1,73 m2). 50% of these patients will be in dialysis, while the other 50% will be pre-dialysis patients.
9666930|NCT04110444||sildenafile group A|received sildenafil citrate orally 20mg every 8 hours based on previous studies18,21 (Respatio tablet, pharma Egypt group) in addition to low molecular weight heparin daily according to the bodyweight at the booking visit (Clexane 20,40,60 mg, Sanofi eventis company) plus small dose of aspirin 75 mg (Aspocid 75mg tablet, CID pharmaceutical) once daily
9666931|NCT04110444||control group B|received low molecular weight heparin as subcutaneous injection once daily plus low dose aspirin 75mg orally once daily in addition to placebo three times daily prepared by a local pharmacy from a domestic manufacturer
9666932|NCT04110314|Active Comparator|Gain-framed portal reminders + Pre-commitment Prompts|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
9666933|NCT04110314|Active Comparator|Gain-framed portal reminders + No pre-commitment prompt|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
9666934|NCT04110314|Active Comparator|Loss-framed portal reminders + Pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
9666935|NCT04110314|Active Comparator|Loss-framed portal reminders + No pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
9715788|NCT04577105||Suspected, probable, or confirmed COVID-19 case|Patients who come to the emergency room with symptoms compatible with a suspected, probable, or confirmed case of SARS-CoV2 infection, in which a chest computed tomography (CT) scan was requested for suspected COVID-19 pneumonia, will be evaluated. On April 1 and August 28, 2020.
9715789|NCT04576845||Study Group|The study will be performed on Caucasian origin children who are among 2 to 6 years of age. The study group will be composed of children (n=31) who had CMA (Ig E-mediated and/or non-Ig E-mediated and/or mixed type) proved with oral food challenge tests in their early childhood (in ages of 0-2). The inclusion criteria to the study group will be to undergo a Cow's milk elimination (CME) diet or took a hypoallergenic formula in 0-2 years of age for at least 3 months or longer due to CMA allergy and improved afterward, and/or to eliminate other nutrients (e.g., eggs, potatoes, wheat flour, soybean, etc.) other than cow's milk between the ages of 0-2 for at least 3 months or longer, and/or to add these nutrients back to their diet in the last 3 months, and/or not receiving hypoallergenic formula for the last 3 months, not to be on the CME diet at present. Thus, no children in the study and control groups will be on a dietary restriction during the study.
9715790|NCT04576689|Experimental|Low dose|One (1) IBE-814 IVT Implant (70 μg Dexamethasone) Route of administration: intravitreal injections
10196055|NCT03198039|Experimental|Group 2|Meditation twice daily for four weeks after surgery
10196056|NCT03198039|No Intervention|Group 3|Control group - will undergo surgery and subsequent hospital stay according to the current standard of care, which does not include meditation
9715791|NCT04576689|Experimental|High dose|Two (2) IBE-814 IVT Implant (140 μg Dexamethasone) Route of administration: intravitreal injections
9715792|NCT04577404|Experimental|MT-1186|Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period
9715793|NCT04576624|Experimental|Lifestyle Intervention|Subjects in the Lifestyle Intervention group will, in six months, receive sixteen group sessions and six individualized treatment sessions.
9715794|NCT04576624|Sham Comparator|Social Activities|Social Activities Group will receive twenty-two group sessions
10196057|NCT03135249|Other|Alemtuzumab treatment.|"Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:~Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.~Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution."
9715795|NCT04576624|No Intervention|Passive Control|Control group will receive patient education materials with each assessment
9715796|NCT04577183|Experimental|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
9715797|NCT04576741|Experimental|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
9715798|NCT04576741|Experimental|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
9715799|NCT04577391|Experimental|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the use of involved side as maximum as possible. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating). In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook the role of the child's dominant hand.
9715800|NCT04577391|Active Comparator|Bimanual training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
9715801|NCT04576754|Experimental|WB001|
9715802|NCT04576754|Sham Comparator|Comparison Condition|
9715803|NCT04576884||Group 1|participants of less than 18 years old
9715804|NCT04576884||Group 2|participants aged from 18 years to 40 year
9715805|NCT04576884||Group 3|participants aged from 41 years to 60 years
9715806|NCT04576884||Group 4|participants over 60 years old
9715807|NCT04576676||Essential Tremor|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Essential Tremor~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
9715808|NCT04576676||Parkinson's Disease|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Parkinson's Disease~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
9715809|NCT04576676||Healthy Individuals|"Healthy individuals living within 3 hours of UTSW~Subjects must be 50 years of age or older~You are healthy and have not being diagnosed with any neurological disease~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
9785789|NCT01260272|Active Comparator|Alternative Snack Group|This group will receive 100 calorie alternative snack packs to consume three times a day with meals. Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables
10196058|NCT03132675|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab
10196059|NCT03130790|Experimental|Varlititib+mFOLFOX6|
10196060|NCT03130790|Placebo Comparator|Placebo+mFOLFOX6|
9715810|NCT04576676||Essential Tremor and Parkinson's Disease|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Essential Tremor~Subjects must have been diagnosed with Parkinson's Disease preceded by at least 3 years of enrollment in study~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
9715811|NCT04576520|Experimental|pharmacopuncture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
9715812|NCT04576520|Active Comparator|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
9715813|NCT04576650|Experimental|Summit system|Implantation of Summit system, consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities.
9715814|NCT04576780||Referred Patients with Large, Complex Colorectal Polyps|Patients referred from outside community care hospitals or ambulatory endoscopy centers to the therapeutic endoscopy group at St. Michaels Hospital via the new integrated management pathway for endoscopic resection of a large or complex colorectal polyp.
9715815|NCT04576728|Experimental|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
9715816|NCT04576728|Placebo Comparator|Placebo|Human albumin 1%
9715817|NCT04576806|Active Comparator|Body temperature fluid bolus of crystalloid|Fluid bolus at 38 degrees celsius of 500ml crystalloid over 15 minutes
9715818|NCT04576806|Experimental|Room temperature fluid bolus of crystalloid|Fluid bolus at 22 degrees celsius of 500ml crystalloid over 15 minutes
9715819|NCT04576559|Experimental|Modified dental visual aids|
9715820|NCT04576559|Active Comparator|Regular dental visual aids|
9715821|NCT04576598|Experimental|Self-management group to increase physical activity levels|This group will perform a self-management program along 6 months. This program will aim to increase the level of physical activity and adherence to healthier lifestyle habits and will be carried out through several sessions that will incorporate: education, goal setting, identification of barriers, self-control and feedback.
9715822|NCT04576598|Active Comparator|Control group|This group will participate in the initial educational session and will be given a leaflet with recommendations for physical activity to follow throughout the six months.
9715823|NCT04576637|Experimental|Neurophysiological monitoring during induction|
9715824|NCT04576611|Experimental|face-to-face|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using face-to-face modality guided by a health professional.
9715825|NCT04576611|Experimental|self-managed|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using self-managed modality through BackFit App.
9715826|NCT04576793|Experimental|Cognitive impairment|"Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties~Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties~Amnestic Alzheimer's disease - a typical version of Alzheimer's disease with memory difficulties"
9715827|NCT04576793|Active Comparator|No cognitive impairment|Healthy controls
9715828|NCT04576533|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
9715829|NCT04576533|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
9715830|NCT04576507|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
9715831|NCT04576858||Cohort 1: Surgical resection + perioperative chemotherapy|
9715832|NCT04576858||Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery|
9715833|NCT04576858||Cohort 3: Definitive chemoradiotherapy|
9715834|NCT04576858||Cohort 4: Chemotherapy with the aim to prolong life expectancy|
9715835|NCT04576858||Cohort 5: Non-chemotherapeutic palliation|E.g. Palliative radiotherapy
9715836|NCT04576481|Active Comparator|Group 1: Text Messaging|Consist of daily text messages on shared reading
9715837|NCT04576481|Experimental|Group 2: Text Messaging + Coaching|Will consist of Group 1 plus personalized coaching.
9715838|NCT04576481|Experimental|Group 3: Text Messaging + Coaching + Lottery|Will consist of Group 2 plus availability of a weekly lottery.
9715839|NCT04576364|Active Comparator|12-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 12-hour postpartum Mgso4
9715840|NCT04576364|Active Comparator|24-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 24-hour postpartum Mgso4
9715841|NCT04576468|Experimental|open flap debridement|envelope full thickness flap reflection, removal of granulation tissue then suturing with simple loop sutures.
10196061|NCT03127696|Experimental|FMT + LMP|FMT and lifestyle modification program
9666695|NCT04325763|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
9666696|NCT04325763|Experimental|TQB2450+Anlotinib(blank)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
10196062|NCT03127696|Experimental|FMT alone|Fecal Microbiota Transplantation
10196063|NCT03127696|Sham Comparator|Sham + LMP|Sham and lifestyle modification program
10196064|NCT03125564|Experimental|Fecal Microbiota Transplantation|FMT infusion and Fecal and Mucosal Microbiota Assessment
10196065|NCT03125564|Sham Comparator|Sham infusion|Infusion with sham and Fecal and Mucosal Microbiota Assessment
9715842|NCT04576468|Experimental|perforated membrane (PM)|envelope full thickness flap reflection, removal of granulation tissue placing resorbable membrane after perforating it over the vertical defect then suturing with simple loop sutures.
9715843|NCT04576468|Experimental|leucocyte platelet rich fibrin (L-PRF)|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF in the defect then suturing with simple loop sutures.
9715844|NCT04576468|Experimental|L-PRF + PM|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF covered by resorbable membrane after perforating it in the defect then suturing with simple loop sutures.
9715845|NCT04576299||Healthcare workers.|"Survey developed specifically for the objective of this study: Healthcare worker perception of patient safety in times of pandemic.~The application will be done through a digital questionnaire in the surveymonkey platform (Link of the instrument: https://es.surveymonkey.com/r/COVIDSP)"
9715846|NCT04576351||1|"Sub cohort 1:~Participants in the WHO NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS CoV-2 infected patients.~Eligibility: consenting adults (age ≥18) hospitalized with definite COVID-19 included in the WHO COVID-19 Study. Participants invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected."
9715847|NCT04576351||2|"Sub cohort 2:~Patients with COVID-19 and neurological symptoms related to COVID-19 admitted to the Norwegian Departments of Neurology or other relevant Departments (both hospitalized and outpatient visits) and persons with neurological symptoms participating in other COVID-19 studies and not already participating in the WHO NOR Solidarity multicenter trial."
10196066|NCT03117309|Experimental|PART A: Nivolumab|Nivolumab 240mg; Nivolumab 360mg
10196067|NCT03117309|Experimental|PART B: Nivolumab + Ipilimumab|Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg
10196068|NCT03116464|Experimental|Intervention Group|Caregiver and patient with dementia dyads who receive the family intervention.
10196069|NCT03085810|Experimental|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks (+/- 14 days) for a maximum of 8 doses throughout the 192 weeks treatment period.
9715848|NCT04576260|Experimental|CBT-I Group|Participants in the CBT-I group will undertake weekly sessions for a duration of 8 weeks with a trained psychologist through Zoom or Skype Calls.
10196070|NCT03085810|Active Comparator|Substudy Group 1|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 3.5 hours every 24 weeks for the remainder of the study duration
10196071|NCT03085810|Experimental|Substudy Group 2|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 2 hours followed by sodium chloride given as a slow infusion over the remaining 1.5 hours to mimic the standard-length infusion (3.5 hour) every 24 weeks for the remainder of the study duration
9715849|NCT04576260|No Intervention|Control group|The control group will be asked to maintain the usual lifestyle for the duration of the study
9715850|NCT04576195|Experimental|Real PENS|One single session of PENS
9715851|NCT04576195|Sham Comparator|Sham PENS|One single session of Sham-PENS
10196072|NCT03073785|Active Comparator|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
10196073|NCT03073785|Experimental|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
9715852|NCT04576403|Active Comparator|Intervention group|Activated mittens
9715853|NCT04576403|Sham Comparator|Control group|Deactivated mittens
10196074|NCT03047135|Experimental|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
9715854|NCT04576286|Experimental|Holmium en bloc resection|Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency
9715855|NCT04576286|Active Comparator|bipolar en bloc resection|bipolar en bloc tumor resection of urinary bladder tumors
9715856|NCT04576208|Experimental|Cohort 1|TAK-788 160 mg, capsules, orally, once daily (QD) with or without a low-fat meal until disease progression or as assessed by the investigator during every 3-week cycle.
9715857|NCT04576208|Experimental|Cohort 2|TAK-788 160 mg, capsules, orally, QD with or without a low-fat meal and antidiarrheal prophylaxis administered during the first 8 weeks of treatment until disease progression or as assessed by the investigator during every 3-week cycle.
9715858|NCT04576130|Experimental|ICD-implantation|Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
9715859|NCT04576130|No Intervention|Standard care|Guideline directed medical therapy
9715860|NCT04576169|Experimental|Central or Radial Tear: Arthroscopic debridement|Arthroscopic debridement
9715861|NCT04576169|Placebo Comparator|Central or Radial Tear: Sham surgery|Diagnostic arthroscopy only (placebo surgery).
9715862|NCT04576169|Experimental|Ulnar Tear: Arthroscopic or open repair|Arthroscopic or open repair
9715863|NCT04576169|Active Comparator|Ulnar Tear: Physiotherapy|Diagnostic arthroscopy and physiotherapy
9715864|NCT04576312|Experimental|Cohort 1|Single dose of UNI911 inhalation (4 mL 0.1% ~ 3,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
9715865|NCT04576312|Experimental|Cohort 2|Single dose of UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
9715866|NCT04576312|Experimental|Cohort 3|Single dose of UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
9715867|NCT04576312|Experimental|Cohort 4|Single dose of UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg)
9715868|NCT04576312|Experimental|Cohort 5|UNI911 inhalation (6 mL 1% ~ 50,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 2,5 days.
9715869|NCT04576312|Experimental|Cohort 6|UNI911 inhalation (1 mL 1% ~ 8,4 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
9715870|NCT04576312|Experimental|Cohort 7|UNI911 inhalation (3 mL 1% ~ 25,2 mg) and intranasal spray (2 x 150 µL, 1% ~ 2,5 mg) BID for 6,5 days.
9715871|NCT04576312|Placebo Comparator|Placebo (applicable for cohorts 1-5)|Placebo, administered in a double-blinded fashion (except for the first subjects of cohorts 1-4) at the same dose and frequency as UNI911 inhalation and intranasal spray.
9715872|NCT04576234|Experimental|intermittent entral feeding group|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest) by using syringe pump and Feeds were administered according to guidelines as the head of the patient's bed was elevated at least 30 degrees from the horizontal before initiating feeding, the feeding schedule was started at a rate of 50 ml/hr in adults to promote tolerance,the administration rate of isotonic formulas increased in 20-25 ml/hr increments every eight hours until the desired rate was achieved, the tube was flushed regularly with 20 to 30 ml of warm water every four hours during continuous feeding and before and after intermittent feeding and medication administration, the gastric residual volume was checked every 4-6 hr routinely
9715873|NCT04576234|Experimental|, feeding bag group|Feeding bag group received hospital blended formual which was 300 ml of feeds every 2hrs with 4hrs rest at night and given in 10 minutes with following the same guidelines in the intermittent enteral feeding group
9715874|NCT04576143|Active Comparator|epirubicin/CTX × 4 - docetaxel × 4, every 3 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 21 days); Cycle 5-8: Docetaxel i.v. 100mg/m2 (One cycle = 21 days) .
9715875|NCT04576143|Experimental|epirubicin/CTX × 4 - paclitaxel × 4, every 2 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 14 days); Cycle 5-8:Paclitaxel i.v. 175mg/m2 (One cycle = 14 days) .
9715876|NCT04576221|Experimental|stacked breathing group|experimental group received staked breathing exercise for 7 days , 3 sessions per day, 7-8 times per session
9715877|NCT04576221|Experimental|CPAP group|experimental group received NIV with CPAP mask
9715878|NCT04576273||Non-parasitic|
9715879|NCT04576273||Parasitic|
9715880|NCT04576039|Experimental|presenting with thickened endometruim|women presenting with thickened endometrium after the use of ulipristalacetate will undergo a saline infusion in the uterus and immediate ultrasonographic control to visualise the morphology of the endometrium.
9715881|NCT04576052||antibiotic-coating|patients who have been treated with an antibiotic-coated nail for tibia-fracture
9715882|NCT04576052||non-coated|patients who have been treated with a non-coated nail for tibia fracture
9715883|NCT04576013|Experimental|Active PNS during training|Individuals in this group will receive active PNS while participating in 2 hours of motor training of the affected arm.
9980382|NCT01391338|Experimental|Lowest dose ASP3652 twice daily|
9980383|NCT01391338|Experimental|Low dose ASP3652 twice daily|
9980384|NCT01391338|Experimental|Medium dose ASP3652 twice daily|
9715884|NCT04576013|Active Comparator|Active PNS before training|Individuals in this group will receive 2 hours of active PNS before participating in 2 hours of motor training of the affected arm.
9715885|NCT04576013|Sham Comparator|Sham PNS during training|Individuals in this group will receive 2 hours of sham PNS while participating in 2 hours of motor training of the affected arm.
9715886|NCT04576026|Experimental|Ketone esters|Ketone esters will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
9715887|NCT04576026|Active Comparator|Placebo|Iso-caloric carbohydrate drink will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
9715888|NCT04576065|No Intervention|Usual Care|Patients randomized to usual care will follow-up with primary care providers and specialists as recommended by hospital providers, or seek medical care as needed after hospital discharge.
9715889|NCT04576065|Experimental|Intervention|Patients randomized to intervention will have 6 months of access after hospital discharge for telehealth visits with a nurse practitioner and an activity tracker providing data to the nurse practitioner about subject's daily level of activity.
9715890|NCT04575974||Adolescents 13-19 years|All adolescents between 13-19 years of age in North Trøndelag county were invited to participate in HUNT 3 and followed up after 11 years.
9715891|NCT04576390|Active Comparator|Group O|On the day of procedure, the recruited patients in Group O will be given Ondansetron 4 mg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
9715892|NCT04576390|Active Comparator|Group P|On the day of procedure, the recruited patients in Group P will be given Palonosetron 75 mcg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
9715893|NCT04575961|Other|Pembrolizumab + Chemotherapie|pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin or carboplatin monotherapy)
9715894|NCT04575818|Experimental|GLPG4059 SAD|Single doses of GLPG4059 at up to 6 dose levels in ascending order
9715895|NCT04575818|Placebo Comparator|Placebo SAD|Single doses of placebo
9980385|NCT01391338|Experimental|High dose ASP3652 once daily|
9980386|NCT01391338|Experimental|High dose ASP3652 twice daily|
9980387|NCT01391338|Placebo Comparator|Placebo|
9980388|NCT01391351|Other|Taxol and carboplatin|blood samples in patients receiving Taxol and carboplatin chemotherapy
9980389|NCT01391351|Other|Taxol, carboplatin and avastin|blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
9980390|NCT01391377|Active Comparator|Niacin / Laropiprant|
9980391|NCT01391377|Placebo Comparator|Sugar Pill (Placebo)|
9980392|NCT01391390|Experimental|Melatonin, antioxidant, oxidative stress|Melatonin is an active treatment for TD.
10196075|NCT03041727|Active Comparator|Standard Group|"The subjects will be treated with a standard protocol of stretching and strengthening exercises , we require them to do the exercises by themselves during five weeks, one a day.~To make sure that they will do the protocol, we'll give them a diary to sign the daily section."
10196076|NCT03041727|Experimental|Intervention group|The subjects will be treated with the same protocol of the Standard Group, but in two section, they will receive a Fascial Manipulation approach.
10196077|NCT03035630|Experimental|Avelumab then Sunitinib for Investigational Arm A|"First-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory an inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
10196078|NCT03035630|Experimental|Sunitinib then Avelumab for Investigational Arm B|"First-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
10196079|NCT02994199|Experimental|Active video gaming|Participants will engage in active video game play.
9715896|NCT04575818|Experimental|GLPG4059 rBA/FE oral suspension fasted|Single dose of GLPG4059 in fasted state
9715897|NCT04575818|Experimental|GLPG4059 rBA/FE tablet fed|Single dose of GLPG4059 in fed state
9715898|NCT04575818|Experimental|GLPG4059 rBA/FE tablet fasted|Single dose of GLPG4059 in fasted state
9715899|NCT04575701||Ulcerative Colitis (UC)|This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
9715900|NCT04575701||Crohn's disease (CD)|This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
9715901|NCT04575701||IBD unclassified|This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
9715902|NCT04575909|Experimental|Recognition, Production Implicit-Explicit|Treatment will begin with 6 visits of emotional prosody recognition treatment followed by 6 visits of emotional prosody production treatment (1-3 implicit, 4-6 explicit).
9715903|NCT04575909|Experimental|Recognition, Production Explicit-Implicit|Treatment will begin with 6 visits of emotional prosody recognition treatment followed by 6 visits of emotional prosody production treatment (1-3 explicit, 4-6 implicit).
9715904|NCT04575909|Experimental|Production Implicit-Explicit, Recognition|Treatment will begin with 6 visits of emotional prosody production treatment (1-3 implicit, 4-6 explicit) followed by 6 visits of emotional prosody recognition treatment.
9715905|NCT04575909|Experimental|Production Explicit-Implicit, Recognition|Treatment will begin with 6 visits of emotional prosody production treatment (1-3 explicit, 4-6 implicit) followed by 6 visits of emotional prosody recognition treatment.
9715906|NCT04575831|Experimental|Intervention|The intervention arm will receive a 12-week multimodal intervention featuring exercise, nutrition, and palliative symptom management.
9715907|NCT04575714||Acute low back pain|Adult patients with acute low back pain
9715908|NCT04575844|No Intervention|Control|24 weeks of observation
9715909|NCT04575844|Experimental|Exercise Alone|24 weeks of treatment
9715910|NCT04575844|Experimental|Liraglutide Alone|24 weeks of treatment
9715911|NCT04575844|Experimental|Exercise + Liraglutide|24 weeks f treatment
9715912|NCT04575584|Experimental|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
9715913|NCT04575584|Experimental|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
9715914|NCT04575584|Experimental|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
9715915|NCT04575584|Placebo Comparator|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
9715916|NCT04575584|Experimental|Part 2: Molnupiravir|Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
9715917|NCT04575584|Placebo Comparator|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
9715918|NCT04575935|Experimental|Arm A (MIS, standard of care chemotherapy)|Patients undergo MIS within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. If during MIS the surgeon thinks complete gross resection can only be accomplished by performing an open procedure, patients may undergo laparotomy instead. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
9715919|NCT04575935|Active Comparator|Arm B (laparotomy, standard of care chemotherapy)|Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
9715920|NCT04575636|Other|Lymphedema patients|MRL examination in lymphedema patients
9715921|NCT04575636|Other|Healthy volunteers|MRL examination in healthy volunteers
9715922|NCT04575688|Active Comparator|Periarticular Injection|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a periarticular injection by the surgeon using 10 milliliters of Exparel mixed with 10 milliliters of bupivicaine 0.5 percent at the end of the procedure.
9785790|NCT01260272|Experimental|Raisin Group|This group will receive raisins to consume three times a day with meals
9980393|NCT01391390|Placebo Comparator|Placebo|Placebo look like the active drug, and same dose.
10196080|NCT02988895|Experimental|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
10196081|NCT02980887||Controls|Healthy controls No intervention as this is an observational study
10196082|NCT02980887||Pulmonary Vascular Disease|Pulmonary Vascular Disease at risk for pulmonary hypertension
10196083|NCT02980887||Pulmonary Hypertension|Those meeting WSPH/WHO group classifications 1-5 of pulmonary hypertension
10196084|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
9715923|NCT04575688|Active Comparator|Popliteal Block|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a popliteal block by the anesthesiologist using 30 milliliters of bupivicaine 0.5 percent in the pre-operative area, prior to surgery, using an ultrasound machine for guidance.
9715924|NCT04575662|Experimental|STAR Treatment|Patients performing STAR treatment
9715925|NCT04575779||Group A|Cyclosporin of a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
9715926|NCT04575779||Group B|Administer cyclosporin daily dose of 3 mg/kg/day in a continuous infusion over 23 h every 24 h.
9715927|NCT04575675|Experimental|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
9715928|NCT04575675|Placebo Comparator|Standard of care|Standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
9980394|NCT01391403|Experimental|Artemisinin, anti-toxoplasma|Artemisinin
9715930|NCT04575805|Experimental|Internet-delivered Combined Cognitive Bias Modification|CBM Version 1 is the combination of internet-delivered Cognitive Bias Modification-Interpretation and internet-delivered Cognitive Bias Modification-Attention interventions taking place over 4 weeks (eight sessions, twice per week).
9715931|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Interpretation|CBM Version 2 is an internet-delivered Cognitive Bias Modification-Interpretation intervention taking place over 4 weeks (eight sessions, twice per week).
9715932|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Attention|CBM Version 3 is an internet-delivered Cognitive Bias Modification-Attention intervention taking place over 4 weeks (eight sessions, twice per week).
9715933|NCT04575805|No Intervention|Wait-List Control|This arm is wait-list control group which will also receive internet-delivered Combined Cognitive Bias Modification intervention after the follow-up assessment
9715934|NCT04575922|Experimental|Nivolumab+Ipilimumab+Radiation Therapy (RT)|"Study cycles are 6 weeks long, participants will receive:~Cycle 1: Nivolumab every 2 weeks during cycle, Ipilimumab 1x on Day 1 of cycle, and Radiation Therapy every other weekday or 2 days for a total of 3 treatments during week 1 of Cycle 1 only.~Cycles 2-4: Nivolumab every 2 weeks during each cycle, Ipilimumab 1x on Day 1 of each cycle~Cycles 5-Disease Progression: Nivolumab every 2 weeks during each cycle"
9715935|NCT04575623||Study group|It will consist of 120 patients suffering from migraine according to international classification of headache
9715936|NCT04575545||HIV positive patients|
9715937|NCT04575545||Patients taking PrEP|
9715938|NCT04575558|Experimental|Hydroxychloroquine + Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD, both for 7 days
9715939|NCT04575558|Placebo Comparator|Hydroxychloroquine + Placebo tablets|Hydroxychloroquine 400mg PO BID 2 times a day + Placebo, both for 7 days
10196085|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
10196086|NCT02972008||patients with constitutional von Willebrand factor (vWF) deficiency|
10196087|NCT02962297|Experimental|treatment group|Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
10196088|NCT02962297|Placebo Comparator|placebo group|A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
10196089|NCT02960087|Active Comparator|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
9715940|NCT04575480|Active Comparator|Group 1|Group 1 will undergo SWL with 3 days between each session.
9715941|NCT04575480|Active Comparator|Group 2|Group 2 will undergo SWL with 7 days between each session
9715942|NCT04575480|Active Comparator|Group 3|Group 3 will undergo SWL with 14 days between each session.
9715943|NCT04575454|Other|Comatose or post-comatose patients|
9715944|NCT04575142|Experimental|CO2 laser device group|Participants who will be undergoing laser treatment for their vocal nodes with a specific laser device. AcuPulse Duo, a CO2 laser is absorbed by water found in soft tissues and is independent of tissue color. It is very precise and causes less damage of the deep tissues, which results in less swelling and faster recovery. The absence of a long healing process means that most patients can resume their normal activities even on the same day The CO2 laser is the preferred laser for use in the operating room.
9715945|NCT04575519|Active Comparator|Control group|Standard of Care (SoC) TB treatment + placebo twice daily during first 4 weeks of TB treatment followed by placebo once daily for an additional 4 weeks.
9715946|NCT04575519|Experimental|SoC TB + ASA group|Standard of Care (SoC) TB treatment + acetylsalicylic acid 300mg twice daily during first 4 weeks of TB treatment followed by aspirin 300mg once daily for an additional 4 weeks.
9715947|NCT04575519|Experimental|SoC TB + IBU group|Standard of Care (SoC) TB treatment + ibuprofen 400mg twice daily during first 4 weeks of TB treatment followed by ibuprofen 400mg once daily for an additional 4 weeks
9715948|NCT04575506|No Intervention|Control group|
9715949|NCT04575506|Active Comparator|Obesity-Non-hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
9785791|NCT01260311||Patients prescribed with Fesoterodine|Patients diagnosed with Over-active bladder and prescribed with fesoterodine.
9980395|NCT01391403|Placebo Comparator|Placebo|Placebo looks like the active drug, with the same dose.
9715950|NCT04575506|Experimental|Obesity-Hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
9715951|NCT04575441|Experimental|Pilates Ball Exercises|Various exercises are conducted with using pilates ball. Sensory feedbacks like proprioception and vestibulation are given. Many physical fitness parameters like balance, coordination, speed and agility are used in this exercise program. Children are taken to the program for 40 min, twice a week during 6 weeks.
9715952|NCT04575441|No Intervention|Without exercise|The children in this group are not included in any kind of exercise/sport program during 6 weeks.
9715953|NCT04575220|Experimental|tele-exercise|Subjects will perform three sessions/week of home exercise using bicycles for 12 weeks
10196090|NCT02960087|Active Comparator|Arm 3 HDR|High Dose Rate brachytherapy: 27 Gy in 2 fractions
9715954|NCT04575194|Active Comparator|Liraglutide 3 mg|Patients will be prescribed sc liraglutide 3 mg/day along with a dietary and physical activity intervention.
9715955|NCT04575194|Active Comparator|Naltrexone/bupropion 32/360 mg|Patients will be prescribed oral naltrexone/bupropion 32/360 mg/day along with a dietary and physical activity intervention.
9715956|NCT04575233|Experimental|Laparoscopic Transversus Abdominis Plane (L-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under laparoscopic control
9715957|NCT04575233|Active Comparator|Ultrasound Transversus Abdominis Plane (U-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under ultrasound control
9715958|NCT04575415||Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.
9715959|NCT04575415||Arm 2:Bevacizumab plus Afatinib/Dacomitinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus second-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks.Afatinib 40 mg or clinical routine dose once daily or Dacomitinib 45mg or clinical routine dose once daily or clinical routine dose would be administered.
9715960|NCT04575415||Arm 3:Bevacizumab plus Osimertinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.
9715961|NCT04575168||Positive for COVID-19|Subjects positive for COVID-19 as indicated by the Standard of Care test.
9715962|NCT04575168||Negative for COVID-19|Subjects negative for COVID-19 as indicated by the Standard of Care test.
9715963|NCT04575363|Experimental|pancreatic adenocarcinoma patient|patient with pancreatic ductal adenocarcinoma
9715964|NCT04575272|Experimental|Continuous Deep Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately deep to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
9715965|NCT04575272|Active Comparator|Continuous Superficial Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately superficial to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
9715966|NCT04575350||Cohort|no intervention.
9715967|NCT04575129||Study Group|No intervention will be applied
9715968|NCT04575116|Experimental|Tafamidis Free acid tablet then tafamidis meglumine capsule|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
9715969|NCT04575116|Experimental|Tafamidis meglumine capsule then Tafamidis Free acid tablet|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
9715970|NCT04575493|Experimental|Test Group|No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
9715971|NCT04575493|Active Comparator|control group|No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
9715972|NCT04575402||CSMC prostate cancer patients receiving ADT|Prostate cancer patients recruited from oncology clinic at Cedars-Sinai Medical Center.
10196091|NCT02913664|Experimental|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
10196092|NCT02913664|Experimental|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP < 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
10196093|NCT02913664|Experimental|IRVR+Ex|A combination of IRVR and aerobic exercise training.
10196094|NCT02913664|Placebo Comparator|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
10196095|NCT02889133|Active Comparator|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
10196096|NCT02889133|Placebo Comparator|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
10196097|NCT02836574|Experimental|Immediate Treatment|Renal Autologous Cell Therapy (REACT®) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of REACT® as soon as REACT® product is made available.
10196098|NCT02836574|Active Comparator|Delayed Treatment|Renal Autologous Cell Therapy (REACT®) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12 months after REACT® product is made available before receiving 2 injections of REACT®.
9715973|NCT04575402||Veterans with prostate cancer|Prostate cancer patients recruited from the Veteran Affairs Oncology Clinic (Durham, NC).
9715974|NCT04575103|Active Comparator|Antipsychotics|Patients treated with antipsychotics as provided by their psychiatrist in order to treat disease best possible and in accordance with guidelines.
9715975|NCT04575103|No Intervention|Control|Healthy controls, not treated with antipsychotics.
9779716|NCT04977362|Active Comparator|Treatment as usual (control group)|The control group undergoes standard heart valve surgery. In this case, no preoperative interventions take place, the patient is operated on the affected heart valve in a minimally invasive procedure without prehabilitation. After surgery, the patient is transfered to an intensive care unit (not a specialized postanesthesia care unit) depending on the individual condition and then transfered to the general ward. Patients receive medical, nursing, and physiotherapeutic care in accordance with current hospital standards.
9779717|NCT04974749|Experimental|REPLAGAL|Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight, infusion, intravenously every other week (EOW) for 52 weeks.
9779718|NCT04974151|Active Comparator|amlodipine (5mg/d)|Amlodipine besylate tablets (5mg/d)
9779719|NCT04974151|Experimental|amlodipine folic acid (5.8mg/d)|Amlodipine besylate and folic acid tablets (5mg:0.8mg)
9779720|NCT04974151|Experimental|amlodipine folic acid (5.8mg/d) + 5-MTHF (0.4mg/d)|Amlodipine besylate and folic acid tablets (5mg:0.8mg) with 0.4mg/d 5-MTHF
9779721|NCT04974138|Active Comparator|CC with amlodipine 5mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besylate tablets (5mg/d)
9779722|NCT04974138|Experimental|CC with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CC genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
9779723|NCT04974138|Active Comparator|CT with amlodipine 5mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besylate tablets (5mg/d)
9779724|NCT04974138|Experimental|CT with amlodipine folic acid 5.8mg/d|For subjects with the MTHFR CT genotype, conducting amlodipine besilate and folic acid tablets (5mg:0.8mg)
9779725|NCT04973982|Active Comparator|ENVARSUS|ENVARSUS used as per licence
9779726|NCT04973982|Active Comparator|ADOPORT|ADOPTION used as per licence
9779727|NCT04972981|Experimental|Part 1: Dose Escalation|In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of ADCT-901 as monotherapy. Participants can receive ADCT-901 until disease progression, adverse event (AE), or other discontinuation criteria, whichever occurs first.
9779728|NCT04972981|Experimental|Part 2: Dose Expansion|"In Part 2 (dose expansion), participants will receive ADCT-901 monotherapy at the dose identified as the RDE/MTD in Part 1 (dose escalation).~Participants will be split into two groups:~Group 1: An indication for which ADCT-901 showed in Part 1 to have preliminary activity.~Group 2: A group of participants with Part 1 indications, except for the one selected in Group 1 of Part 2. No more than 30% of participants with the same indication are allowed in this basket group.~Participants can receive ADCT-901 until disease progression, AE, or other discontinuation criteria, whichever occurs first."
9779729|NCT04970459||Patients with Marfan syndrome or related syndromes|Children aged at least 3 years old or adult with Marfan syndrome or related syndromes
10196099|NCT02818582|Active Comparator|GS-5734 100mg given intravenously daily for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given GS-5734 100mg intravenously daily for 5 days
9779730|NCT04969887|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 480mg every 4 weeks until progression (up to 2 years)
9779731|NCT04969861|Experimental|BEMPEG + Pembrolizumab|Bempegaldesleukin plus pembrolizumab every 3 weeks (q3w) for up to 35 cycles (approximately 2 years).
9779732|NCT04969861|Active Comparator|Pembrolizumab Monotherapy|Pembrolizumab monotherapy q3w for up to 35 cycles (approximately 2 years).
9779733|NCT04963933|Experimental|Patients treated with the device|Patients treated with the Nautilus will be followed up
10196100|NCT02818582|Placebo Comparator|Normal saline intravenously for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given normal saline intravenously daily for 5 days
9779734|NCT04959110|Experimental|Acute Liver Failure|Acute liver failure critically ill patients receiving CRRT
9779735|NCT04959110|Experimental|Acute on top Chronic Liver Failure|Acute on top chronic liver failure critically ill patients receiving CRRT
9779736|NCT04956289|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
9779737|NCT04947709|Experimental|Physical activity intervention group|The physical activity intervention will be structured to increase moderate-to-vigorous intensity aerobic physical activity, to achieve the 60-minute goal, five days per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity intervention.
9779738|NCT04947709|Other|Delayed-intervention control group|Participants randomized to the delayed-intervention control group will serve as the control group for 12 weeks, and will not receive physical activity intervention during this time and will not receive weekly support calls. After completion of the control group, participants will be offered physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations. This delayed-intervention control group design is used not only to boost recruitment, but to eventually confer the benefits of physical activity to all those who enter the trial.
9779739|NCT04944771|Experimental|Treatment ABC|Participants will be randomized to receive oral doses of Treatment A, Treatment B and Treatment C.
9779740|NCT04944771|Experimental|Treatment ACB|Participants will be randomized to receive oral doses of Treatment A, Treatment C and Treatment B.
9715976|NCT04575051|Active Comparator|Residents|Residents will be exposed to the Consult Model and then the Engage Model. Hearing Specific Quality of Life and Satisfaction with Social Participation are the outcome measures. Hearing Specific Quality of Life is measured using the HHIE with a range of scores from 0-40 with a lower score revealing less handicap. Satisfaction with Social Participation is measured using the Satisfaction with Participation in Discretionary Social Activities Short form 7a with a range of scores from 7-35 with a higher score meaning higher satisfaction.
9980396|NCT01391416||CKD stage 3-4|CKD stage 3-4 from Thai SEEK study
9715977|NCT04575051|Active Comparator|Family|Families will be surveyed related to burden during the Consult and Engage Model of Care. Family Burden will be measured using the Zarit Burden scale with a range of scores from 0-16 and a lower scoring revealing less burden.
9715978|NCT04575051|Active Comparator|Staff|Staff of the Assisted Living/Personal Care Facilities will be surveyed related to work satisfaction during the Consult and Engage Model of Care. Staff work satisfaction will be measured with the Michigan Organizational Assessment Questionnaire (MOAQ) with a range of scores from 3-18 and a lower score revealing higher satisfaction.
9715979|NCT04574999|Experimental|0.005% Estriol group|0.005% Estriol (50 μg/g) gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
10196101|NCT02809677|Other|Non-Interventional Longitudinal Study|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
10196102|NCT02789007|Other|parabolic flight|To evaluate Structural and functional changes, Cognitive performance, and specifically spatial cognition, Key neurotrophins...
9715980|NCT04574999|Placebo Comparator|Placebo group|Placebo gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
9715981|NCT04574921|Experimental|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
9715982|NCT04574921|Sham Comparator|Sham|Exposure to LTS device set to continues color matched white light for 1 hour a day for consecutive days
9715983|NCT04574934|Experimental|the study group|study group received the traditional physical therapy program plus aquatic therapy
9715984|NCT04574934|No Intervention|the control group|control group received traditional physical therapy program only.
9715985|NCT04574804|Experimental|online training program|online training program Participants receive access to online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis, which they will be instructed to and encourage to complete over the 6 intervention period.
9715986|NCT04574804|No Intervention|control group|control group Participants do NOT receive access to the online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis during the intervention period.
10196103|NCT02761122|Experimental|Patients with lichen|"Patients with non-erosive lichen planus, erosive lichen planus or lichen sclerosus.~Human biological samples :~Blood sample~Skin or mucosal brushing~Skin or mucosal biopsy"
10196104|NCT02740985|Experimental|Arm A|AZD4635 monotherapy as nanoparticle suspension 125 mg BID
9715987|NCT04574973|Experimental|Anodal tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
9715988|NCT04574973|Experimental|Cathodal tDCS|Subjects will receive 20 minutes of active, excitatoryinhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
9715989|NCT04574973|Experimental|Dual tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere and inhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
10196105|NCT02740985|Experimental|Arm B|AZD4635 monotherapy as nanoparticle suspension 75 mg QD
9715990|NCT04574973|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the affected upper extremity.
9715991|NCT04574726|Experimental|virtual environment|Balance test in virtual environment with a virtual reality software executed in a 6DOF Occulus Quest helmet and a motion capture software with a Kinect Azure DK camera.
9715992|NCT04574726|Active Comparator|reel environment|Balance test in real environment with a motion capture software and a Kinect Azure DK camera.
9715993|NCT04574960|Experimental|Neoadjuvant Chemotherapy Arm|Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy).
9715994|NCT04574960|Active Comparator|Adjuvant Chemotherapy Arm (Standard of Care)|"Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy.~Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin.~Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles.~Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles."
9779741|NCT04944771|Experimental|Treatment BAC|Participants will be randomized to receive oral doses of Treatment B, Treatment A and Treatment C.
9779742|NCT04944771|Experimental|Treatment BCA|Participants will be randomized to receive oral doses of Treatment B, Treatment C and Treatment A.
9980397|NCT01391416||hyperhomocysteine group|CKD stage 3-4 from Thai SEEK study
9980398|NCT01391429|Experimental|Video decision support tool|Video decision support tool for goals-of-care options
9980399|NCT01391429|No Intervention|Verbal description|Standard verbal description of goals-of-care options provided by an inpatient palliative care team
9980400|NCT01391442|Other|family|each family, composed of 4 characters at least, is studied
9715995|NCT04575090||Sub-Study 1|Patients in substudy 1 will be identified by the PI from the clinic as individuals who are currently experiencing statin related muscle complaints or who have had severe reactions to statins in the past. There is going to be only one visit which will last for apprximately 3.5 hrs. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
9715996|NCT04575090||Sub-Study 2|"Subjects will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
9715997|NCT04574947|Active Comparator|Intravenous lidocaine|
9715998|NCT04574947|Experimental|Topical lidocaine|
10196106|NCT02740985|Experimental|Arm C|AZD4635 monotherapy as nanoparticle suspension 100 mg QD
9715999|NCT04574947|Placebo Comparator|Placebo|
9716000|NCT04575012|Experimental|Deferred invasive strategy|
9716001|NCT04575012|Other|Early invasive strategy|
10196107|NCT02740985|Experimental|Arm D|AZD4635 as nanoparticle suspension 75 mg QD plus durvalumab
10196108|NCT02740985|Experimental|Arm E|AZD4635 as nanoparticle suspension 100 mg QD plus durvalumab
10196109|NCT02740985|Experimental|Arm EA|AZD4635 as nanoparticle suspension plus enzalutamide
9716005|NCT04574817|Experimental|HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
9716006|NCT04574778|Active Comparator|Group 1: IV acetaminophen and oral placebo|Group 1 will receive 1000 mg of IV acetaminophen approximately 30 minutes prior to skin closure and will receive oral placebo in the holding area prior to surgery
9716007|NCT04574778|Active Comparator|Group 2: oral acetaminophen|Group 2 will receive 1000 mg of PO acetaminophen in the holding area and will not receive an IV placebo.
9716008|NCT04574791|No Intervention|Multimodal Pain Regimen|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol.
9716009|NCT04574791|Experimental|Multimodal Pain Regimen + Tizanidine|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol supplemented with standing doses of oral tizanidine in the hospital and for 14 days after discharge
9716010|NCT04574648|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the non-adherence information such that community pharmacists can view the information prior to dispensing medications.
9716011|NCT04574648|No Intervention|Standard care (ADE information retained locally)|Patients in the control arm will have their information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their information will not be visible to other providers via PharmaNet.
9716012|NCT04574700|Experimental|knee joint mobilization and traction|Tibiofemoral, Tibiofibular joint anterioposterior mobilization, keltonborn knee traction Transcutaneous electrical nerve stimulation(TENS) and quadriceps strengthening
10196110|NCT02740985|Experimental|Arm AA|AZD4635 as nanoparticle suspension plus abiraterone acetate
10196111|NCT02740985|Experimental|Arm F|AZD4635 as nanoparticle suspension plus durvaluamb in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
10196112|NCT02740985|Experimental|Arm G|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
10196113|NCT02740985|Experimental|Arm H|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with other solid tumours.
10196114|NCT02740985|Experimental|Arm I|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
10196115|NCT02740985|Experimental|Arm J|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
10196116|NCT02740985|Experimental|Arm K|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with colorectal carcinoma.
10196117|NCT02740985|Experimental|Arm KD|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy-naïve patients with colorectal carcinoma.
10196118|NCT02740985|Experimental|Arm L|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with other solid tumours.
10196119|NCT02740985|Experimental|Arm CA|AZD4635 capsule formulation monotherapy 75 mg, 150 mg, and 200 mg QD. A lower dose of 125 mg or 100 mg may be given. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CA. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycle 1 and Cycle 2 will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
10196120|NCT02740985|Experimental|Arm CB|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus durvalumab and oleclumab. The pharmacokinetics of AZD4635 capsule formulation will be characterized on Cycle 1, 2, and 4 (Day 1) in Arm CB. Steady-state pharmacokinetics will be assessed on Cycle 2 Day 15. Cycle 1 will be administered in a 3-week cycle to assess the safety and dose-limiting toxicity (DLT). PKs will also be collected on Day 1 of Cycles 3 and 5.
9716013|NCT04574700|Active Comparator|Post isometric relaxation|Post isometric relaxation on hamstring, TENS and quadriceps strengthening.
9716014|NCT04574674|Experimental|Flexibility exercise group|"Participants will be asked to follow a 12-week flexibility exercise training programme. Participants will be asked to perform a minimum amount of flexibility exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants will perform 6 flexibility exercises per week (2 different for legs, 1 shoulder and arms, 1 chest, 1 back and 1 core). Passive static stretching exercises will be performed."
9716015|NCT04574674|Experimental|Resistance exercise group|"Participants will be asked to follow a 12-week home-based exercise programme. Participants will be asked to perform a minimum amount of resistance exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.~Participants in the resistance exercise group will be asked to perform a total of 6 exercises per week (2 different leg exercises, 1 shoulder exercise, 1 chest exercise, 1 back exercise and 1 core exercise). Body weight and resistance bands exercises will be used. Participants will be asked to perform each set to complete as many repetitions as possible until fatigue."
9716016|NCT04574687|Active Comparator|Neurodevelopmental Techniques|Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
9716017|NCT04574687|Experimental|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
9716018|NCT04574570|Other|interventional patient|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
9716019|NCT04574323|Experimental|Paleolithic lifestyle group|The Paleolithic lifestyle (PL) intervention during radiotherapy consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed. Patients were supposed to start the PL intervention at least two days prior to the first irradiation and to protocol their food consumption on two days during the first week on the diet. They were also asked about their compliance to the PL intervention at each weekly measurement appointment.
9716020|NCT04574323|Other|Standard diet group|This group is on a standard diet while receiving radiotherapy.
9716021|NCT04574661|Active Comparator|Static stretching|Static stretching to lower limb muscles
9716022|NCT04574661|Experimental|Intermittent occlusion|Intermittent occlusion to lower limb
9716023|NCT04574440||multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap during surgery. The patient's surgery and subsequent medical care will not be altered.
9716024|NCT04574505|Experimental|NUT|1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks
9716025|NCT04574505|Placebo Comparator|Placebo|1 tablet of Placebo per day + standard diet for 8 weeks
9716026|NCT04574453|Experimental|Iracross|1 course of IRACROSS (crosslinked 2% Hyaluronic Acid) at baseline, consisting of a mono-dose intra-articular administration (2ml).
9716027|NCT04574453|Active Comparator|Iraline|1 course of IRALINE (linear 2% Hyaluronic Acid); each course consists of 3-5 intra-articular administrations (2ml) at weekly intervals (from week 1 to 3, 4 or 5, depending on each patient's need)
10196121|NCT02740985|Experimental|Arm CC|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus docetaxel. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CC. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycles will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
9716028|NCT04574388|Active Comparator|open label placebo|participants will take open label placebo pills TID and in conjunction with other PRN analgesics
9716029|NCT04574388|No Intervention|treatment as usual|participants will take PRN analgesics as usual
9716030|NCT04574414||Children with Attention Deficit Hyperactivity Disorder|Cases
9716031|NCT04574414||Children without Attention Deficit Hyperactivity Disorder|Population controls
9716032|NCT04574596||3GCR ceftriaxone-resistant-E. coli|Positive blood culture for above resistant e coli. Observational there will be no intervention
9716033|NCT04574596||3GCS ceftriaxone-susceptible-E. coli|Positive blood culture for above susceptible e coli. Observational there will be no intervention
9716034|NCT04575064|Other|Standard of Care (SoC)|This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
9980401|NCT01391455|No Intervention|Spermatic Cord in contact with mesh|Where the spermatic cord has been allowed to remain in contact with the mesh.
10196122|NCT02728258|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9716035|NCT04575064|Experimental|Remdesivir + SoC|Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
9716036|NCT04574544|Experimental|Zinc supplementation|The 25 supplemented children had received an oral dose of 10 mg of zinc sulphate per day for 14 days
9980402|NCT01391455|Experimental|Spermatic Cord is isolated from the mesh|The inguinal ligament is interposed between the cord and the mesh and then repaired. This isolates the cord from the mesh and the splinting function of the overlying inguinal ligament.
9980403|NCT01391481|Experimental|Perfluorocarbon|
9980404|NCT01391481|Placebo Comparator|Sterile Water for Injection|
9980405|NCT01391494|Experimental|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
9980406|NCT01391494|Experimental|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
9980407|NCT01391494|Experimental|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
9980408|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
9980409|NCT01391494|Placebo Comparator|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
9980410|NCT01391494|Experimental|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
9980411|NCT01391494|Experimental|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
9980412|NCT01391494|Experimental|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
9980413|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
9980414|NCT01391494|Placebo Comparator|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
9980415|NCT01391494|Experimental|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
9980416|NCT01391494|Experimental|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
9666697|NCT04325763|Placebo Comparator|TQB2450(blank)+Anlotinib(blank)|TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
9666698|NCT04320251|Experimental|1|The single observational cohort
9666699|NCT04318938|Active Comparator|Standard Arm with any available ALK TKI|"st line: Any approved 2nd-generation TKI according to investigator's choice~nd line: Any available ALK TKI according to investigator's choice (patients from the standard Arm A can be offered brigatinib in the 2nd line)"
9666700|NCT04318938|Experimental|Experimental Arm with Brigatinib|"st line: 90 mg brigatinib once daily p.o. for the first 7 days (lead-in) followed by 180 mg brigatinib once daily p.o. afterwards, starting with day 8~nd line: Any available ALK TKI according to investigator's choice"
9666702|NCT04308902||Children previously enrolled in the OptiMoM Fortifier Study|This is an observational study of children who were previously enrolled in a trial (Bovine vs. Human Milk-Based Fortifier Study) between 2014 and 2016 during which time they were randomized to have their feeds (mother's own milk or pasteurized donor breastmilk) nutrient enriched with a human milk-based fortifier or a bovine protein-based fortifier.
9666703|NCT04308902||Term-born Comparison|This is an observational study of children born at full term (>= 37 weeks gestation) and weighing more than 2500g. These children will be recruited from the communities in which the OptiMoM participants live.
9666704|NCT04307836|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
9666705|NCT04307836|No Intervention|Control group|Subjects are not treated with the renal denervation, not sham, after randomization and maintained baseline anti-hypertensive medications
9666706|NCT04306120|Active Comparator|noxious cold group|The group received noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
9666707|NCT04306120|Active Comparator|noxious heat group|The group received noxious heat (46 - 47°C) stimuli on the affected leg for 30 minutes.
9666708|NCT04306120|Active Comparator|alternative thermal stimulation group|The group received alternative noxious heat (46 - 47°C) and noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
9666709|NCT04305184|Experimental|ASP0598 SAD|A single topical application of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 4 dose levels.
9666710|NCT04305184|Experimental|ASP0598 MAD|Multiple topical applications of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 2 dose levels with additional treatment days.
9666711|NCT04305184|Experimental|ASP0598 Single Dose Expansion|A single topical application of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 2 dose levels.
9666712|NCT04305184|Experimental|ASP0598 Multiple Dose Expansion|Multiple topical application of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 2 dose levels with additional treatment days.
9666713|NCT04305184|Placebo Comparator|Pooled Placebo in SAD|For each dose level ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
9666714|NCT04305184|Placebo Comparator|Pooled Placebo in MAD|For each dose level ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
9666715|NCT04305184|Placebo Comparator|Placebo in Single Dose Expansion|ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
9666716|NCT04305184|Placebo Comparator|Placebo in Multiple Dose Expansion|ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
9666717|NCT04304911|Experimental|UP in blended format|Clinicians will follow the UP therapist manual, 2nd edition, recently translated by Osma and Crespo (13,14). The same contents through a digital material (video and audio) will be integrated in the UP-APP. The program can be developed in a range of 12 to 16 sessions. The UP includes 8 modules
9666718|NCT04304911|Active Comparator|Treatment as usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
9666719|NCT04302064|Experimental|Eplontersen|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of Eplontersen administered SC.
9666720|NCT04302064|Placebo Comparator|Placebo|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of Eplontersen-matching placebo administered SC.
9666721|NCT04301310|Experimental|Treatment Group|
10196123|NCT02703623|Experimental|Arm 2A (abiraterone acetate, prednisone, apalutamide)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.
10196124|NCT02703623|Experimental|Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
9716037|NCT04574544|Experimental|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
10196125|NCT02703623|Active Comparator|Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
9716038|NCT04574466|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by a physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
9716039|NCT04574466|Experimental|Problem Management Plus|"The participants who are assigned to the intervention group will receive five sessions of PM+, a psychological intervention which has been developed by the WHO. PM+ is a new short, transdiagnostic (i.e., not specifically aimed at treating a certain mental disorder) program aiming to reduce common mental health symptoms and improve psychosocial functioning.~PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, and accessing social support. These elements have been recommended in recent WHO guidelines. PM+ has proven to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan."
9716040|NCT04574622|Experimental|Five true ESWT sessions|"A total of five sessions (1x/week) were conducted.~A total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
9716041|NCT04574622|Experimental|Three true ESWT sessions and two sham ESWT sessions|"A total of three true ESWT (week 1, 3 and 5) and two sham ESWTs in (week 2 and 4) were conducted.~For true ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars.~For sham ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle with a 1 cm gap between between the probe and subject's skin. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
9716042|NCT04574479|Placebo Comparator|Placebo|Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
9716043|NCT04574479|Experimental|Fascia iliaca block|Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery
9716044|NCT04574765||Healthcare Worker|Individuals who work within a food production, healthcare, research or clinical organization of participating institutions.
9716045|NCT04574310||Frozen embryo transfer (FET)|Collect retrospectively data on embryo implantation rate
10196126|NCT02697422|Experimental|Peer health coach intervention group|Eligible participants will be randomly assigned to receive a home-visit peer health coach intervention to promote health outcomes and behavior change among Veterans with multiple cardiovascular disease (CVD) risk factors.
10196127|NCT02697422|No Intervention|Control group|Participants who meet the same eligibility criteria as participants in the intervention group will be randomly assigned to receive no intervention. Participants will continue to receive their regular, usual primary care.
9716046|NCT04574310||Intracytoplasmic sperm injection (ICSI)|Collect retrospectively data on embryo implantation rate
9716047|NCT04574310||oocyte donation|Collect retrospectively data on embryo implantation rate
9716048|NCT04573894||Positives blood cultures|Collection of clinical and biological data of patients with blood cultures positives for potential contaminants, as well as PCT levels measurements, from January 2016 to May 2019 at the Nancy CHRU
10196128|NCT02684032|Experimental|Letrozole Cohort|Letrozole combination cohort in dose escalation
10196129|NCT02684032|Experimental|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
9716049|NCT04573959|Experimental|SV-3 Capsule Endoscopy|CapsoCam SV-3 Capsule Endoscopy system will perform in a manner consistent with the performance of the CapsoCam SV-3 capsule endoscopy systems.
9716050|NCT04574037||follow up of stroke patients with a upper limb deficit|Usual follow up of stroke patients with a upper limb deficit
9716051|NCT04574167|Experimental|tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes)
9716052|NCT04574167|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
9716053|NCT04574284|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
9716054|NCT04574284|Experimental|TQB2450|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
9716055|NCT04574284|Experimental|Anlotinib|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
9716056|NCT04574050|Experimental|SELF-BREATHE|Access to a self -guided, internet -based intervention for patients with chronic breathlessness known as SELF-BREATHE
9716057|NCT04574050|No Intervention|Control|standard / currently available NHS care
9716058|NCT04574141|Experimental|spray before tablet|
9716059|NCT04574141|Experimental|tablet before spray|
9716060|NCT04574180|Active Comparator|Group 1|Zirconia crown anterior (NuSmile, Houston, Texas, USA).
9716061|NCT04574180|Active Comparator|Group 2|Zirconia crown posterior (NuSmile, Houston, Texas, USA).
9716062|NCT04574180|Active Comparator|Group 3|Stainless steel crown (3M-ESPE, St. Paul, Minnesota, USA)
9716063|NCT04574180|Active Comparator|Group 4|Strip Crown (3M-ESPE, St. Paul, Minnesota, USA)
9716064|NCT04573907|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
9716065|NCT04573907|Active Comparator|Reference formulation of Levothyroxine|Eutirox 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
9716066|NCT04574193|Experimental|Continuing Care App|Participants will receive the Continuing Care app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy).
9716067|NCT04574193|Active Comparator|Treatment As Usual|Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.
9716068|NCT04574128|Experimental|Retransfusion of cardiotomy blood or not|Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.
9716069|NCT04574128|No Intervention|No retransfusion of cardiotomy blood|
9716070|NCT04574271|Experimental|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
9716071|NCT04574271|Active Comparator|Usual dietary advice and exercise prescription|Generalized dietary advice and exercise prescription in elder subjects.
9716072|NCT04573855|Experimental|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
9716073|NCT04573855|No Intervention|Control|
9716074|NCT04574206|Experimental|Elaborative Reminiscence (ER)|ER is a communication strategy used between a caregiver and child to support children's cognitive and emotional development. ER involves a caregiver and child jointly reminiscing about a past event that they personally experienced, to co-create a coherent narrative that describes the event from both their perspectives. ER consists of two crucial elements, the use of elaborative language (e.g. open ended questions, contributing new information to the conversation) and specific talk focused on recollections of the past as opposed to observations of the present.
9716075|NCT04574206|Sham Comparator|Present Tense Talk (PTT)|PTT is an active control intervention, designed to ensure that caregivers/ guardians in this group spend a similar amount of time engaging in conversation with their children but do not use elaborative reminiscing language. The focus will be on describing activities as they are happening in real time; PTT caregivers will be asked to avoid reference future or past events .
9716076|NCT04574063|No Intervention|Breast cancer risk leaflet only|
9716077|NCT04574063|No Intervention|Breast cancer risk leaflet PLUS SNPs|
9716078|NCT04574063|Experimental|Lifestyle website only|
9716079|NCT04574063|Experimental|Lifestyle website PLUS SNPs|
10196130|NCT02684032|Experimental|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
10196131|NCT02684032|Experimental|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
9980417|NCT01391494|Experimental|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
9980418|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
10196132|NCT02684032|Experimental|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
9716080|NCT04574063|Experimental|Lifestyle website PLUS group coaching|
9716081|NCT04574063|Experimental|Lifestyle website PLUS group coaching PLUS SNPs|
9716082|NCT04573985|Experimental|Serious Game Eurekoi intervention|1 session in group using the serious game eurekoi
9716083|NCT04573985|No Intervention|Control group|no intervention
9716084|NCT04574011|Experimental|Fluid challenge responder|If the ratio of the stroke volume change after passive leg raising is the same or larger than 10%, the patient is assigned to RESPONDER group.
9716085|NCT04574011|Experimental|Fluid challenge non-responder|If the ratio of the stroke volume change after passive leg raising is less than 10%, the patient is assigned to RESPONDER group.
9716086|NCT04573829|Experimental|Non-drug approaches at home|Non-drug approaches at home three visits per week during six months and psycho-education for the caregivers one time per week for six months.
9716087|NCT04574245||Resectable group|
9716088|NCT04574245||Potentially resectable group|
9716089|NCT04574245||Unresectable group|
9716090|NCT04573803|Experimental|MAST DURATION - <3 months|TBI patients with early seizures (within first 7 days following trauma) will receive a short course of up to 3 months of either Phenytoin Sodium or Levetiracetam.
9716091|NCT04573803|Experimental|MAST DURATION - >6 months|TBI patients with early seizures (within first 7 days following trauma) will receive a longer course of at least 6 months of either Phenytoin Sodium or Levetiracetam.
9716092|NCT04573803|Experimental|MAST PROPHYLAXIS - Phenytoin Sodium|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Phenytoin Sodium as seizure prophylaxis.
9716093|NCT04573803|Experimental|MAST PROPHYLAXIS - Levetiracetam|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Levetiracetam as seizure prophylaxis. Dosing will be as prescribed clinically by the treating physician.
9980419|NCT01391494|Placebo Comparator|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
10196133|NCT02684032|Experimental|Arm D|Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion
9716094|NCT04573803|No Intervention|MAST PROPHYLAXIS - no treatment|TBI patients, without an acute symptomatic seizure, will not receive any anti-epileptic drug.
9716095|NCT04573712|Experimental|Fatigue Severity Scale scores assessment|Fatigue Severity Scale scores assessment
9716096|NCT04573790||Trained in eFONA|Trained participants completed our eFONA workshop within the last six month prior to participating in this study
9716097|NCT04573790||Untrained in eFONA|Untrained participants had never taken part in our institutional eFONA workshop
9716098|NCT04573543||Patients with Non-alcoholic fatty liver disease|120 patients diagnosed with NAFLD
9716099|NCT04573543||Controls|40 healthy controls
9716100|NCT04573647||Treatment group|All participants in this trial will be in the treatment group. They will administer Oxervate following the FDA approved guidelines: 1 drop to the affected eye 6 times per day for 8 weeks.
10196134|NCT02668770|Experimental|Dose Escalation Group: MGN1703 + Ipilimumab|"Participants receive MGN1703 on Days 1, 8, and 15 of all cycles as an injection under the skin. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long. Participants receive a total of 4 treatment cycles for a total of 12 weeks on treatment."
10196135|NCT02668770|Experimental|MTD Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or subcutaneous manifestations.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
10196136|NCT02668770|Experimental|MTD Group: MGN1703 (intratumoral injection) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or or subcutaneous manifestations.~MGN1703 given by intratumoral injection at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
9716101|NCT04573491|Experimental|Pharmacogenetic test|Medication review including results from pharmacogenetic testing
9716102|NCT04573725|Experimental|5 mg|Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
9716103|NCT04573725|Experimental|10 mg|Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
9716104|NCT04573725|Experimental|30 mg|Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
9716105|NCT04573725|Placebo Comparator|Placebo|Period in which participants received single placebo prior to bedtime
9716106|NCT04573426||Overweight/Obese+Drug+Stigma|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
9716107|NCT04573426||Overweight/Obese+Drug+Control|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
9716108|NCT04573426||Overweight/Obese+Placebo+Stigma|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
9716109|NCT04573426||Overweight/Obese+Placebo+Control|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
9716110|NCT04573426||Normal Weight+Placebo+Stigma|40 participants with normal weight will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
9716111|NCT04573374|Active Comparator|Biodentine|Biodentine (BD; Septodont, St Maur-des-Fosses, France) is a calcium silicate capping material. Biodentine is mixed according to manufacturer's instructions and placed in a 2-3 mm layer above the pulp tissue using an amalgam carrier and gently packed using a condenser. Initial setting is achieved after 12 minutes.
9716112|NCT04573374|Active Comparator|Portland cement|Preparation of Portland cement: Industrial Portland cement is mixed with Bisthmus oxide or Barium sulphate radio-opacifier in a 3:1 ratio. The mix is sieved through silk sieve then sterilized in hot air oven at 135 ֯C for 2 hours. Portland cement is mixed in a 3:1 powder: distilled water ratio and placed in the pulp chamber and condensed against a moist cotton pellet. A small cotton pellet moistened with saline is placed in the pulp chamber against PC for 5 seconds to ensure water uptake then removed
9980420|NCT01391520|Experimental|CRMD001-Deferiprone|CRMD001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
9980421|NCT01391520|Placebo Comparator|Placebo|3 placebo tablets matching the appearance of the experimental treatment arm (CRMD001) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
9980422|NCT01391533|Experimental|Dose Escalation|Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m^2 up to 960 mg/m^2
9980423|NCT01391572|Experimental|A|After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy
9716117|NCT04573517|Experimental|Early amniotomy|Subjects randomized to this arm will undergo amniotomy within 2 hours of removal of Foley balloon.
9716118|NCT04573517|Active Comparator|Delayed amniotomy|Subjects randomized to this arm will undergo amniotomy at least 4 hours after removal of Foley balloon.
9716119|NCT04573764|Active Comparator|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|
9716120|NCT04573764|Placebo Comparator|Placebo|
9716121|NCT04573634||Health Care Workers|Health-care workers undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
9716122|NCT04573634||Eligible Patients|Patients undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
9716123|NCT04573634||Quarantining Individuals|Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
9716124|NCT04573348||Groups 1-4|no intervention will be performed in this study, only blood drawn
9716125|NCT04573361|No Intervention|Group Control|Patients having no access to chiropractic treatment during the trial
9980424|NCT01391572|Active Comparator|B|After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy
9980425|NCT01391585|Experimental|text message recipients|Patients will be recruited to receive text messages
10196137|NCT02668770|Experimental|MTD Post XRT Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy treated with radiation (XRT) within the past 2 weeks.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
10196138|NCT02665065|Experimental|Iomab-B|Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
10205428|NCT00882050|Experimental|Exentatide 0.41 ng/kg/min|"Experimental: IV Exenatide to be infused by intravenous method at 0.41 ng/kg/min (0.099 pmol/kg/min) over 3 to 6 hours.~Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin,Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
9666722|NCT04300270||Validation cohort|Participants in validation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
9666723|NCT04300270||Clinical implementation cohort|Participants in a clinical implementation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
9666724|NCT04293601|Experimental|Experimental group|"All enrolled neonates will receive interventions that will be performed with different frequency and method according to newborns' risk factors, as well as the following standard interventions received by control group's newborns:~appropriate use of hydrocolloid, headbands, masks and prongs~frequently assess skin integrity~humidity and heat gases"
9666725|NCT04293601|Other|Standard care|"Newborns have received the interventions according to local protocol (standard nursing care) in 2018, as detailed in the assigned intervention"
9666726|NCT04291690|No Intervention|Control Group|Usual clinical care as prescribed by their treating clinicians; which may or may not include physiotherapy, geriatric consultation, nutritional consultation and supplementation, and treatment of anemia.
9666727|NCT04291690|Experimental|Intervention Group|Multi-component intervention in addition to usual care; which may include - in a targeted fashion - physical training for those with physical weakness, cognitive stimulation for those with cognitive impairment, oral nutritional supplementation for those with malnutrition, and intravenous iron replacement therapy for those with iron deficiency anemia.
9666728|NCT04291404|No Intervention|Standard of Care (Control) Arm|Standard of care treatment, which may include a combination of the following, at the discretion of the treating team and family: parent/ caregiver support, child life services, healthcare provider support, etc.
9666729|NCT04291404|Experimental|Intervention Arm|Addition of distraction via an immersive, interactive VR experience to Standard of Care
9666731|NCT04288687|Other|Niraparib Arm (only arm)|Niraparib 200 mg by mouth daily (2 x 100 mg pills) on a 28 day cycle
9666732|NCT04288661|No Intervention|Drain|The patients of this arm undergo perianastomotic drain placement, as per standard of care institutional practice
9666733|NCT04288661|Experimental|No drain|The patients of this arm do not undergo perianastomotic drain placement.
9666734|NCT04288154|Experimental|EMS Group - Experimental|EMS device will be turned on during exercise for this group.
9666735|NCT04288154|Placebo Comparator|EMS Group - Control|EMS device will be turned off during exercise for this group.
9666736|NCT04286295|Experimental|Cytisine|Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
9666737|NCT04286295|Active Comparator|NRT+|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.
9666738|NCT04285879|Experimental|BFR Exercise Group|"In addition to the standard ACL protocol, patients in this study will utilize the Owen Recovery Science exercise protocol for BFR [18]. The following guidelines will be followed concerning exercise progression, occlusion pressure and difficulties with volume achievement.~A total of 20 youth and adolescent patients undergoing a surgical procedure for ACL reconstruction at Connecticut Children's Elite Sports Medicine and completing physical therapy at Connecticut Children's Sports Physical Therapy will be recruited for this study."
9666739|NCT04285879|No Intervention|Non-BFR exercise group|As part of this pilot study, the investigators will additionally collect prospective controls. This population will be patients not participating in physical therapy at Connecticut Children's but underwent ACL reconstruction by Elite Sports Medicine
9666740|NCT04285827|Experimental|CSL889 Cohort A1 (Dose 1)|CSL889 administered as a single IV infusion
9666741|NCT04285827|Experimental|CSL889 Cohort A2 (Dose 2)|CSL889 administered as a single IV infusion
9666742|NCT04285827|Experimental|CSL889 Cohort A3 (Dose 3)|CSL889 administered as a single IV infusion
9666743|NCT04285827|Experimental|CSL889 Cohort A4 (Dose 4)|CSL889 administered as a single IV infusion
9666744|NCT04285827|Experimental|CSL889 Cohort A5 (Dose 5)|CSL889 administered as a single IV infusion
9666745|NCT04285827|Experimental|CSL889 Cohort A6 (Dose 6)|CSL889 administered as a single IV infusion
9666746|NCT04285827|Experimental|CSL889 Cohort B1 (low dose)|CSL889 administered as a single IV infusion
9980426|NCT01391598|Active Comparator|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
9980427|NCT01391598|Placebo Comparator|Saline|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
9980428|NCT01391624|Experimental|Omega 3|The group was treated with omega 3 fatty acids for 2 months.
9980429|NCT01391624|Placebo Comparator|Placebo|The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
9980430|NCT01391637||HuCNS-SC transplanted subjects in the lead-in phase|Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
9666747|NCT04285827|Experimental|CSL889 Cohort B2 (high dose)|CSL889 administered as a single IV infusion
9666748|NCT04285229|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind and extended treatment periods.
9666749|NCT04285229|Placebo Comparator|Placebo|Placebo given SC during the double-blind period and then ixekizumab will be given SC during the extended treatment periods.
9666750|NCT04282629|Experimental|Milrinone|"milrinone group benefiting from an identical treatment to the standard care group and in addition, administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely."
9666751|NCT04282629|Placebo Comparator|Standard Care|The standard care group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.
9666752|NCT04282408|Experimental|Treatment|Group treated with 3D printed brace
9666753|NCT04282148|Experimental|ABT NG DES 48 EECSS|Participants will receive ABT NG DES 48 EECSS device
9666754|NCT04280939|Active Comparator|spinal anesthetic without intrathecal narcotic|spinal anesthetic with standard painkillers without intrathecal narcotics
9666755|NCT04280939|Experimental|spinal anesthetic with morphine|spinal anesthetic with 100 micrograms of intrathecal morphine
9666756|NCT04280939|Experimental|spinal anesthetic with hydromorphone|spinal anesthetic with 20 micrograms of intrathecal hydromorphone
9666757|NCT04280276|Active Comparator|Group 1 - Patients with high IPV (designated as ≥ 30%).|Patients with high IPV (designated as ≥ 30%).
9666758|NCT04280276|Active Comparator|Group 2 - patients with normal IPV (< 30%).|Patients with normal IPV (< 30%). Will assess risk of subclinical acute rejection in patients with high IPV compared to normal IPV. All tacrolimus 12 h trough levels in patients with stable allograft function at least 3 months post-transplant.
9666759|NCT04277975|Active Comparator|A: liberal post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + liberal opioid prescription provided prior to surgery (standard prescription for opioid prescribed prior to surgery)
9666760|NCT04277975|Experimental|B: restricted post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + opioid prescribed only 'as needed' after discharge
9666761|NCT04276571|Experimental|GRAIL|
9666762|NCT04276571|No Intervention|No treatment|
9666763|NCT04275323|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
9666764|NCT04275323|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
9666765|NCT04274491||Pelvic Organ Prolapse Surgery Patients|Participants with greater than or equal to stage II pelvic organ prolapse who are scheduled for reconstructive surgery will be recruited. Participants will be asked to complete a preoperative online survey regarding their health, recovery expectancy, and different roles. Additional online surveys will be send on postoperative days 14 and 42 to measure postdischarge surgical recovery
9666766|NCT04274049|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
9666767|NCT04274049|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
9666770|NCT04273672||Parkinson's Disease|Subjects with Parkinson's Disease
9666771|NCT04273672||Control|Subjects without Parkinson's Disease
9666772|NCT04273165|Active Comparator|Etravirine Dose 1|Etravirine dose 200 mg per diem(100+100)
9666773|NCT04273165|Active Comparator|Etravirine Dose 2|Etravirine dose 400 mg per diem (200+200)
9666774|NCT04272840|No Intervention|Standard Care|Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record).
10196139|NCT02665065|Active Comparator|Conventional Care|Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
10196140|NCT02652429|Experimental|Inhaled Nitric Oxide (iNO)|Pulsed iNO 75 mcg/kg IBW/hour
10196141|NCT02650648|Experimental|Humanized Anti-GD2 Antibody Hu3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10^6/kg in level 1; 14.9x10^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
9716126|NCT04573361|Experimental|Group Chiropractic Care one session|Patients having access to in-person chiropractic treatment once during the trial
9716127|NCT04573361|Experimental|Group Chiropractic Care multiple sessions|Patients having access to in-person chiropractic treatment more than once during the trial
9716128|NCT04573621|Active Comparator|Pelvic drain|Placement of a pelvic drain
9716129|NCT04573621|Experimental|No pelvic drain|No pelvic drain placed
9716130|NCT04573257||normotensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
9716131|NCT04573257||Prehypertension group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
9716132|NCT04573257||hypertensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
9716133|NCT04573465|Experimental|Phone Coaching Condition|Participants will receive weekly, 10-15 minute phone coaching from a trained peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. Coaches will adhere to an ACT-based protocol that includes reinforcing adherence, identifying and problem solving non-adherence, strengthening and generalizing ACT skills, and using ACT skills to increase commitment to ongoing program adherence.
9716134|NCT04573465|Experimental|Text Message Coaching Condition|Participants assigned to the text messaging condition will receive weekly text messages from their peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. These text messages will reflect content delivered in the phone coaching group, but through a briefer protocol that accounts for the abbreviated, asynchronous nature of texting. Text messages will similarly focus on reinforcing adherence, problem solving non-adherence, strengthening ACT skills, and using ACT to increase program adherence. However, these areas will be covered in short messages and with limited exchanges between participants and coaches due to the asynchronous nature of texting.
9716135|NCT04573465|Active Comparator|No Coaching Condition|Participants will be asked to use ACT Guide, an online program for general mental health, over the course of 10 weeks while receiving no coaching.
9980431|NCT01391650|Experimental|biomechanic of the knee|
9980432|NCT01391676||Trabeculectomy|glaucoma patients undergoing trabeculectomy with mitomycin c 0,02%
9716138|NCT04573153|Experimental|Treatment Arm|Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
9716139|NCT04573153|Placebo Comparator|Placebo Arm|Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.
9716140|NCT04573608|Experimental|Papacarie-Duo|
9716141|NCT04573608|Active Comparator|Atraumatic Restorative Treatment|
9716142|NCT04573088|Experimental|ABICOL|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
9716143|NCT04573088|No Intervention|CONTROL|No acceptance-based intervention or other discussion related to the patients' fears and worries will be applied.
9779743|NCT04944771|Experimental|Treatment CAB|Participants will be randomized to receive oral doses of Treatment C, Treatment A and Treatment B.
9779744|NCT04944771|Experimental|Treatment CBA|Participants will be randomized to receive oral doses of Treatment C, Treatment B and Treatment A.
9779745|NCT04944771|Experimental|Treatment DEF|Participants will be randomized to receive oral doses of Treatment D, Treatment E and Treatment F.
9779746|NCT04944771|Experimental|Treatment DFE|Participants will be randomized to receive oral doses of Treatment D, Treatment F and Treatment E.
9779747|NCT04944771|Experimental|Treatment EDF|Participants will be randomized to receive oral doses of Treatment E, Treatment D and Treatment F.
9980433|NCT01391689|Experimental|Arm I (antineoplastic therapy)|Patients receive diindolylmethane (BioResponse) PO BID for approximately 18 months.
9980434|NCT01391689|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for approximately 18 months.
9716144|NCT04573192|Experimental|Phase 1 part: Dose Finding|"Phase I part:~Dose Finding Patients will be treated in cohorts according to a traditional 3+3 design with lomustine on Day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26, of a 42-days cycle at different dose levels.~The RD will be confirmed following a traditional 3+3 design.~Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine~The dose of 13 ug/kg L19TNF will be declared the RD in case none of three or not more than one out of 6 patients experienced a DLT. Dose limiting toxicity will be assessed during the dose-escalation from Day 1 through Day 42 after the first administration of lomustine and study drug (Cycle 1). Not more than 2 patients might be treated simultaneously in Cycle 1."
9716145|NCT04573192|Experimental|Phase II part: Signal Seeking|"118 Patients will be randomized 1:1 and treated with either lomustine on day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24, and 26 of a 42-days cycle at the RD established in the phase I part of the study or with lomustine on day 1 of a 42-days cycle.~Treatment Arm 1: L19TNF plus Lomustine~Treatment Arm 2: Lomustine"
9716146|NCT04573270|Experimental|COVID-19 Patients Experimental|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
9716147|NCT04573270|Placebo Comparator|COVID-19 Patients Placebo|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
9716148|NCT04573270|Experimental|Healthcare Providers Experimental|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
9716149|NCT04573270|Placebo Comparator|Healthcare Providers Placebo|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
9716150|NCT04573218|Placebo Comparator|Group A|Glucose.
9716151|NCT04573218|Active Comparator|Group B|250 mg Oil Palm Phenolics.
9716152|NCT04573049|Experimental|Levosimendan|Levosimendan 0.1µg/kg/min will last for 24h after the valve is released.
9716153|NCT04573049|Placebo Comparator|Placebo|5% glucose 0.1µg/kg/min administration will continue for 24h after the valve is released.
9716154|NCT04572919|Active Comparator|group A|Patients were randomly assigned to undergo lateral advancement flap
9716155|NCT04572919|Active Comparator|group B|Patients were randomly assigned to undergo classic Limberg flap
9716156|NCT04572932|Active Comparator|group 1:Probiotic arm|first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks
9716157|NCT04572932|Active Comparator|Group 2:Placcebo arm|the second group received only itopridehcl 50mg by the same dose for four weeks.
9716158|NCT04572698|Experimental|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
9716159|NCT04572698|Active Comparator|EYLEA|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
9716160|NCT04572867|Experimental|Aquapheresis|Per protocol, if randomized to Aquapheresis arm (AQ), all diuretics are discontinued and AQ will be administered as per established protocol. BMP and CBC will be checked prior to initiation and as needed, 7-10 days, 30, 60 and 90 days post discharge. Note, aquapheresis rate is to be decreased by 100 cc/hr if Hgb increases by 1gm/dL, and stopped if rate is decreased to 50 cc/hr or reaches euvolemia, whichever comes first.
9716161|NCT04572867|Active Comparator|IV Diuretics|Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If a patient in IV arm is refractory to maximum 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
9716162|NCT04572659|Experimental|Group intervention|
9716163|NCT04572659|Experimental|Couple intervention|
9716164|NCT04572659|No Intervention|No intervention|
9716165|NCT04572685|Experimental|LY03010 Process 1|"Drug Product of Process 1 ( P1): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P1 using a non-sterile Active Pharmaceutical Ingredients (API) with an absolute ethanol recrystallization was manufactured by an optimized production process"
9716166|NCT04572685|Experimental|LY03010 Process 2|"Drug Product of Process 2 (P2): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.~LY03010 P2 using a sterile Active Pharmaceutical Ingredients (API) with an isopropanol recrystallization was manufactured by the same optimized production process as that used in P1."
9716167|NCT04572685|Experimental|INVEGA SUSTENNA|INVEGA SUSTENNA 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study
9716168|NCT04572672|Active Comparator|Purse lip breathing with number counting arm|"1) Position: The patient lies down in a semi-supine position, the bed is adjusted by 45-60 degrees, 2) Pursed-lip breathing and number counting one and two during inspiration, and 3) Number counting, one, two, three, and four during exhalation for the first 15 minutes (min) of each hour, total study time was 3 hours or until the patient was discharged from the ER."
9716169|NCT04572672|No Intervention|Control arm|The patients who were allocated to the control group received usual nursing care i.e. bed rest in a supine position in a quiet area. Patients were advised to limit their activity. The frequency of the vital signs monitoring and pharmacologic treatment were the same as the intervention group.
9716170|NCT04572945||1- Cases: Diabetic patients with CKD.|classified according to estimated GFR into 5 stages according to KIDGO 2012 classification.
9716171|NCT04572945||2- Controls: Diabetic patients without CKD.|defined as patients who have normal kidney function test, normal urine analysis and normal ultrasound findings.
9779748|NCT04944771|Experimental|Treatment EFD|Participants will be randomized to receive oral doses of Treatment E, Treatment F and Treatment D.
9716172|NCT04572724|Experimental|Sacubitril/Valsartan treatment group|"Sacubitril/Valsartan will be administered step by step with a titrated dose. When patients switching to Sacubitril/Valsartan from RAS inhibitor, a washout period of at least 36 hours is required to decrease the risk of angioedema.~All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis."
9716173|NCT04572724|Active Comparator|RAS inhibitor treatment group|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis.
9716174|NCT04572997|Experimental|Full analysis set (FAS)|The full analysis set (FAS) consisted of all patients who received at least one dose of study drug.
9716175|NCT04572594||Inflammatory myofibroblastic tumor|tissue of Inflammatory myofibroblastic tumor lession
9716176|NCT04572607|No Intervention|Control group 1|
9716177|NCT04572607|No Intervention|Control group 2|
9716178|NCT04572607|No Intervention|Control group 3|
9716179|NCT04572607|No Intervention|Control group 4|
9716180|NCT04572607|No Intervention|Control group 5|
9716181|NCT04572607|No Intervention|Control group 6|
9716182|NCT04572607|No Intervention|Control group 7|
9716183|NCT04572607|Experimental|Honey group 1|
9716184|NCT04572607|Experimental|Honey group 2|
9716185|NCT04572607|Experimental|Honey group 3|
9716186|NCT04572607|Experimental|Honey group 4|
9716187|NCT04572607|Experimental|Honey group 5|
9716188|NCT04572607|Experimental|Honey group 6|
9716189|NCT04572620||group 1(rituximab)|
9716190|NCT04572620||group 2 (abatacept)|
9716191|NCT04572542|Experimental|Camrelizumab + Apatinib + nab-paclitaxel|Camrelizumab combined with Apatinib mesylate tablets and nab-paclitaxel in the second-line treatment of advanced gastric cancer
9716192|NCT04572555|Experimental|Heat Treatment Group|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak. The subjects were instructed on the application of the thermophores. Thermoforming was applied wrapped in towels in order to shield the subjects from the effects of direct heat. In a study, heat packs that had a temperature of 38.9 °C were used for treatment of dysmenorrhea. In this study, the temperature of the water used in the thermoforming process was 45 °C. Considering the risk of the thermophores cooling down and the shielding provided by the towels, the water temperature was kept higher compared to those in other studies. The temperature of the water was measured using a liquid thermometer. Heat treatment was applied for 20 minutes without interruptions.
9716193|NCT04572555|No Intervention|Control Group|No Intervention
9716194|NCT04572763|Experimental|Dose Escalation Copanlisib + Venetoclax|"Phase 1~Dose escalation will occur using a 3+3 design~Copanlisib will be administered IV on days 1, 8 and 15 in 28 day cycle~Venetoclax will be administered orally daily for each 28-day cycle. During cycle 1, a venetoclax dose ramp-up is performed in the outpatient setting"
9716195|NCT04572763|Experimental|Recommended phase II dose (RP2D) Copanlisib + Venetoclax|Patients will be treated with copanlisib in combination with venetoclax, administered at the Recommended phase II dose (RP2D).
9716196|NCT04572386|Active Comparator|Light cure universal bond|light cured 3m single bond universal
9716197|NCT04572386|Active Comparator|self cure universal bond|self-cure universal bond (Palfique, Tokuyama, Japan)
9716198|NCT04572464|Experimental|Experimental|Mindfulness Based Guided Meditation
9980435|NCT01391702||Labouring woman with epidural in situ|Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
9980436|NCT01391715|Active Comparator|Double dose rabeprazole|Rabeprazole 20m bid per day will be given for 2 weeks
9980437|NCT01391715|Placebo Comparator|standard dose rabeprazole|rabeprazole 20mg per day will bi given for 2 weeks
9980438|NCT01391728|Active Comparator|Lifestyle counseling|
9980439|NCT01391728|No Intervention|Control|
9980440|NCT01391741|Experimental|Walking with visual cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
9980441|NCT01391741|Active Comparator|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
9980442|NCT01391754|Experimental|SafeCare with Coached Implementation|Home-based services with the SafeCare model, implemented with in vivo provider coaching as quality control
9980443|NCT01391754|Experimental|SafeCare without Coaching|Home-based services using the SafeCare model, implemented without in vivo coached implementation quality control
9980444|NCT01391754|Experimental|Services As Usual with Coaching|Usual home based services, with in vivo coached implementation quality control
9980445|NCT01391754|Active Comparator|Services As Usual Without Coaching|Usual home based services without in vivo coached quality control
9980446|NCT01391767||NuOss XC|Bone grafting material used in this group will be NuOss XC.
9980447|NCT01391767||NuOss Particulate|Bone grafting material used in this group will be NuOss Particulate.
9980448|NCT01391780||Group 1|Patients with stress urinary incontinence
9980449|NCT01391780||Group 2|Patients with urgency urinary incontinence.
9980450|NCT01391806||Breast cancer|Patients selected for breast-conserving surgery based on conventional radiological methods, following the criteria recommended by the Norwegian Breast Cancer Group
9980451|NCT01391845|Experimental|UPA, 300UI FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
9980452|NCT01391845|Placebo Comparator|No UPA, 300FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
9980453|NCT01391845|Experimental|UPA, FSH 225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
9980454|NCT01391845|Placebo Comparator|no UPA, FSH225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
9980455|NCT01391871||PRO-Kinetic DES|Patients receiving PRO-Kinetic drug-eluting stent
9980456|NCT01391871||Endeavor Resolute DES|Patient receiving Endeavor Resolute zotarolimus-eluting stent
9980457|NCT01391884||Dialysis, Non-diabetic|Hemodialysis
9980458|NCT01391884||Healthy control|
9980459|NCT01391897||in- and out-patient psychotherapy patients|All included patients are highly selected in- and outpatients in a department of psychosomatic medicine (Germany) undergoing high dose psychotherapy (e.g. group therapy, creative therapy, cbt and psychodynamic psychotherapy).
9980460|NCT01391910||post endoscopic sinus surgery for chronic rhinosinusitis|Patients who have undergone functional endoscopic sinus surgery for treatment of chronic rhinosinusitis and completed a pre-surgery SNOT-20
10196142|NCT02649764|Experimental|Treatment (fludarabine phosphate, cytarabine, prexasertib)|Patients =/< 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Patients > 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3, cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
9716225|NCT04572516|Experimental|Topical group|Topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
9716226|NCT04572516|Experimental|Injection group|20 units of BTX_A (2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
9716227|NCT04572269||Subjects with OSA|Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI >5)
9716228|NCT04572113||No collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are not wearing a cervical collar
9716229|NCT04572113||DJO collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a DJO cervical collar
9716230|NCT04572113||Miami J collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a Miami J cervical collar
10196143|NCT02643498|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
10196144|NCT02643043|Other|UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
10196145|NCT02635633|Experimental|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
9716231|NCT04572334|Other|visual acuity and refractive outcome for Tecnis Eyhance|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
9716232|NCT04572334|Other|visual acuity and refractive outcome for Tecnis ZCB00|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
9716233|NCT04572139||Young participants|18-45 years old
9716234|NCT04572139||Old participants|55-80 years old
9716235|NCT04572139||Oldest old participants|over 80 years old
9716236|NCT04572282|Experimental|Mentora|Remote symptoms monitoring with mobile app
9716237|NCT04572360|Experimental|Cardiorespiratory Exercise plus Chinese Herbal Medicines Group|"Includes:~1.12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities.~2.Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
9716238|NCT04572360|Experimental|Cardiorespiratory Exercise Group|"Includes:~A 12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities."
9716239|NCT04572360|Experimental|Chinese Herbal Medicines Group|"Includes:~Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
9716240|NCT04572360|No Intervention|Waiting List Group|The waiting list control sign will be adopted to conceal allocation results from the patients and further to reduce selection and confounding bias and increase their adherence to the study. Patients in the waiting list control group will receive no treatment in the study period (including a 12-week intervention period and a 12-week follow-up period). However, they will receive Chinese herbal medicines after the completion of the study (i.e., after the 3rd wave of measurements in the 25th weeks).
9716241|NCT04572477|Other|[18F]THK-5351|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
9779749|NCT04944771|Experimental|Treatment FDE|Participants will be randomized to receive oral doses of Treatment F, Treatment D and Treatment E.
9779750|NCT04944771|Experimental|Treatment FED|Participants will be randomized to receive oral doses of Treatment F, Treatment E and Treatment D.
9779751|NCT04944654|Experimental|Assigned intervention|Biktarvy OD for 96 weeks
9716242|NCT04572477|Other|[18F]AV-45|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
9716243|NCT04572204||Conservative group|
9716244|NCT04572204||interventional group|
9716245|NCT04572425|Active Comparator|Guided imagery|10 minutes of guided imagery (using Apple iPad and headphones, subject watches 10 minute video of a guided-imagery session depicting a peaceful walk through a forest with instrumental background music and 2-dimensional imagery)
9716246|NCT04572425|Experimental|Virtual reality|10 minutes of virtual reality (using study-administered Facebook Oculus Go VR headset with headphones, subject engages with VR application Forest of Serenity (Holosphere VR®, Birmingham, UK) that features a forest environment with voice narration that can be played in a seated or fixed position.
9716247|NCT04572217|Experimental|Medication Group|"Adolescent patients post vertical sleeve gastrectomy who have had inadequate weight loss, who consented for use of off-label medications prescribed at the discretion (one or both) of physician.~Patients will be followed every 2-12 weeks over one year.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
9716248|NCT04572217|No Intervention|Non-Medication Group|"Adolescent patients post vertical sleeve gastrectomy who had inadequate weight loss and did not consent for use of off-label medications.~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
9980461|NCT01391936|Other|Tension Band Wiring|Patients in this arm will receive the tension band wiring technique for fixation of their olecranon fracture.
9980462|NCT01391936|Other|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
10196146|NCT02629419|Experimental|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
10196147|NCT02610855|Active Comparator|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
9980463|NCT01391949|Experimental|Detailed feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
9716252|NCT04572373||SMOFlipid group|"TPN and SMOFlipid support were indicated for patients who received NPO for more than 3 days, such as those with repeated laparotomy, staged biliary reconstruction, massive nasogastric (NG) drainage (>500 mL/day), ileus, diarrhoea, poor digestion (NG extraction >50 mL/time), and chylous ascites.~Furthermore, SMOFlipid was discontinued when the platelet count decreased to 40,000/μL or less. In all cases, heparinisation was prescribed to maintain the aPTT level between 1.5 and 2 times the normal controlled level at least for 10-14 days, with daily blood examination conducted. Oral administration of dipyridamole (75 mg, QID) for 3 months was indicated for stimulation of antiplatelet activity when the platelet count increased to 40,000/μL or more."
9716253|NCT04572373||non SMOFlipid group|On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group and the SMOFlipid group , respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.
9716254|NCT04572347||Nurses working in PUTH|Participants will be recruited from Peking University Third Hospital through cluster sampling. Female registered nurses, licensed practical nurses and/or midwives with informed consent are included in this study. The exclusion criteria are student nurses and training nurses.
9716255|NCT04572490||Narrow platform implant|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
9980464|NCT01391949|Active Comparator|Basic feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
9980465|NCT01391975|Experimental|Surveillance and proactive intervention|
9980466|NCT01391975|No Intervention|Control and reactive intervention|
9980467|NCT01391988|Active Comparator|Electric Scalpel Mastectomy|Radical mastectomy with electric scalpel
9980468|NCT01391988|Experimental|Harmonic scalpel mastectomy|Radical Mastectomy with harmonic scalpel
9980469|NCT01392001||Cohort|
9980470|NCT01392014|Active Comparator|dihydroartemisinin-piperaquine|
10196148|NCT02610855|Active Comparator|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
10196149|NCT02610855|Other|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
10196150|NCT02596503|Experimental|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
9980471|NCT01392014|Active Comparator|Dihydroartemisininpiperaquine primaquine|
9980472|NCT01392040||Patients in oral anticoagulant therapy|Patients taking oral anticoagulant therapy
9980473|NCT01392066||Breast cancer patients and their partners|Patients with breast cancer and their cohabiting partners/spouses
9716256|NCT04572490||Regular platform implants|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
10196151|NCT02589509|Experimental|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
9716257|NCT04571970|Experimental|Single Arm|6.5 × 10^10 GC/g brain mass of RGX-121
10196152|NCT02589509|Experimental|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
9716258|NCT04572178|Experimental|Cash payment and brief behavioral counseling|The intervention consists of in person counseling and cash payment. The participants receive 25 Euro per week if they have succeeded in quitting smoking. Quitting smoking is evaluated by carbon monoxide measurements twice a week.
9716259|NCT04572087|Experimental|Cognitive Control Training + Verum stimulation|This arm consists of the cognitive control training (six sessions) combined with 2mA anodal tDCS over the right dlPFC (F4) during the training for 20 minutes.
9716260|NCT04572087|Active Comparator|Cognitive Control Training + Sham stimulation|This arm consists of cognitive control training (six sessions) with sham-tDCS. 2 mA Sham-tDCS (40 seconds of tDCS) is applied to the right dlPFC (F4) before the trainings starts.
9716261|NCT04572308|Experimental|CD7 CAR-T|Patients will be treated with CD7 CAR-T cells
9716262|NCT04571957||Donors with NASH|Donors with NASH underwent donor optimization protocol
9716263|NCT04571957||Donors without NASH|Donors without NASH
9716264|NCT04572074|Active Comparator|Arm 1 (Guided imagery)|10 minutes of guided imagery experience
9716265|NCT04572074|Experimental|Arm 2 (Virtual reality)|10 minutes of virtual reality experience
9716266|NCT04571853|Experimental|PNE-explained group|The participants in the PNE-explained group will be explained the fact sheets with an explanatory video (due to COVID-19 circumstances) conducted by the therapist M.S. The video will last one hour approximately and it contains a presentation by Mayte Serrat with a view of the fact sheets. This group will be given one week to watch the video and comprehend its content.
9716267|NCT04571853|Active Comparator|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
9716268|NCT04571853|Active Comparator|TAU group|Participants allocated into this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professional.
9716269|NCT04571866|Experimental|Beta-glucan bread|Participants will receive a standardised meal consisting of beta-glucan-enriched bread (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participants will be asked to spend approximately 10 minutes consuming the standardised meal.
9716270|NCT04571866|Sham Comparator|Control bread|Participants will receive a standardised meal consisting of a wheat bread with no additives (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participant will be asked to spend approximately 10 minutes consuming the standardised meal.
9716271|NCT04571879|Experimental|Arm 1|"Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr.~Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg)."
9716272|NCT04571879|Experimental|Arm 2|"Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg).~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
10196153|NCT02581215|Experimental|Arm A: Experimental Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks."
10196154|NCT02581215|Placebo Comparator|Arm B: Placebo Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab"
10196155|NCT02560597|Experimental|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
10196156|NCT02554253|Active Comparator|ketamine|Ketamine induction
10196157|NCT02554253|Active Comparator|Propofol|Propofol induction
9716273|NCT04571879|Placebo Comparator|Arm 3|"Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
9716274|NCT04571905|Other|Syntellix Treatment Arm|General anaesthesia, open fracture reduction, insertion of the appropriate screw with x-ray control and documentation intraoperatively, cast immobilisation Use of bioresorbable Magnezix CS or CBS Screws, if intraoperatively suitable bioresorbable screws not available, use of conventional ostesynthesis screws
9716275|NCT04571918|Experimental|Group A: Biodegradable spacer|Intervention group
9716276|NCT04571918|Active Comparator|Group B: control group|Control group
9716277|NCT04571762|Experimental|Single arm|Patients with low-risk, intermediate-risk and low-volume metastatic prostate cancer eligible for stereotactic body radiotherapy will be recruited.
9716278|NCT04571775|Active Comparator|Qi-Shield user group|
9716279|NCT04571775|Sham Comparator|Sham Qi-Shield user group|
9716280|NCT04571775|No Intervention|No Qi-Shield device group|
9716281|NCT04571788||FCB group|FCB group received FCB implantation
9716282|NCT04571788||Control group|Control group undergoes silicone scleral pad surgery
9716283|NCT04572048|Other|Single-day NRP training|This group will follow the single-day NRP training course that is currently the standard. It usually takes 8 hours to complete this training course and the nurses are released from their clinical duty to attend the training course.
10196158|NCT02535091|Experimental|YKP3089|Multiple dose
10196159|NCT02529189|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
10196160|NCT02529189|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
10196161|NCT02513563|Experimental|Carboplatin/Paclitaxel/AZD1775|Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
10196162|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec|Talimogene Laherparepvec
10196163|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec + Pembrolizumab|Combination treatment of Talimogene Laherparepvec and Pembrolizumab
10196164|NCT02507791|Experimental|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
9716284|NCT04572048|Experimental|Longitudinal one year NRP Training|This group will follow the longitudinal NRP training course. The longitudinal NRP training course will consist of nine 30-minute modules that will be taught every 6-8 weeks over a period of one year. The nurses will attend the different modules of the training course at their work place and during their work shift so they will have to be released from their clinical duty only 30 minutes at a time.
9716285|NCT04571437|Active Comparator|Chemo endocrine treatment (A)|Letrozole 2.5mg PO daily + Capecitabine 500mg/m2 bid PO continously
9716286|NCT04571437|Active Comparator|Endocrine treatment only (B)|Letrozole 2.5mg PO daily
9716287|NCT04571489|Experimental|Gimatecan group|All patients will receive gimatecan (0.8mg/m2, on days 1 to 5, PO, every 4 weeks) until progressive disease (PD).
9716288|NCT04571489|Placebo Comparator|placebo group|All patients will receive tegafur, gimeracil and oteracil potassium (40-60mg, twice daily, on days 1 to 14 , PO, every 3 weeks) or gemcitabine (1000mg/m2, on days 1、8, IV, every 3 weeks) until progressive disease (PD).
9716289|NCT04571463||HUCS A|Mothers visiting the prenatal care units within the Helsinki area.
9716290|NCT04571463||HUCS HAL|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Helsinki area.
9716291|NCT04571463||PHHYKY A|Mothers visiting the prenatal care units within the Lahti area.
9716292|NCT04571463||PHHYKY HALSO|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Lahti area.
9716293|NCT04571671||Study group|Women with Müllerian anomalies who have received an oocyte donation. The diagnosis of Müllerian anomalies is established when a cavity is demonstrated uterine abnormality with any of the defects described in the American classifications or European in transvaginal ultrasound, hysteroscopy or hysterosalpingography (HSG). The differential diagnosis in case of doubts is established with 3D ultrasound, MRI or hystero / laparoscopy. All the septa have been resected prior to performing the OVODON cycle.
9716294|NCT04571671||Control group|Patients who receive donated oocytes and who do not present Müllerian anomalies. An absence of AM, a transvaginal ultrasound, an HSG or a normal hysteroscopy with a uterine cavity with a normal shape and absence of intracavitary images is considered
9716295|NCT04571528|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
9716296|NCT04571528|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
9716297|NCT04571528|Active Comparator|Physiotherapy part of VIRTUA FIBROWALK|The physiotherapy part of the VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE) and therapeutic exercise.
9716298|NCT04571476|Experimental|UTB-VBN-EBUS group|Ultrathin bronchoscope with a 3.0-mm outer diameter and a 1.7-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN and EBUS.
9716299|NCT04571476|Active Comparator|TB-VBN-EBUS-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN-EBUS and a 1.95-mm outer diameter guide sheath.
9716300|NCT04571476|Active Comparator|TB-VBN-EBUS-non-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using conventional biopsy forceps and cytology brush with the guidance of VBN and EBUS, but without guide sheath.
9716301|NCT04571593|Experimental|Digital Yoga Nidra|"Participants will voluntarily complete a ~30-minute remote Yoga Nidra practice, synchronously (through Zoom Wednesdays at 10 pm ET) or asynchronously (through YouTube, using the Zoom recording, any time they like).~They may voluntarily repeat this practice as often as they like. Recordings are updated weekly, to reflect the ongoing Zoom class. Yoga Nidra scripts from Satyananda Saraswati's Yoga Nidra book (1976) are used for this class."
9716302|NCT04571684|Experimental|Intervention Arm (HITSystem 2.1)|Participants enrolled at intervention sites will received HITSystem 2.1-supported PMTCT services through 6 months postpartum. Interventions received will include: text messages to patients to support medication adherence, appointment attendance, and hospital delivery and algorithm-driven alerts to notify providers when follow up services are missed.
9716303|NCT04571684|No Intervention|Control Arm (Standard of care)|Participants enrolled at control sites will receive standard of care PMTCT services, with no HITSystem 2.1 tracking or follow up.
9716304|NCT04571502|Experimental|Full Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the experimental arm will have access to use CareHeroes AND the newly developed AAC app. Provider will receive information via the AAC app.
9716305|NCT04571502|Active Comparator|Minimal Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the minimal intervention arm will have access to use CareHeroes but only a paper version of the newly developed AAC app.
9716306|NCT04571749|Experimental|Customized Or to ICU handoff protocol|Tailored implementation strategies will be used in 12 ICUs to facilitate the uptake and sustained use of a customized handoff protocol to be used by clinicians at the time of patient care transition from the operating room to the intensive care unit.
9716307|NCT04571996|Experimental|ODM-104 and Panadol Zapp|
9716308|NCT04571892|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
9716309|NCT04571710|Experimental|Treatment group|Intervention: Drug: SHR1258 400mg
9716310|NCT04571580|Placebo Comparator|placebo|
9716311|NCT04571580|Experimental|reteplase 9mg|
9716312|NCT04571580|Experimental|reteplase 18mg|
9716313|NCT04571450|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
9716314|NCT04571424|Experimental|Cohort 1: BIIB133 Dose 1|Participants will receive single IV infusion of BIIB133 Dose 1.
9716315|NCT04571424|Experimental|Cohort 2: BIIB133 Dose 2|Participants will receive single IV infusion of BIIB133 Dose 2.
10196165|NCT02507791|Active Comparator|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
10196166|NCT02498600|Active Comparator|Group I (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
10196167|NCT02498600|Experimental|Group II (nivolumab, ipilimumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
9716316|NCT04571424|Placebo Comparator|Cohort 1-2: Placebo|Participants will receive single IV infusion of matching placebo to BIIB133.
9716317|NCT04571606|Active Comparator|Liposomal Bupivacaine|Pre-operative ultrasound guided interscalene nerve block with 10 mL 1.3% liposomal bupivacaine (Exparel) and 10 mL 0.5% bupivacaine
9716318|NCT04571606|Active Comparator|Peripheral Nerve Catheter|Pre-operative ultrasound guided interscalene nerve block with 20 mL of 0.25% bupivacaine and placement of peripheral nerve catheter with 10 mL/hr 0.2% bupivacaine infusion via OnQ pump.
9716319|NCT04571372||Patients with severe aortic stenosis or severe aortic regurgitation|Patients with severe aortic stenosis or severe aortic regurgitation
9716320|NCT04571203|Experimental|Phase I Study of Combined DD Kidney and HCT Transplant|Single arm Phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion
9716321|NCT04571268||Healthy validation subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for the purpose of developing and validating the biomechanical models used to track scapular motion
9716322|NCT04571268||Healthy comparison subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for comparison of shoulder motion and muscle activation patterns with RCT subjects
9716323|NCT04571268||RCT subjects|Subjects who have sustained a major rotator cuff tear
9716324|NCT04571242|Active Comparator|DTM-SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and participants tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
9716325|NCT04571242|Active Comparator|Conventional SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and subjects tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
9716326|NCT04571034|Sham Comparator|Control Group|Healthy adults receiving sham comparator.
9716327|NCT04571034|Experimental|Medium-Intensity Roller Massage|Healthy adults receiving medium-intensity roller massage.
9716328|NCT04571034|Experimental|High-Intensity Roller Massage|Healthy adults receiving high-intensity roller massage.
9716329|NCT04571164|Experimental|LY03003|
9716330|NCT04571164|Placebo Comparator|Placebo|
10196168|NCT02441686|Experimental|Bortezomib, Lenalidomide, Dexamethasone|"After the screening procedures confirm eligibility to participate in the research study: Each participant will be given a study drug-dosing diary for each treatment cycle. The diary will also include special instructions for taking the study drugs.~- Study Drugs:~Bortezomib- subcutaneous injection on predetermined days of each cycle~Lenalidomide oral daily on predetermined days of each cycle.~Dexamethasone oral on predetermined days of each cycle"
10196169|NCT02418832|Other|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
9716331|NCT04571021|Experimental|I-DEPT|Novel triage. The triage nurse can adjust the triage category one level of urgency down or one or two levels up.
9716332|NCT04571021|Active Comparator|DEPT|Existing triage algorithm
9716333|NCT04571294|Experimental|group A|PALN removal
9716334|NCT04571294|No Intervention|group B|No PALN removal
9716335|NCT04571151|Active Comparator|Lexette + Sorilux|"Halobetasol Propionate Topical Foam (Lexette Foam) + Calcipotriol Foam (Sorilux Foam) for 2 weeks~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g."
9716336|NCT04571151|Placebo Comparator|Lexette + Vehicle|"Halobetasol Propionate Topical Foam (Lexette Foam) + Vehicle Foam for 2 weeks~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.~Vehicle Foam would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application."
9716337|NCT04571151|Active Comparator|Sorilux|"Calcipotriol Foam (Sorilux Foam) for 6 weeks~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 6 weeks. SORILUX Foam contains calcipotriene 50 mcg/g."
9716338|NCT04571151|Placebo Comparator|Vehicle|"Vehicle Foam for 6 weeks.~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.~Vehicle Foam would be applied over the affected area twice daily for 6 weeks."
9716339|NCT04570969|No Intervention|standard of care|Peri-operative analgesia by opioids
9716340|NCT04570969|Experimental|Peri operative regional analgesia|Peri-operative analgesia by Continuous bilateral Erector Spinae Catheters
9716341|NCT04571190|Experimental|Prenatal MBSR|The prenatal MBSR program consists of nine two-hour sessions including teachings in mindfulness meditation and yoga. The program is taught by an experienced MBSR instructor with relevant clinical expertise.
9716342|NCT04571190|No Intervention|Usual care|Standard clinical practice, usual care (TAU), imply routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Usual care include a multidisciplinary approach involving preventive counselling by midwifes, physicians and social workers throughout the pregnancy and follow-up until the early post-partum period.
9716343|NCT04570982||Convalescent Plasma with SOC|All patients will receive CPT and SOC
9716344|NCT04570917|Experimental|Intervention group (INT)|An online learning module targeted to reduce ageism will be delivered to the INT group.
9716345|NCT04570917|Active Comparator|Control group (CON)|An online learning module on diversity and cultural competence will be delivered to the CON group.
9716346|NCT04570995|Active Comparator|fish oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing fish oil encapsulated in soft gel capsules.
9716347|NCT04570995|Placebo Comparator|safflower oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing a placebo oil product (safflower oil) encapsulated in soft gel capsules.
9779752|NCT04944121|Experimental|RSLV-132|RSLV-132 is an enzymatically active ribonuclease designed to digest the ribonucleic acid contained in autoantibodies and immune complexes and thereby render them biologically inert. A dose of 10 mg/kg will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
9779753|NCT04944121|Placebo Comparator|Placebo|Sodium chloride 0.9% will be administered by intravenous infusion on Days: 1, 8, 15, 29, 43, and 57
9779754|NCT04941066|Experimental|Active neurofeedback|Receiving feedback signals from the rumination-related brain functional connectivity.
9779755|NCT04941066|Sham Comparator|Sham neurofeedback|Receiving artificially generated feedback signals.
9980474|NCT01392079|Experimental|Alemtuzumab|"30 mg alemtuzumab will be administered subcutaneously 3 times weekly for 4 weeks (total of 12 doses of 30 mg alemtuzumab) with premedication (as needed) and infection prophylaxis; combined with oral dexamethasone 40 mg total dose for 4 days every 2 weeks; evaluation at end of cycle (i.e. after 12 doses of 30 mg alemtuzumab).~If CR is documented after week 4 (12 doses of 30 mg alemtuzumab) or 8 (24 doses of 30 mg alemtuzumab), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted at this time point.~After a maximum of three 4-week cycles (total of 36 doses of 30 mg alemtuzumab, in case of interruptions this may take longer than 12 weeks), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted. Maintenance treatment with alemtuzumab will continue for a maximum of two years, with evaluation every three months, unless there is PD."
9779757|NCT04936542|Other|Sequence 1|Participants will receive one cycle of aboBoNT-A followed by one cycle of onaBoNT-A in the selected overactive upper limb muscles
9980475|NCT01392105|Active Comparator|Mesenchymal stem cell treatment group|
9716348|NCT04571125||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
9716349|NCT04571125||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
9716350|NCT04571008|Placebo Comparator|Placebo|At least 16 weeks of placebo.
9716351|NCT04571008|Experimental|NMN supplementation|At least 16 weeks of NMN.
9716352|NCT04570930|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of Health- Related Quality of Life (HRQOL) and receive personalized pushes over a six-month (180 day) period.
9716353|NCT04570930|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period (without the personalized feedback).
9716354|NCT04571073|Experimental|Treatment arm|The only arm in the study was the intervention arm as this is a pilot study.
9716355|NCT04571112|Experimental|NBM ON|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.~The NBM ON arm will have constant NBM stimulation for 8 weeks."
9716356|NCT04571112|Sham Comparator|NBM OFF|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.~The NBM OFF arm will have NBM stimulation turned off for 8 weeks."
9716357|NCT04571346|Active Comparator|the classical TOT procedure|performing the trans-obturator procedure through the standard vertical incision
9716358|NCT04571346|Experimental|2 paramedian vertical incisions|performing the trans-obturator procedure through a new technique of 2 paramedian vertical incisions
9716359|NCT04570956|Experimental|Oral Tamoxifen 10 mg/day|Oral Tamoxifen 10 mg/day
9716360|NCT04570956|Experimental|Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day|"Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day~+oral placebo"
9716361|NCT04570956|Experimental|Control|Oral and gel placebo
9716362|NCT04570891|Experimental|FICB|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
9716363|NCT04570891|Placebo Comparator|Control|No regional block is provided at the end of surgery.
9716364|NCT04570761|Experimental|ON-Stim|acoustic stimulation
9716365|NCT04570761|Sham Comparator|OFF-Stim|no acoustic stimulation
9716366|NCT04570722|Other|Single arm study|Patients with a history of axillary surgical lymph node procedures (SLNP) presenting for routine radiographic scan will complete baseline measures: bilateral volumetric measurements and self-reported symptoms. Patients will undergo SOC contralateral arm intravenous access attempt. After one failed attempt, ipsilateral intravenous access instead of pedal or neck access will be offered per research protocol. Nursing documentation will reflect the failed venipuncture and categorize a reason for the failed attempt.
9716367|NCT04570735||patients with type 2 diabetes and diabetic kidney disease|
9716368|NCT04570735||patients with type 2 diabetes and no diabetic kidney disease|
9716369|NCT04570735||patients with obesity, no diabetes and no kidney disease|
9716370|NCT04570709|No Intervention|Control|Patients in the control arm will receive standard of care.
9716371|NCT04570709|Experimental|Intervention|Patients in the intervention arm will receive the PACT intervention provided by a multidisciplinary team of RNs, OTs, and PTs.
9716372|NCT04570865|Experimental|Dapagliglozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
9716373|NCT04570748|Experimental|Group A|Direct anterior hip arthroplasty with capsule repair.
9716374|NCT04570748|Active Comparator|Group B|Surgery that the surgeon will not perform capsule repair after performing an initial capsulectomy during total hip arthroplasty
9716375|NCT04570852|Experimental|Intensive monitoring of patients|State of the art biochemical assessment of patients with acute pancreatitis including multi-OMICS focusing on transcriptomics and proteomics.
9716376|NCT04570813|Experimental|artistic activities|"participants will do a 3-month cycle of weekly artistic activities at the MAMAC Museum, which are structured 2-h-long art-based workshops"
9716377|NCT04570813|No Intervention|No artistic activities|The control group is composed of participants who do not take part in art-based activities,
9716378|NCT04570826|Experimental|Meditation program|The experimental group participated in the Meditation program during one month, eight sessions with a total of sixteen hours.
9716379|NCT04570826|Active Comparator|Scientific descriptions about meditation|The control group received scientific descriptions about meditation.
9716380|NCT04570579||Observational cohort|"This is a prospective, nonrandomized study of patients undergoing bilateral cataract surgery with implantation of the spherical Vivity and/or Vivity toric IOL. Preoperative patient data such as age, sex, prior ocular history, medical history, and intraocular lens calculations/formulae used will be recorded. Uncorrected and best-corrected visual acuity will be measured at distance (4m), intermediate (60cm) and near (40cm). All 3 surveys will be administered prior to surgery (at baseline) and at 3 months postoperative, regarding spectacle independence, visual disturbances, and visual quality. A proper perioperative record will be maintained, documenting planned IOL implantation, actual IOL implant used, use of femtosecond laser, use of intraoperative aberrometry, and use of pupillary expansion devices. Patients will be examined 1 day (postoperative day 1), 1 week (postoperative week 1), 1 month (postoperative month 1) and 3 months (postoperative month 3) following surgery."
9716381|NCT04570592|Placebo Comparator|Granisetron|Granisetron 1 mg (1ml) + Normal saline 1ml
9716382|NCT04570592|Experimental|Granisetron and Dexamethasone|Granisetron 1mg (1ml) + Dexamethasone 4mg (1ml)
10196170|NCT02382406|Experimental|Arm A: Phase I Dose Finding Cohort|"Twelve subjects will be enrolled and treated with carboplatin AUC 6 IV on Day 1, nab-paclitaxel 100 mg/m^2 IV on Day 1, Day 8, and Day 15, pembrolizumab 2* mg/kg IV on Day 1 for 4 cycles. pembrolizumab (Phase I) treatment for Cohort 1 will continue for a maximum duration of 4 21-day cycles~Phase I, Cohort 1 Maintenance Therapy:~Participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles, maintenance therapy with MK-3475 2* mg/kg will continue on D1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or a maximum of 2 years from C1D1.~If unacceptable toxicity is seen in Phase I Cohort 1, 12 additional participants will be enrolled in Cohort 2 and treated with carboplatin AUC 6 IV on D1, nab-paclitaxel 100 mg/m2 IV on D1, D8, and D15, MK-3475 2*mg/kg IV on D1 starting C2. MK-3475 (Phase 1) treatment for Cohort 2 will continue for a maximum duration of 3 21-day cycles (C2-4 only)."
10196171|NCT02382406|Experimental|Arm B: Phase II Investigational Treatment|"Subjects will be treated with carboplatin AUC 6 given IV on Day 1, nab-paclitaxel 100 mg/m^2 given IV on Day 1, Day 8, and Day 15, and pembrolizumab 200mg IV on Day 1 of each cycle. Pembrolizumab Phase II treatment will continue for a maximum duration of 4 cycles (cycle = 21 days).~Maintenance Therapy For participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles of induction therapy, maintenance therapy with MK-3475 2* mg/kg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from C1D1.~*As additional data from ongoing trials becomes available, the dose of MK-3475 may be adjusted."
10196172|NCT02378766|Experimental|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
10196173|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
10196174|NCT02353819|Experimental|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
10196175|NCT02323880|Experimental|Treatment (selinexor)|Patients receive selinexor PO once weekly (days 1, 8, 15, and 22). Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
10196176|NCT02308527|Active Comparator|Temozolomide|Temozolomide Days 1-5 every 4 weeks
10196177|NCT02308527|Experimental|Bevacizumab + Temozolomide|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
10196178|NCT02308527|Experimental|Irinotecan + Temozolomide|Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
10196179|NCT02308527|Experimental|Bevacizumab + Irinotecan + Temozolomide|Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
10196180|NCT02308527|Experimental|Temozolomide + Topotecan|Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
10196181|NCT02308527|Experimental|Bevacizumab + Temozolomide + Topotecan|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
10196182|NCT02308527|Experimental|Dinutuximab beta + Temozolomide|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
10196183|NCT02308527|Experimental|Dinutuximab beta + Temozolomide + Topotecan|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
9666936|NCT04110314|Active Comparator|No portal reminder + Pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal but do receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
9666937|NCT04110314|No Intervention|No portal reminders + No pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal and do not receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
9666938|NCT04109456|Experimental|Part 1, Monotherapy Arm|The safety and tolerability of IN10018 monotherapy will be assessed. Other dose levels may be explored if necessary.
9666939|NCT04109456|Experimental|Part 2, Combination Arm|"The safety and tolerability of IN10018 in combination with Cobimetinib will be assessed. Other dose levels may be explored if necessary.~A modified 3+3 design will be used."
9666940|NCT04108429|Experimental|Mobile self-help intervention|Participants will have open access to the IntelliCare system.
9666941|NCT04108039|Active Comparator|GnRH antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering.
9666942|NCT04108039|Experimental|Micronized progesterone|In the progesterone cycle, endogenous LH suppression will be accomplished by oral administration of micronized progesterone (200 mg) once a day at bed time, from stimulation day 1 and continuing until ovulation triggering.
9666943|NCT04103892|Experimental|CLE-100 (oral esketamine)|"Part A: 1 oral tablet of CLE-100 once daily (in addition to current anti-depressant drug) for 1 week.~Part B: 1 oral tablet of CLE-100 once daily (in addition to current anti-depressant drug) for 4 weeks."
9666944|NCT04103892|Placebo Comparator|placebo|"Part A: 1 oral tablet of Placebo once daily (in addition to current anti-depressant drug) for 1 week.~Part B: 1 oral tablet of Placebo once daily (in addition to current anti-depressant drug) for 4 weeks."
9666945|NCT04103216|Active Comparator|Intervention arm|"Child will be receive the Nitazoxanide treatment for 3 days with probiotics (L reuteri DSM 17938 ) for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.~L reuteri DSM 17938 will be 2×108 CFU and will receive 5 drops orally twice daily for a consecutive 7 days."
9666946|NCT04103216|Placebo Comparator|Control arm|"Child will be receive the Nitazoxanide treatment for 3 days with placebo for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.~Placebo will receive 5 drops orally twice daily for a consecutive 7 days."
9666947|NCT04102371|Experimental|Balanced fluids (BF)|Balanced fluids (BF), including Lactated Ringer's and PlasmaLyte, will be administered to patients randomized to the experimental arm. BF will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
10196184|NCT02308527|Other|Dinutuximab beta + Topotecan + Cyclophosphamide|Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
10196185|NCT02272595||Arm A - Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
9716383|NCT04570696||Adult haemophilia patients|Adult (≥ 18 years old) haemophilia patients, only men
9716384|NCT04570514||Obesity|Patients with Obesity. BMI>=25
9716385|NCT04570514||Non-Obesity|Patients without Obesity. BMI<25
9716386|NCT04570475|Experimental|vitamin D+multivitamin|
9716387|NCT04570475|Active Comparator|placebo+multivitamin|
9716388|NCT04570878|Experimental|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
9716389|NCT04570878|Active Comparator|Control|No regional block is provided at the end of surgery.
9716390|NCT04570540||OSA|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9.
9716391|NCT04570540||OSA+SH|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during sleep, defined by the presence of intermittent hypercapnia as measured by transcutaneous capnometry and arterialized capillary blood gas analysis.
9716392|NCT04570540||OHS|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during wakefulness, defined by a PCO2>45mmHg as measured by arterialized capillary blood gas analysis.
9716393|NCT04570683|Active Comparator|AFL monotherapy|Singe dose AFL as monotherapy, 100 mJ
9716394|NCT04570683|Active Comparator|AFL+nivolumab|Single dose AFL 100 mJ followed by immediate intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
9716395|NCT04570683|Active Comparator|nivolumab monotherapy|Intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
9716396|NCT04570449|Experimental|Fluoxetine|"Participants instructed to take fluoxetine 20 mg capsule orally daily for 8 weeks in the following schedule:~Week 1 = 1 pill (20 mg), Week 2 = 2 pills (40 mg), Weeks 3-6 = 3 pills (60 mg), Week 7 = 2 pills (40 mg), Week 8 = pill (20 mg)"
9716397|NCT04570449|Placebo Comparator|Placebo|"Participants instructed to take fluoxetine placebo capsule matching fluoxetine orally daily for 8 weeks in the following schedule:~Week 1 = 1 pill, Week 2 = 2 pills, Weeks 3-6 = 3 pills, Week 7 = 2 pills, Week 8 = pill"
9716398|NCT04570527||Obesity|BMI>=25
9716399|NCT04570527||Non-Obesity|BMI<25
9716400|NCT04570566|Experimental|titanium mish|horizontal alveolar ridge augmentation with non-resorbable titanium mish .evaluation after 4 months
9716401|NCT04570566|Experimental|pericardium membrane|horizontal alveolar ridge augmentation with resorbable pericardium membrane then .evaluation after 4 month.
9716402|NCT04570410|Experimental|Subgroup1:Patients who can tolerate cisplatin chemotherapy|"GC plus Tislelizumab Participants receive GC (Gemcitabine plus cisplatin), in combination with Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W~Biological: GC GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks"
9716403|NCT04570410|Experimental|Subgroup2:Patients who cannot tolerate cisplatin chemotherapy|"Tislelizumab Participants receive Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W"
9716404|NCT04570774|Experimental|Facilitatory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
9716405|NCT04570774|Active Comparator|Facilitatory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and sham high-frequency rTMS over the ipsilateral cerebellar hemisphere.
9716406|NCT04570774|Experimental|Inhibitory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
9716407|NCT04570774|Active Comparator|Inhibitory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and sham rTMS over the ipsilateral cerebellar hemisphere.
10196186|NCT02272595||Arm B - Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
10196187|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
10196188|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
10196189|NCT02216032|Experimental|Treatment Group|We will deliver the TMW Curriculum to 106 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
9716408|NCT04570371|Experimental|Intervention|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches in which the intervention will be implemented per the study schedule.
9716409|NCT04570371|No Intervention|Control Arm|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches. The control arm consists of all patients receiving surgery in implementation tranches in which the intervention has not been implemented yet (per the study schedule).
10196190|NCT02216032|Other|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
10196191|NCT02178072|Other|HPV positive|HPV positive patients
10196192|NCT02178072|Other|HPV negative|HPV negative patients
10196193|NCT02121184|Active Comparator|Group A|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
9716410|NCT04570553|Experimental|V-care uterine manipulator|Patients in the V-care uterine manipulator arm will undergo standard staging surgery utilizing a V-care uterine manipulator in the standard fashion
9716411|NCT04570553|Active Comparator|Sponge stick|Patients in the sponge stick arm will undergo standard staging surgery utilizing a non-invasive sponge stick for cervical delineation.
9716412|NCT04570462|Experimental|Experimental Arm- Induction of Mild Hypothermia Protocol|Determination of metabolic rate by the metabolic cart (noninvasive connection of the device to the ventilator for 20 minutes). Initiate hypothermia (established Northwell hypothermia status post cardiac arrest protocol) using the Arctic Sun. The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.
9716413|NCT04570189||Phase I|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with the Auscul-X, a conventional stethoscope and an electronic stethoscope (Littmann 3200).
9716414|NCT04570189||Phase II|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with an Auscul-X with wireless capability, a conventional stethoscope and an electronic stethoscope (Littmann 3200). Phase II shall begin upon appropriate Health Canada approvals for the Auscul-X with wireless capability.
9716415|NCT04570319|Experimental|Probiotic Bths-08|a capsule containing the probiotic blend (nutritional complement)
9716416|NCT04570319|Placebo Comparator|Placebo|a capsule containing placebo comparator
9716417|NCT04570215|Active Comparator|Gotcha! Therapy Application|"Participants will receive the Gotcha therapy daily for six weeks.Participants are required to use the app everyday for a maximum of 45 minutes. After this time they enter a twelve week block with no therapy or maintenance of therapy (see Gotcha maintenance arm).~This aim of this arm is to invesitgate the efficacy of the Gotcha therapy for proper-noun anomia in mild-moderate patients with dementia (Alzheimer's disease, vascular dementia and mixed)"
9716418|NCT04570215|Active Comparator|Gotcha! Therapy Application: Maintenance|"Participants will receive the Gotcha therapy for six weeks as described in the Gotcha arm. After this time they enter a twelve week block of maintenance of therapy gains made in the initial six week therapy block.~The maintenance block consists of a weekly test of the Gotcha outcome measure to monitor the therapy gains made during the therapy block. If any previously correctly named person is incorrectly named during these weekly tests then the participant must complete a 'top-up' therapy session. They will then be tested again the following week.~The aim of this arm is to compare Gotcha maintenance with Gotcha, to see if extra testing and therapy is required to maintain gains made during an initial intense therapy block."
9716419|NCT04570397|Experimental|Interventional arm|ravulizumab
9716420|NCT04570397|No Intervention|Control arm|patients in this arm will recieve standard care
9716421|NCT04570345|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)
9716422|NCT04570345|Active Comparator|Aspirin with P2Y12 receptor inhibitor|Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)
9716423|NCT04570111|Active Comparator|Standard Care Diet|After the controlled feeding study, participants in this group will follow the standard care diet for the remainder of pregnancy with the assistance of a study dietitian. The standard care study diet will provide the standard 40% Carb/20% Pro/40% Fat as energy, distributed consistently across 3 meals and 2 snacks.
9716424|NCT04570111|Experimental|Macro-Optimized Diet (MOD)|After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.
10196194|NCT02121184|Experimental|Group B|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
9716425|NCT04570228|Active Comparator|Treatment group|Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.
9779758|NCT04936542|Other|Sequence 2|Participants will receive one cycle of onaBoNT-A followed by one cycle of aboBoNT-A in the selected overactive upper limb muscles
10196195|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
10196196|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
10196197|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
9716426|NCT04570228|Sham Comparator|Sham control group|A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.
9716427|NCT04570124|Experimental|Remote Surveillance|Women will use the home blood pressure monitoring device to record their blood pressure everyday for the first postpartum week, and then weekly until postpartum week 6.
10196198|NCT01972919|Experimental|Radiation therapy plus chemotherapy|MR guided dose escalated radiation therapy plus concurrent chemotherapy in unresectable non-metastatic pancreas cancer. Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction and concurrent Gemcitabine or Capecitabine.
10196199|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
9716428|NCT04570293|Experimental|The LMP group|The LMP group will receive lidocaine patches (active patches) measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w).
9716429|NCT04570293|Placebo Comparator|The control group|The control group will receive vehicle patches that are identical to the active patch, except for the absence of lidocaine, without any optical differences.
9716430|NCT04570254|Experimental|Patients with septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.~With the following specifications:~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.~The dose of pentoxifylline that all patients will receive is as follows:~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
9716431|NCT04570254|Experimental|Patients without septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.~With the following specifications:~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.~The dose of pentoxifylline that all patients will receive is as follows:~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
9716432|NCT04570137|Experimental|1|This arm received the arabinoxylan/ß-glucan mix first.
9716433|NCT04570137|Experimental|2|This arm received the inulin/oligofructose mix first.
9716434|NCT04570072|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum, each at a dosage of 3.0 × 10^10 colony forming unit per 2g sachet.
10196200|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
10196201|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
10196202|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
10196203|NCT01905813|Experimental|INCB040093|
9716435|NCT04570072|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
9716436|NCT04570150|Active Comparator|Sugammadex|
9716437|NCT04570150|Placebo Comparator|Neostigmine|
9716438|NCT04570306||Belimumab-treated SLE patients|SLE patients with active disease who will be started on add-on treatment with belimumab on top of standard of care.
9716439|NCT04570033|Experimental|patients with hyperparathyroidism|We prospectively enrolled 65 consecutive patients with primary hyperparathyroidism (PHPT) who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study
9716440|NCT04570020||Clinically-Selected Scleral Lens|The clinically-selected lens is based on slit lamp assessment. This lens will be compared against an OCT-selected lens.
9716441|NCT04570020||OCT-Selected Scleral Lens|The OCT-selected lens is based on OCT measurements. This lens will be compared against a clinically-selected lens.
9716442|NCT04570202|No Intervention|Usual Care|Subject from this group are screened positive for psychological distress but they will only receive standard of care.
9716443|NCT04570202|Experimental|Eye Movement Desensitization & Reprocessing Group|Subject from this group are screened positive for psychological distress. They will receive 12 sessions of Eye Movement Desensitization & Reprocessing therapy by a trained therapist over three months in addition to standard of care.
9716444|NCT04570241|Active Comparator|Group A-Malaria toolkit|School children shall be trained on key malaria messages with a malaria toolkit. From the training received, the pupils will carry out awareness-raising in communities with key messages learnt.
9716445|NCT04570241|No Intervention|Group B-No malaria toolkit|"School children shall not be trained on key malaria messages with a malaria toolkit. Pupils will not carry out awareness-raising in communities with key messages.~."
9716446|NCT04570059|Experimental|Intervention program|Intervention group
9716447|NCT04570059|Active Comparator|Usual Care|Control group
9716448|NCT04569968|Experimental|Expiratory muscle training group|Daily expiratory muscle training for four weeks will be applied.
9716449|NCT04569968|No Intervention|Control group|Nothing will be applied except for the hospital conventional physiotherapy program.
10196204|NCT01905813|Experimental|INCB040093 in combination with itacitinib (INCB039110)|
10196205|NCT01898637|Active Comparator|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
10196206|NCT01898637|Other|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
10196207|NCT01804998|Experimental|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in this arm
10196208|NCT01804998|Active Comparator|Laparoscopy Assisted Gastrectomy|Conventional procedure is laparoscopy assisted gastrectomy in early gastric cancer patient.
9716450|NCT04569773||Participants undergoing surgery for clinical|Participants will be undergoing surgery for clinical stage I endometrioid endometrial cancer
9716451|NCT04569721|Experimental|CT guided splanchnic cryoablation|Obese patients with type 2 diabetes receiving CT guided splanchnic cryoablation.
9716452|NCT04569838|Experimental|Bendamustine hydrochloride injection|Bendamustine hydrochloride injection 120 mg/m² or 100 mg/m² intravenously (IV) on Day 1 and Day 2 of 21-day cycle (6-8 cycles maximum) for non-hodgkin's lymphomas or chronic lymphocytic leukemia. After 6-8 cycles, the course of treatment could be added based on patient's benefit and investigator's determination.
9716453|NCT04569877|Experimental|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution
9716454|NCT04569877|Placebo Comparator|Placebo nebuliser solution|Placebo nebuliser solution
9716455|NCT04569825|Active Comparator|Local Nasal Steroid|Application of Local Nasal Steroid for the COVID-19 patients with anosmia
9716456|NCT04569825|Placebo Comparator|Normal Saline|Application of Normal Saline for the COVID-19 patients with anosmia
9716457|NCT04569916|Experimental|treatment group|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
9716458|NCT04569929|Active Comparator|control|conventionally manufactured Polymethyl Methacrylate (PMMA) mandibular implant overdentures
9716459|NCT04569929|Experimental|intervention|digital light processed (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdentures
9980476|NCT01392105|Placebo Comparator|Control group|All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)
9980477|NCT01392131|Active Comparator|Oncoxin will be administered orally|20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
9980478|NCT01392131|Active Comparator|Supportive treatment|20 patients with hepatocellular carcinoma will receive supportive treatment only
9980479|NCT01392144||Nitric Oxide Breath Analysis|Nitric Oxide Breath Test + Questionnaires
9716462|NCT04569890|Experimental|CZP|Certolizumab pegol: subcutaneous CZP at 200mg twice a week.
9716463|NCT04569890|Active Comparator|GC+HCQ|"Hydroxychloroquine: HCQ at 200mg daily, and if tolerated, escalated to 400 mg daily.~Glucocorticoid: continuous usage GC at 10mg a day from Week 0 to Week 52.~At 24 week, non-responders (ΔDAS28<0.6) will switch to the other group. Participants switched to CZP group will taper their dose of GC gradually, if they have an improvement in disease activity (two successive DAS28<2.6). If participants have a disease flare (increased DAS28>0.6) during a reduction in corticosteroid dose, then they will resume their previous dose. Weekly step-down GC scheme: 10mg-7.5mg-5mg-2.5mg-0mg."
9716464|NCT04569669|Experimental|Patients diagnosed with Coronary Artery Disease（CAD）by CCTA|Patients admitted to hospital with the diagnosed of CAD by CCTA and who accept to participate to the study will undergo the invasive coronary angiography, fractional flow reserve (FFR) will be measured during the invasive coronary angiography.Outcome measures were comparing FFRct to FFR.
9716465|NCT04569682|Active Comparator|transrenal artery perfusion group|
9716466|NCT04569682|Experimental|transrenal vein perfusion group|
9716467|NCT04569539|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane
9716468|NCT04569487|Active Comparator|Sarcopenic population|"Diagnosed sarcopenia following definition of the EWGSOP2:~Muscle strength assessed by the handgrip test <27 kg~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA <7.0 kg/m2"
9716469|NCT04569487|Active Comparator|Non sarcopenic population|"Non-sarcopenic population adapted from the EWGSOP2:~Muscle strength assessed by the handgrip test ≥ 27 kg~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA ≥ 7.0 kg/m2"
9716470|NCT04569500|Experimental|PETAL program|Patients with total laryngectomy and their close relatives, benefiting from the therapeutic education program PETAL
9716471|NCT04569500|No Intervention|Usual care|Patients with total laryngectomy and their close relatives, benefiting from the usual care
9716472|NCT04569981|Active Comparator|Climbing Group (CG)|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
9716473|NCT04569981|Active Comparator|Unsupervised active group (UAG)|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
9716474|NCT04569474|Experimental|Dressing Group|use of sterile transparent dressing
9716475|NCT04569474|No Intervention|Standard Group|non-sterile transparente dressing
9980480|NCT01392157|Active Comparator|copper intrauterine device|100 women will be allocated to receive a TCu380A intrauterine device
9980481|NCT01392157|Active Comparator|LNG-releasing intrauterine system|100 women were allocated to receive a LNG-IUS
9716476|NCT04569812|Experimental|Standard CPR|After Informed Consent Document (ICD) signature, participants were randomised (to the Standard CPR group) to perform standard CPR (30:2) in a flowchart-assisted resuscitation for 5min in a manikin model
9716477|NCT04569812|Experimental|Chest compressions only|After ICD signature, participants were randomised (to the CC only CPR group) to perform chest compressions only in a flowchart-assisted resuscitation for 5min in a manikin model
9716478|NCT04569643||Main|Patients with cerebral small vessel disease and periodic limb movement index equal or more than 15 movements per hour of sleep.
9716479|NCT04569643||Control|Patients with cerebral small vessel disease and periodic limb movement index less than 15 movements per hour of sleep.
9716480|NCT04569994|Experimental|Part 1|Healthy volunteers will receive either NNC0363-0845 or placebo
9716481|NCT04569994|Experimental|Part 2|Participants with T1D will receive either NNC0363-0845 or insulin degludec
9716482|NCT04569994|Experimental|Part 3|Participants with T1D will receive NNC0363-0845
9716483|NCT04569617|Active Comparator|upper limb endurance protocol|UL endurance protocol - elbow flexion
9980482|NCT01392157|Active Comparator|ENG-releasing implant|100 women will receive an LNG-IUS
9980483|NCT01392196|Other|Single arm|Renal Denervation
10196209|NCT01524536|Other|Steroid Challenge|A single oral dose of prednisone (1 mg/kg rounded to the nearest 5mg) was administered to all participants. The following day, participant began glucocorticoid therapy of prednisone 30 mg oral daily for one week followed by a standardized taper until a minimally effective dose was achieved or participant tapered to prednisone 5 mg oral daily.
10196210|NCT01485874|Experimental|Doxil + BIBF 1120|
10196211|NCT01424982|Experimental|Treatment (combination chemotherapy, ponatinib hydrochloride)|See Detailed Description.
10204812|NCT04858295|Active Comparator|Texting Arm|"Participants will receive automated text message reminders to check their blood pressure (BP) at least three days per week (participants will choose which days and times to receive reminders). Participants will transmit BP readings with text message to the Way to Health server. If a BP reading is not received within 3 hours, another reminder will be sent. Automated text message feedback will be sent with a tailored message. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
10204813|NCT04858295|Active Comparator|mHealth app Arm|"Participants randomized to the mHealth app (Omron Connect) arm will receive reminder messages to check their BP via push notifications from the Omron Connect app at least three times weekly. Upon receipt of the BP reading to the research platform from Omron Connect, participants will receive automatic tailored text message feedback similar to the texting arm. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
10204814|NCT04856176|Experimental|GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed|All patients will receive GM-CSF plus maintenance pembrolizumab with or without pemetrexed, following completion of 4 cycles of chemo-immunotherapy
9716484|NCT04569617|Active Comparator|upper limb strength protocol|UL strength protocol - elbow flexion
10204815|NCT04855630|Experimental|Sleep Only|
10204816|NCT04855630|Active Comparator|Exercise Only|
10204817|NCT04855630|Active Comparator|Exercise + Sleep|
10204818|NCT04853043|Experimental|Cetuximab|
10204819|NCT04838990|Active Comparator|conventional visit|Regular outpatient visit
10204820|NCT04838990|Experimental|phone visit|Remote visit via phone
10204821|NCT04838990|Experimental|video visit|Remote visit via videochat
9716485|NCT04569617|Active Comparator|lower limb endurance protocol|LL endurance protocol - knee extension
9716486|NCT04569617|Active Comparator|lower limb strength protocol|LL strength protocol - knee extension
9716487|NCT04569760|Experimental|Cannabinoid Oil - Oral Preparation|"50mg CBD: 2mg of THC in each 1ml drop in MCT Oil, flexibly dosed at 200-800 mg per day.~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in increments of 200 mg (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach 800 mg/day/week by Week 4."
9716488|NCT04569760|Placebo Comparator|Placebo Oil - Oral Preparation|"MCT Oil~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (a volume equivalent to the maximum of 800 mg/day total dose of High CBD).~The dose will be titrated in incremental volumes equivalent to 200 mg of active product (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach the volume equivalent to 800 mg/day/week by Week 4."
9716489|NCT04569565|Experimental|PleurX catheter intervention|Participants will undergo placement and follow up monitoring of PleurX catheter.
9716490|NCT04569656|Experimental|treatment|6 week treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg
9716491|NCT04569292||Cancer patients|"confirmation of COVID-19 in the laboratory (RT-PCR techniques);~suspected cases of COVID-19; clinically diagnosed based on symptoms (fever> 37.5 °, decrease in oximeter saturation by at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis and rhinorrhea) + close contact a COVID-19 subject positive;~asymptomatic cases; diagnosed based on positive swab results but without symptoms"
9716492|NCT04569396||Non-Alcoholic Fatty Liver Disease|A total of 72 severely or morbidly obese patients with non-alcoholic fatty liver disease and associated co-morbidities like diabetes and hypertension were enrolled into the study.
9716493|NCT04569630|Experimental|Intervention group|
9716494|NCT04569578|Experimental|Policy|The policy will be implemented on preschool level.
9716495|NCT04569578|No Intervention|Regular practice|The control preschool will continue their regular practice.
9716496|NCT04569318|Experimental|Treatment Arm|Treatment with treatment beam.
9716497|NCT04569370||Scoring Factor|Intervention: Procedure: Laparoscopic cholecystectomy
9716498|NCT04569370||Difficult criteria|Intervention: Procedure: Laparoscopic cholecystectomy
9716499|NCT04569188|Experimental|convalescent plasma|Cohort of elderly patients treated with convalescent plasma
9716500|NCT04569058|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
9716501|NCT04569240|Other|Dexcom G6 continuous glucose monitor|All patients will have a Dexcom G6 continuous glucose monitor placed pre-operatively. The glucose readings will be collected for 10 days or upon discharge from the ICU and data will be compared with arterial blood glucose readings or venous Accu-Check Inform II glucose readings
9716502|NCT04569110||Pleural infection|Patients with clinically confirmed ongoing pleural infection.
9716503|NCT04569110||Negative control|Patients without pleural infection.
10196212|NCT01307046|Experimental|MK-0954A|Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
10196213|NCT01307046|Active Comparator|Losartan|Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.
10196214|NCT01307033|Active Comparator|MK-954H (L50/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)
9716504|NCT04569071|Experimental|Sinovation Laser Ablation System treatment|Sinovation Laser Ablation System treatment
10196215|NCT01307033|Experimental|MK-0954A (L100/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension
10196216|NCT01231971||Cognitively Normal (CN)|150 newly enrolled participants with no apparent memory problems, and CN participants followed from the ADNI1 study
10196217|NCT01231971||Early Mild Cognitive Impairment (EMCI)|100 newly enrolled early amnestic MCI participants, and approximately 200 EMCI participants will be followed from the ADNI-GO study
10196218|NCT01231971||Late Mild Cognitive Impairment (LMCI)|150 newly enrolled late MCI participants, and LMCI participants followed from the ADNI1 study
10196219|NCT01231971||Alzheimer's Disease (AD)|150 newly enrolled mild AD participants
10196220|NCT01231971||Significant Memory Concern (SMC)|100 newly enrolled participants with Significant Memory Concern (SMC)
10196221|NCT01191151||Orthopedic injury, osteoarthritis|All eligible patients receiving orthopedic, sports medicine, arthroscopy and related surgery or nonoperative treatment
10196222|NCT01041807||All participants|Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)
10196223|NCT00954226|Experimental|Arm I (standard-dose erlotinib hydrochloride)|Patients receive standard-dose erlotinib hydrochloride PO QD for 2-3 weeks (up to 8 weeks if surgery is delayed).
10196224|NCT00954226|Experimental|Arm II (high-dose erlotinib hydrochloride)|Patients receive high-dose erlotinib hydrochloride PO QD for 2-3 weeks (2-8 weeks for current smokers or up to 8 weeks if surgery is delayed).
10196225|NCT00801372||Pre-existing Fibroblast MCB|Pre-existing fibroblast donors for hESC derivation project
10196226|NCT00756639|Experimental|Radiation|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks. On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
9716505|NCT04569305|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy was applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of technique was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
9716506|NCT04569305|Active Comparator|Conventional treatment|Simple moist gauze dressing applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of treatment was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
9716507|NCT04569019||Health care workers|The study will be conducted among UCKWUM healthcare professionals, i.e. doctors, nurses, paramedics, laboratory workers, pharmacists, and administration workers. Based on previous research, the group should include at least 200 participants
9779759|NCT04928703|Experimental|Arm 1|Visit 2: Placebo - Placebo; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Ketamine
9779760|NCT04928703|Experimental|Arm 2|Visit 2: Placebo - Ketamine; Visit 3: Placebo - Placebo; Visit 4: Placebo - Ketamine
9779761|NCT04928703|Experimental|Arm 3|Visit 2: Placebo - Ketamine; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Placebo
9779762|NCT04922645|Experimental|Ferric citrate (commercially available, Auryxia)|Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
9779763|NCT04922645|Active Comparator|Standard of care phosphate lowering therapy|Non-Auryxia phosphate-lowering therapy administered as standard of care.
9779764|NCT04918693||Participant|All 15 participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.
9779765|NCT04918693||Trainee|All 15 trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner
9779766|NCT04915937|Experimental|Study Infant Formula|Feed ad libitum during study period
9779767|NCT04910815|Experimental|Primary recruitment|Capsules will be ingested within 30 minutes prior to endoscopy pre- and post-antimicrobial intervention (if the patients has had a treatment) to determine if it can be used to identify increased microbial load through gas detection, and to identify responders to therapy.
9779768|NCT04910815|Active Comparator|Active SIBO Arm - Rifaximin|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of Rifaximin (550g) 1 capsule twice a day for 14 days. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
9980484|NCT01392209|Experimental|Bevacizumab & Stereotactic Radiotherapy|This will be a multicenter (MSKCC and UCSF) phase I dose escalation study to determine the maximum tolerated dose (MTD) of hypofractionated stereotactic radiotherapy when administered in combination with a fixed dose of bevacizumab.
9716508|NCT04569214|Placebo Comparator|A - Placebo Control|4 tablets of placebo
9716509|NCT04569214|Experimental|B - PAZ320 Low Dose|2 tablets of PAZ320 and 2 tablet of placebo
9716510|NCT04569214|Experimental|C - PAZ320 High Dose|4 tablet of PAZ320
10196227|NCT00739674|Active Comparator|Losartan-Based Regimen Alone (L Group)|Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.
10196228|NCT00739674|Experimental|Diet Management and Losartan-Based Regimen (DML Group)|Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.
9716511|NCT04569279|Active Comparator|Warfarin arm|Patients randomly assigned to (W) group will receive an adjusted dose of warfarin with targeted INR of 2.0 to 3.0.
9716512|NCT04569279|Experimental|Rivaroxaban arm|Patients randomly assigned to (R) group will receive 20mg rivaroxaban daily if CrCl>50 mL/min using Cockcroft-Gault equation or 15mg rivaroxaban daily if CrCl 30-50 mL/min.
9716513|NCT04569409|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
9716514|NCT04569409|Placebo Comparator|Vehicle sheet|Hydrogel sheet without allogenic mesenchymal stem cell
9716515|NCT04569422||ephedrine drop|
9716516|NCT04568928|Experimental|OLTP/PE+FES first, then OLTP/PE+sham FES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE+FES).~One week break. 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton combined with SHAM functional electrical stimulation (OLTP/PE + shamFES).~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression. For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. For the sham FES, all parameters will be the same except that a subthreshold current intensity (i.e. not producing palpable muscle contraction) will be delivered. FES timing and duration is already built into the device."
9716517|NCT04568928|Experimental|OLTP/PE+shamFES first, then OLTP/PE+FES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined with SHAM functional electrical stimulation (OLTP/PE+ shamFES).~One week break. 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE + FES).~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression. For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. For the sham FES, all parameters will be the same except that a subthreshold current intensity (i.e. not producing palpable muscle contraction) will be delivered. FES timing and duration is already built into the device."
10196229|NCT00731757|Experimental|1|Patients being treated with Humira.
10196230|NCT00730717|Experimental|1|Patients who are not concurrently receiving methotrexate treatment for pyoderma gangrenosum
10196231|NCT00730717|Experimental|2|Patients who are receiving concurrent methotrexate for pyoderma gangrenosum
10196232|NCT00579566||1|Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
10196233|NCT00546754|Experimental|1|Drug Arm
9716518|NCT04568928|Active Comparator|OLTP/PE noFES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined (OLTP/PE) One week break 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton (OLTP/PE)~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression."
9716519|NCT04568941|Experimental|Preoperative Vacuum-Assisted Biopsy|Preoperative vacuum-assisted biopsy was performed within 10 days before final surgery. The tumor were excised almost.
9716520|NCT04568941|Experimental|Preoperative Core Needle Biopsy|Preoperative core needle biopsy was performed within 10 days before final surgery. The needle biopsy were performed with 3 needles.
9716521|NCT04568941|Experimental|Intraoperative Excisional Biopsy|The tumor was excised intraoperatively.
9716522|NCT04568915|Experimental|Dry Needling-Group|Tens, Stretching, Strengthening(girdle), Neck Isometrics, DN
9716523|NCT04568915|Active Comparator|Maitland-Group|Tens Stretching, Strengthening(girdle), Neck Isometrics, Maitland joint mobilization
9716524|NCT04569227|Experimental|Active EC-18|
9716525|NCT04569227|Placebo Comparator|Placebo|
10196234|NCT00546754|Active Comparator|2|active comparator
9716526|NCT04568694|Experimental|Delayed Lung Transplantation|Patients that received lung(s) delayed for transplantation
9716527|NCT04568694|Active Comparator|Conventional Lung Transplantation|Reference Therapy
9716528|NCT04568668|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized adverse drug event information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The adverse drug event information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the adverse drug event information such that community pharmacists can view the adverse drug event information prior to dispensing medications.
9716529|NCT04568668|No Intervention|Standard care (ADE information retained locally)|Patients in the control group will have their adverse drug event information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their adverse drug event information will not be visible to other providers via PharmaNet.
9716530|NCT04568720||Shanghai General Hospital|
10196235|NCT00479713|Experimental|1|Arm 1: drug
10196236|NCT00479713|Active Comparator|2|Arm 2: active comparator
10196237|NCT00406783|Experimental|5-mg Desloratadine tablet|
10196238|NCT00406783|Placebo Comparator|Placebo tablet|
10196239|NCT00405964|Experimental|5-mg Desloratadine tablet|
10196240|NCT00405964|Placebo Comparator|Placebo tablet|
10196241|NCT00383721|Experimental|MF/F MDI 400/10 mcg BID|
10196242|NCT00383721|Experimental|MF/F MDI 200/10 mcg BID|
10196243|NCT00383721|Experimental|MF MDI 400 mcg BID|
10196244|NCT00383721|Active Comparator|Formoterol MDI 10 mcg BID|
10196245|NCT00383721|Placebo Comparator|Placebo MDI BID|
9716531|NCT04569097|Experimental|Patient group|lingual strengthening
9716532|NCT04569097|No Intervention|Healthy controls|Healthy normal swallow
9716533|NCT04568746|Other|patients with qSOFA ≥ 2|adult patients with a qSOFA score ≥ 2 at the screening in the emergency department, will be referred to the emergency vital room
9716534|NCT04568746|Other|patients with qSOFA <2|adult patients with a qSOFA score < 2 at the screening in the emergency department, will be referred to the box
9716535|NCT04568889|Experimental|Government/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
9716536|NCT04568889|Experimental|Government/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
9716537|NCT04568889|Experimental|Government/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
9716538|NCT04568889|Experimental|Government/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
9716539|NCT04568889|Experimental|Researchers/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
9716540|NCT04568889|Experimental|Researchers/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
9716541|NCT04568889|Experimental|Researchers/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
9716542|NCT04568889|Experimental|Researchers/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
9716543|NCT04568889|Experimental|Government/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
9716544|NCT04568889|Experimental|Government/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
9716545|NCT04568889|Experimental|Government/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
9716546|NCT04568889|Experimental|Government/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
10196246|NCT00383552|Experimental|MF/F MDI 100/10 mcg BID|
9716547|NCT04568889|Experimental|Researchers/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
9716548|NCT04568889|Experimental|Researchers/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
9716549|NCT04568889|Experimental|Researchers/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
9716550|NCT04568889|Experimental|Researchers/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
9716551|NCT04568785|Experimental|Brief Intervention group|Intervention consisted of a standardized Brief Intervention, which varied depending on the reason the patient had given for refusing the vaccination.
10196247|NCT00383552|Experimental|MF MDI 100 mcg BID|
10196248|NCT00383552|Experimental|F MDI 10 mcg BID|
10196249|NCT00383552|Placebo Comparator|Placebo BID|
10196250|NCT00383435|Experimental|MF/F MDI 400/10 mcg BID|
10196251|NCT00383435|Experimental|MF/F MDI 200/10 mcg BID|
9716552|NCT04568785|Active Comparator|Control group|the control group intervention was the normal advice that professionals used to give their patients
10196252|NCT00383435|Experimental|MF MDI 400 mcg BID|
10196253|NCT00383435|Active Comparator|Formoterol MDI 10 mcg BID|
10196254|NCT00383435|Placebo Comparator|Placebo MDI BID|
10196255|NCT00381485|Experimental|MF/F MDI 400/10 mcg BID|"Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
9716553|NCT04568863|Experimental|Melatonin|(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
9716554|NCT04568863|Placebo Comparator|Placebo|(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
10196256|NCT00381485|Experimental|MF/F MDI 200/10 mcg BID|"Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
10196257|NCT00381485|Active Comparator|MF MDI 400 mcg BID|"Mometasone Furoate 400 mcg taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
9716555|NCT04568824|Experimental|GraphoLearn reading intervention|GraphoLearn is a research-based treatment, delivered as an engaging computer game. Players match auditory targets (e.g., phonemes, rimes) to visual targets (single letters, letter sequences, words). The complexity of the items within each level is ordered such that at each level, the most frequent and regular mappings are introduced first based on measures such as orthographic/phonological neighborhood size and morphological family size. GraphoLearn allows the children to practice and reinforce lessons at their own individual trial pace and provides a record of performance progress that can be used to guide analyses.
9716556|NCT04568824|Active Comparator|Vektor math control|We selected an active control to maximize the specificity of the treatment outcomes; to this end, math games are among the most commonly used. Game sessions support learning numerical mathematical skills and cognition related to mathematical skills. In addition to math, this game contains training tasks for visuospatial working memory, spatial visualization and visuospatial reasoning. The overall theme of the game and feedback style are similar to those in GraphoLearn.
9716557|NCT04568772|Active Comparator|Atovaquone/Proguanil 250/100 mg|A single oral administration of atovaquone/proguanil 250/100 mg
10196258|NCT00379288|Experimental|MF/F 200/10 mcg BID|
9716558|NCT04568772|Experimental|Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day
9716559|NCT04568772|Experimental|Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day
9716560|NCT04568772|Experimental|Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day
9716561|NCT04568603|Experimental|Methadone + ISL|Methadone-maintained participants (20 to 200 mg once daily [QD] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9 and ISL 60 mg once on Day 2.
9716562|NCT04568876|Active Comparator|PEA Group|Normast® MPS (mPEA and umPEA 300mg + 600mg) oral suspension: 2700mg/die in 3 doses for 28 days, in add-on to standard therapy
9716563|NCT04568876|Other|Control Group|Standard therapy only
9716564|NCT04568525|Active Comparator|COVID - 19 patients|
9716565|NCT04568525|Active Comparator|COVID - 19 and pneumonia patients|
9716566|NCT04568525|Active Comparator|Health patients|
9716567|NCT04568655||COVID-19 patients need noninvasive ventilation|
9716568|NCT04568707|Experimental|Covid-19 infection|Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
9716569|NCT04568837|Experimental|Corticosteroid|Participants in this group will receive a daily dose of corticosteroids on postoperative day one and two after spine fusion surgery
9716570|NCT04568837|No Intervention|Control|Participants in this group will receive no steroids on postoperative day one and two after spine fusion surgery.
9716571|NCT04568577|Experimental|tensioned tape|The tensioned tape group will apply weekly with gradual tension calculated by measuring the initial length of the tape. From the first week of application, there will be a 5% increase in tension up to the fifth week.
9716572|NCT04568577|Active Comparator|tape without tension|The tensionless tape group will receive the application of the tape weekly without tensioning during the five weeks.
9716573|NCT04568512|Placebo Comparator|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
9716574|NCT04568512|Active Comparator|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
9716575|NCT04568681||Patients with dystonia|Patients with dystonia who have clinically been deemed candidates for DBS surgery.
10196259|NCT00379288|Experimental|MF/F 400/10 mcg BID|
10196260|NCT00379288|Active Comparator|F/SC 250/50 mcg BID|
10196261|NCT00379288|Active Comparator|F/SC 500/50 mcg BID|
9716576|NCT04568473|Experimental|PRG Barrier Coat (SHOFU Inc., Japan)|"BioSmart Light Cured Protective Shield with bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology.~S-PRG filler possesses a three-layer structure with a stabilized glass-ionomer-like structure surrounding multifunctional glass fillers, and is subsequently protected by a surface modified layer."
9716577|NCT04568473|Experimental|EMBRACE™ Varnish (Pulpdent Corporation, USA)|"Resin-based 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release.~The incorporation of CXP™ (xylitol-coated calcium and phosphate) in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish"
9716578|NCT04568473|Active Comparator|Duraphat® (Colgate Palmolive Company, New York, NY)|It is attributed to the reactivity of the fluoride by adsorbing to the surface and attracting calcium ions forming loosely-bound calcium fluoride (CaF2)- like reservoir which is also considered responsible for the anticaries mechanism and protection against cariogenic acid attack.
9716579|NCT04568213|Experimental|Hypochlorous Gel Application|
9716580|NCT04568239||M184V + group and M184 - group|
9716581|NCT04568369|Experimental|Treatment group|Patients will engage in a four-week treatment protocol (20 treatments). This was chosen as it is the midpoint between typical depression and migraine protocol durations. If available, patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. If not available, a standardized atlas brain with Montreal neurologic institute (MNI) coordinates will be used for navigation. The DLPFC will be located through MNI coordinates (-48, 26, 36) vs. (-41, 21, 38). The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, with a frequency of 10 Hz, 10 trains of 60 pulses/train (total of 600 pulses) and inter-train interval of 45s.
10196262|NCT00378378|Experimental|MFNS 100 mcg QD for subjects 6 to less than 12 years|Mometasone Furoate nasal Spray (MFNS) 100 mcg once per day (QD) for subjects 6 to less than 12 years of age
10196263|NCT00378378|Placebo Comparator|Placebo QD for subjects 6 to less than 12 years|
9716582|NCT04568369|Sham Comparator|Sham group|In the sham condition, a sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
9716583|NCT04568278|Experimental|Intervention Group|a mobile application using the PRO-CTCAE along with usual care
9716584|NCT04568278|No Intervention|Controlled Group|Usual care
9716585|NCT04568070|Experimental|Stroke|Stroke patients who applied to the Physical Medicine and Rehabilitation outpatient clinic, met the inclusion criteria and volunteered to participate in the study
9716586|NCT04568265|Experimental|APG-1387 12 mg combined with entecavir 0.5 mg|
9716587|NCT04568265|Experimental|APG-1387 20 mg combined with entecavir 0.5 mg|
10196264|NCT00378378|Experimental|MFNS 200 mcg QD for subjects 12 to less than 18 years|
9716588|NCT04568265|Experimental|APG-1387 30 mg combined with entecavir 0.5 mg|
9716589|NCT04568265|Experimental|entecavir 0.5 mg|
9716590|NCT04568226|Experimental|ConquerFear Intervention|Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.
9716591|NCT04568226|Active Comparator|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.
9716592|NCT04568252|Experimental|Intervention|Millimetric wave emission bracelet.
9716593|NCT04568252|Sham Comparator|Control|Placebo bracelet.
9716594|NCT04568343|Experimental|small bowel bleeding patient|with suspicious small bowel bleeding,patient will recieve Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule later for evaluations
9716595|NCT04568317|Experimental|Smartwatch group|iCBT intervention 'Space from Depression' with smartwatch as an additional means to self-report data on mood, sleep and physical activity in the 'Space from Depression' program (n=35).
9716596|NCT04568317|Active Comparator|Treatment as usual group|iCBT intervention 'Space from Depression' (n=35).
9716597|NCT04568291|Active Comparator|routine treatment|routine treatment
9716598|NCT04568291|Experimental|model treatment|model treatment
9716599|NCT04568421||Treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
9716600|NCT04568421||Not treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases not treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
9716601|NCT04568304|Experimental|Toripalimab Injection + chemotherapy group|
9716602|NCT04568304|Placebo Comparator|Placebo + chemotherapy group|
9716603|NCT04568096|Active Comparator|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
9716604|NCT04568096|Placebo Comparator|The standard therapy|The infected patients will receive the standard therapy for COVID-19 for 14 days
9716605|NCT04568057|Active Comparator|NIR Transcranial phototherapy device|The active transcranial phototherapy device. 1068 nm NIR Transcranial phototherapy PBM-T device An air-cooled LED helmet with a peak wavelength of 1068 nm, spectral width of 60 nm, and a 6-minute internal timer was used. The average optical power output of the combined arrays is circa 3.8 Watts, 12mw/sq. cm. The total energy to be delivered to the cranium is 1368J (3.8 x 360) per treatment session.
10196265|NCT00378378|Experimental|MFNS 200 mcg BID for subjects 12 to less than 18 years|
10196266|NCT00378378|Placebo Comparator|Placebo QD for subjects 12 to less than 18 years|
10196267|NCT00378378|Experimental|MFNS 100 mcg BID for subjects 6 to less than 12 years|
10196268|NCT00378378|Placebo Comparator|Placebo BID for subjects 6 to less than 12 years|
10196269|NCT00378378|Placebo Comparator|Placebo BID for subjects 12 to less than 18 years|
10196270|NCT00196742||Patients with Fabry disease|No experimental intervention is given. A patient with Fabry Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
10196271|NCT00196742||Pregnant women with confirmed diagnosis of Fabry|No experimental intervention is given. Pregnant women with confirmed diagnosis of Fabry that are participating in the Fabry Registry and consented to participate in the Fabry Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with agalsidase beta) and irrespective of the commercial product with which she may be treated.
9716606|NCT04568057|Placebo Comparator|Placebo Device.|Placebo cranial device. The external appearance of the device is identical to that of the active device but no NIR light is emitted.
9716607|NCT04568044||Group A: Mild to moderate COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
9716608|NCT04568044||Group B: Severe to critical COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
9716609|NCT04568044||Group C: Controls (non-pregnant)|"Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness.~A blood sample will be taken on 1 day and at 1 time point."
9716610|NCT04568044||Group D: Pregnant or postnatal with COVID-19|"Current pregnant or postnatal COVID-19 infected (age 18-50 years old) Pregnant or postnatal who were diagnosed with COVID-19 less than 8 months previously (age 18-50 years old). Singleton pregnancies only.~For most participants in this group, blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months).~However, for pregnant women admitted to hospital with severe COVID-19, we will aim to collect earlier timepoints (day 1-3, day 5-7 and then day 7-14). Thereafter, we will follow the above mentioned the long-term schedule (i.e. 1, 4, 8, 12 months)."
9716611|NCT04568044||Group E: Pregnant or postnatal with influenza|"Current pregnant or postnatal influenza infected (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
9716612|NCT04568044||Group F: Pregnant and have received the influenza vaccine|"Current pregnant and due to receive the influenza vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
9716613|NCT04568044||Group G: SARS-CoV-2 vaccinated pregnant/postnatal women|"Current pregnant or postnatal (within 6 weeks of birth) and due to receive the SARS-CoV-2 vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
9716614|NCT04568044||Group H: SARS-CoV-2 vaccinated non-pregnant women|"Non-pregnant and due to receive the SARS-CoV-2 vaccine (age 18-50 years old).~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
9716615|NCT04568187|Active Comparator|cryolipolysis machine on Left inner thigh|Zeltiq machine as intervention procedure was carried out on left inner thigh (treated side) for 1 hour through cool sculpting procedure with CIF (Cooling Intensity Factor: -73 mW/cm2).
9716616|NCT04568187|Sham Comparator|radiofrequency on right thigh|The radio frequency method was applied on right thigh (control side) as sham procedure for 30 minutes through 3000 Hz- amplitude modulated frequency at once.
9716617|NCT04568161|Experimental|pre and post chemotherapy assessments|The patients will be assessed before and after chemotherapy treatment.
9716618|NCT04568135||survey|
9716619|NCT04567966|Experimental|Cortical bone plate|A cortical plate was harvested from the external oblique ridge and split in half. Then one plate was fixed at a distance from the atrophied ridge and autogenous bone chips were used to fill the gap between the plate and the ridge.
9716620|NCT04567966|Active Comparator|Cortico-cancellous block graft|A cortico-cancellous block graft was harvested from the symphysis of the mandible and fixed to the atrophied ridge.
9716621|NCT04567797|Experimental|Exoskeleton|To compare the efficacy of four different exoskeleton devices, all participants will be asked to finish simulated construction tasks with each exoskeleton. Additionally, all participants will be asked to finish the same tasks without wearing an exoskeleton for reference.
9716622|NCT04568018||1 cohort|"Patients with mild ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
9716623|NCT04568018||2 cohort|"Patients with moderate ARDS, who are on spontaneous breathing.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
9716624|NCT04568018||3 cohort|"Patients with mild ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
9716625|NCT04568018||4 cohort|"Patients with moderate ARDS, receiving NIV and high-flow oxygen therapy.~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
9716626|NCT04567758|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
9716627|NCT04567758|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
10196272|NCT00185744|Experimental|Accelerated Partial Breast Irradiation|lumpectomy with accelerated partial breast irradiation
10196273|NCT00185744|Active Comparator|Standard Therapy|lumpectomy and whole breast irradiation
10196274|NCT00151424|Experimental|1|asenapine 5-10mg BID
10196275|NCT00151424|Placebo Comparator|2|Placebo
10196276|NCT00151424|Active Comparator|3|olanzapine 10-20 mg QD
10196277|NCT00089895|Experimental|Eptifibatide|Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
10196278|NCT00089895|Placebo Comparator|Placebo|Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
10196279|NCT02765854|Experimental|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
10196280|NCT02765854|Experimental|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
10196281|NCT02765854|Active Comparator|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
10196282|NCT02761057|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate PO on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
10196283|NCT02761057|Experimental|Arm II (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
10196284|NCT02761057|Experimental|Arm III (crizotinib closed to accrual 12/5/18)|Patients receive crizotinib PO BID on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
10196285|NCT02761057|Experimental|Arm IV (savolitinib closed to accrual 12/5/18)|Patients receive savolitinib PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
10196286|NCT02750540|Active Comparator|Product A dose|Product A will contain tenofovir (TFV) 220 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
10196287|NCT02750540|Active Comparator|Product B dose|Product B will contain tenofovir (TFV) *660 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
10196288|NCT02750540|Active Comparator|Product C dose|Product C will contain tenofovir (TFV) *660 mg in 125 mL hypo-osmolar solution at half the osmolarity of iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
10196289|NCT02750540|Placebo Comparator|Take-home normal saline (NS) enema|The normal saline (NS) solution will be provided following administration of Product A which is iso-osmolar. The volume of NS enema (120 mL) was selected to approximately match that of Product A (125 mL)
9716628|NCT04567901||Trauma Patients|The enrolled patients experienced trauma from different injuries and were hospitalized for treatment and admitted to the ICU. 700 older trauma patients (age equal to or more than 65 years) were finally included in the study.
9716629|NCT04567914||Adolescent idiopathic scoliosis|Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness of AIS patients diagnosed by a specialist. Spirometry evaluation was performed by the investigator
9716630|NCT04567914||Adolescent healthy individuals|Healthy adolescents aged 10-18 were selected. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness. Spirometry evaluation was performed by the investigator.
9716631|NCT04567875||CRPC patients|CRPC patients without evidence of distant metastasis are eligible
9716632|NCT04567823|Experimental|Microalgae I|Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans)
9716633|NCT04567823|Experimental|Microalgae II|Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans)
9716634|NCT04567823|Placebo Comparator|Smoothie|Smoothie (without microalgae) and standardised background diet (defined menu plans)
9716635|NCT04567823|No Intervention|Control|no intervention (no smoothie, no menu plans)
9716636|NCT04567953|Experimental|Saliva and NP paired specimen collection|
10196290|NCT02750540|Placebo Comparator|Take-home half normal saline (½ NS) enema|The ½ normal saline (½ NS) solution will be provided following administration of Product C which is hypo-osmolar. The volume of the ½ NS enema (120 mL) was selected to approximately match that of Product C (125 mL)
10196291|NCT02737956||AMI patients with treatment of PCI|All the patiets treat with PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
9716639|NCT04567771|Experimental|Treatment (radiation therapy, questionnaires)|Patients undergo standard of care proton or intensity modulated radiation therapy. Patients also complete quality of life questionnaires and adverse event assessments over 10-15 minutes each at baseline, at the end of radiation therapy, and at 1 month, 1 year, and 3 years post-radiation therapy.
9716640|NCT04567940|Experimental|Intervention group|Behavioural multicomponent intervention
9716641|NCT04567940|No Intervention|Control group|Usual care
9716642|NCT04568447|Experimental|IMOOVE|Patients will undergo IMOOVE® treatment for 6 weeks, two times per week for a total of 12 treatments.
9716643|NCT04567641||Enteral Nutrition|
9716644|NCT04567641||Parenteral nutrition|
10196292|NCT02737956||Medication|All the patiets treat with medication (standard secondary prevention) without PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
10196293|NCT02709161|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
10196294|NCT02709161|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
9716645|NCT04568356|Experimental|Antigen rapid test for COVID-19|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
9716646|NCT04567576||Exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed infection by 2019-nCoV (COVID-19) who at the time of diagnosis (of infection) receive pharmacological treatment with disease modifying antirheumatic drugs (DMARDs).
9716647|NCT04567576||Un-exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed 2019-nCoV (COVID-19) infection who at the time of diagnosis (of infection) are not receiving pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs).
9716648|NCT04568109|Experimental|Exposure-based cognitive-behavior therapy|Patients are treated in accordance with a manualized protocol (Gloster et al., 2011)
9716649|NCT04568109|No Intervention|Wait-List control condition|Patients are assessed prior to and after a 12-week waiting period. Patients are treated after this 12-week delay.
9716650|NCT04567628||TDM Cohort|Participants diagnosed with inflammatory bowel disease (IBD) (UC or CD) within Takeda Canada Patient Support Program (PSP) group who received treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 along with the biomarker testing and TDM at pre-specified intervals during their treatment will be observed retrospectively.
9716651|NCT04567628||Historical Cohort|Participants diagnosed with IBD (UC or CD) within Takeda Canada PSP group who received treatment with vedolizumab 300 mg, infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 but did not undergo biomarker testing or TDM during their treatment will be observed retrospectively.
9716652|NCT04568083||Ticagrelor cohort|Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.
9716653|NCT04568083||Non-ticagrelor cohort|Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.
9716654|NCT04568330|Other|Best support care (BSC)|Interventions for comparison group (group C) who received BSC alone were (1) informed of potential presentations of HFSR, (2) asked for wearing waterproof gloves before execute household or work with water, (3) provided the method of contacting with healthcare specialists for confirming early diagnosis of HFSR, and (4) asked for self-report when they occurred symptoms of HFSR.
9716655|NCT04568330|Experimental|BSC plus moisture cream|The A group with BCS plus moisturizing cream received the interventions as the comparison group, was given the moisturizing cream (dimethicone, fragrance free, Aveeno, United States) for 9 times and was instructed how to use the cream. The education of usage included (1) using the cream twice a day from 3 days before starting sorafenib and each week post starting sorafenib, (2) scooping out nut-sized cream with a unique spoon each time, (3) gently applied the cream evenly on symmetrical palms below wrists and symmetrical soles below ankles each time, (4) wore unique cotton gloves immediately after the appalment of cream for 30 minutes each time.
9716656|NCT04568330|Active Comparator|10% urea-based cream|The B group with BCS plus 10% urea-based cream had the similar interventions as the A group with BCS plus moisturizing cream except being given the cream container with different component (10% urea; Sipharr, Taiwan). The outlook of the containers with the two kinds of cream was the same. All the cream looks white and grey.
9716657|NCT04567459|No Intervention|control group: chemotherapy|No intervention
9716658|NCT04567459|Experimental|experimental group: chemotherapy and nutrition support|Premium amino acids 1pc bid for 6 months
9716659|NCT04567446||Patients who will start cancer treatment|"Collection of biological samples (stool, blood, saliva) and data from patients included in the study will be performed:~By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).~Collection of biological resources (all samples will be collected in fresh):~Stool: collected at diagnosis, before initiating anticancer treatment, during treatment~Blood: 40 mL collection before, 3 and 6 months of treatment cancer~Saliva: 5 mL collection before initiation of treatment cancer~Collection of clinical data corresponding to each patient included in the study by a clinical research assistant"
9716660|NCT04567433||CHEST Study|Participants in the CHEST trial long term sepsis cohort
9716661|NCT04567433||ARISE Study|Participants in the ARISE study long term follow-up cohort
9716662|NCT04567433||ADRENAL study|Participants in the ADRENAL study
9980485|NCT01392222||patients who have had surgery or have scheduled surgery|In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
9984507|NCT04028843|Experimental|Healthy Beginnings|Participants will receive the SmartMoms smartphone application, a wireless connected scale, and a Fitbit. The Healthy Beginnings program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the SmartMoms smartphone application, personalized feedback from counselors, and evidence-based behavioral intervention delivered throughout pregnancy.
9984508|NCT04028206|No Intervention|Control Group|No intervention on sarcopenic subjects screened (based on the AWGS definition).
10196295|NCT02682836|Experimental|single arm|Walk with Ease physical activity intervention
10196296|NCT02600936||Registry|A retrospective and prospectively maintained registry of patients who have undergone or will undergo vein stent placement for proximal venous outflow obstruction
10196297|NCT02600182|Experimental|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
10196298|NCT02600182|No Intervention|Control|Routine physical therapy will be performed.
10196299|NCT02589522|Experimental|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
10196300|NCT02589522|Experimental|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
10196301|NCT02577354|Experimental|Treatment|
10196302|NCT02577354|Experimental|Control|
9716663|NCT04567472|Experimental|Online HEADS: UP|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
10196303|NCT02551718|Experimental|Treatment (chemosensitivity testing, chemotherapy)|Leukemia cells purified from blood or bone marrow samples are analyzed for sensitivity to individual drugs and drug combination and by next generation sequencing.
10196304|NCT02549144|Experimental|High fat/cholesterol diet|High-fat/high-cholesterol (HFHC) normocaloric diet for 14 days.
10196305|NCT02549144|Experimental|Low fat/cholesterol diet|Low-fat/low-cholesterol (LFLC) normocaloric diet for 14 days.
10196306|NCT02520791|Experimental|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
10196307|NCT02474173|Experimental|Treatment (onalespib, paclitaxel)|"SAFETY RUN-IN: Patients receive onalespib IV over approximately 1 hour on day -7.~TREATMENT: Patients receive paclitaxel IV over 60 minutes on day 1, 8, and 15. Patients also receive onalespib IV over 1 hour beginning on days 8 and 15 of cycle 1 and on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
10196308|NCT02471807|Experimental|Edwards FORMA Tricuspid Transcatheter Repair System|Edwards FORMA Tricuspid Transcatheter Repair System
9716664|NCT04567394|Experimental|Intervention|Participants randomized to the Intervention group will complete questionnaires at baseline, 1 month, 3 months, and 6 months and will receive 4 weeks of the PNC-txt intervention.
9716665|NCT04567394|No Intervention|Waitlist Control|Participants randomized to the waitlist control group will complete questionnaires at baseline, 1 month, 3 months, and 6 months.
9716666|NCT04567563|Active Comparator|Remote Ischemic Condition|
9716667|NCT04567563|No Intervention|Standard of Care|
9716668|NCT04567238|Experimental|Reduced Use Condition|Participants in the reduced use condition will be provided mobile contingency management, in which they are paid to provide marijuana saliva readings that suggest they have been abstinent from marijuana use.
9716669|NCT04567238|No Intervention|Control Condition|Participants in the control condition will be asked to provide marijuana saliva readings, but they are not paid for abstinent readings. Instead, their payments are yoked to the average amount of payment made by two participants in the reduced use condition.
9716670|NCT04567147|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus casei, Bafidobacterium animals, Bifidobacterium longum, Bifidobacterium bidium and Lactobacillus plantarum, each at a dosage of 3.0E+10 CFU per 2g sachet.
9716671|NCT04567147|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
9716672|NCT04567199||Cytosorb recipients|"Patients receiving Cytosorb due to septic shock.~SOFA score, Changes in catecholamine support after CytoSorb initiation Survival to discharge ICU Survival >28d Thromboembolic events~General data:~Need of catecholamines Type of extra-corporal treatments Anticoagulation medication Concomitant allogenic blood products Concomitant factor concentrates Bleeding events Vital signs Underlying Disease SAPSII, SAPSIII, SOFA Scores (on 1st day of treatment) Type of Pathogen (gram+, gram-, fungi) Sepsis Multi Organ Failure~Data records:~Myoglobin, CK (creatine kinase), CK-MB, Fibrinogen D-dimers, Antithrombin III, Procalcitonin Creatinin, urea, Natrium, Potassium, Bilirubin, GOT (glutamate-oxalacetate transaminase), GPT, GGT (glutamate-pyruvate transaminase), PT (prothrombin time) aPTT (activated partial thromboplastin time) CRP (C reactive protein) Blood count Further parameters if of interest"
9984509|NCT04028206|Active Comparator|Exercise + HMB Group|Sarcopenic subjects on combined treatment of elastic-band exercise and HMB supplementation
9984510|NCT04028206|Active Comparator|Vibration Treatment + HMB Group|Sarcopenic subjects on combined treatment of vibration treatment and HMB supplementation
10196309|NCT02321514|Experimental|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement
10196310|NCT02207504|Experimental|crizotinib and enzalutamide|"A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.~Crizotinib- given orally daily-28 day cycle~Enzalutamide- given orally daily-28 day cycle"
10196311|NCT02196961|No Intervention|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
10196312|NCT02196961|Experimental|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
10196313|NCT02118610|Experimental|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
10196314|NCT02118610|Placebo Comparator|Sugar Pill|
10196315|NCT02083250|Experimental|Treatment (vorinostat, chemotherapy, SCT)|"CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.~TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0."
10196316|NCT01909570|Experimental|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
9716673|NCT04567199||Non Cytosorb recipients|"Patients not receiving Cytosorb due to septic shock.~Patients not treated with CytoSorb under suspicion for inflammation, septic shock or SIRS will be searched for same characteristics as the first group.~These groups will be matched when parameters like epidemiology, infectious parameters, prognostic scores, age, gender amount of catecholamines fit best.~Parameters as in Group of Cytosorb recipients"
9716674|NCT04567225|Experimental|Early Glargine|All consecutive adult patients getting admitted to Medical ICU and meet the inclusion criteria and accepted to receive insulin glargine early as per the protocol. They will receive insulin glargine 0.4 unit/kg within 4 hours from initiating the IV Insulin Infusion, as per the Cleveland Clinic DKA protocol.
9716675|NCT04567225|Active Comparator|Standard practice (Late Glargine)|Retrospective, prespecified and matched sample of consecutive adults who admitted to the same Medical ICU with a diagnosis of DKA in the period between January 1st 2019 till the Institutional Review Board (IRB) approval date and didn't receive basal insulin before Anion Gap closure.
9716676|NCT04567290|Experimental|Chewed ticagrelor|"Ticagrelor pills. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement and after signed informed consent. Patients will be asked to chew, but not to swallow, during at least 40 seconds in presence of investigation staff.~Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed"
9716677|NCT04567290|Active Comparator|Swallowed ticagrelor|"Ticagrelor integral tablet. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement is drawn. Patients will swallow the loading dose followed by 25-40 ml of water.~Drug: ticagrelor (Brilinta) 90 mg tableta, 2 tablets swallowed"
9716678|NCT04567108|Active Comparator|Maintain SSBs (Control)|Instruction to maintain baseline intake of SSBs
9716679|NCT04567108|Experimental|Substitute Aspartame ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with aspartame
9716680|NCT04567108|Experimental|Substitute Sucralose ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with sucralose
9716681|NCT04567108|Experimental|Substitute Water|Instruction/guidelines to eliminate SSBs and replace with water
9716682|NCT04567043|Experimental|Mindfulness-Oriented Recovery Enhancement+JITAI|Participants will attend a telehealth Mindfulness-Oriented Recovery Enhancement (MORE) group plus mindfulness JITAI weekly for eight weeks.
9716683|NCT04567043|Active Comparator|Supportive Psychotherapy|Participants will attend a telehealth supportive psychotherapy group weekly for eight weeks.
9716684|NCT04567524|Active Comparator|Arm 1|"• LYN-005: Size 00EL capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone.~AND~• IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient."
9716685|NCT04567524|Placebo Comparator|Arm 2|"• LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate.~AND~• IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets."
9716686|NCT04567316|Experimental|[14C]-radiolabelled BI 1358894|[14C]-radiolabelled BI 1358894 (part 1)
9716687|NCT04567316|Experimental|BI 1358894|BI 1358894 (part 2)
9716688|NCT04567329|Experimental|NOV03|100% perfluorohexyloctane 4 times daily (QID)
9716689|NCT04567329|Placebo Comparator|Saline solution|0.6% sodium chloride solution 4 times daily (QID)
9716690|NCT04566952|Experimental|Anlotinib combined With dose-reduced olaparib|Anlotinib-olaparib combination therapy until disease progression
9716691|NCT04567173|Experimental|Anti-SARS-CoV-2 convalescent plasma|About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
9716692|NCT04567173|No Intervention|Standard of care|Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways
9716693|NCT04566848||Gastrointestinal cancers|Patients with advanced stage colorectal cancer, gastric cancer and pancreatic cancer who develop malignant ascites
9716694|NCT04566848||Control|Patients with intraabdominal ascites with benign reasons (liver cirrhosis, Congestive heart failure, etc.) .
9716695|NCT04567069|Experimental|DC vaccine|Vaccine made from autologous dendritic cells loaded with MG-7 antigen.
9716696|NCT04567069|Experimental|DC vaccine + CTL (cytotoxic lymphocyte)|Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.
9716697|NCT04567069|Experimental|DC vaccine + PD-1 monoclonal antibody (Sintilimab Injection)|Sintilimab injection is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
9716698|NCT04566874|Other|Spira-A with HCT/p DBM|Single level Spira-A 3D printed Titanium ALIF Device with HCT/p DBM
9716699|NCT04566874|Active Comparator|Medtronic PEEK ALIF with Infuse|Single level Medtronic Divergent-L/Perimeter PEEK ALIF Device with Recombinant Bone Morphogenic Protein-2 (Infuse)
9984511|NCT04024787|Experimental|Immediate intervention|
9984512|NCT04024787|No Intervention|Waitlist|
9984513|NCT04021394||Non-metastatic, high-risk hormone sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
10196317|NCT01909570|Active Comparator|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
9716700|NCT04566809|Experimental|Experimental group: FES+CBA|FES+CBA participants executed FES and CBA treatment which means that during the stimulation they manipulated different tools. In particular, for the first ten sessions the participants were invited to manipulate specific objects: squares, rectangles and pyramids of different sizes; touch on plastic test tubes coated with materials of different consistency; these two exercises were performed both with open and closed eyes. Finally, for the last ten sessions the participants were asked to execute specific tasks, depending on person's life before the lesion.
9716701|NCT04566809|Active Comparator|Control Group: FES|FES participants received only FES to improve their manipulating skills without the interaction with objects, but only with the muscle contraction induced by the devices.
10196318|NCT01857934|Experimental|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.~Cells for infusion are prepared using the CliniMACS System."
9716702|NCT04566796|Active Comparator|(Group N)|patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.
9716703|NCT04566796|Experimental|(Group S)|the patients will receive Sugammadex 2mg/kg IV. As the reversal agent
9716704|NCT04567212||Male-group|in this group we will enroll only male with asthma
9716705|NCT04567212||Female-group|in this group we will enroll only female with asthma
9716706|NCT04566913|Experimental|Patients recruited from Cairo University|"After Cone beam CT assessment , The patient is assigned for nonsurgical periodontal phase then an impression is taken for stent formation to facilitate tissue thickness measurement .~> After 2 weeks , the patient is assigned for surgical phase to extract the palatal and apical aspect of the tooth and leave the buccal portion .~Socket preservation is attempted in the socket , using 'genbioss ' bone graft. Modified free gingival graft is done on the pontic site to cover the buccal root shield and the bone graft .~Post operative instructions include :~Analgesics (Prufen 400 mg ) three times for three days~Antibiotic (Augmentin 1gm ) twice daily for one week The patient will be assured to contact the operator of any unexpected complications occured ."
9779769|NCT04910815|Placebo Comparator|Active SIBO Arm - Placebo|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of placebo capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
9779770|NCT04907305||Feed-forward PRO|Participants in this group will participate in monthly learning collaborative webinars. Feed-forward of patient reported outcomes (PRO) data collected from the main study (NCT04735406) will be used.
9779771|NCT04907305||Control Group (Usual Care)|Participants in the control group will receive usual care practices during the clinical encounters.
9779772|NCT04906395|Experimental|Active Comparator: TOL2506|TOL2506 in combinatination with standard endocrine therapy (Tamoxifen & Aromatase Inhibitors)
9779773|NCT04906018||volunteer group - BMI less than 30|Each subject with a BMI less than 30 will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
9779774|NCT04906018||volunteer group - BMI of 30 and above|Each subject with a BMI of 30 and above will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
9779775|NCT04902703|Experimental|Sargramostim|250 mcg/m2/day subcutaneously 5 days/week for 24 weeks
9779776|NCT04902703|Placebo Comparator|Placebo Control - Saline|Placebo comparator (saline) subcutaneously 5days/week for 24 weeks
9779777|NCT04898673|Experimental|CP1110 Sound Processor|
9779778|NCT04898673|Active Comparator|CP1000 Sound Processor.|
9779779|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
9779780|NCT04886973|Experimental|Subjects with a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) < 2.5|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids. The dose will be calculated considering the 25% of the estimated protein per day (1 g/kg/day). This dose will be placed in a short peripheral intravenous catheter and administered at a rate of 1.5ml per minute, using an infusion pump. The patient will be monitored all the time by a physician.
9779781|NCT04881045|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07257876 at escalating dose levels.
9779782|NCT04881045|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1.
9779783|NCT04881045|Experimental|Dose Expansion (Part 2) - Cohort 2 (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1.
9779784|NCT04880850|Experimental|insulin icodec + insulin aspart|Participants will get once weekly injections in combination with 2-4 times daily injections of insulin aspart
10196319|NCT01841177|Experimental|Therapeutic Drug Monitoring|The intervention is [1] regular measurement of milrinone levels; [2]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
9716707|NCT04566835|Experimental|Education Group|Taking the Health Promotion Program with cartoons and comics for Children with Asthma
9716708|NCT04566835|Other|Control Group|Taking standart care
9716709|NCT04567030|Experimental|Experimental group A (AI Group: EG-A)|Behavioral: AI intervention For the EG-A, a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
9716710|NCT04567030|Experimental|Experimental group B (AI with humanized Group: EG-B)|"Behavioral: AI intervention For the EG-B,a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.~The humanized counseling will also send to patients' mobile phone about each patients oral hygiene condition and advises."
9716711|NCT04567030|No Intervention|Control group (CG)|the control group(CG) only have standard oral hygiene education
9716712|NCT04567004|Other|Control|The control arm will show the products with no label.
9716713|NCT04567004|Experimental|Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
9716714|NCT04567004|Experimental|Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
9716715|NCT04567004|Experimental|Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
9716716|NCT04566770|Experimental|MID A|20 participants(18-49), Ad5-nCoV , two doses, Intramuscular administration
9716717|NCT04566770|Placebo Comparator|MID B|10 participants(18-49), Ad5-nCoV-placebo , two doses, Intramuscular administration
10196320|NCT01841177|Active Comparator|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
10196321|NCT01817192|Active Comparator|Observation|Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
10196322|NCT01817192|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.
10196323|NCT01789983||Breast Cancer Patients 60+|Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease.
10196324|NCT01789983||Lung Cancer Patients 60+|Lung Cancer Patients age 60 and above who have stage I, II or III disease
9716718|NCT04566770|Experimental|MIN A|100 participants(6-17), Ad5-nCoV , two doses, Intramuscular administration
9716719|NCT04566770|Placebo Comparator|MIN B|50 participants(6-17), Ad5-nCoV-placebo , two doses, Intramuscular administration
9716720|NCT04566770|Experimental|OLD A|100 participants(56 years of age and above), Ad5-nCoV , two doses(Low dose), Intramuscular administration
9716721|NCT04566770|Experimental|OLD B|100 participants(56 years of age and above), Ad5-nCoV , two doses(Middle dose), Intramuscular administration
9716722|NCT04566770|Placebo Comparator|OLD C|50 participants(56 years of age and above), Ad5-nCoV-placebo , two doses, Intramuscular administration
9716723|NCT04566770|Experimental|EBOV A|34 participants, Ad5-nCoV , two doses, Intramuscular administration
9716724|NCT04566770|Placebo Comparator|EBOV B|17 participants, Ad5-nCoV , two doses, Intramuscular administration
10196325|NCT01789983||Colon Cancer Patients 60+|Colon cancer patients age 60 and above who have stage II or III disease.
10196326|NCT01721343|Experimental|Arm I (enhanced usual care)|Patients undergo enhanced usual care comprising telephonic monitoring with monthly status reports provided to their oncology care teams for 6 months.
10196327|NCT01721343|Experimental|Arm II (enhanced usual care, RCM)|Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered telephonically by the Fitness Care Manager (FCM) and adapted, as required, by a local physical therapist for 6 months.
10196328|NCT01721343|Experimental|Arm III (enhanced usual, RCM, PCM)|Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the FCM as in Arm II, and receive optimized pain management through a nurse Pain Care Manager (PCM) for 6 months.
9716725|NCT04566783||Women and men fulfilling PGAD-criteria|"Inclusion criteria:~- Female and male patients or subjects between 18-65 years of age fulfilling the diagnostic criteria of persistent genital arousal disorder (PGAD) according to Leiblum & Nathan (2001).~Exclusion criteria:~- Any exclusion criteria for magnetic resonance imaging (MRI), mental retardation, severe and acute somatic or mental disease such as acute psychosis, brain damage, Alzheimer's disease, severe bacterial infection requiring immediate medical treatment.~Age:~- 18 - 65 years of age~Gender:~- Female and male subjects"
9716726|NCT04566783||Controls|"Inclusion criteria:~- Age and education matched healthy controls."
9716727|NCT04566757|Experimental|Umbilical Cord Plasma Infusion|Infusion of 50cc of Umbilical Cord Blood Plasma bi-monthly for 6 months
9716728|NCT04566861|Experimental|Anxious pregnant women - intervention group|100 pregnant women who have at least mild anxiety will be randomized to the intervention group where they will receive six one-on-one core sessions of Cognitive Behavioral Therapy during pregnancy (plus possible booster sessions)
9716729|NCT04566861|No Intervention|Anxious pregnant women - enhanced usual care group|100 pregnant women who have at least mild anxiety will be randomized to the enhanced usual care group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
9716730|NCT04566861|No Intervention|Non-anxious pregnant women - healthy control|100 pregnant women who do not have symptoms of anxiety or depression be followed in the healthy control group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
9716731|NCT04566523||Control Group|Chronic respiratory patients who undergo a home-based exercise training program with a rehabilitation coach supervision.
9716732|NCT04566523||Tele Group|Chronic respiratory patients who undergo a home-based exercise training program online.
9716733|NCT04566822|Experimental|High-touch intervention|"6 live video coaching sessions~Coaching/feedback is tailored to the individual and adaptive to their progress~Member can send the Coach messages between sessions, but the Coach will not respond until the live session"
9716734|NCT04566822|Experimental|medium-touch intervention|"3 live video coaching sessions~2 live videos are optional (recommended for end of Weeks 3 and 5, but member can take advantage of them anytime)~2-4 pre-recorded video sessions at end of the week. Pre-recorded videos provided in the absence of live sessions~Chat messaging between sessions with 24-48 hour response time"
9716735|NCT04566822|Experimental|low-touch intervention|"1 Live video coaching session (week 1)~Chat messaging with 24-48 hour response time"
9716736|NCT04566822|Sham Comparator|Sleep education control|"Weekly sleep education for six weeks~No interaction with coach"
9980486|NCT01392222||who chose to not have immediate surgery|In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
9980487|NCT01392235|Experimental|Drug: Famitinib|
9980488|NCT01392274||pCLE|This trial will study only one group which will receive a standard ERCP procedure followed by pCLE
9984514|NCT04021394||Low-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
9716741|NCT04566744|Experimental|Physical tool use, tool making and construction|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a physical tool, making a physical tool or building a construction. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools as well as when we build constructions.
9716742|NCT04566744|Experimental|Use of modern physical tools and stone tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a modern physical tool or a stone tool. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools irrespective of whether they are modern or old (i.e., stone tools).
9716743|NCT04566744|Experimental|Use of modern physical, arbitrary and digital tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when watching video clips of individuals using either a modern physical tool, an arbitrary tool (e.g., a washing machine) or a digital tool (e.g., a touchscreen). Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we observe others using different kinds of tools, which have appeared progressively over technological evolution.
9716744|NCT04566744|Experimental|Physical tool use and Internet|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when estimating the capacity to solve a mechanical problem with modern physical tools either alone or with the help of a Internet Tutorial. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we imagine and estimate solving a mechanical problem alone or with the help of the Internet;
9716745|NCT04566679|Experimental|Butyrate|oral butyrate (500mg) once or twice per day
9716746|NCT04566679|Placebo Comparator|Placebo|oral placebo once or twice per day
9716747|NCT04566341||Feasibility of OCT TCE in identifying signs of PD|Participants that fulfill our Inclusion/Exclusion criteria will be asked to swallow our Capsule Imaging device.
9716748|NCT04566471||PPP and GPP|Palmoplantar pustulosis (PPP) and Generalized pustular psoriasis (GPP) are rare chronic inflammatory skin diseases, characterized by repeated episodes of sterile pustules in several months or years, associated with erythrokeratodermia generally. Both two diseases are easy to cause skin rupture, leading to bleeding and pain.
9716749|NCT04566718||Group A|Obese women who have been treated with metformin for one year prior to the study.
9716750|NCT04566718||Group B|Obese women who have been treated with metformin for at least three years prior to the study.
9716751|NCT04566549|Placebo Comparator|Placebo group|Shampoo base without probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance.
9716752|NCT04566549|Active Comparator|Test group|Shampoo base with probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance、Heat-killed Lactobacillus paracasei powders (5x10^8 cells/ g-shampoo).
9984515|NCT04021394||High-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
9716753|NCT04566705||Women with uterine rupture|Women with uterine rupture
9716754|NCT04566705||Women without uterine rupture|Women without uterine rupture
9716755|NCT04566588|Experimental|Early apical release holmium enucleation of the prostate|Early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
9716756|NCT04566588|Active Comparator|Classic holmium enucleation of the prostate|Classic holmium enucleation of the prostate (HoLEP), as a surgical treatment for benign prostatic hyperplasia
10196329|NCT01697527|Experimental|Treatment (gene and vaccine therapy)|"CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~TRANSPLANT: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV on day 0. Patients also receive NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy ID on days 1, 14, and 30 and aldesleukin SC BID on days 1-14. Patients may receive 3 additional doses of NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy after day 90."
10196330|NCT01591577|Experimental|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
9716757|NCT04566614||Biliary Tract Cohort|Patients with suspected biliary tract cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
9716758|NCT04566614||Bladder Cancer Cohort|Patients with suspected bladder cancer (localised and metastatic) will be offered ctDNA to support their diagnosis, in cases where cystoscopy and biopsy are difficult to obtain due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. A positive ctDNA result will be supportive of a diagnosis of bladder cancer, their treatment may be prioritised and decided based on this result in conjunction with radiological findings, patient presentation and after discussion between the treating physician and patient
9716759|NCT04566614||Pancreatic Cancer Cohort|Patients with suspected pancreatic cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
9716760|NCT04566614||Gastrointestinal Stromal Tumour Cohort|Those with suspected Gastrointestinal Stromal Tumour Cohort (GIST) are eligible for this study. KIT and PDGFR mutation detected using ctDNA in conjunction with radiological features will be supportive of a diagnosis of GIST. This may allow for the use of directed targeted therapy, or prioritise surgical resection in some cases. Patients with histological diagnosis will not be eligible for this study. However, patients with inadequate tissue for KIT/PDGFR analysis will be eligible for PREVAIL-ctDNA to confirm the diagnosis of GIST and help guide treatment decisions
9716761|NCT04566614||Lung Cancer Cohort|The use of ctDNA in the diagnosis and adaptive management of patients with lung cancer is well established, however not funded by NHS. As aerosol-generating bronchoscopy procedures have reduced due to the COVID-19 pandemic, patients with suspected lung cancer may be offered ctDNA to support the diagnosis. A positive ctDNA result in conjunction with radiological findings will assist in prioritising those suitable for upfront surgical resection, radiotherapy or systemic anti-cancer treatment. It may provide sufficient genotypic information to guide standard of care targeted therapies (usually two tests are required - biopsy and then next generation sequencing of extracted DNA), including in patients without sufficient tissue for EGFR and ALK testing which can be detected using ctDNA. The use of ctDNA to guide treatment decisions in this cohort will not require signed consent as it is considered a standard approach (not yet NHS funded)
10196331|NCT01572714|Active Comparator|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
9716762|NCT04566614||Colorectal Cancer Cohort|Patients with suspected colorectal cancer will often be referred following either suspicion on imaging or faecal immunochemical testing (FIT). FIT testing results will be used to prioritise patients for screening colonoscopy, in conjunction with the PREVAIL-imaging risk stratification pathway
9716763|NCT04566315|Other|ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS|SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
9984516|NCT04021394||Metastatic castrate-resistant prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
9716764|NCT04566627|Experimental|YSLQQ group|"Schools in this group implemented Yo Sé Lo Que Quiero program. This is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
9716765|NCT04566627|No Intervention|Control Group|Schools in this group implemented the usual preventive actions to reduce substance use. Usually, these actions are not manualized.
9716766|NCT04566237|Experimental|24 months follow up after vitrectomy|Objective Scatter Index (OSI) and Average Lens Density (ALD) at inclusion, then 3 months, 12 months and 24 months after vitrectomy
9716767|NCT04566354|Other|Sprint exercise|Three bouts of 30-s sprint exercise with 20 min rest in between. Three fat biopsies obtained ar rest before first sprint, 15 min after and 120 min after third sprint Blood samples from stomach vein and arteria during the whole experiment
9716768|NCT04566224|Experimental|Macintosh 2 group|Using Macintosh size 2 blade for direct laryngoscope intubation according to randomization
9716769|NCT04566224|Active Comparator|Macintosh 3 group|Using Macintosh size 3 blade for direct laryngoscope intubation according to randomization
9716770|NCT04566120|Experimental|Cinnamon extract mouthwash|Participants will be exposed to cinnamon extract mouthwash and will be instructed to use 10 ml of cinnamon extract mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
9716771|NCT04566120|Active Comparator|Chlorohexidine based mouthwash|Participants will be exposed to chlorohexidine based mouthwash. and will be instructed to use 10 ml of 0.12% chlorhexidine based mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
9716772|NCT04566458||Single arm|Her2 positive mBC patients who have received at least 3 lines of treatment in the metastatic setting.
9716773|NCT04566562||Study Group|Brain scans, cognitive tests, blood biomarkers
9716774|NCT04566367|Active Comparator|Standard White Light Imaging|In this group the participants will be examined by white light endoscopy first and secondly with blue laser imaging technique during the same gastroscopy.
9716775|NCT04566367|Experimental|Blue Light Imaging|In this group the participants will be examined by blue laser imaging technique first and secondly with standard white light during the same gastroscopy.
9716776|NCT04566107|No Intervention|Enhanced Usual Care|The enhanced usual care group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, individuals in the enhanced usual care group will receive the mobile health platform to record medications taken and BlueTooth devices to record physiologic measurements.
9716777|NCT04566107|Experimental|mHealth|The mHealth group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Subjects receive BlueTooth devices to record physiologic measurements.
9716778|NCT04566107|Experimental|mHealth Plus|The mHealth group plus will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth plus group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Participants receive BlueTooth devices to record physiologic measurements. The m-Health Plus group will receive real-time virtual visits with a nurse practitioner/community health worker team. Virtual visits are similar to an office follow-up visit with an health care provider using Zoom technology to allow for face-to-face interaction with the patient.
9716779|NCT04566146|Other|45 patients with subacromial impingement syndrome|Forty-five patients between the age 18 and 45 years old, will be referred by orthopaedist as subacromial impingement syndrome (stage Ⅰ and ⅠⅠ Neer's classification)
9716780|NCT04566055||Prospective observational cohort|
9716781|NCT04566042|Experimental|ACT video game|
9716782|NCT04566081|Active Comparator|iTALKbetter: deterministic|"Participants will receive the deterministic version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter:deterministic version will randomise the order all of the words that are to be trained and participants will cycle through all of these words regardless of their performance until complete at which point the order is re-randomised and participants begin the cycle again."
9716783|NCT04566081|Active Comparator|iTALKbetter: reactive|"Participants will receive the reactive version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.~iTALKbetter reactive version is identical to the deterministic version for the first cycle only. From then on the words participants are trained on can change depending on their performance on that word over a number of cycles. Words that participants are failing to retrieve over a number of cycles will be retired from the therapy as they are deemed too difficult for a given participant. Similarly words that are correctly retrieved over a number of consecutive cycles are also retired from the therapy as they are deemed to have been learned. In this way iTALKbetter reactive version will gradually give each participant a personalised corpus of words that they can train on, focusing on the words where they stand to make the most improvements."
9716784|NCT04566302|Experimental|SECM Skin Imaging|The SECM skin imaging procedure will be very similar to that by the FDA approved RCM devices. First, the skin lesion (such as a mole) will be identified on a forearm of the subject. The lesion will be imaged first with a dermatoscope, and then with the SECM device. A dermatoscope is a hand-held device used for the visual observation of the epidermis. It is a superior surface contact microscope used to examine skin lesions.
9716785|NCT04566211|Experimental|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
9716786|NCT04566211|Active Comparator|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
9716787|NCT04565912|Experimental|Sage extract mouthwash|Natural product mouthwash
9716788|NCT04565912|Active Comparator|Chlorohexidine mouthwash|Synthetic mouthwash
9716789|NCT04565964|Other|Health behaviors|Health behavior intervention for one month will be provided to every participant. We will teach children's guardians (care-giver) how to change the health behaviors to clean indoor environment, including the health behaviors in bedroom, kitchen room, restroom, refrigerator, washing machine, and incense burning hall.
9716790|NCT04565626|Experimental|Intervention|Participants will receive additional exercise by independent use of a peddle bike on the weekends. This is in addition to their usual physiotherapy
10196332|NCT01572714|Active Comparator|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
10196333|NCT01572714|Active Comparator|Physical Activity Plus Fatigue|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
9716791|NCT04565626|No Intervention|Control|This arm will receive usual physiotherapy
9716792|NCT04565613|No Intervention|Standard care group|The participants will receive feeding as per standard of care (without protein or any other supplementations).
9716793|NCT04565613|Experimental|Study interventional group|The participants will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds.
9716794|NCT04565678|Experimental|Treatment Sequence 1: ABCD|Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
9716795|NCT04565678|Experimental|Treatment Sequence 2: BDAC|Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
9716796|NCT04565678|Experimental|Treatment Sequence 3: CADB|Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
9716797|NCT04565678|Experimental|Treatment Sequence 4: DCBA|Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
9716798|NCT04565639|Experimental|Experimental Power Hand Orthosis|Participants will test the improved grip strength using the powered hand orthosis system.
9716799|NCT04565639|Experimental|Experimental Power Hand Orthosis - Tasks of Daily Living|Participants will test the improved ability to perform tasks of daily living using the powered hand orthosis system.
9716800|NCT04565587|Other|Videofluoroscopy|All participants will undergo a Videofluoroscopy when swallowing different viscosity levels of the thickener Tsururinko Quickly (japanese thickener)
9716801|NCT04565652|Experimental|ICD Defibrillation|Detection of ICD shock during elective ICD implant using the investigational device
9716802|NCT04565886|Sham Comparator|control|Non-surgical mechanical instrumentation 3x. Each time the laser will be held in place but will not be activated.
9716803|NCT04565886|Experimental|laser|Non-surgical mechanical instrumentation 3x with adjunctive diode laser application according to the protocol of the Department of Periodontology, University of Bern
9716804|NCT04565847|Active Comparator|Healthy Control - Active Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
9716805|NCT04565847|Placebo Comparator|Healthy control - Placebo Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized 0.9% Saline given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
9716806|NCT04565860|Active Comparator|X-tra fil (bulk-filling) (X-traB)|X-tra fil composite placed as bulk-filling
10196334|NCT01516190|Active Comparator|Exercise Group|Supervised exercise sessions and independent exercise
10196335|NCT01516190|Active Comparator|Mind-Body Group|Surgical preparation program
10196336|NCT01512888|Experimental|Treatment|Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT
10196337|NCT01453946|Other|Entocort|Study Medication
10196338|NCT01444092|Experimental|Entocort|Study Medication
9716807|NCT04565860|Active Comparator|X-tra fil (incremental) (X-traI)|X-tra fil composite placed as incremental
9716808|NCT04565860|Active Comparator|Filtek Bulk (bulk-filling) (FBB)|Filtek Bulk composite placed as bulk-filling
9716809|NCT04565860|Active Comparator|Filtek Bulk (incremental) (FBI)|Filtek Bulk composite placed as incremental
9716810|NCT04565938|Experimental|one-step self-etch adhesive with enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive with enamel etching
9716811|NCT04565938|Experimental|one-step self-etch adhesive without enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive without enamel etching
9716812|NCT04565938|Experimental|two-step etch-and-rinse adhesive|Non carious cervical lesions which will receive composite-resin restorations, with a two step etch-and-rinse adhesive
9716813|NCT04565873||P1|Primigravida in group 1
9716814|NCT04565873||M1|Multipara in group 1
9716815|NCT04565873||P2|Primigravida in group 2
9716816|NCT04565873||M2|Multipara in group 2
9716817|NCT04565704|Experimental|Development of novel optical imaging technologies|Consented participants will allow their endoscopist to collect 3 additional biopsies from the participants. These biopsies will be used to develop our imaging techniques at our lab. We will use the standard of care histology images from the endoscopy procedure as a control comparison.
9716818|NCT04565795|Experimental|Placement of ureteral stent post ureteroscopy|Subjects with unilateral ureteral or renal stone fragments who have undergone an uncomplicated ureteroscopy (UURS)
9716819|NCT04565821|Experimental|Feasibility of trans-nasal IPD probe|The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability
9716820|NCT04565548|Experimental|Intervention|Participants will receive the newly developed theory-guided program for 12 weeks.
9716821|NCT04565548|Active Comparator|Control|Participants will receive the usual care and non-hypertension related text messaging for 12 weeks.
9716822|NCT04565509|Active Comparator|General Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.
9716823|NCT04565509|Active Comparator|Focus/Targeted Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.
9716824|NCT04565509|Active Comparator|Best Message Alone|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.
9716825|NCT04565509|Active Comparator|Best Message + Augmented Message or Implementation Strategy|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
9716826|NCT04565561||Neovas BRS group|Neovas BRS group, n=20
9716827|NCT04565561||DCB group|DCB group, n=20
9716828|NCT04565522||Hemodialysis or peritoneal dialysis patients|Hemodialysis or peritoneal dialysis Covid negative patients
9716829|NCT04565522||dialysis staff healthcare professionals|dialysis staff Covid negative healthcare professionals
9716830|NCT04565496|Experimental|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
9716831|NCT04565366||Spinal Cord Injury|Individuals recently admitted to hospital and diagnosed with acute, traumatic spinal cord injury.
9716832|NCT04565366||Trauma Control|Individuals recently admitted to hospital and diagnosed with an acute, traumatic injury that is not spinal cord injury.
9716833|NCT04565366||Healthy Control|Generally healthy individuals not recently diagnosed with an acute, traumatic injury (including spinal cord injury).
9716834|NCT04565314|Experimental|Plumpy'Mum|Mother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area.
9716835|NCT04565340||Induction of labor with Foley catheter|Induction of labor with Foley catheter
9716836|NCT04565340||Induction of labor with Propess|Induction of labor with Propess
9980489|NCT01392287|Experimental|Memantine hydrochloride|Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
9716837|NCT04565327|Experimental|Cohort A: Single Dose/Image|Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than one minute then undergo MRI over 5 minutes at baseline
9716838|NCT04565327|Experimental|Cohort A: Multiple Dose/Images|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute then undergo MRI over 5 minutes at baseline and 4 weeks after beginning treatment
9716839|NCT04565301|Placebo Comparator|Group C|The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).
9716840|NCT04565301|Active Comparator|Group D|The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
9716841|NCT04565301|Active Comparator|Group N|The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
9716842|NCT04565405|Experimental|AB (Detergent (A) followed by sterile water (B))|"Sequence: Detergent (A) followed by sterile water (B)~The inner cannula will be cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the first visit, and then cleaned with sterile water in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
9716843|NCT04565405|Experimental|BA (Sterile water (B) followed by detergent (A))|"Sequence: Sterile water (B) followed by detergent (A)~The inner cannula will be cleaned with sterile water in the first visit, and then cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
9716844|NCT04565457|Experimental|Participants Scanned|All participants will be scanned with a CBCT system equipped with 2D antiscatter grid technology, referred to as research CBCT. Each participant will also be scanned with a standard clinical CBCT as part of their standard clinical care, which will serve as the baseline, or control.
9716845|NCT04565093|Experimental|iPACK|In this group, participants will receive a peripheral nerve anesthetic block that is iPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) to cover posterior knee pain after total knee arthroplasty (TKA). This anesthetic block will be performed by assigned anesthesiologist under ultrasound guidance.
9716846|NCT04565093|Placebo Comparator|Periarticular local infiltration analgesia (LIA)|In this group, participants will receive a mixture of bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) that will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This local anesthetic infiltration is commonly performed by the operating orthopedic surgeon during TKA for postoperative pain control.
9716847|NCT04565444|Experimental|Ketone|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and carbohydrate control.
9716848|NCT04565444|Experimental|Ketone + Protein|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and 10g of whey protein.
9716849|NCT04565444|Experimental|Protein|Carbohydrate control and 10g of whey protein.
9716850|NCT04565431||Group 1: Multiple Sclerosis|"Individuals with RRMS who are going to be starting Tysabri as determined by Neurologist as part of clinical care.~Intervention: Drug: Tysabri"
9716851|NCT04565431||Group 2: Healthy Controls|Healthy individuals who are age, gender and education matched to the MS group.
9716852|NCT04565054|Experimental|Abemaciclib plus ET|Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
9716853|NCT04565054|No Intervention|Standard-of-care ET|"Standard-of-care ET according to clinical guidelines.~Premenopausal patients:~Either aromatase inhibitor + GnRH agonist~or Tamoxifen +/- GnRH-agonist (as per investigator´s decision) or~Postmenopausal patients:~Either Aromatase inhibitor~or Tamoxifen OR"
9716854|NCT04565002|Experimental|EG|The TEDS protocol will consist of the following parameters: a) frequency of 30 Hz; b) pulse width of 0.4 ms; c) respiratory rate of 15 irpm; d) holding time of 1 s; e) rise time of 1 s; f) 2 s descent time; and g) 2 s non-stimulus time. Phrenics equipment (Dualpex 961, Quark®) will be used. The positioning of the electrodes will be performed according to a study by Cancelliero et al. (2012), who proposed the placement of two electrodes in the right and left paraxiphoid regions, and two others in the direction of the axillary midline, over the seventh intercostal space, also on the right and left sides.
9716855|NCT04565002|No Intervention|CG|The control group will undergo the same assessments as the experimental group, but the TEDS will not be applied.
9716856|NCT04565184|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
9716857|NCT04565184|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
9716858|NCT04565262|Experimental|NAs+IFN-α|NAs+IFN-α/ 96w
9716859|NCT04565262|Other|NAs+(IFN-α+ NAs )|NAs/48w+(IFN-α+ NAs)/96w
9716860|NCT04565132|Experimental|HD-tDCS|Each patient received a total of six sessions of anodal HD-tDCS of right DLPFC.
9716861|NCT04564989||HPV+ OPSCC Patients|Patients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.
9716862|NCT04564950||Control|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
9716863|NCT04564950||Periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
9980490|NCT01392313|Experimental|Carnitine|Participants will be given Creatinine supplements
9716864|NCT04564950||Coronary heart disease|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
9716865|NCT04564950||Coronary heart disease + periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
9716866|NCT04565197|Experimental|Group intervene with convalescent plasma|"Review effect of Plasma therapy as clinical trial among hospitalized patients with COVID-19 infection.~Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
9716867|NCT04565171|Experimental|Participants with renal impairment|Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.
9716868|NCT04565171|Experimental|Participants with normal renal function|Participants with normal renal function will receive a single dose of Yimitasvir Phosphate Capsule.
9716869|NCT04565223|Experimental|Cognitive behavioral therapy (CBT)|"5 sessions of Cognitive behavioral therapy for insmonia and an extra session for benzodiazepine withdrawal (if necessary).~The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal"
9716870|NCT04565223|No Intervention|Usual care|Usual care from GPs or nurses
9716871|NCT04564911|Experimental|Flash Glucose Monitoring and Education|Participants randomised to the experimental arm will receive an education package and wear the flash glucose monitoring system. They will use sensor glucose data for self-management.
9716872|NCT04564911|Active Comparator|Capillary Glucose Monitoring and Education|Participants randomised to the control arm will receive an education package and self-manage their glucose levels utilising a standard capillary blood glucose device, and keeping a glucose diary for the duration of the intervention period.
9716873|NCT04565015|Experimental|GC5107|Immune Globulin Intravenous (Human), 10% Liquid
9716874|NCT04564924||MRI & DXA patients|No intervention
9716875|NCT04564924||MRI & DXA volunteers|No intervention
9716876|NCT04564937|Experimental|SCT510A dose level 1 treatment|SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously
9716877|NCT04564937|Experimental|SCT510A dose level 2 treatment|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously
9716878|NCT04564937|Experimental|SCT510A dose level 3 treatment|SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously
9716879|NCT04564937|Experimental|SCT510A dose level 4 treatment|SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously
9716880|NCT04564729|Experimental|Decision Aid|The shared decision aid (SDA) includes factual information about the World Health Organization pain ladder, the 0-10 numeric rating score pain scale, pharmacologic pain management options, opioid medication benefits and risks and predicted post-discharge opioid requirements based on previous modeling in total knee arthroplasty patients. Subjects in the decision aid group will view the decision aid and have the opportunity to participate in shared decision-making for their discharge opioid prescriptions.
9716881|NCT04564729|No Intervention|Control|Subjects in the control group will undergo standard care and discharge practices. Baseline pain and psychosocial factors will be documented as well as postoperative pain and analgesic consumption.
9716882|NCT04564859|Experimental|Noninvasive Ventilation group|Noninvasive Ventilation group initial setting： Insp. Pressure：12 ~ 16 centimeter of water Exp. Pressure ： 4 ~ 6 centimeter of water FiO2：Keep oxygen saturation measured by pulse oximeter：> 92% By condition, gradually tap 2~3 centimeter of water inspiratory positive airway pressure Keep Tidal volume：6~10 ml/kg
9716883|NCT04564859|Active Comparator|Heated Humidified High-Flow Nasal Cannula group|Heated Humidified High-Flow Nasal Cannula group initial setting： Flow setting: 50 L/m FiO2：Keep oxygen saturation measured by pulse oximeter > 92% temperature:37 ℃ By condition, gradually tap Flow 5 L/m
9716884|NCT04564768|Experimental|Intervention group|Online Mindfulness-Based Cancer Recovery
9716885|NCT04564768|No Intervention|Control group|Treatment as usual
9716886|NCT04564872|Experimental|HSK7653 10 mg|
9716887|NCT04564872|Experimental|HSK7653 25 mg|
9716888|NCT04564872|Active Comparator|Linagliptin 5 mg|
9716889|NCT04564651|Experimental|platelet transfusion treatment|
9716890|NCT04564651|No Intervention|standard medical treatment|
9716891|NCT04564664|Other|High-flow nasal cannula oxygen therapy|
9716892|NCT04564664|Other|Standard oxygen therapy|
9716893|NCT04564313|Experimental|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
9716894|NCT04564391|Active Comparator|Whey protein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of whey protein (=60 g / day)
9716895|NCT04564391|Active Comparator|Casein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of casein (=60 g / day)
9716896|NCT04564391|Active Comparator|pea protein supplement, 2x 30g/day|Three weeks, twice daily supplementation with 30 g of pea protein (=60 g / day)
9716897|NCT04564391|Placebo Comparator|placebo arm|Three weeks, twice daily supplementation with 30 g of placebo (=60 g / day)
9716898|NCT04564521|Experimental|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
9716899|NCT04564521|Active Comparator|Normal saline|Normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
9716900|NCT04564495|Experimental|Live zoom exercise classes|Participants will engage in a live zoom exercise session. Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
9716901|NCT04564495|Active Comparator|Recorded zoom exercise classes|Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks, using a pre-recorded class that they can do according to their own schedule. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
9716902|NCT04564326|Active Comparator|Group C|Patients will be assigned to receive opioids analgesia before spinal anesthesia in the form of intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between before positioning the patient for spinal anesthesia.
9716903|NCT04564326|Experimental|Group P|Patients will be assigned to receive Pericapsular Nerve Group Block (PENG Block) before positioning the patient for spinal anesthesia.
9716904|NCT04564326|Experimental|Group F|Patients will be assigned to receive Fascia Iliaca Block (F.I Block) before positioning for spinal anesthesia.
9716905|NCT04564690|Experimental|QUARTET®|Consumption of three QUARTET® (n-3 PUFA, selenium, vitamin E, lutein enriched) hen eggs per day for three weeks
9716906|NCT04564690|Experimental|Control|Consumption of three regular hen eggs per day for three weeks
9716907|NCT04564716|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
9716908|NCT04564716|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
9716909|NCT04564586|Other|Enhanced Intervention Group (EIG)|The Enhanced Intervention Group was a subgroup of the participants that were invited for voluntary weekly meet-n-greet sessions in the Primary Care Clinic. These sessions were information and not educational sessions for the intervention. The entire EIG concept was to test a social component of participants by providing an informal opportunity for a DPPFit social group. The group sessions were terminated after only 5 weeks as a result of the Covid-19 pandemic. They were the only component of the DPPFit study that were face-to-face.
9716910|NCT04564352||2|Adansonia digitata (Baobab)
9980491|NCT01392313|Placebo Comparator|Placebo|participants will be given creatinine placebo
9980492|NCT01392339|Experimental|CPAP|CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
9980493|NCT01392352|Experimental|Pazopanib|Patients will receive 800mg (2 X 400mg tablets) of pazopanib, to be administered once daily orally for 12 weeks or until development of hypertension (defined as VHyp), whichever occurs first.
9716914|NCT04564456|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
9716915|NCT04564456|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
9716916|NCT04564430|Placebo Comparator|Control group|IV Saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland) in an equal quantity as the study drug is administered at tourniquet inflation
9716917|NCT04564430|Experimental|Intervention group|Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) is administered at tourniquet inflation
9716918|NCT04564300|Experimental|Oral contraceptive users|
9716919|NCT04564300|Active Comparator|Non-oral contraceptive users|
9716920|NCT04564196||Induction of Labor|"Samples collected from women who present for induction of labor.~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be collected at the following time points for patients presenting for induction of labor:~A) Baseline: At presentation to labor and delivery unit and prior to initiation of augmentation of labor. A total of 1 sample.~B) End of 1st stage of labor: At complete cervix dilatation and prior to starting to push. A total of 1 sample will be taken.~C) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
9716921|NCT04564196||Spontaneous Labor|"Samples will be collected from women who present in spontaneous labor~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.~Samples will be taken at the following endpoints:~A) End of 1st stage of labor: At completely cervix dilated and prior starting pushing. A total of 1 sample will be taken.~B) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 1 sample will be taken."
9716922|NCT04564144|Experimental|Volunteers receiving the prepared orodispersible tablets|6 human volunteers will receive the prepared orodispersible tablets plus a commercial one all containing Meclizine HCl in a parallel manner.
9716923|NCT04564235|Experimental|Indication for a genome-wide analysis in the proband|
9716924|NCT04563949||PLA-|PLA- initially and repeat testing 1-2 years later
9716925|NCT04563949||PLA+|Not eligible for the study
9716926|NCT04564131|Experimental|reflexology practice|"Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism.~Experimental group participants will be given 10 sessions of reflexology massage twice a week for 5 weeks. A total of three follow-ups will be performed in the 1st session, the 5th session and the 10th session. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied."
9779785|NCT04880850|Active Comparator|Insulin glargine + insulin aspart|Participants will get once daily injections in combination with 2-4 times daily injections of insulin aspart
9980494|NCT01392365||Crohn' disease|The group of patients whose final diagnosis is Crohn's disease
9980495|NCT01392365||Intestinal tuberculosis|The group of patients whose final diagnosis is intestinal tuberculosis
9980496|NCT01392391|Experimental|Exercise|Task-oriented exercise training (aerobic, strength, and balance exercises)
9716927|NCT04564131|Experimental|Control|Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism. 1. 3. 5. A total of three follow-ups will be done once in the week. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied.
9716928|NCT04564183||Full Cohort|Entire study population
10196339|NCT01419067|Other|Craniopharyngioma Patients|"Craniopharyngioma patients will have limited surgery and a 5mm clinical target volume margin in combination with proton therapy. Proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). Patients who have had radical surgery or limited surgery prior to enrollment on this study and have no evidence of tumor will be observed for 5 years.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine will be given to aid in tumor visualization."
9716929|NCT04564183||Sub-Cohort|Randomly selected sub-cohort from the larger group of all participants
9716930|NCT04563910||less than 2 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
9716931|NCT04563910||2-5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
9716932|NCT04563910||more than 5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
9716933|NCT04564170||ED|Patients with Eating Disorders
9716934|NCT04564170||HC|Healthy Controls without eating disorders
9716935|NCT04564248|Experimental|website access for families|
9716936|NCT04564248|No Intervention|standard care|
9716937|NCT04563884||Patients with deafness|Patients aged 12 months to 17 years with deafness
9716938|NCT04563884||Controls|Normal-hearing patients aged 12 months to 17 years
9716939|NCT04563897||HBV/HCV|
9716940|NCT04563897||Fatty liver disease|
9716941|NCT04563897||Liver background after systematic treatment|
9716942|NCT04563897||normal hepatic background|
9716943|NCT04564118||Group 1|retrospective data on treatment from EMC
9716944|NCT04564118||Group 2|Treatment assignment using medicBC CDSS platform in the same cohort of patients
9716945|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 1|"Part 1: Participants will receive Treatment A (100 mg AT suspension in water via NG administration) in Period 1, Treatment B (100 mg acalabrutinib capsule suspension via NG administration) in Period 2, and Treatment C (100 mg AT suspension in water via NG administration plus 20 mg rabeprazole) in Period 3.~Part 2: Participants will receive Treatment D (100 mg AT suspension in water via NG administration) in Period 1 and Treatment A in Period 2."
9716946|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 2|"Part 1: Participants will receive Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3.~Part 2: Participants will receive Treatment A in Period 1 and Treatment D in Period 2."
9716947|NCT04564066|Experimental|efgartigimod IV|intravenous infusions of efgartigimod
9716948|NCT04564066|Experimental|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
9716949|NCT04564222|Experimental|Micronutrient Enriched Crackers (MECs)|"Micronutrient Enriched Crackers (MECs) are a deep-fried snack product rich in iron, zinc, calcium, and vitamin A made from chicken liver and chicken eggshell powder.~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
9716950|NCT04564222|Placebo Comparator|Placebo|"Placebo Crackers are a deep-fried snack product made from the basic cracker ingredients (mainly wheat flour) with the addition of Pangium edule seeds to provide a color similar to the intervention product (MECs).~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
9716951|NCT04563936|Experimental|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
9716952|NCT04563936|Active Comparator|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
9716953|NCT04563975|Experimental|Chemotherapy and programmed death 1 inhibitor|Docetaxel /nab-paclitaxel in combination with Toripalimabs
9716954|NCT04563858||Cardiac patients|
9716955|NCT04564053|Experimental|LNA043|LNA043
9716956|NCT04564053|Placebo Comparator|placebo|
9716957|NCT04564209|Experimental|Treatment|The treatment group will be exposed to the infographic intervention when they present for clinic/study visits. During their visit with the provider, the provider offer health education while using infographics.
9716958|NCT04564209|No Intervention|Control|The control groups will receive standard health education.
9716959|NCT04563819||Newborns with DDH|Newborns (born 1988-90) with sonographic hip dysplasia (DDH)
9716960|NCT04563819||Newborns without DDH|Newborns (born 1988-90) without sonographic hip dysplasia (DDH)
9716961|NCT04563819||Hip dysplasia at skeletal maturity|Subjects that show signs of acetabular dysplasia at skeletal maturity (age 17-19 years), in 2007-09, when hip radiographs and salivary samples were collected.
9980497|NCT01392391|Active Comparator|Stroke Care|"Best Medical Care in Jamaica adapted from the American Stroke Association Get with the Guidelines."
9980498|NCT01392430|No Intervention|Arm A|Continuation of prophylaxis of opportunistic infections
9980499|NCT01392430|Experimental|Arm B|Discontinuation of opportunistic infections
9980500|NCT01392456|Active Comparator|Retentive Anchor Group|23 fully edentulous patients will receive Retentive Anchors (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
9980501|NCT01392456|Active Comparator|Magnet Group|23 fully edentulous patients will receive Magnets (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
9716962|NCT04563962|Experimental|Contingency Management-ART|Contingency management intervention with incentives tied to provision of urine samples with detectable levels of Tenofovir (TFV).
9716963|NCT04563962|Active Comparator|Contingency Management-Methamphetamine|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
9716964|NCT04563871|Experimental|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
9716965|NCT04564001|Experimental|A ( Infliximab)|Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
9716966|NCT04564001|Experimental|B (Tocilizumab)|Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
9716967|NCT04563650|Experimental|COVID-19 positive resident|
9716968|NCT04563650|Active Comparator|COVID-19 negative resident|
9716969|NCT04563663|Experimental|One session|One session of talus posteriorization.
9716970|NCT04563663|Experimental|Two sessions|Two sessions of talus posteriorization.
9716971|NCT04563663|Experimental|Three sessions|Three sessions of talus posteriorization.
9716972|NCT04563663|Experimental|Four sessions|Four sessions of talus posteriorization.
9716973|NCT04563585||Muscle strength|Maximal voluntary isometric (MVIC) knee flexion and extension strength were measured using a handheld dynamometer (HDD) (Lafayette Instrument Company, Lafayette, IN).
9716974|NCT04563585||Lower Extremity Vertical Power|Lower extremity vertical power was identified through the use of the VertiMetric (Lafayette Instrument Company, Lafayette, IN) according to protocols suggested by Ambegaonkar et al.
9716975|NCT04563585||Trunk Extension Endurance|Trunk extension endurance was measured using the Biering-Sorensen test as previously described
9716976|NCT04563585||Upper Limb Performance|The Davies test (DT) was used to assess upper body agility and stabilization.The Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST) was utilized to assess shoulder performance function and stability according to protocol suggested by Goldbeck and Davies.
9716977|NCT04563585||Lower Limb Performance|The Shark Skill Test (SST) was developed in order to assess lower extremity agility and neuromuscular control.
9716978|NCT04563598||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
9716979|NCT04563598||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
9980502|NCT01392456|Active Comparator|Locator Group|23 fully edentulous patients will receive Locator (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
10196340|NCT01332968|Active Comparator|Rituximab+Chemotherapy|Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
9716982|NCT04563728|Active Comparator|Camera Group|"1) The camera(s) will be a stationary device installed by the study technician on the ceiling of a common living area of the participant's home. The camera(s) will record video and audio data to be stored in our secure data base. The cameras will be purchased from YI Technology (see more details in Section 1.7). A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Highlighted video and audio data will be reviewed daily by the study technician. If there is evidence of abuse, exploitation, and neglect on these video and audio data, a report will be made to APS and the IRB."
9716983|NCT04563728|Active Comparator|Mock Camera Group|"2) The mock camera(s) will be a stationary device installed on the ceiling of a common living area of the participant's home. They will not record video or audio but will be installed with a sensor chip and a Wi-Fi connection, which will notify the study team if the device has been touched, tampered, altered, or disrupted power sources. After installing the device, the study technician and study coordinator will test the anti-tampering sensor to ensure potential future tampering will be detected. A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Daily check-ins to assess whether elder abuse may have been experienced by the participant will occur by phone or other preferred mode of communication. In the event of reported abuse, exploitation, and neglect, despite not being mandatory reporters, we will report to NJ APS and the IRB."
9716984|NCT04563728|No Intervention|Usual Care|Each participant will receive educational packages about elderly community-living.
9716985|NCT04563754|Experimental|mHRME and HRA|"5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed.~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
9716986|NCT04563689|Experimental|actve|oral rinse
9716987|NCT04563689|Placebo Comparator|placebo|distilled water,
9779786|NCT04880668|No Intervention|Control - No aerosol box|Participants will perform the AGMP without an aerosol box
9779787|NCT04880668|Experimental|Intervention - Aerosol box|Participants will perform the AGMP with an aerosol box
9716988|NCT04563767||Infinitome|All patients will be in the same cohort. No intervention will be administered. Patients will undergo a structural magnetic resonance imaging (MRI) as part of their standard of care. Added on will be the resting state fMRI (rs-fMRI). The rs-fMRI data will be analyzed.
9716989|NCT04563572|Experimental|PPG Smartwatch|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.~CardioWatch 287 is a novel non-invasive monitoring device manufactured by the MMT company. The device monitors heart rhythm, heart rate (HR) and respiratory rate (RR) based on peripheral PPG signal.~In this arm, we will test the quality of the algorithm integrated into the smartwatch."
9716990|NCT04563572|Experimental|PPG Bracelet|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.~A PPG-sensor is also integrated into a bracelet Basler Band manufactured by the MMT company, which is a simplified multisensory device.~In this arm, we will test the quality of the algorithm integrated into the bracelet."
9716991|NCT04563468|Experimental|Strength inspiratory muscle training group|Strength IMT
9716992|NCT04563468|Sham Comparator|Endurance inspiratory muscle training group|Endurance IMT
9716993|NCT04563390|Experimental|Projection-based augmented reality exposure therapy|Intervention group that receives the projection-based augmented reality to carry out the exposure therapy for cockroach phobia.
9716994|NCT04563390|Experimental|In vivo exposure|Intervention group that receives traditional in vivo exposure therapy for cockroach phobia.
9716995|NCT04563390|No Intervention|WL Control|Waiting list control group.
9716996|NCT04563416||Patients who need undergo magnifying endoscopy|
9716997|NCT04563299|Experimental|Dextenza|Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
9716998|NCT04563299|Active Comparator|Topical Corticosteroids|Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
9716999|NCT04563260|Placebo Comparator|Control group|Control group receives the intravenous normal saline 2 mL.
9717000|NCT04563260|Experimental|Palonosetron group|Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL.
9717001|NCT04563533|Experimental|adults of phase I|Healthy people aged 18-59
9717002|NCT04563533|Experimental|teenagers of phase I|Healthy people aged 6-17
9717003|NCT04563533|Placebo Comparator|elderly of phase I|Healthy people 60 years old and above
9717004|NCT04563533|Experimental|Toddler of phase I|Healthy people aged 2-5
9717005|NCT04563533|Placebo Comparator|Infants of phase I|6 weeks old-2 years old healthy person
9717006|NCT04563533|Experimental|elderly of phase II|Healthy people 60 years old and above
9717007|NCT04563533|Placebo Comparator|Toddler of phase II|Healthy people aged 2-5
9717008|NCT04563533|Experimental|Infants of phase II|6 weeks old-2 years old healthy person
9717009|NCT04563442||covid 19|complications and comorbidities
9717010|NCT04563364|Experimental|Hospital-Home|This group will receive an interdisciplinary intervention of education to parents for get better outcomes of motor development.
9717011|NCT04563364|Active Comparator|Control Intervention|Control group will receive a conventional treatment given by the institutions
9717012|NCT04563494|Active Comparator|IV Dexmethsone and oral placebo|
9717013|NCT04563494|Active Comparator|Oral dexamethasone and IV placebo|
9717014|NCT04563351|Active Comparator|conventional inferior alveolar nerve block (IANB)|37 patients received Inferior Alveolar Nerve Block (IANB) for dental treatment of mandibular posterior teeth.
9717015|NCT04563351|Experimental|Intraligamentary Anesthesia (ILA)|35 patients received Intraligamentary Anesthesia (ILA) for dental treatment of mandibular posterior teeth.
9717016|NCT04563507|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
9717017|NCT04563507|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
9717018|NCT04563312|No Intervention|Balance Assessment|The Flamingo Balance Test and Y Balance Test were used to evaluate static and dynamic balance, respectively.
9717019|NCT04563312|No Intervention|Coordination Assessment|Coordination was assessed using the Hexagon Test.
9717020|NCT04563312|No Intervention|Lower Extremity Functional Performance Assessment|Lower extremity functional performance was evaluated using the Single Leg Hop Test.
9717021|NCT04563312|Experimental|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
9717022|NCT04563429|Experimental|Treatment Group|
9717023|NCT04563429|No Intervention|Control Group|
9717024|NCT04563624|Experimental|ceramic cad cam blocks|
9717025|NCT04563624|Active Comparator|composite cad cam blocks|
9717026|NCT04563403|Experimental|Treatment with Multiple Stimuli|Projection-based augmented reality therapy (P-ARET) with Multiple Stimuli (MS) (P-ARET MS). Intervention group that receives P-ARET treatment varying the stimuli available in the system (different cockroaches in colour, size, etc).
9717027|NCT04563403|Experimental|Treatment with Single Stimuli|Projection-based augmented reality therapy (P-ARET) with Single Stimuli (SS) (P-ARET SS). Intervention group that receives P-ARET treatment using a single stimulus (one cockroach).
9717028|NCT04563221|Experimental|Balloon occlusion microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter.
9717029|NCT04563221|Experimental|Standard microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter.
9717030|NCT04562857|Active Comparator|obstructive sleep apnea|interval exercises (intervention) on bicycle for patients with AF and OSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
10196341|NCT01332968|Experimental|Obinutuzumab+Chemotherapy|Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
10196342|NCT01265784|Experimental|TP-434, 1.5 mg/kg q24h|TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
10196343|NCT01265784|Experimental|TP-434, 1.0 mg/kg q12h|TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
9717031|NCT04562857|Active Comparator|Central sleep apnea|interval exercises (intervention) on bicycle for patients with AF and CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
9717032|NCT04562922|Experimental|Lifemel|"LifeMel is bee-honey obtained using Zuf Globus Ltd technology: it is produced in Israel and distributed by VitalMel in Italy. In Italy Ministry of Health has listed it as a food supplement.~Two tea spoons (5 g each) of honey were administered to subjects on each day of the chemotherapy treatment."
9717033|NCT04562883|Experimental|Single Culture|"Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the washing dish containing Maturation Medium and wash them thoroughly. Then transfer COCs one by one to the Culture dish with Maturation Medium."
9717034|NCT04562883|Experimental|Group Culture|"Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the washing dish containing Maturation Medium (Group Culture) by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the IVM dish with Maturation Medium (Group Culture)."
9717035|NCT04563052|Experimental|Education|Air pollution educational module exposure.
9717036|NCT04563156||Severe Covid-19 Survivors|Severe Covid-19 survivors previously admitted in the hospital
9717037|NCT04563169|Experimental|Video consultation|Patients in the video consultation group will receive video consultations.
9717038|NCT04563169|No Intervention|Face-to-Face consultation|Patients in the usual care group will receive face-to-face consultations.
9717039|NCT04563182||Muscle strength|GMed strength was assessed with the use of a Lafayette Manual Muscle Tester (Lafayette Instruments; Lafayette, Indiana, USA).
9717040|NCT04563182||Horizontal Jumping Performance|Lower extremity horizontal jumping was measured using the single leg hop (SLH) test as previously described
9717041|NCT04563182||Vertical Jumping Performance|To measure the single-leg vertical jump (SLVJ), the participants stood on the ground with their foot flat distributing their weight evenly on both feet.
9717042|NCT04563182||Dynamic Balance|The Y-Balance Test (YBT) was used to dynamic balance
9717043|NCT04563182||Static Balance|The Stork balance test (SBT) was used to measure static balance performance
9717044|NCT04562974|Experimental|One group of 30 healthy subjects|Perception and memory tasks inside a MRI-scanner for all participants
9717045|NCT04563091|Experimental|Interventional group|"The study population will consist of 6 evaluable, outpatient patients with chronic kidney failure who need to perform hemodialysis thrice weekly for their survival.~In the case of drop out of a patient will be enrolled another patient to arrive at 6 patients evaluable both at the end of Period A and at the end of Period B of the study"
9717046|NCT04563013|Sham Comparator|Sham tVNS|The participants under conventional radiochemotherapy were applied with sham tVNS at the earlobe for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
9717047|NCT04563013|Active Comparator|tVNS|The participants under conventional radiochemotherapy were applied with transcutaneous vagus nerve stimulation at the tragus for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
9717048|NCT04563117||Automatic registration|
9717049|NCT04563117||Point-based registration|
9717050|NCT04562844|Experimental|Social cognition|
9717051|NCT04563208|Placebo Comparator|Arm A: Placebo|Placebo administered
9717052|NCT04563208|Active Comparator|Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)|Ribavirin/Nitazoxanide (RBV/NTZ) administered
9717053|NCT04563000|Experimental|Vitamin C|Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
9717054|NCT04563000|Placebo Comparator|Placebo|Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
9717055|NCT04562961|Experimental|Schizophrenia caregiver (relative)|
9717056|NCT04562909||Premature children|Premature children born before than 32 weeks were included.
9717057|NCT04562909||Healthy Control Group|Age matched healthy controls
9717058|NCT04562987|Active Comparator|Core|All participants will receive the Core component, which includes access to weekly telecoaching, weekly emails from the interventionist, a smartphone app, and a Fitbit monitor. Telecoaching will include discussion of general cancer-related and wellness topics, and the smartphone app will have basic activity monitoring features.
9717059|NCT04562987|Experimental|Move|Telecoaching calls for Move participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on reducing prolonged sitting. Smartphone app features include activity monitoring that visualizes progress toward Move-based goals and goal achievement badges specific to Move.
10196344|NCT01265784|Active Comparator|Ertapenem, 1 g q24h|Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
10196345|NCT01033916|No Intervention|STRICT Glucose Control (80-120 mg/dL)|The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
9717060|NCT04562987|Experimental|Exercise|Telecoaching calls for Exercise participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on engaging in 30 minutes of moderate-intensity physical activity per day (in 10+ minute bouts). Smartphone app features include activity monitoring that visualizes progress toward Exercise-based goals and goal achievement badges specific to Exercise.
9717061|NCT04562987|Experimental|Combo (Move+Exercise)|Includes telecoaching that encourages behavior adoption and goal setting focused on reducing prolonged sitting and engaging in 30+ minutes of physical activity per day. Participants are able to visualize progress toward Move and Exercise goals and are eligible to receive achievement badges for Move and Exercise.
10196346|NCT01033916|Active Comparator|LIBERAL (Target Glucose:121-180 mg/dL)|
10196347|NCT00936078||Non-donors/controls|People who have not donated a kidney.
9717063|NCT04563065|Experimental|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy (11,13) and published by Barakat model (10).~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
9717064|NCT04563065|No Intervention|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
9717065|NCT04562805|Experimental|DynamX Bioadaptor|Elixir Medical DynamX™ Sirolimus Eluting Coronary Bioadaptor
9717066|NCT04562805|Active Comparator|Medtronic Resolute Onyx Stent|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
9717067|NCT04562818||Daunorrubicin|Patient treated with daunorrubicin
9717068|NCT04562818||Idarrubicin|Patient treated with idarrubicin
9717069|NCT04562506|Active Comparator|Real rTMS stimulation|real deep excitatory, high frequency rTMS with H-coil stimulation
9717070|NCT04562506|Sham Comparator|Sham rTMS stimulation|sham high frequency H-coil stimulation
9717071|NCT04562662|Experimental|Intervention group|Single arm (all participants receive interventions)
9717072|NCT04562532|Experimental|Firehawk group|Participants implant Firehawk stent(s)
9717073|NCT04562532|Active Comparator|2nd generation DES|Participants implant Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific), or Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic), or Sirolimus eluting stents (Orsiro- Biotronik)
9717074|NCT04562649|Experimental|Intervention|Wise App that delivers medication adherence reminders and community health worker sessions
9717075|NCT04562649|No Intervention|Control|Standard of care
9717076|NCT04562441|Experimental|Axitinib and Avelumab|"Axitinib: 5 mg bd po Day 1 to Day 28~Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks"
9717077|NCT04562675|Experimental|Intervention group (IG)|LHA intervention group (IG)
10196348|NCT00936078||Living Kidney Donors|
10196349|NCT00719966||Group 1 (hormone receptor-positive)|Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity.
10196350|NCT00719966||Group 2 (hormone receptor-negative)|Patients do not receive adjuvant treatment.
10196351|NCT00637832|Experimental|single group|
10196352|NCT00577577|Experimental|rhIGF-I/rhIGFBP-3|
10196353|NCT00577577|Placebo Comparator|Placebo|
9717078|NCT04562675|Placebo Comparator|Control group (CG)|brochure-only control group (CG)
9717079|NCT04562545|Active Comparator|Maximum Bite Advancement|
9717080|NCT04562545|Experimental|Incremental Bite Advancement|
9717081|NCT04562493|Active Comparator|Magnesium sulphate group|Effect of transforaminal Magnesium sulphate on oxidative stress markers and radicular pain
9717082|NCT04562493|Experimental|Ozone Group|Effect of transforaminal Ozone on oxidative stress markers and radicular pain
9717083|NCT04562493|Other|Steroid group|Effect of transforaminal steroids on oxidative stress markers and radicular pain
9717084|NCT04562571|Experimental|Charter & patient information leaflets|A public commitment charter promoting antibiotic stewardship, signed by the general practitioner (GP) and displayed in the practice waiting room; a non-prescription pad, to be distributed to patients when an antibiotic is not needed; and a patient information leaflet to be used when antibiotics were prescribed
9717085|NCT04562571|No Intervention|Control|No intervention, eligible general practitioners randomised in the control group not informed of the intervention
10196354|NCT00548236|Experimental|1|Immediate participation in a 16-week exercise program
10196355|NCT00548236|No Intervention|2|Control population; will receive exercise plan after 16-week control period
9717086|NCT04562753|Active Comparator|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
9717087|NCT04562753|Active Comparator|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
9717088|NCT04562688|Experimental|Arm A|Participants assigned to Arm A will engage in CICADAS app only for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period. Participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician.
9717089|NCT04562688|Experimental|Arm B|Participants assigned to Arm B will engage in PEERS + CICADAS for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
9717090|NCT04562688|Experimental|Arm C|Participants assigned to Arm C will engage in PEERS + Active Comparator for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
9779788|NCT04873700||All Participants|Participants diagnosed with moderate to severe UC or CD will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of UC and CD.
9779789|NCT04858035|Experimental|Online Speech Training|"Participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. All participants will receive 12 sessions of perceptual training over 4 weeks. Finally, participants will complete a 3-session maintenance phase in which perception and production are probed but not treated. Perception will be measured using the identification and category goodness judgment.~Following completion of perception training all participants will complete two weeks of production training. The production training will consists of 4, 60-minute sessions. Each session will provide instruction and practice trials."
9779790|NCT04852055|No Intervention|Usual Care|Patients and proxies in assisted living centers randomized to the usual care arm have advance care planning discussions with a clinician at admission, annually, and sometimes with a hospitalization or other change in condition. There is no standardized decision- or conversation-support tools used to have these discussions.
9779791|NCT04852055|Experimental|Information|Patients and proxies in assisted living centers randomized to the information arm will receive a letter from their clinician with a link to an educational video describing the goals of care and how specific treatment decisions align with these goals. Patients and proxies will also continue to receive usual care advance care planning conversations.
9779792|NCT04844944||Heart Failure|Hospitalized patients diagnosed with Heart Failure. No Intervention.
9779793|NCT04844944||Coronary Artery Disease|Hospitalized patients diagnosed with Coronary Artery Disease. No Intervention.
9779794|NCT04844944||Atrial Fibrillation|Hospitalized patients diagnosed with Atrial Fibrillation. No Intervention.
9980503|NCT01392482||treatment with antipsychotics|40 LHU covering about 18 millions inhabitants distributed all over Italy with a coverage of nearly 100% of Italian regions. All subjects will be included in the analysis who have received treatment with antipsychotics (typical and / or atypical) between January 1, 2009 and June 30, 2010 and diagnosed with schizophrenia and / or Bipolar Disorder.
9779796|NCT04822363|Experimental|Group A: Healthy|Low Dose Aspirin - 81mg daily for 7 days
9779797|NCT04822363|Experimental|Group B: Healthy|High Dose Aspirin - 325mg daily for 7 days
9779798|NCT04822363|Experimental|Group C: Healthy|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
9779799|NCT04822363|Experimental|Group D: Obese|Low Dose Aspirin - 81mg daily for 7 days
9779800|NCT04822363|Experimental|Group E: Obese|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
9779801|NCT04821531|Experimental|PT Pal|Experimental Arm-PT PAL Participants randomized into this arm will receive exercise instructions via Pt_PAL. PT PAL is a mobile health technology used to facilitate communications between Care teams and patients, by allowing the team to send web-based exercise routines, surveys and educational materials. The PT Pal app captures patient activity adherence and reports
9779802|NCT04821531|Active Comparator|Exercise Manual|Control Arm- Exercise Manual Participants randomized into this arm will use the exercise manual to obtain their exercise instructions
9779803|NCT04806503|Experimental|UNR844 Low|UNR844 Low ophthalmic solution; one drop twice-a-day for three months
9779804|NCT04806503|Experimental|UNR844 Medium 1|UNR844 Medium 1 ophthalmic solution; one drop twice-a-day for three months
9779805|NCT04806503|Experimental|UNR844 Medium 2|UNR844 Medium 2 ophthalmic solution; one drop twice-a-day for three months
9779806|NCT04806503|Experimental|UNR844 High|UNR844 High ophthalmic solution; one drop twice-a-day for three months
9779807|NCT04806503|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution; one drop twice-a-day for three months
9779808|NCT04801810|Experimental|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
9779809|NCT04801810|Sham Comparator|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
9779810|NCT04772989|Experimental|Dose Escalation Q3W Cohorts|Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
9779811|NCT04772989|Experimental|Dose Escalation Q4W Cohorts|Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
9980504|NCT01392521|Experimental|Arm 1|
9980505|NCT01392534||Group 1|
9980506|NCT01392586|Experimental|Upfront surgery|Upfront surgery followed by systemic treatment
9717091|NCT04562584|Experimental|MyHomeDoc|Comparison of MyHomeDoc pulse oximetry readings with arterial blood saturation laboratory analysis in the same subject
9717092|NCT04562727|Experimental|Only MWA|Only preform MWA, chemotherapy isn't necessary
9717093|NCT04562727|Active Comparator|MWA combined with perioperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed before MWA and after MWA
9717094|NCT04562727|Experimental|MWA combined with postoperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed after MWA
9717095|NCT04562519|Experimental|diabetic HD group|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
9717096|NCT04562519|Active Comparator|Nondiabetic goup|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
9717097|NCT04562636|Experimental|Environment-focused Meatless Monday messages|Four environmental messages from the Meatless Monday campaign.
9717098|NCT04562636|Experimental|Health-focused Meatless Monday messages|Four health messages from the Meatless Monday campaign.
9717099|NCT04562636|Other|Neutral Message|Four neutral messages about checking one's credit score.
9717100|NCT04562350|Experimental|Intervention group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Anoia in the course of 2020-21.
9717101|NCT04562350|No Intervention|Control group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Osona in the course of 2020-21.
9717102|NCT04562259||patients with Kimmerle's anomaly|patients who have a complete or incomplete bony bridge over the posterior arch of the first cervical vertebra
9717103|NCT04562402|Active Comparator|Phacoemulsification with endoscopic cyclophotocoagulation|Cataract extraction via phacoemulsification along with endoscopic cyclophotocoagulation of the ciliary body.
9717104|NCT04562402|Active Comparator|Phacoemulsification alone|Cataract extraction via phacoemulsification.
9717105|NCT04562389|Experimental|Phase 1a: Cohort 1: Selinexor 40 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 40 milligrams (mg) of selinexor oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg twice a day (BID).
9717106|NCT04562389|Experimental|Phase 1a: Cohort 2: Selinexor 60 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 60 mg of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
9717107|NCT04562389|Experimental|Phase 1a: Cohort -1: Selinexor 20 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 20 mg of selinexor oral tablet twice weekly (BIW) of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
9717108|NCT04562389|Experimental|Phase 1b: RP2D: Selinexor and Ruxolitinib 15/20 mg|Participants with MF will receive recommended safe dose (estimated in Phase 1a) of selinexor oral tablets on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
9717109|NCT04562389|Experimental|Phase 2: Selinexor RP2D and Ruxolitinib 15/20 mg|Participants with MF will receive recommended safe dose (estimated in Phase 1b) of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
9717110|NCT04562389|Active Comparator|Phase 2: Ruxolitinib 15/20 mg|Participants with MF will receive ruxolitinib oral tablets 15 or 20 mg BID.
9717111|NCT04562623||Cohort A : High grade serous ovarian carcinoma|
9717112|NCT04562623||Cohort B :Breast carcinoma SBR grade II or III|Breast carcinoma SBR grade II or III superior to 3 cm
9717113|NCT04562623||Cohort C : Extended Breast carcinoma In situ|Extended Breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy
9717114|NCT04562311|Experimental|Chidamide with Immunotherapy|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
9717115|NCT04562454|Experimental|Normal group|Specific diet with CGM for 5days
9717116|NCT04562454|Experimental|T1DM group|Specific diet with CGM for 5days
9717117|NCT04562454|Experimental|T2DM group|Specific diet with CGM for 5days
9717118|NCT04562454|Experimental|other type of diabetes group|Specific diet with CGM for 5days
9717119|NCT04562337|Experimental|SHR1316+Chemotherapy +Radiotherapy|Paiticipant receive SHR-1316 、Chemotherapy and Radiotherapy
9717120|NCT04562415|Active Comparator|Active rTMS group|chronic ischemic stroke patients receiving active low frequency repetitive transcranial magnetic stimulation therapy and physical therapy
9717121|NCT04562415|Active Comparator|Active cTBS group|chronic ischemic stroke patients receiving active continuous theta burst stimulation therapy and physical therapy
9717122|NCT04562415|Sham Comparator|Sham cTBS group|chronic ischemic stroke patients receiving sham continuous theta burst stimulation therapy and physical therapy
9717123|NCT04562025|Experimental|UC-MSCs treatment group|"Conventional treatment plus UC-MSCs:~Participants will receive conventional treatment plus 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2，week3)."
9717124|NCT04562025|Placebo Comparator|Placebo control group|"Conventional treatment plus Placebo:~Without UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2，week3."
9717125|NCT04562064||keratoconus group|patients with keratoconus implanted with the Myoring 360 degree, KeraRing 355 degree, KeraRing one segment, KeraRing two segments ICRS .corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system .pentacam data that will be included
9717126|NCT04562168|Experimental|Diagnostic Test: ML model|The diagnostic capacity of the ML model will be compared with that of the general practitioners and with dermatologist.
9717127|NCT04562207|Experimental|Patients|Addition of a nasopharyngeal swab before surgery
9779812|NCT04772989|Experimental|Dose Escalation Q6W Cohort|Selected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies.
9779813|NCT04772989|Experimental|Dose Expansion Cohort 1|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
9717128|NCT04562051||stratified prophylaxis group|The process of stratified prophylaxis was as follows. 1) If the recipient's HBsAb level is more than 100 IU/L and the donor is HBV DNA-, the recipient will not receive any preventive measures; 2) If the recipient's HBsAb is more than 100 IU/L and the donor is HBV DNA+, the recipient receives antiviral treatment for 1 month; 3) If the recipient's HBsAb is between 10 and 100 IU/L, the recipient is treated with single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status; 4) If the recipient's HBsAb is less than 10 IU/L, the recipient will receive single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status.
9717129|NCT04562051||Routine prophylaxis group|Transplant centers adopted routine prophylaxis based on clinical experience
9717130|NCT04561934|Experimental|resin modified glassionomer cement|Application of Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE)
9717131|NCT04561934|Active Comparator|silver diamine flouride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
9717132|NCT04562155|Experimental|BAY1817080 dose A BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
9717133|NCT04562155|Experimental|BAY1817080 dose B BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
9717134|NCT04562155|Experimental|BAY1817080 dose C BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
9717135|NCT04562155|Placebo Comparator|Placebo|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
9717137|NCT04562272|Active Comparator|Mechanical unloading|Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment
9717138|NCT04562272|No Intervention|Standard care|Standard treatment of AMI after PCI according to guidelines.
9717139|NCT04561843||case group|Women complaining of any of the pelvic floor disorder symptoms such as: Pelvic organ prolapse (POP), Stress urinary incontinence (SUI), urgency symptoms of obstructed defecation, fecal incontinence (FI), pelvic pain, and/or sexual problems.
9717140|NCT04561843||control group|Women not complaining of any of the pelvic floor disorder symptoms
9717141|NCT04561960|Active Comparator|Control|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush and fluoridated toothpaste containing 1450ppm of fluoride"
9717142|NCT04561960|Experimental|Miswak|Participants will be trained to chew and condition a miswak stick Participants will be asked to use the miswak stick twice daily
9717143|NCT04561960|Experimental|Miswak Paste|"Participants will be trained to perform oral hygiene using the modified bass technique.~The participants will be asked to brush their teeth twice daily using a manual tooth brush a non-fluoridated toothpaste containing miswak extract"
9717144|NCT04562103|Experimental|Epinephrine QLB|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
9717145|NCT04562103|Active Comparator|Plane QLB|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
9717146|NCT04561804||LISESTYLE INTERVENTION|LOW CARB LOW GLYCEMIC LOAS DIET
9717147|NCT04561804||WEGHT LOSS SURGERY|SLEEVE OR MINBYPASS SURGERY
9717148|NCT04561635|Experimental|Intervention group|The intervention group was supplemented with three sachets of MMS each week for every other day for a period of 12 months. Each sachet containing 1 g consisting of ten vitamins and five minerals. It was to be sprinkled over a cooked meal or dissolved in a drink for the child. Written instruction for using and storing the MMS in simple language with visuals was given prior to the supplementation. The intervention group also received health and nutrition advice at 3, 6 and 9 months after supplementation begins.
9717149|NCT04561635|No Intervention|Control group|The control group received health and nutrition advice that were similar to intervention group and delivered by the investigator at 3, 6 and 9 months after the study began.
9717150|NCT04561921|Experimental|megnesium sulphate|Injection of 1.8 mL of an anaesthetic solution containing 1% magnesium sulphate , and 1.8% mepivacaine HCL with .06mg Levonordefrin HCl during inferior alveolar nerve block.
9717151|NCT04561921|Active Comparator|mepivacaine HCl|Injection of 1.8 mL of a local anaesthetic solution containing 1.8% mepivacaine HCL with .06mg Levonordefrin HCL during inferior alveolar nerve block
9717152|NCT04561622||Bipolar patients|Bipolar patients (type I,II, NOS) of the bipolar disorder expert center of CHU Grenoble Alpes.
9717153|NCT04561622||Healthy controls|Volunteers without any psychiatric disease matching inclusion criteria
9717154|NCT04561778|Active Comparator|HOT-CRT|Subjects randomized to HOT-CRT will undergo CRT as described below. His bundle pacing lead will be placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and LV timing may be optimized to achieve maximal resynchronization. This will be at the discretion of the implanting physician. Only FDA approved leads and devices will be used.
9717155|NCT04561778|Active Comparator|Biventricular Pacing|Subjects randomized to biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.Only FDA approved leads and devices will be used.
9779814|NCT04772989|Experimental|Dose Expansion Cohort 2|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
9980507|NCT01392586|Other|Systemic therapy|Systemic therapy possibly followed by local treatment of the breast tumor
9717156|NCT04561791|Experimental|Feasibility of TCE & Prevalence of BE|"Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment~Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH"
9717157|NCT04561895||control group|healthy volunteers with absence of NAFLD
9717158|NCT04561895||test group|patients with confirmed NAFLD diagnosis
9717159|NCT04561674|Experimental|Experimental Group|"The patients in the experimental group participated in Web-Based Patient Education with Colostomy and Ileostomy on computer between the third and seventh days after surgery.~The cards with the website address, username and the website QR code were given to the patients in order to be able to receive education after discharge.The patient and her family received the training from any computer or smartphone connected to the internet."
9717160|NCT04561674|No Intervention|Control group|The clinical routine was applied to the control group.
9717161|NCT04561882|Experimental|Transcatheter exclusion of atrial septal aneurysm|Transcatheter reconstruction of atrial septum might be achieved with PFO occluder through transseptal perforation in patients with ASA.
9717162|NCT04561999||Patients with Superficial Lymphadenopathy|
9717163|NCT04561687|Active Comparator|Azelastine and Nasal Budesonide|Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older
9717164|NCT04561687|Active Comparator|Montelukast and Nasal budesonide|Montelukast 5mg 6-14years old and 10mg for older
9717165|NCT04561687|Placebo Comparator|Nasal Budesonide and Placebo|Placebo once daily
9717166|NCT04561947|Active Comparator|TT+CTG|The combined connective tissue graft (CTG) with tunnel technique (TT)
9717167|NCT04561947|Experimental|TT+CGF|The combined concentrated growth factor (CGF) membrane with tunnel technique (TT)
9717168|NCT04561544|Experimental|Intervention in Fall 2020|Participants will receive the intervention in Fall 2020
9717169|NCT04561544|Other|Intervention in Spring 2021|Control in Fall 2020
9717170|NCT04561583|Other|LED light source system for endoscope|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).Test grop use LED light source system for endoscope
9717171|NCT04561583|Other|Pinpoint Endoscopic Fluorescence Imaging System|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).control group use Pinpoint Endoscopic Fluorescence Imaging System (Model: PC9000)
9717172|NCT04561739|Experimental|Drug-coated balloon|
9717173|NCT04561739|Active Comparator|Drug-eluting stent|
9717174|NCT04561765|Experimental|iCanCope|In this group, individuals will receive the iCanCope-NF program. The intervention will be delivered on a restricted password-protected mobile application. Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
9717175|NCT04561765|Experimental|iCanCop+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
9717176|NCT04561765|No Intervention|Control Group|The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
9717177|NCT04561830|Active Comparator|group 1|underwent laparoscopic-assisted excision of mesorectum
9717178|NCT04561830|Active Comparator|group 2|open excision of mesorectum
9717179|NCT04561466|Experimental|treatment group|"14 adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative.~Befizal® 200 mg will be tested for one year"
9717180|NCT04561856|Active Comparator|Group1|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume intravenously.
9717181|NCT04561856|Active Comparator|Group2|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume perinural plus 2 ml of normal saline intravenously.
9717182|NCT04561856|Placebo Comparator|Group3|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 2 ml of normal saline intravenously.
9717183|NCT04561414|Other|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope
9980508|NCT01392599|Experimental|Surgery|Patients with CRPS Type II
9980509|NCT01392612|Other|Erythropoietin|all subjects received epo iv.
9717184|NCT04561414|Other|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The control group use Ureteral stent (Cook Ireland Ltd.)
9717185|NCT04561726|Experimental|Study Group|"All of the 20 participants in the study group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.~Additionally, CTM was applied to the volunteers in study group for 6 weeks, 2 sessions in a week.CTM applied to lumbosacral area (basic region), lower toracal, scapular, interscapular and cervical regions, respectively."
9717186|NCT04561726|Active Comparator|Exercise Group|All of the 20 participants in the exercise group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
9717187|NCT04561505|Active Comparator|Holmium laser enucleation of prostate|patients that undergo Holmium laser enucleation of prostate (HoLEP) procedure
9717188|NCT04561505|Active Comparator|monopolar transurethral resection of prostate|patients that undergo monopolar transurethral resection of prostate
9717189|NCT04561817|Active Comparator|PI3K/AKT mutations (altered)|Participants with recurrent epithelial ovarian cancer with PI3K/AKT mutations (altered)
9717190|NCT04561817|Active Comparator|Without PI3K/AKT mutations (non-altered)|Participants with recurrent epithelial ovarian cancer without PI3K/AKT mutations (non-altered)
9717191|NCT04561752|Experimental|Treatment Sequence A-B|Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
9717192|NCT04561752|Experimental|Treatment Sequence B-A|Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
9717193|NCT04561349|Experimental|Task-oriented training (TOT)|Task-oriented training consisted of different functional tasks for lower limbs to improve balance and walk
9717194|NCT04561349|Active Comparator|Conventional rehabilitation treatment|Conventional rehabilitation treatment includes mat activities and range of motion (ROM) of all limbs, Lower limb strengthening and stretching, walking, cycling
9717195|NCT04561596|Experimental|Autohypnosis|
9717196|NCT04561596|Other|Control|
9717197|NCT04561531|Experimental|Intermittent bolus|In intermittent bolus of 3%NaCl group ,patients will receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and then follow plasma sodium,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
9717198|NCT04561531|Experimental|Traditional continuous drip|In traditional continuous drip of 3%NaCl group ,patients will receive 3%NaCl adjust rate start from 1 ml/kg/hr and follow plasma sodium every 1 hour,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
9717199|NCT04561219|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
9717200|NCT04561219|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days
9717201|NCT04561284|Experimental|Indigestible fiber supplementation|Participants will receive an indigestible fiber supplementation (classified) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals.
9717202|NCT04561284|Placebo Comparator|Placebo supplementation|Participants will receive placebo supplementation (Maltodextrin) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals. The amount of maltodextrin taken will be isocaloric with the amount of indigestible fiber.
9717203|NCT04561609|Active Comparator|CO2 treated|Patients receiving treatment with transcutaneous application of gaseous CO2 on lower limbs
9717204|NCT04561609|Placebo Comparator|control|Patients receiving placebo treatment with air on lower limbs
9717205|NCT04561492|Experimental|[68Ga]Ga-PentixaFor|
9717206|NCT04561570||Study Group: Vivity ACRYSOF IQ IOL|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
9717207|NCT04561570||Control Group: ACRYSOF IQ IOL|Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
9717208|NCT04561271|Experimental|foot reflexology|patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. The technique consists in stimulating reflex zones of foot, each zone corresponding to a specific organ. Almond oil will be used. The session is accompanied by relaxing music
9717209|NCT04561271|Sham Comparator|toucher massage|patients will receive one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
9717210|NCT04561167|Experimental|Cuspal reduction in MOD Cavity in endodontically treated teeth|Cavity design is of prime importance for the restoration of endodontically treated teeth. The cavity design plays an important role in the protection of the remaining tooth structure as well as the restoration. Cuspal reducuction and further coverage by the CAD/CAM generated indirect resin composite restoration has been proved in literature by the retrospective study done by (Chrepa V et al 2014) which studied 189 posterior endodontically treated teeth receiving indirect composite onlays with a median follow up time of 37 months and suggested this type of restoration as a viable option with 100% tooth survival and 96.8% restoration survival.
9717211|NCT04561167|Active Comparator|No cuspal reduction in endodontically treated teeth|In the present study, choosing the comparator to be the cavity design without cuspal reduction and further coverage (inlay) is done as an attempt to reduce the application of inlays in endodontically treated teeth. In accordance to the in-vitro study done by (M. D. Al Amri et al 2016) which tested the fracture resistance of endodontically treated mandibular first molars with conservative access cavity and different restorative techniques, catastrophic failures were highest in the composite group (100%), followed by the inlay and the amalgam groups (91.67%) and this was referred to the adhesive bonding mechanism of the composite restoration and the wedging effect of the inlay and the amalgam restorations (Rivera EM andWalton RE 2015)
9717212|NCT04561440||molecular karyotyping|
9717213|NCT04561440||cytogenic karyotyping|
9717214|NCT04561258|Experimental|Low Dose Cohort|A single infusion of ≥1x10e8 and <1x10e9 genetically modified T cells.
9717215|NCT04561258|Experimental|High Dose Cohort|A single infusion of ≥1x10e9 and <5x10e9 genetically modified T cells.
10196356|NCT00392327|Active Comparator|Arm A (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD five days a week for 6 weeks. Patients also receive vincristine sulfate IV over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim SC or IV beginning on day 4 and continuing until blood counts recover (at least 10 days).~Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity."
10196357|NCT00392327|Experimental|Arm B (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients receive vincristine sulfate and undergo radiation therapy as in Arm A. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm A."
10196358|NCT00392327|Experimental|Arm C (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm A. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive isotretinoin PO BID on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm A maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
9717216|NCT04561427||Pediatric Patients with narcolepsy|"Patients between 0 and 18 years old~Patients diagnosed with primary or secondary narcolepsy~From both gender"
9717217|NCT04561479|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training, inspiratory muscle training and progressive resistance training
9717218|NCT04561479|Sham Comparator|Control Group|Control group will receive alternative upper extremity exercises and breathing exercises.
9717219|NCT04560985|Experimental|Hydrophilic sealant|UltraSeal XT hydro™ sealant ®
9717220|NCT04560985|Active Comparator|Hydrophobic sealant|Helioseal-F Sealant ®
9717221|NCT04561401|Experimental|rTMS + IPRP|25 youth aged 10-18 years with severe chronic pain will be invited to partake in the Intensive Pain Rehabilitation Program, where they will receive Repeated Transcranial Magnetic Stimulation as one of their treatment interventions.
9717222|NCT04561401|Active Comparator|IPRP|Youth within this arm will not be receiving the rTMS intervention. Rather, they will only be enrolled within the IPRP.
9717223|NCT04560946|Experimental|PACT|Personalized Augmented Cognitive Training (PACT)
9717224|NCT04560946|Active Comparator|ETAU|Enhanced Treatment As Usual (ETAU)
9717225|NCT04561024||RT-PCR Positive Patients|RT-PCR confirmed patients positive for SARS-CoV-2
9717226|NCT04561024||Negative patients|RT-PCR confirmed patients negative for SARS-CoV-2 or patients with CXR performed before the emergence of COVID-19 pandemic
9717227|NCT04560959|Experimental|tACS arm|The patient would receive strings of tACS stimulations in 77.5 HZ, each string would last for 1 second, followed by an interval of 5 seconds. A total of 600 strings would be sent out to the patients.
9717228|NCT04561336|Experimental|avelumab plus cetuximab|avelumab at a dose of 10 mg/kg once every 2 weeks plus cetuximab at a starting dose of 400 mg/m2 by i.v.infusion over 120 minutes at first dose and at the dose of 250 mg/ m2 by i.v.infusion over 60 minutes for subsequent infusions every week.
9717229|NCT04561037|Active Comparator|Control Group|Control group patients received traditional physical therapy treatment. The traditional physical therapy treatment program consisted of TMJ mobilization techniques include distraction, anterior glide, anterior glide with pre-positioned mouth opening, medial/lateral glides, caudal-anterior-medial (CAM) glide, and CAM glide with pre-positioned mouth opening and isometric exercises against resistance for muscles of mastication.
9717230|NCT04561037|Experimental|Study Group|Study group patients received PEMFT, using EMG 8400 PEMF device (made in Italy, by EME) in addition to physical therapy treatment program.
10196359|NCT00392327|Experimental|Arm D (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm B. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm C. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive continuation therapy as in Arm C."
9717231|NCT04561310|Experimental|Post facilitation stretch|Post facilitation stretch with Maitland mobilization
9717232|NCT04561310|Active Comparator|Active release technique|Active release technique with Maitland mobilization
10196360|NCT00165256|Experimental|Observation (omission of RT)|Wide excision of DCIS; no radiotherapy (RT).
10196361|NCT00116220|Active Comparator|Treatment 1|External beam radiation therapy + 6 months total androgen ablation
9717233|NCT04560907|Experimental|Aquablation|
9717234|NCT04560907|Active Comparator|HoLEP|
9717235|NCT04561076|Experimental|Sequence 1|Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
9717236|NCT04561076|Experimental|Sequence 2|Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
10196362|NCT00116220|Active Comparator|Treatment 2|External beam radiation therapy
9717237|NCT04561076|Experimental|Sequence 3|Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
9717238|NCT04560842|Experimental|Conventional oxygen devise|Chose devise to keep patient's SpO2 > 92%
9717239|NCT04560842|Active Comparator|High flow nasal cannula|High flow oxygen device
9717240|NCT04560894|Experimental|SCT-I10A+SCT510|
9717241|NCT04560894|Active Comparator|Sorafenib|
9717242|NCT04561063|No Intervention|Arm A: No pharmacological intervention (PPE only)|No intervention
9717243|NCT04561063|Active Comparator|Arm B: Nitazoxanide (NTZ)|Nitozoxanide administered
9717244|NCT04561063|Active Comparator|Arm C: Sofosbuvir/daclatasvir (SOF/DCV).|Sofosbuvir/daclatasvir administered
9717245|NCT04560764|Experimental|Virtual Reality + Action Observation Therapy|Participants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
10196363|NCT00099086|Experimental|Experimental Arm|
9717246|NCT04560764|Sham Comparator|Virtual Reality + Landscape video|Participants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
9717247|NCT04560803|Experimental|Epidermal Grafting|This irradiated area of the skin will be treated with autologous epidermal grafts
9717248|NCT04560803|No Intervention|No treatment|This irradiated area will not receive any treatment
9717249|NCT04560920|Experimental|Experimental|This group will contribute PGD and it will be available in the study visit.
10196364|NCT00085202|Experimental|Stratum 1 (high-risk group)|"Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
10196365|NCT00085202|Experimental|Stratum 2 (average-risk group)|"Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
10196366|NCT05187507|Other|Children using fluoridated toothpaste|
10196367|NCT05187507|Other|Children using low- fluoridated toothpaste|
10196368|NCT05187507|Experimental|Children using Theobromine toothpaste (2%).|
10196369|NCT05187507|Experimental|Children using Theobromine toothpaste(4%)|
10196370|NCT05187494|Other|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine 2% with Epinephrine 1:80000, Korea) will be performed and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
9717250|NCT04560920|No Intervention|Control|This group will contribute PGD but it will not be available during a study visit, it will be available to the provider in a subsequent visit.
9717251|NCT04560660|Experimental|Ketamine and prolonged exposure (PE)|Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
9717252|NCT04560660|Placebo Comparator|Midazolam and prolonged exposure (PE)|Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
10196371|NCT05187494|Experimental|EMLA cream only|The palatine mucosa will be dried with a cotton ball 2*2 and then 0,2 g of Emla cream will be applied for 3 minutes . During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
9717254|NCT04560790|Experimental|BD111 Adults single group Dose|Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.
9717255|NCT04560712|Experimental|Arm I (acupuncture, usual care)|Beginning the day after surgery, patients undergo acupuncture sessions over 25 minutes QD for up to 7 days. Patients also undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
9717256|NCT04560712|Active Comparator|Arm II (usual care)|Patients undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
9717257|NCT04560465|Experimental|group A: Cases that had tranexamic acid infusion|Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour
9717258|NCT04560465|Placebo Comparator|Group B: Control|control were given perioperative placebo at the rate of 100mls per hour
9717259|NCT04560855||Covid19 Patients|Patients diagnosed as COVID-19 positive and managed on an outpatient basis.
9980510|NCT01392638|Placebo Comparator|sugar pill|Intervention: sugar pill
9717260|NCT04560322|Experimental|Venetoclax-Obinutuzumab +/- Acalabrutinib|"A treatment cycle is defined as 28 consecutive days. Participants with undetectable MRD (uMRD) at 1 year will complete an additional 1 year of VO then stop therapy.~Participants with high detectable MRD at 1 year will complete an additional 1 year of VO plus acalabrutinib then stop therapy.~Participants with low detectable MRD at 1 year will complete an additional 1 year of VO alone. If this eradicates MRD, they will stop therapy. If there is still residual MRD, they will complete an additional 1 year of IVO then stop therapy.~If progression occurs on VO, I will be added and IV will be administered indefinitely. After 2 years, V may be stopped and I continued as monotherapy at investigator discretion.~Infused Study Drug: Obinutuzumab on Days 1, 2, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 1-6~Oral Study Drugs: Venetoclax daily starting on Cycle 1 Day 22~Oral Drug: acalabrutinib daily for Days 1-28 (if applicable)"
9717261|NCT04560387|Experimental|Interventional|"Physician-lead complex program of weight-reducing interventions including education, diet counselling and regular physical activity aimed at achieving and maintaining a 10% reduction of baseline body weight.~Bariatric surgery - sleeve gastrectomy in a subgroup of subjects with BMI > 35 kg/m2, i.e. standard indication of bariatric surgery (patients with BMI > 35 kg/m2 and a presence of metabolic or other complications)."
9717262|NCT04560387|No Intervention|Conservative|Routine treatment of obesity
9717263|NCT04560751||Lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within ten days after TACE.
9717264|NCT04560478|Active Comparator|Pro Seal Sealant|ProSeal Sealant was applied to the facial surfaces of the maxillary anterior teeth (canine to canine)
9717265|NCT04560478|Active Comparator|MI Varnish|MI Fluoride Varnish was applied to the maxillary anterior teeth (canine to canine)
9717266|NCT04560400|Sham Comparator|No Concussion Conventional KD|Participants without concussion history perform conventional King-Devick Test.
9717267|NCT04560400|Active Comparator|No Concussion Reverse KD|Participants without concussion history perform reverse King-Devick Test.
9717268|NCT04560400|Sham Comparator|Single Concussion Conventional KD|Participants with 1 concussion history perform conventional King-Devick Test.
9717269|NCT04560400|Active Comparator|Single Concussion Reverse KD|Participants with 1 concussion history perform reverse King-Devick Test.
9717270|NCT04560400|Sham Comparator|Multiple Concussion Conventional KD|Participants with 2 or more concussion history perform conventional King-Devick Test.
9717271|NCT04560400|Active Comparator|Multiple Concussion Reverse KD|Participants with 2 or more concussion history perform reverse King-Devick Test.
9717272|NCT04560491||Frozen section|Patients underwent intraoperative sentinel node examination by frozen section
9717273|NCT04560491||Scrape cytology|Patients underwent intraoperative sentinel node examination by scrape cytology
9980511|NCT01392638|Active Comparator|sildenafil|Intervention: sildenafil citrate
9717274|NCT04560699|Active Comparator|Physiotherapeutic group|medical care and physiotherapeutic treatment
9980512|NCT01392651||Women with urinary stress incontinence|
9717275|NCT04560699|Active Comparator|medical care group|Medical care
9779815|NCT04772989|Experimental|Dose Expansion Cohort 3|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
9779816|NCT04772989|Experimental|Dose Expansion Cohort 4|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
9779817|NCT04772989|Experimental|Dose Expansion Cohort 5|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
9779818|NCT04766437|Experimental|Prasugrel or ticagrelor monotherapy|Once daily 10 mg prasugrel or twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 60 mg prasugrel or 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
9779819|NCT04765423|Experimental|NaF PET/CT scan and F-18 fluciclovine PET/CT|"Visit 1: Participant receives a whole body [F-18] NaF PET/CT (diagnostic study)~Visit 2: Participant receives a whole body [F-18] fluciclovine PET/CT within 3 weeks of Visit 1"
9779820|NCT04763408||Lenvatinib|Participants with advanced or unresectable HCC will initiate treatment with lenvatinib capsules based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
9779821|NCT04763408||Sorafenib|Participants with advanced or unresectable HCC will initiate treatment with sorafenib tablets based on physicians decision and will be observed until withdrawal of consent, loss to follow-up, death or until the end of the study (up to 7 years) whichever occurs first.
9779822|NCT04762160|Experimental|Tazmetostat in combination with rituximab|Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1 (C1D1). Tazemetostat will be administered from C1D1 to the end of Cycle 24, for 24 months of therapy or until disease progression, unacceptable toxicity, or withdrawal of consent. Rituximab will be administered by either subcutaneous injection or IV infusion according to the regional product prescribing information, labeling and institutional guidelines. Rituximab will be administered at a dose of 375 mg/m2 on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles.
9779823|NCT04740034|Experimental|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
9779824|NCT04740034|Experimental|Dose Expansion|An expansion cohort in subjects with mCRPC will be enrolled after RP2D is established.
9779825|NCT04733664|Experimental|Cohort 1|Patients will receive one dose of visible fluorescent injectate (VFI)™ and one dose of iohexol approximately 4 hours prior to undergoing dialysis followed by a second dose of VFI and iohexol approximately 1 hour after completing dialysis.
9779826|NCT04732065|Experimental|Arm A: ONC206 for participants with diffuse midline gliomas + prior therapy|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
9980513|NCT01392690|No Intervention|Waiting list control - no intervention|No intervention. After the post-test they were offered the prevention program.
9980514|NCT01392690|Experimental|Dominique's handy tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
9980515|NCT01392716|Experimental|Single arm|
9717276|NCT04560348|Experimental|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program An 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure games, and one adventure day camp (2 sessions). One session per week, 3 hours for each session. A variety of cognitive behavioral skills are taught in lectures and these skills are practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. The adventure training includes a day adventure camp and five 40-minute adventure games in the beginning of each workshop. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework are used in the intervention program.
9717277|NCT04560816|Experimental|Treatment Sequence 1|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: ALXN1840.~Period 2: Placebo-matching ALXN1840.~Period 3: Moxifloxacin."
9717278|NCT04560816|Experimental|Treatment Sequence 2|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: ALXN1840.~Period 2: Moxifloxacin.~Period 3: Placebo-matching ALXN1840."
9717279|NCT04560816|Experimental|Treatment Sequence 3|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Placebo-matching ALXN1840.~Period 2: ALXN1840.~Period 3: Moxifloxacin."
9717280|NCT04560816|Experimental|Treatment Sequence 4|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Placebo-matching ALXN1840.~Period 2: Moxifloxacin.~Period 3: ALXN1840."
9717281|NCT04560816|Experimental|Treatment Sequence 5|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Moxifloxacin.~Period 2: ALXN1840.~Period 3: Placebo-matching ALXN1840."
9717282|NCT04560816|Experimental|Treatment Sequence 6|"On Day 1 of each period, participants will receive a single dose of the following study interventions:~Period 1: Moxifloxacin.~Period 2: Placebo-matching ALXN1840.~Period 3: ALXN1840."
9717283|NCT04560569|Experimental|Group A|ABT weekly and 3BNC117 bi-weekly
9717284|NCT04560569|Experimental|Group B|both ABT and 3BNC117 treatment bi-weekly
9717285|NCT04560335|Experimental|Coach to fit|CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about 15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly.
9717286|NCT04560335|Other|Treatment as usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
9717287|NCT04560556||POC Testing Alone|POC HIV testing (the current standard of care) will be conducted for persons entering jail during the first two-month period.
9717288|NCT04560556||POC and 4th Generation Testing|POC plus 4th Generation HIV Testing will be conducted for persons entering jail during the second two-month period.
9717289|NCT04560556||4th Generation Testing Alone|4th Generation HIV Testing will be conducted for persons entering jail during the third two-month period.
9717290|NCT04560426|Experimental|Naked eyes & Instrument assistance|Identify the parathyroid glands through the experience of surgeons and assistance of instrument.
9717291|NCT04560426|No Intervention|Naked eyes only|Identify the parathyroid glands only through the experience of surgeons.
9717292|NCT04560673|Experimental|Group I (neurofeedback training, duloxetine)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
9717293|NCT04560673|Experimental|Group II (neurofeedback training)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks.
9717294|NCT04560673|Experimental|Group III (duloxetine)|Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
9717295|NCT04560374|Experimental|Experimental Group|Crochet octopus was delivered to the hands of the neonates in the experimental group 10 minutes before heel lance process and they were contacted with the crochet octopus up to 10 minutes after the procedure.
9717296|NCT04560374|No Intervention|Control Group|Control group neonates were performed all the process without delivering them any crochet octopus.
9717297|NCT04560283|Experimental|Experimental group receiving HYALOGYN®|
9717298|NCT04560283|Placebo Comparator|Control group undergoing expectant management|
9717299|NCT04560270|Experimental|Only arm|Blood samples to analyze ctDNA
9717300|NCT04560257|Experimental|Group intervene with HFNC|Review effect of HFNC as clinical trial among hospitalized patients with COVID-19 infection.
9717301|NCT04560244|Experimental|SHR 1701+radiotherapy|SHR-1701 Simultaneously Combined with High Fractionation and Low-dose Radiotherapy
9717302|NCT04559880|Experimental|Tranexamic Acid|"Intra-procedural tranexamic acid (TXA) - 1 gram, IV~Post-procedural tranexamic acid (TXA) - 1 gram, oral, three times per day for 5 days"
9980516|NCT01392729||Cohort|
9980517|NCT01392755|Experimental|1|
9980518|NCT01392755|Experimental|2|
9980519|NCT01392768|Experimental|Levetiracetam|
9980520|NCT01392768|Placebo Comparator|Placebo|
9980521|NCT01392781||normoweight PCOS patients|
9980522|NCT01392781||normoweight controls|
9980523|NCT01392781||overweight plus obese PCOS patients|
9980524|NCT01392781||overwqeight plus obese controls|
9980525|NCT01392794|Experimental|orally-disintegrating (OD) tablet precedence group|
9980526|NCT01392794|Experimental|conventional tablet precedence group|
9980527|NCT01392807|Experimental|Group 1|Normal hepatic function, 25 mg NKTR-118 administered orally
9717303|NCT04559958||non-dialysis CKD group|Participants with estimated glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2 more than three months and without regular dialysis will be enrolled in non-dialysis CKD group.
9717304|NCT04559958||ESRD group|Participants with eGFR ≤15 mL/min/1.73 m2 and underwent regular dialysis will be recruited in ESRD group.
9717305|NCT04559958||control group|Participants with eGFR ≧60 mL/min/1.73 m2 and without evidence of kidney damage such as albuminuria or abnormal findings on renal imaging will be enrolled in control group.
9717306|NCT04559919||Adults with epilepsy|"Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in VGR at the time of inclusion.~Based on the clinical information, patients can be categorized into relevant groups; single seizure, seizure-free with epilepsy, and drug-resistant epilepsy. Subgroups may also be selected based on age, sex, epilepsy sub-diagnosis, cause of epilepsy, use of a particular antiepileptic drug, or experience of a particular side effect."
9717307|NCT04559867|Active Comparator|Needle Knife Fistulotomy|The study doctor will gain access to the bile ducts using the cutting technique called a needle knife fistulotomy. When using this technique, the study doctor makes a cut directly into the bile duct.
9717308|NCT04559867|Active Comparator|Sphincterotomy|The study doctor will gain access to the bile ducts using the cutting technique called a sphincterotomy. Using this method, a heated metal wire cuts the opening to the bile duct after a wire has been passed into it.
9717309|NCT04559997|Experimental|Exercise+FU|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 6 years.
9717310|NCT04559997|Active Comparator|Exercise|After 3 weeks of intensive treatment, no special exercises are performed as a control.
9717311|NCT04559997|No Intervention|Controll|No intervention.
9717312|NCT04560010|Experimental|Group 1|TXA
9717313|NCT04560010|No Intervention|Group 2|no TXA
9717314|NCT04559854|Experimental|Mindful After Cancer|Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.
9717315|NCT04560231|Experimental|Group intervene with Remdesivir|Review effect of Remdesivir as clinical trial among hospitalized patients with COVID-19 infection. 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
9717316|NCT04560023|Experimental|Exposition to multimedia content|Ad hoc design multimedia content in a tablet (video with sound and subtitles).
9717317|NCT04560023|No Intervention|Standard procedures|Standard procedures.
9717318|NCT04560075|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages will receive a monthly check-in text prompt. Based on their response, the participants then receive either general psychoeducational videos and prompts to continue to monitor mental health or are then prompted to endorse stressors and symptoms they are experiencing to prompt awareness of treatment targets in daily life.
9717319|NCT04560075|Active Comparator|Psychoeducational Videos (PE) Only|Participants will receive a web link to a library of 4 PE videos. These brief 2-minute videos include general information about self-care during college.
9717320|NCT04560062||Population in Quito|576 randomly chosen patients with diabetes in District 17D06, Quito (Ecuador)
9717321|NCT04560062||Population in Esmeraldas|576 randomly chosen patients with diabetes in Eloy Alfaro District, Esmeraldas (Ecuador)
9717322|NCT04560153|Experimental|patient living with HIV|
9717323|NCT04560218|Experimental|Uterotonic agents group A|Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab
9717324|NCT04560218|Experimental|Uterotonic agents group B|Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo sublingually 2 tab
9717325|NCT04560218|No Intervention|Uterotonic agents group C|Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2 tab
9717326|NCT04560205|Experimental|Group intervene with Tocilizumab|"Review effect of Tocilizumab as clinical trial among hospitalized patients with COVID-19 infection.~Participants with severe disease will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory biomarkers."
9717327|NCT04559971|Experimental|1.0mg/kg|Drug: SLN124
9717328|NCT04559971|Placebo Comparator|Placebo|
9717329|NCT04559971|Experimental|3.0mg/kg|Drug: SLN124
9717330|NCT04559971|Experimental|Optional Cohort|An additional dose level may be explored
9717331|NCT04560036|Other|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
9717332|NCT04560049|Experimental|Phenolisation|Surgical pit excision and phenolisation of sinus tract
9717333|NCT04560049|Active Comparator|Silver Nitrate Irrigation|Surgical pit excision and silver nitrate irrigation of sinus tract
9717334|NCT04560114|Experimental|Essential oils|Inhalation will be carried out via an inhaler stick containing essential oils (Mentha x Piperita; Citrus Limon; Zingiber Officinale)
9717335|NCT04560192|Active Comparator|Intervention group|Treatment with the mindfulness based emotion regulation therapy (MBERT) in block 1, no study-treatment in block 2 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy).
9717336|NCT04560192|Other|Treatment as usual (TAU)|No study-treatment in block 1 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy), treatment with the mindfulness based emotion regulation therapy (MBERT) in block 2.
9717337|NCT04560192|No Intervention|Control condition|Healthy subjects will get a single TSST session.
9717338|NCT04559841|Active Comparator|bone substitute; NanoBone® (group 1, control group)|a synthetic bone substitute consisting of nanocrystalline hydroxyapatite and silica fabricated in a sol-gel process.
9717339|NCT04559841|Experimental|simvastatin + NanoBone (group 2, test group)|medications used to treat hypercholesterolemia
9717340|NCT04559828|Active Comparator|Pomace olive oil|50 g of pomace olive oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
9717341|NCT04559828|Active Comparator|High-oleic sunflower oil|50 g of high-sunflower oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
9717342|NCT04559516|Experimental|Mobile application-based home exercise intervention|"The exercise program will be administered over 12 weeks through the Ethica mobile app. Participants will perform exercise sessions at home guided by instructional video accessed via Ethica, six days per week. The program will include a combination of education, endurance, strength, and respiratory muscle training.~The Ethica mobile app will provide a daily alert and a daily exercise video. There will be background monitoring of step counts and actigraphy will be monitored for one week intervals at baseline, at week six, and at week twelve."
9717343|NCT04559516|Active Comparator|Standard care|No supervised exercise session will be performed. Symptoms and quality of life will be monitored in the same manner as the intervention group, and participants will receive the same educational message alerts through the Ethica app as the exercise intervention group.
9980528|NCT01392807|Experimental|Group 2|Mild hepatic impairment, 25 mg NKTR-118 administered orally
9980529|NCT01392807|Experimental|Group 3|Moderate hepatic impairment, 25 mg NKTR-118 administered orally
9717346|NCT04559490||Standard formula|Participants receiving intact protein lactose-based formula, exclusively for at least 3 months.
9717347|NCT04559490||Sensitive|Participants receiving intact protein glucose/sucrose- based formula, exclusively for at least 3 months.
9717348|NCT04559425||Prospective observational cohort 1|Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
9717349|NCT04559425||Prospective observational cohort 2|Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
9717350|NCT04559607|Experimental|Experimental group: TACE+Camrelizumab+Apatinib|Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
9717351|NCT04559607|Active Comparator|Control group: TACE|TACE
9717352|NCT04559503|Experimental|İntervention Group|Progressive relaxation exercises were applied once a day for four weeks in the intervention group in addition to the standard treatments. The patients were called 3 times each week on the telephone, and it was monitored whether they continued to do the exercises.
9717353|NCT04559503|No Intervention|Control group|The control group received standard treatment.
9717354|NCT04559789|Experimental|Digital Lifestyle Intervention|Participants randomized to the intervention arm will receive access to a digital intervention consisting of the MindMate cognitive health app and Neurotrack's personalized health coaching platform.
9717355|NCT04559789|Active Comparator|Health Education|Participants randomized to the control arm will receive digital health education materials that mirror the content in the app.
9717356|NCT04559776|Experimental|typically developing toddlers|toddlers with a typical development and with less than 3 years old and less than 6 months of independent walking
9717357|NCT04559776|Experimental|unilateral cerebral palsy toddlers|toddlers with a unilateral cerebral plasy and with less than 3 years old and less than 6 months of independent walking
9717358|NCT04559412|Experimental|Sofusa Enbrel|Enbrel® administered by the Sofusa® DoseConnect™ delivery system
9717359|NCT04559724|Experimental|Indego-Assisted Gait Rehabilitation|"Every session of Indego-assisted gait rehabilitation will last 30 minutes, excluding preparation times (dressing, measurements, and adaptation of the brace to the anthropological measures of the various patients). The Indego program will be set based on the patient's ambulatory abilities, assessed by the Functional Ambulation Classification (FAC):~subjects unable to walk or high-.assistance needed (FAC = 0-2): Motion + program;~Subjects able to walk with mid/mini assistance or with supervision only (FAC = 3-5): Therapy + program.~During the treatment, the program change from Motion + to Therapy + is allowed based on the experts' opinion."
9717360|NCT04559672||Laminoplasty Group|Patients who underwent cervical laminoplasty surgery due to myelopathy.
9717361|NCT04559672||Laminectomy and Fusion Group|Patients who underwent cervical laminectomy and fusion surgery due to myelopathy.
9717362|NCT04559737|No Intervention|Usual Care|Patients will receive Auto-Monitoring text messages. The Auto-Monitoring tool that will be used is a function within Somnoware (Somnoware, Inc.) patient management platform, which is the national KP benchmarked platform for sleep management software. Fixed scheduled follow-up visits will be scheduled at 1-month (telephone encounter), 3-months (in-person or video encounter), and 1-year (in-person or video encounter). This sequence of follow-up visits reflects current real-world practice. Patients are eligible for additional visits when self-initiated. Sleep questionnaires will be delivered at 1, 3, and 6 months and at 1 year.
9717363|NCT04559737|Active Comparator|Case Management|Patients will undergo the same follow-up process as described in the Usual Care Pathway. A population CM dashboard (Somnoware, Inc.) will be used to automatically identify PAP strugglers (defined as <70% nights with ≥4 hours use during the preceding month) for 1 year. Video encounters will be triggered for these select patients for troubleshooting. Additionally, throughout this 1-year period, Q1 window of <70% nights >4 hours will trigger a phone call and at the discretion of the case manager convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year.
9717364|NCT04559568|Experimental|LY3522348 (Part A)|LY3522348 administered orally.
9717365|NCT04559568|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
9717366|NCT04559568|Experimental|LY3522348 (Part B)|LY3522348 administered orally. Some participants will also receive midazolam.
9717367|NCT04559568|Placebo Comparator|Placebo (Part B)|Placebo administered orally. Some participants will also receive midazolam.
9717368|NCT04559386|Experimental|Overall trial|People who complete the questionnaire.
9980530|NCT01392820|Experimental|TC-5214|
9980531|NCT01392820|Placebo Comparator|Placebo|
9717369|NCT04559308|Experimental|metformin arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.
9717370|NCT04559308|Active Comparator|control arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel followed by surgery.
9717371|NCT04559191|No Intervention|HbA1c-guided group|Glycemic control is controlled by guideline-recommended HbA1c control.
9717372|NCT04559191|Active Comparator|CGM-guided group|Glycemic control is controlled by CGM-guided control.
9717373|NCT04559165|Experimental|sericin and chitosan cream|Apply sericin and chitosan cream on pressure ulcer 2 times/day for 21 days.
9717374|NCT04559165|Active Comparator|Cavilon cream|Apply cavilon cream on pressure ulcer 2 times/day for 21 days.
9717375|NCT04559100||Severe and critical COVID-19 survivors|"Radiological alterations assessed by chest radiography and/or thoracic computed tomography Lung function alterations assessed by spirometry, diffusing capacity for carbon monoxide, 6 minute walk.~Quality of life alterations: saint george respiratory questionnaire"
9717376|NCT04559113|Experimental|Group intervene with Methylprednisolone|"Review effect of Methylprednisolone as clinical trial among hospitalized patients with COVID-19 infection.~Anyone of the following Corticosteroids dose will be given to moderate disease patients of COVID-19~0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day. *Note: in Diabetic patients' dose of methyl prednisolone should be divided in doses preferably 40mg BD."
9717377|NCT04559204|Experimental|experimental group|408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
9717378|NCT04559204|Active Comparator|control group A|408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
9717379|NCT04559204|Active Comparator|control group B|408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
9717380|NCT04559295|Experimental|Stem Cells (BMC)|Subjects in the BMC arm received an injection of bone marrow concentrate
9717381|NCT04559295|No Intervention|Control|Subjects in the control arm received no treatment for their condition
9717382|NCT04559360|Active Comparator|Active group - PRESTOapp users|Once users are recruited, an independent researcher will randomize the participants using a 1:1 sequential method in two groups of 76 individuals and will assign a 6-digit identification code (IC) to each participant. The IC will be given to the participant on a reminder card and will be used to access the app guaranteeing its confidentiality. The name of the subjects and their respective code will be stored in independent servers for methodological, security and legal reasons. The intervention group will be asked to use the app for a period of 2 months. The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
9717383|NCT04559360|No Intervention|Control group|The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
9717384|NCT04559321|Active Comparator|Holmium laser|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser.
9717385|NCT04559321|Experimental|Trilogy|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with LithoClast Trilogy EMS and 1.5 mm x 440 mm probe
9717386|NCT04559269||Cohort 1|Cohort of 98 patients suffering from sleep disorders hospitalized between September 2017 and January 2019 in the Sleep Medicine Center of the Croix Rousse Hospital (Lyon) for objective sleepiness evaluation with polysomnography and MWT.
9717387|NCT04559763||Healthy Adult Volunteers|
9717388|NCT04559087|Experimental|Natural Orifice Specimen Extraction Surgery|
9717389|NCT04559087|Sham Comparator|Conventional laparoscopy|
9717390|NCT04558853|Experimental|Autologous NK cells|"The investigation product is a cell suspension based on ex vivo expanded NK cells from patients with MM. The treatment is strictly autologous. The IP is given as three infusions with escalating doses.~Mode of administration Intravenous infusions. Dose levels~First infusion; 5x10^6 cells/kg body weight~Second infusion; 50x10^6 cells/kg body weight~Third infusion; 100x10^6 cells/kg body weight"
9717391|NCT04559074|Experimental|Interventional|Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
9717392|NCT04559074|No Intervention|Observational|This group will record blood pressure readings and data on a daily basis for a total of 3 months. They will not take any medication. They will be reviewed on a monthly basis in consultations.
9717393|NCT04558944|No Intervention|Control group|This group received pain and pruritus medication as needed, received the usual physical therapy as per the protocol of our burn unit, as well as compression garments, silicone sheets and gels and moisturizing cream twice a day. Additionally, the patients were advice on reducing sun exposure and applying +50SPF sunblock on a daily basis.
9717394|NCT04558944|Experimental|Extracorporeal Shock Wave Therapy group|This group received the same treatment as the control group plus Extracorporeal Shock Wave Therapy (The DermaPACE® System, SANUWAVE Health Inc., USA) with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
9717395|NCT04559152|Experimental|Zinc Supplementation Group|Zinc capsule (20mg) was taken in the morning after meals once daily for 12 weeks. All subjects in this arm were also given iron and folic acid tablets in accordance with the Indonesian government program.
9717396|NCT04559152|Placebo Comparator|Placebo Group|Placebo (sugar tablet) was taken in the morning after meals once daily for 12 weeks. All subjects were also given iron and folic acid tablets in accordance with the Indonesian government program. Each placebo tablet was inserted into a capsule of the same shape and color with zinc capsule
9717397|NCT04558983||Retinitis Pigmentosa|Patients with Retinitis Pigmentosa
9717398|NCT04558996||OBS COVID 3|"Objective/s The purpose of this study was to test if pregnant patients with COVID-19 have more obstetrical morbidity than those non-infected.~Determine the variables that are associated with more maternal and neonatal morbidity.~Quantify the risk of adverse pregnancy outcomes (e.g., miscarriage, stillbirth, growth restriction) and neonatal outcomes (e.g., NICU, prematurity, death, birth defects).~Design Longitudinal cohort case study to quantify the obstetrical and perinatal morbi-mortality throughout all hospitals in Spain with a universal, consecutive PCR based screening program.~Recruitment: 1st March 2020 to 30 September 2020. Spanish sites collected in Appendix 1."
9717399|NCT04558996||OBS COVID 4|Substudy 4. Epidemiological prevalence study Objective/s Determine the prevalence of SARS_COV2 infection in Spanish pregnant women Design Cross-sectional study. The nQuery Advisor Release 7.0 software was used to calculate the sample size, based on the available data. As we do not have data on the prevalence of COVID-19, we set an expected percentage of 50% (a situation that maximizes the sample size) of asymptomatic women during delivery. We determined the sample size for a COVID-19 delivery prevalence study with an expected prevalence of 50%, a 95% confidence level and 5% accuracy, resulting in a sample size of 1056 pregnant women.
9717400|NCT04558814|Other|Systemic lupus erythematosus patients|Evaluation of serum galectin-9 level
9717401|NCT04558814|Other|Control group|Evaluation of serum galectin-9 level
9717402|NCT04559542||Female material art athletes|Females practicing material art during recruitment time, in Oslo-area in Norway
9717403|NCT04559048||FK506-treated group|In FK506-treated group, the patients who underwent liver transplant are treated with FK506 immunosuppressive therapy.
9717404|NCT04559048||control group without FK506 treatment|In control group, the patients who underwent liver transplant are treated without FK506.
9717405|NCT04558892|Experimental|Nephrotic syndrome - fixed dose (NS-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
9717406|NCT04558892|Experimental|Nephrotic syndrome - adjusted dose (NS-AD)|Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
9717407|NCT04558892|Active Comparator|Control - fixed dose (C-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
9717408|NCT04558606|Experimental|Sonic toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~Each patient is instructed by the hygienist in the correct use of the sonic toothbrush"
9717409|NCT04558606|Active Comparator|Manual toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).~Each patient is instructed by the hygienist in the correct use of the manual toothbrush"
9717410|NCT04559477|Experimental|Static extension endurance exercise|static back extension endurance exercise
9717411|NCT04559477|Active Comparator|Dynamic extension endurance exercise|dynamic back extension endurance exercise
9717412|NCT04558788||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
9717413|NCT04558788||Colitis|Patients with active colitis
9717414|NCT04558788||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
9717415|NCT04558801|Experimental|Mobile application-based lifestyle change program|"This arm receives the mobile application-based lifestyle change program at baseline. The mobile application-based lifestyle change program consists of twice a week content for the first 6 months, continuing with less frequent content for the following 6 months. The follow-up period is 6 months. Weight is measured and blood samples (lipids, glucose and metabolic syndrome measures) are collected at 0, 6, 12, and 18 months.~The mobile application-based counselling contains aspects of cognitive behavior therapy and persuasive system design and consists of twice a week reminders, tasks, self-monitoring, and reflection."
9717416|NCT04558801|Active Comparator|"The waiting-list control"|"The waiting-list control arm will receive mobile application-based lifestyle change program after 6 months, following same principles as Mobile application-based lifestyle change program-arm, excluding follow-up period (6 months of waiting list, 6 months of more intense and 6 months of less intense application use)."
9717417|NCT04558697|Experimental|Shepherd's Purse extractum oleosum vagitories|Vagitories containing Calendulae extractum oleosum 5,5% (w/w), Bursae pastoris extractum oleosum 5,5% (w/w), Matricariae extractum oleosum 5,5% (w/w), Hyperici extractum oleosum 5,5% (w/w) and Millefolii extractum oleosum 5,5% (w/w) as active component
9980532|NCT01392833|Active Comparator|steroids|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day for six months followed by oral prednisone 0.2 mg/kg every other day for a further six months.
9980533|NCT01392833|Experimental|steroids plus azathioprine|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further six months.
9717418|NCT04558697|Experimental|Tea tree oil vagitories|Vagitories containing tea tree oil, 200 mg per each vagitorie as active component
9717419|NCT04558697|Experimental|Hyperici extractum oleosum vagitories|Vagitories containing Hyperici extractum oleosum 32% (w/w) as active component
9717420|NCT04558697|Active Comparator|Vagitories - Probiotic|Commercially available vagitories with probiotic
9717421|NCT04558723|Experimental|ICD group|Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.
9717422|NCT04558723|No Intervention|Optimal HF care group|Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.
9717423|NCT04558710||CGM|CGM users
9717424|NCT04558710||SMBG|Non-CGM users
9717425|NCT04558567|Other|Open-Label|
9717426|NCT04558645||Patients with type 1 diabetes mellitus|Patients with Type 1 diabetes mellitus willing to participate in the study
9717427|NCT04558645||Healthy controls|Healthy controls without chronic disease willing to participate in the study
9779827|NCT04732065|Experimental|Arm B: ONC206 + radiation therapy for newly diagnosed participants|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
10196372|NCT05187494|Experimental|chemical permeability enhancer DMSO with EMLA cream|The palatine mucosa will be dried with a cotton ball and then EMLA cream will be mixed with a permeability enhancer in the laboratory of pharmaceutical industries at the Faculty of Pharmacy at Damascus University according to the following: Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
10196373|NCT05187494|Experimental|Oral patches with EMLA Cream|The palatine mucosa will be dried with a cotton ball and then 0.2 g of EMLA cream 5% will be applied by using an oral patch 14*14 mm for 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
9717428|NCT04558736|Experimental|Haploidentical HCT|"To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability.~Cells for infusion are prepared using the CliniMACS System."
10196374|NCT05187494|Experimental|Micro-needle patches dissolved with EMLA Cream|The palatine mucosa will be dried with a cotton ball 2*2 and then 0.2 g of EMLA cream 5% will be applied by using an micro-needle patch 14*14 mm, 0,25 micron for 3 minutes.
9717429|NCT04558515||Case|Symptomatic patients positive for malaria by PCR
10196375|NCT05187481|Experimental|Experimental Group|The experimental group will take Jianpi Huatan dispensing granule while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
9717430|NCT04558515||Control|Symptomatic patients negative for malaria by PCR
9717431|NCT04558684|Experimental|radiotherapy, chemotherapy and PD1 inhibitor|Treatment will comprise 5 daily fractions of radiotherapy at 5 Gy per fraction followed by chemotherapy and immunotherapy. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard surgery.
9717432|NCT04558541|Experimental|Sensitivity to phonological rules: Children|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern; Arm 3: Family Resemblance/Prototype Pattern
9717433|NCT04558541|Experimental|Sensitivity to semantic category cues: Children|Arm 1.Referential cue during OR learning.
9717434|NCT04558580|No Intervention|Standard of Care|
9717435|NCT04558580|Experimental|Rufinamide|
9717436|NCT04558762||Women who had a MUS inserted.|Women who underwent surgery with insertion of a MUS due to SUI 2006-2010 in Sweden with the MUS coming out retropubic (TVT) or through foramen obturatorium (TOT).
9717437|NCT04558762||Controls|Women who have not had a MUS inserted due to stress urinary incontinence. Matched in age.
9717438|NCT04558398|Experimental|Resistance exercise training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
9717439|NCT04558398|Experimental|High-intensity interval training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
9980534|NCT01392846||Resolute Integrity|Patients receiving Resolute-Integrity stent
9980535|NCT01392872|Other|sclerosis|
9717442|NCT04558463|Experimental|Favipiravir|The favipiravir group received loading dose and maintenance dose of Favipiravir for 2 up to 7 days in addition to standard therapy
9717443|NCT04558463|Active Comparator|Oseltamivir|The oseltamivir group was given oseltamivir for 7 days.
9717444|NCT04558411|No Intervention|Control Group (assessment only)|This group will receive assessments only.
9717445|NCT04558411|Experimental|Assessment + Intervention Group|This group will receive assessments and the 14 brief intervention videos.
9779828|NCT04732065|Experimental|Arm C: ONC206 + radiation therapy, DMGs with evidence of first progression but previously untreated|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
9779829|NCT04732065|Experimental|Arm D: ONC206 Therapy, Primary malignant brain tumors with progression|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
9779830|NCT04707469|Experimental|Oral semaglutide 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68).
9779831|NCT04707469|Experimental|Oral semaglutide 25 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12) and 25 mg (week 13-68).
9779832|NCT04707469|Active Comparator|Oral semaglutide 14 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8) and 14 mg (week 9-68).
9785204|NCT01245673|Experimental|Prevnar, T Cells, Lenalidomide, MAGE A-3|All patients will receive a priming immunization with a MAGE-A3/GM-CSF vaccine with adjuvant Hiltonol® (Poly-ICLC) along with the pneumococcal conjugate vaccine/PCV control vaccine about 10 days before a steady-state mononuclear cell apheresis. Patients will then undergo hematopoietic stem cell mobilization. All patients will receive high-dose melphalan followed by hematopoietic stem cells on day 0. On day +2, patients will receive anti-CD3/anti-CD28-costimulated autologous T cells. At days 14, 42, and 90, patients will receive MAGEA3/GM-CSF (+Hiltonol® Poly-ICLC) and PCV booster immunizations followed by restaging studies and immune assessments at day +100. At day 100, after immunizations and restaging, patients will start Revlamid® (Lenalidomide) maintenance therapy followed by 2 additional MAGE-A3 and PCV immunizations at days 120 and 150.
9980536|NCT01392898|Experimental|liraglutide|
9980537|NCT01392898|Active Comparator|insulin|
9717446|NCT04558242|Active Comparator|Genix LLLT Therapeutic Cap|This is a low-level light device containing 150, 650 nanometer LEDs and 50, 940 nanometer LEDs of equal energy output, fixed at 10 milliwatts in a low profile helmet.
9717447|NCT04558242|Sham Comparator|Sham Non-therapeutic Placebo Cap|Sham Placebo Cap low profile helmet containing no low-level light.
9717448|NCT04558333||LTx (lung transplant) patients|identification of possible biomarkers
9717449|NCT04558229|No Intervention|Standard of Care Clinician Counseling|
9717450|NCT04558229|Experimental|Additional Standardized Counseling|
9717451|NCT04558099|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
9717452|NCT04558099|No Intervention|Wait-list control|Usual practice
9717453|NCT04558268|Experimental|treatment group|
9717454|NCT04558268|Placebo Comparator|placebo group|
9717455|NCT04558307||Observational Intervention|Rapid SARS-CoV-2 testing strategy
9717456|NCT04558307||Behavioral Intervention|Community-driven messages to promote COVID-19 testing
9717457|NCT04558177|Experimental|Stimulation Group|Will receive ~1.5mA transcranial stimulation for 20 minutes, 5x per week from a direct current stimulator
9717458|NCT04558177|Sham Comparator|Device placed only, no stim|Same as experimental group but the stimulation from the direct current stimulator will be initiated and then stopped
9717459|NCT04558060|Experimental|Virtual Standardized Patient|Training for 45 minutes at each training time point with a computer program that presented a virtual human patient and two simulated patient encounters. The virtual standardized patient involves a branching story line. Participants select 1 of 3 computer-generated response options at each conversational pause: 1) a response that is consistent with the principles and skills of MI, 2) an MI inconsistent response, or 3) a response that is mixed - partly consistent and partly inconsistent with MI.
9717460|NCT04558060|Active Comparator|Academic Study|Study of a summary handout of motivational interviewing concepts and techniques for 45-minutes.
9717461|NCT04558424|Experimental|Intervention group|This group will consist of 50 patients who will be treated with zinc and vitamin C at a dose of 220 mg and 1 gram orally daily for 10 days in addition to their standard treatment
9717462|NCT04558424|Placebo Comparator|Placebo group|This group will consist of 50 patients who will receive placebo at a dose same dose for 10 days in addition to their standard treatment.
9717463|NCT04558372|Experimental|Group 1- 43 COVID-19 patients|COVID-19 patients breath normally via disposable non-rebreathing mask
9717464|NCT04558372|Experimental|Group 2- 40 non COVID-19 patients|Non COVID-19 patients breath normally via disposable non-rebreathing mask
9717465|NCT04558372|Experimental|Group 3- suspected COVID-19 patients|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
9717466|NCT04558281|Experimental|Active Treatment|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)
9717467|NCT04558281|Placebo Comparator|Placebo|This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline
9717468|NCT04558086|Experimental|Reduce pain and fear|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
9717469|NCT04558086|Experimental|control group|To develop the intervention strategies of hospitalized school-age children with IV placement, using photo book to further examine the effectiveness of reducing IV pain and fear.
9980538|NCT01392911|Active Comparator|10 mg/kg rifampicin|7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.
9717472|NCT04558008|Experimental|Online MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
9717473|NCT04558008|No Intervention|Wait-list control|Usual practice
9717474|NCT04558073|Experimental|Body Project (BP)|The BP intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
9717475|NCT04558073|Experimental|Healthy Weight Program (HW)|The HW intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
9717476|NCT04558073|No Intervention|Waiting-list (WL)|The waiting list will consist of two assessments each separated by a one-month interval. Following this waiting time, participants will receive the BP intervention.
9717477|NCT04558034|Active Comparator|Interventioncryotherapy/control|Subjects will have one mitt/one slipper and serve as their own control
9717478|NCT04558034|No Intervention|standard of care|Subjects will have two mitts/slippers
9717479|NCT04557774||Liver cirrhosis group|All included patients were asymptomatic at the baseline with no evidence of neurological impairment. Patients with a history of moderate alcohol drinking plus hepatitis B/C virus infection, medication for sedation, MELD (Model for End-stage Liver Disease) score of more than 20, OHE, seizure, head trauma, stroke, dementia, Parkinson's disease, or any kind of focal neurologic deficits were excluded. Any patients who were suspected of alcohol induced direct neurologic damages such as Wernicke's encephalopathy, alcohol induced spinal cord disease, or alcohol induced peripheral nerve disease were excluded. After evaluating the data including the laboratory findings, image findings, endoscopic findings, and medical records of all these patients, as well as liver biopsy findings for some patients, we sub-classified these 88 patients into two groups: alcoholic LC and viral LC. Finally, 80 patients (viral: 37; alcohol: 43) with compensated LC were prospectively considered in this study.
9717480|NCT04558021|Experimental|Intervention Arm-I|Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
9717481|NCT04558021|Placebo Comparator|Intervention Arm-II|10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
9717482|NCT04557930|No Intervention|Usual Care Control|The control arm occurs prior to receipt of the video game intervention. Each hospital group 'crosses over' from control to intervention at a randomized time point.
10196376|NCT05187481|Placebo Comparator|Control Group|The experimental group will take Placebo granule (containing 1/10 of the formula dose of Jianpi Huatan Granule) while receiving chemotherapy and/or targeted therapy, once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
9717483|NCT04557930|Experimental|Video Game Intervention|Each hospital group 'crosses over' from control to intervention at a randomized time point by receiving a study iPad and playing the video game loaded on the iPad.
9717484|NCT04557878|Experimental|Hypertonic Dextrose Solution|
9717485|NCT04557878|Active Comparator|Liquid Phase Concentrated Growth Factor (LPCGFs)|
10196377|NCT05187468|Experimental|ESWT 1|Extracorporeal Shockwave Therapy 1000 pulses, 60 mJ, 10 Hz
10196378|NCT05187468|Experimental|ESWT 2|Extracorporeal Shockwave Therapy 2000 pulses, 60 mJ, 10 Hz
10196379|NCT05187468|Active Comparator|Ultrasound therapy, Massage, Heat Pack|10 Min massage 5 min US therapy 10 min Heat pack
9717486|NCT04557826|Experimental|RD19 Experimental Device|RD19 Experimental Device used twice/day for 3 minutes each use at least 4 hours, and preferably 8-12 hours, apart
9717487|NCT04557722|Active Comparator|Group 1: 0-30° technique.|Procedure: 0-30° Biplanar Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
9717488|NCT04557722|Active Comparator|Group 2: new 0-90° technique.|Procedure: new 0-90° Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
9717489|NCT04557982||Children aged 3 < 4 years|Children aged 3 < 4 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
9717490|NCT04557982||Children aged 4 < 5 years|Children aged 4 < 5 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
10196380|NCT05187429|Experimental|Dose escalation phase (Cohort A)|Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: 0.1, 0.3 or 1.0 mg/kg Duration: Single dose administered on Study Day 7
10196381|NCT05187429|Experimental|Randomization phase (Cohort B)|Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: determined from Cohort 1 Duration: single dose administered on Day 0 (baseline)
10196382|NCT05187429|Placebo Comparator|Randomization phase comparator (Cohort B)|Comparator: saline Dose form: infusion Dose route: intravenous Duration: single dose administered on Day 0 (baseline)
10196383|NCT05187403|Experimental|Laquinimod - Single Ascending Doses|One single dose of laquinimod eye-drops. There are up to four planned dose levels.
9717491|NCT04557982||Children aged 5 < 6 years|Children aged 5 < 6 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
9717492|NCT04557839|Active Comparator|Traditional physical therapy balance exercise|Traditional physical therapy including balance exercise on mate and swiss ball.
9717493|NCT04557839|Experimental|proprioception based balance training|proprioception based balance training with eye open and close on soft , firm and foam surface.
9717494|NCT04557852||Anterior transvaginal mesh group|Women received anterior transvaginal mesh surgery without concomitant mid-urethral sling surgery.
9717495|NCT04557709||Observational (chart review)|Patients' medical charts are reviewed.
10196384|NCT05187403|Placebo Comparator|Placebo - Single Ascending Doses|One single dose of placebo eye-drops.
10196385|NCT05187403|Experimental|Laquinimod - Multiple Dose|Eye-drops administered once daily for 14 days. The dose level will be defined in the SAD-part of the study.
10196386|NCT05187403|Placebo Comparator|Placebo - Multiple Dose|Eye-drops administered once daily for 14 days.
10196387|NCT05187299|Experimental|Group with an observation tool|In this group (OT +), each student will complete an observer tool each time another dyad is performing
10196388|NCT05187299|No Intervention|Group without observation tool|In this group (OT-), the student will not use the observer tool and will observe other students without any physical support.
10196389|NCT05187234|Experimental|Education|Experimental: intervention group The patients were interviewed 3 times, initially at the 1st month and at the 3rd month. All forms were initially administered to patients in the intervention group. Patients were randomly assigned to the intervention group and participated in a one-on-one Roy Adaptation Model-based training program consisting of an initial 30-45 minute session. Hemodialysis Patient Education Manual prepared by the researchers was applied to the patients in the intervention group during the training. All forms were re-administered to the patients in the intervention group in the 1st and 3rd months.
10196390|NCT05187234|No Intervention|Control|Education and training manual based on the Roy adaptation model was not given to the patients.
10196391|NCT05187156|Experimental|Intervention|Veterans will participate in a novel intervention to improve PTSD and social support
10196392|NCT05187156|Active Comparator|Treatment as usual|Veterans will participate in usual care in PCMHI
9717496|NCT04557943|Active Comparator|Sodium Hyaluronate|Hyaluronate sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
9980539|NCT01392911|Experimental|20 mg/kg Rifampicin|7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
9717497|NCT04557943|Experimental|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
9717498|NCT04557904|Experimental|Group A: Craniocervical flexion exercises|Exercise protocol were performed over a 4 week duration under the command of a supervisor. Subjects were asked not to obtain any other particular intervention for cervical ache. Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible.
9717499|NCT04557904|Experimental|Group B: Scapular stabilization exercises|Group B performed scapular stabilization workout for 30 minutes per session, three days a week for four weeks. The scapular stabilization exercises were made up of four stages
9717500|NCT04557865|Experimental|Participants receving 18F-PMPBB3 (APN-1607) PET imaging|Single arm, open label
9717501|NCT04557787|Active Comparator|Intermittent catheter; SpeediCath® standard Female|Standard of care
9980540|NCT01392911|Experimental|25 mg/kg Rifampicin|7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
9717502|NCT04557787|Experimental|New intermittent catheter variation 1 for females|Intermittent catheter variation 1 for females. The new catheters are not named at this point but are intended for intermittent drainage of the bladder.
9717503|NCT04557787|Experimental|New intermittent catheter variation 2 for females|Intermittent catheter variation 2 for females. The new catheters are not named at this point but are intended for intermittent drainage of the bladder.
9717504|NCT04557410|Experimental|Receiving Supplement|Participants receive supplement PolyMVA. Dose is 2 teaspoons twice a day.
9717505|NCT04557475|Experimental|ASA Group|Receives standard of care and intervention.
9717506|NCT04557475|No Intervention|SOC Group|Receives standard of care (SOC), only
9717507|NCT04557397|Other|Part A|Subjects will receive fruquintinib, alone and with itraconazole.
9717508|NCT04557397|Other|Part B|Subjects will receive fruquintinib, alone and with rifampin.
10196393|NCT05187130|Experimental|Intervention|Mindfulness-based breathing and music therapy was applied
9717509|NCT04557241|Experimental|Brief Intervention arm|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process (as described in the Intervention section). This arm will introduce the intervention and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection.
9717510|NCT04557241|Placebo Comparator|Placebo Control arm|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (As described in the Placebo Control section). This arm will introduce the control infographic and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection."
9717511|NCT04557384|Experimental|Ramucirumab|Ramucirumab given subcutaneously (SC).
9717512|NCT04557358||Rheumatic diseases outpatients|"All the rheumatic diseases outpatients from the National Institute of Medical Sciences and Nutrition that will assist their usual medical care posterior of stopped it during the COVID-19 pandemic.~In order to explore how the patient´s disease activity, patient´s quality of life, and psychopathology will change with the reintegration at medical care, randomization 200 rheumatic diseases outpatients that will respond RAPID-3 (disease activity/disease severity), WHOQOL-BREF instrument (quality of life), DASS-21 instrument (depression and anxiety), IER-R (posttraumatic stress)"
9717513|NCT04557345||Biological prostheses INC|"Prosthetic valve manufactured in the National Institute of Cardiology Ignacio Chávez."
9717514|NCT04557345||Imported Biological aortic prostheses|St Jude EPIC and Carpentier-Edwards Perimount
9717515|NCT04557345||Mechanical prostheses|St Jude Masters HP, Carbomedics Standart, ON-X Life Technologies, Edwards Mira, Carbomedics Orbis, Medtronic Hall and Medtronic ATS.
9717516|NCT04557345||Control|In subjects who come to donate blood products altruistically, in the blood bank service of the INC, with prior informed consent, the subjects will be matched with PO patients of CVA by age and gender.
10196394|NCT05187130|No Intervention|Control|No intervention has been made
10196395|NCT05187104|Experimental|Patients with age-related macular degeneration receiving standard treatment and retinal stem cells|Patients with age-related macular degeneration receiving standard treatment and autologous retinal stem and progenitor cells
10196396|NCT05187104|Active Comparator|Patients with age-related macular degeneration receiving standard treatment|Patients with age-related macular degeneration receiving standard treatment
9980541|NCT01392911|Experimental|30 mg/kg Rifampicin|7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
9980542|NCT01392911|Experimental|35 mg/kg Rifampicin|7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
9980543|NCT01392911|Experimental|40 mg/kg Rifampicin|7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
10196397|NCT05187078|Experimental|IUD placement with allis clamp|
10196398|NCT05187078|Active Comparator|IUD placement with single tooth tenaculum|
10196399|NCT05187052||Group 1 (REI group)|Group 1 included patients that were intubated using rigid endoscope-assisted orotracheal intubation (REI) (0°, 45°, and 70°), 18-cm rigid telescope (Storz, Germany), full-HD camera (Olympus, USA), and Macintosh blade.
10196400|NCT05187052||Group 2 (V-MAC Group)|Group 2 included patients that underwent endotracheal intubation using a V-MAC (Besdata, China) videolaryngoscope and Magill forceps.
9717517|NCT04557462|Experimental|LNP023|All participants are receiving 200 mg b.i.d
9717518|NCT04557319|Experimental|GNR-038, 25 МЕ/kg|Recombinant C1-esterase (25 ME/kg) inhibitor intravenous infusion
10196401|NCT05187052||Group 3 (FFEI group)|Group 3 included patients that underwent flexible fiberoptic endotracheal intubation (FFEI Group, Storz, Germany).
10196402|NCT05187000|Sham Comparator|Sham Stimulation Group for Cross Study|Sham stimulation will be delivered on the patients head using a sham coil in the crossover study.
9717519|NCT04557319|Experimental|GNR-038, 50 МЕ/kg|Recombinant C1-esterase (50 ME/kg) inhibitor intravenous infusion
9717520|NCT04557319|Experimental|GNR-038, 100 МЕ/kg|Recombinant C1-esterase (100 ME/kg) inhibitor intravenous infusion
9717521|NCT04557657|Experimental|Control Group Resin cement|Control group Using resin cement
9717522|NCT04557657|Active Comparator|Intervention Group Active Cement|Intervention Group Using active cement bio activa
9717523|NCT04557332|Experimental|Mobile app|In this arm, participants received a mobile app to support ART medication adherence.
9717524|NCT04557332|No Intervention|Control|In this arm, participants received care as usual.
9717525|NCT04557267|Experimental|Group A (dosage A)|The lower dose of the active drug
9717526|NCT04557267|Experimental|Group B (dosage 2)|The middle dose of the active drug
9717527|NCT04557267|Experimental|Group C (dosage 3)|The higher dose of the active drug
9717528|NCT04557267|Placebo Comparator|Group D (placebo)|Placebo
9717529|NCT04557579||Bifocal group|Patients in bifocal group implanted with Restor +2.5D IOL (Alcon, Fort Worth, TX, USA) in bilateral eyes
9717530|NCT04557579||Extended depth of focus group|Patients in extended depth of focus group implanted with EDOF Symfony IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
9717531|NCT04557579||Monofocal group|Patients in monofocal group implanted with Sensar AR40e IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
9717532|NCT04557514|Active Comparator|platelet rich plasma injection in post burn facial scar|"prp in subgroup allocation 1:1 Obtain WB by venipuncture in acid citrate dextrose (ACD) tubes~Do not chill the blood at any time before or during platelet separation.~Centrifuge the blood using a 'soft' spin.~Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube."
9717533|NCT04557514|Active Comparator|fat injection in post burn facial scar|After aspiration of the fatty tissue, it is important that nonviable components of the aspirate, such as oil, blood, and local anesthetics are removed and, at the same time, the quality, integrity, and viability of the adipocytes and the inherent mesenchymal stem cells in the aspirate be maintained. Processing techniques are sedimentation , filtering and washing There is no consensus as to the optimal method of fat graft preparation.
9717534|NCT04557163|Experimental|Subjects receiving TS-142 and itraconazole|Eligible subjects will receive a single dose of 5 mg TS-142 on Day 1. Subjects will also receive twice-a-day of 200 mg itraconazole on Day 3 and an once-daily single dose of 200 mg itraconazole from Day 4 to Day 7 and single dose of 1 mg TS-142 on Day 6.
9717535|NCT04557423|Active Comparator|Evidence-Based Intervention|Culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided.
9717536|NCT04557423|Experimental|HPV Self-Sampling|Previously tested evidence-based intervention (i.e. culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided). Participants will also receive a self-sampling kit.
9717537|NCT04557293|Experimental|CPAP Treatment|Patients with OSA will undergo cognitive assessment before starting CPAP treatment and after six months of CPAP use.
9717538|NCT04557293|No Intervention|Control Group|We will enrol a control group of subjects without sleep disorders and comparable to OSA patients for age and schooling. Control group will undergo cognitive assessment.
9717539|NCT04557553|Experimental|Lagenbone|Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months.
9717540|NCT04557306|Experimental|CBT101 q2w|CBT101 (2-6 x 10^9 cells), every 2 weeks
9717541|NCT04557306|Experimental|CBT101 q4w|CBT101 (2-6 x 10^9 cells), every 4 weeks
9717542|NCT04557605|Active Comparator|No face mask|Progressive step-exercise cycling test to exhaustion wearing no face mask
9717543|NCT04557605|Experimental|Disposable face mask|Progressive step-exercise cycling test to exhaustion wearing a 3-ply disposable face mask
9717544|NCT04557605|Experimental|Cloth face mask|Progressive step-exercise cycling test to exhaustion wearing a cloth face mask
9717545|NCT04557137||NET|"Study A:~A cross-sectional study that investigates 250 patients (Cohort A) with neuroendocrine neoplasia, encompassing both patients with neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC).~Study B:"
9717546|NCT04557137||Newly diagnosed NET|A prospective study that investigates 30 newly diagnosed NET patients over three months (Cohort B) who are offered palliative treatment with somatostatin analogues.
9717547|NCT04557202|Active Comparator|Group A|Group A had 58 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha1-blockers for one week preoperatively and another two weeks postoperatively
9717548|NCT04557202|Placebo Comparator|Group B|62 patients who underwent non-stented ureteroscopy and laser and received placebo.
9779833|NCT04704531|Experimental|Group 1|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) BID in OU during 30 days.
9779834|NCT04704531|Experimental|Group 2|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
9779835|NCT04704531|Experimental|Group 3|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) 6 times per day in OU during 30 days.
9717549|NCT04556942|Experimental|Group 1 (Immediate Group)|"Group 1:~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:~Flow mediated dilation measurement~Blood pressure, pulse, blood oxygenation saturation measurement~Fit bit tracker counting steps and distance during 7 days~SGRQ (St Georg Respiratory Questionnaire)~Withdrawal of a blood sample for preservation for later examinations~This group will receive endobronchial valve placement (EVP) within 1-2 weeks after T0.~At T1 which will be 4-6 weeks after EVP the measurements done at T0 will be repeated."
9717550|NCT04556942|Other|Group 2 (Delayed Group)|"Group 2:~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:~Flow mediated dilation measurement~Blood pressure, pulse, blood oxygenation saturation~Fit bit tracker counting steps and distance during 7 days~SGRQ (St Georg Respiratory Questionnaire)~Withdrawal of a blood sample for preservation for later examinations~This group will receive endobronchial valve placement (EVP) 6-8 weeks after T0. A few days before that the investigators repeat the measurement taken at T0."
9717551|NCT04556955|Placebo Comparator|post isometric relaxation and exercises|Group A included Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier and conventional exercise program ; this program included Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions).This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the End of treatment, i.e. ROM, pain intensity by NPRS and PPT , functional disability.
9717552|NCT04556955|Experimental|Graston technique and exercises|Group B included Graston Technique to Upper Trapezius and Levator Scapulae.This instrumented-assisted soft tissue massage applied with deeper pressure to the area of concern.The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions). This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the END of treatment , i.e. ROM, pain intensity by NPRS and PPT , functional disability.
9717553|NCT04557020|Experimental|Arm A|
9717554|NCT04557020|Active Comparator|Arm B|
9717555|NCT04556903|Experimental|Bilateral Arm Training|Bilateral Arm Training
9717556|NCT04556903|Active Comparator|modified constrained induce movement therapy|modified constrained induce movement therapy
9717557|NCT04556877||Intraabdominal pressure under 12 mmHg|Patients with intraabdominal pressure under 12 mmHg
9717558|NCT04556877||Intraabdominal pressure between 12-20 mmHg|Patients with intraabdominal pressure between 12-20 mmHg
9717559|NCT04556877||Intraabdominal pressure over 20 mmHg|Patients with intraabdominal pressure over 20 mmHg
9717560|NCT04557033|Experimental|Mindful Meditation|"The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.~The My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media~Participants will be asked to complete brief surveys before and after the intervention activity."
9717561|NCT04556994|Active Comparator|Phase 1 Cardiac Rehabilitation|Phase 1 Cardiac Rehabilitation
9717562|NCT04556994|Experimental|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Phase 1 Cardiac Rehabilitation with lower limb paddling
9717563|NCT04556851|Experimental|HSK7653 10 mg|
9717564|NCT04556851|Experimental|HSK7653 25 mg|
9717565|NCT04556851|Placebo Comparator|Placebo|
9717566|NCT04556929|Experimental|Intraoperative imaging of 5-ALA during tumour resection|Participants will undergo 5-ALA guided tumour resection via craniotomy with the aim of achieving maximal safe tumour resection without significant neurological deficit. On completion of tumour resection, digital images will be taken of the resection cavity under blue light using (i) an in-built camera in the operative microscope and (ii) an ultra-high sensitivity camera attached to the side arm of the operative microscope. Biopsies approximately 5x5x5mm in size will then be taken from the anterior, posterior, lateral and inferior areas of the resection cavity which were imaged. These biopsies will be analysed by histopathology to determine the presence of glioma cells.
9717567|NCT04557007||Treatment-naive NSCLC patients|Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.
9717568|NCT04556721|Experimental|Sugammadex|After surgery and general anesthesia, a clinically-appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade. Either 2 mg/kg or 4 mg/kg dosing will be used based on the level of neuromuscular blockade at the time of reversal. Administer as single IV bolus injection infused over 10 seconds into existing IV line. Dose is based on actual body weight (mg/kg).
9717569|NCT04557046|Other|Group A: Sample Collection|Nasal Swab and Saliva Sample Collection
9717570|NCT04557046|Other|Group B: Sample Collection|Nasal swab, Capillary Blood (from fingerstick) and Saliva Collection
9717571|NCT04557046|Other|Group C: Sample Collection|Nasal Swab, Throat Swab and Saliva Sample Collection
9717572|NCT04557046|Other|Group D: Sample Collection|Nasopharyngeal Swab and Saliva Sample Collection
9717573|NCT04557046|Other|Group E: Sample Collection|Nasal swab
9717574|NCT04556747|Other|VR - Distraction|
9717575|NCT04556747|Other|VR - Biofeedback|
9717576|NCT04556786|Experimental|Transitions of care|The study participants in this aim received usual care plus medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist.
9717577|NCT04556786|No Intervention|Usual care|The study participants in this arm received usual care.
9717578|NCT04557072||The selective alpha-blockade group|Patients treated with selective alpha-blockade before pheochromocytoma surgery
9717579|NCT04557072||The non-selective alpha-blockade group|Patients treated with non-selective alpha-blockade before pheochromocytoma surgery
9717580|NCT04556812|Experimental|Study group|"underwent four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
9717581|NCT04556812|Placebo Comparator|Control group|traditional soft tissue surgery
9717582|NCT04556760|Experimental|Cohort 1|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (72 mg AZD9567 followed by 40 mg prednisolone [AB sequence group] or 40 mg prednisolone followed by 72 mg AZD9567 [BA sequence group]).
9717583|NCT04556760|Experimental|Cohort 2|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (40 mg AZD9567 followed by 20 mg prednisolone [AB sequence group] or 20 mg prednisolone followed by 40 mg AZD9567 [BA sequence group]).
9717584|NCT04556760|Active Comparator|Cohort 3|Participants will be randomised in a ratio of 1:1 to receive placebo and prednisolone over two 72 hour periods in a cross over design (placebo followed by 5 mg prednisolone [AB sequence group] or 5 mg prednisolone followed by placebo [BA sequence group]).
9717585|NCT04556825|Experimental|Study group|Arthroscopic treatment with PRP injection
9717586|NCT04556825|Placebo Comparator|Control group|Arthroscopic treatment with normal saline injection
9717587|NCT04556864||Description Group|"For each patient included in the study, the secondary variables will be noted in the patient's data collection logbook.~This is followed by radial artery cannulation (if absent), and connection to the HemoSphere/EV1000 platform~After the daily visit, the PI/collaborating investigators (CI) will measure the clinical, treatment, and mechanical ventilation parameters of the patient during the last 24 hours.~Daily arterial analysis will be requested~This information collection process will be followed for 5 days. At the end of the information collection period, the IP will perform two downloads, the engineering download, and the standard download in which the values are monitored every 20 seconds.~These will be noted in the secondary variables of the data collection logbook, along with the patients' ICU discharge date.~In-hospital mortality will be monitored during admission to a conventional hospital ward.~Records will be closed upon discharge of the patient."
9717588|NCT04556799|Experimental|Study group|3D osteotomy template for derotation osteotomy with the aid of computer-assisted simulated surgery technique
9717589|NCT04556799|Experimental|Control group|traditional osteotomy technique
9717590|NCT04556708|Active Comparator|saline control group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
9717591|NCT04556708|Active Comparator|ozone group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozoned water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
9717592|NCT04556708|Active Comparator|chlorhexidine group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
9717593|NCT04556695||Questionnaire survey|An initial online questionnaire, based on the International Sedentary Assessment Tool (ISAT), will be distributed to General Practice Specialty Trainees (GPSTs) and General Practitioners (GPs) throughout Northern Ireland.
9717594|NCT04556695||Accelerometer study|A purposive sample of questionnaire respondents will be asked to participate in the accelerometer study. This purposive sample will be based on responses to the online questionnaire. The aim will be to obtain a varied sample, based on questionnaire responses, by selecting individuals with a range of demographic characteristics and self-reported levels of sedentary behaviour. Some participants will also be asked to complete a further online survey, while wearing the accelerometer, regarding their health, wellbeing, burnout and fatigue.
9980544|NCT01392911|Experimental|45 mg/kg Rifampicin|7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
9980545|NCT01392911|Experimental|50 mg/kg rifampicin|7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
9980546|NCT01392911|Experimental|55 mg/kg Rifampicin|7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
9980547|NCT01392924|Experimental|SAR245408|single cohort: SAR245408 administered once daily
9980548|NCT01392937|Active Comparator|All-in-One Light multipurpose|Used All in One light multipurpose with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
10196403|NCT05187000|Experimental|Individualized rTMS Group for Cross Study|Real stimulation will be delivered on individualized target using a real coil in the crossover study.
9717595|NCT04556695||Semi-structured interview study|A purposive sample comprising participants of the accelerometer study will be asked to participate in semi-structured interviews. This purposive sample will be based on the accelerometer data. The aim will be to obtain a varied sample, based on accelerometer data, by selecting individuals with a range of different levels of sedentary behaviour, demographic and workplace characteristics. The final number of participants will depend on the saturation of information.
9717596|NCT04556604||1|First cycle of the audit on consenting practice pre intervention
9980549|NCT01392937|Active Comparator|Aquify care|Use Aquify care with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
9980550|NCT01392950|Active Comparator|Air Optix Aqua|Compare safety and efficacy using OptiFree Replenish solution
9717597|NCT04556604||2|Second cycle of the audit on consenting practice to assess change following intervention
9717598|NCT04556604||3|Third cycle of the audit on consenting practice to assess long term compliance
9717599|NCT04556513||Patient|Patient hospitalized in ICU for PCR-proven SARS-COV-2 infection
9717600|NCT04556539|Experimental|SC10914 group|
9717601|NCT04556409|Experimental|low intensity pulsed ultrasound|20 women were treated by low intensity pulsed ultrasound (5 min, 0.5 w/cm2, 1MHZ with 20% duty cycle, 3 times/ week for 4 weeks plus static abdominal and pelvic floor exercises.
9717602|NCT04556409|Experimental|low level laser therapy|20 women were treated by low level laser therapy (Gallium Aluminum Arsenide Laser), 808nm, 4J/cm2, pulsating signal, 60 seconds for each point, 30 Mw/cm2, 3 times/week for 4 weeks plus static abdominal and pelvic floor exercises.
9717603|NCT04556409|Placebo Comparator|static abdominal and pelvic floor exercises|20 women were the control group who received only static abdominal and pelvic floor exercises. , 3 times/week for 4 weeks.
9717604|NCT04556643|Experimental|Intervention Group|Two sessions will be given to pregnant women in Intervention group. One session breathing exercises training will be given during first stage of labor by the investigator. During training all participants in Intervention group will be instructed to perform breathing exercises during the second stage of labor.
9717605|NCT04556643|No Intervention|Control Group|Usual hospital delivery protocol will be followed.
9717606|NCT04556422|Active Comparator|Sauna alone|Sauna exposure for 30 minutes
9717607|NCT04556422|Experimental|Exercise and Sauna|Cycling exercise for 15 minutes followed by sauna for 15 minutes
9717608|NCT04556578|Experimental|High-flow ECCO2R|Extracorporeal support using high flow circulation
9717609|NCT04556448|Experimental|Aligners|Invisalign treatment
9717610|NCT04556448|Active Comparator|Traditional braces|Clear braces
9717611|NCT04556552|Experimental|Active non-invasive Vagal nerve stimulation (VNS)|Active non-invasive Vagal Nerve Stimulation (nVNS) with opioid cues.
9717612|NCT04556552|Sham Comparator|Sham stimulation|Sham stimulation of vagus with opioid cues
9717613|NCT04556669|Experimental|CD22（aPD-L1）CAR-T cells|
9717614|NCT04556591|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of health related quality of life (HRQOL) over a three-month (90 day) period (without the personalized feedback).
9717615|NCT04556591|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of health related quality of life (HRQOL) and receive personalized pushes over a three-month (90 day) period.
9779836|NCT04701684|Experimental|Direct tot Angiography Suite (DTAS) triage workflow|
9779837|NCT04701684|Active Comparator|Conventional CT/MR triage workflow|
9779838|NCT04696055|Experimental|Regorafenib+Pembrolizumab|Participants with advanced hepatocellular carcinoma (HCC) progressed on 1L anti-PD-1/PD-L1 therapy.
9779839|NCT04683250|Experimental|TAS0953/HM06 Phase 1|Dose escalation and dose expansion until recommended Phase 2 dose determined
9779840|NCT04683250|Experimental|TAS0953/HM06 Phase 2|Treatment phase at recommended Phase 2 dose in three different populations
9779841|NCT04673019|Experimental|Immediate Intervention|"The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months:~Months 1- 3 (Approximately Day 1-Day 90)~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator. We are interested in learning whether the phone calls are necessary or if the Nurse AMIE platform can stand alone and see the same effect.~Months 4-6 (Approximately Day 91-180) o Participant will continue to use Nurse AMIE, but without phone calls from study facilitator"
9980551|NCT01392950|Active Comparator|Clariti|Compare safety and efficacy of the lens using OptiFree Replenish solution
9980552|NCT01392976|Experimental|CO-1.01 Formulation B|
9980553|NCT01392976|Active Comparator|CO-1.01 Formulation A|
9980554|NCT01393002||INABBRA|Participating hospitals in the INABBRA alliance.
9980555|NCT01393015|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
9779842|NCT04673019|Other|Delayed Intervention|"The delayed intervention group will receive the intervention 3 months after consent (3 months of no intervention followed by with 3 months of intervention, for a total of 6 months); the participant will follow the pattern listed below:~Months 1- 3 Approximately (Day 1-Day 90)~o No use of Nurse AMIE~Months 4-6 (Approximately Day 91-180)~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator"
9779843|NCT04664101|Experimental|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
9785205|NCT01245699|No Intervention|Before RTAVF and post-event debriefing|Before scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
9785206|NCT01245699|Active Comparator|After RTAVF and post-event debriefing|After scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
9717616|NCT04556344|Experimental|Emotional skills|3 individual sessions in which patients are going to learn how to identify, understand, express and regulate emotions
9717617|NCT04556344|Sham Comparator|Short free talk and relaxation|3 individual sessions in which patients are going to follow relaxation instructions after a non-directive talk about their current or past experience of cancer.
9717618|NCT04556396|Experimental|Intervention arm|This arm will receive cone beam CT to perform an abdomen-pelvis CT scan immediately following initial percutaneous nephrolithotomy, before the patient emerges from general anesthesia, to allow the surgeon to determine whether additional work is needed or whether the procedure can be concluded without requiring further imaging or future interventions.
9717619|NCT04556396|No Intervention|Retrospective arm|This arm will contain a retrospective cohort of patients who underwent surgery prior to the enrollment of the intervention arm. These patients received the standard of care, namely helical CT postoperative day one.
9717620|NCT04556110|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
9717621|NCT04556110|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
9717622|NCT04556136|Experimental|Standing Phototherapy Kiosk (SPK)|Volunteers assigned to this group were administered phototherapy treatments in a standing phototherapy kiosk once every other week, for 10 weeks. The treatment usually lasts no more than 10 minutes and is based on the Fitzpatrick skin type classification tool, which is self-reported via the computer touch screen in the kiosk.
9717623|NCT04556136|Active Comparator|Oral Supplement|Volunteers assigned to this group were provided with a 10-week supply (70 pills) of a vitamin D3 supplement. Consented subjects were instructed to take one 600 IU pill by mouth each day for ten weeks. They were instructed to take this with a meal. This dose is the RDA for adults between 18 and 70 years old according to the Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.
9717624|NCT04556214|Experimental|Liver Transplant|The patients will be transplanted according to standard procedures by the institutional protocol. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
9717625|NCT04556292|Experimental|SC10914 group|
9717626|NCT04556058|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
9717627|NCT04556058|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
9717628|NCT04556227|Experimental|Simultaneous Cycle/Cognitive Training|After discharge from the hospital the group will engage in recumbent cycling with simultaneous cognitive training on a tablet.
9717629|NCT04556227|No Intervention|Usual Care|After discharge from the hospital the group will complete baseline activies.
9717630|NCT04556279||hyperaldosteronism surgical treatment|Hypertensive patients with primary hypersldosteronism, treated with surgery
9717631|NCT04556279||hyperaldosteronism medical treatment|Hypertensive patients with primary hypersldosteronism, treated with aldosterone blockade.
9717632|NCT04556279||hypertensive control|Hypertensive patients shown not to have primary hyperaldosteronism
9717633|NCT04556201|Experimental|Thulium Fiber Laser lithotripsy|Subjects who have a medical indication for ureteroscopy, percutaneous nephrolithotomy (PCNL) or mini PCNL
9717634|NCT04556032|Experimental|L-Ergothioneine 10 mg/d|Participants will receive L-Ergothioneine 10 mg capsule orally once daily for 16 weeks.
9717635|NCT04556032|Experimental|L-Ergothioneine 25 mg/d|Participants will receive L-Ergothioneine 25 mg capsule orally once daily for 16 weeks.
9717636|NCT04556032|Placebo Comparator|Placebo|Participants will receive placebo orally once daily for 16 weeks.
9785207|NCT01245738||Participants|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.
10196404|NCT05186987|Sham Comparator|Start with: Concentric (normal) cycling|
10196405|NCT05186987|Experimental|Start with: Eccentric cycling|
10196406|NCT05186961||caregivers|Person who provided primary care for children younger than 18 years with swallowing disorders.
9717637|NCT04556175|Experimental|Oral Health|Motivational interviewing sessions will involve in-person visits by Community Health Workers focused on the mitigation of behavioral risk factors for early childhood caries, with two sessions provided before childbirth and four more sessions at 6, 12, 18 and 24 months after childbirth. Children receive up to 4 fluoride varnish applications during the study. Early cohort of enrollees will be followed up in a 7th visit solely for oral health assessment.
9717638|NCT04556175|Active Comparator|Healthy Lifestyle|Didactic educational sessions delivered in-person by Community Health Workers cover nutrition and diet, physical activity, breastfeeding/formula feeding, substance use, mental/emotional health, personal and family goals, prenatal/postpartum health care access, labor and delivery, family support, infant/child care, oral health, and development milestones. Children receive up to 2 fluoride varnish applications during the study. Early cohort enrollees will be followed up in a 7th visit solely for oral health assessment.
9717639|NCT04556253|Experimental|treatment arm|Subjects will receive AK104 by intravenous administration.
9717640|NCT04556149||Case|Inpatients with confirmed COVID-19 with pulmonary symptoms
9717641|NCT04556149||Matched Control|Inpatients without COVID-19 with non-pulmonary diagnoses or symptoms
9717642|NCT04556071|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until disease progression
9717643|NCT04555837|Experimental|Treatment (alisertib, pembrolizumab)|Patients receive alisertib PO BID on days 1-7 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9717644|NCT04555889|Experimental|lung recruitment maneuver (LRM) group|The lung recruitment maneuver (LRM) will be done by increasing of PEEP 0,2 cm H2O every 3 minutes, until reach the opening pressure. After that PEEP decrease gradually until get the closing pressure. Than the investigators will back to the opening pressure for 3 minutes, and the final PEEP will be put backo 0,2 above closing pressure.
9717645|NCT04555889|No Intervention|without lung recruitment maneuver (LRM) group|Another group get standart protocol only.
9717646|NCT04555772||Healthy Group|Patients who had been treated and recovered physically and gained cognitive functions completely.
9717647|NCT04555772||Sequel Group|Patients who could not gain their physical and cognitive functions.
9717648|NCT04555772||Exitus Group|Patients who did not respond to the treatments and lost their lives within 28 days of admission.
9717649|NCT04556006|No Intervention|Control|The patients in the control group received only the standard care provided by the clinicians. After the collection of post-test data, the content of the training was also explained to these patients and the study was completed by giving them the training guide.
9717650|NCT04556006|Active Comparator|İntervention|The training program was applied by the researcher who also work as an academic nurse. The contact information of the patients was obtained and the contact information of the researcher was also given to the patients. In order to consolidate the information given, the training guide was given to the patients in the intervention group. After the training, the patients in the intervention group were contacted again in the 2nd week by using face-to-face interview and in the 4th-8th and 12th weeks by phone calls. During these interviews, the questions of the patients, if any, were answered and the problems they faced regarding the disease management were tried to be solved. In the last interview, an appointment day was determined to meet face-to-face at home, workplaces or hospital according to the preferences of the patients.
9717651|NCT04555746|Experimental|Physical activity|Physical activity
9717652|NCT04555746|No Intervention|Control|Waiting list
9717653|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 1 group|Two subjects in this group will receive NL005 for 0.05ug/kg respective in D1.
9717654|NCT04555824|Experimental|Dose 2 groupRecombinant Human Thymosin β4|Two subjects in this group will receive NL005 for 0.25ug/kg respective in D1.
9717655|NCT04555824|Experimental|Dose 3 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 0.5ug/kg respective in D1.
9717656|NCT04555824|Experimental|Dose 4 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 2ug/kg respective in D1.
9717657|NCT04555824|Experimental|Dose 5 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 5ug/kg respective in D1.
9717658|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 6 group|Eight subjects in this group will receive NL005 for 12.5ug/kg respective in D1.
9717659|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 7 group|Eight subjects in this group will receive NL005 for 25ug/kg respective in D1.
9717660|NCT04555824|Placebo Comparator|Placebo|Two subjects in each dose group（0.5/2/5/12.5/25ug/kg）were given placebo respective in D1. A total of 10 subjects were given placebos.
9717661|NCT04555850|Experimental|Recombinant Human Thymosin β4 0.5ug/kg|10 subjects in this group will receive NL005 for 0.5ug/kg respective.Continuous administration for 10 days.
9717662|NCT04555850|Experimental|Recombinant Human Thymosin β4 2.0ug/kg|10 subjects in this group will receive NL005 for 2.0ug/kg respective.Continuous administration for 10 days.
9717663|NCT04555850|Experimental|Recombinant Human Thymosin β4 5.0ug/kg|10 subjects in this group will receive NL005 for 5.0ug/kg respective.Continuous administration for 10 days.
9717664|NCT04555850|Other|Placebo|Two subjects in each dose group (0.5/2/5ug/kg) were given placebo for 10 days.A total of six participants were given a placebo.
9717665|NCT04555876|Experimental|high tone external muscle stimulation|"- HiTop 191 appliance (gbo Medizintechnik AG, Rimbach, Germany) Device HiToP® 4 touch gbo Medizintechnik AG, this modern high-tech design with brushed aluminum surface and the 15 TFT LC D full color touch screen monitor offer to the health care professional an indispensable feature."
9717666|NCT04555876|Experimental|stationary bicycle|supervised regular aerobic exercise program on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks.
9717667|NCT04555642||therapy group|lymphoma patients planned chemotherapy or immunotherapy scheme
9717668|NCT04555642||healthy control group|Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.
9717669|NCT04555668|Experimental|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch
9717670|NCT04555668|Active Comparator|Hamstring Stretch Program|Hamstring Stretch Program and Knee -flexor eccentric training
9717671|NCT04555694|Active Comparator|Restasis and Lotemax|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes and Lotemax ophthalmic solution twice a day in both eyes.
9717672|NCT04555694|Active Comparator|Restasis and Dextenza|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes, as well as receiving Dextenza insertion in both lower lids.
9717673|NCT04555694|Active Comparator|Restasis|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes
9717674|NCT04555733|Experimental|Cohort 1: Lemborexant 5 mg|Participants will receive a single dose of lemborexant 5 milligram (mg) tablet, orally on Day 1.
9717675|NCT04555733|Experimental|Cohort 2: Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1 followed by a washout period of approximately 14 days further followed by multiple doses of lemborexant 10 mg tablets, orally, once daily from Day 15 through Day 28.
10196407|NCT05186896||Residents of areas at high risk of environmental crisis|1000 adult males and females living in areas declared at high risk of environmental crisis in the areas of Caltanissetta (Italy) and Tunis (Tunisia).
10196408|NCT05186831|Experimental|Text-based monitoring|Patients will be asked to take their BP two times daily and text their BP to the study phone number twice a day for 14 days.
9980556|NCT01393015|Active Comparator|Rotameter (flowmeter)|A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.
9717676|NCT04555733|Experimental|Cohort 3: Lemborexant 25 mg|Participants will receive a single dose of lemborexant 25 mg (1*5 mg tablet and 2*10 mg tablet), orally on Day 1.
9717677|NCT04555941|Experimental|active iTBS|The patient is treated with iTBS stimulation according to protocol with an active coil.
9717678|NCT04555941|Sham Comparator|Sham iTBS|The patient is treated with Sham-iTBS stimulation according to protocol with an inactive coil.
9717679|NCT04555707|Experimental|Otezla + Enstilar|
9717680|NCT04555655|Experimental|Chicken extract supplement|
9717681|NCT04555655|Experimental|Peptides supplement|
9717682|NCT04555655|Placebo Comparator|Placebo|
9717683|NCT04555538||Atrial Fibrillation Group|
9717684|NCT04555538||Non-Atrial Fibrillation Group|
9717685|NCT04555980|Experimental|Warm patch|the injection site was covered with warm patch.
9717686|NCT04555980|Placebo Comparator|Cotton patch|the injection site was covered with cotton patch.
9717687|NCT04555564|Experimental|Technicium 99 MAA|Participants will receive bronchial artery administration of Technicium 99 MAA
9980557|NCT01393028|Experimental|Cardiac CT|Cardiac CT (CT calcium and/or CT angiography), followed by stress testing, invasive angiography or neither depending on the CT scan result
9717688|NCT04555512|Active Comparator|Standard-care interval-training group|Subjects will complete a standard interval-training program that remains constant for the entire 12 weeks of cardiac rehabilitation.
9717689|NCT04555512|Experimental|Progressive interval-training group|Subjects will complete an interval-training program during which the number of intervals and the duration of each interval are changed across the 12-week cardiac rehabilitation program.
9717690|NCT04555993|Active Comparator|Transversus abdomis plane block|Patients will receive Transversus abdomis plane block
9980558|NCT01393028|Other|Standard care|Standard diagnostic management, including stress testing and/or invasive angiography
9717691|NCT04555993|Experimental|Erector spinae plane block|Patients will receive Erector spinae plane block.
9717692|NCT04555525|Experimental|sarecycline|weight-based dose per label by mouth once daily for 12 weeks
9717693|NCT04555525|Other|Centrum Adult Multivitamin|one tablet by mouth daily for 12 weeks
9717694|NCT04555629|Experimental|Advanced Cognitive Stimulation Therapy Hong Kong|"Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. It has also been translated and adapted for the Hong Kong Chinese population.~ACST-HK will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee, or care home staff."
9717695|NCT04555629|No Intervention|Treatment as usual|Standard care in care homes
9717696|NCT04555460|Active Comparator|Decompressive surgery|Decompressive surgery was performed with a large hemicraniectomy that removed, ipsilateral to the stroke, a bone flap as large as possible including temporal, frontal, parietal, and some occipital squama.
9717697|NCT04555460|Active Comparator|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke. Administration of intravenous mannitol (0.25 to 0.5 g/kg) or furosemide was given only in patients whose condition was rapidly worsening because of brain edema, without additional recommendations on loading doses.
9717698|NCT04555499||Suspected stroke|Patients with suspected stroke who are evaluated by paramedics
9717699|NCT04555486|Experimental|DCR-PHXC|Participants that are at least 12 years old will receive a single dose of 3 mg/kg DCR-PHXC (or nedosiran) via subcutaneous (SC) injection. Participants that are 6-11 years old will receive a single dose of 3.5 mg/kg DCR-PHXC (nedosiran) via SC injection.
9980559|NCT01393041|Other|Angio-Seal VIP|
9980560|NCT01393067|Active Comparator|study group NEPS|implantation of multiple non-expandable plastic stents
9980561|NCT01393067|Active Comparator|group cSEMS|implantation of a self-expandable metal stent (cSEMS)
10196409|NCT05186831|Active Comparator|Online patient portal|Patients will be asked to take their BP two times daily. They will be given instructions on how to upload BP readings to the online patient portal and will be asked to upload all BP readings. This represents enhanced standard of care.
10196410|NCT05186805|Experimental|tapinarof cream|Tapinarof (DMVT-505) cream, 1% applied topically once daily
10196411|NCT05186792||myco well participants|Retrospective analysis of patient records. No new patients recruited.
10196412|NCT05186727|Active Comparator|Researcher-Group|Education delivered in a group session by a member of the research team
10196413|NCT05186727|Active Comparator|Research-One on One|Education delivered telephonically one-on-one by a member of the research team
10196414|NCT05186727|Active Comparator|Patient Ambassador-Group|Education delivered in a group session by a Patient Ambassador (a peer mentor)
9717700|NCT04555486|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|Participants will receive a single dose of Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo.
9717701|NCT04555174||Orsiro Mission DES|All subjects will be implanted with the Limus Eluting Orsiro Mission Stent System and followed up until 60 months.
9717702|NCT04555187||Covid19-positive|Covid19 test positive. age >= 18 y.
9717703|NCT04555187||Covid19-negative|Covid19 test negative. age >=18y
9717704|NCT04555213|Experimental|Dose Escalation Cohort 1 - NOX66 400mg|NOX66 400 mg suppository OD
9717705|NCT04555213|Experimental|Dos Escalation Cohort 2 - NOX66 600mg|NOX66 600 mg suppository OD
9717706|NCT04555213|Experimental|Dose Escalation Cohort 3 - NOX66 800mg|NOX66 800 mg daily (400 mg suppository BID)
9717707|NCT04555213|Experimental|Dose Escalation Cohort 4 - NOX66 1200mg|NOX66 1200 mg daily (600 mg suppository BID)
9717708|NCT04555213|Experimental|Dose Escalation Cohort 5 - NOX66 1800mg|NOX66 1800 mg daily (600 mg suppository TID)
9717709|NCT04555213|Experimental|Dose Expansion - NOX66 Recommended Phase 2 Dose|Dose Expansion: NOX66 RP2D
9717710|NCT04555083||CAI group|Case group is CAI group that recruit patients complain of ankle insatiability and giving way mainly
9717711|NCT04555083||control group|control group recruits participants with non injured ankle, matched with case group in gender and dominant limb
9717712|NCT04555304|Experimental|KH903 + Paclitaxel|IV KH903 4 mg/kg IV paclitaxel 80 mg/m²
9717713|NCT04555304|Active Comparator|Placebo + Paclitaxel|IV Placebo IV paclitaxel 80 mg/m²
9717714|NCT04555421|Experimental|Lumen device usage and diet guidelines|
9717715|NCT04555291|Experimental|Drug Ropivacaïne 2 mg/ml|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
9717716|NCT04555291|Placebo Comparator|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
9717717|NCT04555395||gonadal|
9717718|NCT04555395||extra-gonadal|
9717719|NCT04555395||chemotherapy|
9717720|NCT04555395||without chemotherapy|
9717721|NCT04555369|Experimental|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
9717722|NCT04555317|No Intervention|Standard of Care|No intervention. Standard of care cancer pathway followed.
9717723|NCT04555317|Active Comparator|Musculoskeletal Health Package|3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
9717724|NCT04555252||Cephalic Duodenopancreatectomy|Patients who underwent scheduled cephalic duodenopancreatectomy and hospitalized in intensive care.
9717725|NCT04555278|Experimental|Active rTMS + Motor control exercises|Active (real) repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
9717726|NCT04555278|Sham Comparator|Sham rTMS + Motor control exercises|Sham repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
9717727|NCT04555278|Experimental|Active rTMS|Active (real) repetitive transcranial magnetic stimulation (20 minutes).
9717728|NCT04555278|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation (20 minutes).
9717729|NCT04555109||COVID-19 Convalescents|The cohort will include up to 1000 persons recovered from COVID-19, ages 17 - 65, that will provide a written consent form to participate in the study, complete questionnaires and provide a blood sample.
9717730|NCT04555382||AKI group|this group are included patients who have not occured acute kidney injury at first, however acute kidney injury are occured soon afterwards during the observation period.
9717731|NCT04555382||non-AKI group|this group are included patients who have not occured acute kidney injury during the observation period.
9717732|NCT04555122|Experimental|Intervention Group|Advertisements will be sent to participants mobile devices to attempt to increase adherence to stay-at-home orders and social distancing. There are 3 types of advertisements. This will occur for 7 days.
9717733|NCT04555122|No Intervention|Control Group|Control Group will be people who will not receive any advertisements.
9717734|NCT04555148|Placebo Comparator|Placebo|Saline
9717735|NCT04555148|Experimental|Low dose Treatment|Low dose treatment
9717736|NCT04555148|Experimental|Medium dose Treatment|Medium dose Treatment
9717737|NCT04555148|Experimental|High dose Treatment|High dose Treatment
9717738|NCT04555447|Experimental|Healthy-agavins|Agavins are branched neo-fructans and were supplemented for a 5-week dose-escalation period in lean participants
9717739|NCT04555447|Placebo Comparator|Healthy-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in lean participants
9717740|NCT04555447|Experimental|Obese-agavins|Agavins are branched neo-fructans that were supplemented for a 5-week dose-escalation period in obese participants
9717741|NCT04555447|Placebo Comparator|Obese-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in obese participants
9717742|NCT04555434|Experimental|Probiotics group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
9717743|NCT04555434|Placebo Comparator|Placebo group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
9717744|NCT04555408|Active Comparator|blue light group|The blue light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
9717745|NCT04555408|Active Comparator|bright light group|The bright light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
9717746|NCT04555408|Placebo Comparator|dim light group|The dim light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
9717747|NCT04554979||Group 1|Duration of COVID-19 symptoms less than 12 days
9717748|NCT04554979||Group 2|Duration of COVID-19 symptoms equal or more than 12 days
9717749|NCT04555005|Other|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
9717750|NCT04555057|Experimental|Music therapy group|"One day before surgery, the participants of music therapy group choose the music they want to listen in the operating room. The total playing time of the selected music is recommended between 5 and 10 minutes.~On the day of surgery, after entering the operating room, listen to personally selected music through the speaker. After the music is over, start anesthesia induction."
9717751|NCT04555057|No Intervention|Control group|The participants of control group wear earmuff to block noise after entering the operating room until induction of anesthesia. All other treatments proceed as conventional treatments.
9717752|NCT04554875||Cohort 1|Derivation Cohort of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
10196415|NCT05186727|Active Comparator|Patient Ambassador- One on One|Education delivered telephonically one-on-one by a Patient Ambassador (peer mentor)
9717753|NCT04554875||Cohort 2|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
9717754|NCT04554875||Cohort 3|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
9717755|NCT04554875||Cohort 4|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
9717756|NCT04554641|Experimental|BioKult Advanced|This is a single arm study, all participants will take Bio-kult Advanced for 56 days (+/- 2days). Participants will be required to take 4 capsules daily.
9717757|NCT04554654||frozen embryo transfer cycles|patients undergoing frozen embryo transfer with artificial hormone replacement
9717758|NCT04554901|Other|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
9717759|NCT04554680|Experimental|Treatment Group|Patients with progressive, metastatic or locally advanced, unresectable radioiodine (RAI)-refractory thyroid cancer of follicular cell origin with mutation involving MAPK signalling pathway, including BRAFV600E mutation or RAS mutation.
9717760|NCT04554615|Active Comparator|Conventional Insulin Therapy|CIT was provided as a continuous infusion of 50 IU of Actrapid HM in 50 ml of 0.9% sodium chloride using a pump, Infusion was adjusted to achieve BG level in range of 180-200 mg/dl.
9717761|NCT04554615|Active Comparator|Intensive Insulin Therapy|IIT was provided as an insulin infu-sion at rate of 1 mU/kg/min and was adjusted to achieve target BG level in range of 80-110 mg/dl.
9717762|NCT04554628|Active Comparator|Urinary human neutrophil gelatinase-associated lipocalin|Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement
9717763|NCT04554628|Active Comparator|Urinary human kidney injury molecule 1 (U-KIM1)|Urinary human kidney injury molecule 1 (U-KIM1) measurement group
9717764|NCT04554992|Experimental|Treatment|All subjects recruited will be transfused with COVID 19 convalescent plasma. A prospective comparison with matched historical controls receiving standard care will be employed.
9717765|NCT04554602||Patient with endometriosis or suspicion of endometriosis|"Information and collection of the non-objection before inclusion~Interrogation, clinical examination, EHP30 and SF36 form at inclusion~MRI, pelvic ultrasound (coupled with fusion ultrasound)~Laparoscopy if indicated after MRI, ultrasound and fusion ultrasound~Monitoring by form and fusion ultrasound at 6 months and then once a year for 3 years"
9717766|NCT04554602||Patient with other gynaecological pathology|"Information and collection of the non-opposition before inclusion~Interrogation, clinical examination, EHP30 and SF36 form at inclusion~MRI, pelvic ultrasound (coupled with fusion ultrasound)~laparoscopy if indicated after MRI, ultrasound and fusion ultrasound"
9717767|NCT04554823|Placebo Comparator|Control Group|Will attend lectures on health education.
9717768|NCT04554823|Experimental|Exercise Group|Will be subjected to a supervised training program of combined exercises for 24 weeks, with a frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week and Will attend lectures on health education.
9717769|NCT04554797|Experimental|Regional Hypothermia group|
9717770|NCT04554797|No Intervention|Control group|
9717771|NCT04554810|Active Comparator|Intervention group|Intervention group participants are the refugees who received the medication management review service and pharmacist's counselling. They have been assessed at baseline and at follow-up after 3 months) home visits.
9717772|NCT04554810|No Intervention|Control group|Control group participants are the refugees who did not received the medication management review service and no pharmacist's counselling wsa provided to them during the study period. They have been assessed at baseline and at follow-up (after 3 months) home visits.
9717773|NCT04554758|Experimental|Sleeve gastrectomy|200 obesity patients who undergo laparoscopic sleeve gastrectomy
9717774|NCT04554758|Experimental|Roux-en-Y gastric bypass|200 obesity patients who undergo laparoscopic Roux-en-Y gastric bypass
9717775|NCT04554862|Active Comparator|the intervention group (M) magnesium sulfate|a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
9717776|NCT04554862|Active Comparator|the intervention group (K) ketorolac|a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
9717777|NCT04554576|Experimental|6-week self-management and remote feedback for 6 months|All participants will receive the 6-week self-management program and after, half the group will be randomized to an every 6th week healthcare provider feedback phone or video visit session for 6 months (4 visits over 24 months).
9717778|NCT04554576|Active Comparator|6-week self-management and control group for 6 months|All participants will receive the 6-week self-management program and after, half will be randomized to a 6 month control grup
10196416|NCT05186714|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
10196417|NCT05186714|Placebo Comparator|Wellnes Education|12 weeks of Wellness Education classes
9717779|NCT04554589|Active Comparator|intervention group|receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .
9717780|NCT04554589|Placebo Comparator|placebo group|receive normal saline 2 ml IV every 8 hours daily .
9717781|NCT04554563|Experimental|Training group|4-week core stability training
9717782|NCT04554563|No Intervention|Control group|Standard physical therapy
9717783|NCT04554433|Active Comparator|Intervention|A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .
10196418|NCT05186701|Experimental|Kinesio taping and Conventional Physical Therapy|Standardized therapeutic kinesio taping (I shaped with 50-100% tension for 72 hours on both shoulders) along with Conventional Physical Therapy including Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
10196419|NCT05186701|Active Comparator|Conventional Physical Therapy|Thermotherapy, myofacial release, exercise therapy (active isolated unilateral stretching of pectoralis minor muscle and strengthening of shoulder retractors).
9717784|NCT04554433|No Intervention|Control|B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .
9717785|NCT04554420|Experimental|Youth Participatory Action Research-Mental Health Curriculum|Youth will be engaged with youth participatory approaches in learning about the intersection of mental health and systemic/community level issues.
9717786|NCT04554511||Training cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
9717787|NCT04554511||Validation Cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
9717788|NCT04554524|Experimental|Chemotherapy+Pembrolizumab|Chemotherapy combined with pembrolizumab.
9717789|NCT04554537|Placebo Comparator|Brain Health Workshop|The BHW training has been used in multiple prior studies as a comparison training program in cognitive training trials It consists of sessions of fact-based information about the brain but does not train cognitive strategies. Topics include neuroanatomy, neuroplasticity, and effects of TBI on cognitive functioning. Other sessions focus on diet, exercise, sleep, and social functioning and their relationships to brain health. Participants are encouraged to share how the topics impact their lives. Participants are given take-home reading materials on related topics that were then discussed at the last session. At home, they were instructed to watch assigned videos but had no other homework.
9717790|NCT04554537|Experimental|SMART|"SMART emphasizes top-down processing by targeting focused attention, assimilation of information, and mental flexibility and innovation, all higher-order cognitive functions driven by the frontal lobes. SMART was delivered in small groups (n = 2 to 8) consisting of two 3-hour sessions over two days, followed by one 3-hour session a month later. Overall, sessions focused on strategic attention, integrative reasoning, and cognitive control functions (Chapman, 2014). Training consists of initial sessions of skills training with the one-month follow-up session being a booster session consisting of review. We modified the training such that all sessions included skills training with briefer review. The first two sessions consisted of strategic attention and integrated reasoning and the final session discussed innovation."
9717792|NCT04554186|Experimental|Serratus anterior plane block|20 patients will receive SAP block with 0.4 ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
9717793|NCT04554186|Active Comparator|Thoracic Paravertebral block|20 patients will receive TPVB 0.4ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
9717794|NCT04554186|Placebo Comparator|Control group|20 patients will receive Fentanyl patch 50 microgram
9779844|NCT04664101|Other|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
9779845|NCT04662931|Experimental|Crizanlizumab|Participants will receive Crizanlizumab at a dose of 5.0 mg/kg.
9779846|NCT04652856|Experimental|Electrical and Sham Electrical Brain Stimulation|Electrical brain stimulation and sham electrical brain stimulation will be administered to all participants.
9779847|NCT04603300|Active Comparator|Active treatment|INT301 dosing as determined by cohort assignment
9779848|NCT04603300|Placebo Comparator|Placebo|Placebo as determined by cohort assignment
9779849|NCT04588298|Experimental|Stage 1: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 1 of the study.
9779850|NCT04588298|Experimental|Stage 1: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 1 of the study.
9779851|NCT04588298|Experimental|Stage 2: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 2 of the study.
9779852|NCT04588298|Experimental|Stage 2: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 2 of the study.
9779853|NCT04588298|Experimental|Stage 2: AZD9833 Dose C|Post-menopausal participants will receive once daily oral dose C of AZD9833 in stage 2 of the study.
9779854|NCT04575311|Active Comparator|Active: Dose Escalation|Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 will be random.
9779855|NCT04575311|Placebo Comparator|Placebo: Dose Escalation|Participants will receive matching placebo as a single oral dose. Assignment to receive matching placebo will be random.
9779856|NCT04573322|Experimental|Lead-in 0.25 mg/kg|0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
9779857|NCT04573322|Experimental|Lead-in 0.50 mg/kg|0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
9779858|NCT04573322|Experimental|Lead-in 1.0 mg/kg|1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
9779859|NCT04573322|Experimental|Lead-in 1.5 mg/kg|1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
9717795|NCT04554407|Experimental|Treatment Group|All participants receive the SOMAVAC® 100 Sustained Vacuum System
9717796|NCT04554199|Experimental|EEG and MMSE measurements before receiving RPD|EEG and MMSE were measured for all participant before wearing the removable partial dentures.
9717797|NCT04554199|Experimental|EEG and MMSE measurements after receiving RPD|EEG and MMSE were measured for all participant after wearing the removable partial dentures
9717798|NCT04554355|Experimental|Intervention group|Participants in this group will receive a three-month PA intervention (60 minutes/session, two sessions/week).
9717799|NCT04554355|No Intervention|Control group|No intervention will be provided, participants in this group need to attend the regular school activities as normal.
9717800|NCT04554329|Active Comparator|bandage contact lens|A bandage contact lens was applied on the eye at the end of the surgery, and the eye was not covered with a patch.
9717801|NCT04554329|Active Comparator|eye patching|Antibiotic eye ointment was applied on the eye, and the eye was covered with a patch at the end of the surgery.
9717802|NCT04554238|Experimental|Armeo spring group|Regarding masking, it is impossible for the treating occupational therapist to be unaware of the treatment to be carried out by the treated patient, just as it is impossible for the patient not to identify the treatment to which they access, therefore, this study is single-blind, considering only who performs the evaluations of the study will not know which group corresponds to the evaluated patient.
9717803|NCT04554238|Active Comparator|Occupational Therapy group|It consists of 5 weeks of intervention, with 3 treatment sessions per week, 40 minutes each time. The patient performs active exercises of the paretic upper limb: bimanual play activities, weight bearing, reaches in various planes of motion that favor shoulder flexion, elbow extension, forearm supination, and dissociated finger movements. In addition to passive mobilizations of the shoulder, elbow and wrist and tactile and proprioceptive sensory stimulation and the use of paretic limbs as support or carrying out prehensions.
9717804|NCT04554342|Experimental|healthy participants starting with candy V01|healthy participants testing a candy in 5 different variations by (unstimulated and stimulated) salivary flow rate (before and after comparison)
9717805|NCT04554342|Experimental|healthy participants starting with candy V02|
9717806|NCT04554342|Experimental|healthy participants starting with candy V03|
9717807|NCT04554342|Experimental|healthy participants starting with candy V04|
9717808|NCT04554342|Experimental|healthy participants starting with candy V05|
9717809|NCT04554082||Preoperative Clinical characteristics and metabolic biomarkers|BMI and biochemical parameters including trace elements in patients undergoing laparoscopic sleeve gastrectomy before surgery
9717810|NCT04554082||9 months' Postoperative metabolic biomarkers|BMI and biochemical parameters including trace elements in patients 9 months after laparoscopic sleeve gastrectomy
9717811|NCT04554108|Active Comparator|Intravenous antibiotic treatment|Intravenous antibiotic treatment started during an initial hospitalization of 3 days, with continuation of oral antibiotic therapy at home for a total duration of antibiotic therapy of 3 weeks
9717812|NCT04554108|Experimental|oral antibiotic treatment|Oral antibiotic treatment started in hospital then continued at home for a total duration of 3 weeks of antibiotic therapy
9717813|NCT04554225||Pulmonary disease patients|Patients with COPD or other pulmonary disease starting to use ambulatory oxygen therapy
9717814|NCT04554368||IA-CEFDCT group|95 patients who underwent IA-CEFDCT and MT for acute anterior stroke.
9717815|NCT04554394|Experimental|CellFX Treated Wart Lesion|CellFX device using pre-defined energy protocols
9717816|NCT04554303||S-amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
9717817|NCT04554303||Amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
9717818|NCT04554290||positive temporal artery biopsy|all adult patients with significant inflammation shown on temporal artery biopsy
9717819|NCT04554498|Experimental|Hemodiafiltration with ATA filter|patients with clinical history of hypersensitivity to polisulfone/poliethersulfone dialysis filters or hypersensitivity to drugs or generic allergens.
9717820|NCT04554498|Active Comparator|Hemodiafiltration with Helixone filter|no history of hypersensitivity to polisulfone/poliethersulfone dialysis filters is assessed; no history of hypersensitivity to drugs or generic allergens is assessed.
9717821|NCT04554056|Experimental|MW05 300μg/kg|Subjects will receive MW05(300 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
9717822|NCT04554056|Experimental|MW05 500μg/kg|Subjects will receive MW05(500 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
9717823|NCT04554056|Active Comparator|PEG-rhG-CSF|Subjects will receive PEG-rhG-CSF(100 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
9717824|NCT04554381|Experimental|JL1|JL1 on acute leukemia
9717825|NCT04554381|Experimental|JL1 and acute leukemia|Assesment of JL1 expression on acute leukemia
9717826|NCT04554771|Experimental|ADAM12 high with tocilizumab and standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
9717827|NCT04554771|Active Comparator|ADAM12 high with standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
9717828|NCT04554771|Experimental|ADAM12 low with tocilizumab and standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
9717829|NCT04554771|Active Comparator|ADAM12 low with standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
9717830|NCT04554446|Experimental|T-MSAT(Motion style acupuncture treatment using Traction)|T-MSAT group receives 3 sessions of T-MSAT; on 2nd, 3rd, 4th day after hospitalization. A trained doctor of Korean medicine with clinical experience conducted the T-MSAT. And T-MSAT group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
9717831|NCT04554446|Active Comparator|Korean medicine treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
10196420|NCT05186675|Experimental|Superselective adrenal arterial embolization|For patients with bilateral idiopathic hyperaldosteronism confirmed by adrenal venous sampling, Superselective adrenal arterial embolization（SAAE）shall be given according to the patient's wishes. The blood pressure, plasma aldosterone and potassium levels, and adverse events were assessed after SAAE. The primary endpoint was the change in home blood pressure at one months, compared with baseline.
9717834|NCT04553835|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).
9717835|NCT04553835|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
9717836|NCT04553835|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.
9717837|NCT04553835|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
9717838|NCT04553952||Gummy smile (GS(+))|
9717839|NCT04553952||Gumms smile(GS(-))|
9717840|NCT04553796||diabetic participants|HBA1C : 6.5% or higher Fasting Plasma Glucose : 126 mg/dl or higher Oral Glucose Tolerance Test : 200 mg/dl or higher Random Plasma Glucose Test : greater than or equal to 200 mg/dl
9717841|NCT04553796||prediabetic participants|HBA1C : 5.7% to 6.4% Fasting Plasma Glucose : 100 mg/dl to 125 mg/dl Oral Glucose Tolerance Test : 140 mg/dl to 199 mg/dl
9717842|NCT04553796||non diabetic participants|HBA1C : less than 5.7% Fasting Plasma Glucose : less than 100 mg/dl Oral Glucose Tolerance Test : less than 140 mg/dl
9717843|NCT04553809|Active Comparator|Kontrol|Patients undergoing examination for lung cancer with the use of electromagnetic navigation bronchoscopy for biopsy sampling
9717844|NCT04553809|Experimental|Intervention|Patients undergoing examination for lunge cancer with the use of electromagnetic navigation bronchoscopy and radial endobronchial ultrasound for biopsy sampling.
9717845|NCT04553978|Experimental|Treatment A|"After an overnight fasting of at least 10 hours, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.~Subjects will be in sitting posture or ambulatory posture for the first 04 hours post-dose unless medically necessary."
9717846|NCT04553978|Experimental|Treatment B|"At least 03 hours after taking dinner, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.~Subjects will be in supine/lateral recumbent positions post-dose till morning when they will wake up unless medically necessary."
9717847|NCT04554017|Experimental|Intervention arm - All participant (Single arm)|Participants received education or health talks on dietary and physical activity behaviours linked to hypertension
9717848|NCT04553861||Healthy subjects|Healthy subjects without blood pressure difference on both arm
9717849|NCT04553887|Experimental|Cohort 1|Previously treated NSCLC patients with EGFR exon 20 insertion mutantion
9717850|NCT04553887|Experimental|Cohort 2|NSCLC Patients with uncommon EGFR Mutation
9717851|NCT04553991|Active Comparator|QL block group|For the ultrasound-guided quadratus lumborum block group, the patient was placed in lateral position . QL was identified medial to the aponeurosis of transversus abdominis muscle. Then the needle was inserted from supero-anterior to postero-inferior and advanced using in plane technique till the needle tip reached the anterolateral border of the QL at its junction with transversalis fascia.An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
9717852|NCT04553991|Active Comparator|TAP block group|For the ultrasound-guided TAP block,The probe was placed in the mid-axillary line above the level of the anterior superior iliac spine, then slided cranially till the three abdominal wall muscles identified (External oblique muscle (EAO), internal oblique muscle (IOM) and transverse abdominis muscle (TAM)). The needle was advanced using in-plane technique till it reached the transvers abdominis plane. An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
9717853|NCT04553705|Experimental|Omega-3/thymoquinone supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA) (3% thymoquinone) per day for one month.~In addition to the standard care"
9717854|NCT04553705|Experimental|Omega-3/thymoquinone / Indian Costus supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Indian Costus) per day for one month.~In addition to the standard care"
9717855|NCT04553705|Experimental|Omega-3/thymoquinone / Quinine pills|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(1g Quinine) per day for one month.~In addition to the standard care"
9717856|NCT04553705|Experimental|Omega-3/thymoquinone / Anise seed capsule|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(450mg anise seed) per day for one month.~In addition to the standard care"
9779860|NCT04573322|Experimental|Randomized Active TSC|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
10196421|NCT05186649||Experimental Group|Consecutive patients with severe mitral stenosis and clot in left atrial appendage (LAA) on transesophageal echocardiography fulfilling the inclusion criteria will be recruited for this study. An ACUSON 128-XP echocardiographic system equipped with omniplane and biplane transesophageal probes will be used for this study. TEE followed by CT Angiography will be performed according to the standard procedure after obtaining informed consent.
9717857|NCT04553705|Experimental|Omega-3/thymoquinone / Deglycyrrhizinated Licorice|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Deglycyrrhizinated Licorice 800 mg ) per day for one month.~In addition to the standard care"
9717858|NCT04553705|Active Comparator|Active Comparator: standard care|The standard protocol care for COVID-19 approved from ministry of health at Saudi arabia
9717859|NCT04553718|Experimental|experimental|
9717860|NCT04553614|Active Comparator|Exercise Referral Scheme|The active Sefton (AS_ERS) is a traditional exercise referral programme providing highly discounted access to council operated leisure centres and a number of partner gyms. Within this access patients will have access to gym and swimming facilities (£2 per visit) and exercises classes (£3 per visit). During the patients first meeting with their LDO a progressive personalised exercise programme will be developed. Following this the patient will attend their local gym or leisure centre for an induction with a staff member(£7 one off fee), enabling them to attend the centre at any time and complete the designed exercise programme. All exercise programmes will be different, but in general will include moderate intensity exercise on gym equipment (treadmill, ergometer etc.) and some basic resistance training. Patients may replace these gym sessions with exercises classes run by the facility. Patients will be encouraged to exercise 3-5 time per week.
9717861|NCT04553614|Experimental|Home-based HIIT|Participants will be instructed to complete each training session in a place of their choosing. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 90% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. The participant will be advised to complete 4 intervals during weeks 1 and 2, with the number of intervals increasing by 1 every 2 weeks (maximum of 9 intervals). The participant will be advised to train 3x per week.
9717862|NCT04553601|Experimental|8F-FDG PET/CT and PET/CT-guide targeted biopsy|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time.
9717863|NCT04553627|Experimental|Interventional cohort|Zeltiq system is a thermoelectric device that applies controlled cooling ot skin. The CoolAdvantage applicators use gentle vacuum pressure to draw tissue into the cup shaped applicator. A gelpad is applied to skin to improve thermal coupling between participant and the applicator cooling surface.
9717864|NCT04553224|Other|All Subjects|Clinical and instrumental measurements
9717865|NCT04553263|Experimental|Contrave|Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg). The dose will be titrated: 8 mg/90 mg on Week 1, 16 mg/180 mg on Week 2, 24 mg/270 mg on Week 3 and 32 mg/360 mg on Week 4. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone.
9980562|NCT01393080|Experimental|Nimotuzumab and TP regimen|"TP Regimen ：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
9717866|NCT04553263|Experimental|Bupropion|Participants will receive daily extended-release oral bupropion (Wellbutrin XL) at a dose of 450 mg. The dose will be titrated: 150 mg on Days 1 and 2, 300 mg on Days 3 and 4, and 450 mg on Day 5. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone. A reduction to 300 mg will permitted to alleviate medication-related adverse effects if they occur.
9717867|NCT04553263|No Intervention|Treatment As Usual|Participants will complete inpatient treatment as usual and will not receive any medication. This arm serves as a TAU control to compare outcomes versus Bupropion and Contrave arms.
9717868|NCT04553653|No Intervention|Baseline|Data on diagnosis and care of patients presenting with acute severe hypertension will be collected at baseline (prior to the implementation of a checklist)
9717869|NCT04553653|Experimental|Intervention arm|The intervention arm will be enrolled after the checklist implementation.
9717870|NCT04553211|Experimental|Expedited Partner Therapy (EPT)|Participants in the EPT arm will receive up to five partner antibiotic treatment packets to deliver to their recent sexual partners following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The intervention will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
9717871|NCT04553211|No Intervention|Control|Participants in the control arm will receive standard-of-care counseling on partner notification following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The same counseling will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
9717872|NCT04553315|Experimental|intervention group|Intervention group was received Chest mobility exercises with Incentive spirometer and segmental breathing exercise and breath stacking technique . The patient in the intervention group was instructed to perform the exercises 3 times per day, 7-8 times per session for one week. Ensure that the patient fully hydrated by maintaining normal daily water requirement in the form of (30-35ml/kg/day) with restriction of intravenous fluids.
9717873|NCT04553315|Experimental|control group|control group will receive only routine hospital care
9717874|NCT04553380|Experimental|community patient group|The community doctor adjusts the basic insulin dosage daily according to the fasting blood glucose of the patient under the guidance of the specialist.
9717875|NCT04553380|Active Comparator|inpatient group|Endocrinologists in the in-patient department use the same basic insulin dose adjustment regimen to treat patients.
9980563|NCT01393080|Placebo Comparator|TP Regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
10196422|NCT05186636||ICU patients receiving renal replacement therapy|All patients in participating ICU's receiving CRRT or IRRT during the study period
9717876|NCT04553302||Psoriatic Arthritis|Patients diagnosed with PsA according to CASPAR criteria by the rheumatologist were included.
9717877|NCT04553302||Rheumatoid Arthritis|Patients diagnosed with RA according to ACR / EULAR 2010 criteria by the rheumatologist were included.
10196423|NCT05186610||FDG PET/CT guided metabolic core needle biopsy group|2- Fluorodeoxyglucose (FDG) PET-positive lesions at initial presentation or at the end of treatment were considered for PET/CT guided biopsy after discussion with the hemato oncologist.
10196424|NCT05186545|Experimental|Experimental|surufatinib + fulvestrant + chidamide
9717878|NCT04553302||Asymptomatic Healthy Group|Participants had any neurological and/or rheumatological diseases, no complaints about the upper extremity. Participants diagnosed with OA according to traditional clinical criteria were excluded from the study.
9717879|NCT04553250|Active Comparator|Conventional technique|"In this group, double-staple colorectal anastomosis will be performed following the technique described by Lee et al: Prior to firing the endostapler, a suture will be placed on the rectal stump that includes both dog ears. After the punch comes out of the endostapler, the point will be tied, which will invaginate the two corners of the staple line on the same punch. Subsequently, the endostapler will be closed and fired, including the dog ears in the anastomotic rims"
10196425|NCT05186532|Experimental|Dry heat group|infra red-light therapy that supplies radiant heat or infra-red rays to produce heat to the episiotomy wound.
9717880|NCT04553250|Active Comparator|Lateral invagination technique|In this group, the circular endostapler will be fired in a conventional way, that is, without having invaginated the two corners of the staple line.
9717881|NCT04553523|Other|Single Arm|Subjects with mild to moderate POAG undergoing cataract surgery & implantation of the Hydrus Microstent
9717882|NCT04553497|Active Comparator|Rehabilitation and interferential current therapy|Flipping a coin was used for simple randomization (tails - interferential current). In this arm, interferential current therapy was applied to the patients in addition to the rehabilitation program.
9717883|NCT04553497|Sham Comparator|Rehabilitation and sham interferential current therapy|Flipping a coin was used for simple randomization (heads - sham). In this arm, sahm interferential current therapy was applied to the patients in addition to the rehabilitation program.
9717884|NCT04553393|Active Comparator|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem dual Specificity targeting CD19 and CD20 decitabine-primed CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.
9717885|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
9717886|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
9717887|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine|The combination of chidamide and decitabine can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function, induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance
9717888|NCT04553484|Experimental|Measuring cardiovascular performance and blood flow|
9717889|NCT04553445|Experimental|Chronotype|Determination whether monthly migraine load is affected by exercise in sync with chronotype
9717890|NCT04553445|Experimental|Green exercise|Determination whether monthly migraine load is affected by exercise in a natural environment
9717891|NCT04553588|Active Comparator|Opioid Disposal Pouch|an opioid disposal pouch to inactivate and dispose of unused opioid medication within the first 30 days after surgery
9717892|NCT04553588|No Intervention|Usual Care|usual medication disposal includes multiple options as desired by patient; for example, flushing down toilet, giving to local pharmacist, giving to police department etc.
9717893|NCT04553510|Experimental|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
9717894|NCT04553510|Active Comparator|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
9717895|NCT04553289|Experimental|exercising into pain|The participants will train during 12 with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. One exercise will be performed with pain ranging between 4 and 7 on a NPRS (Numeric Pain Rating Scale) and the rest of the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. At week 9, patients will continue to exercise with pain between 0 and 2 in all exercises. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
9717896|NCT04553289|Active Comparator|exercising with no/slight pain|The participants will train during 12 weeks with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. All the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
9717897|NCT04553458||Favorable outcome|Cure or stable disease
9717898|NCT04553458||Unfavorable outcome|Progressive (deteriorate/Recurrence) or Death
9717899|NCT04553549||Transradial approach|"The procedure will be done using standard criteria as per operator preference. All interventional cases at our institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
9717900|NCT04553328|Active Comparator|Group T|Group (T) received ultrasound guided (US) combined ipsilateral transverse abdominis plane (TAB) and ilioinguinal- iliohypogastric (ILIH) nerve block
10196426|NCT05186532|Active Comparator|Moist heat group|warm sitz bath in which a woman is asked to sit in a warm water tub up to the hip level.
10196427|NCT05186506|Experimental|Ensatinib|225 mg administered once daily orally for two years.
9717901|NCT04553328|Active Comparator|Group I|Group (I) received US guided ipsilateral illioinguinal- illiohypogastric nerve block only.
9717902|NCT04553198|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 3 weeks.
9717903|NCT04553198|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 3 weeks.
10196428|NCT05186506|Active Comparator|Platinum-Based Chemotherapy|Patients in the chemotherapy group were allowed to cross into the Ensatinib treatment group after the disease progressed.
9980564|NCT01393093|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
10196429|NCT05186493|Experimental|Locally advanced pelvic cancer that requires total pelvic exenteration|Adult patients (>18 years) with locally advanced pelvic cancer that require pelvic exenteration considered eligible for robot- assisted minimally invasive surgery by the respective multidisciplinary teams
9717904|NCT04553159|Experimental|Adipose Derived Stem Cell(ADSC) arm|"Participants allocated to this arm will have tumescent liposuction performed on them to obtain lipoaspirate. The lipoaspirate will then be processed to obtain the stromal vascular fraction. This Adipose derived stromal vascular fraction which contains stem cells will then be infiltrated into the keloid tissue as a single dose infiltration.~This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6)."
9717905|NCT04553159|Active Comparator|Triamcinolone Acetanoide (TAC) arm|Participants in this arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid. This will be a single dose infiltration of 40mg/cubic centimetres of keloids.
9717906|NCT04553185||Parkinson's disease patients|Patients with idiopathic or familial Parkinson's disease
9717907|NCT04553172||Affected family members|Affected family members
9717908|NCT04553172||Affected PM|Affected PM
9717909|NCT04553146|Experimental|Interventional arm|immediate implant placement in posterior sites using a custom-made sealing socket abutment combined to alveolar ridge preservation
9717910|NCT04552873|Experimental|EXPERIMENTAL GROUP|the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)
9717911|NCT04552873|Placebo Comparator|CONTROL GROUP|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
9717912|NCT04552782|Experimental|Alcohol CBM + PTSD CBM|
9717913|NCT04552782|Experimental|Alcohol CBM + PTSD Sham|
9717914|NCT04552782|Experimental|Alcohol Sham + PTSD CBM|
9980565|NCT01393093|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
9980566|NCT01393093|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
9980567|NCT01393093|Experimental|TACE-KMG(withou chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
9717915|NCT04552782|Sham Comparator|Alcohol Sham + PTSD Sham|
9717916|NCT04552821||Control|Non-sepsis and non-ARDS adults receiving mechanical ventilation
9717917|NCT04552821||Sepsis complicated with mild ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for mild ARDS
9717918|NCT04552821||Sepsis complicated with moderate/severe ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for moderate/severe ARDS
9980568|NCT01393119|Experimental|3000mg GTx-758 daily|loading dose 3000mg GTx-758 daily + maintenance dose of 1000mg
9980569|NCT01393119|Experimental|3000 mg GTx-758 daily|loading dose of 3000mg GTx-758 daily + maintenance dose of 2000mg GTx-758 daily
9980570|NCT01393119|Experimental|1500 mg GTx-758 BID|Loading dose of 1500 mg GTx-758 BID + maintenance dose of 1000mg GTx-758 daily
9980571|NCT01393119|Experimental|1500mg GTx-758 BID|loading dose of 1500mg of GTx-758 BID + maintenance dose of 2000mg GTx-758 daily
9717923|NCT04553055||community pharmacists|
9717924|NCT04552756|Experimental|Patients irradiated for high-grade glioma|Participants who receive radiotherapy or radiochemotherapy for glioblastoma (grade IV), anaplastic astrocytoma (grade III) or anaplastic oligodendroglioma (grade III).
9717925|NCT04552977|Experimental|fluzoparil+temozolomide|Participants receive fluzoparil and temozolomide
10196430|NCT05186441|Active Comparator|DMPFC iTBS|DMPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
10196431|NCT05186441|Active Comparator|DLPFC iTBS|DLPFC iTBS group has 30 patients. Each receive 20 times DMPFC iTBS therapy. During the iTBS, a 5-min train treatment(110%RMT, 2s on and 8s off, 900 pulses in total）was applied to the left DMPFC.
9980572|NCT01393145|Experimental|Group 1|
9980573|NCT01393145|Active Comparator|Group 2|
9980574|NCT01393171|Active Comparator|Polypropylene Mesh|Site-specific cystocele repair with polypropylene mesh augmentation
9980575|NCT01393171|Placebo Comparator|Anterior Colporrhaphy|Anterior vaginal prolapse repair with anterior colporrhaphy with no graft.
9980576|NCT01393171|Active Comparator|Porcine Dermis|Site-specific cystocele repair with porcine dermis augmentation
9980577|NCT01393184|Experimental|Radiotherapy + Nimotuzumab|"Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F~Nimotuzumab (Nimo) weekly Nimo (200 mg) × 8, started 1 w before RT"
9980578|NCT01393184|Active Comparator|Radiotherapy (RT)|Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F
9980579|NCT01393197|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
9717928|NCT04553029||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
9717929|NCT04553029||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
9717930|NCT04553029||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
9717931|NCT04553029||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
9717932|NCT04552951|Active Comparator|Active|Receiving 1 dose of 100.000 iu of Cholecalciferol when the COVID 19 Disease is diagnosed
9717933|NCT04552951|No Intervention|Control|No vitamin D
9717934|NCT04552860|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
9717935|NCT04552886|Experimental|Dendritic cell vaccine: Starting dose|This arm will evaluate the safety of administering a total dendritic cell dose of 3.5 x 10^6. A total of 3-6 patients will be enrolled with this dose. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
9717936|NCT04552886|Experimental|Dendritic cell vaccine dose de-escalation|If unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 1.75 X 10^6.
9717937|NCT04552886|Experimental|Dendritic cell vaccine dose escalation one|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 7.0 X 10^6.
9717938|NCT04552886|Experimental|Dendritic cell vaccine dose escalation two|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 7.0 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1.4 X 10^7.
9717939|NCT04552808|Experimental|Yimitasvir Phosphate Capsules|The mechanism of action of Yimitasvir is the specific inhibition of HCV non-structural protein NS5A
9717940|NCT04553094|No Intervention|Group 1|No physical training
9717941|NCT04553094|Experimental|Group 2|Endurance training
9717942|NCT04553094|Experimental|Group 3|Muscle building training
9717943|NCT04553094|Experimental|Group 4|Training combining endurance + muscle building
9717944|NCT04552964|Other|Single arm|This will be a single centre, single-arm, prospective pilot study.
9717945|NCT04553042|Experimental|Treatment Sequence ABC|Participants will receive a single dose of seltorexant as formulation (Test 1) (Treatment A) in Treatment Period 1, followed by a single dose of seltorexant as formulation (Test 2) (Treatment B) in Treatment Period 2, followed by a single dose of seltorexant as formulation (Reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
9717946|NCT04553042|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
9717947|NCT04553042|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
9717948|NCT04553042|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
9717949|NCT04553042|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
9717950|NCT04553042|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
9717951|NCT04553016|Experimental|1: Vaccine|"At Week 0, volunteers receive 5.0 x 10^10 virus particles (vp) of ChAdOx1.tHIVconsv1 (C1) administered intramuscularly (IM). The dose is divided in 2 and administered in the deltoid muscle of each arm.~At week 4,1.0 x 10^8 Plaque forming units (PFU) of MVA.tHIVconsv3 (M3) administered IM and 0.9 x 10^8 PFU of MVA.tHIVconsv4 (M4) are administered IM simultaneously, one into the deltoid muscle of each arm."
9717952|NCT04553016|Placebo Comparator|2. Placebo|Normal sterile saline (0.9% Sodium Chloride solution) administered IM as Placebo, the volume is matched to that of the vaccines and administered in the deltoid muscle of each arm at Week 0 and at week 4 .
9717953|NCT04552743|Experimental|MGTA-145 and Plerixafor HSC Mobilization|Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.
9717954|NCT04552938||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA between June 2018 and May 2019.
9980580|NCT01393197|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
9717955|NCT04552717|Experimental|Intervention|"Participants will complete a web based pre-assessment and then given access to the app My Grief for three months followed by a web based post-assessment and an interview via telephone regarding their experiences of using the app, and follow-up questionnaires."
9717956|NCT04552717|No Intervention|Waitlist controll|Participants will get access to the app after three months.
9717957|NCT04552574|Experimental|Intervention group|All subjects will intake HMR(Home meal replacement)-type omega-3-balanced-diet for 4 weeks.
9717958|NCT04552574|No Intervention|Control group|No intervention for 4 weeks.
10196432|NCT05186441|Sham Comparator|placebo|The placebo research received similar pseudo-stimulation treatment, which was the same as the treatment site and method of true stimulation, but during stimulation, the coil used B65 8 zigzag coil, which was flipped 180 degrees, and only produced stimulation sound during treatment, but did not produce irritating magnetic field. It can produce a placebo effect.
9717959|NCT04552522|Experimental|Shrimp allergy with Intend to eat shrimp|Case shrimp Immunoglobulin E mediated allergy and intend to eat shrimp and start oral immunotherapy for shrimp
9717960|NCT04552522|No Intervention|Shrimp allergy with avoid shrimp|Case shrimp allergy with avoid shrimp
9717961|NCT04552483|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
9717962|NCT04552483|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days.
9717963|NCT04552457|Experimental|No activity restrictions|
9717964|NCT04552457|Active Comparator|Activity restrictions|
9717965|NCT04552548|No Intervention|Control group|the patients will receive regular analgesics (1 µg /kg fentanyl with induction and 15mg/kg paracetamol before extubation)
9717966|NCT04552548|Active Comparator|TAP group|the patients will receive bilateral TAP block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
9717967|NCT04552548|Active Comparator|quadratus lumborum group|the patients will receive bilateral quadratus lumborum block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
9717968|NCT04552509|Other|Observation|Observational study of patient efficacy and side effects
9717969|NCT04552444||the death group|Through the corresponding treatment, the patients who died within 28 days
9717970|NCT04552444||the survival group|Through the corresponding treatment, the patients who survived within 28 days
9717971|NCT04552600|Experimental|NuvastaticTM 1000 mg|NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months.
9717972|NCT04552600|Active Comparator|Placebo|NuvastaticTM (without active) will be given orally, three times per day for 12 months
9717973|NCT04552613|Experimental|Standard programme group|EGFR-TKI targeted therapy
9717974|NCT04552613|Active Comparator|controlled programme group|EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
9779861|NCT04573322|Placebo Comparator|Randomized Placebo|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
9779862|NCT04567251|Experimental|Namzaric® arm|Arm 1 will take daily Namzaric® for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
9779863|NCT04567251|Placebo Comparator|Placebo arm|Arm 2 will take daily placebo for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
9779864|NCT04555135|Experimental|Colonoscopy Procedure with EndoVigilant Software|Colonoscopy Procedure is performed with EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
9779865|NCT04555135|No Intervention|Colonoscopy Procedure without EndoVigilant Software|Colonoscopy Procedure is performed without EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
9779866|NCT04552288|Experimental|Participants with eosinophil-related cutaneous events|Study participants will have grade 2/3 eosinophil-related cutaneous adverse events
9779867|NCT04525703|Experimental|Pathways for Parents|
9779868|NCT04521621|Experimental|Part 1, Cohort A: Triple-Negative Breast Cancer|This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9980581|NCT01393197|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
9779869|NCT04521621|Experimental|Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9779870|NCT04521621|Experimental|Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9779871|NCT04521621|Experimental|Part 2 Dose Level 1, Solid Tumors+Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9779872|NCT04521621|Experimental|Part 2 Dose Level 2, Solid Tumors+Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9779873|NCT04521621|Experimental|Part 2 Dose Level 3, Solid Tumors+Liver Metastases|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9980582|NCT01393197|Experimental|TACE-KMG(without chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
9980583|NCT01393210|Active Comparator|low-calorie diet|Intervention was low-calorie diet only for 12 weeks.
9717975|NCT04552379|Active Comparator|Interferon|Peginterferon beta-1alfa will be made available from Biogen Inc. Switzerland. 125 micrograms of pegylated IFNß1alfa (PLEGRIDY, Biogen) administered on Study Days 1, 6 and 11 (i.e. for a total of 3 doses) via subcutaneous injection.
9717976|NCT04552379|No Intervention|Standard of Care|Standard of Care; following national guidelines regarding self-isolation and infection prevention
9717977|NCT04552418|Experimental|Potato-based dietary starch supplement|Patients undergoing cancer treatment with dual immune checkpoint inhibitors (ICI) will receive potato-based dietary starch supplements.
9717978|NCT04552561|Experimental|My MS Toolkit|10 Participants asked to use My MS Toolkit and meet weekly with a study coach via telephone.
9717979|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation, Parent Education|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum) and Parent Education
9717980|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum), but no Parent Education
9717981|NCT04552678|Experimental|Healthy Eating, Active Play, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, and Parent Education
9717982|NCT04552678|Experimental|Healthy Eating + Active Play|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, but no Parent Education
9717983|NCT04552678|Experimental|Healthy Eating, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, and Parent Education
9717984|NCT04552678|Experimental|Healthy Eating + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, but no Parent Education
9717985|NCT04552678|Experimental|Healthy Eating + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, and Parent Education
9717986|NCT04552678|Experimental|Healthy Eating Only|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, but no Parent Education
9717987|NCT04552678|Experimental|Active Play, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, and Parent Education
9717988|NCT04552678|Experimental|Active Play + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, but no Parent Education
9717989|NCT04552678|Experimental|Active Play + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, and Parent Education
9717990|NCT04552678|Experimental|Active Play Only|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, but no Parent Education
9717991|NCT04552678|Experimental|Self-Regulation + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, and Parent Education
9717992|NCT04552678|Experimental|Self-Regulation Only|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, but no Parent Education
9717993|NCT04552678|Experimental|Food Literacy + Parent Education|Classrooms receive the core Food Literacy Curriculum, and parents are invited to complete web-based education modules.
9717994|NCT04552678|Experimental|Food Literacy Only|Classrooms only receive the core Food Literacy Curriculum, and no other intervention materials or parent education.
9717995|NCT04552639|Active Comparator|Treatment as usual|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, excluding the NEAT group.
9717996|NCT04552639|Experimental|Treatment as usual and NEAT group|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, alongside NEAT group.
9717997|NCT04552626|Experimental|Prolonged sitting (social breaks)|
9717998|NCT04552626|Experimental|Prolonged sitting with step-up exercise break|
9717999|NCT04552626|Experimental|Prolonged sitting with simple resistance activity breaks|
9718000|NCT04552405|Other|FAP patients|FAP patients who underwent prophylactic total colectomy
9718001|NCT04552301|Experimental|Cognitive Processing Therapy and Targeted Asthma Education|Intervention group - Cognitive Processing Therapy and Targeted Asthma Education
9718002|NCT04552301|Active Comparator|Psychotherapy and General Asthma Education|Control group - Psychotherapy and General Asthma Education
9718003|NCT04552249||Group 1|
9718004|NCT04552249||Group 2|
9718005|NCT04552249||Group 3|
9718006|NCT04552249||Group 4|
9718007|NCT04552249||Group 5|
9718008|NCT04552249||Group 6|
9718009|NCT04552145|Active Comparator|surgery|Decompression surgery
9718010|NCT04552145|Active Comparator|physiotherapy|Physical therapy program
9718011|NCT04552158|No Intervention|controlled group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management only
9718012|NCT04552158|Experimental|experimental group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management and nutritional management in the form of the Mediterranean diet
9718013|NCT04552652|Experimental|High-intensity interval training - telerehabilitation|12 weeks of high-intensity interval training. Three sessions per week will be performed (36 total sessions).
9718014|NCT04552652|Active Comparator|Moderate-intensity continuous training - telerehabilitation|12 weeks of moderate-intensity continuous training. Three sessions per week will be performed (36 total sessions).
9718015|NCT04552314||patients after primary MMC-augmented trabeculectomy|
9718016|NCT04552366|Experimental|Group A: Intramuscular administration|24 subjects. 5E10 VP of Ad5-nCoV on Day 0 and on Day 56.
9718017|NCT04552366|Experimental|Group B: Mixed administration|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0 and a mucosal administration of 2E10 VP on Day 28.
9718018|NCT04552366|Experimental|Group C: Mucosal administration, high dose|24 subjects. A mucosal administration of 2E10 VP of Ad5-nCoV on Day 0 and Day 28.
9718019|NCT04552366|Experimental|Group D: Mucosal administration, low dose|24 subjects. A mucosal administration of 1E10 VP of Ad5-nCoV on day 0 and Day 28.
9718020|NCT04552366|Active Comparator|Group E: Intramuscular administration, one dose|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0.
9718021|NCT04552366|Experimental|Group F: Intramuscular administration, two doses|24 subjects. Two intramuscular administrations of 5E10 VP of Ad5-nCoV at left and right arms on day 0.
9718022|NCT04552132|Experimental|GentleWave|Patients randomly assigned to the GentleWave group will receive irrigation and activation of irrigants with the GentleWave device (multisonic energy) by Sonendo.
10196433|NCT05186415|Experimental|diagnostic arm|The echocardiography team will perform baseline echocardiographic views of the right ventricle without contrast. The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations. Dosages and timing of administration as well as patient size and transducer type will be recorded for each patient. The total cumulative dose of Lumason from the clinical study and the research study will not exceed the maximum recommended dose by the manufacturer, 4.8 mL. A single injection will not exceed the maximal FDA-recommended dose of 2.4 mL per single injection. These echocardiographic views of the right ventricle with ultrasound enhancing agent will be compared to the measurements made without the use of ultrasound enhancing agents, and the measurements made in MRI.
10196434|NCT05186389||"Control Group"|"15 non-obese participants considered metabolically-healthy : control group"
10196435|NCT05186389||Obese group (Ob)|"15 severely obese participants, candidates for bariatric surgery, but without T2D: obese group (Ob)"
10196436|NCT05186389||Obese and Type 2 Diabetes group (ObD)|"15 participants who are both severely obese, candidates for bariatric surgergy and diagnosed with T2D: obese and diabetic group (ObD)."
10196437|NCT05186363|Active Comparator|Intervention|SMC eligible kids aged 3-59 months who will receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
10196438|NCT05186363|Active Comparator|Control|SMC eligible kids aged 3-59 months who will not receive a standard SMC intervention of 4 cycles of SPAQ over 4 months.
9718023|NCT04552132|Active Comparator|EndoActivator|Patients randomly assigned to the EndoActivator group will receive irrigation via a side-vented needle and activation using the EndoActivator (sonic energy) by Dentsply Sirona.
9718024|NCT04552431|Placebo Comparator|Placebo|Men assigned to placebo
9718025|NCT04552431|Experimental|Ciprofloxacin alone|Men assigned to Ciprofloxacin alone
9718026|NCT04552431|Experimental|Tamsulosin alone|Men assigned to Tamsulosin alone
9718027|NCT04552431|Experimental|Combination of ciprofloxacin and tamsulosin|Men assigned to a combination of ciprofloxacin and tamsulosin
9718028|NCT04552002|Experimental|Synbiotic group|"Intervention group:~Will receive synbiotic supplements: one capsule/day. Each capsule contains 20 billion CFU multi-strain probiotics + prebiotics (inulin and oligosaccharides) for a duration of 6 months."
9718029|NCT04552002|No Intervention|Placebo group|Will receive a placebo. The placebo will be similar to the synbiotic supplements in appearance.
9718030|NCT04552184|Active Comparator|GPOEM|
9718031|NCT04552184|Sham Comparator|SHAM|
9718032|NCT04551989||Participants with EGPA who have received NUCALA treatment|Data will be collected of participants who have already received NUCALA for 96 weeks in routine clinical practice.
9718033|NCT04552093|Experimental|Colorectal liver metastases|Patients with potentially resectable colorectal liver metastases will undergo hepatic artery infusion pump placement. Subsequent hepatic artery infusion of floxuridine via the HAIP as well as standard of care Dutch systemic chemotherapy (FOLFOX or FOLRIRI) will be administered in a combined chemotherapy schedule.
9718034|NCT04551924|Experimental|dose 1|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
9718035|NCT04551924|Experimental|dose 2|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
9718036|NCT04551924|Experimental|dose 3|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
9718037|NCT04551924|Experimental|dose 4|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
9718038|NCT04551924|Active Comparator|Naropin|Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
9718039|NCT04551937|Placebo Comparator|Control|4-5 week period where participant will consume control beverage
9718040|NCT04551937|Experimental|Prebiotic|4-5 week period where participant will consume the intervention beverage
10196439|NCT05186350|Active Comparator|SpyGlass group|ERCP plus SpyGlass group
10196440|NCT05186350|Active Comparator|ESWL group|ERCP plus ESWL
10196441|NCT05186298|Experimental|AcrySof® IQ PanOptix® (Alcon Laboratories, Inc., Fort Worth, TX)|The subject will be implanted bilaterally during cataract surgery
10196442|NCT05186298|Experimental|Synergy® (Johnson & Johnson Surgical Vision, Santa Ana, CA)|The subject will be implanted bilaterally during cataract surgery
9718041|NCT04552353|Experimental|Vaway Lyo-Injection|Voriconazole, 200 mg/vial
9718042|NCT04552353|Active Comparator|Vfend Lyo-Injection|Voriconazole, 200 mg/vial
9718043|NCT04552106|Active Comparator|Group 1|10 subjects
9718044|NCT04552106|Active Comparator|Group 2|10 subjects
9718045|NCT04552106|Active Comparator|Group 3|10 subjects
9718046|NCT04552106|Active Comparator|Group 4|10 subjects
9718047|NCT04552106|Active Comparator|Group 5|10 subjects
9718048|NCT04552054|Active Comparator|CT guided localization|Computerized Tomography(CT)-guided percutaneous lung puncture staining marker localization
9718049|NCT04552054|Experimental|MR+3D guided localization|Mixed reality(MR)+3D printing-guided percutaneous lung puncture staining marker localization
9718050|NCT04552119||HEALICOIL Knotless Suture REGENESORB|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless REGENESORB
9718051|NCT04552119||HEALICOIL Knotless PEEK|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless PEEK
9718052|NCT04552067|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
9718053|NCT04552067|Active Comparator|Enoxamed|patients are given a curative dose of Enoxaparin (ENOXA)
9718054|NCT04551833|Experimental|Group (T) : 30 patients (Tramadol group)|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 1.5 mg/kg Tramadol.
9718055|NCT04551833|Experimental|Group (D) : 30 patients (Dexamethasone group):|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 8mg of Dexamethasone
10196443|NCT05186259|Active Comparator|Patients with chronic tinnitus|Patients with chronic subjective tinnitus (> 3 months)
10196444|NCT05186259|Active Comparator|Patients with chronic idiopathic neck pain|Patients with chronic idiopathic neck pain (> 3 months)
10196445|NCT05186259|Active Comparator|Patients with chronic tinnitus and chronic neck pain|Patients with chronic tinnitus and chronic neck pain (> 3 months)
9718058|NCT04551755|Active Comparator|Ivermectin plus Doxycycline plus standard care|Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours 2) Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes 3) Standard symptomatic and supportive treatment; Tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements
9718059|NCT04551755|Placebo Comparator|Placebo plus standard care|"1) Standard symptomatic and supportive treatment with placebo; Standard treatment includes tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements.~Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days"
9718060|NCT04551859|Other|Sacrospinofixation|After accepting the surgeon's proposal to perform a sacrospinofixation to treat the pelvic organ prolapse, participation in this study will be proposed to the patient. It will not change the management or the course of the surgery
9718061|NCT04551703|Experimental|Adrenaline saline irrigation|Adrenaline saline irrigation will be prepared by adding one ampule of 0.1 percent adrenaline in one liter bag of normal saline, which made the adrenaline concentration in the solution 1:100 000
9718062|NCT04551703|No Intervention|Normal saline irrigation|Normal saline bag will be used for irrigation during the procedure
9718063|NCT04551950|Experimental|Cohort 1A:M7824+cisplatin/carboplatin+paclitaxel+bevacizumab|
9718064|NCT04551950|Experimental|Cohort1B:M7824+cisplatin or carboplatin+paclitaxel|
9718065|NCT04551950|Experimental|Cohort 2: M7824+cisplatin+ radiotherapy|
9718066|NCT04551872|Experimental|Obese High Risk|200 participants with BMI ≥30 and 10-year ASCVD risk ≥20%
9718067|NCT04551872|Experimental|Obese Low Risk|200 participants with BMI ≥30 and 10-year ASCVD risk <7.5%
9718068|NCT04551872|No Intervention|Non-Obese High Risk|100 participants with BMI 18-25 and 10-year ASCVD risk ≥20%
9718069|NCT04551872|No Intervention|Non-Obese Low Risk|100 participants with BMI 18-25 and 10-year ASCVD risk <7.5%
9718070|NCT04551976|Experimental|Mindful Video Game Then Laundry Group|Receive mindfulness prompt and play their video game first and fold laundry second.
9718071|NCT04551976|Experimental|Mindful Laundry Then Video Game Group|Receive mindfulness prompt and fold laundry first, play their video game second.
9718072|NCT04551976|No Intervention|Control Video Game Then Laundry Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will play their video game first and fold laundry second.
9718073|NCT04551976|No Intervention|Control Laundry Then Video Game Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will fold laundry first and will play their video game second.
9718074|NCT04551664|Experimental|EVT group|Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.
9718075|NCT04551664|Active Comparator|Best medical management group|Patients in this group will receive best medical management alone.
9718076|NCT04551794|Experimental|Online self-help program with additional peer support|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
9718077|NCT04551794|No Intervention|No intervention: waitlist-control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 9 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
9718078|NCT04551794|Experimental|Online self-help program with therapeutic guidance|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences and difficulties concerning the program on a weekly basis with a therapeutic guide on the phone.
9718079|NCT04551729|Active Comparator|Fluid restriction|Patient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.
9718080|NCT04551729|Experimental|Liberal fluid intake|Patient will receive a lifestyle advice for liberal fluid intake for 3 months.
9718081|NCT04552015|Other|volunteers|two different types of diagnostic tools (TST vs microneedle) will be used to screen for latent TB infection
9718082|NCT04551768|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
9718083|NCT04551768|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
9718084|NCT04551781|Experimental|steroid|20 mg prednisolone for 14 days
9718085|NCT04551781|Placebo Comparator|control|controll
9718086|NCT04551651|Active Comparator|ApplTree reminder app intervention|A reminding app developed with features that, based on previous research, will increase use and ease of use for individuals with ABI when setting smartphone reminders.
9718087|NCT04551651|Active Comparator|Google Calendar reminder app intervention|A widely available calendar app that can be used to set reminders.
9718088|NCT04551534|Experimental|DNL201|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
9718089|NCT04551534|Placebo Comparator|Placebo|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
10196446|NCT05186259|Active Comparator|Healthy controls|Healthy controls without tinnitus or pain complaints
10196447|NCT05186246|Experimental|Experimental Combination Cream Group|Subjects were randomized to have combination cream to be applied on one side of the face twice daily post fractional CO2 laser. The subjects were evaluated on day 3 and day 7 post fractional CO2 laser. Combination cream consisted of Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate cream
9718090|NCT04551456|Placebo Comparator|Placebo Infusion PBS|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Assigned Interventions:~Biological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo"
9718091|NCT04551456|Experimental|Single dose Infusion WJMSCs|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Biological/Vaccine:~WJMSCs Vs.placebo"
9718092|NCT04551456|Experimental|Infusion WJMSCs multiple doses|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Biological/Vaccine:~WJMSCs Vs.placebo"
9718093|NCT04551573|Experimental|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
9718094|NCT04551573|Experimental|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
9718095|NCT04551274|Experimental|Music Therapy|Participants in the music therapy group will complete a 4 week music therapy program, with a minimum of 2 sessions per week.
9718096|NCT04551274|No Intervention|Control|Control group participants will not experience any intervention
9718097|NCT04551391||Case|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI determined as:~Previous (within 3 years) eGFR >45 mL/min/1.73m2 OR no history of kidney disease if no recent (within 3 years) blood results available AND~Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value AND~Increasing creatinine >= 27μmol/L above index value within 48 hours"
9718098|NCT04551391||Control|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to hospital without AKI: (eGFR > 60).~This group will be recruited contemporaneously with, and matched to, AKI participants by:~Age (± 5 years)~Sex~AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not AND/OR (ii) History of cardiovascular disease or not"
9718099|NCT04551287||Training dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
9718100|NCT04551287||SYSMH internal validation dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
9718101|NCT04551287||TAHGMU external validation dataset|600 slides from 600 eligible individuals were obtained in the Third Affiliated Hospital of Guangzhou Medical University (TAHGMU, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
9718102|NCT04551287||GWCMC external validation dataset|600 slides from 600 eligible individuals were obtained in Guangzhou Women and Children Medical Center (GWCMC, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Cervical Cancer Artificial Intelligence Screening System (CAISS).
9718103|NCT04551287||Prospective validation dataset|A prospective validation dataset was conducted to distinguish the diagnostic performance of the cytotechnician, CAISS, and CAISS-assisted groups, in which 2,780 eligible slides from 2,780 individuals were obtained and prospectively labeled between August 28, 2020 and October 16, 2020 at SYSMH.
9980584|NCT01393210|Active Comparator|low calorie diet plus beta-glucan|Intervention was low-calorie diet plus BETA-GlLUCAN 1.3D-1.6D 500 mg daily for 12 weeks.
9980585|NCT01393223|Active Comparator|LP-08 80mg|4 weekly intravesical administration of LP-08 80mg
9980586|NCT01393223|Active Comparator|LP-08 20mg|4 weekly intravesical administration of LP-08 20mg
9980587|NCT01393223|Placebo Comparator|Normal Saline|Four weekly normal saline intravesical administration
9980588|NCT01393236||patients|patient characteristics are specified in H-2-2010-011
9980589|NCT01393236||controls|age matched to patients described in protocol H-2-2010-011
9980590|NCT01393249||ALL, Asparaginase, pancreatitis|Patients that have been scanned and have had blood tests
9980591|NCT01393262||Healthy Escort|
9980592|NCT01393262||Hand Service patient|
9980593|NCT01393275|Active Comparator|Rehabilitation intervention group|The group is performing a strength endurance training intervention in addition with rehabilitation exercise intervention.
9718104|NCT04551287||Randomized controlled trial|a prospective randomized controlled trial was conducted to compare the performance of the cytotechnician, CAISS, and CAISS-assisted groups in SYSMH. Here, 618 slides were collected between August 13, 2020, and December 14, 2020, to build the SYSMH randomized controlled trial. The remaining 608 slides after quality control were randomly assigned (1:1:1) to the CAISS group (n = 201), the cytotechnician group (n = 203), and the CAISS-assisted combination group (n = 204).
9718105|NCT04551638||Online Videogame Players|One cohort of healthy young adults players of online video games.
9718106|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
9718107|NCT04551339|Active Comparator|High dose Zinc (PreserVision AREDS formulation soft gels or tablets)|Subjects will have a high dose Zinc supplementation in combination with Copper, Vitamin C/E and beta-carotene
9718108|NCT04551339|Active Comparator|Multivitamin with 11mg of zinc|Subjects in this arm will have a multivitamin supplement with 11mg of zinc
9718109|NCT04551209|Experimental|Apical patency group|Patients in which apical patency is maintained.
9718110|NCT04551209|No Intervention|Non- apical patency group|Patients in which apical patency is not maintained
9718111|NCT04551612||Patients with cholesteatoma|Patients with cholesteatoma in one ear that will compared with the other healthy one.
9718112|NCT04551170|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
9718113|NCT04551170|Placebo Comparator|Placebo|Placebo capsule by mouth once daily or Placebo elixir by mouth q6h
9718114|NCT04551404|Experimental|Study Intervention(s) A|"TRNS bilateral temporal regions combined with AS for 20 minutes~Sham-tRNS bilateral temporal regions combined with Sham-AS for 20 minutes"
9718115|NCT04551404|Experimental|Study Intervention(s) B = Control Intervention|"TRNS bilateral temporal regions for 20 minutes~Sham-tRNS bilateral temporal regions for 20 minutes"
9718116|NCT04551118|Experimental|tACS group|Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
9718117|NCT04551118|Experimental|tDCS group|Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
9718118|NCT04551118|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current continued less than 30s.
9718119|NCT04551261|Experimental|Part A|Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.
9718120|NCT04551261|Experimental|Part B|Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.
9718121|NCT04551443|Placebo Comparator|Placebo PBS|Standard therapy+Intravenous infusion PBS in patients with AMI
9718122|NCT04551443|Active Comparator|WJMScs|Standard therapy+Intravenous infusion WJMSCs in patients with AMI
9718123|NCT04551248||PCV13 recipients (children)|Children < 5 years who had received PCV10 or PCV13 from May, 2014 to December, 2018 under the national childhood immunization program in South Korea.
9718124|NCT04551248||PPSV23 recipients (elderly adults)|Persons 65 years or older who had received at least one dose of PPSV23 between January, 2014 and December, 2018 under the national immunization program in South Korea.
9718125|NCT04551248||Influenza vaccine recipients (elderly adults)|Persons 65 years or older who had received at least one dose of influenza vaccine (as comparator) between January, 2014 and December, 2018 under the national immunization program in South Korea.
9718126|NCT04551027|Experimental|compensatory cognitive treatment|compensatory cognitive treatment intervention, focusing on learning cognitive strategies to overcome cognitive deficits.
9718127|NCT04551027|No Intervention|control group|standard ambulatory treatment
9718128|NCT04551014|Experimental|With EverLift|Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.
9718129|NCT04551014|Experimental|Without EverLift|Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.
9718130|NCT04551040|Experimental|Primary Cohort|Titrating doses of terazosin starting at 1mg daily and increasing to 5mg daily on a weekly basis for five weeks.
9718131|NCT04551079|Experimental|TAK-994 Dose A+ Placebo + TAK-994 Dose B|TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
9718132|NCT04551079|Experimental|TAK-994 Dose B + TAK-994 Dose A + Placebo|TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
9718133|NCT04551079|Experimental|Placebo + TAK-994 Dose B+ TAK-994 Dose A|TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose B tablets orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
9718134|NCT04550819|Experimental|IEBSs in malignant extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with malignant extrahepatic biliary stricture
9718135|NCT04550819|Active Comparator|CPBSs in malignant extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with malignant extrahepatic biliary stricture
9718136|NCT04550819|Experimental|IEBSs in benign extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with benign extrahepatic biliary stricture
9718137|NCT04550819|Active Comparator|CPBSs in benign extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with benign extrahepatic biliary stricture
9718138|NCT04550806||GDM|
9718139|NCT04550806||non-GDM|
9718140|NCT04550767||local infections|local infections
9718141|NCT04550767||systemic infections|systemic infections
9718142|NCT04550689|Active Comparator|Xenograft|
9718143|NCT04550689|Active Comparator|Allograft|
9718144|NCT04550949|Experimental|QL1206|QL1206 injection(120mg)was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
9718145|NCT04550949|Active Comparator|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
9718146|NCT04550793||Intervention|The stroke patients who receive botulinum toxin injection at affected brachialis and/or biceps brachials.
9718147|NCT04550793||Control|The stroke patients who do not receive botulinum toxin injection at affected brachialis and/or biceps brachials in the past 3 months.
9718148|NCT04550923|Experimental|Investigational device (non-rigid) group|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device.
9718149|NCT04550923|Active Comparator|Control device (rigid) group|Use rigid (PEEK) interbody fusion device .
9718150|NCT04550845|Experimental|Specific Aim 1|In specific aim 1, twelve focus group interviews (AA and rural White men with localized prostate cancer and caregivers, N = 50 dyads or N = 100 participants) will be conducted to explore comprehension of prognostic genomics as well as facilitators and barriers to genomic health literacy and to assess the acceptability and value of the revised PCLA education video.
9718151|NCT04550845|Experimental|Specific Aim 2|In specific aim 2, participants will be randomized into intervention versus control group. Twenty focus groups (AA and rural White men with localized prostate cancer and caregivers, N = 80 dyads or N = 160 participants) will be conducted to culturally conceptualize the study intervention and to provide qualitative contextual evaluation. The design for this aim is a randomized controlled, parallel group, repeated measures, non-blinded trial, with a nurse-delivered tailored prostate cancer education, communication coaching, and the prognostic genomics revised Prostate Cancer Literacy Video compared to the prognostic genomics revised Prostate Cancer Literacy Video.
9718152|NCT04551001|Experimental|Cold forcep|Cold forcep polypectomy performed for polyps <=3mm.
9718153|NCT04551001|Experimental|Cold snare|Cold forcep polypectomy performed for polyps <=3mm.
9718154|NCT04550728|Experimental|FES+robot|Participants in this group will have FES during ankle robot training
9718155|NCT04550728|Active Comparator|Robot|Participants in this group will have ankle robot training only
9718156|NCT04550975|Experimental|Advanced Cognitive Stimulation Therapy|Advanced Cognitive Stimulation Therapy (ACST), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. ACST will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee or care home staff.
9718157|NCT04550975|No Intervention|Treatment as usual|Standard care in care homes
9718158|NCT04550897|Experimental|BM7PE treatment|"The BM7PE treatment will be administered as a 20-minute i.v. infusion. The treatment is repeated after 2 weeks (day 15). The patients will be treated as in-patients and will stay at the hospital until toxicity have decreased to grade 2 and or plasma AST and or ALT levels has started to decrease. For at least a minimum of 3 days.~The dose administered to the patient will be 2.5, 5.0, 7.5, 10.0, 15.0 and 20.0 μg/kg body weight."
9718159|NCT04551196|Active Comparator|Alternating Regimen|A regimen of acetaminophen and ibuprofen alternating doses every 3 hours.
9718160|NCT04551196|Active Comparator|Combined Regimen|A regimen of acetaminophen and ibuprofen dosed together every 6 hours.
9718161|NCT04551105|Active Comparator|First session: manual review first and then review with CADx|"Each rater will interpret the Dataset A cases in different random order without any assistance of artificial assistance first, and then interpret the Dataset B cases in different random order with BR-USCAD DS."
9718162|NCT04551105|Active Comparator|First session: review with CADx first and then manual review|"Each rater will interpret the Dataset A cases in different random order with BR-USCAD DS first, and then interpret the Dataset B cases in different random order without any assistance of artificial assistance."
9718163|NCT04551105|Active Comparator|Second session: manual review first and then review with CADx|"At least 4 weeks after first session for memory washing out. Each rater will interpret the Dataset A cases in different random order without any assistance of artificial assistance first, and then interpret the Dataset B cases in different random order with BR-USCAD DS."
9718164|NCT04551105|Active Comparator|Second session: review with CADx first and then manual review|"At least 4 weeks after first session for memory washing out. Each rater will interpret the Dataset A cases in different random order with BR-USCAD DS first, and then interpret the Dataset B cases in different random order without any assistance of artificial assistance."
9718165|NCT04550910|Other|Arm A|40 Gy /15 fx / 3 weeks, 5 days per week, is a dose prescribed (after randomization ) for Breast Cancer patients indicated for adjuvant RTH after mastectomy
9718166|NCT04550910|Experimental|Arm B|28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy is a dose prescribed (after randomization )for Breast Cancer patients indicated for adjuvant RTH after mastectomy
9718167|NCT04550702||Women received Mirabegron|Women with overactive bladder syndrome received Mirabegron
9718168|NCT04550663|Experimental|KD-025 CAR-T cells|NKG2D-based CAR-T cells infusion
9718169|NCT04550598|Experimental|HD-tCES|The experiment group will receive active HD-tCES.
9718170|NCT04550598|Sham Comparator|Sham HD-tCES|The sham control group will receive sham HD-tCES.
9718171|NCT04550416|Experimental|ProMark Information and Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
9718172|NCT04550416|No Intervention|Standard Practice|Physicians will care for online virtual patients as they normally would in practice.
9718173|NCT04550429|Active Comparator|60 mmHg MyoSure Hysteroscopic Morcellator Device|The rationale for this experimental arm is that the pressurization can result in excess fluid being absorbed by the patient without a substantial benefit to surgical outcome. Minimizing the pressure from 80 mmHg (which is standard of care) to 60 mmHg used during this procedure may optimize outcome without compromising visualization of the surgeon. The research procedure will take place in the operating room of the minimally invasive gynecologic surgery department.
9718174|NCT04550429|Sham Comparator|80 mmHg MyoSure Hysteroscopic Morcellator Device|This is the standard of care pressurization for this procedure at Northwestern Medicine and will be the control group for the study
9718175|NCT04550442|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax PO daily on days 1-14 and azacitidine IV over 15 minutes or SC on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
9718176|NCT04550351|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
9718177|NCT04550351|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
9718178|NCT04550351|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
9779874|NCT04521621|Experimental|Part 2, Cohort D: Hepatocellular Carcinoma (HCC)|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9779875|NCT04521621|Experimental|Part 2, Cohort E: Gastric Carcinoma|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
9779876|NCT04516746|Experimental|AZD1222|Approximately 20,000 participants randomized to the AZD1222 arm
9779877|NCT04516746|Placebo Comparator|Placebo|Approximately 10,000 participants randomized to the saline placebo arm
9779878|NCT04513145|Experimental|Treatment Group (Ropivacaine)|The treatment group will consist of patients undergoing total knee arthroplasty who receive standardized 100 cc periarticularinjection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients will then receive 10cc of ropivacaineinto their adductor canal.This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
9779879|NCT04513145|Placebo Comparator|Control Group (Saline)|The control group will consist of patients undergoing total knee arthroplasty who receive a standardized periarticular injection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients randomized in this group will then receive 10cc of saline into their adductor canal. This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
9779880|NCT04510090|Experimental|EP547 Single Dose|Single doses of EP547
9779881|NCT04510090|Experimental|EP547 Multiple Doses|Multiple doses of EP547
9779882|NCT04510090|Placebo Comparator|Placebo Single Dose|Single doses of placebo
9779883|NCT04510090|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo
9779884|NCT04503720|Experimental|CLoWI|"CLoWI (ropivacaine) and PCA (normal saline)~The local anaesthetic infusion will be administered via 2 catheters using a ON-Q® (Halyard) delivery system that will be placed under direct vision by the surgeon at the time of wound closure. 40 mls of 0.25% ropivacaine are infiltrated in the preperitoneal plane. 0.5% ropivacaine will be infused at a rate of 4mls/hour (2mls/hour in each catheter).~The dosage 40 mls of 0.25% ropivacaine and 0.5% ropivacaine at 4mls/hr (20mg/hr) over 4 days will be less than the recommended toxic dose of 3-4 mg/kg."
9779885|NCT04503720|Active Comparator|PCA|"PCA (Morphine) and CLoWI (normal saline)~Morphine will be administered via the standard PCA protocol in accordance to the hospital's Acute Pain Service Programme:~Concentration: 1mg/ml~Bolus (Loading): 1mg~Lockout Interval: 5 minutes~Maximum hourly dose of 10mg"
9779886|NCT04498351|Placebo Comparator|cotrol group|
9779887|NCT04498351|Active Comparator|dexmedetomidine group|
9779888|NCT04498351|Active Comparator|magnesium sulphate group|
9779889|NCT04498351|Active Comparator|dexmedetomidine and magnesium sulphate group|
9779890|NCT04497584|Experimental|Afatinib + Prednisone|"Afatinib 40 mg PO daily~Prednisone 40 mg PO daily starting 7 days after Afatinib"
9779891|NCT04492215|Experimental|Physicians trained in motivational interviewing|Patients followed by general practitioners trained in motivational interviewing
9779892|NCT04492215|No Intervention|Physicians did not trainned in motivational interviewing|Patients followed by general practitioners who did not receive motivational interviewing.
9779893|NCT04487964|Active Comparator|the conventional therapy according to the MOH protocol.|Patients who are receiving conventional therapy according to the MOH protocol.
9779894|NCT04487964|Active Comparator|conventional therapy +Liquorice cap and Boswellia Serrata gum|Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy
10196448|NCT05186246|Placebo Comparator|Placebo comparator|Subjects were randomized to have placebo cream to be applied on the other side of the face twice daily post fractional CO2 laser. Placebo cream were packaged in identical-looking containers with combination cream. The subjects were evaluated on day 3 and day 7 post fractional CO2 laser.
9779896|NCT04485013|Experimental|Phase 1a, Monotherapy Dose Escalation|
9779897|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)|Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)
9779898|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)|Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)
9779899|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)|Cohorts will enroll subjects with advanced/metastatic colorectal cancer (CRC)
10196449|NCT05186233|Active Comparator|Non-personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their habitual sleep schedule. Participants will follow these recommendations over the course of two weeks.
10196450|NCT05186233|Experimental|Personalized light condition|Participants will receive light exposure recommendations from the SHIFT mobile application based on their activity levels. Participants will follow these recommendations over the course of two weeks.
10196451|NCT05186220|Experimental|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx or Carto system), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
10196452|NCT05186220|Active Comparator|Permanent pacemaker implantation|A dual chamber pacemaker implantation will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
10196453|NCT05186194|Experimental|Experimental (Treatment) Group|Oral vitamin D1000IU, 1/day, calcium 1200mg, 1/day, for 8 weeks.
10196454|NCT05186194|Placebo Comparator|Control Group|Oral placebo, for 8 weeks.
10196455|NCT05186181||group RISEN STAR|Patients with Stanford B-type aortic dissection will be treated with endovascular repair with in situ needle fenestration of left subclavian artery.
10196456|NCT05186142||Patients hospitalized for treatment of lymphoedema|Patients hospitalized for treatment of lymphoedema
10196457|NCT05186103||HS-ASD|high-severity ASD
9718179|NCT04550637||Anticoagulant therapy after percutaneous left atrial appendage|Oral apixaban
9718180|NCT04550286|Experimental|Intervention Group|"Intervention points in time include:~Baseline measure~Installation of the study app~Advice on general enhancements regarding study environment and behavior (BCT 4.1)~Students are to develop up to three action plans (BCT 1.4) and coping plans (BCT 1.2) to reduce smartphone interference during exam preparation periods by putting the smartphone away~Students receive weekly questionnaire (t1-t3) and one questionnaire after their first exam (t4). All these questionnaires concern their academic performance and well-being. A short questionnaire (t5) asks for the participants' exam grades approx. 2 months after their exam. A time period of 2 months has been chosen to ensure that universities have enough time to announce the grades.~During the whole period of the study, the mobile application tracks the students' smartphone behavior (i.e., daily smartphone use, daily screen activations, and specific app usage)."
9718181|NCT04550286|Active Comparator|Control Group|Control points in time include all parts except for number 4. Here students in the control group will receive questionnaires on general health behavior in order to achieve an equal questionnaire completion time compared to the intervention group.
9718182|NCT04550338|Experimental|Tranexamic Acid Treatment|
9718183|NCT04550338|Placebo Comparator|Placebo Treatment|
9718184|NCT04550520|Experimental|study part 1: healthy adult volunteers|22 Healthy volunteers: The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
9718185|NCT04550520|Experimental|study part 2: adult patients with primary polydipsia or central diabetes insipidus|If results of study part 1 suggest that glucagon stimulates copeptin (proof of concept),10 patients with primary polydipsia and 10 patients with central diabetes insipidus will be additionally included (study part 2): The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
9718186|NCT04550325|Experimental|Immune gamma globulin (IgG)|Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion
9718187|NCT04550234|Experimental|Treatment 1|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1.
9718188|NCT04550234|Experimental|Treatment 2|Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1.
9718189|NCT04550234|Experimental|Treatment 3|Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1.
9718190|NCT04550234|Experimental|Treatment 4|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1.
9718191|NCT04550234|Experimental|Treatment 5|Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1.
9718192|NCT04550611|Experimental|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|will receive blood group -specific MP-IVIG in a regimen of 2 g/kg bodyweight, usually as 0.4 g/kg bodyweight per day for five consecutive days within two weak of onset of symptoms.
9718193|NCT04550611|Experimental|plasmapheresis|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
9718194|NCT04550559|Active Comparator|Group 1|The patients in group 1 were instructed to masturbate at least 3-4 times a week
9718195|NCT04550559|Other|Group 2|The patients in group 2 were prescribed oral tamsulosin 0.4 mg once daily
9718196|NCT04550559|No Intervention|Group 3|The patients in group 3 acted as controls and received only standard medical therapy
9718197|NCT04550182|Experimental|Individual positioning schedule|Pressure ulcer prevention cares are provided according to the positioning schedule for every patient.
9718198|NCT04550182|No Intervention|Standard care|Pressure ulcer prevention cares are provided according to usual practice of the ICU. Frequency and modality of positioning applied to the patients are collected.
9718199|NCT04550221|Experimental|Intervention|The Shauriana intervention is aimed at promoting sexual health and preventing HIV through a comprehensive prevention toolbox including PrEP. Components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions.
9779900|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (CRC)|Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR colorectal cancer (CRC)
9718200|NCT04550221|Active Comparator|Standard care|Standard care includes clinic-based HIV counseling and testing, screening for symptoms of sexually transmitted infections (STI), and individual counseling about HIV prevention methods. Standard of care counseling for HIV prevention in Kenya includes general information about HIV transmission and discussions of risk reduction including condom use. PrEP counseling sessions focus on PrEP knowledge, adherence tips, and strategies to address adherence barriers.
9718201|NCT04549961||patients admitted to intensive care units|all patients that are present on an intensive care unit on nutritionday
9718202|NCT04550624|Experimental|Interventional Arm|This is an open-label, multi-center, phase II trial of lenvatinib in combination with pembrolizumab in patients with advanced cholangiocarcinoma (CCA) who have progressed on standard systemic therapy. All participants will be administered Pembrolizumab 200mg IV on day 1 and Lenvatinib 20mg PO daily days 1-21 of each cycle (21 days).
9718203|NCT04550104|Active Comparator|Radiotherapy only|
9718204|NCT04550104|Experimental|Olaparib + radiotherapy|
9718205|NCT04550104|Experimental|AZD1390 + radiotherapy|
9718206|NCT04550104|Experimental|TBD1 + radiotherapy|DDRi to be decided
9718207|NCT04550104|Experimental|TBD2 + radiotherapy|DDRi to be decided
9718208|NCT04550104|Experimental|TBD3 + radiotherapy|DDRi to be decided
9718209|NCT04550117|Experimental|Intraspinal Pressure Monitoring|A fiberoptic pressure monitoring device will be placed into the subarachnoid space at the site of traumatic spinal cord injury
9718210|NCT04549935|Active Comparator|Group A Dextenza|Drug: Dextenza 0.4mg Opthalmic Insert The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion, The attributes of the insert reduce risks for improper corticosteriod tapering and unwanted peaks and troughs in drug concentration.
9718211|NCT04549935|Active Comparator|Group B Topical Prednisolone|Drug: Topical Prednisolone Standard of care topical drop treatment
9718212|NCT04550026|Experimental|Inhalation of HTP|Inhalation of HTP for 30 minutes
9718213|NCT04550026|Active Comparator|Sham inhalation of HTP|Sham usage of HTP for 30 minutes
9718214|NCT04550039|Experimental|Body-weight-supported treadmill training|Participants complete prescribed gait training program for at least three weeks or until they discharge.
9718215|NCT04550039|Experimental|EksoNR exoskeleton|Participants complete prescribed gait training program for at least three weeks or until they discharge.
9718216|NCT04550078|Active Comparator|Calcium Carbonate|800 mg calcium as calcium carbonate in capsules consumed orally once with a standardized meal.
9718217|NCT04550078|Experimental|Calcium-enriched permeate|800 mg calcium as calcium permeate in capsules consumed orally once with a standardized meal.
9718218|NCT04550078|Placebo Comparator|Maltodextrin|0 mg calcium as placebo capsules with maltodextrin consumed orally once with a standardized meal.
9718219|NCT04549857|Experimental|intervention group|The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.
9718220|NCT04549857|Placebo Comparator|Placebo group|The placebo group only used base oil (sweet almond oil).
9718221|NCT04549857|No Intervention|Control group|No intervention
9718222|NCT04550299|Active Comparator|Group A|single bundle technique with the use of bioabsorbable implants
9718223|NCT04550299|Active Comparator|Group B|single bundle technique with the use of Bio-Intrafix
9718224|NCT04550299|Active Comparator|Group C|double bundle technique with the use of bioabsorbable implants
9718225|NCT04550299|Active Comparator|Group D|double bundle technique with the use of Bio-Intrafix
9718226|NCT04550156|No Intervention|Control Arm|Patients are treated according to current local standards
9718227|NCT04550156|Experimental|Colorectal Bundle Arm|Patients are treated according to the colorectal bundle
9718228|NCT04549805||Patients without myocardial injury|Patients without myocardial injury will be recruited in a 2:1 fashion stratified by peak high-sensitivity cardiac troponin I concentration above and below a threshold of 5 ng/L.
9718229|NCT04549922|Placebo Comparator|Placebo|1.2 mL Normal Saline, single dose subcutaneous, after randomization
9718230|NCT04549922|Active Comparator|ISIS 721744|1.2 mL ISIS 721744, single dose subcutaneous, after randomization
9718231|NCT04550273|Experimental|study group|The study group (n=20) will receive three sessions of aerobic walking exercise per week for 3 months in addition to the traditional medical treatment
9718232|NCT04550273|No Intervention|control group|The control group (n=20) will receive no training
9718233|NCT04549727||infants with surgical NEC|Infants who undergo surgery for NEC disease
9718234|NCT04549727||Infants with GI surgical diseases other than NEC|Infants who undergo surgery for other GI diseases than NEC
9718235|NCT04549844|Active Comparator|the intervention group (G A)|Group general anaesthesia plus peribulbar block : Total 35 cases who will receive general anesthesia with peribulbar block (bupivacaine 0.5 % xylocaine 2% hyaluronidase with total volume 0.06 mg \kg (bupivacaine : (xylocaine :hyaluronidase ) 1:1) Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
9718236|NCT04549844|Placebo Comparator|the control group (G B )|"General group: Total 35 cases who will receive general anesthesia only, i.e., without peribulbar block. (Fentanyl 1µg\kg, atracurium 0.5 mg\kg and propofol 2mg \kg.~After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane."
9718237|NCT04550507|Experimental|Group A: Mindful Sensory Awareness|Group A: Mindful Sensory Awareness receives the mindful sensory awareness intervention during the first 8-week period, and receives no active intervention delivery during the second 8-week period.
9779901|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC)|Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR (KRAS wild type) colorectal cancer (CRC)
10196458|NCT05186103||LS-ASD|low-severity ASD
10196459|NCT05186103||control|typical development
10196460|NCT05186090|Experimental|24-week resistance exercise program|Participants will engage in supervised 24-week resistance exercise program with goal of maintaining 180 minutes of exercise per week.
10196461|NCT05186090|No Intervention|Wait-list control group|Control group will be asked to maintain their usual lifestyle.
10196462|NCT05186077||Healthy Controls|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
10196463|NCT05186077||Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
10196464|NCT05186077||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed or manic with their current episode lasting at least 6months and not responding to 2 or more adequate evidence-based treatments for BDI or BDII.
10196465|NCT05186064|Experimental|whole genome sequencing after standard of care resection at first relapse|
10196466|NCT05186038||Population of children and adolescents between 2 and 18 years old|Population of children and adolescents between 2 and 18 years old who are diagnosed with celiac disease or are suspected to suffer the disease.
10196467|NCT05186025||Adults|adult patients aged ≥ 18 with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
10196468|NCT05186025||Children|children aged from >5 to 17 years with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
10196469|NCT05186012|Experimental|Arm A (Single agent)|
10196470|NCT05186012|Experimental|Arm B (combo)|
10196471|NCT05185999|Experimental|Single Arm|Intraperitoneal infusion with 500 mL of sodium-free 30% Icodextrin/ 10% Dextrose solution
10196472|NCT05185908||Group 1|The patients undergoing laparoscopic transperitoneal nephrectomy.
10196473|NCT05185895|Sham Comparator|Start with: Concentric (normal) cycling|
10196474|NCT05185895|Experimental|Start with: Eccentric cycling|
9718238|NCT04550507|Other|Group B: Mindful Sensory and Body Awareness|Group B: Mindful Sensory and Body Awareness receives no active intervention delivery during the first 8-week period, and during the second 8-week period receives an intervention combining the mindful sensory awareness content received by Group A with the mindful body awareness check-in approach.
9718239|NCT04549701|Experimental|CAVAL US group|Patients assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to the treating medical team, in addition to standard care. Diuretic titration: There will not be a specific treatment protocol, but clinicians will be encouraged to tailor treatment, particularly with the use of diuretics, according to the number of B-lines and dilation in the IVC. The therapeutic objective will be discharge patients normal CAVAL US, with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory alterations that contraindicate discharge.
9718240|NCT04549701|Active Comparator|Standard of care group|Patients assigned to this group will receive standard care, and diuretic titration will be based on standard practice (physical examination, symptoms, and laboratory results). The therapeutic objective will be discharge patients with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory abnormalities that contraindicate discharge.
9718241|NCT04550143||Septic Shock|
9718242|NCT04549688|Experimental|Focal therapy|
9718243|NCT04549714|Experimental|High AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
9718244|NCT04549714|Experimental|Middle AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
9718245|NCT04549714|Experimental|Low AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
9718246|NCT04549883|Experimental|Performing after session|LB control during hip extension after intervention
9718247|NCT04549662|Experimental|Group A|Powdered formula containing whey protein and arginine (Active A) and lipid bolus containing omega 3 fatty acids. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
9718248|NCT04549662|Active Comparator|Group B|Powdered formula containing whey protein and arginine (Active A) and placebo oil. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
9718249|NCT04549662|Placebo Comparator|Comparator|Powdered formula containing whey protein (Active B) and placebo oil. Participants will mix the powder (Active B) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
9718250|NCT04549870|Active Comparator|Roflumilast|Roflumilast 500 microgram daily (capsule)
9718251|NCT04549870|Placebo Comparator|Placebo|Placebo (capsule)
9718252|NCT04549909||preimplantation genetic testing for aneuploidy (PGT-A) Group|Patients who have undergone preimplantation genetic testing for aneuploidy (PGT-A) (transfer of own frozen embryo)
9718253|NCT04549909||endometrial receptivity array (ERA) Group|Patients who have undergone frozen embryo transfer (FET) with endometrial receptivity array (ERA) test (embryos from own or donated oocytes)
9718254|NCT04549909||CONTROL OWN (CO) Group|Control group of FET from own oocytes (without ERA or PGT-A)
9718255|NCT04549909||CONTROL DONATED(CD) Group|Control group of FET from donated oocytes (without ERA or PGT-A)
9718256|NCT04549974|Experimental|Passive heat exposure|
9718257|NCT04549779|Experimental|Group I (low volume)|patients will receive 5 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
9718258|NCT04549779|Experimental|Group II (intermediate volume)|patients will receive 10 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
9718259|NCT04549779|Experimental|Group III (high volume)|patients will receive 15 ml levobupivacaine 0.25% ultrasound-guided interscalene brachial plexus block.
9718260|NCT04549584||metaplastic breast cancer|Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.
9718261|NCT04549584||non-metaplastic breast cancer|Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer
10196475|NCT05185882||1|"Single leg squat without a clue or focusing method~Single leg squat with an external focus~Sinlge leg squat with an internal focus"
10196476|NCT05185869|Experimental|AG+SHR6390|Subjects will receive SHR6390 plus nab-paclitaxel and gemcitabine
9718262|NCT04549675|Experimental|Arm 1 Sun Safe Partners Online Intervention|Web-based intervention called Sun Safe Partners Online. Website developed by the study team. Participants received individual username and password to login.
9718263|NCT04549675|Active Comparator|Generic Online Sun Safety Information intervention|Publicly online available skin cancer and sun protection information emailed to participants in 4 seperate email links.
9718264|NCT04549831||SARS-CoV-2 PCR positive individuals|Adult (> o equal to 18 years) SARS-CoV-2 PCR positive individuals with different clinical outcome: from asymptomatic to severely affected COVID-19 patients.
9718265|NCT04549948|Experimental|0.017X0.025 Stainless Steel Archwire|Leveling of COS using 0.017X0.025 Stainless Steel (SS) Archwire A reverse COS using 0.017X0.025 SS was used to correct the excessive COS in the lower arch.
9980594|NCT01393275|Placebo Comparator|Placebo rehabilitation|The group is performing a strength endurance training intervention in addition with placebo rehabilitation exercise intervention.
9980595|NCT01393288|Placebo Comparator|Ondansetron|
9980596|NCT01393288|Placebo Comparator|Lorazepam|
9980597|NCT01393288|Placebo Comparator|Aprepitant|
9718266|NCT04549948|Experimental|0.019X0.025 Stainless Steel Archwire|A reverse COS using 0.019X0.025 SS was used to correct the excessive COS in the lower arch.
9718267|NCT04549948|Experimental|0.021X0.025 TMA archwire|A reverse COS using 0.021X0.025 TMA archwire was used to correct the excessive COS in the lower arch.
9718268|NCT04549987|Experimental|Without changing working archwire|Extraction space closed using the same working archwire throughout 3 visits after insertion
9718269|NCT04549987|Experimental|With changing working archwire|The extraction space closed having the working archwire changed monthly.
9718270|NCT04549649|Experimental|Group A (Experimental oocyte triggering approach)|0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) associated with two ampoules of Ovitrelle (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be administered subcutaneously simultaneously for final oocyte triggering.
9718271|NCT04549649|No Intervention|Group B (Routine oocyte triggering approach)|Two ampoules of Ovitrelle® (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be injected subcutaneously for final oocyte triggering.
9718272|NCT04549636||healthy COVID-19+|Individuals who recently recovered from COVID-19 and who have no history of lung disease
9718273|NCT04549636||asthmatic COVID-19+|Individuals who recently recovered from COVID-19 and who have asthma
9718274|NCT04549636||healthy COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
9718275|NCT04549636||asthmatic COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have asthma
9718276|NCT04549818|Experimental|sacral neuromodulation|Sacral neuromodulation group, will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
9718277|NCT04549818|No Intervention|medical therapy|this group will be treated with sustained release morphine tablets for pain control
9718278|NCT04549441||WALANT|The participants undergo distal radius plating surgery via wide-awake local anesthesia no tourniquet technique. In this group, mean arterial pressure, heart rate, and numeric rating scale for pain were measured by nursing staff in the operation theatre seven times perioperatively, namely before surgery (T0) and at the time of injection of local anesthesia (T1), skin incision (T2), fracture reduction (T3), plating and screwing (T4), skin closure (T5), surgery completion (T6).
9718279|NCT04549441||GA|The participants undergo distal radius plating surgery via general anesthesia induced by an anesthesiologist. The anesthesia team continuously monitored patients' intraoperative physiological status. MAP and HR in group B were marked after induction (T1) and at the other six same time points as in the group WALANT.
9980598|NCT01393314|Active Comparator|Honeywell HomMed Telemonitor|
9980599|NCT01393314|No Intervention|usual care|
9980600|NCT01393327|Experimental|Respiratory and exercise therapy|Early after PEA postoperative three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks.
9980601|NCT01393340|Placebo Comparator|Placebo|
10196477|NCT05185856|Sham Comparator|Start with: Concentric (normal) cycling|Patients that are allocated to this arm will start with normal cycling
9980602|NCT01393340|Active Comparator|Omalizumab|
9980603|NCT01393353|Sham Comparator|Computer game|Nintendo Wii
9980604|NCT01393353|Experimental|Cognitive Training with Cogniplus|CogniPlus
9980605|NCT01393366|Other|Without AMA|Patient will be follow only like usual practice
9980606|NCT01393366|Other|With AMA|Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
9980607|NCT01393418||Subjects undergoing cardiac surgery|
9980608|NCT01393431||EBC pH|Observational study
9980609|NCT01393470||Cohort A (Trial Cohort, Vaccinated during HPV-008)|"Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.~Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
9718280|NCT04549285|Experimental|hCT-MSC infusion|Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician.
9718281|NCT04549454|Experimental|Intervention App|Students in arm of the study will have a parent who has access to the following content in the parent app: (a) FITSTART+ PBI materials (personalized normative feedback quiz, information on college student drinking, and alcohol-specific advice for parents of first year students); (b) general advice for parents of college students (e.g., improving communication; reducing conflict); (c) information about university resources; and (d) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
10196478|NCT05185856|Experimental|Start with: Eccentric cycling|Patients that are allocated to this arm will start with eccentric cycling
9718282|NCT04549454|Placebo Comparator|Control App|Students in this arm of the study will have a parent who has access to the following content in the parent app: (a) general advice for parents of college students (e.g., improving communication; reducing conflict); (b) information about university resources; and (c) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
9718283|NCT04549467|Experimental|Dolutegravir + lamivudine|Dolutegravir 50 mg, 1 tablet QD plus lamivudine 300 mg, 1 tablet QD
9718284|NCT04549467|Active Comparator|Dolutegravir + emtricitabine/tenofovir (FTC/TDF)|Dolutegravir 50 mg, 1 tablet QD plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
9718285|NCT04549753|Experimental|tDCS stimulation group|Patients receive four sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system.
9718286|NCT04549506||ASD group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. All ASD participants were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders 5th Edition's (DSM-5) diagnostic criteria (APA, 2013) and conﬁrmed by clinical consensus. ASD individuals were recruited from a community autism program and referred to children's health doctors and child psychiatrists. Exclusion criteria for all participants were neurological abnormalities, a history of epilepsy or seizures, head trauma and IQ <75. The subjects did not participate in any intervention or drug programs during the experimental period.
9718287|NCT04549506||Control group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. The participants in the age- and sex-matched control group were recruited from the local community, and screened for major psychiatric illnesses by conducting structured interviews.
9980610|NCT01393470||Cohort B1 + B2|"Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.~Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.~Cohort B2 (Trial Cohort, Non-Vaccinated)"
9718289|NCT04549519||Stable group|Participants display knee valgus less or equal to 15° at 45° knee flexion in the descending phase of the squat on both legs
9718290|NCT04549519||Unstable group|Participants display knee valgus greater than 15° at 45° knee flexion in the descending phase of the squat on one leg or both legs
9718291|NCT04549545|Active Comparator|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session. Each side of the nose will be treated with up to four (4) non-overlapping applications of RF energy at the junction of the upper and lower lateral cartilage on the lateral nasal wall. Treatment settings to be used are: temperature 60° C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (24 months)."
9718292|NCT04549545|Sham Comparator|Sham Control Procedure|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
9718293|NCT04549415|Active Comparator|metformin|Metformin, 1000 mg b.i.d, 12 months
9718294|NCT04549415|Active Comparator|lifestyle modification|Lifestyle modification Standard Principles
9779902|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)|Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
9779903|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)|Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
10196479|NCT05185830|Experimental|Interactive robot|Children in the interactive robot will be mobilized for the first time with interactive robots.
10196480|NCT05185830|No Intervention|Control group|Children in the control group will be mobilized with nurses
10196481|NCT05185804|Experimental|Group DD217|Study drug Dimolegin - DD217, 60 mg orally, 1 time per day
10196482|NCT05185804|Active Comparator|Group Clexane|Reference drug Clexane, 40 mg subcutaneously, 1 time per day
10196483|NCT05185791||Pre-ERAS® implementation phase|"Current clinical practice~Current perioperative management~All consecutive patients included for CRS+-HIPEC treatment~Period of inclusion : 3 months (01.10.2021 - 31.12.2021)~Survey of intended changes in clinical practice will be sent to each leader center~No specific intervention. Only descriptive recordings of pre-intra-post-operative clinical endpoints (ERAS® core items) and demographic parameters.~Clinical and surgical outcomes will be recorded until 30 postoperative days (POD). Functional recovery parameters will be recorded for the first 5 POD"
10196484|NCT05185791||Post-ERAS® implementation phase|"After implementation 2 months of delay before starting the recordings~Clinical practice and perioperative management with new practice according guidelines and local commitment for the new change~All consecutive patients included for CRS±HIPEC treatment~Period of inclusion : 3 months (01.03.2022 - 31.05.2022)~Max 2 months of delay allowed between the two phases~Intervention will take place during an implementation period of 2 months. This period will let the centers to set the newly implemented clinical practices.~After that, the remaining 3 months of the study will consist in descriptive recordings of pre-intra and post-operative clinical endpoints and demographic parameters (ERAS® core items).~Clinical and surgical outcomes will be recorded until 30 postoperative days (POD). Functional recovery parameters will be recorded for the first 5 POD."
9718295|NCT04549532|Experimental|T-MD Intervention Group|Participants will be prescribed 1+ interventions tailored to affected domains.Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.Autonomic-Graded aerobic exercise. Perform daily aerobic exercise, goal 80% HR max on a stationary bike/treadmill/walking/jogging.
10196485|NCT05185765|Active Comparator|Brown bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
9718296|NCT04549532|Active Comparator|Behavioral Management|Participants in control group will receive standardized behavioral management strategies including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion. Clinicians will discuss and review a behavioral strategies handout with each participant and answer any questions they may have about the information in the handout. Contact time between clinicians and patients will be similar to avoid effects associated with more or less contact time.
10196486|NCT05185765|Active Comparator|Wholemeal bread (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
9718297|NCT04549389|Active Comparator|Group A|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (1/week) by using Dornier Aries 2 shockwave machine (energy level 7)
9718298|NCT04549389|Active Comparator|Group B|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (2/week) by using Dornier Aries 2 shockwave machine (energy level 7)
9718299|NCT04549064||Patients with pancreatic cancer|Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.
9718300|NCT04549064||Healthy Control|healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors.
9718301|NCT04549038|Experimental|Cases|Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.
9718302|NCT04549038|No Intervention|Controls|Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.
9718303|NCT04549623|Experimental|Group ETCO2|Novel end-tidal carbon dioxide monitoring device is used for sedation.
9718304|NCT04549623|Experimental|Group Reg|Peripheral oxygen saturation (SpO2) and respiratory motion are regularly monitored during sedation.
9718305|NCT04549220||Delivery (Birth) Cohort|All women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age delivering a live infant or stillbirth at Kawempe Referral Hospital over a 6-month pilot phase will be invited to participate in the study until a sample size of at least 5000-6000 women is achieved.
9718306|NCT04549220||Active Surveillance Cohort|This is expected to improve capacity for managing and investigating infants <3 months of age presenting with suspected sepsis at Kawempe Neonatal Intensive Care Unit (NICU), Postnatal Ward, and Acute Paediatric Wards and Mulago Hospital Paediatric Acute Care Unit, through provision of supplies for blood culture, CSF culture and nasopharyngeal swabs. Mothers/caretakers of Neonates that are diagnosed with GBS through this active case surveillance will be invited to participate in the study and will be enrolled following written informed consent.
9718307|NCT04549142||Pregnant women- high level pollution|Exposed to high levels of pollution (PM2.5)
9718308|NCT04549142||Pregnant women- low level pollution|Exposed to low levels of pollution (PM2.5)
9718309|NCT04549142||Non-pregnant women-high level pollution|Exposed to high levels of pollution (PM2.5)
9718310|NCT04549142||Non-pregnant women-low level pollution|exposed to low levels of pollution (PM2.5)
9718311|NCT04549129|Experimental|Intervention group|Participants randomized to the intervention group will receive breastfeeding education and teaching of hand expression using a breastfeeding education video and associated breastfeeding website, as well as hands-on teaching of hand expression techniques during their 36 week visit.
9718312|NCT04549129|Active Comparator|Control group|Participants randomized to the control group will receive usual breastfeeding education during their 36-week visit.
9718313|NCT04549194|Experimental|Tyrosine - External Operation|1-month L-Tyrosine treatment following 4-month external operation
9718314|NCT04549194|Experimental|Placebo - External Operation|1-month Placebo treatment following 4-month external operation
9718315|NCT04549194|Experimental|Tyrosine - Rear Base|1-month L-Tyrosine treatment following 4 months at rear base
9718316|NCT04549194|Experimental|Placebo - Rear Base|1-month Placebo treatment following 4 months at rear base
9779904|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (TNBC)|Cohorts will enroll subjects with advanced/metastatic triple negative breast cancer (TNBC)
10196487|NCT05185765|Active Comparator|Wholemeal bread without crust (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
9718317|NCT04549181|No Intervention|Phase I: Qualitative|Rural HF dyads will participate in a one-time telephone-based semi-structured interview to explore the types of HF-related problems that rural HF dyads experience and how these problems are managed.
9718318|NCT04549181|Experimental|Phase II: Problem-Solving for Rural HF Dyads|The dyadic problem-solving intervention will be provided by a HF specialist nurse. The nurse will conduct the initial telehealth (virtual, telephone) session and provide dyads with an intervention booklet containing examples of common HF-related problems experienced by rural dyads and suggested management strategies tailored to the rural sociocultural context. The nurse will lead dyads in a card sorting task intended to help dyads prioritize current HF-related problems and will guide dyads in developing management strategies for the highest priority problem. Dyads will utilize these strategies until the next session at which time the nurse will guide dyads in evaluating the effectiveness of chosen strategies. The iterative process then begins again. Dyads will receive 7 follow-up telephone sessions with the nurse. In the intervention, the nurse will focus on problems related to self-care, including those specific to the rural population.
9718319|NCT04549012|Active Comparator|group A|will receive oxytocin
10196488|NCT05185765|Active Comparator|White bread, water based (commercially available)|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
10196489|NCT05185765|Active Comparator|White hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
9718320|NCT04549012|Active Comparator|group B|will receive tranexamic acid plus oxytocin
9718321|NCT04548843|Experimental|Cohort 1 & Cohort 2|"3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells).~3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells)."
9718322|NCT04548804|Experimental|Control|Control subjects receiving body-surface potential mapping (BSPM) and CT-scan.
9718323|NCT04548804|Experimental|Diseased|Diseased subjects receiving body-surface potential mapping (BSPM) and CT-scan. Outcome measures from these procedures will be compared to controls.
9718324|NCT04548765|Active Comparator|Standard Letter|The standard letter describes the importance of getting screened and instructs recipients how to use the FIT kit for screening at home.
9718325|NCT04548765|Experimental|Letter with Risks|The standard letter is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; it also explains why test kits are being sent to disarm skepticism about the program.
9718326|NCT04548765|Experimental|Letter with Risks and Options|In addition to the enhancements added by the letter with risks, the letter also includes a table comparing FIT kit and colonoscopy. Presenting different screening options allows recipients to make the choice that best suits them. In addition, presenting multiple options increases the chance that recipients get screened in one way or another.
9718327|NCT04548765|Experimental|Letter with Risks, Options, and Consequences for Inaction|In addition to the enhancements added by the letter with risk, the comparison table includes comparisons of the consequences of getting screened vs. waiting for symptoms to appear.
9718328|NCT04548856|Other|IA-Microsurgical clipping group (ruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of an acutely ruptured cerebral aneurysm
9718329|NCT04548856|Other|IB-Microsurgical clipping group (unruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of unruptured cerebral aneurysm
9718330|NCT04548856|Other|IIA-Endovascular embolization group (ruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of an acutely ruptured cerebral aneurysm
9718331|NCT04548856|Other|IIB-Endovascular embolization group (unruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of unruptured cerebral aneurysm
9718332|NCT04548986|Other|single arm|single arm study
9718333|NCT04548921||Participants with Friedreich's Ataxia|Participant diagnosed with Friedreich's Ataxia aged between 2 and 50 years of age
9718334|NCT04548895||LTCF residents and involved health practitioners|"The intervention will take place in nursing homes, assisted living facilities and long-term care facilities (LTCF) in the United States (henceforth collectively referred to as LTCF).~Staff who work in the participating LTCF ≥ 20 hours/week and who have direct contact with the residents are also eligible to participate and to employ the biometric monitoring equipment in their private residences."
9718335|NCT04548687|Active Comparator|carbon dioxide insufflation|patients with planned minimally invasive or repeated cardiac surgery using standard methods of deaeration of cardiac cavities, supplemented with carbon dioxide insufflation during surgery + standard methods of deaeration of cardiac cavities
9718336|NCT04548687|Other|no carbon dioxide|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
9718337|NCT04548934|Active Comparator|No PPE|Cardiopulmonary resuscitation without wearing personal protective equipment (PPE)
9718338|NCT04548934|Experimental|PPE|Cardiopulmonary resuscitation while wearing personal protective equipment (PPE)
10196490|NCT05185765|Active Comparator|Brown hard roll (commercially available)|Participants consume half a roll, and masticate and expectorate half of 1 cm thick slice
10196491|NCT05185765|Active Comparator|White soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
9718339|NCT04548960|Other|cancer patients|cancer patients To explore the phenomena of resistance during the therapeutic response and/or the progression of the pathology, the investigatorswill used a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq) from blood and tumor samples and immunological profil by ELISA
9718340|NCT04548609|Experimental|Inhibitory Control/ Fear Extinction|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
9718341|NCT04548609|Experimental|Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
9718342|NCT04548635|Experimental|VR-PAT|Virtual Reality administered during burn dressing changes
9718343|NCT04548635|No Intervention|Control|Dressing changes performed without Virtual Reality (other distraction methods available in the home allowed).
9718344|NCT04548700|Experimental|Dose-finding and dose-expansion|"Dose-finding stage: Patients with treatment-naïve PTCL will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 12 mg/m2.~Dose-expansion stage: Patients with treatment-naïve PTCL will receive liposomal mitoxantrone hydrochloride at RP2D in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 or 21 days per cycle)."
9718345|NCT04548726||Sapien 3|Patients with aortic stenosis treated with Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) TAVI
9718346|NCT04548726||Myval|Patients with aortic stenosis treated with Myval (Meril Life Sciences Pvt. Ltd., India) TAVI
9718347|NCT04548674|Placebo Comparator|Positive Control Group|Whiteness HP 35%
9718348|NCT04548674|Experimental|Laser Group|Whiteness HP 35% + Laser
9718349|NCT04548674|Experimental|CPP Group|Whiteness HP 35% + CPP
9718350|NCT04548674|Experimental|Nano Group|Whiteness HP 35% + NANO
9718351|NCT04548674|No Intervention|Negative Control|Without intervention
9718352|NCT04548622|Experimental|Non-randomized bilateral rTMS|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
9718353|NCT04548479|Active Comparator|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure (PEP) breathing
9718354|NCT04548479|No Intervention|INS group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Inspiratory incentive spirometry breathing
9718355|NCT04548531|No Intervention|Usual Care Arm|This arm will be a usual care arm. Patients may call to schedule a colonoscopy or other tests as desired.
9718356|NCT04548531|Experimental|Shared Decision Making Arm|This is the intervention arm. Patients will receive a shared decision making information sheet in the mail and will be able to receive decision coaching from study staff to support selection of an option if desired.
9718357|NCT04548414||Sepsis group|The patients in this group are diagnosed sepsis with the sepsis 3.0 definition.
9718358|NCT04548414||Control group|The recruited volunteers in this group are healthy.
9718359|NCT04548336|Experimental|Motor Imagery|
9718360|NCT04548336|Experimental|Action Observation|
9718361|NCT04548336|Placebo Comparator|Placebo group|
9718362|NCT04548544|Experimental|TARA training|
9718363|NCT04548544|No Intervention|Control|
9779905|NCT04482972||DCB|DCB group: Patients treated with drug coated balloon (DCB) only angioplasty (all-comers: STEMI, NSTEMI, Stable angina)
9779906|NCT04482972||DES|DES group: Patients treated with drug eluting stent (DES) angioplasty (all-comers:STEMI, NSTEMI, Stable angina)
9779907|NCT04478734|Experimental|Moderate doses|moderate doses of combination therapy applying the minimum average dosage of thiamine and biotin used in patients with BTBGD
10196492|NCT05185765|Active Comparator|Brown soft bun (commercially available)|Participants consume half a bun, and masticate and expectorate 1/8th of a bun
9779908|NCT04478734|Experimental|High doses|high doses of the combination therapy applying the average standard dosage of thiamine and biotin used in patients with BTBGD.
9779909|NCT04478084|Experimental|Group 1: pediatric participants; VRVg-2|VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
9779910|NCT04478084|Active Comparator|Group 2: pediatric participants; Verorab|Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
9779911|NCT04478084|Experimental|Group 3: adult participants; VRVG-2 + ERIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
9779912|NCT04478084|Active Comparator|Group 4: adult participants; Verorab + ERIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
9779913|NCT04478084|Experimental|Group 5: adult participants; VRVG-2 + HRIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
9779914|NCT04478084|Active Comparator|Group 6: adult participants; Verorab + HRIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
9980611|NCT01393470||Cohort C (Referent Cohort, Non-Vaccinated)|"Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.~Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).~Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
9779916|NCT04461600|Experimental|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
9779917|NCT04447534|Experimental|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine alone
9779918|NCT04447534|Experimental|Chloroquine or hydroxychloroquine with zinc|Chloroquine or hydroxychloroquine with zinc
9779919|NCT04441307|Active Comparator|Healthy Foundations|A community-based parenting education program with individual family check ins will be implemented to all participants assigned to this arm.
9779920|NCT04441307|Experimental|Family Foundations|An adapted Family Foundations parenting program for expecting first time parents with individual family check ins will be implemented to all participants assigned to this arm.
9779921|NCT04431752||Healthy Volunteer|10 healthy volunteers to undergo radiographic examinations of the knee joint.
9779922|NCT04431752||Kellgren-Laurence grading I Osteoarthritis Knee|10 patients in Kellgren-Laurence grading I to undergo radiographic examinations of the knee joint.
9779923|NCT04431752||Kellgren-Laurence grading II Osteoarthritis Knee|10 patients in Kellgren-Laurence grading II to undergo radiographic examinations of the knee joint.
9779924|NCT04431752||Kellgren-Laurence grading III Osteoarthritis Knee|10 patients in Kellgren-Laurence grading III to undergo radiographic examinations of the knee joint.
10196493|NCT05185765|Active Comparator|Ciabatta (commercially available)|Participants consume half a mini ciabatta, and masticate and expectorate half of 1 cm thick slice
10196494|NCT05185765|Active Comparator|Croissant (commercially available)|Participants consume half a croissant, and masticate and expectorate half of 1 cm thick slice
10196495|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 65 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
10196496|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 85 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
9718364|NCT04548362|Experimental|Meat meals|This arm contains a 4-way cross-over intervention study with meats
9718365|NCT04548362|Experimental|Starchy meals|This arm contains a 4-way cross-over intervention study with
9718366|NCT04548557|No Intervention|Control|They will not receive any intervention
9718367|NCT04548557|Experimental|IVIG group|They will reveive intravenous immunoglobulin therapy
10196497|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 105 min, ambient cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
10196498|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 65 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
10196499|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 85 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
10196500|NCT05185765|Active Comparator|Whole wheat bread produced by bakery, proofing time 105 min, vacuum cooling|Participants consume half a slice, and masticate and expectorate 1/4th of rectangular bottom part
10196501|NCT05185752|Active Comparator|Erector Spinae Plane Block (ESP block)|"The patient is positioned in the prone position, the probe is used to locate in cross-section the T4 spinous process. Next, using a lateral scan, approximately 3 cm away, the costotransverse joint is located, and then change to sagittal ultrasound vision. By locating the intertransverse line with the probe, the following anatomical structures can be identified: three longitudinal muscles (trapezius, rhomboid, erector spinae).~The needle enters in a single punction at an angle of 45º, in the cranio-caudal direction, until it touches the apex of the costotransverse image. Subsequently, 30 cc of 0.25% bupivacaine are administered in the depth of the erector spinae, which will remain elevated."
9718368|NCT04548323||Motor Imagery in Sedentary subjects|
9718369|NCT04548323||Motor Imagery active subjects|
9718370|NCT04548388|Experimental|Bobath approach|Bobath approach
9718371|NCT04548388|Experimental|whole body vibration|whole body vibration
9718372|NCT04548440|Experimental|Preoperative Sintilimab plus Nab-paclitaxel and Cisplatin|"Patients receive the following regimen every 3 weeks:~Sintilimab 200mg IV on Day 1; Albumin-bound paclitaxel 125 mg/m2 IV on Day 1 and Day 8; Cisplatin 75mg/m2 IV on Day 1; Standard hydration regimen on Day 0-3~After 2-4 cycles, radiological evaluation and multidisciplinary assessment will be performed. If radical resection is possible, surgery is to be performed 3-6 weeks after the last chemotherapy session. In the case of a R0 resection, the investigator will decide whether to perform adjuvant therapy depending on the patient's condition; in the case of R1 or R2 resection, concurrent chemoradiotherapy is recommended. If the multidisciplinary assessment considers that radical resection is not possible, radical concurrent chemoradiotherapy is performed."
9718373|NCT04548466|No Intervention|CONTROL group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization.
9718374|NCT04548466|Experimental|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure breathing (PEP bottle)
9718375|NCT04548401||Antiplatelet-N group|Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy
9718376|NCT04548401||Antiplatelet-Y group|Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor)
9718377|NCT04548453|Experimental|Uterine EMG during labor|Multichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor.
9718378|NCT04548154|Experimental|Proximal Resistance Training|Participants will receive 6 one-on-one supervised intervention visits and 8 telerehabilitation visits over 10 weeks. For the first 4 weeks intervention frequency will start with 1x/ week in clinic and 1x/ week via telerehabilitation, and the participant will be asked to perform exercises 2x/ week independently. For the final 6 weeks there will be 1x week supervised visits (weeks 6 and 8 in person, and weeks 5,7, 9, and 10 via telerehabilitation) and the participant will be asked to perform exercises 3x/ week independently.
9718379|NCT04548518|Active Comparator|GPO Tri Fluvac vaccine|408 participants will receive a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1)pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) produced by the Government Pharmaceutical Organization (GPO), Thailand. The vaccine to be administered by intramuscular (IM) injection.
9779925|NCT04431752||Kellgren-Laurence grading IV Osteoarthritis Knee|10 patients in Kellgren-Laurence grading IV to undergo radiographic examinations of the knee joint.
9980612|NCT01393483||patients endoscopically resected|In patients with endoscopically resected T1 disease (40 patients in 2 years) if available, we will stain the initial endoscopic tumor specimen, as well as any subsequent specimen obtained at each routine 3(+/- 2) month interval endoscopy.
10196502|NCT05185752|Active Comparator|Pectoral Nerve type II Block (PECS II block)|"The patient is positioned supine, with the ipsilateral upper limb extended. The clavicular external third line is drawn. In parallel, the lower costal line and the infraclavicular space are highlighted. The probe obtains an image that allows the identification of the pectoralis major and pectoralis minor.~If colour Doppler is added, the acromiothoracic artery is identified and must be avoided.~The needle enters at an angle of 45º from medial to lateral, and 20 cc of 0.25% bupivacaine are administered. Next, needle advances in the interfascial space between the pectoral minor and serratus anterior and 10 cc of 0.25% bupivacaine are administered."
9718380|NCT04548518|Active Comparator|Licensed Influenza vaccine|408 will receive a Licensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1) pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
9718381|NCT04548349|Experimental|Altreno Group|
9718382|NCT04548349|Experimental|BPO Group|
9718383|NCT04548349|No Intervention|Control Group|During the entire study period, the subjects in the control group will not be allowed to use any antibacterial wash, other than approved OTC cleansers.
9718384|NCT04548102|Experimental|Fetal Movement Counting|Fetal movement counting
9718385|NCT04548102|No Intervention|standard antenatal follow up care|Women in the control group received the antenatal hospital standard care.
9718386|NCT04548427|Experimental|CKD-352|
9718387|NCT04548427|Active Comparator|Diquafosol Sodium 3%|
9718388|NCT04548284|Experimental|Periorbitally Injected Glucocorticoids|Glucocorticoids periorbital injection. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
9718389|NCT04548284|No Intervention|Observe|Observe and wait.
9718390|NCT04548141|Experimental|Active adults|Adults coming for a visit for sports activity participation and submitted the SAPHIR questionnaire
9718391|NCT04548271|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy and had prior treatment with PD-1 antagonists. Every patients will receive apatinib 250mg orally every day starting 14 days prior to Camrelizumab. Then apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
9718392|NCT04548219|Experimental|Mirikizumab (Reference)|Reference formulation of mirikizumab administered as a subcutaneous (SC) injection.
9718393|NCT04548219|Experimental|Mirikizumab (Test)|Test formulation of mirikizumab administered as a SC injection.
9718394|NCT04548258|Experimental|electric welded metal framework|using electric welding device to intraorally join metal framework where the study aim to save time and cost and eliminate lab errors
9718395|NCT04548258|Experimental|conventional cast metal technique|using the conventional casting technique to join metal framework and compare it with the electric welding technique
9718396|NCT04548180||TBI BIAFAC|100 TBI subjects with BIAFAC will be enrolled. No intervention
9718397|NCT04548050||mothers informed by untrained nurse|
9718398|NCT04548050||mothers informed by trained nurse|
9718399|NCT04548050||mothers informed by nurses trained 6 months ago|
9718400|NCT04548115|Experimental|ARTISAN Condition|Participants assigned to this arm will engage in ARTISAN, a 5-weekly, 15-hour group-based arts and heritage intervention programme with specific intervention components including curated museum tours, facilitated storytelling and professionally-led art-making. The weekly intervention covers the five ARTISAN themes of national heritage, social bonds, adversity and resilience, dreams and aspiration, and community art exhibition.
9718401|NCT04548115|Experimental|Intergenerational Participatory Arts Condition|Participants assigned to this arm will engage in the participatory arts-making component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based professionally-led art-making that covers the five ARTISAN themes.
9718402|NCT04548115|Experimental|Intergenerational Art-space Condition|Participants assigned to this arm will engage in the cultural space component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based a group-based curated museum tour that covers the five ARTISAN themes.
9718403|NCT04548115|Experimental|Inter-generational Storytelling Condition|Participants assigned to this arm will engage in the storytelling component of the ARTISAN Intervention framework. Youths and senior participants in this condition will be paired to engage in a 5-weekly, 5-hour, group-based guided storytelling activity that covers the five ARTISAN themes.
9718404|NCT04548115|Experimental|Control Condition|Participants assigned to this arm will engage in a 5-weekly, 5-hour, group-based physical activity session conducted in the community.
9718405|NCT04547894|Experimental|ASC09F|ASC09F one tablet at a time, once per day, up to 7 days.
9718406|NCT04547829|Experimental|PEG-rhG-CSF|pegylated recombinant human granulocyte-colony stimulating factor subcutaneous injection
9718407|NCT04548011|Experimental|Three times a week group|Twenty participants in three times a week group will receive acupuncture treatment 3 times per week (every other day) for 4 weeks, 12 sessions totally. The acupuncture operation as above. Participants will not be not allowed to take any other medication or accept any treatment for FD. should not be accepted during the study. In case of unbearable symptoms, the assistant researchers will detailly document.
9718408|NCT04548011|Experimental|Once a week group|Twenty participants in once a week group will receive acupuncture treatment 1 time per week for 4 weeks (Weekly fixed day), 4 sessions totally. Other inventions will be same as the Three times a week group.
9718409|NCT04548011|No Intervention|Waiting for treatment group|After the health education（such as dietary adjustment for FD patients）, the participants will be followed up for 4 weeks. At the end of the follow-up, the patients could be given free acupuncture treatment (the invention will be similar with that of the Three times a week group) for 4 weeks at will.
9718410|NCT04547933||OAB-wet|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency and urinary incontinence (UI) were allocated to the overactive bladder syndrome (OAB) -wet group.
9718411|NCT04547933||OAB-dry|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency but without incontinence were allocated to the OAB-dry group.
9718412|NCT04547933||UI|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of UI but without urgency were allocated to the UI group.
9718413|NCT04547933||Nocturia|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 2 episodes of nocturia but without urgency and UI were allocated to the nocturia group.
9718414|NCT04547933||Frequency|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 8 episodes of daytime frequency but without urgency, UI and nocturia were allocated to the frequency group.
9718415|NCT04547933||Normal|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women without urgency, UI, nocturia nor frequency were allocated to the normal group.
9718416|NCT04547972|Active Comparator|Higher-load limbs|This treatment arm will have participants performing resistance training with loads of ~80% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
9718417|NCT04547972|Active Comparator|Lower-load limbs|This treatment arm will have participants performing resistance training with loads of ~30% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
9718418|NCT04547686|Experimental|Smoke-Free Homes intervention|Participants in the intervention condition will receive the expanded Smoke-Free Homes intervention. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
9718419|NCT04547686|Active Comparator|Control|The usual care/control arm will receive mailed information on the QL (quitline), and a connection to the QL at their request. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
9718420|NCT04548037||Patients with transient global amnesia|
9718421|NCT04548037||Healthy volunteers|
9718422|NCT04547764|Experimental|TAP group|
9718423|NCT04547764|Active Comparator|Vitapex group|
9718424|NCT04547907|Experimental|nab-PHP|Albumin binding paclitaxel + trastuzumab+ patuzumab
9718425|NCT04547907|Active Comparator|TCbHP|Docetaxel + carboplatin + trastuzumab + patuzumab
9718426|NCT04547660|Experimental|Convalescent Plasma|Transfusion of 2 aliquots of 300 ml of frozen convalescent plasma, 2 days apart, thawed at 37 degrees Celsius before infusion. Best supportive care except for investigational interventions.
9718427|NCT04547660|Active Comparator|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
9718428|NCT04547855|Experimental|experimental group|anlotinib combined with dose-dense temozolomide
9718429|NCT04547842|Active Comparator|Group M: patients receive Mirtazapine|the patient will receive an oral disintegrating tablet (ODT) of mirtazapine 30 mg with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 min as a placebo 1 h preoperatively
9718430|NCT04547842|Active Comparator|Group D: patients receive Dexamethasone|the patient will receive a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 min, 1 h preoperatively.
9718431|NCT04547777|Experimental|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (4613.2 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours
9718432|NCT04547959|Experimental|C-CURVE PEEK|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in PEEK or Titane is used
9718433|NCT04547959|Experimental|C-CURVE Titane|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in PEEK or Titane is used
9718434|NCT04548089|Experimental|Immediate Intervention Group|Participants assigned to the immediate intervention group will engage in a 4-week 2.5-hour Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) with intervention elements of brief psycho-education, weekly mindfulness meditation, facilitated creative art making, reflective writing, group sharing and discussion.
9718435|NCT04548089|Experimental|Waitlist Control Group|Participants assigned to the wait-list control group will not receive Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) until one month after baseline assessment.
9718436|NCT04547634|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
9718437|NCT04547634|No Intervention|Control|Subjects will be told to continue with their normal activity of daily living. After the intervention in the experimental group, the control group will be offered intervention.
9718438|NCT04547621|Experimental|HSRT+IMRT+Temozolomide|"Intensity-modulated radiotherapy 20Gy/10fx, 5 days a week for 2 weeks.~Hypofractionated stereotactic radiotherapy 30Gy/5fx, 5 days a week for 1 week.~Temozolomide once daily (75mg/m2/d) orally administered concurrently with radiotherapy."
9718439|NCT04547608|Other|group PRi|received immediate injection of rocuronium after propofol administration,
9718440|NCT04547608|Other|group PRd|rocuronium injection when bispectral index score became below 60 after propofol administration
9718441|NCT04547348|Experimental|Denosumab treated group|Participants will receive a 60 mg subcutaneous injection of Prolia upon randomization and on week 28 after the first injection provided remission of the Charcot foot has not been achieved by then
10196503|NCT05185752|Active Comparator|Serratus-Intercostal Fascial Plane Block (SIFP block)|"The patient is positioned supine, with the ipsilateral upper extremity at a 90º angle. The fourth, fifth, and sixth intercostal spaces are identified in the mid-axillary line. In coronal section, it is possible to appreciate the subcutaneous cellular tissue, the serratus anterior, and the intercostal muscles.~The needle is introduced at an angle of 30º. From caudal to cranial and resting the needle on the fourth rib, 30 cc of 0.25% bupivacaine are administered between the serratus anterior and lateral intercostal muscles."
9718442|NCT04547348|Placebo Comparator|Placebo treated group|Participants will receive an injection of placebo produced by the same provider as the prolia drug of equivalent volume at the same time points as the treated group
9718443|NCT04547322|Experimental|VR application group|The experimental group received VR application in the preoperative period for 10 minutes.
9718444|NCT04547322|No Intervention|Control group|The control group received the routine procedure in the unit clinic where the study was conducted. The routine procedure of the unit includes patients are taken to the operating room on a stretcher and wait on the stretcher in the surgery waiting room until the operation room is prepared.
9718445|NCT04547426|Active Comparator|red wine and snuff|regular red wine and moist snuff
9718446|NCT04547426|Active Comparator|red wine and nicotine-free snuff|regular red wine and nicotine-free snuff
9718447|NCT04547426|Active Comparator|non alcoholic red wine and regular moist snuff|non alcoholic red wine and regular moist snuff with nicotine
9718448|NCT04547426|Placebo Comparator|non-alcoholic red wine and nicotine-free snuff|Non-alcoholic red wine and nicotine-free snuff
9718449|NCT04547387||Carotid Artery Stenting|Consecutive patients with symptoms or signs of ischemic cerebral injury eligible for endovascular carotid artery revascularization using direct carotid artery access and MicroNET covered carotid stent plaque exclusion under cerebral protection by temporary flow reversal
9718450|NCT04547361|Experimental|Cohort 1: Dose 1 E2511 or Placebo|Participants will receive Dose 1 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
9718451|NCT04547361|Experimental|Cohort 2: Dose 2 E2511 or Placebo|Participants will receive Dose 2 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
9718452|NCT04547361|Experimental|Cohort 3: Dose 3 E2511 or Placebo|Participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 (Treatment Period 1) under fasted condition followed by Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 7 (Treatment Period 2) under fed condition. A washout period of 6 days will be maintained between the doses.
9718453|NCT04547361|Experimental|Cohort 4: Dose 4 E2511 or Placebo|Participants will receive Dose 4 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
9718454|NCT04547361|Experimental|Cohort 5: Dose 5 E2511 or Placebo|Participants will receive Dose 5 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
9718455|NCT04547361|Experimental|Cohort 6: Dose 6 E2511 or Placebo|Participants will receive Dose 6 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
9718456|NCT04547361|Experimental|Cohort 7: Dose 3 E2511 (Elderly Participants) or Placebo|Elderly participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
9718457|NCT04547231||Deferral of PCI group|Patients with a vessel determined to defer revascularization after FFR measurement who undergo CCTA within 90 days before FFR measurement will be included.
9718458|NCT04547231||PCI group|Patients with a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) with available coronary CT angiography within 90 days before FFR measurement will be included.
9718459|NCT04547244||T2DM patients with CRTd with automatic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an automatic optimization of CRTd.
9718460|NCT04547244||T2DM patients with CRTd with echocardiographic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an echocardiography guided optimization of CRTd.
9718461|NCT04547452|Experimental|Sintilimab Combined with SBRT|"Patients will be randomly placed in either of the two arms. Participants enrolled in this arm treated to a total dose of 35-80Gy in 5-8 fractions with stereotactic radiotherapy to a liver or lung or any metastatic lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year."
9718462|NCT04547452|Active Comparator|Sintilimab|Participants enrolled in this arm treated with sintilimab administered intravenously at 200 mg every 3 weeks for up to 1 year.
9718463|NCT04547309|Experimental|68Ga/18F-HER2 Affibody PET/CT scan|
9718464|NCT04547335||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
9718465|NCT04547569|Experimental|Adaptation to altered auditory feedback|fMRI measurement of brain activity during speech production under altered auditory feedback
9718466|NCT04547569|Experimental|Speech production|fMRI measurement of brain activity during normal speech production
9718467|NCT04547569|Experimental|Vibrotactile discrimination|fMRI measurement of brain activity during a vibrotactile discrimination task
9718468|NCT04547543|Other|Video consultation|Patients in this group will have a continuous positive pressure follow-up visit by videoconsultation
9718469|NCT04547543|No Intervention|Face-to-face consultation|Patients in this group will have a continuous positive pressure follow-up visit by face-to-face consultation
9718470|NCT04547439|Active Comparator|Control|Placebo
9718471|NCT04547439|Active Comparator|Melatonin|Melatonin
9785208|NCT01245751|Experimental|Group 1: Booster Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
10196504|NCT05185726|Experimental|Mini-KIDS|Mini-KIDS is a direct treatment based on principles of stuttering modification, with pseudo-stuttering, that is, deliberate stuttering, as one of the main components. The program for 4-6-year old children consists of four stages: Stage 1 = desensitization, Stage 2 = modification, Stage 3 = identification and Stage 4 = generalization. The program for 2-4-year old children does not include stage 3. Speech therapist and parent(s) are the speech model for the child. They add normal dysfluencies to their speech. Later on in treatment and if necessary, children learn to recognise and alter their stuttering moments.
10196505|NCT05185726|Experimental|Social-Cognitive Behaviour Treatment|The social cognitive behaviour therapy contains 5 treatment phases: (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training (Boey, 2010). This treatment is not directed at the speech of the children, but rather at the cognitive and emotional aspects that surround the stuttering.
9718474|NCT04547296|Experimental|BRS group|After entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.
9718475|NCT04547296|Experimental|ARS group|After entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.
9718476|NCT04547504|Active Comparator|Pembrolizumab|Pembrolizumab
9718477|NCT04547504|Active Comparator|Chemotherapy-Pembrolizumab|Chemotherapy and Pembrolizumab
9718478|NCT04547218||Elderly patients|"Above 65 year old patients undergoing elective surgery Inclusion criteria I. Geriatric patients ( age more than 65 y/o) II. All elective surgeries under GA~Exclusion criteria I. Refuse to participate in the study II. Patients with cognitive disorders such as dementia and Alzheimer's disease"
9718479|NCT04547530|Active Comparator|Vitamin D|"Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
9718480|NCT04547530|Placebo Comparator|Placebo|"Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.~If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment.~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
9718481|NCT04547205|Experimental|AK109|
9718482|NCT04546997||Patients with ocular blunt trauma|Patients with previous ocular blunt trauma in one eye.
9718483|NCT04546997||Control Group|Healthy fellow eyes without actual and previous ocular trauma
9718484|NCT04546945||control cases|normal healthy person
9718485|NCT04546945||Patients|Patients with hematologic malignancies. Newly diagnosed.
9718486|NCT04546802|Active Comparator|Immediate treatment|This group will undergo immediate treatment of the HCV once HCC complete response (CR) has been confirmed
9718487|NCT04546802|Active Comparator|Delayed treatment|This group will delay commencement of the HCV treatment until 6 months after HCC complete response (CR) has been confirmed
9718488|NCT04547153|Experimental|LD-FUD|5-Fu 200mg/m2/day continuously for 20 days; Docetaxel 25mg/m2, days 1, 8 and 15; Repeated every four weeks.
9718489|NCT04546880|Experimental|Group 1:Breathing and Stabilization Exercise Group|Breathing exercises combined with stabilization exercises
9718490|NCT04546880|Active Comparator|Group 2: Stabilization Exercise Group|Only Stabilization exercises therapy
9718491|NCT04546815||Gram-positive cocci infection|No intervention. The clinical data of patients (including demographic information, details of anti-infective therapy, imaging and laboratory testings) will be collected and analyzed.
9718492|NCT04546984|Experimental|Single dose of HEC96719 （Part 1，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC96719 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
9718493|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 1）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
9718494|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 2）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
9718495|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 3）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
9718496|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 4）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
9718497|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 5）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
9718498|NCT04546789|Experimental|Group 1: Normal Hepatic Function|Healthy participants who have normal hepatic function with sex, age (± 10 years; >= 18 years old and =< 79 years old), and weight (± 10 percent; >= 50 kilogram (kg) and =< 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).
9718499|NCT04546789|Experimental|Group 2: Mild Hepatic Impairment|Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).
9718500|NCT04546789|Experimental|Group 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).
9718501|NCT04546867|Other|Sonography arm|Sonography is being performed by expericenced investigators to visualize a pancreatic stent in the pancreatic duct. If the stent is being visualized, an endoscopy will be performed to remove the stent. Otherwise, x-ray will be needed to confirm the sonographic finding of a dislodged pancreatic stent with no further need of intervention. If x-ray finds a pancreatic stent in situ opposingly to ultrasound, an endoscopy will be performed to confirm the stents position and eventually remove it.
9718502|NCT04547127|Experimental|Convalescent anti-SARS-CoV-2 MBT Plasma + SMT|Participants will receive 2 consecutive transfusions of 200 to 250 milliliters (ml) of ABO-compatible convalescent plasma with each unit of plasma, obtained from the same convalescent donor, which will be administered on Day 1 using standard procedures for administration of fresh frozen plasma. Participants weighing less than 45 kilograms (kg) will receive two transfusions of 10 ml of convalescent plasma per kilogram of body weight with each unit of plasma obtained from the same convalescent donor. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
9718503|NCT04547127|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.
9718504|NCT04547088|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy. Every patient will receive Apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
9718505|NCT04547114||SARS-CoV-2- infected|Detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
9718506|NCT04547114||non infected|Lack of detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
9718507|NCT04546854|Experimental|Conservative - Binding Appeal|
9718508|NCT04546854|Experimental|Liberal - Individulizing Appeal|
9718509|NCT04547179|Experimental|BLAfit® usage|In this arm, subjects will used the fixed orthotic device called BLAfit® for one minute of facial exercise a day for three months.
9718510|NCT04547179|Experimental|fremanezumab-vfrm|Subjects in this arm will receive three Ajovy® (fremanezumab-vfrm) injections at the start of month 2. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
9718511|NCT04547179|Placebo Comparator|Saline injection|This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
9718512|NCT04547101|Experimental|AK104|
9718513|NCT04547010|Experimental|Intervention group|In four weeks of intervention study the participants instructed to receive (60 mg) of soy-isoflavone supplement per day, after this period the Bone Mineral Density was assessed by Dual X-ray Absorptiometry scan to evaluate the effect of soy-isoflavone supplement on Bone mineral density.
9718514|NCT04547036||Endothelial cell count measurment|
9718515|NCT04546893|Experimental|1904B CAR-T|Patients will be treated with CD19 CAR-T cells
9718516|NCT04546828|Experimental|Gemcitabine, Cisplatin, and Nab-Paclitaxel|"Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days"
9718517|NCT04546776||Faecal and saliva sampling|A minimum of 4 and a maximum of 8 sample sets will be asked for over the study period
9718518|NCT04546932|Experimental|Lung-protective mechanical ventilation|Vt=7 ml/kg IBW; an intraoperative 10 cmH2O in PEEP, recruitment maneuvers applying a stepwise increase in PEEP.
9718519|NCT04546932|No Intervention|Conventional mechanical ventilation|the tidal volume was set at 10 ml/kg IBW without PEEP and (recruitment maneuvers) RM
9718520|NCT04546906|Experimental|CD22 CAR-T|Patients will be treated with CD22 CAR-T cells
9718521|NCT04546763||Paroxysmal Atrial Fibrillation Patients|This will be a single arm study of patients with paroxysmal atrial fibrillation. Subjects will be wearing the Study Watch and Zio XT Patch concurrently for up to 14 days.
9718522|NCT04547049|Active Comparator|Non-first-degree donor|Each patient receive graft from a non-first degree donor aged ≤40
9718523|NCT04547049|Active Comparator|First-degree donor|Each patients receive graft from a first-degree donor aged >50
9718524|NCT04546490|Experimental|Pressure release|It will be applied with the patient in a supine position. The therapist will clamp his first and second fingers over the Myofascial Trigger Point located on the upper trapezium, it will be marked previously. The pressure will increase as the therapist perceives a reduction in the resistance offered by the soft tissue under his finger within a period of 90 seconds.
9718525|NCT04546490|Experimental|Ischemic pressure|Patient in supine position, the therapist performs pressure with first and second finger in PGM marked previously, this is performed until the patient tolerance, when the patient refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier. Repeat the process for 90 seconds.
9718526|NCT04546490|No Intervention|Control Group|Patient in supine position on the stretcher, the therapist performs a clamp with the first and second finger on the upper trapezius muscle without making any pressure on it during 90 seconds
9718527|NCT04546594||Orthopedic surgery|
9718528|NCT04546594||Thoracic surgery|
9718529|NCT04546594||Gynecological surgery|
9980613|NCT01393483||patients treated primarily with surgery|In patients who undergo surgery as their primary therapy, serum will be obtained at the time of surgical resection, and at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months.
9718532|NCT04546503|Active Comparator|Continuous Regional Analgesia group|Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4 + perinerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H
9718533|NCT04546503|Experimental|Control Group|group with general anesthesia and without locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4
9718534|NCT04546659|Experimental|Group A|Osteoarthritic patient receiving Conventional therapy and Retrowalking
10196506|NCT05185726|Active Comparator|Lidcombe Program|The Lidcombe Program (LP) is an operant program that directly provides verbal feedback to the child's stutter-free speech (mainly) and the child's stuttering (occasionally). The program comprises two stages: Stage 1 in which (near) zero levels of stuttering are achieved and Stage 2 in which the achieved (near) zero levels of stuttering are maintained for a long period of time. The LP usually takes between 11 to 23 (60-minute) treatment sessions to achieve the goals of Stage 1, i. e. (near) zero levels of stuttering.
9718535|NCT04546659|Active Comparator|Group B|Osteoarthritic patient receiving Conventional therapy
9718536|NCT04546464|Experimental|Experimental Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
9718537|NCT04546464|No Intervention|Standard care|
9718538|NCT04546672|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
9718539|NCT04546672|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+Glycopyrrolate 0.2 mg per 1 mg of neostigmine administered) IV once at the end of surgery
9779926|NCT04420663|Experimental|Manometer Group|"Therapeutic thoracentesis will be performed in a sitting position. wide bore catheter as a pleural catheter will be inserted into the pleural cavity. simple water manometer will be connected to the pleural catheter via 3-way adapter.connected to the infusion lines with one draining into the drainage collection bottle and the other pre-flushed with normal saline hanging down till 40 cm below the puncture site and then rising up (forming a U) with the ascending arm taped to the IV stand. baseline pleural pressure will be registered before the beginning of pleural fluid withdrawal. Pleural pressure curve will subsequently be registered after the withdrawal of each 200 ml of pleural fluid up to a total volume of 1000 ml."
9779927|NCT04420663|No Intervention|Conventional Group|Therapeutic thoracentesis will be performed in a sitting position. The skin will be cleaned with betadine antiseptic solution. Pleural aspiration should take place in a clean area using full aseptic techniques. 5-10 cc Lidocaine 2% will be given as local anesthetic in the site of puncture. the IV cannula is advanced till fluid is aspirated. Then, the needle is withdrawn and the catheter is fixed to two 3-way adapters fixed in series placed in between. connected to the infusion lines with one draining into the drainage collection bottle.
9779928|NCT04412837|Experimental|CBD Patch|Topical CBD patch to be worn for 24 hours and changed daily for the course of 4 weeks.
9779929|NCT04412837|Placebo Comparator|Control Patch|Control placebo patch to be worn for 24 hours and changed daily for the course of 4 weeks.
9779930|NCT04395001|Experimental|behavioral intervention, nurse support plus medication|Subjects randomized to this arm will receive duloxetine, web-based Cognitive Behavioral Therapy (CBT) and nurse support.
9779931|NCT04395001|Experimental|behavioral intervention plus medication|Subjects randomized to this arm will receive duloxetine and web-based Cognitive Behavioral Therapy (CBT).
9779932|NCT04395001|Active Comparator|medication only|Subjects randomized to this arm will receive duloxetine only.
9779933|NCT04394663|Experimental|High-dose oral PPI|Omeprazole 80 mg/day (40 mg twice a day) per oral route for 72 hours
9779934|NCT04394663|Active Comparator|Standard IV PPI|Pantoprazole 8 mg/hour IV continuous drip for 72 hours
9779935|NCT04391309|Experimental|anti-CD14 + SOC|"Anti-CD14: 150 participants randomized to 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 intravenously.~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
9779936|NCT04391309|Placebo Comparator|Placebo + SOC|"150 participants randomized to Placebo diluent on Days 1-4 intravenously.~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
9779937|NCT04384627|Active Comparator|Pre-IC GTV|The gross tumor volume (GTV) is delineated according to the pretreatment tumor extension
9779938|NCT04384627|Experimental|Post-IC GTV|The gross tumor volume (GTV) is delineated according to the post-IC tumor extension
9779939|NCT04378751|Experimental|Decision aid video|Participants receiving the intervention will complete a pretest, watch the decision aid video, and complete posttest via tablet computer facilitated by Patient Navigators.
9779940|NCT04378751|Active Comparator|Genetic counseling informational brochure|Participants receiving the control will complete pretest, review a genetic counseling brochure with the Patient Navigators, and complete posttest via tablet computer facilitated by a Patient Navigator.
9779941|NCT04377945|Experimental|Part 1, JM-010 component Group A|Part 1, JM-010 component Group A
9779942|NCT04377945|Experimental|Part 1, JM-010 component Group B|Part 1, JM-010 component Group B
9779943|NCT04377945|Experimental|Part 1, JM-010 component Group C|Part 1, JM-010 component Group C
9779944|NCT04377945|Placebo Comparator|Part 1, Placebo Group|Part 1, Placebo Group
9779945|NCT04377945|Experimental|Part 2, JM-010 combination Group A|Part 2, JM-010 combination Group A
9779946|NCT04377945|Experimental|Part 2, JM-010 combination Group B|Part 2, JM-010 combination Group B
9779947|NCT04377945|Experimental|Part 2, JM-010 component Group C|Part 2, JM-010 component Group C
9779948|NCT04377945|Placebo Comparator|Part 2, Placebo Group|Part 2, Placebo Group
9779949|NCT04375124|No Intervention|non-peptide group|This group will receive routine treatment and care for COVID-19.
9779950|NCT04375124|Active Comparator|peptide group|This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
9718540|NCT04546685|Other|Usual Care (waitlist)|Participants will continue their usual clinical care.
9718541|NCT04546685|Experimental|Single-Session Pain Relief Skills Class (Empowered Relief)|A 2-hour class that will be delivered by a clinical psychologist via videoconference to participant cohorts.
9718542|NCT04546438|Experimental|MiraDry® treatment|"The miraDry System is a noninvasive method that utilizes microwave energy to destroy the sweat glands at the dermal-fat interface.~Each participant will be scheduled one MiraDry ® treatment with the possiblity of a second intervention approximately three months apart if the primary objective is not fullfilled efter the first."
9718543|NCT04546477|Other|Single Arm|"135 patients stratified in 2 groups:~90 FEM-POP patients: SFA-P1~45 Isolated POP Patients: P1, P2, P3 only"
9718544|NCT04546412||Fresh oocytes|Sibling oocytes not subjected to vitrification prior to assessment
9718545|NCT04546412||Vitrified-thawed oocytes|Sibling oocytes subjected to vitrification using the Cryotop® - Open System and thawing prior to assessment
9718546|NCT04546360||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement based on two-dimensional shear wave elastography, gallbladder wall thickness, spleen thickness, spleen long diameter and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, albumin, prothrombin time, international normalized ratio).
9718547|NCT04546282||Osimertinib treated patients|Patients with metastatic adenocarcinoma of the lung for whom a 3rd generation TKI therapy is proposed and a search for resistance mutation by blood analysis as part of the usual management.
9718548|NCT04546347|Experimental|14CAZD9833 Infusion NMT 22.8 kBq/5mL|Dose 1 14CAZD9833 Solution for Infusion
9718549|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet type A
9718550|NCT04546347|Experimental|AZD9833 Oral Solution|Dose 1 AZD9833 oral solution
9718551|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 1|Dose 1 AZD9833 film-coated tablet type B
9718552|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 2|Dose 2 AZD9833 film-coated tablet type A
9718553|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 2|Dose 2 AZD9833 film-coated tablet type B
9718554|NCT04546308|Experimental|Exercise training|The participants will undergo 8 weeks of whole-body resistance exercise training followed by a 4-week detraining. The central hemodynamic and muscle stiffness variables will be measured pre, post-training, and post-detraining.
9718555|NCT04546308|No Intervention|Sedentary control|The participants will undergo 12 weeks of intervention without exercise training. The central hemodynamic and muscle stiffness variables will be measured pre, 8th, and 12th week.
9718556|NCT04546334|Experimental|Group A|Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block
9718557|NCT04546334|Experimental|Group B|Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment.
9718558|NCT04546334|Experimental|Group C|Patients that will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment.
9718559|NCT04546256|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
9718560|NCT04546256|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
9718561|NCT04546295|Experimental|Brushlink|
9718562|NCT04546295|Active Comparator|Water-flosser|
9718563|NCT04546295|Placebo Comparator|Interproximal Brush|
9718564|NCT04546269|Experimental|Fully-guided|Single-tooth implant placed using a fully computer-guided approach
9718565|NCT04546269|Active Comparator|Conventionally guided|Single-tooth implant placed using a conventionally guided approach
9718566|NCT04546321||HIE group (I)|All fullterm newborn admitted to the NICU with Hypoxic Ischemic Encephalopathy during the study period
9718567|NCT04546321||TTN group(II)|All fullterm babies with Transient Tachypnea of the Newborn admitted to the NICU during the study period
9718568|NCT04546035|Experimental|500 pulses|In this group, patients received one single rESWT session consisting of 500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
9718569|NCT04546035|Experimental|1,000 pulses|In this group, patients received one single rESWT session consisting of 1,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
9718570|NCT04546035|Experimental|1,500 pulses|In this group, patients received one single rESWT session consisting of 1,500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
9718571|NCT04546035|Experimental|2,000 pulses|In this group, patients received one single rESWT session consisting of 2,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
9718572|NCT04546139||amateur badminton player|
9718573|NCT04546139||elite badminton player|
9718574|NCT04546048|Experimental|Exercise group (EG)|The exercise group (EG) were received an 8-week resistance training program in addition to standard post-transplant physiotherapy follow-up.
9718575|NCT04546048|No Intervention|Control Group (CG)|"The control group (CG) were received only standard physiotherapy program.~The usual post-transplant care consisting of preoperative patient education, respiratory physiotherapy program, active/active assistive exercises of cervical, upper and lower extremities, and early mobilization.~Patients were instructed about the postoperative physiotherapy process including all details within the preoperative education. Respiratory physiotherapy consisted of positioning, lung expansion exercises and bronchial hygiene techniques.~They were allowed to pursue their normal daily activities and mobilized as early as possible when clinically stable."
9779951|NCT04374565|Experimental|Study participants|A total of 29 eligible subjects will be enrolled to receive high titer anti-SARS-CoV-2 plasma. Participants will be compared to a historical control group via retrospective chart review.
9718576|NCT04546100|Experimental|Maternal-Infant Exercise Program|"In the postpartum period, give the intervention group Maternal-Infant Exercise Program and encourage them to do exercise. The Parent-Child Exercise Program can be divided into three stages. Videos will be provided in each stage. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
9718577|NCT04546100|Placebo Comparator|Regular postpartum exercise guidance|"Another group will receive Regular postpartum exercise guidance. The guidance includes chest exercises, neck exercises, leg exercises, hip exercises, abdominal exercises, vagina contraction exercises, and uterine contraction exercises, starting from the third day after delivery to one month after delivery. The detail information will refer to the General Hospital of Tri-Services Provided the postpartum health education manual-postpartum exercise (p.8-10)"
9718578|NCT04546165|Active Comparator|manipulation group|manipulation plus exercise
9718579|NCT04546165|Active Comparator|myofascial release group|suboccipital inhibition plus exercise
9718580|NCT04546165|Active Comparator|exercise group|only exercise
9718581|NCT04546646|Experimental|GROUP A (Elastic Band Exercises)|Warm up: for 10 min, Exercise: Lower limb exercises using elastic band for 30 min. Cool down: Self-stretches 5 min.
9718582|NCT04546646|No Intervention|GROUP - B (No Intervention)|Routine activities of daily living
9718583|NCT04546529|Active Comparator|TsMS active|Patients undergoing real Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
9718584|NCT04546529|Sham Comparator|TsMS sham|Patients undergoing placebo Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
9718585|NCT04546022|Other|GSP measurement|For the GSP measurement, subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes. Sixty minutes after- G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of GSP value.
9718586|NCT04545970|Active Comparator|Anti-aging Serum|"Dosage form: Serum composed of water, thickener, and bioactive ingredients including antioxidants and peptides.~Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
9718587|NCT04545970|Placebo Comparator|Placebo Serum|"Dosage form: Serum composed of water and thickener. Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.~Study Duration: 12 weeks."
9718588|NCT04546607|Experimental|Nuvastatic TM|Nuvastatic TM (C5OSEW5050ESA) capsule 1000 mg administered orally 3 times a day for 9 weeks.
9718589|NCT04546607|Placebo Comparator|Placebo|Excipient, without Nuvastatic TM (C5OSEW5050ESA) capsule administered orally 3 times a day for 9 weeks.
9718590|NCT04546061|Experimental|Project Uplift Intervention|A 6-month long intervention for young adult sexual and gender minorities, ages 18-35.
9718591|NCT04545957|Experimental|Phase I MRI Simulation|"This research study involves a screening period to determine eligibility.~- Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data."
9718592|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track A|MR-only Radiation Therapy Simulation MRI-simulation and synthetic CT to plan treatment
9718593|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track B|Adjusted Margin or / Dose Painted RT Based on Imaging of MR Simulator (e.g. biological imaging or higher resolution imaging)
9718594|NCT04545996|Active Comparator|Cervical Rang of Motion Exercises.|Cervical exercises for mechanical neck pain.
9718595|NCT04545996|Experimental|Cervical Exercises.|Cervical exercises for the management of mechanical neck pain.
9718596|NCT04545931|Experimental|Posterior tibial nerve stimulation|First arm will undergo posterior tibial nerve stimulation ( one session per week for 12 weeks )
9718597|NCT04545931|Experimental|Desmopressin|Second arm will receive medical treatment (desmopressin 0.2 mg . single evening dose ) for 12 weeks
9718598|NCT04545944|Experimental|Midazolam single doses / Vonoprazan multiple doses|Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10
9718599|NCT04545983|Active Comparator|ACD|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
9718600|NCT04545983|Experimental|ACDA|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
9718601|NCT04545918||Infertile Female|90 female patients with infertility undergoing an ovarian stimulation with use of exogenous gonadotropins.
9718602|NCT04546243||osteosarcoma patients receiving resections|
9718603|NCT04546243||osteosarcoma patients receiving radiotherapy|
9718604|NCT04545879|Experimental|Raw garlic juice|Raw garlic juice treatment group
9718605|NCT04545892|Experimental|Capsaicin|From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate.
9718606|NCT04545840||Study group|Zirconia Implants will be placed. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.
9718607|NCT04545801|Active Comparator|Ketamine Group|Patients recieving 0.25 mg/kg of ketamine 5 minutes after spinal anesthesia
9718608|NCT04545801|Placebo Comparator|Placebo Group|
9718609|NCT04545762|Experimental|Treatment Regimen|"Apheresis (1 day): Autologous lymphocytes/ mononuclear cell collection will be collected through standard apheresis procedures as per University of California, San Francisco (UCSF) institutional practices~CAR-T cell manufacturing (estimated ~13-14 days)~Lymphodepleting chemotherapy: 3 days of immunosuppressive chemotherapy. Cyclophosphamide given at a dose of 300 mg/m2/IV and fludarabine given at 30 mg/m2 /IV on days -5, -4, and -3.~CAR-T cell infusion (1 day): The infusion of CAR-T cells targeting CD19 will occur over 5-30 minutes."
10196507|NCT05185687|Experimental|First Come, First Served|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the First Come, First Served plan description."
9718610|NCT04545723|No Intervention|Control group|In every cluster designated as a control group, patients aged 65 or older will be selected according to the inclusion criteria. The difference here is that patients will be given the standard opportunistic screening instead: pulse palpation and a 12-lead ECG when an irregular rhythm is found. This is current best practice.
9718611|NCT04545723|Active Comparator|Intervention group|In every cluster designated as an intervention group, patients aged 65 or older will be selected according to the inclusion criteria. Within this group, high-risk patients will be identified using the CHARGE-AF score, and will be prescribed the FibriCheck® app.
9718612|NCT04545788|Active Comparator|A|4-6 INH EMB PZA Pto AM Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, AM: Amikacin, Cfz: Clofazimine, Mfx: Moxifloxacin) A group is the control group which includes injectable drugs (AM).
9718613|NCT04545788|Experimental|B|4-6 INH EMB PZA Pto LZD Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, LZD: Linezolid, Cfz: Clofazimine, Mfx: Moxifloxacin) B group is the experimental groups which is total oral short-term therapy.
9718614|NCT04545788|Experimental|C|4-6 BDQ LZD MFX CS CFZ / 5MFX CS CFZ (BDQ: Bedaquiline, LZD: Linezolid, Mfx: Moxifloxacin, CS: Cycloserine, Cfz: Clofazimine) C group is another experimental groups which is also total oral short-term therapy, and includes new anti-TB drugs: BDQ.
9718615|NCT04545463|Active Comparator|Insoluble Fibre|Cookies with insoluble fibre (wheat bran)
9718616|NCT04545463|Active Comparator|Soluble Fibre|Cookies with soluble fibre (Psyllium plantago)
9718617|NCT04545463|Experimental|FIBRACEP|Cookies with FIBRACEP
9718618|NCT04545697|Experimental|Patient Decision Support|Instructions will be provided for installation and use of a smartphone recording app 7-60 days before an oncology consultation. Participants will share the recording with the Patient Support Corps (PSC), who will summarize the recording, send it to the participant's oncologist for review, then return an annotated summary to the participant within a week of the consultation.
9718619|NCT04545437||ICU|Patients treated on a general adult intensive care unit
9718620|NCT04545684|Experimental|Mental practice|
9718621|NCT04545684|Placebo Comparator|Placebo group|
9718622|NCT04545528||Test group|100 Patients that were referred to our stone clinic for follow up with risk factors for stone recurrence like metabolic syndrome and diabetes, uric acid stones etc. In addition to seeing our urologist and nephrologist these patients will also be referred to a nutritionist in order to balance risk factors and will be followed for one year with our usual blood tests and imaging
9718623|NCT04545528||Control group|100 Patients that were referred to our stone clinic for follow up without risk factors for stone recurrence will see our urologist and nephrologist and will be followed for one year with our usual blood tests and imaging
9718624|NCT04545359|Experimental|Neurofeedback Group|Participants from this group perform actual neurofeedback training, i.e they are instructed to control -- decrease -- in real-time a sound that is inversely related to the amplitude of their own alpha activity, obtained from Melomind EEG signals.
9718625|NCT04545359|Sham Comparator|Control Group|Participants from this group perform sham neurofeedback based on the feedback sounds generated by the participants from the Neurofeedback Group at the same step of the training program.
9718626|NCT04545450|Active Comparator|Testosterone Undecanoate plus dutasteride|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day
9718627|NCT04545450|Placebo Comparator|Testosterone Undecanoate plus placebo|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill
9718628|NCT04545710|Experimental|Single Arm, POC|"Single arm, POC Safety and Efficacy~Osimertinib 80 mg QD Abemaciclib 150mg BID"
9718629|NCT04545632||Patients|Patients receiving chemotherapy with ethanol-containing docetaxel
9718630|NCT04545372|Experimental|the study group|the study group (GA) was treated only by the disease modifying drug (interferon beta-1a) in addition to aerobic exercise.
9718631|NCT04545372|No Intervention|the control group|control group (GB)was treated only by the disease modifying drug (interferon beta-1a)
9718632|NCT04545398|Experimental|Pasture-raised|The meal contains grass/pasture fed beef
9718633|NCT04545398|Experimental|Grain-fed|The meal contains grain-fed beef
9718634|NCT04545398|Placebo Comparator|Meat Alternative|The meal contains a meat alternative
9718635|NCT04545398|Experimental|Lamb|The meal contains lamb
9718636|NCT04545645|Active Comparator|Neural Stress Provoked by the Median Nerve|
9718637|NCT04545645|Experimental|Neural stress provocation with cognitive auditory distraction|
9718638|NCT04545645|Experimental|Providing neural stress with a motor distraction|
9718639|NCT04545645|Experimental|Neural stress provocation with both distractions|
9718640|NCT04545333||ALL|patients diagnosed with acute lymphoblastic leukemia
9718641|NCT04545333||CLL|patients diagnosed with chronic lymphocytic leukemia
9718642|NCT04545333||MM|patients diagnosed with multiple myeloma
9718643|NCT04545333||NHL|patients diagnosed with non-Hodgkin lymphoma
9718644|NCT04545320|Placebo Comparator|Usual care control group|Subjects in the usual care control group will receive a health education program to provide the usual care information. This program will include 3-month biweekly sessions (70 minutes each session, total 6 sessions) for obesity-related health briefing, dietary caloric restriction advice, lifestyle counselling/consultation and stretching exercise.
9718645|NCT04545320|Experimental|HIIT group|A 3-month intervention of HIIT will be given to participants allocated to this group. The once-a-week HIIT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform brisk walking for four 4-min bouts at 85%-95% maximal heart rate (HRmax) with a 3-min active recovery walk at 50%-70% HRmax between each session. There will be a 5-min warm-up and cool-down in each exercise session. The duration of each exercise session will be 35 minutes. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
9718646|NCT04545320|Experimental|MICT group|A 3-month intervention of MICT will be given to participants allocated to this group. The once-a-week MICT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform mild walking exercise for ~47 minutes at an intensity of 65-75% HRmax. This exercise volume matches the HIIT volume. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
9718647|NCT04545203|Experimental|Slow-Stroke Back Massage Group|
9718648|NCT04545203|No Intervention|Control group|
9718649|NCT04545229|Experimental|Active VR-PAT|Active VR-based Pain Alleviation Tool (VR-PAT) group played smart phone VR-PAT during the burn dressing changes.
9718650|NCT04545229|Experimental|Passive VR-PAT|Passive VR-based Pain Alleviation Tool (VR-PAT) group watched smart phone VR-PAT games without interaction during the burn dressing changes.
9718651|NCT04545229|No Intervention|Standard Care Control|Standard care control group used regular distraction such as background music or no distraction.
9718652|NCT04544982|Active Comparator|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
10196508|NCT05185687|Experimental|Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Random plan description."
9718653|NCT04544982|Placebo Comparator|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
9718654|NCT04545034|Experimental|Water aerobic exercise protocol|Walter aerobic exercise session would be used to treat blood pressure in elderly hypertensive people.
9718655|NCT04545034|No Intervention|Control Group|No exercise intervention would be used.
9718656|NCT04545138|Experimental|cognitive training during treadmill training group|Cognitive training combine treadmill training is an intervention that can challenge participants by practicing different tasks simultaneously.
9718657|NCT04545138|Active Comparator|treadmill training group|Treadmill training as an active control.
9718658|NCT04545099|Experimental|Sugammadex|Administration of Sugammadex
9718659|NCT04545099|Active Comparator|Neostigmine|Administration of Neostigmine
9718660|NCT04545060|Experimental|VIR-7831|
9718661|NCT04545060|Placebo Comparator|Placebo|
9718662|NCT04545073||Post-refractive trifocal IOL|
9718663|NCT04544839|Experimental|ADLC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the ADLC (test) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the ADLC group will receive the LOC attachments.
9718664|NCT04544839|Active Comparator|LOC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the LOC (control) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the LOC group will receive the ADLC attachments.
9718665|NCT04545086|Experimental|VBE Group|Video Based Education was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
9718666|NCT04545086|Experimental|MT Group|Music Therapy was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
9718667|NCT04545086|No Intervention|Control Group|Routine Information was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation was done.
9718668|NCT04545307|Experimental|Allogenic transplant of BM-MSCs|"Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo button (pellet) is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
9779952|NCT04365478|Experimental|rSWT group|Radial Extracorporeal Shock Wave Therapy on spastic muscles of upper limb
9779953|NCT04365478|Active Comparator|Control group|conventional physiotherapy
9779954|NCT04364737|Active Comparator|Convalescent donor plasma|
9779955|NCT04364737|Placebo Comparator|Lactated ringer's solution or sterile saline solution|
9779956|NCT04362748|Experimental|Dose Escalation Phase|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
9718669|NCT04545190|Active Comparator|Glucose|"Glucose will be ingested at three time points during resistance training (RT): 30 min prior to RT (30 g glucose mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (30 g, 300 ml), and immediately after completion of training (30 g, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Placebo will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 100 mg Stevia powder mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. During this time frame, participants will ingest glucose and protein supplements only)"
9718670|NCT04545190|Placebo Comparator|Placebo|"Placebo will be ingested at three time points during resistance training (RT): 30 min prior to RT (100 mg Stevia powder mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (100 mg, 300 ml), and immediately after completion of training (100 mg, 300 ml).~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).~Glucose will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 30 g glucose mixed with 3 x 300 ml sugar-free Fun light lemonade.~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. I.e.: during this period, participants will ingest placebo and protein supplements only)"
9718671|NCT04545294|Experimental|Active theta (6Hz) in-phase tACS|θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany), via 10 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), at 6 Hz frequency, 2 mA current intensity without DC offset, with 100 cycles ramp-up/ramp-down and a 0° relative phase, for 20 min, twice-daily on 5 consecutive weekdays.
9718672|NCT04545294|Sham Comparator|Sham tACS|During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.
9718673|NCT04545164|No Intervention|Usual Care|Participants in the usual care arm will receive no specific trial intervention. Usual care includes tests routinely available at Zomba Central Hospital, including (but not limited to) conventional (plain film) chest X-ray, urine Alere LAM and sputum Xpert Mtb/Rif on treating clinician request.
9718674|NCT04545164|Experimental|DCXR-CAD and FujiLAM and usual care|Participants randomized to the intervention arm will receive TB screening using DCXR-CAD and urine FujiLAM. The CAD score and FujLAM results will be appended into their medical notes for treating clinicians to see. If patients have a CAD score above a pre-determined threshold the study team will attempt to collect sputum for Xpert Mtb/Rif. Chest X-ray images will be available for clinicians to view. This is in addition to usual care (detailed above).
10196509|NCT05185687|Experimental|Disadvantaged Priority & Random|"Respondents will view the following description: The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:~Below this statement, respondents will view the Disadvantaged Priority & Random plan description."
9718675|NCT04545164|Other|Diagnostic cohort|Patients in the observational enhanced diagnostic arm will receive an enhanced package of diagnostics. This is a smaller arm (1 in 9 of all clusters) and is observational only - participants in this arm do not contribute to trial outcomes.
9718676|NCT04544943|Experimental|Cohort 1|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The total body surface area (BSA) dosed will be either 9% or 27% BSA. Part A will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control, applied at 9% or 27% BSA.
9718677|NCT04544943|Experimental|Cohort 2|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients in Cohort 2. Part B will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control.
10196510|NCT05185648|Experimental|post-training scores|evaluating qualities of trauma care after standard trauma traning
10196511|NCT05185635|Experimental|Healthy Spanish-speakers|
10196512|NCT05185596|Experimental|Trans-esophageal echocardiography|Transesophageal Echocardiography during advanced life support for out of hospital cardiac arrest will be performed.
9718678|NCT04544969||Chemotherapy|Patients treated with palliative chemotherapy
9718679|NCT04544956|Experimental|Participants receiving 300 mg GSK3228836|Eligible participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).
9718680|NCT04544878||Pediatric patients|All term children from birth to 18 years of age admitted in the PICU
9718681|NCT04544878||Adult patients|All patients >18 years of age
9718682|NCT04545268|Sham Comparator|Control group|
9718683|NCT04545268|Experimental|NMES group|
9718684|NCT04544813|Experimental|Cohort A: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 subcutaneously (SC).
9718685|NCT04544813|Experimental|Cohort B: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
9718686|NCT04544813|Experimental|Cohort C: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
9718687|NCT04544813|Experimental|Cohort D: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
9718688|NCT04544813|Experimental|Cohort E: JNJ-77474462 IV (Wave 1)|Participants will receive single dose of JNJ-77474462 intravenously (IV).
9718689|NCT04544813|Experimental|Cohort F: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
9718690|NCT04544813|Experimental|Cohort G: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
10196513|NCT05185544||neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
9718691|NCT04544813|Experimental|Cohort H: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
9718692|NCT04544813|Experimental|Cohort I: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
9718693|NCT04544813|Active Comparator|Cohort J: Anakinra SC|Participants will receive a SC injection of anakinra once daily for 3 days.
9718694|NCT04544826|Experimental|Cohort 1: JNJ-77474462 (Low Dose) or Placebo|Participants will receive single low dose of JNJ-77474462 or matching placebo as subcutaneous (SC) injection.
9718695|NCT04544826|Experimental|Cohort 2: JNJ-77474462 (Medium Dose) or Placebo|Participants will receive single medium dose of JNJ-77474462 or matching placebo as SC injection.
9718696|NCT04544826|Experimental|Cohort 3: JNJ-77474462 (High Dose) or Placebo|Participants will receive single high dose of JNJ-77474462 or matching placebo as SC injection.
9718697|NCT04544644|Experimental|treatment arm|AK104+anlotinib
9718698|NCT04544592|Experimental|UCD19 CART infusion|Lymphodepleting chemotherapy following by infusion of UCD19 CAR-T
9718699|NCT04544683|Other|Cervical Pain for 6 months or less and scheduled for TFESI|Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to and before receiving a first cervical TFESI. The baseline examination and all baseline questionnaires will be completed within 2 weeks before the first cervical TFESI. Participants will be given a daily pain diary chart to record NRS and percentage improvement during the 1st month post-injection. Participants will be contacted in the 1st week post-injection with a standardized questionnaire about their symptoms and a reminder about the 4 week (+/- 1 week) post-injection follow up. Routine scheduled follow-up by clinic visit or telephone call will occur at 4 weeks (+/- 1 week), 8 weeks (+/- 2 weeks), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month), at which times all follow-up measures will be obtained.
10196514|NCT05185518|Experimental|Use of novel insulin injection port|subjects inject insulin through a glucose sensing port
10196515|NCT05185518|No Intervention|use of standard SC injections|subjects inject insulin through standard rotating subcutaneous sites.
10196516|NCT05185505|Experimental|Atezolizumab + Bevacizumab|Patients will receive transarterial chemoembolization (TACE) every 3 months, with a maximum of 4 treatments, plus atezolizumab combined with bevacizumab.
10196517|NCT05185414|Other|RNA sequencing in genetically solved lissencephaly cases|RNA expression patterns in lissencephalies. RNA sequencing will be applied to the genetically solved lissencephaly cases. The acquired information on RNA expression patterns will be implemented in unsolved lissencephaly cases.
10196518|NCT05185414|Other|RNA sequencing in genetically unsolved lissencephaly cases|Obtain a genetic diagnosis in unsolved lissencephaly cases by implementation of RNA expression patterns obtained in arm 1.
10196519|NCT05185297|No Intervention|Standard care|Participants will continue with standard care provided by the family physician.
10196520|NCT05185297|Experimental|Recreational Futsal, plus standard care|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
9718700|NCT04544696||Patients with chronic non cancer pain|Patients with chronic non cancer pain, treated with opioids and having completed the POMi questionnaire
9718701|NCT04544657||stroke group|
9718702|NCT04544657||normal group|
9718703|NCT04544722|Experimental|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
9718704|NCT04544722|Active Comparator|Lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
9718705|NCT04544579||Ascending aortic dissection patients|Ascending aortic dissection patients
9718706|NCT04545255|Active Comparator|active|A shockwave device with a probe that conveys shockwave energy
9718707|NCT04545255|Sham Comparator|sham|A shockwave device with specially designed probe which has the shockwave energy blocked
9718708|NCT04544566|Experimental|Test product A new adhesive material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
9718709|NCT04544566|Experimental|Test product B new adhesion material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
9980614|NCT01393483||patients who undergo chemo-radiation prior to surgery|a serum sample will be obtained : 1) prior to initiation of therapy, 2) following the completion of induction chemotherapy, 3) at the time of surgical resection, and 4) at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months. The availability of tissue for staining will determine whether or not patients are evaluable for Group 3.
10196521|NCT05185284|Experimental|Favipiravir (Areplivir)|Arm 1 (n=106) receives the study drug Areplivir for parenteral administration as follows: Day 1 1600 mg 2 times a day, Day 2-10 800 mg 2 times a day. Administration will be done intravenously by drip infusion for 2 hours. The course of treatment is 10 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient.
9718710|NCT04544566|Active Comparator|Comparator|The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
9718711|NCT04544774||Allergic rhinitis patients|Patients with persistent or intermittent allergic rhinitis complaints, confirmed by skin prick tests and/or immunocap for specific IgEs, that start with AIT treatment.
9718712|NCT04544761||1-5 Years post|Persons with Spinal Cord Injury occurring between 1-5 years prior
9718713|NCT04544761||5-15 Years post|Persons with Spinal Cord Injury occurring between 5-15 years prior
9718714|NCT04544761||>15 Years post|Persons with Spinal Cord Injury occurring at least 15 years prior
9718715|NCT04544748|Other|Cohort 1|GNR-051 (0.1 mg/kg)
9718716|NCT04544748|Other|Cohort 2|GNR-051 (0.3 mg/kg)
9718717|NCT04544748|Other|Cohort 3|GNR-051 (1 mg/kg)
9718718|NCT04544748|Other|Cohort 4|GNR-051 (3 mg/kg)
9718719|NCT04544748|Other|Cohort 5|GNR-051 (10 mg/kg)
9718720|NCT04544553|Other|SMS reminder|This arm receive SMS reminder for the follow-up of DR Screening
9718721|NCT04544553|Other|No SMS reminder|This arm did not receive SMS reminder for the follow-up of DR Screening
9718722|NCT04544631|Experimental|Active VR|"Participants in the active VR group played a virtual reality game entitled Virtual River Cruise. In this game, an otter floats down a river on a boat and players activate snow-blowing statues along the shore by focusing on them. The statues will emit snow if they are correctly aimed at by the child, and a thermometer placed in the front of the boat shows decreased temperatures as more snowflakes are blown. As feedback to reinforce continued engagement, a scoreboard placed beside the thermometer will show children the number of statues he/she has activated. Additionally, as the temperature drops, snow and ice will start piling up on the boat and its surroundings, providing an enhanced cooling experience for pediatric burn patients. Children interact with the immersive virtual reality environment by tilting their head, minimizing potential interference with the dressing change procedure."
9718723|NCT04544631|Experimental|Passive VR|Participants in the passive VR group were immersed in the same virtual reality environment as the active VR group, without any interactions with the VR game.
9718724|NCT04544631|No Intervention|Standard Care Control|Participants in the standard group received routinely used distraction tools provided in the clinical setting, such as iPads, music, books, and/or talking.
9718725|NCT04544306|No Intervention|Control arm|Standard of Care (intravenous antimicrobial therapy according to the American Heart Association Guideline 2015)
9718726|NCT04544306|Experimental|Partial oral treatment arm|The mode of antimicrobial delivery is switched to oral therapy after at least 10 days of IV therapy, guided by antimicrobial susceptibility
9718727|NCT04544228|Experimental|ketamine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml ketamine
9718728|NCT04544228|Experimental|Neostigmine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml neostigmine
9718729|NCT04544228|Active Comparator|Control|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml normal saline.
9718730|NCT04544540|Experimental|One-Unit|Patients will be randomized to receive 1-unit of red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 1-unit
9718731|NCT04544540|Experimental|Two-Unit|Patients will be randomized to receive 2-unit sof red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 2-units
9779957|NCT04362748|Experimental|Dose Expansion Phase: Group 1|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
9779958|NCT04362748|Experimental|Dose Expansion Phase: Group 2|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
9779959|NCT04361669||Intervention|Patients that receive pharmacist-delivered services in the pilot program
9779960|NCT04361669||Control|Patients that do not receive pharmacist-delivered services in the pilot program
9779961|NCT04361656||Current standard of care preparation|Current Standard of Care for inpatient colonoscopy: The dose of PEG-ELS will be large-volume (4-Liter) administered as either single-dose if colonoscopy is scheduled BEFORE 11 a.m. (250 mL orally every 15 minutes between 6 p.m. and midnight the day prior to procedure), or split-dose if the colonoscopy is scheduled AT or AFTER 11 a.m. (First dose: 2-Liters; 250 mL orally every 15 minutes between 6-8 p.m. the day prior to procedure. Second dose: 2-Liters; 250 mL orally every 15 minutes to be completed 5 hours before the scheduled time of the procedure).
9779962|NCT04361656||Lubiprostone Intervention|"The study entails giving two doses of Lubiprostone in addition to the standard large-volume polythene glycol-electrolytes solution (PEG-ELS) according to the time of the procedure as follow: If the colonoscopy is scheduled BEFORE 11a.m. the patient will receive in addition to the PEG-ELS: Lubiprostone 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy.~If the colonoscopy is scheduled AT or AFTER 11a.m. the patient will receive in addition to PEG-ELS: Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS"
9779963|NCT04356287|Experimental|One infusion of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at months 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.
9779964|NCT04356287|Experimental|Two infusions of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.
9779965|NCT04356287|Placebo Comparator|Placebo infusions|Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A.
9779966|NCT04354155|Experimental|Thromboprophylaxis|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 mg/kg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
9779967|NCT04345107|Experimental|SY-009-1mg/d-1|0.5mg BID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-1mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
9779968|NCT04345107|Experimental|SY-009-1mg/d-2|1mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8.Start at the same time as the SY-009-1mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
10196522|NCT05185284|Active Comparator|Standard of care|"Arm 2 (n=108) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site. Might include Favipiravir tab, Remdesivir or other recommended schemes.~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
9718732|NCT04544345|Experimental|His bundle pacing, AV optimized|Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.
9718733|NCT04544345|Sham Comparator|Backup VVI pacing|Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.
9718734|NCT04544462||Infertile patients|Patients attending an IVF center for infertility treatment
9718735|NCT04544371||normal weight patients|patients with body mass index =18-24.9 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area in semi-sitting and right lateral positions
9718736|NCT04544371||obese patients|patients with body mass index >30 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area semi-sitting and right lateral positions
9718737|NCT04544332||Unsweetened Supplement|Infants will receive 10 exposures to the unsweetened small quantity lipid nutritional supplement (SQ-LNS) at home
9718738|NCT04544332||Sweetened Supplement|Infants will receive 10 exposures to the sweetened small quantity lipid nutritional supplement (SQ-LNS) at home
9718739|NCT04544319|Experimental|Arm I|Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
9718740|NCT04544319|Experimental|Arm II|Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg
9718741|NCT04544215|Experimental|MPCs-derived exosomes Dosage 1|low-dose group
9718742|NCT04544215|Experimental|MPCs-derived exosomes Dosage 2|high-dose group
10196523|NCT05185271|Experimental|Dyad- focused strategy training intervention|"The dyad-focused strategy training intervention protocol will be developed to help dyads manage the needs that they have as transitioning to the community.~The following theoretical frameworks and guidelines will be used to guide the development of the intervention: (1) the strategy training guideline outlined by Skidmore et al; (2) Bodenmann's framework of dyadic coping; and (3) Self-efficacy theory."
10196524|NCT05185245|Experimental|Liver Transplantation|
10196525|NCT05185232||Patients with complex congenital heart disease|Complex congenital heart disease will be defined by previously published classification including those listed in the American heart association/ American college of cardiology guidelines for the care of adults with congenital heart disease.
9718743|NCT04544215|Placebo Comparator|No exosomes|No MPCs-derived exosomes
9718744|NCT04544033||mild group|"Amendment to MOH COVID-19 Protocol:~Patient with mild clinical symptoms & clinically table.~CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line."
9718745|NCT04544033||moderate group|"Amendment to MOH COVID-19 Protocol:~Patient with non-specific and specific respiratory infection (pneumonia).~CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening)."
9718746|NCT04544033||severe group|"Amendment to MOH COVID-19 Protocol:~Patients with respiratory distress (RR > 30/min, Sa02 < 92 at room air).~Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours.~CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening)."
9718747|NCT04544137|Experimental|BOKS + SFSP|Children randomized to the BOKS + SFSP will be invited to attend the one-hour BOKS program four days per week for eight weeks during the summer. The BOKS program will be run by Lifespan employed staff in the hour before the SFSP lunch service at two community locations.
9718748|NCT04544137|No Intervention|SFSP|Children randomized to the SFSP alone group will be asked to participate in the SFSP as they would have otherwise.
9718749|NCT04544046|Active Comparator|Usual Care|Participants assigned to the standard care arm will receive standard oncology care and attend regular clinic visits. Participants on the standard care arm will complete questionnaires from baseline up to 6 months following enrollment.
9718750|NCT04544046|Experimental|Supportive Oncology Care at Home|"The research study procedures include:~Remote monitoring of symptoms, vitals, and body weight~Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and experience with cancer (e.g. quality of life, symptoms)~Data collection from medical record"
9718751|NCT04544059|Experimental|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
9718752|NCT04544085|No Intervention|control group|Patients in the control group will not receive any noise management intervention
9718753|NCT04544085|Experimental|experimental group|Patients in the experimental group will receive noise management. The intervention measures mainly include the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.We will strengthen the education of medical staff to ensure the effective implementation of the noise management.
9718754|NCT04543929|Active Comparator|exercise|exercise prescription + standard of care
9718755|NCT04543929|No Intervention|no exercise|no exercise prescription + standard of care
9980615|NCT01393496|Experimental|"liberal transfusion triggers"|"liberal guidelines for red blood cell transfusions"
9980616|NCT01393496|Active Comparator|"restrictive transfusion triggers"|"restrictive guidelines for red blood cell transfusions"
10196526|NCT05185232||Patients with non-complex congenital heart disease|Non-complex congenital heart disease will be defined by previously published classification including those listed in the American heart association/ American college of cardiology guidelines for the care of adults with congenital heart disease.
9718756|NCT04544176||Exposed Cohort|This group will include patients attending radiology outpatient appointments in 2020 in our period of interest from the peak of the first wave of the pandemic, who were subsequently tested for SARS-COV2 within 28-days of their attendance.
9718757|NCT04544176||Unexposed Cohort|This group will form the control group and comprises all individuals who attended radiological appointments during the same period for each hospital in 2019 but not 2020.
9718758|NCT04544163|Experimental|Magnesium sulphate- Fentanyl|30 mg per kg MgSo4 infusion in 100 ml saline over 10 minutes
9718759|NCT04544163|Experimental|Fentanyl 4 mic|4 mic per kg fentanyl i.v
9718760|NCT04544163|Active Comparator|Fentanyl|2 mic per kg fentanyl i.v
9718761|NCT04544163|Experimental|Lidocaine- Fentanyl|Lidocaine 1.5 mg/kg
9718762|NCT04543799||A1|"Group A1 consists of patients with prostate cancer receiving ADT as part of their standard care for either locally advanced or metastatic disease.~Group A1 consists of a combination of two groups; B1, metastatic patients receiving ADT both with and without an oral AR targeted agent, and not receiving radiotherapy and B2, locally advanced patients receiving ADT alongside radiotherapy"
9718763|NCT04543799||A2|patients with localised prostate cancer receiving radiotherapy only
9718764|NCT04543747||Patients implanted with HVAD System|Patients who require treatment with HVAD for use as bridge to cardiac transplantation (BTT) or destination therapy (DT) within the re-examination period are eligible for enrollment into the MCS Korea PMS. Patient consent may be obtained prior to HVAD implant or after receiving HVAD implant. Waiver of consent may be allowed if allowed by site's Institutional Review Board (IRB) or Ethics Committee (EC).
9718765|NCT04543851|Experimental|CARA positioning|Planning and Treatment using the CARA Device
9718766|NCT04543968|Experimental|hydroxytyrosol (HT) intake|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
9718767|NCT04543968|Experimental|hydroxytyrosol (HT) intake and withdraw|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
9718768|NCT04543773|Experimental|rTMS|Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
9718769|NCT04543916|Experimental|Dose Level 1|Venetoclax 50mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
9718770|NCT04543916|Experimental|Dose Level 2|Venetoclax 100mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
9718771|NCT04543916|Experimental|Dose Level 3|Venetoclax 200mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
9718772|NCT04543916|Experimental|Dose Level 4|Venetoclax 400mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
9718773|NCT04543916|Experimental|Dose Level 5|Venetoclax 600mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
9718774|NCT04543916|Experimental|Phase 2 Expansion Cohort|Venetoclax recommended phase 2 dose (RP2D) by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
9718775|NCT04543955|Experimental|Arm 1: Low-Dose Telotristat|Participants in this group will receive 750mg Telotristat per day.
9718776|NCT04543955|Experimental|Arm 2: High-Dose Telotristat|Participants in this group will receive 1500mg Telotristat per day.
9718777|NCT04543864|Experimental|electric welded metal framework|
9718778|NCT04543864|Experimental|conventional casted metal framework|
9718779|NCT04543890|Active Comparator|Hyperfrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
9718780|NCT04543890|Experimental|Hypofrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/15 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
9718781|NCT04543669|Experimental|Adacel®|All participants will receive one booster dose of commercially available Adacel® (TdaP-Tetanus, diphtheria, acellular pertussis) vaccine
9718782|NCT04543708|Active Comparator|Incision drainage|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Incision drainage arm will benefit from drainage of the tonsillar abscess under local anesthesia and then be hospitalized for intravenous antibiotics. If the incision drainage fails, they will get a tonsillectomy under general anesthesia."
9718783|NCT04543708|Active Comparator|Tonsillectomy|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Tonsillectomy arm will benefit from tonsillectomy under general anesthesia and then be hospitalized for intravenous antibiotics."
9718784|NCT04543942|Experimental|Males|Participants in this group will be adult male heavy drinkers.
9718785|NCT04543942|Experimental|Females|Participants in this group will be adult female heavy drinkers. Data will be segregated by menstrual cycle phase - the late follicular or mid-luteal phase.
9718786|NCT04544020||subjects|subjects with alcoholic hepatitis receiving NG feeding
9718787|NCT04543721||24-h-ABPM|
9980617|NCT01393509|Experimental|PU-H71|This Phase 1 trial will be an open-label, dose-escalation study of single-agent PU-H71 in patients with advanced solid malignancies and lymphoma.
9980618|NCT01393522|Active Comparator|Milnacipran|
9718788|NCT04543604|Experimental|Test group1 - Leaflet with visual aid|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. Along, pictograms were supplemented to display the prevalence of disease with and without the known indicator.
9718789|NCT04543604|Experimental|Test group2 - Leaflet with visual aid (L-NVA)|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. No pictograms were supplemented.
9718790|NCT04543604|No Intervention|• Control group - No leaflet (NL)|Only verbal information was provided to the patient during initial interview.
9718791|NCT04543656|Experimental|AI-Based Lifestyle Recommendations Group|Participants in this group receive AI-based, personalized lifestyle recommendations based on analysis of their activity tracker and blood pressure data.
9718792|NCT04543656|Active Comparator|Control Group|Participants in this group do not receive the lifestyle recommendations, but are provided with an identical activity tracker and blood pressure monitor.
9718793|NCT04543565|Experimental|Trial group|subject in this group will receive Pradefovir mesylate tablet and the placebo of tenofovir disoproxil fumarate tablet, once daily for 96 weeks
9718794|NCT04543565|Active Comparator|Control group|subject in this group will receive tenofovir disoproxil fumarate tablet and the placebo of Pradefovir mesylate tablet, once daily for 96 weeks.
9718795|NCT04543448|Other|Traditional Rehabilitation|Traditional Rehabilitation program was included strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs in all individuals. Indıvıduals participated in 2 training sessions per week for 4 weeks. Each training session consisted of a 5-minute non-balance coordination exercise, a 30-minute balance and coordination exercise, a 10-minute stretching and strengthing.
10196527|NCT05185219|Experimental|Valerian|generic name: XIE CAO CONC dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
9718796|NCT04543448|Experimental|Cervical Mobilization|Cervical Mobilization program, cervical mobilization techniques were applied to the patients for 30 minutes in addition to the traditional program. Cervical mobilization includes suboccipital relaxing techniques, myofascial muscle relaxing techniques for Levator scapula, trapezius, scalenes muscles. These techniques were applied bilaterally.
9718797|NCT04543396|Experimental|Physical Thearpy + Resistance Training|Subjects will receive standard of care treatments from their physical therapist. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
9980619|NCT01393522|Placebo Comparator|Sugar Pill|
9718798|NCT04543396|No Intervention|Physical Thearpy|Subjects will receive standard of care treatments from their physical therapist. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
9718799|NCT04543396|Experimental|Chiropractic Care + Resistance Training|Subjects will receive standard of care treatments from their chiropractor. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
9718800|NCT04543396|No Intervention|Chiropractic Care|Subjects will receive standard of care treatments from their chiropractor. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
9718801|NCT04543279|Experimental|Part A: Fostamatinib|The starting dose of fostamatinib is 100 mg twice daily (BID). After the first cycle, if no major dose related safety issue is observed and the platelet count is less than 50K/microL, then the fostamatinib dose will be increased to 150 mg BID for the next 2 cycles; otherwise the dose may be continued at 100 mg BID.
9984517|NCT04020718|Experimental|Early assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 4 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
9984518|NCT04020718|Experimental|Late assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 8 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
10196528|NCT05185219|Placebo Comparator|Control|generic name: placebo (Caramel Colors dyed starch) dosage form: capsule dosage: 500 mg/capsule, 6 capsules a day frequency: 3 times a day after each meal, 2 capsules each time duration: 30 days
9718802|NCT04543279|Experimental|Part B: Fostamatinib + Ruxolitinib|"After 3 cycles of fostamatinib monotherapy, all patients with a sustained platelet count ≥ 50K/microL, will continue on the current fostamatinib dose plus ruxolitinib at the recommended dose per standard prescribing guidelines for an additional 9 cycles.~Patients who do not reach platelet count of at least 50K/microL but who achieve clinical benefit per the treating provider may continue on single agent fostamatinib for up to 12 total treatment cycles. If these patients achieve a sustained platelet count of ≥ 50K/microL at any point prior to Cycle 10 Day 1, then they may be eligible to enroll in Part B of the study and continue treatment with fostamatinib and ruxolitinib for the remainder of the study."
9718803|NCT04543578||Patients unfit for Surgery with mild-moderate acute cholecyst|Conservative treatment (antibiotics, etc). EUS-guided gallbladder drainage will be considered in recurrent acute cholecystitis and in patients with no improvement in 48-72h after admission.
9718804|NCT04543578||Patients unfit for Surgery with severe acute cholecystitis|Percutaneous cholecystostomy or Endoscopic Ultrasound (EUS)-guided cholecystostomy (the latter is not 24/7 available). Palliative care may also be considered in patients with very serious conditions and low life expectancy.
9718805|NCT04543578||Patients suitable for Surgery with high and intermediate risk|"Admission in Gastroenterology Department. antibiotic treatment. Close follow-up of posible AC complications. Once choledocholithiasis is solved or ruled our, the patient will be considered for same-admission cholecystectomy or programmed cholecystectomy.~High risk: Endoscopic Retrograde Cholangiopancreatography (ERCP) will be performed.~Intermediate risk: EUS or Magnetic Resonance Cholangiopancreatography prior to consider ERCP."
9718806|NCT04543578||Patients suitable for Surgery with low risk|"Admission in Surgery Department. According to the AC severity:~Mild-moderate AC: check de ASA/Charlson comorbidity index.~ASA I-II/Charlson <6: laparoscopic cholecystectomy~ASA > =III/Charlson >=6: close follow-up 24-48h. Consider laparoscopic cholecystostomy (if no improvement is achieved)~Severe AC: consider Intensive Care Unit admission. Percutaneous cholecystectomy."
9718807|NCT04543318|Experimental|Deep temporal nerves group|this group will use deep temporal nerves for reactivation of affected upper facial nerve branch
9718808|NCT04543318|Active Comparator|Masseteric nerve group|this group will use masseteric nerve for reactivation of affected upper facial nerve branch (gold standard)
9718809|NCT04543552||Bladder Scan|Subjects who are scheduled to undergo urodynamic studies.
9718810|NCT04543370|Experimental|Treatment A|2 mg midazolam on Day 1 and 36 mg deflazacort on Day 2.
9718811|NCT04543370|Experimental|Treatment B|2000 mg edasalonexent TID on Day 1 to Day 11 with 2 mg midazolam on Day 10 and with 36 mg deflazacort on Day 11.
9718812|NCT04543331||treatment naïve patients|Patients being the first time treated for nAMD
9718813|NCT04543331||pre-treated patients|Patients already being treated for nAMD
9718814|NCT04543474|Active Comparator|Group 1|Patients starting with a low lactose diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low FODMAP diet for 3 weeks
9718815|NCT04543474|Active Comparator|Group 2|Patients starting with a low FODMAP diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low lactose diet for 3 weeks.
9718816|NCT04543357||All participants|Household contacts of a participant in study C3391003
9718817|NCT04543487|Experimental|Control Group|Group name
9718818|NCT04543292|Experimental|MATFILL|Prosthetic chimney filling with MATFILL prior to other sealing materials to protect the screww head.
9980620|NCT01393548|Experimental|brompheniramine + phenylephrine|Fixed dose combination of brompheniramine + phenylephrine
9718819|NCT04543162||patients with Mild Traumatic Brain Injury|patients with Mild Traumatic Brain Injury
9718820|NCT04543032|Experimental|study group|the patients in this group will receive sensorimotor training for 6 weeks in addition to medical care.
9718821|NCT04543032|No Intervention|control group|the patients in this group will receive medical care only.
9718822|NCT04543084|Other|Single-Subject Design|Each participant will go through a baseline phase and then an intervention phase.
9718823|NCT04543045||Stage 1|20 patients will be interviewed once, which will be approximately 60 minutes in duration. The interviews will be audio recorded.
9718824|NCT04543045||Stage 2|Five patients who participated in stage 1 will take part in a cognitive interview, which will be approximately 60 minutes in duration.The interviews will be audio recorded.
9718825|NCT04543110|Experimental|Single Arm|Immune-Modulating Radiation with Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
9718826|NCT04543097|No Intervention|Usual care|Participants randomised to the usual care arm will continue to receive care as usual for their health and vocational needs. For most patients, this will comprise usual clinical care, without formal vocational advice.
9718827|NCT04543097|Experimental|Usual care plus vocational support|Vocational support following a stepped care model based on the principles of case management in addition to usual primary care.
9980621|NCT01393548|Active Comparator|brompheniramine + pseudoephedrine|Fixed dose combination of brompheniramine + pseudoephedrine
9980622|NCT01393561|Experimental|Group 1|Fixed dose combination of brompheniramine + phenylephrine.
10196529|NCT05185206|Active Comparator|Analysis of post-operative sensitivity after caries removal using conventional steel bur|Caries will be excavated using a carbide on one side of the arch and restoration will be done with Cention-N(commercially available restorative material) as per manufacturer's instructions.Thermal stimulation (refrigerant spray Endo-Ice) will be used to evaluate the type of sensitivity. The pain intensity will be recorded with the Visual Analog Scale.
10196530|NCT05185206|Experimental|Analysis of post-operative sensitivity after caries removal using polymer bur|Caries will be excavated using a polymer on one side of the arch and restoration will be done with Cention-N(commercially available restorative material) as per manufacturer's instructions.Thermal stimulation (refrigerant spray Endo-Ice) will be used to evaluate the type of sensitivity. The pain intensity will be recorded with the Visual Analog Scale.
9980623|NCT01393561|Placebo Comparator|Group 2|Placebo
9980624|NCT01393574|Experimental|Melatonin treatment|Treatment with Melatonin before sleep for 1 month - 3 mg for body weight <40kg, 6mg for body weight >40kg
9980625|NCT01393574|Active Comparator|Stimulants treatment|Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.
9718828|NCT04543422|Experimental|Green tea extracts|Patients in this arm received green tea extract capsules
9718829|NCT04543422|Placebo Comparator|Placebo|Patients in this arm received placebo treatment
9718830|NCT04543227||Retrospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries between August 2015 - August 2019.
9718831|NCT04543227||Retrospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure between August 2015 - August 2019.
9980626|NCT01393587|Experimental|Experimental|
9718832|NCT04543227||Prospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries after July 2020.
9718833|NCT04543227||Prospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure after July 2020.
9718834|NCT04543175||Chemotherapy breast cancer patients|Newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy with the following drugs (Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel were followed until they complete four cycles of chemotherapy.
9718835|NCT04543058|Experimental|BeatPark Experimental Group|Group of participants who will make its self-rehabilitation in walking program using BeatPark application, delivering synchronized music adapted to the patient walking progression.
9718836|NCT04543058|Active Comparator|Control Group with Music at Random Tempo|Group of participants who will make its self-rehabilitation in walking program using an application delivering music at random tempo.
9718837|NCT04543058|Active Comparator|Control Group without Music|Group of participants who will make its self-rehabilitation in walking program using an application without music.
9718838|NCT04543188|Experimental|PF-07284890 (Part A monotherapy)|Monotherapy dose escalation of PF-07284890
9718839|NCT04543188|Experimental|PF-07284890+binimetinib (Part A combo-therapy)|Combination dose escalation of PF-07284890 + binimetinib
9718840|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 1)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or Non-Small Cell Lung Cancer (NSCLC), with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
9718841|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 2)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
9718842|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 3)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with asymptomatic brain involvement, and prior BRAF inhibitor utilization
9718843|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 4)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and prior BRAF inhibitor utilization
9718844|NCT04543188|Experimental|Expansion Phase (Part B Cohort 5)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors
9718845|NCT04543188|Experimental|Drug-Drug Interaction Substudy|PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor
9718846|NCT04543136|Active Comparator|SpeediCath® standard Male|Standard of care
9718847|NCT04543136|Experimental|New intermittent catheter variation 1 for male|New intermittent catheter variation 1 for male.
9718848|NCT04543136|Experimental|New intermittent catheter variation 2 for male|New intermittent catheter variation 2 for male
9718849|NCT04543149||Case|Patients with idiopathic granulomatous mastitis
9718850|NCT04543149||Control|Healthy volunteers
9718851|NCT04543266||Patients with Progressive Disease|Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease
9718852|NCT04543266||Patients without Progressive Disease|Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease
9718853|NCT04543123|Sham Comparator|sham tDCS treatment group|the current rose slowly for 30 seconds, descended for 30 seconds, and then remained at zero for 29 minutes
9718854|NCT04543123|Experimental|active tDCS treatment group|2mA of current was delivered during the 30 minutes of treatment
9718855|NCT04542928|Placebo Comparator|routine care|The controlled group will receive routine functional treatment activities, a facial cleansing instruction and five facial cleansing videos.
9718856|NCT04542928|Experimental|experimental group|experimental group is required to receive a nurse leading 50- minute face care group every two weeks
9718857|NCT04542941|Active Comparator|Intervention arm|The participants will receive COVID Convalescent Plasma in addition to the standard of care received by all COVID 19 patients
9718858|NCT04542941|No Intervention|Control arm|The participants under this arm will receive the COVID 19 standard of care
9718859|NCT04543006|Other|Covid-19|only arm: Covid-19 proven by PCR
9718860|NCT04543630|Active Comparator|Particulated autogenous bone|Particulated autogenous bone is considered the gold standard for sinus floor augmentation. The bone will be harvested locally
9980627|NCT01393652|Experimental|Cohort 1: Experimental intervention: PF-05105679 or placebo|Cohort 1
9980628|NCT01393652|Experimental|Cohort 2: Experimental intervention: PF-05105679 or placebo|Cohort 2
9980629|NCT01393652|Active Comparator|Cohort 3: Experimental intervention PF-05105679 or placebo and|Cohort 3
9980630|NCT01393665|Placebo Comparator|Placebo|
9980631|NCT01393665|Experimental|PENNEL capsule|1cap or 2cap T.I.D
9980632|NCT01393678|Experimental|PENNEL|2cap T.I.D
9980633|NCT01393678|Active Comparator|NISSEL|"NISSEL~BDD (biphenylmethyl dicarboxylate) ................25mg~2cap T.I.D"
9980634|NCT01393691|Experimental|CBT with parent combined play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
9718861|NCT04543630|Experimental|Advanced platelet-rich fibrin|Advanced platelet-rich fibrin will be be obtained through a blood sample from the participant
9718862|NCT04542967|No Intervention|Control group|They will receive the standard care for critically ill inpatients.
9718863|NCT04542967|Experimental|Convalescent plasma group.|They will receive standard care for patients with severe COVID-19 disease and convalescent plasma disease.
9718864|NCT04542811|Experimental|Intervention group|Intervention group will take 12 sessions of acupuncture addition to their prophylaxis treatment. Acupuncture points will be bilateral LI-4, LI-11, ST-8, ST-44, SP-6, GB-1, GB-14, GB-20, LR-3, and GV-14, GV-20. Sterile and single-use stainless steel acupuncture needles measuring 0.25x25 mm will be inserted to a depth of 10 mm and be retained for 30 minute without any further stimulation. Acupuncture will be performed by an acupuncturist with an acupuncture practitioner licence from the Turkish Ministry of Health. Adverse events will be monitored for all acupuncture sessions.
9718865|NCT04542811|No Intervention|Control Group|Control group will take only their migraine prophylaxis treatment. Participants will followed-up 3 months.
9980635|NCT01393691|Active Comparator|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
10196531|NCT05185193|Experimental|radiofrequency stimulation|Participants received radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
10196532|NCT05185193|Sham Comparator|sham stimulation|Participants received a sham stimulation similar to a radiofrequency stimulation three times a day for 30 minutes once a day. After the end of the first session intervention, there was a washout period and the next intervention was started at a time point when the next menstruation was not likely (8-18 days after the onset of menstruation).
9718866|NCT04542707|Active Comparator|Joint manipulation|Grade V-Thrust manipulation with audible sound and without audible sounds of T7, MTP 2 and MCP2 joints.
9718867|NCT04542707|Active Comparator|Exercise|Aerobic, anaerobic, and yoga exercises
9718868|NCT04542707|Active Comparator|Soft tissue massage|Instrument assisted soft tissue massage
9718869|NCT04542746|Experimental|Minimally invasive surgical technique|The intra-bony defects of subjects allocated in test group were treated with a combination of minimally invasive surgical technique (MIST) and enamel matrix derivative( EMD).
9718870|NCT04542746|Active Comparator|Conventional open flap debridement with papilla preservation|The intra-bony defects of control group were treated using a combination of conventional open flap debridement with papilla preservation (COFD+PP) and EMD.
9718871|NCT04542694|Experimental|Favipiravir (Areplivir)|"Arm 1 (n=100) receives the study drug Areplivir film-coated tablets:~on day 1 of therapy - 1600 mg (8 tablets) 2 times a day; on days 2-14 of treatment - 600 mg (3 tablets) 2 times a day. The drug is taken orally every 12 hours, swallowing whole tablet without chewing and washing down with a glass of water. The course of treatment is 14 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient."
9718872|NCT04542694|Active Comparator|Standard of care|"Arm 2 (n=100) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health (but not Favipiravir) by decision of the investigator and taking into account the availability of drugs at the study site. Might include hydroxychloroquine (with or without azithromycin), chloroquine, lopinavir/ritonavir or other recommended schemes.~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
9718873|NCT04542993|Active Comparator|Resveratrol and Zinc Picolinate combination therapy|Resveratrol and Zinc Picolinate combination therapy
9718874|NCT04542993|Placebo Comparator|Resveratrol Placebo and Zinc Placebo combination therapy|Placebo Resveratrol and Placebo Zinc combination therapy
9718875|NCT04542889|Experimental|Absolute coronary resistances and IMR after angioplasty|Patients with STEMI by acute occlusion of a large caliber coronary artery that had been admitted to hospital less than 12 hours and revascularized by primary angioplasty with good final result.
9718876|NCT04542616|Active Comparator|Baerveldt 350|The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
9718877|NCT04542616|Active Comparator|Ahmed ClearPath 250|The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
9718878|NCT04542876|Experimental|Ayurveda|Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.
9718879|NCT04542915||U.S. licensed dental hygienists|Dental hygienists licensed in the United States. No intervention will be administered.
9718880|NCT04542837|Experimental|KN046 plus Lenvatinib|
9980636|NCT01393756|Experimental|Lenalidomide dose 25 mg|
9980637|NCT01393769|Experimental|Melphalan|Intra-arterial chemotherapy with melphalan, via direct administration by catheterization of the ophthalmic artery. Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume: a)3 mg for patients under 10 kg and tumour volume size under 1,5 cm3; b)5 mg for patients over 10 kg and tumour volume over 1,5 cm3; c)4 mg in all other situations(tumour volume over 1,5 cm3 in patients under 10 kg or tumour volume under 1,5 cm3 in patients over 10 kg).
10196533|NCT05185180||Males with Category III Chronic Pelvic Pain Syndrome|Category III is subdivided into inflammatory (IIIa) and noninflammatory (IIIb) subtypes, based on the presence of white blood cells in expressed prostatic secretions (EPS). Category III prostatitis or chronic pelvic pain syndrome (CPPS) is the most common prostatitis observed in medical practice with a prevalence rate in the general population from 5% to 14.2%. CPPS is a poorly understood entity characterized by pelvic or perineal pain, irritative voiding symptoms, and sexual dysfunction.
10196534|NCT05185180||Control Group|The control group will consist of men with no history of Chronic Pelvic Pain or any underlying condition.
10196535|NCT05185115|Experimental|Intervention group (A)|Patients treated with 3 liters per minute oxygen delivered via nasal cannula duration hospitalization
9718881|NCT04542863|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 18F-DX600 PET/CT scans.
9718882|NCT04542902|Experimental|Allergic asthma patients|Allergic asthma patients and sensitization to house dust mites (D. pteronyssinus) allergen.
9718883|NCT04542902|Experimental|Severe eosinophilic asthma patients|
9718884|NCT04542902|Active Comparator|Healthy subjects as a control group|Healthy subjects without allergic and other chronic respiratory diseases (control group).
9718885|NCT04542772|Experimental|Mirror Therapy + Standard of Care|Participants in this group will receive standard of care based on their needs along with mirror therapy education.
9718886|NCT04542772|Active Comparator|Standard of Care|Participants in this group will receive only standard of care based on their needs.
9718887|NCT04542629|Experimental|RITUXIMAB|rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses
9718888|NCT04542629|Active Comparator|KETOGENIC DIET|"The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.~Diets that produce a state of ketosis are referred to as ''ketogenic"
9718889|NCT04542629|Active Comparator|TRACE ELEMENTS|. Essential trace elements that include zinc, copper, magnesium, and selenium
9980638|NCT01393782|Active Comparator|Angiotensin|The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for MAP goals as outlined in the protocol.
9980639|NCT01393782|Placebo Comparator|Control|Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
9980640|NCT01393795|Placebo Comparator|Tegaderm|
9718890|NCT04542629|Active Comparator|CORTICOSTEROID|corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month
9718891|NCT04542668|Other|Cycling as first intervention|Cycling -> Running -> Inotropy -> Resting
10196536|NCT05185115|Other|Control group (B)|No oxygen therapy during hospitalization
9718892|NCT04542668|Other|Running as first intervention|Running -> Cycling -> Inotropy -> Resting
9718893|NCT04542759|Active Comparator|Besifloxacin|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
9718894|NCT04542759|Placebo Comparator|Hydroxypropyl methylcellulose|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
9718895|NCT04542655|Other|Cycling first|Ergometer cycling then treadmill running then rest
9718896|NCT04542655|Other|Running first|Treadmill running then ergometer cycling then rest
9718897|NCT04542733|Active Comparator|mTORi with reduced-dose tacrolimus|Patient will received everolimus with target trough concentration of 3-6 ng/mL and tacrolimus with target trough concentration of 2-4 ng/mL. Duration for this regimen would be at least 3 months.
9718898|NCT04542733|Active Comparator|reduced-dose tacrolimus|Patient will receive tacrolimus with target concentration of 3-6 ng/mL with or without leflunomide 100 mg/day loading dose for 5 days, followed by 40 mg/day thereafter. Duration for this regimen would be at least 3 months.
9718899|NCT04542798|Experimental|NPPG (neuropatic pain group) PRF|Pulsed radiofrequency neuromodulation of dorsal root ganglia
9718900|NCT04542798|Active Comparator|NPPG (neuropatic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
9980641|NCT01393795|Active Comparator|Qutenza|
9980642|NCT01393808|Experimental|Paricalcitol|
9980643|NCT01393808|Placebo Comparator|placebo|
9980644|NCT01393834|Experimental|Delayed cord clamping|Delayed cord clamping for 30 seconds
9980645|NCT01393834|Experimental|Milking of the cord|Milking of the cord 4 times in 10 seconds
9980646|NCT01393834|No Intervention|Immediate cord clamping|Immediate cord clamping after delivery
10196537|NCT05185063||Out of Hospital Cardiac Arrest|
9718901|NCT04542798|Experimental|NMPG (nociceptive/mechanic pain group) WCRF|Water cooled radiofrequency of the medial branch of the dorsal nerve
9718902|NCT04542798|Active Comparator|NMPG (nociceptive/mechanic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
9718903|NCT04542538||COVID-19 critical care patients|All patients who have received intensive care with COVID-19 in Sweden until May 27, 2020. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
9718904|NCT04542538||Sepsis critical care patients|All patients who have received intensive care with severe sepsis or septic shock in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
9718905|NCT04542538||ARDS critical care patients|All patients who have received intensive care with ARDS in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
9718906|NCT04542447|Active Comparator|Nuvastatic + standard treatment|5 patients, dosage: 3000 mg of Nuvastatic™ (C5OSEW5050ESA) each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
9980647|NCT01393860||Aliskiren|Diabetic nephropathy
9980648|NCT01393873||Bariatric surgery pts with Type 2 DM|Primary bariatric surgery pts with Type 2 DM
9980649|NCT01393886|Experimental|Laparoscopic Greater Curvature Plication|Only one treatment arm
10196538|NCT05185037||Caesarian Section Patient|Obstetric patient
10196539|NCT05184972||Non-reported patients treated for in-hospital cardiac arrest|
10196540|NCT05184972||Reported patients treated for in-hospital cardiac arrest|
9718907|NCT04542447|Placebo Comparator|Placebo|5 patients, dosage: 3000 mg of placebo each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
9718908|NCT04542395|Experimental|Increasing Uptake of COVID-19 Testing and Vaccination|"This is a pre-experimental one group pretest-posttest design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
9718909|NCT04542356|Experimental|experimental group|patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy
9718910|NCT04542356|Placebo Comparator|control group|patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC<1✕109/L
9718911|NCT04542499|Experimental|Tavapadon|Participants will receive a tavapadon tablet titrated 5 to 15 milligrams (mg) once daily (QD) orally for 27 weeks.
9718912|NCT04542499|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
9779969|NCT04345107|Experimental|SY-009-2mg/d-1|1mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
9779970|NCT04345107|Experimental|SY-009-2mg/d-2|2mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
9779971|NCT04345107|Experimental|SY-009-4mg/d|2mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. If the test and safety assessment of 4mg daily dose group (2mg bid) are completed and the dose termination standard is not met, the test will be terminated; if the safety assessment during or after the test reaches the dose termination standard, the study of 3mg daily dose group (1.5mg bid) will be carried out, and then the test will be terminated.
9779972|NCT04345107|Experimental|SY-009-3mg/d|1.5mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
9779973|NCT04345107|Placebo Comparator|SY-009 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
9779974|NCT04342182|Experimental|Convalescent plasma|Standard of care plus 300mL of convalescent plasma from COVID-19 recovered donors
9779975|NCT04342182|No Intervention|Standard of care|standard of care (supportive care, oxygen, antibiotics)
9779976|NCT04339166|Experimental|Group A|Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.
9779977|NCT04339166|No Intervention|Group B|Single thawed blastocyst transfer with blastocyst selection according to morphologic score.
9779978|NCT04335110|Other|Intervention|Care Partners and Persons with Dementia. Up to 40 Care Partners and their 40 care-recipients with ADRD will participate in this study. The primary focus of this study is on Care Partners, however, we will gather subjective and objective data on participants with Alzheimer's Disease and Related Dementias (ADRD) to assess the effect of the intervention on Care Partner affective responses to caregiving and quality of life for both. STELLA participants will be recruited from the existing cohort of patients, and their Care Partners, who are enrolled in the Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology) ORCASTRAIT Life Laboratory (OSLL).
9779979|NCT04332341|Experimental|Nicotinamide riboside (NR)|
9779980|NCT04328207|Other|No financial incentive|This group will receive standard of care eye health education alone and no financial incentive for completing a referral visit.
9779981|NCT04328207|Experimental|Financial incentive|This group will receive a financial incentive once the referral visit is completed (if one was required) as well as eye health education.
9779982|NCT04312139||Fast progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated fast progression from moderate to severe aortic valve stenosis: echocardiographic dVmax>0.25 m/sec/year (difference in transaortic Vmax).
9779983|NCT04312139||Slow progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated slow progression from moderate to severe aortic valve stenosis: echocardiographic dVmax<0.15 m/sec/year (difference in transaortic Vmax).
9779984|NCT04312139||Prospective Moderate Aortic Valve Stenosis|100 consecutive prospectively enrolled patients with moderate aortic valve stenosis. Plus 20 patients accounting for 20% drop-out rate, total prospective cohort = 120 patients.
9779985|NCT04312139||Negative calcium score group|50 patients at intermediate to high risk for Cardiovascular Disease (CVD) and negative aortic valve and coronary calcium score at CT scan, prospectively followed-up. Plus 10 patients accounting for 20% drop-out rate, total control cohort = 60 patients.
9980650|NCT01393912|Other|Stratum A Patients|The patients are newly diagnosed Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 3 (170 mg/m^2).
9980651|NCT01393912|Other|Stratum B Patients|The patients are recurrent, refractory or progressive high-grade glioma including Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 4 (220 mg/m^2).
9980652|NCT01393925|Experimental|parecoxib, normal saline|
9980653|NCT01393938|Other|Mullerian Duct Anomaly|
9718913|NCT04542473|Active Comparator|Pancreatic Enzymes (PE)|"Pancreatic enzymes formulated as 5000 IE lipase, 3600 IE amylase and 200 IE protease per 100 mg of granules, packaged as sachets. The target dose is 3000 IU lipase/kg, twice daily (1440 IU/kg amylase/80 IU/kg protease), which is the dose used for children with cystic fibrosis and exocrine pancreas insufficiency. For oedematous malnutrition, weight for dosing is reduced by 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands to allow a lower range of 2000 IU/kg/day and upper range of 4000 IU/kg/day:~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)~---------------------------------------------------------------------------------------------------------- 2.50 4.99 2 10000 4000 2000 5.00 7.49 4 20000 4000 2670 7.50 9.99 6 30000 4000 3000 10.0 15.0 8 40000 4000 2667"
9718914|NCT04542473|Placebo Comparator|Placebo-PE|"Oral/enteral placebo matching active Pancreatic Enzymes (PE). Dose presentation in whole sachets of 100mg of granules. For oedematous malnutrition, weight for dosing is reduced by a pragmatic 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands:~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)~----------------------------------------------------------------------------------------------------------------------------------------- 2.50 4.99 2 Nil Nil Nil 5.00 7.49 4 Nil Nil Nil 7.50 9.99 6 Nil Nil Nil 10.0 15.0 8 Nil Nil Nil"
9718915|NCT04542473|Active Comparator|Ursodeoxycholic acid (UA)|The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.
9718916|NCT04542473|Placebo Comparator|Placebo-UA|The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.
9718917|NCT04542460|No Intervention|Optimal Medical Treatment|CTO patients receiving optimal medical treatment
9718918|NCT04542460|Active Comparator|Optimal Medical Treatment and PCI|CTO patients receiving PCI in ajunction to optimal medical treatment
9718919|NCT04542226||Adult patients hospitalized with COVID-19|Patients eligible for enrollment into the study
9980654|NCT01393951|Experimental|sc dose 1|subcutaneous (sc) vaccination of ASP7374 dose-1
9718920|NCT04542213|Experimental|DPP4 inhibitor + insulin|Patients assigned to this group of treatment will receive Linagliptin 5mg orally once daily plus a basal-bolo insulin scheme
9718921|NCT04542213|Active Comparator|Insulin scheme alone|Patients assigned to this group will receive only a basal-bolus insulin scheme
9980655|NCT01393951|Experimental|sc dose 2|subcutaneous vaccination of ASP7374 dose-2
9980656|NCT01393951|Experimental|im dose 3|intramuscular (im) vaccination of ASP7374 dose-3
9718924|NCT04542265|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
9718925|NCT04542265|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
9718926|NCT04542265|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil A + vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
9718927|NCT04542265|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
9718928|NCT04542161|Active Comparator|NAC 900mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period
9980657|NCT01393977|No Intervention|control|Outpatient in hospital
9980658|NCT01393977|Active Comparator|rehabilitation|interventions: rehabilitation
9718929|NCT04542161|Active Comparator|NAC 3600mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period
9718930|NCT04542161|Placebo Comparator|NAC 0mg/day (Placebo)|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period
9718931|NCT04542369|Experimental|ES-SCLC|Induction therapy: BGB-A317 200mg, qd, ivgtt, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles. Maintenance therapy: BGB-A317 200mg, qd, ivgtt, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death).
9980659|NCT01393977|Experimental|Stem Cell Transplantation|interventions: stem cell transplantation
9980660|NCT01394016|Experimental|LY2835219|
9980661|NCT01394029||deferasirox|
9980662|NCT01394042|No Intervention|No intervention|All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
9980663|NCT01394055|Active Comparator|RM-131|
9980664|NCT01394055|Placebo Comparator|Placebo|
9980665|NCT01394094|Experimental|Gum Chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
9980666|NCT01394094|No Intervention|Conventional|Conventional postoperative feeding schedule
9984519|NCT04014530|Experimental|Phase I dMMR and pMMR|2-4 groups of 3 patients treatment with 200mg i.v. Pembrolizumab q3w and dose escalation of Ataluren in order to determine the Ataluren MTD. These patients can either be pMMR/dMMR CRC and dMMR EC patients.
10196541|NCT05184946|Experimental|Anti-PD1 combined with SOX|Camrelizumab will be administered one day before SOX regimen.
10196542|NCT05184907|Experimental|RME Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing with 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
9718932|NCT04542109|Experimental|READyR A|Group A will start the READyR intervention immediately after the baseline Session 1. The READyR program consists of a 3-session, values-based needs assessment intervention designed to match objectively-assessed in-home activity patterns with subjective reports of participants' care values. The goal of the intervention is to address unmet dementia-related care needs and help couples prepare for the future, and reduce strain on their relationship, and help maintain their health and well-being. Session 2 will occur approximately 3 weeks after Session 1, and Session 3 will occur approximately 3 weeks after Session 2. Session 3 also includes follow-up assessments.
9718933|NCT04542109|Active Comparator|READyR B (wait list comparison)|Group B - the wait list comparison group - will have a 60-minute support session (comparator intervention) about 3 weeks after the baseline Session 1. The support session will include general information about dementia-related care needs that does not take into account the individual participant's care values or objective in-home activity patterns. They will also receive a check-in call approximately 3 weeks later, with follow-up assessments. Group B will begin the READyR intervention sessions following completion of follow-up assessments.
9718934|NCT04542018|Experimental|Study patients with IBS-D|Patients with diarrhea-predominant IBS who will undergo a low FODMAP diet for 4 weeks
9718935|NCT04542304|Active Comparator|Metolazone then placebo|Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.
9718936|NCT04542304|Placebo Comparator|Placebo then Metolazone|Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.
9718937|NCT04542122|No Intervention|Choices then judgements|
9718938|NCT04542122|Active Comparator|Judgements then choices|Switch in the order of clinical cases in the survey
9718939|NCT04542252|Experimental|Group 1|SyB V-1901 alone, Simultaneous administration of SyB V-1901 and cyclosporine, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
9718940|NCT04542252|Experimental|Group 2|Simultaneous administration of SyB V-1901 and cyclosporine, SyB V-1901 alone, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
9718941|NCT04541966||Nuchal translucency> = 99th percentile and <3.5mm|Nuchal translucency> = 99th percentile and <3.5mm
9718942|NCT04541966||Nuchal translucency> = 3.5 mm|Nuchal translucency> = 3.5 mm
9718943|NCT04541706|Experimental|Lorlatinib|The recommended dosage of lorlatinib is 100 mg orally once daily, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.
9718944|NCT04541719|Active Comparator|Patient-controlled remifentanil analgesia|Patients will received Patient-controlled remifentanil analgesia starting from labour pain until delivery
9718945|NCT04541719|Placebo Comparator|Epidural analgesia|Patients will received continuous epidural analgesia starting from labour pain until delivery
9718946|NCT04541732|Experimental|Thoracic epidural block|Patients will receive thoracic epidural block following induction of general anaesthesia
9718947|NCT04541732|Active Comparator|Bilateral quadratus lumborum block|Patients will receive Ultrasound-guided bilateral quadratus lumborum block following induction of general anaesthesia
9718948|NCT04541927||BCL11B|BCL11B intragenic pathogenic variant
10196543|NCT05184907|Active Comparator|Information Only Arm|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
9718949|NCT04541901|Experimental|Deep massage and Cold water immersion|
9718950|NCT04541901|Active Comparator|Superficial Massage and Water immersion in room temperature|
9718951|NCT04541901|No Intervention|Control/Rest|
10196544|NCT05184855|Experimental|Blueberry|26 g freeze-dried blueberry powder per day or approximately one cup fresh blueberries equivalent; two weeks intake.
10196545|NCT05184855|Placebo Comparator|Placebo|26 g placebo powder per day matched for color, taste, aroma; two weeks intake.
10196546|NCT05184829|Active Comparator|systemic lymph node dissection group|systemic lymph node dissection group
10196547|NCT05184829|Experimental|selective lymph node dissection|selective lymph node dissection
9718952|NCT04541836||healthy control|healthy volunteer with no clinically relevant finding on physical examination at screening visit will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.
9718953|NCT04541836||PSP|"Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP as possible or probably PSP will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later."
9718954|NCT04541862||Critically ill patients|
9718955|NCT04541823|Experimental|Desflurane|Patients allocated to this arm will receive desflurane during the maintenance of anesthesia.
9718956|NCT04541823|Placebo Comparator|Propofol|Patients allocated to this arm will receive propofol during the maintenance of anesthesia
9718957|NCT04541758|Experimental|surgical treatment|Minimally invasive internal fixation under spontaneous respiratory anesthesia and analgesic treatment and chest strap fixation
9718958|NCT04541758|Experimental|Conservative treatment|analgesic treatment and chest strap fixation
9718959|NCT04541875||Cystic fibrosis|"Patients aged 18+ and diagnosed with cystic fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
9718960|NCT04541875||Hemophilia A or B|"Patients aged 18+ and diagnosed with hemophilia A or B.~Patients will answer the MAR-Scale once every three months for a year."
9718961|NCT04541875||Idiopathic pulmonary fibrosis|"Patients aged 18+ and diagnosed with idiopathic pulmonary fibrosis.~Patients will answer the MAR-Scale once every three months for a year."
9718962|NCT04541875||Myasthenia gravis|"Patients aged 18+ and diagnosed with myasthenia gravis.~Patients will answer the MAR-Scale once every three months for a year."
9718963|NCT04541875||Sickle cell disease|"Patients aged 18+ and diagnosed with sickle cell disease.~Patients will answer the MAR-Scale once every three months for a year."
9718964|NCT04541641|Experimental|osteotome group|
9718965|NCT04541641|Experimental|New Reverse Drilling technique|
9718966|NCT04541784|Active Comparator|3 counselling sessions with gynaecology-oncology nurses|Patients randomized to the control group will receive standardized care, 3 counselling sessions with a gynaecology-oncology nurse and written information at three points in time during 6 months after diagnosis/surgery.
9718967|NCT04541784|Experimental|Mobile app and 3 counselling sessions (WOMAN-PROIII)|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III. Counselling sessions will take place at 3 points in time during 6 months after diagnosis/surgery. Additionally, the gynaecology-oncology nurse will instruct the patient to use the mobile app. It includes a diary for symptom assessment and gives graphical feedback. Further, the app includes disease and treatment related information. If a symptom occurs the app will give an evidence-based recommendation (Kobleder et al., 2016). The patients can use the app whenever they want for a period of six months."
9718968|NCT04541953|Active Comparator|Telerehabilitation|
9718969|NCT04541953|Active Comparator|In-Person Rehabilitation|
9718972|NCT04541771|Experimental|drug group|The trial group will receive their usual feeds plus daily probiotic (Lactobacillus Reuteri DSM 17938) addition 1 drop/kg/dose(. minimum of 20 million live Lactobacillus Reuteri are present in One drop) twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
9718973|NCT04541771|Placebo Comparator|control group|this group is control group and will receive normal saline drops as 1 drop/kg/ dose mixed in enteral feed
9718974|NCT04541940|Active Comparator|Telerehabilitation|
9718975|NCT04541940|Active Comparator|In-Person Rehabilitation|
9718976|NCT04541680|Experimental|Nintedanib|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
9718977|NCT04541680|Placebo Comparator|Placebo|Control group will receive Placebo BID for 12 months in addition to SoC. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient. Standard of care may include pulmonary rehabilitation.
9718978|NCT04541693|Other|Hip revision|Revision to cup and stem, cup only or stem only.
9718979|NCT04541511|Experimental|Healthy subject|"Healthy subject will be asked to performed two 6-minutes walking test : one in a corridor and one on the non-motorized treadmill.~Oxygen saturation, heart rate and Borg score will be collected before and after each test."
9718980|NCT04541511|Experimental|Patients|Patients will be asked to to performed a 6-minutes walking test on the non-motorized treadmill and to answer a questionnaire regarding the acceptability and ease of use of the new method.
9718981|NCT04541914|Experimental|Validation group|Evaluation for diagnostic efficacy of peripheral blood marker-based molecular diagnostic method for antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT)
9718982|NCT04541628|Experimental|SIG-001|B-Domain Deleted Human Factor VIII (BDD-hFVIII) Producing Spheres
9718983|NCT04542005|Experimental|q3h albuterol|Using q3h as discharge criteria from hospital
9718984|NCT04542005|No Intervention|q4h albuterol|Using q4h as discharge criteria from hospital
9718985|NCT04541550|Experimental|Low Dose AMP-001|12.5 mg AMP-001 in 3 ml Saline
9718986|NCT04541550|Experimental|Medium Dose AMP-001|25 mg AMP-001in 3 ml Saline
9984520|NCT04014530|Experimental|Phase II dMMR|Mismatch repair deficient CRC or EC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
9718987|NCT04541550|Experimental|High Dose AMP-001|50 mg AMP-001 in 3 ml Saline
9718988|NCT04541602||Dysphagia-positive|"critically ill patients more than 17 years of age~matching study inclusion criteria~confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
9718989|NCT04541602||Dysphagia-negative|"critically ill patients more than 17 years of age~matching study inclusion criteria~newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
9718990|NCT04541602||Controls|"healthy volunteers without any neuromuscular disease~swallowing dysfunction ruled out using FEES"
9718991|NCT04541576|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
9779986|NCT04300309|Experimental|artemether lumefantrine (2.5 mg:30 mg)|artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
9718992|NCT04541563|Experimental|Immediate Treatment Arm|The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks.
9718993|NCT04541563|Sham Comparator|Delayed Treatment Arm|In the delayed treatment arm, the participants will receive a sham device that looks exactly the same, but only provides treatment for 2 seconds. At week 4, sham arm participants will be unblinded and shipped an active device (limited to Level 2 output even if a participant raises the dial beyond that). The delayed arm participants will continue with active devices for the remaining 4 weeks of the trial.
9718994|NCT04541173|Active Comparator|Arm A|TARE alone
9718995|NCT04541173|Experimental|Arm B|TARE then Bevacizumab and Atezolizumab
9718996|NCT04541459|Sham Comparator|Sham Qi-Shield user group|
9718997|NCT04541459|Active Comparator|Qi-Shield user group|
9718998|NCT04541147|Experimental|Dexamethasone plus analgesics|oral dexamethasone of 0.5mg/kg/day (max of 8mg/day), administered on post-operative days 1,3,5,7 in addition to standardized course of analgesics (opioids/acetaminophen/NSAIDs).
9718999|NCT04541147|Active Comparator|analgesics alone|standardized course of analgesics (opioids/acetaminophen/NSAIDs)
9719000|NCT04541303|Experimental|Intervention|Topical application of tranexamic acid to granulating wound defect status post Mohs micrographic surgery.
9719001|NCT04541303|Placebo Comparator|Placebo|Topical application of normal saline to granulating wound defect status post Mohs micrographic surgery.
9719002|NCT04541160||Suspected community-acquired pneumonia patients|Suspected community-acquired pneumonia patients that will be evaluated by an imaging method
9719003|NCT04541485|Experimental|Experimental: Cohort 1 (96 mg)|24 mg/0.1 mL x 4 sites
9719004|NCT04541485|Experimental|Experimental: Cohort 2 (288 mg)|72 mg/0.3 mL x 4 sites
9719005|NCT04541485|Experimental|Experimental: Cohort 3 (480 mg)|120 mg/0.5 mL x 4 sites
9719006|NCT04541485|Experimental|Experimental: Cohort 4 (672 mg)|168 mg/0.7 mL x 4 sites
9719007|NCT04541485|Experimental|Experimental: Cohort 5 (960 mg)|240 mg/1.0 mL x 4 sites
9719008|NCT04541329|Experimental|Tildrakizumab treatment|
9719009|NCT04541277|Experimental|Tislelizumab with DAN hypmethylation agent +/- chemotherapy|"Decitabine, 20 mg/m2/d, IV, on days 1-5; or Azacitidine, 75 mg/m2/d,SC, on days 1-7.~Aclamycin hydrochloride, 20 mg/d, IV, on day 1, 3, and 5 (For relapse/resistance AML, on days 1-5.); or idarubicin hydrochloride,10 mg/d, IV, on day 1, 3, and 5.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cytarabine,100 mg, IV, q12h/d. For patients with one of the following conditions, cytarabine,10 mg, SC, q12h/d: (1) There are obvious heart, lung, and kidney complications; (2) Bone marrow is hypoproliferative; (3) Age> 75 years old; (4) Age> 60 years old who are unfit for standard-dose chemotherapy.~Recombinant human granulocyte colony stimulating factor injection, 5 μg/kg, SC, from day 0 to stop of chemotherapy after the WBC count exceeds 10.0×10^9/L; or Pegylated recombinant human granulocyte stimulating factor injection Liquid, 100 μg/kg, SC, on day 0.~Tislelizumab,200 mg, IV, on the next day after chemotherapy was stopped."
9719010|NCT04541394|Experimental|MolecuLight group|Patients with infected wounds received MolecuLight photography during debridement operation to evaluate the adequacy of remission of infected biofilm and facilitate wound healing
9719011|NCT04541394|No Intervention|Control group|Patients with infected wounds received debridement operation by surgeon's clinical experiences to decide the extension of wounds
9719012|NCT04541316||Short term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-5 weeks post implantation
9719013|NCT04541316||Mid term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-4 months post implantation
9719014|NCT04541316||Long term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 6-8 months post implantation
9719015|NCT04541238||Novel template report|"The last 100 consecutive and anonymized MRI investigations for primary perianal fistula reported according to standard practice by dedicated radiologists (the last 10 reports from each of 10 international centers) are reviewed blindly and independently by two experienced radiologists (based on case load, years of experience and publications on anal fistula) using a novel template incorporating 8 key descriptors.~A third independent experienced radiologist will resolve any disagreement and assess the presence of descriptors in the original report compared to the novel template."
9719016|NCT04541199|Active Comparator|Conventional|
9719017|NCT04541199|Experimental|Closed-loop|
9719018|NCT04541264||Model reconstruction cohort|160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group.
9719019|NCT04541264||Internal validation cohort|40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group.
9719020|NCT04541264||External validation cohort|100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group.
9719021|NCT04541342|Experimental|osteoarthritic with genu varus|initial arthroscopy and high tibial osteotomy to be followed later by a second look arthroscopy with plate removal
9719022|NCT04541446|Experimental|Residents to receive Dynamic Haptic Robotic Training|
9719023|NCT04541446|Experimental|Residents to receive Advanced Dynamic Haptic Robotic Training|
9719024|NCT04541420||Eribulin|Eribulin 1.4mg/m2 d1,8 iv q3w
9719025|NCT04541134|Other|Group 1|
9719026|NCT04541134|Other|Group 2|
9719027|NCT04540991|Active Comparator|Ankylos dental implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Ankylos dental implants (Dentsplay Sirona, Charlotte, USA) areused in the first group of patients.
9779987|NCT04280458|Experimental|Intervention group|patients will receive intensive care of rehabilitation of psychomotor
9719028|NCT04540991|Active Comparator|Dentium SuperLine implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Dentium SuperLine implants (Dentium Co., Seoul, Korea) is used in the second group of patients-.
9719029|NCT04541615|Active Comparator|Group 1: Online didactic to proficiency PBP+|Group 1 Pre-trained group will receive information on how to optimally perform the ORSI chicken anastomosis task and the material will be delivered online via the ORSI e-learning platform. They will be given access to the material two weeks before their training. Unlike the other groups, Group 1 will be required to study the material to a pre-defined performance benchmark or proficiency level. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
9719030|NCT04541615|Active Comparator|Group 2: Online didactic PBP+|The Pre-trained group (Group 2) will receive the exact same information as Group 1 on how to optimally perform the ORSI chicken anastomosis task but they are not required to study the material to a pre-defined proficiency benchmark. The time they spend on the task and effort expended will be logged. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
9719031|NCT04541615|Active Comparator|Group 3: Standard training group|The standard trained group will receive face-to-face lectures on how to perform the ORSI chicken anastomosis task. It will not differ from what they would normally receive during a traditional surgery training course when they arrive at the ORSI academy for their training. The content of the face-to face lecture is the same as in the e-learning courses. After the face-to face lecture, the participants have to perform the orsi chicken anastomosis task.
9719032|NCT04541615|Active Comparator|Group 4: Apprenticeship Group|The apprenticeship trained group will not receive face-to-face lectures or e-learning on how to perform the ORSI chicken anastomosis task. They will however receive hands-on practical one-to-one training during a traditional surgical training course, with deliberate practice. During this course, clinicians will train the participants on how to perform the orsi anastomosis task. They will also receive published materials describing how best to perform the task and mentoring on suturing and knot tying by a task expert who will guide their performance.
9719033|NCT04541043|Experimental|active treatment|Nefecon 16 mg once daily by mouth for 9 months
10196548|NCT05184816|Experimental|Deferoxamine (DFO)|This study is an open-label, non-randomized, single-center, dose escalation phase 1a study of intrathecal deferoxamine (IT-DFO) in patients with leptomeningeal metastases (LM) from solid tumor malignancies, followed by a phase 1b dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with LM from non-small cell lung cancer (NSCLC). Study objectives will include safety (1a/1b), pharmacokinetics (PK) and pharmacodynamics (PD) of IT-DFO (1a/1b), and preliminary anti-tumoral efficacy in patients with LM from NSCLC (1b).
10196549|NCT05184803|Experimental|treatment|treatment arm(docetaxel, oxaliplatin, S-1)
9719036|NCT04541004|Experimental|HDM SLIT Tablet|House dust mite (HDM) Sublingual allergy immunotherapy tablet
9719037|NCT04541368|Experimental|Administration of CS1 Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
9719038|NCT04540874|Experimental|Treatment group|
9719039|NCT04540874|Placebo Comparator|Placebo group|
9719040|NCT04540926|Experimental|COVID-19 Pneumonia control group|COVID-19 pneumonia patients with standar treatment: enoxaparin 0.5 mg/kg S.C. once, Clarithromycin 500 mg twice an metylprednisolone 0.5 mg/kg once endovenous.
9719041|NCT04541251|Experimental|Camrelizumab + Nab-paclitaxel + Carboplatin|
9719042|NCT04540809||Psoriatic arthritis group (PsAG)|The evaluation was made using dynamometer, goniometer, mobile application, and Purdue pegboard test.
9719043|NCT04541095|Experimental|EX_IMF group|Infants will receive infants formula with large amounts of beta-palmitate (EX_IMF).
9719044|NCT04541095|Active Comparator|ST_IMF group|Infants will receive infants formula with low amounts of beta-palmitate (ST_IMF).
9719045|NCT04541095|No Intervention|HM group|Infants will receive human milk (HM).
9719046|NCT04541069|Experimental|Social Communication and Emotional Skill Development (SCESD)|This arm will get the intervention which is the Early Childhood Development (ECD) training.
9719047|NCT04541069|No Intervention|Control|This arm will not get any intervention.
9719048|NCT04540900|Active Comparator|KB301|non-integrating HSV-1 vector expressing human type III collagen injection
9719049|NCT04540900|Placebo Comparator|Placebo|sterile isotonic saline injection
9719050|NCT04540965|Experimental|Telaglenastat and Famotidine|Famotidine
9719051|NCT04540965|Placebo Comparator|Telaglenastat and Placebo for Famotidine|Placebo for famotidine
9719052|NCT04540783|Active Comparator|Group 1 - G1|bitemporal anodal stimulation and cathodal stimulation at supraorbital region.
9719053|NCT04540783|Active Comparator|Group 2 - G2|dorsolateral prefrontal anodal stimulation and cathodal stimulation at contralateral supraorbital region.
9719054|NCT04540783|Sham Comparator|Group 3 - G3|sham anodal stimulation over bitemporal or dorsolateral prefrontal cortex (randomized) and sham cathodal over the orbitofrontal region.
9719055|NCT04540653|Other|Standard vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, aged ≥50 years old, using a standard vaccination schedule (three doses of 20 μg, in months 0, 1, 6).
9719056|NCT04540653|Experimental|Reinforced vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, in individuals aged ≥50 years, using a reinforced vaccination schedule (three doses of 40 μg, in months 0, 1, 6).
9719057|NCT04540666|Experimental|VR group|VR program will be displayed throughout the surgery.
9719058|NCT04540666|Placebo Comparator|Non-VR group|VR program will be turned off throughout the surgery.
9719059|NCT04540731||NAFLD and diabetes/NASH and fibrosis|Patients with NAFLD and type 2 diabetes (or insulin-resistance) or with any stage of fibrosis in the inclusion visit will be followed over time in a prospective cohort study with scheduled visits. Patients without diabetes/insulin-resistance or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study.
9779988|NCT04280458|Active Comparator|Control group|patients will receive standard care
10196550|NCT05184790||Brain cancer|Patients having radiation therapy for treatment of brain cancer.
10196551|NCT05184790||Breast cancer|Patients having radiation therapy for treatment of breast cancer.
9719060|NCT04540731||NAFLD without diabetes/NASH without fibrosis|Patients without diabetes (or insulin-resistance) or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study
9719061|NCT04540562|Experimental|Intervention|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
9719062|NCT04540549|Experimental|intervention group|Jogging or cycling ≥5 days/week, 30-60 min/d
9719063|NCT04540549|No Intervention|control group|The control group was encouraged to maintain their lifestyle.
9719064|NCT04540354|Experimental|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will not receive an ICD device
9719065|NCT04540354|Active Comparator|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive an ICD device
9719066|NCT04540744|Experimental|Treatment Sequence AB|Participants will receive a single oral dose of fixed dose combination (FDC) of macitentan/tadalafil (10 milligram [mg]/20 mg) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of a free combination of 10 mg macitentan and 20 mg tadalafil in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
9719067|NCT04540744|Experimental|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
9719068|NCT04540692|Active Comparator|Start with Cyclophosphamide + Doxorrubicin|Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.
9719069|NCT04540692|Experimental|Start with Docetaxel or Paclitaxel|Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.
9719070|NCT04540679|Active Comparator|Inpatient - Standard Care Delayed Platform|Patient will receive standard inpatient care and provided access to the platform 6 weeks after inpatient discharge with support provided by the VIP coach.
9719071|NCT04540679|Active Comparator|Inpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the inpatient program
9719072|NCT04540679|Active Comparator|Outpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the outpatient program. If patient is transitioning from the inpatient program, their access to the platform will be guided by which group they were originally assigned to (i.e. if a 6 week delay is applicable).
9719073|NCT04540419|Experimental|Ad5-nCoV single dose|375 subjects, Ad5-nCoV containing 5E10 vp, single dose
9719074|NCT04540419|Placebo Comparator|Placebo single dose|125 subjects, Placebo containing 0 vp, single dose
9719075|NCT04540367|No Intervention|No Intervention: Control|Participants in this group performed the exercises without the blood flow restriction therapy cuff
9719076|NCT04540367|Experimental|Experimental: BFR|Participants in this group performed the exercises with the blood flow restriction therapy cuff
9719077|NCT04540614|Experimental|Intervention|70 participants receiving active comparator treatment plus experimental
9719078|NCT04540614|Active Comparator|Control|70 participants receiving active comparator treatment
9719079|NCT04540328|Other|Non-surgical peridontal treatment|Patients with chronic periodontitis received non-surgical periodontal treatment, including scaling and root planing and polishing within 14 days under local anesthesia with manual and ultrasonic devices and standardized oral hygiene instructions including methods of tooth-brushing and interdental cleaning were also given to each one. A professional supragingival plaque control was applied on a regular basis every month.
9719080|NCT04540640|Experimental|Subnormothermic Perfusion|Kidneys retrieved for transplantation will undergo subnormothermic oxygenated perfusion using the study device and perfusion solution for at least 1 hour prior to transplantation into the recipient.
9719081|NCT04540601|Active Comparator|Cancer patients, randomized A|Patients in high-dose antiresorptives with bone metastases
9719082|NCT04540601|No Intervention|Cancer patients, randomized B|Drug Holiday as standard operation procedure
9719083|NCT04540406|Experimental|NBT-NM108 + Usual Care|
9719084|NCT04540406|Active Comparator|Usual Care Only|
9719085|NCT04540627|Placebo Comparator|Placebo|Sodium Chloride 0.9% Solution (Normal Saline)
9719086|NCT04540627|Active Comparator|Palivizumab (Synagis™)|Sterile vial 50mg/0.5mL
9719087|NCT04540263||Sleeve Gastrectomy|Patients who underwent Sleeve gastrectomy operation
9719088|NCT04540263||Gastric Bypass|Patients who underwent Gastric Bypass operation
9719089|NCT04540393|Experimental|Arm A|Single arm
9719090|NCT04540289|Active Comparator|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
9719091|NCT04540289|Experimental|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
9779989|NCT04276779|Experimental|Alcohol and Negative Mood|
9779990|NCT04276779|Placebo Comparator|Placebo and Negative Mood|
9779991|NCT04276779|Active Comparator|Alcohol and Positive Mood|
9779992|NCT04276779|Placebo Comparator|Placebo and Positive Mood|
9719092|NCT04540510|Active Comparator|OPEP therapy added to standard pneumonia care|The intervention group will be asked to use an OPEP device twice daily, with the help of study investigators, for a total of at least 5 minutes per session. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the pneumonia.
9719093|NCT04540510|Active Comparator|Standard pneumonia care|The control group will continue to receive the usual care that their hospital team prescribe for them to treat the pneumonia.
9719094|NCT04540471|Experimental|MT group|The participants in MT group will receive music therapy 1 day per week for 1 hour with total 12hours in12 consecutive weeks after initial enrollment. Initial evaluation at the first session, including patient's vital sign, consciousness and spirit. The music therapy will consist of therapeutic singing, interpersonal communication, melody intonation therapy and rhythmic hands slapping. During therapeutic singing session, the music therapists will sing a song first and then the patients sing it after them. Interpersonal communication activity will be led by the music therapist and passed on to one patient to another patient. Melody intonation therapy will comprise communication, chatting and read aloud by using melody.
9719095|NCT04540471|Placebo Comparator|Control group|control groups will receive comprehensive in-patient education program for 12 consecutive weeks
9719096|NCT04540250||Study group of Rheumatoid arthritis patients|RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.
9719097|NCT04540237||Case|Patients with idiopathic granulomatous mastitis
9719098|NCT04540237||Control|Healthy volunteers
9719099|NCT04540224||Luminal A|Breast cancer patients with Luminal A phenotype
9719100|NCT04540224||Luminal B|Breast cancer patients with Luminal B phenotype
9719101|NCT04540224||Triple Negative|Breast cancer patients with Triple negative phenotype
9719102|NCT04540224||Control|Healthy volunteers
9719103|NCT04540159||Case|Advanced stage Colorectal cancer patients with intraabdominal ascites
9719104|NCT04540159||Control|Liver cirrhosis and congestive heart failure patients with intraabdominal ascites
9719105|NCT04540146||Case|End Stage Colorectal Cancer patients with intraabdominal ascites
9719106|NCT04540146||Control|Congestive heart failure and liver cirrhosis patient who had intraabdominal ascites
9719107|NCT04539925||Industrial area|
9719108|NCT04539925||Non-industrial area|
9719109|NCT04539990|Experimental|Behavioral Sleep Treatment|"Parents of children with autism will come to two group meetings (up to 5 families in each group) where they will be receive information regarding sleep hygiene and behavioral techniques for reducing sleep onset delays and night awakenings. The program will last 8 weeks. Meetings will be held on week 1 and week 3. In addition parents will receive a weekly phone call where they will be asked about their ability to implement the behavioral techniques.~Sleep of the children will be measured using questionnaires, sleep diaries and with a Fitbit sensor before and after the program."
9719110|NCT04540029||COVID-19 Exposed Pregnancy (CEP)|Women who were pregnant and delivered during the outbreak of COVID-19 pandemic in Italy, and their infants.
9719111|NCT04540029||Non-Exposed Pregnancy (NEP)|Women who were pregnant and delivered during an anticipated COVID-19 free period in Italy, and their infants.
9719112|NCT04540172|Experimental|Music Therapy|music therapy was applied in the practice room. Environmental noise was reduced as much as possible; the room was dimly lit. The students were asked to close their eyes after sitting comfortably in a chair and focus on the music by asking them to imagine a different memory and place that would relax them instead of the thoughts that occupied their minds. The music was played through a portable computer for 15 minutes under the supervision of the researchers using an mp3 player program on the computer.
9719113|NCT04540172|Experimental|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercises were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association. Warning messages were hung on the door of the room, environmental noise was reduced as much as possible, and the room was provided with dim lighting. The students were asked to close their eyes and breathe deeply after sitting comfortably in a chair. After taking two deep breaths, they were told to dangle their arms and relax as much as possible. The hands, shoulders, neck, chest, abdomen, hips, legs, feet, toes, and facial muscles were made to relax while they breathed and relaxed while exhaling. They were asked to store the experience into their memories thoroughly so that they could recall this feeling for comfort during the day."
9719114|NCT04540172|No Intervention|Control|No additional method was applied in the control group.
9719115|NCT04539912|Experimental|angulated screw-retained group(AG)|
9719116|NCT04539912|Active Comparator|cemented group (CG)|
9719117|NCT04539977|Experimental|ES-SCLC|"Induction therapy: TQB2450 1200mg, d1, q3w, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles.~Maintenance therapy: TQB2450 1200mg, d1, q3w, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
9719118|NCT04539977|Experimental|LS-SCLC|"Neoadjuvant therapy: TQB2450 1200mg, d1, q3w, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles.~Surgery or/and radiotherapy: the patients will receive surgery or/and radiotherapy, or multi-disciplinary treatment.~Adjuvant therapy: TQB2450 1200mg, d1, q3w, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
9719119|NCT04540055||Paravertebral (Group P)|Patients underwent MRM under the combination of general anesthesia and paravertebral block.
9719120|NCT04540055||General Anesthesia (Group G)|Patients underwent MRM under general anesthesia.
9719121|NCT04540081|Experimental|CLOVER arm|This arm will contain clinics that utilize the CLOVER intervention
9719122|NCT04540081|No Intervention|Standard of Care arm|This arm will contain clinics that do not utilize the CLOVER intervention
9719123|NCT04540185|Experimental|Standard dose bivalent oral polio vaccine|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
9719124|NCT04540185|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|Saline administered orally on a sugar lump
10196552|NCT05184790||Head and neck cancer|Patients having radiation therapy for treatment of head and neck cancer.
10196553|NCT05184790||Kidney cancer|Patients having radiation therapy for treatment of kidney cancer.
9719125|NCT04540185|Experimental|Standard dose of NA-831|Drug: neuroprotection NA-831 30 mg of NA-831in a capsule administered orally
9719126|NCT04540185|Placebo Comparator|Comparable Placebo- 30mg|30 mg of placebo in a capsule administered orally
9719127|NCT04540185|Experimental|Standard dose of bivalent OPV and NA-831|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump Plus 30 mg of neuroprotection drug NA-831 in a capsule administered orally
9719128|NCT04540185|Placebo Comparator|Comparable Placebo|Placebo of a vaccine administered orally on a sugar lump Plus 30 mg of a placebo in a capsule administered orally
9719129|NCT04539951|Active Comparator|serotonin treatment|In experimental phase I, all recruited subjects provide written informed consent before any related procedures. Participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
9719130|NCT04539951|Active Comparator|sequenced treatment alternatives|If participants in In Experimental phase I do not achieve remission, they will be will be randomly assigned to the second-step treatment (Experimental phase II). The second-step therapy will consist of five treatment options including higher-than-usual-maximal dosage of sertraline, switching to fluvoxamine, switching to venlafaxine, augmentation with memantine, and augmentation with aripiprazole.
9719131|NCT04540016|Other|Arm Ⅰ|25 mg of 80 µCi [14C]HSK7653.
9719132|NCT04539769|Active Comparator|BI group|Conventional Billroth I reconstruction
9719133|NCT04539769|Experimental|BII group|Billroth II reconstruction with 100-cm long biliopancreatic limb
10196554|NCT05184790||Liver cancer|Patients having radiation therapy for treatment of liver cancer.
10196555|NCT05184790||Pancreatic cancer|Patients having radiation therapy for treatment of pancreatic cancer.
9719134|NCT04539769|Experimental|RY group|Roux-en-Y reconstruction with 100-cm long Roux limb
9719135|NCT04539782|Experimental|Physiotherapy intervention|Pelvic floor muscle training given by a physiotherapist in four sessions and follow up phone calls twice in 14 weeks
9719136|NCT04539782|No Intervention|No intervention|Standard care
9719137|NCT04539860||Healthy Controls|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
9719138|NCT04539860||Patients|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
9719139|NCT04539847|Experimental|High-end hearing aid|Patients will be fitted with premium level hearing aid technology
9719140|NCT04539847|Experimental|Basic hearing aid|Patients will be fitted with basic level hearing aid technology
9719141|NCT04539886|Experimental|CellFX System|The CellFX System consists of a electrical pulse console combined with a handpiece coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm). Based on the size of the SH lesion and treatment tip used, a predetermined treatment energy setting is selected to deliver a sequence of electrical pulses to the SH lesion area directly beneath the treatment tip.
9719142|NCT04539886|Active Comparator|Intralesional Electrodesiccation|Intralesional Electrodesiccation involves using a Hyfrecator electrosurgical unit and a non-insulated epilation needle electrode to apply a high-frequency electric current within the lesion.
9719143|NCT04539600|Experimental|induction chemotherapy + anti-PD-1 antibody|Camrelizumab (200 mg, Q3w, 2 cycles in total) combined with induction chemotherapy (taxane-containing regimen, Q3w, 2 cycles in total) followed by concurrent radiotherapy and chemotherapy.
10196556|NCT05184790||Prostatic cancer|Patients having radiation therapy for treatment of prostate cancer.
10196557|NCT05184790||Spinal neoplasm|Patients having radiation therapy for treatment of spinal cancer.
10196558|NCT05184790||Cardiac arrhythmia|Patients having radiation therapy for treatment of cardiac arrhythmia
9719144|NCT04539626|Experimental|Estrogen Therapy|"Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg~Dosage form: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)"
9719145|NCT04539626|No Intervention|Control Group|Patients who will receive conventional COVID-19 treatment
9719146|NCT04539756|Active Comparator|Active control condition|Participants in the active control condition will receive the same number of text message reminders and will complete the same number of writing activities as the intervention group. The writing activity for the active control condition will ask them to list their activities for that day.
9719147|NCT04539756|Experimental|Positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
9719148|NCT04539821|Other|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials. First, the patient is mailed or emailed (based on their preference) an informational packet prior to intake appointment. Second, using the collaborative medication management model established in VHA,3 the intake appointment is led by the CPS using a standardized intake evaluation. The CPS and physician design a plan presented to the patient. If BUP switch is offered and accepted, the physician completes additional brief evaluations, including a history, medication review, treatment planning, and discussion of other VCPM components, using two-way audio-video visits (with telephone as a back-up).
10196559|NCT05184764|Experimental|AP-SA02|Anti-staphylococcal bacteriophage
10196560|NCT05184764|Placebo Comparator|Placebo|Inactive isotonic solution
10196561|NCT05184725|No Intervention|Control Group|Patients will follow the usual care procedures and after each procedure they answer questionnaires related to pain and stress levels (VAS), Anxiety and depression levels (HADS), health-related quality of life (HRQoL), mental wellbeing (SWEMWBS), self-efficacy (GSE) and Patient Activation status (PAM-13).
10196562|NCT05184725|Experimental|SaMD CARINAE|Intervention group will be exposed to the use of SaMD CARINAE for 2 months approximately, a patientcentred digital health support program. The intervention trial will include a total of 4 visits: 1. Baseline (2-4 weeks before surgery); 2. Hospital admission (1-3 days before surgery); 3. Hospital discharge (1 week after the surgery approx.); 4. Post-operative day 14 (2 weeks after the surgery approx). After each visit and intervention trial with SaMD CARINAE the experimental group answer the same questionnaires of the control group, above mentioned Participants allocated to the intervention group will also be asked to complete questionnaires about usability, satisfaction and subjective experience.
10196563|NCT05184712|Experimental|AK112 in combination with Pemetrexed and Carboplatin|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
10196564|NCT05184712|Placebo Comparator|Placebo in combination with Pemetrexed and Carboplatin|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
9719149|NCT04539613||group1|Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added
9719150|NCT04539613||group2|Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)
9719151|NCT04539587||adjuvant hormonal therapy for breast cancer|Women more than 18 years old, with hormone receptor-positive early BC, with completed surgery as well as chemotherapy and/or radiotherapy, if indicated, and had begun their hormonal therapy for less than 6 months.
9984521|NCT04014530|Experimental|Phase II pMMR|Mismatch repair proficient CRC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
10196565|NCT05184686|Active Comparator|noise(low-level) and RF(low-level)|
10196566|NCT05184686|Active Comparator|noise(high-level) and RF(low-level)|
10196567|NCT05184686|Active Comparator|noise(high-level) and RF(high-level)|
10196568|NCT05184686|Active Comparator|noise(low-level) and RF(high-level)|
10196569|NCT05184673|Active Comparator|hatha thermo-neutral|The hatha classes will hold each pose for 5 breaths in a room temperature (~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
10196570|NCT05184673|Active Comparator|hatha hot|The hatha hot classes will hold each pose for 5 breaths in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
10196571|NCT05184673|Active Comparator|flow thermo-neutral|The flow hot classes will flow from each pose (one breath per movement) a room temperature (~70 degrees Fahrenheit) space. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
10196572|NCT05184673|Active Comparator|flow hot|The flow hot classes will flow from each pose (one breath per movement) in a room heated to 95 degrees Fahrenheit. Yoga sessions will be led by a 500hr Registered Yoga Teacher. This reduces the risk for injury due to the extensive training the yoga teacher will have received and the knowledge of cuing and sequencing for best practice. All study personnel will be vaccinated against SARS-CoV-2, reducing the risk of spreading SARS-CoV-2.
10196573|NCT05184647||Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with total splenectomy for non Malignant hemoglobinopathie
10196574|NCT05184647||Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie|Children under 18 years olds with partial splenectomy for non Malignant hemoglobinopathie
10196575|NCT05184634|Active Comparator|Working group|The data of the control group will be compared with the data of the study group.
10196576|NCT05184634|Active Comparator|Control Group|The data of the study group will be compared with the data of the control group.
10196577|NCT05184621|Active Comparator|efficacy|Including Primary outcome: changes in axial length of the eye. Secondary outcome: Equivalent spherical lens variation Other indicators: ① Changes in visual acuity with lenses, corrected visual acuity, and intraocular pressure.② Observation of changes in corneal thickness, anterior chamber depth, ciliary body thickness, and crystal thickness.Observation of fundus tissue structure of macula and peri-optic disc area. Observation of fundus choroidal/retinal thickness.Adherence index: frequency of device use.
10196578|NCT05184621|Active Comparator|safety|"Description of safety parameters: Adverse events, device defects during the test.~Method and time selection for evaluation, recording, and analysis of safety parameters. Adverse events and device defects were recorded from the beginning of each subject's enrollment to the end of the group for evaluation. Safety indicators:① Incidence of allergic reactions.② Posterior image time more than 5 minutes.③ The decrease of near vision.④ The grade of side effects such as self-induced photophobia and blurred vision.⑤ Elevated intraocular pressure, headache, nausea, and vomiting, etc."
10196579|NCT05184608|Experimental|Cycling combined with cognitive tasks|
10196580|NCT05184608|Active Comparator|Cycling|
10196581|NCT05184595|Active Comparator|Carfilzomib delivered in OH only|"Patients receive the whole treatment in OH. Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
9719152|NCT04539691|Experimental|Magnet group|"Women wearing magnet~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
9719153|NCT04539691|Sham Comparator|Sham group|"Women wearing sham~a magnet, or sham device indistinguishable from the magnet (determined randomly), will be placed on her abdomen. If the pain is predominately in her abdomen, the device will be placed on the location with the most pain. If the pain is predominantly in the subjects back, the device will be placed on the lower abdomen on the midline between the umbilicus and the pubic bone."
9719154|NCT04539652|Experimental|Experimental group|
9719155|NCT04539639|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+Placebo 75mg Bid
9719156|NCT04539639|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 100mg Bid
9719157|NCT04539639|Experimental|Jaktinib 100mg Bid|Jaktinib 100mg Bid+ Placebo 75mg Bid
9719158|NCT04539639|Placebo Comparator|placebo|Placebo 100mg Bid+ Placebo 75mg Bid
9719159|NCT04539574|Experimental|Diagnostic (7T MRI)|Patients undergo 7T MRI over 60 minutes.
9719160|NCT04539496|Experimental|dose confirmation and the phase II study|To determine the MTD and RP2D of XZP-3287; To determine the RP2D of XZP-3287 combined with endocrine therapy; To determine the efficacy and safety of XZP-3287 in HR positive HER2 negative advanced breast cancer
9719161|NCT04539483|Experimental|HDIT101|Topical application of HDIT101 solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
9719162|NCT04539483|Placebo Comparator|Placebo to HDIT101|Topical application of placebo solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
9719163|NCT04539301||Derivation cohort|In the derivation cohort, we will determined the conversion factor linking apixaban, rivaroxaban, fondaparinux, or danaparoid measured level, on the one hand, and heparin anti-Xa activity, on the other hand.
9719164|NCT04539301||Validation cohort|"In the validation cohort, for each tested anticoagulant, we will used the conversion factor determined in the derivation cohort to infer the estimated level of anticoagulant from heparin anti-Xa activity:~estimated anticoagulant level = conversion factor for this anticoagulant × heparin anti-Xa activity~The agreement between measured and estimated levels of each factor-Xa inhibitor will be assessed."
9719165|NCT04539535|Experimental|Down syndrome|We did the General Movements Assessment on standard mattress and experimental mattress in infants with Down syndrome on the same day.
9719166|NCT04539535|Experimental|Typically infants|We did the General Movements Assessment on standard mattress and experimental mattress in typically infants on the same day.
9719167|NCT04539314|Placebo Comparator|Control group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%)
9719168|NCT04539314|Active Comparator|Dexmedetomidine 0.5 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 0.5 μg / kg as an adjuvant
9719169|NCT04539314|Active Comparator|Dexmedetomidine 1 μg group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 1 μg / kg as an adjuvant
9719170|NCT04539405||Memsorb|M for memsorbTM group with the minimal gas flow possible (sevoflurane administration at 0.2L.min-1) with the ventilator Draeger A-500 Perseus,
9719171|NCT04539405||Dräegersorb|D for DraegersorbTM group with gas flow at 2L.min-1 (classical sevoflurane administration) with the same ventilator Draeger A-500 Perseus.
9719172|NCT04539171|Experimental|Intervention|Pain neuroscience education (Health education) and Physical exercise program: 6 weekly sessions (2 hours each), and a reminder session one month later
9719173|NCT04539171|No Intervention|Control|Standard of care.
9719174|NCT04539145|Experimental|Chocolate PTA balloon|
9719175|NCT04539145|Other|POBA|Intervention with regular baloon
9719176|NCT04539509|Active Comparator|Monitoring|Participants will be given a heart rate monitor to wear on their wrist for the duration of the study (i.e. until recovered, or 8 weeks post-injury, whatever comes first).
9719177|NCT04539509|Placebo Comparator|Monitoring + Treadmill Test|In addition to wearing the heart rate monitor, participants will undergo a treadmill test at each appointment.
9719178|NCT04539509|Experimental|Monitoring + Treadmill Test + Specific Exercise Prescription|In addition to wearing the heart rate monitor, and completing a treadmill test at each appointment, participants will receive an exercise prescription based on the results of the treadmill test. They will be prescribed 30 minutes of structured aerobic exercise, 5 times per week, at a heart rate determined by their treadmill test.
9719179|NCT04539210|Experimental|Electric Welded Metal Framework|A preexisting or prepared flat surface area of the welding abutment of implant at central incisor position at one side (right or left) will serve as the welding point. A titanium bar will be shaped following the curvature of the implants positioned. At this point, temporary titanium implant abutments will be welded with the titanium bar in the oral cavity, using the Syncrystallization Unit. Finally, the prosthetic framework, created by welding the titanium bar to the implant abutments, will be removed and opaque will be applied in order to avoid metal shining through the acrylic resin. The framework is picked up to denture with hard liner, and screwed to the denture.
9719180|NCT04539210|Experimental|cast metal framework|On a verified analogue model, occlusion blocks will be constructed for adjustment of vertical dimension and bite registration. Afterwards, CCM abutments will be fastened over the analogues of the placed implants, followed by waxing, spruing and casting. The resultant cast metal framework will be inserted inside the patient's mouth on the right or left installed implants to insure passivity of fit. In case of framework misfit, separation will be performed using a disc, followed by intraoral splinting and soldering. After framework soldering, another try-in will be done to insure framework fit.
9719181|NCT04539288||Gestational diabetes mellitus|Women who were diagnosed GDM in 24-28 gestation weeks.
9719182|NCT04539340|Other|Cohort 1 GNR-055 (0.3 mg/kg)|GNR-055 (0.3 mg/kg) Single intravenous administration GNR-055
9719183|NCT04539340|Other|Cohort 2 GNR-055 (0.5 mg/kg)|GNR-055 (0.5 mg/kg) Single intravenous administration GNR-055
9719184|NCT04539340|Other|Cohort 3 GNR-055 (1 mg/kg)|GNR-055 (1 mg/kg) Single intravenous administration GNR-055
10196582|NCT05184595|Experimental|Carfilzomib delivered in OH and HaH combined|"Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.~For the HaH patients group, the first injection of each cycle is delivered in OH. The rest of the cycle is delivered at home by HaH after a clinical examination (by nurse or general practitionner).~Primary and secondary endpoints are collected at day 1 of cycle 3, 6, 9, 12, 18 and one month after.~Patients leave the protocol prematurely due to treatment failure, toxicity or patient wishes. For those patients, the end of study visit will be done one month after ending treatment."
10196583|NCT05184582|No Intervention|Standard|Routine information on the benefit of physical activity
9719185|NCT04539340|Other|Cohort 4 GNR-055 ( 2 mg/kg)|GNR-055 ( 2 mg/kg) Single intravenous administration GNR-055
9719186|NCT04539340|Other|Cohort 5 GNR-055 (3 mg/kg)|GNR-055 (3 mg/kg) Single intravenous administration GNR-055
9719187|NCT04539249|Experimental|Magnesium sulphate|Combination of intravenous magnesium sulphate, intravenous paracetamol and rectal diclofenac
9719188|NCT04539249|Active Comparator|Pentazocine|Combination of intramuscular pentazocine, intravenous paracetamol and rectal diclofenac
9719189|NCT04539158|Active Comparator|single-DCCV group|"Patients randomized to single-DCCV will be given a single 200J shock using the primary (or right anterior-left posterior) pair of pads."
9719190|NCT04539158|Experimental|dual-DCCV group|"Patients assigned to dual-DCCV will receive two simultaneous 200J shocks (from both the primary and secondary set of defibrillator pads), totaling 400J delivered."
9719191|NCT04539457|No Intervention|Usual care|Neither the 'Desktop Helper (version 10)' will be integrated in the EMR system nor the 'e-learning' will be offered to GPs. However, to prevent attenuation of usual care, GPs will be free to adjust any medication on their own initiative or to use any other aid to decrease inappropriate prescribing in COPD patients.
9719192|NCT04539457|Active Comparator|Only desktop helper|Only the 'Desktop Helper (version 10)' will be integrated in the EMR system. Specifically, GPs will receive a notification about the 'Desktop Helper (version 10)'. This notification will inform general practitioners about the option in the Medicom Smart Module to identify COPD patients with comorbidities who have one or more 'medication-comorbidity clashes' (i.e. undesired interactions between medications for COPD and comorbid conditions).
9719193|NCT04539457|Active Comparator|Only E-learning|Only the 'e-learning' will be offered to GPs. Herein, GPs, will be invited to perform an e-learning module which provide information about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
9719194|NCT04539457|Active Comparator|Both dekstop helper and e-learning|Both 'Desktop Helper (version 10)' will be implemented in the EMR system. GPs will subsequently be notified about the possibility to detect COPD patients with 'medication-comorbidity clashes'. The implementation of the 'Desktop Helper (version 10), will be accompanied by e-learning offered to GPs. about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
9719195|NCT04539197||IgG4-RD group|300 IgG4-RD were enrolled and followed up for more than 6 months. Peripheral blood of all patients were collected at baseline, disease remission and relpase for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline, each follow up were collected.
9719196|NCT04539197||other autoimmune disease group|200 patients( RA, SLE, pSS, BD, et al) were enrolled in this study. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
9719197|NCT04539197||IgG4-RD mimicker group|60 IgG4-RD mimickers (pancreatic cancer, cholangiocarcinoma, vasculitis, lymphoproliferative diseases, inflammatory bowel disease, kimura disease) were collected. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
9719198|NCT04539197||healthy control group|100 healthy controls were collected. Peripheral blood of healthy controls were collected at baseline for plasmablast/plasma cells detection. Demographic features of healthy controls were collected.
9719199|NCT04539132|Experimental|Intervention Group|"The intervention group will participate in the 6-month interdisciplinary comprehensive rehabilitation program. The ABI Wellness (ABIW) program aimed at this population would be 7 hours a week (2 days per week will be scheduled for the intervention group), consisting of around 4 hours of cognitive training (through specified drills, cognitive exercises focused on executive functioning), 1 hour of physical exercise, 1 hour of mindfulness sessions (meditation) and scheduled break times."
9719200|NCT04539132|No Intervention|Control Group|"The non-intervention group or control group will have all the same pre-tests administered as the intervention group, however, will not participate in the cognitive program. The control group will be required to complete the assessment periods only, however, keep a record of their daily activities in a log format which is presented in the materials included herein. No other intervention or programming will be provided."
9719201|NCT04539119|Experimental|Entecavir and Tenofovir|
9719202|NCT04539119|Active Comparator|Entecavir|
9719203|NCT04539379|Active Comparator|magnesium sulfate|intravenous infusion of magnesium sulfate at a dose of 4 gm intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..
9719204|NCT04539379|Active Comparator|labetolol|The patients will be given intravenous infusion of labetolol (Trandate™, 5mg/ml) available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with 20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the infusion as required every 15 - 30min to a maximum dose of 160mg/hr.
9719205|NCT04538820|Active Comparator|control|patients with BMI=18.5-24.9 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
9719206|NCT04538820|Active Comparator|4 mg|patients with BMI>30 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
10196584|NCT05184582|Experimental|Intervention|High-intensity interval and strength training during neoadjuvant chemotherapy
9719207|NCT04538820|Active Comparator|8 mg|patients with BMI>30 kg/m2 will be received 8 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
9719208|NCT04538833|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin-bound paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
9719209|NCT04538833|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel application, (placebo as a single infusion)
9719210|NCT04538885|No Intervention|control group|No intervention
9719211|NCT04538885|Experimental|experimental group|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)
9719212|NCT04538963|Experimental|Banded Tooth|This tooth will have an orthodontic band and glass ionomer cement placed as an intervention for interproximal incipient caries.
9719213|NCT04538963|No Intervention|Non-banded Tooth|This tooth will be monitored per standard of care; encourage good dental hygiene at home.
9719214|NCT04539002|Experimental|MS: Cycle|Twenty-two participants in the clinical trial arm will be randomized to MS:Cycle: an aerobic exercise intervention on a stationary ergometer. Participants will exercise thrice weekly for 30 minutes with graded supervision for 24 weeks.
9719215|NCT04539002|Active Comparator|MS: Take Control|Twenty-two participants in the clinical trial arm will be randomized to MS: Take Control (MSTC): a monthly, hour-long MS education control group led by a trained facilitator.
9719216|NCT04538807||Lumbar disc herniation|Patients are complaining of lower extremity radiating pain due to lumbar disc herniation.
9719217|NCT04539054|Experimental|Pre-Workout Condition|This condition consisted of the ingestion of one serving of the pre-workout supplement.
9719218|NCT04539054|Experimental|Caffeine Condition|This condition consisted of the ingestion of 6 mg of caffeine per kg of body mass.
9719219|NCT04539054|Placebo Comparator|Placebo condition|This condition consisted of the ingestion of a placebo.
9719220|NCT04538716|Experimental|SVF-gel|Transconjunctival blepharoplasty associated with associated with stromal vascular fraction gel (SVF-gel)
9719221|NCT04538716|Experimental|fat transposition|Transconjunctival blepharoplasty associated with fat transposition
9719222|NCT04538924|Other|MINOCA (group I) - conventional MI treatment|Traditional MI treatment with optimal doses of statin, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), beta-blockers (BB) and dual antiplatelet therapy (DAPT).
9719223|NCT04538924|Other|MINOCA (group II)|Treatment with a low-dose statin and ACEI/ARB. In case of vasospasm, calcium channel blockers.
9719224|NCT04538612|Experimental|measure capillary refill time|
9719225|NCT04539353||chronic pain|Patients with chronic pain, regardless of the cause of the pain.
9719226|NCT04539444|Experimental|CD19/22 CART cells combined with PD-1 inhibitors|Patients will receive PD-1 inhibitor on the first day after CART cell infusion
9719227|NCT04539418|Active Comparator|Vitamn K2 Treated patients|Vitamin K2 will be given to patients randomized to ARM 1 three times a week at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
9719228|NCT04539418|Placebo Comparator|Placebo Group|Placebo will be given to patients randomized three times a week to ARM 2 at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
9719229|NCT04538638|Active Comparator|Mesenteric Sparing ileocolic resection|Standard procedure for CD, ileocolic resection without removal of the mesentery.
9719230|NCT04538638|Active Comparator|Central mesenterectomy ileocolic resection|Experimental procedure for CD: ileocolic resection in which the mesentery is taken up to the level of the ileocolic trunc.
9719231|NCT04538547|Experimental|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
9719232|NCT04538547|Active Comparator|Non Accelerated Radiotherapy|Concurrent Chemoradiotherapy followed by 3 cycles adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday.
9719233|NCT04538846|Experimental|Culinary Art Therapy Group|Patients with eating disorders that will participate in a weekly session of culinary art therapy group.
9719234|NCT04538846|No Intervention|No Culinary Art Therapy Intervention|Patients with eating disorders that are not scheduled to come to the outpatients ward on the day of intervention.
9719235|NCT04538521|Experimental|Niacin in early-stage mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
9719236|NCT04538456||used electronic Patient Reported Outcome Measures|Lung cancer patients who have used the electronic Patient Reported Outcome Measures system before and after COVID-19 lock down or new patients who have completed their first electronic Patient Reported Outcome Measures after COVID-19 lock down.
9719237|NCT04538456||never used electronic Patient Reported Outcome Measures|Lung cancer patients who have never completed electronic Patient Reported Outcome Measures.
9719238|NCT04538417|Other|Residual Limb Pain in affected amputated limb|Patient has residual limb pain in amputated limb and is scheduled to receive standard of care treatment of cooled radiofrequency ablation.
9719239|NCT04538768|Experimental|Mesh Augmentated|
9719240|NCT04538768|Other|Direct Suture|
9719241|NCT04539015||Group-I|Patients randomized to the Group-I will receive PREVENA Plus, which is currently being used at our institution (Prevena, KCI) and it is FDA-approved device. Dressings will be applied under sterile conditions at the end of the surgery while still in the operating room and will continuously apply for 5 days.
9719242|NCT04539015||Group-II|"Subjects randomized to SOC surgical incision dressing arm will receive SOC dressing for 4 days immediately following surgery. The closed incision will be covered with materials which may include sterile gauze pieces, surgical tape and tegaderm.~Any material used for the SOC dressing will be documented."
9980667|NCT01394107||Pregnant|"50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.~Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent."
10196585|NCT05184530||Statin Group|AMI patients with Statin therapy.
9719243|NCT04538391|Active Comparator|bupivacaine group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.
9719244|NCT04538391|Active Comparator|meloxicam group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.
9719245|NCT04538391|Active Comparator|placebo group|included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline.
9719246|NCT04538326|Other|Single|Participants exercised in two counter balanced blocks: repeated (standard of care and self-paced repeated custom game) and random (Kinect game and game-paced random custom game). Exercise bouts were for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. Data were collected in a single session lasting two hours.
9719247|NCT04538443||hemodialysis group|One hundred children with ESRD who are treated with hemodialysis and their caregivers will participate in this study. They will be recruited from Nephrology Unit at Abo-Elreesh Hospital, Cairo University
9719248|NCT04538508|Experimental|Diathermy|Participants that receive 10 sessions of radiofrequency diathermy of 12 minutes of duration
9719249|NCT04538508|Active Comparator|Control|Participants that perform supervised exercises for three weeks
9719250|NCT04538872|Experimental|MS group implicit|
9719251|NCT04538872|Experimental|MS group explicit|
9719252|NCT04538872|Active Comparator|HC group implicit (Healthy Controls)|
9719253|NCT04538872|Active Comparator|HC group explicit (Healthy controls)|
9719254|NCT04538937||Subjects with eosinophilia and respiratory manifestation|
9719255|NCT04538937||Healthy subjects|
9719256|NCT04539080||Pre-operative transversus abdominis plane block|
9719257|NCT04539080||Post-operative transversus abdominis plane block|
9719258|NCT04538313|Experimental|High dose group|10^10 TIL
9719259|NCT04538313|Experimental|Low dose group|10^9 TIL
9719260|NCT04538313|Experimental|Extension set|The number of TIL is decided by dose escalation experiment.
9719261|NCT04538469||Group 1|Admitted prior to COVID visitation restrictions introduced
9719262|NCT04538469||Group 2|Admitted following the introductions of visitation restrictions due to COVID 19 pandemic
9719263|NCT04538781||Same Day Discharge|Patients undergoing a-fib ablation procedures who were closed with VASCADE MVP and were discharged the same day.
9719264|NCT04538677||F2F-Group|Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic.
9719265|NCT04538677||VC-group|Patients who preferred a video consult were seen over a video connection.
9719266|NCT04538365|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
9719267|NCT04538365|Experimental|Hand antisepsis with triclosan solution|Effectiveness of pre-surgical hand washing in reducing bacterial load using triclosan 0.5% solution
9719268|NCT04538625|Placebo Comparator|Placebo|Subjects randomized to the placebo arm, will receive oral doses of matching placebo tablets twice daily with or without food.
9719269|NCT04538625|Experimental|Crofelemer|Subjects randomized to the crofelemer arm, will receive oral doses of crofelemer 125mg delayed-release tablets twice daily with or without food.
9779993|NCT04260698|Experimental|omidubicel|"Omidubicel is a cryopreserved stem/progenitor cell based product comprised of:~Ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (cultured fraction (CF))~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. CF and NF, will be kept frozen until they are thawed and infused on the day of transplantation."
9779994|NCT04257058|Experimental|Electronic educational material|Participants will complete an online pre-test survey via REDCap. One week after the pre-test survey is completed, AYAs will be sent electronic media via email to review on their own. Study staff will confirm receipt and review of material and schedule a post-test survey to be completed in REDCap two weeks after material is reviewed.
9779995|NCT04256408|Experimental|Treatment group|Treatment group
9779996|NCT04255602|Experimental|low dose ticagrelor|After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation
9779997|NCT04255602|Active Comparator|standard dose ticagrelor|subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation
9779998|NCT04250402||Arm 1|"Endoscopic submucosal dissection. Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.~Other Name: ESD"
9779999|NCT04250402||Arm 2|"Distal subtotal gastrectomy with D2 lymphadenectomy. After exclusion of T4b, bulky lymph nodes, or distant metastasis case, distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally."
9780000|NCT04250402||Arm 3|Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
9780001|NCT04250402||Arm 4|Proximal gastrectomy with D2 lymphadenectomy. The type of reconstruction will be jejunal interposition with double anastomosis method.
9780002|NCT04248517|Experimental|mHealth intervention group|participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
9780003|NCT04248517|No Intervention|Treatment as Usual group|participants will undergo their routine treatment.
9780004|NCT04242394||Chronic gallbladder diseases|Routine ERCP participants with chronic gallbladder diseases
9780005|NCT04242394||Without Chronic gallbladder disease|Routine ERCP participants without chronic gallbladder diseases
9780006|NCT04238637|Experimental|Arm 1|Durvalumab
9719270|NCT04538690|No Intervention|Control Group|Age and sex matched non interventional, healthy control group
9719271|NCT04538690|Experimental|Exercise Group|Individuals who are taken part of shoulder exercises with painful shoulder disorders.
9719272|NCT04538976|No Intervention|Control|Patients in the control group will receive standard care.
10196586|NCT05184530||Ezetimibe Group|AMI patients with Statin plus Ezetimibe therapy.
9719273|NCT04538976|Active Comparator|Sildenafil|Patients in the Sildenafil group will receive standard care and targeted Sildenafil-treatment.
9719274|NCT04539067|Experimental|HMG group|Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG
9719275|NCT04539067|Experimental|H FSH plus HHMG|Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation
9719276|NCT04538079||Feasibility/Accuracy/Reproducibility|The first 20 participants will be analysed for feasibility and the first 40 ECHOs for accuracy/reproducibility of non-invasive Cardiac Output Monitoring with ECHO as reference Method.
9719277|NCT04538079||Prediction of Circulatory Failure|Together with the Feasibility/Accuracy/Reproducibility Cohort this group's results will be analysed for prediction of circulatory failure defined as an ultrasound abnormality (IVH grade 3 - 4) or death within the first two weeks of life.
9719278|NCT04538300|Active Comparator|Group Gum|"Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.~Degree of nausea and Abramowitz Emezis score were evaluated as the interventions. If PONV persists second chewing gum was gived. 15 minutes later PONV was evaluated. If PONV was persisted ondansetron 4 mg, then dexamethasone 4 mg , then propofol 10 mg intravenously were given, respectively."
9719279|NCT04538300|Active Comparator|Group Control|In Group Control, Degree of nausea and Abramowitz Emezis score were evaluated as the interventions in recovery room. If patients with moderate and severe nausea were given 4 mg ondansetron intravenously. If PONV continues, we planned to give dexamethasone 4 mg and propofol 10 mg intravenously, respectively.
9719280|NCT04538248||Continuous|Continuous
9719281|NCT04538248||Discontinuous|Discontinuous
9719282|NCT04537988|Experimental|Feasibility and usability intervention trial|Pre-post evaluation of a 3-month pilot-trial of an electronic health (eHealth) intervention
9719283|NCT04538027|Active Comparator|6 weeks|Microdiscectomy was done at 6 weeks of starting symptoms
9719284|NCT04538027|Active Comparator|3 months|Microdiscectomy was done at 3 months of starting symptoms
9719285|NCT04538027|Active Comparator|6 months|Microdiscectomy was done at 6 months of starting symptoms
9719286|NCT04538001|Experimental|Balloon implantation|Arthroscopic implantation of this sub-acromial balloon
9719287|NCT04538001|Active Comparator|Rotator cuff repair|Partial rotator cuff repair
9719288|NCT04538014|Experimental|Lu AF88434|
9719289|NCT04538196|Experimental|R Education|Invervention: Resident who receives education on documentation and coding at the beginning of the surgical rotation
9719290|NCT04538196|No Intervention|R no Education|Resident who does not receive information on documentation and coding at the beginning of the surgical rotation
9719291|NCT04538209||canditates for variceal eradication|patients with documented liver cirrhosis (Based on clinical, laboratory and ultrasonographic findings) undergoing either primary or secondary prophylaxis variceal eradication at endoscopy unit of El-Rajhi hospital, Assuit University
9719292|NCT04538235||Bi-block (Serratus and erector spinae block) group|"The Bi-block consisted in performing an ESP block followed by a SAP block on the side ipsilateral to the thoracic surgery. For the ESP block, 40 ml of Ropivacaine 2mg/ml were injected under the erector spinae muscle plane, at the level of the 4th thoracic vertebra. For the SAP block, 40 ml of Ropivacaine 2 mg/ml were injected under the serratus anterior muscle plane. The cumulative dose of Ropivacaine did not exceed 3 mg/kg.~Regional anesthesia was performed before surgery."
9719293|NCT04538235||Thoracic Epidural Analgesia (TEA) group|"The thoracic epidural was performed according to a standardized protocol, with a Tuohy needle via the median puncture technique, at the level of T4-T5 intervertebral space. After a test dose of 2 to 3 ml of Lidocaine, 5 to 10 ml of a mixture of Ropivacaine 2 mg/ml and Sufentanil 0.5 µg / mL were injected. Epidural continuous administration was performed with the same mixture of anesthetic connected to a CADD Solis ™ pump set according to a PCEA protocol adapted to the patient's weight (continuous flow rate from 3 to 6 ml/h, self-administered bolus dose from 3 to 5 ml, refractory period 30 min).~Regional anesthesia was performed before surgery."
9719294|NCT04538118||Patient with a shoulder problem|Patients with shoulder problems between 18-65 years of age and being volunteered
9719295|NCT04537975|Active Comparator|C2Rx|Hemofiltration device
10196587|NCT05184530||PCSK9i Group|AMI patients with Statin plus PCSK9i therapy.
9719296|NCT04537975|Active Comparator|Standard of Care (SOC)|Standard of Care based on protocol inclusion/exclusion criteria
9719297|NCT04538274|Experimental|Patient researcher intervention|Intervention conducted by trained patient researchers to restart CPAP in addition to usual care
9719298|NCT04538274|No Intervention|Usual care|Usual care
9719299|NCT04538157|Experimental|Comprehensive Geriatric Assessment|Specialist co-ordinated care (known as comprehensive geriatric assessment, or CGA) was developed to address medical, social, mental health, and physical needs with the help of a skilled multi-disciplinary team.
9719300|NCT04538157|No Intervention|Usual Care|Usual Care
9780007|NCT04238637|Experimental|Arm 2|Durvalumab in combination with Tremelimumab
10196588|NCT05184530||Triple Group|AMI patients with Statin plus Ezetimibe plus PCSK9i therapy
10196589|NCT05184517|Experimental|Arm I|Oph1 0.5% CsA ophthalmic formulation followed by Restasis 0.05% CsA ophthalmic formulation
10196590|NCT05184517|Experimental|Arm II|Restasis 0.05% CsA ophthalmic formulation followed by Oph1 0.5% CsA ophthalmic formulation
10196591|NCT05184491|Active Comparator|Naïve patients - ACO therapy|One hundred patients naive to H. Pylori eradication therapy will receive ACO therapy for 14 days (amoxicillin 1 g with breakfast and dinner, clarithromycin 500 mg with breakfast and dinner and lansoprazole 40 mg twice daily before meals).
10196592|NCT05184491|Experimental|Naïve patients - LNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
9719301|NCT04538053|Active Comparator|Intervention|Children will receive high-dose oral cefalexin 37.5 mg/kg/dose (max 1.5 g) four-times daily (QID) for 2 to 4 days followed by oral cefalexin 25 mg/kg/dose (max 1 g) QID for a total course of 3 weeks
9719302|NCT04538053|Active Comparator|Standard Therapy|Children will receive IV cefazolin 50 mg/kg/dose (max 2 g) three-times daily (TDS) for 2 to 4 days followed by oral cefalexin 25 mg/kg/dose (max 1 g) four-times daily (QID) for a total course of 3 weeks
9719303|NCT04538131|Active Comparator|conventional SCS|
9719304|NCT04538131|Experimental|sensor-driven position-adaptive SCS|
10196593|NCT05184491|Experimental|Naïve patients - MNDL therapy|One hundred patients naive to H. Pylori eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
10196594|NCT05184491|Experimental|Treatment-experienced patients- LNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
9719305|NCT04538183|Experimental|WO 5000|Body lotion pH 4 for topical application
9719306|NCT04538183|Experimental|WO 5001|Body lotion pH 5.8 for topical application
9719307|NCT04538183|No Intervention|No product use|Untreated control area
9719308|NCT04538105|Sham Comparator|Sham Injection|20cc of Normal Saline 0.9%
9719309|NCT04538105|Experimental|Articular Branch Block (ABB)|20cc of 0.5% Bupivacaine with epinephrine 1:200,000
9719310|NCT04538170||ORC|Group orchidectomy following cancer
9719311|NCT04538170||GAC|Group sex reassignment surgery
9719312|NCT04537780|Placebo Comparator|group 1|(Control group n= 22): Patients will receive Placebo once daily at bedtime for 12 weeks..
9719313|NCT04537780|Experimental|Group 2|"Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.~The treatment duration will be 12 weeks."
9719314|NCT04537754|Experimental|clinician|Comparison of LED and diode laser
9719315|NCT04537767|Experimental|ES group|Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.
9719316|NCT04537767|Placebo Comparator|control group|Patients randomly assigned to the control group were treated with placebo.
9719317|NCT04537728|Experimental|My Healthy Brain Version 2|an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of CD
10196595|NCT05184491|Experimental|Treatment-experienced patients- MNDL therapy|One hundred patients who were unresponsive to previous eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
10196596|NCT05184478|Experimental|Group A (MC then placebo)|Group A will receive medicinal cannabis during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive placebo during Treatment Period 2 (70 days).
10196597|NCT05184478|Experimental|Group B (placebo then MC)|Group B will receive placebo during Treatment Period 1 (70 days), followed by a 7 day dose reduction and 21 day wash-out period, then will receive medicinal cannabis during Treatment Period 2 (70 days).
9719318|NCT04537845||with cancer pain|
9719319|NCT04537845||without cancer pain|
9719320|NCT04537663|Experimental|Bacille Calmette-Guérin (BCG)|Intradermal injection of BCG-Vaccine SSI [Statens Serum Institut]) - Danish strain 1331.
9719321|NCT04537663|Placebo Comparator|Placebo|Intradermal injection of sterile 0.9% NaCl.
9719322|NCT04537858|Experimental|Virtual reality therapy first|Subjects with COVID-19 who will start the first day of the protocol with Virtual Reality tasks in the morning and then in the second period, in the afternoon, will perform the conventional exercises (n = 25)
9719323|NCT04537858|Experimental|Conventional therapy first|Subjects with COVID-19 who will start the first day with conventional exercises in the morning and in the second period, in the afternoon, will perform activity with virtual reality (n = 25).
9719324|NCT04537676||DFU Participants|A cohort of 200 DFU patients who have been prescribed the Podimetrics System by their healthcare providers will be recruited upon providing informed consent. Potential participants will be asked to indicate their interest in participating in this patient empowerment study during their initial phone consultation for mat set-up with the Podimetrics care-management team. Participants will be followed for one year and answer a set of identical questionnaires at three time points: at baseline, at 6-month and at 12-month post enrollment.
9719325|NCT04537819|Experimental|The main group|"1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Imupret oral drops in the age-related dosage of 6 times per day for 6 days with the subsequent transition to the regime of 15 drops / 3 times in a day according to the patient's condition.~6. Paracetamol as antipyretic, if necessary."
9719326|NCT04537819|Other|The comparison group|1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Paracetamol as antipyretic, if necessary.
9719327|NCT04537520|Experimental|Experimental Group|treatment with the device Kerecis Omega3 Wound
9719328|NCT04537520|No Intervention|Control Group|treatment with SOC treatment
9719329|NCT04537546|Experimental|Elasto compression belt|all patients must wear the belt 2 months after laparoscopic digestive surgery.
9719330|NCT04537689|Experimental|Ixekizumab|"Participants will be offered ixekizumab as first-line systemic treatment for moderate to severe PsO. The indication for ixekizumab will be equivalent to current registered indications. Standard dose of subcutaneous ixekizumab for moderate to severe PsO will be given at 160 mg at week 0, followed by ixekizumab 80mg at weeks 2, 4, 6, 8, 10 and 12, then 4 weekly thereafter, for a total duration of 6 months.~Ixekizumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO.~Relapses will be managed as per standard care."
9719331|NCT04537689|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
9719332|NCT04537611|Experimental|dHb contrast compared to gadolinium contrast imaging|Subjects will be referred for a clinical gadolinium contrast perfusion exam. Gas manipulation will be supplied by a programmable computer-controlled gas delivery system while subjects are in the MRI scanner. In addition to their prescribed clinical scans, two additional scans will be obtained: 1) a structural sequence (, followed by 2) a BOLD-EPI sequence while inducing changes of PO2. PO2 will be held at a baseline of 45-50 mmHg for 60s. For 10 s, the lung PO2 will be transiently raised to peak PO2 of 90-120 mmHg (normoxia) within 2 s transition, and then returned to baseline. Alternatively, the baseline may be at normoxia and the gas challenges will target PO2 of 45-50 mmHg. A total of 4 such ventilatory challenges will be applied over 6 min while maintaining normocapnia.
9719333|NCT04537494|Active Comparator|Prevention|Oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks
9719334|NCT04537494|Other|Treatment-as-needed|Supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age
9719335|NCT04537481|Experimental|Normal fertilization group|Sperm samples from the successful fertilization IVF cycles were collected.
9719336|NCT04537481|Experimental|Low fertilization group|Sperm samples from the low fertilization IVF cycles were collected.
9719337|NCT04537572|Other|Sample Collection Method|All subjects will provide samples via traditional phlebotomy, finger-stick, and saliva collection.
9719338|NCT04537702|Active Comparator|Tradition Counseling Group (TG)|After completion of baseline surveys, the TG subjects will be referred to a formal pre-test consultation with a genetic counselor. TG subjects will complete an electronic family history questionnaire (FHQ) within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review errors and clarify any ambiguities in the pedigree. The TG subjects will then meet with the genetic counselor. After counseling, participants will be given the option to undergo a multi-gene panel genetic test. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice, patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. Subjects will complete a post-education distress and anxiety survey (IES) either via an email link to a confidential REDCap survey link 1-2 weeks after formal consultation.
9719339|NCT04537702|Experimental|Streamlined Group (SG)|"After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. All subjects will then have the option to opt out and receive formal genetic counseling prior to making a decision about testing. If the subject elects to undergo genetic testing, she will fill out the standard genetic testing consent form. As per standard practice of the clinical genetic service at Duke Cancer Institute (DCI), patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. SG subjects will complete an FHQ within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review common errors and clarify any ambiguities in the pedigree. Subjects will complete a post-education distress and anxiety survey (IES) via either an email link to a confidential REDCap survey link or over the phone 1-2 weeks after education."
9719340|NCT04537585|Experimental|Tomeka|Number of participants with treatment-TOMEKA® usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour
9719341|NCT04537585|Experimental|"Vernonia amygdalina"|"Number of participants with Vernonia amygdalina herbs usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour"
9719342|NCT04537533|Experimental|first group|1st group (A) will include 30 patients: each one will receive 15mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 10mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
9719343|NCT04537533|Active Comparator|second group|2nd group (B) will include 30 patients: : each one will receive 5mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 1mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
9719344|NCT04537533|Placebo Comparator|Third group|3rd group (C){controlled group} will include 30 patients: each one will receive saline (placebo) injection and infusion all through the operation.
9719345|NCT04537468|Other|Skin sample collection|Skin sample collection for gene expression analyses.
9719346|NCT04537338||Active / Recovered Cases|"Active Cases:~Diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.~Most of the cases of Covid-19 are treated at CCSS hospitals or clnics.~Recovered cases:~Are subjects previously diagnosed with Covid-19 via a positive PCR test who were considered recovered because they had two consecutive negative PCR tests."
9719347|NCT04537338||Community control group|The community control group will be frequency-matched on age, sex and area of residence. Two controls per case will be selected as follows
9719348|NCT04537338||Household survey|"Are a household contact of a person diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.~A household will be defined as a group of persons living together who share a kitchen. To be considered eligible for inclusion a contact must have spent at least one night per week in the living area since onset in the index case."
9719349|NCT04537403|Experimental|Aim 1A|Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery
9719350|NCT04537403|Experimental|Aim 1B|Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery
9719351|NCT04537455|Experimental|Abnormal cardiac conduction|patients with abnormal cardiac conduction will undergo an ultra-high frequency electrocardiogram
9719352|NCT04537442|Experimental|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
9719353|NCT04537390|Other|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
9980668|NCT01394107||Control|50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
9719354|NCT04537325|Active Comparator|RenalGuard group|
9719355|NCT04537325|No Intervention|Control group|
9719356|NCT04537221||No transfusions|Patients receiving no perioperative blood transfusions (PBT)
9719357|NCT04537221||Transfusions|Patients receiving perioperative blood transfusions (PBT)
9719358|NCT04537312|Experimental|Supportive care (RNSM, surveys)|RNMS Surveys
9719359|NCT04537351|Experimental|CYP-001|The investigational medicinal product used in this study is known as CYP-001. The active agent in CYP-001 is Cymerus™ MSCs. CYP-001 is supplied as 100 million Cymerus MSCs formulated in 20 mL cryoprotectant medium. On D1 and D3, each participant randomised to receive CYP-001 will receive an IV infusion of 2 million Cymerus MSCs/kg of body weight (up to a maximum of 200 million cells per infusion).
9719360|NCT04537351|No Intervention|Standard of care|Control participants will be randomised to received standard of care treatment.
9719361|NCT04537091|Experimental|ESWT group: rESWT|rESWT treatment was applied to patients
9719362|NCT04537091|Experimental|PRP group: PRP injection|PRP treatment was applied to patients
9719363|NCT04536883|Experimental|Microscopy confocal|"The fibroscopy is carried out according to the usual procedure of the service. During the fibroscopy, for all patient, the confocal microscopy procedure begins.~After the end of confocal procedure, 5 to 6 transbronchial biopsies are performing"
9719364|NCT04537143||Control|Non-AMD eyes
9719365|NCT04537143||AMD|AMD eyes
9719366|NCT04537169||Mild congenital ptosis|children with mild congenital ptosis
9719367|NCT04537169||Moderate congenital ptosis|children with moderate congenital ptosis
9719368|NCT04537169||Severe congenital ptosis|children with severe congenital ptosis
9719369|NCT04536896|Active Comparator|Traditional face-to-face teaching method|In this arm, participants underwent a 6-hour traditional face-to-face lecture on breastfeeding education in a classroom at a university. Course was divided into 4 1.5-hour sessions during a time span of two weeks.
9719370|NCT04536896|Experimental|Breastfeeding smartphone app|In this group, participants downloaded a smartphone application which contained an online breastfeeding education course. Participants freely navigated through the smartphone app during a time span of two weeks.
9719371|NCT04536909||Non-surgical|A non-surgical group for comparison, they will conduct a training program tailored for the kyphoscoliotic patients. The inclusion criteria is the same as for the surgical group.
9719372|NCT04536909||Surgical|Patients operated with correction of kyphotic- or scoliotic deformity.
9719373|NCT04537000|No Intervention|control group|The strategies of red blood cell transfusion for the pediatric patients in this group will be made by the attending doctors in charge based on the current transfusion guidelines. The attending doctors decide when to start blood red cell transfusion and order the volume of the blood red cell as the usual clinical practice.
9719374|NCT04537000|Experimental|study group|For study group, the clinical condition score must be identified every time red blood cell transfusion is considered. The strategies of red blood cell transfusion for the pediatric patients in this group, including the trigger and the volume, will be made based on the comparison between the clinical condition score and the Hb concentration.
9719375|NCT04537182|Experimental|LVRS treatment group|A bilateral lung volume reduction surgery (LVRS) by video-assisted thoracoscopic surgery (VATS) is performed under general anesthesia with double lumen endobronchial intubation. Unilateral treatment is accepted in cases with severe adhesions or intraoperative instability making a bilateral procedure unsafe.
9719376|NCT04537182|Active Comparator|BLVR study group|Unilateral bronchoscopic lung volume reduction with endobronchial valves (EBV) is performed using a flexible bronchoscope under general anesthesia and under full attendance of an anesthesiologist. Valves are placed unilaterally in segmental or subsegmental bronchi in the target lobe with the goal of complete atelectasis.
9719377|NCT04537065||preterm infants without ROP|
9719378|NCT04537065||preterm infants with regressed ROP|
9719379|NCT04537065||preterm infants with threshold ROP|
9719380|NCT04537065||full-term infants|
9719381|NCT04536844|Experimental|Telehealth follow-up group|Rheumatoid arthritis patients in remission who will be followed by an electronic app
9719382|NCT04536844|Placebo Comparator|Conventional follow-up group|Rheumatoid arthritis patients in remission who will attend conventional prescheduled visits in the outpatient clinic
9719383|NCT04537130|Experimental|Experimental|The investigational medical product, the IN01 vaccine, will be administered in two phases to those patients in the experimental arm: the induction phase and the maintenance phase. During the induction phase IN01 vaccine will be administered on day 1 and will be repeated on Day 14, Day 28, Day 42 and day 56. During the maintenance phase, the vaccination will be administered every 2 months with the same dosage and administration mode as during induction.
9719384|NCT04537130|No Intervention|Control|The patients enrolled in the control arm of the study will receive standard of care.
9719385|NCT04537052|Experimental|Onl Femoral vein|Ultrasound-guided controlled injection begins, and the venous diameter and gap between valves are reduced
9719386|NCT04537260|No Intervention|Control Arm (Standard of Care)|The control group took the knowledge-based survey about induction of labor prior to meeting their provider (midwife or obstetrician) on the day of scheduled induction. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction with the labor and delivery process.
9719387|NCT04537260|Experimental|Intervention Arm (Educational video)|The intervention group had the opportunity to watch the 3-minute educational video. The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8. After watching the video, the participant was asked to take the knowledge-based survey. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction.
9980669|NCT01394120|Experimental|Tarteted Therapy|
9980670|NCT01394120|Active Comparator|Standard Chemotherapy|
9719388|NCT04537273||Localy advanced Cervical Cancer|Patients with Localy advanced Cervical Cancer confirmed by pathology, clinical exams and computed tomography scan, treated with concurrent chemoradiotherapy.
9719389|NCT04536818||Time to surgery ≤12 hours|Waiting time to surgery ≤12 hours from hospital presentation.
9719390|NCT04536818||Time to surgery >12 hours|Waiting time to surgery >12 hours from hospital presentation.
9719391|NCT04536922|Experimental|iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
9719392|NCT04536961|Experimental|Part A: Reference Treatment|
9719393|NCT04536961|Experimental|Part A Prototype|
9719394|NCT04536961|Experimental|Part C Reference Treatment|
10196598|NCT05184465|Experimental|Bupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% bupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
9719395|NCT04536961|Experimental|Part C: Prototype|
9719396|NCT04536961|Experimental|Part B: Treatment 1|
9719397|NCT04536961|Experimental|Part B: Treatment 2|
9719398|NCT04536961|Experimental|Part B: Treatment 3|
9719399|NCT04536961|Experimental|Part B: Treatment 4|
9719400|NCT04536961|Experimental|Part B: Treatment 5|
9719401|NCT04536987|Experimental|low-dosage robot therapy|12 sessions of robotic therapy over 4-5 weeks
9719402|NCT04536987|Experimental|hi-dosage robot therapy|24 sessions of robotic therapy over 8-10 weeks
9719403|NCT04536948|Experimental|Group 1|Cooling gel application
9719404|NCT04536948|Active Comparator|Group 2|Cold pack was applied
9719405|NCT04537117||Pediatric dentists|Pediatric dentists following Facebook groups for pediatric dentists and practicing dentistry nowadays
9719406|NCT04536805|Experimental|Metformin + SBRT at total dose of 30 Gray (Gy)|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy, (day 0 to day 10)"
9719407|NCT04536805|Experimental|Metformin + SBRT at total dose of 36 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy (day 0 to day 12)"
9719408|NCT04536805|Experimental|Metformin + SBRT at total dose of 25 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 5 Gy (day 0 to day 10)"
9719409|NCT04536779|Experimental|Individuals with low mobility (Disabled and Elder)|minimum 8-10 training sessions in at least three months.
9719410|NCT04536870|Experimental|STAREE Statin group|Participants in STAREE trial randomised to statin
9719411|NCT04536870|Experimental|STAREE Placebo group|Participants in STAREE trial randomised to placebo
9719412|NCT04536831|Experimental|Vitamin D group|Consisted of 48 patients selected on admission via lottery method those will be given Vitamin D mega dose
9719413|NCT04536831|Placebo Comparator|Normal Saline group|Consisted of 48 patients selected on admission via lottery method those will be given Normal saline
9719414|NCT04536610|Experimental|Experimental group|Providing structured OP education in addition to the informative leaflet. (The leaflet contained the same information as the OP education program)
9719415|NCT04536610|Active Comparator|Control group|Giving only the informative leaflet. (The leaflet contained the same information as the OP education program)
9719416|NCT04536558|Experimental|olanzapine plus fosaprepitant-based triple regimen|Olanzapine（5mg p.o. d1-d5）plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
9719417|NCT04536558|Placebo Comparator|Placebo plus fosaprepitant-based triple regimen|Placebo plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
9719418|NCT04536389||group A|women with normal uterine cavity and normal cervix by office hysteroscopy.
9719419|NCT04536389||group B|women with normal uterine cavity with hysteroscopically detected cervical abnormality.
9719420|NCT04536662|Experimental|Group hydrocortisone|
9719421|NCT04536662|Experimental|Group Prednisone|
9719422|NCT04536662|Experimental|Group Dexamethasone|
9719423|NCT04536649|Experimental|Standard-dose Photon Radiotherapy|The patients will receive standard-dose photon radiation (60Gy/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle)
9719424|NCT04536649|Experimental|Standard-dose Proton Radiotherapy|The patients will receive standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
9719425|NCT04536649|Experimental|Standard-dose Proton Radiotherapy plus Carbon-Ion Boost|The patients will receive carbon-ion radiation boost (15GyE/3F for residual lesion) priot to standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), then adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
9719426|NCT04536454|Experimental|[18F]FPyGal|"Cancer patients will first be treated with a tumor type-specific neo-adjuvant chemotherapy regimen (standard-of-care); subsequently, they will undergo surgical resection of their primary tumors in a curative intention.~After the end of the neo-adjuvant therapy a tracer injection with [18F]FPyGal solution will be administered (study intervention). Immediately after the injection a dynamic PET/MR imaging of the tumor sites including heart or large arterial blood pools will be conducted over 90 minutes."
9785209|NCT01245751|Experimental|Group 2: First Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
9719427|NCT04536753||Suspected large for gestational age (LGA)|Women with pregnancies suspected to be complicated by fetuses weighing more than the 90th centile on customised growth chart and induced for this reason prior to 287 days as the main indication without diabetes.
9719428|NCT04536753||Women with diabetes (DM)|Women with diabetes in pregnancy induced at between 259 and 266 days if on treatment and 273 days if gestational diabetes managed with diet alone.
9719429|NCT04536753||Control|All other women induced at or after 280 days of gestation
9719430|NCT04536675|Experimental|VI/UME|Anoro (Vilanterol 25mcg/Umeclinidium 62.5mcg) in Ellipta device Inhaled through mouth once daily
9719431|NCT04536675|Placebo Comparator|Control|Placebo (including lactose monohydrate) in Ellipta device Inhaled through mouth once daily
9719432|NCT04536363|Active Comparator|Standard therapeutic protocol|"Dexamethasone (4mg ampoule, intravenous)~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~Enoxaparin (40mg prefilled syringe)~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)~Low molecular weight heparin (5000IU prefilled syringe)"
9719433|NCT04536363|Experimental|Standard Therapeutic Protocol + PGE1 Analog|"Analog of PGE1 + Standard therapeutic protocol~Standard medical treatment:~Dexamethasone (4mg ampoule, intravenous)~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~Enoxaparin (40mg prefilled syringe)~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)~Low molecular weight heparin (5000IU prefilled syringe)"
10196599|NCT05184465|Experimental|Levobupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% Levobupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
9719434|NCT04536441|Experimental|Treatment|Ultra Brief Online Mindfulness-based Intervention
9719435|NCT04536441|Placebo Comparator|Control|This arm requires participants to answer questions about themselves.
9719436|NCT04536597|Experimental|Quince seed jelly group|
9719437|NCT04536597|Experimental|Breast milk group|
9719438|NCT04536597|Other|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
9719439|NCT04536636|Active Comparator|Control|The patients on this arm received usual medical care
9719440|NCT04536636|Active Comparator|DHA supplementation|The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)
9719441|NCT04536766|Experimental|Enhanced Sleep Health Education|50 families will be randomly assigned to receive sleep health education delivered in two telephone sessions by Beds for Kids staff members, in addition to receiving the standard Beds for Kids program (bed, bedding, written sleep education materials). The first session will occur approximately 2-3 days before bed delivery. The second 15-20-minute session will occur approximately one week following bed delivery. Sleep health education training and supervision of Beds for Kids staff members will be provided by board-certified Behavioral Sleep Medicine providers. Sleep health information will be manualized and will consist of evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs.
9719442|NCT04536766|Active Comparator|Beds for Kids Standard Program|50 families will be randomly assigned to the standard Beds for Kids program, which includes a bed, bedding, and written sleep education materials.
9719443|NCT04536740|Other|PDL-treated PWS|PWS treated with PDL before will be treated with PDT
9719444|NCT04536740|Experimental|without treatment PWS|PWS without treatment before will be treated with PDT
9719445|NCT04536584|Experimental|Arm A: personalized coaching for physical activities|This arm consists of providing patients with a personalized coaching focused on exercise and physical activity, with or without connected watch.
9719446|NCT04536584|Active Comparator|Arm B: standard supportive approach|The standard supportive approach will consist in recommendations made during visits with the oncologist. The delivery of post-treatment care by oncologists and their team systematically provide exercise advice patients including recommendations for strength training and aerobic activity.
9719447|NCT04536532|Experimental|HEC121120 tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
9719448|NCT04536532|Placebo Comparator|HEC121120 placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
9719449|NCT04536532|Active Comparator|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
9719450|NCT04536532|Placebo Comparator|entecavir placebo tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
9719451|NCT04536727|Experimental|Intervention|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content.
9719452|NCT04536727|Placebo Comparator|Wait list|Participants randomized to the wait list group, receive the 8-week Fit & Strong! intervention after the intervention group has completed it.
9719453|NCT04536415|Experimental|Oseltamivir Phosphate 75 mg capsules (Yangtze River)|During the study session, healthy participants will be administered a single dose of Oseltamivir Phosphate capsules 75 mg of Yangtze River Pharmaceutical (Group) Co., Ltd., China under Fed condition.
9719454|NCT04536415|Active Comparator|Tamiflu capsules 75 mg (Genentech, Inc.)|During the study session, healthy participants will be administered a single dose of Tamiflu capsules 75 mg of Genentech, Inc. under Fed condition.
9719455|NCT04536311|Experimental|Paravertebral block in surgical stabilization of rib fractures under awake or appropriate sedation|patients receive internal fixation for multiple rib fractures using paravertebral nerve block anesthesia in awareness status and keep spontaneous breath
9719456|NCT04536220||pancreatic mass diagnosed benign|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.
9719457|NCT04536220||pancreatic mass diagnosed malignant|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.
9780008|NCT04238338||high MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
9780009|NCT04238338||low MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
9780010|NCT04236947|Experimental|SCPP-YA group|SCPP-YA adapted to Chile consist of ten sessions promoting self-regulation strategies, prosocial, and problem-solving skills. It also includes a module (6 sessions) specially designed for substance use prevention, developing social competence, and assertiveness to deal with peer pressure. These 16 sessions will be implemented during an academic year (2020), and complemented with three booster sessions the following year (2021).
9780011|NCT04236947|No Intervention|Control Group|The control schools will continue providing their traditional preventive actions.
9980671|NCT01394133||HIV+ Female|HIV infected women between 21-40 years of age, not receiving oral contraceptives.
9780013|NCT04229992|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
9780014|NCT04229992|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
9780015|NCT04229992|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
9780016|NCT04229992|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
9780017|NCT04224766|Experimental|suprascapular nerve block with costoclavicular infraclavicular|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL bupivacaine 0.5%, then single shot US-guided costoclavicular block (CCB) with 10 ml bupivacaine 0.5%.
9780018|NCT04224766|Active Comparator|Interscalene brachial plexus block|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL bupivacaine 0.5%.
9780019|NCT04214587||baseline assessment group|n=150 patiënts for baseline assessment
9780020|NCT04214587||clinical need for reintervention group|n=20-30 patiënts for re-bronchoscopy
9780021|NCT04214587||clinical stable controls|n=20 stable treated control patiënts
9980672|NCT01394146|Experimental|Subjects with healthy kidney function|
9780022|NCT04210882|Experimental|12-week Moderate-Intensity Exercise Program|"Exercise intervention: Participants will complete 57 total sessions of moderate-intensity exercise (walking while tracking heart rate) over 12 weeks. Exercise intensity, frequency, and session duration will increase during the first 4 weeks of the intervention until participants are completing five (5) sessions weekly and walking for 30 min each session at 60-75% of Heart Rate Reserve (HRR) (moderate-intensity exercise), as follows:~Week 1: Three sessions, lasting ≥ 15 minutes, at 50-75% of HRR; Week 2: Four sessions, lasting ≥ 20 minutes, at 50-75% of HRR; Week 3: Five sessions, lasting ≥ 30 minutes, at 50-75% of HRR; Weeks 4-12: Five sessions, lasting ≥ 30 minutes, at 60-75% of HRR"
9780023|NCT04187378|No Intervention|Control Group|Body temperature of the patients will be measured in the pre-operative service and in the waiting room. Sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
9785210|NCT01245751|Experimental|Group 3: First Dose Participants ≥60 and <70 years of age|Herpes zoster history-negative participants ≥60 and <70 years of age who have never received Zoster Vaccine, Live
9980673|NCT01394224|Experimental|Levetiracetam IV Infusion (1500 mg)|
9980674|NCT01394224|Experimental|Levetiracetam tablets (1500 mg)|
9980675|NCT01394237||Operated by laparoscopic sacrocolpopexy|Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007
9980676|NCT01394263|Active Comparator|Zoladex goserelin implant.|Zoladex goserelin implant: D, L-lactic and glycolic acids copolymer. Injected subcutaneously into the upper abdominal wall.
9980677|NCT01394263|Experimental|Histrelin Acetate implant|Histrelin hydrogel implant, 3 cm x 3.5 mm, containing 50 mg of histrelin acetate, surgically placed subdermally into the inner aspect of the upper arm.
9719458|NCT04536129|Experimental|Group A: glaucoma|OSD patients with glaucoma
9719459|NCT04536129|Active Comparator|Group B: no glaucoma|OSD patients without glaucoma
9719460|NCT04536155||patient with chronic pain|
9719461|NCT04536233|Placebo Comparator|control group|
10196600|NCT05184465|Experimental|Hyperbaric bupivacaine|"Spinal anesthesia was administered to the patients for anesthetic support of the surgical intervention.Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table.Spinal anesthesia was performed with 3 ml of 0.5% Hyperbaric bupivacaine. Then the patient was placed on his back.Surgery was allowed to start after 40 minutes if the upper level of the sensory block reached the Th10 segment."
10196601|NCT05184439||Study group after surgery|33 children and adolescents (39 knees) with recurrent patellar dislocation were treated with MPFL reconstruction using the adductor magnus tendon between 2010 and 2012. The group is under clinical observation with evaluation being made.
10196602|NCT05184426||Exposed: Positive anti-HLA antibodies|Heart transplant patients who have developed antiHLA antibodies after transplant
9719462|NCT04536233|Experimental|experimental group|
9719463|NCT04536246|Active Comparator|BQT Group|Procedure on this arm = bone quadriceps tendon reconstruction
9719464|NCT04536246|Other|SBHT Group|Procedure on this arm = single-bundle hamstring tendon reconstruction
9719465|NCT04536506|Experimental|Treatment group|Bobath group received 45 min of sessions three times weekly for 12 weeks.
9719466|NCT04536506|Active Comparator|Control group|Vojta group received the following three times weekly for 12 weeks.
9719467|NCT04535973||study group|female postmenopausal women with burning mouth syndrome
9719468|NCT04535973||control group|female postmenopausal women without burning mouth syndrome
9719469|NCT04536259|Experimental|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
9719470|NCT04536259|Experimental|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
9719471|NCT04536259|Experimental|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
9719472|NCT04536090|Experimental|Isoquercetin (IQC-950AN)|1000 mg Isoquercetin b.i.d. on day 1, then 500 mg Isoquercetin b.i.d. for 27 more days, plus standard of care (as defined below)
9719473|NCT04536090|No Intervention|Standard of care|This arm will receive standard of care based on national guidelines. This may change as new information regarding best practice emerges.
9719474|NCT04536051|Experimental|Group 1a: single dose ChAdOx & paracetamol|Participants will receive a single standard dose of ChAdOx1 nCOV19 vaccine plus paracetamol
9719475|NCT04536051|Active Comparator|Group 1b: single dose MenACWY & paracetamol|Participants will receive a single dose of MenACWY plus paracetamol
10196603|NCT05184426||Non-exposed: Negative anti-HLA antibodies|Heart transplant patients without antiHLA antibodies with similar transplant date to its correspondent case.
9719476|NCT04536051|Experimental|Group 1c: two dose ChAdOx & paracetamol|Participants will receive two standard doses of ChAdOx1 nCoV-19 vaccine, 4-12 weeks apart, plus paracetamol
9719477|NCT04536051|Active Comparator|Group 1d: two dose MenACWy/saline & paracetamol|Participants will receive MenACWY prime, and Saline Placebo boost (0.5mL) plus paracetamol
9719478|NCT04536142||Brain tumors|Subjects with operable supratentorial brain tumors
9719479|NCT04536142||Healthy subjects|Healthy subjects
9719480|NCT04536493|Active Comparator|1 application|Patients receive single dose LET
9719481|NCT04536493|Active Comparator|3 applications|Patients receive 3 doses of LET
9719482|NCT04535960|Experimental|Liraglutide|Liraglutide Subcutaneous Total Dose 1.8mg daily for 6 weeks
9719483|NCT04535960|Experimental|Empagliflozin|Empagliflozin Tablets Total Dose 25mg daily for 6 weeks
9719484|NCT04536181|Placebo Comparator|3 months group|Subjects will receive 12-weeks of placebo following randomization
9719485|NCT04536181|Experimental|6 months group|12 Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone.
9719486|NCT04536428|Experimental|ClearEndoclip|This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.
9719487|NCT04536428|Active Comparator|EZ clip|This arm is a group in whom EZ clip would be used for the treatment of bleeding.
9719488|NCT04536714|Experimental|Intervention group|34 participants. Received Pythagorean Self-Awareness program
9719489|NCT04536714|No Intervention|Control group|35 participants. Received usual care
9719490|NCT04535895|Experimental|Simultaneous integrated boost arm|
9719491|NCT04536012|No Intervention|Control|Via the Way to Health platform, all patients will receive daily text messages that inform them of their previous day's step count for 24 weeks.
9785211|NCT01245751|Experimental|Group 4: First Dose Participants ≥50 and <60 years of age|Herpes zoster history-negative participants ≥50 and <60 years of age who have never received Zoster Vaccine, Live
9785212|NCT01245764|Experimental|GARDASIL™ 9 to 12 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
9719492|NCT04536012|Experimental|Intervention|"Participants have a 4-week ramp-up towards their step goal and are asked to maintain the goal for the rest of the study. They receive daily texts informing them if they met their step goal and biweekly texts to encourage walking for exercise.~Participants are entered into a game. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and partner to discuss ways they can help the participant meet their goal. Every 8 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
9719493|NCT04535947|Placebo Comparator|Vehicle|Vehicle
9719494|NCT04535947|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Active
9719495|NCT04536337|Experimental|ALG-000184|Oral tablet(s) of ALG-000184 in HV or CHB subjects once daily for up to 4 weeks
10196604|NCT05184374|Experimental|subcutaneous injection of gonadorelin is facilitated by GnRH pump|After non-dose GnRH stimulation test on day 1, GnRH pump pulse subcutaneous injection of gonadorelin on the next day until one month.
10196605|NCT05184361|Experimental|Intermittent energy restriction (IER)|"Initially participants will undergo 2-weeks of neutral energy balance (EB). After this, the IER will consist of: 2-weeks of energy restriction interspersed with 1-week in neutral EB (total of 23-week period).~At the end, 8-weeks in neutral EB will be required."
10196606|NCT05184361|Active Comparator|Continuous energy restriction (CER)|Similarly to IER, CER participants will undergo 2-weeks of neutral EB. After this, the CER will consist of: 16-weeks of continuous energy restriction. At the end, 8-weeks in neutral EB will be required.
9719496|NCT04536337|Placebo Comparator|Placebo|Oral tablet(s) of placebo in HV or CHB subjects once daily for up to 4 weeks
9719497|NCT04535908|Experimental|Hypofractionated radiotherapy|
9719498|NCT04535869|No Intervention|A)standard therapy group|No intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol
9719499|NCT04535869|Active Comparator|B)Standard Therapy group plus Ant-HCV drugs|Intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol plus sofosbuvir 400 mg and Daclatasvir 200mg
9719500|NCT04535856|Experimental|Low-dose group|"Low-dose group (5 x 10^7cells):~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 2 vials for low-dose group"
9719501|NCT04535856|Experimental|High-dose group|"High-dose group (1 x 10^8 cells):~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 4 vials for High-dose group"
9719502|NCT04535856|Placebo Comparator|Control group (placebo)|"Control group (placebo):~No Drug substance: 4 vials for Place group"
9719503|NCT04535622|Experimental|Exercise group|A structured exercise instruction for facedown posture-related pain will be provided to the patients, and patients will go through three times of self-exercise sessions everyday according to the training provided.
9719504|NCT04535622|No Intervention|Control group|Patients are going to maintain face-down posture but no specific exercise instruction will be provided.
9719505|NCT04535843||myasthenia gravis|300 MG patients are anticipated for precision diagnosis and disease monitoring.
9719506|NCT04535817|Experimental|Treatment Group|Subjects will receive subcutaneous treatment of 300mg of omalizumab during the 24-week treatment period. One injection will be administered every 4 weeks.
9719507|NCT04535830|Experimental|Flash glucose monitor system(FSL)|Except at baseline and at the end of the experiment,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month.
9719508|NCT04535830|No Intervention|Self-monitoring blood glucose(SMBG)|People at SMBG group will wear the sensor at baseline and at the end of the experiment for data analysis only,and will have a care visit every month.
9719509|NCT04535531|Experimental|SB206 10.3% berdazimer|SB206 10.3% berdazimer topically once daily
9719510|NCT04535531|Placebo Comparator|vehicle gel|Vehicle gel topically once daily
9719511|NCT04535570||Pre Transplant|All 20 patients will have the energy expenditure measured in the pre-transplantation in order to compare with post-transplant data.
9719512|NCT04535570||Post Transplant|All 20 patients will have the energy expenditure measured in the post transplantation in order to compare with the pre-transplant data.
10196607|NCT05184322|Experimental|Cohort 1|Cohort 1 will enroll 10 healthy participants, doses ranging from 2mg to 7mg.
9719513|NCT04535752|Experimental|ANX009, Single Ascending Doses|Single dose of ANX009 with a 7-day follow-up before escalation to the next dose level.
9719514|NCT04535752|Placebo Comparator|Placebo, Single Ascending Doses|Single doses of matching placebo
9719515|NCT04535752|Experimental|ANX009, Multiple Ascending Doses|ANX009 once daily on Days 1-14
9719516|NCT04535752|Placebo Comparator|Placebo, Multiple doses|Matching placebo once daily on Days 1-14
9719517|NCT04535804|Active Comparator|Aspirin group|100 mg of low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
9719518|NCT04535804|Placebo Comparator|placebo group|100 mg of placebo was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
9719519|NCT04535713|Experimental|Single arm|A total of 260 patients will receive gemcitabine 600 mg/m2 (maximum dose: 1000 mg) on D1 and D8, doxorubicin 18 mg/m2 on D1 and D8 (maximum dose: 32 mg), docetaxel 25 mg/m2 on D1 and D8 (maximum dose: 42 mg), on Days 1 and 8. After the first cycle, nivolumab 240 mg IV will be added on Day 1 of each cycle (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.
9719520|NCT04535765|Experimental|experimental group|The experimental group began to perform warm water sitz bath 6 hours after the operation (the day of the operation).Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
10196608|NCT05184322|Experimental|Cohort 2|Cohort 2 will enroll 10 healthy participants, doses ranging from 2mg to 15mg.
9719521|NCT04535765|Other|control group|The control group began to perform warm water sitz bath at 8:00 in the morning on the first day after the operation as usual.Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
9719522|NCT04535518|Active Comparator|the standard group|"IVIG 2 g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
9719523|NCT04535518|Experimental|the standard + infliximab group|"IVIG 2 g/kg once, given within 12 to 24 hours;~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.~Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours."
9719524|NCT04535739|Experimental|PCI group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy and prophylactic cranial irradiation。
9719525|NCT04535739|Other|control group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy。
9719526|NCT04535427|Placebo Comparator|Control|Participants in this arm will receive placebo per day.
9719527|NCT04535427|Experimental|Low dose L-arginine|Participants in this arm will receive 9g (3g tid) L-arginine per day.
9719528|NCT04535427|Experimental|High dose L-arginine|Participants in this arm will receive 15g (5g tid) L-arginine per day.
9719529|NCT04535700|Experimental|pioglitazone|
9719530|NCT04535700|Other|Standard of care treatment|
9719531|NCT04535388|Other|LK scleral lens|LK scleral lens (Lucid Korea LTD, Seoul, Republic of Korea) are worn for 12 weeks.
9719532|NCT04535375|Other|Preterm infants < 28 weeks gestational age|For infants born before 28 0/7 weeks, standard of care consists of brain ultrasound performed on admission, day 1, day 2, day 3, day 7, and then weekly until discharge.
9719533|NCT04535375|Other|Preterm infants born between 28 0/7 and 31 6/7 weeks|For infants born between 28 0/7 and 31 6/7 weeks, brain ultrasound is performed on admission, once between day 1 and 3, once between day 7 and 10, and then 2-weekly until discharge or transfer.
9719534|NCT04535362|Active Comparator|menthol cigarettes|Will smoke only menthol cigarettes for two weeks
9719535|NCT04535362|Active Comparator|non menthol cigarettess|Will only smoke non menthol cigarettes for two weeks
9719536|NCT04535245||LCI testing|LCI testing will be performed on all study subjects
9719537|NCT04535271|Experimental|Single arm|Trabectedin 24 h CIV 0.5 mg/m2 D1 and D8 Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8
9719538|NCT04535037|Experimental|DTPa-HBV-IPV/Hib Investigational Group|All subjects in this group receive 3 doses (2 primary doses and 1 booster dose) of DTPa-HBV-IPV/Hib vaccine co-administered with 3 doses of pneumococcal 13-valent conjugate vaccine at 2, 4, and 12 months of age.
9719539|NCT04535037|Active Comparator|DTaP5-HBV-IPV-Hib Comparator Group|All subjects in this group receive 3 doses (2 primary doses and 1 booster dose) of DTaP5-HBV-IPV-Hib vaccine co-administered with 3 doses of pneumococcal 13-valent conjugate vaccine at 2, 4, and 12 months of age.
9719540|NCT04535284|Experimental|Coaching|"Health Coaching-in-Context includes coaching by trained coaches up to 10 sessions over teleconference."
9719541|NCT04535284|No Intervention|Usual Care|The usual care group does not get any intervention but continues with any of their usual activities that would otherwise would have been provided to them.
9719542|NCT04535310|Experimental|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
9719543|NCT04535115|Experimental|Group 1|Starting LRM (Lung Recruitment Maneuver)
9719544|NCT04535115|Experimental|Group 2|Starting VtC (Tidal Volume Challenge)
9719545|NCT04535258|Other|First-movers|The first four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
9984522|NCT04012944|Experimental|Cordella™ Pulmonary Artery Sensor System|The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management
9719546|NCT04535258|Other|Second-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
9719547|NCT04535258|Other|Third-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
9719548|NCT04535258|Other|Fourth-movers|After three months, the last four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
9719549|NCT04535167|Experimental|PF-07304814|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
9719550|NCT04535167|Placebo Comparator|Placebo|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
9719551|NCT04534985|Experimental|Time Restricted Feeding|Instructed to eat within an 8-hr window, beginning within 3 hrs of waking. In addition, provide current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
9719552|NCT04534985|Active Comparator|Healthy Eating Advice without Time Restricted Feeding|Curriculum for the healthy eating control group will emphasize current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
9719553|NCT04535024|Experimental|Treatment Arm|"A total of 60 MSS oligometastatic colorectal cancer patients will receive multisite SABR followed by Sintilimab within one week from completion.~The dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
9719554|NCT04535336|Experimental|Vitality acupunch (VA)|The VA program took 40 minutes to complete and included 3 phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allowed the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands were used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group received the VA program led by the instructors, who were trained an certified by the PI, 3 times per week and 40 minutes per session for 6 months.
10196609|NCT05184322|Experimental|Cohort 3|Cohort 3 will enroll 10 healthy participants, doses ranging from 7mg to 30mg.
9719555|NCT04535336|Active Comparator|Control|Participants in the control group continued with their daily activities as usual.
9719556|NCT04535180||Hemophilia|
9719557|NCT04535206||With AT-Ⅲ, PC, PS activity decreased|Any decreased in AT-Ⅲ, PC, PS activity before catheter intubation is regarded as the exposure group
9719558|NCT04535206||AT-Ⅲ, PC, PS activity are at normal value|The activities of AT-Ⅲ, PC and PS are all at normal values before catheter intubation
9719559|NCT04534998|Experimental|Robotic-assisted partial nephrectomy|Partial nephrectomy will be performed using a robotic-assisted laparoscopic approach.
9719560|NCT04534998|Active Comparator|Open partial nephrectomy|Partial nephrectomy will be performed using an open retroperitoneal approach.
9719561|NCT04535063|Other|severe pneumonia arm|patients with severe COVID19 pneumonia defined by: spontaneous breathing patients with respiratory failure requiring O2 nasal cannula more than 3 L/min or reservoir oxygen mask and SaO2 less than 95% or patients with critical pneumonia define by mechanical ventilation with less than 300 mmHg PaO2/FiO2 or shock or multi-organic dysfunction
9719562|NCT04534595||Students attending SBHCs|The students enrolled in 5 schools with the school based health clinic implemented would be studied in terms of their experience during the COVID-19 pandemic.
10196610|NCT05184322|Experimental|Cohort 4|Cohort 4 will enroll 10 otherwise 'healthy' participants with obesity, doses ranging from 7mg to 30mg.
10196611|NCT05184322|Experimental|T2026 tablet|Tablet containing no ecnoglutide but T2026 2 participants receiving T2026 tablet will be enrolled in each cohort.
9719563|NCT04534621||Brazilian chiropractors|A cross-sectional survey will be performed with this population (Brazilian chiropractors) to assess outcomes regarding what is the current impact and what measures they have implemented while facing the COVID-19 pandemic.
9719564|NCT04534855|Experimental|Treprilimab treatment group|Treprilimab 240mg ivdrip Q3W until progression or unacceptable toxicity
9719565|NCT04534712||PROGRESSION|Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
9719566|NCT04534712||NON PROGRESSION|Cohort B with those who improved by two points on the ordinal scale without any further progression
9719567|NCT04534829|Experimental|Ultrasound-Guided SIJ RFA|"Utilizing short axis views, the S1, S2 and S3 foramen and tubercles would be localized and marked by a surgical skin marker. Then, the ultrasound transducer will be moved laterally to achieve a long axis view between the S1 and S2 tubercle. Local skin and subcutaneous tissue freezing would be performed with Lidocaine 1% utilizing a 30-gauge needle. An 18-gauge radiofrequency (RF) cannula will be directed utilizing an in-plane approach toward the S2 and S3 lateral branches between the S2 and S3 tubercles. A small amount of 1% lidocaine will be injected in order to provide comfort.~The RF generator will be set to continuous monopolar RF ablation and the needle will be heated to 80 degrees Celsius for 90 seconds. The needle will then be repositioned proximally to obtain a slightly larger burn in a similar fashion previously described. A similar approach will be utilized for the S1 lateral branch RF ablation between the S1 and S2 tubercles."
9719568|NCT04534829|Active Comparator|Fluoroscopic-Guided SIJ RFA|An anterior-posterior approach is used to identify the S1-S3 foramen. A 3-inch spinal needle would be used for marking. Local tissue freezing would be accomplished with Lidocaine 1% and a 30-G needle. An 18-G RF cannula will be positioned over the 12 o'clock position of the S1 foramen and a second cannula placed in the 2 o'clock or 10 o'clock position for the right and left respectively (4-5 mm distance between the cannula). A small amount of 1% lidocaine will be injected for comfort. A lateral projection is taken to ensure the needles are not placed into the foramen. The RF generator will be set to continuous bipolar RF ablation and heated to 80 degrees Celsius for 90 seconds. Then another 18-G RF cannula will be positioned at the 4 o'clock or 8 o'clock position (4-5 mm distance between the cannula) to achieve the second RF ablation. The third RF ablation will be performed with the RF cannula at the 6 o'clock position. An identical fashion is utilized at the S2 and S3 foramen.
9719569|NCT04534699|Experimental|Hepatic Impaired|KBP-5074 0.5mg tablet orally, Single dose
9719570|NCT04534699|Experimental|Matched-control Healthy|KBP-5074 0.5mg tablet orally, Single dose
9780024|NCT04187378|Experimental|Underbody Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown underbody blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
10196612|NCT05184322|Placebo Comparator|Placebo tablet|placebo containing no ecnoglutide or T2026 2 participants receiving placebo tablet will be enrolled in each cohort.
10196613|NCT05184283||Prospective Cohort|Information will be collected from participants regarding their physical activity assessment (standard exercise recommendations in the peritransplant period will be given to patients including 30-45 minutes ambulatory activity 3 to 5 times per week) and body composition assessment will be done by routine MRI with an additional 6-8 minute scan using AMRA® Profiler 4 MasS by performing volumetric quantification of fat and water images acquired with 2-point Dixon magnetic resonance imaging (MRI).
10196614|NCT05184270|Experimental|Sleep Measurements|LFP recording from STN using externalized wires or implanted neurostimulator, while simultaneously recording clinical surface EEG and applying AS during deep sleep.
9719571|NCT04534868|Other|Patient Acceptance and satisfaction for teledermoscopy|"The aim of the first part of the study is to evaluate patients' skin monitoring habits, their knowledge of skin cancer, and their preconceptions about new telemedicine tools such as teledermoscopy. This is a written quantitative questionnaire with answers to tick.~An explanatory folder will be given to patients and they will be asked to read it beforehand in order to allow a good understanding of the terms used and the goal of the project. This part will include 70 to 100 patients.~The second part of the study is a qualitative study and the aim of it is to evaluate the satisfaction, acceptance and future expectations of those who have benefited from teledermoscopy. Individual and anonymous interviews, lasting 15 to 20 minutes, intended for patients who have benefit of teledermoscopy at the office. An explanatory folder will also be given to the patients concerned in order to explain to them the procedure of the interview. This part will include 8 to 10 patients."
9719572|NCT04534751|Experimental|Intervention Group- Clotting Factor Concentrates|"Fibryga + Octaplex (Fibrinogen + PCC)~Fibrinogen Concentrate 4g (Fibryga) + Prothrombin Complex Concentrate 2000 IU (Octaplex) in the first and second massive hemorrhage protocol (MHP) packs."
9719573|NCT04534751|Active Comparator|Control Group: Standard FP transfusion|Frozen Plasma (FP)
10196615|NCT05184127|Experimental|MIR 19 ®|Study participants from experimental groups, in addition to standard COVID-19 therapy, received the MIR 19 ® (2 inhalations per day with a single dose of 1.85 or 5.55 mg at intervals of 7-8 hours for 14 days).The standard therapy in this group included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
10196616|NCT05184127|Active Comparator|Standard COVID-19 therapy|In the comparison group, therapy was carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.The standard therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
9719576|NCT04534543|Other|Imaging|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
9719577|NCT04534803|Experimental|BCG Vaccine|Participants randomized to the BCG arm will receive BCG vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
10196617|NCT05184114|Active Comparator|Recovered COVID-19 patients|Recovered COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
9719578|NCT04534803|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm.
9719579|NCT04534530||Experimental|"The experimental group systematic screening for ischemic heart disease will be identified during the screening period by performing at least one systematic screening examination, regardless of the frequency, for ischemic heart disease in patients. diabetics at very high cardiovascular risk, without known coronary heart disease, by at least one non-invasive functional cardiovascular exploration outside the resting ECG."
9719580|NCT04534530||Control|"The control group Absence of systematic screening for ischemic heart disease will be identified during the pre-selection period by the absence of a non-invasive functional cardiovascular exploration (examinations mentioned above) in T2D with very high cardiovascular risk, with no known coronary heart disease, apart from performing a resting ECG"
9719581|NCT04534816|Experimental|Indocyanine Green|patients abdominal injuries and repair will be investigated using Indocyanine Green
9719582|NCT04534790|No Intervention|Not radiotherapy|control group
9719583|NCT04534790|Experimental|Radiotherapy|patientis with treatment with radiotherapy 1 Gy to Whole lung.
9719584|NCT04534894||DM group and DCM group|DM group: type 2 diabetes with normal diastolic function DCM group: type 2 diabetes with diastolic dysfunction
9719585|NCT04534608||Asymptomatic children w/out an underlying condition|
9719586|NCT04534608||Asymptomatic children with underlying condition(s)|
9719587|NCT04534608||Children with COVID-19 symptoms w/out an underlying condition|
9719588|NCT04534608||Children with COVID-19 symptoms with underlying condition(s)|
9719589|NCT04534725|Experimental|prophylaxis|"This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months.~Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections."
9719590|NCT04534725|Experimental|Post-Exposure Prophylaxis|"This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days~Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections."
9719591|NCT04534725|Experimental|Moderate COVID-19 infection|"This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks~Participants will be followed for 60 days to assess effectiveness and safety."
9785213|NCT01245764|Experimental|GARDASIL™ 13 to 15 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
9719592|NCT04534725|Experimental|Severe COVID-19 infection|"This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.~Participants will be followed for 60 days to assess effectiveness and safety."
9719593|NCT04534777||Consciousness disorder patients|"The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches.~Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years."
9719594|NCT04534634|Experimental|Experimental group|IFN-α combined with CAR T-cells therapy
9719595|NCT04534634|No Intervention|Control group|CAR T-cells therapy
9719596|NCT04534504|Experimental|SG-uncut JJB|For SG-uncut JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
9719597|NCT04534504|Active Comparator|SG-JJB|For SG-JJB procedure, after SG was finished, the jejunum was transected 20-cm distal to Treiz ligament. After that, another 200-cm jejunum was measured and side-to-side jejunojejunal anastomosis was made. The anastomotic and mesenteric defects were closed by hand suture.
9719598|NCT04534764|Experimental|TEST/CONTROL|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Test/Control)
9719599|NCT04534764|Experimental|CONTROL/TEST|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Control/Test)
9719600|NCT04534426|Active Comparator|Postoperative topical arnica montana cream|In this arm, Arnica group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
9719601|NCT04534426|Active Comparator|Postoperative topical mucopolysaccharide polysulfate cream|In this arm, Mucopolysaccharide polysulfate group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
9719602|NCT04534426|Other|Control group|In this arm control group consisted of 20 patients who were treated with only standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
9719603|NCT04534491|Experimental|Oxytrol|Subjects decided to purchase Oxytrol.
9719604|NCT04534439|Experimental|APX-115|Oral administration of APX-115 400mg, daily
9719605|NCT04534439|Placebo Comparator|Placebo|Oral administration of APX-115-matching placebo 400mg, daily
9719606|NCT04534478|Active Comparator|Control Group|Prednisone 0.75mg / Kg / d 4 weeks; 0.5mg / Kg / d 4 weeks; 20mg / d 4 weeks; 10mg / d 6 weeks; 5mg / d 6 weeks (6m)
9719607|NCT04534478|Active Comparator|Experimental group|Prednisone 0.5mg / Kg / d 3 weeks, 20mg / day 3 weeks; 15mg / day 2 weeks; 10mg / day 2 weeks, 5mg / day 2 weeks and discontinue.
9719608|NCT04534465|Experimental|Dosing arm 1|MiraLAX Sachet (17g) + Flavor blend (2g mannitol total)
9719609|NCT04534465|Experimental|Dosing arm 2|MiraLAX Sachet (17g) + Flavor blend + additional 2g mannitol (4g mannitol total)
9719610|NCT04534465|Experimental|Dosing arm 3|MiraLAX Sachet (17g) + Flavor blend + additional 4g mannitol (6g mannitol total)
9719611|NCT04534465|Experimental|Dosing arm 4|MiraLAX Sachet (17g) + Flavor blend + additional 6g mannitol (8g mannitol total)
9719612|NCT04534465|Experimental|Dosing arm 5|MiraLAX Sachet (17g) + Flavor blend + additional 8g mannitol (10g mannitol total)
9719613|NCT04534062|Experimental|Group A|Participants in Group A will perform PNF D2 flexion and extension with free weights (PNF D2 FW) The intensity of exercise will be determined for each individual by using maximum repetition test (1 repetition maximum 1-RM). The intensity will be kept 50 % of the maximal load. 3 sets of PNF D2 FW Flexion (flexion-abduction and external rotation) and PNF D2 FW Extension (extension-adduction-internal rotation) respectively will be performed on each upper limb with 10 repetitions per set. All exercises will be performed with a rest interval of 30 seconds to 1 minute between the sets.
9719614|NCT04534062|Experimental|Group B|Participants in this group will perform 3 sets of PNF D2 flexion (flexion-abduction and external rotation) and extension (extension-adduction-internal rotation) respectively with elastic bands after assessing the 1-RM test starting with a lightest resistance and gradually progressing to the higher level. Subsequently, 71% to 86% of 1-RM will be taken as a target range of the resistance for the training that will be applied through Elastic Resistance Band in accordance with values that are provided on the Thera-Band website. Moreover, each set will consist of 10 repetitions for both D2 flexion and Extension and a resting interval of 60 seconds between two consecutive sets. The procedure will be repeated for both limbs.
9719615|NCT04534062|Experimental|Group C|The participants in the Group C or control group will perform the PNF D2 flexion and extension without any resistance. Three sets consist of 10 repetitions of each pattern for both upper limbs will be performed with an interval of 60 seconds between two consecutive sets.
9719616|NCT04534140|Experimental|HBKB Capsule|Experimental group participants will take one capsule of the HBKB botanical dietary supplement orally, once daily
9719617|NCT04534140|Placebo Comparator|HBKB Capsule Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
9719618|NCT04534075|Experimental|Additional dietary fiber through Psyllium husk|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. Altogether the fifteen capsules contains 5.5 g dietary fiber in psyllium husk.
9785214|NCT01245764|Experimental|GARDASIL™ 16 to 26 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
9719619|NCT04534075|Placebo Comparator|Placebo (no additional dietary fiber)|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. The capsules contain placebo (maltodextrin) and have a similar look as in the experimental arm.
9719620|NCT04534244|No Intervention|Control group|Treatment of the tributary veins by phlebectomy
9719621|NCT04534244|Experimental|Experimental group|Endovenous steam treatment of the tributary veins
9719622|NCT04534348||Control|All central-line-associated blood stream infections (CLABSI) diagnosed during the year previous the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
9719623|NCT04534348||CUROS|All central-line-associated blood stream infections (CLABSI) diagnosed during the year after the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
9719624|NCT04534296|Experimental|Early Mobilization Group (EM group)|Early mobilization will be performed in this arm. Critically ill children will be assessed for appropriate activity within 24 hours of intubation. When the safe criteria is met, early mobilization goals will be set according to the children's clinical conditions, developmental maturity, strength and endurance. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily.
9719625|NCT04534296|Active Comparator|Routine Care Group (RC group)|Routine care strategy without early mobilization will be performed in this arm. It includes the clinical status management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
9780025|NCT04187378|Experimental|Surgical Access Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown surgical access blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
9780026|NCT04187352|Experimental|CS1001+ Fluorouracil+Cisplatin|
9780027|NCT04187352|Active Comparator|Placebo+ Fluorouracil+Cisplatin|
9780028|NCT04185298|Active Comparator|Group 1 (No treatment)|Group 1: Participants will have continuous activity monitoring (via Fitbit)
9780029|NCT04185298|Experimental|Group 2 (Experimental)|Group 2: Participants will receive the mSIM treatment and have their activity monitored continuously (via Fitbit)
9780030|NCT04184362|Experimental|Experimental group tested at the active treatment site|The theranova empower device will be tested at the active treatment site.
9780031|NCT04184362|Sham Comparator|Control sham group tested at the sham control treatment site|The theranova empower device will be tested the sham control treatment site.
9780032|NCT04183673|Experimental|Laser-cryo-usual care|Sessions 5 days a week for 3 weeks. Each session includes laser therapy+ cryo-thermal followed by standard rehabilitation program
9780033|NCT04183673|Active Comparator|usual care|Sessions 5 days a week for 3 weeks. Each session includes only standard rehabilitation program
9780034|NCT04176549||Ectopic Pregnancy|Patients diagnosed with ectopic pregnancy Samples collected: Plasma, Serum, Urine, Oral swab, Vaginal Swab If surgery required for tubal ectopic: Fallopian tube, peritoneal washing, trophoblast
9780035|NCT04176549||Surgical termination of pregnancy|Patients undergoing elective surgical termination of pregnancy Samples collected: Plasma, Serum, Urine, Oral swab Vaginal swab, Trophoblast
9780036|NCT04176549||Elective hysterectomy and salpingo-oophorectomy|Patients undergoing elective hysterectomy and salpingo-oophorectomy Samples collected: Fallopian tube, peritoneal washing
9780037|NCT04172441|Experimental|dasiglucagon first then placebo|48 hours of dasiglucagon sc infusion starting at 10 µg/hr with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
9780038|NCT04172441|Experimental|placebo first then dasiglucagon|48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hr (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
9780039|NCT04142892|Experimental|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD). 3 weeks of (+/-3 days) of ONA treatment
9780040|NCT04128514||Enrolled subjects|"Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation.~The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects."
9780041|NCT04125693|Experimental|Cancer patients|Patients from completed Bayer clinical trials, who received rogaratinib as monotherapy or combination therapy for the treatment of cancer.
9780042|NCT04125498|Active Comparator|OMT|Osteopathic manual treatment
9780043|NCT04125498|Active Comparator|OMT plus self-massage|Patients will be submitted to OMT and then they will be invited to practice a self-massage at home.
9780044|NCT04125498|Sham Comparator|Placebo|Similar to OMT without pressure.
9780045|NCT04125498|Active Comparator|Placebo plus self-massage|Patients will be submitted to placebo manual treatment and then they will be invited to practice a self-massage at home.
9780046|NCT04120402|Experimental|EP-104IAR 25 mg|A single use intra-articular injection containing 25 mg of EP-104IAR
9780047|NCT04120402|Placebo Comparator|Placebo (vehicle)|A single use intra-articular injection containing no active ingredients
9780048|NCT04118062|Other|Metastatic Uveal Melanoma|Questionnaires and semi-structured individual interviews with patients with Metastatic Uveal Melanoma
9780049|NCT04118062|Other|Triple Negative Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Triple Negative Breast Cancer
9780050|NCT04118062|Other|Luminal B Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Luminal B Breast Cancer
9662448|NCT04010747|Active Comparator|Mental Health Services Consultation and Waitlist|This consultation will consist of a 30 minute appointment in which participants can speak with a clinician knowledgeable about psychosis treatment resources. He/she can recommend specific programs, educational websites, and/or support groups that might be relevant for the participant's family. Participants will then be placed on a 6-week waitlist, after which they will have the opportunity to participate in the active intervention (four sessions of MILO).
9662449|NCT04010396||Recipients of Bovine Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
9662450|NCT04010396||Recipients of Mechanical Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
9662451|NCT03988283|Experimental|Personalized neoantigen DNA vaccine|Patients will receive the vaccine on a 28-day cycle. It will be given weekly (+/- 3 days) during Cycle 1 (i.e., C1D1, C1D8, C1D15, C1D22) as a priming phase followed by booster injections on Day 1 (+/- 7 days) of each subsequent cycle (i.e., C2D1, C3D1, etc.). Vaccine administration will continue indefinitely until development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression.
9662452|NCT03986229|Active Comparator|With compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
9662453|NCT03986229|Active Comparator|Without compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
9662454|NCT03972202|Experimental|Patients with cerebellar ataxia (CA)|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
9662455|NCT03972202|Active Comparator|Matched controls|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
9662456|NCT03972202|Experimental|Additional healthy volunteers|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI) Transcranial magnetic stimulation (TMS)
9662457|NCT03943550|Experimental|RO7049665|Participants will receive a subcutaneous (SC) dose of RO7049665 every 2 weeks for 4 doses.
9662458|NCT03943550|Placebo Comparator|Placebo|Participants will receive a SC dose of matching placebo every 2 weeks for 4 doses.
9662459|NCT03934697|Experimental|Imaginal Exposure Session|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
9662460|NCT03933072|Experimental|patients with complete spinal cord injury|the planned interventions have been described in the section below
9662461|NCT03914014|Active Comparator|intervention|connective tissue manipulation
9662462|NCT03914014|Placebo Comparator|placebo ultrasound|placebo ultrasound
9662463|NCT03914014|No Intervention|control|control group
9662464|NCT03890900|Other|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
9662465|NCT03873493|Experimental|Venetoclax + Ibrutinib|Venetoclax at a predetermined dose according to a prescribed dosing schedule orally once daily (QD) plus Ibrutinib Dose A orally QD.
9662466|NCT03868540|Experimental|BI 1291583|
9662467|NCT03868540|Placebo Comparator|Placebo|
9662468|NCT03848325|Experimental|Sleep deprivation|All subjects will be provided an 8 hour opportunity for sleep (Night 1) followed by outcome assessment the next morning (Day 1). They will then be kept awake the subsequent 24 hours including Night 2, followed by outcome assessment the following morning (Day 2).
9662469|NCT03844048|Experimental|Venetoclax|Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.
9662470|NCT03843073|Experimental|Connected Catheter Users|
9662471|NCT03797690|Experimental|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure. End of treatment will be considered as the last session of needle aponeurotomy.
9662472|NCT03797690|Active Comparator|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy). End of surgical treatment will be considered as the removal of the stitches (two weeks after the surgical treatment).
9662473|NCT03781089|Experimental|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K < 4.0 mEq/L, and patiromer will be discontinued if K < 3.5 mEq/L.
9662474|NCT03781089|No Intervention|Usual care arm|Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
9662475|NCT03741881||Patients with haemophilia|Patients with haemophilia A or B and with or without inhibitors
9662476|NCT03719456|Experimental|Flexible ureteroscope|
9662477|NCT03714854|Active Comparator|Deep brain stimulation ON|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
9662478|NCT03714854|Placebo Comparator|Deep brain stimulation OFF|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
9662479|NCT03706079|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
10196618|NCT05184114|Experimental|non-COVID-19 patients with viral respiratory infections|non-COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
10196619|NCT05184114|Experimental|Volunteers as age and gender matched controls.|Volunteer controls will undergo one CMR examination. At time of CMR examinations, patients will have blood tests.
10196620|NCT05184114|Experimental|Volunteers who planning to receive a 2-dose COVID-19 vaccine as vaccination controls|Vaccination controls will undergo two CMR examinations. The scans will take place (i) within 2 weeks before received 1st dose of COVID-19 vaccine and (ii) within 2 weeks (preferably 5-7 days) after receiving the 2nd dose of COVID-19 vaccine. At time of CMR examinations, patients will have blood tests.
10196621|NCT05184101|Experimental|Nebulised heparin|Participants assigned to 'nebulised heparin' will receive nebulised heparin in addition to the standard care required as determined by the treating team.
9662480|NCT03706079|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
9662481|NCT03680872|Experimental|Spinal Cord Injury Participants|This group consists of individuals with tetraplegia receiving an investigational device called the Bidirectional Neural Bypass System.
9662482|NCT03667846|Placebo Comparator|Placebo|Placebo
9662483|NCT03667846|Experimental|Topiramate|Week 0-1: 25 mg qhs Week 1-2: 25 mg qAM, 25 mg qhs Week 2-3: 25 mg qAM, 50 mg qhs Week 3-4: 50 mg qAM, 50 mg qhs Week 4-5: 50 mg qAM, 75 mg qhs Week 5-6: 75 mg qAM, 75 mg qhs Week 6-7: 75 mg qAM, 100 mg qhs Week 7-8: 100 mg qAM, 100 mg qhs Week 8-10: 100 mg qAM, 100 mg qhs Week 10-12: 100 mg qAM, 100 mg qhs Week 12-14: 2-week taper
9662484|NCT03662906|Experimental|Electroacupuncture|Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.30 mm in diameter, 75 mm in length or 0.40 mm diameter, 100 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
9662485|NCT03662906|Sham Comparator|Sham electroacupuncture|Sham Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.20 mm in diameter, 25 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
9662486|NCT03635190|Experimental|Interventional|Orbital Circumferential Atherectomy
9662487|NCT03615976|Active Comparator|group A|group A with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done for all patients with arthroscopic patellar denervation will be done
9662488|NCT03615976|Active Comparator|GROUP B|operative group B with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score HIGH TIBIAL osteotomy will be done without arthroscopic patellar denervation
9662489|NCT03598478|Experimental|TC-MPT group|Tai Chi-muscle power training group
9662490|NCT03598478|Active Comparator|TC group|Tai Chi group
9662491|NCT03598478|Active Comparator|MPT group|Muscle power training group
9662492|NCT03598478|No Intervention|Control group|Usual medical care is allowed.
9662493|NCT03580928|Experimental|Acalabrutinib/Venetoclax/Obinutuzumab|"Acalabrutinib will be administered orally twice daily at 100 mg bid~Venetoclax will be administered orally once daily, with dose ramp-up from 20 mg up to a final dose of 400 mg~Obinutuzumab will be administered as per standard of care for 6 months with dosing at 100 mg on cycle 1 day 1, 900 mg on cycle 1 day 2, and then 1,000 mg on cycle 1 days 8, 15, and day 1 of cycles 2-6"
9662494|NCT03559855|Experimental|Real Essentials|The Real Essentials curriculum is delivered in class to students by the Center for Relationship Education staff. It consists of 5 to 6 hours of healthy relationship education.
9662495|NCT03559855|No Intervention|Class as Usual|For the Class-as-Usual condition, there is no change in class content. Teachers offer what they typically offer.
9662496|NCT03534323|Experimental|Duvelisib +Venetoclax,|"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.~Duvelisib will be administered orally twice daily~Venetoclax will be administered orally daily~All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation"
9662497|NCT03531853|Experimental|Imaging patients|Get uveitis patients and ER patients to image their eyes
9662498|NCT03530852|Experimental|Relizorb treatment|Patients will have tube feeds placed through chamber and evaluate wean from parenteral nutrition
9662499|NCT03520231|Experimental|Denosumab and Standard Chemotherapy|"Denosumab, given subcutaneously at a dose of 120 mg, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
9662500|NCT03520231|Placebo Comparator|Denosumab Placebo and Standard Chemotherapy|"Denosumab placebo, given subcutaneously, every 4 weeks.~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.~Calcium, orally at a dose of 1000 mg, once daily.~Vitamin D, orally at a dose of 400 IU, once daily."
9662501|NCT03517085|Experimental|DTX401 Dose 1|DTX401 solution for intravenous (IV) infusion
9662502|NCT03517085|Experimental|DTX401 Dose 2|DTX401 solution for intravenous (IV) infusion
9662503|NCT03517085|Experimental|DTX401 Dose 3|DTX401 solution for intravenous (IV) infusion
9662504|NCT03517085|Experimental|DTX401 Dose 4|DTX401 solution for intravenous (IV) infusion
9662505|NCT03513614|Active Comparator|ALND|Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla.
9662506|NCT03513614|Active Comparator|No ALND|Tailored axillary surgery followed by regional nodal irradiation including the full axilla.
9662507|NCT03458988|Other|All patients|Nellcor™ Adult SpO2 Sensor
9662508|NCT03456193|Experimental|LA transplantation|The left atrium and pulmonary veins will be transplanted into the recipient
9662509|NCT03451578|Other|Advanced Dry macular degeneration|
9662510|NCT03434509|Experimental|Tai Chi|Ongoing, continuous Tai Chi and mindful movement instruction, 1 hour, twice per week
10196622|NCT05184101|No Intervention|Standard care|Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin.
10196623|NCT05184049|Experimental|Epalrestat|oral epalrestat (50mg/ time, 3 times/day) + conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
10196624|NCT05184049|Experimental|The control group|conventional hypoglycemia + oral mecobalamin (0.5mg/ time, 3 times/day) for half a year
10196625|NCT05184023|Experimental|Treatment group|
9719628|NCT04534179|Experimental|Vacuum myofascial therapy and physical activity|The protocol would last 5 weeks, group received fifteen 30-minute sessions of vacuum myofascial therapy and fifteen sessions physical activity program similar to the control group per week.
9719629|NCT04534179|Active Comparator|Physical activity Program|The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 30 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
9719630|NCT04534257|Experimental|Angioplasty with SELUTION Sirolimus DCB|Subjects with infra-inguinal occlusive lesions will be treated with SELUTION Sirolimus DCB
9719631|NCT04534088|Active Comparator|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|The VR tool was an attention control and was not weight related.
9719632|NCT04534088|Experimental|Standard Behavioral Weight Loss plus Weight-Related VR app|The Intervention's VR tool was designed to enable practice of behavioral skills taught in weekly group meetings, including managing social and home environmental cues for eating and activity.
9719633|NCT04534101||Inpatient Subjects|Inpatients will be presented with an informed consent. If they sign the consent, they will then be given a VR headset pre- programmed with content that they may use for the duration of their stay. GI patients headsets will be collected when they are discharged. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford. Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered. Patient who are hospitalized for chronic pain will be allowed to take the VR headset home for month and be asked to return it at their followup outpatient visit.
9719634|NCT04534101||Outpatient Subjects|Outpatient: Patient's who are about to undergo gastrointestinal disease testing or be seen for an outpatient GI appointment will be presented with an informed consent. If they sign the consent, they will be given the VR headset to use prior to their procedure. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford Medicine Box.Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered.
9719635|NCT04534192|Experimental|JADE balloon|Non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C & D lesions in patients with chronic limb threatening ischemia.
9719636|NCT04534374|Experimental|Resistance exercise|The experimental intervention is a session of resistance exercise described in the intervention section.
9719637|NCT04534374|Active Comparator|Stretching exercise|The active control intervention is a session of stretching exercise described in the intervention section.
9719638|NCT04534452|Experimental|Phenylephrine HCl|Subjects have a documented and/or self-reported history of allergic rhinitis with nasal congestion for at least 2 years.
9719639|NCT04534010|Experimental|NACgraft patients|uni- or bilateral engraftment surgery will be performed
9719640|NCT04534582|Experimental|HLX14 group|HLX14 are given subcutaneous injection at a single dose of 60 mg.
9719641|NCT04534582|Active Comparator|EU-Prolia® group|EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
9719642|NCT04534036|Active Comparator|Multi-Strain Synbiotic (PDS-08)|PDS-08 is a rationally defined microbial consortium consisting of 9 strains, with FOS-inulin as prebiotic. Participants will be instructed to take 1 sachet daily for the duration of the trial.
9719643|NCT04534036|Placebo Comparator|Placebo|Placebo sachets for PDS-08 will contain potato or tapioca maltodextrin matched for color and texture. Participants will be instructed to take 1 sachet daily for the duration of the trial.
9719644|NCT04533971|Experimental|WBC group|"Criteria~documented diagnosis of MS,~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3~no contraindications for WBC treatments found in the medical examination~no other serious chronic diseases identified that may affect the results of the tests carried out~readiness to participate in daily WBC~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
9719645|NCT04533971|No Intervention|Control Group|"Criteria~documented diagnosis of MS,~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3~no contraindications for WBC treatments found in the medical examination~no other serious chronic diseases identified that may affect the results of the tests carried out~readiness to participate in daily WBC~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
9719646|NCT04533672|Experimental|Single study arm|
9719647|NCT04533789|Experimental|the control group|Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
9719648|NCT04533789|Experimental|virtual reality|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min.
9719649|NCT04533789|Experimental|Task oriented|Group 3 the study group received the same physical therapy program 30 min. plus task oriented training for 30 min.
9780051|NCT04118062|Other|Pediatric Cancer|Questionnaires and semi-structured individual interviews with parents of children with cancer.
9780052|NCT04118062|Other|Expert Patients|Focus groups (or group interviews) and DELPHI consensus method with expert patients
9780053|NCT04118062|Other|Researchers and Clinicians|Focus groups (or group interviews) and DELPHI consensus method with Researchers and Clinicians
10196626|NCT05184023|Sham Comparator|Sham group|
10196627|NCT05184010|Experimental|arthroscopic release with ulnar nerve mini open release|
9719650|NCT04533776|Experimental|PEER-INTERACTION GROUP SUPPORT|"All the sessions of the research took place in a classroom in the hospital. The sessions lasted an average of 90 minutes with two 45-minute sections. During the break, which lasted about 20 minutes, gluten-free products were offered. During the break, adolescents were given the opportunity to chat and interact with each other.~Peer interactive group support was implemented for 3 months with an interval of one week. A total of 6 sessions were held with the study group. Adolescents in the study group were contacted by phone before each session. The day before the session, a text message was sent to all participants informing the location and time of the meeting. The contents of the first and second sessions in relation to the study were created beforehand. However, contents of the third, fourth, fifth and sixth sessions were prepared after the first two sessions."
9719651|NCT04533776|Experimental|routine health care- control group|Peer interactive group support was not provided to the control group.
9980678|NCT01394289|Experimental|Biological/Vaccine: Lolium allergen extract|Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
9719652|NCT04533932||Elastography|
9719653|NCT04533828|Experimental|68Ga-FAPI-04 PET/CT scanning|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
9719654|NCT04533607|Active Comparator|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
10196628|NCT05184010|Placebo Comparator|arthroscopic release alone without ulnar nerve mini open release|
9719655|NCT04533607|No Intervention|Waitlist control|Services as usual.
9719656|NCT04533646|Experimental|Fixed Dosing, Followed by Carbohydrate Counting|Dosing of premeal insulin with fixed doses
9719657|NCT04533958|Experimental|HypnoVR Arm|During each Docetaxel infusion, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
9719658|NCT04533958|No Intervention|Control Arm|Patients receive the docetaxel infusions under standard conditions (no medical hypnosis in virtual reality intervention)
9719659|NCT04533841|Active Comparator|Misoprostol + propranolol|Patient who receive misoprostol then after 30minutes receive propranolol
9719660|NCT04533841|Placebo Comparator|Misoprostol + placebo|Pt who will receive misoprostol then after 30minutes receive placebo
9719661|NCT04533698||Resternotomy|
10196629|NCT05183997|Placebo Comparator|Group (A) : 30 patients (control group):|Patient will receive 20 to 30 ml bupivacaine plus 2 ml of normal saline .
9719662|NCT04533698||No resternotomy|
9719663|NCT04533984|Experimental|Intervention with 28-day self-injection of Forteo|The active study medication FORTEO is recombinant human parathyroid hormone analog, [rhPTH]. The study medication Forteo (teriparatide [rDNA origin] injection) (Eli-Lilly, Indiana, USA), will be self-administered via a blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20 mcg dose of the medication daily for 28 days. Following this period the participant will receive standard physical therapy until full-return to duty.
10196630|NCT05183997|Experimental|Group (B) : 30 patients (verapamil group):|Patient will receive 20 to 30 ml bupivacaine plus 5 mg of verapamil diluted in 2 ml of normal saline.
10196631|NCT05183971||(1) Degenerative Cervical Myelopathy|Chinese subjects aged 40 or above who have radiological evidences of Degenerative Cervical Myelopathy, both symptomatic and asymptomatic with Nurick Grade less than 3 will be included.
10196632|NCT05183971||(2) Healthy Controls|Chinese healthy controls aged 40 or above who have no myelopathic sign of Degenerative Cervical Myelopathy with Nurick Grade less than 3 will be included.
9719664|NCT04533984|Placebo Comparator|Placebo with 28-day self injection of inactive substance|Participants will self-administered a placebo substance normal in a replica, blinded, injection pen via in the abdominal wall or thigh daily for 28 days. Following this period the participant will receive standard physical therapy until full-return to duty.
10196633|NCT05183958|Experimental|Combined radiotherapy group|"Chemotherapy :TP program (paclitaxel 175mg/m 2 d1, carboplatin AUC=5 d1 IV Q3W; or paclitaxel 175mg/m 2 d1, cisplatin 75mg/m 2 d1, or paclitaxel 175mg/m 2 d1, cis Platinum 25mg/m 2 d1-3 IV (Q3W, up to 4 cycles). Fluorouracil + cisplatin, cisplatin 80 mg/m 2 d1 IV and 5-Fu 800 mg/m 2 continuous IV d1-5 Q3W (up to 4 cycles).Or cisplatin 50mg/m 2 IV d1; LV 200mg/m 2 IV d1; 5-Fu 2000mg/m 2 24 hours continuous IV d1; or cisplatin 80mg/m 2 IV d1, capecitabine 1000mg/m 2 PO BID d1-14.~Camrelizumab :200mg every 3 weeks,maximum 6 cycles.~The experimental group received radiotherapy of the lesion within 8 weeks after the end of chemotherapy and immunotherapy. Immunotherapy shall be started within 8 weeks after the end of all radiotherapy.~The maintenance immunotherapy of the two groups was: Camrelizumab 200mg Q3W, until PD or toxicity is intolerable or up to 24 months."
10196634|NCT05183958|Placebo Comparator|Non-radiotherapy group|"Chemotherapy :TP program (paclitaxel 175mg/m 2 d1, carboplatin AUC=5 d1 IV Q3W; or paclitaxel 175mg/m 2 d1, cisplatin 75mg/m 2 d1, or paclitaxel 175mg/m 2 d1, cis Platinum 25mg/m 2 d1-3 IV (Q3W, up to 4 cycles). Fluorouracil + cisplatin, cisplatin 80 mg/m 2 d1 IV and 5-Fu 800 mg/m 2 continuous IV d1-5 Q3W (up to 4 cycles).Or cisplatin 50mg/m 2 IV d1; LV 200mg/m 2 IV d1; 5-Fu 2000mg/m 2 24 hours continuous IV d1; or cisplatin 80mg/m 2 IV d1, capecitabine 1000mg/m 2 PO BID d1-14.~Camrelizumab :200mg every 3 weeks,maximum 6 cycles.~The control group continued Camrelizumab after 3 weeks of the 4 cycles of chemotherapy combined with immunotherapy.~The maintenance immunotherapy of the two groups was: Camrelizumab 200mg Q3W, until PD or toxicity is intolerable or up to 24 months."
10196635|NCT05183919|Experimental|AKL-T01|Digital treatment
9980679|NCT01394328||Persons with Dementia|Persons with Dementia are identified by the Modified Blessed Dementia Rating Scale and the IQCODE
9980680|NCT01394341|Active Comparator|T2D, Dialysis, Liraglutide|Daily liraglutide treatment Chronic dialysis treatment
9980681|NCT01394341|Placebo Comparator|T2D, Dialysis, Placebo|Daily placebo Chronic dialysis treatment
9980682|NCT01394341|Active Comparator|T2D, Normal kidney function, Liraglutide|Daily Liraglutide treatment Normal kidney function
9980683|NCT01394341|Placebo Comparator|T2D, Normal kidney function, Placebo|Daily placebo treatment Normal kidney function
9719665|NCT04533724|Experimental|Study group|Recruit 30 outpatient/inpatient schizophrenia patients (dominant negative symptoms) in Shanghai Mental Health Center .
9719666|NCT04533724|No Intervention|Healthy control group|15 cases of normal healthy people (control group) with similar eating habits and ages in the same region were matched with study group.
9719667|NCT04533867||Ondansetron|In Group B (n = 50): Intravenous injection of ondansetron 0.1 mg/kg diluted up to 5 mL with normal saline solution in a maximum dose of 8 mg is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
9719668|NCT04533867||Palonosetron|The antiemetics used are palonosetron in Group A (n = 50): Intravenous injection of Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
9719669|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
9719670|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) a pre-commitment prompt
9719671|NCT04533685|Active Comparator|Direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
9719672|NCT04533685|Active Comparator|Direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling
9719673|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment + Pre-Appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
9719674|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) a pre-commitment prompt
9719675|NCT04533685|Active Comparator|No direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
9719676|NCT04533685|Active Comparator|No direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling for a flu vaccine appointment
10196636|NCT05183893|Experimental|Experimental: L-Citrulline|5 g of L-citruline + 5 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the product, which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
9719677|NCT04533685|No Intervention|Control Arm|Participants will not receive any reminder/recall messages regarding influenza vaccination via the patient portal or other intervention components
10196637|NCT05183893|Experimental|Experimental: Citrulline-malate|8g of citrulline-malate + 2 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the products which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
10196638|NCT05183893|Placebo Comparator|Placebo|10g of maltodextrin plus additives (Lifepro®).
9719678|NCT04533919||Basic science (dorsal root ganglia collection)|Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
9719679|NCT04533893||BLS Training Group (Students without prior BLS Training)|"After completing training mode of the serious game module, participants were asked to choose the self-test mode of the serious game module.~the participants were asked to practice their hands-on skills in simulation center under the supervision of educators. After familiarization with the system using self-training mode, the participants were asked to proceed the BLS Hands-on training app with the simulator under the supervision of the educator.~Conventional OSCE score of each participant was obtained by watching the recorded sessions of BLS trainings."
9719680|NCT04533906|Experimental|Carrageenan|Subjects sucking carageenan containing lozenge
9719681|NCT04533620|Active Comparator|Standardized CIRT|Patients will receive standardized CIRT with a dose of 63 GyE/21 fx.
9719682|NCT04533620|Experimental|Individualized CIRT|A previously predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
9719683|NCT04533477|Experimental|Routine surgery with reconstructing FCS|The participants undergo FCS reconstruction during the routine standardized surgery.
10196639|NCT05183880|Active Comparator|Crystalline vitamin C supplementation|1000 mg of vitamin C ingested in crystalline form
10196640|NCT05183880|Experimental|Phosphatidylcholine-lipid microencapsulated vitamin C supplementation|1000 mg of vitamin C ingested in phosphatidylcholine-lipid microencapsulated form
10196641|NCT05183841|Active Comparator|Bronchodilator|The intervention will be a combination of 2 drugs, ipratropium (20 mcg) and fenoterol (50mcg). Ipratropium is an anticholinergic bronchodilator, and fenoterol is a beta-agonist bronchodilator. The medication will be delivered to the patient via an inhaler device with spacer, at leat 20 minutes before the constant load exercise test (CLET). Patient will be asked for a total exhalation, followed by an appropriate spacer mouthpiece placement and the first of eight puffs (30 seconds interval between puffs) will be delivered through the oppositte extremity of the spacer. Patient will be instructed to perform five tidal volume breaths for each puff.
9719684|NCT04533477|Active Comparator|Routine surgery|The participants undergo routine standardized surgery.
9719685|NCT04533490|Experimental|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 (200mg ivgtt q3w) from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
9662511|NCT03431480|Experimental|hCBMNC|Autologous human placental cord blood mononuclear cells (buffy coat fraction)
9662512|NCT03425331|Experimental|Nivolumab+Ipilimumab|Nivolumab will be administered once every 2 weeks intravenously Ipilimumab will be administered once every 6 weeks intravenously
9662513|NCT03361189|Experimental|CLS-On|Subjects in this arm will programmed to CLS-on to received closed loop stimulation-based pacing.
9662514|NCT03361189|No Intervention|CLS-Off|Subjects in this arm, will be placed in a standard pacing mode (i.e. AAIR or DDDR).
9662515|NCT03218410|Active Comparator|surgical pulmonary embolectomy|
9662516|NCT03218410|Active Comparator|catheter-directed thrombolysis|
9662517|NCT03177772||LTC Facility 1|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
9662518|NCT03177772||LTC Facility 2|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
9662519|NCT03177772||LTC Facility 3|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
9662520|NCT03176927|Experimental|Gastroparesis|"magnetogastrogram~Diabetes with and without gastroparesis ; Idiopathic gastroparesis"
9662521|NCT03176927|Experimental|Gastrectomy|"magnetogastrogram~Total or partial gastrectomy group"
9662522|NCT03176927|Experimental|Functional dyspepsia|"magnetogastrogram~Children with functional dyspepsia"
9662523|NCT03176927|Experimental|Chronic nausea|"magnetogastrogram~Children with chronic nausea"
9662524|NCT03176927|Experimental|Control participants|"magnetogastrogram~Group without any gastrointestinal diseases."
9662525|NCT03171805|Experimental|Propranolol group|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
9662526|NCT03171805|No Intervention|control group|Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
9662527|NCT03171545|Experimental|Patient Activation|This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling.
9662528|NCT03171545|Experimental|Provider Education|This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
9662529|NCT03171545|No Intervention|No Intervention|Patients in clinic receive usual care.
9662530|NCT03171545|Experimental|Patient and Provider|This arm includes both Patient Activation and Provider Education interventions
9662531|NCT03127826|Active Comparator|Usual Care|"Managing Low Back Pain pamphlet from DoD/VA~No specific guidance regarding physical therapy (PT) or other referrals, thus decision to refer or not will be made by the primary care manager (PCM) according to their preference"
9662532|NCT03127826|Experimental|Risk Stratified Care|"Managing Low Back Pain pamphlet from DoD/VA~Self-management education and tools~2-item spinal manipulation screening/delivery if indicated~Low Risk:~Home Exercise Program as indicated~No referral for ongoing physical therapy~Medium Risk and High Risk~Referral to physical therapy for ongoing care at physical therapists discretion~Managed by a psychologically informed physical therapy trained physical therapist"
9662533|NCT03111173|Other|Holter device|Holter device to be attached to a Singleton or twin pregnant women at 32 weeks gestation to full term
9662534|NCT03107416|Experimental|Bumetanide|Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
9662535|NCT03098329|Experimental|Ct/GC screening|Community screening of men for Ct and GC is not normally done. We are testing to see if this intervention will impact the rates of Ct and GC among women
9662536|NCT03094234|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
9662537|NCT03094234|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
9662538|NCT03042468|Experimental|All subjects|"177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)~68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging"
9662539|NCT03034564|Active Comparator|1|Active group started 100 mg TID, increased by 100 mg per interval (i.e. 100 TID) every 2 days till on 600 TID, or until intolerable dose is achieved at which time the next highest dose will be maintained (increments of 100 TID will be used).
9662540|NCT03034564|Placebo Comparator|2|Dosing regimen identical to active group
9662541|NCT03034538|Active Comparator|100mg|Zonegran 100mg
9662542|NCT03034538|Active Comparator|200mg|Zonegran 200mg
9662543|NCT02981108|Experimental|Escalation Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
9662544|NCT02981108|Experimental|Escalation Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
9662545|NCT02981108|Experimental|Escalation Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
9662546|NCT02981108|Experimental|Escalation Cohort 4|Oral Once-Daily Administration of HS-10296 260mg
9662547|NCT02981108|Experimental|Escalation Cohort 5|Oral Once-Daily Administration of HS-10296(MTD)
9662548|NCT02981108|Experimental|Expansion Cohort 1|Oral Once-Daily Administration of HS-10296 220mg
9662549|NCT02981108|Experimental|Expansion Cohort 2|Oral Once-Daily Administration of HS-10296 260mg
9662550|NCT02981108|Experimental|Expansion Cohort 3|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
9980684|NCT01394354|Experimental|1|"Vorinostat. To determine the MTD, dose escalation for Vorinostat will be conducted following the 3 + 3 design The first cohort of 3 patients will be given 100mg/d on days 1-4, 8-11, 15-18. The second cohort of 3 new patients will be treated with Vorinostat 200mg/d. The third cohort will be given Vorinostat 300mg/d. Cycles will be repeated every 28 days. Maximum treatment cycles: 6. Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 BSA an days 1, 8, 15.~Doxorubicin will be administered i.v. with a total dose of 18mg/m2 BSA per cycle (9mg/m2 BSA, d1 and 8).~Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) or 20mg (all other cycles) on d1, 8, 15, and 22."
9980685|NCT01394367|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
9662551|NCT02981108|Experimental|Phase 2 Expansion|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
9662552|NCT02918162|Experimental|Pembrolizumab|"All study subjects will receive standard of care chemotherapy regimen for 3 cycles prior to and 3 cycles following surgery in combination with Pembrolizumab with an additional cycle of Pembrolizumab (4 total) in the pre-operative period. Additionally subjects will complete 12 months of maintenance Pembrolizumab (14 additional doses to complete 17 post-operative cycles) following completion of post-operative chemotherapy.~Standard of care combination chemotherapy regimen has a 21-day cycle."
9662553|NCT02900651|Experimental|Phase I - All|advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma.
9662554|NCT02891993|Experimental|IMPROVED Intervention|"Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer.~The clinical team will view reports detailing their patients' symptom burden~Clinicians will be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
9662555|NCT02891993|Active Comparator|Usual Care|"Patients randomized to Usual Care will self-report their symptoms each day using a tablet computer~Patients will report their symptoms to their clinicians as they usually would~Clinicians will not be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
9662556|NCT02880319|Experimental|Oligometastatic Disease|"Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
9662557|NCT02880319|Experimental|Metastatic Disease|"Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.~Dosage will be determined by physician"
9662558|NCT02877823|Experimental|Treatment|"Home delivery of bottled water supplying 48 oz. /day for the child and 24 oz. /day per other household members (up to 6 family members).~Child pedometer use and activity tracking to encourage child physical activity/goal setting and engage parents in monitoring their child's health behavior.~Family Navigator Services by telephone with the parent to help engage and empower parents in child healthy lifestyle changes. They will also be able to assist with resource needs for the household (food/housing services).~Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks daily and limit fruit juice to one hundred percent real fruit juice."
9662559|NCT02877823|Active Comparator|Control|Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks and limit fruit juice to one hundred percent real fruit juice.
9662560|NCT02868112|Experimental|Transdisciplinary Intervention|"Patients randomized to the Transdisciplinary Intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool.~-Investigators will test a two-visit Transdisciplinary Intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit."
9662561|NCT02868112|Active Comparator|Usual Care|Participants receiving Usual Oncology Care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
9662562|NCT02819518|Experimental|Part 1: Pembrolizumab + Nab-paclitaxel|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
9662563|NCT02819518|Experimental|Part 1: Pembrolizumab + Paclitaxel|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
9662564|NCT02819518|Experimental|Part 1: Pembrolizumab + Gemcitabine/Carboplatin|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an Area Under the Curve (AUC) 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
9662565|NCT02819518|Experimental|Part 2: Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS one of three chemotherapy regimens: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
9662566|NCT02819518|Active Comparator|Part 2: Placebo + Chemotherapy|Participants receive placebo (normal saline) IV on Day 1 of each 21-day cycle PLUS one of three chemotherapy regimens: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
9662567|NCT02802124|Experimental|carbon-ion radiotherapy for tumor away from GI|For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels [55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx] are planned within the Phase I part.
9719686|NCT04533412|Experimental|Targeted self-management barrier support|Intervention group - Targeted self-management barrier support, home-based pulmonary rehabilitation, and emergency medication with community health workers
9719687|NCT04533412|Active Comparator|Guided COPD education|Control group - Guided COPD education with a COPD educator
9719688|NCT04533516|Experimental|Manual Therapy additional over Inspiratory muscle training|Participants receive manual therapy protocol session three times a week for 12 weeks. The manual therapy protocol session lasts 30 minutes and included of the following manual therapy techniques: suboccipital decompression, gliding of the cervical vertebral articulations in the anterior/posterior direction, myofascial release of sternocleidomastoid and trapezius muscles, gliding of sternoclavicular joint in the anterior/posterior direction, myofascial release of intercostal muscles and paravertebral muscles, diaphragmatic release, rib raising, mobilization of scapulothoracic joint, and gliding of the thoracic vertebral articulations in the anterior/posterior direction. And all participants receive inspiratory muscle training.
9719689|NCT04533516|Active Comparator|Inspiratory Muscle Training|Participants receive only inspiratory muscle training by using Threshold Inspiratory Muscle Training device. Training load is 40% of the measured maximum inspiratory pressure, weekly. Participants receive inspiratory muscle training session for 30 min-per day, 7 days per week, for 12 weeks.
9719690|NCT04533425||Patients with syncope|Patients who present to the ED with syncope
9719691|NCT04533386|Experimental|BSMM|Intervention arm will include motivational interview-consistent discussion with a peer change agent and use of a mobile application to record and review sexual risk behaviors with participants.
9719692|NCT04533542||Arm I (3 video or telephone conferences)|Participants attend up to 3 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on 3 randomly assigned conditions (combinations of carrier and nicotine concentrations).
9719693|NCT04533542||Arm II (2 video or telephone conferences)|Participants attend up to 2 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on a nicotine-free condition and 3 randomly assigned conditions (combinations of carrier concentration and nicotine form).
9719694|NCT04533334||Pediatric|FOB measurement of the distance between carinae and right upper lobe and carinae and labium oris in paediatric population
9719695|NCT04533308|Experimental|VR intervention|Participants will have a session in VR for 20-30 minutes each working day. They can choose natural 360-degrees scenes from different locations in the world with or without interactions with animals. The equipment will include HTC Vive (HTC Corporation).
9719696|NCT04533308|No Intervention|Control|Patients in the control group will not receive any psychological interventions.
9719697|NCT04533139||Vaccine, pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
9719698|NCT04533139||Vaccine, post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
9719699|NCT04533139||Vaccine, not receiving transplant|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
9719700|NCT04533230|Experimental|Educational intervention with prescription feedback|The manager and physicians at each intervention center will participate in a brief educational intervention about benzodiazepines and benzodiazepine-like hypnotics and receive 12 months of targeted feedback on prescription of these drugs. The education will cover national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics.
9719701|NCT04533230|Active Comparator|Information on guidelines|The manager and physicians at each center in the active control group will receive written information on national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics. These centers will not receive the onsite educational intervention or 12 months of targeted prescription feedback.
9719702|NCT04533230|No Intervention|No active intervention: standard care|The manager and physicians at each primary health care center in the passive control group will receive no active intervention. The passive control group will consist of primary health care centers that are not actively participating in the study. Data will be gathered from regional registers and databases. Thus, there will be no need to contact or communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
9719703|NCT04533217|Active Comparator|Vertebroplasty|Patients treated with vertebroplasty in addition to regular medical treatment.
9719704|NCT04533217|No Intervention|Regular treatment|Patients treated with regular medical treatment.
9719705|NCT04533178|Active Comparator|Restriction of sports activities|No sports during the 6 week treatment period
9719706|NCT04533178|Experimental|Restriction of sports activities and soft spinal brace|No sports and use of a soft spinal brace 16 hours per day during the 6 week treatment period
9719707|NCT04533295|Experimental|Acupuncture and IVF|Acupuncture and IVF
9719708|NCT04533295|Sham Comparator|Sham acupuncture and IVF|Sham acupuncture and IVF
9719709|NCT04533347|Active Comparator|Tafenoquine|Tafenoquine two 100 mg oral tablets 1x/day on Days 1,2,3 and 10
9719710|NCT04533347|Placebo Comparator|Placebo|Placebo two tablets 1x/day on Days 1,2,3 and 10
9719711|NCT04533243|Experimental|2.5ug/h transdermal fentanyl|
9719712|NCT04533243|Active Comparator|Oral immediate-released morphine|
9719713|NCT04533321|Other|Patients genotyped positive for MET-N375S polymorphism|will be treated with orally administered daily dose of afatinib (Gilotrif®) in a fasting state (1 hour before or 2 hours after meals).
9719714|NCT04533113|Experimental|VitreBond LC|VitreBond LC used as a liner after selective carious tissue removal.
9980686|NCT01394367|No Intervention|respiratory and exercise therapy|
9719715|NCT04533113|Experimental|Biodentine|Biodentine used as a liner after selective carious tissue removal.
9719716|NCT04533113|Experimental|Theracal|Theracal used as a liner after selective carious tissue removal.
10196642|NCT05183841|Placebo Comparator|Placebo|The placebo will be delivered via an inhaler device with spacer (identical to the bronchodilator device), at least 20 minutes before the constant load exercise test (CLET). Patient will be asked for a total exhalation, followed by an appropriate spacer mouthpiece placement and the first of eight puffs (30 seconds interval between puffs) will be delivered through the oppositte extremity of the spacer. Patient will be instructed to perform five tidal volume breaths for each puff.
10196643|NCT05183841|No Intervention|Control|A paired healthy control group will be assessed by a constant load exercise test (75% from maximal load achieved on the cardiopulmonary exercise test) concomitant to the optoelectronic plethismography to compare mechanical respiratory parameters to the bronchiectasis patients during the placebo assessment. In addition they will also use an accelerometer for 7 consecutive days.
10196644|NCT05183815|Experimental|massage|
9719717|NCT04533048|Experimental|MW33|
9719718|NCT04533048|Experimental|Placebo|
9719719|NCT04532931|Placebo Comparator|Arm A|Paracetamol (SOC)
9719720|NCT04532931|Experimental|Arm B|SOC plus Artesunate-Amodiaquine
10196645|NCT05183789||Cases|Malnourished children with acute diarrhea
9719721|NCT04532931|Experimental|Arm C|SOC plus Pyronaridine-Artesunate
9719722|NCT04532931|Experimental|Arm D|SOC plus Favipiravir plus Nitazoxanide
9719723|NCT04532931|Experimental|Arm E|SOC plus Sofosbuvir/daclatasvir
9719724|NCT04533087||Candida blood stream infection|
9719725|NCT04533087||Aspergillosis|
9719726|NCT04533087||Rare mold infections|
9719727|NCT04533269|Experimental|Active|Arnica montana and Ledum palustre infused Pad
9719728|NCT04533269|Placebo Comparator|Placebo|Pad (Matching appearance with Active)
9719729|NCT04532918|Experimental|Verinurad + allopurinol|The subjects will receive single oral dose of verinurad 7.5 mg and allopurinol 300 mg under fasted condition.
9719730|NCT04532918|Experimental|Verinurad + allopurinol + cyclosporine|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and cyclosporine 600 mg under fasted condition.
9719731|NCT04532918|Experimental|Verinurad + allopurinol + rifampicin|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and rifampicin 600 mg under fasted condition.
9719732|NCT04533009|Active Comparator|tramadol/acetaminophen|Tramadol-paracetamol two tablets 37,5mg/325mg twice daily up to five days for patients undergoing spinal surgery
9719733|NCT04533009|Placebo Comparator|placebo|Placebo two tablets twice daily up to five days for patients undergoing spinal surgery
9719734|NCT04532996|Experimental|Trauma-focused psychodynamic psychotherapy|Twice-weekly psychotherapy for 20-24 sessions.
9719735|NCT04533282||Acute IHD with STEMI and PCI|"Acute ischemia in IHD is represented by the recruitment of patients presenting with ST-elevation myocardial infarction (STEMI patients) to the Meilahti Cardiac Care Unit (CCU) and admitted for Percutaneous Coronary Intervention (PCI) revascularization. The informed consent and blood samples from these patients will be collected during the first 72 hours after PCI, during their stay either in CCU or medical ward.~Inclusion of this cohort to the IHD-EPITRAN opens the possibility to identify novel circulative epitranscriptomic biomarkers representing acute ischemic myocardial damage as well as particularly insightful comparison of acute and chronic states of IHD when compared against the second study cohort."
9719736|NCT04533282||Chronic IHD and elective CABG|"The second study cohort composes of patients with stable IHD phenotype with angina pectoris or exertional dyspnea provoked by either moderate or severe physical exertion, corresponding either NYHA or CCS classes II to IV, respectively, destined to undergo an elective coronary artery bypass grafting (CABG) operation as method for revascularization. The duration of stable symptoms must exceed a month in order to exclude acute events.~The obtained blood samples from this main cohort of the IHD-EPITRAN project provides insightful overview into the circulation-borne RNAs' epitranscriptomic landscape for identification of novel biomarkers for stable IHD. Furthermore, availability of right atrial appendage tissue pieces following CABG surgery from this patient cohort gives invaluable organ-specific information in its own right as well as a crucial reference point, against of which the alterations observed in circulation can be compared."
9719737|NCT04533282||Elective aortic valve stenosis (AVS) replacement therapy|"The third study cohort consists of patients admitted for surgical (open heart surgery) valve replacement due to aortic valve calcification and critical stenosis with no IHD as a comorbidity. As to elective CABG patients, here patients are also required to be either moderately or severely symptomatic equaling NYHA or CCS II to IV classes, respectively.~This cohort will provide insights into how the pathological pressure overloaded left ventricular remodelling is reflected to the epitranscriptomes of the supposedly relatively spared right atrial appendage tissue and blood RNA. Comparison of this data to the data of the first two IHD study cohorts opens the window to assess the possible differences for these differing pathologies, thus functioning as an active control cohort."
9719738|NCT04533282||IHD-negative healthy controls verified by coronary CT|The fourth study cohort shall consist of patients referred to Meilahti Heart Unit's Coronary Artery Computerised Tomography (CT) Angiogram imaging in order to investigate the possibility of atherosclerotic coronary artery disease (i.e. IHD) behind symptoms such as pressing chest pain (i.e. angina pectoris) or abnormal dyspnea provoked by exertion. Based on the results from CT angiogram, only those patients' blood samples are selected for further study that show negative results for IHD (no visualisation of either atherosclerotic strands or plaques in coronary arteries). This patient cohort functions as a critical IHD-healthy control group in the IHD-EPITRAN project (i.e. negative control).
9719739|NCT04533035||Single cohort|30 patients undergoing hallux valgus surgery
9719740|NCT04533204|Experimental|Mnemonic strategy training|Training using mnemonic strategies
9719741|NCT04533204|Active Comparator|Spaced retrieval training|Training using spaced retrieval
9719742|NCT04532944|Other|patients with MS|20 relapsing-remitting and 20 progressive MS patients
9719743|NCT04532944|Other|healthy controls|15 age- and sex-matched healthy controls
10196646|NCT05183789||Control|Non-malnourished children with acute diarrhea
10196647|NCT05183750|Other|Adult with isolated medial compartmental knee osteoarthtitis|
9719744|NCT04533061||Lung Transplant, Vaccine|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
10196648|NCT05183737|Active Comparator|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis
10196649|NCT05183737|Placebo Comparator|Placebo Group|Participants will receive microcapsules containing arabic gum and cornstarch with the same weight and characteristics as the intersecting microcapsules
9719745|NCT04533061||Healthy Control, Vaccine|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
9719746|NCT04532905|Sham Comparator|without previous strength training experience|control (untrained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
9719747|NCT04532905|Experimental|with previous strength training experience|experimental (trained) group will receive intervention as five exercises: dumbbell bent row over, dumbbell deadlift, dumbbell lunge. dumbbell shoulder press, and dumbbell squat
9719748|NCT04532957|Experimental|Group 1|Multiple doses 100mg Healthy subjects receive multiple doses of KBP-7072 (100mg) or Placebo (100mg) QD capsules daily for a total of 10 days
9980687|NCT01394380|Experimental|artificially sweetened beverages|subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
9719749|NCT04532957|Experimental|Group 2|Multiple doses 200mg Healthy subjects receive multiple doses of KBP-7072 (200mg) or Placebo (200mg) QD capsules daily for a total of 10 days
9719750|NCT04532957|Experimental|Group 3|Multiple doses dose tbd Healthy subjects receive multiple doses of KBP-7072 (tbd) or Placebo(tbd) QD capsules daily for a total of 10 days
9719751|NCT04532853||COPD patients|
9719752|NCT04532983|Active Comparator|fixation group|; group A; patients underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was fixed in position using absorbable Vicryl tacks (abstack30 medtronic),
9719753|NCT04532983|Active Comparator|non fixation group|group B patient underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was placed in position without fixation.
9719754|NCT04532892|Placebo Comparator|Placebo|Morning and night tablets with no active ingrédients. Morning and night tablets are different.
9719755|NCT04532892|Experimental|Dietary supplément|Morning and night tablets with active ingrédients. Morning and night tablets are different.
9719756|NCT04532970|Placebo Comparator|Standard|"Eligible patients will be randomized to one of the treatment arms, which will involve 5 phone-delivered counseling sessions over a 9 week treatment phase. SC will be based on the 2008 PHS Clinical Practice Guideline (Fiore et al., 2008) and on SC in our ongoing two-site trials (R01DA025078; R01CA165001) This intervention arm will begin with a pre-quit session designed to help participants prepare for their Target Quit Day (TDQ). The TQD session will occur at week 1. The SC arm will focus on self-monitoring, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, relapse prevention, and homework. The pre-quit session prepares participants for their TQD by reviewing their experience with quitting, beliefs about smoking/quitting, perceived barriers to cessation, and creating a quit plan to identify smoking triggers and implement alternative strategies to manage those triggers without smoking."
9719757|NCT04532970|Experimental|BAPS|Key components of BAPS include activity monitoring and rewarding activity scheduling, assessment of personal goals and values, assessment and altering of avoidance behavior and other maladaptive coping strategies, and contingency management. BAPS focuses on reducing stress pile-up and loss of pleasure that accompanies the cessation process and on identifying and establishing environmental/social changes to promote abstinence. BAPS addresses smoking as a behavior that prevents and restricts opportunities for contact with healthy rewarding behaviors. These changes are achieved through altering daily routines previously associated with smoking in ways that increase pleasure and mastery across life domains, reducing rumination, and increasing behavioral skills to prevent return to smoking as a means of avoiding stressors.
9719758|NCT04532866|Experimental|Isolation and Confinement|Six crew members will spend 8 months isolated and confined in the spaceflight analog NEK in Moscow.
9719759|NCT04532866|No Intervention|Control Group|Up to ten participants matched for age, gender, and educational background undergo the same test protocol as the experimental group at identical points in time but without being isolated and confined in the NEK facility.
10196650|NCT05183711||Nurse anesthetist|In this study, the investigator team designs to use self-evaluating form as a tool for any competencies evaluation. The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. The participant could download the self-evaluating form (google form, no personal identity record) via QR code.
10196651|NCT05183672|Experimental|Intervention group|Participants will receive three tertiary stroke care consultations provided by stroke nurses via telecare in 3 months.
10196652|NCT05183672|Placebo Comparator|Control group|Participants will receive three usual face-to-face consultations provided by stroke nurses in 3 months
10196653|NCT05183594|Experimental|TSupport group|"Subjects will receive TSupport 4 sachets (5 grams/sachet) orally twice daily. Morning dose and evening dose should be administrated at about the same time every day and irrelevant to meals.~Supportive care duration: 24 weeks."
9719760|NCT04532775|Other|group C|"This study was conducted on 100 patients. Patients were divided according to the injected drugs into two equal groups (50 patients each):~1- Group (C): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of normal saline (0.9 %) with a total volume of 4 ml."
9719761|NCT04532775|Other|group M|2- Group (M): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of preservative free magnesium (200 mg) with a total volume of 4 ml. Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol). Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
9719762|NCT04532879|Experimental|All patients enrolled|"Bowel habits before and after the HygiRelief procedure will be assessed.~Samples will be sent for microbiome evaluation."
9719763|NCT04532476|Experimental|Laser treated side|Group of 22 participants whose mucose around right maxillary permanent molar was treated with laser.
9719764|NCT04532476|Placebo Comparator|Placebo side|Placebo side was LEFT side.It was treated the same way as right with the difference that the laser was switched off, but with the maintained sound signal, implying laser was working, so participants were blinded to the allocation of the group, only the operator knew whether the side is laser treated or placebo.
9719765|NCT04532658|Experimental|Intervention arm|Surgeons randomly assigned to the intervention arm
9719766|NCT04532658|No Intervention|Control arm|Surgeons randomly assigned to the control arm
9719767|NCT04532840|Active Comparator|Group A: (control group)|This group includes 30 patients will receive routine medical treatment and routine physical therapy as (Exercising, Positioning and splinting, Pressure Therapy and Massage).
9719768|NCT04532840|Experimental|Group B: (Study group)|This group includes 30 patients will receive cryotherapy (at least 10 minutes at -14 degree , 2 sessions per week , for 10 weeks ) in addition to routine medical and physical therapy treatment.
9719769|NCT04532580||AI- Aided performances|
9719770|NCT04532580||AI- Unaided performances|
9719771|NCT04532671|Other|Poly ether ether ketone (PEEK)|Poly ether ether keton (PEEK) is acknowledged as a high-performance polymer in engineering & medical applications due to its favorable mechanical and chemical properties.
9719772|NCT04532671|Other|CADCAM poly ether ether ketone (PEEK)|PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks.
9719773|NCT04532671|Active Comparator|indirect resin composite|In CAD/CAM resin composite blocks, properties of flexibility and ease of use similar to that of resin composite are combined with durability and surface finish properties similar to that of ceramics
9719774|NCT04532684|Active Comparator|Duloxetine|33 patients received 60 mg/day of duloxetine HCL orally for 12 weeks
9719775|NCT04532684|Active Comparator|Pregabalin|33 patients received 300 mg/day of pregabalin orally for 12 weeks
9719776|NCT04532736|Experimental|Methotrexate|10 mg Emthexate, PO, once a week during 8 weeks
9719777|NCT04532736|Active Comparator|Methylprednisolone|8 mg/day Prednol, PO, for 8 weeks
9719778|NCT04532736|Active Comparator|Control|200 mcg/day, intranasal mometasone furoate, for 8 weeks
9719779|NCT04532801|Experimental|kisspeptin-10|kisspeptin infusion
9719780|NCT04532801|Placebo Comparator|placebo|placebo
9719781|NCT04532788|Active Comparator|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
9719782|NCT04532788|Active Comparator|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
9719783|NCT04532593|Experimental|Stem cell group|
9719784|NCT04532593|Placebo Comparator|Control|
9719785|NCT04532762|Experimental|Coldamaris akut|One puff (140µl) into each nostril
9719786|NCT04532762|Placebo Comparator|Placebo|One puff (140µl) into each nostril
9719787|NCT04532723|Experimental|ExoAtlet II|Safety/feasibility of utilizing the ExoAtlet II in a clinical setting with a group of individuals with SCI
9719788|NCT04532710|Placebo Comparator|Placebo low dose|Application of 2 placebo eye drops once daily for 8 days.
9719789|NCT04532710|Active Comparator|Tacrosolv low dose|Application of 1 Tacrosolv eye drop once daily for 8 days.
9719790|NCT04532710|Placebo Comparator|Placebo high dose|Application of 1 placebo eye drop once daily for 8 days.
9719791|NCT04532710|Active Comparator|Tacrosolv high dose|Application of 2 Tacrosolv eye drops once daily for 8 days.
9719792|NCT04532567|Experimental|GLPG1205 dose A|Participants will receive a single dose with dose A of GLPG1205 on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
9719793|NCT04532567|Placebo Comparator|Placebo dose A|Participants will receive a single dose placebo on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
9719794|NCT04532567|Experimental|GLPG1205 dose B|Participants will receive 14 days q.d. dosing with dose B of GLPG1205 on Days 1 to 14.
9719795|NCT04532567|Placebo Comparator|Placebo dose B|Participants will receive 14 days q.d. dosing placebo on Days 1 to 14.
9719796|NCT04532606|Experimental|Remimazolam group|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain Bispectral Index (BIS) value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
9719797|NCT04532606|Active Comparator|Propofol group|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
9719798|NCT04532697|Active Comparator|Chinese Medicine|Uncaria Rhynchophylla (Gou-Teng)
9719799|NCT04532697|Placebo Comparator|Placebo treatment|Placebo
9719800|NCT04532398|Other|Swallowing test|
9785215|NCT01245764|Placebo Comparator|Placebo 9 to 12 Years Old|Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
9785216|NCT01245972|No Intervention|Control|No treatment administered
9980688|NCT01394380|No Intervention|regular sodas|subjects will continue their usual consumption of sweetened sodas
9719801|NCT04532411||Pre-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing prior to implementation of the Hexapod personal protective booths.
9719802|NCT04532411||Post-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing after implementation of the Hexapod personal protective booths.
9719803|NCT04532372|Experimental|Phase I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Patients may receive SOC drugs in addition to leflunomide.
9719804|NCT04532372|Experimental|Phase II Arm I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
9719805|NCT04532372|Placebo Comparator|Phase II Arm II (placebo, SOC)|Patients receive placebo PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
9719806|NCT04532385|Experimental|GTE|Green tea extract, 400 mg every 12 hours for 12 weeks
9719807|NCT04532385|Placebo Comparator|Placebo|Calcined magnesia, 400 mg every 12 hours for 12 weeks
9719808|NCT04532554|Experimental|Growth hormone|Recombinant GH will be used for those patients
9719809|NCT04532554|Placebo Comparator|Placebo|Saline will be used
9719810|NCT04532216|Experimental|Study group|
9719811|NCT04532216|Other|Control group|
9719812|NCT04532229|Experimental|Experimental|Nimotuzumab+CRT(concurrent IMRT and TMZ)
9719813|NCT04532268|Experimental|Administration of Humanized CD19 CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
9719814|NCT04532060|Experimental|Antimicrobial Photodynamic Therapy|Patients treated with Antimicrobial Photodynamic Therapy
9719815|NCT04532060|Experimental|Nystatin|Patients treated with Nystatin antifungal drug.
9719816|NCT04532281|Experimental|Administration of Murine CD19 CAR T-cells|
9719817|NCT04532177|Experimental|Active|
9719818|NCT04532112|Experimental|Intubated Subjects with the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by anesthesiologists trained in device use.
9719819|NCT04532112|Placebo Comparator|Intubated Subjects without the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by same cohort of anesthesiologists trained in device use.
9719820|NCT04532151|Other|Early SSc group|"Patients with SSc according to the criteria ACR / EULAR 2013, without scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements.~Patients will be reassessed at M24. The participation of each subject will be 24 months, with two visits of one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
9719821|NCT04532151|Other|Established SSc group|"Patients with SSc according to criteria ACR / EULAR 2013 with scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
9719822|NCT04532151|Other|Control group:|"Patient without systemic sclerosis Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The participation of each subject will be one hour.~The clinical data corresponding to the current practice will be collected in a study specific case report form."
9719823|NCT04532164|Experimental|Photoallergic reaction test|During the Induction Phase, participants received Butenafine HCl 1% on the treated irradiated skin test site followed by UV irradiation and on the treated non-irradiated skin test site without UV radiation, two times per week for three consecutive weeks. After 10 days of Rest Phase, during the Challenge Phase, participants received same procedure on the two virgin sites (treated sites) as in Induction Phase, and two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Test sites were evaluated at 24, 48, and 72 hours after irradiation using the same grading scale used during Induction Phase.
9719824|NCT04532099|Other|LID018869, then AOHP (Part A)|Lehfilcon A contact lenses worn first, followed by senofilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
9719825|NCT04532099|Other|AOHP, then LID018869 (Part A)|Senofilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of each wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
9719826|NCT04532099|Active Comparator|Biofinity (Part B)|Comfilcon A contact lenses worn bilaterally (in both eyes) for approximately 30 days, with a scheduled visit at approximately Day 15 of the wear period. Lenses will be removed nightly for cleaning and disinfection with CLEAR CARE contact lens solution.
9719827|NCT04532073|Experimental|Eurythmy therapy exercises|As part of the ENTAiER trial: In group sessions á 5 patients with a qualified therapist: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by an eurythmy manual and an exercise video. This supplements the regular care.
9785217|NCT01245972|Experimental|PDL Setting 1|PDL Setting 1: 15 J/cm2, 3ms pulse length, no dynamic cooling, 7mm spot size, 10% overlap between the pulses, 2 passes
9980689|NCT01394393|Experimental|ECT|Experiential-Cognitive Therapy for Obesity
9980690|NCT01394393|Active Comparator|BCT|Cognitive behavioral treatment program
9980691|NCT01394393|Sham Comparator|NT|Nutritional groups In this condition (NT) the participants enter only 5 weekly nutritional groups held by dietitians.
9719828|NCT04532073|Experimental|Tai Chi exercises|As part of the ENTAiER trial:In group sessions of 5 patients each with a qualified teacher: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by a Tai Chi Manual and an exercise video. This complements the regular care
9719829|NCT04532073|Active Comparator|Standard Care Only|"As part of the ENTAiER trial:Brochure with detailed description of various evidence-based measures for fall prevention, prepared for the specific age group (https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf)~- Recommendation to visit the family doctor and discuss fall prophylaxis with her"
9719830|NCT04532138|Active Comparator|C-MAC Video laryngoscope awake intubation|In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using Videolaryngoscope (C-MAC) with Hyperangulated blade (D-blade) Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied.
9719831|NCT04532138|Experimental|VS-CMAC Rigid Fiberoptic Stylet awake intubation|"In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.~Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied."
9719832|NCT04532034|Experimental|Peer-Delivered Decision Support Intervention|
9719833|NCT04532203|Experimental|Administration of CAR T-cells|Dose escalation follows the standard 3+3 doseescalation design. A total of 3 dose levels are set for subjects.
9719834|NCT04532242|Experimental|fMRI Participants|Participants will be scanned in an fMRI session lasting approximately 45-50 minutes and will be shown negative images for which they will have to take on a cognitive reappraisal tactic. All participants will be taken through the scanner with the same reappraisal protocol for each participant.
9719835|NCT04532333|Experimental|Bivalirudin|Bivalirudin at full dose Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
9719836|NCT04532333|Active Comparator|Heparin|Heparin first dose at 0.6mg/kg(75U/kg) Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
9719837|NCT04531878|Experimental|BSEP trafficking abnormal group|Patients with ABCB11 missense mutations that were speculated to affect the BSEP trafficking
9719838|NCT04531852||At risk older adults|Home-dwelling older adults entitled to preventive home visit, who had a risk profile for loss of physical function and disability identified through a multi-domain screening instrument
9719839|NCT04531865|Experimental|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
9719840|NCT04531865|Placebo Comparator|Rituximab Only|First course Course Rituximab at Randomization. Addition of Maintenance Placebo tablets matching Mycophenolate mofetil from 4 Month onwards.
9719841|NCT04531917|Experimental|Pain Neuroscience Education + Behavioural Graded Activity|Patients allocated to the intervention group will receive a 12-week treatment program that consists of 6 sessions, in which 'Pain Neuroscience Education' and 'Behavioural Graded Activity' will be integrated.
9719842|NCT04531917|Active Comparator|Usual care|"Patients allocated to the control group will receive an information leaflet from Kom op tegen kanker regarding Pain in and after cancer."
9719843|NCT04531761|Experimental|Immediate Access to Parent Support Program|
9719844|NCT04531761|No Intervention|Waitlist Control|
9719845|NCT04532021||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
9719846|NCT04532021||control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
9719847|NCT04531787||Vaccine, Pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
9719848|NCT04531787||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
9719849|NCT04531787||Vaccine, Healthy Controls|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
9719850|NCT04531800|Experimental|Study Group|The necrotic bone was removed with rotating burs, curettage was performed, and the surface of the bone was smoothened. CGF was then applied to the surgical area in the study group (n=14), and the area was primarily closed after additional releasing incisions were made to the periosteum to assure tension-free soft tissue closure.
9719851|NCT04531800|Experimental|Control Group|The surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy, in the control group (n=14).
9719852|NCT04531774|Experimental|RECHARGE|4 1-hour sessions of RECHARGE are delivered online using Skype for Business within 2 weeks.
9719853|NCT04531774|Active Comparator|Online self-study of stress management strategies|Self study during 2 weeks.
9719854|NCT04531956|No Intervention|Before group|In the before group (BG) GPs will execute care as usual in the decision-making process for a diagnostic trajectory for memory complaints.
9719855|NCT04531956|Active Comparator|After group|In the after group (AG), a patient decision aid will be added to the decision-making process provided by the GP.
9719856|NCT04531930||Surgery Group|Colorectal surgery
9719857|NCT04531930||Enhanced Colonoscopy Group|Enhanced colonoscopic treatment and surveillance
9719858|NCT04531930||Self Choice Group|The patients choose the interventional methods, even do nothing.
9719859|NCT04532008|No Intervention|Control Group|No intervention
9719860|NCT04532008|Experimental|Treatment Group|Experimental group received 12 session of group based depression treatment, a matched savings program, financial literacy training, agricultural training, and a cash transfer.
9719861|NCT04531683|Experimental|electroacupuncture|patients will receive electroacupuncture at 3 acupoints (Bladder meridian of foot-taiyang 33 and 35（BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 8 weeks(24 times in total), followed with 24-weeks follow up. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 × 40 mm at SP 6. Standardised electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
9719862|NCT04531683|Sham Comparator|sham electroacupuncture|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
9719863|NCT04531683|Other|life style counselling group|patients randomised to this group will receive a one-time life style counselling at the enrolment to improve their daily behaviour to expedite the recovery of their mixed urinary incontinence. Then the patients will be followed up for 20 weeks.
9980692|NCT01394406|Experimental|Ketamine group|
9719864|NCT04531813|Experimental|Cumulative Irritation Test|Participants received butenafine HCl 1% cream on the skin test site, 0.3% solution of sodium lauryl sulfate on the skin Positive Control test site, and a blank patch on the skin Negative Control test site daily (excluding weekends) for 21 days, or 15 applications.
9719865|NCT04531696|Other|Standard|"UPTIDER consists of 8 substudies:~Pilot phase~Invasive Lobular Carcinoma (ILC) substudy~Inflammatory Breast Cancer (IBC) substudy~Molecular heterogeneity and treatment response substudy~Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy~Metabolomics substudy~Liquid biopsy substudy~Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different."
9719866|NCT04531748|Active Comparator|Toremifene + Melatonin|"100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening), 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).~60mg oral toremifene daily days 1-14."
9719867|NCT04531748|Active Comparator|Melatonin + Placebo|100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening) and 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
9719868|NCT04531748|Placebo Comparator|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions
9719869|NCT04531735||Group 1|COVID positive infants
9719870|NCT04531735||Group 2|RSV positive infants
9719871|NCT04531514|Experimental|Sensitivity to phonological rules & referents: Toddlers|Arm 1: OR condition with a referent; Arm 2: OR condition without a referent; Arm 3: Family Resemblance condition with a referent; Arm 4: Family Resemblance condition without a referent.
9719872|NCT04531527|Experimental|Phototoxicity reaction test|Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.
9719873|NCT04531566|Experimental|Oral Feed Intervention Group|
9719874|NCT04531566|Active Comparator|Usual care|
9719875|NCT04531826|Active Comparator|Group A|Five-strand hamstring autograft group
9719876|NCT04531826|Placebo Comparator|Group B|Quadripled hamstring autograft group
9719877|NCT04531631|Other|Group 1|receive a single oral dose of dorzagliatin 75mg tablet on visit 2 and receive one placebo tablet on visit 3
9719878|NCT04531631|Other|Group 2|receive a single oral dose of one placebo tablet on visit 2 and receive dorzagliatin 75mg tablet on visit 3
9719879|NCT04531436|Experimental|Intervention|Brief mindful eating intervention
9719880|NCT04531371|Experimental|dexemedetomidine|dexemedetomidine was administered intravenously after induction of general anesthesia.
9719881|NCT04531371|Active Comparator|magnesium sulphage|magnesium sulphate was infused through out the surgery after induction of general anaesthesia.
9719882|NCT04531371|Placebo Comparator|saline|nothing was given just saline during the operation.
9719883|NCT04531618|Experimental|Family Nurture Intervention (FNI)|Receives a FNI session over Zoom in the Well Baby Nursery and 3 subsequent Zoom sessions over the next 3 months.
9719884|NCT04531618|No Intervention|Standard of Care (SC)|SC receives the regular standard of care in the Well Baby Nursery and no intervention.
9719885|NCT04531501||Patients suspected to have Covid-19|Individuals suspected to have COVID-19 who are admitted to Gloucestershire Hospitals NHS Foundation Trust facilities for treatment for COVID-19. Individuals with full mental capacity.
9719886|NCT04531501||Patients tested positive for Covid-19|Individuals tested positive for COVID-19 at Northern Care Alliance NHS Group using an NHS NPS test who are accessible within 24 hours and consent to providing a saliva sample and further NPS sample for Chronomics.
9785218|NCT01245972|Experimental|PDL Setting 2|PDL Setting 2: 7.5 J/cm2, 3ms pulse length, no dynamic cooling, 10mm spot size, 10% overlap between the pulses, 2 stacked pulses
9785219|NCT01246050|Experimental|Arm 1: Received HF Training|Providers will receive 3 days of HF training, receive access to clinical pharmacist medication titration serviced and receive performance feedback
9980693|NCT01394406|Placebo Comparator|Saline group|
9980694|NCT01394419|Experimental|NAC group|N-acetylcysteine
9980695|NCT01394419|Placebo Comparator|Placebo group|Saline
9719887|NCT04531540|Experimental|Repeated Insult Patch Test|During the Induction Phase, participants received 0.2 g Butenafine HCl 1% covered by an occlusive patch on the upper back skin test site three times a week for a total of 9 applications. Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system. After 14 days of Rest Phase, on the first day of Challenge Phase, participants received same procedure on original Induction Phase test site and on a virgin test site. The patches were removed and the sites scored 48 hours after application and scored again at 96 hours after application. The test sites were evaluated using the Induction Phase scoring system.
9719888|NCT04531423|Experimental|SSRI + golimumab|Participants will be administered with SSRI+golimumab . Golimumab will be administered at the dose of 50mg every month during the acute phase.
9719889|NCT04531423|Active Comparator|SSRI +placebo|Participants will be administered with SSRI+placebo
9719890|NCT04531605|Experimental|Intervention|"12-week program of combined life-skills training and financial incentives (YBank program) described in more detail below.~Life-skills training: Every 4 weeks through the 12 week program, life-skills training sessions will be delivered during peer-group sessions at the clinic. Topics include economic empowerment, financial literacy, healthy relationships, and anti-retroviral therapy (ART) adherence.~Financial incentives: The incentives program combines an immediate financial reward with a long-term savings opportunity. For clinic attendance, 500 RWF (~$0.50) will be deposited into participants' mobile money short-term account, where funds will be immediately accessible, and 1500 RWF (~$1.50) will be deposited into their savings account upon completing the program. If participants demonstrate a suppressed viral load at a clinic appointment, an additional 1000 RWF (~$1) will be deposited to their short-term account and 3000 RWF (~$3) into their saving account."
9719891|NCT04531657||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
9719892|NCT04531657||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
9719893|NCT04531384|Experimental|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 weekly individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants.
9719894|NCT04531384|Other|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions, which consisted of weekly group and/or individual therapy, as determined by the clinical team.
9719895|NCT04531670|Experimental|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
9719896|NCT04531670|Active Comparator|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
9719897|NCT04531306|Active Comparator|Pre-tape|
9719898|NCT04531306|Experimental|With tape 1|
9719899|NCT04531306|Experimental|With tape 2|
9719900|NCT04531306|Experimental|Post-tape|
9719901|NCT04531358|Active Comparator|Callergin|One puff (140 microliter) into each nostril
9719902|NCT04531358|Active Comparator|Alpin Alpensalz|One puff (140 microliter) into each nostril
9719903|NCT04531358|Experimental|no treatment|Patients do not receive a treatment
9719904|NCT04531397|Placebo Comparator|ACEI treatment|Drug: ACEI will be given once daily
9719905|NCT04531397|Experimental|Dapagliflozin+ACEI treatment|Drug: ACEI, will be given once daily Drug: Dapagliflozin, will be given once daily
9719906|NCT04531722|Experimental|drug-resistant temporal lobe epilepsy|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe. The electro-physiological data that will be gathered is not altered and this methodology will not impact standard clinical care, except and will not to extend the duration in the OR - the measurements will occur during the clinical electrocorticography (ECoG; intracranial electroencephalography (iEEG)) procedure by 15 min.
9719907|NCT04531267|Active Comparator|Individualized nutrition|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
9719908|NCT04531267|No Intervention|Control group|Participants do not receive any supplements, they stay with the original medication plan.
9719909|NCT04531475|Experimental|X842 50 mg QD|X842 50 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
9719910|NCT04531475|Experimental|X842 100 mg QD|X842 100 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
9719911|NCT04531475|Experimental|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, orally, once daily and X842 placebo-matching capsule, orally, once daily up to 4 weeks.
9719912|NCT04531202||Patients with confirmed or suspected of coronavirus infe|Clinical and laboratory data will be collected throughout the acute illness period. Research data will be integrated with information available from hospital and regulatory files.
9719913|NCT04531228|Experimental|Experimental: TACE-HAIC plus lenvatinib|chemo-lipiodolization, followed by FOLFOX-based chemotherapy artery infusion (HAIC). Lenvatinib was administrated two or four days after TACE-HAIC.
9719914|NCT04531150|Experimental|Cohort 1|Subjects will be randomized to receive either placebo or 20 mg INV-101
9719915|NCT04531150|Experimental|Cohort 2|Subjects will be randomized to receive either placebo or 80 mg INV-101
9719916|NCT04531150|Experimental|Cohort 3|Subjects will be randomized to receive either placebo or 160 mg INV-101
9719917|NCT04531150|Experimental|Cohort 4|Subjects will be randomized to receive either placebo or 320 mg INV-101
9719918|NCT04531150|Experimental|Cohort 5|Subjects will be randomized to receive either placebo or 500 mg INV-101
10196654|NCT05183568|Experimental|Mindful Self-Compassion|"Participants will undergo an 8-week self-help program consisting of assigned weekly chapters in the workbook entitled The Mindful Self-Compassion Workbook: A Proven Way to Accept Yourself, Build Inner Strength, and Thrive (Neff & Germer, 2018), paired with daily guided meditations provided through a free smartphone app that was developed by the Centre for Mindfulness Studies, a Canadian-based mental health charity."
9719919|NCT04531345||Case Group|Patients with Covid 19 PCR (+) results
9719920|NCT04531345||Control Group|Healthy volunteers
9719921|NCT04531644|Experimental|Study|the patients in this group will be treated with double stimulation
9719922|NCT04531644|Active Comparator|Control|the patients in this group will be treated with conventional ovarian stimulation
9719923|NCT04531332|Experimental|Continuous infusion|Patients will be received linezolid 600 mg intravenous Loading dose over 30 to 60 minutes followed by 1200 mg/ day by Continuous infusion (50 mg /hr)
9719924|NCT04531332|Active Comparator|Intermittent dosing|Patients will be received Linezolid 600 mg intravenous twice daily over 30 to 60 minutes
9719925|NCT04531319||Case Group|Covid 19 (+) patients
9719926|NCT04531319||Control Group|Healthy volunteers
9719927|NCT04530877|Experimental|Exclusive enteral nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
9719928|NCT04530877|Active Comparator|Infliximab|the participants with active CD accept anti-TNF therapy (Infliximab) at 0week, 2week, 6week, 14week. Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
9719929|NCT04531163|Experimental|Interventional|"First arm is experimental, given (NAC) for 2 months in 1200mg/day dosing.~Both arms are assigned to pre-treatment analytical tests and post treatment all test analysis are repeated to compare drug effect with placebo group."
9719930|NCT04531163|No Intervention|Non-interventional|Second arm has no intervention. It is only used to compare results of analytical tests with the first interventional arm.
9719931|NCT04531072|Experimental|ATVr-arm|10 participants living with HIV and having uncomplicated Falciparum malaria were administered: Atazanavir-ritonavir (300/100 mg) one tablet once daily continuously + tenofovir-lamivudine (300/300 mg) one tablet once daily continuously and artemether-lumefantrine (80/480 mg) one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
9719932|NCT04531072|Active Comparator|AL-arm (Control)|10 participants who were HIV negative but having uncomplicated Falciparum malaria were administered: Artemether-lumefantrine 80/480 mg, one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
9719933|NCT04530942|Experimental|Active DBS then Sham DBS|After 6 months open-lable period, some patients will take DBS ON for one week with the optimal stimulation parameters and then take DBS OFF for one week.
9719934|NCT04530942|Experimental|Sham DBS then Active DBS|After 6 months open-lable period, some patients will take DBS OFF for one week and then take DBS OFF for one week with the optimal stimulation parameters.
9719935|NCT04530864|Experimental|DEXTENZA Insert|This prospective study will use a self controlled design for 35 eyes. Patients scheduled to undergo routine cataract surgery in at least one of their eyes will have their pre-surgical measurements performed, IOL calculated and surgery planned. Then they will receive insertion of an intracanalicular dexamethasone insert into the inferior punctum. At 2 weeks (+/- 2 days) post-insertion, patients will return for an identical set of measurements. The IOL will be calculated and the surgery planned based on post-insert data. The insert will be removed if present (manually or via saline irrigation). This self controlled design allows for greater control of potential confounders tied to participants' systemic and ocular health.
9719936|NCT04530851|No Intervention|Conventional care|This group is conventional care of pregnant women after Cesarean section
9719937|NCT04530851|Experimental|ERAS protocol|This protocol for improve outcome of pregnant women after Cesarean section
9719938|NCT04531098|Experimental|Sci-B-Vac-SciGen|The tri-antigenic HepB vaccine, Sci-B-Vac-SciGen (SciGen Israel Ltd., produced in a new production facility located in Rehovot, Israel) contains three recombinant proteins of hepatitis B virus (HBV) envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-SciGen was supplied in a final volume of 1.2 ml vials
9719939|NCT04531098|Active Comparator|Engerix-B|The mono-antigenic HepB vaccine, Engerix-B (GSK), contains the small S recombinant protein. Engerix-B was supplied in 1.0 ml vials.
9719940|NCT04531098|Experimental|Sci-B-Vac-BTG|The tri-antigenic HepB vaccine, Sci-B-Vac-OLD BTG (Bio-Technology General (BTG) Ltd., Rehovot, Israel.) contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-OLD BTG was supplied in a final volume of 1.2 ml vials
9719941|NCT04531488|Experimental|Powered Mobility Training Simulator|Powered mobility simulator- the McGill Immersive Wheelchair Simulator (MiWe) was developed for adults. In a previous study the simulator was found valid for use with children. Participants were provided a laptop, joystick and the software program- MiWe- to practice at home or school
9719942|NCT04531488|Active Comparator|Training with Powered Wheel Chair|Participants were provided with a powered wheelchair to practice at home or school
9719943|NCT04530916|Experimental|Blueberry|22 g blueberry powder per day
9719944|NCT04530916|Placebo Comparator|Control|22 g placebo control powder per day
9719945|NCT04531137|Experimental|CLA-fortified milk powder|Respondents will receive CLA-fortified milk powder containing 3.4 gram for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
9719946|NCT04531137|Other|Placebo|Respondents will receive a placebo milk powder for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
9980696|NCT01394432|Active Comparator|Group 1 (PCI+SC implantation)|Endocardial Stem cells implantation with Noga system
9785220|NCT01246050|Active Comparator|Arm 2: No HF Training|CBOC Providers in the same CBOC who did not received HF Training, access to clinical pharmacist services or performance feedback
9980697|NCT01394432|Placebo Comparator|Group 2 (PCI+Placebo)|Placebo
9980698|NCT01394445|Active Comparator|Physostigmine|
9719947|NCT04530955|No Intervention|Control Arm|"Patients randomized to the Control Arm that have been implanted with the valve-gated pump will be started on an equivalent dose (without change to the medication concentration) as prior to implant. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be modified, the dose can be modified as clinically indicated. Multiple dosing decreases may be performed if the patient is clinically demonstrating a reduction in spasticity that is profound and negatively impacting function, or if the patient is demonstrating signs of baclofen overdose.~The criteria for dosing decrease will be clinical discretion."
9719948|NCT04530955|Active Comparator|Study Arm|"Patients randomized to the Study Arm will be started on a 20% dose reduction (without change to the medication concentration) through the newly implanted valve-gated pump. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be increased or decreased, the dose can be increased/decreased as clinically indicated. If the dose increases with the valve-gated pump reach the patients' baseline dose and the patient's spasticity is worse than his or her spasticity at baseline, then the patient will be considered a primary endpoint failure.~The criteria for dosing increase will be clinical discretion."
9719949|NCT04531124||control group without an integrated management|
9719950|NCT04531124||observational group with an integrated management|
9719951|NCT04530968||Emerged from Minimally Conscious State (EMCS)|Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic
9719952|NCT04530968||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
9719953|NCT04530968||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
9719954|NCT04530968||Healthy controls (HCs)|Healthy controls (HCs)
9719955|NCT04531280|Experimental|Home hospital care|Patients receive hospital-level care in their home, as a substitute to traditional hospital care.
9719956|NCT04530903|Experimental|Group Clonidine|Group Clonidine will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine and 75 µg of clonidine per side.
9719957|NCT04530903|Placebo Comparator|Control|Group Control will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine per side; 0.5 ml of 0.9% NaCl will be added to each syringe to homogenise the volume in order to remain blind.
9719958|NCT04531033|Placebo Comparator|Placebo|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
9719959|NCT04531033|Experimental|Low dose 10 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
9719960|NCT04531033|Experimental|High dose 15 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
9719961|NCT04530929|Active Comparator|Group PROBIOTIC|The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies). Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
9719962|NCT04530929|Placebo Comparator|Group PLACEBO|Placebo created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.. Competitors used placebo for three months at a dose of 2x2 capsules daily.
9719963|NCT04530448|Active Comparator|Standard of Care|Standard of Care treatment
9719964|NCT04530448|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
9719965|NCT04530474|Experimental|Ivermectin|Single dose of 0.15-2 mg/kg/dose to a maximum of 12 mg
9719966|NCT04530474|Placebo Comparator|Placebo|Single dose of 2-4 placebo pills
9719967|NCT04530669|Experimental|study group|"in the active arm patients will receive high tone power therapy in addition to the physical therapy conventional selected exercise program"
9719968|NCT04530669|Sham Comparator|control group|"the sham arm will receive the same physical exercise program with sham high tone power therapy."
9719969|NCT04530500||Arm 1|Males first tested positive for SARS-CoV-2 at the site (medical center) with CAG length <24 (based on the CoVAST Test)
9719970|NCT04530500||Arm 2|Males first tested for SARS-CoV-2 at the site (medical center) with CAG length >=24 (based on the CoVAST Test)
9719971|NCT04530396|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
9719972|NCT04530396|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
9719973|NCT04530578|Experimental|NEBULIZED HEPARIN|"Nebulized Heparin (UNF)5000 IU in Saline Solution1 ml every 8 hours plus Enoxaparine 40mg /d or 60mg/d, adjusted by BMI and calculated creatinine clearance .~Device to nebulize without producing aerosolization:~To nebulized heparin we have a modified a fullface snorkel mask, in which instead of the discharge valve a connector for the Venturi has been placed, and in the air outlet / inlet of the snorkel it has been adapted a connector made with 3D printing for the insertion of a disposable antiviral filter (filters commonly used in Mechanical Respiratory Assistance devices).~The mask is made of materials that allow its sterilization with the STERRAT Hydrogen Peroxide plasma system, available at the institution."
9719974|NCT04530578|Active Comparator|Enoxaparine|Enoxaparin 40mg/d or 60mg/d adjusted by BMI and calculated creatinine clearance
9719975|NCT04530786||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
9719976|NCT04530786||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
9719977|NCT04530422|Experimental|• Group I (Sofosbuvir plus Ledipasvir)|Patients assigned to this group (125 patients) were received Sofosbuvir plus Ledipasvir, once daily for 15 to 21 days as minimum and maximum duration of therapy, respectively.
9980699|NCT01394445|Placebo Comparator|Placebo|
10196655|NCT05183555|Experimental|Patients with definite IE will be included and referred for 18F-FDG PET/CT in the study|Fourteen patients with definite IE according to the modified Duke criteria (Li) will be included and referred for 18F-FDG PET/CT in the study. A 68Ga-DOTATOC PET/CT scan will be performed specifically for research at 24 hours.
10196656|NCT05183503||TMD group|Patients diagnosed with TMD
10196657|NCT05183451|Experimental|LG (Group A)|En- masse retraction using NiTi closed coil springs rendering 200 g/side were employed following first premolars extraction and insertion of buccal TADs to provide maximum anchorage. Retraction was done along with the application of LLLT till the end of retraction.
10196658|NCT05183451|Active Comparator|NLG (Group B)|En- masse retraction using NiTi closed coil springs rendering 200 g/side were employed following first premolars extraction and insertion of buccal TADs to provide maximum anchorage. No LLLT was applied to this group
9719978|NCT04530422|Active Comparator|Group II (Oseltamivir plus HCQ & Azithromycin)|"Patients in this group (125 patients) were received the local medical committee of Almaza Fever Hospital guided standard treatment protocol for COVID-19:~Oseltamivir 150 mg q 12 hours for 10 days ;~HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.~Additional conservative medications were also given. Patients were evaluated as scheduled on day 0, 5 & 11 clinically"
9719979|NCT04530591||Patient Participants|"This group of participants will complete a survey about their opioid use history and their preferences for a device-based intervention. They will then participate in a semi-structured interview to provide feedback on non-functional, looks-like prototypes of such a device."
9719980|NCT04530721||stroke group|
9719981|NCT04530721||normal group|
9719982|NCT04530617|Active Comparator|Camostat mesilate|100 mg tablet, 600 mg/day. Oral, 2 tablets three times a day, after a meal (600 mg total daily dose) Days 1-14.
9719983|NCT04530617|Placebo Comparator|Camostat Placebo|Matched placebo
9719984|NCT04530617|Active Comparator|Artemisia annua|Tea 225mg per bag,1350 mg/day. Oral, one 8 oz brewed tea (two bags) three times a day, Days 1-14.
9719985|NCT04530617|Placebo Comparator|Artemisia annua Placebo|Matched placebo
9780054|NCT04102254|Experimental|ANT recording and stimulation|Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation. Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery. Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered. Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place. Up to three times daily, standard intermittent high-frequency stimulation [130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
9780055|NCT04085367|Experimental|MAL 16.8% Cream|Participants received two treatment session at least 2 weeks apart. Investigator applied a thin layer of methyl aminolevulinate (MAL) hydrochloride 16.8% cream to each lesion during treatment. At 30 minutes after cream application, participants went outside in daylight for 2 hours (Daylight photodynamic therapy [DL-PDT]). After this time, the cream was removed by investigative site personnel by washing the skin with gentle skin cleanser.
9780056|NCT04085367|Placebo Comparator|MAL Vehicle Cream|Participants received two treatment session at least 2 weeks apart. Investigator applied a thin layer of vehicle cream to each lesion during treatment. At 30 minutes after cream application, participants went outside in daylight for 2 hours (DL-PDT). After this time, the cream was removed by investigative site personnel by washing the skin with gentle skin cleanser.
9780057|NCT04084366|Experimental|OBI-999 Escalation phase|Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).
9780058|NCT04084366|Experimental|OBI-999 Expansion Phase|Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.
9780059|NCT04073810||Myocardial infarction|Patients with recent MI
9780060|NCT04071977|Active Comparator|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
9780061|NCT04071977|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
9780062|NCT04063995|Experimental|Excitatory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment with 10 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 15 minutes and a total of 1500 beats in the form of a 5 seconds 10 Hz stimulation followed by a 25 seconds interval.
9780063|NCT04063995|Experimental|Inhibitory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 25 minutes and a total of 1500 beats in the form of 1 Hz stimulation.
9780064|NCT04063995|Sham Comparator|Sham repetitive transcranial magnetic stimulation group|Single session of sham application for a total of 25 minutes. Sham application will be performed by holding the probe of the device vertically to the vertex. The device will be operated at the lowest operating power of 1 to produce the same stimulation sounds like the active application. The device operating at this power is not likely to give any stimulation due to the probe being held upright.
9780065|NCT04063670|Active Comparator|Control|Routine, standard-of-care treatment
9780066|NCT04063670|Experimental|Video Intervention|Routine, standard-of-care PLUS peri-operative video series
9780067|NCT04055909|Experimental|nangibotide 1|
9780068|NCT04055909|Experimental|nangibotide 2|
10196659|NCT05183438||patients with metachronous colorectal adenomas|
10196660|NCT05183438||patients without metachronous colorectal adenomas|
9719986|NCT04530708|No Intervention|A: Standard of care|Normal standard of care and follow-up.
10196661|NCT05183386|No Intervention|Control Group|The dental socket heals spontaneously
10196662|NCT05183386|Experimental|Experimental group|Distinct bone graft regeneration strategies (PRGF, Autologous bone and DFDBA)
9719987|NCT04530708|Experimental|B: Thoracic radiotherapy|Addition of thoracic radiotherapy to 36 Gy after medical treatment.
10196663|NCT05183373||Aneurysmal coronary artery disease|Patients with coronary artery ectasia or/and aneurysm diagnosed during coronary angiography
10196664|NCT05183373||Abdominal aortic aneurysm|Patients with diagnosed with abdominal aortic aneurysm
9719988|NCT04530695|Experimental|Arm A: Deep Cleaning|participants with periodontitis will undergo treatment by scaling and root planing (SRP)
9719989|NCT04530695|No Intervention|Arm B: No cleaning|participants with periodontitis will undergo no periodontal treatment
9719990|NCT04530487|Experimental|Treatment (conditioning regimen, HSCT)|"CONDITIONING REGIMEN: Patients receive thiotepa IV over 2-4 hours, etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -3 and -4.~TRANSPLANT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive PO. Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90."
9719991|NCT04530370|Experimental|Recovered covid 19 plasma|
9719992|NCT04530370|Placebo Comparator|controlled|
9719993|NCT04530240||ERA-1 Group|Before the introduction of the MELD≥30 allocation scheme August 2010 - July 2014
9719994|NCT04530240||ERA-2 Group|After the introduction of the MELD≥30 allocation scheme August 2014 - July 2018
9719995|NCT04530201|Other|Sample collection|Women will self-collect two first-void urine samples at home, the day prior to colposcopy. During the colposcopy visit, the clinician will collect an additional cervical smear. Colposcopy and histology results (when available) will be used as reference test.
9719996|NCT04530266|Active Comparator|Persons with knee osteoarthritis|
9719997|NCT04530266|Placebo Comparator|Healthy controls|
9719998|NCT04530357|Experimental|Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9719999|NCT04530357|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9720000|NCT04530357|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9720001|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9720002|NCT04530357|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder
9720003|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
9720004|NCT04530331|Experimental|Intervention group|Providing nutrition education.
9720005|NCT04530331|No Intervention|Control group|Without any intervention.
9720006|NCT04529954|Experimental|Open-Label Safety|Participants roll-over from DA071976
9720007|NCT04530045||critically ill patients|Critically ill patients receiving continuous infusion of piperacillin/tazbactam or cefepim and dosage of plasma concentration of the B lactam administered
9720008|NCT04530136|Experimental|Ruconest|Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
9720009|NCT04530136|Other|Standard of Care|SOC
9720010|NCT04529993|Experimental|Interstitial pulmonary fibrosis|
9720011|NCT04529993|Experimental|Chronic obstructive pulmonary disease|
9720012|NCT04529993|Experimental|Healthy volunteers|
9720013|NCT04530084|Experimental|Diagnosed with open angle glaucoma|
9720014|NCT04530292|Experimental|intervention by a pediatric nurse at the child's home|"The pediatric nurse will visit the patient's home 3 times during the first six months of the discovery of diabetes in children. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit can be organized according to the needs of families.~The pediatric nurse will ensure the implementation of learning in terms of drug therapy (modality of insulin administration, adaptation of insulin doses) and diet, according to the knowledge acquired during the initial hospitalization. She will offer her help to the families to make a connection with the school and after-school activities of the child.~In addition to these visits, the child and his family will come to the hospital as part of the regular medical follow-up: consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes."
10196665|NCT05183373||Coronary artery disease|Patients with diagnosed with coronary artery disease
10196666|NCT05183334|Placebo Comparator|group 1|patients with PE
10196667|NCT05183334|Experimental|group2|patients with PE
10196668|NCT05183334|Experimental|group 3|patients with PE
10196669|NCT05183334|Experimental|group 4|patients with PE
10196670|NCT05183295|Experimental|Experimental: Nonessential Amino Acid Restriction (NEAAR) Medical Food|This is a single arm study in which all subjects will receive NEAAR medical food and standard of care FDA approved chemotherapy. Each week NEAAR medical food will be consumed 5 consecutive days followed by 2 days of habitual food.
10196671|NCT05183269|Experimental|Virtual reality|Normal procedure with the use of a virtual reality monitor
9720015|NCT04530292|No Intervention|Classic strategy (for retrospective group)|The child and his family benefited from a consultation with a pediatric nurse at 1 month of the discovery of T1D and had medical consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes. The data from this group were collected in a previous study (collection of retrospective data) for children whose parents were in a precarious social situation and whose management was traditional.
9720016|NCT04530097|Experimental|RFA+MLT|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
9720017|NCT04530097|No Intervention|RFA|Radiofrequency ablation was performed immediately after enrollment, and a placebo treatment program was given for 6 months after 1 week after radiofrequency.
9720018|NCT04530188|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
9720019|NCT04530188|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already used in our ICU
9720020|NCT04530318|Experimental|TolDec|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
9720021|NCT04530318|Placebo Comparator|Placebo|Placebo of dendritic cells
9720022|NCT04530071|Experimental|CordSTEM-DD(0.7x10^7 cells|Tissuefill+saline+CordSTEM-DD(0.7x10^7 cells)
9720023|NCT04530071|Experimental|CordSTEM-DD(2.1x10^7 cells)|Tissuefill+saline+CordSTEM-DD(2.1x10^7 cells)
9720024|NCT04530123|Placebo Comparator|Cohort 1: Placebo (2 Infusions)|Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 placebo-matching intravenous (IV) infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
9720025|NCT04530123|Experimental|Cohort 1: TAK-101 2 mg/kg (1 Infusion) + Placebo (1 Infusion)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
9720026|NCT04530123|Experimental|Cohort 1: TAK-101 2 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
9720027|NCT04530123|Placebo Comparator|Cohort 2: Placebo (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
9720028|NCT04530123|Experimental|Cohort 2:TAK-101 4 mg/kg (1 Infusion)+placebo (1 Infusion)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
9720029|NCT04530123|Experimental|Cohort 2: TAK-101 4 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
9720030|NCT04530123|Experimental|Cohort 2: TAK-101 1 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
9720031|NCT04530227|Experimental|Camrelizumab combined with chemotherapy|"Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy.~Interventions:~Biological: Camrelizumab"
9720032|NCT04529811|Experimental|Formulation 1 - Low Dose|Rifaximin Formulation 1 Capsules
9720033|NCT04529811|Experimental|Formulation 1 Capsules - Mid Dose|Rifaximin Formulation 1 Capsules
9720034|NCT04529811|Experimental|Formulation 1 Capsules - High Dose|Rifaximin Formulation 1 Capsules
9720035|NCT04529811|Experimental|Formulation 1 Capsules - Max Dose|Rifaximin Formulation 1 Capsules
9720036|NCT04529811|Placebo Comparator|Formulation 1 Capsules - Placebo|Placebo Formulation 1 Capsules
9720037|NCT04529811|Experimental|Formulation 2 - Low Dose|Rifaximin Formulation 2 Capsules
9720038|NCT04529811|Experimental|Formulation 2- Mid Dose|Rifaximin Formulation 2 Capsules
9720039|NCT04529811|Experimental|Formulation 2 - High Dose|Rifaximin Formulation 2 Capsules
9720040|NCT04529811|Experimental|Formulation 2 - Max Dose|Rifaximin Formulation 2 Capsules
9720041|NCT04529811|Placebo Comparator|Formulation 2 - Placebo|Placebo Formulation 2 Capsules
9720042|NCT04529811|Experimental|Formulation 3 - Low dose|Rifaximin Formulation 3 Capsules
9720043|NCT04529811|Experimental|Formulation 3 - Mid dose|Rifaximin Formulation 3 Capsules
9720044|NCT04529811|Experimental|Formulation 3 - High dose|Rifaximin Formulation 3 Capsules
9720045|NCT04529811|Experimental|Formulation 3 - Max dose|Rifaximin Formulation 3 Capsules
9720046|NCT04529811|Placebo Comparator|Formulation 3 - Placebo|Placebo Formulation 3 Capsules
10196672|NCT05183269|No Intervention|no virtual reality|Normal procedure without the use of a virtual reality monitor
10196673|NCT05183204|Experimental|Arm 1: Newly diagnosed MGMT unmethylated glioblastoma|
10196674|NCT05183204|Experimental|Arm 2: Recurrent glioblastoma, regardless of methylation status|
10196675|NCT05183191|Experimental|Intervention group|
10196676|NCT05183152|Experimental|NMES-BCI|Sensory-threshold electrical stimulation is delivered to the flexors/extensors of the forearm contingent to the voluntary activation of the motor cortex by motor imagery of hand flexion/extension as detected by a closed-loop BCI.
9720048|NCT04529447||Patient satisfaction survey|Jaseng Hospital of Korean medicine conducted a pen and paper survey on patient satisfaction with regard to its COVID-19 response in inpatients hospitalized and outpatients visiting during March 23-25, 2020.
9720049|NCT04529759|Active Comparator|Control Infant Formula|Feed ad libitum
9720050|NCT04529759|Experimental|Experimental Infant Formula|Feed ad libitum
9720051|NCT04529486|Experimental|Group 1: Kinesio taping|Kinesio taping was applied to the study group to improve posture and improve function in the shoulder area. Measurements were carried out for the study group before and after application (with tape on). The tape was then removed and the measurements were repeated after 1 week.
9720052|NCT04529486|No Intervention|Group 2: Control|No application was made to the control group.
9720053|NCT04529785|Active Comparator|SVC only|Patients in Group 1 will receive an SVC isolation only
10196677|NCT05183152|Active Comparator|Visual-BCI|Bar-based visual feedback is provided on a screen contingent to the voluntary activation of the motor cortex by motor imagery of hand flexion/extension as detected by a closed-loop BCI.
10196678|NCT05183139|Experimental|Cohort A: Ixazomib 4 mg + Pomalidomide 4 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with pomalidomide 4 mg, capsules, orally from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of pomalidomide or dexamethasone can start at that dose level in the study.
9720054|NCT04529785|Active Comparator|SVC isolation with substrate modification and VoM inf|Patients in Group 2 will receive an SVC isolation with substrate modification and vein of Marshal ethanol infusion
9720055|NCT04529746|Experimental|EVERYbody Project: Professional facilitator version|"The EVERYbody Project is a dissonance body image intervention created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and through an iterative process of student-driven feedback. The Body Project manual (Stice et al., 2006) was adapted to retain key dissonance activities while expanding the gender focus, adding an exploration of the diversity characteristics within appearance ideals, and adjusting activities to be inclusive of diversity characteristics. Several adapted versions of the intervention were piloted with groups of college students and further adapted based on feedback.~Facilitators received 16 hours of training on the EVERYbody Project manual and facilitation guidelines."
9720056|NCT04529746|No Intervention|Waitlist control group|Participants allocated to the waitlist completed assessments at time points parallel to those in the EVERYbody Project condition and were offered the EVERYbody Project upon completing the one-month follow-up assessment.
9720057|NCT04529681|Experimental|Intervention Group|Intervention group will be equipped with Stroke Riskometer Apps and informational leaflets. In the beginning of the study, investigators will guide the participants to download and install the Stroke Riskometer Apps and how to use the application to measure, monitor and self-manage the stroke risk. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
9720058|NCT04529681|Other|Control Group|Control group will be given the informational leaflets consist of stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
9720059|NCT04529668|Experimental|group I|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will receive vitamin D supplementation
9720060|NCT04529668|Active Comparator|group II|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will NOT receive vitamin D supplementation
9720061|NCT04529590||Patients with cardiovascular events after 18 years|"Analyzing metabolic markers screened and optimized by multivariate statistical with plasma metabolic profiles from peripheral blood samples of different groups.~Positive patients' samples will be collected at baseline."
9720062|NCT04529590||Patients without cardiovascular events after 18 years|For negative patients' samples will be collected at baseline as negative control.
9720063|NCT04529694|Active Comparator|Cognitive-only Intervention|This condition includes cognitive interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
9720064|NCT04529694|Active Comparator|Behavioral-only Intervention|The condition includes behavioral interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
9720065|NCT04529642||Stroke Group|Inclusion criteria were as follows: age above 18, Mini-Mental State Examination ≥ 24, ability to provide written informed consent and to understand the test instructions, and the presence of a single stroke. Exclusion criteria were as follows: more than one stroke, stroke area other than the cerebral cortex, or concomitant neurological disease and pathology of the locomotor system. This group has been analysed also dividing the subjects according to the stroke phase in 3 subgroups: Acute phase group, Subacute phase group, Chronic stroke group
9720066|NCT04529642||Healthy Group|Healthy subjects age matched with the stroke group
9720067|NCT04529603|Experimental|Arm 1|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
9720068|NCT04529434|Experimental|Arm 1|Households living in novel-design houses.
9720069|NCT04529434|Other|Arm 2|Households living in traditional African houses.
9780069|NCT04055909|Placebo Comparator|Placebo|
9720070|NCT04529525|Active Comparator|Ivermectin|"The dose of ivermectin in patients who are randomized to the active substance depends on the weight of the patient:~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
9720071|NCT04529525|Placebo Comparator|Placebo|"The dose of placebo in patients who are randomized to the this depends on the weight of the patient:~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
9720072|NCT04529551|Experimental|1601A, 1601B product use order|Subjects will use 1601A for 1 week and then 1601B for 1 week.
9720073|NCT04529551|Experimental|1601B, 1601A product use order|Subjects will use 1601B for 1 week and then 1601A for 1 week.
9720074|NCT04529512|Experimental|Receiving DEXTENZA® 1-3 days prior to surgery|Participants to receive DEXTENZA® 1-3 days prior to surgery
9720075|NCT04529512|Experimental|Receiving DEXTENZA® 1-2 weeks prior to surgery|Participants to receive DEXTENZA® 1-2 weeks prior to surgery
9720076|NCT04529512|Experimental|Receiving DEXTENZA® 1 month prior to surgery|Participants to receive DEXTENZA® 1 month prior to surgery
9720077|NCT04529512|No Intervention|Not receiving the DEXTENZA® implant|Participants will not receive the DEXTENZA® implant
9720078|NCT04529382||Cohort 1: Unanticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 1 will be FNAIT cases that were not antenatally treated with by maternal IVIg administration (or other forms of fetal therapy).
9720079|NCT04529382||Cohort 2: Anticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 2 will be FNAIT cases which were anticipated antenatally by maternal IVIg administration according to our local protocol.
9720080|NCT04529408||COVID-19 Follow up clinic|Patients attending routine post-COVID-19 follow up clinic
9720081|NCT04529408||Pulmonary Disease clinic|Patients attending routine outpatient appointment for pulmonary disease
9720082|NCT04529421||Students, Higher Education Institution 1|All first, second, and third year students at Higher Education Institution 1 who agree to take part in study.
9720083|NCT04529421||Students, Higher Education Institution 2|All first, second, and third year students at Higher Education Institution 2 who agree to take part in study.
9720084|NCT04529421||Students, Higher Education Institution 3|All first, second, and third year students at Higher Education Institution 3 who agree to take part in study.
9720085|NCT04529421||Students, Higher Education Institution 4|All first, second, and third year students at Higher Education Institution 4 who agree to take part in study.
9720086|NCT04529421||Students, Higher Education Institution 5|All first, second, and third year students atHigher Education Institution 5 who agree to take part in study.
9720087|NCT04529421||Students, Higher Education Institution 6|All first, second, and third year students at Higher Education Institution 6 who agree to take part in study.
9720088|NCT04529421||Students, Higher Education Institution 7|All first, second, and third year students at Higher Education Institution 7 who agree to take part in study.
9720089|NCT04529421||Students, Higher Education Institution 8|All first, second, and third year students at Higher Education Institution 8 who agree to take part in study.
9720090|NCT04529421||Students, Higher Education Institution 9|All first, second, and third year students at Higher Education Institution 9 who agree to take part in study.
9720091|NCT04529421||Students, Higher Education Institution 10|All first, second, and third year students at Higher Education Institution 10 who agree to take part in study.
9720092|NCT04529421||Students, Higher Education Institution 11|All first, second, and third year students at Higher Education Institution 11 who agree to take part in study.
9720093|NCT04529421||Students, Higher Education Institution 12|All first, second, and third year students at Higher Education Institution 12 who agree to take part in study.
9720094|NCT04529421||Students, Higher Education Institution 13|All first, second, and third year students at Higher Education Institution 13 who agree to take part in study.
9720095|NCT04529421||Students, Higher Education Institution 14|All first, second, and third year students at Higer Education Institution 14 who agree to take part in the study.
9720096|NCT04529330||fractures with blister appeared|tibial plateau fractures with blister observed
9720097|NCT04529330||fractures without blister appeared|tibial plateau fractures without blister observed
9720098|NCT04529356|Sham Comparator|Simple acetaminophen treatment|Acetaminophen will be taken when patients suffered from headache during the study. No specific dosage and frequency was required for this group as long as the participants record the exact drug usage.
9720099|NCT04529356|Active Comparator|Simple acetaminophen combined with low-frequency rTMS|Apart from acetaminophen usage, low frequency TMS (1HZ) will be used in patients three times a month for 6 months.
9720100|NCT04529356|Experimental|Simple acetaminophen combined with high-frequency rTMS|Apart from acetaminophen usage, high frequency TMS (10HZ) will be used in patients three times a month for 6 months.
9720101|NCT04529213|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel
9720102|NCT04529213|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel
9720103|NCT04529213|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
9720104|NCT04529083|Experimental|Intervention|Mixed Reality System for virtual mirror therapy
9720105|NCT04529031|Active Comparator|RFPP group intervention|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices.
9720106|NCT04529031|Sham Comparator|attentional control condition (group process)|Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy. Parents will receive 4 sessions of relaxation techniques.
9720107|NCT04529057|Experimental|Tooth-borne (Hyrax) expander|
9720108|NCT04529057|Experimental|Tooth tissue-borne (KBME) expander|
9720109|NCT04529057|Experimental|Bone-borne (MIDME) expander|
9720110|NCT04529044|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30-40 minutes during weeks 1, 8, 16, and 24 in the absence of disease progression or unacceptable toxicity.
9720111|NCT04529135|Experimental|Dexmedetomidine|IV,0.2~0.8 µg/kg/hr
9720112|NCT04529135|Active Comparator|Remifentanil|IV,0.05~0.2 µg/kg/min
9720113|NCT04529187|Active Comparator|DEX group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a dexmedetomidine infusion in a rate of of 0.7 ug.kg-1.hr-1will be initiated. After 5 minutes of dexmedetomidine therapy a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
9720114|NCT04529187|Active Comparator|MID group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a single dose of midazolam (2 mg intravenously) will be given to each participant in this arm. After 5 minutes of midazolam administration a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
9720115|NCT04529148|Experimental|The treatment group|Ginkgo biloba dropping pills (63mg / pill), oral, 5 pills each time, three times a day,12 weeks totally. ( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
9720116|NCT04529148|Placebo Comparator|The control group|Mimetic drug of ginkgo biloba dropping pills (63mg / pill),oral, 5 pills each time, three times a day,12 weeks totally.( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
9720117|NCT04529369|Experimental|Prominent middle lobe BPH satisfactory channel after MLO PVP|
9720118|NCT04529369|Active Comparator|Prominent middle lobe BPH unsatisfactory channel after MLO PVP|
9720119|NCT04529343|Experimental|Virtual Reality Group|To the virtual reality group; In addition to upper extremity exercises applied 2 days a week, upper extremity rehabilitation via virtual reality glasses will be performed 3 days a week for 6 weeks and each session will be 45 minutes.
9720120|NCT04529343|Active Comparator|Control Group|Upper extremity exercises will be applied to the participants in the control group 2 days a week for 6 weeks.
9720121|NCT04529005|Experimental|Angiotensin II (Giapreza)|
9720122|NCT04529317|No Intervention|Regular diet|The study was a cross-over pilot clinical study consisting of two periods. The first period was only an observational and monitoring phase where participants just continued with their regular diet (RD), for this reason all participants initiated this period and wash-out term was no needed.
9720123|NCT04529317|Experimental|Quinoa diet|With the data of the first phase obtained, the subjects began the second period in which they had to undergo a nutritional intervention with a quinoa diet (QD).
9720124|NCT04529200|Experimental|1. Comprehensive fall prevention protocol group (CARE)|every week protocol change for every patient according to 1 repetition maximum
9720125|NCT04529200|Active Comparator|2. Conventional balance training group|conventional protocol commonly used for rehabilitation
9720126|NCT04529018|Experimental|Healthy Volunteers|A group of 5 healthy volunteers will be tested with the PET radiotracer [18F]CETO to assess safety of tracer administration, and evaluate uptake by the normal adrenal glands.
9720127|NCT04529018|Experimental|Patients with primary aldosteronism|A group of 6 patients with Primary Aldosteronism (3 with unilateral and 3 with bilateral disease) will be tested with up to two administrations of the PET radiotracer [18F]CETO, to assess safety of tracer administration, evaluate the ability of [18F]CETO to distinguish between unilateral and bilateral cases of PA, and determine the effect of Dexamethasone in improving the quality of PET-CT images acquired following administration.
9720128|NCT04528992|Experimental|Physical Therapy with BFR|Participants will begin BFR therapy as early as 2 weeks after surgery. The initial 2 weeks after surgery, or prior to initiation of BFR will consist of the physical therapy following the surgeon's postoperative protocol.
9720129|NCT04528992|Active Comparator|Physical Therapy without BFR|Participants will undergo standard physical therapy following the surgeon's postoperative protocol.
9720130|NCT04529226|Experimental|Clozapine|Pharmaceutical Form: Tablet ATC Code: N05AH02
9720131|NCT04529226|Active Comparator|Control|Usual antipsychotic medication used in the treatment of treatment-resistant psychosis.
9720132|NCT04528979|Experimental|Primary root canal treatment|Primary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
9720133|NCT04528979|Experimental|Secondary root canal treatment|Secondary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
9720134|NCT04529161|Experimental|Group A|Diet followed by routine eating
9720135|NCT04529161|Experimental|Group B|Routine eating followed by diet
9720136|NCT04528914|Experimental|Low-FODMAP diet|37 participants.
9720137|NCT04528914|No Intervention|Regular diet|"37 participants. The regular diet will reflect the habitual FODMAP intake in a normal diet.~Diets in both groups will be matched in terms of total energy, fat, protein, carbohydrates and dietary fiber with the usual participant's diet."
9720138|NCT04528966|Experimental|Treatment Group|Group that have received whole-body vibration treatment in addition to conventional physiotherapy
9720139|NCT04528966|Active Comparator|Control group|Group that have received conventional physiotherapy only
9720140|NCT04528628|Experimental|MDD with melancholic features|
9720141|NCT04528628|Experimental|MDD with atypical features|
9720142|NCT04528628|Experimental|MDD with anxious distress|
9720143|NCT04528628|Experimental|MDD (overall)|
9720144|NCT04528953|Experimental|interval group|
9720145|NCT04528953|Experimental|Qigong exercise|
9720146|NCT04528953|Active Comparator|continuous walking|
9720147|NCT04528758|Experimental|Dosimetry group|Patients in the dosimetry group will be imaged with the radio-pharmaceutical Rhodamine 6G at different time points. 0-120, 30-150, 60-180
9720148|NCT04528758|Active Comparator|Stable Heart Patients|Stable heart patients will be given a rest/stress PET/CT with Rhodamine 6G myocardial perfusion study to determine myocardial blood flow
9720149|NCT04528706|Experimental|MIN-102|
9720150|NCT04528862|Experimental|Nature|
9720151|NCT04528862|Sham Comparator|Urban|
9720152|NCT04528589||Mothers|Women with adverse childhood experiences referred for treatment in gestational week 20-30
9720153|NCT04528589||Therapists|Clinicians with experience of providing psychotherapy to women with adverse childhood experiences referred for treatment during pregnancy
9720154|NCT04528797|Experimental|Levothyroxine|Levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
9720155|NCT04528797|Experimental|Methylprednisolone|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later.
9720156|NCT04528797|Experimental|Combination|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later plus levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
9720157|NCT04528797|No Intervention|Control|No levothyroxine or methylprednisolone administered.
9720158|NCT04528602|Experimental|Control (Extended leg position) Group|In the control (Extended leg position) group of the study, diaper change will be performed after the legs of the babies are brought to extension.
9720159|NCT04528602|Experimental|Experimental (Legs are flexed toward abdomen) Group|In the experimental (Legs are flexed toward abdomen) group, the diaper change will be performed after the legs of the babies are brought closer to the abdomen while maintaining their flexion leg position.
9720160|NCT04528693|Experimental|Intervention|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will perform, for a period of 3 months, 3 times a week, strength training, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software.
9720161|NCT04528693|No Intervention|Control|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will be asked to maintain their current level of physical activity and their diet for a period of 3 months.
9720162|NCT04528745||Patients with cancer receiving cytostatic treatment|Consecutive patients referred for cytostatic treatment or in treatment with cytostatic agents for colorectal or pancreatic cancer
9720163|NCT04528888|Active Comparator|LMWH group|The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). Patients in this group will be administered enoxaparin at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment with enoxaparin will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The treatment will be administered subcutaneously, daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
9720164|NCT04528888|Experimental|LMWH + steroids group|"The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization).~Patients in this group will receive enoxaparin and methylprednisolone. Enoxaparin will be administered at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered subcutaneously daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14."
9720165|NCT04528888|Experimental|UFH + steroid group|The treatments will be initiated as soon as possible after randomization (maximum 12h). Patients will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
9720166|NCT04528823|No Intervention|Standard care (control arm)|Strategy 1: Symptoms screen, CXR and TST (standard)
9720167|NCT04528823|Active Comparator|GeneXpert (GX)|Strategy 2: Symptoms screen, Genexpert and TST
9720168|NCT04528823|Active Comparator|CXR for all/NoTST|Strategy 3: Symptoms screen, CXR but NO TST
9720169|NCT04528784|Experimental|Intervention|Transcutaneous tibial nerve stimulation will be applied as follows: 18 sessions of 30 minutes duration, delivered three times a week over a 6 week period using TENS device with 10 Hertz (Hz), and pulse width 200µs. The intensity of stimulation will be at the sensory and motor threshold by tingling sensation on sole of the foot with flexion of big toe and /or fanning of other toes.
9720170|NCT04528615|Experimental|CCK In-Person Sessions|This group received the in-person CCK intervention.
9720171|NCT04528615|Active Comparator|CCK Printed Materials|This group received select printed CCK materials.
9720172|NCT04528927|Experimental|HCQ+Azithromycin|"Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Usual standard treatment"
9720173|NCT04528927|Experimental|HCQ+Azithromycin+Zinc|"HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Zinc: 220 mg per day for 10 days~Usual standard treatment"
9720174|NCT04528927|Experimental|Azithromycin+Doxycycline|"Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days~Doxycycline: 200 mg per day for 10 days.~Usual standard treatment"
9720175|NCT04528654|Experimental|Intervention App Group|The intervention group will be instructed to download the chosen hypertension mobile health app (Sphygmo BP) via a link provided on the platform. The hypertension app has blood pressure tracking and monitoring features and they are instructed to use the app. They will also receive a link to the Heart and Stroke foundation website which includes information on hypertension management and measuring blood pressure.
9720176|NCT04528654|No Intervention|Educational Control Group|The control will comprise usual care including any anti-hypertensive medication and lifestyle changes, and the link to the Heart and Stroke Foundation website which includes information on hypertension management and measuring blood pressure.
9720177|NCT04528550|Experimental|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection in acute phase. Each included patient will receive a single dose of 100 million autologous bone marrow-derived mononuclear cells.
9720178|NCT04528550|Placebo Comparator|Control|Included patients will receive the same amount of saline through lumbar injection.
9720179|NCT04528849|Active Comparator|Early dose increment|Patients who have received 25 IU gonadotropin dose increment on 7th day of ovulation induction
9720180|NCT04528849|Active Comparator|Late dose increment|Patients who have received 25 IU gonadotropin dose increment on 14th day of ovulation induction
9720181|NCT04528485|Experimental|Sea swimming|8 sessions over 4 weeks of swimming-based activities in the sea
9720182|NCT04528472|Experimental|Acupuncture Treatment|Acupuncture Treatment: main point: DU20, DU24, MS7, LI4, ST40 Oral Medicine Rehabilitation Treatment
9720183|NCT04528472|Experimental|Regular Treatment|Acupuncture Treatment Oral Medicine Rehabilitation Treatment
9720184|NCT04528277|Experimental|LGTB treatment group|The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine (150mg per capsule, 450mg po tiw) plus isoniazid (100mg per tablet, 400mg po tiw).
9720185|NCT04528277|No Intervention|LGTB no treatment group|The LGTB no treatment group will not take any medication related to preventive treatment of tuberculosis.
9720186|NCT04528277|No Intervention|non-LGTB group|The non-LGTB group will not take any medication related to preventive treatment of tuberculosis.
9720187|NCT04528160|Experimental|Pain neuroscience education and exercise|"This group will receive an 8-week intervention (1 session per week) of pain neuroscience education and exercise.~PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will include mobility, balance and strength exercises."
9720188|NCT04528160|Active Comparator|Usual care|This group will receive usual care administered by general practitioners at primary care.
9720189|NCT04528121|Experimental|study group|(CoDuSe) exercise inform of core stability, dual tasking, and sensory strategies the conventional selected exercise program inform of static and dynamic balance training exercises
9720190|NCT04528121|Experimental|control group|the conventional selected exercise program inform of static and dynamic balance training exercises
9780070|NCT04051944|Experimental|Rozanolixizumab|Subjects in this arm will receive predefined subcutaneous doses of rozanolixizumab at a specified frequency.
9780071|NCT04049643|Active Comparator|Audiologist-Based|In this group, the audiologist-based fitting will be used to provide hearing aids.
9780072|NCT04049643|Experimental|Service-Only|In this group, hearing aids that have minimum amplification will be fitted by audiologists.
9780073|NCT04049643|Experimental|Device-Only|In this group, hearing aids will be provided with minimum services from audiologists.
9780074|NCT04039204|Experimental|Elagolix|Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.
9780075|NCT04039204|Active Comparator|Oral contraceptives (Ortho Cyclen)|Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.
9780076|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells + gemcitabine/nab paclitaxel|"Patients in the anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
9780077|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|"Patients in the anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will have achieved at least stable disease during the Bridging Therapy Period with NLIR + FU/FA, and will receive the CAR-T cells in Cycles 1 and 3 and the NLIR/FU/FA regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
9785221|NCT01246063|Experimental|Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)|Dose Level 0: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (27 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
9720191|NCT04528368|Experimental|Convalescent Plasma + Standard treatment|Participants will receive the standard treatment and convalescent plasma
9720192|NCT04528368|No Intervention|Standard treatment|Participants will receive the standard treatment
10196679|NCT05183139|Experimental|Cohort B: Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with lenalidomide 25 mg capsules, orally, from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally, on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of lenalidomide or dexamethasone can start at that dose level in the study.
10196680|NCT05183113|Experimental|Acute Intermittent Hypoxia|Both healthy participants and those with spinal cord injury will receive the acute intermittent hypoxia (AIH) intervention. All participants are imaged pre- and post-AIH intervention, and thus serve as a self-comparison to observe the hypothesized improvement in bilateral hand strength.
10196681|NCT05183100|Experimental|Experimental Condition (Neurodynamics Treatment)|Neurodynamic treatment for about 13 minutes in supine position. It will be comprised of three stages, and the tensioner technique of the tibial nerve will be used.
10196682|NCT05183100|Active Comparator|Control Condition|Lying in supine.
10196683|NCT05183087||Special Operations Forces (SOF) Personnel|n=30 SOF Personnel
10196684|NCT05183074|Experimental|MR-linac group|Pts received ultra-hypofractionated RT for primary w/o adjacent oligo-metastatic diseases on 1.5-Tesla MR-Linac
9720193|NCT04528290|Experimental|Group A (reference): Current ozanimod capsule formulation|Single oral dose of ozanimod 0.92 mg
9720194|NCT04528290|Experimental|Group B (test): Ozanimod granule formulation|Single oral dose of ozanimod 0.92 mg using Sprinkle capsule. Ozanimod Sprinkle Capsule will be opened, and the entire contents sprinkled onto a teaspoon (5 mL) of applesauce.
9720195|NCT04528511||Low burden of new-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization. Among this subset of patients, those who have a NOAF burden value<10.87% (previously established) will be divided into the low burden group.
9720196|NCT04528511||High burden of new-onset atrial fibrillation|For patients with NOAF complicating AMI, those who have a NOAF burden value≥10.87% (previously established) will be divided into the high burden group.
9720197|NCT04528381|Other|Laparoscopy|Diagnostic and therapeutic laparoscopy
9720198|NCT04528173|Active Comparator|Traditional Care Group (TCG)|Traditional anesthetic with opioids group will receive institutional standard clinical care for tonsillectomy, including a standardized opioid dose at the beginning of the case and again at the end if needed. Dexmedetomidine and Ketorolac will not be used intra-operatively in this cohort to prevent confounding.
9720199|NCT04528173|Experimental|Opioid-Free Group (OFG)|Opioid-Free group will receive institutional standard clinical care for tonsillectomy, without opioids, but including Dexmedetomidine and Ketorolac.
9720200|NCT04528186||1|Low eating index scores(50-70)
9720201|NCT04528186||2|High eating index scores(Above 70)
9720202|NCT04528147|Experimental|Yi Jin Jing Tiger Roaring Speech Rehabilitation|Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.
9720203|NCT04528147|Experimental|Conventional Speech Rehabilitation|"Patients will receive speech rehabilitation recommended by The Parkinson's Foundation.~Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total."
9720204|NCT04528394|Experimental|Photon combined with Carbon ion|The participants received photon: 56 Gy/28 Fx for high-risk area(CTVhigh), 50.4 Gy/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
9720205|NCT04528394|Experimental|Proton combined with Carbon ion|The participants received proton: 56 GyE/28 Fx for high-risk area(CTVhigh), 50.4 GyE/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
9720206|NCT04528420|Experimental|Optimised arm|Patients will be taken care of early and optimally way.
9720207|NCT04528420|No Intervention|Standard arm|Patients will be monitored as in standard practice
9720208|NCT04528095|Experimental|Clozapine|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml
9720209|NCT04528095|Experimental|Clozapine+Amisulpride|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d
9720210|NCT04528095|Experimental|Clozapine+Gingke biloba|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Gingke biloba 120-360mg/d
9720211|NCT04528095|Experimental|MECT|MECT:The treatment lasted for 4 months,16 times in total
9720212|NCT04528095|Experimental|MST|MST:The treatment lasted for 4 months,16 times in total
9720213|NCT04528095|Experimental|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
9720214|NCT04528316|Active Comparator|Control Group/Pilates Core Stability Exercises program Group|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~Stage I: Warm-up: consists of four Pilates motions:~Breathing:~Rolling back:~Coccyx-curl:~Hundred breathing:~Stage II: Work-out: consists of twelve Pilates motions:~Single leg stretch:~Straight leg raise:~Basic bridge:~Bridging variation:~Quadruped:~Clap with seal motion~Mermaid twist:~Swimming:~Double leg stretch:~Shoulder bridge:~Swan dive:~Leg full front:~Stage III: Cool-down: consists of three Pilates motions:~Rest position:~Cat with arm/leg extension:~Breathing:"
9720215|NCT04528316|Experimental|Balance Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Balance Program
9720216|NCT04528316|Experimental|Coordination Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Coordination Exercises.
9720217|NCT04528056|Experimental|Ambrisentan+Sulfasalazine|
9720218|NCT04528056|Active Comparator|Ambrisentan+Sulfasalazine's placebo|
9720219|NCT04528056|Experimental|Ambrisentan's placebo+Sulfasalazine|
9720220|NCT04528056|Placebo Comparator|Ambrisentan's placebo+Sulfasalazine's placebo|
9720221|NCT04528004|Experimental|Nicotinamide riboside|"Participants randomized to Nicotinamide Riboside (NR) and scheduled to receive an LVAD will receive nicotinamide riboside (NR) capsules according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
9720222|NCT04528004|Placebo Comparator|Placebo|"Participants randomized to Placebo and scheduled to receive an LVAD will receive Placebo capsules according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
9720223|NCT04528043||critically ill patients|critically ill patients admitted in one of the 5 ICUs of the university hospital of Nancy during the year 2016 with documented third group enterobacteriaceae infection and/or colonization with third group enterobacteriaceae
9720224|NCT04528264|Experimental|Ultrasound guided|Intraoperative high frequency ultrasound used to guide the reduction of depressed zygomatic arch.
9720225|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction of zygomatic arch fracture will be conducted without any intraoperative imaging.
9720226|NCT04527601||ELGAN admissions during peak three months of COVID-19 pandemic|
9720227|NCT04527601||ELGAN admissions in the three corresponding months of 2019|
9720228|NCT04527692||Child|Children/adolescents from 1 to 18 years of age with a serious illness requiring follow-up by a regional pediatric palliative care resource team and/or temporarily hospitalized.
9720229|NCT04527692||Parents|Adult person with parental authority over a child between the ages of 1 and 18 who is a carrier of a serious illness and requires follow-up by a regional pediatric palliative care resource team and/or is temporarily hospitalized.
9720230|NCT04527848|Experimental|small amount of undiluted C3F8|
9720231|NCT04527848|Active Comparator|large amount of diluted C3f8|
9720232|NCT04527848|Active Comparator|small amount of undiluted SF6|
9720233|NCT04527848|Active Comparator|large amount of diluted SF6|
9720234|NCT04527718|Experimental|Cohort 1|611 dose 1 (45mg) plus placebo
9720235|NCT04527718|Experimental|Cohort 2|611 dose 2 (150mg) plus placebo
9720236|NCT04527718|Experimental|Cohort 3|611 dose 3 (300mg) plus placebo
9720237|NCT04527718|Experimental|Cohort 4|611 dose 4 (450mg) plus placebo
9720238|NCT04527718|Experimental|Cohort 5|611 dose 5 (600mg) plus placebo
9720239|NCT04527913|Experimental|Control group|15 patients receiving oral hygiene instructions as determined by their group allocation (use of manual toothbrush alone)
9720240|NCT04527913|Experimental|Test group 1|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus dental floss)
9720241|NCT04527913|Experimental|Test group 2|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus interdental brushes)
9720242|NCT04527913|Experimental|Test group 3|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus rubber interdental picks)
9720243|NCT04527822|Experimental|Discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
9720244|NCT04527822|Active Comparator|Standard Care|
9720245|NCT04527939|Active Comparator|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
9720246|NCT04527939|Sham Comparator|magnification chromoendoscopy.|magnification chromoendoscopy.
9720247|NCT04527783|Experimental|experimental group|"Each subject will perform a variety of VR exercises to reduce impairments in their finger range of motion, speed and strength.~It includes a glove-shaped sensor device and a software application."
9720248|NCT04527783|Active Comparator|control group|Each subject will perform usual care rehabilitation aimed at improving manual dexterity
9720249|NCT04527640|Experimental|Synbiotic Arm|Patients receiving synbiotics: Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 Colony Forming Unit (CFU) and Fructooligosaccharides (FOS) 60 mg, 2 capsules/day for 60 days
9720250|NCT04527640|Placebo Comparator|Placebo Arm|Patients receiving placebo capsules containing saccharum lactis (2 capsules/day for 60 days)
9720251|NCT04527796|Other|rehabilitation|All included patients get an pre-intervention and a post intervention analysis
9720252|NCT04527809|Experimental|tDCS-active|tDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area.
9720253|NCT04527809|Sham Comparator|tDCS-sham|tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
10196685|NCT05183061||Hypotensive group|Hypotenson is defined as systolic blood pressure (SBP) < 80 mmHg or a drop more than 20% from baseline SBP for longer than 10 minutes or a drop that requires treatment either vasopressor or inotropic drugs.
9720254|NCT04527562|Active Comparator|TRAETMENT GROUP|Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
9720255|NCT04527562|Placebo Comparator|CONTROL /PLACEBO GROUP|"COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo.~Standard care of enrolled study patients will consist:~Isolation facility~Symptomatic treatment with Paracetamol, Fexofenadine~Steam inhalation/Gurgle of Lukewarm water.~Ensuring of hand wash (20 seconds each time) and ideally wearing mask.~Monitoring by the attending nurses."
9720256|NCT04527653|Experimental|Tixel Treatment|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology
9720257|NCT04527471|Active Comparator|Ensifentrine + Standard of Care|30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection
9720258|NCT04527471|Placebo Comparator|Placebo + Standard of Care|15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection
9720259|NCT04527536||early-set BMJ group|Infants were admitted to our hospital at 4-7 days of age and were followed up to 28 days. Other pathological jaundice factors were excluded.Those who met the criteria were the early-onset BMJ group.
9720260|NCT04527536||late-onset BMJ group|Infants were admitted to our hospital after 7 days of age and were followed up to 28-42 days or until the jaundice disappeared. Other pathological jaundice factors were excluded..Those who met the criteria were late-onset BMJ
9720261|NCT04527536||healthy control|During the same period, the healthy newborns who were born in the obstetrics department of our hospital. These newborns were mainly breastfed or breastfed, and grew well. They were enrolled at 7-14 days of age and were followed up to 28-42 days without pathological jaundice.
9720262|NCT04527341||cardiac surgery patients in ICU|
9720263|NCT04527679|Experimental|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
10196686|NCT05183061||Non-hypotensive group|The pateints who did not develop hypotensive episodes as aforementioned.
9720265|NCT04527861|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
9720266|NCT04527861|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（3~5 ports）.
9720267|NCT04527406|Experimental|Early surgical group|The subjects in this group received early surgical treatment, and they are arranged to be admitted to the hospital for surgical treatment after admission. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction.
9720268|NCT04527406|Active Comparator|Traditional surgical treatment|This group of subjects received conservative treatment with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5.
9720269|NCT04527952|Experimental|Time-restricted feeding (TRF)|Participants will eat the majority of their calories in the day. More specifically participants will consume 70% of their total calories before 5 pm and the remaining 30% after 5 pm.
9720270|NCT04527952|Active Comparator|Intermittent fasting (IF)|This involves eating all of one's meals within a specific time (e.g. 8 hours) frame and fasting for the remaining hours (16 hours) in a day.
9720271|NCT04527952|Active Comparator|Alternate day fasting (ADF)|This involves complete fasting (i.e. no food or caloric containing beverages, only water consumption) for roughly an entire 36-hour period, followed by an ad libitum feeding day.
10196687|NCT05182996|Other|smoking education|smoking education
10196688|NCT05182983||People with digestive tract diseases|
9720274|NCT04527354|Experimental|Treamid 50 mg|1 tablet of Treamid 50 mg once a day during 4 weeks of treatment period.
9720275|NCT04527354|Placebo Comparator|Placebo|1 tablet of Placebo once a day during 4 weeks of treatment period
9720276|NCT04527328|Experimental|AKST1210 apheresis device|The AKST1210 column will be connected to the dialysis circuit during each dialysis session.
9720277|NCT04527328|Placebo Comparator|Control column|A sham control with no effect on the dialyzed blood will be used.
9720278|NCT04527432|Other|All participants|Survey at 6 and 12 months time with optional antibody tests
9720279|NCT04527250|Experimental|Experimental:1mg|ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
9720280|NCT04527250|Experimental|Experimental:2mg|ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
9720281|NCT04527250|Experimental|Experimental:5mg|ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
9720282|NCT04527250|Experimental|Experimental:10mg|ASC41 two tablets (10mg) single oral dose at Day 1.
9720283|NCT04527250|Experimental|Experimental:20mg|ASC41 four tablets (20mg) single oral dose at Day 1.
9720284|NCT04527250|Placebo Comparator|Placebo:1mg|ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
9720285|NCT04527250|Placebo Comparator|Placebo:2mg|ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
9720286|NCT04527250|Placebo Comparator|Placebo:5mg|ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
9720287|NCT04527250|Placebo Comparator|Placebo:10mg|ASC41 placebo two tablets (10mg) single oral dose at Day 1.
9720288|NCT04527250|Placebo Comparator|Placebo:20mg|ASC41 placebo four tablets (20mg) single oral dose at Day 1.
9720289|NCT04527484|Active Comparator|Group A|SHR-1314 Vial
9720290|NCT04527484|Active Comparator|Group B|SHR-1314 PFS
10196689|NCT05182983||Healthy people|
9720291|NCT04527276|Active Comparator|Chlorhexidine|5 ml of 0,12 % Chlorhexidine (CHX) solution is applied to the intervention group for oral care
9720292|NCT04527276|No Intervention|Placebo Group|Group of patients who received standard oral care
9720293|NCT04527458||Hospitalisations|All hospitalised COVID patients
9720294|NCT04527458||Critical care|All hospitalised COVID patients in critical care
9720295|NCT04527263|Active Comparator|group A|subjected to institutional protocol of diagnosis of acute appendicitis
9720296|NCT04527263|Active Comparator|group B|subjected to institutional protocol of diagnosis of acute appendicitis plus measurement of urinary 5-HIAA
9720297|NCT04527224|Experimental|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
9720298|NCT04527835||patients suspected for viral myocarditis|All patients admitted with unexplained heart failure in the last 3 months will be investigated for viral myocarditis by the use of 12 lead ECG, echocardiography, Cardiac MRI , coronary angiography, Endomyocardial biopsy ( optional ), serological tests including ELIZA,Extraction of nucleic acid, Determination of viral genome by using PCR., Quantitative real-time PCR to assess viral load, Immunohistochemistry analysis of EMB.
9720299|NCT04527705|Active Comparator|1-vist endodontic retreatment|Non-surgical root canal retreatment performed in one visit
9720300|NCT04527705|Active Comparator|2-vist endodontic retreatment|Non-surgical root canal retreatment performed in two visits
9720301|NCT04527666||Anticoagulation group|Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.
9720302|NCT04527666||Control group|Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.
9720303|NCT04527211|Experimental|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
9720304|NCT04527211|Placebo Comparator|Placebo|Oral administration of placebo of similar characteristics every week for seven weeks
9720305|NCT04528030|Other|Treatment starting with an on ON cycle|The treatment will start ON cycle for 6 hours, followed by OFF cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
9720306|NCT04528030|Other|Treatment starting with an on OFF cycle|The treatment will start OFF cycle for 6 hours, followed by ON cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
9720307|NCT05140811|Experimental|Relapse/Refractory AML|"IMM01 and Azacitidine in Relapse/Refractory AML~Interventions:~Drug: IMM01 Drug: Azacitidine"
9720308|NCT05140811|Experimental|Relapsed or Refractory MDS|"IMM01 and Azacitidine in Relapse/Refractory MDS~Interventions:~Drug: IMM01 Drug: Azacitidine"
9720309|NCT05140811|Experimental|Treatment naive AML|"IMM01 and Azacitidine in treatment naive AML~Interventions:~Drug: IMM01 Drug: Azacitidine"
9720310|NCT05140811|Experimental|Treatment naive MDS|"IMM01 and Azacitidine in treatment naive MDS~Interventions:~Drug: IMM01 Drug: Azacitidine"
9720311|NCT05140772|Active Comparator|group I|Patient were received 0.5gm/kg/day IV glutamine infusion (dipeptiven 100ml contains 20 g N(2)-L-alanyl-L-glutamine (= 8.20 g L-alanine, 13.46 g L-glutamine) Water for Injections).
9720312|NCT05140772|Placebo Comparator|group II|Patients received an equivalent volume of normal saline daily for 7 days.
9720313|NCT05140746|Experimental|PET/CT for prediction of NAC efficacy|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT will be scanned before, during or after NAC.
9720314|NCT05140733||Fusion|1 or 2 levels fusion surgery
9720315|NCT05140733||Foraminotomy|1 or 2 levels lumbar foraminotomy
9720316|NCT05140720|Experimental|6 weeks - 6 months of age|Group 1: Age group from 6 weeks - 6 months
9720317|NCT05140720|Experimental|7 - 11 months of age|Group 2: Age group from 7 - 11 months
9720318|NCT05140720|Experimental|12 - 24 months of age|Group 3: Age group from 12 - 24 months
9720319|NCT05140707|Experimental|Intervention|For the patients in this group, a virtual reality device was provided to the patients and patients wear it during the port catheter implantation and after the port catheter implantation when they felt pain.
9720320|NCT05140707|No Intervention|Control|For the patients in this group, there wasn't any specific intervention during or after the port catheter implantation.
9720321|NCT05140681|Experimental|apical group|FibReORS with apically flap positioning 2 mm below the bone crest (apical group)
9720322|NCT05140681|Active Comparator|Crestal group|FibReORS with apically flap positioning at the level of bone crest (crestal group).
9720323|NCT05140668|Active Comparator|Supraclavicular central venous catheterization approach group|supraclavicular central venous catheterization group catheter is inserted in supraclavicular fossa (an indentation immediately above the clavicle) with a long-axis in plane approach
9720324|NCT05140668|Active Comparator|Infraclavicular central venous catheterization approach group|infraclavicular central venous catheterization group catheter is inserted in infraclavicular fossa (an indentation, immediately below the clavicle, above the third rib and between the deltoid muscle laterally and medioclavicular line medially) with a short-axis out-of-plane approach
9720325|NCT05140629|Placebo Comparator|Placebo (OGTT)|The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
9720326|NCT05140629|Experimental|Intervention (OGTT plus Baobab fruit extract)|The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW).
9720327|NCT05140616|Experimental|Study of Chidamide in the Treatment of Steroid-resistant/Steroid-dependent Severe cGVHD|Subjects receive twice a week dose of 15mg of Chidamide tablets
9720328|NCT05140603||Cases|Patients who received a doravirine-based regimen.
9720329|NCT05140577||18-30 years old|Subjects in this group is aged between 18 ans 30 years old
9720330|NCT05140577||31-65 years old|Subjects in this group is aged between 31 ans 65 years old
9720331|NCT05140577||65+ years old|Subjects in this group is aged over 65 years old
9720332|NCT05140525|Active Comparator|participants with inoperable CTEPH|subject with inoperable Chronic thromboembolic Pulmonary Hypertension
9720333|NCT05140525|Active Comparator|post PTE residual CTEPH|Subject with post pulmonary endarterectomy (PTE) residual Chronic Thromboembolic Pulmonary Hypertension
9720334|NCT05140512|Experimental|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
9720335|NCT05140512|Active Comparator|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
9720336|NCT05140486|Experimental|Shortwave diathermy and perceptual training|The subjects in this group will receive shortwave diathermy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks after endoscopic optic nerve decompression surgery.
9720337|NCT05140486|No Intervention|Nonrehabilitation|The subjects in the nonrehabilitation group will not only receive any rehabilitation therapy after endoscopic optic nerve decompression surgery.
9720338|NCT05140460|Experimental|Intervention|
9720339|NCT05140460|Active Comparator|Control|
9720340|NCT05140447|Active Comparator|Admira 50º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 50º C
9720341|NCT05140447|Active Comparator|Admira 70º C|in this subgroup the patient's teeth was restored with Admira fusion extra resin composite preheated to 70º C
9720342|NCT05140447|Active Comparator|Viscalor 50º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 50º C
9720343|NCT05140447|Active Comparator|Viscalor 70º C|in this subgroup the patient's teeth was restored with Viscalor resin composite preheated to 70º C
9720344|NCT05140395|Experimental|Pre transfusion control|Pre control transfusion with the referent reagent and the in study reagent
9720345|NCT05140356|Experimental|High amplitude repeated transcranial magnetic stimulation|Applied high amplitude repeated transcranial magnetic stimulation
9720346|NCT05140356|Experimental|Low amplitude repeated transcranial magnetic stimulation|Applied low amplitude repeated transcranial magnetic stimulation
9720347|NCT05140356|No Intervention|healthy control group|No intervention
9720348|NCT05140343|Experimental|Kardia Mobile ECG Monitoring (KMCM)|Standard care with clinical follow-up plus Kardia Mobile ECG Monitoring.
9720349|NCT05140343|No Intervention|24-hour Holter monitoring|Standard care with clinical follow-up plus repeating 24-hours Holter ECG (month 1, 6, 12)
9720350|NCT05140317||Group 1|The direct stargegy group included patients with implanation of the THV without predilatation The reference group included patients with direct implanation of tne THV withour predilaation
9720351|NCT05140317||Group 2|the echographists were blinded regarding the groups of the patients
9720352|NCT05140304|Other|A|
9720353|NCT05140226|Experimental|Physical Training (PT)|Participants in the PT group will perform eight weeks of home-based physical exercise training.
9720354|NCT05140226|Experimental|Cognitive-Physical Training (C-PT)|Participants in the C-PT will perform eight weeks of home-based cognitive and physical training.
9720355|NCT05140200|Experimental|Cohort 1: Participants receiving GSK3511294 at Dose level 1|
9720356|NCT05140200|Experimental|Cohort 2: Participants receiving GSK3511294 at Dose level 2|
9720357|NCT05140161|Experimental|Collagen 1|Medium porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
9720358|NCT05140161|Experimental|Collagen 2|High porosity collagen sponge is used in the operated nail grooves. The hallux is covered with a non-stick dressing, five gauze surrounding it and a cohesive bandage
9720359|NCT05140161|No Intervention|Control group|No hemostatic device is used in the nail grooves. No hemostatic device is used in the nail grooves. Only non-stick dressing, five gauze pads and cohesive bandage are used
9720360|NCT05140135|Experimental|Recovery Oriented Cognitive Therapy (CT-R)|Therapists implement CT-R in weekly sessions for approximately 9 months while supported by a clinical supervisor. Therapists will have completed a supervised CT-R training case prior to the initiation of the randomized controlled trial. CT-R will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. The therapist will use techniques to engage the patient in the adaptive mode, which involves activating cognitions, affects, motivation, and behaviors by engaging the individual in personally meaningful activities.
9720361|NCT05140135|Active Comparator|Continued Usual Care|
9720362|NCT05140122||Primary caregivers of individuals with Dravet Syndrome|
9720363|NCT05140109|Experimental|Cognitive-dissonance based program|Group program of 8 sessions of one hour and a half.
9720364|NCT05140109|Active Comparator|Mindfulness-based program|Group program of 8 sessions of one hour and a half.
9720365|NCT05140109|Active Comparator|Person-centered program|Group program of 8 sessions of one hour and a half.
9720366|NCT05140096|Experimental|Treatment AB|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A) and later will receive single oral loading dose of 400 mg fluconazole tablets on Day 1, one hour prior to a single oral dose of 100 mg acalabrutinib in Period 2 (Treatment B).
9720367|NCT05140096|Experimental|Treatment AC|Participants will receive a single oral dose 100 mg acalabrutinib capsule on Day 1 of Period 1 (Treatment A), and later will receive oral dose of 200 mg iscavuconazole capsules three times daily (approximately every 8 hours apart) on Day 1, followed by 200 mg iscavuconazole capsule once daily from Day 2 to Day 5 with a single oral dose of 100 mg acalabrutinib capsule coadministered on Day 5 in Period 2 (Treatment C).
9720368|NCT05140083|Experimental|68Ga-NOTA Evans Blue PET/CT in Patients with Lymphatic System Related Diseases|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA Evans Blue will be injected subcutaneously. PET/CT imaging will be performed at 5-30 min post- injection. Visual and quantitative method will be used to assess the PET/CT images.
9720369|NCT05140057|Experimental|Protocol 1|1L of Moviprep® solution the night before the procedure
9720370|NCT05140057|Experimental|Protocol 2|1L of Moviprep® solution up to 2h before the procedure
9720371|NCT05140057|Experimental|Protocol 3|0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum
9720372|NCT05140057|Experimental|Protocol 4|1L of Moviprep® solution after the capsule had reached the duodenum
9720373|NCT05140018||Kidney Transplant Recipients with an immunological high risk for ABMR|"Kidney transplant recipients ≥18 years old~About to receive a post mortal or living donor renal transplant~Immunological high risk for rejection~Luminex positive DSAs ; or~Retransplantation with repeated mismatch ; or~Husband to wife donation (after fathering children); or~Offspring to mother donation"
9720374|NCT05140018||Living Kidney Donors|Participants who are about to donate their kidney to a Recipient with a high immunological risk (as described above)
9720375|NCT05139979|Experimental|Webinar-Based Intervention|Breathing and Wellness Webinar: two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
9720376|NCT05139979|Placebo Comparator|Control|This group will be asked to wait for 3 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes two yogic breathing practices (Simha Kriya and Naddi Shuddi) and a guided meditation (Isha Kriya).
9720377|NCT05139966|Placebo Comparator|G0 - placebo|All placebo mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, NO FLUORIDE WAS INCORPORATED.
9720378|NCT05139966|Experimental|G1: 100% - sodium fluoride (100% free NaF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm NaF (SODIUM FLUORIDE) WAS INCORPORATED.
9720379|NCT05139966|Experimental|G2: 50% nano fluoride (225 ppm, 50% free NaF + 50% nanoF)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (50% free NaF + 50% nanoF) WAS INCORPORATED.
9720380|NCT05139966|Experimental|G3: 100% nano fluoride (225 ppm)|These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (100% nanoF) WAS INCORPORATED.
9720381|NCT05139927|Experimental|Condition 1|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - ON Component D: Navigation
9720382|NCT05139927|Experimental|Condition 2|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - ON Component D: Self-test kit
9720383|NCT05139927|Experimental|Condition 3|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - ON Component D: Navigation
9720384|NCT05139927|Experimental|Condition 4|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - ON Component D: Self-test kit
9720385|NCT05139927|Experimental|Condition 5|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Navigation
9720386|NCT05139927|Experimental|Condition 6|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Self-test kit
9720387|NCT05139927|Experimental|Condition 7|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Navigation
9720388|NCT05139927|Experimental|Condition 8|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Self-test kit
9720389|NCT05139927|Experimental|Condition 9|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Navigation
9720390|NCT05139927|Experimental|Condition 10|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Self test kit
9720391|NCT05139927|Experimental|Condition 11|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Navigation
9720392|NCT05139927|Experimental|Condition 12|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Self test kit
9720393|NCT05139927|Experimental|Condition 13|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Navigation
9720394|NCT05139927|Experimental|Condition 14|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Self test kit
9720395|NCT05139927|Experimental|Condition 15|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Navigation
9720396|NCT05139927|Experimental|Condition 16|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Self test kit
9720397|NCT05139823|No Intervention|Control|Controls receive usual care, which is a digital communication to the local home care team including a discharge care plan to the home care system, including information about the discharge diagnoses, and recommendations for particular attention to specific bodily functions and medical treatment regime. The patient's PCP receives a discharge summary from the treating hospital physician as usual.
9720398|NCT05139823|Experimental|Intervention|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
9720399|NCT05139784||Type 1 diabetes|As defined by the presence of hyperglycemia and/or islet auto-antibodies.
9720400|NCT05139784||Other forms of diabetes or autoimmune endocrinopathy|Type 2 diabetes, ketosis-prone diabetes, familial diabetes, secondary diabetes, immunotherapy-induced diabetes; and/or autoimmune endocrinopathies.
9720401|NCT05139784||No diabetes|No diabetes or impaired glucose tolerance; no cancer, infectious or immune pathologies; no other condition related to autoimmune and metabolic alterations that may bias the variables under study.
9720402|NCT05139784||Lymphadenectomy planned at the occasion of an abdominal surgery|Patients undergoing a lymphadenectomy during surgery for the treatment of their underlying pathology.
9720403|NCT05139771|Other|EndoArt® Artificial Endothelial Layer|EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema. One arm - all subjects will be implanted with EndoArt®.
9720404|NCT05139758|Experimental|hemiplegic cp|it will be classified into two subgroups according to body mass index to underweight and healthy weight .
9720405|NCT05139758|Experimental|diplegic cp|it will be classified into two subgroups according to body mass index to underweight and healthy weight .
9780078|NCT04037241|Active Comparator|2nd Line: Gemcitabine /nab paclitaxel Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving gemcitabine plus nab paclitaxel will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
9780079|NCT04037241|Active Comparator|2nd Line: NLIR + FU/FA Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
9780080|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab paclitaxel plus gemcitabine during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
9780081|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus Capecitabine|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Capecitabine chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nanoliposomal irinotecan fluorouracil/leucovorin during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
9780082|NCT04037241|Active Comparator|3rd Line: NLIR+FU/FA Alone|Patients randomized to the chemotherapy alone treatment arm who developed disease progression during the Bridging Therapy Period while receiving nab paclitaxel plus gemcitabine will be treated with nanoliposomal irinotecan plus fluorouracil/leucovorin during the Treatment Period.
9780083|NCT04037241|Active Comparator|3rd Line: Capecitabine Alone|Patients that developed disease progression during the Bridging Therapy Period while receiving nanoliposomal irinotecan plus 5-FU/leucovorin will be treated with capecitabine during the Treatment Period.
9780084|NCT04031521||Sickle cell pain crisis|
9780085|NCT04031521||Sickle cell steady-state|
9780086|NCT04030299|Experimental|OTC Group|In this group, the over-the-counter fitting will be used to provide hearing aids.
9780087|NCT04025879|Experimental|Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo|
9780088|NCT04025879|Placebo Comparator|Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac.|
9780089|NCT04021719||OnTrackNY LHS Participants and Stakeholders|OnTrackNY participants and stakeholders, including past participants, family members, clinicians, administrators, payors, and state leadership
9780090|NCT04017702||Pregnant women with gestational age between 32-40 weeks.|100 patients scheduled for cesarean section under neuraxial anesthesia with 150 mcg intrathecal or 3-mg epidural morphine.
9780091|NCT04017702||Patients post anesthesia care units (PACU) and surgical floor.|100 patients scheduled to receive General Anesthesia (GA) and planned to receive opioid intravenously (boluses/patient controlled analgesia (PCA).
9780092|NCT04017702||Patients in step down/ICU.|50 patients suffered from rib fracture and 50 patients after weaning from mechanical ventilation and extubation.The Expiron will provide continuous information about the respiratory status (tidal volume, respiratory rate and minute ventilation) of non-intubated patients specifically: sleeping or awake; with the use of incentive spirometry; the response to medications and other interventions (such as paravertebral/epidural block); the need for endotracheal re-intubation.
9780093|NCT04014179|Experimental|Immediate Intervention (Dried Blood Spot)|Blood samples will be tested for HCV RNA from dried blood spot cards.
9780094|NCT04014179|Experimental|Immediate intervention (Point-of-care testing)|Blood samples will be tested for HCV RNA using the Xpert HCV Viral Load Fingerstick point-of-care assay.
9780095|NCT04014179|Active Comparator|Delayed intervention (Dried Blood Spot)|There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing from dried blood spots.
9780096|NCT04014179|Active Comparator|Delayed intervention (Point-of-care testing)|There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing using the point-of-care assay.
9780097|NCT04004793|Experimental|Dapagliflozin plus intensive lifestyle intervention|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
9780098|NCT04004793|Placebo Comparator|Placebo plus intensive lifestyle intervention|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
9780099|NCT03994159|Experimental|PARO emotional robot|"Quasi-experimental before after study of the impact of the PARO robot on team dynamics among caregivers in geriatric wards caring for patients with dementia.~Pre intervention period: no PARO robot. Post-intervention period: with the PARO robot."
9780100|NCT03988595|Experimental|aerobic training 90 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
9720406|NCT05139719|Experimental|HEC585 tables does A|HEC585 dose A once daily, up to 24 weeks
9720407|NCT05139719|Experimental|HEC585 tables does B|HEC585 dose B once daily, up to 24 weeks
9720408|NCT05139719|Placebo Comparator|placebo|Placebo once daily, up to 24 weeks
9720409|NCT05139667|Experimental|tacrolimus/corticosteroid|topical steroids ( triamcinolone acetonide 0.1 %), tacrolimus paste and tacrolimus patch
9720410|NCT05139667|Active Comparator|corticosteroids|topical corticosteroid
9720411|NCT05139667|Active Comparator|tacrolimus|topical tacrolimus patch and tacrolimus paste
9720412|NCT05139641|Placebo Comparator|control group|
9720413|NCT05139641|Experimental|counseling theraphy|
9720414|NCT05139641|No Intervention|Retrospective data|
9720415|NCT05139563||Placebo injection|This group will first receive 3 mL intramuscular injections of a 20% fat emulsion (Intralipid 20%) every 2 months for 6 months.
9720416|NCT05139563||Placebo implant|This group will first receive a single-use subdermal implant in the inner side of the upper arm for a duration of 6 months before removal.
9720417|NCT05139524||Health facility based cohort|Cohort of individuals with acute or reported fever enrolled at health facilities and followed up for upto 24 months.
9720418|NCT05139524||Community survey|Individuals enrolled in study as part of a cross sectional survey in the community.
9720419|NCT05139472|Experimental|Treatment Arm|This arm of the study will take 10 mg empagliflozin daily for 12 weeks
9720420|NCT05139433|Experimental|Intervention Group|Participants in this arm will receive 5 internet-delivered cognitive-behavioral intervention and will have access to 15 educational videos
9720421|NCT05139433|Active Comparator|Active Control Group|Participants in this arm will have access to 15 educational videos.
9720422|NCT05139407|Experimental|Workshop|"The workshop is to discuss methods in various fields through activities, discussions, and lectures. It is an academic way to encourage participation, innovation, and predict solutions, suitable for people from different positions and ethnic groups to think, discuss, and communicate.~Each Intervention includes information relevant to how the Intervention was administered to participants in the associated Arm.~Workshop intervention for students: basketball training plan, basketball lesson plan, energy supply in muscle exercise, exercise prescription, track, and field mapping, basketball rules. All patients were intervened according to the frequency of 3 hours/once a week."
9720423|NCT05139407|Experimental|Oral examination|"The oral examination is a way of examination, which requires the examination to answer questions orally. Content intervention includes the comment, teacher's question and answer, proposition explanation, and proposition debate. In addition, each Intervention provides information relevant to how the Intervention was administered to students in the associated Arm.~Specific interventions for students: basketball training plan, basketball lesson plan, energy supply system, exercise prescription formulation, track and field venue planning, basketball game rules. All oral examinations take 90 minutes/once/week."
9720424|NCT05139329||Patients with symptoms of typical/atypical chest pain|Patients will be retrospectively included based on their presenting ICD codes or symptoms of typical/atypical chest pain, and those patients with positive ischemic workup will be excluded. The patients with negative ischemic workup will be included, and through chart review these patients will be followed to further assess their continued diagnostic workup.
9720425|NCT05139238|Active Comparator|Oral Nifedipine|Oral nifedipine: Once diagnosis of hypertensive emergency is confirmed on repeat blood pressure, patients randomized to oral nifedipine will receive 10mg initially, with repeated doses of 20mg every 20min, for up to a maximum of 5 doses or until the therapeutic blood pressure goal of <160 systolic and <105 diastolic is achieved. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
9720426|NCT05139238|Active Comparator|Intravenous labetalol|Intravenous Labetalol: Patients randomized to IV labetalol will receive 20mg initially, followed by escalating doses of 40mg, 80mg, 80mg, then 80mg every 20 minutes until the therapeutic goal is achieved, for a maximum of 5 doses. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.
9720427|NCT05139186|Experimental|WL+AI|Colonoscopy in white light and artificial intelligence
9720428|NCT05139186|Experimental|WL|Colonoscopy in white light
9720429|NCT05139095|Experimental|Cohort A|Population: ultra high-risk gestational trophoblastic neoplasia
9720430|NCT05139095|Experimental|Cohort B|Population: high-risk chemo-refractory or relapsed gestational trophoblastic neoplasia
9720431|NCT05139082|Other|CDK4/6 inhibitor (TQB3616) + PD-L1 monoclonal antibody (TQB2450)|TQB3616 capsules (120/150/180mg p.o. qd, d1-d21) combined with TQB2450 injection (1200mg ivgtt, d1)
9720432|NCT05139069|Experimental|Trauma-Informed Pre-Exposure Prophylaxis Implementation Toolkit|The Toolkit to be developed in the proposed study includes components from the women-specific Pre-Exposure Prophylaxis care continuum theoretical model and implementation challenges, and is adapted to identify and provide care to women experiencing intimate partner violence. Overall, the Toolkit is designed to create culturally-congruent, intimate partner violence-informed clinical settings; and equip clinical staff with the knowledge and skills they need to address HIV prevention for African American women; and integrate intimate partner violence into Pre-Exposure Prophylaxis care services.
9720433|NCT05138978|Experimental|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
9720434|NCT05138978|Other|Colgate Cavity Protection|Toothpaste
9720435|NCT05138939|Placebo Comparator|Control|Participants in this group are randomized to receive Isocaloric beverage (a beverage that has similar caloric content to the red wines) as the first intervention.
9720436|NCT05138939|Experimental|Red wine A|Participants in this group are randomized to receive red wine A as the first intervention (can be the younger or older vintage).
9720437|NCT05138939|Experimental|Red wine B|Participants in this group are randomized to receive red wine B as the first intervention (can be the younger or older vintage)
9720438|NCT05138926|Experimental|Cervical manipulation group|high speed, low amplitude cervical manipulation
9720439|NCT05138926|Sham Comparator|Control group|placebo mobilization without manipulation
9720440|NCT05138913|Experimental|Study group|Arthroscopic treatment with TXA injection
9720441|NCT05138913|Placebo Comparator|Control group|Arthroscopic treatment with normal saline injection
9720442|NCT05138861|Experimental|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|TP-03, topical ocular administration in healthy adults. Single and multiple doses for 42 days.
9720443|NCT05138835|Active Comparator|Group 1|Subjects will receive BTX in the glabella and forehead regions, using a traditional injection technique commonly utilized in aesthetic medicine. The traditional injection technique will deposit the neurotoxin into the targeted muscles; with up to 24 units being injected into the forehead and 20 units in the glabella.
9720444|NCT05138835|Experimental|Group 2|Subjects will receive the traditional, deep injection technique, in addition to a superficial intradermal injection technique, which uses micro-aliquots of toxin. The superficial technique will deposit 0.1 units of toxin at 5mm intervals, at the level of the deep dermis.
9720445|NCT05138809|Experimental|Exercise|Use online exercise platform
9720446|NCT05138796|Experimental|TP-05 SAD|Single dose of TP-05 (lotilaner oral capsules) at 4 dose levels in ascending order
9720447|NCT05138796|Experimental|Placebo SAD|Single dose of Placebo
9720448|NCT05138796|Experimental|TP-05 MAD|Four doses of TP-05 (lotilaner oral capsules) at 3 dose levels in ascending order
9720449|NCT05138796|Experimental|Placebo MAD|Four doses of Placebo
9720450|NCT05138796|Experimental|TP-05 Fasted|Single dose of TP-05 (lotilaner oral capsules) in a fasted state
9720451|NCT05138796|Experimental|Placebo Fasted|Single dose of placebo in a fasted state
9720452|NCT05138744|Experimental|Virtual reality treatment|Use of google maps with virtual reality to virtually situate the participants into scenarios that are motivating for them (i.e., the beach, a mountain, a park, etc.) at their choice.
9720453|NCT05138653|Experimental|Single Ascending Dose (SAD) Cohorts 1-3|In Cohorts 1 and 2, all participants will receive treatment with up to 3 single oral doses of CVL-354 and/or 1 single oral dose of placebo in a 4-period crossover design. The starting dose of CVL-354 will be 0.5 mg. Participants will be randomized to 1 of 4 treatment sequences. Cohort 3 may be used to evaluate additional doses or evaluate food effect, depending on the results from Cohorts 1 and 2.
9720454|NCT05138653|Experimental|Multiple Ascending Dose (MAD) Cohorts 1-5|All participants will receive treatment with multiple oral doses of CVL-354 (dose and regimen to be determined) or matching placebo for 14 days.
9720455|NCT05138627|Experimental|intervention|"Teaching of oral cryotherapy by the investigator in the hospital,~Implementation of oral cryotherapy accompanied by the investigator in the hospital~Individual application of oral cryotherapy at home by patients"
9720456|NCT05138627|No Intervention|control|Routine procedures in the clinic were performed on the first course (day 0) when the patients came to receive adjuvant chemotherapy and every 21 days thereafter, and oral cryotherapy was not applied to the patients. Before applying the first adjuvant chemotherapy, Nausea Vomiting Training and Guide was given to have equal conditions with the patients in the intervention groups.
9720457|NCT05138588|Experimental|VERUM|"In the verum experimental condition, participants will receive the experimental rTMS stimulation sessions, meaning the rTMS sessions targeting the insular cortex, taking into account the insular hypoperfusion (through MRI images) of each patient."
9720458|NCT05138588|Sham Comparator|CONTROL|"In the control experimental condition, participants will receive the control rTMS stimulation sessions, meaning the rTMS sessions will target the occipital cortex."
9720459|NCT05138562|Placebo Comparator|Placebo|4 Placebo capsules
9720460|NCT05138562|Active Comparator|TU2670 High Dose|320mg, QD
9720461|NCT05138562|Active Comparator|TU2670 Medium Dose|240 mg, QD
9720462|NCT05138562|Active Comparator|TU2670 Low Dose|120 mg, QD
9720463|NCT05138523||Non-cirrhotic|Non-cirrhotic HCV patients; 12 weeks treatment
9720464|NCT05138523||Cirrhotic|Cirrhotic HCV patients; 24 weeks treatment
9720465|NCT05138510||Stage 0|Ductal carcinoma in situ. Timing: start of endocrine therapy
9720466|NCT05138510||Stages I-III Surgery first|Invasive cancer. Surgery first Timing: start of endocrine therapy
9720467|NCT05138510||Stages I-III, neoadjuvant chemotherapy first|Invasive cancer. Neoadjuvant chemotherapy first Timing: during neoadjuvant chemotherapy
9720468|NCT05138510||Stage IV|Metastatic cancer, chemotherapy only, no invasive surgery Timing: 2 months into treatment
9720469|NCT05138510||Survivors|Timing: any time
9720470|NCT05138484|Experimental|M. sylvestris mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
9720471|NCT05138484|Active Comparator|CHX mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
9720472|NCT05138484|Placebo Comparator|Placebo mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
9720473|NCT05138445|Experimental|Arm 1: FAME-W intervention|Four-week self-management education programme
9720474|NCT05138445|Active Comparator|Arm 2: FAME-W handbook|Self-guided FAME-W handbook
9720475|NCT05138432|Other|Intervention Group|Monthly fruit and vegetable vouchers for 12 months, to start immediately after enrollment.
9720476|NCT05138432|Other|Delayed Intervention Group|Monthly fruit and vegetable vouchers for 12 months, to start after a 6-month waiting period.
9720477|NCT05138367|Experimental|UCA-PSC|Subsequent to isolation and culture of UCA-PSCs, UCA-PSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the National Institute for China Food and Drug Control) were injected into the ovaries of patients with hormone replacement treatment, which consisted of Premarin (0.625 mg/days on days 1 through 25) combined with Provera (10 mg/day for 10 days a month with monthly withdrawal bleeding).
9720478|NCT05138367|Experimental|WJ-MSC|Subsequent to isolation and culture of WJ-MSCs, WJ-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the National Institute for China Food and Drug Control) were injected into the ovaries of patients with hormone replacement treatment, which consisted of Premarin (0.625 mg/days on days 1 through 25) combined with Provera (10 mg/day for 10 days a month with monthly withdrawal bleeding).
9720479|NCT05138354|Active Comparator|Control group|Patients received a 4-week treatment program (12 treatment sessions, three times a week). Patients received the conservative treatment protocol comprised of ultrasound, hot pack application, and exercises.
10196690|NCT05182970|Active Comparator|Metformin on top of standard care|Metformin will be prescribed by the Investigator at the study site and dispensed at pharmacy of choice by the patient. Metformin will be recommended to be gradually titrated to minimize gastrointestinal side effects with a start dose of 500 mg 1x1 for 1 week and thereafter 500 mg 1x2 with an individualised target dose of 2000 mg daily depending on tolerability. The goal is to a have minimal dose of 500 mg 1x2. Patients will be informed to stop medication in events of sever nausea, vomiting or dehydration according to standard practice. The threshold for metformin titration or adding another drug during follow-up is recommended to be assessed individually by the Investigator at the study site, responsible for the patient. Patients with eGFR <60 cannot be included in the MIMET study. If GFR is between 30-45 ml/min during the study, metformin should be reduced to 1000 mg daily. Metformin is contraindicated if GFR <30 ml/min. Standard care will be the same as in the control arm.
9720480|NCT05138354|Experimental|Intervention group|Patients received a 4-week treatment program (12 treatment sessions, three times a week). Patients received LLLT and myofascial release combined with the control intervention. the conservative treatment protocol comprised of ultrasound, hot pack application, and exercises
9720481|NCT05131451|No Intervention|Usual care with educational reinforcement|Standard of care referral to Eye Care Provider (ECP) for the diabetic eye exam with educational reinforcement
9720482|NCT05131451|Experimental|Diabetic Retinopathy Exam|Point of care (POC) Diabetic Retinopathy Exam using Autonomous AI on non-mydriatic fundus camera
9720483|NCT05127941||Patient group|Patients under effective anticoagulation with rivaroxaban or apixaban and treated with andexanet alfa
9720484|NCT05127915|Experimental|Therapeutic|The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
9720485|NCT05127915|Experimental|Prophylactic - Test|The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
9720486|NCT05127915|Active Comparator|Prophylactic - Control|The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.
9720487|NCT05126719|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
9720488|NCT05126121|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy consisting of vonoprazan and three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, clarithromycin,levofloxacin,tinidazole,metronidazole.
9720489|NCT05125653|Experimental|NIR/ICG Arm|Indocyanine Green Fluorescent Cholangiography and Intraoperative Angiography will be done during the Laparoscopic Cholecystectomy
9720490|NCT05125653|Active Comparator|WL Arm|Conventional white light was used for Laparoscopic Cholecystectomy
9720491|NCT05108688|Active Comparator|Mirtazapine Therapy group (M group)|
9720492|NCT05108688|Active Comparator|Sumatriptan Therapy group (S group)|
9720493|NCT05108688|Placebo Comparator|Control group ( C group)|
9720494|NCT05108584|Experimental|Group 1 - Level 3 PPE and video laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
9720495|NCT05108584|Experimental|Group 2 - Level 3 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 3 PPE (coverall jumpsuit, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and direct laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
9785792|NCT01260324||NAION cases|From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
9720496|NCT05108584|Experimental|Group 3 - Level 2 PPE and direct laryngoscope|Pre-anesthesia visit aims to assess the participant's physical status based on the American Society of Anesthesiologists score and assessment of the airway. Researcher then explained about the study and plan for anesthesia using an endotracheal tube and personal protective equipment according to the group. While in the operating room, the intubation operator was assisted by an assistant who already used appropriate PPE. Coveralls or hazmat suits and surgical gowns used must match the size. The intubation operator was resident of Anesthesiology and Intensive Therapy study program (stage II) and accompanied by an independent resident (stage III) and an anesthesiologist on duty. The operator used level 2 PPE (surgical gown/apron, face shield, goggles, N95 mask, surgical mask, boot, scrub, and two layered gloves) and video laryngoscope for intubation of the participants. Researcher was in charge for recording time and event during the intubation process according to the study form.
9720497|NCT05103891|Experimental|Binimetinib 15 mg / Binimetinib 45 mg|2 periods
9720498|NCT05103891|Experimental|Binimetinib 45 mg / Binimetinib 15 mg|2 periods
9720499|NCT05099211|Experimental|Patients muscle strengthening|
9720500|NCT05099211|Experimental|Aerobic Training Patients|
9720501|NCT05099211|Active Comparator|Healthy patients|
9720502|NCT05080790|Experimental|5 cycles (Q5W) of dinutuximab beta, interleukin-2 and zoledronic acid|5 cycles (Q5W) of dinutuximab beta, 20mg/m2/day, interleukin-2, 5.4x10^6, and zoledronic acid, 4 mg
9720503|NCT05080179|Experimental|Self-Benefit/Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
9720504|NCT05080179|Experimental|Self-Benefit/No Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. They did not read any information about the number of Pennsylvanians who downloaded the app."
9720505|NCT05080179|Experimental|Other Benefit/Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
9720506|NCT05080179|Experimental|Other Benefit/No Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They did not read any information about the number of Pennsylvanians who downloaded the app."
9720507|NCT05065450|Experimental|Brain Stimulation|Neurosurgical epilepsy patients that undergo placement of medial temporal electrode for seizure localizations will be recruited. All participants will view a series of images of emotionally-neutral objects on a computer screen. After each item presentation, they will randomly undergo either active-BLAES or sham-stimulation. Over subsequent days, free recall and recognition memory for these items, relative to new distractor items will be tested. Memory for items presented with and without stimulation will be compared. Brain activity recorded in the medial temporal lobe during item presentations will be used to predict subsequent memory. Such good and bad memory states (biomarkers) will be used to perform closed-loop stimulation when bad memory states are detected in order to enhance subsequent memory.
9720508|NCT04997135||Meibography Subjects|Eligible subjects will undergo testing to evaluate the Meibomian gland appearance
9720509|NCT04983797|Experimental|OPTRELL Mapping Catheter|Participants diagnosed with cardiac arrhythmias who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for Atrial and ventricular procedures will be using multi-electrode OPTRELL mapping catheter.
9720510|NCT04963153|Experimental|Treatment (erdafitinib, enfortumab vedotin)|Patients receive erdafitinib PO QD on days 1-28 and enfortumab vedotin IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9720511|NCT04927351|Experimental|Intervention|New electronic medical record based discharge medication order set.
9720512|NCT04927351|No Intervention|Control|Usual Care
9720513|NCT04918017|Experimental|Treatment based on subtypes: Epigastric Pain Syndrome (EPS)|EPS: treat with esomeprazole 40mg OD (proton pump inhibitor)
9720514|NCT04918017|Experimental|Treatment based on subtypes: Post Prandial Distress Syndrome (PDS)|PDS: treat with itopride 50mg TDS (prokinetic)
9720515|NCT04918017|Experimental|Treatment based on subtypes: Overlapped EPS/ PDS|Overlapped EPS/PDS: treat with itopride 50mg TDS first and add esomeprazole 40mg OD (if partially responded) or change to esomeprazole 40mg OD (if not responded)
9720516|NCT04918017|Active Comparator|Treatment with Proton Pump Inhibitor regardless of subtype|Treat with esomeprazole 40mg OD (proton pump inhibitor) regardless of subtype of functional dyspepsia
9720517|NCT04900246|Experimental|Visual Inspection + BWX Radiographic Assessment + Assessment of the iTero Element 5D scan|In this group, the evaluations will follow this order. First the visual inspection, then the bitewing X-ray assessment and, lastly, the iTero assessment.
9720518|NCT04900246|Experimental|Visual Inspection + Assessment of the iTero Element 5D scan + BWX Radiographic Evaluation|In this group, the evaluations will follow this order. First the visual inspection, then the iTero assessment and, lastly, the bitewing X-ray assessment.
9720519|NCT04846530||Approved products will be placed in small boluses (0.2 mL) intradermally|Subjects will be assigned to receive two products each from the RHA® line of products (RHA® 1, RHA® 2, RHA® 3, and RHA® 4).
9720520|NCT04615832|Experimental|Toffee Full Face Mask|Toffee Full Face Mask: Full face mask for PAP therapy applied in a home environment for 2 weeks.
9720521|NCT04601155||AlloSure Group|Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years. For the quarterly AlloSure tests, approximately 20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) to analyze the presence of donor-derived cell-free DNA.
9720522|NCT04601155||Control Group|The control group was never followed with AlloSure as part of their post-transplant follow-up care. Matched control data will originate from UNOS SRTR data.
9720523|NCT04590248|Experimental|Adavosertib|Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
9720525|NCT04510363||cardiac arrest survivors|cardiac arrest survivors
9720526|NCT04510363||age- and sex-matched controls|age- and sex-matched controls
9720527|NCT04505254|Experimental|Treatment (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID every 12 hours starting on day 1 of cycle 1, and obinutuzumab IV over 4-6 hours on days 1 and 2 of cycle 3, and day 1 of cycles 4-8. Patients who do not achieve a complete response or remission after cycle 8 may receive single-agent acalabrutinib therapy PO BID for an additional 6 cycles at the discretion of their treating physician. Patients who are in partial response or who have stable disease receive an additional 6 cycles of acalabrutinib PO BID and obinutuzumab IV. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9720528|NCT04502693|Experimental|MenB_0_2_6 Group|Participants receive rMenB+OMV NZ vaccine as 3 dose schedule at Day 1, 61 and Day 181 or as 2 dose schedule at Day 1 and Day 61 and 1 dose of MenACWY vaccine at Day 211.
9720529|NCT04502693|Experimental|MenB_0_6 Group|Participants receive rMenB+OMV NZ vaccine as 2 dose schedule at Day 1, and Day 181, 1 dose of MenACWY vaccine at Day 61 and 1 dose of Placebo at Day 211.
9720530|NCT04502693|Experimental|ABCWY-1 Group|Participants receive 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
9720531|NCT04502693|Experimental|ABCWY-2 Group|Participants receive 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
9720532|NCT04502693|Experimental|ABCWY-3 Group|Participants receive 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
9720533|NCT04502693|Active Comparator|ACWY Group|Participants, receive 1 dose of MenACWY vaccine at Day 1, 1 dose of placebo at Day 61 and 2 doses of rMenB+OMV NZ vaccine at Day 181 and Day 211.
9720534|NCT04467801|Experimental|Treatment|"Ipatasertib, 400 mg once daily, Oral, Days 1-14 of each 21 day cycle (2 weeks on and 1 week off).~Docetaxel, 75 mg/m2, Intra-venous, Day 1 of each 21 day cycle."
9720535|NCT04459871|Experimental|The experimental group|The topical recombinant human thrombin(rhThrombin) was prepared into 1000IU/mL solution with 10ml normal saline and used in combination with absorbable gelatin spongeat at appropriate bleeding evaluation site(s).
9720536|NCT04459871|Placebo Comparator|The control group|The placebo was prepared into a solution with 10mL normal saline and used in combination with absorbable gelatin sponge at appropriate bleeding evaluation site(s).
9720537|NCT04455139|Active Comparator|Treatment 1a|IVitC melphalan (randomized) in case of vitreous relapse only
9720538|NCT04455139|Experimental|Treatment 1b|IVitC topotecan (randomized) in case of vitreous relapse only
9720539|NCT04455139|Active Comparator|Treatment 2a|IAC melphalan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
9720540|NCT04455139|Experimental|Treatment 2b|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
9720541|NCT04455139|No Intervention|Treatment 2c|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with prior intra-arterial treatment
9720542|NCT04455139|No Intervention|Treatment 3a|sequential administration of IVitC melphalan and IAC melphalan in case of combined vitreous and retinal/diffuse subretinal relapse, if no pretreatment with intra-arterial treatment
9720543|NCT04455139|No Intervention|Treatment 3b|sequential administration of IVitC melphalan and IAC melphalan and topotecan, in case of combined vitreous and retinal/diffuse subretinal relapse, if prior pretreatment with intra-arterial treatment
9720544|NCT04447183|Experimental|Test group|The test group of patients who took thyroid hormone medicine and were euthyroid [i.e. their thyroid stimulating hormone (TSH) levels are normal], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
9720545|NCT04447183|Experimental|Control group|The control group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e. their TSH levels were high,TSH≥30mU/L), and were given oral radioiodine.
9720546|NCT04435392|Experimental|Part 1: Cohort 1, 0.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 0.5% Cream will be applied topically twice daily.
9720547|NCT04435392|Experimental|Part 1: Cohort 2,1.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 1.5% Cream will be applied topically twice daily.
9720548|NCT04435392|Experimental|Part 1: Cohort 3, 2.5% Jaktinib Qd|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically Once daily.
9720549|NCT04435392|Experimental|Part 1: Cohort 4, 2.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically twice daily.
9720550|NCT04435392|Placebo Comparator|Dose extension: Vehicle Control|the Vehicle Control cream will be applied topically twice daily
9720551|NCT04435392|Experimental|Dose extension: low-dose group, X%|X% based on results of part 1. The Jaktinib Hydrochloride X% Cream will be applied topically twice daily
9720552|NCT04435392|Experimental|Dose extension: high-dose group, Y%|Y% based on results of part 1. The Jaktinib Hydrochloride Y% Cream will be applied topically twice daily
9720553|NCT04433182|Experimental|Single arm Copa-RB|Induction phase with Copanlisib, Rituximab and Bendamustina. Maintenance phase (for patients who reach at least SD after induction) with Copanlisib in monotherapy.
9720554|NCT04426695|Experimental|On Low-Flow Oxygen|Cohort 1 (C1): O2 saturation >93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
9720555|NCT04426695|Experimental|With COVID-19 symptoms but not requiring supplemental O2|Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
9720556|NCT04426695|Experimental|High O2 No Mechanical Ventilation|Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
9720557|NCT04426695|Experimental|On Mechanical Ventilation|Cohort 3 (C3): On mechanical ventilation
9720558|NCT04417088|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to Carboplatin administration.
9720559|NCT04412486|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Transfusion of COVID-19 convalescent plasma to participants with serious or life threatening complications from COVID-19 or are at high risk to develop serious complications.
9720560|NCT04380545|Experimental|Treatment (fluorouracil, interferon alpha 2b, nivolumab)|Patients receive fluorouracil IV continuously on days 1-7 and 15-21 and recombinant interferon alpha 2b-like protein SC on days 1, 3, 5, 15, 17, and 19. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 3, patients receive nivolumab IV over 30 minutes on day 1, fluorouracil IV continuously on days 1-7 and 15-21, and recombinant interferon alpha 2b-like protein interferon alpha 2b SC on days 1, 3, 5, 15, 17, and 19. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9720561|NCT04360096|Experimental|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
9720562|NCT04360096|Experimental|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
9720563|NCT04341246||Cases|Cases are defined as those patients who have undergone liver biopsy and have confirmed NASH and fibrosis
9720564|NCT04341246||Controls|Controls are patients have undergone a liver biopsy with neither significant NASH nor significant fibrosis
9720565|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 50mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
9720566|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 75mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
9720567|NCT04312594|Placebo Comparator|Placebo and Basic treatment|Mimic tablets of Jaktinib Dihydrochloride Monohydrate 50mg BID and 75mg BIDand basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
9720568|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA less than 20|The first 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score less than 20.
9720569|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA more than 20|The second 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score more than 20.
9720570|NCT04282018|Experimental|Part A: BGB-10188 Monotherapy Dose Escalation|BGB-10188 capsules administered orally once daily (QD) in 5 cohorts of escalating doses
9720571|NCT04282018|Experimental|Part B: BGB-10188 + Zanubrutinib Dose Escalation|BGB-10188 capsules administered orally QD at a dose level less than RP2D and RP2D in combination with zanubrutinib 160mg (2*80mg capsules) administered orally twice daily (BID)
9720572|NCT04282018|Experimental|Part C: BGB-10188 + Zanubrutinib Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part B in combination with zanbrutinib 160mg (2*80mg capsules) administered orally BID
9720573|NCT04282018|Experimental|Part D: BGB-10188 + Tislelizumab Infusion Dose Escalation|BGB-10188 capsules administered orally QD in upto 4 cohorts of escalating doses in combination with tislelizumab 200mg IV infusion administered every 3 weeks (Q3W)
9720574|NCT04282018|Experimental|Part E: BGB-10188 + Tislelizumab Infusion Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part D in combination with tislelizumab 200mg IV infusion administered Q3W
9720575|NCT04279314|Experimental|Trofinetide|
9720576|NCT04265755|Experimental|Single arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
9720577|NCT04246476||Parkinson disease|People living with Parkinson disease.
9720578|NCT04246476||Controls|Age-matched controls.
9720579|NCT04239924|Experimental|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program
9780101|NCT03988595|Experimental|aerobic training 150 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
9785793|NCT01260324||Controls|From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
10196691|NCT05182970|No Intervention|Standard care alone|Standard care according to national guidelines. In Sweden there is no pharmacological intervention recommended for individuals with prediabetes at present. Standard care includes diet and life-style advice, which will be given to both groups in the same manner according to local routines, based on the present guidelines. Secondary preventive treatment includes physical activity, participating in exercise program, dietary habits, BMI and or waist circumference, smoking and EQ-5D will be followed in accordance with the routinely reported SWEDEHEART-SEPHIA variables.
10196692|NCT05182957|Experimental|Anti-PD-1 monoclonal antibody+Lenalidomide+Azacitidine|Anti-PD-1 monoclonal antibody plus Lenalidomide, Azacitidine
9720580|NCT04238416|Experimental|IV BCAA + Lactulose|IV Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
9720581|NCT04238416|Active Comparator|Lactulose alone|Oral Lactulose alone
10196693|NCT05182944|Experimental|After 2 cycles of neoadjuvant therapy,non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（2 cycles Camrelizumab+Albumin Paclitaxel +Cisplatin and Camrelizumab maintenance treatment）
10196694|NCT05182944|Active Comparator|After 2 cycles of neoadjuvant therapy, non-pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
9720582|NCT04213729|Active Comparator|Crohn's Disease (CD) Control Group|Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
9720583|NCT04213729|Experimental|Experimental CD Low Fat Diet (LFD) Group|Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
9720584|NCT04213729|Experimental|Experimental CD LFD + DPS Group|Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
10196695|NCT05182944|Experimental|After 2 cycles of neoadjuvant therapy, pCR patients adjuvant treatment|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）
10196696|NCT05182944|Active Comparator|After 2 cycles of neoadjuvant therapy, pCR patients adjuvant treatment(BSC)|After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）
9720585|NCT04201496|Experimental|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)
9720586|NCT04201496|Experimental|Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks|Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)
9720587|NCT04201496|Active Comparator|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)
9720588|NCT04201496|Active Comparator|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)
9720589|NCT04195919|Experimental|Group1|Hemodialysis patients(MDRD-eGFR ≤ 15 mL/min/1.73m2)
9720590|NCT04195919|Experimental|Group2|Healthy control(MDRD-eGFR ≥ 90 mL/min/1.73m2)
9720591|NCT04191655|Experimental|High Definition White Light Colonoscopy|
9720592|NCT04191655|Active Comparator|Dye Spraying Chromo-colonoscopy|
9720593|NCT04181320|No Intervention|Venous Leg Ulcer Standard of Care|Subjects will recieve standard of care treatment.
9720594|NCT04181320|Experimental|Venous Leg Ulcer Standard of Care with Granulox|Subjects will recieve standard of care treatment with Granulox added as an adjunct therapy.
9720595|NCT04145219|Experimental|Active treatment|HDM SLIT-tablet plus allergy and asthma rescue medication
9720596|NCT04145219|Placebo Comparator|Placebo|Placebo oral tablet plus allergy and asthma rescue medication
9720597|NCT04129216|Experimental|Tamoxifen arm|for premenopausal patients
9720598|NCT04129216|Experimental|Letrozole arm|for postmenopausal patients
9720599|NCT04129216|Experimental|Exemestane arm|for postmenopausal patients
9720600|NCT04128969|Experimental|Carnitine supplementation (CS+)|Carnitine supplementation in liquid form, sugar free.
9720601|NCT04128969|Placebo Comparator|Placebo (CS-)|Placebo comparator liquid similar in appearance and taste to CS+.
9720602|NCT04113733||Crohn's Disease|This group consists of patients with a diagnosis of Crohn's disease undergoing colonoscopy for clinical care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
9720603|NCT04113733||Control|This group will include patients undergoing screening colonoscopy as part of standard of care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
9720604|NCT04113733||Cooperative Human Tissue Network|This group will consist of non-IBD patients and Crohn's disease patients participating in the Cooperative Human Tissue Network (CHTN). The CHTN will be utilized to obtain surgical specimens from these patients. The patients will be screened and consented via the CHTN protocol. No additional samples in the form of blood or stool will be collected. Associated clinical data will be collected through medical record review.
9720605|NCT04106414|Experimental|Nivolumab alone|Nivolumab 480 mg every 4 weeks.
9720606|NCT04106414|Experimental|Nivolumab with IDO-inhibitor, BMS- 986205|Nivolumab 480 mg every 4 weeks with BMS-986205 100 mg.
9720607|NCT04102618|Experimental|Cohort 1 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole
9720608|NCT04102618|Experimental|Cohort 2 (closed to enrollment)|HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
9720609|NCT04102618|Experimental|Cohort 3 (closed to enrollment)|TNBC patients who will receive pelareorep plus atezolizumab
9720610|NCT04102618|Experimental|Cohort 4 (closed to enrollment)|HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
9720611|NCT04102618|Experimental|Cohort 5 (closed to enrollment)|HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
9720612|NCT04102618|Experimental|Cohort 6|HER2+ (irrespective of HR status) (6 patients) who will receive pelareorep + trastuzumab
9720613|NCT04093258|Experimental|Test/Control|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
10196697|NCT05182918||Patients in OMT and other SUD treatment|Patients in opioid maintenance treatment and other substance use disorder treatment
9720614|NCT04093258|Experimental|Control/Test|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
9720615|NCT04088539|Experimental|Group A|"CSD participants will receive a combined intervention:~Brief intervention using AWARD advice at baseline,~Video-based health education"
9720616|NCT04085601|No Intervention|Standard of Care (SOC) excluding complement inhibitors|
9720617|NCT04085601|Experimental|1,080mg APL-2 administered subcutaneously twice weekly|
9720618|NCT04083326|Experimental|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
9720619|NCT04083326|No Intervention|Conventional care group|Conventional care consists of specialist assessment in conjunction with pre-operative surgical visits and patient education. Patients in the conventional care group are provided with pre- and postoperative information face-to-face by paper-based method. Patients will be admitted and mobilised on the day of the surgery, and discharged one to three days after surgery. The follow-up visit, conducted by a physiotherapist, is conducted after 6 to 8 weeks post-discharge for patients with TKA and after 8 to 12 weeks for patients with THA.
9720620|NCT04059926||Patients with lumen metal apossing stent|
9720621|NCT04052880|Experimental|Daratumumab with dose-attenuated VRd|SubQ Daratumumab with Dose-Attenuated VRd
9720622|NCT04042792||ADA for ≥12 weeks and concomitant MTX therapy|PiRD patients with ADA for ≥12 weeks and concomitant MTX therapy (oral or subcutaneous)
9720623|NCT04042792||ADA for ≥ 12 weeks without MTX|PiRD patients with ADA for ≥ 12 weeks without MTX ≥ 12 weeks (or never exposed to MTX)
9720624|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 50mg bid|Oral tablet for 24 weeks
9720625|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 150mg qd|Oral tablet for 24 weeks
9720626|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 200mg qd|Oral tablet for 24 weeks
9720627|NCT04018755|Experimental|treatment|anakinra 100 mg subcutaneous once daily
9720628|NCT04011826|Experimental|Experimental: Experimental trial nasal mask|Experimental trial nasal mask: Participants will be placed on this arm for a total of 14±3 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm. Participants on the extension will use this trial mask for a further six months after Visit 3.
9720629|NCT04011618|Placebo Comparator|Placebo|16 patients to receive 1 homologated placebo capsule (calcined magnesia 500 mg) every 12 hours along 12 weeks
9720630|NCT04011618|Experimental|Ellagic acid|16 patients to receive 1 homologated intervention capsule (ellagic acid 500 mg) every 12 hours along 12 weeks
9720631|NCT04006756|Experimental|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
9720632|NCT04006756|Active Comparator|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
9720633|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-front line|histologically or cytologically confirmed solid tumor who have received no prior treatment
9720634|NCT03993379|Experimental|CX-072 in combination with ipilimumab|histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor
9720635|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Progressed|histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy
9720636|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Neoadjuvant|neo-adjuvant study in subjects with histologically confirmed solid tumor
9720637|NCT03990870|Experimental|Experimental Treatment|dCBGT + WASABI
9720638|NCT03990870|Active Comparator|Active Comparator|dCBGT Only
9720639|NCT03956615|Other|Clinically Suspected or Pathologically Confirmed Multiple Myeloma.|Patients with a clinically suspected or pathologically confirmed multiple myeloma.
9720640|NCT03946462|Experimental|NO Group|
9720641|NCT03946462|Placebo Comparator|Placebo Group|
9720642|NCT03906227|Active Comparator|low CD5+ /on maintenance|Subjects in remission with Cluster of Differentiation (CD)19+CD5+ lower than 43% will continue on maintenance immunosuppression (Maintenance Therapy Group)- no randomization.
9720643|NCT03906227|Active Comparator|high CD5/ on maintenance|Subjects in remission with CD19+CD5+ 43% or greater, randomized to continue on maintenance immunosuppression (Maintenance Therapy Group)
9720644|NCT03906227|Experimental|high CD5 / NO maintenance|Subjects in remission with CD19+CD5+ 43% or greater , randomized to NO maintenance immunosuppression (NO Maintenance Therapy Group)
9720645|NCT03899844||Cognitively normal|896 of the 1120 enrolled will not exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
9720646|NCT03899844||Cognitively impaired|224 of the 1120 enrolled will exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
9720647|NCT03886415|Experimental|Jaktinib hydrochloride tablets 1|This is the dose group was given once a day. Jaktinib hydrochloride tablets 1 200mg qd dose group
9720648|NCT03886415|Experimental|Jaktinib hydrochloride tablets 2|This is the dose group was given twice a day. Jaktinib hydrochloride tablets 2 100mg bid dose group
9720649|NCT03881748|Experimental|Manual acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points.
9720650|NCT03881748|Experimental|Electro-acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points with additional application of weak electrical stimulation
9720651|NCT03878030||Subjects with spinal muscular atrophy types 2 and 3|Intrathecal nusinersen will be administered to all subjects per FDA approved label.
9720652|NCT03869177|Other|Intervention arm|Clusters (psychiatric outpatient clinics) in the intervention arm receives a comprehensive implementation support program during the trial period.
9720653|NCT03869177|No Intervention|Control arm|Clusters (psychiatric outpatient clinics) in the control arm receives no implementation support during the trial period.
9720654|NCT03868592|Experimental|Gastric sleeve surgery|before and after weight loss from bariatric surgery
9720655|NCT03853616|Experimental|Phase I: DL 0: 1x10e5 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
9720656|NCT03853616|Experimental|Phase I: DL 1: 5x10e5 MB-CART19.1 cells|Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
9720657|NCT03853616|Experimental|Phase I: DL 2: 1x10e6 MB-CART19.1 cells|Dose evaluation will start in Cohort 3 with Dose Level 2, sparing Dose Level 1. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
9720658|NCT03853616|Experimental|Phase I: DL 3: 3x10e6 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.
9720659|NCT03853616|Experimental|Phase II - Recommended dose MB-CART19.1|Phase II will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively.
9720660|NCT03803059|Experimental|Wrinkles of the Neck|Microneedle treatment neck areas.
9720661|NCT03772158|Experimental|Treatment A|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
9720662|NCT03772158|Experimental|Treatment B|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water. Subjects will be instructed to chew the tablet completely before swallowing.
9720663|NCT03772158|Experimental|Treatment C|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
9720664|NCT03772158|Active Comparator|Treatment D|Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
9720665|NCT03772158|Active Comparator|Treatment E|Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
9720666|NCT03762590|Experimental|Doxy.me plus Color Genomics Arm (Arm 1)|"Participants in this arm will receive genetic education through an online platform called Doxy.me~The Doxy.me session will consist of two parts: 1) a pre-recorded genetic education video 2) a live interactive video conferencing session with a GENERATE genetic counselor~After completing the Doxy.me session and post intervention questionnaires, participants will be directed to the Color Genomics study portal where they may elect to review Color Genomics' genetic education content or proceed directly to order genetic testing~Intervention is Doxy.me genetic education +/- genetic education via Color Genomics website"
9720667|NCT03762590|Experimental|Color Genomics Only Arm (Arm 2)|"Participants in this arm will access genetic education on the Color Genomics website which includes both written information and an educational video~After accessing the Color Genomics website, participants may elect to review educational content or proceed directly to order genetic testing~Intervention is genetic education via Color Genomics website"
9720668|NCT03758742|Experimental|High-Fruit Diet|
9720669|NCT03723590|Experimental|Esterified hyaluronic acid matrix|
9720670|NCT03720392|Experimental|FMT Capsules|"Two doses of FMT: one standard dose starting within four (4) days from the start of the conditioning regimen prior to HCT and one non-standard dose starting within 4 weeks after engraftment after HCT.~A standard dose of oral FMT is 15 capsules per day for two consecutive days,"
9720671|NCT03720392|Placebo Comparator|Placebo Capsules|"Two doses of placebo, instead of FMT: one starting within four (4) days from the start of the conditioning regimen prior to HCT and the second one starting within 4 weeks after engraftment after HCT.~A standard dose of oral Placebo is 15 capsules per day for two consecutive days,"
9720672|NCT03697512|Experimental|Ibrutinib and Rituximab|"Induction PART A, from Day 1 to Day 56.~Patients will be treated with:~Ibrutinib 560 mg/day continuously up to Day 56;~Rituximab 375 mg/m2 intravenously at Day 1, and then subcutaneous (1400 mg, flat dose) at Day 8, 15 and 22 of cycle 1.~Induction PART B, from Day 57 to Day 196.~Patients will be treated with:~Ibrutinib 560 mg/day continuously up to Day 196;~Rituximab subcutaneous (1400 mg, flat dose) at Day 1 every 28 days for 4 cycles.~Maintenance PART C, from Day 197 to Day 730.~Patients will be treated with:~- Ibrutinib 560 mg/day continuously up to Day 730."
9720673|NCT03680625|Active Comparator|Passive Distraction|The child will watch a video on an iPad® during the pin removal procedure and/or removal of sutures.
9720674|NCT03680625|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment using an Oculus Quest® head-mounted device throughout the pin removal procedure and/or removal of sutures.
9720675|NCT03658486|Other|Exercise|12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
9720676|NCT03653988|Active Comparator|PEC I/II block - pre-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction case. The intervention administered to Group I will having the block performed by the anesthesiologist after induction of general anesthesia and prior to surgical incision.
9720677|NCT03653988|Experimental|PEC I/II block - intra-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction cases. Group II will have the block administered by the surgeon after mastectomy is performed and before reconstruction.
9720678|NCT03613727|Experimental|IV Vitamin C followed by oral Vitamin C|All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
9720679|NCT03596697|Experimental|CRV431|Either single or multiple doses of varying dose levels
9720680|NCT03596697|Placebo Comparator|Placebo|
9720681|NCT03596697|Experimental|TDF|300 mg TDF
9720682|NCT03591614|Experimental|Dendritic cell DKK1 vaccine|5-10x106 DKK1 loaded dendritic cells. Three doses will be given two weeks apart, followed by 11 months of observations.
9720683|NCT03558854|Active Comparator|ASA group|Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks
9720684|NCT03558854|Placebo Comparator|Placebo oral capsule group|Identical pill containing placebo, taken once daily for 04 weeks
9720685|NCT03545126||Progressive Supranuclear Palsy (PSP)|N=12 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
9720686|NCT03545126||Corticobasal Degeneration (CBD)|N=8 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
9720687|NCT03545126||Frontotemporal Dementia: MAPT|N=12 Family members with or at-risk of tau mutations (e.g. P301L) Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
9720688|NCT03543852|Experimental|SurvivorLink|Participants receiving treatment at a pediatric cancer survivor clinic randomized to this study arm will receive education on how to use SurvivorLink, late effects of treatment, and survivorship care through the system.
9720689|NCT03543852|No Intervention|Usual care|Participants receiving treatment at a pediatric cancer survivor clinic randomized to the usual care study arm will receive the SurvivorLink intervention beginning at Month 12.
9720690|NCT03531580|Experimental|Healthy volunteers|six healthy volunteers: 3 male (age 20-40; 40-60 and 60+) and 3 female (age 20-40; 40-60 and 60+)
9720691|NCT03521999|Active Comparator|AboutFace|Veterans in the AboutFACe arm will receive access to an online peer-to-peer digital storytelling resource for Veterans with PTSD
9720692|NCT03521999|Placebo Comparator|Enhanced Usual Care (eUC)|Veterans in the Enhanced Usual Care (eUC) arm will receive an education brochure for PTSD
9720693|NCT03515226|Active Comparator|Traditional Training|20 hours of didactic education and training in CBT principles, depression assessment and cultural competency and 25 hours in dyad role playing of CBT manualized treatment sessions with supervision.
9720694|NCT03515226|Experimental|ITS based training|Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.
9720695|NCT03495960|Experimental|Lenalidomide (experimental arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses"
9720696|NCT03495960|Active Comparator|Procarbazine (comparator arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.~Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses"
9720697|NCT03495960|Other|Radiotherapy, temozolomide and rituximab (single arm part B)|"Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive~whole-brain radiotherapy (2340 cGy in 5 weekly fractions)~temozolomide 75 mg/m2/d during radiotherapy~4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.~Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses."
9720698|NCT03486301|Experimental|Single Agent BDB001|"A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle.~Then dosage escalation will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached."
9720699|NCT03486301|Experimental|BDB001 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study."
9720700|NCT03451916|Experimental|PLX-PAD|• Arm 1 - PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte.
9720701|NCT03451916|Placebo Comparator|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
9720702|NCT03444753|Experimental|Arm A|BMS-986299
9720703|NCT03444753|Experimental|Arm B|BMS-986299 in combination with nivolumab and ipilimumab
9720704|NCT03439930|Active Comparator|Uni-axial|Subjects in this group perform exercises on an uni-axial balance board
9720705|NCT03439930|Active Comparator|Multidirectional|Subjects in this group perform exercises on a multidirectional balance board
9720706|NCT03430895|Experimental|combination of durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting at Week 16 for 9 doses (total treatment duration of 12 months).
9720707|NCT03409458|Experimental|PT-112 in combination with avelumab|"PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion~Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study."
9720708|NCT03406312||Gastric Bypass Surgery population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
9720709|NCT03406312||Control population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
9720710|NCT03389438|Experimental|Experimental arm|Participants who were treated with autologous Tcm cells immunotherapy.
9720711|NCT03389438|No Intervention|No intervention arm|Participants who were treated with no autologous Tcm cells immunotherapy.
9984523|NCT04011150|Experimental|Variable volume Automated Mandatory Bolus (VVAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VVAMB programme. The programme uses higher doses with lower frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
9720714|NCT03366272|Active Comparator|(R)-GemOx|eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)
9720715|NCT03366272|Experimental|Nivo-(R)-GemOx|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
9720716|NCT03321617|Experimental|POMA 40mg BID (80mg)|Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.
9720717|NCT03321617|Experimental|POMA 80mg BID (160 mg)|Subject will take 80 mg pomaglumetad methionil (POMA) twice a day for 14 days
9720718|NCT03321617|Experimental|POMA 120mg BID (240mg)|Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days
9720719|NCT03321617|Experimental|POMA 160 mg BID (320 mg)|Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days
9720720|NCT03299179||Natural cycle|15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.
9720721|NCT03299179||Anti-conception|15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.
9720722|NCT03272178||Triathlon knee total knee arthroplasty|50 Patients who are assigned to Triathlon knee, half cemented/half cementless
9720723|NCT03272178||Depuy knee total knee arthroplasty|50 Patients who are assigned to Depuy knee, half cemented/half cementless
9720724|NCT03243058|Active Comparator|Treatment Arm|ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.
9720725|NCT03243058|Experimental|Treatment-Placebo Arm|Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.
9720726|NCT03243058|Placebo Comparator|Placebo|Participants in this group will receive a placebo injection for two years.
9720727|NCT03230838|Experimental|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum 1 g and 0.5 g/dose) administered intravenously (IV) every 8 hours for 7-14 days
9720728|NCT03230838|Active Comparator|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for 7-14 days
9720729|NCT03218605|Experimental|healthy active participants|
9720730|NCT03189862|Experimental|CHAMP|CHAMP, is a mastery climate motor skills interventions, that provides children the opportunity to establish behaviors that reinforces decision-making while participating in a variety of challenging movement & physical activity tasks. Duration of CHAMP is 30 min/day 4 days/week for 30 weeks. CHAMP consist of a) a 2-3 min of motor skill introductory activity that includes a group motor activity, the teaches the lesson, includes a demonstration, and understanding of developmentally appropriate learning clues b) 25 min of motor skill instruction & practice where preschoolers engage in 3-4 motor activity stations that align with the TARGET structures c) & 2-3 min motor skill closure activity that involves a review of the lesson & critical elements.
9720731|NCT03189862|No Intervention|Control - Free Play|The control/free play condition will be the preschools typical activity programs (i.e., outdoor/indoor recess) and will be implemented according to the existing procedures within the preschool centers. The centers outdoor program consist of outdoor free-play activity on a large playground area with a variety of play structures (swings, slides, ladders) that promote gross movement and activity in preschoolers. For the control condition, there will be no planned instruction nor activities provided by the classroom teachers.
9720732|NCT03183778|Experimental|Patiromer + Research Diet|"During the first phase (week 2), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (less than or equal to 1 serving/day), and eliminates high-potassium fruits and vegetables.~During the second phase (weeks 3 and 4), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources."
9720733|NCT03176615|Experimental|Group A (Cross-over Group 1)|Subjects randomly assigned to two experimental diets. This arm will receive high-fat meals first, followed by a washout period of two-seven days and then low-fat meals.
9720734|NCT03176615|Experimental|Group B (Cross-over Group 2)|Subjects randomly assigned to two experimental diets. This arm will receive low-fat meals first, followed by a washout period of two-seven days and then high-fat meals.
9720735|NCT03147508||Neck pain patients|
9720736|NCT03113955|Experimental|single -arm|A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
9720737|NCT03034096|Experimental|Propofol infusion|Maintenance of general anesthesia with propofol infusion
9720738|NCT03034096|Experimental|Volatile agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
9720739|NCT03029234|Experimental|Carfilzomib with Dexamethasone|"Participants will receive carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants will also receive 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle.~Participants will receive treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, non-compliance, or intercurrent illness or worsening of a chronic condition, whichever occurs first."
9720740|NCT03016338|Experimental|Niraparib +TSR-042|200/300 mg Niraparib by mouth once a day for 21 days cycle. 500 mg of TSR-042 intravenously on the first day of each cycle.
9720741|NCT02995694|Experimental|Test|Estradiol Vaginal Cream
9720742|NCT02995694|Active Comparator|Reference.|Estrace Vaginal Cream
9720743|NCT02995694|Placebo Comparator|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
9720744|NCT02983045|Experimental|Dose Escalation: Combination of NKTR-214 + nivolumab|NKTR-214 in escalating doses will be combined with one of the two proposed doses of nivolumab. The goal of this dose escalation Part 1 of the study is to find the RP2D.
9720745|NCT02983045|Experimental|Dose Expansion: Combination of NKTR-214 + nivolumab|"Combination of NKTR-214+nivolumab in combination with cytotoxic chemotherapies for the following 2 cohorts of the Part 2:~NSCLC 1L nonsquamous plus platinum/pemetrexed NSCLC 1L squamous plus platinum/taxane"
9720746|NCT02983045|Experimental|Experimental: Combination of NKTR-214 + nivolumab + ipi|NKTR-214 will be combined with nivolumab and ipilimumab. The goal of this dose schedule finding part of the study is to define the RP2D and administration schedule.
9720747|NCT02983045|Experimental|Dose Expansion of the Part 3 RP2D|Experimental Combination of NKTR-214 + nivolumab + ipilimumab that may enroll between 12-26 patients per tumor type
9720748|NCT02926833|Experimental|KTE-C19 + ATZ|Participants will receive conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days. Treatment with ATZ will begin 21 days following KTE-C19 (Phase 1 Cohort 1), 14 days following KTE-C19 (Phase 1 Cohort 2), and 1 day following KTE-C19 (Phase 1, Cohort 3 & Phase 2).
9720749|NCT02886247||participants|individuals with a personal or family history of pancreas tumors
10196698|NCT05182736|Experimental|TRAIL intervention|"The TRAIL program is comprised of a multi-tier system of strategies:~Universal Strategies (delivered school-wide),~Targeted Strategies (delivered to the target grade level in the evaluation sample)~Intensive Strategies (delivered to select at-risk students)"
10196699|NCT05182736|No Intervention|Control|"Students in the comparison schools receive the normal ninth grade health curriculum, Reproductive and Health Safety Education."
9720750|NCT02863107||Observational (questionnaire, biospecimen collection)|"PATIENTS: Patients complete questionnaires over 30-50 minutes about work, family history, medical history, health habits, and experience as a cancer survivor (quality of life, well-being, concerns, types of health care, and follow-up care received). Patients also undergo collection of blood or saliva samples. Active patients, who have undergone treatment at MD Anderson Cancer Center within the past year, complete additional questionnaires at enrollment, 6 months, 12 months after treatment completion, and then every years for up to 6 years. Also, active patients who are consented to the study more than 5 years from surgery, they may complete the survivorship questionnaire once. Patients medical records are also reviewed.~FAMILY MEMBERS: Participants complete questionnaires over 10-15 minutes. Participants also undergo collection of blood or saliva samples once."
9720751|NCT02750657||Patients with advanced pancreatic ductal adenocarcinoma|
9720752|NCT02729844||Neolifes Heart|All premature infants, admitted at the neonatal intensive care unit (NICU) of the University Medical Centre Groningen, born <30 weeks or birth weight < 1000 gram, who participate in NeolifeS
9720753|NCT02706262|No Intervention|Metabolically normal lean - Baseline testing only|"Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
9720754|NCT02706262|No Intervention|Metabolically normal obese - Baseline testing only|"Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.~Dietary intervention - None."
9720755|NCT02706262|Experimental|Metabolically abnormal obese - Mediterranean diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A nutritionally balanced diet that includes fruits, vegetables, fish, beans, whole grains, and olive oil with approximately 50% of daily calories coming from complex carbohydrates, 30% of calories from fat, and 20% of calories from protein."
9720756|NCT02706262|Experimental|Metabolically abnormal obese - Low carbohydrate ketogenic diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A very-low-carbohydrate, adequate protein, high-fat diet containing 20 grams of carbohydrate or less per day (about 5% of calories), derived mainly from vegetables."
9720757|NCT02706262|Experimental|Metabolically abnormal obese - Plant-based very-low-fat diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.~Dietary intervention - A plant-based diet high in complex carbohydrates and low in fat, protein, and sodium, with approximately 70% of daily calories from carbohydrates, 15% from fat, and 15% from protein."
9720758|NCT02700698||Healthy lean|Healthy lean women, 25-35 years
9720759|NCT02700698||Overweight/obese with/without IR|Overweight/obese with/without insulin resistant women, 25-35 years
9780102|NCT03988595|Experimental|aerobic training 225 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
9780103|NCT03988595|Experimental|aerobic training 300 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
9780104|NCT03987581|Experimental|CBT + mCM + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment, mobile contingency management for alcohol abstinence, and a monetary incentive for 30-day abstinence at the 6-month follow-up.
9780105|NCT03987581|Experimental|CBT + mCM + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and mobile contingency management for alcohol abstinence. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up.
9780106|NCT03987581|Experimental|CBT alone + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and a monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
9780107|NCT03987581|Active Comparator|CBT alone + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
10196700|NCT05182710|Experimental|Stress Inoculation Training|Intervention Arm
10196701|NCT05182710|Active Comparator|Alternative Training|Best practice/control
9720760|NCT02699086|Experimental|Low dose + Low dose|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 + 28 days
9720761|NCT02699086|Experimental|Low dose + High dose|1 PDC-1421 Capsule for 28 days + 2 PDC-1421 Capsules for 28 days, trice daily, p.o. after meals
9720762|NCT02698865|Experimental|MONOVISC|MONOVISC High Molecular Weight Hyaluronan
9720763|NCT02698865|Placebo Comparator|Saline|Physiologic saline
9720764|NCT02660086|Experimental|Personalized feedback|Emails and letters providing personalized nutrition feedback about food choices and health, social norms, and financial incentives for healthy food choices
9720765|NCT02660086|No Intervention|Control|Monthly letters with general nutrition information
9720766|NCT02653755|Active Comparator|Ineligible for omission of RT|Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.
9720767|NCT02653755|Active Comparator|Eligible for omission of RT|Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.
9980700|NCT01394458|Experimental|30 % ethanol/ 4 % sodium citrate group|For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
9720769|NCT02535325|Experimental|Treatment (pemetrexed, methoxyamine, cisplatin, RT)|"CYCLES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine hydrochloride PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.~CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.~Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
9720770|NCT02530177||Patients having CYTOTOXIC CHEMOTHERAPY|Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.
9720771|NCT02530177||Patients having ENDOCRINE THERAPY|Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits.
9720772|NCT02530177||COMPARATOR (menopausal women)|Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort.
9720773|NCT02498951|Experimental|Arm I (obinutuzumab)|Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity
9720774|NCT02498951|Active Comparator|Arm II (observation)|Patients undergo observation for a total of 2 years.
9720775|NCT02398747|Experimental|AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD|50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
9720776|NCT02335749|Experimental|Treatment with Small Area Applicator|Each enrolled subject was treated on a single thigh, in the distal region.
9720777|NCT02318732|Experimental|Group 1|APPS intervention will be implemented in Group 1 communities prior to implementation in Group 2 communities.
9720778|NCT02318732|Active Comparator|Group 2|APPS intervention will be implemented in Group 2 communities following implementation in Group 1 communities.
9720779|NCT02257567|Experimental|Arm A (Phase II Randomization): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
9720780|NCT02257567|Active Comparator|Arm B (Phase II Randomization): BR in FL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
9720781|NCT02257567|Experimental|Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
9720782|NCT02257567|Active Comparator|Arm D (Phase II Randomization): BR in DLBCL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
9720783|NCT02257567|Experimental|Arm E (Phase II Expansion): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
9720784|NCT02257567|Experimental|Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
9720785|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
9720786|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
9720787|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
9720788|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
9720789|NCT02257567|Experimental|Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
9720790|NCT02257567|Experimental|Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
9720791|NCT02149537|Experimental|hydroxyurea|500mg of hydroxyurea/day during 6 months
9720792|NCT02149537|No Intervention|No treatment|No hydroxyurea treatment during 6 months
9720793|NCT02141074|Experimental|50 EDs (exposure days)|
9720794|NCT02129647|Experimental|Axitinib|5 mg axitinib orally twice daily, with increase to 7 mg orally twice daily and 10 mg orally twice daily after 2 and 4 weeks, respectively, provided no adverse reactions (i.e., not exceeding grade 2 toxicities) and normotensive and not receiving antihypertension medications. Axitinib will be given continuously in 28-day cycles until disease progression or unacceptable toxicity.
9720795|NCT02071901|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine by mouth (PO) daily (QD) until platelet counts reach >= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.
9720796|NCT01959139|Active Comparator|Phase II: mFOLFIRINOX|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 1.5 hours on day 2, and 5-fluorouracil (5-FU) IV over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9720797|NCT01959139|Experimental|Phase II: mFOLFIRINOX + PEGPH20|Patients receive pegylated recombinant human hyaluronidase (PEGPH20) IV over 10 minutes on day 1 and oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and 5-fluorouracil (5-FU) as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9720798|NCT01959139|Experimental|Phase I|PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours
9720799|NCT01870193|Active Comparator|Young controls|Young controls will be studied before and after receiving cysteine and glycine for 2 weeks
9720800|NCT01870193|Active Comparator|Elderly active|Elderly subjects in the active group will receive glycine plus cysteine (as n-acetylcysteine) for 4 months, and be studied at baseline, 2 weeks and 4 months
9720801|NCT01870193|Placebo Comparator|Elderly placebo|Elderly subjects in the placebo group will receive alanine for 4 months, and be studied at baseline, 2 weeks and 4 months
9720802|NCT01865396|Experimental|early palliative care|Interventional palliative care, after diagnosis and once a month.
9720803|NCT01865396|Active Comparator|Standard care|Patients will receive the standard oncologic care.
9720804|NCT01805284|Experimental|Linezolid|
9720805|NCT01705067|Other|Journey II BCS TKA|Subjects having TKA with Journey II BCS Total Knee System
9720806|NCT01679132|Experimental|BAROSTIM NEO System|Subjects implanted with the BAROSTIM NEO System.
9720807|NCT01640483|Active Comparator|supportive|
9720808|NCT01640483|Active Comparator|interpretative|
9720809|NCT01640483|Active Comparator|mixed supportive/interpretative|
9720810|NCT01620918|Experimental|2 types of healing abutment|Patients who are in need of minimal 2 dental implants, who will receive both types of healing abutments.
9720811|NCT01597778|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive haploidentical bone marrow transplant using a reduced intensity conditioning regimen.
9720812|NCT01597778|Experimental|Double Umbilical Cord Blood Transplant|Participants will receive a double umbilical cord blood transplant using a reduced intensity conditioning regimen.
9720813|NCT01522976|Experimental|Arm I (azacitidine and lenalidomide)|Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
9720814|NCT01522976|Experimental|Arm II (azacitidine)|Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
9720815|NCT01522976|Experimental|Arm III (azacitidine and vorinostat)|Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
9720816|NCT01471834|Experimental|Device and Medical Management|Participants will be implanted with the BAROSTIM NEO System and will continue to receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
10196702|NCT05182697|Experimental|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
9720818|NCT01337128|Experimental|Carotid endarterectomy (CEA)|Patients with carotid stenosis who are randomly assigned to a carotid endarterectomy.
9720819|NCT01337128|Experimental|Carotid Stenting (CAS)|Patients with carotid stenosis who are randomly assigned to a carotid stenting.
9720820|NCT01337128|No Intervention|matched control group|Matched control group.
9720821|NCT01286272|Experimental|Arm A (ofatumumab, bendamustine hydrochloride)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1 and bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses."
10196703|NCT05182697|Active Comparator|CBD oil|CBD- active CBD oil with twice daily and CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
9720822|NCT01286272|Experimental|Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses."
9720823|NCT01191073|Experimental|CAD/CAM fabricated dentures|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
9720824|NCT01191073|Active Comparator|traditional fabricated dentures|group receiving traditional fabricated dentures (double blind)
9720825|NCT01145495|Experimental|Treatment (lenalidomide, rituximab)|Patients receive lenalidomide PO QD on days 1-21. Treatment with lenalidomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 and in weeks 13, 21, 29, and 37 in the absence of disease progression or unacceptable toxicity.
9720826|NCT01139970|Experimental|Treatment (temozolomide and veliparib)|"Patients receive veliparib PO QD on day 1 and twice daily on days 4-12 and temozolomide PO QD on days 3-9 of course 1.~Beginning at least 30 days after the start of treatment, patients receive veliparib PO BID on days 1-8 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients achieving complete remission receive 5 more courses in the absence of disease progression or unacceptable toxicity."
9720827|NCT01134601|Experimental|Selumetinib (AZD6244): 50 mg & Capecitabine: 825 mg/m^2|LEVEL 1 - Cycle = 49 days: AZD6244: 50 mg by mouth (PO) everyday (QD) Capecitabine: 825 mg/m^2 by mouth (PO)
9720828|NCT01118026|Experimental|ABVD +/- BEACOPP + radiation|"Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles.~Patients undergo a PET scan following two cycles of ABVD. If the PET scan is negative, then the patient will receive four more cycles of ABVD (a total of 6 cycles of ABVD). If the PET scan is positive, then the patient receives four cycles of escalated BEACOPP for 21 days (a total of 4 cycles).~3-6 weeks after BEACOPP therapy, patients receive radiation therapy for 5 days per week (a total of 3.5 weeks).~All patients will be followed for a maximum of ten years."
9720829|NCT01004367|Experimental|1|Environmental- and individual based components carried out in the school.
9720830|NCT01004367|No Intervention|2|No intervention
9720831|NCT00903500|Experimental|1|Daily physical activity
9720832|NCT00903500|No Intervention|2|Usual care
10196704|NCT05182684|Experimental|Single arm|Electrocardiograms were measured by VP-100 for more than 6 hours and transmitted to a central server.
9720833|NCT00879086|Active Comparator|Eribulin mesylate|
9720834|NCT00879086|Active Comparator|Ixabepilone|
9720835|NCT00864227|Experimental|Umbilical Cord Blood Transplantation|Participants will receive a double unit Hematopoietic Umbilical Cord Blood Stem Cell Transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
9720836|NCT00737321||2- Diabetics without wound (s)|These group of subject will be control arm, included who have good glycemic control diabetic with HbA1c 8.4 or lower and also without any open wounds. Samples will be collected.
9720837|NCT00737321||1-Subjects with diabetes with wound|This group of subjects will have wound and come for couple of follow up visits for saliva collection, biopsy collection and blood draw.
9720838|NCT00734019||P.F.C. Sigma Knee System|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
9720839|NCT00731731|Experimental|Treatment (radiation therapy, vorinostat, temozolomide)|Patients undergo radiotherapy and receive vorinostat PO QD on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients also receive temozolomide PO QD on days 1-42. Beginning 4-6 weeks later, patients receive vorinostat PO QD on days 1-7 and 15-21 and temozolomide PO QD on days 1-5. Treatment with vorinostat and temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9720840|NCT00685360|Experimental|Delamanid 100 mg BID + OBR|"Participants received delamanid 100 milligrams (mg) (two 50 mg tablets), orally, BID with two matching placebo tablets plus optimized background regimen (OBR) for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on World Health Organization (WHO) guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
9720841|NCT00685360|Experimental|Delamanid 200 mg BID + OBR|"Participants received delamanid 200 mg (four 50 mg tablets), orally, BID plus OBR for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
9720842|NCT00685360|Placebo Comparator|Placebo + OBR|"Participants received four placebo tablets matching 50-mg tablets of delamanid, orally, BID plus OBR for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
9720843|NCT00588991|Experimental|Treatment (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9720844|NCT00336063|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9720845|NCT00299728|Experimental|Arm A; 100 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|100 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
9720846|NCT00299728|Experimental|Arm B; 400 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|400 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
10196705|NCT05182671||Children diagnosed with bowel and bladder dysfunction|Children who are between the ages of 5-12 and diagnosed with bladder- bowel dysfunction by pediatric urologist.
9720848|NCT00095784|Experimental|Treatment (decitabine)|Patients receive decitabine SC on days 1-5 and 8-12. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
9720849|NCT00070499|Experimental|Arm I (QD imatinib mesylate)|Patients receive imatinib mesylate PO QD. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
9720850|NCT00070499|Experimental|Arm II (BID imatinib mesylate)|Patients receive imatinib mesylate PO BID. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
9720851|NCT00070499|Experimental|Arm III (dasatinib)|Patients receive dasatinib PO BID. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
9720852|NCT04525781||1|
9720853|NCT04525508||Normal glucose tolerance (NGT)|Those of the study population with one normal Oral glucose tolerance test (OGTT)
9720854|NCT04525508||Dysglycemia|Those of the study population with one dysglycemia (IFG and/or IGT)
9720855|NCT04525508||Diabetic OGTT|Those of the study population with one Diabetic OGTT
9720856|NCT04525443||Patients with active SARS-CoV-2 infection.|Patients admitted for COVID-19 at Hospital Clínico San Carlos with positive SARS-CoV-2 polymerase chain reaction (PCR).
9720857|NCT04525443||Patients with past, not active, SARS-CoV-2 infection.|Patients with past infection (not active), demonstrated by serology and PCR.
9720858|NCT04525443||People without concurrent or past SARS-CoV-2 infection|Health personnel from the Cardiology Service of Hospital Clínico San Carlos who demonstrate by serology that they have not had SARS-CoV-2 infection.
9720859|NCT04525586||It's just an observational study, no interventions|children with recurrent wheezing
9720860|NCT04525287||Severe COVID-19|Patients who have one of the following conditions during treatment: 1. Respiratory distress, RR≥30 beats/min; 2. In resting state, mean oxygen saturation≤93%; 3. Arterial oxygen partial pressure ( PaO2)/Inhalation Oxygen Concentration (FiO2) ≤300mmHg (1mmHg=0.133kPa); 4. Respiratory failure occurs and mechanical ventilation is required; 5. Shock occurs; 6. ICU monitoring and treatment is required for combined other organ failure.
9720861|NCT04525287||Mild COVID-19|The patient only showed symptoms such as fever and respiratory tract in general, and no severe symptoms occurred during the visit and follow-up.
9720862|NCT04525313||training set|58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2013.01 and 2017.12.
9720863|NCT04525313||validation set|another 58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2018.01 and 2022.12.
9720864|NCT04524117||Group A(vulnerable plaque group)|Lipid plaques with fibrous cap thickness less than 65um, erosion and coronary artery dissection detected by OCT are defined as vulnerable plaque.
9720865|NCT04524117||Group B(stable plaque group)|Lipid plaques with fibrous cap thickness more than 65um detected by OCT are defined as vulnerable plaque.
9720866|NCT04523597||toracic hyperkyphosis|children with COBB angle ≥ 45˚
9720867|NCT04523597||control|children with kyphosis index < 13 measured using the flexicurve ruler
9720868|NCT04519307||Group 1|The newborns with covid 19 infection
9720869|NCT04519307||Group 2|The newborns with no covid 19 infection
9720870|NCT04519255||Screening of clinically cured patients with severe COVID-19|①Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
9720871|NCT04519255||Screening of clinically cured patients with mild COVID-19|①Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
9720872|NCT04519255||Healthy people who are not infected with COVID-19|① Volunteers who are not infected with COVID-19; ②Age > 18 years, age < 85 years, no gender restriction; ③ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ④ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
9720873|NCT04518839||Group with regional anaesthesia|
9720874|NCT04518839||Group with general anaesthesia|
9720875|NCT04518592||Severe Major Depressive Disorder|
9720876|NCT04518592||control , healthy|
9720877|NCT04517305||Pyrotinib plus vinorelbine|Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.
10196706|NCT05182632|Experimental|Group pelvic floor tele-rehabilitation|12 weekly treatment online sessions + daily home exercise program
10196707|NCT05182619|Active Comparator|ultrasoung guided stellate block|stellate ganglion will have ultrasound-guided block via bupivacaine for sympathectomy and enhancement of cerebral blood flow
10196708|NCT05182619|Active Comparator|nimodipine infusion|intravenous nimodipine will be given for enhancement of cerebral blood flow
10196709|NCT05182554|No Intervention|Control|No intervention in this arm; the study team will examine publicly available county- and zip code-level outcomes in this group.
9720878|NCT04515914||Decitabine therapy|The patients are treated with decitabine at least 1 cycles
9720879|NCT04515914||non-Decitabine therapy|The Patients are diagnosed as MDS and do not be treated with decitabine therapy
9720880|NCT04515485||Patients undergoing laparoscopy|The participants are patients that have undergone the laparoscopic surgery.
9720881|NCT04514003||SARS-CoV-2 PCR positive cases|Antibody tests will be performed every 6 months for 2 years
10196710|NCT05182554|Experimental|Treatment 1: Direct|Facebook users in the area receive ads which include videos of health professionals telling them to get vaccinated. The health professionals answer common questions about Covid-19 vaccines (e.g. are they safe / are they free).
9720882|NCT04514003||SARS-CoV-2 PCR negative cases|Antibody tests will be performed at baseline
9720883|NCT04514003||Population controls|A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.
9720884|NCT04514016||HIV positive participants with positive COVID-19 results|Participants in this group will have a RT-PCR and Coronavirus Disease (COVID) -19 specific antibody testing at baseline, 1 month and 3 month visits.
9720885|NCT04514016||HIV positive participants with negative COVID-19 results|Participants in this group will have a RT-PCR and COVID-19 specific antibody testing at baseline only.
9720886|NCT04513847||Control|Psoriasis patients treated with non-biologic
9720887|NCT04513847||Non-Control|Psoriasis patients treated with biologic
9720888|NCT04510467||case group|RMD patients with COVID 19 infection
9720889|NCT04510467||control group|RMD patients without COVID 19 infection
9720890|NCT04509128||A|Subjects hospitalized for a COPD acute exacerbation, undergoing arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, at admission and discharge.
9720891|NCT04509128||B|Subjects referred for pulmonary rehabilitation (PR) after a hospitalized COPD exacerbation, undergoing pulmonary function test, arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, before and after PR.
9720892|NCT04509037||Liposuction Assisted Breast Reduction|
9720893|NCT04509037||Open Incision Breast Reduction|
9720894|NCT04508465||OMEGA|Patients who have undergone major emergency abdominal surgery including the stomach, small or large bowel, or rectum for conditions such as perforation, ischemia, abdominal abscess, bleeding or obstruction.
9720895|NCT04508101||drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty with suction drainage positioning
9720896|NCT04508101||non-drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty without suction drainage positioning
9720897|NCT04506177||Permanent Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) suture for vaginal mesh attachment
9720898|NCT04506177||Delayed Absorbable Monofilament Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using delayed absorbable monofilament (polydioxanone, PDS) suture for vaginal mesh attachment
9720899|NCT04505176||1|20 patients being in the HHHNFC. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
9720900|NCT04505176||2|20 patients in the CPAP group. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
10196711|NCT05182554|Experimental|Treatment 2: Friends|Facebook users in the area receive ads which include videos of health professionals encouraging them to help their friends to get vaccinated. There is also a link in the ad to a website build by the study team. This website hosts videos which answer common questions about vaccination (the same videos which are directly served to Facebook users in Treatment 1).
9720901|NCT04504162||outpatient|Patients visiting a psychiatric hospital
9720902|NCT04503577||Bladder cancer patients|
9720903|NCT04503408||cystic fibrosis with abnormal glucose tolerance|cystic fibrosis with abnormal glucose tolerance Cystic fibrosis patients with descripted that impaired glucose tolerance or cystic fibrosis related diabetes by oral glucose tolerance test
9720904|NCT04503408||cystic fibrosis with normal glucose tolerance|cystic fibrosis with normal glucose tolerance Cystic fibrosis patients with descripted that normal glucose tolerance by oral glucose tolerance test
9720905|NCT04502784||Chronic Kidney Disease|This group will consist of 10 patients who have previously been diagnosed with chronic kidney disease and are receiving intravenous iron due to anaemia.
9720906|NCT04502784||Intestinal failure|This group will consist of 10 patients who have previously been diagnosed with intestinal conditions and are receiving intravenous iron due to anaemia.
9720907|NCT04502784||Healthy Volunteers|This group will consist of 20 healthy volunteers. This group will act as a comparator for the CKD and intestinal failure groups.
9720908|NCT04501887||Matched therapy|Molecular profiling performed with actionable molecular alterations detected and target therapy was then conducted
9720909|NCT04501887||Unmatched therapy|Molecular profiling performed with actionable molecular alterations detected but therapy was conducted based on the guideline treatment
9720910|NCT04501887||No marker|Molecular profiling performed without any actionable molecular alterations detected, tranditional therapy based on the guideline was then conducted
9720911|NCT04501497||NSCLC cohort (N=800)|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
10196712|NCT05182554|Experimental|Treatment 3: Gossips|Facebook users in the area receive ads which include videos of health professionals encouraging them to nominate their most influential friends to help their friends get vaccinated. The difference from Treatment 2 is that the health professionals call on Facebook users to get their most influential friends to do the convincing about the vaccine. There is also a link in the ad to a website built by the study team. This website hosts videos which answer common questions about vaccination (the same videos that are directly served to Facebook users in Treatment 1).
10196713|NCT05182515|No Intervention|Standard of Care|Standard of care including Dexamethasone
9720912|NCT04501497||ED-SCLC cohort (N=400)|Patients with extensive disease small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
9720913|NCT04499768||control|the age-related cataract patients
9720914|NCT04499768||DR group|the cataract patients with mild/moderate NPDR
9720915|NCT04499430||1|"Group 1: 29 weeks and six days of gestation and earlier~Group 1a: complementary feeding began chronologically in the sixth month~Group 1b: Complementary feeding corrected at sixth month"
9720916|NCT04499430||2|"Group 2: Those whose gestational age is between 30 weeks and 33 weeks and sixth days~Group 2a: complementary feeding began chronologically in the sixth month~Group 2b: complementary feeding started in the sixth month, corrected"
9720917|NCT04499430||3|"Group 3: Those whose gestational age is between 34 weeks and 37 weeks and sixth day~Group 3a: complementary feeding began chronologically in the sixth month~Group 3b: complementary feeding started in the sixth month, corrected"
9720918|NCT04498481||Breast cancer patients|HR+/HER2- advanced/metastatic breast cancer patients in the USA.
9720919|NCT04498559||Patients undergoing total hip replacement|Patients at HSS Main Campus undergoing primary total hip replacement surgery, age range between 18 and 80 years old, and English speaking
9720920|NCT04497753||Can't fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.~Record whether the subject feels bitterness, if there is no feeling, the test is over."
9720921|NCT04497753||Can fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.~Record whether the subject feels bitterness, If there is a sensation, put the adhesive strip on the upper edge of the subject's mask and put on the hood to carry out the above fitness test again.~Record whether the subject feels bitterness, if not, the test is over. If there is any sensation, ask the subject to change to a medical surgical mask, and put an adhesive strip on the upper edge of the mask, and put on the hood to carry out the above fitness test again."
9720922|NCT04497675||Can't fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.~Record whether the subject feels bitterness, if not, let the subject puts on the hood, carry out the fitness test again and record the results."
9720923|NCT04497675||Can fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.~If the subject feels bitterness, stick the adhesive strip on the upper edge of the subject's mask and perform the direct spray test again. Record whether the subject feels bitterness, if not, ask the subject to put on the hood, carry out the fitness test again and record it. If there is a feeling, ask the subject to change to a medical surgical mask and put an adhesive strip on the upper edge of the mask, then conduct the direct spray test again, and record the test results."
9720924|NCT04495985||Thyrogen (rh-TSH)|Group 1: Female patients prepared for radioactive iodine treatment by rh-TSH (Thyrogen)
9720925|NCT04495985||Withdrawal from thyroid hormone|Group 2: Female patients prepared for radioactive iodine treatment by withdrawal from thyroid hormones
9780108|NCT03983824|Experimental|Treatment (peposertib, mitoxantrone, etoposide, cytarabine)|Patients receive peposertib PO BID on days 2-21, mitoxantrone IV over 15 minutes, etoposide IV over 60 minutes and cytarabine IV over 60 minutes on days 1-5 in the absence of disease progression or unacceptable toxicity.
9780109|NCT03977311|Experimental|MR-HIFU|-The study team will determine the tumor volume to be treated per standard-of-care diagnostic MRI or CT imaging. An array of scans will be used to align the participant with the HIFU system, optimize heat delivery to the patients, and/or monitor aspects related to the participant such as motion. Vendor-provided software will be used with the participant in each position to create a customized treatment plan for heat delivery. The HIFU device will then be used to apply clinical levels (41-42°C) of heat to the tumor volume. Regions will be heated to the 41-42°C for up to 60 minutes in one session (either before or after radiation) on one day per five to ten standard radiation therapy fractions, with a maximum of 6 days of hyperthermia over the course of their standard, indicated radiation therapy treatment.
9780110|NCT03973918|Experimental|Treatment Cohort 1 AA & GBM|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
9780111|NCT03973918|Experimental|Treatment Cohort 2 anaplastic PXAs|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
9780112|NCT03973918|Experimental|Surgical Arm|"Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery~Tumor; research blood; CSF samples~post surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle"
9780113|NCT03973918|Experimental|Treatment Cohort 3 Other Tumors|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle~Research Bloods"
9780114|NCT03971253||Peficitinib|Participants will receive peficitinib once daily after meal.
9780115|NCT03969329|Experimental|Etelcalcetide|Patients will receive etelcalcetide in addition to standard of care
9780116|NCT03969095|Experimental|Immediate|Participants in the immediate intervention arm will begin a 4-week intervention tongue pressure resistance training protocol within 10 days of their baseline Videofluoroscopic Swallowing Evaluation assessment, with 2 face-to-face 1-hour visits per week under direct supervision of a speech-language pathologist. These treatment sessions will be supplemented by daily home practice of the intervention.
9720926|NCT04493762||PSO/PSA|Patients diagnosed with psoriasis or psoriatic arthritis
9720927|NCT04493762||RA|Patients diagnosed with rheumatoid arthritis
9720928|NCT04493814||Cohort|All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
9720929|NCT04491721||Rituximab Biosimilar HLX01 in Combination With CHOP|Rituximab Biosimilar HLX01 in Combination With CHOP,in Previously Untreated Subjects With CD20+ DLBCL.
9720930|NCT04491721||MabThera in Combination With CHOP|MabThera in Combination With CHOP，in Previously Untreated Subjects With CD20+ DLBCL.
9720931|NCT04491227||Kidney disease in COVID-19|"Chronic Kidney Disease (CKD): Known diagnosis of chronic kidney disease; prior evidence of markers of kidney damage for 3 months (microalbuminuria, proteinuria >300mg/24 hrs or abnormalities in imaging tests) or the presence of glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months calculated with CKD-EPI equation, with or without other signs of kidney damage as described above.~ESKD: Patients that are dialysis dependent.~Suspected AKI: Oliguria (<200 mL/6 hours) and any AKI-related clinical signs or symptoms (see table 1) or urinalysis/dipstick abnormality. All suspected AKI cases must be confirmed prior to enrollment.~Confirmed AKI: Meeting of at least one of the modified KDIGO Criteria~Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours~Increase or decrease in serum creatinine > 50% from reference in 7 days~Urine output < 400 ml/day~Functioning Kidney transplant:"
9720932|NCT04490928||complete revascularization|All patients who underwent complete myocardial revascularization
9720933|NCT04490928||incomplete revascularization|All patients who did not complete myocardial revascularization
9720934|NCT04490928||without revascularization|All patients who were not revascularized
9720935|NCT04490122||Inhalational|will receive inhalational anesthesia
9720936|NCT04490122||Total intravenous|will receive total intravenous anesthesia with propofol infusion(100-150 mcg/kg/min) and dexmedetomedine 0.3mcg/kg/h.
9720937|NCT04488562||Patients with COVID-19|Patients with proven COVID-19 and abnormalities on chest X-Ray/HRCT, admitted at the hospital. Patients are included around the time of discharge from the hospital or at their regular outpatient clinic visit 6 weeks after discharge, depending on the clinical status of the patient at time of discharge.
9720938|NCT04488302||Implant group|Patients with 1 or more implants with CBCT, ultrasound and open-bone images
9720939|NCT04487795||under 18 years old|
9720940|NCT04487795||18-40 years old|
9720941|NCT04487795||41-60 years old|
9720942|NCT04487795||over 60 years old|
9720943|NCT04487873||Bronchiectasis|Having been diagnosed with non-cystic fibrosis bronchiectasis
10196714|NCT05182515|Experimental|Therapeutic plasma exchanges|Drug: Therapeutic plasma exchanges at day 1, 3 and 5 plus Standard of care including Dexamethasone
10196715|NCT05182489|Experimental|Medtronic Adaptix™ titanium implants|This arm will use Medtronic Adaptix™ titanium implants supplemented with a pedicle screw system. Both cages will be used in conjunction with a 50:50 mixture of autograft: allograft using milled local autograft bone and GRAFTON™ DBM DBF (no iliac crest autograft will be utilized).
9720944|NCT04487873||Healthy individuals|Healthy individuals without chronic disease
9720945|NCT04487665||positive COVID-19|patient diagnosed by nasopharyngeal positive COVID-19
9720946|NCT04487379||Group with edentulous ridge|This group had edentulous ridge planning to receive a dental implant and had ultrasound and cone-beam computed tomography images of the ridge.
9720947|NCT04486027||Healthy|Healthy individuals not smoking, not using Disease-Modifying Anti-Rheumatic Drugs (DMARD) and/or anti-inflammatory drugs other than cortisol and methotrexate, not receiving chemotherapy, not being hypothyroidic
9720948|NCT04486027||Active Rheumatoid Arthritis|Active Rheumatoid Arthritis meeting American College of Rheumatology (ACR) RA remission criteria
9720949|NCT04486027||Rheumatoid Arthritis in remission|Rheumatoid Arthritis in remission meeting American College of Rheumatology (ACR) RA remission criteria
9720950|NCT04485676||Dalbavancin|"Patients to be included in this study have been treated with Dalbavancin according to clinician's judgement and clinical practice according national or international guidelines.~Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Information about dosing treatment will be collected."
9720951|NCT04484376||Other invasive candida infection|Patients with invasive candida infection due a Candida specie othr than Candida Auris.
9720952|NCT04484376||Candida Auris related invasive infection|Candida Auris related invasive candida infection.
9720953|NCT04483518||HBV patients|HBV patients with HBsAg positive and/or HBV DNA positive
9720954|NCT04482608||pMMR/MSS mCRC patients|The metastatic colorectal cancer patients with proficient mismatch repair or microsatellite stable status.
9720955|NCT04482608||dMMR/MSI-H mCRC patients|The metastatic colorectal cancer patients with deficient mismatch repair or microsatellite instability high status.
9720956|NCT04482205||precovid group|those who were operated from fJanuary first to March 15
9720957|NCT04482205||covid|those operated from March 16, to May 31, 2020
9720958|NCT04479410||Drug resistant epilepsy patients|Patients with drug resistant epilepsy underwent epilepsy surgery
9720959|NCT04479150||Pandemic Covid-positive cohort|All Covid-positive patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
10196716|NCT05182489|Active Comparator|Medtronic CAPSTONE® PEEK cage|This arm will use Medtronic CAPSTONE® PEEK cage supplemented with a pedicle screw system. Both cages will be used in conjunction with a 50:50 mixture of autograft: allograft using milled local autograft bone and GRAFTON™ DBM DBF (no iliac crest autograft will be utilized).
9720960|NCT04479150||Pandemic Covid-negative cohort|All Covid-negative patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
9720961|NCT04479150||Control cohort|Pre-pandemic cohort: all patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2019.
9720962|NCT04477174||Group A|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores. After 2 weeks, the participants match again.
9720963|NCT04477174||Group B|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores.
9720964|NCT04476914||Family Member|Family members of ICU patients admitted with respiratory failure from COVID-19
9720965|NCT04476758||Fungal Infection Group|Have had a fungal species isolated from sputum and/or BAL culture on >= 2 separate occasions in the 18 months preceding study visit and do not have a diagnosis of ABPA (N=10).
9720966|NCT04476758||Control Group|Have never previously isolated fungus from sputum, BAL, or OP swab (N=10).
10196717|NCT05182450|Experimental|Active capsule|Colored capsule containing 300 mg mango leaf extract (Zynamite®) standardized to contain ≥ 60% mangiferin. Supplied by PLT Health Solutions, Inc.
9720967|NCT04476758||ABPA Group|"Previous diagnosis of ABPA as defined by CFF guidelines, regardless of the amount of fungal infection or history thereof.~• ABPA Minimum diagnostic criteria per CFF: Acute or subacute deterioration, total serum IgE > 500 IU per mL, immediate cutaneous reactivity to Aspergillus or in vitro IgE antibody to A. fumigatus, and either a new or recent chest imaging change that has not responded to antibiotics and standard physiotherapy OR precipitin to A. fumigatus or IgG antibody to A. fumigatus1 (N=5). Culture positive sputum is not required for ABPA diagnosis and is not taken into account for the diagnosis per CFF guidelines."
9720968|NCT04475263||Carbon monoxide exposure|Confirmed exposure to carbon monoxide
9720969|NCT04474912||Control group|Healthy volunteers with no symptoms or signs of rheumatoid arthritis or osteoarthritis
9720970|NCT04474912||Rheumatoid arthritis group|Rheumatoid arthritis (RA) patients fulfilled 2010 American college of rheumatology (ACR) classification criteria. A patient is considered having definite RA if he/she scores at least 6 points in the established classification system
9720971|NCT04474912||Osteoarthritis group|Osteoarthritis (OA) patients fulfilled 1990 ACR criteria for the classification and reporting of osteoarthritis of the hand. A patient is considered having hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands
9720972|NCT04474275||Study group 1|Primiparous women who gave birth with ceserean section
9720973|NCT04474275||Study group 2|Primiparous women who gave birth with vaginal route delivery without episiotomy
9720974|NCT04474275||Study group 3|Primiparous women who gave birth with vaginal route delivery with episiotomy
9720975|NCT04474275||Control group|Nulliparous women
9720976|NCT04474028||Hood group|The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood.
9720977|NCT04474028||Direct spray group|The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively.
9780117|NCT03969095|Active Comparator|Delayed|Participants in the delayed intervention arm will begin their involvement with a 4-week waiting period after the baseline Videofluoroscopic Swallowing Evaluation. Treatment will commence after the second Videofluoroscopic Swallowing Evaluation and will follow the same schedule for the tongue pressure resistance training, supplemented by daily home practice.
9780118|NCT03948971|Other|Venogram Group|Participants in this group have a scheduled clinically indicated a cerebral angiogram procedure and will undergo a Venogram.
9780119|NCT03943589|Experimental|Imlifidase|"One (1) dose of imlifidase, 0.25 mg/kg, will be administered IV over 30 minutes, Day 1.~IVIg, 0.4 g/kg, will be administered for 5 consecutive Days, starting on Day 3 at least 48 h after imlifidase administration."
9780120|NCT03929822||Contrast-Enhanced Spectral Mammography (CESM)|Women called back from an abnormal screening mammogram/tomosynthesis exam will be offered CESM as part of their diagnostic work up. The radiologist will interpret the low energy images and record their findings.
9780121|NCT03927716|Experimental|SB206 12%|SB206 12% topically once daily
9780122|NCT03927716|Placebo Comparator|Placebo|Placebo topically once daily
9780123|NCT03908125|Other|Continuous Glucose Monitoring Device|
10196718|NCT05182450|Placebo Comparator|Placebo capsule|Colored capsule, appearance-matched to the active experimental capsule
10196719|NCT05182437|Experimental|LINAC-based Stereotactic Radiotherapy|The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone (EZ) with the neurologist, radiologist and neurosurgeon.
9780125|NCT03904524|Experimental|SET-to-MEET|This is a single arm, open trial that will be conducted in parallel in 3 separate ICUs. Each site will receive the SET-to-MEET intervention.
9780126|NCT03897595|Other|Mpact cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
9780127|NCT03893487|Experimental|Treatment (fimepinostat, tumor resection)|"Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.~MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor."
9780128|NCT03892720|Experimental|Treatment (SBRT)|Patients undergo stereotactic body radiation therapy with either standard radiation treatment software or HyperArc software technology for 2-3 fractions per week over a 2-week period for 5 fractions.
9780129|NCT03886649|Experimental|Copanlisib + Venetoclax|Phase Ib -> dose escalation with 2 expansion cohorts
9780130|NCT03884270|Experimental|Hypnotherapy|7 sessions of on-line hypnotherapy treatment over the course of 12 weeks (1 new session every 2 weeks)
9780131|NCT03880019|Experimental|Treatment (olaparib, temozolomide)|Patients receive olaparib PO BID and temozolomide PO QD on days 1-7. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9780132|NCT03877991|Experimental|CBD-sesame oil capsule|12 volunteers will receive a single oral dose of CBD in a sesame oil vehicle filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
9720978|NCT04473612||Neuromuscular low physical status group|Patients diagnosed of Neuromuscular disease with low physical status
9720979|NCT04473612||Neuromuscular high physical status group|Patients diagnosed of Neuromuscular disease with high physical status
9720980|NCT04473612||Control group|Healthy subjects
9720981|NCT04473755||ADHD|This group will include participants who meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
9720982|NCT04473755||Non-ADHD|This group will include participants who do not meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
9720983|NCT04473352||Single Group|Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.
9720984|NCT04472663||Cohort 1|Retrospective Long-term Chart Review
10196720|NCT05182437|No Intervention|Current standard care|Current standard care includes anti-epileptic drugs and neuromodulation (i.e. Deep Brain Stimulation or Vagus Nerve Stimulation and/or Anti-epileptic continuation).
9720985|NCT04472663||Cohort 2|Prospective-Retrospective Chart Review and Humanistic Burden
9720986|NCT04472533||CTEPH|Patients diagnosed with chronic thromboembolic pulmonary hypertension
9720987|NCT04472533||CTED|Patients diagnosed with chronic thromboembolic disease but no evidence of pulmonary hypertension
9720988|NCT04472533||Control|Healthy control subjects
9720989|NCT04472754||A(healthy control group)|patients who did not have ischemic stroke and whose TCM constitution was dialectically peaceful;
9720990|NCT04472754||B|Patients with no ischemic stroke and whose TCM constitution was dialectical with damp phlegm constitution
9720991|NCT04472754||C|patients with ischemic stroke diagnosed with phlegm dampness syndrome
9720992|NCT04472754||D|patients with ischemic stroke diagnosed as non-phlegm dampness syndrome
9720993|NCT04472325||Atypical Parkinson's Disease patients|This group consists of patients includes 35 patients with Progressive Supranuclear Paralysis (PSP), 35 patients with Multiple System Atrophy (MSA), and 35 patients with Cortico-Basal Degeneration (CBD).
9720994|NCT04472325||Idiopathic Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD)
9720995|NCT04472325||Healthy volunteers|"The 96 healthy volunteers should meet the following criteria:~Between 50-80 years old~Right-handed~MMSE score greater than or equal to 26~Able to understand study requirements and give informed consent"
9720996|NCT04471051||COVID19 Convalescent Plasma Treatment|Hospitalized COVID19 patients who receive COVID19 Convalescent Plasma under Expanded Access protocol NCT04372368.
9720997|NCT04470817||Participants With Essential Hypertension|Participants diagnosed with essential hypertension and whom have been prescribed azilsartan medoxomil as a monotherapy or taken concomitantly with other anti-hypertension therapies in a routine clinical practical setting, will be observed prospectively over a period of 6 years.
9720998|NCT04470830||Participants With Essential Hypertension|Participants diagnosed with essential hypertension who have been treated with azilsartan medoxomil/chlorthalidone FDC as an early therapy for participants whose blood pressure is not properly controlled by monotherapy or who require administration of multiple drugs in order to reach the target blood pressure, will be observed prospectively over a period of 5 years.
9720999|NCT04470700||subjects with greater than 3years delay|Subjects with delay in treatment of Urinary incontinence greater than three years
9721000|NCT04470700||subjects with less than three years delay|Subjects with delay in treatment of Urinary incontinence lesser than three years
9721001|NCT04469894||Niemann-Pick Type A|Also referred to as Infantile Neurovisceral ASMD
9721002|NCT04469894||Niemann-Pick Type A/B|Also referred to as Intermediate form or Chronic Neurovisceral ASMD
9721003|NCT04469894||Niemann-Pick Type B|Also referred to as Chronic Visceral ASMD
9721004|NCT04469894||Niemann-Pick Type C (Early Infantile)|Onset at less than 2 years of age
9721005|NCT04469894||Niemann-Pick Type C (Late Infantile)|Neurodegenerative form (late-infantile) onset at 2-6 years of age
9721006|NCT04469894||Niemann-Pick Type C (Juvenile)|Neurodegenerative form (juvenile) onset at 6-15 years of age
9721007|NCT04469894||Niemann-Pick Type C (Adult)|Psychiatric neurodegenerative form (adult) onset at greater than 15 years of age
9721008|NCT04469543||MTHFR polymorphism|
9721009|NCT04467008||One group of patients|
9721010|NCT04466969||HF|"Patients with HF with reduced Ejection Fraction (HFrEF) is enrolled if patients meet following criteria within 6 months:~Ejection Fraction ratio（EF） ≤40%~New York Heart Association(NYHA) class II-IV"
9721011|NCT04466969||stages of CKD (stage 3b)|"CKD is diagnosed based on the following e Glomerular Filtration Rate (eGFR) categories:~Stage 3b: 30 mL/min/1.73m2 ≤ eGFR <45 mL/min/1.73m2"
9721012|NCT04466969||Stages of CKD (stage 4)|"CKD is diagnosed based on the following eGFR categories:~15 mL/min/1.73m2 ≤ eGFR <30 mL/min/1.73m2"
9721013|NCT04466969||stages of CKD (stage 5)|"CKD is diagnosed based on the following eGFR categories:~eGFR <15 mL/min/1.73m2"
9721014|NCT04466969||Treated by potassium binders|Patients who have been treated by Potassium Binders
9721015|NCT04466631||Observative longitudinal|The participants won't receive any support during the post surgery period.
9721016|NCT04466189||Pancreatic Cancer Patients Treated With Proton Beam Therapy|Pancreatic Cancer Patients Treated With Proton Beam Therapy
9721017|NCT04464278||Case group: weight loss ≥ 5%|
9721018|NCT04464278||Control group: weight loss ≤ 5%|
9721019|NCT04460911||PAL + FUL|Patients who initiated palbociclib-fulvestrant combination therapy as first-line or beyond therapy in the advanced or metastatic setting.
9721020|NCT04460911||FUL Mono|Patients who received fulvestrant monotherapy as first-line or beyond therapy in the advanced or metastatic setting.
9721021|NCT04456426||Patients treated with COVID-19|All populations of patients admitted with COVID-19 in healthcare institutions involved. No intervention but standard care designed by national guidelines will be provided.
9721022|NCT04454333||Hospitalized caused by COVID-19|A total of 466 patients hospitalized with the diagnosis of SARS-COV-2 at the University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital were retrospectively screened. 212 of these patients did not answer the calls, 34 of them could not be reached because they gave the wrong phone number beforehand. 4 of the patients called by the phone had communication problems due to language problems and 10 people did not want to fill the questionnaire. 206 of them were contacted by the phone and their pain and myalgia in the head, neck-back, waist, shoulder and hip regions before, during and after SARS-COV-2, their anxiety and depression levels after SARS-COV-2, and their quality of life were questioned.
9721023|NCT04453267||Patient Arm.|"Consecutive patients undergoing elective percutaneous coronary intervention (PCI) or isolated coronary artery bypass grafting (CABG) for symptomatic stable angina (SA) despite optimal medical therapy at the University Hospital Southampton NHS Foundation Trust will be prospectively enrolled (n=86).~No interventions administered. 40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
9721024|NCT04453267||Age and gender matched controls|"Age and gender-matched patients being investigated for chest pain with unobstructed coronary arteries, defined as coronary stenosis ≤ 30% in any major epicardial vessel on CT or invasive coronary angiography, will also be recruited as controls (n=86).~40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
9780133|NCT03877991|Experimental|CBD-LNL capsule|12 volunteers will receive a single oral dose of CBD-LNL formulation filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
9780134|NCT03877991|Experimental|CBD powder form capsule|12 volunteers will receive a single oral dose of CBD in powder form filled in a hard gelatin capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
9780135|NCT03872947|Experimental|Arm A: TRK-950 + FOLFIRI|"Colorectal Cancer~TRK-950 will be administered intravenously (IV) on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
9780136|NCT03872947|Experimental|Arm B: TRK-950 + Gemcitabine/Cisplatin|"Cholangiocarcinoma or Bladder Cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Cisplatin will be administered by infusion. Then, Gemcitabine will be administered as an IV infusion."
9780137|NCT03872947|Experimental|Arm C: TRK-950 + Gemcitabine/Carboplatin|"Ovarian Cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Gemcitabine will be administered as an intravenous infusion. On day 1, following the administration of TRK-950 and Gemcitabine, Carboplatin will be administered IV."
9780138|NCT03872947|Experimental|Arm D: TRK-950 + Ramucirumab/Paclitaxel|"Gastric Cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Ramucirumab will be administered as an IV infusion. Paclitaxel will be dosed on days 1, 8 and 15, after the Ramucirumab on days 1 and 15 and after the TRK-950 on day 8."
9780139|NCT03872947|Experimental|Arm E: TRK-950 + PD1 inhibitors|"•Solid Tumors~E-1: TRK-950 + Nivolumab~•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.~E-2: TRK-950 + Pembrolizumab~•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
9780140|NCT03872947|Experimental|Arm F: TRK-950 + Imiquimod Cream|"Palpable subcutaneous malignant lesions~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. Imiquimod cream is to be applied 5 of 7 days in a row with 2 days rest for a maximum of 2 cycles (total 6 weeks)."
9780141|NCT03872947|Experimental|Arm G: TRK-950 + Bevacizumab|"Renal Cell Carcinoma~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Bevacizumab will be administered as an IV infusion."
9780142|NCT03872947|Experimental|Arm H: TRK-950 + PD1 inhibitors|"•Melanoma~H-1: TRK-950 + Nivolumab~•TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.~H-2: TRK-950 + Pembrolizumab~•TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
9780143|NCT03872947|Experimental|Arm J: TRK-950 + FOLFIRI|"Colorectal Cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
9780144|NCT03872947|Experimental|Arm K: TRK-950(Lower-dose) + Gemcitabine / Carboplatin / Bevacizumab|"Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. Gemcitabine will be administered as an intravenous infusion on days 1 and 8. On day 1, following the administration of Gemcitabine, Carboplatin will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next. After 6 cycles of chemotherapy the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease."
9721025|NCT04451993||OSAS PATIENTS|mild, moderate and severe OSAS patients
9721026|NCT04451993||HEALTHY INDIVIDUALS|healthy individuals without chronic disease
9721027|NCT04451512||CSP|
9721028|NCT04451512||HSP|
9721029|NCT04451460||Hyponatremia|Hyponatremic small cell cancer patients
9721030|NCT04451460||Normonatremia|Normonatremic small cell cancer patients
9721031|NCT04450719||Group 1: Patients with lung cancer|Exercise capacity [6-minute walk test (6-MWT)], pulmonary functions [spirometry], respiratory [maximal inspiratory and expiratory pressures (MIP-MEP), mouth pressure device] and peripheral muscle strength [dynamometer], physical activity level [metabolic holter], dyspnea [Modified Medical Research Council dyspnea scale (MMRC)] and quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] were evaluated in patients with lung cancer. Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
10196721|NCT05182424|Experimental|Myndlift BPT Immediate Treatment|After the completion of consent, a battery of baseline assessments will be completed by the parent. Children will not be involved in the study assessment or interventions-only parents/caregivers. Parent(s) will be emailed baseline and post-treatment assessment surveys through Qualtrics to complete. Following completion of baseline assessment, study staff will meet with the parent via Zoom to review any questions with the consent and review and discuss questions/issues with the baseline assessment. Following completion of the post-treatment assessment, study staff will meet with the parent via Zoom to review and discuss questions/issues with the post-treatment assessment. Following this review, the post-treatment interview will be completed. Having study staff present has been found useful by parents should they have any questions or concerns about items on surveys.
9721032|NCT04450719||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were performed in healthy individuals.
9721033|NCT04449731||Adult population (> 18 years old)|Around 30000 adults (> 18 years old) from 22 different countries.
9721034|NCT04449406||Individuals at risk of developing PDAC|"Symptomatic participants (via direct recruitment to UroPanc and via study/tissue bank(s) i.e. UCL ADEPTs study)~Asymptomatic participants (via study/tissue bank(s) i.e. University of Liverpool EUROPAC registry)~Medical history, demographic information and concomitant medications information will be collected at baseline, together with blood and urine samples. Urinary biomarkers and plasma CA19-9 will be measured and the results compared with imaging data (and pathology, if it becomes available)."
9721035|NCT04448626||Healthy subject|Healthy subject
9721036|NCT04448626||Stable COPD patients|Stable COPD patients
9721037|NCT04448626||Exacerbation COPD patients|Exacerbation COPD patients
9721038|NCT04447157||Microspherophakia|This is a non-interventional study(NIS). All the patients diagnosed as microspherophakia are included in the study and recieved intraocular lens implantation
9721039|NCT04445610||A|mild
9721040|NCT04445610||B|moderate
9721041|NCT04445610||C|severe
9980701|NCT01394458|Experimental|Heparin 1000 U/ml|For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
9721044|NCT04444791||Cohort|This cohort study only set up one group. The habits and health status of mothers and their offspring will be followed up and observed. The participants will be divided into more than one group according to the variables (e.g. age, physical activity, dietary patterns, sleep quality.).
9721045|NCT04444661||HIT-resistance exercise|High Intensity Resistance Exercise
9721046|NCT04444661||Non exercising control|Control group that maintained life style and physical activity habits
9721047|NCT04444531||Ozone autohemotherapy plus standard treatment|
9721048|NCT04444531||Standard treatment alone|
9721049|NCT04440410||Hidradenitis suppurativa|Subjects with active mild, moderate, or severe HS disease using the HS-PGA assessment
9721050|NCT04440410||Atopic Dermatitis|Subjects with active moderate or severe AD disease using the PGA assessment
9721051|NCT04440098||Isolated Observational group|All participants socially restricted as a result of COVID-19
9721052|NCT04437927||Prospective patients|30 consecutive patients with cardiac FDG PET prescribed
9721053|NCT04437927||Control|30 patients referred for cardiac FDG PET in the nuclear medicine department of the Centre Hospitalier Princesse Grace
9721054|NCT04437589||Exposure group|In this group the treatment applied for postoperative pain involves Free-opioid anesthesia (LKDi).
9721055|NCT04437589||Control group|In this group the treatment applied for postoperative pain involves an opioid-based anesthesia.
9721056|NCT04434976||delayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
9721057|NCT04434976||undelayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
9721058|NCT04435080||Non-rehabilitation|The patients hospitalised in ICU who were provided all the intensive care managements except for rehabilitation interventions (discharged from intensive care unit before April 14, 2020)
9721059|NCT04435080||Rehabilitation|The patients hospitalised in ICU who were provided rehabilitation interventions in addition to all the intensive care managements. (discharged from intensive care unit after April 14, 2020)
9785794|NCT01260350|Experimental|Group 1: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
9721060|NCT04434898||Ｍild cognitive impairment patients|"The patients with mild cognitive impairment have a Clinical Dementia Rating score of 0.5. First, we will evaluate the correlation between diffusion MRI and the clinical severity and cognitive decline of patients. Second, we will evaluate if diffusion MRI can predict if these patients will develop Alzheimer's Disease and hence be involved in the third year of the study. Patients with mild cognitive impairment should meet the following criteria:~Between 50-80 years old~Right-handed~Clinical Dementia Rating score equal to 0.5~For patients who have a CDR score of 0.5, should be diagnosed by clinician's judgement of clinical information, daily living activities, and extent of neuropsychological disorders~Able to understand study requirements and give informed consent"
9721061|NCT04434898||Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD), 15 patients with Progressive Supranuclear Paralysis (PSP), 15 patients with Multiple System Atrophy (MSA), and 15 patients with Cortico-Basal Degeneration (CBD). In differential diagnosis in the first year of the study, diffusion MRI will be used for a retrospective study.
9721062|NCT04434898||Healthy volunteers|"The healthy volunteers should meet the following criteria:~Between 50-80 years old~Right-handed~MMSE score greater than or equal to 26~Able to understand study requirements and give informed consent"
9780145|NCT03872947|Experimental|Arm L: TRK-950 + Gemcitabine / Carboplatin / Bevacizumab|"Platinum Sensitive epithelial ovarian, primary peritoneal or fallopian tube cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. Gemcitabine will be administered as an intravenous infusion on days 1 and 8. On day 1, following the administration of Gemcitabine, Carboplatin will be administered as an intravenous infusion. Also on Day 1 of each cycle, Bevacizumab will be administered IV next. After 6 cycles of chemotherapy the patient will be transitioned to maintenance treatment. On Day 1 of each maintenance cycle, Bevacizumab will be administered IV. Maintenance treatment will be continued as long as there is no evidence of progressive disease."
9780146|NCT03872947|Experimental|Arm M: TRK-950(Lower-dose) + Topotecan|"Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer~TRK-950 will be administered IV on days 1, 8 and 15 of a 21-day cycle. Topotecan will be administered as an intravenous infusion daily for 5 consecutive days of a 21 day cycle. On day 1 TRK-950 will be administered IV after the topotecan infusion."
9780147|NCT03872947|Experimental|Arm O: TRK-950(Lower-dose) + PLD|"Platinum Resistant epithelial ovarian, primary peritoneal or fallopian tube cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. PLD will be dosed as IV on Day 1 of each cycle. On days that TRK-950 and PLD are both dosed, PLD will be dosed first."
9780148|NCT03872947|Experimental|Arm Q: TRK-950(Lower-dose) +Ramucirumab/Paclitaxel|"Gastric cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. On all dosing days, TRK-950 will be administered IV after the relevant combination regimen is dosed. On days 1 and 15, ramucirumab will be administered IV. Paclitaxel will be dosed on days 1, 8 and 15, after ramucirumab on days 1 and 15, before TRK-950 on day 8."
9780149|NCT03872947|Experimental|Arm R: TRK-950(Lower-dose) +Bevacizumab|"Renal cell carcinoma cancer~TRK-950 will be administered IV on days 1, 8, 15, and 22 of a 28-day cycle. Bevacizumab will be dosed as IV on Day 1 and 15 of each cycle. On days that TRK-950 and Bevacizumab are both dosed, Bevacizumab will be dosed first."
9780150|NCT03872388|Experimental|Group I (atorvastatin)|Patients receive standard of care atorvastatin PO QD for up to 24 months.
10196722|NCT05182424|Other|Waitlist Control Group|Following completion of consent and baseline assessment, parent participants randomly assigned to the waitlist condition will be requested to wait for a period of 12 weeks before accessing the program, modules, and receiving therapist support. They will be required to answer the time 2 (at 12 weeks following completion of the baseline assessment) assessment prior to starting the process. The time 2 assessment for the waitlist condition is identical to the post-treatment assessment for participants in the Myndlift BPT group except that questions related to experience with Myndlift BPT will not be included.
9780151|NCT03872388|Active Comparator|Group II (capecitabine)|Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
9780152|NCT03870386|Experimental|EUS-BD with LAMS|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts < 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts > 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
9780153|NCT03870386|Active Comparator|Traditional transpapillary metal stent via ERCP|A duodenoscope is advanced orally to the papilla. The bile duct is then cannulated with a sphincterotome using the guidewire-assisted technique. A cholangiogram is then performed followed by insertion of a self-expanding metal biliary stent. The performance of a biliary sphincterotomy prior to stent insertion and the choice of stent size (10x 40 mm, 10 x 60 mm, 10x 80 mm) will be at the discretion of the endoscopist.
9780154|NCT03859466|Experimental|Intervention Arm|For each of this packages exactly half of the envelops will be filled with control (20/20) or intervention (20/20) information: This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
9780155|NCT03859466|No Intervention|Control Arm|For each of this packages exactly half of the envelops will be filled with control (20/20) or intervention (20/20) information This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
9980702|NCT01394471|Experimental|oxytocin|Twice daily treatment of oxytocin will be administered by subjects
9721063|NCT04433442||Participants with Moderate to Severe Plaque Psoriasis|Participants will receive risankizumab (prefilled syringe for injection) as prescribed by the physician in routine clinical practice.
10196723|NCT05182385|Experimental|hematological relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~Refractory BCP-ALL to primary induction therapy, including at least three cycles of standard chemotherapy~Untreated first relapse of BCP-ALL with first remission duration < 12 months or~Second or greater relapse of BCP-ALL or refractory relapse or~Relapse of BCP-ALL any time after allogeneic HSCT"
10196724|NCT05182385|Experimental|molecular relapse|"Diagnosis of Ph-negative, CD19-positive B-precursor acute lymphoblastic leukemia according to WHO classification:~-Positivity of MRD marker of immunoglobulin/T-cell receptor gene rearrangements of greater than 0.1% if in first or second remission of BCP-ALL"
10196725|NCT05182372|Experimental|Enhanced dCBT-I|This group will complete d-CBTI and be assigned a coach that will help with completion of the treatment and will be available to call personally to discuss questions and issues.
10196726|NCT05182372|No Intervention|Control dCBT-I|Participants in this group will complete dCBT-I individually without assistance from a healthcare provider
9721064|NCT04432870||MGH Patients|Patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic at Massachusetts General Hospital
10196727|NCT05182307|Experimental|Treatment|DurAVR™ THV System
9721065|NCT04431869||Mothers that contract SARS-CoV-2 during pregnancy|"To evaluate evidence for in-utero vascular accidents that may manifest as intestinal atresias and limb abnormalities in the first 30 days of life as well as rates of preterm labor, fetal growth restriction and spontaneous abortions in pregnant females that contract the SARS-CoV-2 virus during gestation.~A multidisciplinary approach in conjunction with maternal fetal medicine (MFM), neonatology, and pathology will identify, and recruit infants whom were exposed to COVID-19 while in-utereo. This project will run in parallel with the institution's COVID-19 in Pregnancy Biobank that intends to obtain needed epidemiological and clinical data linked to biosamples to provide insight into SARS-CoV-2 in pregnant women and their infants. This study will request access to enrolled women infected during gestation and their neonates to assess for the conditions suggestive of in-utero vascular accidents such as intestinal atresias or limb anomalies."
9721066|NCT04431869||Infants noted to have intestinal atresias or limb anomalies|"To evaluate children identified in the neonatal intensive care unit (NICU) as having evidence of intestinal atresias or limb anomalies for potential asymptomatic carriers of COVID-19 that could have contracted the disease during the pregnancy.~Mothers of children identified will undergo SARS-CoV-2 antibody testing to identify the possibility of asymptomatic carriers which may have occurred during the pregnancy."
9721067|NCT04429659||Group 1, patients with amblyopia and partially refractive ET|children with both amblyopia and partially refractive accommodative esotropia
9721068|NCT04429659||Group 2, patients with refractive ET|children with refractive esotropia
9721069|NCT04428918||Cohort 1|Allogeneic HCT recipient or patient pending receipt of HCT
9721070|NCT04427748||congenital cataract group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and IOL implantation are perfomed ERG
9721071|NCT04427748||age-matched normal children group|age-matched normal children are perfomed ERG
9721072|NCT04427800||CKD G4|Chronic kidney disease stage (G4). (eGFR < 30 mL/min/1.73m2)
9721073|NCT04427800||CKD G5|Chronic kidney disease stage (G5). (eGFR < 15 mL/min/1.73m2) with imminent initiation of RRT
9721074|NCT04427800||ESRD on ICHD|End stage renal disease on in centre haemodialysis
9721075|NCT04427800||ESRD on HHD|End stage renal disease on home haemodialysis
9721076|NCT04427800||ESRD on PD|End stage renal disease on peritoneal dialysis
9721077|NCT04427800||Post-transplant|Participants post-transplant
9721078|NCT04426071||SCI, brain injury, stroke Participants|Those 18 years of age and older, diagnosed with a stroke, spinal cord injury (traumatic and non-traumatic), or acquired brain injury (of all severities, including concussion) living in the community will be included. Additionally, only those the cognitive capacity to understand and complete the measures will be included. Those who consent will complete an online survey on enrollment into the study, and subsequently at 3 and 6 months.
9721079|NCT04425213||Normal weight|BMI < 25 kg/m2
9721080|NCT04425213||Overweight|BMI : 25 - 29.9 kg/m2
9721081|NCT04425213||Moderate obesity|BMI : 30 - 39.9 kg/m2
9721082|NCT04425213||Severe obesity|BMI : > or = 40 kg/m2
9721083|NCT04424446||NIH staff|NIH staff undergoing standard NIH COVID-19 screening willing to donate additional research samples.
9721084|NCT04423315||patients with covid-19 pneumonia|patients with covid-19 pneumonia above 18 years old who were diagnosed by pcr testing and computed tomography of thorax
9721085|NCT04422626||Critically ill COVID-19 patients, who receive CytoSorb therapy|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) CytoSorb therapy on consultant's discretion.
9721086|NCT04422873||in-centre|Currently dialysing in-centre
9721087|NCT04422873||home|Currently dialysing at home
9721088|NCT04422080||Keratoconus patient|Patient with keratoconus disease diagnosed on videotopography
9721089|NCT04422080||Healthy patient|Patient consulting for keratoconus screening with no keratoconus on videotopography
9721090|NCT04420286||Hospital having ICU beds|Hospital having ICU beds during COVID-19 outbreak in France
9721091|NCT04420312||Group 1|Enrolled the Covid-19 patients with a negative CT Pulmonary Angiogram.
9721092|NCT04420312||Group 2|Enrolled the Covid-19 patients in whom only a CT was performed.
9980703|NCT01394471|Placebo Comparator|Control spray|Self administration twice daily of intranasal spray that does not contain oxytocin
9721093|NCT04420143||MLX - Medial Lateral Expandable Lumbar Interbody System|Patients who underwent lumbar interbody fusion with the MLX expandable interbody implant will be included in the MLX - Medial Lateral Expandable Lumbar Interbody System cohort.
9721094|NCT04420143||XLX ACR Interbody System|Patients who underwent lumbar interbody fusion with the XLX ACR expandable interbody implant will be included in the XLX ACR Interbody System cohort.
9721095|NCT04420507||GDM group|pregnant women who are diagnosed after 75g OGTT test between 24~27+6 gestational weeks
9721096|NCT04420507||health group|pregnant women who pass the 75g OGTT test and aren't diagnosed as GDM, and also don't have any other conditions, like hypertensive disorders, IBD, gastrointestinal ulcer, and so on.
10196728|NCT05182294|Active Comparator|Conventional symmetric nasal cannula|The patient's breathing pattern will be assessed by inductive plethysmography while using the cannula and receive HFNT for 2 hours during the first session. Patients will then be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session. Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered
9721097|NCT04420013||exposed group|for CRC patients with non-resectable hepatic metastases: surgery for CRC combined with RFA.
9721098|NCT04420013||no-exposed group|for CRC patients with resectable metastases: surgery only without RFA.
9721099|NCT04419194||Observation|Observation
9721100|NCT04418817||Modulus XLIF Interbody System|
9721101|NCT04417283||Mother-infant dyads|Mother and/or infant participants will provide a series of biological specimens, including blood, urine, and microbiome samples. Additionally, each participant will wear a silicone wrist band each trimester to capture environmental exposures and will fill out study surveys related to diet, environmental exposures, and social factors.
9721102|NCT04416490||Patients|Patients with high-risk stage II or stage III primary colon cancer who have received curative resection
9721103|NCT04415710||Group|Women with diagnosed Sjogren syndrome
9721104|NCT04415437||healthy|Healthy participants
9721105|NCT04415437||mentally ill|Participants with mental disorders
9721106|NCT04415437||physically ill|Participants with organic disease
9721107|NCT04415437||mentally and physically ill|Participants with mental disorders and organic disease
9721108|NCT04415502||Measuring of CTHRc1 , its correlation with RAdisease activity|Measuring of CTHRc1 levels and its correlation with RA disease activity
9780156|NCT03855943|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
9780157|NCT03849716||Participants with atopic dermatitis (AD)|Participants included in observational study OBS15333 (atopic dermatitis pediatric registry) who consent to enter this companion study LPS15496. Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enter either protocol, and neither protocol OBS15333 nor LPS15496 specifies assignment of any drug intervention
9780158|NCT03848286|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
9780159|NCT03846310|Experimental|Dose Escalation Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
9780160|NCT03846310|Experimental|Dose Escalation Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
9780161|NCT03846310|Experimental|Dose Expansion Arm 1|Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
9780162|NCT03846310|Experimental|Dose Expansion Arm 2|The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
9780163|NCT03846024|Experimental|RibFx belt arm|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
9780164|NCT03846024|No Intervention|Control|"Patients in the control arm receive normal standard of care for rib fractures at the participating institution.~The current standard of care for rib fractures at the University of Vermont (participating institution) is as follows: includes oral and IV analgesia and other multimodal pain control as appropriate, including muscle relaxants such as methocarbamol (robaxin) unless there is a contraindication, pulmonary hygiene/toilet and respiratory care (including frequent evaluations by physicians, respiratory therapists, and nursing staff, early mobilization, and monitoring for pulmonary complication (via vital signs, pulse oximetry, oxygen requirement, chest imaging if appropriate)."
9780165|NCT03835949|Experimental|TJ004309 plus Atezolizumab|TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
9980704|NCT01394484|Experimental|Arm 1|Four servings of dairy foods per day for 42 days, followed by washout for 42 days, followed by dietary supplements for 42 days
9780166|NCT03834519|Experimental|Pembrolizumab + Olaparib|Participants receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).
9980705|NCT01394484|Experimental|Arm 2|Dietary Supplements for 42 days, followed by washout for 42 days, followed by 4 servings of dairy foods for 42 days.
9721109|NCT04413877||Descriptive cohort study|"Prospective cohort study of community-dwelling adults ≥65-year-old living at home, with no other exclusion criteria than the inability to use the ICOPE Apps or communicate by telephone/video-call for any reason (cognitive or limited access to technologies like telephone/video-call).~Cohort study, designed to determine the incidence of frailty in community-dwelling older people during 1-year follow-up, starting the recruitment at a certain point of the COVID-19 pandemic and beyond."
9721110|NCT04413474||Study group|Unselected critically ill patients who met the inclusion criteria
9721111|NCT04413058||Female healthcare workers|Healthy female healthcare workers at Covid 19 clinic in Istanbul, Turkey
9721112|NCT04412499||Methylphenidate + parent-training programm|Methylphenidate and participation in a parent-training programme
9721113|NCT04412499||Methylphenidate alone|Methylphenidate alone
9721114|NCT04411784||Main group|Patient with Acute Severe Ulcerative Colitis based on Modified Truelove and Witts Severity Index managed during the study period
9721115|NCT04411784||Control Group|Patients with ASUC managed in the unit from 1st Jan to 31st June 2019
9721116|NCT04410757||Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply POCUS examinations in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
9721117|NCT04410757||No Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply routine bedside examination techniques in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
9721118|NCT04410952||no EES|Patients with a Type-C pelvic ring fracture who underwent no external emergency stabilization (EES) for the posterior pelvic ring
9721119|NCT04410952||Pelvic binder|Patients with a Type-C pelvic ring fracture who received a pelvic binder for emergency stabilization of the posterior pelvic ring
9721120|NCT04410952||Pelvic C-clamp|Patients with a Type-C pelvic ring fracture who received a pelvic C-clamp for emergency stabilization of the posterior pelvic ring
9721121|NCT04410484||1|Admitted patients with IBD (with IBD OR due to COVID) whether tested or not tested for COVID between 1st March and 30th June 2020
9721122|NCT04410484||2|Patients with IBD self-isolating with suggestive COVID19 symptoms (Fever or persistent Cough) or tested positive for COVID19 during same period
9721123|NCT04410484||3|Patients with active IBD identified during the same study period. (definition: increased symptoms suggestive of flare, raised calprotectin, raised CRP, endoscopy or imaging during the previous 6 weeks showing active disease and contacted/reviewed during the study period , admission with IBD ( These will be identified through your helpline/ virtual clinics/Hot clinics/flare lines
9721124|NCT04410484||Control Group|Consecutive patients with active IBD between 1st March 2019-30th June 2019
9721125|NCT04409184||Convalescent subjects|Convalescent, now asymptomatic, subjects with documented prior COVID-19 due to SARS-CoV-2 infection
9721126|NCT04409184||Healthy controls|
9721127|NCT04408976||Software practices|Patients with urinary tract infection in practices using the clinical decision support software
9721128|NCT04408976||Control practices|Patients with urinary tract infection in practices not using the clinical decision support software
9721129|NCT04407637||neck pain patients|Patients with acute non-specific neck pain were consecutively recruited from a private manual physiotherapy center as sample of convenience. Inclusion criteria were acute (<3months) non-specific neck pain with a neck disability index (NDI) > 8% and a Numerical Pain Rating Scale (NPRS) >3 . Patients were excluded if they reported any of the following: a history of neck surgery, dizziness caused by neck or head movements and cervical radiculopathy diagnosed by a physician.
9721130|NCT04407637||healthy|Healthy control participants were included if they reported a NDI < 8% and a NPRS =0. They were excluded if they reported neck pain during the last year, radiating symptoms in the shoulder or arm regions, or headache. Participants with a history of neck trauma or in treatment for spinal disorders or reporting pain during the manual assessment were excluded as well.
9721131|NCT04407936||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention
9721132|NCT04407598||Glenfield Complex COPD Clinic Cohort|Patients previously seen in the complex COPD clinic at the Glenfield Hospital.
9721133|NCT04406519||Hemophilia Group|The inclusion criteria in the hemophilia group were as follows; patients aged 6 to 18 years who developed HA in at least one of the lower limb joints due to severe haemophilia (total lower limb HJHS ≥3); to be receiving prophylaxis but have no major bleeding that could affect the musculoskeletal system in the past two weeks; and who did not perform regular physical activity and sports.
9721134|NCT04406519||Control Group|The control group was consisted of healthy peers. The exclusion criteria in the control group were as follows: who had any auditory and visual impairment; who underwent orthopedic injuries including lower limb; and who had any neurological or cognitive impairment that could affect balance.
9980706|NCT01394497|Experimental|NAC procurement protocol|The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco-regional infusion into the portal vein before cross-clamping.
9721135|NCT04406038||Healthy adults|Healthy adults randomly sampled from the population of Saint Petersburg
9721136|NCT04404582||Klebsiella pneumoniae|patients with Klebsiella pneumoniae infection had different results of the drug sensitivity test. we compared the prognosis of these patients.
9721137|NCT04402801||Standard of Care Telemedicine Cohort|This cohort will have telemedicine visits in lieu of in-person clinic visits
9721138|NCT04402801||Standard of Care In-Person Cohort|
9721139|NCT04401930||Free-living elderly|"Free-living elderly over the age of 65 living in Metropolitan Area of Milan, in apparent good health conditions.~Male and Female"
9721140|NCT04401969||Patients with eumycetoma lesions|Patients with eumycetoma lesions
9721141|NCT04401969||Patients with actinomycetoma lesions|Patients with actinomycetoma lesions
9721142|NCT04401969||Patients with lesions of unknown causality|Patients with lesions of unknown causality
9721143|NCT04401592||disease and control|
9721144|NCT04399733||Ethnicity|Patients will be segmented on a 1:1:1 ratio similar to the EMPOWER-1 study based on ethnicity (White, Black, South Asian).
10196729|NCT05182294|Active Comparator|AIRVO 2; new asymmetric nasal cannula|The patient's breathing pattern will be assessed by inductive plethysmography while using the cannula and receive HFNT for 2 hours during the first session. Patients will then be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session. Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered
9721145|NCT04399291||Residential care facility residents|Older adults recruited from care homes in Northern Ireland
9721146|NCT04398342||Children with Cerebral Palsy in Denmark|Children diagnosed with cerebral palsy born 2003 - 2020 and registered in the Danish Cerebral Palsy Follow-up Program.
9780167|NCT03834519|Active Comparator|Abiraterone + Prednisone or Enzalutamide|Participants receive abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone 10 mg as one 5 mg tablet BID until progression OR Participants receive enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules OR two 80 mg tablets QD until progression.
9780168|NCT03825588|Experimental|ASAP + BRITE + TAU (treatment as usual)|Participants in this arm receive the ASAP (As Safe As Possible) intervention, during their transition from inpatient to outpatient care, as well as the BRITE smart phone app for distress tolerance/emotion regulation and safety planning. Participants will also receive usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
9780169|NCT03825588|Experimental|BRITE + TAU (treatment as usual)|Participants in this arm will receive the BRITE smart phone app for distress tolerance/emotion regulation and safety planning as they proceed from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
9780170|NCT03825588|Experimental|ASAP + TAU (treatment as usual)|Participants in this arm will receive the ASAP (As Safe As Possible) intervention during their transition from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
9780171|NCT03825588|Active Comparator|TAU (treatment as usual) alone|Participants in this grouping are studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
9780172|NCT03815890|Experimental|1A; LumB|Nivolumab
9780173|NCT03815890|Experimental|1B; TNBC|Nivolumab
9780174|NCT03815890|Experimental|2A; LUMB|Nivolumab and ipilimumab
9780175|NCT03815890|Experimental|2B; TNBC|Nivolumab and ipilimumab
9780176|NCT03815890|Experimental|3B; TNBC, High TIL|Nivolumab and ipilimumab
9780177|NCT03811275|Experimental|Sequence #1|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention A followed by nine 30 minute sessions (over 3 weeks) of intervention B.
9780178|NCT03811275|Experimental|Sequence #2|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention B followed by nine 30 minute sessions (over 3 weeks) of intervention B.
9780179|NCT03809780|Experimental|Lenalidomide,dexamethasone|"high dose: lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly~low dose: lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly Schedule"
9780180|NCT03807856|Active Comparator|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
9780181|NCT03807856|Active Comparator|Standard of Care|Standard treatment for acute pancreatitis
9780182|NCT03795168|Experimental|Transcranial vibrating system effect|"Participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. During the first 2 weeks (4 visits), 20 participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) and the other 20 participants without. The following 2 consecutive weeks (4 visits), participants will perform their PT exercises wearing the TCVS if they weren't previously, or won't wear the device during their PT exercises if they were previously.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
9780183|NCT03795168|Sham Comparator|Vs transcranial vibrating system sham|"40 participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. Participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) at optimal vibrating frequency or wearing the TCVS at irrelevant vibrating frequency (sham). The TCVS and TCVS sham will be labeled A or B by the sponsor. The investigators and participants will not know which TCVS is optimal or sham. The sponsor will randomly assign participants TCVS A or B.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
9780184|NCT03792360|Experimental|Single Arm|
9780185|NCT03786471|Active Comparator|Health Systems-Based Dementia Care|Dementia care that is based in the health care system, which partners with community-based organizations to provide comprehensive, coordinated, patient-centered care. The health system-based dementia care arm uses a Dementia Care Specialist (Nurse Practitioner or Physician Assistant) supervised by a physician to tailor and facilitate dementia care delivery in collaboration with the primary care physician (co-management). The Health Systems-Based Dementia Care arm is based on UCLA's Alzheimer's and Dementia Care Program.
9721147|NCT04397809||Acute Pulmonary Exacerbation (APE)|Those subjects presenting with APE will be treated with at least two pathogen specific I.V. antibiotics, as dictated by their treating physician and compliant with standard guidelines for care of an APE.
9721148|NCT04397809||Baseline Health|Those subjects presenting at baseline health will be identified by their treating physician as such and will not be starting on any treatments for APE.
9721149|NCT04397237||Systemic Lupus Erythematosus|Consecutive Systemic Lupus Erythematosus patients followed-up in each service
9721150|NCT04397237||Sjogren's Syndrome|Consecutive Sjogren's Syndrome patients followed-up in each service
9721151|NCT04397237||Axial Spondyloarthritis|Consecutive Axial Spondyloarthritis patients followed-up in each service
9721152|NCT04397237||Rheumatoid Arthritis|Consecutive Rheumatoid Arthritis patients followed-up in each service
9721153|NCT04397237||Giant Cell Arteritis|Consecutive Giant Cell Arteritis patients followed-up in each service
9721154|NCT04397042||recurrent pregnancy loss|Group 1 included thirty women admitted to our clinic for termination of pregnancy due to absence of fetal cardiac activity or absence of fetal pole on ultrasonographic examination. Patients with a history of two or more unexplained first trimester miscarriages and no live births were included in the study
9721155|NCT04396964||surgery|subjects undergoing multilevel lumbar fusion
9721156|NCT04396704||Botox|all eligible subjects, in a reverse consecutive order, initiated on onaBoNT-A from 01 March 2015 to 29 May 2017.
9721157|NCT04396704||Dysport|all subjects meeting inclusion/exclusion criteria and initiated on aboBoNT-A from 30 May 2017 to 30 March 2019.
9721158|NCT04396171||Probable bruxism(+)|
9721159|NCT04396171||Probable bruxism(-)|
9721160|NCT04394247||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
9721161|NCT04393857||Oocyte donors|Healthy Oocyte donors fulfilling the criteria for oocyte donation are eligible. Patients may not have received any antibiotics or vaginal products (other than for menstrual hygiene - such as tampons) for the last 1 month. Informed consent is mandatory.
9721162|NCT04390555||CV involvement|Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).
9721163|NCT04390555||Control|Patients with COVID-19 without preexisting cardiac involvement.
9721164|NCT04389658||Asymptomatic population|Subjects who underwent PCR and ELISA tests for the diagnosis of COVID-19: mainly asymptomatic individuals from three main areas of Spain (Madrid, Barcelona and Valencia) with high impact of COVID-19 that have performed the PCR and ELISA test for the diagnosis of COVID-19 before initiating the work immediately after Spanish lockdown.
9721165|NCT04388540||Jamaica|School aged children 6 - 12 years living in Jamaica
9721166|NCT04388540||Trinidad and Tobago|School aged children 6 - 12 years living in Trinidad and Tobago
9721167|NCT04388540||Belize|School aged children 6 - 12 years living in Belize
9721168|NCT04388540||Barbados|School aged children 6 - 12 years living in Barbados
9721169|NCT04388540||St. Lucia|School aged children 6 - 12 years living in St. Lucia
9721170|NCT04388540||Grenada|School aged children 6 - 12 years living in Grenada
9721171|NCT04388540||St. Vincent & the Grenadines|School aged children 6 - 12 years living in St. Vincent & the Grenadines
9721172|NCT04388540||Antigua|School aged children 6 - 12 years living in Antigua
9721173|NCT04388540||Dominica|School aged children 6 - 12 years living in Dominica
9721174|NCT04388540||St. Kitts and Nevis|School aged children 6 - 12 years living in St. Kitts and Nevis
9721175|NCT04386928||Elderly patients with hematological disease|older than 60 years who received hematopoietic stem cell transplantation (HSCT)
9721176|NCT04386603||shoulder-tip pain group|The patients in this group have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
9721177|NCT04386603||non-shoulder-tip pain group|The patients in this group don't have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
9721178|NCT04386044||Hospital in-patients|Cross-sectional study of hospital in-patients admitted with COVID-19 n=200
9721179|NCT04386044||Controls (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
9721180|NCT04386044||Cases (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
9721181|NCT04386395||Immuno Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
9721182|NCT04386395||Cortico Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. According to RECOVERY study, early routine administration of dexamethasone 6 mg/day over 10 days. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
9721183|NCT04384913||MA (mechanical alignment)|Patients in group MA (mechanical alignment) will be operated according to mechanical implantation technique. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation.
9721184|NCT04384913||KA (kinematic alignment)|Patients in group KA (kinematic alignment) will be operated according to kinematic implantation technique. The kinematic cutting blocks will be designed to resurface the femoral and tibial bones to restore each patient´s pre-arthritic anatomy and Joint line. Based on a available CT dat the prearthritic anatomy is reconstructed by compensating bone defects and restoring the physiological cartilage height of 1,7mm. Femoral Flexion is evaluated by the anterior Cortex of the distal femur, tibia slope is defined to 3° due to ACL (Anterior Cruciate Ligament) loss, but cab be adapted during surgery.
9721185|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Poor response|"If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction treatment, in many sites ifosfamide at high doses and MTP-PE (Muramyl tripeptide phosphatidylethanolamine), is incorporated in addition to adriamycin.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM (Adriamycin) 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)~All the product are used as commercial formulation~Other Names:~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
9721186|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Good response|"If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction treatment, in many centers the option of additional administration of methotrexate, CDDP (Cisplatinum) and adriamycin will be chosen.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)~All the product are used as commercial formulation~Other Names:~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
9721187|NCT04383288||No overexpression of ABCB1 / P-glycoprotein|"If there is no overexpression of ABCB1 / P-glycoprotein, the administration of methotrexate, adriamycin and cisplatin will be chosen in many sites.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total length 34 weeks~All the product are used as commercial formulation~Other Names:~methotrexate cisplatin doxorubicine"
9721188|NCT04380727||Almitrine|Administration of 4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, France), over 30-45 min followed by 12 mcg/kg/min infusion rate. Because of a shortage of drug store at national level, a protocol using continuous infusion was not considered. Some patients may receive the drug for 36 hours depending on availability..
9721189|NCT04380727||Control|To eliminate the eventuality of a spontaneous evolution of hypoxia, these patients were matched to control COVID-19 patients treated without almitrine (time control).
9780186|NCT03786471|Active Comparator|Community-Based Dementia Care|Dementia care that is based in community organizations, which gives equal attention to patients and their primary family or friend caregivers. The community-based dementia care arm uses Care Consultants (Social Workers or Nurses). Patients with dementia are engaged in the program whenever possible. Caregivers can be the sole program participant, when patients are too impaired. The program establishes a long-term relationship between Care Consultants and families. The exact content of assistance provided is tailored to the preferences of individual patients and caregivers, and is holistic in the range of potential concerns of problems addressed. The Community-Based Dementia Care arm is based on the Benjamin Rose Institute on Aging's Care Consultation Program.
9780187|NCT03786471|Other|Usual Care|Dementia care that most closely corresponds to traditional care. This arm will also receive standardized educational materials (hard copies and internet-based resources), referral to the Alzheimer's Association 1-800 national helpline to speak to a master's level consultant for decision-making support, crisis assistance, and caregiver education, as well as referral to local programs and services.
9780188|NCT03784209||lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
9980707|NCT01394497|No Intervention|Standard procurement procedure|Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back-table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.
9980708|NCT01394536|Sham Comparator|1|"Sham device - an EAS band placed over the P6 acupoint that will be turned off (inactive)."
9780191|NCT03780543|Active Comparator|HBeAg-negative Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were standard of care nucleos(t)ide (SOC NrtI)-suppressed and HBeAg-negative will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time they will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years.
9780192|NCT03780543|Active Comparator|HBeAg-positive Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were SOC NrtI-suppressed and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated. Subjects who meet the virologic response criteria will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years. Subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.
9827873|NCT02471586|Active Comparator|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.~At the end of the procedure, a final IVUS imaging run must be performed.~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
9980709|NCT01394536|Active Comparator|2|The second arm will use the ReliefBand (Aeromedix, Jackson, WY), an FDA-approved, reusable, battery-operated electroacustimulation device.
9980710|NCT01394549||Cardiology|The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study.
9980711|NCT01394562|Experimental|Ferinject (ferric carboxymaltose)|
9980712|NCT01394562|Other|Standard of Care|Standard of care. IV iron is not permitted
9721190|NCT04379440||" Acute Ward Patients  care setting cohort"|Acute Ward Hospitalised patients with suspected or known SARS-CoV-2 infection
9721191|NCT04379440||" Nursing Homes (RSA)  care setting cohort"|Nursing Home Resident Older Adult suffering from Suspected or known SARS-CoV-2 infection
9721192|NCT04379440||" Home and Outpatients' Care  cohort"|Outpatients at risk of SARS-CoV-2 infection
9721193|NCT04379440||" Dementia Outpatients  cohort"|Outpatients suffering from Dementia according to NIA-AA criteria, at risk of SARS-CoV-2 infection and on Treatment with anti-cholinesterase- dugs and/or anti-psychotics
9721194|NCT04379440||" At home  cohort"|Outpatients at risk of SARS-CoV-2 infection
9721195|NCT04379440||" Outcomes  cohort"|Age≥65 years as target population Hospitalised patients diagnosed with SARS-CoV-2 infection
9721196|NCT04379141||hypotension|Patients with hypotension after induction of anesthesia
9721197|NCT04379141||non-hypotension|Patients without hypotension after induction of anesthesia
9721198|NCT04378504||ACS|All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
9721199|NCT04377724||ETH cohort|employees or students at ETH Zurich, Switzerland
9721200|NCT04377113||RCC patients|"RCC patients (30 pts) will include patients with kidney cancer (renal cell cancer).~Investigators will collect and analyze:~blood sample,~urine sample,~kidney tissue sample (healthy tissue, carcinomatous tissue and borderline tissue between them)."
9721201|NCT04377113||Healthy patients|"In this group (30 patients) will be recruiting healthy patients (volunteer).~Investigators will collect and analyze:~blood sample."
9721202|NCT04376801||Tension-band Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed tension-band fixation after olecranon osteotomy were classified into Tension-band Fixation Group.
9721203|NCT04376801||Plate Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed plate fixation after olecranon osteotomy were classified into Plate Fixation Group.
9721204|NCT04376749||preterm infants received caffeine|preterm infants aged between 28 to 34 weeks gestational age who received caffeine therapy either for prophylaxis or treatment
9980713|NCT01394575|Experimental|IMRT-SIB|
9721205|NCT04376749||preterm infants received no caffeine|preterm infants aged between 28 to 34 weeks gestational age who received no caffeine therapy
9721206|NCT04376398||COVID-19|Any pediatric or adult patient with COVID-19 or suspected of COVID-19 scheduled for any intervention
9721207|NCT04374695||patients with COVID-19|Patients with positive RT-PCR for SARS-CoV-2, and patients with négative RT-PCR for SARS-CoV-2 but clinical presentation highly suggestive of COVID-19, and typical COVID-19 abnormalities on chest CT-Scan.
9721208|NCT04374695||patients without COVID-19|Patients with négative RT-PCR for SARS-CoV-2 and chest CT-Scan or chest X-ray not suggestive of COVID-19
9721209|NCT04371289||COVID-19 outpatients|Mild COVID-19 outpatients managed by General Practitioners in Northern Italy (Lombardy)
9721210|NCT04371289||COVID-19 inpatients|Mild, moderate and severe inpatients managed in different Italian Hospitals, mostly in Northern Italy (Lombardy)
9721211|NCT04371003||WNND|40 subject with West-Nile Neuroinvasive Disease will be recruited
9721212|NCT04371003||WNF|40 subject with West-Nile Fever will be recruited
9721213|NCT04371003||controls|20 control will be recruited. These controls will be aged matched to the cases.
9721214|NCT04370132||Group of patient with liver venous deprivation|Group of patient with liver venous deprivation
9721215|NCT04370132||Group of patient with portal embolization|Group of patient with portal embolization
9721216|NCT04369183||Study Group|Patients with primary focal segmental glomerulosclerosis or minimal change disease who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.
9721217|NCT04367974||1|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，they were given intraperitoneal twice daily in the first bag and the fourth bag for 5 days，and given 1g once daily in the fourth bag for 9 days. Total treatment duration was 2 weeks.
9721218|NCT04367974||2|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，and were given once daily in the fourth bag. Total treatment duration was 2 weeks.
9721219|NCT04367610||Study Group|Kidney transplant recipients with biopsy-proven acute or chronic antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.
9721220|NCT04367792||Patients died with Covid-19 disease|Sample of patients died with Covid-19 disease and pulmonary disease
9721221|NCT04367792||Patients died with Covid-19 and cardiovascular disease|Sample of patients died with Covid-19 disease and pulmonary disease with clear cardiovascular involvement
9721222|NCT04367792||Patient died with myocarditis|Sample of patient died with different types of myocarditis without Covid-19 disease. These samples are used as control and are part of database of previously collected samples of CVPath Institute Inc.
9721223|NCT04366765||COVID-19 suspects|Patients presenting with suspected COVID-19 to the emergency department of the University Hospital Basel.
9721224|NCT04365647||1|Patient's in whom there is increase in tumor size after craniotomy
9721225|NCT04365647||2|Patient's in whom there was either no increase in tumor size or decrease in tumor size after craniotomy
9785795|NCT01260350|Experimental|Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.
9980714|NCT01394588||Cardiac Surgery Patients|Competent Adult Patients going for elective cardiac surgery.
9980715|NCT01394640||Healthy Volunteers|Healthy people without any serious comorbidity (no immunosuppressive treatment, no autoimmune disease, no cancer) receiving the same vaccine
9721226|NCT04365634||Diabetes|Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.
10196730|NCT05182281|Experimental|Whole Body Vibration and Infrared Therapy Group|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm 20 minutes daily session, 2 days per weeks for 3 months.1000 mg Ca and 880 IU vitamin D treatment were given.
10196731|NCT05182281|Active Comparator|Infrared Therapy Group|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm 20 minutes daily session, 2 days per weeks for 3 months.1000 mg Ca and 880 IU vitamin D treatment were given.
10196732|NCT05182281|Other|Classical Treatment Group|1000 mg Ca and 880 IU vitamin D treatment were given.
10196733|NCT05182268||endoscopic ear surgery group(EES)|
9721227|NCT04365634||Non-diabetes|Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes.
9721228|NCT04365634||Survivors|COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
9721229|NCT04365634||Non-survivors|COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data.
9721230|NCT04365140||positive ACD to nickel|Patients with positive epicutaneous patch test to nickel
9721231|NCT04365140||negative ACD to nickel|Patients with negative epicutaneous patch test to nickel
9721232|NCT04363567||CKD 1|"Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+.~20 patients, maximun 4 patients with diabetes."
9721233|NCT04363567||CKD 2|"Patients with Chronic kidney disease stage 2: Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease. eGFR: 60-89.~20 patients, maximun 4 patients with diabetes."
9721234|NCT04363567||CKD 3|"Patients with Chronic kidney disease stage 3: Moderately reduced kidney function. eGFR: 30-59.~20 patients, maximun 4 patients with diabetes."
9721235|NCT04363567||CKD 4|"Patients with Chronic kidney disease stage 4: Severely reduced kidney function. eGFR: 15-29.~20 patients, maximun 4 patients with diabetes."
9721236|NCT04363567||CKD 5|"Patients with Chronic kidney disease stage 5: Very severe kidney function. eGFR: <15.~20 patients, maximun 4 patients with diabetes."
9721237|NCT04363567||Dialysis|Patients with end stage renal disease in dialysis. 20 patients, maximun 4 patients with diabetes.
9721238|NCT04363567||Healthy|20 healthy people. Control group
9780193|NCT03780543|Active Comparator|Subjects from Parent Study ABI-H0731-202|"Subjects who on Day 1 of parent study ABI-H0731-202 (NCT03577171) were treatment-naive and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~Subjects who meet the virologic response criteria at Week 52 will continue to receive ABI-H0731 + SOC NrtI for an additional 96 weeks, after which time their viral response will be evaluated at Week 148. Subjects who meet the virologic response criteria at Week 148 will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years, while those subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.~Subjects with insufficient virologic response at Week 52 will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks."
9780194|NCT03771898|Experimental|SHP611|Participants will receive 150 milligrams (mg) of SHP611 intrathecally (IT) via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once weekly for 210 weeks.
9780195|NCT03769025|Experimental|Remote Observed Dosing|One group will be assigned to Remote Observed Dosing (ROD) and will have all of their Suboxone® doses remotely observed. The intervention is remote observed dosing
9780196|NCT03769025|Active Comparator|Attention Control|The attention control (AC) group will not have their dosing observed but will send a text message confirming they have taken their study medication to the study team daily matching contact with the study team. Text message confirming that they have taken their study medication is the intervention
9780197|NCT03767881|Experimental|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
9780198|NCT03749928|Experimental|OstiSense biosensor - active|Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
9780199|NCT03749928|Placebo Comparator|OstiSensor biosensor - not activated|Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
10196734|NCT05182268||microscopic ear surgery group(MES)|
10196735|NCT05182203||JAK inhibitors|RA patients treated with JAK inhibitors
10196736|NCT05182203||TNF inhibitors|RA patients treated with TNF inhibitors
9721239|NCT04362852||Cancer|No intervention
9721240|NCT04362852||Atopic Dermatitis/Eczema|No intervention
9721241|NCT04361565||Individuals diagnosed for COVID-19|
9721242|NCT04361539||Elite adolescent badminton players|The population was all the elite adolescent badminton players from a high-level club. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed from September 2018 to May 2019.
9980716|NCT01394640||Onco-hematologic patients|Patients with lymphoma or myeloproliferative diseases or multiple myeloma either receiving chemotherapy or in follow-up or treated with allogeneic hematopoietic stem cell transplant.
9721243|NCT04361864||RUTI|patients with at least 3 episodes of UTI during 2019
9721244|NCT04361864||UTI|patients with one or two episodes of UTI during 2019
9721245|NCT04359693||SARS-CoV2 group|Patients receiving invasive mechanical ventilation for more than 48h with SARS-CoV-2 infection
9721246|NCT04359693||Flu group|Patients receiving invasive mechanical ventilation for more than 48h with influenza infection
9721247|NCT04359693||No viral infection group|Patients receiving invasive mechanical ventilation for more than 48h with no viral infection at ICU admission
9721248|NCT04359498||LAR for rectal cancer|Retrospective chart review for surgical complications related to the LAR surgery, the stoma (diverting loop ileostomy) creation and the stoma reversal procedure after LAR for rectal cancer.
9721249|NCT04359459||Mild COVID-19|Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.
9721250|NCT04359459||Severe COVID-19|Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.
9721251|NCT04359459||Very Severe COVID-19|Patients with very severe disease admitted to intensive care, who require mechanical ventilation.
9721252|NCT04359173||Hypothermic machine perfusion (HMP)|patients who underwent kidney transplantation following HMP
9721253|NCT04359173||Static cold storage (SCS)|patients who underwent kidney transplantation following SCS
9721254|NCT04359719||Group mild melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
9721255|NCT04359719||Group Moderate-severe melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
9721256|NCT04358640||Employees of Nîmes University Hospital (France)|Employees of Nîmes University Hospital (France)
9721257|NCT04357496||Participants with SARS-COV-2|Participants tested positive for SARS-COV-2 aged 60 years or older
9721258|NCT04357236||Experimental Group|The experimental group received 18F-FDG PET examination
9721259|NCT04357236||Control Group|The control group received 18F-FDG PET examination
9721260|NCT04357314||Patients with STEMI in 2019|Patient with acute myocardial infarction between March 17, 2019 and April17, 2019
9721261|NCT04357314||Patients with STEMI in 2020|Patient with acute myocardial infarction between March 17, 2020 and April17, 2020.
9721262|NCT04355702||Lupus patients treated by hydroxychloroquine|Lupus patients treated by hydroxychloroquine
9721263|NCT04355702||Lupus patients not treated by hydroxychloroquine|Lupus patients not treated by hydroxychloroquine
9721264|NCT04354818||People living with HIV|
9721265|NCT04354818||Recipients of Solid Organ Transplants|
9721266|NCT04354818||People Living with Cancer|
9721267|NCT04354818||People with acquired immunodeficiency|Patients with acquired immunodeficiency associated with other immunosuppressive therapy.
9721268|NCT04354818||People with primary immunodeficiency|
9721269|NCT04354558||survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
9721270|NCT04354558||non-survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
9721271|NCT04354519||Confirmed Cases|"Diagnosed by health professional / Covid-19 test~Monitored through fortnightly questionnaires"
9721272|NCT04354519||Not Covid-19 cases|"Through self report no suspicion of COVID-19, tested by fortnightly questionnaire.~non Covid Cases can become COVID cases through self report."
9721273|NCT04354519||Suspected Covid-19 Cases|"Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed.~Fortnighly questionnaire"
9721274|NCT04353583||ICU patients|Patients with COVID-19 requiring ICU care
9721275|NCT04353583||Non-ICU patients|In-hospital patients with COVID-19 not requiring ICU care
9721276|NCT04353349||Patients operated with an open approach|
9721277|NCT04353349||Patients operated with minimally invasive robotic approach|
9721278|NCT04353349||Patients operated with VATS approach|
9721279|NCT04352699||Naive patients|Group of naive patients who have undergone elective or emergency surgery during the study period
9721280|NCT04352335||Cohort 1：ICI treatment with immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.
9721281|NCT04352335||Cohort 2：ICI treatment without immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs).
9721282|NCT04352309||Participants Treated With Glecaprevir/Pibrentasvir (GLE/PIB)|Participants will receive GLE/PIB over 8 weeks of therapy as prescribed by their physicians.
9721283|NCT04350424||Propofol Arm|Outpatients receiving anesthesiologist-administered propofol for elective outpatient endoscopic procedures
9721284|NCT04350424||Opioid / Benzodiazepine Arm|Outpatients receiving endoscopist-administered opioid / benzodiazepine for elective outpatient endoscopic procedures
9721285|NCT04349865||Idiopathic PD|PD patients without the LRRK2 G2385R mutation
9721286|NCT04349865||LRRK2 G2385R PD|PD patients with the LRRK2 G2385R mutation
9721287|NCT04349865||LRRK2 G2385R carriers|Subjects without PD who screen positive for the LRRK2 G2385R mutation
9721288|NCT04349865||Controls|Subjects without PD who screen negative for the LRRK2 G2385R mutation
9721289|NCT04349449||Vedolizumab Participants|Participants diagnosed with moderate to severe CD from approximately 20 investigational sites will be observed over a period of 12 months after initiation of treatment with vedolizumab, intravenous infusion under standard clinical care.
9721290|NCT04347824||low risk|"This group has a normal urine status on admission to hospital. Abnormal urine status is defined anuric OR as 2* or more of the following findings:~urine osmolarity below normal values~leukozyturia~hematuria~albuminuria/ proteinuria * if urine is positive for nitrite or bacteria, abnormal urine status is defined as 3 or more of the findings."
9721291|NCT04347824||intermediate risk|This group has an abnormal urine status on admission to hospital WITHOUT serum-albumin below 2.0 g/dl AND WITHOUT antithrombin III level below 70%.
9721292|NCT04347824||high risk|This group has an abnormal urine status on admission to hospital PLUS serum-albumin below 2.0 g/dl OR antithrombin III level below 70%.
9721293|NCT04348084||who developed POPF|Patients undergone curative distal pancreatectomy for PDAC who developed POPF
9721294|NCT04348084||who did not develop POPF|Patients undergone curative distal pancreatectomy for PDAC who did not develop POPF
9721295|NCT04346342||Mechanical ventilation|COVID patients receiving invasive mechanical ventilation
9721296|NCT04345354||Patient with continuous positive airway pressure treatment|
9721297|NCT04345354||without continuous positive airway pressure treatment|
9721298|NCT04345328||Roux-en-Y gastric bypass|Patients who were planned for surgery with Roux-en-Y gastric bypass and were operated
9721299|NCT04345328||Sleeve Gastrectomy|Patients who were planned for surgery with Sleeve Gastrectomy and were operated
9721300|NCT04345328||Control group|Obese patients involved in a weight loss program that focuses on diet and lifestyle changes
9721301|NCT04344977||Convalescent survivors of COVID-19|Convalescent survivors of COVID-19: history of COVID-19 like illness or positive test for SARS-CoV-2 and has the protocol-specified minimum anti-SARS-CoV-2 neutralizing antibody titer
9780200|NCT03740841|Other|LUNII|The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
9780201|NCT03740841|No Intervention|Without LUNII|Usual pre-operative visit.
9780202|NCT03720678|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal or colorectal cancer.
9780203|NCT03720678|Experimental|Dose Expansion-GE|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal cancer
9780204|NCT03720678|Experimental|Dose Expansion-CRC|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with colorectal cancer
9780205|NCT03715465|Active Comparator|Estimated DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before estimated dim light melatonin onset.
9780206|NCT03715465|Experimental|Measured DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before measured dim light melatonin onset.
9780207|NCT03713528|Other|Treatment Group|The treatment group includes any patient with an acute perioperative periprosthetic infection, acute hematogenous infection, or unresectable infection with a gram positive organism sensitive to vancomycin and treated with intraoperative intraosseous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics under guidance of an infectious disease specialist, and indefinite antibiotic chronic suppression.
9780208|NCT03702374|Experimental|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
9780209|NCT03702374|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
9780210|NCT03697356|Experimental|Rituximab&Bortezomib&Lenalidomide&Dexamethasone|
9780211|NCT03690544|Experimental|Single Arm|Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
9780212|NCT03689660|Experimental|Virtual Reality Training|Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
9780213|NCT03689660|Experimental|Biofeedback Training|Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
9980717|NCT01394653|Experimental|orally-disintegrating (OD) tablet precedence group|
9980718|NCT01394653|Experimental|conventional tablet precedence group|
9980719|NCT01394666||CP-CML patients who have failed Imatinib 400 mg daily|
9721302|NCT04344366||group A|children with low birth weight
9721303|NCT04344366||group B|children with normal birth weight
10196737|NCT05182190|Active Comparator|Control - White bread|Commercial white bread in a 50 gram available carbohydrate dose
10196738|NCT05182190|Active Comparator|Control - whole black beans|Whole boiled black beans (Zenith) in a 50 gram available carbohydrate dose
10196739|NCT05182190|Experimental|Knife Mill pasta|Heat treated black bean flour made with standard Knife Mill techniques
9721304|NCT04344327||Patients with COVID-19|Patients hospitalized in conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)
9721305|NCT04344145||Target Group|This group includes frontline healthcare workers who are actively involved in the management of the Covid-19 outbreak: from emergency units, non-intensive Covid-19 and intensive Covid-19 units. They will fill self-reported questionnaires and scales upon their inclusion.
9721306|NCT04344145||Control group|"This group includes healthcare workers who are actively involved in usual medical care units, referred in this study as non-Covid-19 units. They will fill same self-reported questionnaires and scales than those filled in the Target group, also upon their inclusion.This group will be the comparator of the Target Group to assess the frontline Covid-19 condition."
10196740|NCT05182190|Experimental|Combined pasta|Black bean flour with medium protein made with novel compression/decompression mill
10196741|NCT05182190|Experimental|Cyclone pasta|Black bean flour with lower protein made with novel compression/decompression mill
9721307|NCT04343846||group A|low birth weight children
9721308|NCT04343846||group B|normal birth weight children
10196742|NCT05182151||Patient|istradefylline 40mg daily over 12 week period
10196743|NCT05182138|Placebo Comparator|Unfortified potato plus placebo|Volunteers given potato with no fortified zinc and a placebo
10196744|NCT05182138|Active Comparator|Zinc Biofortified potato plus placebo|Volunteers given potato biofortified with zinc and a placebo
10196745|NCT05182138|Active Comparator|Unfortified potato plus zinc supplement|Volunteers given potato with no fortified zinc and a zinc supplement
10196746|NCT05182112|Experimental|Conformal Radiation Therapy (RT) and Chemotherapy|Upon enrollment in the study, patients will undergo radiation simulation. Following simulation, patients will initiate gemcitabine and cisplatin chemotherapy given every 2 weeks for 1 cycle to allow for RT planning, after which RT will be initiated. Weekly cisplatin will be continued and delivered concurrently with RT. After the completion of RT, bi-weekly gemcitabine and cisplatin will be continued until disease progression.
10205429|NCT00882050|Placebo Comparator|Placebo IV NSS|"Placebo of IV normal saline solution as comparator.~Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
9721309|NCT04343534||Original Shared Decision Making Process scale|Patients receive the original version of the Shared Decision Making Process scale.
9721310|NCT04343534||Revised Shared Decision Making Process scale|This group completes a new version of the scale with different wording for several items.
9721311|NCT04342442||Steroid-refractory a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-refractory a GvHD
9721312|NCT04342442||Steroid-responsive a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-responsive a GvHD
9721313|NCT04342299||Responders|"Responders are participants who show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
9721314|NCT04342299||Non-responders|"Non-responders are participants who do not show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
9721315|NCT04339387||Coronavirus Disease 2019 positive, suitable for discharge|Patients with Coronavirus Disease 2019 who do not require supplemental oxygen, do not require intensive care unit-level care, and do not die.
9721316|NCT04339387||Coronavirus Disease 2019 positive, not suitable for discharge|Patients with Coronavirus Disease 2019 who do require supplemental oxygen, do require intensive care unit-level care, or do die.
9721317|NCT04337762||Healthy|Healthy adult individuals residing in the United States with no history of COVID-19
9721318|NCT04337762||COVID-19 Confirmed|United States adults that have tested positive for SARS-CoV-2 virus which causes the human disease COVID-19 (IE novel coronavirus) or those that have been exposed to a confirmed case and are awaiting testing
9721319|NCT04335149||COREVALVE|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a COREVALVE
9721320|NCT04335149||EDWARDS|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a EDWARDS
9721321|NCT04332237||Hypothermia group|Hypothermic trauma patients or hypothermic patients with traumatic brain injury specifically.
9721322|NCT04332237||Normothermia group|Normothermic trauma patients or normothermic patients with traumatic brain injury specifically.
9721323|NCT04332484||Acute on Chronic Liver Failure|All patients of Acute on chronic liver failure according to CANONIC definition, aged more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
9980720|NCT01394679|Active Comparator|18-F-FDG Imaging Agent|18 F FDG followed by PET/CT imaging
9980721|NCT01394679|Experimental|99m Tc-EC-DG imaging agent|99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and < 1 mg EC-DG
9721324|NCT04332484||Cirrhosis of Liver|All patients with cirrhosis of liver with age more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
9721325|NCT04331847||Quantitative observational descriptive study|among women presenting for abortion-related complications
9721326|NCT04331847||Qualitative study|among women with a near-miss or a potentially life-threatening complication
9721327|NCT04331847||Rapid health facility assessment with the health professional|in charge of Post-Abortion Care
9721328|NCT04331847||Knowledge Attitudes, Practice and Behavior quantitative survey|among health care providers involved in the management of abortion-related complications
9721329|NCT04330118||20 patients with DRESS syndrome|
9721330|NCT04330118||20 patients with drug induced MPE with eosinophilia|patients with drug induced maculopapular exanthema (MPE) with eosinophilia
9721331|NCT04330118||20 patients with drug induced MPE without eosinophilia|
9721332|NCT04330118||20 Healthy subjects|
9721333|NCT04329260||Pediatric population|"Children between 3 to 18 years old with severe (BMI> IOTF-30) and early (before the age of 6) obesity.~A Saliva sample for screening of the deletion Δ6-8 of LEPR gene will be performed for each child."
9721334|NCT04329260||Adult member family|The screening of the same deletion according the same procedure will be proposed to the adult family member if the child presents the deletion Δ6-8 of LEPR gene.
9780214|NCT03689660|Other|Conventional Rehabilitation|Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
9780215|NCT03683524|Experimental|Experimental group|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
9780216|NCT03683524|Active Comparator|Control group|continuation of their current stable ART
9780217|NCT03680131|Active Comparator|EB01 Cream Placebo|EB01 Cream containing 0% EB01 w/w applied BID
9780218|NCT03680131|Experimental|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
9780219|NCT03680131|Experimental|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
9780220|NCT03680131|Experimental|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
9780221|NCT03672292|Experimental|SCY-078 plus Voriconazole|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks"
9780222|NCT03672292|Placebo Comparator|Voriconazole mono-therapy|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).~Treatment duration = minimum 6 weeks/Max 13 weeks"
9780223|NCT03670251|Other|Blood sampling|blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
9780224|NCT03660683|Experimental|Group A Dapa|Dapagliflozin 10 mg + Saxagliptin Placebo
9780225|NCT03660683|Active Comparator|Group B DapaSaxa|Dapagliflozin 10mg + Saxagliptin 5mg
9780226|NCT03660683|Placebo Comparator|Placebo|Placebo Oral Tablet
9780227|NCT03651336|Other|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
9780228|NCT03629756|Experimental|Dose Escalation|3+3 design, including a DLT evaluation period. Etrumadenant RP2D will be determined in this part with escalating doses of oral etrumadenant in combination with a fixed dose of IV zimberelimab.
9780229|NCT03629756|Experimental|Dose Expansion-advanced clear-cell RCC|Etrumadenant at RP2D + zimberelimab
9780230|NCT03629756|Experimental|Dose Expansion-mCRPC|Etrumadenant at RP2D + zimberelimab
9780231|NCT03621696|Experimental|Arm 1: POAmCRT|"Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
9780232|NCT03621696|Experimental|Arm 2: POAmRT|"Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
9780233|NCT03621696|Experimental|Arm 3: POACRT|"Patients with clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)~The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
9980722|NCT01394731|Experimental|Paracetamol 1|
9721335|NCT04327258||All patients|Patients undergoing elective surgery with anesthesia
10205430|NCT00790829|Experimental|A, B|Group B received a seven-milligram transdermal patch and Group A received a placebo patch.
10205431|NCT00212121|Active Comparator|1|low dose boost (16 Gy)
9721338|NCT04324684||Covid19 pneumonia with comorbidities|"Patients with pneumonia from Covid 19 with at least one of the following comorbidities:~Hypertension~Obesity and/or type 2 diabetes~Cardiovascular disease~Chronic obstructive lung disease"
9721339|NCT04324684||Covid2 pneumonia without comorbidities|Without any of the following comorbidities
9721340|NCT04323891||Higher Trainee/Service Doctor|
9721341|NCT04321564||Nullipar pregnant women|
9721342|NCT04321564||multipar pregnant women|
9721343|NCT04321213||Healthcare professionals in the Region of Västmanland|Healthcare professionals of all professions working in-hospital with patient contact at two hospitals in the Region of Västmanland, Sweden. Data is collected by questionnaires.
9721344|NCT04321213||Healthcare professionals in the Region of Dalarna|Healthcare professionals of all professions working in-hospital with patient contact at three hospitals in the Region of Dalarna, Sweden. Data is collected by questionnaires.
9721345|NCT04321057||Group questionnaire|Patient's height and weight are asked by questionnaire in this group. It includes patients at the cardiological department of Saarland University.
9721346|NCT04321057||Group male doctor|Patient's height and weight are asked by a male doctor in this group. It includes patients at the cardiological department of Saarland University.
9721347|NCT04321057||Group female doctor|Patient's height and weight are asked by a female doctor in this group. It includes patients at the cardiological department of Saarland University.
9721348|NCT04321057||Group male nurse|Patient's height and weight are asked by a male nurse in this group. It includes patients at the cardiological department of Saarland University.
9721349|NCT04321057||Group female nurse|Patient's height and weight are asked by a female nurse in this group. It includes patients at the cardiological department of Saarland University.
9721350|NCT04321057||Group family doctor|Patient's height and weight are asked by questionnaire in this group. This is the control group,including patients at a family doctor.
9721351|NCT04320862||Duke Health region and beyond|Individuals in the Duke Health region as well as individuals beyond the Duke Health region who have flu-like symptoms, a viral test order for COVID-19, confirmed COVID-19, or concern for exposure to COVID-19.
9721352|NCT04320849||Patients with Biotronik Leads|"Patients with these models: LSiello S, Solia S~Description: Active Fixation Leads"
9721353|NCT04320849||Patients with Boston Scientific Leads|"Patients with these models: 4452, 4453, 4456, 4457~Description: FINELINE II/FINELINE II Sterox Passive Fixation (polyurethane)~Boston Scientific 4463, 4464, 4465, 4469, 4470, 4471 FINELINE II/FINELINE II Sterox EZ Positive Fixation (polyurethane)"
9721354|NCT04320849||Patients with Abbott Leads|"Patients with these models: LDA 210Q~Description: Optisure Single Coil Defibrillation Lead"
9721355|NCT04320849||Patients with Medtronic Leads|"Patients with these model: 6935M~Description:Quattro Secure Single Coil Defibrillation Lead"
9721356|NCT04319523||COPD patients|
9721357|NCT04319523||Healthy subjects|
9721358|NCT04318912||COPD patients|Adults age 40 or older with a diagnosis of chronic obstructive pulmonary disease (COPD) having been prescribed any COPD treatment (initial or subsequent) outside of a clinical trial.
9721359|NCT04318457||Brochoscopy|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during bronchoscopy will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
9721360|NCT04318457||ERCP|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during ERCP will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
9721361|NCT04318418||Cases|Patients who developed severe COVID-19 disease (including fatal events)
9721362|NCT04318418||Controls|Infected patients who did not develop severe COVID-19 respiratory disease (including individuals who recovered from the infection)
9721363|NCT04318301||ACEI/ARB|COVID-19 patients with hypertension who had previously taken ACEI/ARB for antihypertensive treatment
9721364|NCT04318301||non ACEI/ARB|COVID-19 patients with hypertension who had not previously taken ACEI/ARB for antihypertensive treatment
9721365|NCT04317690||High Cholesterol|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high cholesterol, who are either taking medication for high cholesterol for 2 years or less; or have discussed managing high cholesterol in the past 2 years. These people will see items only pertaining to high cholesterol.
9721366|NCT04317690||High Blood Pressure|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high blood pressure, who are either taking medication for high blood pressure for 2 years or less; or have discussed managing high blood pressure in the past 2 years. These people will see items only pertaining to high blood pressure.
9721367|NCT04317690||Colorectal Cancer Screening|People between the ages of 50-75 with no previous diagnosis of colon cancer, who have been screened for colon cancer (or discussed screening for colon cancer) in the past 2 years, or who had first colon cancer screening in past 2 years. These people will see items only pertaining to colon cancer screening.
9721368|NCT04317690||Breast Cancer Screening|Females between the ages of 40-50 with no previous diagnosis of breast cancer who have had mammogram (or discussed having a mammogram) in the past 2 years, or had first mammogram in past 2 years. These people will see items only pertaining to breast cancer screening.
9721369|NCT04317690||Prostate Cancer Screening|Men between the ages of 45-69 with no previous diagnosis of prostate cancer who have been screened for prostate cancer (or discussed screening for prostate cancer) in the past 2 years or had first prostate cancer screening in the past 2 years. These people will see items only pertaining to prostate cancer screening.
9721370|NCT04317014||cases|early puberty girls of Han Chinese
10205432|NCT00212121|Experimental|2|high boost (26 Gy)
9721371|NCT04317014||controls|normal development girls of Han Chinese
10196747|NCT05182086|Experimental|Intervention group|Patients that are allocated to the intervention group will participate in a 12 week lifestyle intervention program consisting of group exercise therapy and dietary advice combined with dietary supplementation. The group exercise therapy will be guided by trained physical therapists. Patients will participate in this part of the intervention twice a week for one hour. The exercise therapy will combine cardiorespiratory with strength training. At the start of the intervention, patients will have an appointment with a nutritional scientist or doctor in which they will receive dietary advise and dietary supplements (ProSource®) to reach the advised caloric and protein intake as composed by the Dutch Centre for Nutrition (Voedingscentrum). Dietary supplements like ProSource® are extensively tested and often used as part of general practice to patients after ICU- or hospital-discharge following critical illness.
10196748|NCT05182086|No Intervention|Standard care|Standard care outpatient post-ICU clinic
10196749|NCT05182034|Experimental|Study Group 1: SMUP-IA-01 (low dose)|Investigational Product - 4.0×10^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
9721372|NCT04316299||AKI|COVID-19 patients with acute kidney injury
9721373|NCT04316299||non-AKI|COVID-19 patients without acute kidney injury
9721374|NCT04315818||study group|expermintal
9721375|NCT04315818||control group|placebo
9721376|NCT04312516||Controls|Healthy volunteers without neurocognitive impairment
9721377|NCT04312516||Patients|Patients undergoing surgical procedure with at least mild cognitive impairment preoperatively
9721378|NCT04311853||practitioner interviews|phone interviews conducted
9721379|NCT04311541||Dexlansoprazole|Participants diagnosed with GERD and initiated treatment with dexlansoprazole MR therapy will be observed prospectively at 150 sites in Russian federation for a period of 2 months.
9721380|NCT04309422||Overexpression of PDL1|Overexpression of PDL1
9721381|NCT04309422||Absence of overexpression of PDL1|Absence of overexpression of PDL1
9721382|NCT04308252||Pharmaco-resistant epilepsy (PRE)|Pharmaco resistant patients are defined by seizures despite adequate dosing of ≥2 anticonvulsant drugs.
9721383|NCT04308252||Pharmaco-sensitive epilepsy (PSE)|Pharmaco-sensitive patients are defined by no seizures for 6 months.
9721384|NCT04308252||Sibling control|Sibling of the of the PRE study participants.
9721385|NCT04307719||Mexican Jewish Community|Sample of Patients from the Mexican Jewish Community to be subjected to genetic testing
9780234|NCT03620747|Experimental|Dupilumab|One dose administered every two weeks. A loading dose may be administered at the start of treatment for some patients (e.g., due to previous Dupilumab treatment discontinuation for more than 6 weeks).
9780235|NCT03616782|Experimental|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
9980723|NCT01394731|Experimental|Paraceatmol 2|
9780237|NCT03599297|Experimental|Bilateral synchronous simultaneous stone surgery|Patients who will be operated for kidney stones at both their kidneys in a single surgery session will be included in the study. Patients will undergo percutaneous nephrolithotomy for one side and flexible ureteroscopy for the other side.
9780238|NCT03584763|Active Comparator|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
9780239|NCT03584763|Experimental|Weekly Umbilical Artery Doppler|will undergo Doppler every week
9780240|NCT03579563|Active Comparator|AUD (audiologist-based)|In this group, the audiologist-based fitting will be used to provide hearing aids.
9780241|NCT03579563|Experimental|OTC (over-the-counter)|In this group, the over-the-counter fitting will be used to provide hearing aids.
9780242|NCT03579563|Experimental|OTC-Plus|In this group, the hybrid fitting will be used to provide hearing aids.
9780243|NCT03574571|Experimental|Docetaxel|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
9780244|NCT03574571|Experimental|Docetaxel with Radium-223|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
9780245|NCT03555552|Experimental|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
9780246|NCT03555552|Active Comparator|Duke Central Automated Laboratory (DCAL)|
9780247|NCT03544268|Experimental|Acoustic Angiography|All clinical patients will be included in the experimental group.
9780248|NCT03544268|Experimental|Image Optimization|In addition to clinical patients, 30 participants will be recruited to aid in optimizing the imaging parameters.
9780249|NCT03542877|Experimental|Oral Cabozantinib|Patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
9780250|NCT03530995|Experimental|Part 1, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1
9780251|NCT03530995|Experimental|Part 1, Period 2|"Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9"
9780252|NCT03530995|Experimental|Part 1, Period 3|"Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4."
9780253|NCT03530995|Experimental|Part 1, Period 4|"Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10."
9780254|NCT03530995|Experimental|Part 2, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.
9780255|NCT03530995|Experimental|Part 2, Period 2|"Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4."
9980724|NCT01394731|Active Comparator|Meperidine|
9980725|NCT01394770|Experimental|Aliskiren|
9980726|NCT01394770|Active Comparator|Amlodipine|
9980727|NCT01394783|Other|Classic laryngoscope|Phase 1 and 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
9721386|NCT04305873||EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test <93%
9721387|NCT04305873||Non-EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test >95%
9721388|NCT04305873||Intermediate EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test of 93-95%
9721389|NCT04305093||Precision Analytical patients|Individuals who had laboratory work completed at Precision Analytical and completed the associated questionnaire on symptoms and comorbidities.
9721390|NCT04303351||0-9 missing teeth|participants with 0-9 missing teeth
9721391|NCT04303351||10-19 missing teeth|participants with 10-19 missing teeth
9721392|NCT04303351||23-31 missing teeth|participants with 23-31 missing teeth
9721393|NCT04303351||Edentulous|participants with no teeth
9721394|NCT04303286||Recovery Group|The liver function of HCC patients on the fifth day after the operation is recovered.
9721395|NCT04303286||Recovery Delay Group|The liver function of HCC patients on the fifth day after the operation is delayed recovered.
9721396|NCT04303286||Control Group|The patients on benign disease of the liver
9721397|NCT04301830||Spinal anesthesia|Patients undergoing cesarean section under spinal anesthesia
9721398|NCT04301817||Prone position|Patients undergoing surgery in prone position
9721399|NCT04300543||Group 1 MS patients|patients with multiple sclerosis
9721400|NCT04300543||Group 2 patients with other neurological disorders|patients with inflammatory or non inflammatory neurological diseases other than multiple sclerosis
9721401|NCT04300543||Group 3 healthy control|No neurological or immunological disease
9721402|NCT04300634||Children whose parents are physiotherapists|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
9721403|NCT04300634||Children whose parents are athletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
9721404|NCT04300634||Parents of children who are atletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
9721405|NCT04300634||Parents of children who are physiotherapist|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
9721406|NCT04300088||Patients with advanced solid cancer treated with anti-PD(L)1|Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.
9721407|NCT04297566||Crohn disease's patients|Crohn's disease patients seen in gastroenterology consultation or coming in day hospital for treatment
9721408|NCT04297098||Asthmatic patients|
9721409|NCT04297098||Allergic patients|
9721410|NCT04297098||Control group|
9721411|NCT04296539||Sedentary|Involving little exercise or physical activity
9721412|NCT04296539||Exercise|Subjects who were performing regularly pilates exercises for at least six months
9721413|NCT04296084||healthy individuals|Volunteer healthy individuals who are between the ages of 20-40 and who do not have any medical condition to affect gait or arm swing.
9721414|NCT04295785||autoimmune necrotizing myopathy beginning before 18|
9721415|NCT04292860||Breast Cancer Pts|Post-operative (lumpectomy or mastectomy) female breast cancer patients who will receive radiation to the whole breast or chest wall and the regional nodes.
9721416|NCT04292327||The ordinary COVID-19|Consistent with the diagnosis of ordinary COVID-19.
9721417|NCT04292327||The heavy COVID-19.|Consistent with the diagnosis of heavy COVID-19.
9721418|NCT04292327||The critical COVID-19|Consistent with the diagnosis of critical COVID-19
9721419|NCT04291911||INTENSIVE CARE UNITS|
9721420|NCT04291274||inhalation anesthesia group|Unilateral and Bilateral cochlear implantation,which used inhalation anesthesia
9721421|NCT04291274||intravenous anesthesia group|Unilateral and Bilateral cochlear implantation, which used intravenous anesthesia
9721422|NCT04288557||Sleep clinic patients|All adult patients, from 18 years and up to and including 65 years of age, on the waiting list for overnight polysomnography (PSG) recording at Leicester General Hospital.
10196750|NCT05182034|Experimental|Study Group 2:SMUP-IA-01 (mid dose)|Investigational Product - 1.0×10^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
9721423|NCT04288557||Healthy volunteers|All adults, from 18 and up to and including 65 years of age without a known sleep disorder.
9721424|NCT04288050||Diabetic subjects under dialysis|Diabetic subjects under dialysis
9721425|NCT04288011||Clinical EDSS|The Kurtzke EDSS, is a clinical rating scale for multiple sclerosis having scores between 0 to 10 that are assigned by a trained clinician. Smaller impairments are assessed at lower scores and disability is assessed at higher scores. It is important to note, however, that despite being denoted on an ordinal scale, each level on the scale is not indicative of an equal change in disability.
9721426|NCT04288011||MLA EDSS|The Kurtzke EDSS, is a clinical rating scale or multiple sclerosis having scores between 0 to 10 that are assigned by a technique based upon several different Machine Learning Algorithms that are combined to produce a single score
9721427|NCT04287998||1|PE group
9721428|NCT04287998||2|Control group
9721429|NCT04286659||Control Group|90 Apparently healthy individuals
9721430|NCT04286659||IBD group|90 Previously or Newly Diagnosed Ulcerative Colitis and Crohn's disease
9721431|NCT04286646||Pupil diameter before/after cataract|The investigators measure the pupil diameter before and after (3 months) cataract. Mesopic and photopic conditions
9721432|NCT04286932||5-12y|
9721433|NCT04286217||No prior hypertension (HTN); no HDP in pregnancy|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
9721434|NCT04286217||No prior HTN; de novo HDP, GH type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
9721435|NCT04286217||No prior HTN; de novo HDP, GH type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
9721436|NCT04286217||No prior HTN; de novo HDP, PE type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
9721437|NCT04286217||No prior HTN; de novo HDP, PE type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
9721438|NCT04286217||No prior HTN; no HDP in pregnancy; postpartum HDP|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
9721439|NCT04286217||Pre-existing HTN; no HDP in pregnancy|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
9721440|NCT04286217||Pre-existing HTN; de novo HDP, GH type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
9721441|NCT04286217||Pre-existing HTN; de novo HDP, GH type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
9721442|NCT04286217||Pre-existing HTN; de novo HDP, PE type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
9721443|NCT04286217||Pre-existing HTN; de novo HDP, PE type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
9721444|NCT04286217||Pre-existing HTN; no HDP in pregnancy; postpartum HDP|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia,with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
9721445|NCT04286217||Other causes of macular injury leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury leading to HDP, either gestational hypertension or preeclampsia
9721446|NCT04286217||Other causes of macular injury not leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury not leading to HDP
9721447|NCT04285801||COVID-19 infection|critically ill patients with COVID-19 infection
9721448|NCT04285723||alpelisib|Patients treated with alpelisib
9780256|NCT03527810|Experimental|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
9780257|NCT03527810|Active Comparator|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.[1] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
9780258|NCT03485677|Experimental|Cohort 1: Eliglustat monotherapy|"Eliglustat for at least two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
10196751|NCT05182034|Active Comparator|Active Control Group|Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)
10196752|NCT05182021||Case group|The case group represented by 50 primigravida women aged 35 y or more during their pregnancy or at the time of delivery
10196753|NCT05182021||Control group|The control group represented by 50 primigravida women aged 20 y : 34 y during their pregnancy or at the time of delivery
10196754|NCT05182008|Experimental|Decision Aid|Patients will be guided to an online interactive decision aid tool.
9980728|NCT01394783|Other|Videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
9980729|NCT01394796|Active Comparator|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
9980730|NCT01394796|Placebo Comparator|Placebo|No active substance is given.
10196755|NCT05182008|Active Comparator|Usual Care|Patients will be guided to visit the clinic website of the Nova Scotia Women's Choice Clinic.
9721449|NCT04285294||RDEB patients with a cSCC|
10196756|NCT05181969||Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Apheresis therapy
10196757|NCT05181969||Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Apheresis therapy
9721450|NCT04285294||Non-RDEB patients with a SCC induced by ultraviolet radiation|
9721451|NCT04285294||Healthy donors without RDEB nor SCC|
9721452|NCT04284384||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years of age or older were invited to participate in HUNT4 70+.
9721453|NCT04284384||HUNT Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age or older were invited to participate in HUNT4 70+.
9721454|NCT04282889||Liver transplantation group|"The study population will include 20 adults (age range of 18 - 75 years) who are undergoing liver transplantation. Inclusion criteria are patients undergoing liver transplantation with English as their native language.~Exclusion criteria include patient's refusal, or on medical anticoagulation therapy. Informed consents will be obtained from the patients who agree to participate in this clinical study."
9721455|NCT04282889||Healthy volunteer|The control population will include 20 adult volunteers (age 18-65 years) who meet the in the American Society of Anesthesiologists (ASA) Physical Status (PS) Classes 1 criteria. Exclusion criteria will be refusal, volunteers on any medication or significant history of bleeding.
9721456|NCT04282213||Control samples|For each case, neuromuscular measurements gathered with GE CARESCAPE B450 monitor (E-NMT module).
9721457|NCT04282213||Case samples|For each case, neuromuscular measurements gathered with TOFCuff monitor.
9721458|NCT04280107||Temporomandibular Dysfunction|For this study, 154 patient files who were admitted to the radiology department of the faculty of dentistry between 2013 and 2019 with complaints such as TMJ pain, mouth opening restriction, joint sound, joint function disorder were scanned retrospectively. Inclusion criteria: TMD patients with MR and CBCT images recorded in the digital archive. Exclusion criteria: Patients who have been operated or treated from TMJ, patients with head and neck trauma, patients with orthodontic treatment.
9721459|NCT04279691||periodontitis and rheumatoid arthritis|group 1: patiernts with periodontitis and rheumatoid arthritis. only
9721460|NCT04279691||periodontitis|group 2: patiernts with periodontitis
9721461|NCT04279730||Inpatient pulmonary rehabilitation|Multidisciplinary inpatient pulmonary rehabilitation program lasting 4 weeks (40 sessions, 2 sessions per day, 5 days per week).
9721462|NCT04279327||cases|cytology positive for malignancy
9721463|NCT04279327||controls|cytology negative for malignancy
9721464|NCT04277208||Arthroscopic Rotator Cuff Repair|
9721465|NCT04277078||Intubated asthma attack|Patients who had been hospitalised with asthma attack, then intubated during hospitalisation.
10196758|NCT05181969||Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Apheresis therapy
10196759|NCT05181969||Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Apheresis therapy
9721466|NCT04277078||Non-Intubated asthma attack|Patients who had been hospitalised with asthma attack without intubation during hospitalisation.
9721467|NCT04275544||Patients with PCs|"HOCM Patients developing postoperative complications (PCs) following septal myectomy.~PCs include all-cause mortality, heart failure, low cardiac output syndrome, stroke, spinal cord injury, acute respiratory distress syndrome, reintubation, reoperation, permanent implantable cardioverter defibrillator, kidney injury, renal failure, liver injury, and liver failure."
9721468|NCT04275544||Patients without PCs|HOCM Patients do not develope postoperative complications following septal myectomy.
9721469|NCT04275154||CAR-T patients|Relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) or acute lymphoblastic leukemia (ALL) with intent to undergo commercially available CAR-T cell therapy
10196760|NCT05181943|Experimental|Laser irradiation (Test group)|laser irradiation over lesion
10196761|NCT05181943|Active Comparator|Conventional treatment (Control group|
9721470|NCT04274621||Patients, family members of patient, medical staff|
10196762|NCT05181917|Experimental|Intervention|Patients assigned to the intervention group will receive the STUDIA application on their mobile device, which has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
9721471|NCT04273711||Obese patients|
9721472|NCT04273711||Non-obese patients|
9721473|NCT04272710||ACEI treatment|hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
9721474|NCT04272710||Control|hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
9721475|NCT04272723||VMP members of the SFMV|VMP (vascular medicine physicians) members of the SFMV (French Society of Vascular Medicine )
9721476|NCT04272723||VMP registered as willing to do medical research|VMP (vascular medicine physicians) registered as willing to do medical research
9721477|NCT04271982||Cohort A|Cohort A includes patients (N=20 000) screened for nutritional risk at Haukeland University Hospital (HUS) during point prevalence surveys between 2008 and 2018. The point prevalence surveys included all adult patients in somatic departments, and were performed 2-4 times per year since 2008. We expect the sample in the study to include approx. 9000 patients ≥ 65 years.
9721478|NCT04271982||Cohort B|"Cohort B includes older service users (≥65 years) with information on nutrition variables from the KPR-registry in the period 2016 to 2018 (n=approx. 270 560). All Norwegian municipalities report data on nutritional risk screening and nutrition plan for individual service users in Kommunalt pasientregister (KPR). These nutritional data will be linked to registry data on health care services use and patient outcome variables from the The Norwegian Patient Registry (NPR)"
9721479|NCT04267406||Cirrhosis|Patients who diagnosed as cirrhosis. 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
9721480|NCT04267406||Non-cirrhotic portal hypertension|Patients who diagnosed as extrahepatic portal hypertension (due to portal vein thrombosis). 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
9721481|NCT04267406||Control|Healthy volunteers, who admitted to our hospital for any complaints, but was not determined any organic disease. 2 ml EDTA blood sample was taken from healthy volunteers, during their hospital admition. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
9780259|NCT03485677|Experimental|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for two years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
9780260|NCT03480464|Experimental|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
9780261|NCT03480464|No Intervention|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
9780262|NCT03477513|Experimental|Single Arm|Dose-escalated radiation therapy
9780263|NCT03465527|Experimental|Prednisolone|"Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days~Hydration, antibiotics, allopurinol, nutritional supplements, and so on."
9785222|NCT01246063|Experimental|Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)|"Dose Level 1: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (36 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.~Dose Level 1: Carfilzomib IV (1 dose level above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (1 dose level above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (1 dose level above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.~Dose Level 2: Carfilzomib IV (2 dose levels above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (2 dose levels above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (2 dose levels above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib."
9785223|NCT01246063|Experimental|Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)|Dose Level 2: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (45 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
9785224|NCT01246063|Experimental|Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)|Dose Level 3: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (56 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
9785225|NCT01246063|Experimental|Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)|Cohort 0: Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
9785226|NCT01246063|Experimental|Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)|Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
9785227|NCT01246076|Experimental|Lenalidomide|"Lenalidomide 50 mg/day for two 28 day cycles.~Patients who have bone marrow aplasia as defined by a cellularity of <10% will be observed till counts recover. If patients do not progress following 2 cycles of HD lenalidomide, they will receive low dose lenalidomide 10 mg daily for 12 cycles."
9785228|NCT01246206|Experimental|Tacrolimus and Thymoglobulin|Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis
9785229|NCT01246258||Test group|Standard tests of balance function
9785230|NCT01246349|Experimental|Motivational Interviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical psychology doctoral student trained in Motivational Interviewing administered six individual motivational interviewing treatment sessions, each 30 minutes in length.
9721482|NCT04264169||• Study group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will be complicated by placenta accreta spectrum
9721483|NCT04264169||• Control group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will not be complicated by placenta accreta spectrum
9721484|NCT04263727||Asthma|Non-Interventional. Patients with asthma will be screened and enrolled into the active Asthma disease-specific cohort.
9721485|NCT04263727||Chronic Obstructive Pulmonary Disease (COPD)|Non-Interventional. Patients with COPD will be screened into the inactive COPD disease-specific cohort.
9721486|NCT04263727||Idiopathic Pulmonary Fibrosis (IPF)|Non-Interventional. Patients with IPF will be screened into the inactive IPF disease-specific cohort.
9721487|NCT04263389||control group|control group is a normal matched group.
10196763|NCT05181917|Active Comparator|Control|The patients assigned to the control group will also receive the STUDIA application on their mobile devices. The insulin dose calculation process is the same as that described for the intervention group. However, the simulation results will be kept hidden from the patient.
10196764|NCT05180292|Experimental|Acute on Chronic Liver failure|
10196765|NCT05180201|Experimental|LP7+FOS|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) with 150mg fructooligosaccharide (FOS) and 100mg maltodextrin, for 7 days.
10196766|NCT05180201|Experimental|LP7|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) plus 250mg maltodextrin, for 7 days.
10196767|NCT05180201|Experimental|LP1+FOS|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) with 150mg FOS and 100mg maltodextrin, for one day, followed by 6 days of placebo (250mg maltodextrin).
10196768|NCT05180201|Experimental|LP1|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) plus 250mg maltodextrin for one day, followed by 6 days of placebo (250 mg maltodextrin).
10196769|NCT05180201|Placebo Comparator|Placebo|Once daily oral administration of placebo (250 mg maltodextrin), for 7 days.
10196770|NCT05179382|Active Comparator|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol.
10196771|NCT05179382|Experimental|Hydration protocol|This intervention will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery.
10196772|NCT05177939|Experimental|NPB-01|Intravenous immunoglobulin
9721488|NCT04263389||study group|study group is a group of chronic mechanical cervical pain
9721489|NCT04262297||Prosthesis users|Prosthesis users with transtibial amputation
9721490|NCT04262297||Able-bodied Controls|Prosthesis users' age-, sex- and dominancy-matched healthy controls
9721491|NCT04261582||AERD participants|Participants with aspirin exacerbated respiratory disease. Adults with aspirin allergy, nasal polyps and adult-onset severe asthma.
9721492|NCT04261582||Healthy controls|Healthy participants that do not have asthma.
9721493|NCT04261582||Non-aspirin sensitive asthma participants|Participants with asthma, but that do not have a sensitivity to aspirin.
9721494|NCT04260074||Oral Cancer group|20 consecutive patients with oral squamous cell carcinoma referred to the Department of Otolaryngology - Head and Neck Surgery
9721495|NCT04260074||Healthy oral mucosa group|20 controls with normal buccal mucosa upon examination.
9721496|NCT04259372||Primary Diagnosis|Analysis of patient blood at primary diagnosis of AML
10196773|NCT05177939|Active Comparator|NPB-01-ME|methylprednisolone sodium succinate
10196774|NCT05177718|Other|Treatment Single Arm|SINGLE ARM: 30 patients with multiple sclerosis treated with Natlizumab infusion given monthly at the dose of 300 mg IV
9721497|NCT04259372||Relapse|Analysis of patient blood at time point of relapse after allo-HCT
9721498|NCT04259372||Remission|Analysis of patient blood during remission after allo-HCT
9721499|NCT04257864||Erlotinib followed by docetaxel|Erlotinib given for twelve consecutive days before docetaxel
9721500|NCT04257864||Docetaxel followed by erlotinib|Erlotinib given for twelve consecutive days after docetaxel
9721501|NCT04257864||Bevacizumab treated|Bevacizumab treated patients
9721502|NCT04257903||Occlusal Splint Therapy|The data of patients who previously received occlusal splint therapy were evaluated. Participants in the study received occlusal splint therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received occlusal splint therapy as part of routine medical care, and a researcher studied the effect of occlusal splint therapy.
9721503|NCT04257903||Low-Level Laser Therapy|The data of patients who previously received Low-Level Laser Therapy were evaluated. Participants in the study received Low-Level Laser Therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received Low-Level Laser Therapy as part of routine medical care, and a researcher studied the effect of Low-Level Laser Therapy.
9721504|NCT04257669||Iron sufficient|Haemoglobin ≥120g/L Serum ferritin > 20μg/L
9721505|NCT04257669||Non-anaemic iron deficient|Haemoglobin ≥120g/L Serum ferritin ≤ 20μg/L
9721506|NCT04257669||Iron deficient anaemic|Haemoglobin <120g/L Serum ferritin ≤ 20μg/L
9721507|NCT04257669||Anaemic without iron deficiency|Haemoglobin <120g/L Serum ferritin > 20μg/L
9721508|NCT04256044||Observational|Observational
9721509|NCT04254276||Symptomatic group|Office workers with neck and shoulder area musculoskeletal pain
9721510|NCT04254276||Asymptomatic group|Office workers without neck and shoulder area musculoskeletal pain
9721511|NCT04253613||periodontal therapy|Systemically healthy subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
9721512|NCT04253613||periodontal+laser therapy|Systemically healthy subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment(NSPT) split-mouth designed study
9721513|NCT04253613||diabetic periodontal therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
9721514|NCT04253613||diabetic periodontal+laser therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment (NSPT) split-mouth designed study
9721515|NCT04251702||Healthy Low-Risk Nulliparous Women in Spontaneous Labor|Healthy Nulliparous women with a Singleton Term fetus in the Vertex position in spontaneous labor.
9721516|NCT04251338||delayed visual maturation|children with delayed visual maturation
9721517|NCT04250818||Control Group|Patients with mTNBC who receive chemotherapy only
9721518|NCT04250818||Experimental Group|patients with mTNBC who receive a combination of chemotherapy and Immunotherapy
9721519|NCT04250103||patient|patients who receive home health care
10196775|NCT05175118|Other|Minimally invasive fixation|Minimally Invasive Surgical Fixation for Unstable Fractures of the distal end Radius in Adults
10196776|NCT05172908|Active Comparator|Group Dexa|"After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study"
9721520|NCT04250103||caregiver|caregivers who take care of patients with home health care
9721521|NCT04247178||Patients undergoing elective orthopaedic surgery|
9721522|NCT04247178||Healthy Volunteers|
9721523|NCT04246840||Study group|15 adult patients who underwent allogenic hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficieny 15 to 45 years ago
9721524|NCT04246840||Control group|15 age-matched healthy individuals
9721525|NCT04245800||Observational|All participants will be part of the prospective observational cohort. If participants develop flu-like symptoms, they will be prompted to complete the flu@home self-test kit. Analysis will be conducted for various subgroups (e.g. age, vaccination status)
9721526|NCT04245891||Control group|boli of ephedrine phenylephrine (45μg/mL-3mg/mL) if the variation of MAP < 20% of baseline (MAP before spinal anaesthesia).
9721527|NCT04245891||Protocol group|continuous infusion of norepinepineprhine at 20 μg/mL, started at 0.05 μg/kg/min. The dosage of norepinephrine was then adjusted to maintain a variation in MAP < 20% of baseline. In case of failure, the use of a control group boli injection was possible.
9721528|NCT04245904||proffesional basketball player|
9721529|NCT04245904||sedentary control|
9721530|NCT04242849||IDH1/2 mutated patients|Patients harboring mutations in IDH1 or IDH2 genes
9721531|NCT04242849||Patients without IDH1/2 mutations|Patients that don´t present any mutation in IDH1/2 genes
9721532|NCT04242784||Spoke Hospital|Patients that undergo the Code Stroke process at Spoke Hospitals
9721533|NCT04242784||Hub Hospital|Patients that undergo the Code Stroke process at Hub Hospitals
9721534|NCT04242784||Transfer|Patients that undergo the Code Stroke process at a Spoke Hospital and transfer to the Hub Hospital
9721535|NCT04241445||novice observers|who have practiced GMA sporadically (def.: < = 2 GMA/week for < = 2 years), have limited experience, and do not use GMA in clinical settings
9721536|NCT04241445||GMA experts|GMA tutors and individuals who have applied GMA regularly (def.: > 2 GMA/week for > 2 years)
9780264|NCT03455582|Experimental|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
9780265|NCT03455582|Active Comparator|Control|40 Healthy controls
9780266|NCT03450343|Experimental|Oral azacitidine + R-ICE|Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
9780267|NCT03443973|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
9780268|NCT03443973|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
9780269|NCT03439839|Experimental|Arm 1|10 patients receiving LNP023 high dose daily over up to approximately 3 years
9780270|NCT03439839|Experimental|Arm 2|5 patients receiving LNP023 low dose daily over up to approximately 3 years
9780271|NCT03437395|Other|Partial Breast Irradiation|All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
9780272|NCT03423121|Experimental|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
9780273|NCT03423121|Placebo Comparator|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
9780274|NCT03421197|Experimental|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
9780275|NCT03421197|Experimental|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
9780276|NCT03421197|Experimental|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
9780277|NCT03421197|Placebo Comparator|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
9780278|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fasting|One tablet of IBUCR 600 mg under fasting condition
9780279|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fed|One tablet of IBUCR 600 mg under fed condition
9780280|NCT03418805|Active Comparator|Advil Ibuprofen table 200 mg-fasting|IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
9780281|NCT03418805|Active Comparator|Motrin IB Ibuprofen Tablets 200 mg-fasting|IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition
9780282|NCT03413384|Experimental|Ceftriaxone|"Name: Ceftriaxone~Dosage form: crystalline powder for intramuscular injection~Dose(s): 1 g~Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
9780283|NCT03413384|Placebo Comparator|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
9780284|NCT03411356|Active Comparator|Daily Caloric Restriction (DCR)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
9721537|NCT04239404||PMI|
9721538|NCT04239404||non-PMI|
9721539|NCT04237636||Patients with post-operative AKI|"Patients developing acute kidney injury (AKI) following heart valve replacement surgery.~AKI was classified according to the KDIGO definition[10]. Stage-1 AKI: increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.5μmol/l) or increase to more than or equal to 150% to 200% (1.5≤x<2) from baseline within 7 days. Stage-2 AKI: Increase in serum creatinine to more than 200% to 300% (2≤x<3) from baseline. Stage-3 AKI: Increase in serum creatinine to more than 300% (3≤) from baseline (or serum creatinine of more than or equal to 4.0 mg/dl (≥ 353.6μmol/l) or when the patient commenced RRT."
9721540|NCT04237636||Patients without post-operative AKI|Patients with normal kidney function (without acute kidney injury (AKI)) following heart valve replacement surgery
9721541|NCT04236375||Normal|Subjects over 45 years old without cognitive dysfunction
9721542|NCT04236375||Mild cognitive decline|Subjects who are diagnosed as mild cognitive decline(MCI) according to neurologists.
9721543|NCT04236375||Alzheimer's disease|Subjects who are diagnosed as Alzheimer's disease(AD) according to neurologists.
9721544|NCT04236375||Vascular dementia|Subjects who are diagnosed as vascular dementia(VD) according to neurologists.
9721545|NCT04236375||Lewy body dementia|Subjects who are diagnosed as Lewy body demenita (DLB) according to neurologists.
9721546|NCT04236375||Frontotemporal dementia|Subjects who are diagnosed as Frontotemporal demenita (FD) according to neurologists.
9721547|NCT04236375||Other dementia|Subjects who are diagnosed as dementia but are not as AD, VD, DLB OR FD.
9721548|NCT04235348||BELIEVE|Consists of subjects referred to a colonoscopy between June 1, 2017, and December 1, 2019, in the hospital of Southern Denmark
9721549|NCT04235543||autistic children aged 6:12 years|show the occurrance of traumatic dental injury compared to normal children
9721550|NCT04235543||normal children aged 6:12 years|show the occurrance of traumatic dental injury
9721551|NCT04235530||VAS and DVAS|To measure the pain score of patients after surgery
9721552|NCT04234984||Conventional radiofrequency treatment|All patients with chronic knee pain who qualify for a conventional RF treatment of the genicular nerves
9721553|NCT04234919||Consented adult lung transplant recipients|
9721554|NCT04234633||SLE patients|Any SLE patients between 18 and 40 years old.
9721555|NCT04233944||Pregnant women and their infants|Mothers and their infants were followed throughout the first two years of the infant's life. Data were collected at enrollment, birth, 3, 6, 9,12, 18 and 24 months from the date of delivery.
9721556|NCT04231487||Essential tremor|"This is not an intervention study.~Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days"
9721557|NCT04231487||Parkinson's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days"
9721558|NCT04231487||Huntington's Disease|"This is not an intervention study.~Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days"
9721559|NCT04231487||Primary Focal Dystonia|"This is not an intervention study.~Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days"
9721560|NCT04231487||Spinocerebellar Ataxia|This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days
9721561|NCT04231487||Functional Movement Disorder|This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days
9721562|NCT04231487||Healthy Controls|"This is not an intervention study.~People with Healthy Controls"
9721563|NCT04231188||Primary Caregiver and infant pair|Primary Caregiver and infant who is less than or equal to 12 months old
9721564|NCT04230486|Experimental|Experimental Group Virtual Reality (VR) Treatment|Visual Auditory Virtual Reality rehabilitation for visual hemianopia
9721565|NCT04230200||Healthy cohort|People who received routine physical examination including blood test, and after 3 year follow-up, have not been diagnosed as any kind of malignant tumor.
9721566|NCT04230200||Malignancy Cohort|People who were diagnosed as one of the following malignant disease: breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer
9721567|NCT04227171||FSH only|GnRH agonist protocol & GnRH antagonist protocol
9721568|NCT04227535||Rheumatoid arthritis - Interstitial lung disease patients|"Assessment are as follows :~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic: chest HRCT scan~Genetic: DNA, mRNA~Biologic: serum"
9721569|NCT04227535||Rheumatoid arthritis - no Interstitial lung disease patients|"Assessment are as follows :~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic: chest HRCT scan~Genetic: DNA, mRNA~Biologic: serum"
9721570|NCT04225546||Patient group|Patients with hemiplegic and diplegic cerebral palsy between 4 - 10 years of age
9721571|NCT04225546||Control group|Healthy volunteer typically developing peers
9721572|NCT04222907||Women screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were screened for GBS during pregnancy
9721573|NCT04222907||Women not screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were not screened for GBS during pregnancy
9721574|NCT04217616||Headache Resistant Participants|Male participants who have never had a headache.
9721575|NCT04217616||Non-Resistant Participants|Male participants who have experienced headache. Age matched.
9721576|NCT04216498||Pre-Transfer Patients aged 10-16 years|
9721577|NCT04216498||Post-Transfer Patients aged 16-25 years|
9721578|NCT04216498||Parents/Guardians of Pre-Transfer Patients|
9780285|NCT03411356|Experimental|Intermittent Fasting (IMF)|Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
9721579|NCT04215874||Dorsal penile nerve block group|"Ultrasound (US) guided dorsal penile nerve block with in plane technique was done.~Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis."
10196777|NCT05172908|Sham Comparator|Group S|"After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 50 mL normal saline in a 50 ml syringe will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study"
9721580|NCT04215874||Caudal epidural block group|A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed 0.25% bupivacaine at a dose of 0.2 ml/kg was administered.
9780286|NCT03399981||Tysabri (TOUCH Cohort)|Participants from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
9780287|NCT03399981||Tysabri (EU MS Cohort)|Participants from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
10196778|NCT05172284||Psoriasis|
9780288|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing"
9780289|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing~Blood sampling:~A blood sample collected by fingerprick"
9780290|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
9780291|NCT03385928|Active Comparator|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl (or in 50ml syringe with 0.9% NaCl) over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
9780292|NCT03385928|Placebo Comparator|Normal Saline (0.9% NaCl)|100 mls (or in 50ml syringe) intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
9780293|NCT03380559|Experimental|Group A : Association (botulinum toxin + corticoid)|
9780294|NCT03380559|Placebo Comparator|Group C : placebo of toxin + corticoid :|
9780295|NCT03380559|Active Comparator|Group T : botulinum toxin + placebo corticoid|
9780296|NCT03375385|Other|Hemodynamic parameters|
9780297|NCT03375385|Other|Ramsay sedation score|
9780298|NCT03375385|Other|Intraoperative side effects|
9780299|NCT03375385|Other|recovery of sedation|
9780300|NCT03374449|Experimental|continuation of the RAS-inhibitors|in the continuation of the RAS-inhibitors arm the treatment will be continued until the morning the day of surgery.
9780301|NCT03374449|Active Comparator|discontinuation of the RAS-inhibitors|In this arm : discontinuation of the RAS-inhibitors 48 hours before surgery Patients won't receive the drug on the morning of the day of the surgery.
9780302|NCT03371108|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
9780303|NCT03371108|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
9780304|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
9780305|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
9780306|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
9780307|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
9780308|NCT03358693||Psoriasis patients receiving brodalumab|Brodalumab
9780309|NCT03358693||Psoriasis patients receiving Ixekizumab|Ixekizumab
9780310|NCT03358693||Atopic dermatitis patients receiving tralokinumab|Tralokinumab
9780311|NCT03358693||Atopic dermatitis patients receiving baricitinib|Baricitinib
9780312|NCT03358693||Atopic dermatitis patients receiving abrocitinib|Abrocitinib
9780313|NCT03358693||Atopic dermatitis patients receiving upadacitinib|Upadacitinib
9780314|NCT03342586||Central Nervous System Lymphoma|Participants will have non-Hodgkins lymphoma involving the brain (primary or secondary)
9780315|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
10196779|NCT05172284||Psoriatic arthritis|
9780316|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
9780317|NCT03340675|Experimental|Oral Ifetroban - Low Dose|Weight based, once daily oral ifetroban
9780318|NCT03340675|Experimental|Oral Ifetroban - High Dose|Weight based, once daily oral ifetroban
9780319|NCT03340675|Placebo Comparator|Placebos|Matching Placebo
9780320|NCT03336372|Experimental|Picato topical gel|
9780321|NCT03329001|Experimental|Stage 1: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase
9780322|NCT03329001|Experimental|Stage 1: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
9780323|NCT03329001|Experimental|Stage 2: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase.
9780324|NCT03329001|Experimental|Stage 2: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
9780325|NCT03329001|Experimental|Stage 3: High fat meal-fasted sequence|Single dose niraparib tablet with a high fat meal followed by single dose of niraparib tablet in a fasted state.
10196780|NCT05172284||Atopic dermatitis|
9721581|NCT04214964||Gynecological cancer|patients who has been pathological diagnosed with Gynecological cancers between 2002 and 2022 in China
9721582|NCT04213326||Cancer Cohort|Subjects interested in the cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
9721583|NCT04213326||Non-Cancer Cohort|Subjects interested in the non-cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
9721584|NCT04212312||Single course of Betamethasone|Women with twin pregnancy who received 1 course of betamethasone between 24 - 34 weeks' gestation.
9721585|NCT04212312||Repeat course of Betamethasone|Women with twin pregnancy who received 2 courses (Repeat course) of betamethasone between 24 - 34 weeks' gestation.
9721586|NCT04212156||TMH test|Patient will be asked to lay supine while the head and neck maintained in a neutral position using a pillow under the head. By using digital depth gauge, the TMH will be measured from the anterior border of the thyroid cartilage directly on the thyroid notch till the anterior border of the mentum
9721587|NCT04210297||Training cohort|Training cohort consists of the cirrhotic patients who collected from January 2018 to December 2019 of Qilu Hospital retrospectively.
9721588|NCT04210297||Internal validation cohort|Internal validation cohort consists of the cirrhotic patients who enrolled from January 2020 of Qilu Hospital prospectively.
9721589|NCT04210297||External validation cohort|External validation cohort consists of the cirrhotic patients who enrolled from January 2020 in Jinan Central Hospital prospectively.
9721590|NCT04209829||Patients with haematological malignancy|Patients, aged 15 years or over, with haematological malignancy (Lymphoma, ALL, MM) integrated into a CAR-T Cells program treatment
9721591|NCT04208295||Patients|Type 2 diabetics
9721592|NCT04208295||Healthy controls|Matched healthy controls
9721593|NCT04205318||study|obese (BMI ≥25.00 kg/m2, n=200)
9721594|NCT04205318||control|non-obese (BMI= 18.50-24.99 kg/m2, n=200)
9721595|NCT04205006||STROKE CARD Cohort|Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).
9721596|NCT04204317||Autofluorescence|"The surgeon will perform the preplanned operation with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date~Duration of surgery~Operation performed~Procedure related comments~Number and location of the visualized glands~Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
10196781|NCT05172284||Chronic urticaria|
10196782|NCT05172284||Suppurative hydrosadenitis|
10196783|NCT05172284||Systemic lupus erythematosus|
9721597|NCT04204317||Control|"The surgeon will perform the preplanned operation without FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date~Duration of surgery~Operation performed~Procedure related comments"
9721598|NCT04201509||ADHD group|Participants in the clinical group were recruited to the project when they were assessed for and diagnosed with ADHD at the Neuropsychiatric Unit of the CAP Clinic in Lund in 2011-2012. The ADHD group was treated as usual in the clinic and re-assessed during 2014-2015.
9721599|NCT04201509||Non-clinical group|Participants in the non-clinical group were recruited recruited 2012 from schools in the same district and among children of the same average age as the ADHD-group 2012. The non-clinical group did not have any intervention during the follow-up time. Th non-clinical group was re-assessed during 2015.
9721600|NCT04200625||Semaglutide|Patients using standard of care weekly GLP-1A analog Semaglutide
9721601|NCT04200625||Dulaglutide|Patients using standard of care weekly GLP-1A analog Dulaglutide
9721602|NCT04200625||Metformin|Patients using standard of care daily Metformin.
9721603|NCT04200378||Subjects undergoing TMVr|Subjects with severe, symptomatic primary mitral regurgitation (MR) scheduled to undergo a transcatheter mitral valve repair (TMVr) as standard of care will have intra-op baseline and post repair blood draws. Pre-procedure and post-procedure transthoracic echocardiograms (TTE) will assess the hemodynamic implications of the repair.
9721604|NCT04200495||Healthy Controls|No sleep-wake disorder present
9721605|NCT04200495||Active Sleep-Wake Disorder|Presence of Sleep-Wake Disorder
9721606|NCT04199663||categories of Socioeconomic Status (SES)|"by proxy gender- and calendar year-specific quintiles of disposable income per household consumption unit.~In logistic regression models of associations with secondary prevention activities and established treatment goals: highest vs. lowest income quintile.~In multivariable Cox regression analyses with stepwise built models: quintiles of disposable income and models including covariates level of education and marital status."
9721607|NCT04199195||Males and females aged at least 60 years.|"A longitudinal study of one cohort of 360 participants aged at least 60 years. Participants will be required to provide a stool sample, provide a blood sample and complete a health questionnaire every 6 months for 4 years. At alternate visits, participants will be required to under go cognitive assessments and physical measurements.~Participants will be required to under go an Optical Coherence Tomography Scan 3 times over 4 years.~Sub group 1 - During a routine care colonoscopy, at least 90 participants will have 6-8 colon tissue biopsies taken for research purposes.~Sub group 2 - Participants from cohort 3 only will be offered an optional brain MRI until the required number of 30 participants is achieved."
9721608|NCT04198415||Venetoclax Participants|Participants prescribed and treated with venetoclax.
9721609|NCT04198025||Patients who underwent colorectal resection|"Patients in this observational study will have undergone CT scan as routine work up prior to resection of elective colorectal cancer.~Psoas muscle density will be measured (in Hounsfield units from CT images) at lumbar vertebral level L3."
9721610|NCT04196920||Cohort with TNF combination therapy|Cohort with TNF combination therapy (infiximab/adalimumab) with azathiorpine
9721611|NCT04196920||Cohort with anti-TNF combination therapy|Cohort with anti-TNF combination therapy (infiximab/adalimumab) with methotrexate
10196784|NCT05172284||Acne vulgaris|
10196785|NCT05172284||Rosacea|
10196786|NCT05172284||Seborrheic dermatitis|
10196787|NCT05172284||Contact dermatitis|
10196788|NCT05172284||Chronic eczema of the hands|
10196789|NCT05172284||Vitiligo|
9721612|NCT04196192||Group 1|All infants aged 0-90 days (inclusive) undergoing routine assessments for fever without source.
9721613|NCT04192396||RIF patients|Repeated implantation failure patients
9721614|NCT04192396||Oocyte/embryo donation program|Patients awaiting for oocyte/embryo-donation recipient patients
9721615|NCT04192188||Test Group|Patients undergoing supportive periodontal therapy and independently antiresorptive therapy.
9721616|NCT04192188||Control Group|Patients undergoing supportive periodontal therapy without the need for antiresorptive therapy.
9721617|NCT04191915||Frail|Participants with 3 or more components of Fried frailty scale
9721618|NCT04191915||Moderately Frail|Participants with 1-2 components of Fried frailty scale
9721619|NCT04191915||Not Frail|Participants without any components of Fried frailty scale
9721620|NCT04191707||Outpatients with Inflammatory Bowel Disease|This study was performed with plasma samples from IBD patients recruited in a previous study after informed consent. (1) IBD outpatients attending the Hospital de Sabadell Gastroenterology Day-care unit were consecutively included for analytical monitoring of immunosuppressant treatment or infliximab infusion
9721621|NCT04190329||10 non-frail (robust) study patients|Patients fulfill 0 criteria according to modified Fried frailty score.
9721622|NCT04190329||10 pre-frail study patients|Patients fulfill 1-2 criteria criteria according to modified Fried frailty score.
9721623|NCT04190329||10 frail study patients|Patients fulfill 3, 4 or 5 criteria according to modified Fried frailty score.
9780326|NCT03329001|Experimental|Stage 3: Fasted-high fat meal sequence|Single dose niraparib tablet in a fasted state followed by single dose Niraparib tablet with a high fat meal.
9780327|NCT03319667|Experimental|Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm|"Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone~Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone"
9780328|NCT03319667|Active Comparator|Bortezomib/Lenalidomide/Dexamethasone = VRd arm|"Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone~Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone"
9780329|NCT03319667|Other|Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm|4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone
9780330|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI >=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
9780331|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
9780332|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
9780333|NCT03274869||Scrub typhus without cardiovascular complications|Any participants with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
9780334|NCT03274869||Scrub typhus with cardiovascular complication|Any participants with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
9780335|NCT03270891|Active Comparator|Delayed intervention (control arm)|Patients in this arm will have PGx test results made available to physicians 3 months after study enrollment
9780336|NCT03270891|Experimental|PGx Test|Patients in this arm will have PGx test results made available to physicians as soon available after enrollment.
9780337|NCT03270176|Experimental|Debio 1143 and Avelumab|"Part A: Participants will receive Debio 1143 100 to 250 milligram (mg) capsule orally at an escalating dose levels for 10 days every 2 weeks along with avelumab 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion every 2 weeks.~Part B: Participants will receive Debio 1143 capsules orally at a recommended phase 2 dose (RP2D) of 200 mg/day (days 1-10 and 15-24 every 28 days ([q4w]) in combination with avelumab IV infusion at the standard dose unless disease progression or unacceptable toxicity occurs, as judged by investigators up to 26 cycles (each cycle is of 28 days)."
9780338|NCT03245489|Experimental|Group 1|Group 1 will be treated with Regimen A, followed by Regimen B. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks. Regimen B is pembrolizumab alone for 6 weeks.
9780339|NCT03245489|Experimental|Group 2|Group 2 will be treated with Regimen B, followed by Regimen A. Regimen B is pembrolizumab alone for 6 weeks. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks.
9980731|NCT01394809|Experimental|Mental Practice|During motor imagery practice a person imagines performing a movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of movement performance. The guideline offers therapists structure and a strategy to deliver subject-specific imagery, and is based on principles of motor learning.
9785231|NCT01246349|Active Comparator|Control Group|The comparison group received six social skills training sessions instead of Motivational Interviewing (MI).
9980732|NCT01394809|Experimental|Mirror Therapy|Mirror therapy is thought to work by using vision of the intact or good arm to replace or drive proprioception in the affected arm, and so normalise the afferent segment of the movement process.
9721624|NCT04190420||Patients|250 patients with primary hypertension
9721625|NCT04190420||Healthy Controls|60 healthy control subjects, matched in age and gender
9721626|NCT04189627||Participants Treated with GLE/PIB|Participants treated with all oral glecaprevir/pibrentasvir (GLE/PIB) and the decision to treat with GLE/PIB is made before the decision to offer an opportunity to join this study. Prescription of the treatment regimen is at the discretion of the physician and in accordance with local clinical practice and label.
9721627|NCT04189692||Patients with Inflammatory Bowel Disease and fatigue|Patients with Inflammatory Bowel Disease and fatigue that participated in the two studies (1,2).
9721628|NCT04189042||Parkinson Group|Patients with Parkinson's Disease (Hoehn and Yahr stage 1-4)
9721629|NCT04189042||Healthy Control|Healthy People
9721630|NCT04187079||IPF|Patients diagnosed with idiopathic pulmonary fibrosis after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
9721631|NCT04187079||Other ILDs|Patients diagnosed with other interstitial diseases other than IPF after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
9721632|NCT04186858||Symptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Symptomatic group where cell samples will be collected from the front surface of the subject's eyes.
9721633|NCT04186858||Asymptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Asymptomatic group where cell samples will be collected from the front surface of the subject's eyes.
9721634|NCT04186195||Diabetic children aged 1-16 years and their families|Diabetic children aged 1-16 years and their families. A child's disease duration must be over 1 year so that possible remission period is over.
9721635|NCT04186130||SB|Children over 3 years old and under 12 years old who have been diagnosed with spinal bifida with spinal MRI. They should not have known inflammatory bowel disease or cloacal anomaly
9721636|NCT04186130||Control|Children over 3 years old and under 12 years without known inflammatory bowel disease or cloacal anomaly
9721637|NCT04184765||Total laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
9721638|NCT04184765||Abdominal hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
9721639|NCT04184219||Group|People potentially interested in health issues
9721640|NCT04183439||Surgeons Interviewed|We recruited surgeons from two University academic health centers, one specializing in adults and the other in children. The surgeons were selected through a snowball technique and emailed to participate. DK and GS interviewed eleven surgical attendings representing 10 surgical specialties. (Table 2) Each subject had at least 10 years of experience in their respective fields and regularly taught residents.
9721641|NCT04182685||ZIKV-exposed children|Children age 5-15 with a positive Zika virus PCR test result.
9721642|NCT04182685||ZIKV-unexposed children|Children age 5-15 who have not had a Zika virus infection as determined by serological assays.
9721643|NCT04180891||successful test|Students that have successfully passed the test procedure (directly with written exam or after written and oral interviews) and that can enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery).
9721644|NCT04180891||failed test|Students that have failed to enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery) after the selection procedure.
9721645|NCT04177316||hypermethylation|The hypermethylation group was defined as differential methylation status of tumor- normal ≥ 5%.
9980733|NCT01394809|Active Comparator|Relaxation training|The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
9980734|NCT01394822||Ultrasound results reported|
9980735|NCT01394822||Ultrasound results NOT reported|
9721646|NCT04177316||hypomethylation/no change|The hypomethylation were defined as differential methylation status of tumor- normal <5%
9721647|NCT04175080||Control|
9721648|NCT04175080||HFpEF group|
9721649|NCT04175080||Hypertensive group|Patients in which the results of BNP/NT-proBNP did not confirm the diagnosis of HFpEF were classified as hypertensive group.
9721650|NCT04172194||PT Group|patients with hepatocellular carcinoma treated by percutaneous thermoablation alone
9721651|NCT04172194||PT+TAC group|patients with hepatocellular carcinoma treated by pecutaneous thermoablation comined in a single session with trans-arterial chemoembolization
9721652|NCT04169581||Experimental Group|The experimental group received 18F-FDG PET examination
9980736|NCT01394835|Experimental|Alpha -1 Antitrypsin|
9721653|NCT04169581||Control Group|The control group received 18F-FDG PET examination
9721654|NCT04169165||compliant patients|Patients with compliance to suggestions on metabolic evaluation and dietary/medical advices
9721655|NCT04169165||non-compliant patient|Patients without compliance to suggestions on metabolic evaluation and dietary/medical advices
9785232|NCT01246401|Active Comparator|Extended-Release Naltrexone|Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
9980737|NCT01394848|Active Comparator|Genous stent group|Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
9980738|NCT01394848|Active Comparator|Xience stent group|Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
9980739|NCT01394848|Active Comparator|Atorvastatin 20mg group|
9980740|NCT01394848|Active Comparator|Atorvastatin 80mg group|
9721656|NCT04168606||Cases with placental abruption|"Cases of placental abruption included in our study will be clinically defined and will not be only diagnosed by histological examination.~All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis."
9721657|NCT04167332||NMIBC|"Patients diagnosed with primary non-muscle-invasive bladder (NMIBC) cancer.~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.~The clinical (demographic, operative and follow-up) and pathological data, and biosamples (blood, urine, bladder cancer tissue) of the patients will be collected in a completely anonymous way."
9780341|NCT03214666|Experimental|GTB-3550 TriKE® (Phase I: Dose Finding Component)|Patients receive a single course of GTB-3550 TriKE® at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of GTB-3550 TriKE® followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
9780342|NCT03214666|Experimental|GTB-3550 TriKE® Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
9780343|NCT03199053|Experimental|Low dose Dapagliflozin|Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
9780344|NCT03199053|Experimental|Low dose/high dose Dapagliflozin|Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c >= 7% at week 12
9780345|NCT03199053|Experimental|Low dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
9780346|NCT03199053|Experimental|Low dose/high dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c >= 7% at week 12
9780347|NCT03199053|Placebo Comparator|Placebo arm|Oral route. Placebo tablets administered for 52 weeks
9780348|NCT03184181|Experimental|EPTE® group|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis (EPTE®). Patient received EPTE® once week for four weeks associated with eccentric exercises device at home.
9780349|NCT03184181|Active Comparator|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
9780350|NCT03181477|Other|radiotherapy + chimiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
9780351|NCT03168750|Other|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup|All patients enrolled will receive the Medacta Masterloc Stem and MPACT cup with Highcross PE liner.
9780352|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA"|"Part 1 Tolerability with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive low-risk intensifications I & II without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA."
9780353|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA"|"Part 1 Tolerability with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive low-risk Intensifications I & II without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
9780354|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | AZA+AE+Sor | AZA+MA+Sor"|"Part 2 Dose Expansion with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and low- risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
9780355|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | DAC+AE+Sor|DAC+MA+Sor"|"Part 2 Dose Expansion with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and low-risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
9780356|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with AZA - Intermediate Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive intermediate risk Intensifications I, II & III without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA,"
9780357|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with DAC - Intermediate Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive intermediate-risk Intensifications I, II & III without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
9780358|NCT03164057|Experimental|"AZA| +ADE | +FLAG+Ida+Sor| +AE+Sor| +MA+Sor| +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - Intermediate-Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and intermediate-risk Intensification I, II, and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
9721658|NCT04164602||elderly patients with newly diagnosed diabetes|"Group with exposure: patients over 60 years of age with diabetes diagnosed within six months (newly diagnosed)~Control Group: without exposure; patients over 60 years, without diabetes."
9721659|NCT04164537||Latina adolescents and parents|Latina adolescent young women experiencing depression and their parents will be recruited from community and primary care settings for one-time individual interviews.
9721660|NCT04164537||Healthcare providers|Primary care and mental health providers who commonly work with Latina adolescent patients will be recruited for focus groups from an integrated primary care clinic.
9721661|NCT04161911||Advanced Hepatocellular Carcinoma (aHCC) cohort|aHCC cohort selected from the Flatiron Health Oncology electronic health record (EHR) data from January 2011 to the most recent data available. The index date will be defined as the start of second or third line nivolumab therapy for aHCC between January 1, 2011 and the most recent data available.
9721662|NCT04158310||Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
9721663|NCT04158310||Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD.
9721664|NCT04158011||CNS ALL at lymphodepletion|Patients with active CNS leukemia at the time of lymphodepletion
9721665|NCT04158011||CNS ALL at inclusion|Patients who were referred to CAR T-cells with CNS disease, which was cleared by the time of lymphodepletion
9721666|NCT04157413||Stunted Group|A comparative cross sectional study will compare stunted group and non-stunted group on amino acid intake, blood amino acid and intestinal permeability. Stunted group is defined as children who have LAZ <-2 SD
9721667|NCT04157413||Non-stunted Group|Non-stunted group will be those with LAZ >= 0.5 SD matching by age and sex with stunted group. Other criteria will be similar. No Intervention will be given to the groups in this proposed protocol.
9721668|NCT04156360||Healthy Volunteers|
9721669|NCT04156360||Patients With Pulmonary Nodule|
9721670|NCT04155892||URI group|This group includes participants <8 years of age undergoing elective procedures with a score of at least 3 on our pre-operative URI survey.
9721671|NCT04155892||non-URI group|This group includes participants <8 years of age undergoing elective procedures with no URI symptoms or recent URI.
9721672|NCT04155502||Social media sites.|These participants will be recruited from advertisements posted on social media websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
9721673|NCT04155502||Informational sites|These participants will be recruited from advertisements posted on informational websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
9721674|NCT04155502||Dating applications|These participants will be recruited from advertisements posted on dating applications. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
9721675|NCT04154839||Atopic dermatitis group|Number of subjects in atopic dermatitis group 0 - < 6 years : 50 subjects 6 - <12 years : 50 subjects 12 - <18 years : 50 subjects Adult (>= 18 years) : 150 subjects Total no. of cases: 300 cases
9721676|NCT04154839||Control group|>= 40 yrs : 150 subjects
9721677|NCT04155060||DM group , non-DM group|Septic patients were divided into the DM group and non-DM group, based on their comorbidity
9721678|NCT04155060||high lactate group,low lactate group|high lactate group (lactate > 2 mmol/L) and low lactate group (lactate ≤ 2 mmol/L), according to the admission lactate level.
9721679|NCT04150510||Online Survey|Individuals who are willing to participate in this online survey
9721680|NCT04148365||Paediatric Uveitis|Patients with Uveitis below the age of 18 years.
9721681|NCT04148131||Group 1, 0-5 months old|Children which is Obstetric brachial plexus palsy and 0-5 months old age have Naracas type 2 lesion.
9721682|NCT04148131||Group 2, 6-24 months old|Children which is Obstetric brachial plexus palsy and 6-24 months old age have Naracas type 2 lesion.
9721683|NCT04148131||Group 3, 25-36 months old|Children which is Obstetric brachial plexus palsy and 25-36 months old age have Naracas type 2 lesion.
9721684|NCT04148625||atrial fibrillation, persistent|Subjects with documented symptomatic persistent or longstanding persistent AF (> than 3 months and < 3 years continuous AF duration) who has failed a previous PVI catheter ablation procedure and/or needs LAA exclusion; and catheter ablation or minimally surgical approach is planned.
9721685|NCT04143503||adult critically ill patients|
9721686|NCT04142905||Patients With Asthma|Subjects with sleep disordered breathing with asthma
9721687|NCT04142905||Patients Without Asthma|Subjects with sleep disordered breathing without asthma
9721688|NCT04142268||Preeclampsia group|PE was defined as diastolic BP of at least 110 mmHg on one occasion or diastolic BP of at least 90 mmHg on two consecutive occasions more than 4 hours apart, in combination with proteinuria (≥300 mg total protein in a 24-hour urine collection and, if this was not available, ≥+2 proteinuria by dipstick analysis on two consecutive occasions at least 4 hours apart) that develops after 20 weeks of gestation in previously normotensive women
9721689|NCT04142268||Control group|Normal pregnancy group
9721690|NCT04141800||Heart failure (HF) outpatients with reduced ejection fraction|"Heart Failure (HF) with reduced ejection fraction (REF): Patients with confirmed diagnosis of HF and with ejection fraction<40%.~Hyperkalaemia: K+values> 5,4 mEq/L.~Optimal doses: the maximum doses of renin-angiotensin-aldosterone related drugs that, according to the physician's judgement, the patient can receive. If any of these drugs (ACIEs, ARB-II, MRAs or sacubitril-valsartan) is de novointroducedat the initial visit, optimal doses will be not considered established.~A previous personal history of diseases and/or outcomes will be registered according to the usual practice of every centre."
9785233|NCT01246401|Placebo Comparator|Placebo|Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release
9721691|NCT04141813||"Pilgrims doing the Camino de Santiago (any route)"|"In the present study we utilized the Ultreya dataset. The Ultreya study is an online longitudinal study aimed at evaluating the effects of the pilgrimage on the Way of Saint James on mental health and wellbeing (www.estudiocamino.org). This pilgrimage involves hundreds of paths around Europe with a common termination at Santiago de Compostela (Spain), and it was one of the most important Christian pilgrimages during the Middle Ages. Currently, it is walked by thousands of people (>300,000 per year)."
9721692|NCT04141280||Insomnia group|According to the inclusion and exclusion criteria, 150 patients with insomnia were selected, which were divided into five groups: liver stagnation fire syndrome, phlegm heat syndrome, yin deficiency fire dysfunction syndrome, heart spleen deficiency syndrome and heart deficiency biliary syndrome.
9721693|NCT04141280||Normal group|According to the inclusion and exclusion criteria, 30 normal people were selected.
9721694|NCT04141228||Patients receiving apixaban|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
9721695|NCT04141228||Patients receiving warfarin|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
9721696|NCT04139447||Healthy subjects|
9721697|NCT04139369||Type 1 Diabetes Mellitus (T1DM)|Type 1 Diabetes Mellitus (T1DM) Children and adolescents with Type 1 Diabetes Mellitus
9721698|NCT04139369||Controls (C)|Controls (C) Healthy individuals matched for gender and age without any autoimmune disease of their own or their first degree relatives
9780359|NCT03164057|Experimental|"DAC|+ADE | +FLAG+Ida+Sor | +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - Intermediate-Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and intermediate-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
9780360|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG-Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I & II and high-risk intensifications I, II & III without azacitidine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
9780361|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I, II & III without decitabine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
9780362|NCT03164057|Experimental|"AZA | + ADE | +FLAG+Ida+Sor| +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
9780363|NCT03164057|Experimental|"DAC |+ADE |+FLAG+Ida+Sor |+AE+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
9780364|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA- High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I Induction II and high-risk Intensifications I or high risk intensification III without azacitidine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
9780365|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I or high risk intensification III without decitabine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
9780366|NCT03164057|Experimental|"DAC |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
9980741|NCT01394861|Experimental|ESD using MASTER Slave Robotic System|
10196790|NCT05171166|Experimental|HAIC-TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with hepatic arterial infusion chemotherapy that consists of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. After 2-4 cycles of HAIC treatment, the sequential TACE therapy would be performed.
9721699|NCT04138199||Participants with Human Immunodeficiency Virus-1 Infection|Human Immunodeficiency Virus-1 (HIV-1) infected and clinically stable patients on dual or triple HAART including Kaletra who switched or planned to switch to generic product of lopinavir/ritonavir
9721700|NCT04135729||Personal trainer (PT)|Cross-sectional study on mental health symptoms in personal trainers
9721701|NCT04135729||Group instructors (GI)|Cross-sectional study on mental health symptoms in group instructors
9721702|NCT04135729||Combined instructors (PT + GI)|Cross-sectional study on mental health symptoms in personal trainers
9721703|NCT04135573||New untreated GD patients|Before treatment and application of anti-thyroid drugs (methimazole) or radioactive iodine treatment
9721704|NCT04135573||Healthy control|No thyroid related diseases and other immune diseases
9721705|NCT04135248||IDF-DAR arm|Insulin management according to IDF-DAR guidelines (IDF-DAR arm) during the fasting period.
9721706|NCT04135248||DAFNE arm|Insulin management according to local experience (DAFNE arm) during the fasting period.
9721707|NCT04134507||Extended Depth of Focus IOL|Post-LASIK patients with implantation of a presbyopia-correcting IOL
9721708|NCT04134507||Monofocal IOL|Post-LASIK patients with implantation of a monofocal IOL
9721709|NCT04134481||low intervention group|from 0-7 clustered nursing intervention
9721710|NCT04134481||high intervention group|from 8-15 clustered nursing intervention
9721711|NCT04133545||DOAC|Direct oral anticoagulant
9721712|NCT04133545||OAC|Vitamin K anticoagulant
9721713|NCT04133207||Patients with advanced HR-positive breast cancer|patients with histologically confirmed HR-positive, HER2-negative advanced (recurrent or metastatic) breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
9721714|NCT04133220||Cases|Patients with acute myeloid leukemia, associated to hyper leukocytosis
9721715|NCT04133220||Control|Patients with acute myeloid leukemia, without hyper leukocytosis
9721716|NCT04132947||Cohort|Cohort Study correlating self reported exercise activity and spiroergometry results
9721717|NCT04132076||Group A: Osteochondral lesion of talus (OLT)|Patients with OLT treated operatively (debridement, microfracture, allograft, mesenchymal stem cells implantation) in Department of Orthopaedic Surgery, University Medical Centre Ljubljana (UMC).
9721718|NCT04132076||Group B: Ankle joint osteoarthrosis|Patients with ankle joint osteoarthrosis treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
9721719|NCT04132076||Group C: Ankle Impingement syndrome|Patients with ankle impingement syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
9721720|NCT04132076||Group D: Ankle instability syndrome|Patients with ankle instability syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
9721721|NCT04131673||African Americans with MS|African American patients seen in the University of Kentucky's Multiple Sclerosis Clinic between the ages of 18 and 80 who have been diagnosed with MS
9721722|NCT04130347||Pancreatic resection|
9721723|NCT04130347||Liver resection|
9721724|NCT04130347||HIPEC surgery|
9721725|NCT04130347||Gynecological debulking surgery|
9721726|NCT04128631||PET/CT|group of patients will do F-18FDG PET/CT scan after negative whole body scan with elevated serum thyroglobulin Antibody or Thyroglobulin levels.
9721727|NCT04128241||Panel of Spanish consumers|A panel of Spanish consumers recruited from various audited and validated internet databases.
9721728|NCT04127565||Pre-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2013 to March 2014.~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units."
9721729|NCT04127565||Post-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2015 to March 2016.~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units.~Additionally analysis of all ambulance calls with telemedical support."
9721730|NCT04127162||alive|
9721731|NCT04127162||dead|
9721732|NCT04125485||Person with Parkinson's|"Inclusion criteria for interview/focus group with people with PD: people with PD living at home, Hoehn & Yahr stage 1-4 (Hoehn and Yahr, 1967), cognitively able to participate, able to speak a conversational level of English, and at different stages of PD (early, mid, later by years of diagnosis) and ages (younger and older).~Exclusion criteria: any hospital admission within the last 1 year, whether for Parkinson's or anything else, that was for more than 24 hours i.e. not day surgery/brief checks in the emergency department after falls; patients diagnosed with PD less than 6 months ago to confirm the diagnosis and allowed them to have time for using the resources for people with PD; unwillingness to participate."
9721733|NCT04125485||Healthcare professional|"Inclusion criteria for interview/focus group for health professionals: Professionals from different disciplines (physician, neurologist, General Practitioners, nurses/specialist nurses, social worker, occupational therapist, mental health workers, physiotherapist, pharmacist, speech therapist) that provide support directly or indirectly to patients with PD and family carers.~Exclusion criteria: Not involved in direct care or support of people with PD or unwillingness to participate."
9721734|NCT04125485||Family carer|"Inclusion and exclusion criteria for all are the same for Interviews and Focus Groups.~Family carers:~Inclusion criteria: family caregivers of PD patients at different stages (early, mid, late) or friends involved in the care process. Also, family caregivers of patients with cognitive impairment will be included.~Exclusion criteria: not being involved in the care of the person with PD or unwillingness to participate in the project, and an ability to speak a conversational level of the English language.~Family carers do not need to have the person they care for in the study also and vice-versa."
9785234|NCT01246466|Experimental|AtriCure Bipolar System combined with a catheter ablation|procedure using the AtriCure Bipolar System plus a catheter ablation
9785235|NCT01246479|Other|No treatment|subjects will be followed up on immunity (analysis of blood samples) and safety
9721735|NCT04125485||Stakeholder|"Stakeholders:~Inclusion criteria: non-NHS professionals or volunteers involved in policy making or working or collaborating in voluntary organisations or from different sectors; (non-NHS) Health Care, Social Services, voluntary sector, employment, food, Pharmaceutical, Education, Political, that have an impact directly or indirectly in the management of PD and development of care pathways for PD or other long-term conditions (when relevant). Exclusion criteria: unwillingness to participate in the project or lack of involvement in strategic planning or involvement in provision of community PD care."
9721736|NCT04120727||Patient|patients with predominant osteoarthritis of the knees
9721737|NCT04120727||Health professionals|health professionals with a link to osteoarthritis (physical and rehabilitation doctor, Rheumatologist, Physiotherapist, family doctor, pharmacist, Adapted physical activity teacher)
9721738|NCT04119531||Patients with insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
9721739|NCT04119531||Patients without insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
9780367|NCT03164057|Experimental|"AZA |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensification I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
9780368|NCT03142867||Control|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The control group will be made of individuals who do not meet the qualifications for a liver biopsy."
9780369|NCT03142867||NAFLD|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD."
9780370|NCT03142867||NASH|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH."
9780371|NCT03112993|Experimental|Sugammadex group|2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
9780372|NCT03112993|Active Comparator|Neostigmine group|"50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.~Dosing will be based on actual body weight not ideal body weight."
9780373|NCT03110315|Experimental|Suvorexant|Suvorexant - 10 mg (one tablet) taken by mouth once daily at bedtime with option to up-titrate to 20 mg (two tablets) taken by mouth once daily at bedtime.
9780374|NCT03110315|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth once daily at bedtime and two tablets taken by mouth daily at bedtime if subject up-titrates.
9780375|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
9780376|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
9780377|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
9780378|NCT03088137|Experimental|Primapur (Follitropin alfa)|
9780379|NCT03088137|Active Comparator|Gonal-f (Follitropin alfa)|
9780380|NCT03084757|Experimental|research of druggable molecular alterations on tumor biopsy|
9780381|NCT03038438|Experimental|Abre|Abre Venous Self-expanding Stent System
9780382|NCT02983487||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing"
9780383|NCT02983487||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing~Blood sampling:~A blood sample collected by fingerprick"
9780384|NCT02983487||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
9780385|NCT02955355|Experimental|HYQVIA|Subjects will continue to receive HYQVIA/HyQvia infusions every 2, or 3, or 4 weeks (±3 days) following the same dose and dosing regimen of the Phase 3 pivotal study (Study 161403).
9780386|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
9780387|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
9780388|NCT02930044|Experimental|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
9780389|NCT02930044|Placebo Comparator|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
9780390|NCT02926222|Experimental|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
9721740|NCT04119206||Control|Normonatremic control, no intervention.
9721741|NCT04119206||Fluid restriction|Hyponatremic patients (serum sodium <135mmol/L): restriction of fluid intake < 1L
9721742|NCT04119206||Tolvaptan 3.75mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 3.75 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
9721743|NCT04119206||Tolvaptan 7.5mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 7.5 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
9721744|NCT04117373||Cohort 1|Patients from the existing Optum insurance claimed database with a confirmed diagnosis of melanoma, basal cell carcinoma, or squamous cell carcinoma who have undergone skin cancer excision surgery followed by interpolated flap repair between the years 2001-2006.
9721745|NCT04117113||Elderly, 60+ hospitalized with Invasive ExPEC Disease|Patients 60 years or older hospitalized with Invasive Extraintestinal Pathogenic Escherichia coli Disease.
9721746|NCT04116268||Obesity|BMI >23kg/m2
9721747|NCT04116268||Control|BMI 18-22.9kg/m2
9721748|NCT04115969||Patients with non-invasive ventilation|
9721749|NCT04115176||smokers + periodontitis|Individuals clinically diagnosed with chronic periodontitis that smoke recruited for this group.
9721750|NCT04115176||nonsmoker + periodontitis|Individuals clinically diagnosed with chronic periodontitis that don't smoke recruited for this group.
9721751|NCT04115150||self-gripping mesh|
9721752|NCT04115150||non-self-gripping mesh|
9721753|NCT04114214||patients with suspected infection or sepsis|All patients admitted with suspected infection or sepsis from January 2018 to February 2018 at Prince of Wales Hospital
9721754|NCT04114409||1|OSAS and type D personality
9721755|NCT04114409||2|OSAS without type D personality
9721756|NCT04114032||High-risk elective surgical patients|"The patient population to be studied are elective patients for non-cardiac surgery.~Age ≥ 45 years of age.~Undergoing intermediate or major non-cardiac surgery requiring an overnight stay in hospital.~With at least one of the following criteria:~History of ischaemic heart disease or peripheral vascular disease (coronary equivalent)~History of stroke or transient ischaemic attack~History of congestive cardiac failure~Diabetes currently on an oral hypoglycaemic agent or insulin~Serum creatinine >175 µmol/L (>2.0mg/dl)"
9721757|NCT04113330||Study Group|Participant vaccinated with CYD Dengue Vaccine and classified as seronegative or undetermined at baseline in previous dengue studies in Colombia
9721758|NCT04111146||1|Liver transplant patients with severe vitamin D deficiency (<10ng/ml)
9721759|NCT04111146||2|Liver transplant patients with vitamin D insufficiency (10-20ng/ml)
9721760|NCT04111146||3|Liver transplant patients with normal vitamin D status (>20ng/ml)
9721761|NCT04109677||SHE player|Female player in the top Swedish handball league
9721762|NCT04109677||Handbollsligan player|Male player in the top Swedish handball league
9721763|NCT04108065||Patients with gestational diabetes mellitus (GDM)|GDM diagnosed according to current Danish guidelines (plasma glucose (PG) concentration at 120 min after a 75 g oral glucose tolerance test (OGTT) ≥9.0 mM)
9721764|NCT04108065||Pregnant women with normal glucose tolerance (control group)|Pregnant women with normal glucose tolerance (fasting plasma glucose (PG) concentration ≤6.0 mM and PG concentration at 120 min after a 75 g-OGTT <7.8 mM)
9721765|NCT04106518||cirrhosis|Patients with alcoholic liver disease without alcoholic hepatitis
9721766|NCT04106518||severe alcoholic hepatitis|Patients with severe alcoholic hepatitis ( Maddrey score ≥32)
9721767|NCT04106518||non-severe alcoholic hepatitis|Patients with non-severe alcoholic hepatitis (Maddrey score <32)
9721768|NCT04105621||Drug addicts|This group included drug addicts lived in drug rehablitation center.
9721769|NCT04105621||Healthy population|We recruited the healthy participants from the Westlake N-of-1 Trials for Macronutrient Intake (NCT04125602) as healthy control
9721770|NCT04105803||De novo HTx|"Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography and coronary angiography is part of the scheduled standard HTx follow-up visits."
9721771|NCT04105803||Longterm HTx|"Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
9780391|NCT02926222|Active Comparator|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
9780392|NCT02926196|Experimental|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
9780393|NCT02926196|No Intervention|Arm Observation|Observation as per guidelines
9780394|NCT02924155|Experimental|SJP002|9 subjects received single dose of SJP002 and then received multiple dose of SJP002
9780395|NCT02924155|Placebo Comparator|Placebo|3 subjects received single dose of placebo and then received multiple dose of placebo
9721772|NCT04105803||PET-scan de novo HTx|"Radiation: Two PET-scans with 11C-acetate tracer will be performed.~Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
9721773|NCT04105153||TKI-treated advanced EGFR+ NSCLC|Patients with advanced EGFR-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors
9721774|NCT04105075||Patients with COPD and obesity|Patients consented to have a blood sample taken
9721775|NCT04105075||Normal body weight patients with COPD|Patients consented to have a blood sample taken
9721776|NCT04105439||control|healthy subjects who do not have the disease
9721777|NCT04105439||patients with Behçet's disease|subjects who do have the disease ( Behçet's disease )
9721778|NCT04104620||patients with neurological syndromes and GAD-Ab|This is a non-interventional study involving clinical data already stored in the database of the Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, or collected by the referral physicians the day of ordinary consultations. No biological sample is necessary to perform this study.
9721779|NCT04104100||Women with nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
9721780|NCT04104100||Women without nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
9721781|NCT04104048||patients who were diagnosed as Anterior STEMI|"Patients who were diagnosed as Anterior STEMI according to criteria developed by the European Society of Cardiology.~Onset of maximal intensity of chest pain within 12 hours before procedure"
9721782|NCT04102163||All Participants|Participants diagnosed with CD and CPF from approximately 20 Spanish hospitals, who will initiate medical or surgical treatment for their CPF within the eligibility period from Sep 2020 to Sep 2021, will be observed prospectively for approximately 31 months.
9721783|NCT04100837||transportal group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transportal technique (femoral tunnel drilling) , before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
9721784|NCT04100837||transtibial group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transtibial technique (femoral tunnel drilling), before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
9780396|NCT02914496|Experimental|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
9780397|NCT02914496|No Intervention|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
9780398|NCT02864485|Experimental|transplantation|Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases
9780399|NCT02849158|Experimental|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
9780400|NCT02836262|Experimental|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
9780401|NCT02835950|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
9780402|NCT02819024|Experimental|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
9780403|NCT02802969|Experimental|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
9780404|NCT02799823|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
9780405|NCT02795247|Active Comparator|Hybrid Transtibial Technique|Reconstruction of the ACL using the hybrid transtibial technique
9780406|NCT02795247|Active Comparator|Accessory Anteromedial Portal Technique|Reconstruction of the ACL using the accessory anteromedial portal technique
9780407|NCT02795247|Active Comparator|Transtibial Technique|Reconstruction of the ACL using the transtibial technique.
9780408|NCT02758054|No Intervention|Usual Care|Participants will experience standard practice for lung cancer early detection.
9780409|NCT02758054|Experimental|Usual Care + Patient Navigation|Participants will experience standard practice for lung cancer early detection plus the intervention.
9780410|NCT02752243|Experimental|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
9785236|NCT01246583|Experimental|Treatment Group A|
9721785|NCT04100421||Mild renal injury|CKD patients with eGFR ≥ 60 ml∙min-1∙ (1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
9721786|NCT04100421||Moderate renal injury|CKD patients with eGFR between 30 ml∙min-1∙(1.73 m2)-1 to 60 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
9721787|NCT04100421||Severe renal injury|CKD patients with eGFR < 30 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
9721788|NCT04100421||Hemodialysis|uremic patients on hemodialysis therapy
9721789|NCT04100421||Peritoneal dialysis|uremic patients on peritoneal dialysis
9721790|NCT04100421||Healthy control|Healthy volunteers with no history of kidney diseases or any chronic diseases which may lead to renal injury.
9721791|NCT04099719||Anyone (>16 years old) registered with services providing drug|retrospective data, no intervention to be administered
9721792|NCT04099030||Opioid shortage|Patients undergoing laparoscopic cholecystectomy during time of Fentanyl drug shortage
9721793|NCT04099030||Normal Opioid supply (no shortage)|Patients undergoing laparoscopic cholecystectomy during time of normal Fentanyl drug supply
9721794|NCT04097249||Healthy subjects|Participants free from any pain specific to the upper limb, chronic pain or other disease.
9721795|NCT04096521||East Jakarta Cohort Study|One group included in the study was originated from mothers who participated in the first data collection pregnancy. The follow-up study included mothers and their children born as the subject in the follow-up in the study. This study also includes peer of the subjects that lived in the same neighbourhood since the first cohort study and have children in the same age with cohort participant
9721796|NCT04096079||OHCA patients|Patients who suffered an out-of-hospital cardiac arrest between 2015 and 2018 in Province of Pavia (Italy), Ticino Region (Switzerland), Wien area (Austria) and Nicosia area (Cyprus) who underwent a coronary angiography.
9721797|NCT04094545||Nasopharyngeal carcinoma(NPC)|The patients (1) were diagnosed with NPC; 2)18< Age <75.
9721798|NCT04094545||Health adults|(1) 18< Age <75, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; None of the patients had rhinitis or used any antibiotics during the three months last 3 months.
9721799|NCT04093856||Diabetic|20 men and women with type 2 diabetes and obesity
9721800|NCT04093856||Non-diabetic|20 normoglycemic men and women with obesity matched for age and sex with diabetic group
9721801|NCT04093661||Children below 1 year|Children <= 1 year for elective surgery
9721802|NCT04091828||Biplar patients|diagnosed by DSM-5 and divided to manic,depressed and mixed last episod
9721803|NCT04091828||controlled subject|not have any medical or psychatric problem affect cognition
9721804|NCT04091568||Awake fibre-optic intubation|Awake fibre-optic intubation
9721805|NCT04091568||Asleep fibre-optic intubation|Asleep fibre-optic intubation
9721806|NCT04091321||Chronic Headache|Women who endorse chronic headache
9721807|NCT04091321||Chronic Back Pain|Women who endorse chronic back pain
9721808|NCT04087785||Positive metastasis|Positive occult lymph node metastasis pathology
9721809|NCT04087785||Negative metastasis|Without lymph node metastasis pathology
9721810|NCT04087473||Prior 2nd generation ALKi|
9721811|NCT04087473||Prior 1st and 2nd generation ALKi|
9721812|NCT04087681||Elderly 60+ preferably those with increased risk of IED|Study participants are aged 60 years or older in stable health, preferably with a history of urinary tract infection in the previous 10 years.
9721813|NCT04087148||patients|patients who were diagnosed as having CAH of at least 1 y duration. and On glucocorticoid replacement therapy .
9721814|NCT04087148||controls|A comparable number of age and sex matched apparently normal children will be included as control.
9721815|NCT04086511||Children with PKU|
9721816|NCT04086511||Age- and sex-matched non-PKU comparison subjects|
9980742|NCT01394874|Experimental|Telephone-linked Communication (TLC)|This group will receive the computer-based telephone counseling.
9721817|NCT04086784||3D-printed Cage|Patients undergoing posterior lumbar interbody fusion with 3D-printed Porous Titanium Alloy Cages at the lowest fusion segment
9721818|NCT04086784||Peek Cage|Patients undergoing posterior lumbar interbody fusion with PEEK Cages at the lowest fusion segment
9721819|NCT04085978||Pre implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2014 - November 30, 2016 who qualify for hypoglycemia protocol
9721820|NCT04085978||Post implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2018 - November 30 2018 who qualify for hypoglycemia protocol
9721821|NCT04085718||Study arm|All included patients will undergo FDGPET/CT scan
9721822|NCT04085588||Group 1|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 2 μg / kg / min ketamine was started in Group 1. By the end of the operation ketamine infusion was reduced to 1 μg / kg / min."
9721823|NCT04085588||Group 2|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 4 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 2 μg / kg /min and continued."
9721824|NCT04085588||Group 3|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 6 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 3 μg / kg /min and continued."
9721825|NCT04084925||Diabetics with NAFLD|Diabetics whose abdominal ultrasound showed that they have NAFLD
9721826|NCT04084925||Diabetics without NAFLD|Diabetics whose abdominal ultrasound showed that they do not have NAFLD
9780411|NCT02734134|Active Comparator|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
9785237|NCT01246583|Placebo Comparator|Treatment Group B|
9721827|NCT04084613||Patients with uncontrolled severe eosinophilic asthma|Asthmatic patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants.
9721828|NCT04084509||Healthy Controls|
9721829|NCT04084509||Idiopathic Parkinson's Disease|
9721830|NCT04084509||Symptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
9721831|NCT04084509||Asymptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
9721832|NCT04084145||CKD|Chronic Kidney Disease stage 1 - 4 followed up in secondary care
9721833|NCT04083391||CAI group|assessment had been done to this group that include patients with ankle sprain injury from more than one year and complain with repetitive injuries, giving way and instability feelings
9721834|NCT04083391||non injured ankle group|assessment had been done to this group that include control participants had not injured their ankle before and matched with CAI in age, gender, dominant side
9721835|NCT04081740||Asthma|The patients included in this group will have asthma, as specified in the inclusion criteria.
9721836|NCT04081740||COPD|The patients included in this group will have COPD, as specified in the inclusion criteria.
9721837|NCT04081740||Bronchiectasis|The patients included in this group will have bronchiectasis, as specified in the inclusion criteria.
9780412|NCT02734134|Active Comparator|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
9780413|NCT02733185|Active Comparator|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
9780414|NCT02733185|Active Comparator|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
9780415|NCT02733185|Active Comparator|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
9780416|NCT02733185|Placebo Comparator|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
9780417|NCT02674503|Experimental|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
9780418|NCT02674503|Placebo Comparator|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
9780419|NCT02666638|Active Comparator|Control Volunteers|MRI on up to a 7T scanner without contrast.
9980743|NCT01394874|No Intervention|Control|This is the control group. They will receive the exercise class, however, they will not receive the telephone counseling.
10196791|NCT05171166|Active Comparator|TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with cTACE or DEB-TACE that mixed with EPI.
9780420|NCT02666638|Experimental|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
10196792|NCT05170711|Experimental|hypotensive anesthesia|hypotensive anesthesia group
10196793|NCT05170711|Active Comparator|normotensive anesthesia|normotensive anesthesia group
9780421|NCT02647437|Experimental|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
9780422|NCT02647437|Experimental|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
10196794|NCT05170139|Experimental|Caffeine|Dietary Supplement: Caffeine supplementation Participants will ingest caffeine in liquid form (3mg/kg) with carbohydrates.
9780423|NCT02637947|Experimental|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
9780424|NCT02637947|Active Comparator|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
9780425|NCT02633085||Fixed Bearing or Mobile Bearing UKA|
10196795|NCT05170139|Placebo Comparator|Control condition|Participants will ingest a drink of carbohydrates without caffeine
10196796|NCT05168423|Experimental|Cohort 1|Cohort 1 (N = 3-6): will receive a single fixed dose of 5x107 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
9780426|NCT02623426|Active Comparator|Dexamethasone intravitreal implant 0.7mg|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Re-treatment criteria:~Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.~IOP of <25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
9780427|NCT02623426|Active Comparator|Intravitreal methotrexate 400µg in 0.1mL|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
9780428|NCT02623426|Active Comparator|Intravitreal ranibizumab 0.5mg in 0.05mL|"Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.~Re-treatment permitted at later time points if re-treatment criteria met."
9980744|NCT01394887|Active Comparator|metformin group|this group received 850 mg metformin twice daily, along with recommended diet and exercise
9721838|NCT04081142||acute respiratory failure group|acute respiratory failure (ARF) group: arterial oxygen partial pressure to fractional inspired oxygen ratio, PaO2/FiO2<300 mmHg and/or peripheral oxygen saturation SaO2<94% under air condition and/or severe dyspnea with respiratory rate >30bpm.
9721839|NCT04081142||control group|postoperative ICU patients without ARF were included
9721840|NCT04080583||Usual Care|People with a chronic lung condition who are physically inactive
9721841|NCT04079400||Tb group|Subjects who underwent bronchoscopy for suspicious endobronchial pulmonary tuberculosis (Tb) observed on chest computed tomography
9721842|NCT04079400||NTM-PD group|Subjects who underwent bronchoscopy for suspicious non-tuberculous mycobacterial pulmonary disease (NTM-PD) observed on chest computed tomography
9721843|NCT04079400||LC group|Subjects who underwent bronchoscopy for suspicious endobronchial lung cancer (LC) observed on chest computed tomography
9721844|NCT04079400||HM group|Subjects who underwent bronchoscopy for hemoptysis
9721845|NCT04079400||Control group|Subjects who underwent bronchoscopy to rule out endobronchial lesion observed on chest computed tomography. Endbronchial lesion should not be typical for any category of respiratory diseases including tuberculosis, NTM-TB and lung cancer.
9721846|NCT04079036||Underweight Adult Male|Male patients with Underweight BMI classification and more than 20 years old https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
9721847|NCT04079036||Healthy Weight Adult Male|Male patients with Healthy Weight BMI classification and more than 20 years old
9721848|NCT04079036||Overweight Adult Male|Male patients with OverWeight or Obese BMI classification and more than 20 years old
9721849|NCT04079036||Underweight Adult Female|Female patients with Underweight BMI classification and more than 20 years old
9721850|NCT04079036||Healthy Weight Adult Female|Female patients with Healthy Weight BMI classification and more than 20 years old
9721851|NCT04079036||Overweight Adult Female|Female patients with Overweight or Obese BMI classification and more than 20 years old
9721852|NCT04079036||Underweight children Male|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
9721853|NCT04079036||Healthy Weight children Male|Male patients less than 20 year old, and with Healthy Weight BMI classification
9721854|NCT04079036||Overweight children Male|Male patients less than 20 year old, and with Overweight or Obese BMI classification
9721855|NCT04079036||Underweight children Female|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
9721856|NCT04079036||Healthy Weight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
9721857|NCT04079036||Overweight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
9721858|NCT04078412||NTM pulmonary disease|Cohort Description: adults NTM pulmonary disease patients diagnose by criteria of American thoracic society guideline
9721859|NCT04077840||NCGS/NCWS patients|Adult patients with a definitive diagnosis of NCWS, based on DBPC wheat challenge, most of them suffering from IBS-like-clinical presentation, according to Rome IV criteria. The patients were consecutively recruited between January 2016 and October 2017 at the outpatient clinics of the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (both in southern Italy)
9721860|NCT04077840||Heathy blood donors|Consecutive healthy blood donors sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients.
9721861|NCT04077840||IBS patients|"Consecutive patients with a diagnosis of IBS unrelated to NCWS or other types of food intolerance/allergy, who were consecutively recruited during the study period and sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients."
9721862|NCT04077138||Focus Groups|"Ten focus groups with transgender women and transgender men will be conducted. . The structure of the focus groups will utilize an interactive Rapid Approach, which differs from traditional focus groups by asking fewer questions and tightly focusing on specific areas of inquiry."
9721863|NCT04077138||In-Depth Interviews|Participants for the IDIs, 10-15 TW and TM, will be selected from among Phase 1 participants. We will create a purposive sample that represents a range of experiences that occurred during Phase 1.
9721864|NCT04075708||Case-group|The case group will consist of women diagnosed with PE after 34 weeks of gestation.
9721865|NCT04075708||Control-group|The control group will include 165 participants who were not diagnosed with PE in their pregnancies.
9721866|NCT04074278||development groups|The development groups included 150 patients derived from outpatients in Peking University First Hospital, between March 1st, 2014 and November 26th 2014.
9721867|NCT04074278||validation groups|The validation groups included 150 patients derived from outpatients in Peking University First Hospital, between November 27th 2014 and December 1st, 2015.
9721868|NCT04073732||family physician team|Family physician team in four regions (Beijing, Shanghai, Hangzhou and Xia'men), including general practitioners, nurses and public health personnel.
9721869|NCT04072523||Observational Study Investigational Product NA|Patients : Type 2 Diabetic Patients
9721870|NCT04072120||R1|"Norwegian citizens aged 45 and above 1.1.1994 - 31.12. 2009 registered in the FS-data during this period.~Sub-sample those attending a cardiovascular health survey who later developed stroke."
9721871|NCT04072120||R2|All Norwegians born in the period 1 January 1940 to 31 December 1959 who survived to 1991.
9721872|NCT04072120||R3|Norwegian citizens aged 45 and above 1.1.2016.
9721873|NCT04071912||ACL|All sports patients who had a muscle evaluation at 3-4 months and 6-8 months after ACL ligamentoplasty since January 2016
9721874|NCT04071860||discovery and learning cohort|Data from this cohort will be used to develop the software algorithms
9721875|NCT04071860||Validation|Data from this cohort will be used to validate the software algorithms
9721876|NCT04071249||Control|Patients who use symptomatic medication as therapy for their allergic rhinoconjuntivitis as recommended by their physician
9721877|NCT04071132||Participants diagnosed with PTSD|
9721878|NCT04071132||Non-PTSD participants|
9721879|NCT04070664||Central vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
9721880|NCT04070664||Peripheral vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
9721881|NCT04068909||acute coronary syndrome|All patients should receive standard therapy for acute coronary syndrome and concomitant diseases. All drugs are prescribed according current guidelines and approved indications.
9721882|NCT04067973||patients|"Premature subjects benefit from the examinations described in the protocol, namely automated refractometry, intraocular air pressure, biometrics (with axial length and pachymetry (corneal thickness) performed by the same machine at the same time), a photo of the fundus (retinophotography) and an OCT RNFL. These examinations are necessary for the follow-up of premature children.~All children examined at Nantes University Hospital benefit systematically from: automated refractometry, intraocular pressure in the air and a photo of the fundus."
9721883|NCT04067973||control|"controls benefit from two additional tests: RNFL OCT and biometrics. The duration of the RNFL OCT is about 2 minutes, with a total of 10 seconds per eye, the rest being computer manipulation.~The biometrics take about 2 minutes to complete, with a total of 30 seconds per eye, the rest being computer manipulation.~These two reviews are conducted on the same day as the initial consultation and directly following the consultation."
9721884|NCT04067635||Conservative Arm|Participants are followed by the research team conservatively. Participants in this arm may choose to undergo any valvular intervention at the discretion of their treating clinical team.
9721885|NCT04067635||Surgical Arm|Participants have already elected upfront to undergo surgical repair (at least, mitral annuloplasty) with their treating clinical team, just prior to enrollment into this study.
9721886|NCT04066686||Young|Participants recruited into one of two groups on age stratification. Young cohort defined as aged 18-65yrs old
9721887|NCT04066686||Elderly|Participants recruited into one of two groups on age stratification. Elderly cohort defined as over 65yrs of age.
9721888|NCT04066855||Chronic Kidney Disease (CKD)|patients diagnosed as CKD
9721889|NCT04066855||Renal transplant|recipients of renal transplantation
9721890|NCT04064450||Heart Failure|Individuals with asymptomatic or symptomatic heart failure
9721891|NCT04064450||Population Controls|Individuals free of heart failure and echocardiographic cardiac dysfunction
9721892|NCT04062825||VIH positive patients without lymphoma|200 VIH positive patients without lymphoma
9721893|NCT04062825||VIH positive patients with lymphoma|20 VIH positive patients with lymphoma
9721894|NCT04062825||healthy volunteers|20 healthy volunteers
9721895|NCT04062409||Sickle cell patients|
9721896|NCT04062409||Asmathic patients|
9721897|NCT04061434||Cardiac resynchronisation therapy recipients|
9721898|NCT04061434||Other cardiac implantable electronic devices recipients|
9721899|NCT04061486||Experimental arm|One half of the oocyte cohort is microinjected with sperm selected by the Fertile technique, while the other half of the patient's oocyte cohort is microinjected with sperm selected by the MACS technique.
9721900|NCT04061499||Hip OA|Individuals with diagnosed hip osteoarthritis
9721901|NCT04061499||Control|Individuals without diagnosed hip osteoarthritis
9780429|NCT02617342|Experimental|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
9780430|NCT02617342|No Intervention|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
9780431|NCT02577861|Experimental|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
9780432|NCT02574481|Experimental|ELUVIA Stent Implantation|Percutaneous stent placement in the SFA/PPA
9780433|NCT02574481|Active Comparator|Zilver PTX Stent Implantation|Percutaneous stent placement in the SFA/PPA
9780434|NCT02565446|Other|MRE|Clinical Cohort: NAFLD COHORT RECRUITED FROM THE LIVER CLINIC: 120 adult subjects evaluated at Mayo Clinic with a diagnosis of NAFLD who are at risk to have NASH will be recruited from our outpatient Liver Disease Clinic. Metabolic syndrome is a strong predictor of NASH and will be used to best identify subjects with a clinical indication for liver biopsy according to AASLD guidelines. The proposed sample size for this experiment will be calculated based on sensitivity and specificity of MRE for differentiating various stages of fibrosis.
9780435|NCT02562040|Active Comparator|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
9780436|NCT02562040|Experimental|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
9780437|NCT02557139|Experimental|Regimen A|Single-dose belumosudil 200 mg tablet in the fasted state
9780438|NCT02557139|Experimental|Regimen B|Single-dose belumosudil 200 mg tablet in the fed state
9780439|NCT02557139|Experimental|Regimen C|Single-dose belumosudil capsules (administered as two 100-mg capsules) in the fed state
9780440|NCT02550886||Patient/Caregiver Dyad|
9780441|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
9785238|NCT01246583|Experimental|Treatment Group C|
9785239|NCT01246583|Placebo Comparator|Treatment Group D|
9721902|NCT04058184||Contact sports players|Athletes who engage in contact sports, football for example. Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
9721903|NCT04058184||Non-contact sports players|Athletes who engage in non-contact sports, swimming for example.Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
9721904|NCT04057651||Hip osteoarthritis waiting for surgery|
10196797|NCT05168423|Experimental|Cohort -1|Cohort -1 (N = 3-6): will receive a single fixed dose of 1x107 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
9721905|NCT04057651||Knee osteoarthritis waiting for surgery|
9721906|NCT04057560||SIBO Group|
9721907|NCT04057560||Control Group|
9721908|NCT04056767||Imaginal PE|
9721909|NCT04056767||Writing PE|
9721910|NCT04055155||Staff/Provider end-users|Testing usability of a technology-enabled behavioral intervention for depression among provider end-users in primary care.
9721911|NCT04055155||Patient participants|Testing acceptability, feasibility, and preliminary effectiveness of a technology-enabled behavioral intervention for depression among patients with depression in primary care.
9721912|NCT04053309||Males undergoing TESE or microTESE|All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.
9721913|NCT04051060||Patients with Bronchial Asthma|
9721914|NCT04051060||Healthy individuals|
9721915|NCT04049071||Case|Cases are patients that are prescribed tocilizumab as escalation therapy for relapsing/refractory GCA
9721916|NCT04049071||Control|Controls are those that are prescribed an alternative escalation therapy (not tocilizumab) for relapsing/refractory GCA.
9721917|NCT04048408||Obstructive lung diseases group|
9721918|NCT04048408||Healthy group|
10196798|NCT05168423|Experimental|Cohort 2|Cohort 2 (N = 3-6): will receive a single fixed dose of 1x108 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
10196799|NCT05168423|Experimental|Cohort 3|Cohort 3 (N = 3-6): will receive a single fixed dose of 5x108 CART-EGFR-IL13Ra2 cells via intravenous infusion on Day 0, following lymphodepleting chemotherapy with cyclophosphamide and fludarabine given over 3 days. Lymphodepleting chemotherapy will be scheduled such that the last day is 3 days (+/- 1 day) prior to the infusion of CART-EGFR-IL13Ra2 cells.
10196800|NCT05166681|Active Comparator|control group|cases allocated to that arm are those cases having their surgical wound closure by the traditional techniques involving subcutaneous layer closure as one or more raws of sutures and then skin layer closure
10196801|NCT05166681|Experimental|Single layer wound closure group|cases allocated to that group are those having their surgical wound closure with the new technique involving part of the subcutaneous layer and the subdermal layer
9721919|NCT04048473||MUH (Mansoura University Hospital)|enrolled 127 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5). Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
9721920|NCT04048473||Ocmu (Oncology center Mansoura University)|enrolled132 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5).Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
9721921|NCT04048746||ASTHMA|"The patient presents to the emergency department for an aggravation of his asthma. The patient later sees an emergency investigator for medical care for his aggravation of asthma. When the patient's condition is stabilized, the investigator checks his eligibility for study and offers to participate. If the patient agrees, the investigator gives him the questionnaire and possibly helps to fill it out.~When the investigator returns to see the patient for a reassessment of his condition, he retrieves the completed questionnaire. He verifies that the patient has completed the questionnaire. Prescriptions and action plans are retrieved by the principal investigator either in digitized format from the patient's computerized medical record or in paper format. Each medication prescription and each action plan are read by the principal investigator and evaluated according to the grids."
9721922|NCT04048330||Women of reproductive age|Women 15 to 40 years of age who are not pregnant or lactating
9721923|NCT04047966||Fetal growth restriction|63 fetuses with defects in fetal growth qith an estimated fetal weight below 10th percentile
9721924|NCT04047966||Control group|63 control fetuses with an estimated fetal weight about the 10th percentile
9721925|NCT04046965||Region XI Head Start children and families|children (800) parents (800) classrooms/teachers (80) program directors (22) center directors (37)
9721926|NCT04045639||Intervention arm|The AF risk prediction algorithm will be run on patient records within the Egton Medical Information Systems (EMIS) data base, in order to identify patients at risk of developing AF
9721927|NCT04045639||Control arm|Patients may be diagnosed with AF through routine clinical practice only
9721928|NCT04043949||Normal|healthy subjects
9721929|NCT04043949||Dry eye group|patients with dry eye
9721930|NCT04043949||Dry eye after treatment|patients with dry eye after treatment
9721931|NCT04042987||Historical Control Group|Retrospective chart review
10196802|NCT05166551|Experimental|Experimental Group|"Acupressure will be applied to the infants in this group by the researcher in accordance with the technique for 1 minute on the GB31 acupuncture point on the leg where the vaccine will be administered.The considerations before and after acupressure application are as follows:~The hands will be washed to warm them up to body temperature.~The acupressure will be applied using the thumb to the GB31 acupuncture point for 1 minute before the vaccine is administered to the infants in the experimental group.~Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher during the vaccination procedure (as soon as the needle enters and immediately after the needle exits). In addition, the HR and SPO2 level of the infants 1 minute before and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
9721932|NCT04042987||Prospective QIP Group|Participants that meet eligibility criteria will be prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption.
9721933|NCT04042636||1|Patients with Bacteremia after trauma
9721934|NCT04042636||2|Patients with non-bacteremia after trauma
9721935|NCT04041557||adults with CHD|Adults with congenital heart disease 18-32 years of age
9721936|NCT04041557||controls|healthy peers
9721937|NCT04039451||people who live in rural areas in Assuit governorate|The study will performed on people who live in rural areas in Assuit governorate (all households) regardless of sex or age.
9721938|NCT04038983||Observational|"ER2 is a simple and standardized clinical tool composed of two sequential components: an assessment followed by recommendations for intervention. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies (21-24). Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
9780442|NCT02515474|Active Comparator|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
9780443|NCT02515474|Active Comparator|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
9780444|NCT02483429|Experimental|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
9780445|NCT02483429|No Intervention|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
9780446|NCT02483429|No Intervention|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
9780447|NCT02451943|Experimental|Doxorubicin + Olaratumab|75 milligrams per meter squared (mg/m^2) doxorubicin administered intravenously (IV) on day 1 of each 21-day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21-day cycle until documented progressive disease (PD) or discontinuation for any other reason.
9780448|NCT02451943|Placebo Comparator|Doxorubicin + Placebo|75 mg/m^2 doxorubicin administered IV on day 1 of each 21-day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21-day cycle until PD or discontinuation for any other reason.
9780449|NCT02436733|Experimental|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
9780450|NCT02436733|Active Comparator|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
9780451|NCT02410512|Experimental|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
9780452|NCT02410512|Experimental|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
9780453|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
9780454|NCT02390427|Experimental|Arm A|"Arm A~- Taselisib with Trastuzumab emtansine (also called T-DM1)~Taselisib administered orally, daily in each treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks)."
9785240|NCT01246713|Placebo Comparator|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
9721939|NCT04038268||Patients|Adults and children, males and females, with IgE mediated pollen, house dust mites, animal dander and moulds respiratory allergy who will initiate aeroallergen AIT, either SCIT, SLIT-drops or SLIT-tablets according to real life clinical standards of practice
9721940|NCT04038268||Prescribers|Doctors who are currently prescribing AIT as part of their regular clinical practice
9721941|NCT04036669||RA patients|RA patients ( N=80; BMI= 26.4± 3.96 ) Eighty patients diagnosed with Rheumatoid arthritis according to American Rheumatology Association criteria and radiographic analysis for at least 10 years previously were randomly involved in this study
9721942|NCT04036669||Healthy control|A healthy control group ( N=80; BMI=22.3± 1.85) eighty age and sex-matched healthy controls were included in the study following the assignment of informed consent.
9721943|NCT04032756||Group 1|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced Tofacitinib therapy (n=360). Previous treatment(s) with biologics or immunosuppressants is (are) permitted. About 20-30% of the Tofacitinib patients will biologic-naiv.
9721944|NCT04032756||Group 2|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy (n=120). Previous treatment(s) with biologics or immunosuppressants is (are) allowed.
9721945|NCT04032145||Observational|All participants who go to the Montreal Museum of Fine Arts will fill out an online questionnaire called: CESAM ( Self Administered Questionnaire). This questionnaire will asse participant's health condition. Moreover, the goal of the questionnaire is to evaluate if art activities may change the participants' health conditions in time.
9721946|NCT04031963||No treatment|Those with colon cancer and with adenomatous polyp and those without a previously mentioned condition.
9721947|NCT04031261||National Validation|All patients must have a diagnosis of severe asthma, be taking high dose inhaled corticosteroids (GINA step 4 & 5), and be aged 16 years or over.
9721948|NCT04031261||Sensitivity to Change|Patients commencing a biologic treatment for their severe asthma (GINA step 4 & 5), as per National Institute for Health and Care Excellence (NICE) guidelines.
9721949|NCT04030975||interview|emergency physicians
9721950|NCT04030728||Group 1: Standardized coaching arm|Patients in this group receive a continuous standardized MOATT based patient education and coaching and optional eMBSR (electronic Mindfulness-Based Stress Reduction) within the first 24 weeks of Abemaciclib treatment.
9721951|NCT04030728||Group 2: Coaching according to local practice|Patients in this group receive a patient management according local routine.
9721952|NCT04030403||Microbial Keratitis participants|151 participants presenting with clinically suspected microbial keratitis will be recruited from St Paul's Eye Unit, Royal Liverpool University Hospital.
9721953|NCT04030403||Healthy control participants|20 participants with no history of microbial keratitis who use no eye drop medication will be recruited.
9721954|NCT04030403||Contact-lens wearers|20 participants with no history of microbial keratitis who are contact-lens wearers will be recruited.
9721955|NCT04030403||Glaucoma eye drop users|20 participants who have no history of microbial keratitis but are on eye drop treatment for glaucoma. This group has been included to assess for changes in the corneal microbiome that could be secondary to drop treatment.
9721956|NCT04030403||Keratoconus participants|30 participants with keratoconus who are undergoing cross-linking will be recruited. These participants as part of the routine cross-linking procedure will have their corneal epithelium removed. This removed epithelium from an otherwise healthy corneal surface will allow for a direct comparison between the corneal microbiome characterised from the corneal impression membrane and that characterised directly from the epithelium.
9721957|NCT04026204||Coronary cannulation after TAVR|Coronary ostia cannulation after TAVR
9721958|NCT04025190||Allogeneic Transplant|All patients seen in the UNC Bone Marrow Transplant clinic who are candidates for allogeneic transplantation attending their pre-admission visit were approached to offer study participation. Study participation included completion of surveys over a time period up to 60 days after their transplant.
9721959|NCT04025086||Study group|"44 patient undergoing spinal surgery in prone position at Gaspare Rodolico Presidium, in which the new Perioperative Goal Directed Therapy protocol has been used"
9721960|NCT04025086||Control group|44 patients who underwent spinal surgery in the period January 2016 - December 2017, in which was not used a Perioperative Goal Directed Therapy approach but a classical hemodynamic monitoring, according to the recommendations of good clinical practice and the international guidelines.
9721961|NCT04024553||bipolar disorder family|Screening priori BD-I/BD-II patients， their relatives with mental illness (including but not limited to BD) and their healthy families.
9721962|NCT04024553||health control|Group-matched non-psychiatric family history health subjects were enrolled, DSM-IV-TR is used for demographic assessment.
9721963|NCT04024202||Patients|"Patients with a positive DAT, a positive eluate and signs of hemolysis~Patients with a positive DAT with complement only, negative eluate, but with hemolysis"
9721964|NCT04024202||Blood donors|Blood donors with a positive direct antiglobulin test and a positive eluate and/or clinically relevant cold auto-antibodies
9721965|NCT04022564||The subjects are diagnosed as MS patient|The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'.
9721966|NCT04022551||Observational|"At Emergency nurses will carry out a test called: Emergency Room Evaluation and Recommendation which contents the following statements:~Being 85 years older and over (Yes/No)~Male (Yes/No)~Home services (Yes/No)~Taking 5 different medication daily (Yes/No)~Use of walking aid (Yes/No)~Disoriented (Yes/No)"
9721967|NCT04019756||Patients with cancer|50 patients ultimately diagnosed with bladder cancer and 50 control patients (diagnosis of cancer reversed at cystoscopy or cystoscopy for another cause)
9721968|NCT04018898||Observational|Each participant will be evaluated at Emergency Department based on ER2 screening tool (Emergency Room Evaluation and Recommendation Form). Six closed-ended format questions (i.e., yes versus no) composed ER2 assessment: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless its type, and temporal disorientation (inability to give the current month and/or year).
9721969|NCT04018222||Lupus Cases|This cohort of patients will involve individuals with a confirmed medical history of Systemic Lupus Erythematosus. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
9721970|NCT04018222||Healthy Controls|This cohort of patients will involve individuals whom do not have a diagnosis of Systemic Lupus Erythematosus or any other rheumatological or auto-immune diseases. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
9721971|NCT04018326||Compliant patients|The compliant patient was defined as a patient who did not miss any follow-up visit until the end of the study period.
9721972|NCT04018326||Loss to follow-up (LTFU)|LTFU was defined as missing any follow-up visit for any interval exceeding 6 months provided that patients eventually resumed care before the end of the study period (time zero was defined as the date of the missed follow-up visit).
9721973|NCT04017273||Observational|The participants of this study will be seen at Emergency Department, and a nurse will perform a test called ER2 ( Emergency Room Evaluation and Recommendation).
9721974|NCT04016571||Adults with Cystic Fibrosis|"All Adults with a confirmed diagnosis of Cystic Fibrosis being admitted for Intra-Venous Antibiotic Treatment of a Pulmonary Exacerbation~This study is observational so no intervention will be carried out."
9721975|NCT04014972||Patients with Myocardial Infarction|
9721976|NCT04012203||Healthy subjects|Participants free from any pain specific to the upper limb during the past 3 months, chronic pain or other disease.
9721977|NCT04009200||circumcision|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
9721978|NCT04009200||inguinal hernia|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
9721979|NCT04008875||Successful weaning/extubation|"Successful weaning will be defined as a patient who completes a planned 30-minute spontaneous breathing trial.~Successful extubation will be defined as a patient who completes a planned 30-minute spontaneous breathing trial and is not reintubated in the first 48 hours after extubation."
9721980|NCT04008875||Failed weaning/extubation|"Failed weaning will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial.~Failed extubation will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial, in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy."
9721981|NCT04007861||Patients with pain|"This will be the group of patients in whom pain is a significant enough problem, that they have been referred to the specialist Pain Management Team. These patients will be identified retrospectively.~Patients seen in Pain Management Clinics between 1st of January 2016 and 31st of December 2018, who have consented to be included in the Pain Management database and have a clinician specified pain diagnosis of pain persistent post-surgical pain following breast cancer treatment will be identified. If these patients have an unclear pain diagnosis, they will not be included."
9721982|NCT04007861||Patients without pain|"This will be the group of patients in whom pain is deemed not to be a significant problem.~Once again, these patients will be identified retrospectively. Appropriately matched patients to the 52 patients in the patients with pain will be identified using records of hospital operating lists by the peri-operative medicine team.~Patients will be matched based upon the following details:~Age (within 5 years of matched case)~Surgical procedure (matched for the following elements:~Surgery to breast tissue (biopsy, lumpectomy, wide-local excision or mastectomy)~+/- Sentinal lymph node biopsy or axillary dissection~+/- Reconstruction~Surgical procedure within 3-months of matched case.~Provided these individuals have not had an appointment with or referral to the Pain Management Team, they will be included in the matched controls."
9721983|NCT04006626||PET group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT
9721984|NCT04006626||FES group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT and 18F-FES PET/CT
9721985|NCT04005703||Pediatric Hodgkin's lymphoma|Children with newly diagnosed Hodgkin's lymphoma
9721986|NCT04005742||Healthy|Participants recruited to the healthy arm of the BORICC Study (BORICC1) at baseline.
9721987|NCT04005742||Polyp|Participants recruited to the polyp arm of the BORICC Study (BORICC2) at baseline, with a prior history of polyps.
9721988|NCT04001634||Dual anti-HER2 group|Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy
9721989|NCT04001452||Level of experience in interventional cardiology|"Total cohort will be grouped according to experience in interventional cardiology, as defined by a single choice questionnaire:~Yearly personal PCI volume Less than 75 / Between 75 and 150 / Between 151 and 250 / More than 250"
9721990|NCT04001452||Level of experience with intravascular ultrasound|"Total cohort will be grouped according to experience with intravascular ultrasound, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
9721991|NCT04001452||Level of experience with optical coherence tomography|"Total cohort will be grouped according to experience with optical coherence tomography, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
9721992|NCT04001452||Level of experience with fractional flow reserve|"Total cohort will be grouped according to experience with fractional flow reserve, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
9721993|NCT04001452||Level of experience with non-hyperaemic pressure ratios|"Total cohort will be grouped according to experience with non-hyperaemic pressure ratios, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
9721994|NCT04001244||Endometriosis (EAP)|Surgical diagnosis of endometriosis (aim equal distribution of stage I/II and stage III/IV disease); at least one pelvic pain >3/10; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
9721995|NCT04001244||Bladder Pain Syndrome (BPS)|Bladder pain syndrome (as defined by ESSIC criteria: pelvic pain, pressure or discomfort for greater than 6 months, perceived to be related to the urinary bladder accompanied by at least one other urinary symptom like persistent urge to void or frequency); no history of endometriosis
9721996|NCT04001244||Endometriosis and Bladder Pain (EABP)|Surgical diagnosis of endometriosis; at least one pelvic pain >3/10; pain perceived by the patient as arising from the bladder AND from other area(s) of the pelvis; at least one urinary symptom (e.g. urge, frequency)
9721997|NCT04001244||Controls|No endometriosis; No pelvic pain (or dysmenorrhea; NRS <3/10)
10205433|NCT00070564|Active Comparator|Arm I|(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
9721998|NCT04001244||Pelvic Pain (PP)|At least one pelvic pain >3/10; no endometriosis; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
9721999|NCT04001270||Patients anti leucine rich glioma inactivated-1 encephalitis|Biomarkers from patients with anti-leucine rich glioma inactivated 1 encephalitis (anti LGI1-E) will be studied. This is a non-interventional study involving biological samples (CSF biomarkers) already stored in biobank repositories. All stored samples were collected as part of the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population.
9722000|NCT04000997||Failure group|Patients with a failure endotracheal extubation
9722001|NCT04000997||Success group|Patients with a successful endotracheal extubation
9722002|NCT03999931||schizophrenia with positive symptoms|schizophrenia with positive symptoms
9722003|NCT03999931||schizophrenia with negative symptoms|schizophrenia with negative symptoms
9722004|NCT03999931||bipolar disorder|bipolar disorder
9722005|NCT03999931||depression|depression
9722006|NCT03999931||panic disorder|panic disorder
9722007|NCT03999931||obsessive-compulsive disorder|obsessive-compulsive disorder
9722008|NCT03999931||control|
9722009|NCT03998358||High Fatigue|TBI patients with significant fatigue as calculated by a score of >= 5.5 on the Fatigue Severity Scale
9722010|NCT03998358||Low Fatigue|TBI patients without significant fatigue as calculated by a score of < 5.5 on the Fatigue Severity Scale
9722011|NCT03997721||Perforation|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal perforation or ( small intestine, large intestine), perforated ventricular or duodenal ulcer
9722012|NCT03997721||Obstruction|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal obstruction
9722013|NCT03997721||Anasomotic leak|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of anastomotic leak following elective surgery.
9780455|NCT02390427|Experimental|Arm B|"Arm B~-Taselisib with T-DM1 and Pertuzumab~Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
9780456|NCT02390427|Experimental|Arm C|"Arm C:~Taselisib with Pertuzumab and Trastuzumab~Cohort C will not open without additional authorization from Genentech~Taselisib is administered oral, daily in each treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
9780457|NCT02390427|Experimental|Arm D|"Arm D~Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel~Cohort will not be opened without additional authorization from Genentech~Taselisib- administered oral, daily in each treatment cycle (3 weeks).~Pertuzumab- administered once via IV per treatment cycle (3 weeks).~Trastuzumab administered once via IV per treatment cycle (3 weeks).~Paclitaxel- administered via IV, weekly for 3 weeks within each cycle."
9780458|NCT02364492|Experimental|MAG-Tn3 + AS15|"3 escalating doses of MAG-Tn3 in combination with a fixed dose of AS15 adjuvant.~For each dose patient will receive 6 injections at 3 interval weeks."
9780459|NCT02348749|Experimental|pts with primary or metastatic neuroendocrine tumors|For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner or PET/CT. In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection. Patients who show lesion detection by MFBG may be eligible for repeat imaging scan with 18 F- MFBG, at the discretion of PI or study investigator(s). All parameters and technical details of scanning will be as per the study and first imaging.
9780460|NCT02335957|Other|Intentional irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
9780461|NCT02335957|Experimental|Incidental irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
10196803|NCT05166551|Placebo Comparator|Placebo Group|"Pressure will be applied by the researcher on a placebo point at least 2 cun above the GB31 acupuncture point, on the leg to be vaccinated, for 1 minute. The considerations before and after pressure are as follows:~The hands will be washed to warm them up to body temperature.~For the infants in the placebo group, pressure will be applied using the thumb for 1 minute to a placebo point that does not coincide with any acupuncture point at least 2 cm above the acupuncture point before the vaccine is administered.~Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher during the vaccination procedure (as soon as the needle enters and immediately after the needle exits). In addition, the HR and SPO2 level of the infants 1 minute before and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
9722015|NCT03993834||Normal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test ≤ 15 seconds
9722016|NCT03993834||Abnormal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test > 15 seconds
9722017|NCT03991793||Sepsis|Severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
9722018|NCT03991793||Control|Absence of severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
9722019|NCT03989843||Frozen embryo transfer|Frozen embryo transfer
9722020|NCT03989843||Fresh embryo transfer|Fresh embryo transfer
9722021|NCT03986684||Non-NAFLD|
9722022|NCT03986684||NAFLD|
9722023|NCT03986333||Control|Children whose drooling was expected to remain relatively stable over 1 month
9722024|NCT03986333||Intervention|Children receiving a treatment to reduce their drooling
9722025|NCT03985644||Fulfilling Hangzhou criteria|"Patients flfilling Hangzhou critieria:~Without macrovascular invasion Tumor burden <=8 cm Preoperative AFP level <=400 ng/mL Histopathologic grades I, II"
9722026|NCT03985644||Exceeding Hangzhou criteria|Patients exceeding Hangzhou critieria
9722027|NCT03984851||Group A: Surgicel Group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
9722028|NCT03984851||Group B: Bipolar Cautery group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
9722029|NCT03983096||test group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used Pegylated liposomal doxorubicin for treat.
9722030|NCT03983096||control group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used epirubicin for treat.
9722031|NCT03982706||MRI-US Fusion|patients undergoing MRI targeted prostate biopsy
9722032|NCT03982706||Focal|patients undergoing focal treatment for localized prostate cancer (HIFU, NanoKnife, Cryotherapy)
9722033|NCT03982147||Stroke patients|Patients with recent ischaemic stroke
9722034|NCT03981224||plasma EBV DNA detectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was detectable.
10205434|NCT00070564|Experimental|Arm II|(closed 11/10/10) Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel and pegfilgrastim as in arm I.
9722035|NCT03981224||plasma EBV DNA undetectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was undetectable.
9722036|NCT03981393||'Less severe hypoxaemia'|PaO2/FiO2 ratio > 68 mmHg (9.1kPa) at decision-to-cannulate
9722037|NCT03981393||'Very severe hypoxaemia'|PaO2/FiO2 ratio ≤ 68 mmHg (9.1kPa) at decision-to-cannulate
9722038|NCT03980158||Upper airway stimulation group|
9722039|NCT03980158||OSA group with conservative / no treatment|
9722040|NCT03980158||Test group without OSA|
9722041|NCT03977818||patients with metastatic softtissue sarcomas diagnosed between 1990 and 2013|
9722042|NCT03977857||28-day nonsurvival or transplantation|patients who died or underwent liver transplantation within 28 days since admission
9722043|NCT03977857||28-day transplantation-free survival|patients who survived without liver transplantation at 28 days since admission
9722044|NCT03976739||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
9722045|NCT03976739||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
9722046|NCT03976739||gastric cancer|patients with gastric cancer according to histopathological results
9722047|NCT03976947||Before group|"The before group is the control group. We collect retrospective data in consecutive patients operated before the implementation of lung recruitment maneuvers protocol"
9722048|NCT03976947||After group|We collect data in consecutive patients operated after the implementation of lung recruitment maneuvers protocol. This lung recruitment maneuvers will be realised along the surgery, (After tracheal intubation, per-CPB, post-CPB). Each recruitment maneuver consisted of applying a continuous positive airway pressure of 30 cm of water for 30 seconds
9722049|NCT03976531||Elderly cancer patients included in randomized controlled trials|
9722050|NCT03976453||Group A|Women who underwent caesarean hysterectomy
9722051|NCT03976453||Group B|Women who underwent lower segment caesarean section
9722052|NCT03976453||Group C|Women who underwent spontaneous Vaginal delivery
9722053|NCT03974971||BPDCN diagnosis group|By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018
9722054|NCT03974763||Test Group|Patients with acute, unilateral, facial paralysis (Bell's Palsy)
9722055|NCT03974763||Control Group|A group of age- and sex-frequency matched 'normal' controls. Based on past research, gender and age are possible confounders of facial movement/function. Thus, the control group will be frequency-matched to the patient group on gender and age.
9780462|NCT02324439|Experimental|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
9780463|NCT02323464||Before surgery|patients scheduled for surgery of colorectal cancer
9780464|NCT02323464||Open surgery for colorectal cancer|investigated after open surgery of colorectal cancer
9780465|NCT02323464||Laparoscopic or robotic surgery|investigated after laparoscopic or robot surgery of colorectal cancer
10196804|NCT05166551|No Intervention|Control Group|Without any intervention, the infants in this group pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher during the vaccination procedure (as soon as the needle enters and immediately after the needle exits). In addition, the HR and SPO2 level of the infants 1 minute before and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded. In terms of the reliability of the research results, the vaccine administration will be carried out by the same nurse working in the vaccine unit in all groups.
10196805|NCT05166291|Experimental|traditional anesthesia (TA)|traditional anesthesia
10196806|NCT05166291|Experimental|comfort-in injection system (CIS)|comfort-in injection system (CIS)
10196807|NCT05166213||Chronic back pain|
10196808|NCT05166213||Clinically significant menopausal complaints|
9827874|NCT02471586|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
9827875|NCT02471586|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
10196809|NCT05166213||Parkinson's disease|
10196810|NCT05166213||Migraine|
10196811|NCT05166213||Cancer-related emesis/nausea|
10196812|NCT05165173|Experimental|Intervention|Based on estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the nanoparticle group.
10196813|NCT05165173|Active Comparator|Comparator|Based on the estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the microparticle group.
10196814|NCT05164471|Experimental|FLT180a|A single dose of FLT180a will be administered. Dose will be determined by enrollment cohort. The first 3 patients will receive 7.7 x 10e11 vg/kg. The dose in subsequent cohorts will be determined by the DMC based on review of data from the prior cohort(s).
10196815|NCT05164315|Experimental|Tailored surgery|Arm 1 will receive tailored surgery. If there are no cancer cells or the margin is negative in the local excision/biopsy during surgery, the operation will be terminated. And if the final pathology result is T2-4, or cancer cells and margin are positive in the frozen section during surgery, or the result of digital rectal examination and visual examination using anoretractor under general anesthesia is not suitable for local excision (visible and palpable tumor nodules), a total mesorectal excision will be performed.
10196816|NCT05164315|Active Comparator|Total mesorectal excision (TME)|Arm 2 will receive TME. Surgery including high ligation of the inferior mesenteric artery and total mesorectal excision will be performed under the lithotomy position. After pelvic dissection, double-stapled anastomosis or transanal anastomosis will be performed, followed by diverting stoma. Abdominoperineal resection with permanent stoma is included.
10196817|NCT05164003|Experimental|CORETOX®|
10196818|NCT05164003|Active Comparator|BOTOX®|
10196819|NCT05163964||Control Group|Prediabetes patients aged 18-65 years old, who plan to continue healthcare services at a community clinic in Malacca, no literacy barries
10196820|NCT05163574|Experimental|High dose|20 patients
10196821|NCT05163574|Active Comparator|Low dose|20 patients
9780466|NCT02323464||Control subjects|Controls from the population without colorectal cancer
9780467|NCT02312258|Placebo Comparator|Placebo|Ixazomib placebo-matching capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (1st interim analysis data cut-off 12 August 2019).
9780468|NCT02312258|Experimental|Ixazomib|Ixazomib 3 mg, capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib 3 or 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (1st interim analysis data cut-off 12 August 2019).
9980745|NCT01394887|Placebo Comparator|placebo group|This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise
9980746|NCT01394913|Experimental|Reumatocept 25mg|50mg each week for 30 weeks
9980747|NCT01394913|Active Comparator|Enbrel 25mg|50mg each week for 30 weeks
9980748|NCT01394965|No Intervention|ECG Mapping|
9836217|NCT02775903|Experimental|Azacitidine + Durvalumab|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
9980749|NCT01395069|Active Comparator|Nepafenac 0.1%|
9980750|NCT01395069|Active Comparator|Ketorolac 0.5%|
9980751|NCT01395069|Placebo Comparator|Placebo|
9980752|NCT01395082||Entire registry group|Participants with potential myopericarditis cases referred to the Registry
9980753|NCT01395095|Experimental|OPTICARE-A|Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
10196822|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A
9722056|NCT03974347||Acute kidney injury, no acute kidney injury|Acute kidney injury after cardiac surgery will be defined by KDIGO criteria, Creatinine rise from baseline and or urine production.
9722057|NCT03974347||No Acute Kidney Injury|No Acute kidney Injury after Cardiac surgery, according to KDIGO AKI definition
9722058|NCT03973970||Test Arm 1- T-SPOT.TB assay|Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
9722059|NCT03973970||Test Arm 2-QuantiFERON-TB Gold Plus assay|Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
9980754|NCT01395095|Active Comparator|OPTICARE-B|Standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions)
9722060|NCT03973723||Patients with NPC after treatment|All patients with NPC without distant metastases who receiving adequate RT dose
9722061|NCT03972839||D-Dimers patients|population recruited in Brest for a period of 1 year: patients for whom a dose of VIDAS D-dimers is prescribed (approximately 3700 patients)
9722062|NCT03972098||ra patients|The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 [8]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young.
9722063|NCT03972098||healthy control|healthy person, similar population
9722064|NCT03971344||Family members of newborns extremely premature|Parents and siblings (if any) of infants born at 30 weeks gestational age or less, or with a birthweight less than 1500 grams.
9722065|NCT03971344||Family members of new pediatric oncology patients|Parents and siblings (if any) of patients with new onset (not relapses) pediatric oncologic diagnoses including liquid, solid, and brain cancer.
9722066|NCT03971344||Family members of critical congenital heart defect patients|Parents and siblings (if any) of newborns with critical congenital heart defects who typically undergo surgery by 12 months of life.
10196823|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B
10196824|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C
9722067|NCT03971344||Family members of children with severe neurological impairment|Parents and siblings (if any) of patients with severe neurologic impairments, associated with substantial functional impairment, relentless progressive deterioration, or substantially shortened life-spans.
9722068|NCT03971006||Immunocompetent ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) and no immunosuppression (excluding patients with HIV infection, solid tumor or hematological malignancies, organ transplant or taking steroids since more than 4 weeks).
9722069|NCT03971006||Immunosuppressed ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) (Berlin definition (2)) and previously known immunosuppression (as listed above). These patients will allow comparing the cell defects observed in the study population to those observed in immunosuppressed patients.
9722070|NCT03971006||Controls|(n=10) Patients undergoing a bronchoscopy with Bronchoalveolar Liquid (BAL) as part of routine care but having neither ARDS nor active lung infection, infiltrating lung disease or immunosuppression. These patients will allow quantifying normal levels of the studied biomarkers in the alveolar and blood compartments.
9722071|NCT03969940||Thermo|Buruli ulcer patients receiving thermotherapy
9722072|NCT03969940||Chemo|Buruli ulcer patients receiving chemotherapy
9722073|NCT03969498||1- Obstetric APS women (oAPS)|No intervention, pure observational study.
9722074|NCT03969498||2-Women positive for F5rs6025 or F2rs1799963 polymorphis|No intervention, pure observational study.
9722075|NCT03969498||3-Women with negative thrombophilia screening (Control group|No intervention, pure observational study.
9722076|NCT03969667||healthy young adults|healthy young adults
9722077|NCT03967366||plasma melatonin 1|Quartile 1 of plasma melatonin
9722078|NCT03967366||plasma melatonin 2|Quartile 2 of plasma melatonin
10196825|NCT05163561|Active Comparator|Sii Licensed IPV|Sii Licensed IPV
10196826|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 1200 mg, 1200 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 1200 mg, 1200 mg) during daily therapy with 2NRTIs for 12 weeks
10196827|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 900 mg, 900 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 900 mg, 900 mg) during daily therapy with 2NRTIs for 12 weeks
9722079|NCT03967366||plasma melatonin 3|Quartile 3 of plasma melatonin
9722080|NCT03967366||plasma melatonin 4|Quartile 4 of plasma melatonin
9722081|NCT03966274||Delirium positive|
9722082|NCT03966274||Delirium negative|
9722083|NCT03964987||Control group|Women with normoevolutionary gestation.
9722084|NCT03964987||Problem group|Patients with GDM.
9722085|NCT03964428||periodontitis|
9722086|NCT03964428||periodontitis with T2DM|
9722087|NCT03964428||control|
9722088|NCT03964649||Truven Health MarketScan Research Database|To compare RA-related costs among patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs (individually, as well as to TNFi and to non-TNFi each combined as groups).
9722089|NCT03963700||Cancer patients with Paraneoplastic neurological syndromes|"Cancer patients with Paraneoplastic neurological syndromes presenting various autoimmune anomalies:~Anti-Hu also known as anti-Neuron specific cell Nuclear Antibodies (anti-ANNA1) (350 patients), uncommon form of brain inflammation associated with an underlying cancer~anti-Yo (130 patients), antibody associated with paraneoplastic cerebellar degeneration~anti-Ma2 (50 patients), antibody associated with paraneoplastic encephalitis~anti-N-methyl-d-aspartate (NMDA) Receptor (350 patients), autoimmune disorder in which antibodies attack N-methyl-D-aspartate-type glutamate receptors~anti-gamma-aminobutyric acid-B (GABAb) receptor (35 patients), autoimmune disorder in which antibodies attack gamma-aminobutyric acid-B receptors~anti-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (15 patients), autoimmune disorder in which antibodies attack alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors~without antibodies (50 patients)."
9722090|NCT03961035||25% cycle ratio|Patients group treated with CPCTSI at a 25% cycle ratio
9722091|NCT03961035||31.3% cycle ratio|Patients group treated with CPCTSI at a 31.3% cycle ratio
9722092|NCT03960333||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
9722093|NCT03960333||Overweight/Obese|Overweight/Obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
9722094|NCT03960333||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance who have been recently prescribed Metformin and have a Body Mass Index (BMI) ≥ 85th percentile for age/sex (n=20) will be recruited. Participants in this cohort will be asked to complete a two study visits approximately 6 months apart.
9722095|NCT03959670||extensive TAAA|including Crawford extent I and II TAAA
9722096|NCT03959670||Crawford extent III TAAA|
9722097|NCT03959670||supra-renal aortic aneurysms|Crawford extent IV TAAA and para-renal abdominal aortic aneurysms.
9722098|NCT03959475||Saint-Etienne Hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
9722099|NCT03959475||Firminy hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
9722100|NCT03959475||South Lyon hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
9722101|NCT03959475||Bordeaux hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
9722102|NCT03959475||Saint-Chamond hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
9722103|NCT03959475||Angers hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
9722104|NCT03959475||Clermont Ferrand hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
9722105|NCT03957616||Paraneoplastic neurological syndromes patients|Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
9722106|NCT03956342||Pediatric Clinicians - Group 1|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This cohort will complete a first round of interviews to assess measure content."
9722107|NCT03956342||Pediatric Clinicians - Group 2|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.~This smaller cohort will be a randomized subset of the original cohort and will complete interviews to assess changes made based on the feedback from the first cohort."
9722108|NCT03955874||INITIAL SBT|Patients who underwent an Spontaneous Breathing Trial prior to extubation. This cohort will be further subdivided into initial patients who initially pass an SBT successes and those who initially fail an SBT.
9722109|NCT03955874||DIRECT EXTUBATION|Patients that were directly extubated without conduct of a prior SBT or tracheostomy
9722110|NCT03955874||DIRECT TRACHEOSTOMY|Patients who underwent a direct tracheostomy without conduct of a prior SBT or extubation
9722111|NCT03955874||No attempt at mechanical ventilation discontinuation|Patients who died without conduct of a prior SBT, extubation or tracheostomy
9722112|NCT03956186||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
9722113|NCT03956186||Non-hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
9980755|NCT01395095|Experimental|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
9980756|NCT01395108|Placebo Comparator|Placebo|Placebo
9980757|NCT01395108|Active Comparator|Nemonoxacin 125mg|Nemonoxacin 125mg
9980758|NCT01395108|Active Comparator|Nemonoxacin 250mg|Nemonoxacin 250mg
9785241|NCT01246713|Active Comparator|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
9980759|NCT01395108|Active Comparator|Nemonoxacin 500mg|Nemonoxacin 500mg
9980760|NCT01395108|Active Comparator|Nemonoxacin 750mg|Nemonoxacin 750mg
10196828|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 600 mg, 600 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 600 mg, 600 mg) during daily therapy with 2NRTIs for 12 weeks
9722114|NCT03954769||Inpatients|Patients admitted to Stanford Hospital and Clinics medical and surgical units
9722115|NCT03954587||Artificial (HRT) Cycles|"Commence estradiol valerate (E2) 4mg from day 2 or 3 of period for 3 days~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily).~Embryo transfer is scheduled on the 5th full day of progesterone administration."
9722116|NCT03954587||Spontaneous natural cycles:|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/mL confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
9722117|NCT03953937||ICP cohort|Patients with idiopathic pancreatitis
9722118|NCT03953872||ARB|Group of angiotensin receptor blockers(ARB) monotherapy users. A subject was considered as an ARB user when the total prescription days of ARB monotherapy was at least 30.
9722119|NCT03953872||combination of CCB and ARB|Group of calcium channel blockers(CCB) and angiotensin receptor blockers(ARB) combination users. A subject was considered as a CCB and ARB combination user when the total prescription days of CCB and ARB combination therapy was at least 30.
9722120|NCT03953872||CCB|Group of calcium channel blockers(CCB) monotherapy users. A subject was considered as a CCB user when the total prescription days of CCB monotherapy was at least 30.
9722121|NCT03953872||No treatment|Group of nonusers of antihypertensives. A subject was considered as a nonuser never received regular antihypertensive treatment or total prescription days of antihypertensives was less than 30.
9722122|NCT03953547||search for antiplatelet resistance|Patients who were hospitalized in the vascular medicine department and who benefited from a search for antiplatelet resistance between April 2014 and November 2017.
9722123|NCT03952871||Intensive care patient with hemodynamic instability|The study group is composed of intensive care patients which already need an invasive monitoring of the cardiac output because of a shock state.
9722124|NCT03951792||Colorectal Cancer Subjects|Subjects under going colorectal resection with colorectal cancer will have tissue and stool collected
9722125|NCT03951792||Benign Colon Resection Subjects|Subjects under going colorectal resection without colorectal cancer will have tissue and stool collected
9722126|NCT03951675||Individuals Living with DMD|90 patients/parents
9980761|NCT01395108|Active Comparator|Nemonoxacin 1000mg|Nemonoxacin 1000mg
10196829|NCT05163535|Other|ELPIDA®|ELPIDA®, 20 mg capsules and 2NRTIs, daily therapy for 12 weeks
10196830|NCT05163496|Experimental|Psilocybin arm|psychedelic assisted psychotherapy + 25mg psilocybin
9722127|NCT03951675||Healthcare Providers to Patients with DMD|40 healthcare providers
9722128|NCT03951532||children with hyperthyroidism|children and adolescents (6 months -17 years included) whose data are present in the SNIIRAM database (DCIR data) and beneficiaries of the general health insurance scheme during the study period (01/01/2006-31/12/2017)
9722129|NCT03951233||K-RAS and EGFR mutated|
9722130|NCT03951233||Wild type|
9722131|NCT03950375||cochlear implantation|"cochlear implantation group : patients undergoing cochlear implantation between December 2018 and June 2019 in the ENT service of Reims universitary hospital."
9722132|NCT03949218||bipolar disorder(BD)|hospitalized patients BD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F31 bipolar disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
9722133|NCT03949218||major depressive disorder（MDD）|hospitalized patients MDD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F32 depressive disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
9722134|NCT03948204||Prostate cancer|Men diagnosed with prostate cancer
9722135|NCT03948204||Men without prostate cancer|Men without prostate cancer matched for age and county
9722136|NCT03947931||General group|Patient with extremely severe ulcerative colitis
9722137|NCT03947749||Patients with HICMP|Patients with PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized into this group.
9722138|NCT03947749||Patients without HICMP|Patients without PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized will be categorized into this group.
9785242|NCT01246791|Experimental|NPC-01|Single oral administration of NPC-01
9785243|NCT01246895||Experimental|Microfracture with BST-CarGel
9785244|NCT01246895||Control|Microfracture without BST-CarGel
9980762|NCT01395121|Experimental|nilotinib|nilotinib 400mgs oral tablets
9980763|NCT01395134|No Intervention|Visualization of the EBSLN and RLN|Visual inspection of the nerves.
10196831|NCT05163496|Active Comparator|Placebo|Psychedelic assisted psychotherapy + 250mg niacin
10196832|NCT05163444|Experimental|Rolling can|Gait analysis with rolling cane
9722139|NCT03947749||Patients at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
9722140|NCT03947749||Patients not at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
9980764|NCT01395134|Experimental|Neuromonitoring of the EBSLN and RLN|Electrical stimulation and monitoring of the nerves' function.
9722141|NCT03947060||Nasal & Frontal sensor position|One group of participants with two modes of measurement. First mode is standard frontal placement of the SedLine® sensor. Second mode is alternative nasal placement of the SedLine® sensor.
9722142|NCT03946540||L-FED sample|All young people treated in Maudsley Child and Adolescent Eating Disorder Service between 1/8/2009 and 31/1/2014.
10196833|NCT05163444|Active Comparator|Quadripod can|Gait analysis with quadripod cane
10196834|NCT05162950||SW CAH|Patients with 21-hydroxylase deficiency, salt wasting form.
9722145|NCT03945435||Normal Glucose Tolerance|Blood glucose level of less than 140 mg/dL at the 2 hour timepoint.
9722146|NCT03945435||Impaired Glucose Tolerance|Blood glucose level of greater or equal to 140 mg/dL at the 2 hour timepoint.
9722147|NCT03943706||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
9722148|NCT03943706||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
9722149|NCT03941470||unexplained recurrent pregnancy loss|peripheral blood sample examined by flowcytometry
9722150|NCT03941470||control fertile multipara|peripheral blood sample examined by flowcytometry
9722151|NCT03941392||Healthy children between 1 and 9 years old|A sample of 1500 apparently healthy children between 1 to 9 years old from urban areas from different regions of Spain.
9722152|NCT03941015||patients with renal desaturation|Patients who underwent a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
9722153|NCT03941015||patients without renal desaturation|Patients who didn't undergo a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
9722154|NCT03941184||SCAD cases|SCAD cases will be identified based on presence of at least one diagnosis code for SCAD followed by manual verification by a trained individual, OR, inclusion in the previously validated SCAD cohort (Tweet 2012).
9722155|NCT03941184||Controls without SCAD|Potential controls will be identified based on absence of any SCAD diagnosis codes.
9722156|NCT03939676||Major Depressive Disorder or Bipolar Disorder|All eligible participants will be included in this single study arm.
9722157|NCT03938675||Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
9722158|NCT03938675||No Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
9722159|NCT03937245||HA-BSI|Patients with HA-BSI treated in an ICU
9722160|NCT03936439||Consecutive stroke patient|All consecutive stroke patients from five time points, i.e. 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018 are selected for analysis.
9722161|NCT03935542||MPI arm|For the MPI arm, patients with severe jailed diagonal branch disease with available MPI in 3 months were selected from the Seoul National University Hospital Cardiac Catheterization and MPI database.
9722162|NCT03935542||CCTA arm|For the CCTA arm, patients from a previous multicenter prospective CCTA registry were retrospectively reviewed for a post-hoc analysis.
9980765|NCT01395147|Experimental|Lu AA21004 group|
9980766|NCT01395160||Adult ADHD|
9980767|NCT01395160||Bipolar Disorder|
9980768|NCT01395160||Healthy control|
9980769|NCT01395173|Placebo Comparator|Control|Subject will undergo standard colonoscopy.
9980770|NCT01395173|Active Comparator|Position change|Subject will under go standard colonoscopy, but also with position changes during colonoscope withdrawal.
10196835|NCT05162950||SV CAH|Patients with 21-hydroxylase deficiency, simple virilising form.
10196836|NCT05162950||NC CAH|Patients with 21-hydroxylase deficiency, non-classic form.
9722163|NCT03933878||Post-transplant recipient BAL samples|No intervention will be administered
9722164|NCT03933878||Donor BAL samples|No intervention will be administered
9722165|NCT03933540||Pediatric Asthma Patients|"Participants are ages 8 years through 17 years and have partially controlled or uncontrolled asthma.~No intervention is included in this study."
10196837|NCT05162950||Carrier CAH|Healthy individuals, heterozygous carriers a mutation in the CYP21A2 gene. Recruited among parents of patients with CAH.
10196838|NCT05162950||Control|Healthy sex and age matched controls
9785245|NCT01246960|Experimental|Ramucirumab|"Oxaliplatin 85 milligrams per square meter (mg/m^2) given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-Fluorouracil (5-FU) 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Ramucirumab 8 milligrams per kilogram (mg/kg) given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
10196839|NCT05162573|Experimental|EBRT + 3 GBq Lu-PSMA|
10196840|NCT05162573|Experimental|EBRT + 6 GBq Lu-PSMA|
10196841|NCT05162573|Experimental|EBRT + 9 GBq Lu-PSMA|
10196842|NCT05162495|Experimental|Arm A|Requiring a diagnostic or screening RT-PCR test for COVID-19.
10196843|NCT05162495|Experimental|Arm B|Positive to COVID-19 in RT-PCR test performed up to 48 hours before screening.
10196844|NCT05162365|Experimental|IBI314|a cocktail of two SARS-CoV-2 S protein IgG1 antibodies, IBI314-A and IBI314-B, in a 1:1 [w/w] ratio
10196845|NCT05162365|Placebo Comparator|Placebo|
9722166|NCT03932539||Twenty-five de-novo heart transplant recipients|Twenty-five de-novo heart transplant recipients will be enrolled, male and female, aging 18-70 years, receiving TAC in combination with steroids and antiproliferative drugs, either Everolimus or Sirolimus.
9722167|NCT03931954||Study population|Patients completing the inclusión criteria
9722168|NCT03931486||Operatively treated patients with Achilles tendon rupture|Cohort of operatively treated patients with acute Achilles tendon rupture.
9722169|NCT03930979||Clearsight measurements|All patients presenting to the ED who have a painful condition for which procedural sedation is required will undergo Clearsight measurements
9722170|NCT03929874||18 ≤ age ≤ 40|18 ≤ age ≤ 40
9722171|NCT03929874||age ≥ 60|age ≥ 60
9722172|NCT03929705||Test Arm 1- T-SPOT.TB assay|T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
9722173|NCT03929705||Test Arm 2 -QuantiFERON-TB Gold Plus assay|QuantiFERON-TB Gold Plus, for each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
9722174|NCT03930004||Type 1 diabetic patients|"Patients diagnosed with type 1 diabetes mellitus with criteria for cardiovascular autonomic neuropathy, asymptomatic, normotensive, with negative medical history of cardiovascular disease.~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
9722175|NCT03930004||Control - Healthy subjects|"Fifteen age- and sex-matched healthy control subjects, asymptomatic, normotensive, with negative medical history of cardiovascular disease.~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
9722176|NCT03928912||without fracture nonunion|The patients who undergone surgery after tibial shaft fracture did not exist fracture nonunion
9722177|NCT03928912||with fracture nonunion|The patients who undergone surgery after tibial shaft fracture existed fracture nonunion
9722178|NCT03928769||Control Group|Patients with traumatic vascular injury, ultimately corresponding to control patients
9722179|NCT03928769||Atheroma Group|"Patients will be included either in the atheromatous group (patients with atheromatous pathology) or in the control group (patients without atheromatous pathology), according to the clinical evaluation.~In the atheromatous group, subjects must have a clinically significant atheromatous pathology.~The investigator must specify the site (s) affected by the atheroma: carotid artery, coronary artery, aorta, renal artery, mesenteric artery or lower limb artery."
9722180|NCT03926273||group 1|Epileptic participants group consisted of 40 adults (15 females and 25 males) clinically and electrophysiological were diagnosed according to the international league against epilepsy classification 2010.
9722181|NCT03926273||group 2|Control group consisted of 40 adults (16 females and 24 males) non - epileptic healthy subjects.
9722182|NCT03925805||Chronic disease|Cardiovascular disease (including diabetes), mental disease, musculoskeletal disease
9722183|NCT03925688||without heterotopic ossification|There had not existed radiographic evidences of heterotopic ossification.
9722184|NCT03925688||with heterotopic ossification|There had existed radiographic evidences of heterotopic ossification or formatted ectopic lamellar bone.
9722185|NCT03925610||Morbidly obese patients with moderate-to-severe OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
9722186|NCT03925610||Morbidly obese patients with no or mild OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
9722187|NCT03925298||group 1|participants with elevated serum troponin level (≥0.01μg/L)
9722188|NCT03925298||group 2|those with normal serum troponin level (<0.01μg/L)
9722189|NCT03925441||Pediatric participants with chronic severe plaque psoriasis|Participants with chronic severe plaque psoriasis receiving adalimumab in routine clinical practice
9722190|NCT03923309||Intended rectal preservation|When rectal preservation (non-operative management or local excision) was agreed by their surgeon.
9722191|NCT03923309||Unintended rectal preservation|When rectal preservation (non-operative management or local excision) was disagreed by their surgeon.
9722192|NCT03923400||JI-GIST|The series comprises 77 patients, of which 29 (37.7%) were located in the jejunum or ileum (JI-GIST).
9722193|NCT03923400||G-GIST|The series comprises 77 patients, of which 48 (62.3%) were located in the stomach (G-GIST).
9722194|NCT03921788||Group 1|Patients with venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
9722195|NCT03921788||Group 2|Patients without venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
9722196|NCT03921788||Group 3|Volunteers without pain syndromes of any location. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
9722197|NCT03921216||Diabetic nephropathy, on hemodialysis|
9980771|NCT01395186|Other|varicocelectomy|varicocelectomy for patients complaining of pain
9980772|NCT01395199|Placebo Comparator|Starch pill|Placebo
10196846|NCT05162287||Patients who are treated in the acute ward of the child and adolescent psychiatry|All children and adolescents aged 12 to 18 years who are treated in the acute ward of the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics at the University Medical Center Hamburg-Eppendorf are recruited.
10196847|NCT05162209|Experimental|Synbiotic|Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x10 9CFU/sachet), fructooligosaccharydes (FOS) 625 mg, oral sachet daily, for 12 weeks
10196848|NCT05162209|Placebo Comparator|Placebo|Oral sachet daily for 12 weeks
10196849|NCT05161871|Active Comparator|Cathodal transcranial direct current stimulation|
10196850|NCT05161871|Sham Comparator|Sham transcranial direct current stimulation|
9722198|NCT03921216||Chronic kidney disease, on hemodialysis|Chronic kidney disease of other causes than Diabetes.
9722199|NCT03921216||Chronic kidney disease, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
9722200|NCT03921216||Diabetic nephropathy, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
9722201|NCT03919643||SLE patients with nephritis|No intervention. Peripheral blood and urine samples will be obtained
9722202|NCT03919643||SLE patients with without nephritis|No intervention. Peripheral blood and urine samples will be obtained
9980773|NCT01395199|Experimental|Amlodipine|Amlodipine 5mg QD
9980774|NCT01395212||Cardiac stem cell therapy 5 years ago|
9980775|NCT01395225||All Patients|There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
9980776|NCT01395238|No Intervention|Wait-List Group|
9980777|NCT01395238|Experimental|Parenting Group|Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
9980778|NCT01395251|Other|Prednisolone|Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
9980779|NCT01395264||Episodic Migraine.|
9980780|NCT01395264||menstrual migraine|
9980781|NCT01395264||Cluster Headache patients|
9980782|NCT01395264||control (non-headache group)|
9980783|NCT01395290|Experimental|cholecalciferol|cholecalciferol 20.000 IU per week
9980784|NCT01395303||myocardial infarction|subjects with myocardial infarction in the Tromsø study end point registry
9980785|NCT01395303||type 2 diabetes|subjects with type 2 diabetes in the Tromsø study end point registry
9722203|NCT03919643||Healthy controls (blood donors)|No intervention. Peripheral blood and urine samples will be obtained
9980786|NCT01395303||stroke|subjects with stroke in the Tromsø study end point registry
9980787|NCT01395303||fracture|subjects with fracture in the Tromsø study end point registry
9722204|NCT03919734||AI ACS/possible ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression equal to or above 50 nmol/l. The patients should not have clinical signs of Cushing Syndrome, such as catabolic skin and muscle changes.
9722205|NCT03919734||AI non-ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression below 50 nmol/l.
9722206|NCT03919734||Treatment with Inhalation Steroids|Patients treated with inhalation steroids with and without ACS/possible ACS but not operated with adrenalectomy.
9722207|NCT03919734||Adrenalectomy|Patients with unilateral AI operated with adrenalectomy
9722208|NCT03919734||Controls|"A Group of Controls matched for sex and age, achieved by the government agency Statistics Sweden (SCB)."
9722209|NCT03918876||Healty Dancers|Healthy adult dancers
9722210|NCT03918876||Injured Dancers|Injured adult dancers
9722211|NCT03918772||Perioperative immediate hypersensitivity|Patients having experienced perioperative immediate hypersensitivity
9722212|NCT03917589||Patients with corticosteroids|Patients who have systematically been treated by high-dose corticosteroids after the delivery
9722213|NCT03917589||Patients without corticosteroids|Patients who haven't been systematically treated by high-dose corticosteroids after the delivery.
9722214|NCT03916874||Pregnant females and her newborn.|A longitudinal study of one cohort of 250 pregnant females less than 22 weeks gestation and her newborn. Swabs and samples (low vaginal, skin, urine, blood and stool) will be requested at one time point during each trimester from the participant. In addition, there are three different questionnaires at trimester 2.
9980788|NCT01395303||cancer|subjects with cancer in the Tromsø study end point registry
9980789|NCT01395303||death|subjects registered as dead in the Tromsø study end point registry
9980790|NCT01395303||aortic stenosis|subjects with aortic stenosis in the Tromsø study end point registry
9980791|NCT01395303||control group|randomly selected controls from the Tromsø study
9980792|NCT01395342|No Intervention|blood pressure and heart rate data|
9984524|NCT04011150|Active Comparator|Automated mandatory bolus (AMB) of variable-frequency (VAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VAMB programme. The programme uses lower doses with more frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
9984525|NCT04009967|Experimental|Prostate Cancer|Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.
9984526|NCT04009057||B/F/TAF|HIV-1 infected adults who initiate B/F/TAF therapy
9984527|NCT04008082||Lenvatinib|Lenvatinib capsules 12 milligram (mg) for participants with body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg for participants with body weight less than (<) 60 kg, orally, once daily as per routine clinical practice.
10196851|NCT05161689|Experimental|Mpowerment-based intervention|YMSM in this arm may be exposed to a multicomponent, multi-level, community mobilization, combination intervention to address the entire HIV Continuum of Prevention and Care.
10196852|NCT05161689|No Intervention|Standard of care|YMSM in this arm will not be exposed to the intervention.
9722215|NCT03916224||Intubated critically ill patients|Critically ill patients older than 18 years old, intubated in an Intensive Care Unit.
9722216|NCT03915249||Allogeneic-HSCT candidates|Physical activity, pulmonary functions (FEV1, FVC, FEV1/FVC, FEF25-75%, PEF), exercise capacity, respiratory (maximal inspiratory and expiratory pressures (MIP, MEP)) and peripheral muscle strength were evaluated in allogeneic-HSCT candidates.
9722217|NCT03915210||Candidates of HSCT|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
9722218|NCT03915210||Healthy individuals|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
9980793|NCT01395355|Experimental|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
9780480|NCT02249650|Experimental|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
9780481|NCT02242942|Experimental|Safety Run-in Obinutuzumab + Venetoclax|Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
9780482|NCT02242942|Experimental|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
9780483|NCT02242942|Experimental|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
9780484|NCT02236832|Experimental|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
9780485|NCT02236832|Experimental|PSP patients|progressive supra nuclear palsy patients
9780486|NCT02236832|Active Comparator|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
9780487|NCT02236832|Experimental|healthy participants|healthy participants that will participate to the TMS study.
9780488|NCT02236832|Experimental|healthy young participants|Healthy participants will be included for an EEG study
9780489|NCT02208271||Control|pre-operative total hip patients with no existing total hip implant
9780490|NCT02208271||Metal on polyethylene|patients who have a failed metal on polyethylene total hip implant and are presenting for revision surgery
9780491|NCT02208271||Metal on Metal|patients who have a failed metal on metal total hip implant and are presenting for revision surgery
9785246|NCT01246960|Placebo Comparator|Placebo|"Oxaliplatin 85 mg/m^2 given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-FU 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Placebo given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
9785247|NCT01246973|Experimental|curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
9785248|NCT01246973|Placebo Comparator|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
9785249|NCT01246986|Experimental|Part A Cohort 1-160 milligram (mg) LY2157299|"Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299.~80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
9785250|NCT01246986|Experimental|Part A Cohort 2 - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
9980794|NCT01395355|Active Comparator|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral weight management techniques.
9980795|NCT01395381|Placebo Comparator|Placebo|
9980796|NCT01395381|Experimental|Albendazole|
9980797|NCT01395407|Experimental|Cohort A|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Dose level Cohort A (Gy)~21~23~25"
10196853|NCT05160545|Experimental|GNC-035|Patients receive GNC-035 intravenous infusion (IV, QW) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles
10196854|NCT05160350|Active Comparator|Probiotic|Familact 2 plus (Zist takhmir pharmaceutical company, Iran), one capsule per day
10196855|NCT05160350|Placebo Comparator|Placebo|Similar capsule in shape and size (Zist takhmir pharmaceutical company, Iran), one capsule per day
10196856|NCT05160311|Other|Optimized Medical Treatment (OMT)|The patient considered non-viable by MRI and randomized to Optimized Medical Treatment (OMT) will be treated according to Optimized Medical Treatment guidelines for Coronary Artery Disease (CAD)
10196857|NCT05160311|Experimental|Angioplasty (PCI) and Optimized Medical Treatment (OMT)|The patient considered non-viable and randomized to Coronary Angioplasty will be treated with drug-eluting stent (PCI) and Optimized Medical Treatment (OMT)
10196858|NCT05159752|Experimental|Afamelanotide|
10196859|NCT05159206|Other|CT group|CT-scan preoperatively, postoperatively and at 3 months, 1 and 2 years. Per-operative navigation based on the CT scan.
10196860|NCT05158920|Experimental|Intervention Group|Participants in the intervention group received Mindfulness-Based Cognitive Therapy in addition to their treatment as usual.
10196861|NCT05158920|No Intervention|Control Group|Participants in the control group received their treatment as usual.
9722219|NCT03912792||XLHED Patients|
9722220|NCT03912792||Healthy Controls|
9722221|NCT03912506||Patient admitted in the ICU for leptospirosis|Patient admitted in the ICU for leptospirosis None intervention was performed according to retrospective design
9722222|NCT03912181||Familial chylomicronaemia syndrome (FCS)|"Patient homozygous or compound heterozygous mutation in lipoprotein lipase (LPL) gene~Patient homozygous or compound heterozygous mutation in any Apolipoprotein A5 (Apo A5), glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2), genes and heterozygous (het) mutation in LPL gene"
9722223|NCT03912181||Multifactorial chylomicronemia syndrome|"Patient with heterozygous mutation in lipoprotein lipase (LPL) , Apolipoprotein A5 (Apo AV), GPI HBP1, LMF1, ApoC2 genes and any additional combination of functional variant~Patient with any additional combination of functional variant in LPL gene Apo AV, glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2) genes"
9722224|NCT03911999||Non-prostate cancer subjects|No clinical evidence of prostate cancer
9722225|NCT03911999||Subjects with pathologically insignificant prostate cancer|Insignificant prostate cancers were organ confined with tumor volumes less than 0.5 cc and Gleason score < 7.
9722226|NCT03911999||Subjects with pathologically significant prostate cancer|Significant cancers are those with either Gleason score > 7, evidences of extra-prostatic extension with positive margins, or seminal vesicles / lymph nodes involvement.
9722227|NCT03910920||Cystic fibrosis patients with PA|All the children with acute or chronic Pseudomonas aeruginosa infection and followed-up in our cystic fibrosis center will be included in this study.
9722228|NCT03909828||Parkinson's disease patients|patients with Idiopathic Parkinsonism
9722229|NCT03909542||Ileostomy Closure|Patients who have undergone an ileostomy closure procedure.
9722230|NCT03909230||Day 2 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
9722231|NCT03909230||Day 4 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
9722232|NCT03907670||CML patients who will receive imatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment (imatinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
9722233|NCT03907670||CML patients who will receive nilotinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(nilotinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
9722234|NCT03907670||CML patients who will receive dasatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(dasatinib) measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
9722235|NCT03907189||Emergent Inflammation|Subjects with emergent inflammation detected by Podimetrics RTM Mat within the last week.
9722236|NCT03907189||No Inflammation|Subjects with no emergent inflammation detected by Podimetrics RTM Mat within the last week.
9722237|NCT03905993||Experimental: unique group.|At V0: 1238 subjects were screened At V1: 1012 subjects (12 later withdrew) gave the following samples: blood, nasal swab,stool. 323 subjects among 1000 gave one additional sample (Skin Biopsy) At V2: 504 subjects came at V2 to perform blood, nasal swab and stool samples
9722238|NCT03902964||women treated for breast cancer in 2017 (cohort A)|all patients who completed breast cancer treatment between January 1 and May 31, 2017. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
9722239|NCT03902964||women treated for breast cancer in 2015 (cohorte B)|all patients who completed breast cancer treatment between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
9722240|NCT03903042||Group 1|Center 1: Traditional camera(Canon) vs Aurora camera
9722241|NCT03903042||Group 2|Center 2: Traditional camera(Zeiss) vs Aurora camera
9722242|NCT03903042||Group 3|Center 3: Traditional camera(Topcon) vs Aurora camera
9722243|NCT03900975||Vulvar Paget Disease|Women with vulvar paget disease
9722244|NCT03900338||PWV>10|Patients with PWV > 10 (SSphygmoCor) in two different measurements
9722245|NCT03900338||PWV<10|Patients with PWV < 10 (SphygmoCor) in two different measurements
9722246|NCT03899272||Osteoarthritis|All new patient present to clinic referred for osteoarthritis for considering joint replacement Present with knee pain (unilateral or bilateral) contributed by osteoarthritis
9722247|NCT03897816||"PERINATAL"|Pregnant women consecutively referred and admitted to the Perinatal Psychiatric Outpatient Department
9722248|NCT03897816||"OUTPTS"|Pregnant women belonging to the Outpatients Psychiatric Department who did not have psychiatric issues linked to their pregnancy or in the relationship with their children
9980798|NCT01395407|Experimental|Cohort B|"Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter).~Dose level Cohort B (Gy)~18~20~22"
9722249|NCT03897816||Healthy controls|Pregnant women the general population, with no history of mental health issues
9722250|NCT03896100||Element 2|Four clinical samples will be taken from each eligible subject and used to assess two clinical removal methods and two in vitro removal methods.
9722251|NCT03896100||Element 3|Four clinical samples will be taken from each eligible subject and used to assess three different storage methods.
9722252|NCT03896100||Element 4|Four clinical samples will be taken from each eligible subject and used to assess different ocular regions.
9722253|NCT03896048||Successful extubation|
9722254|NCT03896048||Failed extubation|Failed extubation will be defined as a patient who in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy.
9780492|NCT02205047|Active Comparator|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
9780493|NCT02205047|Experimental|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
9722255|NCT03894410||Continuing Lapatinib|Patients continued using treatment containing Lapatinib after progression on Lapatinib.
9722256|NCT03894410||Change HER-2 treatment|Patients changed to another HER-2 targeted treatment after progression on Lapatinib (ado-trastuzumab emtansine, trastuzumab, etc.).
9722257|NCT03894410||Lapatinib plus capetabine|Patients used lapatinib plus capetabine.
9722258|NCT03894410||Lapatinib plus Trastuzumab and one chemotherapy|Patients used lapatinib plus trastuzumab and one chemo regimen.
9722259|NCT03892954||adolescents with CFS ( n= 100)|Participants with CFS who had constant or persisting fatigue lasting 3 months with the severe functional disability to such extent that prevents normal school attendance and also had no drug prescriptions (including hormone contraceptives), any medical or psychiatric disorder that might explain the fatigue were included in this study
9722260|NCT03892954||health control ( n=50).|healthy control subjects with no CFS
9722261|NCT03891836||medical students|All students from the chosen classes in each study year will be invited to complete self-administered questionnaire
9722262|NCT03891745||prone group|prone extubation
9722263|NCT03891745||supine group|supine extubation
9722264|NCT03890705||postpartum women|Women aged (15-49) and had given birth in the past 12 months
9722265|NCT03890874||First year medical students|First year medical students of jubilee mission medical college and research institute
9722266|NCT03890445||Adalimumab Biosimilar (Hyrimoz)|Patients with moderate-to-severe CD receiving Hyrimoz™ treatment according to the Hyrimoz™ label at the discretion of the investigator
9722267|NCT03890445||Infliximab Biosimilar (Zessly)|Patients with moderate-to-severe CD receiving Zessly™ treatment according to the Zessly™ label at the discretion of the investigator
9722268|NCT03890146||intensive care patients|patient hospitalised in intensive care unit veinous and capillary ponction
9722269|NCT03889951||group 1|group of ALL patients with IKZF1 deletion mutation.
9722270|NCT03889951||group 2|group of ALL patients with no detected mutation
9722271|NCT03889574||combination of aspirin, P2Y12 Inhibitor with a NOAC|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
9722272|NCT03889574||combination of aspirin, P2Y12 Inhibitor with warfarin|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
9722273|NCT03887728||Artificial (HRT) Cycles|"Commence estradiol tablets (E2) 4mg from day 2 or 3 of period for 3 days~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 10 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily). Embryo transfer is scheduled 5 days following the initial initiation of progesterone"
9722274|NCT03887728||Spontaneous natural cycles|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5nmol /L confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
9722275|NCT03887351||JGH Cohort|This cohort will not be subjected to any intervention.
9722276|NCT03887351||RVH Cohort|This cohort will not be subjected to any intervention.
9722277|NCT03886974||Adults with type 1 diabetes|People with T1D who are 18 years or older.
9722278|NCT03886974||Parents of adults with type 1 diabetes|Parents who have adult children with type 1 diabetes.
9722279|NCT03886974||Healthcare providers managing patients with type 1 diabetes|Licensed healthcare providers who are managing patients with T1D (whether in adult or pediatric practice).
9722280|NCT03885648||Cases|Women's age will range 25-70 years. Cases will be women diagnosed and surgically intervened of breast cancer, stages I and II.
9722281|NCT03885648||Controls|Controls will be women surgically intervened of breast augmentation or reduction.
9722282|NCT03885193||HMS plus group|HMS plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
9722283|NCT03885193||ACT plus group|ACT plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
9722284|NCT03883854||1 group|"Complete iron profile~serum iron~serum ferritin~total iron binding capacity~transferrin saturation (TSAT)"
9722285|NCT03883867||Normal|The subject population will involve 10 non-pregnant women. The tactile imaging reprifucibility sub-group will include 5 non-pregnant subjects with 2 tactile imaging examinations completed in one session. All other subjects will have a single tactile imaging examination.
9722286|NCT03883867||Pregnant|The subject population will involve 10 pregnant women without known complications at 36-37 weeks of pregnancy scheduled for a regular examination. All pregnant subjects should be examined weekly after completing 36th week of an uncomplicated pregnancy. Routine gynecologic examination includes external and internal obstetrical examination.
9780494|NCT02205047|Experimental|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
9785251|NCT01246986|Experimental|Part B - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
9722287|NCT03883152||Head and neck cancer|Eating difficulty is one of the most common problems for head and neck cancer (HNC), in particular, who are in advanced disease stage and receive surgery, radiation (RT) or concurrent radio-chemotherapy (CCRT) (Vissink, Burlage, Spijkervet, Jansma, & Coppes, 2003; Lazarus et al., 2014). The consequences of multi-treatment bring structural and functional changes in oral, pharynx, or larynx and influence the normal eating process (Logemann et al., 2006; Lazarus et al., 2013; Patterson, McColl, Wilson, Carding, Rapley, 2015; McLaughlin, 2014).
9722288|NCT03881566||Immunocompetent sepsis patients|Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
9722289|NCT03881566||Immunocompromised sepsis patients|Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
10196862|NCT05158608|Active Comparator|Cyclophosphamide on day +3,+4 at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
9722290|NCT03881566||Patients without sepsis|Patients who admitted intensive care unit without sepsis
9722291|NCT03881241||Study Treatment|EVOS SMALL PLating System
9722292|NCT03881046||lung cancer|
9722293|NCT03881046||healthy control group|
9722294|NCT03880643||Study Group|Patients with primary membranous nephropathy who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to at least one set of prior therapies including corticosteroids, alkylating agents or calcineurin inhibitors.
9722295|NCT03880617||Chronic Myeloid Leukemia (CML)|For CML, the first-line targeted drug is imatinib, and then second line as nilotinib and dasatinib. In the past, the median survival of CML is around 4 to 6 years (NCI, 2008). Fortunately, the launch of the targeted therapy, the median survival is expected to approach normal life expectancy for most patients. However, limited to the less than 20 years of advent of TKI, the exact effects on survival time is not yet determined.
9722296|NCT03880617||Gastrointestinal Stromal Tumor (GIST)|For patients with GIST, the imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) (Heinrich et al, 2003) is the first line drug and sunitinib as the second line drug. Sunitinib is an anti-angiogenesis agent by virtue of targeting multiple tyrosine kinases, including the vascular endothelial growth factor receptors (VEGFR). With these target drugs, the survival of advanced GIST patients is prominently prolonged (Lamba, Ambrale, Lee, Gupta, Rafiyath, & Liu D, 2012). The median overall survival (OS) of advanced GIST patients increased from 18 to 57 months with imatinib therapy (Blanke et al, 2008).
9722297|NCT03880682||Study Group|Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.
9722298|NCT03880526||Semi-Structured Interview|Participants will choose to participant in an individual in-depth interview to be conducted by investigators to gain information about the participant's background, cancer status and treatment.
9722299|NCT03880526||Focus Groups|Participants may choose to participate in one of three focus groups of no more than 10 participants in each group to to gain information about the participant's background, cancer status and treatment.
9722300|NCT03880214||stem cells transplanted pediatric patients|screen pediatric patients at least 3 months after they undergo allogeneic hematopoietic stem cells transplantation to detect any risk factors for developing oral manifestations of chronic graft -versus-host disease during this period
9780495|NCT02198794|Experimental|Part A: SD-809|Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
9780496|NCT02198794|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
9780497|NCT02198794|Active Comparator|Part B: SD-809|Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
9780498|NCT02198794|Experimental|Part C: SD-809|EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.
10196863|NCT05158608|Experimental|Cyclophosphamide on day +3,+4 at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
10196864|NCT05157880|Experimental|Experimental Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily skills.
10196865|NCT05157880|Active Comparator|Control Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily educational.
10196866|NCT05157230|Experimental|exercise|volunteers in this group do shoulder/arm exercises after vaccine injection and fill in the pain diary
10196867|NCT05157230|No Intervention|no-exercise|volunteers in this arm only completed the pain diary without any intervention
10196868|NCT05157061|Experimental|GOS arm|A single daily dose of a food supplement containing GOS for 8 weeks
10196869|NCT05157061|Placebo Comparator|Placebo arm|A single daily dose of maltodextrin, matching in taste, smell, appearance, and solubility, but without active ingredients (i.e. GOS), for 8 weeks
9722301|NCT03877029||Study II|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women who have never attended BreastScreen Norway despite of several invitation, and who are diagnosed with symtomatic breast cancer.~Both groups of women will receive the questionnaire."
9722302|NCT03877029||Study III|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women with interval breast cancer after attending BreastScreen Norway~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway~Women free from breast cancer"
9722303|NCT03877029||Study IV|"Women with a screen-detected breast cancer after attending BreastScreen Norway~Women with interval breast cancer after attending BreastScreen Norway~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway"
10196870|NCT05156983|Experimental|PROTHROMPLEX TOTAL 25 IU/kg|Participants will receive PROTHROMPLEX TOTAL 25 international unit per kilogram (IU/kg) single intravenous infusion on Day 1 (prior to surgery) as an initial dose and an additional dose of 25 international unit per kilogram (IU/kg). PROTHROMPLEX TOTAL can be administered during the surgery if deemed necessary by the surgeon. The total dose of PROTHROMPLEX TOTAL administered to the participant should not exceed 50 IU/kg or 5,000 IU, whichever is smaller.
9722304|NCT03876847||Spontaneous Coronary Artery Disection|The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.
9722305|NCT03876847||Control|A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.
9722306|NCT03876522||Lafora Disease Patients|Documented genetic diagnosis of Lafora disease; clinical diagnosis of Lafora disease and a sibling with a known mutation in EPM2A or EPM2B; clinical diagnosis of Lafora disease and a previously undescribed mutation in EPM2A or EPM2B; asymptomatic siblings if mutation positive prior to enrollment.
9722307|NCT03876236||Rest|Quiet rest in supine position, 2 hrs.
9722308|NCT03874702||Ischemic stroke patients with <4.5 hours of onset .|analysis of the computed tomography without contrast and detection of early changes, scoring with ASPECTS score and integration to the machine learning data base.
9722309|NCT03873012||OCT-guided group|OCT-guided PCI with EES or BES
9722310|NCT03873012||Angiography-guidance group|Angio-guided PCI with EES or BES
9722311|NCT03872531||Cohort 1|Includes age group 3-5 with a cap at 20 subjects. This is a retrospective, observational study
9722312|NCT03872531||Cohort 2|Includes age group 6-10 with a cap at 30 subjects. This is a retrospective, observational study
10196871|NCT05156983|Active Comparator|4F-PCC|Participants will receive 4F-PCC (excluding prothromplex total and activated 4F-PCC) as SOC on Day 1 (prior to surgery). The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding label specified limits can be given during the surgery if required.
9722313|NCT03872531||Cohort 3|Includes age group 11-15 with a cap of 30 subjects. This is a retrospective, observational study
10196872|NCT05156528|Experimental|Experimental group|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine, 0.5ml/dose, 2 doses with an interval of 30 days.
10196873|NCT05156528|Placebo Comparator|Placebo group|Aluminium phosphate adjuvant, 0.5ml/dose, 2 doses with an interval of 30 days.
9722314|NCT03872531||Cohort 4|Includes age group 16-20 with a cap of 20 subjects. This is a retrospective, observational study
9722315|NCT03872531||Cohort 5|Includes age group 21-30 with a cap at 20 subjects. This is a retrospective, observational study
9722316|NCT03872531||Cohort 6|Includes age group 31-40 with a cap at 20 subjects. This is a retrospective, observational study
9722317|NCT03872531||Cohort 7|Includes age group 41 and over with a cap at 35 subjects. This is a retrospective, observational study
9722318|NCT03872440||EGFR T790M patients|EGFR T790M patients who have progressed on osimertinib or other third generation (mutant selective) EGFR TKI therapy
9722319|NCT03872440||EGFR exon 19 del or L858R patients|EGFR exon 19 del or L858R patients who have progressed on first line osimertinib
9722320|NCT03872440||Exon 20 insertion mutations patients|Patients with Exon 20 insertion mutations (n=10; regardless of drug therapy). Includes EGFR Exon 20 and up to two HER2 Exon20 patients
9722321|NCT03871868||study group|In Woman With Myoma Uteri
9722322|NCT03871868||control group|In Woman Without Myoma Uteri
9722323|NCT03871270||Participants|Those with severe chronic illnesses, which included but were not limited to various forms of advanced cancer, blood dyscrasias, graft vs. host disease, and rare genetic conditions.
9722324|NCT03870074||Responders|Patients with improvement of at least one NYHA class after one year from CRT.
9722325|NCT03870074||Non-responders|Patients with no improvement of at least one NYHA class after one year from CRT.
9722326|NCT03869580||Stent infection|Patients diagnosed with urinary tract infection associated with double J stent
9722327|NCT03869580||No stent infection|Patients with double J stent without infection during the study period
10196874|NCT05155865|Experimental|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
9722328|NCT03868332||inflammatory bowel diease patients|
9722329|NCT03868332||normal indivuals|
9722330|NCT03868163||Glecaprevir plus Pibrentasvir|"Participants in this observational study will receive treatment with glecaprevir and pibrentasvir for up to 16 weeks for treatment of chronic hepatis C (CHC) genotypes 1, 2, 3, 4, 5, or 6.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice, international guidelines and/or label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
9722331|NCT03866590||Patients being at risk for Pyruvate Kinase Deficiency|Patients, older than 5 years and younger than 30 years old, being at risk for Pyruvate Kinase Deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined aetiology
9722332|NCT03866135||patients with osteoporosis|Osteoporosis has been operationally defined on the basis of bone mineral density (BMD) assessment. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy women (a T-score of <-2.5 SD)
9722333|NCT03866135||patients without osteoporosis|Bone mineral densities of patients were based on the World Health Organization (WHO) classification of a T score between -1 and -2.5 for osteopenia
9722334|NCT03865810||Gastric Surgery|Adult patients undergoing elective gastric surgery for cancer
9722335|NCT03864861||Elective Bariatric Surgery|Patients older than 18 undergoing elective bariatric surgery
9722336|NCT03864796||cases of newly diagnosed ITP|no intervention
9722337|NCT03864796||cases of ITP after responding to treatment|no intervention
10196875|NCT05155865|Active Comparator|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
9722338|NCT03864796||healthy subjects|no intervention
9722339|NCT03864640||Colorectal cancer|Patients with colorectal cancer
9722340|NCT03864692||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
9722341|NCT03864692||Normotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
9722342|NCT03864055||Pediatric Otogenic CSVT|Children with Otogenic Cerebral Sinus Vein Thrombosis (CSVT)
9722343|NCT03862742||Patients admitted to the hospital|We will recruit patient volunteers from the Scripps Green Hospital and Scripps Memorial Hospital inpatient teaching services.
10196876|NCT05155774|Active Comparator|Control group, controlled every 6th week|"This group was controlled every 6th week, in accordance with what is deemed to be golden standard for treatment with a Twin Block orthodontic appliance."
9780503|NCT02193191|Experimental|Plerixafor|Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
9780504|NCT02185209|Experimental|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
9780505|NCT02185209|Active Comparator|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
9780506|NCT02185209|Active Comparator|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
9780507|NCT02176434|Experimental|Tolerance|Combined kidney and hematopoietic stem cell transplantation from the same donor.
9780508|NCT02165410|Experimental|Eye tracking and RMI|
9780509|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
9780510|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
9780511|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
9780512|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
10196877|NCT05155774|Experimental|Test group, controlled every 4th week|This group was controlled every 4th week, testing if a more frequent control interval would increase compliance with a Twin block orthodontic appliance.
9780513|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
9780514|NCT02135679||Cohort 6|(Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy)
9780515|NCT02121405|Experimental|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
9780516|NCT02121405|Active Comparator|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine adjuvant chemotherapy.
9780517|NCT02066623||Implantation of ABSORB Scaffold|Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
9780518|NCT01989585|Experimental|Arm I (dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9780519|NCT01989585|Experimental|Arm II (dabrafenib, trametinib, and navitoclax)|Patients receive navitoclax PO QD days -7 to -1 of cycle 1 only. Patients also receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9780520|NCT01933958||Group 1|Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
9785796|NCT01260350|Experimental|Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.
9722344|NCT03859557||4-Quadrant Random Forceps Biopsy|Random sampling within a quadrant of esophageal tissue using forceps.
9722345|NCT03859557||WATS biopsies|Wide area transepithelial sampling with computer aided pathologic interpretation of tissue.
9722346|NCT03858348||fluticasone / salmeterol treatment|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol (Group A)
9722347|NCT03858348||fluticasone / salmeterol and extra LAMA|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol and extra a long-acting muscarinic receptor antagonist (anticholinergic, LAMA) (Group B).
9722348|NCT03856840||Bullous Pemphigoid Patients|Bullae and blood serum, which are obtained before and under treatment, will be compared in each other regardless of any condition.
9722349|NCT03856476||Dyslipidemia group|Children and adolescents with dyslipidemia
9722350|NCT03856476||Control group|Children and adolescents without dyslipidemia
9722351|NCT03856138||diarrhea with probiotics supplement|The children suffered from diarrhea, gastroenteritis oral probiotics during the clinical course
9722352|NCT03856138||diarrhea without probiotics supplement|The children suffered from diarrhea, gastroenteritis no oral probiotics during the clinical course
9722353|NCT03856138||healthy control|The children without diarrhea/ gastroenteritis
9722354|NCT03855618||1 case group|Consecutive 10 post-stroke patients in intensive rehabilitation treatment with an acute event occurring no later than 15 days from admission to the SOR Neurological Foundation don Gnocchi ONLUS IRCCS; age 18-90. It is required to sign an informed consent to the patient's participation in the study or if unable to sign, of the proxy.
9722355|NCT03854695||Cohort 1|Cohort 1: clinically uninfected (1A and 1C) ulcers.
9722356|NCT03854695||Cohort 2|Cohort 2: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) with no recent antibiotic therapy (within 28 days)
9722357|NCT03854695||Cohort 3|Cohort 3: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) on antibiotic therapy
9722358|NCT03853759||Patients with Heart Failure|
9722359|NCT03853759||Healthy İndividuals|
9722360|NCT03850808||decline in left ventricular function|This group will be patients in whom a decline in left ventricular systolic function was found.
9722361|NCT03850808||preserved left ventricular function|This group will consist of patients in whom left ventricular systolic function is preserved.
9722362|NCT03850353||OSAS|Patients with Obstructive Sleep Apnea (AHI>15 in a sleep study)
9722363|NCT03850353||Dizziness|Patients with Dizziness (defined as a non-spinning sensation, without illusion of movement)
9722364|NCT03850353||No OSAS No Dizziness|Patients without dizziness and no evidence for OSAS (subjects referred for the ENT or the Sleep clinic with no dizziness and no evidence of OSAS )
9722365|NCT03848377||Automated EMG/SSEP monitored|"In this study, all patients will be monitored for SSEP and EMG. For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored.~As this is an observational study, no intervention is planned."
9722366|NCT03847662||Community Based Production and Access of Complimentary Foods|"Nine communes were randomly selected with the cluster inclusion criteria as having high levels of; agricultural production, childhood under-nutrition and food security. This was carried out in the three rural mountainous provinces of Lao Cai, Lai Chau, and Ha Giang. In each of these provinces, one district and three subsequent communes were selected, for a total of 9 communes. The districts of Bat Xat, Tam Duong, and Vi Xuyen were selected in Lao Cai, Lai Chau and Ha Giang province respectively. This second stage district sampling selected sites with similar characteristic of population density, area, number of women of reproductive age(15-35y), percentage of children(<2y), income primarily from agricultural production, poverty and climate data.~Changes were observed on food security and nutritional status with exposure to community based self reported purchasing local agricultural products and access to locally produced fortified complimentary foods."
9722367|NCT03846999||Long-term breast cancer survivors|"Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.~Analyze comorbidities and patterns of use of health services by tumor characteristics."
9722368|NCT03846999||Women without history of cancer|Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
9722369|NCT03846635||Patients with Suspected Cellulitis|"Patients who undergo an infectious diseases consultation for suspected cellulitis of the upper or lower limbs are eligible to be enrolled. Patients who consent to participation will have chart data extracted and undergo a skin surface temperature measurement of the affected area and surrounding skin using a commercially available infrared thermometer. The dimensions of suspected cellulitis are also measured.~Patients with cellulitis admitted to hospital undergo daily measurements of temperature and dimensions. These patients are also asked standardized questions about their symptoms based on the patient global impression of improvement scale."
9722370|NCT03843762||Adolescents|Adolescents, male or female, ages 11 - 17. Participants will complete 7 days/nights of actigraphy and sleep-based EEG and questionnaires.
9722371|NCT03843619||Non-E-referral|Patients who are referred in the traditional manner between two separate organizations.
9722372|NCT03843619||E-referral|Patients who are referred in an automated manner between two separate organizations.
9722373|NCT03842566||20-29 Years Old|
9722374|NCT03842566||30-39 Years Old|
9722375|NCT03842566||40-49 Years Old|
9722376|NCT03842566||50-59 Years Old|
9722377|NCT03842566||60-69 Years Old|
9722378|NCT03842566||70-79 Years Old|
9722379|NCT03842306||Study Cohort|Patients undergoing rapid sequence intubation in the emergency department for which end tidal oxygen was monitored.
9722380|NCT03842111||Region XI Head Start children and families|children (1049) parents (1049) classrooms/teachers (73) program directors (21) center directors (36)
9722381|NCT03841162||Patients with suspected sepsis|Patients for whom blood cultures are drawn at the Emergency Department or the department of Infectious Diseases/Nephrology
9722382|NCT03840824||Cancer Survivor|Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
9722383|NCT03840824||Similar aged healthy controls|Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
9722384|NCT03840824||Late Reproductive Age|Pre-menopausal, healthy women of late reproductive age
9722385|NCT03840928||Ankylosing Spondylitis|
9722386|NCT03840928||Fibromyalgia|
9722387|NCT03840928||Gout|
9722388|NCT03840928||Crohn's-related Arthritis|
9722389|NCT03840928||Juvenile Idiopathic Arthritis|
9722390|NCT03840928||Lupus|
9722391|NCT03840928||Myositis|
9722392|NCT03840928||Osteoarthritis|
9722393|NCT03840928||Osteoporosis|
9722394|NCT03840928||Psoriasis|
9722395|NCT03840928||Psoriatic Arthritis|
9722396|NCT03840928||Rheumatoid Arthritis|
9722397|NCT03840928||Scleroderma|
9780521|NCT01924819|Experimental|Preoperative chemoradiotherapy|"2 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 3 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~5 weeks preoperative chemoradiotherapy.~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
9780522|NCT01924819|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine) OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
9780523|NCT01877655|Experimental|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
9780524|NCT01877655|Placebo Comparator|Placebo|Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
9780525|NCT01861314|Experimental|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9780526|NCT01749969|Experimental|SAR650984 (isatuximab)|"SAR650984 (isatuximab) (escalating dose) plus lenalidomide 25 mg on Days 1 to 21 plus dexamethasone 40 mg on Days 1, 8, 15, 22 in 28-day cycles for all cohorts up to disease progression.~For Q2W cohorts: SAR650984 (isatuximab) on Days 1 and 15 of every cycle. For QW/Q2W cohorts: SAR650984 (isatuximab) on Days 1, 8, 15, and 22 of first cycle and Days 1 and 15 of every subsequent cycle."
9780527|NCT01668082|Experimental|surgical resection of a brain tumor|"The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.~--------------------------------------------------------------------------------"
9780528|NCT01653535|Experimental|Fast Track Eligible|"Participants in the Experimental group received the Fast Track intervention. Intervention included school-based curriculum attended by high-risk children, parents, program staff, and occasionally teachers, home visiting, the the in-class PATHS prevention program."
9780529|NCT01653535|No Intervention|Control Group|Participants in the Control group were not eligible to receive the Fast Track intervention. These children received other services as usual, and served as the randomized comparison group for examining Fast Track program impacts
9780530|NCT01588054||adults, cervical deformity, surgical treatment|Adults 18years or older at time of enrollment, cervical deformity to include kyphosis (C2-7 greater than 10 degrees) or scoliosis (coronal cobb greater than 10 degrees), plans for surgical treatment of cervical deformity
9780531|NCT01126255|Active Comparator|1|Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
9780532|NCT01126255|Experimental|2|Progesterone 8%, topical application, once daily about 2 g, during 12 weeks
9780533|NCT01037907|Experimental|BGC20-0134 (Pleneva TM)|Structured lipid
9780534|NCT01037907|Placebo Comparator|Placebo control|Placebo - dummy pill
9780535|NCT00935090|Experimental|3'-deoxy-3'-[18F]fluorothymidine|The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
9780536|NCT00849888|Experimental|Atypical Complete DiGeorge|Thymus Transplantation with Immunosuppression
9780537|NCT00849888|Experimental|Typical Complete DiGeorge|Thymus Transplantation without Immunosuppression
9780538|NCT00597441|Experimental|I|Thymic tissue from third party donor
9780539|NCT00433589|Active Comparator|Chemotherapy randomization: Arm I (anthracycline-based)|"FEC 100~Canadian CEF~CAF~FAC~E-CMF"
9780540|NCT00433589|Experimental|Chemotherapy randomization: Arm II (docetaxel and capecitabine)|"Docetaxel~Capecitabine"
9780541|NCT00433589|Active Comparator|Endocrine therapy randomization: Arm I|2 years of tamoxifen followed by 5 years of letrozole
9780542|NCT00433589|Experimental|Endocrine therapy randomization: Arm II|7 years of letrozole
9722398|NCT03838757||Patients|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
9722399|NCT03838757||Healthy controls|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
9722400|NCT03838653||Left main bronchus (LMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the left main bronchus (correct placement).
9722401|NCT03838653||Right main bronchus (RMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the right main bronchus (incorrect placement).
9722402|NCT03838471||Central sensitization symptoms|This group will contain persons with a clinically relevant degree of symptoms of CS (CSI score ≥40).
9722403|NCT03838471||No Central sensitization symptoms|This group will contain persons with a lower degree of symptoms of CS (CSI score < 40).
9722404|NCT03838458||Study|Children with isolated hypospadias
9722405|NCT03838458||Control|Children with planned circumcision
9722406|NCT03837600||Healthy Cohort|Participants who have smoked less than 5 pack-years, have quit smoking for more than 15 years and have no known lung diseases.
9722407|NCT03837600||High-risk Cohort|Participants who are at high risk for lung cancer including current smokers who have smoked for more than 30 pack-years and have not quit within 15 years.
9722408|NCT03837600||Cancer Cohort|Participants who have been diagnosed with lung cancer.
9722409|NCT03837587||Patients group|Patients with temporomandibular disorders
9722410|NCT03835546||Early treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy presenting recent HIV-1 infection. Recent HIV-1 infection was defined as having a positive plasma viral load and/or p24 antigen with a negative ELISA or having a positive ELISA and undetermined Western-Blot, or having a positive ELISA and absence of p31 antigen in a positive Western-Blot, or seroconversion ELISA in less than 3 months.
9722411|NCT03835546||Regularly treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy, did not fulfil the criteria for recent HIV-1 infection, and had an estimated time >6 months reported by the patient and/or by the responsible physician since HIV transmission.
9722412|NCT03835546||Seronegative volunteers|HIV-uninfected volunteers, matched to age, sex, and educational level with groups A and B.
9722413|NCT05278949|Other|The scleral pocket for the primary implanted IOL|single arm
9722414|NCT05278923|No Intervention|clean airway|CPR and endotracheal intubation in an airway without regurgitation
9722415|NCT05278923|Experimental|regurgitation airway|CPR and endotracheal intubation in an airway with regurgitation
9722416|NCT05278910|Placebo Comparator|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour.
10196878|NCT05155488||Participants With MPS II|Retrospective data of participants diagnosed with MPS II will be collected from the database (DATASUS) from January 1st, 2008 to September 30th, 2020 in this observational study.
9722417|NCT05278910|Experimental|Fish oil + Roasted wheat flour|Assign fish oil capsule and roasted wheat flour.
9722418|NCT05278910|Experimental|Soybean oil + Vegetable and fruit extracts|Assign soybean oil capsule and Vegetable and fruit extracts.
9722419|NCT05278910|Experimental|Fish oil + Vegetable and fruit extracts|Assign fish oil capsule and Vegetable and fruit extracts.
9722420|NCT05278897|Experimental|Soft Tissue Adapted Biocompatible Hyaluronic Acid|Soft Tissue Adapted Biocompatible Hyaluronic Acid is a clear solution of sterile 1% sodium hyaluronate (10 mg/mL) contained in a 1.2 mL pre-filled syringe. Patients will receive two injections, spaced 2 to 3 days apart (for ankle sprains) or 7 days apart (for elbow injections).
9722421|NCT05278884|Experimental|ACLS and then VAST teaching intervention|For each hospital, the intervention will be to pair a 2-day technical resuscitation skills training adapted from the ACLS/AHA and a 3-day VAST course for a multidisciplinary team of 20 participants (i.e., nurses, doctors, non-physician anesthesia providers). Participants' resuscitation skills will be tested at 4 time points: immediately before the ACLS course, immediately after the ACLS course, immediately after the VAST Course, and at 4 months post training.
9722422|NCT05278871|Experimental|CSI ultrasound measurement|Participants will have standard volumetric tape measurement across multiple arm locations for lymphedema followed by CSI ultrasound measurements of the same anatomic sites.
9722423|NCT05278845|Experimental|Treatment Sequence 1|SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fasted conditions.
9722424|NCT05278845|Experimental|Treatment Sequence 2|SLC SLC-391 10 mg capsules (manufactured by China Gateway Pharmaceutical Development Co. (Shanghai, P.R. China)) administered as 5 x 10 mg capsules under fed conditions.
9722425|NCT05278832|Experimental|QLS31905|QLS31905 injection
9780543|NCT00433589|Active Comparator|Treatment decision randomization: Arm I|chemotherapy-decision-making according to clinical criteria (using Adjuvant! Online)
9722426|NCT05278819|Experimental|upper extremity elevation|performing intervention A (5 repetitions of upper extremity elevation), and then crossed over to intervention B (5 repetitions of upper extremity with deep breathing).
9722427|NCT05278819|Experimental|upper extremity elevation with deep breathing|performing intervention B (5 repetitions of upper extremity with deep breathing), and then crossed over to intervention A (5 repetitions of upper extremity elevation).
9722428|NCT05278806|Experimental|Equity Dashboard and Community Health Worker Support|After the step in which the primary care providers are randomized to receiving intervention, one group of providers will receive the equity dashboard data and their eligible patients (Black, Indigenous and People of Color [BIPOC] patients and patients with limited English proficiency [LEP]) will receive additional clinical support from a community health worker (CHW), who will focus specifically on addressing hypertension control.
9722429|NCT05278806|Experimental|Equity Dashboard and Population Health Coordinator Support|After the step in which the primary care providers are randomized to receiving intervention, a second group of providers will receive the equity dashboard data and their eligible patients (Black, Indigenous and People of Color [BIPOC] patients and patients with limited English proficiency [LEP]) will receive additional clinical support from a population health coordinator (PHC), who will focus specifically on addressing hypertension control.
9722430|NCT05278806|No Intervention|Delayed intervention|Black, Indigenous and People of Color (BIPOC) patients and patients with limited English proficiency (LEP) before their primary care providers are randomized to receiving the intervention. (By the end of the 12 steps, all BIPOC/LEP patients will be assigned to an experimental group)
9722431|NCT05278806|No Intervention|Usual Care|Patients who are not eligible for additional clinical support (i.e. White and English speaking patients).
9722432|NCT05278793|Experimental|Intermittent|This group will receive ferrous fumarate 200mg intermittent three times a week on alternate days.
9722433|NCT05278793|Active Comparator|Daily|This group will receive ferrous fumarate 200mg once daily.
9722434|NCT05278780|Experimental|Asynchronous screening|Participants will be screened for medication abortion eligibility using written or online materials and questionnaires, without a synchronous conversation between the prescribing clinician and the patient.
9722435|NCT05278767|Experimental|application group|The mobile health application (https://play.google.com/store/apps/details?id=com.sanberk.bariatriksurgery) prepared for patients undergoing bariatric surgery was completed in 6 stages. After the mobile application has been developed, a short (20-minute) brief contains information about the mobile application in the pre-operative polyclinic for the patients who are planned for bariatric surgery. The patient was followed for three months. Data were collected from the patient every month (4 times).
9722436|NCT05278767|No Intervention|control group|Standard care and follow-up protocols were applied to the patients.The patient was followed for three months. Data were collected from the patient every month (4 times).
9722437|NCT05278741|Experimental|Surgery for unilateral breast reconstruction|"Patients treated in oncological surgery at the Center Georges-François Leclerc (CGFL) in Dijon for unilateral breast reconstruction after therapeutic total mastectomy.~Before the surgery, 2 questionnaires will be completed by patients : BREAST-Q and DASH. Also, the isokinetic test and EMG will be performed.~After the surgery, 2 questionnaires will be completed at one month, 3 months and 6 months. The Two tests will be performed at 3 moths and 6 months after the surgery."
9722438|NCT05278728|Experimental|Nimotuzumab and Irinotecan|Nimotuzumab： 200, 400, 600 or 800mg weekly until progression or AEs Irinotecan：180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
9722439|NCT05278715|Experimental|optic pathway glioma|
9722440|NCT05278702||hemodialysis|
9722441|NCT05278702||peritoneal dialysis|
9722442|NCT05278650|Other|Communities Adopting Senior PharmAssist Implementation Toolkit|"Three communities will commit to learning how to implement the evidence-based, multi-component intervention, Senior PharmAssistTM (SPA), designed to improve function and quality of life of older adults with limited incomes using the SPA toolkit.~The toolkit, co-developed with community leaders, will help to create a community model for implementation that addresses equitable access to medications, medication management, and community supports that promote physical function and healthy aging in place."
9722443|NCT05278637|Active Comparator|Aspirin 81mg/day, Aspirin 325mg/day, Aspirin washout, Ticagrelor 90mg BID|
9722444|NCT05278637|Active Comparator|Aspirin 325mg/day, Aspirin 81mg/day, Aspirin washout, Ticagrelor 90mg BID|
9722445|NCT05278637|Active Comparator|Ticagrelor 90mg BID|
9722446|NCT05278585||RAP TAVI group|All patients in sinus rhythm with TAVI
9722447|NCT05278559||Adolescents living with HIV|- ALHIV with a viral load result of less than <1000 copies/mL and aged between 13-19 years
9722448|NCT05278533|Experimental|BioPlete™ Advanced Formula|"BioPlete™ Advanced Formula in Capsule~Intervention: Dietary Supplement: Multi-Vitamin"
10196879|NCT05153772|Experimental|Pb212-DOTAMTATE|investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors
10196880|NCT05153720|Experimental|Ultrasound guided erector spinae plane block|Unilateral erector spinae plane block will be performed under ultrasound guidance
10196881|NCT05153720|Active Comparator|Ultrasound guided caudal block|Caudal block will be formed under ultrasound guidance
10196882|NCT05151159||FIGO group 1A1|20 subjects with tumor invasion depth up to 1 mm
10196883|NCT05151159||FIGO group 1A2|20 subjects with an invasion depth of 1 - 3 mm
10196884|NCT05151159||FIGO group 1B1|20 subjects with invasion depth up to 2 cm
10196885|NCT05151159||FIGO group 1B2|20 subjects with tumor invasion depth> 2 cm 20 subjects with tumor invasion depth> 2 cm
10196886|NCT05150782|Experimental|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin(2%), boswellia serrata (1,5%) and ascorbic acid (6%).
10196887|NCT05149742|Experimental|Cases: Patients with severe to profound hearing loss|Patients aged between 45 to 64 years with severe to profound bilateral post-lingual sensorineural hearing loss with a maximum intelligibility of 70% (disyllabic words) in free-field silence with hearing aids at 60 dB SPL
10196888|NCT05149742|Active Comparator|Controls: 90 matched subjects with normal hearing|Healthy controls aged between 45 to 64 years with normal hearing on pure-tone audiometry (as function of ISO 7029 reference)
10196889|NCT05149560|Experimental|Ticagrelor|Ticagrelor 90 mg twice daily for 12 months
9722449|NCT05278533|Placebo Comparator|Placebo|"Rice Flour in a capsule~Intervention: Other: Placebo"
9722450|NCT05278494|Experimental|Dextromethorphan|
9722451|NCT05278494|Placebo Comparator|Placebo|
9722452|NCT05278481|Active Comparator|Reward Message with standard introduction|
9722453|NCT05278481|Active Comparator|Reward Message with culturally tailored introduction|
9722454|NCT05278481|Active Comparator|Threat/Self-efficacy with standard introduction|
9722455|NCT05278481|Active Comparator|Threat/Self-efficacy with culturally tailored introduction|
9722456|NCT05278481|Active Comparator|Social norms message with standard introduction|
9722457|NCT05278481|Active Comparator|Social norms message with culturally tailored introduction|
9722458|NCT05278468||case group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University who had positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
9722459|NCT05278468||control group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University with negative positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
9722460|NCT05278455|Experimental|Lifestyle Medicine Group|Lifestyle medicine smartphone app The lifestyle medicine app contains eight weekly modules that cover healthy eating, exercise, stress management, sleep management, lifestyle psychoeducation, and goal setting.
9722461|NCT05278455|No Intervention|Waitlist Control Group|The waitlist control group will receive access to the lifestyle medicine app at the end of the study.
9722462|NCT05278429|Active Comparator|Myosuit arm|Patients perform exercise training with the Myosuit
9722463|NCT05278429|Other|Control arm|Patients perform exercise training without the Myosuit
9722464|NCT05278416|Active Comparator|Lumoral treatment -device and Lumorinse tablets|Subjects will receive detailed instructions for the use of Lumoral treatment -device and Lumorinse tablets. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day.
9722465|NCT05278416|No Intervention|Standard of Care|Subjects will receive oral hygiene instructions for the sonic toothbrushing and the use of interdental cleaning devices. They will not receive an additional intervention.
9722466|NCT05278390|Experimental|Thoracic CT Scan|
9722467|NCT05278377||Apprenti en Action (intervention group)|"Apprenti en Action consists of six, one-hour culinary workshops offered once a week during school hours."
9722468|NCT05278377||Control group|"Students in the control group do not receive the Apprenti en Action program."
9722469|NCT05278338|Experimental|Group a|JMT103 45 mg
9722470|NCT05278338|Experimental|Group b|JMT103 60 mg
9722471|NCT05278338|Experimental|Group c|JMT103 90 mg
9722472|NCT05278338|Active Comparator|Group d|Denosumab 60 mg
9722473|NCT05278338|Placebo Comparator|Group e|Placebo
9722474|NCT05278325|Experimental|Telephone Intervention|Two planned phone call by health care professionals after 8 and 16 weeks adjusting acute and preventive treatment
9722475|NCT05278325|No Intervention|Business as usual|No planned phone calls
9722476|NCT05278312|Experimental|Otago Exercise Program|Older adults will receive the Otago Exercise Program for 8 weeks plus health awareness videos.
9722477|NCT05278312|No Intervention|Control group|Older adults will receive only health awareness videos every 2 weeks.
9722478|NCT05278286|Experimental|Crawli Group|Participants from the Crawli Group will benefit from the crawling stimulation intervention with the crawliskate
9722479|NCT05278286|Active Comparator|Mattress Group|Participants from the Mattress Group will benefit from the tummy time intervention
9722480|NCT05278286|No Intervention|Control Group|Control group infants benefit from usual care.
9722481|NCT05278273|Experimental|At home cognitive training|We recruited 20 adults (10 female, mean age = 68.3 years, SD = 6.75) as the at-home training group. We assessed cognitive health status for participants using a self-report questionnaire and the Mini-Mental State Examination (MMSE), and all participants were deemed cognitively healthy (MMSE > 26). At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility.
9722482|NCT05278260|Placebo Comparator|Control|
9722483|NCT05278260|Experimental|Active|
9722484|NCT05278247|Experimental|single arm for all subjects|all subjects receive the same diagnostic measurement
9722485|NCT05278234|Experimental|Intervention arm|Participants will engage in a 7-week multicomponent chronic pain self-management program.
9722486|NCT05278234|No Intervention|Usual care control arm|After completing the 12 month telephone survey, control group participants will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a workshop that provides key intervention content and individualized goal-setting guidance.
9980799|NCT01395407|Experimental|Cohort C|"Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter).~Dose level Cohort C (Gy)~15~17~19"
9722488|NCT05278182|Experimental|Naoxintong Capsule|Naoxintong Capsule
9722489|NCT05278182|Placebo Comparator|Placebo|Placebo
9980800|NCT01395420|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
9980801|NCT01395420|Experimental|2|CAZ104 (3000mg Ceftazidime/1000mg Avibactam)
9980802|NCT01395433|Active Comparator|Treatment A|Conventional escitalopram
9980803|NCT01395433|Experimental|Treatment B|Escitalopram test treatment B
9980804|NCT01395433|Experimental|Treatment C|Escitalopram test treatment C
9980805|NCT01395446||prolonged neutropenic patients|patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia of prolonged duration
9980806|NCT01395459|No Intervention|control|Care as usual is given.
9980807|NCT01395459|Experimental|IVR only|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable.
9722490|NCT05278156|Experimental|CPL500036 low dose|Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.
9722491|NCT05278156|Experimental|CPL500036 high dose|Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.
9722492|NCT05278156|Placebo Comparator|Placebo|Patients are to receive placebo administered once dail for 28-days treatment period.
9722493|NCT05278143||type1diabetes patients who use CGM|Males and females diagnosed with T1D, aged less than 18 years old who are currently under the care of the Unit of Endocrinology and Diabetes of Bambino Gesù Children's Hospital, Rome, Italy and who already use continuous glucose monitoring (CGM) systems are eligible to be involved in the study. Participants will wear an additional non-invasive wearable device, Medtronic Zephyr BioPatch, for recording physiological data for three days.
10196890|NCT05148962|Experimental|Cohort 1: 1 Dose 10 mcg GRT-R910 after AstraZeneca Standard of Care|Participants (including 2 sentinels) receive 1 dose of 10 mcg GRT-R910 (after AstraZeneca standard of care).
9722494|NCT05278130|Active Comparator|Intervention Arm|The intervention-arm will have a pelvic exam performed with vaginal swab collection at their initial obstetric visit (standard of care). The women undergoing the intervention will then subsequently undergo additional vaginal swab collections in 2 week intervals starting at 16 weeks gestational age until 34 weeks gestational age. Subjects will be informed of the results of the vaginal swab. If positive for an infection, subjects will be provided with the appropriate treatment in pregnancy.
9722495|NCT05278130|No Intervention|Control Arm|The control arm will undergo the standard of care with vaginal swab collection at their initial obstetric visit. The control arm will not undergo additional vaginal swab collections unless otherwise indicated under standard of care (further testing for bacterial vaginosis is completed in women who describe symptoms with the diagnosis or present for preterm contractions and/or pelvic cramping). There will be no placebo for the control group.
9722496|NCT05278078|Other|psychological support|Psychological support will be given to the experimental group.
9722497|NCT05278078|Other|nutritional education|Nutrition education will be given to the experimental group.
9722498|NCT05278078|Other|psychological support and nutritional education|psychological support and nutritional education will be given to the experimental group.
9722499|NCT05278078|Other|no intervation|No intervention will be applied to the control group
9722500|NCT05278065|Experimental|Electronic cigarette|Participants in this experimental condition will be provided with a 4th generation electronic cigarette device and disposable cartridges.
9722501|NCT05278065|No Intervention|Smoking As Usual|Participants in this assessment-only condition will continue smoking as usual.
9722502|NCT05278052|Active Comparator|ARM A: Standard maintenance therapy alone|Maintenance systemic therapy/ observation
9722503|NCT05278052|Experimental|ARM B: Local consolidative radiation therapy (LCRT)|Radiation therapy to all oligometastatic sites including primary loco-regional disease
9722504|NCT05278026||HFrEF|heart failure with reduced ejection fraction
9722505|NCT05278026||HFpEF|heart failure with preserved ejection fraction
9722506|NCT05278026||nonfailing control|patients without heart failure
9722507|NCT05278013|Experimental|Glue Group (GG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
9722508|NCT05278013|No Intervention|No Glue Group (NG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
9722509|NCT05277987|Experimental|HEC-016|Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells
10196891|NCT05148962|Experimental|Cohort 2: 1 Dose 30 mcg GRT-R910 after AstraZeneca Standard of Care|Participants (including 2 sentinels) receive 1 dose of 30 mcg GRT-R910 (after AstraZeneca standard of care).
9722510|NCT05277974|Active Comparator|Group B.|group B will receive Inj Bupivicain only in Erector Spinae Plane Block.
9722511|NCT05277974|Active Comparator|Group D|group D will receive Inj Bupivicain plus Dexamethasone in Erector Spinae Plane Block.
9722512|NCT05277961|Experimental|UVR Dose 1x3SED|UVR Dose 1x3 standard erytheme dose (SED)
9722513|NCT05277961|Experimental|UVR dose 3x1SED|UVR dose 3x1 standard erythema dose (SED)
9722514|NCT05277948|Active Comparator|treatment group|Active thumbtack needle will be used for the treatment group
9722515|NCT05277948|Sham Comparator|control group|Sham thumbtack needle will be used for the control group
9722516|NCT05277935|Active Comparator|Use of the WeCancer app combined with the smartwatch|The Wecancer app will be used in a way, combined with a smartwatch, similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), feedback to the patient in the comments made, guidance on physical and eating exercises, reception and support from the Wecancer multidisciplinary team, consisting of a navigator nurse, psychologist, nutritionist and physiotherapist. During the survey period, participants should report their symptoms on the Wecancer app whenever possible, preferably daily.
9722517|NCT05277935|No Intervention|Using the WeCancer app|The Wecancer application similar to those used in professional fitness programs, with active measures, which may include, for example: notifications with personalized advice (via chat), patient feedback on the comments made, guidance on physical and dietary exercises, reception and support of the Multidisciplinary cancer team composed of a navigator nurse, a psychologist, nutritionist and physiotherapist. During the research period, participants must report your symptoms in the Wecancer app whenever possible, preferably daily.
9780544|NCT00433589|Experimental|Treatment decision randomization: Arm II|chemotherapy-decision-making according to genomic prognosis using the 70-gene signature
9780545|NCT00308685|Experimental|Albuterol-HFA-BAI|ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
9780546|NCT00308685|Placebo Comparator|Placebo-HFA-BAI|Placebo
10196892|NCT05147532|Other|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714
10196893|NCT05147311|Experimental|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~At approximately 100-days post-HSCT, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~-Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
10196894|NCT05147311|No Intervention|Usual Care Control|Participants in the Usual Care Control arm will receive regular social work assessments as part of HSCT recovery and work does not focus on PPWB skill building or cognitive strategies.
9980808|NCT01395459|Experimental|IVR+PCC|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable. Furthermore, if remained unscreened, these participants receive person to person follow up telephone calls from a prevention care coordinator (PCC) to address barriers.
10205435|NCT00070564|Active Comparator|Arm III|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
10205436|NCT00070564|Experimental|Arm IV|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel as in arm III.
9980809|NCT01395472|Experimental|TBI - Experimental Sample|TBI patients will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
9722520|NCT05277883||Group|All patients scheduled for a total knee arthroplasty without any previous lower limb deformities or previous hip/knee surgery will be enrolled. A long leg standing x-ray and a CT scan of the lower limb will be obtained for every patient.
9722521|NCT05277870|Active Comparator|control|Standard eyedrops of IOP-lowering medications
9722522|NCT05277870|Experimental|Nanodropper|Microdrops of IOP-lowering medications using Nanodropper adaptor
9722523|NCT05277844|Active Comparator|Arm 1: Continuation of TKI therapy alone|Patients in this arm will continue to receive standard treatment of TKI alone
9722524|NCT05277844|Experimental|Arm 2: Continuation of TKI therapy + Local Consolidative Radiation therapy to 1-5 sites|Patients will receive local consolidate radiation therapy to all oligo-metastatic sites plus radiation therapy to primary disease in addition to TKI
9722525|NCT05277831|Experimental|Guided Imagery Intervention|Guided Imagery Intervention
9722526|NCT05277831|Active Comparator|Standard Behavioral Control|Standard Behavioral Control
9722527|NCT05277805||EMPOWER-UP participants|People with cancer, diabetes, or mental disorders answering the EMPOWER-UP questionnaire
9722528|NCT05277779||control|non-obese （BMI<25kg/m2）controls without known endocrine diseases, cardiac disease, or other comorbidities, and with unremarkable imaging results.
9722529|NCT05277779||metabolically healthy obese|obese individuals having no more than one of the metabolic syndrome components (with exception of increased waist circumference) and without impaired glucose tolerance (defined as a 2-hour post loading glucose level of 7.7-11.1mmol/L )
9722530|NCT05277779||metabolically unhealthy obese|obese individuals with more than one metabolic syndrome components or impaired glucose tolerance
9722531|NCT05277766|Experimental|Nal-IRI (Onivyde) - 30mg/m²|PIPAC with Onivyde (30 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
9722532|NCT05277766|Experimental|Nal-IRI (Onivyde) - 45mg/m²|PIPAC with Onivyde (45 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
9722533|NCT05277766|Experimental|Nal-IRI (Onivyde) - 60mg/m²|PIPAC with Onivyde (60 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
9722534|NCT05277766|Experimental|Nal-IRI (Onivyde) - 75mg/m²|PIPAC with Onivyde (75 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
9722535|NCT05277766|Experimental|Nal-IRI (Onivyde) - 90mg/m²|PIPAC with Onivyde (90 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
9722536|NCT05277740||CIS|Diagnosis of Clinically Isolated Syndrome (CIS) with abnormal MRI.
9722537|NCT05277740||RRMS|Diagnosis of Relapsing-Remitting MS (RRMS).
9722538|NCT05277740||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
9722539|NCT05277701|Experimental|Lazertinib|
9722540|NCT05277688|Experimental|experimental group|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; pelvic radiotherapy: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
9722541|NCT05277688|Active Comparator|controlled group|pelvic radiotherapy alone: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
9980810|NCT01395472|Active Comparator|Healthy Controls|healthy volunteers will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
9980811|NCT01395472|Active Comparator|TBI Controls|Patients will be submitted to a protocol of stretching for 30 minutes
9980812|NCT01395485|Experimental|Cohort 2|Adolescents - Ages 13 to <17
9980813|NCT01395485|Experimental|Cohort 1|Adolescents - Ages 12 to <13
9980814|NCT01395485|Experimental|Cohort 4|Adults - Ages 18 to <=50
9980815|NCT01395485|Experimental|Cohort 3|Adolescents - Ages 17 to <18
9980816|NCT01395498||fiberoptic bronchoscopy|patients undergoing fiberoptic bronchoscopy who are not immunocompromized and in whom an opportunistic infection is not suspected.
9980817|NCT01395511|Experimental|Acupuncture|"About ten acupuncture points are selected from the following points to be used. Local Acupoints : SI14, SI15, BL10, BL12, BL13, BL14, TE15, GB20, SI9~Distal Acupoints :~Upper extremities: LU6, LU7, LU9, LI11, HT3, SI2, SI3, SI5, SI7, PC4, PC6, TE5~Lower extremities: SP3, SP4, BL59, BL60, BL61, BL62, BL66, KI3, KI4,KI6, KI7, GB40, GB41, LR4~All Acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Most of acupuncture were inserted vertically 1~1.5cm in depth until patient can feel De-Qi. (No more additional stimulation)"
9722542|NCT05277675|Experimental|Neoadjuvant therapy+ RFA|After confirmation of HCC recurrence by imaging exam, subjects will receive neoadjuvant therapy (immune checkpoint inhibitors + targeted therapy) and then RFA
9722543|NCT05277675|Active Comparator|RFA alone|After confirmation of HCC recurrence by imaging exam, subjects will receive RFA treatment only.
9722544|NCT05277662|Experimental|Precision diagnostics profiling|The study will involve subjects with endoscopically, laboratory and clinically confirmed diagnoses of organic and functional intestinal pathology or none of the above (healthy volunteers). All diagnoses are defined in accordance with the validated criteria presented in the clinical guidelines for the diagnosis and treatment of functional bowel pathology (Irritable Bowel Syndrome), 2020, Crohn's Disease (approved by the Ministry of Health of the Russian Federation, 2020), Ulcerative Colitis (approved by the Ministry of Health of the Russian Federation, 2020), in accordance with international criteria of ECCO-ESGAR Guidelines, 2018, 2019. After the initial screening and inclusion in the study, intestinal biopsy samples are taken in accordance with the applied endoscopic examination technique during the endoscopic examination. These biopsy samples will be further used for molecular and immunological diagnostics.
9722545|NCT05277649|Experimental|Experimental Group|Performance of a warm-up and cool-down exercise programme for the cervical and mandibular region before and after instrumental practice.
10196895|NCT05146674|Active Comparator|Tadalafil group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
10196896|NCT05146674|No Intervention|Control group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
9722546|NCT05277649|No Intervention|Control Group|"Participants in the control group will not make any changes in their instrumental practice habit.~At the end of the study, participants in the control group will be asked to perform the exercises tested in the experimental group."
9722547|NCT05277597|Experimental|The group (ET+S )|Participants exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.
9722548|NCT05277597|Active Comparator|The group (ET)|Participants exercised 60 minutes, 3 times per week
9722549|NCT05277545|Experimental|The effect of teknology addiction training on the experimental group|The arm explanations for which the analyzes of the research have not been completed yet cannot be made.
9722550|NCT05277545|Active Comparator|Comparison of the experimental group and control group on technology addiction|The arm explanations for which the analyzes of the research have not been completed yet cannot be made.
9722551|NCT05277532|Active Comparator|Type 1 diabetes with overweight|High intensity interval training (HIIT), a single bout, randomly performed either in the morning or in the afternoon in a cross-over design.
9722552|NCT05277532|Active Comparator|Overweight but otherwise healthy control subjects|High intensity interval training (HIIT), a single bout, randomly performed either in the morning or in the afternoon in a cross-over design.
9722553|NCT05277506|Experimental|smile arc protection bonding strategy group|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
9722554|NCT05277506|Active Comparator|MBT placement guide group|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide
9780547|NCT01125514|Experimental|Furosemide 60 mg|Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
9780548|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 150 mg|Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
9780549|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 300 mg|Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
9780550|NCT01125566|Active Comparator|Arm B: trastuzumab with vinorelbine|patients receive weekly intravenous infusion of trastuzumab and vinorelbine
9780551|NCT01125566|Experimental|Arm A: BIBW 2992 with vinorelbine|patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
9780552|NCT01125605||Adults > 12 years|adult patients and patients older than 12 years
9780553|NCT01125605||Children 6-12 years|children between 6 and 12 years
9780554|NCT01125605||Children 1-6 years|children between 1 and 6 years
9780555|NCT01125722|Active Comparator|Investigator Placement Group|
9780556|NCT01125722|Active Comparator|Subject Placement Group|
9780557|NCT01125748|Experimental|Omalizumab|Participants received omalizumab subcutaneously at the same dose and dosing interval as administered prior to enrollment in this study. The dose of omalizumab was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
10196897|NCT05146635|Active Comparator|Intravesical immunotherapy (BCG) group|
10196898|NCT05146635|Active Comparator|Intravesical chemotherapy (Epirubicin) group|
10196899|NCT05145569|Experimental|Carboplatin/paclitaxel + Bintrafusp alfa (M7824)|Bintrafusp alfa (M7824) (2400 mg flat dose IV), in combination with chemotherapy including carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
9722555|NCT05277454|Experimental|HMPL-653 open-label treatment arm|"Dose-escalation Stage:~Participants will be treated with escalating doses of HMPL-653 to determine the MTD and RP2D.~Dose-expansion Stage:~Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of HMPL-653 in TGCT and specific advanced solid tumors."
9722556|NCT05277428|Experimental|Lactobacillus Plantarum APsulloc 331261(GTB1)|Take GTB1 capsule once daily for 4 weeks
10196900|NCT05145569|Active Comparator|Carboplatin/paclitaxel|Carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
10196901|NCT05143333||Post acute COVID-19|Severity of COVID-19 will be determined based on patient classification within the PACT (Johns Hopkins Post-acute COVID-19 Team) clinic. Specifically, patients followed in the PACT-ICU clinic required ICU stays of ≥48 hours and high-flow nasal cannula/non-invasive ventilation or mechanical ventilation. Those followed in the PACT-Base clinic have less severe disease that does not necessitate ≥48 hours in the ICU but does qualify for PACT clinic referral based on either (1) ongoing pulmonary and/or rehabilitation needs at the time of hospital discharge, or (2) persistent pulmonary or functional deficits at 4-6 weeks post infection without hospitalization.
10196902|NCT05142020||GDM group|Specimen collection and clinical follow-up
9722557|NCT05277428|Placebo Comparator|Placebo|Take placebo capsule once daily for 4 weeks.
9722558|NCT05277415|Active Comparator|Ghrelin infusion|Ghrelin infusion 30 pmol/kg/min, 0.50 ml/min during 120 minutes
9722559|NCT05277415|Placebo Comparator|Placebo|Saline 0.50 ml/min during 120 minutes
9722560|NCT05277389|Sham Comparator|Control|Individuals in this group will practice object manipulation tasks without the START (Startle Adjuvant Rehabilitation Therapy) intervention
9722561|NCT05277389|Experimental|START|Individuals in this group with practice object manipulation tasks with the START condition (startling acoustic stimuli applied during 33% of trials)
9722562|NCT05277376|Active Comparator|BEMT Formulation SU-E-101413-85|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
9722563|NCT05277376|Active Comparator|BEMT Formulation SU-E-101413-87|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
9722564|NCT05277376|Active Comparator|BEMT Formulation SU-E-101413-89|PK evaluation of 6% BEMT after multiple applications of a topical sunscreen formulation.
9722565|NCT05277363||Prospective cohort|Parents/caregivers of participants with SURF1 deficiency will provide information regarding diagnosis, onset of symptoms, and course of the disease and participants will be assessed prospectively over time using standardized qualitative and quantitative tools.
9722566|NCT05277350|Active Comparator|Cohort 1|6 participants on SNIPR001 (Dose 1 BID for 7 days) and 2 participants on placebo
10196903|NCT05142020||Control group|Specimen collection and clinical follow-up
10196904|NCT05141461|Sham Comparator|Group C|The patients will be received an ultrasound-guided interscalene brachial plexus block with 15 mL bupivacaine 0.5%.
10196905|NCT05141461|Experimental|Group Dex|The patients will be received an ultrasound-guided interscalene brachial plexus block with 15 mL bupivacaine 0.5% and 5 mg intravenous dexamethasone.
9722567|NCT05277350|Active Comparator|Cohort 2|6 participants on SNIPR001 (Dose 2 BID for 7 days) and 2 participants on placebo
9722568|NCT05277350|Active Comparator|Cohort 3|12 participants on SNIPR001 (Dose 3 BID for 7 days) and 8 participants on placebo
9722569|NCT05277311|Experimental|LongShengZhi capsule|Experimental group
9722570|NCT05277311|Placebo Comparator|LongShengZhi capsule placebo|Placebo group
9722571|NCT05277259|Active Comparator|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
9722572|NCT05277259|Active Comparator|Kinesiotaping|The Kinesiotaping method is a therapeutic taping technique which alleviates pain.
9722573|NCT05277259|Active Comparator|Conventional Physical Therapy|Hotpack, therapeutic ultrasound and tens applications.
9722574|NCT05277246|Active Comparator|1% NaOCIL|2 ml of 1% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
9722575|NCT05277246|Active Comparator|2.5% NaOCI|2 ml of 2.5% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
10196906|NCT05140967|Experimental|High Intensity Interval Training (A)|Exercise training with intermittent bouts of high intensity
10196907|NCT05140967|Experimental|Moderate Intensity Continous Training (B)|Exercise training with constant workload
10196908|NCT05140824|Placebo Comparator|Placebo|0.9% sodium chloride solution
9722576|NCT05277246|Active Comparator|5.25% NaOCI|2 ml of 5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
9722577|NCT05277220||Thermography|
9722578|NCT05277194|Experimental|KeepCalm App|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism. The app uses physiological stress tracking, assessed using heart rate monitoring, to indicate when challenging behaviors are likely to occur. The app then recommends strategies to help prevent the onset of challenging behaviors. The app can also be used to track trends in triggers, behaviors, and strategies, and to communicate this information to parents and other members of a child's educational team.
9780558|NCT01125748|Placebo Comparator|Placebo|Participants received placebo subcutaneously at the same dosing interval as omalizumab was administered prior to enrollment in this study.
10196909|NCT05140824|Experimental|TJ202|TJ202 injection
9722579|NCT05277194|No Intervention|Waitlist Control|Individuals assigned to the waitlist control condition will gain access to the KeepCalm app following the study's completion. During the trial, they will not receive any intervention, but will complete baseline and post-intervention measures during the trial.
9722580|NCT05277155|Experimental|Intervention Group (BEJO Red Ginger Extract)|84 patients, dosage: BEJO Red Ginger Extract orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)
10196910|NCT05140291|Experimental|Dry needling|Experimental Group
10196911|NCT05140291|Sham Comparator|Sham Needling|Sham Group
9722581|NCT05277155|Placebo Comparator|Control Group (Placebo)|84 patients, dosage: Placebo orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)
9722582|NCT05277142|Experimental|Group (A)|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
9722583|NCT05277142|Experimental|Group (B)|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks.
9722584|NCT05277129||Stroke patients|
9722585|NCT05277103|Experimental|Stay-Play-Talk with iPad Intervention|Peers without disabilities will be taught to be active communication partners using an iPad with voice output app as a speech-generating device, then paired up to play with one child with ASD for 16 sessions over 8 weeks. Focal child behaviors are assessed in different pre-treatment contexts (i.e., eye tracking, structured play, and naturalistic classroom settings), and rate of communication will be collected to predict gains children make in social communication with peers after treatment.
9722586|NCT05277090|Experimental|polyethyleneglycol only|participants take 2L of polyethyleneglycol only
9722587|NCT05277090|Experimental|polyethyleneglycol puls Inulin|participants take 2L of polyethyleneglycol, subsequently take 15g inulin per day.
10196912|NCT05139888|Experimental|Single wavelength light (red) only|Arm 1 will test the core technology of the ToeFX system; this study reproduces methods well-described in the literature. After application of the formulation, nails affected by onychomycosis are exposed to red light at a wavelength of 630-660 nm intensity of 200 mW/cm2.
10196913|NCT05139888|Experimental|Dual wavelength light (red/blue)|Some research has shown that exposure to mild blue light can have anti-inflammatory effects that would improve patient onychomycosis outcomes. We will assess whether inclusion of blue light in the protocol affects the clinical outcome.
9722588|NCT05277090|Experimental|polyethyleneglycol puls probiotic combination product|"Participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
9722589|NCT05277038||Clonidine vs Zopiclone for insomnia|Consecutive adult patients who underwent pain management at a Canadian pain clinic. The patients were subsequently prescribed and provided zopiclone 3.75mg tablet (1-2 tablets per dose), and clonidine 0.1mg tablet (1-2 tablets per dose). They were advised to take either clonidine or zopiclone on alternate nights. For each medication, they alternated the doses of 1 tablet or 2 tablets at subsequent nightly administrations. The four possible medication doses were zopiclone 3.75mg, zopiclone 7.5mg, clonidine 0.1mg, and clonidine 0.2mg; as shown on the sleep diary in Figure 1. The recommended orders of treatment were zopiclone 7.5mg, clonidine 0.1mg, zopiclone 3.75mg, clonidine 0.2mg; or clonidine 0.2mg, zopiclone 3.75mg, clonidine 0.1mg, zopiclone 7.5mg. Each patient participated in the study treatment and completed the sleep diary for 3 continuous weeks. Therefore, each of the four medication doses was used five times by each patient.
9722590|NCT05276999|Experimental|Echocardiographic Screening of school age children|Echocardiographic screening of school age children in Tororo and Iganga districts in Uganda to measure the prevalence of RHD before and two years after the deployment of an integrated strep infection education and treatment package.
9722591|NCT05276999|Experimental|Healthcare worker knowledge|Health care worker representatives from 101 facilities (n=101) will participate in primary educational workshops in identifying and treating GAS pharyngitis.
9722592|NCT05276999|Experimental|Health seeking behavior in the community|To increase health seeking behavior for sore throat thorough a multifaceted community awareness campaign that includes school based education, VHT lead education, education of patients seeking evaluation of sore throat at HC, and public service announcements
10196914|NCT05137223||Adolescent Only Focus Groups|20 early adolescents (ages 10-14) with physician-diagnosed persistent asthma (i.e., prescribed a controller medication) receiving care at a FQHC
10196915|NCT05137223||Caregiver Only Focus Groups|20 informal caregivers (e.g., parent, grandparent) of early adolescents with physician-diagnosed persistent asthma receiving care at a FQHC
10196916|NCT05137223||Adolescent and Caregiver Focus Groups|20 adolescents with physician-diagnosed persistent asthma receiving care at a FQHC and caregivers (both of whom did not participate in either previous group)
10196917|NCT05137093||Healthy subjects|Healthy subjects
10196918|NCT05137093||Atopic dermatitis|Atopic dermatitis
10196919|NCT05136950|Experimental|Secondary in-the-bag IOL fixation group|In-the-bag IOL fixation is the experimental arm
10196920|NCT05136950|Active Comparator|Secondary ciliary sulcus IOL fixation group|Ciliary sulcus IOL fixation is the control arm
10196921|NCT05136807||Observational (quality of life questionnaire)|Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.
10196922|NCT05133518|Active Comparator|MELT-300|Participants will receive a single dose of MELT-300 sublingual, rapidly dissolving tablet containing 3 mg of midazolam and 50 mg of ketamine.
10196923|NCT05133518|Active Comparator|Midazolam alone|Participants will receive a single dose of midazolam 3 mg sublingual tablet.
10196924|NCT05133518|Active Comparator|Ketamine alone|Participants will receive a single dose of ketamine 50 mg sublingual tablet.
10196925|NCT05133518|Placebo Comparator|Placebo|Participants will receive a single dose of a matching placebo sublingual tablet.
9722593|NCT05276986|Experimental|DOMS protocol group|DOMS was induced for the trunk muscles with a load equals to 80% of the maximum repetitive voluntary contraction. Pulmonary function parameters, respiratory muscle strength and endurance, exercise capacity, pain, fatigue, and dyspnea perception severity were recorded before DOMS and at the 24th and 48th hours after DOMS.
9722594|NCT05276960|Active Comparator|Regular supplementation|Baseline dose of 2000 IU of vitamin D3, based on Cystic Fibrosis Foundation (CFF) treatment guidelines. According to serum vitamin D levels, 2000 IU increments will be performed whenever 25-OH-VitD (25-hydroxy vitamin D) values < 30 ng/ml are found.
9722595|NCT05276960|Experimental|Enhanced Supplementation|Basal dose of 4000 IU of vitamin D3. According to serum vitamin D levels, increments of 4000 IU will be made each time 25-OH-VitD values < 30 ng/ml are found.
9722596|NCT05276934||Evolution of brain imaging in Non-traumatic Intracranial Hemorrhage|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome
9722597|NCT05276921||Patient|Postoperative ICU patient
9722598|NCT05276908|Experimental|mTLIP10|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
10196926|NCT05130411|Experimental|DLM - Test product|The dietary supplement is designed to be taken in servings of two gummies per day.
9722599|NCT05276908|Experimental|mTLIP20|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
9722600|NCT05276895|Active Comparator|(Quercetin +Fisetin)|"20 participants with symptomatic knee osteoarthritis and ultrasonography defined effusion-synovitis will take natural Senolytic agents.~The senolytic agents act by Hit-and-run strategy therefore, intermittent dosing regimens will be applied. 1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks.over 12 weeks"
9722601|NCT05276895|Active Comparator|Quercetin +Fisetin +Glycyrrhizin)|20 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis will take Quercetin 1250 mg + Fisetin 1000 mg for 3 consecutive days followed by 100mg/day Glycyrrhizin for one week every 3 weeks over 12 weeks .
9722602|NCT05276895|Placebo Comparator|Placebo|Placebo controlled group
9722603|NCT05275738|Active Comparator|Nicotinamide|Participants will receive 750mg nicotinamide tablets 1+1 per day (1.5g) for 6 weeks and after that 2+2 per day (3.0g).
9722604|NCT05275738|Placebo Comparator|Placebo|Participants will receive 750mg placebo tablets 1+1 per day for 6 weeks and after that 2+2 per day.
9722605|NCT05272722||Infants (under age of 1 year old)|ECG assessment and Holter monitoring
9722606|NCT05272722||1 - 5 years old children|ECG assessment and Holter monitoring
9722607|NCT05272722||6 -12 years old children|ECG assessment and Holter monitoring
9722608|NCT05272722||13-18 years old adolescents|ECG assessment and Holter monitoring
9722609|NCT05267860|Experimental|Patients with a prophylactic drain after cholecystectomy|
9722610|NCT05267860|No Intervention|Patients without using any prophylactic Drainage after cholecystectomy|
9722611|NCT05266209|Experimental|Experimental (coconut oil group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Moisturizers are applied to the thorax, back, arms and legs by massage, respectively, and the skin is absorbed. If it is to be applied for the first time, it is applied to a small area of the body under the control of a doctor. If there is no reaction, it is applied by massaging other areas. Since the babies to be included in the sample group are borderline and moderately premature (34-37W), 3-4 ml/kg (coconut oil)moisturizer will be applied.~Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday). Routine care will be applied to the skin of the newborns in the control group in the hospital. The control group will be evaluated using the NSCE form 3 days a week (Monday, Thursday, Sunday)."
9722612|NCT05266209|Other|Experimental (sunflower oil group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Moisturizers are applied to the thorax, back, arms and legs by massage, respectively, and the skin is absorbed. If it is to be applied for the first time, it is applied to a small area of the body under the control of a doctor. If there is no reaction, it is applied by massaging other areas. Since the babies to be included in the sample group are borderline and moderately premature (34-37W), 3-4 ml/kg (sunflower oil) moisturizer will be applied.~Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday)."
10196927|NCT05130060|Experimental|Treatment (PolyPEPI1018, TAS-102)|Patients receive PolyPEPI1018 SC at 4 injection sites on days 1 and 15 and trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-15. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
10196928|NCT05129592|Active Comparator|Nicotine corrective control|A factual message about nicotine that does not contain a causal explanation for what actually causes tobacco-caused disease or an explanation for why the misperception that nicotine causes cancer may have come to be believed.
10196929|NCT05129592|Experimental|Nicotine corrective with causal explanation|A factual message about nicotine that contain a causal explanation for what actually causes tobacco-caused disease: tar and chemicals created in tobacco smoke when tobacco is lit on fire.
10196930|NCT05129592|Experimental|Nicotine corrective with reason for misperception|A factual message about nicotine that contains an explanation for why the misperception may have come to be believed: that health messaging often discuses nicotine and tobacco-caused disease at the same time and people incorrectly make the connection that nicotine causes cancer.
10196931|NCT05129592|Experimental|Nicotine corrective with both components of coherence|A factual message about nicotine that contains both a causal explanation for what actually causes tobacco-caused disease and an explanation for why the misperception may have come to be believed.
10196932|NCT05128786|Experimental|CCT301-38|To determine the safety, tolerability, DLT and MTD of CCT301-38 cell therapy in patients with AXL-positive relapsed or refractory sarcomas.
9722613|NCT05266209|No Intervention|No Intervention (Control group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Routine maintenance of the intensive care unit will be implemented. Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday). Routine care will be applied to the skin of the newborns in the control group in the hospital. The control group will be evaluated using the NSCE form 3 days a week (Monday, Thursday, Sunday)"
9722614|NCT05261659|Experimental|TMR group|Patients will receive a sound while they receive a positive feedback for their performance of exposure therapy (ET). They will also receive the sound during REM sleep.
9722615|NCT05261659|Active Comparator|Control group|Patients will not receive a sound while they receive a positive feedback for their performance of exposure therapy (ET). They will receive the same sound as the experimental group during REM sleep under the same conditions.
9722616|NCT05258942||Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery|Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery
9722617|NCT05258942||Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)|Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)
10196933|NCT05124899|Experimental|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
9722618|NCT05258942||Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery|Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery
9722619|NCT05258942||Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery|Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery
10196934|NCT05124899|Experimental|CAP Herbal Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Herbal Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
10196935|NCT05124899|Experimental|CAP Mountain Berry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Mountain Berry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
9722620|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)|Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)
9722621|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Mitra Clip|Heart Failure Patients Scheduled for Transcatheter Mitra Clip
9722622|NCT05258942||Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation|Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation
9722623|NCT05258942||Heart Failure Patients Scheduled for Stellate Gangliectomy|Heart Failure Patients Scheduled for Stellate Gangliectomy
9722624|NCT05258942||Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery|Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery
9722625|NCT05258942||Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery|Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery
9722626|NCT05258903|Experimental|Ulnar artery|Ulnar artery cannulation under USG-guidance
9722627|NCT05258903|Active Comparator|Radial artery|Radial artery cannulation under USG-guidance
9722628|NCT05258851|Experimental|Ceftazidime-avibactam|Ceftazidime-avibactam 2.5 grams intravenous (IV) every 8 hours infused over two hours for a duration of 7-14 days, with dose adjustment for renal impairment according to the FDA prescribing information. Patients who have a positive Xpert Carb-R screening test or culture for CRE with metallo-beta-lactamases will receive aztreonam added to ceftazidime-avibactam.
9722629|NCT05258851|Active Comparator|Colistin|Colistin (9-million-unit loading dose IV followed with 9 million units IV daily divided into 3 doses), for 7 to 14 days. Patients with renal impairment will receive antibiotics with adjusted doses based on their glomerular filtration rate or the use and type of renal replacement therapy according to the 2019 International Consensus Guidelines for the Optimal Use of the Polymyxins.
9722630|NCT05258409|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
9722631|NCT05258409|Experimental|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
9722632|NCT05258266|Experimental|ZX-101A Dose Level A|ZX-101A administered orally at level A once daily in a 28-day cycle
9722633|NCT05258266|Experimental|ZX-101A Dose Level B|ZX-101A administered orally at level B once daily in a 28-day cycle
9722634|NCT05258266|Experimental|ZX-101A Dose Level C|ZX-101A administered orally at level C once daily in a 28-day cycle
9722635|NCT05258266|Experimental|ZX-101A Dose Level D|ZX-101A administered orally at level D once daily in a 28-day cycle
10196936|NCT05124899|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
10196937|NCT05123027|Experimental|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|
9722636|NCT05258266|Experimental|ZX-101A Dose Level E|ZX-101A administered orally at level E once daily in a 28-day cycle
9722637|NCT05257421|Experimental|shockwave group|
9722638|NCT05257421|Active Comparator|exercise group|
9722639|NCT05257421|Active Comparator|combined group|
9722640|NCT05257278||MonoPlus®|Patients undergoing orthopedic surgery with soft tissue approximation
9722641|NCT05257213|Active Comparator|Heparin solution|Administration of 3 ml heparin solution into the uterine cavity via a syringe immediately post operative hysteroscopy.
9722642|NCT05257213|Active Comparator|Anti-adhesion barrier gel|Intrauterine application of 2 ml biodegradable anti-adhesion barrier gel immediately post operative hysteroscopy.
9780559|NCT01125774|Experimental|Telcagepant|Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
10196938|NCT05123027|Active Comparator|Treatment As Usual Peer|
9722643|NCT05255887|Experimental|Informing patients group|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in the experimental group by face-to-face interview method.
9722644|NCT05255887|No Intervention|Control Group|patients who were no intervation
9722645|NCT05255731|Active Comparator|Laser Group (GL)|Patients will be submitted to a low power laser application immediately after suturing of the surgical area. The radiation emission shall be conducted according to protocol.
9722646|NCT05255731|Placebo Comparator|Control Group (CG)|In these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off.
9722647|NCT05255640||patients with ischemia of the lower limbs|
9722648|NCT05255120|Experimental|Intensified preoperative information|The patient participating in the intervention group is evaluated preoperatively based on an algorithm. This information is designed according to a checklist which includes how the procedure is performed, rules of conduct in connection with and after the procedure and what the patient can expect after surgery.
9722649|NCT05255120|No Intervention|Control group|The patient who participates in the control group receives information about participation in the study as a control, ie without information about the intervention. The patient will then be planned for the procedure according to current, local routines.
9722650|NCT05255107|Sham Comparator|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard-of-care treatment and Sham CXL and administration of artificial tears.
9722651|NCT05255107|Experimental|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. PESCHKE-L Solution is a riboflavin 5'-phosphate 0.23% ophthalmic solution that functions as a photosensitizer and is indicated for use with the PXL Platinum 330 Illumination System. Designed to be used when there is epithelial disruption as can occur with a corneal ulcer or wound. It does not contain benzalkonium chloride. It is intended to achieve rapid absorption.
10196939|NCT05122676|Experimental|MI-CARE program|Those automatically identified as eligible and randomized to the MI-CARE arm are outreached by a study nurse care manager and offered the 12-month long virtual Collaborative Care program by telephone or video visits. Individuals are free to accept or decline the offer (e.g., stop/restart, not accept right away) during the 12 months after their randomization date.
10196940|NCT05122676|No Intervention|Usual care|Those identified as eligible and randomized to the usual care arm have no contact with the study. All outcome data for both study arms are collected from secondary, electronic sources.
10196941|NCT05121259|Experimental|Exercise Guide|Single group feasibility group. Single group (intervention group) will be given access to the intervention (Exercise Guide UK) for eight-weeks.
9722652|NCT05255016|Sham Comparator|Standard of care + Sham CXL + Artificial Tears|Standard-of-care treatment and Sham CXL and administration of artificial tears.
9722653|NCT05255016|Experimental|Standard of care + CXL + Riboflavin 0.25% TE Solution|Standard of care treatment and the experimental combination product. The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. The riboflavin solution is an isotonic (0.9%) sodium chloride solution containing 0.25% riboflavin, 1% hydroxypropylmethylcellulose, and 0.007% benzalkonium chloride, adjusted to a pH of 7.0, and packaged in 2 mL sterile syringes for topical ophthalmic use.
9722654|NCT05254548|Experimental|ACT-539313 with or without a standard combination (probe substrate)|Treatment arm has 4 in-house treatment periods. In Treatment Period 1, participants will receive a single oral dose of the standardized combination (probe substrate: containing flurbiprofen [50 mg], midazolam [2 mg] and omeprazole 20 [mg]) on Day 1. Participants will be discharged from the study site on Day 2 and will be re-admitted on Day 7. In Treatment Period 2 (morning of Day 8) a first oral dose of 100 mg ACT-539313 will be administered. One hour later a single oral dose of the probe substrate will be administered. In the evening of Day 8, a second oral dose of 100 mg ACT-539313 will be administered. During Treatment Period 3 (morning of Day 9, ending on the evening of Day 14) oral doses of 100 mg ACT-539313 will be administered in the morning and evening. In Treatment Period 4 (Day 15), a single oral dose of 100 mg ACT-539313 together with the probe substrate will be administered. The participants will receive the last dose of ACT-539313 in the evening of Day 15.
10196942|NCT05120947|Experimental|42 Gray (Gy) Radiation|42 gy of radiation therapy will be administered in 10 fractions.
10196943|NCT05120947|Experimental|39 Gray (Gy) Radiation|39 gy of radiation therapy will be administered in 8 fractions.
10196944|NCT05120947|Experimental|32.5 Gray (Gy) Radiation|32.5 gy of radiation therapy will be administered in 5 fractions.
10196945|NCT05120804|Active Comparator|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
10196946|NCT05120804|Experimental|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus brief and structured counseling on family functioning
10196947|NCT05119140|Experimental|Mesalamine and Hydroxychloroquine|All participants will be on Mesalamine and Hydroxychloroquine
10196948|NCT05119075|Experimental|Dopaminergic ON-drug state first, dopaminergic OFF-drug state second|"The following examinations and assessments will be performed at visit 3 on regular treatment in dopaminergic ON-drug state and at visit 4 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs):~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
10196949|NCT05119075|Experimental|Dopaminergic OFF-drug state first, dopaminergic ON-drug state second|"The following examinations and assessments will be performed at visit 3 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs) and at visit 4 on regular treatment in dopaminergic ON-drug state:~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
10196950|NCT05117320|Experimental|AI support|
10196951|NCT05117320|No Intervention|Non-AI support|
10196952|NCT05114824|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy
10196953|NCT05114824|No Intervention|Control Group|Control group
9722655|NCT05253872|Experimental|Intervention group|Patients in the intervention arm will receive follow-up conducted by melanoma nurses, where the patients will get tools to cope with the melanoma diagnosis and structured training in skin self-examination
9722656|NCT05253872|No Intervention|Control group|Patients in the control arm will receive clinical follow-up according to the current standard of care for their clinical stage.
9722657|NCT05253690|Active Comparator|speculum guided|view-guided approach using a speculum
9722658|NCT05253690|Experimental|manual guided|manual guided approach at cervical examination
9722659|NCT05250440||(a1)Emmetropia: +0.75 to -0.75 D|age: 12 to 18 years old
9722660|NCT05250440||(a2)Mild myopia: -1.00 to -3.00 D|age: 12 to 18 years old
9722661|NCT05250440||(a3)Moderate myopia: -3.25 to -6.00 D|age: 12 to 18 years old
9722662|NCT05250440||(a4)High myopia: >-6.00 D|age: 12 to 18 years old
9722663|NCT05250440||(b1)Emmetropia: +0.75 to -0.75 D|age: 18 to 35 years old
9722664|NCT05250440||(b2)Mild myopia: -1.00 to -3.00 D|age: 18 to 35 years old
10196954|NCT05114512|Experimental|RAPTOR Physical Therapy Intervention|RAPTOR intervention: hybrid in-person + telehealth physical therapy care for rural-dwelling individuals with knee osteoarthritis
10196955|NCT05113056|Experimental|Non-randomized|All subjects will be ablated using the Acutus Medical Pulsed Field Ablation System (PFA System) in the management of their atrial fibrillation.
10196956|NCT05111964|Experimental|HIFU Treatment of STS or Intra-abdominal Desmoid Tumour|All participants receive HIFU to their target tumour, hence this is a single arm study with 4 recruitment pathways.
10196957|NCT05111262|Active Comparator|As needed inhaled corticosteroid and long-acting beta-agonist|Symptom-driven ICS/LABA treatment strategy
10196958|NCT05111262|No Intervention|Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist|Continue maintenance ICS and SABA therapy
10196959|NCT05107752|Experimental|Stellate ganglion block (SGB) treatment during cognitive processing therapy (CPT)|Participants will receive 12 sessions of cognitive processing therapy (CPT) for PTSD combined with SGB during the first week of CPT.
10196960|NCT05107752|Experimental|SGB three months after completing CPT|Participant will receive 12 sessions of cognitive processing therapy (CPT) for PTSD and will receive SGB three months after completing the CPT sessions.
10196961|NCT05105477|Experimental|HPI Arm|AcumenTM HPI Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.
9722665|NCT05250440||(b3)Moderate myopia: -3.25 to -6.00 D|age: 18 to 35 years old
9722666|NCT05250440||(b4)High myopia: >-6.00 D|age: 18 to 35 years old
9722667|NCT05248854|Experimental|Sensorimotor exercise training|SM program included combination of traditional hip and knee exercise, various balance and proprioceptive exercises.
9722668|NCT05248854|Experimental|Core Stabilization exercise training|Core stabilization exercise program contained traditional hip and knee ROM exercise combining the core stabilization as mat activities
9722669|NCT05235165|Experimental|Arm A (thoracotomy)|Patients undergo open thoracic surgery (thoracotomy).
9722670|NCT05235165|Experimental|Arm B (thoracoscopy)|Patients undergo thoracoscopy (video-assisted thoracoscopic surgery or VATS).
9722671|NCT05232851|Experimental|Arm A (PDS0101)|Patients receive PDS0101 SC on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
9722672|NCT05232851|Experimental|Arm B (PDS0101, pembrolizumab)|Patients receive PDS0101 SC on day 1 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
9722673|NCT05232240||Non-hypertensive patients with Ischemic Cerebrovascular Disease|The patients are diagnosed as ischemic cerebrovascular disease (ICVD) and less than 90 days after the onset of ischemic stroke or transient ischemic attack. The patients have no definite diagnosis of hypertension, and are not under anti-hypertension treatment. The blood pressure measured 5~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥ 2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).
9722674|NCT05230368|Experimental|1 cycle of treatment (Cohort 1 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3~romidepsin (5mg/m²) at days 4, 11, 18"
9722675|NCT05230368|Experimental|2 cycles of treatment (Cohort 2 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37~romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52"
9722676|NCT05230368|Experimental|4 cycles of treatment (Cohort 3 = 5 patients)|"decitabine (5mg/m²) at days 1, 2, 3, 35, 36, 37, 70, 71, 72, 105, 106, 107~romidepsin (5mg/m²) at days 4, 11, 18, 38, 45, 52, 73, 80, 87, 108, 115, 122"
9722677|NCT05227794|Experimental|Compassion-Based Intervention|Participants in this condition are assigned to an empirically supported 8-week online compassion-based intervention protocol. The intervention includes a weekly 2-hour educational session and a recommendation of 15-30-mins of daily meditation, and real-world assignments to practice compassion.
10196962|NCT05105477|Placebo Comparator|Non-HPI arm|Non-protocolized standard of care management per clinician and provider judgement
10196963|NCT05102383|Active Comparator|Habitual lens optimization|All subjects are re-fit with habitual Biofinity Toric lenses to optimize vision.
10196964|NCT05102383|Active Comparator|Daily disposable lenses|All subjects are fit with daily disposable lenses with water surface treatment.
10196965|NCT05100355|Active Comparator|Opacification|Contrast agent injection
10196966|NCT05100355|Experimental|Physiological serum injection|Physiological serum injection
10196967|NCT05099107|Active Comparator|Treatment|congenital myopathy patients in this group will receive daily oral salbutamol, three times daily.
9722678|NCT05227794|Experimental|Mindfulness-Based Intervention|Participants in this condition are assigned to an empirically supported 8-week online mindfulness-based intervention protocol. The intervention includes a weekly 2-hour educational session, a recommendation of 15-30 minutes of daily meditation, and an optional 6-hour one-day retreat.
9722679|NCT05227794|No Intervention|Waitlist Control (WL)|The WL control group will complete all study assessments on the same schedule as the intervention arms. At the time of the final follow-up assessment, participants will be randomly assigned to one of the interventions (CCT or MBSR) with the same instructors.
9722680|NCT05222464|Other|Standard of Care Intervention|Standard of care intervention - The intervention will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
9722681|NCT05221281|Experimental|Intervention: Multimodal intervention consisting of four core components.|"Core Component 1: Individualized Assessment~Core Component 2: Transition Facilitation with a Navigator~Core Component 3: Participant Skills-building~Core Component 4: Structured Educational eLearning Curriculum"
9722682|NCT05221281|Other|Control: Standard of care|Routine Care
9722683|NCT05216913||Endometrial cancer survivors|
10196968|NCT05099107|No Intervention|Non treatment|Congenital myopathy patients in this group will not receive any salbutamol nor placebo.
9722684|NCT05214209|Experimental|Intervention arm|Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum over a period of 4 weeks through the app. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participant can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
10196969|NCT05093894|Active Comparator|Group 1: Microlyte will be cut into strips and placed on the surgical incision|Microlyte will be cut into strips and placed on the surgical incision
9722685|NCT05214209|Active Comparator|Usual care arm|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises."
9722686|NCT05213091|Experimental|Otago Exercise Group|Otago Exercise program wil be applied to the elderly.
9722687|NCT05213091|No Intervention|Control Group|The elderly wil be expected to continue their daily life.
10196970|NCT05093894|No Intervention|Group 2: Nothing will be placed on the surgical incision|Nothing will be placed on the surgical incision
10196971|NCT05090111|Experimental|ALG-055009|Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
10196972|NCT05090111|Placebo Comparator|Placebo|Oral dose(s) of placebo in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
9722688|NCT05212454|Experimental|capecitabine group|All enrolled cases should be given standard chemotherapy, radiotherapy and endocrine therapy according to the Chinese Society of Clinical Oncology (CSCO) guidelines for the treatment of breast cancer, with the specific regimen decided by the doctor according to the condition. After the completion of standard chemotherapy, capecitabine 1250mg/m2 should be given orally twice a day for 2 weeks of the 3-week treatment course, and the total duration of treatment is 8 courses, which can be given simultaneously with radiotherapy and endocrine therapy. Premenopausal patients may use ovarian suppressants as needed.
9722689|NCT05209763|Active Comparator|Standard rehabilitation|patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
9722690|NCT05209763|Experimental|More intensive rehabilitation|"patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.~patient daily exercises using the rehabilitation device MOTOmed Letto 2 for a minimum of 5 days, maximum duration not limited, minimum duration of exercise 20 minuts once daily~exercise duration will be recorded daily and total time (in hours) at the end of the hospital stay"
9722691|NCT05209763|Active Comparator|Standard nutrition|- nutrition determined by the attending physician according to recommendations for age, type of acute illness and comorbidities
9722692|NCT05209763|Experimental|More intensive nutrition|"determined by the attending physician according to recommendations for age, type of acute illness and comorbidity~- in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day and in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day for 5 days"
9722693|NCT05206344|Other|Without Clowns - Clowns (WC-C)|Firstly a painful act without the presence of the clown duo, then in a second time the same painful act in the presence of the clown duo
10196973|NCT05089864|Other|Early stent placement|Stent placement 5-7 weeks post-STAR procedure
10196974|NCT05089864|Other|Later stent placement|Stent placement 12-14 weeks post-STAR procedure
9722694|NCT05206344|Other|Clowns- Without clowns (C-WC)|Firstly a painful act with the presence of the clown duo, then in a seconde time, the same painful act without the presence of the clown duo
10196975|NCT05089643|Experimental|CA|Anlotinib 10mg Qd D1-14 Capecitabine 1G /m2 Bid D1-14 / Q21D
10196976|NCT05085613|Active Comparator|Vaccine Corrective Control|A message that explains why people are hesitant to accept the FDA authorized COVID vaccines are safe and effective and how the vaccines are evaluated as safe and effective by FDA.
10196977|NCT05085613|Experimental|Vaccine corrective with economic recovery framing|"The content of the control message with the addition of the text, If everyone gets vaccinated, we can keep schools, stores, and other businesses open so more Americans can keep working and supporting their families. The message will also include a picture of an open for business sign."
10196978|NCT05085613|Experimental|Vaccine corrective with freedom framing|"The content of the control message with the addition of the text, Everyone getting vaccinated is the key to freedom! A vaccine can give us the freedom to hang out with friends, shop, and worship together again safely. The message will also include a picture of an American flag."
9722695|NCT05198843|Experimental|Treatment (icosapent ethyl, dasatinib)|Patients receive icosapent ethyl PO BID and dasatinib PO QD in each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9722696|NCT05198830|Experimental|Arm I (methoxyamine, usual care)|Patients receive methoxyamine PO on day 1 of each cycle, pemetrexed IV over 10 minutes on day 1 of each cycle, and cisplatin IV over 60 minutes on day 3 of each cycle. Beginning day 3, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
9722697|NCT05198830|Active Comparator|Arm II (usual care)|Patients receive pemetrexed IV over 10 minutes and cisplatin IV over 60 minutes on day 1 of each cycle. Beginning day 1 of each cycle, patients also undergo radiation therapy daily Monday-Friday. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after cycle 2, patients receive durvalumab IV over 60 minutes every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
9722698|NCT05198544|Experimental|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Subjects will receive weekly application of Ham along with standard of care therapy for eight (8) weeks unless healing occurs prior to 8 weeks.
9722699|NCT05197673|Experimental|Intervention group|This arm will receive TPB intervention to build positive attitudes towards COVID-19 related preventive behaviour (e.g., good compliance with infection control measures, encouraging uptake of testing and vaccination), subjective norms (tackling strategies for perceived social pressure from others or normative beliefs), and improve perceived behavioural control towards risks of outbreaks in workplace.
9722700|NCT05197673|No Intervention|Control group|Control group will receive only general health information.
9722701|NCT05187650|Experimental|Ekso and FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton combined with gait-synchronized FES using the FES RehaMove2.
9722702|NCT05187650|Active Comparator|Ekso without FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton without applying FES.
10196979|NCT05085613|Experimental|Vaccine corrective with humor|"The content of the control message with the addition of the text, Unfortunately, everyone getting vaccinated means leaving the house again. The message will include a meme of a cat being pulled/rescued from a window with text boxes labeling the cat as People at home working in sweatpants and the rescuer as COVID Vaccines."
9722703|NCT05186272|Experimental|Intervention|Use of mHealth mindfulness meditation app 10-20 min daily for 6 weeks
10196980|NCT05085470|Experimental|Reinfection group|Participants will be exposed three times to 20 male Schistosoma mansoni cercariae (weeks 0, 9, and 18)
9722704|NCT05186272|Active Comparator|Active control|Listening to web-based nature sounds 10-20 min daily for 6 weeks
10196981|NCT05085470|Active Comparator|Infection control group|12 participants who will undergo a placebo mock infection with water twice (weeks 0 and 9) and will be exposed once to 20 male Schistosoma mansoni cercariae (week 18)
10196982|NCT05082545|Experimental|Dose escalation:SHR-2002+SHR-1316|SHR-2002 +SHR-1316 C1D1 SHR-2002,C1D22 SHR-2002+SHR-1316, C2 SHR-2002+SHR-1316
10196983|NCT05082545|Experimental|Dose expansion stage: SHR-2002+SHR-1316|Dose expansion of SHR-2002 will be decided after finishing few cohorts in Dose escalation part.
10196984|NCT05082545|Experimental|Indication expansion stage：SHR-2002+SHR-1316|Indication expansion of SHR-2002 will be decided after finishing few cohorts in Dose expansion part.
9722708|NCT05179226|Experimental|Ferric Derisomaltose|"All subjects (a total of 200) will be treated with Ferric Derisomaltose. 12 subjects (half of the 24 subjects participating in the PK-part of the trial) will be treated with 10mg/kg while the remaining subjects will be treated with 20 mg/kg.~."
9722709|NCT05176223|Experimental|Treatment (68GA PSMA PET/CT)|Patients undergo 68GA PSMA PET/CT scans at baseline, and after 3, 6, 9, and 12 cycles of standard of care immunotherapy in the absence of disease progression or unacceptable toxicity.
9722710|NCT05174884|Experimental|Single Casea S pellet|In Part 1 of this study, four women will each have a single Casea S pellet (22.2 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
9722711|NCT05174884|Experimental|Two Casea S pellets|In Part 2 of this study, eight women will each have two Casea S pellets (44.4 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
9722712|NCT05174884|Experimental|Variable Casea S pellets|Based on PK modeling from Parts 1 and 2, the investigator will select one or more doses of Casea S for Part 3. In Part 3 of this study, approximately 18 women will each have Casea S pellets (range 1-3 pellets) inserted into the inner aspect of the non-dominant upper arm.
9722713|NCT05173493||Amoxicillin-Furazolidone-containing quadruple group|Patients in amoxicillin-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
9722714|NCT05173493||Amoxicillin-Levofloxacin-containing quadruple group|Patients in amoxicillin-Levofloxacin-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
9722715|NCT05173493||Tetracycline-Furazolidone-containing quadruple group|Patients in tetracycline-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), tetracycline 500 mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
9722716|NCT05169398|Experimental|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea).
10196985|NCT05080075|Experimental|Participants receiving a platelet rich plasma injection|All patients in the study will be receiving a platelet rich plasma injection, and we will be following their clinical outcomes
9722717|NCT05168618|Experimental|Treatment (cabozantinib, atezolizumab)|Patients receive cabozantinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9722718|NCT05168202|Experimental|CC-95251 monotherapy|
9722719|NCT05168202|Experimental|CC-95251 + azacitidine|
9722720|NCT05157048|Experimental|Marketing condition A|Participants will be randomized to a marketing condition.
9722721|NCT05157048|Experimental|Marketing condition B|Participants will be randomized to a marketing condition.
9722722|NCT05154838||Patients with Pilonidal Abcess|All adult (18+) patients presenting at surgical assessment unit requiring treatment for pilonidal abscess. Wounds will be drained, cleaned and packed as per usual clinical practice. Extra standard wound swabs will be collected for additional microbiological analyses. Control wound dressings will be placed on adjacent, unaffected area of skin for 24 hours.
9722723|NCT05154565|Experimental|Immediate intervention (Group A)|Meditation intervention applied during Phase 1 of the study. During Phase 2, the formal meditation intervention is not completed, but participants are followed for outcome measurement. Participants may continue to use meditation in their daily routines or return to their usual routines.
9722724|NCT05154565|Other|Delayed intervention (Group B)|No intervention is applied in Phase 1 of the study. This group serves as the control group for Phase 1. The meditation intervention is applied in Phase 2 of the study.
10196986|NCT05079945|Experimental|Spinal cord Tractography|Healthy volunteer having the tractography exam
9722725|NCT05326724|Experimental|Acupuncture|
9722726|NCT05326711|Experimental|Telerehabilitation-based motor imagery training|"The first 2 weeks of the treatment period, will reserved for implicit motor imagery / lateralization training. It will be performed by the noi group application application that can be downloaded to the participants' mobile devices. Participants will be asked to use the app 3 times a day. In each application session, the right / left discrimination of the region in the photograph will be requested within 5 seconds and 30 photographs will be shown for each painful region. Each session will last 2-3 minutes on average. For 3rd to 8th weeks of the treatment period telehabilitation-based motor imagery training will be given to the participants individually, in synchronization, using the Google Meet videoconference platform, under the guidance of a physiotherapist. The duration of the sessions will last 20-30 minutes."
9722727|NCT05326711|No Intervention|Control|No specific intervention
9722728|NCT05326685|Experimental|Intervention|video with korotkoff sounds
9722729|NCT05326685|No Intervention|Control|standart practice
9722730|NCT05326672|Experimental|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
9722731|NCT05326672|Placebo Comparator|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
9722732|NCT05326659|Experimental|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
10196987|NCT05078333|No Intervention|exercise|All patients in all three groups will perform 15 sessions (for 3 weeks, weekdays), cervical area isometric strengthening exercises, active ROM exercises and stretching exercises for 15 minutes a day with the same physiotherapist.
10196988|NCT05078333|Active Comparator|exercise+HILT|In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
9722733|NCT05326659|Placebo Comparator|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
9722734|NCT05326646|Experimental|IBS patients|Patients suffering from IBS according to Rome IV criteria
9722735|NCT05326633|No Intervention|UC only|LTACH control group receiving usual care (UC) only.
9722736|NCT05326633|Active Comparator|MRP+HPRO+NMES+UC|LTACH group receiving mobility based rehabilitation (MRP) + neuromuscular electric stimulation (NMES) + high protein supplementation (HPRO) + usual care (UC)
9722737|NCT05326607|Other|First Arm|
9722738|NCT05326607|Other|Second Arm|
10196989|NCT05078333|Active Comparator|exercise+dry needling|In addition to the exercise program, dry needling (on 3 trigger points on the bilateral trapezius muscle) will be applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
10196990|NCT05077631|Experimental|ACD856|
9722739|NCT05326594|Experimental|Physical Therapy|
9722740|NCT05326581||PATIENTS|patients benefiting from an MRI examination as part of their care
9722741|NCT05326581||VOLUNTEERS|healthy volunteers among staff.
9780560|NCT01125774|Placebo Comparator|Placebo|Placebo was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
9780561|NCT01125800|Experimental|LDE225 233mg/m2 daily dose|Pediatric dose.
9780562|NCT01125800|Experimental|LDE225 372mg/m2 daily dose|Pediatric dose.
9780563|NCT01125800|Experimental|LDE225 425 mg/m2 daily dose|Pediatric dose.
9780564|NCT01125800|Experimental|LDE225 680 mg/m2 daily dose|Pediatric dose.
9780565|NCT01125800|Experimental|LDE225 800 mg/m2 daily dose|Adult dose
9780566|NCT01125813|Experimental|human cl-rhFVIII|
9780567|NCT01125917|Experimental|BTDS|Buprenorphine transdermal patch
9780568|NCT01125930|Placebo Comparator|Vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
9780569|NCT01125930|Active Comparator|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
9780570|NCT01126060|Active Comparator|Fibrin sealant|usage of fibrin sealant after surgery
9780571|NCT01126060|No Intervention|Control|No usage of fibrin sealant
10196991|NCT05077631|Placebo Comparator|Placebo|
9722742|NCT05326542|Experimental|ESWL and ERCP|The patients will receive intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP will be greater than 48h. ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
9722743|NCT05326542|Active Comparator|LL and ERCP|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
9722744|NCT05326529|Active Comparator|Traditional Cardiac Rehabilitation (Hospital based programme)|Traditional Cardiac Rehabilitation will involve 8 hospital-based exercise sessions, and one virtual education day over 8 weeks, supervised by CR health care professionals.
9722745|NCT05326529|Experimental|Traditional combined with Web-based Cardiac Rehabilitation|Traditional combined with Web-based Cardiac Rehabilitation. Patients will attend 8 hospital-based exercise sessions and one virtual education day over 8-weeks with access to additional web-based (MyHeart app) exercise and educational information.
9722746|NCT05326529|Experimental|Web-based Cardiac Rehabilitation|Web-based Cardiac Rehabilitation, using MyHeart app introduced during a pre-CR assessment, will follow an 8-week individualised self-managed platform, allowing contact with the CR health professionals via app messages only (no direct contact for web-based CR).
9722747|NCT05326516|Experimental|SNDX-5613 and Chemotherapy Regimen 1|Participants with acute lymphoblastic leukemia/mixed phenotype acute leukemia (ALL/MPAL) will receive SNDX-5613 every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 1.
9722748|NCT05326516|Experimental|SNDX-5613 and Chemotherapy Regimen 2|Participants with ALL/MPAL or acute myeloid leukemia (AML) will receive SNDX-5613 every 12 hours in combination with 2 treatment cycles of Chemotherapy Regimen 2.
9722749|NCT05326464|Experimental|Tofacitinib 5 mg|Participants will take the 5mg Tofacitinib twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
9722750|NCT05326451|Experimental|active tDCS|
9722751|NCT05326438|Experimental|CIRCLE mHealth app|"The investigators will trial a modified version of the mHealth app called Connections with Alaska Native/American Indian people who want to change the way they use alcohol."
9722752|NCT05326412|Experimental|Itepekimab|"This arm includes participants from 3 populations: Part A-former smokers, Part B-former smokers and Part B-current smokers.~Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 12 weeks"
9722753|NCT05326399||renal biopsy|Standard percutaneous biopsy has been performed in all participants. Light microscope, fluorescence microscope and electron microscope were used for assessment of kidney issue
10196992|NCT05075694|Experimental|Experiment|Therapeutic touch is a treatment that takes an average of 15-20 min, in which energy in the universe is transferred through the hands of the practitioner to eliminate the imbalance in the individual's energy field and facilitate healing.
9722754|NCT05326386|No Intervention|Control|Via the Way to Health platform, all participants will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.
9722755|NCT05326386|Experimental|Intervention|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
9722756|NCT05326347|Experimental|Rollover subjects|For rollover subjects, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation at 24 mg. From Week 1 onward, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 51 weeks.
9722757|NCT05326347|Experimental|New subjects|In medication switching period, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation 24 mg, and the dose of the other antipsychotics will be gradually reduced, finally switching to monotherapy with 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) by Week 4. In treatment period, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 52 weeks.
9722758|NCT05326321|Experimental|Virtual Reality Glasses Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure. After the AVF cannulation procedure was completed and 10 minutes later, the VAS and Hemodynamic Variables Follow-up Form were reapplied, and the 2nd and 3rd measurements were obtained. Patients' satisfaction was measured with VAS 10 minutes after the procedure. During the application of virtual reality glasses, a screen was pulled between the patients in the intervention and control groups so that there would be no interaction.
9722759|NCT05326321|No Intervention|Control group|Without any application to the patients in the control group, the AVF cannulation procedure before HD was performed with the constant site-area puncture technique used by the clinic (after the patient was placed in the fowler position, the arterial needle was 3 cm away from the anastomosis at an angle of 20°-45° towards the distal, and the venous needle was from the arterial needle. 3-5 cm more proximal, again at an angle of 20°-45°) was performed by the HD nurse. The 1st, 2nd and 3rd measurements were obtained as in the intervention group.
9722760|NCT05326308||Study Cohort|150 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
9722761|NCT05326295||Breast cancer patients|
9722762|NCT05326282|Experimental|Multi-parametric and micro ultrasound|Transrectal ultrasound imaging in men with suspected or known low grade prostate cancer using both standard and micro-ultrasound technology
9722763|NCT05326269|Active Comparator|Intervention group|Terbutaline 0.5 mls (0.25 mg) , subcutaneously
9722764|NCT05326269|Placebo Comparator|Control group|Placebo (normal saline) 0.5 mls , subcutaneously
9722765|NCT05326256|Experimental|PSSE Group|Physiotherapy Scoliosis Specific Exercises (PSSE), 45-minute exercise session with the supervisor, twice a week for 12 weeks
10196993|NCT05075694|Placebo Comparator|Placebo|Placebo: Mimic Touch The placebo group will receive mimic touch instead of therapeutic touch. In this procedure, the therapeutic touch will be imitated, but the real procedure of the therapeutic touch will not be perform to the experimental group.
10196994|NCT05073627|No Intervention|Baseline|The investigators measure the baseline of dicloxacillin and the probe drug dabigatran etexilate.
9722766|NCT05326256|Experimental|Vestibular Exercise Group|Vestibular exercises to be added to PSSE exercises, 45-minute exercise session with the supervisor, twice a week for 12 weeks
10196995|NCT05073627|Experimental|Dicloxacillin treatment|The investigators measure the concentration of dicloxacillin after 9 and 27 days and the concentration of dabigatran after 10 and 28 days of continuously taking dicloxacillin.
10196996|NCT05072795|Experimental|Stress Induction|
10196997|NCT05072600|Experimental|arm 1|All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.
9722767|NCT05326243|Experimental|CD19-targeted chimeric antigen receptor T-cell|Patients will receive a lymphodepletion chemotherapy with fludarabine plus cyclophosphamide for three consecutive days(Day -5 to Day -3) before infusion of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T). Patients will receive the CD19 CAR-T(also known as PL001) infusion on Day 0.
9722768|NCT05326230|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (PRDS-001- Paradise™ System)
9722769|NCT05326230|Sham Comparator|Sham Control|Renal Angiogram
9722770|NCT05326217|No Intervention|Control Group|non-dysmenorrhea population with original lifestyle
10196998|NCT05071144||Pediatric Spine Deformity Patients|Standard of care surgery using robotics coupled with navigation
10196999|NCT05069662||Patients treated with oral anticancer drugs|Patients treated with oral anticancer drugs followed in the Oncoral program
10197000|NCT05067556|Experimental|Intervention|Acceptance and Commitment Therapy for Chronic Pain (ACT-CP)
10197001|NCT05067543||Tornier Perform Humeral System - Stem|Partial or total shoulder arthroplasty using the Tornier Perform Humeral Stem.
10197002|NCT05066490|Experimental|endurance exercise|This group received endurance exercises only.
10197003|NCT05066490|Experimental|resistance exersise plus endurance exersise|This group received resistance exercises followed by endurance exercises.
10197004|NCT05065879|Experimental|Hypertension group|Hypertension group will enroll 330 subjects with hypertension (aged 60 years or older).
10197005|NCT05065879|Experimental|Diabetes group|Diabetes group will enroll 330 subjects with diabetes (aged 60 years or older).
10197006|NCT05065879|Experimental|Combined Diseases group|Combined Diseases group will enroll 300 subjects with both hypertension and diabetes (aged 60 years or older).
10197007|NCT05065879|Active Comparator|Healthy people group|Healthy people group will enroll 480 subjects with no medical history of hypertension or diabetes (aged 60 years or older).
9722771|NCT05326217|No Intervention|Dysmenorrhea|dysmenorrhea population without exercise intervention
9722772|NCT05326217|Experimental|Dysmenorrhea+Aerobic Exercise|dysmenorrhea population with aerobic exercise intervention
9722773|NCT05326217|Experimental|Dysmenorrhea+Resistant Exercise|dysmenorrhea population with resistant exercise intervention
9722774|NCT05326178|Experimental|General information about depression|Exposure to general information about depression
9722775|NCT05326152|Experimental|IntralesionaL Hepatitis B vaccine|0.2 ml of hepatitis B vaccine injected in the largest wart and repeated every 2 weeks till clearance of warts or for a maximum of 5 sessions
9722776|NCT05326152|Experimental|Intramuscular Hepatitis B vaccine|"0.5 ml injected in the deltoid muscle for those who were younger than 19 years at the time of study and 1 ml for those who were 20 years and older at the time of study.~Three injections were done at 0, 1, and 4 months."
10197008|NCT05065541|Experimental|Part 1|
10197009|NCT05065541|Experimental|Part 2|
10197010|NCT05065541|Experimental|Part 3|
10197011|NCT05065099|Experimental|OnTRACK Intervention|"In the intervention condition, HCPs will be trained in the usage of the OnTRACK system.~They will be oriented to the educational videos, the symptom tracking, and the interpretation of the data that is provided by the patients and families, and the associated management strategies based on that data. Additionally, patients and parents will be trained to use the OnTRACK smartphone app on their phone from diagnosis to recovery (or 12 weeks if not recovered), including daily exertional monitoring symptom ratings and use of the educational videos. School personnel will be introduced to the OnTRACK app and the data summary features in the school dashboard and the associated supports that can be provided to the student based on that data."
10197012|NCT05065099|No Intervention|Treatment as Usual|"In the control condition, the HCP provides usual/standard care to the patients and parents as is the practice within the specific clinic. The OnTRACK app and the educational modules are not provided."
10197013|NCT05064488|Experimental|Part-1: Evobrutinib + Digoxin + Metformin + Rosuvastatin|
10197014|NCT05064488|Experimental|Part-2: Evobrutinib + Sumatriptan|
10197015|NCT05064202|Experimental|Impella CP|ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the experimental arm will be treated with an Impella CP (+/- standard of care)
10197016|NCT05064202|Other|Standard of care|ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the control arm will be treated with inotropes (standard of care)
10197017|NCT05063981||CRSwNP|10 patients with severe refractory eosinophilic asthma plus CRSwNP
9722777|NCT05326152|Placebo Comparator|Intralesional saline|0.2 ml of saline injected in the largest wart and repeated every 2 weeks till clearance of warts or for a maximum of 5 sessions
9722778|NCT05326139|Active Comparator|Tranexamic acid|Group TA (n=25): TA ( Tranexamic acid, 250mg/2.5 ml inj ) soaked pledgets were placed under the skin flap to cover the osteotomy line
9722779|NCT05326139|Placebo Comparator|Isotonic saline|Group Co (n=25): Isotonic saline ( NaCl, 0.9 %) soaked pledgets were placed under the skin flap to cover the osteotomy line
9722780|NCT05326126|Experimental|Coronary physiology evaluation|Patient will undergo TAVI and then Myocardial fibrosis will be evaluated on images acquired at the time of the cardiac CT obtained for TAVI planning. Briefly, an extra late post-contrast acquisition image will be acquired. The delayed post-contrast scan will be reconstructed with a soft convolution kernel and will be reformatted in the short- and long-axis planes (slice thickness 8 mm; gap 0 mm) in average mode.
9722781|NCT05326113|Experimental|Physiotherapy|"Patients will undergo physiotherapy and will be regularly examined by an assigned physician.~Initial physiotherapy will last 60minutes, other therapies will last 30minutes. Physiotherapy will aim on diaphragmatic breathing and dynamic neuromuscular stabilization exercises. In the 1st month, the patient attends physiotherapy once a week In the 2nd, 3rd and 4th month, the patient attends physiotherapy once every 14 days.~Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.~During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an on-demand regime or discontinue them altogether).~The use of PPIs will be accurately documented."
9722782|NCT05326113|Active Comparator|Control group|"Control group will undergo standard treatment of reflux with PPIs and will be regularly examined by an assigned physician.~Symptomatic patients will take PPIs based on the recommendation of the treating physician who will recommend a dose of PPIs. Used PPIs will be Emanera 1x40mg (standard dose), 2x40mg (higher dose) or 1x40mg on demand.~All patients with esophagitis LA A/B/C will be treated with IPP-Emanera 1x40mg for at least 6 weeks at the start of the study.~During the follow-up period, patients may, in agreement with the attending physician, reduce the dose of PPIs (from twice a day to once a day, from once a day to an on-demand regime or discontinue them altogether).~The use of PPIs will be accurately documented."
9722783|NCT05326100|Active Comparator|Conventional Therapy (CPT) Group|Each session will include vestibular exercises, customized to address the participant's symptoms of vestibular dysfunction and functional ability.
10197018|NCT05063981||No CRSwNP|10 patients with severe refractory eosinophilic asthma and no CRSwNP
10197019|NCT05061524|Experimental|YH35324|"Part A: A single dose of the YH35324 will be administered subcutaneously in 5 dose groups (0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses~Part B: A single dose of the YH35324 will be administered subcutaneously. The dose of YH35324 will be determined after the safety, tolerability, PK, and PD data in Part A are reviewed"
10197020|NCT05061524|Placebo Comparator|Placebo|"Part A: A single dose of the Placebo will be administered subcutaneously in 5 Cohorts(Dose groups=0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses~Part B: Placebo is not administered in Part B"
10197021|NCT05061524|Active Comparator|Xolair® for injection (Omalizumab)|"Part A: A single fixed dose of the Omalizumab 300mg will be administered subcutaneously in 4 Cohorts(Dose groups of YH35324=1, 3, 6, and 9 mg/kg)~Part B: A single dose of the Omalizumab 300mg will be administered subcutaneously."
9722784|NCT05326100|Active Comparator|CAREN Group|The CAREN group will undergo vestibular physical therapy that will include virtual environment (VE) applications on the CAREN.
9722785|NCT05326100|Experimental|Augmented Reality (AR) Group|The AR group will undergo vestibular physical therapy that will include VE applications on the AR HMD.
9722786|NCT05326087|Active Comparator|Antagonist group|Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
9722787|NCT05326087|Experimental|PPOS group|Women will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger.
9722788|NCT05326074|Experimental|Animal assisted therapy cohort|This arm will be the group that is randomized to receiving animal assisted therapy during outpatient office visits.
9722789|NCT05326074|No Intervention|Control therapy cohort|This arm will be the group that will receive the standard outpatient psychiatric treatment without animal therapy.
9722790|NCT05326035|Experimental|Experimental： WJ05129 tablets|Twice daily (except for single dose), 12 hours apart, fixed time is recommended
9722791|NCT05326022|Experimental|medical therapy group|formed of 20 patients to whom ordinary medical therapy as the pervious groups and placebo shame laser had been applied.
9722792|NCT05326022|Experimental|medical therapy and Microcurrent group|formed of 20 patients to whom the microcurrent therapy had been applied with ordinary medical therapy.
10197022|NCT05061251|Experimental|BAY 2402234|Patients will receive 1 dose (5mg) orally, per day of BAY 2402234 for the 2 days prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery, for a total of 3 administered doses.
10197023|NCT05060627|Experimental|Belantamab-Mafodotin + Carfilzomib+ dexametasona|"In the phase 1 of the study, aiming to establish the recommended phase 2 dose (RP2D), patients will be included following the classic 3 + 3 design.~Once the DLT assessment period is completed and the MTD is defined, the recruitment will continue in the expansion phase 2.~Combination treatment will be administered at the recommended Phase 2 dose (RP2D) based on the results of the phase 1 dose escalation part of the study:~Belantamab mafodotin on day 1 at the RP2D, every 8 weeks, intravenously (IV).~Carfilzomib will be given at the RP2D weekly IV on days: 1, 8, and 15 of every 4-week cycle (Q4W).~Dexamethasone will be given at the dose of 40 mg (or 20 mg if patient > 75 years old) on days: 1, 8, 15 and 22 Q4W.~From month 13 onwards carfilzomib treatment will be given on day 1 and 15 of every 4-weeks cycles. Belantamab will be given at the RP2D every 8 weeks and Dexamethasone 40mg on days 1, 8, and 15 of every 4-week cycle."
10197024|NCT05059938|Experimental|MyFitnessPal user|Patients will be shown how to download and use MyFitnessPal onto the patient's smartphone. The patient will be asked to use the application to aid in the patient's weight loss plan over up to six months.
10197025|NCT05059938|No Intervention|Traditional Weight Loss Counseling|Patients will be given traditional weight loss counseling from the physician and monitored over up to six months.
9722793|NCT05326022|Experimental|medical therapy and Low-Level Laser Therapy group|formed of 20 patients to whom the Low Level Laser Therapy had been applied with ordinary medical therapy.
9722794|NCT05325996|Experimental|Moderate Glaucoma|"Subjects between ages 20-80 years with a diagnosis of mild and moderate Open Angle Glaucoma in at least one eye with 20/50 vision or better will be included in this study. All subjects will have the Olleyes Perimeter measure their own visual acuity and field once a week during a 2 year period and iCare home to measure their eye pressure 3 times a day for 7 days every 3 months during a 2 year period.~All patient will have their routine glaucoma assessment with the standard 24-2 Automatic Perimetry Humphrey Field Analyzer at baseline and every 6 months during a 2 year period; and Spectralis Optical Coherence Tomography thickness of peripapillary RNFL and macular ganglion cell at baseline and yearly during a 2 year period."
9722795|NCT05325983|Experimental|lemonade ice cubes|10 ml lemonade ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
9722796|NCT05325983|Placebo Comparator|water ice cubes|10 ml water ice cubes in mouth, 45 seconds, 90 seconds, 135 seconds, 180 seconds respectively
9722797|NCT05325957||Norepinephrine variation|Patients with septic shock, cardiac output monitoring device with the PICCO2 system or swan ganz catheter and decision by the physician in charge to modify the norepinephrine dose.
9722798|NCT05325957||Fluid infusion|Patients with septic shock, cardiac output monitoring device with the PICCO2 system or swan ganz catheter and decision by the physician in charge to give fluid infusion
9722799|NCT05325944|Experimental|Self-guided digital intervention for NSSI|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface.
9722800|NCT05325944|Experimental|Digital intervention for NSSI with coaching|The self-guided digital intervention for NSSI will consist of 8 weekly modules containing psychoeducation and skill-based practice, and daily ecological momentary assessments. All content is delivered by a highly interactive conversational agent that guides users through the app content via a text-like interface. This arm will additionally receive lightweight coaching which consists of a one 20-30 minute engagement call at the beginning of treatment. Thereafter, coaches will check in with participants via medium of participants choice twice per week and respond to patient texts, calls, or emails.
9722801|NCT05325944|Active Comparator|Active control|The active control arm will receive 8 weekly modules with psychoeducational components only, without the interaction features or EMA for personalization.
9722802|NCT05325931|Experimental|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal Low Add Power (LA) and High Add Power (HA)
9722803|NCT05325931|Active Comparator|samfilcon A for Presbyopia|B+L ULTRA for Presbyopia Low Add Power (LA) and High Add Power (HA)
9722804|NCT05325905||Healthy|bleeding on probing (BoP) ≤ 10% of the sites, probing depth (PD) ≤ 3 mm and no indication of clinical attachment level (CAL) or radiographic bone loss
9722805|NCT05325905||Gingivitis|gingival inflammation (BoP ≥ 10% of the sites, red-blue discoloration of the gingiva and edema) PD ≤ 4 mm and no clinical attachment or radiographic bone loss
9722806|NCT05325905||Periodontitis|PD ≤ 5 mm, radiographic bone loss, and 3-4 mm CAL in at least 30% of the sites
9722807|NCT05325892||IDH|Diabetic patients with maintenance hemodialysis who developed hypotension during hemodialysis therapy.Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by ≥10 mm Hg associated with symptoms that include: abdominal discomfort; yawning; sighing; nausea; vomiting; muscle cramps; restlessness; dizziness or fainting; and anxiety.
9722808|NCT05325892||non-IDH|Diabetic patients with maintenance hemodialysis who did not develop hypotension during hemodialysis treatment.Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by ≥10 mm Hg associated with symptoms that include: abdominal discomfort; yawning; sighing; nausea; vomiting; muscle cramps; restlessness; dizziness or fainting; and anxiety.
9722809|NCT05325879||Asymptomatic Individuals|Individuals aged between 18-50 who volunteered to participate in the study, will form the control group.
9722810|NCT05325879||Individuals with neck pain|Individuals with neck pain aged between 18-50 who volunteered to participate in the study, will form the study group.
9722811|NCT05325866|Experimental|Part 1: Monotherapy Dose Exploration|Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive 1 of 2 dose regimens of bemarituzumab to determine recommended Phase 2 dose.
9722812|NCT05325866|Experimental|Part 2: Monotherapy Dose Expansion|Participants across multiple primary epithelial solid tumors with centrally determined FGFR2b overexpression and relapsed/refractory unresectable and/or metastatic disease will receive the dose of bemarituzumab identified as the recommended Phase 2 dose during Part 1.
9722813|NCT05325827|Experimental|Group A: H-FICB under ultrasound guidance before general anesthesia|Group A was subjected to a high fascia iliaca compartment block under ultrasound guidance before general anesthesia.
9722814|NCT05325827|No Intervention|Group B: FBC combined with SBC under ultrasound guidance before general anesthesia|Group B was subjected to a femoral nerve block combined with a sciatic nerve block under ultrasound guidance before general anesthesia.
9722815|NCT05325801|Experimental|BMCA and GPRC5D dual target CAR-T cells （OriC321）|
9722816|NCT05325788|Other|Single daily message followed by location-based messaging|Participants in this condition receive a single daily message through the intervention app for two weeks (14 days) followed by location-based messaging for two weeks (14 days).
9722817|NCT05325788|Other|Location-based messaging followed by single daily message|Participants in this condition receive location-based messaging through the intervention app for two weeks (14 days) followed by a single daily message for two weeks (14 days) .
9722818|NCT05325762|Experimental|Propofol|
9722819|NCT05325762|Active Comparator|Dexmedetomidine|
9722820|NCT05325762|Placebo Comparator|saline|
9722821|NCT05325749||unaffected|newborns without developmental features having no variations according to an inherited diseases screening;
9722822|NCT05325749||affected|newborns showing either phenotypic features or deviations according to MS screening
9722823|NCT05325749||refused families|parents refused to enroll their newborns to the study
9722824|NCT05325749||unaffected born prematurely|newborns without specific developmental features having no variations according to an inherited diseases screening, born before term
9722825|NCT05325749||unaffected wirh family history|newborns without developmental features having no variations according to an inherited diseases screening but with affected relative(s)
9722826|NCT05325749||unaffected wirh prenatal phenotype|newborns without developmental features at birth and on, having no variations according to an inherited diseases screening which had been observed to show signs of developmental features during prenatal ultrasound examination
9722827|NCT05325736||sleeve gastrectomy surgery|participants undergoing sleeve gastrectomy surgery for weight reduction
9980818|NCT01395511|No Intervention|Waiting list group|"No Intervention Comparator~The waiting-list group did not receive acupuncture treatment and participants were permitted to receive usual care including physical therapy and exercise and were not permitted to take analgesics and antiphlogistics during the periods."
9980819|NCT01395563|Experimental|1|pancreatic cancer patients
9722828|NCT05325736||gastric bypass surgery|participants undergoing gastric bypass surgery for weight reduction
10197026|NCT05059886||lower limb amputee|No intervention, pure observational study
10197027|NCT05058222|Active Comparator|Deep breathing ex (10 reps) Group|The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
9722829|NCT05325736||cholecystectomy|participants undergoing cholecystectomy
9722830|NCT05325723||Intervention group|"30 second audio phonocardiogram (PCG) recordings at each of the five standard cardiac auscultatory positions using an Apple iPhone®.~the assessment of VHD by echocardiogram, as reported by the echocardiography laboratory."
9722831|NCT05325710|Active Comparator|TD2 standard|Standard TD2 follow-up
9722832|NCT05325710|Experimental|TD2+ study Nurse|Specific study nurse follow-up every 4 months in addition of standard FU.
9722833|NCT05325697|Experimental|Single - Arm|12 weeks intervention with a combined physical exercise program (vivifrail) and oral nutritional supplementation (Moltein Plus)
9722834|NCT05325684|Experimental|PD-L1 rechallenge|
9722835|NCT05325671|Experimental|transarticular multimodal drug infiltration|infiltration the mixture into intraarticular by catheter guided approach
9980820|NCT01395563|Experimental|2|pancreatic cancer patients
9980821|NCT01395589|Active Comparator|Injectable + oral vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
9980822|NCT01395589|Active Comparator|Oral-only Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
10197028|NCT05058222|Experimental|Deep breathing ex (30 reps) Group|The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
10197029|NCT05057936||Control|Healthy healthcare workers
10197030|NCT05057936||Chronic kidney disease (CKD)|CKD stage 3-5 (eGFR < 60 mL/min/1.73m3)
10197031|NCT05057936||Dialysis patients|CKD stage 5 requiring HD
10197032|NCT05057936||kidney transplant patients|patients receiving kidney transplantation for more than 3 months
10197033|NCT05057936||dialysis patients|CKD patients requring continuos ambulatory peritoneal dialysis
10197034|NCT05051982|Experimental|Study Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the study group, the monitor will be in full view of the anesthesiologist administering the anesthetic.
9722836|NCT05325671|Active Comparator|periarticular multimodal drug infiltration|"3 location of infiltration~hip capsule~gluteus medius and short external rotator~gluteus maximus"
9722837|NCT05325658||Oropharyngeal dysphagia|Patients with oropharyngeal dysphagia. Patients will be examined before and after combination therapy.
9722838|NCT05325645|Experimental|Brexpiprazole QW 48mg|Brexpiprazole QW 48mg, tablet, once weekly, for seven weeks(Initial dose Brexpiprazole QW 24mg)
9722839|NCT05325645|Placebo Comparator|Placebo|
9722840|NCT05325632|Experimental|Lead In - Dose level 1|Six participants will be treated at dose level 1: DC vaccine given at the dose of 50 million once per week for 6 weeks
9722841|NCT05325632|Experimental|Lead In: Dose Level 2|Six participants will be treated at dose level 2: DC vaccine given at the dose of 100 million once per week for 6 weeks
9722842|NCT05325632|Experimental|Expansion|An additional 22 participants will be enrolled at dose level 2 if determined to be safe in lead in phase to have a total of 28 evaluable participants for pathologic response assessment (including 6 pts from the lead in phase).
9980823|NCT01395602|Placebo Comparator|placebo|placebo pill
9980824|NCT01395602|Active Comparator|cabergoline|cabergoline pill
9980825|NCT01395615||Cohort|
9980826|NCT01395641|Experimental|Gene therapy|Intracerebral infusion of AAV2-hAADC viral vector will be performed
9722843|NCT05325593|Experimental|Romiplostim plus dexamethasone (ROM + DEX)|Dexamethasone 40 mg daily x 4 days only in the first cycle and subcutaneous romiplostim weekly for up to 12 months
9722844|NCT05325593|Active Comparator|Dexamethasone (DEX)|Dexamethasone 40 mg daily x 4 days for up to 3 cycles every 14 to 28 days
9722845|NCT05325580|Placebo Comparator|Placebo Group|1g paracetamol + 20 min infusion of saline serum
9722846|NCT05325580|Experimental|magnesium group|1g paracetamol + 20 min infusion of 2g magnesium
9722847|NCT05325567|Active Comparator|1 incision technique|a mini-open incision that allows adequate exposure of the transverse carpal ligament (TCL), while staying distal to the distal wrist crease.
9722848|NCT05325567|Active Comparator|Two incision technique|A two-incision open carpal tunnel release techniques to ensure complete release both proximally and distally
9722849|NCT05325554|Experimental|Research Group|multi-mode rehabilitation
9980827|NCT01395654|Experimental|Standard rechallenge, Slow rechallenge|
10197035|NCT05051982|No Intervention|Control Group|Prior to the induction of anesthesia, the Sedline monitor will be placed on the patient's head to ensure the monitor is working properly. For those in the control group, an apparatus will be placed over the monitor will not be in view of the anesthesiologist. The
9722850|NCT05325554|No Intervention|control group|control group
10197036|NCT05050279|Placebo Comparator|Placebo|Delgocitinib placebo capsule
10197037|NCT05050279|Experimental|Active dose 1|Delgocitinib capsule (Dose 1)
10197038|NCT05050279|Experimental|Active dose 2|Delgocitinib capsule (Dose 2)
9722851|NCT05325541|Experimental|Arms 1|Game-Based Rehabilitation received total 24 sessions, 45-50 minutes/session, 3 times/week for total 8 weeks.
9722852|NCT05325541|Placebo Comparator|Arms 2|Conventional Rehabilitation received total 24 sessions, 45-50 minutes/session, 3 times/week for total 8 weeks.
9722853|NCT05325528|Experimental|study group|patients in this arm will be treated with Tislelizumab in Combination with Oxaliplatin and Tegafur
9722854|NCT05325515|Active Comparator|Fosamax (conventional alendronate)|Conventional alendronate 70mg weekly for 16 weeks
9722855|NCT05325515|Experimental|Binosto (effervescent and buffered alendronate)|Effervescent and buffered alendronate70mg weekly for 16 weeks
9722856|NCT05325502|Placebo Comparator|Placebo|7 days placebo intake.
9722857|NCT05325502|Active Comparator|Acute caffeine|6 days placebo followed by 1 day caffeine intake.
9722858|NCT05325502|Experimental|Daily caffeine|7 days caffeine intake
9722859|NCT05325476|Experimental|JomPrEP App Group|Participants in the TAU group will receive the JomPrEP app with major intervention features inactivated; information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The Research Assistant will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
9722860|NCT05325476|Active Comparator|Treatment as usual|Participants in the JomPrEP group will be provided with full app access. The Research Assistant will use an onboarding checklist to orient participants to download the app and its use. Participants will be encouraged to explore and use all components of the app. Participants will be able to personalize the frequency, timing, and content for daily adherence support and weekly behavioral feedback messages and receive reminders for regular PrEP care. Participants can also contact the Research Assistant using the chat function for support and assistance with linkage to services.
9722861|NCT05325463|Experimental|conventional|
9722862|NCT05325463|Active Comparator|ultrasound- guided|
9722863|NCT05325450|Experimental|Training A|Training A in Unilaterally postlingually-deafened adult cochlear implanted candidates
9722864|NCT05325450|Experimental|Training B|Training B in Unilaterally postlingually-deafened adult cochlear implanted candidates
9722865|NCT05325450|Active Comparator|Control|Training in bilaterally postlingually-deafened adult cochlear implanted candidates
9722866|NCT05325437|Experimental|Experimental Group|Laparoscopic splenectomy and azygoportal disconnection
9722867|NCT05325424|Other|Experimental Group|Laparoscopic splenectomy
9722868|NCT05325398|Active Comparator|patients with NAFLD|17 patients will receive molecular hydrogen
9722869|NCT05325398|Placebo Comparator|probands in the control group|13 probands in the control group who will receive placebo.
9980828|NCT01395667|Experimental|Bevacizumab + CCRT followed by surgery|Bevacizumab 5 mg/kg every 2 weeks + radiotherapy 45~55 Gy/25 fractions, followed by total mesorectal excision
9722871|NCT05325359||Multiple sclerosis|. Inclusion criteria for volunteers; Individuals with relapsing-remitting type MS, who are between 18-65, EDSS scores between 1 ≤ and ≤ 5.5, individuals who score 24 and above in Mini Mental State Examination and who can walk a minimum of 20 m independently will be included. In addition, exclusion criteria for volunteers; Severe spasticity of the lower extremities (Ashworth score 3 or 4), having an acute MS attack or a history of an attack in the last 1 month, having an orthopedic or systemic problem that would prevent participation in the tests, having another neuromuscular disorder other than MS, visual involvement or diplopia, and is that he has a cardio-pulmonary problem that will prevent him from participating in the tests.
9722872|NCT05325346|Experimental|VLX-1005|Intravenous administration of VLX-1005 with measurements of PK and PD
9722873|NCT05325346|Active Comparator|Argatroban|Intravenous administration of argatroban with measurements of PK and PD
9722874|NCT05325346|Other|VLX-1005 and Argatroban|Intravenous co-administration of VLX-1005 and argatroban with measurements of PK and PD
9722875|NCT05325333|Experimental|Retrieval practice during word learning: expanding schedule|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) . Four nouns will be learned in an expanding spaced retrieval practice condition; four will be learned in a standard spaced retrieval practice condition. In the standard spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase from 0 to 3 words. In the expanding spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase gradually from 0 to 1 to 3 words."
9722876|NCT05325320|Experimental|Stigma Reduction Intervention|Participants randomized to the experimental condition will receive the SMI/SIA Stigma Reduction Intervention.
9722877|NCT05325320|Other|Disaster Preparedness Course|Participants randomized to the control condition will receive a Disaster Preparedness Course, addressing the basics of natural disaster preparedness.
9722878|NCT05325307|Experimental|Acupressure Group (experimental)|The experimental group will be given acupressure.
9722879|NCT05325307|Placebo Comparator|Placebo Acupressure Group (control)|The placebo group will be given placebo acupressure
9722880|NCT05325294|Experimental|MiniMed 780G System Utilizing Insulin Lyumjev®|Subjects with insulin-requiring type 1 diabetes age 2-80 using the MiniMed 780G system with Insulin Lyumjev® for a period of three months.
9980829|NCT01395680||cancer adolescent|
10197039|NCT05050279|Experimental|Active dose 3|Delgocitinib capsule (Dose 3)
10197040|NCT05050279|Experimental|Active dose 4|Delgocitinib capsule (Dose 4)
10197041|NCT05038332|Active Comparator|Moderately Hypo-fractionated Radiation Therapy|20 fractions of moderately hypofractionated radiation therapy over no more than 5-6 weeks.
10197042|NCT05038332|Experimental|Ultra-Hypofractionated Radiation Therapy|5 fractions of ultra-hypofractionated radiation therapy with at least one day between each treatment over the course of no more than 3-4 weeks
9722881|NCT05325281|Experimental|CPI-613® (Dose level -1.0 250 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
9722882|NCT05325281|Experimental|CPI-613® (Dose level 1.0 500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
9722883|NCT05325281|Experimental|CPI-613® (Dose level 2.0 1,000 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
9722884|NCT05325281|Experimental|CPI-613® (Dose level 3.0 1,500 mg/m^2)|Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
9722885|NCT05325281|Experimental|CPI-613® Maximum Tolerated Dose (MTD)|MTD of CPI-613® from initiation of treatment to 30 days after treatment. MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m^2 and up to 1,500 mg/m^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
9722886|NCT05325268||Monteggia Cohort|Including all Patients. Patients who had suffered a Monteggia fracture and were treated with osteosynthesis
9980830|NCT01395693|Experimental|Salt Lake mask system|
9980831|NCT01395706|Experimental|ICG flourescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial. A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
9722889|NCT05325242|Experimental|Elbow Artery Embolization (EAE)|Patients will undergo EAE with Embozene microspheres (75 micron). The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the patient's pain.
9980832|NCT01395719|No Intervention|Non remote ischemic conditionin(non-rIC)|Patients receiving kidney transplantation from a deceased donor. This group does not receive remote ischemic conditioning, but has a tourniquet on the leg (not inflated).
10205437|NCT00070564|Experimental|Arm V|Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
9722890|NCT05325229|Experimental|Docetaxel combined with Bevacizumab|Docetaxel for Injection (Albumin-bound) will be administrated once every 3 weeks at a dose of 75 mg/m^2 or 100 mg/m^2; Bevacizumab will be administrated once every 3 weeks at a dose of 15mg/kg.
9722891|NCT05325216|Experimental|POPRC group|pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
9722892|NCT05325216|Active Comparator|SRC group|standard radical cystectomy with orthotopic ileal neobladder
9722893|NCT05325203|Experimental|JS002 150mg Q2W for 24 weeks|40 patients will be enrolled in this arm
9722894|NCT05325203|Placebo Comparator|placebo 150mg Q2W for 24 weeks|20 patients will be enrolled in this arm
9722895|NCT05325203|Experimental|JS002 450mg Q4W for 24 weeks|40 patients will be enrolled in this arm
9722896|NCT05325203|Placebo Comparator|placebo 450mg Q4W for 24 weeks|20 patients will be enrolled in this arm
9722897|NCT05325190|Experimental|Intervention group|Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
9722898|NCT05325177|Active Comparator|Group 1 infants|(n=15) will receive three doses of standard-dose Ibuprofen Motrin® (10-5-5 mg/kg), 1 dose every 24 hours after enrollment (Day 1), for a total of 3 doses.
9722899|NCT05325177|Sham Comparator|Group 2 infants|(n = 15) will receive three doses of high-dose Ibuprofen Motrin® (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses.
9722900|NCT05325151|Experimental|Arm I (GCPP intervention)|Patients receive GCPP intervention consisting of a series of educational videos on pre-genetic test information.
9980833|NCT01395719|Experimental|Remote ischemic conditioning (rIC)|Patients receiving kidney transplantation from a deceased donor. This group receives remote ischemic conditioning by inflating a tourniquet on the leg during surgery, before reperfusion of the kidney.
9980834|NCT01395732|Experimental|1|
9980835|NCT01395745|Experimental|blisibimod weekly dose|
9980836|NCT01395745|Placebo Comparator|Placebo|
9980837|NCT01395771|Experimental|Phone call|New cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
9980838|NCT01395836||Treatment|"The treatment group will be medically managed based on data obtained from monthly transmissions of the implanted Cardiac Monitor."
9980839|NCT01395836||Control Group|"The control group will be managed in the usual standard of care with physicians blinded to their ICM data."
10197043|NCT05034341|Experimental|Multimodal Prehabilitation Arm|"The Multimodal Prehabilitation group will receive:~An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to a home exercise program. Patients' compliance will be monitored by phone each week.~Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar-free.~Pain and Neuroscience Education: Per University of Florida Health Pain and Neuroscience program at Shands hospital.~Standard Clinical Care: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with a focus on preoperative cognitive assessment."
10197044|NCT05034341|Active Comparator|Standard Clinical Care Comparison Arm|"The Standard Clinical Care Comparison group will receive:~Education related to preoperative activity and home based exercise program.~Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment.~A final preoperative visit before surgery where a second set of functional assessment will be implemented"
10197045|NCT05031494|Experimental|YH003 with Toripalimab in subjects with unresectable /metastatic melanoma|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment;
9722901|NCT05325151|Active Comparator|Arm II (conventional genetic counseling)|Patients receive conventional genetic counseling.
9722902|NCT05325138||Parents|Parents of girls aged 9-14 years old
9722903|NCT05325125||Children who have completed treatment for Tuberculosis|Children < 18 years, who had drug sensitive pulmonary tuberculosis, either bacteriologically confirmed or not and who have completed treatment within the preceding 1 month before enrolment
9722904|NCT05325112||FFRCT Group|Sites who have CCTA and FFRCT analysis incorporated into their standard evaluation of chest pain in the ED/observation unit.
9722905|NCT05325112||Control Group|Sites who have CCTA but not FFRCT incorporated into the ED/observation unit.
9722906|NCT05325086|Experimental|Adapted information arm|"In parallel with an inpatient PR program, 4 visits will be carried out: V0 : Inclusion / V1 : Randomization / V2 : Follow-up / V3: End-stay.~At V1:~Adapted information to the characteristics of a greater openness to experiences will be delivered to patient.~The following questionnaires will be filled : Big Five Inventory BFI-FR, St. George's Respiratory SGRQ, Dyspnea-12, Self-efficacy for managing chronic disease SEMCD-6, Brief Illness Perception B-IPQ, COPD Anxiety Revised CAF-R, Patient Health PHQ-9, Montreal Cognitive Assessment Mini-MoCA~At V2:~*Semi-structured individual interviews will be performed. Questions will relate to the information distributed during V1 (adapted information), allowing to assess the understanding and the appropriation of it.~At V3:~The following questionnaires will be filled: SGRQ,Dyspnea-12,SEMCD-6,B-IPQ,CAF-R~In addition, some questions will be asked to verify the adherence to information and the potential contamination bias"
9722907|NCT05325086|Sham Comparator|Neutral information arm|"In parallel with an inpatient PR program, 4 visits will be carried out: V0 : Inclusion / V1 : Randomization / V2 : Follow-up / V3: End-stay.~At V1:~Neutral information will be delivered to patient.~The following questionnaires will be filled : Big Five Inventory BFI-FR, St. George's Respiratory SGRQ, Dyspnea-12, Self-efficacy for managing chronic disease SEMCD-6, Brief Illness Perception B-IPQ, COPD Anxiety Revised CAF-R, Patient Health PHQ-9, Montreal Cognitive Assessment Mini-MoCA~At V2:~*Semi-structured individual interviews will be performed. Questions will relate to the information distributed during V1 (neutral information), allowing to assess the understanding and the appropriation of it.~At V3:~The following questionnaires will be filled: SGRQ,Dyspnea-12,SEMCD-6,B-IPQ,CAF-R~In addition, some questions will be asked to verify the adherence to information and the potential contamination bias"
9722908|NCT05325073|Other|EPO Arm|
9722909|NCT05325021||Axial myopia|children have anisometropia due to axial myopia, axial length will be measured by optical biometry device in millimeter (mm).
9722910|NCT05325021||Refractive myopia|children have anisometropia due to refractive myopia, axial length will be measured by optical biometry device in mm.
9722911|NCT05325021||Axial hyperopia|children have anisometropia due to axial hyperopia, axial length will be measured by optical biometry device in mm.
10197046|NCT05031494|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment;
10197047|NCT05031494|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment;
10197048|NCT05030363|Experimental|Upfront ALDH enzyme supplement|Upfront ALDH enzyme supplement; After randomization, patients will receive ALDH enzyme supplement twice a day for consecutive 14 days during chemotherapy (period 1; day 1 to day 14) until unacceptable toxicity, or consent withdrawal. Patients will visit clinic on day 15, then will be followed on day 29 without ALDH enzyme administration during subsequent chemotherapy (period 2).
9722912|NCT05325021||Refractive hyperopia|children have anisometropia due to refractive hyperopia, axial length will be measured by optical biometry device in mm.
9722913|NCT05325008|No Intervention|Control|Immunosuppression reduction/modification
9722914|NCT05325008|Experimental|Interventional|Immunosuppression reduction/modification + Intravenous Immunoglobulin infusion
9722915|NCT05324982|Placebo Comparator|Placebo|Single acute administration of oral Placebo liquid (MCT oil).
9722916|NCT05324982|Experimental|Oral administration of 25mg CBG|Single acute administration of 25mg CBG suspended in MCT oil.
9722917|NCT05324982|Experimental|Oral administration of 50mg CBG|Single acute administration of 50mg CBG suspended in MCT oil.
9722918|NCT05324982|Experimental|Oral administration of 100mg CBG|Single acute administration of 100mg CBG suspended in MCT oil.
9722919|NCT05324982|Experimental|Oral administration of 200mg CBG|Single acute administration of 200mg CBG suspended in MCT oil.
9780572|NCT01126099|Experimental|Prazosin|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
10197049|NCT05030363|Other|Delayed ALDH enzyme supplement|Delayed ALDH enzyme supplement; patients will not take ALDH enzyme supplement during chemotherapy after randomization on day 1 to day 14 (period 1). On day 15, Patients will visit for subsequent chemotherapy and start ALDH enzyme supplement twice a day for 14 consecutive days during chemotherapy (period 2; day 15 to day 29).
10197050|NCT05029284|Experimental|teleABLE|Participants will complete 12 teleABLE sessions via videoconferencing, guided by an intervention therapist and participant workbook.
10197051|NCT05027789|Active Comparator|Self-Guided Group|Subjects in this group will be provided education on memory support strategies and healthy lifestyles. Participants will decide how they want to implement this information into their daily lives. The study will also provide information on various commercially available digital and other tools that might help participants implement healthy changes their lives. One in every three participants will be enrolled in this group (selected randomly).
10197052|NCT05027789|Active Comparator|Structured Group|Subjects in this group will will be provided with specific recommended behavior targets (e.g., like how much exercise you should engage in each week). Participants will also receive an iPad to use throughout the study and follow up period with the digital application installed. Subjects will be asked to use the digital application to record their activity and to receive reminders to complete this information. Two in every three participants will receive the iPad and digital application. Participants in this group will receive training on how to use the digital application. The researchers can install the digital application on the subjects' personal iPad or smartphone if they prefer.
10197053|NCT05027633|Other|pembrolizumab, docetaxel, and cisplatin or carboplatin|IV
9722920|NCT05324969|Experimental|MM-based MI group|Intervention group parents will receive 9 intervention sessions every other week by trained staff via 9 online sessions via Zoom or phone calls. Each intervention session will last 30-40 minutes. Intervention group parents will receive 3 text messages per week. No in-person contacts will be conducted without MSU department permission. All assessments will be delivered remotely with guided phone calls or zoom conference. The assessment of dyads' BMI, %BF, and WC will be obtained remotely from the parents using the scale and measuring tape delivered to their home.
9722921|NCT05324969|Other|Control group|Control group parents will receive a total of 9 emailed packets of educational materials (without information related to the mindfulness-based motivational interviewing [MM-based-MI]). The pre and post assessments will be collected the same way as the participants at intervention group.
9780573|NCT01126099|Placebo Comparator|Placebo|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
9780574|NCT01126268|Experimental|Retapamulin ointment 1%|
9780575|NCT01126359|Placebo Comparator|Lidocaine then Placebo-Saline|
9780576|NCT01126359|Active Comparator|Placebo-Saline then Lidocaine|
9780577|NCT01126424|Experimental|Solifenacin|Participants received 21 days of treatment with 5 mg solifenacin, in tablet form once a day.
9780578|NCT01126424|Active Comparator|Oxybutynin|Participants received 21 days of treatment with 10 mg oxybutynin (1 x 5 mg twice daily) in capsule form.
9780579|NCT01126424|Placebo Comparator|Placebo|Participants received 21 days of treatment with placebo.
9780580|NCT01126437|Experimental|tiotropium 2.5 mcg and placebo|Patients receive one of the active tiotropium arms daily
9780581|NCT01126437|Active Comparator|tiotropium 18 mcg and placebo|Patients receive one of the active tiotropium arms daily
9980840|NCT01395849||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol during study period
9780582|NCT01126437|Experimental|tiotropium 5 mcg and placebo|Patients receive one of the active tiotropium arms daily
9780583|NCT01126541|Experimental|A|1000 mg IV rituximab
9780584|NCT01126541|Experimental|B|2 x 1000 mg IV rituximab
9780585|NCT01126580|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
9780586|NCT01126580|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
9780587|NCT01126580|Active Comparator|Metformin|"Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52~Placebo: subcutaneously (SC), once weekly for 52 weeks"
9780588|NCT01126593|Placebo Comparator|Placebo group|The placebo group will receive the same subacromial infusion catheter as the study group.However, the reservoir will be filled with 200cc of 0.9% normal saline.
9780589|NCT01126593|No Intervention|Control group|The control group patients will receive no continuous infusion catheter.
9780590|NCT01126593|Experimental|Study Group|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The infusion rate will be 4cc per hour.
9780591|NCT01126619||Anti-TNF|Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor (anti-TNF) agent prior to enrollment according to national approved indications and reimbursement guidelines.
9780592|NCT01126671|Active Comparator|Low Dose Vitamin D|Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
9780593|NCT01126671|Active Comparator|High Dose Vitamin D|Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
9780594|NCT01126723|Experimental|Tai Chi group|
9780595|NCT01126723|Active Comparator|Educational Control group|
9785252|NCT01246986|Experimental|Part C Cohort 1 - 160 mg LY2157299 + 800 mg Sorafenib|"80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
9980841|NCT01395862||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period
10197054|NCT05026463|Experimental|Inspiratory support level with PMI equal to -2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
10197055|NCT05026463|Experimental|Inspiratory support level with PMI equal to 0|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
9722922|NCT05324956||Postmenopausal Women|Postmenopausal women be between 40-79 years and being diagnosed with osteoporosis or osteopenia
9722923|NCT05324943|Experimental|FLT201|FLT201 is an advanced therapy investigational medicinal product (ATIMP) administered as a single intravenous infusion.
9722924|NCT05324930|Placebo Comparator|Control group|After conventional therapy consisting of debridement, infection control and offloading, patients received a saline-moistened gauze dressing (control group) for wound care.
9722925|NCT05324930|Experimental|Experimental group|After conventional therapy consisting of debridement, infection control and offloading, patients received the piscean collagen dressing (the study group) for wound care.
9722926|NCT05324917||lymphoma patients|Patients with Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and other mature B-lymphoma patients. Patients were randomly divided into two groups for PK blood collection. There were 12 blood sampling sites in each group.
9722927|NCT05324917||Patients with B lymphoproliferative diseases|Patients with hematopoietic stem cell transplantation and Epstein-Barr virus associated b-cell lymphoproliferative diseases, b-cell lymphoproliferative changes, immune thrombocytopenia, and autoimmune hemolytic anemia. Patients were randomly divided into two groups for pharmacokinetics blood collection. There were 12 blood sampling sites in each group.
9722928|NCT05324904|Active Comparator|group 1|this group will be intralesionaly injected with vitamin D3
9722929|NCT05324904|Active Comparator|group 2|this group will be intralesionally injected with acyclovir
9722930|NCT05324891|Active Comparator|Fentanyl|Neonates received fentanyl infusion during postoperative phase.
9722931|NCT05324891|Active Comparator|Dexmedetomidine|Neonates received dexmedetomidine infusion during postoperative phase.
9722932|NCT05323058|Experimental|tulsi extract|4% tulsi extract as intervention
9722933|NCT05323058|Active Comparator|benzydamine hydrochloride|0.15% benzydamine hydrochloride
9722934|NCT05322642|Experimental|Experimental: (UP-A)|The UP-A (Ehrenreich et al., 2008) is an emotion-focused, transdiagnostic CBT for adolescents A 10-session youth-focused programmed by adapting the core modules of UP-A, for indicated prevention and school settings.
9722935|NCT05322642|Active Comparator|Active control condition|"The active control condition will be based on the 10 session of Progressive Relaxation Training programme of Bernstein and Borkovec.~It follows a similar structure as the UP-A. A group format will be used."
9722936|NCT05321056|Experimental|Intervention group: Mask on model face|"The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
9722937|NCT05321056|No Intervention|Control group: No mask on model face|"No mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
9722938|NCT05319509|Experimental|gameChange|
9722939|NCT05319145|Active Comparator|Control group|Treatment as usual. Mainly based on standard physical rehabilitation.
9722940|NCT05319145|Experimental|Intervention group|Based on the results of the CGA, a tailored multidisciplinary intervention will be proposed, focused on a multicomponent physical exercise program with nutritional recommendations.
9722941|NCT05318417|Other|Children and adults with unilateral hearing loss/single-sided deafness|
9722942|NCT05317403|Other|AML without Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC > 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
9722943|NCT05317403|Other|AML with Down Syndrome|The subject receives 2 courses of therapy approximately 35 days each. Venetoclax: Days 1-14 Azacitidine and Vorinostat: Days 1-5 Filgrastim Days: 5 start and continue until post-nadir ANC > 500 cells/mm3 Fludarabine and Cytarabine Days 6 - 10 IT Cytarabine Day 0 or 1, optional between day 35 and 42
9722944|NCT05311618|Experimental|NGM438 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
9722945|NCT05311618|Experimental|NGM438 Combination Dose Finding with Pembrolizumab|Part 1b NGM438 plus pembrolizumab
9722946|NCT05311618|Experimental|Biopsy Cohort with NGM438 Monotherapy Lead-in Followed by Combination Therapy with Pembrolizumab|Part 1C NGM438 followed by NGM438 plus pembrolizumab
9722947|NCT05311579|Experimental|Ovarian cancer patients with increased CA125|Patients with CA125 >35 U/ml or increased to 2 x nadir, and with no evidence of imaging recurrence after completion of 1st-line platinum-based chemotherapy
9722948|NCT05311566|Experimental|Patients with primary IB2-IIIB cervical cancer|Patients with primary IB2-IIIB cervical cancer, including squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma.
9722949|NCT05311150|Active Comparator|Narrow band imaging bronchoscopy|The narrow band imaging mode uses two narrow bands of light with wavelengths of 390-445 nm and 530-550 nm.
9722950|NCT05311150|Active Comparator|White light bronchoscopy|The white light bronchoscopy mode uses the entire range of white light wavelengths, 400-700 nm.
9722951|NCT05311072||PEA cohort|patients with CTEPH receiving PEA
9722952|NCT05311072||BPA cohort|patients with CTEPH receiving BPA
9722953|NCT05311072||Non-interventional cohort|CTEPH patients without PEA or BPA
10197056|NCT05026463|Experimental|Inspiratory support level with PMI equal to +2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
10197057|NCT05023811|Experimental|[14C]RIST4721|[14C]RIST4721 oral solution
10197058|NCT05023005|Experimental|Piriformis Strain-Counterstrain|The treatment group will receive strain-counterstrain for the piriformis muscle.
10197059|NCT05023005|Sham Comparator|Hamstring Strain-Counterstrain|The sham group will receive strain-counterstrain treatment for the hamstring muscle.
10197060|NCT05022667|Experimental|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the total thyroidectomy procedure.
10197061|NCT05022667|No Intervention|Standard of Care|The surgeon will not use the PTeye and will proceed with the total thyroidectomy as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
10197062|NCT05022641|Experimental|PTeye|The surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
10197063|NCT05022641|No Intervention|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
10197064|NCT05016843|Experimental|CBT, 8 weeks and access to forum.|
9722954|NCT05310487|Experimental|162|The dose-escalation stage will be conducted sequentially at 5 dose levels, which are 100 mg in the pre-test, and 200 mg, 400 mg, 800 mg and 1200 mg in the formal test. Two healthy adult subjects will be enrolled at 100 mg dose level and all given 162. At the start of each level with the exception of 100 mg level which there are only two subjects, two sentinel subjects will be randomized 1:1 to 162 or placebo. The remaining subjects will be randomized 5:1 to receive a single ascending dose of 162 or placebo.
9722955|NCT05310487|Placebo Comparator|placebo|At the start of each level with the exception of 100 mg level which there are only two subjects, two sentinel subjects will be randomized 1:1 to 162 or placebo. The remaining subjects will be randomized 5:1 to receive a single ascending dose of 162 or placebo.
9722956|NCT05309369|Experimental|Preferred Music - Visit 1, Nature Sounds - Visit 2|
9722957|NCT05309369|Placebo Comparator|Nature Sounds - Visit 1, Preferred Music - Visit 2|
9722958|NCT05308498||ESView software with ProScan|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
9722959|NCT05308498||Rapid software with SBI|evaluate the performance of the NaviCam SB Capsule System ProScan software feature in comparison with the PillCam SB3 Capsule system SBI feature
9722960|NCT05307081||1|
9722961|NCT05306873|Experimental|MMF|Participants will receive 500 mg mycophenolate mofetil (MMF) bid for 7 days, followed by 500mg and 1,000mg MMF in divided doses for 7 days. They will then continue at a stable dose of 1,000mg MMF bid. Visits to evaluate AEs, vital signs, hematology and chemistry, study medication compliance, medication use, disease status, participant reported outcomes, and to obtain biomarker samples will occur every 4 weeks after randomization
9722962|NCT05306873|Placebo Comparator|Placebo for MMF|Participants will receive 500 mg corresponding mycophenolate mofetil (MMF) placebo bid for 7 days, followed by 500mg and 1,000mg corresponding MMF placebo in divided doses for 7 days. They will then continue at a stable dose of 1,000mg corresponding MMF placebo bid. Visits to evaluate AEs, vital signs, hematology and chemistry, study medication compliance, medication use, disease status, participant reported outcomes, and to obtain biomarker samples will occur every 4 weeks after randomization
9722963|NCT05306873|Experimental|MMF+ Placebo for Voclosporin|Participants randomized in this arm will receive up to 24 weeks of mycophenolate mofetil (MMF) plus placebo for voclosporin, also during the first 2 weeks of treatment, a single intramuscular injection of 80 mg methylprednisolone acetate may be administered if needed to achieve amelioration of symptoms without meeting the definition of treatment failure in Stage 3 and without a requirement to stop Stage 3 study-provided medication
9722964|NCT05306873|Experimental|MMF+ Voclosporin|Participants randomized in this arm will receive up to 24 weeks of mycophenolate mofetil (MMF) plus voclosporin, also during the first 2 weeks of treatment, a single intramuscular injection of 80 mg methylprednisolone acetate may be administered if needed to achieve amelioration of symptoms without meeting the definition of treatment failure in Stage 3 and without a requirement to stop Stage 3 study-provided medication
9722965|NCT05306782|Experimental|Transcranial Random Noise Stimulation|Transcranial Random Noise Stimulation (1.5 mA, High Frequency) administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
9722966|NCT05306782|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (1.5 mA, anodal) administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
9722967|NCT05306782|Sham Comparator|Sham Direct Current/Random Noise Stimulation|Sham stimulation administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
9722968|NCT05306483|Active Comparator|Ventricular septal defect closure surgery|Surgical closure would be done under general anesthesia, hypothermic cardiopulmonary bypass and cardioplegic arrest. Chest would be opened through standard median sternotomy Surgical techniques would be determined according to the nature of every defect and includes direct closure, patch closure which involves the use of autologous pericardium; however, polyethylene terephthalate (Dacron; C.R Bard, Haverhill, MA) and expanded polytetrafluoroethylene (Gore-Tex; W.L. Gore & Associates, Inc.,AZ) may be occasionally used. These patches are held with continuous or interrupted sutures. Direct closure (without a patch may be done for the very small defects.Most VSDs would be repaired through right atriotomy to avoid the the undesirable effects of the trans ventricular approach.
9722969|NCT05306483|Active Comparator|catheter closure of ventricular septal defect|"Under general anesthesia, patients will be fully heparinized (100IU/Kg) with follow up by activated clotting time. IntraoperativeTEE will be done for more detailed assessment of the defect size, relation to the surrounding structures especially the distance from the tricuspid and the aortic valve to guide the procedure and for proper assessment after device positioning yet before its release.~Left ventricular angiogram will be done in LAO 60, cranial 30 projection to define location and size of the defect. Accordingly, proper selection of the device siz."
10197065|NCT05016843|Experimental|CBT, 16 weeks and access to forum.|
10197066|NCT05016843|Experimental|CBT, 8 weeks and no access to forum.|
10197067|NCT05016843|Experimental|CBT, 16 weeks and no access to forum.|
10197068|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and access to forum.|
10197069|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and access to forum.|
10197070|NCT05016843|Experimental|Psychodynamic therapy, 8 weeks and no access to forum.|
9722970|NCT05305235|Experimental|RISE Guide|"The RISE (RCT for Innovating Stress-related eHealth) Guide is based on CAST, an anxiety sensitivity intervention effective in reducing anxiety sensitivity, posttraumatic stress, depression, and anxiety. RISE Guide delivers psychoeducation and cognitive-behavioral therapy principles in an interactive, audio-visual format discussing the stress response, myth-busting cognitive distortions related to stress, and facilitating safe exposure to feared sensations. Participants then complete a validated cognitive bias modification (CBM-I) for interpretation biases related to anxiety sensitivity. Finally, intervention principles are reinforced using ecological momentary intervention (EMI), in which surveys and personalized reminders are delivered based on symptoms reported during ecological momentary assessments (EMAs)~RISE Guide delivered by smartphone via Qualtrics and is completed in ~45 minutes over 2 weeks, with EMI weeks 1-7 post-assault."
9722971|NCT05305235|Active Comparator|Relaxation Control|Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.
10197071|NCT05016843|Experimental|Psychodynamic therapy, 16 weeks and no access to forum.|
10197072|NCT05016843|Experimental|Waitlist, 8 weeks and access to forum.|
9722972|NCT05298722|Other|Study arm|Imaging with CT-scan and MRI-DWI and peripheral blood samples for liquid biopsy
9722973|NCT05298631|Experimental|Treatment group 1: stabilization exercises|"stabilization exercises~Chin tuck~Cervical extension~Shoulder shrugs~Shoulder rolls~Scapular retraction (15 repetitions 1 set) with TENS(10 mins before each session for 10 min at the back of the neck), stretching of trapezius, Pectorals minor, sternocleidomastoid, levator scapulae (5 rep 10 sec hold 1 set in both sides ) and cold pack (10 min at the back of neck at the end of each session)"
9722974|NCT05298631|Active Comparator|Treatment group 2: dynamic exercises|"dynamic exercises~Cervical extension-dynamic isometric.~Cervical Flexion-Dynamic isometric.~Chest flies exercises (15 repetitions 1 set) with TENS(10 mins before each session for 10 min at the back of the neck), stretching of trapezius, Pectorals minor, sternocleidomastoid, levator scapulae (5 rep 10 sec hold 1 set in both sides ) and cold pack (10 min at the back of neck at the end of each session)"
9722975|NCT05298306|Experimental|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion on separate days at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, LAT8881 will be given as a single intravenous infusion. The dose will be determined from the results of Part A."
9722976|NCT05298306|Placebo Comparator|Placebo|Matching placebo will be given as a single intravenous infusion in Part A and Part B
9722977|NCT05298150|Experimental|Dynamic cycling|The cycling parameters will change according to motor performance of the participants. Motor performance will be measured by assessing the change in tremor and movement speed.
9722978|NCT05298150|Active Comparator|Forced cycling|The cycling parameters will not change regardless of the motor performance. Motor performance will be measured by assessing the change in tremor and movement speed.
9722979|NCT05297656|Experimental|Experimental Group|"A total of 8 sessions of graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~All patients will also receive home exercise therapy including stretching of the trapezius muscle and posture exercises"
9722980|NCT05297656|Sham Comparator|Sham Comparator Group|"A total of 8 sessions of sham graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~Sham graston massage is not a deep tissue massage, but will be performed with the device superficially, without applying pressure and mobilization.~All patients will also receive home exercises."
9722981|NCT05297656|Other|Control group|The volunteers in the control group will be only given home exercise therapy including stretching of the trapezius muscle and posture exercises
9722982|NCT05297591|Experimental|breast cancer patients|Women and men diagnosed with breast cancer waiting for surgery
9722983|NCT05294939|Experimental|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
9722984|NCT05294939|Placebo Comparator|Control product|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
9722985|NCT05294705||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), Brief Observation of Symptoms of Autism (BOSA), Childhood Autism Rating Scale-2(CARS-2) and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
9722986|NCT05294705||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
10197073|NCT05016843|Experimental|Waitlist, 16 weeks and access to forum.|
10197074|NCT05016843|Experimental|Waitlist, 8 weeks and no access to forum.|
10197075|NCT05016843|Experimental|Waitlist, 16 weeks and no access to forum.|
10197076|NCT05014789|Experimental|Control-IQ 2.0 technology 2.0 on the t:slim X2 insulin pump|"Each subject will use different combinations of new features of the system each week, in random order, over the next 4 weeks, using the t:slim X2 insulin pump with Control-IQ technology 2.0.~The first 5 subjects in the study will complete a 48 hour session with multiple challenges during use of Control-IQ technology 2.0, before moving on the outpatient portion of the trial."
10197077|NCT05013840||Physicians using neuromodulation|
10197078|NCT05013008|Experimental|Finerenone (BAY94-8862)|Finerenone tablet
10197079|NCT05013008|Placebo Comparator|Placebo|Matching placebo
10197080|NCT05008484|Experimental|NMES Plus Vitamin D|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach and 2000IU oral vitamin D supplementation daily for 9 months.
10197081|NCT05008484|Experimental|Passive movement plus vitamin D|Subjects will undergo 9 months of simple passive movement exercise at home and 2000IU oral vitamin D supplementation daily for 9 months.
10197082|NCT05008328|Experimental|Music Therapy plus Standard Care|Music therapy intervention in addition to standard hospital care during an SBT.
10197083|NCT05008328|Active Comparator|Standard Care|Standard hospital care during an SBT.
10197084|NCT05007639||Patients diagnosed BEFORE implementation of the public health intervention program|All adult patients (≥18 years old) diagnosed between 1 November 2006 and 31 December 2007 in the Aquitaine and Midi-Pyrénées administrative districts in South-West France (6 million inhabitants, 10% of the French population) with primary STS of any stage were included. Patients with visceral, bone, uterus or Kaposi's sarcoma, gastrointestinal stromal tumors, or mesotheliomas were not included. Patients being treated for recurrence, and patients diagnosed outside of the administrative districts were not eligible. STS diagnoses were made in public or private pathology laboratories. Data were collected from all relevant sources: pathology reports, medical records from private and public centers,
10197085|NCT05007639||Patients diagnosed DURING implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 january 2008 and 31 october 2008."
10197086|NCT05007639||Patients diagnosed AFTER implementation of the public health intervention program|"Same eligibility criteria as for the group before implementation of the public health intervention program, except that patients were diagnosed between 1 November 2008 and 31 December 2009."
10197087|NCT05005754|Experimental|Probiotics|Subjects are instructed to take one capsule of probiotics daily for a total of 3 months
10197088|NCT05005754|Placebo Comparator|Placebo Control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
10197089|NCT05000788|Experimental|Qigong Group|
10197090|NCT05000788|Active Comparator|Exercise Group|
10204822|NCT04836767||people with a history of COVID-19|"COVID-19 Group Inclusion Criteria~Having been diagnosed with COVID-19 at least 12 weeks ago,~Being literate,~Being in the age range of 18-65,~Volunteering to participate in research,~To be clinically stable, to be under control if any accompanying comorbid conditions (such as hypertension, diabetes),~Not having any orthopedic and neurological problems that might interfere with evaluating peripheral muscle strength, balance and exercise capacity.~COVID-19 Group Exclusion Criteria~Those with an ICU hospitalization history due to the diagnosis of COVID-19,~Recent myocardial infarction and pulmonary embolism.~Having accompanying chronic diseases,~Those who have any orthopedic or neurological disorders that will prevent walking,~Another COVID-19 PCR Test positivity in the last 12 weeks,~Not being able to cooperate and adapt to exercise test due to neurological influences such as cerebrovascular disease or psychiatric disorders,"
10204823|NCT04836767||healthy people|"Healthy Group Inclusion Criteria~Not having COVID-19,~Being literate,~Being in the age range of 18-65,~Volunteering to participate in research. The Criteria for Not Including the Healthy Group in the Study~Those who have any orthopedic or neuromuscular disorders that will prevent walking,~Having any chronic illness or psychiatric conditions or mental afflictions that may interfere with cooperation or compliance with exercise tests."
10204824|NCT04826471|Experimental|DermoRelizema ecofoam|DermoReizema ecofoam for 42 days, 2 times per day
10204825|NCT04826367|Experimental|Exercise Group (EG)|"The participants in the EG will perform relaxation exercises in groups of up to 8 people, 3 days a week for 6 weeks via WhatsApp (© 2020 WhatsApp, Inc.) or Zoom (© 2012-2020 Zoom Video Communications, Inc.) applications. Relaxation exercises will be performed with the Progressive Relaxation Exercises (PRE) technique defined by Jacobson et al.[11] Tele-rehabilitation sessions will last approximately 40 minutes of each, accompanied by a physiotherapist who has 8 years of experience in the field of oncological rehabilitation."
10205438|NCT00070564|Experimental|Arm VI|Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim as in arm V. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
9980842|NCT01395875||COPD patients with moderate exacerbations|COPD patients with COPD-related using ICD-9 codes physician office/outpatient visit with a dispensing for oral corticosteroid (OCS) or antibiotic (ABX) within 5 days of the visit (Phy+Rx)
9980843|NCT01395927|Experimental|001|Canagliflozin Type=1 unit=mg number=300 form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10,Rifampin Type=2 unit=mg number=300 Form=capsule route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
9980844|NCT01395940|Experimental|KLH-2109, lower dose|
9722987|NCT05294328|Experimental|Combination ophthalmic solution (LNZ101) dosed bilaterally|Aceclidine/Brimonidine combination ophthalmic solution
9722988|NCT05294328|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|Aceclidine ophthalmic solution
9980845|NCT01395940|Experimental|KLH-2109, higher dose|
9980846|NCT01395953|Active Comparator|Buspirone|
9980847|NCT01395953|Placebo Comparator|Placebo|
9722989|NCT05294328|Experimental|Vehicle Ophthalmic Solution dosed bilaterally|Proprietary Vehicle ophthalmic solution
9980848|NCT01395979|Experimental|Cognitive Processing Therapy for Sexual Risk (CPT-SR)|The CPT-SR condition will be comprised of 10 individual therapy sessions fully integrating sexual risk reduction counseling into cognitive therapy for sexual abuse-related trauma.
10205439|NCT05207007||posterior polar cataracts|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
9980849|NCT01395979|Active Comparator|Time-Matched Control (TMC)|The TMC will be comprised of sexual risk reduction counseling/education and supportive psychotherapy.
9980850|NCT01395992|Experimental|Asenapine 5 mg|Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
9722990|NCT05292352|Experimental|Low Free Sugar Diet (LFSD) Intervention|The 1-year dietary intervention will be accomplished by adapting and extending a Social Cognitive Theory (SCT) guided low sugar intervention. SCT is a framework that helps explain how people regulate their behavior through control and reinforcement to achieve goal-directed behavior that can be maintained over time.
9722991|NCT05292352|No Intervention|Usual Care Control|Usual Care (Control group): Parents of enrolled children in the usual care group will be provided printed material on healthy family lifestyle at the beginning of the study. The control group will complete all of the same research visits and assessments as the intervention group.
9722992|NCT05291169|Experimental|Omeza Combination Therapy + SOC|the Omeza Combination Therapy under investigation includes two Over the Counter (OTC) drugs, Omeza®Lidocaine Lavage for wound bed preparation and Omeza® Skin Protectant, and an FDA cleared 510(K) medical device, Omeza® Collagen Matrix.
10197091|NCT05000710|Experimental|study arm|"Study treatments include:~Durvalumab at D1 and q4w + Tremelimumab at C1D1 and C4D1. Radiotherapy 11 fractions (start at D21)."
9722993|NCT05291169|No Intervention|SOC|Cleaning and deriding the Study ulcers and compression management
9722994|NCT05287828||Indicators validation - Group A|"This group is composed with the contrasted pre-op CT scan of the 40 patients recruited.~The classification criterion is contrasted CT scan."
9722995|NCT05287828||Indicators validation - Group B|"This group is composed with the non-contrasted CT scan of the 40 patients recruted.~This group is composed with pre-op non-contrasted CT scans to validate the possibility to use the device on the first scan realised on patient, when there is a suspicion of a disease. The classification criterion is non-contrasted CT scan."
9722996|NCT05287828||Indicators validation - Group C|"This group is composed with the post-op contrasted CT scan of the 35 pathological patients listed above (25 AAA, 5 TAA, 5 JAA).~This last group is composed with post-op CT scans. These scans are realised in a purpose of follow-up. The classification criterion is post-op CT scan of patient with a AAA, TAA or JAA."
9722997|NCT05287828||Indicators validation - Group D|"This group is composed with the post-op non-contrasted CT scan of the 35 pathological patients above (25 AAA, 5 TAA, 5JAA).~To decrease risks for patients, practicians are doing more non-contrasted CT scan. Moreover, they still need the indicators to realize the follow-up of the patient after its surgery. This group is to evaluate the possibility for the software to analysis this type of scan. The classification criterion is post-op non-contrasted CT scan of patient with a AAA, TAA or JAA."
9722998|NCT05287828||Stent migration group|25 patients are added to the 25 patients treated with EVAR (25 AAA) recruted in part 1 in order to have more significative results.
9722999|NCT05285683|Active Comparator|Methylphenidate|0.5mg/kg
9723000|NCT05285683|Active Comparator|Carbidopa/levodopa,|25mg/100mg
9723001|NCT05285683|Placebo Comparator|Placebo|Oral Pill
9723002|NCT05283811|Other|Epilepsy Monitoring Unit|Patient's behavioral and neural activity via computer tasks and questionnaires are monitored in the Epilepsy Monitoring Unit
9723003|NCT05283811|Other|Neuropace RNS Device|Patients are implanted with RNS device to treat their seizure activity
9723004|NCT05282485|Experimental|Synbiotic Group|A synbiotic combining 2'-Fucosyllactose (2'-FL) human milk oligosaccharides (HMO) with B.infantis (probiotic) will be administered to infants from 4 to 24 weeks of age.
9723005|NCT05282485|Placebo Comparator|Placebo Group|Maltodextrin will be administered to infants from 4 to 24 weeks of age.
9723006|NCT05281601|Experimental|AZD7442|All participants will receive a single dose of AZD7442 on Day 1, either IM (AZD8895 followed by AZD1061) or IV (AZD8895 + AZD1061 concurrently).
9723007|NCT05275101|No Intervention|Control|Individuals who have not experienced suicidal ideation will not complete a suicide intervention.
9723008|NCT05275101|Experimental|Crisis Response Planning (CRP)|The crisis response planning (CRP) session will last between 30 minutes to 1-hour. It will occur face-to-face with a trained study therapist. The CRP session involves the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The CRP active component involves a collaborative process in which the therapist invites the patient to share the events, symptoms, and contextual factors leading up to and surrounding the participant's suicidal crisis. Next, the patient and therapist identify the patient's personal warning signs for an emotional crisis, self-management coping skills, patient's reasons for living, and sources of social support. These components are written, by the patient, on an index card. The index card serves as a concrete reference for patients in the real-world.
9785253|NCT01246986|Experimental|Part C Cohort 2 - 300 mg LY2157299 + 800 mg Sorafenib|"150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
9980851|NCT01395992|Experimental|Asenapine 10 mg|Participants who were randomized to asenapine 10 mg BID during the P05691 study will be assigned to receive asenapine 10 mg BID on this extension study.
10197092|NCT04997616|Experimental|25 mg/day dose of Happy Lane CBD (Lower Dose)|One 25 mg Happy Lane CBD gel capsule per day (25 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days.
10197093|NCT04997616|Experimental|50 mg/day dose of Happy Lane CBD (Larger Dose)|Two 25 mg Happy Lane CBD gel capsules per day (50 mg/day total dose) for 10 consecutive days at approximately the same time of day (±1 hour) on each of these days. Both capsules will be taken at the same time as each other.
10197094|NCT04985968|Experimental|Cobitolimod 250 mg|"Dose of 250 mg cobitolimod~2 treatments during induction study and subsequently every third week"
10197095|NCT04985968|Experimental|Cobitolimod 500 mg|"Dose of 500 mg cobitolimod~2 treatments during induction study and subsequently every third week"
10197096|NCT04985968|Placebo Comparator|Placebo|"Dose of Placebo~2 treatments during induction study and subsequently every third week"
10197097|NCT04985227|Experimental|Home weight monitoring|Weighing scales will be provided to the parents to weigh their infant and enter the weight daily during the weekdays into the patient portal.
10197098|NCT04985227|No Intervention|Control|The parents will visit their Primary Care office in the usual manner as recommended by their Pediatrician.
10197099|NCT04983173|Experimental|Experimental: Clomiphene Citrate (CC) + rFSH|Ovarian Stimulation with CC+rFSH
10197100|NCT04983173|Active Comparator|rFSH|Ovarian Stimulation with rFSH
10197101|NCT04981418|Active Comparator|Control group|will receive standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource. The physiotherapist will teach participants a standardised programme of exercises, typical of those provided within usual physiotherapy practice. Written explanation/illustrations of these exercises will be provided and the women asked to undertake these at home, three times/week.
10197102|NCT04981418|Experimental|Intervention group|"In addition to the control groups intervention of exercise and advice, women in the intervention group will be fitted with the customised pelvic support shorts (DM Orthotics Ltd, https://www.dmorthotics.com).~Prior to the first physiotherapy session, those women allocated to the intervention group will have recieved the support shorts in the post together with standardised written information on wear time/washing. At the first physiotherapy session (one hour), the woman will be asked to try them on so that the physiotherapist can review the fit and comfort of the shorts. The physiotherapist will reinforce the written advice about wear time and care of the shorts, and answer any queries / brainstorm any issues. At session two (30 minutes), ~10 days later, the physiotherapist will review the fit and wearing of the shorts, problem solve any issues that have arisen, and review exercises to ensure they are being performed correctly."
10197103|NCT04973917|Experimental|conventional ventilation mode|respiratory support after cardiac surgery. Vt < 6 ml/kg PBW, driving pressure < 13 cmH2O
9723009|NCT05275101|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual session will last between 30 minutes to 1-hour. It will occur face-to-face with a trained study therapist. It will include the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The therapist will conduct a semi-structured suicide risk assessment interview, after which subjects will complete a self-guided safety plan worksheet. The worksheet takes approximately 10-minutes to complete and will be done independently.
10197104|NCT04973917|Experimental|intelectual mode - Intelivent ASV|closed loop mode of mechanical ventilation Vt < 6 ml/kg PBW, driving pressure < 13 cmH2O
9723010|NCT05275023|Experimental|Arm 1: JNJ-73763989 + PD-1 Inhibitor + Nucleos(t)ide analog (NA)|Participants will receive JNJ-73763989 subcutaneous (SC) injections and single dose of programmed cell death protein receptor-1 (PD-1) inhibitor as intravenous (IV) infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, tenofovir alafenamide [TAF] or entecavir [ETV]).
9723011|NCT05275023|Experimental|Arm 2: JNJ-73763989 + PD-1 Inhibitor + NA|Participants will receive JNJ-73763989 SC injections and multiple doses of PD-1 inhibitor as IV infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, TAF or ETV).
9723012|NCT05274776|No Intervention|NVK Guidelines|The NVK guidelines use 8 maternal and 15 neonatal risk factors, each categorized as either red flag or non-red flag. These criteria guide clinicians on the management in case of suspected EOS. Briefly, antibiotic treatment is recommended if at least one red flag and, or, two or more non-red flags are present. An observation period of at least 12 hours is recommended if one non-red flag is present. Antibiotics are recommended when an infection is suspected during this observation. Newborns without EOS risk factors, with a good clinical condition, and a gestational age of more than 36 weeks will be discharged. If the guidelines recommend an observation period, the newborn with a good clinical condition is discharged after repeating physical examination. In case antibiotic treatment is started, discharge depends on the duration of treatment and the clinical course. At discharge, parents are instructed to call the hospital in case of signs of infection within the first 14 days of life.
9723013|NCT05274776|Experimental|EOS Calculator|Using the EOS calculator application between 0-24 hours after birth, maternal EOS risk factors combined with the physical examination of the newborn are used to assign a risk category and accompanying clinical recommendation based on estimated EOS incidence for each newborn at-risk for an infection. The EOS calculator results are used to guide clinical management on performing either a diagnostic work-up and start of antibiotics for (suspected) EOS, or a conservative approach with routine controls of vital parameters every 3 hours. In case of routine controls, re-evaluation of physical appearance by a pediatric resident or pediatrician will take place within 24 hours postpartum. Newborns will be observed for at least 24 hours. In case antibiotics are started, the need for further treatment is depending on blood culture results, infection parameters, and clinical condition of the newborn. Discontinuation of antibiotics and discharge is at the discretion of the treating physician.
9723014|NCT05274516|Experimental|Single Ascending Doses, 6 dose levels|HRS-2261 oral tablet Matching placebo to HRS-2261
9723015|NCT05274516|Experimental|Multiple Ascending Doses, 3 dose levels|HRS-2261 oral tablet Matching placebo to HRS-2261
9723016|NCT05272735|Experimental|Hepatitis B Vaccine (Recombinant)|Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
9723017|NCT05272254|Experimental|Povidone Iodine|10% povidone iodine + fluoride varnish
9723018|NCT05272254|Placebo Comparator|Placebo|Placebo (iced tea) + fluoride varnish
9723019|NCT05269186|Experimental|Virtual reality|Virtual reality session performed before the planning CT scan
9723020|NCT05269186|No Intervention|Normal care|Normal care without intervention
9723021|NCT05268133|Experimental|Aronia|An aronia melanocarpa extract. Study volunteers will receive a daily oral dose of 160 mg AME for 6 weeks.
9723022|NCT05268133|Placebo Comparator|Control|Cellulose. Study volunteers will receive a daily oral dose of 160 mg cellulose for 6 weeks.
9723023|NCT05266365|Experimental|Video-based exercise group|Each subject in the video-based exercise group will receive a treatment protocol consisting of stretching exercises, strengthening exercises and functional exercises for knee and hip.
9723024|NCT05266365|Active Comparator|Standard exercise group|Each subject in the standard exercise group will receive a treatment protocol consisting of stretching exercises, strengthening exercises and functional exercises for knee and hip.
9723025|NCT05266339|Experimental|Cross-education group|Each subject in the cross-education group will receive a treatment protocol consisting of cross-education (training of the contralateral limb) and standard exercise program applied after arthroscopic rotator cuff repair.
9723026|NCT05266339|Active Comparator|Standard exercise group|Each subject in the standard exercise group will receive a treatment protocol consisting of standard exercise program applied after arthroscopic rotator cuff repair.
9723027|NCT05264844|Experimental|masking tape group|Masking tape will be used
9723028|NCT05264844|No Intervention|standard catheter dressing group|Medical plaster to be used (It is routine practice in the clinic.)
9723029|NCT05263492|Experimental|Pembrolizumab & Lenvatinib|Lenvatinib, 20 mg administered orally (PO) once daily (QD) during each 21-day cycle, and Pembrolizumab, 200 mg administered by intravenous (IV) infusion on day 1 of each 21-day cycle.
9723030|NCT05254977||B.V. HOSPITAL|Local population in surrounding premises of site
9723031|NCT05254977||Baldia Hall Yazman|Local population in surrounding premises of site
9723032|NCT05254977||CIVIL HOSPITAL Bahahwalpur|Local population in surrounding premises of site
9723033|NCT05254977||DDHO KPT|Local population in surrounding premises of site
9723034|NCT05254977||Govt Girls Elementry School|Local population in surrounding premises of site
9723035|NCT05254977||Govt Higher Secondary School|Local population in surrounding premises of site
9723036|NCT05254977||Govt Sadiq Higher Secondary School|Local population in surrounding premises of site
9723037|NCT05254977||Govt TibIA College Bahawalpur|Local population in surrounding premises of site
9723038|NCT05254977||CEO Office DHA BWP|Local population in surrounding premises of site
9723039|NCT05254977||Papulation Welfare office APE|Local population in surrounding premises of site
9723040|NCT05254977||RHC Ballah Jhulan|Local population in surrounding premises of site
9723041|NCT05254977||RHC Channi Goth|Local population in surrounding premises of site
10197105|NCT04973085|Experimental|Cold circulated water|Research staff will help position the participant on the bed of the MRI scanner. An adhesive wrap will be applied to the front of the participant's neck. Participants will be in constant communication with study personnel throughout the intervention by means of a 2-way intercom. When ready, the water circulation machine will be turned on. Water will circulate from the machine, through a long set of tubes, to the neck wrap, then back to the machine in a closed-loop system. At the beginning of the intervention, body temperature water will be circulated through the neck wrap. Over 5-10 minutes, the study coordinator and the participant will work together to slowly lower the temperature of the circulated water to identify the lowest tolerable temperature. The participant will be maintained at the lowest tolerable temperature for the remainder of the 2 hour intervention, and can adjust the temperature of the circulated water as often as desired throughout the study.
9723042|NCT05254977||RHC Choona wala|Local population in surrounding premises of site
9723043|NCT05254977||RHC Dera Bakha|Local population in surrounding premises of site
9723044|NCT05254977||RHC Headrajkan|Local population in surrounding premises of site
9723045|NCT05254977||RHC Khanqah sharif|Local population in surrounding premises of site
10197106|NCT04973085|Active Comparator|Body temperature circulated water|The procedure for the body temperature study arm is identical to the cold study arm, except the water temperature will be kept at body temperature for the duration of the 2 hour intervention.
9723046|NCT05254977||RHC Khutri Banglow|Local population in surrounding premises of site
9723047|NCT05254977||RHC Kud Wala|Local population in surrounding premises of site
9723048|NCT05254977||RHC Lal Sohanra|Local population in surrounding premises of site
9723049|NCT05254977||RHC Mubarkpur|Local population in surrounding premises of site
9723050|NCT05254977||RHC Qaimpur|Local population in surrounding premises of site
9723051|NCT05254977||RHC Uch Sharif|Local population in surrounding premises of site
9723052|NCT05254977||Special Education Degree Colage|Local population in surrounding premises of site
9723053|NCT05254977||THQ HOSPITAL, AHMADPUR|Local population in surrounding premises of site
9723054|NCT05254977||THQ HOSPITAL, HASILPUR.|Local population in surrounding premises of site
9723055|NCT05254977||THQ KHAIR PUR TAMEWALI|Local population in surrounding premises of site
9723056|NCT05254977||THQ YAZMAN|Local population in surrounding premises of site
9723057|NCT05254977||TMA Office Hasilpur (NEW)|Local population in surrounding premises of site
9723058|NCT05253937||Intracoronary Epinephrine administration during cardiac arrest|
9723059|NCT05253937||Peripheral intravenous Epinephrine administration during cardiac arrest|
9723060|NCT05253937||Central intravenous Epinephrine administration during cardiac arrest|
9723061|NCT05251051|Active Comparator|Intervention Group|"At NICU discharge, infants will be referred to Illinois Early Intervention. A coordinator (the navigator) will assist families in engaging with Early Intervention and completing all enrollment requirements.~At NICU discharge, infants will be provided with standard home pediatric therapy services weekly for up to 14 weeks. These will be initiated within 2 weeks of discharge."
9723062|NCT05251051|Other|Control Group|At NICU discharge, infants will be referred to Illinois Early Intervention. A coordinator (the navigator) will assist families in engaging with Early Intervention and completing all enrollment requirements. If transitional services were recommended by the NICU providers, the navigator will help families identify these services and obtain the necessary referrals.
9723063|NCT05250947|Experimental|PRP Injection Arm|The FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP. The targeted final PRP volume of 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint.
9723064|NCT05249127|Experimental|64Cu-SAR-bisPSMA|Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-bisPSMA.
9723065|NCT05245799|Active Comparator|Speech Language Therapy|Children who are deaf/hard of hearing will receive standard of care speech and language therapy with a speech language pathologist. Reading time is prescribed 20 min, 3x/week.
9723066|NCT05245799|Experimental|Speech Language Therapy + Digital Phase|Children who are deaf/hard of hearing will receive standard of care speech and language therapy with a speech language pathologist with the addition of the digital app named, Hear Me Read, that will be used to achieve reading, speech and language goals through interactive digital storybook reading. Reading time is prescribed 20 min, 3x/week.
9723067|NCT05239793|Other|JUUL e-cigarette|JUUL e-cigarette containing 5% nicotine strength pods
9723068|NCT05236673||Patients who have started at first time on Jardiance®|
9836218|NCT02775903|Active Comparator|Azacitidine Alone|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
9836219|NCT02775916|Experimental|CDZ173|Capsule
9723069|NCT05236296|Experimental|EASE-CG Intervention|"Participants will be offered one EASE-CG therapy session every week for up to 12 weeks. Each session will last for approximately 30-60 minutes, delivered by a trained therapist at our center. Frequency and/or length of sessions may vary to accommodate the needs and availability of each participant.~Outcomes will be assessed at baseline, 1, 3, 6, 9, and 12 months. Participants may be invited to brief, semi-structured interviews."
9723070|NCT05222373|No Intervention|Standard care|Standard care: will include the CHW curriculum focused on diabetes education and connecting individuals to appropriate resources in the community (materials in Spanish and English).
9723071|NCT05222373|Active Comparator|CBT-based lifestyle intervention group|CBT-based lifestyle intervention: standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English).
9723072|NCT05219201|Sham Comparator|Sham cryotherapy full time patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their full-time rehabilitation stay"
9723073|NCT05219201|Sham Comparator|sham cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-30°C) during their part-time rehabilitation stay"
9723074|NCT05219201|Active Comparator|cryotherapy full-time hospitalized patient (inpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their full-time rehabilitation stay"
9723075|NCT05219201|Active Comparator|cryotherapy part-time hospitalized patient (outpatient)|"Patients benefiting from 15 session of sham partial-body cryotherapy session (-120°C) during their part-time rehabilitation stay"
9723076|NCT05216263|Experimental|Atogepant|Participants will receive atogepant once daily during the 24-week treatment period.
9723077|NCT05213741|Experimental|Magnetic-assisted colonoscopy group|Participants in this group will recieve magnetic-assisted colonoscopic examination
9723078|NCT05210439|Experimental|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment from the date of the last positive blood culture
9723079|NCT05210439|Active Comparator|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment from the date of the last positive blood culture
9723080|NCT05209451|Active Comparator|Control Condition - No additional study intervention|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material.
9723081|NCT05209451|Experimental|Loaner Digital Device|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material. Participants in this group will also receive a loaned Bluetooth enabled iPad with data plan coverage for the study duration.
9723082|NCT05209451|Experimental|Loaner Digital Device + Coaching Support|Subjects will receive a 12-week, digital, evidence-based behavioral health program for smoking cessation delivered through the patient portal and a written guide on existing digital access resources along with any other necessary material. Participants in this group will also receive a loaned Bluetooth enabled iPad with data plan coverage for the study duration plus up to six coaching call, 15-20 minutes in duration.
9723083|NCT05206864|Experimental|SBD111|
9723084|NCT05206864|Placebo Comparator|Placebo|
9723085|NCT05204160|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9723086|NCT05204147|Experimental|Treatment (Ac225-DOTA-M5A)|Patients receive Ac225-DOTA-M5A IV over 25 minutes on day 1.
10197107|NCT04972916|Other|Patient Navigation-based Tobacco Harm Reduction Intervention|All participants will receive a smoking cessation educational brochure and patient navigation intervention delivered over 2 months.
9723087|NCT05202860|Experimental|HPV vaccine|Commercially available nonavalent HPV vaccine (Gardasil(R) 9) given intramuscularly at baseline, month 2 and month 6
9723088|NCT05202860|Placebo Comparator|Isotonic Saltwater Vaccine|0.9% NaCl given intramuscularly at baseline, month 2 and month 6
9723089|NCT05201950|Experimental|Virtual simulation|- Virtual simulation group: Participants will log in to the virtual simulation software from home and play 2 cases (1 case of sepsis, 1 case of trauma). Learners are instructed to play each case as many times as they like within 70 minutes, to reach the highest score possible in that time. This process is proctored, with participants sharing their screen over video conferencing with study team members (JCL or LZY) to ensure adherence to time limit and cases played.
9723090|NCT05201950|Active Comparator|Team based in situ simulation|- Team based in situ simulation group: Faculty observing and debriefing learners at the mock code will be variable and consist of a wide range of NUH emergency department faculty outside of this study, due to logistical constraints in having the same faculty being present consistently in the entire year. The in situ simulation will cover 1 case of sepsis, and 1 case of trauma, with case content matched to the cases in the virtual simulation group, and time matched at 70 minutes.
9723091|NCT05201937|Experimental|Arm A: Panel 1 (JNJ-64281802 High Dose Regimen)|Participants will receive Loading Dose (LD) 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by maintenance Dose (MD) 1 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
9723092|NCT05201937|Experimental|Arm A: Panel 2 (JNJ-64281802 High Dose Regimen)|Participants will receive LD 1 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 2 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
9723093|NCT05201937|Experimental|Arm B: Panel 3 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 3 of JNJ-64281802 once daily on Days 3, 10, 17 and 24.
9723094|NCT05201937|Experimental|Arm B: Panel 4 (JNJ-64281802 Low Dose Regimen)|Participants will receive LD 2 of JNJ-64281802 twice daily on Days 1 and 2 followed by MD 4 of JNJ-64281802 once daily on Days 3, 6, 10, 13, 17, 20, 24, and 27.
9723095|NCT05201937|Experimental|Arm C: Panel 5 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
10197108|NCT04971044|Experimental|COACH Intervention|COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for 4-6 year old children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
9723096|NCT05201937|Experimental|Arm C: Panel 6 (JNJ-64281802 [Optional])|Participants dosing regimen(s) will be determined based on the results of Study Arm A and Study Arm B.
9723097|NCT05201794|Experimental|High-dose JNJ-64281802 regimen (HDR)|Participants will receive JNJ-64281802 400 milligrams (mg) loading dose (LD) twice daily for 48 hours (2 days), followed by JNJ-64281802 150 mg maintenance dose (MD) once daily for 26 days in fed conditions.
9723098|NCT05201794|Experimental|Low-dose JNJ-64281802 regimen (LDR)|Participants will receive JNJ-64281802 150 mg LD twice daily for 48 hours (2 days), followed by JNJ-64281802 50 mg MD once daily for 26 days in fed conditions.
9723099|NCT05201794|Placebo Comparator|Placebo|Participants will receive JNJ-64281802 matching placebo LD and MD from Day 1 to Day 28.
9723100|NCT05197140|Active Comparator|4 ounce beef patty|Subjects consume one beef patty of 4 ounces of cooked meat.
9723101|NCT05197140|Experimental|4 ounce vegetarian burger|Subjects consume one patty of 4 ounces of cooked vegetarian product.
9723102|NCT05197140|Experimental|2x 4 ounce vegetarian burger|Subjects consume two patties of 4 ounces of cooked vegetarian product.
9723103|NCT05197075|Experimental|Darunavir/Cobicistat (DRV/COBI) Fixed Dose Combination (FDC)|Participants will receive the DRV/COBI FDC tablet for oral use, dispersed in water on Day 1.
9723104|NCT05196737|No Intervention|Non-Intervention Week Reflex Measurements|Baseline reflex measurements will be collected during the first week of the study (Visits 1-4). No dry needling will occur during this week. The aim of this arm is to track any natural variability in nervous system excitability at the same time points as reflex measurements during the intervention week.
9723105|NCT05196737|Experimental|Dry Needling Reflex Measurements|All participants who participated in baseline reflex measurements during week 1 will continue to the second week of the study (Visits 5-7). Participants will receive dry needling to relieve spasticity in the target calf muscle (middle gastrocnemius) during Visit 5. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to DDN, immediately after DDN, 90 minutes after DDN, 24 hours after DDN, and 72 hours after DDN. These assessments will examine how you move your leg and how your nervous system responds to non-invasive nerve stimulation.
9723106|NCT05192083|Experimental|Intervention group|The intervention group will receive a smartphone-based self-management support programme, including a 30-min face-to-face or online session at baseline, 3 phone calls (week 2, week 4 and week 6) and 2-month mobile messages in addition to usual care.
9723107|NCT05186428|Other|"The before period"|
9723108|NCT05186428|Experimental|"the after period"|
9723109|NCT05185739|Active Comparator|Pembrolizumab|
9723110|NCT05185739|Active Comparator|Lenvatinib.|
9723111|NCT05185739|Experimental|Pembrolizumab and Lenvatinib.|
9723112|NCT05184699|Active Comparator|Food supplement Endocalyx|Thirty patients with psoriatic disease will randomized to receive 4 capsules a day of the food supplement Endocalyx for 4 months
9723113|NCT05184699|Placebo Comparator|Placebo|Thirty patients with psoriatic disease will randomized to receive 4 capsules a day of the placebo for 4 months
9723114|NCT05180448|Experimental|Coach Share On + Group Share On + Friend/Family Share On|
9723115|NCT05180448|Experimental|Coach Share On + Group Share On + Friend/Family Share Off|
9723116|NCT05180448|Experimental|Coach Share On + Group Share Off + Friend/Family Share On|
9723117|NCT05180448|Experimental|Coach Share On + Group Share Off + Group Share Off|
9723118|NCT05180448|Experimental|Coach Share Off + Group Share On + Friend/Family Share On|
9723119|NCT05180448|Experimental|Coach Share Off + Group Share On + Friend/Family Share Off|
9723120|NCT05180448|Experimental|Coach Share Off + Group Share Off + Friend/Family Share On|
9723121|NCT05180448|Experimental|Coach Share Off + Group Share Off + Friend/Family Share Off|
9723122|NCT05180175|Experimental|Access to protein profile|
10197109|NCT04971044|Active Comparator|Educational Control|The control arm will consist of a school readiness intervention developed by education and literacy experts on our team and implemented at local libraries. It will include 1) child lessons from Puente de Cuentos, a systematic, language-based curriculum focused on dual language storytelling (narrative language), and 2) parent sessions designed to improve parents' knowledge and skills related to improving children's language production and storytelling skills, to ultimately support school readiness.
10197110|NCT04970472||patients with Urothelial bladder carcinoma|collection of blood, urines, stool and tumor samples
10197111|NCT04969068|Experimental|The median effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg|The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size).The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement)'
9723123|NCT05180175|No Intervention|No access to protein profile|
9723124|NCT05179915|Experimental|Experimental Group|The experimental group will be administered 15-minute therapeutic touch in the latent phase and after it finishes, the participating pregnant woman will be asked to rest for 30 minutes.
9723125|NCT05179915|Placebo Comparator|Placebo Group|After the mimic (sham) therapeutic touch finishes, the pregnant woman will be asked to rest for 30 minutes.
9723126|NCT05176418|Active Comparator|delivery rate for nicotine dose 1mg/70kg|delivery rate 50,35, 16.6 and 12.5 ug per second
9723127|NCT05176418|Active Comparator|Delivery rate for nicotine dose 0.2mg/70kg|delivery rate 10,5, 3.3 and 2.5
9723129|NCT05171777|Experimental|Treatment A|Participants will receive atezolizumab SC followed by atezolizumab IV.
9723130|NCT05171777|Experimental|Treatment B|Participants will receive atezolizumab IV followed by atezolizumab SC.
9723131|NCT05165550|Experimental|Cohort 1|Elsulfavirine 20 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
9836220|NCT02775916|Placebo Comparator|Placebo|Capsule matching Placebo
9723132|NCT05165550|Experimental|Cohort 2|Elsulfavirine 40 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
10197112|NCT04967391|Experimental|Tumescence During STSG Harvest|Prior to the split thickness skin graft (STSG) harvest, the tumescence technique will injection of 100-150 mL normal saline with 1:500,000 epinephrine injected into a deep dermal thigh tissue plane with 18-gauge spinal needle on a 60 mL syringe.
10197113|NCT04967391|No Intervention|No Intervention|"Patients randomized to no tumescence will have their free flap donor site reconstructed with a split thickness skin graft (STSG) harvested at 0.0175 inches using the dermatome to obtain a graft from the thigh."
9723133|NCT05165550|Experimental|Cohort 3|Elsulfavirine 80 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
9723134|NCT05161936|Experimental|Lumasiran Dose 1|Participants will be administered lumasiran by subcutaneous (SC) injection.
9723135|NCT05161936|Experimental|Lumasiran Dose 2|Participants will be administered lumasiran by SC injection.
9723136|NCT05161936|Placebo Comparator|Placebo|Participants will be administered placebo by SC injection.
10197114|NCT04967248||alpelisib in combination with fulvestrant|Patients treated with alpelisib in combination with fulvestrant
10197115|NCT04966689|Experimental|combined speech and music therapy|the telerehabilitation intervention that include both speech therapy and music therapy at the same time
9723137|NCT05160558|Experimental|Cohort 1: BIIB132 Dose 1 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 1 or matching placebo, intrathecally (IT), every 4 weeks (Q4W), up to Day 85.
9723138|NCT05160558|Experimental|Cohort 2: BIIB132 Dose 2 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 2 or matching placebo, IT, Q4W, up to Day 85.
9723139|NCT05160558|Experimental|Cohort 3: BIIB132 Dose 3 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 3 or matching placebo, IT, Q4W, up to Day 85.
9723140|NCT05160558|Experimental|Cohort 4: BIIB132 Dose 4 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 4 or matching placebo, IT, Q4W, up to Day 85.
9723141|NCT05160558|Experimental|Cohort 5: BIIB132 Dose 5 or Matching Placebo|Participants will be randomized to receive BIIB132 Dose 5 or matching placebo, IT, either Q4W or every 12 weeks (Q12W), up to Day 85 or every 8 weeks (Q8W) up to Day 57.
9723142|NCT05159700|Experimental|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
9723143|NCT05153239|Experimental|Lurbinectedin|Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)
9723144|NCT05153239|Experimental|Lurbinectedin plus Irinotecan|"Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):~Irinotecan (Day 1 and Day 8)~Lurbinectedin (Day 1)"
9723145|NCT05153239|Active Comparator|Control arm|"Best Investigator's choice prior to randomization between:~Irinotecan on Day 1 q3wk~Topotecan on Days 1-5 q3wk"
9780596|NCT01127061|Experimental|Exercise Training|Participants in the exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The protocol will be custom designed in consultation with an exercise physiologist based on data from the initial cardiopulmonary stress test. Exercise regimen will begin at a low level of intensity then increase in duration and training intensity to a goal of 60 minutes a day and 70% of the heart rate reserve during the 1st month of the study protocol with maintenance of the program thereafter. There is no need to come to a participating site for actually doing the exercise regimen. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
9780597|NCT01127061|No Intervention|Usual Activity|Participants in this group are not restricted in their activities. They simply are not guided in their physical activities by the study team. At the end of the 4 month study period, they will also receive an individualized exercise prescription for personal use.
10197116|NCT04966689|Active Comparator|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
10197117|NCT04966689|Active Comparator|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
9780598|NCT01127087|Experimental|RYGB CaOx Stone Formers|"Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
9780599|NCT01127087|Experimental|Idiopathic Hyperoxaluria CaOx Stone Formers|"Subjects with idiopathic hyperoxaluria.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
9780600|NCT01127139||Czech patients with essential hypertension|Czech hypertensive patients (women and men) with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg who can be treated with fixed-combination Tarka®.
9780601|NCT01127165|Experimental|Zonisamide Low Dose Group|
9780602|NCT01127165|Experimental|Zonisamide High Dose group|
9780603|NCT01127321|Placebo Comparator|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
9780604|NCT01127321|Experimental|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
9780605|NCT01127321|Experimental|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
9780606|NCT01127321|Experimental|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
9780607|NCT01127321|Experimental|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
10197118|NCT04965519|Experimental|RC48-ADC|Eligible subjects received RC48-ADC treatment after enrollment, at a dose of 2.0 mg/kg, once every 2 weeks (the dosing time window in all cycles is -1 to 2 days), and the administration method is intravenous Drip.
10197119|NCT04958668|Active Comparator|Volatile procedere|Intensive care treatment with demand-adapted sedation with volatile anaesthetics
10197120|NCT04958668|No Intervention|Conventional procedere|Conventional Intensive care treatment with demand-adapted sedation with intravenous sedatives
10197121|NCT04957953||Pregnant Women Vaccinated against Covid-19|Woman over 18 years of age who has received at least one Covid-19 vaccine during her pregnancy, regardless of the trimester of pregnancy.
10197122|NCT04952389|Experimental|Acupuncture Therapy Group|Subjects will undergo ten sessions of acupuncture therapy with a licensed acupuncturist in addition to the standard of care.
9723146|NCT05151692|Experimental|Cohort 1: Nipocalimab|Participants will receive a single intravenous (IV) dose of nipocalimab Dose 1 on Day 1.
9723147|NCT05151692|Experimental|Cohort 2: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 2 on Day 1.
9723148|NCT05151692|Experimental|Cohort 3: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 3 on Day 1.
9723149|NCT05150977||Idiopathic hypersomnia|Observation
9723150|NCT05148780|Other|Participants with Acute Respiratory Infections (ARI) in Outpatient Setting|Participants presenting with ARIs in an outpatient setting who are at high risk of progressing to severe disease will be screened for viral respiratory pathogens (respiratory syncytial virus [RSV], Influenza, severe acute respiratory syndrome coronavirus 2 [SARS-COV-2]) by collecting a nasal swab. If a participant is positive for RSV and/or influenza virus and/or SARS-CoV-2 based on a study test or standard-of-care (SOC) polymerase chain reaction (PCR)-based test, the participant will be eligible for enrollment in the study in the home-based short-term and long-term follow-up phases.
9723151|NCT05146804|Other|BroccoCress/Affilla Cress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
9723152|NCT05146804|Other|Affilla Cress/Broccocress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
9723153|NCT05140941|Experimental|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet, one tablet taken once daily for 84 days
9723154|NCT05139836||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe atopic dermatitis.
9723155|NCT05139810|Experimental|donidalorsen: Cohort A|Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
9723156|NCT05139810|Experimental|donidalorsen: Cohort B|Participants will be administered donidalorsen by subcutaneous (SC) injection for up to 25 weeks.
9723157|NCT05139810|Placebo Comparator|Placebo: Cohort A|Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
9723158|NCT05139810|Placebo Comparator|Placebo: Cohort B|Participants will be administered donidalorsen-matching placebo by subcutaneous (SC) injection for up to 25 weeks.
9723159|NCT05137431||High Flow Nasal Oxygenation-HFNO|The current will be adjusted from 50-70 liters. The patient's SpO2 value will be maintained at at least 92%. Arterial blood gas will be checked at the 1st hour
9723160|NCT05137431||Non-Invasive Ventilation-NIV|Tidal volume will be adjusted to be 6-8 ml/kg. The respiratory rate will be <30. The patient's SpO2 value will be maintained at at least 92%. The PEEP value will be 5 cmH2O. At the 1st hour, arterial blood gas will be checked.
9723161|NCT05134441|Experimental|IMU-838|"IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.~Formulation:~Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning."
9723162|NCT05134441|Placebo Comparator|Placebo|Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.
9723163|NCT05133323|Experimental|Lu AG09222 High Dose|Participants will receive a single high dose of Lu AG09222 by intravenous (IV) infusion.
9723164|NCT05133323|Experimental|Lu AG09222 Low Dose|Participants will receive a single low dose of Lu AG09222 by IV infusion.
9723165|NCT05133323|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to Lu AG09222 by IV infusion.
9723166|NCT05130970|Experimental|CSL312|Administered IV and SC
9723167|NCT05130970|Placebo Comparator|Placebo|Administered IV and SC
9780608|NCT01127373|Experimental|radiation therapy via multi-beam IMRT|This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.
9780609|NCT01127438|Active Comparator|fospropofol disodium Subgroup 1 Lower Dose|
9780610|NCT01127438|Active Comparator|: fospropofol disodium Subgroup 1 Approved Dose|
9780611|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Lower Dose|
10197123|NCT04952389|Active Comparator|Standard of Care|Subjects will be treated with two times daily budesonide rinses and olfactory (sense of smell) training. This is considered the current standard of care in the treatment of olfactory dysfunction.
10197124|NCT04951570||Hematoma Expansion (HE) group|
10197125|NCT04951570||non-HE group|
10197126|NCT04946721||1.BMT Patients (Study)|Patients prior to receiving a bone marrow transplant will be recruited during their initial intake prior to their BM transplant through the PI's regularly scheduled appointment with these patients.
10197127|NCT04946721||2.Controls|Patients with no history of eye disease or cancer history
10197128|NCT04943549|Active Comparator|Group (A)|History of addiction.
9723168|NCT05128682|Other|Urodynamic testing with and without pudendal nerve stimulation|"The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the dose and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject."
9723169|NCT05128578|Experimental|LEAP Intervention Arm|"Half of the recruited patients (anticipate 20) will participate in 12 weekly sessions to teach self-pain management tools and skills. In addition to alternating weeks of group and individual sessions, participants will track their activities using the LEAP workbook provided during the first meeting, as tracking is a key component of most pain-self management interventions and is intended to address self-regulation. All patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
9723170|NCT05128578|Active Comparator|Usual Care|Half of the recruited patients (anticipated 20) will receive usual care under the control arm of this study. These participants will not receive the intervention.
9723171|NCT05121766|Experimental|Study arm - Omega 3 supplement|Omega-3 (EPA+DHA) - Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day). Each capsule has 252mg of EPA and 102mg of DHA.
9723172|NCT05121766|Placebo Comparator|Control arm - placebo|3 Soybean Oil Placebo capsules 2x/day (a total of 6 mini-capsules per day).
9723173|NCT05112939|Experimental|Panel A: Rilpivirine (RPV) Long-acting (LA)|Patients will receive one dose of RPV LA (formulation 1) under different conditions (Treatment A and B) on Day 1.
9723174|NCT05112939|Experimental|Panel B: RPV LA|Patients will receive one dose of RPV LA (formulation 2) under different conditions (Treatment C and D) on Day 1.
9723175|NCT05112939|Experimental|Panel C: RPV LA|Patients will receive one dose of RPV LA (formulation 1) under different conditions (Treatment E and F) on Day 1, based on interim data of Panel A and/or B.
9723176|NCT05112939|Experimental|Panel D: RPV LA|Patients will receive one dose of RPV LA (formulation 2) under different conditions (Treatment G and H) on Day 1, based on interim data of Panel A and/or B.
9723177|NCT05102734||Topical nitroglycerin|A topical nitroglycerin solution will be applied to the area of interest
10197129|NCT04943549|Placebo Comparator|Group (N)|No history of addiction to any drug.
10197130|NCT04941326|Active Comparator|Spinal mobilization group|Spinal mobilization will be applied to the application group for 4 weeks in addition to the treatments applied to the sham group
9723178|NCT05101486|Experimental|Group 1: Ad26.RSV.PreF-based Vaccine|Participants will receive a single intramuscular (IM) injection of Ad26.RSV.PreF-based vaccine on Day 1 (non-aged lot).
9723179|NCT05101486|Experimental|Group 2: Ad26.RSV.PreF-based Vaccine|Participants will receive a single IM injection of Ad26.RSV.PreF-based vaccine on Day 1 (aged lot 1).
9723180|NCT05101486|Experimental|Group 3: Ad26.RSV.PreF-based Vaccine|Participants will receive a single IM injection of Ad26.RSV.PreF-based vaccine on Day 1 (aged lot 2).
9723181|NCT05095727|Experimental|mRNA-3745|Participants will receive a single IV dose of mRNA-3745 on Day 1.
9723182|NCT05094128||Participants Receiving Upadacitinib|
9723183|NCT05087628|Experimental|PRV-3279|Sterile solution for intravenous administration, every 4 weeks
9723184|NCT05087628|Experimental|Placebo|Sterile solution for intravenous administration, every 4 weeks
9723185|NCT05083585|Experimental|Group 1: Phase 3 Clinical Trial Material (CTM)|Participants will receive a single intramuscular (IM) injection of adenovirus serotype 26 (Ad26). respiratory syncytial virus (RSV). prefusion conformation-stabilized F protein (preF)-based vaccine on Day 1, which is a Phase 3 CTM.
9723186|NCT05083585|Experimental|Group 2: Phase 2b CTM|Participants will receive a single IM injection of Ad26.RSV.preF-based vaccine on Day 1, which is a Phase 2b CTM.
9723187|NCT05083260|Experimental|NE3107|orally administered NE3107 20 mg twice daily (BID)
10197131|NCT04941326|Sham Comparator|Sham group|Diaphragmatic stimulation with proprioceptive neuromuscular facilitation techniques (PNF), diaphragmatic breathing techniques, costal mobilization treatments and sham mobilization will be applied to the sham group.
9723188|NCT05083260|Placebo Comparator|placebo|orally administered placebo, twice daily
9723189|NCT05077176|Active Comparator|CoronaVac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
9723190|NCT05077176|Experimental|Turkovac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
9723191|NCT05074914|Experimental|Adenocarcinoma of the oesophagus|curative oesophagectomy
9723192|NCT05074914|No Intervention|Barrett's oesophagus|Weight stable patient under survelliance with Barrett's oespophagus
9723193|NCT05071313|Experimental|Group 1: Coadministration (CoAd) Group|Participants will receive Ad26.RSV.preF-based vaccine and quadrivalent high dose influenza vaccine concomitantly on Day 1 and placebo on Day 29.
9723194|NCT05071313|Experimental|Group 2: Control Group|Participants will receive placebo and quadrivalent high-dose influenza vaccine on Day 1 and Ad26.RSV.preF-based vaccine on Day 29.
9723195|NCT05071053|Experimental|Tusamitamab ravtansine+Ramucirumab|"Part 1: participants to receive an intravenous (IV) dose of tusamitamab ravtansine in combination with an IV dose of ramucirumab on Day 1 of Cycle 1 followed by an additional IV dose of tusamitamab in combination with IV dose of ramucirumab at Day 1 Cycle 2 of 14-day cycle in all subsequent cycles.~Part 2: participants to receive the recommended dose of tusamitamab ravtansine established in the Part 1 in combination with IV dose of ramucirumab on Day 1 of Cycle 1 followed by IV dose of tusamitamab in combination with IV dose of ramucirumab at Day 1 Cycle 2 of 14-day cycle in all subsequent cycles."
9723196|NCT05070546|Experimental|Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)|Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.
9780612|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Approved Dose|
9723197|NCT05070546|Placebo Comparator|C1 G2: Healthy Adults, 18-59 Years (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
9723198|NCT05070546|Experimental|C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)|Participants will receive a single IM injection of study vaccine on Day 1.
9723199|NCT05070546|Placebo Comparator|C2 G4: High Risk Adult, 18-59 Years (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
9723200|NCT05070546|Experimental|C3 G5: Adults, 65 Years and Older (RSV Vaccine)|Participants will receive a single IM injection of study vaccine on Day 1.
9723201|NCT05070546|Placebo Comparator|C3 G6: Adults, 65 Years and Older (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
9723202|NCT05068596|Experimental|study groip|received the designed physical therapy program as the control group. In addition, they received progressive resistive functional strength training in the plantigrade foot position.
9723203|NCT05068596|Other|control group|received a designed physical therapy program
9723204|NCT05067998||IV Vitamin Therapy Treatments|IV vitamin infusion therapy involves inserting an IV line into a vein in your arm to administer a high concentration of liquid vitamins, antioxidants, amino acids, and minerals into your bloodstream. The therapy may be for only one vitamin or a cocktail of nutrients.
9723205|NCT05067998||Herbal Medicine, Tincture (Liquid Vitamins)|Tinctures are concentrated herbal extracts made by soaking the bark, berries, leaves (dried or fresh), or roots from one or more plants in alcohol or vinegar. The alcohol or vinegar pulls out the active ingredients in the plant parts, concentrating them as a liquid. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort. Herbal Medicine is type of medicine that uses roots, stems, leaves, flowers, or seeds of plants to improve health, prevent disease, and treat illness.
9723206|NCT05067998||Supplements|Dietary supplements are substances you might use to add nutrients to your diet or to lower your risk of health problems such as osteoporosis or arthritis. Dietary supplements come in the form of pills, capsules, powders, gel capsules and tablets, extracts, or liquids. Dietary supplements come in a variety of forms, including tablets, capsules, gummies, and powders, as well as drinks and energy bars. Popular supplements include vitamins D and B12; minerals like calcium and iron; herbs such as echinacea and garlic; and products like glucosamine, probiotics, and fish oils.
9723207|NCT05067998||Vitamins (Orally)|Vitamins are substances that our bodies need to develop and function normally. They include vitamins A, C, D, E, and K, choline, and the B vitamins (thiamin, riboflavin, niacin, pantothenic acid, biotin, vitamin B6, vitamin B12, and folate/folic acid). Vitamins are essential nutrients that enable your body to work properly and to stay healthy. Most vitamins can be found in the food that we eat or from vitamin supplements.
9723208|NCT05066217|Placebo Comparator|Placebo|Placebo Comparator: Matching Placebo - Cohort 2 Matching placebo will be administered twice a day (BID) in equally divided doses with food.
9723209|NCT05066217|Experimental|Active|"Drug: EPX-100 drug product is an oral aqueous solution of clemizole hydrochloride and provided in a concentration of 5 mg/mL.~Other Name: Cohort 1"
9723210|NCT05064787|Other|Single Arm Cohort Receiving Digital Health Coaching|All study participants will be enrolled in a 6-month digital health coaching program.
9723211|NCT05054140|Experimental|IMU-838|IMU-838 as tablet; Administration: Oral - daily
9723212|NCT05054140|Placebo Comparator|Placebo|Matching placebo as tablet; Administration: Oral - daily
9723213|NCT05053659|Experimental|Loncastuximab tesirine & venetoclax|"Participants will receive a baseline disease assessment via PET/CT in FDG avid lymphomas; CT scan (chest, abdomen, pelvis; inclusion of neck in selected cases). Bome marrow biopsy in selected cases.~Premedication includes:~Allopurinol (to reduce uric acid) 300mg orally daily starting day -1 and continuing at least until day 7 of each cycle.~Dexamethasone (steroid pre-medication) 4mg orally twice daily on day -1, day 1 and day 2 of each cycle.~Adequate oral hydration starting on day -1 or -2, defined as 1 - 2 liters of oral intake of liquids in 24 hours~Study treatment to be given every 21 days.~Loncastuximab tesirine (50 - 150 μg/kg) intravenously (IV) on day 1 of each 21-day cycle~Venetoclax (400 - 800 mg) orally, every day on days 1 - 5 of each 21-day cycle. Dose ramp-up on cycle 1 (over days 1 - 5 for target dose 400mg, 1 - 6 for target dose 600mg and 1 - 7 for target dose 800mg"
9980852|NCT01396031|Experimental|Excercise|Cardiovascular exercise Standing Hip Abduction Step-up/Step-down Wall Slide Sit-to-Stand Activity / Exercise Diary 3 times per week x ~1 month
9980853|NCT01396109|Active Comparator|Group I|Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
9723216|NCT05047250|Experimental|Atezolizumab|Participants will receive IV infusion of atezolizumab on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
9723217|NCT05047250|Active Comparator|Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)|Participants will receive platinum-based chemotherapy consisting of a platinum agent (carboplatin or cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel (squamous disease).
9723218|NCT05043441|Experimental|Acceptance and commitment therapy (ACT) group|10 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
9723219|NCT05043441|Sham Comparator|Psychoeducation control group|Care as usual with psychoeducation materials provided
9723220|NCT05036980|Experimental|0.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 0.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
9723221|NCT05036980|Experimental|1.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 1.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
9723222|NCT05036980|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
9723223|NCT05029622|Experimental|Triptorelin formulation for Intramuscular injection (IM).|
9723224|NCT05024097|Experimental|Radiation therapy and etrumadenant (AB928)|Enrolled patients will receive Radiation therapy of 25 Gy in 5 fractions along with etrumadenant 150mg oral drug taken once daily. this will then be followed by 9 cycles of FOLFOX in combination of etrumadenant and zimberelimab investigational drugs.
10197132|NCT04939532|Active Comparator|Text-Messaging (TM)|Population health management intervention that analyzes electronic health record data to automatically identify participants with high risk for either infection or severe disease and proactivity reaches those participants via text message for testing needs (as advised by state and/or federal guidelines) and testing recommendation when applicable. This is a bi-directional text messaging system.
9723225|NCT05014646|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9723226|NCT05011513|Experimental|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
9723227|NCT05011513|Placebo Comparator|Placebo|Orally administered Placebo
9723228|NCT05007080|Experimental|Part 1: Group 1 (Dose Selection Cohort): Ad26.COV2.S Dose Level 1 (Lower Volume): 1-Dose Regimen|Participants will receive 1 dose of Ad26.COV2.S at dose level 1 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
9723229|NCT05007080|Experimental|Part 1: Group 2 (Dose Selection Cohort): Ad26.COV2.S Dose Level 2: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
9723230|NCT05007080|Experimental|Part 1: Group 3 (Dose Selection Cohort): Ad26.COV2.S Dose Level 3: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
9723231|NCT05007080|Experimental|Part 1: Group 4 (Dose Selection Cohort): Ad26.COV2.S Dose Level 1: 2-Dose Regimen|Participants will receive 2-dose of Ad26.COV2.S at dose level 1 on Day 1 and 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at 12 months after the last vaccination (vaccination 2) with active vaccine at dose level based on the Independent Data Monitoring Committee (IDMC) and sponsor review of safety and immunogenicity data generated post-dose 1 and 2.
9723232|NCT05007080|Experimental|Part 1: Group 5 (Dose Selection Cohort): Ad26.COV2.S Dose Level 2: 2-Dose Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at 12 months after the last vaccination (vaccination 2) with active vaccine at dose level based on the IDMC and sponsor review of safety and immunogenicity data generated post-dose 1 and 2.
9723233|NCT05007080|Experimental|Part 1: Group 6 (Dose Selection Cohort): Ad26.COV2.S Dose Level 3: 2-Dose Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at 12 months after the last vaccination (vaccination 2) with active vaccine at dose level based on the IDMC and sponsor review of safety and immunogenicity data generated post-dose 1 and 2.
9723234|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 1 [Standard or Lower Volume])|Participants will receive 1-dose of Ad26.COV2.S at dose level 1 (standard or lower volume) on Day 1 (based on the IDMC and sponsor review of Day 28 and Day 85 data from Part 1). After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
9723235|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1 (based on the IDMC and sponsor review of Day 28 and Day 85 data from Part 1). After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
9723236|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1 (based on the IDMC and sponsor review of Day 28 and Day 85 data from Part 1). After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
10197133|NCT04939532|Active Comparator|Text-Messaging plus Patient Navigation (TM+PN)|Population health management intervention that includes the same bi-directional text-messaging system as Arm 1 (the text messaging condition) with the addition of patient navigation. Patient navigation includes real-time assistance from a community health worker to address barriers, provide motivation, and assist with logistics of COIVD testing.
9723237|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 2): 2-Doses Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57 (based on the IDMC and sponsor review of Day 28 and Day 85 data from Part 1). After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
9723238|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Dose Level 3): 2-Doses Regimen|Participants will receive 2 doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57 (based on the IDMC and sponsor review of Day 28 and Day 85 data from Part 1). After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
10197134|NCT04937153|Experimental|Single arm|GEN1046 open label, single arm trial where GEN1046 will be administered
10197135|NCT04931667|Experimental|0.07 mg Lorecivivint|One intra-articular injection of 0.07 mg Lorecivivint in 2 ml vehicle in one or both knees as clinically indicated. Bilateral injection of 0.07 mg LOR are allowed.
10197136|NCT04928482|Experimental|27 session group|Participants in this arm will receive 27 sessions of backward walking training.
10197137|NCT04928482|Active Comparator|18 session group|Participants in this arm will receive 18 sessions of backward walking training.
10197138|NCT04926623|Experimental|CGM with Structured Education|CGM with Structured Education
10197139|NCT04926623|Active Comparator|CGM with Standard Education|CGM with Standard Education
10197140|NCT04926623|Active Comparator|SMBG with Standard Education|SMBG with Standard Education
10197141|NCT04924712||Initial disease : nephrotic INS vs INS in remission|"25 nephrotic INS patients in primary visit: harvesting of 25 ml supplementary blood, urine and feces. No intervention, no treatment administration other than usual/routine INS treatment.~vs. the same 25 patient in INS remission : harvesting of 25 ml supplementary blood, urine and feces at the remission visit. No intervention."
9723239|NCT05007080|Experimental|Part 2 (Dose Expansion Cohort): Ad26.COV2.S (Selected dose level [SDL])|Participants will receive 2 doses of SDL on Day 1 and Day 57 (based on the IDMC and sponsor review of Day 28 and Day 85 data from Part 1). After 6 months of first vaccination, participants may receive 1 or 2 doses of selected formulation.
9723240|NCT05006352|Experimental|DNL343 (High Dose)|
9723241|NCT05006352|Experimental|DNL343 (Low Dose)|
9723242|NCT05006352|Placebo Comparator|Placebo|
9723243|NCT05004740||Lactating birthing persons delivering at Sinai Health System or from the general population|
9723244|NCT05003583|Experimental|Experimental Condition|Speaking while viewing images with negative and neutral valence
9723245|NCT04999111|Experimental|Cohort 1: Group 1: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single intramuscular (IM) injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
9723246|NCT04999111|Experimental|Cohort 1: Group 2: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
9723247|NCT04999111|Experimental|Cohort 1: Group 3: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with Ad26.COV2.S will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
9723248|NCT04999111|Experimental|Cohort 2: Group 4: Ad26.COV2.S (Dose Level 1)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 1 on Day 1.
9723249|NCT04999111|Experimental|Cohort 2: Group 5: Ad26.COV2.S (Dose Level 2)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 2 on Day 1.
9723250|NCT04999111|Experimental|Cohort 2: Group 6: Ad26.COV2.S (Dose Level 3)|Participants who have previously received primary vaccination with BNT162b2 will receive single IM injection of Ad26.COV2.S booster vaccination at dose level 3 on Day 1.
9723251|NCT04998331||Participants With CD30-positive Lymphoma|All participants diagnosed with relapsed/refractory (R/R) cHL, CTCL (mycosis fungoides [MF] and cutaneous anaplastic large cell lymphoma [pcALCL]) and sALCL with CD30 positive, and who have previously achieved a CR or PR with BV treatment and subsequently experienced disease progression/relapse and were administered BV retreatment will be observed retrospectively from their initiation of BV treatment until participant's inclusion date in the study or until treatment discontinuation due to toxicities or any cause. All study data will be collected retrospectively from the medical records.
10197142|NCT04924712||Post-transplantation recurrence : recurring vs non-recurring INS|"25 INS patients recurring the initial disease after renal transplantation in post-recurrence visit: harvesting of 25 ml supplementary blood, urine and feces. No intervention, no treatment administration other than usual/routine INS treatment.~vs. the 25 others INS patient non recurring after renal transplanatation: harvesting of 25 ml supplementary blood, urine and feces. No intervention."
9723252|NCT04996719|Experimental|Rapamycin|find safe doses for patients who have heart failure with preserved ejection fraction
9723253|NCT04991753|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 10 along with standard-of-care background therapy.
9723254|NCT04991753|Experimental|Group 2: Nipocalimab|Participants will receive nipocalimab IV q2w through Week 10 along with standard-of-care background therapy.
9723255|NCT04989517|Experimental|AT193|Topical applied daily
9723256|NCT04989517|Placebo Comparator|Placebo|Topical applied daily
9723257|NCT04989387|Experimental|Treatment Group A Dose Escalation and Expansion|INCA00186 will be administered as monotherapy every 2 or every 4 weeks.
9723258|NCT04989387|Experimental|Treatment Group B1 Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab. INCA00186 will be administered every 2 or 4 weeks and retifanlimab will be administered every 4 weeks.
9723259|NCT04989387|Experimental|Treatment Group B2 Dose Escalation and Expansion|INCA00186 will be administered in combination with INCB106385. INCA00186 will be administered every 2 or 4 weeks and INCB106385 will be administered once or twice daily.
9723260|NCT04989387|Experimental|Treatment Group C Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab and INCB106385. INCA00186 will be administered every 2 to 4 weeks, retifanlimab every 4 weeks and INCB106385 once or twice daily.
10197143|NCT04922021|Experimental|LEO 138558|Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
10197144|NCT04922021|Placebo Comparator|Placebo|Participants will receive injections of placebo from Week 0 (baseline) to Week 16 (end of treatment).
10197145|NCT04921215|Active Comparator|0 hours of sleep restriction|Bedtime will be the same as baseline.
9723261|NCT04982393||Patients with PH1|Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
9723262|NCT04978740|Experimental|Participants affected by cutaneous and systemic mastocytosis|Participants affected by cutaneous and systemic mastocytosis with or without eye disabilities
9780613|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Lower Dose|
10197146|NCT04921215|Experimental|1.5 hours of sleep restriction|Bedtime will be 1.5 hours later than baseline.
10197147|NCT04921215|Experimental|3 hours of sleep restriction|Bedtime will be 3 hours later than baseline.
10197148|NCT04921215|Experimental|4.5 hours of sleep restriction|Bedtime will be 4.5 hours later than baseline.
10197149|NCT04921098|Experimental|Refractory glaucoma|
10197150|NCT04919811|Experimental|Taletrectinib|Single-arm trial whereby all consented, enrolled, eligible patients receive taletrectinib
10197151|NCT04913441|Experimental|Routine physical therapy|"Patients in this group will get every session of 30 min 3 times per week on alternative days for 12 weeks~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~ROM exercises repeats 5 times for 10 minutes"
10197152|NCT04913441|Experimental|Manual physical therapy with routine physical therapy|"Patients in group B will get every session 30 minutes 3 times per week on alternative days~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~Mulligan technique (NAGS and SNAGS) will repeats 5 times for 10 minutes"
9980854|NCT01396109|Active Comparator|Group II|Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with Mesh
9980855|NCT01396122|Experimental|PROSIMA group|Reconstructive surgeries with GYNECARE PROSIMA* were performed in all patients.
9723265|NCT04977583|Experimental|Screening|Participants in this arm will be screened for unmet social needs and receive a post card that includes a list of generic VA crisis and homeless hotlines.
9723266|NCT04977583|Experimental|Awareness|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, and receive a Resource Sheet tailored to the unmet needs identified in the unmet need screen. The Resource Sheet will include the names of available resources within the VA and/or local community that can help to address the identified need(s) and contact information and hours of operation.
9723267|NCT04977583|Experimental|Assistance|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, receive a tailored Resource Sheet, and be offered assistance from a Social Worker. If accepted, the SW will contact the participant and work with them over a period of 8 weeks to help facilitate their connection to resources than can help to address the unmet need(s) identified in the unmet need screen.
9723268|NCT04973566|Experimental|Part 1: Etanercept and Nipocalimab|Participants will receive a single subcutaneous (SC) dose of etanercept on Day 1 in Period 1 followed by single intravenous (IV) infusion of nipocalimab on Day 29, SC administration of etanercept followed by an IV infusion of nipocalimab on Day 43 and then a single dose of nipocalimab IV infusion on Day 57 in Period 2 of Part 1. There will be a wash-out period of 28 days between Day 1 of Period 1 and Day 29 of Period 2 in Part 1.
10197153|NCT04913441|Experimental|Stretching physical therapy with routine physical therapy|"Patients in this group will get every session 30 minutes 3 times per week on alternative days~TENS and hot pack for 15 minutes~Ultra sound for 5 minutes~Stretching exercises repeats 5 times for 10 minutes"
10197154|NCT04912843|Experimental|NR082 injection|0.5E9 viral genomes (vg), 0.05 mL eye/dose ,single-dose,only one eye per subject; 1.5E9 viral genomes (vg), 0.05 mL eye/dose single-dose,only one eye per subject; 4.5E9 viral genomes (vg) , 0.05 mL eye/dose single-dose,only one eye per subject Part 1: Dose-Finding；The recommended dose (safe and effective dose) of the Part 2 study will be determined jointly by the SRC, IDMC, sponsor and the drug regulatory authority after the interim analysis in Part 1 is completed.
9723269|NCT04973566|Experimental|Part 2 (Cohort 1): Nipocalimab|Participants will receive a single IV infusion of nipocalimab on Day 1 in Cohort 1 of Part 2.
10197155|NCT04912843|Sham Comparator|sham-injection|Part2.Second Stage: randomized, double-blind, sham-injection control study One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
10197156|NCT04910373|Experimental|Experimental Extensively Hydrolyzed Formula|Administered during food challenge and at home feeding period
9723270|NCT04973566|Experimental|Part 2 (Cohort 2): Nipocalimab and Hydroxychloroquine (HCQ)|Participants will receive a single oral dose of HCQ film-coated tablets once daily from Day 1 to Day 22 and a single IV infusion of nipocalimab on Day 8 in Cohort 2 of Part 2.
10197157|NCT04910373|Placebo Comparator|Placebo Extensively Hydrolyzed Formula|Administered during food challenge
10197158|NCT04909229|Experimental|PEAR-003b PDT Intervention|Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
10197159|NCT04909229|Placebo Comparator|Control Arm|Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
10197160|NCT04905173|Experimental|Hypertrophic Cardiomyopathy|Subjects with a documented diagnosis of hypertrophic cardiomyopathy (HCM) will have an echocardiogram at rest followed by an echocardiogram with Valsalva maneuver as part of regular care. If these tests show no severe obstruction, subjects will continue with both squat-to-stand and amyl nitrite.
10197161|NCT04902131|Experimental|MENOPUR pen|
10197162|NCT04902131|Active Comparator|MENOPUR powder|
10197163|NCT04899622|Experimental|Combined MBSR and exercise|Group A will take part in live online weekly mindfulness sessions based on the Mindfulness Based Stress Reduction (MBSR) programme, in addition to supervised exercise classes.
10197164|NCT04899622|Active Comparator|Online Self-Management Guide|Group B will be invited to interact with an online self-management guide accessible in the members area of the study website.
10197165|NCT04897672||case|case: Children aged 6 to 17 years old reffered to the pediatric cardiology consultation with a chronic renal disease and renal insufficiency
9723271|NCT04968912|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
9723272|NCT04968912|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
9723273|NCT04968912|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
9980856|NCT01396135|Experimental|Single dosing|Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
9980857|NCT01396135|Experimental|Multiple dosing|Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
9723276|NCT04963738|Experimental|Group 1: JNJ-73763989|Participants with moderate renal impairment will receive a single subcutaneous (SC) injection of JNJ-73763989 on Day 1.
9980858|NCT01396174|Active Comparator|Standard Online Support Group|
10197166|NCT04897672||control|control : Children aged 6 to 17 years old reffered to the pediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography
9723277|NCT04963738|Experimental|Group 2: JNJ-73763989|Participants with severe renal impairment or end-stage renal disease (ESRD) will receive a single SC injection of JNJ-73763989 on Day 1.
9723278|NCT04963738|Experimental|Group 3: JNJ-73763989|Participants with normal renal function will receive a single SC injection of JNJ-73763989 on Day 1.
10197167|NCT04896866|Experimental|Antimicrobial stewardship|Antimicrobial stewardship prospective audit and feedback on physicians attending to patients admitted with community-acquired COVID-19 pneumonia to beds randomized to antimicrobial stewardship intervention.
10197168|NCT04896866|No Intervention|No antimicrobial stewardship|No antimicrobial stewardship prospective audit and feedback.
10197169|NCT04896606|Experimental|SARS-CoV-2 CTLS + Standard of Care|Patients will get family donor derived SARS-CoV-2 cytotoxic t-lymphocytes up to 5 times every 2 weeks along with Standard of care of COVID-19.
9723279|NCT04961541|Experimental|Group A - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
9723280|NCT04961541|Experimental|Group B -ICC Vaccine Formulation|2 doses of Formulation 2. 1 dose each on Days 0 and Day 56.
9723281|NCT04961541|Experimental|Group C - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
10197170|NCT04896606|Active Comparator|Standard of Care Only|Patients will NOT received COVID CTLs but will get standard of care.
9723282|NCT04961541|Experimental|Group D - ICC Vaccine Formulation|2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
9723283|NCT04961541|Experimental|Group E - ICC Vaccine Formulation|2 doses of Formulation 4. 1 dose each on Days 0 and Day 56.
9723284|NCT04961541|Experimental|Group F- ICC Vaccine Formulation|2 doses of Formulation 5. 1 dose each on Days 0 and Day 56.
9723285|NCT04961541|Experimental|Group G- ICC Vaccine Formulation|2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.
9723286|NCT04961541|Experimental|Group H- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
9723287|NCT04961541|Experimental|Group I- ICC Vaccine Formulation|2 doses of Formulation 8. 1 dose each on Days 0 and Day 56.
9723288|NCT04961541|Experimental|Group J -ICC Vaccine Formulation|2 doses of Formulation 9. 1 dose each on Days 0 and Day 56.
9723289|NCT04961541|Experimental|Group K - ICC Vaccine Formulation|2 doses of Formulation 10. 1 dose each on Days 0 and Day 56.
9723290|NCT04961541|Experimental|Group L - ICC Vaccine Formulation|2 doses of Formulation 11. 1 dose each on Days 0 and Day 56.
10197171|NCT04893512|Experimental|Orally administered CoV2-OGEN1- 2 dose schedule|50mcg,100mcg and 200mcg will be tested as single oral dose on day 1 and day 15. The dose will be in the form of oral suspension.
10197172|NCT04893291|Active Comparator|Everolimus Eluting Stent|
10197173|NCT04893291|Experimental|Magic Touch Sirolimus Coated Balloon|
10197174|NCT04889599|Experimental|BH009 (Docetaxel Injection)|Patients will receive single dose BH009 75 mg/m2, as a 1-hour IV infusion.
9723291|NCT04961541|Experimental|Group M -ICC Vaccine Formulation|2 doses of Formulation 12. 1 dose each on Days 0 and Day 56.
9723292|NCT04961541|Experimental|Group N- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
9723293|NCT04961541|Experimental|Group O - qNIV with Matrix-M1 adjuvant|2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70.
9723294|NCT04961541|Experimental|Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant|2 doses of Formulation 14. 1 dose each on Days 0 and Day 56.
9723295|NCT04956627|Experimental|BMS-986166|
9723296|NCT04956627|Experimental|BMS-986166 + Itraconazole|
9723297|NCT04956627|Experimental|BMS-986166 + Phenytoin|
9723298|NCT04956627|Experimental|BMS-986166 + Gemfibrozil|
9723299|NCT04951622|Experimental|Nipocalimab|"Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.~Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion from OLE Day 1 to 24 weeks. Participants who are stable on the q2w dosing regimen can be transitioned to a dosing regimen every 4 weeks (q4w) during OLE phase."
9723300|NCT04951622|Placebo Comparator|Placebo|Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.
9723301|NCT04938986|Experimental|IMMUNOSCORE®|
9723302|NCT04931615|Placebo Comparator|without ARTISS|Surgery performed without active comparative
9723303|NCT04931615|Active Comparator|with ARTISS|Surgery performed with active comparative
9723304|NCT04931095|Placebo Comparator|Placebo cannabis + placebo alcohol|Participants administer oral cannabis containing 0mg THC in combination with a placebo alcohol drink.
9723305|NCT04931095|Experimental|low dose cannabis with placebo alcohol|Participants administer oral cannabis containing 10mg THC in combination with a placebo alcohol drink.
9723306|NCT04931095|Experimental|high dose cannabis with placebo alcohol|Participants administer oral cannabis containing 25mg THC in combination with a placebo alcohol drink.
9723307|NCT04931095|Experimental|low dose cannabis with low dose alcohol|Participants administer oral cannabis containing 10mg THC in combination with an alcohol drink (0.05 percent BAC).
9723308|NCT04931095|Experimental|high dose cannabis with low dose alcohol|Participants administer oral cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).
9723309|NCT04931095|Experimental|Placebo cannabis + low dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).
9780614|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Approved Dose|
9780615|NCT01127581|Experimental|MVI 200|MVI 200 mcg vaginal insert
10197175|NCT04889599|Active Comparator|Docetaxel Injection|Patients will receive single dose Docetaxel Injection 75 mg/m2, as a 1-hour IV infusion.
9723310|NCT04931095|Experimental|Placebo cannabis + high dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).
10197176|NCT04886141|No Intervention|Standard of Care treatment with Scales|Patients will receive the standard of care restorative procedure with the addition of the FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale to create a baseline data of pain to compare with the experimental group.
9723311|NCT04920084|Experimental|Plant-based meals|Patients who will be administered a whole-foods plant-based diet for 12 weeks with nutrition counselling for 24 weeks.Participants will be asked to complete a survey via MSK Engage and a notification will be sent via email notification.
9723312|NCT04909593|Experimental|Spinal Cord Stimulation|SCS trial systems including external trial stimulators, lead(s)/extensions(s), and operating room (OR) cable(s)/extender(s) and optional sensor.
9723313|NCT04908722|Experimental|Group 1: Ad26.COV2.S Dose Level 1|Participants in the main study and sub study will receive intramuscular (IM) injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 1 on Days 1 and 57.
9723314|NCT04908722|Experimental|Group 2: Ad26.COV2.S Dose Level 2|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 2 on Days 1 and 57 in the main study.
9723315|NCT04908722|Experimental|Group 3: Ad26.COV2.S Dose Level 3|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 3 on Days 1 and 57.
9723316|NCT04908722|Experimental|Group 4: Ad26.COV2.S Dose Level 4|Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 4 on Days 1 and 57 in the main study.
9723317|NCT04908722|Experimental|Group 5: Ad26.COV2.S Dose Level 5|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 5 on Days 1 and 57.
10197177|NCT04886141|Experimental|Virtual Reality Headset|Instead of receiving the Nitrous that would be used to help calm patients during the standard of care restorative procedure. Patients will be given a the Oculus Quest 2 Virtual realty headset and a video will be played. The FLACC pain scale, Wong Baker FACES Pain rating and Houpt scale data will be collected to compare the patients pain level between the two groups.
10197178|NCT04885218|Experimental|Cohort 1：SHR-1209 / placebo|
9723318|NCT04908722|Experimental|Group 6: Ad26.COV2.S Dose Level 6|Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 6 on Days 1 and 57.
9723319|NCT04907968|Experimental|Dose Escalation - Module A (UPGRADE-A)|XMT-1536 (Upifitabmab Rilsodotin) + carboplatin is administered in groups of patients who will receive doses of XMT-1536 that increase over time.
9723320|NCT04907968|Experimental|Dose Expansion - Module A (UPGRADE-A)|Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, a new group of patients will receive XMT-1536 (Upifitamab Rilsodotin) at this fixed-dose + carboplatin.
9723321|NCT04906980|Experimental|JNJ-64281802|Participant will receive 2 initial loading doses of JNJ-64281802, 800 milligram (mg) every 8 hours (q8h) followed by 4 doses of 400 mg q8h then 2 single doses of 400 mg on Day 4 and Day 5.
9723322|NCT04906980|Placebo Comparator|Placebo|Participants will receive oral dose of matching placebo q8h and once daily on Day 4 and Day 5.
9723323|NCT04899336|Experimental|Parts 1 and 2: ExPEC9V|Participants of Part 1 and Part 2 will receive a single intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) on Day 1.
9723324|NCT04899336|Placebo Comparator|Parts 1 and 2: Placebo|Participants of Part 1 and Part 2 will receive a single IM injection of matching placebo on Day 1.
9723325|NCT04899024|Experimental|PARTI and CM (Contingency Management)|The PARTI intervention will be delivered in five individual sessions during a 12-week contingency management protocol for PrEP adherence
9723326|NCT04899024|Active Comparator|Attention-Control and CM (Contingency Management)|The attention-control condition will consist of five individual sessions where participants complete self-report measures and neutral writing exercises during a 12-week contingency management protocol for PrEP adherence
9723327|NCT04895553||Cohort Apixaban|"patients who have switched from low molecular weight heparin (LMWH) to apixaban at the recommended dose of the treating physician.~FDA approved dose 10 mg twice daily (BID) for 7 days followed by 5 mg PO BID OR physician prescribed dose"
9723328|NCT04895501|Active Comparator|running with stiff shoes|21 km of running with stiff shoes followed by a time-to-exhaustion run.
9723329|NCT04895501|Experimental|running flexible shoes|21 km of running flexible shoes followed by a time-to-exhaustion run.
9723330|NCT04885452||Patients treated with casirivimab/imdevimab according to the ATU protocol|
9723331|NCT04885452||Patients treated with bamlanivimab/etesevimab according to the ATU protocol|
9723332|NCT04885452||Patients treated with Xevudy according to the authorisation for early access (AAP) protocol|
10197179|NCT04885218|Experimental|Cohort 2：SHR-1209 /placebo|
9723333|NCT04885452||Patients treated with Paxlovid according to the authorisation for early access (AAP) protocol|
9723334|NCT04883905||Patients with AHP|Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.
9723335|NCT04883619|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) from Week 0 through Week 50 along with standard-of-care treatment of mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved complete renal response (CRR) may have the option to participate in the long-term extension (LTE) until unblinding of the study.
9723336|NCT04883619|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
9780616|NCT01127581|Active Comparator|Dinoprostone Vaginal Insert (DVI)|10 mg Dinoprostone vaginal insert
9980859|NCT01396174|Experimental|Prosocial Online Support Group|
10197180|NCT04885218|Experimental|Cohort 3：SHR-1209 / placebo|
10197181|NCT04883814|Experimental|Initial Staging|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive locally advanced breast cancer
10197182|NCT04883814|Experimental|Suspected disease recurrence|FES PET/CT will be compared to CT/bone scan for detection of unsuspected distant metastases in patients with ER-positive breast cancer and suspected disease recurrence
10197183|NCT04877587|Experimental|Ascorbate in combination with Gemcitabine|"The study will begin with a safety run-in.~A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. Gemcitabine is administered following standard fixed dose infusion practice adopted at The University of Iowa Hospitals & Clinics. Ascorbate is infused prior to gemcitabine. Cycles are 28 days. Patients will be treated for a total of 6 cycles and assessed every 2 cycles for disease response."
10197184|NCT04875455|Experimental|Experimental: POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|PhysIOL POD F GF: 50 (bilateral implantation) PhysIOL POD F: 50 (bilateral implantation) Alcon PanOptix: 20 (bilateral implantation) In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
9723337|NCT04883619|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
9723338|NCT04882878|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids [GCs]).
9723339|NCT04882878|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
9723340|NCT04882878|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
9723341|NCT04877691|Experimental|Anifrolumab|Solution for injection in aPFS
9723342|NCT04877691|Placebo Comparator|Placebo|Solution for injection in aPFS
9723343|NCT04873362|Active Comparator|Arm A: Placebo + Trastuzumab Emtansine|Participants will receive an intravenous (IV) infusion of placebo prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
9723344|NCT04873362|Experimental|Arm B: Atezolizumab + Trastuzumab Emtansine|Participants will receive an IV infusion of atezolizumab prior to the IV infusion of trastuzumab emtansine on Day 1 of each 21-day cycle for a total of 14 cycles.
9723345|NCT04852822||Observational (biospecimen collection, medical record review)|"For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical records are also reviewed.~For patients enrolled after vaccination, they will undergo collection of blood samples at 1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose."
9723346|NCT04851873|Experimental|OAV101|Participants will receive a single IV dose administration of OAV101
9723347|NCT04851483|Experimental|Group 1_BAY2328065 _male participants|Approximately 6 participants will be randomly assigned to one of the 2 study intervention sequences (Group 1 or Group 2).
9723348|NCT04851483|Experimental|Group 2_BAY2328065 _male participants|Approximately 6 participants will be randomly assigned to one of the 2 study intervention sequences (Group 1 or Group 2).
9723349|NCT04851483|Experimental|Group 3_BAY2328065 _male participants|Approximately 8 participants will be assigned to the study intervention with one fixed sequence.
9723350|NCT04851483|Experimental|Group 4_BAY2328065 _female participants|Approximately 9 participants will be randomly assigned to receive BAY2328065.
9723351|NCT04851483|Placebo Comparator|Group 4_Placebo _female participants|Approximately 3 participants will be randomly assigned to receive placebo.
9723352|NCT04848558|Experimental|Part 1: Single Dose Cohorts|Participants will receive subcutaneous (SC) injection or intravenous (IV) infusion of nipocalimab or placebo in single ascending doses on Day 1 in Cohorts 1-6 and SC administration in optional Cohorts 7-8.
9723353|NCT04848558|Experimental|Part 2: Multiple Dose Cohorts|Participants will receive up to 4 weekly SC injections of nipocalimab or placebo on Days 1, 8, 15, and 22 in Cohort 1 or 4 biweekly SC injections on Days 1, 15, 29, and 43 in optional Cohort 2.
9723354|NCT04805593|Experimental|WaveLight EX500 excimer laser system|Laser-assisted in situ keratomileusis (LASIK) surgery using the WaveLight EX500 excimer laser system
9723357|NCT04777331|Experimental|Prasinezumab|Participants will receive an IV infusion of prasinezumab every 4 weeks (Q4W).
9723358|NCT04777331|Placebo Comparator|Placebo|Participants will receive placebo as an IV infusion Q4W.
9723359|NCT04771416|Experimental|Part 1: Dose Escalation Cohorts designed to identify the optimal dose of PBKR03|"Cohort 1: Subjects aged >4 to <9 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 2: Subjects aged >4 to <9 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 3: Subjects aged >1 to <4 months Drug: PBKR03 1.5 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~Cohort 4: Subjects aged >1 to <4 months Drug: PBKR03 5.0 x 10^11 GC/g* Single dose of PBKR03, via intra cisterna magna~*GC/g: genome copiesy per gram of estimated brain weight"
9723360|NCT04771416|Experimental|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBKR03|"Cohort 5: Subjects aged >1 to <9 months Drug: PBKR03 Single dose of PBKR03, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1.~*GC/g: genome copiesy per gram of estimated brain weight"
9723361|NCT04770935|Experimental|efanesoctocog alfa (BIVV001)|A single IV dose of BIVV001 will be administered to each patient
9723362|NCT04763200|Experimental|Impella Arm|Impella CP® or Impella 2.5 placement prior to high-risk PCI
9723363|NCT04763200|Active Comparator|Control Arm|Subjects randomized to the Control group will be treated per standard of care PCI with or without an intra-aortic balloon pump (IABP).
9723364|NCT04754334|Placebo Comparator|Placebo|placebo dosed QD
9723365|NCT04754334|Experimental|ORMD-0801|ORMD-0801 8 mg QD
9723366|NCT04754217||Group 1|VAVGJ
9723367|NCT04754217||Group 2|CAVGJ
10197185|NCT04874376|Experimental|IOL retrospective data collection|Experimental arm: Premium Monofocal intraocular lens.
10197186|NCT04870047|Experimental|p64 MW HPC Flow Diverter + SAPT|
10197187|NCT04870047|Experimental|p64 MW Flow Diverter + DAPT|
10197188|NCT04860947||MS patients|
10197189|NCT04855396||Patients with Severe Traumatic Brain Injury|Participants will be enrolled in the HOBIT trial
10197190|NCT04842643|Experimental|Epoch 2 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 50 and 200 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once a week until the study drug becomes commercially available (approximately 3 years). All participants of this arm will have assigned Epoch 2 of previous study (TAK-664-3001). The dose of IGSC will be established in previous study.
9723368|NCT04753164|Experimental|100 mg twice daily (b.i.d.) ACT-539313|
9723369|NCT04753164|Placebo Comparator|Placebo|
9723370|NCT04739423|Experimental|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
9723371|NCT04739423|Experimental|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 co-administered with matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
9780617|NCT01127607|Experimental|stimulant medication|blinded lisdexamfetamine at the optimal dose for the individual participant as previously determined during the med optimization portion of the study
9780618|NCT01127607|Placebo Comparator|placebo pill|placebo medication identical in appearance to active med
9780619|NCT01127633|Experimental|Solanezumab|
9780620|NCT01127633|Placebo Comparator|Placebo|
9780621|NCT01127646|Experimental|Atomoxetine|Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 25-80 mg of atomoxetine orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 25-80 mg of atomoxetine orally, once daily for 1-5 days.
9780622|NCT01127646|Active Comparator|Osmotic-release oral system methylphenidate|Participants received 18-54 mg of osmotic-release oral system (OROS) methylphenidate orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 1-5 days.
9780623|NCT01127659|Active Comparator|diabetes with HH-active|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
9780624|NCT01127659|No Intervention|diabetes with normal testosterone|Eugonadal subjects with diabetes. They will not be treated
9780625|NCT01127659|Active Comparator|obese with HH-active|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
9780626|NCT01127659|No Intervention|obese with normal testosterone|Eugonadal non-diabetic obese subjects. They will not be treated
9780627|NCT01127659|Placebo Comparator|Diabetes with HH-placebo|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
9780628|NCT01127659|Placebo Comparator|Obese with HH-placebo|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.
9780629|NCT01127737|Placebo Comparator|Control|
9780630|NCT01127737|Active Comparator|Intervention|Educational intervention consisting of a mnemonic and a workbook used by kidney transplant recipients (KTRs) to assist with early detection of SCCs.
9780631|NCT01127763|Experimental|RAD001+carboplatin|Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.
9780632|NCT01127893|Experimental|Tanezumab 10 mg|
9780633|NCT01127893|Experimental|Tanezumab 5 mg|
9780634|NCT01127893|Experimental|Tanezumab 2.5 mg|
9780635|NCT01128049|Active Comparator|Normal Patient Population|Non-Dry Eye patient population (intervention remains the same across all arms)
9780636|NCT01128049|Active Comparator|MGD Patient Population|Meibomium Gland Dysfunction population(intervention remains the same across all arms)
9780637|NCT01128049|Active Comparator|ADDE Population|Aqueous Deficient Dry Eye population(intervention remains the same across all arms)
9780638|NCT01128153|Experimental|Saxagliptin 5 mg once daily|
9780639|NCT01128153|Placebo Comparator|Placebo once daily|
9780640|NCT01128179|Experimental|Lanthanum carbonate|
9780641|NCT01128179|Placebo Comparator|Placebo|
9780642|NCT01128192|Experimental|Pasireotide 600 µg sc bid|n=19. Pasireotide 600 µg sc bid
9780643|NCT01128192|Experimental|Pasireotide 900 µg sc bid|n=19. Pasireotide 900 µg sc bid
9780644|NCT01128192|Experimental|Pasireotide 1200 µg sc bid|n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.
9780645|NCT01128244|Experimental|Vitamin B6 Effects in OC Users|"All subjects will be given an infusion of labeled serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.~The results from analysis of vitamin B6 and these amino acids in blood will provide us with specific measurements of the rates of two aspects of metabolism (Primary Outcomes 1 and 2) and specific measurements of vitamin B6 nutritional status (Primary Outcomes 3 and 4)."
9780646|NCT01128270|Experimental|1A: Chloral Hydrate and DCA: Env|Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
9723372|NCT04726514|Experimental|SleepFlex Treatment|
10197191|NCT04842643|Experimental|Epoch 3 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|"Participants will receive between 100 and 400 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once every 2 weeks until the study drug becomes commercially available (approximately 3 years). All participants of this arm will have assigned Epoch 3 of previous study (TAK-664-3001).The dose of IGSC will be established in previous study (TAK-664-3001).~For participants who discontinue Epoch 3 and enter Study TAK-664-3002, the dose regimen will be determined on a case-by-case basis."
10197192|NCT04842422|Experimental|Earliest Stage Treatment of Aktinic Keratosis|
10197193|NCT04841304||Patients receiving hemodialysis with diabetes|Patients receiving chronic hemodialysis with a diagnose of Type 1 diabetes or Type 2 diabetes (diagnosed according to the criteria of the World Health Organization) and receiving glucose-lowering treatment
10197194|NCT04841304||Patients receiving hemodialysis without diabetes|Patients receiving chronic hemodialysis without diabetes (no known diagnosis of diabetes, and HbA1c < 48 mmol/mol at inclusion)
10197195|NCT04840641|No Intervention|Baseline|The investigators measure the baseline of flucloxacillin and cocktaildrugs.
10197196|NCT04840641|Experimental|Flucloxacillin treatment|The investigators measure the concentration of flucloxacillin after 9 and 27 days and the concentration of cocktaildrugs after 10 and 28 days.
10197197|NCT04838223||Neuropathic Corneal Pain with Ocular Surface Discomfort|Participants diagnosed with neuropathic corneal pain with ocular surface discomfort
9723373|NCT04722575|Experimental|ARM A|"Arm A BRAF mutated patients. Over a period of 6 weeks (1) + (2):~Vemurafenib 960 mg bid p.o. from week 1 to week 6.~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
9723374|NCT04722575|Experimental|ARM B|"Arm B BRAF mutated patients. Over a period of 6 weeks (1) + (2) + (3):~Vemurafenib 720 mg bid p.o. from week 1 to week 6.~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6. Week 4 off.~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 4 and day 1 of week 7).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
9723375|NCT04722575|Experimental|ARM C|"Arm C BRAF WT patients. Over a period of six weeks (1) + (2):~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6,~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 1 and day 1 of week 4).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
9723376|NCT04722055||Study group|Single arm of continuously enrolled participants. All eligible participants will be included in the study according to the inclusion criteria. In addition to giving stool samples for multigene methylation test, eligible participants need to undergo colonoscopy examination and have their biopsies taken when necessary (gold standard).
9723377|NCT04720664|Experimental|oral SM-88|SM-88 taken with three conditioning agents: methoxsalen, phenytoin, and sirolimus
9723378|NCT04717375|Experimental|BND-22 Dose Escalation (Sub-Part 1A)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 will be administered intravenously (IV), every 2 weeks (Q2W)."
9723379|NCT04717375|Experimental|BND-22 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W)."
9723380|NCT04717375|Experimental|BND-22 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. BND-22 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W)."
9723381|NCT04717375|Experimental|BND-22 Dose Expansion (Part 2)|Will include three expansion cohorts enrolling patients with advanced stage squamous cell carcinoma of the head and neck, gastric or gastroesophageal junction adenocarcinoma, and non-small cell lung cancer. Enrollment will start after the RP2D of BND-22 has been established. BND-22 will be administered intravenously (IV), every 2 weeks (Q2W).
9980860|NCT01396200|Experimental|Hydroxychloroquine (Cohort B)|Infusional cyclophosphamide 300mg/m2/day for 4 days IV and dexamethasone 40mg/day orally or IV for 4 days on days 1 through 4. Hydroxychloroquine oral will be given on days 5 through 28 of cycle 1 and every day of all subsequent cycles (to be given with milk or food at approximately the same time each day)
10197198|NCT04838223||Neuropathic Corneal Pain with Dry Eye Disease|Participants diagnosed with dry eye disease and neuropathic corneal pain
9723382|NCT04713579||Premature infants|Infants born prematurely requiring a stoma for condition such as necrotizing enterocolitis (NEC) or spontaneous intestinal perforation (SIP).
9723383|NCT04713579||Term Infants|Infants born closer to term requiring a stoma e.g. for congenital causes of bowel obstruction such as intestinal atresia, gastroschisis or meconium ileus
9723384|NCT04689048|Other|PET/CT, MRI|In total, three 18F-fluciclovine PET/CT brain scans (pre-, interim-, and post-treatment) will be performed according to the study calendar. Generic name is Axumin and will be administered as an intravenous bolus. May administer diluted or undiluted. The maximum volume of undiluted 18F-fluciclovine is 5 mL. After administration, flush with normal saline to ensure full delivery of the dose.
9723385|NCT04677504|Experimental|Arm A: Atezo+Bev+CisGem, followed by Atezo+Bev|Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
9723386|NCT04677504|Active Comparator|Arm B: Atezo+PBO+CisGem, followed by Atezo+PBO|Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive placebo matching bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
9723387|NCT04671576|Active Comparator|Control Formula|A standard, milk-based, infant formula.
10197199|NCT04838223||NCP or Dry Eye in patients with ocular surface discomfort|Participants diagnosed with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort
10197200|NCT04837378|Experimental|Abdominal Massage Group|Abdominal massage process stage; After the preliminary test data were obtained, the hands were warmed and creamed with vaseline, abdominal massage was applied to the patient in the supine position for 15 minutes. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
10197201|NCT04837378|Experimental|In-bed Exercise Group|In-bed exercise process phase; After the pre-test data were obtained, the patient was applied passive in-bed exercises for approximately 15 minutes in all extremities in the supine position. After 24 hours, gastrointestinal complications and comfort parameters were recorded.
10197202|NCT04837378|No Intervention|Control Group|Control group stage; Gastrointestinal complications and comfort parameters were recorded in this group at the same time as the experimental groups without any intervention.
9723388|NCT04671576|Experimental|Investigational Formula|An organic milk-based infant formula.
9723389|NCT04667104|Experimental|Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)|Participants will receive combination treatment with JNJ-73763989+ nucleos(t)ide analog (NA) for 12 weeks during Treatment Period 1 and the participants who meet the eligibility criteria for PegIFN-alpha2a at Week 12 will receive combination treatment with JNJ-73763989 + NA plus PegIFN-α2a for 12 weeks during Treatment Period 2.
9723390|NCT04661033|Experimental|Isatuximab Part A/Cohort 1|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
9723391|NCT04661033|Experimental|Isatuximab Part A/Cohort 2|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
10204826|NCT04826367|No Intervention|Control Group (CG)|Participants in this group will have a brochure with simple exercises (relaxation exercises involving the upper and lower extremities) in sitting and lying positions. They will be advised to be as active as possible at home and to take mild walks at home. Any supervised exercise program will not apply to participants in the CG. If the participants apply any regular exercise program within 6 weeks, the participants in this group will be excluded from the study.
10204827|NCT04820335|Experimental|Immediate Treatment Group|Participants will complete 7, 60-minute SEMAT sessions over 7 weeks with their group.
9723392|NCT04661033|Experimental|Isatuximab Part A/Cohort 3 (optional)|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
9723393|NCT04661033|Experimental|Isatuximab Part B|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
9723394|NCT04660344|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
9723395|NCT04660344|Placebo Comparator|Arm B: Placebo|Placebo will be administered intravenously on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
9723396|NCT04655586|Experimental|rNAPc2 Higher Dose|loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5
9723397|NCT04655586|Experimental|rNAPc2 Lower Dose|loading dose of 5 ug/kg SC on Day 1 followed by 3 ug/kg SC on Days 3 and 5
9723398|NCT04655586|Active Comparator|Heparin|heparin at either prophylactic or therapeutic doses per Standard of Care at Institution
9723399|NCT04647786|Experimental|Humidified and Augmented gas flows|
9723400|NCT04647786|Experimental|Humidified but not Augmented gas flows|
9723401|NCT04647786|Experimental|Not Humidified but Augmented gas flows|
9723402|NCT04647786|No Intervention|Neither humidified nor augmented gas flows|
9723403|NCT04647786|Experimental|Use of finalised device (SEA CtV) in final phase|
9723404|NCT04647786|No Intervention|Standard care (no SEA CtV)|
9723405|NCT04641975|Experimental|Mirabegron Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily pediatric equivalent dose (PED) low dose of IP (Investigational Product) orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
9723406|NCT04641975|Placebo Comparator|Placebo Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
9723407|NCT04641975|Experimental|Mirabegron Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
9780647|NCT01128270|Experimental|1B: Chloral Hydrate Env dose|Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
9780648|NCT01128270|Experimental|2A: Chloral Hydrate and DCA therapeutic|Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
9723408|NCT04641975|Placebo Comparator|Placebo Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
9723409|NCT04632940|Experimental|Arm A|pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
9723410|NCT04632940|Placebo Comparator|Arm B|matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
9723411|NCT04630145|Experimental|Group A: Bedaquiline (BDQ) + Clarithromycin (CAM) + Ethambutol (EB)|Participants will receive BDQ 400 milligrams (mg) (4*100 mg tablets) once daily (qd) from Week 1-2 (loading phase), BDQ 200 mg (2*100mg tablets) bi-weekly (biw) from Week 3 to 48 (maintenance phase) and CAM 400 mg twice daily (2*200 mg tablets) along with EB 500-750 mg qd or maximum daily dose of 1.0 gram for up to Week 48.
10197203|NCT04837027|Experimental|Aerobic training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
9723412|NCT04630145|Active Comparator|Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB|Participants will receive maximum of 4 capsules of RFP 450 mg daily (or maximum daily dose of 600 mg), CAM 400 mg (2*200 mg tablets) twice a day along with EB 500-750 mg daily followed by 2 capsules of RBT 150 mg once a day (qd) or maximum daily dose of 1.0 gram for up to Week 48.
10204828|NCT04820335|No Intervention|Delayed Treatment Control|Participants will not receive the intervention immediately. After 8 weeks, participants in this arm will complete the SEMAT. This is not a crossover design, because the treatment effects from those in the immediate treatment group can not be taken away.
9723413|NCT04629872|Experimental|endovascular treatment with fingolimod|
9723414|NCT04629872|No Intervention|endovascular treatment without fingolimod|
9723415|NCT04620733|Experimental|Seladelpar 10 mg|
9723416|NCT04620733|Placebo Comparator|Placebo|
9723417|NCT04620733|Experimental|Seladelpar 5 mg|
9723418|NCT04615273|Experimental|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
9723419|NCT04615273|Placebo Comparator|Placebo|Placebo for Lonapegsomatropin administered once-weekly by subcutaneous injection
9723420|NCT04615273|Active Comparator|Somatropin|Somatropin administered once-daily by subcutaneous injection
9723421|NCT04615247|Experimental|Yoga Program|The study yoga intervention is designed to provide instruction and practice in selected yoga postures and techniques chosen by an expert panel for their potential to improve pelvic pain in women.
9723422|NCT04615247|Active Comparator|Physical Conditioning Program|A low-impact, muscle stretching and strengthening program.
9723423|NCT04614948|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1 and Day 57. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
9723424|NCT04614948|Placebo Comparator|Placebo|Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
9723425|NCT04603183|Experimental|Interventional Arm (Arm A)|Abemaciclib 150 mg orally twice daily (BID) during each 28 day cycle combined with ET (2.5 mg letrozole, orally administered and taken daily during each 28-day cycle, or 500 mg fulvestrant, by intramuscular [IM] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter.
9723426|NCT04603183|Active Comparator|Control Arm (Arm B)|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
9723430|NCT04589663|Experimental|Mometasone furoate followed by QMF149|Single inhaled dose of mometasone furoate on Day 1 followed by a single inhaled dose of QMF149 on Day 6
9723431|NCT04585789|Experimental|Panel 1: JNJ-73763989+ NA|Ongoing and new participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (last injection at Week 44) and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets) once daily up to 48 weeks. Participants may receive optional treatment with pegylated interferon alpha-2a (PegIFN-alpha-2a) after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion. As per amendment-5, JNJ-56136379 is no longer included as part of the study intervention and all participants are counted as single arm in each panel.
9780649|NCT01128270|Experimental|2B: Chloral Hydrate Therapeutic|Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)
9780650|NCT01128296|Experimental|Hydroxychloroquine + Gemcitabine (HcGc)|Hydroxychloroquine orally twice daily in combination with gemcitabine for 31 days prior to surgical resection
9780651|NCT01128361|Experimental|Aerobic Exercise|
10197204|NCT04837027|Active Comparator|Balance training|Balance Training A physical therapist will tailor a home balance training program for each participant based on pre- training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance
10197205|NCT04831684|Placebo Comparator|Group A|
10197206|NCT04831684|Experimental|Group B|
10197207|NCT04830124|Experimental|Advanced Cutaneous Melanoma|Patients with unresectable and/or metastatic cutaneous melanoma
10197208|NCT04830124|Experimental|Advanced mucosal melanoma|Patients with unresectable and/or metastatic mucosal melanoma
10197209|NCT04829617|Experimental|PP-MI Intervention|Participants will receive a 12-week, Positive Psychology-Motivational Interviewing (PP-MI) intervention. Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. Each weekly session will include PP and goal setting portions. In the PP portion, a study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. Additionally for the goal-setting portion, the trainer will (a) review their goals and health behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
10204829|NCT04813796|Experimental|mRNA-1283 Dose Level 1|Participants will receive 2 intramuscular (IM) injections of mRNA-1283 at Dose Level 1 on Day 1 and Day 29.
10204830|NCT04813796|Experimental|mRNA-1283 Dose Level 2|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 2 on Day 1 and Day 29.
10204831|NCT04813796|Experimental|mRNA-1283 Dose Level 3|Participants will receive 2 IM injections of mRNA-1283 at Dose Level 3 on Day 1 and Day 29.
9723432|NCT04585789|Experimental|Panel 2: JNJ-73763989+ NA|Ongoing and new participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) and NA treatment (ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks. Participants may receive optional treatment with PegIFN-alpha-2a after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion. As per amendment-5, JNJ-56136379 is no longer included as part of the study intervention and all participants are counted as single arm in each panel.
9723433|NCT04577651|Experimental|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with a 16-contact Directional Lead
9723434|NCT04573881|Experimental|Treatment Group|This is a single arm study that intends to treat all enrolled subject with the histotripsy device.
9723435|NCT04572854|Experimental|Group 1|Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
9723436|NCT04572854|Other|Group 2|No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
9723437|NCT04563234|Experimental|COFLEX training|Neurocognitive training, delivered via a mobile device app
9723438|NCT04563234|Active Comparator|Crossword group|Access to crossword puzzles via a mobile device app
9723439|NCT04561518||Patients with ATTR amyloidosis|Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
9723440|NCT04561518||Pre-symptomatic Carriers|Pre-symptomatic carriers with a known disease-causing TTR mutation will be eligible for the study and will follow routine clinical care.
9723441|NCT04556526|Experimental|Group A: Ad26.ZEBOV, MVA-BN-Filo|Participants will receive intramuscular (IM) injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp]) on Day 1, followed by modified vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U]) on Day 57.
9723442|NCT04556526|Other|Group B: No vaccination during pregnancy|Participants (pregnant women) in control Group B will not receive any vaccination during pregnancy. However, women in this group will receive the 2-dose vaccination regimen at the earliest 6 weeks after delivery/termination of pregnancy that is Dose 1 of Ad26.ZEBOV vaccine (0.5 mL) (5*10^10 vp) on Day 1 by IM injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 Inf U) vaccine by IM injection 56 days after Dose 1.
9723443|NCT04546425|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
9723444|NCT04546425|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
9723445|NCT04544267|Experimental|QIV-HD|One injection of QIV-HD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
9723446|NCT04544267|Active Comparator|QIV-SD|One injection of QIV-SD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
9723447|NCT04542486|Experimental|The conventional approach:|Gingivoplasties and removal of excess gingival tissues through the conventional scalpel technique using a reverse bevel.
9723448|NCT04542486|Active Comparator|The intervention approach:|"Gingivoplasties and elimination of excess gingival tissues through the use of Soft tissue trimmer."
9723449|NCT04535544|Experimental|Immediate Active Treatment arm: JNJ-73763989 + NA|Participants will receive JNJ-73763989 subcutaneous (SC) injection every 4 weeks (Q4W) along with NA (entecavir [ETV], tenofovir disoproxil, or tenofovir alafenamide [TAF]) once daily for 144 Weeks in Part 1 and 2.
9723450|NCT04535544|Placebo Comparator|Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA|Participants will receive matching placebo to JNJ-73763989 SC injection Q4W along with NA (ETV, tenofovir disoproxil, or TAF) once daily for 52 Weeks followed by JNJ-73763989 SC injection Q4W along with NA once daily for 96 weeks in Part 1 and 2.
9780652|NCT01128361|Active Comparator|Stretching|
9723451|NCT04535453|Experimental|Groups 1-6|Participants will receive a 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 57 at different dose levels (Groups 1-3), or a single-dose Ad26.COV2.S vaccination regimen at different dose levels (Groups 4-5), or placebo (Group 6). At unblinded phase, participants in Group 6 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Groups 1-5) or placebo (Group 6).
9723452|NCT04535453|Experimental|Groups 7-8|Participants will receive 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 29 at fixed dose level (Groups 7) or placebo (Groups 8). At unblinded phase, participants in Group 8 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Group 7) or placebo (Group 8).
9780653|NCT01128387|Experimental|Dose Level -1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
10197210|NCT04829617|Active Comparator|MI-alone Intervention|This condition will mirror the MI component of the PP-MI intervention. During the first three sessions, participants will learn about the causes and types of HF, risk factors for cardiovascular disease, and methods for monitoring risk factors and symptoms. Then participants will complete nine sessions related to physical activity, a low sodium diet, and medication adherence. Weekly tasks (e.g., brainstorming barriers) will be assigned, completed between calls, and reviewed at the following call. Finally, participants will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
10197211|NCT04827992|Experimental|Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment|This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.
10197212|NCT04827992|Active Comparator|Prescription Opioid Taper Support (POTS) treatment alone|This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.
10197213|NCT04825236|Experimental|Decision Aid Users|Patients with CF who are given access to the MyVoice:CF decision aid
10197214|NCT04825236|Experimental|CF Healthcare Providers|Members of the adult CF care team who interact with patients who have used the decision aid
10197215|NCT04825210|Experimental|Integrated Behavioral Health - Prevention (IBH-P)|The IBH-P intervention addresses four areas: 1) assessment of emotional and behavioral adjustment, 2) parental education on important supports for emotional and behavioral health, 3) modeling and guidance on nurturing and responsive parenting, and 4) addressing parental concerns about and promoting child self-regulation. The primary focus of IBH-P is promoting infant self-regulation by teaching mothers how to soothe and calm their baby. Trauma-informed and relationship building methods are emphasized to acknowledge maternal experiences with violence and adversity and the desire to establish a strong working alliance. IBH-P is distinguished from Bright Futures through its emphasis on experiential learning, modeling of effective parenting skills, in-session practice and feedback, and proactive problem-solving. Families in IBH-P will receive all standard care elements of the well-child visit including pediatrician implementation of Bright Futures curriculum.
10197216|NCT04825210|Active Comparator|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|The Bright Futures control condition consists of standard of care in addressing emotional and behavioral health as provided by pediatricians. Pediatricians will follow the 4th edition of the Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents [pocket guide]. Guidelines are provided for topics to discuss and anticipatory guidance at each well-child visit. In contrast to IBH-P, there is an emphasis on didactic presentation, teaching mothers about developmental milestones, and responding to questions and concerns. These include discussions of crying, soothing, and feeding, although self-regulation is not a unifying theme.
10197217|NCT04824105|Experimental|Neurostimulation Group|"On one study day, participants will complete experimental tasks during functional magnetic resonance imaging. On two other study days, participants will complete tasks before and after receiving repetitive transcranial magnetic stimulation (rTMS). All participants will receive rTMS to ventromedial prefrontal cortex on one study day, and to pre-supplementary motor area on another study day.~Two stimulation procedures will be used, one for ventromedial prefrontal cortex and one for pre-supplementary motor area. For both targets, 3 sessions of 600 pulses at 110% of resting motor threshold will be presented over 30 minutes. For ventromedial cortex, a session will involve intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. For pre-supplementary motor area, a session will involve continuous theta burst presented in 3-pulse bursts with 15 pulses/ sec."
10197218|NCT04820582||Delphi Panel|A group of international experts comprising patients experts, gynecologists, radiologist, psychologists, nurses and researchers, were identified based on their expertise in the field or due to your active role in an endometriosis patient association that have accepted to participate to this study.
10197219|NCT04820218|Other|Without Try-on glasses|Subjects will be asked to measure their visual acuity without their try-on glasses
9780654|NCT01128387|Experimental|Dose Level 1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)
10197220|NCT04818398|Experimental|DS-6016a dose level 1|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
10197221|NCT04818398|Experimental|DS-6016a dose level 2|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
10197222|NCT04818398|Experimental|DS-6016a dose level 3|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
10197223|NCT04818398|Experimental|DS-6016a dose level 4|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
10197224|NCT04818398|Experimental|DS-6016a dose level 5|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
10197225|NCT04818398|Experimental|DS-6016a dose level 6|Participants will be randomized to receive a single, subcutaneous injection of DS-6016a.
10197226|NCT04818398|Placebo Comparator|Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
10204832|NCT04813796|Experimental|mRNA-1273|Participants will receive 2 IM injections of mRNA-1273 at a pre-specified dose for this study on Day 1 and Day 29.
9723453|NCT04535453|Experimental|Groups 9-10|Participants will receive 2-dose Ad26.COV2.S vaccination regimen at Days 1 and 85 at fixed dose level (Group 9) or placebo (Group 10). At unblinded phase, participants in Group 10 initially receiving placebo will be offered 2 doses of Ad26.COV2.S vaccine at a single dose level, at a 28-day interval. Participants will also receive a single antigen presentation injection with single dose level of Ad26.COV2.S at 4 months after second vaccination (Group 9) or placebo (Group 10).
9723454|NCT04535453|Experimental|Groups A-C|Participants will receive a single dose Ad26.COV2.S vaccination regimen at Day 1 at fixed dose level (Groups A and B) or placebo (Group C). At approximately 6 months of study participation (unblinded phase), participants in Group C initially receiving placebo will receive Ad26.COV2.S vaccine at a single dose level, at a 56-day interval.
9723455|NCT04518098|Experimental|Intervention group|Participants in the IG will receive the STABLE intervention, which entails orientation, and undertaking a remotely delivered resistance and balance training regimen 3 times weekly for 3 months
9723456|NCT04518098|No Intervention|Control group|Participants in the CG will not receive the intervention, and will be advised to carry out their usual daily activities.
9723457|NCT04516369|Experimental|Voretigene neparvovec|1.5 E11 vg (0.3 mL subretinal injection in each eye, 6-18 days apart)
9723458|NCT04510038|Experimental|Active Colchicine Arm|Arm of Covid-19 hospitalized patients (with evidence of cardiac injury) treated with colchicine plus current standard of care.
9723459|NCT04510038|Active Comparator|Control Group|Arm of Covid-19 hospitalized patients (with evidence of cardiac injury) treated with current standard of care only.
9723460|NCT04504968|Experimental|Intervention group|Multimodal intervention:
9723461|NCT04504968|Placebo Comparator|Usual care group|Usual care group
10197227|NCT04815317|Active Comparator|Basal|"The impact of these stimulations will be compared to that of a control stimulus.~The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise.~The sensitive control condition will be achieved by administering fresh air on the calf.~An pressure support (+5) increment will be performed to ensure comparability of subsequent experimental sequences and their effect on dyspnea."
10197228|NCT04815317|Experimental|Intervention|"Patients will be subjected to sensory stimuli that may be auditory or sensitive.~The sensory stimulations will be administered by a research nurse. The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes.~Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes."
9723462|NCT04501328|Experimental|CIC+VA-CRAFT|Coaching Into Care plus VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
9723463|NCT04501328|Active Comparator|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
10197229|NCT04810975|Other|The effect of exercise A on musculoskeletal health|
10197230|NCT04810975|Other|The effect of exercise B on musculoskeletal health|
9723464|NCT04498923||Bupivacaine with dexamethasone|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone was injected for one plexus or peripheral nerve."
9723465|NCT04498923||Bupivacaine with dexamethasone and epinephrine|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone 0,02% and epinephrine 0,00018% was injected for one plexus or peripheral nerve."
9723466|NCT04469556|Active Comparator|Modified Folfirinox|"Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
9723467|NCT04469556|Active Comparator|Gemcitabine/nab-Paclitaxel|"Gemcitabine/nab-Paclitaxel administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
9723468|NCT04464226|Experimental|Darolutamide (BAY1841788)|Participants enrolled in the current study will use the dose they were assigned to in the feeder study they come from.
9723469|NCT04461795|Experimental|AJOVY (fremanezumab-vfrm)|Participants received 225 mg/1.5 mL solution via single-dose prefilled syringe administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for 12 weeks.
9723470|NCT04458831||Cohort 1|Patients with multiple myeloma (MM) and are considered as RRMM according to the International Myeloma Working Group (IMWG) criteria
9723471|NCT04453982||Human milk donors|
9723472|NCT04453969||Breastfeeding mothers positive for COVID-19|
9723473|NCT04452500|Experimental|CORT108297|CORT108297- 180mg daily for 7 days
9723474|NCT04452500|Placebo Comparator|Placebo|Placebo- 180mg daily for 7 days
9723475|NCT04445844|Experimental|Treatment (pelareorep, retifanlimab)|Patients receive pelareorep IV over 60 minutes on days 1, 2, 15, and 16. Patients also receive INCMGA00012 IV over 60 minutes on day 3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9723476|NCT04442737|Experimental|D/C/F/TAF FDC Arm (Immediate Switch)|Participants will be immediately switched to a regimen of darunavir 800 milligram (mg)/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily for 48 weeks.
9723477|NCT04442737|Active Comparator|INI + TAF/FTC Arm (Delayed Switch)|Participants will continue to receive current baseline integrase (INI)-based regimen plus Tenofovir Alafenamide/Emtricitabine (TAF/FTC) antiretroviral (ARV) regimen for 24 weeks. After 24 weeks participants will switch to a regimen of D/C/F/TAF FDC once daily for an additional 24 weeks.
9723478|NCT04439539|Experimental|Cohort 1: Participants Enrolled Prior to Protocol Amendment 5 is in Effect|During the Induction phase, participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with NA (either tenofovir disoproxil or tenofovir alafenamide tablets orally) treatment. At the start of consolidation phase, participants will be randomized to receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and JNJ-56136379 with NA in arm 1 and arm 2 (without PegIFN-alpha-2a). According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
9780655|NCT01128400||rs1761667- AA genotype|subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.
9780656|NCT01128400||rs1761667-GG genotype|subjects who are homozygous of CD36 genotype rs1761667-G allele.
9723479|NCT04439539|Experimental|Cohort 2: Participants Enrolled After Protocol Amendment 5 is in Effect|Following implementation of protocol amendment- 5 and 6, all participants will receive JNJ-73763989 subcutaneously along with NA (tenofovir disoproxil tablets orally) for 36 weeks (induction phase). In the consolidation phase, participants will receive PegIFN-alpha-2a subcutaneously in addition to JNJ-73763989 and NA for 12 weeks. According to predefined criteria NA treatment may be continued during the follow up (FU) phase. JNJ-56136379 (JNJ-6379) was discontinued as per amendment 6 of the study.
10197231|NCT04810377|Experimental|EUS-guided gastroenterostomy in malignant gastric outlet obstruction|The patients with malignant gastric outlet obstruction will be confirmed as follows: Histopathological report of cancer, thoracoabdominal tomography and impaired tolerance to oral feeding (tolerance to liquids only or null).
10197232|NCT04805021||Patients in the Acquired Hemophilia A group.|
10197233|NCT04805021||patients in the constitutional hemophilia A group.|
9723480|NCT04439331|Experimental|Treatment (defactinib)|Patients receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9723481|NCT04439188|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9723482|NCT04439149|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9723483|NCT04437238|Experimental|Intervention - KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
10197234|NCT04805021||patients in the control subjects group.|
9723484|NCT04437238|Placebo Comparator|Control|Participants allocated to the control condition will receive care as usual but will be asked to complete the health risk questionnaire at baseline, 3- and 6-month follow-up via an online survey to collect outcomes data. The control group will receive full access to KeepWell at the conclusion of the study.
9723485|NCT04436276|Experimental|Cohort 1a|Participants (healthy adults aged greater than or equal to (>=)18 to less than or equal to (<=) 55 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received coronavirus disease-2019 (COVID-19) vaccination (as primary regimen or additional dose) if the last vaccination was >=6 months ago, will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
9723486|NCT04436276|Experimental|Cohort 1b|Participants (healthy adults aged >=18 to <= 55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was >=6 months ago will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
10197235|NCT04805021||patients in the group of patients with inflammatory pathology.|
10197236|NCT04802863|Experimental|Five doses of XNW4107 with imipenem/cilastatin|Each subject will receive a total of five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin via IV infusion administered every 6 hours with each administration infused over 60 minutes.
10197237|NCT04802746|Experimental|Sequence ABC in Part A|Study participants randomized to this arm will receive Staccato Placebo (A) and two fixed doses of Staccato alprazolam Dose 1 (B) and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
10197238|NCT04802746|Experimental|Sequence BCA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato alprazolam Dose 2 (C), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
9723487|NCT04436276|Experimental|Cohort 2a|Participants (healthy adults aged >=18 to <=55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1, followed by booster vaccination at 6, 12 or 24 months with same dose or matching Placebo. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was >= 6 months ago, will be offered to receive a single ad hoc booster dose of Ad26.COV2.S and who are not willing to receive a single ad hoc booster dose of Ad26.COV2.S will continue to receive booster vaccination.
9780657|NCT01128400||rs1761667-AG genotype|Heterozygous of CD36 gene rs1761667-A genotype.
9785254|NCT01246986|Experimental|Part D Cohort 1 - 160 mg LY2157299 + 8 mg/kg Ramucirumab|"80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
9723488|NCT04436276|Experimental|Cohort 2b|Participants (healthy adults aged >=18 to <=55 years) will receive Ad26.COV2.S in the primary regimen or matching Placebo on Day 1 and 57, followed by booster vaccination at 8, 14, and 26 months (that is, 6, 12, or 24 months after completion of the primary regimen) with same dose or matching Placebo. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine and who are not willing to receive single dose of Ad26.COV2.S vaccine will continue to receive booster vaccination. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was >= 6 months ago, will be offered to receive a single ad hoc booster dose of Ad26.COV2.S and who are not willing to receive single ad hoc booster dose of Ad26.COV2.S will continue to receive booster vaccination.
9780658|NCT01128413|Experimental|Fluid Optimization (FO)|"Cheetah NICOM® (non-invasive cardiac output monitoring) Passive Leg Raise Testing (PLRT) that demonstrates a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) will receive a 500ml normal saline bolus. NICOM® PLRT with SVI or CI <15% will receive a saline lock. If bolused, NICOM® PLRT will be performed within 10 minutes after the bolus with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements. If saline locked, NICOM® PLRT will be performed every 30 minutes with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements.~Additionally, USCOM®, IVC Ultrasound collapsibility, CURVES Questionnaire, and repeat lactate measurements will be performed."
10197239|NCT04802746|Experimental|Sequence CAB in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato Placebo (A), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
10197240|NCT04802746|Experimental|Sequence ACB in Part A|Study participants randomized to this arm will receive Staccato Placebo (A), Staccato alprazolam Dose 2 (C), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
10197241|NCT04802746|Experimental|Sequence BAC in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato Placebo (A), and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
10197242|NCT04802746|Experimental|Sequence CBA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato alprazolam Dose 1 (B), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
10197243|NCT04802746|Experimental|Staccato alprazolam in Part B|Study participants randomized to this arm will receive Staccato alprazolam at pre-specified time points in Part B.
10197244|NCT04802746|Placebo Comparator|Staccato placebo in Part B|Study participants randomized to this arm will receive Staccato placebo at pre-specified time points in Part B.
10197245|NCT04801043|Experimental|Cohort 1: Healthy young females|Healthy young females participants, ≥ 18 to ≤ 45 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
10197246|NCT04801043|Experimental|Cohort 2: Healthy elderly males|Healthy elderly male participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
10197247|NCT04801043|Experimental|Cohort 3: Healthy elderly females|Healthy elderly female participants, ≥ 65 years of age, randomized to receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg.
10197248|NCT04801043|Placebo Comparator|Placebo to XNW 4107 & imipenem/cilastatin|Matching placebo for XNW4107 and imipenem/cilastatin
10197249|NCT04800874|Experimental|Cohort 1|Subjects will receive 6 grams of BBP-418 once daily x 90 days, then 12 grams twice daily (BID, a least 8 hours apart) of BBP-418 daily until study completion.
10197250|NCT04800874|Experimental|Cohort 2|Subjects will receive 6 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
10197251|NCT04800874|Experimental|Cohort 3|Subjects will receive 12 grams of BBP-418 twice daily (BID, at least 8 hours apart) x 90 days, then 12 grams BID of BBP-418 daily until study completion.
10197252|NCT04800354|Experimental|Nurse-led Mindfulness Based Intervention|
10197253|NCT04800354|Active Comparator|Nurse-led Pain Psychoeducation|
10197254|NCT04800315|Experimental|Dose 1: CC-93538 SC QW|Administration of CC-93538 Subcutaneous (SC) Once weekly (QW) for 16 weeks.
10197255|NCT04800315|Experimental|Dose 2: CC-93538 and Placebo SC Q2W|Starting at the baseline visit, active IP will be administered. On the alternate weeks, placebo will be administered to maintain the blind.
10197256|NCT04800315|Experimental|Dose 3: CC-93538 and Placebo SC Q2W|"Starting at the baseline visit, active IP and matching placebo will be administered.~On the alternate weeks, placebo will be administered weekly to maintain the blind."
10197257|NCT04800315|Placebo Comparator|Placebo SC QW|Administration of placebo each week.
10197258|NCT04797858|Experimental|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to others in their social networks.
10197259|NCT04797858|Active Comparator|Test referral distribution|Participants in the test referral arm receive multiple COVID-19 test referral cards and text messages to distribute to others in their social networks.
10197260|NCT04796324|Experimental|Ixabepilone|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
10197261|NCT04795544|Experimental|cuff inflation by the residual volume|"LMA will be inserted with the initial inflating volume correspondent to residual volume group (RV group):~volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 mL syringe without plunger is connected to the laryngeal cuff for 5 minutes"
10197262|NCT04795544|Experimental|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group)
10197263|NCT04795544|Placebo Comparator|unchanged cuff inflation volume|LMA will be inserted unchanged (NV group): LMA is unpacked and used without inflating or deflating the cuff.
10197264|NCT04794595||sepsis group with CBP|The child with sepsis should be treated with CBP， but could not receive this treatment for various reasons
10197265|NCT04794595||sepsis group without CBP|The child with sepsis should be treated with CBP and received this treatment
10197266|NCT04794569|Experimental|Tinzaparin|initial 3-week lead-in course of low molecular weight heparin (tinzaparin 175 units/Kg sc daily) followed by a direct oral anticoagulant (rivaroxaban 20mg po daily) for at least 3 months
10197267|NCT04794569|Active Comparator|Rivaroxaban|Direct oral anticoagulant only (rivaroxaban 15mg po BID for 3 weeks followed by rivaroxaban 20mg po daily ) for at least 3 months
10197268|NCT04793776|Experimental|Manage Emotions to Reduce Aggression (MERA)|MERA is 3 individual 90-minute sessions delivered over 3 weeks.
9723489|NCT04436276|Experimental|Cohort 3|Participants (good or stable health adults aged >=65 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was >=6 months ago will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
9723490|NCT04428853|Experimental|exercise|A schedule has designed by the researcher for group yoga therapy of the participant twice a week, each session lasting for 75- minutes for the duration of 8 weeks
9723491|NCT04421664|Experimental|Treatment|Participants in this arm will receive the study drug, hydroxychloroquine.
9723492|NCT04421664|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
9723493|NCT04410965|Experimental|teriflunomide|daily oral administration of teriflunomide 14 mg for 24 weeks
10197269|NCT04793776|Active Comparator|Present Centered Psychotherapy (PCT)|PCT delivered in 3 individual 90-minute sessions over 3 weeks.
9723494|NCT04406103|Experimental|Sleepwell|Mailed information package includes 2 Sleepwell booklets (How to get your sleep back and How to stop sleeping pills)
9723495|NCT04406103|Active Comparator|Empower|Mailed information package includes 2 Empower booklets (You may be at risk AND How to get a good night's sleep without sleeping pills)
9723496|NCT04406103|No Intervention|TAU|Treatment-as-usual group: no mailed intervention package.
9723497|NCT04405999|Experimental|Bromhexine hydrochloride Group|medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride
9723498|NCT04405999|No Intervention|Control Group|medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride
9723499|NCT04397159|Experimental|Combination Exercise|Flywheel resistance exercise plus aerobic exercise
9723500|NCT04397159|No Intervention|Standard-of-care|Participants will maintain standard-of-care and current activity levels during the course of the study.
9723501|NCT04396340|Experimental|Dose Escalation|XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.
9723502|NCT04396340|Experimental|Confirmation of Dose|New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose
9723503|NCT04383587|Other|Serologic Arm|Enrolled participants will have COVID19 IgG antibody testing performed.
9723504|NCT04381494|Other|Observational/Other|Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions.
10197270|NCT04791371|Experimental|Type 2 Diabetes|Participants aged 30-55 with type 2 diabetes
9723505|NCT04364958|Experimental|Intervention group|Patients who agree participant and will sign the informed consent, will complete the baseline assessment. Then, those allocated to the intervention group will review the web-based PtDA (shown on the computer), with the help of a researcher if necessary, and then will fill the questionnaires assessing the outcome measures in the same web interface.
9723506|NCT04364958|Active Comparator|Control group|Patients allocated to the control group will receive a web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care, and they will also complete the same questionnaires.
9723507|NCT04364555|Active Comparator|Active/active|The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
9723508|NCT04364555|Active Comparator|Placebo/active|The bottle for use in the morning contains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
9723509|NCT04364555|Placebo Comparator|Placebo/placebo|Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
9723510|NCT04353778|No Intervention|PLWH|People living with HIV (HIV)
9723511|NCT04353778|No Intervention|Healthy Controls|Healthy controls who do not have HIV
9723512|NCT04353778|Active Comparator|Pyridostigmine|PLWH on pyridostigmine 30mg PO TID
9723513|NCT04353778|Placebo Comparator|Placebo|PLWH on placebo
9723514|NCT04353778|Other|nVNS|PLWH to undergo non-invasive vagal nerve stimulation
9723515|NCT04351334||Patients with ALK-positive NSCLC|
9723516|NCT04349059|Active Comparator|Plant-based arm|Sequence one as outlined in the Study Description section consists of 7 visits to the doctors office, following a plant based diet and using the The Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
9723517|NCT04349059|Active Comparator|Animal-based arm|Sequence two as outlined in Study Description section consists of 7 visits to the doctors office, following a animal based diet and using the The Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
10197271|NCT04791371|Experimental|Healthy overweight control|Participants aged 30-55 with BMI 25-40 without type 2 diabetes
10197272|NCT04791176|Experimental|Lenvatinib and IMRT|Concurrent Lenvatinib and IMRT, followed Lenvatinib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
10197273|NCT04787562|Experimental|Cohort 1: normal renal function|Participants with an eGFR ≥ 90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
10197274|NCT04787562|Experimental|Cohort 2: Mild renal insufficiency|Participants with an eGFR 60 to <90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
10197275|NCT04787562|Experimental|Cohort 3: Moderate renal insufficiency|Participants with an eGFR 30 to <60 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
10197276|NCT04787562|Experimental|Cohort 4: Severe renal insufficiency|Participants with an eGFR 15 to <30 mL/min/1.73m2 receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
9980861|NCT01396200|Experimental|Rapamycin (Cohort A)|Infusional cyclophosphamide 300 mg/m2/day for 4 days IV and dexamethasone 40 mg/day orally or IV for 4 days on days 3 through 6. Rapamycin oral loading dose will be given on day 1 followed by an oral daily dose for an additional 5 days (days 2 through 6) to be given on an empty stomach at approximately the same time each day suggested 11 am)This dosing schedule is the same for all cycles.
9980862|NCT01396252|Experimental|Arm1: BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
9980863|NCT01396252|Placebo Comparator|Arm 2: Placebo matching BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
9723521|NCT04336163|Experimental|Prospective Study Group|For the experimental group, the laser surgeon will be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on the measurements.
9723522|NCT04336163|Other|Prospective Control Group|For the control group, the laser surgeon will not be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on standard of care, intuition, and experience.
9723523|NCT04335539|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg of cefiderocol and participants ≥34 kg will receive 2000 mg.
9723524|NCT04335539|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered via IV every 8 hours on Day 1 and continuing for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg of cefiderocol and participants ≥34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
9723525|NCT04334538|Active Comparator|S-RUTF|Children will receive approximately 150 kcal/kg/d of standard ready to use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
9723526|NCT04334538|Experimental|oat-RUTF|Children will receive approximately 150 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
10197277|NCT04787562|Experimental|Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy|Participants with ESRD receiving HD therapy at least 3 times a week for at least 3 months prior to Screening visit receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
9723527|NCT04330482|Other|Internet Links|A tablet pre-loaded with a list of internet links relating to dementia caregiving that participants will be instructed to use at least 4 times weekly for 3 months.
9723528|NCT04330482|Experimental|CARE-Well App|A tablet pre-loaded with the CARE-Well app that participants will be instructed to use at least 4 times weekly for 3 months.
9723529|NCT04307186|Experimental|BAY1747846 + Gadobutrol|Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of BAY1747846.
9980864|NCT01396291|Experimental|Asenapine|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
9980865|NCT01396291|Placebo Comparator|Placebo|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
9980866|NCT01396304|Experimental|Restore Calcium Alginate Dressing Silver|Restore Calcium Alginate Dressing Silver under compression wrap
9723533|NCT04297826|Experimental|Harvest for Health|The study is a gardening intervention among 150 older cancer survivors and individuals living with chronic disease (cardiovascular disease and diabetes) in the states of Alabama and Mississippi. This program focuses on 15 counties where a Community Health Advisor training program is in place (Bullock, Calhoun, Dallas Madison, Marengo, Monroe, Sumter, Talladega, Walker Counties in Alabama and Boliver, Granada, Humphrey, Panola, Sunflower, and Yazoo Counties in Mississippi). Participants are paired with Cooperative Extension certified Master Gardeners to plant a vegetable garden at their place of residence (the intervention). Baseline, midpoint, and 1 year follow up will occur. Previous pilot work provides an established relationship with the Cooperative Extension as well as training mechanisms for the Master Gardeners.
9723534|NCT04297358|Experimental|Stroke patients|40 consecutive sessions of hyperbaric oxygen will be administered at a pressure of 2 absolute atmosphere (ATA) to 10 patients. If there are drop outs, recruitment will be continued until a total of 10 patients with at least 30 sessions.
9980867|NCT01396304|Active Comparator|Aquacel Ag Wound Dressing|Aquacel Ag Wound Dressing under compression wrap
9980868|NCT01396330|Other|Stress|
9980869|NCT01396343||Pediatric MS Case|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
10197278|NCT04786756|Active Comparator|Lateral Approach of Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
10197279|NCT04786756|Active Comparator|Medial Approach of Costoclavicular Block|US-guided medial approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
10197280|NCT04784715|Experimental|Arm A|Trastuzumab deruxtecan (T-DXd) with pertuzumab-matching placebo
9723535|NCT04284813|Experimental|Telemedicine|Community Reinforcement and Family Training for first episode psychosis delivered via telemedicine (CRAFT-FT) with 6-8 weekly sessions of 60-minute therapy.
10197281|NCT04784715|Experimental|Arm B|Trastuzumab deruxtecan (T-DXd) with pertuzumab
10197282|NCT04784715|Active Comparator|Arm C|Standard of care
10197283|NCT04783519|Experimental|BASICS + SLEEP|The BASICS + SLEEP intervention will integrate BASICS feedback and the Motivational Interviewing (MI) process described in the BASICS arm with Brief Behavioral Therapy for Insomnia (BBTI) content and materials. The BASICS + SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals. Booster contacts serve as opportunities to adjust the sleep restriction schedule, problem-solve challenges, and further build motivation.
9723536|NCT04280536|Experimental|Cohort A|Patients with prior exposure to fluoropyrimidines
9723537|NCT04280536|Experimental|Cohort B|Patients without prior exposure to fluoropyrimidines
9723538|NCT04279769|Experimental|Cohort 1|CB-280 twice daily at 50 mg for 14 days
10197284|NCT04783519|Active Comparator|BASICS|The BASICS condition will meet for 2 sessions of 45-75 minutes. Content depends on the degree to which participants discuss the feedback, have questions, and/or explore behavior change options. Therapists review feedback components with participants, eliciting personally relevant reasons to change as domains are explored. When the participant is ambivalent about change, therapists work with them to explore and resolve that ambivalence. The method is non-confrontational and utilizes exploration of personalized graphic feedback (i.e., frequency, quantity, and peak use alongside perceived and actual norms for alcohol/MJ use) to increase motivation for change by highlighting ways alcohol and/or marijuana use could be incongruent with goals or values. Beliefs, expectations, and motives for use are discussed as are strategies to minimize risks and consequences. Booster sessions address questions and problem-solve challenges that have arisen since the session.
9723539|NCT04279769|Experimental|Cohort 2|CB-280 twice daily at 100 mg for 14 days
9723540|NCT04279769|Experimental|Cohort 3|CB-280 twice daily at 200 mg for 14 days
9723541|NCT04279769|Experimental|Cohort 4|CB-280 twice daily at 400 mg for 14 days
9723542|NCT04279769|Placebo Comparator|Placebo|Placebo twice daily for 14 days
9723543|NCT04277858|Experimental|Neoadjuvant chemotherapy and surgery|"Docetaxel and Cisplatin x 3 cycles followed by Transoral robotic surgery and neck dissection.~Carboplatin may be used instead of Cisplatin."
10204833|NCT04813796|Experimental|Placebo / mRNA-1283|Participants will receive 1 IM injection of study drug-matching placebo on Day 1 and 1 IM injection of mRNA-1283 at a pre-specified dose on Day 29. Participants may be offered an opportunity to receive an additional injection of mRNA-1273 at the pre-specified dose on Open-Label Day 1.
9723544|NCT04277546|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
9723545|NCT04277546|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
9723546|NCT04272736|Experimental|Low calorie protein substitute|Single arm designed, 3 day baseline, 28 day on the lower calorie amino acid based liquid protein substitute.
9723547|NCT04271501|No Intervention|Control|Area without surgical intervention. Ultraviolet Lamp (UVB)
9723548|NCT04271501|Active Comparator|Melanocyte-Keratinocyte Transplantation|Autologous skin cell suspension prepared by laboratory based melanocyte-keratinocyte transplantation procedure technique applied to a surgically prepared area of depigmentation
9723549|NCT04271501|Experimental|RECELL 1:5|Regenerative epidermal suspension diluted 1:5 applied to a surgically prepared area of depigmentation
9723550|NCT04271501|Experimental|RECELL 1:10|Regenerative epidermal suspension diluted 1:10 applied to a surgically prepared area of depigmentation
9723551|NCT04271501|Experimental|RECELL 1:20|Regenerative epidermal suspension diluted 1:20 applied to a surgically prepared area of depigmentation
9723552|NCT04258943|Experimental|Single Agent Bosutinib|Bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML). A treatment cycle is defined as 28 days
9723553|NCT04249401||Reduced dose NOAC|Participants with NVAF initiating treatment with reduced doses of individual non-vitamin K antagonist oral anticoagulants (NOACs)
9723554|NCT04249401||Vitamin K antagonists (VKA)|Participants with NVAF initiating treatment with vitamin K antagonists (VKA)
9723555|NCT04243226|Experimental|this study is to develop exercise prescription of TBI patients|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve cognitive performance, depression relief and quality of life with improvement of CBF. This will be a three-year study, with the first two year using a mixed method to explore the feasibility of such a safety exercise prescription. In the second to third year, a randomized clinical control trial will be applied in TBI patients to evaluate the effectiveness of programmed aerobic exercise to promote cognitive status, 6 minutes walk test, depression relief and quality of life.
9723556|NCT04243226|No Intervention|No exercise prescription in TBI patients|Routine Care of TBI Patients
9723557|NCT04241978|Experimental|Intervention group|The participants will complete the baseline assessment and will be asked to read the project information sheet. Then, patients allocated to the intervention group will review the PtDA accompanied by the researcher and will complete the questionnaires assessing the outcome measures, in the same web interface.
9723558|NCT04241978|Active Comparator|Control group|Patients in the control group will follow the same procedure, but they will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
9723559|NCT04241250|Experimental|EAW+SCES|Three months of exoskeleton training followed by 6 months of epidural stimulation.
9723560|NCT04241250|Experimental|EAW+TS|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
9723561|NCT04236908|Experimental|Group 1 (NSAIDS only)|NSAIDs only (naproxen 500mg by mouth twice a day as needed)
9723562|NCT04236908|Experimental|Group 2 (Acupuncture+GV26)|Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
9723563|NCT04236908|Experimental|Group 3 (Battlefield Acupuncture+NSAIDS)|Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
9723564|NCT04236908|Experimental|Group 4 (Battlefield Acupuncture+GV26+NSAIDS)|GV26 with manual tonification + Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed).
9723565|NCT04233554|Experimental|Intervention Arm - Implementing Patient Priorities Care|Practice staff and providers will be trained on how to identify patient health priorities. Staff and clinicians will implement Patient Priorities Care, document priorities in EHRs, and align patient priorities with health care decisions.
9723566|NCT04233554|No Intervention|Control Arm|Control arm practices will receive no intervention and patients will receive usual care.
9723567|NCT04232657|Experimental|Romosozumab Treatment (baseline to month 11)|Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.
9723568|NCT04232657|Placebo Comparator|Placebo (baseline to month 12)|Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.
9723569|NCT04232657|Active Comparator|Denosumab (month 12 to month 24)|Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).
9723570|NCT04228783|Experimental|Active Vaccine: Group 1 (Ad26.ZEBOV-Lot A, MVA-BN-Filo-Lot 1)|Participants will receive Intramuscular injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp], Lot A) on Day 1, followed by Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U], Lot 1) on Day 57.
9723571|NCT04228783|Experimental|Active Vaccine: Group 2 (Ad26.ZEBOV-Lot B, MVA-BN-Filo-Lot 2)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot B) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 2) on Day 57.
9723572|NCT04228783|Experimental|Active Vaccine: Group 3 (Ad26.ZEBOV-Lot C, MVA-BN-Filo-Lot 3)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot C) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 3) on Day 57.
10197285|NCT04783519|No Intervention|Assessment Only Control|Participants in Assessment Only Control (AOC) condition will complete all assessments (including survey, daily, actigraphy) at the same time as participants in the 2 active interventions. AOC will also attend an in-person meeting to verify identity, provide rationale for daily monitoring, control for time/attention, and participants in all conditions including AOC will receive referrals for community services to address alcohol and MJ use, sleep, and other mental health concerns. No participants will be deprived of services; use of outside services will be tracked to assist with interpretation of outcomes. AOC condition will be offered BASICS + SLEEP after 3-month follow-up.
10197286|NCT04783272|Experimental|Treatment|Photoacoustic Computed Tomography (PACT) Imaging
9723573|NCT04228783|Placebo Comparator|Control Vaccine: Group 4 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9 percent [%] saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57.
9723574|NCT04228783|Experimental|Booster Cohort: Group 5 (Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, a single Lot) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, a single Lot) on Day 57 and a booster dose of Ad26.ZEBOV (at a dose of 5*10^10 vp, a single Lot) 4 months after Dose 2 (on Day 177).
10204834|NCT04806594|Experimental|Papix acne scar|Papix acne scar gel for 8 consecutive weeks, 2 times per day
10204835|NCT04805008|Experimental|Intervention|Lactation cookies
10204836|NCT04805008|Placebo Comparator|Control|Control cookies
10204837|NCT04804904|Experimental|TQ-B3101: Fed + Fast|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fed condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fasted condition on Day 1 of treatment period 2.
10204838|NCT04804904|Experimental|TQ-B3101: Fast+Fed|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fed condition on Day 1 of treatment period 2.
9723575|NCT04228783|Placebo Comparator|Booster Cohort: Group 6 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9% saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57 and a booster dose of matching placebo on Day 177.
9780659|NCT01128413|Active Comparator|Routine Care (RC)|Patients randomized to receive routine ED care will receive IV fluid administration per the treating clinicians discretion. The Cheetah NICOM®PLRT, USCOM®, IVC Ultrasound collapsibility, and CURVES Questionnaire will be performed and repeat lactate measurements will only be revealed to the routine care arm if they are used as part of the provider's routine care.
9780660|NCT01128426||1|
9780661|NCT01128543|Active Comparator|lapatinib 1250mg|Patients will receive 1250mg lapatinib once a day for 24 weeks.
9780662|NCT01128543|Active Comparator|Vinorelbine 25mg/sqm|Patients will receive vinorelbine 25mg/sqm IV Day 1 and Day 8, every 3 week for 24 weeks.
9780663|NCT01128569|Placebo Comparator|Placebo|Placebo Inhaler
9780664|NCT01128569|Active Comparator|inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)|ICS/LABA inhaler
9723576|NCT04226391||RAS Partial Nephrectomy|
9723577|NCT04226391||RAS Radical Prostatectomy|
9723578|NCT04225039|Experimental|Cohort A|Subjects in this arm (N=16) receive a single priming dose of both INCMGA00012 (500mg) and INCAGN01876 (300mg) prior to stereotactic radiosurgery (SRS), then undergo SRS (8 Gy x 3 fractions). Following SRS, INCMGA00012 (500mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) are resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
9780665|NCT01128569|Active Comparator|ICS|ICS inhaler
10197287|NCT04782921|Experimental|Gel 40|Application of Gel 40
10197288|NCT04782921|Active Comparator|Gen-Os|Application of Gen-Os
10197289|NCT04782791|Experimental|Nivo + SOX|Nivolumab plus SOX
10197290|NCT04782791|Active Comparator|Nivo|Nivolumab
10197291|NCT04780841|Experimental|RDX013 Cohort 1|RDX013 low dose oral dosage, twice daily
10197292|NCT04780841|Experimental|RDX013 Cohort 2|RDX013 low, mid dose oral dosage, twice daily
10197293|NCT04780841|Experimental|RDX013 Cohort 3|RDX013 high, mid dose oral dosage, twice daily
9780666|NCT01128595|Active Comparator|ICS|
10197294|NCT04780841|Experimental|RDX013 Cohort 4|RDX013 high dose oral dosage, twice daily
10197295|NCT04780841|Experimental|RDX013 Part B|RDX013 dose from Part A oral dosage, twice daily
10197296|NCT04780841|Placebo Comparator|Placebo Part B|oral dosage, twice daily
10197297|NCT04780698|Experimental|Study Cohort|
10197298|NCT04777643|Experimental|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
10197299|NCT04777643|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
10197300|NCT04776018|Experimental|Phase 1b, Part 1 - Dose Escalation: Arm A - TAK-981 Twice Weekly (BIW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg subcutaneous (SC) injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks in Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 BIW intravenous (IV) infusion on Days 1, 4, 8, 11 and 15 in Cycle 1 and 2 (each Cycle is of 28 days) followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
10197301|NCT04776018|Experimental|Phase 1b, Part 1 - Dose Escalation: Arm B - TAK-981 Weekly (QW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg SC injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks from Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 QW IV infusion on Days 1, 8, 15, and 22 in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks. up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
10197302|NCT04776018|Experimental|Phase 1b, Part 2 - Lead-in Cohort: TAK-981 + Daratumumab and Hyaluronidase-fihj|"Daratumumab and hyaluronidase-fihj: 1800 mg SC injection QW once weekly in Cycles 1 and 2 , (each cycle is of 28 days) followed by every 2 weeks in Cycle 3 through 6 , followed by every 4 weeks up to Cycle 24 until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: As per dose and schedule of TAK-981 defined in Phase 1b Part 1."
10197303|NCT04776018|Experimental|Phase 2 - Dose Expansion: TAK-981 + Daratumumab and Hyaluronidase-fihj or Mezagitamab|TAK-981 at RP2D as determined in Phase 1b. Mezagitamab at a fixed dose of 600 mg SC injection or Daratumumab and Hyaluronidase-fihj at a fixed dose of 1800 mg weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycle 3 through 6, followed by every 4 weeks up to Cycle 24 or until disease progression unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
10197304|NCT04773197|Experimental|Coach-assisted C-CBT with BtB|Participants will receive coach- assisted Beating the Blues (BtB), a C- CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
10197305|NCT04773197|Active Comparator|Coach-assisted animated C-CBT with EMW|Participants will receive coach- assisted Entertain Me Well (EMW), an animated C-CBT program, which contains 8 weekly sessions. A coach will provide between session support throughout the 8 sessions.
10197306|NCT04773197|Active Comparator|Standard stand-alone C-CBT with BtB|Participants will use the stand-alone BtB for 8 weekly sessions, without coach assistance.
10197307|NCT04772937|Other|LLETZ group|LLETZ (large loop excision of the transformation zone) is one of several possible surgical interventions for treating cervical dysplasia.
10197308|NCT04772937|Other|LEEP group|LEEP (loop electrosurgical excision procedure) is one of several possible surgical interventions for treating cervical dysplasia.
10197309|NCT04771611|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
10197310|NCT04771611|Placebo Comparator|Placebo|Subjects will receive placebo
10197311|NCT04768426|Experimental|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day cycles
10197312|NCT04766385|Experimental|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
10197313|NCT04766086|Experimental|GBS6 and Tdap|Hexavalent group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
10197314|NCT04766086|Experimental|GBS6 and Placebo|Hexavalent group B streptococcus vaccine and Placebo
10197315|NCT04766086|Experimental|Placebo and Tdap|Placebo and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
10197316|NCT04766034|Sham Comparator|Control|The grocery shopping simulation will not include any discounts or bundles
10197317|NCT04766034|Active Comparator|Discount|The grocery shopping simulation will include discount on eligible fruits and vegetables
10197318|NCT04766034|Active Comparator|Bundles|The grocery shopping simulation will include healthy bundle defaults with no discount
10197319|NCT04766034|Active Comparator|Bundles and Discount|The grocery shopping simulation will include healthy bundle defaults plus a discount
10197320|NCT04764292|Experimental|Contrast-enhanced mammography|Women who meet criteria for supplemental screening MRI, but who are unable to have MRI for medical/access/cost reasons, will be invited to have screening with contrast-enhanced mammography. Women will also have standard-of-care mammography/tomosynthesis per usual clinical practice.
9723579|NCT04225039|Experimental|Cohort B sub-arm #1|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 (500mg) + INCAGN01876 (300mg) + SRS. Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (500 mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
9723580|NCT04225039|Experimental|Cohort B sub-arm #2|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 + INCAGN01876 (without SRS). Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (IV every 4 weeks) and INCAGN01876 (IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
9723581|NCT04222790|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
9723582|NCT04222790|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
9723583|NCT04222634|Other|MDT for oligoprogressive lesions in CRPC|"metastasis-directed therapy:~radiotherapy (SBRT or conventional radiotherapy in case of local recurrence or untreated primary tumor)~metastasectomy~salvage lymphadenectomy~salvage prostatectomy in case of local recurrence or untreated primary tumor"
9723584|NCT04216810|Active Comparator|Exercise group|Exercise group
9723585|NCT04216810|Experimental|Exercise group and dry cupping|Exercise and dry cupping
9723586|NCT04216043|Experimental|RUSF skimmed milk powder|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
9723587|NCT04216043|Experimental|RUSF milk protein concentrate and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
9723588|NCT04216043|Experimental|RUSF soy protein and whey permeate|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
9723589|NCT04216043|Experimental|RUSF soy and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
10197321|NCT04762836|Experimental|Augmented learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of DCS two hours prior to conditioning and fMRI
10197322|NCT04762836|Placebo Comparator|Baseline learning|Conditioning and extinction of a nocebo response to the activation of a sham electrode, controlled within subjects. All participants in this arm receive a double-blind oral dose of placebo two hours prior to conditioning and fMRI
10197323|NCT04758949|Experimental|FL-101 Monotherapy|30 patients will receive FL-101 prior to surgery.
10197324|NCT04758949|Experimental|FL-101 + Nivolumab|30 patients will receive FL-101 and Nivolumab prior to surgery.
10197325|NCT04758949|Active Comparator|Nivolumab + Placebo|30 patients will receive Nivolumab and placebo prior to surgery.
10197326|NCT04758312|Experimental|MY-Skills Mobile Intervention|MY-Skills Mobile is an 8-week intervention merging yoga and self-management offered via remote tools including Zoom (video-conferencing software), Canvas (education software), and Qualtrics (survey software) that can be accessed via a computer or tablet. The self-management content is delivered primarily through asynchronous tools that include educational videos and interactive activities for goal setting, action plan, monitoring goals, and problem-solving practice. Yoga is offered synchronously via Zoom two-times per week for 60 minutes (120 minutes per week). The synchronous yoga sessions will be offered at a time that best accommodates participants' schedules. Yoga will become progressively challenging over the eight weeks and will include seated and standing postures.
10197327|NCT04755660|Experimental|Exercise behavior change group (EBCG)|Behavior Change Theory-based intervention + Resistance Exercise
10197328|NCT04755660|Active Comparator|Elastic band resistance exercise group( EBRG)|Elastic Band Resistance Exercise
10197329|NCT04755660|Sham Comparator|Usual care (UC)|usual care: exercise education
10197330|NCT04750395|Experimental|Haloperidol|Every 24 hours, patients will receive two regular doses of OT Haloperidol 2.5mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
10197331|NCT04750395|Experimental|Olanzapine|Every 24 hours, patients will receive two regular doses of OT Olanzapine 5.0mg. Patients may also receive up to two breakthrough doses within a minimum interval of one hour from the last dose. In total, up to four doses of medication will be prepared.
10197332|NCT04743947||Patients with kidney failure receiving dialysis|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in dialysis patients (hemodialysis or peritoneal dialysis).
10197333|NCT04743947||Kidney transplant patients|Analysis of data received from clinical practice about the SARS-CoV-2 vaccination response in kidney transplant patients.
10197334|NCT04743947||age-matched controls in non-dialysis, non-kidney transplant patients|Historical cohort of aged matched non-dialysis and non-kidney transplanted patients who received a SARS-CoV-2 vaccination.
10197335|NCT04743362||Participants with muco-cutaneous lesions|Participants will have muco-cutaneous lesions for non-invasive evaluation (including normal skin or mucosa and benign lesions) and will be identified by their physicians or fellows during routine clinical care.
10204839|NCT04801550|Active Comparator|Millimeter wave emitter status 1|Somatosensory stimulus during Magnetoencephalography (MEG) records
10197336|NCT04741282|Experimental|pulmonary telerehabilitation plus progressive muscle relaxation training|This group will perform six week pulmonary rehabilitation program and progressive muscle relaxation exercise at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
10197337|NCT04741282|Active Comparator|pulmonary telerehabilitation|This group will perform six week pulmonary rehabilitation program at theirs home, with two supervised sessions by physiotherapist per week via videoconferencing.
10197338|NCT04739735|Experimental|Computer Controlled -Intraligamentary Anaesthesia (CC-ILA)|"CC-ILA will be administered using the Wand-STA system according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted mandibular teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle."
9723590|NCT04215991|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg cefiderocol and participants ≥34 kg will receive 2000 mg.
9723591|NCT04215991|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered via IV every 8 hours for an expected 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
10197339|NCT04739735|Active Comparator|Conventional Injection of Inferior Alveolar Nerve Block|"In the control group, a standard technique for the Inferior Alveolar Nerve Block (IANB) will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed between the two primary molars on the opposite side of the arch, entering the tissues at the level of the occlusal plane or slightly lower until bony resistance is met.~Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. Two-thirds the needle length should be inserted. The needle is withdrawn, then 0.5 ml as a long buccal infiltration distal to the second primary molar is administered."
9723592|NCT04215991|Active Comparator|Multiple Dose Phase: Standard of Care Alone|Participants will receive standard of care treatment according to local standards.
10197340|NCT04737031|No Intervention|Usual Care|Clinicians and patients will receive no further interventions beyond usual practice.
10197341|NCT04737031|Experimental|Clinician Nudge|Clinicians will receive a nudge via Best Practice Alert within the EMR
10197342|NCT04737031|Experimental|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status.
10197343|NCT04737031|Experimental|Clinician and Patient Nudge|Both strategies described above will be used.
10197344|NCT04735965|Experimental|Dexmedetomidine group|
10197345|NCT04735965|Active Comparator|Meperidine group|
10197346|NCT04735965|Placebo Comparator|Control group|
10197347|NCT04734535|Experimental|investigational|HEMOBLAST™ Bellows
10197348|NCT04734535|Active Comparator|control|absorbable gelatin sponge with thrombin
10197349|NCT04734379|Experimental|Treatment|Oral fasudil 180 mg/day
10197350|NCT04731272|Experimental|Dulaglutide|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of dulaglutide therapy in the intervention period.
10197351|NCT04731272|No Intervention|Observation|The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of no intervention in the observation period.
10197352|NCT04730037|Active Comparator|Edoxaban group|
10197353|NCT04730037|Active Comparator|Warfarin group|
10197354|NCT04725643||Implant Group|Adults who are choosing to get a replacement Nexplanon and agree to track and report their bleeding patterns for one month before replacement and 3 months after.
10197355|NCT04725136|Experimental|High-dose repeat administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 3 repeated subcutaneous injection at 4 week intervals
10197356|NCT04725136|Experimental|High-dose single administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
10197357|NCT04725136|Experimental|Low-dose repeat administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 3 repeated subcutaneous injection at 4 week intervals
10197358|NCT04725136|Experimental|Low-dose single administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
10197359|NCT04725136|Placebo Comparator|Placebo|Normal saline(0.9% NaCl) 3 repeated subcutaneous injection at 4 week intervals
10197360|NCT04724681|Active Comparator|Monitoring arm|Patients in this arm will have their vital signs monitored with continuous wireless devices and patients in this arm will be monitored with standard Early Warning Score
10197361|NCT04724681|No Intervention|standard Early Warning Score arm|Patients in this arm will be monitored with standard Early Warning Score
10197362|NCT04722536||Cervico-isthmic cerclage|Are included in this group the women who underwent cervico-isthmic cerclage between January 1, 2010 and April 1, 2019, in 3 hospitals of the Hospices Civils de Lyon, respecting the inclusion and exclusion criteria, to assess the primary and secondary outcomes before and after performing the cerclage.
10197363|NCT04721925|No Intervention|Control group|Link to an educational website about alcohol; link to resources.
10197364|NCT04721925|Experimental|Social media messaging|Health coaching via social media for 8 weeks
9723593|NCT04206059|Experimental|CLASS-D Cohort|Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.
9723594|NCT04199988||Athletes with shoulder pain|Overhead athletes with shoulder pain
9723595|NCT04199988||Athletes without shoulder pain|Overhead athletes without shoulder pain
9723596|NCT04194450|Experimental|Ketone monoester|Acute dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.3 ml/kg body weight)
9723597|NCT04194450|Placebo Comparator|Placebo|Acute dose of flavour-matched placebo.
9723598|NCT04184622|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
10197365|NCT04714190|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
10197366|NCT04714190|Active Comparator|Physician's Choice|Participants will receive physician choosed chemotherapy from the following options: Paclitaxel Injection or Irinotecan Hydrochloride Injection or Apatinib Mesylate Tablets oral.
10197367|NCT04712721|Experimental|Glioblastoma Multiforme|All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
9723599|NCT04184622|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
9723600|NCT04184622|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
9723601|NCT04184622|Placebo Comparator|Placebo|Placebo administered SC once a week.
9723602|NCT04183309||Pediatric anesthetized patients|Pediatric anesthetized patients undergoing abdominal laparoscopy surgery (simple-arm study).
9723603|NCT04182620|Experimental|Catheter ablation + renal denervation|Catheter ablation + renal denervation
9723604|NCT04182620|Active Comparator|Catheter ablation only|Catheter ablation
9723605|NCT04170738|Experimental|Adderall|dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth
9723606|NCT04166630|Experimental|ICU Acquired Weakness Group|Participants with a score less than 48 on the Medical Research Council (MRC) Scale will be classified as having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
9723607|NCT04166630|Experimental|No ICU Acquired Weakness Group|Participants with a score of 48 or greater on the Medical Research Council (MRC) Scale will be classified as not having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
10197368|NCT04712721|Experimental|Brain Metastasis from Breast Cancer|All eligible participants will receive recommended dose of [68Ga]-FF58 of 3 Megabecquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
10197369|NCT04712721|Experimental|Gastroesophageal adenocarcinoma|All eligible participants will receive recommended dose of [68Ga]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) [but not more than 250 and not less than 150 MBq]
9723608|NCT04162847|Experimental|Mobile Coached Intervention|This group will receive access to the mobile intervention for 6 months. They will be assigned to the primary program (i.e., anxiety, depression, or eating disorders) they screen positive for. If a person screens positive for more than one disorder, they will be given the choice of which program they want to start with. They will also be provided preventive interventions for anxiety, depressive, or eating of disorders they may not have but be at risk for. After two weeks in the program, the coach will assign the components presumed to be essential to intervention effects for comorbid disorder(s) and risk factors.
9723609|NCT04162847|No Intervention|Referral to Counseling Center|This group will receive information about how to make an appointment at their counseling center and will be encouraged to do so.
10197370|NCT04712721|Experimental|Pancreatic ductal adenocarcinoma|All eligible participants will receive recommended dose of [68Ga]FF58 of 3 Megabecquerel (MBq)/Kg (+/-10%) [but not more than 250 and not less than 150 MBq]
10197371|NCT04711473|Active Comparator|Colonoscopy Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in colonoscopy, and including a referral for the procedure at a local endoscopy center. Participants will be provided a phone number if interested in navigated colonoscopy scheduling.
10197372|NCT04711473|Experimental|Choice|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in their choice of either colonoscopy or mailed fecal immunochemical testing (FIT). The letter will include both a referral for the colonoscopy at a local endoscopy enter and a FIT kit with a lab requisition and instructions for completion.
10197373|NCT04711473|Experimental|FIT Only|Participants in this arm will receive a letter from their provider informing them they are overdue for colon cancer screening and requesting their participation in FIT testing. The letter will include a FIT kit with lab requisition and instructions for completion.
10197374|NCT04708600|Experimental|Group 1|Sham therapy Intervention 1: PET Intervention 2: ART
10197375|NCT04708600|Experimental|Group 2|Sham therapy Intervention 1: ART Intervention 2: PET
10197376|NCT04705779|Experimental|HARMONY|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
10197377|NCT04705779|Active Comparator|Nutrition and Exercise Education Workgroup (NEEW)|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
10197378|NCT04705571|Experimental|MorpheusV Applicator (active)|
10197379|NCT04705168||Participants displaying nevi|"Participants displaying a phenotype that consists of ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) > 5 mm in diameter. These patients have atypical mole syndrome, which is a high-risk nevus phenotype and the target patient population in this study."
10197380|NCT04704999|Active Comparator|Low dose tafenoquine (5mg/kg) with a fixed weight dependent dose|"The doses are as follows;~Weight range Low dose~>21-25 kg 200 mg~26-40 kg 200 mg~41-50 kg 300 mg~51-60 kg 400 mg~61-80 kg 400 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
10197381|NCT04704999|Active Comparator|Medium dose tafenoquine (9mg/kg) with a fixed weight dependent dose|"The doses are as follows;~Weight range Medium dose~>21-25 kg 200 mg~26-40 kg 300 mg~41-50 kg 400 mg~51-60 kg 500 mg~61-80 kg 600 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
10197382|NCT04704999|Active Comparator|High dose tafenoquine (12.5mg/kg) with a fixed weight dependent dose|"The doses are as follows;~Weight range High dose~>21-25 kg 300 mg~26-40 kg 400 mg~41-50 kg 600 mg~51-60 kg 600 mg~61-80 kg 600 mg~Tafenoquine will be given as 100 mg coated tablets. Whole tablets will be given, and dosing will be based on weight bands."
10197383|NCT04704011|Experimental|Arm 1: Basic Needs Assessment|-Patients will receive a phone call from a research team member 2-4 weeks before their colposcopy appointment. The team member will remind the patient of the date and time of their appointment and conduct a basic needs assessment. Those who have at least one unmet basic need or are unsure of their current needs will be referred to the 24-hr assistance hotline, 2-1-1 United Healthy Way Missouri. After the date of their appointment, patients will be contacted to ask whether they contacted 2-1-1 and used any recommended services.
10197384|NCT04704011|Active Comparator|Arm 2: Usual Care Cohort|-Patients will receive an automated phone call two weeks before their colposcopy appointment to remind them of the date and time of their visit.
9723610|NCT04158375|Experimental|Insulin Resistant Exercise Group|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Resistance training will be performed using a combination of upper and lower body exercises using machine and free weights. Upper body exercises are chest press, incline press, seated row, lat pull down, triceps extension, biceps curl and lateral raises. Major muscle groups for upper body exercises will include chest (pectoralis major and minor), arm (biceps and triceps), shoulder (deltoids) and back (latissimus dorsi and rhomboids). Lower body exercises are leg press, lunge (with body weight progressing to dumbbells), seated leg extension, seated leg curl, calf raises and abdominal crunches. Major muscle groups for the lower body exercises will be thighs (quadriceps and hamstrings), calves (gastrocnemius and soleus) and core (rectus abdominus and obliques).
9723611|NCT04158375|No Intervention|Insulin Resistant Control Group|Participants in this group will perform no exercise for the 3 month study period.
9723612|NCT04158375|No Intervention|Insulin Sensitive Lean Group|Participants in this group will have a baseline study for comparison to the insulin resistant groups.
9723613|NCT04155424|Experimental|Eculizumab|"All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.~After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks."
9723614|NCT04152200|Experimental|Lumasiran|All participants will receive open-label lumasiran.
10197385|NCT04702802|Experimental|Arm 1; PRO-149|Viscoelastic substance PRO-149 (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
10197386|NCT04702802|Active Comparator|Arm 2; Healon® EndoCoat|Viscoelastic substance Healon® EndoCoat (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
10197387|NCT04702789|Experimental|Arm 1; Dorzolamide-timolol-brimonidine and latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
10197388|NCT04702789|Experimental|Arm 2; Dorzolamide-timolol and latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
9723615|NCT04147325||Prospective Cohort|Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, will receive Antiretroviral Therapy (ART) in accordance with clinical practice and will be included in a Test and Treat model of care at the outpatient clinic of the center.
9723616|NCT04147325||Historical Cohort|Naive HIV-1 infected participants who had their first care visit at the outpatient clinic of the center through 2017 will be included in this cohort.
9980870|NCT01396343||Pediatric Control|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
9723618|NCT04144959||Patients with lower extremity acute limb ischemia|
9723619|NCT04142658|Experimental|Apixaban|Apixaban 5 mg twice daily(BID) or 2.5 mg BID
9723620|NCT04142658|Active Comparator|Warfarin|Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)
9723621|NCT04133792|Experimental|Simvastatin|Simvastatin 40 mg administered orally daily for 5 years.
10197389|NCT04702776|Experimental|Arm 1; Humylub Ofteno® PF|Humylub Ofteno® PF (sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) ophthalmic solution applied QID for 30 days.
10197390|NCT04702776|Active Comparator|Arm 2; Hyabak®|Hyabak® PF (sodium hyaluronate 0.15%) ophthalmic solution applied QID for 30 days.
10197391|NCT04702776|Active Comparator|Arm 3; Lagricel Ofteno® PF|Lagricel Ofteno® PF (sodium hyaluronate 0.4%) ophthalmic solution applied QID for 30 days.
10204840|NCT04801550|Sham Comparator|Millimeter wave emitter status 2|Somatosensory stimulus during Magnetoencephalography (MEG) records
9723622|NCT04133792|Placebo Comparator|Placebo|Placebo for Simvastatin 40 mg administered orally daily for 5 years.
9723623|NCT04129554|Experimental|JNJ-73763989+ JNJ-56136379+ NA|Participants will receive fixed dose of JNJ-73763989 subcutaneous injection once every 4 weeks along with fixed dose of JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) once daily up to 48 weeks.
9780667|NCT01128595|Active Comparator|ICS/LABA|
9780668|NCT01128595|Active Comparator|LABA|
9780669|NCT01128595|Placebo Comparator|Placebo|
9980871|NCT01396356||ablation procedure|
9980872|NCT01396369|Active Comparator|Birth control|
9980873|NCT01396369|Experimental|Birth control plus Brevail|
9980874|NCT01396460||bariatric patients|Bariatric post operative patients were compared with morbid obese population
10197392|NCT04702308|Experimental|Intervention Group|The intervention will contain two components: 1) a non-interruptive best practice advisory (BPA) in the Epic Storyboard and 2) a default suggested calculator tab in the MDCalc Connect app. Six clinical decision rules will be included: Canadian CT Head Rule, Canadian C-spine Rule, HEART Score, PERC Rule, Wells' PE Criteria and Wells' DVT Criteria. Predefined criteria based on chief complaint, patient age and vital signs will be used to determine when a decision rule may be relevant in a patient encounter. When a patient meets all of the predefined criteria, the intervention will be triggered.
9723624|NCT04129554|Placebo Comparator|Placebo for JNJ-73763989+ Placebo for JNJ-56136379+ NA|Participants will receive matching placebo for JNJ-73763989 subcutaneous injection once every 4 weeks with matching placebo for JNJ-56136379 once daily and NA treatment (either ETV, TDF or TAF) once daily up to 48 weeks.
9723625|NCT04119050|Experimental|M281 administered every 4 weeks (double-blind period)|Participants will receive M281 administered every 4 weeks alternating with placebo every 4 weeks during the 24 weeks double-blind period.
9723626|NCT04119050|Experimental|M281 administered every 2 weeks (double-blind period)|Participants will receive M281 administered every 2 weeks during the 24 weeks double-blind period.
9723627|NCT04119050|Experimental|Placebo administered every 2 weeks (double-blind period)|Participants will receive M281 matching placebo administered every 2 weeks during the 24 weeks double-blind period.
9723628|NCT04119050|Experimental|M281 administered every 4 weeks (open-label extension period)|Participants will receive M281 administered every 4 weeks during the 28 weeks open-label extension period.
9723629|NCT04119050|Experimental|M281 administered every 2 weeks (open-label extension period)|Participants will receive M281 administered every 2 weeks during the 28 weeks open-label extension period.
10197393|NCT04702308|No Intervention|Control Group|The control group will be usual care. Specifically, providers in the control group will not receive the clinical decision rule alert or the default suggested calculator tab in the MDCalc Connect app. The control group providers will have access to the MDCalc Connect app in its standard form and functionality.
9723630|NCT04099849|Experimental|Group A|"Diet-ZnBfR zinc biofortified rice-based diet~Diet- CR conventional rice-based diet"
9723631|NCT04099849|Experimental|Group B|"Diet-ZnBfR zinc biofortified rice-based diet~CR + Zn conventional rice-based diet plus zinc fortificant (Diet-CR+Z)."
10197394|NCT04700111|Experimental|Treatment 1 - DOT Pattern|Spectacle lens or treatment 1
9723632|NCT04095442|Active Comparator|Cepacol|
9723633|NCT04095442|Sham Comparator|Tom's Natural Mouthwash|
9723634|NCT04093934|Experimental|Intervention|Children in the intervention arm will receive sessions of psychosocial stimulation every two weeks at the community clinics for one year. The intervention includes songs, games, book and toy activities for undernourished children and nutritional and developmental messages for their mothers.
9723635|NCT04093934|No Intervention|Wait-listed control|The wait-listed controls will be only tested at baseline and after a year. Following completion of the 2nd test, they will be included in the study and receive the same intervention provided to children in the experimental arm.
9723636|NCT04092582|Experimental|MTPS9579A|
10197395|NCT04700111|Active Comparator|Treatment 2 - Control Spectacles|Comparator lens or control arm
9723637|NCT04092582|Placebo Comparator|Placebo|
10197396|NCT04699422|Active Comparator|Experimental group|Patients in the experimental group will receive the serratus anterior plane block combined with postoperative PCIA with Piritramide.
10197397|NCT04699422|Sham Comparator|Control group|Patients in the control group will receive postoperative PCIA with Piritramide.
10197398|NCT04697563|Active Comparator|Laser|"Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia.~Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions."
10204841|NCT04800627|Experimental|Treatment (pevonedistat, pembrolizumab)|Patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9723638|NCT04091867|Experimental|sEphB4-HSA with CRT|"sEphB4-HSA: Loading dose at fixed dose of 10mg/Kg per below schema on D1 Concurrent dose per below schema D15-43 and given on an every other week basis Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).~Cetuximab:~Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window~RT:~6930 cGy IMRT starting D15-D18"
9723639|NCT04090424|Experimental|NovoSorb BTM|Application of NovoSorb BTM to study lesions
9723640|NCT04090424|Active Comparator|Standard of Care|Application of the institution's standard to care to study lesions.
9723641|NCT04087018|Experimental|TMB-H|Participants with a tumor biomarker status of TMB-H will receive zimberelimab every 3 weeks.
9723642|NCT04087018|Experimental|Strata Immune Signature positive|Participants with a tumor biomarker status Strata Immune Signature positive will receive zimberelimab every 3 weeks.
9723643|NCT04083287|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
9836221|NCT02776033|Experimental|GSK2982772 receivers in Cohort 1|Randomized subjects will receive GSK2982772 BID (approximately 12 hours apart) via oral route for 84 days.
9723644|NCT04083287|Active Comparator|Group I = ISCB group|In group I, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
9723645|NCT04082910|Experimental|Conditional therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was initially given from the day of CRS diagnosis confirmation post CAR T cell infusions till CRS remission in patients without bulky tumor burden. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
9723646|NCT04082910|Experimental|Prophylactic therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was given starting from the day before CAR T infusion till CRS remission in patients with bulky disease. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
9723647|NCT04074330|Experimental|Phase 1,Aggressive/Indolent Non-Hodgkin Lymphoma (aNHL/iNHL):TAK-981(10-160 mg)+Rituximab 375 mg/m^2|TAK-981 (at increasing dose levels from 10 milligram [mg] to 160 mg), infusion, intravenously, once on Days 1 and 8 OR on Days 1, 4, 8, and 11 twice weekly (BIW) every 21 days in each 21 day treatment cycle in combination with rituximab 375 milligram per square meter (mg/m^2), infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or disease progression (PD) or unacceptable toxicity. Dose levels will be escalated based on available safety, PK and pharmacodynamic data.
10197399|NCT04697563|Placebo Comparator|Placebo Laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
9723648|NCT04074330|Experimental|Phase 2, Cohort A: r/r DLBCL Progressed to CAR T-cell therapy|TAK-981 recommended Phase 2 dose (RP2D), infusion, intravenously, once on Days 1 and 8 OR on Days 1, 4, 8, and 11 BIW every 21 days in each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity in participants with r/r diffuse large B-cell lymphoma (DLBCL) progressed or relapsed after a prior chimeric antigen receptor (CAR) T-cells therapy that has received approval by a health authority for the treatment of DLBCL.
9723649|NCT04074330|Experimental|Phase 2, Cohort B: r/r DLBCL with no CAR T-cell Prior Therapy|TAK-981 RP2D, infusion, intravenously, once on Days 1 and 8 OR on Days 1, 4, 8, and 11 BIW every 21 days in each 21 day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity in participants with r/r DLBCL that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy and no prior therapy with CAR T-cells.
9723650|NCT04074330|Experimental|Phase 2, Cohort C: r/r FL Progressed to Systemic Therapies|TAK-981 RP2D, infusion, intravenously, once on Days 1 and 8 OR on Days 1, 4, 8, and 11 BIW every 21 days in each 21 day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to 12 months or PD or unacceptable toxicity in participants with r/r follicular lymphoma (FL) that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy.
9723651|NCT04064437||Individuals with type 1 diabetes|
9723652|NCT04064437||Healthy controls|
10197400|NCT04695431||Patients from the BLU-285-2101 and BLU-285-2202 studies|Patients with advanced systemic mastocytosis who received treatment with avapritinib as part of the BLU-285-2101 and BLU-285-2202 studies
9723653|NCT04053166|Experimental|Individualized home-based physical activity|The subjects of this arm will have a daily goal in number of steps based on the initial 2 first week evaluation of daily number of steps. They will wear connected wrists, and will be contacted twice a month by phone call by the adapted physical activity trainer to revaluate these goals.
9723654|NCT04053166|Active Comparator|Control group|The subjects of this arm will not have evaluation of daily steps and recommendations regarding physical activity and sedentary behaviour. They will be asked to live as usual.
10197401|NCT04695431||External Control Group|Patients with advanced systemic mastocytosis that received best available therapy
9723655|NCT04041284|Experimental|fremanezumab|monthly 225 mg. In the open-label extension phase starting at week 12, all patients will receive active treatment with a quarterly dose of 675 mg sc
10197402|NCT04693429|Experimental|PRO-172|PRO-172 Ophthalmic Solution QID (four times per day). Single arm.
10197403|NCT04693260|Other|Hand-held Device Supported by Mobile Application|Insight device ETDRS measurement compared to a standard ETDRS chart
10197404|NCT04693247|Active Comparator|Refraction with a Hand-held Refraction Device|This is the device that will be compared to a standard device.
10197405|NCT04693247|Other|Autorefractor|Standard Device
10197406|NCT04690374||Desmoplastic small round cell tumor (DSRCT)|Collect historical/longitudinal clinical, radiographic and molecular features of DSRCT patients as documented in medical records to improve knowledge about DSRCT
10197407|NCT04688242|Experimental|Treatment Arm|Anal dilatation plus probiotics per anus Q3D, starting from 2 weeks after proctectomy until reduction of ileostomy.
10197408|NCT04688242|No Intervention|Control Arm|No anal dilatation or probiotics per anus was allowed, from 2 weeks after proctectomy until reduction of ileostomy.
10197409|NCT04686773|Experimental|AZD1222 5×10^10 vp + rAd26-S (1.0±0.5) х 10^11vp|Subjects will receive 1 intramuscular (IM) injection of 5×10^10 viral particles (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×10^11 viral particles (nominal) on Day 29 of the study.
9723656|NCT04041284|Placebo Comparator|Placebo|
9723657|NCT04039113|Active Comparator|Tezepelumab|Tezepelumab, SC, Q4W
9723658|NCT04039113|Placebo Comparator|Matching Placebo|Matching placebo, SC, Q4W
9723659|NCT04035473|Active Comparator|Sequence A (Oraxol, IV paclitaxel)|"The treatment sequences will be:~A Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2 B IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2"
9723660|NCT04035473|Active Comparator|Sequence B (IV paclitaxel, Oraxol)|"The treatment sequences will be:~A IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2 B Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2"
10197410|NCT04686266|Experimental|ViCCY: Health Information + Health Coaching|This group will receive 10 front-loaded sessions of virtual health coaching by trained Health Coaches over 6 months with content based on the theoretical framework our prior research. Sessions are provided using tablets. Initially, sessions are weekly to build the relationship, but the frequency of sessions decreases over time
9723661|NCT04035382|Experimental|Labor Induction|Induction of labor between 39 0/7 to 39 6/7 weeks. Cervical ripening and induction method will be left to the managing clinician. However, combination method of cervical ripening with prostaglandin or oxytocin and Foley catheter, followed by oxytocin infusion and amniotomy will be encouraged.
9723662|NCT04028947|No Intervention|Standard TKA|Subjects will have the standard procedure.
9723663|NCT04028947|Active Comparator|TKA with Neurectomy|Subjects will the nerve excised and protected with soft tissue.
9723664|NCT04025463|Other|Intervention|Hybrid type II effectiveness/implementation study design - pre-post design with each participant serving as his or her own control.
9723665|NCT04016532|Other|Patient malnourished or at risk of undernutrition|Dietary follow-up at home: 4 visits (D15, D30, D60, D90)
9723666|NCT04016532|Other|Not undernourished patients|Dietary follow-up at home: 3 visits ( D30,D60, D90)
9723667|NCT04012931|Experimental|Rilpivirine (RPV) (25 mg or adjusted weight-based dose)|Participants will receive rilpivirine (RPV 25 milligram [mg], adjusted weight-based dose) orally once daily in combination with an investigator selected background regimen (that is investigator-selected antiretrovirals [ARVs] such as nucleoside/nucleotide reverse transcriptase inhibitor [N{t}RTIs] and integrase inhibitors) for 48 weeks.
9723668|NCT04001881||Hypotension group|spinal anesthesia in Hypotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
9723669|NCT04001881||Normotension group|spinal anesthesia IN Normotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
9723670|NCT03999424|Experimental|Autologous human Schwann cells|All participants will receive autologous human Schwann cells harvested from their own sural nerve.
9723671|NCT03995966|Active Comparator|Subtype 2 Automatically Maintained SIB|
9723672|NCT03995966|Active Comparator|Subtype 3 Automatically Maintained SIB|
9723673|NCT03993457|Other|CRP<1, CRP consistent antidepressant selection|Participants with CRP<1 will be prescribed escitalopram
9723674|NCT03993457|Other|CRP> or equal to 1, CRP consistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed bupropion XL
9723675|NCT03993457|Other|CRP<1, CRP inconsistent antidepressant selection|Participants with CRP< 1 will be prescribed bupropion XL
9723676|NCT03993457|Other|CRP> or equal to 1, CRP inconsistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed escitalopram
9723677|NCT03993301|Experimental|Probiotic A formula|Infant Formula with Lactobacillus salivarius.
9723678|NCT03993301|Experimental|Probiotic B formula|Infant Formula with Bifidobacterium lactis.
10197411|NCT04686266|No Intervention|Health Information|Caregivers in the Health Information group are asked to spend at least 30 minutes weekly using the computer tablet provided to you by the study team to access recommended websites
10197412|NCT04684953|Active Comparator|Thyroid autotransplantation|Implantation of 5-10 gm thyroid gland after mincing it in saline in quadriceps femoris muscle.
10197413|NCT04684953|Other|control group|the patients in this group won't undergo thyroid autotransplantation. instead, hormonal replacement therapy shall be prescribed for them.
10197414|NCT04682483||Cardiogenic Shock Patients|"Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below.~Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP < 60mmHg or a >30mmHg drop in MAP from baseline, SBP < 90mmHg or a >30mmHg drop in SBP from baseline, Pulse > 100, Cardiac Index < 2.2, Cardiac Power Output ≤ 0.6 or PAPI < 1.0.~Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets."
10197415|NCT04676594||Diagnosis of Pulmonary Fibrosis on Chest CT|Retrospective chart review of patients with a diagnosis of pulmonary fibrosis on chest CT.
10197416|NCT04676451|Experimental|Femto-AK Patients|Femtosecond laser assisted cataract surgery with creation of astigmatic keratotomies for the correction of corneal astigmatism.
10197417|NCT04676386||PD1/PD-L1|Standard of Care: PD1/PD-L1 monotherapy
10197418|NCT04676386||PD1/PD-L1 + chemo|Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination
9723679|NCT03993301|Placebo Comparator|Regular formula|The infant formula without any probiotic.
9723680|NCT03992040||Reinforced SSIAD (SSIADR arm )|"Reinforced Home Nursing Care Services: Patients with a score between 11 and 21 on the regional public health authorities (ARS) score.~This arm will benefit from better coordination and delivery of care, which can reduce hospitalizations and visits to emergency departments"
9723681|NCT03992040||Classic SSIAD (Control arm)|Classic Home Nursing Care Services. For this arm, no direct benefit is expected since taking care, even for the heaviest patients, corresponds to current practice.
9723682|NCT03989245||Target arm: UCC (Cognitive Behavioural Unit)|Patients receiving care in Cognitive Behavioural Unit (UCC )
10197419|NCT04674020|Experimental|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI).
10197420|NCT04673786|Experimental|CT-P43|All patients who were initially randomized to the CT-P43 group on Day 1 (Week 0) will continue their treatment with CT-P43 until Week 40.
10197421|NCT04673786|Active Comparator|Stelara|Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.
10197422|NCT04668443||Prospective participants in D²EFT study|HIV-positive persons who are eligible for the D²EFT study will be proposed to receive the research-related information with the set of pictures (GIC)
10197423|NCT04668443||Researchers obtaining informed consent for D²EFT study|Healthcare givers involved in the participant informed consent process of D²EFT
10197424|NCT04667637|Placebo Comparator|0.9% NaCl|Intravenous injections of 0.9% NaCl BID for 12 ±2days.
10197425|NCT04667637|Experimental|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 12 ±2days.
10197426|NCT04667416|No Intervention|Standard of Care (SOC)|Participants will receive SOC for chronic ulcers of the lower extremities.
10197427|NCT04667416|Experimental|PalinGen Flow Treatment plus SOC|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
10197428|NCT04666545|Experimental|Intervention|"This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to help and enable the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation."
10197429|NCT04666545|No Intervention|Usual Care (control)|In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
10197430|NCT04661748|Active Comparator|Intervention arm|Active alarms
10197431|NCT04661748|No Intervention|no intervention|No alarms
10197432|NCT04659317|Active Comparator|Opioid Group|"Participants will receive encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
10197433|NCT04659317|Experimental|Placebo Group|"Participants will receive encapsulated placebo tablets x24, to take po q6 hours as need for pain after surgery Safety Prescription: Oxycodone5 mg po q6 hours as needed for pain"
10197434|NCT04657315|Other|The investigational drug into the Intratumoral administration|The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery
10197435|NCT04655690|Experimental|NNC0471-0119|Participants randomised to NNC0471-0119
10197436|NCT04655690|Active Comparator|Faster aspart|Participants randomised to faster aspart.
10197437|NCT04653389|Experimental|Preoperative TACE+Sintilimab+/-Radiotherapy of vein tumor thrombus+postoperative Sintilimab|The first TACE and immunotherapy will be performed at the same time on the first day of treatment. Anti-PD-1 Injection will be administered every three weeks ,until the disease progresses according to mRECIST criteria or intolerable toxicity or the patients' request, or surgery.Hypofractionated radiation therapy will be adopted for Type Vp2, Vp3 PVTT or Type Vv2 HVTT about 2 weeks after the first TACE.If the imaging examination 4 weeks after the surgery confirm that there is no recurrence and no contraindications to receive immunotherapy, anti-PD-1 antibody adjuvant therapy can be started.Every 21 days is a course of treatment, and the longest medication duration lasts for 6 months.
10197438|NCT04652843|Other|Idiopathic REM sleep behavior disorders|Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
10197439|NCT04652843|Other|Beginning Parkinson's disease|Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy
10197440|NCT04652843|Other|Parkinson's disease state Phase|Group of 20 patients with Parkinson's Disease for more than 5 years
10197441|NCT04652843|Other|Control|Group of 20 patients undergoing coloscopy for family screening for digestive polyps
10197442|NCT04652583|Active Comparator|Active Stimulation 20 minutes|Intramuscular stimulation
10197443|NCT04652583|Active Comparator|Active Stimulation 60 minutes|Intramuscular stimulation
10197444|NCT04652583|Sham Comparator|Sham Stimulation 20 minutes|Muscle-free-zone stimulation
10197445|NCT04651296|Experimental|compassion meditation|10 week, group-based manualized compassion meditation training
10197446|NCT04651296|Active Comparator|health education|10 week, group-based manualized health education protocol
10197447|NCT04646564|Active Comparator|control arm|standard of care
10197448|NCT04646564|Experimental|study arm|radiotherapy + standard of care
10197449|NCT04641312|Experimental|LY3457263 - Part A|Escalating single doses of LY3457263 administered subcutaneously (SC) to healthy participants
10197450|NCT04641312|Placebo Comparator|Placebo - Part A|Placebo administered SC to healthy participants
10197451|NCT04641312|Experimental|LY3457263 - Part B|Escalating single doses of LY3457263 administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
10197452|NCT04641312|Placebo Comparator|Placebo - Part B|Placebo administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
10197453|NCT04640220|Experimental|Adhesive capsulitis in breast cancer survivors|Intra-articular steroid injection
10197454|NCT04639336||Patients with Pompe disease|
10197455|NCT04639141|Active Comparator|Synbiotic|"Dosing: one sachet/dose per day for 12 weeks. The combination includes: Lactobacillus rhamnosus (1x10^10 CFU/dose), Lactobacillus plantarum (4 x 10^9 CFU/dose), Bifidobacterium animalis subsp. lactis (5 x 10^9 CFU/dose), Bifidobacterium longum (1 x 10^9 CFU/dose) + 4g/dose of partially hydrolysed guar gum (PHGG).~Mode of administration: oral."
10197456|NCT04639141|Experimental|Synbiotic + gut-directed hypnotherapy|"Includes the daily oral synbiotic (as pervious described) + a home-based therapy program.~Home-based therapy program: based on the Manchester model of gut-directed hypnotherapy (GDH) adapted for use in children with ASD. The GDH core therapy focus areas will be relaxation, control of gut function and ego-strengthening.~Schedule: daily use of a home-based audio recordings. The program will consist of six (6) therapy sessions/recordings over 12 weeks. Each recording (sessions 1 through 6) is to be used daily for a fortnight. Each session is approximately 15-20 minutes in duration."
9723683|NCT03989245||Control arm: SSR (Geriatric Follow-up and Rehabilitation Unit)|Patients receiving care in Geriatric Follow-up and Rehabilitation Care Unit (SSR)
10197457|NCT04636853|Experimental|Affected Individual|A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
10197458|NCT04635787||Healthy Adults|Adults 18 years or older
10197459|NCT04635787||COVID19|Adults 18 years or older diagnosed with COVID 19
10197460|NCT04635423|Experimental|V503|Participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
9723684|NCT03988400|Experimental|Sensory augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
9723685|NCT03988400|Active Comparator|Random vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
10197461|NCT04635423|Placebo Comparator|Placebo|Participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.
10197462|NCT04634383|Experimental|WFMA Cortical Visual Prosthesis Single-arm Study|The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.
10197463|NCT04631120|Active Comparator|Standard of Care|The proposed arm will involve an initial assessment using the Clinical Dementia Rating (CDR) Scale and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score for patients and Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard educational material from the AA and Association for the Advancement of Retired Persons (AARP). Two phone sessions with a study nurse will occur post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment; a summary of these and professional education on national evidence-based guidelines will be mailed to the patient's PCP of record. Education provided in this arm will be both patient- and caregiver-centered.
9723686|NCT03982199|Experimental|Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, 1C and 1D to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, 3 years and 4 years respectively after the first vaccination.
9723687|NCT03982199|Placebo Comparator|Group 2: Placebo|Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, 2C, 2D and will first receive Ad26.RSV.preF based vaccine at years 1, 2, 3 and 4. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.
9723688|NCT03978325|Active Comparator|Control|This arm will complete a standard prehabilitation intervention.
9723689|NCT03978325|Experimental|HIIT Intervention|This group will complete a pre-operative high intensity interval training programme.
9723690|NCT03978130|Experimental|mHealth-CR|
9723691|NCT03978130|No Intervention|Usual Care|
9723692|NCT03974061|Experimental|Brief Acceptance and Commitment Therapy|Participants randomized to the Acceptance and Commitment Therapy (ACT) arm will receive one, 1-hour intervention session followed by five weekly 30-45 minute intervention sessions delivered via telephone.
9723693|NCT03974061|Active Comparator|Brief Alcohol Intervention|Participants randomized to the Brief Alcohol Intervention (BI) will receive the following telephone-based sessions over the duration of six weeks: a 30-45 minute session of a brief alcohol intervention, a 5-10 minute booster call, a reminder phone call for the next intervention session, a 30-45 minute intervention session, a 5-10 minute booster, and a reminder phone call for the post-treatment appointment.
9723694|NCT03970538|Experimental|Treatment Arm|Treated with the LimFlow System
9723695|NCT03964415|Experimental|Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine|Participants will receive adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) via intramuscular (IM) injection into the deltoid muscle at months 0 (Day 1) and 3 (preferably the deltoid of the non-dominant upper arm) and, Ad26.Mos4.HIV together with Clade C and Mosaic gp140 HIV bivalent vaccine IM into the deltoid muscle at Months 6 and 12 (different deltoid for each injection).
9723696|NCT03964415|Placebo Comparator|Group 2: Placebo|Participants will receive placebo into the deltoid muscle on Months 0 (Day 1), 3 (1 injection), 6 and 12 (2 injections).
9723697|NCT03958734|Other|Low physical activity/fitness|Participants will be classified as into low-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
10197464|NCT04631120|Experimental|Integrated Dementia Practice Unit Arm|"The integrated practice unit design is a coordinated, team-based, comprehensive, technology enabled, family focused care delivery design comprised of:~Dementia Central: Nurses, physicians, psychologists, social workers, and other relevant healthcare providers that will meet monthly to review participants progress and issues. Telehealth visits would facilitate home care.~Dementia Mobile: A nurse and lay health educator team will perform monthly visits, conduct assessments of subjects and provide education/coaching.~Dementia Link: Technologies that facilitate communication between Dementia Central and Dementia Mobile and foster proactive collaboration/coaching for study subjects include an mHealth software that allows for real time intervention/communication between professional teams and dyads, combined with management of dyads for multiple parameters like health metrics, behavioral measures and stress management and a portal tailored to specific clinical needs."
10197465|NCT04626947|Other|Open label|Single arm
10197466|NCT04626466||Non-metastatic prostate, rectum, canal, endometrium, cervix or vaginal cancer Radiotherapy treatment|
10197467|NCT04625153|Experimental|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
10197468|NCT04625153|Experimental|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
10197469|NCT04623138||Garmin Study Device Group|Individuals who are randomly assigned to receive the Garmin vívosmart® 4
10197470|NCT04623138||Empatica Study Device Group|Individuals who are randomly assigned to receive the Empatica E4
9980875|NCT01396460||control group|morbid obese population
10197471|NCT04614324|Experimental|RhinAer ARC Stylus Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nostrils treated in the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve.
10197472|NCT04611802|Experimental|SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period. One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 or Day 21 in Crossover Vaccination Period.
10197473|NCT04611802|Placebo Comparator|Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. One dose of Placebo (Saline) on Day 0 or Day 21 in Crossover Vaccination Period.
10197474|NCT04611763|Experimental|Pre FA Group|
10197475|NCT04611763|Active Comparator|Post FA Group|
10197476|NCT04608786|Experimental|Combined the therapy using Capecitabine and PD-L1|PD-L1 antibody ZKAB001 D1 5mg/kg every three weeks,up to 16 cycles or 1 year of treatment or the patient has tumor recurrence or metastasis Capecitabine 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis
10204842|NCT04798248|Experimental|Momentary Affect Regulation - Safer Sex Intervention|Momentary Affect Regulation - Safer Sex Intervention (MARSSI) is the treatment condition. MARSSI aims to enhance an individual's motivation to change risk behaviors, provides skills to address depression's effects on behavior, and prompts and reinforces healthy affect regulation, cognitive behavioral skill use, and behavior change in daily life.
10204843|NCT04798248|Sham Comparator|Podcast Health Group|The Podcast Health Group is the control counterfactual condition.
10204844|NCT04792073|Experimental|Avelumab and Radiation Therapy|Will receive avelumab at the FDA approved dose and schedule of 800 mg IV over 60 minutes every 2 weeks (+/- 3 days) until treatment intolerance or disease progression occurs.Comprehensive Ablative Radiation Therapy (CART) will be initiated between the first and second dose of avelumab. Comprehensive ablative radiation therapy will be given according to guidelines
10204845|NCT04782687|Experimental|Selinexor plus DRd|"Lenalidomide 25 mg orally on Days 1-21 of each 28-day cycle~Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those >75 years old may be administered a weekly dose of 20 mg dexamethasone.~Daratumumab 1800 mg subcutaneous injection once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter.~Selinexor 60 mg on Days 1, 8, 15, of cycles 1-3, with a planned dose-reduction to 40 mg on Days 1, 8, 15 for cycles beyond 3. If patient was previously dose reduced prior to cycle 4, then at cycle 4 planned dose reduction, you will again decrease dose by 1 level."
10204846|NCT04768322|Experimental|Early Left Ventricular Assist Device and Guideline Directed Medical Therapy|The intervention group will receive an early left ventricular assist device implantation (bridge to transplantation, bridge to candidacy or destination therapy) in addition to guideline directed medical therapy within 21 days of randomization.
10204847|NCT04768322|Other|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists if tolerated.
10204848|NCT04752150|Active Comparator|Group ESPB = Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
10204849|NCT04752150|Active Comparator|Group RIB = RIB group|In group RIB, RIB block will be performed with patients in the lateral decubitus position while the surgical site up. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 30 ml 0,25% bupivacaine will be injectted into the fascial plane.
10204850|NCT04744272|Active Comparator|Intervention|Participants randomised to the intervention arm will be provided with access to the digital web-based application (app) myAsthma.
10204851|NCT04744272|No Intervention|Control|Participants randomised to the control arm will continue with standard care processes
10204852|NCT04742673|Placebo Comparator|Placebo|"Participants will flow through the trial in the following manner:~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~Pre-randomization phase: twice daily assessments of mental status~Randomize delirious patients: IV guanfacine or placebo~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
10204853|NCT04742673|Experimental|IV Guanfacine|"Participants will flow through the trial in the following manner:~Consent in ICU: perform required inclusion/exclusion assessments; discuss study goals, activities, and requirements; obtain informed consent~Pre-randomization phase: twice daily assessments of mental status~Randomize delirious patients: IV guanfacine or placebo~Interventional Trial phase: study drug administration, mental status assessments, safety monitoring~Blood draws: collect blood samples on Interventional Trial Phase days 1 and 2~Follow-up assessments: telephone and online questionnaires at 30, 90, and 180 days after hospital discharge."
9980876|NCT01396473|No Intervention|control|
9980877|NCT01396473|Experimental|Policy and Environmental Change|
9980878|NCT01396499|Experimental|BKM120|Oral BKM120 starting dose 80 mg once daily.
9723698|NCT03958734|Other|High physical activity/fitness|Participants will be classified as into high-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
9723699|NCT03958019|Experimental|Intervention Group|12 week multidisciplinary program consisting of; i) supervised and home-based aerobic and resistance training, ii) 1:1 dietary counselling, and iii) group education sessions.
9723700|NCT03958019|No Intervention|Control|Usual care control group
9723701|NCT03957252||Training Cohort|1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than or equal to than 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
9723702|NCT03957252||Validation Cohort|Up to 1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than or equal to 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
9723703|NCT03952962|Experimental|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
9723704|NCT03952962|Experimental|Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
10197477|NCT04608773|Other|Biotene Spray, followed by Refresh Spray|The Biotene Spray followed by Refresh Spray Arm will be asked to complete a 2 week trial using Biotene Spray first, then will be asked to complete a 2 week trial using Refresh Spray second. (after the appropriate 1 week washout periods have been completed)
9723705|NCT03938870||Experimental: Group 1|30 Young Normal Controls(YNC) ages 18 & Older will enroll to evaluate leucine infusion methods of labeling, vs. the oral method. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
9723706|NCT03938870||Experimental: Group 2|Group 30 CDR > 0. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
9723707|NCT03938870||Experimental: Group 3|Group of 40 CDR = 0 Age Matched. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
9723708|NCT03938415|Experimental|Acupuncture|Acupuncture
9723709|NCT03938415|Active Comparator|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone
9723710|NCT03935867|Experimental|C-PROFET group|Community-dwelling, older adults participating in a home-based program -- C-PROFET, our adaptation of Prevention Of Falls in the Elderly Trial (PROFET).
9723711|NCT03933670|Experimental|Diagnostic (HP C-13 MRI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute, then undergo MRSI after 1-2 minutes. Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks following HP C-13 MRSI.
9723712|NCT03929757|Experimental|Arm 1: Ad26.ZEBOV, MVA-BN-Filo|Participants will be administered 0.5 mL of Ad26.ZEBOV vaccine (5*10^10 viral particles [vp]) on Day 1 by intramuscular (IM) injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 infectious units [Inf U]) vaccine by IM injection on Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit. Upon completion of the main study, participants in the extension phase who were originally randomized to the control arm will receive the same vaccine regimen as the participants in the Ad26.ZEBOV, MVA-BN-Filo arm of the main study.
9723713|NCT03929757|Active Comparator|Arm 2: MenACWY|Participants will be administered 0.5 mL of MenACWY vaccine by IM injection on Day 1 and Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.
9723714|NCT03916237|No Intervention|CONTROL|Control group
9723715|NCT03916237|Experimental|GROUP A no referral|Screener does not document need for home visit or medical legal partnership referral.
9723716|NCT03916237|Experimental|GROUP B1 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener does not document need for medical legal partnership.
10197478|NCT04608773|Other|Refresh Spray, followed by Biotene Spray|The Refresh Spray, followed by Biotene Spray Arm will be asked to complete a 2 week trial using Refresh Spray first, then will be asked to complete a 2 week trial using Biotene Spray second. (after the appropriate 1 week washout periods have been completed)
10197479|NCT04607200|Experimental|Monotherapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks for up to 24 months
9723717|NCT03916237|Experimental|GROUP B2 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener documents need for medical legal partnership.
9723718|NCT03916237|Experimental|GROUP C1 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener does not document need for medical legal partnership.
9723719|NCT03916237|Experimental|GROUP C2 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener documents need for medical legal partnership.
10197480|NCT04607200|Experimental|Combination Therapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks + AGEN1884 - dose of 1 mg/kg IV every 6 weeks (following AGEN2034 infusion), for up to 24 months
10197481|NCT04603911|Active Comparator|Control|Control arm will receive standard of care solution for the ESPB block
10197482|NCT04603911|Active Comparator|Liposomal Bupivicaine|Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block
10197483|NCT04603027|Experimental|Cohort 1|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 0.8 x 10^11 cells, capsule, once daily, 16 weeks
10197484|NCT04603027|Experimental|Cohort 2|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 3.2 x 10^11 cells, capsule, once daily, 16 weeks
10197485|NCT04603027|Experimental|Cohort 3|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 8.0 x 10^11 cells, capsule, once daily, 16 weeks
9723720|NCT03916237|Experimental|D medical legal partnership only|Screener does not document need for home assessment. Screener does not document need for medical legal partnership.
9723721|NCT03915418|Experimental|Connected tools|1 night at home with connected tools only and 1 night at hospital with connected tools and PSG.
9723722|NCT03906747||Patients|Patients at their end-of-life (EOL) phase attending the emergency department
9723723|NCT03906747||Family members and next-of-kin of (EOL) patients|Family members and next-of-kin of EOL patients in the emergency department
9723724|NCT03906747||Healthcare workers|Comprised of doctors in the emergency department, nurses and general practitioners
9723725|NCT03906435|No Intervention|Control Arm|Standard of care information given by NICU staff and Follow up Clinic staff, including information about health care, diagnosis, medications, daily cares, anticipatory guidance, and discharge prep information.
9723726|NCT03906435|Experimental|Intervention CBT Arm|In addition to Standard of care information that the control arm receives, this arm will also receive 5 CBT sessions focusing on past NICU trauma, emotional coping, parental perceptions of child vulnerability, and helpful parenting and emotional coping skills.
9723727|NCT03905694|Experimental|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
9723728|NCT03904147|Experimental|Roll-In|TriClip Device treatment for physicians requiring additional training prior to beginning randomized cohort enrollment.
9723729|NCT03904147|Active Comparator|Randomized Cohort|TriClip (Device) Group vs. Medical Therapy (Control) Group
9723730|NCT03904147|Experimental|Single Arm|Subjects in which it is believed TR is not going to be reduced to moderate or less severity will receive the TriClip device.
9723731|NCT03891264|Experimental|CBD Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 4-week trial of a liquid formulation of CBD.
9723732|NCT03890497|Active Comparator|Full dose of IPV|IPV first dose between 9 -13 months with second dose administered 2 months later.
9723733|NCT03890497|Active Comparator|Fractional Dose of IPV|fIPV first dose between 9 -13 months with second dose administered 2 months later
9723734|NCT03876678|Experimental|Light therapy and oral L. salivarius|Light therapy and taking 1 L. salivarius probiotic capsule two times everyday for 7 days.
9723735|NCT03876678|Experimental|Light therapy and oral B. Animalis subsp. Lactis|Light therapy and taking 1 B. Animalis subsp. Lactis probiotic capsule two times everyday for 7 days.
9723736|NCT03876678|Placebo Comparator|Light therapy and oral placebo|Light therapy and taking 1 placebo capsule two times everyday for 7 days.
9723737|NCT03874104|Experimental|Study product|Extensively Hydrolysed Formula containing Pre- and Probiotics
9723738|NCT03870152|Experimental|EC treatment (Intervention Arm)|Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: a bronchoscopy surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
9723739|NCT03870152|No Intervention|AFB Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: bronchoscopy surveillance at 6, 12, 24, and at 36 months post-randomisation; with further bronchoscopy surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
9723740|NCT03860428|Active Comparator|Rectal ibuprofen|Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg
9723741|NCT03860428|Active Comparator|Intravenous paracetamol|Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days
9723742|NCT03860428|Sham Comparator|Expectant Treatment|Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.
9723743|NCT03827187|Experimental|Motor imagery based Brain computer interfacing|Brief assessment of motor imagery in response to command, auditory feedback training and responding to binary yes-no closed questions through Electroencephalography based Brain-computer interfacing.
9723744|NCT03823131|Experimental|Arm A: Tavo-EP, pembrolizumab, epacadostat|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks. Epacadostat will be administered at the dose level determined in the dose escalation safety lead-in.
9723745|NCT03823131|Experimental|Arm B: Tavo-EP, pembrolizumab|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks.
10197486|NCT04602312|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce coronavirus-related catastrophizing."
9723746|NCT03823131|Experimental|Arm C: Tavo-EP, pembrolizumab, CORVax|Tavo-EP will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30-minute IV infusion at a dose of 200 mg every 3 weeks. CORVax will be administered at a total dose of 0.2 mg of (S) protein plasmid in 120 microliter (uL) per lesion intratumorally into a maximum of 4 lesions of at least 0.3 mm in diameter for a total plasmid dose of 0.8 mg on treatment days 1 and 29 of cycle 1 followed by electroporation of the plasmid solution in infiltrated regions. On days when both tavo and CORVax is administered to the same lesions, tavo and CORVax will each be injected into the lesion followed by electroporation.
9723747|NCT03819049|Experimental|Cohort 1: ExPEC10V (Low Dose)|Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.
10197487|NCT04602312|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
9723748|NCT03819049|Experimental|Cohort 1: ExPEC10V (Medium dose)|Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.
9723749|NCT03819049|Experimental|Cohort 1: ExPEC10V (High dose)|Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.
9723750|NCT03819049|Experimental|Cohort 1: ExPEC4V|Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.
10197488|NCT04602312|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
9723751|NCT03819049|Experimental|Cohort 1: Prevnar 13|Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.
9723752|NCT03819049|Experimental|Cohort 2: ExPEC10V|Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.
9723753|NCT03819049|Placebo Comparator|Cohort 2: Placebo|Participants will be randomized to receive a single IM injection of matching placebo on Day 1.
9723754|NCT03813160|Experimental|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily
9723755|NCT03813160|Experimental|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily
9723756|NCT03813160|Placebo Comparator|Placebo|Subjects will receive placebo twice daily
10197489|NCT04602312|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
9723757|NCT03811236|Experimental|Cold exposure|
9723758|NCT03811236|No Intervention|Room temperature|
9723759|NCT03808870|Experimental|NBM-BMX|
10197490|NCT04602286|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce pain intensity and unpleasantness."
10197491|NCT04602286|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
10197492|NCT04602286|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
10197493|NCT04602286|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
10197494|NCT04595266|Active Comparator|Control|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab).
9723760|NCT03808350|Placebo Comparator|Families Excluded From Presence at Procedures|Families not invited to remain for ICU procedures
9723761|NCT03808350|Active Comparator|Families Invited to Be Present at Procedures|Families invited to remain for ICU procedures
9723762|NCT03799653||Nurses|All subjects are registered nurses in Xiamen, China
9723763|NCT03796676|Placebo Comparator|Placebo|Placebo
9723764|NCT03796676|Experimental|PF-04965842 100 mg QD|active
9723765|NCT03796676|Experimental|PF-04965842 200 mg QD|active
9723766|NCT03796273|Experimental|Arm I (ketoconazole)|Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
9723767|NCT03796273|Active Comparator|Arm II (standard surgery)|Patients undergo standard surgery.
9723768|NCT03760744|Experimental|CDT with Negative Pressure|CDT with LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
9723769|NCT03760744|Active Comparator|CDT alone|CDT alone without LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
9723770|NCT03742102|Experimental|Arm 1|durvalumab + paclitaxel
9723771|NCT03742102|Experimental|Arm 2|durvalumab + paclitaxel + capivasertib
9723772|NCT03742102|Experimental|Arm 5|durvalumab + paclitaxel + oleclumab
9723773|NCT03742102|Experimental|Arm 6|durvalumab + trastuzumab deruxtecan
9723774|NCT03742102|Experimental|Arm 7|durvalumab + datopotamab deruxtecan
9723775|NCT03732898|Experimental|New Programming Paradigm|This arm will include patients receiving stimulation with a new programming paradigm
9723776|NCT03731637||New-onset diabetes|Subjects with biochemically-defined new-onset diabetes
9723777|NCT03727919|Experimental|Early Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided within the first 6 weeks post-stroke
9723778|NCT03727919|Experimental|Delayed Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided between week 8 and week 12 post-stroke
9723779|NCT03726294|Experimental|NBM-BMX|
9780670|NCT01128621|Other|Part A|Part A is open label, in T2DM subjects on established metformin monotherapy. Subjects will receive a single dose of GSK1292263 with food. This will permit a comparison of GSK1292263 exposures in this cohort with those observed in study GPR111598 in which T2DM subjects were drug naïve or washed off prior anti-diabetic medications.
9836222|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 1|Randomized subjects will receive placebo BID via oral route for 84 days.
9723780|NCT03720821|Experimental|Cognitive Training + fMRI|"Participants will complete Trail Making Test (TMT) A & B (both electronic and paper-pencil), the paper-pencil Color-Word Matching Stroop Test (CWMST), and its electronic version called Color Match, and a computer-based subset of NCPT (Neurocognitive Performance Test). In addition, participants will also complete Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and the Resilience Scale questionnaires at baseline.~Participants will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.~Participants will be asked to undergo 2 functional magnetic resonance imaging (fMRI) sessions. One prior to, and one after the 5-week cognitive training period."
10197495|NCT04595266|Experimental|Experimental|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
10197496|NCT04594798|Experimental|Experimental: Polatuzumab Vedotin and R-CHOP|The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)
9723781|NCT03707262|Experimental|Donor CD34+ and CD3+ cell infusion|"The investigational products are (1) an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells (≥ 5 million cells per kilogram) followed by (2) an infusion of CD3+ cells (5 million cells per kilogram) from an HLA-identical sibling living donor.~The cells are infused around Day 11 post-transplant after the following pre-conditioning regimen:~5 doses of rATG (1.5 mg/kg IV per day for 5 days, starting on the day of transplant)~10 doses of TLI (120 centigray [cGY] x 10 fractions, starting the day after transplant)"
9723782|NCT03706833|Experimental|Edwards PASCAL System - CLASP IID|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with degenerative mitral regurgitation
9723783|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IID|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients with degenerative mitral regurgitation
9723784|NCT03706833|Experimental|Edwards PASCAL System - CLASP IIF|Transcatheter mitral valve repair with the Edwards PASCAL System in patients on guideline directed medical therapy with functional mitral regurgitation
9723785|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IIF|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients on guideline directed medical therapy with functional mitral regurgitation
9723786|NCT03702270|Experimental|Penicillin Allergic Floor Patients- Experimental|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
9723787|NCT03702270|No Intervention|Penicillin Allergic Floor Patients- Control|Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.
9723788|NCT03693365||Patients undergoing surgeries|"Patients undergoing surgery with general anesthesia and controlled mechanical ventilation with indication of invasive arterial blood pressure.~Classification ASA 2-4"
9723789|NCT03691610|Experimental|Group 1|MenACYW conjugate vaccine + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
9723790|NCT03691610|Active Comparator|Group 2|MENVEO® + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
9723791|NCT03691610|Experimental|Group 3|MenACYW conjugate vaccine at 17 to 19 months of age and 20 to 23 months of age
9723792|NCT03691610|Active Comparator|Group 4|Menactra® at 17 to 19 months of age and 20 to 23 months of age
9723793|NCT03687333|Experimental|Alglucosidase Alfa therapy|Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.
9723794|NCT03681184|Placebo Comparator|Placebo|Lumasiran-matching placebo (normal saline [0.9% NaCl]) was administered subcutaneously (SC) at Day 1 and Months 1, 2 and 3 during the 6-Month Double-blind (DB) Period, followed by lumasiran SC, 3.0 mg/kg, at Months 6, 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month Open-label Extension (OLE) period.
9723795|NCT03681184|Experimental|Lumasiran|Lumasiran was administered SC, 3.0 mg/kg, at Day 1 and Months 1, 2 and 3 during the 6-Month DB Period, followed by lumasiran SC, 3.0 mg/kg at Month 6, and lumasiran-matching placebo SC at Months 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month OLE period.
9723796|NCT03667443|Active Comparator|Myo-inositol plus folic|
9723797|NCT03667443|Active Comparator|Myo-inositol + folic a. + α-lactalbumin|
9723798|NCT03656510|Experimental|High Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 2.5 milligram per kilogram (mg/kg) (Age Group 1: greater than or equal to [>=] 28 days and less than [<] 3 months of age), 3 mg/kg (Age Group 2: >=3 months and <6 months of age) and 4.5 mg/kg (Age Group 3: >=6 months and less than or equal to [<=3] years of age) orally twice daily for 7 days.
9723799|NCT03656510|Experimental|Low Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 0.85 mg/kg (Age Group 1: >=28 days and <3 months of age), 1 mg/kg (Age Group 2: >=3 months and <6 months of age) and 1.5 mg/kg (Age Group 3: >=6 months and 3 years of age) orally twice daily for 7 days.
10197497|NCT04592536|Experimental|CVL-865|High dose CVL-865 (25mg) Low dose CVL-865 (7.5mg)
10197498|NCT04592536|Active Comparator|Alprazolam|Active Comparator Alprazolam with extended release oral tablets; 1 tablet BID
10197499|NCT04592536|Placebo Comparator|Placebo|Placebo Comparator matching oral tablets for CVL-865, capsule for Alprazolam
10197500|NCT04591106||Group 1|50 healthy subjects and 50 subjects with NAFLD between ages of 6-17 years old. Will receive 1 MRI/MRE exam. the MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
9723800|NCT03656510|Placebo Comparator|Placebo|Participants will be randomized to receive matching placebo (i.e. high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose) orally twice daily for 7 days.
9723801|NCT03656380|Experimental|Mepolizumab 300 mg|Subjects will receive Mepolizumab 300 mg subcutaneously (SQ) monthly for 6 months
9723802|NCT03656380|Other|Placebo, followed by Mepolizumab 100 mg|This arm will receive placebo, followed by Mepolizumab 100 mg. Subjects will receive placebo subcutaneously (SQ) monthly for 3 months, followed by Mepolizumab 100 mg subcutaneously (SQ) monthly for 3 months. Mepolizumab will be administered with 2 SQ injections of placebo and 1 SQ injection of Mepolizumab 100 mg to maintain blinding.
9723803|NCT03646071|Experimental|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
9723804|NCT03646071|Experimental|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
9723805|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
9723806|NCT03622515|Experimental|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
9723807|NCT03622515|No Intervention|Group C|Bispectral index (BIS)/Sedline monitoring
9723808|NCT03597165|Experimental|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
9723809|NCT03597165|Active Comparator|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
9723810|NCT03595774|Placebo Comparator|Placebo|3.3 mL/kg concentrated beet root juice *depleted of nitrate* Other names: Beet It Sport Nitrate 400 placebo
9723811|NCT03595774|Active Comparator|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice *depleted of nitrate*~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
9723812|NCT03595774|Active Comparator|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate~Other names:Beet It Sport Nitrate 400"
9723813|NCT03556332|Experimental|Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab & HCT|After receiving four 28-day cycles of Dara-CRd, eligible patients will then undergo HCT with high dose melphalan conditioning. Sixty to ninety days after HCT, patients will receive another 4 cycles of Dara-CRd.
9723814|NCT03544099|Experimental|Pembrolizumab for NPC patients|Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
9723815|NCT03540771|Active Comparator|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
9723816|NCT03540771|Active Comparator|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
9723817|NCT03523377|Experimental|prolonged overnight fasting|Participants randomized to the fasting arm will be instructed on how to use the SMS texting app to indicate the beginning and end of the nightly fast. In the first 2-4 weeks following randomization, intervention participants will complete three phone calls with study staff trained in motivational interviewing. These calls will be used to reinforce the prolonged overnight fasting instructions, identify barriers to prolonged overnight fasting, and support successes where they have occurred.
10197501|NCT04591106||Group 2|60 subjects with Liver Disease and Fibrosis between ages of 6-17 years old. Will receive 1 MRI/MRE exam. the MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
10197502|NCT04591106||Group 3|15 healthy subjects and 15 at-risk subjects (mother had gestational diabetes) between ages of 1-6 months old. Will receive 1 MRI scan.
10197503|NCT04591054|Active Comparator|Extended Vision IOL|Vivity
10197504|NCT04591054|Active Comparator|Neutral Aspheric Monofocal IOL|enVista [MX60E]
10197505|NCT04591015|Experimental|DD-CA|In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
10197506|NCT04591015|Active Comparator|Usual Care (UC)|UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
10197507|NCT04587440|Experimental|Patient|"All patients will have a clinical examination before surgery and another 3 months after surgery, each including :~A medical examination~3 pelvic inclination measurements (1 sitting, 1 lying and 1 standing). These measurements will be done by ultrasound devices.~2 EOS X-rays (1 standing and 1 sitting) of the lower limbs and spine~Harris hip score~Pain quantification thanks to an EVA scale~hand-ground distance"
10197508|NCT04574882||Case|Patients ages 40-74 with and without CHD (IICD 10: I63, I20-I25 ) within the last 6 months who receive care in the University of Pennsylvania Health System (UPHS).
10197509|NCT04574882||Control|Patients aged 40-74 who have non-cardiovascular-related chief compliant.
10197510|NCT04568629|Experimental|Algorithm Arm|Participants received prognostic advice from a prognostic algorihm.
10197511|NCT04568629|Experimental|Clinician arm|Participants recieved prognostic advice from another clinician.
10197512|NCT04565418|Experimental|Exercise training|12 week high-intensity interval training (3 sessions per week): Before and after exercise, subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws and indirect calorimetry.
10197513|NCT04564677||Patients eligible for laparoscopic ventral mesh rectopexy|Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for laparoscopic ventral mesh rectopexy (LVMR)
10197514|NCT04561700|Experimental|Reporting of sucking patterns captured by Instrumented Bottle|Weekly reporting on objective measurements of sucking activity during oral feeding
10197515|NCT04561700|Sham Comparator|Control|Weekly reporting on traditional measurements of sucking activity during oral feeding (no objective measurements reported)
9836223|NCT02776033|Experimental|GSK2982772 receivers in Cohort 2|Randomized subjects will receive GSK2982772 TID (approximately 8 hours apart) via oral route for 84 days
9723818|NCT03523377|Active Comparator|usual care|Participants randomized to the usual care arm will be instructed to eat a heart-healthy diet and exercise for at least 30 minutes five days a week, which is usual counseling in our clinics.
9723819|NCT03519074|Experimental|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
9723820|NCT03513302|Placebo Comparator|placebo|
9723821|NCT03513302|Active Comparator|nitrate|
9723822|NCT03502707|Placebo Comparator|Cohort (C)1 Group (G)1: Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
9723823|NCT03502707|Experimental|C1 G2: RSV preF Protein|Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.
9723824|NCT03502707|Placebo Comparator|C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
10197516|NCT04558489|Experimental|IPR + GMI|Participants receiving IPR + GMI will complete a 30-minute on-line intervention via qualtrics that covers the following topics: (1) Educate youth and caregiver that thoughts and emotions are not fixed but are malleable and subject to change; (2) provide youth and families with a brief intervention that instills hopefulness through an action plan for managing internalizing symptoms; (3) assist with developing system of support to access during times of distress; and (4) educate the caregiver on the importance of these interventions.
9723825|NCT03502707|Experimental|C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.
9723826|NCT03502707|Experimental|C1 G5: RSV preF Protein|Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
9723827|NCT03502707|Placebo Comparator|C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
9723828|NCT03502707|Experimental|C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
10197517|NCT04552535||Second line (2L) afatinib|Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
9723829|NCT03502707|Placebo Comparator|C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.
9723830|NCT03502707|Experimental|C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
10197518|NCT04552535||Second line (2L) chemotherapy|Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
10197519|NCT04549896|Experimental|CT scan|CT scan with a last generation 256 slice machine of occluded coronary artery before CTO PCI
10197520|NCT04549896|Active Comparator|Control|No CT scan before CTO PCI
9723831|NCT03502707|Experimental|C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo|Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
9723832|NCT03502707|Experimental|C2 G11: Ad26.RSV.preF and Placebo|Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
9723833|NCT03502707|Experimental|C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
9723834|NCT03502707|Experimental|C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
10197521|NCT04549597|Experimental|Cohort 1: Straight Switch|Patients stop taking phosphate binders and start tenapanor 30 mg twice daily
10197522|NCT04549597|Experimental|Cohort 2: Decrease Phosphate Binder by 50%|Decreases phosphate binder dose by at least 50% with the ability to switch the binder regiment from thrice daily (TID) to BID or once a day and initiates tenapanor 30 mg BID
10197523|NCT04549597|Experimental|Cohort 3: Phosphate Binder Naive|Phosphate binder naive patients are enrolled as Cohort 3 and receive tenapanor with a starting dose of 30 mg/BID
10197524|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM + Tech Detailing|
9723835|NCT03502707|Experimental|C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
9723836|NCT03502707|Experimental|C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
9723837|NCT03502707|Experimental|C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo|Data from C1 G10 will be pooled with those of C2 G16. Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and placebo in 1 arm on Day 57.
9723838|NCT03502707|Experimental|C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and placebo in another arm on Day 1.
9723839|NCT03502707|Placebo Comparator|C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo in separate arms on Day 1 and in only 1 arm on Day 57.
9836224|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 2|Randomized subjects will receive placebo TID via oral route for 84 days.
9723840|NCT03502707|Experimental|C3 G19: Selected Regimen (SR)|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12 and month 24. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.
9723841|NCT03502707|Experimental|C3 G20: SR + Placebo for SR|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and Month 24, and a placebo at Month 12. The participants who are randomized to two-dose regimen will receive selected regimen on Day 1 and Day 57, and a placebo at Month 12.
9723842|NCT03502707|Placebo Comparator|C3 G21: Placebo for SR|If a one-dose regimen is selected, participants in this group will receive placebo for SR on Day 1 and at Month 12 and Month 24. The participants who are randomized to two-dose regimen will receive placebo for SR on Day 1, Day 57, and Month 12.
9723843|NCT03498612|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
9723844|NCT03485430|Active Comparator|Intervention|Receives tapering of opioid dose at baseline
9723845|NCT03485430|No Intervention|Control|Waiting-list. Receives tapering after 4 months.
9723846|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
9723847|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
9723848|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.~Patients will receive rogaratinib plus atezolizumab combination treatment."
9723849|NCT03441308|Active Comparator|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
10197525|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM|
10197526|NCT04549259|Experimental|Social Support + Stigma Reduction + Technology Detailing|
10197527|NCT04549259|Experimental|Social Support + Stigma Reduction|
10197528|NCT04549259|Experimental|Social Support + SBCM + Technology Detailing|
10197529|NCT04549259|Experimental|Social Support + SBCM|
10197530|NCT04549259|Experimental|Social Support + Technology Detailing|
10197531|NCT04549259|Experimental|Social Support|
10197532|NCT04549259|Experimental|Stigma Reduction + SBCM + Technology Detailing|
10197533|NCT04549259|Experimental|Stigma Reduction + SBCM|
9723850|NCT03441308|Placebo Comparator|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
9723851|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
9723852|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
9723853|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
9723854|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
9780671|NCT01128621|Placebo Comparator|Part B - PLA|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
10197534|NCT04549259|Experimental|Stigma Reduction + Technology Detailing|
10197535|NCT04549259|Experimental|Stigma Reduction|
10197536|NCT04549259|Experimental|SBCM + Technology Detailing|
10197537|NCT04549259|Experimental|SBCM|
10197538|NCT04549259|Experimental|Technology Detailing|
10197539|NCT04549259|No Intervention|HIV Information Only|This arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.
10197540|NCT04547582|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
9723855|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
10197541|NCT04543526||Obese patients|Obese patients eligible for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.
10197542|NCT04543344|Experimental|Low Dose|Repeated multiple doses
10197543|NCT04543344|Placebo Comparator|placebo|Repeated multiple doses
10197544|NCT04543344|Experimental|High Dose|Repeated multiple doses
10197545|NCT04542824|Experimental|epcoritamab|Open label, single arm trial where epcoritamab will be administered
10197546|NCT04542421|Experimental|Lung ultrasound Implementation arm|Hospitalists undergo training to use lung ultrasound in their patients hospitalized with COVID
10197547|NCT04541979|Active Comparator|Aerosolized DNase I|
10197548|NCT04541979|Placebo Comparator|NaCl|
10197549|NCT04541797|Placebo Comparator|Control|Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
10197550|NCT04541797|Experimental|Intervention|Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
10197551|NCT04541654||Variant in the TP53 Gene in blood or saliva|Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history
10197552|NCT04541498||Population of Poland|Exposure to short term long term effects of air pollution and climate change
10197553|NCT04541498||Patients with Acute Coronary and Cerebral Syndromes|Exposure to short term long term effects of air pollution and climate change
10197554|NCT04538560|Experimental|Polar body biopsy group|The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
10197555|NCT04538560|No Intervention|Control group|The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.
10197556|NCT04537507||Patients underwent coronary angiography|We reviewed medical notes of patients hospitalized for coronary angiography because of exacerbated angina (recurrent chest pain, classical stable angina, long history of chest pain/angina or other symptoms such as dyspnea). We excluded patients with acute coronary syndromes (ACS), Tako-tsubo cardiomiopathy and history of ischemic heart disease, as well as those referred for coronary angiography before heart valve surgery. Prior cardiosurgical valve replacement was also the exclusion criterion.
10197557|NCT04537039|Other|All the participants.|This study only includes 1 arm.
10197558|NCT04536350|Experimental|Aviptadil Treatment|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
10197559|NCT04536350|Placebo Comparator|Placebo Treatment|Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
10197560|NCT04535609|Experimental|REN001|Once daily
10197561|NCT04535609|Placebo Comparator|Matched placebo|Once daily
10197562|NCT04533945|Other|FreeStyle Libre Device|Inpatients admitted to the medical-surgical units that are eligible for the trial will have the FreeStyle Libre device will be placed by the inpatient diabetes team at the discharge and glucose log will be obtained in 2 weeks followed by Hba1c in 3 months.
10197563|NCT04531553|Active Comparator|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 & T6 with bolus 20 ml of bupivacaine 0.25% then bupivacaine 0.1% infused at a rate of 6 mL/h for 48 hours.
10197564|NCT04531553|Active Comparator|ESPB with bupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of bupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted bupivacaine 0.1%, infused at a rate of 6 mL/h for 48 hours.
10197565|NCT04531553|Active Comparator|ESPB with bupivacaine and dexometedomidne|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of bupivacaine 0.25% plus 0.5mic/ml dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted bupivacaine 0.1% and dexmedetomidine 0.5 μg/mL infused at a rate of 6 mL/h for 48 hours.
10197566|NCT04530032|Experimental|TBI KD|TBI subjects on a ketogenic diet
10197567|NCT04530032|Sham Comparator|TBI SD|TBI subjects on a standard (normal) diet
10197568|NCT04529577|Experimental|His-bundle pacing first|Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.
10197569|NCT04529577|Experimental|RV apical pacing first|Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.
10197570|NCT04529265|Experimental|Methylene Blue group|The first dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: 1mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
10197571|NCT04529265|Placebo Comparator|Control group|The first dosage: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: normal saline in total 50 ml volume intravenous administration before the end of surgery within 30 minutes.
10197572|NCT04528680|Experimental|SC9/ABX|Infusion of albumin-bound paclitaxel immediately followed by sonication using the SC9 device and microbubbles in order to open the blood-brain barrier.
10197573|NCT04528303|Experimental|Whole genome sequencing|
10197574|NCT04528303|Active Comparator|Whole exome sequencing|
10197575|NCT04528238|Experimental|Relaxing Visual Immersion|The patients will benefit a Relaxing Visual Immersion during the intravenous treatment for their cancer.
10197576|NCT04528238|No Intervention|No sensitive stimulation|The patients will not receive Relaxing Visual Immersion during the intravenous treatment for their cancer.
9723856|NCT03441048|Experimental|Lintuzumab Ac225 Recommended Phase 2 Dose (RP2D)|The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
9723857|NCT03437720|Experimental|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
9723858|NCT03437720|Experimental|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
9723859|NCT03437720|Placebo Comparator|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
9723860|NCT03437720|Placebo Comparator|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
9723861|NCT03425526|Experimental|Treatment (allogeneic adenovirus-specific CTLs)|Within two weeks of enrollment, patients receive allogeneic adenovirus-specific CTLs IV over 30 minutes. Patients may receive additional allogeneic adenovirus-specific CTL infusions at the discretion of the investigator in the absence of disease progression or unacceptable toxicity.
10197577|NCT04525430|Experimental|Group 1|only childbirth education group
9723862|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
9723863|NCT03393182|Experimental|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
9723864|NCT03393182|Experimental|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
9723865|NCT03384641|Experimental|Bedaquiline|Participants will receive bedaquiline 200 (milligram) mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet three times a week (tiw) for 6 weeks with at least 48 hours between doses.
9723866|NCT03366220|Experimental|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
9723867|NCT03366220|Active Comparator|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
9723868|NCT03345576|Experimental|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
9723869|NCT03345576|Sham Comparator|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
10197578|NCT04525430|Experimental|Group 2|childbirth education and was subjected to a birth plan group
10197579|NCT04525430|No Intervention|Group 3|standard care group
10197580|NCT04523376|Experimental|Sickle Cell Disease|Patients with Sickle Cell Disease (SCD) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
9723870|NCT03338959|Experimental|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
9723871|NCT03337698|Active Comparator|Stage 1: Cohort 1: Atezolizumab|"Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria."
9785797|NCT01260350|Experimental|Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.
10197581|NCT04523376|Experimental|Beta Thalassemias Major|Patients with Beta Thalassemias Major (BTM) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
10197582|NCT04522674|Experimental|Autologous platelet rich plasma|0.5 mL of activated autologous PRP will be injected by fluoroscopic guidance into the affected lumbar facet joint (s) depending on the number of affected levels. A max of 4 joints will be injected per patient.
10197583|NCT04522180|Experimental|IONIS-GHR-LRx Dose 1|Single dose of IONIS-GHR-LRx Dose 1 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
9723872|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723873|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723874|NCT03337698|Active Comparator|Stage 1: Cohort 2: Docetaxel|"Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723875|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
10197584|NCT04522180|Experimental|IONIS-GHR-LRx Dose 2|Single dose of IONIS-GHR-LRx Dose 2 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
10197585|NCT04522180|Experimental|IONIS-GHR-LRx Dose 3|Single dose of IONIS-GHR-LRx Dose 3 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
10197586|NCT04520685|Experimental|Arm 1: 12 weeks of study drug then 15 weeks of placebo|Subjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks.
9723876|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + CPI-444|"Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723877|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723878|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Ipatasertib|"Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723879|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Docetaxel|"Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723880|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab|"Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
9723881|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin|Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
9723882|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin|Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
10197587|NCT04520685|Experimental|Arm 3: 15 weeks of placebo then 12 weeks of study drug|Subjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks.
9723883|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + RO6958688|Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
9723884|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Docetaxel|"Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2."
9723885|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Linagliptin|Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
9723886|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan|Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
9785798|NCT01260350|Experimental|Group 5: SOF 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.
10197588|NCT04520685|Experimental|Arm 3: 27 weeks of study drug|Subjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment.
10197589|NCT04517565|Experimental|Patients with SWS or high-risk facial port-wine birthmark|All patients with SWS brain involvement (based on previous imaging) or facial port-wine birthmark indicating a high risk for SWS brain involvement will undergo a brain MRI and neuro-psychology testing.
10197590|NCT04516785||Intervention|FIT and urine VOC samples followed by colonoscopy
10197591|NCT04516291|Placebo Comparator|Placebo|No drug
10197592|NCT04516291|Experimental|Vupanorsen 80 mg every 4 weeks|80 milligrams (mg) given subcutaneously every 4 weeks.
10197593|NCT04516291|Experimental|Vupanorsen 60 mg every 2 weeks|60 mg given subcutaneously every 2 weeks.
10197594|NCT04516291|Experimental|Vupanorsen 120 mg every 4 weeks|120 mg given subcutaneously every 4 weeks.
10197595|NCT04516291|Experimental|Vupanorsen 80 mg every 2 weeks|80 mg given subcutaneously every 2 weeks.
10197596|NCT04516291|Experimental|Vupanorsen 160 mg every 4 weeks|160 mg given subcutaneously every 4 weeks.
10197597|NCT04516291|Experimental|Vupanorsen 120 mg every 2 weeks|120 mg given subcutaneously every 2 weeks.
9723887|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy|Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
9723888|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Evolocumab|Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
9723889|NCT03333655|Other|Checkpoint Inhibitor Therapy|Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.
9723890|NCT03333486|Experimental|Treatment (fludarabine, cyclophosphamide, TBI, PBSCT)|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.
9723891|NCT03310944|Active Comparator|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
9980879|NCT01396564|Active Comparator|Metformin|Randomized patients are given 850 mg of metformin daily, increased to 1700 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
10197598|NCT04516291|Experimental|Vupanorsen 160 mg every 2 weeks|160 mg given subcutaneously every 2 weeks.
9723892|NCT03310944|Experimental|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
9723893|NCT03310944|Experimental|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
9723894|NCT03310944|Experimental|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
9723895|NCT03291522||Men with azoospermia|Ultrasound-guided rete testis flushing and aspiration
9723896|NCT03283878|Experimental|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose."
9780672|NCT01128621|Active Comparator|Part B - Active|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
10197599|NCT04515329|Experimental|Cyclosporine + Artificial Tears|Cyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control).
10197600|NCT04515329|Other|Artificial Tears|Preservative-free artificial tear drops 4 times a day (Control).
10197601|NCT04513028|Experimental|Treatment|"All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan.~Pembrolizumab: 200 mg/100mL IV in three week intervals~Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days"
10197602|NCT04512586|Experimental|His-pacing plus AV node ablation|"A His-pacing lead in combination with a backup RV pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. A standard DDD pacemaker or CRT-P device from Medtronic will be used.~A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed."
10197603|NCT04512586|Active Comparator|Pulmonary vein isolation|Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.
10197604|NCT04508790|Experimental|Treatment (leflunomide, pomalidomide, dexamethasone)|Patients receive leflunomide PO on days 1-28, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10197605|NCT04507152|Experimental|Blood flow restriction resistance training|
10197606|NCT04507152|Active Comparator|Resistance training|
10197607|NCT04506372|Experimental|Intervention group|Perioperative withdrawal of ACEI/ARB.
10197608|NCT04506372|Active Comparator|Control group|Perioperative continuation of ACEI/ARB.
10197609|NCT04505865|No Intervention|Usual care|Optimally tolerated medical therapy
10197610|NCT04505865|Experimental|Stress reduction|Optimally tolerated medical therapy and stress reduction course for 8 weeks
10197611|NCT04505098|Active Comparator|Intervention|
10197612|NCT04505098|No Intervention|Usual Care|
10197613|NCT04504357|No Intervention|Arm A- No intervention|Participants randomized to Arm A will receive no research intervention.
10197614|NCT04504357|Experimental|Arm B- U=U app|"Participants randomized to Arm B will receive controlled exposure to the tablet-based U=U app."
9723897|NCT03283878|Experimental|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.)."
9723898|NCT03259503|Experimental|Treatment (olaparib, high-dose chemotherapy, transplant)|Patients receive olaparib PO BID on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine IV over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
9723899|NCT03247634|Experimental|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
9723900|NCT03235739|Experimental|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
9723901|NCT03235739|Placebo Comparator|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
10197615|NCT04504357|Active Comparator|Arm C- clinical exposure demonstration|Participants randomized to Arm C will be shown U=U videos in clinic waiting rooms and the tablet-based app will be integrated into routine counseling
10197616|NCT04503668|Active Comparator|Nk1-RA|Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
9723902|NCT03215810|Experimental|TIL+ Nivolumab|Tumor-infiltrating Lymphocyte Therapy (TIL) + Nivolumab Treatment Plan: Tumor harvest, Tumor-infiltrating Lymphocytes growth, 4 cycles of nivolumab, cytoreductive chemotherapy with cyclophosphamide and fludarabine, TIL infusion, Interleukin-2 treatment.
9723903|NCT03188965|Experimental|Dose escalation of BAY1895344 in Part A|Single-agent dose-escalation part. Part A has the objective to define the MTD and / or RP2D.
9723904|NCT03188965|Experimental|J-arm of Part A|Single-agent dose-escalation part in Japanese patients. J-arm has the objective to confirm the MTD (or RP2D) dose is safe and tolerable in Japanese patients.
9836225|NCT02776553|Experimental|Active (physical training program)|physical activity + behavioral therapy + nutritional intervention
10197617|NCT04503668|Experimental|Olanzapine|Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.
10197618|NCT04502823|No Intervention|Control Group|"Clinical practice: Management by Doppler and CTG findings.~In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification:~Fetuses with an EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~Fetuses with an EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks."
10197619|NCT04502823|Experimental|Intervention Group|Management based on sFlt-1/PlGF values
10197620|NCT04502550||Parkinson's Disease patients with DBS, no stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
10197621|NCT04502550||Essential Tremor patients with DBS|"This cohort will serve as a control group (no basal ganglia pathology). A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a TCI system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Experiments will be completed with DBS off."
10197622|NCT04502550||Parkinson's Disease patients with DBS, Gpi stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads during propofol induced loss of consciousness."
10197623|NCT04502550||Parkinson's Disease patients with DBS, Gpe stimulation|"This cohort will serve as as the observed group, displaying basal ganglia pathology.~A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads during propofol induced loss of consciousness."
10197624|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpe stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpe via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
10197625|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, Gpi stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will be stimulated at the Gpi via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
10197626|NCT04502550||Parkinson's Disease patients undergoing DBS surgery, no stimulation|"A syringe pump controlled by Stanpump implementing the Eleveld Pharmacokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.~Participants will not receive any stimulation via DBS leads, and cortical activity will be recorded via ECoG during propofol induced loss of consciousness."
10197627|NCT04502472|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Patients hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome and meet eligibility criteria
10197628|NCT04502407|Experimental|De-intensified Cisplatin-based Chemoradiation|This is a non-randomized study, with all patients undergoing de-intensified post-operative cisplatin-based chemoradiation. Dosage level and duration of administration will be determined by whether the patient is high risk or not as assessed by the treating investigator.
10197629|NCT04501588|Experimental|Parent Learning Style 1|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
9723905|NCT03188965|Experimental|Dose expansion of BAY1895344 in Part B|Single-agent expansion part. Once the MTD has been defined, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study. Once the MTD dose has been confirmed is safe and tolerable in Japanese patients, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study.
9723906|NCT03188965|Experimental|Part A.1: Single-agent dose escalation part|Part A.1 - single-agent dose escalation part with alternative dosing schedule Patients with histologically confirmed solid tumors or NHL known to be positive for ATM loss and/or ATM deleterious mutations will be included.
9723907|NCT03179761|Experimental|Group I (HD-TIV)|Patients receive HD-TIV intramuscularly once at baseline and once between 28-42 days.
9723908|NCT03179761|Active Comparator|Group 2(SD-QIV)|Patients receive SD-QIV intramuscularly once at baseline and once between 28-42 days.
9723909|NCT03176277|Experimental|ONO-7475 (Part A)|Successive dose escalation cohorts to determine MTD/OBD
9723910|NCT03176277|Experimental|ONO-7475 + venetoclax (Part D)|Successive dose escalation of ONO-7475 cohorts + venetoclax
9723911|NCT03150004|Experimental|CLAG-M regimen|Patients' treatment cycle is 30 days.
9723912|NCT03140371|Experimental|High energy high protein peptide feed|"This is a one-arm study. Each patient recruited onto the study will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
9723913|NCT03125811|Active Comparator|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
9723914|NCT03125811|Other|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
9723915|NCT03091725|Experimental|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
9723916|NCT03091725|Active Comparator|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
9723917|NCT03081143|Experimental|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
9723918|NCT03081143|Active Comparator|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
9723919|NCT03060629|Experimental|Group 1|Participants will receive Ad26.Mos4.HIV 5*10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 [microgram] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
9723920|NCT03060629|Placebo Comparator|Group 2|Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
9723921|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
9723922|NCT03037398|Active Comparator|Novel Arm|Programming completed by a novel method
9723923|NCT03037398|Other|Standard of Care Arm|Programming completed as Standard of care
9785799|NCT01260350|Experimental|Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.
10197630|NCT04501588|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
10197631|NCT04501588|Active Comparator|Learning Style 1 (Parent)|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
10197632|NCT04501588|Active Comparator|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
10197633|NCT04499456|Active Comparator|Control|Waiting list control receiving the PNF after the last assessment
9723924|NCT03036930|Experimental|Prevention (Gardasil 9 HPV vaccine)|Participants receive the first dose of the recombinant human papillomavirus nonavalent vaccine IM at baseline, at least 30 days prior to the kidney transplant surgery. The second dose is given at least one month after the first dose. The third dose is given at least five months after the first dose and at least three months after the second dose. The timing of the second and third doses is dependent on the scheduling of the kidney transplant surgery. Patients are followed up at 6- and 12-months after the kidney transplant surgery to measure vaccine-induced immune responses. Patients may receive either one, two, or all three vaccine doses prior to the kidney transplant surgery, and are offered additional visits at least one year after the surgery to complete any remaining doses of the three-dose vaccine series.
10197634|NCT04499456|Experimental|Single PNF|Receives PNF after the first assessment only
10197635|NCT04499456|Experimental|Boosted PNF|Receives PNF after every assessment
10197636|NCT04495166|Experimental|Motherly app with brief psychotherapy|Participants in this arm will receive intervention via Motherly 1.0, an app that delivers behavioral activation strategies and psychoeducational content to promote changes in sleep, nutrition, and physical activity habits. It has also functionalities that help participants to engage in prenatal care, breastfeeding, and social support, and to stimulate child development. In addition will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
10197637|NCT04495166|Active Comparator|Educational app (Active control)|Participants in this arm will have access to a psychoeducational app (active control) which delivers content about gestation, maternal health and mental health, and child development. In addition, they will undergo will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
10197638|NCT04493541|Experimental|BMS-986256|
10197639|NCT04493541|Placebo Comparator|Placebo|
10197640|NCT04481672|Experimental|Magnesium Sulfate|"Starting the night before surgery participants will receive intravenous infusion of magnesium over approximately 36 hours. Dosage amounts will vary among participants as the study is determining the highest dose of magnesium that can be administered safely without severe or unmanageable side effects. The first 5 participants of the study will all receive the same dose of magnesium. The decision to test other doses of magnesium in 5 additional participants will depend on magnesium levels and dose tolerance outcomes in the first 5 participants.~Participants will be followed for 4 days and undergo blood test to measure magnesium levels at the time of hospital admittance, the morning prior to the surgery, twice immediately after surgery, and twice a day for 3 days after the surgery."
9723925|NCT03034811|Other|PPK subjects|Subjects that receive the Persona Partial Knee system
9723926|NCT02998645|Experimental|Eltrombopag + cyclosporine|Planned duration of treatment with eltrombopag & cyclosporine is 6 months (for all patients); the planned duration of treatment with cyclosporine (cyclosporine tapering) is 18 months (for responder patients only).
9723927|NCT02989857|Active Comparator|AG-120|Participants received AG-120 500 mg, tablet, orally, once daily (QD) in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 24 months.
9723928|NCT02989857|Placebo Comparator|Placebo|Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 24 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.
9723929|NCT02989857|Experimental|After Cross over to AG-120|Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle for up to approximately 24 months.
9723930|NCT02983799|Experimental|gBRCAm;|germline BRCA mutant
9723931|NCT02983799|Experimental|sBRCAm and germline BRCA wild type;|somatic BRCA mutant, germline BRCA wild type
9723932|NCT02983799|Experimental|myChoice® HRD positive and BRCAwt;|genomic instability positive and no BRCA mutation
10197641|NCT04481607|Experimental|TQB3454 tablets|TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.
10204854|NCT04734990|Experimental|Treatment (azacitidine, seclidemstat)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7. Patients also receive seclidemstat PO QD on day 1 of cycle 1 and PO BID on days 2-28 of cycle 1 and on days 1-28 of all subsequent cycles. There are 6 planned dose levels for seclidemstat: 300 mg, 450 mg, 600 mg, 900 mg, 1200 mg and 1500 mg. Successive cohorts of eligible patients will be treated with azacitidine. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9723933|NCT02983799|Experimental|myChoice® HRD negative and BRCAwt|genomic instability negative and no BRCA mutation
9723934|NCT02974725|Experimental|LXH254+LTT462|
9723935|NCT02974725|Experimental|LXH254+Trametinib|
9723936|NCT02974725|Experimental|LXH254+Ribociclib|
9723937|NCT02971683|Active Comparator|Abatacept subcutaneous + Standard Treatment|Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
9723938|NCT02971683|Placebo Comparator|Placebo of Abatacept subcutaneous + Standard Treatment|Placebo of Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
9723939|NCT02961322|Experimental|lobo isthmectomy|
10197642|NCT04481568|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and nurse assistants who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff: mental health assistants with high school level education, who receive training in de-escalation and crisis prevention techniques and provide direct personal care to psychiatric patients. On the intervention unit, these PES purposefully engage patients with BPSD. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of HCGs towards patients. IV. Staff Training (please refer to NCT# 04179721 for more details on staff support and training).
9723940|NCT02935686|Experimental|Group 1: Ad26.Mos4.HIV + Clade C gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12, followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
9723941|NCT02935686|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + combination of 125 mcg Mosaic gp140 and 125 mcg Clade C gp140 mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
9723942|NCT02935686|Placebo Comparator|Group 3: Placebo|Participants will receive a single placebo injection at Weeks 0 and 12, followed by two placebo injections at Weeks 24 and 48.
10197643|NCT04481568|Active Comparator|The attention control condition|The attention control condition will consist of a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 nursing assistants (1:8 ratio), that primarily cohorts older patients with geriatric syndromes.
10197644|NCT04480710|Experimental|CRV431 75mg|CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions
9723943|NCT02935686|Experimental|Group 1b: Ad26.Mos4.HIV + gp140 HIV Bivalent Vaccine|Participants enrolled in the LTE phase will receive late boost vaccination Ad26.Mos4.HIV and bivalent gp140 within 4 weeks prior to Week 192 until 4 months after Week 192 (that is, approximately 3 years after the 4th vaccination of the primary vaccination series).
9723944|NCT02935686|Placebo Comparator|Group 2b: Placebo|Participants will receive placebo injection at Week 192 -4 weeks/+4 months, that is, approximately 3 years after the 4th vaccination of the primary vaccination series.
10197645|NCT04480710|Placebo Comparator|Placebo, 75mg|Placebo, softgel capsule, QD, 28 days, fasted conditions
9723945|NCT02902211|Experimental|Ankle foot orthosis|Patients will wear an off-the-shelf, carbon composite AFO that is adjusted for them for three months. The patients will be asked to wear the AFO at all times except when they are in bed or showering/bathing. The instructions given to the patients about walking will be to follow the instructions from their doctor regarding risk factor management and exercise.
9723946|NCT02902211|Active Comparator|Control|Patients will be asked to follow the instructions from their doctor regarding risk factor management and exercise for three months.
9723947|NCT02875860|Other|Standardized postnatal care (Expectant)|Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
9723948|NCT02875860|Experimental|Prenatal Intervention (FETO)|Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
9723949|NCT02875548|Experimental|Open-label Tazemetostat|Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.
9723950|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
9723951|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
9723952|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
9723953|NCT02845271|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
10197646|NCT04480710|Experimental|CRV431 225mg|CRV431, softgel capsule, 225mg, QD, 28 days, fasted conditions
9723954|NCT02845271|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
9723955|NCT02842359|Experimental|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
9723956|NCT02842359|Active Comparator|Irbesartan|Irbesartan will be given orally daily for 28 days
10197647|NCT04480710|Placebo Comparator|Placebo, 225mg|CRV431, 3 softgel capsules, 225mg, QD, 28 days, fasted conditions
10197648|NCT04474613|Experimental|Liquid biopsy|A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
10197649|NCT04470778|Experimental|BMS-986256|
9723957|NCT02842359|Active Comparator|Atorvastatin|Atorvastatin will be given orally daily for 28 days
9723958|NCT02831959|Experimental|NovoTTF-200M device|"NovoTTF-200M device Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-200M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head.~The treatment enables the patient to maintain regular daily routine."
9723959|NCT02831959|Active Comparator|Best Standard of Care|Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
9723960|NCT02825160||Ventavis|Ventavis treatment group
9723961|NCT02813785|Experimental|Atezolizumab|Participants will receive atezolizumab until loss of clinical benefit and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
9723962|NCT02813785|Active Comparator|Docetaxel|Participants will receive docetaxel until disease progression per standard RECIST v1.1 criteria or unacceptable toxicity and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
10197650|NCT04470778|Experimental|BMS-986256 + Famotidine|
10197651|NCT04470388|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 capsule Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days.
9723963|NCT02803437||Xofigo / Cohort 1|Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
10197652|NCT04470388|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days.
10197653|NCT04464798|Experimental|Cohort A- Monotherapy in R/R lymphoma subjects|Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
9723964|NCT02796937|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
9723965|NCT02788045|Experimental|Group 1A: Ad26.Mos.HIV|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
9723966|NCT02788045|Placebo Comparator|Group 1B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
9723967|NCT02788045|Experimental|Group 2A: Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants will be included in an optional Long-term Extension (LTE) phase (3 years or 4 years Follow-up after Week 72, every 6 months visit) to assess immunogenicity and safety (serious adverse events [SAEs]).
9723968|NCT02788045|Placebo Comparator|Group 2B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
9723969|NCT02759094|Experimental|Treatment with RefluxStop device|All enrolled subjects will receive treatment for their GERD using the RefluxStop device intervention
9723970|NCT02740634|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
9723971|NCT02740634|Experimental|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
9723972|NCT02736344||BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
9723973|NCT02682992|Experimental|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
10197654|NCT04464798|Experimental|Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects|"Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
10197655|NCT04464798|Experimental|Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects|"Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6."
10197656|NCT04464798|Experimental|Cohort D - Monotherapy in other lymphomas subtype subjects|"Subjects with other lymphoma subtype who have been allocated to Cohort D will receive CC-220 monotherapy (MonoT).~- Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles."
10197657|NCT04464798|Experimental|Cohort E - CC-220 and rituximab in B-cell lymphoma subjects|"Subjects with aggressive B-cell lymphoma who have been allocated to Cohort E will receive CC-220 in combination with rituximab~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
10197658|NCT04464798|Experimental|Cohort F - CC-220 and rituximab in FL and MZL subjects|"Subjects with follicular lymphoma (FL) (1 to 3a) and marginal zone lymphoma (MZL) who have been allocated to Cohort F Part 2 will receive CC-220 in combination with rituximab.~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2"
10197659|NCT04464798|Experimental|Cohort G -CC-220 and obinutuzumab in FL and MZL subjects|"Subjects with FL (1 to 3a) and MZL who have been allocated to Cohort G will receive CC-220 in combination with obinutuzumab.~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15 and on D1 of every 28-day cycle from C2 to C6."
10197660|NCT04464603|Experimental|Arm A (InterFACE)|"Participants that will use the mHeath InterFACE tool during the simulation-based pediatric scenario.~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
9723974|NCT02679508|Experimental|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
9836226|NCT02776553|Active Comparator|Control|nutritional intervention
9723975|NCT02679508|Active Comparator|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
9723976|NCT02678312|Experimental|Part 1: LCZ696 open label|LCZ696 open label either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril or standard of care for heart failure treatment, if patient consents to participate in Part 2.
10197661|NCT04464603|Active Comparator|Arm B (Conventional methods)|"Participants that will use conventional methods during the simulation-based pediatric scenario.~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
9723977|NCT02678312|Active Comparator|Part 2: Enalapril|The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose).
9723978|NCT02678312|Experimental|Part 2:LCZ696|LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight.
9723979|NCT02661542|Experimental|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723980|NCT02661542|Experimental|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723981|NCT02661542|Experimental|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723982|NCT02661542|Experimental|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723983|NCT02661542|Experimental|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723984|NCT02661542|Experimental|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723985|NCT02661542|Experimental|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723986|NCT02661542|Experimental|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723987|NCT02661542|Experimental|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
10197662|NCT04463719|Experimental|Intervention group|Counseling using the electronic conversation aid
10197663|NCT04463719|Active Comparator|Control Group|Routine counseling only
9723988|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723989|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
9723990|NCT02633059|Experimental|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
9723991|NCT02631577|Experimental|Atezolizumab-G-lena 15mg|Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
9723992|NCT02631577|Experimental|Atezolizumab-G-lena 20mg|Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.
9723993|NCT02609750|Experimental|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
9723994|NCT02609750|Active Comparator|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
9723995|NCT02573779||Infants fed mother's own milk|Infants fed >50% mother's own milk with enteral feeding.
10197664|NCT04461483|Experimental|Part 1, Cohort 1; TAK-935 200 mg|Part 1, Cohort 1; TAK-935 200 mg, tablets, orally once on Days 1 in fasted state.
9723996|NCT02573779||Donor milk fed infants|Infants fed <50% mother's own milk (and thus >50% donor human milk) with enteral feeding.
9723997|NCT02548351|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
9723998|NCT02548351|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
9723999|NCT02548351|Placebo Comparator|Placebo|One tablet daily for the remainder of the study
9724000|NCT02546713|Other|Group 1|Abutments with a concave configuration of the subcritical contour (emergence shape).
10197665|NCT04461483|Experimental|Part 1, Cohort 2; TAK-935 600 mg|Part 1, Cohort 2; TAK-935 600 mg, tablets, orally once on Days 1 in fasted state.
9724001|NCT02546713|Other|Group 2|Abutments with convex configuration of the subcritical contour (emergence shape)
10197666|NCT04461483|Experimental|Part 1, Cohort 3; TAK-935 1200 mg|Part 1, Cohort 3; TAK-935 1200 mg, tablets, orally once on Days 1 in fasted state.
10197667|NCT04461483|Placebo Comparator|Part 1, Cohort 1-3; Placebo|Part 1, Cohort 1-3; TAK-935 placebo-matching tablets, orally once on Days 1 in fasted state.
9724002|NCT02494986|Experimental|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other antiretrovirals (ARVs).
10197668|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 100 mg|Part 2, Cohort 4: TAK-935 100 mg, tablets, orally twice on Days 1-7 in fasted state with multiple doses with titration.
10197669|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 200 mg|Part 2, Cohort 4: TAK-935 200 mg, tablets, orally twice on Days 8-14 in fasted state with multiple doses with titration.
9724003|NCT02468024|Active Comparator|Arm 1 lung surgery|Sublobar Resection (SR)
9724004|NCT02468024|Experimental|Arm 2 radiation therapy|Stereotactic Ablative Radiotherapy (SAbR)
9780673|NCT01128621|Active Comparator|Part B - Sitagliptin|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
9780674|NCT01128738|Active Comparator|GSK1358820|Onabotulinum toxin type A
9780675|NCT01128738|Placebo Comparator|Placebo|Placebo
9780676|NCT01128829|Experimental|water-sucralose|"Subjects in this group drank water 10 min before drinking a glucose load on their first oral glucose tolerance test (OGTT) and drank sucralose 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
9780677|NCT01128829|Experimental|sucralose-water|"Subjects in this group drank sucralose 10 min before drinking a glucose load on their first OGTT and drank water 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
9780678|NCT01128842|Experimental|Neratinib + Capecitabine|Neratinib + Capecitabine
9780679|NCT01128894|Experimental|albiglutide|weekly albiglutide subcutaneous injection
9780680|NCT01128894|Active Comparator|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
9780681|NCT01128946|Experimental|Fluoride Toothpaste 1|Fluoride toothpaste containing sodium fluoride (NaF)
9780682|NCT01128946|Experimental|Fluoride Toothpaste 2|Fluoride toothpaste containing stannous fluoride (SnF) and NaF.
9780683|NCT01128946|Experimental|Fluoride Toothpaste 3|Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.
9780684|NCT01128946|Active Comparator|Reference Dentifrice|Low fluoride toothpaste containing NaF
9780685|NCT01128959|Experimental|Intravenous Carbamazepine (IV CBZ)|
9780686|NCT01128972|Experimental|Test Dentifrice + Test Mouth Rinse (MR)|Test fluoride dentifrice and test fluoride MR
9780687|NCT01128972|Experimental|Test Dentifrice + Sterile Water Rinse|Test fluoride dentifrice and sterile water rinse
9780688|NCT01128972|Experimental|Placebo Dentifrice + Test MR|Placebo dentifrice and test fluoride rinse
9780689|NCT01128972|Active Comparator|Reference Dentifrice + Sterile Water Rinse|Marketed fluoride dentifrice with sterile water rinse
9780690|NCT01128972|Placebo Comparator|Placebo Dentifrice + Sterile Water Rinse|Placebo dentifrice and sterile water rinse
9780691|NCT01129011|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
9780692|NCT01129011|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
9780693|NCT01129024|Experimental|Lusutrombopag|Participants received lusutrombopag 0.5 mg administered orally once a day for up to 3 years or until study termination. The dose was adjusted based on platelet counts. If a subject's platelet count remained < 50,000/μL, the dose could have been increased by 0.25 mg up to a maximum dose of 2.0 mg.
9780694|NCT01129102|Experimental|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
9780695|NCT01129102|Active Comparator|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
9780696|NCT01129102|Placebo Comparator|Placebo|Placebo for NPC-01
9780697|NCT01129115|Active Comparator|Nonexercise control group|
9780698|NCT01129115|Experimental|Aerobic Exercise Group 1|
9780699|NCT01129115|Experimental|Aerobic Exercise Group 2|
9780700|NCT01129115|Experimental|Aerobic Exercise Group 3|
9780701|NCT01129128|Active Comparator|Echinacea preparation 1|Commercially available Echinacea purpurea product
9780702|NCT01129128|Active Comparator|Echinacea preparation 2|Commercially available Echinacea purpurea product
9780703|NCT01129128|Placebo Comparator|Placebo|Inert liquid that is similar in appearance and taste to the active Echinacea products
9780704|NCT01129141|Experimental|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
9724005|NCT02408315|Placebo Comparator|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
9724006|NCT02408315|Placebo Comparator|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
9724007|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
9724008|NCT02354014|Experimental|TMC207/Background Regimen (BR)|There will be 4 age-based cohorts. Participants will be enrolled concurrently in Cohorts 1 and 2 followed by sequential enrollment of Cohorts 3, 4. Cohort 1: >= 12 to < 18 years: bedaquiline (TMC207) tablet orally as 400 mg, once daily(qd),for first 2 weeks, followed by TMC207, 200 mg 3 times per week (tiw) for 22 weeks; Cohort 2: >=5 to <12 years: TMC207 tablet given orally as 200 mg, qd, for first 2 weeks, followed by TMC207, 100 mg, tiw for 22 weeks. Cohort 3: >=2 to <5 years: TMC207 8 milligram per kilogram (mg/kg) qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw for 22 weeks. Cohort 4: 0 months to <2 years: TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3. TMC207 will be given in combination with Background Regimen for Multidrug Resistant Tuberculosis (MDR-TB) according to WHO/National Tuberculosis Program (NTP) guidelines/current standard of care.
10197670|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 300 mg|Part 2, Cohort 4: TAK-935 300 mg, tablets, orally twice on Days 15-21 in fasted state with multiple doses with titration.
10197671|NCT04461483|Placebo Comparator|Part 2, Cohort 4: Placebo|Part 2, Cohort 4: TAK-935 placebo-matching tablets, orally twice on Days 1-21 in fasted state.
10197672|NCT04459559|Experimental|Intervention|Using the Tactile Cueing Device
10197673|NCT04457401|Experimental|Probiotic|1 capsule daily for 8 weeks, containing 3 x 10^9 colony forming units/capsule of a Bifidobacterium strain
10197674|NCT04457401|Placebo Comparator|Placebo|1 capsule daily for 8 weeks containing the same carrier material and is similar in size, shape and taste to probiotic
9724009|NCT02300233|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
9724010|NCT02300233|Experimental|Volanesorsen 300 mg weekly|Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks.
9724011|NCT02300233|Experimental|Volanesorsen 300 mg biweekly, post Week 13|Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.
9724012|NCT02274987|Experimental|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
9724013|NCT02269150|Experimental|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
9724014|NCT02269150|Active Comparator|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
10197675|NCT04456920|Experimental|Experimental group 1|PRO (Patient Reported Outcomes) gathered via a phone consultation
9724015|NCT02211209|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
9724016|NCT02211209|Experimental|Volanesorsen|Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
9724017|NCT02193958|Experimental|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
9724018|NCT02193958|Experimental|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
9724019|NCT02193958|Experimental|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
9724020|NCT02193958|Experimental|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
9724021|NCT02193958|Experimental|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
9724022|NCT02193958|Experimental|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
9724023|NCT02193958|Experimental|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
9724024|NCT02193958|Experimental|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
9724025|NCT02193958|Experimental|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
9724026|NCT02125461|Experimental|MEDI4736|MEDI4736 (intravenous infusion)
9724027|NCT02125461|Placebo Comparator|PLACEBO|Placebo (matching placebo for intravenous infusion)
10197676|NCT04456920|Experimental|Experimental group 2|e-PRO self-completed via connected objects (tablet/phone)
10197677|NCT04456920|No Intervention|Control group|group without e-PROs (standard care)
10204855|NCT04712851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 4 cycles (24 weeks).
10204856|NCT04710992|Sham Comparator|Needling Group|The needle will be inserted for 90 seconds without galvanic current.
10197678|NCT04449276|Experimental|Dose Escalation CVnCoV|"Participants will be vaccinated with CVnCoV at escalating dose levels on Day 1 and Day 29. Safety data will inform the decision to continue enrolling at the current dose level, or to proceed to dose escalation. Initially, dose levels of 2, 4 and 8 μg will be evaluated.~Dose levels of 2, 4, 6, 8 and 12µg will be evaluated with potential increase to dose levels up to 20 μg."
10197679|NCT04449276|Placebo Comparator|Dose Escalation Placebo|Participants will be given placebo on Day 1 and Day 29.
9724028|NCT02058459|Active Comparator|Targeted Lung Denervation|active targeted lung denervation
9724029|NCT02058459|Sham Comparator|Sham-Control|non-active targeted lung denervation
9724030|NCT02027155|Active Comparator|AR09 solution|AR09, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
9724031|NCT02027155|Placebo Comparator|Placebo (for AR09 solution)|Placebo; normal saline
9724032|NCT02022592|Experimental|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
9724033|NCT02022592|Active Comparator|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
9724034|NCT02022514|Experimental|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
9724035|NCT02022514|Active Comparator|Conventional medical treatment|Conventional medical treatment
9724036|NCT02000115|Experimental|Randomized IDE Cohort, Portico Valve|"Portico transcatheter aortic valve and Portico delivery system.~Status: ACTIVE, NOT ENROLLING."
9724037|NCT02000115|Active Comparator|Randomized IDE Cohort, CAV|"Any FDA approved, commercially-available transcatheter aortic valve (CAV).~Status: ACTIVE, NOT ENROLLING."
9724038|NCT02000115|Experimental|Nested Valve-in-Valve Registry|"Subjects who have documented failed aortic surgical valve prosthesis and are deemed eligible to receive a transcatheter Portico valve~Status: ACTIVE, ENROLLING."
9724039|NCT02000115|Experimental|FlexNav Delivery System Study|"Portico transcatheter aortic valve and FlexNav delivery system~Status: ACTIVE, NOT ENROLLING"
9724040|NCT01958086|Experimental|Neural Communication System|The Neural Communication System consists of two Neuroport Multi-Port Arrays, which are descried in detail in the intervention description. One Neuroport Multi-Port Array is inserted into the posterior parietal cortex, an area of the brain used in reach planning. The second Neuroport Multi-Port Array is inserted into the motor cortex, which is primarily responsible for controlling movement. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
9724041|NCT01916122|Experimental|(FES) PET/CT for Imaging|"FES PET/CT studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 5 mCi (+/- 10%) of FES PET/CT will be injected intravenously. 60 (+/- 10) minutes following tracer injection, the patient will be positioned on a GE Discovery PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first, 60-80mAs, 120-140kVp, with a 5mm slice thickness while the patient was free breathing. PET will be acquired at 3-5 minutes per bed position using the 3D mode, approximately 6-7 bed positions. FES PET/CT imaging will take less than 60 minutes. Scans will be reconstructed with iterative reconstruction.~If follow-up FES PT/CT scans are performed on a patient, then the same parameters will be used as the initial FES PET/CT scan."
9724042|NCT01899976|Other|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
9724043|NCT01888653|Placebo Comparator|Comparison-Training-Program|Placebo-training program: attention control training (ACT), is identical to the ABM protocol except that during the presentation of the trials where a threat word is presented, the probe will appear with equal frequency in the position of the threat and neutral word. Thus, neither threat nor neutral words provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes
9724044|NCT01888653|Active Comparator|Attention Biased Modification|Attention-bias-modification treatment (ABM) is designed to implicitly modify patients' biased threat attendance via computerized training protocols. During each session, 240 trials (80 neutral-neutral pairs, 160 threat-neutral pairs) will be presented. On trials where participants see one neutral word and one threat word, the probe will always follow the neutral word location. Thus, although there is no specific instruction to direct attention away from threat words, on 66% of all trials (and 100% of the threat-neutral trials) the position of the neutral word will indicate the position of the target probe.
9724045|NCT01854814|Experimental|mycophenolate mofetil|mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
9724046|NCT01854814|Active Comparator|losartan|maximus tolerated labeled dose of losartan
9724047|NCT01837862|Experimental|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
9724048|NCT01837862|Experimental|High-grade Glioma/Pontine Glioma|"Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.~*High grade arm enrollment complete, no additional spots"
9724049|NCT01813227|Experimental|Carfilzomib|Carfilzomib 20 mg/m2 on day 1, 2 then 56 mg/m2 days 8, 9 and 15, 16 over 30 minutes every 28 days. Dexamethasone 4 mg (8 mg if > 45 mg/m2) orally each day of carfilzomib therapy. If less than a partial remission (PR) after 4 cycles, add rituximab 375 mg/m2 on day 16 of each cycle. Patients who meet the criteria for progression prior to 4 cycles of therapy will have rituximab added to their treatment. For patients receiving rituximab, the carfilzomib dose will be decreased to 27 mg/m2. Patients will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
10197680|NCT04447339||Open|Prophylactic NSM cases by Open approach
10197681|NCT04445103||History of malaria|Individuals with a history of malaria infection
10197682|NCT04445103||Controls|Individuals without a history of malaria infection
10197683|NCT04445103||Symptomatic malaria|Patients with symptomatic malaria infection (complicated and uncomplicated)
10204857|NCT04710992|Experimental|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
10197684|NCT04442724|Experimental|Single Arm - Bladder Chemo-Radiotherapy|Fiducial marker placement & cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.
10197685|NCT04437277|Experimental|Patients consenting|
10197686|NCT04425395|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while producing vocalisations. Produced vocalisations will be audio recorded and physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
10197687|NCT04423822||Firefighter|Firefighter with high cardiovascular risk
10197688|NCT04422964|Experimental|Intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
10197689|NCT04422964|No Intervention|control group|The standard procedure without the 3D obturator.
10197690|NCT04418427|Experimental|1|6E11 vg/eye ADVM-022 +/- aflibercept 2mg IVT
10197691|NCT04418427|Experimental|2|2E11 vg/eye ADVM022 +/- aflibercept 2mg IVT
9724050|NCT01791478|Experimental|Treatment (PI3K inhibitor BYL719, letrozole)|Patients receive PI3K inhibitor BYL719 PO QD and letrozole PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9724051|NCT01719055||Boston Scientific SCS Systems|Subjects permanently implanted with a Boston Scientific neurostimulation systems
9724052|NCT01698840|Experimental|Investigational Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Investigational Nutrition group will receive vitamin D drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
9724053|NCT01698840|Placebo Comparator|Routine Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Routine Nutrition group will receive placebo drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
9724054|NCT01695317|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine tablets
9724055|NCT01695317|Placebo Comparator|Sugar pills|Glucose with lemon acid
9724056|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
10197692|NCT04418427|Active Comparator|3|Aflibercept 2mg IVT
10204858|NCT04710992|Experimental|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
9724057|NCT01683825|Other|F-18 florbetapir PET-Healthy Controls|Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
9724058|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Reproducibility Subjects|Some of the individuals with documented cardiac amyloidosis from arm 1 will undergo a second F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) within 30 days to measure reproducibility
9724059|NCT01668953|Experimental|Platelet Rich Plasma (PRP) Injection|Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
9724060|NCT01668953|Active Comparator|Whole Blood Injection|Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
9724061|NCT01668953|Active Comparator|Dry Needle Fenestration|Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
9724062|NCT01668953|Placebo Comparator|Sham Injection|Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
9724063|NCT01652092|Other|Arm A: Fully Myeloablative regimen|For use in patients with diseases including Wiskott-Aldrich syndrome, MHC Class II deficiency, hypomorphic SCID, etc. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, cyclophosphamide 50 mg/kg IV plus MESNA on days -9 through -6, busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2 and stem cell infusion on day 0.
9724064|NCT01652092|Other|Arm B: Reduced Toxicity Ablative Regimen|For use in patients with diseases including SCID, CGD, CHS and other CID. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m^2 IV on days -5 through -2 and stem cell infusion on day 0.
9724065|NCT01652092|Other|Arm C: Reduced Intensity Conditioning|For use in patients with diseases including HLH. Receives Alemtuzumab 0.2 mg/kg intravenously (IV) on days -14 through -10, fludarabine phosphate 30 mg/m^2 IV on days -8 through -4, melphalan 140 mg/m^2 IV on day -3 and stem cell infusion on day 0.
9836227|NCT02776670|Experimental|SYSTANE BALANCE|Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
10204859|NCT04710992|No Intervention|Control Group|Non-intervention control group
10204860|NCT04705025|Experimental|Supportive care (BNT001 app, CBSM, interview)|Prior to participating in the study patients complete an online baseline questionnaire to assess anxiety and depression and general quality of life, as well as some specific questions related to their coping. They are also interviewed by a clinician who rates their level of anxiety and depression. After this, patients use the BNT001 app and undergo 10 sessions of CBSM over 45-60 minutes each consisting of cancer-specific educational videos, guided relaxation training, interactive exercises, and discussion modules. Following completion of the 5th session, patients undergo a telephone check-in assessment to see how things are going, update their treatments and medications, and schedule a phone call to assess for adverse events. At the end of the 10th session, patients complete a post-treatment online questionnaire and a phone debriefing interview to discuss their experience with the intervention.
10197693|NCT04416555|Placebo Comparator|VR googles using exposure sham program|The study groups will receive VR googles and the sham program
10197694|NCT04416555|Active Comparator|VR googles and the real VR program experience.|The study group will receive the VR googles and the real VR program experience.
9724066|NCT01652092|Other|Arm D: No Preparative Regimen|For use in patients with complete SCID phenotype with no evidence of maternal engraftment or residual immune function who will be receiving their stem cell transplantation from a genotypically matched donor.
9724067|NCT01590095|Active Comparator|Water quality|90 clusters, approx. 720 newborns
9724068|NCT01590095|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
9724069|NCT01590095|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
9724070|NCT01590095|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
9724071|NCT01590095|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
9724072|NCT01590095|Active Comparator|Nutrition + Combined WASH|90 clusters, approx. 720 newborns
9724073|NCT01590095|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
9724074|NCT01515748|Other|Surgery + Adjuvant Chemotherapy (SC)|Participants underwent surgery within 2 weeks after randomization followed by adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 milligrams per square meter (mg/m^2) administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after End-of-Treatment (EOT) until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 8 years).
9724075|NCT01515748|Experimental|Neoadjuvant Chemotherapy +Surgery +Adjuvant chemotherapy (CSC)|Participants received neo-adjuvant chemotherapy with Docetaxel 50 mg/m^2 intravenously (IV) for greater than or equal to (>=)1 hour (hr) on Day 1 of each treatment cycle plus Oxaliplatin 100 mg/m^2 IV for >=2 hr on Day 1 of each treatment cycle plus S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily from Day 1 to 14, of each treatment cycle followed by surgery approximately 1-3 weeks after completion of neo-adjuvant chemotherapy and adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after EOT until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 8 years).
9724076|NCT01508962||Healthy individuals (controls)|
9724077|NCT01508962||Individuals affected with ALS (sporadic or familial)|
9724078|NCT01505569|Other|Arm A: Patients with High Risk or Relapsed Solid Tumor|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, busulfan (1.1 mg/kg IV every 6 hours on days -8 through -6), melphalan (50 mg/mg^2 on days -5 and -4), thiotepa conditioning (250 mg/m^2 IV over 2 hours on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0) and, if appropriate, disease specific radiation therapy at day +60.
9724079|NCT01505569|Other|Arm B: Certain CNS Tumors|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, carboplatin (dose based on GFR and age 17 mg/kg/day IV or 510 mg/m^2/day IV) , thiotepa conditioning (10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0). This will be repeated up to 2 additional 30 day cycles.
9724080|NCT01505569|Other|Arm C: Germ Cell Tumors|"High-Dose Chemotherapy (3 cycles)~Carboplatin AUC=8 & Etoposide 400 mg/m^2 daily, days -4, -3, and -2 every 21 days~Autologous Stem Cell Infusion ≥ 3 x 106 CD34+ cells/kg Day 0 Cycles 1, 2 and 3~TI Chemotherapy & PBSC Collection.~Paclitaxel 200mg/m^2 IV over 3 hours on Day 1 every 14 days for 2 cycles~Ifosfamide 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles~Mesna 2000 mg/m^2 on Days 1-3 every 14 days for 2 cycles~G-CSF 10 μg/kg sub q daily on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first~Leukapheresis starting on approx. day 11 and continued daily until reaching the collection goal of ≥ 8 x 106 CD34+ cells/kg) or day 15, whichever occurs first"
9724081|NCT01505569|Other|Arm D: Certain CNS Tumors|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (3 cycles)~Day -8, -7, -6: Carboplatin as calculated from AUC of 7 approx.~Day -5, -4, -3: Thiotepa 10 mg/kg, Etoposide 8.3 mg/kg~Day 0: Autologous Hematopoietic Cell Reinfusion~Day +1: Begin G-CSF(filgrastim) 5 mcg/kg"
10197695|NCT04415177|Experimental|VR Program A|Software with active intervention
10197696|NCT04415177|Active Comparator|VR Program B|Software without active intervention
10197697|NCT04412863|Experimental|Cohort 1d|VIR-2218 given by subcutaneous injection
10197698|NCT04412863|Experimental|Cohort 2d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
10197699|NCT04412863|Experimental|Cohort 3d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
10197700|NCT04412863|Experimental|Cohort 1e|VIR-2218 given by subcutaneous injection
10197701|NCT04412863|Experimental|Cohort 2e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
10197702|NCT04412863|Experimental|Cohort 3e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
10197703|NCT04412863|Experimental|Cohort 1f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
10197704|NCT04412863|Experimental|Cohort 2f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
10197705|NCT04412863|Experimental|Cohort 3f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
10197706|NCT04412785|Experimental|Single Arm|Cyclosporine; oral or IV route of administration, per investigator discretion. Duration of administration up to 14 days, as tolerated.
10197707|NCT04403633|Experimental|Receiving Educational Tool|Patients in this arm will receive the educational tool after the pretest in addition to usual care.
10197708|NCT04403633|No Intervention|Receiving Usual Care|Patients in this arm will receive usual care after the pretest.
10197709|NCT04403295|Experimental|collaborative specialty care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
10197710|NCT04403295|Active Comparator|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
10197711|NCT04402008|Experimental|Phase 1: Once Daily Dosing|Dose finding at 8 mg, 12 mg, or 16 mg of poziotinib once daily in 28-day treatment cycles.
9724082|NCT01505569|Other|Arm E: Neuroblastoma|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (day -7 to day -0)~Day -7: anti-seizure prophylaxis with lorazepam or levetiracetam~Day -6 - -3: Busulfan IV q24 hours x 4 doses~Day -1: Melphalan 140 mg/m2 IV~Day 0: Autologous Hematopoietic Cell Reinfusion"
10197712|NCT04402008|Experimental|Phase 1: Twice Daily Dosing|Dose finding at 4 mg, 6 mg, or 8 mg of poziotinib twice daily in 28-day treatment cycles.
9724083|NCT01487928|Experimental|Human Milk Cream Group|For infants randomized to the human milk cream group, the human milk (either mother's own or donor) being provided to the infant will be tested each time a new container is used to prepare feedings. The test will be for the caloric content of the milk using a commercially available device provided for this purpose. If the caloric level falls below 20 kcal/oz for any test, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. The amount added will be calculated to the nearest mL rounding down for 0.1-0.4mL and up for 0.5-0.9 mL to avoid imprecision due to the measuring device used in the nutrition preparation area.
9724084|NCT01487928|No Intervention|Control Group|For infants randomized to the Control group, human milk and human milk derived fortifier will be provided according to the institutional standard of care and there will be no use of the milk analysis (mother's own or donor), which is typical for the vast majority of neonatal intensive care units.
10197713|NCT04402008|Experimental|Phase 2: Once Daily Dosing or Twice Daily Dosing|"Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.~Cohort 1: EGFR exon 20 insertion mutations~Cohort 2: HER2 exon 20 insertion mutations"
9724085|NCT01483079||Former preterm infants|A cohort of infants less than or equal to 1250 grams birth weight that received donor human milk products in the NICU will be recruited and followed. Some infants recruited will be from a previously studied population of very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.
9724086|NCT01327105|Experimental|TVU|
10197714|NCT04396041||Patients treated for Pulmonary Arteriovenous Malformation|All participants in the study will be patients who have been treated for Pulmonary Arteriovenous Malformation using Microvascular Plugs, Amplatzer Vascular Plugs or Detachable coils.
10197715|NCT04394650|Experimental|CC-98633|Subjects will receive CC-98633 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
10197716|NCT04394637||PROSe-ICD|PROSe-ICD [NCT00733590/ Institutional Review Board (IRB) NA_00045142], a large prospective cohort study of patients who received an ICD for primary prevention.
9724087|NCT01204983||Observational|"This is a quality improvement project to evaluate the current standard of care of nutritional management for very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.~There is no randomization, there are no control subjects, and therefore there is no probability of group assignment."
9724088|NCT01196936|Experimental|Arm I (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
9724089|NCT01196936|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
9724090|NCT01127854||Cases|
9724091|NCT01127854||Controls|
9724092|NCT01127451|Experimental|Denileukin Diftitox on Days 1 to 4|Participants received Denileukin Diftitox 12 mcg/kg/day (microgram per kilogram) on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks).
9724093|NCT01127451|Experimental|Denileukin Diftitox on Days 1, 8, and 15|"Participants received Denileukin Diftitox 12 mcg/kg/day on Days 1, 8, and 15 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks).~ARM 2 was closed. Participants experiencing clinical benefit (irSD, irPR, or irCR per irRC) after 4 cycles of treatment, may continue their denileukin diftitox treatment for up to 8 cycles."
9724094|NCT01068249|Experimental|Letrozole + RAD001|Letrozole and RAD001 (Everolimus)
9724095|NCT01054196|Experimental|all patients|subjects will receive daily doses of lenalidomide starting on Day -5 of transplant and melphalan on Days -2 and -1.
9724096|NCT01004874|Experimental|Bevacizumab, XRT, Temozolomide, Topotecan|Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
9724097|NCT00924456|Experimental|Transcendental Meditation program|a natural effortless mental technique practiced sitting quietly 20 minutes twice a day
9724098|NCT00924456|Placebo Comparator|Wait list control|student subjects on wait list control
9724099|NCT00799864|Experimental|Rilpivirine (TMC278)|The patients received rilpivirine with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a background regimen in cohort 1 [aged greater than or equal to (> =) 12 to less than (<) 18 years] for up to 240 weeks which is already completed and recruitment closed and will receive this treatment in cohort 2 (children aged > = 6 to < 12 years) for up to 48 weeks. The NRTIs include zidovudine, abacavir, or tenofovir disoproxil fumarate in combination with lamivudine or emtricitabine.
9724100|NCT00317616||Unaffected individuals from families in which the genetic cause of ALS is known|This population would include pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
9724101|NCT00268476|Active Comparator|Arm A: Standard of Care|Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]
9724102|NCT00268476|Experimental|Arm B: Zoledronic Acid|(ADT + zoledronic acid) NO LONGER RECRUITING
9724103|NCT00268476|Experimental|Arm C: Docetaxel|(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
9724104|NCT00268476|Experimental|Arm D: Celecoxib|(ADT + celecoxib) NO LONGER RECRUITING
10197717|NCT04394637||Reynolds study|Functional Energetics (Reynolds study, NA_00037404), a study with conventional contrast-enhanced 1H MRI to determine ventricular geometry, global and regional function, as well as infarct size characteristics following delayed contrast enhancement.
10197718|NCT04392804|Experimental|0.1 ml 4% articaine|single dose of 0.1 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
10197719|NCT04392804|Experimental|0.2 ml 4% articaine|single dose of 0.2 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
9724105|NCT00268476|Experimental|Arm E: Zoledronic Acid & Docetaxel|(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
9724106|NCT00268476|Experimental|Arm F: Zoledronic Acid & Celecoxib|(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
9724107|NCT00268476|Experimental|Arm G: Abiraterone|(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
9724108|NCT00268476|Experimental|Arm H: M1 RT|(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
9724109|NCT00268476|Experimental|Arm J: Abiraterone * Enzalutamide|(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
9724110|NCT00268476|Experimental|Arm K: Metformin|(ADT + Metformin) RECRUITING IN SELECTED SITES
9724111|NCT00268476|Experimental|Arm L: tE2|(Transdermal oestradiol) RECRUITING
9724112|NCT00136500||Individuals affected with ALS|This population be sporadic or familial ALS.
9724113|NCT00136500||Unaffected individuals from families in which the genetic cause of ALS is known|This population includes pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
9724114|NCT00136500||Individuals affected with an ALS-related neurodegenerative disease|This would include FTD, MSP, IBMPFD, etc.
9724115|NCT00136500||Healthy controls|
9724116|NCT05153083||patient undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Subjects undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA) using cryoablation of intercostal nerves
9724117|NCT05141799|Active Comparator|high-intensity laser therapy (HILT)|"we will apply the HILT device to the most painful area of the wrist in two phases. In both phase I and phase II, the laser will be applied using continuous circular movements.~The first three sessions (phase I) will be used to provide analgesic effects at an intermittent phase, applying a 75 sec, 8 W, 6 J/cm2 treatment for a total of 150 J of energy. The subsequent six sessions (phase II) will provide a biostimulatory effect at a continuous phase, applying a 30 sec, 6 W, 120 to 150 J/cm2 treatment. The HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks."
9724118|NCT05141799|Sham Comparator|sham HILT|We will apply the HILT device to the most painful area of the wrist by using continuous circular movements, but the laser instrument will switched off during applications. The sham HILT will be applied for a total of nine treatment sessions over a period of three consecutive weeks.
9724119|NCT05136677|Experimental|Arm A|
9724120|NCT05136677|Experimental|Arm B|
9724121|NCT05133908|Active Comparator|Digital Sleep Hygiene and Self-Monitoring Control|Participants assigned to this condition will receive an app to track sleep and offers sleep hygiene recommendations
9724122|NCT05133908|Experimental|dCBTi-ADHD|Participants assigned to this condition will receive a 7-module digital cognitive behavioral therapy for insomnia (dCBTi) tailored for adults with ADHD
9724123|NCT05133219|Experimental|Research Group|"Participants will be received Intensified sensory therapy.~Other: Occupational Therapy Activities of Daily Living Training~Intervention: Other: Occupational therapy intervention"
9980880|NCT01396564|Active Comparator|Pioglitazone|Randomized patients are given 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
9980881|NCT01396577|Active Comparator|3 x 2-mg perampanel|
10197720|NCT04392804|Experimental|0.3 ml 4% articaine|single dose of 0.3 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
10197721|NCT04389450|Experimental|PLX-PAD interval high dose|PLX-PAD will be administered via 15 IM injections (1 mL each). Each subject will be treated twice, with an interval of 1 week between treatments.
10197722|NCT04389450|Experimental|PLX-PAD low dose|PLX-PAD 300, single administration, second administration of placebo after 1 week.
10197723|NCT04389450|Placebo Comparator|Control Group A|Placebo, two administrations, 1 week apart
10197724|NCT04389450|Experimental|PLX-PAD high dose|PLX-PAD, single administration
10197725|NCT04389450|Placebo Comparator|Control Group B|Placebo, single administration
10197726|NCT04388891|Experimental|Minimally supervised therapy|This group will undergo minimally supervised therapy with the robot ReHapticKnob.
10197727|NCT04388865|Experimental|Control|Usual Care
10197728|NCT04388865|Experimental|Clinical Hovering|Remote monitoring with feedback to social support
9724124|NCT05133219|Experimental|Control Group|"Participants will be received Occupational Therapy.~Other: Activities of Daily Living Training"
9980882|NCT01396577|Active Comparator|6mg perampanel|
9980883|NCT01396590|Active Comparator|6 x 2 mg perampanel|
9980884|NCT01396590|Active Comparator|12 mg Perampanel|
9980885|NCT01396616|Experimental|Single Arm|The enrolled subject will be implanted with Toric IOL manufactured by AuroLab
10197729|NCT04387851||Placebo|Placebo effects are defined as the positive effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have positive effects.
10197730|NCT04387851||Nocebo|Nocebo effects are defined as the negative effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have negative effects.
10204861|NCT04704271|Active Comparator|Delta-9-Tetrahydrocannabinol (THC)|4 mg vaporized THC will be administered.
10204862|NCT04704271|Placebo Comparator|Placebo|Inhaled placebo (no active cannabinoids)
9724125|NCT05127304||Chronic obstructive pulmonary disease (COPD) patients treated with Tiotropium Bromide/Olodaterol|COPD patients who initiated treatment with Tiotropium Bromide/Olodaterol between 01 June 2015 and 30 November 2019
9724126|NCT05127304||COPD patients initiated treatment with Furoate/Umeclidinium/Vilanterol|COPD patients who initiated treatment with Furoate/Umeclidinium/Vilanterol between 01 June 2015 and 30 November 2019
9724127|NCT05117502|Experimental|intermittent Theta Burst Stimulation|Participants will receive 2 treatments of intermittent Theta Burst Stimulation, each two weeks apart. First session will be iTBS alone, the second session will be combined iTBS with APT (Attention processing training).
9724128|NCT05117502|Placebo Comparator|Placebo intermittent Theta Burst Stimulation|Placebo iTBS participants will not receive any stimulation as the coil will be switched to placebo (P) setting. To maintain double-blind in A and P settings, Veterans and researchers wear headphones connected to a sham noise generator. Participants will receive 2 treatments of placebo intermittent Theta Burst Stimulation, each two weeks apart. First session will be iTBS alone, the second session will be combined placebo iTBS with APT (Attention processing training).
9724129|NCT05117255|Experimental|Experimental: Computer-delivered cognitive behavioral therapy hybrid for comorbidity|Four, approximately 60 minute each, computerized therapy sessions delivered on an interactive computerized platform. All participants are undergoing a standard 28 day residential alcohol treatment program.
9724130|NCT05117255|Active Comparator|Control: Progressive Muscle Relaxation Training (PMRT)|Four, one-hour computerized segments delivered on an interactive computerized platform teaching Progressive Muscle Relaxation Training (PMRT). All participants are undergoing a standard 28 day residential alcohol treatment program.
9724131|NCT05117255|No Intervention|Treatment as Usual (TAU)|Participants are undergoing a standard 28 day residential alcohol treatment program. No study intervention.
9724132|NCT05117203|Experimental|WB-EMS group|
9724133|NCT05117203|Experimental|EMS group|
10197731|NCT04386616|Placebo Comparator|All Placebo|Participants randomized to this arm received one intravenous (IV) infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo on Day 1. A second IV infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo (same placebo as the first infusion) was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
10197732|NCT04386616|Experimental|MSTT1041A|Participants randomized to this arm received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
10197733|NCT04386616|Experimental|UTTR1147A|Participants randomized to this arm received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
10197734|NCT04385433|Experimental|EXPERIMENTAL GROUP|RADIOTHERAPY + PRAVASTATIN
10197735|NCT04385433|Placebo Comparator|CONTROL GROUP|RADIOTHERAPY + PLACEBO
10197736|NCT04385108|Experimental|hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:~Patients with severe disease requiring on admission ICU management for ARDS,~Non-severe hospitalized patients with secondary clinical worsening requiring ICU management,~Non-severe hospitalized patients without clinical worsening requiring ICU management."
10197737|NCT04385108|Experimental|healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
10197738|NCT04384393|Experimental|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
10197739|NCT04379206||Men who have sex with men|MSM receiving a self-test kit with optional assistance
10197740|NCT04378270|Experimental|PopSole™ offloading device|This is an external insole device that fits into a shoe and is reusable for a given subject, not for one-time use. It is comparable to other off-the-shelf insoles readily available and presents minimal risk to the participant during the four weeks of study participation.
10197741|NCT04377711|Active Comparator|Group 1|Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI
10197742|NCT04377711|Placebo Comparator|Group 2|Participants receive Placebo matching Alvesco , twice daily for 30 days via pMDI
10197743|NCT04376333|Active Comparator|STD+CBT|Standard conservative dental orofacial pain care + cognitive-behavioral coping skills treatment
10197744|NCT04376333|Experimental|STD+IATP|Standard conservative dental orofacial pain care + Individualized Assessment and Treatment Program; a highly individualized coping skills training procedure.
10197745|NCT04375878|Active Comparator|MS1819 2240 mg/day vs PERT arm,|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
10197746|NCT04375878|Active Comparator|MS1819 4480 mg/day vs PERT arm|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
10197747|NCT04371198|Experimental|Organoid|
10197748|NCT04370119||(1) Healthcare workers|All healthcare workers at University Medicine Greifswald who were enrolled in the study between 04/2020-08/2020
10197749|NCT04370119||(2) Healthcare workers in high-risk areas of the hospital (intensive care, emergency medicine)|Healthcare workers at University Medicine Greifswald who were enrolled in the study between 01/2021-03/2021
10197750|NCT04370119||(3) Healthcare workers after SARS-CoV-2 vaccination|Healthcare workers at University Medicine Greifswald who received a SARS-CoV-2 vaccination within the last 7-21 days
10197751|NCT04369599|Experimental|V/Q System|Participants with acute respiratory failure will undergo therapy with the V/Q System.
10204863|NCT04685213|Active Comparator|Active E-Stim|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
10197752|NCT04369560|Experimental|Magnetic Resonance Imaging|Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
10197753|NCT04369131|Experimental|Intervention|All participants will receive intervention in four conditions: (a) no FES, (b) calves only FES, (c) quads and abdominals only FES, and (d) calves, quads, and abdominals FES. Session-by-session alternation among conditions will occur in a unique, predetermined, randomized order for each participant.
9724134|NCT05117203|Sham Comparator|Control group|
9724135|NCT05113706||Bystander not emotional distressed|If caller is not emotional distressed the first minute of the call
10197754|NCT04362618|Experimental|Muscle Strengthening Training (MST)-group|Subjects allocated to the MST group (n=30) will perform a muscle strengthening training program of 12 weeks.
10197755|NCT04362618|Experimental|Behavioral Graded Activity (BGA)-group|Subjects allocated to the BGA group (n=30) will perform a rehabilitation program according to the principles of behavioural graded activity for a period of 12 weeks.
10197756|NCT04362618|No Intervention|Control group|Subjects allocated to the control group (n=30) have to maintain their current life-style and treatment (if any) and to refrain from other new interventions during 24 weeks.
10197757|NCT04360460|Experimental|Experimental|Virtual reality followed by translation into related functional tasks in a real life setting for 2 weeks + conventional therapies
10197758|NCT04360460|Active Comparator|Control|Virtual reality followed by translation into non-related functional tasks in a real life setting for 2 weeks + conventional therapies
9724136|NCT05113706||Bystander emotional distressed|If caller is emotional distressed the first minute of the call
9724137|NCT05108441|Other|Echo|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris
9724138|NCT05102162|Active Comparator|Continuous Antibiotic Dose Over 24 hours Arm|Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.
10197759|NCT04360213||Children with Asthma|"Patients ages 1 to 17 years old~Patients in the Emergency Department or admitted to the hospital for asthma exacerbation."
10197760|NCT04360213||Children with allergy|"Patients ages 1 to 17 years old~Patients scheduled to do an oral food challenge"
10197761|NCT04356690|Experimental|Cohort 1 - Etoposide|"Participants that are on ventilation Etoposide 150 mg/m2 daily days 1 and 4~If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
9724139|NCT05102162|Active Comparator|Intermittent Antibiotic Dose Over 30 minutes|Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.
9724140|NCT05099003|Experimental|Treatment (selinexor and radiation therapy)|"CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance.~MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
9724141|NCT05096208|Experimental|RSVpreF vaccine Group 1|RSVpreF
9724142|NCT05096208|Experimental|RSVpreF vaccine Group 2|RSVpreF
9724143|NCT05096208|Experimental|RSVpreF vaccine Group 3|RSVpreF
9724144|NCT05096208|Placebo Comparator|Placebo dose|Placebo
9724145|NCT05094336|Experimental|Part 1a and 1b, Phase 1: AMG 193 Monotherapy Dose Exploration|Participants with MTAP-null solid tumors will receive escalating doses of AMG 193 to estimate the MTD and/or the RP2D.
9724146|NCT05094336|Experimental|Part 1c, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:~MTAP-null squamous NSCLC."
9724147|NCT05094336|Experimental|Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel|Participants with MTAP-null NSCLC will receive escalating doses of AMG 193 + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.
9724148|NCT05094336|Experimental|Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion|Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of AMG 193 + docetaxel.
9724149|NCT05094336|Experimental|Part 3: AMG 193 Phase 2|Participants with MTAP-null NSCLC will receive AMG 193.
9724150|NCT05094336|Experimental|Part 1d, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:~MTAP-null adenocarcinoma NSCLC"
10197762|NCT04356690|Experimental|Cohort 2 - Etoposide|"Participants that are NOT on ventilation Etoposide 150 mg/m2 daily days 1 and 4~Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4. If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
10197763|NCT04356690|No Intervention|Cohort 1 - Control|Standard of care therapy in participants that are on ventilation
9724151|NCT05094336|Experimental|Part 1e, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:~MTAP-null cholangiocarcinoma"
9724152|NCT05094336|Experimental|Part 1f, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:~MTAP-null head and neck squamous cell carcinoma (HNSCC)"
9724153|NCT05094336|Experimental|Part 1g, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:~MTAP-null pancreatic adenocarcinoma"
9724154|NCT05094336|Experimental|Part 1h, Phase 1: AMG 193 Monotherapy Dose Expansion|"Participants will receive the identified MTD/RP2D of AMG 193 in the following cohort:~MTAP-null solid tumor other than squamous or adenocarcinoma NSCLC, cholangiocarcinoma, HNSCC, pancreatic adenocarcinoma, primary brain tumor, and lymphoma."
9836228|NCT02776670|Active Comparator|REFRESH OPTIVE|Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days
9836229|NCT02776683|Experimental|All patients|
10197764|NCT04356690|No Intervention|Cohort 2 - Control|Standard of care therapy in participants that are NOT on ventilation.
10197765|NCT04356209|Experimental|EXPERIMENTAL GROUP|ePRO intervention + PRAVASTATINE treatment
9724155|NCT05088915|Experimental|BREATHE Primary Care Intervention for PTSD (PCIP)|"BREATHE PCIP is a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms for use with individuals who have a diagnosis of PTSD or probable PTSD. The treatment will be considered delivered when patients have learned and practiced breathing retraining and have discussed the symptoms of PTSD (Sessions 1 through 3)."
9724156|NCT05088915|Active Comparator|Trauma-Focused Cognitive Behavioral Therapy|TF-CBT model is a brief (8-25 session), cognitive-behavioral, resiliency-building, components- and phase-based model for trauma-impacted children or adolescents and their parents and caregivers.
9724157|NCT05088915|Active Comparator|Treatment As Usual|Receive standard care treatment and provided information on free or low cost mental health care referrals in the Los Angeles Area.
9724158|NCT05087875|Experimental|TRAC: Tracking and Reducing Alcohol Consumption|"The TRAC intervention focuses on increasing motivation and building skills to reduce alcohol use and involves 8, 30-minute sessions with an interventionist. Session 1 is done via video chat to build rapport. Sessions 2-8 are done via phone.~Participants will complete smartphone-based self-monitoring of alcohol use. Each morning, participants complete a mobile survey indicating if they drank the previous day and if so, how many drinks they had. Surveys will be programmed using REDcap and sent via a link in the reminder text message. Additionally, participants will be prompted at a random time between 5-11pm and asked to complete a breathalyzer reading using a mobile app to determine blood alcohol content (BAC). If safety concerns are identified (e.g., BAC ≥0.30; blackouts), the interventionist will refer the AYA to a licensed provider with expertise in substance use treatment."
9724159|NCT05087875|Active Comparator|Control|Participants in the control group will receive educational materials regarding alcohol consumption and strategies for reducing their use (materials available from American Cancer Society and NCI Alcohol and Cancer Factsheet). They will also participate in smartphone monitoring of alcohol use on the same schedule as participants in the intervention group. This will allow us to compare daily alcohol use data between the two conditions and evaluate the added component of weekly counseling in TRAC.
9724160|NCT05083546|Experimental|Intervention|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
9724161|NCT05083546|Placebo Comparator|Control|sugar pill
9724162|NCT05076578|Experimental|Evaluate the harvesting of micografts in healthy and patients with chronic wounds|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
9724163|NCT05072535|Experimental|Part 1-Group A|Subjects will receive 200 mg HA121-28 tablet A on Day 1 of the first cycle, followed by tablet B on Day 36 of the second cycle, in the fasted state.
9724164|NCT05072535|Experimental|Part 1-Group B|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle, followed by tablet A on Day 36 of the second cycle, in the fasted state.
9724165|NCT05072535|Experimental|Part 2-Group C|Subjects will receive 200 mg HA121-28 tablet B on Day1 of the first cycle in fasted state, followed by tablet B on Day 36 of the second cycle in the fed state.
9724166|NCT05072535|Experimental|Part 2-Group D|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle in the fed state, followed by tablet B on Day 36 of the second cycle in fasted state.
9724167|NCT05071365|Experimental|Videos|"Single Arm study: All participants recruited to the study will be allocated to a single arm- videos in which participants will be able to access self help videos for plantar fasciitis"
10197766|NCT04356209|Other|CONTROL GROUP|PRAVASTATINE treatment ( without ePRO)
9724168|NCT05064670|Experimental|Exercise|The intervention group will, in addition to routine clinical care according to (inter-) national guidelines, receive an exercise program of resistance and aerobic exercise delivered online in group exercise classes twice weekly, behaviour change counselling sessions and exercise maintenance phone calls.
9724169|NCT05064670|No Intervention|Control|The control group will receive routine clinical care according to (inter-) national guidelines
9724170|NCT05058248|Active Comparator|Pudendal block|Ultrasound-guided bilateral pudendal block at the start of surgery, in gynecological position: injection of 15 mL of 0.475% Naropein in each ischiorectal fossa.
9724171|NCT05058248|Other|the standard method|Operated and anesthetized patients according to the standard method within the department
9724172|NCT05053360|Experimental|Healing Touch|Subjects in this arm get a HT session post cesarean
9724173|NCT05053360|Active Comparator|Control|Subjects in this arm get a control activity of equal duration
9724174|NCT05052983|Experimental|Nemolizumab|
9724175|NCT05052983|Placebo Comparator|Placebo|
9724176|NCT05050214|Experimental|Experimental: GAZYVA, GAZYVARO(Obinutuzumab)|Participants will receive Obinutuzumab 1000 mg solution for infusion (total dose of 3000 mg in 30 days).
9724177|NCT05049980|Experimental|Medical treatment|Patients choosing medical treatment with Mifégyne® and MisoOne®
9724178|NCT05049980|Active Comparator|Surgical treatment|Patients choosing surgical treatment by endo-uterine aspiration.
10197767|NCT04355364|Experimental|Experimental group|Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.
10197768|NCT04355364|Active Comparator|Control group|Patients will receive the usual care in accordance with good practice.
9724179|NCT05047536|Experimental|KZR-261 with standard therapy: open-label|"Part 1 (Dose Escalation)~The initial dose cohort of the Dose Escalation will receive 1.8 mg/m2 of KZR-261. Subjects will receive 3 doses in a 28-day cycle.~___________________________________________~Part 2 (Dose Expansion)~Following safety review of all Dose Escalation cohorts and determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), KZR-261 will be evaluated for safety and preliminary efficacy in 4 tumor-specific cohorts and 1 all-tumor cohort to determine the recommended phase 2 dose (RP2D). The 4 tumor-specific cohorts will include:~melanoma (including uveal melanoma)~colorectal cancer~prostate cancer~mesothelioma"
10197769|NCT04354168|Experimental|Nthabi mHealth Application|Twenty women from each of the ten district hospitals will be recruited for a total of 200 participants. Each district hospital will have a separate administrative page on the Nthabi server where women will be enrolled with a unique username and password. Upon enrollment, the women will be asked to engage with Nthabi for two months to discuss the relevant content areas they are interested in learning more about.
10197770|NCT04354025|Experimental|Recipient: FLAG + CIML NK Cells + IL-2|-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
9724180|NCT05045261|No Intervention|A - Standard of care NUC|Patients will continue their standard of care NUC treatment
9724181|NCT05045261|Experimental|B - NUC discontinuation|Patients will stop their NUC treatment 28 weeks after enrolment
9724182|NCT05045261|Experimental|C - NUC discontinuation after SLGN treatment|"Patients will take from enrolment~their standard of care NUC treatment for 28 weeks then stop~3mg SLGN weekly for 24 weeks then stop"
9724183|NCT05044845||Hemophilia B patients|Patients ≥12 years of age with a diagnosis of moderate (FIX ≥1% and ≤2%) or severe (<1%) hemophilia B
9724184|NCT05044845||Parents or Caregivers|Parents or caregivers to patients with hemophilia 12-17 years of age
9724185|NCT05044845||Healthcare Workers|Doctors, nurses, social workers, and educators who participate in the care of hemophilia B patients
9724186|NCT05034328||Healsea® Children: isotonic seawater based nasal spray supplemented with natural Symbiofilm® extract|Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed.
9724187|NCT05034328||Conventional therapies|Children will receive conventional therapies for common cold as needed, nasal irrigation excluded
9724188|NCT05027477|Active Comparator|Radical Prostatectomy|Patients in this group will undergo Radical prostatectomy. There will be about 67 people in this group.
9724189|NCT05027477|Experimental|TULSA Procedure|Patients in this group will undergo TULSA Procedure. There will be about 134 people in this group.
9724190|NCT05023980|Experimental|Arm A (Pirtobrutinib)|Pirtobrutinib administered orally
9724191|NCT05023980|Active Comparator|Arm B (BR)|Bendamustine plus rituximab administered intravenously (IV)
9724192|NCT05015478|Active Comparator|Active Tailored Rhythmic Lighting|1 hour intervention period where active lighting is experienced by participants.
9724193|NCT05015478|Placebo Comparator|Inactive Placebo Rhythmic Lighting|1 hour intervention period where an inactive, placebo lighting condition is experienced by participants.
9980886|NCT01396629||single group|the intra ocular lenses will be loaded in the cartridge.
9980887|NCT01396642|Experimental|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
9980888|NCT01396642|No Intervention|Routine Skin Care|Neonates in this group will receive routine skin care as per unit protocol
9980889|NCT01396655|Experimental|docetaxel + doxorubicin|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks.
9980890|NCT01396694||all|All patients requiring arthroscopy or arthroplasty
9724199|NCT05011890|Other|Single-arm|Participants will be assigned to the single-arm involving weekly monitoring of their patient-reported outcomes using Moovcare®.
9724200|NCT05003258|Other|Patients with RVO|Dexamethasone Intravitreal Implant is used in patients with Macular ar edema due to retinal vein occlusion either from the start or after unsatisfactory response to anti - VEGF
9724201|NCT05001646|Experimental|In-home EMF protection device|
9724202|NCT04996654|Experimental|Exergame|Participants will perform a twelve-week training intervention in addition to their usual care as provided by the memory clinics where the patients are recruited. The training intervention will be prescribed according to a newly developed exergame-based intervention concept that consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) perceptual-motor function.
9724203|NCT04996654|Active Comparator|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
9724204|NCT04986631|Experimental|Topiramate|Individuals will receive 75 mg of topiramate daily. The dose will start at 25 mg daily for the first week. The second week participants will receive 50 mg daily. Starting at week 3 participants will take 75 mg daily.
9980891|NCT01396707|Experimental|Herceptin+XELOX|
9724207|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD1222|Previously vaccinated with AZD1222, dosing on day 1
9724208|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD2816|Previously vaccinated with AZD1222, dosing on day 1
9724209|NCT04973449|Other|mRNA booster: one dose of AZD1222|Previously vaccinated with an mRNA vaccine, dosing on day 1
9724210|NCT04973449|Other|mRNA booster: one dose of AZD2816|Previously vaccinated with an mRNA vaccine, dosing on day 1
9724211|NCT04973449|Other|2 doses of AZD1222, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
9724212|NCT04973449|Other|2 doses of AZD2816, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
9724213|NCT04973449|Other|2 doses of AZD2816, 12 weeks apart|Previously unvaccinated. First dose day 1, second dose day 85
10197771|NCT04354025|Other|Donor:|-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.
10197772|NCT04352101|Experimental|Bupropion|Participants randomized to take bupropion for 8 weeks.
9980892|NCT01396720|Active Comparator|fluvoxamine|
10197773|NCT04352101|Active Comparator|Escitalopram|Participants randomized to take escitalopram for 8 weeks.
10197774|NCT04350463|Experimental|Arm A: SCLC in ICI naïve subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
10197775|NCT04350463|Experimental|Cohort B: SCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
10197776|NCT04350463|Experimental|Cohort C: sqNSCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
9724214|NCT04973449|Other|one dose of AZD1222 + one dose AZD2816, 4 weeks apart|Previously unvaccinated. Dose of AZD1222 on day 1, dose of AZD2816 on day 29
9780705|NCT01129141|Other|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
9780706|NCT01129206|Experimental|Arm I|Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9780707|NCT01129245|No Intervention|Control cycle|Control menstrual cycle
9780708|NCT01129245|Experimental|Pre-LH surge celecoxib administration|Pre-LH surge dosing of celecoxib
9780709|NCT01129245|Experimental|Post-LH surge celecoxib administration|Post-LH surge dosing of celecoxib
9780710|NCT01129284|Experimental|Acthar gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
9780711|NCT01129336|Experimental|Patients without bone metastases|Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.
9780712|NCT01129336|Experimental|Patients with bone metastases|Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy)
9780713|NCT01129440|Active Comparator|Fluoride Varnish|Topical fluoride varnish (FV) applications every 6 months
9780714|NCT01129440|Experimental|FV + Glass Ionomer Sealants|Topical fluoride varnish (FV) applications every 6 months, and fluoride-releasing glass ionomer sealants (GIS) placed on primary molars at baseline and annually, as needed
9785255|NCT01246986|Experimental|Part D Cohort 2 - 300 mg LY2157299 + 8 mg/kg Ramucirumab|"150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
10197777|NCT04347408||Healthy Children|Healthy children of healthcare workers between 2 and 15 years of age
10197778|NCT04347408||Paediatric Multisystem Inflammatory Syndrome|Children admitted to hospital with Paediatric Multisystem Inflammatory Syndrome
10197779|NCT04347408||Serious Infection|Children admitted to hospital with serious infections
10197780|NCT04345302|Experimental|Brief motivational treatment|"Participants in the intervention group will receive the Brief Motivational Treatment, which is a primary care-adaptation of the Motivational Enhancement Therapy as manualized in the Project MATCH [19]. This treatment consists of four 45-minute sessions, provided by a psychologist at weeks one, two, six, and twelve. The first three sessions, occurring during the first six weeks, are more active regarding the behavioural change, while the last session functions as closure and review of the process. If a participant asks for more support, they will be able to attend up to two extra sessions before the last one.~The main adaptations are:~The translation into Chilean Spanish.~Update of Motivational Interview concepts.~Companion training material that includes a demonstrative video and practical exercises.~An adapted personalized feedback procedure.~Information on additional resources available in the primary care centre and the community."
10204864|NCT04685213|Sham Comparator|sham E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
10204865|NCT04682340||Hashimoto's Group|Thyroid antibody positive and hypothyroidism
10204866|NCT04682340||Graves' Group|Thyroid antibody positive and hyperthyroidism
9785256|NCT01246999|Active Comparator|Live Attenuated Influenza vaccine|LAIV 0.2 ml will be given intranasally followed by LAIV 0.2 mg given intranasally 28 days later
9785257|NCT01246999|Active Comparator|Trivalent Influenza Vaccine 2010-2011|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 8 years intramuscularly followed by a second dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly 28 days later
9980893|NCT01396720|Active Comparator|citalopharm|
9980894|NCT01396733|Active Comparator|Low dose group|Patients who will receive 600 mg/day alpha-lipoic acid
9980895|NCT01396733|Active Comparator|High dose group|Patients who will receive 1,200 mg/day alpha-lipoic acid
9984528|NCT04002180||Vedolizumab 300 mg|Vedolizumab (Genetical Recombination) 300 mg, IV infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
9984529|NCT03997968|Experimental|CYT-0851 dose escalation|Part A: CYT-0851 administered orally in rising doses QD or BID for 28 day cycles
9724215|NCT04961190|Active Comparator|Prolonged Exposure Therapy|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
9724216|NCT04961190|Active Comparator|Pharmacotherapy|20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
10197781|NCT04345302|Active Comparator|Enhanced usual care|"All participants will receive an educational brochure on alcohol use disorder, with self-help materials and guides on how to get additional support.~The physicians within the PC centre will also receive information on how to diagnose alcohol use disorders, prescription guides for the medications that are available for treating these disorders in the PC centre (mainly Disulfiram and any other if available), and directions on when and where to refer clients for treatment."
10197782|NCT04342962|Experimental|Experimental arm|"12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cycles of therapy; each cycle is 21 days.~Patients will receive the study drug until disease progression or in case of toxicity."
10197783|NCT04341896||Caregivers|Prior obese living kidney donors who served as the primary caregiver for their recipient
9724217|NCT04961190|Active Comparator|Combined treatment (Prolonged Exposure and Pharmacotherapy)|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
10197784|NCT04341896||Non-caregivers|Prior obese living kidney donors who were not the primary caregiver for their recipient
10197785|NCT04340362|Experimental|VX-147|Subjects will receive VX-147 orally at Dose 1 for 2 weeks and at Dose 2 for 11 weeks.
10197786|NCT04336943|Experimental|Treatment (durvalumab, olaparib)|All patients receive durvalumab IV over 1 hour on day 1 of each cycle. Patients with CDK12 mutation and MMRd/MSI-high also receive olaparib PO BID on days 1- 28 of cycles 3-6. Patients with homologous recombination mutation also receive olaparib PO BID on days 1-28 of cycles 1-6. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
10197787|NCT04334889||Chronic low back pain (CLBP)|All CLBP patients should present with non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months.
10197788|NCT04334889||Asymptomatic controls|Asymptomatic participants should have had no history of LBP requiring medical attention during the last two years and no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics.
9724218|NCT04944017|Experimental|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
9724219|NCT04944017|Placebo Comparator|Saline Infusion|Participants will receive 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry
9724220|NCT04941456|Active Comparator|Open Tracheostomy|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
9724221|NCT04941456|Experimental|PMV in place|Participants will perform the six-minute walk test each session to assess ambulation distance, alternating between the open tracheostomy (standard) versus the Passy-Muir Valve in place intervention on sequential days to compare results.
9724222|NCT04941222|Experimental|"With robotic seal PARO"|The robot will be made available to the patient by the caregiver in charge of the patient for 5 minutes before a toilet and for the duration of the treatment (about 10 minutes), twice a week for 16 weeks.
9724223|NCT04941222|No Intervention|"Without robotic seal PARO"|The care of the patient during the toilet will be carried out according to the modalities currently in use in the facility.
9724224|NCT04938323|Experimental|BCG Vaccine|Participants randomized to the BCG Vaccine Arm will receive the vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
9724225|NCT04938323|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines': upper arm.
9724226|NCT04935606|Experimental|Usual Care|Usual Care participants will receive their standard medical care as usual (no provider advice or telephone coaching sessions) and all screening and study assessments. To reduce biases, Usual Care arm patients will be given a cancer screening booklet and will be shown a cancer screening Video Doctor. They will also receive 2 re-contact telephone sessions at weeks 2 and 6 corresponding to the timing of the coaching sessions for the QUIT and QUIT-Mobile arms. All participants will also receive re-contact calls monthly from 7-weeks to 12-months. The re-contact calls (5 min) provide attention control for the Usual Care arm, motivate continued trial participation by reminding them of the next research assessment, but do not provide an active intervention. At study end, the Usual Care arm will receive the QUIT video doctor and drug use reduction booklet brochure materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
9724227|NCT04935606|Experimental|QUIT|The QUIT brief intervention protocol will consist of 5 steps corresponding to the 5A's approach for assisting behavior change in the clinic setting (Ask, Advise, Assess, Assist, and Arrange) that will focus on patients' HSD (highest scoring drug on the baseline ASSIST) use in the past 30 days.
9724228|NCT04935606|Experimental|QUIT-Mobile|"QUIT-Mobile will include a mobile platform with self-monitoring surveys and feedback message and robust data transfer protocols across three mobile technology platforms to meet diverse patient's preferences and needs regardless of literacy and phone type: a mobile-optimized web-app (using any smart phone's web-browser, not native apps), SMS (text-messaging), and IVR (automated voice calls for low literacy patients). Data collected during this study on patient platform preferences and exploratory analyses on intervention efficacy across platform types will inform the development of future effectiveness trials that can evaluate effectiveness of different mobile platforms."
9724229|NCT04930328||Retrospective Data Collection|Retrospective Data Collection
9724230|NCT04929080|Experimental|JS004 200mg, Q3W until to 2 years|Part A: phase I: 3-6; phase II: 66.
9724231|NCT04929080|Experimental|JS004 600mg, Q3W until to 2 years|Part A: phase I: 3-6; phase II: 66.
9724232|NCT04929080|Experimental|240mg JS001+100mg JS004, Q3W until to 2 years|Part B: phase I: 6; phase II: 68.
10204867|NCT04682340||Control Group|Thyroid antibody negative and euthyroidism
10204868|NCT04668326|Active Comparator|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
9724233|NCT04929080|Experimental|240mg JS001+200mg JS004, Q3W until to 2 years|Part B: phase I: 6; phase II: 68.
10197789|NCT04332692|Experimental|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination focusing on congestion~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone follow-up"
9724234|NCT04923347|Experimental|Participants receiving FF/UMEC/VI via ELLIPTA inhaler|
9724235|NCT04923282|Active Comparator|Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo|single 1-hour IV infusion of 0.8 mg/kg recAP or placebo
9724236|NCT04923282|Active Comparator|Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo|single 1-hour IV infusion of 1.6 mg/kg recAP or placebo
9724237|NCT04923282|Active Comparator|Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo|single 1-hour IV infusion of 3.2 mg/kg recAP or placebo
9724238|NCT04923282|Active Comparator|Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3|1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3
10197790|NCT04327557|Experimental|MBCP Childbirth Education Course|This arm will undergo the 9-week MBCP course.
9724239|NCT04909801|Experimental|Arm 1: Abatacept + Methotrexate|
9724240|NCT04909801|Experimental|Arm 2: (Adalimumab + Methotrexate) followed by (Abatacept + Methotrexate)|
9724241|NCT04909463|No Intervention|Unilateral rib fractures only, no device intervention|Unilateral rib fractures only, no device intervention
9724242|NCT04909463|Experimental|Unilateral rib fractures, device intervention|Unilateral rib fractures, will receive device intervention
9724243|NCT04909463|No Intervention|Bilateral rib fractures, no device intervention|Bilateral rib fractures, no device intervention
9724244|NCT04909463|Experimental|Bilateral rib fractures, device intervention|Bilateral rib fractures, will receive device intervention
9724245|NCT04903353|Active Comparator|Treatment with Risperidone|Patients prescribed Risperidone
9724246|NCT04903353|Active Comparator|Treatment with Aripiprazole|Patients prescribed Aripiprazole
9724247|NCT04901455|Experimental|COPD Frequent Exacerbators|Individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
9724248|NCT04901455|Experimental|COPD Infrequent Exacerbators|Individuals with less than two episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months
9724249|NCT04901455|Experimental|Healthy Control|Individuals with spirometry-confirmed normal lung function and no asthma history
9724250|NCT04898322|Experimental|2.5mg SY-005|
10197791|NCT04327557|Active Comparator|Non-MBCP Childbirth Education Course|This arm will undergo the TAU (treatment as usual) childbirth education course (one that does not have a huge mindfulness component).
9724251|NCT04898322|Experimental|5mg SY-005|
9724252|NCT04898322|Experimental|10mg SY-005|
9724253|NCT04898322|Placebo Comparator|Placebo|
9984530|NCT03997968|Experimental|CYT-0851 dose expansion|Part B: CYT-0851 administered orally at the selected Phase 2 dose for 28 day cycles
10197792|NCT04323943|Experimental|Carbon-AFO (C-AFO)|Manufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.
10197793|NCT04323943|Active Comparator|Custom-made thermo-plastic orthosis (CM-AFO)|Own custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.
10197794|NCT04323943|No Intervention|Without orthosis (NO)|No orthosis - patient will wear only their shoes
10197795|NCT04322149|Experimental|AT-1501|4 sequential dose cohorts
10197796|NCT04321044|Other|Renal Denervation|We attempt to identify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch
10197797|NCT04320979|Experimental|internal mammary nodal irradiation|chest wall and supraclavicular nodal+-axillary plus internal mammary nodal irradiation
10197798|NCT04320979|Active Comparator|no-internal mammary nodal irradiation|ipsilateral chest wall and supraclavicular +-axillary nodal irradiation
10197799|NCT04312711|Experimental|intervention|All participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference
10204869|NCT04668326|Experimental|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
10204870|NCT04667338||Cohort A: NT1 Participants|Participants with confirmed diagnosis of narcolepsy type 1 (NT1) defined by the International Classification of Sleep Disorders, Third Edition (ICDS-3) will be observed for up to 24 months.
9724258|NCT04891692|Experimental|Phasic Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's phasic setting. Treatment at 3 kHz, modulation 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
9724259|NCT04891692|Experimental|Combined Treatment Group|Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's combined (tonic and phasic) setting. Treatment at 3 kHz, modulation 4 Hz and 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.
9724260|NCT04889157|Experimental|PF-06882961|Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg
9724261|NCT04889157|Placebo Comparator|Placebo|Placebo
9724262|NCT04888624|Experimental|DrySee® dressing with moisture detection|DrySee® dressing with moisture detection
9724263|NCT04888624|Active Comparator|Tegaderm® + Pad transparent film dressing|Tegaderm® + Pad transparent film dressing
9724264|NCT04886063|Experimental|Treatment|Daily subcutaneous (SC) injection of ATH-1017
9724265|NCT04883333|Experimental|Cohort A1 LEO 153339|Single ascending dose (Part 1)
9724266|NCT04883333|Experimental|Cohort A2 LEO 153339|Single ascending dose (Part 1)
9724267|NCT04883333|Experimental|Cohort A3 LEO 153339|Single ascending dose (Part 1)
9724268|NCT04883333|Experimental|Cohort A4 LEO 153339|Single ascending dose (Part 1)
9724269|NCT04883333|Experimental|Cohort A5 LEO 153339|Single ascending dose (Part 1)
9724270|NCT04883333|Experimental|Cohort A6 LEO 153339|Single ascending dose (Part 1)
9724271|NCT04883333|Experimental|Cohort A7 LEO 153339|Single ascending dose (Part 1)
9724272|NCT04883333|Experimental|Cohort B1 LEO 153339|Single ascending dose (Part 1)
9724273|NCT04883333|Placebo Comparator|All SAD cohorts placebo|Single ascending dose (Part 1), all participants receiving placebo in Cohorts A1-A7 and B1
9724274|NCT04883333|Experimental|Cohort C1 LEO 153339|Multiple ascending doses (Part 2)
9724275|NCT04883333|Experimental|Cohort C2 LEO 153339|Multiple ascending doses (Part 2)
9724276|NCT04883333|Experimental|Cohort C3 LEO 153339|Multiple ascending doses (Part 2)
9724277|NCT04883333|Experimental|Cohort C4 LEO 153339|Multiple ascending doses (Part 2)
9724278|NCT04883333|Experimental|Cohort C5 LEO 153339|Multiple ascending doses (Part 2)
9724279|NCT04883333|Experimental|Cohort C6 LEO 153339|Multiple ascending doses (Part 2)
9724280|NCT04883333|Placebo Comparator|All MAD cohorts placebo|Multiple ascending doses (Part 2, all participants receiving placebo in Cohorts C1-C6)
9724281|NCT04877756|Experimental|Arm A 2.0 mg/cm OLX10010 biweekly|Arm A- half the scar treated with 2.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
10197800|NCT04309461|Active Comparator|Stress Management Group|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
9724282|NCT04877756|Experimental|Arm B 5.0 mg/cm OLX10010 biweekly|Arm B- half the scar treated with 5.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
10197801|NCT04309461|Experimental|Adapted MBC2 Group|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
10197802|NCT04302207|Experimental|High intervention hospital (Nationwide Childrens Hospital)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; provider surveys measuring the acceptability, appropriateness, feasibility, and perceived burden of piloted strategies; review of patient data extracted from electronic health record 1-year pilot, 10 months post-pilot data
10197803|NCT04302207|No Intervention|Low intervention hospital (Childrens Hospital Colorado)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; review of patient data extracted from electronic health record 1-year pilot, 10 months post-pilot data
9724283|NCT04877756|Experimental|Arm C 2.0 mg/cm OLX10010 weekly|Arm C- half the scar treated with 2.0 mg/cm of OLX10010 weekly, other half treated with OLX Placebo
9724284|NCT04866342|Experimental|Servo control - Masimo oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
9724285|NCT04866342|Active Comparator|Servo control - Nellcor oximetry technology (Oxygen Assist Module, IntellO2, Vapotherm)|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard clinical practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
9984531|NCT03997968|Experimental|CYT-0851 and rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab on Day 1 and bendamustine on Days 1 and 2 of each 28 day cycle
9724288|NCT04858412|Active Comparator|HMB enriched amino acid arm|The patients randomized to the HMB enriched amino acid (HMB/EAA) arm will be given HMB/EAA for 90 days.
9724289|NCT04858412|Placebo Comparator|Balanced amino acid arm|The patients randomized to the Balanced amino acid (BAA) arm will be given BAA for 90 days.
9724290|NCT04857918|Experimental|Social identity informed virtual running group|Participants will join running groups of six people (males and females) for eight weeks. Each running group will be given the group goal/challenge to collectively run/brisk walk the distance across the province of British Columbia (940 km) over the course of the eight week intervention (Estabrooks et al., 2008), and encouraged to complete 150 minutes of moderate-to-vigorous exercise per week. Participants can record other moderate-to-vigorous exercise to contribute to the group goal. Running groups will be created on the fitness application Strava, and participants will record/post their runs on the Strava app so that members of their running group can provide 'kudos' and words of encouragement. Running groups will have a weekly a coffee chat (via Zoom) to socialize and discuss their experiences running/exercising and progress and challenges associated with meeting the group goal. Participants will also be provided running tip videos, phone armbands, and t-shirts with the study logo.
9724291|NCT04857918|Active Comparator|Attention control group|This group of participants will act as an attention control condition. This group will be asked to download the fitness application Strava to their smartphone, and track all of their runs and walks on Strava. Similar to the intervention group, participants will be provided with phone armbands to carry their phone during a run or walk so they can record the run or walk on Strava, and will be asked to try participating in 150 minutes of moderate-to-vigorous exercise per week.
9724292|NCT04855032|Experimental|Reactive Perturbations|
9724293|NCT04855032|Experimental|Proactive Perturbations|
9724294|NCT04850599|Experimental|Treatment (isatuximab, carfilzomib, pomalidomide)|Patients receive isatuximab IV over 30-60 minutes on days 1, 8, 15, and 22 of cycle 1, and days 1 and 15 of subsequent cycles, carfilzomib IV over 10 to 30 minutes on days 1, 8, 15, and pomalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9724295|NCT04844762|Active Comparator|usual brand menthol cigarette (UBMC)|Study participant's usual brand menthol cigarette
9724296|NCT04844762|Active Comparator|menthol roll-your-own cigarette (mRYO)|Mentholated pipe tobacco in a roll-your-own cigarette tube
10197804|NCT04302103|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
10197805|NCT04302103|Experimental|RC18 240 mg|Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
9724297|NCT04844762|Active Comparator|menthol filtered little cigar (mFLC)|The menthol filtered cigar will be Cheyenne (Cheyennecigars.com) Seneca (senecacigars.com)
10197806|NCT04296942|Experimental|1/M7824 (Bintrafusp alfa) + Bavarian Nordic (BN)-Brachyury|"Arm 1 - Triple Negative Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury."
10197807|NCT04296942|Experimental|2/M7824 + BN-Brachyury + Ado-trastuzumab emtansine (T-DM1)|"Arm 2 - Estrogen receptor (ER)-/progesterone receptor (PR)-/Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury. These investigational agents will be added to standard of care treatment called Ado-trastuzumab emtansine (T-DM1)."
9724298|NCT04844762|Active Comparator|non-menthol cigarette (nmC)|The non-menthol cigarette will be Newport non-menthol cigarettes.
10197808|NCT04296942|Experimental|3/M7824 + BN-Brachyury + T-DM1 + Entinostat|"Estrogen receptor (ER)-/progesterone receptor (PR)-/Human Epidermal Growth Factor Receptor 2 (HER2)+ Breast Cancer.~Bifunctional fusion molecule involving programmed death-ligand 1 (PD-L1) with transforming growth factor beta (TGF-b) sequestering agent added to a vaccine for the tumor associated antigen called brachyury as well as to an oral histone deacetylase (HDAC) inhibitor called entinostat. These investigational agents will be added to standard of care treatment called Ado-trastuzumab emtansine (T-DM1). (T-DM1)."
9724300|NCT04839562|Experimental|solriamfetol|Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
9724301|NCT04839562|Placebo Comparator|placebo|Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
9724302|NCT04837586|Active Comparator|Standard Care|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic
9724303|NCT04837586|Active Comparator|Simple Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a simple scale.
10197809|NCT04292912|Experimental|Participants receiving GSK2798745|
10197810|NCT04291599|Experimental|Experimental Arm - Ketorolac (Opioid-Sparing)|Patients assigned to this arm of the study will follow the standardized step-up approach to pain management per the hospital Evidenced Based Guideline (EBG). If analgesia is not obtained with first-line medications such as acetaminophen, the patient will be given the NSAID ketorolac intravenously every 6 hours at the standard weight-based dose throughout hospitalization. If the patient experiences continued pain, they (or their guardian/ caregiver) may request a rescue medication in the form of low-dose morphine (or an alternative opioid if allergic to morphine) at 0.025 mg/kg/dose every 4 hours.
10204871|NCT04667338||Cohort B: NT2 Participants|Participants with confirmed diagnosis of narcolepsy type 2 (NT2) defined by the ICDS-3 will be observed for up to 24 months.
10204872|NCT04651153|Experimental|UCB7853|Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points
9724304|NCT04837586|Active Comparator|EHR-Connected Scale|Individuals in this arm will receive standard care for their obesity in the Pediatric Weight Management Clinic and will be encouraged to self-weigh daily utilizing a Smart scale that is connected to the Electronic Health Record (EHR).
9724305|NCT04833309|Experimental|Pharmacopuncture therapy|Pharmacopuncture will be administered to the subjects in the pharmacopuncture therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
10204873|NCT04651153|Placebo Comparator|Placebo|Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points
9724306|NCT04833309|Active Comparator|Physical therapy|Physical therapy will be applied to the subjects in the physical therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
9724307|NCT04832984|Experimental|Intervention arm|Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum through the app over a period of 24 weeks. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participants can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
9724308|NCT04832984|Active Comparator|Usual care arm|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises."
9724309|NCT04829903|Active Comparator|Group DUL|Group taking Dulaglutide injections
9724310|NCT04829903|Placebo Comparator|Group LIR|Group taking Liraglutide injections
9724311|NCT04823208|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
9724312|NCT04823208|Placebo Comparator|Placebo|Placebo administered SC
9724313|NCT04817891|Experimental|Experimental: HD-tDCS|Maximum 4 milliAmp (mA) per channel of HD-tDCS treatment for 20 minutes, for 10 sessions. Total mA dose determined by individualized computational models.
9724314|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide Low Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
9724315|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide High Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
10197811|NCT04291599|Active Comparator|Control Arm - Conventional Treatment/Standard of Hospital Care|Patients assigned to this arm of the study will be treated per institutional policy and procedural care as dictated by established hospital order sets and at the discretion of the provider. This may involve the step-up approach per the hospital EBG utilizing acetaminophen or ibuprofen as first-line agents; however, it remains at the discretion of the treating provider. The current standard of care for children presenting to the ED is based on prescribing order sets within the electronic medical record (EMR). Physicians in the BCH emergency department choose in an intermittently-prescribed manner, standard doses of analgesia including acetaminophen (Tylenol) or ibuprofen per the hospital EBG, as well as opioids (morphine, hydromorphone).
10197812|NCT04290741|Experimental|Auricular (Battlefield) Acupuncture|Auricular acupuncture involves placement of needles based on battlefield acupuncture protocol which involves the placement of needles in up to 5 sites on each ear to treat pain.
9724316|NCT04813822|Active Comparator|Gyno-Daktarin® Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
10197813|NCT04290741|Experimental|Peripheral Acupuncture|Peripheral acupuncture involves placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
10197814|NCT04290741|No Intervention|Control|Standard of care without acupuncture
10197815|NCT04286126|Active Comparator|bilateral DMPFC|This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.
10197816|NCT04286126|Active Comparator|right OFC|This arm will receive continuous theta-burst stimulation to the right OFC site.
10197817|NCT04278885|Experimental|Lanadelumab|
10197818|NCT04278872|Experimental|SJX-653|Participants will receive SJX-653
10197819|NCT04278872|Placebo Comparator|Placebo|Participants will receive placebo
10197820|NCT04270669|Experimental|RC28-E 0.5mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 0.5mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
10197821|NCT04270669|Experimental|RC28-E 1.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
10197822|NCT04270669|Experimental|RC28-E 2.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
9724317|NCT04798378|Experimental|Treatment Arm|Participants will received a customized NuroSleeve and undergo 8 weeks of occupational therapy using the NuroSleeve (45 minutes three times per week).
9724318|NCT04791228|Experimental|All Patients|LTLD 50 mg/m2 will be administered intravenously over 30 minutes on day 1 of every 21-day cycle. MR-HIFU hyperthermia will follow infusion (+/- 30 minutes) for one hour to a target area with a target temperature of 40-45°C followed by ablation therapy (>55°C). The HIFU hyperthermia regimen will have a duration of at least 60 minutes and will then be followed by ablation therapy. Patients may receive up to a total of 6 cycles. Subsequent treatment cycles may treat alternative target lesions. Disease status will be evaluated using standard imaging techniques (CT/MR) post each cycle.
9724319|NCT04786262|Experimental|VX-880|
9724320|NCT04784754|Placebo Comparator|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
9724321|NCT04784754|Experimental|Melatonin 3 mg|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
9724322|NCT04784754|Experimental|Melatonin 30 mg|Melatonin capsules will be prepared using hypromellose capsules containing 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
9724323|NCT04771403|Experimental|FMPD AP system|Participants will use the FMPD AP system for automated insulin delivery for a 76 hour study visit.
9724324|NCT04771403|Experimental|MPC AP System|Participants will use the MPC AP system for automated insulin delivery for a 76 hour study visit.
9724325|NCT04768608|Experimental|PD1-PSMA-CART|Patients undergo leukapheresis by receiving cyclophosphamide and fludarabine on days -6 to -4, and then receive PD1-PSMA-CART intravenous injection (IV) at split doses from day 0 on.
10197823|NCT04269356|Experimental|BMS-986256|
10197824|NCT04266249|Experimental|Arm A (pCR after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE.ADJUVANT THERAPY: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate."
9724326|NCT04762771|Active Comparator|Active|Hospitalized covid-19 patients treated with colchicine plus current care per institution treating physicians.
9724327|NCT04762771|No Intervention|Control|Hospitalized covid-19 patients treated with current standard of care (per institution treating physicians) alone.
10197825|NCT04266249|Experimental|Arm B (residual invasive disease after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.~POST-OPERATIVE/ADJUVANT THERAPY: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate."
10197826|NCT04263974|Experimental|Smartphone Application|"A protocol of exercises and general recommendations based on the current scientific evidence will be provided through a smartphone application. A follow-up of the use of the application will be carried out. The treatment protocol will last 6 months, during which a minimum of 4 weekly sessions of exercises will be carried out at home.~Each pathology will have an unique program of exercises and recommendations."
10197827|NCT04263974|Active Comparator|Conventional Treatment|Those in this group will received the conventional treatment protocol provided within the Andalusian Public Health System. This will consist on the delivery of an exercise program and recommendations using a sheet of paper. Participants will be told to perform the exercises during 6 months, with minimum of 4 weekly sessions of exercise that will be carried out at home.
10197828|NCT04261686|Other|COVERA Vascular Covered Stent|COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.
10197829|NCT04254653|Experimental|Immediate Intervention|Participants receive diabetes nutrition education classes immediately.
10197830|NCT04254653|Experimental|Wait list intervention|Participants wait listed (control) for 3 months and then receive the diabetes nutrition education classes.
10197831|NCT04253548|Experimental|iPeer2Peer Program|Participates in the iPeer2Peer Program
10197832|NCT04249492|Experimental|IOL implantation experimental|Experimental arm: Enhanced depth of focus (EDOF) intraocular lens.
10197833|NCT04249492|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens.
10197834|NCT04247971||Obese, early-onset asthmatics|Obese adults (BMI>or= 30) between the ages of 21-60 with an initial asthma diagnosis at <12 years of age
10197835|NCT04247971||Obese, late-onset asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with an initial asthma diagnosis at >12 years of age
10197836|NCT04247971||Obese non-asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with no asthma diagnosis
10197837|NCT04246788|Experimental|Cohort 1 : experimental group|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
10197838|NCT04246788|Active Comparator|Cohort 2 : controle group|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
10197839|NCT04242810|Active Comparator|Active rTMS|rTMS applied over memory task-based brain target
10197840|NCT04242810|Placebo Comparator|Sham rTMS|Sham rTMS applied over memory task-based brain target
10197841|NCT04242654|Experimental|Doppler ultrasound|Placement of Doppler US on chest to obtain newborn's heart rate.
10197842|NCT04242654|No Intervention|Stethoscope|Placement of stethoscope on chest to obtain newborn's heart rate.
10197843|NCT04241341|Experimental|axillary lymph node dissection with ILR|
10197844|NCT04241341|Active Comparator|axillary lymph node dissection (ALND) without ILR|
10197845|NCT04240470|Experimental|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
10197846|NCT04228354|Experimental|Semaglutide 0.68 mg/mL|Semaglutide administered with the PDS290 pen-injector
10197847|NCT04228354|Experimental|Semaglutide 1.0 mg/mL|Semaglutide administered with the PDS290 pen-injector
10197848|NCT04223531|Other|Saline|Each participant will receive a saline infusion of normal saline 0.9%NaCl
10197849|NCT04222504|Experimental|Intervention Salons|Intervention: Behavioral: Provision of sexual health preventative services in the salon setting
10197850|NCT04222504|No Intervention|Control Salons|No Intervention
10197851|NCT04221464|Experimental|Tumors and blood collection|"For all the patients include in the study :~Blood samples will be collected at different times : before any treatment, at every surgery, one month after any surgery, at progression.~Tumours and not tumours tissues will be collected at different times : Before any surgery, one month after any surgery~In parallel to this biological collection, standardized clinical data will be entered into a database treatment, at every surgery"
10197852|NCT04220619|No Intervention|Conventional ACLS|Patients who have conventional ACLS during in-hospital Cardiac arrest, they will not have RescueTEE
10197853|NCT04220619|Experimental|RescueTEE guided ACLS|Patients who have RescueTEE guided ACLS
10197854|NCT04213807|Experimental|MAA868|Subcutaneous injection on Day 1 with two subsequent monthly injections
10197855|NCT04213807|Placebo Comparator|Placebo|Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
10197856|NCT04207255|Experimental|Cohort 2: Opaganib with abiraterone|
10197857|NCT04207255|Experimental|Cohort 3: Opaganib with enzalutamide|
10197858|NCT04207255|Experimental|Cohort 1a: Opaganib with abiraterone|
10197859|NCT04207255|Experimental|Cohort 1b: Opaganib with enzalutamide|
9724328|NCT04748120|Active Comparator|Operative management|Treatment with surgery
9724329|NCT04748120|Active Comparator|Non-operative management|Treatment with antibiotics
9724330|NCT04741308|Experimental|CBT group|Patients randomly assigned to CBT group will receive 8 times of CBT treatment during chemotherapy.
9724331|NCT04741308|No Intervention|non-CBT group|"Patients randomly assigned to non-CBT group will receive four sessions of health education in a month after surgery.~Each session will last 1 hour, including lectures and Q&A . The content of each session is different, including: diagnosis and treatment of colorectal cancer, adverse reactions and management of chemotherapy, nutritional support during chemotherapy and physical exercise during chemotherapy."
10197860|NCT04198597|Experimental|Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
10197861|NCT04198597|Experimental|Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
9724332|NCT04732845|Experimental|Group A - NHL/CLL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.~Participants with CD19+ lymphomas and chronic lymphocytic leukemia will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at dose level 1 (DL1) on day 0.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
9724333|NCT04732845|Experimental|Group B - ALL|"Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done.~Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m^2 Fludarabine from day -5 to day -3.~Participants with Acute Lymphoblastic Leukemia (and lymphoblastic lymphoma as a solid tumor equivalent) will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at DL1 on day 0 and 7.~The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD."
9724334|NCT04731623|Experimental|ION904|Single ascending dose of ION904 will be administered by SC injection on Day 1.
9724335|NCT04731623|Placebo Comparator|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection on Day 1.
9724336|NCT04726709|Experimental|Poised for Parkinson's|Alexander-technique-based online course to increase embodied agency in people with Parkinson's disease and their care partners.
9724337|NCT04725630|Experimental|Subsidized Healthy Food Prescription Incentive|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider and a weekly incentive of $10.50/household member to purchase healthy foods in supermarkets for 6 months. The list of incentive-eligible foods includes whole, minimally processed foods with little to no added fat, sugar or salt from all food groups.
9724338|NCT04725630|Active Comparator|Healthy Food Prescription Comparison|Participants will receive a one-time healthy food prescription pamphlet from their healthcare provider. The pamphlet closely mimics current standard of care for patients with diabetes in Alberta (i.e., nutrition counselling).
10197862|NCT04198597|Experimental|Process-based treatment, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
9724339|NCT04718389|Experimental|Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatment|Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active comparator (participant's anti-Interleukin-5/ 5 receptor [anti-IL-5/5R] treatment prior to randomization): either placebo matching mepolizumab or placebo matching benralizumab. All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
9724340|NCT04718389|Active Comparator|Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab)|Participants will receive active comparator (participant's anti-IL-5/5R treatment prior to randomization): either mepolizumab or benralizumab, plus placebo matching GSK3511294 (Depemokimab). All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
9724341|NCT04715022|Placebo Comparator|Placebo infusion|Saline will be administered over 2 hours
9724342|NCT04715022|Active Comparator|Ascorbic acid infusion|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the University of Kansas (KU) Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
9780715|NCT01129531|Experimental|AGN-214868 3.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.
9780716|NCT01129531|Experimental|AGN-214868 16.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.
10197863|NCT04198597|Experimental|Process-based treatment, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
10197864|NCT04194411||Valve surgery|Patients older than 65 years and undergoing elective valvular heart surgery
9780717|NCT01129531|Placebo Comparator|Placebo|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
10197865|NCT04194229||Group 1|Patients that receive Cytoflavin® medication i/v drop infusion at a dose of 10 ml of solution for injection per 200 ml of 0.9 % sodium chloride solution for 10 days in addition to a set of neurorehabilitation activities
9780718|NCT01129557|Active Comparator|Tekturna|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months
9836230|NCT02776904|Other|Healthy athlete|Healthy athletes (14-18 years old) enrolled in sports program in local schools.
10197866|NCT04194229||Group 2|Patients that subjected to the standard set of neurorehabilitation activities for 10 days without being prescribed Cytoflavin® medication
10197867|NCT04193033|Experimental|FLOW intervention|Sites receive the FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
10197868|NCT04193033|No Intervention|Waitlist until Time 2|Arm 2: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 2.
10197869|NCT04193033|No Intervention|Waitlist until Time 3|Arm 3: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 3.
10197870|NCT04190186|Active Comparator|Biotronik ICM-guided AF management|ICM obtained data will be actively used to guide and monitor treatment .
9724343|NCT04713475|Experimental|Part 1: Dose Escalation Cohorts designed to identify the optimal dose of PBGM01|"Cohort 1: Late Onset Infantile GM1 Gangliosidosis (Type 2a)~Assigned Intervention:~Drug: PBGM01 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBGM01, via intra cisterna magna~Cohort 2: Late Onset Infantile GM1 Gangliosidosis (Type 2a)~Assigned Intervention:~Drug: PBGM01 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBGM01, via intra cisterna magna~Cohort 3: Early Onset Infantile GM1 Gangliosidosis (Type 1)~Assigned Intervention:~Drug: PBGM01 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBGM01, via intra cisterna magna~Cohort 4: Early Onset Infantile GM1 Gangliosidosis (Type 1)~Assigned Intervention:~Drug: PBGM01 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBGM01, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
9724344|NCT04713475|Experimental|Part 2: Expansion Cohort designed to confirm the safety and efficacy of PBGM01|"Cohort 5: Late Onset Infantile GM1 Gangliosidosis (Type 2a)~Assigned Intervention:~Drug: PBGM01 Single dose of PBGM01, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1.~Cohort 6: Early Onset Infantile GM1 Gangliosidosis (Type 1)~Assigned Intervention:~Drug: PBGM01 Single dose of PBGM01, via intra cisterna magna Dose to be used for the confirmatory cohorts in Part 2 will be defined after a review of data from Part 1."
9724345|NCT04700501|Other|EYB Implementation study|All participants will have the opportunity to access an online CBT life skills learning programme.
9724346|NCT04695119||Adult patients with septic shock|"All adult (>=18 yo) patients admitted to participating ICUs with septic shock defined according to the Sepsis III criteria.~Purely observation study with no intervention. Patients are exposed to septic shock and treatment according to standard departmental protocols at each centre."
10197871|NCT04190186|No Intervention|Conventional AF Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
10197872|NCT04188834|Experimental|Sensory Flicker Stimulation|"Patients will be exposed to Sensory Flicker Stimulation.~In one experiment, patients will be exposed, for about 10 minutes at a time, to a sequence of sensory flicker trials each lasting a few seconds. Each trial may include the following modalities and frequencies of flicker:~Modalities: auditory only, visual only, or audiovisual combined. Subjects may be exposed to individual pulses of light and/or sound (i.e. around or less than 1 pulse per second).~Frequencies: random, or anywhere from 5Hz to 100Hz. Subjects may be exposed to sensory flicker at a given frequency or random frequency for up to 1h at a time~In another experiment, patients will undergo a behavioral task in which they will be exposed to one of 2 flicker conditions on separate days.~Comfortable parameters (e.g., light intensity and volume intensity) for the subject will be found. If such parameters cannot be found, exposure of the patient to visual and/or auditory stimuli will be stopped."
9724347|NCT04695080|Active Comparator|Cladribine (MAVENCLAD®)|
9724348|NCT04695080|Placebo Comparator|Placebo|
9724349|NCT04693715|Experimental|RNS60 0.5 mL/kg/h|RNS60 0.5 mL/kg/h infusion for 48h (up to a maximum of 60 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
9724350|NCT04693715|Experimental|RNS60 1 mL/kg/h|RNS60 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
9724351|NCT04693715|Placebo Comparator|Placebo 1 mL/kg/h|Placebo (normal saline) 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
9724352|NCT04689516|Experimental|Control Group|will receive a hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively and will stop after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
9724353|NCT04689516|Experimental|The TFC Group|will receive hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively . The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
9724354|NCT04687683|Experimental|Post Isometric Relaxation Group|The participants in this group will receive post isometric relaxation stretching in modified cross body position.
9724355|NCT04687683|Experimental|Isolytic Stretching Group|The participants in this group will receive isolytic stretching in modified cross body position.
9724356|NCT04687683|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position.
9724357|NCT04686682|Experimental|JAB-8263 Part1|Monotherapy, dose escalation
9724358|NCT04686682|Experimental|JAB-8263 Part 2|Monotherapy, dose expansion
9724359|NCT04683575|Experimental|experimental group|Patients with differentiated thyroid carcinoma with low blood selenium are treated with selenium yeast（dosage form：capsule dosage：200μg bid duration: 5 years）.
9724360|NCT04683575|Placebo Comparator|Placebo control group|Patients with differentiated thyroid cancer with low blood selenium are given placebo treatment（dosage form：capsule dosage：200μg bid duration: 5 years）
10205440|NCT05207007||posterior lenticonus|"Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation were performed in these patients.~Drug: Subconjunctival dexamethasone and general anesthesia All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia."
10205441|NCT05206916|Other|evaluation of cryotherapy as treatment for obstructive sleep apnea patients|
9724361|NCT04683575|No Intervention|No intervention group|Patients with differentiated thyroid cancer with low blood selenium are not treated.
9724362|NCT04681625|Active Comparator|Standard silodosin treatment|Peroral treatment with silodosin at a dose of 8 mg daily
9724363|NCT04681625|Experimental|Standard silodosin treatment with PFMT|Peroral treatment with silodosin at a dose of 8 mg daily Intervention: Behavioural: Pelvic floor muscle training (PFMT) with suppressive urgency technique
10197873|NCT04188834|Active Comparator|Electrical Flicker Stimulation|"Patients will be exposed to direct electrical brain stimulation with low-amplitude current, at given flicker frequencies. Patients will be exposed to frequencies ranging from 5-100Hz, for up to 10 seconds at a time. Initially, frequencies of 5.5Hz and 40Hz will be tested.~During brain stimulation sessions, bipolar electrical stimulation will be applied to one or more areas of the brain at a time either with or without associated behavioral task. Stimulation in the absence of any behavioral task will be applied in order to assess the subject's neurophysiological response to stimulation and to identify the optimal stimulation parameters for use during behavioral task. Stimulation during behavioral task will be applied in an attempt to affect the subject's behavior."
10204874|NCT04650646|Experimental|Hypoglycaemic clamp i combination with exercise|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with an exercise session. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
10204875|NCT04650646|Experimental|Hypoglycaemic clamp in combination with bed rest|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with bed rest. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
10204876|NCT04645173||CanGaroo Envelope|Participants who received a CanGaroo envelope during CIED implantation
9724364|NCT04675034|Experimental|Cohort 1|Dose A: MEDI7352 Q2W
9724365|NCT04675034|Experimental|Cohort 2|Dose B: MEDI7352 Q2W
9724366|NCT04675034|Experimental|Cohort 3|Dose C: MEDI7352 Q2W
9724367|NCT04675034|Experimental|Cohort 4|Dose D: MEDI7352 Q2W
9724368|NCT04675034|Placebo Comparator|Cohort 5:|Placebo to match MEDI7352 Q2W
9724369|NCT04659863|Experimental|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
9724370|NCT04659863|Placebo Comparator|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
9724373|NCT04648436|Other|Early surgery|
9724374|NCT04648436|Other|Initial conservative treatment|
9724375|NCT04648059||Lupus nephritis +ve|This group consists of patients with Lupus nephritis
9724376|NCT04648059||Lupus nephritis -ve|This group consist of patients with SLE without Lupus nephritis
9724377|NCT04625270|Experimental|Part A|To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib, for subsequent evaluation for efficacy in the Expansion Phase (Part B)
9724378|NCT04625270|Experimental|Part B|To determine the efficacy of the optimal regimen identified from Part A
9724379|NCT04622683|Experimental|Control Group- Healthy, Lean Individuals|Determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels in lean, healthy control subjects.
9724380|NCT04622683|Active Comparator|Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance|Determine whether three episodes of porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
9724381|NCT04620330|Experimental|Part A|To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib, for subsequent evaluation for efficacy in the expansion phase (Part B).
9724382|NCT04620330|Experimental|Part B|To determine the efficacy of the optimal regimen identified from Part A
9724383|NCT04619745|Experimental|Intervention Group|All children enrolled in the study will complete five study visits. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity. The intervention group will complete individualized, parent-led, home and play-based activity plans for 6 months, beginning as soon as the child returns to the inpatient unit. The activities in the plan will be tailored to each phase of treatment (in hospital, discharge to week 7, week 8 to 6 months), follow a standardized format and provide content individualized to each child's age and previous visit assessments.
9724384|NCT04619745|Experimental|Wait List Control Group|All children enrolled in the study will complete five study visits. After the first visit is complete, children will be randomized to either the intervention or wait-list control study group. Control participants will follow the same schedule of assessments at each visit, but the intervention will be provided between the 12-month and 16-month assessments. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity.
9724385|NCT04610944|Experimental|Intervention|Intervention nursing homes will receive the training and control nursing homes will complete assessments, but not receive the training.
9724386|NCT04610944|Active Comparator|Waitlist Control|After the intervention nursing homes complete the training, the waitlist control nursing homes will crossover and complete the training.
9724387|NCT04609878|Experimental|Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
9724388|NCT04609878|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
10197874|NCT04180904|Active Comparator|Diet 1|Diet 1 will focus on the dietary pattern and monitor types of foods, supplementary nutrition, and provide nutritional support with a dietitian.
10197875|NCT04180904|Active Comparator|Diet 2|Diet 2 will focus on the dietary pattern and monitor the amount of food, complimentary nutrition, and nutritional support with a dietitian.
10197876|NCT04180904|No Intervention|Diet 3|Diet 3 will focus on healthy dietary patterns and provide nutritional support with a dietitian.
10197877|NCT04180709|Experimental|Sleepio Intervention + Treatment As Usual (TAU)|Participants will receive the online Sleepio intervention to be completed approximately once per week, at least 6 sessions during the 8-week period, and complete daily sleep diaries. In addition they will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis care team.
9724389|NCT04609878|Active Comparator|Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
9724390|NCT04609878|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg
10197878|NCT04180709|No Intervention|Treatment As Usual (TAU) alone|Participants will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis care team. They will however be offered access to the Sleepio intervention during the follow-up period of the study.
10197879|NCT04180488|Experimental|Study A Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
10197880|NCT04180488|Placebo Comparator|Study A Matched Placebo|placebo, on top of non-sedating H1-antihistamine
9724391|NCT04608435||Male Group|
10197881|NCT04180488|Experimental|Study B Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
10197882|NCT04180488|Placebo Comparator|Study B Matched Placebo|placebo, on top of non-sedating H1-antihistamine
9724392|NCT04608435||Female Group|
9724393|NCT04607005|Experimental|Participants receiving mepolizumab + Standard of care (SoC)|Participants will receive one dose of 100 mg mepolizumab SC on top of SoC every 4 weeks during the 52-week treatment period.
10197883|NCT04179721|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and NAs who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of hospital caregivers towards patients. IV. Staff Training
9724394|NCT04607005|Placebo Comparator|Participants receiving placebo + SoC|Participants will receive one dose of placebo via SC route on top of SoC, every 4 weeks during the 52-week treatment period.
9724395|NCT04604821|Experimental|Enhanced Milieu Teaching|Child-caregiver dyads receive up to 24 speech-language therapy sessions (50minutes, 2x per week for 3 months) where parents are taught by the interventionist to use Enhanced Milieu Teaching Strategies. Children and their families may continue to participate community-based educational programs.
9724396|NCT04604821|Other|Community Treatment as Usual|Child-caregiver dyads may continue to participate in community-based educational programs. Researchers provide up to 4 educational sessions to caregivers (50 minutes, every 3 weeks). During educational sessions parents are taught developmental milestones from the CDC Learn the Signs Act Early Public Health Campaign.
10197884|NCT04179721|Active Comparator|The attention control condition|The control group consists of NAs that work on a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 NA (1:8 ratio), that primarily cohorts older patients with geriatric syndromes. All components of the intervention arm are the same with the exception of the PES staff. The control arm (NAs) will receive the same training as the intervention arm.
9724397|NCT04598269|Experimental|ATI-1777 topical solution 2.0% w/w|ATI-1777 topical solution 2.0% w/w, twice daily
9724398|NCT04598269|Placebo Comparator|Vehicle|Vehicle topical solution, twice daily
9724399|NCT04587479|Experimental|JAB-8263|Monotherapy, dose escalation
9724400|NCT04581863|Active Comparator|COVID Watch|COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
10197885|NCT04178135|Experimental|rLH supplementation from day 1 of stimulation|rLH supplementation from day 1 of stimulation
10197886|NCT04178135|Active Comparator|rLH supplementation from day 6 of stimulation|rLH supplementation from day 6 of stimulation
10197887|NCT04177706|Experimental|Group A (Ketamine)|
9724401|NCT04581863|Experimental|PCORI Pulse|This arm is COVID Watch + pulse oximeter device. Patients sent a pulse oximeter will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is >3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
9724402|NCT04573387|Active Comparator|Fixed-time drainage|Drainage will be removed after 48 hours.
9724403|NCT04573387|Experimental|Exhaustive drainage|Drainage will be removed when postoperative hematoma volume is minimized with repeated urokinase injection into hematoma cavity through catheter.
10197888|NCT04177706|Placebo Comparator|Group B (Placebo)|
10197889|NCT04176913|Experimental|Anti-CD20 Allogeneic CAR-T Cell Therapy|An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
10197890|NCT04176133|Experimental|Dose Level 1|Subjects will receive entolimod as a single dose administered intramuscularly (1mcg)
10197891|NCT04176133|Experimental|Dose Level 2|Subjects will receive entolimod as a single dose administered intramuscularly (3mcg)
10197892|NCT04176133|Experimental|Dose Level 3|Subjects will receive entolimod as a single dose administered intramuscularly (10mcg)
9724404|NCT04572737|Experimental|Experimental|Participants will take part in an 8-week home-based activity plan to break up sitting time by 60 minutes per day.
9724405|NCT04566380|Experimental|ONO-4538 Monotherapy cohort|480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice
9724406|NCT04566380|Experimental|Combination therapy cohort|ONO-4538 at 360 mg IV Q3W, and Chemotherapies (S-1 + Oxaliplatin [SOX] therapy or Capecitabine + Oxaliplatin [CapeOX] therapy) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.
9724407|NCT04562038|Experimental|YC-PEM e-PRO|Participants are administered an electronic patient-reported outcome measure to obtain information about parent priorities, and they obtain a summary report of their responses to share with their early intervention team for discussion during the annual IFSP meeting.
9724408|NCT04562038|No Intervention|Family Assessment|Participants are scheduled to complete a semi-structured family interview to obtain information about parent priorities, for use during the annual IFSP meeting
9724409|NCT04559698|Experimental|immediate training group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the immediate training group will take part in the first 11-week course.
9724410|NCT04559698|Experimental|waitlist control group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the waitlist control group will take part in the second 11-week course.
9724411|NCT04559685|Experimental|Arm A Dose-escalation|In Arm A, the dose-escalation cohort, there will be 3 cohorts of ascending MRgFUS power/energy dose combinations with a fixed SONALA-001 dose and fixed surgical time. Arm A will determine the power/energy dose combination for Arm B.
9724412|NCT04559685|Experimental|Arm B Time-escalation|In Arm B, the time-escalation cohort, the SONALA-001 and power/energy dose combination will be fixed. Participants will be enrolled into two time cohorts (2 days and 6 days post-SDT).
9724413|NCT04558827|Experimental|Low Carb / Time Restricted Feeding|Participants will eat a low carbohydrate diet (30-60 grams) in a time restricted feeding window (2 meals within 8 hours) daily for the duration of the study (6 months).
9724414|NCT04556981|Experimental|M72/AS01E vaccine|
9724415|NCT04556981|Placebo Comparator|Placebo|
10197893|NCT04176133|Placebo Comparator|Placebo|Subjects will receive a placebo as a single dose administered intramuscularly (no study drug); placebo that looks exactly like the study drug, but contains no active ingredient.
10197894|NCT04174092|Experimental|rheumatoid arthritis|Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months
10197895|NCT04174092|Experimental|spondyloarthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
10197896|NCT04174092|Experimental|Psoriatic arthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).~Patients will be seen at 3, 6 and 12 months"
10197897|NCT04173247|Experimental|KeraStat Skin Cream Arm|Patients randomized to the KeraStat arm will be provided with KeraStat Skin Cream for application as often as needed but at least twice daily, morning and evening using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
10197898|NCT04173247|Active Comparator|Routine Skin Care Arm (RSC Arm)|Patients randomized to this arm will apply commercially available products from a list provided at least twice daily using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
9724416|NCT04555616|Placebo Comparator|Control Group|Alzheimer's disease patients and caregivers.
9724417|NCT04555616|Experimental|Standard Environmental Design|Alzheimer's disease patients and caregivers.
9724418|NCT04555616|Experimental|Individualized Environmental Design Protocol|Alzheimer's disease patients and caregivers.
9724419|NCT04554147|Experimental|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
9724420|NCT04550130|Experimental|low dose (1.8 L)|Patients in this arm will be treated with one column (Leukapheresis) and 1.8 L blood will be filtered.
9724421|NCT04550130|Experimental|high dose (3.6 L)|Patients in this arm will be treated with Two column (Leukapheresis) and 3.6 L blood will be filtered.
9724422|NCT04546568|Experimental|Servo control - Leoni plus CLAC|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
9780719|NCT01129557|Active Comparator|Diovan|Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months
9836231|NCT02776904|Other|Concussed athletes|Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.
10197899|NCT04172558|Active Comparator|BTX100 group|ICI of Botox 100 U
10197900|NCT04172558|Active Comparator|Trimix group|ICI of Trimix
10197901|NCT04166331|Placebo Comparator|Control|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
9724423|NCT04546568|Active Comparator|Servo control - IntellO2 Precision Flow, Vapotherm|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
9724424|NCT04545177|Experimental|Tissue Preservation System (TPS)|Tumor tissue will be obtained, processed, and then transported remotely to undergo multiple tests, including gene panel DNA sequencing, DNA methylation array, and bulk as well as single-cell transcriptome analyses (RNA-seq)
9724425|NCT04540822|Experimental|peripheral venous catheter with compress|Insertion of a peripheral venous catheter with a compress inserted below the catheter-extension tube junction
9724426|NCT04540822|Active Comparator|peripheral venous catheter without compress|Insertion of a peripheral venous catheter without any compress inserted below the catheter-extension tube junction.
9780720|NCT01129557|Active Comparator|Tekturna & Diovan|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily & Diovan (Valsartan), an angiotensin receptor (ARB) 160 mg by mouth once daily for 9 months
9780721|NCT01129583|Experimental|Botulinum Toxin|100 U injected into biceps, 100 U into brachialis
9780722|NCT01129583|Placebo Comparator|Saline|100 U injected into biceps, 100 U into brachialis
9780723|NCT01129609||Participants with Successful Secondary Endovascular Treatment|
10197902|NCT04166331|Experimental|Experimental|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
10197903|NCT04166071|Active Comparator|Naltrexone|
10197904|NCT04166071|Placebo Comparator|Placebo|
10197905|NCT04163874|Experimental|Fiasp-plus-Placebo with Full Carbohydrate Counting|Fiasp insulin and placebo insulin infusion in two insulin pumps with full carbohydrate counting.
10197906|NCT04163874|Placebo Comparator|Fiasp-plus-placebo with Simple Meal Announcement|Fiasp insulin and placebo (saline) insulin infusion in two insulin pumps using the simple meal announcement system.
10197907|NCT04163874|Active Comparator|Fiasp-plus-Pramlintide with Simple Meal Announcement|Fiasp insulin and pramlintide insulin infusion in two insulin pumps using the simple meal announcement system.
10197908|NCT04158895||Patients enrolled in differentiated service delivery models|
10197909|NCT04158895||Patients not enrolled in DSD models|
10197910|NCT04158869||Cases|Patients with pMDD, enrolled in the Investigator-initiated clinical trial IICT (ClinicalTrials.gov Identifier: NCT03167307)
10197911|NCT04158869||Controls|Controls matched to cases according to age, sex and school education
10197912|NCT04158089|No Intervention|No intervention|"Participants in the No intervention group will receive treatment (e.g., prenatal care) as usual."
10197913|NCT04158089|Experimental|Attachment Exercises|"Participants in the Attachment Exercises group will receive daily texts over the 2-week intervention period with activities to do from home that are designed to increase feelings of attachment (e.g., read a children's book aloud; sing a nursery rhyme; picture giving the baby a bath; tell the baby a story; etc.)."
10197914|NCT04140526|Experimental|ONC-392 Treatment as single agent|"The Part A study will test ONC-392 intravenous (IV) infusion up to five predefined dose levels: 0.1 mg/kg (cohort 1), 0.3 mg/kg (cohort 2), 1 mg/kg (cohort 3), 3 mg/kg (cohort 4) and 10 mg/kg (cohort 5) of ONC-392 as monotherapy every 21 days (Q3W). The treatment will continue for up to 1 year, or discontinued upon disease progression, or unacceptable toxicity, or voluntary withdraw. The Part A study will determine the maximal tolerable dose (MTD) and the recommended Phase 2 dose in monotherapy (RP2D-M).~In Part C, Arms A-C, H-M monotherapy expansion cohorts will further assess the safety and efficacy of ONC-392 in dose level of RP2D-M as monotherapy in pancreatic cancer, triple negative breast cancer and non small cell lung cancer with driver mutations."
10197915|NCT04140526|Experimental|ONC-392 in combination with pembrolizumab|"The Part B1 study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of pembrolizumab. The dose for pembrolizumab will be fixed at 200mg/cycle dosed every 21 days (Q3W).~The Part B1 will start at one level below RP2D-M dose for ONC-392 and 200mg of pembrolizumab. When 2 DLTs occur before 6 patients are enrolled, the ONC-392 dose will be decreased to the next dose level until ≤ 1/6 patients treated at that dose develops a DLT. This dose level will be designated RP2D-C.~In Part C, the expansion cohorts Arm D to G will assess the safety and efficacy of ONC-392 in RP2D-C dose level and Pembrolizumab combination therapy in non small cell lung cancer, melanoma and Merkel cell carcinoma."
10197916|NCT04140526|Experimental|ONC-392 in combination with Osimertinib|The Part B2 study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of Osimertinib of 80 mg PO, QD in non small cell lung cancer with EGFR mutations. The Part B2 will start at one level below RP2D-M dose for ONC-392. The goal is to define the RP2D-C-TKI.
10197917|NCT04137367|Experimental|Active Affective Bias Modification|Computer based Affective Bias Modification
9780724|NCT01129622|Experimental|Letrozole, Breast enhancement, Safety|Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .
9780725|NCT01129765||Parents of congested children|Parents of children less than six years of age with nasal congestion for which nasal suctioning and salt water irrigation is traditionally recommended.
9780726|NCT01129778|Experimental|Received Zegerid (Ome-NaBic)|Administered Ome-NaBic 40 mg orally 1 h before breakfast and bedtime
9785258|NCT01246999|Active Comparator|TIV followed by LAIV|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly followed by LAIV given in a dose of .2 ml intranasally 28 days later
9785259|NCT01246999|Active Comparator|LAIV followed by TIV|LAIV will be given in a dose of .2 ml intranasally followed by a dose of TIV given in a dose of .25 ml 2 years to 36 months or .5 ml 37 months to 9 years intramuscularly 28 days later
10197918|NCT04137367|Sham Comparator|Sham Affective Bias Modification|Computer based sham Affective Bias Modification
10197919|NCT04132804|Experimental|Tai Chi Treatment|All patients in the trial will receive 1-hour Tai Chi lessons once per week for a total of 8 weeks.
10197920|NCT04130022|Other|Fasted Children|
10197921|NCT04129996|Experimental|camrelizumab in combination with nab-paclitaxel and famitinib|
9724427|NCT04516733|Other|single arm|patient with glioblastoma
9724428|NCT04515524||ROP patients from VGFTe-ROP-1920|Retinopathy of prematurity (ROP) who were treated with aflibercept and/or laser photocoagulation in study VGFTe-ROP-1920.
9724429|NCT04498806|Experimental|Intervention|Pre-op appointment, patient will receive Fitbit device to track physical activity.
9724430|NCT04498611|Experimental|breast DCIS patients|Breast DCIS patients who diagnosed by tissue biopsy except excisional biopsy before surgery, and who agreed to taking the breast MRI.
9724431|NCT04496479|Experimental|LYG-LIV0001|Open label group of subjects with end stage liver disease receiving increasing doses of the experimental therapy.
9724432|NCT04494074|Experimental|Fever Control by external cooling|External cooling during 48 hours to obtain normothermia
9724433|NCT04494074|No Intervention|Fever respected, no cooling|Fever respect without any antipyretic therapy
9724434|NCT04492475|Experimental|Remdesivir plus Interferon Beta-1a|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 44 mcg of interferon beta-1a administered by a 0.5 mL subcutaneous injection on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
9724435|NCT04492475|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and a 0.5 mL placebo injection administered subcutaneously on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
9724436|NCT04491383|Experimental|Tocovid Suprabio (HOV-12020)|200mg, twice 1 day, 12 months
10197922|NCT04125134|Experimental|Hypertonic Saline Responders|Subjects who qualify as hypertonic saline responders will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
10197923|NCT04125134|Experimental|Hypertonic Saline Non-responders|Subjects who qualify as hypertonic saline non-responders will be dispensed the same instructions and treatment as the Hypertonic Saline Responders. They will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
9724437|NCT04491383|Placebo Comparator|Placebo|200mg, twice 1 day, 12 months
9724438|NCT04491006|Experimental|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
9724439|NCT04491006|Experimental|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
10197924|NCT04123197|Other|Young Participants with Prior MI|Participants aged 60 or less who experienced a MI within the last 8 months will undergo a stress challenge to assess MSI and will then be followed for 3 years.
10197925|NCT04121598||Normal Weight Control|Adolescents with a BMI percentile under 85%.
10197926|NCT04121598||Overweight/Obese Control|Adolescents with a BMI percentile at 85% or higher.
9724440|NCT04491006|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
9724441|NCT04489888|Experimental|Pembrolizumab + Carboplatin + Paclitaxel|Participants will receive pembrolizumab plus carboplatin plus paclitaxel. Pembrolizumab will be administered via intravenous (IV) infusion at a dose of 200 mg on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Carboplatin will be administered via IV infusion at area under curve (AUC) 5 mg/mL/minute on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months). At investigator's choice, paclitaxel will be administered via IV infusion at a dose of 100 mg/m^2 on Day 1 and Day 8 of each 21-day cycle for up to 6 cycles (up to ~4 months) or at a dose of 175 mg/m^2 on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months).
10197927|NCT04121598||Overweight/Obese Experimental|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes.
10197928|NCT04120766|Experimental|Treatment|Nicorandil 20mg qd
10197929|NCT04120766|Placebo Comparator|Placebo|Matched placebo qd
9724445|NCT04486911|Experimental|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
9724446|NCT04483206|Experimental|Treatment (Melphalan-based autologous transplant)|Patients receive high dose (100 mg/m2) melphalan IV over 30 minutes on day -3 and PK-directed melphalan IV over 30 minutes on day -1 to achieve set cumulative melphalan exposure levels. Patients then undergo stem cell infusion on day 0.
10197930|NCT04120584|Experimental|Forma Eye treatment|
10197931|NCT04120025|No Intervention|Control Group|Subject will continue standard of care for GERD symptoms
9724447|NCT04478838|Experimental|Extended Dosing Group|Participants taking olanzapine or risperidone will be switched to an alternate day dosing schedule.
10197932|NCT04120025|Experimental|Treatment Group|Subjects will continue with usual care but will also receive diaphragm training (belly breathing) instructions using verbal, visual and tactile cues for proper contraction of the diaphragm as a home program
10197933|NCT04111666|Experimental|AL101 IV|"Up to four single ascending doses (SAD IV cohorts)~Multiple doses of AL101 administered IV (MD IV cohort)"
10197934|NCT04111666|Placebo Comparator|Saline Solution|"Saline solution will be administered with the following:~Single IV infusion for four single ascending doses (SAD IV cohorts) in a ratio of 8 active and 3 placebo subjects~Multiple IV infusions for the MD IV cohort in a ratio of 8 active and 2 placebo subjects"
9724448|NCT04478838|No Intervention|Treatment as Usual group|Participants will continue to take their olanzapine or risperidone following the same prescribed daily schedule.
9724449|NCT04478071|Experimental|vadadustat|
9724450|NCT04478071|Placebo Comparator|placebo|
9785260|NCT01247064|Experimental|Nebulized 3% Saline|
10197935|NCT04111666|Experimental|AL101 SC|"Single fixed dose levels of AL101 administered SC~Multiple fixed dose of AL101 administered SC"
10197936|NCT04110496|Experimental|RTX-134|Escalating doses of RTX-134 will be administered by intravenous infusion one time
9724451|NCT04474483|Placebo Comparator|Control|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
10197937|NCT04105998|Experimental|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU) at the first visit. Then at the next visit, they will receive Intramuscular injection of (1 milliliter) saline.
10197938|NCT04105998|Experimental|Placebo, Then Oxytocin|Subjects in this arm will receive intramuscular injection of (1 milliliter) saline at the first visit. Then at the next visit, they will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU).
10197939|NCT04103619|Active Comparator|AccuTite|15 patients will receive AccuTite treatment only
10197940|NCT04103619|Active Comparator|AccuTite & Morpheus 8 Arm|15 patients will receive AccuTite and Morpheus8 treatment and additional 2 monthly Morpheus8 treatments
10197941|NCT04103450|Experimental|Vibegron|Participants will receive 75 milligrams (mg) vibegron orally once daily (QD).
10197942|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
10197943|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
10197944|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
10197945|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
10197946|NCT04094844|Active Comparator|Roadmap 2.0|"Roadmap 2.0 mobile app + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).~Includes caregivers of adult patients and caregivers of pediatric patients"
10197947|NCT04094844|Experimental|Roadmap 2.0 with Positive Activities|"Roadmap 2.0 mobile app (patients), Roadmap 2.0 with mobile Positive Activities app (caregivers) + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).~Includes caregivers of adult patients and caregivers of pediatric patients"
10204877|NCT04645173||TYRX Envelope|Participants who received a TYRX envelope during CIED implantation
10205442|NCT05206851|Experimental|Manual Lymphatic Drainage and Hot pack|
9724452|NCT04474483|Experimental|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
9724453|NCT04468451|Experimental|ROC-48 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 48 hours for a total of 12-week intervention.
9724454|NCT04468451|Active Comparator|ROC-24 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 24 hours for a total of 12-week intervention.
9724455|NCT04468451|Active Comparator|Control group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. The participant's clinical occupational therapist will be responsible for the regular therapy. The dosage will be their regular dosage for a total of 12-week intervention.
9724456|NCT04467866|Experimental|ROC-Stand(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
9724457|NCT04467866|Experimental|ROC-Stand(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
9724458|NCT04467866|Active Comparator|Control(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. The other occupational therapist will be responsible for regular therapy.
9724459|NCT04467866|Active Comparator|Control(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. The other occupational therapist will be responsible for regular therapy.
9724460|NCT04466215|Active Comparator|CORT118335|900 mg (6 x 150 mg) tablets daily taken orally for one week
9724461|NCT04466215|Placebo Comparator|Placebo|Six placebo tablets taken orally for one week
9724462|NCT04458428|No Intervention|Control|No other non-standard of care activities will be performed
9724463|NCT04458428|Experimental|Intervention|Will be signed up for the automated short message service (SMS)
9724464|NCT04440189|Placebo Comparator|Placebo|Subjects will receive an injection of Lactated Ringers in their index knee
9724465|NCT04440189|Experimental|Stromal Vascular Fraction (SVF)|Subjects will receive an injection of Stromal Vascular Fraction in their index knee
10197948|NCT04091165||Study Group|"Participants will be identified for inclusion by leaders of the GI Clinic after GI surgery has been scheduled. Upon consenting, participants will be instructed how to download and use the mobile phone application My Plate Calorie Counter."
10197949|NCT04087642|Experimental|Intraoperative Crede manoeuver|"Method 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak.~In this group, the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly."
9724466|NCT04437498|Experimental|nVNS|non invasive vagal nerve stimulation
9724467|NCT04437498|Sham Comparator|sham|sham stimulation
9724468|NCT04424966|Experimental|Arm 1|"Phase 0: 125 mg of infigratinib administered orally for 7 days prior to surgical resection.~Expansion Cohort: 125 mg of infigratinib administered orally for 21 days of a 28-day treatment cycles."
9724469|NCT04417777||Polynesian patient|Patient with dilatation of idiopathic bronchi
10197950|NCT04087642|Active Comparator|Preoperative prolapse reduction cough stress test|"An examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak.~In this group, the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly."
9724470|NCT04417777||Relatives of polynesian patient|Healthy
9724471|NCT04410380|Experimental|Electronic tablet|Spanish-speaking parents receive electronic tablet and teaching about use
9724472|NCT04401579|Experimental|Remdesivir plus Baricitinib|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
9724473|NCT04401579|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
9724474|NCT04391595|Experimental|Arm 1|400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
9724475|NCT04387552|Experimental|Prenatal SS/Postnatal BF|Prenatal Safe Sleep/Postnatal Breastfeeding Mobile Health Messages
9724476|NCT04387552|Experimental|Prenatal BF/Postnatal SS|Prenatal Breastfeeding/Postnatal Safe Sleep Mobile Health Messages
9724477|NCT04387552|Experimental|Prenatal SS/Postnatal SS|Prenatal Safe Sleep/Postnatal Safe Sleep Mobile Health Messages
9724478|NCT04387552|Experimental|Prenatal BF/Postnatal BF|Prenatal Breastfeeding/Postnatal Breastfeeding Mobile Health Messages
9724479|NCT04385498|Experimental|BREATHE Intervention|Five session program, with additional sessions provided based on the individual's learning style and needs. Sessions are designed to be 20 to 30 minutes long, to accommodate the needs of the primary health care centers. Sessions will ideally be conducted once per week, but may be conducted as infrequently as once per month.
9724480|NCT04385498|Active Comparator|Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm.
9724481|NCT04383743|Experimental|Treatment (pembrolizumab, aMVAC)|Patients receive pembrolizumab IV over 30 minutes on day 1 of weeks 0, 3, and 6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC on day 1 or 2 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care radical cystectomy.
9724482|NCT04370756|Active Comparator|Ex only|Participants will perform 8 weeks of supervised exercise training (EX).
9724483|NCT04370756|Experimental|EX + BR|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of beetroot juice (BR).
9724484|NCT04348981|Experimental|Wearable|All patients eligible to enroll in the Enhanced Recovery after Cardiac Surgery pathway will be offered a wearable fitness tracking device.
9724485|NCT04344184|Active Comparator|Infusion|L-Ascorbic Acid (Vitamin C), intravenous infusion
9724486|NCT04344184|Placebo Comparator|Standard of care|Dextrose 5% Water
10197951|NCT04082416|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.
9724487|NCT04336982|Experimental|CC-90009 in combination with venetoclax and azacitidine|"CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Venetoclax will be administered orally QD.~Azacitidine will be administered intravenously or subcutaneously on planned dosing days for each cycle."
9724488|NCT04336982|Experimental|CC-90009 in combination with gilteritinib|CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Gilteritinib will be administered orally QD.
9724489|NCT04328727|Experimental|eltrombopag|Participants will receive eltrombopag in combination with r-ATG and CsA.
9724490|NCT04323033|Experimental|PERS stent|20 Patients will receive PERS stent
9724491|NCT04323033|Active Comparator|NEPTUN C stent|20 Patients will receive NEPTUN C stent
9724492|NCT04321460|Experimental|LRG-002|LRG-002 once daily for 14 days
9724493|NCT04321460|Placebo Comparator|Placebo|Placebo once daily for 14 days
9724494|NCT04320628|Experimental|Experimental|Target ulcer cleansed with NaOCl. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NaOCl.
10197952|NCT04082416|Placebo Comparator|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 52 times.
9724495|NCT04320628|Placebo Comparator|Control|Target ulcer cleansed with NSS. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NSS.
9724496|NCT04319276|Experimental|Dose-escalation Phase (500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
9724497|NCT04319276|Experimental|Dose-escalation Phase (1,000 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
9724498|NCT04319276|Experimental|Dose-escalation Phase (1,500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
9724499|NCT04319276|Experimental|Dose-expansion Phase|A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
10197953|NCT04080115|Experimental|Attention Training Technique (ATT)|
10197954|NCT04080115|Active Comparator|Sham intervention control condition|
9724500|NCT04311996|Experimental|Friend and Target Both|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
9724501|NCT04311996|Experimental|Friend Provides Support|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
9724502|NCT04311996|Experimental|Unfamiliar Peer and Target|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
10197955|NCT04078386|Experimental|RC18 240mg|
10197956|NCT04078386|Experimental|RC18 160 mg|
10197957|NCT04078386|Placebo Comparator|Placebo|
10197958|NCT04075136|Active Comparator|Arm A: Lucentis|A standard of care treatment of 0.05ml/0.5mg Lucentis given every 4 weeks for 48 weeks.
10197959|NCT04075136|Experimental|Arm B: Lucentis & PDT Laser|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence.
10197960|NCT04075136|Experimental|Arm C: Lucentis, PDT Laser and Triescense|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence and an intravitreal injection of 0.5ml-2mg Triescence at the time of PDT treatment.
9724503|NCT04311996|Experimental|Alone|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
9724504|NCT04307628|Active Comparator|Walnut|Eat 2 ounces of walnuts provided by the study. Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
9724505|NCT04307628|Placebo Comparator|Nut-Free|Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
9724506|NCT04304131|Experimental|Colorectal cancer|Confirmed colorectal cancer under colonoscopy
10197961|NCT04074967|Experimental|Phase Ib ARRY-614 + nivolumab|"Participants with advanced solid tumors will receive ARRY-614 in combination with nivolumab.~(histologically confirmed metastatic or unresectable malignancy with lacking curative measures; nivolumab must be available and appropriate for proposed therapy)"
10197962|NCT04074967|Experimental|Phase Ib ARRY-614 + nivolumab + ipilimumab|"Participants with advanced solid tumors will received ARRY-614 in combination with nivolumab + ipilimumab.~(histologically confirmed metastatic or unresectable malignancy with lacking curative measures; nivolumab and ipilimumab must be available and appropriate for proposed therapy)"
10197963|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab|Participants with of NSCLC and HNSCCC will receive ARRY-614 combined with nivolumab.
10197964|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab + ipilimumab (melanoma)|Participants with melanoma will receive ARRY-614 combined with nivolumab + ipilimumab.
10197965|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab + ipilimumab (RCC)|Participants with RCC will receive ARRY-614 combined with nivolumab + ipilimumab.
10204878|NCT04645173||No Envelope|Participants who did not receive an envelope during CIED implantation
10205443|NCT05206851|Active Comparator|Hot Pack|
10205444|NCT05206786|Experimental|Control group. Conventional preventive work out|
9724507|NCT04304131|Experimental|Colon polyp|Confirmed colorectal polyp under colonoscopy
10197966|NCT04074772||Healthy Controls|This group will consist of healthy controls between the ages of 18 and 70-years-old. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be used to train a neural network to identify points of interest in a generalized patient population.
10197967|NCT04074772||Movement Disorder Patients|This group will consist of movement disorder clinic patients between the ages of 18 and 70-years-old with a diagnosed or putative movement disorder. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
9724508|NCT04304131|Active Comparator|Healthy|Confirmed no cancer nor polyp under colonoscopy
9724509|NCT04296617||Observational (medical chart review)|Patients' medical charts are reviewed.
9724510|NCT04289597||Obese patients|Obese patients with BMI>30
10197968|NCT04074772||Age-Matched Controls|This group will consist of relatives of movement disorder clinic patients that are visiting with them to serve as age-matched controls (within 10 years of patient's age). Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
10197969|NCT04074759|Experimental|FPT155 monotherapy|The study consists of dose escalation and cohort expansions
10197970|NCT04074759|Experimental|FPT155 in combination with pembrolizumab|The study consists of dose escalation and cohort expansions
10197971|NCT04074174|Experimental|NNC0174-0833 treatment-free period; NNC0174-0833 treatment|During the NNC0174-0833 treatment-free period participants will receive OC tablets and acetaminophen. During the NNC0174-0833 treatment period participants will receive OC tablets and acetaminophen in addition to NNC0174-0833.
9724511|NCT04287959|Active Comparator|A: wean to 30%|wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.
9724512|NCT04287959|Active Comparator|B: wean to 21%|wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.
10197972|NCT04073992|Experimental|Cognitive behavioral treatment of insomnia (CBT-I)|Eight weeks of cognitive behavioral treatment of insomnia.
9724513|NCT04282967|Experimental|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
10197973|NCT04072861|Experimental|Cohort 1|9 mg RBT-9, single dose
10197974|NCT04072861|Experimental|Cohort 2, Healthy Volunteers|27 mg RBT-9, single dose
10197975|NCT04072861|Experimental|Cohort 3, Healthy Volunteers|90 mg RBT-9, single dose
10197976|NCT04072861|Experimental|Cohort 4, Subjects with CKD Stage 3|27 mg RBT-9, single dose
10197977|NCT04072861|Experimental|Cohort 5, Subjects with CKD Stage 3|90 mg RBT-9, single dose
10197978|NCT04072861|Experimental|Cohort 6, Subjects with CKD Stage 4|27 mg RBT-9, single dose
9724514|NCT04282356|Experimental|Intraperitoneal chemotherapy|Cisplatin 100mg/m2 during surgery IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8 after surgery with at least 3 courses performed (up to 4-6 allowed)
9724515|NCT04280705|Placebo Comparator|Placebo|200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
9724516|NCT04280705|Experimental|Remdesivir|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.
9724517|NCT04276584|Active Comparator|Positive airway pressure (PEP)|Deep inspiration followed by expiration to a resistance of 10-15 cm water pressure. Done three times, each time with 10 inspiration/expiration cycles
9724518|NCT04276584|Experimental|Speaking loudly|Speaking loudly during 3 minutes.
9724519|NCT04276584|Experimental|Singing|Singing a Swedish song. The study will end with this song.
9785261|NCT01247064|Placebo Comparator|Nebulized 0.9% Normal Saline|
9785262|NCT01247090|Active Comparator|Group 1: Vasopressin - Very Low Dose|0.15 mU per kg per minute
9785263|NCT01247090|Active Comparator|Group 2: Vasopressin - Low Dose|0.30 mU per kg per minute
10197979|NCT04072861|Experimental|Cohort 7, Subjects with CKD Stage 4|90 mg RBT-9, single dose
10197980|NCT04071587|Experimental|BCI training|Patients randomized to this group will receive up to12 (minimum 8) sessions of BCI training with the RecoveriX system (gtec, Austria). The system combines EEG driven functional electrical stimulation with visual feedback. BCI training is provided as a part of standard training of the impaired upper limb.
10197981|NCT04071587|Active Comparator|Control|Patients randomized to this control group will receive standard physiotherapy and occupational therapy for their impaired upper limb.
10197982|NCT04070456|Experimental|Intervention sites-Tablet-based SDH tool|All clinicians and primary care teams at a practice that are randomized to the intervention will receive the tablet-based SDH tool.
10197983|NCT04070456|No Intervention|Control sites|Care as usual, no tablet-based SDH tool.
10197984|NCT04068831|Experimental|Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
10197985|NCT04068831|Experimental|Talazoparib and Avelumab (FH- or SDH-deficiency)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
10197986|NCT04065516|Experimental|Argon Plasma Coagulation of the gastroesophageal junction|Participants with abnormal acid exposure after peroral endoscopic myotomy for achalasia, will be treated by ablation of the gastroesophageal junction with hybrid argon plasma coagulation
10197987|NCT04063579|Experimental|Patients with heart failure with preserved ejection fraction|
10197988|NCT04063579|Experimental|Non-heart failure patients|
10197989|NCT04063579|Experimental|Normal Volunteers|
10197990|NCT04063384|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
9724520|NCT04270838|Experimental|Group AC1 (Adult low dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 2.5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724521|NCT04270838|Experimental|Group AC2 (Adult high dose)|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724522|NCT04270838|Experimental|Group AC3 (Adult preferred dose)|Volunteers aged 18-45 years. Volunteers will receive a preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724523|NCT04270838|Experimental|Group AV1 (Adult single-visit Verobab)|Volunteers aged 18-45 years. Volunteers will receive Rabies IRV on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724524|NCT04270838|Experimental|PC1a (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a standalone dose of 1×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724525|NCT04270838|Experimental|PC1b (Paediatric low dose)|Volunteers aged 2-6 years. Volunteers will receive a half adult preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724526|NCT04270838|Experimental|PC2 (Paediatric high dose)|Volunteers aged 2-6 years. Volunteers will receive a full adult preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The adult preferred dose will be 2.5×10^10 vp OR 5×10^10 vp. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724527|NCT04270838|Experimental|PC3 (Paediatric preferred dose)|Volunteers aged 2-6 years. Volunteers will receive a paediatric preferred dose of ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). The paediatric preferred dose will be 50-100% of the adult preferred dose. All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724528|NCT04270838|Experimental|PV1 (Paediatric single-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0 followed by two doses of Rabies IRV (simulated PEP), one on D365 (SPEP+0) and one on D379 (SPEP+14). All participants will receive Verorab as a 4 site ID on SPEP+0, and Verorab as a 2 site ID on SPEP+14.
9724529|NCT04270838|Experimental|PV2 (Paediatric two-visit Verobab)|Volunteers aged 2-6 years. Volunteers will receive Rabies IRV (Verorab) as a 2 site ID on D0 followed by another dose on D7. All participants will also receive Verorab as a 4 site ID on D365 (SPEP+0) and Verorab as a 2 site ID on D379 (SPEP+14).
9724530|NCT04267536||Participants treated with upadacitinib monotherapy|Participants will receive upadacitinib for 12 months as prescribed by the physician
9724531|NCT04267536||Participants treated with upadacitinib in combination with MTX|Participants will receive upadacitinib in combination with MTX as prescribed by the physician for 12 months
10197991|NCT04063384|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
10197992|NCT04061421|Experimental|ASTX727 + itacitinib|ASTX727 and itacitinib will be taken by mouth
10197993|NCT04057664||Multidisciplinary Group Therapy|Multidisciplinary group therapy for women with chronic pelvic or belly pain
10197994|NCT04054713|Active Comparator|Chromoendoscopy with acetic acid and targeted biopsies|Acetic acid is prepared at a concentration of 2.5%, after initial cleaning is done, it will be applied with a 7 French spray catheter, starting the proximal application performing a uniform application on the area of intestinal metaplasia an then will be timed for mucous visualization in search of areas of loss of acetowhitening, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the esophageal face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal (glands evenly distributed with normal or abnormal crypt density (compact crypts with increased density; focal irregularity or disorganized crypts; absence of a cryptic pattern), once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
9785264|NCT01247090|Placebo Comparator|Group 3: Placebo|No Dose
9785265|NCT01247220|Experimental|Peripheral Laser + Ranibizumab|Angiography-directed peripheral laser + ranibizumab
10197995|NCT04054713|Active Comparator|Seattle protocol|Take random biopsies by quadrants every 2 centimeters biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction begins, taking tissue every 2cm from the 4 quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
10197996|NCT04050033|Experimental|Treatment Arm|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments (Tx.1, Tx.2 and Tx.3).
10197997|NCT04044781|Experimental|Test Group|Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
10204879|NCT04615533||Frail older adults, assessment|Frail older adults, assessment Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinetti Blance and Gait Scale
10204880|NCT04606628|Experimental|Intervention|Participants will consume 2 capsules containing eggshell membrane(ESM) with breakfast every day in 4 weeks.
9785266|NCT01247220|Active Comparator|Ranibizumab|Ranibizumab
9785267|NCT01247272|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
9724532|NCT04265170|Experimental|Single-arm|Eligible patients are treated with BlastX and VAC. The subjects return to the center three times per week for dressing changes and application of BlastX. The duration of the trial is four weeks and 8 weeks for larger wounds (2 subjects only). Subjects undergo study procedures (biopsy for quantitative tissue culture, photography, fluorescence imaging and swabbing for protease testing) on a weekly basis. The standard of care for pressure ulcers will be continued including debridement, off-loading, and nutritional supplementation when appropriate.
9724533|NCT04262466|Experimental|IMC-F106C - Arm A - Phase 1|Dose Escalation
9724534|NCT04262466|Experimental|IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1|Dose Escalation
9724535|NCT04262466|Experimental|IMC-F106C - Phase 2|Monotherapy dose expansion
10197998|NCT04044469|Experimental|Immunization-enhancement|This group receives an immunization-promoting manipulation aimed at triggering negative appraisals of the medical information received and questioning the validity of the medical reassurance. For this purpose, a standardized information text is presented to the participants after receipt of the doctor's report, in which it is stated that the standard medical diagnosis in gastroenterology is often not particularly accurate and that serious diseases are from times to times overlooked. As a further factor contributing to the non-detection of diseases, it is mentioned that doctors are often under time pressure and thus do not have sufficient time to ask patients for all important information. It is believed that communicating this information will result in participants continuing to report high probabilities of serious illness despite the previously received findings report.
9724536|NCT04258046|Experimental|Oral Trametinib|Patients will receive oral trametinib once daily
9724537|NCT04245345|Other|Single-arm|
9724538|NCT04243512|Experimental|Time-restricted eating|Participants will be asked to follow a TRE meal pattern for 14 consecutive days. Participants will be encouraged to consume food and beverages only within a 10-h time window for the 14-day intervention, with the exception of water, which will be encouraged at any time.
10197999|NCT04044469|Experimental|Immunization-inhibition|The aim of the immunization-inhibiting manipulation is to increase the probability that the normal test results obtained will be used to reduce worries about a serious illness. The participants of this group receive - analogous to the immunization-promoting group - a standardized information text which states that the standard medical diagnosis in gastroenterology is very accurate and that the physicians are very often correct in their initial diagnostic assessment, especially with regard to the assessment of a serious organic disease. This is supported by two scientific publications. The aim of this information is to increase the value of the results obtained, so that the participants are more reassured as a result of the inconspicuous test results and use them to correct their health-related concerns.
10198000|NCT04044469|Experimental|Control group|This group does not receive additional information after the doctor's report.
9724539|NCT04224493|Active Comparator|Tazemetostat + R2 Arm|"tazemetostat 800mg administered PO twice daily in continuous 28-day cycles.~rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles."
9724540|NCT04224493|Placebo Comparator|Placebo + R2 Arm|"placebo administered PO twice daily in continuous 28-day cycles.~rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles."
9724541|NCT04224064|Experimental|Healthy subjects cohort|A single blood sample will be made in healthy subjects.
9724542|NCT04224064|Experimental|Liposarcoma patients cohort|Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
9724543|NCT04218409|Active Comparator|oxycodone (5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin
9724544|NCT04218409|Active Comparator|Oral oxycodone (5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
9724545|NCT04218409|Active Comparator|oxytocin+placebo|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
9724546|NCT04218409|Sham Comparator|placebo+placebo|Serves as the control
9724547|NCT04218409|Active Comparator|Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin
9724548|NCT04218409|Active Comparator|Oral oxycodone (2.5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
9724549|NCT04214392|Experimental|Treatment (CAR T cell therapy) I|Arm 1 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via single delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one CAR T cell infusion delivered intracranial intratumoral or intracavitary [ICT] and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T cell treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
9724550|NCT04214392|Experimental|Treatment (CAR T cell therapy) II|Arm 2 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy and the lateral ventricle. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with two CAR T cell infusions (intracranial intratumoral or intracavitary [ICT]) and also into the lateral ventricle (intracranial intraventricular [ICV]) and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
9724551|NCT04208750|Experimental|R-Refraction|
9724552|NCT04208750|Active Comparator|S-Refraction|
10198001|NCT04040959|Experimental|Nicotinamide Riboside|Each nicotinamide riboside capsule contains 250 mg of nicotinamide riboside chloride mixed with microcrystalline cellulose. Dosage: 500 mg by mouth twice a day for 3 months.
10198002|NCT04040959|Placebo Comparator|Placebo|Matched placebo capsules.
10198003|NCT04038541|Other|Prebiotic/ Probiotic|These subjects will be assigned to first receive prebiotics (Prebiotin Prebiotic Fiber Stick Pac) for 6 weeks. Then after a 6 week wash-out period, subjects will take probiotics (Visbiome®) for 6 weeks (followed again by a 6 week washout period).
10198004|NCT04038541|Other|Probiotic/ Prebiotic|These subjects will be assigned to first receive probiotics (Visbiome®) for 6 weeks. Then after a 6 week wash-out period, subjects will take (Prebiotin Prebiotic Fiber Stick) for 6 weeks (followed again by a 6 week washout period).
10198005|NCT04037007|Active Comparator|Fistulotomy - High experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in high experienced endoscopists.
10198006|NCT04037007|Active Comparator|Fistulotomy - Low experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in low experienced endoscopists.
10198007|NCT04037007|Active Comparator|Conventional (guidewire) cannulation- High experience|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in high experienced endoscopists.
10198008|NCT04037007|Active Comparator|Conventional (guidewire) cannulation - Low experienced.|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in low experienced endoscopists.
10198009|NCT04036942|Active Comparator|Hybrid argon plasma.|"After diagnostic endoscopy investigators will proceed to use argon plasma probe for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will use the jet included in the argon plasma probe with effect 20 to 40 system for the injection of the background submucosa in the marking area, applying 0.9% saline solution with methylene blue, to achieve adequate Submucosal elevation for application or argon plasma with high voltages (100 watts, 1.5 liters / min) using forced coagulation mode, applying plasma argon to 1cm above the Z line in the esophageal mucosa and 2cm below it towards the gastric mucosa, argon will be applied until a carbonization effect of the mucosa is achieved, once the application of the therapy is performed mucosal lavage and immersion technique to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications"
10198010|NCT04036942|Active Comparator|Band mucosectomy|After diagnostic endoscopy investigators will proceed to use the tip of a polypectomy snare for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will perform submucosal elevation with the injection of 0.9% saline with carmine indigo and adrenaline 1:10000, after adequate submucosal elevation investigators will proceed with the help of a band ligation cap to suction and release the elastic band in the previously marked and elevated tissue, proceeding to resect the previously ligated tissue with polypectomy loop below the elastic band with forced coagulation (Effect 2, 40 W), until the marked mucosa is completely resected (average used of 5 elastic bands, reviewing the work area for complications like bleeding or perforation.
10198011|NCT04031768|Other|0-2-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~0 minutes 2 minutes 5 minutes 5 minutes"
10198012|NCT04031768|Other|0-5-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~0 minutes 5 minutes 2 minutes 5 minutes"
10198013|NCT04031768|Other|2-0-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~2 minutes 0 minutes 5 minutes 5 minutes"
10198014|NCT04031768|Other|5-0-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~5 minutes 0 minutes 2 minutes 5 minutes"
10198015|NCT04031768|Other|2-5-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~2 minutes 5 minutes 0 minutes 5 minutes"
10198016|NCT04031768|Other|5-2-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~5 minutes 2 minutes 0 minutes 5 minutes"
10198017|NCT04030325|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
10198018|NCT04030325|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
10198019|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
10198020|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
10198021|NCT04030325|No Intervention|Assessment Only Control|Participants complete baseline survey, longitudinal follow up assessments, and pre- and post- event surveys.
10198022|NCT04028687||Taperloc Complete Stems|Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.
10204881|NCT04606628|Experimental|Placebo|Participants will consume 2 capsules with no bioactive substance (placebo) with breakfast every day in 4 weeks.
10204882|NCT04604782|Experimental|adolescents aged 12 to <18 years|
10204883|NCT04604782|Experimental|children aged 2 to <12 years|
10204884|NCT04604782|Experimental|infants aged 1 to <24 months and who weigh at least 3 kg|
9724553|NCT04200300||Nurses working with patients with mental disorders|Nurses in Germany currently working with patients with mental disorders
9724554|NCT04193605|Active Comparator|Mindfulness Based Stress Reduction|MBSR sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
9724555|NCT04193605|No Intervention|Standard of Care|The control condition will continue receiving usual care or standard of care.
9724556|NCT04187482|Experimental|Exercise training group|All participants will be receiving same exercise training intervention
9724557|NCT04177992|Experimental|Servo control|"Automated control of oxygen. The oxygen saturation target range will be set to 93%.~Automated oxygen control can be over-ridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
9724558|NCT04177992|No Intervention|Manual control|Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.
9724559|NCT04167358|Experimental|Participants receiving linerixibat|Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER [Group 1]) and Phase 3 study (212620 GLISTEN [Group 2]), will receive linerixibat.
9724560|NCT04165733||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
10198023|NCT04027855|Other|collection of PBMC from healthy donors|"Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
10198024|NCT04027049|Experimental|Supine cycle ergometry of the lower extremities|Patients will receive two 20 minute cycle ergometry sessions separated by at least 4 hours in addition to usual care. The cycle will be set to a gear of zero and will begin in passive mode, the patient will be able to actively cycle if patients are able.
9724561|NCT04165720||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
9724562|NCT04162210|Experimental|Participants receiving Belantamab mafodotin|Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W
9724563|NCT04162210|Active Comparator|Participants receiving pom/dex|Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.
9724564|NCT04161391|Experimental|TPX-0046|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0046.~The food-effect sub-study determines the effect of food on a dose of TPX-0046 at the RP2D dose level.~The Phase 2 part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.~Phase 2 Cohorts:~Cohort I (NSCLC + RET fusion, RET TKI Therapy Naive)~Cohort II (NSCLC + RET fusion, RET TKI Therapy Pre-treated)~Cohort III (MTC + RET mutation, RET TKI Therapy Naive)~Cohort IV (MTC + RET mutation, RET TKI Therapy Pre-treated)~Cohort V (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Naive)~Cohort VI (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Pre-Treated)"
9980896|NCT01396746||People with Post Stroke Conditions|(a) having acquired stroke at least 1 year before testing. (b) Chronic weakness and/or spasticity of the affected side. (c) Independent stair-climbers (with hand-rail). (d) With cognitive level sufficient to comprehend instructions. (e) age range between 40-69. (f) Use of walking aid is permitted as long as the participant is able to walk on a treadmill with hand-rail. (g) No heart failure or other medical conditions that preclude participation in the study.
9980897|NCT01396759|Experimental|bubble CPAP|Children will receive bubble CPAP Bubble-CPAP, which requires a source of gas flow (typically 6-8 L/ minute in a neonate), an air-oxygen blender, a humidifier and a T-piece. The expiratory arm is inserted in a bottle of water and the level of CPAP delivered is equivalent to the length of the expiratory tubing that remains under water. Robust equipment is now available at a fraction of the cost of mechanical ventilators. Bubble-CPAP has potential advantages over the mechanical ventilation, such as lower cost, ease of application by nursing staff, lower risk of complications, and has been proposed as an inexpensive method of delivering CPAP in developing countries.
9980898|NCT01396759|Experimental|High flow air/ oxygen mix|High flow air/ oxygen mix is useful in reducing the indication of mechanical ventilation (4); however, there is a lack of randomized studies comparing it with bubble CPAP or with standard flow O2 supplementation by nasal prongs. High flow air/oxygen mix uses flows of 2 litre per kg per minute of blended air / oxygen mix, usually with a low fraction of inspired oxygen (say 25-40%).
10198025|NCT04027049|No Intervention|Control|Patients will receive usual care only.
10204885|NCT04602624|Experimental|SAGE-718|Participants will receive a single dose of SAGE-718 oral tablets, once daily in the morning for 14 days.
9724571|NCT04157296|Experimental|CBT and computerized cognitive training (CCT)|Participants will play CCT games at home 5 times per week for two weeks before beginning CBT and for two weeks after the first CBT session. Then participants will have CCT games immediately prior to CBT for nine more weeks (one time a week).
9724572|NCT04157296|Active Comparator|Cognitive behavioral therapy|Participants will receive CBT sessions once a week for 12 weeks.
9724573|NCT04156893|Experimental|RH genotype matched red cell transfusions|Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.
9724574|NCT04153565|Experimental|PBZ @ 200 mg/m2 IV + CIS @ 75 mg/m2 IV + PMX @ 500 mg/m2 IV|PBZ @ 200 mg/m2 IV every 3 weeks (Q3W) in combination with CIS @ 75 mg/m2 IV, and PMX @ 500 mg/m2 IV for 4-6 cycles followed by monotherapy of PBZ up to 35 cycles from the first dose of the study in treatment phase (approximately 2 years)
9724575|NCT04151017|Experimental|Autologous fibrin glue|
9724576|NCT04151017|Active Comparator|Sutures|
9724577|NCT04149912||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
9724578|NCT04146064||Validation cohort: NSCLC|"Patients with advanced/metastatic NSCLC planned for IO-treatment in one of the following categories~Pembrolizumab monotherapy first-line~Pembrolizumab or nivolumab monotherapy in second or later line"
10198026|NCT04026646|Experimental|Proprioceptive Neuromuscular Facilitation stretching exercises|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
9724579|NCT04146064||Cohort 1: NSCLC|Patients with advanced/metastatic NSCLC planned for Pembrolizumab-chemotherapy combination therapy first-line
9724580|NCT04146064||Cohort 2: Melanoma|"Patients with advanced/metastatic melanoma planned for IO-treatment in one of the following categories~Nivolumab/ipilimumab combination treatment 1L~Pembrolizumab or nivolumab monotherapy treatment 1L~Ipilimumab monotherapy 2L"
10198027|NCT04026646|Experimental|Static stretching exercises|Passive Static Stretching exercises will be performed 2 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
10198028|NCT04026425|Experimental|ME/CFS|Adults with ME/CFS
10198029|NCT04026425|Active Comparator|Healthy controls|Healthy, low-active adults
10198030|NCT04023942|Active Comparator|Low carb - App-based group|Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
10198031|NCT04023942|Active Comparator|Low carb - Newsletter-based group|"Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
10198032|NCT04023942|Active Comparator|Low fat - App-based group|Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
10198033|NCT04023942|Active Comparator|Low fat - Newsletter-based group|"Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
10198034|NCT04023071|Experimental|FT516 Monotherapy|FT516 monotherapy in adult subjects with r/r AML.
10198035|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies|FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
10198036|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies on an Extended-Dosing Schedule|FT516 on an extended-dosing schedule in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
10198037|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies following Bendamustine Conditioning|Bendamustine conditioning followed by FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
10198038|NCT04021966|Experimental|Laser|In this arm, participants will have 3 real laser treatments first, followed by 3 consecutive sham treatments.
10198039|NCT04021966|Sham Comparator|Sham|In this arm, participants will have 3 sham treatments first, followed by 3 consecutive real laser treatments.
10198040|NCT04019262|Active Comparator|40 Gy in 15 fractions|Patients randomized to 40 Gy in 15 fractions will receive 75 mg/m^2 temozolomide per day for 15 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
10198041|NCT04019262|Active Comparator|25 Gy in 5 fractions|Patients randomized to 25 Gy in 5 fractions will receive 150 mg/m^2 temozolomide per day for 5 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
10198042|NCT04008628|Active Comparator|Nitrous oxide|Inhalation of a 50%/50% mixture of nitrous oxide and oxygen. Reassurance of the child during procedure
10198043|NCT04008628|No Intervention|Standard care|Infants will be reassured as currently performed in routine clinical practice
10198044|NCT04008004|Experimental|EDP-514 HV SAD Cohorts|EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration
9724581|NCT04146064||Cohort 3: Mixed solid tumor cohort|Patients with advanced/metastatic solid tumors such as Head&Neck tumors, kidney cancer and urothelial cancer planned for IO-treatment
9724582|NCT04146064||Cohort 4: NSCLC|Patients with advanced/metastatic NSCLC planned for treatment with Chemotherapy-only (either platinum-based combination treatment or docetaxel monotherapy)
9724583|NCT04126733|Experimental|Regorafenib + Nivolumab|
9724584|NCT04116398|Experimental|Ozurdex®, 700µg dexamethasone intravitreal injection|Intravitreal injection of dexamethasone (Ozurdex®)
9724585|NCT04112589|Experimental|Level dose 1 - 40mg, 14 days|Patients will receive an induction cycle (40mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
9785268|NCT01247272|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
9785269|NCT01247285|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
9785270|NCT01247285|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
10198045|NCT04008004|Experimental|EDP-514 HV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days
9724586|NCT04112589|Experimental|Level dose 2 - 60mg, 14 days|Patients will receive an induction cycle (60mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
9724587|NCT04112589|Experimental|Level dose -1 - 60mg 7days|Patients will receive an induction cycle (60mg Quizartinib for 7 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
9724588|NCT04112589|Experimental|Level dose -2 - 40mg 7 days|Patients will receive an induction cycle (40mg Quizartinib for 7days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
9724589|NCT04111939|Experimental|Wave 1 - Intervention|Communities in Wave 1 will receive the CTH intervention during the first 30 months of the trial. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
9724590|NCT04111939|Other|Wave 2 - Wait-list comparison|Communities in Wave 2 will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
9724591|NCT04109716|Experimental|Interpersonal Psychotherapy-Adolescent Skills Training|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) is an indicated group depression prevention program. In IPT-AST, adolescents learn communication (e.g., using I statements, striking while the iron is cold) and interpersonal problem-solving strategies and apply these strategies to their relationships to decrease conflict, increase social support, and improve overall social functioning. IPT-AST consists of 1 or 2 individual pre-group sessions, 1 mid-group session, 8 weekly group sessions, and up to 6 individual booster sessions. Parents are invited to attend the mid-group session so the adolescents can apply the interpersonal strategies in a conversation with a parent. The purpose of the booster sessions is to monitor symptoms and apply the interpersonal strategies to current stressors. These sessions are designed to help solidify the interpersonal skills and address current problems before they result in a worsening of symptoms.
9724592|NCT04109716|Active Comparator|Services as Usual (SAU)|Investigators anticipate that counselors in SAU will see youth in the study for brief, periodic sessions and/or will refer youth for treatment in the community. Counselors will be permitted to see the adolescents as often as they would like throughout the course of the study (up to 15-months post-baseline). Investigators will ask counselors to complete a form each time they see a teen, noting the length of the session, whether the session was scheduled or not, and the topics discussed.
9724593|NCT04106154|Experimental|Intervention|The kinesiology intervention will involve physical activity education appropriate to the MC&D delivered in a group format through twelve 2.5-hour weekly sessions49 (30 hours of kinesiology support). The sessions will combine participation in physical activities appropriate to the MC&D with education and goal-setting discussions. Each week, children will be guided to develop an individualized SMART (Specific, Measurable, Agreed upon, Realistic, Time-based) plan for changing their activity behaviour. Their weekly SMART plan, which will require an additional 2 hours per week, will specify the home/community activities they will do prior to the next session.
9724594|NCT04106154|No Intervention|Control|Patients in the control group will continue with clinical care as usual. To encourage their cooperation, children in the control group will be offered the intervention after all of their study visits have been completed.
9724595|NCT04099524|Experimental|active tDCS|We will apply the stimulation for 20 minutes using current at 1.5mA with a ramp up and ramp down period of 30 seconds at the start and end of the session.
9724596|NCT04099524|Sham Comparator|sham tDCS|tDCS will ramp up for 30 seconds with 1 mA current and then ramp off within 10 seconds. As 30 seconds is too short for tDCS to have any effects, this will be the control condition. tDCS is on for 30 seconds because that is usually the only time individuals would experience tingling and itching - a factor we aim to equate between experimental and control conditions.
9724597|NCT04099095|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed
9724598|NCT04099095|Active Comparator|Delayed Appointment|Wait-list control group who receive Social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed
9724599|NCT04080986|No Intervention|Standard Arm|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
10198046|NCT04008004|Placebo Comparator|EDP-514 HV SAD Placebo Cohort|Matching placebo, orally, once daily in one single administration
10198047|NCT04008004|Placebo Comparator|EDP-514 HV MAD Placebo Cohort|Matching placebo, orally, once daily for 14 days
9785800|NCT01260350|Experimental|Group 7: SOF+RBV 12 wk: GT 1, TE|Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
10198048|NCT04008004|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days
10198049|NCT04008004|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days
10198050|NCT04007952|No Intervention|Intervention 1 (Control)|No anterior gastropexy will be performed.
10198051|NCT04007952|Experimental|Intervention 2 (Treatment)|Anterior gastropexy will be performed.
10198052|NCT04005651|Experimental|POD L GF|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the POD L GF arm. Subjects will be implanted bilaterally with the European Conformity (CE) marked POD L GF trifocal IOL and assessed according to the study visit schedule.
10198053|NCT04005651|Active Comparator|Symfony®|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
10198054|NCT04005651|Active Comparator|AcrySof®|Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
10198055|NCT04005027|Experimental|Intermittent graded exercise (INT)|The intermittent graded exercise test (INT) increase treadmill speed incrementally using three minute stage duration on a motorised treadmill. However, the speed within each three minute exercise bout will vary every 30 s between the target speed, and a complete pause for 30 s. The acceleration of the treadmill belt will be set to its maximum capability.
10198056|NCT04005027|Active Comparator|Continuous graded exercise (CONT)|The continuous graded exercise test (CONT) will increase treadmill speed incrementally using three minute stage duration on a motorised treadmill
10198057|NCT04002843|Experimental|- Virgin patients with Botulinum Toxin, first injection|"Experimental: - Virgin patients with Botulinum Toxin, first injection~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of the elbow flexor muscle chosen (biceps brachialis, anterior brachialis), located ultrasonographically.~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
9724600|NCT04080986|Active Comparator|Double Sequential Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
10198058|NCT04002843|Experimental|- Injected group: Patients already injected|"- Injected group: Patients already injected~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of in one elbow flexor muscle (biceps brachialis, anterior brachialis), located ultrasonographically.~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
10198059|NCT04002843|Other|Control|healthy patient matched in age and sex to included patients
9724601|NCT04080986|Active Comparator|Vector Change Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
9724602|NCT04080427|Placebo Comparator|Placebo capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
9724603|NCT04080427|Experimental|Dronabinol 7.5 milligram oral capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
9724604|NCT04070157|Experimental|Lofexidine|
9724605|NCT04070157|Placebo Comparator|Placebo|
9724606|NCT04061382||Randomised selection of population - Group 1|Group 1 will be focusing on COVID-19, diphtheria and group C invasive meningococcal disease. The investigators are aiming to recruit around 2300 individuals and the investigators are aiming to ensure that sample is broadly representative of the region according to IMD (Index of Multiple Deprivation scores). PHE have generated a list of all postcodes in recruiting regions and determining the quintiles of IMD within that region. Participants interested in taking part in the study will contact sites to arrange a visit. Basic demographic characteristics will be collected by questionnaire and/ or case report form (CRF) and will include: DOB, gender, GP details, Ethnic group, association with communities of special interest, household income and vaccination history.The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
9785801|NCT01260350|Experimental|Group 8: SOF+RBV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
9980899|NCT01396759|Active Comparator|Standard O2 supplementation by nasal prongs|Standard O2 supplementation by nasal prongs @ 0.5-2.0 litre per minute
9980900|NCT01396772|Experimental|PREPARE education program|This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
9984532|NCT03997968|Experimental|CYT-0851 and gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine on Day 1, 8 and 15 of each 28 day cycle
10198060|NCT04001946|Other|G-button Securement Device|Subjects will be provided instructions and a 12-week supply of test devices, sufficient to change the gauze dressing at least once per day.
10198061|NCT04001946|No Intervention|Standard Dressing|Subjects will be provided instructions and a 12-week supply of tape and gauze (current standard of care), sufficient to change the gauze dressing at least once per day.
9724607|NCT04061382||Group 2|"Group two will focus on 0-19 year olds only. They will not be restricted to the post code sampling. Instead this will include standard recruitment methods such as social media advertisements within the normal recruiting regions for each site. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients. The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.~A proportion of participants from this group from selected sites will also provide up to a maximum of three blood samples for separation of peripheral blood mononuclear cells (PBMCs) to evaluate T cell responses. These participants can be either seronegative or seropositive at their Visit 1."
9724608|NCT04061382||Group 3|Group three will consist of up to 300 participants aged 0-19 from the Black, Asian and Minority ethnic population aged 0-19 years. They will not be restricted to the post code sampling and will be recruited at a sub-set of sites depending on capacity and the demographic profile of the local population. Recruitment will be by multiple approaches, including mail outs, radio and advertising in community (e.g. community centres, religious establishments) or Pharmacies and GP practices where we have ethics approval for them to act as PICs. These can vary according to each site's experience and their contacts within their local community on how is best to approach the BAME community. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients.
9724609|NCT04057573|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
9724610|NCT04057573|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
9724611|NCT04052425|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
9724612|NCT04052425|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
9724613|NCT04051606|Experimental|Regorafenib|160 mg regorafenib 3 weeks on/ one week off in participants with Avastin refractory Glioblastoma, continued until progression or toxicity. Participants will receive an MRI every 8 weeks.
9724614|NCT04033926|Other|Arm A|"Treatment Period 1: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks~Treatment Period 2: Placebo SC weekly for 16 weeks"
9724615|NCT04033926|Other|Arm B|"Treatment Period 1: Placebo SC weekly for 16 weeks~Treatment Period 2: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks"
9724616|NCT04029077||Vapor group|Bronchoscopic lung volume reduction treatment using Vapor
9780727|NCT01129804|Experimental|Network Support|Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
9780728|NCT01129804|Active Comparator|Packaged Cognitive-Behavioral Treatment|The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.
9780729|NCT01129882|Experimental|Aripiprazole IM depot|Active treatment of monthly doses of aripiprazole IM depot (300 mg or 400 mg)
9780730|NCT01129921|Active Comparator|Decompression with mild® Device Kit|Fluoroscopically guided percutaneous lumbar decompression using the Vertos mild® Device Kit for bone and tissue removal to decompress the targeted stenosed level(s).
9780731|NCT01129921|Sham Comparator|Sham lumbar decompression|Sham procedure of fluoroscopically guided percutaneous placement of mild® Device Kit instrumentation with no removal of bone or tissue.
9780732|NCT01129960|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
9780733|NCT01129960|Experimental|Eslicarbazepine acetate 1200 mg QD|
9780734|NCT01129960|Experimental|Eslicarbazepine acetate 1600 mg QD|
9780735|NCT01129960|Placebo Comparator|Placebo|
9780736|NCT01130051|Experimental|Colcrys® 0.6 mg intact tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
9780737|NCT01130051|Experimental|Colcrys® 0.6 mg tablet on applesauce|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
9780738|NCT01130103|Experimental|Paroxetine|Paroxetine and Prolonged Exposure Therapy
10198062|NCT04001894|Experimental|Ticagrelor|To observe the safety and efficacy of standard-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
10198063|NCT04001894|Active Comparator|Clopidogrel|To observe the safety and efficacy of standard-dose clopidogrel in Chinese patients with Stable Coronary Artery Disease
10198064|NCT03995264|Experimental|Ultrasound group|Ultrasound-guided radial artery cannulation
9780739|NCT01130103|Placebo Comparator|Placebo pill|Placebo pill plus Prolonged Exposure Therapy
9780740|NCT01130168|Experimental|Placebo/ISMN ER/Amlodipine (Sequence 1)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
9780741|NCT01130168|Experimental|ISMN ER/Amlodipine/Placebo (Sequence 2)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
9780742|NCT01130168|Experimental|Amlodipine/Placebo/ISMN ER (Sequence 3)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
10198065|NCT03995264|Placebo Comparator|Palpation group|Radial artery cannulation with palpation technique
9724617|NCT04023409||Severe COPD patients|Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
9724618|NCT04021641||Participants with Typical Hearing|From 5 age groups from their 6 years of age to adulthood
9724619|NCT04021641||Participants with Hearing Impairment|Participants with various degree of hearing impairment
10198066|NCT03994887|Experimental|Experimental group|Patients under general anesthesia will be included.
9724620|NCT04013152|Experimental|clinical database|
9724621|NCT04002401|Experimental|Axicabtagene Ciloleucel and Rituximab Combination|Participants will receive rituximab, and fludarabine and cyclophosphamide conditioning chemotherapy, followed by axicabtagene ciloleucel and additional rituximab.
9724622|NCT03988023|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
9724623|NCT03988023|Placebo Comparator|Saline|Saline solution, 4 mL, single intra-articular injection
9724624|NCT03983070|Active Comparator|Control Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 80% maximal Watts, and deadlifts at 60% of one-repetition maximum.
9724625|NCT03983070|Experimental|Blood Flow Restriction and Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include the application of blood flow restriction during two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 40% maximal Watts, and deadlifts at 30% of one-repetition maximum. Blow flow restriction will be applied at 80% occlusion during both exercise modalities.
9724626|NCT03976999|Experimental|Biological collection|"For all the patients include in the studie :~Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~Tissue samples (tumor tissue and healthy tissue) collected during the surgery~In parallel to this biological collection, standardized clinical data will be entered into a database"
9724627|NCT03976362|Experimental|Pembrolizumab + Carboplatin + Taxane + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until centrally verified progressive disease, physician decision or intolerable toxicity."
9724628|NCT03976362|Active Comparator|Pembrolizumab + Carboplatin + Taxane + Olaparib Placebo|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS matching maintenance olaparib placebo twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib placebo until centrally verified progressive disease, physician decision or intolerable toxicity."
9724629|NCT03973333|Experimental|IMC-C103C - Monotherapy IV dose escalation|n= approximately 28 patients to establish the MTD/expansion dose
9724630|NCT03973333|Experimental|IMC-C103C and atezolizumab dose escalation|n=approximately 12 patients to establish the MTD/expansion dose
9724631|NCT03973333|Experimental|IMC-C103C - expansion|Patients will be enrolled n=9-24 per expansion cohort (up to 4 total): metastatic/unresectable tumors of interest patients treated at the expansion dose of IMC-C103C to assess preliminary anti-tumor efficacy
9724632|NCT03973333|Experimental|IMC-C103C monotherapy SC dose escalation|Patients will be enrolled n=9-12 to establish the MTD/expansion dose
9724633|NCT03972033|Experimental|Eye Movement Desensitization and Reprocessing|"The DeprEND manualized protocol (Hofmann, Ostacoli, et al., 2015) is based on the eight-phase protocol by Shapiro (2001) that was adapted for the treatment of depression by the European Depression EMDR Network and used in previous studies (Hase et al., 2015; Hofmann et al., 2014; Ostacoli et al., 2018). EMDR targets will be selected using the Adaptive Information Processing model that looks for stressful events linked with depression. The DeprEnd Fidelity Rating Scale will be used to assess treatment fidelity. The scale will be completed by trained EMDR therapists who will listen to the audio recordings of the sessions.~In each centre, EMDR is provided by psychotherapists specialized in Level II EMDR and with a minimum of three years of experience in treating patients with depression. They receive extensive training and supervision in the manualized protocol established for the study, from a certified senior EMDR instructor."
9724634|NCT03972033|Active Comparator|Cognitive Behavioral Therapy|Treatment protocol is based on the principles described by Beck (Beck et al., 1979) will be utilized. The treatment includes behavioral activation and cognitive restructuring with homework assignments. In each centre, CBT treatment is performed by psychotherapists with certified training in CBT techniques and a minimum of three years of experience in treating patients with depression. They receive regular CBT supervision to ensure that the quality of their CBT treatment was maintained.
9724635|NCT03971877||Patients admitted in ICU or oncohaematology ward|
9724636|NCT03965494|Experimental|AXL inhibitor BGB324 then surgery|Participants receive AXL inhibitor BGB324 PO QD on days 1-5, then undergo surgery 3-6 hours after last dose. Within 45 days, participants receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10198067|NCT03990311|Experimental|Intervention|The experimental arm receives 2 months of sodium restricted prepared meals plus dietary counseling followed by 3 months of counseling alone.
10205445|NCT05206786|Experimental|Intervention group. Gluteus maximus strengthening specific program|
9724637|NCT03965494|Experimental|Surgery then AXL inhibitor BGB324|Participants undergo surgery, then within 45 days receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9724638|NCT03963414|Experimental|Cohort 1|Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.
9724639|NCT03963414|Experimental|Cohort 2|Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.
9724640|NCT03961815|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
9724641|NCT03961815|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
9724642|NCT03955211|Experimental|Treatment Group 1|A single dose of HTX-011 administered via instillation into the surgical site.
9724643|NCT03955211|Experimental|Treatment Group 2|A single dose of HTX-011 administered via instillation into the surgical site and a scheduled non-opioid multimodal analgesic (MMA) regimen.
9724644|NCT03948490|Other|Arm 1 Cohort 1: Interventional arm/In-person rehab|"The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.~n = 20 patients"
9724645|NCT03948490|Experimental|Arm 1 Cohort 2: Interventional arm/ReMind iPad app|"The ReMind iPad-based cognitive rehabilitation was developed with collaborators at Tilburg University, The Netherlands, and is an evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors. Brain plasticity-based computerized cognitive training is a newly developing field of therapeutics for neurological and psychiatric disorders that uses frequent game-like training sessions to drive improvements in cognitive functions.~n = 20 patients"
10198068|NCT03990311|Placebo Comparator|Control|The control arm receives 5 months of usual care followed by 2 months of receipt of sodium restricted prepared meals.
10198069|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts A|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
10198070|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts B|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
10198071|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C1|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic colorectal cancer
10198072|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C2|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic endometrium cancer
10198073|NCT03988920|Experimental|Tenapanor w/Sevelamer|Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level
10198074|NCT03988920|Experimental|Sevelamer w/Tenapanor|Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed
10198075|NCT03988270|Experimental|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
10198076|NCT03988270|No Intervention|Control|Participants in the control group will not receive any pre-surgical instructions for exercise in the access arm
10198077|NCT03986580|Other|Annular closure device|Single arm study; all patients treated with an annular closure device
10198078|NCT03985033|Experimental|L-PRF|Post-extraction sockets will be filled with autologous leucocyte and platelet-rich fibrin (L-PRF) clot.
10198079|NCT03985033|No Intervention|Control|Post-extraction sockets will be left to heal spontaneously with natural blood clot.
10198080|NCT03982485|Experimental|Arm I|Apatinib+Paclitaxel+Cisplatin
10198081|NCT03982485|Active Comparator|Arm II|Paclitaxel+Cisplatin
10198082|NCT03973931|No Intervention|Usual Care|This group will not receive an intervention. We have included a usual care group to demonstrate the impact of the text messaging interventions above and beyond usual care given that many prior medication adherence interventions have demonstrated small to negligible effects.
9724646|NCT03948490|Experimental|Arm 1 Cohort 3: Interventional arm/Healthy SMS texting|"The mobile phone texting intervention was developed with collaborators at Zuckerberg San Francisco General Hospital and is currently being studied in individuals with depression and traumatic brain injury. Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.~n = 20 patients"
9724647|NCT03948490|No Intervention|Arm 2 Cohort 4: Longitudinal arm/Upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
9785802|NCT01260350|Experimental|Group 9: SOF+RBV 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
10198083|NCT03973931|Experimental|Generic Nudge|A generic reminder text will be delivered to patients to refill their medication at days 1, 3, 5, 7 and 10 after they been labeled as non-adherent.
10198084|NCT03973931|Experimental|Optimized nudge|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1, 3, 5, 7 and 10 after they have been labeled as non-adherent.
10205446|NCT05206760||Trial participants|Patients with severe traumatic brain injury requiring craniotomy or ICP bolt insertion
9724648|NCT03948490|No Intervention|Arm 1 Cohort 5: Longitudinal arm/No upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
9724649|NCT03948490|Other|Arm 1 Cohort 1A: Telehealth Cognitive Rehabilitation|"The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning. During treatment implementation, patients acquire, apply, and adapt evidenced based strategies based on neuropsychological testing and conjointly developed treatment planning goals.~N=20"
9724650|NCT03943927|Experimental|Pharmacogenetic-guided metoprolol management|
9724651|NCT03931980|Experimental|Robotic surgery|Patients undergoing robotic surgery for removal of rectal cancer.
9724652|NCT03931980|Experimental|Laparoscopic surgery|Patients undergoing laparoscopic for removal of rectal cancer
9980901|NCT01396772|Other|Control arm|Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
9980902|NCT01396798||Children with an acute illness|Children aged 1 month to 16 years of age, which attend the A&E department of UZLeuven with an acute illness episode of maximum 5 days.
9724655|NCT03914326|Experimental|Oral semaglutide|One tablet daily for 3.5 to 5 years
9724656|NCT03914326|Placebo Comparator|Placebo|One tablet daily for 3.5 to 5 years
9724657|NCT03900884|Experimental|Letrozole + Palbociclib + Venetoclax|"The Letrozole dose is 2.5 mg (D1-28) for all dose levels.~Starting dose Level 1: Palbociclib 100 mg (D1-21) and Venetoclax 100 mg (D1-21) daily."
9724658|NCT03874897|Experimental|CAR-CLDN18.2 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
9724659|NCT03867552|Experimental|Altered gas (86% CO2, 10% N2O, 4% O2)|Surgery with the use of the altered insufflation gas (86% CO2, 10% N2O, 4% O2)
9724660|NCT03867552|Active Comparator|Standard gas (100% CO2)|Surgery with the use of the standardized gas (100% CO2)
9724661|NCT03866603||Parkinson´s disease individuals|The participants that are clinically diagnosed with Parkinson's disease
9724662|NCT03859895||Observational (without bone scan)|Former Observational Arm participants of the ZiPP trial.
9724663|NCT03859895||Observational (with bone scan)|Former Interventional Arm participants of the ZiPP trial.
9980903|NCT01396824||Heart failure|Heart failure patients attending a HF clinic with depressed LVEF (< 45%) or ≥ 1 hospital admission due to HF decompensation.
9724664|NCT03853330|Active Comparator|Thoracic Epidural Analgesia group|25 patients will receive ultrasound-guided thoracic epidural analgesia for multiple fracture ribs at the level of T8 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
9724665|NCT03853330|Active Comparator|Erector spinae plane block group|25 patients will receive ultrasound-guided ESP block for multiple fracture ribs at the level from T1 to T5 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
9724666|NCT03851120|Experimental|Intervention|150 pregnant women will be given Probiotics and 480 mg DHA, psychosocial stimulation, and healthy eating education
9724667|NCT03851120|Placebo Comparator|Control|150 pregnant women will be given placebo probiotics and 240 mg DHA, psychosocial stimulation, and healthy eating education
9724668|NCT03850691|Experimental|Cohort 1: Nivolumab|
9724669|NCT03850691|Experimental|Cohort 2: Nivolumab & Ipilimumab|
9724670|NCT03834740|Experimental|Cohort 1: last dose 1 to 3 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 1: last ribociclib+everolimus dose 1 to 3 hours prior to craniotomy for tumor resection"
9724671|NCT03834740|Experimental|Cohort 2: last dose 7 to 9 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 2: last ribociclib+everolimus dose 7 to 9 hours prior to craniotomy for tumor resection"
9724672|NCT03834740|Experimental|Cohort 3: last dose 23 to 25 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 3: last ribociclib+everolimus dose 23 to 25 hours prior to craniotomy for tumor resection"
9724673|NCT03832192|Experimental|care.coach Avatar|
9724674|NCT03832192|No Intervention|Control|
9724675|NCT03823690|Active Comparator|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated.~A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
9980904|NCT01396850||Psychotic Group|
9980905|NCT01396850||Anxiety|
9980906|NCT01396850||Depressed|
9980907|NCT01396850||Control Group|
9980908|NCT01396863|Active Comparator|First treatment HDF|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination day. During the second examination day the patient will receive treatment with low flux hemodialysis.
10198085|NCT03973931|Experimental|Optimized nudge plus AI Chat Bot|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1 and 3 after they have been labeled as non-adherent. If the patient has not filled their medication on days 5 and 7, in addition to receiving an optimized nudge text, an AI will conduct interactive chat via a chat bot to assess barriers filling the medication as described in Aim 1 above. If they still have not filled the medication, they will receive another message on day 10.
9724676|NCT03823690|Active Comparator|Pyloro-duodenal stent|The uncovered DS used in this study is Wallflex (Boston, Natick, MA, USA), made of nitinol wire, with a diameter of 22mm and length of 6, 9, 12cm. This stent is a braided stent with high axial force, good flexibility and conformability.
9724677|NCT03816956|Experimental|Study treatment|Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously on the day of randomization.
9724678|NCT03816956|Placebo Comparator|Placebo treatment|Control group: Placebo administered intravenously on the day of randomization.
9724679|NCT03805100|Experimental|Xlucane|Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
9724680|NCT03805100|Active Comparator|Lucentis|Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
9724681|NCT03801785|Experimental|Children induced to suck pacifiers.|Children will suck a pacifier of identical shape and type and will be allowed other NNS habits.
9724682|NCT03801785|No Intervention|Children induced to stop sucking.|Children will be induced by DDSs to stop sucking and their parents will be advised how to stop their children's NNS habits.
9724683|NCT03793465|Experimental|Tart Cherry Concentrate|Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Servings (1 ounce or 2 tablespoon/serving) per day for three days
9724684|NCT03784820|Experimental|UNITE|UNITE is a manualized cognitive-behavioral couple therapy (CBCT) intervention that engages the couple to address the core psychopathology of BED.
9724685|NCT03784820|Active Comparator|CBT-E|CBT-E is a trans-diagnostic cognitive behavioral individual therapy treatment for eating disorders. It has been shown to be effective in numerous controlled and open trials.
9724686|NCT03769532|Experimental|Pembrolizumab + Azacitidine|"Pembrolizumab (IMP): 200 mg i.v. (fixed dose) / Azacitidine (SOC): 75 mg/m2 s.c.~maximum duration of treatment: up to 24 weeks"
9724687|NCT03764098|Experimental|Guanfacine ER|Guanfacine extended release (6mg/day ER). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
9724688|NCT03764098|Placebo Comparator|Placebo|Administered orally twice a day at 8:00 AM and 8:00 PM Days 1-23, then orally once a day at 8:00 PM.
9724689|NCT03758651||Williams syndrome - Onsite participation|Individuals with Williams syndrome who will participate in the study at Massachusetts General Hospital (MGH)
9724690|NCT03758651||Williams syndrome - Convention participation|Individuals with Williams syndrome (WS) who will have a more limited evaluation at a convention focusing on WS, such as the WS Association convention.
9980909|NCT01396863|Active Comparator|First treatment HD|The patient will receive treatment with low flux hemodialysis during the first examination day. During the second examination day the patient will receive treatment with pre-dilution hemodiafiltration.
9980910|NCT01396876|Active Comparator|Clown|A clown is present during venipuncture
9980911|NCT01396876|No Intervention|No clown|
9980912|NCT01396889|Experimental|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months
10204886|NCT04596033|Experimental|Multiple Low Dose (MLD)|GEN-011 is administered by IV infusion at 4-week intervals, up to 5 doses maximum. Each dose is followed by IL-2 administration. MLD patients will not undergo lymphodepletion.
10204887|NCT04596033|Experimental|Single High Dose (SHD)|GEN-011 is administered as a single IV infusion at the maximum available cell yield, after the patient completes a fludarabine/cyclophosphamide lymphodepletion regimen. The single GEN-011 dose is followed by IL-2 administration.
10204888|NCT04595292||older adults, assessment|
9724691|NCT03758651||Williams syndrome - Remote participation|Individuals with Williams syndrome (WS) who will participate in the study remotely by filling out a questionnaire and providing information by mail.
9724692|NCT03758651||Healthy Controls|Healthy individuals without Williams syndrome who will participate in the study at the Massachusetts General Hospital
9980913|NCT01396889|Placebo Comparator|Placebo|Placebo
9980914|NCT01396902|Active Comparator|Standard of care|
10204889|NCT04591834||Observational|No Intervention
10204890|NCT04585256|Active Comparator|Trendelenburg|Women positioned in the trendelenburg position during external cephalic version.
10204891|NCT04585256|No Intervention|Control|Women positioned on their back during external cephalic version.
10204892|NCT04580225|Active Comparator|Group A: Partial Wrist Arthrodesis without Triquetral Excision|Four-Corner Arthrodesis
10204893|NCT04580225|Active Comparator|Group B: Partial Wrist Arthrodesis with Triquetral Excision|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision
10204894|NCT04571840|Active Comparator|mpMRI|Multiparametric MRI
10204895|NCT04571840|Experimental|bpMRI|Biparametric MRI
10204896|NCT04567186|Experimental|Test/Control/Control|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Test/Control/Control).
10204897|NCT04567186|Experimental|Control/Test/Test|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Control/Test/Test).
10204898|NCT04561102||COVID-19 asymptomatic population|COVID-19 asymptomatic Rollins College community
10204899|NCT04561089||COVID-19 asymptomatic population|COVID-19 asymptomatic Illumina personnel
9980915|NCT01396902|Experimental|Text Messaging|
9980916|NCT01396915||High or Normal Dietary Protein Intake|
10204900|NCT04559893|Experimental|Collaborative Care|Intervention is administered to patients in this arm. Care to be delivered via collaborative care.
9980917|NCT01396928||"J pouch"|"Anastomosis coloanal wiht j pouch reservoir"
9980918|NCT01396928||Transverse coloplasty pouch|Coloanal anastomosis with transverse coloplasty pouch reservoir
9724693|NCT03756259|Other|Pneumonia perception arm|Caregivers of children under five will be interviewed qualitatively to understand in depth on perception of pneumonia. These will be mothers, fathers and grandmothers of these children. Once the formative research is done, it will inform design of an intervention whereby the caregivers will be recruited to be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject. The LHWs will also be trained on pneumonia case finding which they will manage at their end and refer if required while doing daily field visits.
9724694|NCT03754257|Experimental|Experimental Electrical Stimulation|Experimental Electrical Stimulation for 40 minutos + conventional physiotherapy, during seven days.
9980919|NCT01396941|Experimental|sleep restriction|The investigators will compare the effects of sleep restriction vs. normal sleep in healthy volunteers, using a randomized crossover study design. Each subject will undergo a period of normal sleep and a period of sleep restriction, separated by a 1-month washout period. Subjects will be randomized to receive either sleep restriction first (later followed by normal sleep) or normal sleep first (later followed by sleep restriction).
9980920|NCT01396980||dialysis patients|dialysis patients, stabil, dialysis dependancy for more than 3 months, with adequate access
9980921|NCT01396993||iTOP|Patients undergoing immediate techniques for oncoplastic surgery (level I only parenchmyl rotation and breast undermining as well as level II using complex reduction plastics for nipple-areola-complex movings) and patients with mastectomy and immediate reconstruction
9980922|NCT01396993||BCT|patients undergoing conservative breast surgery
9980923|NCT01397006|Experimental|Pregabalin|
9980924|NCT01397006|Placebo Comparator|Placebo|
9980925|NCT01397019|Experimental|FOLFIRINOX|
9980926|NCT01397032|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
9980927|NCT01397032|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
9980928|NCT01397045|Active Comparator|Video-assisted lung segmentectomy|Patients undergoing VATS segmentectomy
9724695|NCT03754257|Sham Comparator|Sham Electrical Stimulation|Sham Electrical Stimulation for 40 minutes + conventional physiotherapy, during seven days.
9724696|NCT03739710|Experimental|Part 1: Participants receiving feladilimab and ipilimumab|
9724697|NCT03739710|Experimental|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448|
9724698|NCT03739710|Experimental|Part 1: Participants receiving dostarlimab plus GSK4428859A/EOS884448 plus GSK6097608|
9724699|NCT03739710|Active Comparator|Part 2: Participants receiving SoC: docetaxel|
9724700|NCT03739710|Experimental|Part 2: Participants receiving feladilimab and docetaxel|
10198086|NCT03973827|Experimental|Low dose|3 patients receiving low dose
10198087|NCT03973827|Experimental|Medium dose|3 patients receiving medium dose
10198088|NCT03973827|Experimental|High dose|3 patients receiving high dose
10198089|NCT03973827|No Intervention|Control|6 patients
9724701|NCT03733028|Experimental|Mobile Intervention for Reducing Anger (MIRA)|Participants in this arm will be provided with a device that has the MIRA application (app) and asked to use the app for a period of 4 weeks.
9724702|NCT03733028|Active Comparator|Mindfulness Intervention|Participants in this arm will be provided with a device that has the Mindfulness application (app) and asked to use the app for a period of 4 weeks.
9724703|NCT03713281|Experimental|Test Lens|Subjects between the ages 40 to 70 years of age and who are adapted contact lens wearers with astigmatism in both eyes will be assigned to the same Test Lens according to the lens wear schedule.
9724704|NCT03707405|Active Comparator|ROC-sit|Ride-On Cars with Sitting Posture (ROC-sit) The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary. The natural play session can be divided into two 20-to-25 sessions depending on the participant's condition. Training will concentrate on building the concept of casual-effect on the switch and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person) in public spaces (e.g., hallways, convenient stores, garden, museum) and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying motor skills for mobility and socialization in natural play session. All the programs will be discussed by the family, the treating therapist and the research team.
9724705|NCT03707405|Active Comparator|ROC-sit45 and stand25|Ride-On Cars with 45-min Sitting and 25-min Standing Postures (ROC-sit45 and stand25) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 45-minute driving with sitting posture and then transfers to the standing posture for driving 25 minutes.
9980929|NCT01397045|Other|Mini thoracotomy|Patients undergoing lung segmentectomy through a mini thoracotomy
9980930|NCT01397097|Experimental|Arm 1|
9980931|NCT01397097|Active Comparator|Arm 2|
9980932|NCT01397110|Active Comparator|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
9980933|NCT01397110|No Intervention|Control group without exercise training|"patients of the control group continue their sedentary lifestyle without given advice for exercise training.~The time before start of rehabilitation (three months) serves as control group. Afterwards patients take part in the training program as well."
9980934|NCT01397123|Experimental|Lifestyle counseling|
9984533|NCT03997968|Experimental|CYT-0851 and capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine on Days to 14 of each 21 day cycle
10198090|NCT03970811|Experimental|Immediate implants with immediate temporization|Immediate implants with simultaneous immediate placement of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
10198091|NCT03970811|Active Comparator|Immediate implants without temporization|Immediate implants without the use of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
9724706|NCT03707405|Active Comparator|ROC-sit25 and stand45|Ride-On Cars with 25-min Sitting and 45-min Standing Postures (ROC-sit25 and stand45) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 25-minute driving with sitting posture and then transfers to the standing posture for driving 45 minutes.
9724707|NCT03707405|Active Comparator|ROC-stand|Ride-On Cars with Standing Postures (ROC-stand) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute standing session can be divided into two 30-minute sessions with 10-minute break, depending on the child's condition with the standing posture.
9724708|NCT03695185|Experimental|ABBV-323|Participants administered with ABBV-323 dose A IV at Week 0 and ABBV-323 dose B for 12 Weeks. Participants who achieve clinical response may enter the maintenance period in which participants are administered with ABBV-323 dose B
9724709|NCT03684070|Experimental|Enhanced Walking|FitBit + Lifestyle counseling/education session(8 weeks) + WeChat motivational messages and peer interaction
9724710|NCT03684070|Active Comparator|Walking Only|FitBit + Lifestyle counseling/education session(8 weeks)
9724711|NCT03675711|Active Comparator|Midline Catheter|Pt. will receive midline catheters.
9724712|NCT03675711|Active Comparator|Standard Peripheral venous Catheter|Pt. will receive a standard Peripheral venous catheter
9724713|NCT03675386|Active Comparator|Control Group|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
9724714|NCT03675386|Experimental|Interventional Group|Patients in the interventional group will be given a Transitional Pain Service follow-up appointment at the following postoperative time points (2 to 6 visits for the first two months, and then 1 to 2 visits on a monthly basis until one year). At each visit, patients will meet with the clinical psychologist and chronic pain specialist. Patients in the intervention group will have access to the Manage My Pain (MMP) App. which allows people living with pain to quickly and easily track their pain and function on a daily basis on their smartphones or a browser on their desktop or mobile device. One-page clinical reports will capture the changes in patients' outcome data between clinical visits over the course in time.Clinic visits can be offered in person at the hospital or over telehealth (video conference) based on the patient's preference and clinician's judgment for telehealth suitability.
9724715|NCT03674944|Experimental|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|This program includes: 1) Dialectical Behavior Therapy (DBT) skills 2) Behavioral coaching 3) Emotional Focused Parent Training (EFPT) 4) Behavioral Weight Loss (BWL) skills.
9724716|NCT03674944|Active Comparator|Behavioral Weight Loss (BWL)|This program includes information about diet and physical activity education, in addition to parent management skills, and behavioral modification principles including: modeling, reinforcement, and operant conditioning.
9724717|NCT03665909|Experimental|Remote activity monitoring|"Receive the remote activity monitoring system (i.e., eNeighbor; see intervention description) over an 18-month period."
9724718|NCT03665909|No Intervention|Control|Control participants do not receive the remote activity monitoring intervention.
9724719|NCT03661645|Active Comparator|Methylprednisolone Treated Group|Subjects in this group will receive single intraoperative course of 10 mg IV dexamethasone & 6 day oral methylprednisolone taper that is 10 mg Intravenous IV dexamethasone and 6 day oral methylprednisolone taper course
10198092|NCT03969888|Experimental|Part 1: ABBV-3067 + Placebo|Participants will receive various dosing regimens for ABBV-3067 plus placebo ABBV-2222 taken orally depending on arm assignment.
10198093|NCT03969888|Experimental|Part 1: ABBV-3067 + ABBV-2222|Participants will receive fixed dose of ABBV-3067 plus various dosing regimens for ABBV-2222 taken orally depending on arm assignment.
10198094|NCT03969888|Placebo Comparator|Part 1 and Part 2: Placebo|Participants in Part 1 and Part 2 will receive placebo ABBV-3067 plus placebo ABBV-2222 taken orally.
10198095|NCT03969888|Experimental|Part 2: ABBV-3067 + ABBV-2222|Participants will receive various dosing regimens for ABBV-3067 plus a fixed dose of ABBV-2222 taken orally depending on arm assignment.
10198096|NCT03969121|Active Comparator|Placebo + Endocrine therapy|Endocrine therapy for 16 weeks plus placebo
10198097|NCT03969121|Active Comparator|Palbociclib + Endocrine therapy|Endocrine therapy for 16 weeks plus Palbociclib
10198098|NCT03966339|Experimental|GH group|Growth Hormone adding to controlled ovarian hyperstimulation
10198099|NCT03966339|No Intervention|control group|regular controlled ovarian hyperstimulation
10198100|NCT03963869|Experimental|Arm A: New Malaria Camp (MC) village|"Receives MC intervention in year 1 and year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
10198101|NCT03963869|Active Comparator|Arm B: No Malaria Camp (MC) village|"Receives Standard Malaria Control in Year 1 and MC intervention in Year 2.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
9724720|NCT03661645|Other|Control Group|Subjects in this group will receive single intraoperative dose of 10 mg IV dexamethasone; that is 10 mg Intravenous (IV) dexamethasone
10204901|NCT04559893|No Intervention|Control|Patients in this arm will receive enhanced usual care.
9724721|NCT03653169|Experimental|Open-Label Active TMS|All subjects will receive open-label treatment with active Transcranial Magnetic Stimulation (TMS)
9724722|NCT03647943|Experimental|Active tDCS|Participants will receive 10 sessions of active tDCS + cognitive training.
9724723|NCT03647943|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of sham tDCS + cognitive training.
9724724|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
9724725|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
9724726|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
9724727|NCT03591952|Active Comparator|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
9724728|NCT03591952|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
9724729|NCT03576313|Experimental|intervention: IVM and DP|Mass Drug Administration with ivermectin (IVM) and dihydroartemisinin-piperaquine (DP) will be given to participants in the intervention villages plus the NMCP standard malaria control intervention
9724730|NCT03576313|Active Comparator|control: standard malaria control intervetions|Participants in the control clusters will receive only standard malaria control interventions such as Artemether Lumefantrine, LLINs, IRS, SMC and IPTp as implemented by the National Malaria Control Program (NMCP) of the Gambia
9724731|NCT03565003|Experimental|JAB-3068 (SHP2 inhibitor)|JAB-3068 will be administered orally in the morning following a fast of approximately 6 hours before on PK collection. Patients will continue to fast for approximately 2 hours after the administration of JAB-3068. On non-PK days patients will fast approximately 2 hours before JAB-3068 and continue to fast for approximately 2 hours afterwards.
9724732|NCT03547908|Experimental|B/F/TAF|B/F/TAF + placebo to match DTG + placebo to match F/TDF
9724733|NCT03547908|Experimental|DTG+F/TDF|DTG + F/TDF + placebo to match B/F/TAF
9724734|NCT03533010|Active Comparator|Ca500mg + VitD800IU|Daily Supplementation with 500mg Calcium plus 800IU Vitamin D3
9724735|NCT03533010|Placebo Comparator|Placebo|Dietary Supplement: Placebo
9724736|NCT03523039|Experimental|Hemoadsorption|Hemoadsorption is performed using a CytoSorb® cartridge.
9724737|NCT03523039|No Intervention|Control|Post-cardiac arrest management will be conducted as per institutional protocols.
9724738|NCT03517813||Cohort 1|"Asymptomatic women at increased risk of breast cancer referred clinically for high risk screening breast MRI or women with newly diagnosed primary unilateral breast cancer referred for evaluation of extent of disease (EOD) in the index breast and screening of the contralateral breast.~All women enrolled on study will complete a clinical breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
9724739|NCT03517813||Cohort 2|"Women receiving MRI for any indication and for whom percutaneous biopsy with ultrasound or MRI guidance has been recommended.~All women enrolled on study will complete a standard breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
9724740|NCT03512275|Experimental|400mg cohort, no prior treatment with anti-TNF agent(s)|N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
9724741|NCT03512275|Experimental|400 mg cohort, prior treatment with anti-TNF agent(s)|N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
10198102|NCT03963869|Active Comparator|Arm C: Old Malaria Camp (MC) village|"Villages already in receipt of MCs prior to study initiation to study longer term effects.~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual)) in the 2 year time frame of phase 1."
10198103|NCT03963011|No Intervention|Arm A: AXR Only|Infants randomized to Arm A will obtain an abdominal x-ray (AXR) as per standard of care
10198104|NCT03963011|Active Comparator|Arm B: AXR + Bowel US|Infants randomized to Arm B will obtain an abdominal x-ray (AXR) as per standard of care and a bowel ultrasound (BUS) as the intervention
10198105|NCT03959319|Experimental|Movement Pattern Training|Focus will be on task-specific training to improve lower extremity movement patterns during basic daily tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Tasks will be prioritized based on patient-report of activity limitations during the baseline examination. For example, during the first visit, the treating physical therapist will begin with the daily and patient-specific tasks that the patient reported as being most bothersome. Exercises will include repeated practice of functional tasks using optimized movement patterns. Based on the participant's performance, the difficulty of the task-specific activities will be progressed by varying the repetitions performed, increasing the load or changing the support surface. The home program will consist of repeated practice of tasks performed during the supervised sessions.
10198106|NCT03959319|Active Comparator|Manual Therapy (Joint Mobilization)|Focus will be on reducing pain and improving pain-free range of motion using manual techniques provided by the physical therapist and exercise performed in the home program. Patient education will include instruction to the benefits of manual therapy and the proposed effects on pain and joint mobility. Joint mobilizations to be used with each patient will be prioritized based on the restrictions, defined as stiffness or pain that is limiting joint range of motion, noted on the patient's baseline examination. For example, during the first visit, the treating physical therapist will begin with the two most restricted motions noted in the baseline exam and perform a standard assessment to determine treatment parameters. The home program will include joint range of motion and stretching exercises to complement techniques performed during the supervised sessions.
10198107|NCT03955627|No Intervention|Enhanced Standard Care|Participants will receive standard care, plus a brochure about hormonal therapy use.
10198108|NCT03955627|Experimental|Treatment (Education plus Exercise)|Participants will receive the same materials as the standard care group, plus participate in group exercise and group discussion sessions.
10198109|NCT03954015|Other|patients over age 30 with suspicious BIRADS 4/5 Lesions|Patients who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with CEDM, CEMR and CEUS.
10198110|NCT03952429|Active Comparator|Active Cognitive Bias App|Participants will receive the Anti-Alcohol App with the Active Cognitive Bias modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
9724742|NCT03486912|Experimental|BMS-986036 Dose Level 1|
9980935|NCT01397149|Experimental|Eltrombopag|In phase II, patients will be randomized (2:1 eltrombopag : placebo) to receive either eltrombopag or placebo to explore the efficacy and confirm the safety of the identified eltrombopag dose from Phase I.
9980936|NCT01397149|Placebo Comparator|Film coated tablet|
10198111|NCT03952429|Placebo Comparator|Inactive Cognitive Bias Modification|Participants will receive the Anti-Alcohol App with the Inactive Cognitive Bias Modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
10198112|NCT03948022|Active Comparator|intramuscular progesterone|progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.
9724743|NCT03486912|Experimental|BMS-986036 Dose Level 2|
9724744|NCT03486912|Experimental|BMS-986036 Dose Level 3|
10198113|NCT03948022|Active Comparator|vaginal progesterone|crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.
9724745|NCT03486912|Placebo Comparator|Placebo|
9724746|NCT03485729|Experimental|Biopsy-mandated|
9724747|NCT03485729|Experimental|Biopsy-optional|
9724748|NCT03485729|Experimental|Dosing twice per week on two consecutive days|
9724749|NCT03475043|Experimental|Auditory training: temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in a temporal (timing/duration) cue for 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear sentences that vary in speech rate for 6, 1-hour training sessions and will receive correct-answer feedback."
10198114|NCT03948022|Experimental|oral dydrogesterone|oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)
10198115|NCT03946111|Experimental|Naltrexone/Bupropion|
10198116|NCT03946111|Placebo Comparator|Placebo|
10198117|NCT03945422|Experimental|Treatment Arm|Subject will receive AccuTite/FaceTite and Morpheus8 treatment
10198118|NCT03943758|Experimental|prepackaged Low-residue diet group|The prepackaged Low-residue diet (Maifu Nutrition Technology Co. Ltd, Beijing, China). One package of the prepackaged Low-residue diet contained quantity of heat amounts to 268 kilocalories with 12.0 g of protein, 9.6 g of lipid, and 34.1 g of carbohydrate.
10198119|NCT03943758|Active Comparator|self-prepared Low-residue group|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy
10198120|NCT03939533|Experimental|Increased Volume Cohort - Cohort 1|Increased volume at each infusion site - patients will receive CUTAQUIG weekly and increase infusion volumes every 4 weeks
9724750|NCT03475043|Active Comparator|Auditory training: non-temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in either stimulus intensity or stimulus frequency during 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear speech in varying levels of noise during 6, 1-hour training sessions and will receive correct-answer feedback."
9724751|NCT03475043|No Intervention|Passive control group (Aims 1 and 2)|Listeners will be evaluated on pre-training and post-training tests, but will receive no training at all.
9724752|NCT03468660|Experimental|Experimental group|Auditory training with feedback
9724753|NCT03468660|No Intervention|Passive control group|Pre-post testing only; no training
9724754|NCT03468660|Active Comparator|Active Control group|Listening task with no feeback
10198121|NCT03939533|Experimental|Increased Infusion Rate Cohort - Cohort 2|Increased infusion rate - patients will receive CUTAQUIG weekly and increase infusion rates every 4 weeks
10198122|NCT03939533|Experimental|Every Other Week Dosing Cohort - Cohort 3|Every other week dosing - patients will receive CUTAQUIG every other week at the equivalent of twice their body-weight dependent [mg/kg] weekly dose
9724755|NCT03465449|Active Comparator|usual care|
9724756|NCT03465449|Experimental|CKD-EDU arm|
9724757|NCT03449511|Active Comparator|Ginger aromatherapy|Ginger essential oil (GIN-106) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
9724758|NCT03449511|Active Comparator|Orange aromatherpy|Orange essential oil (ORG-114) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
9724759|NCT03449511|Active Comparator|Lavender aromatherapy|Lavender essential oil (LAV-110) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
9724760|NCT03449511|Placebo Comparator|Jojoba aromatherapy|"Jojoba oil in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles. One drop of jojoba oil is on the other three aromatherapy inhalers. Jojoba oil is a carreir oil for essential oils which will be used as a comparator and placebo in this study."
9724761|NCT03436238||MINSS cohort|"Adult patients >= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital.~Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com)."
9980937|NCT01397175|Active Comparator|Biolimus-eluting stent|Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
9980938|NCT01397175|Active Comparator|Everolimus-eluting stent|Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
10198123|NCT03937596|Experimental|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
9980939|NCT01397175|Active Comparator|Zotarolimus-eluting stent|Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA
9980940|NCT01397188|Experimental|PiCCO group|Intervention: Device: Picco- thermodilution catheter
9980941|NCT01397188|Sham Comparator|sham group|No PiCCO Intervention
9980942|NCT01397214|Experimental|Megace F|Megace F oral suspension
9980943|NCT01397214|Active Comparator|Megace OS|Megace acetate oral suspension
9980944|NCT01397240|Experimental|Albis|Drug: Albis Tab 2 tab, twice a day
9980945|NCT01397240|Placebo Comparator|Placebo|Placebo 2 tab, twice a day
10198124|NCT03937596|Placebo Comparator|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
9724762|NCT03435354|Experimental|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
9724763|NCT03435354|No Intervention|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
9724764|NCT03435003|Experimental|Intervention Arm|"A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.~B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
9724765|NCT03435003|Active Comparator|Control Arm|"A) Pre-operatively: No intervention~B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
9724766|NCT03434769|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
9724767|NCT03414983|Experimental|Arm A|Nivo + SOC
9724768|NCT03414983|Active Comparator|Arm B|SOC
9724769|NCT03397251|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
9724770|NCT03393013|Experimental|KZR-616 60 mg + standard therapy (Phase 2)|60 mg dose level of KZR-616 selected based on data from the Phase 1 dose escalation and administered to patients with active Lupus Nephritis in combination with standard therapy.
9724771|NCT03393013|Experimental|KZR-616 45 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and complete.
9724772|NCT03393013|Experimental|KZR-616 60 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and complete.
10198125|NCT03936465|Experimental|Arm 1 Cohort A|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.~Patients with unselected relapsed or refractory solid tumors or lymphoma"
10198126|NCT03936465|Experimental|Arm 1 Cohort B|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.~Patients with relapsed or refractory solid tumors or lymphoma that have defined molecular features predicted to increase sensitivity to BET inhibition"
9724773|NCT03393013|Experimental|KZR-616 75 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and complete.
9724774|NCT03383692|Experimental|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
9724775|NCT03383692|Experimental|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 followed by 200 mg daily (QD) until Day 21 of Cycle 3
9724776|NCT03378128|Experimental|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
9724777|NCT03377361|Experimental|Part 1 Cohort 1 3rd Line (3L): nivolumab + trametinib|
9724778|NCT03377361|Experimental|Part 1A Cohort 2 2nd Line (2L): nivolumab + ipilimumab + trametinib|
9724779|NCT03377361|Experimental|Part 1A Cohort 3 (2L): nivolumab + ipilimumab + trametinib|
9724780|NCT03377361|Experimental|Part 2 Cohort 4 (3L): nivolumab + ipilimumab + trametinib|
9724781|NCT03377361|Experimental|Part 2 Cohort 5 (3L): Regorafenib|
10198127|NCT03936465|Experimental|Arm 2 Cohort A|"Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.~Patients with relapsed or refractory CNS tumors or CNS metastatic tumors"
10198128|NCT03936465|Experimental|Arm 2 Cohort B|"Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.~Patients with relapsed or refractory CNS tumors or CNS metastatic tumors that have defined molecular features predicted to increase sensitivity to BET inhibition"
10198129|NCT03928158|Experimental|LCZ 696|Initial dose - 50 mg twice daily, up-titration to 200 mg twice daily. Patients will also receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
9724782|NCT03377361|Experimental|Part 1B Cohort 6 (2L): nivolumab + ipilimumab + trametinib|
9724783|NCT03371251|Experimental|Phase 1b: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
9724784|NCT03371251|Placebo Comparator|Phase 1b: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
9785803|NCT01260350|Experimental|Group 10: SOF+RBV 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.
10198130|NCT03928158|Active Comparator|Valsatran|Initial dose - 40 mg twice daily, up-titration to 160 mg twice daily. Patients also will receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
10198131|NCT03928080||Experimental cohort|Primary study to assess diagnostic accuracy
9724785|NCT03371251|Experimental|Phase 2: BOS161721|Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
9724786|NCT03371251|Placebo Comparator|Phase 2: Placebo|Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
9980946|NCT01397266|Active Comparator|Active TMS|active rTMS delivered to the left dorsolateral prefrontal cortex
9980947|NCT01397266|Placebo Comparator|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
9984534|NCT03997786|Active Comparator|Part A|Part A is a DOSE FINDING COMPONENT: OPEN LABEL PK lead-in and safety component
9984535|NCT03997786|Experimental|Part B Part 1: Placebo and active comparator controlled study|
9984536|NCT03997786|Experimental|Part B-1 and B-2: Randomized withdrawal and retreatment after relapse|
9984537|NCT03997786|No Intervention|Part B 3: Efficacy and Safety Follow-up|
9984538|NCT03997786|Experimental|Part C: LTE|
9984539|NCT03997526||3C Patch treatment|Medicare beneficiaries with diabetes and hard-to-heal non-healing ulcers of the foot will receive usual care (i.e., care consistent with the IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes) supplemented by the application of the 3C Patch (A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process)
9984540|NCT03995589|Experimental|Walking Group|
9984541|NCT03995589|Active Comparator|Control|
10198132|NCT03928080||Confirmation cohort|Second cohort to confirm results from the first study on independent population
9724798|NCT03359434|Experimental|Two measuring methods of blood pressure|
9724799|NCT03349268|Active Comparator|Pulsed xenon ultraviolet light (PX-UV) Device Emitting Germicidal UV|Pulsed xenon ultraviolet light (PX-UV) Device to be used to disinfect rooms following post-discharge terminal cleaning
10198133|NCT03926052|Active Comparator|LDX|
10198134|NCT03926052|Placebo Comparator|Placebo|
10198135|NCT03924193|Active Comparator|LDX|
10198136|NCT03924193|Active Comparator|Cognitive-Behavioral Therapy|
10198137|NCT03924193|Active Comparator|LDX and Cognitive Behavioral Therapy|
10198138|NCT03922880|Experimental|Advanced Uveal Melanoma|
10198139|NCT03921281|Experimental|treatment group|The treatment group (n=38) will receive scalp acupuncture combined with rehabilitation treatment for 3 times per week for 12 weeks.
9724800|NCT03349268|Sham Comparator|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
9724801|NCT03321656|Active Comparator|Tacrolimus|0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally
10198140|NCT03921281|Other|control group|The control group (n=38) will receive rehabilitation treatment for 3 times per week for 12 weeks.
10198141|NCT03920722|Experimental|Rituximab|Experimental regimen: One year Glucocorticoid treatment and Rituximab IV 1 gram on Day 1 and 15
9724802|NCT03321656|Experimental|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
9724803|NCT03307785|Experimental|Part A: TSR-042 and niraparib 200 mg QD|Patients will receive TSR-042 500 milligram (mg), intravenous (IV) infusion on Day 1 of every cycle (every 3 weeks [Q3W]) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (every 6 weeks [Q6W]) beginning on Day 1 of Cycle 5 along with niraparib 200 mg, once daily (QD), orally on Days 1 to 21 repeated Q3W.
10198142|NCT03920722|Placebo Comparator|Rituximab-Placebo|Standard regimen: One-year Glucocorticoid treatment and Placebo-Rituximab IV on Day 1 and 15
10198143|NCT03907943|Other|Surgical treatment of carotid endarterectomy|The change in the cognitive function will be assessed in all patient undergoing carotid endarterectomy.
10198144|NCT03902314|Active Comparator|Lidocaine|Lidocaine infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
10198145|NCT03902314|Placebo Comparator|Saline|Saline infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
10198146|NCT03902080|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 24 weeks.
10198147|NCT03902080|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 24 weeks.
10198148|NCT03900832|Placebo Comparator|PAD without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
10198149|NCT03900832|Experimental|PAD warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
10204902|NCT04554212|Active Comparator|Standard Physical Therapy with Sham BFRT|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
9724804|NCT03307785|Experimental|Part A: TSR-042 and niraparib 300 mg QD|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg, QD, orally on Days 1 to 21 repeated Q3W.
9785804|NCT01260350|Experimental|Group 11: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.
10198150|NCT03900832|Placebo Comparator|PAD neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
10198151|NCT03900832|Experimental|PAD heating suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
9724805|NCT03307785|Experimental|Part B: TSR-042 and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 milligram per square meter (mg/m^2), IV infusion on Day 1 Q3W administered for 4 to 6 cycles.
9724806|NCT03307785|Experimental|Part C: TSR-042, niraparib 200 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 200 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kilogram (kg), IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
9724807|NCT03307785|Experimental|Part C: TSR-042, niraparib 300 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
9724808|NCT03307785|Experimental|Part D: TSR-042, carboplatin-paclitaxel and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W administered for 4 to 6 cycles; and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
10198152|NCT03900832|Experimental|PAD lower limb warm water immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
10198153|NCT03900832|Placebo Comparator|Healthy subjects without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
9724809|NCT03307785|Experimental|Part E: TSR-042 and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation) administered for 6 cycles (each cycle is 21 days).
10198154|NCT03900832|Experimental|Healthy subjects warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
9724810|NCT03307785|Experimental|Part F: TSR-042, TSR-022, and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); and TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W administered for 5 cycles (each cycle is 21 days); and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation).
9724811|NCT03307785|Experimental|Part G: TSR-042 and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (every week [Q1W]) of every 3 week cycle for 4 to 6 cycles.
9980948|NCT01397279|Active Comparator|Botnia clamp|hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
9980949|NCT01397279|Active Comparator|hyperinsulinemic euglycemic clamp|hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
9980950|NCT01397305|Experimental|Modufolin and Pemetrexed|Modufolin ( [6R] 5,10-methylenetetrahydrofolate) and Pemetrexed
9980951|NCT01397318||Experimental Group|
9980952|NCT01397318||Control Group|
9980953|NCT01397331|Active Comparator|Inhalational anesthesia|Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
9980954|NCT01397331|Active Comparator|TIVA|Group of patients undergoing the surgery under total intravenous anesthesia
10198155|NCT03900832|Placebo Comparator|Healthy subjects neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
10198156|NCT03900832|Experimental|Healthy subjects heat suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
10198157|NCT03900832|Experimental|Healthy subjects lower limb immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
10198158|NCT03900715|Experimental|Luspatercept Administration|Luspatercept will be administered as a subcutaneous injection every 3 week (21 days; Q3W), at an initial dose level of 1.0 mg/kg. Doses may be titrated up starting at dosing visit Week 7 Day 1 (W7D1)
9724812|NCT03307785|Experimental|Part H: TSR-042, TSR-022, and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (Q1W) of every 3 week cycle for 4 to 6 cycles.
9980955|NCT01397357||suspected Myocardial Ischemia|Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.
9724813|NCT03307785|Experimental|Part I: TSR-042, TSR-022, and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days).
10198159|NCT03899467|Experimental|Arm 1: biological dose group|"400mg/day of proxalutamide~Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
10198160|NCT03899467|Experimental|Arm 2: MTD dose group|"500mg/day of proxalutamide~Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
9724814|NCT03300804|Active Comparator|20-herb formulation|Active herb
9724815|NCT03300804|Placebo Comparator|Placebo|Placebo herb formulation
9724816|NCT03287414|Experimental|VAY736|VAY736 administered subcutaneously (s.c.) every 4 weeks
9980956|NCT01397370|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 14 days, starting from 5 mg/day
9980957|NCT01397370|Placebo Comparator|Placebo oral solution|Once daily dosing for 14 days
9980958|NCT01397383||Vitamin D deficiency|Patients with low serum vitamin D (25-hydroxy vitamin D < 32 ng/ml)
9980959|NCT01397383||Control group|Patients with normal serum vitamin D level (serum 25-hydroxy vitamin D > 32 ng/ml)
9980960|NCT01397396|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
9724817|NCT03287414|Placebo Comparator|Placebo|Placebo administered subcutaneously (s.c.) every 4 weeks
9724818|NCT03284242|Experimental|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
9724819|NCT03277638|Experimental|Pembrolizumab injections 7 days before surgery|Patients will have intravenous pembrolizumab 7 days before surgery with Laser Interstitial Thermotherapy
9724820|NCT03277638|Experimental|Pembrolizumab injections 14 days after surgery|Patients will have intravenous pembrolizumab 14 days after surgery with Laser Interstitial Thermotherapy
9980961|NCT01397396|Placebo Comparator|Sham IMT|Sham Inspiratory Muscle Training
10198161|NCT03898037|Experimental|lifestyle intervention group|"Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up."
9724821|NCT03277638|Experimental|Pembrolizumab injections 35 days after surgery|Patients will have intravenous pembrolizumab 35 days after surgery with Laser Interstitial Thermotherapy
9780743|NCT01130168|Experimental|ISMN ER/Placebo/Amlodipine (Sequence 4)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
9780744|NCT01130168|Experimental|Placebo/Amlodipine/ISMN ER (Sequence 5)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
9780745|NCT01130168|Experimental|Amlodipine/ISMN ER/Placebo (Sequence 6)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.
9780746|NCT01130272|Experimental|Eluxadoline 5 mg|Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks.
9780747|NCT01130272|Experimental|Eluxadoline 25 mg|Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
9780748|NCT01130272|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks.
9780749|NCT01130272|Experimental|Eluxadoline 200 mg|Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks.
9780750|NCT01130272|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks.
9780751|NCT01130337|Experimental|1|
9780752|NCT01130493|Other|IPX066-CLE-OLE|Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)
9780753|NCT01130493|Other|CLE-IPX066-OLE|Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)
9980962|NCT01397435||Gaucher|We will enroll 15 children who have a confirmed diagnosis of Gaucher disease.
9980963|NCT01397435||Healthy volunteers|We will enroll 15 age and gender matched controls.
9984542|NCT03994874|Experimental|PolyCore PUF|PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.
9984543|NCT03994874|Active Comparator|Control|Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.
9984544|NCT03983382||HER2-Positive Breast Cancer|
9724822|NCT03261323|Active Comparator|Immediate breast reconstruction|The surgical schedule will follow unaltered standard protocol for immediate reconstruction right after the patient's mastectomy. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and at different time points during the follow up. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
9724823|NCT03261323|Experimental|Delayed breast reconstruction|Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
9724824|NCT03250013|Experimental|Children and adolescents with ADHD|Children and adolescents medicating for ADHD of any subtype (presentation) with comorbidities
10198162|NCT03898037|Experimental|metformin intervention group|"Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.~The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
10198163|NCT03898037|Experimental|lifestyle combined with metformin intervention group|"Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
9724825|NCT03182166|Experimental|Patients treated with golimumab|"The optimization procedure is:~For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.~For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
10198164|NCT03898037|No Intervention|routine clinical education group|Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.
10198165|NCT03894501|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
9724826|NCT03161028|Experimental|Arm 1: Lipoic Acid|59 subjects receive oral lipoic acid 1200mg daily
9724827|NCT03161028|Placebo Comparator|Arm 2: Placebo|59 subjects receive placebo daily
9724828|NCT03130777|Experimental|TPVR - Main Cohort|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.
9724829|NCT03130777|Experimental|TPVR - PDS Registry|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).
9980964|NCT01397474|No Intervention|Control|The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume > 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
9984545|NCT03983343|No Intervention|control group|Standard technique: Suturing the perineal skin with fast-absorbable running sutures (Vicryl Rapide 3-0).
9984546|NCT03983343|Active Comparator|intervention group|Closing the perineal skin using adhesive glue- exofin® (Octyl-2-cyanoacrylate)
9724830|NCT03107403|Experimental|Healthy subjects|
10198166|NCT03894501|Other|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
9724831|NCT03090737|Experimental|Nivolumab|Specified Dose on Specified Days
9724832|NCT03088826|Active Comparator|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
9724833|NCT03088826|Active Comparator|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
9724834|NCT03054909|Experimental|Arm 1: ALT-803 subcutaneous only|
9724835|NCT03054909|Experimental|Arm 2: ALT-803 intraperitoneal and subcutaneous|
10198167|NCT03893799|Experimental|Cohort 1, Healthy Volunteers|Dose A, single dose
10198168|NCT03893799|Experimental|Cohort 2, Healthy Volunteers|Dose B, single dose
10198169|NCT03893799|Experimental|Cohort 3, Healthy Volunteers|Dose C, single dose
10198170|NCT03893799|Experimental|Cohort 4, Subjects with CKD Stage 3|Dose D, single dose
10198171|NCT03893799|Experimental|Cohort 5, Subjects with CKD Stage 3|Dose E, single dose
10198172|NCT03893799|Experimental|Cohort 6, Subjects with CKD Stage 4|Dose F, single dose
9724836|NCT03043872|Experimental|Arm 1|durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
9724837|NCT03043872|Experimental|Arm 2|durvalumab+EP (carboplatin or cisplatin + etoposide)
10198173|NCT03893799|Experimental|Cohort 7, Subjects with CKD Stage 4|Dose G, single dose
10198174|NCT03893799|Experimental|Cohort 8, Subjects with CKD Stage 3 or 4|Dose H, single dose
9724838|NCT03043872|Active Comparator|Arm 3|EP (carboplatin or cisplatin + etoposide)
10198175|NCT03893799|Experimental|Cohort 9, Subjects with CKD Stage 3 or 4|Dose I, single dose
10198176|NCT03885245|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
9724839|NCT03035643|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
9724840|NCT03034018|Experimental|suvorexant|suvorexant 10-20 mg taken at bedtime for four weeks
9724841|NCT03034018|Placebo Comparator|placebo|placebo taken at bedtime for four weeks
10198177|NCT03885245|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
10198178|NCT03879538|Active Comparator|The nitrous oxide group|Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
10198179|NCT03879538|Placebo Comparator|The Control Group|Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
10198180|NCT03874325|Experimental|Safety Run In: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
9724842|NCT03024437|Experimental|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
9724843|NCT03024437|Experimental|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
9724844|NCT03024437|Experimental|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 or PDL1 inhibitor.~Patients in Cohort B will be treated with the same combination therapy as in Cohort A."
9724845|NCT03023696|Experimental|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
9724846|NCT03023696|Active Comparator|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
9724847|NCT03021460|Experimental|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10198181|NCT03874325|Experimental|Expansion: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
10198182|NCT03873038|Experimental|Part 1, Panel A: MK-2060 (8 mg)|Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.
10198183|NCT03873038|Experimental|Part 1, Panel B: MK-2060 (20 mg)|Participants will receive a single 20-mg dose of MK-2060 via IV infusion.
9724848|NCT03016169|Other|Treatment|All subjects will receive the Trifecta GT valve
9724849|NCT03000855|Active Comparator|ECDS|EUS-guided choledocho-duodenostomy
9724850|NCT03000855|Active Comparator|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
9724851|NCT02989402|Experimental|Rivastigmine patch|15 cm2 patch sizes loaded with 27 mg of rivastigmine
9724852|NCT02986048||Proton Beam Therapy|All patients treated with proton beam therapy at the UH Proton Therapy Center who consent to have their health information recorded, including whether the cancer was cured and if any complications occur ed due to treatment
9724853|NCT02974036||Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
9724854|NCT02940080|Experimental|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
9724855|NCT02940080|Experimental|Yellow potato|350 g of steam-cooked mashed potatoes in water
9724856|NCT02915939|Experimental|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
9724857|NCT02915939|No Intervention|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
9724858|NCT02908750|Experimental|osimertinib and fexofenadine|Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
10198184|NCT03873038|Experimental|Part 1, Panel C: MK-2060 (40 mg)|Participants will receive a single 40-mg dose of MK-2060 via IV infusion.
10198185|NCT03873038|Experimental|Part 2: MK-2060 (25 mg)|Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 3 weeks (Weeks 2-4).
10198186|NCT03873038|Placebo Comparator|Part 1 (Panels A, B, C) and Part 2: Placebo|Part 1: Participants will receive a single dose of placebo via IV infusion. Part 2: Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via infusion weekly for 3 weeks (Weeks 2-4).
10198187|NCT03872999|Experimental|Attentional Control|Visuo-spatial attentional tasks with simple stimuli during functional magnetic resonance imaging (fMRI) scanning.
10198188|NCT03853317|Experimental|Treatment with avelumab, haNK™ and N-803|The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on Blinded Independent Central Review (BICR).
10198189|NCT03847402|Experimental|GDD intervention|The early integrated intervention for GDD
10198190|NCT03847402|Active Comparator|GDD non-intervention|Community intervention for GDD
10198191|NCT03847402|Experimental|ASD intervention|The early integrated intervention for ASD
10198192|NCT03847402|Active Comparator|ASD non-intervention|Community intervention for ASD
10198193|NCT03847402|Experimental|ADHD intervention|The early integrated intervention for ADHD
10198194|NCT03847402|Active Comparator|ADHD non-intervention|Community intervention for ADHD
10198195|NCT03845985|Experimental|Seeking Safety + Signs of Safety toolkit|Participants randomized to receive the intervention will be provided 12 one-hour weekly individual treatment sessions with one of four ASL-fluent study clinicians in Massachusetts. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
10198196|NCT03845985|No Intervention|Assessment-only Waitlist Control|Participants randomized to the waitlist control condition will be offered the opportunity to receive the 12-session Seeking Safety + Signs of Safety toolkit intervention after an approximate 16 week waiting period. This 16 week waiting period is equivalent to the current waitlist to receive psychotherapy services through the PI's outpatient clinic. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
10198197|NCT03840486|Active Comparator|Non-rebreather mask (NRBM)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-rebreather mask (NRBM) overlying the sensor. The participants will be randomized to the order of their treatment sequence as follows: oxygen at 15 LPM for 3 minutes, at 35 LPM for 3 minutes, or at flush rate (55 LPM) for 3 minutes. The maximal reading at the end of this will be recorded, then the study subjects will be allowed to rest until their EtO2 returns to their baseline. They will then be placed back on NRBM at flush rate, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
10198198|NCT03840486|Active Comparator|Non-invasive ventilator mask (NIV)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-invasive ventilator mask (NIV) overlying the sensor. Participants will be randomized to the order of their treatment sequence as follows: NIV at 50% FiO2 for 3 minutes, NIV at 75% FiO2 for 3 minutes, NIV at 100% FiO2 for 3 minutes, the maximal reading at the end of this trial will be recorded. The study subjects will be allowed to rest until their EtO2 returns to their baseline, then they will be placed back on NIV at 100% FiO2, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
9724859|NCT02893787||Patients treated with anthracyclines in childhood|
9724860|NCT02893787||Healthy volunteers|
9724861|NCT02892123|Experimental|ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy|
9724862|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia~Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.~Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
9724863|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.~Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.~Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.~Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
9724864|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:~Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.~After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.~Ocular and systemic health data will be extracted from the study participant's medical record."
9724865|NCT02843191|Active Comparator|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
9724866|NCT02843191|Experimental|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
9724867|NCT02819596|Experimental|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
10198199|NCT03837184|Experimental|Onasemnogene Abeparvovec-xioi|Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously.
10198200|NCT03834688|Experimental|Induction|Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
9724868|NCT02819596|Experimental|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
10198201|NCT03833934||Plasma Next Generation Sequencing (NGS)|Subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent directly by the subjects to the central laboratory (Resolution Bioscience) for plasma NGS. Plasma NGS results will be returned to the subject, their treating physician and study team, aiming to return results within 2 weeks by Resolution Bioscience.
10198202|NCT03833128|Experimental|Group 1 - Part A|REN001 Low Dose oral once daily x 12 weeks
10198203|NCT03833128|Experimental|Group 2 - Part A|REN001 High Dose oral once daily x 12 weeks
10198204|NCT03833128|Experimental|Group 3 - Part B|REN001 High Dose oral once daily x 12 weeks
10198205|NCT03831165|Experimental|melatonin 3mg + Acyclovir 400mg|Group I - melatonin 3mg + Acyclovir 400mg
10198206|NCT03831165|Active Comparator|Acyclovir 400mg|Group II - Acyclovir 400mg twice a day
10198207|NCT03831165|Placebo Comparator|placebo + melatonin 3mg|Group III - placebo + melatonin 3mg
10198208|NCT03830723|Other|Rekovelle (Follitropin delta)|All participants will receive a prescription for study medication Rekovelle (follitropin delta)
10198209|NCT03829007|Experimental|PD-L1 imaging|89Zr-durvalumab iv injection followed by a PET/CT scan at day 5 after injection.
10198210|NCT03828786|Active Comparator|Endometrial scratching group|Endometrial scratching will be done with a Pipelle in uterus.
10198211|NCT03828786|No Intervention|Control group|This group will proceed with intrauterine insemination without endometrial scratching according to clinic's standard procedure
10198212|NCT03826056|Active Comparator|Current standard education group|A study team member will use the current hospital standard educational material to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
10198213|NCT03826056|Experimental|New personalized education group|A study team member will use the new personalized educational materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
10198214|NCT03825172||Group I|Caudal Epidural Ultrasonography will be performed in patients aged between 1-24 months
10198215|NCT03825172||Group II|Caudal Epidural Ultrasonography will be performed in patients aged between 25-48 months
10198216|NCT03825172||Group III|Caudal Epidural Ultrasonography will be performed in patients aged between 49-84 months
10198217|NCT03821688|Experimental|SAS-JB|laparoscopic single anastomosis sleeve jejunal bypass
10198218|NCT03821688|Active Comparator|MGB|laparoscopic mini gastric bypass
10198219|NCT03821688|Active Comparator|LSG|laparoscopic sleeve gastrectomy
10198220|NCT03820947|Experimental|VenaSeal™ Closure System|CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping
10198221|NCT03820947|Active Comparator|Endothermal Ablation (ETA)|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA
9724869|NCT02819596|Experimental|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
9724870|NCT02819596|Experimental|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
9724871|NCT02778165|No Intervention|Usual Care|Patients receiving usual care are typically referred to CR at the time of discharge from the acute care center via paper or electronic systematic referral (completed by a physician or nurse practitioner). Additionally, a conversation with the patient regarding CR by a healthcare provider may occur, however this communication is not always a consistent occurrence. Once referred, patients will await contact from a CR program in their region/area and if actual program enrollment occurs, this usually happens between 8 to 10 weeks post discharge.
9980965|NCT01397474|Experimental|PPTFM|"The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a bad peripheral perfusion (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2."
9980966|NCT05269316|Experimental|IMP9064 Monotherapy|Dose-escalation IMP9064 administered orally on empty stomach once/twice daily
9980967|NCT05269303|Experimental|Intervention group|Participants will receive a 3-month Live With Wearable Monitoring Device program.
9980968|NCT05269303|No Intervention|Control group|Usual care. As with the participants in the intervention group, those in the control group can utilize the features in the Wearable Monitoring Device.
9980969|NCT05269290|Experimental|Ingavirin®, syrup, 30 mg/5 ml|Ingavirin®, syrup, 30 mg/5 ml will be administered on top of standard therapy
9980970|NCT05269290|Placebo Comparator|Placebo|Placebo will be administered on top of standard therapy
9980971|NCT05269251||Axillary Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
9724872|NCT02778165|Experimental|MyCaRe Android Application|The MyCaRe mobile application (education and symptom monitoring which includes pain, mood scales, wound monitoring) and Fitbit accelerometer (steps walked, distance) will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit Inspire 2 before leaving hospital. They will be asked to input data (pain, mood, wounds, activity, blood sugar, blood pressure) daily if possible in first 2 weeks and once weekly thereafter until 6 to 8 weeks or until entry to a cardiac rehabilitation program.
10198222|NCT03820947|Active Comparator|Surgical Stripping|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)
10198223|NCT03820947|Other|VenaSeal™ Closure System VLU Study|CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System
9724873|NCT02750215|Experimental|Capmatinib (INC280)|"Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib.~After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles"
10198224|NCT03811535|Experimental|Somapacitan weekly|Participants will receive somapacitan weekly for 52 weeks (main trial period). Participants completing the main trial period in both the treatment arms ('Somapacitan weekly' and 'Norditropin® daily') will receive somapacitan weekly for 3 years (extension trial period).
10198225|NCT03811535|Active Comparator|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks (main trial period).
10198226|NCT03808922|Experimental|Cohort 1 and Cohort 2 Treatment|DAS181 4.5mg qd x 7 OR 10 days
10198227|NCT03808922|Placebo Comparator|Cohort 1 and Cohort 2 Placebo|Placebo qd x 7 OR 10 days
9724874|NCT02747498|Active Comparator|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
9724875|NCT02747498|Experimental|Posterior box isolation in addiction to pulmonary vein isolation|Posterior box isolation in addiction to circumferential pulmonary vein isolation
9724876|NCT02673333|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
10198228|NCT03808922|Experimental|Cohort 3|DAS181 4.5mg qd x 7 OR 10 days (≥ 40 kg) DAS181 2.5mg qd x 7 OR 10 days (< 40kg)
10198229|NCT03808922|Experimental|Cohort 4|DAS181 4.5mg qd x 7 OR 10 days
10198230|NCT03808922|Experimental|DAS181 COVID-19 Treatment|DAS181 4.5mg q12h x 7 OR 10 days
10198231|NCT03808922|Placebo Comparator|DAS181 COVID-19 Placebo|Placebo q12h x 7 OR 10 days
10198232|NCT03806166|Experimental|Shorter Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by one week or less of systemic antibiotic therapy, for bone and joint infection.
10198233|NCT03806166|Active Comparator|Long Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by four weeks or more of systemic antibiotic therapy (standard treatment recommended by international guidelines), for bone and joint infection.
10198234|NCT03804008|Active Comparator|Fundamental advice and a heel cup|
10198235|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise|
10198236|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise and injection|
9724877|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
9980972|NCT05269251||Infraclavicular Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
9984547|NCT03980925|Experimental|Nivolumab + platinum-doublet chemotherapy|"Induction Phase: Nivolumab 360 mg IV plus Carboplatin IV (AUC=5) plus Etoposide 10mg/m2/day on days 1-3D, all every 3 weeks up to 6 cycles followed by Nivolumab 480mg for 24 months or until PD, death or toxicity.~Order of administration: Nivolumab, Carboplatin, Etoposide~Maintenance Phase Nivolumab 480 mg IV will be administered every 4 weeks (±3 days) for 2 years."
9984548|NCT03980509|Experimental|Curcumin|Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.
10198237|NCT03803943|Experimental|Parent-Implemented Communication Intervention (PICT)|Participants assigned to the PICT condition will receive weekly hour long intervention sessions in their home for 6 months. Parents will learn four sets of communication support strategies: (a) visual (e.g., modeling language within the child's line of sight), (b) interactive (e.g., following the child's attentional focus), (c) responsive (e.g., responding to all communicative attempts), and (d) linguistically stimulating (e.g., modeling language targets, expanding child communication).
10198238|NCT03803943|Placebo Comparator|No Intervention - Business-as-usual control|Participants assigned to the BAU control group will not receive the PICT intervention.
10198239|NCT03802123|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
10198240|NCT03801863||Ultrasound-guided Erector Spinae Block|Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
9724878|NCT02658565|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
9724879|NCT02658565|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
9724880|NCT02639702|Experimental|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
10198241|NCT03801863||No Ultrasound-guided Erector Spinae Block|Patients with no peripheral nerve block to serve as the control.
10198242|NCT03801174|Experimental|Partner-assisted intervention|Patients and partners will receive intervention
10198243|NCT03801174|Active Comparator|Patient-only intervention|Patients will receive intervention
10198244|NCT03800641|Experimental|oral administration|oral administration of dexmedetomidine 4μg/kg
10198245|NCT03800641|Active Comparator|intravenous administration|intravenous administration of dexmedetomidine 0.8μg/kg
10198246|NCT03800641|Experimental|nasal administration|nasal administration of dexmedetomidine 1μg/kg
10198247|NCT03799562|Experimental|Pregnenolone|Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
10198248|NCT03799562|Placebo Comparator|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
10198249|NCT03799523|Experimental|Subjects undergoing breast radiotherapy|At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
9724881|NCT02639702|No Intervention|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
10198250|NCT03796104||Deficiency of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency
10198251|NCT03796104||Presence of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production
10198252|NCT03788512||AICVD patients with CoCCA|acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
10198253|NCT03787082|Experimental|Chlorhexidine Gluconate Mouthwash|rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
9724882|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
9724883|NCT02595879|Experimental|Treatment (triapine, chemoradiation)|Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy.
9724884|NCT02555254|Experimental|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
9984549|NCT03979547|Experimental|Exercise intervention|The exercise program will be similar to the Exercise in All ChemoTherapy (ENACT) study which combines in-person and home-based strength training and aerobic exercise five days a week.
9984550|NCT03979547|No Intervention|Standard of Care|Subjects are instructed to maintain their current activity level.
9724885|NCT02555254|Experimental|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
10198254|NCT03787082|Placebo Comparator|Placebo Mouthwash|rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
10198255|NCT03782493|Experimental|Enhanced Milieu Teaching-Sentence Focus|The study intervention is a behavioral intervention which will include individually teaching caregivers to use the intervention strategies from the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention using a manualized protocol (Teach-Model-Coach-Review). Caregivers will participate in 66 intervention sessions across 18 months, targeting vocabulary and grammar as well as the transition to decontextualized language.
9724886|NCT02444728|Active Comparator|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
9724887|NCT02444728|Active Comparator|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine & Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
9724888|NCT02381353|Active Comparator|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
10198256|NCT03782493|No Intervention|Business-as-usual control|Caregivers in the control group will participate in community-based intervention services and receive the same printed intervention instructions, books, and toys at the same intervals as the treatment group, but will not receive EMT-SF intervention.
10198257|NCT03779113|Experimental|Treatment|All patients to received study drug (HMPL-523)
10198258|NCT03779009|Experimental|Tracer injection|
10198259|NCT03773419|Experimental|Texting Intervention (T-WRITE)|Computer-based treatment targeting written language via texting (90 minutes a day, 5 days a week for 4 weeks)
10198260|NCT03773419|Active Comparator|HandWriting Intervention (ORLA+WTG)|Computer-based treatment targeting written language via handwriting (90 minutes a day, 5 days a week for 4 weeks)
10198261|NCT03772951|Active Comparator|Cognitive Remediation Therapy|The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
10198262|NCT03772951|Placebo Comparator|Clozapine|Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
10198263|NCT03771612|Active Comparator|Naproxen|
10198264|NCT03771612|Placebo Comparator|Placebo|
10198265|NCT03770858||Crisaborole and wearable sensor|Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.
10198266|NCT03763591|Experimental|Psychological Skills Group (e.g., Active Intervention)|10-week Psychological Skills Group.
10198267|NCT03757845|No Intervention|Control diet|
10198268|NCT03757845|Experimental|Mediterranean diet|
10198269|NCT03757689|Experimental|Neoadjuvant Pembrolizumab|Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
10198270|NCT03753087|Experimental|Empagliflozin|Patients will receive standard care for Heart Failure and Diabetes Mellitus + Empagliflozin 10mg once daily
10198271|NCT03753087|Active Comparator|Control|Patients will receive standard care for Heart Failure and Diabetes Mellitus with no SGLT-2 inhibitors
10198272|NCT03744715|Experimental|Poziotinib|Poziotinib
9724889|NCT02381353|Experimental|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
9724890|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
9724891|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
9724892|NCT02334345|Experimental|EVOSKIN|Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
9724893|NCT02334345|Active Comparator|TRIXIERA|Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
10198273|NCT03744676|Experimental|Lisocabtagene maraleucel|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
10198274|NCT03743194|Active Comparator|Bupi HCl plus liposomal bupi|"Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.~An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic."
10204903|NCT04554212|Active Comparator|Standard Physical Therapy with BFRT|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
9724894|NCT02296918|Experimental|Double combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
9724895|NCT02296918|Experimental|Double combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
9724896|NCT02296918|Experimental|Triplet combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with rituximab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
9724897|NCT02296918|Experimental|Triplet combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
9724898|NCT02258594|No Intervention|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units~Usual Care on four Oncology units"
9724899|NCT02258594|Experimental|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
9724900|NCT02258594|No Intervention|Post-Implementation - Usual Care|Usual Care on two Oncology Units
9724901|NCT02100397|Experimental|Dose|A dose of S.paratyphi will be given to up to 20 participants to determine the attack rate.
9724902|NCT01989624||Pancreatic Adenocarcinoma|
9724903|NCT01984346|Experimental|Convergent Procedure|Procedure/Surgery: Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
9724904|NCT01984346|Active Comparator|Standalone Endocardial Catheter Ablation|Procedure/Surgery: Endocardial Catheter Ablation Treatment
10198275|NCT03743194|Placebo Comparator|Control Group|Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.
10198276|NCT03739073|Experimental|Patient with coronary arterial indication|A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).
10198277|NCT03737045|Other|Decision Aid Testing|Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
10198278|NCT03735420|Experimental|Xanthohumol|Participants will receive 24 mg of 98% pure xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
10198279|NCT03735420|Placebo Comparator|Placebo oral capsule|Participants will receive vehicle (rice protein) by mouth once daily with the first daily meal.
10198280|NCT03734237|Active Comparator|Egg based influenza vaccines|Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
9724905|NCT01828112|Experimental|Ceritinib|Patients in this arm received 750 mg of ceritinib.
9724906|NCT01828112|Active Comparator|Chemotherapy|Patients in this arm received chemotherapy of either pemetrexed or docetaxel as determined by BIRC.
9984551|NCT03979534|Experimental|Diet group|"Diet follow-up to personalize a low-protein diet for each patient. All patients following a low protein diet one month or more compose the diet group."
9724907|NCT01816152|Active Comparator|Active Intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.
9724908|NCT01816152|Placebo Comparator|Inactive intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients
9724909|NCT01787409|Experimental|Treatment (cholecalciferol)|Vitamin D sufficient patients receive no intervention. Vitamin D insufficient patients receive cholecalciferol PO once weekly for 12 weeks and then once monthly for a total of 36 months.
9724910|NCT01750281|Experimental|Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
9724911|NCT01750281|Experimental|Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 60 mg/m2 intravenously administered on day 1 of each 21 day cycle.
10198281|NCT03734237|Active Comparator|Recombinant influenza vaccines|FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
10198282|NCT03734237|Active Comparator|Cell-culture based influenza vaccines|Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
10198283|NCT03733353|Other|Cohort 1|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose=1/10th of HED, capsule, once daily, 15 days
10198284|NCT03733353|Other|Cohort 2|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose= 1 x HED, capsule, once daily, 15 days
10198285|NCT03733353|Other|Cohort 3|12 subjects with mild to moderate psoriasis; 8 on EDP1815, 4 on placebo. Dose= 1 x HED, capsule, once daily, 29 days
9724912|NCT01750281|Experimental|Placebo twice daily + Docetaxel 75 mg/m2|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
9724913|NCT01426529|Experimental|major allele homozygous|we will compare this arm with the minor allele carrier arm
9724914|NCT01426529|Experimental|minor allele carriers|we will compare this arm with the major allele homozygous arm
9724915|NCT01353118|No Intervention|gastric bypass|Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
9980973|NCT05269251||Interscalene Brachial Plexus Block|Our study includes 3 groups, 33 patients each who underwent axillary, infraclavicular and interscalene blocks. In the study, which of the axillary, infraclavicular and interscalene blocks will be preferred, will be decided by an experienced anesthesiologist in accordance with the type of surgery to be performed. Demographic data, comorbidities, and smoking will be questioned in each group, arterial blood pressure, heart rate, body temperature, radial artery diameter and flow velocities will be recorded before peripheral nerve block is applied, and tissue oxygenation will be measured with Near Infrared Spectroscopy (NIRS) in the extremities with and without block. Tissue oxygenation, radial artery flow velocity and diameters, body temperature will be measured simultaneously at 0(basal)-5-10-15-20-25 and 30th minutes after the application of the block. test will be applied and the success of the procedure will be determined accordingly.
9980974|NCT05269238|Other|control group patient|performing lumbar punctures by students with standard training
9980975|NCT05269238|Experimental|experimental group patient|performing lumbar punctures by students with standard training and an augmented reality simulator
9980976|NCT05269212|Active Comparator|Usual care|
9980977|NCT05269212|Active Comparator|Personalized biopsychosocial rehabilitation program|
9980978|NCT05269160|Experimental|Dermaprazole 1% (Arm A:Head and neck)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
9724916|NCT01353118|Active Comparator|Gastric bypass 2|Gastric bypass 2 (Group B):Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
9980979|NCT05269160|Experimental|Dermaprazole 1% (ArmB: Breast)|Dermaprazole cream at a concentration of 1% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
9724917|NCT01252953|Experimental|Anacetrapib|
9724918|NCT01252953|Placebo Comparator|Placebo anacetrapib|
9724919|NCT01211418|Experimental|Integrative Meditation|
9980980|NCT05269160|Experimental|Dermaprazole 2% (Arm A: Head and neck)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
9980981|NCT05269160|Experimental|Dermaprazole 2% (Arm B: Breast)|Dermaprazole cream at a concentration of 2% will be applied to the skin twice daily starting from CT simulation throughout the radiation treatment period.
10198286|NCT03733353|Other|Cohort 4|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED capsule, once daily, 29 days
10198287|NCT03733353|Other|Cohort 5|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED, mini-tablets in capsule, once daily, 29 days
10198288|NCT03733353|Other|Cohort 6|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose=5 x HED, mini-tablets in capsule, once daily, 29 days.
10198289|NCT03733353|Other|Cohort 7|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 5 x HED, capsule, once daily, 56 days
10198290|NCT03733353|Other|Cohort 8|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 8 x HED, tablet, once daily, 56 days
9724920|NCT01211418|Active Comparator|Nondirective Therapy|
9724921|NCT01126333||Long term Sirolimus or Tacrolimus|"Ths study cohort will consist of participants who successfully completed two years of the original Spare the Nephron (STN) study, a two year prospective multi-center study where participants were assigned to receive either center-specific CNI regimen (assigned at the time of transplantation) or were switched to replace the CNI with Sirolimus therapy.~In this current long-term follow-up study, we will approach patients who previously enrolled in the STN study and offer them the opportunity to enroll to be followed-up for another 3 years. There will be no change in immunosuppression unless clinically indicated. The majority of effort is standard care with every 6 month follow-up appointments.Participants will be required to consent to participate in the three year extension study."
9724922|NCT01012609|Experimental|pts with high-grade astrocytoma|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
10198291|NCT03733353|Other|Cohort 9|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 2 x HED, capsule, once daily, 56 days
10198292|NCT03733353|Other|Cohort 10|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 4 x HED, capsule, once daily, 56 days
10198293|NCT03731221|Experimental|Bupi HCl plus liposomal bupi|PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine
10198294|NCT03731221|Active Comparator|Bupi HCl plus saline|PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline
10198295|NCT03730337|Experimental|ONO-7475 monotherapy|
10198296|NCT03730337|Experimental|ONO-7475 in combination with ONO-4538|
9724923|NCT01012609|Experimental|pts with diffuse pontine tumor|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
10198297|NCT03730051|Active Comparator|Gadoterate meglumine contrast|0.2 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection at a rate of 2 mL/second. The FDA-approved product labeling provides weight-adjusted dose volumes as follows: 30 kg: 6 mL; 40 kg: 8 mL; 50 kg: 10 mL; 60 kg: 12 mL; 70 kg: 14 mL; 80 kg: 16 mL; 90 kg: 18 mL; 100 kg: 20 mL; 110 kg: 22 mL; 120 kg: 24 mL; 130 kg: 26 mL; 140 kg: 28 mL; 150 kg: 30 mL.
10204904|NCT04547725|Experimental|CRS-IP (Arm-A)|Stage IV gastric cancer with limited peritoneal carcinomatosis (peritoneal carcinomatosis index [PCI] ≤ 10)
10204905|NCT04547725|Experimental|CRS-IP (Arm-B)|Stage IV gastric cancer with positive peritoneal wash cytology (CY1/P0)
10198298|NCT03730051|Experimental|Gadobutrol contrast|0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
10198299|NCT03729570|Experimental|ePrEP|Participants will receive the ePrEP home care system for telemedicine PrEP, permitting initiation and persistence in PrEP care. The ePrEP home care system consists of: a smartphone application (app) for video-based telemedicine PrEP consultations with a clinician; secure messaging; a system to track shipments to & from participants; and behavioral risk surveys that are complemented by home specimen kits. Self-collected specimens will be mailed to laboratories for routine, guideline-based testing for PrEP care. Home specimen collection will be used to determine the primary study outcome of tenofovir-diphosphate levels.
10198300|NCT03729570|No Intervention|Standard of care|Participants will be referred to a publicly available website that geolocates the nearest PrEP provider. They will receive standard of care, defined as what a member of the general public would be able to access for PrEP services. Home specimen self-collection will be used to determine the primary study outcome of tenofovir-diphosphate levels. Additional research assessments will include quarterly surveys.
10198301|NCT03729180|Other|Pain Cohort|Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.
10198302|NCT03729180|Experimental|Pharmacogenomic (PGx) Arm [Randomization Arm 1]|All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.
10198303|NCT03729180|Other|Control Arm [Randomization Arm 2]|All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
10198304|NCT03727776|Experimental|H.P. Acthar ®|Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.
10198305|NCT03727776|No Intervention|Controls|Subjects will be managed per the standard of care.
10204906|NCT04537806|Experimental|Brexanolone|Participants receiving mechanical ventilation as standard of care will receive brexanolone as a single, continuous, intravenous (IV) infusion for 60 hours.
10204907|NCT04537806|Placebo Comparator|Placebo|Participants receiving mechanical ventilation as standard of care will receive matching placebo as a single, continuous, IV infusion for 60 hours.
10204908|NCT04527367||VHD patients|Patients with moderate and severe valvular heart diseases
9827876|NCT02471651|Active Comparator|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
10204909|NCT04526704|Experimental|Treatment Continuation Cohort|Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.
10204910|NCT04526704|Experimental|Treatment-Free/Re-Treatment Cohort|Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).
10204911|NCT04517344|Experimental|Arm 1, HFNC 1 L/kg/min|The infant that is randomized to the HFNC therapy arm 1 will be placed on high flow at 1 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If oxygen saturation (SpO2) is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%.
10204912|NCT04517344|Experimental|Arm 2, HFNC 1.5 L/kg/min|The infant that is randomized to the HFNC therapy arm 2 will be placed on high flow at 1.5 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%.
10204913|NCT04517344|Experimental|Arm 3, HFNC 2 L/kg/min|The infant that is randomized to the HFNC therapy arm 3 will be placed on high flow at 2 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%.
10204914|NCT04504487|Experimental|Early drain removal - POD3|Drain removal on POD3 if drain bilirubin is less than 3mg/dl and serous in nature.
10204915|NCT04504487|Placebo Comparator|Routine Drain Removal|Drain removed routinely when the output is less than 100ml and serous in nature
10204916|NCT04481425|Other|intervention group|Text messages will be sent to the subjects through the investigator, including giving popularization of psychiatric knowledge, coping skills, emotional regulation strategies, and brief care. Two or three times a week for two months.
10204917|NCT04481425|No Intervention|control group|Subjects both collected in the outpatient department and the ward were randomly divided into the control group and regularly followed up.
10204918|NCT04471779|Experimental|Disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity, family history of Alzheimer's disease, and their APOE genotype.
10204919|NCT04471779|No Intervention|Non-disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity and family history of Alzheimer's disease alone.
10204920|NCT04471168|Experimental|Cryo-Auriculotherapy|Patients benefit from 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
9980982|NCT05269134|Experimental|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotic treatment.
9724924|NCT00920387|Experimental|Full Dose LSD (200 mcg)|200 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
9980983|NCT05269134|Placebo Comparator|DAIR + Placebo + Antibiotics|Placebo will be administered in conjunction with antibiotic treatment.
9980984|NCT05269108|Experimental|Fluoroscopy-free RIRS|Patients will be treated by RIRS without fluoroscopy
9980985|NCT05269108|Active Comparator|Standard RIRS|Standard RIRS under fluoroscopy-guidance will be performed
9980986|NCT05269056||Stage I-II gastric cancer|Cell-free DNA collected from plasma samples of 200 patients with stage I-II gastric cancer will undergo whole-genome sequencing
9980987|NCT05269056||Healthy controls|Cell-free DNA collected from plasma samples of 100 non-cancer individuals will serve as controls
10198306|NCT03724695|No Intervention|Control|Usual Care
10198307|NCT03724695|Experimental|AHCAH Nudge|"The investigators have developed methods for sending nudges to clinicians via secure text messages to primary teams to alert them that their patient was identified as high-risk for 6-month mortality and that an AHCAH liaison would visit their patient to discuss the AHCAH program and to facilitate enrollment if the patient was amenable. The investigators propose that these secure text messages would be sent to the teams of patients randomized to the intervention by the AHCAH liaison within 72 hours of eligibility identification (to allow for the liaison not being available over the weekend). The investigator team will track all aspects of messaging and timing. Clinicians can choose to opt out a patient from the liaison visit and AHCAH enrollment within a two-hour timeframe."
10198308|NCT03721328|Experimental|Experimental|Joint irrigation with vancomycin and tobramycin
10198309|NCT03721107|Experimental|Cohort C: Blautix|Participants diagnosed with Irritable bowel syndrome subtype C (IBS-C) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10^10 to10^11 most probable number (MPN).
10198310|NCT03721107|Placebo Comparator|Cohort C: Placebo|Participants diagnosed with IBS-C received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.
10198311|NCT03721107|Experimental|Cohort D: Blautix|Participants diagnosed with Irritable bowel syndrome subtype D (IBS-D) received two capsules of Blautix orally, twice daily for 8 weeks. Maximum daily dose of Blautix (strain of Blautia hydrogenotrophica) will be 10^10 to10^11 MPN.
10198312|NCT03721107|Placebo Comparator|Cohort D Placebo|Participants diagnosed with IBS-D received two capsules of placebo matched to Blautix orally, twice daily for 8 weeks.
10198313|NCT03715985|Experimental|NeoPepVac|Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
10198314|NCT03715153|Experimental|BUMETANIDE/S95008|
10198315|NCT03715153|Placebo Comparator|PLACEBO|
9980988|NCT05269030|Experimental|Case group|The patients will receive ivermectin nasal drops
9980989|NCT05269030|Active Comparator|Control group|The patients will receive local steroid spray
9980990|NCT05269017|Experimental|Case group|The case group patients will receive vitamin D3 nasal drops
9724925|NCT00920387|Active Comparator|Active Placebo LSD (20 mcg)|20 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
9724926|NCT00867802|Experimental|Mindfulness- Based Stress Reduction: Active Comparator|Mindfulness-Based Stress Reduction program
9724927|NCT00540774|Other|Oral tissue|Imaging of oral structures and pathologies
9724928|NCT00494234|Experimental|KU-0059436 (AZD2281) 100 mg BID|
10198316|NCT03711838|Experimental|N-Acetylcysteine|N-Acetylcysteine supplementation: Orally, 40 mg/kg per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 40mg/kg per day in 3 doses (250 ml each).
10198317|NCT03711838|Active Comparator|Placebo|Placebo administration: Orally 750 ml per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 750 ml per day in 3 doses (250 ml each).
10198318|NCT03709277|Experimental|Pharmacist-Driven Intervention|The study group will receive a targeted, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
10198319|NCT03709277|No Intervention|Standard of Care|The Standard of Care Group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.
10198320|NCT03706898|Experimental|Elpida® fasting|Elpida® 20 mg single dose fasting
10198321|NCT03706898|Experimental|Elpida® after meal|Elpida® 20 mg single dose after meals
10198322|NCT03706898|Experimental|Elpida® (in subjects with mild hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with mild hepatic impairment (Child - Pugh Class А)
10198323|NCT03706898|Experimental|Elpida® (in subjects with moderate hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with moderate hepatic impairment (Child - Pugh Class B)
9724929|NCT00494234|Experimental|KU-0059436 (AZD2281) 400 mg BID|
9724930|NCT00458835|Active Comparator|Ciclesonide 300 mcg intranasally via aqueous nasal spray|
9724931|NCT00458835|Active Comparator|Ciclesonide 300 mcg intranasally via HFA nasal aerosol|
9724932|NCT00458835|Active Comparator|Ciclesonide 320 mcg orally inhaled via HFA MDI|
9724933|NCT00403559|Experimental|Elidel Cream (pimecrolimus)|Elidel Cream to be applied twice daily for 4 weeks
9724934|NCT00403559|Active Comparator|Ketoconazole Cream (Nizoral)|Ketoconazole Cream to be applied twice daily for 4 weeks
9724935|NCT00353938|Experimental|Full Dose MDMA-assisted therapy (125 mg)|Three 8-hour sessions of MDMA-assisted therapy with 125 mg of MDMA, followed by a supplemental dose of 62.5 mg MDMA
9980991|NCT05269017|Active Comparator|Control group|The control group will remove local corticosteroid spray
9724936|NCT00353938|Active Comparator|Active Placebo MDMA-assisted therapy (25 mg)|Three 8-hour sessions of MDMA-assisted therapy with 25 mg of MDMA, followed by a supplemental dose of 12.5 mg MDMA
9980992|NCT05268965||Patients meeting DSM-5 criteria for PTSD.|
9980993|NCT05268965||Group 2: Healthy controls who experienced a traumatic event but did not meet DSM-5 criteria for PTSD|
9724937|NCT00176436|Active Comparator|active|Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
9724938|NCT00176436|Placebo Comparator|Placebo|Placebo medication, diet support group, group counseling and exercise
9724939|NCT00006436|Experimental|Arm 1|Combination chemo and biological therapy
9980994|NCT05268965||Group 3: Healthy controls who did not experience a traumatic event|
9980995|NCT05268952|Experimental|GEP-NET and lung-NET patients|Liquid biopsies and scans
9980996|NCT05268913||Women with BRCA1/2 genes|
9980997|NCT05268913||Women with breast cancer|
9724940|NCT05283343||Adults 20 years old or older|
9724941|NCT05283330|Experimental|²¹²Pb-DOTAM-GRPR1|In the dose escalation portion, a classic 3+3 design will be utilized. Doses will be increased by approximately 30% in subsequent cohorts as per Table 1. The maximum total dose that may be administered to a subject per cycle is 5.5 mCi +/- 10%. The maximum total dose that may be administered to a subject in the MAD regimen is 24 mCi over 4 cycles.
9724942|NCT05283317|Active Comparator|Patients received MSCs|10 patients with sepsis and septic shock and received MSCs&standart therapy
10198324|NCT03706898|Experimental|Elpida® & sofosbuvir & daclatasvir|Drug-drug interactions of sofosbuvir 400 mg + daclatasvir 60 mg and Elpida® 20 mg, single dose fasting
10198325|NCT03706898|Experimental|Elpida® & dolutegravir|Drug-drug interactions of dolutegravir 50 mg and Elpida® 20 mg, single dose fasting
10198326|NCT03705000|Experimental|Slit Stent II|The Slit Stent II (investigational) device is created by modifying an existing FDA cleared lacrimal stent (BIKA, manufactured by FCI Opthalmics) by adding additional 3 mm and 35 mm long slits of equal depth.
10198327|NCT03705000|Active Comparator|BIKA for DCR|The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device.
10198328|NCT03697278|No Intervention|Control group|Using clinical routinely regime device to use and monitor postoperative controlled pain (PCA) after surgery.
10198329|NCT03697278|Experimental|Smith medical CADDsolis|This study group use a new device to use and monitor postoperative controlled pain (PCA) after surgery.
10198330|NCT03694002|Experimental|Arm A (ramucirumab, carboplatin, paclitaxel)|Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.
10198331|NCT03694002|Active Comparator|Arm B (carboplatin, paclitaxel)|Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
10198332|NCT03692611|Experimental|Skills to Manage Pain (STOMP)|The intervention group will receive treatment as usual plus the STOMP behavioral intervention. The STOMP behavioral intervention consists of 12 intervention sessions (6 group and 6 individual sessions). The sessions will be completed over a period of 12-16 weeks from enrollment. The first intervention session will be a group session for all participants followed by individual and then alternating group and individual sessions for the rest of the intervention. The intervention group will utilize a study manual on pain management in which they will use with each session.
10198333|NCT03692611|Active Comparator|comparison group|The comparison group will receive treatment as usual.The comparison group will also be provided with the intervention manual, however, no additional treatment will be provided to participants allocated to the control group. The group will not receive the PSM intervention.
10198334|NCT03691727|Experimental|tirofiban hydrochloride (AGGRASTAT®)|"tirofiban hydrochloride (AGGRASTAT®) administered continuously over the course of 7 days.~MRI Neurological Exam Vital Signs Questionnaires"
10198335|NCT03691727|Active Comparator|Standard of Care Control Arm|Standard of Care Treatment MRI Neurological Exam Vital Signs Questionnaires
10198336|NCT03690336||Patients with haemophilia B|Patients with haemophilia B treated with nonacog beta pegol who report adverse events to the PedNet and EUHASS, and possibly other national or international registries.
10198337|NCT03689920|Active Comparator|WaveWriter Settings|WaveWriter Programming
9724943|NCT05283317|No Intervention|Patients not received MSCs|20 patients with sepsis and septic shock and not received MSCs, only received standart therapy
9724944|NCT05283304|Experimental|Injectable Buprenorphine (BUP-inj)|Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable buprenorphine (300 mg dose) every 4 weeks
9980998|NCT05268913||Women with obesity|
10198338|NCT03689920|Active Comparator|Conventional Settings|Conventional Programming
10198339|NCT03689608|Experimental|Intermittent Fasting (IF)|3 days fasting per week
10198340|NCT03689608|Experimental|Daily Restriction (DR)|daily energy restriction
10198341|NCT03689608|Other|standard care (SC)|usual care
10198342|NCT03689101|Experimental|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7) to count endometrial CD138.
10198343|NCT03688425|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
10198344|NCT03688425|Active Comparator|IOL implantation active comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
9724945|NCT05283304|Placebo Comparator|Injectable Placebo (PBO-inj)|Following successful titration to 16 mg of daily sublingual buprenorphine, the participants will then transition to injectable placebo (300 mg dose) every 4 weeks.
9780754|NCT01130532|Active Comparator|2.5 milligram (mg) titrated to 5 mg Tadalafil|2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
9780755|NCT01130532|Active Comparator|5 mg Tadalafil|5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
9780756|NCT01130532|Placebo Comparator|Placebo|for 12 weeks
9780757|NCT01130597|Experimental|patiromer|spironolactone + patiromer
9780758|NCT01130740|No Intervention|Arm 1|usual care
9980999|NCT05268900|Placebo Comparator|Volume control ventilation group|Patients' lungs will be ventilated with volume control ventilation mode
9981000|NCT05268900|Active Comparator|Pressure control ventilation-volume guaranteed group|patients' lungs will be ventilated with Pressure control ventilation-volume guaranteed mode
9981001|NCT05268887|Experimental|Parkinson's Active Arm|Exposure to active sensory stimulation (40Hz) for 30-60 minutes.
9724946|NCT05283291|Experimental|İmaginary group|"Expert opinion for the scenario will be taken from a psychologist and a psychiatric nurse.~The flow of the script; It will start with breathing exercises and continue with the safe place application, after affirming the functionality that is said while in a safe place in the mind, it will be in the form of waking up by turning to the body and returning to the present.~Headphones will be provided for each patient by the researcher. In the first meeting, the voice recordings will be transferred to the phones of the individuals via the phone in the Neurosurgery Service. Communication with the patient will be provided in accordance with the pandemic rules.~The audio recording will be played twice, in the evening before the operation and on the evening of the operation day."
9981002|NCT05268887|Sham Comparator|Parkinson's Control Arm|Exposure to control stimulation (sham) for 30-60 minutes.
9981003|NCT05268861|Experimental|Training with EA feedback|Subjects will undergo training with the EA-VR game that includes a 15 degree elbow flexion error.
9724947|NCT05283291|No Intervention|Control group|In the routine care applied to the patients, the vitals of the patients are followed, drug treatments are administered and the motor functions of the patients are monitored. In addition, analgesics are routinely administered in the ward for pain and no attempt is made for sleep.
9981004|NCT05268861|Sham Comparator|Training without EA feedback|Subjects will undergo training with the EA-VR game that does not include EA feedback.
9981005|NCT05268848|Experimental|Termography PRE|Foot thermography before lining test
9981006|NCT05268848|Experimental|Termography POST|Foot thermography after wearing 2 types of liner for three hours (one on each foot)
9724948|NCT05283278|Active Comparator|Lactoferrin Bovine group|Group A (20 preterm neonates) which will receive lactoferrin (100mg/day)
9724949|NCT05283278|Active Comparator|Lactoferrin Bovine with probiotics group|Group B (20 preterm neonates) which will receive lactoferrin (100mg/day) in combination with the probiotic
10198345|NCT03688399|Experimental|IOL Implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
9981007|NCT05268848|Active Comparator|Thermographic comparations|Thermographic comparations between PRE and POST measurements
9981008|NCT05268835|Active Comparator|Clindamycin 150mg|Patients receiving 150mg of clindamycin (Dalacin C, Pfizer) after surgery every 8 hours
9981009|NCT05268835|Active Comparator|Clindamycin 300mg|Patients receiving 300mg of clindamycin after surgery every 8 hours
9981010|NCT05268835|Active Comparator|Clindamycin 600mg|Patients receiving 600mg of clindamycin after surgery every 12 hours
9981011|NCT05268822|Active Comparator|Movement control exercise with specific breathing techniques|Movement control exercise with specific breathing techniques (experimental group)
9724950|NCT05283278|Placebo Comparator|Placebo group|Group C (40 preterm neonates) which is a placebo group.
9981012|NCT05268822|Active Comparator|Movement control exercise without specific breathing techniques|Movement control exercise without specific breathing techniques (control group)
9724952|NCT05283239||Women with persistent HR-HPV infection|In the enrollment, women with persistent HR-HPV infection for more than 18 months will be included in this study. All participants will be followed up at 6th month, 12th month, 18th month and 24th month after baseline of recruitment.
9724953|NCT05283226|Experimental|NRC-2694-A In Combination with paclitaxel|Patients will receive NRC-2694-A 300 mg orally once daily and paclitaxel 175 mg/m² IV infusion over approximately 3 hours once in 21 days for 6 cycles or more.
9724954|NCT05283200|Experimental|Yoga|"The goal for the yoga intervention is to provide participants with instructor-guided safe, gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, anxiety symptoms, disability, and improve quality of life.~Participants enrolled in the Yoga intervention group will receive one month of Instructor-Guided 70-minute virtual live yoga classes, twice per week, led by an experienced yoga therapist and co-instructor. During Months 2-3 participants in the Yoga Intervention will receive one 70-minute virtual live yoga class per week. Each session will have a set of specific poses, breathing exercises, meditation, and yoga philosophies developed by our yoga experts."
9724955|NCT05283200|Experimental|Cognitive Behavioral Therapy|"The goal of the Cognitive Behavioral Therapy (CBT) intervention is to provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, depression and anxiety symptoms, disability and improve quality of life.~Participants enrolled in the CBT intervention group will receive 3 months of Instructor-Guided 90-minute, virtual group counseling session, once per week, led by a psychologist and a co-therapist."
9981013|NCT05268770||Tinnitus patients with good hearing|
9981014|NCT05268770||Healthy controls with good hearing|
9981015|NCT05268757|Experimental|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
9981016|NCT05268757|Placebo Comparator|Placebo|In this group participants will receiveplacebo twice a day (morning and evening) for at period of 28 days (14 days with oral hygiene discontinuation followed by 14 days with regular oral care).
9981017|NCT05268718|Experimental|Nanogel photothermal therapy|After the subjects were enrolled in the study, the eyes were coated with Au-Ag-Cu2O nano-gel once (the concentration was 26.4μg/mL, the dosage was suitable to cover the ulcer surface evenly, and the dosage was recorded). Combined with mdl-n-808-10w near-infrared laser (China changchun new industry photoelectric technology) combined with photothermal therapy (laser wavelength 808 nm, power 1.5W/cm2, temperature controlled at 40℃, lasting 10min)
9981018|NCT05268718|Active Comparator|Voriconazole eye drops|Voliconazole eye drops (once in half an hour) were also used in the control group.
9981019|NCT05268718|Placebo Comparator|Normal saline|Normal saline eye drops (once in half an hour) were also used in the control group.
9981020|NCT05268705|Active Comparator|High-carbohydrate-low-fat-low-protein diet|
10198346|NCT03688399|Active Comparator|IOL Implantation Comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
10198347|NCT03687567||HBA|alpha-Thalassemia
10198348|NCT03687567||HBB|beta-Thalassemia
10198349|NCT03685487||patients with failures of decolonization S. aureus|patients with failures of decolonization S. aureus in their nose
10198350|NCT03682614|Experimental|HCG group|All patients will accept HCG 500IU intrauterine injection 2 days before blastocyte transfer
10198351|NCT03682614|Placebo Comparator|control group|All patients will accept same dose of culture medium intrauterine injection 2 days before blastocyte transfer
10198352|NCT03680781|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
10198353|NCT03680677||Cancer Directed Therapy or Best Supportive Care|Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care
10198354|NCT03680677||Transplant|Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy
9724956|NCT05283200|Experimental|Music|"The aim of this intervention is for participants to learn and develop skills to reduce stress which may, in turn, decrease seizure frequency and improve quality of life. Participants will be exposed to a variety of ways that they might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.~Participants enrolled in the Music Intervention group will receive one month of Instructor-Guided Intervention 70-minute virtual live music therapy sessions, twice per week, led by an experienced music therapist and co-instructor. An two months of a 70-minute virtual live music therapy session once per week."
9981021|NCT05268705|Active Comparator|Low-carbohydrate-high-fat-low-protein diet|
9981022|NCT05268705|Active Comparator|Low-carbohydrate-low-fat-high-protein diet|
9981023|NCT05268692|Active Comparator|GS|gemcitabine plus S-1
9981024|NCT05268692|Active Comparator|GnP|gemcitabine plus nab-paclitaxel
9981025|NCT05268627|Active Comparator|Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections|
10198355|NCT03677947|Active Comparator|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning and overvalued ideas. IBCT does not include exposure, but aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
10198356|NCT03677947|Active Comparator|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, patients will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention).
10198357|NCT03675724|Experimental|Treatment|Fisetin 20mg/kg/day, orally for 2 consecutive days
10198358|NCT03675724|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
10198359|NCT03672227|Experimental|Mealtime Matters Training|This group of teachers will get a 3 hour nutrition training, followed by 2 one hour booster sessions.
10198360|NCT03672227|No Intervention|Family Style Dining in Head Start|This group of teachers will not get the 3 hour nutrition training until the study has concluded.
10198361|NCT03671603||Iodixanol|Participants will receive Iodixanol 270 mg I/ml or Iodixanol 320 mg I/ml injection as a part of routine clinical practice at the medical discretion of the physician.
10198362|NCT03666377|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
10198363|NCT03666377|Experimental|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
10198364|NCT03660722|Other|Blood and urinary sample|Blood and urinary sample in HIV 1 positive adults initiating treatment
10198365|NCT03660228|Experimental|Peri-Transfusion QOL Assessment|"Participants will be given a study packet containing a paper copy of the QUALMS~Study participants will fill out the survey on the day before their first/next pRBC transfusion.~Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site~The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results"
10198366|NCT03660215|No Intervention|control group|usual charge
10198367|NCT03660215|Experimental|experimental group|"Mediation:~The mediator will intervene on several levels: planning of care according to the medical prescriptions on a support adapted and comprehensible by the patient according to his level of health literacy and his linguistic capacities, coaching on the management of the chronic diseases, possible orientation towards a workshop of therapeutic education, appointments calendar, clear indication of treatment changes, provision of contact information for allied health professionals , assistance in making appointments, possible accompaniments at a professional health."
10198368|NCT03647852|Experimental|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
10198369|NCT03647852|Active Comparator|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
10198370|NCT03645070|No Intervention|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
10198371|NCT03645070|Active Comparator|Single probe thermometer|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
10198372|NCT03645070|Active Comparator|Multi-probe|Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
10198373|NCT03644849|Experimental|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
10198374|NCT03644849|Sham Comparator|Sham laser intervention group|
10198375|NCT03637010|Other|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
10198376|NCT03634982|Experimental|RMC-4630|RMC-4630 for oral administration
10198377|NCT03630211|Experimental|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
10198378|NCT03629327|Active Comparator|ASA 325mg|Daily uptake of 325mg ASA
10198379|NCT03629327|Active Comparator|No drug|no drug
10198380|NCT03629327|Active Comparator|ASA 81mg|daily uptake of 81mg ASA
10198381|NCT03621813|Other|Control|Participants maintain their current activity level.
10198382|NCT03621813|Active Comparator|Exercise Rehabilitation|Participants will exercise 2x/week at training facilities and at home one day a week.
10198383|NCT03617198|Experimental|Cohort 1|Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells. All other study procedures are the same as Cohort 2.
10198384|NCT03617198|Experimental|Cohort 2|Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells. All other study procedures are the same as Cohort 1.
10198385|NCT03613740|Experimental|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
10198386|NCT03613740|Placebo Comparator|Placebo|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
10198387|NCT03604913|Active Comparator|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
10198388|NCT03604913|Active Comparator|B(Bentall operation)|Undergo Bentall operation
10198389|NCT03604159|Experimental|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
10198390|NCT03604159|Active Comparator|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.
10204921|NCT04471168|Sham Comparator|Control group|Patients benefit from 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
10204922|NCT04467723|Experimental|Treatment|"Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.~Pirfenidone (Esbriet) orally (PO) with food according to this schedule:~Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID"
9981026|NCT05268627|Active Comparator|liraglutide|
9981027|NCT05268588|Experimental|Intervention Arm|The mHealth education and social support intervention includes tailored weekly educational content via interactive voice recognition and an android application, a phone-based provider-moderated group discussion, a provider-moderated group text chat, and referral to care as needed. Individuals are enrolled into groups of 20, have two intervention sessions prenatally and then have weekly meetings through six months postpartum for a total of 26 sessions.
9981028|NCT05268588|No Intervention|Control Arm|Standard postnatal care.
9981029|NCT05268562|Active Comparator|Anesthesia induction with Ketamine|Subjects will receive Ketamine to begin anesthesia for their cardiac surgery.
9981030|NCT05268562|Active Comparator|Anesthesia induction with Propofol|Subjects will receive Propofol to begin anesthesia for their cardiac surgery.
9724957|NCT05283200|No Intervention|Standard of Care|Participants randomized to the Standard of Care Control Group will receive their usual standard epilepsy care. Participants will receive a brief monthly call for checking-in and collection of seizure frequency. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
9724958|NCT05283200|No Intervention|Enhanced Standard of Care|Participants randomized to the Enhanced Standard of Care Control Group will receive their usual standard epilepsy care and weekly scheduled, scripted, follow-up phone calls from a study team member to check-in on their health, epilepsy management, and seizure frequency. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
9724959|NCT05283122|Experimental|The Mostafa Maged technique to prevent and control post-partum bleeding in placenta previa cases|primigravida patients with placenta previa conditions and their ages between ( 18 - 30 ) years old
9724960|NCT05283109|Experimental|Tumor Associated Antigen Peptide Vaccine in Combination with Hiltonol|The study vaccine is comprised of three different peptides (small proteins) mixed with Hiltonol®. The three peptides that make up the study vaccine are called pp65, EphA2, and survivin.
9981031|NCT05268536|Active Comparator|resistance exercise|Participants will perform Squat walking with resistance band, Butt blaster, Mussel with resistance band, Hip extension with resistance band, and Ankle dorsiflexion exercises with resistance band. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
9984552|NCT03979534|No Intervention|Control group|Patients who accepted to take part of the study but refused the low protein diet and patients who discontinued the diet on the first month compose the control group.
9724961|NCT05283096||Patients with chronic inflammatory rheumatic disease|
9724962|NCT05283070||Control|Volunteers without preexisting chronic pain and/or mental health issues
9724963|NCT05283070||Patients with chronic pain|Patients with chronic pain and/or mental health issues
10198391|NCT03602885|Experimental|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
10198392|NCT03602885|Active Comparator|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
10198393|NCT03596671|Experimental|Treatment arm|RENOVA iStim™ System implanted patients
10198394|NCT03593590||Ocrelizumab|Participants with relapsing or primary progressive MS receiving ocrelizumab under routine clinical care.
10198395|NCT03592693|Experimental|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
10198396|NCT03592693|Placebo Comparator|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
10198397|NCT03591380|Experimental|Experimental: Belimumab|Belimumab 10mg/kg will be administered IV at the following intervals: at the time of transplant (Day 0), then post-transplant at 2, 4, 8, 12, 16, and 20 weeks.
10198398|NCT03589105|Experimental|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
10198399|NCT03587740|Experimental|T-DM1|T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.
10198400|NCT03586102|Experimental|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
10198401|NCT03586102|Active Comparator|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
10198402|NCT03583580|Experimental|Accelerated Partial Breast Irradiation|Accelerated partial breast irradiation (APBI) to the region of tumour bed
10198403|NCT03582800|Experimental|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
10198404|NCT03581344|No Intervention|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
10198405|NCT03581344|Experimental|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
10198406|NCT03578172|Experimental|Experimental-HMG stimulation group|Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer
10198407|NCT03578172|Active Comparator|Control-HRT group|Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer
10198408|NCT03578081|Experimental|Arm I (fosaprepitant dimeglumine, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, fosaprepitant dimeglumine IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
10204923|NCT04446650|Experimental|Fedratinib Administration|The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.
9984553|NCT03979417||Liver fibrosis F0-F1|Blood draw and liver resection at the liver surgery
9984554|NCT03979417||Liver fibrosis F2-F3|Blood draw and liver resection at the liver surgery
9724964|NCT05283057|Active Comparator|Group 1: Empagliflozin|25 patients with glomerulonephritis and proteinuria who were treated with Empagliflozin
9724965|NCT05283057|Placebo Comparator|Group 2:|25 patients with glomerulonephritis and proteinuria who were treated with standard treatment and placebo
9724966|NCT05283044|Other|Biopsy liquid contributive|Patients presenting for whom ct DNA sequencing
9724967|NCT05283005|Active Comparator|alveolar cleft patients will be treated by conventional technique|Reconstruction of alveolar cleft by autogenous cancellous bone from the anterior iliac crest (gold standard technique).
9724968|NCT05283005|Experimental|alveolar cleft patients will be treated by double cortex technique|Reconstruction of alveolar cleft by autogenous double iliac cortico-cancellous bone blocks from the anterior iliac crest.
9780759|NCT01130740|Experimental|Arm 2|Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
9724969|NCT05282992|Experimental|Native type II collagen|Native type II collagen
9724970|NCT05282992|Placebo Comparator|Placebo|Placebo
9724971|NCT05282979|Experimental|Tixel 2|Tixel 2 Treatment, 4 treatment sessions, followed by 2 Follow up sessions, 1 and 3 months after last treatment visit. Subject would be questioned about pain level, subjective downtime assessment and subjective response assessment. Images would be taken at the baseline and in Follow up visits.
9724972|NCT05282966||Prospective Cohort with QSant Testing|2,000 participants will be enrolled across sites within 90-days post-kidney transplant and followed for 24-months
9724973|NCT05282966||Retrospective Control Cohort without QSant Testing|2,000 site-matched controls from UNOS database who underwent a kidney transplant no more than 5 years prior to the study completion date
9724974|NCT05282953|Experimental|Patients with Retinitis Pigmentosa|
9724975|NCT05282914|Experimental|UI058|
9724976|NCT05282914|Active Comparator|UIC202004|
9724977|NCT05282836|Experimental|Intervention|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in the treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
9724978|NCT05282836|No Intervention|No intervention|Usual care refers to the standard-of-care (including oxygen therapy) recommended by guidelines.
9724979|NCT05282823||Treatment Subjects|Subjects will be clinically indicated for pulmonary vein isolation ablation procedure (in compliance with instructions for use (IFU)/Tenpubunsyo as legally approved conditions) for the treatment of paroxysmal AF.
9981032|NCT05268536|Active Comparator|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
9981033|NCT05268523|Experimental|Education and Strategies Intervention Group|Participants will use a videoconferencing system to participate in the Education and Strategies Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
9724980|NCT05282810||cartilage tympanoplasty|use cartilage in tympanoplasty for recuurent perforation
9724981|NCT05282810||temporalis fascia graft in tympanoplasty|use temporalis fascia as a graft in tympanoplasty for recuurent perforation
10198409|NCT03578081|Active Comparator|Arm II (placebo, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, placebo IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment (with no placebo) may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
10198410|NCT03576131|Experimental|GEN1029 (HexaBody®-DR5/DR5)|Open label, single arm trial where GEN1029 will be administered
9724982|NCT05282797|Experimental|100 mg of ANEB-001|
9724983|NCT05282797|Experimental|50 mg of ANEB-001|
9724984|NCT05282797|Placebo Comparator|Placebo|
9724985|NCT05282784|Experimental|Hyperthermia group|Hyperthermia Radiotherapy
10198411|NCT03574454|Other|Phase 1 - Mixed Scan Data Training Set|Machine learning (ML): A mixed data set of 200 WB-MRI scans comprising scans obtained from 40 healthy volunteers (scanned for the purposes of the study), 40 previously acquired inactive myeloma WB-MRI scans and 120 previously acquired active myeloma WB-MRI scans, in which machine learning and convolutional neural networks will be trained to recognise healthy marrow, treated inactive previous myeloma and active myeloma. An algorithm will be developed for testing in phase 2.
10204924|NCT04435158|Experimental|Cohort 1：SHR-1222|Subcutaneous injection of SHR-1222 dosage 1 monthly × 6 months
10204925|NCT04435158|Experimental|Cohort 2：SHR-1222|Subcutaneous injection of SHR-1222 dosage 2 monthly × 6 months
9724986|NCT05282784|Active Comparator|Control|Radiotherapy
9724987|NCT05282771|Experimental|Halobetasol Propionate and Tazarotene Topical lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
9724988|NCT05282771|Active Comparator|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
9981034|NCT05268523|Active Comparator|Mindfulness Skills Intervention Group|Participants will use a videoconferencing system to participate in the Mindfulness Skills Intervention composed of 1 session per week (1.5 hrs/session) over the course of 8 weeks.
9981035|NCT05268523|No Intervention|No-Treatment Control Group|Participants adhere to the standard of care (no study treatment) for 8 weeks.
9984555|NCT03979417||Liver Fibrosis F4|Blood draw and liver resection at the liver surgery
9984556|NCT03978936|Experimental|MTM-EAM|Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM]
10204926|NCT04435158|Experimental|Cohort 3：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 monthly × 6 months
9724989|NCT05282771|Placebo Comparator|Placebo Control|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
9724990|NCT05282758|Experimental|Interdisciplinary team treatment + add on Intervention - Free Movement Dance|Interdisciplinary team treatment + add on Intervention - Free Movement Dance as a physiotherapy intervention
9724991|NCT05282758|Active Comparator|Interdisciplinary team treatment + add on Modified person-centered progressive resistance exercise|Interdisciplinary team treatment + add on Control group - modified person-centered progressive resistance exercise as a physiotherapy intervention
9724992|NCT05282745||Women with high-grade squamous intraepithelial lesion (HSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as high-grade squamous intraepithelial lesion (HSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
9724993|NCT05282732||aHD: Acute haemodialysis patients|
9724994|NCT05282732||cHD: Chronic haemodialysis patients|
9724995|NCT05282719|Experimental|Treatment regime|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
10198412|NCT03574454|Other|Phase 2 - Mixed Scan Data Validation Set|Machine Learning (ML): A mixed data set of 353 WB-MRI scans as that comprising 50 healthy volunteers (scanned for the purposes of the study), and previously acquired scans from 303 myeloma patients, 100 of whom have inactive disease and 203 of whom have active myeloma. The scans will be read by radiologists in random order either with or without the support of for the detection of active myeloma. The diagnostic performance of the radiology reads with or without the machine learning support will be measured against an expert panel reference standard.
10198413|NCT03574454|Other|Phase 3 - Disease Burden Paired Data Set|Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
10198414|NCT03570021|Active Comparator|Group 1|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].
10198415|NCT03570021|Experimental|Group 2|total thyroidectomy alone without neck dissection. This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
10198416|NCT03569878|Experimental|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
10198417|NCT03569878|Active Comparator|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
10198418|NCT03562832|Experimental|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
10198419|NCT03561259|Experimental|131I-MIBG|131I-MIBG
10198420|NCT03561259|Experimental|131I-MIBG + Vorinostat|131I-MIBG + Vorinostat
10198421|NCT03551522|Experimental|Seladelpar 10 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
10198422|NCT03551522|Experimental|Seladelpar 20 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
10198423|NCT03551522|Experimental|Seladelpar 50 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
10198424|NCT03551522|Placebo Comparator|Placebo|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
10198425|NCT03551522|Experimental|Seladelpar 50 mg (OLE phase)|Subjects enrolled will receive seladelpar 50 mg daily for and additional 52 weeks.
10198426|NCT03548532|Active Comparator|36.6°C|Embryos of these patients will be cultured at 36.6°C from day 0 after ICSI, untill day 6.
10198427|NCT03548532|Experimental|37.1°C|Embryos of these patients will be cultured at 37.1°C from day 0 after ICSI, untill day 6.
10198428|NCT03542812|Experimental|Single-dose|"Participants will be enrolled into the two groups, Group 1 (which will consist of 10 participants) and Group 2 (which will consist of 8 participants) in an alternating basis. Both Group 1 and Group 2 participants will receive a single, 150 mg/kg dose of oral L-citrulline. Population PKs will be done for both groups, at up to 3 time points.~Multiple interim time points and following completion of enrollment into Groups 1 and 2, data analysis will be done and results reviewed by the data safety monitoring board (DSMB). After the DSMB review is complete, enrollment into Group 3 will begin."
10198429|NCT03542812|Experimental|Steady-state|To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
10198430|NCT03542682|Active Comparator|Individuals given Standard Bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
10198431|NCT03542682|Active Comparator|Individuals given Quick bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
10198432|NCT03539601|Experimental|Crisaborole ointment, 2%|This treatment arm will be administered both in Cohort 1 and Cohort 2.
10198433|NCT03539601|Active Comparator|Hydrocortisone butyrate cream, 0.1%|This treatment arm will be administered in Cohort 1 only.
10198434|NCT03539601|Active Comparator|Pimecrolimus cream, 1%|This treatment arm will be administered in Cohort 2 only.
10198435|NCT03539601|Placebo Comparator|Crisaborole Vehicle|This treatment arm will be administered both in Cohort 1 and Cohort 2.
10198436|NCT03539458|Experimental|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
10198437|NCT03536676|Active Comparator|Traditional School Breakfast Program|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8.
10198438|NCT03536676|Experimental|'Egg-Cellent' Breakfast in the Classroom|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8 but will include an additional 2 large eggs/breakfast.
10198439|NCT03535688|Experimental|D-cycloserine|D-cycloserine 200 mg BID (twice daily)
10198440|NCT03535688|Placebo Comparator|Placebo|Placebo BID (twice daily)
10204927|NCT04435158|Experimental|Cohort 4：SHR-1222|Subcutaneous injection of SHR-1222 dosage 4 every 2 months × 6 months
10198441|NCT03535350|Experimental|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
10198442|NCT03535350|Experimental|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
10198443|NCT03534011|Experimental|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
10198444|NCT03532451|Experimental|Cohort 1: Nivolumab|Nivolumab 480 mg IV on week 0 and week 4
10198445|NCT03532451|Experimental|Cohort 2: Nivolumab/Lirilumab|Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
10198446|NCT03522844|Experimental|Mindfulness-Based Stress Reduction (MBSR)|
10198447|NCT03522844|Active Comparator|Escitalopram|
10198448|NCT03516994|Experimental|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
10198449|NCT03516994|Active Comparator|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
10198450|NCT03514719|Experimental|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-avelumab PET
10198451|NCT03514121|Experimental|Phase 1a dose escalation/1b dose expansion|The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
10198452|NCT03513939|Experimental|T1DM Cell Pouch™ Recipients|Eligible Type 1 Diabetes Mellitus (T1DM) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch™ intervention
10198453|NCT03513770|Experimental|Ketorolac|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
10198454|NCT03513770|Placebo Comparator|Control|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
10198455|NCT03505099|Experimental|onasemnogene abeparvovec-xioi|One-time intravenous infusion of onasemnogene abeparvovec-xioi at 1.1 X 10^14 vg/kg
10198456|NCT03500640|Active Comparator|DPP Plus: 30-minute calls|Following the 6-month, 16-session, DPP core program, 30-minute group telephone calls will be implemented. Structured behavioral DPP maintenance sessions with a healthy aging focus occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
10198457|NCT03500640|Placebo Comparator|DPP Minimal: 15-minute calls|Following the 6-month, 16-session, DPP core program, 15-minute group telephone calls will be implemented. Social-support sessions occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
10198458|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
10198459|NCT03496792|Experimental|Tilt + external pressure|"Tilt + external pressure on legs performed in both BP elevated with standing and BP maintained with standing groups."
10198460|NCT03496792|Placebo Comparator|Tilt + no external pressure|"Tilt + no external pressure performed in both BP elevated with standing and BP maintained with standing groups."
10198461|NCT03496792|Experimental|Limb occlusion + negative pressure|"Limb occlusion + negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
10198462|NCT03496792|Placebo Comparator|Limb occlusion + no negative pressure|"Limb occlusion + no negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
10198463|NCT03494647|Active Comparator|Cheetah Heel Cup|Subjects randomly assigned to this group will receive the Cheetah Heel Cup at their initial visit.
10198464|NCT03494647|Active Comparator|The X Brace|Subjects randomly assigned to this group will receive the X Brace at their initial visit.
10198465|NCT03492112|Experimental|People attending needle syringe programs in Australia|Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.
10198466|NCT03488524|Experimental|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
9724996|NCT05282706|Experimental|Pain Symptoms Arm|Subjects who will receive physical or occupational therapy experiencing pain prior to therapy session.
9724997|NCT05282706|Experimental|Nausea Symptom Arm|Subjects who will receive physical or occupational therapy experiencing nausea prior to therapy session.
9780760|NCT01130844|Experimental|MMX Mesalamine (30mg/kg)|
10198467|NCT03484520|Experimental|Venetoclax + Dinaciclib|Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.
10198468|NCT03480126|Placebo Comparator|Herbal Tea 1|Placebo Tea should will be ingested 3 times per day for 3 months
10198469|NCT03480126|Experimental|Herbal Tea 2|Experimental Herbal Tea A will be ingested 3 times per day for 3 months
10198470|NCT03480126|Experimental|Herbal Tea 3|Experimental Herbal Tea B will be ingested 3 times per day for 3 months
10198471|NCT03480126|Experimental|Herbal Tea 4|Experimental Herbal Tea C will be ingested 3 times per day for 3 months
10198472|NCT03479671|No Intervention|Saline|Insulin sensitivity (rate of glucose disposal)
10198473|NCT03479671|Experimental|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
10198474|NCT03479671|Experimental|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
9981036|NCT05268510|Experimental|Chemotherapy plus Pembrolizumab followed by Pembrolizumab and Olaparib|"Chemotherapy plus Pembrolizumab 2 cycles à 6 weeks:~Pembrolizumab+mod FOLFOX-6:~Pembrolizumab 400 mg 30 min. day 1~Oxaliplatin 85 mg/m² 2h day 1, 15, 29~Leucovorin 400 mg/m² 2h day 1, 15, 29~5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29~or~Pembrolizumab+CapOx:~Pembrolizumab 400 mg 30 min. day 1~Oxaliplatin 130 mg/m² 2h day 1,22~Capecitabine 1.000 mg/m² bid. day 1-14, 22-35~Consolidation phase Pembrolizumab and Olaparib max 16 cycles à 6 weeks:~Pembrolizumab 400 mg 30 min. day 1~Olaparib 300 mg bid. cont. day 1 to 42"
9984557|NCT03978936|Active Comparator|EAM only|Electronic Adherence Self-Management [EAM] only
10198475|NCT03477890|Active Comparator|Intervention group (coronary function test results disclosed)|Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter >=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
10198476|NCT03477890|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking and protocol adherence is prospectively monitored.
10198477|NCT03476642|Active Comparator|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
10198478|NCT03476642|Active Comparator|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
10198479|NCT03473353|Other|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
10198480|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
10198481|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
10198482|NCT03469193|Active Comparator|internal PUC implanted with mechanical ancillary|
10198483|NCT03469193|Experimental|Internal PUC implanted with robotic assistance|
10198484|NCT03464136|Experimental|Group 1 (Ustekinumab)|Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram [mg/kg]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.
10198485|NCT03464136|Active Comparator|Group 2 (Adalimumab)|Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
10204928|NCT04435158|Experimental|Cohort 5：SHR-1222|Subcutaneous injection of SHR-1222 dosage 5 every 2 months × 6 months
10204929|NCT04435158|Experimental|Cohort 6：placebo|Subcutaneous injection of placebo × 6 months
9724998|NCT05282706|Placebo Comparator|Placebo Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session.
10204930|NCT04432090|Experimental|MBX-2982 first then placebo- Volunteers with Type 1 diabetes|This will be followed by a second study period in which they will be crossed over to the other treatment.
10204931|NCT04432090|Active Comparator|Healthy Volunteers|this group will not receive any medication. It will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
10204932|NCT04432090|Experimental|Placebo first then MBX-2982- Volunteers with Type 1 diabetes|
10204933|NCT04432077|Experimental|Treatment|All participants receive the DINOSAUR intervention
10204934|NCT04429399|Other|High positive end-expiratory pressure Ventilation|patient ventilated fixing high level of positive end expiratory pressure
10204935|NCT04429399|Other|Low positive end-expiratory pressure Ventilation|patient ventilated fixing low level of positive end expiratory pressure
10204936|NCT04423614|Experimental|Inspiratory Muscle Training (IMT)|Pre-operative inspiratory muscle training
10204937|NCT04423614|Experimental|Relaxation Breathing (RLX)|Relaxation breathing exercises
10204938|NCT04414930|Placebo Comparator|TCT + PBO|
10204939|NCT04414930|Active Comparator|TCT + AMPH|
10204940|NCT04409418|Experimental|Experimental Group|If the patient is randomized to the experimental group (lower arm), the research staff will direct the insert to place the catheter into the forearm at least 10 cm away from the antecubital fossa.
10204941|NCT04409418|Active Comparator|Control Group|Control group (upper arm). If the patient is in the control group the research staff will direct the inserter to place the catheter into the upper arm vein at least 2 cm above the antecubital fossa.
10205447|NCT05206747|Experimental|Blue-blocking glasses|Participants will wear orange/amber colored lenses that filter wavelengths of light in the blue spectrum while awake from 6 p.m. to 8 a.m.
9724999|NCT05282706|No Intervention|Standard of Care Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session that decline the option to use an aromatherapy patch.
10198486|NCT03462498|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
10198487|NCT03462498|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
10198488|NCT03454035|Experimental|Open-label, single arm Phase I|Ulixertinib added to palbociclib
10198489|NCT03443791|Experimental|women enrolled|pregnant women enrolled in trial
10198490|NCT03443791|Other|newborns of female study participants|newborns will be tested to determine if virus is present.
10198491|NCT03439657|Experimental|Co-Ad Group|Adults aged ≥50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
10198492|NCT03439657|Active Comparator|Control Group|Adults aged ≥50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
10198493|NCT03430037|Experimental|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
10198494|NCT03430037|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
10198495|NCT03422562|Active Comparator|Probiotic|Florababy probiotic (0.5g per day) will be started at or after 72 hours of life and will be administered in 1ml sterile water prior to feed.
10198496|NCT03422562|No Intervention|Control|Standard of care arm
9984558|NCT03978637|Experimental|Itacitinib 300 mg|Phase 1: Itacitinib 300 mg twice daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
9984559|NCT03978637|Experimental|Itacitinib 400 mg|Phase 1: Itacitinib 400 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
10198497|NCT03422016||autistic spectrum disorder|intelligence quotient IQ>85 age 4-25yrs
10198498|NCT03422016||control|age 4-25yrs no eye disorder
10198499|NCT03421041|Experimental|Dexamethasone group|
10198500|NCT03421041|No Intervention|control group|
10198501|NCT03417583|No Intervention|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
10198502|NCT03417583|Experimental|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
10198503|NCT03412786|Experimental|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
10198504|NCT03412786|Experimental|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
10198505|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs|Single infusion of 200 million cells per patient.
10198506|NCT03406585|Placebo Comparator|Sham transplantation (placebo)|Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
10198507|NCT03404726|Experimental|Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28-day cycles with once daily oral administration of BAY2402234
10198508|NCT03404726|Experimental|Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
10198509|NCT03404726|Experimental|Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
10198510|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
10198511|NCT03393975|Experimental|Prophylaxis Cohort I|Participants randomized to SOC arm in prophylactic treatment cohort will receive a single dose intravenous (IV) infusions of 40 international units per kilogram (IU/kg) BAX-930 ORT product followed by a PK dose of their current SoC at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for 6 months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.
10198512|NCT03393975|Experimental|Prophylaxis Cohort II|Participants randomized to BAX-930 arm in prophylactic cohort will receive a PK dose of their current SoC product followed by a single dose IV infusions of 40 IU/kg BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT once Q2W for the next six months followed by SOC for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
10204942|NCT04408105||Primary Care Providers|400 eligible primary care providers (PCPs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible PCPs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for providers to complete a paper survey at PCP clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
9725000|NCT05282693|Experimental|ReMag|Liquid Lemon flavor drink containing 300 mg magnesium chloride (Regmag) consumed twice daily for 9 days
9725001|NCT05282693|Placebo Comparator|ReMag Placebo|Liquid Lemon flavor drink placebo comparator consumed twice daily for 9 days.
10198513|NCT03393975|Experimental|On Demand Cohort I|Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
10198514|NCT03393975|Experimental|On Demand Cohort II|Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg [+/- 4 IU/kg] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg [+/- 2 IU/kg] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg [+/- 1.5 IU/kg] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
10198515|NCT03387449|Experimental|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
10198516|NCT03386968|Experimental|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
10198517|NCT03386968|Active Comparator|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
10198518|NCT03377790|Active Comparator|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% [w/v] cantharidin) solution.
10198519|NCT03377790|Placebo Comparator|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
9725002|NCT05282680||Type 2 diabetes|Subjects with a diagnosis of type 2 diabetes
9725003|NCT05282680||Type 1 diabetes|Subjects with a diagnosis of type 1 diabetes
9725004|NCT05282680||Diabetic kidney disease|Subjects with diabetic kidney disease (presence of albuminuria +/- eGFR<=60m/kg/m2) or history or presence of end stage renal disease
9725005|NCT05282667|Experimental|Resorbable cross-linked barrier membrane|Bone graft will be covered with a resorbable barrier membrane to exclude undesired cells from the area aimed at being regenerated (peri-implantitis bone defect)
10198520|NCT03376477|Experimental|Lenalidomide plus GM-CSF Vaccine plus Prevnar13|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration."
10198521|NCT03376477|Placebo Comparator|Lenalidomide Only|Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.
10198522|NCT03376477|Placebo Comparator|Lenalidomide plus GM-CSF Vaccine|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline."
10198523|NCT03370952|Active Comparator|new approach|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:~Delivery of affected ovary outside the abdominal cavity:~A transverse mini-laparotomy is done (2-3 cm) in the midline 2 cm above the symphysis pubis.~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
10198524|NCT03370952|Active Comparator|Laproscopic ovarian cystectomy|classic laparoscopic ovarian cystectomy
10198525|NCT03367871|Experimental|Pembrolizumab, Chemotherapy, Bevacizumab|On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).
10198526|NCT03366779|Other|Surgery with 6mm ACD|ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
10198527|NCT03365882|Experimental|Arm I (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10198528|NCT03365882|Experimental|Arm II (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I.
10198529|NCT03365609|Experimental|T-group|T-group(triple therapy)
10198530|NCT03365609|Experimental|S-group|S-group( sequential therapy)
10198531|NCT03365609|Experimental|B-group|B-group( bismuth quadruple therapy )
10198532|NCT03365609|Experimental|C-group|C-group( concomitant therapy)
10198533|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
9725006|NCT05282667|Experimental|No barrier membrane|Bone graft will be solely packed in the peri-implantitis bone defect with no membrane to cover
9725007|NCT05282654|No Intervention|Usual Care (Arm 1)|During the 18-month Baseline Period (Arm 1, n=450) patients will be enrolled and receive usual care to develop the initial predictive model.
9725008|NCT05282654|No Intervention|Usual Care (Arm 2)|During the 30-month Main Trial (RCT) Period, patients will be randomized to usual care (Arm 2, n=425). Data collection for post-discharge AE determination will occur during both periods.
10198534|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
10198535|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
10198536|NCT03353675|Experimental|TG4010/Chemotherapy/Nivolumab|
10198537|NCT03351049|Experimental|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
10198538|NCT03351049|Active Comparator|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
9725009|NCT05282654|Experimental|Intervention (Arm 3)|During the 30-month Main Trial (RCT) Period, patients will be randomized to the intervention (Arm 3, n=425). Data collection for post-discharge AE determination will occur during both periods.
9725010|NCT05282641|Experimental|Collagen hydrolysate|30 subjects will consume the protein hydrolysate daily for 4 weeks
9725011|NCT05282641|Placebo Comparator|Placebo|30 subjects will consume the placebo daily for 4 weeks
9725012|NCT05282628|Experimental|Building Better Brains and Behavior program (B4 Preterm)|Online learning modules completed sequentially and in conjunction with live coaching sessions led by a trained therapist.
9725013|NCT05282602|Experimental|Wii Fit Based Exercises|Group A will receive Wii fit Based Exercises
9981037|NCT05268484|Experimental|TBI Intervention Group|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
9981038|NCT05268484|No Intervention|TBI Control Group|No intervention is provided
9725014|NCT05282602|Experimental|Proprioceptive Training|Group B will receive proprioceptive training
9725015|NCT05282589|Experimental|Lumbopelvic manipulation and conventiontional therapy|Group A an experimental group was given conventional therapy and lumbopelvic manipulation. conventional therapy include TENS and Hot pack for 20 minutes , hamstrings stretching, calf stretching,transversus abdominis strengthening and lumber multipedes muscle strengthening. while lumbopelvic manipulation include high velocity thrust given in posterior direction to ASIS.
10198539|NCT03341715|Experimental|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
9725016|NCT05282589|Active Comparator|conventional therapy|Group B, control group was given only conventional therapy which include TENS and Hot pack for 20 minutes , hamstrings stretching, calf stretching,transversus abdominis strengthening and lumber multipedes muscle strengthening . 1 set of 10 repetitions, 3 sessions per week with a total of 12 sessions.
9725017|NCT05282576|Active Comparator|Experimental Group|We applied neurophysiological facilitation techniques in addition to conventional rehabilitation.
9725018|NCT05282576|Other|Control Group|Critical ill patients was applied their conventional physiotherapy
9725019|NCT05282563|Other|The safety of esophagojejunostomy in total gastrectomy for gastric cancer|The safety of esophagojejunostomy depends on the integrity of the anastomosis, sufficient blood supply and satisfactory tension. Early tight mucosal anastomosis and the proliferation of mucosal epithelial cells can reduce the stimulation of digestive fluid to the anastomotic wound.Professor Zhao Yuzhou surgical team proposed double and a half layered esophagojejunal anastomosis to improve the safety of anastomosis. This method is simple and has no special requirements for the selection of instruments and sutures. It can be carried out in all levels of hospitals. In order to verify the value of this method in gastrointestinal reconstruction of gastric cancer, Professor Zhao Yuzhou surgical team plans to carry out a multicenter, randomized controlled study throughout the province.
9725020|NCT05282537||In person academic activities group|"University students of health sciences area returning to in person academic activities in Mexico.~All unviersity students will return to in person academic activities in March, 2022, for that reason a limitation is that it is no possible to have a control group (Nobody is goint to continue in virtual academic activities)."
9725021|NCT05282511||Patients with acute myocardial infarction|Patients with acute myocardial infarction
9725022|NCT05282511||Healthy controls|Healthy controls
9725023|NCT05282511||Patients with vasospastic angina|Patients with vasospastic angina
9725024|NCT05282472|Experimental|with surgical mask|all participants who were applied CPET with surgical mask
9725025|NCT05282472|Active Comparator|without surgical mask|all participants who were applied CPET without surgical mask
9725026|NCT05282459|Experimental|Enasidenib mesylat|Participants will self administer the enasidenib orally everyday.
9725027|NCT05282446|Experimental|INV-202|INV-202 25mg by mouth once daily
9725028|NCT05282446|Placebo Comparator|Placebo|Matching placebo by mouth once daily
9725029|NCT05282433|Experimental|Research Group|Patients with advanced hepatocellular carcinoma who had failed previous standard 1/2-line therapy and could not tolerate or reject existing therapies.
9725030|NCT05282420|Active Comparator|Ranibizumab group|Ranibizumab injection monthly for 3 successive months
9981039|NCT05268484|No Intervention|Healthy Control|No intervention is provided
9981040|NCT05268471|Experimental|Positional Device (PD)|Vibrating positional device (Nightbalance, Philips) to treat positional obstructive sleep apnea
10198540|NCT03341715|Placebo Comparator|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
10198541|NCT03341156|Experimental|Kcentra (PCC)|Half of subjects enrolled will be randomized to the Kcentra (PCC) group.
10198542|NCT03341156|Active Comparator|Frozen Plasma Product, Human|Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.
10198543|NCT03341078|Placebo Comparator|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
10198544|NCT03341078|Active Comparator|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
10198545|NCT03341078|No Intervention|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
10198546|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
10198547|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
10198548|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
9981041|NCT05268471|Active Comparator|Continuos Positive Airway Pressure (CPAP)|Continuos Positive Airway Pressure (standard treatment) to treat obstructive sleep apnea
10198549|NCT03331640|Experimental|OFF|
9725031|NCT05282420|Active Comparator|Aflibercept group|Aflibercept injection monthly for 3 successive months
9725032|NCT05282407|Experimental|Experimental group|Tenolid Tab
9725033|NCT05282407|Active Comparator|Control group|Viread Tab
9725034|NCT05282381||Cohort of renal transplant recipients|
9725035|NCT05282368|Experimental|Intervention (PHM)|This pathway is intended to be a tool to enhance support for a mother/birthing person and her caregiving partner, facilitate communication with healthcare providers, and promote development of caregiving to optimize maternal-fetal, infant, and family health.
9725036|NCT05282368|No Intervention|Usual Care Group (UC)|The control group participants will receive care as usual.
9725037|NCT05282355|Experimental|Astaxanthin|The astaxanthin group received 12 mg/day of astaxanthin. Each capsule contained 6 mg of astaxanthin and sunflower oil, and each subject ingested one capsule in the morning and one in the evening.
10198550|NCT03331640|Experimental|FOLFIRI|
10198551|NCT03330418|Experimental|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
9725038|NCT05282355|Placebo Comparator|Placebo|The placebo group ingested two capsules per day, one in the morning and one in the evening. Each capsule contained sunflower oil and mimicked the size and appearance of the astaxanthin supplement.
9725039|NCT05282342||Transplants with low levels of physical activity (GTB)|
9725040|NCT05282342||Transplants with moderate levels of physical activity (GTM)|
9725041|NCT05282342||Transplants with high levels of physical activity (GTA)|
9725042|NCT05282342||Healthy sedentary people (GSS)|
9725043|NCT05282329|Experimental|tACS group|Participants receive tACS 20-min sessions in a 5-day sequence for four consecutive weeks,combined with original and stable medication. Active group participants were administered 2 mA alternating current delivered with alpha frequency, delivered over the temporal lobe.
9725044|NCT05282329|Sham Comparator|Sham group|Controls received sham stimulation with the same protocol.
9725045|NCT05282303||DIESPB|Dual injection of erector spinae plane block
9725046|NCT05282303||TPVB|Thoracic paravertebral block
9725047|NCT05282303||SAB|Serratus anterior plane block
9725048|NCT05282303||PIB|Parasternal ıntercostal block
9725049|NCT05282290|Experimental|Experimental group|"Lower systolic blood pressure to 90-110 mm Hg.~Blood pressure not lower than 90/60 mm Hg~Hypotensive maintenance treatment for 48 hours."
9780761|NCT01130844|Experimental|MMX Mesalamine (60 mg/kg)|
9780762|NCT01130844|Experimental|MMX Mesalamine (100 mg/kg)|
9981042|NCT05268445|Active Comparator|Chemical angioplasty|Chemical angioplasty using intra-arterial Nimodipin
9981043|NCT05268445|Active Comparator|Chemical and Mechanical angioplasty|Balloon angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Neurospeed balloon) or Adjustable remodeling mesh angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Comaneci) in association with intra-arterial Nimodipin
9981044|NCT05268406|Experimental|Single arm|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
9981045|NCT05268380||Household contact study|Investigation of Covid-19 index cases' households for TB infection and disease, HIV seropositivity, Covid-19 active infection and previous infection.
9981046|NCT05268380||Primary healthcare facility study|Investigation of primary healthcare facility attendees for TB infection and disease, HIV seropositivity, Covid-19 active infection and previous infection.
9981047|NCT05268354|Experimental|Training group|6-week neuromuscular training program
10198552|NCT03330418|Experimental|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
10198553|NCT03323892|Active Comparator|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
9725050|NCT05282290|Active Comparator|The control group|"Subjects with basic blood pressure(BBP) > 140/90 mm Hg should have BBP lowered to about 140/90 mm Hg.~Subjects whose BBP was less than 140/90mm Hg were kept BBP."
9981048|NCT05268354|No Intervention|Control group|
9981049|NCT05268315|Experimental|Brief Psychoeducational Intervention|Parents of children with cancer who complete the study participate in a brief, 1-session psychoeducational intervention.
9725051|NCT05282251|Experimental|Pain managment after VATS|
9725052|NCT05282225|Experimental|MI-SP +supportive Texts + monitoring (Sequence A)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group A: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge.
9725053|NCT05282225|Experimental|MI-SP + monitoring (Sequence D)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group D: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge.
9981050|NCT05268302|Experimental|Low Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10^2 Plaque Forming Units
9725054|NCT05282225|Experimental|MI-SP + supportive Texts + monitoring + portal follow-up for non-responders (Sequence B).|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group B: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the portal follow-up for non-responders.
9725055|NCT05282225|Experimental|MI-SP + supportive Texts + monitoring + booster call for non-responders (Sequence C)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group C: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of supportive Texts and monitoring post discharge in addition to the booster call for non-responders.
9725056|NCT05282225|Experimental|MI-SP + monitoring + portal follow-up for non-responders (Sequence E)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group E: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the portal follow-up for non-responders.
9981051|NCT05268302|Experimental|Medium Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10^3 Plaque Forming Units
9981052|NCT05268302|Experimental|High Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)|0.95 x 10^4 Plaque Forming Units
10198554|NCT03323892|Experimental|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.~Intervention = second sperm sample"
10198555|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
9725057|NCT05282225|Experimental|MI-SP + monitoring + booster call for non-responders (Sequence F)|Sequencing of intervention components (Phase 1 and Phase 2) resulting in Sequence or Group F: Participants will receive the in-person MI-enhanced safety plan (MI-SP) during hospitalization followed by 4 weeks of monitoring post discharge in addition to the booster call for non-responders.
9725058|NCT05282199|Experimental|IMT group|In the group of post-COVID patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
9725059|NCT05282186|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
9725060|NCT05282186|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health.
9725061|NCT05282160|No Intervention|Control Group|The control group (G1) will be composed of puerperal women over 18 years of age attended by Lucila Balalai Municipal Maternity in Londrina. Recruitment will be done through a chart review, which will include single-fetus primiparous that delivered on full term without intercurrence (between 37 and 42 weeks).
9725062|NCT05282160|Experimental|Epino Group|The study group (G2) will be composed of women over 18 years of age, primigravidae, between 30 and 32 weeks of gestation attended by the Basic Health Units of the central region of Londrina. Only those who agree to participate in the study and sign the free and informed consent form will be included.
9725063|NCT05282134|Experimental|Wet cupping therapy|The intervention group will undergo 3 successive wet cupping therapy (WCT) sessions once in a month throughout 3 months (On 0, 30, and 60 days. Cups will be held for 5 minutes on the 5 regions of the C7 cervical spine (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupoint) and bilateral T6-8 lateral spine (BL44-46) points, which are recommended areas for headache, Then, these areas where the blood supply has increased will be drawn with a sterile lancet and the cup will be applied again and left for 10 minutes, and then the cups will be removed and the accumulated blood will be cleaned.
9725064|NCT05282134|Experimental|Acupuncture|Acupuncture application will be done by manually needling selected acupuncture points specific to the disease twice a week for 4 weeks. After the needles are placed, they will be manipulated to create a feeling of de-qi and left for 20 minutes.
9725065|NCT05282134|No Intervention|Control|Control group will not receive any intervention
9785805|NCT01260350|Experimental|Group 12: SOF+RBV+LDV 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
9981053|NCT05268289|Active Comparator|Iptacopan + standard of care (part 1)|Iptacopan + standard of care
9981054|NCT05268289|Placebo Comparator|Placebo matching iptacopan + standard of care (part 1)|Placebo matching iptacopan standard of care
9981055|NCT05268289|Active Comparator|Iptacopan + standard of care (part 2)|Iptacopan + standard of care
9981056|NCT05268289|Active Comparator|Iptacopan + placebo (part 2)|Iptacopan + placebo standard of care
10198556|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
10198557|NCT03319316|Experimental|Cohort 1 - Non-squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
10198558|NCT03319316|No Intervention|Cohort 1 - Non-squamous - Arm B|Patients receive a maintenance treatment of pemetrexed
10198559|NCT03319316|Experimental|Cohort 2 - Squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
9981057|NCT05268289|Active Comparator|Placebo matching iptacopan + standard of care (part 2)|Placebo matching iptacopan + standard of care
9725066|NCT05282095||Women aged from 18-35 with histopathologically confirmed CIN2|In the enrollment, women whose cervical histopathological results have been diagnosed as cervical intraepithelial neoplasia (CIN2) for the last 3 months with abnormal results will be included in this study. All participants will be followed up twice, at 6th month and 12th month.
9725067|NCT05282082||Patients at the moment of their admission to the hospital in one of the three cities|Swabs will be taken from patients who are willing to participate.
9725068|NCT05282082||"Healthy volunteers living in high-risk areas in one of the three cities."|Swabs will be taken from healthy volunteers who are willing to participate.
9725069|NCT05282056|Experimental|CAD analysis|The XVision COVID-19 computer aided diagnostic software is used by radiologist at CT analysis time
9725070|NCT05282056|No Intervention|No CAD analysis|No CAD analysis is shown to radiologist.
9725071|NCT05282043|Experimental|post COVID-19 group|In this group cases, who were infected with COVID-19 and had at least 12 weeks after diagnosis, will be allocated. Those should have no symptoms of COVID-19 such as fever, cough, ageusia, anosmia, diarrhea, arthralgia, myalgia, sore throat, headache, chest pain.
9725072|NCT05282043|Active Comparator|healthy control group|In this group cases, who were not infected with COVID-19 will be allocated.
9725073|NCT05282030|Experimental|Severe Renal Impairment (RI) group (Part A only)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
9725074|NCT05282030|Experimental|Normal Renal Function group (Part A and B)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
9725075|NCT05282030|Experimental|Moderate RI group (Part B only conditional)|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
9725076|NCT05281978|Experimental|Decrease Sedentary Time + Increase MVPA|Participants in this group will receive a 12-week, social cognitive theory-based intervention targetting reduction of daily sedentary time. This information will be delivered to them in the form of Zoom workshops, a program workbook, personalized step count goals, and a private social media page. The aim of this component will be to have participants displace their daily sedentary time with light-intensity physical activity, such as casual walking. The second component of this intervention will be increasing participants' weekly MVPA engagement. Participants will participate in 1 live, virtual aerobics-based exercise class per week and complete 2 additional sessions on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
9725077|NCT05281978|Active Comparator|Increase MVPA only|Participants in this group will only receive the MVPA-promoting component (which will be the same delivery as the intervention group). Participants in this arm will participate in 1 live, virtual aerobics-based exercise class per week (held separately from the intervention group) and will complete 2 additional exercise classes on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
9725078|NCT05281965|Experimental|Experimental group|
9725079|NCT05281965|Placebo Comparator|Placebo group|
9725080|NCT05281952|Experimental|endoscopic ligation|
9725081|NCT05281952|Active Comparator|Supra-selective embolization|
9725082|NCT05281939|Active Comparator|Artificial intelligence diagnostic group|Women who show abnormalities in cervical cancer screening and require referral for colposcopy. Colposcopy was performed with the aid of an Artificial intelligence (AI) system.
9981058|NCT05268276|Experimental|study group|"the study group will recelve adesigned protocol of care that entails three interventions as the following1) Application of ice gel pad on perineal trauma for the first 24 hours post partum 2) Performance of pelvic floor exercises (Kegel exercises) from six hours till one week postpartum 3) Application of warm compresses after 48 hours and through the first week postpartum.~The investigator will perform demonstration and then redemonstration by the women on each intervention will be done. A designed booklet (developed previously) that explains each intervention will be given to each woman."
9981059|NCT05268276|No Intervention|control group|The control group will receive the routine hospital care only
9981060|NCT05268237|Experimental|Part 1: Open Label|Part 1 of the trial will utilise an open label, single ascending dose, repeated treatment design. It will involve 3 subjects, each of whom will receive three single ascending doses of SL liraglutide (3, 12, 30mg and subcutaneous (SC) liraglutide (active comparator) with a mixed meal tolerance test (MMTT), separated by 1 week washout between doses.
9981061|NCT05268237|Experimental|Part 2: Investigator blind|Part 2 of the trial will utilise an investigator-blind, sponsor open, placebo-controlled, randomised, repeated treatment study design. It will involve 12 subjects. Each subjects will receive one of three possible doses of SL-liraglutide (to be decided by the Safety Monitoring Committee following analysis of the results from Part 1), SL-placebo or SC liraglutide in a randomised order with MMTT separated by 1 week washout between doses.
10198560|NCT03319316|No Intervention|Cohort 2 - Squamous - Arm B|Patients will have observation
10198561|NCT03317860|Sham Comparator|Sham tDCS plus RTP|Single session of bilateral sham parietal cortex tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
10198562|NCT03317860|Active Comparator|Active tDCS plus RTP|Single session of bilateral active parietal cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
10198563|NCT03317496|Experimental|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
10198564|NCT03317496|Experimental|Group A Cohort A2|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
9981062|NCT05268198|Experimental|Intervention/Treatment|Single dose, oral inhalation (nebuliser solution)
9981063|NCT05268198|Placebo Comparator|Placebo|Placebo
9981064|NCT05268185|Active Comparator|Moderna Booster Recommendation|Participants assigned to this arm will be recommended to receive the Moderna vaccine for their Covid-19 booster shot.
9725083|NCT05281939|No Intervention|Gynecologist diagnostic Group|Women who show abnormalities in cervical cancer screening and require referral for colposcopy. Colposcopy is performed independently by a gynecologist without any external assistance.
9725084|NCT05281926|Experimental|Poly-ICLC|Hiltonol is a poly-ICLC developed by the Oncovir, Inc. A phase I study of hiltonol monotherapy in solid tumors was completed (NCT01984892). Clinical trials of hiltonol plus ICIs are undergone in various type cancers (NCT03721679, NCT02834052).
9981065|NCT05268185|Active Comparator|Pfizer Booster Recommendation|Participants assigned to this arm will be recommended to receive the Pfizer vaccine for their Covid-19 booster shot.
9725085|NCT05281913|Experimental|Intervention Group|A web-based Simulation Game concerning marital positive skills in remarriage, positive co-parenting strategies and positive stepparent-stepchild relationship skills.
9725086|NCT05281913|No Intervention|Control|No intervention
10198565|NCT03317496|Experimental|Group A Cohort A3|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
9725087|NCT05281900|Experimental|Physically active volunteers|All volunteers who meet the inclusion criteria will be included in the study.
9725088|NCT05281887||ischemic stroke|According to diagnostic criteria
9981066|NCT05268159||Stroke patients|Stroke patients admitted to the Lille Neurological rehabilitation unit after a first-ever hemispheric stroke, assessed at the subacute phase (< 6months)
9981067|NCT05268120|Active Comparator|A|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
9725089|NCT05281887||healthy control|without any retinal diseases
9725090|NCT05281874|Placebo Comparator|Control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
9725091|NCT05281874|Experimental|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
9725092|NCT05281874|Experimental|Positive Change (+Change) Plus Booster|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation. It is provided at baseline and a booster at 6 months.
9725093|NCT05281861|Experimental|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|The onlays will be constructed from Zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic system
9725094|NCT05281861|Active Comparator|Lithium disilicate (IPS e-max press) ceramic onlay restoration|The onlays will be constructed from Lithium disilicate (IPS e-max press) glass ceramic system
9725095|NCT05281848|Active Comparator|Smoker-Periodontitis; Non-surgical periodontal treatment|
9725096|NCT05281848|Active Comparator|Nonsmoker-Periodontitis;Non-surgical periodontal treatment|
9725097|NCT05281848|No Intervention|Healthy|
9725098|NCT05281822|Experimental|Experimental group|The BMI (kg/m2) was calculated by measuring the height and weight of the women in the experimental groups. Then, the women in the experimental group were provided with stress management training to help cope with stress conditions, how to use positive coping in conditions in case of stress and tension. In terms of the reliability of the training, each woman was interviewed face-to-face, which lasted for 30-40 minutes.
9725099|NCT05281809|Experimental|Treatment Arm|CAR -T-cell collection, infusion
9725100|NCT05281796||healthy patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
9725101|NCT05281796||gingivitis patient|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
9725102|NCT05281796||patients with Stage III periodontitis|Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained
9725103|NCT05281783|Experimental|Percutaneous Radiofrequency Ablation|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
9725104|NCT05281770||Erenumab|Patients will be treated with this drug within standard of care treatment
9725105|NCT05281770||Galcanezumab|Patients will be treated with this drug within standard of care treatment
9725106|NCT05281770||Fremanezumab|Patients will be treated with this drug within standard of care treatment
9725107|NCT05281718|Experimental|Patient Group|In vitro spiking experiments will be realized in plasmas from patients with severe haemophilia A on emicizumab using increasing concentrations of factor IX (rFIX), Activated prothrombin complex (aPCC) and recombinant VIIa (rFVIIa).
9981068|NCT05268120|Active Comparator|B|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.
9981069|NCT05268094|Experimental|Ductal Artery Stent|Transcatheter ductal artery shunt will be placed by the interventional team. Drug-eluting coronary stent brand, length, and diameter are determined by the interventional team.
9981070|NCT05268094|Experimental|Systemic-to-Pulmonary Artery Shunt|Surgical systemic-to-pulmonary artery shunt performed by the interventional team. SPS diameter, length, and material will be determined by the surgeon performing the intervention.
9981071|NCT05268081|Experimental|Virtual specialist conferences|The group of general practices who participates in the virtual specialist conferences with endocrinologists.
9981072|NCT05268081|No Intervention|Standard of care|Receives the usual, standard practice.
9981073|NCT05268068|Experimental|Dose A of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose A and then followed for 140 days.
9981074|NCT05268068|Experimental|Dose B of Risankizumab for Subcutaneous (SC) Injection|Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.
9981075|NCT05268068|Experimental|Dose C of Risankizumab for Intravenous (IV) Infusion|Participants will receive IV infusion of risankizumab at dose C and then followed for 140 days.
9725108|NCT05281653|Experimental|Neuromuscular Training Group|Athletes in this group will receive progressive neuromuscular exercise training in addition to routine 2 weekly training sessions.
9725109|NCT05281653|Experimental|Control Group|The routine will continue with 2 workouts per week.
10198566|NCT03317496|Experimental|Group A Cohort A4|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
9725110|NCT05281640|Experimental|Affect Dysregulation intervention|"The AD module focuses on skills training in relation to identifying and labelling feelings, emotion management, distress tolerance, and acceptance of feelings and experiencing positive emotions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
9981076|NCT05268055|Experimental|"Sign Here training intervention"|"Participants randomized to the experimental condition will view the version of the Sign Here training film tailored to their role as researcher or healthcare provider."
9981077|NCT05268055|Other|Intervention as usual|"Participants randomized to intervention as usual will review a paper copy of the NIH Guidelines on Communicating Informed Consent for Individuals who are Deaf or Hard-of-Hearing and Scientists, i.e., the standard NIH guidance on how to communicate informed consent to Deaf or hard-of-hearing individuals."
9981078|NCT05267990|Active Comparator|coronary artery calcium-guide|"1500 asymptomatic T2DM patients who will receive Coronary artery calcium (CAC) imaging using 256 sliced multi-detector computerized tomography (MDCT) scanner If CAC score >0, Treadmill ECG or Thallium201 Scan would be arranged. If Treadmill ECG or Thallium201 show significant ischemia, further study such as CT angiography or coronary angiography will be arranged.~If CAC score > 100， Aspirin 100mg QD will be suggested to decrease the cardiovascular risk in patients with low risk of bleeding. Previous studies revealed aspirin for patients with CAC score>100 at low bleeding risk indicated net benefit If CAC score > 400，statin therapy will be suggested to control lipidemia aggressively and target LDL level<70 mg/dL"
9725111|NCT05281640|No Intervention|Treatment as usual (1)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
9725112|NCT05281640|Experimental|Negative Self Concept intervention|"The NSC module focus on the impact of trauma on one's self concept, how to stay in the present moment and combat dissociation, introduce self - compassion and mindfulness skills, challenge thinking patterns including tackling negative thoughts rules and assumptions that relate to ones-self, how to be more nurturing towards one's self, explore personal qualities and develop a balanced view of self.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
9725113|NCT05281640|No Intervention|Treatment as usual (2)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
9725114|NCT05281640|Experimental|Disturbed Relationships intervention|"The DR module will focus on exploration and revision of maladaptive schemas, effective assertiveness, awareness of social context, and flexibility in interpersonal expectations and behaviours that are displayed in social interactions.~The module will be delivered by a trained therapist,in each site. Sessions are one hour long and six sessions will be delivered over an 8-week therapy window."
9725115|NCT05281640|No Intervention|Treatment as usual (3)|TAU will include ongoing standard care - antipsychotic medication as well as monitoring by psychiatrists and community psychiatric nurses (CPNs).
9725116|NCT05281627||Emergency Laparotomy Patients|All adult patients (18+) who have undergone Emergency Laparotomy surgery, are recovering well (no illness which is expected to limit life to <6m post op) and have sufficient English-language and cognitive skills to complete the study questionnaires.
9725117|NCT05281627||Family Caregivers|Adult (18+) family members, close friend or caregivers of the individual who has received EmLap treatment have sufficient English-language and cognitive skills to complete the study questionnaires.
9725118|NCT05281614|Experimental|Arm A|Arm A will receive 6 weeks of vedolizumab after 8 weeks of etanercept. Final study visit at 52 weeks.
9725119|NCT05281614|Experimental|Arm B|Arm B will receive 6 weeks of vedolizumab only. Final study visit at 52 weeks.
9725120|NCT05281575|Active Comparator|Treatment as Usual BFS (TAU BFS)|Continuation of existing Baby Friendly Spaces program activities in integrated nutrition centers, which are not manualized and without re-training have naturally drifted in fidelity to the intervention and supervision approach due to time since initial training.
9981079|NCT05267990|No Intervention|usual care|The investigators will enroll 500 age, gender, risk factor matched T2DM patient from our hospital. The doctor in charge will give usual care according to the Diabetes associate of Taiwan clinical practice guidelines for diabetes care.
9981080|NCT05267977|Active Comparator|cephalosporin|cephalosporin
9725121|NCT05281575|Experimental|Enhanced BFS|The implementation-enhanced BFS intervention includes re-training using newly developed training materials that focus on building core therapeutic engagement skills. Ongoing supports include brief guidance sheets for each of the most commonly delivered BFS activities, as well as newly established group supervision focused on BFS, discussion facilitation, activities and self-care.
9725122|NCT05281523|Experimental|Participants receiving depemokimab (GSK3511294)|
9725123|NCT05281523|Placebo Comparator|Participants receiving Placebo|
9725124|NCT05281497|Experimental|Intervention group|Each participant was provided with a wearable device. Each participant downloaded an app (WowGoHealth app) to connect with the health management platform. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics. We also built a LINE group to inspire the intervention group.
9725125|NCT05281497|Placebo Comparator|Control group|Each participant was provided with a wearable device. Each participant downloaded an app (WowGoHealth app) to connect with the health management platform. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. We did not encourage exercise or build a LINE group.
9725126|NCT05281458|Experimental|Early endoscopic interventions for AP|Participants in the intervention group will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
10198567|NCT03315832|Experimental|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
10198568|NCT03315832|Placebo Comparator|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
10198569|NCT03312309|Experimental|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
10198570|NCT03306615|Experimental|Treatment Arm|Hyaluronidase plus saline
10198571|NCT03306615|Placebo Comparator|Control Arm|Normal Saline
10198572|NCT03306342|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
10198573|NCT03300518|Other|pretreatment group|the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
10198574|NCT03300518|Other|control groups|In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
10198575|NCT03300505|Experimental|ARRx + Enzalutamide|"Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.~Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)"
10198576|NCT03299478||NSCLC patients|
10198577|NCT03299309|Experimental|PEP-CMV|Cytomegalovirus (CMV)-specific peptide vaccine (PEP-CMV)
10198578|NCT03294434||High Grade Glioma|Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
10198579|NCT03294330|Experimental|Patients with Melanoma or Breast Cancer|The SPY machine used in conjunction with the IC-green kit will be used exclusively to identify sentinel nodes in patients diagnosed with Melanoma or Breast Cancer who are undergoing sentinel lymph node biopsy.
10198580|NCT03294109|Experimental|study|liposomal bupivacain
10198581|NCT03294109|No Intervention|control|no intervention
9725127|NCT05281458|No Intervention|Standard endoscopic interventions for AP|Participants in the control group will have postponed drainage, preferably until AP progress to the walled-off necrosis stage.
9725128|NCT05281445|Experimental|Tic suppression|Children with tics will undergo a tic suppression experimental paradigm.
9725129|NCT05281432||Pes planus individuals|The aim of this study was to evaluate the static and dynamic balance status of male individuals diagnosed with pes planus.
9725130|NCT05281419|Experimental|Intralesional triamcinolone injection with whole breast detection radical surgery|
9725131|NCT05281419|Active Comparator|Whole breast detection radical surgery|
9725132|NCT05281406|Experimental|Osimertinib in combination with platinum-based chemotherapy|all patients received a platinum-based chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed) for a maximum of 4 cycles (q3w) in combination with 80 mg Osimertinib daily
9725133|NCT05281393|No Intervention|Control|Access to mobile health platform for resources and information about PrEP
9725134|NCT05281393|Experimental|Experimental|Access to mobile health platform for resources and information about PrEP plus sessions with peer health support navigator, social app interactions, goal setting capabilities
9725135|NCT05281380|Other|Intervention with vitamin supplement|Intervention with vitamin supplement Multi-E and Multi-G
9981081|NCT05267977|Active Comparator|cephalosporin and aminoglycoside|the combination of cephalosporin and aminoglycoside.
9984560|NCT03978637|Experimental|Itacitinib 600 mg|Phase 1: Itacitinib 600 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration
9725136|NCT05281367|Experimental|Breast milk odor group|It is a non-pharmacological method of pain control in which 3 cc of breast milk will be dripped onto a sterile pad and It will be placed at a distance of 10 cm from the nose of the newborn. Precisely, premature newborns' own mothers' milk will be used. For this, mothers of newborns will be contacted and breast milk will be provided for the day of the procedure.
9725137|NCT05281367|Experimental|Facilitated tucking group|It is a non-pharmacological method of pain control in which the arms and legs are slowly contracted and placed close to the body. In this method, the baby is placed on its side, the baby's back is gently bent, the legs are folded at an angle of more than 90 degrees, the shoulders are folded up to 90 degrees, and the care hands are placed either on the head near the mouth or Placed on the baby's face.
10198582|NCT03290521|Experimental|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
10198583|NCT03290521|Experimental|B- No Washing (NL)|No washing was performed before the end of surgery
10198584|NCT03283137|Experimental|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
10198585|NCT03278119||Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, having mild to severe obstructive sleep apnea~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
10198586|NCT03278119||No Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, without OSA~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
10198587|NCT03277196|Experimental|Ivacaftor Arm|
10198588|NCT03277196|No Intervention|Observational Arm|
10198589|NCT03273413|Placebo Comparator|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
10198590|NCT03273413|Active Comparator|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
10198591|NCT03269409|Sham Comparator|Hip Decompression with lactated ringers|Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
10198592|NCT03269409|Experimental|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
10198593|NCT03269084||Children at HLA-conferred risk for T1D|
10198594|NCT03268005|Experimental|Faster aspart + insulin degludec with or without metformin|
10198595|NCT03268005|Active Comparator|NovoRapid/NovoLog + insulin degludec with or without metformin|
10198596|NCT03266315|Experimental|Probiotics|subjects will be randomly assigned to receive FloraBaby
10198597|NCT03266315|Placebo Comparator|Placebo|subjects will be randomly assigned to receive placebo
10198598|NCT03257618|Experimental|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
10198599|NCT03247764||patients with the comorbidity of epilepsy and depression|the clinical data, psychological assessment, and drug treatments will be investigated in patients with the comorbidity of epilepsy and depression
10198600|NCT03240003|Experimental|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of standard GC-MRT
10198601|NCT03240003|Active Comparator|non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
10198602|NCT03240003|Experimental|GC-MRT-modified|Group 3 will receive a 4-week (8-sessions) course of modified GC-MRT.
10198603|NCT03238976|Experimental|Nature sounds exposure|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~Patients in the nature sounds group will be exposed to continuous nature sounds during the core needle biopsy (CNB) procedure.~The CNB procedure will continue as planned with nature sounds playing instead of the supportive dialogue. All sounds will be played out of a speaker situated in the corner of the room."
10198604|NCT03238976|No Intervention|Standard care (supportive dialogue)|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~The CNB procedure will continue as planned with supportive dialogue which will be played out of a speaker situated in the corner of the room. This group follows the current standard of care."
10198605|NCT03235518||Structure Interviews with FSW|Structured interviews with 200 purposively sampled FSW will be conducted. These interviews will be conducted prior to focus group discussion (FGD) and in-depth qualitative interview (IDI) with FSW. Structured interviews will take approximately 45-60 minutes to complete and will be administered privately in Kiswahili, Dholuo or English by trained female research staff. Quantitative interviews will be administered to conduct an assessment of FSW sociodemographics, sexual behaviour patterns and HIV-related knowledge, attitudes and practices regarding HIV prevention and other factors that might affect initiation and adherence to PrEP use, ability to use PrEP covertly, HIV testing history, mobility patterns, social networks, pregnancy intentions, ability to use condoms consistently with clients, and regular partners, and interpersonal violence from clients, regular partners and the police.
10198606|NCT03235518||Focus Group Discussions with FSW|Three to five FGDs of up to 10 FSW per group will be conducted. These FGD will take place prior to FSW IDI. FSW who participated in FGDs will be ineligible for participation in the IDI. All group discussions will last approximately 1.5 to 2 hours and be conducted in Kiswahili, Dholuo or English. Each group discussion will be facilitated by trained female research staff and held in a private space at a pre-specified location. The themes that will be explored in the FGDs include: FSW social networks, participation in PrEP studies, barriers and facilitators to PrEP use and use of resource transfers for PrEP adherence. In addition, participants will complete a brief demographic survey.
10198607|NCT03235518||In-Depth Qualitative Interviews with FSW|30 IDI will be conducted with FSW. FSW who participated in FGDs will be ineligible for participation in the IDI. All in-depth interviews will be conducted by trained female research staff using a semi-structured interview guide. All interviews will be held in a private space at a pre-specified location within the community. The topics that will be discussed in the IDI with FSW include demographics, social support, dynamics of sex work, HIV prevention methods (including condom use), perception of HIV risk and development of PrEP intervention.
10198608|NCT03235518||In-Depth Qualitative Interviews with MC|30 IDI will be conducted with MC. All IDI will last approximately 60-90 minutes and be conducted in Kiswahili, Dholuo, or English. Each interview will be conducted by a trained male research staff using semi-structured interview guide. All interviews will be held in a private space at a pre-specified location. Topics include demographics, relationships with FSW, HIV prevention methods (including use of condoms), perception of HIV risk and development of PrEP intervention.
10198609|NCT03235518||In-Depth Qualitative Interviews with HCPs|30 IDI will be conducted with health care provider (HCP). All IDI will last approximately 60-90 minutes and be conducted in English. Each interview will be conducted by trained research staff using a semi-structured interview guide. Interviews will be held in a private space at the health facility where they work or another venue preferred by the HCP. Topics include demographics, health care needs of FSW and sources of care, HIV prevention needs of FSW, PrEP for FSW and training needs for HCP.
10198610|NCT03232164|Experimental|18F-DCFPyL PET|We will have three separate sub-studies evaluating 18F-DCFPyL PET imaging of prostate cancer in three prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, and (3) androgen-resistant metastatic disease.
9981082|NCT05267964|Active Comparator|Epping resection arthroplasty|During the Epping resection-suspension arthroplasty the trapeziectomy is performed, the flexor carpi radialis tendon is divided into two parts and one of these is stripped and cut proximally. To prevent shortening of the first ray with following loss of strength, this tendon strip is pulled through a drill hole in the base of the 1st metacarpal from ulnar palmar to radial dorsal. The rest of the tendon strip is sutured to a roll replacing the os trapezium.
9981083|NCT05267964|Active Comparator|CMC I prosthesis group|During implantation of the prosthesis the CMC joint is opened and 3 mm of the metacarpal base as well as osteophytes are resected. Following the release of the trapezium the first metacarpal and the trapezium are prepared for the prosthesis by broaching and drilling. After the test-implants have shown satisfying joint tension and anatomic conditions, the HA coated stem and cup are pressfit inserted in the appropriate size followed by the modular head.
9981084|NCT05267951|Experimental|Open-loop Stimulation|Continuous stimulation
9981085|NCT05267951|Experimental|Close-loop Stimulation|Intended movement-based stimulation.
9981086|NCT05267912|Experimental|ORGANOTREAT 01|"To assess the feasibility of timely generating chemograms from PDOs in advanced CRC.~To assess the proportion of patients treated according to the chemogram tumor board (CTB)'s recommendations on the basis of their personalized chemogram.~To assess the efficacy and safety of chemogram-driven treatment in advanced CRC."
9725138|NCT05281367|Experimental|Non-nutritive sucking group|It is a non-pharmacological method used to control pain in infants. In this method, babies suck without receiving the nutrient. This can be done by a pacifier, a parent's hand or a nurse.
9725139|NCT05281367|Experimental|control grup|The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick.
9725140|NCT05281354|No Intervention|standard care|Follow-up according to standard practice
9725141|NCT05281354|Experimental|multimodal intervention|Addition of a treatment to normalise resting energy expenditure according to the observed abnormalities
9725142|NCT05281328|Experimental|CAM2029 once weekly|0.5 mL CAM2029 10 mg, subcutaneous (SC) injection, once weekly
9725143|NCT05281328|Experimental|CAM2029 once every 2 weeks|0.5 mL CAM2029 10 mg, SC injection, every 2 weeks and 0.5 mL placebo, SC injection, once every 2 weeks (alternating with CAM2029 dosing)
9981087|NCT05267912|Experimental|ORGANOTREAT 02A|is a single-arm, Phase II study to evaluate the efficacy of chemogram-driven treatment in patients with advanced, pretreated solid cancers of low-to-intermediate incidence and/or with a PDO take-on rate <50%. The primary endpoint is the Growth Modulation Index (GMI), defined as PFSn/PFSn-1, where PFSn is the -progression-free survival (PFS) time on study treatment and PFSn-1 the PFS time within the previous treatment line.
9981088|NCT05267912|Experimental|ORGANOTREAT 02B|is a randomized Phase II study to compare the efficacy of chemogram-driven treatment vs SoC in patients with advanced, pretreated solid cancers with a PDO take-on rate ≥50%. A cross-over will allow patients enrolled in the control arm to benefit from chemogram-based treatment. Patients for whom no chemogram can be obtained will not be randomized and they will be treated according to SoC. The primary endpoint will be PFS. The study will include multiple strata, each for a different tumor type (e.g., stratum 1, pancreatic ductal adenocarcinoma (PDAC); stratum 2, CRC; etc.). Each stratum will be conducted and analyzed independently from the other strata.
10198611|NCT03228186|Experimental|Pevonedistat plus Docetaxel|Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle
10198612|NCT03226756|Experimental|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
10198613|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
9725144|NCT05281328|Placebo Comparator|Placebo|0.5 mL placebo, SC injection, once weekly
9725145|NCT05281289|Experimental|Kinesio-tape application+stretchinge exercises|"the patient received AYstripof KT was applied to the testing leg 30% tension for 48h and was asked to assume comfortable supine position and the therapist applied 15 seconds of passive stretch to the calf muscle followed by 30 seconds of rest and this exercise was repeated 6 times per session for 2 days and ecieved instructions about dealing with calf cramps with self low sustained stretch of calf muscle."
9725146|NCT05281289|Experimental|self low sustained strestch|the patient recieved instructions about dealing with calf cramps with self low sustained stretch of calf muscle.
10198614|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
10204943|NCT04408105||Gastroenterologists|100 eligible gastroenterologists (GIs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible GIs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for GIs to complete a paper survey at provider clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
9981089|NCT05248061|Active Comparator|Group A|home exercise program
9981090|NCT05248061|Experimental|Group B|PRP+home exercise program
9981091|NCT05247333|Experimental|Patients presenting with minor ailments or requesting a non-prescription product.|"Community pharmacists working with agreed protocols with primary care physicians respond to all type of patients presenting with minor ailments or requesting a non-prescription product.~Following this consultation, patients are followed up after ten days."
9981092|NCT05247307|Experimental|Intervention|"Treatment in the intervention group:~Infusion of 300 cc of convalescent donor plasma from COVID 19, administered within more than 168 hours from the onset of symptoms Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
9981093|NCT05247307|Active Comparator|Control|"Treatment in the control group:~For the study to be blind, the infusion of non-convalescent donor plasma, obtained before the start of the epidemic, is required to guarantee the absence of anti-COVID antibodies in the plasma of the control group.~Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
9981094|NCT05246891||Rehabilitation nursing intervention|Functional respiratory rehabilitation exercise plan. Motor exercise plan. Cardiorespiratory optimization. Early diagnosis of potential problems associated.
9981095|NCT05246891||Rehabilitation nursing not intervention|General nursing care
9725147|NCT05281276|Experimental|chidamide (20 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (20 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
9725148|NCT05281276|Experimental|chidamide(30 mg) BIW in combination with celecoxib (CC)|"Chidamide: The dosing schedule is four/six tablets (30 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days.~Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast.~A treatment cycle is defined as a period of 4 weeks (28 days)"
9725149|NCT05281263|Experimental|Group 1, young adult cohort (age 18-59)|BLB-201 administered as a single dose of 10^7.5 PFU by intranasal route on Day 1
9725150|NCT05281263|Experimental|Group 2, older adult cohort (age 60-75)|BLB-201 administered as a single dose of 10^7.5 PFU by intranasal route on Day 1
9725151|NCT05281250|Experimental|Supervised physical exercise|Supervised exercise (aerobic + strength + flexibility) depending on the functional capacity of each patient, during hospitalization
9725152|NCT05281250|No Intervention|Control|Patients will receive recommendations about exercising during hospitalization.
9725153|NCT05281237|Experimental|AVECURE FLEXIBLE MICROWAVE ABLATION PROBE FOR LUNG NODULES|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Ablation Procedure- MWA will be used to treat solitary pulmonary nodules up to 3cm.~CT scan will then be performed to evaluate the radiological changes 2 - 4 weeks after the ablation procedure.~Surgery will be performed to remove the lung nodule and the tissue will be evaluated by pathology."
9725154|NCT05281198|Experimental|Experimental: tart cherry|dietary supplement: tart cherry juice
9725155|NCT05281198|Placebo Comparator|Placebo|dietary supplement: placebo juice
9725156|NCT05281185|Active Comparator|Severe haemophilia A patients with weight-based prophylaxis|Severe haemophilia A patients with low-dose standard half-life concentrates weight-based prophylaxis
9725157|NCT05281185|Experimental|Severe haemophilia A patients with low dose extended half-life PK-guided prophylaxis|Severe haemophilia A patients with low-dose extended half-life concentrates PK-guided prophylaxis
9725158|NCT05281172|Experimental|Guided Self-Change therapy|
9725159|NCT05281172|Active Comparator|Psychoeducation program about healthy habits|
9725160|NCT05281159|No Intervention|Standard of Care|This group will receive a standard SMS text message indicating that they have a MyChart message from their provider about CRC screening and should follow a link to be screened.
9725161|NCT05281159|Experimental|"Risk Information"|This group will receive an SMS text message highlighting their risk for CRC.
9725162|NCT05281159|Experimental|"Risk Information + Action"|This group will receive an SMS message highlighting their risk for CRC and the importance of taking quick action.
9725163|NCT05281133|Experimental|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
9725164|NCT05281133|No Intervention|The group not using virtual reality glasses|In the control group, during the splint a video was not watched.
9725165|NCT05281120|Active Comparator|mechanical intervention group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the active platform (inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
9725166|NCT05281120|Placebo Comparator|mechanical placebo group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the placebo platform (not inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
9780763|NCT01130883||Respiratory Infections|Czech patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid®SR treatment 6 weeks prior to the next Klacid®SR dose or in intervals: 7-week - 3- month, 4- month - 12- month, 13- month - 24- month prior to the next Klacid®SR dose (next Klacid®SR dose = dose administered within this PMOS).
10198615|NCT03225170|Experimental|Self-affirmation (SA) group|"Immediately prior to the scheduled cancer genetic counseling appointment, clients:~completed standardized questionnaires on self-affirmation (SA) intervention that focused on positive values of personal importance. The SA intervention required clients to rank 11 items (artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity) from most important to least important and to elaborate on one that was most important to them and why;~6-item standardized measure of anxiety questionnaire;~after the genetic counseling session, clients were required to fill out a post session questionnaire"
10198616|NCT03225170|Sham Comparator|Control group|"Immediately prior to the scheduled cancer genetic counseling appointment, clients:~completed similar standardized questionnaire as the SA group, with a non-affirming exercise. The non-intervention required clients to rank 11 items (artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity) from most important to least important and to elaborate on the 9th ranked item and why it might be important to someone else;~6-item standardized measure of anxiety questionnaire;~after the genetic counseling session, clients were required to fill out a post session questionnaire"
10198617|NCT03222882|Experimental|RIF group|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
10198618|NCT03222830|Experimental|RIF group|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
10204944|NCT04408105||Patients|500 eligible patients will be recruited across the 7 participating sites to complete a survey. The survey will be distributed to eligible patients at the time of a clinic appointment, via telephone, or via a REDCap internet survey that will allow for 2 additional electronic phone call reminders and 1 email reminder.
9780764|NCT01130896||MRI and Cardiac Devices|Clinically indicated MRI (all types) in patients with implanted pacemakers and ICD
9780765|NCT01130974|Experimental|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
9981096|NCT05246748|Experimental|Intervention group|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
9981097|NCT05246748|Active Comparator|Control group|The control group received solely standard education program for one sessions in prenatal period.
9981098|NCT05246657||intervention|EUS-guided Entero-biliary Anastomosis
9981099|NCT05246098||Adults|Adult survivors of severe acute respiratory syndrome (SARS) SARS-CoV-2 disease admitted to participating ICUs. Adults are defined as adults as greater than or equal to, 18 years old. We will include adults with a confirmed diagnosis of COVID-19.
9780766|NCT01130974|Active Comparator|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
9780767|NCT01131052|Active Comparator|BASAL PLUS|Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed
9780768|NCT01131052|Active Comparator|sliding scale regular insulin (SSRI)|Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed
9780769|NCT01131065|Experimental|Hepatitis B immune globulin|Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
9780770|NCT01131078|Experimental|Bevacizumab + Irinotecan + Capecitabine (1000 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle. Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice daily (Day 2 to 15). Cycle length was 3 weeks consisting of 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
9780771|NCT01131078|Experimental|Bevacizumab + Capecitabine (1250 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle in combination with capecitabine administered orally at 1250 mg/m^2 twice daily (Day 1 to 14). Cycle length was 3 weeks with 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
9725167|NCT05281107|Placebo Comparator|Placebo, 500 mg calcium|Participants received 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
10198619|NCT03220854|Experimental|A: SBRT (body) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
9725168|NCT05281107|Active Comparator|600 IU vitamin D + 500 mg calcium|Participants received 600 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
9725169|NCT05281107|Active Comparator|1200 IU vitamin D + 500 mg calcium|Participants received 1200 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
10198620|NCT03220854|Experimental|B: Patients receiving SBRT and SRS (body and brain) irradiation|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
9725170|NCT05281107|Active Comparator|4000 IU vitamin D + 500 mg calcium|Participants received 4000 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
9725171|NCT05281081|Active Comparator|levobupivacaine with morphine|30 patients will have intraperitoneal instillation of levobupivacaine with added morphine at the end of laparoscopic cholecystectomy operation
9725172|NCT05281081|Experimental|levobupivacaine with magnesium sulfate|30 patients will have intraperitoneal instillation of levobupivacaine with added magnesium sulfate at the end of laparoscopic cholecystectomy operation
9725173|NCT05281068|Experimental|Iguratimod and Danazol|Iguratimod is given at a dose of 25 mg bid. Danazol is given at 200mg bid for 12 weeks.
9725174|NCT05281068|Active Comparator|Danazol|Danazol is given at 200mg bid for 12 weeks.
9725175|NCT05281055||EVT group|Patients who received endovascular thrombectomy for acute ischemic stroke with large vessel occlusion.
9725176|NCT05281003|Experimental|Pembrolizumab + Chemo|"Neoadjuvant setting (Pembrolizumab in combination with chemotherapy): Up to 4 cycles concurrent administrations of (1) Paclitaxel, which are administrated intravenously at 150 mg/m^2 dosage on Day 1 of each 3-week cycle; (2) Cisplatin, which are administrated intravenously at 80 mg/m^2 dosage on Day 1 of each 3-week cycle; (3) Pembrolizumab, which are administrated intravenously at 200 mg dosage on Day 1 of each 3-week cycle.~Adjuvant setting (Pembrolizumab in combination with chemotherapy): All participants who are assessed as ineligible or unnecessary for surgery after neoadjuvant treatment may be eligible for up to an additional 17 cycles (approximately 1 year) of Pembrolizumab treatment in combination with chemotherapy."
9725177|NCT05280990|Experimental|Future Liver Remnant Function (FLRF)|Preoperative FLRF risk assessment via 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS)
9725178|NCT05280990|Active Comparator|Future Liver Remnant Volume (FLRV)|Preoperative FLRV assessment by CT/MRI volumetry
9725179|NCT05280977|Experimental|POST ISOMETRIC RELAXATION|
9725180|NCT05280977|Experimental|POST FACILITATION STRETCHING|
9725181|NCT05280964|Experimental|Intervention|Enrolled into a 6 month coaching program from January 1 2021 to June 30 2021
9725182|NCT05280964|No Intervention|Control/Wait-list|No intervention from January 1 2021 to July 1 2021 (they were offered the coaching program from July 1 2021-Dec 31 2021)
9725183|NCT05280951|Experimental|Focused-PPC Group|Focused-PPC will be implemented in 12 groups (3 groups per health center), with each group having 8 postpartum women. Each group will meet at 1-2 weeks, 6 weeks, and monthly thereafter for up to 1 year postpartum following the Ghana Health Service (GHS) postnatal care schedule.
9981100|NCT05246098||Pediatrics|Pediatric survivors of severe SARS-CoV-2 disease admitted to participating pediatric intensive care units (PICUs). The investigators define children as less than 18 years old. We will include pediatric patients with COVID-19 and those with multi-system inflammatory syndrome in children (MIS-C).
9981101|NCT05245825|Experimental|Flaxseed and dietary plan|30 g of ground flaxseed daily and a dietary plan
9981102|NCT05245825|Other|Control|Dietary plan controlled in alpha-linolenic acid consumption
10198621|NCT03220854|Experimental|C: Patients receiving SRS (brain) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
10204945|NCT04400838|Experimental|Group 1 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
9725184|NCT05280951|Active Comparator|Standard PNC Group|The control group will contain parallel number of participants as the intervention group in each health center
9725185|NCT05280938|Experimental|MAAPI Intervention|The MAAPI intervention is an 8-week adapted mindfulness intervention based upon Kabat-Zinn's MBSR. The intervention includes spirituality, self-empowerment, interdependence, and story-telling which are salient to AAW. Session topics include Tasting Your Life, Seeing and Believing, The Scent of Roses, When Life Hurts, Hearing Your Own Cries, Embracing Inner Peace, Holding on, Welcoming Stillness. Each session will include an introduction, opening mindfulness practice, class responses to the previous week, review guidelines for class, guided individual reflection, group go-around/discussion, yoga, abdominal breathing, body scan, conclusion, and home practice. Face to face sessions 1, 4, 8 will be in a quiet room to allow group sitting or free floor space. Sessions 2, 3, 5, 6, are virtual on the zoom app. Participants receive practice links and a program workbook. Program attendance, type/amount of practice (weekly logs), and changes in mindfulness will be included in data analysis.
9785806|NCT01260350|Experimental|Group 13: SOF+RBV+LDV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
9981103|NCT05245422|Active Comparator|Cow's milk intact protein infant formula|Control
9981104|NCT05245422|Experimental|Partially hydrolyzed cow's milk protein infant formula|Investigational
9981105|NCT05244655||Patients without painscores available during hospital stay|
9981106|NCT05244655||Patients with painscores available during hospital stay|
9725186|NCT05280938|Active Comparator|Educational Program|"The Education Program (attention control group) will be an 8-week educational program matched in duration and frequency to the MAAPI intervention. Session topics are:1) Perineum and Incision Care, 2) Safe Sexual Practices, 3) Understanding Infant Feeding Methods, 4) How to Communicate Effectively with your Child's Health Care Providers, 5) Healthy Eating, 6) Infant Changing and Baths, 7) Infant Safety at Home, and 8) Utilizing Support from Family and the Community.~Sessions will be given in groups by the same expert clinicians/educators for all cohorts. Subject receipt of the attention control will be monitored by attendance. Control group instructor will not include content on stress reduction or methods (yoga, meditation, etc.) taught in the MAAPI intervention. Classes will be given in the same setting as the MAAPI intervention, at the same time but on a different evening, to avoid crossover of effects."
9725187|NCT05280925|Experimental|Episodic Future Thinking|Participants will generate vivid, episodic events and be prompted via a guided smartphone app to engage in EFT in their daily lives. EFT will be paired with diet and physical activity support.
9725188|NCT05280925|Active Comparator|Healthy Information Thinking|Participants will be prompted via a guided smartphone app to thinking about their written responses to informational health vignettes during their daily lives. The HIT condition will be paired with diet and physical activity support.
9725189|NCT05280899|Active Comparator|Partial Weight-bearing (PWB)|Patients will PWB for 3 weeks following surgery, followed by a gradual return to FWB.
9981107|NCT05244395|Experimental|Duchenne Muscular Dystrophy Gait Assessment Scale|The DMD-GAS was developed using the two-round Delphi method. After a detailed literature review, the items of scale were compiled. The DMD-GAS was designed to consist of 10 items and each item scored as 0,1,2. The DMD-GAS was presented to the expert group (10 physical therapists), who had experience in the management of patients with DMD. According to the scale items, it is classified as 2: no compensation, 1: minimal compensation, and 0: excessive compensation for the relevant body part.
9981108|NCT05244252|Experimental|Group A|Two drugs dexmeditomidine and bupivacaine will be given in TAP block
9981109|NCT05244252|Active Comparator|Group B|One drug bupivacaine will be given in TAP block
9725190|NCT05280899|Experimental|Weight-bearing As Tolerated (WBAT)|Patients will WBAT immediately following surgery.
9725191|NCT05280873|Experimental|Experimental group|Grade 3-4 checkpoint inhibitor-related pneumonitis
9725192|NCT05280873|Experimental|Control group|Grade 3-4 checkpoint inhibitor-related pneumonitis
9981110|NCT05243251|Active Comparator|Olanzapine|82 patients will receive olanzapine 5 mg daily at night for 4 weeks
9981111|NCT05243251|Placebo Comparator|Placebo|82 patients will receive placebo for 4 weeks
9981112|NCT05242367|Active Comparator|Active VeNS|
9981113|NCT05242367|Sham Comparator|Sham VeNS|
9725193|NCT05280860|Experimental|Group R: bilateral RSB under ultrasound guidance after general anesthesia|Group R was subjected to a bilateral RSB under ultrasound guidance after general anesthesia.
9725194|NCT05280860|No Intervention|Group G: simple general anesthesia|Group G received simple general anesthesia.
9981114|NCT05242198||Rectus sheath block group (Group R)|Patients who underwent rectus sheath block
9981115|NCT05242198||Control group (Group C)|The patients that did not apply any fascial plane block
9981116|NCT05241847|Experimental|Pediatric liver transplant recipients|"As this is a single arm trial, all eligible liver transplant recipients and their caregivers will be enrolled in this arm.~Eligible participants are children who received a liver transplant at least 1 year prior to enrollment at a participating SNEPT center and continue to receive their post-transplant care at that center."
9981117|NCT05241483||fever|Remote patient monitoring. fever values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
9725195|NCT05280821|Active Comparator|Consecutive Day Dosing|This arm will daily receive iron capsules for 3 months, followed by daily placebo capsules for 3 months.
9725196|NCT05280821|Experimental|Alternate Day Dosing|This arm will receive iron capsules alternating with placebo capsules for 6 months.
9725197|NCT05280769|Experimental|Use of oral nicotine pouch - 2 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
9785271|NCT01247298|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive stereotactic body radiation therapy (SBRT) which is 3 radiation treatments at 15 Gy, for a total of 45 Gy. Patients will be given Trans-Arterial Chemoembolization (TACE), prior to enrollment. (TACE is not performed as part of this clinical study, even though it is part of the inclusion criteria.)
9981118|NCT05241483||pulse|Remote patient monitoring. pulse values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
9981119|NCT05241483||blood pressure|Remote patient monitoring. Blood pressure values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
9981120|NCT05241483||oxygen saturation|Remote patient monitoring. oxygen saturationvalues recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
9984561|NCT03978637|Experimental|Itacitinib|Phase 2: Itacitinib administered orally at the recommended dose from Phase 1.
9725198|NCT05280769|Experimental|Use of oral nicotine pouch - 4 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
9725199|NCT05280769|Experimental|Use of oral nicotine pouch - 8 mg|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
9981121|NCT05241483||glucose|Remote patient monitoring. glucose values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
9981122|NCT05240014|Experimental|Exoskeleton|Participants in this arm of the study will perform various tasks while wearing the modular powered orthosis
9981123|NCT05239624|Experimental|enfortumab vedotin in combination with pembrolizumab|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles. Patients can proceed to surgery prior to completion of cycle 6 at the discretion of the investigator and urologist if toxicities prevent completion of 6 cycles of treatment. Enfortumab vedotin will be capped at a maximum dose of 125 mg for each infusion (for patients who weigh > 100 kg). Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles. After completion of 3 cycles patients with have imaging assessment, and patients with progression of disease as measured by distant metastases will be removed from the study. At completion of cycle 6, patients will have repeat imaging assessment and proceed to cystectomy within 4-8 weeks. Following cystectomy, patients will resume pembrolizumab monotherapy on day 1 of each 21-day cycle for an additional 11 doses (Cycles 7-17), to complete 1 year of pembrolizumab therapy.
9981124|NCT05238090|Other|Control group|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
9725200|NCT05280769|Active Comparator|Use of smokeless tobacco|On four separate occasions, participants will come to the research center and be asked to use a nicotine pouch or smokeless tobacco provided by the study team two separate times. The nicotine pouches or smokeless tobacco contain different amounts of nicotine. Participants will not know the concentration of nicotine in the nicotine pouch, but they will know the concentration and brand of the smokeless tobacco (it will be their usual brand). All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes.
10198622|NCT03219034|Experimental|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
10198623|NCT03219034|Experimental|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
10198624|NCT03207620||smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology"
10198625|NCT03207620||non-smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology"
9725201|NCT05280756|Experimental|Home-based transcranial direct current stimulation (tDCS)|
9725202|NCT05280756|Sham Comparator|Sham home-based transcranial direct current stimulation (tDCS)|
9725203|NCT05280730||Boys with DMD|Boys ages 3 and above will be enrolled.
9725204|NCT05280730||Healthy boys|Healthy boys as a control group for brain imaging.
9785272|NCT01247350|Experimental|2 mg LY3009104 (Cohort 1)|2mg administered once on day 1 (single dose)
9981125|NCT05238090|Experimental|Experimental|Passive and active analytical stretching exercises described by Neiger and Simons , applying them to the muscle chain involved in lateral epicondylitis described by Busquet
9984562|NCT03978000|Active Comparator|IBP-9414|
9984563|NCT03978000|Placebo Comparator|Placebo|
9984564|NCT03977779|Experimental|Prophylactic biodegradable pancreatic stent placement|
9984565|NCT03974243|Experimental|treatment group|"In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.~Intervention: Drug: Chiauranib and Chidamide"
9984566|NCT03972657|Experimental|Dose Escalation Cohorts|In a series of dose escalation cohorts, patients will receive a 3-week monotherapy lead-in of 3 weekly doses of REGN5678 followed by REGN5678 and cemiplimab in combination.
9984567|NCT03972657|Experimental|Dose Expansion Cohorts|In a series of dose expansion cohorts, patients will receive 3-week monotherapy and then combination therapy of REGN5678 at the recommended phase 2 dose (RP2D) and cemiplimab
9984568|NCT03971461|Experimental|Lutathera|
9984569|NCT03970109|Active Comparator|ANS-6637 - 200mg|200 mg ANS-6637 (given as 2 x 100 mg tablet) once a day
9984570|NCT03970109|Active Comparator|ANS-6637 - 600mg|600 mg ANS-6637 (given as 2 x 300 mg tablet) once a day
9984571|NCT03970109|Placebo Comparator|Matched Placebo|2 placebo tablets once a day
10198626|NCT03198598|Experimental|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
10198627|NCT03198598|No Intervention|MS patients with EDSS from 0 to 5.5 for control|
10198628|NCT03198598|Experimental|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
9981126|NCT05228145|Experimental|Cohort 1|The study treatment is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).
10198629|NCT03198598|No Intervention|MS patients with EDSS from 6 to 8 for control|
10198630|NCT03198598|No Intervention|Healthy subjects|
10198631|NCT03187769|Experimental|ALKS 3831|Coated bilayer tablet
10198632|NCT03187769|Active Comparator|Olanzapine|Coated bilayer tablet
9725205|NCT05280704|Other|Group A|Will undergo volar technique 1st with 4 mL of 1% lidocaine and then dorsal technique 2nd with 4 mL of 0.9% sterile saline. This is a 1-time dose.
9981127|NCT05219110|Experimental|Hyperhydration|"In this study arm, all eligible children are admitted for the administration of intravenous fluids.~The following specifics will form the basis of the fluid management protocol:~Reversal of dehydration: Initial ED rehydration strategies should focus on rapidly reversing dehydration.~Infusion of 200% of maintenance fluids x 24 hours~If hematocrit reduction < 20% from initial value, repeat step #2 [infusion of 200% maintenance fluids x 24 hours].~Oral fluids permitted ad lib.~Once the target hematocrit reduction is achieved (20% decrement in initial HCT) AND a 10% weight gain, adjust total IV fluid volume to maintain targeted weight gain: insensible plus output (i.e., urine plus stool)."
9725206|NCT05280704|Other|Group B|Will undergo volar technique 1st with 4 mL of 0.9% sterile saline and then dorsal technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
9725207|NCT05280704|Other|Group C|Will undergo dorsal technique first with 4 mL of 1% lidocaine and then volar technique second with 0.9% sterile saline. This is a 1-time dose.
9725208|NCT05280704|Other|Group D|Will undergo dorsal technique 1st with 4 mL of 0.9% sterile saline and then volar technique 2nd with 4 mL of 1% lidocaine. This is a 1-time dose.
9725209|NCT05280691|Other|Family Support Intervention|Families in the intervention group receive the Family Support Intervention in addition to usual care
9981128|NCT05219110|Active Comparator|Conservative Fluid Management|The conservative fluid management arm has been designed to align and integrate into existing local practice patterns. Implementation of this approach will allow institutions and their practitioners to choose their management of protocol eligible children. All children will undergo a protocolized baseline evaluation that includes reversal of dehydration (if present) and follow-up plan (see Pre-Pathway care). The fluid management decision in the ED (i.e., to treat dehydration) will be at the discretion of the clinical care team. In the absence of evidence of microangiopathy (i.e., normal urinalysis, LDH, hemoglobin and platelet counts, and creatinine concentrations), the decision to admit the child to hospital or discharge the child to home will be at the discretion of the clinical care team. If microangiopathy is present (i.e., abnormal urinalysis, LDH, hemoglobin or platelet counts, or creatinine concentrations) admission for monitoring will be required.
9725210|NCT05280691|No Intervention|Usual Care|Families in the control group will receive usual care.
9725211|NCT05280678|Experimental|SH2018-10 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
9725212|NCT05280678|Experimental|SH1514-08 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
9725213|NCT05280665||The non-specialized group|Patients who were operated by a non-specialized surgeon. Non-specialized surgeons were defined as general surgeon who does not have the characteristics of a specialized gastric cancer surgeon.
9785273|NCT01247350|Experimental|5 mg LY3009104 (Cohort 2)|5mg administered once on day 1 (single dose)
9785274|NCT01247350|Experimental|10 mg LY3009104 (Cohort 3)|10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
9981129|NCT05217901|Experimental|14C-labeled ASP0367|Participants will receive a single oral dose of [14C]ASP0367 solution under fasting conditions on day 1.
9981130|NCT05217680|Experimental|PRO-169|Bevacizumab 1.25 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
9984572|NCT03967925|Active Comparator|Belimumab|Weekly 200mg SC injections of belimumab for 12 months
9984573|NCT03967925|Placebo Comparator|Belimumab placebo|Weekly SC injections of belimumab placebo for 12 months
10198633|NCT03180749||Patients implanted with vendor B anchor|
10198634|NCT03169686|Experimental|Intervention Group|"Participants who allocate to the intervention group will receive regular messages providing smoking cessation related information, such as advice, support, and distraction by professional team. One to six messages will be sent per day for the time leading up to the quit date and 12 weeks after quit data.~One to three messages will be sent per week until the end of the 24 weeks follow up after quit data. They will also be encouraged to send self-help, peer support messages in their group. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points."
9725214|NCT05280665||The specialized group|"Patients who were operated by a specialized gastric cancer surgeon. Specialized gastric cancer surgeons were defined as surgeons who meet all of the criteria for a specialized gastric cancer surgeon.~Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~Who identified themselves as primarily gastric surgeons during the study period~Whose annual gastric cancer surgery volume is more than 21"
9981131|NCT05217680|Active Comparator|Lucentis ®|Ranibizumab 0.5 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
10198635|NCT03169686|No Intervention|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points.
10198636|NCT03168438|Experimental|Arm 1: Letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
10198637|NCT03168438|Experimental|Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.
9725215|NCT05280652|Experimental|Family intervention group|Families (dyads parent and child) will attend culinary-nutritional workshops with theoretical and practical nutritional and culinary information (knowledge and skills to prepare healthy and easy menus) to follow a sustainable Mediterranean diet.
9725216|NCT05280652|Experimental|Parent-only intervention group|Parents will attend culinary-nutritional workshops with theoretical and practical nutritional and culinary information (knowledge and skills to prepare healthy and easy menus) to follow a sustainable Mediterranean diet.
9725217|NCT05280652|Active Comparator|Control|Families (dyads parent and child) will attend nutritional workshops with theoretical information to follow a sustainable Mediterranean diet.
9725218|NCT05280639|Experimental|Simplified block protocol|subjects in this group will perform a simplified post operative rehabilitation program using a simplified wooden block protocol
9981132|NCT05207696||Platelet-rich fibrin (PRF)|A total of 28 sites from 12 patients who underwent papilla reconstruction with PRF placed with semilunar incision in the maxillary anterior region were included in PRF group. ( Data of 12 patients were included in the study.)
9981133|NCT05207696||Connective tissue graft (CTG)|A total of 27 sites from 8 patients who underwent papilla reconstruction with CTG placed with semilunar incision in the maxillary anterior region were included in CTG group. (Data of 8 patients were included in the study.)
10204946|NCT04400838|Experimental|Group 1 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
9725219|NCT05280639|Active Comparator|Usual care|Subjects in this group will perform formal physical therapy or a home exercise program consistent with AAOS standards.
9725220|NCT05280626|Experimental|A: PD-1+R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group A uses Sindilizumab + R-CHOP, with Sindilizumab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles, CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
9725221|NCT05280626|Active Comparator|B: R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP and plans for 5 cycles. CR patients in group B are followed up for observation.
9725222|NCT05280613|Experimental|Family Check-Up|"Families randomized to the Family Check-Up arm will be connected with a clinician who will provide the Family Check-Up. The Family Check-Up® (FCU) is an ecologically sensitive, evidence-based intervention that was developed to decrease childhood EBP by 1) assessing known ecological (child, family and contextual) risk and protective factors; 2) engaging parents in a tailored plan to enhance positive parenting and family management skills; and 3) connecting families to a tailored suite of child and family services and supports. Services may include an evidence-based suite of parenting sessions (Everyday Parenting Curriculum [EPC]) created by FCU developers for direct tailoring to the FCU feedback session."
9725223|NCT05280613|Active Comparator|Treatment as Usual|Treatment as Usual participants will be connected to a Family Service Coordinator within the Autism Program, who can direct the family to appropriate services and resources. Services may include consultation on child behaviours, workshops on various topics, parenting programs, Applied Behaviour Analysis, support groups, and group recreational programs. Families in the treatment as usual arm will be offered the Family Check-Up upon completion of the study.
9725224|NCT05280600||NMDAR-antibody encephalitis|Children and young people (ages 8-24 years) with a diagnosis of NMDAR-antibody encephalitis.
9725225|NCT05280600||Antibody-negative autoimmune encephalitis|Children and young people (ages 8-24 years) with a diagnosis of autoantibody-negative but probable autoimmune encephalitis or definite autoimmune limbic encephalitis.
9725226|NCT05280600||Healthy control|Healthy children and young people (ages 8-24 years).
9725227|NCT05280587|Experimental|Technological Group|Technological group (TG) patients will undergo robotic treatment for the improvement balance through the robotic platform (Hunova® Movendo Technology srl, Genova, IT), 3 times per week for 45 minutes each, in addition to the conventional treatment (total 180 minutes per day). In particular, the technological rehabilitation performed employing a footboard will be mostly aimed at improving the balance both in sitting and standing position, and will be proposed static and dynamic exercises, exercises dual-task exercises, and exercises to improve trunk control.
9725228|NCT05280587|No Intervention|Control Group|Congrol Group (CG) patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive neuromuscular facilitation, etc.).
9725229|NCT05280535|Experimental|Study Protocol|All participants will receive all laboratory protocol components in a within-person randomized order across two sequential laboratory sessions.
9981134|NCT05204381|Experimental|Theta Stimulation followed by Alpha Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
9984574|NCT03959878|Experimental|Gastrostomy Tube|Non-hospitalized outpatients undergoing placement of a gastrointestinal gastrostomy tube (GIG tube) or GI jejunostomy tube (GIJ tube) will receive the usual Standards of Care related to the placement of a GIG or GIJ tube and the Constant Pressure Skin Disk.
9725230|NCT05280522||Repeated Measures Experiment|Participants are positioned in an isokinetic dynamometer (Biodex System 4 Isokinetic Dynamometer , Biodex Medical Systems, Inc., Shirley, NY) with the knee flexed to approximately 90 degrees. After 3-4 submaximal warm up contractions, participants generate maximum knee extension force while vigorous verbal encouragement is provided. Two trials are collected with 30 seconds between trials. The maximum forces from the 2 trials is used to determine the target force of 20% MVIC used for the volitional and NMES contractions and to normalize the force of the muscle contractions.
9725231|NCT05280509|Experimental|Phase 1b - Dose Level 1|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
9725232|NCT05280509|Experimental|Phase 1b - Dose Level 2|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
10198638|NCT03164278|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
10198639|NCT03164278|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
10204947|NCT04400838|Experimental|Group 1 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost (4-6 weeks apart)
9725233|NCT05280509|Experimental|Phase 1b - Dose Level 3|450 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle combined with the subject's pre-study stable dose of ruxolitinib.
9725234|NCT05280509|Experimental|Phase 2 - Cohort 1 JAKi treatment-naïve MF|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose of ruxolitinib will be based on the subject's baseline platelet count."
9725235|NCT05280509|Experimental|Phase 2 - Cohort 2 suboptimal response to Ruxolitinib|"The RP2D of TL-895 as determined in Phase 1b will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.~The dose schedule will be the stable ruxolitinib dose schedule as the subject is currently taking prior to entry into the study."
9725236|NCT05280496|Experimental|Metformin|Participants will be given a daily prescription of metformin for 12 months postpartum. At 12 months and again at 15 months (3 months off the drug), HbA1c and weight will be assessed.
9725237|NCT05280483|Experimental|Fed states in healthy subjects|A single 25mg dose of ABSK021 administered in a fed state.
9725238|NCT05280483|Experimental|Fasted states in healthy subjects|A single 25mg dose of ABSK021 administered in a fasted state.
9725239|NCT05280470|Experimental|DS-7300a (8 mg/kg)|Participants will be randomized to receive DS7300a at 8 mg/kg.
9725240|NCT05280470|Experimental|DS-7300a (12 mg/kg)|Participants will be randomized to receive DS7300a at 12 mg/kg.
9725242|NCT05280444|Experimental|Lipiodol-TACE with Idarubicin|The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
9725243|NCT05280431|Experimental|Experimental Group (AGREE)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the AGREE exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
9725244|NCT05280431|Experimental|Experimental Group (FEXO)|15 sessions, 3 sessions per week. Each session consists of 45 minutes of training with the FEXO exoskeleton. The training session is customized to the patient's needs and can be adapted to his/her improvement during the intervention.
9725245|NCT05280431|Other|Control Group (Conventional therapy)|15 sessions, 3 sessions per week. Each session consists of 45 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke.
9725246|NCT05280418|Active Comparator|Tezepelumab|"Tezepelumab 210 mg subcutaneous injections every 4 weeks as an investigational drug.~Sterile tezepelumab will be provided 110 mg/mL pre-filled vial, with a dose of 210 mg delivered by pre-filled syringe."
9725247|NCT05280418|Placebo Comparator|Matched placebo|Sterile placebo for tezepelumab will be provided in identically matched pre-filled syringes.
9725248|NCT05280392||People living with HIV|PLWH who were offered to participate in the EHVA T02/ANRS VRI07 clinical trial
9725249|NCT05280379||Participants with non-medullary thyroid carcinoma|30 patients with non-medullary thyroid carcinoma, who are going to get surgery
9725250|NCT05280379||Participants with colon carcinoma|30 participants with colon carcinoma, who are going to get surgery
9725251|NCT05280366|Other|Streamline Surgical System|Streamline Surgical System procedure administered
9725252|NCT05280366|Active Comparator|iStent Inject W|iStent Inject W implanted
9981135|NCT05204381|Experimental|Alpha Stimulation followed by Theta Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
9981136|NCT05204290|Experimental|Stereotactic Body Radiotherapy and Pembrolizumab Treatment|MRI scans of your spine (before treatment, 2 months after treatment, and 6 months after treatment) and immunotherapy with Pembrolizumab
9725253|NCT05280353|Experimental|lymphadenectomy without drainage and with Glubran|Application of Glubran 2 in axillary dissection with the objective of seroma reduction. No drain
10198640|NCT03164278|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
10198641|NCT03154996|Experimental|Long term CED of Topotecan|An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
10198642|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
10198643|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 40mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 40 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
9725254|NCT05280353|No Intervention|Lymphadenectomy without drainage|No intervention required, only axillary dissection without drain
9725255|NCT05280340|Experimental|Anakinra|"First 6 enrolled infants given 1.5mg/kg anakinra alternate daily IV for first 3 weeks of life.~Remaining 18 enrolled infants given 1.5mg/kg anakinra daily IV for the first 3 weeks of life"
9725256|NCT05280327|Experimental|experimental group|virtual reality application
9725257|NCT05280327|No Intervention|control group|standard care group
9725258|NCT05280314|Experimental|Cohort A - Melanoma|"Cutaneous resectable Stage IIIB, IIIC, or IIID melanoma or oligometastatic IV melanoma.~Neoadjuvant Treatment (6 weeks): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) weekly, and intravenous Pembrolizumab 200mg Q3W × 2.~Adjuvant Treatment (12 months): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) every 3 weeks (Q3W) for the first 18 weeks, followed by every 6 weeks (Q6W), and intravenous Pembrolizumab 400mg Q6W."
9725259|NCT05280314|Experimental|Cohort B - SCCHN|"Squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity, oropharynx, hypopharynx, or larynx, HPV+/-, T1N1-N2b or T2-4N0-N2b.~Neoadjuvant Treatment (6 weeks): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) weekly, and intravenous Pembrolizumab 200mg Q3W × 2.~Adjuvant Treatment (12 months): Subcutaneous IO102-IO103 (IO102 85 μg and IO103 85 μg) every 3 weeks (Q3W) for the first 18 weeks, followed by every 6 weeks (Q6W), and intravenous Pembrolizumab 400mg Q6W."
9725260|NCT05280301|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 38 degrees celsius, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
9725261|NCT05280288|No Intervention|The control group (Standard care)|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management under follow-up having usual care alone conducted by physicians and therefore not able to use the app Bone@BC in any versions (access denied).
9725262|NCT05280288|Experimental|The intervention group|Intervention: This arm will be assigned to the intervention which will be that the participants will be invited to become active users of the app Bone@BC version 4.0 combined with usual care alone.
9725263|NCT05280275|Experimental|Part 1: Dose Finding|"Belantamab mafodotin will be administered as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose:~Cohort 1: 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle~Cohort 2: 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle~Administration schedule for daratumumab 1800mg SC (fixed dose):~Cycles 1-2: days 1, 8, 15, 22 Cycles 3-6: days 1, 15 Cycles 7+: day 1~Lenalidomide: 25 mg/d on day 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants < 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years"
9725264|NCT05280262|Other|Group 1 Asymptomatic|"Group 1 - Prospective cohort of children and young adults enrolled at diagnosis and followed longitudinally~Patients will be evaluated at 5 time-points (Baseline - Follow Up 1-4 [FU1-4]) during therapy using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. In addition one saliva sample (or stored DNA from a remission bone marrow sample extracted during routine trial procedures) will be collected as a source of germline DNA and a clinical report form will be completed at study entry and at completion of the study. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
9836232|NCT02777021||Early Discharge Patients|Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
9725265|NCT05280262|Other|Group 2 Symptomatic|"Group 2 - Children and young adults with Stroke-like syndrome/PRES and /or seizures (SPS)~Following a diagnosis of SPS, patients and their families can be approached for informed consent to enter this study within 4 weeks following SPS event. If consent is obtained, patients will be evaluated at up to 7 timepoints, or until end of treatment, using a computer-based short age-appropriate neurocognitive test battery (CogState) and paired CSF samples taken at the time of routine scheduled lumbar punctures. Follow up visit 2 will take place at 12 months, with Follow up 3-7 [FU3-7] scheduled at 6 monthly timepoints. CSF samples will be collected at the time of the patient's scheduled therapeutic treatment with no additional sampling."
9981137|NCT05186558|Experimental|penpulimab, lenalidomide, rituximab, gemcitabine and oxaliplatin（Penpulimab-R2-GemOx)）|penpulimab: 200 mg q2w, iv, drip R2-GemOx: lenalidomide 10 mg，po; Rituximab 375mg/m2, iv, drip; Gemcitabine 1000mg, po; Oxaliplatin 100mg/m2, iv, drip;
10198644|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 60mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
10198645|NCT03149822|Experimental|Phase 2: Pembrolizumab 200 mg plus Cabozantinib at the RP2D|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib at the RP2D orally once daily for up to 35 cycles, until disease progression, unacceptable toxicity, or consent withdrawal. All participants who stop pembrolizumab after 35 cycles with SD or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping pembrolizumab from the initial treatment phase.
10198646|NCT03147885|Experimental|Treatment (selinexor, RCHOP)|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. RCHOP will be given at standard dosing every 21 days. In the phase 1 part there is dose escalation for Selinexor in a 3+3 design. Treatment will be given for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or better will receive maintenance selinexor PO on days 1, 8, 15, and 22 every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9725266|NCT05280249|Experimental|Both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air. For 20 participants who met the inclusion criteria, first 10 minutes of warm-up exercises, then 20 minutes of moderate-intensity (65% of heart rate) walking, followed by 15 minutes of low-intensity (50% of the maximum repetitions) resistance exercises will be trained in the presence of a physiotherapist. resistance exercises will be performed for shoulder flexors and abductors, elbow flexors and extensors, hip flexors and extensors, knee flexors and extensors, hip abductor muscle groups. At the end of each session, 5 minutes of stretching exercises will also be trained.
10198647|NCT03146156|Experimental|Lifestyle Intervention|Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.
10198648|NCT03146156|No Intervention|Usual Care|The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.
10198649|NCT03145532|Experimental|Real tDCS plus robotic training|Children will receive 20 min of real tDCS stimulation per session, followed by robotic training for 1 hr.
9725267|NCT05280249|No Intervention|Control group|The exercise program will not be implemented. Evaluations will be made at the beginning and end of the study.
9725268|NCT05280236|Active Comparator|Propofol|Patients receiving general anesthesia with propofol-based total intravenous anesthesia
10198650|NCT03145532|Sham Comparator|Sham tDCS plus robotic training|Children will receive 20 min of sham tDCS stimulation per session, followed by robotic training for 1 hr.
10198651|NCT03141034|Experimental|Irinotecan plus ramucirumab|-Patients will receive ramucirumab intravenously on an outpatient basis at a dose of 8 mg/kg over the course of 60 minutes on Day 1 of each 14-day cycle. They will then receive irinotecan intravenously at a dose of 180 mg/m2 over the course of 90 minutes on Day 1 of each 14-day cycle.
10198652|NCT03132038|Experimental|Nivolumab|Nivolumab will be given every two weeks for a maximum of one year (12 cycles) at a dose of 3 mg/kg to be administered as a 60 minute IV infusion
9725269|NCT05280236|Experimental|Remimazolam|Patients receiving general anesthesia with remimazolam-based total intravenous anesthesia
10198653|NCT03128021|Active Comparator|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
10198654|NCT03128021|Placebo Comparator|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
9725270|NCT05280223|Active Comparator|Dexmeditomidine group|injection of 1 microgram/kg dexmedetomidine + 10 cc saline injection nearby median nerve as hydrodissection
9725271|NCT05280223|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
9725272|NCT05280210|Experimental|Neoadjuvant therapy based on PTC drug screening|Patients will receive neoadjuvant therapy based on PTC drug screening. The regimen is complied with NCCN and CSCO guidelines. PD-1 inhibitor will be used if effective in drug screening.
9725273|NCT05280210|No Intervention|Neoadjuvant therapy based on clinical experience|Patients will receive neoadjuvant therapy based on clinical experience. The regimen is complied with NCCN and CSCO guidelines.
9725274|NCT05280197|Experimental|liposomal bupivacaine plus free bupivacaine|
9725275|NCT05280197|Placebo Comparator|normal saline|
9725276|NCT05280184|Experimental|Coin2Dose|BEI intervention that also combines automated text message reminders to dose for insulin; will test Contingent and Non-Contingent BEI
9725277|NCT05280184|No Intervention|Standard Care Control|Standard care control group; will not receive automated text message reminders to dose for insulin nor BEI for daily BOLUS scores
9981138|NCT05183490|Experimental|Group A: Allogenic Stem Cell Transplant Recipient (SCT)|"Dose levels selected for Group A are based on previous experience with VST cells in HCT recipients and are lower than in Group B (SOT recipients), as donor-derived R-MVST cells are more likely to persist in recipients of HCT from the same donors. Thus, there is theoretically a higher risk for development of GVHD in this subset of patients. Each group will undergo independent dose escalation.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
9981139|NCT05183490|Experimental|Group B: Solid organ transplant recipients (SOT)|"In SOT recipients, the study will use higher doses of R-MVST cells, as the infused anti-viral T cells are less likely to persist long-term and cause GVHD, based on the safety profile of PyVST cells used for therapy of PML in non-HCT subjects.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
9725278|NCT05280171|Experimental|Teach back|Discharge information was explained by the principal investigator. It includes pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.
9725279|NCT05280171|Active Comparator|Standard of Care|Discharge information as per the standard existing routine. Than assessed the recall and patient engagement of CLD patients in general ward regarding discharge instructions by structure questionnaires for patients recall, and PAM for patient's
10198655|NCT03128021|Other|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
10204948|NCT04400838|Experimental|Group 2 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
9725280|NCT05280158|Active Comparator|Standard-dose|mRNA-1273 (Moderna COVID-19 vaccine) 50 ug
9981140|NCT05181683|Experimental|Co-formulated casirivimab+imdevimab SC|Randomized 1:1
9725281|NCT05280158|Experimental|Mid-Dose|mRNA-1273 (Moderna COVID-19 vaccine) 100 ug
9725282|NCT05280158|Experimental|High-Dose|mRNA-1273 (Moderna COVID-19 vaccine) 200 ug
9725283|NCT05280145|Experimental|Patients benefitting ultrasound examination|This is the only arm of the study. Patients with an indicative clinical picture that leads the clinician to resort to the use of an ultrasound to potentially support the diagnosis will be examined to verify the presence of pleural effusion or intra-abdominal effusion, or to identify basilic vein. The patients will be assessed first with the echOpen device and second witn an ultrasound routinely used in the department. In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating.
9981141|NCT05181683|Experimental|Co-formulated casirivimab+imdevimab IV|Randomized 1:1
9981142|NCT05175456|Experimental|Bedjet arm|All participants will complete a baseline study period of 4 weeks and then will be provided the Bedjet system.
9981143|NCT05173701|Experimental|Probiotics|Administration of a mixture of probiotics once daily for three months
9981144|NCT05173701|Placebo Comparator|Placebo|Administration of a placebo (maltodextrin) once daily for three months
9981145|NCT05172752|Other|Citizen Science Training|Study participants in this condition will participate in training and in-home sampling for disinfection by-products.
9981146|NCT05172752|Other|Stakeholder Consultation Core Membership|Study participants in this condition will participate in quarterly meetings and deliberative activities of the project's Stakeholder Consultation Core.
9981147|NCT05170035|Experimental|MMS + Autologous patch|Mohs micrographic surgery + Autologus patch formed from 18 ml venous blood sample collected from the patient + polymycin-terramycin B ointment and a Jelonet applied on top of the patch.
9981148|NCT05170035|Active Comparator|MMS + Secondary intention healing|Mohs micropgraphic surgery + Polymycin-terramycin B ointment + dry wound dressing
9981149|NCT05156372|Experimental|Exercise Intervention|Participants will engage in 2-3 supervised high intensity aerobic and resistance exercise sessions per week.
9981150|NCT05156372|No Intervention|Control|Participants will continue daily routine as usual and given an informational flyer on physical activity and cancer.
9981151|NCT05154058|Active Comparator|Control: electrocautery|Primary patients with Osteoarthritis (OA) undergoing Total Knee arthroplasty (TKA) will be randomly assigned into either the control or investigational group. The control arm of the study will undergo medial sub periosteal release with electrocautery.
9981152|NCT05154058|Active Comparator|Investigational: sharp dissection.|Primary patients with OA undergoing TKA will be randomly assigned into either the control or investigational group. The investigational arm will undergo medial sub periosteal release using sharp dissection.
9981153|NCT05144932|Experimental|StrokeAlarm use|This is a single arm study. All participants will be instructed to use the StrokeAlarm medical device for 1 month.
9785275|NCT01247350|Experimental|14 mg LY3009104 (Cohort 4 )|14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
9981154|NCT05143307|Experimental|Long Term Follow Up|Participants who received EBT-101 in a previous intervention study will undergo long term follow up
9984575|NCT03958006|Experimental|Cochlear implantation|Simultaneous cochlear implantation with tumor resection
9984576|NCT03955042|Experimental|Pemetrexed|Pemetrexed
9981155|NCT05124821||Certofix Paed|Paediatric patients in need for short-term (≤ 30 days) catheterisation of the superior vena cava using the Seldinger technique for infusion and volume therapy or parenteral nutrition, for administration of highly osmolar or very vein-irritating solutions/drugs, for continuous or intermittent monitoring of the central venous pressure, for blood sampling, or when peripheral venous puncture is not possible in state of shock, in patients with injured extremities or no detectable peripheral veins.
9981156|NCT05119413|Experimental|New traitement|Thiamidol, retinoid, topical steroid preparation
9981157|NCT05119413|Other|Kligman's trio|Application once a day for 12 weeks
9981158|NCT05113810|Experimental|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
9725284|NCT05280132|Experimental|Personalized strategy|"Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.~A broad panel respiratory mPCR FA-PPP is performed on a respiratory tract sample collected 12 hours after inclusion.~After inclusion (D0), an algorithm of early antibiotic adaptation and discontinuation will be applied immediately and repeated every day until day 7.~This algorithm of early antibiotic adaptation and discontinuation is based on a multimodal approach, using:~The appearance of sputum (clinical approach);~PCT values and kinetics (biological approach);~Results of mPCR FA-PPP (microbiological approach)."
9725285|NCT05280132|Other|Usual strategy|"Usual antibiotic treatment~Left at the discretion of the physician as in usual practice"
9725286|NCT05280119|Experimental|Patients benefitting ultrasound examination|This is the only arm of the study. Patients with an indicative clinical picture that leads the clinician to resort to the use of an ultrasound to potentially support the diagnosis will be examined to verify the presence of pleural effusion or intra-abdominal effusion, or to identify basilic vein. The patients will be assessed first with the echOpen device and second witn an ultrasound routinely used in the department. In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
9725287|NCT05280093|Experimental|Hybrid sinus node sparing ablation procedure|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
9725288|NCT05280067|Experimental|Investigational Device The ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. The ZetaFuse™ Bone Graft is only for implantation into the vertebral body.
9725289|NCT05280054|Experimental|AV-101|AV-101 360 mg oral capsules single dose
9725290|NCT05280054|Experimental|AV-101 + Probenecid|AV-101 360 mg oral capsules + 1000 mg Probenecid
9725291|NCT05280028||Tibolone|Tibolone 2.5 mg per day
9725292|NCT05280028||Indivina|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate 2.5 mg (MPA) per day
9981159|NCT05113810|Active Comparator|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
9981160|NCT05107440|Experimental|BREATHE|This is an eight-week intervention involving two sessions per week, hosted virtually on Zoom. The main session is scheduled to last 60 min and the session hosts remain online for an additional 15 minutes to answer individual questions on the management of symptoms and activities that have not been addressed during the main session. The content was developed based on clinical experience, best available evidence for the management of specific symptoms (chronic fatigue, post-exertional malaise, breathing discomfort) in other conditions, including post-viral syndromes, and the current understanding and recommendations for rehabilitation of people living with long COVID. Long COVID can be isolating, and challenges often interfere with everyday lifestyle and socialization. The investigators have incorporated breakout rooms (where the group is divided into two smaller groups based on current activity limitations) to include elements of peer support.
9725293|NCT05280015|Active Comparator|Microbiotherapy in addition of venlafaxin|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the microbiotherapy during 12 weeks. The microbiotherapy is GynMDD devlopped by Gynov and which is composed by a probiotic associated to polyphenol and an amino acid.
9981161|NCT05101135|Experimental|JT-001|Drug: JT-001
9981162|NCT05101135|Placebo Comparator|JT-001 Placebo|Drug: JT-001 Placebo
9981163|NCT05092698|Active Comparator|Vit_D_suppl|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube weekly followed by 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
9981164|NCT05092698|Placebo Comparator|Vit_D_placebo|Patients will receive 45 ml of herbal oil orally or via feeding tube followed by 45 ml of herbal oil weekly followed by two drops of herbal oil daily until discharge or death.
9981165|NCT05091450|Experimental|Couple-based I-BMS intervention for infertility|The I-BMS intervention will be conducted face-to-face and in group format. It comprises four 3-hour sessions within one month. Two registered social workers who are professionally trained on I-BMS intervention model will deliver the intervention.
9725294|NCT05280015|Placebo Comparator|calibration arm|Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the placebo therapy during 12 weeks.
9725295|NCT05280002|Experimental|Adipose Tissue derived Total-Stromal-Cells (TOST)|Adipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cells plus standard conservative care.
9725296|NCT05280002|No Intervention|Control|Standard Conventional Treatment
9725297|NCT05279989|Experimental|Seated Tai Chi Qigong|Participants will receive daily text messages and emails to distribute videos and record which sessions were completed. Participants can participate in 10-, 20-, or 30- min TCQ practices. Total weekly practice time will be recommended between 50-150 minutes/week (~10-30 min/day on most days). A library of existing TCQ videos will be used. All videos will demonstrate seated practice with discussions on how to accommodate mobility limitations of various types.
9725298|NCT05279989|Placebo Comparator|Control|The control arm will receive text messages and emails with links to health information videos for the same time lengths as the intervention group. Existing video content will be reviewed and adapted to assure avoidance of topics that can impact outcome variables.
9725299|NCT05279976|Experimental|Children receiving education-Intervention group 1 (35 children)|Children in the intervention group 1 will be told by the researchers the operation preparation room and the pre-anesthesia process with a picture booklet. It will be ensured that the child and parent are together during the training. The booklet, which is printed separately for each child, will be given to the child and the parent after an average of 15-20 minutes of narration is completed. Simultaneous visual presentation will be made with the content of the picture booklet being explained to the child. While one of the researchers will explain the pre-operative process from the picture booklet, the other will explain the pre-operative preparation process simultaneously with the picture booklet by putting on the bonnet, mask and glove, and with the balloon inflated by the child. In this way, the pictures shown in the picture booklet will be matched with the real environment.
10198656|NCT03128021|Active Comparator|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
10198657|NCT03126513|Experimental|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
10198658|NCT03120624|Experimental|Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
9981166|NCT05091450|Other|Waitlist control|Couples allocated in the waitlist control group will begin the I-BMS intervention (same as the intervention group) after completing the 1-month follow-up assessment.
9981167|NCT05089292|Experimental|Chinese Immigrants|NYC Chinese immigrants provided with narrative breast health education
9981168|NCT05086445|Experimental|LY3502970 (Part A)|Single doses of LY3502970 administered orally.
9725300|NCT05279976|Experimental|Children who are distracted-Intervention group 2 (35 children)|"Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.~Usage of Kaleidoscope: It is a game tool that reproduces the outside image when viewed from inside the kaleidoscope. This image is obtained thanks to the glasses placed inside the kaleidoscope at different angles, and the images change as the kaleidoscope is rotated. Inside the kaleidoscope, there are mirrors or glasses placed with an inclination of 60 degrees. When viewed from one side of the kaleidoscope, images are often seen that are not the same."
9725301|NCT05279976|No Intervention|Control group of children (35 children)|After obtaining informed consent from the children and parents included in the control group after randomization, the pre-test (first measurement) will be applied. The final test (Second Measurement) will be applied immediately after the child wears the surgical gown.
9725302|NCT05279976|Experimental|Parents of children receiving education-Intervention group 1 (35 parents)|The parents of children included in intervention group 1 will also be in intervention group 1.It will be ensured that the child and parent are together during the training. The booklet, which is printed separately for each child, will be given to the child and the parent after an average of 15-20 minutes of narration is completed.
9981169|NCT05086445|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally.
9725303|NCT05279976|Experimental|Parents of distracted children-Intervention group 2 (35 parents)|The parents of children included in intervention group 2 will also be in intervention group 2. Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes.
9725304|NCT05279976|No Intervention|Control group of parents (35 parents)|The parents of children included in control group will also be in control group.
9981170|NCT05086445|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
9981171|NCT05086445|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
9981172|NCT05077254|Experimental|Pfizer-BioNTech COVID-19 Vaccine Booster + SOC IS Regimen|"Participants will receive an additional dose (1 dose) of the Pfizer-BioNTech COVID-19 vaccine and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
9981173|NCT05077254|Experimental|Pfizer-BioNTech COVID-19 Vaccine Booster+SOC IS Reduction|"Participants will receive an additional dose (1 dose) of the Pfizer-BioNTech COVID-19 vaccine, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
9725305|NCT05279950|Active Comparator|Piezoelectric|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence >18 kHz) powered by a piezoelectric device
9725306|NCT05279950|Experimental|Magnetostrictive|Full-mouth ultrasonic debridement will be performed with a ultrasonic tip (vibration frequence >18 kHz) powered by a magnetostrictive device.
10204949|NCT04400838|Experimental|Group 2 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks apart
10204950|NCT04400838|Experimental|Group 2 b1|.Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
10204951|NCT04400838|Experimental|Group 4 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp (Abs 260)
10204952|NCT04400838|Experimental|Group 4 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
10198659|NCT03120624|Experimental|Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)|Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
9725309|NCT05279924|Experimental|Ivoirian Boys with severe Hemophilia A treated with Emicizumab|All Ivoirian boys with severe Hemophilia A (with and without inhibitors) on prophylaxis with Emicizumab
9725310|NCT05279911|No Intervention|Control|Implants were randomly inserted in 20 non-lased T2DM patients (Control)
9725311|NCT05279911|Experimental|Low level laser therapy|Implant were randomly inserted in 20 lased T2DM patients (Intervention)
9981174|NCT05077254|Experimental|Moderna COVID-19 Vaccine Booster + SOC IS Regimen|"Participants will receive an additional dose (1 dose) of the Moderna COVID-19 Vaccine and will continue to take their standard of care transplant immunosuppressive medications without alterations in schedule and dosing.~SOC IS: Standard of Care transplant immunosuppression regimen"
9725312|NCT05279898|Experimental|Multimodal General Anesthesia (MMGA Bundle) - EEG Guided|"Routine anesthetic induction~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.2% ropivacaine on both sides of the sternum after anesthetic induction but before surgical incision (total of 40mL)~Ketamine (0.1 to 0.2 mg.kg/hr)~Remifentanil (0.05-0.4 mcg/kg/min)~Dexmedetomidine (0.2-0.5 mcg/kg/hr)~Rocuronium intermittent bolus (TOF)~Propofol infusion (15 to 200 mcg/kg/min)~Postop~Standard pain management protocol~IV Acetaminophen~IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~Other oral pain medications as per standard of care (Oxycodone, etc)~Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion~PIFB on postoperative day 1 (provided they are extubated/getting ready to be extubated)(for intervention group)~Lidocaine patches"
9725313|NCT05279898|No Intervention|Standard of Care/Control|"EEG monitoring will be blinded, and not guide anesthesiologists. Patients will receive standard/routine anesthesia practice intraoperatively.~Postoperative Propofol infusion (15 to 200 mcg/kg/min) ± Sevoflurane~Standard pain management protocol~IV Acetaminophen (1 gram) x 4 doses at 6 hour intervals starting from 1 hr after ICU arrival~IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~Other oral pain medications as per standard of care (Oxycodone, etc)~Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion~Lidocaine patches"
9725314|NCT05279872|Experimental|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
9725315|NCT05279859|Experimental|Dose Escalation (Part 1): ERAS-007 plus gilteritinib|ERAS-007 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
9725316|NCT05279859|Experimental|Dose Escalation (Part 2): ERAS-601 plus gilteritinib|ERAS-601 will be administered in combination with gilteritinib to study participants with R/R FLT3 mutated AML in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
9725317|NCT05279859|Experimental|Dose Expansion (Part 3): ERAS-007 plus gilteritinib|ERAS-007 will be administered at the recommended dose (as determined from Part 1) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
9725318|NCT05279859|Experimental|Dose Expansion (Part 4): ERAS-601 plus gilteritinib|ERAS-601 will be administered at the recommended dose (as determined from Part 2) in combination with gilteritinib to study participants with R/R FLT3 mutated AML.
9725319|NCT05279820|Active Comparator|Partial Pulpotomy|After pulp exposure 2-3 mm of the pulp tissue will be amputated, a calcium silicate based material will be placed over the pulp and the tooth will be restored.
9725320|NCT05279820|Active Comparator|Full Pulpotomy|After pulp exposure the entire coronal pulp to the level of canal orifices will be amputated , calcium silicate based material will be placed over the pulp and the tooth will be restored.
9981175|NCT05077254|Experimental|Moderna COVID-19 Vaccine Booster +SOC IS Reduction|"Participants will receive an additional dose (1 dose) of the Moderna COVID-19 vaccine, with concurrent reduction of their standard of care transplant immunosuppression regimen (IS), per protocol.~SOC IS Reduction: Standard of Care transplant immunosuppression regimen reduction, per protocol"
9981176|NCT05073419|Active Comparator|Control|Post-AMI patients in this arm will receive standard of care
9725321|NCT05279807|Active Comparator|Zofenopril 30mg|Single dose Phase (4 weeks): patients will be treated with Zofenopril 30 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
9981177|NCT05073419|Experimental|ICM|Post-AMI patients in this arm will receive standard of care and an ICM
9981178|NCT05060913|Experimental|5% EMLA Cream|EMLA cream will be applied over buccal mucosa of one side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
9725322|NCT05279807|Active Comparator|Amlodipine 5mg|Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
9725323|NCT05279781|Active Comparator|Root canal treatment group|This group will receive complete root canal therapy
10198660|NCT03110380|Experimental|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet + dolutegravir (DTG) placebo tablet + emtricitabine/tenofovir alafenamide (F/TAF) placebo tablet administered without regard to food for at least 48 weeks.
9725324|NCT05279781|Active Comparator|Pulpotomy group|This group will receive full pulpotomy
9725325|NCT05279768|Experimental|WJ-MSCs|Patients will be given 0.3 million kg/bb WJ-MSCs, tablet (placebo), and nasal drop 0.5 ml/day (growth medium).
9725326|NCT05279768|Experimental|Secretomes|Patients will be given tablet (placebo), infus placebo (NaCl 0.9%), and nasal drop 0.5 ml/day (Secretomes).
10198661|NCT03110380|Active Comparator|DTG + F/TAF|DTG 50 mg tablet + F/TAF FDC tablet + B/F/TAF placebo tablet administered without regard to food for at least 48 weeks.
10198662|NCT03110380|Experimental|Open-label Phase B/F/TAF from B/F/TAF|Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
10198663|NCT03110380|Experimental|Open-label Phase B/F/TAF from DTG + F/TAF|Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
10198664|NCT03109262|Experimental|Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans|All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans
9725327|NCT05279768|Experimental|WJ-MSCs and Secretomes|Patients will be given tablet (placebo), infus 0.3 million kg/bb WJ-MSCs, and nasal drop 0.5 ml/day (Secretomes).
9725328|NCT05279755|Experimental|Prosetin|Part A: single-ascending dose; Part B: multiple doses (7 days)
10198665|NCT03100240|Experimental|Experimental group|Modified Supper Long Protocol
10198666|NCT03100240|No Intervention|control group|long protocol
9725329|NCT05279755|Placebo Comparator|Placebo|Part A: single-ascending dose; Part B: multiple doses (7 days)
9725330|NCT05279729|No Intervention|Control|
9725331|NCT05279729|Experimental|Weight Watchers (WW)|
9725332|NCT05279729|Experimental|Healthi app|
9725333|NCT05279716|Experimental|omidenepag isopropyl 0.02mg|Instill 1 drop of Eybelis ophthalmic solution 0.002% once a day into the affected eye.
9725334|NCT05279703|Active Comparator|0.03 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
9725335|NCT05279703|Active Comparator|0.02 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
9725336|NCT05279703|Active Comparator|0.01 mcg group|epinephrine infusion will be started after subarachnoid block until 5 minutes after delivery of the baby
9981179|NCT05060913|Active Comparator|20% Benzocaine gel|Benzocaine gel will be applied over buccal mucosa on another side for 1.5 minutes of Maxillary of Mandibular anterior teeth.
9981180|NCT05060289||Modeling group|The data of modeling group is used to construct a predictive model of DILI endpoint events.
9981181|NCT05060289||Validation group|Validation group is used to validate the predictive model externally.
9725337|NCT05279690|Experimental|Cohort 1 low-dose colchicine|Participants with metastatic solid tumors who will receive low-dose colchicine (0.6 mg oral BID)
9725338|NCT05279690|Experimental|Cohort 1 high-dose colchicine|Participants with metastatic solid tumors who will receive high-dose colchicine (0.6 mg oral TID)
9981182|NCT05057715|Active Comparator|Cohort 1|Single dose of 3.3x10(12) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
9981183|NCT05057715|Active Comparator|Cohort 2|Single dose of 1x10(13) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
9981184|NCT05057715|Active Comparator|Cohort -1|In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.
9725339|NCT05279690|Experimental|Cohort 2 Participants with post-radical surgery|Participants with post-radical surgery for high-risk clinically localized urothelial cancer will receive colchicine 0.6 mg oral BID.
9725340|NCT05279664|Experimental|Intervention (RIC + standard of care for NEC)|Neonates randomized to the intervention arm will receive RIC and will continue to receive the standard of care for NEC.
9725341|NCT05279664|Sham Comparator|Control (Standard of care for NEC)|Neonates randomized to the control arm will receive the standard of care for NEC. The research fellow or nurse responsible for performing RIC will be performing sham inflation/deflation of the blood pressure cuff connected to a dummy arm to mimic the noise of the cuff for neonates in the control arm.
9725342|NCT05279638||psoriasis vulgaris patients|psoriasis vulgaris patients , both sex , 18,55 years old
9725343|NCT05279638||healthy participants|
9725344|NCT05279625|Experimental|Interval exercise training|Interval exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
9725345|NCT05279625|Experimental|continuous exercise training|continuous exercise training using either elastic band, dumbbells, treadmill, cycling for 6 months
9725346|NCT05279625|Experimental|machine-assisted exercise training|machine-assisted exercise training for 6 months
10198667|NCT03099005|Active Comparator|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
10198668|NCT03099005|Active Comparator|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
10198669|NCT03099005|Active Comparator|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
10198670|NCT03084926|Experimental|MP0274|
10198671|NCT03078478|Experimental|IDeg 200 U/mL|
10198672|NCT03078478|Active Comparator|IGlar 300 U/mL|
10198673|NCT03077191||Quality of life|Quality of life of breast cancer patients treated with conservative surgery (quadrantectomy) and adjuvant hypofractionated whole breast radiotherapy according to the institutional standard regimen, to a total dose of 40 Gy in 15 fraction over 3 weeks will be measured with EORTC quality of life questionnaires QLQ-C30 and QLQ-BR23, before the start of the radiotherapy, at the end of the radiotherapy and subsequently at every follow-up visit (the first at 6 months after the end of the treatment, then annually for 5 consecutive years after the first follow up visit).
9725347|NCT05279625|Active Comparator|traditional rehabilitation|traditional rehabilitation for 6 months
9981185|NCT05054439|Experimental|SI-B001 combined with paclitaxel|SI-B001 in combination with paclitaxel for the treatment of recurrent metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) with disease progression or intolerance.； The patient had previously received anti-PD-1 mab ± platinum-based chemotherapy； Patients' previous treatment line should be ≤2L.
9725348|NCT05279586|Active Comparator|patients that will receive lactulose|Cirrhotic patients who were recovered from HE will be randomized into lactulose group receiving 30-60 ml of lactulose orally in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
9725349|NCT05279586|Active Comparator|patients that will receive colistin|colistin group receiving colistin sulfate 1.5 million I.U. tablet orally twice
9981186|NCT05051254|Experimental|Respiratory muscle impairment|Minor patients with primary or secondary impairment of respiratory muscles and followed at Necker Hospital
9981187|NCT05046795|Experimental|Revefenacin inhalation solution 175 mcg QD.|Revefenacin inhalation solution 175 mcg QD.
9981188|NCT05046795|Placebo Comparator|Placebo inhalation solution QD.|Placebo inhalation solution QD.
9981189|NCT05038592|Experimental|Treatment (decitabine, tagraxofusp-erzs)|Patients receive decitabine IV over 60 minutes on days 1-5, and tagraxofusp-erzs IV over 15 minutes on days 1-3. Cycles of decitabine repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment with tagraxofusp-erzs repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
9981190|NCT05038020|Experimental|AKST4290|Subjects will receive AKST4290, 400mg twice daily, for 24 weeks
9981191|NCT05038020|Placebo Comparator|Placebo|Subjects will receive matching Placebo, twice daily, for 24 weeks
9725350|NCT05279573|Experimental|Combination of Omega-3 based product and botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
9725351|NCT05279573|Experimental|Omega-3 based product|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
10198674|NCT03073278|Other|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
10198675|NCT03073278|Other|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
9725352|NCT05279573|Experimental|Botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
9725353|NCT05279573|Placebo Comparator|Control group|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
10198676|NCT03073278|Other|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
10198677|NCT03072134|Experimental|Unresectable disease|Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
10198678|NCT03072134|Experimental|Resectable disease|Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
10204953|NCT04400838|Experimental|Group 4 c1|Volunteers will receive two doses of ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs260) prime and 2.2x10^10vp (qPCR) boost*, at least 4 weeks apart
9725354|NCT05279547|Active Comparator|Arm 1 (First constant-load then interval bed-cycling protocol)|"During Day 1, patients will be familiarized with the constant-load and interval bed-cycling exercise against no resistance. Patients will be also randomized in the two arms of the study before the determination of the appropriate exercise intensities to be subsequently use during the constant-load and interval bed-cycling protocols on Day 2 and Day 3. Exercise intensities will be determined so that the volume of training during the two protocols will be equal.~During Day 2, patients randomized to arm 1 will perform the constant-load bed-cycling protocol. During Day 3, patients who executed the constant-load bed-cycling protocol on Day 1 (arm 1) will perform the interval bed-cycling protocol."
9780772|NCT01131078|Experimental|Bevacizumab + Capecitabine (650 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 Week cycle in combination with capecitabine administered orally at 650 mg/m^2 twice daily (Day 1 to 21). Cycle length was 3 weeks with 3 weeks of capecitabine treatment without interruptions. Participants received the same regimen until unacceptable toxicity, PD, or participant withdrawal.
9780773|NCT01131104||Cohort 1|Participants with NAION who have used PDE5 inhibitors
10204954|NCT04400838|Experimental|Group 5 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (Abs 260)
9780774|NCT01131130|Experimental|Investigational contact lens|Bausch & Lomb
10204955|NCT04400838|Experimental|Group 5 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
10204956|NCT04400838|Experimental|Group 5 b1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x1010vp, (qPCR)
10204957|NCT04400838|Experimental|Group 5 c1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (qPCR)
9780775|NCT01131130|Active Comparator|Acuvue Oasys Contact Lens|Johnson & Johnson Lens
10204958|NCT04400838|Experimental|Group 5 d1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
9780776|NCT01131130|Active Comparator|Air Optix Aqua|Ciba Vision
10204959|NCT04400838|Experimental|Group 5 e1|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10^11 vp/mL), 4-6 weeks apart
10204960|NCT04400838|Experimental|Group 5 f1|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
10204961|NCT04400838|Experimental|Group 6 a1|Volunteers will receive a single dose ofChAdOx1 nCoV19 vaccine, 5x1010vp (qPCR)
10204962|NCT04400838|Experimental|Group 6 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 5x1010vp (Abs260) prime and 0.5mL (3.5 - 6.5 × 1010 vp, Abs 260)* boost* at least 4 weeks apart
10204963|NCT04400838|Experimental|Group 7 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
9725355|NCT05279547|Active Comparator|Arm 2 (First interval then constant-load bed-cycling protocol)|"During Day 1, patients will be familiarized with the constant-load and interval bed-cycling exercise against no resistance. Patients will be also randomized in the two arms of the study before the determination of the appropriate exercise intensities to be subsequently use during the constant-load and interval bed-cycling protocols on Day 2 and Day 3. Exercise intensities will be determined so that the volume of training during the two protocols will be equal.~During Day 2, patients randomized to arm 2 will perform the interval bed-cycling protocol. On Day 3 they will perform the constant-load bed-cycling protocol."
9981192|NCT05036122|Experimental|Whole-body exercise in healthy adults (Aim 1)|Subjects will have blood [lactate] measurement obtained with the LabClasp device while completing an exercise stress test on a treadmill or bicycle.
10198679|NCT03067259|No Intervention|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
10198680|NCT03067259|Other|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
10198681|NCT03061539|Experimental|Nivolumab & Ipilimumab|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
10198682|NCT03052634|Experimental|RC48-ADC 1.5 mg/kg (HER2 Positive)|
9981193|NCT05036122|Experimental|ICU patients susceptible to developing sepsis (Aim 2)|Subjects will have blood [lactate] measurement obtained with the LabClasp device as frequently as required for clinical purposes
9981194|NCT05025267|Other|Enteral Tube-fed Adults|Adults being fed an enteral formula with a feeding tube
9725356|NCT05279534|Experimental|Probiotic|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS) status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
9725357|NCT05279534|Placebo Comparator|Control|The control study product is identical in packaging and formulation except that none of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485 and Pediococcus acidilactici CECT7483 (probiotic bacteria) are present. The Control product contains maltodextrin (E1400, qs) only, in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
9725358|NCT05279521|Experimental|Experimental group|Mandatory exercise the lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
9725359|NCT05279521|No Intervention|Control group|Voluntary exercise the lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
9725360|NCT05279508|Experimental|Prevention treatment group|"10 week stroke prevention program with six group sessions on pre-set themes targeting modifiable stroke risk factors . The group sessions are chaired by health professionals but also consists of peer learning to support change in lifestyle habits and activity patterns and reduce stroke risk. The change process is supported with a mHealth application for daily registrering of six domains; stroke risk factors, EEA, stress and goal achievement.~A lifestyle and stroke risk analysis will be performed at baseline measures, at follow up and at 12 month follow up."
9725361|NCT05279508|No Intervention|Standard treatment group|Usual care within primary healthcare. At baseline, follow up and at 12 month follow up a lifestyle and stroke risk analysis will be conducted.
9725362|NCT05279495|Other|Loaded CANNAXR|"In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks.~In a double-blinded fashion, 250 mg CANNAXR cream and 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks."
10198683|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Positive)|
10198684|NCT03052634|Experimental|RC48-ADC 2.5 mg/kg (HER2 Positive)|
10198685|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|
9780777|NCT01131182|Experimental|Sitagliptin|Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
10198686|NCT03046927|Experimental|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
10198687|NCT03046927|Placebo Comparator|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
9780778|NCT01131182|Active Comparator|Sulfonylurea|Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
9780779|NCT01131260|Experimental|Open Group|• Fetal STAN monitor electrode inserted and data available to caregivers
9780780|NCT01131260|Other|Masked Group|•Fetal STAN monitor electrode inserted, but data masked to the caregivers
10198688|NCT03042988|Experimental|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
10198689|NCT03042988|Sham Comparator|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
9981195|NCT05022602|Experimental|Imagio|Imagio Grayscale only probe and Imagio Duplex probe in ultrasound only and OA modes
10198690|NCT03042416|Experimental|18F-DOPA scan|18F-DOPA (4 MBq/kg, minimum 110 MBq, maximum 600 MBq) intravenous. Single-dose 20-80 minutes prior to PET/CT scan of brain or whole body (depending on specific imaging protocol for patient).
9780781|NCT01131299|Active Comparator|Alpha cyclodextrin first then placebo|Randomized subjects will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks. After the one week washout, the subjects will receive 2 tablets orally of placebo (three times a day for 12-14 weeks).
9981196|NCT05022459||Emicizumab Prophylaxis|This group will include patients on standard of care Emicizumab prophylaxis for Hemophilia A
10198691|NCT03040921|Experimental|Uterine Transposition|Patients submitted to uterine transposition.
10198692|NCT03040661|Experimental|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
10198693|NCT03040661|Active Comparator|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
9725363|NCT05279482||group treated with standard dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
9725364|NCT05279482||group treated with mega dose methyl prednisolone|patients with positive PCR and requiring oxygen therapy
9981197|NCT05022459||FVIII Prophylaxis|This group will include patients on standard of care FVIII prophylaxis for Hemophilia A
9981198|NCT05016505|Experimental|Compliance through reduction (relocation and reduction of personal smoking) and cessation|Smokers will be referred by the survey team to peer educators from a community-based organization trained to provide peer to peer health education including tobacco cessation support. The peer educator will coordinate smoking cessation support, including serving as a liaison between participant and research team, providing information regarding the smoke-free policy and opportunities for relocation, and connecting participant to access to tobacco replacement therapy and/or physician support if deemed appropriate.
9984577|NCT03954743|Experimental|HRV PCV-free Liq Group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in liquid formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
10198694|NCT03037242|Other|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
9725365|NCT05279456|Experimental|Spikogen vaccine|Spikogen vaccine 25 micrograms by intramuscular injection on study days 1, 22 and 112
9725366|NCT05279443|Experimental|yoga-based exercises|
9725367|NCT05279417|Experimental|ATI-450 20mg BID plus Methotrexate|ATI-450 20mg oral tablet BID with a stable weekly dose of Methotrexate
9725368|NCT05279417|Experimental|ATI-450 50mg BID plus Methotrexate|ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate
10198695|NCT03036683|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
9725369|NCT05279417|Placebo Comparator|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of Methotrexate
9725370|NCT05279404|Experimental|Group A - electroacupuncture|"electroacupuncture group Insert stainless steel acupuncture needles into Neiguan (cathode) and Jianshi (anode) on both sides and twist the needles.~After that, the electroacupuncture machine was connected and 2 Hz electrical stimulation was administered for 30 minutes.~The stimulation intensity was mainly based on slight muscle contractions and no pain in the subjects. At this time, cardiac function and electrogastrogram were recorded at the same time."
9725371|NCT05279404|Sham Comparator|Group B - Sham electroacupuncture|Sham electroacupuncture group The method was the same as that of the electroacupuncture group, but the needles were only acupuncture under the skin of Neiguan and Jianshi without twisting the needles. The electroacupuncture machine was connected but no electrical stimulation was administered.
9725372|NCT05279391|Active Comparator|SOC|Patients included in this arm treated with the standard of care (SOC), including dexamethasone plus heparin, with or without the addition of antibiotics and remdesivir
9725373|NCT05279391|Active Comparator|TOCI|Patients included in this arm treated with the SOC plus Tocilizumab (single IV dose: 8mg/kg)
9725374|NCT05279391|Active Comparator|ANA|Patients included in this arm treated with the SOC plus Anakinra (200mg twice daily IV for 3-6 days, then 100 mg/twice daily, for up to 10 days in total)
9725375|NCT05279391|Active Comparator|COMBI|Patients included in this arm treated with the SOC plus the combination of Tocilizumab, Baricitinib and inhaled DNase (COMBI) as a rescue treatment.
9725376|NCT05279339|No Intervention|Control|Participants will not perform any exercise
9725377|NCT05279339|Experimental|Exercise|Participants will perform an exercise recommended for preventing neck and shoulder pain
9725378|NCT05279326|Experimental|Intervention arm|Participants will receive virtual SMAs and usual care. Virtual SMAs will last 90 minutes, every 3 weeks, in 18 weeks through an online platform, at no cost to participants beyond the use of the device and the internet.
9725379|NCT05279326|No Intervention|Control arm|Participants will be at usual care and follow their usual contact with health services.
9725380|NCT05279287||Minimally invasive surgical procedure|Patients undergoing any minimally invasive procedure can be included in the study. Initial focus will be on robotic prostatectomy and robotic TME (rectal cancer removal).
9725381|NCT05279261|Experimental|Experimental group|Undergo the axillary approach
9725382|NCT05279235|Experimental|JT001& Favipiravir Placebo|JT001 (VV116):Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days Favipiravir placebo:Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days
9725383|NCT05279235|Active Comparator|Favipiravir & JT001 Placebo|Favipiravir:Day 1: 1600mg, Q12H X 1 day; Day 2~5: 600mg, Q12H X 4 days JT001 (VV116) placebo:Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
9725384|NCT05279222|Experimental|gait training|
9725385|NCT05279209|Experimental|Sclerotherapy|Patients who receive uterine artery embolization for symptomatic fibroids
9725386|NCT05279209|Active Comparator|Surgery|Patients who receive uterine artery embolization for symptomatic fibroids
9725387|NCT05279183|Active Comparator|Erythritol|20 volunteers receive erythritol dissolved in 300 mL tap water as oral preloads (3 times 100mL). The dosage will be calculated based on the participants ratings of the sweetness intensity (matched sweetness to 10 % sucrose).
9725388|NCT05279183|Active Comparator|Sucrose|20 volunteers receive 30g sucrose dissolved in 300 mL tap water as oral preloads (3 times 100mL).
9725389|NCT05279183|Active Comparator|Sucralose|20 volunteers receive sucralose dissolved in 300 mL tap water as oral preloads (3 times 100mL). The dosage will be calculated based on the participants ratings of the sweetness intensity (matched sweetness to 10 % sucrose).
9725390|NCT05279170|Experimental|children|"Compression of adjacent vessels (jugular vein and carotid artery), near the left paratracheal area. The risk of compression of the vessels will be assessed before performing the maneuver.~At the screening time before the intervention, we will perfom an ultrasonography measurement while we applied the maneuver in order to eliminate a risk of compression of the vessels, defined as a reduction in diameter of 50%."
9981199|NCT05016505|Experimental|Compliance through resident endorsement|Buildings assigned will be targeted for a series of 2 in-residence programs that involve community forums and the creative arts to garner resident endorsements of smoke-free living environments. Premised on resident engagement, this arm seeks to impact social and physical dimensions of the residential environment to achieve compliance. The sessions will: 1) inform residents of risks associated with smoking and secondhand smoke; 2) identify reasons to have a smoke-free home, 3) ask residents to sign a pledge on paper and/or virtually; 4) display smoke-free signage on doors and/or social media pages with an original hashtag (#Smokefree[building address]); and 5) refer residents to the Smoke-free NYCHA website for information on the policy and existing cessation resources.
9981200|NCT05016505|Experimental|Compliance through reduction/cessation plus resident endorsement (combined)|The combined intervention will be carried out in the buildings assigned to this RCT arm, which will provide in-residence programs based on the resident endorsement treatment and the smoking relocation/cessation treatment. Both will occur simultaneously with one geared toward all building residents (resident endorsement) and the other targeting smokers (smoking relocation/cessation) with the goal of reducing both personal smoking and secondhand smoke exposure.
9984578|NCT03954743|Active Comparator|HRV Lyo group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries.
9725394|NCT05279144|Experimental|Experimental|Ventrogluteal region IM injection will be applied to the children in the intervention group, which is recommended by the literatureIn order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
9725395|NCT05279144|No Intervention|No Intervention|Vastus Lateralis IM injection, which is the routine practice of the clinic, will be applied to the children in the control group of the study. In order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
9725396|NCT05279118|Experimental|Ketogenic diet arm|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
10198696|NCT03036683|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
10198697|NCT03026387|Other|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are suicide attempters without psychotic features"
10198698|NCT03016377|Experimental|iC9-CAR19 cells|The 3+3 design in adult subjects and an independent study using 3+3 design in pediatric subjects. The starting dose of 5 x 10^5 transduced cells/kg will enroll 3 adult subjects in the initial cohort. If there are no dose limiting toxicities w/in 4 weeks of the cell infusion in these 3 subjects, then the next cohort will evaluate 1 x10^6 transduced cells/kg in adults. If there is toxicity in 1/3 patients in the initial cohort, the cohort will be expanded to enroll up to 6 adult patients. If the dose level 1 is determined to be above the tolerated cell dose, de-escalation would occur to dose level -1 where subjects would receive 1 x 10^5 transduced cells/kg. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before administration of iC9-CAR19 T cells.
10204964|NCT04400838|Experimental|Group 7 b1|Volunteers will receive two doses of ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)* 4-6 weeks apart
9725397|NCT05279118|Active Comparator|ACTH arm|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
9725398|NCT05279105||Humanitarian workers|Staff working in humanitarian organisations will be recruited for interviews
10204965|NCT04400838|Experimental|Group 8 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
9981201|NCT05016505|No Intervention|Standard NYCHA approach (control)|Buildings and study participants assigned to this arm will be recruited and followed over a 12-month period to assess outcomes. No additional programs or services will be delivered to the buildings or residents assigned to this arm beyond standard programs that NYCHA may provide to support the smoke-free mandate. Field staff will document any policy-related signage, activities or information to which these participants are exposed.
9725399|NCT05279105||Internally displaced persons|Internally displaced persons living in conflict settings will be recruited for interviews
10198699|NCT03016377|Experimental|Expansion Cohort Second Administration of iC9-CAR19 cells|"After the recommended phase 2 dose (RP2D) of iC9-CAR19 T cells has been determined in adults, up to 18 additional adult subjects will be enrolled in an expansion cohort at the RP2D. In the expansion cohort, subjects will be offered a second infusion of iC9-CAR19 T cells based on B-cell recovery and minimal residual disease (MRD) status. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before second administration of iC9-CAR19 T cells.~Subjects in the expansion cohort who experience ≥grade 2 CRS or ICANS, did not respond to the initial dose of the standard of care treatment will be enrolled in a sub-study of rimiducid."
10198700|NCT03009487|Experimental|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
10198701|NCT03009487|Placebo Comparator|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
10198702|NCT03009487|Placebo Comparator|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
10198703|NCT03002519|Experimental|PLX-R18|Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.
9725400|NCT05279092|Active Comparator|Bupivacaine-Liposomal Bupivacaine (B-LB)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an Interspace between the popliteal artery and capsule of the posterior knee (iPACK) block.
9725401|NCT05279092|Experimental|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (B-DEX-MPA)|Nerve blockade administration will be carried out per standard of care. All patients will receive single injection under ultrasound guidance with adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
9725402|NCT05279079||Group 1|Drug-associated AP: patients aged 18 or more years undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
9725403|NCT05279079||Group 2|Other cause AP: patients aged 18 or more years not undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
9984579|NCT03954223|Experimental|LSC + blinded CGM|Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
9725404|NCT05279079||Group 3|Chronic pancreatitis: patients aged 18 or more years with symptomatic chronic pancreatitis confirmed by CT or MRI
9725405|NCT05279079||Group 4|Pancreas cancer: patients aged 18 or more years with biopsy proven pancreas cancer
10198704|NCT02999022|Experimental|Lithium carbonate|Lithium carbonate 300mg capsule; once per day for 2 weeks.
10198705|NCT02999022|Placebo Comparator|Lactose placebo|Lactose placebo capsule; once per day for 2 weeks.
10198706|NCT02998892|Active Comparator|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
9725406|NCT05279079||Group 5|Diabetes mellitus: patients aged 18 or more years with type 1 or type 2 diabetes mellitus in receipt of insulin or oral hypoglycaemics
9725407|NCT05279079||Group 6|Healthy volunteers
9725408|NCT05279066||Patients scheduled to undergo an elective cardiac ultrasound|All cardiac patients undergoing an elective cardiac ultrasound as an outpatient at UCLA may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented prior to their scheduled ultrasound.
9725409|NCT05279066||Patients with a pulmonary arterial catheterization scheduled or completed|All patients hospitalized in the cardiac ICU at UCLA with a pulmonary arterial catheterization scheduled or completed may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented during their hospital stay.
9725410|NCT05279040||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis who will be initiating Trikafta treatment
9725411|NCT05279027|Experimental|PET imaging|This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma.
9725412|NCT05279014|Active Comparator|Exercise in a fed-state|12-weeks of exercise training, 50-minutes, 3 days per week performed 1.5-3 hours after a high-carbohydrate meal (1 g/kg body mass).
9725413|NCT05279014|Experimental|Exercise in a fasted-state|12-weeks of exercise training, 50-minutes, 3 days per week performed after at least an 8-hour fast. A high-carbohydrate meal (1 g/kg body mass) will be consumed after exercise.
9725414|NCT05279001|Experimental|Jaktinib|
10198707|NCT02998892|Experimental|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
10198708|NCT02993263|Other|Noncardiac surgery|VectraplexECG System with CEB® will be recorded after surgery and on day 1, 2 and 3 post operatively
9725415|NCT05278988|Active Comparator|Group A|Treatment according to WHO MDR-TB treatment guidelines (2019).
9725416|NCT05278988|Experimental|Group B(PRS Regimen V)|bedaquiline, delamanid, clofazimine, pyrazinamide
9725417|NCT05278975|Experimental|Phase 1 - Dose Escalation|RSO-021 administered in increasing doses as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle.
10198709|NCT02992275|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
10198710|NCT02985684|Experimental|Device|ASD closure with the GORE® CARDIOFORM ASD Occluder
10198711|NCT02982538|Other|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
9981202|NCT05011058|Experimental|Nanatinostat with Valganciclovir|"Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily.~Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week."
9981203|NCT05009355|Experimental|experimental|A Group: Consisted of 20 patients who were treated with scaling and root planing in conjunction with 2g antioxidant Vit (C)
9981204|NCT05009355|No Intervention|Control|A Group: consisted of 20 patients who were treated with scaling and root planing.
9981205|NCT05003661|Experimental|Mother's voice|Neonates receive the intervention that recording of mother's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
10198712|NCT02982538|Other|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
10198713|NCT02966782|Experimental|Venetoclax monotherapy (Cohort 1)|
10198714|NCT02966782|Experimental|Venetoclax + azacitidine (Cohort 2)|
9725418|NCT05278975|Experimental|Phase 2 - Dose Expansion - MPE from non-mesothelioma solid tumors|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from non-mesothelioma solid tumors.
9725419|NCT05278975|Experimental|Phase 2 - Dose Expansion - MPE from mesothelioma|RSO-021 administered at the MTD/RP2D as a solution for pleural infusion through an indwelling IP catheter, administered as a single dose on Day 1 of each week of a 21-day treatment cycle in patients with MPE from mesothelioma.
9725420|NCT05277753|Experimental|CART/CTL/DCvac cells to treat T-ALL|
10198715|NCT02966782|Experimental|Safety Expansion (Cohort 3)|
10198716|NCT02964897|Experimental|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
9725421|NCT05276518||o Group (1): 30 cases who will undergo Two Layer Uterine Closure|o After the delivery the first group will undergo Two Layer Uterine Closure: Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.
9725422|NCT05276518||o Group (2): 30 cases who will undergo single layer uterine closure.|The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa
9725423|NCT05275998|Experimental|Sentinel Group 1|10 HIV-1 infected subjects will receive one infusion of 2400 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
9725424|NCT05275998|Experimental|Sentinel Group 2|10 HIV-1 infected subjects will receive one infusion of 3600 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
9725425|NCT05275998|Experimental|Sentinel Group 3|10 HIV-1 infected subjects will receive one infusion of 4800 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
9725426|NCT05275998|Experimental|Core Group 1|20 HIV-1 infected subjects will receive three infusions of each antibody, TMB-365 and TMB-380 every 8 weeks, at doses to be determined and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 28.
9725427|NCT05275998|Experimental|Core Group 2|20 HIV-1 infected subjects will receive three infusions of each antibody, TMB-365 and TMB-380 every 8 weeks, at doses to be determined and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 28.
9725428|NCT05275998|Experimental|Core Group 3|20 HIV-1 infected subjects will receive two infusions of each antibody, TMB-365 and TMB-380 every 12 weeks, at doses of 4800 mg each and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 28.
9725429|NCT05275920||Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
9785276|NCT01247350|Placebo Comparator|Placebo|administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
9981206|NCT05003661|Experimental|Father's voice|Neonates receive the intervention that recording of father's voice of reading children's book. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
9984580|NCT03954223|Experimental|LSC+TLE + blinded CGM|Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
10198717|NCT02964897|Other|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
10198718|NCT02963025|Other|THE HIGHER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 10 cmH2O with lung recruitment maneuvers
9725430|NCT05275920||In-Basket Message group|Providers will receive a monthly in-basket messages linking to a list of patients who have been seen in the past 2 months or will be seen in the upcoming month with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, date of last visit, and date of next visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
9725431|NCT05275920||Control group|Patients who will receive the current standard practice of care (no BPA or in-basket message)
9725432|NCT05274542|Experimental|high intensity with blood flow restriction group|
9725433|NCT05274542|Active Comparator|high intensity without blood flow restriction group|
9725434|NCT05273281|Experimental|TAQLA|Transabdominal plain block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
9725435|NCT05273281|Experimental|TAQLB|Quadratus lumborum block -group. Ropivacaine Hydrochloride Inj 5mg/ml 20 ml perineurally per side.
9725436|NCT05273281|No Intervention|TAQLC|Control group. Pain relief only with intravenous and peroral drugs.
9725437|NCT05273255|Experimental|FMT-Recipients|"FMT-Recipients are patients with stage IV cancer, who have not sufficiently responded (stable disease or non-response) after at least 1 full cycle of ICI therapy. These patients will undergo the FMT procedure after the colon cleansing performed per routine treatment protocols at the Departement of Gastroenterology at the University Hospital of Zürich.~The stool is donated by FMT-Donors, which are patients with any solid cancer stage III or IV cancers, who received any ICI-Therapy and have experienced a durable partial or complete response.~FMT infusate will be administered via colonoscopy."
9725438|NCT05273203|Experimental|Control|No intervention. Participated only in measurements at baseline and at 6 months.
9984581|NCT03954223|Experimental|LSC+TLE+ real time feedback via CGM|Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
9725439|NCT05273203|Experimental|FIM-1|Participated in a supervised 6 months football training program once per week and in measurements at baseline and at 6 months.
9725440|NCT05273203|Experimental|FIM-2|Participated in a supervised 6 months football training program twice per week and in measurements at baseline and at 6 months.
9725441|NCT05273203|Experimental|FIM-3|Participated in a supervised 6 months football training program thrice per week and in measurements at baseline and at 6 months.
9725442|NCT05268809|Experimental|Ketogenic Diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies. Metabolic Meals will be delivered to KETO subjects' homes via courier, consisting of 3 meals a day plus snacks, targeting 70% fat, 20% protein, 10% carbohydrates.
9725443|NCT05268809|No Intervention|Diet as usual|The Diet As Usual (DAU) participants will be asked to maintain their current dietary habits and will be discouraged from starting new diets during the 4-week study.
9725444|NCT05267886|Active Comparator|Inotrope|Participants randomized to receive the inotrope will be initiated on inotrope therapy at starting doses and titrated according to standard clinical care. During reassessment, the treating physicians will make a decision about adjustment of the inotrope dose (increase, maintain or decrease) based on hemodynamics, end-organ perfusion, vasopressor support and clinical exam. Dobutamine doses will be 2.5, 5.0, 7.5, 10 and >10 ug/kg/min and milrinone doses will be 0.125, 0.250, 0.375, 0.5 and >0.5 ug/kg/min. These dose stages are identical to those used in Capital Do-Re-Mi and reflect current standard of care.
9725445|NCT05267886|Placebo Comparator|Placebo|Participants in the placebo arm will have an intravenous solution of 0.9% NaCl running at a standardized rate, comparable to the infusion rate of the inotrope arm.
9725446|NCT05267106|Experimental|Cohort A: IDH-wild-type GBM|Participants with recurrent isocitrate dehydrogenase (IDH)-wild-type glioblastoma (GBM) harboring fibroblast growth factor receptors 1 and/or 3 (FGFR1-3) fusions or rearrangements (FGFR1-3 in-frame fusions, any FGFR2 rearrangement, or FGFR1/3 rearrangement with known partner).
9725447|NCT05267106|Experimental|Cohort B: primary CNS tumors and adult-type diffuse gliomas|Participants with other recurrent primary central nervous system (CNS) tumors, adult-type diffuse gliomas, including IDH-mutant astrocytoma, IDH-mutant and 1p/19q codeleted oligodendroglioma, or pilocytic astrocytomas, harboring FGFR1-3 fusions or rearrangements (FGFR1-3 in-frame fusions, any FGFR2 rearrangement, FGFR1/3 rearrangement with known partner).
10198719|NCT02963025|Other|THE LOWER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 5 cmH2O without lung recruitment maneuvers
9780782|NCT01131299|Placebo Comparator|Placebo first then Alpha cyclodextrin|Participants will receive 2 tablets orally of placebo (three times a day for 12-14 weeks). The subjects will have a one-week washout. After the washout, the participants will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks.
10198720|NCT02961881|Experimental|blinatumomab|
10198721|NCT02954523|Experimental|Phase I and Phase II|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily), Level -1 (70 mg once daily), Level 1 (the starting dose - 50 mg twice daily), Level 2 (70 mg twice daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive.~The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion."
10198722|NCT02936102|Experimental|FAZ053 single agent|
10198723|NCT02936102|Experimental|FAZ053 + PDR001|
10198724|NCT02935907|Experimental|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
10198725|NCT02931097|Active Comparator|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
9725448|NCT05267106|Experimental|Cohort C: GBM or recurrent primary CNS tumors|Any recurrent GBM or recurrent primary CNS tumor, including adult-type diffuse gliomas and pilocytic astrocytomas, with a known or likely FGFR1-3 activating mutation. All gliomas and glioneuronal and neuronal tumors with a known or likely FGFR 1-3 activating mutation are also eligible.
10198726|NCT02931097|Active Comparator|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
10198727|NCT02931097|Sham Comparator|Sham stimulation|No deep brain stimulation
9725449|NCT05266586|Placebo Comparator|Placebo|once-daily placebo tablet and placebo capsule
9981207|NCT05003661|No Intervention|control group|When the infants undergoing heel puncture procedure, the control group were under routine care. And the pain of high-risk newborns was measured with the Heartbeat, Respiration, SPO2 and Neonatal Infant Pain Scale (NIPS) in three minutes before the heel puncture, during the puncture, and the first, fifth and tenth minutes after the puncture.
9725450|NCT05266586|Experimental|monotherapy|once-daily obicetrapib 10 mg tablet and placebo capsule
9725451|NCT05266586|Experimental|combination therapy|once-daily obicetrapib 10 mg tablet and ezetimibe 10 mg capsule
9725452|NCT05266495||Brolucizumab|patients who received their first injection of Brolucizumab either during the active recruitment period (1 year prospective) or during the 6 months pre-start of the recruitment (6 months retrospective)
9981208|NCT04986449|Experimental|Intervention group|All families will receive the culinary and nutritional intervention. Changes before-after will be assessed regarding culinary skills, knowledge and attitudes of families on cooking with plant-based foods
10198728|NCT02927249|Experimental|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
9725453|NCT05266469||Ofatumumab|Patients prescribed with Ofatumumab
9725454|NCT05266469||Ocrelizumab|Patients prescribed with Ocrelizumab
9725455|NCT05265468|Experimental|Jones Group (Strain Counterstrain)|Jones Group consist in 90 seconds in a ralease positioning of no pain in muscle acortation
9725456|NCT05265468|Active Comparator|Lewit Group|Lewit Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques
10198729|NCT02927249|Placebo Comparator|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
9725457|NCT05265468|Active Comparator|Chaitow Group|Chaitow Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques and deep diaphragmatic respiration
9725458|NCT05265468|Placebo Comparator|Placebo Group|Placebo Group only have to mantain no pain positioning for 3 minutes
9725459|NCT05265273|Experimental|Nipocalimab|Participants aged 2 to less than [<] 18 years of age will receive nipocalimab once every two weeks for 24 weeks. After Week 24, all participants will have the option to enroll in long term extension (LTE).
9725460|NCT05262998|Active Comparator|CONTROL|Plate fixation
9725461|NCT05262998|Experimental|INTERVENTION|Intramedullary Screw
9725462|NCT05262257|Experimental|Lifestyle intervention group|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
9725463|NCT05262257|Experimental|Metformin treatment group|on the basis of lifestyle intervention, patients were given metformin 2-3 times a day (starting with 2times), 0.5g each time.
9725464|NCT05262257|Experimental|Dapagliflozin treatment group|on the basis of lifestyle intervention, patients took Dapagliflozin orally, once a day, 10mg at a time.
9725465|NCT05262257|No Intervention|Healthy control group|no intervention.
9725466|NCT05261867||Diabetic patients treated with SGLT2-I|Diabetic patients treated with SGLT2-I alone or in combination with other oral anti-diabetic (OAD) agents. Patients were considered in the SGLT2-I group if it was started at least 1 month prior to index hospitalization.
9725467|NCT05261867||Diabetic patients treated with other oral anti-diabetic (OAD) agents|Diabetic patients treated with other oral anti-diabetic agents alone.
9725468|NCT05261750|Experimental|Auto-Dendritic Adjuvant Therapy|Patients will be given standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
9725469|NCT05261750|Experimental|Allo-Dendritic-secretome and Auto-Dendritic Adjuvant Therapy|Patients will be given standrad medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
9725470|NCT05261568|Experimental|experimental group|"The first application is carried out by a researcher close to the polyclinic with care and demonstration.~The application will be suggested by hanging it from side to side in sitting position. They will be informed about the same application conditions in their own practice at home.~The program, which will last for 6 weeks, will continue from the home environment after a video surveillance observed by the beneficiary.~Periods of entry and exit times thanks to the mobile program. It will be done over the phone by the people who will come for 6 weeks. history book, lack of tools, etc. a website will be searched. Adhering to application products through study. A total of 42 sessions for 6 weeks, 7 days a week. About 30min. It is used to benefit from training to benefit from sustained progression. Apart from that, he can enjoy wearing it by dressing casually and casually."
9725471|NCT05261568|No Intervention|control gruop|"The control group did not receive any intervention other than their own treatment during the study.~will not be applied. Progressive relaxation exercise application to the individuals included in the control group personal information form, Pittsburgh sleep quality index, fatigue severity scale will be applied as test-post-test."
9725472|NCT05260892||Narrow GM|Patients presenting at least onde edentulous site rehabilitated with Narrow GM implant
10198730|NCT02924272|Experimental|Ixazomib|Ixazomib capsule, orally, at same dose and schedule that participants were receiving in the parent study until disease progression, clinical deterioration in the investigator's judgment, experience an unacceptable toxicity, withdraw consent, pursue an alternative therapy, meet other study-specified reasons for discontinuation of study drug, or until the participant is transitioned to ixazomib through commercial channels, including reimbursement for the participant's indication, whichever is sooner. Participants who were receiving a combination therapy with ixazomib and another medication(s) will continue to receive the combination regimen.
9725473|NCT05260723|Experimental|Sit Less|The primary goal of the Sit Less arm is to reduce the total amount of time spent sitting each day and break up prolonged bouts of sitting.
9725474|NCT05260671|Experimental|Penpulimab+cetuximab|Erbitux 500 mg/m2 without immunotherapy for 14 days prior to first cycle. Cetuximab Injection 500 mg/m2 and Penpulimab Injection 200 mg are intravenously infused on Day 1 (D1) of Cycle 1, with 14 days as one cybcle. Penpulimab for up to 96 weeks (48 cycles)
9725475|NCT05260476||Reablement group|"The home reablement program will be implemented by a physical therapist according to Long-term Care Reablement Operational Guidelines announced by the Ministry of Health and Welfare of Taiwanese government"
9725476|NCT05260476||Non-reablement group|This group will only receive general home care service without the reablement program.
9725477|NCT05260359|Active Comparator|6% BEMT HRIPT|During the challenge phase of the HRIPT portion of the study, there will be 6 patches (2 product patches, 2 vehicle controls. 1 saline control and 1 empty patch), leaving out the positive control.
9725478|NCT05260359|Active Comparator|6% BEMT Cumulative Irritation Study|During the Cumulative Irritation portion of the study there will be 7 patches (2 product patches, 2 vehicle controls, 1 positive control, 1 low-irritancy control, and 1 empty patch). The low-irritancy control patch will be a saline patch. The positive control will be a SLS patch. The negative control will be an undosed patch.
9725479|NCT05260333|Experimental|Transperineal ultrasound cervical exam|Patients will undergo transperineal cervical exam via Butterfly iQ ultrasound.
9981209|NCT04983823|Experimental|Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|"Optimization of pharmacotherapy:~This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.~Exercise intervention: Individualized training program will be provided by an exercise physiologist"
9981210|NCT04983823|Active Comparator|Usual care|All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).
10198731|NCT02916472|Experimental|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
9725480|NCT05260333|Active Comparator|Digital (manual) cervical exam|Patients will undergo traditional digital cervical exam via examiner's fingers.
9725481|NCT05259852|Experimental|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|
9981211|NCT04981587|Experimental|Intervention group|This is the group that receives strength exercise in addition to usual treatment
9981212|NCT04981587|Other|Control group|This is the group that only receives usual treatment
9981213|NCT04980807||CMT Patients|Individuals with Charcot-Marie-Tooth Disease Types 1 and 2.
9981214|NCT04980807||Healthy Controls|Healthy age-matched volunteers
9981215|NCT04980014||NesinaAct® Tablet|Participants with a diagnosis of Type 2 Diabetes who took NesinaAct® tablet, a fixed dose combination of alogliptin along with pioglitazone, as prescribed by the physician, are observed in this study.
9981216|NCT04975269|Active Comparator|Acetazolamide|Acetazolamide (active)
9981217|NCT04975269|Placebo Comparator|Placebo|Placebo
9725482|NCT05259852|Active Comparator|Food Assistance and Cessation Resources Navigation|
9725483|NCT05258864|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
9725484|NCT05258864|No Intervention|Control|No Intervention Control
10198732|NCT02916472|Active Comparator|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
9725485|NCT05257252|Experimental|"Persons With Disability Friendly Nursing Education Program"|Intervention group after determining the students according to the research criteria, they were randomized into intervention and control groups. Firstly, pre-tests were applied to the students in the experimental group.
9725486|NCT05257252|No Intervention|"non-Persons With Disability Friendly Nursing Education Program"|Firstly, Pre-tests were applied to the students in the control group. No intervention was applied to this group. Posttests were made 3 months after pre-test.
9725487|NCT05256732|Experimental|AT-527|
9725488|NCT05256732|Placebo Comparator|Placebo|
9725489|NCT05254912|Active Comparator|6% BEMT in sunscreen oil (SU E 101413 85)|"Assess the photoallergic potential of Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
10198733|NCT02915679|Other|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:~81 depressed patients admitted after a recent suicidal act (<8 days)~81 depressed subjects with a past history of suicidal act (>1month)~80 depressed subjects without any personal history of suicidal behaviour"
9725490|NCT05254912|Other|Sunscreen oil Vehicle (SU E 101413 91)|"Vehicle Control: Assess the photoallergenic potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT.~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
10204966|NCT04400838|Experimental|Group 8 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
9725491|NCT05254912|Active Comparator|6% BEMT in petrolatum (SU E 101413 82)|"Assess the photoallergenic potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum~Approximately 0.15 g or 0.15 ml of each product and vehicle control will be applied. Two doses (one irradiated and one non- irradiated) of the investigational products and two doses (one irradiated and one non- irradiated) of the vehicle controls will be applied to back of each subject once on Day 1 under occlusive patches. Patches will remain in place for approximately 24 hours and will be removed by clinical study staff on Day 2. During the challenge phase, two undosed negative control occlusive patches will also be also applied. Subjects will return to the laboratory 24 hours and 48 hours post-irradiation for dermal evaluations. Dermal scores obtained during the challenge phase will be reported for each site."
9725492|NCT05254808|Active Comparator|Fosfomycin in a single dose of 3000mg on day 1|Fosfomycin-trometamol Single dose scheme: 3000mg taken orally once (arm A)
9725493|NCT05254808|Experimental|Extended dosing of 3000mg fosfomycin on day 1 and 3|Fosfomycin-trometamol Extended dosing scheme: 3000mg taken orally on day 1 and day 3 (arm B)
9725494|NCT05254808|Active Comparator|Nitrofurantoin 100mg bid (slow release) for 5 days|Nitrofurantoin 100mg b.i.d. in slow release form (Furabid) taken orally for 5 days (arm C)
9725495|NCT05253547|Experimental|Healthy climate-friendly dietary guidelines|Personalised healthy dietary recommendations aimed at reducing diet-related greenhouse gas emissions
9725496|NCT05253547|Active Comparator|Healthy eating guidelines|Personalised healthy dietary recommendations based on Ireland's Healthy Eating Guidelines
9725497|NCT05253313|No Intervention|Conventional|Patients who are eligible for surgery are randomized to MRI scan or standard curative surgery. Patients in this arm will receive standard care according to danish standards without pre-operative MRI scans.
9725498|NCT05253313|Other|MRI scan|This arm includes patients who have been randomized to pre-operative MRI scans.
9725499|NCT05252286|Experimental|video watching|In the video-watching group, a patient will follow the exercise instructions from watching the video. The exercise content in video are set during the patient conducting the rehabilitation program. Then, the therapist will select 3 to 5 groups of movements pattern needed to be enhanced catching from the video for the patient to practice when returning the bedside after the rehabilitation programs.
9725500|NCT05252286|Active Comparator|paper sheet|For the paper sheet group, the therapist will prepare the exercise leaflet, suitable for the patients, in advance, and select three to five groups of movement exercises on the leaflet that his/her therapist deem the patients needed to be enhanced. When the patients ends his/her rehabilitation program, they can practice following the instructions on the leaflet for them-self in bedside.
9981218|NCT04975204|Experimental|TQB3909 Tablets|Take 100-1200mg once a day; Oral administration on an empty stomach, 28 days as a cycle.
9725501|NCT05252286|Placebo Comparator|oral health education group|In the oral health education group, the program is similar to the paper sheet group without providing any exercise paper sheet the patient but oral education.
9725502|NCT05252234||Group 1|Patients undergoing elective surgeries with past history of COVID-19 infection during the past six months
9725503|NCT05250596|Experimental|Colchicine and Atorvastatin|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge plus Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
9725504|NCT05250596|Active Comparator|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
9725505|NCT05250362|Experimental|Treatment|
9725506|NCT05249634|Experimental|treatment|JATENZO daily for 6 months
9725507|NCT05249036|Experimental|Ultrasound guided arterial cannulation|Anaesthetist will use real-time ultrasound guidance to guide arterial cannulation
9725508|NCT05249036|Active Comparator|Palpation guided arterial cannulation|Anaesthetist will use palpation (standard-of-care) technique to guide arterial cannulation
9725509|NCT05248165||Coronary artery disease requiring percutaneous coronary intervention|Chronic or acute coronary syndrome requiring percutaneous myocardial revascularization.
9725510|NCT05248035||Patient|Adult patient hospitalized in ICU for a duration of mechanical ventilation longer than 48 hours
9725511|NCT05247970|Experimental|Part 1: S-309309|Participants will receive S-309309 at specific timepoints in a fasted state.
9725512|NCT05247970|Experimental|Part 2: S-309309 and Midazolam|Participants will receive S-309309 and Midazolam at specific timepoints fed state.
9725513|NCT05247970|Placebo Comparator|Part 1 and 2: Placebo|Participants will receive a matching placebo to S-309309 at specific timepoints in either a fed or fasted state.
9725514|NCT05246605|Experimental|From supine to prone to supine position|Prone position
9725515|NCT05245097|Experimental|Intervention Group|"The intervention group will be assigned a Tango Belt to be worn around the waist for up to 24 hours a day (removed for bathing, charging of device and upon request) for 6 months. The Tango Belt (the Device) is a wearable belt designed to enable safer mobility of geriatric individuals (≥ 65 years of age) at risk for fall injury by mitigating major hip injuries due to falls by deploying an airbag around the hips upon sensing a serious hip-impacting fall-in-progress to protect the hips from ground impact forces."
9725516|NCT05245097|No Intervention|Control Group|The the clinical site's electronic medical record (EMR) database will be reviewed determine their long-term care patient population's initial eligibility for meeting the study inclusion criteria beginning at the time frame 6 months prior to the institutional review board (IRB) approval date. Subjects eligible for the control group must meet the requirements of the inclusion and exclusion criteria except for the waist circumference and need for consent. Eligible subjects' electronic health records will be mined for the baseline, midpoint, and final study metrics.
9725517|NCT05243472|No Intervention|Control group|Participants in the control group will not receive any intervention during the study period.
9725518|NCT05243472|Experimental|Protein nutritional supplement group|Participants in the intervention group will receive protein-enriched soups (24-30g of protein) per day for 12 weeks. Protein may come from either soy, bean or milk products.
9725519|NCT05243329|Experimental|Psilocybin treatment for treatment-resistant PTSD|"Experimental Treatment:~Experimental: Psilocybin~10mg (low dose) on Day 7~25mg (high dose) on Day 14~Treatment Description:~Drug: Psilocybin drug product suspension~Psilocybin is manufactured as a bulk API powder. The psilocybin drug product suspension is prepared by a compounding pharmacist at the clinic site. The psilocybin drug product suspension will be mixed in a glass with water to produce the psilocybin solution for oral consumption. Subjects will be instructed to orally consume the study medication in the glass in its entirety.~Psilocybin will be administered in the following doses and at the following time points for this study:~1 mL of 10mg/mL (low dose) on Day 7 (10 mg)~2.5 mL of 10 mg/mL (high dose) on Day 14 (25 mg)"
9725520|NCT05242549|Experimental|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance)"
9981219|NCT04971720|Experimental|Sacubitril/Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
9981220|NCT04971720|Experimental|Sacubitril/Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
9981221|NCT04971720|Active Comparator|Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
9725521|NCT05242549|No Intervention|wait-list|Routine care
9725522|NCT05242432|Experimental|Cohort (C)1 Group (G)1: Adults, 60 years and older (Ad26/protein preF RSV Vaccine)|Participants will receive a single intramuscular (IM) injection of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26/protein preF RSV) vaccine on Day 1.
9725523|NCT05242432|Placebo Comparator|C1 G2: Adults, 60 years and older (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
9725524|NCT05242432|Experimental|C2 G3: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Ad26/protein preF RSV Vaccine)|Participants will receive a single IM injection of Ad26/protein preF RSV vaccine on Day 1.
9725525|NCT05242432|Placebo Comparator|C2 G4: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Placebo)|Participants will receive a single IM injection of matching placebo on Day 1.
9725526|NCT05241288|Experimental|Albuterol eMDPI DS (ProAir® Digihaler®)|This arm will receive the intervention of the Albuterol eMDPI DS for three months.
10198734|NCT02915549|Experimental|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
9725527|NCT05239871||Women with surgical diagnosis of parametrial endometriosis|This cohort will include patients with surgical diagnosis of parametrial endometriosis
9981222|NCT04971720|Active Comparator|Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
9725528|NCT05239871||Women without surgical diagnosis of parametrial endometriosis|This cohort will include patients without surgical diagnosis of parametrial endometriosis
9981223|NCT04968106|Other|Standard Arm A: treatment by neoadjuvant chemotherapy|Treatment by doxorubicin and ifosfamide followed by surgery
9981224|NCT04968106|Experimental|Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab|Treatment by doxorubicin, ifosfamide and retifanlimab followed by surgery
9725529|NCT05239754|Experimental|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
9725530|NCT05239637|Experimental|Previous|Heparin stopped before ECMO decannulation
9725531|NCT05239637|Experimental|Afterwards|Heparin reduced after ECMO decannulation
9725532|NCT05238142|Experimental|MiniMed 780G System|Adult participants with insulin-requiring type 2 diabetes age 18-80 using the MiniMed 780G system for a period of up to 45 day run-in and 3 month study phase.
9984582|NCT03952663|Experimental|Group I|inferior alveolar nerve lateralization for dental implant placement ,and platelet rich fibrin membrane is placed around the nerve.
9984583|NCT03952663|Active Comparator|Group II|inferior alveolar nerve lateralization for dental implant placement without placement of platelet rich fibrin membrane around the nerve.
9984584|NCT03947671|Experimental|Body wrap|This group will receive the body wraps post surgery to maintain normothermia.
10198735|NCT02915549|Active Comparator|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
10198736|NCT02914535|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
10198737|NCT02914535|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 336 weeks
10198738|NCT02914535|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
9725533|NCT05237453|Experimental|MR-guided adaptive radiotherapy|Patients receive Photon radiotheray as an MR-guided adaptive radiotherapy
10198739|NCT02914535|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 336 weeks
9725536|NCT05237180|Experimental|patient group|8 training sessions on spatial localisation
9725537|NCT05237180|No Intervention|control croup|Non training sessions
9780783|NCT01131312|Experimental|Cytology|Referred to colposcopy if cytology is high grade
9725538|NCT05236244|Experimental|İntervention group|Diaphragmatic breathing exercises: First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks of diaphragmatic breathing exercises +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
10198740|NCT02914535|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 336 weeks
9981225|NCT04962711|Experimental|Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)|"Optimization of pharmacotherapy: Cardioprotection with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol).Participants will be initially treated with ramipril at a dose of 1.25 or 2.5mg (according to baseline systemic arterial pressure), once or twice a day, and gradually up-titrated to 10mg/day, or to the maximal-tolerated dose. In patients receiving at least 2.5mg/day of ramipril, metoprolol will be started at an initial dose of 50 (25mg twice a day) and progressively up-titrated to the maximal dose of 100mg/day. Patients will be reviewed every 2 weeks during the up titration phase.~Exercise intervention: Individualized training program provided by an exercise physiologist."
9981226|NCT04962711|Active Comparator|Usual care|Provided by participants' usual healthcare professional(s), guided by a brochure regarding optimal risk factor management addressing hypertension, lipids, alcohol intake and tobacco use.
9981227|NCT04954807|Active Comparator|Human Milk Fortifier|human milk fortifier which contains protein, lipid, carbohydrate and micronutrients
9981228|NCT04954807|Placebo Comparator|placebo|Placebo is made of polysaccharides (0.9 g/1 g placebo) and maltose (0.1 g/1 g placebo) and minerals.
10198741|NCT02908087|Active Comparator|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
10198742|NCT02908087|Placebo Comparator|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
10204967|NCT04400838|Experimental|Group 9 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
10204968|NCT04400838|Experimental|Group 10 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
9984585|NCT03947671|Active Comparator|Tylenol|This group will receive the standard of care of monitoring temperature and administering Tylenol if a fever develops.
9725539|NCT05236244|No Intervention|Control Group|First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks break +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
9725540|NCT05235399||Preterm infants who are born before 32 weeks of gestation.|The study aims to recruit preterm infants who are born before 32 weeks of gestation.
9725541|NCT05232825|Active Comparator|Ocrelizumab: Intravenous (IV) formulation|Participants will receive the first dose of ocrelizumab IV as two IV infusions given 14 days apart. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between SC doses. Participants will undergo 48 weeks of study treatment.
9725542|NCT05232825|Experimental|Ocrelizumab: Subcutaneous (SC) formulation|Participants will receive the first dose of ocrelizumab SC as one SC injection at a dose which is expected to result in non-inferior exposure to ocrelizumab IV. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between the first and second SC doses, and between subsequent SC doses. Participants will undergo 48 weeks of study treatment.
9725543|NCT05232630|Experimental|- Group 1A.|Patients with genetic testing showing a pathogenic or likely pathogenic variant in main synaptopathy genes (SYNGAP1 and STXBP1)
9725544|NCT05232630|Experimental|Group 1B.|Patients with genetic testing showing a pathogenic or likely pathogenic inverted duplication of chromosome 15 [inv-dup (15)].
9725545|NCT05232630|Experimental|Group 1C.|Patients with neuroimaging showing multifocal or bilateral malformations of cortical development.
9725546|NCT05232630|Experimental|Group 2.|Electroclinical diagnosis of Continuous Spikes and Waves during Sleep (CSWS) syndrome, with baseline video-EEG monitoring showing epileptiform activity occupying at least 50% of slow sleep tracing, after failing at least 3 antiseizure medications
9725547|NCT05232578|Experimental|Arm A- early salvage radiotherapy (eSRT)|Early salvage radiotherapy (eSRT) will be administered immediately after the confirmation of the biochemical relapse (prostate-specific antigen PSA level increase to ≈ 0,2 ng/ml) after radical prostatectomy with defined risk factors and no clinical recurrence signs on prostate specific membrane antigen positron emission tomography and computed tomography (PSMA PET/CT).
9725548|NCT05232578|Experimental|Arm B- delayed salvage radiotherapy (dSRT)|The patient is by the biochemical relapse analysis (PSA level 0,2 ng/ml) referred for further follow-up of PSA values. dSRT is initiated, if PSA further increase to values of ≥ 0.4 ng/ml is confirmed and the presence of a potential clinical relapse is excluded with repeated PSMA-PET-CT in line with standard procedures
9725549|NCT05232357|Experimental|Endoscopic nerve staining|Methylene blue (MB) solution was used as nerve staining agent. Routine endoscopic submucosal injection of MB solution for mucosal nerve staining was used to identify and evaluate the neural architecture and special morphology of normal gastrointestinal mucosa, adenoma and malignant lesions.
9725550|NCT05231018|Experimental|Psychotherapy|The population of interest includes COVID-19 patients previously or currently hospitalized at the Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, according to inclusion and exclusion criteria.
9780784|NCT01131312|Experimental|Human Papillomavirus (HPV)|Referred to colposcopy if cytology is high grade or HPV +
9780785|NCT01131312|Experimental|Colposcopy|All refer to colposcopy
9780786|NCT01131325|Experimental|Nilotinib|
9780787|NCT01131351|Experimental|Delamanid 250 mg BID+ OBR|Participants received delamanid five 50 milligrams (mg) (250 mg) tablets, twice a day (BID), along with at least 2 additional anti-TB medications per optimized background regimen (OBR) for up to 28 weeks.
9780788|NCT01131351|Experimental|Delamanid 300 mg BID+ OBR|Participants received delamanid six 50 mg (300 mg) tablets, BID, along with at least 2 additional anti-TB medications per OBR for up to 28 weeks.
9780789|NCT01131494|Experimental|Swallowing exercises|
9780790|NCT01131507|Experimental|EUR-1008 (APT-1008)|
9780791|NCT01131520|Experimental|Computerized Brief Intervention|Computerized one-session brief intervention for drug use
9725551|NCT05230693|Experimental|SPARC Group|
9725552|NCT05230693|Active Comparator|Enhanced Standard Care Control Group|
9725553|NCT05230667|Active Comparator|PRP injection (PRP group)|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.
10204969|NCT04400838|Experimental|Group 11|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
9981229|NCT04944745|Experimental|Myofascial release (MFR)|The pectoral MFR will be completed by an experienced registered massage therapist (RMT). They will stand on the participant's right side slightly rotated to the left facing towards the participant's left hip and apply a cross-hand MFR technique to the superficial pectoral fascia on the right side. The therapist will begin by placing the distal region of the anterior palm of the anchoring hand (therapist's right hand) on the right edge of the anterior sternum at the level of the 3rd to the 6th ribs on the skin and the draping over the pectoral fascia. They will then apply a gentle posterior pressure to hold the fascia in place. The forearm of the mobilizing hand (RMT's left hand) will be directed to the right shoulder wit hate right forearm crossing over the left and the contact of are of the mobilizing hand will be the skin superficial to the pectoral fascia and insertion of pectorals major on the anterior aspect of the humerus. This will be held for four minutes.
9981230|NCT04944745|Sham Comparator|Soft-touch Control (CON)|This control treatment will be set up the same way in regards to the RMT's hand placement, except no pressure will be applied. The RMT's hands will simply be resting over the contact points. This treatment will also be held for four minutes.
9981231|NCT04941937|Experimental|Arm I: Selinexor+Thalidomide+Dexamethasone|Arm I is given XTd regimen Selinexor 60mg/d QW, Thalidomide 100mg/d, d1-28 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
9981232|NCT04941937|Experimental|Arm II: Selinexor+Lenalidomide+Dexamethasone|Arm II is given XRd regimen Selinexor 60mg/d QW, Lenalidomide 25mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
9981233|NCT04941937|Experimental|Arm III: Selinexor+Pomalidomide+Dexamethasone|Arm III is given XPd regimen Selinexor 60mg/d QW, Pomalidomide 4mg/d, d1-21 and Dexamethasone 40mg/d QW) in approximately 30 subjects. 4 weeks per cycle and include a total of 12 cycles.
9981234|NCT04927806|Experimental|SilverKnight group|Silver Knight is an anti-microbial additive that uses silver ions to disrupt the normal enzymatic activities of bacteria
9981235|NCT04927806|No Intervention|Control group|The control group uses standard ventilator circuits.
9981236|NCT04925986|Experimental|Group 1A: PD-L1 1-49%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
9981237|NCT04925986|Experimental|Group 1B: PD-L1 1-49%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
9981238|NCT04925986|Experimental|Group 2A: PD-L1 ≥ 50%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
9981239|NCT04925986|Experimental|Group 2B: PD-L1 ≥ 50%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
9981240|NCT04899271|Experimental|Ladarixin|The treatment group will receive 400 mg b.i.d. for 13 cycles of 14 days on/14 days off)
10204970|NCT04400838|Experimental|Group 12|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
9725554|NCT05230667|Active Comparator|Corticosteroid injection (CS group)|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.
9725555|NCT05230667|Active Comparator|Normal saline injection (NS group)|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.
9725556|NCT05229302|Experimental|Intervention|Secondary students with suicidal ideation participating in the intervention (Reframe-IT). The students will be referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment
9725557|NCT05229302|Active Comparator|Control|Secondary students referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment.
9780792|NCT01131520|Active Comparator|Counselor delivered brief intervention|This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
9981241|NCT04899271|Placebo Comparator|Placebo|The control group will receive matched placebo
9981242|NCT04896372|Experimental|ACT intervention|The ACT condition (comprehensive of standard care) comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and a psychological intervention based on ACT combined with a standard psychological assessment and support to the hospitalization.
9981243|NCT04896372|Other|Standard care|The TAU comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and the standard psychological assessment and support to the hospitalization
10198743|NCT02901483|Experimental|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 6 levels (L1- 5% + 40mg/m2 weekly cisplatin, L2- 10% + 40mg/m2 weekly cisplatin, L3- 15% + 40mg/m2 weekly cisplatin, L4-22% + 100mg/m2 tri-weekly cisplatin, L3a- 15% + 100mg/m2 tri-weekly cisplatin, and L5- 33% + 100mg/m2 tri-weekly cisplatin) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
9725558|NCT05229146|Experimental|Episodic Future Thinking|"Mothers will receive episodic future thinking (EFT). Mothers will meet with a peer mother who will administer the EFT intervention, including generation of several specific future events reflecting positive interactions with their child. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, mothers will receive daily text messages over the course of two weeks including a reminder cue generated as part of the EFT and a prompt to remember these episodes in vivid detail."
9981244|NCT04893096|Experimental|MOR202 (felzartamab) infusion|Participants will receive active treatment for a total of nine doses during 24 weeks.
9981245|NCT04884165|Experimental|Intervention|Remote monitoring using SRETT (CE marked device) + home mechanical ventilation (non-invasive ventilation, NIV) and usual care.
9725559|NCT05229120|Experimental|Episodic Future Thinking|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic future thinking focused condition. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention, focused on generating future, pleasant events with their children. After the intervention session, parents will receive a daily postcard over the course of two weeks including a reminder cue generated as part of the episodic future thinking (EFT) intervention and a prompt to remember these episodes in vivid detail.
9725560|NCT05229003|Experimental|cohort A|"Anlotinib + Irinotecan:~Anlotinib, 10mg, oral, once daily, D1-10, q2W; Irinotecan, 180mg/m2, iv drip, d6, q2w."
9725561|NCT05229003|Experimental|cohort B|"Anlotinib + Penpulimab + Irinotecan:~Anlotinib, 8mg, oral, once daily, d1-10, q2w; Penpulimab 200mg, i.v. d6, q2w; Irinotecan, 180mg/m2, iv infusion, d6, q2w."
9725562|NCT05227755|Active Comparator|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
10198744|NCT02891759|Experimental|Group A: Alloderm RTU|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group A will receive Alloderm RTU~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
10204971|NCT04400838|Active Comparator|Single dose MenACWY|Groups 1 a2, 2 a2, 4 a2, 5 a2, 5 b2, 5 c2, 6 a2, 7 a2 & 8 a2 will receive a standard single dose of MenACWY vaccine
9725563|NCT05227755|Experimental|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
9725564|NCT05226195|Experimental|Group 1: Sterile Kinesio tape application|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
9725565|NCT05226195|No Intervention|Group 2: Control group|The standard post-surgical protocol applied in our clinic will be applied to Group 2. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
9725566|NCT05226104|Other|Healthy Participants|Subjects who are interested in treatment for facial fine lines and wrinkles will be recruited for the study.
9725567|NCT05225207||All Participants|Participants with uHCC who are prescribed with Lenvima within the scope of the approved label for Korea under the medical judgment of the investigator will be enrolled and observed for up to 12 months.
9725568|NCT05224349||Group A|Participants with stable oral anti-spasticity treatment for at least 4 weeks prior to study entry
9725569|NCT05224349||Group B|Participants with no anti-spasticity therapy for at least 4 weeks prior to study entry
9725570|NCT05222802|Experimental|Dose Escalation (Part 1)|ERAS-801 will be orally administered to study participants with recurrent GBM in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
9725571|NCT05222802|Experimental|Dose Expansion (Part 2)|ERAS-801 will be orally administered at the recommended dose (as determined from Part 1) to study participants with recurrent GBM harboring alterations in EGFR.
9725572|NCT05222620|Other|Arm A (single fraction SRS)|Patients undergo single fraction SRS.
10204972|NCT04400838|Active Comparator|Two dose MenACWY 4 - 6 weeks|Groups 1 b2, 2 b2, 4 b2, 5 d2, 7 b2, 8 b2, 9 a2 & 10 a2 will receive two doses of MenACWY 4-6 weeks apart
9981246|NCT04884165|Active Comparator|Control|Home mechanical ventilation (non-invasive ventilation, NIV) with usual care.
9981247|NCT04877860|Experimental|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Access to the PaiNEd system.
9981248|NCT04877860|Active Comparator|Multimodal rehabilitation program + traditional biomedical information|Physical recovery program (multimodal) with a duration of 8 weeks. Three weekly sessions on alternate days lasting 60 minutes each one. 4 individual manual therapy sessions (1 session every 2 weeks). Dossier with traditional biomedical recommendations on the management of pain and disability.
9981249|NCT04877860|Active Comparator|Control group|Information dossier with recommendations on pain control and dysfunction improvement.
9725573|NCT05222620|Other|Arm B (fractionated SRS)|Patients undergo fractionated SRS.
9725574|NCT05221931|Active Comparator|DES group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DES group, latest second-generation DES will be used (Ultimaster Tansei) during the index procedure"
9725575|NCT05221931|Experimental|DCB group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DCB group, SeQuent Please or SeQuent Please NEO will be used during the index procedure."
9725576|NCT05221203|Experimental|Training|Participants in this arm will perform seven bodyweight training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
9725577|NCT05221203|No Intervention|Control|Participants in this arm will receive no intervention.
9725578|NCT05221177|Experimental|Training|Participants in this arm will perform six suspension training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
9725579|NCT05221177|No Intervention|Control|Participants in this arm will receive no intervention.
9725580|NCT05218993||Development of the new dual task test|the new two different method of dual task measurement and a traditional dual task measurement method and also, cognitive and performance measurement test will be conducted.
9981250|NCT04873817||IonicRF Generator and compatible accessories|IonicRF Radiofrequency Generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator will be used.
9981251|NCT04856436||Pregnant women with exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and were filled at least one benzodiazepine prescription during the first trimester (first 90 days of pregnancy).
9725581|NCT05218993||Collecting the normative values|Better dual task measurement method (from the two methods) will be conducted at different football levels.
9725582|NCT05218993||Measurement of the athletes in return to sport stage|new dual task measurement method and other return to sport measurements will be conducted on athletes who wish to return to sport.
9725583|NCT05218668|Experimental|Fasudil|Oral fasudil 180 mg/day or 240 mg/day
9725584|NCT05218382|Experimental|VR group|The participants will have the the virtual reality headset with immersive virtual reality.
9725585|NCT05218382|Placebo Comparator|Placeob group|The participants will have the virtual reality headset put on but blank screen.
9725586|NCT05215717|Experimental|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
9725587|NCT05215717|Active Comparator|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
9725588|NCT05215093|Experimental|Direct physiotherapy pathway|People with acute low back pain will directly go to a physiotherapist, who will treat the patient without prescription of the general practitioner.
9725589|NCT05215093|Active Comparator|Usual care pathway|People with low back pain will receive usual care by the general practitioner (with or without referral to physiotherapy).
9725590|NCT05213286|Other|Patients referred for assessment of ASD, non-ASD psychiatric patients and control group|All three groups will be tested with RAADS-R-DK and ZAQ. The results from these diagnostic tests will be compared to gold standard clinical assessments in specialized multidisciplinary teams
9725591|NCT05213221|Experimental|Treatment group|Envafolimab, Lenvatinib and TACE
9725592|NCT05212857|Experimental|systemic treatment combined with radical treatment and radiotherapy|"All recruited participants would receive long-term and unified systemic treatment. Systemic treatment is defined as chemical castration plus new-generation anti-androgen therapy.~For the primary lesion:~The preferred local treatment for primary lesion is radical prostatectomy. Patients who refuse surgery or whose tumors cannot be surgically resected after 3 months' systemic treatment could receive radical radiotherapy.~For the metastatic lesion:~Radiotherapy for metastatic lesions would be performed between 4 weeks and 24 weeks after the local treatment for primary lesion. Stereotactic body radiation therapy (SBRT) is preferred, which could treat all the detected lesions at once or in stages."
9725593|NCT05212545|Placebo Comparator|Placebo|10 g maltodextrin per day
9725594|NCT05212545|Experimental|Prebiotic Supplement|10 g Prebiotic supplement + maltodextrin per day
9725595|NCT05212545|Experimental|Prebiotic combination|10 g prebiotic supplement+ prebiotic oligosaccharide per day
9725596|NCT05212545|Experimental|prebiotic oligosaccharide|10 g maltodextrin + prebiotic oligosaccharide per day
9725597|NCT05209425|Active Comparator|Regular Vitamin D3 1000IU|The first group receives regular Vitamin D3 1000IU
9725598|NCT05209425|Active Comparator|Microencapsulated Vitamin D3 1000IU|The second group receives microencapsulated Vitamin D3 1000IU
9725599|NCT05209425|Active Comparator|Regular Vitamin D3 2500IU|The third group receives regular Vitamin D3 2500IU
9725600|NCT05209425|Active Comparator|Microencapsulated Vitamin D3 2500IU|The fourth group receives microencapsulated Vitamin D3 2500IU
9981252|NCT04856436||Pregnant women without exposure to benzodiazepines|Women who gave birth during 2011-2018, were aged 20-45 years and did not fill a benzodiazepine prescription during the 3 months before the pregnancy onset through the end of the first trimester
9981253|NCT04853212|Active Comparator|SPA patient|Patients with SPA
9981254|NCT04853212|Sham Comparator|Subject without SPA|Health subjects without SPA, planned to undergo a digestive endoscopy.
9981255|NCT04835129|Experimental|Safety Run-in|Six subjects will be enrolled. Isatuximab (10 mg/kg) intravenous (IV) on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) by mouth (PO) days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
10204973|NCT04400838|Active Comparator|Two dose MenACWY minimum 4 weeks|Groups 1 a4, 2 a4, 4 c2, 5 a4, 6b2 will receive two doses of MenACWY at least 4 weeks apart
9981256|NCT04835129|Experimental|Expansion|"Forty-seven subjects with relapsed and/or refractory multiple myeloma will be enrolled.~Isatuximab (10 mg/kg) IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) PO days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle."
9981257|NCT04829539|Experimental|Group I (BBT-CI)|Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
9981258|NCT04829539|Active Comparator|Group II (HEAL)|Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
9981259|NCT04814264|Experimental|Sex-matched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is matched to their sex (donor and recipient sex are the same). Patients in this arm will receive RBCs matched to their sex until discharge from hospital or death.
10198745|NCT02891759|Experimental|Group B: Cortiva 1mm Allograft Dermis|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group B will receive Cortiva 1mm Allograft Dermis~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
10198746|NCT02874651|Experimental|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
9725601|NCT05209087||Children with Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy who are between Levels 1-4 (continuing ambulation) according to Brooke Lower Extremity Functional Classification will be included in the study. This classification method was designed on the basis of the classification method to determine the functional status of the lower and upper extremities in the clinical evaluation of Duchenne Muscular Dystrophy.
9725602|NCT05208528|Experimental|ES1 group|Participants treated with Bifidobacterium longum ES1 for 2 months.
9725603|NCT05208528|Experimental|HT-ES1 group|Participants treated with heat treated version of ES1 for 2 months.
9725604|NCT05208528|Placebo Comparator|Control group|Participants treated with maltodextrin for 2 months.
9725605|NCT05206695|Experimental|Multi-condition Pathway Intervention|The multi-condition pathway intervention consists of pathways clinicians select from to guide the care of children with asthma, pneumonia, or bronchiolitis. Key implementation strategies include audit and feedback, plan-do-study-act cycles, and electronic order sets.
9725606|NCT05206695|No Intervention|Standard of Care|Hospitals randomized to the control arm will not receive the multi-condition pathway intervention or any external supports for implementation. They will continue to provide current standards of care.
9725607|NCT05206474|Experimental|IRADYN|"One group, all patients will receive IRADYN® (intra-articular administration).~One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
9725608|NCT05206136||Neck Pain Group|Patients with neck pain
9725609|NCT05206136||Low Back Pain Group|Patients with low back pain
9725610|NCT05206136||Healthy Individuals|Patients with no pain in neck or low back region
9725611|NCT05205980|Experimental|Training group|This arm will receive a single-session perturbation training treatment on a treadmill under the protection of a safety harness.
9725612|NCT05205980|Sham Comparator|Control group|This arm will not receive perturbation training but will go through harnessed walking on the same treadmill for the same time as the other group.
9725613|NCT05205733|No Intervention|In-Clinic Semen Analysis Testing|Men needing semen analysis for infertility work-up.
10198747|NCT02874651|Placebo Comparator|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
10204974|NCT04392544||Pediatric|Pediatric CF population age 10-18 years.
10204975|NCT04392544||Adult|Adult CF population age ≥ 18 years.
10204976|NCT04391920||COVID-19 ICU Patients|
9725614|NCT05205733|Experimental|No in-clinic semen analysis testing|Men needing semen analysis for infertility work-up.
9725615|NCT05203822|Experimental|Tepotinib then Itraconazole|Participants will receive a single dose of tepotinib on Day 1 and Day 12 in morning. On Day 12 tepotinib is administered concomitantly with Itraconazole. Intraconazole is administered once daily in morning from Day 8 to Day 18.
9725616|NCT05201911|Experimental|Injection of I-124 AT03.|Single arm only, no placebo or comparator
9725617|NCT05201092|Experimental|[14C]-Lu AG06466|Participants will receive a single oral dose of [14C]-Lu AG06466 on Day 1 in the fed state.
9780793|NCT01131585|Experimental|Active laser photocoagulation and ranibizumab|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
10198748|NCT02873195|Experimental|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10198749|NCT02873195|Active Comparator|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9981260|NCT04814264|Experimental|Sex-mismatched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is not matched to their sex (donor and recipient sex are not the same). Patients in this arm will receive RBCs mismatched to their sex until discharge from hospital or death.
9725618|NCT05199311|Experimental|Starting Dose -1|"CC-220/Iberdomide: 1.1 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
9725619|NCT05199311|Experimental|Dose Level 1|"CC-220/Iberdomide: 1.3 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~CC-220 dose level 1 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level -1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
9981261|NCT04785339|Experimental|one-arm, pre-post design|This study will test an intervention in adult Latinx immigrants. There will be no control condition or other comparators. One condition will only provide data at pre (baseline) and post. The only comparison will be across time, but not across conditions as this will be the only condition and all participants will receive the same intervention.
9981262|NCT04783779|Experimental|STARgraft-2|Participants will be implanted with 6mm diameter STARgraft-2 grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
9981263|NCT04782180|Experimental|Rapid PrEP group|Participants will receive PrEP i.e. Descovy for 12 months at the syringe services program.
9981264|NCT04772742|Experimental|Eptinezumab|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
9981265|NCT04772742|Placebo Comparator|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
10198750|NCT02871726|Experimental|TRUS-Robot and TRUS|TRUS and TRUS-Robot will be used during prostate biopsy
9725620|NCT05199311|Experimental|Dose Level 2|"CC-220/Iberdomide: 1.6 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~CC-220 dose level 2 enrollment will occur following an independent safety review two months after the first 10 patients have completed at least 2 cycles of therapy at dose level 1.~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
9725621|NCT05199311|Experimental|Dose Level -2|"CC-220/Iberdomide: 0.75 mg [CC-220 dosing schedule: daily for 21 days of each 28-day cycle]~Carfilzomib: 20 mg/m2 C1D1 56 mg/m2 thereafter [Days 1, 8, 15 per 28-day cycle]~Dexamethasone: 40 mg (≤ 75 years) 20 mg (> 75 years) [Days 1, 8, 15, 22 per 28-day cycle]~Treatment will continue with carfilzomib, iberdomide, and dexamethasone for up to 4 cycles (28 days) at the physician's discretion followed by the Autologous Stem Cell Transplant. Patients will be followed every 3 months for up to 2 years, or until PD or the start of a new line of therapy."
9725622|NCT05199233|Experimental|Muse S™ Headband system for post-Covid Syndrome|Subjects will utilize the Muse S™ Headband system at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
9725623|NCT05198635||Group 1|
9725624|NCT05198635||Group 2|
9725625|NCT05198219|Experimental|Rhinolaryngoscope Ambu® aScope™ 4 Rhinolaryngo|All approved procedures performed during the study period.
9725626|NCT05198219|Active Comparator|Conventional reusable rhinolaryngoscope|All procedures performed during the study period.
9725627|NCT05197465||Patients undergoing major abdominal surgery|The investigators aim to conduct a prospective observational, cohort study including all patients undergoing a major open abdominal surgery.
9725628|NCT05193968|Other|Experimental: Healthy Women Volunteers|Hot Flash frequency will be assessed in the study subjects during a screening period. Participants can then chose to participate 1 or 2 study visits- Protocol 1: Microvascular function and/or Protocol 2: Autonomic function
9725629|NCT05193851|Experimental|healthy subjects|12 healthy Chinese adult subjects, both male and female, are treated with ricolinostat
9981266|NCT04757857|Active Comparator|Rivaroxaban 10 mg|Participants will receive, from the 1st to the 14th day, a dose of 10 mg of rivaroxaban - OA (Oral Administration).
9981267|NCT04757857|No Intervention|Best locally standardized care|According to the study protocol, participating investigators are advised to follow the best available local practice in each participating site. There is no formal recommendation for any particular COVID-19 treatment, except symptomatic therapies.
9984586|NCT03947671|Experimental|Tylenol with body wrap|This group will receive the standard of care of monitoring temperature but will be administered Tylenol and body wraps if a fever develops.
9984587|NCT03946969|Experimental|Sintilimab + Liposomal Paclitaxel + Cisplatin + S-1|Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.
9725630|NCT05192538|Experimental|Endoscopic endoloop pre-test treatment|Endoscopic endoloop pre-test treatment is a less invasive reversible endoscopic treatment to predict whether the gastroesophageal reflux can be alleviated in order to ultimately decide whether to undergo irreversible surgery or endoscopic treatment.
9725631|NCT05191277|Experimental|Open discontinuation (OD)|Participants will discontinue their antidepressant medication and will be fully informed about treatment (i.e., high expectation).
9981268|NCT04757714|Other|COPD Patients|"Patients agreeing to participate in the study and meeting the inclusion and non-inclusion criteria will have:~The high-resolution peripheral scanner (HRpQCT) of the tibia and radius~a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)~to complete:~a physical activity questionnaire (PHAS instrument)~a COPD quality of life questionnaire (St George Hospital)~A search for sarcopenia by studying the strength of the grip (dynamometer)"
9981269|NCT04719910|Experimental|Study group|The study group will watch 15 minute long videos of cooking and preparing the food of the patient's preferred type of food prior to be taken to the operating room.
9981270|NCT04719910|Placebo Comparator|Placebo group|The control group will watch 15 minute long non-food related videos.
9725632|NCT05191277|Experimental|Hidden discontinuation (HD)|Participants will discontinue their antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
9725633|NCT05191277|Experimental|Open continuation (OC)|Participants will remain on their initial antidepressant medication and will be fully informed about treatment (i.e., high expectation).
9725634|NCT05191277|Experimental|Hidden continuation (HC)|Participants will remain on their initial antidepressant medication, but will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
10198751|NCT02871726|Active Comparator|Routine TRUS/Fusion biopsy|Just Uronav will be used during prostate biopsy
9725635|NCT05190705|Experimental|Loncastuximab Tesirine + Dexamethasone|"Participants will be given~Loncastuximab Tesirine on Day 1 of every 28 day study cycle and continue for up to 6 cycles.~Participants will also receive pre-medications to reduce the chance of having a sensitivity reaction to the study treatment. Participants who tolerate the study treatment without a reaction may have pre-medications changed per determination of their doctor.~Dexamethasone will be given prior to study treatment on Day -1 or up to 2 hours prior to loncastuximab tesirine and the day after treatment"
9725636|NCT05190328|Experimental|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with the Muscle energy technique."
9725637|NCT05190328|Experimental|Active Release Technique|"Experimental: Active Release Technique: The therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient will be instructed to actively move the muscle from a shortened to lengthened position and thereby breaking adhesions.1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with active release technique"
9725638|NCT05189860|Experimental|C-MIC Device|Device plus Standard of Care
9981271|NCT04710524|Placebo Comparator|Placebo|orally administer placebo BID for 13 weeks except on Day 91 subject receive a single dose
9981272|NCT04710524|Experimental|FM101 150 mg BID|orally administer FM101 150mg BID for 13 weeks except on Day 91 subject receive a single dose
10198752|NCT02870855|Experimental|HCG group|intrauterine injection of HCG before blastocyst transfer
10198753|NCT02870855|No Intervention|Control group|blastocyst transfer
10198754|NCT02855476||Early Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD
10198755|NCT02855476||Late Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD, but who have a higher burden of disease compared to the Early Pre-manifest HD cohort
10198756|NCT02855476||Early Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage I or Stage II HD
10198757|NCT02855476||Moderate Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage III HD
10198758|NCT02855476||Late Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage IV-V HD
9981273|NCT04710524|Experimental|FM101 300 mg BID|orally administer FM101 300mg BID for 13 weeks except on Day 91 subject receive a single dose
9981274|NCT04700176|Experimental|Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Len + Dex (Cohort A) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
9981275|NCT04700176|Experimental|Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Pom + Dex (Cohort B) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
9981276|NCT04699240|Active Comparator|Clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
10198759|NCT02855476||Controls|Have no known family history of HD; or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD.
10198760|NCT02852161|Experimental|MACE|MACE procedure
10198761|NCT02852161|Active Comparator|OGD|Clinically indicated gastroscopy
10204977|NCT04386187|Experimental|Arm 1: Experimental Feeding|Small glutathione-rich meals will be prepared and delivered to participants for 12 weeks.
9981277|NCT04699240|Active Comparator|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times + Lactobacillus Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
9981278|NCT04696744||CTCO|adults with squamous cell carcinoma of the oropharynx with a curative aim
10198762|NCT02851056|Experimental|Survivin Vaccine and Autologous HCT|Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
10204978|NCT04386187|Active Comparator|Arm 2: Education Control|Standard of care medical nutrition education for type 2 diabetes will be provided in the form of electronic handouts and web-based resources.
9725639|NCT05187715|Experimental|Simvastatin with Standard Medical Treatment|Simvastatin 40mg OD plus standard treatment plus standard treatment (excluding Pentoxiphylline)
9725640|NCT05187715|Active Comparator|Placebo with Standard Medical Treatment|Matched placebo plus standard treatment (excluding Pentoxiphylline)
9981279|NCT04696497|Other|Muscular Assessment|All the patients will received the muscular assessments
9981280|NCT04695054|Experimental|Buzzy and EMLA Cream|In the experimental group children will receive the application of EMLA cream 60 minutes before the needle procedure and the use of Buzzy device during the procedure.
9725641|NCT05185986|Experimental|Home based Pilates exercises|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
9725642|NCT05185986|Experimental|Combination of Home-based Pilates exercises and Home-based Cognitive Rehabilitation exercises|In addition to performing home-based Pilates exercises described in arm 1, this group will also perform home-based cognitive rehabilitation exercises for 8 weeks and 3 sessions per week. The interval between each session is at least 48 hours and each session will take between 30 to 45 minutes. Cognitive rehabilitation exercises are in pen and paper and each session includes two exercises in the areas of planning, cognitive organization, cognitive flexibility and working memory. All exercises will be explained to the subjects by a cognitive rehabilitation specialist, and in addition, explanations of all the exercises in each session will be available for participants in the separate voices. During the intervention period, in addition to the Pilates specialist, the cognitive rehabilitation specialist contacts the group 2 participants on a weekly basis and monitors their rehabilitation exercises.
9725643|NCT05185986|Other|Waiting list group|This group is the waiting list group and acts as a control group and will be instructed to maintain their preintervention physical and cognitive activity levels during the intervention. After 8 weeks of intervention, Pilates exercises and cognitive rehabilitation exercises will be provided to the participants of this group for their own use.
9725644|NCT05184062|Experimental|AZD7442|co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion.
9725645|NCT05184062|Placebo Comparator|Placebo|co-administration of a single dose of 600mg placebo by intravenous (IV) infusion.
9725646|NCT05183685|Experimental|Intervention group|The participants will receive alternative telecare consultation and face to face consultation every 14 weeks.
9725647|NCT05183685|Placebo Comparator|Control group|The participants will receive usual face to face consultation every 14 weeks.
9981281|NCT04695054|Active Comparator|EMLA Cream|In the control group children will receive the application of EMLA cream 60 minutes before the needle procedure
9725648|NCT05183529|Experimental|Patients undergoing polysomnography|
9725649|NCT05182242|Experimental|Patients|Pregnant women with sonographic signs
9725650|NCT05182242|Other|Health professionals|biologists, geneticists, obstetricians, midwives of the Pluridisciplinary Centers of Prenatal Diagnosis and genetic services
9725651|NCT05182229|Active Comparator|Clinic-Based Lymphedema Therapy|
9725652|NCT05182229|Active Comparator|Home-Based Lymphedema Therapy|
9725653|NCT05181761|Experimental|Left Hand with gel polish|The participants will receive gel nail polish on their left hand. The right hand will remain natural (no gel polish)
9725654|NCT05181761|Experimental|Right Hand with gel polish|The participants will receive gel nail polish on their right hand. The left hand will remain natural (no gel polish).
9725655|NCT05179967|Experimental|WeFlow-JAAA Stent Graft System|
9780794|NCT01131585|Active Comparator|Active laser photocoagulation and sham injection|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
9780795|NCT01131676|Experimental|BI 10773 low dose|BI 10773 tablets once daily
9981282|NCT04693416|Experimental|Intrapersonal Stigma Reduction|The intervention will include education about substance use disorders (diagnosis, prognosis, and treatment), goal setting to assist the individual in preparing for change, and decisional balance to assist the individual in measuring the costs and benefits about disclosure of mental health problems and exercises to practice how to disclose. Facilitation of an intake assessment for treatment will be offered (with assistance in making the appointment, getting transportation and childcare, and securing a pro-bono status at a outpatient treatment facility).
9981283|NCT04693416|Experimental|Interpersonal Stigma Reduction|The intervention for family members and support persons of enrolled intrapersonal participants will include education about substance use disorders (diagnosis, prognosis, and treatment), stigma reduction, and how to provide support for someone with substance use disorder.
9981284|NCT04685902||Adult patients with tracheostomy|Adult patients who currently have a tracheostomy and receive an order for one-way speaking valve trial
9984588|NCT03945643|Active Comparator|Sildenafil administration|Administration of 50mg sildenafil one time, one hour prior to measurements
9725656|NCT05179876|Experimental|Participants Using Study Interventions in Pulmonary Hypertension Parent Studies|Participants who have completed a parent study (which indicated a positive benefit-risk), benefit from their study intervention maintenance and have no other alternative local treatment option will be enrolled in this study and will continue to receive study interventions (macitentan or selexipag or fixed dose combination (FDC) of macitentan/tadalafil) during the course of the study as already received in the parent studies. Following enrollment, remote (example: telephone calls) or on-site visits with the investigator will be scheduled every 6 months to collect efficacy and safety information until study intervention is made available in the country or the sponsor decides to terminate the study prematurely.
9725657|NCT05179031|Other|Arm 1|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9725658|NCT05179031|Other|Arm 2|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9725659|NCT05179031|Other|Arm 3|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9725660|NCT05179031|Other|Arm 4|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9981285|NCT04682496|Experimental|intratendon vascularization|Intratendon vascularization will be quantified using a proprietary methodology using ImageJ 1.47v image analysis software, determining the different variables related to the Doppler signal within an intratendon region of interest.
9981286|NCT04669639|Experimental|The block group (a)|Patients were randomized in a 1:1 :1ratio, group (a) will receive SSN. The nerve blocks The procedure will be performed after induction of anaesthesia and endotracheal intubation.
9981287|NCT04669639|Experimental|The block group (b)|Patients were randomized in a 1:1:1 ratio. group (b) will receive the Erector spinae plane block. The procedure will be performed after induction of anesthesia and endotracheal intubation.
10204979|NCT04378933|Experimental|Amber Glasses and Fixed Wake|Participants will wear glasses with amber lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will also be required to wake up at the same time (±30 mins).
9725661|NCT05179031|Other|Arm 5|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9725662|NCT05179031|Other|Arm 6|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9725663|NCT05179031|Other|Arm 7|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9981288|NCT04669639|Placebo Comparator|control group|Patients were randomized in a 1:1:1 ratio. this group will receive general anesthesia (GA) only
9981289|NCT04669444|Experimental|Low Driving Pressure Protocol|The patients ventilator driving pressure will be decreased (as tolerated by the patient) for 2 hours while on extracorporeal membrane oxygenation (ECMO) support.
9981290|NCT04661267|Experimental|Supplement formula|Patients randomized to the experimental group will receive daily 1-ounce doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
9725664|NCT05179031|Other|Arm 8|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9725665|NCT05179031|Other|Arm 9|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
9725666|NCT05177731|Experimental|Investigational ( venetoclax, decitabine)|"Randomized participants will receive induction as decitabine on days 1-5 and venetoclax daily on days 1-28.~Second Induction (if not reach complete remission, but the percentage of blaste cells in bone marrow decreased by more than 50%):Re-induction with pre-induction therapy.~Consolidation: If patients with favorable risk and MRD (Minimal Residual Disease) negative or refuse to allo-HSCT (Hematopoietic stem-cell transplantation), high dose cytarabine (2g/m3 q12h days 1-3) for 4 cycles. If patients with intermediate or poor risk or favorable risk but MRD positive, high dose cytarabine for 1-2 cycles and follow up with allo-HSCT."
9981291|NCT04661267|Placebo Comparator|Placebo formula|Patients randomized to the control group will receive a daily 1-ounce doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
9984589|NCT03945643|Placebo Comparator|Placebo administration|Administration of 50mg placebo one time, one hour prior to measurements
9725667|NCT05177731|Experimental|"Standard of Care (Conventional Induction 7+3)"|"Randomized participants will receive cytarabine and idarubicin per standard of care as follows:~Induction: cytarabine on days 1-7 and idarubicin (12mg/m2) on days 1-3 .~Second Induction (if not reach complete remission, but the percentage of blaste cells in bone marrow decreased by more than 50%): Re-induction with pre-induction therapy.~Consolidation: If patients with favorable risk and MRD negative or refuse to allo-HSCT, high dose cytarabine (2g/m3 q12h days 1-3) for 4 cycles. If patients with intermediate or poor risk or favorable risk but MRD positive, high dose cytarabine for 1-2 cycles and follow up with allo-HSCT."
9725668|NCT05177289|Experimental|Treatment group|Patients allocated to the treatment group will receive scalp cooling combined with thrice weekly PBM sessions during the CTx course and until one month after the end of CTx.
9984590|NCT03941574|Experimental|HLX10|
9984591|NCT03937219|Experimental|Experimental Arm|Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
9984592|NCT03937219|Active Comparator|Control Arm|Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
9984593|NCT03935269|Experimental|Intervention with Ambulatory Therapy|Caregivers of participants with high-grade glioma will undergo standard Cereset Research Office (CRO) in-office treatment for a total of five (5) treatments. Ambulatory therapy with the Cereset Research Wearable (CRW) will be available to caregivers while they are attending routine radiation therapy with glioma patients.
10204980|NCT04378933|Active Comparator|Clear glasses and Free Wake|Participants will wear identically appearing glasses with clear lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will not be given instructions regarding sleep schedule.
9725669|NCT05177289|Active Comparator|Control group|Patients allocated to the control group will receive scalp cooling during their CTx course.
9981292|NCT04658095|Active Comparator|Ab-interno canaloplasty and trabeculotomy (both up to 360 degrees) using the OMNI Surgical System|
9981293|NCT04658095|Active Comparator|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System|
9981294|NCT04658095|Active Comparator|Ab-interno implantation of iStent inject (2 microstents)|
9981295|NCT04652102|Experimental|Randomized Observer-blinded Phase 2b: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9725670|NCT05177250|Other|Case group|50 cases with type 2 DM.
9725671|NCT05177250|Other|Control group|50 subjects not diabetics.
9725672|NCT05176639|Experimental|Phase 1 MAD study part|Healthy participants and participants with TED will be randomized to receive two intravenous infusions of VRDN-001 or placebo with an interval of 3 weeks.
9725673|NCT05176639|Experimental|Phase 2 extension study part|Participants with TED will be randomized to one of two VRDN-001 doses/dosing regimens or placebo. The doses/dosing regimens may include doses up to 20 mg/kg with the dosing interval and duration to be defined based on the results of the MAD study part.
9725674|NCT05172271|Sham Comparator|Sham TEST|Anesthesia alone
9725675|NCT05172271|Experimental|Transcranial Electric Stimulation Therapy (TEST)|TEST involves bifrontal electrical brain stimulation at a dose below the seizure threshold, applied in the same manner as standard electroconvulsive therapy (ECT), with scalp electrodes, under anesthesia, using a standard ECT device (modified or unmodified) that can deliver a range of doses below seizure threshold.
9981296|NCT04652102|Placebo Comparator|Randomized Observer-blinded Phase 2b: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9981297|NCT04652102|Experimental|Randomized Observer-blinded Phase 3: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9725676|NCT05170477|Experimental|Apical aptency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically
9725677|NCT05170477|Active Comparator|Non-apical patency|in Gp B apical patency will not be maintained
9725678|NCT05167565|Experimental|Infants aged around 3 month|80 infants aged around 3 months will be included in this study up to around 12.5 months
9981298|NCT04652102|Placebo Comparator|Randomized Observer-blinded Phase 3: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
9981299|NCT04652102|Experimental|Open-label Phase|"After unblinding, the trial will shift from a randomized observer-blinded to an open-label design, and the following cohorts will be defined:~Cohort A: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to receive an authorized/licensed vaccine for preventing COVID-19 (AV) as standard of care through their national vaccination program.~Cohort B: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to remain in the trial without receiving any AV.~Participants on the placebo arm will be withdrawn."
9984594|NCT03934437|Experimental|mLTCR|The mLTCR intervention consists of two smartphone applications (app), one for patients and one for patient supporters, to help facilitate communication.
9984595|NCT03934437|Active Comparator|LTC|Existing linkage to care and retention (LTCR) services which are standard-of-care
9725679|NCT05166369|Experimental|Intervention targeted to healthcare providers (paediatricians, nurses and pharmacists) (ITHP)|"Professionals in the PC centres allocated to this group will receive a complex intervention, delivered remotely, which will include the following components:~i) Web based training that will include: communication skills training and optimal management of acute non-complicated RTI, including a specific training on delayed antibiotic prescription.~ii) By-monthly feedback about the rate of antibiotic prescription and consumption for RTI, center level and individual pediatrician level (information automatically gathered from electronic health records)."
9725680|NCT05166369|Experimental|Intervention targeted to parents (ITP)|PC centres allocated to this group will display posters and flyers to inform parents and/or caregivers about a mobile app. It will provide detailed information about respiratory tract infections and optimal use of antibiotics. The app will include information that will be of use before the consultation, but it will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making. Importantly, the app will allow tailoring the guidance provided according to the type of infection or number of days with symptoms. The app will be accessible through an app store or directly using a QR (quick response) code to facilitate uptake. Professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI, at center level and individual pediatrician level (information automatically gathered from electronic health records).
9725681|NCT05166369|Experimental|Intervention targeted to patients and/or patient´s parents and to the healthcare providers (ITHP*P)|Centres allocated to this group will receive the two interventions described above (intervention targeted to parents plus intervention targeted to providers).
9725682|NCT05166369|No Intervention|Control group|The centers allocated to this arm of the study will continue with their usual care. To avoid a potential Hawthorne effect (observer effect) these centers will not be informed about their participation as controls.
9725683|NCT05164172|Experimental|Eptinezumab 300 mg|Participants will receive 3 intravenous (IV) infusions of eptinezumab 300 mg (weight adjusted) at Weeks 0, 12, and 24.
9725684|NCT05164172|Experimental|Eptinezumab 100 mg|Participants will receive 3 IV infusions of eptinezumab 100 mg (weight adjusted) at Weeks 0, 12, and 24.
9725685|NCT05159830|Experimental|Cannabidiol (CBD)|CBD Group from 20mg x 2/day up to 600mg/day
9725686|NCT05159830|Placebo Comparator|PLACEBO (PCB)|PCB Group from 20mg x 2/day up to 600mg/day
10198763|NCT02843646|Experimental|Walk Aide training|This group of children will receive six weeks of Walk Aide training. During training, children will wear the Walk Aide. This device triggers ankle dorsiflexion, and controls the timing and duration of personal nerve stimulation during the swing phase of gait. The duration of the stimulus is gradually increased along with the wearing of the Walkaide. Subjects will begin by wearing the prosthesis for 30 minutes. The wearing time will be increased to waking hours of the subject, depending on their age. The electrodes will be placed on the client before the session is to begin, and taken off immediately after WalkAide usage. The skin will be checked before and after WalkAide electrode usage. The skin will be cleaned with an alcohol wipe before the electrodes are applied.
10198764|NCT02843646|Placebo Comparator|Delayed Walk Aide training|This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
10198765|NCT02841618|Experimental|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks Phase 1: N=39 adults single arm Phase 2: N=42 adults
10198766|NCT02841618|Placebo Comparator|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks Matched for Phase 2: N=42 adults
10198767|NCT02840877|Other|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
10198768|NCT02840643|Experimental|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
9725687|NCT05158972||Dymista®|Dymista® (Azelastine hydrochloride and Fluticasone propionate) nasal spray as prescribed within routine clinical practice
9725688|NCT05158309|Experimental|Capsaicin|Capsaicin condition: in this condition participants received pain using a (5x10 cm) 8% topical capsaicin patch on the volar part of the dominant right forearm.
9725689|NCT05158309|Placebo Comparator|Placebo|Placebo condition: participants received no pain.
9725690|NCT05156671|Experimental|Adrecizumab (HAM 8101)|Adrecizumab (HAM 8101) on top of standard of care. Adrecizumab (HAM8101) is a humanized IgG1 monoclonal antibody (mAb). 4 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion.
9725691|NCT05156671|Placebo Comparator|Placebo/ control substance (NaCl 0.9%)|100 mL saline as single dose infusion
9981300|NCT04641091||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
9981301|NCT04641091||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
9981302|NCT04628481|Experimental|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
9981303|NCT04628481|Placebo Comparator|Placebo|matching placebo b.i.d. for 13 cycles of 14 days on/14 days off
9981304|NCT04625972|Experimental|AZD7442|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
9981305|NCT04625972|Placebo Comparator|Placebo|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
9725692|NCT05155189|Experimental|C-CAR031|Autologous C-CAR031 administered by intravenous (IV) infusion
9725693|NCT05153343|Experimental|flonoltinib 25mg|1 case，The starting dose，Take the medicine once on D1 ，D 5 through 21.
9725694|NCT05153343|Experimental|flonoltinib 50mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
9725695|NCT05153343|Experimental|flonoltinib 100mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
9725696|NCT05153343|Experimental|flonoltinib 150mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
9725697|NCT05153343|Experimental|flonoltinib 225mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
9725698|NCT05153343|Experimental|flonoltinib 325mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
9981306|NCT04609137|Experimental|Early drain removal|Participants will have an early drain removal (before postoperative day 3 (POD 3)) if specific conditions will be verified
9981307|NCT04609137|Active Comparator|Standard drain removal|Participants will receive the current standard of care at San Raffaele Hospital.
9981308|NCT04604522||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of blood samples and 3 brushings of the airway during SOC bronchoscopy. After the bronchoscopy, patients undergo 2 nasal brushings (swabs). Patients' medical records are also reviewed for data collection.
9725699|NCT05153265||Residents|We plan to distribute a survey to the Stanford anesthesiology residents to determine their assessment of the bleeding risk of nerve blocks. The survey will list the most common nerve blocks and ask the resident anesthesiologists at Stanford whether the block is low/intermediate/high risk based on a scoring system of location relative to critical structures, compressibility, and whether bleeding or hematoma would be readily apparent.
9780796|NCT01131676|Experimental|BI 10773 high dose|BI 10773 tablets once daily
9780797|NCT01131676|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
9725700|NCT05153265||Attending physicians|We plan to distribute a survey to the Stanford anesthesiology attending physicians to determine their assessment of the bleeding risk of several different nerve blocks. The survey will list the most common nerve blocks and ask Stanford anesthesiologists whether the block is low/intermediate/high risk based on their experience with nerve blocks.
9725701|NCT05153122|Experimental|Investigational SenseGuard Device|Patients undergo SG monitoring at least twice daily before and after receiving treatment.
9981309|NCT04604353|Experimental|PRS score group|Risk information provided on the basis of Polygenic Risk Score combined with the Pooled Cohort Equation
9981310|NCT04604353|Active Comparator|CCS score group|Risk information provided on the basis of Coronary Calcium Score combined with the Pooled Cohort Equation
9981311|NCT04600674|Experimental|delayed cord clamping|DCC performed at 60 sec after birth
9981312|NCT04600674|Experimental|early cord clamping|ECC performed at 15 sec after birth
9981313|NCT04598815|Experimental|Sirolimus|Sirolimus for 12 weeks
9725702|NCT05152979|Experimental|Telepractice treatment (TP-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy through an online platform."
9725703|NCT05152979|Active Comparator|In-clinic treatment (IC-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy in person at a clinic."
10198769|NCT02840643|Experimental|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
10198770|NCT02834975|Experimental|Pembrolizumab, Paclitaxel + Carboplatin|"The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:~Pembrolizumab 200mg intravenously (IV);~Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);~Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);~Carboplatin IV area under the curve (AUC) of 6."
9725704|NCT05152680|Experimental|[14C]-NV-5138|[14C]-NV-5138 oral solution
9725705|NCT05147376|Experimental|Curcumin mouthwash|The curcumin mouthwash contains the final concentration of 1 μM curcumin, water, xylitol, and food coloring agent.
9725706|NCT05147376|Sham Comparator|Placebo mouthwash|The placebo mouthwash contains water, xylitol, and food coloring agent.
9725707|NCT05144945|Experimental|RIV4|RIV4 single injection at Day 1
9725708|NCT05144945|Active Comparator|IIV4|IIV4, single injection at Day 1
9725709|NCT05144893|Experimental|Virtual Mindfullness-Based Support Group|The virtual mindfulness-based intervention with social support groups will meet once a week for 4 weeks, each session will be 60 minutes. Each group will have 3-8 participants. The groups will be closed, meaning the same group of participants meet with the same instructor (unless a backup instructor is needed due to unavoidable reasons). Groups will be completed using the video conferencing application.
9725710|NCT05139732||control|Healthy participants
9725711|NCT05139732||Functional Neurological Disorder (FND)|People with the subtype functional paralysis
9725712|NCT05139732||Spinal Cord Injury (SCI)|Incomplete and complete paralysis with the ability to hold a pen
9725713|NCT05138783|Other|PRECISION1, then Biotrue|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for 8 -0/+3 days in a daily disposable modality.
9725714|NCT05138783|Other|Biotrue, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for 8 -0/+3 days in a daily disposable modality.
9725715|NCT05138380|Experimental|Foot orthoses|
9725716|NCT05138380|Sham Comparator|Flat shoe insert|
9725717|NCT05137990|Experimental|HIIT Exercise Intervention|At home (N=12): Participants will complete an exercise session 3 times a week for 14 weeks. Each participant will receive a pre-assembled stationary bicycle to use to complete each session, an iPad to receive the intervention virtually from exercise trainers through Zoom, and a Fitbit to assess real-time heart rate.
9725718|NCT05137990|Placebo Comparator|Stretching Intervention|At home (N=12): Participants will complete a stretching protocol 3 times a week for 14 weeks. Participants will be asked to complete weekly records of flexibility compliance.
9725719|NCT05137743|Experimental|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia (CBT-I).
9981314|NCT04598815|Experimental|Methylprendnisolone|Methylprednisolone for 12 weeks
9981315|NCT04598087|Experimental|Prehabilitation|- Tailored exercise prescription involving aerobic and resistance training, supported by a clinical exercise physiologist.
9981316|NCT04593940|Active Comparator|Standard of Care + infliximab or matching placebo|infliximab (single dose IV 5mg/kg given on day 1) or matching placebo
9981317|NCT04593940|Active Comparator|Remdesivir + abatacept or matching placebo|abatacept (single dose IV 10 mg/kg up to 1,000 mg given on day 1) or matching placebo
9981318|NCT04593940|Active Comparator|Remdesivir + cenicriviroc or matching placebo (closed to enrollment as of 3-Sep-2021)|cenicriviroc [tablet, Day 1/Loading Dose: 450 mg (300mg morning and 150mg evening) Day 2 - 29/Maintenance Dose: 300 mg (150 mg BID) through Day 29]. or matching placebo
9981319|NCT04593784|Experimental|Cohort 1|Subjects receive 60 mg edoxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 3 hours after administering edoxaban, study drug (ciraparantag or placebo) will be intravenously administered.
9981320|NCT04593784|Experimental|Cohort 2|Subjects receive 10 mg apixaban orally every 12 hours on Days 1 to 3, with a final dose in the morning on Day 4. On Day 4, approximately 4 hours after administering apixaban, study drug (ciraparantag or placebo) will be intravenously administered.
9725720|NCT05137743|Active Comparator|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
9725721|NCT05137587|Active Comparator|Group P|Patients sedated with propofol
9725722|NCT05137587|Active Comparator|Group K|Patients sedated with ketamine
9725723|NCT05137574|Active Comparator|Group P|Patients sedated with propofol
9981321|NCT04593784|Experimental|Cohort 3|Subjects receive 20 mg rivaroxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 4 hours after administering rivaroxaban, study drug (ciraparantag or placebo) will be intravenously administered.
9981322|NCT04593758|Experimental|CPI-613 + Hydroxychloroquine|dosing regimen was 2.5 mg/kg hydroxychloroquine PO followed 2 hours later by 1,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 2.5 mg/kg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.
9981323|NCT04584294|Experimental|Intervention (MyPath)|Patients scheduled to see providers randomized to this arm will receive a weblink to the decision tool via text message after study enrollment and prior to their scheduled visit.
9981324|NCT04584294|No Intervention|Uusal Care|Patients scheduled to see providers randomized to the usual care arm will receive no intervention and will receive usual primary care.
10198771|NCT02829671|Other|Patients with major depressive disorders|
9981325|NCT04579042|Experimental|Septoplasty Using Cartilaginous Batten Graft|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
10198772|NCT02809131|Experimental|Saline irrigation|Saline irrigation
9725724|NCT05137574|Active Comparator|Group K|Patients sedated with ketamine
9725725|NCT05136729|Experimental|Face-to-face Self-Natural Posture Exercise training|Off-line training
9725726|NCT05136729|Active Comparator|Online Self-Natural Posture Exercise training|"Virtual training~This group as a wait-list control group will receive online SNPE intervention after serving as an untreated comparison group."
9725727|NCT05135806||Group 1|Remote evaluation first: participants will undergo a comprehensive neuropsychological assessment administered remotely via telephone calls or videoconferencing. Each participant will take part to the second evaluation (face-to-face) 8 weeks later.
9725728|NCT05135806||Group 2|Face-to-face evaluation first: participants will undergo a comprehensive neuropsychological assessment administered face-to-face. Each participant will take part to the second evaluation (remotely via telephone calls or videoconferencing) 8 weeks later.
9725729|NCT05132829|Other|Cefazolin and Indomethacin|Control arm- perioperative cefazolin and indomethacin
9725730|NCT05132829|Experimental|Azithromycin + control|perioperative azithromycin, cefazolin and indomethacin
9725731|NCT05132335|Experimental|Experimental: Imaging Biomarkers|Each study subject is is studied in four session: twice after overnight fast and twice after liquid meal injestion using PETMRI imaging. Adipose and skeletal muscle pefusion and fatty adic uptake are measured and and the repeability of results tested for these two situations. In PEt studies PET/MRI Scan with radioactive water ([15O]-H2O) and [18F]-FTHA are used as tracers. In this experimental study number of subjects studied is rather small. Therefore volunteers with and without T2 diabetes are analysed together and not on different arms.
9725732|NCT05132127|Experimental|sutimlimab|Participants in Japan with CAD who have completed CARDINAL or CADENZA studies will receive sutimlimab (BIVV009). The dosing schedule consists of an initial dose (Day 0), followed by a dose one week later (Day 7), which is followed by a maintenance dose every other week beginning on Day 21.
9725733|NCT05130437|Experimental|mRNA-3927|Participants will receive the applicable dose identified during Study mRNA-3927-P101 (NCT04159103) on Day 1. The dose can be adjusted based on Sponsor recommendation.
9725734|NCT05130034|Experimental|Home-based pulmonary rehab for fibrotic interstitial lung disease|Subjects diagnosed with fibrotic interstitial lung disease will participate in a home-rehab program that promotes more physical activity in daily life.
10198773|NCT02809131|Active Comparator|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
10198774|NCT02798471|Experimental|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
10198775|NCT02798471|Experimental|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
9780798|NCT01132118|Other|Placebo then HCQ|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
9780799|NCT01132118|Other|HCQ then Placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
9780800|NCT01132144|Experimental|Endometrial injury group|Endometrial biopsy was performed once with a pipelle de Cornier® in the month before initiating controlled ovarian stimulation.
9780801|NCT01132144|Sham Comparator|Control group|Introduction of the speculum and wiping of the cervix with gaze for 30 seconds.
9780802|NCT01132313|Experimental|2|4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
9780803|NCT01132313|Experimental|1|4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
9780804|NCT01132313|Experimental|3|16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
9780805|NCT01132313|Experimental|4|28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
9780806|NCT01132313|Experimental|5|40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
9981326|NCT04576910|Experimental|"Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
9725735|NCT05128526|Experimental|Short foot exercise without respiratory exercises|"The participant will place by the researcher in the standing position so that the width between both feet will equal the width of the pelvis and the second toe will align with the patella. During the Short Foot Exercise, the participant will ask to position the spine straight, maintain the pelvis in a neutral position, and place the centerline of the body. The starting position will be set by the researcher under the same conditions as the midway between the feet. The subjects will give feedback from the researchers to assist in the maintenance of accurate body alignment. SFE, only in a standing position.~The participants will keep in contact with the fibular head of the target bar to maintain a constant position during Short Foot Exercises. Afterward, surface EMG measurements will be taken from the same muscle groups for 10 seconds during the foot shortening exercises while without breathing."
9725736|NCT05128526|Experimental|Short Foot Exercise With Respiratory Exercise|The participants will keep in contact with the fibular head of the target bar to maintain a constant position during Short Foot Exercises. Afterward, surface EMG measurements will be taken from the same muscle groups for 10 seconds during the foot shortening exercises while with breathing.
9981327|NCT04576910|Experimental|"Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
9725737|NCT05126966|Experimental|Ranibizumab|Subjects will have the implant (filled intra-operatively prior to implantation with approximately 20 µL of the 100-mg/mL formulation of ranibizumab [approximately 2-mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Subjects will have their implant refilled with ranibizumab at weeks 36 and 72.
9725738|NCT05126966|Active Comparator|Aflibercept|Subjects will receive intravitreal injections of aflibercept (2mg) administered in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment.
9725739|NCT05125237||Amiloride|Exposure group
9725740|NCT05125237||Triamterene|Reference group
9725741|NCT05125224||Dihydropyridine calcium channel blocker|Exposure group
9981328|NCT04576910|Experimental|"Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
9981329|NCT04576910|Experimental|"Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
9981330|NCT04576910|Experimental|"Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
9725742|NCT05125224||Hydrochlorothiazide|Reference group
9981331|NCT04574089|Experimental|Baofukang Suppository 7 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days
9981332|NCT04574089|Experimental|Baofukang Suppository 14 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days
9981333|NCT04572503|Experimental|Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty In Management of Mild and Moderate Obstructive Sleep Apnea Syndromea using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
9981334|NCT04571515|Experimental|MR-107A-01 15 mg once in a 24-hour period|Oral tablet one day of dosing
9981335|NCT04571515|Experimental|MR-107A-01 10 mg once in a 24-hour period|Oral tablet one day of dosing
9981336|NCT04571515|Experimental|MR-107A-01 15 mg twice in a 24-hour period|Oral tablet one day of dosing
9981337|NCT04571515|Experimental|MR-107A-01 10 mg twice in a 24-hour period|Oral tablet one day of dosing
10198776|NCT02786615|Experimental|Peer Unity|Subjects assigned to this arm would receive a 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
10198777|NCT02786615|No Intervention|Pre-implementation|Subjects assigned to this arm would not receive the group-delivered intervention.
9981338|NCT04571515|Placebo Comparator|Placebo twice in a 24-hour period|Placebo tablet one day of dosing
9981339|NCT04570488|Experimental|Intervention|Display of risk score/ colored flag in Epic patient list column; will be viewable to all frontline workers
9981340|NCT04570488|No Intervention|Control|"No display (hidden) of risk score/ colored flag in Epic patient list column; not viewable to all frontline workers"
9981341|NCT04557800|Experimental|DNL151|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
9981342|NCT04557800|Placebo Comparator|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
9981343|NCT04552587|Experimental|HEART|Patients and caregivers will complete a HEART visit virtually or in person. The visit includes a needs assessment that generates a tailored care plan with messages, referrals and educational materials for discussion with a nurse. Caregivers will receive brief training about the HEART App and then use the App for 4 weeks with bi-weekly real-time prompts and feedback.
9981344|NCT04541667|Active Comparator|Air for luminal inflation|Patients randomized into this arm will have luminal inflation using air.
9981345|NCT04541667|Active Comparator|Carbon Dioxide for luminal inflation|Patients randomized into this arm will have luminal inflation using carbon dioxide.
9981346|NCT04519073|Placebo Comparator|Placebo|0.5 mL of diluent (phosphate buffer)
9981347|NCT04519073|Experimental|V-306 low dose|V-306 at 15 µg
9981348|NCT04519073|Experimental|V-306 intermediate dose|V-306 at 50 µg
10198778|NCT02785952|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10198779|NCT02785952|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10198780|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
10198781|NCT02784171|Active Comparator|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
10198782|NCT02784171|Active Comparator|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
9981349|NCT04519073|Experimental|V-306 high dose|V-306 at 150 µg
9981350|NCT04517682||Positive for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a positive result.
9981351|NCT04517682||Negative for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a negative result.
9981352|NCT04510194|Experimental|Treatment Arm - Metformin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the metformin alone.
9981353|NCT04510194|Placebo Comparator|Treatment Arm - Placebo Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the placebo.
9981354|NCT04510194|Experimental|Treatment Arm - Ivermectin Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the ivermectin alone.
9981355|NCT04510194|Experimental|Treatment Arm - Fluvoxamine Only Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the fluvoxamine alone.
9981356|NCT04510194|Experimental|Treatment Arm - Metformin and Fluvoxamine Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and fluvoxamine.
9981357|NCT04510194|Experimental|Treatment Arm - Metformin and Ivermectin Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive metformin and ivermectin.
9725743|NCT05123417|Experimental|Intervention Group|Intervention group students will be educated with educational materials (lecture presentation, video) will be uploaded through the system in accordance with the flipped learning model, and students will be asked to come prepared to the planned lesson. No classical presentations will be made to the students, but the education will be carried out in the form of question and answer discussion, in line with the Flipped Learning model. After the lesson, the questions of the students who have questions will be answered.
9725744|NCT05123417|No Intervention|Control Group|The training, consisting of control group students will be trained with Powerpoint presentation, which will last 20-30 on average, will be given in accordance with the traditional education model. After the lesson, the questions of the students who have questions will be answered.
9725745|NCT05122819|Experimental|Group A|Intraligamentary Injection by Jet Injector
9725746|NCT05122819|Experimental|Group B|Intraligamentary Injection by regular Dental Anesthesia Syringe
9981358|NCT04509076|Experimental|PrEP iT! (plus usual PrEP care)|The PrEP iT! intervention is a mobile-optimized website with components tailored for young men who have sex with men on PrEP.
9981359|NCT04509076|Placebo Comparator|Usual PrEP care only|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
9981360|NCT04508907|Experimental|Arm 1: Pre-emptive Treatment Arm|Single arm study were all recipients of HCV viremic organs will receive combination therapy.
9981361|NCT04503603|Experimental|Lanadelumab 300 mg|Participants will receive single dose of lanadelumab 300 mg intravenous (IV) infusion on Day 1 followed by second dose on Day 4.
9981362|NCT04503603|Placebo Comparator|Placebo|Participant will receive single dose of lanadelumab matching placebo (normal saline) IV infusion on Day 1 followed by second dose on Day 4.
9981363|NCT04500756|Active Comparator|Metformin group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
10198783|NCT02784171|Active Comparator|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years
10198784|NCT02758717|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity.
10198785|NCT02748616|Experimental|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
10198786|NCT02747849|Placebo Comparator|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
9725747|NCT05122819|Active Comparator|Group C|Inferior Alveolar Nerve Block
9725748|NCT05120089|Experimental|muscle energy technique|Muscle energy technique is an associate degree of osteopathic manipulation methodology. The muscles of patients were used, on request, to type a singular controlled position, in a very specific direction, and against a distinctly executed therapist-applied counterforce. Muscle energy technique could be a post-isometric relaxation, because it reduces the tone of a muscle or cluster of muscle after a brief period following an isometric contraction. The result of post-isometric relaxation is mediated by receptive input from Golgi connective tissue organ (GTO) that has associate degree repressive result on the antagonist muscles mediated by the muscle spindle receptive. The technique will be applied for two month (3 session/week)
9725749|NCT05120089|Experimental|myofacial release|The technique will be applied for two month (3 session/week). All participants underwent ipsilateral side bending in a side-lying position, with the goals being de-rotation and scoliosis reduction.
9725750|NCT05119374|Experimental|Investigational SenseGuard Device|All subjects use SenseGuard Device for twice daily monitoring of respiratory parameters.
9725751|NCT05118529|Active Comparator|Sitting in bed|Sitting in bed with 60 degrees elevated back-rest during 20 minutes
9725752|NCT05118529|Experimental|Sitting in chair|Sitting in chair during 20 minutes
9725753|NCT05116917|Experimental|Experimental Arm|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days).
9725754|NCT05114941|Experimental|Immunoadsorption group|Protein A immunoadsorption therapy
9981364|NCT04500756|Placebo Comparator|Placebo Group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
9981365|NCT04500366|Active Comparator|Socialization|Participants randomized to the socialization arm will receive once-weekly phone calls from medical student volunteers for a total of 12-weeks (n=35). This program pairs health professional student volunteers with older adults in the community to provide social comfort while heightened physical distancing measures are in place during the current COVID-19 pandemic. Attendance and duration of the phone calls will be logged.
9725755|NCT05114941|Active Comparator|intravenous immunoglobulin group|Treatment with intravenous immunoglobulin
9725756|NCT05114876|No Intervention|Standard of Care|Standard of care
9725757|NCT05114876|Active Comparator|Intervention|Multicomponent delirium-risk prevention bundle
9725758|NCT05114265|Experimental|Part 1: Single ascending dose|Single dose of oral KUR-101 or oral placebo
9725759|NCT05114265|Experimental|Part 2: Three-way crossover|Single dose of oral KUR-101, oral placebo and oral OxyNorm
9725760|NCT05114161|No Intervention|Standard care|All participants/caregivers will be asked for consent for point-of-care (POC) blood C-reactive protein (CRP), nasopharyngeal swab for virology/Mycoplasma testing, and urine for pneumococcal antigen (UAg) testing, but, since this testing will not affect care, these are optional (ie. refusal will not preclude enrolment). The RA will phone the caregiver at Day 2-5, Day 14-21, and Day 30 post-enrollment, for outcome ascertainment. Caregivers will be asked to fill out a daily diary (either electronically or on paper) to record the participant's symptoms, clinical progress, and possible drug adverse effects. Caregivers will also be instructed on how to take patient temperature. All participants whose symptoms do not progressively improve will be encouraged to return to the ED to be reassessed, as per standard of care.
9780807|NCT01132313|Experimental|6|28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
9981366|NCT04500366|Experimental|Multi-Modal Frailty Rehabilitation|Multi-modal frailty rehabilitation will involve virtual care including 1x/week socialization, 2x/week exercise (small group physiotherapy live-streamed sessions), nutrition (virtual consult), and medication support (virtual pharmacist consult) all through a videoconferencing system.
9981367|NCT04497220|Placebo Comparator|Nocebo Group|Participants in this group will receive the control treatment
9780808|NCT01132313|Experimental|7|28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
9780809|NCT01132313|Experimental|8|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
9780810|NCT01132313|Experimental|9|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
9981368|NCT04497220|Experimental|Positive Connotation Group|Participants in this group will receive the experimental treatment.
9984596|NCT03932318|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles.~Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
9984597|NCT03927001|Other|Intervention|NeVa Stent Retrievers
9984598|NCT03926988|Other|Intervention|NeVa Stent Retriever
10198787|NCT02747849|Active Comparator|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
9981369|NCT04474509|Experimental|FACT Module Engagement|During this module, patients will have the opportunity to increase their motivation to change and encourage the engagement in committed actions, consistent with their life values. Patients are invited to reflect on what is important in their lives, which values make their life worth living, and which actions they could take to live a meaningful life, in accordance with personal values. The use of metaphors and experiential exercises will facilitate the process of exploring personal values, identifying life directions and related behaviors. For example, the 80th Birthday Party metaphor requires participants to imagine there is a party in honor of their birthday and the time comes when people are starting to give speeches and try to answer the question about what they want to hear people at the party say. This exercise help patients in wondering what person they want to be with themselves and others.
9725761|NCT05114161|Experimental|Novel Care Pathway|Once a child is diagnosed with non-severe CAP (community-acquired pneumonia) in the ED, specific radiographic findings and point-of-care CRP testing will identify those who require antibiotic treatment immediately. The next day, results of multiplex respiratory pathogen and urine pneumococcal antigen (UAg) testing will be integrated into the care plan, along with additional clinical information about the child gathered remotely, to ensure that only children at appreciable risk for bacterial infection receive antibiotics. Our care pathway uses already-available testing (NPS) in new ways, integrates newer diagnostics (point-of-care CRP, UAg), and includes properly-timed clinical follow up to change how children with non-severe CAP are managed.The research team will follow-up with the participant and caregiver the next day, 2-5 days, 7-21 days and day 30 post-enrolment to ensure clinical stability.
10198788|NCT02741193|Experimental|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
9725762|NCT05112731||First Ischemic Cardiac Event|Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up
9725763|NCT05112315|Experimental|Predigraft|Subjects will have a clinical follow-up based on site standard of care and benefit from follow-up using Predigraft in addition of the standard of care: the investigator will receive an alert every time there is a subject's instability, instability based on the following criteria: allograft survival assessed by iBox decreased by at least 5% in the last 12 months.
9725764|NCT05112315|No Intervention|Standard of Care|Subjects will have a clinical follow-up based on site standard of care.
9725765|NCT05110495|Experimental|Xentuzumab|All patients will be allocated to receive Xentuzumab
9725766|NCT05108376|Experimental|Intervention Arm|The Visensia Safety Index (VSI) will be used to alert RACE staff of patient deterioration.
9725767|NCT05105776|No Intervention|Physiotherapy only|
9725768|NCT05105776|Experimental|Active galvanic stimulation (GVS; week 1) to sham GVS (week 2)|Physiotherapy + translingual neurostimulation provided throughout
10198789|NCT02738866|Experimental|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
10198790|NCT02734797||Pediatric patients|This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
9725769|NCT05105776|Experimental|Sham GVS (week 1) to active GVS (week 2)|Physiotherapy + translingual neurostimulation provided throughout
9725770|NCT05105776|Experimental|Active GVS throughout weeks 1 + 2|Physiotherapy + translingual neurostimulation provided throughout
9725771|NCT05102591|Other|Standard-of-Care IV Group|Patients randomised to the standard of care IV group will receive a single, 45-minute stimulation from a sham remote electrical neuromodulation (REN) device, which will not administer the typical electrical stimulation (modulated frequency of ~ 0.083 Hz and a modulated pulse width of 40-550 µs), and will be given a single dose IV ketorolac and IV metoclopramide, at a dose of 0.5 mg/kg (for a maximum 30 mg) and 0.15 mg/kg (for a maximum 10mg), respectively. Metoclopramide will be infused over 15-30 minutes and ketorolac will be administered as a direct IV push over 1-5 minutes.
9725772|NCT05102591|Other|REN Group|Patients randomised to the REN group will receive a single 45-minutes stimulation from the REN device (modulated frequency of 100-120 Hz and a pulse width of 400 µs) and will also receive two doses of normal saline though an IV. Two doses of saline will be used to match the dosage, route of administration, and duration to ketorolac and metoclopramide, as described above in the standard-of-care IV group.
9725773|NCT05102188||African American adults with poor sleep|Individuals with self-identified poor sleep quality and/or quantity
9725774|NCT05101174|Experimental|Integrated Intervention Group|"Participants will attend the trainer-supervised program, which includes multiple physical fitness training, meditation, and social interaction, for 90 minutes/ session, 2 sessions/week for 6 months.~Intervention: Behavioral: aerobic exercise, resistance exercise, coordinative exercise, flexibility, social interaction, and meditation."
9725775|NCT05101174|Active Comparator|Active Control Group|"The active control group will be invited to attend the online educational course at a frequency of 2 sessions per week for 90 minutes each to eliminate the experimental expectation effect.~Intervention: Behavioral: online educational program."
9725776|NCT05100251|Experimental|WBC100|WBC100
9780811|NCT01132313|Experimental|10|24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
9780812|NCT01132313|Experimental|11|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
9984599|NCT03926260|Experimental|ctDNA analysis|additional blood sample of 20 ml
10198791|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
9780813|NCT01132313|Experimental|12|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
9780814|NCT01132326|Experimental|Droxidopa|Open-Label Droxidopa
10198792|NCT02730429|Placebo Comparator|Letrozole + placebo|"letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity. Letrozole is administered as standard of care in both study arms.~Placebo for palbociclib once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity."
9725777|NCT05099809||Hyperthermia|"Patients with locally advanced cancers reporting to Department of Radiotherapy at MGIMS who fulfil the eligibility criteria would be included in the study. Depending on the ongoing departmental protocols for various tumors the patients could be treated with either:~Radiotherapy and Hyperthermia~Concurrent chemoradiotherapy and hyperthermia~Neoadjuvant chemotherapy and hyperthermia followed by surgery and/or radiotherapy Hyperthermia would be delivered using a shortwave diathermy unit operating at 27.1 MHz.~Tumour response would be evaluated using RECIST criteria 1.1 while the acute and late morbidities would be scored as per CTCAE v5.0 guidelines. Outcome measures for each site would be undertaken and evaluated in terms of~Locoregional disease control~Disease free survival~Overall Survival~Acute morbidity~Late morbidity"
9725778|NCT05099445|Experimental|Group 1: Normal Renal Function|Participants with normal levels of renal function will receive a single oral dose of INCB000928 200 mg on Day 1.
9725779|NCT05099445|Experimental|Group 2: Mild Renal Impairment|Participants with mild levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
10198793|NCT02730429|Experimental|Letrozole + palbociclib|"Palbociclib 125mg once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity.~letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity.~Letrozole is administered as standard of care in both study arms."
10198794|NCT02730416|Experimental|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
10198795|NCT02730416|Placebo Comparator|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
9725780|NCT05099445|Experimental|Group 3: Moderate Renal Impairment|Participants with moderate levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
9984600|NCT03925584|Experimental|Music Therapy|Implement standardized nurse-led music therapy for neonates post congenital heart surgery who are admitted to the cardiac intensive care unit.
10198796|NCT02719977|Experimental|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
10198797|NCT02719002|Experimental|OCT C-scan|
10198798|NCT02710279|Other|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
9725781|NCT05099445|Experimental|Group 4: Severe Renal Impairment|Participants with severe levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.
9725782|NCT05099445|Experimental|Group 5: Kidney Failure|Group 5 participants with ESRD maintained on HD will receive a single dose of INCB000928 on Day 1 of each of 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB000928.
9725783|NCT05098626||Individuals Working Remotely|Individuals aged between 18-60 and working remotely, who volunteered to participate in the study, will form the study group.
9725784|NCT05097222|Experimental|Active PBMT|Participants will receive 50minutes of PBMT, three times a week, for 8 weeks.
10198799|NCT02694094||Adults on Chronic ketogenic diets|Adults who have been on Modified Atkins or ketogenic diets for over 1 year
10198800|NCT02694094||Adults naive to ketogenic diets|Adults who have never been on Modified Atkins or ketogenic diets
10198801|NCT02693821|Experimental|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
10198802|NCT02693821|Placebo Comparator|Placebo|300mg of Placebo per day (two doses), orally during 30 days
10198803|NCT02678871|Other|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
10198804|NCT02678689|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|An age-appropriate dose of BMN 190 administered via intracerebroventricular (ICV) infusion every other week (qow) for a duration of 144 weeks.
10198805|NCT02671890|Experimental|Cohort I (gemcitabine hydrochloride and disulfiram)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO on days 1-28 or days 1-35.
10198806|NCT02671890|Experimental|Cohort II (chemotherapy and disulfiram)|Patients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.
10198807|NCT02664181|Experimental|Oral THU/decitabine + Nivolumab|Oral THU ~10 mg/kg, followed by oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
10198808|NCT02664181|Active Comparator|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
9725785|NCT05097222|Sham Comparator|Sham PBMT|Participants will receive 50minutes of Sham PBMT, three times a week, for 8 weeks. The Sham device will appear to function like the treatment device without providing any power intensity (0% power). At 0% power, no light is emitted from the LEDs.
9725786|NCT05096260|Experimental|Sequence 1: Active at Week 8|Five churches will enter the intervention phase, where study participants from enrolled churches will receive text messages and Motivational Interviewing to increase the uptake of the COVID-19 vaccine.
9725787|NCT05096260|Experimental|Sequence 2: Active at Week 16|Five additional churches will enter the intervention phase (now 10 active), where study participants from enrolled churches will receive text messages and Motivational Interviewing to increase the uptake of the COVID-19 vaccine.
9725788|NCT05096260|Experimental|Sequence 3: Active at Week 24|Five additional churches will enter the intervention phase (now 15 active), where study participants from enrolled churches will receive text messages and Motivational Interviewing to increase the uptake of the COVID-19 vaccine.
10198809|NCT02658812|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec IT on day 1. Cycles repeat every 3 weeks in cycle 1 and every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
10198810|NCT02643966|Experimental|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
10198811|NCT02640586|Experimental|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
10198812|NCT02636530|Experimental|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
10198813|NCT02636530|Experimental|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
10198814|NCT02633397|Experimental|Riociguat|Treatment Arm
10198815|NCT02633397|Placebo Comparator|Placebo|Placebo Arm
10198816|NCT02633241|Other|Dexmedetomidine (bolus and infusion)-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg and Propofol100mcg/kg/minute to accomplish an MRI examination.
10198817|NCT02633241|Other|Dexmedetomidine (bolus only)-Propofol arm|Patients in this cohort will receive dexmedetomidine 1mcg/kg over 5 minutes and then propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion to accomplish MRI
10198818|NCT02626715|Active Comparator|Reduced-Intensity Conditioning|"Campath (alemtuzumab), Droxia (hydroxyurea), Fludara (fludarabine), Alkeran (melphalan), Thiotepa (triethylenethiophosphoramide)~Trade Name (generic name)"
10198819|NCT02626715|Active Comparator|Myeloablative Conditioning|"Campath (alemtuzumab), Thiotepa (triethylenethiophosphoramide) , Fludara (fludarabine), Busulfex (busulfan)~Trade Name (generic name)"
10198820|NCT02602756|Active Comparator|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
10198821|NCT02602756|Experimental|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
10198822|NCT02602119|Experimental|OTL38|Dosage calculated by weight of individual
10198823|NCT02585232|Active Comparator|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment - much like an interview guide - which then immediately shapes development of concrete action plans."
9981370|NCT04474509|Experimental|FACT Module Openness|"Participants attending this module are guided to recognize and distancing themselves to stressful thoughts, feelings and sensations. They will learn to read suffering as part of human experience, without self-judgment and self-condemnation. Rather, therapist will encourage the patient's assumption of an open and acceptable approach to internal experiences. Throughout the module, therapist will help patients to reflect on their usual, but ineffective efforts to solve personal problems, and encourage the adoption of new responsive strategies based on acceptance and defusion from personal distress.~An example of metaphor used during the Module is The Passenger on a bus. In this metaphor patient have to imagine to be a driver bus and his every thought is a passenger that gets on and off the bus. This exercise help patients to accept, defuse from, and reduce the power of their thoughts."
10198824|NCT02585232|Experimental|Care Consultation + Counseling (CC+C)|Care Consultation + Counseling (CC+C): is consistent with the original CC protocol in that the therapist partners with each dyad in a patient-centered way to prioritize unmet needs as identified during the CC initial assessment. Once this phase has been completed, typically within the first 2 sessions, the CC+C therapist will determine when to initiate counseling sessions targeting 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.). The counseling component of the CC+C intervention incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework.
9981371|NCT04474509|Experimental|FACT Module Awareness|The module comprises meditation exercises and experiences aimed to learn how to act intentionally with awareness about personal thought and sensations without automatically reacting. Participants are supported to recognize their actions and the context where they occur and learn to choose to respond with action consistent with their values and not automatically. Therapist will propose breathing exercises, body scan and others mindfulness experiences. Participants will be encouraged to sitting comfortably, close the eyes, feel themselves in contact with the present moment they are living, paying attention to their breath, noticing the rhythm and any other aspect of the experience of breathing. Then, the therapist guides the participant's attention on the body, noting any part of their body from the head to feet. Then, the sounds around, any noises that could distract their attention on themselves.
9981372|NCT04473430|Experimental|Real-time Dexcom CGM, then Point-Of-Care Blood Glucose Group (Intervention-Control Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use a real-time/personal CGM for 4 weeks (Intervention-Control Group), then 2 weeks of wash-out period, and cross over to use POC BG for 4 weeks.
9981373|NCT04473430|Experimental|Point-Of-Care Blood Glucose (Control) then Real-time Dexcom CGM Group (Control-Intervention Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use POC BG for 4 weeks, then 2 weeks of wash-out period, and cross over to use a real-time/personal CGM for 4 weeks (Control-Intervention Group).
9981374|NCT04472416|No Intervention|Standardized analgesic protocol alone|Abdominal VAC dressing change using an standardized analgesic protocol alone.
9981375|NCT04472416|Experimental|VRD + standardized analgesic protocol|Abdominal VAC dressing change using standardized analgesic protocol + virtual reality device
10198825|NCT02583789|Active Comparator|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
9725789|NCT05096260|Experimental|Sequence 4: Active at Week 32|Five additional churches will enter the intervention phase (now 20 active), where study participants from enrolled churches will receive text messages and Motivational Interviewing to increase the uptake of the COVID-19 vaccine.
9725790|NCT05096260|Experimental|Sequence 5: Active at Week 40|Five additional churches will enter the intervention phase (now 25 active), where study participants from enrolled churches will receive text messages and Motivational Interviewing to increase the uptake of the COVID-19 vaccine.
9725791|NCT05096260|Experimental|Sequence 6: Active at Week 48|Five additional churches will enter the intervention phase (now 30 active), where study participants from enrolled churches will receive text messages and Motivational Interviewing to increase the uptake of the COVID-19 vaccine.
9981376|NCT04466540|Experimental|Hydroxychloroquine (HCQ)|HCQ group participants will receive a dose of 400mg twice daily (BID) in the first day, and a dose of 400 mg once daily (OD) from the second day of treatment, in a total of 7 days.
9981377|NCT04466540|Placebo Comparator|Placebo|The placebo group will follow the same regimen of administration
9725792|NCT05096260|No Intervention|Control|Participants will have access only to publicly available about the COVID-19 vaccine risks and benefits, until they cross-over into the intervention arm.
9725793|NCT05095883||healthy|Children in this group will be healthy category according to CDC chart which ranged from BMI-for-age 5th to 85th percentiles
9725794|NCT05095883||overweight|Children in this group will be overweight category according to CDC chart which ranged from BMI-for-age 85th to 95th percentiles
10198826|NCT02583789|Placebo Comparator|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
10198827|NCT02583269|Experimental|Arm 1 (muscadine grape skin extract) 1 pill 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
9725795|NCT05095883||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age > 95th percentiles
9981378|NCT04456972|Experimental|One arm only|
9981379|NCT04456946|Experimental|Group of Low Level Laser Therapy|
9725796|NCT05095883||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age < 5th percentiles
9981380|NCT04456946|Experimental|Group of Occlusal Splint Treatment|
9981381|NCT04454918|Experimental|TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg|TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 micrograms (μg) [approximately 1 microcurie (μCi)], IV infusion, once on Day 1 of Treatment Period 1, followed by a Washout Period of 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 μCi), solution, orally, once on Day 1 of Treatment Period 2.
9981382|NCT04453449||No sedation|Patients who will undergo the diagnostic lumbar medial branch blocks without sedation (control group).
9981383|NCT04453449||Sedation|Patients who will undergo the diagnostic lumbar medial branch blocks with midazolam sedation (treatment group).
10198828|NCT02583269|Experimental|Arm 2 (muscadine grape skin extract) 2 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
10198829|NCT02583269|Experimental|Arm 3 (muscadine grape skin extract) 3 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
10198830|NCT02583269|Experimental|Arm 4 (muscadine grape skin extract) 4 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
10198831|NCT02583269|Experimental|Arm 5 muscadine grape skin extract) 5 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
10198832|NCT02567643|Experimental|Stereotactic Radiosurgery|
10198833|NCT02564159|Experimental|High-risk patient for malnutrition acquired in ICU|Patients admitted in ICU and treated with mechanical ventilation with expected duration of 48 hours or more
10198834|NCT02564159|Other|Controls patients: Elective surgery|"Controls patients: Elective surgery (neurosurgery, thoracic surgery, vascular surgery)~- Patients admitted in a post-operative care unit of the university hospital of Nantes after elective surgery with expected duration ICU length of stay < 48 hours"
10198835|NCT02556606|Experimental|Ketamine 0.10 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
10198836|NCT02556606|Experimental|Ketamine 0.25 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
9780815|NCT01132378|Active Comparator|Mini-midvastus approach|Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.
9981384|NCT04451668|Experimental|FT218|once nightly sodium oxybate extended release oral solution (FT218)
9981385|NCT04440839|Experimental|Intervention|Telemedicine specialty consultation for patients
9981386|NCT04440839|No Intervention|Standard Care|Standard in person referral to a specialist
9981387|NCT04427501|Experimental|LY3819253|700 mg, 2800 mg, 7000 mg, LY3819253 administered intravenously (IV)
9981388|NCT04427501|Experimental|LY3819253 + LY3832479|350 mg, 700 mg, 2800 mg LY3819253 + 700 mg, 1400 mg, 2800 mg LY3832479 administered IV or subcutaneously (SQ)
9981389|NCT04427501|Placebo Comparator|Placebo|Placebo administered IV
10198837|NCT02556606|Experimental|Ketamine 0.50 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
10198838|NCT02556606|Active Comparator|Midazolam 0.03 mg/kg|randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg
10198839|NCT02546999|Experimental|botox|Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
10198840|NCT02546999|Placebo Comparator|placebo|Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
10198841|NCT02545283|Experimental|Idasanutlin plus Cytarabine|Participants will receive induction therapy idasanutlin and cytarabine for 5 Days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.
10198842|NCT02545283|Placebo Comparator|Placebo plus Cytarabine|Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.
9725797|NCT05095584|Experimental|validity and reliability of 3 meter backward walking test|"This study was conducted as test-retest design and the psychometric properties of 3-m backward walk test were examined in LLA. The Rivermead Mobility Index, 3-m backward walk test, Berg Balance Scale, Timed Up and Go test were applied to the patients. An experienced physiotherapist performed all these tests. In order to measure test-retest reliability, the second evaluations (retest) were carried out by the same physiotherapist two days following the first evaluation (test). A same evaluator collected data in order to avoid the inter-rater variability error rate between the evaluations. The patient was evaluated at one time of the day for test and retest."
9725798|NCT05092750|Experimental|FerroTraceTM (magnetic tracer)|a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.
9981390|NCT04427137|Experimental|Accelerated LFR|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients that have responded to treatment will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
9981391|NCT04415333|Experimental|Sodium Butyrate [5 mmol] first, then Sodium Butyrate [80 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-days washout period, they will return to testing office to self-administer the other enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
9981392|NCT04415333|Experimental|Sodium Butyrate [80 mmol] first, then Sodium Butyrate [5 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-day washout period, they will return to the testing office to self-administer the other enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
9725799|NCT05091983||Restrictive eating disorder group|Adolescents between 12 and 18 y.o. Restrictive eating disorders diagnosis (Anorexia Nervosa or ARFID) answering DSM-5 criteria
9725800|NCT05091983||Control group|Adolescents between 12 and 18 y.o. No eating disorders
9725801|NCT05091060|Experimental|Erchonia HLS|635 nanometers (nm) laser application
9725802|NCT05090475|Experimental|Hospital A-team led intervention in Koprivnica Križevci County|Hospital A-team will give educational outreach intervention to primary care physicians
9981393|NCT04415333|No Intervention|Control|African Americans with normal blood pressure (control group) will not perform self-administration of the enema. They will submit to 1 blood draw and wear the 24-hour ambulatory blood pressure monitor for 1-day.
9981394|NCT04385992|Experimental|All enrolled patients|Enrolled patients following inclusion criteria
9981395|NCT04375332|Experimental|HARPOON™ Beating Heart Mitral Valve Repair System|Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
9981396|NCT04372953|Active Comparator|Static PEEP Group|Delivery of PEEP at 5-6 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). FiO2 and other aspects of respiratory care are then titrated using a standardised resuscitation algorithm.
9981397|NCT04372953|Experimental|Dynamic PEEP Group|"Dynamic delivery of PEEP at 8 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). PEEP levels increased step-wise to 10 and/or 12 cmH2O if FiO2/respiratory care needs to be escalated as per a standardised resuscitation algorithm.~If an infant shows evidence of respiratory improvement during resuscitative care, PEEP will be reduced in a stepwise method by 2 cmH2O each reduction, but to no lower than 8 cmH2O."
9981398|NCT04367922|Experimental|Positive emotion skills invervention|Participants will go through a 6-week positive emotion skills course where 1 new skill opens each week.
10198843|NCT02535286|Experimental|TG-1501 + Ublituximab + Umbralisib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Umbralisib oral daily dose TG-1501 IV infusion at scheduled intervals
9981399|NCT04366336|Experimental|Blood Flow Restriction Training|"Blood flow restriction training (BFRT) uses a specialized tourniquet system to restrict arterial inflow and venous outflow to the limb during low-load resistance exercise.~BFRT involves placing the pressure cuff before the start of therapeutic exercises.~Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching"
9981400|NCT04366336|Active Comparator|Standard Physical Therapy|Subjects will receive American College of Sports Medicine guided-strength training Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
9981401|NCT04364867|Experimental|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
9725803|NCT05090475|No Intervention|Control group|Primary care physicians in Bjelovar Bilogora county will not receive intervention
9725804|NCT05090436|Experimental|Schroth Exercise|The Schroth Method is a nonsurgical option for scoliosis treatment. It uses exercises customized for each patient to return the curved spine to a more natural position. The goal of Schroth exercises is to de-rotate, elongate and stabilize the spine in a three-dimensional plane. it will be applied 3 session per week for 3 months.
9981402|NCT04364867|Active Comparator|Pain pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
9981403|NCT04361240||Ancillary Cohort|No Intervention: Subjects will be followed before, during and for up to 1 year after radiation with echocardiogram, blood draw, and symptoms and activity survey.
9981404|NCT04351711||Patients SARS-CoV-2 with respiratory failure|Patients in intensive care
9981405|NCT04351711||Patients SARS-CoV-2 without respiratory failure|Patients hospitalized in normal hospital wards
9981406|NCT04351711||HEALTHY VOLUNTEERS|HEALTHY VOLUNTEERS
9981407|NCT04351711||NON-COVID-19 PATIENTS|Patient hospitalized at the CHU of Nîmes for an infection by a virus other than SARS-CoV-2
9981408|NCT04351711||PAUCISYMPTOMATIC SARS-COV-2+ PATIENTS|Patient positive for SARS-CoV-2 by RT-PCR at the CHU of Nîmes and presenting at most moderate clinical signs without respiratory insufficiency (O2 saturation greater than or equal to 96%) during the confinement period
9981409|NCT04351711||convalescent patients|Additional 1-year follow-up visit
9981410|NCT04347343|Experimental|COMBO|Neuromuscular Electrical Stimulation and Blood Flow Restriction (COMBO) in addition to standard postoperative rehabilitation.
10198844|NCT02534168|Experimental|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
10198845|NCT02532231|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle.
10198846|NCT02531126|Experimental|RPC0163 (Ozanimod)|
10198847|NCT02524171|Experimental|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
10198848|NCT02524171|No Intervention|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
10198849|NCT02513407|Experimental|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for > 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
10198850|NCT02513407|Active Comparator|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
9981411|NCT04344769||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
9981412|NCT04344769||Healthy individuals as controls|Age and gender-matched healthy controls
9981413|NCT04340739||Cohort 1 (8 Patients)|A wireframe mock-up of the GEMINI platform will be usability tested by 8 chronic pain patients from whom feedback will be collected by completing a virtual semi-structured interview. Outcomes: Quantitative Testing Data from Usability Testing Prompt. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
10198851|NCT02508467|Experimental|Fisogatinib (BLU-554)|Fisogatinib (BLU-554) capsules for oral administration.
10198852|NCT02507505|Active Comparator|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
10198853|NCT02507505|Active Comparator|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
10198854|NCT02494570|Experimental|ABI-009|
10198855|NCT02494167|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for AML or MDS
10198856|NCT02494167|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for AML or MDS
9981414|NCT04340739||Cohort 2 (16 Patients)|"A live version of GEMINI will be beta-tested by 16 chronic pain patients through completing a faux medical group visit (MGV). This will include things like exploring the education topics available, interacting with the other participating patients, and interacting with a medical provider posing as the faux group's health care provider, all in order to robustly test the system in a live environment. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide."
9981415|NCT04340739||Cohort A (8 Healthcare Providers)|Eight healthcare providers will be divided into pairs, and these pairs will each conduct a faux medical group visit (MGV) with faux patients (staff will pose as patients). They will be asked to complete the faux session as if it were actual patients of theirs, conduct pre- and post-session tasks, and provide usability feedback on the platform. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
9981416|NCT04339998||Patients with Suspected or Confirmed COVID-19|Patients 18 years of age and older under investigation for COVID-19 and those patients that are positive for COVID-19 at University of Minnesota Medical Center and Bethesda Hospital. Informed consent will be obtained from the patient or decision maker prior to study inclusion
9981417|NCT04333888|Experimental|Treatment|
9981418|NCT04333888|No Intervention|Control|
9981419|NCT04326036|Experimental|Lipoaspiration|Closed sterile, disposable microcannula of small volume adipose tissue, including the stromal vascular fraction (SVF) (cells and stromal tissue
9981420|NCT04326036|Experimental|Isolation & Concentration of cSVF|Isolation & Concentration of cellular stromal vascular fraction (cSVF) using Healeon Centricyte 1000 Centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
9725805|NCT05090436|Experimental|Functional Electrical Stimulation|30 minutes of Functional Electrical Stimulation (FES) three times a week for 3 months. Two electrodes were attached on the lateral parts of the convex side of the body, and two others on the erector spinae muscles. FES (CU-FS1; Novastim, Korea) was set at a frequency of 35 Hz, with a 250-μs pulse width. Electrical stimulation lasted for 6 seconds, followed by a 6-second rest.
9725806|NCT05089760||Infants with bacteria sepsis|Infants diagnosed with culture-proven sepsis
9725807|NCT05088408|Active Comparator|Control|Bowel preparation as usual. Colonoscopy.
9725808|NCT05088408|Experimental|Dietary supplement|"Bowel preparation as usual plus two bottles of the dietary supplement Resource® Energy Apricot.~Colonoscopy."
9981421|NCT04326036|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 250 cc of sterile Normal Saline IV solution and deployed though 150 micron in-line filtration and intravenous route over 30-60 minute timeframe
9981422|NCT04326036|Other|Liberase TM|Use of sterile Liberase TM enzyme to allow cSVF separation and isolation
9981423|NCT04326036|Other|Sterile Normal Saline|250 cc of sterile Normal Saline for Intravenous with sterile 150 micron in-line filtration for suspension of the concentrated cSVF and deployment IV
10198857|NCT02489422|Experimental|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
10198858|NCT02489422|Active Comparator|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
9981424|NCT04324580|Active Comparator|Delayed mobilization/Formal physical therapy group|Participants will be placed into a volar-based plaster splint post-operatively. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. After that, participants will be placed into a custom thermoplastic splint by a therapist. This will be worn for 5 weeks. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks. The splint will be removed only for formal and home physical therapy and hygiene.
9981425|NCT04324580|Active Comparator|Immediate mobilization/self guided physical therapy group|Participants will be placed into a soft dressing after surgery. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. This group will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
9981426|NCT04317417|Experimental|Condition 1|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
9981427|NCT04317417|Experimental|Condition 2|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
9981428|NCT04317417|Experimental|Condition 3|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
9981429|NCT04317417|Experimental|Condition 4|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
9725809|NCT05088252|Experimental|Desflurane Inhalational Anesthesia|
9725810|NCT05088252|Active Comparator|Propofol Total Intravenous Anesthesia|
9725811|NCT05087485|Experimental|Basic science|This group will be exposed to a written learning content that includes both the presentation and underlying reason of dermoscopic criteria
9725812|NCT05087485|Experimental|visual criteria|This group will be exposed to a written learning content that includes only the presentation of dermoscopic criteria
9725813|NCT05087186|Experimental|Intervention|Group sessions with psychological therapists
9780816|NCT01132378|Active Comparator|Medial Parapatellar Approach|Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.
9981430|NCT04317417|Experimental|Condition 5|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
9981431|NCT04317417|Experimental|Condition 6|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
9981432|NCT04317417|Experimental|Condition 7|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
9981433|NCT04317417|Experimental|Condition 8|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
10198859|NCT02487251|Experimental|Experimental: Phase 1 Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
9981434|NCT04317417|Experimental|Condition 9|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
9981435|NCT04317417|Experimental|Condition 10|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
9981436|NCT04317417|Experimental|Condition 11|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
9981437|NCT04317417|Experimental|Condition 12|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
9981438|NCT04317417|Experimental|Condition 13|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
9981439|NCT04317417|Experimental|Condition 14|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
9981440|NCT04317417|Experimental|Condition 15|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
9725814|NCT05086432|Experimental|Sputum-guided management|During Weeks 0 to 16, participants randomized to the intervention arm will receive open-label sputum-guided management of airway inflammation (Table 1 in protocol) identified during screening (Figure 2 in protocol). Airway eosinophilia will be treated with regular inhaled corticosteroids based on the severity of eosinophilic inflammation. In participants with airway neutrophilia, as per the standard of care, sputum culture and sensitivity will be sent, and pathogenic organisms treated. Those participants with airway neutrophilia with negative cultures will be treated with thrice weekly Azithromycin (250mg). Combined eosinophilia and neutrophilia will receive treatment with both ICS and Azithromycin as per Table 2 in protocol.
10198860|NCT02487251|Experimental|Experimental: Phase 1 Mealtime support activities|Participants will engage in mealtime support activities such as healthy eating classes, cooking demonstrations, provision of cookware, receipt of mealtime ingredients, receipt of prepared meals, make and eat meals).
10198861|NCT02487251|Experimental|Experimental: Phase 2- Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
10198862|NCT02487251|Experimental|Experimental: Phase 2- Meal Delivery and Receipt of Cookware|Participants will receive two prepared meals weekly for 12 weeks and will receive a comprehensive set of cookware
9725815|NCT05086432|Active Comparator|Standard of Care|Participants in this arm will receive standard of care treatment as determined by their ILD specialist who will be blinded to the results of the sputum analysis.
9725816|NCT05083442|Active Comparator|Group 1 - LLLT|Subject receive Laser treatments and Lifestyle Modifications
9981441|NCT04317417|Experimental|Condition 16|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
9981442|NCT04317417|Experimental|Condition 17|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
9981443|NCT04317417|Experimental|Condition 18|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
10198863|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
10198864|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
9725817|NCT05083442|Sham Comparator|Group 2 - SHAM|Subject receives Sham Laser treatments and Lifestyle Modifications
10198865|NCT02476968|Other|Olaparib|Open Label Drug
9725818|NCT05081882|Experimental|Kava Intervention|
9725819|NCT05081882|Placebo Comparator|Placebo Control|
9725820|NCT05080842|Experimental|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. Up to 30 participants will participate in this dose escalation arm.
9725821|NCT05080166|Experimental|Clinicians Interviews|Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.
9981444|NCT04317417|Experimental|Condition 19|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
9981445|NCT04317417|Experimental|Condition 20|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
9981446|NCT04317417|Experimental|Condition 21|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
9981447|NCT04317417|Experimental|Condition 22|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
9981448|NCT04317417|Experimental|Condition 23|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
9981449|NCT04317417|Experimental|Condition 24|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
10198866|NCT02465593|Experimental|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
10198867|NCT02465268|Experimental|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
10198868|NCT02465268|Experimental|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
9725822|NCT05080166|Experimental|Lymphoma Survivors Field Test|A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
9725823|NCT05080166|Experimental|UPLYFT Pilot|Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program.
9725824|NCT05077852||Cystoscopy Bladder Cancer|Patients diagnosed with primary bladder cancer at the base, trigone or neck of the bladder by cystoscopy.
9725825|NCT05077852||Cystoscopy IPP|Patients diagnosed with intravesical prostate protrusion (IPP) at the base, trigone or neck of the bladder by cystoscopy.
9725826|NCT05076760|Experimental|MEM-288 Intratumoral Injection|"Patients with accessible, subcutaneous, or superficial lymph node lesion ≥ 1 cm3 that is palpable will receive intratumoral injection of MEM-288 once every 3 week (planned 2 doses, maximum 6 doses) at one of three dose cohort levels.~Dose cohort level 1 (1 x 10^10 viral particles)~Dose cohort level 2 (3.3 x 10^10 viral particles)~Dose cohort level 3 (1 x 10^11 viral particles)"
9725827|NCT05075707|No Intervention|control group|Participants will receive the descriptive medication by neurologist
9725828|NCT05075707|Experimental|electromagnetic group|Participants will receive the descriptive medication by neurologist in addition to electromagnetic therapy. Electromagnetic therapy will be applied for 20 min/session for three days each week for two months.
9725829|NCT05075707|Experimental|low laser therapy group|Participants will receive the descriptive medication by neurologist in addition to low laser therapy. Low laser therapy will be applied for 20 min/session for three days each week for two months.
9725830|NCT05075486|Experimental|Intervention group|Group who recieve collaborative quality improvement during study period.
10198869|NCT02465268|Placebo Comparator|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
10198870|NCT02460835|Experimental|Adaptive Radiation Therapy|
10198871|NCT02443896|Experimental|Sealant applied to molars|"All 'sealable' permanent molars will be sealed: Occlusal fissures and where appropriate, buccal pits (on lower molars) and palatal pits (on upper molars) will be sealed.~If patient compliance is adequate, a resin based sealant will be used as the first choice material. The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard."
10198872|NCT02443896|Sham Comparator|No sealant applied to molars.|No molars will be sealed.
10198873|NCT02436707|Active Comparator|R-GDP|"Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
9725831|NCT05075200|Experimental|Group I|Participants with glomerular filtration rate (GFR) < 60 mL/min/1.73m2 (and dialysis)
9725832|NCT05075200|Experimental|Group II|Participants with GFR ≥ 60 mL/min/1.73m2
9981450|NCT04317417|Experimental|Condition 25|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
9725833|NCT05074446|Experimental|intensivist in the experimental group|Stereotype threat manipulation will be performed on the intensivist in the experimental group just before they are taken into the testing room.
9725834|NCT05074446|No Intervention|intensivist in the control group|The intensivist in the control group will not be given any prior information.
9725835|NCT05074446|Experimental|non-intensivist in the experimental group|Stereotype threat manipulation will be performed on the non-intensivist in the experimental group just before they are taken into the testing room.
9725836|NCT05074446|No Intervention|non-intensivist in the control group|The non-intensivist in the control group will not be given any prior information.
9725837|NCT05074238|Experimental|Sunscreen Application|The study participant will be instructed to start applying the sunscreen provided to them to the randomly assigned half of the wound (A or B).
9725838|NCT05074238|Experimental|No Suncreen Application|The study participant will be instructed to not apply the sunscreen provided to them to the randomly assigned half of the wound (A or B).
9725839|NCT05074212|Experimental|Complex Linear Closure|The study participant will receive two layers of sutures to close the wound.
9725840|NCT05074212|Experimental|Second Intention Healing|The study participant will not have any sutures placed.
9725841|NCT05071937|Experimental|ZEN003694 + Talazoparib|"ZEN003694: 48.0 mg daily (oral) in 28-day cycles~Talazoparib: 0.75 mg daily (oral) at the same time as ZEN003694"
10198874|NCT02436707|Experimental|Ibrutinib plus R-GDP (ACCRUAL COMPLETE)|"Ibrutinib 560 mg PO -- D1 - D21~Rituximab 375 mg/m2 IV 1.5 - 6 hours D1 (prior to cisplatin)~Gemcitabine 1000 mg/m2 IV 30 min D1, D8~Dexamethasone 40 mg daily PO -- D1 - D4~Cisplatin 75 mg/m2 IV 1 hour D1"
9725842|NCT05071768|Experimental|ACT|Focused ACT Group Treatment
9725843|NCT05071469|No Intervention|Control Group (CG)|Patients in the control group which waiting an appointment for the physiotherapy program received no intervention.
9780817|NCT01132482|Experimental|Sildenafil|Subjects will receive escalating doses of sildenafil
9780818|NCT01132482|Placebo Comparator|Placebo|During the placebo arm, subjects receiving placebo will have sham dose escalation to maintain blinding.
9780819|NCT01132495|Other|Cohort A: PCI plus OMT|PCI plus optimal medical treatment
9981451|NCT04317417|Experimental|Condition 26|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
10198875|NCT02436707|Experimental|R-DICEP|"Rituximab 375 mg/m2 IV 1.5-6hrs Day 1 and Day 5 prior to Cisplatin~Mesna 1.75 g/m2 IV 24 hour Cycle 1, Day 2, Day 3 and Day 4~Cyclophosphamide, 1.75 g/m2 IV 2 hours, Day 2, Day 3 and Day 4~Etoposide 350 mg/m2 IV 2 hours, Day 2, Day 3 and Day 4~Cisplatin 35 mg/m2 IV, 2 hours, Day 2, Day 3 and Day 4~G-CSF 300 mcg (<60kg); 480 mcg (60-90kg); 600 mcg (>90kg); SC, Daily, starting Day 15 until apheresis completed."
10198876|NCT02436707|Experimental|Selinexor + R-GDP|"Selinexor - 40mg PO, D1, D3, D8~Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
9725844|NCT05071469|Experimental|Kinesiotaping Group (KG)|The first strip was a Y-strip for inhibition of the supraspinatus and was applied from its insertion to origo with paper-off tension. This strip was applied with the patient in a position of combining contra-lateral cervical side bending and the arm reaching behind the back. The second strip was an I-strip with Y shape at the end of tape. It was applied from the coracoid process around the posterior deltoid with approximately 50% to 75% tension and downward pressure applied for a mechanical correction.
9725845|NCT05071469|Experimental|Mulligan Mobilization Technique Group (MG)|The physiotherapist glided the humeral head in a postero-lateral-inferior direction with thenar eminence. The patient performed the offending movement while the glide was sustained. This movement should now become pain-free. Passive overpressure could be given by the patient at the end of the newly available range using his/her other hand. The hand of the physiotherapist should also move along with the movement in order to sustain the glide along the treatment plane. When the patient moved his/her shoulder, rotation of the scapula allowed upward. MT was applied 10 repetitions for each session, 30 sec rest period between sets, 4 sessions with 24 hours between 2 treatment seasons.
9725846|NCT05071430|Active Comparator|Active Treatment (HB-01)|Approximately 40 patients will receive HB-01 active study drug.
9725847|NCT05071430|Placebo Comparator|Placebo Treatment|Approximately 40 patients will receive a matched placebo.
9981452|NCT04317417|Experimental|Condition 27|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
9981453|NCT04317417|Experimental|Condition 28|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/Achievable Goals and 5) Acts of Kindness
9981454|NCT04317417|Experimental|Condition 29|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
9725848|NCT05068440|Experimental|Zanubrutinib|administered orally
9725849|NCT05068271|Experimental|Multi-Domain Exercise Program|"Time: 6 months, total of 180 min of exercise per week.~Intervention: aerobic training, muscular fitness training, balance, flexibility, meditation and social interaction."
9725850|NCT05068271|Active Comparator|Active Control Group|"Time: 6 months, total of 180 min of online educational course per week.~Intervention: educational materials relating to the effects of exercise on cognitive function and aging-related cognitive decline."
10198877|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
10198878|NCT02424019|Experimental|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
9981455|NCT04317417|Experimental|Condition 30|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
9725851|NCT05065944||Pre-Anesthesia Evaluation: Telemedicine|Pre-Anesthesia evaluation conducted remotely via video conferencing
9725852|NCT05065944||Pre-Anesthesia Evaluation: In person|Pre-Anesthesia evaluation conducted in person
9981456|NCT04317417|Experimental|Condition 31|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
9981457|NCT04317417|Experimental|Condition 32|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
9981458|NCT04309500|Experimental|African-American Participant-Co-Participant Dyads|5 Non-Hispanic African-American participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT).
9981459|NCT04309500|Experimental|White Participant-Co-Participant Dyads|5 Non-Hispanic White participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT)
9981460|NCT04286581|Experimental|Igel Larnygeal Mask Airway|Group 1 will receive the I-Gel Laryngeal Mask Airway for airway maintenance during general anesthesia
9981461|NCT04286581|Active Comparator|Ambu Auragain Laryngeal mask airway|Group 2 will receive the Ambu Auragain Laryngeal Mask Airway for airway maintenance during general anesthesia
10198879|NCT02422368|Experimental|Methylprednisolone + ASTED|"ASTED (Antioxidant Supplements for Thyroid Eye Disease) includes : B-Carotene (6 mg)+ Vit.C (200 mg) + Vit.E (200 mg) + Nicotinamide(20mg) + Selenium(200mic.) + Zinc oxide (8 mg) + Copper gluconate or oxide (1mg) + Manganese chloride (1.8 mg), Twice a day for 6 months~Methylprednisolone includes :~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow up."
10198880|NCT02422368|Placebo Comparator|Methylprednisolone + Placebo|Placebo Twice a day for 6 months Methylprednisolone prescribes as the same as arm 1
9725853|NCT05065866|Experimental|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of CC-486 in combination with Duvelisib in patients with lymphoid malignancy. Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 6 dose levels will be used.
9725854|NCT05065047|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over 30 minutes every 8 weeks
9725855|NCT05064722|Experimental|SNAP-S|Creation of a D-I diversion in participants undergoing primary sleeve gastrectomy (SNAP-S cohort)
10198881|NCT02420847|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|Patients receive ixazomib citrate PO, gemcitabine hydrochloride IV over 90 minutes, and doxorubicin hydrochloride IV over 15-30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10205448|NCT05206747|Sham Comparator|Lightly-tinted glasses|This control will involve glasses that selectively filter short wavelength (e.g., ultraviolet), but not visible blue light during the same time window. Participants will wear these glasses while awake from 6 p.m. to 8 a.m.
9780820|NCT01132495|Other|Cohort A: OMT alone|Optimal medical treatment alone
9725856|NCT05064722|Experimental|SNAP-PS|Creation of a D-I diversion in participants who have experienced inadequate weight loss following sleeve gastrectomy (SNAP-PS cohort)
9725857|NCT05064683|Experimental|white noise|The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
9725858|NCT05064683|Experimental|facilitated tucking|The newborns in the facilitated tucking were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.
9725859|NCT05064683|No Intervention|control|Newborns in the control group did not receive any treatment other than routine applications while receiving Nasal CPAP support in the neonatal intensive care unit.
9981462|NCT04283227|Experimental|OTL-200 Gene Therapy|OTL-200 is an autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
9981463|NCT04283071||Patient|Progressive MS patients administered clinical examination measures including EDSS, nine-hole PEG test, patient reported outcomes measures and kinematic assessment of upper limb function
9981464|NCT04283071||Control|Healthy volunteers administered nine-hole PEG test and kinematic assessment of upper limb function
9981465|NCT04268823|Experimental|QBW251|Oral use, one capsule twice daily.
9725860|NCT05063604|Experimental|Citalopram 20-40 mg|Participants received citalopram 20 mg tablet once or twice daily for 12 weeks.
9981466|NCT04268823|Placebo Comparator|Placebo|Oral use, one capsule twice daily.
9981467|NCT04266080|Experimental|childhood cancer survivors & and one parent/legal guardian|The study plans to recruit 30 childhood cancer survivors and a parent/legal guardian for each survivor. Participants will be provided with a Fitbit Inspire HR wearable device to record their step counts for two weeks pre-intervention, and over the six-month follow-up period (3-month intervention and 3month follow-up).
9981468|NCT04255784|Experimental|Active iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days. Each session will deliver 1800 pulses of active iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
9981469|NCT04255784|Sham Comparator|Sham iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days, using a sham coil that reproduces auditory and tactile sensations of stimulation and has an identical external appearance. Each session will deliver 1800 pulses of sham iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
10198882|NCT02402647|Experimental|CREST|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
9725861|NCT05063604|Experimental|Psychotherapy|Participants received one psychotherapy session weekly for 12 weeks.
9725862|NCT05063461||sevoflurane with remifentanil|patients receive standardized sevoflurane with different concentrations of remifentanil
9725863|NCT05060276|Experimental|STI-3258|Intravenous infusion to be given with prophylaxis for infusion reactions, evaluating up to five dose cohorts including: 8 mg/kg, 12 mg/kg, 16 mg/kg, 20 mg/kg, and 24 mg/kg.
9725864|NCT05060003|Experimental|Arm 1: Atezolizumab + Tiragolumab|"Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).~Tiragolumab is given as an IV infusion every 4 weeks at a dose of 840 mg over 60 minutes (+/- 15 minutes).~Treatment can continue for up to 13 cycles."
9725865|NCT05060003|Active Comparator|Arm 2: Atezolizumab|"Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).~Treatment can continue for up to 13 cycles."
9725866|NCT05058196|Other|Whole breast radiotherapy after surgery|WBRT will be delivered at 50 Grays (2 Grays x 25 fractions), 5 days/week for 5 weeks after breast surgery
9725867|NCT05058196|Other|Intra Operative Radiotherapy|IORT will be delivered at a single dose of 20 grays to the tumor bed during breast surgery
9725868|NCT05058196|No Intervention|no radiotherapy|No radiotherapy will be administrated to the patients during or after breast surgery
9725869|NCT05055921|Experimental|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
9725870|NCT05055427|Experimental|• Experimental: Investigational arm|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) and the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.
9725871|NCT05055427|No Intervention|• Controlled arm|Patients receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline
9780821|NCT01132495|Other|Cohort B|FFR > 0.80; treatment according to local practice
9780822|NCT01132508||Treatment|
9981470|NCT04248829|Experimental|Lazertinib + Gefitinib-matching placebo|Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule
9981471|NCT04248829|Active Comparator|Gefitinib + Lazertinib-matching placebo|Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule
9981472|NCT04248218|No Intervention|Normal/Control|Control Group/Standard Care
9981473|NCT04248218|Active Comparator|Active Rehabilitation Group/Case|Active Rehabilitation Cohort/Intervention
10198883|NCT02402647|Active Comparator|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
10198884|NCT02400242|Experimental|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
9725872|NCT05052333||Examining the psychosocial impacts of Covid-19 in Pakistan.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Urdu-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
9725873|NCT05052333||Examining the psychosocial impacts of Covid-19 in Iraq.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Arabic-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
9725874|NCT05052333||Examining the psychosocial impacts of Covid-19 in Turkey.|This is exploratory research and data will be obtained on a set of measures (N=500) using a unilingual (Turkish) survey with longitudinal assessment after 3 weeks of initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
9725875|NCT05052333||Examining the psychosocial impacts of Covid-19 in Bangladesh.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Bangla) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
10198885|NCT02393183|Experimental|ASTED|"Antioxidant Supplements for TED (ASTED):~to evaluate the effect of selected antioxidant vitamins and minerals supplement (Twice daily)~β- Carotene (3 mg)~Vit C (100 mg)~Vit E (Alpha-Tocopherol Acetate): 60 IU~Vit D (500 IU)~Zinc (4 mg, elemental)~Copper (0.5 mg, elemental)~Selenium 100 µg (as Sodium Selenite)"
10198886|NCT02393183|Active Comparator|Selenium|Selenium (100mic) Twice daily
9981474|NCT04245397|Experimental|Oral Dose of S-682|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
9981475|NCT04233814|Sham Comparator|Placebo|Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)
9725876|NCT05052333||Examining the psychosocial impacts of Covid-19 in Malaysia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a bilingual (Malay-English) survey. Data will be obtained longitudinally after 12 months of initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
9725877|NCT05052333||Examining the psychosocial impacts of Covid-19 in Indonesia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Indonesian) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
9981476|NCT04233814|Experimental|SAD Cohort 1|LTI-03 20 mg delivered qd x 1 day via DPI
9981477|NCT04233814|Experimental|SAD Cohort 2|LTI-03 40 mg delivered qd x 1 day via DPI
9981478|NCT04233814|Experimental|SAD Cohort 3|LTI-03 80 mg delivered qd x 1 day via DPI
10198887|NCT02393183|Placebo Comparator|Placebo|Placebo Twice daily
10198888|NCT02379520|Experimental|Group A|HPV Specific T Cells
10198889|NCT02379520|Experimental|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
10198890|NCT02359838|Other|Usual Care|Frail/pre-frail hematologic oncology patients receive usual care
10198891|NCT02359838|Active Comparator|Geriatrician Co-Management|Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician
10198892|NCT02354131|Experimental|Niraparib monotherapy|Niraparib mono therapy until progression
10198893|NCT02354131|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
9725878|NCT05052333||Examining the psychosocial impacts of Covid-19 in Somalia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Somalia-English) longitudinally. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
9725879|NCT05051306|Experimental|High-load resistance exercise|4 high-load resistance exercises that target all major muscle groups.
9725880|NCT05051306|Experimental|Low-load resistance exercise|4 low-load resistance exercises that target all major muscle groups.
9725881|NCT05051306|No Intervention|Sedentary control|Subjects in control trial stayed sedentary during the period.
9725882|NCT05049590|Experimental|Intervention Group|Perform blood conservation in the operating room (OR).
9725883|NCT05049590|No Intervention|Control Group|Blood conservation will not be performed in the OR.
9725884|NCT05048459|Active Comparator|Standard surveillance|This surveillance approach involves the participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
9981479|NCT04233814|Experimental|MAD Cohort 1|LTI-03 dose at 20mg once daily x 14 days via DPI
9981480|NCT04233814|Experimental|MAD Cohort 2|LTI-03 dose at 40mg once daily x 14 days via DPI
9981481|NCT04233814|Experimental|MAD Cohort 3|LTI-03 dose at 2.5 mg once daily x 14 days via DPI
9981482|NCT04233814|Experimental|MAD Cohort 4|LTI-03 dose at 5 mg once daily x 14 days via DPI
9981483|NCT04233814|Experimental|MAD Cohort 5|LTI-03 dose at 5 mg twice daily x 14 days via DPI
9981484|NCT04232761||CRPC patients|Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan
9981485|NCT04232059|Active Comparator|Group 1: hyperventilation|• Group 1: hyperventilation (ETco2 25-30 mm Hg) for 20 minutes that will start immediately after skin incision followed by normoventilation (ETco2 31-35 mm Hg) for another 20 minutes.
9725885|NCT05048459|Experimental|Telemedicine surveillance (tele-surveillance)|Tele-surveillance involves the participant staying at home while their healthcare providers follow their condition and give them the care they need. They can communicate with their healthcare team through face-to-face video conferencing on their desktop computer, laptop, smart phone, or tablet. They can also communicate with their healthcare team by phone.
9981486|NCT04232059|Active Comparator|Group 2: normoventilation|• Group 2: normoventilation (ETco2 31-35 mm Hg) for 20 minutes immediately after skin incision followed by hyperventilation (ETco2 25-30 mm Hg) for another 20 minutes.
9981487|NCT04225156|Experimental|efgartigimod|patients receiving efgartigimod
9981488|NCT04215146|Active Comparator|Cohort 1|Patients receive paclitaxel alone.
9725886|NCT05046002||Prospective (cases)|Patients who develop new symptoms of suspected myocarditis/pericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath, or pain with breathing; palpitations; diaphoresis or sudden death. The symptoms can also be non-specific, including fatigue, abdominal pain, dizziness or syncope, edema, cough or irritability, vomiting, poor feeding, tachypnea or lethargy in young children
9725887|NCT05046002||Prospective (Control Positive)|Family members/relatives who have been vaccinated in a similar timeframe with the participant and had similar reactions
9725888|NCT05046002||Prospective (Control Negative)|"Family members/relatives who have been vaccinated in a similar timeframe with the participants but did not experience myocarditis side-effects.~If a relative is not available, then a voluntary control who has received the same COVID-19 vaccine in a similar time frame can be recruited."
9725889|NCT05046002||Retrospective|Identified patients, previously diagnosed with the condition, at participating centers
9725890|NCT05040568|Experimental|Cetuximab|given to patients with high-risk colorectal cancer
9780823|NCT01132547|Experimental|Arm I cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
9981489|NCT04215146|Experimental|Cohort 2|Patients receive pelareorep + paclitaxel.
10198894|NCT02347202|Experimental|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
10198895|NCT02347202|Other|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
10198896|NCT02335944|Experimental|Phase IB part- NSCLC with EGFR activating mutations|NSCLC participants who have previously documented EGFR mutation and progressed on EGFR TKI treatment
9981490|NCT04215146|Experimental|Cohort 3|Patients receive pelareorep + paclitaxel + avelumab.
9981491|NCT04212286|Experimental|Diagnostic CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions with Diameters ≤ 2cm will receive CEUS and EOB-MRI examinations.
9981492|NCT04208971||BEAGLE Participants|Adult patients who have not been previously diagnosed with AF, are eligible for anticoagulation and have AI-predicted risks based on a normal sinus rhythm ECG.
9981493|NCT04192357|Experimental|M3F program|Participants will receive the M3F program. The M3F program is divided into three phases method, being the first two of weight loss and the third phase of weight maintenance.
9981494|NCT04192357|Active Comparator|Low-carb diet|Participants will receive the low-carb diet program. The low-carb diet program is divided into two phases method, being the first of weight loss which follows a low carb diet, and a second phase of weight maintenance.
9981495|NCT04188379|Experimental|efgartigimod|Patient receiving efgartigimod
9981496|NCT04188379|Placebo Comparator|Placebo|Patients receiving placebo
9981497|NCT04182373|Experimental|KW-3357|72 IU/kg
9981498|NCT04182373|Placebo Comparator|placebo|
9981499|NCT04161495|Experimental|Prophylaxis|Participants will receive BIVV001 once-weekly (QW) during a prophylaxis treatment regimen for 52 weeks
10198897|NCT02335944|Experimental|Phase II- Group 1 (EGFRmut, any T790M, any MET, 2/4L antineoplastic, EGFR TKI resistant)|NSCLC participants with previously documented activating EGFR mutation, with any T790M and MET dysregulation status, who received one to three lines of systemic antineoplastic therapy prior to study entry including one line maximum of first or second generation EGFR TKI and who progressed on this EGFR TKI treatment line.
10198898|NCT02335944|Experimental|Phase II- Group 2 (EGFRmut, de novo T790M, any MET, 1/3L antineoplastic, EGFR TKI naïve)|NSCLC participants harboring T790M mutation in de novo setting, irrespective of the activating mutation status who are treatment naïve or received maximum 2 lines of systemic antineoplastic therapy prior to study entry, but no therapy known to inhibit EGFR.
9981500|NCT04161495|Experimental|On Demand|Participants will receive BIVV001 on demand for 26 weeks, followed by a switch to a prophylaxis treatment regimen with BIVV001 for 26 weeks.
9981501|NCT04155216|Experimental|Guided imagery|Relaxation and guided imagery program
9981502|NCT04141423|Active Comparator|Tregopil 30 mg|Dose level cohort with a sentinel dosing design
9981503|NCT04141423|Active Comparator|Tregopil 45 mg|Dose level cohort with a sentinel dosing design
9981504|NCT04141423|Active Comparator|Tregopil 60 mg|Dose level cohort with a sentinel dosing design
9981505|NCT04141423|Active Comparator|Derived Dose level|Derived Dose level cohort with a sentinel dosing design (60 mg fixed preprandial dose plus an additional 30 mg postprandial rescue dose, if required)
9981506|NCT04131738|Experimental|Baricitinib 2 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice~Baricitinib will be administered PO at a starting dose of 2 mg daily from Day -3 to Day 100~After Day 100, for patients already dose reduced to 2 mg daily, reduce baricitinib to 2 mg every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
9981507|NCT04131738|Experimental|Baricitinib 4 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice~Baricitinib will be administered PO at a starting dose of 4 mg daily from Day -3 to Day 100~After Day 100, for patients at a dose of 4 mg daily, reduce baricitinib to 2 mg daily for one month, then every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
9981508|NCT04130165|Experimental|Matched donor human milk|Infants randomized to the matched donor human milk arm, will receive donor human milk which is matched to their mother's secretor status.
9981509|NCT04130165|No Intervention|Standard issue donor human milk|Infants randomized to the standard issue donor human milk arm, will receive donor human milk which is prepared without consideration of secretor status as per standard practice.
9981510|NCT04120220|Experimental|Heavy Cream|Participants will receive a meal containing 30 g of fat prepared with heavy cream.
9981511|NCT04120220|Experimental|Soybean Oil|Participants will receive a meal containing 30 g of fat prepared with soybean oil.
9981512|NCT04111107|Experimental|Drug Administration Based on Next Gen Sequencing Report|Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.
9981513|NCT04104672|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The dose expansion dose level will be determined in this part with escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose (RP2D) and the standard nab-paclitaxel and gemcitabine chemotherapy regimen in participants with advanced pancreatic cancer.
9981514|NCT04104672|Experimental|Dose Expansion(AB680+Zimberelimab+nab-paclitaxel(NP) & gemcitabine (Gem):Cohort A1 (front-line/1L)|Participants with advance pancreatic cancer, naïve to any prior treatment will receive AB680 (at the RP2D identified during dose escalation) combined with Zimberelimab and the standard nab-paclitaxel (NP) and gemcitabine (Gem) (NP/Gem) chemotherapy regimen
9981515|NCT04104672|Experimental|Dose Expansion (AB680 + NP/Gem): Cohort A2 (front-line/1L)|Participants with advance pancreatic cancer who are naïve to any prior treatment will receive AB680 (at the RP2D identified during dose escalation) and the standard NP/Gem chemotherapy regimen.
9981516|NCT04104672|Experimental|Dose Expansion (AB680 + Zimberelimab + NP/Gem): Cohort B (second-line/2L)|Participants with advance pancreatic cancer who have received 1 prior line of treatment will receive AB680 (at the RP2D identified during dose escalation) combined with Zimberelimab and NP-Gem chemotherapy regimen.
9981517|NCT04099888|Experimental|PCI treatment in conjunction with Standard of Care (SoC)|Arm A: Fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by gemcitabine/cisplatin chemotherapy
9981518|NCT04099888|Active Comparator|Standard of Care (SoC)|Arm B: Gemcitabine/cisplatin chemotherapy
9981519|NCT04093596|Experimental|ALLO-647, ALLO-715, Nirogacestat|
9981520|NCT04076618|Experimental|Weight Loss plus Vest|
9981521|NCT04076618|Active Comparator|Weight Loss Plus Resistance Exercise Training|
9981522|NCT04076618|Active Comparator|Weight Loss|
9981523|NCT04072393|Experimental|Home-based cardiac rehabilitation|"The intervention consists of a prescribed course of home-based cardiac rehabilitation: 36 sessions, three times a week, one hour each, over a period of 12 weeks.~Each customized exercise session includes three phases:~a 5- to 10-minute warm-up which consists of stretching, flexibility movements, and aerobic activity which gradually raises the heart rate to the desired level~a conditioning or training phase, which consists of 20 to 45 minutes of continuous or discontinuous aerobic activity~a cool down for 5 to 10 minutes consisting of low-intensity exercise that permits a gradual recovery from the conditioning phase~The patient will complete a brief questionnaire on the teleHeart application after completing each exercise session on how well they tolerated the exercise. The patient's CR team will receive daily updates from the patient's teleHeart application. Based on feedback from the application, the CR team may modify the patient's exercise program going forward."
9981524|NCT04068012|Experimental|Intervention|Ventilator management using the proposed protocol in both acute and weaning phases
9981525|NCT04059484|Experimental|Amcenestrant|Daily amcenestrant dose administered orally under fed or fast condition
9981526|NCT04059484|Active Comparator|Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator|"Control treatment of the choice of the physician depending on each participant's medical condition and in accordance with the approved label may include 1 of the following treatments used as monotherapy.~Fulvestrant~Aromatase inhibitors (anastrozole, letrozole, exemestane)~Selective estrogen receptor modulator (Tamoxifen)"
9984601|NCT03924167|Experimental|Families Receiving Weaving Healthy Families Intervention|The Weaving Healthy Families curriculum is a cognitive-behavioral, support group model for high-risk families related to alcohol, tobacco, or other drugs (ATOD) and/or or domestic violence, child abuse, or neglect. This curriculum is tailored for all ages (i.e., (a) parents/caregivers; (b) early childhood (4-7); (c) children (8-10); and (d) adolescent (11-18) and is aimed at reducing alcohol and other drug (AOD) abuse, promote unity, address mental health problems, strengthen parenting skills, and bolster wellness and resilience.
9984602|NCT03924167|No Intervention|Families who have not yet receive the Weaving Healthy Families|Baseline group --data will be collected prior to receiving the intervention in this stepped-wedge trial design.
9725891|NCT05036590|Active Comparator|Control group|"The design is a stepped-wedge cluster randomized controlled trial. The study will be conducted in 9 centers (clusters) and will be conducted in 6 successive phases of 4 months each.~During the first period, groups will be in the control period, then sequentially and according to a randomly defined order, at each time, one group will go into the intervention period after a transition period of 4 months allowing the intervention to be deployed (training of three health professionals for each center and then implementation of the BREF program).~Thus, each cluster will belong successively to the control group and the intervention group. During the control period, caregivers will be supported according to the usual practices of each center. During the intervention period, the BREF program will be offered to all eligible caregivers."
10198899|NCT02335944|Experimental|Phase II- Group 3 (EGFRmut, T790M negative, any MET, 1L antineoplastic)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, and any MET status who never received any prior line of systemic antineoplastic systemic therapy prior to study entry.
9981527|NCT04056689|Experimental|DNL151 Low Dose|
9981528|NCT04056689|Experimental|DNL151 Mid Dose|
9981529|NCT04056689|Experimental|DNL151 High Dose|
9981530|NCT04056689|Placebo Comparator|Placebo|
9981531|NCT04051229|Experimental|Exercise Training Group|All 20 participants will be assigned to this arm. These individuals will participate in 6 weeks of a moderate supervised aerobic exercise training program.
9981532|NCT04032418|Active Comparator|Arm I (200mg pembrolizumab 3 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
9725892|NCT05036590|Experimental|intervention group|Thus, each cluster will belong successively to the control group and the intervention group. During the intervention period, the BREF program will be offered to all eligible caregivers.
9725893|NCT05036538|Experimental|Relaxation intervention with natural sounds|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
9725894|NCT05036538|Experimental|Relaxation intervention with natural sounds and binaural beats|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
9725895|NCT05036538|Experimental|Relaxation intervention with natural sounds and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
9725896|NCT05036538|Experimental|Relaxation intervention with natural sounds, binaural beats and virtual reality|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
9725897|NCT05036538|No Intervention|Control without Intervention|
9725898|NCT05036317|Experimental|Empagliflozin|Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg. Empagliflozin is an orally available inhibitor of SGLT2 and approved for the treatment of type 2 diabetes mellitus and will be given per os once daily in the morning for 28 days.
9725899|NCT05036317|Placebo Comparator|Placebo|Placebo provided by Boehringer Ingelheim Switzerland. Per os once daily in the morning for 28 days.
9725900|NCT05036044||With moderate or severe carotid-cerebral artery disease|moderate (stenosis 50-69%) or severe (stenosis 70-100%) carotid-cerebral artery disease
9725901|NCT05036044||Without moderate or severe carotid-cerebral artery disease|mild (stenosis 30-49%) or no (stenosis 0-29%) carotid-cerebral artery disease
9725902|NCT05034367|Experimental|Healthy persons|The responses of the healthy subjects are utilized to create reference ranges for a normal cough response to mannitol
9725903|NCT05026957|Active Comparator|Control group|Participating in regular cardiac rehabilitation
9725904|NCT05026957|Experimental|Intervention|Participating in regular cardiac rehabilitation + using the shared-decision making application
9725905|NCT05026905|Other|GASL arm|"eligible patients will receive gemcitabine 800 mg/m2 on day 1, nab-paclitaxel 125 mg/m2 on day 1, S-1 orally 60-100 mg/day [depending on patient's baseline body surface area (BSA)] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~BSA < 1.25 m2: 60 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day~BSA ≥ 1.5 m2: 100 mg/day"
9725906|NCT05026905|Other|GAP arm|eligible patients will receive gemcitabine 800 mg/m2, nab-paclitaxel 125 mg/m2 and oxaliplatin 75mg/m2 on day 1 in a 2-week cycle.
9725907|NCT05025397|Experimental|Cohort A1: Danavorexton Low Dose|Danavorexton low dose or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
9725908|NCT05025397|Experimental|Cohort A2: Danavorexton Middle Dose|Danavorexton middle dose or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
9780824|NCT01132547|Placebo Comparator|Arm II placebo|Patients receive an oral placebo twice daily for 8 weeks.
9981533|NCT04032418|Experimental|Arm II (200mg pembrolizumab 12 weeks)|Patients receive 200mg pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
9981534|NCT04023162|Experimental|Biomedical (Physiotherapy) group|Therapy Exercise and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
9981535|NCT04023162|Experimental|Biopsychosocial (Graded Activity) group|Operant Conditioning implement in Physiotherapy, Therapy Exercises and Back School; 8 sessions during 4 weeks (2 times a week), with one session lasting 60 min.
9981536|NCT04023162|No Intervention|Usual care|Usual care and written instructions on Therapy Exercise and Back School for self-care.
9981537|NCT04002388|Experimental|Activity Monitor Group|This arm will receive a FitBit and will be asked to wear this for one year
9981538|NCT04002388|Active Comparator|Usual Care Group|The usual care group will NOT receive a FitBit
9981539|NCT03993821|Experimental|Burosumab|Burosumab, which is FDA-approved for X-linked hypophosphatemic rickets, will be given monthly, for a total of 12 months and titrated to achieve a target fasting serum phosphorus level within normal range for age. The chosen starting dose of burosumab will be 0.3 mg/kg given SQ Q4W. The maximum dose allowed in this protocol is 2.0 mg/kg. Burosumab will be administered via subcutaneous (SC) route.
9981540|NCT03982693|Active Comparator|Active|edetate disodium (EDTA)dff active infusion
10198900|NCT02335944|Experimental|Phase II- Group 4 (EGFRmut, any T790M, any MET, 1L (treatment naïve) 2-3L antineoplastic)|NSCLC participants with previously documented EGFR activating mutations and any T790M and MET status who were treatment naïve or failed maximum 2 prior lines of any systemic antineoplastic therapy for advanced disease.
9725909|NCT05025397|Experimental|Cohort A3: Danavorexton High Dose|Danavorexton high dose or danavorexton placebo-matching infusion, single, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
9725910|NCT05025397|Experimental|Cohort P: Danavorexton TBD|"Danavorexton dose to be decided (TBD) or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction and primary maintenance anesthetic.~Dose of danavorexton will be based on the review of observed safety and tolerability data and pharmacokinetic (PK) data of previous cohorts."
9725911|NCT05025280||hearing loss|According to the audiological test results, individuals with a pure tone average of more than 25 dB in the better ear and with less than 10 dB difference between the air-bone conduction thresholds
9725912|NCT05025280||normal hearing|According to the audiological test results, individuals with a pure tone average of 25 dB or less in both ears and with less than 10 dB difference between the air-bone conduction thresholds
9725913|NCT05020769|Experimental|SI-B001 combined with osimertinib_A|Patients with locally advanced/metastatic NSCLC progressed on 3rd generation EGFR-TKI treatment.
9725914|NCT05020769|Experimental|SI-B001 combined with osimertinib_B|Patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment and with T790M negative mutation.
9725915|NCT05020769|Experimental|SI-B001 combined with osimertinib_C|Patients with locally advanced/metastatic NSCLC and with EGFR exon20ins mutation.
9725916|NCT05019638|Active Comparator|Regional anesthesia group|Standard single-shot anesthesia consists of bupivacaine 0.25% with epinephrine 1:400,000.
9725917|NCT05019638|Experimental|Local multimodal analgesia group|Local multimodal analgesia composition will include 5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
9725918|NCT05018884||Patients without SSI|Patients who underwent surgery and who developed a surgical site infection (SSI) during 30 days after surgery
9725919|NCT05018884||Patients with SSI|Patients who underwent surgery and who didn't develop a surgical site infection (SSI) during 30 days after surgery
9725920|NCT05016609|Experimental|POC HCV antibody group (Arm A)|This group will receive POC HCV antibody testing via fingerprick using the OraQuick HCV antibody test (OraSure) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
9725921|NCT05016609|Experimental|POC HCV RNA group (Arm B)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will receive POC HCV viral load testing via fingerstick using the Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
9981541|NCT03982693|Placebo Comparator|Placebo|Placebo infusion
9981542|NCT03972930|Experimental|Hypofractionated Radiotherapy for Soft Tissue Sarcoma|Participants will be treated with 3-8 fractions, with the maximum prescribed dose to the Planning Tumor Volume (PTV) volume being 60 Gy delivered over a period of at most 8 weeks.
9981543|NCT03972488|Experimental|Lutathera plus long-acting octreotide|
9981544|NCT03972488|Active Comparator|high dose long-acting octreotide|
10198901|NCT02335944|Experimental|Phase II- Group 5 (EGFRmut, T790M-, MET GCN≥5, 2L, EGFR TKI resistant)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, acquired MET amplification who have progressed on one prior line of therapy for advanced/metastatic NSCLC disease.
10198902|NCT02333162|Experimental|Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60."
9780825|NCT01132612|Experimental|Fixed-time interval regimen|Secukinumab 150 mg subcutaneous (sc) administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter
9981545|NCT03964545|Experimental|EFP neurofeedback|Ten sessions of EFP neurofeedback training. EEG is picked up with scalp electrodes, processed in real-time and returned to patients. One session lasts 30 min.
9981546|NCT03964545|No Intervention|Treatment as usual|Like patients from the treatment arm, these patients are on current residential treatment.
9981547|NCT03959735|Experimental|High Intensity Interval Training (HIIT)|"50% of participants (inpatients with a diagnosis of severe mental illness) will be randomised to HIIT. HIIT will be conducted twice a week for 12 weeks using a stationary bike. Each session will have the following structure: 4-minute warm-up, followed by 5X1 minute intervals at 85-95% of maximum heart rate, interspersed with active pauses of 90 seconds cycling at approximately 60-70% of maximum heart rate, and a 4-minute cool-down. Each exercise session will take 19 minutes to complete (11 minutes of HIIT + warm-up and cool-down). However, the amount of HIIT will be adapted for people who may be unable to complete the above target and gradually build up until they can complete the recommended amount.~All exercise sessions will be conducted in a 1:1 environment with a participant and a member of the research team who will supervise the exercise session."
9981548|NCT03959735|No Intervention|Treatment As Usual (TAU)|50% of participants will be randomised to TAU. They will be provided with details of the local hospital gym availability and instructed to maintain their usual dietary habits
9725922|NCT05016609|Experimental|Test and treat group (ArmC)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will be provided a starter pack of HCV treatment (epclusa). POC tests results will be confirmed through standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. HCV RNA positive participants will continue treatment. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
9725923|NCT05016609|No Intervention|Control|This group will receive the standard of care for HCV testing and treatment. Participants in this group will fill out a short behavioural questionnaire and a clinical questionnaire.
9780826|NCT01132612|Experimental|Treatment at start of relapse regimen|Placebo administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter. If relapse, then switch to secukinumab 150 mg sc administered every 4 weeks
9780827|NCT01132612|Experimental|Open-label|Secukinumab 150 mg sc administered every 4 weeks
9780828|NCT01132651|Experimental|Chillow cooling pillow|This group of subjects will follow their current eczema regimen with the addition of using the cooling pillow at night to sleep on.
9780829|NCT01132651|Placebo Comparator|Standard of care (regular pillow at night)|This group of subjects will serve as the control group following a their current eczema care regimen, including sleeping on their normal pillow.
9780830|NCT01132664|Experimental|HER2+ metastatic breast cancer|Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
9780831|NCT01132664|Experimental|HER2+ metastatic breast cancer with BM|Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
9780832|NCT01132690|Experimental|30 units/kg|
9780833|NCT01132690|Experimental|60 units/kg|
9780834|NCT01132755|Experimental|Patients who require diagnostic laparoscopy|Diagnostic peritoneal lavage will be performed at the time of laparoscopy utilizing a Veress needle/Seldinger technique to insert a peritoneal dialysis catheter. This is not a new technique. The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon.
9780835|NCT01132807|Experimental|Treatment (chemotherapy and F-18 PET/CT)|See Detailed Description
9780836|NCT01132820|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9780837|NCT01132846|Active Comparator|Low dose Dopamine|"Drug: Dopamine~Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study"
9780838|NCT01132846|Placebo Comparator|Placebo|Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
10198903|NCT02318342|Experimental|Pre-existing bioprosthetic aortic valve|Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
10198904|NCT02316184|Placebo Comparator|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
9780839|NCT01132846|Active Comparator|Low Dose Nesiritide|Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
10198905|NCT02316184|Active Comparator|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
10198906|NCT02306122|Experimental|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
9981549|NCT03951454|Experimental|Conexiones|5 telephone sessions of Conexiones, with each session delivered 2 weeks apart across a total period of 8 weeks
9981550|NCT03951454|Other|Taking Time|1 telephone session consisting of a scripted protocol guiding participants through the NCI's Taking Time Booklet.
9981551|NCT03945292|Experimental|ARO-AAT|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 15 total doses."
9780840|NCT01133158|Experimental|R-BMD|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years
9780841|NCT01133171|Experimental|Dashboard Plus Nurse|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling plus a computerized dashboard intervention.
9780842|NCT01133171|Experimental|Nurse Alone|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling.
9780843|NCT01133171|No Intervention|Control|Patients randomized to this group were followed retrospectively to collect data on their primary care visits and laboratory results and past medical history over the 12 month study period. They had no contact with study personnel and did not receive any type of intervention.
9780844|NCT01133275|Experimental|Lenalidomide and Prednisone Therapy|All participants received lenalidomide and prednisone therapy for 6 cycles (24 weeks). Each cycle is 28 days (4 weeks).
9780845|NCT01133379|Experimental|PO-019|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride (12027-019)
9780846|NCT01133379|Experimental|PO-020|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride (12027-020)
9981552|NCT03945292|Placebo Comparator|Placebo|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 15 total doses."
9981553|NCT03937713|Experimental|BBTI plus eszopiclone|participants randomized to the combination therapy will receive eszopiclone 2 mg orally at bedtime or placebo starting with the BBTI sessions for a period of 2 weeks in combination with 4 sessions of BBTI over 4 weeks.
9725924|NCT05016271|Experimental|True air purifier group|Children in this group will receive an intervention of air purifiers with high-efficiency particulate air (HEPA) filters.
10198907|NCT02306122|Experimental|Information patient default doctor|Patient nonadherence information sent to physician
10198908|NCT02306122|No Intervention|Control patient default doctor|Control - no intervention
10198909|NCT02306122|Experimental|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
10198910|NCT02306122|Experimental|Information patient choice doctor|Patient nonadherence information sent to physician
9725925|NCT05016271|Sham Comparator|Sham air purifier group|Children in this group will receive an intervention of air purifiers without high-efficiency particulate air (HEPA) filters.
9725926|NCT05015088||Gastrocnemius Stretching Group|The study will enroll 20 healthy subjects between the ages of 18 to 65 years old. Individuals will be recruited from multiple locations. Exclusion criteria include: any boney or tendinous foot/ankle operative procedure, diagnosis of neuromuscular disorder, any previous ankle fracture or degenerative changes that would limit dorsiflexion range of motion. Participants must have no obvious gait asymmetries demonstrated through observation. In addition, participants who are pregnant will be excluded from participation in the study.
9725927|NCT05014659|Experimental|Creatine monohydrate|Participants received 4 x 5g doses of creatine monohydrate (powdered form) for 5 days, followed by 1 x 5g doses of creatine monohydrate (powdered form) for 23 days.
9725928|NCT05014659|Placebo Comparator|Placebo|Participants received 4 x 5g doses of placebo (powdered Maltodextrin) for 5 days, followed by 1 x 5g doses of placebo (powdered Maltodextrin) for 23 days.
9725929|NCT05013216|Experimental|KRAS peptide vaccine|
9725930|NCT05010733|Experimental|Thick-Layer Technique|Total hip arthroplasty using the Exeter V40 cemented femoral stem [Stryker Orthopaedics, Mahwah, New Jersey].
9981554|NCT03937713|Active Comparator|BBTI|participants randomized to BBTI will receive 4 sessions of BBTI over 4 weeks.
9981555|NCT03871751|Experimental|Safe and Sound Protocol|All child participants will participate in 1 pre-intervention assessment and 1 post-intervention assessment. The auditory intervention (i.e., Safe and Sound Protocol, SSP) will last for 1 hour per day, for 5 consecutive days.
9981556|NCT03817502|Experimental|Cariprazine 1.5 mg/d|Cariprazine capsules, oral administration, once daily.
9981557|NCT03817502|Experimental|Cariprazine 4.5 mg/d|Cariprazine capsules, oral administration, once daily.
9981558|NCT03817502|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
9725931|NCT05010733|Active Comparator|Thin-Layer Technique (French Paradox)|Total hip arthroplasty using the Müller Straight Stem [Zimmer, Winterthur, Switzerland].
9981559|NCT03816683||Single cohort (registry) of MCL patients|Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 6 months and treatment is ongoing at the time of enrollment.
9981560|NCT03810768||Intensive Care Patients|Postoperative high-risk patients who have been admitted to intensive care after surgery
9981561|NCT03800602|Experimental|Treatment (nivolumab, metformin)|Patients receive metformin PO BID starting on day 1. After 14 days of metformin only period patients also receive nivolumab IV every 4 weeks starting on day 15. Courses repeat every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity or consent withdrawal.
10198911|NCT02306122|No Intervention|Control patient choice doctor|Control - no intervention
10198912|NCT02306122|Experimental|Information patient information doctor|Patient nonadherence information sent to physician
10198913|NCT02306122|No Intervention|Control patient information doctor|Control - no intervention
10198914|NCT02306122|Experimental|Information doctor|Physician receives nonadherence information, but there is no opportunity for pharmacist action
10198915|NCT02306122|Experimental|Choice doctor|Physician receives nonadherence information, and can choose to request pharmacist action
10198916|NCT02306122|Experimental|Default doctor|Physician receives nonadherence information; pharmacist action will be triggered unless physician cancels action
10198917|NCT02304991|Experimental|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
9725932|NCT05009927|Experimental|Imatinib interruption|Immediate interruption of imatinib until progressive disease. In case of 1st relapse, imatinib will be reintroduced at 400mg/d and further increased at 800mg/d in case of 2nd relapse after re-introduction.
9725933|NCT05009927|No Intervention|Imatinib maintenancce|Maintenance of imatinib at the last dose routinely taken by the patient in the 10-year period prior to randomization (either 300 or 400 mg once daily). In case of progressive disease imatinib will be increased up to 800mg/day.
9725934|NCT05005559|Experimental|Vaccine candidate|
9981562|NCT03773523|Experimental|Experimental: active tDCS|Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
9981563|NCT03773523|Sham Comparator|Sham Comparator: sham tDCS|Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function. There will be a total of 5 sham tDCS sessions.
9981564|NCT03741335|Experimental|Strength Training|Participants wear a weighted vest while performing exercises using functional movement patterns used in everyday activities (chair rises, 90° squats, side-to-side squats, toe raises, lunges (forward, lateral, backward, walking), multi-directional step ups). Participants attend supervised, group-based moderate-intensity strength training program remotely 3 times per week for 60 minutes per session.
9981565|NCT03741335|Active Comparator|Stretching Control|Participants attend a supervised flexibility program where they will perform a series of whole body stretching exercises with a focus on developing and maintaining a healthy back. Participants attend a supervised, group-based supervised flexibility program remotely 3 times per week for 60 minutes per session.
10198918|NCT02304991|Placebo Comparator|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
9981566|NCT03741335|Experimental|Tai Ji Quan Training|An integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements. Participants attend a supervised, group-based tai ji quan program remotely where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
9981567|NCT03735849|No Intervention|Pre-treatment|Biopsy collected but was not randomized to any treatment group
9725935|NCT05005559|Placebo Comparator|Saline placebo|
9725936|NCT05004259|Experimental|Arm 1|Six weekly doses of subcutaneous daratumumab 1,800mg and hyaluronidase 30,000U.
9725937|NCT05002816|Experimental|Belantamab Mafodotin and Elotuzumab Arm|"Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.~Belantamab mafodotin will be administered via IV infusion. There will be 2 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested. ."
9725938|NCT05001958|Experimental|Action observation|
9725939|NCT05001711|Experimental|WHO Group 2|
9981568|NCT03735849|Experimental|Group 1: VRC07-523LS|Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
9981569|NCT03735849|Experimental|Group 2: VRC07-523LS|Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
9981570|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)|
9981571|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)|
9981572|NCT03725345|Experimental|Alcohol Group|Participants will consume an alcoholic beverage consisting of a 1:5 ratio of 95% ethyl alcohol and orange juice
9981573|NCT03725345|Placebo Comparator|Placebo Group|Participants will consume a placebo beverage of orange juice
9981574|NCT03708159|Experimental|active tDCS + mindfulness meditation|Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
9981575|NCT03708159|Sham Comparator|sham tDCS + mindfulness meditation|Participants randomized to this group will receive sham tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
9981576|NCT03703297|Experimental|Durvalumab + Placebo|Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.
9984603|NCT03915327|Experimental|Intravenous iron group|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
10205449|NCT05206734||Cases|All incident cases of Inflammatory Bowel Disease (IBD); comprising of Ulcerative Colitis, Crohn's Disease and IBD Unclassified in children, adolescents and young adults up to their 25th birthday. Cases will be defined based on an algorithm using diagnostic codes from the electronic medical record (EMR).
9725940|NCT05001711|Experimental|WHO Group 3|
9725941|NCT05000632|Experimental|Smoke Free SafeCare (SFSC)|Providers randomized to this group will receive additional SFSC training and will disseminate SFSC program to families who report having a smoker in the home.
9725942|NCT05000632|Active Comparator|Standard SafeCare|Providers randomized to this group will disseminate the Standard SafeCare program to families who report having a smoker in the home.
9725943|NCT05000515|Experimental|High-resistance inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
9725944|NCT05000515|Active Comparator|Aerobic exercise|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
9725947|NCT04998539|Experimental|Upright wheelchair forward and occupant upright|Participant will push an upright wheelchair forward over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
9725948|NCT04998539|Experimental|Upright wheelchair backward and occupant upright|Participant will pull an upright wheelchair backwards over a 5 m soft surface with the wheelchair occupant in the upright body position. The participant will perform the task once.
9725949|NCT04998539|Experimental|Wheelie wheelchair forward and occupant upright|Participant will push a wheelchair using the wheelie technique forward over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
9725950|NCT04998539|Experimental|Wheelie wheelchair backward and occupant upright|Participant will pull a wheelchair using the wheelie technique backwards over a 5 m soft surface with the wheelchair occupant in the upright body position.The participant will perform the task once.
9725951|NCT04997941|Experimental|Tamoxifen 40mg|Tamoxifen 20mg b.i.d - Participants will be treated for 14 days.
9725952|NCT04997941|Active Comparator|Tamoxifen 20mg|Tamoxifen 10mg b.i.d - Participants will be treated for 14 days.
9780847|NCT01133379|Sham Comparator|PO-021|Vehicle Control Mouthrinse (without potassium oxalate and without fluoride) (12027-021)
9780848|NCT01133392|Experimental|Insulin Lispro A|20 units (U) subcutaneously (SC)
9780849|NCT01133392|Active Comparator|Insulin lispro B|20 units (U) subcutaneously (SC)
9780850|NCT01133405|Experimental|LY2886721 Part 1: Cohort A/B|Single (7 milligram (mg), 15 mg, 25 mg, 35 mg) doses of LY2886721 administered orally in up to three of three study periods
9780851|NCT01133405|Placebo Comparator|Placebo Part 1: Cohort A/B|Single dose in up to 1 period
9981577|NCT03703297|Experimental|Durvalumab + Tremelimumab|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.
9981578|NCT03703297|Placebo Comparator|Placebo + Placebo|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
9981579|NCT03699553|Experimental|Intervention|Participants will receive the online LARKSPUR intervention which lasts about 5-6 weeks, receiving the positive emotions skills through the website, and logging on to the website for about 5-10 minutes each day for that period. Assessments will be taken at baseline, post-intervention (8 weeks after the baseline), and 12 weeks after baseline (1 month post intervention).
9981580|NCT03699553|Active Comparator|Emotion Reporting Control|Participants will report their emotions for 5-6 weeks by logging on to the website for about 5 minutes each day. Assessments will be taken at baseline, 8 weeks after baseline, and 12 weeks after baseline. After 12 weeks, participants will receive access to the LARKSPUR intervention online.
9981581|NCT03691857|Other|Acute non-traumatic dyspnea patients|Patients with acute non-traumatic dyspnea managed in the emergency department to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation)
9725953|NCT04997226|Active Comparator|tDCS over the left DLPFC with adaptive memory game|"The stimulation will be carried out using a battery-powered mobile device made by Neurocon with two 5 x 5 cm electrodes The anodal electrode will be positioned above the F3 region of a standard EEG cap that is parallel to the cortical DLPFC region. The return electrode will be placed over the right eyebrow. The electrodes will remain on the subjects head for 50 minutes - the entire duration of the session. 1mA stimulation will be given for 15 minutes, then a 20-minute break and again 15 minutes of 1 mA stimulation. This protocol has been shown to improve the duration of the stimulus effect (Monte-Silva et al., 2013)."
9725954|NCT04997226|Placebo Comparator|Sham tDCS over the left DLPFC with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 50 minutes, similar to the active tDCS arm.
9725955|NCT04997226|Active Comparator|tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but stimulation method will be employed at 2mA intensity for 20 minutes at theta-gamma coupling using a laplacian montage (Alekseichuk et al., 2016).
9981582|NCT03663361|Experimental|SMART Intervention|"The SMART intervention will utilize the elements of the Standard of Care intervention, and will also include Sensorimotor Improvements and other specific additions that will focus on sensory inputs, motor outputs, and integration of the sensory and motor pathways."
9981583|NCT03663361|Active Comparator|Standard of Care Intervention|The Standard of Care intervention will include restoration of ankle joint range of motion, strength and functional movement.
9981584|NCT03662126|Experimental|Part A Cohort 1|KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
9981585|NCT03662126|Experimental|Part A Cohort 2|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
9981586|NCT03662126|Experimental|Part A Cohort 3|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
9981587|NCT03662126|Experimental|Part A Cohort 4b|KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
9981588|NCT03662126|Experimental|Part B Arm 1 KRT-232|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
9981589|NCT03662126|Active Comparator|Part B Arm 2 Best Available Therapy|Best available therapy at the discretion of the investigator, on a 28-day cycle.
9981590|NCT03623321|Experimental|Drug - pimavanserin|Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
9981591|NCT03620058|Experimental|CART22-65s monotherapy|
9981592|NCT03620058|Experimental|CART22-65s in combination with huCART19|
9981593|NCT03610724|Experimental|Tisagenlecleucel|CAR-positive viable T cells infusion
9981594|NCT03602859|Placebo Comparator|Participants receiving SOC+placebo|Participants in this arm will receive SOC (carboplatin+paclitaxel+bevacizumab) in cycle 1 followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab along with niraparib placebo and dostarlimab placebo.
9981595|NCT03602859|Active Comparator|Participants receiving SOC+niraparib|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab with niraparib and dostarlimab placebo.
9981596|NCT03602859|Experimental|Participants receiving SOC+dostarlimab|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of bevacizumab with niraparib and dostarlimab.
9981597|NCT03602066|Experimental|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
9981598|NCT03602066|Placebo Comparator|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
9981599|NCT03600883|Experimental|Phase 1 Dose Exploration Part 1 monotherapy|"Cohorts with food effect and alternative dosing regimens~Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort"
9780852|NCT01133405|Experimental|LY2886721 Part 2: Cohort C|Single 10 mg dose of LY2886721, dose determined by Part 1
10198919|NCT02303821|Experimental|Phase 1b: Dose Escalation 1|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine.~Subjects will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle.~Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
10198920|NCT02303821|Experimental|Phase 1b: Dose Escalation 2|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy and then have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
9725956|NCT04997226|Placebo Comparator|Sham tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 20 minutes, similar to the active tACS arm.
9981600|NCT03600883|Experimental|Phase 1 Dose Expansion Part 2 monotherapy|Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently
9981601|NCT03600883|Experimental|Phase 2 monotherapy|Additional subjects will be enrolled in the dose expansion to confirm the recommended phase 2 dose. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose
9981602|NCT03600883|Experimental|Phase 1 combination arm with sotorasib and anti PD-1/L1|Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)
9725957|NCT04996004|Experimental|Dose Escalation|
9981603|NCT03600883|Experimental|Phase 1 monotherapy treatment naive advanced NSCLC|Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.
9981604|NCT03600883|Experimental|Phase 2 monotherapy dose comparison|Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy
9981605|NCT03584815|Active Comparator|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
9981606|NCT03584815|Active Comparator|Physiotherapy|"Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.~Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
9981607|NCT03580473|Experimental|SATURNO II|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
9725958|NCT04996004|Experimental|Dose Expansion Low Dose (Cohort A)|
9981608|NCT03580473|Active Comparator|Vigadexa®|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
9981609|NCT03575832|Experimental|Supportive care (exercise, nutrition counseling)|Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.
9984604|NCT03915327|No Intervention|Control group|Clinical management, including surgical procedures, anesthesia, and perioperative management, are performed in accordance with standard clinical practice.
10198921|NCT02303821|Experimental|Phase 2: Aged ≥ 12 months at screening|"All subjects aged ≥ 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 4 week cycle of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine) if subjects showed no disease progression at the end of the Induction Cycle."
10205450|NCT05206734||Controls|People without a diagnosis in their electronic medical record (ERM) of Inflammatory Bowel Disease, matched on age group, sex, ethnicity (consistent with UK census categories: White, Asian, Black, Mixed, Other), index of multiple deprivation based on postcode, and by practice where numbers allow.
10205451|NCT05206721|Experimental|Intervention group|
10205452|NCT05206721|No Intervention|Control group|
9725959|NCT04996004|Experimental|Dose Expansion High Dose (Cohort B)|
9725960|NCT04995835|Experimental|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.
9725961|NCT04995588|Other|Blood test|Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes
9725962|NCT04994444|Experimental|Preloading|Participants will be started on nicotine patch 3 weeks prior to quit date. At quit date they will use patch and lozenge or gum for 8 weeks.
9981610|NCT03572621|Experimental|Experimental group|Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
9981611|NCT03572621|Sham Comparator|Control group|Patient without therapeutic education.
9981612|NCT03572621|Other|Partner|Patient's partner.
9981613|NCT03565640|Active Comparator|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
9981614|NCT03565640|Experimental|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
9981615|NCT03564067|Other|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
9981616|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
9981617|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
9725963|NCT04994444|Active Comparator|Standard treatment|Participants will start combination nicotine replacement therapy (patch/gum or patch/lozenge) on their assigned quit date. NRT will be provided for 8 weeks.
9981618|NCT03552393|Experimental|Mircera|Mircera will be administered subcutaneously once every 4 weeks
9725964|NCT04993677|Experimental|Melanoma Arm|SEA-CD40 + pembrolizumab
9981619|NCT03525418|Experimental|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
9981620|NCT03525418|Experimental|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
9984605|NCT03913832|Experimental|sirolimus drug coated balloon (SCB)|Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)
9984606|NCT03913832|Active Comparator|paclitaxel releasing coronary balloon catheter.|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter
9725965|NCT04993677|Experimental|NSCLC Arm|SEA-CD40 + pembrolizumab + pemetrexed + carboplatin
9725966|NCT04993183|Experimental|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, service-learning seminar, disability simulation workshop, and two community contact sessions.
9725967|NCT04993001|Active Comparator|Emergence from general anesthesia with an open lung extubation strategy|
9725968|NCT04993001|Placebo Comparator|Emergence from general anesthesia with a conventional extubation strategy|
10205453|NCT05206708|Active Comparator|Standard care group|Standard psychodynamic therapy
10205454|NCT05206708|Experimental|Personalized care|Psychodynamic therapy or interactive guidance therapy
10205455|NCT05206682|Experimental|Vaginal Repair with Zoladex|CSD patients were treated with vaginal repair of CSD in combination with Zoladex (3.6 mg, AstraZeneca UK Limited) . In the group of VR With Zoladex, the patients start oral metformin from 4 weeks before the operation to 1 week after the operation. The dose is 3.6mg per 4 weeks. The detailed procedure of Vaginal Repair has been described in our previous study.
10205456|NCT05206682|No Intervention|Vaginal Repair without Zoladex|The detailed procedure of Vaginal Repair has been described in our previous study.
10205457|NCT05206669|Experimental|Cancer Messages - Young Adults|Messages providing information about the use of HPV vaccines to prevent cancer.
9725969|NCT04988464|Experimental|Sleep Scholar|Sleep Scholar is a fully automated, single-session, self-guided, internet-based CBT-I intervention that participants will read from a web browser on their electronic device. Sleep Scholar's content was adapted from Ellis and colleague's, Morin's, and Perlis and colleague's protocols for therapist-guided CBT-I interventions. Sleep Scholar will be completed in approximately 30 minutes and consists of three successive text-based modules: Sleep Education, Initiating Sleep, and Enhancing Sleep Quality. New content (e.g., vignettes and quizzes) was created to tailor the intervention to college students. For example, after each module, short multiple choice and/or true-false question will be administered to assess participants' understanding of Sleep Scholar's strategies. Participants will be automatically provided feedback on their responses to ensure their understanding of Sleep Scholar's strategies.
9725970|NCT04988464|Placebo Comparator|Building Healthy Habits|Building Healthy Habits will be used as the control condition. It combines two modules being utilized as the control condition in an ongoing randomized controlled trial. It is a single-session, self-guided, internet-based intervention that participants will read from a web browser on their electronic device. Building Healthy Habits was piloted by undergraduate research assistants to ensure that it was approximately the same duration as Sleep Scholar (i.e., 30 minutes). It consists of two successive text-based modules focused on healthy movement and healthy eating.
9725971|NCT04987489|Experimental|Etavopivat 400 mg daily - SCD with transfusions|Patients with sickle cell disease on chronic red blood cell transfusions
9725972|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia with transfusions|Patients with thalassemia on chronic red blood cell transfusions
10205458|NCT05206669|Experimental|Cancer Messages - Parents of Adolescents|Messages providing information about the use of HPV vaccines for their adolescent children to prevent cancer.
10205459|NCT05206669|Experimental|Genital Wart Messages - Young Adults|Messages providing information about the use of HPV vaccines to prevent genital warts.
10198922|NCT02303821|Experimental|Phase 2: Aged < 12 months at screening|"All subjects aged < 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a modified 5 week cycle (based on Interfant-06) of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 5 week cycle (modified based on Interfant-06) of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if subjects showed no disease progression at the end of the Induction Cycle."
10198923|NCT02292108|Experimental|Hypnosis and dietetic counselling|Patient will benefit of usual dietetic counselling and experimental hypnosis
9725973|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia|Patients with thalassemia not on chronic red blood cell transfusions
9725974|NCT04986956|Placebo Comparator|Placebo|The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.
9725975|NCT04986956|Active Comparator|Whole coffee cherry extract|Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (<2%; <4mg) levels of caffeine. The only content of the supplement is WCCE - there are no excipients, binders, or flow agents, nor are there any other materials. The coffee cherry is subjected to a food-grade water ethanol extraction; thus, after extraction, only 100% coffee-based components remain. 200mg of WCCE will be administered daily for 28 days.
10198924|NCT02292108|Other|dietetic counselling|Patient will only benefit of usual dietetic counselling
10198925|NCT02288702||Normal|This is the group with no neurological problems or syndrome
9725976|NCT04986618|Experimental|One-way Nordic Exercise Group|
9725977|NCT04986618|Experimental|Two-way Nordic Exercise Group|
9981621|NCT03525418|No Intervention|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
9981622|NCT03524170|Experimental|Treatment (M7824, radiation therapy)|Patients receive M7824 IV over 1 hour every 14 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days after second dose of M7824, patients undergo radiation therapy QD for 5-10 days depending on the site of disease in the absence of disease progression or unacceptable toxicity.
9981623|NCT03518060||Subjects receiving Juluca|Approximately 250 virologically suppressed HIV positive subjects on a stable antiretroviral regimen as indicated in local SmPC of Juluca will be included in the study. The subjects will be followed for approximately 3 years during routine clinical practice.
9981624|NCT03511664|Experimental|177Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)|Patients randomized to receive the investigational product will receive 7.4 gigabequerel (GBq) (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) may be used
10198926|NCT02288702||Down syndrome|This is the group with Down syndrome
9725978|NCT04986618|No Intervention|Control Group|
10198927|NCT02287311|Experimental|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
10198928|NCT02287311|Experimental|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
9725979|NCT04982575|Experimental|Cagrilintide 2.4 mg and semaglutide 2.4 mg|Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
9725980|NCT04982575|Active Comparator|Cagrilintide 2.4 mg and placebo (semaglutide)|Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
10198929|NCT02287311|Experimental|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
10198930|NCT02281097|Active Comparator|Vagal Stimulation First|"Vagal stimulation to improve upright heart rate modulation and symptoms is given on first tilt study day.~Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on second tilt study."
10198931|NCT02281097|Placebo Comparator|Placebo First|"Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on first tilt study day.~Vagal stimulation to improve upright heart rate modulation and symptoms is given on second tilt study day."
9725981|NCT04982575|Active Comparator|Semaglutide 2.4 mg and Placebo (cagrilintide)|Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
9780853|NCT01133405|Experimental|LY2886721 Part 2: Cohort D|Single 35 mg dose of LY2886721, dose determined by Part 1
9780854|NCT01133405|Placebo Comparator|Placebo Part 2: Cohort C/D|Single dose
9780855|NCT01133418|Experimental|Cognitive Training|Computerized Progressive Attention Training
9785277|NCT01247363|Experimental|LY2608204|Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
10198932|NCT02279771|Active Comparator|transanal anastomotic reinforcement|Low anterior resection with TME plus anastomotic transanal reinforcement without protective ileostomy/colostomy (transanal anastomotic reinforced arm:TAR-LAR)
10198933|NCT02279771|Active Comparator|protective ileostomy group|Standard low anterior resection with TME plus protective ileostomy/colostomy (S-LAR)
10198934|NCT02271919|Experimental|Group I (varenicline and placebo)|Patients receive varenicline PO QD or BID, placebo patches QD, and placebo lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
9725982|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #1|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the pre-incision, intra-op, mid-surgery, end of surgery, or continuous time points:~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~Local anesthetic (0.25% or 0.5% bupivacaine + 1:200K epinephrine)~Bilateral ultrasound guided pudendal nerve block (20-40 cc of 0.25% bupivacaine + 1:200K epinephrine)~Ultrasound guided Continuous Infraclavicular Brachial Plexus Block~Ultrasound guided Continuous Femoral Nerve Block~Pecs I & II Block (0.25% bupivacaine: 15-30ml per side for Pecs I-III)"
9981625|NCT03511664|Other|Best supportive/best standard of care (BS/BSOC) alone|Patients randomized to this arm will receive best supportive/best standard of care (BS/BSOC) as determined by the investigator
9981626|NCT03495180|Experimental|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
9981627|NCT03493802||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
9981628|NCT03493802||Healthy individuals as controls|Age and gender-matched healthy controls
9725983|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #2|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the intra-op, post-op, or end of surgery time points:~Bilateral ultrasound-guided Transversus Abdominis Plane Block (40-60cc of 0.25% bupivacaine with 1:200K epinephrine)~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
9725984|NCT04979338|Active Comparator|Surgery-specific general anesthetic + local anesthetic at incision site|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the mid-surgery or end of surgery time points:~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
9981629|NCT03490331|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
9981630|NCT03484143|Active Comparator|Active Neuro RX Gamma device|Neuro RX Gamma device delivers low-energy near-infrared light, through 5 diodes, to the brain transcranially and intranasally
9981631|NCT03484143|Sham Comparator|Sham Neuro RX Gamma device|Sham Neuro RX Gamma device is identical in appearance and sound as the active Neuro RX Gamma device but does not emit low-energy near infrared light
9981632|NCT03481556|Experimental|A (melflufen+bortezomib+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with bortezomib at 1.3mg/m² S.Q. on Days 1, 4, 8, 11 and dexamethasone 20 mg (12 mg ≥ 75 years) Days 1, 4, 8, 11 and 40 mg (20 mg ≥ 75 years) on Day 15 and 22 of each 28-day cycle.
9981633|NCT03481556|Experimental|B (melflufen+daratumumab+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with daratumumab 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Dexamethasone p.o. 40 mg weekly (20 mg weekly for patients age ≥ 75 years).
9984607|NCT03913819||substance abuse group|Patients with voiding dysfunction secondary to substance abuse in a special clinic
9984608|NCT03911830|Experimental|Exercise followed cold water immersion|Exercise program on cycloergometer and its submerged recovery
10198935|NCT02271919|Placebo Comparator|Group II (placebo, nicotine patch and lozenge)|Patients receive placebo tablets PO QD or BID, nicotine patches QD, and nicotine lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
9725985|NCT04979286|Experimental|Kinesiotaping Group|Y strip kinesiotaping will be applied to both the gastrocnemius muscles with approximately 20% tension.
9725986|NCT04979286|Placebo Comparator|Placebo Group|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
10198936|NCT02270840||CRT-D|Patients currently implanted with a single or dual chamber pacemaker or ICD will be upgraded to CRT.
9725987|NCT04979052|Active Comparator|Interferon-Gamma|Recombinant Interferon-Gamma 1b combined with standard therapy
9725988|NCT04979052|No Intervention|Standard of care|Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.
10205460|NCT05206669|Experimental|Genital Wart Messages - Parents of Adolescents|Messages providing information about the use of HPV vaccines or their adolescent children to prevent genital warts.
9785278|NCT01247428|Experimental|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
10198937|NCT02270840||Only ICD|"In the ICD arm, choosing single or dual chamber device is based upon the investigator's discretion.~Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only)."
10198938|NCT02270359|Other|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
10198939|NCT02267863|Experimental|Dose Escalation and Expansion|APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.
10198940|NCT02263729|Active Comparator|losartan|Subjects will taken 50mg of losartan per day for 4 weeks
10198941|NCT02263729|Placebo Comparator|placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
9981634|NCT03462342|Experimental|A. Olaparib Pill + AZD6738.|"Cohort A: Recurrent platinum-sensitive ovarian cancer (progression greater than 6 months from last receipt of platinum-based chemotherapy), approximately 37 patients could be treated with an interim analysis after 17 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
9981635|NCT03462342|Experimental|B. Olaparib Pill + AZD6738.|"Cohort B: Recurrent platinum-resistant ovarian cancer (progression less than or equal to 6 months of the last receipt), approximately 37 patients could be treated with an interim analysis after 12 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
9981636|NCT03462342|Experimental|C. Olaparib Pill + AZD6738.|"Cohort C: PARP inhibitor (PARPi) resistant (subjects who have progressed on a PARPi), patients must be platinum-sensitive, and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 subjects could be treated.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
9725989|NCT04976101|Experimental|Sinusoidal Galvanic Vestibular Stimulation|"Treatment:~1. Stimulation of the vestibular nerves with 0.025 Hz, 2 mA sinusoidal galvanic vestibular stimulation Depending on initial results, changes in frequency may range up to 0.1 Hz."
9725990|NCT04976101|Placebo Comparator|Placebo|"Treatment:~1. Placebo (sham) (no current given however the electrodes and devise is placed and computer keys pressed). Depending on initial results, changes in frequency may range up to 0.1 Hz."
9981637|NCT03462342|Experimental|D-1. Olaparib Pill + AZD6738.|"Cohort D Part I: Patients will be platinum sensitive/platinum resistant ovarian cancer. Patient may or may not have received prior PARPi and will be enrolled irrespective of their BRCA status. The number of subjects treated will depend on the number of dose levels explored with a minimum of 12 subjects up to 30 subjects.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
9725991|NCT04974892||low dose aspirin|high-risk women given LDA at ≤16 weeks.
9725992|NCT04974892||Non responders to low dose aspirin|high-risk women who have not responded to LDA and have gone on to develop PE.
10205461|NCT05206669|Active Comparator|Control Messages - Young Adults|Messages providing information about HPV vaccines that did not mention prevention of other diseases or conditions.
10205462|NCT05206669|Active Comparator|Control Messages - Parents of Adolescents|Messages providing information about HPV vaccines for their adolescent children that did not mention prevention of other diseases or conditions.
10205463|NCT05206578|Experimental|AGT2, AGZ|
9725993|NCT04973150|Experimental|the children were given gauze covering training in one eye or both eyes|According to the operation method, the children were given gauze covering training in one eye or both eyes.
9725994|NCT04973150|No Intervention|Using regular tablet computer to play cartoon animation video|
9725995|NCT04973124|Active Comparator|SEVODEX Group|The SEVODEX group will receive intraoperative dexmedetomidine at a fixed infusion rate of 0.25 mcg/kg/h
9725996|NCT04973124|Placebo Comparator|SEVO Group|The SEVO group will not receive dexmedetomidine during surgery.
9725997|NCT04971278||HealthFirst Intervention|Patients attributed to HealthFirst who will receive the intervention
9725998|NCT04971278||HealthFirst Control|Patients attributed to HealthFirst who will not receive the intervention
9725999|NCT04971278||Mortality Model Intervention|Patients who are identified as High Risk by the mortality predictive model and who receive the intervention.
9726000|NCT04971278||Mortality Model Control|Patients who are identified as High Risk by the mortality predictive model and who do not receive the intervention.
9726001|NCT04971005|Experimental|Intervention (aHSCT)|Autologous Hematopoietic Stem Cell Transplantation. Mobilisation will be performed with 2 g/m2 cyclophosphamide and 10 μg/kg G-CSF from day 5 until apheresis is completed. Conditioning will be 200 mg/kg cyclo-phosphamide and Anti-T-lymphocyteglobuline (Grafalon®, Neovii) with cu-mulative doses of 20 mg/kg given on day +1 (10 mg/kg) and day +2 (10 mg/kg).
9726002|NCT04971005|Active Comparator|Control|In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).
9726003|NCT04969939|Experimental|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
9726004|NCT04969939|Placebo Comparator|Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)|Participants will receive placebo as an add on to semaglutide 2.4 mg.
10198942|NCT02263274|Experimental|Direct Cortical Measurement|Consented subjects will also have transcranial electrodes applied at four extracranial sites, below the sterile dressing and distant from the surgical skull defect. The four electrodes will be placed in uniform positions based on the standard 10-10 electrode system, at the temples bilaterally (positions F9 and F10) and at the occiput bilaterally (positions PO9 and PO10). Subjects will be stimulated according to a predetermined set of parameters which fall well within empirically and computationally determined safety thresholds, as discussed above. The entire stimulation protocol is described in detail in section 5, and is anticipated to last no longer than 30 minutes.
9726005|NCT04969939|Experimental|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
9726006|NCT04969939|Placebo Comparator|Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)|Participants will receive placebo as an add on to semaglutide 2.4 mg.
9726007|NCT04969276|Experimental|Group 1: Fluzone HD and Covid-19 vaccine|Concomitant administration of Fluzone High-Dose Quadrivalent vaccine and COVID-19 mRNA Vaccine
9981638|NCT03462342|Experimental|D-2 Olaparib Pill + AZD6738.|"Cohort D Part II: Patients with ovarian cancer who are PARP inhibitor (PARPi) resistant (patients who have progressed on a PARPi). Patients must be platinum-sensitive and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 patients will be treated.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
9981639|NCT03428581|Experimental|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
9981640|NCT03428581|Active Comparator|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
9981641|NCT03412747|Experimental|Bimekizumab Arm 1|Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
9981642|NCT03412747|Experimental|Bimekizumab Arm 2|Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
9726008|NCT04969276|Active Comparator|Group 2: Fluzone HD vaccine|Administration of Fluzone High-Dose Quadrivalent vaccine alone
9981643|NCT03412747|Active Comparator|Adalimumab Arm|Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
9726009|NCT04969276|Active Comparator|Group 3: Covid-19 vaccine|Administration of COVID-19 mRNA Vaccine alone
9726010|NCT04969120|Active Comparator|(group 1) receiving intravenous metoclorpramide|this group receive 10mg intravenous metoclopramide
9726011|NCT04969120|Placebo Comparator|(group 2) receiving placebo|this group receive 10mg intravenous placebo(0.9 sodium chloride)
9981644|NCT03406949|Experimental|obrindatamab + retifanlimab|B7-H3 x CD3 DART protein + anti-PD-1 antibody
9981645|NCT03400982|Experimental|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
10198943|NCT02261415|Experimental|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
10198944|NCT02261415|Placebo Comparator|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
10205464|NCT05206578|Active Comparator|AGT2|
10205465|NCT05206578|Experimental|AGT4, AGZ|
9726012|NCT04968964|Experimental|Cohort 1: Scheduled to receive first line therapy|"Scheduled to receive 1st line therapy with endocrine therapy + any FDA-approved CDK 4/6 inhibitor~Serum samples (analyzed using DiviTum® TKa) at Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months. Treating physician will evaluate the patient & review any updated results of the institutional standard of care monitoring tests. Following receipt of DiviTum® TKa value, the treating physician will review the preceding locked Study Care Plan and record any changes"
9726013|NCT04968964|Experimental|Cohort 2: Currently receiving first line therapy|"1st line therapy with endocrine therapy + any FDA-approved CDK 4/6 inhibitor for ≤ 24 months with stable disease~Serum samples (analyzed using DiviTum® TKa) at Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months. Treating physician will evaluate the patient & review any updated results of the institutional standard of care monitoring tests. Following receipt of DiviTum® TKa value, the treating physician will review the preceding locked Study Care Plan and record any changes"
9726014|NCT04968964|Experimental|Medical Oncologists|-Will be completing the Study Care Forms at Baseline, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24 and every 12 weeks thereafter until disease progression or 36 months.
9726015|NCT04968574|Experimental|ENV-101|taladegib, 200 mg tablet, once daily for 12 weeks
9726016|NCT04968574|Placebo Comparator|placebo|placebo, tablet, once daily for 12 weeks
9726017|NCT04967534|Experimental|WB-EMS|
9726018|NCT04967534|Sham Comparator|social contact control group|
9785279|NCT01247571|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9981646|NCT03377270|Experimental|RST|Respiratory Swallow Training Arm
9981647|NCT03377270|No Intervention|Standard of Care|Standard of Care Arm
9981648|NCT03377270|Other|Home Practice Arm|RST + Home Practice Arm
9981649|NCT03336983|Other|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
9981650|NCT03336983|Experimental|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
9981651|NCT03333382|Active Comparator|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
9726019|NCT04966377|Experimental|Intervention Group|Intervention Group First, pre-tests were applied to the women in the experimental group. A 4-week training program created by taking into account the cultural characteristics of Syrian women; Explaining breast health, Explaining breast structure, Cancer, Breast cancer, Early diagnosis and its importance, BSE application, CBE and mammography, Barriers on breast cancer, Cancer Early Diagnosis, Screening and Education Center. A 'Nurse-directed screening counseling telephone support line' will be established for the women in the experimental group. Then, motivational interviews will be applied to the women in the experimental group by the researcher, who emphasizes the importance of early diagnosis in line with the health belief model. Reminders will be made by phone every week in the 3rd month. The final tests will be held 4 months after the end of the training.
9981652|NCT03333382|Active Comparator|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
9981653|NCT03308578|Experimental|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
9981654|NCT03308578|Placebo Comparator|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
9981655|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) >=5
9981656|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) < 5
9981657|NCT03283813|Active Comparator|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
9981658|NCT03283813|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
9981659|NCT03283657|Experimental|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
9726020|NCT04966377|No Intervention|Control Group|Pre-tests will be applied to the women in the control group. No intervention will be applied to the women in this group and post-tests will be performed 4 months after the pre-test.
9981660|NCT03283657|Active Comparator|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
9726021|NCT04965753|Experimental|FHD-609|Up to approximately 70 patients will be enrolled in dose escalation and expansion.
9981661|NCT03283384|Other|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
9726022|NCT04964557|Experimental|AZD8233|AZD8233 for subcutaneous use
9726023|NCT04964557|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection
10198945|NCT02256696|Experimental|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
9726026|NCT04962607||Study Group|"Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.~Exposure of a vital pulp due to caries.~No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.~The possibility of proper restoration of the teeth."
9726027|NCT04962607||control group|"Asymptomatic primary molars with deep carious lesions scheduled for regular treatment.~Exposure of a vital pulp due to caries.~No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract.~The possibility of proper restoration of the teeth."
9981662|NCT03283384|Active Comparator|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
9981663|NCT03283384|Experimental|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
9981664|NCT03268954|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 milligram per square meter (mg/m^2), intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+/-10) infusion, intravenous, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity.
9981665|NCT03268954|Experimental|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles until disease progression or unacceptable toxicity.
9981666|NCT03267836|Experimental|Avelumab + Proton Therapy|"Avelumab will be started concurrently with proton therapy (up to 3 days before or after is permissible) and administered every 2 weeks for 3 months~Proton therapy 20 CGE (cobalt gray equivalent) will be given over 5 daily fractions of 4 CGE per day during weekdays~After 3 months of avelumab, patient will have a brain MRI evaluation, and radiological response will be assigned based on the iRANO criteria. Surgery will be performed as per routine clinical care~If the brain MRI after 3 months of avelumab shows complete response with no signs of residual tumor, no surgery will be indicated, and the patient may continue to take adjuvant avelumab for an additional 3 months.~After the patient has recovered from the surgery and if deemed medically eligible by the treating physician to receive additional immunotherapy, avelumab will be restarted and administered every 2 weeks for an additional 3 months"
9981667|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
9726028|NCT04961957|Active Comparator|Waterproof padding|Waterproof, short leg walking cast for 3-7 weeks
9726029|NCT04961957|Active Comparator|Non-waterproof padding|Non-waterproof, short leg walking cast for 3-7 weeks
9726030|NCT04956718|Other|CPT first|"Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa."
9726031|NCT04956718|Other|CPT+placebo first|"Participant will be told and read about the 'pain medication' (= Placebo NaCl Nasal spray). Thereafter participant will self-administer a nasal spray, which is in fact a placebo nasal spray containing NaCl solution and Cold Pressor Test (CPT) is performed.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa"
9726032|NCT04951947|Experimental|Arm A|Treatment arm
9726033|NCT04948632|Active Comparator|Complete LeoMed application|LeoMed application with integrated artificial intelligence
9726034|NCT04948632|Placebo Comparator|Basic LeoMed application|LeoMed application without artificial intelligence
9726035|NCT04945590|Experimental|Latino/Hispanic Virtual Intervention Program|Latino/Hispanic individuals will participate in culturally tailored virtual intervention program following a community-based collaborative design.
9726036|NCT04945018|Experimental|HS-001 Low dose|HS-001 Low dose Administration
9726037|NCT04945018|Experimental|HS-001 High dose|HS-001 High dose Administration
9726038|NCT04939584|Experimental|Intervention|"The study will be conducted using the venous cannulations that are standard of care for the indicated procedure. Additional access points may be necessary if access to coronary sinus is difficult from existing femoral venous cannulations. Sterile study leads or EP catheters will be temporarily placed into the RA, CS, and RV (for R-wave sensing using intracardiac electrograms - optional) which will be connected to the investigational device (CESS).~Up to two MPTs will be delivered and subject responses following each MPT regarding perception and acceptability of MPT to treat AF will be obtained. MPT voltages will not exceed 100V."
9981668|NCT03245827|Active Comparator|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
9981669|NCT03245827|Placebo Comparator|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
9726039|NCT04938284|Experimental|PAS and VNS|
9726040|NCT04938284|Active Comparator|PAS and sham VNS|
9981670|NCT03245827|No Intervention|Obese males with normal testosterone|comparison group
9981671|NCT03245827|No Intervention|lean males with normal testosterone|comparison group
9981672|NCT03170375|Experimental|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
9981673|NCT03170375|Active Comparator|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
9981674|NCT03170375|Experimental|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
10198946|NCT02256696|Experimental|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
10198947|NCT02256696|Active Comparator|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
9981675|NCT03170375|Placebo Comparator|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
9726041|NCT04938284|Active Comparator|PAS|
9726042|NCT04938284|Active Comparator|VNS|
9726043|NCT04936776||Text message 1|Text messaging frame = safety and cleanness of clinic site. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
9726044|NCT04936776||Text message 2|Text messaging frame = importance of vaccines. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
9726045|NCT04936776||No text message|No text sent.
9726046|NCT04934462|Other|non-surgical treatment|All participants will undergo 6 months of non-surgical treatment.
9726047|NCT04934462|Other|arthroscopic treatment|Those participants with failed non-surgical treatment at 6 months will undergo arthroscopic treatment.
9981676|NCT03169231|Experimental|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
9981677|NCT03169231|Experimental|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
9981678|NCT03169231|Experimental|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
9981679|NCT03169231|Experimental|Study Group D|Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
9981680|NCT03169231|Placebo Comparator|Study Group E|Single peripheral IV infusion of placebo.
9981681|NCT03164993|Placebo Comparator|Arm Chemotherapy + Placebo|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + placebo
10205466|NCT05206578|Active Comparator|AGT4|
10198948|NCT02251704|Other|Study Group|Subjects 6 months to <10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
10198949|NCT02225600|Other|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
9981682|NCT03164993|Active Comparator|Arm Chemotherapy + Atezolizumab|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + Atezolizumab
9981683|NCT03149757|Experimental|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
9981684|NCT03149757|Active Comparator|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
9981685|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
9981686|NCT03129321|Experimental|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
9981687|NCT03129321|Active Comparator|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
9981688|NCT03129321|Placebo Comparator|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
9981689|NCT03121534|Experimental|Blinatumomab|"Induction phase consists of a single cycle of Blinatumomab therapy. Blinatumomab initiated at 9 mcg/day from day 1-7, followed by 28 mcg/day from day 8-14 (week 2). This is followed by 112 mcg/day from day 15-56. The induction cycle is 8 weeks in duration.~Patients who achieve an objective response after induction are eligible to receive one further cycle of Blinatumomab consolidation, delivered at 112 mcg/day by continuous vein infusion from day 1-28 (total of 4 weeks). Consolidation may be initiated 4-8 weeks after completion of the induction infusion of Blinatumomab.~Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment."
9981690|NCT03116997|Experimental|Neuromuscular blockade reversed with neostigmine/gly|
9726048|NCT04934189|Experimental|Empowerment Self-Defense Training- Pilot Trial 1|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW.
9981691|NCT03116997|Active Comparator|Neuromuscular blockade reversed with sugammadex|
9981692|NCT03107611|Experimental|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
9981693|NCT03107611|Active Comparator|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
9981694|NCT03107611|Placebo Comparator|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
9981695|NCT03089866||ASA Patients I or II|Participants are healthy (BMI <35), 55years and older, and have the ability to follow instructions. In this population we will quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
9981696|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
9981697|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
9981698|NCT03083977|Experimental|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
9981699|NCT03040726|Experimental|Group I (netupitant, palonosetron hydrochloride)|Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.
9981700|NCT03040726|Placebo Comparator|Group II (placebo)|Patients receive placebo PO on days 1, 6, and 11.
9981701|NCT02988544|Experimental|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
9981702|NCT02988544|No Intervention|Control group|No intervention on blastocoelic
9981703|NCT02982915|Experimental|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
9981704|NCT02982915|Experimental|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
9981705|NCT02982915|Experimental|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
10198950|NCT02225600|Active Comparator|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
10198951|NCT02223520|Active Comparator|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
10198952|NCT02223520|Placebo Comparator|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
10198953|NCT02220309||Anxiety and mood disorders|
10198954|NCT02193048||Patients newly diagnosed with Crohn's disease|This study will evaluate a new clinical scoring system in patients receiving routine treatment
10198955|NCT02162472||Adalimumab|Subjects will receive adalimumab as standard of care for psoriasis
10198956|NCT02162472||Methotrexate|Subjects will receive methotrexate as standard of care for psoriasis
10198957|NCT02147184||SSRI Group|Participants within one month of starting an SSRI
10198958|NCT02147184||Unmedicated Group|No treatment with SSRIs
10198959|NCT02143401|Experimental|Treatment (navitoclax, sorafenib tosylate)|Patients receive navitoclax PO QD on days 1-21 (days 1-28 cycle of 1 only) and sorafenib tosylate PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9981706|NCT02904811|Experimental|Intervention group|"Testing for Ct infection immediately~Participants will perform self-taken vaginal samples.~The positive results for Ct will be examined and treated and their partner will also be informed to do so."
9726049|NCT04934189|Experimental|Empowerment Self-Defense Training- Pilot Trial 2|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW. The intervention administered in Trial 2 will be an tailored version of the curriculum used in Trial 1, adapted based on Trial 1 data.
9726050|NCT04934189|Experimental|Empowerment Self-Defense Training- Pilot Trial 3|Refinement and assessment of the feasibility and acceptability of the Empowerment Self-Defense curriculum will occur in Phase 2 through the delivery of the tailored ESD curriculum to 3 groups of 16 TW. The intervention administered in Trial 3 will be an tailored version of the curriculum used in Trial 2, adapted based on Trial 2 data.
10198960|NCT02141282|Experimental|ABT-199 after ibrutinib therapy|Single daily doses increasing weekly as tolerated
10198961|NCT02141282|Experimental|ABT-199 after ibrutinib or idelalisib therapy|Single daily doses increasing weekly as tolerated
9726053|NCT04930029||OAGB150|One anastomosis gastric bypass with 150cm biliary limb
9726054|NCT04930029||OAGB200|One anastomosis gastric bypass with 200cm biliary limb
9981707|NCT02904811|Experimental|Control group|Testing for Ct infection at the end of the study
9981708|NCT02880774|Experimental|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
9981709|NCT02880774|Placebo Comparator|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
9981710|NCT02871219|Experimental|Treatment (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 8, and 15 of course 1 and day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR or CRu may receive up to an additional 12 cycles of lenalidomide.
9981711|NCT02801136|Experimental|ReACT for PNES|ReACT consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
9981712|NCT02801136|Active Comparator|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
9981713|NCT02801136|No Intervention|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires and computer tasks.
9981714|NCT02798588|Experimental|Comatose patients in ICU|
9981715|NCT02777047|Experimental|Intervention|The interdisciplinary multimodal intervention is led by a clinical pharmacologist and includes: a detailed discharge medication reconciliation and management plan focused on oral anticoagulants at hospital discharge; a circle of care handover and coordination with patient, hospital team and community providers; and early post-discharge follow-up virtual medication check-up visits at 24 hours, 1 week, and 1 month.
10198962|NCT02141282|Experimental|ABT-199 after idelalisib therapy|Single daily doses increasing weekly as tolerated
10198963|NCT02126553|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9726055|NCT04927871|Experimental|Hybridized Lyfestile Intervention|The participants will receive three interventions including Total Diet Replacement, Medical Nutrition Therapy, and the Diabetes Prevention Program
9726056|NCT04927871|Active Comparator|Only Diabetes Prevention Program|The comparison group will receive only the Diabetes Prevention Program
10198964|NCT02122198|Placebo Comparator|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
10198965|NCT02122198|Active Comparator|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.~Weekly application of estradiol patch 0.075mg/d months 6-9.~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
10198966|NCT02095288||Healthy volunteers|Blood draw
10198967|NCT02081105|Other|PEEP 5|level of PEEP of 5 cm H2O randomly applied to the patient
10198968|NCT02081105|Other|PEEP 15|level of PEEP of 15 cm H2O randomly applied to the patient
10205467|NCT05206552||Parturients above the age of 18|Study participants will include women after labour whom gave birth to a healthy neonate at 37 weeks with the ability to comply with study requirments
9726057|NCT04927247|Experimental|inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
9726058|NCT04927247|Placebo Comparator|placebo|Placebo administered IV
9981716|NCT02777047|No Intervention|Control|Patients allocated to the control group will receive usual care, plus the URL to Thrombosis Canada website. Usual care in the participating sites includes OAC management by family doctors except for new thromboembolic events which will be followed short term by thromboembolism or hematology specialists, complicated atrial fibrillation which will have cardiology involved temporarily, and a small proportion of warfarin management which is provided in an anticoagulation clinic. This choice of control group is the most relevant for generalizability to both academic and community practices.
9981717|NCT02720016|Experimental|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
9726059|NCT04927221|Experimental|DC371739 20mg Dose MAD|Orally administered DC371739 tablets QD afer meal
9726060|NCT04927221|Placebo Comparator|DC371739 Placebo MAD|Placebo orally administered
9981718|NCT02720016|Active Comparator|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
9981719|NCT02720016|Active Comparator|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
9981720|NCT02692105|Active Comparator|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
9981721|NCT02692105|Experimental|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
9726061|NCT04926103|Experimental|Open label FMT therapy|FMT from a related or unrelated healthy donor screened for known communicable disease
9984609|NCT03911687|No Intervention|Control Group|"Control data will be collected in the CONCERN CDS system that will be live in the EHR, but in silent release mode (e.g., not providing notification to clinicians)."
9984610|NCT03911687|Experimental|Intervention Group|"Experimental data will be collected in the CONCERN CDS system that will be live in the EHR in active release mode (e.g., providing CONCERN CDS system notification to clinicians)."
9984611|NCT03911128||Participants with newly diagnosed ALL|
9984612|NCT03910166|Experimental|DCB group|use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm
9984613|NCT03910166|Active Comparator|BMS group|use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group
9726065|NCT04915014|Experimental|laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)|One arm benefiting from a laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)
9726066|NCT04915014|Sham Comparator|laparoscopic Roux-en-Y gastric bypass (RYGB)|One arm benefiting from a laparoscopic Roux-en-Y gastric bypass (RYGB)
9984614|NCT03905148|Experimental|Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.|Combination doses of, Mirdametinib at once a day and lifirafenib at once a day And Mirdametinib at twice a day and lifirafenib at once a day
9984615|NCT03905148|Experimental|Part B: Group 1|Non-small cell lung cancer with confirmed K-RAS mutations, approximately 15 participants
9726067|NCT04914676|Experimental|Prospective HiDAC Treatment (HiDAC 123)|Subject on this arm will be treated with HiDAC prospectively.
9726068|NCT04914676|Other|Historical HiDAC Treatment (HiDAC 135)|Subjects on this arm will be historical controls who have previously received treatment with HiDAC.
9726069|NCT04912505|Experimental|Single arm|Sequential variations of daily aspirin intake time
9984616|NCT03905148|Experimental|Part B: Group 2|Endometrial cancer with confirmed K-RAS mutations, approximately 15 participants
9726070|NCT04912492|Active Comparator|RealConsent 1.0 with Alcohol|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target breath alcohol concentration (BrAC=.08).
9726071|NCT04912492|Active Comparator|RealConsent 1.0 with Placebo|Men assigned to complete a web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
9726072|NCT04912492|Experimental|RealConsent2.0 with Alcohol|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to alcohol intoxication arm (target BrAC=.08).
9726073|NCT04912492|Experimental|RealConsent2.0 with Placebo|Men assigned to complete a revised web-based multi-media sexual violence and bystander intervention prevention program. Men assigned to a no-alcohol placebo control arm.
9726074|NCT04912492|Active Comparator|Stress Management with Alcohol|Men assigned to complete a web-based stress management program. Men assigned to alcohol intoxication arm (target BrAC=.08).
9726075|NCT04912492|Active Comparator|Stress Management with Placebo|Men assigned to complete a web-based stress management program. Men assigned to a no-alcohol placebo control arm.
9785280|NCT01247675|Experimental|ACP-001, 0.02 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.02 mg hGH/kg/week for 4 weeks
9981722|NCT02607956|Experimental|B/F/TAF|B/F/TAF + DTG + F/TAF placebo administered without regard to food for at least 144 weeks.
9981723|NCT02607956|Active Comparator|DTG + F/TAF|DTG + F/TAF+ B/F/TAF placebo administered without regard to food for at least 144 weeks.
9981724|NCT02607956|Experimental|Open-label Phase B/F/TAF from B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
9981725|NCT02607956|Experimental|Open-label Phase B/F/TAF from DTG + F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
9981726|NCT02587572|Experimental|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.
9981727|NCT02587572|Placebo Comparator|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
9981728|NCT02587572|Experimental|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.
9726076|NCT04911309|Active Comparator|Group 1: 12 weeks functional exercise training followed by standard therapy|"12 weeks functional exercise training twice per week, each session lasting 60 min, additionally to standard therapy. Training sessions will be performed in a group-setting consisting of minimum 4 and maximum 8 participants and coached by experienced sport scientists with the supervision of a medical doctor. The exercises will be individually pants and constantly recorded in order to allow a progression over the course of the 12 week-period. The motor tasks and exercises will be tailored to individual capacity by experienced and trained sport scientists and coaches, therefore insuring the participants' safety and a continuous and progressive monitoring of training load.~After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks."
10198969|NCT02079948|Active Comparator|Methotrexate + Folic Acid|Participants in the methotrexate condition will consume a dose of 15 mg/week of methotrexate during months 2 - 6. Participants will also consume 1 mg of folic acid/day for six days per week.
10198970|NCT02079948|Placebo Comparator|Placebo + Folic Acid|Participants in the placebo condition will consume microcrystalline cellulose once per week. The number of capsules consumed on this day will match the number of capsules consumed by participants in the methotrexate condition. There are no active ingredients in the placebo capsules.
9981729|NCT02587572|Experimental|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.
9981730|NCT02579655|Active Comparator|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
9981731|NCT02579655|Active Comparator|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
10198971|NCT02079948|Experimental|Functional MRI Experimental Tasks|15 participants will be randomly assigned to complete the fMRI visits at the baseline and 6 month.
10198972|NCT02079948|Experimental|Muscle Biopsy|10 participants will be randomly assigned to complete the skeletal muscle tissue sample at the baseline and 6 month visits.
10198973|NCT02073292|Experimental|c-RFA|cooled radiofrequency ablation
9981732|NCT02579655|Active Comparator|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
9981733|NCT02579655|No Intervention|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
9981734|NCT02564523|Experimental|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
9981735|NCT02564523|Experimental|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
9981736|NCT02564523|Experimental|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
9984617|NCT03905148|Experimental|Part B: Group 3|Tumor type of interest based on preliminary anti-tumor clinical activities observed in Part A, approximately 15 participants
10198974|NCT02073292|Active Comparator|t-RFA|thermal radiofrequency ablation
10198975|NCT02060188|Experimental|Nivolumab Monotherapy|
10198976|NCT02060188|Experimental|Nivolumab + Ipilimumab|
10198977|NCT02060188|Experimental|Nivolumab + Ipilimumab Cohort C3|
10198978|NCT02060188|Experimental|Nivolumab + Ipilimumab + Cobimetinib Cohort C4|
10198979|NCT02060188|Experimental|Nivolumab + BMS-986016 Cohort C5|
10198980|NCT02060188|Experimental|Nivolumab + Daratumumab Cohort C6|
10205468|NCT05206487|Experimental|Polydextrose|Patients will receive PDX 15 days prior and for a 6 month periods after TIPS.
9981737|NCT02560961|Experimental|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
9981738|NCT02560961|Placebo Comparator|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
9981739|NCT02501096|Experimental|Lenvatinib + Pembrolizumab|Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma.
9981740|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
9981741|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
9981742|NCT02474017|Experimental|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
9981743|NCT02456857|Experimental|Treatment (DAE)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over about 3 hours on day 1, bevacizumab IV over 90 minutes on day 1, and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients will not receive bevacizumab during cycle 4 of therapy. Patients then undergo surgery.
9981744|NCT02445768|Experimental|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
9981745|NCT02420912|Experimental|Cohort I (nivolumab, ibrutinib)|Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9981746|NCT02420912|Experimental|Cohort II (nivolumab, previous ibrutinib)|Patients receive nivolumab as in Cohort I and continue previous ibrutinib treatment.
9981747|NCT02420912|Experimental|Cohort III (nivolumab, ibrutinib)|Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9726077|NCT04911309|Active Comparator|Group 2: 12 weeks standard therapy / treatment followed by 12 weeks functional exercise training|"12 weeks standard therapy / treatment; the standard therapy group receives no additional exercise sessions. After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks.~After 12 weeks the groups will switch the intervention method. Group 2 will perform the same intervention which Group 1 received over the first course of 12 weeks."
9726078|NCT04910711|Active Comparator|DTG/LNG|Receiving dolutegravir-based antiretroviral therapy and initiating the levonorgestrel implant
9981748|NCT02294799|Other|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
9981749|NCT02294799|Placebo Comparator|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
9981750|NCT02232152|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid, fluorouracil)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 and fluorouracil IV over 46 hours on days 2-4. Courses repeat every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
9726079|NCT04910711|Other|NEG/LNG|HIV negative, not receiving antiretroviral therapy and initiating the levonorgestrel implant
9726080|NCT04910711|Active Comparator|DTG/MPA|Receiving dolutegravir-based antiretroviral therapy and the depot medroxyprogesterone acetate injection
9726081|NCT04910711|Other|NEG/MPA|HIV negative, not receiving antiretroviral therapy and receiving the depot medroxyprogesterone acetate injection
9726082|NCT04909216|Experimental|Mindful Attention Workshop|50 participants will be randomized to the Mindful Attention Training (MAT) workshop. The 90-minute workshop will be conducted in group, online format.
9726083|NCT04909216|No Intervention|Waitlist Control|"50 participants will be randomized to the waitlist control condition (as usual condition)."
9981751|NCT02215122|Experimental|MGR001|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via CRC749 inhaler.
9981752|NCT02215122|Experimental|Advair® Diskus®|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Diskus® inhaler.
9981753|NCT02215122|Experimental|Seretide™ Accuhaler™|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Accuhaler™ inhaler.
10198981|NCT02055053|Experimental|anesthetic intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.
9726084|NCT04908683|Experimental|Group 1: Respiratory Syncytial Virus (RSV) vaccine|All participants in the active group will receive study vaccine at Day 1 and will be re-randomized at Day 365 to receive study vaccine in subgroup 1a and placebo in subgroup 1b.
9981754|NCT02112734|Active Comparator|vitamin D|400 IU /daily cholecalciferol/vitamin D
9981755|NCT02112734|Placebo Comparator|placebo|carrier formulation minus vitamin D
9981756|NCT02094716|Experimental|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
9981757|NCT02094716|Experimental|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
9981758|NCT02094716|Placebo Comparator|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
9981759|NCT02094716|Placebo Comparator|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
9981760|NCT02094261|Experimental|AZD9291|Once daily tablet 80 mg
9981761|NCT01988493|Experimental|Phase 1b: Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
9981762|NCT01988493|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
9981763|NCT01988493|Experimental|Phase 1b: Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
9981764|NCT01988493|Experimental|Phase 2: Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
9726085|NCT04908683|Placebo Comparator|Group 2: Placebo|Participants will receive a single Intramuscular (IM) injection of matching placebo on Day 1 and Day 365.
9981765|NCT01988493|Experimental|Phase 2 Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
9726086|NCT04908189|Experimental|Deucravacitinib|
10198982|NCT02055053|Placebo Comparator|Saline intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.
9726087|NCT04908189|Placebo Comparator|Placebo|
9981766|NCT01974765|Experimental|Enzalutamide|"After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.~All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting."
9981767|NCT01953926|Experimental|Neratinib monotherapy|Neratinib monotherapy in HER2 mutated cancers including cervical, salivary gland, and lung cancers containing EGFR exon 18 mutations.
9726088|NCT04908189|Other|Apremilast|
9726089|NCT04907695||Video Laryngoscopy|Seeking all patients undergoing intubation for which the clinician chooses to use Video Laryngoscopy. The participants will undergo intubation with the investigators chosen device.
9726090|NCT04905810|Experimental|Treatment (azacitidine, decitabine, venetoclax)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 (for patients with prior decitabine use), or decitabine IV on days 1-5 (for patients with prior azacitidine), and venetoclax PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9726091|NCT04904965|Experimental|Propofol Group 1|Patients will receive induction of anesthesia with Propofol at a rate of 2.0 mg/kg/hr.
9981768|NCT01953926|Experimental|Neratinib and Trastuzumab|Neratinib and Trastuzumab in HER2 mutated (TNBC, HR-negative) breast cancers.
9981769|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Randomized)|Neratinib, Fulvestrant and Trastuzumab or Fulvestrant and Trastuzumab or Fulvestrant alone in HER2 mutated (HR-positive with prior CDK4/6i) breast cancers.
9981770|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Non-Randomized)|Neratinib, Fulvestrant and Trastuzumab in HER2 mutated (HR-positive with CDK4/6i naïve) breast cancers.
9981771|NCT01922440||Natpar(a)|Participants receiving parathyroid hormone (rhPTH(1-84) (Natpar[a]) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.
9981772|NCT01922440||Conventional Therapy|Participants receiving conventional therapy/standard of care (including calcium supplements, active vitamin D, vitamin D) for treatment of chronic hypoparathyroidism as per standard clinical practice will be enrolled and evaluated during the study period.
9981773|NCT01868139|Experimental|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
9981774|NCT01843504|Active Comparator|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
9981775|NCT01843504|Placebo Comparator|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
9984618|NCT03904134|Other|Donor Search Prognosis: MUD Very Likely|Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a >90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
9984619|NCT03904134|Other|Donor Search Prognosis: MUD Very Unlikely|Patients who are Very Unlikely to find a MUD, defined as having a <10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
9726092|NCT04904965|Experimental|Propofol Group 2|Patients will receive induction of anesthesia with Propofol at a rate of 4.0 mg/kg/hr.
9981776|NCT01798004|Experimental|Treatment (induction therapy, consolidation therapy, ASCT)|"INDUCTION THERAPY:~COURSES 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for 2 courses.~COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 3 weeks for 2 courses.~COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, and doxorubicin hydrochloride IV over 24 hours on days 1-3. Treatment repeats every 3 weeks for 1 course.~Treatment continues in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. Patients undergo ASCT on day 0.~Some patients also undergo EBRT after induction and consolidation."
9981777|NCT01776164||Patient with FRDA|Patients affected by Friedreich's ataxia
9981778|NCT01776164||Healthy controls|Healthy volunteers age- and gender-matched with no neurological disease identified.
9981779|NCT01762605|Experimental|Supportive Care|No casting or splinting, supportive care only by parents
9981780|NCT01762605|Active Comparator|Cast|Casting for 4 weeks
9981781|NCT01751906|Experimental|Absorb BVS|Subjects receiving Absorb BVS
9981782|NCT01751906|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
9981783|NCT01724606|Experimental|Radiotherapy with Sorafenib|This is a single institution, open label, prospective, phase I clinical trial using standard 3+3 design. Histologically confirmed metastatic adenocarcinoma of the breast with radiologic evidence of new and/or progressive brain metastases (BM) with a clinical indication for WBRT will be enrolled.
9981784|NCT01687608|Experimental|AskBio009 Dose Escalation|Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy
9981785|NCT01620658|Active Comparator|standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
9726093|NCT04904965|Experimental|Propofol Group 3|Patients will receive induction of anesthesia with Propofol at a rate of 6.0 mg/kg/hr.
9726094|NCT04904965|Experimental|Propofol Group 4|Patients will receive induction of anesthesia with Propofol at a rate of 8.0 mg/kg/hr.
9726095|NCT04903392|Experimental|Backward Walking Group|Conventional therapy + Backward Walking Training
9726096|NCT04903392|Other|Forward Walking Group|Conventional therapy + Forward Walking Training
9726097|NCT04903327|Experimental|COVI-MSC|Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4
9726098|NCT04903327|Placebo Comparator|Placebo|Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4
9726099|NCT04898439|Experimental|Green school|The children from schools that are being greened will be investigated and compared to the control school. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing.
9726100|NCT04898439|No Intervention|control school|The children from schools that are not being greened will be investigated and used as a control group. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing
9726101|NCT04895267|Experimental|Real Low-field thoracic magnetic stimulation (LF-ThMS)|Crossover, single-blind session of low field thoracic magnetic stimulation (real LF-ThMS)
9981786|NCT01620658|Experimental|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
9981787|NCT01620658|Experimental|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
9981788|NCT01460810|Experimental|1000CsK Silicon Oil Tamponade|In 20 patients, a standard three-port vitrectomy will be performed. Following a standard air-fluid exchange, the eye will be filled with Silikon-1000 silicone oil in standard fashion. At a subsequent surgery, a standard two-port pars plana vitrectomy will be performed to remove the silicone oil and replace it with saline. The removed silicone oil will be tested onsite for traces of radiation.
9981789|NCT01447628|Active Comparator|Ferinject or CosmoFer followed by Placebo|"IV iron formulation used in Europe - Ferinject - given over 15 minutes~IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours~IV Iron given at Week 0, Placebo (saline) given at Week 12."
9981790|NCT01447628|Placebo Comparator|Placebo followed by Ferinject or CosmoFer|"Placebo comparator~Placebo (saline) given at Week 0, IV Iron given at Week 12."
9981791|NCT01409200|Experimental|Arm I (antiandrogen therapy, axitinib, surgery)|Patients receive antiandrogen therapy per standard care and axitinib PO BID for 4 months. Patients then undergo radical prostatectomy and pelvic lymph node dissection.
9981792|NCT01409200|Active Comparator|Arm II (antiandrogen therapy, surgery)|Patients receive antiandrogen therapy per standard care for 4 months and then undergo radical prostatectomy and pelvic lymph node dissection.
9981793|NCT01175356|Experimental|Treatment (131I-MIBG, chemotherapy)|See Detailed Description.
9981794|NCT01072084||Patients with food allergy|
9981795|NCT01072084||Healthy subjects|
9981796|NCT00744484|Experimental|B1|B1 - training in water
9981797|NCT00744484|Experimental|S1|S1 - training on land
9981798|NCT00703222|Experimental|Dose Level 1|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
9981799|NCT00703222|Experimental|Dose Level 2|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
9981800|NCT00667329|Experimental|2CdA + Cyclophosphamide + Rituximab|2CdA 1.5 mg/m^2 subcutaneous injection three times daily x 7 days. Cyclophosphamide 40 mg/m^2 PO twice daily x 7 days. Rituximab 375 mg/m^2 IV once weekly x 4 weeks.
9726102|NCT04895267|Sham Comparator|Sham Low-field thoracic magnetic stimulation (LF-ThMS)|In the same patients the coils are positioned in the same coordinates for sham exposure, but the pulse generator is not turned on. Subjects are blinded for the real LF-ThMS or sham stimulation conditions.
9981801|NCT00608764||NHW COPD Participants|Non-Hispanic white participants with COPD
9981802|NCT00608764||NHW Control Group|Non-Hispanic white participants with normal spirometry (do not have COPD)
9981803|NCT00608764||AA COPD Participants|African-American participants with COPD
10198983|NCT02034110|Experimental|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib will be administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib will be administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects will take their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
10198984|NCT02004275|Experimental|Arm I (pomalidomide, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
10198985|NCT02004275|Experimental|Arm II (pomalidomide, dexamethasone, ixazomib)|Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10198986|NCT02003690|Experimental|Dialectical Behavior Therapy + Pharmacotherapy|Dialectical Behavior Therapy + Pharmacotherapy
10198987|NCT02003690|Active Comparator|Standard of Care Psychotherapy + Pharmacotherapy|Standard of Care Psychotherapy + Pharmacotherapy
10198988|NCT02000284||General ASD|150 general ASD children
9981804|NCT00608764||AA Control Group|African-American participants with normal spirometry (do not have COPD)
9981805|NCT00515853|Experimental|Biofeedback|Received feedback
9981806|NCT00515853|No Intervention|No biofeedback|Did not received feedback
9981807|NCT00492167|Experimental|Beta-Glucan and Monoclonal Antibody 3F8|"This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer < 1,000 U/mL.~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.~After completion of study treatment, patients are followed periodica"
9981808|NCT00409435|Active Comparator|pyridostigmine|Active study drug
9981809|NCT00409435|Placebo Comparator|Placebo|Control
9981810|NCT00003458|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9981811|NCT05274815|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
9981812|NCT05274789|Placebo Comparator|Placebo group|Use 250 ml of saline as placebo group.
9981813|NCT05274789|Experimental|Experimental group|Use dexmedetomidine as experimental group
9981814|NCT05274750|Experimental|Participants receiving depemokimab (GSK3511294)|
9981815|NCT05274750|Placebo Comparator|Participants receiving placebo|
9981816|NCT05274737|Experimental|Initial Immobilization with the novel sling|20 patients will be placed in the novel sling after surgery for the first two weeks. For the second two weeks (days 15-28) they will crossover and utilize the standard abduction sling. For the final two weeks (days 29-42) they will choose their preferred sling type and use it for the remainder of six week immobilization period.
9981817|NCT05274737|Experimental|Initial Postoperative Immobilization with the standard abduction sling|20 patients will be placed in the traditional abduction sling after surgery for the first two weeks. For the second two weeks (days 15-28) they will crossover and utilize the novel sling. For the final two weeks (days 29-42) they will choose their preferred sling type and use it for the remainder of six week immobilization period.
9981818|NCT05274724|Active Comparator|Standard institutional protocol, without teleconsultation.|standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty.
9981819|NCT05274724|Active Comparator|Teleconsultation during the ambulance journey to the place of care.|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
9981820|NCT05274685|Experimental|covid positive with acute kidney injury receiving early renal replacement|
9981821|NCT05274685|Experimental|covid positive with acute kidney injury under conservative management|
9981822|NCT05274659|Active Comparator|KJ103 dose group 1|KJ103 single dose
9981823|NCT05274659|Active Comparator|KJ103 dose group 2|KJ103 single dose
10198989|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
10198990|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
10198991|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
10198992|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
9981824|NCT05274659|Active Comparator|KJ103 dose group 3|KJ103 single dose
9981825|NCT05274659|Active Comparator|KJ103 dose group 4|KJ103 single dose
10198993|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
9726104|NCT04888156||GAT IOP below 15 mmHg|Glaucoma patients with an IOP measured with GAT below 15 mmHg prior performance of self-tonometry with iCare Home
9981826|NCT05274659|Active Comparator|KJ103 dose group 5|KJ103 single dose
9981827|NCT05274659|Placebo Comparator|Matching placebo for each dose group|placebo, single dose
9981828|NCT05274633||Participants With PNH|Data will be collected on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as per clinical practice.
9981829|NCT05274581||Course participants|Course participants er general practitioners who have signed-up to participate in an ultrasound course
9981830|NCT05274568|Experimental|[18F]UCB-2897|"Administration of Investigational Agent:~Study center personnel will administer [18F]UCB-2897 as an IV injection. Prior to PET imaging, participants will have an IV catheter (for radiopharmaceutical administration) inserted according to standard clinical practice. Each participant will receive a single injection of [18F]UCB-2897. [18F]UCB-2897 will be injected IV at a dose of not more than 10 mCi, with a maximum mass dose of 10 μg and maximum volume of 10 mL. The injection will be followed by a 10 mL saline flush. Qualified study staff will accompany participants during PET imaging procedures."
9981831|NCT05274529|Experimental|Study group|All the participants will be in the same group and have the same intervention programmes options to choose from.
9981832|NCT05274490||copd patients with covid infection|
9981833|NCT05274490||non-copd patients with covid infection|
9981834|NCT05274477|Experimental|Fampridin SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 26 days depending on the individual scheduling of each subject."
9981835|NCT05274477|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
9726105|NCT04888156||GAT IOP equal or above 15 mmHg|Glaucoma patients with an IOP measured with GAT equal or above 15 mmHg prior performance of self-tonometry with iCare Home
9726106|NCT04887077|Experimental|Kiplin intervention|Kiplin intervention composed of the access to a mobile app and to telecoaching sessions. The number of teleocaching sessions per week will decrease over 3 months.
10198994|NCT02000219|Experimental|Oxabact OC5 capsule|"This is an open-label study so all patients will receive the active drug product, Oxalobacter formigenes, OC5. This will be administered as an enteric-coated capsules twice daily for 6 weeks of treatment.~In Germany, the protocol has been amended such that patients can receive OC5 for a further 3 year of continued treatment after the initial part of the study."
9981836|NCT05274438|Experimental|JS001+Imatinib Mesylate|Imatinib: 400mg qd po. Toripalimab: 240mg q3w ivgtt. The longest cumulative use period of the two drugs was 2 years.
9981837|NCT05274412|Active Comparator|Control group|Participants in this group will receive protocolized hemodynamic management based on advanced hemodynamic monitoring and dynamic parameters.Keep pulse pressure variation >12%; keep cardiac index >2L/min/cm^2; keep mean arterial pressure > 65mmHg.
9726107|NCT04887077|Active Comparator|face-to-face supervised PA (usual care at the University Hospital of Clermont-Ferrand, France)|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
9981838|NCT05274412|Experimental|HPI group|Participants in this group will receive protocolized hemodynamic management based on advanced hemodynamic monitoring, hypotension prediction index (HPI), and dynamic parameters.Keep HPI <85; pulse pressure variation >12%; keep cardiac index >2L/min/cm^2; keep mean arterial pressure > 65mmHg.
9981839|NCT05274386|Other|Averaging time 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
9981840|NCT05274386|Other|Averaging time 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
9981841|NCT05274386|Other|Averaging time 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
9981842|NCT05274360|Experimental|Experimental Group|Mobile evidence-based aphasia therapy
9981843|NCT05274360|Active Comparator|Control Group|Conventional aphasia therapy
9981844|NCT05274295|Experimental|Cytori Celution System in Chronic Non-Healing diabetic Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
9981845|NCT05274282|Experimental|Intervention Group|10 sessions of Animation Therapy (1 session/week)
9981846|NCT05274282|No Intervention|Control Group|No intervention
9981847|NCT05274269|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
9981848|NCT05274269|Placebo Comparator|Placebo|Participants will receive placebo matched to ELX/TEZ/IVA in the morning and placebo matched to IVA in the evening.
9981849|NCT05274256|Other|patients with missing teeth in maxillary aesthetic zone|
9981850|NCT05274230|Experimental|MDMA-Assisted Psychotherapy Participants|Participants who have completed the MDMA-Assisted Psychotherapy and consented to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable) as this is where the TVS seems to be most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature.10-14 The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
9981851|NCT05274217|Experimental|Immediate group|Study participants in the immediate group will be randomly assigned to start the intervention immediately at the beginning of the fall trimester.
9981852|NCT05274217|Experimental|Waitlist group|Study participants in the waitlist group will be randomly assigned to start the intervention at the beginning of the winter trimester.
9981853|NCT05274191|Experimental|A single arm, open-label Phase II clinical study.|"All subjects enrolled will receive the following treatment：Pyrotinib±standard treatment.~Pyrotinib 400 mg/ D (once a day, at the same time each day) until the progression of disease; Chemotherapy regimens follow the programme cycle recommended by the guidelines or as determined by the investigator.~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
10198995|NCT01978938|Experimental|Eravacycline|Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.
10198996|NCT01978938|Active Comparator|Levofloxacin|Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.
10198997|NCT01977638|Experimental|CXD101|Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
9981854|NCT05274178|Experimental|Study Group|All participants will be wearing the Audeo P hearing devices for this study.
9981855|NCT05274152|Experimental|Patients IVR for Lower Limb and Knee Rehabilitation after surgery in children|"Patients will use the IVR during each physiotherapy session after surgery until their discharge from hospital, which is expected to comprise one 10 minute session per day for 3-5 days.~During each session, child participants will rate their anxiety, perceived pain and feedback any feelings about the experience."
9981856|NCT05274152|Other|Occupational Therapist perceptions of the effectiveness of the IVR|"She recruited the patients, gave out devices, administered the outcome measures and provided us with feedback about their experience with the VR game.~At the end of the trial, an interview (10 minutes) with the OT was conducted by a research nurse."
9981857|NCT05274139|Experimental|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt, temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
9981858|NCT05274139|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
9981859|NCT05274113|Active Comparator|Group 1: Block with Ropivacaine + Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine and 4 mg of dexamethasone will be administered
9981860|NCT05274113|Active Comparator|Group 2: Ropivacaine Block + IV Dexamethasone|Before surgery an ultrasound guided supraclavicular block with ropivacaine will be administered and patients will receive dexamethasone intravenously
9981861|NCT05274100|Experimental|Group 1: Risankizumab Dose A|Participants will receive risankizumab dose A.
9981862|NCT05274100|Experimental|Group 2: Risankizumab Dose B|Participants will receive risankizumab dose B.
9981863|NCT05274100|Experimental|Group 3: Risankizumab Dose C|Participants will receive risankizumab dose C.
9981864|NCT05274100|Experimental|Group 4: Risankizumab Dose D|Participants will receive risankizumab dose D.
10198998|NCT01976065|Other|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
10198999|NCT01976065|Experimental|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
9981865|NCT05274100|Experimental|Group 5: Risankizumab Dose D|Participants will receive risankizumab dose D.
9981866|NCT05274087|Experimental|Group 1|Participants will receive Regimen A (15-minute autoinjector (AI) warm-up time) in Period 1, Regimen B (30-minute AI warm-up time) in Period 2 followed by Regimen C (45-minute AI warm-up time) in Period 3.
10199000|NCT01976065|Experimental|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
10199001|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
10199002|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
10199003|NCT01940822|Experimental|Energy drink first, then placebo drink|Participants will receive an energy drink at the first study visit, and a placebo drink at the second study visit.
10199004|NCT01940822|Experimental|Placebo drink first, then energy drink|Participants will receive a placebo drink at the first study visit and an Energy Drink at the second study visit.
10199005|NCT01940757|Experimental|25 Necator americanus Hookworm Larvae|
10199006|NCT01940757|Experimental|50 Necator americanus Hookworm Larvae|
10199007|NCT01940757|Experimental|75 Necator americanus Hookworm Larvae|
10199008|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.~300 participants with an isolated cognitive complaint and an age of 60 years or more."
10199009|NCT01878669|Placebo Comparator|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
10199010|NCT01878669|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
10199011|NCT01878344|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
10199012|NCT01878344|Placebo Comparator|Saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
10199013|NCT01854385|Experimental|Sumatriptan|Open label study of sumatriptan to treat post-traumatic headache. Subjects will use sumatriptan 100 mg at the onset of headache pain and may repeat the dose if not pain-free in 2 hours. Subjects will receive a maximum of 18 pills for use over two months. Subjects will maintain a daily headache diary.
10199014|NCT01844856|Experimental|Eravacycline, 1.0 mg/kg q12h|Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
10199015|NCT01844856|Active Comparator|Ertapenem, 1.0 g q24h|Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
9981867|NCT05274087|Experimental|Group 2|Participants will receive Regimen B in Period 1, Regimen C in Period 2 followed by Regimen A in Period 3.
9981868|NCT05274087|Experimental|Group 3|Participants will receive Regimen C in Period 1, Regimen A in Period 2 followed by Regimen B in Period 3.
9981869|NCT05274074|No Intervention|Aim 1|
9981870|NCT05274074|Experimental|Aim 2|We will be utilizing the Life Enhancing Activities or Caregivers (LEAF) intervention to display that social networks' can be used as a means of reinforcing the positive life skills of the intervention; and that these same skills will enhance social networks, increase mutual satisfaction in social interactions, and boost motivation to reach out to others, thus combatting social isolation.
9981871|NCT05274048|Experimental|Neratinib plus TDxD|Neratinib oral daily days 1-21 plus TDxD on day 1 administered intravenously of a 21 day treatment cycle.
9981872|NCT05274009|Experimental|Extreme heat event simulation + no cooling (control)|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
9981873|NCT05274009|Experimental|Extreme heat event simulation + recommended cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
9981874|NCT05274009|Experimental|Extreme heat event simulation + hybrid cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
9981875|NCT05273983|Experimental|Behavioural Activation Treatment|Two intervention sessions with a psychologist and an use of a mobile scheduling app over the course of 6 weeks.
9981876|NCT05273970|Experimental|Behavioral testing under intracranial monitoring|Patients will undergo behavioral tasks while being monitored by intercranial electrodes
10199016|NCT01825278||Single group, obese surgical patients with monitoring strip|All eligible patients will have a monitoring strip prospectively applied to their right chest
10199017|NCT01817166|Placebo Comparator|Placebo|"Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
10205469|NCT05206461||Hemiparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Hemiparetic CP
9981877|NCT05273957|Experimental|Case Manager|Patients are followed up by a case manager
9981878|NCT05273957|Active Comparator|Standard-of-care|Patients are followed up only by the neurologist
9981879|NCT05273944|Active Comparator|Reference product-R|Caelyx® (Janssen-Cilag International NV); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Reference Product (Caelyx®) in Cycle 1, will receive the Test Product (Lipodox®) in Cycle 2. Cycle is defined as 28-42 days (RT).
9981880|NCT05273944|Experimental|Test Product-T|Lipodox® (Sun Pharmaceutical Industries Ltd.); 20 mg/10 mL (50 mg/m2 dose). As this is a crossover study, subjects receiving the Test Product (Lipodox®) in Cycle 1, will receive the Reference Product (Caelyx®) in Cycle 2. Cycle is defined as 28-42 days (TR).
9981881|NCT05273866|Experimental|Virtual reality|Virtual reality video application
9981882|NCT05273866|No Intervention|control group|control group
9981883|NCT05273853|Other|Patients with high risk of hypernasality|In 1958, Gibb indicated an incidence of hypernasality (escape of air from nose as in patients with cleft palate) postadenoidectomy in approximately 1of 2000 cases. Closure pattern of velopharyngeal valve in children is veloadenoidal rather than velopharyngeal closure. Adenoid tissue is vital to velopharyngeal closure in children and its removal necessitates a change in the closure pattern of velopharyngeal valving. These changes are easily overcome if there is no anatomic abnormality
9981884|NCT05273840|Placebo Comparator|life intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given to the patients until the end of the visit.
9981885|NCT05273840|Experimental|nutritional supplement intervention group|On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given, and at the same time, nutritional supplements(Ivital Control) are given to instead a meal per day. 2 bags once a day until the end of the visit.
9981886|NCT05273827|Experimental|neoadjuvant immunotherapy group|Anti-PD-1 monoclonal antibody (Nivolumab，Pembrolizumab, Sintilimab, or Sugemalimab) 200 mg intravenously in combination with cis-platinum and paclitaxel/pemetrexed
9981887|NCT05273827|Placebo Comparator|control group|platinum-containing dual-agent chemotherapy(cis-platinum and paclitaxel/pemetrexed)
9981888|NCT05273814|Experimental|Tislelizumab+Bevacizumab+Pemetrexed|"Bevacizumab，7.5mg/kg，d1; Pemetrexed，500mg/m2，d1; Tislelizumab，200mg，d4; Q3W for 4 cycles;~Maintenance treatment ： Tislelizumab，200mg，d1; Bevacizumab，7.5mg/kg，d1; Q3W for 2 years"
10199018|NCT01817166|Experimental|Vit D|"Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
9981889|NCT05273801|No Intervention|Clinician Arm (period 1) - behavior prior to HR intervention|The investigators will monitor baseline behavior of providers in regards to sessions and how frequently heart rate (HR), rating of perceived exertion (RPE) and intensity is monitored and subsequent sessions are performed/modified through observation.
9981890|NCT05273801|Active Comparator|Clinician arm (period 2) & Patient arm (control - HR monitor, no feedback)|Participants will receive 1 week of HR monitoring in their group sessions where visual feedback is not provided during group session. The investigators will monitor overall HR response, mean HR and time in target HR zone, RPE and clinician behavior to HR monitor on patient during these sessions.
9981891|NCT05273801|Experimental|Clinician arm (period 3) & Patient arm (active - HR monitor, with feedback)|The same participants will receive 1 week of HR monitoring with visual feedback during group sessions. The investigators will monitor overall HR response, mean time HR and time in target zone, RPE, and clinician behavior to HR monitoring with visual feedback.
9981892|NCT05273775|Experimental|single arm|HRS5091 + probe drugs (Midazolam Maleate Tablets+Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Digoxin Tablets+ Rosuvastatin Calcium) + Vitamin K1 Tablets
9981893|NCT05273723|Experimental|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase walking by 2,000 more steps per day between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined using a modified version of the Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous participants.
9981894|NCT05273710|Other|Zinc absorption study|Zinc absorption is determined from each of 3 test meals in all subjects.
9981895|NCT05273684|Experimental|4*4 followed by 10*1 or 10*1 followed by 4*4|Following baseline measurements, participants are allocated to the random sequence, by which they will complete the two HIIT protocols ⟨http://www.randomization.com⟩ and based on this, patients are randomized to a specific testing sequence.
9981896|NCT05273658|Placebo Comparator|Placebo|Placebo cannabis and placebo alcohol
9981897|NCT05273658|Experimental|Cannabis, No alcohol|18.16% THC, placebo alcohol
9981898|NCT05273658|Experimental|Cannabis, Low dose alcohol|18.16% THC, .07 breath alcohol concentration
9981899|NCT05273658|Experimental|Placebo cannabis, High dose alcohol|<.1% THC, .10 Breath alcohol concentration
9981900|NCT05273658|Experimental|Placebo cannabis, Low dose alcohol|<.1% THC, .07 breath alcohol concentration
9981901|NCT05273619|Experimental|XC8, film-coated tablets, 10 mg|
9981902|NCT05273619|Placebo Comparator|Placebo|
9984620|NCT03904134|Other|Donor Search Prognosis: MUD Less Likely|Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
9984621|NCT03900793|Experimental|Dose Escalation and Expansion|"Part 1: This is a study escalating doses (Dose level 1-3) of losartan on a continuous daily dosing schedule and sunitinib (escalating on dose level 4) on a daily dosing with 4 weeks on, 2 weeks off. A cycle of therapy is 6 weeks (42 days).Dosing will be performed based on body surface area (BSA). This portion of the study uses a 3+3 design (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level).~Part 2: Once the Maximally Tolerated Dose (MTD) has been determined, 12 patients will enroll to the expansion cohort. These patients will receive the MTD as long as less then 33% of patients experience dose-limiting toxicities."
9984622|NCT03900468|Experimental|Active Deep Brain Stimulation (DBS)|
9984623|NCT03897439|Active Comparator|Usual Care (UC)|196 African American smokers will receive 12 weeks of smoking cessation counseling and 18 weeks of nicotine patch.
9984624|NCT03897439|Experimental|Optimized Care (OPT)|196 African American smokers will receive 12 weeks of smoking cessation counseling. They will receive the nicotine patch and up to two pharmacotherapy adaptations (VAR, BUP+NP) based on verified smoking status at Weeks 2 and 6 for a total of 18 weeks of pharmacotherapy.
10199019|NCT01801709|Experimental|AAVrh.10cuARSA|intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.
10199020|NCT01795508|Experimental|PMTO|Parent Management Training Oregon
10199021|NCT01795508|Active Comparator|TAU|Other kinds of family treatment
10199022|NCT01788306|Active Comparator|Intervention (OOPEN+BBCC)|Study intervention, overdose prevention, education, intervention, brief behavioral change counseling, take-home naloxone, referral to local available resources.
9984625|NCT03895827|Active Comparator|Passive Referral Control|Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.
10199023|NCT01788306|No Intervention|Control|Standard of care, referral to local available resources.
10199024|NCT01783535|Experimental|Stratum A|"Participants with early bilateral or unilateral (unifocal or multifocal) retinoblastoma (R-E I-III, IC A-B; R-E IV with IC A or B; or IC C with limited sub-retinal seeding), and participants with bilateral disease in whom the advanced eye has been enucleated upfront (without any high risk histopathology) and the remaining eye has early stage disease (as defined above).~Interventions (see detailed description): vincristine, carboplatin, topotecan, filgrastim or PEG-filgrastim, and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
10199025|NCT01783535|Experimental|Stratum B|"Participants considered candidates for conservative management including those:~Participants with bilateral retinoblastoma who have R-E IV-V and IC D in one eye~Participants with advanced unilateral (unifocal or multifocal) retinoblastoma (R-E IV-V and IC D-E) who demonstrate foveal sparing by the tumor during EUA. Due to foveal sparing, these patients have potential for vision preservation.~Interventions (see Detailed Description): vincristine, topotecan, carboplatin, etoposide, filgrastim or PEG-filgrastim and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
9981903|NCT05273580||Patients|Eligible patients will be identified by the Nurse Practitioner Cancer & Palliative Care.
9981904|NCT05273580||Carers|The respective carers who are identified by the Nurse Practitioner Cancer & Palliative Care as eligible participants.
9981905|NCT05273554|Experimental|Pembrolizumab|by vein over about 30 minutes on Day 1 of each cycle.
10199026|NCT01783535|Experimental|Stratum C|"Participants with advanced (R-E IV-V and IC D-E) unilateral retinoblastoma who require upfront enucleation. Participants will be assessed and treated by low, intermediate or high risk.~Interventions (see Detailed Description): vincristine, cyclophosphamide, MESNA, doxorubicin, etoposide, carboplatin, filgrastim or PEG-filgrastim, enucleation"
10199027|NCT01783535|Experimental|Stratum D|"Participants with bilateral retinoblastoma who may require upfront enucleation for one eye due to advanced disease (R-E IV-V and IC E).~Interventions (see Detailed Description): vincristine, carboplatin, topotecan, etoposide, enucleation, filgrastim or PEG-filgrastim, focal therapy, including cryotherapy, laser photocoagulation, thermotherapy (and thermo-chemotherapy) and episcleral plaque brachytherapy, and external beam radiation or proton beam radiation in select cases."
10199028|NCT01776723|Experimental|I: Dose Escalation - Ruxolitinib|"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day [BID] dosing) according to the rolling six Phase I design."
10199029|NCT01776723|Experimental|II: Maximum Tolerated Dose - Ruxolitinib|Phase II: Treatment at Maximum Tolerated Dose (MTD).
10199030|NCT01756222||Bicuspid Aortic Valve Disease Patients|Patients with the diagnosis of BAV disease.
9726112|NCT04883931|Experimental|Intervention group|With in 48-72 hour after birth, infants will receive 0.5 ml breast milk for own mother as a eye drop twice in a day until the discharge or need for laser coagulation. Fresh milk was used as eye drop ( not exceed 6 hours after milking).
9981906|NCT05273554|Experimental|Lenvatinib|2 lenvatinib capsules at the same time by mouth every day while on study.
9981907|NCT05273528|Experimental|V-01-351/V-01D bivalence vaccine|
9981908|NCT05273476|Experimental|strip|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft
9981909|NCT05273463|Experimental|Video-Based Education Group|Approximately 4 weeks before scheduled surgery, participants will receive the video-based intervention regarding pre-and postoperative care for ACL reconstruction.
9981910|NCT05273463|Experimental|Virtual Classroom Course Group|Approximately 4 weeks before scheduled surgery, participants will receive the classroom-based intervention regarding pre-and postoperative care for ACL reconstruction.
9981911|NCT05273463|No Intervention|Standard of Care Group|Participants will receive verbal and written pre-and postoperative instruction as typically received by all ACL reconstruction patients treated by the attending physicians before and after surgery.
9981912|NCT05273450|Experimental|Quitline Information with Reinforcement|
9981913|NCT05273450|No Intervention|Quitline Information Only|
9981914|NCT05273437|Experimental|System Identification|All participants in the study will go through a system identification experiment everyday for 270 days.
9981915|NCT05273424||no groups|A cohort of CKD patients on hemodialysis
9981916|NCT05273398|Experimental|Treatment|Single arm of treatment
9981917|NCT05273385|Experimental|Glaucoma Arm: Nanodropper|Participants will receive the Nanodropper with instructions and attend clinic visits at 2, 4, and 6 months. Surveys will be administered to adult participants and parents of child participants (under 18 years of age) in clinic at the end of the study that will be conducted as an open-ended interview expected to take less than 5 minutes
9981918|NCT05273385|Experimental|Glaucoma Arm: Nanodropper + iCARE|Participants will receive the Nanodropper with instructions and attend clinic visits at 2, 4, and 6 months. Surveys will be administered to adult participants and parents of child participants (under 18 years of age) in clinic at the end of the study that will be conducted as an open-ended interview expected to take less than 5 minutes. Along with following protocol for the Nanodropper portion, participants 6 patients will also measure their IOP at home at Months 1, 3, 5
9981919|NCT05273385|Active Comparator|Glaucoma Arm: Standard of Care Dropper|Participants will receive standard of care eye dropper with instructions and attend regular clinic visits.
9981920|NCT05273372|Experimental|Oxaloacetate|500 mg anhydrous enol-oxaloacetate in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
9981921|NCT05273372|Placebo Comparator|Placebo|500 mg white rice flour in hypromellose capsules (veggie caps). 2 capsules with breakfast and 2 capsules with lunch (1,000 mg BID) for 90 days.
9981922|NCT05273346|Experimental|Comprehensive Conservative TCM Treatment Group|"Traditional Chinese medicinal ointment;~Acupotomy;~Cupping therapy with bamboo cup;~Oral Chinese medicine granules."
10199031|NCT01744041|Experimental|Dyadic Interpersonal Psychotherapy|Brief Interpersonal Psychotherapy during pregnancy followed by dyadic mother-infant psychotherapy for one year postpartum
10199032|NCT01744041|Active Comparator|Enhanced Treatment as Usual|Personalized referral to community resources for depression treatment
10199033|NCT01738204||Females with endometriosis|Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group.
9981923|NCT05273346|Active Comparator|Modern Medicine Conservative Treatment Program Group|"Epidural Steroid Injections (ESIs);~Interferential current therapy;~Thermal therapy;~Oral painkillers."
9981924|NCT05273333|Other|Ultra-gyn®|ovule
9981925|NCT05273294|Experimental|Ultrasound group|Anesthesiologist will convenient color ultrasound high frequency 12MHZ array probe perpendicular to the neck, by the glottal down, until the thyroid isthmus, and ring cartilage level, ring cartilage level diameter by ultrasound, to avoid the effect of inspiration and breath on airway diameter, measurement timing should choose after anesthesia induction, mask pressure gas 1min, suspended pressure ventilation for 5s, ultrasonic measurement time is not more than 10s.Repeated measurements were averaged three times, and the maximum outer diameter of the catheter was selected, that is, the maximum outer diameter was selected closest to the measured value.
9981926|NCT05273294|No Intervention|Control group|tracheal catheter models are usually selected through traditional experience, according to the age formula in Clinical Anesthesiology, People's Health Press (i. e., 2.5 for preterm infants, 3.5 at 1-6 months, 4.0 at 6-12 months).
9981927|NCT05273268|Active Comparator|Control Arm|The control arm (target enrollment; n=180) will receive the US government-standard guidelines for dietary advice in the form of the USDA dietary recommendations digital leaflet.
9981928|NCT05273268|Experimental|Intervention Arm|The intervention arm (target enrollment; n=180) will receive personalized dietary guidelines created by machine learning algorithms using their personal anthropometric, gut, dietary and medical information as inputs. The guidelines will be delivered in the form of a smartphone/ smart device app.
9981929|NCT05273229|Experimental|Virtual Gait and Physical Exercise|"Virtual Gait and Physical Exercise Virtual Gait The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.~Physical Exercise Specific gait exercise was conducted."
9981930|NCT05273229|Sham Comparator|Documental projection and Physical Exercise|"Physical Exercise Specific gait exercise was conducted.~Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed."
9981931|NCT05273229|Experimental|Virtual Gait|only the virtual gait program will be carried out, detailed in Arm I.
9981932|NCT05273229|Sham Comparator|Virtual Gait Sham|Documental projection The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
9981933|NCT05273216||Observational Study (no different study arms)|Prospective, longitudinal, multicenter, observational study to investigate hemodynamic changes (by TCD and perfusion MRI) and blood biomarkers as predictors of reperfusion injury / intracranial hemorrhage after stroke thrombectomy of the anterior cerebral circulation
9981934|NCT05273190|Experimental|Vibrotactile Stimulation|
9785281|NCT01247675|Experimental|ACP-001, 0.04 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.04 mg hGH/kg/week for 4 weeks
9981935|NCT05273164|Experimental|Perceptual Discrimination Training|Training will involve Gabor patch and other visual stimuli discrimination exercises that focus on improving signal-to-noise resolution and attentional control with minimal working memory/cognitive control effects. On each training trial, participants are required to distinguish a target stimulus among a set of distractor stimuli. The similarity between target and distractors increases in level of difficulty based on an adaptive perceptual processing staircase function. Consecutive correct responses lead to increased modulation of the distractors to be more similar to the target, while 1 incorrect response drops the user to an easier level. Difficulty is adapted to maintain an 80% correct response rate. Each session will consist of 4 exercises requiring ~45 minutes. with 40 trials for each exercise.
9981936|NCT05273164|Active Comparator|Cognitive Control Training|"Training will involve maintaining accurate representations of cognitive context (the rule) in working memory during response selection. On each training trial, participants must observe stimuli, and hold the correct response context on-line in order to select the correct response from among the stimuli. Training is adaptive using a staircase function, such that two consecutive correct responses increases either the speed of stimuli presentation or the working memory load via an increased number of stimuli that are presented; one incorrect response reduces the cognitive load. Each session will consist of 45 exercises requiring ~45 minutes."
9981937|NCT05273138||Systemic sclerosis patients|Patients fulfilling the ACR/EULAR criteria for systemic sclerosis
9981938|NCT05273138||Healthy subjects|
9981939|NCT05273073|Active Comparator|Probiotics group|83 participants received probiotics for 12-week
9981940|NCT05273073|Placebo Comparator|Placebo group|83 participants received placebo for 12-week
9981941|NCT05273034|Experimental|1-h sepsis bundle|
9981942|NCT05273034|No Intervention|Current practice|
10199034|NCT01738204||Females without surgical diagnosis of endometriosis|Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital.
10204981|NCT04368559|Experimental|Group 1: Rezafungin for Injection|Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 13 weeks. Subjects will receive oral placebo for standard antimicrobial regimen (SAR) azole prophylaxis and oral placebo for SAR anti-PCP prophylaxis in accordance with the respective SAR dosing regimens for each. For subjects who are switched to a SAR IV regimen, oral placebo for SAR azole prophylaxis will be changed to IV placebo.
9981943|NCT05273021||participants with substance use problems|"There are 2 subgroups:~Participants without intellectual disabilities~Participants with intellectual disabilities with and without severe mental illness"
9981944|NCT05272982||Successful weaning group|Criteria of weaning included resolution of the primary cause of intubation, adequate cough without excessive tracheobronchial secretions, PaO2 > 60 mmHg with positive end-expiratory pressure ≤ 8 cmH2O, fraction of inspired oxygen ≤ 0.4, respiratory rate < 30 per minute, appropriate pH for patients' baseline respiratory status, and stable cardiovascular status.
9981945|NCT05272982||Failed weaning group|Weaning failure will be defined as a patient need for reintubation or noninvasive ventilation within 48 h after extubation due to the presence of one or more of the following criteria: altered mental status tachypnea (respiratory rate more than 35 breaths per minute), oxygen saturation less than 90% or PaO2 less than 60 mmHg on a fraction of inspired oxygen of 40%, an apparent increase in accessory respiratory muscle activity, evident facial signs of respiratory distress and hemodynamic instability (Heart rate >140 b/min, systolic blood pressure >180 or < 90mmHg )
10204982|NCT04368559|Active Comparator|Group 2: Oral Antifungal|Subjects in SAR treatment group will receive 400 mg oral fluconazole once daily for 13 weeks. Fluconazole may be switched, due to acute clinically significant GVHD, to 300 mg oral posaconazole twice daily on the first day of the medication switch and 300 mg once daily, thereafter. However, subjects who are switched to posaconazole cannot be switched back to fluconazole. Azole-based antifungal therapy (fluconazole or posaconazole) can be switched from daily oral therapy to daily IV therapy at the discretion of the Investigator. In addition, subjects in the SAR group will receive anti-PCP prophylaxis with oral TMP/SMX (80 mg TMP/400 mg SMX) once daily.
10204983|NCT04364048|Experimental|Induction durvalumab, chemoradiation, consolidation durvalumab|Induction durvalumab at 1500 mg intravenously (IV) on Day 1 of a four week cycle for 1 cycle, followed by concurrent definitive chemoradiation, followed by consolidation durvalumab at 1500 mg IV Day 1 of every 4 week cycle for up to 12 cycles.
10204984|NCT04352036||patient|
9981946|NCT05272969||LOPD group|50 Patients with genetically confirmed late-onset Pompe disease.
9981947|NCT05272969||Control group|15 Patients with histologically confirmed inclusion body myositis (IBM), 15 patients with genetically confirmed spinal muscular atrophy type 3 (SMA3) and 15 patients with genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) will serve as a control group.
10199035|NCT01733147|Placebo Comparator|Placebo|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive a placebo which looks exactly like the study drug, but contains no active ingredient, to be taken orally for six months.
9981948|NCT05272956|No Intervention|control group|Enteral feeding is carried out with a syringe pump
9981949|NCT05272956|Experimental|intervention group|the first enteral feeding is pushed with a syringe by the nurse. Following enteral feeding attempts are pushed with a syringe by the parents. Bolus feeding speed is at the discretion of the person pushing the syringe (nurse or parent) and is adjusted to the child's signs of discomfort. When the parents are absent, enteral feeding is carried out with a syringe pump
9981950|NCT05272917|Experimental|head and neck cancer patients with radiotherapy AND chemotherapy|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) + chemotherapy
9981951|NCT05272917|Experimental|head and neck cancer patients with radiotherapy only|patients included for a head and neck cancer and treated by radiotherapy (+/- surgery) without chemotherapy
9981952|NCT05272917|Active Comparator|healthy volunteers|healthy volunteers paired with experimental patients on age (+/- 5 years), gender, tobacco status
9981953|NCT05272904|Active Comparator|Conventional closure method|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
9981954|NCT05272904|Experimental|Quilting|The implemented intervention is the quilting suture technique. The subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin. No wound drain is placed.
9981955|NCT05272891|Experimental|Experimental|audio book will be played
9981956|NCT05272891|No Intervention|Control Group|No application will be made
10199036|NCT01733147|Active Comparator|Omega-3 polyunsaturated fatty acids|Subjects with known Barrett's Esophagus (no dysplasia and low-grade dysplasia) will receive Omega-3 free fatty acids supplements to be taken orally for six months.
9981957|NCT05272878|Active Comparator|IRBESARTAN|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit, based on clinical and biological tolerance. Treatment will be continued for 12 months, unless a side effect would occur.
9981958|NCT05272878|Placebo Comparator|Placebo|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit, based on clinical and biological tolerance. Treatment will be continued for 12 months, unless a side effect would occur.
9981959|NCT05272865|Active Comparator|Dronabinol 5mg/mL|Drug: Dronabinol (SYNDROS) Oral solution of SYNDROS (5 mg/mL)
9981960|NCT05272865|Experimental|THC F1|Drug: THC Oral solution of THC (5 mg/mL)
9981961|NCT05272865|Experimental|THC F2|Drug: THC:CBG Oral solution of THC (5 mg/mL) & CBG (5 mg/mL)
10199037|NCT01726452|Experimental|A (Modified MAGIC) OR Arm A: FLOT|"Modified MAGIC: The modified MAGIC regimen encompasses 3 cycles of chemotherapy pre-surgery and 3 cycles post-surgery. The regimen is a combination of epirubicin, cisplatin or oxaliplatin and a choice of 5-fluorouracil or capecitabine. Each cycle lasts 21 days.~FLOT: The FLOT regimen encompasses 8 cycles of chemotherapy in total , 4 cycles of chemotherapy pre-surgery and a further 4 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 14 days/2 weeks."
9726113|NCT04883931|Placebo Comparator|Placebo group|With in 48-72 hour after birth, infants will receive 0.5 ml 0.9% normal saline as a eye drop twice in a day until the discharge or need for laser coagulation.
9726114|NCT04883359||Healthy Volunteers|From the Washington, D.C. metropolitan area
9726115|NCT04883242|Experimental|Treatment (isatuximab, carfilzomib, pomalidomide, steroid)|"INDUCTION: Patients receive isatuximab IV on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
10204985|NCT04352010|Experimental|"Online-Intervention Res-Up!"|Participants in the Res-Up! group get access to Res-Up! while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
9981962|NCT05272865|Experimental|THC F3|Drug: THC:CBC Oral solution of THC (5 mg/mL) & CBC (5 mg/mL)
9981963|NCT05272852|Experimental|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
9981964|NCT05272839|Experimental|Hypoglycemic food group|The patient will choose 2 food products clinically validated against diabetes, at the same dosage and the same mode of preparation as in the reference clinical trials. This will be done additionally to healthcare advice and standard medication if any.
9981965|NCT05272839|Placebo Comparator|Control group|The control group will receive only dietary advice and standard medication if any.
9981966|NCT05272813|Experimental|MS-553 Low Dose|MS-553 Low Dose PO BID
9981967|NCT05272813|Experimental|MS-553 Mid Dose|MS-553 Mid Dose PO BID
9981968|NCT05272813|Experimental|MS-553 High Dose|MS-553 High Dose PO BID
9981969|NCT05272774|Experimental|Intervention group|The intervention group will get a 6-week online stress recovery intervention with the support from therapist.
9981970|NCT05272774|Experimental|Control group|The control group will use the intervention with on-demand support. The control group will participate in the program at the same time as the intervention group.
9981971|NCT05272761||Oronasal Route|Patients will sleep in the sleep lab for CPAP titration wearing a custom oronasal mask with 2 open oral and nasal compartments. The titration was split between the first half of the night and the second half. The titration will be started with the patient remaining for 90 minutes with the pressure he uses at home (supine position and in lateral decubitus), after a period of 90 minutes the patient will be titrated in order to abolish respiratory events in both positions of the body.
9981972|NCT05272761||Oral Route|"Group/Cohort Interventions Oronasal Route~Patients will sleep in the sleep lab for CPAP titration using a custom 2-compartment oronasal mask. In this titration, the nasal compartment will be closed and the patient will be titrated only through the oral route. The titration split between the first half of the night and the second half. The titration will be started with the patient staying for 90 minutes with the pressure used at home (during the supine position and lateral position), after the 90 minute period the patient will be titrated in order to abolish respiratory events in both positions of the body."
9981973|NCT05272709|Experimental|Cohort 1M (Monotherapy dose escalation cohort)|This cohort will recruit patients with solid tumours.
9981974|NCT05272709|Experimental|Cohort 2M: mCRPC (Monotherapy expansion cohort)|This cohort will recruit patients with mCRPC only.
9981975|NCT05272709|Experimental|Cohort 2M: MSI/MMR defective tumours (Monotherapy expansion cohort)|This cohort will recruit patients with MSI/MMR defective tumours only.
9981976|NCT05272709|Experimental|Cohort 2M: TNBC (Monotherapy expansion cohort)|This cohort will recruit patients with TNBC only.
9981977|NCT05272696|Experimental|Experimental|"All enrolled patients will receive two cycles of chemotherapy consisting of nab-paclitaxel (260 mg/m² on days 1), cisplatin (75 mg/m² on days 1), and Pembrolizumab (200 mg on days 1). Each cycle is repeated every 21 days.~After induction therapy, patients with PR but the maximum diameter of tumor > 3cm or SD or PD can receive surgery directly. After surgery, adjuvant CRT will be given for patients with high-risk factors.~After induction therapy, patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive CRT. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment."
9726116|NCT04880980|Active Comparator|Efficacy of double dose oral terbinafine in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral terbinafine for the treatment of dermatophyte skin infections.
9981978|NCT05272670|Experimental|Experimental group|A 4-week digital foot self-management program will be provided to the participants in experimental group.
9981979|NCT05272670|No Intervention|Control group|The control group received routine care that are required to attend the education sessions in the diabetes clinic according to their scheduled appointments. Routine care included routine check-ups and foot care education.
9981980|NCT05272644|Active Comparator|urethral hypermobility-surface electromyographic biofeedback only|Participant will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
9981981|NCT05272644|Experimental|urethral hypermobility-surface electromyographic biofeedback and electrical stimulation|Participant will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
9981982|NCT05272644|Active Comparator|intrinsic sphincter deficiency-surface electromyographic biofeedback only|Participant will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
9981983|NCT05272644|Experimental|intrinsic sphincter deficiency-surface electromyographic biofeedback and electrical stimulation|Participant will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
9981984|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 5mcg + MF59|DoCo-Pro-RBD-1 antigen 5mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
9981985|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1)15mcg + MF59|DoCo-Pro-RBD-1 antigen 15mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
9981986|NCT05272605|Experimental|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1) 45mcg + MF59|DoCo-Pro-RBD-1 antigen 45mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered intramuscularly in a one dose regimen, on Day 1
9981987|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 10mcg|MIPSCo-mRNA-RBD-1 antigen 10mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
9981988|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 20mcg|MIPSCo-mRNA-RBD-1 antigen 20mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
9981989|NCT05272605|Experimental|SARS-CoV-2 beta variant RBD mRNA vaccine (MIPSCo-mRNA-RBD-1) 50mcg|MIPSCo-mRNA-RBD-1 antigen 50mcg administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
9981990|NCT05272605|Placebo Comparator|Normal saline (0.9%)|Normal saline (0.9%) administered intramuscularly as a 0.5 mL dose in a one dose regimen on Day 1
9981991|NCT05272592||Nursing staff|Certified local-and-international inpatient-and-outpatient nurses specialised in urology, perioperative nurses, and urology-specific advanced practice nurses/nurse practitioners will be included.
9981992|NCT05272553|Experimental|Narrative Exposure Therapy|This is a single case series design which focuses on assessing whether Narrative Exposure Therapy could reduce symptoms of traumatic stress in cancer survivors; no comparator will be included.
9981993|NCT05272540||Day case surgery|Adult patients who are operated on as outpatients in day surgery. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before and after the surgery is added.
10199038|NCT01726452|Experimental|B (CROSS)|Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.
10199039|NCT01719666|Other|isolated MPFL reconstruction|
9981994|NCT05272540||In patient surgery|Adult patients who are operated on as inpatients in hospital care. Treatment and care follow clinical routine. Weighing on a scales measuring bioelectrical impedance data before the surgery and every morning during hospital stay is added.
9981995|NCT05272501|Experimental|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
9981996|NCT05272501|No Intervention|Usual care|The usual care group may participate in usual activities at the nursing home e.g. physio- and occupational therapy, listening to calming music, holdning hands with care-takers.
9981997|NCT05272488|Experimental|Manual therapy and nervous vagus stimulation|Subjects will received manual therapy combined with nerve vagus stimulation.
9981998|NCT05272488|Active Comparator|Manual therapy|Subjects will received isolated manual therapy techniques.
9981999|NCT05272475|Experimental|Chamomile Tea|Subjects will consume a single serving of chamomile tea on the visit day. The tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
9982000|NCT05272475|Experimental|Chamomile Extract Capsule|Subjects will consume a single chamomile capsule on the visit day. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
9982001|NCT05272462|Experimental|Treatment|Participants in this arm will be treated with minoxidil. This treatment will be given daily by mouth.
9982002|NCT05272449|Experimental|Evaluation of a disposable sound sensor for recording respiration during sleep|PneaVoX sensor, CIDELEC
9982003|NCT05272436|Experimental|Patients IVR for Upper Limb Motor Impairment Rehabilitation in children and at home trial|"For the purpose of the trial, patients had their usual OT/PT appointments but were asked to use the IVR games to do the prescribed home exercises. Before consenting to participate, each patient was offered a 5-10 minute experience of the game to familiarise themselves with how it worked and to check for problems. Written and verbal consents were taken from parents and children.~The pre-trial PedsQL was administered in the initial OT/PT appointment. Children were then asked to use the IVR system for approximately 15 minutes twice a day. Trial participation lasted three weeks during the prescribed treatment weeks.~Following the at-home trial, patients and parents returned the equipment to the clinic in the final appointment and the SUS and the post-trial Peds QL were administrated by OT/PT in person. In addition, they participated in semi-structured interviews as described above."
9982004|NCT05272436|Other|Occupational Therapist perceptions of the effectiveness of the IVR|"She recruited the patients, gave out devices, administered the outcome measures and provided us with feedback about their experience with the VR game.~At the end of the trial, an interview (10 minutes) with the OT was conducted by a research nurse."
9982005|NCT05272410||cases|Patients colonized or infected with CPE
9726117|NCT04880980|Active Comparator|Efficacy of double dose oral itraconazole in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral itraconazole for the treatment of dermatophyte skin infections
9982006|NCT05272410||controls|Patients not colonized or infected with CPE
9982007|NCT05272371|Experimental|Intervention arm|Chemoimmunotherapy arm.
9982008|NCT05272358||strategy 1: sarcoma MDTB before surgery and initial management in the NETSARC network|Patients who had a sarcoma-specialized multidisciplinary tumour board (MDTB) before the initial surgery and complete initial management (including surgery) in the network (also including patients who had a sarcoma-specialized MDTB after the initial surgery and complete initial management in the network) (strategy 1)
9982009|NCT05272358||strategy 2: sarcoma MDTB before surgery and initial management outside the NETSARC network|Patients who had a sarcoma-specialized MDTB before the initial surgery and initial management (including surgery) outside the network (strategy 2)
9982010|NCT05272358||strategy 3: sarcoma MDTB after surgery and initial management outside the NETSARC network|Patients who had initial management (including surgery) outside the network and a sarcoma-specialized MDTB after initial surgery (strategy 3)
10199040|NCT01719666|Experimental|MPFL reconstruction and Lateral retinaculum release|
9785282|NCT01247675|Experimental|ACP-001, 0.08 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.08 mg hGH/kg/week for 4 weeks
9785283|NCT01247675|Active Comparator|Omnitrope, 0.04 mg hGH/kg/wk|Once daily subcutaneous injection of human Growth Hormone (Omnitrope) equivalent to 0.04 mg hGH/kg/week for 4 weeks
9982011|NCT05272358||strategy 4: No sarcoma MDTB and initial management outside the NETSARC network|Patients who had an initial management (including surgery) outside the network, without sarcoma-specialized MDTB neither before nor after the initial surgery (strategy 4).
9982012|NCT05272293|Experimental|expanded haploidentical NK cell immunotherapy|After a cycle of chemotherapy a patient receive three intravenous infusions of expanded haploidentical NK cells.
9982013|NCT05272267|Active Comparator|AI-assisted|AI-assisted models providing diagnosis and prognostic information
9982014|NCT05272267|Placebo Comparator|Usual care|usual care without AI-assisted models providing diagnosis and prognostic information
9982015|NCT05272215||Patient group|"Pre-BaS: Patients administered for BaS, Department of Endocrinology either Odense University Hospital, Odense, Denmark or Hospital of Southwest Jutland, Esbjerg, Denmark~Post-BaS: (3, 6, 12 months postoperatively, then yearly) Department of Surgery, Southwest Jutland, Esbjerg, Denmark~Pre-BC: Patients administered for BC, Department of Plastic Surgery, Odense University Hospital, Odense, Denmark or Department of Plastic Surgery, Southwest Jutland, Esbjerg, Denmark.~Post-BC: (3, 6, 12 months postoperatively, then yearly), department of Plastic Surgery, Odense University Hospital; Hospital of Southwest Jutland, Esbjerg.~Normative group: Reference scores of the general population from an international sample of 10 countries and country specific scores. This study sample is submitted for publication elsewhere."
9982016|NCT05272189|Experimental|Experiment|All participants are tested in all conditions of this experiment.
10199041|NCT01715324|Experimental|Growth Hormon|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.
9982017|NCT05272176|Experimental|Coping Long Term with Active Suicide Program (CLASP)|"The CLASP intervention is an adjunctive, telehealth-based behavioral intervention designed to reduce suicidal behavior among individuals at high risk for suicide going through periods of transition. CLASP is designed to intervene on four risk factor targets: ongoing treatment engagement, problem-solving, social and family support, and hopelessness. In addition to these general factors, the CLASP provider also has the flexibility to identify and target certain patient-specific risk factors (e.g., substance misuse) for intervention.~CLASP will begin after completion of the baseline assessment (prior to discharge), and will continue for 6 months post-discharge. CLASP will be comprised of: a) 3 initial sessions while participants are still inpatients (can occur post-discharge if needed); b) 12 brief telehealth sessions over 6-months post-discharge; c) 6 brief SO telehealth sessions."
9982018|NCT05272176|No Intervention|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided as part of routine care in the Veterans Health Administration (VHA) following inpatient hospitalization. Study staff will provide no additional treatment in this arm.
9982019|NCT05272163|Experimental|Main Experiment|This is a single arm study where all participants are tested on 1-2 hours of visual search.
9982020|NCT05272137||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
9982021|NCT05272124|Experimental|Hip Abductor Strengthening|This group received quadriceps and hip abductor strengthening along with patellar mobilization and stretching exercises.
9982022|NCT05272124|Active Comparator|Traditional Physical Therapy|This group received quadriceps strengthening along with patellar mobilization and stretching exercises.
9726118|NCT04877457|Experimental|Ocrelizumab|Three courses of ocrelizumab will be administered over the course of the study.
9726119|NCT04877457|Placebo Comparator|Placebo|Three courses of placebo will be administered over the course of the study.
9982023|NCT05272111|Experimental|Fascia Therapy|Group A will receive Fascia therapy
9982024|NCT05272111|Experimental|Facial Manipulation|Group B will receive Facial manipulation
9982025|NCT05272020|Other|TAVI|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment
9982026|NCT05272020|Other|AVR|Cardiopulmonary exercise testing, 6 minute walking test, QOL assessment, Myocardial + aortic valve biopsy
9982027|NCT05271981||Female who underwent uterine artery embolisation for uterine pathology|
9982028|NCT05271968|No Intervention|Control|Standard Care : The classic treatment recommended is the prescription of an oral drug, Ivermectin to be taken two times at one or 2 weeks interval. And recommendations on the need to change the clothes and the linen of the bedding the following day after taking the drug, washing them at more than 50° as well as all the clothes three days before are explained. The first course of oral treatment is swallowed at the BOPC, while the second course is given to be swallowed one week later.
9982029|NCT05271968|Experimental|Intervention|Patients in this interventional arm will come back to BOPC the following day after intake the treatment (D1 and D8) to take a shower and to receive again new clothes
9982030|NCT05271942|Experimental|Tilt and Tumble|"The patients of this group will undergo cataract surgery using the Tilt and Tumble technique."
10199042|NCT01715324|No Intervention|Control|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).
10199043|NCT01712789|Experimental|Pomalidomide plus Dexamethasone|Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
10199044|NCT01672060|Experimental|Nurse-Family Partnership (NFP)|
10199045|NCT01672060|Active Comparator|Existing services|
10199046|NCT01668225||G-CSF FIV nat|Patient following a natural In Vitro Fecondation cycle
9785284|NCT01247922|Experimental|Erlotinib|Participants who received erlotinib in a continuous oral dose of 85 mg/m^2 per day until dose modification, interruption or study discontinuation occurred.
9785285|NCT01247974|Experimental|CorMatrix ECM for Pericardial Closure|Pericardial closure with CorMatrix ECM
9982031|NCT05271942|Active Comparator|Divide and Conquer|"The patients of this group will undergo cataract surgery using the Divide and Conquer technique."
9982032|NCT05271916|Experimental|Combined treatment group|Dacomitinib+Anlotinib: Patients will be treated with combined Dacomitinib and Anlotinib.
9785286|NCT01247974|No Intervention|Control|No Pericardial Closure
9982033|NCT05271916|Active Comparator|Dacomitinib monotherapy group|Dacomitinib: Patients will be treated with Dacomitinib.
9982034|NCT05271890|Experimental|Immediate periodontal treatment|Subjects assigned to this group were receiving non-surgical periodontal treatment as well as oral hygiene instructions immediately after their inclusion. All subjects were undergone full periodontal and rheumatologic clinical examinations both at baseline and 90 days after the completion of the treatment. Blood collection for the analysis of the serum concentration of CRP, ESR, Fibrinogen, IL-6 and TNF-α was also performed at baseline and 90 days after periodontal treatment.
10199047|NCT01665794|Experimental|PdC Group|Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
10199048|NCT01665794|Experimental|PdC + Dara Group|Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
10199049|NCT01651403|Experimental|Tenofovir DF (Blinded Randomized Treatment)|Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
10199050|NCT01651403|Placebo Comparator|Placebo to match TDF (Blinded Randomized Treatment)|Participants will receive TDF placebo for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
10199051|NCT01651403|Experimental|Tenofovir DF (Open-label Treatment)|Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).
10199052|NCT01651403|Experimental|Tenofovir DF (Open-label Extension Phase)|Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in participants of their age and weight.
10199053|NCT01604876|Experimental|light condition 1 + day night structure|exposure to 10.000 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
9982035|NCT05271890|No Intervention|Delayed periodontal treatment|Subjects assigned to this group were receiving non-surgical periodontal treatment 90 days after baseline evaluation. All subjects were undergone full periodontal and rheumatologic clinical examinations both at baseline and 90 days after. Blood collection for the analysis of the serum concentration of CRP, ESR, Fibrinogen, IL-6 and TNF-α was also performed at baseline and 90 days after.
9982036|NCT05271877||Pregnant women|Pregnant women, regardless of the gestational age.
9982037|NCT05271864||Group A|diabetes mellites
9982038|NCT05271864||Group B|hypertension
9982039|NCT05271864||Group C|hyperlipidemia
9982040|NCT05271838|Experimental|High protein diet|High protein diet (2/g/kg/day)
9982041|NCT05271838|No Intervention|Standard Nutritional care|Standard nutritional care.
9982042|NCT05271838|Experimental|Magnesium|Magnesium oral supplementation
9982043|NCT05271838|No Intervention|Standard: No magnesium supplementation|No supplementation
9982044|NCT05271812||Mothers|All women delivered in the recruitment center
9982045|NCT05271812||Staff|All staff working in the labor and delivery areas of the recruiting center.
9982046|NCT05271786||Tracheostomized patients|Patients who underwent percutaneous tracheostomy performed for any reason
9982047|NCT05271760||S group|Single-shot Spinal group
9982048|NCT05271760||E group|Continuous Epidural
9982049|NCT05271760||C group|combined spinal-epidural
9982050|NCT05271747|Active Comparator|Lactoflora colicare|Probiotic multi-strain formulation comprising Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 in sunflower oil and medium-chain triglyceride oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
9982051|NCT05271747|Active Comparator|Reuteri gotas|Probiotic single-strain formulation comprising Lactobacillus reuteri DSM17938 in sunflower oil and medium-chain trygliceride oil. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
9982052|NCT05271734|Experimental|Single arm -lid retractor placement|Placement of a lid retractor the find out if the corneal limbus is exposed to 360 degrees
9982053|NCT05271695||The patients with type 2 diabetes|"Patients with a diagnosis of Type 2 Diabetes Mellitus and HbA1c ≤ 7%~Patients using or not using oral antidiabetic drugs~Patients who inject insulin once or twice a day or repeated insulin injections"
9982054|NCT05271695||The healthy controls|"Patients diagnosed with Type I Diabetes Mellitus,~Patients with HbA1c > 7%~Those with gestational diabetes,~Breastfeeding diabetics,~Patients with renal dysfunction,~Patients with acute and chronic infection status"
9982055|NCT05271682|Experimental|Part 1: 0.4 mg|FHND6091, 0.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
10199054|NCT01604876|Active Comparator|light condition 2 + day night structure|exposure to 200 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
10199055|NCT01599520|Experimental|Spanish-Language Self-Administered Training + Usual Care|Participants randomized to this arm will receive Spanish-Language Self-Administered Training + Usual Care.
10204986|NCT04352010|Experimental|"Online-Intervention REMOTION"|Participants in the REMOTION group get access to REMOTION while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
10204987|NCT04352010|Experimental|Wait-control group|Participants in the wait-control group will not get access to the online-tools while waiting for psychotherapy or while in psychotherapy. Participants will answer questionnaires after inclusion, six weeks later and twelve weeks later.They get access to one of the online-tools after 12 weeks.
9785287|NCT01248065|Placebo Comparator|Ciclesonide + placebo|
9982056|NCT05271682|Experimental|Part 1: 0.8 mg|FHND6091, 0.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
9982057|NCT05271682|Experimental|Part 1: 1.4 mg|FHND6091, 1.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
9982058|NCT05271682|Experimental|Part 1: 2.0 mg|FHND6091, 2.0 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
9982059|NCT05271682|Experimental|Part 1: 2.8 mg|FHND6091, 2.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
9982060|NCT05271682|Experimental|Part 1: 3.6 mg|FHND6091, 3.6 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
9982061|NCT05271682|Experimental|Part 2: lower dose expansion|FHND6091, a lower dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
9982062|NCT05271682|Experimental|Part 2: MTD pr MTD-1 dose expansion|FHND6091, MTD or MTD-1 dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period
9982063|NCT05271656|Experimental|C-Scan System|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
9982064|NCT05271630||Single Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving single maintenance therapy with an immunomodulatory drug after Autologous Stem Cell Transplant for Multiple Myeloma
9982065|NCT05271630||Double Maintenance After Autologous Stem Cell Transplant|Prospectively enrolled cohort of patients receiving double maintenance therapy with the combination of an immunomodulatory drug and a proteasome inhibitor after Autologous Stem Cell Transplant for Multiple Myeloma.
9982066|NCT05271578|Experimental|Smokers|Conventional tobacco cigarette smokers
9982067|NCT05271578|Experimental|Vapers|Electronic cigarette vapers
9982068|NCT05271552|Active Comparator|Cohort 1- 40 Micrograms|Sublingual film containing 40 Micrograms Dexmedetomidine
10204988|NCT04344444|No Intervention|Arm A|Supportive Care only
9982069|NCT05271552|Active Comparator|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
9982070|NCT05271552|Placebo Comparator|Placebo|Sublingual Placebo film
9982071|NCT05271539|Active Comparator|The first group, Lucentis alone group|The first group received 3 monthly intravitreal injections of 0.5 mg in 0.05 mL ranibizumab alone (Lucentis, by Novartis), aspirated from vial through 5-micron sterile filter needle (19-gauge × 1-1/2 inch), with a 1-mL syringe and injected through a 30-gauge × ½ inch sterile injection needle.
9982072|NCT05271539|Active Comparator|The second group, Lucentis dexamethasone group|The second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN).
10199056|NCT01599520|Active Comparator|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
10199057|NCT01575990|Experimental|Making A Decision About CRC Screening|A decision support intervention that is a literacy sensitive paper based tool with educational information targeted to the patient's age and gender.
10199058|NCT01575990|Placebo Comparator|Drivers 65 Plus|The placebo comparator is an attention control with information about driving tips for drivers age 65 and older.
9982073|NCT05271513|Active Comparator|real transcranial magnetic stimulation plus real transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds over the hand area plus 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-dorsal vertebrae for consecuative 10 days (5 days/week)
9982074|NCT05271513|Active Comparator|real transcranial magnetic stimulation with sham transcutaneous magnetic stimulation of spinalcord|the patient will receive real rTMS 2000 pulses for each hand area 20Hz 80% of Motor threshold of the hand, 10 trains, each train 10 seconds plus sham stimulation 1000 pulses 10 Hz 80% of the motor threshold of the leg 10 trains, and each train 10 seconds over the mid-dorsal vertebrae for 10 consecutive days (5 sessions/week)
9982075|NCT05271500|Active Comparator|group(1)|40 post covid 19 patients will receive laser acupuncture
9982076|NCT05271500|Placebo Comparator|group(2)|40 post covid patients will receive placebo laser acupuncture in which laser will be off
9726120|NCT04876131|Experimental|Arm 1, 1 dose|"Single dose IV to cover Gram negative bacteria followed by 2 days of oral antibiotics~Single dose IV to cover Enterococcus spp~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data. Once the IV component is complete the patient will be given an oral antibiotic (cefalexin) on day 2 and 3 of the study."
9726121|NCT04876131|Active Comparator|Arm 2, 3 doses|"3 doses IV to cover Gram negative bacteria~3 days IV antibiotics to cover Enterococcus spp~IV antibiotics are as per local institutional guidelines and microbiology eg: IV gentamicin with or without IV benzylpenicillin. Gentamicin is used when Gram Negative coverage is appropriate, benzylpenicillin is also used when Enterococcus coverage is appropriate, depending on local microbiology data."
9785288|NCT01248065|Experimental|Ciclesonide + Vitamin D|
9982077|NCT05271487|Experimental|Multi-Step Botanical Skin Care Regimen|The patient will be provided with and instructed to use a cleanser, toner, oil control cream, exfoliating facial scrub, clay mask, acne spot treatment, and body scrub for the duration of the study.
9982078|NCT05271474|Experimental|Intervention Arm|Participants will be assigned to use Sibel sensor and download the ANNE ONE platform to their mobile devices. The Sibel sensors are to be worn on the sternum and index finger and can be attached using provided replaceable gel adhesive. The Sibel sensors will transmit data to the ANNE ONE platform. The ANNE ONE platform will send automated alerts to the CRC via email when a patient is flagged as uncontrolled, which will occur when a patient's vitals reach or pass one of the safety thresholds.
9982079|NCT05271474|No Intervention|Control Arm|These patients will be followed by the Clinical Research Coordinator for CAT scores, emergency department visits and hospitalizations.
9982080|NCT05271461|Active Comparator|Circulatory exercises group .|Circulatory exercises.
9982081|NCT05271461|Experimental|LLLT group .|Low level laser Therapy + circulatory exercises.
9982082|NCT05271448|Experimental|Continue ACEI or ARBs|Randomized to continue on prescribed ACE1 or ARBs
9982083|NCT05271448|Active Comparator|Hold ACEI or ARBs|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-72 hours post)
9982084|NCT05271422|Experimental|Experimental Group|Dry eye disease patients (n=12)
9982085|NCT05271422|Sham Comparator|Control Group|Dry eye disease patients (n=12)
9982086|NCT05271396||Temporomandibular Joint Dysfunction Group|Being diagnosed with Temporomandibular Joint Dysfunction
9982087|NCT05271396||Healthy-matched Group|Being healthy according to WHO criteria
10199059|NCT01567722||HIV-positive diffuse large B-cell lymphoma cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.
10199060|NCT01567722||HIV-positive lung cancer cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
10199061|NCT01560572|Active Comparator|standard immunosuupression|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg
9982088|NCT05271370|Experimental|PRO 140 350 mg|PRO 140 350mg weekly SQ injection.
9982089|NCT05271370|Experimental|PRO 140 525 mg|PRO 140 525mg weekly SQ injection.
9982090|NCT05271370|Experimental|PRO 140 700 mg|PRO 140 700mg weekly SQ injection.
9982091|NCT05271344|Placebo Comparator|Placebo Group|Placebo products for probiotics, prebiotics, omega 3 and vitamin D
9982092|NCT05271344|Experimental|Treated Group|Omega 3 fatty acids for 7 days (before starting conventional oral immunonutrition supplement), Probiotics for 14 days before and after the operation, Prebiotics for 14 days before and after the operation, Vitamin D for 6 days before the operation.
9982093|NCT05271331|Experimental|ESP block|Patient will receive ESP block one level above surgery with ropivacaine 0.35% 20 ml per side Patient will receive preoperative wound infiltration with Saline 40 ml
9982094|NCT05271331|Active Comparator|Wound infiltration|Patient will receive ESP block one level above surgery with Saline 20 ml per side Patient will receive preoperative wound infiltration with ropivacaine 0.35% 40 ml
9982095|NCT05271318|Experimental|TILT-123 and Pembrolizumab|"Patients will receive multiple administrations of TILT-123 and Pembrolizumab.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
9982096|NCT05271279|Experimental|OVV-01 Injection+IBR900 Cell Injection|OVV-01 injection combined with IBR900 cell injection, 2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10^9 cells per cycle.
9982097|NCT05271253|Active Comparator|Group (C)|caudal group, where caudal anaesthesia was given using 1 mL/kg dose of 0.25% bupivacaine without epinephrine.
9982098|NCT05271253|Active Comparator|Group (D)|Dexmedetomidine (D) group, where Dex. (Precedex, hospira, Egypt) 0.8 μg/kg was given intravenously over 10 min as a loading dose, and then infused at a rate of 0.4 μg/kg/h
9982099|NCT05271253|Placebo Comparator|Group (P)|Placebo (P) group, where normal saline instead of Dex was given in volume (ml) and rate (ml/h) calculated related to the patient's body weight.
9982100|NCT05271240|Experimental|SIACI of Bevacizumab (Avastin) with Temozolomide and Radiation|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
9982101|NCT05271240|Active Comparator|Standard of care Temozolomide and Radiation|Standard of care Temozolomide and Radiation
9982102|NCT05271227||Cardiogenic Shock Patients|"Cardiac output and Carotid Blood flow is measured before & after PLR test, then percent change is calculated were increase in cardiac output with 10 % or more is considered volume responder.~Measurements can be repeated as needed, and fluid resuscitation continues until no further response to passive leg raising is noted."
9982103|NCT05271201|Experimental|mild intensity group|Received mild intensity treadmill training according to Martti Karvonen's formula.
10199062|NCT01560572|Experimental|steroidfree|maintenance immunosuppression with tacrolimus OD (target range 6-10 ng/ml), mycophenolic acid (2 dd 540 mg)
10199063|NCT01560572|Experimental|low dose tacrolimus|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg. After 6 months lowering of tacrolimus OD maintenance 3-5 ng/ml
10199064|NCT01559805|Experimental|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
9982104|NCT05271201|Experimental|moderate intensity group|Received moderate intensity treadmill training according to Martti Karvonen's formula.
9982105|NCT05271188|Active Comparator|Group 1 who will receive IPACK block|This group of patients will receive IPACK block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
9982106|NCT05271188|Active Comparator|Group 2 who will receive adductor canal block|This group of patients will receive adductor canal block immediately before spinal anaesthesia then follow up for 24 hrs to register first pain sensation and analgesic requirements
9982107|NCT05271175|Experimental|Active TMS & Neutral videos|Received active iTBS stimulation while watching neutral videos
9982108|NCT05271175|Experimental|Active TMS & Smoking videos|Received active iTBS stimulation while watching smoking-related videos
9982109|NCT05271175|Sham Comparator|Sham TMS & Smoking videos|Received sham stimulation while watching smoking-related videos
9982110|NCT05271162|Active Comparator|Empagliflozin|Empagliflozin, 10 mg q.d; p.o
9982111|NCT05271162|Placebo Comparator|Placebo|Placebo 1 tabl q.d; p.o
9982112|NCT05271149|Other|Control group|conventional physical therapy based on neurodevelopmental techniques, This program will be given for 1 hour, 3 days a week for 12 weeks
9982113|NCT05271149|Experimental|study group|conventional physical therapy and orthosis (Thera togs) : the child will wear the orthosis for twelve weeks, from 8 to 10 hours a day, during daily-life activities. The child's guardian (mother) will be trained and will receive a DVD recording, with a step-by-step demonstration on the fitting of TheraTogs® in the child. Markings were made in TheraTogs® to facilitate and improve fitting. All necessary support will be offered, with weekly monitoring in person to control the fitting of the orthosis, as well as for possible questions or clarifications.in addition to conventional physical therapy as the control group
9982114|NCT05271136|Active Comparator|Cell 1: Anti-aging Serum|"Dosage form: Anti-aging Serum~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum.~Study Duration: 7 days"
9982115|NCT05271136|Active Comparator|Cell 2: Anti-aging Serum and Facial Moisturizer|"Dosage form: Anti-aging Serum and Facial Moisturizer~Frequency of Dosage: two times daily. Subjects are asked to apply 2 pumps of the Anti-aging Serum, and then 2 pumps of the Facial Moisturizer to the global face.~Study Duration: 7 days"
9982116|NCT05271123||Study group|Children were evaluated using spirometer to assess forced expiratory volume at first second and peak expiratory flow and gross motor function classification system to assess the functional level.
9982117|NCT05271110|Experimental|Treatment cohort|Adult patients (ECOG 0-1) with a resectable (or previously resected) PDAC and either synchronous or metachronous liver metastases are the target population of this study.
10199065|NCT01559805|Active Comparator|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
9982118|NCT05271058|Sham Comparator|Control group 1|23 eyes that did not receive any intraoperative steroids
9982119|NCT05271058|Active Comparator|Dexamethasone group 2|23 eyes that received intracameral dexamethasone
9982120|NCT05271058|Active Comparator|Triamcinolone (TA) group 3|23 eyes that received intracameral triamcinolone (TA)
9982121|NCT05271045|Experimental|fortified canola oil with vitamins A and D and γ-oryzanol|daily intake of fortified canola oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g & 2130 ppm γ-oryzanol/30g)
9982122|NCT05271045|Active Comparator|fortified canola oil with vitamins A and D|daily intake of fortified canola oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g)
9982123|NCT05271045|Placebo Comparator|fortified sunflower oil with vitamins A and D|daily intake of fortified sunflower oil (385 IU vitamin D/ 30g & 154 IU vitamin A/30 g)
9982124|NCT05271032||Septic Patients|
9982125|NCT05270980|Experimental|Intervention Group (Cohorting)|
9982126|NCT05270980|No Intervention|Control Group (No Cohorting)|
9982127|NCT05270954|Active Comparator|Group 1 (Phase 1)|All volunteers randomized to Group 1 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
9982128|NCT05270954|Active Comparator|Group 2 (Phase 1)|All volunteers randomized to Group 2 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
9982129|NCT05270954|Active Comparator|Group 3 (Phase 2)|All volunteers randomized to Group 3 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 5 μg, twice, within a 28-day period.
9982130|NCT05270954|Active Comparator|Group 4 (Phase 2)|All volunteers randomized to Group 4 will be administered the Betuvax-CoV-2 drug according to the following scheme: 20 μg + 20 μg, twice, within a 28-day period.
9982131|NCT05270954|Placebo Comparator|Group 5 (Phase 2)|Volunteers randomized to Group 5 will be administered a placebo reference drug (0.9% aqueous sodium chloride solution), twice, within a 28-day period.
9982132|NCT05270941|Active Comparator|Control Groups|"Control groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups"
9982133|NCT05270941|Experimental|Test Group|"Test groups. This clinical trial was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+T-PRF) or control (CAF+SCTG) groups after initially evaluating the clinical parameters and randomized by coin flip method.~Intervention: Procedure: Control groups Intervention: Procedure: test groups"
9982134|NCT05270928|Experimental|IBI346|
9982135|NCT05270915|Experimental|Family supportive EOLC|The intervention 'family supportive EOLC' was developed based on the international guidelines of family-centered care (25) with additional aspects of care and support. The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
9982136|NCT05270915|Active Comparator|The standard EOLC|The standard EOLC included the international guidance of palliative care and EOLC in neonatology (21-23). In China, parents are often the decision-makers of their infant's treatment and the NICU clinicians usually respect the parent's decision (24). After parents have decided to withdraw treatment, standard EOLC is initiated and includes monitoring of vital signs and withholding or withdrawing rescue procedures such as intubation and intravenous infusion. Unnecessary lines are removed and pain management is provided by analgesia. Comfort care is provided by nurses including basic care such as skin care and oral care. After the infant died, the NICU physician informs the parents by phone.
9982137|NCT05270889|Experimental|Tislelizumab+Zanidatamab|
9982138|NCT05270876|Experimental|Investigational|Recipients of cochlear implant or suitable for implantation
9982139|NCT05270876|Active Comparator|Standard of Care|Recipients of cochlear implant or suitable for implantation
9982140|NCT05270863|Experimental|BRIMOCHOL™ PF|A single drop in each eye at a visit.
9982141|NCT05270863|Active Comparator|Carbachol PF|A single drop in each eye at a visit.
9982142|NCT05270863|Active Comparator|Brimonidine tartrate|A single drop in each eye at a visit.
9982143|NCT05270837|Experimental|Pegvaliase|
9982144|NCT05270837|Other|Drug: Diet Only|Participants will be managing their PKU with diet alone. Participants in the diet-only control arm will be required to maintain and adjust dietary and medical protein food intake through Week 72, initiating pegvaliase treatment beginning Week 73 and, from Weeks 73 through 145.
9982145|NCT05270824|Experimental|radical surgery after neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)|After randomization, patients received radical surgery after the neoadjuvant immunotherapy (albumin Paclitaxel + Seggio + PD-1 inhibitor)
9982146|NCT05270824|Active Comparator|radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)|After randomization, patients received radical surgery after neoadjuvant chemotherapy (albumin Paclitaxel + Seggio)
9982147|NCT05270785|Experimental|Suicidal Teens Accessing Treatment - Primary Care (STAT-PC)|This group will undergo a brief, suicide prevention intervention based on motivational interviewing that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management
9982148|NCT05270785|Experimental|Youth-Nominated Support Team (YST-III)|This group will undergo a brief, suicide prevention intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation.
9982149|NCT05270772|Experimental|CAR-T-19 Cells|The patients with CD19+ relapse or refractory B-ALL will receive a single infusion of autologous CAR-T-19 cells, with the escalated dose ranging from 0.5×10^6/kg to 5.0×10^6/kg CAR+ cells.
10199066|NCT01543633|Experimental|Active Study Arm|Subjects recruited into this study will be required to undergo a base MRI scan of the brain. On a separate day propofol will be administered with concurrent EEG while subjects respond to stimuli.
10199067|NCT01542736|Experimental|Reduced radiation with concurrent chemotherapy|Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
10199068|NCT01535807|Active Comparator|CorMatrix Group|"The treatment Cormatrix group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique."
10199069|NCT01535807|No Intervention|Control|"The control No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
10199070|NCT01491789|Experimental|Virtual Sailing|you will be doing 60 minutes of Virtual Sailing training, 1 time a week for 12 weeks
9982150|NCT05270733|Experimental|Treatment|Patients will be treated with ustekinumab (90mg at week 0 and week 4 by subcutaneous injection) for 8 weeks followed by treatment with guselkumab (100mg at week 0 and week 4 by subcutaneous injection) or risankizumab (150mg at week 0 and week 4 by subcutaneous injection)
9982151|NCT05270720|Experimental|experimental group|This arm will evaluate the safety of administering a total dendritic cell dose of 5x106. A total of 3 to 6 patients will be enrolled. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
9982152|NCT05270681|Experimental|Individuals with HD|Participants with a confirmed diagnosis of Huntington's disease
9982153|NCT05270681|Experimental|Care Partners|Participants' care partners
9982154|NCT05270655|Experimental|Cognitive-behavioural intervention|Five sessions of cognitive-behavioural intervention will be delivered on a weekly basis.
9982155|NCT05270655|No Intervention|Usual care|Participants in the control group will receive the usual psychosocial care provided by the staff nurses. To offer them attention, a research assistant in each hospital will meet them every week for 10 minutes to ask them about treatment adherence and any other concerns. The parents will be invited to attend it if they want to do so. Each participant will be given an appointment slip and reminded with a phone call two days before the next appointment. For participants whose medical appointment is more than a week, the research will contact them via phone.
9982156|NCT05270642|Experimental|HCC patients guided by Plan for Microwave Thermal Field|The plan for HCC patients undergoing microwave ablation would be refer to Plan for Microwave Thermal Field system
9982157|NCT05270629||Lower limb lymphedema patients|This was a retrospective cohort propensity score-matched study. Patients with lower limb lymphedema were enrolled.
9982158|NCT05270616|Experimental|robotic surgery group|minimally invasive lung surgery using the Davinci robotic system to assist.
9982159|NCT05270616|Active Comparator|uniport surgery group|VATS minimally invasive lung surgery under the uniportal status.
9982160|NCT05270616|Active Comparator|multiple- port surgery group|VATS minimally invasive lung surgery under the multiple- port status.
9982161|NCT05270603||ICARUS Calculator Raters (Intervention Group)|Surgeons and anesthesiologists will be asked to use the ICARUS Calculator to grade a subset of 10 clinical scenarios selected from a list of the clinical scenarios and examples from the publications of the 5iAE systems
9982162|NCT05270603||Cognitive Grading Raters (Control Group)|Surgeons and anesthesiologists will be asked to use the ICARUS Calculator to grade a subset of 10 clinical scenarios (same as the Intervention group) selected from a list of the clinical scenarios and examples from the publications of the 5iAE systems
9982163|NCT05270590||group A|periareolar approach
9982164|NCT05270590||group B|submamary approach
9982165|NCT05270577|Experimental|Prehabilitation|Prehabilitation with physical exercise, psychological support, nutritional support and smoking/alchohol stop
9982166|NCT05270577|Active Comparator|Standard care|Standard preoperative recomendations
9982167|NCT05270564|Active Comparator|Drain|Surgical drains used as routine
9982168|NCT05270564|Experimental|No drain|No surgical drain used
9982169|NCT05270551|Active Comparator|Group 1|Without augmentation
9982170|NCT05270551|Active Comparator|Group 2|With augmentation
9982171|NCT05270538|Active Comparator|comparison of clinical and gasometric parameters between the study group and the control group|"To carry out the study, we defined a control group and a study group distributing them between the two groups. The control group will perform the exercise, without using a mask, while the study group will perform the exercise using Masks Zero Mask Sewing Virus Bac-Off Lupo® for the duration of the exercise.~The exercise consisted of 15 minutes of treadmill without inclination interspersing every 2 minutes at speeds 10 Km/h and 12 Km/h, being by definition of a dynamic aerobic exercise of intensity 4 of 5 in the Borg scale- classification of the intensity of physical exercise. Physical activity was performed in water deprivation and fasting at least 30 minutes before the start of activated."
9982172|NCT05270525|Experimental|Treatment Sequence 1|Treatment Period 1 (blinded Ensifentrine) followed by Treatment Period 2 (blinded Placebo)
9982173|NCT05270525|Experimental|Treatment Sequence 2|Treatment Period 1 (blinded Placebo) followed by Treatment Period 2 (blinded Ensifentrine)
9982174|NCT05270486||Group A|group A undergoing TELD (transforaminal endoscopic lumbar discectomy) with electromagnetic navigation system
9982175|NCT05270486||Group B|group B undergoing TELD with X-ray fluoroscopy (gold standard)
9982176|NCT05270473|Active Comparator|group A: b lynch|B lynch uterine compressive suture was done
9982177|NCT05270473|Active Comparator|group B : Nusicaa suture|Nusicaa uterine compressive suture was done
9982178|NCT05270447|Experimental|Total laparoscopic hysterectomy (TLH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
10199071|NCT01481974|Experimental|Treprostinil|This is a single center, open-label, dose-escalation Phase I/II study of Treprostinil.
10199072|NCT01465100|Experimental|Hepatocyte Transplantation|See Below.
10204989|NCT04344444|Experimental|Arm B|Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5
10204990|NCT04344444|Experimental|Arm C|Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5
10204991|NCT04342715||Patients|Patients who have a diagnosis of visceral leishmaniasis and will be treated with SSG/PM
10204992|NCT04342715||Control|Healthy volunteers
9982179|NCT05270447|Other|Total laparoscopic hysterectomy (TLH) control group|routine care+ advising
9982180|NCT05270447|Experimental|Total abdominal hysterectomy (TAH) Connetive tissue massage group|Connective tissue massage+ routine care+ advising
9982181|NCT05270447|Other|Total abdominal hysterectomy (TAH) control group|routine care+ advising
9982182|NCT05270434|Experimental|Endoscopic group <12h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
9982183|NCT05270434|Active Comparator|Endoscopic group 12-36h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 12-36h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
9982184|NCT05270434|Active Comparator|Endoscopic group >36h|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP is greater than 36h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary.
9982185|NCT05270421|Experimental|Intervention Group|"40 mg of furosemide IV + IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
9982186|NCT05270421|Active Comparator|Control Group|"IV midazolam + 1000 ml of normal saline 30 minutes before ESWL~+ Standard ESWL"
9982187|NCT05270395|Experimental|mPal intervention|Participants in this group will receive the mPal intervention. mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider. mPal's provider content (not randomized) will include education. System-level modifications will also be made to the electronic health record to facilitate palliative care discussions and referrals.
9982188|NCT05270395|No Intervention|Standard of care|Participants in this group will receive standard of care (applies to patients only).
9982189|NCT05270382|Active Comparator|Cetylpyridinium chloride/pH adjuster 1|A mouthwash contains cetylpyridinium chloride and pH adjuster 1.
9982190|NCT05270382|Placebo Comparator|Placebo 1|A mouthwash without cetylpyridinium chloride and pH adjuster 1
9982191|NCT05270382|Active Comparator|Cetylpyridinium chloride/pH adjuster 2|A mouthwash contains cetylpyridinium chloride and pH adjuster 2.
9982192|NCT05270382|Placebo Comparator|Placebo 2|A mouthwash without cetylpyridinium chloride and pH adjuster 2
9982193|NCT05270369|Experimental|digital cognitive behavioural therapy for insomnia (CBTI)|The digital CBTI group will receive 6-session on their smartphone application
9982194|NCT05270369|Experimental|group cognitive behavioural therapy for insomnia (CBTI)|The group CBTI will receive 6-session CBTI in group
9982195|NCT05270369|No Intervention|waitlist|The waitlist group will receive treatment sessions after about 10 weeks' time
9982196|NCT05270343|Experimental|Vitamin D|In 99 subjects of 3-18yr with newly-onset T1D, oral administration of 140IU/kg qd of cholecalciferol will be given until the serum 25(OH)D3 was maintained at the upper limit of normal range(50-80 ng/ml[125-200 nmol/L], ≤100 ng/ml[≤250 nmol/L]) for the loading peroid. And then oral administration of 70IU/kg qd of cholecalciferol for the maintenance period, meanwhile combined with intensive Insulin therapy for 12 months.
9982197|NCT05270343|No Intervention|Insulin|In 99 subjects of 3-18yr with newly-onset T1D, only intensive insulin therapy will be given for 12 months.
9982198|NCT05270278||1. Eosinophilic AB - initiated biological treatment against IL-5 or IL-5R|"initiated biological treatment - mepolizumab or benralizumab~judged by the treating physician, the patient cannot indicated treatment of type anti IgE or anti IL-4R"
9982199|NCT05270278||2. Eosinophilic AB - initiated biological treatment against IgE or IL-4R|"initiated biological treatment - omalizumab or dupilumab~judged by the treating physician, patient cannot indicated treatment type anti IL-5 or anti IL-5R"
9982200|NCT05270278||3. Eosinophilic AB - initiated biological treatment against IgE or IL-4R, or against IL-5 or IL-5R|"initiated biological treatment - omalizumab or dupilumab, or mepolizumab or benralizumab~judged by the treating physician, the patient could be potentially indicated to treatment with all 4 alternatives"
9982201|NCT05270278||4. Non-eosinophilic AB - without indication for biological treatment|"no biological treatment initiated~judged by the treating physician, the patient cannot be indicated to biological treatment"
9982202|NCT05270265|Experimental|Group 1 (low dose)|8-10 volunteers receiving three doses of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
9982203|NCT05270265|Experimental|Group 2 (standard dose)|8-10 volunteers receiving three doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56 via intramuscular injection (IM) in the deltoid region of the arm
10204993|NCT04333537|Experimental|Sentinel Lymph Node (SLN) Biopsy|Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy.
10199073|NCT01442649|Experimental|Arm A : bevacizumab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Bevacizumab 5 mg/kg IV every 2 weeks."
10199074|NCT01442649|Experimental|Arm B : cetuximab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Cetuximab : 500 mg/m² IV every 2 weeks"
10199075|NCT01345578|Experimental|Hepatocyte Transplantation|See Below
10199076|NCT01330719|Experimental|Diseased periodontal treatment|Scaling and root planing along with systemic antibiotics (Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days).
10199077|NCT01330719|Active Comparator|Conventional periodontal treatment|Standard periodontal prophylaxis
10199078|NCT01283438|Experimental|Barricaid Device|Intervention: Barricaid Device
10199079|NCT01283438|Active Comparator|Standard of Care|Standard (Limited) Discectomy Only
10199080|NCT01147666|Experimental|Cohort A-1 (Roxadustat 1.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.0 milligrams (mg)/kg, administered orally 3 times weekly (TIW) in the morning of the day after dialysis (interdialytic days) for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 grams [g]/deciliter [dL]) will be based upon regular monitoring of Hb.
10199081|NCT01147666|Experimental|Cohort A-2 (Roxadustat 1.5 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
10199082|NCT01147666|Experimental|Cohort A-3 (Roxadustat 2.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
9982204|NCT05270265|Experimental|Group 3 (fractional dose)|8-10 volunteers receiving two doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0 and 28, followed by one dose of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on day 56 via intramuscular injection (IM) in the deltoid region of the arm
9982205|NCT05270252|No Intervention|Control group|no intervention
9982206|NCT05270252|Experimental|Intervention group|Interdisciplinary educational intervention with a combination of active educational methods.
9982207|NCT05270239|Experimental|Working Memory Training in MS patients|This group of patients will perform a computerized n-back training, which includes a sequence of 2-back and 3-back blocks.
9982208|NCT05270239|Experimental|Virtual Reality Training in MS patients|"This group of patients will perform a Virtual Reality Ball Task training. This task contains 6 trials of increasing difficulty."
9982209|NCT05270226|Experimental|Group A|After being randomly allocated, group A participants had first evaluation (out of 3, pre-intervention) and immidiatlly recived Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE).
9982210|NCT05270226|Experimental|Group B|After being randomly allocated, group B participants had first evaluation (out of 4), then waiting-phase of 10-11 weeks, and after second evaluation (pre-intervention) start Work-MATE intervention process.
9982211|NCT05270200|Experimental|Azacitidine combined with Chidamide|Patients will recieve six courses of azacitidine 100mg through a needle under your skin on Days 1-5.Each course is 28 days long.At the same time patients will recieve oral chidamide 5mg per day for no more than 2 years.
9982212|NCT05270187|Experimental|Scanning Gorup|"Patients in this group will receive facial massage, facial expression exercises and a Multiwave Locked System Laser with energy density 10 J/cm2. Laser will scan the affected side after calculating the distance and the total energy delivered to the one side of the face.~The average treatment area is 50 cm2. The energy density was 10 J/cm2 with a total energy of 500 J and the treatment time is approximately 15 minutes. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles."
9982213|NCT05270187|Experimental|Point laser Group|Patients in this group will received facial massage, facial expression exercises and laser at predetermined eight points on the affected side of the facial muscles. the hand piece is positioned perpendicular to 8 points which is located on the superficial roots of the facial nerve of the affected side. Each point will receive an energy density of 10 J/point with total energy delivered to the patient during one session of 80 joules. The time of application 90 sec/point. laser is calibrated by the manufacture company before the starting the experiment and periodically during the sessions. The laser probe will be away from the eye region. Both patients and therapist wear a laser googles.
9982214|NCT05270187|Placebo Comparator|Control Group|patients in this group will receive only facial massage, facial expression exercises and placebo laser. Facial expression exercises include active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
9982215|NCT05270174||lncRNA-ELNAT1 high expression group|
9982216|NCT05270174||lncRNA-ELNAT1 low expression group|
9982217|NCT05270161|Experimental|Test Group 1 (T1)|Multiple gingival recessions in the anterior region of the mandible treated with the tunnel technique.
9982218|NCT05270161|Experimental|Test Group 2 (T2)|Isolate gingival recessions in the anterior region of the mandible treated with the laterally closed tunnel technique.
9982219|NCT05270161|Active Comparator|Control Group 1 (C1)|Multiple gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
9982220|NCT05270161|Active Comparator|Control Group 2 (C2)|Isolate gingival recessions in the anterior region of the mandible will be treated using the free gingival graft technique.
9982221|NCT05270161|Experimental|Gel Group (G)|The donor area on the palate will be treated using hyaluronic acid gel and green tea applied by the participant 3 times a day for 7 days.
9982222|NCT05270161|Active Comparator|Clot Group (CO)|No material will be placed in the donor area, only the clot will be kept in position by means of sutures.
9982223|NCT05270148|Experimental|HIIT Group|Participants are enrolled in a high-intensity interval training exercise program
9982224|NCT05270148|Active Comparator|FatMax Group|Participants who are enrolled in a moderate-intensity continuous training exercise program
9982225|NCT05270148|No Intervention|Control|Participants who do not receive an exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
9982226|NCT05270135|No Intervention|Control|Control pharmacies will not receive the intervention training, coaching or materials. They will track the sale of syringes upon request and they will participate in the surveys.
9982227|NCT05270135|Experimental|ASAP Intervention|ASAP intervention pharmacies will receive the CEU training, coaching from research staff, ASAP materials and tracking for the sale of syringes. They will also participate in surveys.
9982228|NCT05270109|Experimental|BiZact|
9982229|NCT05270109|Active Comparator|Cold Steel|
9982230|NCT05270096||Relapsed leukemia|"T-ALL:~First relapse with high MRD after re-induction Newly diagnosed with high MRD after consolidation~B-ALL:~1st relapse high risk group, Second or higher relapse, post CAR-T or post HSCT~AML:~Second or higher relapse"
9982231|NCT05270083|Active Comparator|Athletes with mild to moderate traumatic brain injury (mTBI) and good outcome|Young athletes who have sustained one or more concussions without persistent cognitive complaints at least one year post-injury
9982232|NCT05270083|Active Comparator|Athletes with persistent cognitive deficits due to mild to moderate traumatic brain injury (mTBI)|Young athletes who have sustained one or more concussions with persistent cognitive complaints at least one year post-injury in spite of medical and cognitive treatment intervention.
9982233|NCT05270070||Digital Booking|Patients bookings done through digital booking system.
9982234|NCT05270070||Traditional Booking|Patients bookings done through traditional booking like telephone or secure email.
9982235|NCT05270044|Experimental|Arm A|Encorafenib and Binimetinib
9982236|NCT05270044|Placebo Comparator|Arm B|Placebo to match Encorafenib Placebo to match Binimetinib
10199083|NCT01147666|Experimental|Cohort A-4 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
10199084|NCT01147666|Experimental|Cohort A-5 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 85-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
9982237|NCT05270031|Experimental|Eustachian tube dilation|Surgical Eustachian tube dilation in general anaesthesia
9982238|NCT05270031|No Intervention|Control Group|nasal saline spray
10199085|NCT01147666|Experimental|Cohort A-6 (Roxadustat 1.3 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.3 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
10204994|NCT04333537|Active Comparator|Elective Neck Dissection (END)|Patients undergo standard END.
9982239|NCT05270018|Experimental|Bacterial Lysate group|Oral / gastric administration of bacterial lysate once a day on an empty stomach, 14.0mg each time for at least 5 days
9982240|NCT05270018|Placebo Comparator|Control group|Oral / gastric administration of normal saline once a day, 14.0ml each time
9982241|NCT05270005||Asymptomatic carotid artery stenosis|Patients with an asymptomatic carotid artery stenosis, defined by 30% to 69% narrowing of the carotid artery according to conventional duplex measurements in the absence of ipsilateral retinal or cerebral ischemia in the preceding 6 months.
9982242|NCT05269992|Experimental|Real food products|The study products are 1) a 1kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed; 2) a 1.5kcal/ml enteral tube feed provided as a 500ml ready to use enteral tube feed, and 3) a 1.5kcal/ml oral nutritional supplement provided in a 200ml ready to drink format. This study is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period aiming to recruit 60 in paediatric patients. During the intervention period, patients will receive one of the three study products (or more if deemed appropriate) for 28 days as a sole source of nutrition or alongside any additional routine nutritional management as required. As such, randomisation was not deemed suitable for this study. The appropriate study product and volume prescribed will be recommended by the investigating dietitian/nurse and agreed with the patient/parent/carer based on their clinical and nutritional requirements.
9982243|NCT05269979|Experimental|Intervention (the Vislanda district)|435 women living in Vislanda responded to a detailed survey and participated in physical exercise and received lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
9982244|NCT05269979|No Intervention|Control (the Tingsryd/Emmaboda districts)|415 women living in Tingsryd and 395 women living in Emmaboda responded to the same detailed survey as the 435 women living in Vislanda.
9982245|NCT05269966|Experimental|Brolucizumab|"Brolucizumab, formerly known as ESBA1008, is a humanized single-chain Fv (scFv) antibody fragment.~Its Intravitreal injections.~Brolucizumab 6 mg will be administered by IVT injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients will receive loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) will be performed based on BCVA and OCT to assess whether the patient will require q8w or q12w dosing."
9982246|NCT05269953|Experimental|Active stimulation|
9982247|NCT05269953|Sham Comparator|Sham stimulation|
9982248|NCT05269953|No Intervention|Waitlist (no stimulation)|Treatment as usual
9982249|NCT05269940|Experimental|ZX-101A Dose Level A|ZX-101A administered orally at level A once daily
9982250|NCT05269940|Experimental|ZX-101A Dose Level B|ZX-101A administered orally at level B once daily
9982251|NCT05269940|Experimental|ZX-101A Dose Level C|ZX-101A administered orally at level C once daily
9982252|NCT05269940|Experimental|ZX-101A Dose Level D|ZX-101A administered orally at level D once daily
9982253|NCT05269940|Experimental|ZX-101A Dose Level E|ZX-101A administered orally at level E once daily
9982254|NCT05269927|Experimental|TD (typically developing) infants|Typically developing infants, infants without familiar risk for ASD or LD.
9982255|NCT05269927|Experimental|HR (high risk) for LD infants|Infants at high risk for language disorders
9982256|NCT05269927|Experimental|HR for ASD infants|Infants at high risk for autism spectrum disorder
9982257|NCT05269914|Experimental|Autologous anti-CD19 CAR-T cell injection|with 1.00×106 CAR+T cells/kg, 3.00×106 CAR+T cells /kg and 9.00×106 CAR+T cells/kg
9982258|NCT05269888||Study group - Ocrelizumab|30 patients with multiple sclerosis on Ocrelizumab (standard of care)
9982259|NCT05269888||Study group - Natalizumab|30 patients with multiple sclerosis on Natalizumab (standard of care)
9982260|NCT05269888||Study group - Alemtuzumab|30 patients with multiple sclerosis on Alemtuzumab (standard of care)
9982261|NCT05269888||Study group - Tecfidera|30 patients with multiple sclerosis on Tecfidera (standard of care)
9982262|NCT05269888||Study group - Fingolimod|30 patients with multiple sclerosis on Fingolimod (standard of care)
9982263|NCT05269888||Study group - Interferon|30 patients with multiple sclerosis on Interferon (standard of care)
9982264|NCT05269888||Study group - off DMT|30 patients with multiple sclerosis off disease modification treatment (DMT) (standard of care)
9982265|NCT05269888||Control group|30 healthy volunteers
9982266|NCT05269875|Other|Advance care planning in heart failure patients|The patient and their closest relative will be offered a palliative care intervention by the Department of Cardiology.
9982267|NCT05269849|Experimental|Oral sirolimus tablets|Sirolimus starting dose of 2 mg once daily, orally adjusted as need to maintain drug blood levels of 6-10 ng/ ml The first dose will be given at the week 12 visit and participants will be observed for 30 min
9982268|NCT05269823|Active Comparator|Ice-therapy|Ice therapy will be provided prior to the provision of the intravitreal injection
9982269|NCT05269823|Placebo Comparator|No Ice-therapy|No ice therapy will be provided prior to the provision of the intravitreal injection
9982270|NCT05269784|Experimental|Completely Tubeless Group|minimally invasive lung surgery under ERAS with completely tubeless protocol: no intubation, no urinary catheter, move the chest drainage as fast as possible according the ERAS guideline on the premise of safety.
9982271|NCT05269784|Active Comparator|Partially Tubeless Group|minimally invasive lung surgery under ERAS with partially tubeless protocol.
9982272|NCT05269732|Experimental|Treatment (9-week online CBT group)|Participants assigned to the treatment group will participate in regularly scheduled visits and any other healthcare they might be receiving (e.g. family doctor, midwife, Obstetrician/Gynecologist, etc.) and in a 9-week group Cognitive Behavioral Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists, social workers, nurses, and/or psychiatrists.
9982273|NCT05269732|No Intervention|Control (treatment as usual)|The control group will receive standard postnatal care from their obstetrician, midwife, and/or family physician
9982274|NCT05269719||Digital nerve injury, surgical treatment, isolated injury|Patient over the age of 18 with an isolated injury to a digital nerve.
9982275|NCT05269719||Digital nerve injury, surgical treatment, concomittant flexor tendon injury|Patient over the age of 18 with an injury to a digital nerve and a concomittant flexor tendon injury.
9982276|NCT05269693|Experimental|the Brief Hope Intervention group|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions in-between.
9982277|NCT05269693|No Intervention|wait-listed control group|Usual community care
9984745|NCT03777462|Experimental|Group C of neoadjuvant chemoradiotherapy|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
10199086|NCT01147666|Experimental|Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.3 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 100 mg, and 150 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
9726122|NCT04874519||Participants with Fibrolamellar Carcinoma/FLC|Participants will have a personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of FLC must be confirmed at MSK or an external hospital)
9982278|NCT05269654|Experimental|injectable poly-L-lactic acid|One side of the subject's hips will be treated with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).
9982279|NCT05269654|Sham Comparator|Normal Saline|One side of the subject's hips will be treated with injectable normal saline
9982280|NCT05269641|Experimental|Almonds|Daily consumption of almonds.
9982281|NCT05269641|Placebo Comparator|Control Snack|Daily non-nut snack will be consumed.
9982282|NCT05269615|Active Comparator|Valsartan tablets|
9982283|NCT05269615|Placebo Comparator|Placebo tablets|
9982284|NCT05269563|Experimental|Double flap technique to secure macular hole closure.|Single ILM flap technique is already performing worldwide; however, sometimes it is associated with flap displacement. To overcome this issue, the double flap technique was tried.
10204995|NCT04333147|Experimental|Participants receiving GSK3196165 in qualifying study|Participants receiving GSK3196165 in their qualifying study will continue to receive GSK3196165 at the same dose level (90 mg or 150 mg weekly) in this study.
10204996|NCT04333147|Experimental|Participants receiving comparator in qualifying study|Participants receiving a comparator (e.g. tofacitinib or sarilumab) in their qualifying study will be re-randomized to receive either GSK3196165 90 mg or 150 mg weekly in this study.
9726123|NCT04872257|Experimental|Oral Vitamin D + NB-UVB Phototherapy|
9726124|NCT04872257|Placebo Comparator|Placebo + NB-UVB Phototherapy|
9726125|NCT04871087|Other|Allay lamp (narrow band green light)|Comparing effects of NBGL vs. white light on anxiety level before and after psychotherapy treatment sessions.
9726126|NCT04868734|Experimental|Supportive Psychotherapy|Supportive Psychotherapy do to subjects
9726127|NCT04868734|No Intervention|Casual Treatment|Do Casual Intervention
9726128|NCT04867928|Experimental|Venetoclax+azacitidine|subjects will receive treatment until alloSCT
9726129|NCT04867395|No Intervention|Usual Care|75 participants will receive standard care, consisting of verbal discharge counseling given by doctors and nurses supplemented by written instructions (all unstandardized).
9726130|NCT04867395|Experimental|Intervention group|75 participants will be randomized to receive behavioral intervention, consisting of discharge counseling using the health literacy-informed discharge instructions
9982285|NCT05269524|Experimental|Treatment|Therapist-guided internet treatment.
9726132|NCT04862754|Experimental|interval training|Aerobic interval training. It consisted of a modified interval cycle ergometer training program (3 days a week for 8 weeks). AIT consisted of 8 min warm up, followed by four times of 4-min intervals with HR at 80% of submaximal predetermined HR, with active phases of 3 min of cycling at 60% of submaximal predetermined HR. The exercise session was terminated by 5 min cool down
9726133|NCT04862754|No Intervention|medical treatment|hypertensive medication
9726134|NCT04851886|Active Comparator|Individual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 sessions of robot-assisted upper-limb rehabilitation. During the sessions, a therapist will administer one-on-one therapy (i.e. each study volunteer will work with a single therapist).
9726135|NCT04851886|Experimental|Group robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will also undergo 18 sessions of robot-assisted upper-limb rehabilitation. However, a therapist will administer the intervention as group therapy with up to three subjects participating in the session at the same time. To facilitate the deliver of the therapeutic intervention, the robot will be equipped with a camera system (called PostureCheck) designed to track the quality of the exercises.
9726136|NCT04849221||Patients|Head trauma, patient operated on for an intracranial lesion, or other condition (hemorrhagic stroke)
9726137|NCT04849221||healthy subjects|No otologic or neurological history
9726138|NCT04846348|Experimental|Skin Guard|"Skin cream combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base:~Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor"
9726139|NCT04845165||Patients with FPL2 genetically confirmed|patients suffering with FPL2 with the R482 codon mutation of the LMNA gene.
9726140|NCT04844567|Experimental|COVVR_A|Participants in the COVVR_A arm complete the synchronous block first, followed by the asynchronous block.
9726141|NCT04844567|Experimental|COVVR_B|Participants in the COVVR_B arm complete the asynchronous block first, followed by the synchronous block.
9982286|NCT05269524|Active Comparator|Attention control|Non-directive supportive contact via email.
9982287|NCT05269485|Experimental|High-dose hypofraction Arm|Irradiation of 60-68Gy/15-17f is administered followed by one-year immunotherapy maintenance.
9982288|NCT05269485|Experimental|Low-dose hypofraction Arm|Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance.
9982289|NCT05269472||Trigeminal Electrophysiology|
9982290|NCT05269472||Controls|
9982291|NCT05269459|Experimental|Cannabidiol (CBD) as Nantheia ATL5|Cannabidiol (CBD) as Liquid Structure Formulation Nantheia ATL5 400mg BID. Administered in 100mg softgel capsules. Each 100mg softgel contains 10% CBD.
9982292|NCT05269459|Placebo Comparator|Placebo|Matching placebo
9982293|NCT05269459|No Intervention|Control Population|Control group for purposes of baseline data collection
9982294|NCT05269446||STEMI patients|STEMI: patients diagnosed with ST-segment elevation myocardial infarction
9982295|NCT05269446||SA patients|SA: patients diagnosed with stable angina
10199087|NCT01147666|Experimental|Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
10199088|NCT01147666|Experimental|Cohort A-9 (Roxadustat 2.0 mg/kg)|Normoresponsive participants (with baseline epoetin alfa dosage 85-150 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
10199089|NCT01147666|Experimental|Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
9726142|NCT04841967|Experimental|TELL Tool Group|Parents in the TELL Tool group will complete a decision support aid that has four interactive, multimedia and multicomponent modules that will be administered digitally. It will take parents about 60 minutes to complete the TELL Tool.
9726143|NCT04841967|Active Comparator|eBook Attention-Control|Parents in the eBook attention-control group will complete one interactive, multimedia and multicomponent program that contains information about good parenting principles and is administered digitally. It will take parents about 60 minutes to complete the eBook attention control.
9726144|NCT04841876||Group-1|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-1, participants will be asked to play three consecutive rugby matches, with 40 min for each match. The total duration will be 2 hours. There is no additional intervention on this group.
9726145|NCT04841876||Group 2|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-2, participants will be asked to only watch the rugby matches. They will not received any intervention.
9726146|NCT04840472|Experimental|111-In panitumumab|The study drug (111In panitumumab) 5 mCi, allowable range 4.5 to 5.5 will be administered on Day 0, and subjects will undergo one 111In panitumumab SPECT/CT imaging anytime between Day 1 and Day of Surgery. Subjects will undergo surgical resection after infusion of 111In panitumumab.
9726147|NCT04831996|Experimental|Treat Group 1 : Normal Renal Function|eGFR: ≥ 90 mL/min/1.73 m^2
9726148|NCT04831996|Experimental|Treat Group 2 : Mild Renal Impairment|eGFR: 60-89 mL/min/1.73 m^2
9726149|NCT04831996|Experimental|Treat Group 3 : Moderate Renal Impairment|eGFR: 30-59 mL/min/1.73 m^2
9726150|NCT04831996|Experimental|Treat Group 4 : Severe Renal Impairment|eGFR: ≤ 29 mL/min/1.73 m^2 and not on Hemo Dialysis
9726151|NCT04831996|Experimental|Treat Group 5 : Kidney Failure|eGFR: ≤ 29 mL/min/1.73 m^2 and on Hemo Dialysis
9726152|NCT04830423|Active Comparator|medikal ozone group|medical ozone group patients diagnosed with knee ostheoarthritis
9726153|NCT04830423|Other|steroid group|steroid group patients diagnosed with knee ostheoarthritis
9726154|NCT04830020|Active Comparator|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt)
9726155|NCT04830020|Placebo Comparator|placebo|5 ml of saline via nebulizer b.i.d.
9726156|NCT04829682|Experimental|ACT for Life|ACT for Life + Treatment as Usual
9726157|NCT04829682|Active Comparator|Present Centered Therapy|Present Centered Therapy + Treatment as Usual
9726158|NCT04826991|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
9726159|NCT04826991|Sham Comparator|Inactive UV Device|A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).
9726160|NCT04826744||Adults with palpebral involvement of atopic dermatitis|
9726161|NCT04826614|Experimental|optimized treatment|early adjust dose or change drug
9726162|NCT04826614|Active Comparator|routine treatment|slowly adjust dose or change drug
9726163|NCT04825223|Experimental|Stage 1: MenB vaccine formulation(s)|Assigned MenB vaccine formulation or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
9726164|NCT04825223|Active Comparator|Stage 1: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
9726165|NCT04825223|Experimental|Stage 2: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, MenQuadfi vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of leading MenB vaccine formulation single injection at Day 366
9726166|NCT04825223|Active Comparator|Stage 2: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of Bexsero vaccine single injection at Day 366
9726167|NCT04825223|Experimental|Stage 3: Men B vaccine formulation(s)|Assigned MenB vaccine formulation and/or MenQuadfi vaccine single injection in the respective dosing schedule at Day 01 and Day 61
9726168|NCT04825223|Active Comparator|Stage 3: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine single injection at Day 01 or Bexsero vaccine single injection at Day 01 and Day 61
9726169|NCT04825223|Experimental|Stage 4: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, Routine Vaccines (RV)s and MenQuadfi vaccine single injection in the respective dosing at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
9726170|NCT04825223|Active Comparator|Stage 4: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine or Bexsero vaccine and RVs in the respective dosing schedule at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
9726171|NCT04823091|Experimental|Fludarabine + Cyclophosphamide + anti-CD7 CAR-T Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (250 mg/kg) on day -5, -4, and -3, followed by the infusion of CAR7-T cells with the dose of 1×10^6/kg and 2×10^6/kg (with an allowance of ±20%). If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
9726172|NCT04821752|Experimental|Toxicant avoidance and glucose dysregulation|To investigate whether or not the excretion of urinary toxicant metabolites is reduced by dietary modification and lifestyle intervention in people with glucose dysregulation; whether the participant's ranked glucose dysregulation correlates with the amount and/or type of toxic metabolites excreted at baseline; and whether the body's immediate response to glucose is improved by the reduction of toxicant burden.
9726173|NCT04816552|Experimental|CHoBI7 mHealth program Arm|The first arm will receive the CHoBI7 mHealth program and a general message on oral rehydration solution (ORS) (CHoBI7 mHealth program Arm) .
9726174|NCT04816552|Active Comparator|Standard Recommendation Arm|The second arm will serve as a Control Arm and only receive a general message on oral rehydration solution (ORS).
9726175|NCT04816006|Experimental|Aerobic Exercise Training|Breast cancer survivors randomized to the intervention group will participate in a moderate-intensity aerobic exercise program for 24 weeks.
9726176|NCT04816006|Active Comparator|Health Education (Control)|Individuals randomized to Health Education will receive individual education and counseling related to general cancer-related health and support across 24 weeks.
9726177|NCT04815902|Experimental|Active Fisetin and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
9726178|NCT04815902|Active Comparator|Active Fisetin and Losartan Placebo|Losartan Placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
9726179|NCT04815902|Active Comparator|Fisetin Placebo and Active Losartan|Losartan 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
9726180|NCT04815902|Placebo Comparator|Control|Losartan placebo 12.5 mg, PO, BID beginning the first day after BMA Concentrate injection and continuing for 30 days. Fisetin Placebo 20mg/kg taken a total of 4 days prior to BMA Concentrate injection (-32 and -31 and -3 and -2) then again after BMA Concentrate injection a for a total of 6 days (32 & 33, 61 & 62 and 90 & 91).
9726181|NCT04814602|Active Comparator|Control|Healthy controls Proglumide 400 mg given once by mouth
9726182|NCT04814602|Experimental|Hepatic Impaired|Cirrhosis Child-Pugh A and B Proglumide 400 mg given once by mouth
9726183|NCT04814173|Experimental|One jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a one-jaw mechanic (mini-implants in the maxillary arch).
9726184|NCT04814173|Experimental|Two-jaw mechanic|Mini-implants anchored total-maxillary-arch-distalization using a two-jaw mechanic (mini-implants in the mandibular arch with class II elastics).
9726185|NCT04814173|Experimental|Traditional treatment|traditional en-mass retraction with first premolars extraction with mini-implants in the maxillary arch.
9726186|NCT04812795|Experimental|Culturally tailored|The anti-smoking and anti-industry messages will be culturally tailored to specifically reach out to young adult SMW. They will receive only messages that are culturally tailored at baseline and weeks 1, 2, and 3.
9726187|NCT04812795|Active Comparator|Non-culturally tailored|The anti-smoking and anti-industry messages will not be culturally tailored. They will receive only messages that are not culturally tailored at baseline and weeks 1, 2 and 3.
9726188|NCT04810962|Experimental|APP13007 0.05% BID|1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
9726189|NCT04810962|Placebo Comparator|Matching Vehicle Placebo|1 drop matching vehicle placebo twice daily for 14 days to study (operated) eye
9726190|NCT04810169||Smart inhaler|Children with smart inhaler
9726191|NCT04807478||Pediatric patients|Pediatric patients with new-onset PNAC
9726192|NCT04806984||Call center phone call|Participants randomized to this arm will receive a phone call from the call center reminding them to schedule their appointments.
9726193|NCT04806984||No call center phone call|Participants randomized to this arm will not receive a phone call from the call center reminding them to schedule their appointments.
9726194|NCT04806984||MyChart message|Participants randomized to this arm will receive an automated MyChart message reminding them to schedule their appointments.
9726195|NCT04806984||No MyChart message|Participants randomized to this arm will not receive an automated MyChart message reminding them to schedule their appointments.
9726196|NCT04804930||patients with systemic scleroderma|
9726197|NCT04804930||healthy subject|healthy subject without systemic scleroderma or known hair or scalp disease
10199090|NCT01147666|Active Comparator|Cohorts A (Epoetin Alfa)|Normoresponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort A. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
10199091|NCT01147666|Experimental|Cohort B-1 (Roxadustat 1.5 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage 125-400 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
10204997|NCT04324606|Experimental|Group 1a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
10204998|NCT04324606|Active Comparator|Group 1b|Volunteers will receive a standard single dose of MenACWY vaccine
10199092|NCT01147666|Experimental|Cohort B-2 (Roxadustat 2.0 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage >115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
10199093|NCT01147666|Active Comparator|Cohort B (Epoetin Alfa)|Hyporesponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort B. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
9726198|NCT04802109|Placebo Comparator|CPR with level D PPE|The participant doing CPR for 5 minutes with wearing level D personal protective equipment with surgical face mask
9726199|NCT04802109|Experimental|CPR with level C PPE|The participant doing CPR for 5 minutes with Level C personal protective equipment with N-95 face mask
9726200|NCT04802109|Experimental|CPR with Level C PPE + PAPR|The participant doing CPR for 5 minutes with Level C personal protective equipment with Powered Air-Purifying Respiratory.
9726201|NCT04800237|Experimental|VQW-765|
9726202|NCT04800237|Placebo Comparator|Placebo|
9726203|NCT04799431|Experimental|Neoantigen Vaccine with Poly-ICLC adjuvant and Retifanlimab|All participants receive this intervention.
9726204|NCT04799327|Experimental|Treatment group A|
9726205|NCT04799327|Experimental|Treatment group B|
9726206|NCT04799327|Experimental|Treatment group C|
10199094|NCT01147666|Placebo Comparator|Cohort B (Placebo)|Hyporesponsive participants will receive placebo matched to roxadustat, administered orally TIW for 19 weeks.
10199095|NCT01069588||Calaxo|Received Calaxo screw
9726207|NCT04799327|Placebo Comparator|Treatment group D|
10199096|NCT01069588||Milagro|Received a Milagro screw
9726208|NCT04798898|Experimental|Intervention (+RFA) arm|Preoperative partial RFA necrosis in the liver metastasis followed by liver resection
9726209|NCT04798898|No Intervention|Control (-RFA) arm|Liver resection
9726210|NCT04798755|Active Comparator|Adalimumab|
9726211|NCT04798755|Active Comparator|Methotrexate|
9726212|NCT04798755|Experimental|Adalimumab+Methotrexate|
9726213|NCT04797884|Experimental|TheraBionic Arm - Active Arm|For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
9726214|NCT04797884|Placebo Comparator|Placebo Arm|For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-specific modulation frequencies and will be activated for >200 one-hour treatment sessions.
10199097|NCT01013415|Experimental|ARM 1|Arm I (N=5) received antiretroviral therapy (ART) plus low dose IL-2 (1.2 million units/m2) subcutaneously daily for 56 days
9726215|NCT04797208|Experimental|Real-Time CGM|This group will have a subcutaneous RT-CGM inserted by a member of the research team. CGM's low and high glucose alerts will be activated. The treating clinical team will be able to remotely monitor glucose data and be notified of low glucose alerts through the linked handset. Hyper- and hypo-glycemia management including insulin dose adjustments by the treating clinical team, will be guided by sensor glucose levels and trends according to written guidelines during the study. Glucose level during and post-hypoglycaemia treatment will be confirmed by capillary blood glucose (CBG) measurements (using the NovaStat® glucometer or similar CE-marked glucose meter).
9726216|NCT04797208|Active Comparator|Capillary blood glucose with masked CGM|This group will have their glucose monitored in hospital using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted by a member of the research team to collect glucose values (glucose values will not be displayed and no glucose alerts will be available). This will removed at the end of the study by the research team.
9726217|NCT04794374|Experimental|Discharged COVID-19 survivors|"Telerehabilitation will be provided by physiotherapists including audio, video visits.~A brochure designed by physiotherapists for COVID-19 survivors will be used. Physiotherapists will call patients weekly and guide, design, modify the exercises accordingly to the patients."
9726218|NCT04792801||Patients with HCC and whose liver transplant plan has been validated|"Prospective inclusion of patients who are candidates for a transplant for CHC at the University Hospital of Lille and Rouen whose transplant project has been validated with a AFP score ≤ 2.~The systematic performance of a PET-CT with FDG and a PET-CT with Choline in all patients. At the end of the entire assessment, the patients will be (or not) registered on the transplant list and, for the patients registered on the list, a follow-up will be carried out at the level of a specialized transplant consultation every 3 months at during which the alphafoetoprotein dosage and abdominal imaging will be updated, until liver transplantation."
9726219|NCT04791748|Experimental|Patients with chronic vestibular deficits|Patients aged 7 to 17 years with chronic vestibular deficits
10199098|NCT01013415|Experimental|ARM 2|Arm 2 (N=5) received ART plus a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
10199099|NCT01013415|Experimental|ARM 3|Arm 3 (n=5) received ART plus IL-2 (1.2 million units/m2) and a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
9726220|NCT04791748|Active Comparator|Controls|Patients aged 7 to 17 years without chronic vestibular deficits
9726221|NCT04788771|Sham Comparator|Tracheal intubation in laparoscopic extraperitoneal hernia repair|Tracheal intubation in laparoscopic extraperitoneal hernia repair
9726222|NCT04788771|Active Comparator|laryngeal mask airway in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
9726223|NCT04788303|Active Comparator|Full intervention|Full intervention: school meal, garden, education, and community workshops
9726224|NCT04788303|Active Comparator|Partial intervention|Partial intervention: garden, education, and community workshops
9726225|NCT04788303|No Intervention|Control|Control: standard of care
9726226|NCT04788108|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
9726227|NCT04788108|Placebo Comparator|Placebo|placebo by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.
9726228|NCT04782999|Active Comparator|Oral glucose tolerance test|"Oral glucose tolerance test with ingestion of 75 g glucose and blood sampling.~This test will be performed before and 3 months after RYGB."
9726229|NCT04782999|Active Comparator|Hyperglycemic clamp with saline infusion combined with arginine test|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 120 min with co-infusion of saline.~After 120 min an arginine test with infusion of 50 g Arginine is performed.~This test will be performed before, 1 week and 3 months after RYGB."
9726230|NCT04782999|Active Comparator|Hyperglycemic clamp with GLP-1 infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusion of intraveneous glucose for 90 min with co-infusion of GLP-1.~This test will be performed before, 1 week and 3 months after RYGB."
9726231|NCT04782999|Active Comparator|Hyperglycemic clamp with GIP infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 90 minutes with co-infusion of GIP.~This test will be performed before, 1 week and 3 months after RYGB."
9726232|NCT04782466|Experimental|Intervention|The participant receives the intervention immediately following baseline measurements.
9726233|NCT04782466|Other|Waitlist attention-control|The participant receives the control condition for 6 months following baseline measurements. After 6 months, the baseline measurements are repeated and then the participant receives the intervention.
9726234|NCT04781543|Experimental|HZN-825 300 mg once daily (QD)|300mg oral tablets given in the morning and placebo in the evening
9726235|NCT04781543|Experimental|HZN-825 300 mg twice daily (BID)|300mg oral tablets given in the morning and evening
9726236|NCT04781543|Placebo Comparator|Placebo|Placebo will be given orally in the morning and evening
9726237|NCT04780035|Experimental|"Group Vaccine"|2,250 volunteers who will be vaccinated with the EpiVacCorona vaccine, twice intramuscularly at a dose of 0.5 ml.
9726238|NCT04780035|Placebo Comparator|"Control Group"|750 volunteers who will be vaccinated with a placebo, twice intramuscularly at a dose of 0.5 ml.
9726239|NCT04776408|Active Comparator|Control group_Use Lung recruitment|Use the Lung recruitment,
9726240|NCT04776408|Experimental|Study group_Use Lung recruitment combined inhaled Nitric oxide|Use the Lung recruitment combined inhaled Nitric oxide,
9726241|NCT04774120||Young Patients (Patients aged 18 to 65 years.)|Propofol infusion rate will be started at 20-25 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
9726242|NCT04774120||Elderly patients (Patients aged 65 to 85 years. )|Propofol infusion rate will be started at 15-20 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
9726243|NCT04773002||Group P|Total intravenous anesthesia (TIVA)
9726244|NCT04773002||Group S|Volatile anestesia
9726245|NCT04771676|Experimental|Oncorine (H101)|H101 diluted in 5ml 0.9% sodium chloride solution in was then intraperitoneally injected through the drainage catheter, the injection dose of H101 was determined by the ascites volume [5.0×10^11 vp for a small amount, 1×10^12 vp - 1.5×10^12 vp for medium amount, and 2×10^12 vp for the massive amount (classification of the ascites amount was described in response evaluation)]. H101 was injected at day 1 and 3.
9726246|NCT04768062|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 96 weeks.
9726247|NCT04767555|Experimental|ILM (inner limiting membrane) peeling|ILM peeling adding to standard vitreous surgery in patients suffering from retinal detachment
9726248|NCT04767555|No Intervention|No Peeling|standard vitreous surgery without ILM peeling in patients suffering from retinal detachment
9726249|NCT04766866|No Intervention|Non-intervention or non-reveal group|Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery
9726250|NCT04766866|Experimental|Intervention group or reveal group|A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
9726251|NCT04764929|Experimental|Helmet CPAP|Patients in the Pediatric Intensive Care Unit (PICU) already receiving CPAP through a facemask or nasal prongs or mask for at least four hours but no more than 48 hours will be transitioned to the Vyatil nonpowered oxygen tent system (Rochester, NY) by trained respiratory therapists per the manufacture's instructions: patient's neck circumference will be measured with a soft tape measure to ensure appropriate sizing. The helmet will be connected to at least 30 liters per minute of high flow medical air with an oxygen blender. The expiratory limb will be attached to the positive end expiratory pressure (PEEP) valve (initially set at 5 centimeters of water pressure) connected to a high-efficiency particulate air (HEPA) filter to prevent any viral particles from being released into the environment. A disposable manometer will be used to measure the pressure within the helmet. Once the flow to the helmet interface is on, the helmet will be sealed and secured with the system's arm straps.
9780856|NCT01133418|Sham Comparator|Non-progressive cognitive training|Children in the control condition will participate in the same tasks as children in the Intervention arm. They will experience the same number of blocks and trials of training as the intervention group. Further, their training will be conducted by the same set of trainers and for the same amount of time as the intervention group. However, children in the control group will remain at the lowest level for each CT task throughout training irrespective of performance.
10199100|NCT00982111|Experimental|Necitumumab + Pemetrexed + Cisplatin|Necitumumab + Pemetrexed + Cisplatin
9982296|NCT05269446||Healthy subjects|Patients with suspected coronary artery disease, but coronary angiography (CAG) indicates no obvious coronary stenosis
9726252|NCT04763356|No Intervention|Usual Care (UC)|The UC group (control) models the current standard of care model. The NTSS-6 will be completed daily by participants using the SCH system. The results will not be reported to their oncology team. Participants will be counseled at study entry to contact their treating care team to manage CIPN symptoms. They will also receive a reminder to do so at the end of each reporting session. UC participants will attend all regular visits with these providers and can receive any type of treatment for their CIPN symptoms. There are no limitations on the therapies that can be prescribed, or the means by which the clinical team communicates with the participant. Treating physicians will be provided with links to the current ASCP and NCCN guidelines but will not be provided with the algorithm as this group is meant to reflect current standard medical practice.
9726253|NCT04763356|Experimental|SCH with NP follow-up (SCH-NP)|Participants will report daily symptom as above. The SCH system will notify the study NP for any of the following symptoms measured by the NTSS6: aching, allodynia, burning, lancinating, numbness, and prickling that are rated as moderate or severe. Participants recording symptoms between 12 am-3 pm will receive a NP call back by 5pm and those between 3pm-12 am will be called the following day. The NP will follow a standardized script to elicit details about the CIPN symptoms and recommend and prescribe CIPN treatment per the treatment algorithm.
9726254|NCT04763109|Experimental|Whole-Body Magnetic Resonance Imaging|
9726255|NCT04762472|Active Comparator|Montelukast|Montelukast 10mg daily (tablet) orally x 26 weeks
9726256|NCT04762472|Placebo Comparator|Montelukast-matched placebo|Placebo (Montelukast identical) tablet 1 daily orally x 26 weeks
9726257|NCT04760548||Train dataset|This group is dedicated to developing an automated algorithm
9726258|NCT04760548||Test dataset|This group is dedicated to testing the performance of an automated algorithm
9726259|NCT04760548||Clinical Validation|This group is dedicated to assessing the clinical validity of the measurement in an independent validation cohort
9726260|NCT04758988|Other|Group A|This group will receive access to the AI augmented digital online educational system and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
9726261|NCT04758988|No Intervention|Group B|"This group is withheld their access to the AI augmented digital online educational system for 2 months.~After the 2 months delay, the subjects in the group are given the same access as the participants in Group A."
9726262|NCT04754139|Experimental|WeChat mobile mini-application|WeChat mini-application will increase knowledge base about sexual health through interactive health education and counseling support on HIV/STI prevention as well as PrEP initiation and/or adherence management.
9726263|NCT04753879|Experimental|Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine|Maintenance of Pembrolizumab and Olaparib
9726264|NCT04752540|Experimental|Mild hepatic impairment|120 mg olorofim
9726265|NCT04752540|Experimental|Moderate hepatic impairment|60 to 120 mg olorofim
9726266|NCT04752540|Active Comparator|Normal hepatic function|120 mg olorofim
9726267|NCT04749459|Experimental|ChapStick Moisturizer, Classic Flavor|This arm will include all the test sites on the participants back where ChapStick Classic Moisturizer (ANZ) will be applied.
9726268|NCT04749459|Experimental|ChapStick Moisturizer, Strawberry Flavor|This arm will include all the test sites on the participants back where ChapStick Strawberry Moisturizer (ANZ) will be applied.
9726269|NCT04749459|Active Comparator|ISO 24444:2010 P2 Standard Sunscreen|This arm will include all the test sites on the participants back where ISO 24444:2010 P2 Standard Sunscreen will be applied.
9726270|NCT04747067|Experimental|High-flux Hemodialysis|patients treated by conventional hemodialysis
9726271|NCT04747067|Experimental|Hemodiafiltration|patients treated by online post-dilution hemodialysis
9726272|NCT04746924|Experimental|Arm A: Tislelizumab plus Ociperlimab|Participants will receive ociperlimab 900 mg intravenously followed by tislelizumab 200 milligrams (mg) intravenously once every 3 weeks.
9726273|NCT04746924|Active Comparator|Arm B: Pembrolizumab plus Placebo|Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
9726274|NCT04746924|Placebo Comparator|Arm C: Tislelizumab plus Placebo|Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
9726275|NCT04745507||Arm 1 / C1|This cohort (C1) consists of 180 patients who receive IEHT in the recruiting sites, fulfil inclusion criteria and gave informed consent regarding their study participation.
9726276|NCT04745507||Arm 2 / C2|"This cohort (C2) consist of 180 patients receiving standard inpatient care (TAU) from the IEHT delivering hospital who fulfil inclusion criteria, are identified through a propensity score (PS) function as optimal control user or rather a PS match and gave informed consent regarding their study participation"
9726277|NCT04745507||Arm 3|360 close relatives or informal caregivers living in the same household of the participating patients who gave informed consent regarding their study participation. Thereby, one relative of each patients who is participating in the trial will be assessed (C1 = 180, C2 = 180).
9726278|NCT04745507||Arm 4:|Staff members of participating study cites as well as local and political stakeholders engaged with IEHT who gave informed consent (approximately n = 100 participants overall).
9726279|NCT04743830|Experimental|Treatment Group|Neurodevelopmental Treatment (Bobath) + Scapular Training Group
9726280|NCT04743830|Active Comparator|Control Group|Neurodevelopmental Treatment (Bobath) Group
9726281|NCT04743609||Bronchiolitis|- children under 24 months of age (≤) with First episode of bronchiolitis
9726282|NCT04743609||Acute otitis media|define with Paradise Criteria) or otorrhea
9982297|NCT05269420|Experimental|SAS-J|single anastomosis sleeve Jejunal Bypass as a revisional bariatric procedure after restrictive bariatric procedures
10199101|NCT00982111|Active Comparator|Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
10199102|NCT00893035||Intermediate prognosis prostate cancer|Intermediate prognosis prostate cancer
10199103|NCT00893035||Breast cancer|conservative treatment and age<60 Boost irradiation and age>60
9726283|NCT04743609||Pneumonia|defined by the presence of opacity of parenchymal condensation and/or pleural effusion on chest X-ray associated with fever
9726284|NCT04741750|No Intervention|Usual Care within Community Clinics|Complete blood count, comprehensive metabolic panel, international normalized ratio, HCV RNA, hepatitis B virus (HBV) serologies, point of care HIV test, and point of care liver fibrosis measurement. HCV genotype if required by patient's insurance for prior authorization. Care for opioid use disorder and skin infection is offered. Completion of the initial visit workup is sufficient to initiate a prior authorization request for DAAs from payers and an appointment for MAT follow-up in a community clinic if indicated. Patient coordination; authorization with insurance companies; scheduling appointments, follow-up, and ancillary support services will be conducted by a Patient Navigator. Patients are seen every 2-4 weeks for monitoring and adherence support. HCV treatment regimens are at the discretion of the treating provider in accordance with AASLD/IDSA guidelines and insurance requirements. Twelve weeks after HCV therapy completion, SVR12 HCV RNA and SVR12 CMP tests will be obtained.
9726285|NCT04741750|Experimental|Simplified Care within a Mobile Medical Unit|Simplified Care treatment is the same as for Usual Care with the exception that it is taking place within a mobile medical clinic that is scheduled to deliver treatment in alignment with regular syringe exchange services.
9726286|NCT04739709|Experimental|APP13007 0.05% BID|1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
9726287|NCT04739709|Placebo Comparator|Matching Vehicle Placebo|1 drop matching vehicle place twice daily for 14 days to study (operated) eye
9726288|NCT04737226|Experimental|Basketballers|
9726289|NCT04737226|Experimental|Volleyballers|
9726290|NCT04737226|Experimental|Runners|
10199104|NCT00881660|Experimental|Fetal Endotracheal Occlusion|Placement and retrieval of the GoldBAL4 or GoldBal2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
10199105|NCT00582842||1|Men with prostate cancer
10199106|NCT00582842||2|Men with prostate cancer
10199107|NCT00193219|Experimental|Intervention|"Bevacizumab 5 mg/kg IV~Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8~5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)~Leucovorin 350 mg IV~Oxaliplatin 85 mg/m2 IV"
10199108|NCT00116142|Other|Arm1: Androgen Suppression Therapy + Radiation Therapy|Androgen Suppression Therapy and Radiation therapy
10199109|NCT00116142|Experimental|Arm 2: Docetaxel + Androgen Suppression Therapy + Radiation Therapy|Docetaxel plus androgen suppression therapy and radiation therapy
10199110|NCT00070018|Experimental|CHOP + RT + Zevalin|Patients first receive 3 cycles (21 days each) of CHOP, consisting of: cyclophosphamide 750 mg/m^2 on day 1, doxorubicin 50 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 1, and prednisone 100 mg on days 1-5. Patients receive 4000-5000 cGy of radiation therapy in 25 fractions, starting 3 weeks after completion of CHOP. 3-6 weeks after completing RT, patients receive Zevalin, which consists of: rituximab 250 mg/m^2 on days 1 and 7, 8 or 9; In-111 ibritumomab tiuxetan 5 mCi within 4 hours after rituximab on day 1; and Y-90 ibritumomab tiuxetan 0.4 mCi/kg within 4 hours after rituximab on day 7, 8 or 9.
10199111|NCT05189743|Experimental|Dermis graft|
10199112|NCT05189743|Experimental|STSG|
10199113|NCT05189678||frailty group|Modified Frailty index score greater than or equal to 0.21
9726291|NCT04734652|Experimental|BIC arm|The Intervention Arm ART regimen is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.
9726292|NCT04734652|Active Comparator|DTG Arm|Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)
10199114|NCT05189678||non-frailty group|Modified Frailty index score is less than 0.21
10199115|NCT05189665|Experimental|Extraperitoneal high sacral ligament suspension Group|We will recruit 62 POP patients ,and perform Surgery Extraperitoneal high sacral ligament suspension surgery on them.
9984746|NCT03776864|Experimental|Treatment (pembrolizumab, umbralisib)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive umbralisib PO daily on days 1-21 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9726293|NCT04733911|Experimental|Eccentric 75|Participants in this arm will perform an eccentric exercise protocol consisted of 75 eccentric repetetions on an isokinetic dynamometer.
9726294|NCT04733911|Experimental|Eccentric 150|Participants in this arm will perform an eccentric exercise protocol consisted of 150 eccentric repetetions on an isokinetic dynamometer.
9984747|NCT03773965|Experimental|Baricitinib|Baricitinib given orally.
10199116|NCT05189665|Active Comparator|Sacrospinous Ligament Suspension Group|We will recruit 62 POP patients ,and perform sacrospinous ligament suspension surgery on them.
10199117|NCT05189626|Experimental|Group A|Muscle energy technique
10199118|NCT05189626|Experimental|Group B|Kaltonborn mobilizations
10199119|NCT05189613|Experimental|Severe Asthma+BE|Patients with severe eosinophilic asthma with co-presence of Bronchiectasis (BE) in treatment with Mepolizumab
10199120|NCT05189613|Active Comparator|Severe Asthma without BE|Patients with severe eosinophilic asthma without Bronchiectasis (BE) in treatment with Mepolizumab
10199121|NCT05189548|Experimental|Adsorbed a cell-free whitening break (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine.
10199122|NCT05189535|Experimental|pentoxifylline 400 mg|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and pentoxifylline 400 mg twice daily for the paclitaxel treatment period.
10199123|NCT05189535|Placebo Comparator|Placebo|Patients will receive paclitaxel 80 mg/m2 once per week for 12 weeks and placebo twice daily for the paclitaxel treatment period..
10199124|NCT05189405||INVOcell IVC|IVF using intravaginal incubation with INVOcell device for embryo development.
9726295|NCT04733911|Experimental|Eccentric 300|Participants in this arm will perform an eccentric exercise protocol consisted of 300 eccentric repetetions on an isokinetic dynamometer.
9726296|NCT04733911|No Intervention|Control|Participants in this arm will receive no intervention.
9726297|NCT04733599||Adults with pain due to brachial plexus avulsion injury|Adult patients with history of brachial plexus avulsion injury referred for consideration of neuromodulation using high frequency neurostimulation will be considered.
9726298|NCT04732793|Experimental|Hyruan ONE®|
9726299|NCT04732793|Active Comparator|Durolane®|
9726300|NCT04732689||Groups/Cohorts|The investigators propose to conduct a prospective observational cohort which will include all consecutive adult liver transplant recipients in each center during a one-year period but will exclude same patients who undergo a retransplantation during the same period of observation.
9726301|NCT04732260|Experimental|letermovir|Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP
9726302|NCT04729634|Other|Mobilization and breathing training|Usual clinical care
9726303|NCT04727411|Experimental|Gel Stent implantation|XEN gel stent: a clear cornea incision in the inferotemporal quadrant was performed, injecting the XEN 45 device into the superonasal quadrant using an ab interno approach. Approximately 15 min before inserting the implant, 0.1 ml of a MMC solution (0.01%) was injected into the superior conjunctiva. Both stand-alone and combined phaco-glaucoma procedures were used.
9726304|NCT04727411|Experimental|Trabeculectomy|Trabeculectomy: the surgical technique is as follows: retro/peribulbar o subtenon's anesthesia, superior corneal traction suture, phacoemulsification through 2.2 with in-the-bag IOL implantation, a fornix-based conjunctival flap, sufficient but not excessive cauterization, application MMC 0,2 mg/ml for 2 minutes under the conjunctiva, then MMC was washed out with 100 ml of saline solution, then a scleral flap (4x3 mm in the trabeculectomy) is dissected. A sclerectomy with punch and peripheral iridectomy were performed, and suture nylon 10/00 sutures was used to place 3 or 4 stiches in the scleral flap
9726305|NCT04723680||Early dose finding cohort|People with Haemophilia who took part in the early dose finding studies
9726306|NCT04723680||Subsequent studies group cohort|People with haemophilia who took part in subsequent gene therapy studies
9726307|NCT04723680||Withdrawn/ineligible Cohort|People with haemophilia who were withdrawn or proved ineligible
9726308|NCT04723680||Not interested cohort|People with haemophilia who are definitely not interested in gene therapy
9726309|NCT04723680||Not offered cohort|People with haemophilia who are interested in gene therapy but have not been the opportunity to take part
9780857|NCT01133522|Experimental|Evolocumab|Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
9780858|NCT01133522|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
9780859|NCT01133626|Placebo Comparator|Placebo|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
9780860|NCT01133626|Experimental|BDP HFA 320 µg/day|Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
9780861|NCT01133626|Active Comparator|Prednisone|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
9780862|NCT01133665|Experimental|Sub Group 1|All Subjects Enrolled in the Trial
9780863|NCT01133678|Experimental|Everolimus|Everolimus 5 mg PO Daily for 2 21-day cycles
9780864|NCT01133678|Experimental|Placebo|Placebo 5 mg PO Daily for 2 21-day cycles
9780865|NCT01133704|Active Comparator|sipuleucel-T (APC8015)|
9780866|NCT01133704|Placebo Comparator|Placebo|
9780867|NCT01133756|Experimental|Lenvatinib plus carboplatin + gemcitabine|Phase IB and Phase II
9780868|NCT01133756|Active Comparator|Carboplatin + gemcitabine|Phase II
9780869|NCT01133821|Placebo Comparator|Placebo|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.
9780870|NCT01133821|Experimental|IPSRT plus quetiapine|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel). This condition will be called IPSRT-QUE.
9780871|NCT01133847|Experimental|Intensive Reading Instruction|Specialized phonologically-based reading instruction provided by well-trained tutors either individually (one-on-one) or to groups of two students for 45 minutes, four days per week, for 16 weeks. The instructional approach includes an individualized combination of published programs targeting word reading and decoding; reading fluency; and reading comprehension.
9780872|NCT01133847|Experimental|ADHD Intervention|Carefully-managed medication and behavioral parent training. Medication treatment begins with a four-week titration period, beginning with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions provided by a psychologist addressing ADHD and its treatment, principals of behavior modification, and evidence-supported practices for managing behavior.
9785289|NCT01248104|Active Comparator|Tranexamic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The TXA group re- ceived a bolus of 10 mg / kg over 15 minutes fol- lowed by an infusion of 1 mg/kg/hr.
9785290|NCT01248104|Active Comparator|Aminocaproic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The EACA group received a bolus of 100 mg / kg given over 15 minutes shortly after induction of anesthesia followed by an infusion of 10 mg/kg/hr.
9726310|NCT04722666|Experimental|MIJ821 (mg/kg) - very low dose|MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
9726311|NCT04722666|Experimental|MIJ821 (mg/kg) - low dose|MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
10199125|NCT05189405||Traditional IVF (tIVF)|Traditional IVF using laboratory equipment and incubators for embryo development
10199126|NCT05189392|No Intervention|21 patients with opsite visible|application of visible opsite plaster on the surgical wound after hip arthroplasty
9726312|NCT04722666|Experimental|MIJ821(mg/kg) - high dose|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
10199127|NCT05189392|Experimental|21 patients with PICO|application of PICO on the surgical wound after hip arthroplasty
9726313|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
9726314|NCT04722666|Placebo Comparator|Placebo|40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
9726315|NCT04722666|Experimental|MIJ821 (mg/kg) - high dose/Placebo|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
9726316|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose/Placebo|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
9726317|NCT04719988|Experimental|Experimental|"Induction treatment~Modified DCF: every 2 weeks for 8 cycles Docetaxel (40 mg/m², day 1), Cisplatin (40 mg/m², day 1) , 5-FU (1200 mg/m²/day for 2 days)~Ezabenlimab: 240 mg intravenous, every 3 weeks for 3 cycles~In case of tumor response:~Two additional cycles of mDCF and one additional cycle of Ezabenlimab (Q3W).~Hypofractionated radiotherapy~Ezabenlimab: 240 mg intravenous, every 3 weeks for 7 cycles~In absence of tumor response:~o Chemoradiotherapy (Intensity-Modulated Radiation Therapy [IMRT]) treatment: Chemoradiotherapy using IMRT will begin 3-4 weeks following the last cycle of induction phase, in the absence of toxicities of grade 1 and/or management of toxicities. It will last 7 weeks and will consist of:~• Standard dose of 45 Gy in 25 fractions over 5 weeks followed by a sequential boost of 14.4 Gy in 8 sessions,~Concomitantly given with:~Capecitabine (825 mg/m²/orally twice daily) from Monday to Friday,~Mitomycin C (10 mg/m² Day 1)"
9726318|NCT04718441|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
9726319|NCT04717440||Patients accepting palliative care|Patients included in an early phase trial and accepting palliative care
9726320|NCT04717440||Patients refusing palliative car|Patients included in an early phase trial but refusing palliative care
9726321|NCT04716725|Experimental|Experimental (68Ga-PSMA-11 PET)|Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.
9726322|NCT04714359|Experimental|MDMA-assisted Psychotherapy|Three open-label sessions of MDMA-assisted psychotherapy with flexible dose of MDMA (80 or 120 mg) and optional supplemental dose of (40 or 60 mg), 1.5 to 2 hours later
9726323|NCT04713592|Experimental|Risankizumab|Participants will receive risankizumab for 52 weeks
9726324|NCT04713592|Placebo Comparator|Placebo|Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
9726325|NCT04712565|Experimental|Astra Tech Implant System Profile EV|Implants with sloped marginal configuration without bone augmentation are used.
9726326|NCT04712565|Active Comparator|Astra Tech Implant System EV|Implants with regular neck design and GBR procedure fixed with two membrane pins will be used.
9726327|NCT04711928||Trained athletes|Active individuals with at least 4 training hours per week.
9726328|NCT04708340|Active Comparator|Arm A: RJX|"RJX 20 mL (10 mL of Vial A plus 10 mL of Vial B) mixed in normal saline, total volume 120 mL, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.~Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).~Patients in Part 1 are allowed to receive only one 7-day cycle of RJX while patients in Part 2 may be treated daily for up to 14 days."
9726329|NCT04708340|Placebo Comparator|Arm B: Placebo|"Placebo (total of 20 mL normal saline) mixed in normal saline IV, total volume 120 mL of normal saline IV, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.~Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).~Patients in Part 1 will not receive placebo.~Patients in Part 2 may be treated daily for up to 14 days."
9726330|NCT04703647||Patients with CRPS type 1: prospective group|"Ambulatory patients of the Clinique romande de réadaptation (CRR) which have a CRPS type 1 of a limb.~Five measurement times (first visit (T0) and then after 3 (T1), 6 (T2), 12 (T3) and 24 (T4) months). At every time point, following data will be collected: physical examination, monitoring of the health and professional status with the physician, and self-administrated questionnaires. Blood sampling will be performed at T0, T1,T2 and T3.~Eight different self-administrated questionnaires will be used, in their French or Portuguese version. Each participants will answer seven questionnaires each time, depending if he/she suffers of arm or leg injury.~We will assess, in blood samples, the expression levels of specific molecules (miRNAs and a selection of cytokines) in patients diagnosed with acute CRPS. In a second time, miRNAs and cytokines profiles will be compared between acute and chronic (CRPS still diagnosed 6 months after the first diagnosis) CRPS patients."
10199128|NCT05189327||Patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease|All patients with diagnosed Nonspecific Ulcerative Colitis and Crohn Disease in the Republic of Kazakhstan.
10199129|NCT05189314||Thyroidectomy|Patients with benign thyroid nodules who undergo surgical resection
10199130|NCT05189314||RFA|Patients with benign thyroid nodules who undergo radiofrequency ablation
10199131|NCT05189301||CHF|CHF for chronic heart failure
10199132|NCT05189301||COPD|COPD for chronic obstructive pulmonary disease
10199133|NCT05189301||control|control for normal controls
10199134|NCT05189288|Experimental|Reference-Test|D418 Tab. - CKD-388 Tab.
10199135|NCT05189288|Experimental|Test-Reference|CKD-388 Tab. - D418 Tab.
10199136|NCT05189249||Case|Patients who have undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
10199137|NCT05189249||Control|Patients who have not undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
9726331|NCT04703647||control group for blood analysis|"For the blood analysis, we will recruit 30 healthy controls who did not report any kind of pain. They will be recruited via posters that will be posted on the billboards of the Hôpital de Sion (employees and visitors) and on the visitor's billboards of the CRR. If this is not enough, we will expand the recruitment perimeter with other locations. The healthy control will be adjusted for age, sex and BMI with the CRPS groups. They will be informed about the study and procedure. The procedure for the blood samples will be the same as for patients.The screening for miRNAs of interest will be performed using a decision tree-based ensemble method (Random Forest). For this step, miRNAs profile of 30 control patients will be compared to the same number of CRPS patients.~The control group will have just one blood analysis."
9726332|NCT04702984|Experimental|LID021201|LID021201 contact lenses worn in both eyes for 7 days. Lenses will be removed nightly for cleaning and disinfection with OPTI-FREE multipurpose solution.
9726333|NCT04701281|Experimental|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
9726334|NCT04699201|Experimental|Prosthesis|Firstly, a laparoscopic cholecystectomy is performed. After suturing the aponeurosis with a J needle and 0 Polydioxanone, a lightweight, large-pore mesh made of PVDF monofilament (polyvinylidene fluoride - DynaMesh-CICAT, FEC Textiltechnik, Germany) will be placed onlay, overlapping 2cm in all directions from the edge of the aponeurosis incision at the umbilical trocar site. The mesh will be fixed to the aponeurosis with cyanoacrylate glue (Glubran®, GEM, Viareggio, Italy).
9726335|NCT04699201|Active Comparator|Control|Firstly, a laparoscopic cholecystectomy is performed. Closure of the aponeurosis will be performed by standard procedure: under direct vision, suturing the aponeurosis with a J needle and 0 Polydioxanone, with a stitch interval of ≤ 5mm.
9726336|NCT04698902||Circumferential calcification|Patients with circumferential pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium >180 degrees)
9726337|NCT04698902||Eccentric calcification|Patients with an eccentric pattern of coronary artery calcification by OCT (Optical coherence tomography) assessment (arc of calcium <180 degrees)
9726338|NCT04698902||Nodular calcification|Patients with calcium nodules identified by OCT (Optical coherence tomography) assessment
9726339|NCT04696835|Experimental|children with hearing aids|
9726340|NCT04696835|Sham Comparator|control group|
9726341|NCT04696640|Experimental|Remote Patient Monitoring|All participants who have successfully established remote data-sharing from their glucose monitors to the research team's Glooko account by conclusion of the one-month baseline period will advance to the six-month intervention period.
9726342|NCT04696198|Experimental|Range of motion|Treatment is based on a set diagnostic and therapeutic protocol and carried out by registered health care professionals that are additionally trained in manual therapy intervention. 30 minutes of treatment will be given once a week over a period of two months
9726343|NCT04696198|Other|Standard care|Standard care
9726344|NCT04694443|Active Comparator|Study group|The study group will receive the multidisciplinary tele-health intervention plus standard medical care
9726345|NCT04694443|Placebo Comparator|Control group|The control group will receive the best standard medical care
9726346|NCT04690231|Experimental|Apatinib+IE|
9726347|NCT04690231|Active Comparator|IE|
9726348|NCT04689295|Other|experiment group|Three dimensional scoliosis therapy method (Schroth) will be applied to the participants for 6 weeks. It consist of 15 different exercises combined with rotational breathing exercise.
9726349|NCT04689295|Other|control group|Traditional scoliosis exercises will be applied to the participants for 6 weeks. It consist of 6 different exercises
9726350|NCT04688684|Experimental|Family-based intervention|These participants will undergo the health coach based intervention with fitness tracker and diet changes, which will be delivered to all family members who meet the inclusion criteria and are enrolled in the study.
9726351|NCT04686435||Non-surgical treatment|Shoulder patients referred for non-surgical treatment after being diagnosed at the medical examination.
9726352|NCT04686435||Surgical treatment|Shoulder patients referred for surgical treatment after being diagnosed at the medical examination.
10199138|NCT05189223|Other|Open Pilot|In Phase 2, all Veterans will receive the active treatment.
9726353|NCT04685655|No Intervention|COVID-19 therapy according to center standard alone|
9726354|NCT04685655|Active Comparator|Therapeutic plasma exchange and COVID-19 therapy according to center standard|
9726355|NCT04677439|Experimental|Flumatinib|
9726356|NCT04677140||experiment group|By a specialist physician with existing anteroposterior and lateral radiographs have been diagnosed with adolescent idiopathic scoliosis
9726357|NCT04675827|Experimental|RCB = 0|"Treatment administration: adjuvant pertuzumab + trastuzumab (P+T) fixed dose combination (FDC) SC for 14 cycles.~Sub-study: 121 of the subjects who achieved a pCR (thus assigned to continue treatment with P+T FDC SC) will be randomised at a 1:1 ratio to receive 3 cycles of P+T FDC SC in the hospital, followed by 3 cycles in another setting outside the hospital, or to the same treatment starting with 3 cycles outside the hospital followed by 3 cycles in the hospital (treatment cross-over period). After the first 6 cycles of adjuvant treatment, subjects will be asked to choose between continuing treatment (for the remaining 8 cycles, for a total of 14 cycles) within or outside the hospital, according to their preference (treatment continuation period). Subjects can request to change from outside the hospital to in the hospital administration (and vice-versa) at any moment during the treatment continuation period, but not in the treatment cross-over period."
10199139|NCT05189223|Experimental|Active Condition|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to the active treatment.
10199140|NCT05189223|Active Comparator|Treatment as Usual|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to treatment as usual.
10199141|NCT05189210|Placebo Comparator|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
10199142|NCT05189210|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
10199143|NCT05189210|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 50
9726358|NCT04675827|Experimental|RCB > 0|Treatment administration:adjuvant T-DM1 for 14 cycles. In subjects whose residual invasive disease is classified per Residual Cancer Burden (RCB) score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.
9726359|NCT04673331||Cystic fibrosis|"Inclusion Criteria:~Having been diagnosed with cystic fibrosis Being over 18 years old The clinical condition is stable Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis~Exclusion Criteria:~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
9726360|NCT04673331||Healthy individuals|"Inclusion Criteria:~Being over 18 years old Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis~Exclusion Criteria:~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
9726361|NCT04671693|Experimental|PASCA intervention|
9726362|NCT04670991|Other|EXATRAC imaging|For each radiotherapy session, patient will first have an Exatrac imaging and then a CBCT imaging. Patient's repositionning will be performed accoding to CBCT data
9726363|NCT04670393|Experimental|FertyBiotic Woman Plus|Participants received FertyBiotic Woman Plus one sachet a day
9726364|NCT04670393|Placebo Comparator|Placebo|Participants received 400 mcg of folic acid once a day
9726365|NCT04669678||Group 1 DOR + ETG|100mg DOR-containing ART [oral tablet taken daily] + 68mg ETG implant (follow up for 30 weeks)
9726366|NCT04669678||Group 2 DOR + DMPA|100mg DOR-containing ART [oral tablet taken daily] + 150mg IM DMPA (follow up for 18 weeks)
9726367|NCT04669678||Group 3 DOR + MPA|100mg DOR-containing ART + 104mg SC MPA (follow up for 18 weeks)
9726368|NCT04669678||Group 4 DOR + IUD|100mg DOR-containing ART + 1 non-hormonal IUD device (follow up for 30 weeks)
9726369|NCT04669678||Group 5 DTG + DMPA|50mg DTG-containing ART + 150mg IM DMPA (follow up for 18 weeks)
9726370|NCT04668885|Experimental|Primary refractory/relapsed AML|Lower dose CPX-351 in participants with primary refractory/relapsed AML. Participants will receive an induction and maintenance phase of CPX-351
9726371|NCT04668885|Experimental|MDS after HMA failure|Lower dose CPX-351 in participants with MDS after HMA failure. Participants will receive an induction and maintenance phase of CPX-351
9726373|NCT04661124|Other|Adult Normal Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
9726374|NCT04661124|Other|Adult Pathology Eyes|see Inclusion/Exclusion criteria; imaged with OCT and/or OCTA
9726375|NCT04659031|Experimental|Cohort D1|X.X mg / kg ABC008
9726376|NCT04659031|Experimental|Cohort D2|X.X mg / kg ABC008
9726377|NCT04659031|Experimental|Cohort D3|X.X mg / kg ABC008
9726378|NCT04659031|Experimental|Cohort D4|X.X mg / kg ABC008
9726379|NCT04659031|Experimental|Cohort D5|tbd (if an alternative dose cohort is needed)
9726380|NCT04657276||Down Syndome|Infants with Down Syndrome
9726381|NCT04656223||MF/IND/GLY Breezhaler® plus Propeller Health|patients receiving MF/IND/GLY Breezhaler® plus electronic inhalation tracking sensor (Propeller Health) according to label
9726382|NCT04656223||Other FDC therapy|patients receiving ICS+LABA+LAMA FDC therapy according to label
9726383|NCT04656210||Group 1: MD type 1 normal|patients with type 1 myotonic dystrophy with normal carbohydrate tolerance
9726384|NCT04656210||Group 2: MD type 1 Diabetes|"patients with type 1 myotonic dystrophy with diabetes. Patients with carbohydrate intolerance (pre-diabetes) who became diabetic at 3 years of age will be divided into Group 2."
9726385|NCT04656158|Experimental|Therapeutic horticulture|handling (gardening equipment) and gardening task (outdoor and greenhouse tasks)
9726386|NCT04656158|Active Comparator|Handiwork|Handling tasks (materials) and handiwork (manufacturing of piece of wooden furniture)
9726387|NCT04655963|Experimental|Dose 1|All participants would receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within a seven-day span. A single session=600 pulses at 120% rMT, iTBS triplets at 50 Hz for 2 s and repeated every 10 s for a total of 190 s to left dlPFC. Total pulses=14,400.
9726388|NCT04655716|Experimental|Sodium bicarbonate|Intravenous sodium bicarbonate infusion
9726389|NCT04655716|No Intervention|Standard care|Standard of care by the clinical team
9726390|NCT04653688|Experimental|Parkinsonian syndromes patients|
9726391|NCT04653688|Sham Comparator|healthy subjects|
9726392|NCT04653584||1|Parkinson Disease patients treated by domperidone according the recommendation
9726393|NCT04653584||2|Parkinson Disease patients treated by domperidone in misuse conditions regarding the recommendation
9726394|NCT04653584||3|Parkinson Disease patients without treathment by domperidone
9726395|NCT04652700|Experimental|Islatravir (ISL) Once Monthly (QM) Group|Participants receive 60 mg tablet of ISL QM, orally plus Placebo to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) tablet once daily (QD) or Placebo to Emtricitabine/Tenofovir Alafenamide (FTC/TAF) tablet QD, orally for up to 24 months of treatment duration.
9726396|NCT04652700|Active Comparator|FTC/TDF or FTC/TAF QD Group|Participants receive 200/245 mg or 200/300 mg of FTC/TDF combination tablet, QD, orally or 200/25 mg of FTC/TAF combination tablet, QD, orally at investigator's discretion plus Placebo to ISL tablet QM, orally for up to 24 months of treatment duration.
9726397|NCT04651439|Experimental|FILGRASTIM|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + ZARZIO@ (30 MU/0,5mL and/or 48 MU/0,5mL - solution of 20 ml diluted in GLUCOSE 5%) administrated by IV or subcutaneous route over a period of 5 consecutive days (1 injection per day during 30 minutes)
9726398|NCT04651439|Placebo Comparator|PLACEBO|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + 20 ml GLUCOSE 5% administrated by IV route over a period of 5 consecutive days (1 injection per day during 30 minutes)
9726399|NCT04650581|Experimental|Ipatasertib + Fulvestrant|
9726400|NCT04650581|Placebo Comparator|Placebo|
9984748|NCT03773393|Experimental|CK0801|All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
9726401|NCT04650087|Active Comparator|Apixaban|Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
9726402|NCT04650087|Placebo Comparator|Placebo|Drug: Placebo Participants will be given study medication at the time of discharge from the hospital. Participants will take the Placebo twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and contact will continue up to day 90 after starting study treatment. Follow up will be through electronic and/or telephone contact depending on the participant's preference, compliance, and medication adherence. Participants will be queried for any clinically relevant endpoints, especially major bleeding or a need to seek healthcare attention for any reason. Follow-up will occur from the time of discharge and through the 30 day study period, with contacts 2 days, 10 days, 20 days, and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
9726403|NCT04648293||Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. Improvement in hemodynamics is exhibited by an increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
9726404|NCT04648293||No Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. No Improvement in hemodynamics is exhibited by no increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
9726405|NCT04646902||HTN_OSA|"Patients with hypertension* with obstructive sleep apnea**~* Hypertension will be defined as: i) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or ii) in untreated patients: office systolic blood pressure values >= 140 mmHg and/ or diastolic blood pressure values >= 90 mmHg.~** OSA will be defined with a polysomnography level 1, 2 or 3 performed within the previous twelve months with:~an apnea-hypopnea index > 5 events per hour (with more than 50% of obstructive events) associated with symptoms (associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory disturbance or observed apnea) or medical/psychiatric disorder (hypertension, coronary artery disease, atrial fibrillation, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder), OR~an apnea-hypopnea index > 15 events per hour, AND~no significant changes in health, medications, or lifestyle since the polysomnography."
9726406|NCT04646902||HTN_NoOSA|Patients with hypertension without obstructive sleep apnea
10199144|NCT05189184|Experimental|Study group|Inductive therapy with Camrelizumab and Apatinib Plus Albumin-bound paclitaxel and cisplatin
9726407|NCT04646902||NoHTN_OSA|Patients without hypertension with obstructive sleep apnea
9726408|NCT04646902||NoHTN_NoOSA|Patients without hypertension without obstructive sleep apnea (healthy controls)
9726409|NCT04646343||group for cross cultural adaptation of questionnaire|Pre final French version of the CISS and PWES will be administered to French native speaking patients suffering from various hand injuries. 30 patients are sufficient. They will be asked to write commentaries on difficulties of questionnaire's items, especially comprehension of the different items (clear or unclear).If the item is considered unclear, the patient is asked to provide suggestions for making the item clearer .The distribution of the responses will be examined for searching missing responses. An item considered unclear by 20 % or more of the patients must be re-evaluated . The definitive version of French-CISS and French PWES (F-CISS and F- PWES) and the verification of the different stages of the cross-cultural adaptation will be validated during a new consensus meeting.
9726410|NCT04646343||group for validation of questionnaire|For the second part (validation study) we will administered F-CISS, F-PWES, F-DASH, F-HFS, F-SF 36 questionnaires and a pain VAS to a population of in and outpatients with hand injuries. We aim to include patients during one year for a total expected of 100 patients.
9726411|NCT04645784|Experimental|Intervention|Receives the supporting student-athlete mental wellness module
9726412|NCT04645784|No Intervention|Waitlist|Receives no intervention
9726413|NCT04643769|Experimental|25 mg ORIN1001 (Active)|25 mg ORIN1001
9726414|NCT04643769|Experimental|50 mg ORIN1001 (active)|50 mg ORIN1001
9726415|NCT04643769|Experimental|100 mg ORIN1001 (active)|100 mg ORIN1001
9726416|NCT04643769|Placebo Comparator|Placebo - 25 mg|Placebo comparator for ORIN1001 at 25 mg
9726417|NCT04643769|Placebo Comparator|Placebo - 50 mg|Placebo comparator for ORIN1001 at 50 mg
9726418|NCT04643769|Placebo Comparator|Placebo - 100 mg|Placebo comparator for ORIN1001 at 100 mg
9726419|NCT04643366|Experimental|Concurrent Chemotherapy/ Radiation Therapy|5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) four 14-day cycles will be given before CRT starts. Pelvic Intensity-modulated radiation therapy (IMRT): 25 Gy in 5 fractions over 5 days + Continuous infusion 5-fluorouracil (5-FU) for 4 days (96 hours) followed by four 14-day cycles of (mFOLFOX6) to be given after CRT ends.
10199145|NCT05189158|Other|HVS-|subjects with no complaint AND a Nijmegen questionnaire score of < 23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS-)
10199146|NCT05189158|Other|HVS+|subjects with complaints AND a Nijmegen questionnaire score of ≥23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS+)
10199147|NCT05189132||Test Group|Adult patients diagnosed with Alzheimer's disease
10199148|NCT05189132||Control Group|The control group will consist of patients who attend consultations at the Faculty of Dentistry of the University of Lisbon, matched for age, gender and other confounding factors, such as smoking and systemic diseases (diabetes).
10204999|NCT04324606|Experimental|Group 1c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 5x10^10vp ChAdOx1 nCoV-19 9 months later
9726420|NCT04642430|Active Comparator|Apixaban group|"5 mg PO, twice daily for 12 months of treatment. A dose reduction* to 2.5 mg twice daily will apply if patients meet 2 of 3 following criteria: age > 80 years; weight < 60 kg; creatinine >133 micromol/L.~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
9726421|NCT04642430|Active Comparator|Rivaroxaban Group|"20 mg PO, once daily for 12 months of treatment. A dose reduction* to 15 mg daily will apply to patients with creatinine clearance <50 ml/min.~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
9726422|NCT04640259||EGFR|
9726423|NCT04640259||ROS1|
9726424|NCT04640259||ALK|
9726425|NCT04640259||KRAS|
9726426|NCT04640259||NSCLC Other|
9726427|NCT04640012|Experimental|DC371739 100mg|Single dose of 100 mg tablet orally administered
9726428|NCT04640012|Placebo Comparator|Placebo|Placebo orally administered
9726429|NCT04639778|Active Comparator|Control Group|In the control group, patients will follow a care pathway respecting the current recommendations : a systematic clinical visit scheduled each year with the multidisciplinary team.
9726430|NCT04639778|Experimental|Experimental Group|In the intervention group, patients will follow a new care pathway with visits triggered by weight evolution
9726431|NCT04633564|Experimental|MYL-1402O|"Patients will begin Period 1 receiving bevacizumab combination therapy (MYL-1402O15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as MYL-1402O ).~In Period 2, eligible patients will continue to receive bevacizumab ( MYL- 1402O) every 3 weeks as monotherapy."
9726432|NCT04633564|Active Comparator|Avastin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin).~In Period 2, eligible patients will continue to receive bevacizumab (Avastin) every 3 weeks as monotherapy."
9726433|NCT04628507||Patients undergoing IVF|
9726434|NCT04625413|Experimental|Experimental: Experimental Arm: single|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awareness.
9726435|NCT04617093|Experimental|Total Patient Population|The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
9982298|NCT05269394|Experimental|E2814 plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
10205000|NCT04324606|Experimental|Group 1d|Volunteers will receive a standard single dose of MenACWY vaccine. 9 moths later they will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 4-12 weeks apart
10205001|NCT04324606|Experimental|Group 2a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
10205002|NCT04324606|Active Comparator|Group 2b|Volunteers will receive a standard single dose of MenACWY vaccine
9726440|NCT04609228||Blood-transfusion non-acceptors|Blood-transfusion non-acceptors
9726441|NCT04609228||Blood-transfusion acceptors|Blood-transfusion acceptors
9726442|NCT04608695|No Intervention|Control ovary|
9726443|NCT04608695|Experimental|Punctured ovary|
9726444|NCT04603157|No Intervention|Standard of Care Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will continue to follow the treatment recommendations of the primary care physician
9726445|NCT04603157|Experimental|Hybrid Exercise Training Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will follow a hybrid exercise training program
9726446|NCT04602845|Experimental|Remimazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 3 mg/2ml remimazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Remimazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
9726447|NCT04602845|Active Comparator|Midazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 2.5 mg/2ml midazolam.~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Midazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
10205003|NCT04324606|Experimental|Group 2c|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and week 8
9726448|NCT04598477|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
9726449|NCT04598451|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
9726450|NCT04598451|Experimental|placebo|patients receiving placebo on top of prednisone
9726451|NCT04597528||Elective induction group|Nulliparous singleton gestations undergoing elective induction between 39weeks and 0days -39weeks and 6 days based on clinical information and evaluation of the earliest ultrasound as described in Gestational Age
10199149|NCT05189093|Experimental|phase I dose escalation part,Phase II efficacy exploratory part and the efficacy confirmation part|"In the phase I dose escalation part,with a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.~5 cohorts will be carried out in parallel in the phase II efficacy exploration part: Cohort 1: Relapsed/refractory diffuse large B-cell lymphoma; Cohort 2: Relapsed/refractory peripheral T-cell lymphoma; Cohort 3: Relapsed/refractory classic Hodgkin's lymphoma; Cohort 4: Relapsed/refractory mantle cell lymphoma; Cohort 5: Relapsed/refractory follicular lymphoma and marginal zone lymphoma; In the efficacy exploration part, each cohort will enroll 15 subjects, a total of 5 cohorts, and 75 cases are expected to be enrolled.~In the phase II efficacy confirmation part, one or two indications with better safety and efficacy among the 5 cohorts in the efficacy exploration phase will be selected."
10199150|NCT05189067|Active Comparator|paclitaxel + trastuzumab|"paclitaxel × 12, every week a cycle, trastuzumab × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Paclitaxel i.v. 80mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
10199151|NCT05189067|Experimental|docetaxel + trastuzumab|"(docetaxel + trastuzumab) × 4, every 3 weeks a cycle; followed by trastuzumab, every 3 weeks a cycle for 9 months.~Docetaxel i.v. 100mg/m2, trastuzumab i.v. loading dose of 8 mg/kg, followed by 6mg/kg"
10199152|NCT05189041|Other|Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
10199153|NCT05189041|Other|Non Ruptured Cerebral Aneurysm|Quantify the aneurysmal pulsation in functional MRI on the patient with Non Ruptured Cerebral Aneurysm
10199154|NCT05189015|Experimental|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
9726452|NCT04597476|Experimental|Fucoidan Group|Fucoidan powder at 4.4 g per sachet (dose) for oral administration. Fucoidan 4.4 g, PO, bid for 24 weeks
9726453|NCT04597476|Placebo Comparator|Potato starch|Potato starch at 4.4 g per sachet (dose) for oral administration. Potato starch 4.4 g, PO, bid for 24 weeks
9726454|NCT04597320|Active Comparator|Fentanyl group|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
9726455|NCT04597320|Experimental|Esketamine group|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
9726456|NCT04596189|Experimental|Dupilumab|Sterile Dupilumab 150 mg/mL will be provided in pre-filled syringes (2.25 total volume) to deliver 300 mg in 2 mL.
9726457|NCT04596189|Placebo Comparator|Placebo|Sterile placebo for Dupilumab will be provided in identically matching pre-filled syringes to deliver 2 mL.
9726458|NCT04596124|Experimental|fitostimoline plus cream|
9726459|NCT04596124|Experimental|fitostimoline plus gauze|
9726460|NCT04596124|Active Comparator|connettivina bio plus cream|
9726461|NCT04596124|Active Comparator|connettivina bio plus gauze|
9726462|NCT04590872|Experimental|Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)|After completion of leukapheresis, patients receive a prime dose of PIpepTolDC intradermally (ID) on Day 0, followed by a boost dose of PIpepTolDC ID on Day 28.
9726463|NCT04590235|Experimental|Selumetinib|All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. Then, selumetinib 25 mg/m^2 oral twice daily will be administered continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first.
9726464|NCT04587427||Radium-223|Subjects who received the treatment of radium-223 during the before or after label change study periods.
9726465|NCT04587128|Experimental|Cohort A: No Previous EGFR|"Participant who have not be previously exposed to anti-EGFR therapies and are in the first or second-line metastatic treatment setting.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle"
9726466|NCT04587128|Experimental|Cohort B: Retreatment|"Participants with treatment refractory disease who have previously benefitted (greater than or equal to 4 months ago) from anti-EGFR therapy.~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle, +/- Irinotecan (180mg/m^2) every 2 two weeks per standard of care"
9726467|NCT04583709|Experimental|ECG Belt|ECG belt will be used to record ECG during baseline rhythm, LBBP in unipolar and bipolar configurations and / or during HOT-CRT using HBP or LBBP. These ECG belt characteristics would then be compared with baseline and existing data on RV pacing and traditional Biventricular pacing.
10199155|NCT05189015|Active Comparator|Amlodipine|- Comparator group: Amlodipine, 5 (10) mg once a day, oral administration
10199156|NCT05189002|Experimental|Group 1a|Patients from groups 1a took the study product once a day in doses 40 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
10205004|NCT04324606|Experimental|Group 2d|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 2.5x10^10vp ChAdOx1 nCoV-19 at week 8
9726468|NCT04576416|Experimental|Intervention|During the three months the intervention group will receive access to the AI augmented digital educational platform and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
9726469|NCT04576416|No Intervention|Control|The control group continues its standard clinical practice without access to the E-app, but does register skin lesions throughout the full 3 month period.
9726470|NCT04573920|Experimental|Atrasentan|Once daily oral administration of 0.75 mg atrasentan for 52 weeks.
9726471|NCT04572646|Other|NRT proposition and exhaled CO measurement|
9726472|NCT04568200|Experimental|durvalumab and neoadjuvant therapy|durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
9726473|NCT04568200|Placebo Comparator|normal saline and neoadjuvant therapy|normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
9726474|NCT04566432||Immune checkpoint inhibitors|
9726475|NCT04566432||Targeted therapy|Targeting ALK, ROS1, MET ex14 skipping
9726476|NCT04565951|Experimental|treatment arm|Participants in this arm will receive the intervention, PsychArmor S.A.V.E.
9726477|NCT04565951|Sham Comparator|sham arm|"Participants in this arm will receive a sham training, not the intervention, consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
9726478|NCT04564339|Experimental|Ravulizumab: LN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
9726479|NCT04564339|Placebo Comparator|Placebo: LN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
9726480|NCT04564339|Experimental|Ravulizumab: IgAN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
9726481|NCT04564339|Placebo Comparator|Placebo: IgAN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
10199157|NCT05189002|Experimental|Group 1b|Patients from groups 1b took the study product once a day in doses 60 mg per os and saline solution subcutaneously. Dose was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product.
9726484|NCT04560140|Experimental|Intervention group|Eligible participants will be randomly assigned to receive usual care with the novel 24-week Narrative and Skills-building Intervention.
9726485|NCT04560140|No Intervention|Usual care group|Participants will receive usual stroke care.
9726486|NCT04559529|Experimental|Levetiracetam (LEV), then Placebo|Participants will first receive two 250mg LEV capsules on the same day. After one week, they will receive two placebo capsules on the same day.
9726487|NCT04559529|Experimental|Placebo, then Levetiracetam (LEV)|Participants will first receive two placebo capsules on the same day. After one week, they will receive two 250mg LEV capsules on the same day.
9726488|NCT04558957|Experimental|FLEBOGRIF|Interventions will be performed using Flebogrif catheter.
9726489|NCT04558749||Study group|The study population comprised women that will attend their routine visit to the antenatal clinic. The study population will be recruited by using simple random sampling method after verbal consent will be obtained. Resident in the Department of Obstetrics and Gynaecology who will be trained to administer the questionnaire will interview women. Face masks will be provided to the study population during the process of data collection.
9726490|NCT04556734|Experimental|Etrasimod 2 mg|
9726491|NCT04556734|Experimental|Etrasimod 3 mg|
9726492|NCT04556734|Placebo Comparator|Placebo|
9726493|NCT04555044|Experimental|Clinolipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
9726494|NCT04555044|Active Comparator|Intralipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
9726495|NCT04554914|Experimental|EBV+ PID LPD|Participants with newly diagnosed or relapsed/refractory EBV+ PID LPD will receive IV tabelecleucel.
9726496|NCT04554914|Experimental|EBV+ AID LPD|Participants with newly diagnosed or relapsed/refractory EBV+ AID LPD will receive IV tabelecleucel.
9726497|NCT04554914|Experimental|EBV+ PTLD CNS|Participants with newly diagnosed or relapsed/refractory EBV+ PTLD CNS will receive IV tabelecleucel.
9726498|NCT04554914|Experimental|EBV+ PTLD (ineligible for first-line therapy or CD20 negative)|Participants with EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease will receive IV tabelecleucel.
9726499|NCT04554914|Experimental|EBV+ sarcoma, including LMS|Participants with newly diagnosed or failed systemic first-line therapy for EBV+ sarcoma will receive IV tabelecleucel.
9726500|NCT04554914|Experimental|CAEBV/ HLH|Participants with newly diagnosed or previously treated CAEBV or EBV viremia with HLH will receive IV tabelecleucel.
9780873|NCT01133847|Experimental|Combined ADHD and Reading Instruction|"All interventions described in Reading Instruction and ADHD treatment arms:~Phonologically-based reading instruction provided for 45 minutes, four days per week, for 16 weeks. Carefully-managed medication and behavioral parent training. Medication treatment begins with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions on parenting a child with ADHD."
9984749|NCT03772145||Tofacitinib|Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy
10199158|NCT05189002|Active Comparator|Group 2|Patients from the control group (group 2) were received Fragmin in accordance with the instruction for medical use (5000 IU s/c once a day with 24-hour interval) and six Placebo tablets masked as study product Dimolegin - DD217 once a day.
10199159|NCT05188950|Experimental|treatment group|The intervention involved the participants' use of the mobile application.
9726501|NCT04553692|Experimental|IGM-8444 Single Agent Escalation|IGM-8444 will be administered intravenously as a single agent.
9726502|NCT04553692|Experimental|IGM-8444 Single Agent Alternate Dosing Escalation|IGM-8444 will be administered intravenously as a single agent on an alternate dosing schedule.
9726503|NCT04553692|Experimental|IGM-8444 + FOLFIRI Escalation|IGM-8444 will be administered intravenously in combination with FOLFIRI.
9726504|NCT04553692|Experimental|IGM-8444 Single Agent Expansion|IGM-8444 will be administered intravenously as a single agent in disease specific cohorts.
9726505|NCT04553692|Experimental|IGM-8444 + FOLFIRI Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI.
9726506|NCT04553692|Experimental|IGM-8444 + FOLFIRI + Bevacizumab (and approved biosimilars) Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI and bevacizumab (and approved biosimilars).
9726507|NCT04553692|Experimental|IGM-8444 + Birinapant Escalation|IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.
9726508|NCT04553692|Experimental|IGM-8444 + Birinapant Expansion|IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.
9726509|NCT04553692|Experimental|IGM-8444 + Venetoclax Escalation|IGM-8444 will be administered intravenously in combination with Venetoclax.
9726510|NCT04553692|Experimental|IGM-8444 + Venetoclax Expansion|IGM-8444 will be administered intravenously in combination with Venetoclax.
9726511|NCT04548778||exocrine pancreatic insufficiency (PEI)|Established diagnosis of PEI based on a routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
9726512|NCT04548778||no exocrine pancreatic insufficiency (no PEI)|No evidence of PEI according to routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
9726513|NCT04546958|Active Comparator|Nutritional counseling arm|Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis
9726514|NCT04546958|Experimental|Nutritional counseling plus whey protein supplements arm|Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of ~0.3 g/kg protein intake.
10199160|NCT05188950|No Intervention|control group|As usual.
9726515|NCT04545047||Exposed|Veterans who received COVID-19 convalescent plasma therapy within 2 days of eligibility
9726516|NCT04545047||Unexposed|Veterans who did not receive COVID-19 convalescent plasma therapy
9726517|NCT04544995|Experimental|Participants receiving Niraparib +Dostarlimab|Participants will receive Niraparib and Dostarlimab.
9726518|NCT04542785|Experimental|Lenient rate control|Treating physicians will target a resting heart rate between 80 and 110 beats per minute on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
9726519|NCT04542785|Active Comparator|Strict rate control|Treating physicians will target a resting heart rate a mean resting heart rate < 80 bpm on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
9726520|NCT04542330|Active Comparator|BCG-Denmark|"Participants that are randomized to the active comparator arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.~Each 0.1 ml dose of vaccine contains between 200,000 to 800,000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
9726521|NCT04542330|Placebo Comparator|Control|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
9726522|NCT04540458|Other|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
9726523|NCT04540458|Other|Placebo|Mother or Mother/Father is given printed picture of 3D ultrasound of fetus
9726524|NCT04539561|Experimental|Pigmentation|Treatment of Hand Pigmentation Using PiQo4 Laser System
9726525|NCT04535596|Experimental|Conventional Exercises|12 week long strength training exercise with the higher loading (%70-80 of 1 Repetitive Maximum)
9726526|NCT04535596|Experimental|Blood Flof Restriction Exercises|12 week long strength training exercise with the lower loading (%20-30 of 1 Repetitive Maximum) by using cuff around the thigh
9726527|NCT04535076|Experimental|Transcatheter Aortic Valve Implantation|
9726528|NCT04535076|Active Comparator|Surgical Aortic Valve Replacement|
9726529|NCT04532346|Experimental|Hydroxychloroquine|Hydroxychloroquine in a dose of 10 mg/kg*d, p.o., bid for 12 months. The maximum daily dose is 400mg.
9726530|NCT04532346|No Intervention|control|control group which do not take hydroxychloroquine for treatment.
9726531|NCT04531839|Experimental|Intervention period|The 1.5-year period during which all six participating centers receive evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation, and collaborative learning
9726532|NCT04531839|No Intervention|Baseline period|The 2-year period before the collaborative quality improvement intervention
9726533|NCT04530799||IAPA+|Influenza patients who develop IAPA during ICU admission
9726534|NCT04530799||IAPA-|Influenza patients admitted to the ICU not developing IAPA
9726535|NCT04530747|Experimental|Metformin|Subjects randomized to this arm will be orally given 2000 mg metformin daily. Metformin dosage will be slowly increased to improve tolerance.
9780874|NCT01133860|Experimental|eltrombopag|
10199161|NCT05188924|Experimental|DKF-306|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
10199162|NCT05188924|Placebo Comparator|Placebo|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
10205005|NCT04324606|Active Comparator|Group 2e|Volunteers will receive two standard single doses of MenACWY vaccine at week 0 and week 8
9726536|NCT04530747|Placebo Comparator|Placebo oral capsule|Subjects randomized to this arm will receive placebo matching study drug.
9726537|NCT04529941|Experimental|Experimental Group|Will receive stimulation ScNS at 3.5mA output
9726538|NCT04529941|Sham Comparator|Control Group|Does not receive therapy
9726539|NCT04527575|Experimental|"EpiVacCorona (An Open Study)"|Group 1: 14 volunteers who will be vaccinated with the EpiVacCorona vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
9726540|NCT04527575|Experimental|"EpiVacCorona (A Simple, Blind, Randomized Study)"|Group 2: Administration of the EpiVacCorona vaccine, intramuscularly, twice, 21 days spaced apart, at a dose of 0.5 ml (43 volunteers)
9726541|NCT04527575|Placebo Comparator|"Placebo (A Simple, Blind, Randomized Study)"|Group 3: Тhe use of placebo (sodium chloride, solvent for the preparation of dosage forms for injection 0.9%) intramuscularly twice space 21 days apart at a dose of 0.5 ml (43 volunteers)
9726542|NCT04526002|Experimental|Concurrent TBS/fNIRS with iTBS and followed by cTBS after 1h|self-explanatory, see Arm Title
9726543|NCT04524702|Experimental|Treatment (paricalcitol, hydroxychloroquine, chemotherapy)|Beginning day -14, patients receive paricalcitol IV three times weekly and hydroxychloroquine PO BID. Patients also receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on days 1, 8, 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9726544|NCT04523649|Experimental|Home-based atrial fibrillation screening group|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
9726545|NCT04523649|No Intervention|Control group|Conventional medical care
9726546|NCT04522154|Other|MR-TTE|Patient receiving cardiac magnet resonance imaging and echocardiography
9726547|NCT04522102|Experimental|Intervention|Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).
10199163|NCT05188911||mCRPC|Patients would be treated with 1000mg abiraterone qd. Patients would be treated with 5mg prednisone bid. Patients would get medical or surgical castration.
10199164|NCT05188872|Experimental|68Ga-Pentixafor|Each subject receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT imaging within the specificed time
9726548|NCT04522102|No Intervention|Comparator|Avoid antiplatelet therapy.
9726549|NCT04520256|Experimental|Core Program Only|
10199165|NCT05188859|Experimental|Treatment|"Regimen:~Sintilimab, 200mg, ivgtt d1, q3w, 21 days per cycle~Anlotinib, 12mg, po, qd, d1-14, q3w, 21 days per cycle~Pemetrexed, 500mg/m², ivgtt , d1, q3w, 21 days per cycle, 4-6 cycles.~Cisplatin, 75mg/m2 , ivgtt, d1, q3w/Carboplatin, AUC 5.0, ivgtt, d1, q3w, 21 days per cycle, 4-6 cycles."
10199166|NCT05188846|Experimental|SDF|
10199167|NCT05188846|Active Comparator|SDF + ART ( SMART technique )|
10199168|NCT05188833|Active Comparator|Deep Transcranial Magnetic Stimulation|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string.
10199169|NCT05188833|Experimental|Deep Transcranial Magnetic Stimulation and Paroxetine|The treatment will be carried out for 6 weeks, 5 days a week, in total 30 sessions; 20 hz using Brainsway H-7 helmet. It will be applied to the mPFC and ACC simultaneously with a total of 2000 beats at a frequency of 50 beats in each string. In addtion to DTMMS, paroxetine will applied.
10199170|NCT05188833|Active Comparator|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression in OCD.
9726550|NCT04520256|Experimental|Social Support|
9726551|NCT04520256|Experimental|Dysregulated Eating|
9726552|NCT04520256|Experimental|Social Support, Dysregulated Eating|
9726553|NCT04520256|Experimental|Exercise|
9726554|NCT04520256|Experimental|Social Support, Exercise|
9726555|NCT04520256|Experimental|Dysregulated Eating, Exercise|
9726556|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise|
9726557|NCT04520256|Experimental|Feedback|
9726558|NCT04520256|Experimental|Social Support, Feedback|
9726559|NCT04520256|Experimental|Dysregulated Eating, Feedback|
9726560|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback|
9726561|NCT04520256|Experimental|Exercise, Feedback|
9726562|NCT04520256|Experimental|Social Support, Exercise, Feedback|
9726563|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback|
9726564|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback|
9726565|NCT04520256|Experimental|VR|
9726566|NCT04520256|Experimental|Social Support, VR|
9726567|NCT04520256|Experimental|Dysregulated Eating, VR|
9726568|NCT04520256|Experimental|Social Support, Dysregulated Eating, VR|
9726569|NCT04520256|Experimental|Exercise, VR|
9726570|NCT04520256|Experimental|Social Support, Exercise, VR|
9726571|NCT04520256|Experimental|Dysregulated Eating, Exercise, VR|
9726572|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, VR|
9726573|NCT04520256|Experimental|Feedback, VR|
9726574|NCT04520256|Experimental|Social Support, Feedback, VR|
9726575|NCT04520256|Experimental|Dysregulated Eating, Feedback, VR|
9726576|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback, VR|
9726577|NCT04520256|Experimental|Exercise, Feedback, VR|
9726578|NCT04520256|Experimental|Social Support, Exercise, Feedback, VR|
9726579|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback, VR|
9726580|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback, VR|
9726581|NCT04519541|Experimental|Neurolyser XR treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
9726582|NCT04512378|Experimental|IU Group Treatment|Clinical intervention arm
9726583|NCT04512170|Experimental|A single dose HEC585（pilot trial arm）|Healthy subjects receive a single dose of HEC585
9726584|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 1）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
9726585|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 2）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
9726586|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 3）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
9726587|NCT04512170|Experimental|Single dose of HEC585 （Part 2，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
9726588|NCT04512170|Experimental|two-period study at 400 mg dose group (part 3，Fed)|Healthy subjects receive Single/multiple doses of HEC585 or matching placebo in two cycles.
9726589|NCT04509570|Other|Treatment: ILI(Intralesional injection)|5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
9726590|NCT04509414|Experimental|dexmedetomidine|2ug/kg intranasal atomized dexmedetomidine
9726591|NCT04509414|Active Comparator|midazolam|0.2mg/kg intranasal atomized midazolam
9726592|NCT04506151|Experimental|Sleep-Opt|12-week intervention that includes self-monitoring, goal setting, motivational enhancement.
9726593|NCT04506151|Active Comparator|Healthy Living|12-week intervention that includes weekly telephone contact, didactic content equal in time and attention to intervention group.
9726594|NCT04505462|Experimental|Study diet|7-day therapeutic diet intervention as experimental group
9726595|NCT04505462|No Intervention|Usual diet|7-day usual diet as control group, no dietary intervention in this group, participants consumed their habitual diet
9726596|NCT04505059|Experimental|Precision cardiac anesthesia|Remifentanil (TCI) for intra-operative analgesia Propofol (TCI) for intra-operative sedation
9726597|NCT04505059|Active Comparator|Conventional cardiac anesthesia|Institutional standard of care.
9726598|NCT04504994|Experimental|exclusion BPD|cyberball exclusion condition - BPD patients
9726599|NCT04504994|Experimental|over-inclusion BPD|cyberball over-inclusion condition - BPD patients
9726600|NCT04504994|Experimental|exclusion healthy controls|cyberball exclusion condition - healthy controls
9726601|NCT04504994|Experimental|over-inclusion healthy controls|cyberball over-inclusion condition - healthy controls
9726602|NCT04502420||Abdominal surgery|People who to be operated in the abdomen are investigated before and after surgery.
9726603|NCT04500574|Experimental|Latanoprost contact lens|The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop.
9726604|NCT04500574|Placebo Comparator|Topical Latanoprost|The placebo arm will have a commercial contact lens with no drug with a nightly 0.005% latanoprost drop.
9726605|NCT04493996|Experimental|Cognitive training group|
9726606|NCT04493996|No Intervention|Control group|
9726607|NCT04493151|Experimental|Imipenem-Cilastatin-Relebactam|Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.
9982299|NCT05269394|Placebo Comparator|Matching placebo (E2814) plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
9982300|NCT05269355|Experimental|Unesbulin and Dacarbazine|Participants will receive unesbulin 300 milligrams (mg) tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/meter squared (m^2) intravenously (IV) once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
9726617|NCT04487613|Active Comparator|Moringa oleifera leaf|Participants received Moringa oleifera leaf 450 mg capsule orally twice daily for 3 days.
9726618|NCT04487613|Placebo Comparator|Placebo|Participants received placebo capsule orally twice daily for 3 days.
9726619|NCT04487548|No Intervention|Control group|The control group will have their preadmission clinic telephone call as normal and may be given advice to quit smoking and information about available smoking cessation resources over the phone.
9726620|NCT04487548|Experimental|Intervention group|The intervention group will be emailed (or postal mailed) the smoking cessation bundle with educational video, brochure, referral to the Smokers' Helpline and direct referral to an online pharmacy for nicotine replacement.
9726621|NCT04485663|Experimental|ALG-010133|Subcutaneous injections of ALG-010133 in HV or CHB subjects up to every 7 days for up to 12 weeks
9726622|NCT04485663|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects up to every 7 days for up to 12 weeks
9726623|NCT04485325|Active Comparator|Tofacitinib|Tofacitinib (Xeljanz®; 5 mg twice daily, p.o.)
9726624|NCT04485325|Active Comparator|Etanercept|Etanercept (Enbrel®; 50 mg once per week, s.c.)
9726625|NCT04484428|Experimental|Treatment Arm A|K-285
9726626|NCT04484428|Active Comparator|Treatment Arm B|Menthol
9726627|NCT04481035|Experimental|N-Acetylcysteine|Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
9726628|NCT04481035|Placebo Comparator|Placebo|Participants will be dosed three times per day with a placebo for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
9726629|NCT04476420|Active Comparator|Steroid group|Participants in group 1 will be given corticosteroid lotion (Betamethasone valerate 0.1%) and will be advised to apply it topically (0.5 ml) on the buccal mucosa thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
10199171|NCT05188807|Experimental|The patient with cervical pathology|we will perform airway ultrasonography before the patients intubations and we will intubate the patients before cervical surgery
10199172|NCT05188794|Active Comparator|group L|Lateral transversus abdominis plane(TAP) block
9726630|NCT04476420|Experimental|Nigella Sativa oil group|Group 2 will be given commercially available, cold pressed N.sativa (Black seed) oil and will be advised to apply it topically over the buccal mucosa (1 ml) thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
9726631|NCT04476238|Experimental|Inosine|2 grams of inosine dissolved in 250 ml of tap water
9726632|NCT04476238|Placebo Comparator|Water|250 ml of tap water only
9726633|NCT04476030|Experimental|Experimental: SAGE-217 + Assigned ADT|Participants will receive SAGE-217 capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
9726634|NCT04476030|Active Comparator|Active Comparator: Placebo + Assigned ADT|Participants will receive SAGE-217-matching placebo capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
9726635|NCT04475705|Active Comparator|Sevoflurane group|patients in this group will receive inhalation anaesthesia with sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
10199173|NCT05188794|Active Comparator|Group P|Posterior transversus abdominis plane block
10199174|NCT05188781||Pembrolizumab combined with Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
10199175|NCT05188768|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
10199176|NCT05188768|Active Comparator|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
10199177|NCT05188755|Active Comparator|Healthy controls|sex and age matched healthy controls
10199178|NCT05188755|Experimental|young adults recovered from lymphoma or Hodgkin's disease|young adults recovered from lymphoma or Hodgkin's disease
10199179|NCT05188742|Experimental|Sequence A|mirabegron 50mg OD x 8 weeks, followed by mirabegron 50mg OD and TTNS for 4 weeks, followed by TTNS twice a week x 8 weeks
9726636|NCT04475705|Active Comparator|propofol group|patients in this group will receive intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
9726637|NCT04473508|Experimental|Treated|active treatment (Local anaesthetic): Local administration of ropivacaine 30 mL (5mg/mL)
10199180|NCT05188742|Experimental|Sequence B|TTNS twice a week x 8 weeks, followed by mirabegron 50mg OD and TTNS for 4 weeks, followed by mirabegron 50mg OD x 8 weeks
10199181|NCT05188651||dental professionals wearing FFP2/N95 masks|
10199182|NCT05188651||dental professionals wearing type IIR fluid resistant surgical masks|
10199183|NCT05188625|No Intervention|Control arm|This group will receive the standard care of face-to-face dietitian counselling sessions.
10199184|NCT05188625|Experimental|Intervention arm|This group will receive online self-paced dietary education, and followed up by telehealth video consultation with dietitian for dietary counselling.
10199185|NCT05188612||Male|Non-interventional patient registry
9726638|NCT04473508|Placebo Comparator|Control|Local administration of Placebo ( Saline Solution)
9726639|NCT04471818|Experimental|Ketamine|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
9726640|NCT04471818|Placebo Comparator|Placebo|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
9726641|NCT04471402||All subjects recruited|"All subjects recruited will be given 3mcg/kg intranasal Precedex through an atomiser, divided equally between two nostrils. They will be observed and sedation score will be recorded every 5 minutes according to the University of Michigan Sedation Scale (UMSS). Pulse oximetry and Blood pressure cuff will be applied whenever they accept these monitoring.~A buccal swab sample will be taken from all children and the identified genes will be analysed and compared between the different responders (fast, normal, slow or non-responders)."
9726642|NCT04469790|No Intervention|SIT|Continuous sitting for 3 hours
10199186|NCT05188612||Female|Non-interventional patient registry
9726643|NCT04469790|Experimental|SIT+WALK|Interrupt sitting with 3-minutes of moderate-intensity walking every 30 minutes for 3 hours
10199187|NCT05188612||Elderly|Non-interventional patient registry
10199188|NCT05188612||Hypertension|Non-interventional patient registry
10199189|NCT05188612||Diabetes|Non-interventional patient registry
10199190|NCT05188612||Dyslipidemias|Non-interventional patient registry
10199191|NCT05188612||Smoking|Non-interventional patient registry
10199192|NCT05188612||Kidney Disease|Non-interventional patient registry
10199193|NCT05188612||Heart Diseases|Non-interventional patient registry
10199194|NCT05188612||Vascular diseases|Non-interventional patient registry
10199195|NCT05188599||Amputee patients|age between 18-65 years, (b) time after amputation ≥ 6 months, (c) unilateral or bilateral amputation above the ankle level
10205006|NCT04324606|Experimental|Group 2f|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
10199196|NCT05188586|Experimental|Cohort 1: 65 years old and older|"Cohort 1 = 65 years old or older. Blood draws will include the early detection pancreatic cancer test.~Time 0 (T0) = blood draw within 90 days of diabetes diagnosis Time 1 (T1) = blood draw 6 month draw from diabetes diagnosis Time 2 (T2) = 12 months from diabetes diagnosis, no blood draw, only medical record search for all patients for evidence of pancreatic neoplasia developed after T1."
10199197|NCT05188586|Experimental|Cohort 2: 50-64 years old|"Cohort 2: 50-64 years old. Blood draws will include the early detection pancreatic cancer test.~Time 0 (T0) = blood draw within 90 days of diabetes diagnosis Time 1 (T1) = blood draw 6 month draw from diabetes diagnosis Time 2 (T2) = 12 months from diabetes diagnosis, no blood draw, only medical record search for all patients for evidence of pancreatic neoplasia developed after T1."
10199198|NCT05188586|Experimental|Imaging Arm|"The negative control arm consists of randomly selected not-detected subjects who will be sent for MRI imaging at each of the three study timepoints, with four non-detected subjects imaged for each detected subject imaged.~At T0 and T1, the subjects in the negative control arm will be pre-specified according to gender and age-matched (within 5 years) to the subjects who tested detected at 4:1 ratio.~Since testing will not occur at T2, subjects who were not-detected at T0 and T1 and showed no evidence of cancer after 12-month EMR review will be gender and age matched (within 5 years) to the detected subjects at T1 at 4:1 ratio."
9726644|NCT04469790|Experimental|EX|Perform 18 consecutive minutes of moderate-intensity walking, then sit for the remaining time
9726645|NCT04469504|Experimental|PREHAB|
9726646|NCT04469504|Active Comparator|control group|
9726647|NCT04468061|Experimental|Sacituzumab Govitecan + Pembrolizumab|"Participants will receive Sacituzumab Govitecan + Pembrolizumab at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of the 21 day cycle Pembrolizumab will be given on day 1 of the 21 day cycle."
9726648|NCT04468061|Experimental|Sacituzumab Govitecan|"Participants will receive Sacituzumab Govitecan at a pre-determined dose during a 21 day cycle.~Sacituzumab Govitecan will be given on days 1 and 8 of a 21-day cycle"
9726649|NCT04468061|Experimental|Retreatment|"Participants randomized to the combination arm (Sacituzumab Govitecan + Pembrolizumab) who stop with CR after at least 24 weeks of treatment may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment. This is termed the Second Course Phase and is only available if the study remains open and the subject meets conditions.~."
9726650|NCT04466358|Experimental|Modified CLOSE protocol|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol, confirmed with multipolar circular mapping catheter.
9726651|NCT04466358|Active Comparator|High density mapping guided pulmonary vein isolation|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol and confirmed with high density mapping of each pulmonary vein antrum, with additional ablation lesions at sites of gap or dormant conduction.
9726652|NCT04462952|Experimental|Adavosertib (AZD1775) monotherapy|Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
9726653|NCT04462952|Experimental|Adavosertib (AZD1775) in combination with gemcitabine|Dose escalation of adavosertib in combination with gemcitabine for patients with advanced solid tumours
10199199|NCT05188573|Experimental|EpiDetect Arm|"Each subject can undergo to up to 3 blood draws; at the time of enrollment (T0), at 6 months (T1) and 12 months (T2) from diabetes diagnosis. After 24 months from diabetes diagnosis, a review of the electronic medical records (EMR) will be performed for all subjects with a not detected test result."
10199200|NCT05188573|Experimental|"EpiDetect not detected MRI Arm"|"A pre-specified number of cases with test results not detected will be randomly selected, gender ratio and age matched to subjects with test results detected and will undergo MRI imaging at T0 (n=226), at T1 (n=208 ) at T2 (n=208 ) and 24 months (n=208) from diabetes diagnosis."
10199201|NCT05188547|No Intervention|Control|No video education, only consultation by the anesthesiologist. No knowledge test before the consultation.
10199202|NCT05188547|No Intervention|Baseline|No video education, only consultation by the anesthesiologist. Also a knowledge test before the consultation.
10199203|NCT05188547|Experimental|Video|Video education and a knowledge test directly afterwards. Consultation by the anesthesiologist after the knowledge test.
10199204|NCT05188547|Experimental|Video Augmented|Video education and consultation by the anesthesiologist directly afterwards. The knowledge test is taken after the consultation.
9726654|NCT04462328|Experimental|Phase I Dose Level 1: Durvalumab + Acalabruitinib|"Acalabrutinib 100 mg twice per day by mouth on days 1-28~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
9726655|NCT04462328|Experimental|Phase I Dose Level 2: Durvalumab + Acalabruitinib|"Acalabrutinib 200 mg twice per day by mouth on days 1-28~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
9726656|NCT04462328|Experimental|Expansion Cohort: Durvalumab + Acalabrutinib|"Acalabrutinib 100 mg or 200 mg (depends on tolerable dose found in Phase I portion of study) twice per day by mouth on days 1-28~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
9726657|NCT04461301|Experimental|Intervention|Patients that meet the inclusion criteria will be randomised and scheduled for surgery at least 2 weeks after the diagnosis/decision to proceed to surgery. This timeframe allows the implementation of a minimal 2 weeks (up to 4 weeks) multidisciplinary prehabilitation program. Prehabilitation program is composed of 4 elements: exercise training, nutritional intervention, correction of anaemia and smoking cessation. An individual treatment strategy will be proposed to the patient by a multidisciplinary team consisting of surgeon, anesthesiologist, dietitian and physiotherapist.
9726658|NCT04461301|No Intervention|Control|Perioperative care of the control group will be based on standardized, multi-element, ERAS recommendations as already implemented in the different participating clinics.
9726659|NCT04460794|Experimental|Ballet-inspired workout programme (Group A)|Participants will continue their usual activities and exercises, and in addition, receive an 8-week home-based programme delivered by trained volunteers via hybrid on-site and virtual contacts, and supported by volunteer healthcare professionals. A self-directed resource package will be developed.
9726660|NCT04460794|Other|Usual care (Group B)|Control participants will continue their usual activities and exercises during the study period. In addition, they will be provided with an information sheet about recommendations with pictorial demonstrations on basic stretching and leg exercises for stroke survivors.
10199205|NCT05188534||BOLD-fMRI|Identifying the language functional cortex in glioma patients with BOLD-fMRI
10199206|NCT05188534||ZOOMit-fMRI|Identifying the language functional cortex in glioma patients with ZOOMit-fMRI
10199207|NCT05188443||COVID-19|Patients tested for COVID-19 with current or previous (last 3 years) radiological imaging
10199208|NCT05188430|Active Comparator|Active treatment|Medical Device (Kaptufat®)
10199209|NCT05188430|Placebo Comparator|Placebo|Placebo
9726661|NCT04457895|Experimental|Experimental arm|"For experimental arm patients, there will be a 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga (the first on site and by videoconference for the others).~Starting the first day of the yoga practice there will be one daily 15 min session at home with My Yoga Guide and the audio guide during 12 weeks."
9726662|NCT04457895|Placebo Comparator|control arm|The control arm patients will have standard care. They will be proposed to participate in the physical therapy - yoga - educational program after the end of the study.
9726663|NCT04457284|Experimental|temozolomide, cisplatin and nivolumab|Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).
9726664|NCT04455295|Experimental|Active Stimulation 0.5|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
9726665|NCT04455295|Placebo Comparator|Lobe Control|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the earlobe. Stimulation 30 second on/30 seconds off for five cycles.
9726666|NCT04455295|Placebo Comparator|Sham Stimulation|0.5mA, 5Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
9726667|NCT04455295|Placebo Comparator|Nonstimulation|Placement of electrode without any stimulation.
9726668|NCT04453917|Experimental|Patients with active PML|Patients with neurological symptoms (< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV
9726669|NCT04451720|Experimental|Risankizumab|In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.
9726670|NCT04451720|Experimental|Placebo|In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.
9726671|NCT04451317||Experimental|Patients involved in a Sport-Health initiative Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
9726672|NCT04451317||Control|Healthy sport subjects. Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
9726673|NCT04449211|Experimental|Participants with massive bone defect|"Adult participants with health insurance regardless of sex having bone defect greater than 5cm due to trauma or tumour resection agree to participate the research.~The customised 3D-Printed implant is manufactured and undergoes post-processing treatment before being ready for implantation surgery."
10199210|NCT05188404||Cannabis Users|Older adults (60 and up) who report pain, sleep problems, and/or negative mood (anxiety and/or depression) and who desire to use cannabis for these issues (n=300)
10199211|NCT05188404||Cannabis Non-users|Older adults (60 and up) who report pain, sleep problems, and/or negative mood (anxiety and/or depression) and do NOT desire to use cannabis for these issues (n=50)
10205007|NCT04324606|Active Comparator|Group 2g|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
10205008|NCT04324606|Experimental|Group 3a|Volunteers will receive one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 4
9726674|NCT04447313|Experimental|Arm I (ACT)|Participants receive ACT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
9726675|NCT04447313|Active Comparator|Arm II (SBT)|Participants receive SBT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
9726676|NCT04446676|Active Comparator|Stem stabilization|Group of patients with stem endoprosthesis stabilization
9726677|NCT04446676|Active Comparator|Sleeve stabilization|Group of patients with sleeve endoprosthesis stabilization
9726678|NCT04442867|Experimental|Intervention group|Subjects will receive nurse-led case management supported by a social service team.The nurse, functioning as a case manager, is involved in the initial assessment of the participant using the Omaha system. After the initial assessment, the NCM will equip participants with the skills required to perform self-care in health maintenance, including self-monitoring of vital signs, medication adherence, and sources of help if needed.
9726679|NCT04442867|Other|Control group|Participants in the control group will receive a monthly social control call from a trained research assistant
9726680|NCT04442152|Experimental|Intervention|See intervention description
9726681|NCT04442152|No Intervention|Control|Participants who were randomized into the control arm were and will be surveyed at the same time point as intervention participants, but did not receive any intervention.
9780875|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 1b)|Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine
10205009|NCT04324606|Experimental|Group 3b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0, a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
10205010|NCT04324606|Experimental|Group 4a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19
10205011|NCT04324606|Active Comparator|Group 4b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
10199212|NCT05188378|Experimental|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
10199213|NCT05188378|Active Comparator|EU-approved RoActemra|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
10199214|NCT05188352|Experimental|Training group|Patients in the training group received supervised aerobic exercise training on the treadmill with the intensity of 60-75% of maximal VO2 for 40-50 minutes, 3 days a week for 8 weeks. Work-load was gradually increased during the eight-week period. In addition, conventional chest physiotherapy and was instructed to continue their daily physical activity program at home patients in this group.
10199215|NCT05188352|Active Comparator|Control group|Patients in the control group received no aerobic exercise training but were asked to continue their chest physiotherapy and daily physical activity program at home.
10199216|NCT05188339|Experimental|4% sodium citrate group|Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.
9726682|NCT04441034|Experimental|Anti-convulsant medication|The participants will be randomized to receiving an anti-convulsant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
9726683|NCT04441034|Experimental|Anti-depressant medication|The participants will be randomized to receiving an anti-depressant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
9726684|NCT04434209|Experimental|NephroCheck-guided interventions|
9726685|NCT04434209|Active Comparator|Standard of Care|Standard of Care assessment and treatment
9726686|NCT04432376|Active Comparator|Active treatment arm|Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
9726687|NCT04432376|Placebo Comparator|Placebo treatment arm|Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days
9726688|NCT04432376|Other|Open-label treatment arm|Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
9726689|NCT04429321|Experimental|Ipilimumab +Nivolumab with Embolization|"Patients initiate ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 480mg flat dose IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities.~Patients will receive 2 cycles of systemic therapy followed by embolization of their primary tumor or metastatic lesion(s) and continue systemic therapy subsequently."
9726690|NCT04424654|Experimental|Bipolar Androgen Therapy (BAT)|Testosterone cypionate 400 mg IM every 28 days for 3 cycles
9726691|NCT04414735|No Intervention|1- Control group (Standard immunosuppression)|1- Control group (n=15): Standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate), according to the clinical protocol of the Nephrology and Kidney Transplant Department.
9726692|NCT04414735|Experimental|2- Treatment group (ECP+Standard immunosuppression)|2- Treatment group (n=15): Extracorporeal photopheresis in combination with standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate) according to the clinical protocol of the Nephrology and Kidney Transplant Department
9982301|NCT05269355|Placebo Comparator|Placebo and Dacarbazine|Participants will receive placebo matching to unesbulin tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/m^2 IV once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
10199217|NCT05188339|Active Comparator|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
9726695|NCT04408248||COVID-19 patients with acute respiratory disease|Adult patients with COVID-19 and moderate or severe respiratory disease
9726696|NCT04406142|Experimental|treatment feasibility|feasibility, safety and effectiveness assessment
9726697|NCT04404660|Experimental|AUTO1|
9726698|NCT04403984||Patients with Luminal A breast cancer|Patients confirmed with Luminal A breast cancer sub type
9726699|NCT04403984||Patients with Luminal B breast cancer|Patients confirmed with Luminal B breast cancer sub type
9726700|NCT04402632|Active Comparator|Surgery Cohort: Control Arm|Control
9726701|NCT04402632|Experimental|Surgery Cohort: Treatment Arm|Treatment
9726702|NCT04402632|Active Comparator|Observational Cohort: Control Arm|Control
9726703|NCT04402632|Experimental|Observational Cohort: Treatment Arm|Treatment
9726704|NCT04400903||Observational (HRV monitoring, questionnaire)|Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.
9726705|NCT04399252|Experimental|LGG Arm|Participants in this arm will be given LGG for 28 days.
9726706|NCT04399252|Placebo Comparator|Placebo|Participants in this arm will be given a placebo for 28 days.
9726707|NCT04398706|Experimental|Group 1|One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
9726708|NCT04398706|Experimental|Group 2|One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
9726709|NCT04398706|Experimental|Group 3|One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
9726710|NCT04398706|Active Comparator|Group 4|One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
9726711|NCT04398706|Experimental|Group 5|Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
9726712|NCT04398706|Experimental|Group 6|Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
9726713|NCT04398706|Experimental|Group 7|Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
9726714|NCT04398706|Active Comparator|Group 8|Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
9726715|NCT04392622|Experimental|d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
9726716|NCT04392622|Experimental|d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
9726717|NCT04392622|Experimental|d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
9726718|NCT04392622|Experimental|d-limonene -8gram|8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation
9726719|NCT04392622|Experimental|de-escalation dose d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
10199218|NCT05188313|Active Comparator|Chemoradiation according to the CROSS regimen|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy."
10199219|NCT05188313|Experimental|Chemoradiation according to the CROSS regimen combined with trastuzumab and pertuzumab|"Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given by intravenous infusion on days 1, 8, 15, 22 and 29.~A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.~Pertuzumab will be administered intravenously first, on Day 1, 22, 43, 64, and 85 using a fixed dose of 840 mg.~Trastuzumab will be administered intravenously on Day 1 of each treatment cycle, using an initial dose of 4 mg/kg on day 1, followed by doses of 2 mg/kg weekly up to week 6. From week 7 onwards trastuzumab will be administered at a dose of 6 mg/kg, every three weeks."
9726720|NCT04392622|Experimental|de-escalation dose d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
9726721|NCT04392622|Experimental|de-escalation dose d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
9726722|NCT04391686||COVID intensive care unit|
9726723|NCT04391686||intensive care unit|
9726724|NCT04391686||obesity|
10199220|NCT05188300|Experimental|Dorsal intercostal artery (DICA) perforator flaps|Retrograde dissection of free style perforator arising from DICA according to region of dorsal spine and identification of paraspinal muscle where perforator vessel was found
9726725|NCT04391556|Experimental|Firmagon|120 mg Firmagon subcutaneous injection after a TEP-PSMA
9726726|NCT04391452|Experimental|Dietary supplement group|Group 1:50 stressed subjects who will have a 28-day intake of dietary supplement. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam. Dietary supplement is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg).
9726727|NCT04391452|Placebo Comparator|Placebo group|Group 2 (Placebo comparator (lactose)): 50 stressed subjects who will have a 28-day intake of placebo. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam.
10199221|NCT05188300|Experimental|Trapezius musculocutaneous perforator flaps|Retrograde dissection of a free style perforator arising as a trapezius myocutenous perforator where the trapezius muscle is identified and a perforator vessel was isolated.
10199222|NCT05188300|Experimental|Lumbar artery perforators flaps|Retrograde dissection of free style perforator arising from lumbar artery according to region of lumbar spine and identification of lumbar fascia where perforator vessel was found
9726728|NCT04390958|Experimental|Neoadjuvant chemotherapy group|Total 6 perioperative chemotherapy composed of nab-paclitaxel, cisplatin and capecitabine every 21 days
9726729|NCT04382118||OWDFO: Open Wedge Distal Femoral Varus osteotomy|
9726730|NCT04382118||CWDFO: Closed Wedge Distal Femoral Varus osteotomy|
9726731|NCT04376983|No Intervention|Control|Patients will get no intervention
9726732|NCT04376983|Experimental|Intervention|Patients will transmit their CRT data every week (first 6 weeks) and then every two week to the Heart Centre Hasselt. The physical activity data will be used to deliver a tailored motivational message to the patient to increase physical activity in this group.
9726733|NCT04376437|Experimental|medical cannabis|All patients will start with 250mcg cannabis flos BID and will follow the titration plan of dose modification according to CIPN relief and adverse events. Maximum dose of 2,000mcg per day is prescribed at the end of titration period, which is continuous for 15 days (about 2 weeks).On 10 weeks visit all patients will be discontinued from the treatment. In case of worsening of neuropathy at any point during the 4 weeks of FU, patients might be able to restart with inhaled MC treatment for no more than 4 weeks. Total treatment in this study will be for no more than 14 weeks.
9726734|NCT04375696|Experimental|Product|60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
9726735|NCT04375696|Placebo Comparator|Placebo|60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
9780876|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 2)|Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine
9780877|NCT01133977|Active Comparator|Dacarbazine (Phase 2)|Participants received dacarbazine
9785807|NCT01260350|Experimental|Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
10199223|NCT05188274|Experimental|T92 group|The dose of T92 was calculated based on body weight, orally twice daily. Supportive care duration: 8 weeks
9726736|NCT04372498|Experimental|Treatment|This is a pivotal trial in members of the same family carrying the V282M nutation in the Gardos channel (KCNN4) and other patients with V282 mutations with demonstrated in-vitro sensitivity to senicapoc. These mutations lead to hyperactivation of the channel and red cell dehydration. Up to 6 patients are eligible to enroll in this study, which will assess effectiveness based on individual changes of primary endpoints over individually established baselines.
9726737|NCT04371679||Endotracheal intubation and ventilation|Patients admitted at ICU that are intubated and ventilated
9726738|NCT04371679||Non-Invasive Ventilation|Patients admitted at ICU who are non-invasively ventilated
9726739|NCT04370873|Experimental|Part 1: MK-5475|Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7.
9726740|NCT04370873|Placebo Comparator|Part 1: Placebo|Participants receive placebo QD via inhalation from Days 1-7.
9726741|NCT04370873|Experimental|Part 2: MK-5475|Participants receive MK-5475 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28.
9726742|NCT04370873|Placebo Comparator|Part 2: Placebo|Participants receive placebo QD via inhalation from Days 1-28.
9726743|NCT04367233|Active Comparator|Placebo group|General anesthesia with fentanyl, propofol and remifentanyl
9726744|NCT04367233|Experimental|Transverse block group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive transverse plan block, with levobupivacaine 0,25% 0,2 ml/kg.
9726745|NCT04367233|Experimental|Quadratus lumborum group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive quadratus lumborum block with levobupivacaine 0,25% 0,2 ml/kg.
9726746|NCT04365998|Experimental|BUBOLight® Device|
9726747|NCT04365790||Patients with triple-negative breast cancer|Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
9726748|NCT04365790||Patients with HER2+ positive breast cancer|Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
9726749|NCT04363684||Longitudinal Arm|Annual clinic visits throughout the length of the study.
9726750|NCT04363684||Biofluid-Focused Arm|Single clinic visit.
9726751|NCT04359147|Active Comparator|Yohimbine|10 mg
9726752|NCT04359147|Active Comparator|Hydrocortisone|10 mg
9726753|NCT04359147|Active Comparator|Yohimbine + Hydrocortisone|10 mg each
9726754|NCT04359147|Placebo Comparator|Placebo|
9726755|NCT04356755|Experimental|autologous cultured ASC|Subcutaneous injections of autologous cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma
9726756|NCT04356755|Placebo Comparator|Placebo|Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma
9726757|NCT04355585|Experimental|Male|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
9726758|NCT04355585|Experimental|Female|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
10199224|NCT05188274|Placebo Comparator|Placebo group|The dose of placebo was calculated based on body weight, orally twice daily. Supportive care duration: 8 weeks
9726759|NCT04352166|Experimental|extended-release buprenorphine (BXR)|Three extended-release buprenorphine (BXR) injections to be administered roughly 28 days apart. The first and second injection will be 300 mg and the third will be 100 mg.
9726760|NCT04352166|Active Comparator|sublingual buprenorphine (BSL)|sublingual buprenorphine (BSL) up to 24 mg will be administered once daily for 12 weeks or length of study participation.
9726761|NCT04349852|Experimental|BrainHQ Cognitive Training Arm|Participants will randomized into the BrainHQ Cognitive Training modules which are 45 minutes training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, noise cancelling head phones will also be provided to the participants. Participants will complete the training protocols in the lab under the study team's supervision to ensure the participants are engaged and are completing the tasks.
9726762|NCT04349852|Other|BrainHQ People Skills Arm|Participants will randomized into the BrainHQ People Skills Modules which are 45 minutes training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, noise cancelling head phones will also be provided to the participants. Participants will complete the training protocols in the lab under the study team's supervision to ensure the participants are engaged and are completing the tasks.
9726763|NCT04349657|Experimental|Supera Peripheral Stent System treatment group|These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).
9726764|NCT04349657|Active Comparator|Endarterectomy treatment group|These patients will be treated surgically with endarterectomy
9726765|NCT04345666|Experimental|Testosterone group|20 patients will receive a 200 mg testosterone cyprionate intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
9726766|NCT04345666|Placebo Comparator|Placebo group|20 patients will receive a sterile saline intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
9726767|NCT04343313|Experimental|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
9726768|NCT04343040|Experimental|perioperative glucose intake|glucose intolerant patients with perioperative glucose (carbohydrate supplement (Preload™) intake before Gastric By-Pass or Sleeve Gastrectomy.
9726769|NCT04343040|Sham Comparator|6 hours of preoperative fasting|glucose intolerant patients receiving 6 hours of preoperative fasting before Gastric By-Pass or Sleeve Gastrectomy.
9726770|NCT04338529||Group Alendronate 6m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 6 months and then followed for another 6 months without medication.
9726771|NCT04338529||Group Alendronate 12m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 12 months.
9726772|NCT04336241|Experimental|Dose escalation of RP2 - superficial tumors|Dose escalation of RP2 alone in 3 cohorts with IT injections in superficial tumors.
9726773|NCT04336241|Experimental|Dose escalation of RP2 - deep/visceral tumors|Dose escalation of RP2 alone in 3 cohorts with imaging guided IT injections in deep/visceral tumors.
10199225|NCT05188248|Experimental|Female participants with Depression|Female participants with mild to moderate depression to determine if a single-session of tDCS can alter negative attention bias. The primary objective is to study if single-session tDCS will affect attention bias in depression and is not meant to treat depression.
9726774|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - superficial tumors|Doses of RP2 (IT) in superficial tumors with nivolumab (IV).
9726775|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - deep/visceral tumors|Imaging guided doses of RP2 (IT) in deep/visceral tumors.
9726776|NCT04336241|Experimental|Seronegative cohort|Doses of RP2 (IT) in HSV seronegative participants.
9726777|NCT04335175||Tourette Syndrome|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
9726778|NCT04335175||Obsessive Compulsive Disorder|Individuals previously diagnosed with obsessive compulsive disorder (OCD). Participants must be 18 years of age or older.
9726779|NCT04335175||Healthy Controls|Individuals with no past or current neurologic or psychiatric illness. Participants must be 18 years of age or older.
9726780|NCT04332523|Experimental|Group 1: Participants with Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
9726781|NCT04332523|Experimental|Group 2: Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
9726782|NCT04332523|Experimental|Group 3: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
9726783|NCT04332523|Experimental|Group 4: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of JNJ-53718678 suspension on Day 1.
9726784|NCT04332367|Experimental|Carboplatin, Taxane And Ramucirumab|Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks
9726785|NCT04324463|Experimental|Colchicine|"Outpatients:~0.6 mg twice daily for 3 days, then 0.6 mg once daily for 25 days (total 28 days).~Inpatients:~1.2 mg followed by 0.6 mg 2 hours later, then 0.6 mg twice daily for 28 days.~(*Depending on availability, 0.6 mg tablets can be substituted by 0.5 mg tablets for a regimen in outpatients of 0.5 mg twice daily for 3 days, then 0.5 mg once daily for 25 days [total 28 days]; and in inpatients of 1.0 mg followed by 0.5 mg 2 hours later, then 0.5 mg twice daily for 28 days)."
9726786|NCT04324463|Experimental|Interferon Beta [This arm is now closed to recruitment]|"Inpatients Only:~0.25 mg by subcutaneous injection on days 1, 3, 5 & 7"
9726787|NCT04324463|Experimental|Aspirin (ASA)|"Outpatients:~75 to 100 mg once daily for 28 days.~Inpatients:~75 to 100 mg once daily for 28 days"
9726788|NCT04324463|Experimental|Rivaroxaban|"Inpatients Only:~2.5 mg twice daily for 28 days."
10199226|NCT05188209|Experimental|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight
9726789|NCT04324463|No Intervention|Usual Care (Control)|Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.
9726790|NCT04322357|No Intervention|Daily Glucocorticoid (GC)|Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.
9726791|NCT04322357|Active Comparator|Twice weekly glucocorticoid with or without exercise|"Patients will be randomized to one of 2 groups:~Twice weekly prednisone alone for 12 months~Twice weekly prednisone for 6 months followed by twice weekly prednisone plus 6 months of structured, supervised and home-based exercise training."
9726792|NCT04322357|Active Comparator|Daily glucocorticoid with exercise|Patients on daily glucocorticoids will undergo 6 months of structured, supervised and home-based exercise training.
9726793|NCT04322305|Experimental|Pregabalin|Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.
9726794|NCT04322305|Placebo Comparator|Placebo|Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.
9726795|NCT04316182|Experimental|Cabozantinib|Cabozantinib at 60 mg/day in monotherapy until symptomatic tumor progression, unacceptable adverse events, patient decision or death
9726796|NCT04314895|Experimental|NanoPac|Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.
9726797|NCT04310358|Experimental|PLM group 1|Participants will do a pretest (Test 1), the 4 short PLMs, an immediate post-test (Test 2) and a remote post-test (Test 1).
10199227|NCT05188131|Experimental|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium in healthy subjects.
10199228|NCT05188131|Placebo Comparator|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (isotonic saline) in healthy subjects.
10199229|NCT05188118|Experimental|Patients with metastatic or unresectable clear cell renal cell carcinoma|Patients with metastatic or unresectable clear cell renal cell carcinoma to receive same sequential treatment strategy. (Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x4 over 12 weeks, then subsequent therapies depending on treatment response for another 12 weeks [Nivolumab for CR/PR/SD, Cabozantinib or Lenvatinib/Everolimus for PROG]).
9726798|NCT04310358|Experimental|PLM group 2|Participants will do a pretest (Test 2), the 4 short PLMs, an immediate post-test (Test 1) and a remote post-test (Test 2).
9726799|NCT04308707||Surgical specialties|
10199230|NCT05188105|Experimental|real tACS|Single session of alpha tACS (12 Hz) at 3 mA over the occipital cortex.
10199231|NCT05188105|Placebo Comparator|sham tACS|Single session of sham tACS over the occipital cortex.
10199232|NCT05188092|No Intervention|Control|Routine fluid deresuscitation in which fluid withdrawal is started and continued at the discretion of the treating physician.
10199233|NCT05188092|Active Comparator|Intervention|Deresuscitation is guided by lung ultrasound observations.
10199234|NCT05188079|Active Comparator|Beetroot Juice|140 ml of beetroot juice (high nitrate dietary supplement)
10199235|NCT05188079|Placebo Comparator|Placebo|Placebo drink looks and tastes like the beetroot juice but has the nitrate removed from the juice.
10199236|NCT05188066||Normal, pathological IVG|We will use placenta and fetal memebranes collected from first trimester termination of pregnancy. This will constitute group IVG.
9726800|NCT04308707||Anesthesiology|
9726801|NCT04307511|Experimental|low dose DAPT therapy|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment
9726802|NCT04307511|Active Comparator|standard dose DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
9726803|NCT04307485|Active Comparator|standard dose ticargrelor based DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
10199237|NCT05188066||Normal and pathological term|We will also use the same specimens collected from third trimester pregnancies . We will call this group normal and pathological..... à finaliser
10199238|NCT05188001||Inpatient non-cardiac surgery patients|Patients aged 45 years and older undergoing inpatient non-cardiac surgery who had MINS protocol ordered for postoperative high sensitivity troponin monitoring based on the CCS guidelines from January 2020 to June 2021.
10199239|NCT05187988|Active Comparator|Supraclavicular approach group|probe placed firmly over the supraclavicular fossa, parallel to the clavicle to obtain a short-axis view of the divisions of the brachial plexus and the subclavian artery, lying on the first rib After skin infiltration with lidocaine 2% a 23-gauge 70mm block needle inserted in-plane with the ultrasound beam, in a lateral-to-medial direction, until the needle tip's positioned at the junction of the first rib and subclavian artery
9726804|NCT04307485|Experimental|low dose ticargrelor based DAPT|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment
9726805|NCT04301778|Experimental|Durvalumab and SNDX-6352|Participants will receive Durvalumab and SNDX-6352.
9726806|NCT04300985|Sham Comparator|Placebo group|Thirty patients in this group will receive infusion of 100 saline solution. After 15 min of beginning of this infusion they will start receiving general anesthesia administration.
9726807|NCT04300985|Active Comparator|Dexmedetomidine group|Thirty patients in this group will receive infusion of dexmedetomidine (0,5 mcg/kg/min). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
9726808|NCT04300985|Active Comparator|Magnesium sulfate group|Thirty patients in this group will receive infusion of magnesium sulfate (20 mg/kg/h). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
9726809|NCT04299997||171 mpMRIs corresponding to consecutive patients who underwent|The mpMRIs were performed on a 1.5T GE MR unit or on a 3T GE or Philips MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging (maximal b value: 2000 s/mm²) and dynamic contrast-enhanced imaging.
9726810|NCT04299581|Experimental|Cryoablation in combination with Camrelizumab|Cryoablation treatment starts at day 1. Camrelizumab will be initiated on day 14 after Cryoablation. Camrelizumab will be administered every three weeks (3mg/Kg, IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
9726811|NCT04296123|Experimental|Intervention|
9726812|NCT04296123|No Intervention|Control|
9726813|NCT04296006|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
9726814|NCT04296006|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
9726815|NCT04289402|Experimental|Personalized tDCS|Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minutes session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
9726816|NCT04289402|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
9726817|NCT04289142|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1.2 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.2 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
9726818|NCT04289142|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
9726819|NCT04289038|Experimental|Autogenic Relaxation|Autogenic Relaxation: It is an exercise program consisting of standard sentences that describe the body's absolute comfort and calm features.
9726820|NCT04289038|Experimental|Virtual Reality|Virtual reality: Playing games via smart phone with virtual reality glasses and headset.
9726821|NCT04289038|Other|Control Group|Routine nursing care and kidney function narration
9726822|NCT04282590|Experimental|Treatment Period 1: TRK-750, Treatment Period 2: placebo|
9726823|NCT04282590|Experimental|Treatment Period 1: placebo, Treatment Period 2: TRK-750|
9785808|NCT01260350|Experimental|Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
9726824|NCT04276792|Experimental|Horizontal implementation approach|The Horizontal implementation approach of the O-TLM intervention is accompanied by facilitated collaboration between Criminal Justice and Community Behavioral Health systems. Direct involvement of stakeholders with differing perspectives and buy-in from agency leadership and policymakers are key elements. The Horizontal approach involves first developing a prototype (including how to modify existing practices, overcome implementation barriers, and manage roles and responsibilities) that are tested and refined before being rolled out systematically to other units within an agency.
9726825|NCT04276792|Active Comparator|Vertical implementation approach|The Vertical implementation approach of the O-TLM intervention relies on the traditional criminal justice system's typical use of a hierarchical structure and the use of a top-down implementation approach (i.e., administrative orders) for directing change. Top-down regulatory and policy changes are viewed as vital levers for driving system change.
9726826|NCT04275531||regional anesthesia|surgical procedures which will be performed under intrathecal anesthesia without sedation
9726827|NCT04275531||sevoflurane|surgical procedures which will be performed under general anesthesia and sevoflurane will be used for maintenance of anesthesia
9726828|NCT04275531||isoflurane|surgical procedures which will be performed under general anesthesia and isoflurane will be used for maintenance of anesthesia
9726829|NCT04275531||propofol|surgical procedures which will be performed under general anesthesia and propofol infusion will be used for maintenance of anesthesia
9726830|NCT04272294|Experimental|Use of Optical Spectroscopy|Optical spectroscopy used to characterize treatment response
9726831|NCT04268693||Study cohort|urinary bisphenol and phthalate levels
9726832|NCT04268485||IPF patients|Patients with an MDT diagnosis of idiopathic pulmonary fibrosis. Patients will be observed over a 12 month period and have serial serum samples taken for KL-6 level.
9726833|NCT04265950|Experimental|Arm 1 (3 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment, and at 2 and 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
9726834|NCT04265950|Experimental|Arm 2 (2 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment and at 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
9726835|NCT04265950|Experimental|Arm 3 (1 dose of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
9726836|NCT04265950|Active Comparator|Arm 4 (1 dose of 9vHPV vaccine)|Participants without HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment . Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
9726837|NCT04263922|Experimental|Huaiqihuang group|Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
9726838|NCT04263922|Active Comparator|Valsartan Group|Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
9726839|NCT04263909|Experimental|sufentanil SL arm|Each patient will receive 30mcg of sufentanil SL prior to extubation in the operating room, and then as needed in the recovery room, guided by pain scores.
9726840|NCT04263064|Active Comparator|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine).
9726841|NCT04263064|Experimental|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
9726842|NCT04261088||Experts in Swiss assisted suicide|Persons in Switzerland who are experts in how assisted suicide is practiced. We will beexamining already collected interviews.
9726843|NCT04257929|Active Comparator|Low dose pitolisant|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 8.9 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 13.35 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning."
9726844|NCT04257929|Active Comparator|High dose pitolisant|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 26.7 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
9726845|NCT04257929|Placebo Comparator|Placebo|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
9984750|NCT03768505|Experimental|Zandelisib (ME-401) open label|Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).
9726846|NCT04257097|Active Comparator|Group A - control group|25 patients will undergo bone regeneration with a titanium reinforced PTFE Mesh (RPM - Osteogenics Lubbock Texas USA), manually shaped and modeled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption (Vitala - Osteogenics Lubbock Texas USA)
9726847|NCT04257097|Experimental|Group B - Test group|25 patients undergo bone regeneration with a custom-made titanium mesh (Yxoss CBR - Reoss Filderstadt Germany), digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption (Bio-Gide - Geistlich Baden Baden Germany)
9726848|NCT04254341||patients with OSA|Subjects that underwent regular sleep studies (PSG) and found to have moderate/severe obstructive sleep apnea
9726849|NCT04254341||subjects without OSA|Subjects that underwent regular PSG and found not to have sleep apnea
9726850|NCT04252105|Experimental|Antioxidant rich diet|
9726851|NCT04252105|No Intervention|Regular diet|
9726852|NCT04251585|Experimental|Low Insulin|Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.
9726853|NCT04251585|Experimental|Medium Insulin|Regular insulin (Novolin-R) 40 international units (10 units) in each nostril twice daily for 21 days, 100 µl volume.
9726854|NCT04251585|Experimental|High Insulin|Regular insulin (Novolin-R) 80 international units (10 units) in each nostril twice daily for 21 days, 200 µl volume.
9726855|NCT04251585|Placebo Comparator|Placebo|0.9% sodium chloride in each nostril twice daily for 21 days, 100 µl volume.
9726856|NCT04250753||Patients with lumbar spinal stenosis|
9726857|NCT04243148|Experimental|Multifactorial intervention|Frail and pre-frail patients will receive multifactorial intervention consisting of home exercise, BCAA supplements and a multispecies probiotic for 12 months.
9726858|NCT04243148|Experimental|Control group|Frail and pre-frail patients will be followed but will not receive any specific intervention.
9726859|NCT04241029|Experimental|Intervention with probiotics|Intervention with the probiotic compound IDOFORM®Travel. The patient will receive four capsules orally every 24 hour (12*10^9 cfu/day) for eight weeks as adjuvant therapy to his/her anti-TNF treatment. The intervention arm will at the end of intervention serve as their own controls compared to baseline data (before intervention).
9726860|NCT04240925|Experimental|Standard NIMV protocol with sigh breaths|
9726861|NCT04240925|Active Comparator|Standard NIMV protocol without sigh breaths|
9726862|NCT04240054|Experimental|Safety Lead-in Cohort A|"Six transplant-eligible multiple myeloma patients with renal impairment will be enrolled.~Bortezomib (1.5 mg/m^2) subcutaneous on days 1,8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
9726863|NCT04240054|Experimental|Expansion Cohort A|"15 transplant-eligible multiple myeloma patients with renal impairment will be enrolled.~Bortezomib (1.5 mg/m^2)subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
9726864|NCT04240054|Experimental|Expansion Cohort B|"20 transplant-eligible non-renal impairment multiple myeloma patients will be enrolled.~Bortezomib (1.5 mg/m^2) subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
9726865|NCT04239716|Experimental|regional anesthesia|combination of erector spinae plane block (ESPB) and interscalene block(IB).the ESPB will be performed using linear ultrasound transducer (Philips® cx 50 extreme edition, USA) and we will inject 20 ml solution(10 ml 0.5% bupivacaine, 5 ml 2% lidocaine, and 5 ml normal saline). the IB will be performed using the same ultrasound machine and injecting the same solution
9726866|NCT04235634||Intra-arterial Prostglandin therapy|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
9726867|NCT04235413|Experimental|Real-Time Incentives Group|Each participant will be randomized using a blocking procedure (SNAP participant or not). The intervention will last 6 months and consist of receiving real-time financial incentives at the point of purchase for eligible fruits and vegetables purchases.
9726868|NCT04235413|No Intervention|Control Group|No intervention administered. Each participant will be randomized using a blocking procedure (SNAP participant or not).
9726869|NCT04234906|Active Comparator|Stage 1, Group 1 - Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
9726870|NCT04234906|Active Comparator|Stage 1, Group 2- Magnesium|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
9726871|NCT04234906|Active Comparator|Stage 2, AMIODARONE|AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
9726872|NCT04234906|Active Comparator|Stage 2, PROCAINAMIDE|PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
9726873|NCT04232982|Experimental|MicroPulse Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered by micropulse waves will be given 4-8 weeks before the Boston keratoprosthesis surgery.
9726874|NCT04232982|Experimental|G-Probe Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered with a diode laser using the G-Probe device, will be given 4-8 weeks before the Boston keratoprosthesis surgery.
9726875|NCT04232982|No Intervention|Historical Cohort|"An historical cohort composed of patients who received a Boston keratoprosthesis between january 2017 and january 2019 will be included. Only patients who did not receive any glaucoma treatment 3 months before their surgery will be included. A total of 10 patients will be selected with the goal of matching the preoperative characteristics of the interventional patients.~This group will serve as the control group in our study. Retrospective chart review will be performed for this branch."
10199240|NCT05187988|Active Comparator|Retroclavicular approach group|the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will be then inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip is constantly seen, until it is positioned posterior to the axillary artery
9726876|NCT04232215|Experimental|HeraBEAT™ Intervention Group|Subjects will monitor their fetal heart beat once weekly using the HeraBEAT™ device. After approximately 8 weeks of monitoring subjects will crossover to using the doppler fetal heart rate monitor
9726877|NCT04232215|Active Comparator|Standard Fetal Doppler Group|Subjects will monitor their fetal heart beat once weekly using the doppler fetal heart rate monitor. After approximately 8 weeks of monitoring subjects will crossover to using the HeraBEAT™ device
9726878|NCT04226664|Active Comparator|Intervention|Bariatric surgery will consist of laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy performed at the discretion of the surgeon and according to local standards.
9726879|NCT04226664|No Intervention|Control|Medical Weight Management (MWM) corresponds to the standard medical practice for weight loss that is available at the local participating centre, and thus reflects the local standard of care.
9726880|NCT04223583|Experimental|Anrotenil hydrochloride capsule|Anrotenil hydrochloride capsule was used to treat soft tissue sarcomas with first-line chemotherapy failure (doxorubicin + ifosfamide). Oral administration was conducted on an empty stomach before breakfast (12mg), and the drug was discontinued for 2 weeks for one week (3 weeks for one cycle) until the disease progressed or became intolerable.
9726881|NCT04222257|Experimental|Short course|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
9726882|NCT04222257|Active Comparator|Standard course|Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
9726883|NCT04220190|Experimental|Single agent RAPA-501 T cells (dose level Arm 1)|Dose level 1 is 20 x 10^6 cells/infusion
9726884|NCT04220190|Experimental|Single agent RAPA-501 T cells (dose level Arm 2)|Dose level 2 is 80 x 10^6 cells/infusion
9726885|NCT04220190|Experimental|RAPA-501 + PC Regimen (Arm 3A)|Arm 3A) RAPA-501 T cell therapy preceded by the 3-day pentostatin- cyclophosphamide (PC) regimen
9726886|NCT04220190|Experimental|RAPA-501 + PC Regimen (Arm 3B)|Arm 3B) RAPA-501 T cell therapy preceded by the 5-day pentostatin- cyclophosphamide (PC) regimen
9726887|NCT04218864|Experimental|Strength for U in Relationship Empowerment (SURE)|Theory-driven and derived from empirical support
9726888|NCT04218864|Active Comparator|Attention, time, and information matched control|Well-validated
10199241|NCT05187975|Experimental|Integrated rehabilitation group|This group will include 101 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation .
10199242|NCT05187975|Active Comparator|Standard care group|The patients were recommended to take one oral tablet of paroxetine hydrochloride (20 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
9726889|NCT04214873|Experimental|POH|Treatment of POH Using PiQo4 Laser System
9726890|NCT04214652|Experimental|IDP-126 Gel|
9726891|NCT04214652|Placebo Comparator|IDP-126 Vehicle Gel|
9726892|NCT04213547|Experimental|Intervention|This will be a single-arm study utilizing a loss-framed incentive intervention to induce increased sleep duration.
9726893|NCT04212598|Experimental|Definitive concurrent chemoradiotherapy or radiotherapy arm|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
9726894|NCT04210999|Experimental|Homebased resistance training|Resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
9726895|NCT04210999|Active Comparator|Supervised resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist and avoidance of pain aggravating activities for 3 months
9726896|NCT04208490|Other|HN-STAR|
9726897|NCT04208490|No Intervention|Usual Care|
9726898|NCT04207710|Experimental|Microbial growth after application of Pain Ease|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Pain Ease numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
9726899|NCT04207710|Experimental|Microbial growth after application of Ethyl Chloride|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Ethyl Chloride numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
10199243|NCT05187962||Women receiving epidural analgesia for labor|Sensory block level check Patients will have their sensory block level checked using 3 modalities: ice, pin prick and soft touch (cotton ball).
10199244|NCT05187910|Active Comparator|Patients with Voice Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
9726900|NCT04205409|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9726901|NCT04199572|Experimental|Diclofenac and Oral Paracetamol|Diclofenac (75mg intramuscular), Placebo (100ml intravenous Normal Saline), Paracetamol (per oral 1gm)
9726902|NCT04199572|Experimental|Diclofenac and IV Paracetamol|Diclofenac (75mg intramuscular), Paracetamol (intravenous1gm in 100ml solution), Placebo (sugar tablets)
9726903|NCT04199572|Experimental|Diclofenac and Placebo|Diclofenac (75mg intramuscular),Placebo (100ml intravenous Normal Saline),Placebo (sugar tablets)
9726904|NCT04195958|Experimental|Omalizumab|
9726905|NCT04191148|Experimental|LBP-EC01|crPhage cocktail
9726906|NCT04191148|Placebo Comparator|Placebo|Lactated Ringer's solution, injection, USP
10199245|NCT05187910|Active Comparator|Patients with Swallowing Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
10199246|NCT05187910|Active Comparator|Patients with Upper Airway Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
9726907|NCT04188860|Experimental|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
9726908|NCT04188847|Experimental|Study group|The patients would accept the regimen of apatinib combined with cisplatin and paclitaxel
9726909|NCT04188639|Experimental|Treatment with emicizumab|
9726910|NCT04182867|Experimental|UK dietary guideline diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). The experimental diet will meet UK dietary guidelines for fiber, salt, sugar, saturated fat, fruit and vegetable intake. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.
9726911|NCT04182867|Other|Shift worker diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). Typical 'shift diet' based on previous research investigating what UK night workers eat. The 'shift diet' will contain ~15% energy from added sugar, 15g fiber, 2.5 portions fruit/vegetable, no whole grains. Required energy intake (calories) for each day to maintain their current body weight. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.
9726912|NCT04173949|Experimental|Ramipril 2.5 MG|Ramipril 2.5 MG orall, daily.
9726913|NCT04170556|Experimental|Regorafenib plus Nivolumab|Regorafenib will be initiated at full dose (160 mg/day; 3 weeks on and 1 week off) in monotherapy for the first 8 weeks. After week 8, regorafenib will be continued in combination with nivolumab, until symptomatic tumor progression, unacceptable adverse events, patient decision or death
9726914|NCT04168008|Experimental|Adherence|Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for ART adherence and engagement in HIV care.
9726915|NCT04168008|Active Comparator|Parenting|Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.
9726916|NCT04167748|Experimental|PGT-A transfer|Transfer of single chromosomally normal (euploid) blastocyst after PGT-A
9726917|NCT04167748|No Intervention|Untested blastocyst transfer|Transfer of single untested blastocyst based on embryo morphology criteria.
9780878|NCT01134016|Experimental|Antroquinonol|"6 dose levels, Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~A maximum of 36 patients were planned based on a criteria of a maximum of 6 patients per cohort: 1 to 6 patients were planned for each dose group in the accelerated phase; 3 to 6 patients for each dose group in the standard phase .~The method of dose escalation in the accelerated titration phase continued to the next higher dose level until a patient experienced MT or a DLT. Standard titration phase start with 3+3 patients. Dose escalation proceeded sequentially between cohorts."
9780879|NCT01134042|Experimental|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
9780880|NCT01134042|Active Comparator|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
9780881|NCT01134042|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks
9780882|NCT01134055|Experimental|investigational arm 1|5 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
9780883|NCT01134055|Experimental|investigational arm 2|5 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
9780884|NCT01134055|Experimental|investigational arm 3|10 mg/mL pazopanib eye drops BID with allowance for as-needed ranibizumab injection
9780885|NCT01134055|Experimental|investigational arm 4|10 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
9780886|NCT01134055|Experimental|investigational arm 5|10 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
10199247|NCT05187897|No Intervention|Standard Care Control|CHVs based at facilities in the control arm will continue to implement the standard of care.
10199248|NCT05187897|Experimental|CHV-NEO Intervention|CHVs based at facilities in the Intervention arm will implement the integrated CHV-NEO two-way SMS messaging intervention with their clients.
10199249|NCT05187884|Experimental|Intervention|
10199250|NCT05187858|Experimental|LNP3794|Participants will receive LNP3794 orally once daily at different doses in 28 day cycles on a continuous basis
10199251|NCT05187819|Experimental|Patients with positive blood test for biomarkers for Alzheimer's disease|"The positive blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false positive blood tests (using the results from the outpatient clinic as a gold standard for the diagnosis)"
9780887|NCT01134055|Placebo Comparator|placebo control arm|Placebo eye drops QID with allowance for as-needed ranibizumab injection
9780888|NCT01134055|Active Comparator|active open-label control arm|Ranibizumab intravitreal injection every 4 weeks
9780889|NCT01134081|Experimental|CelTx™|Living bilayered cell therapy product
9780890|NCT01134081|Active Comparator|Free Gingival Grafts|Harvested tissue from palate
9780891|NCT01134107|Experimental|Insulin Lispro 6 Day (6D)|
9780892|NCT01134107|Active Comparator|Insulin Aspart 6 Day (6D)|
9780893|NCT01134198|Active Comparator|Mifepristone|Mifepristone 600mg
9726918|NCT04166487|Experimental|Pembrolizumab Cycles 1-2|"For the first two cycles, Pembrolizumab will be administered at a predetermined dose every 3 weeks.~InVision plasma draw will take place at Cycle 1 Day 1 and Cycle 2 Day 1, with return of results to the treating oncologist prior to Cycle 3 Day 1.~At Cycle 3, patients will be re-registered per the inclusion criteria into 3 arms;~PEMBROLIZUMAB Alone~PEMBROLIZUMAB + Doublet Chemotherapy"
9726919|NCT04166487|Experimental|Pembrolizumab Alone, Cycle 3+|"- Following imaging assessment at Cycle 3, participants will continue pembrolizumab alone if the following responses are observed:~Response of Partial Response/Complete Response~Response of Stable Disease with plasma response~Response of Progressive Disease without worsening cancer symptoms AND plasma response"
9726920|NCT04166487|Experimental|Pembrolizumab + Doublet Chemotherapy, Cycles 3+|"Following imaging assessment at Cycle 3, participants will receive pembrolizumab in combination with platinum doublet chemotherapy if they have a response of stable disease without plasma response, OR no plasma response and response of progressive disease without worsening cancer systems. Platinum doublet should be histology-appropriate and will be given on-label, per treating oncologist.~PEMBROLIZUMAB~Chemotherapy multiple agents systemic~PEMETREXED~CARBOPLATIN~PACLITAXEL"
9726921|NCT04162665|Experimental|Preoperative MR-guided Radiation Therapy|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25 Gy at 5 Gy per fraction. The clinical target volume will include the entire stomach and locoregional lymph nodes. Radiation must be delivered with MR guided radiation therapy (MRgRT) and daily adaptive planning. The stomach and OARs must be redrawn each day for the adaptive plan. Plans should be adapted to meet OAR constraints or improve coverage as needed for each day's unique anatomy~Chemotherapy will be given as per standard of care. It should begin 2 to 4 weeks after completion of radiotherapy and will consist of CAPOX (capecitabine/oxaliplatin) for 5 cycles.~Standard of care gastrectomy or esophagogastrectomy within 2-4 weeks following completion of chemotherapy~All stage II-III patients should receive 3 cycles of CAPOX postoperatively for a total of 8 cycles of CAPOX. Postoperative CAPOX should start within 3 months of surgery."
9726922|NCT04161066|Experimental|Open-label|Psilocybin with guided counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
9726923|NCT04157790|No Intervention|Neutral|Suggested to follow European Society of Cardiology guidelines for NSTEMI
9726924|NCT04157790|Active Comparator|CARE score|calculation of the CARE score and prescription for troponins assays or not according to the result (score > 1: troponins assays ; score < 2: no troponins assays)
9726925|NCT04155411|Experimental|Dasatinib 70 mg|
9726926|NCT04153539|Experimental|Walking along a busy road|Participants in this group will be asked to walk along a busy road for 4.5 hours.
9726927|NCT04153539|Active Comparator|Walking in a traffic-free park|Participants in this group will be asked to walk in a traffic-free park for 4.5 hours.
9726928|NCT04152473|Experimental|Proglumide|Open labelled proglumide treated
9726929|NCT04152382|Experimental|LY3462817 - Intravenous (IV)|LY3462817 administered as IV infusions.
9726930|NCT04152382|Placebo Comparator|Placebo - IV|Placebo administered as IV infusions.
10199252|NCT05187819|Active Comparator|Patients with negative blood test for biomarkers for Alzheimer's disease|"The negative blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false negative blood tests (using the results from the outpatient clinic as a gold standard for the diagnosis)"
10199253|NCT05187806|Experimental|Experimental group|"After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions of 30-60 (mean 45 min) min each. The sessions were structured according to the Behavior Change Stage Identification Form developed by the researcher by making use of the trans-theoretical model and adapting it to diabetic patients. The subject of the first session was Opening, Structuring the Discussion, and Establishing the Agenda; the subject of the second session was Improving Motivation for Change; the subject of the third session was Summarizing, Support, and Talking about the Change; and the subject of the fourth session was Evaluation . The discussions were completed in four weeks, with one discussion held every week. The final test and the Diabetes Self-Management Instrument were applied again to the members of the intervention group in the third month after completion of the MI method sessions."
9726931|NCT04152382|Experimental|LY3462817 - Subcutaneous (SC)|LY3462817 administered as SC injections. (SC administration is discretionary/optional.)
9726932|NCT04152382|Placebo Comparator|Placebo - SC|Placebo administered as SC injections. (SC administration is discretionary/optional.)
9726933|NCT04152382|Experimental|LY3509754|LY3509754 administered orally.
9726934|NCT04152382|Placebo Comparator|Placebo|Placebo administered orally.
9726935|NCT04152213|Experimental|Low GI diet group|"The components of the Low GI diet group include:~(1) A one-off, 60-minute, face-to-face, educational session conducted by the research nurse for GI knowledge input. (2) An informational booklet will be given out during the education session. (3) Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after completing the face-to-face education session."
9726936|NCT04152213|Placebo Comparator|Control group|"The components of the control group include:~(1) Pamphlets from the Department of Health about obesity and a balanced diet based on the food pyramid will be distributed. (2)Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after receiving the pamphlets."
9726937|NCT04151628|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
9726938|NCT04150133|Active Comparator|Traditional Clear Liquid Arm|Following instructions with FDA-labeled clear liquids
9726939|NCT04150133|Experimental|Low Residue Diet Arm|Following instructions for a low residue diet along with FDA-labeled clear liquids
9726940|NCT04147858|Experimental|NYX-2925 50 mg|NYX-2925 50 mg administered orally.
9726941|NCT04147858|Experimental|NYX-2925 100 mg|NYX-2925 100 mg administered orally.
9726942|NCT04147858|Placebo Comparator|Placebo|Placebo administered orally.
9726943|NCT04143061|Experimental|Group 1|MenACYW conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
9780894|NCT01134198|Placebo Comparator|placebo|Placebo
10199254|NCT05187806|No Intervention|Control group|The control group received routine treatment. The final test and the Diabetes Self-Management Instrument were applied again to the members of the control group in the third month.
10199255|NCT05187793|Experimental|Olokizumab|"Subject randomized to receive intravenous infusion of 0,8 ml solution of Olokizumab, one (128 mg), or two (256 mg) doses, in addition to standard therapy in line with the current temporary guidelines Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) of the Ministry of Health of Russian Federation.~Standard therapy includes:~Baricitinib, p.o., 4 mg once daily for 7 days~Favipiravir, p.o.,~for patients weighing <75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day;~for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)~dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours."
10199256|NCT05187793|Active Comparator|Standard therapy|"Standard therapy in line with the current temporary guidelines Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) of the Ministry of Health of Russian Federation including:~Baricitinib, p.o., 4 mg once daily for 7 days~Favipiravir, p.o.,~for patients weighing <75 kg: 1600 mg twice daily on Day 1, then 600 mg twice daily from the 2nd to the 10th day;~for patients weighing ≥ 75 kg: 1800 mg twice daily on Day 1, then 800 mg twice daily from the 2nd to the 10th day; (Patients who have started etiotropic therapy with favipiravir or remdesivir prior to randomization will continue the initiated treatment.)~dexamethasone at doses of 4 - 20 mg / day or methylprednisolone at a dose of 1 mg / kg / intravenous injection every 12 hours."
10199257|NCT05187754|Experimental|Intervention Group|
10199258|NCT05187754|No Intervention|Control Group|
9726944|NCT04143061|Active Comparator|Group 2|Menactra® conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
9726945|NCT04143061|Experimental|Group 3|MenACYW conjugate vaccine, 1 vaccination, adults in India aged ≥ 56 years
9726946|NCT04143061|Active Comparator|Group 4|Quadri Meningo™, 1 vaccination, adults in India aged ≥ 56 years
9726947|NCT04143061|Experimental|Group 5|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in India aged 2 to 17 years
10199259|NCT05187741|Experimental|Daily message group|This group would be receiving text messages intended to improve treatment adherence and text reminders for appointments to improve care retention.
10199260|NCT05187741|No Intervention|Control group|This group would be just observed through the same period as the intervention group but the participants will only receive the standard care provide by the clinic.
10199261|NCT05187728||adenomyosis group|CSD with adenomyosis
10199262|NCT05187728||non-adenomyosis group|CSD without adenomyosis
9726948|NCT04143061|Active Comparator|Group 6|Menactra®, 1 vaccination, children and adolescents in India aged 2 to 17 years
9726949|NCT04143061|Experimental|Group 7|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
9726950|NCT04143061|Active Comparator|Group 8|Menactra®, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
9726951|NCT04139798|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
10199263|NCT05187689|Experimental|Virtual reality and mental health literacy intervention|This arm will participate in an interactive virtual reality experience to learn and practice mental health literacy and psychological first aid skills, supplemented by mhealth SMS with informational bidirectional messages.
9726952|NCT04139798|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.6% sodium chloride solution) 4 times daily (QID)
9726953|NCT04138680|Experimental|Active Biofeedback|The patients in the active group will receive one active biofeedback training session.
9726954|NCT04138680|Sham Comparator|Sham Biofeedback|The patients in the sham group will receive one sham biofeedback training session.
9726955|NCT04135989|Other|Cre8 AES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
9726956|NCT04135989|Other|Cre8 AES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
9726957|NCT04135989|Other|Synergy EES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
10199264|NCT05187689|Experimental|Group Problem Management+ and VR/mental health literacy|This arm will participate in an interactive virtual reality experience to learn and practice mental health literacy and psychological first aid skills, supplemented by mhealth SMS with informational bidirectional messages. This arm will also participate in an 5-week Group Problem Management Plus intervention, a group based problem solving intervention.
10199265|NCT05187689|No Intervention|Control|This is a waitlist control. After Arms 1 and 2 are complete, the waitlist will receive the Group Problem Management Plus 5 week intervention on its own.
10199266|NCT05187676|Experimental|Oxygen cutaneous saturation rate (ScO2) then transcutaneous oxygen partial pressure (TcPO2)|ScO2 values will be measured using IPAM first then TcPO2 values will be measured using Periflux6000. ALways in the same order.
9726958|NCT04135989|Other|Synergy EES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
9726959|NCT04134728|Experimental|GSK3196165 90 mg|Entire treatment period (24 Weeks): GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
9726960|NCT04134728|Experimental|GSK3196165 150 mg|Entire treatment period (24 Weeks): GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
9726961|NCT04134728|Active Comparator|Sarilumab 200 mg|Entire treatment period (24 Weeks): Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
10199267|NCT05187663|Active Comparator|Study group|In the test group, implant surface decontamination was performed with photodynamic therapy.
9726962|NCT04134728|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
9726963|NCT04134728|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
9726964|NCT04134728|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
9726965|NCT04132999|Active Comparator|Family-informed intervention (INT)|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team.
9726966|NCT04132999|Active Comparator|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
9726967|NCT04130802|Experimental|OCS-01 1.5% mg/mL QD|eye drops
9726968|NCT04130802|Experimental|OCS-01 1.5% mg/mL BID|eye drops
9726969|NCT04130802|Placebo Comparator|Placebo (Vehicle) BID|eye drops
9726970|NCT04130659|Experimental|Marial® + PPI (generic omeprazole)|Marial® + PPI (generic omeprazole) Application: following the Summary of Product Characteristics Marial®: 1 stick of Marial® twice a day after meals from day 1 to 28 Omeprazole 20 mg cps: once a day from day 1 to 28
9726971|NCT04130659|Active Comparator|PPI alone (generic omeprazole)|PPI alone (generic omeprazole) Application following the Summary of Product Characteristics Omeprazole 20 mg cps: once a day from day 1 to 28
9726972|NCT04129073||Cardiac arrest patients admitted to Intensive Care treatment|Intensive Care treatment; Utilization of neuroprognostication tools
9726973|NCT04128436|Other|Progesterone levels|Patients will be divided into groups according to quartiles (25/50/75) of progesterone levels. Optimal range of progesterone levels for ongoing pregnancy rate will be calculated.
9726974|NCT04125043||RRT Group|Pediatric patients undergoing ocular screening tests
9726975|NCT04123535|Experimental|Undifferentiated Pleomorphic Sarcoma (UPS)|All enrolled participants will be scheduled to receive pre-operative MRgFUS with the ExAblate 2000/2100 MRgFUS system 1-4 weeks prior to surgical resection of their tumor or approximately 2 weeks after a pre-procedure biopsy of the metastatic tumor target depending on diagnosis at enrollment. For patients enrolled with metastatic disease, pre and post-MRgFUS biopsy samples will be obtained.
9726976|NCT04121468|Other|Group A|"Placebo for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
9726977|NCT04121468|Other|Group B|"Placebo for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
9726978|NCT04121468|Other|Group C|"Placebo for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
9726979|NCT04120558||Through knee amputees|Community dwelling individuals with through knee amputation of all mobility levels.
9726980|NCT04120558||Above knee amputees|Community dwelling individuals with above knee amputation of all mobility levels.
9726981|NCT04120480|Experimental|Testing|Participants randomized to this arm will be sent a kit to collect a genetic sample from a swab of their mouths. The kit will have instructions on how to collect the genetic sample and how to send it in a postage-paid envelope to the testing laboratory (OneOme). OneOme will process the sample and The study pharmacist will scan the results and enter any related information into the participant's KPCO electronic health record. If any changes to the participant's medication(s) are recommended (for example: a dose decrease or increase, stop taking your current medication and start another), the study pharmacist will contact the participant's KPCO prescriber directly to discuss the recommendations. The prescriber may contact the participant to change the participant's medication(s).
9726982|NCT04120480|No Intervention|Usual Care|Participants randomized to this arm will NOT be tested. They will receive usual care and the research will not involve study visits or in-person contact.
9726983|NCT04117932|Experimental|"Arm ustekinumab"|Patients with bullous pemphigoid, treated using ustekinumab in association during 8 weeks with superpotent topical corticosteroids
9726984|NCT04117412|Other|Patients with COPD|Patients with COPD will undergo two different one bout of exercise training after maximal exercise test.
9726985|NCT04117087|Experimental|KRAS peptide vaccine, Nivolumab, and Ipilimumab|
9726986|NCT04116073|Experimental|INCMGA00012 (PD-1 antibody)|All participants will receive the interventional study drug; INCMGA00012.
9726987|NCT04115267||Combined modality|Patients receiving radiotherapy and a molecular agent for the treatment of cancer
9726988|NCT04112342|Other|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin.
10199268|NCT05187663|Active Comparator|Control group|In the control group, implant surface decontamination was performed with 1% chlorhexidine gel.
10199269|NCT05187585|Sham Comparator|radiograph interpretation without the support of the RAYVOLVE app|
9726989|NCT04112342|Other|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin
9726990|NCT04112342|Other|Cohort 3|Patients who will receive palliative radiation (+/-concurrent systemic therapy) for any tumor involving the skin.
9726991|NCT04112342|Other|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin.
9726992|NCT04108104|Experimental|Low-dose group|Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
9726993|NCT04108104|Experimental|High-dose group|Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg [2 tablets of 5 mg] once a day slow-release: evening administration)
9726994|NCT04108104|Placebo Comparator|Placebo group|Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)
9726995|NCT04106258|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
10199270|NCT05187585|Experimental|radiograph interpretation with the support of the RAYVOLVE app|
9726996|NCT04106258|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
9726997|NCT04105738||Difficult airways|Documented history of difficult airways.
9726998|NCT04105738||Control (Not difficult airways)|Age matched with normal airways to be used as controls
9726999|NCT04102735|Active Comparator|Over-the-nose facemask|The AF541 oro-nasal mask is used with the over-the-nose mask cushion.
9727000|NCT04102735|Experimental|Under-the-nose facemask|The AF541 oro-nasal mask is used with the under-the-nose mask cushion.
9727001|NCT04101916|Experimental|Paired Associative Stimulation|
9727002|NCT04101916|Sham Comparator|Sham|
9727003|NCT04098393|Experimental|patients hematologic malignancies other than multiple myeloma|A. Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels. B. Melphalan (70mg/m2/day) administered on days -6 and -5. C. Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
10199271|NCT05187572|Experimental|Reminiscence Therapy (RT)|The RT program is composed of activities that follow older adults' lifespan (e.g., school, professional life, travelling, holidays and celebrations, historical dates/moments). Such activities allow older adults to revive and share life-changing/significant moments and integrate them into their autobiographical narrative. The program was developed and validated by Gil and colleagues for Portuguese older adults with cognitive decline.
10205012|NCT04324606|Experimental|Group 4c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later
9727004|NCT04098393|Experimental|patients with multiple myeloma|A. Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels. B. Melphalan (70 mg/m2/day) administered on days -6 and -5. C. Fludarabine (25 mg/m2/day) administered on days -6, -5, -4, -3, -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
9727005|NCT04098250|Experimental|Erenumab|140 mg erenumab
9727006|NCT04098250|Placebo Comparator|Placebo|placebo comparator
9727007|NCT04090099|No Intervention|Group C|PCA (Patient controlled analgesia) and morphine consumption will be monitored in the postoperative period.
9727008|NCT04090099|Active Comparator|Group ES (Erector Spina Plane)|A high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle. A dose of 0.25% bupivacaine will be injected which is shown to spread both above and below the T5 level. The same process will be implemented on the other side.
9727009|NCT04090099|Active Comparator|Group PS (Para Sternal Block)|Before the wire is inserted into the sternum, the sternotomy and mediastinal tube regions will be infiltrated with a mixture of bupivacaine and saline.
9727010|NCT04088513|Experimental|Aspirin|Drugs:Aspirin
9727011|NCT04088513|Active Comparator|Clopidogrel|Drugs:Clopidogrel
9727012|NCT04087980|Experimental|Poseidon System Treatment|
9727013|NCT04084964|Experimental|Study group|These patients receive the home-hospitalisation platform
9727014|NCT04082611|Active Comparator|Group 1 - Data-driven clinical recommendations (CR)|Data-driven clinical recommendations (CR)
9727015|NCT04082611|Experimental|Group 2 - Data-driven coached multi-modal intervention (MMIC)|Data-driven coached multi-modal intervention (MMIC)
9727016|NCT04080947|Placebo Comparator|Control group|26 patients will receive placebo (Control group)
9727017|NCT04080947|Experimental|Montelukast group|26 patients will receive montelukast 10 mg/ day
9727018|NCT04074590|Experimental|LYS006|Experimental drug
9727019|NCT04074590|Placebo Comparator|Placebo|Placebo comparator
9727020|NCT04074148|Experimental|Diabetes Prevention Education Program|Diabetes Prevention Education Program
9727021|NCT04074148|Experimental|control|Diabetes Prevention Education brochure
9727022|NCT04072887|Active Comparator|QBW251 450 mg|QBW251 450 mg
9727023|NCT04072887|Active Comparator|QBW251 300 mg|QBW251 300 mg
9727024|NCT04072887|Active Comparator|QBW251 150 mg|QBW251 150 mg
9727025|NCT04072887|Active Comparator|QBW251 75 mg|QBW251 75 mg
9727026|NCT04072887|Active Comparator|QBW251 25 mg|QBW251 25 mg
9727027|NCT04072887|Placebo Comparator|QBW251 Placebo|QBW251 Placebo
9727028|NCT04064931||recurrent abortion|women of childbearing age who have spontaneous abortion within 20 weeks of pregnancy for 2 or more consecutive times.
9727029|NCT04064931||normal pregnancy history|Women of childbearing age who had a normal pregnancy history and are not in pregnancy status now.
9727030|NCT04064931||general population|Women of childbearing age in general examination.
10205013|NCT04324606|Active Comparator|Group 4d|Volunteers will receive two standard single doses of MenACWY vaccine a minimum of 4 weeks apart
9727031|NCT04064164|Experimental|Treatment|The treatment NHs will received immediate feedback from the Speeko App after each recording sessions
9727032|NCT04064164|No Intervention|Control|The Control NHs will not receive app feedback until all recording sessions are complete.
9727033|NCT04060199|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
9727034|NCT04060199|Placebo Comparator|Placebo|Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
9727035|NCT04056910|Experimental|Concurrent dosing of ivosidenib and nivolumab|Ivosidenib will be administered concurrently with nivolumab on a Q28 day schedule.
9727036|NCT04056624|Experimental|Low dose|1 x 6 ounces of carotenoid-containing juice (6 mg carotenoids/6 oz)
9727037|NCT04056624|Experimental|High dose|2 x 6 ounces of carotenoid-containing juice (12 mg carotenoids/12 oz)
9727038|NCT04056624|Placebo Comparator|Placebo|12 ounces of apple juice (negligible carotenoids 0.06 mg/12 oz)
9727039|NCT04053478|Experimental|Myometrium + Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine (from 10 -10M to 10 -3M)
9727040|NCT04053478|Experimental|Myometrium + Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine(from 10 -10M to 10 -3M)
9727041|NCT04053478|Experimental|Myometrium + Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine(from 10 -10M to 10 -3M)
9727042|NCT04053478|Experimental|Umbilical artery + Ephedrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine (from 10 -10M to 10 -3M)
9727043|NCT04053478|Experimental|Umbilical artery + Phenylephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine(from 10 -10M to 10 -3M)
9727044|NCT04053478|Experimental|Umbilical artery + Norepinephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine(from 10 -10M to 10 -3M)
9727045|NCT04051879||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
9727046|NCT04051879||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype.
9727047|NCT04051879||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
9727048|NCT04046549|Experimental|Belatacept+VIB4920|Participants will be admitted to the transplant center for the administration of VIB4920 and belatacept and will be discharged on Day 3/4 at the discretion of the investigator. Participants will return to the study center to receive study drugs (VIB4920 and /or belatacept) weekly for 2 visits, then every 2 weeks for 5 visits, and then monthly for 9 visits for safety monitoring.
9727049|NCT04045496|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
9727050|NCT04040673||Normal benign|participants with normal benign nodules (no cancer)
9727051|NCT04040673||Follicular thyroid cancer|participants with follicular thyroid cancer
9727052|NCT04040673||Papillary thyroid cancer|participants with papillary thyroid cancer
10205014|NCT04324606|Experimental|Group 5a|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 ≤ 16 weeks apart, and a third dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months
9727053|NCT04040673||Anaplastic thyroid cancer|participants with anaplastic thyroid cancer
9727054|NCT04040673||Medullary thyroid cancer|participants with medullary thyroid cancer
9727055|NCT04035551||patients receiving home parenteral nutrition|Includes patients receiving home parenteral nutrition for any indication.
9727056|NCT04034056||Obinutuzumab|
9727057|NCT04031014|Experimental|Active treatment|Treatment with the active treatment protocol of the BTL EMSELLA device twice per week for six treatments total
9727058|NCT04031014|Sham Comparator|Sham treatment|Treatment with the sham protocol of the BTL EMSELLA device twice per week for six treatments total
9727059|NCT04027309|Active Comparator|Arm A (Midostaurin)|Midostaurin (50 mg BID PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
9727060|NCT04027309|Experimental|Arm B (Gilteritinib)|Gilteritinib (120 mg QD PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
9727061|NCT04025905|Experimental|Social Cognition Training Program|This program is taken from two validated cognitive remediation programs: the SCIT program and the RC2S program : perception of social situations - emotional processes and social perception;interpretation of social situations - theory of mind and attributions;acting in social situations - social skills training
9727062|NCT04025905|Sham Comparator|Informations program|Educational team Information will be given to participants about work environment, social environment, stress management, sleep management, treatments. It will also include socialization sessions with board games or cultural activities.
9727063|NCT04022733|Placebo Comparator|Moderate NMB group|
9727064|NCT04022733|Experimental|Deep NMB group|
9727065|NCT04021524|Active Comparator|Hibiclens Soap|
9727066|NCT04021524|Experimental|BPO Soap|
9727067|NCT04018196|Experimental|Experimental group|Patient aged over 80 years old will be included. They will have motor imagery training of manual task and motor imagery training of motor task.
9727068|NCT04018196|Active Comparator|Control group|Patient aged over 80 years old will be included. They will have emotionally neutral film as training of manual task and emotionally neutral film as training of motor task.
9780895|NCT01134263|Experimental|CYD Dengue Vaccine Phase III Lot 1|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
9780896|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 2|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
9727069|NCT04017130|Experimental|Part 1: Dose Escalation|"Weekly Dosing Intravenous (IV) infusion of MT-0169 every 7 days: Days 1, 8, 15, and 22 in a 28-day treatment cycle.~Every 2 Weeks IV infusion of MT-0169 every 14 days: Days 1 and 15 in a 28-day treatment cycle with escalating doses starting at the MTD/RP2D determined by the weekly dose escalation cohort.~Patients will continue to receive treatment until progressive disease, unacceptable toxicity or withdraw from the study for other reasons. Decision to escalate/deescalate/stay on the same dose/discontinue MT-0169 will be based on number of DLTs per number of patients enrolled at each dose level as predetermined by the mTPI-2 statistical model. Subsequent doses will be determined by the frequency and severity of adverse events in previous cohorts. The investigator and sponsor review of available safety, PK, pharmacodynamics, and efficacy data in the previous cohorts will also be factored in the decision."
9727070|NCT04017130|Experimental|Part 2: Dose Expansion in patients with RRNHL: Weekly Dosing|This cohort will receive intravenous infusion of MT-0169 every 7 days on Days 1, 8, 15, and 22 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Weekly Dose Escalation of Part 1.
9727071|NCT04017130|Experimental|Part 2: Dose Expansion in Patients with RRMM who are also Daratumumab RR: Weekly Dosing|This cohort will receive intravenous infusion of MT-0169 every 7 days on Days 1, 8, 15, and 22 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Weekly Dose Escalation of Part 1.
9727072|NCT04017130|Experimental|Part 2: Dose Expansion in Patients with RRMM who are Anti-CD38 Therapy naïve: Weekly Dosing|This cohort will receive intravenous infusion of MT-0169 every 7 days on Days 1, 8, 15, and 22 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Weekly Dose Escalation of Part 1.
9727073|NCT04017130|Experimental|Part 2: Dose Expansion in patients with RRNHL: Every 2 Weeks|This cohort will receive intravenous infusion of MT-0169 every 14 days on Days 1 and 15 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Biweekly Dose Escalation of Part 1.
9727074|NCT04017130|Experimental|Part 2: Dose Expansion in Patients with RRMM who are also Daratumumab RR: Every 2 Weeks|Each cohort will receive intravenous infusion of MT-0169 every 14 days on Days 1 and 15 in a 28- days treatment cycle. The dose administered will be the MTD/RP2D in the Biweekly Dose Escalation of Part 1.
10199272|NCT05187572|Experimental|Cognitive Stimulation (CST)|"The CST intervention was based on the Making a Difference program, specifically developed for older adults with cognitive decline and previously adapted and validated to the European Portuguese language and culture. This program offers a sequence of activities that covers different cognitive domains and promotes older adults' socialization and self-esteem."
10199273|NCT05187559|Experimental|First Group|Neuromuscular exercise program with standard physiotherapy with no visual feedback.
9727075|NCT04014322|Experimental|E-cigarette|All participants will be instructed to switch completely from combustible cigarettes to e-cigarettes for the next 8weeks. They will be assessed at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks.
9727076|NCT04010357|Experimental|Abemaciclib|"Subjects will receive Abemaciclib (200 mg), orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.~Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment."
9727077|NCT04005105|Active Comparator|Intensive management|"Baseline mean blood pressure (MAP) and central venous pressure (CVP) will be measured to calculate baseline mean perfusion pressure. Intra-surgical values of ± 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group~1 based on cardiac index and MPP will be followed for 24 hours."
9727078|NCT04005105|No Intervention|Standard management|MAP during surgery will be maintained > 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed.
9727079|NCT04004325|Experimental|Cohort A|
9727080|NCT04004325|Experimental|Cohort B|
9727081|NCT04002297|Experimental|zanubrutinib plus rituximab|
9727082|NCT04002297|Active Comparator|bendamustine plus rituximab|
9727083|NCT04001192|Experimental|exercise|exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
10199274|NCT05187559|Experimental|Second Group|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
9727084|NCT04000672|Active Comparator|HTO with navigation|High Tibial Osteotomy is offered to patients with symptomatic medial compartment knee osteoarthritis (OA)
9727085|NCT04000672|Experimental|HTO with navigation + PSI jig|"3D printed patient specific metal jigs (PSI jig) are created based on the pre-operative CT image. After that, calibrated osteotome is used to achieve the desired correction with the use of navigation for overall lower limb alignment, which is the same as the Active Comparator group."
9727086|NCT03999853|Experimental|Conventional Therapy / Butyrate|This arm will be receiving usual therapy for the first study period then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) after washout and cross-over
9727087|NCT03999853|Experimental|Butyrate / Usual Therapy|This arm will be receiving 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) placebo for the first study period then usual therapy after washout and cross-over
9727088|NCT03999658|Experimental|Extranodal NK/T-cell lymphoma (ENKTL)|Intravenous STI-3031 (anti-PD-L1 antibody)
9727089|NCT03999658|Experimental|Peripheral T-cell lymphomas (PTCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
9727090|NCT03999658|Experimental|Diffuse large B-cell lymphoma (DLBCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
9727091|NCT03999658|Experimental|Biliary tract cancers (BTC)|Intravenous STI-3031 (anti-PD-L1 antibody)
10199275|NCT05187169|Active Comparator|Treatment A|4.0 mg VS-6766, following an overnight fast of at least 10 hours
10199276|NCT05187169|Active Comparator|Treatment B|4.0 mg VS-6766, administered 30 minutes after the start of a high-fat/high-calorie meal breakfast
9727092|NCT03997981||Breast cancer patients with weekly/biweekly paclitaxel regimen|
9727093|NCT03997981||Breast cancer patients receiving docetaxel regimen|
9727094|NCT03997981||Lymphoma patients receiving vincristine regimen|
9727095|NCT03997981||Multiple myeloma patients receiving bortezomib regimen|
9727096|NCT03997981||Colorectal cancer patients receiving oxaliplatin-based regimens|
9727097|NCT03992612|Other|control group|The patients received usual medical care.
9727098|NCT03992612|Experimental|MBPM- Minfulness- Based Pain Management|"Psychological intervention with 8 group sessions ( 8 -10 subjects) with a duration of 2 and a half hours per session and a weekly periodicity (total hours 1080).~It is centered on training on the awareness of physical, cognitive and emotional sensations, and the attentional processes to become an observer of one's own thoughts and emotions. With the aim to provide greater flexibility to manage pain"
9727099|NCT03988855|Experimental|Part 1|10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days.
9727100|NCT03988855|Experimental|Part 2|30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days
9727101|NCT03987789|Active Comparator|Low PEEP group|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
9727102|NCT03987789|Experimental|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers
9727103|NCT03986372|Experimental|PRP injection, once|PRP injection, once
9727104|NCT03986372|Experimental|PRP injection, twice|PRP injection, twice, 2 weeks apart
9727105|NCT03986372|Experimental|PRP injection, 3 times|PRP injection, 3 times, 2 weeks apart
9727106|NCT03985540|Experimental|memory experimental group|Experimental group will receive memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
9727107|NCT03985540|Placebo Comparator|Placebo comparator memory|Placebo controlled group will receive placebo memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
9727108|NCT03985540|Experimental|Processing speed|Processing speed group will receive processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
9727109|NCT03985540|Placebo Comparator|Processing speed placebo|Placebo controlled group will receive placebo processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
9727110|NCT03984994|Experimental|Aerobic exercise training followed by resistance training|Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training
9727111|NCT03984994|Active Comparator|Resistance training followed by aerobic exercise training|Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training
9727112|NCT03980483|Experimental|GSK3196165 90 mg|Entire treatment period (52 Weeks): GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and more than or equal to (>=)5 mg/week folic (or folinic) acid as standard of care (SoC).
9727113|NCT03980483|Experimental|GSK3196165 150 mg|Entire treatment period (52 Weeks): GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
9727114|NCT03980483|Active Comparator|Tofacitinib|Entire treatment period (52 Weeks): Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
9727115|NCT03980483|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
9727116|NCT03980483|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
9727117|NCT03980483|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
9727118|NCT03979443|No Intervention|Inpatient|patients staying in the hospital for 1-3 nights after surgery
9727119|NCT03979443|Active Comparator|Outpatient|discharge on the day of the surgery, usually within 6-8 hours after procedure
9727120|NCT03976973|Experimental|Intervention|Participants with inoperable pseudomyxoma peritonei or peritoneal mucinous tumour that meet the entry criteria and consent to the intervention will receive intratumoural treatment/s with the combination drug BromAc. The drug product will be injected directly into the tumour via a radiologically placed drain
9727121|NCT03970837|Experimental|GSK3196165 90 mg|Entire treatment period (52 Weeks): GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
9727122|NCT03970837|Experimental|GSK3196165 150 mg|Entire treatment period (52 Weeks): GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
9727123|NCT03970837|Active Comparator|Tofacitinib 5 mg|Entire treatment period (52 Weeks): Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
10199277|NCT05174520|Active Comparator|Routine Physical Therapy group|"Routine physical therapy group includes thermotherapy for 10 mins, transcutaneous electrical nerve stimulations for 10 mins. Exercises such as: Pelvic tilts, bridging exercise, William flexion exercises and stretching will be performed for 7-10 repetitions.~Treatment duration will be 25 minutes."
10205015|NCT04324606|Experimental|Group 5b|Volunteers will receive two standard single doses of MenACWY vaccine ≤ 16 weeks apart, a dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) at 9 months then a second dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) 4-12 weeks later
9727124|NCT03970837|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
9727125|NCT03970837|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
9727126|NCT03970837|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
9727127|NCT03968406|Experimental|Treatment (talazoparib, radiation therapy)|Patients receive talazoparib PO QD beginning on days -10 to -7 and continuing for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy 5 days a week (Monday-Friday) for up to 7 weeks.
9662568|NCT02802124|Experimental|carbon-ion radiotherapy for tumor adjacent to GI|"For tumor location which is adjacent to gastrointestine (less than 1 cm).We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.~Three dose levels (carbon 60GyE/15Fx, carbon 67.5GyE/15Fx, carbon 75GyE/15Fx) are planned within the Phase I part."
9662569|NCT02787187|Active Comparator|Standard resection|Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
9727128|NCT03964532|Experimental|Phase I/Phase II|Talazoparib (1mg by mouth [PO] daily D1-28) will be provided as monotherapy for the first cycle. Starting with cycle 2 and for all subsequent cycles, treatment with avelumab (800 mg intravenously [IV] D1 every 2 weeks) will be added to talazoparib.
9727129|NCT03963895|Experimental|AB002 (E-WE-thrombin) Dose 1|Participants will receive a single dose of 1.5 mcg/kg E-WE thrombin.
9727130|NCT03963895|Experimental|AB002 (E-WE-thrombin) Dose 2|Participants will receive a single dose of 3.0 mcg/kg E-WE thrombin.
9727131|NCT03963895|Placebo Comparator|Placebo|Participants will receive a single dose of placebo
9727132|NCT03963622|Active Comparator|Control|Standard ventilation strategy.
9727133|NCT03963622|Experimental|Respiratory Mechanics|The goal of this arm is to individualize tidal volume (VT) and PEEP according to respiratory mechanics.
9727134|NCT03962231|Active Comparator|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid re-education exercises, assisted arm elevation and scapula control exercises.
9727135|NCT03962231|Active Comparator|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises with focus on lateral rotation, medial rotation and arm elevation.
9727136|NCT03955055|Experimental|Early Capsule Group|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the clinical decision unit. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
9727137|NCT03955055|No Intervention|Standard of Care Work-up|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
9662570|NCT02787187|Experimental|Extended resection|Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
9662571|NCT02766998|Experimental|Preserved umbilical vein|Preserved umbilical vein as shunt/conduit
9662572|NCT02549833|Experimental|Vaccines before and after surgery|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery), every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine), and two booster vaccines (Weeks A32 and A48).
9662573|NCT02549833|Active Comparator|Vaccines after surgery only|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every 3 weeks after standard-of-care surgery to remove the WHO grade II glioma only (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine) and two booster vaccines (Weeks A32 and A48). Patients will not receive vaccines before surgery.
9662574|NCT02468180|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
9662575|NCT02468180|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
9662576|NCT02433509|Experimental|HUCB monocyte cells w/ Mannitol in acute ischemic stroke|"The cord blood need to be infusion within less than 10 days after the onset of stroke, with the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
9662577|NCT02302105|Active Comparator|Prostate Only|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV
9662578|NCT02302105|Experimental|Whole Pelvis|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .
9662579|NCT02234557|Experimental|Tai Chi|Tai Chi instruction, 1 hour, twice per week Home Tai Chi practice with video, requesting 15-30 minutes, 3 times per week, monitored by practice log
9662580|NCT02207465|Experimental|Subtrial 1-Arm A (Dose Level 1 of Abraxane)|Determine if it is safe or not (via occurrence of dose limiting toxicities) for patients to receive both Abraxane and radiation therapy.
9662581|NCT02207465|Experimental|Subtrial 1-Arm B (Dose Level 2 of Abraxane: 3+4 enrollment)|Determine the maximum dose of Abraxane that is allowable and safe for patients receiving both Abraxane and radiation therapy.
9662582|NCT02207465|Experimental|Subtrial 2- Abraxane 125mg; Borderline get 55cGY, unresectable get 57.5cGY until next escalation|
9662583|NCT02081157||Breast Mastopexy with or without reduction using GalaFlex Mesh|Breast mastopexy with or without reduction, using GalaFLEX mesh
9727138|NCT03951116|Experimental|Dose escalation cohort of FCN-437c|"The dose-escalation cohort:~Participants will receive FCN-437c monotherapy once daily (QD) for 21 days followed by a 7 day rest period (28-day cycle).~FCN-437c will be administered orally.~Participants with histologically or cytologically confirmed advanced unresectable/metastatic solid tumor will participate in this cohort."
9727139|NCT03950024|Experimental|with arthrogenic Muscle Inhibition|
9727140|NCT03950024|Active Comparator|without arthrogenic Muscle Inhibition|
9727141|NCT03942094|Experimental|Nilotinib|
9727142|NCT03941275||Subjects undergoing bi-plane fluoroscopy|
9727143|NCT03936361|Active Comparator|Statin|The same statin agent and dose that subjects were using at the time of ICH onset.
9727144|NCT03936361|No Intervention|No-statin|Subjects will discontinue the statin agent that they were taking at the time of ICH onset. No placebo will be prescribed for these subjects.
9727145|NCT03931902|Experimental|Laryngeal Mask Airway (LMA)|Using laryngeal mask airway as the airway device during general anesthesia
9727146|NCT03931902|Active Comparator|Endotracheal Tube (ETT)|Using endotracheal tube as the airway device during general anesthesia
9727147|NCT03931070|Experimental|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
9727148|NCT03931070|Placebo Comparator|Placebo|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
9727149|NCT03920293|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
9727150|NCT03920293|Placebo Comparator|Placebo|Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.
9727151|NCT03920267|Experimental|BMS-986165 Dose 1|
9727152|NCT03920267|Experimental|BMS-986165 Dose 2|
9727153|NCT03920267|Experimental|BMS-986165 Dose 3|
10205016|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 20mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
9727154|NCT03919981||nephropathic cystinosis patients receiving cysteamine|nephropathic cystinosis patients receiving cysteamine. The blood samples of the group will be used to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype.
9727155|NCT03915106||Bracing|AIS patients undergoing bracing to control the spinal curve progression
9727156|NCT03915106||Surgical|Severe AIS patients requiring surgical intervention to correct the spinal curve
9727157|NCT03912454|Experimental|BMAC Injection|
9727158|NCT03909750|Experimental|Lipoaspiration Microcannula ARM 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
9727159|NCT03909750|Experimental|Isolation-Concentration Adipose cSVF ARM 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
9727160|NCT03909750|Experimental|Normal Saline IV ARM 3|Sterile Normal Saline IV with cSVF
9727161|NCT03907748|Experimental|Music Intervention|The music intervention will be provided to participant dyads (people with dementia and their cohabiting family caregivers) allocated to the first intervention. Caregivers will be trained to use the music intervention in three 2-hour training sessions with an intervention trainer (a music therapist). Training will take place at the dyad's home. The caregiver will then be asked to deliver the music intervention to the person with dementia at least 5x per week for 30 minutes.
9727162|NCT03907748|Active Comparator|Reading Intervention|The reading intervention will be provided to participant dyads (people with dementia and their cohabiting caregivers) allocated to the second intervention. Caregivers will be trained to use the reading intervention in three 2-hour training sessions with an intervention trainer. Training will take place at the dyad's home. The caregiver will then be asked to deliver the reading intervention to the person with dementia at least 5x per week for 30 minutes.
9727163|NCT03907748|No Intervention|Standard Care|Participant dyads (people with dementia and their cohabiting caregivers) allocated to the standard care group will not receive any training or be asked to deliver an intervention.
9727164|NCT03904199|Experimental|Basal-Prandial-Correctional Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization. Adjustments will be made in real time to reach the target range.
9727165|NCT03904199|Active Comparator|Standard of Care Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.
9727166|NCT03897036|Experimental|CX-4945 28 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 28 of each treatment cycle
9727167|NCT03897036|Experimental|CX-4945 21 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 21 of each treatment cycle
9727168|NCT03897036|Experimental|Expansion CX-4945 Locally Advanced BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
9727169|NCT03897036|Experimental|Expansion CX-4945 Metastatic BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
9727170|NCT03896581|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen.
9727171|NCT03896581|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo.
9727172|NCT03895567|Experimental|ABC|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
9727173|NCT03895567|Experimental|ACB|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
9727174|NCT03895567|Experimental|BAC|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
9727175|NCT03895567|Experimental|BCA|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
9727176|NCT03895567|Experimental|CAB|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
9727177|NCT03895567|Experimental|CBA|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
9727178|NCT03890601||Biological APS|50 Asymptomatic patients with aPL antibodies and prolonged APTT
9727179|NCT03890601||Obstetrical APS|50 patients with Obstetrical aPL syndrome
9727180|NCT03890601||Thrombosis APS|APS with a personal history of venous or arterial thrombosis (50 patients)
9727181|NCT03889119|Active Comparator|Elekta Versa HD|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
9727182|NCT03889119|Other|Agility Systems|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
9727183|NCT03886064|No Intervention|Control group|Only measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling.
9727184|NCT03886064|Other|Interventional group|Measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling followed by multi-behavioral intervention adapted to local resources.
9727185|NCT03882073|Experimental|Intervention group|Modified amputation procedure
9727186|NCT03882073|Active Comparator|Control group|Standard amputation procedure
9727187|NCT03878550||Cases|Male and female adult patients with early-stage hepatocellular carcinoma against a background of liver cirrhosis.
9727188|NCT03878550||Controls|Male and female adult patients with liver cirrhosis at risk for hepatocellular carcinoma.
9727189|NCT03878212|Experimental|mHealth+I|This group of participants will receive a proactive mHealth with interactivity program which includes two main elements: 1) mHealth application designed by the research team with the information technological support by Smartone and 2) nurse case management supported by a social service team
9727190|NCT03878212|Active Comparator|mHealth|The mHealth group will have access to the health content on the mHealth platform. This group 2018 HMRF Open Call Proposal Section 13: Proposed Research Project 5 will enjoy the same content and client-initiated help if needed. Same as the above group, the client is invited to use the mHealth application. A reminder message will pop up on the screen of smartphone when participants have not used it for more than one week. The participants are encouraged to read the self-care information that is featured in the app. There is a button for the client-imitated call if they would like to consult a nurse.
9727191|NCT03878212|No Intervention|Control|All groups will receive usual community services. The study district provides community-based health talks and basic health checks such as measuring blood pressure and blood glucose that are accessible to all residents, and their participation is voluntary. Both health and social services are available in the community for those who need help, including referral for further help if appropriate. These services are however episodic with design for continuity of care. No mHealth application will be provided to the participants in this group but the individuals are free to do their own surfing for e-health information.
9727192|NCT03875547||Patients with haemophilia B|Both patients who have not previously been exposed to Refixia® and patients previously exposed to Refixia® in one of the clinical trials can be included.
9727193|NCT03875209|Experimental|Arm 1: 10E8.4/iMab IV or SC HIV-|Arm 1; Groups A-C; 3 dosing groups: HIV-uninfected individuals
10199278|NCT05174520|Experimental|Experimental group|"Experimental group includes 6-7 repetitions of Muscle energy technique on Quadratus Lumborum muscle and Routine physical therapy, i.e Thermotherapy, transcutaneous electrical nerve stimulations, Pelvic tilts, bridging exercise, William flexion exercises and stretching will be performed for 7-10 repetitions.~Treatment duration will be 40 minutes."
9727194|NCT03875209|Experimental|Arm 2: 10E8.4/iMab IV HIV-|Arm 2; Groups D-F; 3 dosing groups: HIV-uninfected individuals
9727195|NCT03875209|Experimental|Arm 3 and 3a: 10E8.4/iMab IV HIV+|Arm 3; Group H; 1 dosing group: HIV-infected individuals with HIV-1 RNA levels between 1,000 and 100,000 copies/mL and cluster of differentiation 4 (CD4)>350 cells/mm3; Arm 3a; Group I; 1 dosing group: HIV-infected and suppressed individuals
9727196|NCT03875209|Experimental|Arm 4: 10E8.4/iMab SC HIV-|Arm 4; Groups J and K: HIV-uninfected individuals
9727197|NCT03873727|Experimental|Prevenar13/ Pneumovax|Prime-boost strategy combining a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar 13, PCV13) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12).
9727198|NCT03873727|Placebo Comparator|Placebo / Pneumovax|Standard strategy combining a single dose of placebo vaccine (Prevenar 13 placebo) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12)
9727199|NCT03873311|Experimental|Azacytidine + HAG Regimen|Azacytidine（75mg/m2 ）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) , Cytarabine 10mg/(m2.d), G-CSF 200ug/(m2.d) )
9727200|NCT03873311|Active Comparator|Azacytidine|75mg/m2
9727201|NCT03870698|Experimental|Laparoscopic group|The patients who underwent laparoscopic procedures for periampullary tumors
10199279|NCT05174494|Active Comparator|Full mouth non surgical periodontal treatment|Each selected subject underwent to full mouth SRP.
10199280|NCT05174494|Placebo Comparator|Control|Each selected subject underwent full mouth traditional oral hygiene.
9727202|NCT03870698|No Intervention|Open group|The patients who underwent open procedures for periampullary tumors
9727203|NCT03860805|Active Comparator|Laparoscopic tubal ligation|Patients who seek for surgical permanent contraception and randomized to laparoscopic tubal ligation
10199281|NCT05171595||no myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
9727204|NCT03860805|Active Comparator|Laparoscopic bilateral salpingectomy|Patients who seek for surgical permanent contraception and randomized to laparoscopic bilateral salpingectomy
9727205|NCT03849274|Experimental|Smart Scar Care Pad+Pressure Garment|For experiment group, subject will be intervened by SSCP plus PG
9727206|NCT03849274|Active Comparator|Pressure Garment|For control group, subject will be intervened by conventional PG only
9727207|NCT03849274|No Intervention|Non-eligible patients (with VSS less than 4)|Non-eligible subjects with VSS less than 4 will be followed up for 6 months and assessment results will be recorded.
9727208|NCT03847428|Experimental|Arm A|Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)
9727209|NCT03847428|Experimental|Arm B|Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)
9727210|NCT03847428|Placebo Comparator|Arm C|Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)
9727211|NCT03843242|Experimental|Pacemaker with Fixed long AV delay|"Patients who meet the inclusion criteria and is implanted with a Biotronik Enitra 8 DR-T pacemaker are eligible.~The pacemaker was programmed with a long and fixed atrioventricular interval for the first 3 months.~Definition of fixed AV delay (than intrinsic AV conduction) • If P-wave exists: intrinsic AV conduction time = As ~ Vs interval in the marker channel sensed AV delay = intrinsic AV conduction time + 20 msec paced AV delay = sensed AV delay + 30 msec • If no P-wave exits: intrinsic AV conduction time = Ap ~ Vs interval in the marker channel paced AV delay = intrinsic AV conduction time + 20 msec sensed AV delay = paced AV delay - 30 msec • If the intrinsic AV conduction time is ≥ 300ms, make paced/sensed AV delay 350/320 msec"
9727212|NCT03843242|Experimental|Pacemaker with VpS® algorithm on|Vp Suppression ON algorithm: This feature promotes the intrinsic AV conduction by only pacing the ventricle when intrinsic conduction becomes unstable or disappears. Depending on the presence or absence of AV conduction, the feature is implemented either in the ventricular pacing suppression state ADI(R), which promotes the intrinsic conduction, or in the DDD(R) ventricular pacing state Vp DDD(R), which provides ventricular pacing. Automatic switching capabilities between those two states promotethe intrinsic conduction as much as possible without harming the patient. Scheduled Vs searching tests look for intrinsic conduction using an extended AV delay of 450ms.
9727213|NCT03843242|Experimental|Pacemaker with IRSplus algorithm on|IRS plus algorithm: This algorithm incorporates two different functions: the first is scan hysteresis, which better enables the heart to pace on its own by periodically extending the search time for its natural pacing stimulus (the intrinsic AV conduction) over six consecutive atrial cycles. The second is the repetitive hysteresis, which recognizes when the heart is not pacing on its own (a consistent loss of intrinsic AV conduction lasting for six consecutive atrial cycles) and switches the mode of the device from extended to basic atrioventricular (AV) delay.
9727214|NCT03842826||Athlete|Male athletes performing sports ≥ 1x/week Age: 18-40 years
9727215|NCT03842657|Other|calcium-free citrate-containing dialysate|Dialysis session will be performed with a non-heparin grafted membrane, a dialysate without calcium (0 mmol/L) and citrate 0.8 mmol/L, a reinjection of a calcium solution (300 mM) according to the ionic dialysance, and no heparin addition
9727216|NCT03842657|Other|heparin-grafted membrane|dialysis session will be performed with a heparin-grafted membrane, a dialysate with calcium (1.65 mmol/L) and citrate 0.8 mmol/L, and no heparin addition
9727217|NCT03841513|No Intervention|Control|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, without the addition of a laparoscopic/robotic Burch colposuspension
9727218|NCT03841513|Active Comparator|Laparoscopic Burch Colposuspension|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, with the addition of a laparoscopic/robotic Burch colposuspension
9727219|NCT03841292|Active Comparator|Active tDCS+Varenicline|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
10205017|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 40mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).
9727220|NCT03841292|Sham Comparator|Sham tDCS+Varenicline|Sham tDCS (Nuraleve, Canada)(30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
9727221|NCT03840343|Experimental|Lower Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
9727222|NCT03840343|Experimental|Higher Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose
9727223|NCT03840291|Experimental|Edoxaban treatment|"Men or women aged ≥ 20 years with NVAF patients who has LAA thrombi documented by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication are eligible.~Patients in this group are taking Lixiana® (Edoxaban) 60mg for resolution of left atrial appendage thrombi~Reduced (30mg) dose is administered in patients with one or more of the following clinical factors:~Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)~Low body weight ≤ 60 kg~Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin,dronedarone, erythromycin, or ketoconazole."
9727224|NCT03835039||HIE|Infants with a diagnosis of HIE
9727225|NCT03832686|Experimental|Virtual Coach App|Participants in the experimental arm (Group A) will receive a comprehensive swallowing rehabilitation app. This study seeks to determine if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation therapy for head and neck cancer. No devices - outside of the Smartphone already owned by the participant - will be used in this study. Similarly, no drugs, biological materials, or other substances will be used.
9780897|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 3|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
9727226|NCT03832686|No Intervention|Standard of Care|The paper group (Group B) will be given paper exercise logs to fill out Participants will be educated regarding potential radiation-related side effects and trained in the same series of swallowing exercises by the SLP. The paper log treatment group will serve as a standard treatment group. As adherence is a primary goal of the target intervention, paper logging will be necessary to determine relative adherence while minimizing reporting bias.
9727227|NCT03830359|Experimental|T2769|T2769 Ophthalmic solution patients treated with 1 drop in each eye 3 to 6 times daily
9727228|NCT03828747|Experimental|Semorinemab|Semorinemab will be administered intravenously in the double-blind treatment period, and semorinemab will be administered intravenously in the optional open-label extension period.
9727229|NCT03828747|Placebo Comparator|Placebo|Placebo will be administered intravenously in the double-blind treatment period.
10199282|NCT05171595||Myocardial injury|In this study, patients were divided into groups of myocardial injury, where patients had TnT elevations (of 20-64 ng/L with an absolute change of ≥ 5 ng/L, or a hsTnT level ≥65 ng/L, both evaluated as due to ischemic etiology) and a group with no myocardial injury.
10199283|NCT05169424||Stiolto initiators|Chronic obstructive pulmonary disease (COPD) patients who initiated with Stiolto Respimat (Tiotropium + Olodaterol (5/5 micrograms (mcg)) between 15 September 2017 and 31st March 2020.
9727230|NCT03827655|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
9727231|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
9727232|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL + Placebo|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
9727233|NCT03824106|Experimental|Arm1.Control|Participants randomized to the control arm will not receive any of the Frailty Rehabilitation Interventions. Participants in the control arm will receive Vitamin D.
9727234|NCT03824106|Experimental|Arm2.Group Exercise|Participants will attend the exercise program, twice-weekly, for 4-months with supplemental home exercise.
9727235|NCT03824106|Experimental|Arm3.Multi-modal Intervention|"Group Exercise/Supplemental Home Exercise: This will be delivered identically to Arm 2.~Nutrition, protein supplementation, and a medication review will also be implemented."
9727236|NCT03822780|Experimental|HCQ Therapy|"Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.~Assess the efficacy and safety of HCQ after 6 months treatment compared with any other routine therapy before HCQ therapy (such as inhaling oxygen, corticosteroid, anti-infection therapy, nutritional support)"
9727237|NCT03818776|Experimental|Arm 1 - 60 CGyE in 20 fractions|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~60 CGyE in 20 fractions (3+3 participants, 3-6 total)"
9727238|NCT03818776|Experimental|Arm 2 - 69 CGyE in 23 fractions followed by expansion cohort a|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~69 CGyE in 23 fractions (3+3 participants, 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)"
9727239|NCT03818386|Experimental|AGuIX® + Whole Brain Radiation Therapy|"Intervention: Drug: AGuIX® + WBRT~Other Names:~Gadolinium-chelated polysiloxane based nanoparticles~3 intravenous injections at 100mg/kg~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~Fr1: AGuIX® injection before the first radiation session~Fr6: AGuIX® injection before the sixth radiation session~30 Gy in 10 fractions of 3 Gy over 2-3 weeks"
9727240|NCT03818386|Active Comparator|Whole Brain Radiation Therapy|Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
9727241|NCT03818165|Experimental|CAR2 Anti-CEA CAR-T cell|3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion
9727242|NCT03817983||MRE review for axSpA|Review of MRE scan for evidence of axSpA in Crohn's disease patients
9727243|NCT03812146|Experimental|PC-TIME|PC-TIME consists of meeting with a behavioral health provider for 5, 30-minute sessions that will be delivered over the course of 8 weeks (spaced about 1-2 weeks apart). PC-TIME sessions integrate two effective treatments: motivational enhancement therapy approaches and brief Prolonged Exposure.
9727244|NCT03812146|Active Comparator|PC-TAU|Primary Care - treatment as usual. Participants in PC-TAU will be referred to the PCMHI mental health provider within their primary care team, and will receive whichever care or intervention is typically provided. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team.
9727245|NCT03803111|Experimental|Initial FCM|Intravenous iron supplementation with FCM, subsequent (after 2 months) exercise training program
9727246|NCT03803111|Experimental|Initial exercise|Exercise training program, subsequent (after 2 months) intravenous iron supplementation with FCM
9727247|NCT03802110|Experimental|Single Arm|Defibrillation threshold (DFT) testing Arm
10199284|NCT05169424||Trelegy initiators|COPD patients who initiated with Trelegy Ellipta (Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg) between 15 September 2017 and 31st March 2020.
10199285|NCT05168956||Sexual offender|Patients followed up in the sexual offender's department of University Hospital of Saint Etienne will be included.
10205018|NCT04317742|Active Comparator|Sleep Healthy Using the Internet (SHUTi) Intervention Group|Participants will receive a direct link to access the SHUTi program (per randomization) from the study team.
9780898|NCT01134263|Experimental|CYD Dengue vaccine - Phase II Lot|Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
10205019|NCT04317742|Active Comparator|Online Patient Education (PE) Control Group|Participants will receive a direct link to access online patient education (per randomization) from the study team.
10205020|NCT04306029|No Intervention|Pre-Intervention|
9727248|NCT03795142|Experimental|single intravenous dose; BGB149|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
9727249|NCT03795142|Placebo Comparator|single intravenous dose; placebo|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
9727250|NCT03787368|Experimental|Dose 1 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 1)
9727251|NCT03787368|Experimental|Dose 2 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 2)
9727252|NCT03787368|Placebo Comparator|Placebo|Single intravenous infusion placebo
9727253|NCT03786796|Experimental|Olaparib|Participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L that have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy with measureable disease on CT imaging according to RECIST 1.1 criteria. Participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose will be increased to 300mg by mouth twice daily provided there are no grade 3 or greater adverse events experienced. Reassessment will occur at least monthly for toxicity. Radiological scans will be performed every 3 months to assess disease response. Treatment will be continued until clinical and/or radiographic progression according to RECIST 1.1 criteria or unmanageable toxicity requiring cessation.
9727254|NCT03779074|Active Comparator|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
9727255|NCT03779074|Experimental|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
9727256|NCT03779074|Experimental|14d high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
9727257|NCT03773666|Experimental|Durvalumab|-Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
9727258|NCT03773666|Experimental|Durvalumab + Oleclumab|"Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle~Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle"
9727259|NCT03768570|No Intervention|Surveillance|
9727260|NCT03768570|Active Comparator|Durvalumab|
9727261|NCT03766958||Registry Patients With Nodify Lung Results|Patients providing consent to have data collected to observe how Nodify Lung results were used in the clinical management of their lung nodules.
9727262|NCT03766958||Contemporaneous Group Without Nodify Lung|Contemporaneous group who did not have Nodify Lung test results for use in the clinical management of their lung nodules.
9727263|NCT03766477||Individuals with sleep bruxism|"Individuals with sleep bruxism evaluated in three different methods regarding their sleep quality:~Pittsburgh Sleep Quality Index (IQSP) and Johansson~Smartphone APP~Polysomnography"
9727264|NCT03766347||Pediatric Neuromyelitis Optica|Participants under the age of 18 that are positive for Aquaporin-4 antibody.
9727265|NCT03761095|Experimental|Unesbulin and Dacarbazine|Participants will receive unesbulin orally twice weekly in combination with dacarbazine IV once every 21 days. First participant will receive dacarbazine 1000 mg/m^2 IV every 21 days in combination with unesbulin 200 mg tablet orally twice weekly. For subsequent participants, the dose level at which treatment is initiated will be selected based on the TITE-CRM using the most up to date dose DLT information from all participants previously treated. Participants will receive unesbulin 300 mg twice weekly in combination with dacarbazine in the expansion cohort. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
9727266|NCT03760575|Experimental|Pembrolizumab with image-guided surgery and chemotherapy|
9727267|NCT03759912||PVI using Ultra-High-Resolution Mapping|The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).
9727268|NCT03757949|Experimental|Arm I (SIM)|Patients receive SIM PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
9727269|NCT03757949|Placebo Comparator|Arm II (placebo)|ARM II: Patients receive placebo PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
9727270|NCT03756961|Active Comparator|Control|"Control group: The patients receive the routine based anesthesiological treatment during bariatric surgery (Gastric By-Pass or Sleeve Gastrectomy). It consists of:~General anesthesia induction: TCI Remifentanil Cpt 6 ng/ml/ Cp 3.2 ng/m, Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) adjusted via BIS (40-60) and Remifentanil Cp 4-10 ng/ml.~Post-operative pain management: Oxycodone 2.5 mg iv if the pain is rated by patient NRS ≧3. Paracetamol 1 g/6 h and Diclofenac 80 mg/24 h."
9727271|NCT03756961|Experimental|Intervention|"Induction: Dexmedetomidine 0.2 micrograms/kg/h iv 5 min, Esketamine 0.1mg/kg + Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) BIS (40-60), Dexmedetomidine 0.2 micrograms/kg/h, Esketamine 0.1-0.3mg/kg/h och 0.1 mg/kg in case of hypertension. At the end of surgery, Lidocaine 1 mg/kg iv (max 4 mg/kg /4 h)~Post-operative: Dexmedetomidine (0.1-0.2 micrograms/kg/h up to 4 h post-operative). If the pain is rated NRS ≧3: Transcutaneous Nerve Stimulation (TENS) with high intensive 40-50 mA for 1 minute, if the patient still NRS ≧3, the TENS treatment is repeated one more time. If pain NRS ≧3 after two treatments with TENS: Esketamine 0.1mg/kg iv + Lidocaine 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS still ≧3 within 30 minutes after both TENS and Esketamine/Lidocaine, 2.5 mg Oxycodone iv, with a 10 minutes intervals until NRS < 3. Perioperative and at discharge, PCC will be used for the second half of the intervention."
9727272|NCT03755128||Pregnant women and their offspring from current pregnancy|
10205021|NCT04306029|Experimental|Post-Intervention|"Postpartum staff has received the Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
9727273|NCT03754699|Experimental|Patients with a therapeutic educational intervention|Arm 1 : Interventional group: A therapeutic educational intervention is performed following pre-anesthesia assessment
9727274|NCT03754699|Active Comparator|Patients without therapeutic educational intervention|Arm 2 : Control group: standard information on pain is performed following pre anesthesia assessment
9727275|NCT03746184||Knee osteoarthritis|Treatment course
9727276|NCT03745924||Patients with haemophilia B|Patients with haemophilia B without current inhibitors
9727277|NCT03745053|Experimental|XLIMUS DES|Xlimus DES Implantation during coronary angioplasty
9727278|NCT03745053|Active Comparator|Synergy DES|Synergy DES Implantation during coronary angioplasty
9727279|NCT03743610|Experimental|Effect of heart rate training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining >65% max heart rate during room air based maximal peak work.
9727280|NCT03743610|Experimental|Effect of saturation of oxygen training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.
9727281|NCT03743610|Active Comparator|Effect of optimized training in simulated altitude|Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.
9727282|NCT03743610|Placebo Comparator|Effect of placebo training in non-simulated altitude|Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.
9727283|NCT03741842|Experimental|COMBO-KEY group|"The participants in the intervention group will receive a home visiting and phone coaching self-management programme (Coaching Ongoing Momentum Building On stroKe rEcovery journeY COMBO-KEY) which is underpinned by Bandura's constructs of self-efficacy and outcome expectation."
9727284|NCT03741842|No Intervention|Usual care group|The participants in the usual care group will receive usual rehabilitation services offered, including services by a community rehabilitation network such as exercise training, physical rehabilitation, or activities organised by stroke support groups.
9727285|NCT03735537|Active Comparator|Teriparatide and zoledronic acid|Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector, given subcutaneously using a self-administered injection device for two years (24 months) followed by a single intravenous 5mg infusion of zoledronic acid.
9727286|NCT03735537|No Intervention|Standard Care|Continuation of existing bone modifying treatment (i.e. bisphosphonate treatment) or no active bone modifying treatment according to the clinical judgement of the local investigator.
9727287|NCT03735290|Experimental|Phase 1b: Cohort 1, ilixadencel + pembrolizumab|3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab I.V. q3w
9727288|NCT03735290|Experimental|Phase 1b: Cohort 2, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w
9727289|NCT03735290|Experimental|Phase 1b: Cohort 3, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w
9727290|NCT03735290|Experimental|Phase 1b: Cohort 4, ilixadencel + pembrolizumab|Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w
9727291|NCT03735290|Experimental|Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.
9727292|NCT03735290|Active Comparator|Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.
9727293|NCT03732794|Experimental|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
9727294|NCT03729947|Active Comparator|Drain placed|Subfascial drain at end of procedure
9727295|NCT03729947|Placebo Comparator|No drain placed|No drain left at the end of study
10205022|NCT04299503|Active Comparator|Crisaborole|ointment applied topically in the morning and in the evening
10205023|NCT04299503|Placebo Comparator|Placebo|ointment applied topically in the morning and in the evening
9727296|NCT03723967|Experimental|Durvalumab with Carboplatin/Paclitaxel|Combination of Durvalumab with Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
9727297|NCT03718832|Experimental|Treatment Group-Begin Now|"Group 1- Will be randomized to the treatment (Begin Now) group for the Fresh Food Farmacy program. Subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program right away when the program opens in their geographic area. Data will be collected during the first 12 months of subject participation and EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total)."
9727298|NCT03718832|No Intervention|Control Group-Begin Later|"Group 2- Will be randomized to the control (Begin Later) group for the FFF program. These subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program approximately 6 months after the program opens in their geographic area. Data will be collected during the first 6 months of subject participation and used as control data for the study. EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total from the start of the trial)."
9727299|NCT03713866|Experimental|EP Imaging and Testing|MRI images,120 lead body surface mapping and NIPS testing will be completed to correlate areas of VT scar.
9727300|NCT03711058|Experimental|Phase I - Copanlisib and Nivolumab (De-Escalation)|
9727301|NCT03711058|Experimental|Phase II - Copanlisib and Nivolumab|
9727302|NCT03708263|Active Comparator|532nm KTP Laser|Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.
9727303|NCT03708263|Experimental|585 nm yellow laser|PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.
9727304|NCT03704298|Experimental|Axicabtagene ciloleucel plus utomilumab|"Phase 1: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel treatment on Day 0 plus utomilumab on study Day 1 or study Day 21 and continuing once every 4 weeks (Q4W) for 6 months or until Progressive Disease, whichever comes first.~Phase 2: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel and utomilumab based on the dose/regimen selected to move forward from the Phase 1 portion of the study as recommended by the internal Safety Review Team."
9727305|NCT03696797|Active Comparator|Treatment Group|Will have a Unit of blood (two cups, the same amount donated at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure your blood count to be sure you are not anemic, and blood pressure to be sure no dehydration. During or after donation, a sports drink is provided to replace the fluid loss. Phlebotomy
9727306|NCT03696797|Sham Comparator|Control Group|Will not donate blood, but will have a needle inserted into a vein in your arm. Both groups will not know which group assignment they have been randomized. Sham Phlebotomy
9727307|NCT03694457|Active Comparator|deltopectoral approach|the patients are treated with deltopectoral approach surgery
9727308|NCT03694457|Other|lateral approach|the patients are treated with a lateral approach surgery
9727309|NCT03692325|Experimental|Nivolumab|"Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle~Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent"
9727310|NCT03690154|Experimental|FN-1501|
9727311|NCT03689842|Experimental|Couple donor - recipient|
9727312|NCT03682536|Experimental|Luspatercept|
9727313|NCT03682536|Active Comparator|Epoetin alfa|
9727314|NCT03675516||Rheumatoid arthritis cases|New onset cases of rheumatoid arthritis
9727315|NCT03675516||Controls|Age, gender and primary care practice-matched controls
9727316|NCT03670069|Experimental|Treatment (itacitinib)|Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9780899|NCT01134263|Placebo Comparator|Placebo|Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
9780900|NCT01134276|Active Comparator|PTBD|biliary drainage : PTBD procedure for obstructive jaundice in patients with periampullary cancer
9780901|NCT01134276|Active Comparator|ERBD|biliary drainage : ERBD/ENBD procedure for obstructive jaundice in patients with periampullary cancer
9780902|NCT01134315||Paricalcitol|Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
9780903|NCT01134315||Calcitriol|Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT). Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
9780904|NCT01134328|Experimental|AC-150 Combo|
9780905|NCT01134328|Active Comparator|AC-150A 0.1%|
9780906|NCT01134328|Active Comparator|AC-150B 0.005%|
9780907|NCT01134328|Other|Vehicle|
9780908|NCT01134393|Experimental|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of blood pressure goal
9780909|NCT01134510|Experimental|C1 esterase inhibitor|10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
9780910|NCT01134510|Placebo Comparator|Placebo|10 subjects placebo [normal saline] in addition to standard of care immunosuppressive therapy.
9780911|NCT01134549|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous injection.
9780912|NCT01134549|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.
9780913|NCT01134562|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous (IV) injection after hemodialysis.
9780914|NCT01134562|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide by intravenous (IV) injection after hemodialysis.
9780915|NCT01134575|Experimental|Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
9780916|NCT01134575|Experimental|Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin)|CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
9780917|NCT01134575|Experimental|Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
10205470|NCT05206461||Diparetic CP|Trunk control, hand function and quality of life were evaluated with the Trunk Control Measurement Scale, 9-Hole Peg Test and Pediatric Quality of Life Inventory in Diparetic CP
10199286|NCT05167266|Experimental|Cognitive psychoeducation|"1) The cognitive intervention is a 4-session, psycho-educative, integrative and multidimensional intervention designed to prevent post-acute cognitive symptoms. Each individual session will last 90' and will concern a specific cognitive domain:~Cognition in covid, fatigue and sleep~Working memory and attentional functioning~Executive functioning~Memory functioning~The structure of the sessions will be similar: (1) explanation about (dys)functioning of processes associated to the domain of interest: (2) identification of problems in daily life translated into functional objectives (e.g. keeping papers organized; scheduling activities to avoid fatigue); (3) discovery and application of (meta)cognitive strategies.~Material (videos, tips,…) will be provided that the patients can consult when needed. The patients will have a diary to complete to explain when they applied the content of the intervention in daily life, and how successful it was."
10199287|NCT05167266|Active Comparator|Affective psychoeducation|"2) The affective intervention is also a psychoeducation program based on four sessions, in which different strategies and resources will be proposed to increase self-efficacy for emotion management:~Recognizing emotions and affective states~Accepting and communicating emotions and difficulties~Accepting the uncertainty associated with difficulties~Behavioural activation~Material (videos, tips,…) will be provided that the patients can consult when needed. The patients will have a diary to complete to explain when they applied the content of the intervention in daily life, and how successful it was."
10199288|NCT05166122|Active Comparator|AI workflow|In AI work flow, patients will be screened by taking normal retinal images and all images will be assessed for the severity of diabetic retinopathy by a computerized artificial intelligence system immediately after the photograph is taken via the Internet and retinal images will be sent to the retinal ophthalmologist for overreading.
9727317|NCT03669887|Experimental|Lifestyle Modification Program|Women randomised into the intervention group received the 1-year lifestyle modification program.
9727318|NCT03669887|No Intervention|Control|Women randomised into the control arm received standard postnatal care.
9727319|NCT03668392|Experimental|Patients on Oncospar|
9727320|NCT03668119|Experimental|Nivolumab + Ipilimumab Combination|
9727321|NCT03668119|Experimental|Nivolumab Monotherapy|
9727322|NCT03661970||Normal subjects hearing group|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
9727323|NCT03661970||Cochlear implant subjects with good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
9727324|NCT03661970||Cochlear implant subjects without good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
9727325|NCT03661723|Experimental|Pembrolizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
9727326|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
9727327|NCT03661723|Experimental|Pembrolizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
9727328|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
9727329|NCT03661372|Active Comparator|Face-to-Face|Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
9727330|NCT03661372|Active Comparator|Robot|Robot Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A robot (telesimulated) standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room via a robot to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
9727331|NCT03660085|Experimental|Arm A - Early Intervention|For 180 days participants in this arm will be exposed to the intervention and 180 days afterwards they will be exposed to the standard of care.
9727332|NCT03660085|Active Comparator|Arm B - Late Intervention|For 180 days participants in this arm will be exposed to the standard of care and 180 days afterwards they will be exposed to the intervention.
9727333|NCT03659461|Experimental|low GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
9727334|NCT03659461|Active Comparator|normal GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin ( Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
10199289|NCT05166122|No Intervention|Manual workflow|Volunteers who have been screened by manual workflow will be screened by imaging the retina and image that are not normal will be sent to assess the severity of diabetic retinopathy by specialist staff.
10199290|NCT05165576|Experimental|Child-centered communication|The child's preparation for the MRI scanning is conducted using a child-centered communication type of interaction
10199291|NCT05165576|Active Comparator|Magnetic Resonance Imaging (MRI) Simulation Toy|The child's preparation for the MRI scanning is conducted through provision of general information about the MRI exam simulated with an MRI toy
10199292|NCT05165576|No Intervention|General information about the Magnetic Resonance Imaging (MRI) exam|The child's preparation for the MRI scanning is based on the provision of routine information about the MRI exam
10199293|NCT05165225|Experimental|Pyrotinib|Experimental: Patients will receive Pyrotinib combined with Epirubicin and Cyclophosphamide followed by Docetaxel
9727335|NCT03650036|Experimental|Group 1|In group 1, Pulp Therapy will be done with the CTZ paste (composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline, 125 mg of zinc oxide) will be manipulate with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use and will be taken at the tip of a number 5 exploratory probe and dispensed at the entrances of the root canals where it will be accommodated with light pressure of sterile cotton balls. The CTZ paste will be protected with a thin layer of gutta-percha, previously heated in an alcohol lamp and placed in a thin layer on the CTZ pulp. The gutta-percha blade will be condensed with medium size amalgam presser and has the objective of physically isolating the CTZ paste from the restorative material.
9727336|NCT03650036|Experimental|Group 2|In Group 2, Pulp Therapy will be done with ZOE paste. The mechanical preparation of the root canals with 2% chlorhexidine solution and first-series K files will be performed. The instrumentation limit shall be 1 mm short of the radiographic apex. After finishing the chemical-mechanical preparation, drying of the root canals with sterile absorbent paper cones and ZOE paste insertion with K files will be performed. The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use. The protection of the ZOE paste will follow the same sequence as the CTZ paste.
9727337|NCT03643133|Active Comparator|Control arm|"Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :~M-API regimen (≤25 years) :~Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2~EI regimen (26-50 years) :~Etoposide 75 mg/m²/d, Day 1-4 Ifosfamide 3 g/m²/d, Day 1-4"
9727338|NCT03643133|Experimental|Experimental arm|Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2 mg/m² twice weekly post-randomisation for 12 weeks then weekly for 24 weeks
9727339|NCT03642067|Experimental|Cohort A/B: Nivolumab and Relatlimab|480mg/160mg (co-administered)
9727340|NCT03642067|Experimental|Cohort C: Nivolumab and Relatlimab|480mg/ 960mg or 480mg/480mg (sequential administration)
9727341|NCT03642067|Experimental|Cohort C: Nivolumab and Relatlimab (co-administration)|480mg/160mg (co-administration)
9727342|NCT03638817|Experimental|Eltrombopag|
9727343|NCT03632720|Experimental|Group 1|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
9727344|NCT03632720|Experimental|Group 2|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2 and 4 months of age; routine pediatric vaccines
9727345|NCT03632720|Active Comparator|Group 3|Meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
9727346|NCT03631290|Experimental|Deprescribing Intervention|
9727347|NCT03628950|Active Comparator|ICSSB group|infraclavicular suprascapular nerve block administered group
9727348|NCT03628950|Active Comparator|ISB group|interscalene nerve block administered group
9727349|NCT03625102|Experimental|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
9727350|NCT03625102|Experimental|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
9727351|NCT03625102|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, twice a day
9727352|NCT03620539|No Intervention|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
9727353|NCT03620539|Experimental|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
9727354|NCT03618849|Experimental|Sham tDCS|Post initial screening and baseline data collection, all study participants (a single cohort of patients) will receive a single dose of sham tDCS for 20 minutes over the left dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex in conjunction with Mozart piano sonata. For sham tDCS, the current will be ramped up and immediately ramped down for 30 seconds. The sham tDCS session will be preceded and followed by behavioral assessments and EEG recording.
10199294|NCT05163522|Experimental|Part 1 (SAD): Participants receiving VH4004280|
10199295|NCT05163522|Placebo Comparator|Part 1 (SAD): Participants receiving placebo|
10199296|NCT05163522|Experimental|Part 2 (MAD): Participants receiving VH4004280|
10199297|NCT05163522|Placebo Comparator|Part 2 (MAD): Participants receiving placebo|
10199298|NCT05163093||Angle closure glaucoma patients with or without abnormal zonular.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
10199299|NCT05163093||Patients with age-related cataract.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
10199300|NCT05162222|Experimental|Danicamtiv, followed by itraconazole + danicamtiv|
10199301|NCT05162222|Experimental|Danicamtiv, followed by diltiazem + danicamtiv|
9785809|NCT01260350|Experimental|Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
10199302|NCT05160896|Experimental|MSS or MSI-L/pMMR, RAS and BRAF are both wild type|"the primary lesion is located in the left colorectal:~SALIRI plus cetuximab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 cetuximab 500 mg/ m² , iv, day 1~the primary lesion is located in the right colorectal:~SALIRI plus bevacizumab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 Bevacizumab 5 mg/kg, iv, day 1"
10199303|NCT05159063||Right heart catheterization|
10199304|NCT05152810|Experimental|Active Transcranial Magnetic Stimulation|
10199305|NCT05152810|Placebo Comparator|Transcranial magnetic resonance imaging placebo|
10199306|NCT05152004|Experimental|High dose dual therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 750 mg q.i.d for 14 days
10199307|NCT05152004|Active Comparator|Hybrid therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 1 g b.i.d. for 7 days, followed by rabeprazole (Pariet) 20 mg, amoxicillin(Amolin)1 g, clarithromycin (Klaricid) 500 mg, and metronidazole (Flagyl) 500 mg b.i.d. for 7 days
10199308|NCT05151315|Active Comparator|Evolution Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the Evolution Total Knee System
10199309|NCT05151315|Experimental|Evolution with NitrX Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the NitrX Evolution Total Knee System which has the specialized protective coating
10199310|NCT05150717|Experimental|[14C]-Jaktinib|Subjects will receive single dose of [14C]-Jaktinib (Suspension, 100mg/150μCi)
10199311|NCT05142943|Experimental|Visual Illusion (VI and therapeutic exercise program (EP)|"the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes. Then a physical exercise program for the upper extremities will be carried out:~General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~Gross mobility and coordination: ball games.~Fine mobility and coordination: writing tasks, puzzles, abacus ...~Strength exercises: shoulder, elbow, wrist, fingers.~Stretching."
10199312|NCT05142943|Sham Comparator|VI sham and EP|the configuration of the work table will be the same as in real IV, although videos of landscapes will be projected on them without any type of human or animal movement appearing on them. This program will last 10 minutes. Afterwards, a physical exercise program for the upper extremities will be carried out, detailed in Arm I.
10199313|NCT05142943|Experimental|VI|only the visual illusion program will be carried out, detailed in Arm I.
10199314|NCT05142943|Sham Comparator|VI sham|
10199315|NCT05127434|Experimental|mRNA-1345|Single injection of mRNA-1345 on Day 1.
10199316|NCT05127434|Experimental|Placebo|Single injection of mRNA-1345 matching-placebo on Day 1.
10199317|NCT05124509||Three doses of BNT162b2 vaccine|Solid organ transplant patients who received three doses of BNT162b2
10199318|NCT05124509||Two doses of Coronavac and one of BNT162b2 vaccine|Solid organ transplant patients who received two doses of CoronaVac and one dose of BNT162b2
10199319|NCT05117151||Observation|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
10199320|NCT05114603|Experimental|Dose-escalation stage|Iinvestigate the safety and determine the MTD of HLX208. Two dose levels of 600mg and 900 mg are planned for dose finding.
10199321|NCT05114603|Experimental|Dose-expansion stage|Patients with advanced melanoma will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX208.
10199322|NCT05110326|Experimental|ERGON Technique Group|Patients in this group will receive ERGON Technique along with conventional therapy
10199323|NCT05110326|Experimental|Proprioceptive Neuromuscular Facilitation(PNF) stretching Group|Patients in this group will receive Proprioceptive Neuromuscular Facilitation (PNF) stretching along with conventional therapy
10199324|NCT05104775|Experimental|study treatment|Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.
10199325|NCT05100901|Experimental|Oral nutritional supplement|Oral nutritional supplement that contains MAG oil
10199326|NCT05099952|Experimental|Arm I - BBT-CI|Patients participate in BBT-CI over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.
10199327|NCT05099952|Active Comparator|Arm II- therapist|Patients meet with therapist over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.
10199328|NCT05099952|Experimental|Observational Study|Patients wear actigraphy watch and complete sleep log at baseline (over the weekend prior to first day of CRT), and weeks 1, 3, and 6 during treatment. Patients also undergo collection of cheek cell samples and may undergo collection of blood samples at weeks 1, 3 and 6 during treatment. Patients' medical records are also reviewed.
10199329|NCT05096936|Experimental|Pilates PBMT|This group will receive training in the Pilates method associated with the effective application of photobiomodulation.
10199330|NCT05096936|Experimental|Pilates|This group will receive training in the Pilates method associated with the not effective (placebo) application of photobiomodulation.
10199331|NCT05096936|Placebo Comparator|PBMT|This group will receive effective application of photobiomodulation and will not perform the pilates method training
10199332|NCT05091398|Active Comparator|Group I|ultrasound-guided erector spinae block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
10199333|NCT05091398|Active Comparator|Group II|ultrasound-guided paravertebral block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
10199334|NCT05091398|Active Comparator|Group III|ultrasound-guided intercostal nerve block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
10199335|NCT05091281|Active Comparator|Group I|After induction of anesthesia intubation was done by Macintosh laryngoscope
10199336|NCT05091281|Active Comparator|Group II|After induction of anesthesia intubation was done by GlideScope®videolaryngoscope
10199337|NCT05091281|Active Comparator|Group III|After induction of anesthesia intubation was done byC-MAC®(D) videolaryngoscope
10199338|NCT05076409|Experimental|All participants|
10199339|NCT05074524|Experimental|rTMS group|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
10199340|NCT05074524|Sham Comparator|Placebo Group|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
10199341|NCT05073224|Experimental|Postpartum|Participants who are six months postpartum will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless Electromyography (EMG) sensors will be used to record EMG and limb steadiness (via Inertial Measurement Units (IMU). Physical activity will be measured by questionnaire and accelerometer.
10199342|NCT05073224|Active Comparator|Nulligravid|Participants who have never been pregnant will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless EMG sensors will be used to record EMG and limb steadiness (via IMUs). Physical activity will be measured by questionnaire and accelerometer.
10199343|NCT05071040|Experimental|Exercise group|Participants will follow a strength exercise program monitored through the use of a specifically designed smartphone application.
10199344|NCT05071040|No Intervention|Control group|Continue their daily routine without exercise prescription.
10199345|NCT05070338|Experimental|Guideline-Based Nudges|
10199346|NCT05070338|Experimental|Peer-Based Nudges|
10199347|NCT05070338|No Intervention|Control|
10199348|NCT05061823|Experimental|Bintrafusp alfa|
10199349|NCT05060068|Placebo Comparator|Placebo group|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
10199350|NCT05060068|Experimental|Low-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
10199351|NCT05060068|Experimental|High-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
10199352|NCT05038982|Experimental|Prurigo Nodularis|Prurigo Nodularis (PN) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
10199353|NCT05038982|Experimental|Chronic Pruritus of Unknown Origin|Chronic Pruritus of Unknown Origin (CPUO) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
10199354|NCT05033353|Active Comparator|Group I|Mechanical ventilation was adjusted to maintain an EtCO2 of 33-38 mm Hg in group I regional cerebral oxygen monitoring
10199355|NCT05033353|Active Comparator|Group II|Mechanical ventilation was adjusted to maintain an EtCO2 of 39-45 mm Hg in group II regional cerebral oxygen monitoring
10199356|NCT05029219|Experimental|Virtual reality group|To become proficient in lumbar transforaminal epidural blocks, participants receive additional training using virtual reality programs after audiovisual education.
10199357|NCT05029219|Active Comparator|Self study group|In order to become proficient in lumbar transforaminal epidural block, participants have self-study time using books and videos after audiovisual education.
10199358|NCT05028062|Active Comparator|XR-NTX 380 mg, intramuscular injection|Subjects will receive an injection of XR-NTX 380 mg (4 mL) repeated once after 4 weeks.
10199359|NCT05028062|Placebo Comparator|Inactive placebo intramuscular injection|Subjects will receive a placebo injection repeated once after 4 weeks.
10199360|NCT05022342||HR-positive HER2-negative ABC/MBC|Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC)/ metastatic breast cancer (MBC) patients
10199361|NCT05022342||PIK3CA mutation positive|Patients with Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) gene mutation positive
10199362|NCT05022095||SCI Patients with ongoing spasticity|SCI Patients that are either seen in clinical routine due to fillings or controls of their intrathecal injection pumps or stationary patients will be informed about the project, they are granted with enough time to decide whether they want participate or not. After giving Informed Consent they will be administered a set of questionnaires including SCI-SETde, PSFS (adapted to german), SCIM-SR in german as well as self-evaluation of spasticity severity and intensity. The SCI-SETde will be filled in again one week later to evaluate test-retest reliability. Overall, the burden for the patients is kept at minimum. There are no expected risks or harm to the patients.
10199363|NCT05018403|Experimental|AON-D21|Single ascending doses by iv infusion.
10199364|NCT05018403|Placebo Comparator|Placebo|Placebo medication identical in appearance to active.
9727355|NCT03618849|Experimental|1-mA tDCS|Post sham-tDCS, we will determine the eligibility of the participant to receive 1 mA of real tDCS based on the occurrence of adverse events and seizures occurring within 5 days of the sham session. After a minimum of 5 days post-sham stimulation (and typically around 7 days later), the participant will receive a single dose of 1-mA current (for head circumference >52 cm; children with head circumference 43-52cm will receive 0.5-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 1-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 1-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
10199365|NCT05017545|Experimental|Cohort 1 (N=5 Subjects)|"The two investigational agents used in this study are carfilzomib and belatacept.~Per protocol, Carfilzomib administered intravenously:~Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43).~Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99).~Per protocol, Belatacept:~-Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert."
10199366|NCT05017545|Experimental|Cohort 2 (N=10 Subjects)|"The enrollment of ten additional subjects and dosing regimen is dependent on the results in Cohort 1.°~Per protocol, Carfilzomib administered intravenously:~Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43).~Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99).~Per protocol, Belatacept:~-Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert.~° May be modified based on the safety and efficacy analysis of Cohort 1."
10199367|NCT05008575|Experimental|antiCD33 CAR NK cells|After preconditioning with chemotherapy, the antiCD33 CAR NK cells will be evaluated
10199368|NCT04988074|Experimental|De-Escalated Therapy|Surgery (TORS) or Low-dose Radiation Therapy (42 Gy)
9727356|NCT03618849|Experimental|2-mA tDCS|Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current (if head circumference >52cm; children with head circumference 43-52cm will receive 1-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
9727357|NCT03614962|Experimental|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
10199369|NCT04988074|Experimental|Non/Minimally De-Escalated Therapy|Surgery + Post-Operative Radiation Therapy (PORT) or 60 Gy Chemo-Radiation Therapy (CRT)
10199370|NCT04987671|Experimental|Treatment with AMX0035|Two sequential study period. In Period 1, subject receive AMX0035 daily for approximately 14 days. In Period 2, subjects receive AMX0035 twice a day, morning and evening, for up to 25 days.
9727358|NCT03614962|Active Comparator|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
9727359|NCT03614962|Active Comparator|Warmth group|All participants will be offered a hat device that elicits warmth only.
10199371|NCT04985630|Experimental|Mitopure Challenge to assess blood levels of Urolithin A after dietary and Mitopure intake|Mitopure challenge with diet (Pomegranate juice- Before) followed by Mitopure supplementation (After) to compare levels in blood spots of UA-Glucuronide (in ng/mL)
9727360|NCT03614962|Active Comparator|TENS group|All participants will be offered a hat device that elicits TENS only.
9727361|NCT03614962|Sham Comparator|control group|All participants will be offered a hat device that without warmth or TENS output.
9727362|NCT03612648|Experimental|TRI-APBI|"Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR~External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
10199372|NCT04984369|Experimental|Never use other BRAF inhibitor therapy|Never use other BRAF inhibitor therapy
10199373|NCT04984369|Experimental|PD after other BRAF inhibitor therapy N=5~40|PD after other BRAF inhibitor therapy
10199374|NCT04984369|Experimental|SD but intolerant after other BRAF inhibitor therapy|SD but intolerant after other BRAF inhibitor therapy
10199375|NCT04971473|Experimental|rhTSH+Thyroid hormone withdrawal|"rhTSH: rhTSH(0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH.Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration.~Thyroid hormone withdrawal: Patients stop taking thyroid hormone for 14 days, and then monitor the level of thyroid stimulating hormone every week. When TSH>30mU/L, an ablative activity of 131I was administered.and scanning was done 48 hours after the radioiodine administration."
10205471|NCT05206448|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 in first study treatment cycle. Participants who ovulate and do not become pregnant will repeat the same treatment protocol for their next study cycle. Participants who do not ovulate will repeat the protocol with Letrozole dose increase of 2.5 mg daily in the next treatment cycle, to a maximum dose of 7.5 mg in the 3rd cycle.
9727363|NCT03608137|Experimental|Cannabis users|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
9727364|NCT03608137|Active Comparator|Non- cannabis users (control group)|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.
10199376|NCT04964284|Experimental|rhTSH group|Patients received thyroid hormone suppression therapy (Euthyrox) . rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
10199377|NCT04964284|Experimental|Thyroid hormone withdrawal group|After randomization, patients with thyroid hormone withdrawal therapy(i.e. Stop taking thyroid hormone for 14 days, and then monitor the level of thyroid-stimulating hormone every week). When TSH>30mU/L, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
10199378|NCT04960813|Experimental|Kidpower - Structured Games|Structured Games Camp.
10199379|NCT04960813|Active Comparator|Kidpower - Playgroup|Playgroup camp
10199380|NCT04957966|Experimental|Music listening vs. No music listening|Random assignment (50:50) of every participant to one of the following two conditions: Music listening after a stressful/discriminatory event (i.e., intervention condition) or no music listening after a stressful/discriminatory event (i.e., control condition).
10199381|NCT04946396|Experimental|dexmedetomidine intravenous infusion|Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).
10199382|NCT04946396|Sham Comparator|0.9% saline solution intravenous infusion|Patients who will receive continuous infusion of 0.9% saline solution (sham group).
10199383|NCT04936958||patients having had an osteomyelitis since 2017|
10199384|NCT04933344||patients having had BJI or PJI treated with daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia or elevation of CPK
10199385|NCT04927403||Chronic gastroenterological diseases - inpatient stay and day clinic|Irritable Bowel Syndrome, Crohn's disease, Ulcerative colitis
10199386|NCT04927403||Chronic Pain patients - inpatient stay and day clinic|Chronic pain syndrome, Rheumatism, Fibromyalgia
10199387|NCT04927403||Oncological diseases - day clinic|all kinds of oncological diseases
10199388|NCT04927403||post Covid syndrome - inpatient stay|post Covid sydrome
10199389|NCT04926129||Subgroup 1|Participant's eye with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) ≥74 letters (Equivalent to: Snellen 6/9 or 20/32; decimal 0.63; Logarithm of the minimum angle of resolution [LogMAR] 0.2) will be enrolled.
10199390|NCT04926129||Subgroup 2|Participant's eye with ETDRS BCVA 34-73 letters, inclusive (Equivalent to: Snellen 6/12 - 6/60 or 20/40 - 20/200; decimal 0.5 - 0.1; LogMAR 0.3-1.0) will be enrolled.
10199391|NCT04925193|Experimental|Arm 1 SPd|"Selinexor 60 mg PO days 1, 8, 15~Pomalidomide 4 mg PO on days 1-21~Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22~28 day treatment cycles"
10199392|NCT04925193|Experimental|Arm 2 SDd|"Selinexor 80 mg PO days 1, 8, 15~Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles >6~Dexamethasone 40 mg PO or IV days 1, 8, 15, 22~28 day treatment cycle"
10199393|NCT04925193|Experimental|Arm 3 SKd|"Selinexor 80 mg PO days 1, 8, 15~Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.~Dexamethasone 40 mg IV or PO days 1, 8, 15, 22~28 day treatment cycle"
10199394|NCT04925180||Physicians|Physicians who have recently prescribed (e.g., within previous 12 months) CPA monotherapy will be invited to complete a brief web-based questionnaire regarding their knowledge of the revised summary of product characteristics (SmPC) and the direct healthcare professional communication (DHPC).
10199395|NCT04907890||Cases|All survivor patients hospitalised for COVID-19 and previously recruited in the CORIST study
10199396|NCT04907890||Controls 1|Individuals who had a positive diagnosis for SARS-Cov-2 infection in the past (at least 6 months) and that was never hospitalised for COVID-19 as he/she had not severe symptoms.
10199397|NCT04907890||Controls 2|Individuals who was never diagnosed for SARS-Cov-2 infection
10199398|NCT04900844|Experimental|CGuard group|Single experimental arm compared vs. objective performace goal
10199399|NCT04886726|Experimental|PTCY and uhCG/EGF|PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
10199400|NCT04886531|Experimental|A|"Weeks 1-3* patients receive either (a) Neratinib, (b) Letrozole or Anastrozole or (c) Neratinib + Letrozole or Anastrozole Weeks 4-24 patients receive Neratinib + Letrozole or Anastrozole and Trastuzumab~*Starting drug intervention varies for the first 3 weeks depending on arms: a, b, and c by randomization."
10199401|NCT04875676|Active Comparator|Cohort 1 (4-week boost vaccination)|(4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4
9727365|NCT03607890|Experimental|Cohort 1: Nivolumab and Relatlimab|480mg/160mg (co-administered)
9727366|NCT03607890|Experimental|Cohort 2: Nivolumab and Relatlimab|480mg/960mg or 480mg/160mg (sequential administration)
9785810|NCT01260350|Experimental|Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
10199402|NCT04875676|Active Comparator|Cohort 2 (8-week boost vaccination)|(8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8
10199403|NCT04875676|Active Comparator|Cohort 3 (12-week boost vaccination)|(12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12
10199404|NCT04866576|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER: 2 pouches per day, each pouch contains (12-15 gms of fermented soy powder)
10199405|NCT04866576|Placebo Comparator|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
10199406|NCT04856800|Experimental|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). 20 g of whey protein will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
10199407|NCT04856800|Placebo Comparator|Placebo|The placebo will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
10199408|NCT04847128|Experimental|Arm I|Participants receive exercise intervention 3 times weekly for 8 weeks.
10199409|NCT04847128|No Intervention|Arm II|Participants keep sedentary life without exercise for 8 weeks.
9727367|NCT03607058|Active Comparator|Kinect + Exercise Training|Xbox Kinect and exercise training will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. A treatment session in this arm will consist of Kinect games for 40 minutes and exercise training for 20 minutes. In this arm, patients will play each game as two repetitions. Each game lasts about 3-4 minutes, and patients will be seated for resting between the games. After 10 weeks washout period only exercise training will be applied for 8 weeks.
9727368|NCT03607058|Active Comparator|Exercise Training|Exercise training will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 10 weeks washout period exercise training and Xbox Kinect will be applied together for 8 weeks.
10199410|NCT04831788||Adults|Adults older than 50 years of age, residing in the city of Novi Sad, Serbia and providing oropharyngeal and nasopharyngeal swab specimen upon signing informed consent
10199411|NCT04829812||Prospective cohort|Prospective cohort with inclusion of consecutive or pseudo-consecutive patients by vascular specialist at their place of practice. Patient follow-up to assess wound progression and compression tolerance
10199412|NCT04807218|Active Comparator|Nutritional Ketosis Intervention Referral|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
10205472|NCT05206448|Experimental|Letrozole + Clomiphene Citrate|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomiphene Citrate 50 mg orally for 5 days on cycle days 3-7. Participants who ovulate and do not become pregnant will repeat the same treatment protocol for their next study cycle. Participants who do not ovulate will repeat the protocol with Letrozole dose increase of 2.5mg daily in the next treatment cycle to a maximum dose of 7.5 mg in the 3rd cycle, while maintaining the same dose of Clomiphene Citrate.
9727369|NCT03606096|Experimental|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
9727370|NCT03606096|Experimental|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
9727371|NCT03606096|Active Comparator|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
9727372|NCT03606096|Active Comparator|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
9727373|NCT03605927|Experimental|Combination Therapy|"BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.~Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care."
9727374|NCT03605680|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
9727375|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
9727376|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
9727377|NCT03605680|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
9727378|NCT03604640|No Intervention|standard care|
9727379|NCT03604640|Experimental|Physical and educational program|
9727380|NCT03601286|Experimental|Lentiviral vector transduced CD34+ cells|Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
9727381|NCT03595098|Experimental|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
9727382|NCT03595098|Active Comparator|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
9727383|NCT03593525|Experimental|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
9727384|NCT03593525|No Intervention|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
9785811|NCT01260350|Experimental|Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
10199413|NCT04807218|Active Comparator|CHHS Standard Care - Delayed Referral to Nutritional Ketosis Intervention|All subjects will be enrolled in Colorado Heart Healthy Solutions (CHHS), which consists of community health worker (CHW) contact and sessions on: 1) cardiovascular disease knowledge; 2) Health behavior change through skill building to improve diet (e.g., portion sizes, increasing fruit/vegetable intake, reducing intake of sugar sweetened beverages, decreasing fast food meals, etc.), increase physical activity, and improve well-being, tailored to individual subjects' risk profile and self-identified goals; and 3) Connection to services including primary care, mental health services if needed, and relevant community programs to address barriers (e.g. food insecurity, need for legal help) or to promote behavior change (e.g. free/low cost exercise programs).
10199414|NCT04804527|Experimental|Intensified physiotherapy|In addition to usual care physiotherapy patients in the intensified physiotherapy group will receive an extra physiotherapy session of up to 30 minutes on every weekday starting on the first postoperative day. The session will include progressive functional training of basic mobility and walking in the ward delivered by an experienced physiotherapist affiliated with the trial. The aim of this additional session is to improve the functional advances achieved during the earlier physiotherapy session.
10199415|NCT04804527|Active Comparator|Usual care physiotherapy|Patients will receive approximately 30 minutes physiotherapy once daily in the ward delivered by the ward's usual physiotherapists i.e. starting on the first postoperative day and thereafter primarily on weekdays until discharge (a mean of 8.82 days after admission). Usual care physiotherapy is individualized taking the patients ability and previous level of functioning into account and includes 1) progressive functional training of basic mobility e.g. in-out of bed, sit-to-stand and walking including progression in walking aid, stair training if possible, and advices toward better physical functional level, 2) basic bed exercises with progression to standing exercises according to a hand-out training program and recommendations on doing exercises daily and being as physical active as possible during the day.
9982302|NCT05269342|Experimental|the nurse-led counseling and after intervention exercise|"The NUCAI aims to help patients manage themselves physically and psychologically by giving support, education, and exercise tracking.~The participants in the control group were care as usual.Intervention group were the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC."
9727386|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
9727387|NCT03590145||Qatari athletes|Participants meeting general inclusion criteria.
9727388|NCT03583307|Experimental|Sirolimus|
9727389|NCT03575351|Active Comparator|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
9727390|NCT03575351|Experimental|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
9982303|NCT05269329|Experimental|XC8, film-coated tablets, 20 mg/day|
9982304|NCT05269329|Experimental|XC8, film-coated tablets, 40 mg/day|
9982305|NCT05269329|Experimental|XC8, film-coated tablets, 80 mg/day|
9727394|NCT03571776|Active Comparator|Surgery|Laparoscopic ovarian cystectomy
9727395|NCT03571776|Active Comparator|Sclerotherapy|US-aspiration and alcohol sclerosis
9727396|NCT03568760|Experimental|SFA treatment|Semantic feature analysis
9727397|NCT03568760|Placebo Comparator|Comprehension training|Comprehension training
9727398|NCT03568188|Experimental|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
9727399|NCT03568123|Experimental|MC polyethylene bearing|Persona Total Knee System with MC polyethylene bearing
9982306|NCT05269329|Placebo Comparator|Placebo|
9982307|NCT05269173|Active Comparator|Active group(low dose group)|Take 5 tablets each time (including 3 tablets of study drug and 2 tablets of placebo), 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.
9982308|NCT05269173|Active Comparator|Active group(high dose group)|Take 5 tablets of the study drug each time, 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.
9982309|NCT05269173|Placebo Comparator|Control group|Take 5 tablets of the control drug (placebo) each time, 3 times a day, 2.7g a day. Take it with warm water half an hour before meals.
9982310|NCT05268224||Dense Breast|Women mammographically categorized as having either heterogeneously dense or extremely dense breast tissue.
9982311|NCT05268003|Experimental|Ponatinib|Patients will continue to take ponatinib 30mg daily continuously daily from Day 1. On Day 1, 20mg for 1 day, 50mg for 1 day, 100mg for 1 day, 200mg for 1 day, then 400mg daily
9982312|NCT05268003|Experimental|Venetoclax|Patients will continue venetoclax 400mg daily on days 1-14 of each 28-day cycle.
9982313|NCT05268003|Experimental|Mini-hyper-CVD|Chemotherapy will be administered in the inpatient setting, starting on day 1 of each of the cycles 2-8.
9982314|NCT05267834||Positive high-risk HPV|Women with adenocarcinoma of the uterine cervix and positive for high-risk HPV (genotype16/18/31/33/35/39/45/51/52/56/58/59/66/68).
9982315|NCT05267834||Negative high-risk HPV|Women with adenocarcinoma of the uterine cervix and negative for high-risk HPV (genotype16/18/31/33/35/39/45/51/52/56/58/59/66/68).
9982316|NCT05262673|Experimental|CART/CTL/DCvac cells to treat B-ALL|
9727400|NCT03568123|Active Comparator|CR polyethylene bearing|Persona Total Knee System with a CR polyethylene liner.
9727401|NCT03560167|Experimental|AccuCinch® Ventricular Restoration System|
9727402|NCT03554057||Intervention Group|All low-risk patients referred for invasive coronary angiography through the Hamilton General Hospital's Heart Investigation Unit Triage will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification with CCTA at HHS and NHS as an alternative to upfront invasive angiography.
9727403|NCT03554057||Control Group|Intervention sites will act as their own controls: outcomes of all eligible patients in the 24-months prior to the implementation of the intervention will be assessed from a routinely collected health administrative database. Eligible patients not undergoing CCTA (patient or physician refusal, or CCTA not available) will be captured and included in the control group as part of a sensitivity analysis during the intervention period
10199416|NCT04799587|Active Comparator|P6 Accupressure Group|The pressure point will be stimulated by the presence of the magnet when positioned properly on the P6 acupressure point. Additional pressure may be applied as desired by the study subject but is not necessary for P6 stimulation.
10199417|NCT04799587|Sham Comparator|Sham Pressure Point|The sham pressure point (distal to the P6 acupressure point).
9727404|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
9727405|NCT03546894||Any FDA Approved ALK Inhibitor Other Than Crizotinib|The dosage, regimen of any Food and Drug Administration (FDA) approved ALK inhibitor (at any point in therapy) other than crizotinib will be decided by participant's prescribing physician and will not be determined by participation in the study.
9727406|NCT03543943|Experimental|Individualized treatment|The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast after surgery. The ankle is held at maximal plantar flexion. Weight bearing is not allowed. After 3 weeks the cast is removed and the injured leg is transferred to a functional brace with 3 heel wedges. The patient will follow standard functional rehabilitation and the follow-up evaluations.
9727407|NCT03543943|Active Comparator|Control group 1|For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
9727408|NCT03543943|Active Comparator|Control group 2|The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
9727409|NCT03543605|Experimental|PROA Experimental|"It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.~The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.~These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.~They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.~The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period."
10199418|NCT04790695|Experimental|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
9727410|NCT03543605|Other|PROA Control|"The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:~Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.~Presentation of the project by the local team in its own center.~Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.~Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).~Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers."
9727411|NCT03541369|Experimental|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
9727412|NCT03541369|Experimental|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
9727413|NCT03535727|Experimental|Cohort 1|(28 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
10205473|NCT05206396||TIL in breast cancer patients who completed neoadjuvant therapy|"Tumour infiltrating lymphocytes will be examined on pre-existing histopathologic samples.~Data will be extracted from the files of the patients including:~Demographic data, clinicopathologic data, pathologic complete response, and date of last follow up."
10205474|NCT05206357|Experimental|Epcoritamab|Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
10199419|NCT04786067|Experimental|Immunosuppression Taper|Patients included in this arm are kidney transplant recipients with stable kidney function currently on or are converting to a Belatacept based immunosuppression regimen. Eligible patients who are deemed immune quiescent after a 3 month monitoring period will undergo sequential withdrawal of immunosuppression medications over a 12 month period from a three drug regimen to a Belatacept only immunosuppression regimen. During the total 15 month period patients will be monitored with monthly clinic visits, blood draws for routine monitoring as well as donor derived cell free DNA and genetic testing through KidneyCare to monitor immune suppression.
10199420|NCT04775680|Experimental|ADG106 combined with PD-1 antibody Dose Escalation Level 1|
10199421|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Dose Escalation Level 2|
9727414|NCT03535727|Experimental|Cohort 2|(21 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
9727415|NCT03535324|Experimental|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
9727416|NCT03535324|Other|Control|There will be no intervention.
9727417|NCT03533816|Experimental|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
9727418|NCT03533816|Experimental|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
9727419|NCT03533517|Experimental|AccuCinch® Ventricular Restoration System|
9727420|NCT03526874|Experimental|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
9727421|NCT03526874|Placebo Comparator|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
9727422|NCT03520751|Experimental|Dose (8.87e11 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
9727423|NCT03519269|No Intervention|Non robotics-assisted Surgical System|Conventional, non-robotics-assisted total knee surgical system
9727424|NCT03519269|Experimental|Navio™ Robotics-assisted Surgical System|Navio™ Robotics-assisted Surgical System
9727425|NCT03514680|No Intervention|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at three consecutive clinic visits: baseline, visit 2, visit 3.
9727426|NCT03514680|Experimental|Period II|"Consented patients will complete the same battery of assessments from the usual care period at the baseline, visit 2, and visit 3 time points.~Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
9727427|NCT03508518|Experimental|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
9727428|NCT03508518|Active Comparator|Care as usual|"Patient will have usual care :~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
9785812|NCT01260350|Experimental|Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
10199422|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Expansion Phase|
10199423|NCT04760613|Active Comparator|Cannabidiol (CBD)|
10199424|NCT04760613|Placebo Comparator|Placebo (PCB)|
10199425|NCT04757363|Experimental|Nivolumab Combined With FOLFOX and Regorafenib|Each treatment cycle consists of 28 days. Patients will initially receive induction therapy with regorafenib (80 mg on days 1-21 of the 28-day cycle) and nivolumab (240 mg on days 1 and 15 of the 28-day cycle). Starting on cycle 2, day 1, patients will also receive FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h). If the patient is not a good candidate for induction regorafenib and nivolumab (i.e. symptomatic from a large burden of disease), 5-FU and oxaliplatin can be added during cycle 1 at the treating physician's discretion. 39 Patients will continue with this regimen until disease progression, unacceptable toxicity, or development of serious intercurrent illness. Treatment will be performed on the scheduled day (±7-day treatment window).
10199426|NCT04755361|Experimental|Housing Outreach Project - Collaboration (HOP-C) + Treatment as Usual|The treatment condition is HOP-C plus treatment as usual (TAU).
10205475|NCT05206318|Experimental|20 participants with topical cysteamine cream|Participants with post-inflammatory hyperpigmentation will apply topical cysteamine cream for a 16 weeks period.
9727429|NCT03506971|Experimental|Participants|"As part of this research, families will benefit from~pediatric nurse's interventions : home visits by a pediatric nurse who will center around three times: a time of observation of the development and progress of the baby, a time for play with the baby and a time to listening the parents.~psychologist's evaluation and joint home visits : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
9727430|NCT03506971|Other|Control|"psychologist's evaluation : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
9727431|NCT03500939|Experimental|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
9727432|NCT03500939|Active Comparator|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
10199427|NCT04755361|No Intervention|Treatment As Usual|TAU for this population reflects the standard array of services accessed by transitional youth populations. Most will have some contact with a youth worker with ranging focus and intensity (none likely to receive case management at HOP-C intensity), and very few will have any routine contact with other professionals or peer support. They may have some sporadic access to skills development programs and primary healthcare providers with mental health and addictions needs addressed primarily through emergency services at times of crisis.
9727433|NCT03498911|Active Comparator|envelope Coronally Advanced Flap (eCAF)|A mucogingival surgery where an envelope flap is coronally advanced and sutured to cover the mucosal recession
9727434|NCT03498911|Experimental|Modified Tunnel Technique (MTT)|A mucogingival surgery where the gingiva is released without reflecting a flap (as described for tunnel techniques) and then coronally advanced and sutured to cover the mucosal recession
9727435|NCT03498105||Emergency Department (ED)|"450-500 participants who will;~self present to the Emergency Department (ED) will chest pain~be brought in by ambulance to ED with acute chest pain~be referred from Primary care or Urgent care centre with cardiac sounding chest pain"
9727436|NCT03498105||Community Cardiology Service (CCS)|This study group will consist of between 80-100 participants who self present to the Community Cardiology Service (CCS) in Milton Keynes primary care surgery
9727437|NCT03498105||Participants with stable angina|This study group will consist of 450-500 participants with stable angina who have been referred for Stress Echocardiography.
9727438|NCT03498105||Elective Coronary Angioplasty|This study group will consist of between 50-100 participants who will have been referred for elective coronary angioplasty
9727439|NCT03498105||Cardio-toxic Chemotherapy|Consecutive patients being initiated on any of the following medication deemed as cardio toxic and requiring cardiac function will be approached to be recruited into the study.
9727440|NCT03498105||Invasive Coronary Angiography|The dynamics and performance characteristics of the CEB during acute coronary occlusion in patients undergoing invasive coronary angiography.
9727441|NCT03496805|Experimental|MGE group|Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
9727442|NCT03496805|Placebo Comparator|Placebo group|Patients will be randomized to placebo. The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of placebo.
9727443|NCT03494933|Experimental|CRT-P group|Intervention: CRT-P implantation
9727444|NCT03494933|Active Comparator|CRT-D group|Intervention: CRT-D implantation
9727445|NCT03492918|Experimental|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
9727446|NCT03488693|Active Comparator|No Regional Radiotherapy|A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
9727447|NCT03488693|Active Comparator|Regional Radiotherapy|A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
9727448|NCT03487666|Experimental|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
10199428|NCT04738292|Experimental|Onapristone In Combination with Fulvestrant|"All participants will receive onapristone 50 mg p.o. BID (twice) daily and fulvestrant (500 mg) intramuscular injection on days 1, 15 (cycle 1), then two weeks later (cycle 2, day1), then once every 28 days thereafter. A cycle is defined as 28 days.~There will be no breaks between dosing cycles."
9727449|NCT03487666|Active Comparator|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
9727450|NCT03487666|Experimental|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
9785813|NCT01260350|Experimental|Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac|Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
10199429|NCT04735536|Experimental|Active Treatment- CT1812|Active Treatment- CT1812 at a dose of 300mg
10199430|NCT04735536|Placebo Comparator|Control - Placebo|Drug: Placebo Non-active study drug
10199431|NCT04724603||patients having had avderse event after phagotherapy for bone or joint infection|
10199432|NCT04715243|Other|control|Face-mask NIV is the standard of care
10199433|NCT04715243|Active Comparator|intervention 1|High flow nasal cannula
10199434|NCT04715243|Active Comparator|Intervention 2|Helmet NIV
10199435|NCT04709458|Experimental|TBX-2400 treatment|Single intravenous infusion of TBX-2400
10199436|NCT04702152|Experimental|Experimental group|This is a within-subject study with a single group of participants
9727451|NCT03485950|Experimental|Group I (ceftolozane-tazobactam)|Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.
9727452|NCT03485950|Active Comparator|Group II (standard of care antibiotic treatment)|Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.
9727453|NCT03483337||recurrent or metastatic head and neck cancer patients|Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest DWI scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at Memorial Sloan Kettering's main campus, will also be imaged weekly during their course of treatment.
9727454|NCT03483337||head and neck cancer or thyroid cancers (differentiated and undifferentiated)|All patients, irrespective of treatment regimen, will be imaged on a 1.5T or 3T MR scanner prior to treatment initiation. Follow up imaging for patients undergoing surgery only will be as per clinical standard of care and not on this protocol. Patients undergoing treatment in radiation oncology and/or medicine will have imaging studies at two months (60 days) and four months (120 days) after completion of all treatments, including systemic therapy if (+/- 2 weeks or 14 days). Imaging on or immediately after systemic therapy treatment (+/- 2 weeks or 14 days) to derive MRI biomarkers indicative of therapeutic mechanisms of action or efficacy will also be performed. Patients who will be receiving radiation therapy treatment will also have recommended weekly imaging during their course of treatment.
9727455|NCT03473366|Experimental|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
9727456|NCT03473366|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
9727457|NCT03472612|Experimental|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
9727458|NCT03467958|Experimental|Administration of oral Ozanimod|
9727459|NCT03467867|Experimental|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
9727460|NCT03464916|Experimental|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
9727461|NCT03464344|Other|Patients with cortical superficial siderosis.|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
9727462|NCT03464344|Other|Patients without cortical superficial siderosis|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
9727463|NCT03461835|Active Comparator|M4|High risk classification if the chance of the PUL being an EP ≥5 %; a calculation based on the average value of the two hCG and the ratio of these two hCG (0 h/48 h). Otherwise a low risk classification is made and a predicted outcome of either an IUP or failed PUL is presented.
9727464|NCT03461835|Active Comparator|NICE|High risk classification if the change in rising hCG levels ≤ 63 % or the change in declining hCG ≤ 50 %. If these cut-offs are exceeded the PUL is classified as low risk and predicted to be either an IUP or failed PUL depending on rising or declining hCG levels.
9727465|NCT03457701|Experimental|rhEPO+57Fe followed by Daprodustat+58Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine [H2] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
10199437|NCT04699630|Experimental|Part A|Participants will receive 5.6 mg/kg U3-1402 intravenously on day 1 every 3 weeks. All participants will undergo pre-treatment biopsies. (An archival tissue sample taken within two months of treatment should be provided if it is not medically feasible to provide a pre-treatment biopsy). Up to 60 participants will be enrolled into this arm.
10199438|NCT04699630|Experimental|Part B|Participants will receive 5.6 mg/kg U3-1402 intravenously on day 1 every 3 weeks. Part B will enroll additional 20 participants in each subgroup that will be defined from Part A (based on ER/PR/HER2/HER3 expression). A total of up to 60 participants (i.e., maximum of 3 subgroups) will be enrolled in Part B.
10199439|NCT04681417|Experimental|Study 1: Melphalan or Melphalan + Topotecan|Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
10199440|NCT04681417|Other|Study 2: Etoposide, carboplatin and vincristine|Neoadjuvant chemotherapy involves 2 to 6 cycles of combined etoposide, carboplatin and vincristine in association with ophthalmologic treatments.
10205476|NCT05206318|Sham Comparator|20 participants with topical vehicle control cream|Participants with post-inflammatory hyperpigmentation will apply topical vehicle-control cream for a 16 weeks period.
9727466|NCT03457701|Experimental|rhEPO+58Fe followed by Daprodustat+57Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
10199441|NCT04670042|Experimental|SPRINT® Peripheral Nerve Stimulation (PNS) System|SPRINT PNS System will be offered to patients with postoperative knee pain following primary unilateral total knee arthroplasty (TKA) who meet eligibility criteria and consistent with established coverage policy. SPRINT PNS System will be implanted for 60 days. At the discretion of the physician, the first lead may be placed to stimulate the nerve innervating the region of greatest pain. If pain is not adequately addressed by the first lead when assessed at 10 days, a second lead may be placed approximately 2 weeks following the initial lead placement.
10199442|NCT04669704|Experimental|Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
10199443|NCT04669704|Active Comparator|Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
10199444|NCT04657640|Experimental|weekly iron and folic acid supplementation (IFA)|
9727467|NCT03457701|Experimental|Daprodustat+57Fe followed by rhEPO+58Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
9727468|NCT03457701|Experimental|Daprodustat+58Fe followed by rhEPO+57Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
9727469|NCT03455465||No intervention|Patients in this arm will not be approached by community health workers during their visit to the Emergency Department.
9727470|NCT03455465||Community Health Worker Program|Participants in this group will be approached by a community health worker during their visit to the Emergency Department with the goal of enrolling them in a comprehensive post-discharge program.
9727471|NCT03452319|Experimental|Pretraining|Increased physical activity daily Daily strength training Daily inspiratory and expiratory muscle training Standard care during hospital stay and continued training after discharge.
9727472|NCT03452319|Active Comparator|Usual care treatment|Standard care including preoperative information and postoperative breathing exercises and mobilization during hospital stay.
9727473|NCT03435536|Experimental|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
9727474|NCT03435458|Experimental|Balloon catheter + oral misoprostol|
10199445|NCT04657640|Experimental|daily multiple micronutrient supplement (MMS)|
10199446|NCT04657640|No Intervention|control|
9727475|NCT03435458|Active Comparator|Oral misoprostol alone|
9727476|NCT03434444|Active Comparator|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M)
9727477|NCT03434444|Active Comparator|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -6M
9727478|NCT03434444|Active Comparator|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M) plus propranol (10 -6M)
9727479|NCT03434444|Active Comparator|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
9727480|NCT03434444|Active Comparator|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -6M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
9727481|NCT03434444|Active Comparator|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M) plus propranolol (10 -6M)
9727482|NCT03431948|Experimental|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
9727483|NCT03431948|Experimental|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
10199447|NCT04651088|Placebo Comparator|Metabolic diet|Controlled metabolic diet arm.
9727484|NCT03429296|Experimental|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
9727485|NCT03429296|No Intervention|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
9727486|NCT03427463|Active Comparator|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
9727487|NCT03427463|Experimental|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
9727488|NCT03426891|Experimental|Combination Therapy|Pembrolizumab and Vorinostat Combined with Temozolomide and Radiotherapy. There are two parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). Dose Expansion: Twenty participants will be treated with vorinostat at the maximum tolerated dose (MTD) from dose escalation phase, pembrolizumab, temozolomide and radiation. During the maintenance phase, participants will receive Temozolomide (for the first 6 months), vorinostat (for 12 months), and pembrolizumab (for 12 months).
9727489|NCT03424850|Experimental|HDR brachytherapy - 21 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.
9727490|NCT03424850|Experimental|HDR brachytherapy - 23 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.
10199448|NCT04651088|Active Comparator|Potassium citrate|
9727491|NCT03424850|Experimental|HDR brachytherapy - 25 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.
9727492|NCT03424421|Experimental|subscapular sling|semitendinosus subscapular sling procedure
9727493|NCT03417544|Experimental|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:~Atezolizumab (IV) every 3 weeks (q3w)]~Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)~High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
9727494|NCT03415425|Active Comparator|Usual Care|The current version of the alert will fire for this arm of the study.
9727495|NCT03415425|Active Comparator|Alert Iteration|A modified version of the alert will fire for this arm of the study.
9727496|NCT03414905||Aspira Catheter & Drainage System|"Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1~The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
9727497|NCT03414424|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
9727498|NCT03410615|Active Comparator|Radiation/Cisplatin|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Cisplatin IV 100 mg/m2 days 1, 22, 43 concurrently with RT"
9727499|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Durvalumab IV 1500 mg q4 weekly for 6 doses."
9727500|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab/Tremelimumab|ARM CLOSED TO ACCRUAL WITH AMENDMENT #1
10199449|NCT04651088|Active Comparator|Sodium Bicarbonate|
10199450|NCT04651088|Active Comparator|Litholyte arm|
9780920|NCT01134627|Experimental|Minocycline group|
10199451|NCT04651088|Active Comparator|Crystal Lite|
9780921|NCT01134627|Placebo Comparator|Placebo Group|
9780922|NCT01134705|Experimental|BDP HFA 320 µg/day|During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
10199452|NCT04651088|Active Comparator|Potassium Bicarbonate|
10199453|NCT04645017|Experimental|Intergenerational Music Program|An intergenerational music program will be administered by adolescent musicians for older adults with early-stage cognitive decline.
10199454|NCT04636203||General population|A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate.
10199455|NCT04636203||Healthcare workers (HCWs)|All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects.
10199456|NCT04631796|Experimental|LID020098|Lehfilcon A contact lenses worn in both eyes for 2 weeks. Lenses will be removed nightly for cleaning and disinfection.
10199457|NCT04625478||Patients having had an osteo-articular infection with Stahylococcus|Patients having had an osteo-articular infection with Stahylococcus managed at the Croix Rousse hospital
10199458|NCT04617756|Experimental|Durvalumab+Gemcitabine/Cisplatin or with Gemcitabine/Carboplatin|This is a single arm including 2 different cohorts : Cohort 1 includes patients on 40mg/ML Gemcitabine/50mg Cisplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles and Cohort 2 includes patients on 40mg/ML Gemcitabine/450mg Carboplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles..
10199459|NCT04595513|Experimental|Stage 1 Open Label|Phase I/II, open-label PK and initial safety analysis. TAVT-18 administered orally twice/daily to achieve precision dosing target of 10 ng/ml. Whole blood sirolimus levels are assessed at defined intervals on days 1, 7, and 14. After day 14, participants can elect to continue open-label treatment with TAVT-18 until 12 months of age. Final developmental outcomes are assessed at 24 months of age.
10205477|NCT05206305|Experimental|AD Patients|Patients with Alzheimer's Disease, as verified by positive A(beta)-PET and/or CSF tau/A(beta) biomarkers, who will receive one hour daily gamma frequency sensory stimulation from the investigational device for an 8 week period.
9727501|NCT03406975|Placebo Comparator|Control Group: Lifestyle Modification|Participants randomized to the control group (lifestyle intervention only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. Control group participants who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL or have a BMI >30 measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program for 12 months.
9727502|NCT03406975|Active Comparator|Treatment Group: ESG Procedure|Participants randomized to the treatment group will proceed to have the Overstitch Edoscopic Sleeve Gastroplasty (ESG) at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. ESG patients who have not achieved >25% EWL at the end of Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
9727503|NCT03404518|Experimental|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
9727504|NCT03404518|Active Comparator|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
9727505|NCT03402841|Experimental|Olaparib|"Olaparib will be supplied as film-coated tablets containing 150 mg or 100 mg of olaparib.~Patients will be administered olaparib orally twice daily (bid) at 300 mg."
9727506|NCT03391635|Experimental|Electroacupuncture|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand needles (0.30×50mm or 0.30×70mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.After acupuncture，the needle handle will be connected with the electrode in the electroacupuncture instrument.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 0.1mA-1.0mA."
9727507|NCT03391635|Active Comparator|TranscutaneousElectricNerveStimulation|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 2mA-5mA."
9727508|NCT03388775||Patients with deep venous thrombosis|"Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.~Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications."
9727509|NCT03376672|Experimental|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
9727510|NCT03376672|Experimental|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
9727511|NCT03376672|Experimental|Standard and low risk maintenance arm|Lenalidomide
9727512|NCT03375723|Experimental|Information on anatomy and physiology, and breathing technique|"Information on anatomy and physiology, and breathing technique~Information about anatomy~Information about physiology~Breathing technique"
10199460|NCT04589832|Experimental|Study Treatment Arm|Phase 1b will determine the MTD of PAC-1 in combination with entrectinib. Study treatment will include: PAC-1 will be taken orally on Days 1-21 and Entrectinib will be taken orally on Days 1-28 of each 28-day cycle. Treatment will continue until disease progression (based on RECIST 1.1 criteria), unacceptable toxicity, subject withdrawal of informed consent, or subject death either from progression of disease, the therapy itself, or from other causes.
9727513|NCT03375723|Active Comparator|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
9727514|NCT03374800|Placebo Comparator|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
9727515|NCT03374800|Active Comparator|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
9727516|NCT03370757|Active Comparator|3-hour bundled care|Infants in this group will have their diaper changed every 3 hours during 3-hour bundled care.
9727517|NCT03370757|Active Comparator|6-hour bundled care|Infants in this group will have their diaper changed every 6 hours.
9727518|NCT03370224|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
9727519|NCT03370224|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
9727520|NCT03367312|Experimental|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
9780923|NCT01134705|Placebo Comparator|Placebo|During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
10205478|NCT05206292|Other|Patient cohort|There is only one patient arm. It corresponds to the cohort of included patients, all of whom had psychotic disorders with no known organic etiology.
10205479|NCT05206253|Experimental|Whole egg powder|Dietary supplementation with whole egg powder after resistance training sessions
10205480|NCT05206253|Active Comparator|Whey protein powder|Dietary supplementation with whey protein powder after resistance training sessions
10205481|NCT05206253|Placebo Comparator|Maltodextrin placebo|Dietary supplementation with maltodextrin placebo after resistance training sessions
9727521|NCT03361852|Experimental|Neo Vax|"Neo Vax is injected into up to 4 different anatomic site.~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~Within +/-3 days of the scheduled administration date for days 15 and 22~Within +/-7 days of days 78 and 134.~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
9727522|NCT03361852|Experimental|NeoVax and pembrolizumab|"Neo Vax is injected into up to 4 different anatomic site.~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,~Within +/-3 days of the scheduled administration date for days 15 and 22~Within +/-7 days of days 78 and 134.~Patients will receive pembrolizumab every 3 weeks starting on day 78~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
9727523|NCT03358706|Experimental|Crohn's Disease or Ulcerative Colitis Participants: Ustekinumab + Probe Cocktail|Participants will receive a single Intravenous (IV) infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8 and a ustekinumab 90 milligram (mg) maintenance dose via subcutaneous (SC) route on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator. The probe cocktail (2 milligram [mg] of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) will be administered orally on Days 1, 22, and 113.
9727524|NCT03358706|Experimental|Healthy Participants: Probe Cocktail|Participants will receive the probe cocktail (2 mg of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) orally on Day 1.
9727525|NCT03350516|Experimental|Daily 500 mg Calcium|
9727526|NCT03350516|Active Comparator|Daily1500 mg Calcium (Standard dose)|
9727527|NCT03349528|Experimental|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
9727528|NCT03349528|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
9727529|NCT03323476|Experimental|Discontinuation of maintenance treatment|
9727530|NCT03323476|Active Comparator|Maintenance of immunosuppressive treatment|
9727531|NCT03322865|Experimental|One Arm|Obinutuzumab i.v.
9727532|NCT03318094|Placebo Comparator|Intact Day|Saline
9727533|NCT03318094|Experimental|Blocked Day|Phentolamine
9727534|NCT03318094|Active Comparator|Vasodilator Comparison|Sodium Nitroprusside
9727535|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
9727536|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
9727537|NCT03314181|Active Comparator|Arm H: DVd Dose|Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1
9727538|NCT03314181|Experimental|Arm G: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
9727539|NCT03314181|Experimental|Arm F: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
9727540|NCT03314181|Experimental|Arm E, Part 2b: VenDVd Dose Expansion|Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
9727541|NCT03314181|Experimental|Arm D, Part 2a: VenDVd Dose Escalation|Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
9727542|NCT03314181|Experimental|Arm B, Part 1b: VenDd Dose Expansion|Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
9780924|NCT01134731|Experimental|paliperidone|dose escalation , levels 1-5 daily dosing ranged from 1-5mg
10199461|NCT04576819||Sepsis cohort|"Inclusion criteria~Patients meeting the Sepsis-3 definition of sepsis or septic shock (the sequential organ failure assessment (SOFA) score will be used for organ failure assessment for Sepsis-3 criteria)~Treatment with an institutional, evidence-based guideline management bundle for sepsis~Within 24 hrs of sepsis recognition~Exclusion criteria:~alternative/confounding diagnosis causing shock (e.g., myocardial infarction or pulmonary embolus),~uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),~advanced directives limiting resuscitative efforts,~organ transplant recipient on immunosuppressive agents,~known pregnancy,~inability to obtain informed consent,~HIV/AIDS with CD4 count < 200,~absolute neutrophil count < 500"
9727543|NCT03314181|Experimental|Arm A, Part 1a: VenDd Dose Escalation|Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
9727544|NCT03312634|Experimental|Palovarotene Chronic/Flare-Up Regimen|Subjects will receive 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing will be adjusted for weight in skeletally immature subjects.)
9727545|NCT03303989|Experimental|pegloticase + MMF|Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.
9727546|NCT03303989|Placebo Comparator|pegloticase + placebo|Participants randomized to this arm will receive pegloticase + placebo
9727547|NCT03301038|Experimental|All Subjects|
9727548|NCT03298659|Experimental|Active iFR-guided revascularization|Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
9727549|NCT03298659|Active Comparator|Deferred CMR-guided revascularization|Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
9727550|NCT03297606|Experimental|Group 1|VEGFR1, VEGFR2, VEGFR3
9727551|NCT03297606|Experimental|Group 2|BCR-ABL, SRC
9727552|NCT03297606|Experimental|Group 3|ALK, ROS1, MET
9727553|NCT03297606|Experimental|Group 4|KIT, PDGFRA, PDGFRB, ABL1
9982317|NCT05261464|Active Comparator|Metoprolol protocol|"Metoprolol tartrate 50 mg will be given if patient's HR is more than 60 bpm.~Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 50-mg metoprolol will be given.~If patient can not reach targeted HR at next 30 minutes, then third dose of 50-mg metoprolol will be given.~If patient can not reach targeted HR at next 30 minutes, then fourth dose of 50-mg metoprolol will be given.~If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 200 mg metoprolol tartrate, then total time will be recorded and patient will proceed to CCTA.~If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
10199462|NCT04575181|Experimental|NNC0286-0965|NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial
10199463|NCT04575181|Active Comparator|Insulin glargine|Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial
10199464|NCT04568642|Active Comparator|Conventional|Device: conventional FiO2 will be selected by the clinician according to the SpO2 target
10199465|NCT04568642|Experimental|Closed-loop|Device: conventional FiO2 will be selected by the closed-loop algorithm according to the SpO2 target
10199466|NCT04566029||Cases|Patients who have been responding to treatment for a long time
10199467|NCT04566029||Controls|Patients who do not respond to treatment
10199468|NCT04564105|Other|Staff of the ICU|The whole staff (nurses and doctors) of the ICU will be recruited to this trial. When they give their informed consent, video-recording of the intubations will be started. After 20 videos, simulations will be run. Also simulations will be recorded. Thereafter 20 further real-life intubations will be recorded. Staff intubating patients before and after won't be same but they will be adjusted for experience related to intubations.
10199469|NCT04560881|Experimental|Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
10199470|NCT04560881|Placebo Comparator|Placeboof Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
10199471|NCT04521608|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants enrolled in the intervention arm will be offered a Home-based pulmonary rehabilitation program with health coaching.
10199472|NCT04521608|No Intervention|Control- Choice|This arm receives the standard of care which includes the choice of PR at a facility or through telehealth. Center based PR involves attending a medical center gym where they can do exercises and receive disease specific education. Telehealth PR is delivered virtually through the computer or telephone.
9727554|NCT03297606|Experimental|Group 5|EGFR
9727555|NCT03297606|Experimental|Group 6|high mutation burden, POLE, POLD1
9727556|NCT03297606|Experimental|Group 7|BRCA1, BRCA2, mutations in HRD
9727557|NCT03297606|Experimental|Group 8|CDKN2A, CDK4, CCND1, SMARCA4
9727558|NCT03297606|Experimental|Group 9|CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
9727559|NCT03297606|Experimental|Group 10|AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
9727560|NCT03297606|Experimental|Group 11|ERBB2
9727561|NCT03297606|Experimental|Group 12|BRAFV600
9727562|NCT03297606|Experimental|Group 13|PTCH1, SMO
9727563|NCT03289143|Experimental|Dose 1 Semorinemab|
9727564|NCT03289143|Experimental|Dose 2 Semorinemab|
9727565|NCT03289143|Experimental|Dose 3 Semorinemab|
9727566|NCT03289143|Placebo Comparator|Placebo|
9727567|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR <60ml/min/1.73m2, including those on dialysis
9727568|NCT03285854||Healthy age and gender matched children|"All children <18 years~Normal renal function (eGFR 90-120ml/min/1.73m2 [calculated by Schwartz formula] in children >1 year and serum creatinine <35μMol/L in children <1 year)~Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
9727569|NCT03283605|Experimental|Durvalumab + tremelimumab and SBRT|All subjects will receive durvalumab (1500 mg IV q4week) and tremelimumab (75mg q4week) for 4 doses, followed by durvalumab alone (1500 mg IV q4week) until disease progression, unacceptable toxicity or patient withdrawal. SBRT will be administered between cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
10199473|NCT04513665|Experimental|Stage 1|Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants.
9727570|NCT03270020|Experimental|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML [Xgeva]
9727571|NCT03266783|Active Comparator|Apixaban group|10 mg PO BID for 1 week, then 5 mg PO BID for 3 months of treatment
9727572|NCT03266783|Active Comparator|Rivaroxaban group|15 mg PO BID for 3 weeks, then 20 mg PO OD for 3 months of treatment
9727573|NCT03257579|Experimental|90 Day Supply|Intervention: At Hamilton Health Sciences a policy change implementing a standardized discharge prescription form of a 90-day supply with 3 repeats for all cardiac medications available on all wards where MI patients are managed.
9727574|NCT03257579|Experimental|Education Alone|At St. Joseph's Hospital and Niagara Health System education regarding the benefits of lengthening prescriptions to a 90 day supply with 3 repeats for all cardiac medications will be implemented.
9727575|NCT03257579|No Intervention|Control|Remaining Ontario cardiac sites will receive usual care and act as concurrent control group.
9727576|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
9727577|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
9727578|NCT03253679|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9727579|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
9727580|NCT03246841|Other|Analysis of the gene panel|The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.
9727581|NCT03244826|Experimental|Shared Care|"For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.~From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.~Shared Care include the following~Formal Care Coordination Plan~Patient Engagement and Education~Local Oncologist Engagement and Education~Patient/Local Oncologist/Transplant Oncologist Web Portal"
9727582|NCT03244826|Other|Usual Care|"Patients receive all follow-up care at DFCI only, which is currently the Standard Care.~Majority of routine visits in first 180 days will be at DFCI."
9727583|NCT03244826|Other|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
9727584|NCT03238053|Active Comparator|Menopausal Laser|20 women with vaginal laser treatment
9727585|NCT03238053|Sham Comparator|Menopausal sham|20 women with probe, no active laser ray
9727586|NCT03238053|Active Comparator|breast cancer laser|20 women with breast cancer with vaginal laser treatment
9727587|NCT03238053|Sham Comparator|breast cancer sham|20 women with breast cancer with vaginal probe, no active laser rays
9727588|NCT03238053|Active Comparator|endometrial cancer laser|20 women with endometrial cancer with vaginal laser treatment
9727589|NCT03238053|Sham Comparator|endometrial cancer sham|20 women with endometrial cancer with vaginal probe, no active laser rays
9727590|NCT03238053|Active Comparator|overactive bladder laser|20 women with overactive bladder with vaginal laser treatment
9727591|NCT03238053|Sham Comparator|Overactive bladder sham|20 women with overactive bladder with vaginal probe, no active laser rays
9727592|NCT03233633|Other|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
9727593|NCT03218683|Experimental|Monotherapy AZD5991|Dose escalation - multiple dose levels
9727594|NCT03218683|Experimental|Monotherapy AZD5991 expansion|Dose expansion
9727595|NCT03218683|Experimental|AZD5991 + venetoclax|Dose escalation - multiple dose levels
9727596|NCT03217357|Active Comparator|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
9727597|NCT03217357|Placebo Comparator|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
9727598|NCT03217097|Experimental|Unmethylated MGMT NET - OX|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
9727599|NCT03217097|Active Comparator|Unmethylated MGMT NET - ALKY|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
10199474|NCT04513665|Experimental|Stage 2|If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy.
9727600|NCT03217097|Experimental|Methylated MGMT NET - OX|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
9727601|NCT03217097|Active Comparator|Methylated MGMT NET - ALKY|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
10199475|NCT04510168||MRI Only|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at least 50-60 people with dementia (as determined by the ongoing NOMAS procedures).
10199476|NCT04510168||MRI and PET|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at 20 participants with dementia and 40 participants without (as determined by the ongoing NOMAS procedures). In addition to MRI, participants in this group will have three PET studies.
10199477|NCT04509284|Experimental|Training|Participants with persistent pain after breast cancer treatment will receive 24 sessions of individualized progressive total body resistance training, supervised by a certified strength and conditioning specialist.
10199478|NCT04509284|Other|Control|Participants with persistent pain after breast cancer treatment will be instructed to continue their everyday lifestyle and be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
10199479|NCT04501562||Subject|
9727602|NCT03214887|Experimental|RV-P1501-4|Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
9727603|NCT03214887|Experimental|RV-P1501-5|Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
9727604|NCT03214887|Experimental|RV-P1501-6|Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution
9727605|NCT03205475|Active Comparator|A. Above Fidelity Phase 1 and Above Fidelity Phase 2|Alternating coaching and streamed or video feedback each week through phase 1, moves to video feedback only for phase 2.
9727606|NCT03205475|Active Comparator|B. Below Fidelity Phase 1 and Above Fidelity Phase 2|Receive weekly coaching in phase 1, move to video feedback only in phase 2
9727607|NCT03205475|Active Comparator|C. Above Fidelity Phase 1, Below in Phase 2- Add Refresher|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
9727608|NCT03205475|Active Comparator|D. Above Fidelity Phase 1, Below in Phase 2- Add Peer|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
9727609|NCT03205475|Active Comparator|E. Below Fidelity Phase 1, Below in Phase 2- Add Refresher|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
9727610|NCT03205475|Active Comparator|F. Below Fidelity Phase 1, Below in Phase 2- Add Peer|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
9727611|NCT03203200|Experimental|health literacy and technology skill building|ZETRA cognitive behavioral and structural
9727612|NCT03203200|No Intervention|Standard Counselling|Standard of care prevention counselling
9727613|NCT03199040|Experimental|Neoantigen DNA vaccine + Durvalumab|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days~For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm."
9727614|NCT03199040|Experimental|Neoantigen DNA vaccine|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days"
9727615|NCT03195699|Experimental|Dose escalation study|"In a 3 + 3 cohort design, three patients are initially enrolled into a given dose cohort. If there is no DLT observed in any of the first three subjects, the trial proceeds with enrolling additional subjects into the next higher dose cohort. If one subject develops a DLT at a specific dose, an additional three subjects are enrolled into that same dose cohort. Development of DLTs in >1 of 6 subjects in a specific dose cohort will determine the MTD and no further dose escalation is done.~Dose Level/TTI-101 (mg/kg/day) administered in divided doses every 12 hours 1/3.2 2/6.4 3/12.8 4/25.6~At the end of the dose escalation phase of the study, the investigators will determine the characteristics of the patients who will be enrolled at the expansion phase of the study."
9727616|NCT03191812|Sham Comparator|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
10199480|NCT04501120|Experimental|APG2575 single agent|APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.
9727617|NCT03191812|Experimental|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
9727618|NCT03191812|Experimental|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
9727619|NCT03191812|Experimental|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
9727620|NCT03187509|Experimental|Weight-Based Torsemide Group|Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
9727621|NCT03187509|Active Comparator|Standard Outpatient Management Group|Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
10199481|NCT04501120|Experimental|APG2575+ reduced-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT.
10199482|NCT04501120|Experimental|APG2575+ standard-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT.
10199483|NCT04501120|Experimental|APG2575+ AZA|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA.
9727622|NCT03181984|Experimental|Hemoporfin|
9727623|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
9727624|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
9727625|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
9727626|NCT03156504|Experimental|Ketamine|Subjects will receive three IV Ketamine Hydrochloride infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers).
9727627|NCT03155100|Experimental|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
9727628|NCT03142893|Experimental|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule & start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection & last blood sample"
9727629|NCT03142893|Experimental|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
9727630|NCT03142893|Experimental|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill & start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection & last blood sample"
9727631|NCT03142893|Experimental|Adrenal/Testis Condition|"10pm - Ganirelix Injection & Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
9727632|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
9727633|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
9727634|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
9780925|NCT01134731|Active Comparator|lithium|dose escalation, level 1-5 daily dosing 300-1500mg
9780926|NCT01134731|Placebo Comparator|placebo|1-5 placebo capsules
10199484|NCT04498715|Experimental|OSTEOSYNTHESIS+SYSTEMIC ZOLEDRONIC ACID|After osteosynthesis, systemic Zoledronic acid 4mg (or any other bisphosphonate) will be given intravenously between day 7-14 post operation.
10199485|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)|During osteosynthesis, cerament BVF will be used for the augmentation of the screw.
10199486|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)+LOCAL ZOLEDRONIC ACID|During osteosynthesis, 5 or 10 mL cerament BVF mixed with 1 or 2 mg Zoledronic acid (or any other bisphosphonate) will be used for the augmentation of the screw.
10199487|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)+SYSTEMIC ZOLEDRONIC ACID|During osteosynthesis, cerament BVF will be used for the augmentation of the screw. Then systemic Zoledronic acid 4mg (or any other bisphosphonate) will be given intravenously between day 7-14 post operation.
10199488|NCT04497961|Experimental|Lenalidomide maintenance|Those randomized to lenalidomide maintenance will receive a maintenance dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.
10199489|NCT04497961|Experimental|Daratumumab maintenance|Those randomized to receive daratumumab maintenance will receive 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.
10199490|NCT04496739|Active Comparator|Group I (educational materials)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website.
10199491|NCT04496739|Experimental|Group II (educational materials, decision support, interview)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the EHR. A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual.
10199492|NCT04483583|Active Comparator|ABCD-GENE >10 - Clopidogrel|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
10199493|NCT04483583|Experimental|ABCD-GENE >10 - Ticagrelor|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
10199494|NCT04483583|Active Comparator|ABCD-GENE <10 - Clopidogrel|Patients with an ABCD-GENE<10 will be treated with clopidogrel (75 mg/qd) for 30 days.
10199495|NCT04474379|Experimental|Strategy Training|Consists of 8-90 minute sessions over 4 weeks. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the therapist teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based) and instructs in their use before and during the training games. In sessions 3-8, the tester tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. After completing the training games, the therapist and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the therapist helps the participant develop written action plans to do so. Plans and goals are reviewed and modified, if necessary, at each session.
10199496|NCT04474379|No Intervention|Process Training|Consists of 8, 90 minute sessions over 4 weeks. In sessions 1 and 2, the therapist teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3-8, the tester tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the therapist. Feedback on accuracy is provided after each training game. This is typical of a process training approach and expects that practice of the training tasks will improve prospective memory ability per se or that participants will develop effective strategies for completing prospective memory tasks on their own. At the end of each session, the therapist reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Goals are reviewed and modified if necessary.
10199497|NCT04471727|Experimental|Part 1 (Dose Escalation)|HPN328 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.
10199498|NCT04471727|Experimental|Part 2 (Dose Expansion)|HPN328 is IV administered once weekly for about 1 hour at the recommended phase 2 dose (2) established in Part 1.
10199499|NCT04471532|Experimental|Behavior change intervention|A 3-month behavior change intervention i.e. one initial, face-to-face, physical activity counselling and two telephone-assisted counselling.
10199500|NCT04471532|No Intervention|Control|No attention
10199501|NCT04470232||Patients with coxofemoral pathologies|"For the transcultural validation, a french version of the 2 self-assessment questionnaires, SUSHI-score and the HOOs-12 score will be produced.~For the psychometric validation, 120 patients with coxofemoral pathologies will pass the two questionnaires. The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
10199502|NCT04469348|Experimental|Healthy volunteers|"Healthy volunteers will be included. They will have nasal swab at the inclusion visit to detect contamination of S. Aureus.~If contamination of S. Aureus: they will have 12 follow-up visits (1 per month)~If no contamination of S. Aureus: their participation stops"
10199503|NCT04469205|Experimental|Intervention Group|intervention group that will receive return-to-work coaching sessions. The intervention consists of 3 individual coaching sessions with a certified professional coach. This personalized accompaniment will complete the standard accompaniment offered to all patients.
9727635|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
9727636|NCT03127111||Adjuvant chemotherapy|Samples from patients with stage III colorectal cancer who are going to receive fluorouracil-based adjuvant chemotherapy will be used for gene mutations analysis, gene methylation analysis, gene expression analysis, SNP analysis, and protein expression analysis.
9727637|NCT03104283|Experimental|Apatinib Group|take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
9727638|NCT03086044|Experimental|HCV NAT Positive Donor|"Intervention: 4 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily~Participants who receive either heart or lung allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant or as soon as the recipient is able to tolerate oral medications after transplantation."
9727639|NCT03086044|Experimental|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring~Participants who receive either heart or lung allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
9727640|NCT03084939|Experimental|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
9727641|NCT03084939|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
9727642|NCT03077776|Experimental|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:~(optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy~At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).~Biopsy of a metastatic site in the event of disease recurrence.~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
9727643|NCT03077061|Active Comparator|Control - Open flap debridement|The surgical procedure includes flap elevation, debridement of the peri-implant defect and decontamination of the implant surfaces using saline for irrigation. Flaps are replaced in their original position and carefully sutured. Patients are provided with post-surgical information and thereafter called in for regular follow-up visits.
9727644|NCT03077061|Experimental|Test - Bone replacement graft|The surgical procedure is identical to the control procedure with the exception of the application of the bone replacement graft. Following decontamination, Bio-Oss Collagen® is placed into the peri-implant bony defect. Flaps are carefully sutured and patients are provided with the same information and follow-up as patients in the control group.
9727645|NCT03069690|Experimental|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
9727646|NCT03069690|Experimental|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
9727647|NCT03069690|Experimental|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
9727648|NCT03069690|No Intervention|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
9727649|NCT03067571|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 3.25-6.5 hours on days 1, 8, 15 and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9727650|NCT03060668|Experimental|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.~Nutritional therapy will be initiated in the first 24 hours after admission.~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
10199504|NCT04469205|No Intervention|Control Group|"control group who will receive the current care which consists of a psychosocial care.~This care consists in offering the patient regular information meetings organized with social workers of the Health Insurance, to consult a psychologist and to access patients' homes at the frequency of their choice and according to their need."
9727651|NCT03060668|Active Comparator|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.~Nutritional formula in this group will be Novasource senior (Nestle Health Care).~Nutritional therapy will be initiated in the first 24 hours after admission."
9727652|NCT03060330|Experimental|LVMR|Modified Laparoscopic Ventral Mesh Rectopexy
9727653|NCT03060330|Experimental|LVMR with STARR|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
9727654|NCT03056157|Experimental|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
10199505|NCT04460183|Experimental|Investigational arm|Participants will receive inhaled RESP301 administered using a nebulizer three times a day for up to 10 days in addition to the standard of care.
10199506|NCT04460183|Active Comparator|Control arm|Participants will receive institutional SOC for the treatment of COVID-19
10199507|NCT04457960|Experimental|JNJ-66525433|Participants will receive JNJ-66525433 in increasing dose level 1 to dose level 4 in Parts 1, 2, and dose level 3 in part 3.
10199508|NCT04457960|Placebo Comparator|Placebo|Participants will receive matching placebo in Parts 1, 2 and 3.
10199509|NCT04454346|Experimental|Double Foley Catheter|The patients allocated to this arm were randomly and did not differ from the Single Foley Catheter or Cook Balloon arm regard to patients' demographic features and characteristics. The connected FCs were inserted into the cervix using long forceps and advanced to the internal os level. One of the Foley balloons was inflated with 80 ml of saline, and the other FC, now the cervicovaginal balloon, was pulled out with mild traction until the balloon could be visualized and inflated with 20 ml of saline. The vaginal speculum was removed, and the cervicovaginal balloon was inflated further to a total of 80 ml of saline. Both catheters were taped to the inner aspect of the thigh without tension
10199510|NCT04454346|Experimental|Single Foley Catheter|The patients allocated to this arm were randomly and did not differ from the Double Foley Catheter or Cook Balloon arm regard to patients' demographic features and characteristics. a 16-F FC was inserted into the cervix using long forceps. Then, the balloon was inflated with 80 ml of saline using a standard 20 ml syringe. The catheter was then pulled out until the balloon covered the internal os. The speculum was removed, and the catheter was fixed under slight tension to the inner aspect of the thigh
10199511|NCT04454346|Experimental|Cook Balloon|The patients allocated to this arm were randomly and did not differ from the Double Foley Catheter or Single Foley Catheter arm regard to patients' demographic features and characteristics. Cook cervical ripening group, the device was applied according to the manufacturer's instructions, and each balloon was inflated with 80 ml saline. The catheter was taped to the inner aspect of the thigh without tension.
10199512|NCT04450706|Experimental|Treatment: all patients|"Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient is eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This first-line of on study therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first uninformed line of therapy.~Patient response is tracked for up to two uninformed lines of therapy. The first line of the therapy started after the biopsy will count as the first uniformed line."
10199513|NCT04450706|Experimental|Physician Questionnaire|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
10199514|NCT04447287|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of ASP8062 concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
10199515|NCT04447287|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants received multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. In the Investigational Period participants were on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants received a single oral dose of placebo concomitantly with buprenorphine/naloxone. The stable dose of buprenorphine/naloxone was down titrated from days 19 through 26.
10199516|NCT04446611|Experimental|Test at 1st ANC + Test-of-Cure (Treatment 1)|Single point-in-time diagnostic screening plus test-of-cure three weeks post-treatment
10199517|NCT04446611|Experimental|Test at 1st ANC + 30-34 gestation (Treatment 2)|Repeated diagnostic screening at first antenatal care and 30-34 weeks gestation
10199518|NCT04446611|No Intervention|Syndromic Management (Control)|Syndromic management (standard of care) at every antenatal care visit per South African National Guidelines.
10199519|NCT04422262||Moli-sani Study sub-cohort|A sample of 2,500 men and women from the Moli-sani Study cohort (2005-2010) who were re-examined in 2017-2020. Participants will be contacted by telephone by researchers of the Moli-sani Study recruitment team in order to collect dietary, lifestyle and psychosocial information and assess potential changes possibly occurred during Phase 1 lockdown.
10199520|NCT04422262||Italian general population|The project will retrospectively collect data through a web-based survey using Google form. The questionnaire consists of the same items used for the Moli-sani sub-cohort. The project aims at including as many subjects' records as possible.
10199521|NCT04421495|Experimental|delamanid containing regimen arm|the only one arm to be studied with delamid-containing regimen.
10199522|NCT04418882||non septic open fracture|patients having had an open fracture without septic evolution
10199523|NCT04418882||septic open fracture|patients having had an open fracture with septic evolution
10199524|NCT04416048|Experimental|Rivaroxaban|Subjects will receive treatment with rivaroxaban. (for more information see intervention description)
10199525|NCT04416048|Other|Standard of Care|Subjects will receive standard of care (SOC) treatment SOC with prophylactic LMWH or UFH
9780927|NCT01134783|Experimental|Intervention Group|The CHOICES intervention included a 1-credit, academic college course focusing on healthy weight behaviors and participation in a social networking and social support website
9780928|NCT01134783|No Intervention|Control Group|Control group (serving as a comparison group)
9727655|NCT03056157|Active Comparator|Present Centered Therapy|PCT is a manualized evidenced-based PTSD treatment used in several large-scale PTSD trials. It incorporates the essential therapeutic elements common to different types of psychotherapies, including supportive empathic listening and unconditional positive regard. The therapist plays an active role, but does not impart any systematic training. The focus is to create an understanding of how the symptoms of PTSD are related to day-to-day difficulties and to help patients develop new, more adaptive responses to these stressors with a problem-focused and problem-solving approach. In prior trials, PCT showed equivalent change to active therapies at the last follow-up. The VA offers PCT as an evidence-based therapy for PTSD.
9727656|NCT03052049|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
9727657|NCT03049306|Placebo Comparator|Placebo Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.
9727658|NCT03049306|Active Comparator|Propranolol Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.
9727659|NCT03049306|Active Comparator|CPAP|Subjects will be admitted to the clinical research unit. They will sleep wearing CPAP according to their usual home settings. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides.
9727660|NCT03047928|Experimental|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
9727661|NCT03045965|Experimental|Salpingectomy|Concomitant salpingectomy at the time of hysterectomy for a benign reason
9727662|NCT03045965|No Intervention|No salpingectomy|No salpingectomy at the time of hysterectomy for a benign reason
9727663|NCT03045744|Experimental|incomplete SCI patients|
9727664|NCT03034330|Experimental|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
9727665|NCT03034330|Active Comparator|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
9727666|NCT03018392|Experimental|Tritanium|TLIF with Tritanium® PL cage and pedicle screw fixation
10199526|NCT04410562|Experimental|Hydroxychloroquine|Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)
10199527|NCT04410562|Placebo Comparator|Placebo|Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).
10199528|NCT04393350|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10199529|NCT04388553|Experimental|Treatment|lumbar ESP block is performed. Before proceeding to ESP block, the back is cleaned with aseptic technique and draped. 40 mL of 0.25% levobupivacaine (or maximum of 2mg/kg body weight made up to same volume) is injected into the ESP.
10199530|NCT04388553|No Intervention|Control|no regional anaesthesia is performed nor saline is injected into the ESP
9727669|NCT03006926|Experimental|lenvatinib 8 or 12 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.
9727670|NCT02998528|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
9727671|NCT02998528|Experimental|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
9727672|NCT02998528|Experimental|Nivolumab plus Ipilimumab|Specified dose on specified days
9785814|NCT01260350|Experimental|Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.
9984751|NCT03768440|Experimental|continuous erector spinae block|An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
10205482|NCT05206240||Study group|The patients considered eligible will form the study group and will start the conventional physical therapy program and radial extracorporeal shock wave therapy delivery (rESWT).
10199531|NCT04379700|Experimental|Embolization Group|23 participants who are aged between 30 to 75 years old, with grade 2 or 3 knee OA on the most recent knee radiographs obtained within 6 months of intervention. Each individual participant will be enrolled for approximately 13 months to complete all study visits from the initial screening visit to last follow up at 12-months post intervention.
10199532|NCT04379505|Experimental|Quad shot radiation|-Radiotherapy will consist of Quad shot radiation delivered on the Ethos ring gantry kV-CBCT combined with linear accelerator system to a dose of 14 Gy in four, twice-daily fractions of 3.5 Gy delivered at least 6 hours apart over two days for a possible total of 3 cycles delivered in 3 to 4 intervals for a cumulative dose of of 42 Gy in 12 fractions. Cycle 2 and 3 of treatment is not mandated per protocol but may be given at the discretion of the treating physician.
10205483|NCT05206214|Experimental|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver
9727673|NCT02993926||Treatment Phase: Enantone|Participants with CPP who were treated with Enantone (≥ 30 μg/kg up to 180 μg/kg) for at least 9 continuous months and who initiated and received the last dose of treatment during the index period from 01 September 1998 to 30 September 2018 (the mean duration of Enantone exposure was 22.3 months, ranging from 10.1 to 52.4 months).
9727674|NCT02993926||Follow Up: Participants No longer Treated for CPP|Participants who had completed their CPP during the treatment phase with Enantone and were no longer on treatment in the follow-up phase (the mean duration of follow up was 8.75 months with a range of 1.9 to 29.5 months).
9727675|NCT02993926||Follow Up: Treated with Non-Enantone GnRHa after Enantone|Participants who were continuing their CPP treatment with a non-Enantone gonadotropin releasing hormone agonist (GnRHa) after treatment with Enantone in the follow-up phase (the mean duration of follow up while on another GnRHa was 10.80 months with a range of 2.8 to 20.5 months, and the mean duration of follow up after stopping treatment was 4.26 months with a range of 0.0 [i.e. 1 day] to 12 months).
9727676|NCT02991521|Experimental|FAST examination after Right sided roll (FASTeR)|Subjects will have a standard FAST exam, and will then be rolled onto their right side and the FAST exam will be repeated.
9727677|NCT02973750||Pre-Surgery Chemotherapy Patients|All participants. Patients receiving chemotherapy with carboplatin and paclitaxel before their debulking surgery, who may have more chemotherapy after surgery. Sampling procedures will include: Baseline Biopsy; Tissue Collection; Blood Draws.
9727678|NCT02970344|Experimental|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
9727679|NCT02970344|No Intervention|Diabetes Education|one 60 minute diabetes education session.
9727680|NCT02967640|Experimental|Ketalar|ketalar injection, subacromial
9727681|NCT02967640|Placebo Comparator|Placebo|physiological sodium chloride (NaCl 9%) injection, subacromial
9727682|NCT02948309|Experimental|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
9727683|NCT02948309|Placebo Comparator|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
9727684|NCT02943291|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
9727685|NCT02943291|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
9727686|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
9727687|NCT02938442|Active Comparator|Control Arm|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
9727688|NCT02938442|Experimental|Chemo+Vaccine Arm|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
9727689|NCT02932579|Active Comparator|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
9727690|NCT02932579|Experimental|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
10205484|NCT05206214|Experimental|mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver
9727691|NCT02928224|Experimental|Safety Lead-in, Triplet Arm|Encorafenib + binimetinib + cetuximab.
9727692|NCT02928224|Experimental|Doublet Arm|Encorafenib + cetuximab.
9727693|NCT02928224|Active Comparator|Control Arm|Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
9727694|NCT02927067|Experimental|Maribavir/ Placebo|Participants will receive 400 milligrams (mg) of maribavir (2*200 mg tablets) twice daily (BID) orally along with a placebo matched to valganciclovir for 8 weeks.
9727695|NCT02927067|Active Comparator|Valganciclovir/ Placebo|Participants will receive 900 mg of valganciclovir (2*450 mg tablets) BID orally along with a placebo matched to maribavir for 8 weeks. Valganciclovir dose may be adjusted to 450 mg BID or 450 mg QD during the study for renal function impairment or neutropenia.
9727696|NCT02905799|Experimental|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
9727697|NCT02905799|Placebo Comparator|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
9727698|NCT02898194||1/Patient Surrogates|Any eligible participant who have acted as a surrogate medical decision-maker.
9727699|NCT02897375|Experimental|Arm A (palbociclib, cisplatin)|Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9727700|NCT02897375|Experimental|Arm B (palbociclib, carboplatin)|Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9727701|NCT02896777|Experimental|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
9727702|NCT02896777|Experimental|Transfer embryos from 7.3±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
9727703|NCT02896777|Experimental|Transfer embryo from 7.4±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
9727704|NCT02861846|Other|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
9727705|NCT02858154|Other|HFNC and low flow oxygen by nasal cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (low flow oxygen by nasal cannula)
9780929|NCT01134887|Experimental|Arm 1: Intervention-Veterans|"Veterans enrolled in the Intervention-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. Just prior to their next scheduled visit an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Educational Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management."
9780930|NCT01134887|Active Comparator|Arm 2: Control-Veterans|"Veterans enrolled in the Control-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
9780931|NCT01134887|Experimental|Arm 3: Intervention-Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians [Monograph for Physicians]. The Four Habits provided practical evidence-based advice for improving patient-physician communication. Second, physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients [Video-Assisted Coaching], but before seeing them for follow-ups. The main goal of this meeting was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management."
9780932|NCT01134887|Active Comparator|Arm 4: Control-Physicians|"Primary care providers randomly assigned to the Control-Physicians arm of the study did not receive coaching or additional resources, and conducted their primary care practice as usual [Control]."
9780933|NCT01134900|Experimental|Dashboard|Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
9780934|NCT01134900|No Intervention|Control|Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
9780935|NCT01134939||HIV-infected women and men|
9780936|NCT01134952|Experimental|Mycophenolate to sirolimus switch|Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF
9785291|NCT01248221|Experimental|Healthy subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
9785292|NCT01248221|Experimental|Dyspeptic subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
9785293|NCT01248364|Experimental|BI 10773 Arm|BI 10773 high dose once daily
9785294|NCT01248416|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
9785295|NCT01248416|Active Comparator|Growth Hormone|Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
9785296|NCT01248416|Active Comparator|Aromatase Inhibitor and Growth Hormone|Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
10205024|NCT04295577||Cohort 1: Retrospective Cohort|"This cohort will include:~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib but in whom quality of life data are not available.~Patients who have previously commenced Niraparib prior to the MONITOR Study opening at the site but are now deceased but will be eligible for retrospective data collection without the need for informed consent.~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site but have discontinued treatment.~Data in respect of AEs, SAEs, ADRs and AESIs will be recorded in Case Report Forms and be identified via the patient's medical records. There is no requirement to complete trial specific SAE reporting forms in this cohort."
10205485|NCT05206201|Experimental|ZY19489 Capsule|Experimental study drug
9727706|NCT02856113|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
9727707|NCT02856113|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
9727708|NCT02852967|Experimental|Belumosudil 200 mg QD + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening
9727709|NCT02852967|Experimental|Belumosudil 200 mg BID (Twice Daily) + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening
9727710|NCT02852967|Experimental|Belumosudil 400 mg QD + Placebo|Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening
9727711|NCT02852967|Experimental|Belumosudil 600 mg/day|Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening
9727712|NCT02852967|Placebo Comparator|Placebo|Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening
9727713|NCT02852538|Experimental|NEW FED TR for Anorexia|NEW FED TR
9727714|NCT02823821|Active Comparator|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
9727715|NCT02823821|Active Comparator|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
9727716|NCT02811432|Experimental|Kangaroo mother care|Skin-to-skin care initiated as soon as possible following randomisation
9727717|NCT02811432|Active Comparator|Standard care|Incubator or radiant warmer
9727718|NCT02810418|Experimental|Arm A1, Dose Level 1 (Phase 1, short infusion) 100µg/kg LMB-100|"Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 +125mg/m^2 nab-paclitaxel~Dose level 1 (DL1) Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving short infusion LMB-100+nabpaclitaxel"
9727719|NCT02810418|Experimental|Arm A1, Dose Level-1 (Phase 1, short infusion) 65µg/kg LMB-100|Arm A1, DL-1, Ph I Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel
9727720|NCT02810418|Experimental|Arm A2 (Phase 2, short infusion) 65µg/kg LMB-100|"Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel~Efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel"
9727721|NCT02810418|Experimental|Arm B1, Dose Level 2 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL2, 48-hr Continuous Infusion Single Agent Lead-in 100µg/kg/day LMB-100 Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving continuous infusion LMB-100 as single agent
9727722|NCT02810418|Experimental|Arm B1, Dose Level 1 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL1, 48-hr Continuous Infusion Single Agent Lead-in 65µg/kg/day LMB-100
9727723|NCT02810418|Experimental|Arm B1, Dose Level 3R Phase I (Continuous infusion single agent lead-in)|Arm B1, DL3R, 24-hr Continuous Infusion Single Agent Lead-in 100µg/kg LMB-100
9727724|NCT02810418|Experimental|Arm B2 Phase I (continuous infusion combination therapy)|Subjects with pancreatic cancer receiving continuous infusion LMB-100 combination therapy
9727725|NCT02799693||Recurrent VT failing RF ablation|Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
9727726|NCT02788981|Experimental|Nab-Paclitaxel+Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
9727727|NCT02788981|Placebo Comparator|Nab-Paclitaxel+Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
9727728|NCT02788773|Experimental|Arm A - Durvalumab plus Tremelimumab|Durvalumab-IV for 60 minutes day 1 every 4 weeks Tremelimumab-IV every 60 minutes day 1, cycles 1-4
9727729|NCT02788773|Experimental|Arm B - Durvalumab alone|Durvalumab-IV for 60 minutes day 1 every 4 weeks
9727730|NCT02786251|Other|BAT+|Individuals with significant amounts of BAT (>20 ml)
9727731|NCT02786251|Other|BAT-|Individuals with no/minimal amounts of BAT (<20 ml)
9727732|NCT02782468|Experimental|Arm 1, Cohort 1: Pevonedistat 25 mg/m^2|Pevonedistat, 25 milligram per square meter (mg/m^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
9727733|NCT02782468|Experimental|Arm 1, Cohort 2: Pevonedistat 44 mg/m^2|Pevonedistat, 44 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
9727734|NCT02782468|Experimental|Arm 2, Cohort 1: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 10 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
9727735|NCT02782468|Experimental|Arm 2, Cohort 2: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
9727736|NCT02781584|Experimental|Cohort 1: SEL 18 mg (Non-cirrhotic)|Non-cirrhotic participants will receive selonsertib (SEL) 18 mg tablet orally once daily for 12 weeks.
9727737|NCT02781584|Experimental|Cohort 2: FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive firsocostat (FIR) 20 mg tablet orally once daily for 12 weeks.
9727738|NCT02781584|Experimental|Cohort 3: CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive cilofexor (CILO) 30 mg tablet once daily for 12 weeks.
9727739|NCT02781584|Experimental|Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
9727740|NCT02781584|Experimental|Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
9727741|NCT02781584|Experimental|Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic)|Non-cirrhotic participants will receive CILO 30 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
10205486|NCT05206201|Placebo Comparator|Placebo|Matching placebo
9727742|NCT02781584|Experimental|Cohort 7: CILO 20 mg (Cirrhotic)|Participants with Child-Pugh-Turcotte Class A cirrhosis will receive FIR 20 mg tablet once daily for 12 weeks.
9727743|NCT02781584|Experimental|Cohort 8: CILO 30 mg (Cirrhotic)|Participants with Child-Pugh-Turcotte Class A cirrhosis will receive CILO 30 mg tablet once daily for 12 weeks.
9727744|NCT02781584|Experimental|Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic)|Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
9727745|NCT02781584|Experimental|Cohort 10: FIR 20 mg + FENO 48 mg|Participants will receive fenofibrate (FENO) 48 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 48 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
9727746|NCT02781584|Experimental|Cohort 11: FIR 20 mg + FENO 145 mg|Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 145 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
9727747|NCT02781584|Experimental|Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g|Participants will receive Vascepa® (VAS) 2 g capsule orally twice daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + VAS 2 g capsule twice daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
9727748|NCT02781584|Experimental|Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg|Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + FENO 145 mg tablet orally once daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
9727749|NCT02772965|Experimental|Methotrexate|"Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.~Folic Acid (1 mg) daily"
9727750|NCT02772965|Placebo Comparator|Sugar pill (placebo)|"Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.~Folic Acid (1 mg) daily"
9727751|NCT02770131||Group 1|To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
9727752|NCT02767557|Experimental|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.~Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
9727753|NCT02767557|Active Comparator|Gemcitabine and nab-Paclitaxel|"Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
9727754|NCT02761811|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
9727755|NCT02761811|Sham Comparator|Masked Procedure|Percutaneous renal artery angiography
9727756|NCT02760290|Experimental|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
9727757|NCT02760290|Active Comparator|Intraperitoneal group|Conventional transperitoneal cesarean will perform
9727758|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
9727759|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
9727760|NCT02746510|Experimental|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV) or a pathogenic sequence variation (exome trio sequencing).
9727761|NCT02744365||Prediction Group|The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
9727762|NCT02744365||PEARL Group|"The women recruited in the biobank through the PEARL Study (NCT02379832) are :~low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)~pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)"
9727763|NCT02744365||GAP Group|The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
9727764|NCT02744365||PREDICTION 2 Group|The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
9727765|NCT02744365||HAUPE Study|Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
9727766|NCT02740452|Other|Ligamys technique|Ligamys technique (device) or standard technique
9727767|NCT02740452|Other|standard technique|Ligamys technique (device) or standard technique
9727768|NCT02738359||1rst arm: optical colonoscopy (OC)|t0: optical colonoscopy; Follow-up: yearly by phone call for three years
9727769|NCT02738359||2nd arm: colon capsule endoscopy (CC)|t0: colon capsule endoscopy -> if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years
9727770|NCT02738359||3rd arm: fecal immunological test (FIT)|"FIT yearly for two years:~t0: FIT -> if positive : OC; t = 1 year: FIT -> if positive : OC; t = 2 years: FIT -> if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years"
9727771|NCT02736565|Experimental|pbi-shRNA™ EWS/FLI1 Type 1 LPX|"Subjects will accrue in 3 to 6-subject escalation cohorts up to a dose of 0.156mg/kg of DNA / single dose.~An intravenous infusion will be administered twice a week for 4 weeks (e.g. Mon and Thurs, preferred) for a total of 8 infusions of the product per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met."
10199533|NCT04373902|Experimental|Physiological-based cord clamping|In PBCC, the Concord will be placed next to the bed of the mother and all equipment will be checked before the second stage of labour has started. The infant will be placed on the platform of the Concord immediately after birth, avoiding any traction or pressure on the cord and avoiding heat loss by radiation heating. The umbilical cord will not be clamped until the infant is considered respiratory stable, which is defined as the presence of a heart rate >100 bpm and preductal oxygen saturation >85%, while using an fraction of inspired oxygen (FiO2) of <0.5. The minimum and maximum times of cord clamping are three and ten minutes after birth, respectively. Oxytocin administration will be postponed until after cord clamping if there are no obstetric concerns. At any time, the attending neonatologist and obstetrician can decide that PBCC should not be performed or be interrupted. In that case, the infant can be placed on the standard resuscitation table for (further) stabilisation.
10199534|NCT04373902|No Intervention|Immediate cord clamping|In the immediate cord clamping group, the cord will be clamped immediately after birth. The infant will then be transferred to the standard neonatal resuscitation table. After cord clamping, all infants will be managed according to the standardised neonatal management protocol for infants with a CDH, which is a consensus of current clinical guidelines by the CDH EURO consortium.
10199535|NCT04352452||RALS|Surgeons perform robot-assisted laparoscopic surgery
10199536|NCT04352452||CLS|Surgeons perform conventional laparoscopic surgery
10199537|NCT04337554||Older healthy|Individuals over 40 years of age
10199538|NCT04337554||Peripheral artery disease|Individuals over 40 years of age with peripheral artery disease.
10199539|NCT04336735|Experimental|Immunization Tool Users|Users will trial a novel transplant-specific immunization tool (app)
10199540|NCT04307433|Experimental|Arm 1|ST Narrative + mHealth: Storytelling narrative video on tablets
10199541|NCT04307433|Active Comparator|Arm 2|mHealth: a video with a voice over presenting didactic materials on tablets
10199542|NCT04307433|Placebo Comparator|Arm 3|Control: non-narrative educational materials will be read
10199543|NCT04302493|Experimental|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course.
9727772|NCT02730130|Experimental|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
9727773|NCT02727452|Experimental|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
9727774|NCT02727452|Active Comparator|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
9727775|NCT02727452|Other|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
9727776|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
9727777|NCT02714062|Placebo Comparator|Placebo|Days 1-56: Placebo
9727778|NCT02714062|Experimental|VI-0521 Mid Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)"
9727779|NCT02714062|Experimental|VI-0521 Top Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
9727780|NCT02707055|Experimental|PF-05190457, then placebo|Participants with alcohol use disorder received PF-05190457 100 mg twice a day for a maximum of 14 days followed by a minimum of 2-day washout period, then placebo twice a day for a maximum of 14 days.
9727781|NCT02707055|Placebo Comparator|Placebo, then PF-05190457|Participants with alcohol use disorder received placebo twice a day for a maximum of 14 days followed by a minimum of 2-day washout period then PF-05190457 100 mg twice a day for a maximum of 14 days.
9727782|NCT02700308|Active Comparator|Conventional vertebroplasty|Conventional vertebroplasty (device's trade at the discretion of the investigator)
9727783|NCT02700308|Experimental|Kyphoplasty|Vertebroplasty with balloon placement and inflation prior to cement injection (device's trade at the discretion of the investigator)
9727784|NCT02696759|Other|Blood & Fecal Collection|Subjects receiving neoadjuvant chemotherapy for advanced breast cancer will be asked to complete questionnaires, provide two blood samples, and provide 2 fecal samples while receiving standard of care neoadjuvant chemotherapy
9727785|NCT02689427|Experimental|Treatment (enzalutamide, paclitaxel)|"Patients receive enzalutamide PO daily on days 1-7 and paclitaxel IV over 2 hours on day 1. Treatments repeat every 7 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: After 12 cycles of therapy, patients undergo surgical resection of primary tumor with or without lymph node biopsy or complete axillary dissection."
9727786|NCT02684214|Experimental|Food secure families|high and marginal household food security
9727787|NCT02684214|Experimental|Food insecure families|low and very low household food security
9727788|NCT02682004||Women with postpartum depression|
9727789|NCT02682004||Women without postpartum depression|
9727790|NCT02673398|Experimental|Treatment (neratinib)|Patients receive neratinib 240mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9727791|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in the respective country.
9727792|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in the respective country.
9727793|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in the respective country.
9727794|NCT02656797|Experimental|AM-B|Topical Amphotericin-B 0.4% liposomal gel
9727795|NCT02656797|Placebo Comparator|Placebo|Placebo gel preparation
9727796|NCT02656290|Experimental|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Pulmonary valve replacement
9727797|NCT02652130|Experimental|Safety population|All participants who were enrolled and had received at least 1 dose of remestemcel-L in Study MSB-GVHD001.
9727798|NCT02644798||ARDS patients|Adult ARDS (according to Berlin definition) patients were enrolled in the trial. The diagnostic criteria included (a) within one week of a known clinical insult or new or worsening respiratory symptoms; (b) chest imaging showing that bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules; (c) respiratory failure not fully explained by cardiac failure or fluid overload; and (d) arterial partial pressure of oxygen / fraction of inspiration oxygen (PaO2/FiO2 ratio, P/F ratio) less than or equal to 300 mmHg.
9727799|NCT02633644|Experimental|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
9727800|NCT02625441|Experimental|Short anti-HER2 treatment|Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles
9727801|NCT02625441|Active Comparator|Standard anti-HER2 treatment|Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
9727802|NCT02617407|Experimental|Livionex® Dental Gel|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
9727803|NCT02617407|Active Comparator|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Study patients assigned to this arm will use PreviDent 5000 plus or Tom's of Maine Children's (age 6 years and younger) toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
9727804|NCT02616393|Experimental|Cohort A: Brain Metastases (BM)|Tesevatinib 300 mg orally (PO) once daily (QD) administered to subjects with NSCLC who had progressed with brain metastases (BM)
9727805|NCT02616393|Experimental|Cohort B: Leptomeningeal Metastases (LM)|Tesevatinib 300 mg PO QD administered to subjects with NSCLC who had progressed with leptomeningeal metastases (LM)
9727806|NCT02616393|Experimental|Cohort C: Brain Metastases at Initial Presentation (BM-IP)|Tesevatinib 300 mg PO QD administered NSCLC who presented initially with BM at initial presentation
9727807|NCT02613728|Active Comparator|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
9727808|NCT02613728|Experimental|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
9727809|NCT02608385|Experimental|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
9727810|NCT02608385|Experimental|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
9727811|NCT02608385|Experimental|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
9727812|NCT02603341|Active Comparator|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
9727813|NCT02603341|Active Comparator|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
9727814|NCT02602288|Experimental|AAR+Behavioral Intervention (EXP)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased tobacco counseling: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke. Mobile phone smoking cessation application: Smartphone based application to support smoking cessation efforts. Nicotine polacrilex: Over the counter nicotine replacement therapy in gum or lozenge form.
9727815|NCT02602288|Active Comparator|AAR+Attention Control Intervention (CTL)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased nutrition counseling: Telephone counseling to promote nutritious eating practices in the family. Mobile phone nutrition application: Smartphone based application to support healthy eating habits
9727816|NCT02593786|Experimental|Nivolumab monotherapy|Nivolumab specified dose on specified days
9727817|NCT02593786|Experimental|Cohort Expansion|Nivolumab specified dose on specified days
9727818|NCT02584478|Experimental|Phase 3 -Active Treatment Arm|"Phase 3: AL3818 8 mg once daily in combination with one background chemotherapy in 21-day cycles. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
9727819|NCT02584478|Other|Phase 3-Control Treatment Arm|"Control Treatment Arm: Background chemotherapy treatment alone. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
9727820|NCT02584478|Experimental|Phase 1b: AL3818 plus carboplatin and paclitaxel|Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.
9780937|NCT01135017|Experimental|Dronedarone|Dronedarone 400 mg twice a day for 12 weeks
9780938|NCT01135017|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day for 12 weeks
9780939|NCT01135069|Active Comparator|Generic|treatment of acne for 12 weeks
10199544|NCT04302493|Active Comparator|Stroke Support Group (SSG)|As a control group, participants will participate in 8 weeks of weekly Stroke Support Group.
10199545|NCT04301102|Experimental|Experimental|"Hemodynamic management will be based on the functional hemodynamic parameters provided by Hemosphere platform with the Acumen IQ sensor, including cardiac output, stroke volume, SVV and Acumen IQ specific parameters: maximal arterial pressure rise (dP/dtmax), dynamic arterial elastance (Eadyn) and HPI~As a pattern replacement of interstitial space, we will use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.~The protocol of action on the intravascular space will be based on the maintenance of systolic volume with colloids (hydroxyethyl starch - Voluvén®)."
10199546|NCT04301102|Other|Control|"Hemodynamic management will be based on the functional hemodynamic parameters provided by the HemoSphere platform® with the FloTrac® sensor, including cardiac output (CO), stroke volume (SV), and stroke volume variation (SVV)~As a pattern replacement of interstitial space, we use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.~The protocol action for the intravascular space will be based on a recently published hemodynamic optimization algorithm (Heming N, Moine P, Coscas R, Annane D. Perioperative fluid management for major elective surgery. British Journal of Surgery. 2020;107:e56-62). The fluid used will be hydroxyethyl starch (Voluven®)."
10199547|NCT04300647|Experimental|Tiragolumab plus Atezolizumab|Participants will receive tiragolumab and atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
10199548|NCT04300647|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
10205025|NCT04295577||Cohort 2: Prospective Cohort|"This cohort will include:~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib and in whom quality of life data is available.~Patients who are due to commence maintenance Niraparib treatment."
10205026|NCT04286243|Active Comparator|Model 1 - Clinic Based Screening|Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
10205027|NCT04286243|Experimental|Model 2 - Community Based Screening|Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
10205028|NCT04283045|Active Comparator|JASPER (6 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 6 weeks. If child is an early responder, he/she will continue to do JASPER daily, 5 times a week, for the remaining 18 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 18 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 18 weeks of the study."
10205029|NCT04283045|Active Comparator|JASPER (12 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 12 weeks. If child is an early responder, he/she will do JASPER for 60 minutes with TA, 5 times a week, for the remaining 12 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 12 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 12 weeks of the study."
10205030|NCT04277325|Experimental|Intervention|Couples will receive 19-21 free sessions of Emotionally-Focused Therapy.
10205031|NCT04277325|No Intervention|Waitlist|Couples will receive no intervention during the trial. After the trial is ended, they will be invited to participate in a weekend intervention meeting.
10205032|NCT04268654|Experimental|Ischemic Conditioning|"Preoperative artery embolization prior to esophagectomy~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
10205033|NCT04268654|No Intervention|Control|"Surgery without previous ischemic conditioning of the gastric conduit~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
10205034|NCT04264403|Active Comparator|Renal Denervation|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. If randomized to the Renal Denervation Group RDN procedure will be applied using the Paradise® Renal Denervation System. The Paradise® Renal Denervation System is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
9727821|NCT02584478|Experimental|Phase 2a: AL3818 plus carboplatin and paclitaxel|Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b.
9727822|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours.
9727823|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours. Infusion started at wake-up time supplemented with an oral IR LD/CD tablet.
10199549|NCT04290286|Experimental|intervention group|TGD people (n = 82) receive 4 months of e-health intervention according to the i2TransHealth model of care (intervention group)
9727824|NCT02567136||Amyotrophic Lateral Sclerosis|Patients with ALS
9727825|NCT02567136||Healthy Controls|Healthy control volunteers
9727826|NCT02563002|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
9727827|NCT02563002|Active Comparator|Standard of Care (SOC)|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
9727828|NCT02549820|Experimental|FETO in CDH|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
9727829|NCT02542657|Experimental|Treatment (PiC-D therapy)|"Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY:~Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9727830|NCT02524834|Experimental|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
9727831|NCT02524327|Experimental|Toolbox: Automated group|"Toolbox: Automated administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index through a controller with a previously described algorithm.~Objective of depth anesthesia: 40-60"
9727832|NCT02524327|Active Comparator|Manual group|"Manual administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index as usually performed in the operative theater.~Objective of depth anesthesia: 40-60"
9727833|NCT02505230|Experimental|Meal Order 1|"[P,P+S,HVP,LVP]~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
9727834|NCT02505230|Experimental|Meal Order 2|"[P+S,HVP,LVP,P]~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
9727835|NCT02505230|Experimental|Meal Order 3|"[HVP,LVP,P,P+S]~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
9727836|NCT02505230|Experimental|Meal Order 4|"[LVP,P,P+S,HVP]~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
9727837|NCT02500381|Experimental|SRP-4045|Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
9780940|NCT01135069|Active Comparator|Brand|Treatment of acne for 12 weeks
9780941|NCT01135069|Placebo Comparator|Placebo|Treatment if acne for 12 weeks as placebo
9780942|NCT01135095|Experimental|low-dose imaging|low dose versus standard dose imaging
10199550|NCT04290286|No Intervention|waiting group|TGD people (n = 82) wait 4 months until they are offered regular care (waiting group), which can include video consultation
10205487|NCT05206188|Experimental|Experimental|Study participants randomized to the experimental condition will receive IPS services as usual in conjunction with the MWW intervention.
9727838|NCT02500381|Experimental|SRP-4053|Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
9727839|NCT02500381|Placebo Comparator|Placebo followed by SRP-4045 or SRP-4053|Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
9727840|NCT02471287||Affected Patients|Participants with eye disease
9727841|NCT02471287||Healthy Volunteers|Unaffected first degree relatives of participants with a known or suspected inherited eyedisease.
9727842|NCT02461225|Active Comparator|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 milliWatts (mW), 635 nanometers (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
9727843|NCT02461225|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light.
9727844|NCT02455531||Transplant-free survivors|Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
9727845|NCT02446262|Other|Substudy 1: Instructed subjects|Participants are instructed about outcomes
9727846|NCT02446262|Other|Substudy 1: Uninstructed subjects|Participants learn through experience
9727847|NCT02446262|Other|Substudy 2: heat group|Participants learn about heat outcomes through conditioning
9727848|NCT02446262|Other|Substudy 2: salt group|Participants learn about salt outcomes through conditioning
9727849|NCT02446262|Other|Substudy 2: sugar group|Participants learn about sugar outcomes through conditioning
9727850|NCT02446262|Other|Substudy 3: healthy volunteers|All participants experience all outcomes, within subjects designs
9727851|NCT02446262|Other|Substudy 4: healthy volunteers|Participants are instructed to attend toward or away from the stimulus
9727852|NCT02446262|Other|Substudy 5: healthy volunteers|Participants experience both placebo and cue-based expectations within subjects
9727853|NCT02443181|Experimental|Activa PC+S|Patients will be implanted with standard DBS electrodes for treatment of essential tremor, at the Vim nucleus of the thalamus, and an additional subdural electrode array overlying hand motor cortex.. The patient will receive standard of care programming for thalamic stimulation for essential tremor. During research study visits, implementation and evaluation of closed-loop DBS using the PC+S system will be performed.
9727854|NCT02427958|Experimental|Leuprorelin|Participants with body weight greater than or equal to (>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.
9727855|NCT02425826|Experimental|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
9727856|NCT02425826|Placebo Comparator|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
9727857|NCT02400567|Active Comparator|Chemotherapy|3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel
9727858|NCT02400567|Experimental|Letrozole Palbociclib|Drugs: letrozole + palbociclib combination
9727859|NCT02384239|Experimental|Palbociclib 100mg and, fulvestrant or tamoxifen|Palbociclib dose 100mg, and either fulvestrant (500 mg IM on days 1 and 15 in the first 28 days, then every 28 days thereafter) or tamoxifen (20 mg PO daily by physician choice)
9727860|NCT02384239|Experimental|Palbociclib 125mg and, fulvestrant or tamoxifen|Palbociclib dose 125mg and either fulvestrant (500 mg IM on days 1 and 15 in the first 28 days, then every 28 days thereafter) or tamoxifen (20 mg PO daily by physician choice)
9727861|NCT02372409|Experimental|Arm A (MRI-guided laser ablation)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~Every 12 weeks (+/- 7 days) for the first year or until disease progression"
9727862|NCT02372409|Experimental|Arm B (MRI-guided laser ablation, doxorubicin, etoposide)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m^2 over 5-30 minutes~Following the completion of doxorubin, etoposide 50 mg/m^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first"
9727863|NCT02361801|Active Comparator|Liberal dobutamine group|All patients will receive dobutamine at the cardiopulmonary bypass weaning
9727864|NCT02361801|Active Comparator|Restrictive dobutamine group|Patients will only receive dobutamine if they present clinical signs of cardiogenic shock
9727865|NCT02356705|Placebo Comparator|Saline Placebo|Control patients will receive intranasal saline
9727866|NCT02356705|Active Comparator|Nasal Midazolam Only|Patients will receive 0.2 mg/kg of intranasal midazolam
9727867|NCT02356705|Active Comparator|Midazolam Plus Xylocaine|Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
9780943|NCT01135186|Other|Sapropterin|open label study of sapropterin dihydrochloride
9727868|NCT02354365||Normal lungs|Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
9727869|NCT02354365||Acute Hypoxic Respiratory Failure|Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
9727870|NCT02354365||Obstructive airway disease|Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
9727871|NCT02353247|Other|Norethindrone acetate (aygestin)|Norethindrone acetate (aygestin) will be used to manage bothersome bleeding. Patients will be prescribed aygestin 5 mg by mouth twice daily for one month, followed by aygestin 5 mg by mouth once daily for two months. Medication will then be discontinued. Patients will be evaluated in the office three months after medication initiation, and then again six months after medication initiation. If the patient is unable to take norethindrone acetate (aygestin) due to medical contraindications or cost, they will receive medroxyprogesterone acetate (provera) 10 mg once daily as alternate oral progesterone. Figure 1 below highlights the study
9727872|NCT02345408|Experimental|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
9727873|NCT02316002|Experimental|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks
9727874|NCT02315703|Experimental|Group 1|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
9727875|NCT02315703|Experimental|Group 2|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
9727876|NCT02315703|Experimental|Group 3|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + placebo injection at Week 24 and 48.
9727877|NCT02315703|Experimental|Group 4|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by modified Vaccinia Ankara (MVA)-Mosaic vaccine + gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant at Week 24 and 48.
9727878|NCT02315703|Experimental|Group 5|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
9727879|NCT02315703|Experimental|Group 6|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + placebo injection at Week 24 and 48.
9727880|NCT02315703|Experimental|Group 7|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant + placebo injection at Week 24 and 48.
9727881|NCT02315703|Placebo Comparator|Group 8|Participants will receive 1 placebo injection at Week 0 and 12; followed by 2 placebo injections at Week 24 and 48.
9727882|NCT02286089|Experimental|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
9727883|NCT02285959|Experimental|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
9727884|NCT02285725|Experimental|Augmented Microdrilling Surgery|
9727885|NCT02285439|Experimental|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
9727886|NCT02285439|Experimental|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
9727887|NCT02285439|Experimental|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
9727888|NCT02285140|Experimental|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
9727889|NCT02285140|Experimental|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
9727890|NCT02285140|Experimental|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
9727891|NCT02285140|Experimental|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
9727892|NCT02254941||Active comparator: Chemotherapy|Metastatic colon cancer and first line treatment with conventional chemotherapy without monoclonal antibody.
9727893|NCT02254941||Experimental: Chemotherapy plus mAb|Metastatic colon cancer and first line treatment with conventional chemotherapy plus monoclonal antibody
9727894|NCT02244411|Experimental|Intervention group|Participants will be assigned an individual diet & physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website & email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables & low-fat dairy products. Calorie goals are based upon weight at study entry & whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing & gradually adding bouts of ≥ 10 minutes in length. Monitoring & Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, & physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits & questionnaires.
9727895|NCT02244411|Active Comparator|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
9727896|NCT02237976|Experimental|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
9727897|NCT02237976|Active Comparator|Routine practice|No specific intervention
9727898|NCT02236351|Placebo Comparator|Control|Patients assigned to the Control Arm will be taught to apply their patches using the standard technique -- applying the patch evenly and flatly around the orbit.
9727899|NCT02236351|Experimental|Pinched Patch|Patients assigned to the Pinched Patch Arm will be taught to apply their patches after pinching the middle of the superior and inferior edges of the patch so that the patch is convex and the center is raised above the eye.
9727900|NCT02229084|Experimental|Part 1 - Chemovax Schedule A|Feasibility - Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
10199551|NCT04283669|Other|Open Label Continuous Treatment|Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as >20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria.
10199552|NCT04270760|Active Comparator|Arm 1 Olpasiran Dose 1|
10199553|NCT04270760|Active Comparator|Arm 2 Olpasiran Dose 2|
10199554|NCT04270760|Active Comparator|Arm 3 Olpasiran Dose 3|
10199555|NCT04270760|Active Comparator|Arm 4 Olpasiran Dose 4|
10199556|NCT04270760|Placebo Comparator|Arm 5 Placebo Dose 5|
10199557|NCT04262154|Experimental|Metastatic Prostate Cancer|Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
10199558|NCT04243330|No Intervention|Implementation as Usual|Implementation support consisting of clinical decision support tools, trainings, technical assistance and quality assurance to support implementation of VA Suicide Risk Identification Strategy. Available to all facilities.
10199559|NCT04243330|Experimental|Audit and Feedback|Audit and Feedback will serve as the first stage implementation intervention for sites that do not meet the benchmark for adequate implementation following 9 months of implementation as usual.
10205488|NCT05206188|No Intervention|Control|Study participants randomized to the control condition will receive IPS services as usual.
9727901|NCT02229084|Experimental|Part 1 - Chemovax Schedule B|Feasibility - Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
9727902|NCT02229084|Experimental|Part 1 - Chemovax Schedule C|Feasibility - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
9727903|NCT02229084|Experimental|Part 1 - Chemovax Schedule D|Feasibility - Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
9727904|NCT02229084|Experimental|Part 1 - Chemovax Schedule E|Feasibility - Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
9727905|NCT02229084|Experimental|Part 2 - Chemovax Schedule C|Primary Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
9727906|NCT02229084|Experimental|Part 3 - Chemovax Schedule C|Expanded Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
9727907|NCT02200276|Other|Influenza Immunization|Influenza immunization in adults over age 75
9727908|NCT02198911|Active Comparator|Order 1|Gum chewing order for sessions, 1-3 respectively: NO GUM, MCC, C
9727909|NCT02198911|Active Comparator|Order 2|Gum chewing order for ice-cream sessions, 1-3 respectively: MCC, C, NO GUM
9982318|NCT05261464|Experimental|Ivabradine protocol|"Ivabradine 5 mg will be given if patient's HR is more than 60 bpm.~Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 5-mg Ivabradine will be given.~If patient can not reach targeted HR at next 30 minutes, then third dose of 5-mg Ivabradine will be given.~If patient can not reach targeted HR at next 30 minutes, then placebo will be given.~If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 15 mg ivabradine with 1 dose of placebo, then total time will be recorded and patient will proceed to CCTA.~If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
10199560|NCT04243330|Experimental|External Facilitation|Audit and Feedback plus External Facilitation will serve as the second stage implementation intervention for sites that still do not meet the benchmark for adequate implementation following 9 months of implementation as usual plus audit and feedback.
9727910|NCT02198911|Active Comparator|Order 3|Gum chewing order for ice-cream sessions, 1-3 respectively: C, NO GUM, MCC
9727911|NCT02166242|Experimental|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
9727912|NCT02157662||No coronary disease and risk factors >=3|
9727913|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
9727914|NCT02157662||No coronary disease and risk factors 0-1|
9727915|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
9727916|NCT02149147||Physical Activity Variety|participants will complete the Self-Efficacy questionnaire, the Physical Activity Enjoyment Scale, the Behavioral Regulation in Exercise-2 questionnaire, and an Outcome Expectations questionnaire. Participants will be instructed to wear the SenseWear® armband which will measure physical activity-related energy expenditure for the course of the study. The armband will be worn every day for at least 10 hours per day. In addition, participants will be asked to complete a physical activity diary to record their physical activity as well as additional information about the environment in which the physical activity was conducted. Participants will be instructed to engage in their normal physical activity regimen, wear the armband, and complete the physical activity diary for 3 weeks.
9727917|NCT02144467||Large-sample healthy participants|MRI scanning.
9727918|NCT02107963|Experimental|Arm 1|Dose escalation of anti-GD2 CAR T cells
9727919|NCT02107963|Experimental|Arm 2|Dose expansion of anti-GD2 CAR T cells
9727920|NCT02103140|Experimental|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
9727921|NCT02103140|No Intervention|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
9727922|NCT02103140|Experimental|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
9780944|NCT01135329|Experimental|Transplant|Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.
9780945|NCT01135368|Experimental|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months."
9780946|NCT01135381|Experimental|CHF patients, IVR-Enhanced Care|Patients with congestive heart failure (CHF) who receive the interactive voice response (IVR) intervention.
9780947|NCT01135381|Experimental|COPD patients, IVR-Enhanced Care|Patients with chronic obstructive pulmonary disease (COPD) who receive the interactive voice response (IVR) intervention.
10199561|NCT04236856|Other|Robotic Endovascular Procedure|Subjects with a clinical indication for endovascular coil and/or stent assisted coiling embolization of cerebral aneurysms will be treated using the CorPath GRX System.
10199562|NCT04226274|Experimental|REN001|Oral
9662584|NCT02045901|Active Comparator|Diclegis|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
10199563|NCT04206891||Group 1|Bilateral lobular invasive breast cancer
10199564|NCT04206891||Group 2|Invasive lobular breast cancer with age at onset <= 45 years
10199565|NCT04206891||Group 3|Invasive lobular breast cancer with family history for breast cancer
10199566|NCT04206891||Group 4|In situ lobular breast cancer with age at onset <= 45 years
9662585|NCT02045901|Placebo Comparator|Placebo|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
9662586|NCT01836068|Experimental|Enfuvirtide monotherapy|Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.
9662587|NCT01550861|Experimental|In vitro Maturation|in vitro maturation of immature oocytes
9662588|NCT01308190|Active Comparator|Chemoradiotherapy+TEM|Preoperative chemotherapy: capecitabine 825 mg/m2 every 12 hours orally, plus Radiotherapy (50.4 Gy). After 6-8 weeks, transanal endoscopic microsurgery (TEM)is done
9662589|NCT01308190|Other|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer
9662590|NCT01210768|Active Comparator|EC|Cyclophosphamide,600 mg/m2 q3wk and Epirubicin,90 mg/m2 q3wk
9662591|NCT01210768|Experimental|LC|liposomal doxorubicin, 37.5 mg/m2 q3wk, and Cyclophosphamide,600 mg/m2 q3wk
9662592|NCT00516373|Experimental|KU-0059436|KU-0059436 administered orally twice daily
9662593|NCT05134376|Experimental|Workgroup|During the repair of the mediolateral episiotomy, the pregnant women included in the study group will be shown a video accompanying the acemaşîrân office with sterile virtual reality glasses with a view of nature.
9662594|NCT05134376|No Intervention|Control|Unlike the experimental group, only video and music applications will not be applied to the pregnant women included in the control group. Other applications will be done in the same way.
9662595|NCT05134350|Experimental|Arm A (LOXO-305 - Fasted)|LOXO-305 administered orally while fasting
9662596|NCT05134350|Experimental|Arm B (LOXO-305 - Fed)|LOXO-305 administered orally with standard meal
9662597|NCT05134350|Experimental|Arm C (Omeprazole + LOXO-305 Fasted)|Omeprazole + LOXO-305 administered orally while fasting
9662598|NCT05134337|Experimental|Part 1 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
9662599|NCT05134337|Experimental|Part 1 Period 2 (Itraconazole + LOXO-305)|Itraconazole + LOXO-305 co-administered orally
9662600|NCT05134337|Experimental|Part 2 Period 1 (LOXO-305 Alone)|LOXO-305 administered orally
9662601|NCT05134337|Experimental|Part 2 Period 2 (Rifampin + LOXO-305)|Rifampin + LOXO-305 co-administered orally
9662602|NCT05134324|Experimental|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. The patient received robotic therapy for upper extremity just after each active TMS sessions
9662603|NCT05134324|Sham Comparator|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil. The patient received robotic therapy for upper extremity just after each sham TMS sessions
9662604|NCT05134324|Experimental|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions. The patient received robotic therapy for upper extremity just after each active tDCS sessions
9662605|NCT05134324|Sham Comparator|sham tDCS|Participants recevied sham stimulation. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
9662606|NCT05134298||Study Kohort|As specified by study population, inclusion and exclusion criteria
9662607|NCT05134272||mCIMT plus NMES|"Phase 1: Infants will receive therapy 1 hour/day, 1 day/week for 3 weeks while wearing a sock 1 hour/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks.~Phase 2:Infants will receive therapy 2 hours/day, 3 days/week for 3 weeks while wearing a splint 24 hours/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks.~Phase 3:Infants will receive therapy 1 hour/day, 1 day/week for 3 weeks while wearing a sock 1 hour/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks."
9662608|NCT05134246||Carotid endarterectomy (CEA)|Patients who are treated with CEA.
9662609|NCT05134246||Carotid artery stenting (CAS)|Patients who are treated with CAS.
9662610|NCT05134233|Experimental|Parameter Trials|Approximately 36 parameter combinations will be tested per study session, expected 6 sessions of trials. Response recorded using TMS and EMG.
9662611|NCT05134220||Chronic Kidney Disease (CKD) patients with acute coronary syndrome|"The CKD patients with or without dialysis who admitted to coronary care unit with chest pain consistent with ACS with any of following features :~Electrocardiogram (ECG) changes:~ST elevation.~ST depression.~T wave inversion.~recent left bundle branch block.~Troponin elevation."
9662612|NCT05134220||Chronic Kidney Disease (CKD) patients without acute coronary syndrome|The CKD patient with or without dialysis with no previous history of ACS.
9662613|NCT05134194|Experimental|Arm A|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
9662614|NCT05134194|Experimental|Arm B|Capecitabine or eribulin or gemcitabine or vinorelbine
9662615|NCT05134181|Active Comparator|Group MTP|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of methylprednisolone with a uniform dose of 2 mL of 2% lidocaine hydrochloride.
9662616|NCT05134181|Active Comparator|- Group TMC|will receive ultrasound-guided intra-articular SIJ injection with 40 mg of Triamcinolone acetonide with a uniform dose of 2 mL of 2% lidocaine hydrochloride .
9662617|NCT05134168|Active Comparator|LIFT|Patients underwent LIFT proecdure
9727923|NCT02098954|Experimental|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
9727924|NCT02097225|Experimental|Treatment (dabrafenib, trametinib, onalespib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9727925|NCT02068794|Experimental|Treatment (MV-NIS infected mesenchymal stem cells)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9727926|NCT02024854|Experimental|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
9727927|NCT02024854|Active Comparator|standard care|after birth the baby is transferred to the neonatal intensive care unit
9727928|NCT02021071||XperGuide|Image-guided needle procedures with XperGuide performed prior to this study within institution (retrospective data).
10199567|NCT04206891||Group 5|In situ lobular breast cancer with family history for breast cancer
9727929|NCT02021071||XperGuide with virtual path planning|Image-guided needle procedures with XperGuide with virtual path planning
9727930|NCT02019641|Experimental|AET|AET will consist of a 10-week regimen of supervised treadmill walking three times a week. The duration of the exercise sessions will progress from 30 minutes to 45 minutes per session over the 10 weeks as tolerated. The intensity of the exercise will be between 70 and 80% of the patient's heart rate reserve.
9727931|NCT02019641|Active Comparator|No AET|control will not engage in AET.No AET (education only)
9727932|NCT02000622|Experimental|Olaparib|Olaparib tablet 300mg bd po
9727933|NCT02000622|Active Comparator|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
9727934|NCT01991184|Experimental|Dose-escalation|
9727935|NCT01974804||Pts having an MRI|Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
9727936|NCT01964261|Experimental|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
10199568|NCT04203537|Active Comparator|CA-008 36 mg|Single administration (0.3 mg/mL concentration)
10199569|NCT04203537|Active Comparator|CA-008 60 mg|Single administration (0.5 mg/mL concentration)
9727937|NCT01933932|Experimental|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
9727938|NCT01933932|Experimental|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
9727939|NCT01927068|Experimental|Global Cohort 1|All subjects to be treated with the Stellarex 035 Drug Coated Balloon (DCB) for Percutaneous Transluminal Angioplasty (PTA).The drug coating is paclitaxel (PTX).
9727940|NCT01927068|Experimental|ISR Cohort 2|All subjects to be treated with the Stellarex 035 Drug Coated Balloon (DCB) for Percutaneous Transluminal Angioplasty (PTA).The drug coating is paclitaxel (PTX).
9780948|NCT01135381|No Intervention|CHF patients, Usual Discharge Care|Patients with congestive heart failure (CHF) who receive usual discharge care (no intervention).
9780949|NCT01135381|No Intervention|COPD patients, Usual Discharge Care|Patients with chronic obstructive pulmonary disease (COPD) who receive usual discharge care (no intervention).
9785297|NCT01248455|Experimental|anti-KIR in Smoldering Multiple Myeloma Patients|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
10199570|NCT04203537|Active Comparator|CA-008 90 mg|Single administration (0.75 mg/mL concentration)
10199571|NCT04203537|Placebo Comparator|Placebo|Single administration
10199572|NCT04195685|Experimental|NFB Intervention and Delayed Intervention|The NFB system will read and interpret a participant's brain wave pattern which will be instantaneously fed back to the participant providing information, to which a participant can respond accordingly. The NFB specialist assumes a coaching role with people training on the NFB special use system to assist in the achievement of a focused relaxed state, which enhances the overall brain functioning. The significance and unique aspect of NFB is the direct impact on physiological dysregulation, which is the basis of this treatment approach. Twenty, one-hour, NFB training sessions will be provided to each participant in the intervention group and Delayed intervention group (those participants who completed the Control Group activities) by a trained NFB specialist over an 8-10-week period. Participants in the intervention group will receive up to 5-sessions but usually 3 sessions a week
10205035|NCT04264403|No Intervention|Sham Procedere|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. In these patients no RDN will be performed.
9662618|NCT05134168|Active Comparator|LIFT+bone marrow mononuclear cell injection|Patients underwent LIFT with bone marrow mononuclear cell injection
9662619|NCT05134142||Observational (Physical tests, questionnaires, record review)|Patients undergo physical performance assessments and complete quality of life assessments and questionnaires pre-hemipelvectomy, at 6 weeks post-hemipelvectomy, and then every 3 months up to 12 months and yearly thereafter for 10 years. Patients who are 1 year out from surgery complete pain-related questionnaires once. Patients who have already undergone hemipelvectomy prior to enrollment undergo medical record review.
9662620|NCT05134103|Experimental|Mindbeacon TAI-CBT for Depression group|Participants randomized to this condition will receive immediate Therapist-Guided Internet-CBT for Depression for 12 weeks.
9662621|NCT05134103|Other|Waitlist Control Group|Participants randomized to this condition will remain on the waitlist for 12 weeks before crossing over and receiving Therapist-Guided Internet-CBT for Depression for 12 weeks.
9662622|NCT05134090||Percutaneous laparoscopy|Laparoscopy with percutaneous grasp (2.9 mm).
9662623|NCT05134090||Conventional laparoscopy|Conventional laparoscopy with conventional laparoscopic trocars (10 or 5 mm).
9662624|NCT05134077|Experimental|kidneys with simple cysts|Patients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
9662625|NCT05134077|Active Comparator|contralateral kidneys without cyst|Рatients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
9662626|NCT05134064||PCa patients underwent 1 h p.i. PSMA PET/CT imaging and 3 h p.i. PSMA imaging|
9662627|NCT05134051|Experimental|Single arm|single arm intervention with IVL in calcified de novo coronary stenoses with indication of plaque modification technique during PCI
9662628|NCT05134025|Experimental|SMART A1|A full dose of meal-time insulin with announced exercise 15-minutes prior to commencement
9662629|NCT05134025|Experimental|SMART A2|a 25% dose reduction in meal-time insulin with exercise announcement 90-minutes prior to commencement
9662630|NCT05134025|Experimental|SMART A3|a 25% dose reduction in meal-time insulin with exercise announcement 45-minutes prior to commencement
9662631|NCT05134012|Experimental|[O-15]-Water PET Cardiac Perfusion Imaging|All participants with suspected CAD will receive two doses of [15-O]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).
9662632|NCT05133986|Experimental|Onion feeding first, couscous feeding second|Participants will report to the laboratory at 8am in a fasted state (water consumption is permitted) and provide a spot baseline urine sample. Participants will then be served a 120g portion of onions (experimental condition), prepared under standardized conditions. Participants shall remain supervised in the laboratory and will only consume water (100mL per hour) for the subsequent 6 hours, after which participants are free to consume their habitual diet (except alcohol, tea coffee, and FVs). In the 24-hour postprandial test period, participants will obtain urine samples at several time-points. Urine collection vessels will be used to obtain samples at 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 hours. This experimental protocol shall be repeated following a 4-day washout period (habitual diet consumption with no restrictions imposed on participants) with 120g of couscous consumed instead of onions, as a control condition.
9662633|NCT05133986|Experimental|Couscous feeding first, onion feeding second|Participants will report to the laboratory at 8am in a fasted state (water consumption is permitted) and provide a spot baseline urine sample. Participants will then be served a 120g portion of couscous (control condition), prepared under standardized conditions. Participants shall remain supervised in the laboratory and will only consume water (100mL per hour) for the subsequent 6 hours, after which participants are free to consume their habitual diet (except alcohol, tea coffee, and FVs). In the 24-hour postprandial test period, participants will obtain urine samples at several time-points. Urine collection vessels will be used to obtain samples at 0-1, 1-2, 2-4, 4-6, 6-12, 12-24 hours. This experimental protocol shall be repeated following a 4-day washout period (habitual diet consumption with no restrictions imposed on participants) with 120g of onions consumed instead of couscous, as an experimental condition.
9662634|NCT05133986|Other|Onion supplementation period|This dose-dependent biomarker validation intervention will include three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised. Participants will be asked to avoid onion intake throughout the supplementation periods, other than the portions provided by researchers. First morning void urine samples will be collected by participants on the morning after the supplementation period and obtained by researchers.
9662635|NCT05133947||CIPN patient|Patient with CIPN symptom
9662636|NCT05133947||Healthy subject|Healthy subject
9662637|NCT05133882|Experimental|Arm 1|Queue 1:Clifutinib Besylate:30mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:30mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
9662638|NCT05133882|Experimental|Arm 2|Queue 1:Clifutinib Besylate:40mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:40mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
9662639|NCT05133882|Experimental|Arm 3|Queue 1:Clifutinib Besylate:60mg qd d8-21;Daunorubicin 60 mg/m2 qd d1-3;Cytarabine 100 mg/m2 qd d1-7 Queue 1:Clifutinib Besylate:60mg qd d1-28 ;Azacitidine 75 mg/m2 qd d1-7
9662640|NCT05133869|Experimental|Baseline + intervention + follow up|All participants receive the same treatment in the same order. First there is a phase without treatment, the baseline phase. The length of this phase is randomly assigned to each participant. Then all participants follow a 42 day intervention, in which direct training and metacognitive training is combined. Afterwards they have a follow-up period, this length of this period is counterbalanced with the length of the baseline period so that the full study adds up to 150 days.
9662641|NCT05133843|Other|Coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
9662642|NCT05133791|Active Comparator|0.5 mg|Annexin A5-CW800, 0.5 mg, 1 dose
9662643|NCT05133791|Active Comparator|1.0 mg|Annexin A5-CW800, 1.0 mg, 1 dose
9662644|NCT05133791|Active Comparator|2.0 mg|Annexin A5-CW800, 2.0 mg, 1 dose
10199573|NCT04195685|No Intervention|Control Group|Participants in the control group will continue with their usual treatment and will receive a 15-minute call once a week for eight weeks from the PI on a health topic. This will help to keep members of the control group engaged in the project and receive the same information that is offered to the intervention group members. The health topics that are generally discussed during NFB sessions include sleep hygiene, basic nutritional concepts, beverage choices, positive thinking, thought reframing, fitness, daily calming activity, and enhancement of focus strategies.
10199574|NCT04175964|Experimental|Group 1|PCO patients that will receive ketogenic diet only
10199575|NCT04175964|Experimental|Group 2|PCO patients that will receive caloric diet with Metformin
9727942|NCT01891318|Experimental|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
9727943|NCT01883817|Placebo Comparator|Placebo|Corn/soy oil placebo capsules that are similar in shape and color to the DHA capsules given over 10 weeks
9727944|NCT01883817|Experimental|DHA Omega-3|Long-chain omega-3 fatty acid docosahexaenoic acid (DHA) at 1,200 mg/day, 600 mg twice daily for 10 weeks
9727945|NCT01859026|Experimental|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.~Phase I will be followed by an expansion Phase Ib."
9727946|NCT01859026|Experimental|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
9727947|NCT01859026|Experimental|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
9727948|NCT01849146|Experimental|Arm I (adavosertib, temozolomide, radiation)|"INITIATION CYCLE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks.~MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
9727949|NCT01849146|Experimental|Arm II (adavosertib, temozolomide)|Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9727950|NCT01838824|Experimental|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
9727951|NCT01838824|Experimental|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
9727952|NCT01837277|Experimental|Dolutegravir|Intervention: Patients will receive ART regimen based on investigational drug Dolutegravir 50 mg QD + TDF 300 mg QD+ 3TC 150 mg BID
9727953|NCT01837277|Active Comparator|Efavirenz|Intervention: Patients who received ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year, befor the use of DTG as SOC for first-line therapy (historic controls)
9727954|NCT01822522|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9727955|NCT01813435|Experimental|Experimental treatment strategy|"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.~Dosage and frequency:~Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)"
9727956|NCT01813435|Active Comparator|Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.~Dosage and frequency:~Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd"
9727957|NCT01792882||Cancer Subjects|
9727958|NCT01790035|Experimental|LGG|LGG (containing 10^10 viable bacteria) taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
9727959|NCT01790035|Experimental|Placebo|Placebo taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
9727960|NCT01790035|No Intervention|No intervention|Patients who prefer not to receive LGG will not be randomized and will receive standard of care RT. These patients will serve as a non-intervention comparator cohort to the first 20 patients and will have specimens collected but will not receive the placebo.
10199576|NCT04175964|Experimental|Group 3|PCO patients that will receive caloric diet only
10199577|NCT04175834|Other|diphenhydramine|25 mg diphenhydramine capsule, generic, sourced from Major Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
10199578|NCT04175834|Active Comparator|cetirizine|10 mg cetirizine tablet, generic, sourced from Mylan Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
10199579|NCT04157985|Active Comparator|Continue Treatment with PD-1/PD-L1 inhibitor|Continued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
10199580|NCT04157985|Experimental|Discontinue Treatment with PD-1/PD-L1-1 inhibitor|Discontinued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
10199581|NCT04141631|Experimental|STOP Group|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~Hb < 13g/dL the day before surgery~Hb ≥ 7g/dL AND ScvO2 > 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb < 7g/dL independently of ScVO2 value"
9727961|NCT01785342||Indeterminate Pulmonary Nodule|The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
10199582|NCT04141631|No Intervention|Control Group|"Only postoperative anemia will be managed:~RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)~Iron sucrose administration if Hb > 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg."
9727962|NCT01779050|Active Comparator|Arm I (definitive therapy)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
9727963|NCT01779050|Experimental|Arm II (definitive therapy, trastuzumab)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
10199583|NCT04137562|Experimental|ADSTEM Inj.|ADSTEM Inj. hAD-MSC 1.0x10^8 cells
10199584|NCT04137562|Placebo Comparator|Placebo|0.9% Normal Saline Inj.
9727966|NCT01765218|Placebo Comparator|Placebo|Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)
9727967|NCT01765218|Active Comparator|Topiramate|In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
9727968|NCT01753414|Other|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
9727969|NCT01753414|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
9727970|NCT01745757||Cohort|first line treatment for metastatic breast cancer
9727971|NCT01731522|Experimental|EF condition|
9727972|NCT01729455||BENLYSTA cohort|Participants with active, autoantibody-positive SLE treated with BENLYSTA at Baseline.
9727973|NCT01729455||Comparison cohort|Participants with active, autoantibody-positive SLE treated without BENLYSTA at Baseline.
9727974|NCT01725425|Experimental|Control|Participants will receive equal amounts of foods.
9727975|NCT01725425|Experimental|Increase Portion Size|Participants will receive increased portion sizes.
9727976|NCT01725425|Experimental|Decrease Portion Sizes|Participants will receive decreased portion sizes.
9727977|NCT01725425|Experimental|Mixed Portion Sizes|Participants will receive mixed portion sizes.
9727978|NCT01711554|Experimental|Treatment (lenalidomide, dinutuximab, isotretinoin)|Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
10199585|NCT04128670|Experimental|Kinesiotape (KT)|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. The tape will be applied with a tension of 10-20%.
10199586|NCT04128670|Placebo Comparator|Placebo Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
10199587|NCT04128670|No Intervention|No Tape|This group will not receive any intervention.
10199588|NCT04125745|Experimental|CXA-10|Oral CXA-10 300 mg once daily for 12 weeks
9727983|NCT01700439|Experimental|EDWARDS INTUITY valve|All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.
9727984|NCT01690299|Experimental|Apremilast 30 mg plus placebo injection|Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
9727985|NCT01690299|Experimental|Etanercept 50 mg plus placebo tablet|Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
10199589|NCT04125277|Experimental|Imaging|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
10199590|NCT04114851|Experimental|Active|Patients who get active monitor NoL
10199591|NCT04114851|No Intervention|control|control no NoL
10199592|NCT04104490||Severe pulmonary arterial hypertension.|"This cohort will consist of patients with severe pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of severe disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
10199593|NCT04104490||Mild-moderate pulmonary arterial hypertension|"This cohort will consist of patients with mild-moderate pulmonary arterial hypertension.~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of mild-moderate disease.~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.~This is an observational study with no interventions."
10199594|NCT04104490||Reference subjects without pulmonary hypertension|Reference subjects will be healthy people, age- and sex-matched to the other two cohorts, who have no pulmonary artery hypertension.
10199595|NCT04102150|Experimental|DS-3201b|
10199596|NCT04091724||Delirium is determined by PAED score|
10199597|NCT04091724||No delirium is determined by PAED score|
10199598|NCT04091347|Experimental|Intervention Arm|The intervention group will receive the intervention for 12 weeks. The wait list control group will have outcomes measured but will not receive the intervention at this time.
10199599|NCT04091347|Active Comparator|Wait List Control Arm|Once the intervention group has completed the intervention the wait list control group will complete the intervention.
10199600|NCT04090229|Experimental|ASLAN004|
10199601|NCT04090229|Placebo Comparator|ASLAN004 Placebo|
10199602|NCT04074928|Experimental|QIVc|Cell-derived Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
10199603|NCT04074928|Active Comparator|Comparator QIV|Comparator Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
10199604|NCT04070768|Experimental|Gemtuzumab Ozogamicin(GO) + Venetoclax|Gemtuzumab Ozogamicin(GO) + Venetoclax
10199605|NCT04058366|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
9662645|NCT05133778|Experimental|Sweet orange and pomegranate extract|Supplementation
9662646|NCT05133778|Placebo Comparator|Maltodextrin|Supplementation
9662647|NCT05133765|Experimental|SMART B1|Usual care pump therapy arm with carbohydrate consumption before exercise
9662648|NCT05133765|Experimental|SMART B2|Advanced hybrid closed loop therapy arm with carbohydrate consumption before exercise
9662649|NCT05133765|Experimental|SMART B3|Advanced hybrid closed loop therapy arm with carbohydrate consumption during exercise
9662650|NCT05133752|Experimental|Nemonoxacin|
9662651|NCT05133713||Catheter directed thrombectomy|
9662652|NCT05133713||Systemic anticoagulation|
9662653|NCT05133687|Experimental|Group (0.8-G)|This group will receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25%
9662654|NCT05133687|Experimental|Group (1.2-G)|This group will receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25%
9662655|NCT05133687|Active Comparator|Group G|This group will receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
9662656|NCT05133635|Active Comparator|Pulse methylprednisolone|250 mg methylprednisolone for 3 days
9662657|NCT05133635|Active Comparator|Tocilizumab|Tocilizumab 400-800 mg for one time
9662658|NCT05133609|Experimental|Group 1|Health professionals who will receive vaccine in the vaccination campaign against SARS-CoV-2.
9662659|NCT05133609|Experimental|Group 2|Patients with immune-mediated inflammatory diseases who will receive vaccine in the vaccination campaign against SARS-CoV-2.
9662660|NCT05133583|Experimental|intervatonal|
9662661|NCT05133583|No Intervention|control|
9662662|NCT05133557|Placebo Comparator|Placebo|Half the participants receiving placebo gum (2 gram; 1 gram xylitol) first,
9662663|NCT05133557|Experimental|BBE gum|Half receiving first the BBE gum (2 gram; 1 gram xylitol and 100 mg BBE) that were identical in size, shape, color and flavor. After 1 week the groups cross-over and chewed the other gum.
9662664|NCT05133544|Active Comparator|Endocuff- AI assisted colonoscopy|Endocuff (Olympus, Hong Kong) and AI assisted colonoscopy will be used first colonoscopy.
9662665|NCT05133544|Active Comparator|AI-assisted colonoscopy|AI assisted colonoscopy will be used first colonoscopy.
9662666|NCT05133544|No Intervention|Conventional colonoscopy|Conventional colonoscopy will be used without AI or Endocuff.
9662667|NCT05133492|Experimental|Interventional|Use of the EAST System for the stabilization treatment of AAA. The device is delivered endovascularly and placed in the AAA sac to deliver the Stabilizer Compound.
9662668|NCT05133479|Experimental|Intervention|Participants receive the Let's Know! intervention in small groups as provided by research staff
9662669|NCT05133479|No Intervention|Business-As-Usual|Participants continue to receive only their typical classroom instruction (i.e., no small groups)
9662670|NCT05133466||Northern pattern|Mothers recruited from Beijing
9662671|NCT05133466||East coastal pattern|Mothers recruited from Wuxi
9662672|NCT05133466||South-western pattern|Mothers recruited from Chengdu
9662673|NCT05133375|Experimental|GROUP A|Macintosh laryngoscope was used for endotracheal intubation.
9662674|NCT05133375|Experimental|GROUP B|McCoy laryngoscope was used for endotracheal intubation.
9662675|NCT05133349|Experimental|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
9662676|NCT05133258|Other|Chronic Suppurative Otitis Media group|Enrolled subjects with persistent otorrhea due to CSOM and prescribed with standard of care (prescription for antibiotic drops from a pharmacy of their choice with specific written instructions for self-administration).
9662677|NCT05133167|Experimental|GROUP A|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage.
9662678|NCT05133167|Experimental|GROUP B|In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage.
9662679|NCT05133102||Control|Patients who have undergone an endoscopy within the last three years and have never been diagnosed with Barrett's esophagus.
10199606|NCT04050150|Experimental|Arm Training in Standing|Task-oriented, functional arm training completed in standing or during walking. All participants receive the same arm training intervention.
10199607|NCT04048512||Resection with intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection with intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio Pulmonary By pass (CPB)
10199608|NCT04048512||Resection without intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection without intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio pulmonary By Pass (CPB)
10199609|NCT04042740|Experimental|Glecaprevir/Pibrentasvir (G/P)|"In Step 1, participants will receive G/P FDC tablets to be taken orally once daily for 4 weeks.~Any participant who experiences viral re-infection, suspected relapse, virologic failure, or undefined post-treatment HCV viremia may enter Step 2. In Step 2, participants may receive G/P FDC tablets orally once daily for 8-16 weeks. Some participants may also receive ribavirin (RBV) tablets orally twice daily. Alternate regimens are allowed in Step 2."
10199610|NCT04039503|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
9727986|NCT01690299|Placebo Comparator|Oral placebo tablets plus SC placebo injections|Identically matching placebo tablets and evaluator/subject-blinded SC injections
9727987|NCT01682317|Experimental|Three Meal|Participants in this condition will be instructed to limit their number of eating frequency to three meals per day.
9727988|NCT01682317|Experimental|Grazing|Participants in the increased eating frequency condition will be instructed to eat > 100 kcals every 2-3 hours.
9727989|NCT01659658|Experimental|IXAZOMIB 4 mg + Dexamethasone 20 mg/day|IXAZOMIB 4 mg, capsules, orally, once on Days 1, 8, and 15; plus dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15, and 22 of each 28-day cycle; dexamethasone may be increased up to 40 mg/day after 4 weeks, if tolerated. Participants may continue to receive treatment until Progressive Disease (PD) or unacceptable toxicity, whichever comes first.
9727990|NCT01659658|Active Comparator|Physician's Choice|"Participants will receive one of the following treatment options as selected by the physician:~Dexamethasone 20 mg/day: dexamethasone 20 mg/day, orally, on Days 1-4, 9-12 and 17- 20 of each 28-day cycle.~Dexamethasone 20 mg/day + Melphalan 0.22 mg/kg: dexamethasone 20 mg/day, orally, on Days 1-4 of each 28-day cycle; plus melphalan 0.22 mg/kg, orally, on Days 1-4 every 28 days.~Dexamethasone 20 mg/day + Cyclophosphamide 500 mg: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 every 28 days.~Dexamethasone 20 mg/day + Thalidomide 200 mg/day: dexamethasone 20 mg/day, orally, weekly Days 1, 8, 15 and 22 of each 28-day cycle; plus thalidomide total dose up to 200 mg/day, orally.~Dexamethasone 20 mg/day+ Lenalidomide 15 mg/day: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus lenalidomide 15 mg/day, orally, for 21 days every 28 days."
9727991|NCT01653925|Experimental|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids.
9727992|NCT01653925|Experimental|Drug intervention first|Intake of 5α-Reductase Inhibitor
9727993|NCT01607502||Patients of our outpatient clinic|Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
9727994|NCT01588119||Dabigatran|in atrial fibrillation
9727995|NCT01588119||Rivaroxaban|in atrial fibrillation and VTE
9727996|NCT01588119||Apixaban|in atrial fibrillation and VTE
9727997|NCT01588119||Edoxaban|in atrial fibrillation and VTE
9727998|NCT01525329|Experimental|Solid Organ Transplant with AKs|Patients who have undergone kidney or liver transplant within 2 years and have at least 4 premalignant skin lesions on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
9727999|NCT01525329|Active Comparator|Actinic Keratoses|Patients with at least 4 actinic keratoses on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
10199611|NCT04039503|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
10199612|NCT04039503|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
10199613|NCT04039503|Placebo Comparator|Placebo|Placebo administered SC once a week.
10199614|NCT04038957|Experimental|SEP-363856|SEP-363856 50mg, 75mg flexible dosing, dosed once daily
10199615|NCT04006717|No Intervention|Control|Routine root canal treatment
10199616|NCT04006717|Placebo Comparator|Low-Level Laser Placebo|Patient informed that laser will be applied but device won't be turned on
10199617|NCT04006717|Experimental|Low-Level Laser Therapy|Low-Level Laser Therapy following root canal treatment
10199618|NCT04006717|Experimental|Intracanal Cryotherapy|Cold saline irrigation before obturation
10199619|NCT04006717|Experimental|Combination of LLLT and ICCT|Both cold saline irrigation before obturation and Low-level laser Therapy after root canal treatment
10199620|NCT03996369|Experimental|Etrasimod 2 mg|
10199621|NCT03996369|Placebo Comparator|Placebo|
10199622|NCT03987217|Experimental|Group I (resistance training)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minute each for 12 weeks.
10199623|NCT03987217|Experimental|Group II (resistance training, creatine supplementation)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minutes each for 12 weeks and receive creatine monohydrate supplementation given orally 4 times daily during week 1, and then QD (once per day) during weeks 2-12.
10199624|NCT03973112|Experimental|HLX10 3 mg/kg + HLX04 5 mg/kg|HLX10 3 mg/kg + HLX04 5 mg/kg, as second-line treatment or above
10199625|NCT03973112|Experimental|HLX10 3 mg/kg + HLX04 10 mg/kg|HLX10 3 mg/kg + HLX04 10 mg/kg,as second-line treatment or above
10199626|NCT03973112|Experimental|HLX10|HLX10 3mg/kg, as second-line treatment or above
10199627|NCT03973112|Experimental|HLX10+HLX04 1L treatment|HLX10 3 mg/kg + HLX04 10 mg/kg: as first-line treatment
10199628|NCT03972254|Experimental|Intervention|Caregivers and their child will interact for 10 minutes while being observed and videotaped. Psychoeducation will be provided and goal setting will occur to ensure dyad specific relationship gains are made.
10199629|NCT03962504|Experimental|written exposure therapy|The WET condition consists of 5 weekly treatment sessions, with the first session lasting 1 hour and each subsequent session lasting approximately 40 minutes. The first session consists of education about common trauma reactions and the WET rationale. The participant is then given general instructions for completing the trauma narratives and specific instructions for completing the first 30-minute narrative writing session. All WET sessions begin with the therapist reading the specific writing instructions, clarifying any questions the person has, and leaving the instructions with the participant during the 30-minute writing session. Writing instructions begin with a focus on the details of the trauma and then shift to the meaning of the trauma event. After 30 minutes of writing, the therapist stops the writing and conducts a 5-10 minute check-in regarding how the writing session went for the participant.
10199630|NCT03962504|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a 8-15, 90 minute trauma-focused treatment which consists of imaginal and in vivo exposures
10199631|NCT03954184|No Intervention|TAU/Control|Sites in the Treatment as Usual (TAU)/Control Arm will receive product training/online support. Sites in the TAU/Control Arm will participate in a one-day product implementation or training session.
10199632|NCT03954184|Experimental|NIATx-TI Framework|Sites in the NIATx-TI Arm will receive product training/online support, and training in the NIATx-TI framework. The NIATx-TI framework will include a pre-implementation (planning) phase, and post-implementation (problem-solving) phase, with training delivered by a NIATx-TI coach.
9728000|NCT01514643||tibial plateau or plafond fracture|Tibial plateau or plafond fracture based on radiographs and/or CT scan will have synovial fluid aspirated from both the injured and uninjured joints in either the operating room if a procedure is planned for within 24 hours or in the emergency department. While the patient is under anesthesia in the operating room, the investigators will obtain blood samples.
9728001|NCT01510678|Experimental|Decrease Condition|In the Decrease Snack Foods condition participants will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
9728002|NCT01510678|Experimental|Increase + Decrease Condition|Families will be encouraged to increase fruits and vegetables and decrease snack foods.
9728003|NCT01510678|Experimental|Increase Condition|A parent and child will be encouraged to increase fruits and vegetables. Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables.
9728004|NCT01486537||theeth undergoing pulpotomy|
9728005|NCT01486537||teeth undergoing pulpectomy|
9728006|NCT01482286|Experimental|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
9728007|NCT01482286|Experimental|Dietary Restriction|Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
9728008|NCT01482286|Experimental|Exercise|Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
9728009|NCT01482286|No Intervention|Control|Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.
9728010|NCT01452152|Experimental|Genotype-directed, clopidogrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
9728011|NCT01452152|Experimental|Genotype-directed, prasugrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
9728012|NCT01452152|No Intervention|Standard of Care|Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.
9785298|NCT01248468|Experimental|Aspirin, acetaminophen and caffeine|AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
9785299|NCT01248468|Active Comparator|Sumatriptan (100 mg)|1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
9785300|NCT01248468|Placebo Comparator|Placebo|1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
10199633|NCT03949504||General population|Male and Female subjects (n=1000) over 34 years of age randomly recruited from the participants to the recall phase of the Moli-sani study
10199634|NCT03949504||Patients with type 2 Diabetes|Male and Female patients with type 2 diabetes (n=550) without (n=200) or with cardiovascular (n=200) or neurological (n=150) complications consecutively admitted to the IRCCS Neuromed
10199635|NCT03945773|Experimental|Cohort A|Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.
10199636|NCT03945773|Experimental|Cohort B|Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.
9728013|NCT01420926|Experimental|Arm A (decitabine)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-10. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9728014|NCT01420926|Experimental|Arm B (decitabine and bortezomib)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 2-11 and 1.3 mg/m^2 bortezomib SC on days 1, 4, 8, and 11. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR or CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9728015|NCT01416285||control group|control group receiving regular education from a nurse
9728016|NCT01416285||Case management group|This is the study group. Extensive education and case management program will be performed in this group.
9728017|NCT01386385|Experimental|Arm I (RT, veliparib, carboplatin, paclitaxel)|Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
9728018|NCT01386385|Active Comparator|Arm II (3D-CRT, placebo, carboplatin, paclitaxel)|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
9728019|NCT01381159|Experimental|Motivational Communication|Up to 3 x 30 minute brief MC sessions within 4-6 week period
9728020|NCT01381159|Placebo Comparator|Control|Usual care
9728021|NCT01375829|Experimental|Treatment (ixabepilone, temsirolimus)|Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9728022|NCT01364051|Experimental|Treatment (cediranib maleate, selumetinib)|Patients receive cediranib maleate PO QD and selumetinib sulfate PO QD or BID on days 1-28 (days 8-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles may be extended to 12 weeks after 1 year of study treatment.
9728023|NCT01358877|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m^2 + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
9728024|NCT01358877|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram [mg/kg] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m^2) + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin AUC 6 (up to 900 milligrams [mg]).
9728025|NCT01352949||Healthy Volunteers|Healthy volunteers without scoliosis or obesity
9728026|NCT01352949||Obesity|Healthy volunteers with obesity
9728027|NCT01352949||Scoliosis|Healthy volunteers with scoliosis but no obesity
9728028|NCT01313351||Device testing|Tears were collected from subjects to apply to the RPS InflammaDry detector and were clinically evaluated.
9728029|NCT01267955|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9728030|NCT01256398|Experimental|Treatment (chemotherapy, transplant)|See Detailed Description
9728031|NCT01253070|Experimental|Treatment (daunorubicin, cytarabine, sorafenib tosylate)|"INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
9728032|NCT01239082|Other|Arm 1|Colonoscopy (one time screening)
9728033|NCT01239082|Other|Arm 2|FIT (annually)
10199637|NCT03914651|Active Comparator|300IU rFSH stimulation group|300IU rFSH stimulation group is defined as patients using gonadotropin-releasing hormone（GnRH）antagonist protocol with a 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation.
10199638|NCT03914651|Experimental|150IU rFSH stimulation group|150IU rFSH Gonal-F® stimulation group is defined as patients using GnRH antagonist protocol with a 150IU rFSH starting dose during controlled ovarian stimulation.
9728034|NCT01232283|Experimental|Apremilast|Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.
9728035|NCT01232283|Placebo Comparator|Placebo|Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( < PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).
9728036|NCT01231516|Experimental|GSK1349572 + Raltegravir Placebo|Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
9728037|NCT01231516|Active Comparator|Raltegravir + GSK1349572 Placebo|Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
9728038|NCT01229943|Experimental|Arm I (octreotide acetate and everolimus)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.
9728039|NCT01229943|Experimental|Arm II (octreotide acetate, everolimus, and bevacizumab)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.
9728040|NCT01194219|Active Comparator|Apremilast|Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
9728041|NCT01194219|Placebo Comparator|Placebo|Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
9728042|NCT01194219|Active Comparator|Apremilast 30 mg|Apremilast 30 mg by mouth (PO) twice a day (BID). Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost). At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study. Non-responders or partial responders (PASI response <75) received additional topical therapies or phototherapy beginning at Week 32.
9728043|NCT01193842|Experimental|Arm A (VR-DA-EPOCH)|Patients receive vorinostat PO QD on days 1-5; rituximab IV on day 1; etoposide IV over 24 hours, doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on days 1-4; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9728044|NCT01193842|Experimental|ARM B (DA-R-EPOCH)|Patients receive rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9728045|NCT01176578|Experimental|T2DM|Type 2 Diabetes Mellitus
9728046|NCT01176578|Experimental|IGT|Impaired Glucose Tolerance
9728047|NCT01176578|Active Comparator|NGT|Normal Glucose Tolerance
9728048|NCT01169831|Experimental|Sedentary Older Adults|
9728049|NCT01169831|Experimental|Older Endurance Athletes|
10199639|NCT03913195|Experimental|Sentinel Group|Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
10199640|NCT03913195|Experimental|Core Group|HIV-infected Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds. Healthy Volunteer Core Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
9728050|NCT01168921|Experimental|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle.
9728051|NCT01064648|Experimental|Arm I (pemetrexed disodium, cisplatin, cediranib maleate))|Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
9728052|NCT01064648|Active Comparator|Arm II (pemetrexed disodium, cisplatin, placebo)|Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
9728053|NCT01061840|Experimental|1 x 10 ^7 cells/injection|Vigil™
9728054|NCT01061840|Experimental|2.5 x 10 ^7 cells/injection|Vigil™
9728055|NCT01061840|Experimental|1 x 10^6 or 4 x 10^6 cells/injection|Vigil™
9785301|NCT01248585|Active Comparator|Dexamethasone|2 x 4 mg dexamethasone tablets taken once daily for 5 days
10199641|NCT03913195|Experimental|Intramuscular Injection Group|HIV-infected Intramuscular Injection Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via Intramuscular Injection. Healthy Volunteer Intramuscular Injection Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via intramuscular injection.
10199642|NCT03906994|Experimental|Subjects with Amblyopia|Adult amblyopia subjects will play the video game Mario Kart Wii
10199643|NCT03896399|Experimental|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
10199644|NCT03894995|No Intervention|Part 1. Focus group discussions on ventilation preferences|Participant's perceived benefits/detriments of having ventilation options in the household and their opinions on the behavior change material developed to encourage increased household ventilation will be explored using 6-9 focus group discussions with 10-12 participants each.
10199645|NCT03894995|No Intervention|Part 2. PM 2.5 pilot|Indoor, outdoor, and personal particulate matter concentrations among ten mother-child pairs and their homes will be monitored.
10199646|NCT03894995|Experimental|Part 3. Intervention|Households will participate in a baseline survey and a Beck-DeGroot-Marshak auction to establish willingness-to-pay for ventilation. If the household wins, or if it is decided to install ventilation in all intervention households, the household will receive installation of a ventilating mechanism.
9728056|NCT01012817|Experimental|Treatment (veliparib and topotecan hydrochloride)|Patients receive veliparib PO on days 1-3, 8-10, and 15-17 (veliparib is omitted on days 1-3 of course 2) and topotecan hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10199647|NCT03894995|No Intervention|Part 3. Control|For 12 month after intervention, the air exchange rate will be measured in all control households.
10199648|NCT03894995|No Intervention|Part 4. Spillover|Households that neighbor enrolled study households will be surveyed and asked whether they, on their own, chose to install a window. If they did install a window, they will be asked how much they paid.
9728059|NCT00980538|Experimental|Etravirine|Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
9728060|NCT00878163|Experimental|Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)|Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9728061|NCT00855803|Experimental|Radiation followed by Vertebroplasty|"Intervention:~This study is one arm. All patients will undergo radiotherapy followed by vertebroplasty. Patients who had prior radiotherapy will undergo 5 fractions of stereotactic body radiotherapy (SBRT) over 30-90 minutes each. Patients has no prior radiotherapy will undergo 1 fraction of SBRT over 30-90 minutes. The full patient population will then undergo vertebroplasty*.~*Vertebroplasty may not be possible for certain patients due to tumor location or safety. In such cases, patients will omit the vertebroplasty but receive all other protocol care and follow-up."
9728062|NCT00843817|Experimental|DRUG|PULMOZYME
10199649|NCT03878199|Experimental|Treatment (CPX-351, ruxolitinib, allogeneic SCT)|See Detailed Description.
9728064|NCT00792948|Experimental|Treatment (chemotherapy, transplant, maintenance)|See Detailed Description
9728065|NCT00790803|Other|Pegaptanib (Macugen)|Open label, non randomized, interventional controlled injection of 0.3mg of Pegaptanib (Macugen) every 6weeks with max of 5 injections over 30weeks.
10199650|NCT03855735|Experimental|Intervention Group (IG)|Those who give birth and relatives who have been arbitrarily assigned to the control group receive online training on different communication models competencies and will gain access to the digital app.
10199651|NCT03855735|No Intervention|No Intervention|Those who give birth and relatives who have been arbitrarily assigned to the control group do not receive any training on different communication models competencies and will not gain access to the digital app. The control group will receive a paper-pencil version.
9728066|NCT00740116|Active Comparator|The Tranexamic acid group|The group of women receiving Tranexamic acid intravenously immediately before the surgery
9728067|NCT00740116|Placebo Comparator|The placebo group|The group of women receiving saline solution (0.9% NaCl) intravenously immediately before the surgery
9728068|NCT00715611|Experimental|1|This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.
9728069|NCT00702494|Experimental|1|Multiple IV doses of TB-403, an antibody directed against PlGF
9728070|NCT00641420|Experimental|Fractional Laser 10mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 10mJ.
9728071|NCT00641420|Experimental|Fractional Laser 40mJ|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 40mJ.
9728072|NCT00579124|Other|1. CliniMACS CD3+/CD19+ depletion|"6/6 or 8/8 matched (fully matched)~1 antigen or allele mismatched (mismatch at A or B or DRB1)~2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B).~Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused."
9785302|NCT01248585|Placebo Comparator|Placebo|2 placebo tablets taken once daily for 5 days
9728073|NCT00579124|Other|2. CliniMACS CD3+/CD19+ depletion|"Stratum 2. CliniMACS CD3+/CD19+ depletion:~Haploidentical match~2 antigen and/or allele mismatched where one of the mismatches includes DRB1~For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum."
9728074|NCT00565617|Experimental|Synergy, Epidural cortical stimulation|Epidural cortical stimulation (medial prefrontal cortex) for treatment resistant depression. The primary aim of this pilot study was to assess the feasibility and safety of EpCS in patients with treatment-resistant depression. Ultimately, for EpCS to be found effective, a much larger double blind placebo controlled study would be needed.
9728075|NCT00551616|Experimental|CDB-2914|
9728076|NCT00551616|Active Comparator|Levonorgestrel|
9728077|NCT00516724|Experimental|1|Carboplatin + KU-0059436
9728078|NCT00516724|Experimental|2.|Paclitaxel + KU-0059436
9728079|NCT00516724|Experimental|3.|Paclitaxel, Carboplatin + KU-0059436
9728080|NCT00515372|Active Comparator|Intervention Group|Weekly phone calls lasting about 30 minutes. Lists of professional resources and referral recommendations will be provided.
9728081|NCT00515372|Other|Usual Care Group|Lists of professional resources and referral recommendations will be provided.
9728082|NCT00505310|Experimental|Emotional Expression Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
9728083|NCT00505310|Experimental|Neutral Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
9728084|NCT00470704|Other|Cohort 1|"This cohort is made up of participants without prior trastuzumab for MBC. Adjuvant or neoadjuvant trastuzumab was allowed, if the interval from trastuzumab completion to recurrence exceeded 1 year.~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
10199652|NCT03847337|Experimental|New to diagnosis|We will test two telemedicine tools with children who have not been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
9728085|NCT00470704|Other|Cohort 2|"This cohort is made up of participants with one to two lines of chemotherapy for metastatic disease with at least one trastuzumab-containing regimen or patients who recurred within 12 months of adjuvant or neoadjuvant trastuzumab with up to one line of metastatic trastuzumab-based therapy~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
9728086|NCT00434837|Experimental|Low-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the Low-tension group will receive the low-tension treatment with initial graft tension set so that the anterior-posterior (A-P) displacement of the reconstructed knee is equal to that of the uninjured knee.
9728087|NCT00434837|Experimental|High-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the High-tension group will receive the high-tension treatment with the initial graft tension set to reduce A-P displacement by 2 millimeters relative to that of the uninjured knee.
9728088|NCT00434837|No Intervention|Uninjured Control Group|Uninjured age, sex, and race matched control group
10199653|NCT03847337|Experimental|Previously diagnosed|We will test two telemedicine tools with children who have been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
10199654|NCT03812107|Experimental|Moderate Treatment Approach|Participants in this arm who relapse will be able to move more freely between follow up steps and are hypothesized to require fewer provider visits than those in the intensive treatment arm.
9728089|NCT00427193|Experimental|Caloric Restriction (CR)|25% caloric restriction
9728090|NCT00427193|Active Comparator|Control, Ad libitum (AL)|Ad libitum energy intake
10199655|NCT03812107|Active Comparator|Intensive Treatment Approach|Participants in this arm who relapse will follow the current guidelines follow up steps of weekly, then every two weeks and finally monthly provider visits.
9728091|NCT00301119||lung cancer screening cohort|observational only. no intervention. current, former and never smokers over age 50 without history of cancer, except for non melanoma skin cancer, no previous treatment with chemotherapy.
10199656|NCT03803423|Experimental|The Donor App|Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.
10199657|NCT03802955|Experimental|ADG106 Dose escalation|
10199658|NCT03778229|Experimental|osimertinib + savolitinib|osimertinib + savolitinib
10199659|NCT03775343||General Anesthesia|"General anesthesia:~25 patients older than 65 years, undergoing elective eye surgery under general anesthesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative.~Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
10199660|NCT03775343||Local anesthesia with sedoanalgesia|"25 patients older than 65 years, undergoing elective eye surgery under local anesthesia in combination with sedoanalgesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
9728092|NCT00301119||r/o lung cancer|observational only. no intervention. patients with CT findings suspicious for lung cancer who are undergoing bronchoscopy and/or surgery.
9728093|NCT00148733|Experimental|Zinc|Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water
9728094|NCT00148733|Placebo Comparator|Placebo|Placebo
9728095|NCT00142584|Experimental|1-NEB|Nebivolol
9728096|NCT00142584|Active Comparator|2-MET|Metoprolol
10199661|NCT03775343||Control Group|"25 patients, not undergoing any operative intervention. To determine a normal reference value of cognitive functions, a group of 25 individuals without an operative intervention will be recruited as a control group.~Intervention: neurocognitive testing (Neurocognitive Test Battery) at 3 determined time points (0, 6 and 24 hours)"
10199662|NCT03749967|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
10199663|NCT03749967|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is ten sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
10199664|NCT03749967|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifteen sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
9728098|NCT00107250|Experimental|AZD2171 + Standard chemotherpay regimens|
9780950|NCT01135394|Experimental|Pioglitazone (Actos)|Participants will have metabolism studies to consist of outpatient X-ray and MR measurements of bone density and body composition, metabolic testing (intravenous glucose tolerance test), and muscle and adipose tissue biopsies. Blood will also be drawn for genetic testing and for microarray studies of leukocytes. Upon completion of the above studies, the participant will begin pioglitazone therapy. Every 4 weeks throughout the drug intervention, glycemic control, lipoprotein profile, and weight will be monitored. After 12 weeks of pioglitazone therapy, the X-ray and MR measurements of body composition, the biopsies, microarray studies for leukocytes and the metabolic tests will be repeated.
9780951|NCT01135420|Active Comparator|Usual Care|Psychiatry inpatient usual care
9780952|NCT01135420|Experimental|Telephone Monitoring|Patients in the TM condition will receive an in-person session while in treatment, followed by monitoring over the telephone for three months after discharge. The intervention will incorporate motivational interviewing to monitor patients' substance use, facilitate entry into outpatient treatment, and encourage 12-step self-help group participation.
9780953|NCT01135498|Experimental|1|
9780954|NCT01135511|Experimental|Treatment 1|
9780955|NCT01135511|Experimental|Treatment 2|
9780956|NCT01135511|Experimental|Treatment 3|
9780957|NCT01135511|Placebo Comparator|Treatment 4|
9780958|NCT01135511|Active Comparator|Treatment 5|
9780959|NCT01135524|Experimental|BTDS|Buprenorphine transdermal patch
9780960|NCT01135537|Experimental|Thymoglobulin|Thymoglobulin 7.5 mg/kg/course prior to HSCT
9780961|NCT01135914|Experimental|Combination Therapy|Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
9780962|NCT01135914|Experimental|Ranibizumab Monotherapy|Participants received ranibizumab intravitreal injection therapy only
9780963|NCT01135914|Active Comparator|Laser Monotherapy|Participants received Laser photocoagulation therapy only
9780964|NCT01135992|Experimental|IGlar/IDeg|
9780965|NCT01135992|Experimental|IDeg 3TW|
9780966|NCT01136174|Experimental|BIBF 1120 50 mg|Low dose for cohort 1
9780967|NCT01136174|Experimental|BIBF 1120 100 mg|Middle dose for cohort 2
9780968|NCT01136174|Experimental|BIBF 1120 150 mg|High dose for cohort 3
9780969|NCT01136174|Placebo Comparator|Placebo|Placebo for cohort 1,2,3
9780970|NCT01136226|Other|Eligard (TM)|Eligard (TM) administered 22.5mg
10199665|NCT03749967|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
9780971|NCT01136291|Other|physical exercise|exercise on obese and overweight pregnant women, routine prenatal care and nutritional counseling
9780972|NCT01136291|No Intervention|no exercise|Routine prenatal care and nutritional counseling. No exercise
9780973|NCT01136356|Experimental|Morphine, then Buprenorphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
9780974|NCT01136356|Experimental|Buprenorphine, then Morphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
9780975|NCT01136382|Experimental|1|Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
9780976|NCT01136382|Placebo Comparator|2|Placebo pMDI 2 inhalations bid
9780977|NCT01136408|Experimental|Dabigatran etexilate 220 mg daily|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
9780978|NCT01136408|Experimental|Dabigatran etexilate 300 mg daily|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
9780979|NCT01136408|Active Comparator|Warfarin|Dose-adjusted warfarin based on target INR values
10199666|NCT03749967|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
10199667|NCT03749967|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
10199668|NCT03749967|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
10199669|NCT03749967|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
10199670|NCT03749967|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
10199671|NCT03749967|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
9728099|NCT05285696|Experimental|[68Ga]-NOTA-hGZP (CSB-111) Injection|Eligible participants will receive a single IV injection of CSB-111 up to 40 micro grams followed by PET/CT imaging at 10, 60, 120 and 180 min post-injection.
9728100|NCT05285670|Experimental|Digital counseling plus interactive two-way SMS dialogue|Participants will receive initial counseling on a tablet followed by automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
9728101|NCT05285670|No Intervention|Control|Control receiving standard of care.
9728102|NCT05285657|No Intervention|Control Arm|Febrile children will be managed according to the IMCI (integrative management of childhood illnesses) and the guideline of diagnostic and treatment (GDT), which are part of the routine system existing in Burkina Faso. Treatment will be done according to the national guideline.
9728103|NCT05285657|Active Comparator|RDTs decisional Arm|The clinical examination based on IMIC will be supported by two-step malaria RDT and bacterial infections RDTs. Prescription will be left to the discretion of the healthcare workers.
9728104|NCT05285657|Active Comparator|e-algorithm Arm|Artificial intelligence integrating multiple layers of clinical information such as clinical examination, signs/symptoms and medical history, and laboratory information such as outcomes of biomarkers (CRP and WBC) and pathogen specific POCT (malaria and bacterial infections) and oximetry will be developed. The e-algorithm will serve to guide the diagnostic and management of febrile infections in children from 2 to 59 months.
9728105|NCT05285644|Experimental|AR 15512 Ophthalmic Solution (0.003%)|0.003% AR 15512 to be administered twice daily for 90 days. Both eyes will be treated.
9728106|NCT05285644|Placebo Comparator|Vehicle|AR-15512 vehicle to be administered twice daily for 90 days. Both eyes will be treated.
9728107|NCT05285618|Experimental|Predicting the perceptual experience of retinal prosthesis patients|This intervention will assess the effect of different stimulation strategies on the perceptual experience of retinal prosthesis patients. We will produce visual percepts in patients either by directly stimulating electrodes (using FDA-approved pulse trains) or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Existing blind users of the Argus II will be recruited for this study. Performance of Argus II users will be compared to performance of sighted subjects viewing a prosthetic vision simulation in virtual reality.
9728108|NCT05285605||Emergency Contraceptive Group|Group of participants receiving emergency contraception in the form of 3 packages of ulipristal acetate to use at home if needed.
9728109|NCT05285579||TKI+ICI|Therapeutic combination tyrosine kinase inhibitor (TKI) + immune checkpoint inhibitors (ICI)
9728110|NCT05285579||ICI+ICI|Therapeutic combination with different immune checkpoint inhibitors (ICI)
9728111|NCT05285566|Experimental|Exparel® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Exparel®
9728112|NCT05285566|Active Comparator|Xylocaine® Injection Group|On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Xylocaine® as part of standard of care.
9728113|NCT05285553|Experimental|MiSight 1 day|MiSight 1 day
9728114|NCT05285553|Active Comparator|Proclear 1 day|Proclear 1 day
9728115|NCT05285501|Experimental|Virtual Therapeutic Garden|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of VRTierOne therapy (20 minutes each)"
9728116|NCT05285501|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:~8 sessions of general fitness training (40 minutes each) 8 sessions of group relaxation and psychoeducation (20 minutes each)"
9728119|NCT05285462|Active Comparator|Usual Care PT|Patients will attend normal course of PT without influence from study team.
9728120|NCT05285462|Experimental|Usual Care PT + VR Pain Education|Patients will attend normal course of PT without influence of duration or frequency of care. Patients will also receive up to 12 session of pain education delivered via VR headset
9728121|NCT05285449|Active Comparator|Dietary Supplement: Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate
9728122|NCT05285449|Placebo Comparator|Dietary Supplement: CBD matching Placebo|Matching Placebo
9728123|NCT05285436|Experimental|CloudCath detection|Active monitoring of dialysate effluent by the CloudCath System.
10199672|NCT03714984|Experimental|Pre operative exercise|The educational pelvic floor intervention group will receive one months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction. Patients and care giver will receive a daily exercise diary to fill at home and will be advised to follow the exercise program.
10199673|NCT03714984|Active Comparator|Control group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
9728125|NCT05285397|Experimental|Liraglutide|drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day
9728126|NCT05285397|No Intervention|Control|Patients with no weight loss drug intervention after bariatric surgery
9728127|NCT05285384|Experimental|SpikoGen COVID-19 Vaccine|
9728128|NCT05285345||Pre-Guideline Implementation|Participants in this group will be recruited during the first 3 months of the study and the time will be used for baseline data collection with existing standards of care around discharge practices of infants with BPD
9728129|NCT05285345||Post-Guideline Implementation|After 3 months, the discharge bundle developed from consensus from the Delphi process will be introduced to both NICUs using Quality Improvement principles. Participants will be recruited after the introduction of the discharge bundle.
9728130|NCT05285332|Experimental|1 Primary and metastatic lesions PCR|surgery 1 Mastectomy OR Breast conserving surgery
9728131|NCT05285332|Experimental|2 Primary lesions NPCR and metastatic lesions PCR|surgery 1 Mastectomy OR Breast conserving surgery
9728132|NCT05285332|Experimental|3 Primary lesions PCR and metastatic lesions NPCR|surgery 2 Resection of metastasis
9728133|NCT05285332|Experimental|4 Primary lesions NPCR and metastatic lesions NPCR|Systemic therapy Endocrine therapy or chemotherapy or targeted therapy
9728134|NCT05285306|Experimental|PEACE Program|3 sessions of tailored coping skills related to pelvic examinations
9728135|NCT05285293|Active Comparator|Group 1 Control|PRF in intra-bony defects
9728136|NCT05285293|Experimental|Group 2 Experimental|PRF and Retinol in intra-bony defects
9728137|NCT05285254|Experimental|Immunization Administration with Certified Child Life Specialist Support (CCLS)|Nursing will administer immunizations to children with the support of a CCLS
9728138|NCT05285254|No Intervention|Current Standard of Care for Immunization Administration|Nursing will administer immunizations to children per their current standard of care.
9728139|NCT05285228|Active Comparator|Control group: allocation to specific taste of fluoride varnish|allocation to specific taste of fluoride varnish
9728140|NCT05285228|Experimental|Test group: child chooses taste of fluoride varnish|child chooses taste of fluoride varnish before dental treatment
9728141|NCT05285215|Experimental|Integrated psychological program (IPP) group|Patients are assigned to have mindfulness training and music listening before and after delivery. Video counselling will be offered if patient is found to have Edinburgh Postnatal Depression Scale (EPDS) equal to or more than 10. Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
9728142|NCT05285215|No Intervention|Non- Integrated psychological program (IPP) group|Questionnaires on psychological and pain assessments will be administered before and after delivery, with the final time point being 2 months after delivery.
9728143|NCT05285163|Experimental|palliative care education|The patients in the intervention group were presented palliative care training in addition to their usual care. The training period lasts at least 45 minutes. After the training, patients were given the book 'Palliative Care in Heart Failure'. In this training, patients were informed about heart failure and pharmacological and non-pharmacological methods for symptoms such as dyspnea, pain, constipation, depression, edema, tiredness, nausea. The patients were followed up by telephone at the first, third, and sixth months after discharge. The patient's symptoms and quality of life were re-evaluated in telephone follow-up. During the follow-up period, the patient's training related to symptoms was repeated. The patients were referred to the physician for the symptoms and problems which they experienced in the house.
9728144|NCT05285163|No Intervention|usual care|Firstly, the usual care provided to patients was described. It was determined that patients were not given regular and comprehensive training on heart failure, and no training was given on palliative care. Written educational material was not given to the patients. Patients were not followed up after discharge. Palliative care was not discussed with patients and their relatives. Also, they were not asked about their preferences. In usual care, Heart failure patients received medical treatment for their symptoms during hospitalization.
9728145|NCT05285137|Experimental|Cohort 1A (sentinel)|Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
10199674|NCT03707093|Experimental|ADG106 Dose escalation|
9728146|NCT05285137|Experimental|Cohort 1A (main)|Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by IM injection
9728147|NCT05285137|Experimental|Cohort 1B (sentinel)|Low dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
9728148|NCT05285137|Experimental|Cohort 1B (main)|Low dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 50 mg CD388 or placebo, administered by SQ injection
9728149|NCT05285137|Experimental|Cohort 2A (sentinel)|Middle dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
9728150|NCT05285137|Experimental|Cohort 2A (main)|Middle dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
10199675|NCT03695172|Active Comparator|TAP block|Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
10199676|NCT03695172|Active Comparator|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
10199677|NCT03695172|Active Comparator|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
10199678|NCT03680287|Active Comparator|Uninterrupted Sleep|Participants will be permitted to sleep without interruption for 8 hours.
10199679|NCT03680287|Experimental|Sleep Disruption|Participants will be repeatedly awakened throughout the night according to a standardized protocol.
9728151|NCT05285137|Experimental|Cohort 2B (sentinel)|Middle dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
9728152|NCT05285137|Experimental|Cohort 2B (main)|Middle dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of 150 mg CD388 or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
9728153|NCT05285137|Experimental|Cohort 3A (sentinel)|High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of CD388 (dose to be determined [TBD] based on observed safety and tolerability but no more than 3-fold the middle dose level) or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
9728154|NCT05285137|Experimental|Cohort 3A (main)|High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of CD388 (dose TBD based on observed safety and tolerability but no more than 3-fold the middle dose level) or placebo, administered by IM injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
9728155|NCT05285137|Experimental|Cohort 3B (sentinel)|High dose level: 2 subjects randomized at a ratio of 1:1 to receive a single dose of CD388 (dose TBD based on observed safety and tolerability but no more than 3-fold the middle dose level) or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
9728156|NCT05285137|Experimental|Cohort 3B (main)|High dose level: 9 subjects randomized at a ratio of 7:2 to receive a single dose of CD388 (dose TBD based on observed safety and tolerability but no more than 3-fold the middle dose level) or placebo, administered by SQ injection, followed by another single dose of the same treatment (CD388 or placebo) administered by the same route 3 months or 5 effective half-lives, whichever is longer, after the first dose
9728157|NCT05285124|Experimental|Intervention of circadian rhythm|After taking melatonin, HD tDCS was used for treatment, and the data before and after treatment were collected
9728158|NCT05285124|Placebo Comparator|No intervention in circadian rhythm|After taking placebo, patients were treated with HD tDCS, and the data before and after treatment were collected
9728159|NCT05285085||Secondary prevention|Individuals with previous myocardial infarction and/or stroke
9728160|NCT05285085||Primary prevention|Individuals with hypertension, diabetes and/or dyslipidemia
9728161|NCT05285085||Unknown diagnosis|Individuals without a previous myocardial infarction and/or stroke or a diagnosis of hypertension, diabetes and/or dyslipidemia
9728162|NCT05285072||Vascular graft infection|Patients with confirmed vascular graft infection according to current syndromic criteria.
9728163|NCT05285072||Vascular graft without infection|Patients with no clinical evidence of infection and CRP less than 5.
9728164|NCT05285059||Patients|8- to 14-years-old children with epilepsy
9728165|NCT05285059||Control|8- to 14-years-old children without neurological, psychiatric, or developmental impairments
9728166|NCT05285020|Experimental|Alter G group|"This group will perform the hospital's standard protocol for these injuries once a day during two weeks.~They carried out the re-education of the gait (at the parallel bars) with a progressive load in scale controlled by the patient.~Also, they carried out a re-education of the gait and progressive loading in the system Alter G (anti-gravity treadmill)."
9728167|NCT05285020|Other|Control group|"This group will perform the hospital's standard protocol for these injuries once a day during two weeks.~They just carried out the re-education of the gait (at the parallel bars) with a progressive load in scale controlled by the patient."
9728168|NCT05285007|Experimental|Primary Intervention Group|The experimental group will receive two interventions to increase dorsiflexion range of motion.
9728169|NCT05285007|Active Comparator|Minimal Intervention Group|The minimal intervention group will read and infographic and complete 5 minutes of treadmill walking.
9728170|NCT05284994|Other|TQ-B3525 Tablets + Osimertinib Mesylate Tablets.|TQ-B3525 tablets combined with osimertinib mesylate tablets, 30 days as a treatment cycle.
9728171|NCT05284968|Experimental|Cell injection|Cell injection
10199680|NCT03632239||GAPP|Individuals undergoing phenotyping by GAPP
9728172|NCT05284942|Experimental|Mycophenolate mofetil|Mycophenolate mofetil oral 500mg twice a day from baseline to week 108
9728173|NCT05284929||Patients with pemphigus|
9728174|NCT05284929||Healthy controls|
9780980|NCT01136655|Experimental|BUD 160/FM 2.25|2.25 μg formoterol (as 80/2.25 μg Symbicort pMDI × 1 inhalation) + 40 μg budesonide HFA pMDI × 2 inhalations
10199681|NCT03599583|Experimental|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
10199682|NCT03599583|No Intervention|Control|Arm 2 will receive standard of care
10199683|NCT03560323|Active Comparator|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
10199684|NCT03560323|Active Comparator|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
10199685|NCT03560323|Active Comparator|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
10199686|NCT03556085|Experimental|Venous sinus stenting|Subjects will have stenting of the transverse-sigmoid sinus
10199687|NCT03554044|Experimental|Cohort I (talimogene laherparepvec, chemotherapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with one of the following chemotherapies: paclitaxel (IV), nab-paclitaxel IV, or gemcitabine / carboplatin IV.~Cycles repeat every 21 days until disease progression or unacceptable toxicity"
10199688|NCT03554044|Experimental|Cohort II (talimogene laherparepvec, endocrine therapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-21 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses.~Cycles repeat every 28 days until disease progression or unacceptable toxicity"
10199689|NCT03552380|Experimental|Entinostat, Nivolumab and Ipilimumab|"Entinostat: 5mg, 3mg, or 2mg orally (PO) on D1, 8, 15 plus Nivolumab: 3 mg/kg IV D1 and Ipilimumab 1 mg/kg IV D1~Each cycle is 21 days"
10199690|NCT03547661|No Intervention|Treatment as Usual|The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.
10199691|NCT03547661|Active Comparator|Integrative Open-Label Placebo|"The intervention will encompass an integrative administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
10205036|NCT04261218|Experimental|Group 1 - Dose Finding|The first 3 patients enrolled in Group 1 will receive tomivosertib at a dose of 100 mg orally twice daily (BID), under fasting conditions, and will be assessed for dose limiting toxicities (DLTs) during this 'run-in' period. They will also receive the first cycle of tomivosertib IN COMBINATION with weekly paclitaxel in the 'post run-in' period. Depending on the occurrence/absence of DLTs, this first group of 3 patients may need to be expanded (up to 9 patients) or the trial may proceed to start enrollment in Group 2 (detailed in the arm below).
9728175|NCT05284916||patients admitted at Sohag University Hospital diagnosed with liver diseases|The study will be conducted in two stages. The first one is a retrospective collection of the data from patients records during the period from Feburary 2017 to January 2018 and the second stage will include agroup of patients that will be admitted to Tropical Medicine and Gastroenterology Department within 6months after protocol acceptance
9728176|NCT05284890|Experimental|CC-99677|
9728177|NCT05284877||Male organ transplant recipients|600 men with a solid organ transplant (heart, lung, liver, kidney or pancreas)
9728178|NCT05284877||Female organ transplant recipients|600 women with a solid organ transplant (heart, lung, liver, kidney or pancreas)
9728179|NCT05284877||Female immunocompetent controls|600 immunocompetent women without organ transplant or other immunosuppressive conditions/treatments
9728180|NCT05284864|Experimental|Early stoma closure|Stoma closure 2-3 weeks after rectal surgery.
9728181|NCT05284864|Active Comparator|Late stoma closure|Stoma closure 16-24 weeks after rectal surgery.
9728182|NCT05284851|Experimental|Experimental group 1|Healthy people in experimental group will receive a dose of Live Attenuated Influenza Vaccine (non freeze- dried)
9728183|NCT05284851|Active Comparator|Positive control group|Healthy people in Positive control group will receive a dose of Live Attenuated Influenza Vaccine ( freeze- dried)
9728184|NCT05284851|Placebo Comparator|Placebo group|Healthy people in placebo group will receive a dose of placebo
9728185|NCT05284838|Experimental|Error Management Training (Difficult)|Participants receive the learning strategy Error Management Training and encounter difficult questions.
9728186|NCT05284838|Experimental|Error Management Training (Easy)|Participants receive the learning strategy Error Management Training and encounter easy questions.
9728187|NCT05284838|Active Comparator|Error Avoidance Training|Participants receive the learning strategy Error Avoidance Training.
9728188|NCT05284825|Experimental|12 Gy in 6 daily fractions|
9728189|NCT05284812|No Intervention|Negative control population group|In population I, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) and BCG pure protein derivative (BCG-PPD) skin test results were negative.The type I population did not take chemical drugs and was not vaccinated, and was only used as immunogenicity control.
9728190|NCT05284812|Other|Sentinel group|In Population Ⅱ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. First, 5 people aged 18-59 years were selected for low dose injection, 5 people aged 18-59 years were selected for high dose injection, 5 people aged ≥60 years were selected for low dose injection, and 5 people aged ≥60 years were selected for high dose injection.
9728191|NCT05284812|Experimental|Low-dose group|In population Ⅲ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅲ population were injected Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02).
9728192|NCT05284812|Experimental|High-dose group|In population Ⅳ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅳ population were injected High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02).
9728193|NCT05284812|Experimental|3 dose of High-dose group|In population Ⅴ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅴ population were injected 3 dose of High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) and 3 dose of Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo.
9780981|NCT01136655|Experimental|BUD 160/FM 4.5|placebo HFA pMDI × 1 inhalation + 4.5 μg formoterol (as 80/2.25 μg Symbicort pMDI × 2 inhalations)
10199692|NCT03547661|Active Comparator|Open-Label Placebo|"The intervention will encompass an administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
10205037|NCT04261218|Experimental|Group 2 - Dose Expansion|It is anticipated that Group 2 patients will receive tomivosertib at a dose of 100 mg orally twice daily (BID) during the 'run-in' period, which is taken in combination with weekly paclitaxel (according to market label) during the 'post run-in' period.
10205038|NCT04251689|Experimental|intervention|mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
10205039|NCT04251689|Placebo Comparator|placebo|0.9% normal saline 100 ml one hour after cisplatin
9662680|NCT05133102||Barrett's Esophagus|Patients who have undergone an endoscopy within the last three years and have histologically confirmed Barrett's esophagus. BE segment must be M>1cm, and has not be treated with endoscopic eradication therapy (focal mucosal resection without subsequent eradication therapy is allowed).
9662681|NCT05133050|Experimental|Experimental group|Drug: Ramipril The initial dose of ramipril is 2.5 mg /d. The blood pressure, blood potassium and blood creatinine is measured every 1-2 weeks. If the blood pressure is normal, the dose of ramipril is adjusted to 5 mg /d after 2 weeks. If the blood pressure is low, the dose of ramipril is reduced to 1.25 mg /d until the blood pressure becomes normal, otherwise, stop ramipril using. If the blood potassium is high (>5.5mmol/L), the dose of ramipril is reduced to 1.25 mg /d until the blood potassium becomes normal, otherwise, stop ramipril using. If the blood creatinine is higher before therapy (≥30%), the dose of ramipril is reduced to 1.25 mg /d until the blood creatinine becomes normal, otherwise, stop ramipril using.
9662682|NCT05133050|No Intervention|Control group|No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system inhibitors (including angiotensin II receptor antagonists, etc.) treatment.
9662683|NCT05133037||Adolescent girls between 13-15 years old|Parental history of eating pathology or no parental history of eating pathology
9662684|NCT05133024|Active Comparator|beetroot juice|Brand: BEET IT sport NITRATE 400 concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
9662685|NCT05133024|Placebo Comparator|nitrate-depleted beetroot juice|Brand: BEET IT sport NITRATE 400 nitrate-depleted concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
9662686|NCT05133011|Experimental|Low muscle strength|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were the last 5%
9662687|NCT05133011|Experimental|Normal groups|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were greater than 5%
9662688|NCT05132998|Experimental|Cardiac Rehabilitation Program (CRP) Group|"Baseline consultation with physiatrist specialized in CRP - addressing CVRF control, comorbidities and disabilities; case-by-case discussion with a cardiologist specialized in CR will be undertaken, for tailoring exercise prescription. Nutritional individualized plan addressing dietary goals. Psychological management addressing psychosocial outcomes and motivation for healthy lifestyle habits~Multidisciplinary team educational meeting: periodic group sessions with health education purposes~Exercise intervention - 2 times/week sessions at CR facilities, supervised by a physiatrist, conducted by physiotherapist. Heart rate (HR) continuously monitored during each session by remote electrocardiographic monitoring or HR monitor. Exercise intensity estimated according to CR guidelines, determined after CV risk stratification, using CPET results."
9662689|NCT05132998|Active Comparator|Community Exercise Group|"a) Besides standard medical and supportive care, psychological and nutritional individual support will be offered on demand, in hospital setting, according to the attending physician standard clinical assessment and usual care.~Exercise intervention - Performed at a community-based facility, comprising 2 sessions/week, prescribed according to current physical activity guidelines for cancer survivors. Exercise intervention will be conducted by an exercise physiologist, internationally certified in exercise for cancer patients"
9662690|NCT05132972|Experimental|Treatment|Group receiving standard COVID-19 treatment and UCMSC infusion
9662691|NCT05132972|Sham Comparator|Control|Group receiving standard COVID-19 treatment and normal saline infusion
9662692|NCT05132959||Patient Group|Patients with supraspinatus tendinosis
9662693|NCT05132959||Control Group|Patients without shoulder pain
9662694|NCT05132946|Active Comparator|Group (B): will receive erector spinae plane block.|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
9662695|NCT05132946|No Intervention|• Group (C): will not receive any block.|
9662696|NCT05132933|Experimental|Shunt-group|Test of three different levels of positive end-expiratory pressure (PEEP)
9662697|NCT05132894||Novice Runners|1-5 miles / week 18+ yo
9662698|NCT05132894||Moderate Runners|6-15 miles / week 18+ yo
9662699|NCT05132894||Advanced Runners|16+ miles / week 18+ yo
9664771|NCT05285267|Experimental|Nurturing Fathers|The Nurturing Fathers program (Perlman, 2021) is an adaptation of the Nurturing Parent program. It is a 13-week program that covers the role of fathers, the importance of nurturance rather than fear in fathering, how to effectively play and discipline a child, how to build relationships with the child and co-parent, and it ends with a graduate ceremony. For the present study, consistent with a prevention approach, the investigators will modify the Nurturing Fathers program to focus on the content directly related to parenting skills. The investigators will implement an eight-week program, which is consistent with the duration of prior, successfully attended father-focused interventions (e.g., Fabiano et al., 2009).
10199693|NCT03537963|Other|Pre-Intervention Qualitative Interviews|Hematopoietic cell transplant (HCT) survivors, caregivers and clinicians will participate in this part of the study. HCT survivor participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. All participants will be asked to participate in either an in-person or telephone interview that will last approximately 1 hour. The interview will be digitally audio-recorded and will ask questions on the trajectory of sleep disturbance in HCT recipients and strategies to manage common barriers to quality sleep, as well as discuss the planned intervention for sleep disturbance in HCT survivors.
9728194|NCT05284812|Placebo Comparator|Placebo group|In population Ⅵ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅵ population were injected Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo.
9728195|NCT05284812|Active Comparator|Adjuvant group|In population Ⅶ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅶ population were injected High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02).
9728196|NCT05284799|Experimental|OVX836 480µg + Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose|"OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1~AND~Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine."
9728197|NCT05284799|Active Comparator|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose + Placebo|"Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine.~AND~Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1"
9728198|NCT05284799|Placebo Comparator|OVX836 480µg + Placebo|"OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1~AND~Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1"
9728199|NCT05284773|Experimental|intervention + standard of care|Caretakers of children 6-59 months old living in communities assigned to the intervention arm will be trained to detect malnutrition using MUAC on their children weekly. Caretakers living in communities assigned to the intervention will also receive usual standard of care.
9728200|NCT05284773|No Intervention|standard of care|Caretakers of children 6-59 months living in communities assigned to the standard of care arm will receive usual acute malnutrition screening. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the Centre de Sante et Promotion Sociale (CSPS).
9982319|NCT05261464|Experimental|Diltiazem protocol|"Diltiazem immediate release (IR) 30 mg will be given if patient's HR is more than 60 bpm.~Monitor BP and heart rate HR every 15 minute to assess targeted HR and side effects until patient's is sent to CCTA.~If patient can not reach targeted HR (less than 60 bpm) at 30 minutes, then second dose of 30-mg diltiazem will be given.~If patient can not reach targeted HR at next 30 minutes, then third dose of 30-mg diltiazem will be given.~If patient can not reach targeted HR at next 30 minutes, then fourth dose of 30-mg diltiazem will be given.~If patient's HR reach targeted HR for 15 minutes apart for 2 times or received total dose of 120 mg 30-mg diltiazem IR, then total time will be recorded and patient will proceed to CCTA.~If patient can not reach targeted HR according to protocol, cardiac imaging specialist will decide whether to give further medication for HR control or proceed to CCTA. Cardiac imaging specialist may be able to consult dispensary."
9982320|NCT05259982|Experimental|Vital root resection|Root resective surgery aiming to preserve pulp vitality
9982321|NCT05254769|Experimental|Neurofeedback Intervention in children with Autism Spectrum Disorder|Neurofeedback therapy will be provided to 35 children with Autism Spectrum Disorder 30 sessions each and cognitive domains will be assessed before and after intervention.
9982322|NCT05254496|Experimental|US Healthy Diet|Participants in this group will be assigned to follow the Healthy US dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern is based on the types and amounts of foods Americans typically consume. The main types of food in this eating pattern include a variety of vegetables; fruits; whole grains; fat-free or low-fat dairy; seafood, poultry, meat, and eggs; and nuts, seeds, and soy products.
9780982|NCT01136655|Experimental|BUD 160/FM 9.0|placebo HFA pMDI × 1 inhalation + 9 μg formoterol (as 80/4.5 μg Symbicort pMDI × 2 inhalations)
9780983|NCT01136655|Placebo Comparator|BUD 160|placebo HFA pMDI × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
10199694|NCT03537963|Experimental|mHealth Stepped-care Intervention|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention, post-intervention questionnaire and interview.
10199695|NCT03537963|Active Comparator|Educational Control Condition|For HCT survivors randomized to this group: Baseline survey, followed by Educational Control intervention, post-intervention questionnaire and interview.
9780984|NCT01136655|Active Comparator|BUD 160/Foradil 12.0|Foradil Aerolizer 12 μg × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
10199696|NCT03537963|Experimental|mHealth Stepped-care Intervention + virtual reality relaxation|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention + virtual reality relaxation component, post-intervention questionnaire and interview.
10199697|NCT03534804|Experimental|Cabozantinib and Pembrolizumab, all patients|
10199698|NCT03527992|Other|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
10199699|NCT03527992|Other|Standard Oxygen therapy|Patients will receive O2 standard therapy
10205040|NCT04232423|Experimental|OLN 0-5-10|Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3
10205041|NCT04232423|Experimental|OLN 5-10-0|Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3
9982323|NCT05254496|Experimental|Mediterranean diet|Participants in this group will be assigned to follow the Mediterranean dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains more fruits and seafood and less dairy than the Healthy U.S.-Style Eating Pattern.
9982324|NCT05254496|Experimental|Vegetarian diet|Participants in this group will be assigned to follow the Vegetarian dietary pattern as presented by the US Dietary Guidelines. As described here https://www.nia.nih.gov/health/usda-food-patterns: This eating pattern contains no meat, poultry, or seafood. Compared with the Healthy U.S.-Style Eating Pattern, it contains more soy products, eggs, beans and peas, nuts and seeds, and whole grains.
9982325|NCT05254392|No Intervention|Usual Care|Participants in the UC arm received the usual/conventional care offered by the hospitals which included: hospital visits on appointment or a sick day, consultations with the physicians, prescription of drugs and routine laboratory tests, review of diagnosis and medications, refilling of prescriptions by patients and referral.
9982326|NCT05254392|Experimental|Pharmacists' Intervention|Participants in the PI arm received routine usual care plus pharmacists' interventions for 12 months. The PI arm received usual care plus face-to-face education on CKD, hypertension as a co-morbidity and its management, and antihypertensive medication adherence at baseline (group education), 6 months and 12 months (individualized according to each patient's needs), CKD patient educational infographic leaflet at baseline, a calibrated sphygmomanometer digital BP monitor (Chidalex®) for HSMBM, a BP logbook at baseline for the recording of BP values daily and hands-on training on BP self-measurement. Also, antihypertensive medication adherence and HSMBM reminder cell phone text messages were sent biweekly throughout the trial period, while phone-in inquiries from the participants and phone-out reinforcement interventions were utilized throughout the trial period
9982327|NCT05253846|Experimental|SCRT--> FOLFOXIRI--> SURGERY|"SHORT-COURSE RT~FOLFOXIRI~IRINOTECAN 165 mg/sqm iv over 60 minutes, day 1 followed by~OXALIPLATIN 85 mg/sqm iv over 2 hours, day 1 in two-way with~LEDERFOLIN 200 mg/sqm iv over 2 hours, day 1 followed by~5-FLUOROURACIL 3200 mg/sqm 48 h-continuous infusion, starting on day 1. The chemotherapy treatment will be repeated every 2 weeks up to 8 cycles.~Surgery with TME should be performed after 4 weeks after the last cycle of chemotherapy"
9982328|NCT05253625|Experimental|lullaby mother|The participant will listen to a lullaby recorded with his mothers voice.
9982329|NCT05253625|Experimental|lullaby female|The participant will listen to a lullaby recorded with a foreign female voice.
9982330|NCT05253625|No Intervention|no lullaby|The participant will not listen to a lullaby.
9728213|NCT05284747|Experimental|Evolocumab + Routine Lipid Management|Participants will receive open-label evolocumab every 2 weeks (Q2W) plus routine lipid management.
9728214|NCT05284747|Active Comparator|Routine Lipid Management|Participants will receive routine lipid management per standard of care (SoC).
9728215|NCT05284734|Experimental|Caudal block group|A 22 gauge 50 mm echogenic block needle placed through the sacrococcygeal membrane into the sacral canal in the longitudinal position, using the in-plane technique Negative aspiration was then performed 0.125% bupivacaine at a dose of 1 ml/kg was administered
9728216|NCT05284734|Experimental|Erector spinae block group|The erector spinae muscle and the transverse process were identified, and a 22 G, 80 mm echogenic block needle was advanced towards the transverse process until contact. Following hydrodissection, 1 ml/kg of 0.125% bupivacaine was injected deep into the erector spinae muscle
9728217|NCT05284721|Active Comparator|Care Coordination Phase III|Family member participants randomized to the active control will receive two brief psychoeducation sessions, two brief check ins across one month and linked to appropriate services.
9728218|NCT05284721|Experimental|Family Peer Navigator model Psychosis Phase III|Family member participants randomized to the Family Peer Navigator condition will participate in two sessions for introduction/assessment, four individual psychoeducation sessions, and six brief check ins delivered by Family Peer Navigators.
9728219|NCT05284708|Other|Clinical Operators|Experimental: 15 healthcare professionals will be recruited for the study. The group includes physiotherapists (PTs), physiotherapist assistants (PTAs), clinical exercise physiologists (EPs), and rehabilitation technicians (RTs), all resident in US and representing the final users of the device. Operators are representative of the final users of the exoskeleton.
9728220|NCT05284695||TAP + RB|transversus abdominis plane block and rectus sheath block
9728221|NCT05284695||ESPB|Erector spinae plane block
9728222|NCT05284695||EOI|External oblique intercostal block
9728223|NCT05284682||Dilated cardiomyopathy|Patients with heart failure on the basis of dilated cardiomyopathy.
9982331|NCT05253495|Experimental|Cohort 1a|"Mature B-cell Non-hodgkin Lymphoma [MB NHL], GROUP B will receive reduction therapy with dexamethasone, vincristine and cyclophosphamide (DOC), then undergo disease assessment. If tumor reduction ≥ 20%, will get induction 1 and 2 with cyclophosphamide, vincristine, methotrexate, rituximab, doxorubicin (COM3RA25D) 1 and 2, then Consolidation 1 with rituximab, cytarabine, methotrexate (R-CYM) . Patients will undergo disease assessment post Consolidation 1. If no residual disease, they proceed to receive Consolidation 2 with R-CYM (R-CYM 2).~Cohort Ia patients with < 20% tumor reduction post DOC will be assigned to Cohort Ib starting at Induction 1. Cohort Ia patients with residual disease post Consolidation 1 will be assigned to Cohort Ib starting at Consolidation 1 polatuzumab vedotin, rituximab, high dose cytarabine, cytarabine, high dose methotrexate, etoposide (Pv-R-CYVE 1)."
9984752|NCT03768440|Active Comparator|continuous paravertebral block|A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
10199700|NCT03523793|Experimental|Physical Therapists - CPG|Cross-sectional stepped wedge design with 16 physical therapy clinics (including approximately 40 physical therapists) being allocated to one of 4 sequences that differ in CPG implementation time (each sequence consisting of 4 clinics). This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
10199701|NCT03523793|Active Comparator|Physical Therapists - Control|This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
10199702|NCT03522129|Active Comparator|Active Treatment- CT1812 560 mg|
10199703|NCT03522129|Active Comparator|Active Treatment- CT1812 280 mg|
10199704|NCT03522129|Active Comparator|Active Treatment- CT1812 90 mg|
10199705|NCT03522129|Placebo Comparator|Placebo Comparator - Placebo|
10199706|NCT03493282|Active Comparator|Active Treatment- CT1812 100 mg|7 subjects randomized to 100 mg CT1812
10199707|NCT03493282|Active Comparator|Active Treatment- CT1812 300 mg|7 subjects randomized to 300 mg CT1812
10199708|NCT03493282|Placebo Comparator|Placebo|7 subjects randomized to matching placebo
10199709|NCT03491267|Experimental|Subjects with alopecia-- area treated|One area will be treated
10199710|NCT03491267|Experimental|Subjects with alopecia-- area un-treated|One area will be un-treated
10199711|NCT03488082|Experimental|Measurement of the bold signal|
10199712|NCT03485287|Experimental|MDMA and Psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
9728224|NCT05284682||Control group without heart failure|Control group from the ablation laboratory without heart failure
9728225|NCT05284643|Experimental|Cohort A: sMRI-Guided RT at 35 Gy in 10 fractions|"Participants will receive a total dose of 3500 centigrays (cGY) (35Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 350 cGy (3.5 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
9728226|NCT05284643|Experimental|Cohort B: sMRI-Guided RT at 40 Gy in 10 fractions|"Participants will receive a total dose of 4000 cGY (40Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 400 cGy (4 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
9728227|NCT05284617|Experimental|Active Treatment: HU6 Planned doses of HU6; N = 31|
9728228|NCT05284617|Placebo Comparator|Placebo Comparator Non-active study drug N = 31|
9728229|NCT05284604|Experimental|Group 1|Peripheral IV Infusion of 100 million vBA-MSCs at baseline and repeated at three months
9728230|NCT05284604|Experimental|Group 2|Peripheral IV Infusion of 100 million vBA-MSCs at baseline and peripheral IV infusion of placebo at three months
9728231|NCT05284604|Placebo Comparator|Group 3|Peripheral IV infusion of placebo at baseline and repeated at three months
10199713|NCT03470675|Placebo Comparator|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
10199714|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
10199715|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
10199716|NCT03467360|Experimental|One experimental arm|non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer
10199717|NCT03453125|Experimental|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
9728232|NCT05284578|Experimental|Self-compassionate writing intervention|Participants assigned to this intervention will be asked to engage in one brief online self-compassionate writing session, where they will be asked to write about and experience their feelings from the perspective of an inner compassionate observer.
9728233|NCT05284578|Experimental|Expressive writing intervention|Participants assigned to this intervention will be asked to engage in one brief online expressive writing session, where they will be asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
9728234|NCT05284578|Active Comparator|Control writing task|Participants assigned to this condition will be asked to engage in a neutral time management writing task.
9780985|NCT01136733|Experimental|Lenvatinib|
9780986|NCT01136733|Experimental|Lenvatinib plus Everolimus|
10199718|NCT03453125|Active Comparator|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
10199719|NCT03452072|Experimental|0.25% Timolol gel under the paraffin gauzes|"Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
10199720|NCT03452072|Active Comparator|Standard of Care dressings|"Vaseline will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
10199721|NCT03433040|Other|non obese|250mg 17 OHP-C
10199722|NCT03433040|Other|obese - control|250mg 17 OHP-C
10199723|NCT03433040|Experimental|obese|500mg 17 OHP-C
9728235|NCT05284565|Other|Results of reading|All patients who were prick tested and accepted to participate in the study, were prospectively included in the study in only one arm. All of their tests were read by the device and the manual procedure.
9728236|NCT05284552|Experimental|Intervention Arm|Drug: Tinzaparin (Innohep®), solution for injection. Administration form: Subcutaneous injection. Dosage: 4500 IU (for subjects weighing below 90 kg) or 8000 IU (for subjects weighing 90 kg and above) daily for 21-28 weeks.
9728237|NCT05284552|No Intervention|Control Arm|
9728238|NCT05284526|Experimental|parkinsonian patients with and without dopaminergic drug treatment|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without dopaminergic drug treatment during the preparation and execution of movements
9728239|NCT05284526|Experimental|parkinsonian patients with and without High-frequency stimulation of the subthalamic nucleus|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without High-frequency stimulation (HFS) of the subthalamic nucleus (STN) during the preparation and execution of movements
9728240|NCT05284526|Active Comparator|control subjects|Electroencephalogram (EEG) of control subjects during the preparation and execution of movements
9728241|NCT05284513|Other|Main hospital|4 regions rollout to clinic sites using stepped wedge design
9728242|NCT05284513|Other|Central region|4 regions rollout to clinic sites using stepped wedge design
9728243|NCT05284513|Other|West region|4 regions rollout to clinic sites using stepped wedge design
9728244|NCT05284513|Other|Northeast region|4 regions rollout to clinic sites using stepped wedge design
9982332|NCT05253495|Experimental|Cohort 1b|MB NHL, GROUP C will receive reduction therapy with DOC. Patients with < 20% tumor reduction will be off protocol. Patients with ≥ 20% tumor reduction get Induction 1 and 2 with cyclophosphamide, doxorubicin, dexamethasone, high dose methotrexate, polatuzumab vedotin, and triple intrathecal chemotherapy (M8A30D CPR) 1 and 2, then Consolidation 1 with Pv-R-CYVE 1. If no residual disease, they get Consolidation 2 (Pv-R-CYVE 2), followed by Maintenance (M) 1 with M8A30D CP, M 2 with Pv-cytarabine/etoposide, M 3 with cyclophosphamide, doxorubicin, dexamethasone and polatuzumab vedotin (A30D CP), and M 4 with Pv-cytarabine/etoposide. Cohort Ib patients with CNS disease will receive additional intrathecal chemotherapy and high dose methotrexate during Consolidation.
9984753|NCT03763708|Experimental|Spinal Cord Stimulation|Each subject will be programmed to different settings.
9728247|NCT05284461|Placebo Comparator|Mechanized parallel abutments|Implants were immediately covered with this type of abutments after insertion. This is the most common procedure. It would be the gold standard
9728248|NCT05284461|Experimental|Anodized parallel abutments|Implants were immediately covered with this kind of abutments after insertion. Only the surface treatment varies to the gold standard
9728249|NCT05284461|Experimental|Mechanized convergent abutments|Implants were immediately covered with this kind of abutments after insertion. Only the geometry of the emergence profile varies with regards to the gold standard
9728250|NCT05284461|Experimental|Anodized convergent abutments|Implants were immediately covered with this kind of abutments after insertion. Both the surface treatment and the geometry vary with regards to the gold standard
9728251|NCT05284448|Experimental|Pentoxifylline Group|25 patients will receive pentoxifylline (Trental SR®) 400 mg three times daily with their standard therapy for 6 months.
9728252|NCT05284448|No Intervention|Control Group|25 patients will receive their standard therapy only
9728253|NCT05284422|Active Comparator|Traditional technique|Peripheral venous catheters inserted to the participants in this arm are inserted with a palpation/visualization guided technique in their hand, arm, foot or head.
9728254|NCT05284422|Experimental|Ultrasound-guided technique|Peripheral venous catheters inserted to the participants in this arm are inserted with an ultrasound-guided technique in their forearm.
9728255|NCT05284409|Active Comparator|Pethidine|(control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia.
9728256|NCT05284409|Experimental|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia.
9728257|NCT05284409|Experimental|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
10199724|NCT03432065|Experimental|Buspirone|Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.
10199725|NCT03405870|Experimental|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
10199726|NCT03405870|No Intervention|Control|Control patients will receive no experimental drug (ie, usual care)
10199727|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA <26
9728258|NCT05284383|Experimental|Open-label counterconditioning|Closed-label conditioning followed by open-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and open-label nocebo reduction suggestions
9728259|NCT05284383|Experimental|Closed-label counterconditioning|Closed-label conditioning followed by closed-label counterconditioning, using moderately painful stimuli (during conditioning) and non-painful stimuli (during counterconditioning), combined with closed-label nocebo suggestions and closed-label nocebo reduction suggestions
9728260|NCT05284383|Active Comparator|Closed-label extinction|Closed-label conditioning followed by closed-label extinction, using moderately painful stimuli (during conditioning) and slightly-painful stimuli (during extinction), combined with closed-label nocebo suggestions during conditioning and no/neutral suggestions during extinction
9728261|NCT05284357||Group 1: Subjects implanted with HUMELOCK I & II® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~53 patients were identified who could be included in this cohort in 4 investigational centers.~subjects implanted in 2011 to 2013"
9780987|NCT01136733|Active Comparator|Everolimus|
9984754|NCT03762161|Experimental|Intervention TAS-102|
10199728|NCT03403257||Caregivers|Primary caregivers of subjects
10205042|NCT04232423|Experimental|OLN 10-0-5|Olanzapine10 tablet in chemotherapy cycle 1, placebo tablet in chemotherapy cycle 2, and olanzapine 5 mg tablet in chemotherapy cycle 3
9728262|NCT05284357||Group 2: Subjects implanted with HUMELOCK II® Reversible System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~Number of patient to be determined following patients files in 4 investigational centers.~subjects implanted in 2011 to 2013"
9728263|NCT05284357||Group 3: Subjects implanted with HUMELOCK Reversed® Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~154 patients were identified who could be included in this cohort in 5 investigational centers.~subjects implanted in 2012 and 2013"
9728264|NCT05284357||Group 4: Subjects implanted with EASYTECH® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~66 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
9728265|NCT05284357||Group 5: Subjects implanted with EASYTECH® Reversed System (Primary intention)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~7 patients were identified who could be included in this cohort in 5 investigational centers subjects implanted in 2013 and 2014"
9728266|NCT05284357||Group 6:Subjects implanted with EASYTECH® Reversible System (Revision of Easytech Anatomic)|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~the number of subjects will depend of revised subjects primary implanted with Easytech Anatomic® along the dedicated period subjects implanted in 2013 to 2014"
9728267|NCT05284357||Group 7: Subjects implanted with HUMERIS® Anatomic Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~11 patients were identified who could be included in this cohort in 3 investigational centers Subjects implanted in 2014 to 2015"
9728268|NCT05284357||Group 8: Subjects implanted with HUMERIS® Reversible Shoulder System|"The number of patients implanted was defined by comparing sales' database of FX Solutions.~72 patients were identified who could be included in this cohort in 2 investigational centers Subjects implanted in 2014 to 2015"
9728269|NCT05284344||patients with newly diagnosed type 2 diabetes|Newly diagnosed, drug-naïve, Chinese patients with type 2 diabetes.
9728270|NCT05284344||Non-diabetic control subjects|
9728271|NCT05284331|Other|follow-up visit at 6 months and 1 year after inclusion.|addition of a follow-up visit at 6 months and 1 year after inclusion. No treatment will be given specifically for this study. Other visits are part of the normal and usual rhythm of follow-up and evaluation of treatment in these patients
9728272|NCT05284305||Patients with history of pregnancy|Patients with DT diagnosed during pregnancy; patients with DT with macroscopic disease in situ at the time of pregnancy (including previous partial resection, recurrent disease, primary disease followed with active surveillance); resected DT without clinical evidence of residual or recurrent disease at the onset of pregnancy.
9728273|NCT05284305||Patients without history of pregnancy|Patients with DT without history of pregnancy
9728274|NCT05284279||Health professionals practicing with children|"To participate, health professionals will have to speak French fluently, practice with children as a dentist (general or pediatric), a general practitioner, or a paediatrician and work in hospital or ambulatory facility. As paediatricians and general practitioners meet the child regularly during the first 6 years of life for medical follow-up, they are key stakeholders in the early detection of caries, referrals to dentist and counselling.~The participants will be recruited using a semi-random sampling method. The sample will be constituted with a maximum variation in age, gender, years in practice, occupation and types of practice (solo, group or interdisciplinary team)."
9728275|NCT05284266|Active Comparator|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, includng Compression garment and exercise program~Self-care program~Individual counseling from a clinical dietician"
9728276|NCT05284266|Experimental|Standard treatment plus additional lymphedema treatment|"Standard Conservative treatment consisiting of:~Physical therapy, includng Compression garment and exercise program~Self-care program~Individual counseling from a clinical dietician Additional lymphedema treatment consising of intermittent pneumatic compression (IPC)"
9728277|NCT05284266|Experimental|Surgical group: Liposuction|Early liposuction, 6-9 months after inclusion in study.
9728278|NCT05284266|Active Comparator|Srugical group: Control|Late liposuction, 18-21 months after inclusion. This group functions as a control group for 1 year before enrolment in the Liposuction group.
9728279|NCT05284253|Experimental|Gold microparticles|Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
9728280|NCT05284253|Active Comparator|Gold thiosulphate|Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
9728281|NCT05284227|Active Comparator|Clinical Decision Support Application guided Anaesthesiological Assessment|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application.
9728282|NCT05284227|Sham Comparator|Standard Anaesthesiological Assessment|Preoperative anaesthesiological assessment using standard procedures of the hospital and a sham clinical decision support application.
9728283|NCT05284188||Open Modified Broström operation group|Patients who accept an open modified Broström operation
9728284|NCT05284188||Arthroscopic Modified Broström operation group|Patients who accept an arthroscopic modified Broström operation
9728285|NCT05284175|Experimental|Orelabrutinib, orally, 50 mg QD|Orelabrutinib, orally, 50 mg QD
9728286|NCT05284162|Experimental|Health coaching|Health coaching
9728287|NCT05284162|No Intervention|Usual care|Usual care
9728288|NCT05284149|Active Comparator|H.S. Supplement|Patients taking Hirsutella Sinensis Nutrient Supplements
9728289|NCT05284149|Placebo Comparator|Placebo|Patients taking placebo
9728290|NCT05284136|Experimental|Crohn's disease exclusion diet (CDED)|16-week course of Crohn's disease exclusion diet (CDED) and Partial Enteral Nutrition.
9728291|NCT05284136|Active Comparator|Steroids|oral prednisolone at an initial dose of 40 to 60 mg/day.
9728292|NCT05284110|Experimental|Walking breaks (WALK)|During this session, participants will be requested to remain seated during 4 hours, but the sitting will be interrupted every 30 min with a 3-min light-intensity walking.
9728293|NCT05284110|No Intervention|Prolonged sitting (SIT)|During this session, participants be requested to remain seated during 4 uninterrupted hours (excepted for visiting the toilet) in a comfortable chair
9728294|NCT05284097|Experimental|Study Intervention|"Subjects will receive the following study vaccines as a 0.5 mL IM injection into the deltoid:~Ad26.ZEBOV at a dose of 5x10^10 vp on Day 1~MVA-BN-Filo at a dose of 1x10^8 Inf U on Day 57"
9728295|NCT05284084|Placebo Comparator|Negative Control|Matched subjects by age, sex and BMI with no BA events, from a pool of 20,032 admission (01JAN2010 to 31DEC2019).
9728296|NCT05284084|Active Comparator|Positive Control|Matched subjects by age, sex and BMI with BA events, from a pool of 20,032 admission (01JAN2010 to 31DEC2019).
9728297|NCT05284084|Experimental|Experimental group|"Consecutive subjects admitted to the ICU (these subjects will be matched with historical controls with and without BA events) from 30MAR2021 to 30MAR2022 on three subgroups:~Head up from the bed 15 degrees + H2 blockers + mouth wash BID~Head up from the bed 30 degrees + H2 blockers + mouth wash BID~Head up from the bed 45 degrees + H2 blockers + mouth wash BID"
9728298|NCT05284058|Experimental|Cardiac Magnetic Resonance Imaging|All patients who are candidates for surgical mitral valve repair through minimally-invasive access according to the standard of care will be considered for inclusion in this clinical study. All patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
9728299|NCT05284045|No Intervention|Usual information|Subjects allocated to this arm will receive the usual information about OSA and CPAP treatment given in clinical practise
9728300|NCT05284045|Active Comparator|Detailed information|Subjects allocated to this arm will also receive the usual information about OSA and CPAP treatment and they will also receive information related to the possible adverse side effects of CPAP treatment. The healthcare professional will enumerate the possible side effects and indicate which are more and less common.
9728301|NCT05284019|Experimental|Eptinezumab|Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.
9728302|NCT05284019|Experimental|Anti-CGRP injectables|Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
9728303|NCT05284019|Experimental|Onabotulinumtoxin-A|Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.
9780988|NCT01136746|Active Comparator|Sliding scale regular insulin|
9780989|NCT01136746|Experimental|Basal-bolus therapy|
9780990|NCT01136772|Experimental|Paliperidone palmitate|Intramuscular injections of paliperidone palmitate 39-234 mg every month
9780991|NCT01136772|Active Comparator|Haloperidol decanoate|Intramuscular injections of haloperidol decanoate 25-200 mg every month
9780992|NCT01136785|Active Comparator|Active CPAP therapy|7 days of treatment in the laboratory with active CPAP therapy.
9780993|NCT01136785|Sham Comparator|Sham CPAP therapy|7 days of sham CPAP therapy in the laboratory.
9780994|NCT01136798|Placebo Comparator|Usual T2 DM med regimen|Subjects will continue on Type 2 DM therapy but will add placebo injected subcutaneously twice daily to their regimen for a total of 6 weeks.
9780995|NCT01136798|Experimental|Usual T2 DM med regimen plus Exenatide|Subjects will continue on Type 2 DM therapy but will add injectable exenatide to their regimen There will be twice daily treatment with subcutaneous injections of 5 µg of Exenatide for 2 weeks followed by 4 weeks of treatment with twice daily subcutaneous injections of 10 µg of Exenatide.
9780996|NCT01136876|Active Comparator|Iopamidol|Non-ionic low-osmolar iodinated contrast media
9780997|NCT01136876|Active Comparator|Iodixanol|Non-ionic iso-osmolar iodinated contrast media comparator
9780998|NCT01136915|Active Comparator|IOPAMIDOL injection 370|
9780999|NCT01136915|Active Comparator|Iodixanol 320|
9781000|NCT01136954|Experimental|1|
9781001|NCT01137006|Experimental|IMC-20D7S (1A-4A Cohorts)|Escalating doses up to 30 milligrams per kilogram (mg/kg) administered intravenously (i.v.) every 2 weeks; includes Cohorts 1A, 2A, 3A, and 4A.
9781002|NCT01137006|Experimental|IMC-20D7S (1B-3B Cohorts)|Escalating doses up to 30 mg/kg administered i.v. every 3 weeks; includes Cohorts 1B, 2B, and 3B.
9781003|NCT01137032|Experimental|Pandel Cream 0.1%|Pandel Cream 0.1%
9781004|NCT01137071|Experimental|Monoclonal antibody hu3S193|Monoclonal antibody hu3S193 will be administered to 51 patients at the dose of 30mg/m2 every other week (total of 12 infusions) for a total of 23 weeks.
10205043|NCT04228679|Experimental|Erbium laser treatment|Women with vaginal laxity treated with real laser.
9781005|NCT01137110|Other|Brief LEV|Administration of three days of levetiracetam twice daily after SAH
9781006|NCT01137110|Other|Extended LEV|Administration of levetiracetam twice daily after SAH
9781007|NCT01137292||Active Treatment|Patients who are eligible for voriconazole treatment according to their physician decision.
9781008|NCT01137370||Patients with TB|
9781009|NCT01137370||People without TB|
9781010|NCT01137396|Experimental|Modafinil|
9781011|NCT01137396|Placebo Comparator|Placebo|
10205044|NCT04228679|Sham Comparator|Sham laser treatment|Women with vaginal laxity treated with sham laser.
9781013|NCT01137474|Experimental|Dapagliflozin, 10 mg|Oral tablets administered as 10 mg once daily for up to 12 weeks
9781014|NCT01137474|Placebo Comparator|Placebo-matching dapagliflozin|Oral tablets administered once daily in the morning
9781015|NCT01137474|Experimental|Dapagliflozin, 2. 5 mg|Oral tablets administered as 2.5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
10205045|NCT04225572|No Intervention|Control Group|Patient will not receive physical therapy treatment or further instruction from the research team. The patient will receive standard care recommended by their medical provider which may or may not include physical therapy treatment.
10205046|NCT04225572|Experimental|Physical Therapy Group|
9728304|NCT05284006||Mucopolysaccharidosis IVA|Patients affected by MPS IVA. The diagnosis of MPS will be confirmed by deficient enzyme activity of < 5% of normal activity level as measured in plasma, leukocytes, or fibroblasts.
9728305|NCT05283980|Experimental|Bupivacaine Group|Receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block
9728306|NCT05283980|Placebo Comparator|Control group|Receive up to 25 ml of normal 0.9% sodium chloride for the Pecs block
9728307|NCT05283967||Adults and children, U.S.|We will conduct a prospective, observational study of the pharmacokinetics of first-line anti-TB drugs (isoniazid, rifampin, and pyrazinamide) among TB patients (i.e. patients with active TB disease).
9728308|NCT05283967||Tanzanian children|We will conduct a prospective, observational study of the pharmacokinetics of first-line anti-TB drugs (isoniazid, rifampin, and pyrazinamide) among TB patients (i.e. patients with active TB disease).
9728309|NCT05283954|Experimental|Combined Regime of Fluoxetine, Prednisolone and Ivermectin|"Fluoxetine: 20mg tablet; 20 mg; once daily for 10 days; oral~Prednisolone: 25 mg tablet; 25mg; once daily for 5 days; oral~Ivermectin: 3 mg tablet; 0.4 mg/kg; once daily for 5 days; oral"
9728310|NCT05283954|Other|Combination of Vitamin C and Albendazole|"Vitamin C: 50 mg tablet; 1 tablet; Once daily for 10 days; Oral~Albendazole; 200 mg; 1 tablet; Once daily for 5 days; Oral~Vitamin C: 50 mg tablet; 0.13 tablet/kg*; Once daily for 5 days; Oral~*Same number of tablets than for Ivermectin"
9728311|NCT05283941|Experimental|Pistachio Group|The pistachio group will receive pistachio nuts in 2-ounce packs. This group will consume one pack every day over the course of the 12-week study.
9728312|NCT05283941|No Intervention|Control (Usual Diet) Group|The control group will not receive pistachio nuts. They will be asked to make no changes and continue to eat their regular diet.
9728313|NCT05283928|Experimental|OsseoDensification (OD) protocol|
9728314|NCT05283928|Active Comparator|standard drilling (SD) protocol|
9728315|NCT05283902||Effectiveness group|There are an estimated 490,000 eligible individuals aged 60 and over statewide for the effectiveness study.
9728316|NCT05283902||Elderly group - Immunogenicity|240 participants from the Effectiveness group, with quotas distributed by sex (50% male and 50% female) and age group, will be invited to participate in biological sample collection for the immunogenicity study.
9728317|NCT05283902||Immunosupressed group|240 biorepository samples from a cohort of immunosuppressed patients with autoimmune diseases who received the fourth dose, in a study conducted by the same team of researchers.
9728318|NCT05283889|Experimental|Group 1 (GRFA)|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
9728319|NCT05283889|Active Comparator|Group 2 (Sham)|The same procedure will be employed as per Group 1 - However, the sham procedure will involve no electrical signal applied to the participant.
9728320|NCT05283876|Active Comparator|Active psoriasis|
9728321|NCT05283876|Active Comparator|Stable psoriasis|
9728322|NCT05283850|Active Comparator|High-Calcium, High- Sodium (HCHS) group|Patients will receive a drip of blinded, intravenous, normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
9728323|NCT05283850|Experimental|High-Calcium, Low- Sodium (HCLS) group|Patients will receive a drip of blinded, intravenous, half-normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
9728324|NCT05283837|Experimental|Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)|Pertuzumab (ZRC-3277) will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
9728325|NCT05283837|Active Comparator|Pertuzumab (Perjeta®, a product of Genentech, Inc.,)|Perjeta® will be administered at a loading dose of 840 mg via IV infusion over 60 minutes (± 10 minutes) in Cycle 1 followed by 420 mg via IV infusion over 30 to 60 minutes in subsequent cycles then be given every 3 weeks, starting 3 weeks later till cycle 6.
9728326|NCT05283798|Experimental|rate of missed threads in the first 6 weeks|To compare efficacy safety & side effects of multiload 375 IUD versus copper T 380 IUD when inserted during elective CS
9728327|NCT05283798|Other|number of bleeding days in first 6 weeks|compare numbers of bleeding days in first 6 weeks and first 6 month
9728328|NCT05283772|Experimental|Experimental|
9728329|NCT05283772|No Intervention|No intervention|
9728330|NCT05283733|Experimental|group A|the group who was subjected to the reverse conversion technique
9728331|NCT05283733|No Intervention|group B|the control group who was completed by open technique
9728332|NCT05283720|Experimental|Arm 1: Dose Escalation|Participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) will receive escalating doses of subcutaneous (SC) epcoritamab in combination with oral lenalidomide in 28 day cycles.
9728333|NCT05283720|Experimental|Arm 2: Dose Escalation|Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
9728334|NCT05283720|Experimental|Arm 3: Dose Escalation|Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
9728335|NCT05283720|Experimental|Arm 1: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral lenalidomide in 28 day cycles.
9728336|NCT05283720|Experimental|Arm 2: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
9728337|NCT05283720|Experimental|Arm 3: Dose Expansion|Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
10199729|NCT03394027|Experimental|Arm 1-ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: estrogen receptor (ER) + breast cancer, triple negative breast cancer, and endometrial cancer
10199730|NCT03391882|Experimental|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
9728338|NCT05283707|Experimental|Intervention Group|"Continuation of standard post-cesarean section care in the clinic.~Implementation of Paula Method Exercises Training Plan 6-8 hours after cesarean section (Paula Method Exercises Practice Card PEUK, Paula Method Exercises Video, Paula Method Exercises Flipcard)~Paula Method Exercises; by the researcher, after cesarean section 0.day 6-8 hours, 1st day morning, 2nd day morning.~Paula Method Exercises; It was applied by the researcher to the patient on the 0th day 6-8 hours, the 1st day in the morning, and the 2nd day in the morning after the cesarean section.~6-8 hours on day 0, morning on day 1, morning on day 2 after cesarean section Evaluation and recording of bowel sounds before and after Paula Method Exercises, application of McGill Pain Scale Short Form,~Evaluation of first flatulence after cesarean section and first defecation"
9728339|NCT05283707|No Intervention|Control Group|"Continuation of standard post-cesarean section care in the clinic.~6-8 hours on day 0, morning on day 1, morning on day 2 after cesarean section Evaluation and recording of bowel sounds, application of McGill Pain Scale Short Form,~Evaluation of first flatulence after cesarean section and first degassing"
9728340|NCT05283694|Experimental|Risankizumab Dose A|Participants will receive 3 Subcutaneous (SC) injections of risankizumab Dose A administered via prepared syringe at Day 1 and followed for 140 days.
9728341|NCT05283694|Experimental|Risankizumab Dose B|Participants will receive 1 SC injection of risankizumab Dose B administered via syringe pump at Day 1 and followed for 140 days.
9728342|NCT05283694|Experimental|Risankizumab Dose C|Participants will receive 1 SC injection of risankizumab Dose C administered via syringe pump at Day 1 and followed for 140 days.
9728343|NCT05283694|Experimental|Risankizumab Dose D|Participants will receive 1 SC injection of risankizumab Dose D administered via prepared syringe at Day 1 and followed for 140 days.
9728344|NCT05283681|Experimental|Risankizumab Dose A|Participants will receive 1 Subcutaneous (SC) injection of risankizumab Dose A administered via Prefilled Syringe (PFS) at Day 1 and followed for 140 days
9728345|NCT05283681|Experimental|Risankizumab Dose B|Participants will receive SC injections of risankizumab Dose B administered via PFS at Day 1 and followed for 140 days
9728346|NCT05283681|Experimental|Risankizumab Dose C|Participants will receive 1 SC injection of risankizumab Dose C administered via Auto-Injector (AI) at Day 1 and followed for 140 days.
9728347|NCT05283668|Experimental|(LASER WITH I-PRF)|Eight sites that were treated with laser method for gingival depigmentation, followed by intra-mucosal field injection of I-PRF
9728348|NCT05283668|Active Comparator|(LASER WITHOUT I-PRF)|Eight sites that were treated with laser technique for gingival depigmentation only
9728349|NCT05283655|Experimental|Intervention group|10 weekly sessions of gut-directed hypnotherapy (behavioral intervention).
9728350|NCT05283642|Experimental|DCI|Oral supplementation with D-chiro-inositol once a day
9728351|NCT05283616|Experimental|pegfilgrastim 3mg|Pegfilgrastim 3mg per chemotherapy cycle
9728352|NCT05283616|Active Comparator|pegfilgrastim 6mg|Pegfilgrastim 6mg per chemotherapy cycle
9728353|NCT05283590||All patients|The IVC will be measured by the automated mode and manual measures will be recorded. All patients will have PPv by LiDCO
9728354|NCT05283564|Other|Administration of Percussive ventilation breathhold (PVB) technique in healthy volunteers|The healthy patient will execute the Percussive ventilation breathhold technique
9728355|NCT05283564|Other|Administration of the PVB-SABR in lung cancer patients|Lung cancer patients will execute a PV breathhold and a verification cone-beam CT scan.
9728356|NCT05283551|Experimental|Single arm|
9728357|NCT05283538|Experimental|Coronary Artery Calcification Evaluation|
9728358|NCT05283525|Placebo Comparator|Placebo Group #1 (6.75 gms Once-A-Day)|Placebo Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 placebo sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
9728359|NCT05283525|Placebo Comparator|Placebo Group #2 (6.75 gms Twice-A-Day)|Placebo Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 placebo sachets; To be taken one in the morning in an empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
9728360|NCT05283525|Active Comparator|TRCAP21 Group #1 (6.75 gms Once-A-Day)|TRCAP21 Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 TRCAP21 sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
9728361|NCT05283525|Active Comparator|TRCAP21 Group #2 (6.75 gms Twice-A-Day)|TRCAP21 Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 TRCAP21 sachets; To be taken one in the morning in empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
9728362|NCT05283499|Active Comparator|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen350 mg
9728363|NCT05283499|Active Comparator|Non-Opioid|Combination analgesic of ibuprofen 400mgacademinophen 350mg
9728364|NCT05283447|Experimental|Intervention|Specific manual therapy for GERD and hiatal hernia
10199731|NCT03391882|Active Comparator|subcutaneous apomorphine|subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
10199732|NCT03382574|Experimental|Arm I (denosumab, risk-reducing salpingo-oophorectomy)|Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.
10199733|NCT03382574|Active Comparator|Arm II (risk-reducing salpingo-oophorectomy)|Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.
10199734|NCT03375359||cfDNA screening|Pregnant women who are referred for FTS or for further follow-up examinations in case of a suspected anomaly or increased nuchal translucency at 11-13 weeks' gestation can be recruited for this study.
9728365|NCT05283447|Placebo Comparator|Control|Manual therapy unrelated to GERD and hiatal hernia
9728366|NCT05283434|Placebo Comparator|Double-Blind Clinical Trial- Placebo Group|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the placebo group will take the recommended doses of sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
9728367|NCT05283434|Experimental|Double-Blind Clinical Trial- Experimental Group|
9728368|NCT05283421|Active Comparator|Active estrogen|Will receive pretreatment with vaginal application of estrogen 30 microgram (three tablets) once a day for 14 days.
9728369|NCT05283421|Placebo Comparator|Placebo|Will receive pretreatment with vaginal application with no estrogen (three tablets) once a day for 14 days.
9728370|NCT05283408|Experimental|Dexmedetomidine infusion on recovey quality with radical mastectomy|Drug: Dexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
9728371|NCT05283408|Experimental|Co-administration dexmedetomidine and low-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
9728372|NCT05283408|Experimental|Combined dexmedetomidine and high-dose esketamine on recovey quality with radical mastectomy|Drug: Dexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
9984755|NCT03758170|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
10199735|NCT03357952|Experimental|Part 1: JNJ-63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ-63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
10199736|NCT03357952|Experimental|Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ-63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
9728374|NCT05283382|Experimental|Cannabidiol|600 mg Cannabidiol Isolate Gel Capsules / participant. One-time dose.
9728375|NCT05283382|Placebo Comparator|Placebo|Same number of placebo capsules / participant. One-time dose.
9728376|NCT05283369|Experimental|Videogame therapy|Participants will receive conventional physical therapy, plus 300 minutes of videogame in-home therapy a week, for 8 weeks.
9728377|NCT05283369|Active Comparator|Conventional therapy|Participants will receive conventional physical therapy, plus conventional occupational therapy, as prescribed by the doctor for 8 weeks.
9728378|NCT05266729|Experimental|AYP-101 1|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
9728379|NCT05266729|Experimental|AYP-101 2|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
9728380|NCT05266729|Placebo Comparator|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
9728381|NCT05265481|No Intervention|Baseline|In this phase, the investigators will not apply any venodilation method.
9728382|NCT05265481|Active Comparator|Tourniquet applied|The investigators will apply a blood pressure cuff tourniquet inflated to 60 mmHg pressure.
9728383|NCT05265481|Active Comparator|Tourniquet plus manual tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein manually.
9728384|NCT05265481|Experimental|Tourniquet plus device tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein with a massage device.
9728385|NCT05265325|Experimental|AND017 Dose Regimen A|AND017 will be administrated orally at dose A three times a week
9728386|NCT05265325|Experimental|AND017 Dose Regimen B|AND017 will be administrated orally at dose B once a week
9728387|NCT05265325|Active Comparator|Epoetin alfa|Investigator will select appropriate epoetin alfa product for the patient under this arm with starting doses and dose adjustment rules according to the epoetin alfa USPI or SmPC.
9728388|NCT05264740|Experimental|Motivational interviewing|
9728389|NCT05264740|Active Comparator|no motivational interviewing|
9781016|NCT01137474|Experimental|Dapagliflozin, 5 mg|Oral tablets administered as 5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
9781017|NCT01137539|Experimental|Gynecare TVT-SECUR system|All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
9781018|NCT01137578|Other|Cohort A: US, MRI with contrast, MRI without contrast|Subjects with a central venous catheter (CVC) in place and asymptomatic for a CVC-related DVT to have an Ultrasound (US), Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
10199737|NCT03335033|Active Comparator|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a > 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
9728390|NCT05263050|Experimental|Cabozantinib|Cabozantinib treatment will start at 40 mg of cabozantinib daily and dose escalate or de-escalate based on pre-specified criteria and at set dosing schedules to allow for smaller median dose changes between adjustments. The de-escalation would be fine-tuned and adjustments would be made in 10 mg average daily dosing increments by utilizing alternate day dosing schedules (e.g 60 mg/40 mg every other day) rather than decreasing by 20 mg (table 1). The maximum dose of cabozantinib is 60 mg daily. Cycles would be 28 days, with weekly follow-up for cycle 1 and bi-weekly follow-up for cycle 2 to allow for prompt dose adjustments, and then monthly. At each check-in, patients that have met the established protocol criteria (outlined in Section 6.3) and were not yet at the maximum dose of 60 mg daily would be eligible for dose-escalation. Patients would also be dose de-escalated as determined by the investigator. Patients who de-escalate may be allowed to re-escalate in the future.
9728391|NCT05262933||coffee (n= 70)|Patients are planned to drink brewed coffee 2 hours before surgery.
9728392|NCT05262933||control (n=70)|Patients are planned to drink water 2 hours before surgery.
9728393|NCT05262582|Experimental|Thymectomy performed with sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
9728394|NCT05262582|Active Comparator|Thymectomy performed with two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
9728395|NCT05262348|Active Comparator|Phase 1a - conventional stimulation|Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.
9728396|NCT05262348|Experimental|Phase 1b - adaptive stimulation|Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.
10199738|NCT03335033|Active Comparator|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
10199739|NCT03323463|Experimental|Arm A: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia. This arm is closed to accrual.
10199740|NCT03323463|Experimental|Arm B: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia.
10199741|NCT03316430||Patients|Patients coming before 16 weeks of gestation at their first planned prenatal visit at the Hôpital Femme Mère Enfant, who planned to deliver at the Hôpital Femme Mère Enfant
9728397|NCT05262205|Active Comparator|sevoflurane group with BIS monitor for depth of anesthesia|child will be anesthetized with sevoflurane 2% and atracurium 0.25mg/kg and paracetamol 15mg/kg, then bispectral index will be recorded after intubation and every five minutes till end of surgery. Position of the globe will recorded every five minutes. Angle of deviation of the globe will be calculated via withdrawing horizontal line passing from the lateral and medial canthi, and another vertical one passing the medial canthus(90-0--90 degree). Bis should be 40-65 to ensure adequate depth of anesthesia. If more than 65 or less than 40, sevoflurane concentration will be adjusted till having the target range. pupillary dilation in surgical eye will be assessed after speculum insertion, 20 minutes after speculum insertion, and before speculum removal by pupil ruler((pupil gauge), whether it will be maintained or not (considered maintained if pupil size equal or more than 5mm).
9728398|NCT05262205|Active Comparator|propofol-midazolam group with BIS monitor for depth of anesthesia|Child will be anesthetized with midazolam 0.05 mg/kg IV bolus and propofol 1mg/kg IV bolus, paracetamol 15mg\kg IV infusion, and atracurium 0.25mg/kg IV bolus ,then anesthesia will be maintained with propofol infusion according to Mcfarlan protocol, then BIS will be recorded after intubation and every five minutes till end of surgery. Position of the globe will recorded every five minutes till the end of surgery. Angle of deviation will be calculated in same way as group A. Bis should be 40-65. If more than 65 or less than 40, sevoflurane concentration will be adjusted till having the target range. pupillary dilation in surgical eye will be assessed after speculum insertion, 20 minutes after speculum insertion, and before speculum removal by pupil ruler((pupil gauge) and will be observed all over the surgery with the help of surgeon feedback whether it will be maintained or not (considered maintained if pupil size equal or more than 5mm).
9728399|NCT05261113||Intervention cohort|Patients that were operated due to liver neoplasms with use of CE-IOUS
9728400|NCT05261113||Control cohort|Patients that were operated due to liver neoplasms without use of CE-IOUS
10199742|NCT03305588|Experimental|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
10199743|NCT03299062|Active Comparator|Parkinson's Disease with Voice Dysfunction Patients|• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor
10199744|NCT03299062|Active Comparator|Other Neurodegenerative Disorders with Voice Dysfunction|• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.
10199745|NCT03299062|Placebo Comparator|Voice Dysfunction|Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.
10205047|NCT04222478|Experimental|Real Auriculotherapy|"Patients benefit from 3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
10205048|NCT04222478|Sham Comparator|Sham Auriculotherapy|Patients are treated according to the same scheme as the experimental group but with semi-permanent needles positioned on non-specific points.
10205049|NCT04209738||Eurythmy Therapy (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified therapist: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by an eurythmy manual and an exercise video. This complements the regular care.
10199746|NCT03286556|Experimental|Autoantibody Reductive Therapy|"Therapeutic Plasma Exchange (TPE) consisting of 1x estimated plasma volume exchanges for 3 successive days (1-3) and then, after a one day interval to enable equilibration of autoantibodies between intra- and extra-vascular spaces, again on days 5, 6, 9, 11, 13, and 15.~Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.~Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19~All subjects in this trial, including patients in this arm, will receive identical empiric antibiotics and steroids. The steroid dose is: Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab."
10199747|NCT03286556|Active Comparator|Treatment as Usual (TAU)|The same steroid regimen as described for the experimental arm, i.e., prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent), and methylprednisolone 100 mg i.v. administered on days 6 and 15, as well as empiric antibiotics.
9728401|NCT05260905||Intervention|All participants will perform 2 experimental sessions, each involving a REHIT exercise session.
9728402|NCT05258890|Experimental|Social Network Counseling|The index patient and influential social network members will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for teamwork counseling and blood pressure education.
9728403|NCT05258890|Active Comparator|Individual Counseling|The index patient will meet via Zoom 3 times over the course of 3 months with a clinical research nurse for blood pressure education.
9728404|NCT05258630|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
9728405|NCT05258630|Active Comparator|D-Homes comparison|Brief diabetes educational session by a diabetes wellness coach.
9728406|NCT05258487||VIBe Grade 1|Intraoperative bleeding of grade 1 as defined by the VIBe scale.
9728407|NCT05258487||VIBe Grade 2|Intraoperative bleeding of grade 2 as defined by the VIBe scale.
9728408|NCT05258487||VIBe Grade 3|Intraoperative bleeding of grade 3 as defined by the VIBe scale.
10199748|NCT03256773||Notmal|No lung Disease
9728409|NCT05258487||VIBe Grade 4|Intraoperative bleeding of grade 4 as defined by the VIBe scale.
9728410|NCT05257681|Experimental|Fissure completion and adhesiolysis arm|Patients will undergo a VATS or robotic interlobar lung fissure completion with pleural adhesiolysis. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
9728411|NCT05257486||NMSC Treatment|Patients who completed Xoft eBx treatment at least five years from the last treatment.
9728412|NCT05255068|Experimental|Arm1|OPTIMAL
9728413|NCT05255068|No Intervention|Arm2|Control
9728414|NCT05252884|Experimental|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy.
9728415|NCT05252884|Active Comparator|routine postoperative calcium and calcitriol|The patient will receive Calcium carbonate + calcitriol
10199749|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
10199750|NCT03256773||PCD|Primary Ciliary Dyskinesia
9728416|NCT05252169|Experimental|Proprioceptive Training|"Proprioceptive training will include : Stair climbing up and down,Standing with feet side by side and up and down,one leg standing,Walking heel to toes,Rising from a standard chair.~Swiss ball activity will be performed passively by the physical therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation that will be performed with stabilized pelvis and hip.~Routine physical therapy will include passive stretching ,strength training and weight bearing exercises. total session will be of 60 minutes."
9728417|NCT05252169|Placebo Comparator|Routine Physical Therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~Passive stretching exercises~Weight bearing exercises~Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
9728418|NCT05251376|Experimental|LYN-014 Extended-Release Levomethadone HCl|Extended-release levomethadone HCl 187 mg administered orally once on Day 8 of the study.
9728419|NCT05249530|Experimental|Force|Chiropractic spinal adjustment with force
9728420|NCT05249530|Active Comparator|Touch|non-force stimulation
9728421|NCT05246449|No Intervention|Standard of care group|with patients starting their regular CPAP/APAP treatment without stratification, with medical follow-up, and with standard home CPAP/APAP service provided by home healthcare,
9728422|NCT05246449|Experimental|VitalCare group|with patients starting their CPAP/APAP treatment and with a personalized follow-up by the homecare provider.
9728423|NCT05245539|Experimental|CVL-231 Dose Level 1|10 mg once daily
9728424|NCT05245539|Experimental|CVL-231 Dose Level 2|30 mg once daily
10199751|NCT03256773||COPD|Chronic Obstructive Lung Disease
9728425|NCT05244486|Experimental|Treatment Arm|Men will begin utilizing PTT 30-60 minutes daily for 5-7 days weekly beginning 1 month post-prostatectomy until 6 months. After 6 months, they will have the option to continue to use the therapy for 3 additional months or discontinue at their discretion.
9728426|NCT05244486|Active Comparator|Control|Men will not utilize PTT for the first 6 months post-prostatectomy. Beginning at 6 months, they may utilize PTT if they desire (open label) until 9 months post-prostatectomy.
9728427|NCT05233163|Experimental|Study Drug Arm|Subjects will take empagliflozin 10 mg oral daily for 12 weeks.
9728428|NCT05229419||acute pediatric poisoning cases|All cases of acute pediatric poisoning of both sexes, in age group less than or equals to 18 years old will presenting to Assiut University Hospital with acute poisoning whose their adverse effects occurring following administration of single dose of a substance or multiple doses exposure within 24 hours.
9728429|NCT05228730|Active Comparator|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Standard Pfizer-BioNTech booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
9728430|NCT05228730|Experimental|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Pfizer-BioNTech booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
9728431|NCT05228730|Active Comparator|AstraZeneca (ChAdOx1-S, or Vaxzevria®) Standard Elasomeran booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
9728432|NCT05228730|Experimental|AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Elasomeran booster group|Received two doses of AstraZeneca as primary COVID-19 vaccine
9728433|NCT05228730|Active Comparator|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Pfizer-BioNTech booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
9728434|NCT05228730|Experimental|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Pfizer-BioNTech booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
9728435|NCT05228730|Active Comparator|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Elasomeran booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
9728436|NCT05228730|Experimental|Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Elasomeran booster group|Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
9728437|NCT05226988|Experimental|Hybrid-RT|hybrid robot-assisted training
9728438|NCT05226988|Experimental|Exo-RT|exoskeleton robot-assisted training
9728439|NCT05226988|Experimental|EE-RT|end-effector robot-assisted training
9728440|NCT05226988|Active Comparator|conventional training groups|
9728441|NCT05223868|Experimental|Group 1: JNJ-77242113 Dose 1 Once Daily (QD) and Placebo|Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
9728442|NCT05223868|Experimental|Group 2: JNJ-77242113 Dose 2 QD and Placebo|Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
10199752|NCT03252340||Drug: ADSTEM Inj.|Participants in Phase I clinical trials treated with ADSTEM Inj.
9728443|NCT05223868|Experimental|Group 3: JNJ-77242113 Dose 3 QD and Placebo|Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
9728444|NCT05223868|Experimental|Group 4: JNJ-77242113 Dose 1 Twice Daily (BID) and Placebo|Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
9728445|NCT05223868|Experimental|Group 5: JNJ-77242113 Dose 3 BID and Placebo|Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
9728446|NCT05223868|Placebo Comparator|Group 6: Placebo|Participants will receive placebo BID from Week 0 through Week 16.
9728447|NCT05222425|Experimental|Treatment group|Patients in the Treatment arm receive Xagrotin extract 2 grams three times a day in combination to the standard of care for sars-cov-2.
9728448|NCT05222425|No Intervention|Control group|Patients in the Control arm received the standard of care for sars-cov-2.
9728449|NCT05222425|Placebo Comparator|Placebo group|Patients in the Treatment arm receive green tea 2 grams three times a day in combination to the standard of care for sars-cov-2.
9728450|NCT05220293|Experimental|Betamethasone Dipropionate Nasal Cream 0.0644% Treatment|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
9728451|NCT05219370|Experimental|CBD rich|Cannabis oil oral drops containing 95 mg/ml CBD; 5 mg/ml THC; 15 mg/ml CBDV ; no CBG, once daily Titration from 0.3 to 1.8 ml/day during 21 days
9728452|NCT05219370|Experimental|CBG rich|"Cannabis oil oral drops containing no CBD; 5 mg/ml THC; no CBDV; 95 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days"
9728453|NCT05219370|Experimental|CBD & CBG rich|"Cannabis oil oral drops containing 47.5 mg/ml CBD; 2.5 mg/ml THC; 7.5 mg/ml CBDV; 47.5 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days"
9728454|NCT05219370|Placebo Comparator|placebo|Placebo oil oral drops once daily. Titration from 0.3 to 1.8 ml/day during 21 days
9728455|NCT05219058||Patients undergoing abdominoperineal excision|
9728456|NCT05219058||Patient undergoing pelvic exenteration|
9728457|NCT05216744|Experimental|Doxycycline plus ceftriaxone|Each subject will receive 100 mg doxycycline twice daily for seven days and a single dose of ceftriaxone 1000 mg intravenously
9728458|NCT05216744|Active Comparator|Doxycycline plus cefixime|Each subject will receive 100 mg doxycycline twice daily for seven days and a single oral dose of cefixime 800 mg
9728459|NCT05214365|Active Comparator|Conventional stimulation|An electrode (in the apical or septal portion) will be implanted at the discretion of the implanter physician. Parameters of (sensing, impedance and threshold) will be measured as is usually done in our center.
9728460|NCT05214365|Active Comparator|Physiological stimulation|Pacing the his-purkinje system.
9728461|NCT05212935||Children below 12 months of age receiving vaccines according to the National Vaccination Plan|"All children who received vaccination in their first 12 months of life between January 2018 and June 2022 in the Regional Vaccination Centers involved in the study.~Children will be classified in sub-groups, according to different vaccination schedules (single or co-administration) and order of vaccine uptake."
9728462|NCT05212480|Active Comparator|Zinc arm|patients received a pill containing 25 mg of zinc twice a day for 15 days
9728463|NCT05212480|Placebo Comparator|Placebo|patients received identical shape, smell, taste and color pill like the protocol treatment twice a day for 15 days
9728464|NCT05208346|Experimental|Canola oil high-fat|Participants randomized to receive a mixed meal with 50 g canola oil
9728465|NCT05208346|Experimental|Coconut oil high-fat|Participants randomized to receive a mixed meal with 50 g coconut oil
9728466|NCT05208346|Experimental|Canola oil low-fat|Participants randomized to receive a mixed meal with 25 g canola oil
9728467|NCT05208346|Experimental|Coconut oil low-fat|Participants randomized to receive a mixed meal with 25 g coconut oil
9728468|NCT05206084|Experimental|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
10199753|NCT03241186|Experimental|Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV|"Cycles 1-4: Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV Day 1 of each Cycle Each Cycle = 21 days~Cycles 5-15: Nivolumab IV 480 mg Day 1 of each Cycle Each Cycle = 28 days"
10199754|NCT03237234|Sham Comparator|Motor Training + Sham tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training while receiving sham transcranial direct current stimulation (tDCS).
10199755|NCT03237234|Experimental|Motor Training + tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training combined with transcranial direct current stimulation (tDCS) delivered at 2mA to the motor cortex.
9728469|NCT05206084|Active Comparator|XIENCE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
9728470|NCT05199298|Experimental|"Mandala Activity-Based Breastfeeding Program"|The group receiving Mandala Activity-Based Breastfeeding Program
9728471|NCT05199298|No Intervention|Control group|the group that did not receive any training/initiative
9728472|NCT05193084||Work Stream 1 (WS1)|"The general aim of this work stream is to assess the hypothesis can the volumes measured by the Heartfelt device be useful in titrating and optimising drug management for patients undergoing home-IV diuretics and after completion of IV-diuretic treatment.?~We will characterise the data collected by the Heartfelt device in the participants' home, correlating it to weight readings (either from the scales or paper weight diary) and medical observations recorded while patients are being treated with IV Diuretics.~Patients from WS1 will be invited to keep the device in their home for 3 months in total, which will therefore cover periods during which they do not receive IV diuretics, but are still at relatively high risk of decompensation. That data will be analysed in the same fashion as the data collected in WS2."
9728473|NCT05193084||Work Stream 2 (WS2)|"The general aim of WS2 is to assess the hypothesis can the Heartfelt device be used to monitor heart failure stability and detect fluid overload in patients recently discharged after an episode of decompensated heart failure?.~This work stream will also aim to examine whether the Heartfelt device gives an indication of the number of days prior to hospital admissions that the Heartfelt device can detect changes in foot volume. This will be achieved by comparing the data collected by the Heartfelt device in the participants' home, and correlating it to weight readings and medical observations. Hospital admissions will be a particularly useful correlation point as it would provide information on the detection of the forming oedema leading up to this event. In future, the information collected during this study will be used to design and power an interventional study to demonstrate the effectiveness of such data in providing a leading indicator of hospitalisation."
9728474|NCT05188937|Experimental|validity and reliability of Dual-task Questionnaire|"This study was conducted as test-retest design and the psychometric properties of Dual-task Questionnaire were examined in patients with MS."
9728475|NCT05187013|Experimental|Hypertension-Specific Education|6 months of mHealth HTN management support via SMS texts including reminders for medication adherence, appointment attendance, and HTN-specific health education and support. Texts will be delivered to support medication adherence and lifestyle changes, and participants will receive appointment reminders before each appointments with a follow-up text and robocall if the appointment is missed.
9728476|NCT05187013|Other|General Health Education|6 months of mHealth including basic healthcare and general health promotion via SMS texts. Blood pressure measurements and adherence assessments will be collected at every shelter visit.
9728477|NCT05183178|Active Comparator|Ticagrelor|Current standard of care
9728478|NCT05183178|Experimental|Prasugrel|New standard of care
9984756|NCT03758170|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
9984757|NCT03754049|Experimental|TLC599 12 mg|12 mg DSP with 100 μmol phospholipid via IA injection;
9728481|NCT05174351|Experimental|HFpEF patients|HFpEF patient who are currently taking beta blockers
9728482|NCT05173961|Experimental|Supportive Care (oncpatient application, survey)|Patients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment.
9728483|NCT05171257||repeat group|patients receiving empiric therapy with the same IV antibiotics from prior
9728484|NCT05171257||change group|patients receiving differing IV antibiotics from prior
10199756|NCT03226106|Experimental|Physical Activity Behavior Intervention|A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
10199757|NCT03226106|Active Comparator|Attention Control|Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
10199758|NCT03225365|Other|Nivolumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab treatment.~30 patients will be included in the arm."
9728485|NCT05163834|Experimental|Efgartigimod-1|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 22
9728486|NCT05163834|Experimental|Efgartigimod-2|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 36
9728487|NCT05163834|Placebo Comparator|Placebo|Weekly placebo infusions and the pneumovax 23 vaccine on day 22
9728488|NCT05161351|Experimental|Baclofen|Participants will receive a single dose of either 10mg, 30mg, 60mg or 90mg of Baclofen administered as oral tablets.
10199759|NCT03225365|Other|Nivolumab + Ipilimumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab + Ipilimumab treatment.~30 patients will be included in the arm."
10199760|NCT03194542|Experimental|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
10205050|NCT04209738||Tai Chi (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified teacher: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by a Tai Chi manual and a practice video. This complements the regular care.
9728489|NCT05161351|Placebo Comparator|Vitamin D3|Participants will receive a single dose of either 20μg, 60μg or 120μg of Vitamin D3 administered as oral tablets.
9984758|NCT03754049|Experimental|TLC599 6 mg|6 mg DSP with 50 μmol phospholipid via IA injection.
10199761|NCT03170869|Experimental|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
10199762|NCT03155607|No Intervention|Standard Care|
9728490|NCT05158166|Experimental|Administration of Daxi|Injectible daxibotulinumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) is an investigational botulinum toxin type A which has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and cervical dystonia and may offer longer-lasting results when compared with onabotulinumtoxinA. Dosage will be same number of units as prior Botox A dose.
9984759|NCT03754049|Active Comparator|DSP 4mg|Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 1 mL via IA injection.
9984760|NCT03752762|No Intervention|Standard Care|Participants will receive standard health care services provided by the Health Secretary
9728493|NCT05153759|Active Comparator|High protein|High protein diet (1.8g/kg body weight)
9728494|NCT05153759|Placebo Comparator|RDA protein|Protein content based on the recommended daily allowance (RDA- 0.8g/kg body weight)
9728495|NCT05152576|Placebo Comparator|Placebo|Placebo will be injected into the forehead on Day 1.
9728496|NCT05152576|Experimental|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
9728497|NCT05152576|Experimental|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
9728498|NCT05152576|Experimental|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
9728499|NCT05152173|Experimental|EN3835 Group|Participant will receive a maximum dose of up to 1.8mg of EN3835 injection
9728500|NCT05152173|Placebo Comparator|Placebo Group|Participant will receive a maximum dose of up to 1.8mg of Placebo injection
9728501|NCT05149417|Placebo Comparator|Standard group|Patients enrolled in this group were discharged and they didn't undergo any intervention within the treatment period.
9728502|NCT05149417|Active Comparator|SMS group|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
9728503|NCT05149417|Active Comparator|telemonitoring group|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
9781019|NCT01137578|Other|Cohort B: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place either symptomatic for a CVC-related DVT or having an incidental diagnosis of CVC-related DVT by radiographic imaging performed for other clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
9781020|NCT01137578|Other|Cohort C: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place having an MRI for clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
9781021|NCT01137604|Experimental|Cohort 1|"Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma [GBM]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator).~Cohort 1 - Bevacizumab~Cohort 1 - Lenvatinib"
9781022|NCT01137604|Experimental|Cohort 2|Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.
9781023|NCT01137604|Experimental|Cohort 3|Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.
10199763|NCT03155607|Experimental|Virtual Reality Distraction|
10199764|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
10199765|NCT03113422|Experimental|Induction Venetoclax|Cycle 1-6: Obinutuzumab intravenously (IV) and bendamustine IV. Cycle 2-6: Venetoclax (oral)
9781024|NCT01137682|Experimental|Pasireotide LAR 40 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
9781025|NCT01137682|Experimental|Pasireotide LAR 60 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
9781026|NCT01137682|Active Comparator|Control arm (octreotide or lanreotide)|"If a patient is randomized to the open label arm the investigator will either:~be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or~continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations."
9781027|NCT01137786|Active Comparator|IOPAMIDOL 370|
9781028|NCT01137786|Active Comparator|IODIXANOL 320|
9781029|NCT01137812|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
9781030|NCT01137812|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
9781031|NCT01137890|Experimental|Zonisamide|Participants administered blind capsules containing either placebo or zonisamide.
9781032|NCT01137890|Placebo Comparator|Placebo|Participants administered only placebo capsules containing lactose.
9781033|NCT01138007|Experimental|323U66 SR 150 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening throughout the treatment phase.
9785303|NCT01248715|Experimental|Oseltamirvir|These patients will receive early oseltamivir plus current, standard empiric antibacterial therapy.
9728504|NCT05145283|Active Comparator|Conestat alfa (Ruconest®) intervention group|The intervention group will receive conestat alfa (Ruconest®) as a 10-minute slow intravenous injection (up to 56 ml) once during the TAVI procedure followed by a second administration (up to 28 ml) again three hours later. The first administration will include a dosage of 100 U/kg (maximum 8400 U) conestat alfa. The dosing of the second administration will be 50 U/kg (maximum 4200 U).
9728505|NCT05145283|Placebo Comparator|saline injection placebo group|Subjects randomized into the placebo group will receive an intravenous normal saline injection with corresponding volume over 10 minutes during the TAVI procedure and three hours later after the first administration.
9728506|NCT05144139|Experimental|Low dose group with mRNA vaccine|25μg with COVID-19 mRNA vaccine
9728507|NCT05144139|Placebo Comparator|Low dose group with placebo|Low dose group with placebo
9728508|NCT05144139|Experimental|High dose group with mRNA vaccine|45μg with COVID-19 mRNA vaccine
9728509|NCT05144139|Placebo Comparator|High dose group with placebo|High dose group with placebo
9728510|NCT05141708||Talazoparib-treated adults with HER2- gBRCAm mBC|Adult patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib treatment in first-line or later line of therapy between January 1, 2018 and September 30, 2020.
9728511|NCT05139368|Experimental|Treatment (hypo-fractionated radiotherapy)|Patients undergo hypo-fractionated radiotherapy over 3 weeks in the absence of disease progression or unacceptable toxicity.
9728512|NCT05137496|Experimental|Ruxolitinib+methylprednisolone|Ruxolitinib and methylprednisolone administered as the first-line therapy
9728513|NCT05137132|Active Comparator|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides
9728514|NCT05137132|Placebo Comparator|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
9728515|NCT05130294|Active Comparator|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides.
9728516|NCT05130294|Placebo Comparator|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
9728517|NCT05124808|Experimental|Intensive glycemic targets|Participants in this arm will target a fasting blood glucose of <90 mg/dL and 1 hour post-prandial blood glucose values <120 mg/dL.
9728518|NCT05124808|Active Comparator|Standard glycemic targets|Participants in this arm will target a fasting blood glucose of <95 mg/dL and 1 hour post-prandial blood glucose values <140 mg/dL.
9728519|NCT05124002|Experimental|H101+HAIC|"Recombinant Human Adenovirus Type 5 (H101): intratumorally injected 3 days before HAIC. 1 vial (5.0 × 10^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10^12 vp) if the maximum diameters of lesion is > 10 cm.~HAIC (FOLFOX): Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium"
9728520|NCT05119179|Experimental|Semaglutide|Semaglutide 0.25 mg subcutaneously weekly for 4 weeks, followed by semaglutide 0.5 mg subcutaneously weekly for 8 weeks.
9728521|NCT05116072|Experimental|Experimental group|Patients benefited from total pancreatectomy for resectable adenocarcinoma of the cephalic region at high risk of postoperative pancreatic fistula, with intaportal/intramuscular islet autotransplantation
9728522|NCT05111990||Maternal pre-gestational BMI 18.5<25|
9728523|NCT05111990||Maternal pre-gestational BMI 25<30|
9728524|NCT05111990||Maternal pre-gestational BMI >30|
9728525|NCT05111886|Experimental|Primary Care Personnel Training|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition.
9728526|NCT05111886|Active Comparator|Primary Care Personnel Training Control|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition. Control group personnel will receive a written description of the referral process but no training.
9728527|NCT05111886|Experimental|Parents eHealth GenPMTO|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
9728528|NCT05111886|Active Comparator|Parents Control|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
9728529|NCT05111886|Other|Therapists|Community therapists trained to deliver GenPMTO.
9728530|NCT05109065||Individuals with primary psychotic disorders|"Participants who have received any of the following diagnoses: schizophrenia, schizoaffective disorder, or schizophreniform disorder.~Participants will have urine toxicology screen, vitals recorded, and blood drawn in a single visit."
9728531|NCT05109065||Healthy Controls|"Healthy participants who do not have any exclusion criteria will undergo an assessment to confirm absence of psychiatric disorder.~Participants will have urine toxicology screen, vitals recorded, and blood drawn in a single visit."
9728532|NCT05107544|Experimental|High Intensity Interval Training|The entire group is going to be undergo the intervention
9728533|NCT05105360|Active Comparator|Petersen's closure group|Petersen's space closure method
9728534|NCT05105360|Experimental|Mefix group|Mesentery fixation method
9728535|NCT05100225|Experimental|PTP-001 200 mg|A single intra-articular injection in the target knee of PTP-001 200 mg.
9728536|NCT05100225|Experimental|PTP-001 100 mg|A single intra-articular injection in the target knee of PTP-001 100 mg.
9728537|NCT05100225|Placebo Comparator|Placebo/saline|A single intra-articular injection in the target knee of 4mL of placebo control - physiological saline (0.9% sodium chloride injection, USP).
10199766|NCT03113422|Experimental|Maintenance Venetoclax|Patients with stable or improved disease will receive venetoclax by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab IV every 2 months for 12 cycles.
10199767|NCT03092609|Experimental|Attention Bias Modification|
10199768|NCT03092609|Active Comparator|Attention Control|
10199769|NCT03066622|Active Comparator|Standard of Care|IV Morphine or any medication per attending decision
10199770|NCT03066622|Experimental|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
10199771|NCT03052920|Experimental|Cochlear Implantation|Cochlear implantation of the poor hearing ear
10199772|NCT03029598|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
10199773|NCT03029104|Active Comparator|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
10199774|NCT03029104|Active Comparator|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
10199775|NCT03029104|Active Comparator|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
10199776|NCT03025386|Other|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
10199777|NCT03020030|Other|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
10199778|NCT03020030|Other|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1~And: No VHR characteristics~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
10199779|NCT03020030|Other|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
10199780|NCT03020030|Other|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
10199781|NCT03020030|Other|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
10199782|NCT03020030|Other|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
10199783|NCT03020030|Other|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
10199784|NCT03020030|Active Comparator|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
9728538|NCT05090072|Active Comparator|- Advance Directives Group|The group that will receive the principal physician intervention, using Advance Directives document as a communication tool between patients and caregivers, to find its efficacy on the promotion of better-prepared surrogates
9728539|NCT05090072|Placebo Comparator|Control Group|The group that will receive the Placebo Intervention, consisting of a clinical evaluation of patients' clinical status, by the physician
9728540|NCT05089032||Physicians|
9728541|NCT05089032||Nurses|
9728542|NCT05083481|Experimental|ASP1570 Monotherapy Dose Escalation|Participants will receive daily dose of ASP1570 in a 21-day cycle.
9728543|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Metastatic Melanoma|Participants who have metastatic melanoma will receive recommended Phase 2 dose (RP2D) of ASP1570 in a 21-day cycle.
9728544|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Non-Small Cell Lung Carcinoma (NSCLC)|Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle.
9728545|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Response Triggered Tumor|Participants who have response triggered tumor type will receive RP2D of ASP1570 daily or a dose level with confirmed response observed that has been cleared and deemed tolerable by the Dose Escalation Committee, in a 21-day cycle.
9728546|NCT05072977|Experimental|TransPRK|
9728547|NCT05072977|Active Comparator|Alcohol PRK|
9728548|NCT05071898|Experimental|Open label administration of semaglutide|Semaglutide: 0.25 mg, sc, q.week for 4 weeks followed by 0.5 mg, sc, q.week for 2 weeks
9728549|NCT05069519|Experimental|Facebook Condition|Participants assigned to this intervention will take part in personalized Facebook health education, receive a smartwatch, receive weekly health education, share sentiments on Facebook, and receive personalized feedback.
9728550|NCT05069519|Experimental|Smartwatch Condition|Participants assigned to this intervention will use a Fitbit to track daily physical activity (PA), share PA data remotely, and receive personalized feedback.
9728551|NCT05069519|Experimental|Combined Condition|Participants assigned to this condition will receive both Fitbit and Facebook health education programs, (The Smartwatch and Facebook Conditions). The investigators will also provide weekly personalized feedback, based on PA data and sentiment analysis, that have been developed in prior pilot studies.
9728552|NCT05069519|No Intervention|Attention Control|Participants assigned to the control condition will not receive any intervention. They will receive a Fitbit smartwatch, and continue with their standard care currently done in their life during the intervention period.
9728553|NCT05067140|Experimental|ARV-766|Oral tablet(s), once or twice daily in 28 day cycles
9728554|NCT05066321|Experimental|Mindfulness Oriented Recovery Enhancement (MORE) Arm|During hospitalization, participants will receive brief mindfulness training individually in person and complete a series of quantitative baseline questionnaires. Participants will complete 1 MORE session weekly for 8 sessions delivered in small groups of up to 5 people. These sessions will be delivered by a social worker in-person at baseline, and via telehealth after discharge. Follow-up surveys will be conducted at 3-, 6-. 9-, and 12- weeks, and an audio-recorded qualitative exit interview (45-60 minutes) will be completed upon completion of the intervention and the 12-week follow-up survey.
9728555|NCT05062915|No Intervention|Baseline population|Historic cohorte for comparisson in study 1. Baseline population 1 all patients with AVS. Baseline 2 population part of baseline 1 but with peripheral cause of AVS. Are offered late onset vestibular rehabilitaion if they have balance deficit.
9728556|NCT05062915|Active Comparator|Study population|"The study population is divided into 2 groups, based on the findings in the clinical investigation.~study population 1: all patients with acute Vestibular syndrome (AVS) Study population 2: all patients from study group 1, with vestibular/peripheral cause of AVS. They are offered early onset rehabilitation.~Arm 1 and 2 are compared for cost-effectiveness and compared to the costs of the diagnosis."
9728557|NCT05062772||Glioblastoma|
9728558|NCT05062070|Active Comparator|5 Percent TolaSure Topical Gel|5% (w/w) TolaSure Gel
9728559|NCT05062070|Placebo Comparator|Topical Vehicle Gel|TolaSure Vehicle Gel
9728560|NCT05061563|Experimental|Period 1|A single dose of elinzanetant and an additional IV (microtracer dose) of [13C5]BAY 3427080 will be administered.
9728561|NCT05061563|Experimental|Period 2|Once daily oral dose of esomeprazole and a single oral dose of elinzanetant will be administered.
9728562|NCT05058716||COVID-19 positive patients|
9728563|NCT05058716||COVID-19 negative patients|
9728564|NCT05053126|Experimental|Lyrica 300 mg|Single Dose
9728565|NCT05053126|Experimental|Lyrica 450 mg|Single Dose
9728566|NCT05053126|Experimental|Lyrica 300mg with Oxycodone 20 mg|Single Dose
9728567|NCT05053126|Experimental|Lyrica 450 mg with Oxycodone 20 mg|Single Dose
9728568|NCT05053126|Active Comparator|Oxycodone 20 mg|Single Dose
9728569|NCT05053126|Placebo Comparator|Placebo|Single Dose
10199785|NCT03020030|Experimental|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL
9728570|NCT05047952|Experimental|Vortioxetine|"Participants aged 18-64 years: start at 10 mg vortioxetine once daily for the first 2 weeks, then dosed up to 20 mg vortioxetine once daily for weeks 2-8.~Participants aged 65+ years: start at 5 mg vortioxetine once daily for the first 2 weeks, then dosed up to 10 mg vortioxetine once daily for weeks 2-8."
9728571|NCT05047952|Placebo Comparator|Placebo|Placebo capsule taken once daily for weeks 0-8.
9728572|NCT05044013|Experimental|JomPrEP App Group|Participants in the JomPrEP group will be provided with full app access and will be encouraged to use all features of the app.
9728573|NCT05044013|Active Comparator|Control Group|Participants in the control group will receive the JomPrEP app with major intervention features inactivated.
9728574|NCT05037760|Experimental|Arm 1a|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) monotherapy
10199786|NCT03020030|Other|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
10199787|NCT03016312|Experimental|Atezolizumab + Enzalutamide|Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
10199788|NCT03016312|Active Comparator|Enzalutamide|Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
10199789|NCT02888587||Control group|no gastrointestinal symptoms
9728575|NCT05037760|Experimental|Arm 1b|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
9728576|NCT05037760|Experimental|Arm 2a|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) monotherapy
9728577|NCT05037760|Experimental|Arm 2b|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
9728578|NCT05037123|Active Comparator|Arm 1 Continuous ketamine infusion group|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.3 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
9728579|NCT05037123|Active Comparator|Arm 2 Ketamine + Saline group|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
9728580|NCT05037123|Placebo Comparator|Arm 3 Placebo group|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
9728581|NCT05035004|Experimental|Post exercise hot water immersion|Moderate intensity cycling for 30 minutes, followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion.
9728582|NCT05035004|Active Comparator|Exercise|Moderate intensity cycling for 30 minutes.
9728583|NCT05035004|Active Comparator|Hot water immersion|Whole-body hot water immersion for 30 minutes, followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion.
9728584|NCT05030818|Experimental|Polypill|Patients will be receiving the polypill at the adequate doses during 3 months
9728585|NCT05030818|Active Comparator|Drugs taken separately|Patients will be receiving during 3 months the same components and at the same doses than with the polypill
9982333|NCT05253495|Experimental|Cohort 2a|Classical Hodgkin lymphoma, INTERMEDIATE RISK will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 2 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1 and 2). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will continue therapy with 4 cycles of Bv-NVD-R (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
9982334|NCT05253495|Experimental|Cohort 2b|COHORT IIb (Classical Hodgkin lymphoma, HIGH RISK) Cohort IIb patients will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment will be performed with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will receive 2 cycles of Bv, nivolumab, doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-NAVD-R 1 and 2), followed by 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
10199790|NCT02888587||Symptomatic group|Patients with Visceral hypersensitivity
10199791|NCT02876172|Experimental|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted therapy.
9728590|NCT05027906|Experimental|AT-1501 Single Arm|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
9728591|NCT05027061||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants receiving oral anticoagulant - Warfarin
9728592|NCT05027061||Cohort 2|NVAF participants receiving oral anticoagulant - Apixaban
9728593|NCT05027061||Cohort 3|NVAF participants receiving oral anticoagulant - Dabigatran
9728594|NCT05027061||Cohort 4|NVAF participants receiving oral anticoagulant - Edoxaban
9728595|NCT05027061||Cohort 5|NVAF participants receiving oral anticoagulant - Rivaroxaban
9728596|NCT05027061||Cohort 6|NVAF participants not receiving oral anticoagulants
9728597|NCT05026632|Experimental|Single NPI-002 Intravitreal Implant|one NPI-002 implant inserted at the time of vitrectomy
9728598|NCT05026632|Experimental|Double NPI-002 Intravitreal Implant|two NPI-002 implants inserted at the time of vitrectomy
9728599|NCT05026632|No Intervention|Control|No implant inserted at time of vitrectomy
9781034|NCT01138007|Experimental|323U66 SR 300 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening during the first week of the treatment phase. At the second week, 323U66 SR 300mg cohort is up-titrated to a daily dose of 323U66 SR 300 mg, administered as 323U66 SR 150 mg tablet twice daily in the morning and in the evening, and the same daily dose is maintained to administer until the end of the treatment phase.
10199792|NCT02799212|Experimental|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
10199793|NCT02799212|Placebo Comparator|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
10199794|NCT02722434|Experimental|Arm I (MC5-A scrambler therapy)|Patients undergo MC5-A scrambler therapy over 30 minutes for 10 consecutive weekdays.
10199795|NCT02722434|Active Comparator|Arm II (TENS therapy)|Patients undergo TENS therapy over 30 minutes daily for 14 days.
10199796|NCT02721979|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
10199797|NCT02709967|Active Comparator|Material support|Writing materials
10199798|NCT02709967|Experimental|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
10199799|NCT02709967|Experimental|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
10199800|NCT02604511|Experimental|Ibrutinib|This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
10199801|NCT02553941|Experimental|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
10199802|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
10199803|NCT02482753|Experimental|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
10199804|NCT02482753|Experimental|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9728600|NCT05020912|Experimental|Photodynamic therapy (PDT)|"Each participant will serve as their own control, receiving PDT for one tumor, no PDT for the second tumor (untreated control).~Visit 1:~Informed consent~Blood draw~Lesion(s) Photographed~(ALA) applied for4 hours~PpIX measured in lesions (PpIX buildup monitored every 30 minutes over a 4 h period)~PDT with blue light~Visit 2 (scheduled for within one of the following time intervals: 1-3 days, 4-7 days, or 8-14 days post-PDT):~Blood draw~Lesion(s) Photographed~Mohs surgery~After procedure, excess frozen BCC tissue will be saved for analysis"
10199805|NCT02482753|Placebo Comparator|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
10199806|NCT02442050|Experimental|del Nido solution|Administering of cardioplegia using del Nido solution in eligible patients.
9728603|NCT05009134||Control|18-55 years, healthy
9728604|NCT05009134||Allergic rhinitis|patients with AR without AIT
9728605|NCT05009134||Allergen immunotherapy|patients with AR with AIT for more than 1 year
9728606|NCT05007483|Experimental|Group 1 (Modified paleolithic elimination diet).|Modified paleolithic elimination diet.
9728607|NCT05007483|Experimental|Group 2 (TROO)|Time Restricted Olive Oil Based (TROO) Ketogenic Diet
9728608|NCT05007483|Active Comparator|Group 3 Control|Dietary Guidelines for Americans Diet
9728609|NCT05001386|Experimental|Lymphoproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .
9728610|NCT05001386|Sham Comparator|Control group|Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)
9728611|NCT05001386|Experimental|Myeloproliferative disorders|Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).
9728612|NCT04987892|Active Comparator|Prostatic Lift|Treatment with the UroLift System
9728613|NCT04987892|Active Comparator|Medication|Treatment with Tamsulosin HCl 0.4mg
9728614|NCT04985825|Experimental|Imgatuzumab monotherapy|
9728615|NCT04984343|Experimental|5 radiation treatments - ARM 1|Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.
9728616|NCT04984343|Active Comparator|2 radiation treatments - ARM 2|Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.
9728617|NCT04977414|No Intervention|Waitlist control group|Hospitals assigned to this group will be placed in on a waitlist to receive the training intervention at a later date
9728618|NCT04977414|Experimental|"Making data count intervention group"|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
9728619|NCT04977167|Experimental|Part 1:HG146 Monotherapy, Dose-escalation Cohort|Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.
9728620|NCT04977167|Experimental|Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort|"Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle.~Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated."
9728621|NCT04977167|Experimental|Part 2B-1：HG146 combination Expansion Cohort 1|Subjects who have not been treated with PD-(L)1 antibody，will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
9728622|NCT04977167|Experimental|Part 2B-2：HG146 combination Expansion Cohort 2|Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
9728623|NCT04976296||Stage I-IIIA NSCLC patients after complete resection|For stage I-IIIA NSCLC patients who underwent complete resection.
9728624|NCT04972786|Sham Comparator|Sham rTMS|Participants will receive sham rTMS for 10-20 minutes.
9728625|NCT04972786|Active Comparator|Active rTMS|Participants will receive active rTMS for 10-20 minutes.
9728626|NCT04972578|Active Comparator|Screw Fixation|
9728627|NCT04972578|Active Comparator|Suture Button|
10199807|NCT02442050|Active Comparator|Blood-based cardioplegia|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol.
9728628|NCT04971733|Experimental|Phase 1b: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 12 weeks in Phase 1b.
9728629|NCT04971733|Experimental|Phase 2: E2814|Participants will receive E2814 as an intravenous infusion at set intervals over 96 weeks in Phase 2.
9728630|NCT04969718|Experimental|LEADS Plus educational posters|A total of six group sessions with students using presentations and videos.
9728631|NCT04969718|Experimental|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers (teachers). This includes both presentations and videos.
9728632|NCT04969718|Experimental|Screening by Professionals programme Plus educational posters|This is an indicated or selective intervention by health professionals who will review assessments (done using structured questionnaires) and refer students where necessary.
9728633|NCT04969718|Active Comparator|Educational poster|The control group will be exposed to the six educational posters.
9728634|NCT04969718|Experimental|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents). This includes both presentations and videos.
9728635|NCT04966117|Experimental|Risk-Guided DMP|The intervention is a 12 month disease management program after hospital discharge for coronary artery disease that is overseen by a cardiac nurse.
9728636|NCT04966117|Active Comparator|Usual Care|Usual care patients will receive standard cardiology care.
9728637|NCT04958382|Experimental|Ciprofol|
9728638|NCT04958382|Placebo Comparator|placebo|
9728639|NCT04949503||study group|Patients of study group were all treated with chemoradiotherapy plus nimotuzumab.
9728640|NCT04949503||control group|Patients of control group were only treated with chemoradiotherapy, and were collected at least 3 times as many patients as the study group.
9728641|NCT04942678||Pediatric patients ages 4-7 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
9728642|NCT04942678||Pediatric patients ages 8-12 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
9728643|NCT04939935|Experimental|Intervention|"Participants randomised to the intervention group receive Metformin XR plus standard of care for 104 weeks.~Dosage will depend on individual participant's level of tolerance to Metformin XR as well as their estimated glomerular filtration rate (eGFR). The dosage will be between 1000-2000mg/day."
9728644|NCT04939935|Placebo Comparator|Control|Participants randomised to the control group receive placebo plus standard of care for 104 weeks.
9728645|NCT04938258|Experimental|Intensive Case Management Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual."
9728646|NCT04933721|Experimental|BCX7353 Capsules 150 mg once daily|Berotralstat (BCX7353) 150 mg capsule orally administered once daily.
9728647|NCT04909671|Active Comparator|CAD arm|Patients allocated to CAD arm will receive during colonoscopy withdrawal high definition white light endoscopy aided with artificial intelligence device (Gi Genius, Medtronic)
9728648|NCT04909671|Placebo Comparator|WLE arm|Patients allocated to WLE arm will receive during colonoscopy withdrawal high definition white light endoscopy as standart of care.
9728649|NCT04908202|Experimental|Deucravacitinib|
9728650|NCT04908202|Placebo Comparator|Placebo|
9728651|NCT04905784|Active Comparator|Control group: Usual brushing.|Usual motivation to brush teeth in the clinic (KAI brushing technique) in addition to brushing teeth by the parents.
9728652|NCT04905784|Experimental|Test group: Differential learning group.|Use of differential learning of tooth brushing at home, including children and parents.
9728653|NCT04903704|Other|Sit to Stand testing|"Participants will undergo an ISWT in the hospital setting. This test is a standard of clinical care and it is essential to the patient assessment on their clinical visit. This test will therefore be conducted first in all cases.~They will be allowed a 30 minute rest before undertaking the 1MSTS test.~Clinical observations (heart rate, blood pressure, oxygen saturations) will be taken before and after both tests. Heart rate and oxygen saturations will be monitored during both tests.~Patient reported measures of dyspnoea and perceived exertion will be recorded on completion of both tests.~Adverse events e.g. dizziness, syncope or the participant becoming unwell be recorded.~Descriptive and inferential statistical analysis will be used to determine the safety of 1MSTS in the hospital setting and comparability between 1MSTS and ISWT for participants. We will also examine comparability between 1MSTS outcomes and other available routinely collected clinical data."
10199808|NCT02436655|No Intervention|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
10199809|NCT02436655|Active Comparator|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
10199810|NCT02420574|Active Comparator|ALB-BENDEX|albendazole, 400 mg, single oral dose, (BENDEX)
10199811|NCT02420574|Active Comparator|ALB-OVIS|albendazole, 400 mg, single-oral dose, (OVIS)
10199812|NCT02403193|Experimental|PBF-509_80 mg|
10199813|NCT02403193|Experimental|PBF-509_160 mg|
10199814|NCT02403193|Experimental|PBF-509_320 mg|
10199815|NCT02403193|Experimental|PBF-509_640 mg|
10199816|NCT02403193|Experimental|PBF509_160 mg +PDR001|
10199817|NCT02403193|Experimental|PBF509_320 mg+PDR001|
10199818|NCT02403193|Experimental|PBF509_640 mg +PDR001|
10199819|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
10199820|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
9984761|NCT03752762|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive SQ-LNS supplement from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits and group sessions. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
9984762|NCT03750461|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
9728656|NCT04882280|Experimental|Low room|Low intensity (80 lux) room light
9728657|NCT04882280|Experimental|Normal room|Normal intensity (150 lux) room light
9728658|NCT04882280|Experimental|Bright room|High intensity (500 lux) room light
9728659|NCT04882280|Experimental|Bright|Very high intensity (1000 lux) room light
9728660|NCT04876729|Experimental|Otago Exercise Program|An individualized Otago Exercise Program will be delivered by community health representatives (CHR) in participants homes. There will be 10 home visits over a 12 month period.
9728661|NCT04876729|No Intervention|Education|The control group will receive education on fall risk reduction. This will be delivered by the CHR with 6 home visits over 12 months
9728662|NCT04876690||All Participants|Participants diagnosed with CD and CPF in the Portuguese routine clinical practice will be assessed. Retrospective data on healthcare resource utilization related with CPF management in the previous three years will be obtained from the medical records.
9728663|NCT04873193|Other|Oscillometry + Pneumotach Procedure with Leo Device measurements|"All patients will undergo oscillometry procedure, followed by pneumotach procedure to measure tidal volume in different sitting positions. The Leo device will be worn throughout both procedures to measure the chest electrical impedance and compare against pneumotach measurements.~Oscillometry and pneumotach are part of standard of care."
9728664|NCT04870528|Experimental|Experimental group|- This group will be composed of 30 patients with lower limb burn of second-degree. Subjects will receive pulsed magnetic field over thigh areas for 24 sessions over a period of 8 weeks (3sessions/week) with receiving strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living.
9728665|NCT04870528|Active Comparator|control group|Subjects will receive strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living for 24 sessions over a period of 8 weeks (3sessions/week)
9728666|NCT04857138|Experimental|Part 1: Dose Escalation (RO7300490 Monotherapy)|Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
9728667|NCT04857138|Experimental|Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)|Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
9728668|NCT04857138|Experimental|Part 3: Dose Expansion (Disease-specific Expansion(s))|Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
9728669|NCT04856215|Experimental|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The medicinal product consists of the murine IgG1 anti-CD66 monoclonal antibody radio-labelled with 111In for imaging and dosimetry and with 90Y for therapy.~Dosage indications The [111In]-labeled anti-CD66 monoclonal antibody (MAb) will be given at an infused activity of 100MBq/sqm between 1-4 weeks before the therapeutic dose of radiolabelled antibody.~[90Y]-yttrium-labeled anti-CD66 MAb will be given as a single infusion on day - 14 prior to transplant. [90Y]-yttrium labelled anti-CD66 MAb will be given to target an absorbed dose to the bone marrow of 45 Gy +/- 10%. The maximum dose to be delivered to the liver and the kidneys is 15 Gy and 10 Gy, respectively."
9728670|NCT04852926||A prospective cohort of patients|Female patients treated for non-metastatic breast cancer and followed up in the Observatory of fertility at Jeanne de Flandre Hospital
10199821|NCT02369536|Active Comparator|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
10199822|NCT02369536|Placebo Comparator|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
10199823|NCT02358681|Experimental|Ketorolac, intranasal|"Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.~Placebo, intravenous."
10199824|NCT02358681|Active Comparator|Ketorolac, intravenous|"Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.~Placebo, intranasal."
10199825|NCT02340026|Experimental|Conventional Therapy|"The conventional treatment group will receive traditional, therapist-directed pediatric physical therapy. Therapy will focus on early gait training strategies and encouragement of normal movement patterns for walking and other age-appropriate movements, with manual guidance or correction of atypical movements from the therapist. This group may use assistive devices, orthoses, and may receive static body weight support for gait training. Therapy activities will be performed in blocks of practice, with the specific activities and level of therapist assistance tailored to each child."
9728671|NCT04849325|Experimental|IBS Titan|
9728672|NCT04849325|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|
9728673|NCT04847388||ART-naive HIV Patients with substance abuse and without substance abuse|Group A Group B
9728674|NCT04847388||Group A and B|Group A: ART-naive HIV seropositive with H/O substance abuse Group B: ART-naive HIV seropositive without H/O substance abuse
9728675|NCT04846127||CanGaroo Envelope|Participants who receive a CanGaroo envelope during their CIED implant.
9728676|NCT04846127||No Envelope|Participants who do not receive an envelope of any kind during their CIED implant.
9982335|NCT05252897|Active Comparator|Endoscopic step-up approach|"After endoscopic drainage of WON, patients will be reassessed 72 hours after the procedure. If there is no clinical improvement 72 hours after drain placement, a CECT is performed to check the adequacy of the drainage. Irrigation of the WON via a nasocystic drain or endoscopic irrigation (step 1) is performed in case of inadequate drainage. If a nasocystic drain is inserted, 500ml of normal saline, twice a day will be used to irrigate the WON. If endoscopic irrigation is performed, only irrigation with normal saline without necrosectomy is allowed.~Patients are again evaluated 72 hours after step 1. In case of improvement, treatment is conservative; otherwise step 2 will be initiated, which is endoscopic necrosectomy. Further endoscopic necrosectomy will be performed until there is clinical improvement."
9982336|NCT05252897|Active Comparator|Direct endoscopic necrosectomy approach|Patients in the DEN group will undergo an immediate endoscopic necrosectomy after LAMS placement and balloon dilatation. A 10Fr 5cm double pigtail plastic stent will be inserted within the LAMS after necrosectomy. Patients will be assessed in 72 hours after the procedure. If there is no clinical improvement, a CECT is performed to check the adequacy of the drainage. DEN will be repeated in case of inadequate drainage. Patients will be reassessed every 72 hours and DEN repeated until there is clinical improvement. Subsequently, necrosectomy is performed weekly until a reassessment CECT at 3 weeks.
9728679|NCT04844684||Obese/non-diabetic patients undergoing gastric bypass surgery|
9728680|NCT04843319|Experimental|VERU-100 at various doses|150 mg, 200 mg, 300 mg or 400 mg of VERU-100
9728681|NCT04843111||Pregnant women and their offspring(s)|Pregnant women and their offspring(s) exposed to MenQuadfi® during their pregnancy or within 30 days prior to their LMP
9728682|NCT04841512|Placebo Comparator|Placebo|Sterile phosphate-buffered saline for injection Single 1mL injection into the facet joint
9728683|NCT04841512|Experimental|XT-150 Dose #1|Lower dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint
9728684|NCT04841512|Experimental|XT-150 Dose #2|Higher dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint
9728685|NCT04839146|Experimental|Group 1: 6 microgram ABNCoV2 with/without MF59 adjuvant|In Group 1 (n=6), subjects will receive 6 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
9728686|NCT04839146|Experimental|Group 2: 12 microgram ABNCoV2 with/without MF59 adjuvant|In Group 2 (n=6), subjects will receive 12 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
9728687|NCT04839146|Experimental|Group 3: 25 microgram ABNCoV2 with/without MF59 adjuvant|In Group 3 (n=6), subjects will receive 25 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
9728688|NCT04839146|Experimental|Group 4: 50 microgram ABNCoV2 with/without MF59 adjuvant|In Group 4 (n=6), subjects will receive 50 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
9728689|NCT04839146|Experimental|Group 5: 70 microgram ABNCoV2 with/without MF59 adjuvant|In Group 5 (n=6), subjects will receive 70 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
9728690|NCT04839146|Experimental|Group 6: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 6 (n=6) will receive the next lower dosage of the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
9728691|NCT04839146|Experimental|Group 7: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 7 (n=6) will receive the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
9728692|NCT04838236|Experimental|MASP app + NRT|MASP is an intervention designed to assist African American smokers with anxiety sensitivity quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal.
10199826|NCT02340026|Experimental|Dynamic Supported Mobility|Children will receive dynamic weight support during all DSM treatment time. The environment will be arranged to encourage active motor exploration, somewhat similar to a play gym for toddlers, to promote the motor variability, engagement, and error experiences that characterize the typical development of upright motor skills and walking. The floor area within 3 feet below either side of the overhead track for a distance of 20 feet (approximately 120 ft2 total) will be defined with colorful thin rubber interlocking mats and arranged with pediatric toys and activities, tailored to the child's interests and to encourage motor skills just beyond his/her current ability. The therapist will minimally assist the child as needed to perform the movements he/she initiates.
9728693|NCT04838236|Other|QuitGuide app + NRT|The QuitGuide app is a standard of care app that allows users to track their nicotine cravings, and provides users with motivational messages.
9728694|NCT04837768|Active Comparator|Serum Progesterone Levels >9.2 ng/ml|These patients will receive only twice-daily vaginal progesterone supplementation following embryo transfer
9728695|NCT04837768|Active Comparator|Serum Progesterone Levels <9.2 ng/ml|These patients will receive twice-weekly intramuscular progesterone supplementation in addition to the twice-daily vaginal supplementation following embryo transfer
10199827|NCT02339168|Experimental|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9728698|NCT04833426|Active Comparator|Testosterone therapy|Daily application of two pump auctions of 16.2mg/ml testosterone gel. Dosage may be altered depending on clinical response
9728699|NCT04833426|Placebo Comparator|Placebo therapy|Daily application of two pump auctions of placebo gel.
9728700|NCT04832932||75 years of age or older|individuals 75 years of age and older who received COVID-19 vaccine
9728701|NCT04832932||65-74 years of age|individuals 65-74 years of age who received COVID-19 vaccine
9728702|NCT04832932||18-64 years of age|Individuals in 18-64 age range who received COVID-19 vaccine
9728703|NCT04832932||MEBO/PATM|Individuals in 18-69 age range with present or past MEBO/PATM symptoms who received COVID-19 vaccine
9728704|NCT04829110|Experimental|A. ETOH|5 Males and 5 Females will receive deuterated water and drink 2.15 ounces of alcohol in the form of vodka and have de novo Lipogenesis measured at 11 time points during and after.
9728705|NCT04829110|Experimental|ETOH + Sucrose|5 Females will receive deuterated water and drink 1.72 ounces of alcohol in the form of vodka + 7 grams of sucrose and have de novo Lipogenesis measured at 11 time points during and after.
9728706|NCT04829110|Experimental|C. Sucrose|5 Females will receive deuterated water and drink a solution containing water and 35 grams of sucrose, and have de novo Lipogenesis measured at 11 time points during and after.
9728707|NCT04824066||Cardiothoracic Surgery Cohort|Adults patients who are scheduled to undergo cardiothoracic surgery and meet the inclusion and exclusion criteria.
9728708|NCT04821544|No Intervention|Control|Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period.
9728709|NCT04821544|Experimental|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
9781035|NCT01138007|Placebo Comparator|Placebo cohort|323U66 SR placebo tablet is orally administered twice daily throughout the treatment phase.
9781036|NCT01138046|Experimental|Lap+weekly Pacli|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
9781037|NCT01138098|Experimental|Infanrix-hexa/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-hexa vaccine in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
10199828|NCT02285816|Experimental|Arm A (MG1MA3 virus alone)|The starting dose of MG1MA3 will be 1 x 10^10 pfu administered by IV on day 1 and day 4.MG1MA3 dose will be escalated as per protocol.
10199829|NCT02285816|Experimental|Arm B- AdMA3 (vaccine prime) alone|Six patients will receive prime AdMA3 vaccine at a dose of 1x10^10 pfu administered IM on day (-14). No dose escalation is planned.
9781038|NCT01138098|Active Comparator|Infanrix-IPV+Hib/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
9781039|NCT01138111|Experimental|Arm 1|
9781040|NCT01138124||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
9781041|NCT01138150|Active Comparator|Treximet|"Fourteen participants randomized to receive Treximet (sumatriptan & naproxen) during an acute migraine attack. Blood drawn for immune & inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet).~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
9781042|NCT01138150|Placebo Comparator|Sugar Pill|"Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune & inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo.~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
9781043|NCT01138475|Active Comparator|Paricalcitol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules,cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
9781044|NCT01138475|Active Comparator|cholecalciferol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
9984763|NCT03750318|Experimental|Aingeal|All patients will wear the Aingeal device as part of the vital sign monitoring with opioid delivery system at ward setting.
10199830|NCT02285816|Experimental|Arm C- AdMA3 plus MG1MA3 (prime + boost)|Prime AdMA3 vaccine will be administered as a single dose of 1x10^10 pfu IM at day (-14) followed by dose escalation of MG1MA3 boost, IV administered on days 1 & 4 at a starting dose of 1 log below the recommended phase II dose (RP2D), as determined in Arm A of this study. MG1MA3 dose will be escalated as defined in protocol.
9728710|NCT04811469|Experimental|CBP-174|CBP-174 oral solution
9728711|NCT04811469|Experimental|Placebo|placebo oral solution
9728712|NCT04806048||Hospitalized patients and outpatients|There may be different types of patients with differing follow-up plan but all will bie considered one group regarding on whether they receive their recommended follow-up plan
9728713|NCT04804592|Experimental|Group A: SiHy CL|Silicone hydrogel (SiHy) CL wear at least 3 days per week and at least 8 hours per day;
9728714|NCT04804592|Experimental|Group B: RGP CL|Rigid gas permeable (RGP) CL wear at least 3 days per week and at least 8 hours per day;
9728715|NCT04804592|Experimental|Group C: no CL wear|No current CL wear for at least 3 months;
9728716|NCT04802798|Experimental|Placebo, Fibre 1, Fibre 2|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
9728717|NCT04802798|Experimental|Placebo, Fibre 2, Fibre 1|All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
9728718|NCT04799691||Invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 first period.
9728719|NCT04799691||Non-invasive strategy group|Patients admitted in ICU with Covid-19 related pneumonia during COVID19 second period.
9728720|NCT04794803|Experimental|Reparixin|Reparixin oral tablets 1200 mg TID for 7 days
9728721|NCT04794803|Active Comparator|Standard of care|Standard of care
9728722|NCT04773782|Experimental|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
9728723|NCT04772651|Experimental|Mediterranean Diet and dietary coaching|Patients receive 3 Mediterranean meals a day for 4 weeks and dietary coaching sessions (á 50 minutes once a week for 4 weeks)
9728724|NCT04772651|Placebo Comparator|Diet as usual and psychoeducation for depression|Patients receive normal hospital diet with 3 meals a day for 4 weeks and psychoeducation sessions (á 50 minutes once a week for 4 weeks)
9728725|NCT04769388|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
9728726|NCT04769388|Active Comparator|Osimertinib 80mg QD|All patients randomized into this will only receive Osimertinib 80mg.
9728727|NCT04765189|Placebo Comparator|Placebo|
9728728|NCT04765189|Experimental|Verum A|
9728729|NCT04765189|Experimental|Verum B|
9728730|NCT04765189|Experimental|Verum C|
9728731|NCT04765150||Observational (electronic health record review, 3 T MRI)|"RETROSPECTIVE: Patients' medical records are reviewed.~PROSPECTIVE: Patients undergo additional 3T MRI imaging over 30 minutes before, during, or after their standard of care 3T MRI for a total of 1.5 hours."
9728732|NCT04759248|Experimental|Atezolizumab in combination with Trastuzumab and Vinorelbine|
9728733|NCT04753710|Experimental|Chloroprocaine|Chloroprocaine 3% ocular gel
9728734|NCT04753710|Placebo Comparator|Placebo|Vehicle for chloroprocaine 3% ocular gel
9728735|NCT04752826|Experimental|Phase I, Part A - Dose escalation and safety of BI-1808 alone|Dose escalation with repeated administrations of BI-1808 infusions as a single agent, in patients with advanced malignacy.
9728736|NCT04752826|Experimental|Phase I, Part B - Dose escalation and Safety of BI-1808 in combination with pembrolizumab|Dose escalation and safety with repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in patients with advanced malignacy.
9728737|NCT04752826|Experimental|Phase IIa - Part A Expansion cohorts of BI-1808 alone|Repeated administrations of BI-1808 infusions as a singel dose in 3 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer , Cutaneous T-cell lymphoma (Sézary Syndrome and Mycosis Fungoides).
9728738|NCT04752826|Experimental|Phase IIa, Part B - Expansion cohorts of BI-1808 in combination with pembrolizumab|Repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in 2 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer.
9728739|NCT04752618|Experimental|P-STAIR|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. P-STAIR is a combination of STAIR and PCIT. STAIR focuses on reduction of PTSD symptoms through enhancement of emotion regulation skills. PCIT focuses on the reduction of negative parenting skills and the increase of positive parenting skills.
9728740|NCT04752618|Active Comparator|Supportive Counseling|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. Supportive counseling has been modified to permit non-trauma discussion of parenting problems. Each session is client-directed and clinicians take an unconditionally supportive role.
9728741|NCT04750720|Experimental|Group with biological samples|Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology). In the vaccine sub-study: additional blood and nasopharyngeal samples before and after vaccination, up to 6 months.
9728742|NCT04745351|Experimental|Remdesivir (RDV)|Participants will receive continued Standard of Care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg from Day 2 up to Day 5.
9728743|NCT04745351|Placebo Comparator|Placebo|Participants will receive continued SOC therapy together with RDV placebo on Day 1 followed by RDV placebo from Day 2 up to Day 5.
9728744|NCT04742062|Active Comparator|ApTOLL single dose|ApTOLL is administered intravenously in a single ascending dose pattern in seven dose levels (0.7mg - 70mg). Levels 1 - 3 include one subject per level and levels 4 - 7 include six subjects per level (1 sentinel + 5 subjects).
9728745|NCT04742062|Placebo Comparator|Placebo single dose|Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).
9728746|NCT04742062|Active Comparator|ApTOLL multiple dose|ApTOLL is administered intravenously every eight hours during 24h (21mg). This arm includes six subjects (1 sentinel + 5 subjects).
9728747|NCT04742062|Placebo Comparator|Placebo multiple dose|Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).
9728748|NCT04738643|No Intervention|Usual Care|TUT Service Only
9728749|NCT04738643|Experimental|Tobacco Use Treatment Service + Varenicline Management|TUTS + Varenicline Management
9728750|NCT04736550|Experimental|Assisted Exercise and I-STOP|Participant will receive Assisted Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
9728751|NCT04736550|Experimental|Voluntary Exercise and I-STOP|Participant will receive Voluntary Rate Exercise (stationary cycling) and psychotherapy for pain (I-STOP). Exercise (supervised) will be offered 3 days/week. I-STOP will be offered 1 day/week.
9728752|NCT04736550|Experimental|No Exercise (TAU) and I-STOP|Participant will receive psychotherapy for pain (I-STOP). I-STOP will be offered 1 day/week.
9728753|NCT04736550|Experimental|Assisted Exercise and No I-STOP (TAU)|Participant will receive Assisted Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
9728754|NCT04736550|Experimental|Voluntary Exercise and No I-STOP (TAU)|Participant will receive Voluntary Rate Exercise (stationary cycling). Exercise (supervised) will be offered 3 days/week.
9728755|NCT04736550|No Intervention|No Exercise (TAU) and No I-STOP (TAU)|Participant will receive their usual behavioral treatment offered at the residential drug treatment center and their medicated assisted treatment (MAT) as applicable.
9728756|NCT04734548|Active Comparator|Phase Ib ApTOLL|ApTOLL is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include six patients.
9728757|NCT04734548|Placebo Comparator|Phase Ib Placebo|Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.
9728758|NCT04734548|Active Comparator|Phase IIa ApTOLL|ApTOLL is administered intravenously (two doses selected in Phase Ib). The two dose levels include 35 patients each one.
9728759|NCT04734548|Placebo Comparator|Phase IIa Placebo|Placebo is administered intravenously in one arm which includes 49 patients.
9728760|NCT04733183|Experimental|Arm1: DTIC + L19TNF|Patients will receive Dacarbazine (DTIC) on Day 1 and L19TNF on Days 1, 3 and 5 every 21 days.
9728761|NCT04733183|Active Comparator|Arm 2: DTIC|Patients will receive Dacarbazine (DTIC) on Day 1 every 21-day cycle .
9728762|NCT04732949|Active Comparator|SNG001|SNG001 via inhalation using Ultra device, once a day for 14 days
9728763|NCT04732949|Placebo Comparator|Placebo|Placebo via inhalation using Ultra device, once a day for 14 days
9728764|NCT04727866|Experimental|Rostral tsDCS|DCS cathode over ~C3-C5 posteriorly, anode over ~C5-T1 anteriorly
9728765|NCT04727866|Experimental|Caudal tsDCS|DCS cathode over ~T1-T4 posteriorly, anode over ~C5-T1 anteriorly
9728766|NCT04727866|Experimental|Coronal tsDCS|DCS cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
9728767|NCT04725474|Experimental|Phase 1 (Part A; dose escalation): CTL-002 Monotherapy + Checkpoint Inhibitor Combination|Up to 5 dose levels with CTL-002 administered as IV monotherapy and in combination with a CPI
9728768|NCT04725474|Experimental|Phase 2 (Part B; expansion): CTL-002 + Checkpoint Inhibitor Combination|At defined dose level(s) with CTL-002
9728769|NCT04724837|Experimental|Part A and Part B: Zibotentan Dose A + Dapagliflozin|Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.
9728770|NCT04724837|Experimental|Part A and Part B: Zibotentan Dose A|Participants will receive once daily oral dose A of zibotentan alone for 12 weeks.
9728771|NCT04724837|Experimental|Part A and Part B: Dapagliflozin|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
9728772|NCT04724837|Placebo Comparator|Part A and Part B: Placebo|Participants will receive once daily oral dose of placebo matched to zibotentan or dapagliflozin for 12 weeks.
9728773|NCT04724837|Experimental|Part B Only: Zibotentan Dose B + Dapagliflozin|Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.
9728774|NCT04724837|Experimental|Part B Only: Zibotentan Dose C + Dapagliflozin|Participants will receive once daily oral dose C of zibotentan and 10 mg dapagliflozin for 12 weeks.
9728775|NCT04717674|Experimental|Drug: [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA)|Participants will undergo two PET/CT scans with the tracer [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid) (FPIA), referred to as [18F]FPIA, on 2 separate visits.
9728776|NCT04715529|Experimental|FZJ-003|
9728777|NCT04715529|Placebo Comparator|Placebo|
9728778|NCT04715438|Experimental|Cohort A: Individuals without cancer|A cohort of individuals without a cancer diagnosis is included for comparison. Because age is an important predictor of the ability to mount an effective immune response to vaccination, partners of patients in cohort B, C, and D.
9728779|NCT04715438|Experimental|Cohort B: patients receiving immunotherapy|Cancer patients receiving immunotherapy
9728780|NCT04715438|Experimental|Cohort C: patients receiving chemotherapy|Cancer patients receiving chemotherapy
9728781|NCT04715438|Experimental|Cohort D: patients receiving chemo-immunotherapy|Cancer patients receiving chemo-immunotherapy
9728782|NCT04713241|Active Comparator|Group A: SOC|Participants will receive the SOC and will also be asked to complete questionnaires to rate their symptoms
9728783|NCT04713241|Experimental|Group B: Electro-Acupuncture|Participants will receive the SOC + a daily 20-30 minute electro-acupuncture treatment from the time of randomization until the return of bowel function. The first treatment will be provided within 48 hours after the diagnosis of postoperative ileus. Participants will receive acupuncture every day until normal bowel movement function returns.
9728784|NCT04710004|Experimental|Brain stimulation via clinically implanted electrodes|Brain will be stimulated in different patterns including synchronized or asynchronous current.
10199831|NCT02269267||Discontinuation of TKI medication|Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years.
10199832|NCT02101788|Active Comparator|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
10199833|NCT02101788|Experimental|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9728785|NCT04697238|Experimental|High load (11 % of body weight vests)|Subjects in this arm will carry heavy weight (11 percent of body weight) vests for 5 weeks.
9728786|NCT04697238|Placebo Comparator|Low load (1 % of body weight vests)|Subjects in this arm will carry heavy weight (1 percent of body weight) vests for 5 weeks.
9728787|NCT04695444|Active Comparator|conventional PVC tube|When performing nasotracheal intubation, clinicians use the conventional PVC tube.
10199834|NCT02081378|Experimental|ABL001 in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with CML
10199835|NCT02081378|Experimental|ABL001+Nilotinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with Nilotinib in adult CML patients
10199836|NCT02081378|Experimental|ABL001 in Ph+ ALL patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with Ph positive ALL patients
9728788|NCT04695444|Experimental|PVC tube with rubber suction catheter|When performing nasotracheal intubation, clinicians use the conventional PVC tube + rubber suction catheter.
9728789|NCT04695444|Experimental|velvet soft PVC tube|When performing nasotracheal intubation, clinicians use the velvet soft PVC tube.
9728790|NCT04691102||Stroke group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
9728791|NCT04691102||Traumatic Brain Injury group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
9728792|NCT04691102||Mild Cognitive Impairment group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
9728793|NCT04691102||Parkinson Disease group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
10199837|NCT02081378|Experimental|ABL001+Imatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with imatinib in adult CML patients
10199838|NCT02081378|Experimental|ABL001+dasatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with dasatinib in adult CML patients
10199839|NCT02043691|Experimental|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
10199840|NCT02043691|Experimental|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
10205051|NCT04209738||Standard Care|"Brochure with detailed description of different evidence-based measures for fall prevention, created for the specific age group (Gleichgewicht & Kraft - Trittsicher durchs Leben https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf) and recommendation to visit the family doctor and discuss fall prophylaxis with him."
9728794|NCT04691102||Multiple Sclerosis group|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
9728795|NCT04691102||Healthy subjects groups|"Patients will undergo electroencephalography (EEG), electromyography (EMG), electrocardiogram (EKG) and electrooculography (EOG) during resting state and the execution of motor tasks. During the records, an inertial sensors-based assessment will be performed on all patients. Three different motor tasks will be considered for postural and gait functions, commonly adopted in the clinical practice (i.e., 10-Meter-Walk, Figure-of-8-Walk, and Fukuda-Stepping tests). To assess the motor function of upper limb, three different tasks, representative of the typical ADL movements, will be considered (Reach Out, Reach and Touch, Reach and Grasp). Each task will be repeated 3 times.~The whole assessment procedure will last approximately 40 minutes."
9728796|NCT04688034|Experimental|OP-724 400 mg / 20 mL / vial (20 mg / mL)|"Dose: [Cohort 1] 140 mg/m2/4 hours (starting dose) , [Cohort 2] 280 mg/m2/4 hours~Administration method: In the single administration, the safety of concomitant use with the investigational drug and antiretroviral drug will be confirmed and then the cycle administration will be started. For the single administration, at 14 days before the first cycle of administration, the dose planned for the first cycle with continuous intravenous administration for 4 hours will be administrated once. When an integrase inhibitor is used in combination as a key drug for antiretroviral drugs, it should be administered at the same time as the start of investigational drug administration only after the single administration. For the cycle administration, the continuous intravenous administration for 4 hours twice a week is defined as one cycle, and 12 cycles (12 weeks in total) will be performed."
9728797|NCT04687228|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
9728798|NCT04687228|Experimental|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
9728799|NCT04686227||Group-1, women with normal uterus|
9728800|NCT04686227||Group-2, women with any uterine malformations|Group-2 is going to be sub-grouped according to ASRM and ESHRE classifications
9728801|NCT04684706|Other|Compressed iTBS schedule|Stimulation 3-pulse 50-Hz bursts at 5-Hz for 2-s trains, with trains every 10 s, for 10 minutes, 10 times a day, for 5 consecutive days.
9728802|NCT04684524|Experimental|Dupilumab|Dupilumab administered every 2 or 4 weeks based on weights
9728803|NCT04684524|Placebo Comparator|Matching placebo|Placebo administered every 2 or 4 weeks based on weights
9728804|NCT04682301||Observational (focus group, interview)|"AIM I: Participants attend a focus group over 1-1.5 hours providing feedback on refining potential methods of SDM.~AIM II: Participants receive the SDM intervention developed in Aim I and provide feedback. Participants may attend a telephone interview over 45 minutes 1 month later."
9728805|NCT04679623|Experimental|Midazolam Injection|Midazolam injection, 10 mg
9728806|NCT04679623|Active Comparator|Seizalam™|Seizalam, 10 mg
9728807|NCT04678856|Experimental|Part A and B: Dupilumab|Dupilumab administered every 2 weeks.
9728808|NCT04678856|Placebo Comparator|Part A and B: Matching placebo|Placebo administered every 2 weeks
9728809|NCT04673448|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-28 of cycle 1. Beginning cycle 2, patients receive niraparib PO QD on days 1-21 and dostarlimab intravenously (IV) on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 6, patients receive niraparib PO QD on days 1-42 and dostarlimab IV on day 1. Cycles repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
9728810|NCT04672824|Experimental|ChAdOx1 RVF group 1|Participants will receive ChAdOx1 RVF 5 x 10^9 vp, delivered intramuscularly
9728811|NCT04672824|Active Comparator|Control group|Placebo (Normal Saline), 0.5ml delivered intramuscularly
9728812|NCT04672824|Experimental|ChAdOx1 RVF group 2|Participants will receive ChAdOx1 RVF 2.5 x 10^10 vp, delivered intramuscularly
9728813|NCT04672824|Experimental|ChAdOx1 RVF group 3|Participants will receive ChAdOx1 RVF 5 x 10^10 vp, delivered intramuscularly
9728814|NCT04669665|Experimental|SLS-002 + Standard of care|Participants will receive SLS-002 (intranasal racemic ketamine) 90 milligram (mg) two times per week for 2 weeks with standard of care treatment
9728815|NCT04669665|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 2 weeks with standard of care treatment
9728816|NCT04668781|Active Comparator|Epidural analgesia|
9728817|NCT04668781|Experimental|Wound catheter analgesia|
9728818|NCT04667013|Experimental|Cohort 1|2 x 300 mg TBN tablets for a total dose of 600 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
9982337|NCT05252858|Experimental|nCAP + ERAS|Participants will have the nCAP Signal Relief Patch and complete Enhanced Recovery After Surgery (ERAS) standard of care. After surgery, the subjects randomized to the intervention group will have the nCAP Signal Relief patch applied to their surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU).
9728819|NCT04667013|Experimental|Cohort 2|4 x 300 mg TBN tablets for a total dose of 1200 mg or 4 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
9728820|NCT04665856|Experimental|Tiragolumab + Atezolizumab + Carboplatin and Etoposide|Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
10199841|NCT02043691|Experimental|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
10199842|NCT01970410|Experimental|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
10199843|NCT01963728|Active Comparator|insulin isophane|daily dose will be titrated based on fasting morning glucose values
10199844|NCT01963728|Active Comparator|insulin glargine|daily dose will be titrated based on fasting morning glucose values
10199845|NCT01936480|Experimental|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
10199846|NCT01936480|Placebo Comparator|Placebo group|Healthy volunteers with QT genotype score in the highest or lowest quintile
10199847|NCT01880567|Experimental|Treatment (ibrutinib, rituximab)|Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10199848|NCT01877070||early stage prostate patients & their partners/close allies|
10199849|NCT01842282|Experimental|Amlexanox|
9728821|NCT04665856|Placebo Comparator|Placebo + Atezolizumab + Carboplatin and Etoposide|Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles
9728822|NCT04660539|Experimental|Satralizumab Treatment|Participants will receive satralizumab subcutaneously (SC) every 4 weeks (Q4W)
9728823|NCT04660214|Active Comparator|Vessel sealing device|Endoscopic diverticulectomy is performed with the LigaSure (TM) device
9728824|NCT04660214|Active Comparator|Dissecting Knife device|Endoscopic diverticulectomy is performed with the SB-Knife(TM) device
9728825|NCT04656067|Active Comparator|Oxytocin(only)|oxytocin is given IV infusion 5-10 minutes before the start of skin incision in the Elective Cesarean Section
9728826|NCT04656067|Active Comparator|Tranexamic acid and Ethamsylate|Tranexamic acid and Ethamsylate are given IV slowly 5-10 minutes before the start of skin incision in the Elective Cesarean Section
9728827|NCT04654013|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
9728828|NCT04654013|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (18 months).
9728829|NCT04653181|Experimental|Iron arm|Half of patients get i.v. iron preoperatively
9728830|NCT04653181|No Intervention|non-iron arm|Half of patients are treated without i.v. iron substitution
9728831|NCT04643353|Experimental|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia)with SMOOTH mode setting, which enables non-ablative, thermal-only operation). The parameters are selected based on extensive preclinical and clinical studies.~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
9728832|NCT04643353|Active Comparator|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
9785815|NCT01260350|Experimental|Group 22: LDV/SOF FDC 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.
10199850|NCT01622335|Placebo Comparator|General anesthesia with oxygen|General anesthesia and Air
10199851|NCT01622335|Experimental|nitrous oxide and general anesthesia|General anesthesia with Nitrous Oxide
10199852|NCT01577836||Robotic assistance, Nîmes|The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.
10199853|NCT01577836||Laparotomy, Marseilles|The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.
10199854|NCT01575886|Experimental|Smoking cessation intervention|This group receives the teachable moment communication process intervention focused on smoking cessation and contributes data at baseline (Time 1) and post intervention (Time 2).
10199855|NCT01575886|Other|Delayed intervention group|This group serves as the comparison group for the evaluation of the smoking cessation intervention at Time 1 and Time 2 data collection to complete the group randomized trial. This group of clinicians then has Time 3 data collection focused on weight management receives a revised intervention focused on teachable moment communication for weight management and has Time 4 data collected to evaluate the teachable moment for weight management training as a pre-post design.
10199856|NCT01509339|Experimental|Vancomycin for Inhalation|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
9728833|NCT04640168|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
9728834|NCT04640168|Experimental|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
9728835|NCT04634357|Experimental|ET140203 T Cells|ET140203 T Cells
9728836|NCT04634201|Experimental|Experimental group|
9728837|NCT04634201|Sham Comparator|control group|
9728838|NCT04631380|No Intervention|CONTROL|THIS GROUP WILL RECEIVE THE PROTCOLL TREATMENT GIVEN TO PATIENTS COVID -POSITIVE TESTED.
9728839|NCT04631380|Experimental|PRAYER|THIS GROUP WILL RECEIVE THE SAME TREATMENT GIVEN TO THE CONTROL GROUP, PLUS PRAYERS BY THEOLOGIANS WHOSE PRAYERS INTERCEDE IN FAVOR OF THEIR PROMPT RECOVERY
9728840|NCT04629820|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
9728841|NCT04629820|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (3 months).
9728842|NCT04626843|Experimental|Intermittent fasting|
9728843|NCT04625465|No Intervention|No Intervention, No Intervention (AA)|Participants do not receive text messages during Interval 2 or Interval 3.
9728844|NCT04625465|Active Comparator|No Intervention, Attention-Control Texts (AB)|Participants do not receive text messages during Interval 2. Participants receive attention control text messages during Interval 3.
9728845|NCT04625465|Experimental|No Intervention, CBT Texts (AC)|Participants do not receive text messages during Interval 2. Participants receive CBT text messages during Interval 3.
9728846|NCT04625465|Active Comparator|Attention-Control Texts, No Intervention (BA)|Participants receive attention control text messages during Interval 2. Participants do not receive text messages during Interval 3.
9728847|NCT04625465|Active Comparator|Attention-Control Texts, Attention-Control Texts (BB)|Participants receive attention control text messages during Interval 2. Participants receive attention control text messages during Interval 3.
9728848|NCT04625465|Experimental|Attention-Control Texts, CBT Texts (BC)|Participants receive attention control text messages during Interval 2. Participants receive CBT text messages during Interval 3.
9728849|NCT04625465|Experimental|CBT Texts, No Intervention (CA)|Participants receive CBT text messages during Interval 2. Participants do not receive text messages during Interval 3.
9728850|NCT04625465|Experimental|CBT Texts, Attention-Control Texts (CB)|Participants receive CBT text messages during Interval 2. Participants receive attention control text messages during Interval 3.
9728851|NCT04619953|Active Comparator|Postural Stability group (PSg)|The Postural Stability group (PSg) will perform 30 minutes of conventional neuromotor rehabilitation and 20 minutes of dynamic postural stability training.
9728852|NCT04619953|Active Comparator|Cognitive-Motor group (CMg)|The Cognitive-Motor group (CMg) performed 30 minutes of conventional neuromotor rehabilitation and 20 minutes of cognitive-motor training.
9728853|NCT04613973||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
9982338|NCT05252858|Active Comparator|ERAS alone|Participants randomized into the control group will receive complete Enhanced Recovery After Surgery (ERAS) standard of care and no nCAP patch.
10199857|NCT01362374|Experimental|Arm A (Doc + Ipat 100mg)|Participants received ipatasertib at a dose of 100 milligrams (mg) once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199858|NCT01362374|Experimental|Arm A (Doc + Ipat 200mg)|Participants received ipatasertib at a dose of 200mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
9728854|NCT04613973||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
9728855|NCT04612868|Experimental|AEYE Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
9728856|NCT04608630|Active Comparator|Denosumab|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
9728857|NCT04608630|Active Comparator|Zoledronic acid|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride, administered via intravenous infusion over at least 15 minutes on Study Day 1.
9728858|NCT04608630|Placebo Comparator|Placebo|Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
9728859|NCT04584112|Experimental|Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel|Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.
9785816|NCT01260454|Experimental|Qutenza patch|All participants actively treated with Qutenza
9785817|NCT01260467|Experimental|memantine arm|
9785818|NCT01260493|No Intervention|Conventional care, controlgroup|conventional care, control group
9728860|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC|Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four doses.
9728861|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC|Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four doses.
9728862|NCT04581538|No Intervention|Control group|This arm is being provided with continued home care as it was before
9728863|NCT04581538|Experimental|E-learning platform & networking platform|This arm is being provided with the e-learning platform and networking platform as components of the 24-h-quAALity package
9728864|NCT04581538|Experimental|Entire intervention|This arm is being provided with the entire intervention (e-learning platform, networking platform and digital care documentation)
9728865|NCT04577157|Experimental|Intervention Arm|"The participants in the intervention group will receive Health@click (seven-item multifaceted educational and reminder module) through WhatsApp. This will be included daily notes for medication reminders, voice messages, Graphics-based Reminders (GBR), Twice-weekly Graphics-based Messages (GBM), and once-weekly lifestyle advice through video in addition to standard care (as being practiced routinely in the hospitals). Besides this, a 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects and interaction with different foods, and psychological support to the participants who feel the need."
9728866|NCT04577157|No Intervention|Control Arm|Participants in the control group will receive no intervention except in standard care (as per being practiced routinely in the hospitals).
9728867|NCT04576702|Experimental|Investigational aIIV4c group|aIIV4c will be administered as a single dose intramuscularly on Day 1
9728868|NCT04576702|Active Comparator|licensed IIV4c type 1 group|IIV4c will be administered as a single dose intramuscularly on Day 1
9728869|NCT04576702|Active Comparator|licensed aIIV4 group|aIIV4 will be administered as a single dose intramuscularly on Day 1
9728870|NCT04576702|Active Comparator|licensed RIV4 type 2 group|RIV4 will be administered as a single dose intramuscularly on Day 1
9728871|NCT04572815|Experimental|Arm I (ustekinumab)|Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive ustekinumab IV. Beginning 8 weeks after receiving IV ustekinumab, patients receive ustekinumab SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
9728872|NCT04572815|Placebo Comparator|Arm II (placebo)|Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive a placebo IV. Beginning 8 weeks after IV placebo, patients receive a placebo SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse, or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
9728873|NCT04571255|Experimental|Intervention group|Participants in the intervention group will receive a minimum of 3 and a maximum of 6 music therapy sessions (i.e. Music-Assisted Relaxation) during a two weeks time frame.
9728874|NCT04571255|No Intervention|Control Group|Treatment as usual.
9728875|NCT04570605|Active Comparator|Standard Urotherapy|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management.
9982339|NCT05252468|Experimental|TaffiX™|TaffiX™ is a Nasal powder personal spray that blocks viruses particles from entering the nasal cells.
9982340|NCT05252468|Placebo Comparator|Lactose powder|Lactose nasal powder will be used as a placebo. It has an identical appearance as TaffiX™ (white powder in an identical bottle).
10199859|NCT01362374|Experimental|Arm A (Doc + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
9728876|NCT04570605|Experimental|Standard Urotherapy + PTENS|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management AND use parasacral percutaneous TENS as additional treatment.
9728877|NCT04566900|Experimental|Active Treatment|Subjects will be given a choice of videos consisting of still images set to music. Whether the video progresses and music continues to play will depend on the subject's ability to maintain frontal gamma oscillatory activity within a prespecified range. Over successive weeks, the parameters for positive feedback (music and video progression) will become incrementally more difficult.
9728878|NCT04566900|Sham Comparator|Placebo|Video and music progression will be random and will not depend on brain activity. Any progression will be by random chance alone.
9728879|NCT04566510|Experimental|Royal Guard|alpha-cypermethrin + pyriproxyfen (PPF)
9728880|NCT04566510|Active Comparator|PermaNet 3.0|deltamethrin + piperonyl butoxide (PBO)
9728881|NCT04558775||Observational Cohort|
9728882|NCT04556565||General population|A representative sample of the general adult population (including those tele-working and working outside of home)
9728883|NCT04556565||Cases and contacts|Recently isolated or quarantined COVID-19 cases and close contacts
9728884|NCT04556565||Healthcare workers|Healthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers)
9982341|NCT05252221|No Intervention|Usual Care|"Usual Care (UC) will consist of treatment as usual, standard and systematic alcohol screening as part of the rooming process conducted by medical assistants, and brief interventions and referrals to addiction treatment delivered by PCPs. PCPs can also prescribe the same AUD medications as those in the ATC arm."
9984764|NCT03749434||Adults with HAIs after VAD therapy|Adult patients who have received a ventricular assist device implant.
9728885|NCT04551898|Experimental|BGB-DXP593 Low Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
9728886|NCT04551898|Experimental|BGB-DXP593 Medium Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
9728887|NCT04551898|Experimental|BGB-DXP593 High Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
9728888|NCT04551898|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, and followed up for safety for up to 85 days
9728889|NCT04551183|Experimental|OnlyGroup|Patients are their own witnesses
9728890|NCT04549610|Experimental|HMB supplementation|"The experimental procedure for each participant in this group includes a one week HMB supplementation.~HMB will be administered in the form of blinded capsules containing 0.5 g HMB per capsule. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 8 capsules (4 x 2 capsules) of HMB in a split dose per day. On training days the supplements will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals during the day."
9728891|NCT04549610|Placebo Comparator|Placebo treatment|The experimental procedure for each participant in this group includes a one-week placebo (PLA) administration. PLA (corn starch) will be placed in the blinded capsules form. PLA will be ingested with at least 250 mL of water. Each participant in this group will ingest 8 placebo capsules a day. On training days the PLA capsules will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals.
9728892|NCT04547712|Experimental|aDBS Single Threshold|Adaptive DBS Single Threshold Mode
9728893|NCT04547712|Experimental|aDBS Dual Threshold|Adaptive DBS DualThreshold Mode
10199860|NCT01362374|Experimental|Arm A (Doc + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199861|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 100mg)|Participants received ipatasertib at a dose of 100mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199862|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 200mg)|Participants received ipatasertib at a dose of 200mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199863|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199864|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199865|NCT01362374|Experimental|Arm C (Pac + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199866|NCT01362374|Experimental|Arm C (Pac + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
10199867|NCT01362374|Experimental|Arm D (Enza + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
10205489|NCT05206175|Experimental|Primary Arm|Components of the Affect Therapeutic Program for MUD Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine-based addiction counseling with clinical personnel, twice-weekly group therapy, and monthly psychiatrist appointments for evaluation and management and medication support, as needed.
9728894|NCT04546516||HYAcorp Lips|HYAcorp Lips is indicated for the restoration of volume and contour of the lips.
9728895|NCT04546516||HYAcorp Face|HYAcorp Face is indicated for volume replacement (filling of folds), medium to deep folds, nasolabial folds, cheek area, glabella. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
9728896|NCT04546152||HYAPROF® SOFT|HYAPROF® SOFT is indicated for volume replacement (filling of folds), fine to medium folds, lip augmentation, periorbital region.
9728897|NCT04546152||HYAPROF® BALANCE|HYAPROF® BALANCE is indicated for volume replacement (filling of folds), deep folds, nasolabial folds, cheek area, glabella folds. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
9728898|NCT04540523|Experimental|Exergaming intervention group|30 minutes of exergaming per session and 5 sessions of exergaming play per week for a 6-month period.
9728899|NCT04540523|Active Comparator|Traditional Physical Activity|Phone consultations and workshops for parents to offer 5 times, 30 minutes per session; traditional physical activity at home for 6 months.
10199868|NCT01362374|Experimental|Arm D (Enza + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
10199869|NCT01362374|Experimental|Arm D (Enza + Ipat 400-600mg)|Participants received ipatasertib at a dose of 400-600mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
9728900|NCT04540523|No Intervention|Attention control group|Continue with usual activities at home with emailed physical activity tips.
9728901|NCT04533737|Experimental|Arm 1 (brodalumab + dummy 1)|"Participants receive:~Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks."
9728902|NCT04533737|Active Comparator|Arm 2 (guselkumab + dummy 2)|"Participants receive:~Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks."
10199870|NCT01320215|Experimental|Robot arm|The patients in this arm will have a robot-assisted promontofixation.
9728903|NCT04531943||TGWSM Using Estrogen|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of only estrogen.
9728904|NCT04531943||TGWSM Using Estrogen plus Progesterone|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of estrogen and progesterone.
9728905|NCT04531943||Cisgender MSM|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of cisgender MSM.
9728906|NCT04531943||TGWSM Initiating Feminizing Hormone Therapy|Cohort 2 participants are in the longitudinal portion of the study and are TGWSM who are planning to initiate feminizing hormone therapy. Individuals in Cohort 2 will participate in study activities for 18 months.
10199871|NCT01320215|Active Comparator|Non-robot arm|The patients in this arm with have a promotofixation via a laparoscopy, but without robot assistance.
10199872|NCT01248247|Experimental|Group 1 - Erlotinib|Erlotinib 150 mg by mouth each day of a 28 day cycle.
9728907|NCT04530760||intraabdominal hypertension group|patients with intraabdominal hypertension defined as intravesical pressure more than 12 mmHg
9728908|NCT04530760||control group|patients with no intraabdominal hypertension
9728909|NCT04523298|Experimental|Laser|
9728910|NCT04523298|Active Comparator|PFE|
9728911|NCT04522323|Experimental|Dose Exploration|The Dose exploration Phase is made up of Part A and Part B. Part A will evaluate the safety and tolerability of MEDI5752 in combination with Axitinib (2 patients), and Part B will evaluate the safety and tolerability of MEDI5752 in combination with Lenvatinib (~27 patients)
9728912|NCT04522323|Experimental|Dose Expansion|Evaluate safety and anti-tumor activity of MEDI5752 in combination with Lenvatinib (~41 patients )
9728913|NCT04502888|Experimental|SL-172154|Intratumoral administration
9728914|NCT04491110|Experimental|Experimental: Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
9728915|NCT04491110|Sham Comparator|Sham Comparator: Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
10199873|NCT01248247|Experimental|Group 2 - Erlotinib + MK-2206|"Erlotinib 150 mg by mouth each day of a 28 day cycle.~MK-2206 135 mg by mouth every week of a 28 day cycle."
10199874|NCT01248247|Experimental|Group 3 - AZD6244 + MK-2206|AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.
9728916|NCT04487067|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)
9728917|NCT04486001|Experimental|Treatment Group|This is single arm study with only comparison to non-treated cohorts at site.
9781045|NCT01138475|Placebo Comparator|placebo|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
9781046|NCT01138501|Experimental|rFVIII|
9781047|NCT01138514|Active Comparator|Clindamycin 1%/Benzoyl Peroxide 5%|
9781048|NCT01138514|Active Comparator|Reference Product|
9781049|NCT01138514|Placebo Comparator|Vehicle|
9781050|NCT01138657|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses every other week (eow) starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
9781051|NCT01138657|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by eow dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
9728918|NCT04472169||Severe haemophila A patients with or without inhibitors|
9728919|NCT04469075|Experimental|topical clindamycin and triamcinolone|Patients who are scheduled to receive TTFields therapy for newly diagnosed GBM will be treated with: topical clindamycin (or approved equivalent) 1% and triamcinolone 0.1%. Participating sites may use an alternative equivalent form of clindamycin, such as a gel, with MSK PI approval
9728920|NCT04466787|Experimental|Spectral Photon Counting Computed Tomography (SPCCT)|The randomized SPCCT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
9728921|NCT04466787|Active Comparator|Dual Energy CT (DECT)|The randomized DECT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
9728922|NCT04465487|Experimental|REGN6569+cemiplimab|REGN6569 lead-in
9728923|NCT04449484|Experimental|MEDI1341|3 doses given at 4 week intervals
9728924|NCT04449484|Placebo Comparator|Placebo|3 doses given at 4 week intervals
9728925|NCT04447469|Active Comparator|10 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
9728926|NCT04447469|Active Comparator|6 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
9728927|NCT04447469|Placebo Comparator|Placebo (Cohort 1)|Non-mechanically ventilated participants administered placebo as a single IV infusion
9728928|NCT04447469|Active Comparator|10 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
9728929|NCT04447469|Active Comparator|6 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
9728930|NCT04447469|Placebo Comparator|Placebo (Cohort 2)|Mechanically ventilated participants administered placebo as a single IV infusion
9728931|NCT04446481|Experimental|MCI patients|Vets with mild cognitive impairment
9728932|NCT04446481|Active Comparator|NC|Normal healthy Veterans
9728933|NCT04442074||Stroke Patients|These patients were hospitalized in the neurology / neurovascular department of the Paris Saint-Joseph Hospital Group, for the management of a transient ischemic infarction or accident for which the diagnosis of ipsilateral carotid diaphragm was accepted, between April 2017 and April 2020.
9728934|NCT04435470||Critical ill children|Critial ill children admited in pediatric intensive care units 1-16 years old
9728935|NCT04435470||Control|Healthy children 1-16 years old
9728936|NCT04433728||Adults Phenylketonuric|Adults patients screened in neonatal period for PKU and treated
9728937|NCT04428489||Idiopathic cytopenia of undetermined significance (ICUS)|
9728938|NCT04428489||Clonal cytopenia of unknown significance (CCUS)|
9728939|NCT04424914|Other|ATTR-CM positive|Participants diagnosed with ATTR-CM by scintigraphy
9728940|NCT04424914|Other|ATTR-CM negative|Participants who are scintigraphy negative for ATTR-CM
9728941|NCT04419519|Experimental|Venetoclax monotherapy|
9728942|NCT04419519|Experimental|Venetoclax with anti-CD20 monoclonal antibody|
9982342|NCT05252221|Active Comparator|ATC Service (intervention)|"ATC components include in-exam-room, real-time videoconferencing or phone contact with the PCPs and their patients, asynchronous, rapid response consultation via email or phone. ATC consultants will offer a flexible service that includes:~Direct patient contact, via video or telephone, during primary care visits~Motivational Interviewing (MI) - informed facilitation of patient engagement in addiction treatment,~Advice to PCP regarding patient-specific treatment options, including pharmacotherapy, addiction treatment, and combined treatments"
9982343|NCT05252208|Experimental|Stretching|Stretching
9982344|NCT05252208|Experimental|Walking|Walking
9982345|NCT05251714|Experimental|Part A: Monotherapy Escalation and Expansion|Dose selection and expansion of CFI-402257
10199875|NCT01248247|Experimental|Group 4 - Sorafenib|Sorafenib 400 mg by mouth twice a day for a 28 day cycle.
9982346|NCT05251714|Experimental|Part B: Combination Escalation and Expansion|Dose selection and expansion of CFI-402257 with Fulvestrant
9982347|NCT05251675|Active Comparator|Coaching Group|This arm will receive physician led coaching during the first 6 months of the study.
9982348|NCT05251675|Placebo Comparator|Non-Coached Group|This arm will not receive physician led coaching until after the Coaching Group is finished with their coaching.
9728949|NCT04405791|Experimental|Active stimulation group|"low intensity transcranial focused ultrasound (tFUS) stimulationThe acoustic intensity output of the FUS transducer was validated at the maximum intensity area using a calibrated needle hydrophone (HNR-500, Onda). The incident acoustic intensity and pressure at the FUS focus were 3W/cm2 spatial-peak pulse-average acoustic intensity (Isppa) and a peak negative pressure (Pr) of 300 kPa. The incident acoustic intensity and pressure at the FUS focus were 3W/cm2, and tone burst duration was 1 ms at 50 % duty cycle (thus, pulse repletion frequency was 500 Hz) for the duration of 300 ms, according to the studies in humans. Each sonication was delivered every 6 s for the duration of 20 min (a total FUS stimulation per each session was therefore 200 times). With a derating factor of 55% reduction in pressure transmission by the human skull, estimated in situ Pr was ~135 kPa with an in situ acoustic intensity of 600 mW/cm2 Isppa ."
9728950|NCT04405791|Sham Comparator|Sham stimluation group|"sham stimulation In case of sham stimulation, the same procedure was repeated without providing actual sonication. No subjects in FUS condition hear/feel any tangible somatosensory phenomena; therefore, the sham condition was indistinguishable."
9728951|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose A|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose A
9728952|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose B|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose B
9982349|NCT05251480|Active Comparator|Standard of Care|The standard of care includes physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment
9982350|NCT05251480|Experimental|DermGEN™|A decellularized dermal matrix created from donated human skin. This arm will receive the same care as the Standard of Care control arm-physical examination, wound debridement, total cast or offloading boot, non-adherent dressing (PolyMem®) for wound covering, weekly visit for ongoing assessment-with the addition of DermGEN™ onto the wound at the first visit.
9728953|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose C|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose C
9728954|NCT04402866|Experimental|Part 1: Placebo for MAD|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
9728955|NCT04402866|Experimental|Part 2: TD-0903|99 subjects will be randomized to receive TD-0903
9728956|NCT04402866|Experimental|Part 2: Placebo|99 subjects will be randomized to receive Placebo
9728957|NCT04400604||1: Patients with minimal risk of extensive fibrosis|TE < 5.8kPa; rule out cut-off value)
9728958|NCT04400604||2: Patients with intermediate risk of fibrosis|
9728959|NCT04400604||Patients with high risk of extensive fibrosis|
9728960|NCT04400604||Patients with compensated cirrhosis biopsy-proven|
9728961|NCT04400604||Patients with a first decompensation|patients with a first decompensation event of cirrhosis after exclusion of HCC.
10199876|NCT01246739|No Intervention|Follow-up|Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
9728962|NCT04400539|Experimental|Malignant Pleural Mesothelioma patients|
9728963|NCT04395599|Experimental|COVID19 patients undergoing visceral surgery|
9728964|NCT04394117|Active Comparator|Standard Care + Angiotensin Receptor Blocker (ARB)|Participants will receive an Angiotensin Receptor Blocker on top of the standard care provided by their institution.
9728965|NCT04394117|Placebo Comparator|Standard Care + Placebo|Participants will receive a placebo on top of the standard care provided by their institution.
9728966|NCT04393753|Experimental|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
9728967|NCT04372108||Ustekinumab New User Cohort|Participants with crohn's disease (CD) or ulcerative colitis (UC) with no prior exposure to ustekinumab, at least 1 year of enrollment records immediately prior to the new use will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
9728968|NCT04372108||Other Biologics Comparator Cohort|Participants with CD or UC with no prior exposure to the individual drugs (for example, infliximab, adalimumab, or vedolizumab) in question, at least 1 year of enrollment records immediately prior to the new use of the comparator biologic will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
9728969|NCT04365673||Readmitted|Patients that were readmitted within 30 days post hospital discharge
9728970|NCT04365673||Not readmitted|Patients that were not readmitted within 30 days post hospital discharge
9728971|NCT04356963|Experimental|Virtual Reality Sessions|All participants will participate in virtual reality sessions.
9728972|NCT04356963|Active Comparator|Comparator Sessions|All participants will participate in tablet-based sessions to content-less sessions wearing the virtual reality headset
10199877|NCT01246739|Experimental|Surgery|Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy
9728973|NCT04339634||Program of All-Inclusive Care for the Elderly|The Program of All-Inclusive Care for the Elderly (PACE) provides comprehensive medical and supportive services for community-dwelling persons, mostly older adults (>55 years), as an alternative to institutionalization. Medical services are provided by an interdisciplinary team of healthcare professionals, Tabula Rasa HealthCare being the pharmacy care provider for several PACE organizations.
9728974|NCT04338945||Residents in surgical areas|
9728975|NCT04335890|Experimental|DC IKKb|Vaccination with IKKb matured RNA loaded Dendritic Cells
9728976|NCT04327388|Experimental|Sarilumab 200 mg|"Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in fraction of inspired oxygen (FiO2) requirement or~Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction."
10199878|NCT01164228|Experimental|Arm A (Sunitinib + Gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
10199879|NCT01164228|Experimental|Arm B (Sunitinib)|Patients receive oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
10199880|NCT01086371|Experimental|RAS walking|Subjects will walk while listening to music 20 minutes per day every day during the study period.
9728977|NCT04327388|Experimental|Sarilumab 400 mg|"Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
10199881|NCT01086371|Active Comparator|RAS no walking|Subjects will be listening to music but not performing walking exercise, for 20 minutes per day every day during the study period.
9728978|NCT04327388|Placebo Comparator|Placebo|"Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
9728979|NCT04314544|Experimental|Arm A|
9728980|NCT04314544|Placebo Comparator|Arm B|
9728981|NCT04314531|Experimental|Arm A|
10199882|NCT01086371|Active Comparator|Walking no RAS|Subjects will be walking without listening to music for 20 minutes per day every day during the study period
10199883|NCT01012167|Active Comparator|1: galantamine/placebo-oxytocin|Subjects randomized to galantamine will receive galantamine and placebo-oxytocin
9728982|NCT04314531|Placebo Comparator|Arm B|
9728983|NCT04314089|Experimental|GT103|Participants will receive GT103 every 3 weeks. GT103 will be escalated from .3mg/kg up 10 to mg/kg or until MTD is found
9728984|NCT04314011|Experimental|HUC-MSCs Group|Human umbilical cord mesenchymal stem cells (1*10^6/kg cells): delivered via peripheral intravenous infusion.
9728985|NCT04314011|Placebo Comparator|Control Group|Placebo:normal saline delivered via peripheral intravenous infusion.
9728986|NCT04308655||Patient participants|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until five days postpartum.
9982351|NCT05251272||Training cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
9728987|NCT04308655||Provider participants|This cohort will include clinicians who provide care for pregnant patients with OUD. Providers will be interviewed and will complete one survey cross-sectionally.
9728988|NCT04297423|Experimental|Plenvu|Plenvu split dose
9728989|NCT04297423|Active Comparator|Citrafleet|citrafleet in split dose
9728990|NCT04293042|Experimental|BK cystitis and/or nephropathy|All patients with symptoms that are consistent with BK cystitis and/or nephropathy (frequency, dysuria, hematuria, elevated creatinine) will have serum quantitative DNA PCR for BK virus level measured in log copies per mL (results also expressed in copies per milliliter), performed in the Children's Hospital of Philadelphia Infectious Disease Diagnostics Laboratory
9728991|NCT04289363||ED patients|Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc.
9728992|NCT04289363||Stakeholders and community leaders|Stakeholders within and outside the hospital, including ED providers, hospital leadership, ED patients, ED staff, and community opinion leaders will be recruited to participate in the IF booster and qualitative focus groups and interviews.
9728993|NCT04289363||ED-initiated BUP patients|ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits and data matching.
9728994|NCT04289363||ED-initiated BUP patients - 2|ED patients who are eligible to receive ED-initiated BUP but unable or unwilling to participate will provide authorization for health services review and data matching with available registry, claims or administrative data.
9728995|NCT04289363||Data-matching ED patients|All ED patients screening positive for non-medical opioid use
9728996|NCT04288271|Experimental|Adherence Intervention|"The objective of the intervention is to improve medication adherence. Patient-participants will use a multi-dose electronic pillbox and adherence tracking website which can provide dose reminders. Patient will form an Adherence Support Team (AST) including the participant, a parent (or other) and the Coach (study coordinator). The Coach will guide the AST to use Action-focused Problem-solving to address personal barriers to adherence. They will then generate concrete if-then plans for how they will behave in a given situation. Intervention participants with excellent adherence will be encouraged to work on building autonomy in medication-taking instead of adherence. Action plans will be able to be modified, if desired, at the 6-week and 10-week check-ins.~HCP-participants at intervention sites will be given the option to login to the adherence tracking website to view the adherence data of their patients. They will also be alerted by study staff to critical non-adherence events."
9728997|NCT04288271|Other|Healthy Living Education Intervention|Patient-participants will receive a healthy living education intervention with the use of an e-pillbox. Contacts with the coach will occur at the same intervals as at adherence intervention sites. Participants will choose one of 3 healthy living topics on which they will receive education in an interactive format. The coach will engage the participant in a semi-scripted conversation on the selected topic. At check-ins, the coach will either continue the conversation on the topic selected at the outset or provide education on another topic. The coach will NOT engage in discussions about adherence and will NOT provide feedback on adherence data.
9982352|NCT05251272||Validation cohort|Patients were fulfilled diagnosis of compensated cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
10199884|NCT01012167|Active Comparator|2: oxytocin/placebo-galantamine|Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine
9728998|NCT04276181||CNaTT|The surgical procedures are described in the section Detailed description
9728999|NCT04273594|Experimental|FemBloc|Investigational device and procedure
9729000|NCT04263467|Experimental|Intervention group|Participants in the intervention group will receive a 6-weeks exercise-based intervention with supervised and group-based exercise training three times a week at the hospital setting. Each training session will consist of intermediate and high intensity interval training. The exercise-based intervention will be combined with standard oncological treatments; checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
9729001|NCT04263467|Experimental|Control group|Participants in the control group will receive standard oncological treatments; immune checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
9781052|NCT01138735|Active Comparator|adapalene/benzoyl peroxide|Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
9982353|NCT05251090|Experimental|Arm 1|Subjects(up to 12 years of age) received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW107 in the second period.
9982354|NCT05250908|Experimental|INTIBIA Therapeutic|Implanted with INTIBIA device and programmed to therapeutic stimulation for the duration of the study.
10199885|NCT01012167|Placebo Comparator|3: placebo-galantamine /placebo-oxytocin|Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin
10199886|NCT00924326|Experimental|1x10^9-1x10^10+ high dose Interleukin-2|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + cryopreserved anti-CD19-CAR PBL
10199887|NCT00924326|Experimental|1x10^9-1x10^10 + high dose Retreat|
10199888|NCT00924326|Experimental|0.5x10^7 cells/kg|
10199889|NCT00924326|Experimental|2.5x10^6 cells/kg|
10199890|NCT00924326|Experimental|1.0x10^6 cells/kg|
9729002|NCT04256941|Experimental|Arm I (ribociclib, palbociclib, abemaciclib, fulvestrant)|Patients receive ribociclib PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive fulvestrant IM for 2 injections over 1-2 minutes each on days 1 and 15 of cycle 1 and day 2 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9729003|NCT04256941|Active Comparator|Arm II (ribociclib, palbociclib, abemaciclib, letrozole)|Patients receive ribociclib orally PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive letrozole PO QD or anastrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9729004|NCT04256421|Experimental|Tiragolumab + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
9729005|NCT04256421|Active Comparator|Placebo + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
9729006|NCT04255745|No Intervention|Assessment-only control|30 Assessment-only control group will be mailed (standard or electronic) NIH/National Institutes on Aging (NIA) Go4Life® educational materials once a month for 3 months. Exercise logs documenting weekly exercise activities, duration, time and effort will be requested to be sent back.
9729007|NCT04255745|Experimental|Intervention|60 Intervention group will receive 12 weeks of supervised resistance training following the American Heart Association and American College of Sports Medicine guidelines for older adults. Exercises will include a mixture of upper-body and lower body strength exercises. Training load will be determined based on initial 1-repetition maximum tests (1-RM). Initial exercise load will start off at low resistance (40-50% 1RM) with more frequent repetitions per exercise, and will gradually increase weight load and intensity over the exercise training period.
9729008|NCT04252625|Active Comparator|Arm 1: Q-Urol|"Patients will be randomized in a 1:1 ratio to receive Q-Urol, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
9729009|NCT04252625|Placebo Comparator|Arm 2: Placebo|"Patients will be randomized in a 1:1 ratio to receive Placebo, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
9729010|NCT04240457|Experimental|Pulsed, accelerated|18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.
9729011|NCT04240457|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination.
9729012|NCT04232384|Active Comparator|Standard paracentesis group (SPG)|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography-guided (in cases the ascites is not clinically detectable).
9729013|NCT04232384|Experimental|Rollover paracentesis group (ROG)|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
9729014|NCT04225871|Experimental|0.3 mg/kg zilucoplan (RA101495)|
9729015|NCT04219800|Experimental|mHealth|"Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~SMS text messages; reminds of activity breaks.~Mobile video instruction for standing pause gymnastics."
9729016|NCT04219800|Other|Control|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
9729017|NCT04218448|No Intervention|Somatosensory evoked potentials without hypnorelaxation|"As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination.~Somatosensory evoked potentials are carried out according to the usual management."
9729018|NCT04218448|Experimental|Somatosensory evoked potentials with hypnorelaxation|As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination. Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes. The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of suggestions and metaphors. The protocol is adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. The investigator, thanks to hypnosis, allows the development of a creative imagination which allows a modification of the relation to space and time.
9729019|NCT04203641|Experimental|L-DOS47 + doxorubicin|Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin [20 mg/m2/week] will be administered in combination with L-DOS47 across all cohorts.
10199891|NCT00924326|Experimental|1.0x10^6 cells/kg (Reduced chemo)|
10199892|NCT00924326|Experimental|2.0x10^6 cells/kg (Reduced chemo)|
10199893|NCT00924326|Experimental|6.0x10^6 cells/kg (Reduced chemo)|
10199894|NCT00924326|Experimental|2.0x10^6 cells/kg (Moderate chemo)|
9982355|NCT05250908|Experimental|INTIBIA Non-Therapeutic|Implanted with INTIBIA device and programmed to non-therapeutic stimulation for the first 3 months, then to therapeutic stimulation for the duration of the study.
10199895|NCT00924326|Experimental|2.0x10^6 cells/kg (9-12 days culture)|
10199896|NCT00591318|Experimental|IV Ceftriaxone|IV Ceftriaxone 2 grams/day
10199897|NCT00591318|Placebo Comparator|IV Placebo|IV Placebo (Normal Saline)
10199898|NCT00321100|Active Comparator|Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
10199899|NCT00321100|Active Comparator|Cetuximab, Oxaliplatin, Capecitabine|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
10199900|NCT05191784|Experimental|GX-I7 and bevacizumab|Bevacizumab at a dose of 10 mg/kg intravenously, and GX-I7 intramuscularly.
10199901|NCT05191771|Experimental|Investigational product|
10199902|NCT05191771|Active Comparator|Comparator|
9664773|NCT05285241|Experimental|Multidirectional exercise group|Multidirectional stepping exercises along with conventional physiotherapy were provided to the patients. Conventional physiotherapy included one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min).
9664774|NCT05285241|Active Comparator|Conventional Physiotherapy Group|One-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min) were provided to the patients.
9664775|NCT05285111|Experimental|Interoceptive Awareness|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
9664776|NCT05285111|Active Comparator|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
9664777|NCT05284955|Experimental|CardioMEMS HF System group|Pharmacological heart failure treatment guided by an implanted wireless pulmonary artery hemodynamic monitor (CardioMEMS HF system)
9664778|NCT05284955|Active Comparator|Standard of care|Standard heart failure medical treatment
9664779|NCT05284903|Other|Experimental: Phonak device with activated feature|The clinical investigation is designed to evaluate clinical performances in terms of speech intelligibility and listening effort. The expected benefit is based on clinical relevant differences. This clinical investigation is divided in three parts including Beamformer benefit, Speech Enhancer benefit and Hearing aid benefit (this part will be performed aided).
9664780|NCT05284903|Other|Comparator: Phonak device with deactivated feature|The comparative testings should be used as reference. The measures will be performed by the same participant group and the same three parts will be evaluated including Beamformer (BF) benefit, Speech Enhancer benefit and Hearing aid benefit. The reference will be performed without these features or with different settings of these features. In case of the Hearing aid benefit, the reference is an unaided fitting.
9664781|NCT05284669|Experimental|Experimental e-learning|The experimental interactive intervention is based on international guidelines for the management of LBP and includes multiple interactions with the participant in a virtual environment. Metaphors and concrete clinical situations are presented to translate the knowledge (i.e. the management of low back pain from a biopsychosocial point of view) to clinical practice. Interactions consists of videos, open and closed questions and audio records.
9664782|NCT05284669|Other|Traditional e-learning|The traditional intervention consists of a traditional online lecture based on international guidelines for the management of LBP without any interaction. The focus is more fundamental (theoretical) without metaphors or clinical cases.
9664783|NCT05284656|Experimental|folic acid Group|20 patients will receive folic acid 500 µg per day with their standard therapy for 6 months.
9664784|NCT05284656|Experimental|Pentoxifylline Group|20 patients will receive Pentoxifylline ( TRENTAL® Tablets, 400 mg) twice daily with their standard therapy for 6 months.
9664785|NCT05284656|Experimental|folic acid and pentoxifylline Group|20 patients will receive combination therapy of folic acid5 mg per day and pentoxifylline ( TRENTAL® Tablets, 400 mg) twice daily with their standard therapy for 6 months
9664786|NCT05284656|No Intervention|control group|20 patients will receive their standard therapy only.
9664787|NCT05284630|Active Comparator|Experimental Group|Exercise follow up with mobile application in patients with chronic neck pain five sessions a week for 4 weeks
9664788|NCT05284630|Active Comparator|Control Group|Home based exercise follow up him/herself in patients with chronic neck pain five sessions a week for 4 weeks
9664789|NCT05284474|No Intervention|Control|"Small fetuses will be classified into 5 severity stages and managed as follows:~SGA: Estimated fetal weight (EFW) between p3 and p10 with normal Dopplers. Ultrasound/2 weeks, elective vaginal delivery at ≥39-40 weeks.~Stage I: EFW ≤p3 p or EFW p3-10 + UA PI >p95 and/or UtA PI >p95, and, at ≥32 weeks, CPR and/or MCA PI <p5, in 2 occasions >12 hours apart. Ultrasound weekly, elective vaginal delivery at ≥37 weeks.~Stage II: AEDF UA in 2 occasions >12 hours apart. Ultrasound every 48-72h, elective Cesarean delivery at ≥34 weeks. Fetal lung maturation at ≥ 33 weeks.~Stage III: DV PI > p95 (or absent DV a wave) or reversed end-diastolic UA >50% of cycles, in both cases in two occasions > 6 hours apart. Ultrasound every 24-48h, elective Cesarean delivery at ≥30 weeks. Fetal lung maturation at ≥ 28 weeks.~Stage IV: reversed DV a wave in two occasions > 6 hours apart. Elective Cesarean delivery at ≥26 weeks. Fetal lung maturation at ≥ 25+5 weeks."
9666429|NCT04522492|Experimental|internet CBT|Internet delivered cognitive behavioral therapy, thru 2 booster sessions. Each session will last 50 minutes. Fist session will involve: psychoeducation about the symptoms, evaluation of the skin picking habit, reinforcement of the habit reversal strategies. After 1 week, the second session will be applied, consisting of: strategies to cope with anxiety (breathing and muscle relaxation techniques) and to cope with depressive status (cognitive restructuring techniques).
9729020|NCT04203290|Active Comparator|General anesthesia|Patients will be applyed 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium for anesthesia induction, after intubation sevoflurane will be used for anesthesia maintenance with low flow anesthesia (0.5 l/min).
9729021|NCT04203290|Active Comparator|General anesthesia combined with thoracic epidural anesthesia|Before anesthesia induction epidural catheter will be inserted giving 7 ml bupivacaine %0.25 in saline + 50 mcg fentanyl after confirming the location of catheter, following 15 minutes the standard anesthesia induction will be applied ( 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium ). For anesthesia maintenance epidural infusion will be applied ( 7ml/h %0.25 bupivacaine solution) together with low flow (0.5 l/min) sevoflurane anesthesia.
9729022|NCT04195945|Experimental|Arm I (CPX-351)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of CPX-351 intravenously IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients who achieve a CR/CRi receive a reduced dose of CPX-351 IV over 90 minutes on days 1, 3, and 5 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
9729023|NCT04195945|Experimental|Arm II (CLAG-M)|"INDUCTION: Patients receive cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients who achieve a CR/CRi receive an intermediate dose of cytarabine IV over 2 hours on days 1-6 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
9729024|NCT04195633|Experimental|Arm A (high dose treosulfan)|Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is > 1,000/uL for 3 consecutive days.
10199903|NCT05191732|Experimental|PRP augmentation ACL reconstruction group|Platelet-rich plasma (PRP) (Dosage form: APA-15)
10199904|NCT05191732|Experimental|PRP+BMC augmentation ACL reconstruction group|Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
10199905|NCT05191732|No Intervention|Traditional ACL reconstruction group|No intervention
10199906|NCT05191706|Experimental|DEXYCU (dexamethasoneintraocular suspension) 9%|A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.
10199907|NCT05191706|Active Comparator|Prednisolone acetate ophthalmic suspension (USP) 1%|Active treatment control, prednisolone acetate ophthalmic suspension(USP) 1%, four times daily (QID)for 28days, followed by a treatment taper at the investigator's discretion.
10199908|NCT05191693||patients with CBD stones up to 8-12mm|72 patients (mean age: 67 years, 52.8% males) were included, of whom 22 (30.5%) had multiple CBD stones, 23 (31.9%) had a history of cholecystectomy, 13 (18.1%) had a periampullary diverticulum and 22 (30.5%) had a previous EST
10199909|NCT05191680|Experimental|Apalutamide 6 months|Participants will receive apalutamide 240 mg (4 x 60 mg tablets) orally once a day for up to 6 months.
10199910|NCT05191680|Experimental|Apalutamide 3 months + Placebo 3 months|Participants will receive apalutamide 240mg (4 x 60 mg tablets) orally once a day for up to 3 months followed by placebo to match apalutamide (4 tablets) orally once a day for up to 3 months.
10199911|NCT05191680|Placebo Comparator|Placebo 6 months|Participants will receive placebo to match apalutamide (4 tablets) orally once a day for up to 6 months.
10199912|NCT05191667|Experimental|Ph1: Patients that can be surgically resected with potential|Patients will receive AN0025 orally once daily (QD) and chemoradiotherapy as neoadjuvant treatment followed by a surgery
10199913|NCT05191667|Experimental|Ph1: Patients can be surgically resected with potential but are evaluated as inoperable later|Patients will receive AN0025 orally once daily (QD) and chemoradiotherapy as neoadjuvant treatment followed by a radical chemoradiotherapy.
10199914|NCT05191667|Experimental|Ph1: Patients with unresectable locally advanced/locally recurrent esophageal cancer|Patients will receive AN0025 orally once daily (QD) and chemoradiotherapy.
10199915|NCT05191654||with Congenital heart diseases|
10199916|NCT05191654||without Congenital heart diseases|
10199917|NCT05191641|Experimental|İntervention group|"PVQ and PedsQL will be used to collect research data. The same measurement tools will be used in the collection of pre-test, mid-term and post-test data. After obtaining the necessary written and verbal permissions from the parents in the intervention group included in the research, 12-week individualized nursing care will be applied. It is planned to make three measurements, namely pre-test, interim evaluation and post-test, from the parents in the intervention groups.~12 Weeks of Individualized Nursing Care~5 individual interviews~A interview after 2 weeks~Telephone consultation"
10199918|NCT05191641|No Intervention|Control group|Pre-test (PVQ and PedsQL) will be applied after obtaining informed consent from the parents included in the control group after randomization. In the pre-test application, an interim evaluation (PVQ and PedsQL) will be applied to the control group 1 week after and the post-test (PVQ and PedsQL) will be applied 4 weeks later. After the post-test application is completed, a five-day individual interview will be applied to the parents included in the control group.
10199919|NCT05191628|Experimental|Visio-AMTRIX|Disk of amniotic membrane apposed or buried on recurrent macular hole by the Investigator after vitrectomy and fluid-gas exchange.
10199920|NCT05191589|Experimental|Intervention Group|In the intervention group trainees will train in an already validated laparoscopic training program with haptic devices.
10199921|NCT05191589|No Intervention|Control|In the control group trainees will complete the same validated training program in the conventional non-haptic setting.
9664827|NCT05281302|Experimental|left-NMV + anodal-tDCS|"Patient will be equipped with vibratory stimulators and with electrodes for tDCS during conventional occupational therapy sessions.~Only the left-side NMV vibrator will be activated."
9781053|NCT01138735|Placebo Comparator|Topical Gel Vehicle|Topical Gel Vehicle applied topically once daily for 12 weeks
9982356|NCT05250739|Experimental|Strength training|Participants completed 16 training sessions of strength training during eight weeks.
10199922|NCT05191563|Experimental|Sequence 1 (Reference-Test)|Period 1: RLD2001-2 + RLD2006, Period2: HCP1904-1
10199923|NCT05191563|Experimental|Sequence 2 (Test-Reference)|Period 1:HCP1904-1, Period 2: RLD2001-2 + RLD2006
10199924|NCT05191498|Experimental|Study patients|All patients receive intratumoral holmium microsphere injections.
10199925|NCT05191459||Heart failure and preserved ejection fraction|42 patients 50-90 years with preserved ejection fraction (EF ≥50%)
10199926|NCT05191459||Heart failure and reduced ejection fraction|42 patients 50-90 years with reduced ejection fraction ((EF≤40%)
9664828|NCT05281016|Experimental|Delayed Intervention Control Group|Participants randomised to the Control Group will be offered standard care and will be introduced to 6 month delayed intervention which consists of the online community LITE programme.
9664829|NCT05281016|Experimental|Intervention Group|Participants randomised to the Intervention Group will receive standard care plus invitation to participate in the online community LITE programme for 4-5 months.
9664830|NCT05280847|Active Comparator|10 ml ESP group|ESP group using 10 ml mixture of local anesthetics and contrast medium
9664831|NCT05280847|Active Comparator|20 ml ESP group|ESP group using 20 ml mixture of local anesthetics and contrast medium
9664832|NCT05279131|Experimental|Tirbanibulin (Klisyri®)|Participants will apply tirbanibulin ointment 1% once daily for 5 days beginning Day 1. Participants will be evaluated for safety, tolerability, and the presence of AK lesions in the treatment field (TF) until completion of the response assessment period at Day 57
9664833|NCT05278962|Active Comparator|SGLT2i|Participants will be asked to take an SGLT2i for 6 months. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
9664834|NCT05278962|Active Comparator|No SGLT2i|Participants will not be asked to take an SGLT2i. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
9664835|NCT05278624|Active Comparator|Active plus vehicle arm|Subjects will be dispensed a tube containing roflumilast and vehicle in topical formulation
9664836|NCT05278624|Placebo Comparator|Vehicle arm|Subjects will be dispensed a tube containing vehicle only in a topical formulation
9664837|NCT05278117|Experimental|complete burst abdomen repair|complete burst abdomen repair
9664838|NCT05278000||Children aged 2-17 years with asthma|Parents of children aged 2-17 years seen at CHU Sainte-Justine asthma clinic with a diagnosis of asthma will be eligible for the study
9664839|NCT05277922|Experimental|C21|15 µg C21 (infusion rate 3 µg/min) 50 µg C21 (infusion rate 10 µg/min) 150 µg C21 (infusion rate 30 µg/min) 500 µg C21 (infusion rate 100 µg/min) 1000 µg C21 (infusion rate 200 µg/min)
9664840|NCT05277922|Experimental|Control group|4 µg nitroprusside (infusion rate 0.8 µg/min) 8 µg nitroprusside (infusion rate 1.6 µg/min) 16 µg nitroprusside (infusion rate 3.2 µg/min)
9664841|NCT05277636|Experimental|125 mg MDMA|MDMA (125 mg)
9664842|NCT05277636|Experimental|125 mg S-MDMA|S-MDMA (125 mg)
9664843|NCT05277636|Experimental|125 mg R-MDMA|R-MDMA (125 mg)
9664844|NCT05277636|Experimental|250 mg R-MDMA|R-MDMA (250 mg)
9664845|NCT05277636|Placebo Comparator|Placebo|Placebo
9664846|NCT05277584||Patients with hyponatremia|
9664847|NCT05276726|Experimental|Phase 1 ,Dose Exploration ,monotherapy|Dose escalation of JAB21822 will be administered as monotherapy to determine the MTD and RP2D
9664848|NCT05276726|Experimental|Phase 2, Dose Expansion, Part1 monotherapy|Part 1 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects with previously untreated advanced non-small cell lung cancer (NSCLC)
9664849|NCT05276726|Experimental|Phase 2 Dose Expansion, Part 2 monotherapy|Part 2 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects who had received at least one previous line of systemic therapy for NSCLC
9664850|NCT05276479||Healthy subjects|Healthy subjects aged 18-30 years
9664851|NCT05276336|Experimental|Intervention Group|Subjects will receive radiofrequency turbinate reduction done in the outpatient clinic, followed by pharmacology treatment (intranasal steroid and AH-1) for 8 weeks.
9664852|NCT05276336|Active Comparator|Control Group|Subjects in the control group will receive only the pharmacology treatment for 8 weeks.
9664853|NCT05275725|Experimental|Sildenafil|
9664854|NCT05275140|Experimental|Experimental group 1 (adapted taekwondo)|The general structure of the adapted taekwondo will include a 10-min warm-up consisting of joint mobility exercises and low intensity aerobic work, then, for 40-min of the adapted taekwondo (will consist of non-contact activities, distributed in 10-min of basic postures and specific movements with the upper limbs and 20-min of lower limb movements performed individually and in pairs with and without the implementation of taekwondo. In addition, choreographies or forms (sequence of arm and leg movements that simulate an imaginary combat) specific to this modality were adapted to the characteristics of older women for 10-min; and will be developed to finish with the cool down for 10-min through dynamic and static flexibility exercises.
9665461|NCT05049772|Experimental|Telerehabilitation-based motor imagery group|Behavioral: Telerehabilitation-based motor imagery group Participants in the Telerehabilitation-based motor imagery group will imagine for the lumbar region exercises (e.g. bridges, knee-to-chest stretches, pelvic tilts) in the sessions in home using the study audio-video motor imagery script for 2 times per week; 30 min per day for 10 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week). In addition, the participants will be given stabilization exercises In addition, the participants will be given stabilization exercises for 10 weeks for 40 minutes, 2 days a week.
9729025|NCT04195633|Experimental|Arm B (low dose treosulfan)|Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A.
9729026|NCT04193787|Experimental|EPIC-P|Participants will enroll in a bio-behavioral intervention aimed at preventing HIV transmission in people who inject drugs.
9729027|NCT04186845|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
9729028|NCT04186819|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
9729029|NCT04185259|Experimental|Acupuncture group|
9729030|NCT04185259|Sham Comparator|Sham acupuncture|
9729031|NCT04185259|No Intervention|Waitlist control group|Participants will receive no treatment for their heel pain for a period of 16 weeks after randomization, and subsequently have the option of 4 weeks (12 sessions) of acupuncture with free of charge at the end of follow-up.
9729032|NCT04184648||There was no adverse systems outcome after PMA36 weeks|Premature infants at PMA36 weeks did not show the following conditions (1) before follow-up tracheotomy; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
9729033|NCT04184648||Death or adverse respiratory outcome after 36 weeks of pma|Premature infants at PMA36 weeks presented the following conditions (1) before tracheotomy during follow-up; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
10205490|NCT05206149|Experimental|Intranasal Administration of Glucagon|Intranasal administration of glucagon in healthy subjects
10205491|NCT05206149|Placebo Comparator|Intranasal Administration of Placebo|Intranasal administration of placebo (isotonic saline solution) in healthy subjects
10205492|NCT05206123||Adolescents with perinatal acquired HIV infection|group of Adolescents with perinatal acquired HIV infection
10205493|NCT05206097|Experimental|Physical Activity Program|
9729038|NCT04180371|Experimental|Phase I - Dose escalation (BT5528)|Cohorts of participants will receive increasing doses of BT5528. It is expected that up to 48 participants will participate in this dose escalation arm.
9729039|NCT04180371|Experimental|Phase I - Dose escalation combination (BT5528 & nivolumab)|Cohorts of participants will receive increasing doses of BT5528 and a standard dose of nivolumab. It is expected that up to 24 participants will participate in this dose escalation combination arm.
9729040|NCT04180371|Experimental|Phase II - Dose expansion 1 (BT5528)|A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 40 patients with non-small cell lung cancer (NSCLC) with EGFR mutation and confirmed EphA2 tumor expression will participate in this dose expansion arm.
9729041|NCT04180371|Experimental|Phase II - Dose expansion combination (BT5528 & nivolumab)|A cohort of participants will receive the selected dose of BT5528 in combination with a standard dose of nivolumab. It is expected that up to 14 participants with non-small cell lung cancer without EGFR mutation and confirmed EphA2 tumor expression will participate in this dose expansion arm.
9729042|NCT04180371|Experimental|Phase II - Dose expansion 2 (BT5528)|A cohort of participants will receive the selected dose of BT5528 as a monotherapy. It is expected that up to 40 patients with NSCLC without EGFR mutation and confirmed EphA2 tumor expression will participate in this dose expansion arm.
9729043|NCT04173169|Experimental|Pre-IVF Treatment with 60 day course of oral GnRH antagonist|Subjects will be randomized to elagolix 200mg BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day.
9729044|NCT04173169|Placebo Comparator|Pre-IVF Treatment with 60 day course of Placebo|Subjects will be randomized to placebo, BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day.
9729045|NCT04166500|Experimental|Intervention|
9729046|NCT04166500|No Intervention|Control|
9729047|NCT04152863|Experimental|IV V937 + Pembrolizumab|Participants receive V937 at a dose of 1 X 10^9 TCID50 by IV infusion on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. V937 will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
9729048|NCT04152863|Experimental|ITu V937 + Pembrolizumab|Participants receive V937 at a dose of 3 X 10^8 TCID50 by ITu injection on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. V937 will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
9729049|NCT04152863|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
9781054|NCT01138826|Active Comparator|treatment A - reference w/ water|
9781055|NCT01138826|Experimental|Treatment B - ODT (test) w/ water|
9781056|NCT01138826|Experimental|Treatment C - ODT (test) w/o water|
9781057|NCT01138917|Experimental|all participants|All participants will receive both ReCell and split-thickness skin graft
10205494|NCT05206071|Experimental|SL 19+22 CAR-T|
10205495|NCT05206045||Patients with Sezary syndrome|Adult patient with Sezary syndrome diagnosed between 1998 and 2020
10205496|NCT05206032||healthy participants|healthy participants
10205497|NCT05206032||acute aortic dissection (AAD)|acute aortic dissection (AAD)
10205498|NCT05206032||acute myocardial infarction (AMI)|acute myocardial infarction (AMI)
10205499|NCT05206032||pulmonary embolism (PE)|pulmonary embolism (PE)
10205500|NCT05206032||angina|angina
10205501|NCT05206019|Experimental|cohort 1: Albuvirtide|Single dose of 320 mg by intervenous drop infusion for 45 min
10205502|NCT05206019|Experimental|cohort 2: Albuvirtide|Single dose of 320 mg by intervenous injection for 0.5 min
9729050|NCT04138927|Experimental|Fostamatinib|"Subjects who at any time during the C-935788-057 study achieved a hemoglobin response will continue at their dose and regimen from the Week 22 visit in the C-935788-057 study.~All other subjects who enter the extension study will initially receive fostamatinib 100 mg PO bid. Starting at Week 4, the initial fostamatinib dose of 100 mg PO bid will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug, based on the Investigator's judgment."
9729051|NCT04135352|Experimental|V938 Dose A + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose A of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously once every 3 weeks (Q3W) beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
9729052|NCT04135352|Experimental|V938 Dose B + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
10199927|NCT05191394|Other|Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.|"Assessment of the possible variation of anti-SARS-CoV-2 antibody titer in adult patients regularly treated with therapeutic plasma exchange.~For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session."
9729053|NCT04135352|Experimental|V938 Dose C + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
9729054|NCT04135352|Experimental|V938 Dose D + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
9729055|NCT04135352|Experimental|V938 Dose B + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
9729056|NCT04135352|Experimental|V938 Dose C + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
9729057|NCT04135352|Experimental|V938 Dose D + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
9729058|NCT04135352|Experimental|Dose Expansion Arm A, Melanoma|This arm will enroll only participants with with a diagnosis of stage III (unresectable) and Stage IV melanoma (any line of therapy). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
9729059|NCT04135352|Experimental|Dose Expansion Arm B, HNSCC|This arm will only enroll participants with a diagnosis of advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
9729060|NCT04127825|Experimental|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a blood conservation technique that entails the removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid and/or colloid replacement.
9729061|NCT04127825|No Intervention|Standard of Care|Standard of care for blood volume maintenance during surgery
9729062|NCT04125550|Experimental|Group P|In Group P, 2-3 mg/kg propofol, 5 µg/kg iv fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 10 mg/kg/h propofol infusion and 5 µg/kg/h fentanyl infusion will be administered.
9729063|NCT04125550|Active Comparator|Group S|In Group S, sevoflurane inhalation (2-8%), 5 microgr/kg intravenous (iv) fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 2% sevoflurane inhalation and 5 µg/kg/h fentanyl infusion will be administered for the maintenance of anesthesia.
9729064|NCT04125342|Experimental|Conditioned NIV in High Risk Patients|
9729065|NCT04125342|Active Comparator|HFOT in High Risk Patients|
9729066|NCT04125342|Experimental|Conditioned NIV in Obese Intermediate Risk Patients|
9729067|NCT04125342|Active Comparator|HFOT in Obese Intermediate Risk Patient|
9729068|NCT04123561|Experimental|TLC599|TLC599 (1mL) IA injection
9729069|NCT04123561|Active Comparator|Dexamethasone sodium phosphate|DSP 4mg (1mL) IA injection
9729070|NCT04123561|Placebo Comparator|Normal Saline|Normal saline (1mL) IA injection
9781058|NCT01138969|Active Comparator|Esomeprazole plus clopidogrel group|esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
10199928|NCT05191342||Rheumatoid arthritis|Patients with rheumatoid arthritis (n=25).
10199929|NCT05191342||Rheumatoid arthritis complicated atrial fibrillation|Patients with rheumatoid arthritis complicated atrial fibrillation (n=25).
10199930|NCT05191342||healthy volunteers|Healthy volunteers (n=25).
10199931|NCT05191329||study group|40 patients with non surgical presbyopic correction e.g. glasses and 80 patients that underwent pseudophakic presbyopic correction with multifocal or trifocal IOLs
10199932|NCT05191212|Experimental|Experimental arm|Cervical indocyanine green injections until real-time visualization of the afferent lymphatic channels bilaterally.
10199933|NCT05191212|Active Comparator|Standart arm|Cervical indocyanine green injections group
10199934|NCT05191199||Normal erectile response|Peak systolic velocity above 35cm/s, EDV below 5cm/s, Erectile score 4 or 3
10199935|NCT05191199||Abnormal erectile response|Peak systolic velocity below 35cm/s, EDV above 5cm/s, Erectile score 2 or 1
10199936|NCT05191186|Active Comparator|grass pollen extract treatment|participants receive 3 injections with Alutard phleum pratense, ALK, grass pollen extract
10199937|NCT05191186|Placebo Comparator|Placebo|Participants receive 3 injections with saline (NaCl 0.9%)
10199938|NCT05191082|Sham Comparator|Control Group (CG)|The palatal wound area will not receive any treatment
10199939|NCT05191082|Experimental|Silk Fibroin Film - SF|The palatal wound area will receive silk fibroin film as a dressing
10199940|NCT05191082|Experimental|Neurotensin-loaded Silk Fibroin Film - SF + NT|The palatal wound area will receive a neurotensin-loaded silk fibroin film as a drug delivery system
10199941|NCT05191069|Experimental|Moringa Oleifera Mouthwash|15ml of Moringa Oleifera mouthwash will be given to be used twice daily for 6 months.
10199942|NCT05191069|Placebo Comparator|Placebo Mouthwash|The mouthwash will have all other ingredients other than Moringa Oleifera extract. Participants will be advised to use 15ml of Placebo mouthwash twice daily for 6 months.
9664882|NCT05268874|No Intervention|Group Control = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
9664883|NCT05268614|Experimental|Chemo-radiotherapy|Participants will receive chemo-radiotherapy.
10199943|NCT05191030|Experimental|Experimental (High-Stress) Arm|"Participants undergoing the experimental (high-stress) arm are exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993). Participants are given five minutes to prepare for a five-minute speech task followed by a five-minute mental arithmetic task in front of two panelists wearing white lab coats (i.e., a male and female research assistant). The speech task posits the participant in a mock interview, with the two panelists listening to the speech in an unresponsive, neutral manner and asking standardized probing questions. Participants undergoing the mental arithmetic task are instructed to subtract odd numbers (i.e., 7 and 13) from a large number (i.e., 2935) as quickly as possible. If the participant makes a mistake, the panelist interrupts them and instructs them to start the task again from the beginning. The panelists also constantly remind the participant to go faster if they start to slow down with the task."
9664885|NCT05268172|Experimental|IFN- Y combined with T cells|First, IFN-γ was combined with CIK cells. After three failed treatments, the CIK cells were replaced with T cells. After three failed treatments, CART cells were finally replaced.
9664886|NCT05266183|Experimental|Simultaneous Variety, Small Portion|3 different foods served in a small portion.
9664887|NCT05266183|Experimental|Simultaneous Variety, Large Portion|3 different foods served in a large portion.
10199944|NCT05191030|No Intervention|Control Arm|Participants undergoing the control arm are presented with low-stress equivalents to the speech and mental arithmetic tasks from the experimental (high-stress) arm. For the speech task, participants are instructed to talk out loud to themselves for five minutes about a movie or book of their choice. Their speech is recorded using a small audio recorder device the research assistant prepares. For the mental arithmetic task, participants are instructed to count by increments of 15 starting from zero to the largest number they can reach. Participants are left in the room alone for the task for five minutes, after which the participant self-reports to the research assistant the number they reached.
10205503|NCT05206019|Experimental|cohort 3: Albuvirtide|Single dose of 320 mg by intervenous injection for 3 min
10205504|NCT05206006|Other|Control Group|As routine care, the choice of the initial antibiotic regimen will be let to the discretion of the emergency physician.
10205505|NCT05206006|Experimental|computerized decision support app (CDSA) Group|
10205506|NCT05205993|Experimental|Intrauterine infusion of antibiotics|Thirty women will receive only intrauterine infusion of antibiotics for 30 days.
10205507|NCT05205993|Experimental|Combination of intrauterine infusion and oral administration of antibiotics|Thirty women will receive a combination of intrauterine infusion and oral administration of antibiotics for 30 days.
10205508|NCT05205993|Active Comparator|Oral administration of antibiotics|Thirty women will receive only oral administration of antibiotics for 30 days.
10205509|NCT05205941|Other|MMV533 (single, oral doses).|Approximately 12 volunteers in 1 cohort, Up to six dose levels between 10 and 160mg
10205510|NCT05205928|Active Comparator|Placebo + closed-loop insulin system|
10205511|NCT05205928|Experimental|Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin system|Semaglutide is a Glucagon-Like Peptide 1 Receptor Agonist. It stimulates GLP1 in the body, which allows for increased satiety, reduced glucagon levels, delayed gastric emptying, and in some, increased insulin secretion. It is a once per week subcutaneous injection.
10205512|NCT05205915|Experimental|Single arm|All patients will receive active treatment which consists of stimulation (tDCS) applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents).
10205513|NCT05205902|Other|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
10205514|NCT05205902|Other|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
10205515|NCT05205876|No Intervention|Control|This group will use the Dexcom application for management of their blood glucose for the duration of the study (8 weeks).
10205516|NCT05205876|Experimental|Intervention|This group will use the Dexcom application for the initial 2 weeks of the study, and switch to using the Eddii application on Day 14 of the study for the remaining 6 weeks of the study.
10205517|NCT05205863|Experimental|Cofact Dose 1|
10205518|NCT05205863|Experimental|Cofact Dose 2|
10205519|NCT05205863|Placebo Comparator|Placebo|
10205520|NCT05205837|Placebo Comparator|Active Comparator - placebo|Intervention: Intramuscular injection - placebo Intervention: Drug: placebo
9781059|NCT01138969|No Intervention|Clopidogrel group|clopidogrel 75 mg qd for 6 months
9982357|NCT05250739|Experimental|Neuromuscular training|Participants completed 16 training sessions of neuromuscular training during eight weeks.
9982358|NCT05250739|No Intervention|Control group|The Control group received no intervention.
9982359|NCT05250583|Experimental|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring.
10199945|NCT05190991|Experimental|RPH-104 80 mg q2w (160 mg q2w) depending on the dose in the core CL04018065 study|RPH-104 80 mg once every 2 weeks subcutaneously or RPH-104 160 mg once every 2 weeks subcutaneously (In case of FMF attack development, patients who receive 80 mg of the drug may be switched to the increased maximum drug dose 160 mg based at the discretion of the investigator. A dose of 160 mg should be administered by two subcutaneous injections in two different quadrants.)
10199946|NCT05190978|Experimental|Acellular Dermal Matrix|Patients will receive ADM during their initial tissue expander placement.
10199947|NCT05190978|Active Comparator|Control|Patients will not receive ADM during their initial tissue expander placement.
10199948|NCT05190952|Active Comparator|Group 1|Control Group (Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure).
10199949|NCT05190952|Active Comparator|Group 2|Ketamine Group (In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes).
10205521|NCT05205837|Active Comparator|Active comparator - treatment|Intervention: intramuscular injection - hCG Intervention: Drug: Letrozole
9664888|NCT05266183|Experimental|Single-Food, Small Portion|1 food served in a small portion.
9664889|NCT05266183|Experimental|Single-Food, Large Portion|1 food served in a large portion.
9664890|NCT05265507|Experimental|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
9664891|NCT05265507|Active Comparator|Ondansetron|Ondansetron (4mg) was intravenously given at the ending of the surgery.
9664892|NCT05265052|Experimental|3D1002 50 mg group (Phase IIa)|3D1002 is given 50 mg twice a day for 2 weeks.
9664893|NCT05265052|Experimental|3D1002 100 mg group (Phase IIa)|3D1002 is given 100 mg twice a day for 2 weeks.
9664894|NCT05265052|Experimental|3D1002 150 mg group (Phase IIa)|3D1002 is given 150 mg twice a day for 2 weeks.
9664895|NCT05265052|Experimental|3D1002 monotherapy group (Phase IIb)|3D1002 at recommended dose plus mimic OxyContin tables, will be given twice a day for 2 weeks.
9664896|NCT05265052|Experimental|OxyContin monotherapy group (Phase IIb)|OxyContin initiating at 10mg per dose plus mimic 3D1002 tablets, will be given twice a day for 2 weeks.
9664897|NCT05265052|Experimental|3D1002 + OxyContin group (Phase IIb)|3D1002 at recommended dose plus OxyContin initiating at 10 mg per dose, will be given twice a day for 2 weeks.
9664898|NCT05264337||Radical Cystectomy|Patients undergoing radical cystectomy with pelvic lymph node dissection for urinary bladder cancer
9664899|NCT05264337||Radical Prostatectomy|Patients undergoing radical prostatectomy with pelvic lymph node dissection for prostate cancer
9664900|NCT05264337||Retroperitoneal|Patients undergoing retroperitoneal lymph node dissection for testicular cancer
9664901|NCT05264337||Other|Patients undergoing other urologic surgery with lymph node dissection of inguinal, iliacal or retroperitoneal lymph nodes
9664902|NCT05263388|Experimental|REKOVELLE (Follitropin Delta)|
9664903|NCT05263388|Active Comparator|GONAL-F (Follitropin Alfa)|
9664906|NCT05261022|Experimental|Love Together, Parent Together Intervention|"Participants will take part in a 3-session writing intervention over the course of 12-week. They will complete a fact-based summary of a recent conflict and answer questions on conflict/conflict-related distress. Next, they will be asked to complete a 9-minute writing task where they reappraise the conflict they previously reported. First, they will watch an instructional video of how to engage in the writing task, by providing definitions and examples of potentially useful conflict reappraisal strategies. Writing prompts include: … Think about this disagreement … from the perspective of a neutral third party who wants the best for all involved…; …what obstacles do you face in trying to take this perspective…?;… How might you be most successful in taking this perspective … over the next 2 weeks? Participants in the intervention group will receive emails to prompt use of the reappraisal strategy between writing sessions."
9664907|NCT05261022|No Intervention|Wait-List Control Group|"Participants will take part in a waitlist control group. They will participate in the same number of assessment/sessions as the experimental group. In the sessions that correspond to the intervention (one session every 4 weeks over the course of 12 weeks as in the intervention group), the waitlist group will complete a basic writing task (identical to the intervention group, wherein they provide a fact-based summary of a recent conflict) and they will complete questions regarding conflict history and conflict-related distress. No other writing tasks will take place.~Following the 3-month assessment, they will be offered the writing intervention."
9664908|NCT05260073||Tirbanibulin (Klisyri®)|Participants will receive tirbanibulin ointment 2.5 mg in 250 mg (single dose packet). The participants will be observed for 24 weeks to gather participant reported outcomes (PROs) and clinical profile.
9664909|NCT05259501|Experimental|Tablet-based approach using the ingestible sensor and smart pill bottle (T-RMIST Arm)|This method utilizes existing technology to 1) remotely confirm and capture the timing of ingestion events, 2) capture the timing of medication handling events and remaining medication doses. The timing of ingestion is tracked using an FDA-cleared ingestible sensor in a capsule that will contain methadone in tablet form.
9664910|NCT05259501|Experimental|Liquid vial-based approach using guided video recording with tamper-aware packaging (L-RMIST Arm)|This method uses automated visual recognition software within the AiCure app and barcoded tamper-evident labels to enhance the security of the take-home regimen currently used in methadone clinics. Single-use liquid methadone vials are made tamper-aware through the application of a barcoded security label.
9664911|NCT05259150|Experimental|Internal Champion (IC) Strategy|In the Planning for Health intervention, the IC implementation strategy will include trainings on transformational leadership principles that address challenges that health leaders face in the church setting to assist them in independently planning the cardiovascular health programming for congregants. Limited assistance from staff will be provided in the Preparing for Health and the Delivery of Health interventions.
9729071|NCT04118283|Experimental|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
9781060|NCT01138995|Active Comparator|Ankle-foot orthosis (AFO) Control Group|"The Control Group will walk with the a usual ankle-foot orthosis (AFO) for 30 weeks."
9781061|NCT01138995|Experimental|Ness L300 Treatment Group|The Original Treatment Group will walk with the Ness L300 for 30 weeks.
9781062|NCT01139008|Active Comparator|metronidazole 1% gel|
9781063|NCT01139008|Active Comparator|azelaic acid 15% gel|
9729072|NCT04118283|Active Comparator|Health and Wellness|Health & Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health & Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
9729073|NCT04111497|Experimental|Treatment (glasdegib)|Patients receive glasdegib PO QD on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
9729074|NCT04109066|Experimental|Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET|Nivolumab with paclitaxel followed by nivolumab with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice
9729075|NCT04109066|Placebo Comparator|Arm B: Placebo combined with neoadjuvant CT and adjuvant ET|Nivolumab placebo with paclitaxel followed by nivolumab placebo with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab placebo with adjuvant (post-surgery) endocrine therapy of investigator's choice
9729076|NCT04106856|Experimental|Treatment (losartan, hypofractionated radiation therapy)|Beginning on day 1, patients receive losartan potassium PO QD. Beginning day 14, patients also undergo hypofractionated radiation therapy over 15 fractions 5 days a week for up to 3 weeks. Patients continue to receive losartan potassium PO QD during radiation therapy and for 28 days after completion of radiation therapy. Patients may begin additional anti-cancer therapy per investigator discretion after the last dose of HRT. Losartan can be given concurrently with additional therapy and Losartan dosing can continue until 28 days after last dose of HRT, regardless of when additional therapy is started.
9729077|NCT04098744|Experimental|Artesunate vaginal insert|Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.
9729078|NCT04098744|Placebo Comparator|Placebo vaginal inserts|Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4. Unblinding will take place at week 15. Participants who do not have histologic regression at week 15 will have the opportunity to cross over to the experimental arm, and start treatment with artesunate vaginal inserts within 4 weeks of the week 15 visit.
9729079|NCT04090190|Other|standard of care anticholinergic treatment|Women presenting to the Urogynecology clinic with urgency urinary incontinence symptoms will receive standard of care anticholinergic treatment and will have their urinary microbiome evaluated before and after treatment
9729080|NCT04070703|Experimental|Cognitively enhanced Tai Ji Quan|Participants in this arm will exercise a series of Tai Ji Quan-based movements with configurations that are specifically designed for older adults to improve cognitive function, dual-task ability, strength/balance, and mobility.
9729081|NCT04070703|Active Comparator|Standard Tai Ji Quan|Serving as an active comparison arm, participants in this intervention will exercise a series of Tai Ji Quan-based movements that are specifically designed for older adults to improve strength/balance, cognitive function, and mobility.
9729082|NCT04070703|Sham Comparator|Stretching|Serving as a control arm, participants in this intervention will engage in a series of light exercise activities consisting of breathing, stretching, and body relaxation.
9729083|NCT04066413|No Intervention|Breastfed group|Non-randomized breastfed reference group
9729084|NCT04066413|Placebo Comparator|Control formula|Group receiving standard infant formula
9729085|NCT04066413|Active Comparator|Formula with HMO|Group receiving standard infant formula supplemented with HMO
9729086|NCT04065087|Experimental|GX-I7|GX-I7 administered until Progression of Disease
9729087|NCT04065087|Placebo Comparator|Placebo|Placebo administered until Progression of Disease
9729088|NCT04063202||Non-cases|Secondary school students (seventh to tenth years of education) without probable depression at baseline interview.
9729089|NCT04060251|Experimental|Group 1, iGetBetter Group|Use only iGetBetter for the 3 months preceding surgery. After surgery, you will be given a new, Post-Op program to use for 2-3 months. For the first 3 weeks, you will only use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks.
9781064|NCT01139021|Experimental|B246_12_M12|Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.
9781065|NCT01139021|Experimental|B246_12M13|Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.
9729090|NCT04060251|Experimental|Group 2, E-vive Group|You will use iGetBetter starting 3 months out from surgery. You will receive CyMedica's electrical-stimulation garment during the preoperative appointment. In addition to iGetBetter, you will wear the conductive garment two times each day for the last 3 weeks before surgery. After surgery, for the first 3 weeks you will only use the conductive garment, and will not use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to wearing the brace, approximately twice per week for the next 6-8 weeks. You will not need to return the brace after this time is up, and you may keep the brace, if you so choose, at no cost.
9729091|NCT04060251|No Intervention|Group 3, Physical Therapy Group|You will receive only iGetBetter for the 3 months preceding surgery. After surgery, you will receive only home physical therapy, and will not use iGetBetter. After those three weeks, you will receive outpatient physical therapy approximately twice per week for the next 6-8 weeks.
9729092|NCT04059588|Experimental|Injection of 2141-V11|Open label study drug 2141-V11 at escalating doses until MTD is determined, and expansion utilizing the MTD.
9729093|NCT04047264|Experimental|Mutant or WT tumor|Patients with suspected or biopsy-proven IDH-mutant tumor. Patients with suspected or biopsy-proven IDH-WT tumor
9729094|NCT04045990|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. rTMS will be administered in an excitatory pattern as 20Hz. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
9729095|NCT04045990|Sham Comparator|SHAM stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory or language performance, or whether practice effects or other non-specific effects are responsible for any changes in memory or language performance which may be observed.
9729096|NCT04044898|Experimental|Low dose|
9729097|NCT04044898|Experimental|High dose|
9729098|NCT04040439||Dexmedetomidine Hydrochloride|"Pediatric patients (45 weeks corrected gestational age to <18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation during and after mechanical ventilation in the intensive care setting"
9729099|NCT04038255|Active Comparator|Usual Care|Participants in this group will receive a brief advice to quit smoking, 6-week supplies of nicotine replacement therapy (NRT), and self-help materials to quit smoking.
9729100|NCT04038255|Experimental|Craving-to-Quit app|"Participants in this group will receive one in-person orientation session, 6-week supply of NRT, the Craving-to-Quit app, and two brief follow-up phone calls."
9729101|NCT04038255|Experimental|In-person Mindfulness Training|Participants in this group will receive twice weekly group sessions (eight total during 4 weeks) that were manualized and delivered by instructors experienced in Mindfulness Training (MT) (a single therapist with >4 years of training in MT).
9729102|NCT04029298|Experimental|HBDC Intervention Group|Immediate enrollment in the 16-week, HBDC education-based intervention, followed by a 12-month observation period
9729103|NCT04029298|Other|Control/Usual Care/Delayed Intervention Group|16-week, HBDC education-based intervention will be delayed by 12 months. Following the delayed intervention, this group will be observed for an additional 12-month period
9729104|NCT04028921||Normal weight, active|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, >=60 min/day of moderate/vigorous physical activity.
9729105|NCT04028921||Normal weight, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, <60 min/day of moderate/vigorous physical activity.
9729106|NCT04028921||Overweight/obese, active|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, >=60 min/day of moderate/vigorous physical activity.
9729107|NCT04028921||Overweight/obese, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, <60 min/day of moderate/vigorous physical activity.
9729108|NCT04028050|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min), followed by intravenous infusion of etoposide 100 milligrams per square meter (mg/m^2) on days 1 through 3 of each cycle during the induction phase (21-day cycle for four/six cycles). On Days 2 and 3, participants will receive etoposide alone. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks until PD, unacceptable toxicity, loss of clinical benefit or study termination by the Sponsor.
9729109|NCT04014868|Experimental|Nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with active nasal high-flow :~Flow : 30 L/min; Temperature : 34°C;~The device will be out of sight of the patient. The device allow for oxygen supplementation (fitting on the back of the device). Usual oxygen prescription (if any) will be adjusted to reach a transcutaneous oxygen saturation superior to 90%. A second fitting will be placed just before the nasal canula to allow for oxygen supplementation during the sham nasal high-flow (device turned OFF) test.~Due to the cross-over design of the study, all patients will perform both interventions."
9729110|NCT04014868|Sham Comparator|Sham nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with a sham nasal high-flow :~The procedure will be exactly the same but the device (out of sight of the patient) will be turned OFF. Oxygen supplementation will be possible through the fitting placed just before the nasal canula.~Due to the cross-over design of the study, all patients will perform both interventions."
10199950|NCT05190952|Active Comparator|Group 3|Dexamethasone Group (In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes).
10199951|NCT05190939|Active Comparator|no-dye/saline|Subjects assigned to the no-dye/saline group will have cystoscopy performed using saline as the bladder distending media and will not utilize any intravenous dye
10199952|NCT05190939|Experimental|dye/saline|Subjects assigned to the dye/saline group will have cystoscopy performed using saline as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
9729111|NCT04008615||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test.~For the purpose of this study, patients will be offered to participate in an additional exercise session in which they will repeat the same procedure (two 6-minute stepper test) but but monitoring cardiopulmonary parameters and gaz exchanges using a face mask, a pneumotachograph and a gaz analyser (indirect calorimetry)."
9729112|NCT04004403|Experimental|Alternate day fasting|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
9729113|NCT04004403|Experimental|Exercise|These participants will participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
10199953|NCT05190939|Experimental|no-dye/water|Subjects assigned to the no-dye/water group will have cystoscopy performed using water as the bladder distending media and will not utilize any intravenous dye
10199954|NCT05190939|Experimental|dye/water|Subjects assigned to the dye/water group will have cystoscopy performed using water as the bladder distending media and will utilize intravenous dye (methylene blue or fluorescein) as a ureteral jet visualization aid
9729114|NCT04004403|Experimental|Combination alternate day fasting plus exercise|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days. They will also participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax."
9729115|NCT04004403|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits.
9729116|NCT04000685|Active Comparator|Yoga exercise group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing, warm up and relaxation exercises.
9729117|NCT04000685|Active Comparator|Spinal stabilization exercise group|Spinal stabilization exercise with three different progressive phases were applied all patients in this group accompanied by physiotherapist.
9729118|NCT04000685|Active Comparator|aerobic walking exercise group|Aerobic walking exercise program applied all patients in this group accompanied by physiotherapist.
9729119|NCT03988543|No Intervention|Usual Care|Patients will receive current standard care of EHR-integrated symptom monitoring.
9729120|NCT03988543|Experimental|Enhanced Care|Patient will receive current standard care of EHR-integrated symptom monitoring, plus patient self-management intervention.
9729121|NCT03985007|Experimental|CDIAG|Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.
9729122|NCT03984968|Experimental|CAR-T infusion|CAR-T cells and feeding T cells were infused into remission patients sequentially,with 5*10e6/kg and 1*10e7/kg respectively for each cycle. Each patient underwent 3 cyles of CAR-T consolidation therapies and was followed up for 2 years.
9729123|NCT03982043|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages aimed at increasing motivations in at-risk adolescents and their parents. The most salient of the following behavior change techniques will be selected and targeted messaging will be deployed on the participants' phone: psychoeducation, cued mood monitoring, adolescent-parent communication prompts, cognitive bias modification, and cues to action. Intervention material will be tailored to baseline characteristics and T2C will generate reports to providers.
9729124|NCT03976375|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.
10199955|NCT05190926|Experimental|Smart Treatment for Anorexia Nervosa Recovery (STAR) app|STAR incorporates elements from the Unified Protocol and Acceptance and Commitment Therapy to reduce emotion avoidance and improve disordered-eating behaviors and negative emotions. Participants will complete 1-2 weekly modules in STAR for 12 weeks. During this time, participants will continue working with their outpatient therapist. Outcome and target engagement measures will be assessed daily or weekly within the STAR app. Participants will complete additional measures of outcome and target engagement at 3-months and 6-months after treatment. Parents will be asked to complete outcome measures at baseline, 12 weeks, 3-months, and 6-months.
10199956|NCT05190926|Placebo Comparator|Present-focused Anorexia Nervosa Coping Treatment (PACT) app|PACT is an adapted form of Present-Centered Therapy and focuses on daily life stressors, problems, and concerns that may impact AN. Participants will complete 1 weekly module in Weeks 1, 2, and 12 and complete a Daily Diary of life stressors thereafter for 9 weeks. During this time, participants will continue working with their outpatient therapist. Outcome and target engagement measures will be assessed daily or weekly within the PACT app. Participants will complete additional measures of outcome and target engagement at 3-months and 6-months after treatment. Parents will be asked to complete outcome measures at baseline, 12 weeks, 3-months, and 6-months.
10199957|NCT05190913|Experimental|Initiative group I|In the active phase of labor, perineal massage will be performed with the device at an interval of one hour.
10199958|NCT05190913|Experimental|Initiative group II|During the active phase of labor, manual perineal massage will be performed with an interval of one hour.
10199959|NCT05190861|Experimental|droplet digital PCR method|Pathogen detection by droplet digital PCR method as an adjunct to traditional microbiological assessments including blood culture
10199960|NCT05190861|Active Comparator|blood culture only|Pathogen detection by microbiological assessments including blood culture
10199961|NCT05190835|Other|Hallux surgery|These are patients operated on for hallux without change of strategy compared to current care
9729125|NCT03976375|Active Comparator|Docetaxel|Participants receive docetaxel at 75 mg/m^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
9729126|NCT03976375|Experimental|Lenvatinib Monotherapy|Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.
9729127|NCT03967522|Experimental|Cabozantinib treatment|All participants will be treated by 60 mg of cabozantinib once daily.
9729128|NCT03967340||Lung transplant|
9729129|NCT03956602|Active Comparator|Pretzels|Subjects consume pretzels to examine postprandial response
9729130|NCT03956602|Experimental|Brazil nuts|Subjects consume Brazil nuts to examine postprandial response
9729131|NCT03956602|Active Comparator|Potato chips|Subjects consume potato chips to examine postprandial response
9729132|NCT03956602|Experimental|Mixed nuts|Subjects consume mixed nuts to examine postprandial response
9729133|NCT03956602|Active Comparator|White bread|Subjects consume white bread to examine postprandial response
9729134|NCT03956602|Experimental|Dried mango|Subjects consume dried mango to examine postprandial response
9729135|NCT03956602|Experimental|Mango fruit|Subjects consume fresh mango to examine postprandial response
9729136|NCT03954886|Experimental|Induced myopic defocus|Subjects will view a television through a lens that induces blur to the retina for one hour. Images of the eye will be captured every 10 minutes
9729137|NCT03954886|No Intervention|No defocus|Subjects will view a television through a lens that induces no blur to the retina for one hour. Images of the eye will be captured every 10 minutes
9729138|NCT03954782|Experimental|Nintedanib|Oral treatment of Nintedanib 150 mg soft capsule
9729139|NCT03954782|Placebo Comparator|Placebo|Oral treatment of placebo soft capsule
9729140|NCT03953560|Experimental|Screening|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~Pulsioximetry.~Electrocardiogram.~Blood sample with determination of NT-ProBNP.~Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis"
9729141|NCT03935854|Experimental|Ketogenic Diet 16 Week Group|Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support
9729142|NCT03932240|Experimental|Fibrinogen Concentrate (FC)|"After separation from bypass, patients will receive platelets and FC. The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
9729143|NCT03932240|Active Comparator|Cryoprecipitate|"After separation from bypass, patients will receive platelets and cryoprecipitate. Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 345mg/dL.~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
9729144|NCT03924661||Single Arm|Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device
9729145|NCT03922997|Experimental|Atezolizumab|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
9729146|NCT03913286|Experimental|Intervention|The participant will be implanted with the Blackrock Microsystems MultiPort system.
9729147|NCT03913143|Experimental|Group 1: Dose 1 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
9729148|NCT03913143|Active Comparator|Group 2: Dose 2 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
9729149|NCT03913143|Sham Comparator|Group 3: Sham|Sham procedure (no experimental drug administered), Day 1, month 3 and every six months there after. After 12 months cross over to active study drug may be initiated
9729150|NCT03912844||Liver resection/liver transplantation after SIRT|The cohort consist of patients that, after decision of a multidisciplinary tumor board have received a SIRT/TARE or will receive a SIRT/TARE to make them later eligible for following liver resection or liver transplantation.
9729151|NCT03899428|Experimental|Immune Checkpoint Therapy|The subjects will receive durvalumab 1500 mg Q4W
9729152|NCT03899428|Experimental|Target Therapy|The subjects will receive tyrosine kinase inhibitors, including sorafenib, lenvatinib, regorafenib, or cabozantinib, daily
10199962|NCT05190835|Other|Metatarsal paddle surgery|These are patients operated on for metatarsal paddle without change of strategy compared to current care
10199963|NCT05190835|Other|Hallux and metatarsal pallet surgery|These are patients operated on for hallux and metatarsal paddle without change of strategy compared to current care
10199964|NCT05190809|Experimental|Study group|Group of female patients who will undergo Goldilocks mastectomy in which they will receive an autologous fat grafting in the remaining breast flaps
10199965|NCT05190796||women with history of recurrent pregnancy loss.|100 women who had history of recurrent pregnancy loss.
9729153|NCT03898895|Experimental|Radiotherapy+anti-PD-1|The total radiation dose is over 40Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
9729154|NCT03885713|Active Comparator|Patients with treatment|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice, or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)-subcutaneus) per clinical practice
9729155|NCT03885713|No Intervention|healthy control|
9729156|NCT03882372|Experimental|Nasal high flow|"Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow."
9729157|NCT03882372|No Intervention|Usual care|"Patient randomized to the control group will have no other specific intervention than their usual care.~Patients under long-term oxygen will preserve their usual flow."
10199966|NCT05190796||women without history of recurrent pregnancy loss.|50 women who had given birth at term (>37 weeks of gestation) to healthy infants (control group)
10199967|NCT05190718||Dysphagia rehabilitation|All interventions are part of routine treatment of dysphagia.
10199968|NCT05190614||thick-gingiva group|After the insertion of the probe into the facial aspect of the sulcus through the gingival margin, the simple visual method is based on the transparency of the periodontal probe through the gingival margin while probing the buccal sulcus at the midfacial aspect of the tooth. When the outline of the underlying periodontal probe can't be seen through the gingival, the gingival phenotype is considered thick.
10199969|NCT05190614||thin-gingiva group|After the insertion of the probe into the facial aspect of the sulcus through the gingival margin, the simple visual method is based on the transparency of the periodontal probe through the gingival margin while probing the buccal sulcus at the midfacial aspect of the tooth. When the outline of the underlying periodontal probe can be seen through the gingival, the gingival phenotype is considered thin.
10199970|NCT05190601||Group 1|Enuresis nocturna with children
10199971|NCT05190575|Experimental|TST001|Drug: TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
10199972|NCT05190562|Experimental|Zinc Sulphate|Zinc Sulphate 25 Mg once daily for one month
10199973|NCT05190536|Experimental|Experimental: Patients in Group 1 undergo Ho:YAG laser|
10199974|NCT05190536|Experimental|Experimental: Patients in Group 2 undergo TFL|
10199975|NCT05190497|Experimental|intervention group|inspiratory muscle training in addition to routine chest physiotherapy in the form of (deep breathing, coughing, and early ambulation)
9729158|NCT03875079|Experimental|Part I Safety Run in: RO6874281 + Pembrolizumab|"Cohort 1.1 (CPI naive and experienced melanoma participants):~Participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2 (CPI experienced melanoma participants only):~Participants will receive RO6874281 in combination with Pembrolizumab via an induction and maintenance schedule for RO6874281: QW three times (D1, D8, D15) followed by Q3W dosing (D22 and subsequent). Pembrolizumab is to be administered Q3W, starting on Day 1. Participants will be observed for 2 pembrolizumab cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part III of this study."
10199976|NCT05190497|No Intervention|control|The Control group received only routine chest physiotherapy
9729159|NCT03875079|Experimental|Part II Expansion: RO6874281 + Pembrolizumab|Part II will start once all participants in Part I Cohort 1.1 have completed the observation period. Approximately 34 participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks).
10199977|NCT05190432|Experimental|Taxifolin/Dihydroquercetin|250mg/day Taxifolin (also known as Dihydroquercetin). One capsule in the morning for 8 weeks.
10199978|NCT05190432|Experimental|Ergothioneine|80mg/day Ergothioneine. One capsule in the morning for 8 weeks.
10199979|NCT05190432|Placebo Comparator|Control|One capsule in the morning for 8 weeks.
10199980|NCT05190419|Experimental|Orismilast modified release tablets 20 mg BID|Oral, twice daily morning and evening
10199981|NCT05190419|Experimental|Orismilast modified release tablets 30 mg BID|Oral, twice daily morning and evening
10199982|NCT05190419|Experimental|Orismilast modified release tablets 40 mg BID|Oral, twice daily morning and evening
10199983|NCT05190419|Placebo Comparator|Placebo tablets BID|Oral, twice daily morning and evening
10199984|NCT05190393||Convex resection group|Patients were used hemivertebra resection procedure on convex side to treat congenital cervical scoliosis.
10199985|NCT05190393||Concave distraction group|Patients were used distraction and lateral opening procedure on concave side to treat congenital cervical scoliosis, without hemivertebra resection.
10205052|NCT04196010|Experimental|Treatment (CI-CLAM, G-CSF)|Patients receive CI-CLAM consisting of cladribine and cytarabine via CIV on days 1-2, 1-3, 1-4, 1-5, or 1-6 depending on dose level assignment, and mitoxantrone via CIV on days 1-2 or 1-3 depending on dose level assignment. G-CSF may be added at the discretion of the treating physician, as per standard of care. Patients that do not achieve a response of MRD-negative CR after the first cycle are eligible to receive a second cycle of CI-CLAM. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
10199986|NCT05190380|Experimental|High intensity|"Intervention: Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.Routine physical therapy including TENS, Hot pack and Deep friction massage along with high intensity exercises will also be delivered along with Muscle Energy Technique. Experimental:High intensity will be treated with high intensity exercises in such a way that~1st and 2nd week; resistance training will be of 50% 1RM with 4 sets of 10 repetitions.~3rd and 4th week: resistance training will be of 70% 1RM with 4 sets of 10 repetitions.~5th and 6th week: the training will be of 80% 1RM with 4 sets of 10 repetitions~Last 4 sessions will be:~7th and 8th week: resistance training will be of 80% 1RM with 5 sets of 10 repetitions."
10205522|NCT05205824|Other|Algorithm validation|all subjects will be measured with inertial measurement units while performing tasks like walking, standing and sitting.
9729160|NCT03875079|Experimental|Part III Expansion: RO6874281 + Pembrolizumab|Part III will start once all participants in Part I Cohorts 1.1 and 1.2 have completed the observation period. Approximately 80 participants will be randomised to receive RO6874281 in combination with Pembrolizumab in either a Q3W or QW/Q3W schedule.
9729161|NCT03862716|Experimental|Intervention|Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
9729162|NCT03862716|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
9729163|NCT03862170|Active Comparator|Ciprofloxacin|Patients in this arm will receive Ciprofloxacin 400mg IV 120mn (prophylactic antibiotic) before their HDR brachytherapy
9729164|NCT03862170|Experimental|Cefazolin|Patients in this arm will receive Cefazolin 2000mg IV 60mn (prophylactic antibiotic) before their HDR brachytherapy
9729165|NCT03862170|No Intervention|No prophylactic antibiotics|Patients in this arm will not receive any prophylactic antibiotics before their HDR brachytherapy
9729166|NCT03860259|Placebo Comparator|Auriculotherapy without nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
9729167|NCT03860259|Active Comparator|Auriculotherapy with nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
9729168|NCT03854526||Patients without Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months and with at least one tooth with coronal dental restoration
9729169|NCT03854526||Patients with Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months, with at least one tooth with coronal dental restoration and presenting a Gougerot Sjogren disease
9729170|NCT03852550|Experimental|Usual Care + MyREADYTransition[TM] BBD App|Participants in the experimental Intervention group continue to get the same care they have been getting (their usual care) and they receive the MyREADY Transition[TM] BBD App e-health application. There are 19 parts in the App with videos and games to help youth learn and practice ways to manage their health. There are approximately 5-7 hours of content in total. Participants will be asked to wait at least one day between the parts. There is a timer in the App to help to moderate pace and align with how young people learn and digest information. Participants can choose how much time they want to take to do the App. It is recommended that participants make their own routine for using it. The recommended shortest and longest intervention exposure times are: 1 part each day (this will take 19 days to do all of the App), 1 part each week (this will take 19 weeks to do all of the App).
9729171|NCT03852550|No Intervention|Control Group: Usual Care|Participants in the no intervention Control group continue to get the same care they have been getting (their usual care). The researchers aim to supply the App to participants in both the intervention and control group for a limited time after participation in the study.
9729172|NCT03848663|Experimental|Patients with scotoma|No remapping (control condition), traditional remapping, personalized remapping
9729173|NCT03848663|Active Comparator|Normally sighted with artificial scotoma|No remapping (control condition), traditional remapping, personalized remapping
9729174|NCT03844997|Experimental|Palbociclib + CPX-351|"Palbociclib will be administered orally on day -1 and -2 at 125 mg PO during the phase IIaportion (dose level 0).Day 0 will be rest and then CPX-351 at 100 u/m2 will be started on days 1, 3, and 5 along with Palbociclib day 2, 4, and 6 followed by rest/monitoring period (day 7-28).~If Grade 3-4 non-hematologic toxicity is observed in 1 or less of 6 patients treated, the study will move to Phase IIb. If Grade 3-4 non-hematologic toxicity is observed in 2 or more of 6 patients treated, 6 additional patients will be treated on the Phase IIa portion at a lower dose level (100 mg po) until a Phase IIb safe dose schedule is defined at which 1 or less out of 6 patients on the Phase IIa experience Grade 3-4 non-hematologic toxicity. After the Phase IIa portion ensures safety, the study will proceed with phase IIb. The phase IIb component is a Simon 2-stage design trial whose objective is to assess the clinical efficacy of the combination of Palbociclib and CPX-351."
9729175|NCT03830749|Experimental|Single Arm|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
9729176|NCT03828461|Experimental|BITS + VR|Facilitated group therapy with behavioral practice; 16 weeks
9729177|NCT03825302||Males with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
9729178|NCT03825302||Females with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
9729179|NCT03815669||Arthroscopic subacromial decompression|Patients referred to arthroscopic subacromial decompression
9781066|NCT01139021|Experimental|B13_15_27|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.
9781067|NCT01139021|Experimental|B12_14_26|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.
10199987|NCT05190380|Experimental|Low intensity|"Intervention: Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.Routine physical therapy including TENS, Hot pack and Deep friction massage along with Low intensity exercises will also be delivered along with Muscle Energy Technique. Experimental:Low intensity Group B will be treated with low intensity exercise in such a way that,~1st and 2nd week; Resistance training will be of 20% 1RM with 4 sets of 15 reps 3rd and 4th week Resistance training will be of 30% 1RM with 4 sets of 15 reps 5th and 6th week: the training will be of 40% 1RM with 4 sets of 15 reps~Last session will be:~7th and 8th week; Training of 40% 1RM with 5 sets of 15 reps"
10199988|NCT05190367||No trauma|Patients suffering from chronic pain without traumatic life events
10199989|NCT05190367||Accidental trauma|Patients suffering from chronic pain who have experienced at least one accidental trauma
9729180|NCT03810729|Active Comparator|Modified Allen's Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on the participant's hand. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
9729181|NCT03810729|Active Comparator|Smartphone assessment|The smartphone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's index finger and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
9729182|NCT03792919|Experimental|Cessation of NAs treatment|Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.
9729183|NCT03792919|Active Comparator|Keep on current NAs treatment|Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.
9729184|NCT03783468|Experimental|light sedation pressure support ventilation|
9729185|NCT03767634||Neonatal population (Project A)|Neonates born between 1st January 2012 and 31st December 2017 and admitted to a neonatal unit in England, Scotland and Wales).
9729186|NCT03767634||No PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who did not receive any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
9729187|NCT03767634||PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who received any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
9729188|NCT03745690|Experimental|Treatment (near-infrared image guided surgical resection)|Patients receive indocyanine green IV on day 0 and undergo near-infrared image guided surgical resection on day 1.
9729189|NCT03710915|Experimental|HG146 capsule treat multiple myeloma|"Experimental: 5/10/15/20 mg HG146 capsule 5 mg starting dose taken orally on Day 1, 3, 5, 7, 9, 11, 13 of each cycle, and off drug for 8 days (3 weeks).~Intervention: Drug: HG146 capsule"
9729190|NCT03684109|Experimental|IDH-Mutant Glioma Patients|Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain.
9729191|NCT03675139|Experimental|Medroxyprogesterone Acetate|EH patients will take MPA (Medroxyprogesterone Acetate) 10mg daily from tenth day of menstruation for 15 days for 3months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium. All of the findings will be recorded.
9729192|NCT03675139|Experimental|dydrogesterone|EH patients will take dydrogesterone 10 mg, 2 tablets twice daily from tenth day of menstruation for 15 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3-month to examine the endometrium. All of the findings will be recorded.
9729193|NCT03660592||operator 1|ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
9729194|NCT03660592||operator 2|a different ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
9729195|NCT03658967|Active Comparator|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
9729196|NCT03658967|Placebo Comparator|Placebo (0.9% physiological saline)|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
9729197|NCT03636243|Other|Group of obese patients with type-2 diabetes|
9729198|NCT03636243|Other|Group of non-diabetic obese patients|
9729199|NCT03617133|Other|Standard arm|General and specific aims of EMBRACEII as well as the multiple quantitative hypotheses are based on technical data, dose volume parameters and clinical results of the prospective observational study EMBRACEI (NCT00920920, 3 year data 2015) and the retrospective RetroEMBRACE (3/5 year data 2015). The performance of EMBRACE II interventions and clinical outcome in terms of disease- (local, nodal, systemic control, OS, CSS) and morbidity-outcome (various organs and endpoints) is thus based on recent clinical evidence with radiochemotherapy and image guided adaptive brachytherapy. The expected effect of EMBRACE II interventions on clinical outcome is estimated from comparative analyses of interventions in subgroups of Retro-/EMBRACE (partly published). Based on the Retro-/EMBRACE benchmark, the estimated outcome including a confidence interval is quantified for each clinical endpoint in the overall cohort as well as different subgroups for an overall expected patient number of 1000.
9781068|NCT01139021|Experimental|B_24_26|Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
10199990|NCT05190367||Interpersonal trauma|Patients suffering from chronic pain who have experienced at least one interpersonal trauma
10199991|NCT05190367||PTSD|Patients suffering from chronic pain and diagnosed with PTSD
9729200|NCT03606486|Experimental|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
9729201|NCT03567889|Experimental|Daromun plus Surgery and Adjuvant therapy (Arm 1)|Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks and adjuvant therapy (Arm 1).
10199992|NCT05190341|Experimental|Ibuprofen|Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 800mg ibuprofen 1 hour before HSG.
9729202|NCT03567889|Active Comparator|Surgery and adjuvant therapy (Arm 2)|Patients in the control arm (Arm 2) will receive direct surgery within 4 weeks from randomization, followed by adjuvant therapy.
9729203|NCT03556462|Experimental|Sleep Health Interventions|"Sleep Health Interventions:~Parents- a) invited to 1 hour workshop about healthy sleep, b) invited to attend a brief (app. 20 minute) Sleep Health Flipchart education either 1-on-1 or in a small group.~Children: exposed to 2 week 40min/day healthy sleep curriculum in the classroom.Agency: Video and print material"
9729204|NCT03556462|No Intervention|Control Period|No Intervention, but data collection
9729205|NCT03549559|Active Comparator|Healthy Subjects|Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
9729206|NCT03549559|Active Comparator|Diabetes Patient Subjects|Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
10199993|NCT05190341|Experimental|Ketorolac|Patients randomized to this arm will receive an identical capsule to the other patient arm, and receive 30mg ketorolac 1 hour before HSG.
10199994|NCT05190289||Compared Group|Patients without inferior clinical outcomes
10199995|NCT05190289||Case Group|Patients with inferior clinical outcomes
9729207|NCT03549559|Experimental|Aortic Stenosis Patient Subjects|Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
9729208|NCT03539068|No Intervention|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
9729209|NCT03539068|Experimental|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
9729210|NCT03537599|Experimental|Treatment (DLI, daratumumab)|Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity.
9729211|NCT03537508|Experimental|Group 1a|MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age
9729212|NCT03537508|Experimental|Group 1b|MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age
9729213|NCT03537508|Active Comparator|Group 2a|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
9729214|NCT03537508|Active Comparator|Group 2b|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
9729215|NCT03499236|Experimental|Treatment|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
9729216|NCT03499236|Other|Control|Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
9729217|NCT03499236|Experimental|Roll in|Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
10199996|NCT05190276||The hematoma group|with symptomatic epidural hematoma after surgery
10199997|NCT05190276||The control group|without symptomatic epidural hematoma after surgery
10199998|NCT05190250||Study group - women with idiopathic infertility|Endometrial biopsy during implantation window Blood analysis
10199999|NCT05190250||Control group - women with naturally conceived offspring|Endometrial biopsy during implantation window Blood analysis
10200000|NCT05190198|Experimental|Experimental group|"The experimental group will receive ankle proprioceptive training.~Ankle proprioceptive training includes the following group of exercises:~Training on the floor for 10 minutes (1-8 weeks)~Training on balance pad for 10 minutes (1-4 weeks)~Training on rocked balance board for 10 minutes (5-8 week)"
10200001|NCT05190198|Active Comparator|Conventional therapy group|"The control group will receive Traditional physical therapy exercises.~Active range of motion exercises for ankle and subtalar joints for 5 minutes.~Functional balance training for 15 minutes involving~Gait training for 10 minutes."
10200002|NCT05190185|Experimental|TAA06 injection|T cell injection targeting B7-H3 chimeric antigen receptor
10200003|NCT05190133|Experimental|Treatment A|
10200004|NCT05190133|Experimental|Treatment B|
10200005|NCT05190120|Active Comparator|Femoral Block|Patients scheduled for knee arthroscopy will have a femoral nerve block done using 0.5% ropivacaine 20ml before surgery.
10200006|NCT05190120|Experimental|Adductor Canal Block|Patients scheduled for knee arthroscopy will have an adductor canal block done using 0.75% ropivacaine 13.3ml before surgery.
9729218|NCT03471377||standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long.
9729219|NCT03471377||assigned a planned case duration value from predictive model|Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.
9729220|NCT03464097|Experimental|Ozanimod|
9729221|NCT03464097|Placebo Comparator|Placebo|
9729222|NCT03462004|Experimental|Cohort 1: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^6.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
9729223|NCT03462004|Placebo Comparator|Cohort 1: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
9982360|NCT05250193|Experimental|DK ScoreTM Coronary Scoring Balloon (DK Score)|DK ScoreTM Coronary Scoring Balloon Manufactured by DK Medical Technolgy CO.,LTD
9982361|NCT05250193|Active Comparator|Non-Slip Element Coronary Dilatation Catheter (NSE)|Non-Slip Element Coronary Dilatation Catheter Manufactured by GOODMAN CO.,LTD
9729224|NCT03462004|Experimental|Cohort 2: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^7.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
9729225|NCT03462004|Placebo Comparator|Cohort 2: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
9729226|NCT03459287|Experimental|INTERCEPT (test)|The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
9729227|NCT03459287|Active Comparator|Conventional (Control)|The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician.
9729228|NCT03458299|Experimental|Motivational Interviewing|The MI intervention will incorporate open-ended questions, personalized feedback, and discussion about participants' alcohol use and drug, associated risk behaviors (e.g., drinking and driving), and the consequences of these behaviors. Individual MI procedures will incorporate the core principles of MI described by Miller and Rollnick, including expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. Therapist interventions will be tailored to the participants' readiness to change/current stage of change (pre-contemplation, contemplation, preparation, action, maintenance, and relapse).
9729229|NCT03458299|Experimental|Psychoeducation|The Psychoeducation session will consist of therapist assisted viewing and discussion of four educational DVDs about adolescent alcohol use, drug use, and driving under the influence provided by Human Relations Media, Mount Kisco, NY (hrmvideo.com).
9729230|NCT03446573|Experimental|DTG + 3TC 50 mg/300 mg|Participants will receive a single tablet of a two-drug regimen of DTG 50 mg + 3TC 300 mg once daily from Day 1 through Week 200 (Early and Late Switch Phase).
9729231|NCT03446573|Active Comparator|TAF based regimen (TBR)|Participants will continue their TBR from Day 1 to Week 148 (Early Switch Phase), and eligible participants will switch to DTG + 3TC once daily from Week 148 to 200 (Late Switch Phase).
9729232|NCT03441100|Experimental|Experimental: IMA202 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.~Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2"
9729233|NCT03440385|Experimental|Administration of oral Ozanimod|
9729234|NCT03440385|Placebo Comparator|Administration of Placebo|
9729235|NCT03440372|Experimental|Administration of oral Ozanimod|
9729236|NCT03440372|Placebo Comparator|Administration of Placebo|
9729237|NCT03434730|Experimental|Adult Participants With High Risk Hematologic Malignancies|
9729238|NCT03424694|Experimental|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
9729239|NCT03424694|Experimental|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
9729240|NCT03419572||Second line therapy|Data collection
9729241|NCT03419572||Third and later line therapy|Data collection
9729242|NCT03418779|Experimental|Control Group|Optimized supportive care, YQF placebo (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
9729243|NCT03418779|Experimental|YQF Group|Optimized supportive care, YQF (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
9781069|NCT01139021|Experimental|B12M13|Subject was randomized in group B13_15_27 but treated as group B12_M13.
9982362|NCT05250141|Experimental|Levodopa and Carbidopa Test Product|Participants will receive one tablet of the test formulation containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
9984765|NCT03749109|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.
9781070|NCT01139047|Active Comparator|metronidazole 1% gel|
9781071|NCT01139047|Active Comparator|azelaic acid 15% gel|
9781072|NCT01139164|Experimental|Single Arm, non-randomized study|
9781073|NCT01139190|Experimental|PL3100|
9781074|NCT01139190|Active Comparator|Naproxen|
9729244|NCT03415867|Experimental|Dose escalation sequential cohorts|Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 24 cycles. Those patients enrolled in the trial that obtain objective clinical benefit under treatment with glasdegib (defined as the achievement of at least a partial response at one or more target organs), will be allowed to proceed to a slow dose withdrawal phase over a period of 6 months after the end of Cycle 24. The dose reduction scheme is fully detailed in the protocol.
9729245|NCT03412045|Experimental|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
9729246|NCT03401788|Experimental|Open Label Belzutifan|Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
9729247|NCT03392090|Experimental|More Good Days video&brief questionnaire|"Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care~The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.~The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences~The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
9729248|NCT03388138|Active Comparator|K-Lens|etafilcon A with ketotifen. Subjects between the ages of 18-40 will be randomized into the K-Lens arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
9729249|NCT03388138|Placebo Comparator|Placebo Contact Lens|1-Day Acuvue. Subjects between the ages of 18-40 will be randomized into the Placebo arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
9729250|NCT03377036|Experimental|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
9729251|NCT03377036|Active Comparator|2D-FFDM|2D full-field digital mammography
9729252|NCT03351348|Active Comparator|Saline + usual post-operative medications|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
9729253|NCT03351348|Experimental|Bupivacaine + usual post-operative medications|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
9729254|NCT03349996|Experimental|LifeStream Peripheral Stent Graft System|Patients treated with the LifeStream Peripheral Stent Graft System
9729255|NCT03335670|Experimental|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.
9729256|NCT03319849|Experimental|NT-501|
9729257|NCT03319849|Sham Comparator|Sham|
9729258|NCT03316300|Experimental|NT-501|
9729259|NCT03316300|Sham Comparator|Sham|
9729260|NCT03289039|Experimental|Neratinib|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)"
9729261|NCT03289039|Experimental|Neratinib + Fulvestrant|"Neratinib will be administered orally once daily~Neratinib is dosed at 240mg (six 40mg tablets)~Fulvestrant will be administered intramuscular as an injection (shot) on day 1 and 15 of cycle 1, day 1 of cycle 2, and then on day 1 of each subsequent cycle.~Fulvestrant is dosed as 250 mg/5mL (x2) for a total of 500 mg via intramuscular injection (two injections)."
9982363|NCT05250141|Experimental|Levodopa and Carbidopa Referent Product|Participants will receive one tablet of the marketed reference containing Levodopa and Carbidopa 250 mg/ 25 mg. The tablet will be taken with water and in a fasting condition.
9982364|NCT05249868||SARS-CoV-2 Infection|"Confirmed SARS-CoV-2 infection diagnosed after 11 May 2020 and registered in electronic health records.~(positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for <5 days is positive on a PRAg test)"
9982365|NCT05249868||NO SARS-CoV-2 Infection|No confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.
9781075|NCT01139411|Experimental|Behavioral Weight Control with Enhanced Parent Involvement|This treatment arm included periodic dyadic sessions with adolescents and their parents, focusing on weight-related communication combined with standard behavioral weight control.
9982366|NCT05249790|Experimental|'Recommended algorithm' cohort|COVID-19 patients treated at home by their family doctors according to the proposed recommendations
9982367|NCT05249790|Active Comparator|Usual care|COVID-19 patients treated at home by their family doctors according to their usual clinical practice expected to be in accordance with AIFA recommendations
9982368|NCT05249387|Experimental|A-967079 Injections + BAM8-22|
9982369|NCT05249387|Experimental|A-967079 Injections and vehicle|
9982370|NCT05249205|No Intervention|Control|Participants in the control group will be asked to maintain their regular lifestyle for the duration of the study. They will not receive an intervention.
9982371|NCT05249205|Experimental|REHIT1|Participants in the REHIT1 group will perform a single REHIT session per week for 6 weeks.
9982372|NCT05249205|Experimental|REHIT2|Participants in the REHIT2 group will perform 2 REHIT sessions per week for 6 weeks.
9982373|NCT05249140|Experimental|Active Repetitive Transcranial Magnetic Stimulation|rTMS parameters are intensity 110% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations), targeting the right DLPFC. To target the dorsolateral prefrontal cortex (DLPFC) for rTMS treatment we will use the traditional method (i.e. the 5cm rule; George et al., 1995, 1996; Herwig et al., 2001, 2003; MacMaster et al., 2019), in which the TMS coil is placed 5 cm anterior to the participant's motor cortex along a line to the nasion. Treatments will occur on weekdays at the same time of day for 4 weeks (20 total).
9982374|NCT05249140|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|For the sham rTMS group, a sham coil is used: this sham method does not emit any magnetic field, and therefor does not affect brain activity, but it does produce auditory sensations that is indistinguishable from active rTMS in naïve subjects
9982375|NCT05248802|Placebo Comparator|Control|Placebo DLBS2411 2 x 1 caplet daily, given everyday for 4 weeks of study period
9729267|NCT03272165|Experimental|MEDI1341|
9729268|NCT03272165|Placebo Comparator|Placebo|
9729269|NCT03262259|Experimental|GSDG Intervention|Cities receiving a multi-component intervention, including screening and brief intervention, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation.
9729270|NCT03262259|No Intervention|Comparison|Comparison cities receiving no evidence-based interventions.
9729271|NCT03254225|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
9729272|NCT03254225|No Intervention|Control|in this arm, the group will remain sedentary for the same period of the experimental group, and they will be invited to engage on the raining program after the sedentary period
9729273|NCT03249792|Experimental|Arm 1: MK-2118 IT Monotherapy|Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
9729274|NCT03249792|Experimental|Arm 2: MK-2118 IT+Pembro Combo Therapy|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
9729275|NCT03249792|Experimental|Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
9729276|NCT03249792|Experimental|Arm 4: MK-2118 SC+Pembro Combo Therapy|Participants receive MK-2118 monotherapy via subcutaneous (SC) injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 36 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 36 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
9729277|NCT03248570|Experimental|DNA damage repair proficient group|Twenty-five subjects with mismatch repair (MMR) intact
9729278|NCT03248570|Experimental|DNA damage repair defective group|Twenty-five subjects with defective DNA repair
9729279|NCT03226301|Experimental|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
9729280|NCT03226301|Experimental|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
9729281|NCT03226301|Experimental|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:~progression according to IWCLL criteria or~MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
9729282|NCT03199924|Active Comparator|Intravenous Magnesium sulfate combined to Diclofenac|Intravenous Magnesium sulfate combined to Diclofenac
9729283|NCT03199924|Active Comparator|intravenous lidocaine combined to diclofenac|intravenous lidocaine combined to diclofenac
9729284|NCT03199924|Active Comparator|diclofenac alone|diclofenac alone
9729285|NCT03196011|Active Comparator|TKR with mechanical alignment|TKR implanted using traditional alignment methods
9729286|NCT03196011|Experimental|TKR using alternative alignment method|TKR implanted using alternative alignment methods
9729287|NCT03173976|Experimental|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
9781076|NCT01139411|Placebo Comparator|Behavioral Weight Control with Minimal Parent Involvement|This treatment arm included standard behavioral weight control delivered to the adolescent with minimal parent involvement.
9781077|NCT01139450|Experimental|Test|Test product that contains the active pharmaceutical ingredient
9781078|NCT01139450|Active Comparator|Reference|Reference product that contains the active pharmaceutical ingredient
9781079|NCT01139450|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
9781080|NCT01139515|Experimental|Treatment A|1 X 20 mg eletriptan
9781081|NCT01139515|Experimental|Treatment B|1 X 40 mg eletriptan
9781082|NCT01139515|Experimental|Treatment C|2 X 40 mg eletriptan
9781083|NCT01139515|Experimental|Treatment D|1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose
9781084|NCT01139580|Experimental|Calcipotriene Foam|Calcipotriene Foam 0.005%,
9982376|NCT05248802|Experimental|DLBS2411|DLBS2411 caplet 2 x 250 mg daily, given everyday for 4 weeks of study period
9982377|NCT05248724|Experimental|Intervention,|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride (10mg/ml Kabi Fresenius Kabi Norway AS),150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride (10mg/ml Braun Medical SA Spain), 30 mg of ketorolac tromethamine (Normon Spain), 300 micrograms of adrenaline (epinephrine Braun Medical SA Spain), and saline 0.9% till reaching 50 ml of volume
9982378|NCT05248724|Placebo Comparator|placebo|Participants in the placebo group received a periarticular infiltration of 50 ml of saline 0.9%.
10200007|NCT05190094|Experimental|Palbociclib + Aromatase Inhibitors (AI) (Letrozole or Anatrozole)|The participants will receive a combination of: Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os). This combination will continue until progression for an average duration of 2 years.
9729288|NCT03171025|Experimental|Nivolumab, all patients|
9729289|NCT03169634|Experimental|short or long stemmed rTKR cemented|
9729290|NCT03169634|Experimental|Cone with short stem|
9729291|NCT03169634|Experimental|Cone with long stem|
9729292|NCT03166319|Experimental|Suspected CNS Vasculitis|Patients with suspected CNS vasculitis will undergo an MRI, including intracranial vessel wall imaging.
9729293|NCT03165734|Experimental|Pacritinib 200 mg BID|To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food
9729294|NCT03165734|Active Comparator|Physician's Choice (P/C) therapy|The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.
10200008|NCT05190081|Experimental|single-task training group|Tasks were completed separately in the single-task training group
9729295|NCT03141099|Active Comparator|Low normal MAP and low normal PaO2|MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
9729296|NCT03141099|Active Comparator|High normal MAP and low normal PaO2|MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
9729297|NCT03141099|Active Comparator|Low normal MAP and high normal PaO2|MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
9729298|NCT03141099|Active Comparator|High normal MAP and high normal PaO2|MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
9729299|NCT03140423|Active Comparator|Arm 1: Routine Care (Mupirocin/CHG)|ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
9729300|NCT03140423|Active Comparator|Arm 2: Iodophor/CHG Decolonization|ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
9729301|NCT03101982|Active Comparator|test|HBO, ASIA score, blood taking
9729302|NCT03101982|No Intervention|control|ASIA score, blood taking
9729303|NCT03101722|Experimental|Huperzine A intervention|Huperzine A intervention: Huperzine A with a dose 0.1~0.2 mg/time, 2 times/day. BTHE：basic treatment and health education
9729304|NCT03101722|Sham Comparator|control|Participants in the BTHE group will receive advice regarding lifestyle modification, avoiding alcohol and cigarette consumption.
9729305|NCT03088852|Active Comparator|Experimental group|After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
9729306|NCT03088852|No Intervention|Control group|control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
9729307|NCT03071965|Experimental|Cohort 1|Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
10200009|NCT05190081|Experimental|dual-task training group|Tasks were completed at the same time in the dual-task training group
10200010|NCT05190081|No Intervention|control group|No intervention was performed in the control group
10200011|NCT05190068|Experimental|Relapsed/refractory B-NHL|"The starting dose of HMPL-760 is initially set as 50 mg, and then the doses of 100 mg, 200 mg, 300 mg, and 400 mg are escalated successively (this dose gradient is assumed).~HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles."
9729308|NCT03071965|Experimental|Cohort 2|Participants completed protocol NTMT-02. Participants received surgery to implant NT-501 or sham surgery to mimic implant procedure. Participants that received NT-501 implant were exposed to ciliary neurotrophic factor (CNTF).
9729309|NCT03068780|Experimental|Oleogel-S10|
9729310|NCT03068780|Placebo Comparator|Control Gel|
9729311|NCT03067610|Experimental|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
9729312|NCT03058796|Active Comparator|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
9729313|NCT03058796|Experimental|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
9729314|NCT03042169|Active Comparator|continuation of chemotherapy|"Patients assigned to arm A will continue to receive the same chemotherapy regimen they received before randomization. Chemotherapy should be restarted between D1 and D30 after randomization.~In case of poor tolerance to the induction chemotherapy, alternative chemotherapy regimen might be discussed, according to local standards and national guidelines (www.tncd.org)."
9729315|NCT03042169|Experimental|surgical removal of the primary tumour and treatment of the metastatic site followed by chemotherapy|"Patients assigned to arm B will undergo gastrectomy (subtotal or total according to the location of the primary tumour) between D1 and D30 after randomization.~Subtotal gastrectomy is recommended if it allows a complete resection of the primary tumour to limit postoperative morbidity in such metastatic situations, based on the results of REGATTA"
9729316|NCT03037385|Experimental|Phase 1 Dose Escalation|Multiple doses of pralsetinib (BLU-667) for oral administration.
9729317|NCT03037385|Experimental|Phase 2 Dose Expansion|Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.
10200012|NCT05190055|Experimental|Minimally invasive spinal fusion surgery|A filler tube with an integrated threaded rod, which can be connected to a surgical drill, was used for rapid and continuous graft filling.
9729318|NCT03037164|Experimental|INTERCEPT (Test)|Red blood cell components treated with the INTERCEPT Blood System for Red Blood Cells ordered and administered to study patients by their treating physicians according to the local standards of care
9729319|NCT03037164|Active Comparator|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
9729320|NCT03036319|Experimental|Active TES|"Participants will receive real tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions."
9729321|NCT03036319|Placebo Comparator|Sham TES|Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 260 sessions.
9729322|NCT03036319|Experimental|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
9729323|NCT03036319|Experimental|Active TES + Cognitively based intervention|This condition combines active TES and cognitively based interventions for some or all of the study sessions
9729324|NCT03036319|Experimental|Sham TES + Cognitively based intervention|This condition combines sham TES and cognitively based interventions for some or all of the study sessions
9729325|NCT03036319|Experimental|Active TES, Sham TES, Cognitively based interventions|This condition combines active and sham TES with cognitively based interventions using a cross-over design
9729326|NCT03036319|Experimental|Active and Sham TES|Participants will receive active and sham TES
9729327|NCT03027609|Experimental|AR-105|One intravenous infusion of AR-105 20mg/'kg
9729328|NCT03027609|Placebo Comparator|Control|Matching placebo
9729329|NCT03015090|Experimental|theophylline|
9729330|NCT03000374|Experimental|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
9729331|NCT02994836|Active Comparator|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
9729332|NCT02994836|Placebo Comparator|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
9729333|NCT02993107|Other|Group 1 (Placebo Crossovers)|Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
9729334|NCT02993107|Other|Group 2 (Active Rollovers)|Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.
9729335|NCT02991690|Experimental|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
9729336|NCT02991690|No Intervention|Control|Standard of care medical treatment, specific to each individual.
9729337|NCT02985957|Experimental|Cohort A (Arm A)|
9729338|NCT02985957|Experimental|Cohort B (Arm B)|
9729339|NCT02985957|Experimental|Cohort C (Arm C)|
9729340|NCT02985957|Experimental|Cohort D (Arm D1)|
9729341|NCT02985957|Experimental|Cohort D (Arm D2)|
10200013|NCT05190055|Active Comparator|traditional spinal fusion surgery|Bone substitutes were filled in the disc space manually using a bone grafting funnel.
10205053|NCT04190693|Placebo Comparator|Follow-up|No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
9729342|NCT02985957|Experimental|Cohort D (Arm D3)|
9729343|NCT02985957|Experimental|Cohort D (Arm D4)|
9729344|NCT02981082|Active Comparator|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
9729345|NCT02981082|Placebo Comparator|Placebo|Twice daily oral doses of placebo for 12 weeks
9729346|NCT02924129|Experimental|Evoke SCS with Feedback|closed-loop/automatic stimulation
9729347|NCT02924129|Active Comparator|Evoke SCS with Conventional|open-loop/manual stimulation
9729348|NCT02916771|Experimental|Ixazomib|"Cycles 1-9~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle~Cycle 10-24~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Supportive measures consistent with optimal patient care may be given throughout the study"
9781085|NCT01139580|Placebo Comparator|Vehicle Foam|Vehicle Foam
9781086|NCT01139658||All comers|
9781087|NCT01139762|Experimental|Tadalafil|
9781088|NCT01139762|Placebo Comparator|Placebo|
9984766|NCT03749109|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
9729349|NCT02915120|Active Comparator|Real Pulsed Radiofrequency|Before needle insertion, the patient's inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches will be identified under ultrasound guidance. RF needles and probes will be advanced to each of the target nerves under ultrasound guidance. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.5 mA to identify the nerve position, the current intensity (mA) will be reduced at < 0,2 mA. During the sensorial stimulation, the patients will be asked if they feel tingling, pain, or discomfort inside the knee. The RF probe will be maintained in place until one of those feelings is elicited. In order to avoid inactivating motor nerves, the nerve will be tested for the absence of fasciculation in the the lower extremity on stimulation of 0,5 mA at 2 Hz.
9729350|NCT02915120|Sham Comparator|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
9729351|NCT02870465||CRIF in operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed in the operating room.
9729352|NCT02870465||CRIF outside of operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed outside of the operating room (i.e.: in clinical setting, the emergency department or minor procedures area).
10200014|NCT05190003|Experimental|Study group I: The first time of patients attending single-level lumbar microdiscectomy|"Study group I:~On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises."
10200015|NCT05190003|No Intervention|Study group II: Control healthy people|"Study group II:~40 people aged 20-65 years. Including criteria: healthy persons without lumbar spine pain for at least 6 months and without lumbar spine surgery."
10200016|NCT05189977|Active Comparator|Sertraline alone at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
10200017|NCT05189977|Active Comparator|Sertraline + brexpiprazole at steady state|To assess the hemodynamic changes associated with the effects of a single dose of prazosin or propranolol in the presence of brexpiprazole + sertraline at steady state compared with a single dose of prazosin or propranolol in the presence of sertraline alone at steady state.
10200018|NCT05189899|Active Comparator|With virtual reality|One hemodialysis session with virtual reality
9729353|NCT02831673|Experimental|DTG + 3TC (50 mg+300 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the subject no longer derives clinical benefit, or (iv) the subject meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
9729354|NCT02831673|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
9729355|NCT02800941||Oral anticoagulant treatment|Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.
9729356|NCT02770703|Experimental|Open inguinal hernia repair (Lichtenstein)|Open inguinal hernia repair using a DynaMesh visible mesh
9729357|NCT02770703|Experimental|Total extraperitoneal inguinal hernia repair (TEP)|Total extraperitoneal inguinal hernia repair using a DynaMesh visible mesh
9729358|NCT02770703|Experimental|Trans abdominal preperitoneal hernia repair (TAPP)|Trans abdominal preperitoneal hernia repair using a DynaMesh visible mesh
9729359|NCT02741700|Experimental|Gout storytelling video|Participants view culturally relevant patient narrated storytelling in African-American Veterans' own voices about their experience with gout and its treatment and a patient narrated slide show of gout and its treatment.
9729360|NCT02741700|Active Comparator|Video about management of another chronic condition|Participants view a patient narrated slide show of roughly the same duration as the experimental arm, summarizing the management of stress, a non-gout chronic condition.
9729361|NCT02703844|Active Comparator|Active|Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 8 weeks, 7 days a week, twice daily for 19 minutes.
9729362|NCT02703844|Sham Comparator|Placebo|"Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 8 weeks in the same manner as the active arm: 7 days a week, twice daily for 19 minutes.~Individuals allocated to this arm will be later crossed over, in unblinded fashion, to the active arm if the treatment shows evidence of efficacy and safety."
10200019|NCT05189899|No Intervention|without virtual reality|One hemodialysis session without virtual reality
9729363|NCT02676193|Experimental|Australian Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using standard Australian marketing for three months.
9729364|NCT02676193|Experimental|Blank Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using blank packaging for three months. Blank packaging will indicate participants brand and will not have any brand-related images or labels.
9729365|NCT02676193|No Intervention|American Packs|Participants assigned the nonintervention group will purchase their US brand of cigarettes in the standard American packaging for three months.
9729366|NCT02635776|Experimental|AR101 powder provided in capsules & sachets|Study product provided as peanut protein in pull-apart capsules or sachets
10200020|NCT05189886||Prospective|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
10200021|NCT05189886||Retrospective|The retrospective phase will collect data from previous TAVR procedures completed between February 2019 and October 1, 2021. Data from up to 200 patient charts will be collected using the Society of Thoracic Surgeons/American College of Cardiology that is maintained by the CMH Cardiology Department. The population will be de-identified as the purpose is to obtain descriptive information from the medical records to utilize for propensity match scoring.
10200022|NCT05189873|Experimental|HRT|HRT protocol : estradiol and progesterone
9729367|NCT02635776|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
9729368|NCT02609724|Experimental|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
9729369|NCT02609724|Active Comparator|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
9729370|NCT02609724|Placebo Comparator|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
9729371|NCT02591784|Experimental|Nimotuzumab group|Nimotuzumab+radiotherapy
9729372|NCT02569450||Intervention arm|Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
9729373|NCT02569450||Hospitals in control arm|Hospitals randomly assigned to the control arm without surgical outcome monitoring
9729374|NCT02545309||SSC-CIP|Patients with secondary sclerosing cholangitis in critically ill patients
9729375|NCT02545309||control|Patients with similar degree of critical illness who do not develop secondary sclerosing cholangitis in critically ill patients
9729376|NCT02518087|Experimental|CPB-oXiris®|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
9729377|NCT02518087|No Intervention|CPB-Standard|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
9729378|NCT02482376|Other|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
9729379|NCT02477826|Experimental|Arm A: Nivolumab|Nivolumab intravenously (IV) as specified
10200023|NCT05189873|Experimental|Long GnRH agonist + HRT|Long GnRH agonist + HRT protocol: Superfect and estradiol and progesterone
10200024|NCT05189769|Experimental|CP/No REACT|Traditional Coping Power for 7th graders, no school wide REACT training
9729380|NCT02477826|Experimental|Arm B: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab IV as specified
9729381|NCT02477826|Experimental|Arm C: Nivolumab + Platinum doublet chemotherapy|Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
9729382|NCT02477826|Experimental|Arm D: Platinum doublet chemotherapy|Chemotherapy administered on specified days of IV chemotherapy
9729383|NCT02425345|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults
9729384|NCT02425345|No Intervention|Usual Activity Control|Usual activity
9729385|NCT02361515|Active Comparator|Moderate Hypofractionated radiotherapy (62Gy)|20 fractions of 3.1Gy
9729386|NCT02361515|Experimental|Stereotactic radiotherapy (37.5Gy)|5 fractions of 7.5Gy)
9729387|NCT02359994|Experimental|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps > 2mm and large needle holes > 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
9729388|NCT02359994|Experimental|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels > 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
9729389|NCT02359994|Experimental|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels > 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
9729390|NCT02359097|Experimental|Diagnostic (DSC/DCE-CBV, SS-CBV mapping)|Patients receive 2 doses (2nd dose optional) of gadoteridol IV and undergo MRI including DSC or DCE-CBV mapping over approximately 45-60 minutes on day 1. Within 3 days, patients receive 3 doses of ferumoxytol non-stoichiometric magnetite IV and undergo MRI including DSC and SS-CBV mapping after each dose over approximately 90 minutes. Patients undergo MRI without contrast 24 hours after ferumoxytol non-stoichiometric magnetite over approximately 30 minutes. This 3 day series of imaging repeats at different stages of disease and may be performed up to 5 times: prior to surgery, prior to chemoradiation therapy, 4-6 weeks post-chemoradiation therapy, at time of progression on gadolinium MRI per RANO criteria, and again at time of progression (if the previous time of progression showed pseudoprogression).
9729391|NCT02336230|Experimental|Remestemcel-L 2×10^6 MSCs/kg|Participants were treated with intravenous (IV) remestemcel-L at a dose of 2×10^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2×10^6 MSCs/kg actual body weight at Screening.
9729392|NCT02334865|Experimental|Group A (vaccine and week-4 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
9729393|NCT02334865|Experimental|Group B (vaccine and week-0 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 4, 6, 8, and 10 for up to 4 doses and then receive a booster in week 16. Beginning in week 0, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
9729394|NCT02207049|Active Comparator|Three Meals (TM)|Preschoolers will be provided their caloric needs within three meals.
9729395|NCT02207049|Active Comparator|Meal plus Snack (M+S)|Preschoolers will be provided three meals and two snacks, with total amount of food provided in the day the same as the Three Meal (TM) arm.
9729396|NCT02207049|Active Comparator|Three Meal plus Snack (TM+S)|Preschoolers will be provided three meals and two snacks with total amount provided in the meals equal to the Three Meal (TM) arm and total amount provided in the snacks equal to Meal plus Snacks (M+S) arm.
9729397|NCT02188745|Experimental|Alternating Therapy|"Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred.~17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day.~Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day.~Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day.~Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day."
9729398|NCT02156232|Active Comparator|TIPS, SPSS Emboliaztion|The covered stents wil be used for TIPS The SPSS will be embolized during the procedure of TIPS
9729399|NCT02156232|Active Comparator|TIPS alone|The covered stents will be used for TIPS No embolization of SPSS will be performed during TIPS
9729400|NCT02041533|Experimental|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
9729401|NCT02041533|Active Comparator|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first~Squamous subjects:~Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or~Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or~Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle~Non-Squamous subjects:~Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle~Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle~Optional crossover:~Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
9729402|NCT02032823|Experimental|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
9729403|NCT02032823|Placebo Comparator|Placebo|Placebo tablets b.i.d. p.o.
9729404|NCT01992861||Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
9781089|NCT01139775|Experimental|Phase 1: LY2603618 130 to 275 mg|"Cycle 1-2 (21-day cycle):~Day 1: pemetrexed 500 milligrams per meter square (mg/m^2) + cisplatin 75 mg/m^2~Day 2: LY2603618 at 130-275 milligrams (mg)~After 2 cycles, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
9785819|NCT01260493|Experimental|integrated health care chain|integrated health care chain. Geriatric assessment at emergency department (ED), case manager with multiprofessional team in the community, support for informal caregivers
10200025|NCT05189769|Experimental|CP/REACT|Traditional Coping Power for 7th graders and school wide REACT training
10200026|NCT05189769|Experimental|CP+/No REACT|New, adapted Coping Power for 7th graders intervention with no school wide REACT training
10200027|NCT05189769|Experimental|CP+/REACT|New, adapted Coping Power for 7th graders, school wide REACT training
10200028|NCT05189704|Experimental|NSAID group|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
10200029|NCT05189704|Active Comparator|Opioid group|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
9729405|NCT01904136|Experimental|Treatment (NK cells, allogeneic stem cell transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and NK cells IV over 30 minutes on day -2 or -1.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive NK cells IV over 30 minutes on day -2 or -1.~TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO TID beginning on day 5 for approximately 6-7 months.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90."
9729406|NCT01849627|Experimental|Low-ED|This condition will focus lowering on the energy density of the diet of the diet. This prescription does not include goals for any other nutrients, thus there are no energy goals.
9729407|NCT01849627|Experimental|Energy Balance|This condition will focus have an energy balance prescription. Participants will be asked to consume a daily energy intake at estimated energy needs for weight loss maintenance.
9729408|NCT01584466|Experimental|Paliperidone|
9729409|NCT01557751|Other|Total knee arthroplasty subjects who are genotyped|All patients will have whole blood drawn for genotyping, and participate in the various assessments (psychosocial questionnaires, qualitative sensory testing, etc).
9729410|NCT01543698|Experimental|dual combination|LGX818 QD and MEK162 BID
9729411|NCT01543698|Experimental|triple combination|LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.
9729412|NCT01462097|Experimental|Aerobic exercise|12 months of treadmill walking and strength training exercise. Exercise is gradually progressed in walking speed and time on the treadmill based on the individual's tolerance, abilities, and safety. For months 1-6 exercise will take place 3 times per week at the research center. For months 6-12 exercise will take place 2 times per week at the center and 1 time per week at home.
9729413|NCT01462097|Active Comparator|Health Education|12 months of Health education sessions which will cover topics important to older adults (safe travel, age-appropriate preventative screenings, resources for reliable health information, and topics relevant to chronic kidney disease). For months 1-6 classes will take place 1 time per week. For months 6-12 classes will take place 1 time per month.
9729414|NCT01363401|Experimental|Test group|Treatment group with HYNR-CS inj.
9729415|NCT01363401|Experimental|Control group|No treatment with HYNR-CS inj.
9729416|NCT01316146|Experimental|CAR.CD30 T cells|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection (IV) according to the dosing schedules: starting with the lowest cell dose (2×10^7 cells/m2) and then escalate the cell dose to the highest cell dose (2×10^8/m2) as per study design.
9729417|NCT01310010|Experimental|Dasatinib|
9729418|NCT01246297|Other|Control|Usual Care
9729419|NCT01246297|Active Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of twice weekly exercise classes with an educational component.
9729420|NCT01235130|Active Comparator|OMEGA-3|Long-Chain N-3 polyunsaturated fatty acids (OMEGA-3)
9729421|NCT01235130|Placebo Comparator|Placebo|Placebo soybean oil
9729422|NCT01085435||EFFORTLESS Main Study|Patients implanted with a CE marked S-ICD System, not participating in Cameron Health's Investigational Device Exemption (IDE) Clinical Study.
9729423|NCT01085435||Extension Phase Sub Study|The Sub-Study patients were preferably recruited from the active EFFORTLESS S-ICD patient population. Patients, who had already completed the EFFORTLESS S-ICD Registry in the past, were considered secondarily for participation in the Sub-Study.
9729424|NCT01048918||No Treatment|
9729425|NCT01045226|Experimental|Arm I|Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.
9729426|NCT00961064|Experimental|1|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
9729427|NCT00951639|Experimental|5g Cassia cinnamon|Experimental treatment group
9729428|NCT00951639|Active Comparator|50 minutes endurnace exercise|Endurance exercise treatment known to influence blood glucose
9729429|NCT00951639|Placebo Comparator|5g Cellulose|Placebo equivalent in weight and appearance to experimental treatment
9729430|NCT00848757|Experimental|Intensive Life-Style Counseling|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the Diabetes Prevention Program (DPP) Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
9729431|NCT00848757|No Intervention|Usual Care Control|Women with pre-diabetes randomized to usual care will be offered 30 minute appointments with a medical provider to review their diagnosis, risk for diabetes, and stress the importance of lifestyle changes to prevent diabetes, including weight loss and exercise and setting individual goals for these. Usual care participants will be encouraged to achieve goals equivalent to the ILI group: to reduce their weight by 7%, and to increase their physical activity to approximately 150 minutes moderate intensity exercise per week. They will be offered a consultation with an FHCHC nutritionist to achieve dietary/weight loss objectives. Participants are offered printed educational materials which are language and literacy-appropriate.
10200030|NCT05188521|Experimental|Cutaneous LP|Subjects with a diagnosis of cutaneous LP will receive Baricitinib (LY3009104) for a 16 weeks treatment period
10200031|NCT05187949||Patients|"Quantitative study: Surveys: 1,067 out of a total of 1,389,725 people of residents of the Valencian Community, Spain. Three groups with quota control: proportional to age (40-50; 50-70; > 70 years) of men aged 40 and over who have not had prostate cancer from each stratum (geographical area and population habitat).~Qualitative study: general population focus groups: 3"
9729432|NCT00719888|Experimental|Treatment (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
9729433|NCT00719888|Experimental|Arm II (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
9729434|NCT00687986|Active Comparator|primary surgery|primary surgical resection
9729435|NCT00687986|Experimental|stereotactic radiotherapy|primary stereotactic radiotherapy
9729436|NCT00503035|Experimental|Celecoxib|Celecoxib 400 mg orally twice daily for 6 months. Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure.
9729437|NCT00378482|Experimental|1|Drug: CP-675,206 (Tremelimumab)
9729438|NCT00306098|Experimental|Islet transplantation|
9729439|NCT00303849|Experimental|Treatment (etoposide, mannitol, melphalan, carboplatin, STS)|Patients receive etoposide phosphate IV over 10 minutes, mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes on days 1 and 2. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Courses repeat every 4 to 6 weeks for up to 12 months.
9729440|NCT00285935|Experimental|Treatment with SSRI|"Depressed participants will receive 8 weeks of treatment with one of the following serotonin-specific reuptake inhibitors:~fluoxetine (Prozac®), sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)~The specific drug used for treatment will be selected by the study clinician based on clinical interviews and the participants preferences. Participants will be monitored for response and side effects by study clinician and will return after 8 weeks for a follow up study visit."
9729441|NCT03835598||Patients with cardiac biological prosthesis|
9729442|NCT03835650||PGP|Patients in early postpartum period experiencing PGP, confirmed with dedicated functional tests
9729443|NCT03835650||no PGP|Patients in early postpartum period, with no symptoms and signs of PGP
9781090|NCT01139775|Experimental|Phase 2: Pemetrexed + Cisplatin + LY2603618|"Cycles 1-4 (21-day cycle):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~Day 2: LY2603618 dose from phase 1 portion of trial~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Experimental Arm (every 21 days):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~Day 2: LY2603618 dose determined from phase 1~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~If, as of 25 Oct 2012, participant was in maintenance therapy and randomized to the experimental arm, the participant is eligible to continue with pemetrexed (Day 1)/LY2603618 (Day 2) therapy if the investigator deems it is in the best interest of the participant and the participant consents."
9781091|NCT01139775|Active Comparator|Phase 2: Pemetrexed + Cisplatin|"Cycle 1-4 (21-day cycle):~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Comparator Arm: Phase 2 (every 21 days):~Day 1: pemetrexed 500 mg/m^2"
9781092|NCT01139801|Active Comparator|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
9781093|NCT01139801|Experimental|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
9781094|NCT01139814|Experimental|Catheter Robot|device
9781095|NCT01139879|Experimental|P400 support surface|All patients will receive the P400 mattress
9781096|NCT01140061|Experimental|Panel A - MK-0873 5.1 mg|In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
9781097|NCT01140061|Placebo Comparator|Panel A - Placebo|In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
9781098|NCT01140061|Experimental|Panel B - MK-0873 25 mg|In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days.
9781099|NCT01140061|Placebo Comparator|Panel B - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
9781100|NCT01140061|Experimental|Panel C - MK-0873 100 mg|In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days.
10200032|NCT05187949||General Practitioners|"Quantitative study: 369 General Practitioners working in two Health Departments in the Valencian Community, Spain (Dept of Health Alicante, General Hospital 19, 255,439 habitants) and (Dept of Health Alicante, S Juan Alicante 17, 233,115 habitants).~Qualitative study: general practitioners focus groups: 2."
9982379|NCT05248711|Experimental|Daily Move|Participants (n=107) will be provided free access to and asked to register for the consumer-based mobile meditation app, Calm, on their phone. Participants will then receive an email containing one year of free access to Calm. Participants will be asked to use the Daily Move component on the Calm app for ~10 minutes per day for 8 weeks.
9982380|NCT05248711|No Intervention|Usual Care|Participants (n=107) will be asked to continue with usual care/routine and complete survey measures at each time point. Participants will be provided with access to the intervention after their study participation.
9982381|NCT05248620|Active Comparator|Active|Amoxicillin/clavulanic acid 500/125mg, tablets, will be administered before each hemodialysis for 6 months
9982382|NCT05248620|Placebo Comparator|Placebo|Placebo tablets, similar to the active drug, will be administered before each hemodialysis for 6 months
10200033|NCT05187949||Urologists|Quantitative study: 345 Urologists working in Valencian Community, Spain Qualitative study: urologists focus groups: 1.
10200034|NCT05186883|Experimental|Treatment with allogenic parathyroid cells|Patients with postoperative hypoparathyroidism receiving standard treatment and allogenic parathyroid cells
10200035|NCT05186883|Active Comparator|Control|Patients with postoperative hypoparathyroidism receiving standard treatment
10200036|NCT05178199|Experimental|Remote Psychological Support Group|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
10205054|NCT04190693|Experimental|IMCY_0098|No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
9664912|NCT05259150|Experimental|Expert Professional (EP) Strategy|In the Planning for Health intervention, the EP implementation strategy will include the use of external professionals to assist health leaders in the planning of cardiovascular health programming for congregants. Staff will assist health leaders in the Preparing for Health and the Delivery of Health interventions.
9664913|NCT05259150|Active Comparator|Comparison Group Strategy|In the Planning for Health intervention, the Comparison Group strategy will include process activities with the health leaders (identification of health leaders, meetings of health leaders, assistance of health leaders with recruitment of congregants for research). Except for data collection, participants (health leaders and congregants) will not be involved in the Preparing for Health or the Delivery of Health interventions.
9664914|NCT05259033|Experimental|IcoSema|Participants will get once weekly dose
9664915|NCT05259033|Experimental|Semaglutide|Participants will get once weekly dose
9664916|NCT05257655|Other|Intervention|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius;
9664917|NCT05257642|Experimental|Cognitive Change Groups|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on cognitive change. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements.
9664918|NCT05257642|Experimental|Mindfulness Groups|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on mindfulness and relaxation. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements
9664919|NCT05257642|Experimental|Problem solving Group|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on problem-solving. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements
9664920|NCT05257642|No Intervention|Control Group|The participants in this group will complete the pre-test measurements, then they will receive an experimental task Cyberball and complete the post-test measurements
9664921|NCT05256290|Experimental|Monotherapy Dose Escalation|Enrolling patients with GBM and NSCLC harboring sensitive EGFR alterations
9664922|NCT05256290|Experimental|Disease-Specific Dose Expansion Cohorts|"Recurrent GBM with confirmed EGFR alterations~NSCLC with uncommon EGFR mutations (eg, G719X), following standard of care therapy with an EGFR inhibitor~NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M)"
9664923|NCT05255809|Experimental|Alexander Technique + Routine Physical Therapy|Routine Physical Therapy+Alexander Technique Verbal Instructions in Trunk stabilising exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
9664924|NCT05255809|Placebo Comparator|Control Group|Routine Physical Therapy duration: two days a week for 16 weeks. Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes.
9664925|NCT05255146|Experimental|Intervention Group: Cryoanalgesia|Patients receiving cryoanalgesia peri-operatively during minimally invasive cardiothoracic surgery
9664926|NCT05255146|No Intervention|Control Group: No Cyroanalgesia|Patients receiving minimally invasive cardiothoracic surgery who do not receive cryoanalgesia.
9664929|NCT05252195||Participants|Participants with Multiple Sclerosis who meet eligibility criteria.
9664930|NCT05250609|Experimental|"Intervention: Endocrown composite."|Composite Endocrown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
9664931|NCT05250609|No Intervention|Comparator / Control: Stainless steel crown.|Stainless steel crown will be used as an extra-coronal restoration in endodontically treated mutilated first permanent molar
9664933|NCT05249777|Experimental|TD0069|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with background treatment.
9664934|NCT05249777|Placebo Comparator|Placebo|Standard dose, 3 capsules/time x 3 times/day x 14 days before breakfast, lunch, and dinner combined with background treatment
9664935|NCT05248841|Experimental|HEC-Glargine Treatment A (Test)|Subjects will receive single doses of Test Formulation HEC-Glargine on Day 1 of Treatment periods 1 and 2 followed by at least 7-21 days washout.
10200037|NCT05178199|Active Comparator|Mindfulness through audio and video|The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
10200038|NCT05175586|Experimental|Group 1|15 patients in the experimental group of percutaneous neuromodulation together with orthopaedic manual therapy (Maitland and Mulligan)
10200039|NCT05175586|Active Comparator|Group 2|15 patients in the experimental group of orthopaedic manual therapy (Maitland and Mulligan).
10200040|NCT05169970|Experimental|Patients with low-intermediate risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions).
10200041|NCT05169970|Experimental|Patients with high risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions) with a boost of up to 45Gy to the dominant intraprostatic lesion as identified on pretreatment MRI plus hypofractionated pelvic EBRT (25Gy in 5 fractions).
10200042|NCT05169697|Experimental|YH002 in combination with YH001|Dose escalation:A traditional 3+3 dose escalation algorithm will be utilized to identify MTD and/or RP2D Dose expansion:One selected dose after the escalation stage will be expanded to enroll additional 20 subjects. The subjects will be divided into two groups：A and B.
10200043|NCT05169216|Experimental|Cognitive-Behavioral Therapy Group|"A mental training program was carried out with the following objectives: (a) to learn to manage their level of activation; (b) to train their ability to concentrate; (c) to optimize their self-confidence; (d) to learn to compete by improving their racing routines; and (d) to integrate mental training into their day-to-day life.~The athletes worked in small groups of four athletes. In addition, the days that the psychologist attended the concentration, he was also present in the training sessions, with the aim of giving them feedback on the strategies acquired. The psychologist was present in various phases throughout the concentration and there was also a constant online monitoring. Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines."
9664936|NCT05248841|Active Comparator|US-Lantus Treatment B (Reference)|Subjects will receive single doses of Reference Formulation Lantus on Day 1 followed of Treatment periods 1 and 2 by at least 7-21 days washout.
9664937|NCT05246904|Active Comparator|audiologist arm|A research audiologist will fit the participant with the hearing devices according to usual clinical best practice procedures.
9664938|NCT05246904|Active Comparator|self-fit arm|Participants will follow manufacturer's printed instructions to complete the self-hearing test using the hearing aids and a provided app to program their hearing aids.
9664939|NCT05246137|Experimental|Experimental: COVID-19 Vaccine HIPRA 40 ug/dose|COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA
9664940|NCT05245773|Experimental|30-day automated hovering + usual care|The intervention arm will get the usual post-discharge call from their practice, typically within 2 business days of discharge. In addition, they will be enrolled in the 30-day automated texting program, wherein they will receive check-in messages on a tapering schedule; they will be free to opt out at any time. They can also message into the platform at any time. Any needs identified through the platform will be escalated to their primary care practice, and they will receive a follow-up phone call from practice staff to address their needs.
9664941|NCT05245773|No Intervention|Usual care|The control arm will continue to receive the usual post-discharge call from their practice, typically within 2 business days of discharge.
9664942|NCT05245253||Trauma patients|Trauma patients 20-60 years of age
9664943|NCT05245006|Experimental|Cohort A: 89Zr-DFO-YS5|Participants receive one dose of 89Zr-DFO-YS5 up to 3 millicurie (mCi), and undergo a whole body PET performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total.
9664944|NCT05245006|Experimental|Cohort B: YS5, 89Zr-DFO-YS5, Multiple Scans|89Zr-DFO-YS5 will be co-administered with unlabeled YS5 antibody. Participants will receive either 20 mg or 50 mg of YS5 prior to imaging and administration of 89Zr-DFO-YS5 and whole body PET scan performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total.
9664945|NCT05245006|Experimental|Cohort C: YS5, 89Zr-DFO-YS5 with scan at progression|89Zr-DFO-YS5 will be co-administered with unlabeled YS5 antibody prior to PET imaging for a single scan. Participants in have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
9665462|NCT05049772|Active Comparator|Stabilization Exercises group|Behavioral: Stabilization Exercises group An exercise program consisting of lumbar stabilization exercises for the participants will be planned for the pelvic ring muscles to develop the neutral lumbar spine. Co-contraction of the transversus abdominus muscle and the multifidus muscle will form the basis of the exercises. Stabilization exercises will be given for 10 weeks for 40 minutes, 2 days a week.
9665463|NCT05049772|No Intervention|Healthy control group|no specific intervention
9665464|NCT05049057|Experimental|Active Drug|Erenumab administered once monthly via two 70-mg subcutaneous injections at 3 time points over a 12-week period.
9665465|NCT05049057|Placebo Comparator|Placebo|Placebo administered once monthly via two subcutaneous injections at 3 time points over a 12-week period.
9665466|NCT05048628|Active Comparator|İce Pieces İmpregnated Group|Impregnation of pieces of ice was delivered to us; one ice cube is planned after wearing and movements automatically by the throat purchase to exit use and sound program, and move with one ice cube after movement. It can be used after extubation. It is in sound class with Visual Analogue Scale (VAS) for the use of customers before and after the application. Extubation is in the last 0. hours, no small application is made, only in sound class with VAS. Evaluated by Stout's Hoarseness Scale
9666430|NCT04522492|Active Comparator|Quality of life promotion|The therapist will send to the patient 2 videos with strategies to improve quality of life during the pandemia (1 video about social support and one video about sleep hygiene). After 1 week, the therapist will send to the patient another 2 videos with strategies do improve quality of life (dietary guidance and guidance on physical activity)
9666431|NCT04518410|Experimental|Bamlanivimab|Administered by IV infusion.
9666432|NCT04518410|Experimental|BRII-196/BRII-198|Administered by IV infusion.
9729444|NCT03834545||cycling group|They attended three sessions of exercise on three different conditions : a classic ergometric bicycle without chairback, an ergometric bicycle with chairback with virtual environment and the other session without virtual environment
9729445|NCT03833960||1-cN0/pN0|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was ypN0.
9729446|NCT03833960||2-cN+/pN0|Patients with initially clinically involved axilla (cN1-2), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was complete axillary remission (ypN0).
9729447|NCT03833960||3-cN0/pN+|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within SLNB was done, followed by ALND because of positive pathological report of sentinel node(s).
9729448|NCT03833960||4-cN+/pN+|Patients with initially clinically positive axilla (cN1-3) submitted to neoadjuvant treatment, followed by surgical procedure within ALND was done and the final pathological report was ypN1-3.
9729449|NCT03833050||Heart Transplant Recipients|"Heart Transplant Recipients meeting the criteria for enrollment and consented will be followed post transplant for 1 year after enrollment into the study.~Blood samples will be obtained at their 1, 3, 6, 12 months and any for cause heart biopsy's obtained. There will be no active intervention for recipients that are enrolled. Results from the samples will not be obtained in real time."
9729450|NCT03832140||Patients with monoclonal gammopathy|
9729451|NCT03832140||patients with a normal plasma protein electrophoresis|
9729452|NCT03831646||dermatological patients|atopic dermatitis and psoriasis patients with mild and moderate severity of dermatoses in the stage of exacerbation
9729453|NCT03831568||Children with given device for mechanical cough|
10200044|NCT05169190|Active Comparator|SGB|SGB, the experimental procedure, is the injection of 7 cc of 0.5% ropivacaine plus 0.5 cc contrast anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle
10200045|NCT05169190|Sham Comparator|Sham|Sham, the placebo control group, is the injection of 7 cc of normal saline plus 0.5 cc contrast anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle
10200046|NCT05169190|No Intervention|Wait-List Control (WLC)|WLC, a control for time, expectancy and safety, is all study procedures without going to the procedure room for injection
9729454|NCT03831529||ICU older patient|Older patient (> 65 years old) admitted to ICU with severe acute cholangitis
9729455|NCT03830710||Group A|30 patients diagnosed with oral leukoplakia
9729456|NCT03830710||Group B|30 patients diagnosed with oral lichen planus
9729457|NCT03830710||Group C|30 patients having oral squamous cell carcinoma with the tongue being the most commonly affected site
9729458|NCT03830710||Group D|30 age and gender matched individuals having no oral mucosal lesions acting as a control group
9729459|NCT03830255||Renal Transplant patients treated with cyclosporine|Detecting the genetic polymorphism affecting cyclosporine level
9729460|NCT03830255||Renal Transplant patients treated with tacrolimus|Detecting the genetic polymorphism affecting tacrolimus level
9729461|NCT03828396||High risk (positive)|Colorectal cancer and advanced adenoma
9729462|NCT03828396||Low risk (Negative)|Healthy people and other colorectal diseases
10200047|NCT05169164||Single group|All adult patients (aged 18 years or older) undergoing elective or emergency surgery with a planned overnight stay. No interventions, only observational.
10200048|NCT05168761||laparoscopic partial nephrectomy|The investigators included all hospitalisations for LPN using CCAM(Classification Commune des actes médicaux) code (JAFC005) after removing the 83 hospitals using RAPN in 2017. LPN complications were from hospitals using exclusively LPN.
9729463|NCT03827330||Patients|Patients who had Candida species growth from blood cultures drawn at the National Institutes of Health
9666433|NCT04518410|Experimental|AZD7442 (IV)|Administered by IV infusion.
9729464|NCT03826225||Study Cohort|All participants are considered to be in the study cohort and will have the study device placed externally on their skin in order to collect human ECG data.
9729465|NCT03825991||Control group|Cohort 1 is a a control group matched 1:5 to the exposed group on sex and age. This group i randomly assigned via Statistics Denmark and does not have a diagnosis of back pain in the time period 2008-2013. They do however have another diseases registered in the Danish Patient Registry, which only contains information on patients having had contacts with the hospital sector i Denmark. Used for study 1.
9666434|NCT04518410|Experimental|Placebo (IV)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and use the same method of administration. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
9666435|NCT04518410|Experimental|SNG001|Administered by inhalation.
9666436|NCT04518410|Placebo Comparator|Placebo (Inhaled solution)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
9729466|NCT03825991||Specific back pain (unexposed)|Cohort 2 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Spinal Disc Herniation DM51.1 and Spinal stenosis DM48.0 (ICD-10 classification).
9729467|NCT03825991||Unspecific back pain (exposed)|Cohort 3 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Other intervertebral disc disorders DM51*-51.1, Dorsalgia DM54, Other disorders of muscle DM62, Postprocedural musculoskeletal disorders not elsewhere classified DM96 and Segmental and somatic dysfunction DM99 (ICD-10 classification)
10200049|NCT05168761||open partial nephrectomy|OPN has its own CCAM codes; they group laparotomy (JAFA019 / JAFA030) and lumbotomy (JAFA008 / JAFA024)
10200050|NCT05168761||robot assisted partial nephrectomy|At the time of this study, RAPN did not have a specific coding. The investigators had contacted the hospitals with Vinci robotic surgical procedures in 2013 and the investigators included here PN from hospitalisations from the 25 centres using exclusively RAPN for more than five years. Thus, in this study, RAPN was performed by experts in robotic surgery.
9729468|NCT03825991||Total population (DM*)|Cohort 4 is the total population including all BPD diagnosis in the time period 2008-2013 in Denmark. This cohort will be used as basis for study 2 and 3, although de definitions of the groups specific back pain (unexposed) and unspecific back pain (exposed) will used in sub-analysis.
10200051|NCT05167162|Active Comparator|Group 1: Compression technique|20 participants make up the compression technique group.
10200052|NCT05167162|Active Comparator|Group 2: Massage techniques|20 participants make up the massage technique group.
9827877|NCT02471651|Active Comparator|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
9827878|NCT02471716|Experimental|Phase 1 FPA008 Dose Escalation|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose or lower dose that provide adequate PK exposure and biologic activity with tolerability.
9827879|NCT02471716|Experimental|Phase 2 FPA008 Dose Expansion|IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
10200053|NCT05167162|Active Comparator|Group 3: Hydromassage|20 participants make up the hydromassage technique group.
10200054|NCT05167162|Active Comparator|Group 4: Active recovery technique.|20 participants make up the active recovery technique group.
10200055|NCT05167084|Experimental|Metyrapone And Hydrocortisone|During one of the study periods, subjects receive hydrocortisone 19.9 mg/d subcutaneously via a pump in a pulsed fashion (eight times/day) and metyrapone per os (starting with a dose of 500 mg/d, then the dose will be increased the next days until 2500mg/d is achieved).
10200056|NCT05167084|Placebo Comparator|Placebo|During the other study period, subjects receive placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion and the same dose of placebo tablets p.o instead of metyrapone.
9827880|NCT02471755|Active Comparator|Electro-acupuncture Group|
9827881|NCT02471755|Placebo Comparator|Sham Electro-acupuncture Group|
9827882|NCT02472145|Experimental|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
9827883|NCT02472145|Active Comparator|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
9827884|NCT02472223|Active Comparator|Betadine 5%|One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
9827885|NCT02472223|Placebo Comparator|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
9827886|NCT02472262|Experimental|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
9982383|NCT05248568|Experimental|Swiss ball|Swiss ball practice can create an unstable environment and play an important role in promoting the development of muscle function and joint stability. It can effectively train the core muscles. Swiss ball practice will be involved in intermediate level training to develop participants' stability and muscle endurance。
9982384|NCT05248568|Experimental|Kettlebell|"Kettlebell training can strengthen the anti rotation ability of the trunk. For example, Kettlebell training has many actions like kettlebell swing. This movement is easy to cause imbalance in the human body, so they can further exercise the trunk stability and anti rotation ability required by athletes."
9982385|NCT05248568|Experimental|Barbell|Barbell is a commonly used and multifunctional strength training instrument. It is usually used as the main instrument to develop the maximum muscle strength and muscle explosiveness. Therefore, this study will involve barbell practice in upper intermediate training and advanced level training
10200057|NCT05167006|Experimental|Group A:|Participants will be treated with routine physical therapy for 20 minutes, five days a week for 12th weeks. Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation.
9666437|NCT04518410|Experimental|AZD7442 (IM)|Administered by IM injection.
9729469|NCT03826095||Multiple Sclerosis|Patients with a clinically definitive diagnosis of MS, 0-5.5 Extended Disability Status Scale range.
9729470|NCT03826095||Healthy individuals|Voluntary healthy individuals with similar age and gender
9729471|NCT03825653||one group|"This study will be carried out on three hundred postmenopausal.They will be selected from gynecological outpatient clinic of (Oum El Masryn Hospital).~their age will range from 60-70 years.Their BMI will not exceed 30 kg/m2. They are complaining from stress urinary incontinence."
9827887|NCT02472262|Experimental|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
9827888|NCT02472262|Active Comparator|Corn Soy Flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
9827889|NCT02472314|Experimental|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
9827890|NCT02472314|Active Comparator|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
9827891|NCT02472314|Experimental|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
9827892|NCT02472314|Active Comparator|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
9729472|NCT03825393||Fibromyalgia|Non-anemic FMS patients who were diagnosed based on 2011 FMS diagnostic criteria of the American Rheumatology College
9729473|NCT03825393||Control|Non-anemic women without a FMS diagnosis
9729474|NCT03825120||Women from original OVA cohort|
9729475|NCT03825003||Basketball Players|Outcome assessments were done.
9729476|NCT03825003||Sedentary Peers|Outcome assessments were done.
9729477|NCT03824470||Group E(rocuronium)|E, after the administration of 1 mg / kg lidocaine, 2 mg / kg propofol, 1 mcg / kg remifentanil and 0.6 mg / kg rocuronium intravenously, patients will be intubated and general anesthesia will be performed when the Tof value is 0.
9729478|NCT03824470||Group R (remifentanil)|1 mg / kg lidocaine, 4 mcg / kg remifentanil and 2 mg / kg propofol intravenously.patients will be intubated and general anesthesia will be performed when the Tof value is 0
9729479|NCT03821948||Average CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with average CRC risk undergoing a standard of care colonoscopy procedure
10200058|NCT05167006|Active Comparator|Group B|The participants will be treated with Perfetti's method and routine physical therapy for 35 minutes, five times a week for 12th weeks. Each participant will receive his/her arms training therapy.
9729480|NCT03821948||Increased CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with increased CRC risk undergoing a standard of care colonoscopy procedure
9729481|NCT03820752||Pediatric chronically ill patients|"Through a questionnaire parents of chronically ill patients will be asked about the vaccination status of all recommended vaccines of their child. Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.~A blood sample to determine antibodies against measles, mumps, rubella and pertussis will be drawn from children who consent to sampling.~The following groups of patients will be questioned: diabetes, allergy, congenital heart disease, cystic fibrosis, immunodeficiency and transplant patients, cancer patients."
9729482|NCT03820752||Adult chronically ill patients|"Through a questionnaire chronically ill patients will be asked about their vaccination status of diphtheria, tetanus,pertussis, flu, pneumococcal and hepatitis B vaccine(s). Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.~A blood sample to determine antibodies against diphtheria, tetanus and pertussis will be drawn.~The following groups of patients will be questioned: diabetes, chronic kidney disease, heart failure, COPD, immunodeficiency and transplant patients, HSCT patients."
9729483|NCT03820349||Cystic Fibrosis|Subjects with cystic fibrosis
9729484|NCT03820349||controls|matched healthy controls
9729485|NCT03820284||Group A|Group A inflammatory bowel disease with helicobacter pylori infection
9729486|NCT03820284||Group B|Inflammatory bowel disease without helicobacter pylori infection
9729487|NCT03820167||Fresh sample|"Morphologically good embryos will be cultured in a culture dish and the supernatants will be collected freshly from culture system at day 3 and stored at -20 ̊ c until being tested.~Quantification of mtDNA in fresh and frozen culture media using qPCR technique."
9729488|NCT03820167||Frozen embryos|Morphologically good embryos scheduled for freezing will be cryopreserved for less than one year and thawed, the supernatant will be collected and stored at -20 ̊ c until being tested. Quantification of mtDNA in fresh and frozen culture media using qPCR technique.
9729489|NCT03820102||Vit D deficiency|Chronic HCV patients with vitamin D deficiency Sustained virological response after treatment
9729490|NCT03820102||Normal Vit D|Chronic HCV patients with normal vitamin D level Sustained virological response after treatment
9729491|NCT03819959||Intensive Care Patients|Polytrauma patients who have been admitted to intensive care
10200059|NCT05166837|Experimental|Cohort 1:2mg/kg|All participants (fasted) received either 2 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10200060|NCT05166837|Experimental|Cohort 2:5mg/kg|All participants (fasted) received either 5 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
9729492|NCT03821090||cases|"Eighty rheumatoid arthritis patients fulfilling American College of Rheumatology (ACR) 2010 classification criteria, all of them will be subjected to~History including disease duration , course and associated diseases~Clinical examination with specific joint examination~RA disease activity will be evaluated by a 28- joint DAS (DAS28).~The Framingham 10 year risk of general cardiovascular disease score will be calculated 5-12-lead ECG~6-Echocardiography 7-Carotid intima media thickness (cIMT)using carotid doppler 8-Venous blood will be withdrawn to do the following laboratory tests~CBC~ESR &CRP~RF& Anti-ccp~Urine analysis , Urea and creatinine , and GFR~Uric acid level~Lipogram~HA1C~TNF α~High sensitive cardiac troponin I (hs-cTnI)"
9729493|NCT03821090||control|"Eighty healthy subjects age and sex matched will be included , all of them will be subjected to~History~Clinical examination .~The Framingham 10 year risk of general cardiovascular disease score will be calculated 4-12-lead ECG~5-Echocardiography 6-Carotid intima media thickness (cIMT)using carotid doppler 8-Venous blood will be withdrawn to do the following laboratory tests~Complete Blood Count (CBC)~Erythrocyte Sedimentation Rate (ESR) &C Reactive Protein(CRP)~Rheumatoid Factor (RF)& Anti-ccp~Urine analysis , Urea and creatinine , and Glomerular Filtration Rate(GFR)~Uric acid level~Lipogram~HA1C~TNF α~High sensitive cardiac troponin I (hs-cTnI)"
9729494|NCT03818425||Clinical Population|In- and Out-Patients diagnosed with depression (F32, F33), anxiety disorder (F40, F41; ICD-10) or posttraumatic stress disorder (F43.1; ICD-10)
9729495|NCT03818425||Healthy Controls|Subjects with no previous or actual mental disorder
10200061|NCT05166837|Experimental|Cohort 3:10mg/kg|All participants (fasted) received either 10 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10200062|NCT05166837|Experimental|Cohort 4:20mg/kg|All participants (fasted) received either 20 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10200063|NCT05166837|Experimental|Cohort 5:30mg/kg|All participants (fasted) received either 30 mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10200064|NCT05165992|Active Comparator|Nebulized Fentanyl|Intervention group (n=100): Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
10200065|NCT05165992|Placebo Comparator|Nebulized 0.9% Saline Solution|Control group (n=100): Administration of nebulized 0.9% saline solution (5 ml of normal saline), over 15 minutes, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
10200066|NCT05165511|Experimental|Executive Function-Enhanced Parent-Based Behavioral Treatment (PBT-EF)|PBT-EF will integrate executive function training with family-based behavioral treatment (FBT) for obesity, the gold-standard behavioral treatment for childhood obesity. PBT-EF will include self-monitoring, calorie reduction, and dietary and physical activity recommendations in addition to planning, organization, and problem-solving skills.
9729496|NCT03817333||ACOS smoking history >20 pack-years|Subjects with asthma-COPD overlap syndrome
9729497|NCT03817333||IRAO smoking history <5 pack-years|Subjects with an incomplete reversibility of airway obstruction
9729498|NCT03816605||control|Cells were cultured in the basic medium containing 2× penicillin and streptomycin antibody.
9729499|NCT03816605||Recombinant FGF19|Cells were cultured in the basic medium with recombinant FGF19 at concentration of 100ng/ml.
9729500|NCT03816605||High-glucose|Cells were cultured in the high-glucose medium at concentration of 25mM.
9729501|NCT03816605||FGF19 and HG|Cells were cultured in the medium with both recombinant FGF19 and high-glucose.
9729502|NCT03816657||Cohort1|Cohort1 (PD-L1+/low NLR)
9729503|NCT03816657||Cohort2|Cohort 2 (PD-L1-/High NLR)
9729504|NCT03816098||elderly patients with dysphagia|
9729505|NCT03816098||elderly patients without dysphagia|
9729506|NCT03815981||Allergic|Collection of blood, stool, urin samples
9729507|NCT03815981||Sensitized|Collection of blood, stool, urin samples
9729508|NCT03815981||Non-Allergic|Collection of blood, stool, urin samples
9729509|NCT03815188||Heart Valve Surgery|Pre-operative patients undergoing heart valve surgery will be selected and data recorded from each patient on the day of their surgery. This patient cohort is required in order to be able to accurately measure their JVP upon physical examination. Patients must have a central line inserted as part of their ongoing clinical management.
9729510|NCT03814915||Study 1 - Prediabetes|"The primary objective of Study 1 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in non-diabetic high-risk participants.~Participants in Study 1 were recruited from existing prospective cohort studies in or around each of the following European cities: Malmö, Sweden (Malmö Diet and Cancer Study); Amsterdam, The Netherlands (Hoorn Study); Copenhagen, Denmark (Inter99); and Kuopio, Finland (METSIM). A clinically practicable screening tool (DIRECT-DETECT) was used to identify at-risk participants from existing cohort studies, who were then recruited into this new prospective cohort study (Study 1)."
9729511|NCT03814915||Study 2- Diabetic|The primary objective of Study 2 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in people who have recently been diagnosed with type 2 diabetes. Participants in Study 2 of DIRECT are recruited from or nearby each of the following European cities: Malmö, Sweden; Amsterdam, the Netherlands; Copenhagen, Denmark; Exeter, UK; Newcastle, UK; Dundee, UK. Potential participants are recruited through targeted searches of existing databases and research registers combined with person-to-person contact at educational clinics and through routine retinal screening programmes.
9729512|NCT03813719||All patients attending Rapid access Gynaecology Clinic|All patients attending Rapid access Gynaecology Clinic for the first time.
9729513|NCT03813589||PMK patients|Patients already implanted with double chamber pacemaker able to detect automatically congestive heart failure and collect atrial events.
9781101|NCT01140061|Placebo Comparator|Panel C - Placebo|In Part II, healthy participants received skin application of placebo cream once daily for 10 days.
9781102|NCT01140061|Experimental|Panel D - MK-0873 200 mg|In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days.
9781103|NCT01140061|Placebo Comparator|Panel D - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
9781104|NCT01140061|Experimental|Panel E and Extension - MK-0873 200 mg|In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days.
9781105|NCT01140061|Placebo Comparator|Panel E and Extension - Placebo|In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.
9781106|NCT01140191|Experimental|WR 279,396|All subjects in this one-arm study will receive topical WR 279,396
9781107|NCT01140295|Active Comparator|1, Miralax|Miralax colonoscopy preparation
9781108|NCT01140295|Active Comparator|2, senna|Senna colonoscopy preparation
9781109|NCT01140347|Experimental|Ramucirumab DP and BSC|
9781110|NCT01140347|Placebo Comparator|Placebo and BSC|
9781111|NCT01140360|Experimental|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
9781112|NCT01140477|Experimental|Crystalens toric IOL|Toric Accommodating Lens Crystalens toric silicone multi-piece accommodating IOL (Models AT-50T/AT-52T)
10200067|NCT05165394|Placebo Comparator|Placebo|Participant follows Placebo schedule (57 days)
10200068|NCT05165394|Experimental|Antidepressant|Participant follows NBI-1065846 schedule (57 days)
10205055|NCT04190433|Active Comparator|Standard Therapy Group|Carvedilol and Lisinopril titrated to maximally tolerated doses as per standard practice
9781113|NCT01140477|Active Comparator|Crystalens IOL|Accommodating Lens Crystalens silicone multi-piece accommodating IOL (Models AT-50SE/AT-52SE)
9781114|NCT01140503|Experimental|apremilast|apremilast 20mg bid
9781115|NCT01140568|Experimental|nilotinib|Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.
9781116|NCT01140646|Experimental|Arm I|The first week of the study is a baseline week where data are being collected but study agent is not being taken. Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
9781117|NCT01140815|Active Comparator|Total|The Smith and Nephew Total Knee System
10200069|NCT05159960|Experimental|180/low|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
9729514|NCT03812666||Severe stroke|Patients with severe (defined as NIHSS score of > 10) acute stroke, either ischemic or hemorrhagic. (n= 150)
9729515|NCT03812666||Moderately stroke|Patients with moderately severe (defined as NIHSS score of > 5 but < 11) acute stroke, either ischemic or hemorrhagic. (n= 25)
9729516|NCT03812666||Mild stroke|Patients with mild (defined as NIHSS score of <6) acute stroke, either ischemic or hemorrhagic. (n= 25)
9729517|NCT03812367||Group 1|The denosumab naïve group
9729518|NCT03812367||Group 2|The zoledronic acid naïve group
9729519|NCT03812367||Group 3|The chronic denosumab (> 1 year with at least 3 biannual injections)
9729520|NCT03812367||Group 4|The chronic zoledronic acid (≥2 years with at least 2 annual injections)
9729521|NCT03812133||Surgical patients|Patients who were electively scheduled for surgery.
9729522|NCT03811132||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
9729523|NCT03811132||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
9729524|NCT03811132||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
9729525|NCT03811132||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
9729526|NCT03810638||Heart Failure Patients|All Heart Failure Patients seen at 3 major academic medical centers.
9729527|NCT03807232||pbARDS|Burn patients who developed post-burn ARDS
9729528|NCT03807232||No pbARDS|Burn patients without development of post-burn ARDS
9729529|NCT03806517||Tremor dominant type group|Tremor dominant type (TDT) group will consist of the patients with tremor premotor symptoms.
9729530|NCT03806517||PIGD dominant type group|Postural instability and gait difficulty dominant type (PIGDT) group will consist of the patients with axial premotor symptoms.
9729531|NCT03806517||Healthy control group|Healthy control group will consist of the subjects with same age and sex matched individuals in PD group.
9729532|NCT03804827||Heart Failure With Sleep Disordered Breathing|AHI3% >/= 5 events per hour of sleep.
9729533|NCT03804827||Heart Failure without Sleep Disordered Breathing|AHI3% < 5 events per hour of sleep.
9729534|NCT03804632||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from October to December 2017 with age 18 and above
9729535|NCT03804593||Group 1|Diagnosis of cirrhosis and no HCC confirmed by medical imaging including MRI or CT performed within 6 months of study enrollment. If lesions are present, a Liver Imaging Reporting and Data System (LI-RADS) score of LR-1 or LR-2.
9729536|NCT03804593||Group 2|Diagnosis of HCC confirmed by medical imaging (MRI or CT performed within 6 months of study enrollment with LI-RADS score of LR-5) and/or biopsy with histopathology.
9729537|NCT03803813||sepsis group|Patients have developed sepsis at ICU admission or during their ICU stay.
9827893|NCT02472353|Active Comparator|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
9729538|NCT03803813||non-sepsis group|Patients do not develope sepsis at ICU admission or during their ICU stay.
9729539|NCT03802474||Group A|girls with primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
9729540|NCT03802474||Group B|girls with normal painless menstruation without primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
9729541|NCT03801993||All Subjects|Subjects with a diagnosis of Cystic Fibrosis (CF) who meet all the inclusion and none of the exclusion criteria will be eligible for participation in this study.
9729542|NCT03802188||SLE Cohort|Investigators will use existing data collected on adult SLE patients enrolled into respective study cohorts from participating centers.
9729543|NCT03802188||Qualitative group|For the interviews, patients with SLE who are currently or have taken Hydroxychloroquine will be recruited from rheumatology clinics in Calgary and Montreal to participate in an interview and/or participate in a brief survey.
9729544|NCT03800043||Children with own caries experience|Children with own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
9729545|NCT03800043||Children without own caries experience|Children without own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
9729546|NCT03799471||IBD with MSK pain|IBD patients with self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, MSK pain features, co-morbidity, and IBD features
9729547|NCT03799471||IBD without MSK pain|IBD patients without self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, co-morbidity, and IBD features
9729548|NCT03799471||Healthy Controls|Healthy controls. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, and co-morbidity.
9729549|NCT03799055||easy intubation|Cormack _Lehane : 1&2
9729550|NCT03799055||difficult intubation|Cormack _Lehane : 3&4
9729551|NCT03799497||Patients suffering from Anorexia Nervosa|Subjects with a diagnostic of anorexia nervosa disorder
9729552|NCT03799497||Control group|Healthy subjects with no psychiatric disorder
9729553|NCT03796949||threatened preterm birth|Women with either preterm labor or preterm prelabor rupture of the membranes. Blood samples taken at time of inclusion in the study.
9729554|NCT03796949||Controls|Women with normal pregnancies. Blood samples taken at time of inclusion in the study, either prelabor (during pregnancy) or during active phase of labor.
9729555|NCT03796611||multiple sclerosis patient|MS is defined according to McDonald criteria 2017. MS patients included have a disease duration of less than 1 year
9729556|NCT03796611||other neurological inflammatory disease|autoimmune encephalitis, myasthenia gravis, chronic inflammatory demyelinating polyradiculitis
9729557|NCT03796611||neurological non inflammatory disease|benign intracranial hypertension, degenerative disorder
9729558|NCT03796611||healthy controls|transfusion volunteers from transfusion center
9729559|NCT03796325||Depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities and depression
9729560|NCT03796325||No-depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities without depression
9729561|NCT03796247||multiple sclerosis|
9729562|NCT03796247||healthy control|
9729563|NCT03793335||Gastric cancer prevention|This prospective study consists of 40,000 participants; after randomization, each arm has 20,000 participants. Arm 1: participants receive H. pylori stool antigen test; Arm 2: participants receive the combination of H. pylori stool antigen test and serum pepsinogen test.
9729564|NCT03793335||Colorectal cancer prevention|This prospective study consists of 40,000 participants; after randomization; each arm has 20,000 participants. Arm 1: participants with positive fecal immunochemical test (FIT) receive routine referral confirmatory diagnosis approach; Arm 2: participants with positive FIT receive routine referral confirmatory diagnosis approach and participants with high FIT results receive additional aggressive referral confirmatory diagnosis approach.
9729565|NCT03791450||pancreaticoduodenectomy|patients underwent pancreaticoduodenectomy in recent ten years.
9729566|NCT03790579||Women with gestational diabetes|We randomly selected the 40 pregnant women diagnosed GDM by two-step procedure based on Carpenter-Coustan criteria at this hospital. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
9729567|NCT03790579||Healthy women|We also randomly selected 40 healthy pregnant with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
9781118|NCT01140815|Experimental|Deuce|The Journey Deuce Bicompartmental Knee System
9781119|NCT01140880|Experimental|Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Increasingly valuable incentives will be provided for urine samples that lack metabolites of stimulant drugs.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
9781120|NCT01140880|Sham Comparator|Yoked Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Incentives will be provided to participants independent of stimulant drug use and determined in the same rate and timing as a randomly selected participant in the active CM condition.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
9781121|NCT01140906|Placebo Comparator|Placebo|
9781122|NCT01140906|Experimental|Vortioxetine: 15 mg|
9781123|NCT01140906|Experimental|Vortioxetine: 20 mg|
10200070|NCT05159960|Experimental|180/high|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
9781124|NCT01140906|Other|Duloxetine: 60 mg|Active Reference
9781125|NCT01141049|Active Comparator|Gabapentin|Gabapentin will be titrated over a 7-day period to the dose target or the maximum tolerated dose. The maximum dose will be 1200mg TID. Participants must be able to tolerate and comply with at least 400 mg daily.
10200071|NCT05159960|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
10200072|NCT05159960|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
10205056|NCT04190433|Experimental|Expanded Therapy Group|Pravastatin 40 mg per day and Spironolactone 25 mg per day in addition to maximally titrated Carvedilol and Lisinopril doses
10205057|NCT04178993|Placebo Comparator|Placebo Comparator: Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
9781126|NCT01141049|Placebo Comparator|Placebo|Placebo capsules will be administered TID.
9781127|NCT01141075|Experimental|Ataluren|"Cycle 1: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 5 mg/kg (morning), 5 mg/kg (midday), and 10 mg/kg (evening); there will then be an interval of 21 up to 42 days without treatment.~Cycle 2: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening); there will then be an interval of 14 days without treatment."
9982386|NCT05248568|Experimental|Medicine balls|Medicine balls are often used to assist patients in injury recovery, rehabilitation and strength training, and play an important role in the field of sports medicine. Its special design and construction make training more functional and in line with the movement chain theory, such as throwing training, so the medicine ball is often used in explosive force and core training. Therefore, this study will involve medicine balls practice in upper intermediate training and advanced level training
9781128|NCT01141205|Experimental|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
9781129|NCT01141205|Placebo Comparator|Saline|Saline
9781130|NCT01141283|Experimental|BTDS|Buprenorphine transdermal patch
9781131|NCT01141374|No Intervention|control group without treatment|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
9781132|NCT01141374|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
9781133|NCT01141374|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
9781134|NCT01141478|Active Comparator|Proton Beam Radiotherapy plus Sorafenib|A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
9729568|NCT03789305||Critically ill patients|Critically ill patients admitted to intensive care for more than 48 hours
9729569|NCT03789279||Distal transradial arterial access|Patients undergoing invasive coronary angiography via the distal radial approach (anatomical snuffbox)
10200073|NCT05154968|Experimental|Sequence 1 (ABCD)|Participants will receive 1 millilitre (ml) subcutaneous (SC) injection of treatment A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at the potential of hydrogen (pH) 5.7) followed by treatments B (higher pain Room Temperature [RT] solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), C (lower pain refrigerated solution contains mannitol), and D (lower pain RT solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
9729570|NCT03788473||Control.|Healthy Pregnant
10200074|NCT05154968|Experimental|Sequence 2 (BDAC)|Participants will receive 1 ml SC injection of treatment B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) followed by treatments D (lower pain RT solution contains mannitol), A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), and C (lower pain refrigerated solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
9729571|NCT03788473||Case.|Pregnant with Periodontal Disease
9729572|NCT03787862||Hyperspectral Imaging (HSI)|Patients scheduled for foot surgery will be imaged using the HSI device. Data will be gathered from the electronic medical record for one year to determines the outcomes of the surgery, any complications, re-hosptializations, re-ulcerations or amputation.
9729573|NCT03785977||Air-Q 5-9kg|Participants weighing 5-9kg may be chosen to wear the Air-Q device.
9729574|NCT03785977||Air-Q 10-14kg|Participants weighing 10-14kg may be chosen to wear the Air-Q device.
9729575|NCT03785977||Air-Q 15-20kg|Participants weighing 15-20kg may be chosen to wear the Air-Q device.
9729576|NCT03785977||ETT 5-9kg|Participants weighing 5-9kg may be chosen to wear the ETT device.
9729577|NCT03785977||ETT 10-14kg|Participants weighing 10-14kg may be chosen to wear the ETT device.
9729578|NCT03785977||ETT 15-20kg|Participants weighing 15-20kg may be chosen to wear the ETT device.
9729579|NCT03784586||Positive EPS - ICD|Patients with inducible sustained ventricular tachycardia or ventricular fibrillation at EPS evaluation underwent ICD implantation
9729580|NCT03784586||Negative EPS - PMK|All non inducible patients underwent PMK implantation
9729581|NCT03780439||infection group and non-infection group|patients were divided into 2 sub-groups according to the presence of infection or not after radical gastrectomy for gastric cancer.
9729582|NCT03780114||interns|intern pediatric dentists
9729583|NCT03779152||non asthmatic subjects|
9729584|NCT03779152||intermittent asthmatics|
9729585|NCT03779152||severe asthmatics sensitive to corticosteroids|
9729586|NCT03779152||severe asthmatics resistant to corticosteroids|
9729587|NCT03779152||moderate asthmatics|
9729588|NCT03777228||Control|Individuals without traumatic brain injury
9729589|NCT03777228||Mild TBI|Individuals with mild traumatic brain injury
9729590|NCT03777228||Moderate to Severe TBI|Individual with moderate to severe traumatic brain injury
9729591|NCT03776396||Experimental cohort|"33 patient undergoing to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania, in which an innovative Perioperative Goal Directed Therapy (PGDT) protocol will be used."
9729592|NCT03776396||Historical control group|"33 patients underwent to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania in 2015, in which a PGDT protocol was not used, but a common hemodynamic monitoring, based on parameters such as central venous pressure and / or invasive arterial pressure, was performed."
9729593|NCT03775941||Cross-Sectional Lifespan Connectomics Study|
9827894|NCT02472353|Experimental|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
9729594|NCT03774862||Medullary carcinoma of colorectal cancers|
9729595|NCT03774862||non-medullary carcinomas of the colorectal cancers|
9729596|NCT03774784||ALECT2 Disease|
9729597|NCT03774264||Xiaflex group|"Patients will be evaluated in our urology clinic at baseline for possible inclusion in our study. All patients at baseline evaluation will be evaluated for duration of symptoms, relationship stability, IIEF and PDQ. All patients will obtain a penile Doppler ultrasound with the aid of a vasoactive substance by a specially trained technician. During this visit, plaque measurements will be taken: location of plaque, distance of plaque from the tip of the penis, degree of curvature measured by goniometer.~Ultrasound characteristics will be documented: Type (Type 1: The plaque appears as a thickening of the tunica albuginea without acoustic shadowing. Type 2: A moderately calcified plaque with a typical ultrasound shadow. Type 3: A severely calcified plaque with typical ultrasound shadowing) and Grade of calcification (grade 1 (<0.3 cm), grade 2 (>0.3 cm, <1.5 cm), grade 3 (>1.5 cm; or ≥ 2 plaques >1.0 cm). Sample data sheet attached as appendix 2."
9729598|NCT03772301||Group 1|At least 200 Jewish Holocaust survivors of the first generation living in Germany and Israel - an equal number in each country
9729599|NCT03772301||Group 2|The second generation, whose parents lived in Europe during the Second World War, now live in Germany (originating from Western and Eastern Europe) - at least 200 participants.
9729600|NCT03772301||Group 3|Third generation of Jewish Holocaust survivors who participated in the first phase, currently living in Germany and Israel - at least 200 participants including at least 100 subjects in each country. These are adults only. The research program does not include children and adolescents
9729601|NCT03771859||Participants who initiate adjuvant treatment with nivolumab|
9729602|NCT03770884||Rheumatoid arthritis|EULAR-ACR criteria Whatever the treatment and the disease activity
9729603|NCT03770884||Axial spondyloarthritis|ASAS criteria for axial disease Whatever the treatment and the disease activity
9729604|NCT03770884||digital osteoarthritis|According to ACR criteria Whatever the treatment and the disease activity
9729605|NCT03770832||Infants at Risk for Atypical Motor Development (high-risk)|
9729606|NCT03770832||Infants Expected to Have Typical Motor Development (low-risk)|
9729607|NCT03769220||inpatient rehabilitation ward|"The first 20 participants will be recruited from the inpatient rehabilitation ward at Robert-Bosch-Hospital (RBK). The treating medical doctor will inform potentially eligible participants about the possibility of being involved in this study. Should participants confirm their interest a research assistant will complete a detailed information session and obtain written informed consent prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
9729608|NCT03769220||outpatient rehabilitation clinic|"Further 20 participants will be recruited through the outpatient rehabilitation clinic at Robert-Bosch-Hospital (RBK). The treating doctor will again inform the potential participant about the study and invite them to participate. A research assistant will complete a detailed information session and written informed consent will be obtained prior enrolment.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
9729609|NCT03769220||community dwelling older adults|"Lastly 20 community dwelling older adults will be invited to participate. Recruitment will occur through advertisement at a locally run seniors fitness group, conducted every Thursday at RBK. Older adults who are interested in being involved will be invited to receive additional information about the study and the involved procedures before providing written informed consent and being enrolled.~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
9781135|NCT01141478|Active Comparator|Sorafenib|Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.
9781136|NCT01141491|Experimental|Arm A|Vaccine plus OPT-821
9781137|NCT01141491|Active Comparator|Arm B - OPT-821 immunologic adjuvant|Patients will be given 10 injections of OPT-821 alone as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
9781138|NCT01141569|Experimental|Treatment (RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9781139|NCT01141595|Experimental|Kuvan®|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
9781140|NCT01141608|Experimental|Vigorous Intensity High Dose Exercise|Usual Care Augmented with Vigorous Intensity High Dose Exercise
9781141|NCT01141608|Experimental|Health Education Intervention|Health Education Intervention
9781142|NCT01141647|Experimental|24-Month Supported Employment|Evidence-Based Supported Employment Vocational Rehabilitation or Other Vocational Services
9785304|NCT01248715|No Intervention|Standard of care|These patients will be treated with the current, standard care, including currently recommended antibiotics or antiviral therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP and ACIP antiviral use guidelines for hospitalized patients with confirmed of suspect influenza, per clinician discretion. In addition these patients with have a NP swab collected for influenza PCR testing and clinical information will be extracted from the medical record.
9785305|NCT01248728|Active Comparator|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
9785306|NCT01248728|Placebo Comparator|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
9785307|NCT01248741|Experimental|HDR prostate brachytherapy|An array of 17 gauge steel needles, 20 cm in length, is inserted under Ultrasound (US) guidance into the prostate and advanced to the base of the prostate. A template is used to maintain spacing and parallelism and the needles are individually locked into the template once positioned. A continuously acquired set of US images is obtained for treatment planning purposes. Each needle is connected to a Varisource afterloader and treatment is delivered using a 10 Curie Iridium-192 source. The needles are then removed.
9785308|NCT01248780|Experimental|Golimumab + methotrexate (MTX)|Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
9785309|NCT01248780|Experimental|Placebo + methotrexate (MTX)|Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
9785310|NCT01248793|Experimental|Placebo|
9785311|NCT01248793|Experimental|Golimumab|
9785312|NCT01248884|Experimental|GSK217744 Group 1|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation A vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
9785313|NCT01248884|Experimental|GSK217744 Group 2|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation B vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
9785314|NCT01248884|Active Comparator|Infanrix hexa Group|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
9785315|NCT01248936|Experimental|Overall Trial|Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor
9785316|NCT01248949|Experimental|MEDI3617 SINGLE AGENT TOTAL|Participants will receive MEDI3617 via intravenous (IV) infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
9729610|NCT03768752||Diastolic Dysfunction|Patients with pre-existing or new diastolic dysfunction.
9729611|NCT03768752||Normal Diastolic Function|Patients with normal diastolic function.
9729612|NCT03768180||Patient with infective endocarditis|All patients diagnosed with infective endocarditis after TAVR
9729613|NCT03767608||Patients with type 2 diabetes mellitus|Patients diagnosed with T2DM according to the ADA
9729614|NCT03767608||Lean healthy controls|Lean healthy controls
9729615|NCT03767465||PembroHIV|HIV-infected subjects with advanced melanoma or other oncological conditions in which the use of immunological checkpoint inhibitors is clinically indicated
9729616|NCT03767127||Appropriate transfusion policy|Patients transfused with high arterial-venous oxygen difference (≥3.7 ml/dl) or non-transfused with low arterial-venous oxygen difference (<3.7 ml/dl)
9729617|NCT03767127||Non-Appropriate transfusion policy|Patients transfused despite low arterial-venous oxygen difference or non-transfused with high arterial-venous oxygen difference
9729618|NCT03766620||Tube Fed Participants|Individuals with diabetes and malnutrition receiving tube feed as sole source nutrition.
9729619|NCT03766230||peribulbar anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using peribulbar anesthesia
9729620|NCT03766230||topical anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using topical anesthesia
9729621|NCT03766230||peribulbar anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using peribulbar anesthesia
9729622|NCT03766230||topical anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using topical anesthesia
9729623|NCT03766230||peribulbar anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using peribulbar anesthesia
9729624|NCT03766230||topical anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using topical anesthesia
9729625|NCT03766230||peribulbar anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using peribulbar anesthesia
9729626|NCT03766230||topical anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using topical anesthesia
9729627|NCT03766230||peribulbar anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using peribulbar anesthesia
9729628|NCT03766230||topical anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using topical anesthesia
9729629|NCT03764384||Hospital Monitoring Group - ALSFRS-R cohort|All patients will be first recruited to this cohort unless at their first visit the investigator deems them eligible for the Home Monitoring Device Group. At the initial screening visit, all patients recruited into the study will undergo routine assessments according to the existing MND protocol, and additionally complete the ALSFRS-R symptom-based assessment questionnaire by interview with the study researchers (with assistance from spouse, family member or carer if required). Patients will continue to complete the ALSFRS-R symptom-based questionnaire at each clinic attendance.
9729630|NCT03764384||Home Monitoring Cohort|"If eligible patients will use the N Tidal CTM, up to 3 times a day (morning, midday and evening) throughout the home monitoring period until the final outpatient clinic visit.~In addition subjects will complete a weekly diary symptom monitoring diary which asks them about their respiratory symptoms, GP attendances, respiratory infections. Patients routine standard of care assessments will also be documented according to the protocol as well as completing the ALSFRS-R at each visit."
9729631|NCT03763994||Control group 1|Never low back pain in the last 3 months
9729632|NCT03763994||Control group 2|occasionally (1-30days) low back pain in the last 3 months
9729633|NCT03763994||Low back pain group 3|frequently (31-60days) low back pain in the last 3 months
9729634|NCT03763994||Low back pain group 4|daily (61-90days) low back pain in the last 3 months
9729635|NCT03762941||Elderly patients acutely admitted|Elderly patients (aged ≥ 65 year) admitted to emergency departments at the Hospital of Southern Jutland or Odense University
9729636|NCT03761420||breast cancer postoperative|got surgery for breast cancer in St Olavs Hospital, Trondheim, during 2004-2013
9729637|NCT03761355||medical student of 6th Year|Students of medical faculty of 6th Year in Medical University of Bialystok, Poland.
9729638|NCT03761290||Pseudphypoparathyroidism type 1A (PHP1A)|Case
9729639|NCT03761290||Pseudopseudohypoparathyroidism (PPHP)|Case
9729640|NCT03761290||Controls|Matched control group
9729641|NCT03758092||SGA vs AGA infants|infants, born at term (37+0/41+3 week gestation), aged 24 months, with a birth weight <10th percentile or between 10th and 90th percentile for sex, gestational age, and birth order, according to Italian neonatal anthropometric charts
9729642|NCT03757065||Systemic Lupus Erythematosus|
9729643|NCT03757065||Sjogren's Syndrome|
9827895|NCT02472366|Other|laser|laser with or without prior history of intraocular corticosteroid therapy
9729644|NCT03757065||Multiple Sclerosis|
9729645|NCT03757065||Systemic Sclerosis|
9729646|NCT03757065||Crohn's Disease|
9729647|NCT03757065||Ulcerative Colitis|
9729648|NCT03757065||Inflammatory Myositis|
9729649|NCT03756909||adenoidectomy group|Operations of adenoidectomy
9729650|NCT03756909||adenotonsillectomy group|Operations of adenotonsillectomy
9729651|NCT03756402||Healthy Subjects|All subjects underwent protein loading test and IRRIV test on the same day. The renal resistive index (RRI) measurements were performed by one trained sonographer using a multi-frequency convex probe through a manual RRI calculations. The RRIs were measured on three interlobular arteries (superior, middle and inferior) in each kidney, and expressed as a mean value. RFR was measured using an oral protein loading test and was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Urinary creatinine and sCr were measured by the enzymatic method (IL testTM Instrumentation(R), Laboratory SpA, Milano, Italy) and by ILab650 (Instrumentation Laboratory, Werfen Group, Barcelona, Spain).
9781143|NCT01141660|Experimental|Endotracheal Tube|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
9781144|NCT01141660|Experimental|Laryngeal Mask Airway|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
9729652|NCT03756376||IRRIV and RFR|Enrolled patients will receive IRRIV test and RFR assessment. RFR will be evaluated through a protein loading test. (1.2 g of protein/Kg of body weight) performed with cooked beef. The RFR was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Concerning the IRRIV test, a weight of 10% of the patient's body weight is applied on the abdominal wall. RRIs is recorded in a middle interlobular artery, every minute for 10 minutes during the echo-renal stress test. The lowest RRI reached is taken as reference (stress RRI). The IRRIV is defined as the percentage difference between baseline RRI and stress RRI
9729653|NCT03755544||Asthma patients|"Male or female patients with diagnosed asthma who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
9729654|NCT03755544||COPD patients|"Male or female patients with diagnosed COPD who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
9729655|NCT03754088||Cystic fibrosis|Three cystic fibrosis patients who are homozygous for the p.Phe508del mutation.
9729656|NCT03754088||Healthy subjects|Three healthy subjects.
9729657|NCT03753828||patients de novo colonized by fungi|Patients in Cystic Fibrosis de novo colonized by fungi during their follow-up
9729658|NCT03753178||patients|70 participants presented with clinical and motor electrophysiological evidence of common peroneal neuropathy at the fibular neck
9982387|NCT05248529|Experimental|Intervention group|Within 12-24 hours before the surgery, the demonstrative education was given based on 'Hip Replacement Adaptation Booklet' and 'Knee Replacement Adaptation Booklet' to the patients in the intervention group.
9982388|NCT05248529|No Intervention|Control gorup|Routine preoperative preparation training was performed to the patients in the control group.
9982389|NCT05248373|Experimental|rAd26 single administration|
9982390|NCT05248373|Experimental|rAd5 single administration|
9982391|NCT05248373|Experimental|prime-boost regimen with rAd26 followed rAd5 administration|
9982392|NCT05248373|Placebo Comparator|placebo|
9982393|NCT05247658|Active Comparator|Therapeutic lens alone|
9982394|NCT05247658|Experimental|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|
9982395|NCT05247645||Rare diseases with predominantly skeletal involvement|The group comprises all patients affected rare diseases with predominantly skeletal involvement
9982396|NCT05247580||Hospital staff caregivers|Necker - Enfants Malades hospital' nurses, nurses' aides, residents and, doctors of medicine.
9982397|NCT05247060||Hypertensive Patients Hospitalized in Internal Medicine|Clinical data will be collected from all consecutive patients diagnosed with arterial hypertension hospitalized in Internal Medicine and able to assume the erect station
9729659|NCT03753178||controls|70 controls
9729660|NCT03752801||Script Review Parents/Caregivers|will have script reviewed and evaluated by parents/caregivers in groups of 5 up to 40 participants until 4/5 parents/caregivers demonstrate that script is understandable and acceptable.
9729661|NCT03752801||Video Review Parents/Caregivers|review and evaluation of the developed educational videos by parents/caregivers up to 20 parents who have not participated in the script review
9729662|NCT03752710||Acute primary angle closure|
9729663|NCT03752710||Acute secondary angle closure induced by LS|
9729664|NCT03752710||Cataract|
9729665|NCT03752710||Primary chronic angle closed glaucoma|
9982398|NCT05246852|Experimental|intervention group|
9982399|NCT05246852|No Intervention|control group|
9982400|NCT05246579||Patients with short cervix|Patients with a short cervix identified on transvaginal ultrasound >5mm and <30 mm
9982401|NCT05246579||Patients with a history of spontaneous preterm birth|Patients with a history of spontaneous preterm birth (<34 weeks)
9982402|NCT05246579||Control/Nulliparous|Nulliparous patients
9982403|NCT05246150||infants receiving nursing care|
9982404|NCT05245851|Experimental|Opportunistic screening for low BMD|Outpatients aged over 50 years undergoing x-ray of the thoracic spine, lumbar spine, chest, pelvis, hand or knee will have their x-rays screened for low BMD by the software-as-a-medical device. If low BMD is identified by the software, a radiologist reviewing the x-ray may choose to incorporate this as an incidental finding in their report to the referring physician.
9982405|NCT05245760|Experimental|All patient|All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.
9982406|NCT05245461||Anterior Cruciate Ligament Reconstruction|Patients who had remnant-preserving anterior cruciate ligament reconstruction
9729666|NCT03752450||ICU patients|All patients admitted to ICU >48 hours will be included. Eventually, a number of these patients will develop hypernatremia and form the cases. The patients who will not develop hypernatremia will be assigned as the controls.
9982407|NCT05245461||Healthy Group|People who had no knee surgery or injury
9982408|NCT05245214||Patients with disc herniation|Having only disc degeneration and not having any other neurological or orthopedic disease. Patients who had previous spinal surgery, patients with lumbar scoliosis, spondylolisthesis or structural defect in the sacrum were excluded from the study.
9982409|NCT05245214||Patient in control group|Patients without disc herniation, severe disc degeneration and spondylolisthesis were included in the control group.
9982410|NCT05245123||Families of rare diseased children|Clinical study participants are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Centre Mannheim due to the rare disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
10200075|NCT05154968|Experimental|Sequence 3 (CADB)|Participants will receive 1 ml SC injection of treatment C (lower pain refrigerated solution contains mannitol) followed by treatments A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), D (lower pain RT solution contains mannitol), and B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
9729667|NCT03752047||Suspicion of Sepsis|Patients who are admitted and are diagnosed with sepsis will be recruited for this investigation.
9729668|NCT03748927||1/ Cohort 1|Subjects with FL-HCC.
9729669|NCT03748901||Full analysis set|Patients with recurrent or metastatic RCC who have initiated first line treatment between 1 January 2010 and 31 December 2015, with representative FFPE of nephrectomy surgical specimen which are suitable for assessment of PD-L1 expression
9729670|NCT03747991||Control Infants|Infants ages 2 months to 12 months who are not on H2RA medication.
9729671|NCT03747991||Treated Infants|Infants ages 2 months to 12 months who are taking H2RA medication.
9781145|NCT01141725|Experimental|Treatment (combination chemotherapy)|Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9781146|NCT01141907|Experimental|Heart Failure Self Care Support|The goal of the Heart Failure Self Care Support Intervention (Navigator Program), delivered by a nurse and community health navigator team over 3 months post discharge from the index hospitalization, was to improve care transitions by providing patients with tools and support that promote knowledge and skills for HF self care as they transition from hospital to home. The multifaceted Navigator Intervention included the following intervention components: HF home automated telemonitoring support, medication and symptom self management, patient-centered record, HF care follow up, and activation of key supporter.
9781147|NCT01141907|Active Comparator|Usual Heart Failure Care|Usual care for HF patients included the following: 1) Referral to HF clinic if the patient has no usual source of HF outpatient care, 2) HF patient education by HF care coordinator (advanced practice nurse), and 3) HF self care guide. All participants were treated by their usual source of HF care in the usual manner.
9781148|NCT01142089|Placebo Comparator|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours)
9781149|NCT01142089|Experimental|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
9781150|NCT01142115|Experimental|Monza|nonCE marked intermittent catheter
9781151|NCT01142115|Active Comparator|control|SpeediCath coated catheter
9781152|NCT01142193|Experimental|USL255|
9781153|NCT01142193|Placebo Comparator|Placebo|
9781154|NCT01142232|Experimental|Melphalan with lenalidomide|Melphalan will be given on Day -2 and Day -1. Lenalidomide will be given from Day -7 to Day +2.
9781155|NCT01142297|Other|dental implant|standard SLA surface and chemically modified surface
9781156|NCT01142310|Active Comparator|Lamotrigine|Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
9781157|NCT01142310|Placebo Comparator|Placebo|Placebo administered the same as the Lamotrigine just described.
9781158|NCT01142323|Experimental|Fenofibrate|fenofibrate 160 mg po daily
9781159|NCT01142336|Experimental|Simvastatin|Simvastatin 40mg qHS for 1 year
9781160|NCT01142336|Placebo Comparator|Placebo|Placebo 1 tablet qHS for 1 year
9781161|NCT01142466|Experimental|Rebif (3x44 mcg) Group|
9781162|NCT01142466|No Intervention|No treatment Group|
10205058|NCT04178993|Active Comparator|Active Comparator: Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
9781163|NCT01142661|Experimental|Eribulin mesylate|
9781164|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate, 2.5 mg|Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
9781165|NCT01142726|Active Comparator|Methotrexate, 2.5 mg, plus abatacept placebo|Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
9781166|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate placebo|Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
9781167|NCT01142791|Other|ExAblate treatment|
9781168|NCT01142908|Experimental|Arm 1|The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
9781169|NCT01142908|No Intervention|Arm 2|The education control group - these participants will receive educational material about CVD reduction.
9781170|NCT01142947|Other|beclomethasone dipropionate (BD)|Patients who meet eligibility criteria will be treated with 6 weeks of beclomethasone dipropionate to assess change in pulmonary function and asthma control. These change will be used as phenotypes in a genetic association study. There is no placebo group.
9781171|NCT01143038|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
9781172|NCT01143051|Active Comparator|Treatment C|Active comparator arm utilizing marketed Primatene Mist with CFC propellant at the labeled dose.
9781173|NCT01143051|Experimental|Treatment 1|T1 is HFA propelled epinephrine inhalation aerosol 125 mcg/inhalation
9781174|NCT01143051|Experimental|Treatment 2|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation
9982411|NCT05245123||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
9982412|NCT05244278|Experimental|Artificial intelligence Medtronic-GI genius for real-time detection|A standard colonoscopy will be performed according to the standard of routine care. The AI system will capture video of the procedure in real time, and provide additional information on the detection of polyps and classification. All optically diagnosed polyps will be removed and sent to the hospital pathology laboratory for histopathological evaluation according to institutional standards.
9729672|NCT03746990||observational|Total of 2015 Libyan school children aged 7 to 16 years, from urban (Tobruk) and rural (Kufra) areas were included in the main study. The children were of almost equal number of both sexes from each age group (table-I) .The total of 1935 children were examined for enamel fluorosis
9729673|NCT03746262||Patients - Stage I treated with surgery|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations, and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
9729674|NCT03746262||Patients - Stage I treated with radiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
9729675|NCT03746262||Patients - Stage II treated with surgery & chemotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
9729676|NCT03746262||Patients - Stage III treated with chemoradiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
9729677|NCT03744585||Cohort 1|Subjects who received at least one dose of cabozantinib during the Authorization for Use (ATU) period (12/09/2016 to 09/12/2016) for the treatment of advanced Renal Cell Carcinoma (RCC).
9729678|NCT03744585||Cohort 2|Subjects who received at least one dose of cabozantinib during the first six months after the ATU period (10/12/2016 to 16/02/2018).
9729679|NCT03744507||Uterine Fibroids|Premenopausal women with uterine fibroids confirmed by an ultrasound.
9729680|NCT03744507||Endometriosis|Premenopausal women with endometriosis diagnosed or confirmed by surgical or direct visualization, or histopathology within 10 years of the Screening visit.
9729681|NCT03743909||patients with aberrant CD markers|by flowcytometry from hospital information system
9729682|NCT03743909||patients without aberrant CD markers|by flowcytometry from hospital information system
9729683|NCT03743493||Prevalence numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017)
9729684|NCT03743493||Prevalence denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017)
9729685|NCT03743493||Guideline A numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
9729686|NCT03743493||Guideline A denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
9729687|NCT03743493||Guideline B numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO inpatient cancer diagnosis OR cancer procedure in the year prior to the index event
9729688|NCT03743493||Guideline B denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO in-patient cancer diagnosis OR cancer procedure in the year prior to the index event
9729689|NCT03743116||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
9729690|NCT03743116||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
9729691|NCT03742024||Children and adolescents|Children and adolescents between the ages of 4 and 17 years old (inclusive)
9781175|NCT01143077|Experimental|Lurasidone Open-Label Arm A|
9781176|NCT01143077|Experimental|Lurasidone Open-Label Arm B|
9781177|NCT01143077|Experimental|Lurasidone Open-Label Arm C|
9781178|NCT01143090|Experimental|Open Label|Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
9729692|NCT03741868||Stage IV non-small cell lung cancer|60 - stage IV non-small cell lung cancer patients will be recruited through the Wake Forest Baptist Comprehensive Cancer Center to complete the quantitative portion of the study. We will use purposive sampling to assure representation of patients at different stages in immunotherapy (i.e., initiating treatment, anticipating scan results, after onset of immune-related side effects).12-15 of the 60 patients who complete the survey and who express interest in providing feedback on programs and participating in future research will be recruited to complete the qualitative portion of the study
9729693|NCT03741829||Samples from transbronchial Biopsy|Samples from participants with SCLC.
9729694|NCT03741738||Non-segmental vitiligo :|"A. Patients aged 19 years or older who were clinically diagnosed with non-segmented leukopenia at Severance Hospital.~B. Patients (36 patients) who experienced worsening symptoms within the last 3 months and 10 patients whose symptoms were stable within 3 months C. Patients with vitiligo lesion at least 3% of the skin"
9729695|NCT03741738||Segmental VT or Focal VT|A. The investigators evaluated patients who were diagnosed as segmental vitiligo clinically on Severance hospital and who were 19 years old or older.
9729696|NCT03741738||Normal control|A. Subjects aged 19 or older who do not have not only vitiligo but also other skin and systemic diseases
9729697|NCT03741491||Birkebeiner with AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) with AF.
9729698|NCT03741491||Birkebeiner without AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) without AF
10200076|NCT05154968|Experimental|Sequence 4 (DCBA)|Participants will receive 1 ml SC injection of treatment D (lower pain RT solution contains mannitol) followed by treatments C (lower pain refrigerated solution contains mannitol), B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), and A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
9729699|NCT03741491||Control with AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier with AF
9729700|NCT03741491||Control without AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier without AF
9729701|NCT03741322||Infants ages 3-24 months with respiratory infections|
9729702|NCT03740789||HBeAg positive|HBeAg positive：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
10200077|NCT05154266|Experimental|Mindfulness Programme|Participants randomized to the mindfulness programme were invited to complete a twelve-week programme called 'Taking it Further'.
9729703|NCT03740789||HBeAg negative|HBeAg negative：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
9729704|NCT03740230||Hepatitis C|Participants with Hepatitis C Genotypes 1 to 6 receiving Maviret (glecaprevir/pibrentasvir) for 8, 12, or 16 weeks.
9729705|NCT03739918||patients with adrenal masses|patients with adrenal mass managed by adrenalectomy
9729706|NCT03738631||Under 35 years|
9729707|NCT03738631||Over 44 years|
9729708|NCT03738085||Previous abdominal surgery group|Previous abdominal surgery group underwent total laparoscopic hysterectomy
9729709|NCT03738085||No previous abdominal surgery group|No Previous abdominal surgery group underwent total laparoscopic hysterectomy
9729710|NCT03738085||Obese patients underwent TAH|BMI≥30 kg/m2
9729711|NCT03738085||Obese patients underwent TLH|BMI≥30 kg/m2
9729712|NCT03737760||Older Adults|Community-dwelling men and women age 70+ years
9729713|NCT03737760||Younger Adults|Healthy young adults, age 20-40 years for baseline assessments only
9729714|NCT03737006||1-(HLHS) effected pregnancies|Consent,blood draw, nose swab, stool collection,questionnaire and review of medical records.
9729715|NCT03737006||2-Other Congenital Heart Defect (OCHD)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
9729716|NCT03737006||3-Healthy Controls (UC)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
10200078|NCT05154266|No Intervention|Waitlist Control|Participants randomized to the waitlist control were asked to carry on as usual and were offered the Taking it Further course at a later time. No data was collected when the waitlist control group took part in the TiF programme.
9729717|NCT03736486||Type 2 Diabetes|Male and female adults of Hispanic and/or Latino heritage with an established diagnosis of Type 2 diabetes.
9729718|NCT03736408||1. Group without Pain - TMJ disorders symptoms|1. The symptoms concerning joints were: the type of sound symptoms (clicking or popping), their frequency and the phase of the movement of lowering and lifting the jaw during which they occurred, occurrence of the tension type headache or back pain. Hypertension of the mastication muscles is frequently connected with a parafunction activity like grinding or clenching the teeth, which cause abnormal pressure on the joints
9729719|NCT03736408||2. Group with Pain and symptoms TMJ disorder|The pain form of the disease is manifested by spontaneous pain in the preaural region, accompanied by pain or tenderness of the mastication muscle. Pain that appears during palpation examination of temporomandibular joints is frequently not related to inflammation of the soft tissue around the temporomandibular joints, as it is claimed by several authors of the paper. The cause of this problem is a long-term overload of soft tissue causally associated with excessive muscle tension, that sometimes even persists for years
9729720|NCT03735719||STEMI patients|Patients with first STEMI treated with primary PCI are recruited in this study.
9729721|NCT03735719||Control group|The control group will consist of patients with risk factors for cardiovascular diseases, but without history of coronary artery disease or heart failure.
9729722|NCT03734783||Patients|HBsAg positive more than 6 months
9729723|NCT03734783||health control|
9729724|NCT03734250||Group Sugammadex HD|Sugammadex used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30ng/ml
9729725|NCT03734250||Group neostigmine HD|Neostigmine used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30 ng/ml
9729726|NCT03734250||Group Sugammadex LD|Sugammadex used as neuromuscular reverse agent with Vitamin D status under 30 ng/ml
9729727|NCT03734250||Group Neostigmine LD|Neostigmine used as neuromuscular reverse agent with Vitamin D status under 30ng/ml
9729728|NCT03731702||General Individuals|Any adult working at the NCI who has not used antibiotics in the past 3 months.
9729729|NCT03731338||Reassured and discharged|patients who are reassured and discharged after first attendance
9729730|NCT03731338||Further diagnostic testing|Patients who went on to have further diagnostic testing
9729731|NCT03731299||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
9729732|NCT03731299||Healthy adults|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
9729733|NCT03730844||Critically ill children|Children admitted to the PICU.
9729734|NCT03730844||Healthy controls|Healthy controls, not admitted to the PICU, without pre-existing medical conditions.
9729735|NCT03730428||pneumonitis group|Patients who developed drug-related pneumonitis after treated with everolims
9729736|NCT03730428||non-pneumonitis group|Patients who didn't develop drug-related pneumonitis after treated with everolims
9729737|NCT03730220||Induction of labour|
9729738|NCT03728517||Subjects who undergo gynecologic surgery|Subjects who will undergo gynecologic surgery via vaginally, laparoscopic , or robotic who require observation or inpatient stay overnight. This group will receive pain medication in the hospital and will also be discharged home with pain medication.
9781179|NCT01143142|Experimental|Tailoring|Individuals assigned to the experimental group will receive a two-page brochure tailored based on their responses to the survey.
9781180|NCT01143142|Active Comparator|Untailored information|Individuals assigned to the control group will receive the CDC vaccine information sheet that is standardly provided.
9781181|NCT01143181|Experimental|Brincidofovir|Subjects received either a weight-based or a fixed-dose of oral brincidofovir (BCV) once weekly or twice weekly for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer.
9781182|NCT01143207|Experimental|Medroxyprogesterone acetate|Single injection of Medroxyprogesterone acetate (hormonal contraceptive)
9781183|NCT01143259|Placebo Comparator|300 mg Polyethylene|
9781184|NCT01143259|Active Comparator|Alvimopan|
9781185|NCT01143272|Active Comparator|Saccharomyces boulardii|Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
9781186|NCT01143272|Placebo Comparator|Microcristallin cellulose|Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
9781187|NCT01143324||MAST™ procedure|
9781188|NCT01143337|Experimental|1|dose1
9781189|NCT01143337|Placebo Comparator|2|Placebo
9781190|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 5 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
9781191|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 2 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
9781192|NCT01143402|Experimental|Arm I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are unable to be treated with temozolomide may be treated with dacarbazine IV every 3 weeks (with approval from the Principal Investigator). Patients who experience disease progression may crossover to arm II.
9781193|NCT01143402|Experimental|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9781194|NCT01143610|Experimental|Newly forming bone|Miller class I or II deep recessions treated by the newly forming bone technique.
9781195|NCT01143610|Active Comparator|Subepithelial connective tissue graft|Miller class I or II deep recessions treated by subepithelial connective tissue graft.
9781196|NCT01143636|Sham Comparator|Active tDCS - pelvic pain patients|ACTIVE tDCS: Subjects will receive a total of 10 consecutive sessions of active tDCS over a two-week period (administered Monday - Friday). During each session, the anode electrode will be placed over the primary motor cortex of the predominantly painful side.
9781197|NCT01143636|Experimental|Sham tDCS - pelvic pain patients|SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
9781198|NCT01143636|Experimental|Active tDCS - healthy|The healthy controls will undergo one day of treatment with active tDCS. All participants will receive both active and sham stimulation in a randomized order.
9781199|NCT01143636|Experimental|Sham tDCS - healthy|The healthy controls will undergo one day of treatment with sham tDCS. All participants will receive both active and sham stimulation in a randomized order.
9781200|NCT01143649|Experimental|active tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday).
9781201|NCT01143649|Experimental|active tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT)
9827896|NCT02472366|Other|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
10200079|NCT05145322|Experimental|Group 1|Group 1: Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins
9729739|NCT03727997||AKI patients stage 3|
9729740|NCT03727672||Tension type headache patients|30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
9729741|NCT03727672||Migraine patients|30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
9729742|NCT03727672||age matched controls|30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives
9729743|NCT03727516||patients undergone elbow surgery|Patients undergone elbow surgery at routine follow up at 2 or 6 months
9729744|NCT03726385||Group I|Group I: The control group. Participants in this group received only NDT based upper extremity rehabilitation. Number of the participants were 19.
9729745|NCT03726385||Group II|Group II: The study group. Participants in this group received NDT based upper extremity rehabilitation + Cogniboard® Light Trainer training. Number of the participants were 19.
9729746|NCT03725826||Acute Myocardial Infarction|Patients (aged 18 and above) with either ST segment elevation or Non-ST segment elevation MI by biomarkers of cardiac injury and symptoms. Cut-off for CPK >2 times and troponin >3 times the upper limit for the lab. Only Patients who undergo coronary revascularization (PCI, CABG), New York Heart Association (NYHA) functional class I-III, and with LVEF < 45% will be enrolled.
9729747|NCT03725800||Aspirin|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using aspirin for mono-antiplatelet therapy.
9729748|NCT03725800||Clopidogrel|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using clopidogrel for mono-antiplatelet therapy.
9729749|NCT03725800||ASIDE|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using ASIDE for mono-antiplatelet therapy.
9729750|NCT03725657||Pediatric|Pediatric Type1 Diabetes Mellitus patients
9729751|NCT03725475||Stage III|stage III Non-small Cell Lung Cancer (NSCLC )
9729752|NCT03725319||Epinephrin injection|Diluted Epinephrin (1:100) in small amounts from 1 to 5 ml is injected into apex of the papilla to stop post sphincterotomy-bleeding
9729753|NCT03725319||Plastic stent insertion|A plastic stent (diameter: 8-11,5F and length of 50 -100mm) is inserted into the common bile duct to stop post sphincterotomy-bleeding
9729754|NCT03724435||Pancreatic Cancer Participants|No intervention will be administered. Assessments are performed as standard of care.
9729755|NCT05142683|Active Comparator|Treatment as Usual|Study involvement for all sites will begin in the TAU condition, which is the typical treatment at the participating community mental health agency. A range of treatments observed in our previous survey of sites will be on offer in these agencies, depending on the preferences and context of the local agency. In typical TAU in community mental health agencies, depressive symptoms and function are not systematically monitored via standardized rating scales. TAU may or may not include referral to psychotherapy and/or parent support. There are no prompts to prescribe specific medications, and/or internal and external referrals to treatment and other services, guided by local service standards.
9729756|NCT05142683|Experimental|CARIBOU-2|"After the CARIBOU-1 pilot study, the Principal Investigator revised the ICP to render it more applicable to community settings as well as offer a second-line psychotherapy (Brief Psychosocial Intervention) for youth who do not engage with, or respond to, cognitive-behavioural therapy. The revised version is called the CARIBOU-2 intervention. The current iteration of the pathway involves a series of steps: (1) structured assessment, including safety assessment; (2) education on depression, sleep and exercise; (3) psychotherapy (with 1st line Cognitive Behavioural Therapy, 2nd line Brief Psychosocial Intervention); (4) a caregiver structured support group; (5) medication options (1st line fluoxetine, 2nd line sertraline); (6) team reviews every four weeks, (meeting with the youth and involved clinicians to review measures and discuss treatment changes); and, (7) discharge and follow-up planning."
9729757|NCT05142670|Experimental|task-oriented training individualized by the gravity perception|The training in the experimental group emphasizes the active use of intact or relatively preserved verticality perception to facilitate reestablishing vertical position of the participants. Additionally, a target such as an interesting person/object or an object with interesting music is used to direct the subject to accomplish a task in order to temporally desist from pathological pushing behavior.
9729758|NCT05142670|Active Comparator|visual feedback treatment|The training in the control group emphasizes the active use of visual feedback to facilitate reestablishing vertical position of the participants.
9729759|NCT05142579|Experimental|ENDOTRACHEAL TUBE HOLDER|Endotracheal tube holder was used for endotracheal tube detection of patients in this group.
9729760|NCT05142579|Active Comparator|BANDAGE|The bandage was used for endotracheal tube detection of patients in this group.
9729761|NCT05142488|Experimental|8 week interval|Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 8 week interval between the first two doses.
9729762|NCT05142488|Active Comparator|12 week interval|Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 12 week interval between the first two doses.
9729763|NCT05142475|Experimental|Tumor Infiltrating Lymphocytes (TIL)|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced breast cancer after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.
10200080|NCT05145322|Experimental|Group 2|Lesion-specific cavity design with wide bevel throughout the cavity margins
10200081|NCT05130099|Experimental|Interdisciplinary complex intervention|
10200082|NCT05130099|No Intervention|Usual care|Six months after the intervention period (T3), the participants randomized to usual care will be offered a modified version of the intervention in line with their personally expressed needs.
10200083|NCT05128253||NASH GROUP|Recruited (n=22) patients with non-alcoholic steatohepatitis.
10200084|NCT05128253||NAFL GROUP|Recruited (n=22) patients with non-alcoholic fatty liver.
9729764|NCT05142462||EUROSCUP Fixe|120 patients who received EUROSCUP Fixe
9729765|NCT05142423|Experimental|AK109+AK104|AK104: 10mg/kg (d1, q3w); AK109: 10mg/kg or 15mg/kg(d1, q3w)
10200085|NCT05118412|Experimental|Lucerne protein concentrate|Lucerne protein concentrate powder presented in the form of a shake.
9729766|NCT05142410||Plasma from women with normal pregnancies|Plasma collected from women with normal pregnancies will be analyzed by mass spectrometry
9729767|NCT05142410||Plasma from women with placenta-mediated complications|Plasma collected from women who developed preeclampsia during pregnancy will be analyzed by mass spectrometry
9729768|NCT05142397||Treated women|HPV positive，pathology result indicate cervical intraepithelial neoplasia
9729769|NCT05142397||Healthy controls|HPV negative, normal cytology
9729770|NCT05142384|Experimental|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 3 (10-15 min calls occurring post-randomization, and 3- and 6-weeks later."
9729771|NCT05142384|Active Comparator|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies.
9729772|NCT05142332|Experimental|Intervention Arm|Covid vaccine educational intervention
9729773|NCT05142332|No Intervention|Non-interventional Arm|Usual care
9729774|NCT05142319|Active Comparator|Homologous mRNA booster vaccine|BNT162b2 + BNT162b2 + BNT162b2 or mRNA-1273 + mRNA-1273 + mRNA-1273
9729775|NCT05142319|Experimental|Heterologous mRNA booster vaccine|BNT162b2 + BNT162b2 + mRNA-1273 or mRNA-1273 + mRNA-1273 + BNT162b2
9729776|NCT05142319|Experimental|Non-mRNA booster vaccine A|BNT162b2 + BNT162b2 + vaccine A or mRNA-1273 + mRNA-1273 + vaccine A
9729777|NCT05142319|Experimental|Non-mRNA booster vaccine B|BNT162b2 + BNT162b2 + vaccine B or mRNA-1273 + mRNA-1273 + vaccine B
9729778|NCT05142319|Experimental|Non-mRNA booster vaccine C|BNT162b2 + BNT162b2 + vaccine C or mRNA-1273 + mRNA-1273 + vaccine C
9729779|NCT05142215|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO).
9729780|NCT05142215|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo procedure for chronic total occlusion (CTO).
9982413|NCT05244265|Experimental|Mindfulness-based stress reduction (MBSR)|The 9 session MBSR program following the manual (Kabat-Zinn, 1982).
10200086|NCT05118412|Experimental|Whey protein concentrate|Whey protein concentrate powder presented in the form of a shake.
10200087|NCT05118256|No Intervention|No intervention - standard of care|A group of patients with PMF will be treated per standard of care on site
10200088|NCT05118256|Experimental|Experimental - Pirfenidone plus standard of care|A group of patients with PMF will be treated with pirfenidone plus standard of care on site
10200089|NCT05117229|Experimental|MetaWear Sensor on radiograph|subjects being considered for surgical orthopedic surgery will have a MetaWear sensor added to their standard of care lateral sit to stand radiograph
9729781|NCT05142202|Experimental|Doubly Accelerated Partial Breast Irradiation after Breast-Conserving Surgery|"All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.~The control group consists of standard adjuvant APBI with multicatheter interstitial brachytherapy technique 8 x 4 Gy in 5 consecutive days or 7 x 4,3 Gy in 4 consecutive days (6 hours minimum gap between the fractions)."
9729782|NCT05142137|Experimental|Novel alpha glucan_dose1|Total of 180 g of the novel alpha glucan per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water)
9729783|NCT05142137|Experimental|Novel alpha glucan_dose2|Total of 80 g of the novel alpha glucan + 100 g glucose syrup per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water)
9729784|NCT05142137|Active Comparator|glucose syrup|Total of 180 g glucose syrup per day, consumed in 4 individual doses (i.e. 4x45 g, with each dose dissolved in 300 ml of water).
9729785|NCT05142085|Experimental|Efficacy of nano-PSO on motor and non-motors symptoms of Parkinson´s disease.|"It is the clinical trial itself where more than 140 subjects will be included:~84 under active treatment and 56 under placebo"
9729786|NCT05142085|Experimental|Effect of nano-PSO on molecular images of PD patients|In this group, the study implicates performing a multitracer PET-scan before treatment, and at 6 months, to 25 subjects in the clinical trial : 15 under active treatment and 10 in the placebo group.
9729787|NCT05142007|Experimental|Hypnosis|"The first treatment arm (targeted suggestion) consist of suggestions about enhancing working memory functions through the instantiation of preinjury working memory ability in the present using age regression, visualizations of neuroplasticity in the present, and posthypnotic suggestions about continued improvement. The overarching theme of the suggestions is that thinking itself will become effortless and reliable, leading to reduced fatigue, better memory, and the absence of information overload."
9729788|NCT05142007|Active Comparator|Mindfulness-based stress reduction|"The second treatment arm (non-targeted suggestion or MBSR) contains no explicit mentioning of brain injury or working memory-related abilities and thus serves to isolate the 'targetedness' of suggestion as well as factoring out other influences from placebo, retest effects, etc."
9729789|NCT05142007|No Intervention|Control group|The (passive) control group receives no contact over and beyond testing.
9729790|NCT05141994|Experimental|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: about once every 4 weeks, taking 3 times after continuous use, effective observation to Week 48.
9729791|NCT05141994|Experimental|4.0mg of BAT5906|16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4.0mg/eye/time, 50μl; duration of administration: once every 4 weeks, 3 times after continuous administration , The effectiveness was observed to the 48th week.
9729792|NCT05141968|Experimental|Vitamin D supplements group|Group A: is the interventional group that supplemented with vitamin D tablets contain 2000 IU once time daily with a meal, for 3 months of intervention.
9729793|NCT05141968|No Intervention|Control group|Group B: is the control group, that did not receive any supplements.
9729794|NCT05141877|Experimental|Propofol Group|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
9729795|NCT05141877|Experimental|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
9729796|NCT05141864|Active Comparator|Acmella oleracea gel group|Formulation with Acmella oleracea will be used during the digital rectal examination.
9729797|NCT05141864|Active Comparator|Lidocaina gel group|The lidocaine gel will be used during the digital rectal examination.
9729798|NCT05141864|Placebo Comparator|Ultrasound gel group|The ultrasound gel will be used during the digital rectal examination.
9729799|NCT05141851|Active Comparator|Implants with 0,7mm threads|Placement of Implants with 0,7mm threads
9729800|NCT05141851|Active Comparator|Implants with 0,3mm threads|Placement of Implants with 0,3mm threads
9729801|NCT05141825|Experimental|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
9729802|NCT05141812||ACLR group|ACLR participants would be 7 months post surgery
9729803|NCT05141812||healthy control group|Healthy uninjured participants who are actively engaged in gaelic football or hurling.
9729804|NCT05141786|Experimental|MRG002|MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).
9729805|NCT05141773|Experimental|Computed adenoma detection system (CADe) and Endocuff|CADe system can detect in the screen suspicion areas of adenomatous polyps. This is an additional help for the endoscopist for the detection of lesions. Endocuff increases the colonic surface examinated
9729806|NCT05141773|Active Comparator|Control group (Endocuff)|Endocuff increases the colonic surface examinated
9729807|NCT05141734||BPPV (benign paroxysmal positional vertigo)|VOR gains were measured by vHIT in both the study group and the control group. The SPV values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
9729808|NCT05141734||Control|VOR gains were measured by vHIT in both the study group and the control group. The SPV values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
9729809|NCT05141656||Single arm|Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent.
9729810|NCT05141643||Participants with pancreatic ductal adenocarcinoma (PDAC)|Participants will have histologically-confirmed pancreatic ductal adenocarcinoma (PDAC)
9729811|NCT05141630|Experimental|group with axillary sentinel or targeted lymph node biopsy alone|The patients with stage II to III breast cancer with biopsy-confirmed nodal metastases who convert to cN0 following NAC is recruited. Eligible patients are treated with axillary sentinel or targeted lymph node biopsy alone. Post-surgery radiation therapy will be administered at the discretion of the radiologist and the nodal radiotherapy must be conducted in patients with low nodal disease.
9982414|NCT05244265|Active Comparator|Treatment as usual (TAU)|Participants take part in their treatment as usual in outpatient habilitation and other services.
9729812|NCT05141617|Experimental|Endoscopic treatment group|Patients in the endoscopic treatment group receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices.
9729813|NCT05141617|Experimental|TIPS group|Patients in the TIPS group receive transjugular intrahepatic portosystem stent-shunt.
9729814|NCT05141591||ENT surgical patients|ASA physical status I-IV adult subjects, ≥ 18 years of age, scheduled for elective ENT surgeries in the Department of ENT at the Medical University of Vienna. On the day before elective ENT- surgery patients will be asked to complete self-administered questionnaires (STOA, APAIS, PCS) concerning their emotional and anxiety state. These questionnaires will be re-tested on the day of surgery and opioid consumption during the stay in the recovery room documented.
9729815|NCT05141565||The Kunshan Elderly Health Study (KEHS)|Community-based observational cohort.
9729816|NCT05141526|Experimental|Non-restrictive satiating intervention|The non-restrictive satiating intervention will include guidelines and recipes to prepare highly satiating meals that will be low in energy density and glycemic index and high in protein, polyunsaturated fats, vitamins and minerals (e.g. calcium), and certain constituents of spices (e.g. capsaicin).
9729817|NCT05141526|Experimental|Conventional restrictive intervention + non-restrictive satiating intervention|Conventional restrictive intervention consisting of a -500 kcal/d calorie deficit (P1) followed by a non-restrictive satiating intervention (P2)
9729818|NCT05141526|Placebo Comparator|Minimal healthy guidelines|Considering recommendations from the latest Canadian Obesity Guidelines, the control group will receive a minimal intervention based on the Canada's Food Guide for Healthy Eating
9729819|NCT05141487||Conditional SNM|This group receives conditional sacral neuromodulation, applied intermittently based on sensor data describing bladder activity.
9729820|NCT05141487||Continuous SNM|This group receives continuous SNM, applied constantly throughout the bladder filling cycle.
9982415|NCT05244148|Experimental|Group A|IP1 - Stérimar BLOCKED NOSE Baby nasal spray + standard of care
10200090|NCT05114733|Experimental|InVEST|4 month treatment condition
10200091|NCT05114733|No Intervention|delayed invest|participants in delayed invest wait four months and are reassessed before taking part in the intervention
9982416|NCT05244148|Experimental|Group B|IP2 - Stérimar Stop & Protect Cold Baby + standard of care
9982417|NCT05244148|Other|Group C|Standard of Care alone
10200092|NCT05108506|Experimental|No strict need to void following surgery before discharge|Participants randomized to this arm will have no strict need to void following surgery before they are discharged.
10200093|NCT05108506|Placebo Comparator|Strict need to void following surgery before discharge|Participants randomized to this arm will have a strict need to void following surgery before they are discharged.
10200094|NCT05106335|Experimental|Treatment Arm A|camrelizumab + famitinib
10200095|NCT05106335|Experimental|Treatment Arm C|famitinib
10200096|NCT05106335|Active Comparator|Treatment Arm B|docetaxel
10200097|NCT05102279|Experimental|Early administration of high-phosphorus diet test group|Group A: 1500 mg phosphorus diet was given on day 1-2, 2500 mg phosphorus diet on day 3-5, 1500 mg phosphorus diet on day 6-7 and 500 mg phosphorus diet on day 8-10
9664948|NCT05243966||Myriad™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
9664949|NCT05243342|Experimental|Dose escalation|Participants will receive escalating doses of XmAb24306 with daratumumab up to the maximum tolerated dose (MTD)
9664950|NCT05243342|Experimental|Dose expansion|Participants will receive XmAb24306 with daratumumab at the recommended phase 2 dose (RP2D)
9664951|NCT05243186|Experimental|MPH walking|The participants will be instructed to work while taking Methylphenidate and walking on a treadmill workstation
9664952|NCT05243186|Placebo Comparator|MPH sitting|The participants will be instructed to work while taking Methylphenidate and sitting at a desk
9664953|NCT05243186|Placebo Comparator|No MPH walking|The participants will be instructed to work without taking Methylphenidate while walking on a treadmill workstation
9664954|NCT05243186|Placebo Comparator|No MPH sitting|The participants will be instructed to work without taking Methylphenidate while sitting at a desk
9664955|NCT05242380|Experimental|Kettlebell Exercise|8-week, 3-day/week supervised training will be applied to the participants in this group. After the initial assessment, patients in this group will receive a one-session education on the pathophysiology of PAH, the benefits of physical activity, and energy conservation techniques during activities of daily living. Pharmacological treatment of patients in this group will be continued.
9664956|NCT05242380|No Intervention|Control|Any intervention will not be performed. After the initial assessment, patients in this group will receive a one-session education on the pathophysiology of PAH, the benefits of physical activity, and energy conservation techniques during activities of daily living. Pharmacological treatment of patients in this group will be continued.
9664957|NCT05241834|Experimental|Phase 1A: LOXO-260 Dose Escalation|LOXO-260 administered orally
9664958|NCT05241834|Experimental|Phase 1B: LOXO-260 Dose Expansion|LOXO-260 administered orally
9664959|NCT05241353|Active Comparator|Standard Self-Monitoring Group|Standard behavioral treatment with a standard (full-frequency) self-monitoring prescription.
9664960|NCT05241353|Experimental|Reduced-Frequency Group|Standard behavioral treatment with a reduced-frequency self-monitoring prescription.
9664961|NCT05239468|Active Comparator|Double Blind (DB) Phase Treatment A: BZF 100 mg Immediate Release (IR) tablet|Each subject will take one OCA placebo tablet, one BZF 100 mg IR tablet and one BZF placebo tablet daily.
9664962|NCT05239468|Active Comparator|Double Blind (DB) Phase Treatment B: BZF 400 mg IR tablet|Each subject will take one OCA placebo tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily
9664963|NCT05239468|Experimental|Double Blind (DB) Phase Treatment C: OCA 5 mg + BZF 100 mg IR|Each subject will take one OCA 5 mg tablet, one BZF 100 mg IR tablet and one BZF placebo tablet, daily.
9664964|NCT05239468|Experimental|Double Blind (DB) Phase Treatment D: OCA 5 mg + BZF 400 mg IR|Each subject will take one OCA 5 mg tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
9664965|NCT05239351|Experimental|Jalucomplex 1|Sixteen patients will be administered Jalucomplex® 1 for the treatment of minor-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
9664966|NCT05239351|Experimental|Jalucomplex 2|Sixteen patients will be administered Jalucomplex® 2 for the treatment of medium-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
9664967|NCT05239351|Experimental|Jalucomplex 3|Sixteen patients will be administered Jalucomplex® 3 for the treatment of major-sized facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects)
9664968|NCT05239169|Experimental|A: Cape+Durva+Treme|Capecitabine + Durvalumab + Tremelimumab
9664969|NCT05239169|Active Comparator|B: Durva+Treme|Durvalumab + Tremelimumab
9664970|NCT05239156|Experimental|Janesse 15|Sixteen patients will be administered Janesse® 15 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
9664971|NCT05239156|Experimental|Janesse 20|Sixteen patients will be administered Janesse® 20 (Cross-linked Hyaluronic Acid) for the treatment of medium-sized facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
9664972|NCT05239156|Experimental|Janesse 25|Sixteen patients will be administered Janesse® 25 (Cross-linked Hyaluronic Acid) for the treatment of major facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
9664973|NCT05239091|Experimental|Dextrose prolotherapy|:%15 dextrose prolotherapy injection will be applied to trigger point
9664974|NCT05239091|Active Comparator|Lidocaine|%2 lidocaine injection will be applied to trigger point
9664975|NCT05237908||TSPACE 3D|the 3D printed cage (TSPACE 3D) is defined as investigational product
9664976|NCT05237908||TSPACE XP|the titanium coated PEEK cage (TSPACE XP) is defined as reference product.
9664977|NCT05237726|Active Comparator|Unfractionated Heparin (UFH) 5000 U q8 hours|Severely burn injuries (BSA≥20%) will receive Unfractionated Heparin (UFH) 5000 U q8 hours as pharmacological VTE prophylaxis
9729821|NCT05141474|Experimental|NEXTGEN-TIL|Subjects will receive a therapy based on Tumor-infiltrating Lymphocyte (NEXTGEN-TIL product) preceded by a preparative non-myeloablative lymphodepleting (NMA-DL) regimen and followed by IL-2 infusion. Patients will be followed-up for 2 years, assessed at weeks 2, 3, 4, 6, 9, 12, 18, 24, 30, 36 (9 months), and then at 1 year, 1,5 and 2 years.
9729822|NCT05141396|Experimental|Intervention - Telehealth- enabled support plus usual audit and feedback for SAT/SBT adherence|Usual audit and feedback + telehealth-enabled support
9729823|NCT05141396|Active Comparator|Control - Usual audit/feedback for SAT/SBT adherence only|Usual audit and feedback
9729824|NCT05141383|Other|Patients with prostate cancer|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level> 4 ng / ml
9729825|NCT05141383|Other|Patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level> 4 ng / ml
9729826|NCT05141383|Other|Healthy donors|Male from 50 to 70 years old with a PSA level <4 ng / mL
9729827|NCT05141279||1|Stable
9729828|NCT05141279||2|Partial response
9729829|NCT05141279||3|Moderate response
9729830|NCT05141279||4|Excellent response
9729831|NCT05141279||5|Complete response
9729832|NCT05141214|Active Comparator|Dietary Consult with Virtual Reality (intervention)|Those in the VR group will receive the same educational dietary review by the registered dietician, and additionally participate in a VR experience through an application called Chaos Café. In Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
9729833|NCT05141214|No Intervention|Dietary Consult without Virtual Reality (SOC)|Those in the SOC group will have the typical appointment, which includes a review of healthy diet choices with a registered dietitian and follow up according to clinic's SOC.
9729834|NCT05141162|Experimental|case group|In the first stage, an information form including socio-demographic characteristics prepared within the framework of the literature and State-Trait Anxiety Inventory will be applied to mothers before surgery. Later, the experimental group will be knitted by the researcher during the surgical operation. The necessary materials (knitting needle and thread) for the knitting attempt will be given to the participants in the experimental group by the researcher. A neutral color, white, will be used as the knitting yarn color. Knitting will start 15 minutes after the child enters the operation and will be knitted for 30-40 minutes on average. At the end of the surgery, the State-Trait Anxiety Inventory scale will be applied again to evaluate the anxiety levels of the participants in the experimental and control groups. The vital signs of the mothers will be measured at the beginning of the operation and close to the end of the operation.
9729835|NCT05141162|No Intervention|control group|An information form including socio-demographic characteristics prepared within the framework of the preoperative literature and State-Trait Anxiety Inventory will be applied to mothers. No attempt will be made to this group. At the end of the surgery, the State Trait Anxiety Inventory scale will be applied again to evaluate the anxiety levels of the participants in the experimental and control groups. The vital signs of the mothers will be measured at the beginning of the operation and near the end of the operation.
9729836|NCT05141136|Experimental|Ultrasound probe sagittal group|A thoracic 2 paravertebra block is performed with the ultrasound probe placed sagittal and the needle in plane with respect to the probe.
9729837|NCT05141136|Active Comparator|Ultrasound probe transverse group|A thoracic 2 paravertebra block is performed with the ultrasound probe placed transverse and the needle in plane with respect to the probe.
9729838|NCT05141097|Experimental|Treatment|Being cared for by an Integrative Medicine provider
9729839|NCT05141097|No Intervention|Control|Being cared for by conventional medicine provider
9729840|NCT05141071|Experimental|Ivabradine|In the study group, Ivabradine(I) group; patients will receive an enteral Ivabradine (dissolved in distilled water) 5mg twice daily (every 12 hours) via a naso-gastric tube.
9729841|NCT05141071|Placebo Comparator|Placebo|the control group, Placebo (P) group; patients will receive 50 ml of saline twice daily also via a naso-gastric tube.
9729842|NCT05141058|Experimental|Prevention of SARS-CoV-2 infection in immunocompromised adult patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and <80 years) HSCT recipients (Arm A)
9729843|NCT05141058|Experimental|Prevention of SARS-CoV-2 infection in immunocompromised pediatric patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for pediatric (≥12 years of age and <18 years) HSCT recipients (Arm B).
9729844|NCT05141045|Experimental|omega-3 PUFA supplement|omega-3 PUFA supplement, 3.0 grams per day
10200098|NCT05102279|Active Comparator|Early administration of low-phosphorus diet test group|Group B: 1500 mg phosphorus diet was given on day 1-2, 500 mg phosphorus diet on day 3-5, 1500 mg phosphorus diet on day 6-7 and 3500 mg phosphorus diet on day 8-10
10200099|NCT05096845|Experimental|V-01 COVID-19 Vaccine|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
10200100|NCT05096845|Placebo Comparator|Placebo control|Intramuscular injection into the lateral deltoid of the upper arm Two doses, one each on Day 0 and 21 (+7 days), respectively.
10200101|NCT05096832|Experimental|V-01 COVID-19 Vaccine|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
10200102|NCT05096832|Placebo Comparator|Placebo control|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
10200103|NCT05092568||covid pregnancy|Pregnant patients with positive polymerase chain reaction assay COVID-19 test results, who were followed up and treated in the pandemic service of Başakşehir Çam and Sakura City Hospital.
9729845|NCT05141045|Placebo Comparator|placebo|safflower oil, 3.0 grams per day
9729846|NCT05141032||Research Subject|Only one group will be made which will contain all subjects recruited into research study.
9729847|NCT05140954|Experimental|Perfect Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC once daily (7 doses per week).
9729848|NCT05140954|Experimental|Moderate Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC 4 times per week
9729849|NCT05140954|Experimental|Poor Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC twice per week
9729850|NCT05140928|Active Comparator|Dadiah Pudding|The mother received 1 cup or 100 g dadiah pudding containing 75-gram dadiah which provide ±260 kcal energy, 6.12g protein, 23.31g fat, 6.49g carbohydrate, and 6.1x 109 CFU/ml lactic acid bacteria.
9729851|NCT05140928|Placebo Comparator|Pudding without dadiah|The mother received 1 cup or 100 g pudding without dadiah containing ±75 kcal energy, 0.3g protein, 0.45 g fat, and 16.2g carbohydrate.
9729852|NCT05140915|Experimental|Intervention|Students in school randomized to the intervention will receive: (1) peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit; (2) peer coaching, facilitated by texting; and (3) gamification, designed to motivate participation.
9729853|NCT05140915|Active Comparator|Control|Students in schools randomized to the control condition will be provided written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
9729854|NCT05140876|Experimental|START mHealth Intervention|Participants randomized to receive the START mHealth intervention will have access to the mHealth application for 6 months following randomization.
9729855|NCT05140876|No Intervention|Website referrals|Participants in this condition will receive no intervention and will have access to a website with resources related to substance use disorder treatment and HIV treatment.
9729856|NCT05140863|Experimental|HSK16149 20mg BID|HSK16149 20mg, orally twice a day for 12 weeks
9729857|NCT05140863|Experimental|HSK16149 40mg BID|HSK16149 40mg, orally twice a day for 12 weeks
9729858|NCT05140863|Placebo Comparator|Placebo BID|placebo, orally twice a day for 12 weeks
9729859|NCT05139199|Experimental|Auricular Point Acupressure|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
9729860|NCT05139199|No Intervention|usual-care group|These participants follows the standard Chemotherapy follow-up consisting of counseling by nurses and doctors.
9729861|NCT05135117|No Intervention|Control|Passive rest - no intervention provided
9729862|NCT05135117|Active Comparator|Ice towel cooling|About 6-12 cooling periods of ice towel lasting between 5-20 minutes will be done and equally distributed throughout the respective trials. Towels dipped in ice water will be placed on subjects necks during this time.
9729863|NCT05135117|Experimental|NeuroRescue Neck Cooling Collar|About 6-12 cooling periods of neck cooling with the NeuroRescue collar lasting between 5-20 minutes will be done and equally distributed throughout the respective trials.
9729864|NCT05129969||Ovarian cancer|"Female patients with high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):~with newly diagnosed FIGO stage IIb-IV OC who are starting systemic treatment, independent of the treatment intention (adjuvant/curative or palliative) or~with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting their systemic treatment for first recurrent/relapsed disease."
9729865|NCT05129969||Endometrial cancer|Female patients with locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.
9729866|NCT05129059|Experimental|Logotherapy|Participants will receive individual logotherapy counseling by the investigator for 8 visits in 4 weeks.
9729867|NCT05129059|No Intervention|Control|Participants will receive routine care.
9729868|NCT05128812|Placebo Comparator|CONTROL GROUP|Nutraceutical placebo intake group
9729869|NCT05128812|Experimental|PLX400mg GROUP|Intake of natural herbal dietary supplement composed of lemon verbena extract (Lippia citriodora).
9729870|NCT05128799||3WP|Patients who had 3WP as part of their end-of-life care
9729871|NCT05128799||Usual Care|Patients who did not have 3WP as part of their end-of-life care
9729872|NCT05127694|Experimental|Vestibular Rehabilitation Group|Investigators applied vestibular rehabilitation in this group. This group was consist of 15 participants. After the evaluation investigators gave the patients repetitive vestibular exercises for 4 weeks and in the first week investigators performed canalith repositioning procedure depending on the affected canal. If affected posterior semicircular canal investigators applied Epley maneuver. If affected horizontal semicircular canal also applied barbeque roll maneuver.
9729873|NCT05127694|No Intervention|Pharmacological Control Group|Investigators did not apply any treatment in this group. Participant in this group just used medications doctor-prescribed.
9729874|NCT05127018|Active Comparator|the average-dose method|With the average-dose method, the dose was individualized according to the severity of anterior gingival exposure pretreatment. For mild gingival smile (3-5 mm), a single-site injection of 2 U botulinum toxin type A [total, 4 U] at both the right and left levator labii superioris alaeque nasi muscles) was administered. For moderate (5-7 mm) and severe (≥7 mm) gingival smile, 3 U and 5 U of botulinum toxin type A, respectively, were injected per side (total, 6 U and 10U, respectively). The injection points were located at bilateral levator labii superioris alaeque nasi muscles and at the Yonsei point26, with half doses administered at each point.
9729875|NCT05127018|Experimental|the higher-dose method|With this method, patients were administered botulinum toxin type A after 8 months when the effect of the previous injection had vanished. The injection dose (U) per side was set as the absolute value of the preoperative anterior gingival exposure (mm). For example, if the preoperative anterior gingival exposure was 5mm, then the patient would be injected with 5 U of botulinum toxin per side (total, 10U). The injection points were located at bilateral levator labii superioris alaeque nasi muscles and at the Yonsei point26, with half doses administered at each point.
9729876|NCT05126095||Trial cohort|"CBCT: before radiotherapy and once a week during radiotherapy~Body weight: before radiotherapy and once a week during radiotherapy~The Patient-Generated Subjective Global Assessment (PG-SGA): before radiotherapy, 1st week, 3rd week and the last week during radiotherapy."
9729877|NCT05125133|Experimental|ITENs + ITWS|Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m² are coated in ITENs and ITWS nets that will be installed to cover opened eaves and windows. This was manufactured by Moon Netting FZCO, United Arab Emirates.
9729878|NCT05125133|No Intervention|Negative arm|The houses allocated NOT to receive ITENs and ITWS.
9729879|NCT05124561|Experimental|Experimental group|6500 participants, Ad5-nCoV-IH, single dose, nebulized inhalation
9729880|NCT05124561|Placebo Comparator|Placebo group|6500 participants, placebo, single dose, nebulized inhalation
9729881|NCT05122793|Experimental|Prevention Group|In addition to the usual treatment (SoC), the prevention group receives an innovative prevention offer tailored to the severity of the heart failure (telemedical connection via health app as well as additional therapy recommendations).
9729882|NCT05122793|No Intervention|Control Group|The control group receives the current standard treatment according to the valid guidelines (Standard of Care = SoC).
9729883|NCT05121727|Active Comparator|Erector Spinae Plane Block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
9729884|NCT05121727|Active Comparator|Deep and Superficial Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 10 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anteror area to superficial serratus anteror area above the serratus anterior muscle and will be injected 2 ml normal saline for hydrodissection. Finally 10 ml of 0.25% bupivacaine will be injected for superficial serratus anetrior block into the interfacial area.
9729885|NCT05120479|Experimental|Experimental arm|"The intervention will be the application of a Kinesiotape (KT) strip on the anterior side of the forearm.~The day of the intervention will proceed as follows:~Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~Skin cleansing with 96% alcohol.~Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension)."
9729886|NCT05120479|Sham Comparator|Control arm|"The intervention will be the application of a tape strip on the anterior side of the forearm. Sham tape appears to be kinesiotape but is an inelastic tape.~The day of the intervention will proceed as follows:~Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~Skin cleansing with 96% alcohol.~Sham tape: exactly the same procedure is followed as experimental arm, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain)."
9729887|NCT05117281|Active Comparator|spinal group|Plain, isobaric levobupivacaine(0.25%) 0.25 mg/kg
9729888|NCT05117281|Active Comparator|caudal group|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
9729889|NCT05116735|Experimental|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
9729890|NCT05114460|Placebo Comparator|Naloxone 0 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana
9729891|NCT05114460|Active Comparator|Naloxone 0 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana
9729892|NCT05114460|Active Comparator|Naloxone 0 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
9729893|NCT05114460|Active Comparator|Naloxone 4 mg + MJ 0.0 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
9729894|NCT05114460|Experimental|Naloxone 4 mg + MJ 12.5 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
9729895|NCT05114460|Experimental|Naloxone 4 mg + MJ 25 mg|Intranasal naloxone in combination with vaped marijuana (MJ)
9729896|NCT05108025|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
9729897|NCT05108025|Experimental|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
9729898|NCT05094219||Observation group|Patients with a confirmed diagnosis of Parkinson's disease will be followed up for 12 months from the date of enrollment.
9781202|NCT01143649|Experimental|tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one session of treatment with active tACS (in which the order in which they receive either sham or active transcranial alternating current stimulation (tACS) stimulation will be randomized).
9827897|NCT02472405|Active Comparator|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
9781203|NCT01143649|Sham Comparator|sham tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday). For the sham session, tDCS is turned off after 30seconds.
9781204|NCT01143649|Sham Comparator|sham tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT). The sham stimulation consists of 30 seconds of stimulation at the beginning of the 40 min of treatment.
9729899|NCT05089175||Women at high risk for preeclampsia|Using FIGO recommended preeclampsia screening model for the first-trimester which combined maternal risk factors, mean arterial pressure, placental growth factor, uterine artery pulsatility index to evaluate pregnant's risk for preeclampsia. Risk value≥1/100 is defined as screened high risk.
9729900|NCT05089175||Women at low risk for preeclampsia|Using FIGO recommended preeclampsia screening model for the first-trimester which combined maternal risk factors, mean arterial pressure, placental growth factor, uterine artery pulsatility index to evaluate pregnant's risk for preeclampsia. Risk value<1/100 is defined as screened low risk.
9729901|NCT05078619|Experimental|TAVI only|Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation without preceding PCI of significant coronary artery disease
9729902|NCT05078619|No Intervention|TAVI with preceding PCI|Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation with preceding PCI of significant coronary artery disease which is currently the standard of care.
9729903|NCT05075993|Experimental|Regimen A: LVGN3616 + LVGN6051 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
9729904|NCT05075993|Experimental|Regimen B: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
9729905|NCT05075993|Experimental|Regimen C: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
9729906|NCT05075993|Experimental|Regimen D: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|given in combination with other drugs to patients with cancers that are advanced, relapsed (have come back), refractory (have not responded to treatment), or metastatic (have spread).
9729907|NCT05075889|Experimental|Benign Bone patients|Patients with Benign Bone tumors requiring intralesional operative management will be administered immunofluorescent indocyanine green 24 hours prior to surgery, imaging of perfused tissues will be performed at the time of tumor removal.
9729908|NCT05071326|Experimental|HealthyLifetime Group|This project is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making.
9729909|NCT05070767|Experimental|Neurolens|Our proprietary contoured prism lens design, commercially known as neurolens.
9729910|NCT05070767|Placebo Comparator|Control lens|A simple refractive error correction lens
9729911|NCT05066997|Experimental|Active treatment arm: OCS-01|"In Stage 1: Active treatment arm: OCS-01 - dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.~. In Stage 2, subjects will receive the dosing regimen from Stage 1 for OCS-01 for 52 weeks."
9729912|NCT05066997|Placebo Comparator|Vehicle placebo arm|"In stage 1: Vehicle: dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.~In Stage 2, subjects will receive the matched dosing regimen for Vehicle for 52 weeks."
9729913|NCT05064449|Experimental|Part 1: Soticlestat 300 mg + Itraconazole 200 mg|Soticlestat 300 milligram (mg), tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by itraconazole 200 mg solution, orally, once daily from Day 1 up to Day 11, further followed by soticlestat 300 mg tablet, orally along with itraconazole 200 mg solution, orally on the morning of Day in Period 2.
9729914|NCT05064449|Experimental|Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by single dose of mefenamic acid 500 mg capsule (first dose only), orally on the morning of Day 1 and 250 mg subsequent doses at every six hours up to Day 7 in Period 2, further followed by soticlestat 300 mg tablet, orally, followed by mefenamic acid 250 mg capsule, orally in morning of Day 2 in Period 2.
9729915|NCT05060978|Active Comparator|Watch your Weight During the Holidays Program|
9729916|NCT05060978|Active Comparator|Relative 5:2 Fasting|
9729917|NCT05060978|Placebo Comparator|Control Group|
9729918|NCT05060562||Post COVID 19 symptoms Positive|The presence of persistent COVID-related symptoms after being cured.
9729919|NCT05060562||Post COVID 19 symptoms Negative|No persistent COVID-related symptoms after cured
9729920|NCT05060380|Experimental|Exercise training|The exercise training group will receive progressive muscle resistive exercise, 10 sets of exercises for 2 times per week for a total of 6 months.
9729921|NCT05060380|No Intervention|Control|The control group will be asked to maintain their normal lifestyle and will be advised to continue their standard care of treatment.
9729922|NCT05046639|Experimental|Treatment group 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
9729923|NCT05046639|Placebo Comparator|Sham preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
9729924|NCT05045066|Experimental|Treatment (cholecalciferol)|Patients with low vitamin D3 levels receive cholecalciferol PO daily for 8 weeks in the absence of unacceptable toxicity.
9729925|NCT05040763|Experimental|COVID-19 Swab Collection|All participants will receive standard of care COVID-19 testing in addition to buccal swab COVID-19 testing
9729926|NCT05037708|Experimental|Group 1|Group 1 receives treatment A for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B was applied to group 1.
9781205|NCT01143649|Sham Comparator|sham tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one day of treatment with sham tACS. All participants received active and sham stimulation in a randomized order.
9781206|NCT01143688|Active Comparator|albuterol inhaler|albuterol
9781207|NCT01143688|Placebo Comparator|placebo inhaler|placebo
9781208|NCT01143688|Placebo Comparator|placebo acupuncture|placebo
9729927|NCT05037708|Active Comparator|Group 2|Group 2 receives treatment B for 4 weeks. Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A was applied to group 2 .
9729928|NCT05033639|Experimental|Treatment Group|Other than the Standard Management of preterm infant, treatment group A infants will receive 6 mg tablet dissolved in 5 ml breastmilk via oral gastric tube administered once a day at 10 pm.
9729929|NCT05033639|Placebo Comparator|Control Group|Human breast milk 5ml would be used as the placebo in this study. It would be indistinguishable from the treatment group as this will also be the diluent used.
9729930|NCT05030350|Experimental|PH94B 3.2 micrograms|100 microliter nasal spray to each nostril up to four times a day as needed for acute anxiety
9729931|NCT05018455|Experimental|Fall prevention intervention program conducted through telehealth|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. Each participant will practice from home, using a zoom system. The duration of each training will be one hour, the frequency of training will be twice a week for three months.
9729932|NCT05018455|Active Comparator|Similar fall prevention intervention program conducted through face to face group training|The training program is based on the principles of the Otago program, designed specifically to prevent falls. It consists set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan. The training will be delivered to a group of 10 participants. The training sessions will be delivered at the local community center, twice a week for one hour for three months.
9729933|NCT05017493|Experimental|Treatment arm|Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.
9729934|NCT05017493|No Intervention|Control arm|Patients in the Control arm received the standard of care for Covid19.
9729935|NCT05014854|Other|Intervention|"Finger and tip pressures are assessed in two phases (A/B). Baseline measurements (A) are collected in the 1st and 2nd therapy session after inclusion. First, data is collected via SEMS (from 2nd grade) or via a sheet with standard forms (1st grade), followed by the recording of a standard sentence (from SEMS) or a standard form at the end of the session. The 2nd session is started and ended with the writing of the chosen standard set. Phase-A-measurements are recorded without feedback.~From the 3rd therapy session on SensoGrip is used with activated feedback (B). At the end of each session, the same standard set used in Phase A is written twice - once with and once without feedback. This order changes each time to minimize possible bias due to habitation to writing with SensoGrip. Data is recorded in both forms. Children can take SensoGrip home from the 4th session on and use it in daily life.~In the last session, SEMS or the standard forms are re-executed as initially applied."
9729936|NCT05011396|Experimental|PH94B|3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time
9729937|NCT05011396|Experimental|Placebo|Placebo intranasal spray (100 microliters to each nostril) one time
9729938|NCT04999982|Experimental|Intervention group- PRE-CARE|Participants will receive the 1:1 PRE-CARE social needs navigation intervention with specific content and delivery strategy which was developed based on 1) quantitative analyses of the association between unmet social needs and ADHD symptoms in a large-scale nationally representative sample of children age 3-5, and 2) in-depth qualitative interviews with parents/guardians of preschoolers with inattention and/or hyperactivity symptoms to identify mechanisms by which unmet social needs exacerbate ADHD symptoms and functioning.
9729939|NCT04999982|Active Comparator|Control group- Care as Usual|Families randomly assigned to the control condition will continue to receive care as usual, which includes screening for social needs annually at well-child visits as recommended by the American Academy of Pediatrics (AAP), followed by provision of information as needed by the family. Families will also be offered the opportunity to make research assessments available to their primary care physician for best continuity of care.
9729940|NCT04992650|Experimental|Breast reconstruction with fat grafting|fat grafting
9729941|NCT04992650|No Intervention|breast reconstruction without fat grafting|No Fat grafting
9729942|NCT04970355|Experimental|Erenumab|Double-Blind Treatment Phase: Participants receive erenumab 280 mg subcutaneous (SC) injections (loading dose, week 0) followed by erenumab 140 mg s.c. in week 4.
9729943|NCT04970355|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Participants receive placebo subcutaneous (SC) injections in week 0 and week 4.
9729944|NCT04963283|Experimental|Cabozantinib 40 mg orally daily in combination with nivolumab 480 mg IV every 28 days.|"Cabozantinib is supplied as 20-mg tablets and will be administered orally at a dose of 40 mg/day.~Nivolumab is supplied in 100 mg/Vial (10 mg/mL) vials and will be administered IV at a dose of 480 mg every 28 days."
9729945|NCT04956159|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) twice daily for two weeks (20 sessions). The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
9729946|NCT04956159|Sham Comparator|Sham iTBS rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse twice daily for two weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.
9729947|NCT04956016|Active Comparator|classic rTMS treatment|Arm A: classic rTMS treatment (use of the 8-shaped coil) and standard therapy
9729948|NCT04956016|Active Comparator|treatment with deep rTMS|Arm B: treatment with deep rTMS (use of the H1-shaped coil (helmet)) and standard therapies
9729949|NCT04941781|Experimental|PIPE-307|Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of [11C] PIPE- 307.
9729950|NCT04938726|Experimental|Ketone Monoester|The ketone used is from KetoneAid and is commercially available as KE4 and will be consumed at 30 mL twice daily (15 g / dose)
9729951|NCT04938726|Placebo Comparator|Placebo|A placebo is being manufactured by KetoneAid to match the taste and other characteristics of the ketone supplement for blinding purposes
9729952|NCT04934358|Experimental|Physical activity program and motivational intervention|Physical activity program agreed with the patient / family and according to functional status (based on the 6-minute walk test) and motivational intervention. In addition to the care provided in usual care, a progressive physical exercise program based on basal functional capacity is prescribed. The exercise will be developed at home.
9729953|NCT04934358|Active Comparator|Treatment as usual|Multidisciplinary rehabilitation provided by professionals in the hospital and primary care settings, according to the individual needs of patients at different times of their recovery and the accessibility and availability of services in the different care settings.
9729954|NCT04926948|Experimental|Treatment (SBRT, immunotherapy)|Patients undergo 3-5 daily fractions of SBRT in the absence of disease progression or unacceptable toxicity. Patients also receive immunotherapy at the discretion of the treating medical oncologist.
9729955|NCT04924907||Dysbiosis microbiota|microbiota with proinflammatory pattern or dysbiosis
10200104|NCT05087251|Experimental|Intervention: Five Psycho-educational Sessions|Approximately 6 weeks after the patient's cancer treatment is complete, participants in the intervention arm will proceed to receive up to 5 study sessions (approximately weekly, ~50 minutes each) with a trained interventionist focused on psychoeducational topics. This arm was designed to enhance patient skills to address key concerns during the transition from treatment to surveillance, using a cognitive-behavioral approach. Sessions will be based on an intervention manual.
9729956|NCT04924907||Normal microbiota|microbiota with antiinflammatory pattern or normal
9729957|NCT04924179|Experimental|Tislelizumab plus Fruquintinib and SBRT|
9729958|NCT04917146||Caregivers (CG)|Caregivers of patients with systemic Scleroderma
9729959|NCT04914312|Experimental|Maqui berry extract and omega-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
9729960|NCT04914312|Placebo Comparator|Control|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
9729961|NCT04912921|Experimental|palmitoylethanolamide|Levagen
9729962|NCT04912921|Placebo Comparator|Placebo|microcrystalline cellulose
9729963|NCT04911075|Experimental|85% TCA Group|"Participants are subject who will undergo an elective total hysterectomy procedure for indications of gynecological organ abnormalities, whether benign, pre-cancerous, or malignant other than cervical pathology.~The 85 percent TCA solution will be applied to participants cervical tissue 24 hours before surgery."
9729964|NCT04906369||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, 2 weeks after the start of treatment, and at the beginning of each new treatment cycle.
9729965|NCT04899973|Experimental|Experimental, LEAD IT! Programming|Participants in the Experimental / LEAD IT! arm will take part in LEAD IT! programming for 18 weeks. The programming will occur twice per week, for a total of 36 sessions.
9729966|NCT04899973|No Intervention|Control, Standard Care / Programming|Participants in the Control arm will receive standard care / programming.
9729967|NCT04887935|Experimental|Dapagliflozin|"Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy~Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy."
9729968|NCT04874714|Experimental|MM09-MG01(30.000-30.000)|30,000 AU/mL of MM09 and 30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
10200105|NCT05087251|Experimental|Enhanced Usual Care: One Psycho-educational Session|At approximately 6 weeks after treatment completion (as defined by our eligibility criteria), control patients will attend one study session (~50 minutes) with a study clinician. This session is designed to control for patient access and connection to psychosocial resources as recommended in recent work.
9729969|NCT04874714|Experimental|MG01(30.000)|30,000 AU/mL of MG01 of subcutaneous immunotherapy once a month for 11 months
9729970|NCT04874714|Experimental|MM09(30.000)|30,000 AU/mL of MM09 of subcutaneous immunotherapy once a month for 11 months
9729971|NCT04874714|Placebo Comparator|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
9729972|NCT04872660|Experimental|GSATP group|Gushen Antai Pill (GSATP, 6g* 9 bags, Beijing boran Pharmaceutical Inc.) was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
9729973|NCT04872660|Placebo Comparator|Placebo group|Placebo pill is made up of a certain amount of starch and glucose, and is shaped like GSATP according to the National Drug Standards of the State Food and Drug Administration of China. Placebo pill was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
9729974|NCT04870216||Medical student|Medical student aged more than 18, presenting menstrual cycles, and agreeing to participate in the study.
9729975|NCT04870138|Experimental|Mixed FA7527/FA1090|Bacterial inoculum containing a mixture of equivalent numbers of the isogenic LptA mutant and wild-type (WT) strain administered once to the anterior urethra. N= up to 25
9729976|NCT04870138|Experimental|Mutant FA7527|Bacterial inoculum containing only the isogenic LptA mutant N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
9729977|NCT04870138|Experimental|Wild-type FA1090|Bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
10200106|NCT05082857|Active Comparator|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others. The study team will collect baseline data during the first home visit and complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
10200107|NCT05082857|Experimental|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking. Young moms will participate in Group Connections for peer interactions and support. After completing the six-week course, teens will begin receiving once a month home visits, ongoing Group Connections, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to other community agencies and resources, as listed above. The study team will collect baseline data prior to the beginning of the virtual What You Do Matters program and will complete monthly questionnaires during each month the mother is enrolled. An outcome assessment and participation in a focus group will be administered the last month of the study.
10200108|NCT05082376|Experimental|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter^2) of ChapStick Lip Moisturizer Original will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
10200109|NCT05082376|No Intervention|Control Arm|No treatment will be applied to the assigned control site.
10200110|NCT05065697||TAVR arm|Symptomatic severe aortic stenosis undergoing transfemoral TAVR of any devices
10200111|NCT05065697||SAVR arm|Symptomatic severe aortic stenosis undergoing isolated bioprosthetic surgical aortic valve replacement
9729978|NCT04863209|Experimental|Upper cervical manipulation group|The patient will be in the supine position. The cephalic hand will make contact with one side of the patient's skull, leaving the sternocleidomastoid muscle between the third and fourth fingers. The caudal hand will make global contact with the patient's skull on the opposite side. The therapist should place his torso on the patient's head, leaving the two forearms aligned with the axis of the patient's spine, as this technique is applied to the axis of the odontoid process of the ax. With neutral flexion-extension the therapist will place the rotation parameter to the opposite side (70-80 degrees) and a small contralateral inclination. Then it will search for the driving barrier with a small axial traction movement. When the driving barrier is found, the thrust should be applied in a helical direction, increasing rotation and traction. It will be applied bilaterally.
9729979|NCT04863209|Experimental|Sphenopalatine ganglion group|The patient will be supine on the bench and the therapist with gloves will sit next to the patient contralateral to the manipulated sphenopalatine ganglion (SPG). One of the therapist's hands will be placed flat in contact with the apex of the patient's head to stabilize it. The patient will be instructed to open his mouth and deviate the mandible laterally to the same side of the ganglion to be treated. The therapist will then apply pressure to the SPG with the fifth finger of your other hand in the patient's mouth, moving up along the alveolar process of the maxilla teeth to reach the pterygoid process. The therapist will keep the patient's head elevated until the lateral pterygoid muscle relaxes. Then, the pressure will be applied into the pterygopalatine fossa. The therapist will then apply gentle pressure on the SPG with the pulp of the fifth finger until tissue relaxation. He will then release the contralateral SPG in the same way.
9729980|NCT04863209|No Intervention|Control Group|The patient will lie down on the bench for 10 minutes.
9729981|NCT04859491|Active Comparator|Carbohydrate|Carbohydrate in the amount of 1.2 g/kg of body weight (bw). Gatorade®, Chicago, IL, USA.
9729982|NCT04859491|Active Comparator|Carbohydrate-Protein|Carbohydrate in the amount of 0.8 g/kg bw (Gatorade®, Chicago, IL, USA) plus protein in the amount of 0.4 g/kg bw (biPro Elite, Agropur Inc., Appleton, WI, USA).
9729983|NCT04859491|Placebo Comparator|Placebo|Flavored water (G Zero, Gatorade®, Chicago, IL, USA).
9729984|NCT04841486||"with history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy with history of spontaneous termination of pregnancy
9729985|NCT04841486||"without history of spontaneous termination of pregnancy group"|pregnant women in the first trimester of pregnancy without history of spontaneous termination of pregnancy
9729986|NCT04825743|Experimental|RUC-4 Dose 1 (0.110 mg/kg)|Subjects will receive a single subcutaneous injection containing RUC-4 Dose 1 (0.110 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
9729987|NCT04825743|Experimental|RUC-4 Dose 2 (0.130 mg/kg)|Subjects will receive a single subcutaneous injection containing RUC-4 Dose 2 (0.130 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
9729988|NCT04825743|Placebo Comparator|Placebo|Subjects will receive a single subcutaneous injection containing Placebo in the ambulance after diagnosis of STEMI and before hospital arrival
9729989|NCT04794517|Experimental|IMP|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
9729990|NCT04794517|Placebo Comparator|Placebo|Placebo, one tablet/die will be administered orally for six-weeks.
9729991|NCT04793633|Experimental|LINFU™ to increase sensitivity of pancreatic juice cytology|LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.
9729992|NCT04789616|Experimental|Maraviroc (Celsentri)|Maraviroc (Celsentri) will be administered to this group. Participants will be administered a dose of 300mg to be taken twice per day for the duration of the exercise intervention (8 weeks).
10200112|NCT05060965|Experimental|Cessation intervention|"All participants will receive nicotine replacement therapy and a referral to both Maryland Quitline and Johns Hopkins Tobacco Treatment Clinic for continued cessation care.~Nicotine replacement therapy: Nicoderm patches, gum, lozenges~Low nicotine dependence: Lozenge (2 mg) or Gum (2 mg) or Patch (7 mg)~Moderate nicotine dependence: Patch (14 mg) and Lozenge (2 mg) or Gum (2 mg)~High nicotine dependence: Patch (21 mg) and Lozenge (4 mg) or Gum (4 mg)~Regardless of the level of nicotine addiction and subsequent dose of nicotine replacement therapy (NRT), participants of this trials are described as recipients of NRT products."
10200113|NCT05060887|Experimental|OVX836 - 180µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180μg dose on Day 1.
9729993|NCT04789616|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. Participants will be administered the placebo identical to the 300mg maraviroc tablet for the duration of the exercise intervention (8 weeks)."
9729994|NCT04785794|Experimental|M2SR dose, 50-64 years of age|Intranasal M2SR vaccine followed by standard, licensed IIV
9729995|NCT04785794|Placebo Comparator|Placebo dose, 50-64 years of age|Intranasal physiological saline followed by standard, licensed IIV
9729996|NCT04785794|Experimental|M2SR dose, 65-85 years of age|Intranasal M2SR vaccine followed by licensed IIV recommended for people 65 years and older
9729997|NCT04785794|Placebo Comparator|Placebo dose, 65-85 years of age|Intranasal physiological saline followed by licensed IIV recommended for people 65 years and older
9729998|NCT04783155|Experimental|12-weeks pulmonary rehabilitation training plus inspiratory muscle training|To assess maximum inspiratory pressure, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home.
9729999|NCT04783155|Placebo Comparator|12-weeks pulmonary rehabilitation plus placebo (inactive) inspiratory muscle|To assess maximum inspiratory pressure with placebo, you will be asked to breathe through a device called POWERBreathe Plus®. This device is commercially available and will be provided to you by the study. You will be asked to use this device twice per day, 5 days per week, for 12 weeks. Each session will require you to breathe into the device 30 times. You can use the device at home. The resistance will be set to about 5% throughout the study.
9730000|NCT04764448|Experimental|Experimental: belcesiran|Patients diagnosed with A1ATD-Associated Liver Disease will be administered belcesiran.
9730001|NCT04764448|Placebo Comparator|Placebo|Patients diagnosed with A1ATD-Associated Liver Disease will be administered Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
9730002|NCT04762212|Active Comparator|Hip with the greatest limitation in flexion range of motion|Participants that have limited hip flexion of less than 101 degrees will be randomly assigned to one of two groups: one intervention group will receive Mobilization with Movement and home program of stretching with over-pressure one group will receive only a home program of stretching with over-pressure.
9730003|NCT04762212|Active Comparator|Hip with the least limitation in flexion range of motion|Participants least limited hip in flexion range of motion will serve as the control group. This limb will not receive an intervention.
9730004|NCT04754802|Experimental|PH94B|3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time
9730005|NCT04754802|Experimental|Placebo|Placebo intranasal spray (100 microliters to each nostril) one time
9730006|NCT04749680|Experimental|Peritoneal dialysis PD|Treatment for 2 weeks either with the comparators PD-Night or Homechoice PD cycler depending on the previous treatment (clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
9730007|NCT04748965||Tibial Vessel Involvement in Patients with peripheral artery disease and CLI|The primary goal is to establish a protocol for performing optimal OCT in below-the-knee vessels. OCT images will be analyzed for lesion characteristics, lesion sizing pre- and post-intervention. This will be analyzed against QVA and IVUS (latter if applicable).
9730008|NCT04729296|Experimental|Golimumab|Golimumab for subcutaneous use
9730009|NCT04729296|Placebo Comparator|Placebo|Placebo syringes and vials matching active drug
9730010|NCT04728061|Experimental|Single Ascending Dose|
9730011|NCT04728061|Experimental|Multiple Ascending Dose|
9730012|NCT04715204|Active Comparator|Formula-75/Formula-100|This arm is the control. Formula-75/Formula-100 are the standard formula recommended by WHO to treat severely malnourished children.
9730013|NCT04715204|Experimental|High Energy Oral Nutrition Supplement|High energy oral nutrition supplement (ONS) has energy density of 1.5 kcal/ml, with protein-energy ratio of 8.9% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation. The high energy ONS is beneficial for children who cannot tolerate large volume of feeding.
9730014|NCT04715204|Experimental|Standard Energy Oral Nutrition Supplement|Standard energy oral nutrition supplement (ONS) has energy density of 1 kcal/ml, with protein-energy ratio of 9.6% and complete micronutrients. It is also named as enteral formula and can be used as a sole source of nutrition. It comes as a ready-to-drink bottled package of 200 mL each. The nutrition fact fulfills the requirement of BPOM (Indonesian Food and Drug Authority) for Special Medical Purpose. The ready-to-drink formula is a safe option to treat severely malnourished patient in terms of hygiene assurance of formula. In Indonesia, many severely malnourished children come from areas with poor access to clean water and proper sanitation.
9730015|NCT04686786|Experimental|CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Week 57 during the treatment period.
10200114|NCT05060887|Experimental|OVX836 - 300µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 300μg dose on Day 1.
10200115|NCT05060887|Experimental|OVX836 - 480µg dose level|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 480μg dose on Day 1.
9730016|NCT04678843|Experimental|Virtual Family-Based Treatment|Family-based treatment is the gold standard treatment for youth and adolescents with anorexia nervosa. A therapist works with the family to help parents take charge of the process of re-feeding their child, and with progress this control is gradually given back to the youth/adolescent. Other developmental issues are discussed in order to help the youth/adolescent get back to normal development.
9730017|NCT04674631||Case group 1|52 patients with score of 12 or more on Leeds assessment of neuropathic symptoms and signs (LANSS) questionnaire will be included in the neuropathic pain group.
9730018|NCT04674631||Case group 2|46 patients with scores less than 12 on LANSS will be included in the group without neuropathic pain.
9730019|NCT04660331|Experimental|Aim I (interview, environmental scan)|Participants participate in a semi-structured interview in-person or via phone over 90 minutes about barriers/facilitators of HPV vaccination in pharmacies. Pharmacies of which the pharmacy staff participants work undergo an environmental scan to characterize the pharmacy's environment, vaccination workflow, and team dynamics.
9730020|NCT04660331|Experimental|Aim 2 (survey, training, communication intervention)|Participants provide feedback on survey questions via cognitive testing. Pharmacy staff complete an online survey over 10-15 minutes to assess the acceptability, appropriateness, and feasibility of providing HPV vaccination to children aged 9-17 in their pharmacies. Pharmacy staff then attend communication training sessions, and then undergo a communication strategy intervention over no more than 120 minutes consisting of identifying vaccine-eligible children and recommending HPV and other vaccines. Pharmacy staff employ the new communication strategy in their pharmacy over 6 months, and then complete an online survey over 10-15 minutes.
9730021|NCT04658641|Active Comparator|Standard clinical pulse shape|Standard clinical pulse shape as used in clinical practice (cathodic stimulation).
9730022|NCT04658641|Experimental|Complex pulse shape|Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse).
9730023|NCT04649060|Experimental|Study Treatment Arm A (melflufen+dexamethasone+daratumumab)|"Treatment will be given in cycles and may be given in an outpatient treatment setting. Each cycle is 28 days.~Melflufen 30 mg i.v. infusion at Day 1 of each cycle~Dexamethasone 40 mg p.o. weekly (if ≥75 years 20 mg weekly).~Daratumumab 1800 mg s.c. Cycle 1 and 2: Day 1, 8, 15 and 22. Cycle 3 to 6: Day 1 and 15. Cycle 7+: Day 1."
9730024|NCT04649060|Active Comparator|Study Treatment Arm B (daratumumab)|"Treatment will be given in cycles and may be given in an outpatient treatment setting. Each cycle is 28 days.~• Daratumumab 1800 mg s.c. Cycle 1 and 2: Day 1, 8, 15 and 22. Cycle 3 to 6: Day 1 and 15. Cycle 7+: Day 1."
9730025|NCT04633863|Experimental|MDI - 101|Artificial tear containing arabinogalactan, trehalose and hyaluronic acid
9730026|NCT04628338|Experimental|IFN-γ|100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12) (or per protocol guidance based on tolerability, response, or DLI infusions)
9730027|NCT04621747|Experimental|Study group|healthy volunteers aged 18-35, balanced sex ratio, all of them undergoing the same battery of psychophysical explorations.
9730028|NCT04617639|Experimental|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
9730029|NCT04617639|Active Comparator|Control group I|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
9730030|NCT04617639|Other|Control group II (observation group)|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel.
9730031|NCT04615754|Experimental|3-OHB vs Saline|3-OHB will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
9730032|NCT04615754|Experimental|Saline vs 3-OHB|Saline will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
9730033|NCT04605549|Experimental|CIN-107 Dose 1|
9730034|NCT04605549|Experimental|CIN-107 Dose 2|
9730035|NCT04605549|Experimental|CIN-107 Dose 3|
9730036|NCT04605549|Placebo Comparator|Placebo for CIN-107|
9730037|NCT04589897|Experimental|Experimental|Manuka honey sinus rinse
9730038|NCT04589897|Active Comparator|Standard|Standard sinus rinse
9730039|NCT04582578|No Intervention|Control Group|The control group will be treated with practice guideline optimal medical therapy for HF.
9730040|NCT04582578|Experimental|BiV-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
9730041|NCT04582578|Experimental|CS-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
9730042|NCT04577677|Experimental|optimization of control anesthetic condition|
9730043|NCT04577677|Experimental|understanding tDCS effect on motor learning|
9730044|NCT04577677|Experimental|understanding tDCS effects on cortical excitability|
10200116|NCT05060887|Placebo Comparator|Saline solution (B. Braun Ecoflac® Plus)|Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day 1.
10200117|NCT05060029|Experimental|Lactobacillus Species Suppositories|Coconut oil fatty acids, hyaluronic acid, patented VagiBIOM Probiotic complex CFU (Lactobacillus crispatus Bi16, Lactobacillus gasseri Bi19, Bacillus coagulans Bi34, Lactobacillus acidophilus Bi14) hydrolyzed cellulose, oligofructose, silica gel, lactic acid
10200118|NCT05060029|Placebo Comparator|Coconut Oil Suppositories|Coconut oil fatty acid suppositories
10200119|NCT05057182|Experimental|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
10200120|NCT05048316|Experimental|eHealth|Weekly video conference groups led by a trained facilitator
9730045|NCT04577677|Experimental|optimizing peripheral nerve stimulation protocols|
9730046|NCT04577677|Experimental|Effect peripheral nerve stimulation on motor learning|
10200121|NCT05042947|Experimental|DLCT|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences, and the experimental group used double-loop coil clamp technology to treat the wound.
10200122|NCT05042947|Active Comparator|Traditional technology|After finding polyps that meet the inclusion criteria, the surgical method for resection was selected according to the operator's preferences.The control group used the traditional hemostatic clip technique to treat the wound
9730047|NCT04574635||Cohort 1 (surgery patients)|Patients undergo collection of blood samples at baseline prior to surgery, at 6 weeks, 3, 6, and 12 months post-surgery, every 6 months during year 2, and at the time of recurrence (if applicable).
9730048|NCT04574635||Cohort 2 (post-operative radiation +/- chemotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, at 6 weeks, 3, 6, and 12 months post-radiotherapy, every 6 months during year 2, and at the time of recurrence (if applicable).
9730049|NCT04574635||Cohort 3 (definitive chemoradiotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, on the day of the final fraction of radiotherapy, at 3 months post-radiotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
9730050|NCT04574635||Cohort 4 (systemic treatment patients)|Patients undergo collection of blood samples at baseline prior to initiation of chemotherapy or immunotherapy, at 4 weeks and 8 weeks after initiation of chemotherapy or immunotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
9730051|NCT04571047||Colorectal cancer patients|Patients diagnosed with colonrectal cancer between 2008-2016
9730052|NCT04566328|Active Comparator|Arm A (daratumumab, lenalidomide, dexamethasone)|INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
9730053|NCT04566328|Experimental|Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9730054|NCT04566328|Active Comparator|Arm C (daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity."
9730055|NCT04563143|Other|Novel stimulation|All subjects will undergo periods of stimulation using novel stimulation patterns
9730056|NCT04562480|Experimental|Treatment (hypofractionated radiation therapy, resection)|Patients undergo hypofractionated radiation therapy QD (except weekends and holidays) over 3 weeks for a total of 15 fractions. Within 3-6 weeks after completion of radiation therapy, patients undergo surgical resection.
9730057|NCT04558190|Experimental|Lipid infusion + MitoQ|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion
9730058|NCT04558190|Placebo Comparator|Lipid infusion + placebo|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion
9730059|NCT04558190|No Intervention|Control|Subjects undergo a hyperinsulinemic isoglycemic clamp
9730060|NCT04558190|Other|Lipid infusion + beta2-agonist|Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol
9730061|NCT04551365|Experimental|Obese patients I|Undergoing lifestyle changes (rehabilitation) along daily intake of chitosan supplement, 4 capsules twice daily at main meals.
10200123|NCT05039554|Active Comparator|acceptance and commitment therapy (ACT) alone|Participants randomized to this cohort will receive only acceptance and commitment therapy.
9730062|NCT04551365|Placebo Comparator|Obese patients II|Undergoing lifestyle changes (rehabilitation) along daily intake of placebo, 4 capsules twice daily at main meals.
9730063|NCT04551365|Experimental|Control I|Daily intake of chitosan supplement, 4 capsules twice daily at main meals.
9730064|NCT04551365|Placebo Comparator|Control II|Daily intake of placebo 4 capsules twice daily at main meals.
9730065|NCT04547491|Other|GDT group|Cardiac optimization with goal-directed therapy, liberal use of vasopressor agents.
9730066|NCT04547491|Experimental|HPI group|Hemodynamic management HPI-based, protocol-based use of fluids, vasopressors and inotropes.
9730067|NCT04535089|Active Comparator|dexmedetomdine|IV bolus dose of 0.5ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5ug/kg/h
9730068|NCT04535089|Active Comparator|lidocaine|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
10200124|NCT05039554|Active Comparator|Valera smartphone application (app) alone|Participants randomized to this cohort will receive the Valera app and will receive a smartphone with network connectivity if necessary.
10200125|NCT05039554|Experimental|ACT + Valera app|Participants randomized to this cohort will receive both ACT and the Valera app (and a smartphone with network connectivity if necessary).
10200126|NCT05039554|Placebo Comparator|treatment as usual (TAU)|Participants randomized to this cohort will not receive any experimental treatments.
9730069|NCT04525534||Placenta accreta spectrum|Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum
9730070|NCT04525534||Phenotypically-matched controlled group|Mother-infant dyads admitted for delivery without placenta accreta spectrum
9730071|NCT04525131|Experimental|CPX-POM|IV over 20 minutes once per day
9730072|NCT04519138|Experimental|Endodrill Model X|Three consecutive samples will be taken using the Endodrill Model X instrument.
9730073|NCT04519138|Active Comparator|Endoscopic ultrasound guided fine-needle aspiration/biopsy|Three consecutive samples will be taken using the the standard method fine-needle aspiration/biopsy.
9730074|NCT04492540|Other|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be 60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
9730075|NCT04492540|Other|The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet program|the control group will receive MIND diet program for 12 weeks
9730076|NCT04488354|Experimental|CLBR001 treated patients|Patients who have been administered with CLBR001
9730077|NCT04487457||Cancer|Patients receiving chemotherapy alone after immunotherapy for NSCLC or bladder cancer or ENT cancer
9730078|NCT04479358|Active Comparator|Sub-study A, Tocilizumab-Free Standard of Care|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive no tocilizumab.
9730079|NCT04479358|Experimental|Sub-study A, Tocilizumab 40mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 40mg.
9730080|NCT04479358|Experimental|Sub-study A, Tocilizumab 120mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 120mg.
9730081|NCT04479358|Active Comparator|Sub-study B, Tocilizumab 400mg or 8mg/kg Standard of Care|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab dose (400mg or 8mgkg).
9730082|NCT04479358|Experimental|Sub-study B, Tocilizumab 40mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 40mg.
9730083|NCT04479358|Experimental|Sub-study B, Tocilizumab 120mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 120mg.
9730084|NCT04462471|Experimental|Participants with thyroid cancer|Eligible participants will have a diagnosis of BRAF mutant RAIR thyroid cancer
9781209|NCT01143701|Experimental|ADHD Collaborative Intervention|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the American Academy of Pediatrics consensus recommendation for evidence-based ADHD care.
9781210|NCT01143701|No Intervention|Typical ADHD care|Physicians in this group will provide typical ADHD care.
9781211|NCT01143714|Active Comparator|A|
9781212|NCT01143714|Placebo Comparator|B|
9781213|NCT01143727|Active Comparator|A|Santyl
9781214|NCT01143727|Active Comparator|B|Tegaderm Hydrogel
9781215|NCT01143766|Active Comparator|Standard sedation|Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.
9781216|NCT01143766|Active Comparator|Gapabentin|Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.
9781217|NCT01143792|Experimental|CRA + HIV prevention|
9781218|NCT01143792|Active Comparator|Case Management + HIV prevention|
9781219|NCT01143792|Active Comparator|MET + HIV prevention|
9781220|NCT01143818||AndroGel (testosterone gel )1%|AndroGel is topical testosterone gel 1% (1 sachet of 5 g contains 50 mg of testosterone), 1 daily dose.
9781221|NCT01143870|Other|Hemoglobin A1C|Diabetes control related to patients using standard hemoglobin A1C
9781222|NCT01143870|Experimental|Face|Face expressing emotion used to depict diabetes control
9781223|NCT01143870|Experimental|Letter grade|Letter grade used to express diabetes control
9781224|NCT01143883|Experimental|Silverlon Dressing|The Silverlon(Cura Surgical, Geneva, IL) dressing is applied to the surgical wound postoperatively. This dressing is coated with silver nylon.
9781225|NCT01143883|Active Comparator|Standard of Care Dressing|The standard plain gauze is used to dress the wound postoperatively
9785317|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q3W ESCALATION|Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
9785318|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q2W TOTAL|Participants will receive MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
10205059|NCT04156828|Experimental|Treatment (copanlisib, R-GCD)|Patients receive copanlisib IV and gemcitabine IV on days 1 and 8, carboplatin IV and rituximab IV on day 1, and dexamethasone PO or IV 30-60 minutes prior to chemotherapy on day 1 and PO in AM or 30-60 minutes prior to chemotherapy on days 2-4. Patients also receive pegfilgrastim SC on day 8 or 9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9730085|NCT04450069|Experimental|Dose Escalation|CLBR001 + SWI019 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD)
9730086|NCT04446442|Experimental|Full Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1 mA will be administered over 20 minutes to the right crusI/II area of the cerebellum with a 15 second fade in period at the beginning and a 15 second fade out period at the end. During the tDCS administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
9730087|NCT04446442|Sham Comparator|Sham Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1mA increased over 15 seconds and immediately decreased over 15 seconds to provide sensation associated with tDCS. During the sham administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
9730088|NCT04444869|Other|Open label single-arm study|All patients will receive concurrent cisplatin and radiation therapy with radiation dose de-escalation to clinically and radiologically uninvolved lymph nodes.
9730089|NCT04443478||Laparoscopic Surgery|Lower Mediastinal Lymphadenectomy should be finished via laparoscopic method.
9730090|NCT04443478||Open Surgery|Lower Mediastinal Lymphadenectomy should be finished via open method.
9730091|NCT04437368|Experimental|GT005 Low Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.
9730092|NCT04437368|Experimental|GT005 High Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.
9730093|NCT04437368|No Intervention|Untreated control|Approximately 25 subjects are planned, with subjects randomised to untreated control.
9730094|NCT04435873||Mail Survey Participants|Approximately 1200 home patients will receive mail surveys. Of these, one thousand and twenty (1,020) patients will be asked to complete the survey once. One hundred and eighty (180) patients will be asked to complete the survey twice.
9730095|NCT04435873||Telephone Survey Participants|Three hundred (300) home patients will be surveyed by phone. Of those, one hundred and twenty will be asked to complete the survey once. One hundred and eighty patients will be asked to complete the phone surveys on two separate occasions.
9730096|NCT04432727|Experimental|ACTIVE FT-CC|Text message reminders will be sent if subject does not use the device for 2 consecutive days.
9730097|NCT04432727|Experimental|PASSIVE FT-CC|Text message reminders will not be sent to subjects.
9730098|NCT04431518|Experimental|Hemodialysis Group|Receipt of JULUCA one pill per day up to 14 days
9730099|NCT04431518|Active Comparator|Normal Renal Function Group|Receipt of JULUCA one pill per day up to 14 days
9730100|NCT04392505|Experimental|The whole study population|All patients will receive durvalumab for up to 1 months after standard treatment With chemoradiotherapy.
9730101|NCT04380077|Experimental|sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
9730102|NCT04380077|Active Comparator|balanced salt solution|vitreous substitution with balanced salt solution during vitrectomy
9730103|NCT04380064|Experimental|Study Group|Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment
9730104|NCT04380064|Active Comparator|Control Group|Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment
9730105|NCT04374630|Experimental|Arm 1|Arm 1 is afuresertib 125 mg PO QD + paclitaxel 80 mg/m2 intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 3 week cycle.
9730106|NCT04374630|Active Comparator|Arm 2|Arm 2 is paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15 of a 3 week cycle
9730107|NCT04374149|Experimental|1 - TPE Alone|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy
9730108|NCT04374149|Experimental|2 - TPE Plus Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or fresh frozen plasma (FFP) replacement if underlying coagulopathy combined with ruxolitinib 5mg po twice daily (BID) beginning day prior to first TPE and continuing BID for total of 14 days.
9730109|NCT04370041|Experimental|Dokimos Plus aortic valve implantation|Dokimos Plus aortic valve implantation in all included patients.
9730110|NCT04363463|No Intervention|Conventional positioning|semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).
9730111|NCT04363463|Experimental|Interventional positioning : prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
9730112|NCT04348500|Active Comparator|Clazakizumab|25 mg in 50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
9730113|NCT04348500|Placebo Comparator|Placebo|50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
9730114|NCT04348019|Experimental|Time restricted feeding|Participants in the intervention arm of the study will consume food and beverages of their choice within one hour of waking and the feeding window will extend 6 hours. Beyond these hours, participants will observe a prolonged fast (i.e., an 18-h overnight fast).
9730115|NCT04348019|Placebo Comparator|Control|Participants in the control arm of the study will fast each night for 8 hours.
9730116|NCT04347941|Experimental|Prone Positioning|Intervention patients will remain up to 16 hours per day in Prone Positioning with 45 minutes breaks for meals
9730117|NCT04347941|Active Comparator|Standard Care|Control patients will receive full standard care. Prone Positioning as a rescue intervention is permitted and is recorded.
9785319|NCT01248949|Experimental|MEDI3617 + PACLITAXEL TOTAL|Participants will receive MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
10200127|NCT05033847|Experimental|Subject last vaccination time is within 30-90 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days
10200128|NCT05033847|Experimental|Subject last vaccination time is within 91-180 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days
10200129|NCT05033847|Experimental|Subject last vaccination time more than 181 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days
10200130|NCT05032495||Heart patients who experienced a cardiac arrhythmia while in hospital|Heart patients who experienced a cardiac arrhythmia while in hospital
10200131|NCT05032495||Heart patients who did not experience a cardiac arrhythmia while in hospital|Heart patients who did not experience a cardiac arrhythmia while in hospital
10200132|NCT05032495||Heart patients with an upcoming procedure that have not had a cardiac arrhythmia|Heart patients with an upcoming procedure that have not had a cardiac arrhythmia
10200133|NCT05032495||Members of the general public|Members of the general public
10200134|NCT05030831|Experimental|INZ-701|The study design is a MAD 3+3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly.
10200135|NCT05028933|Experimental|EPCAM CAR-T|"The first stage: single dose escalation The classic 3+3 dose escalation test. The starting dose refers to the results of the previous test of subsequent subjects. In this study, 3 increasing dose levels were set up, with 3 to 6 cases per dose.~The first dose group is 3×10^5/kg, allowing 10% dose error.~The second dose group is 1×10^6/kg, allowing 10% dose error.~The third dose group is 3×10^6/kg, allowing 10% dose error. Each dose group must complete the DLT observation before entering the next dose group; when the first subject in the same dose group has no DLT observed for at least 14 days after cell infusion, the subsequent subjects can receive cell infusion.~The second stage: combined radiofrequency/microwave ablation for the treatment of advanced digestive system malignant tumors with liver metastases"
10200136|NCT05019560|Active Comparator|Group A|"In group A:~The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.~Patients received inhalation induction using sevoflurane 8% and fentanyl 2 µg/kg was administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated then atracurium 0.5 mg/kg was given intravenously and sevoflurane reduced to 2%, then laryngoscopy and intubation were done when action of neuromuscular blocker (NMB) was confirmed by the disappearance of T3,T4. During this time, mask assisted ventilation with 100% oxygen was used to achieve normocapnia"
9730118|NCT04331561|Experimental|Sensory Re-weighting|Adults with self-reported visually-induced dizziness will be recruited to help establish the feasibility and tolerability of the testing and training methods, as well as observe for any effects of the sensory re-weighting intervention. Tests involve assessing motion sickness, vision, somatosensation, balance, and perception of verticality. The treatment provided is designed to facilitate re-weighting of sensory feedback for orientation and balance. Participants will serve as their own controls.
9730119|NCT04329325|Experimental|Blinatumomab & Concurrent Oral Tyrosine Kinase Inhibitor (TKI)|Patients may receive steroids and hydroxyurea pre-study entry and receive a 7-day steroid prephase before starting TKI therapy. Planned initial TKI is dasatinib 140 mg daily; dasatinib dose may be reduced or TKI may be changed to a different agent under certain conditions. Induction consists of continuous TKI + 24 days of dexamethasone, followed by taper of dexamethasone, with bone marrow aspirate/biopsy (BMA) and CNS prophylaxis at days 22 and 43. Patients achieving morphologic complete response post-induction proceed to consolidation with up to 3 cycles of blinatumomab (28-day cycles, 14 days between cycles) + TKI, with BMA and CNS prophylaxis between cycles. Patients achieving complete molecular response may proceed to maintenance with up to 4 more cycles of blinatumomab (28-day cycles with 28 days between cycles) + TKI, with CNS prophylaxis between cycles and BMA after cycles 5 and 7. Patients can come off study to undergo allogeneic hematopoietic cell transplantation at any time.
9730120|NCT04316572|Experimental|mental health specialist video consultation|"The intervention group will receive five video consultations with psychotherapists directly in the GP's practice.~The consultations will be carried out via the web portal of a certified video service provider (arztkonsultation ak GmbH). The patient will be located in the GP's practice and the psychotherapist in his practice or another suitable room. Patients are scheduled for five sessions of 50 minutes."
9730121|NCT04316572|No Intervention|treatment as usual by the GP|Routine treatment by the GP, which may or may not include conversations about psychosocial problems and/or referral to specialised services (e.g., inpatient therapy, counseling, self-help).
9730122|NCT04315610|Experimental|Access to mobile application|This application will help parents to recognize symptoms of reduced health status in their infant, provide decision-making support, increase their communication skills with health professionals, and provide easier access to quality assured information. At first login, the diagnosis, treatment, and contacts in the health service are registered to provide parents with personalized information that is adapted to their infant's needs. Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application.
9730123|NCT04315610|Active Comparator|Treatment as usual|This group receives traditional oral and written information about their child's heart defect and further follow-up.
10205060|NCT04147039|Experimental|Intervention|Receives the MINISTOP 2.0 mobile phone app for 6 months
10205061|NCT04147039|No Intervention|Control|Receives standard care through primary child health care
10205062|NCT04121676|Experimental|2-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
10205063|NCT04121676|Experimental|3-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
10205064|NCT04121676|Experimental|4-Week Monotherapy with AGEN2373|3+3 Dose escalation of AGEN2373 administered by IV.
9730124|NCT04308694|Experimental|Pharmacy-based methadone treatment|Participants will have their usual methadone dose administered and dispensed at a participating pharmacy. All other methadone services including counseling, drug testing, and medical services will be delivered as usual at the Methadone Program.
9730125|NCT04286347|Experimental|HCV, HBV, HIV testing|All patient ≥ 18 years-old with a next planned surgery in Lariboisiere Hospital, Paris, France, able to give written informed consent for testing will be proposed to be tested for HIV and HCV if no previous testing found in the medical record and will be proposed to be tested for HBV if the patient belong to a high-risk group: high prevalence area (Asia, sub-Saharan Africa, French Indies, East and South Europe, North-Africa, Middle-East, India, Pakistan, South-America), IVDU, prisoners, unprotected sexual intercourses.
9730126|NCT04283383|Experimental|Intervention training|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out, and the improvement of knowledge and skills will be evaluated, as well as the improvement of quality of care based on clinical indicators.
10200137|NCT05019560|Active Comparator|Group B|"In group B:~The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.~In group B: propofol 1.5 mg/kg and fentanyl 2 µg/kg were administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated and then atracurium 0.5 mg/kg was given intravenously. Propofol infusion 6 mg/kg/hr was started, until action of neuromuscular blocker (NMB) was confirmed by disappearance of T3,T4, then laryngoscopy and intubation were done. The used dosing regimen is according to previous guidelines [8] [9].No inhalational agent was used. Mask assisted ventilation was used to achieve normocapnia."
10200138|NCT05009290|Experimental|Treatment group：SHR3680 + ADT|
10200139|NCT05009290|Placebo Comparator|Treatment group : Placebo + ADT|
10200140|NCT04994509|Experimental|Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF|"Participants will receive the following for at least 52 weeks:~Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Alafenamide (F/TAF) once daily~Oral LEN 600 mg on Days 1 and 2"
9730127|NCT04283383|No Intervention|control|
9730128|NCT04250207|Experimental|K-321 QID|K-321 Ophthalmic Solution Dose A
9730129|NCT04250207|Experimental|K-321 BID|K-321 Ophthalmic Solution Dose B
9730130|NCT04250207|Placebo Comparator|Placebo|Vehicle Solution Dose
9730131|NCT04247009|Active Comparator|Meat|Patients with RA served a meal of meat
9730132|NCT04247009|Active Comparator|Fish|Patients with RA served a meal of fish
9730133|NCT04247009|Active Comparator|Vegan|Patients with RA served a vegan meal
9730134|NCT04247009|Active Comparator|Meat controls|Matched controls served a meal of meat
9730135|NCT04228172||Parkinson's disease (PD) glucocerebrosidase (GBA) carriers|Parkinson's disease subjects with GBA mutation
9730136|NCT04228172||Parkinson's disease (PD) non glucocerebrosidase (GBA) carriers|Parkinson's disease subjects without GBA mutation
9730137|NCT04223765|Experimental|CAR.k.28/CAR.k.4-1BB|Up to 12 patients will receive a single infusion of CAR.k.28. The starting dose will be 2.5x10^5 cells/kg of each product. Up to 3 dose levels of CAR.k.28 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 8 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and bendamustine. Patients with a known history of intolerance to bendamustine may be considered for lymphodepletion with fludarabine and cyclophosphamide.
9730138|NCT04216524|Experimental|Treatment (SL-401, venetoclax, chemotherapy)|See detailed description.
9730139|NCT04213300||Low carbohydrate dietary group|"Participants n = 23~Participants:~Male, female or unspecified gender;~18 years of age or over;~Type 1 diabetes for ≥1 year from diagnosis date and~Individuals who administer insulin using multiple daily injections."
9730140|NCT04198454|Active Comparator|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking. This is considered a standard measure in the recovery of lower extremity wounds and often recommended.
9730141|NCT04198454|Other|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound.
9730142|NCT04198454|Experimental|Compression bandages with FACL|Class I compression (20-30 mmHg) bandage or stocking with FACL.
9730143|NCT04187196|Experimental|Sedation with propofol group|Participants in this group will be randomized to sedation with bolus dosing of propofol for cardioversion.
9730144|NCT04187196|Experimental|Sedation with methohexital group|Participants in this group will be randomized to sedation with bolus dosing of methohexital for cardioversion.
9730145|NCT04181879|Experimental|Intervention|GPs will receive the intervention package and conduct medication reviews with recruited patients
9730146|NCT04181879|No Intervention|Usual care|GPs will continue to treat recruited patients as usual
9730147|NCT04175574|Experimental|Intervention group|The intervention consist of the patients in the experimental group listening to pre-recorded music played through a set of noise cancelling Sony headphones which are padded for extra comfort from a Sony Digital Walkman. The duration of the intervention is 30 minutes without interruption, such as eating, talking and being on their mobile phones.
9730148|NCT04175574|No Intervention|Control group|Whereas, patients in the control group will be given similar headphones but without any music. They will also be briefed not to eat, talk and being on their mobile phones.
9730149|NCT04174196|Experimental|Participants with Plasmacytoma|Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas
10200141|NCT04994509|Experimental|Blinded Phase: LEN + PTM F/TDF|"Participants will receive the following for at least 52 weeks:~SC LEN 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~Oral LEN 600 mg on Days 1 and 2"
10200142|NCT04994509|Experimental|Blinded Phase: Placebo LEN + F/TAF|"Participants will receive the following for at least 52 weeks:~SC placebo LEN every 26 weeks~Oral F/TAF 200/25 mg once daily~Oral PTM LEN on Days 1 and 2"
10200143|NCT04994509|Experimental|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:~SC placebo LEN every 26 weeks~Oral F/TDF 200/300 mg once daily~Oral PTM LEN on Days 1 and 2"
9730150|NCT04172038|Experimental|Phase I: Physical Therapy (PT)|Initial Randomization: The initial PT treatment session will occur within 7 days of enrollment in the study. Precise dosage (i.e, number of PT sessions) will be at the discretion of the physical therapist directing the participant's care, up to a maximum of 2-3 sessions per week over the 6-week Phase I treatment period.
9730151|NCT04172038|Experimental|Phase I: Move to Health (M2H)|"Initial Randomization: M2H is a key component of Army Medicine's System for Health, along with the Performance Triad. It is a person-centered, holistic, and experience-centric approach to promoting healthy behaviors (nutrition, physical activity, sleep, instrinsic factors, extrinsic factors). Precise dosage (i.e, number of M2H sessions) will be at the discretion of the health coaches. Sessions may be delivered in-person or utilize technology including text messaging, telephone, e-mail, video chat, app-based self-management etc."
9730152|NCT04172038|Experimental|Phase II: Combine PT & M2H|Sequential Randomization: Participants randomized to receive a combination of PT and M2H as a Phase II intervention will continue their Phase I treatment (either M2H or PT). The participant will begin the treatment component that was not part of their Phase I intervention.
9730153|NCT04172038|Experimental|Phase II: MORE Mindfulness|Sequential Randomization: Participants randomized to receive mindfulness as a Phase II intervention will discontinue their Phase I treatment. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment was designed specifically to address symptoms and underlying mechanisms of chronic pain in the military context and is led over 8 individual sessions.
9730154|NCT04130971||Patients without neoadjuvant treatment|
9730155|NCT04130971||Patients with short course radiotherapy|
9730156|NCT04130971||Patients with long course chemoradiotherapy|
9730157|NCT04130971||Patients with short course radiotherapy and deferred surgery|
9730158|NCT04109885|Experimental|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
9730159|NCT04109885|Active Comparator|Standard treatment|Intravenous administration of prochlorperazine and diphenhydramine.
9730160|NCT04107948|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
9730161|NCT04107948|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
9730162|NCT04102280|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
9730163|NCT04097067|Experimental|Treatment (low-dose radiation therapy)|"Patients undergo low-dose radiation therapy with daily 2 Gy ad 20 Gy (ISRT with IMRT & IGRT).~Blood draw for biomarker-analysis (at baseline visit/ after 4 Gy/ after 10 Gy / after 20 Gy RT/ at 3 and 6 months after RT)"
9730164|NCT04089553|Experimental|Module 1|"Module 1 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with durvalumab in post-standard of care therapy for metastatic castration resistant prostate cancer (mCRPC) patients. In Module 1 approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635.~Patients will receive AZD4635 75 mg PO QD monotherapy for 2 weeks (Cycle 0). Starting with Cycle 1, durvalumab 1500 mg IV Q4W will be added to continuous AZD4635 dosing."
9730165|NCT04089553|Experimental|Module 2|"Module 2 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with oleclumab in post-standard of care therapy for metastatic castration resistant prostate cancer (mCRPC) patients. In Module 2 approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635 plus oleclumab.~Patients will receive a dose of AZD4635 75 mg PO QD and oleclumab 1500 mg IV Q2W for the first 4 doses and Q4W thereafter. Patients who began treatment at the AZD4635 50 mg dose will continue with that dose. The first dose of oleclumab will begin on Cycle 0 Day 1. For Cycle 1, oleclumab will be administered on Day 1 and Day 15. For Cycle 2 and beyond, oleclumab will be administered on Day 1 of each cycle Q4W."
9730166|NCT04079751|Active Comparator|Neutral Mechanical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
9730167|NCT04079751|Active Comparator|Anatomical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
9730168|NCT04078737|Experimental|Ticagrelor plus Aspirin Group|Ticagrelor of loading dosing of 180mg followed by 90mg bid for 3 months plus aspirin of loading dose of 75-300mg followed by 75mg daily for 21 days
9730169|NCT04078737|Active Comparator|Clopidogrel plus Aspirin Group|Clopidogrel of loading dosing of 300mg followed by 75mg daily for 3 months plus aspirin loading dose of 75-300mg followed by 75mg daily for 21 days
9730170|NCT04058197|Experimental|Active|Deferoxamine (DFO) Intradermal Delivery Patch (DIDP), 45mg DFO daily, up to 12 weeks
9730171|NCT04058197|Placebo Comparator|Placebo|Placebo
9730172|NCT04018248|Experimental|Treatment (BR101801):Phase Ia (dose escalation)|Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
10200144|NCT04994509|Experimental|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.~Participants randomized to F/TAF or F/TDF will receive SC LEN 927 mg on OLE Day 1 and OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2."
10205065|NCT04121676|Experimental|Combination Therapy with 3-week AGEN2373 Monotherapy Lead-In Combination with 6-week AGEN1181|3+3+3 Dose escalation of AGEN2373. AGEN2373 and AGEN1181 administered by IV.
10205066|NCT04121676|Experimental|Combination Therapy with 3-week AGEN2373 in combination with 6-week AGEN1181|3+3+3 Dose escalation of AGEN2373. AGEN2373 and AGEN1181 administered by IV.
9730173|NCT04018248|Experimental|Treatment (BR101801):Phase Ib (dose expansion)|"Group A: Subjects with diffuse large B-cell lymphoma (DLBCL) including MYC-altered DLBCL and transformed DLBCL (20 subjects).~Group B: Subjects with PTCL NOS and PTCL AITL (12 subjects).~Group C: Subjects with CLL/SLL, other B-cell lymphoma such as, but not limited to mantle cell lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, or PTCL (20 subjects)."
10200145|NCT04994509|Experimental|Pharmacokinetic (PK) Tail Coverage Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.~Additionally, participants that either prematurely discontinue the study drug during the blinded phase or choose not to continue in the LEN OLE phase (if randomized to LEN in the blinded phase) or who discontinue the study drug in the LEN OLE phase are also eligible to transition to the PK Tail Coverage phase.~Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last LEN injection."
10200146|NCT04990323|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen (Preferred: Clo/Flu/Bu90, Alternative: MIDI)~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
10200147|NCT04989829|Experimental|Treatment group|
9730174|NCT04018248|Experimental|Treatment (BR101801):Phase II|The subject population will be restricted to subjects with PTCL NOS or PTCL AITL
9730175|NCT04012814|Experimental|Subject treatment group|Treatment group receiving up to 4 diode treatments and up to 8 RF treatments.
9730176|NCT03999411|Placebo Comparator|Usual Care|Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.
9730177|NCT03999411|Active Comparator|Smoking cessation only intervention|"Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the Crave-to-Quit app, and two brief follow-up phone calls."
9730178|NCT03999411|Experimental|Combined smoking cessation and HIV intervention|Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.
9730179|NCT03967912|Experimental|MOVE UP for Caregivers|12-week lifestyle intervention focusing on diet and activity
9730180|NCT03963830|Experimental|MOVE UP-Sustainability|12-week lifestyle intervention focusing on diet and activity
9730181|NCT03958981|Experimental|castor oil group|60 mL of castor oil in 140 mL of orange juice
9730182|NCT03958981|Placebo Comparator|placebo group|Patients will receive sunflower oil as a placebo
9730183|NCT03937635|Experimental|Arm I (daratumumab, lenalidomide, dexamethasone)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 in courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9730184|NCT03937635|Experimental|Arm II (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9730185|NCT03932032|Experimental|Attention Bias Modification Treatment|Attention Bias Modification Treatment is a computer-based attention training program.
9730186|NCT03932032|Sham Comparator|Neutral Control Task|Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.
9730187|NCT03931174|Active Comparator|Addiction Technology Transfer Center (ATTC) Training|Half of the opioid treatment centers will receive the ATTC training strategy.
9730188|NCT03931174|Experimental|Enhanced ATTC (E-ATTC) Training Strategy|Half of the opioid treatment centers will receive the E-ATTC training strategy.
10200148|NCT04981275||Women with PCOS|Women previously diagnosed with PCOS not using hormonal therapy and without other significant health or endocrine issues
10200149|NCT04981275||Healthy controls|Women self-identifying as generally healthy, not using hormonal therapy, and without any significant health or endocrine issues
10200150|NCT04981132|Experimental|Education Group|Group 1: Patients will have pain neuroscience education (PNE)
10200151|NCT04981132|Experimental|Exercise group|Group 2: Patients will have progressive therapeutic exercise training (PTE)
10200152|NCT04981132|No Intervention|Control Group|Group 3: Participants will be taken for the waiting list
10200153|NCT04971486|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
10200154|NCT04971486|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
9785320|NCT01248949|Experimental|MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL|Participants will receive MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
10200155|NCT04963452|Placebo Comparator|Group 1|Normal weight BMI 20-24.9 kg/m2
10200156|NCT04963452|Active Comparator|Group 2|Morbid Obese BMI : 40-49.9 kg/m2
10200157|NCT04961697|Experimental|PICU with diaries|"The main family member of a critically ill child will receive a diary upon PICU admission.~Except for the diaries intervention, this group of patients will be submitted to usual PICU routine care."
10200158|NCT04961697|No Intervention|PICU without diaries|This group of critically ill patients and family members will not receive diaries, but will also be submitted to usual PICU routine care.
10200159|NCT04953338||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
9730191|NCT03907462|Experimental|Treatment One|Participants assigned to the SMART 2.0 with technology and personal health coaching treatment group (i.e., treatment one) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total, and 4) technology-mediated, real-time individual health coaching. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; be asked to interact with their online group via social media as frequently as possible; and speak with their health coach at a predetermined session schedule.
9730192|NCT03907462|Experimental|Treatment Two|Participants assigned to the SMART 2.0 technology alone treatment group (i.e., treatment two) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, and 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; and be asked to interact with their online group via social media as frequently as possible.
9730193|NCT03907462|No Intervention|Control|Participants assigned to the control group will receive a consumer-level wearable and scale with a corresponding app to use at their discretion.
9730194|NCT03892369|Experimental|Alcohol|The participant receive 0.5 g ethanol per kg body weight over 10 minutes. Subsequently blood samples are taken frequently the next ten hours.
9730195|NCT03878589|Active Comparator|Oxytocin Crossover Placebo Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of oxytocin (OT) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of placebo (P) twice a day will be self-administered.
9730196|NCT03878589|Active Comparator|Placebo Crossover Oxytocin Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of placebo (P) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of oxytocin (OT) twice a day will be self-administered.
9730197|NCT03872414|Experimental|Healthy Younger Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
9730198|NCT03872414|Experimental|Healthy Older Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
9730199|NCT03872414|Experimental|Parkinson Disease Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
9730200|NCT03872414|Active Comparator|Control Group|Participants will receive rt-fMRI training to increase primary auditory cortex activation.
10200160|NCT04953338||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
10200161|NCT04947332|Other|Auto-inoculation recipients|Auto-inoculation of wart to be performed
9730201|NCT03868410|Active Comparator|cPMD rTMS + Training|New Approach
9730202|NCT03868410|Active Comparator|iM1 rTMS + Training|Conventional Approach
9730203|NCT03862131|Experimental|MyoStrain® unblinded treatment arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk Group~The unblinded treatment arm will enhance patient management by augmenting standard of care with serial MyoStrain® monitoring of the impact of cancer therapy on myocardial function.~Higher Risk unblinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
9730204|NCT03862131|Active Comparator|MyoStrain® blinded control arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk group~The blinded control arm will provide investigators with LVEF and LVEDV/LVESV measurements, which are clinical, in conjunction with standard of care~Higher Risk blinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
9730205|NCT03848481|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
9730206|NCT03848481|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
9730207|NCT03803605|Experimental|VRC07-523LS + Vorinostat (VOR)|Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.
10200162|NCT04945720|Experimental|Hepatic artery infusion chemotherapy（HAIC） plus Durvalumab|The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours). All chemo-drugs were given by HAI.Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
10200163|NCT04945083|Experimental|Experimental Nutritional Pudding|2 servings per day
10200164|NCT04944290|Experimental|Perrigo active|
10200165|NCT04944290|Active Comparator|Reference active|
10200166|NCT04943328|Other|TrendHip®|
10200167|NCT04939090|Experimental|Arm I (olanzapine)|Patients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
9730208|NCT03799991|Experimental|Vestibular therapy|Vestibular therapy (Vestibular physical therapy) entails an 8-week course of exercises delivered by a physical therapist designed to improve vestibular function.
9730209|NCT03799991|Active Comparator|Active control|"The active control regimen consists of eye movement exercises (e.g. smooth pursuit eye movements) and also general conditioning exercises (e.g. range of motion exercises, lifting light weights with the arms and legs). This regimen is vestibular neutral in that head movements which specifically challenge the vestibular system are avoided."
9730210|NCT03799198|Experimental|WMP + Rx|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately one year. After discussing with the study doctor, participants will receive one of the following listed 5 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) lorcaserin or lorcaserin extended-release, 3) phentermine/topiramate extended-release, 4) naltrexone/bupropion extended-release and 5) liraglutide 3.0 mg.
10200168|NCT04939090|Active Comparator|Arm II (megestrol acetate)|Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
9730211|NCT03799198|Active Comparator|WMP alone|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately one year.
9730212|NCT03776461|Experimental|80 pin applicator|
9730213|NCT03776461|Active Comparator|160 pin applicator|
9730214|NCT03774394|Experimental|Diabetes Mellitus patients with Chronic Kidney Disease|"Patients with CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
9730215|NCT03774394|Active Comparator|Diabetes Mellitus patients without Chronic Kidney Disease|"Patients without CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
9730216|NCT03770728|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) subcutaneous (SC) injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
9730217|NCT03770728|Experimental|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
9730218|NCT03770728|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and was maintained at the 4 mg dose through-out the treatment duration, up to Week 30.
9730219|NCT03770728|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 3 and later up-titrated to 6 mg and was maintained at the 6 mg dose through-out the treatment duration, up to Week 30.
9730220|NCT03762135|Experimental|Full version of the LIITah App.|Participants will be given the LIITAH app. which consists of 1) enhanced location identification (ELI), 2) self reported nutrients by annotated photos (SNAP), 3) delivery of individually and culturally tailored point of purchase (POP) prompts along with tailored messages sent at other times of the day, 4) use of app. in connection with parents, 5) goal setting, 6) a point system
9730221|NCT03762135|Active Comparator|Partial App. (ELI and SNAP only)|Participants will be given only the ELI and SNAP components. It will detect their presence in a restaurant and allow users to document their purchases by submitting annotated photos, but it will not deliver any POP prompts encouraging them to make healthy choices, or messages at other times of the day.
10200169|NCT04930094|Experimental|Secukinumab 300 mg|AIN457
9730222|NCT03760146|Experimental|60 years and above 20vPnC/Saline|20vPnC and saline
9730223|NCT03760146|Active Comparator|60 years and above 13vPnC/PPSV23|13vPnC and PPSV23
9730224|NCT03760146|Experimental|50 through 59 years of age 20vPnC|20vPnC
9730225|NCT03760146|Experimental|18 through 49 years of age 20vPnC|20vPnC
9730226|NCT03760146|Active Comparator|50 through 59 years of age 13vPnC|13vPnC
9730227|NCT03760146|Active Comparator|18 through 49 years of age 13vPnC|13vPnC
9730228|NCT03760081|Experimental|ASP1650, Dose Level 1|Participants received ASP1650 dose level 1 as intravenous infusion, every two weeks (Q2W) starting on Cycle 1 Day 1(C1D1) for up to a maximum of 12 cycles, or until disease progression, toxicity requiring study treatment cessation, start of another anticancer treatment, or until study discontinuation criteria was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
10200170|NCT04930094|Placebo Comparator|Placebo|Placebo
10200171|NCT04929236|Experimental|Panzyga High Dose|
10200172|NCT04929236|Experimental|Panzyga Low Dose|
10200173|NCT04924166|Placebo Comparator|Placebo|matching capsule PO
10200174|NCT04924166|Active Comparator|HCORT|180 mg capsule PO
10200175|NCT04923841|No Intervention|Control|Subjects in control will receive single vision spectacle lenses and a placebo desk lamp
10200176|NCT04923841|Experimental|BLT monotherapy|Subjects in BLT monotherapy group will receive a high intensity light box for bright light therapy and single vision spectacle lenses
10200177|NCT04923841|Experimental|BLT and DIMS|Subjects in BLT and DIMS group will receive a high intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
10200178|NCT04922840|Experimental|High-intensity exercise (HIIT)|"Usual care; CVD risk assessment, lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication.~The 12-week intervention is carried out as individual or group sessions with maximal 4 patients, supervised by physiotherapists in primary health care. The HIIT group complete two weekly HIIT sessions and a third weekly session with exercise at moderate intensity. Exercise is tailored to each individual to provide the same relative exercise stress and to ensure progression. Target exercise intensity is tracked by a heart rate monitor.~Individual exercise session are recorded in a training diary. Succeeding the intervention, a questionnaire will be distributed to patients in the HIIT group. Semi-structured interviews will target physiotherapists supervising HIIT and 5-7 patients in the HIIT group."
9730229|NCT03760081|Experimental|ASP1650, Dose Level 2|Participants received ASP1650 dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criteria as met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
9730230|NCT03750331|Active Comparator|traditional patient follow-up|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule (every other week up to 6 months post-transplant, once a month up to year 1, every three months up to year 2 and every 6 months thereafter)
9730231|NCT03750331|Experimental|medically-tailored follow-up with Ap'Telecare|a group of patients assisted by Ap'Telecare and consulting their Transplant Centre following a less stringent schedule of consultations (every month up to 6 months, every other month up to year 1, every six months up to year 2 and once a year thereafter).
9730232|NCT03737110|Experimental|Rilonacept|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to double-blinded administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
9730233|NCT03737110|Placebo Comparator|Placebo|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to placebo SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
9730234|NCT03713905|Experimental|GLS-010|Use Full-human anti-pd-1 monoclonal antibodies for treatment
9730235|NCT03713684|Placebo Comparator|Placebo|Participants received placebo (matched to efpeglenatide) subcutaneous (SC) injection once weekly up to Week 56 on top of basal insulin alone or in combination with oral antidiabetic drugs (OADs).
9730236|NCT03713684|Experimental|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs.
9730237|NCT03713684|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and maintained at the 4 mg dose through-out the treatment duration up to Week 56.
9730238|NCT03713684|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 4 and later up-titrated to 6 mg and maintained at the 6 mg dose through-out the treatment duration up to Week 56.
9730239|NCT03712410|Active Comparator|Group 1 (PISCES face to face)|"Family caregivers will receive three sessions of the PISCES intervention in person. The agenda for the first face to face visit for caregivers (suggested timeline 5-7 days after hospice admission) includes an explanation of the purpose of the visit/call. During the first session, the interventionist works on steps one and two of the ADAPT model, namely Attitude and Defining the Problem and Setting Realistic Goals. During the second visit (suggested timeline 11-13 days after hospice admission) the interventionist covers steps three and four of the ADAPT model. Step three encourages caregivers in being creative and generating alternative solutions. Step four focuses on predicting the consequences and developing a solution plan. The third visit (suggested timeline 16-18 days after hospice admission) focuses on step five, namely trying out the solution plan and determining if it works."
9730240|NCT03712410|Experimental|Group 2 (PISCES delivered in a hybrid format)|In this group, participants will receive the PISCES intervention in three sessions; however, the first session will be delivered face to face and the other two via video. The three intervention sessions will be scheduled with a suggested timeline between days 5 and 18 of the hospice admission. The first session will take place in person (suggested timeline 5-7 days after hospice admission). After the first session where the in-person encounter will allow for the establishment of rapport between the interventionist and the caregiver, the second session (suggested timeline 11-13 days after hospice admission) and the third session (suggested timeline 16-18 days after hospice admissions) will be conducted via live videoconferencing. If the caregiver already has access to a computer and Internet, they will utilize the videoconferencing solution. If videoconferencing is not feasible, the sessions will be delivered over the regular phone.
9730241|NCT03712410|Experimental|Group 3 (PISCESplus)|"PISCESplus is meant to be an enhanced version of the PISCES intervention including the original problem solving therapy modules with the addition of positive reappraisal elements. The suggested timeline for the first session which will be in person is 5-7 days after hospice admission. At the end of the first session, the interventionist will ask the caregiver to take the time to think about and identify some positive aspects of caregiving.~At the end of the second session (which is scheduled to take place via video approx. 11-13 days after admission) the interventionist will ask the caregiver to go over the benefits or positive aspects of caregiving that they had identified and ask them to comment as to why they perceive these as positive or beneficial.~The third session will also take place via video."
9730242|NCT03695783|Experimental|Online decision aid called IBD&me|IBD&me is an online, freely available tool that allows patients to explore decision-making around biologic therapies for IBD at their own pace. It includes an educational component and an interactive exercise with a series of ratings tasks that generates a personalized preferences report for patients to share and discuss with their physician.
9730243|NCT03695783|Active Comparator|Standardized educational material|PDF file corresponding to the CCFA's online resource on biologic therapies, which is a well-researched and clearly presented overview of IBD biologic therapies, but without an active shared-decision making component.
9730244|NCT03681483|Experimental|RO5126766 (CH5126766)|The study will begin with a standard 3+3 design. The study will enroll 3 patients at the previously identified MTD15 (4mg two times per week on days 1 and 4). The period of evaluation for dose limiting toxicity will be through completion of cycle 1. If ≤1 of the 3 initial patients at the proposed dose experience a DLT, then 3 additional patients will be enrolled for a total of 6 planned patients at that dose level. Otherwise, 3 patients will be enrolled at dose level -1. If ≤ 1 of these patients experience a DLT, then 3 additional patients will be enrolled at the same dose level. If more than 1 patient experiences a DLT in dose level -1, the study will be terminated.
9730245|NCT03673020|Experimental|ASV® AGEN2017|ASV® AGEN2017 + QS-21 Stimulon® Adjuvant Vaccine
9730246|NCT03665688|Experimental|Outpatient Dilapan-S|"After Dilapan-S® placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue.~Subjects will also be instructed to return to L&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours"
9730247|NCT03665688|Active Comparator|Inpatient Dilapan-S|"After Dilapan-S® placement, subjects will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
9730248|NCT03660384|Experimental|SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
9730249|NCT03660384|Experimental|C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
9730250|NCT03660371|Experimental|PPV/MP|Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
9730251|NCT03660371|Active Comparator|PPV without MP|Control Group: Subjects do not undergo ILM peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
9730252|NCT03660345|Experimental|PPV/MP|Study Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo pars plana vitrectomy with internal limiting membrane peeling
9730253|NCT03660345|Active Comparator|Intravitreal Injection|Control Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo intravitreal ziv-aflibercept monotherapy according to a fixed treatment schedule
9730254|NCT03648645|Experimental|AH Telemonitoring|Self measurement of blood pressure
9730255|NCT03644550|Experimental|1/LMB- 100+pembrolizumab|"LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles.~LMB-100 140mcg/kg Intravenous infusion (IVI), Days 1, 3, 5 in cycles 1, 2. Pembrolizumab 200mg IVI, every (Q) subsequent cycle on Day 1."
9730256|NCT03641469|Experimental|Green Sun Dynamic Brace|Historical measures of brace effectiveness (in- and out-of-brace Cobb angles), wear time, and brace-related quality of life will be compared to those measured after the subject is fit with a Green Sun dynamic brace.
9730257|NCT03613038|Other|Phonetic complexity effects|Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity. Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
9730258|NCT03599661||Fertilit-e|Participants review Fertilit-e content, undergo interviews about issues of content, functionality, and ease of use, and complete questionnaires over 45-60 minutes.
9730259|NCT03591822|Other|Arm AB : Intervention under study x Control intervention|Subjects receive intervention A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by intervention B during which patients will benefit from a systemic pain assessment without the PARO robot.
9730260|NCT03591822|Other|Arm BA: Control intervention x Intervention under study|Subjects receive intervention B during which they will benefit from a systemic pain assessment without the PARO robot, followed by intervention A during which patients will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator.
9730261|NCT03577522|Active Comparator|Avenir cementless hip stem|Total hip arthroplasty: Avenir vs Corail
9730262|NCT03577522|Active Comparator|Corail HA-coated hip stem|Total hip arthroplasty: Corail vs Avenir
9730263|NCT03571763||acute ischemic stroke patient|acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months
9730264|NCT03557970|Experimental|Treatment (JNJ-40346527)|Participants receive JNJ-40346527 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9730265|NCT03548519|Experimental|Attention Training|OCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
9730266|NCT03548519|Active Comparator|Active placebo training|OCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
9730267|NCT03548519|Experimental|PSE and Attention Training|OCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
9730268|NCT03526484|Active Comparator|Standard of Care|The control group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will be reported to the doctor performing the procedure. The provider may require participants to take antibiotics and/or delay their procedure as a result of the urinalysis.
9730269|NCT03526484|Experimental|Experimental|The experimental group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will NOT be reported to the doctor performing the procedure. Instead, the provider will conduct the procedure without looking at or acting upon the results of the urinalysis. The urinalysis and urine culture results will be monitored by the research team, and the participant will be informed if the urine culture results are positive for an infection.
9730270|NCT03524235|Experimental|Subjects|Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion
9730271|NCT03524235|No Intervention|Controls|Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis.
9781226|NCT01143896|Experimental|Arm 1: Depression Collaborative Care|Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
9781227|NCT01143896|No Intervention|Arm 2: Usual Care|Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.
9781228|NCT01144026|Experimental|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
9781229|NCT01144026|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
9781230|NCT01144052|Active Comparator|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
9781231|NCT01144052|Experimental|Interferon-beta-1b|250 mcg (8 MIU) subcutaneous injections every other day
9781232|NCT01144143|Experimental|Infliximab|
9781233|NCT01144143|Placebo Comparator|Salt Water|
9781234|NCT01144143|Active Comparator|Methylprednisolone acetate|
9781235|NCT01144182|No Intervention|Current Best Practice (CBP)|CBP received no intervention and only current best practices for inpatient HF care.
9781236|NCT01144182|Active Comparator|Quality improvement program (QIP)|Comprehensive quality improvement program (QIP) intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
9781237|NCT01144286|Placebo Comparator|placebo|placebo pessary, single dose
9781238|NCT01144286|Experimental|Arasertaconazole nitrate 150 mg|Arasertaconazole nitrate 150 mg pessary, single dose
9781239|NCT01144286|Experimental|arasertaconazole nitrate 300 mg|Arasertaconazole nitrate 300 mg pessary, single dose
9730272|NCT03514901|Experimental|Experimental combination beyond Focal Progression|Local treatment (i.e. surgery, radiotherapy) + Vemurafenib 240mg tablets (4 tabs/twice daily for 28 consecutive days) + Cobimetinib 20mg tablets (3 tabs/day for 21 consecutive days) beyond focal progression.
9730273|NCT03514901|Active Comparator|Pembrolizumab or Nivolumab|Pembrolizumab daily dose 2 mg/kg milligram(s)/kilogram or Nivolumab daily dose 3 mg/kg milligram(s)/kilogram.
9730274|NCT03499808|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
9730275|NCT03498638|Experimental|Couples Therapy|Couples Therapy
9730276|NCT03498638|Placebo Comparator|Control|Couples Therapy after an 8 week waiting period
9730277|NCT03478462|Experimental|CLR 131|CLR 131 intravenous administration
9730278|NCT03471624|Experimental|Tenofovir Alafenamide for 24 months|Subjects on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.
9730279|NCT03462966|Experimental|Therapeutic|40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.
9730280|NCT03462251|Experimental|Arm A|Combination of ribociclib and aromatase inhibitor or fulvestrant
9730281|NCT03462251|Active Comparator|Arm B|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
9730282|NCT03409289||ROSC RUSH Exam|The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .
9730283|NCT03396770|Active Comparator|Control group|Standard clinical routine
9730284|NCT03396770|Experimental|Nephrocheck group|Nephrocheck test
9730285|NCT03369197|Experimental|Intervention: Nasal Mask|Nasal anesthesia mask with positive pressure
9730286|NCT03369197|Active Comparator|Control: Nasal cannula|Nasal Cannula with standard care
9730287|NCT03368196|Experimental|DS-8201a|DS-8201a administered by intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W)
9730288|NCT03338647|Active Comparator|TACE|Transarterial chemoembolization with drug eluted beads or doxorubicin/lipiodol
9730289|NCT03338647|Experimental|SBRT|Stereotactic radiation therapy with risk adapted dose prescription
9730290|NCT03325101|Experimental|Treatment (apheresis, pembrolizumab, cryosurgery, mDCs)|Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
9730291|NCT03318120|Experimental|Progressive Resistance Training|Participants assigned to this arm will receive progressive resistance training under the supervision of a personal trainer at a gym facility close to their home. They will be required to perform these exercises twice a week for the first six months. They will be monitored with an activity monitor.
9730292|NCT03318120|No Intervention|Control Arm|The control arm offered to subjects with dystonia and other involuntary muscle disorders, participants will be followed at baseline and 6 months similar to what will be done in active exercise arm but this arm will not receive exercise. They will be monitored with an activity monitor.
9730293|NCT03284034|Active Comparator|Cyrolipolysis|
9730294|NCT03284034|Experimental|Deoxycholic Acid|
9781240|NCT01144286|Experimental|arasertaconazole 600 mg|Arasertaconazole nitrate 600 mg pessary, single dose
9730295|NCT03256435|Experimental|Treatment Arm|RAMP PrEP initiation, adherence, and retention intervention package as well as standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
9730296|NCT03256435|No Intervention|Control Arm|Standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
9730297|NCT03220477|Experimental|pembrolizumab plus guadecitabine and mocetinostat|Pembrolizumab given IV; guadecitabine given SQ, mocetinostat given PO.
9730298|NCT03217422|Experimental|Arm 1|VAY736 Dose 1
9730299|NCT03217422|Experimental|Arm 2|VAY736 Dose 2
9730300|NCT03217422|Experimental|Arm 3|VAY736 Dose 3
9730301|NCT03217422|Placebo Comparator|Arm 4|Placebo
9730302|NCT03087760|Experimental|Single Arm|Single Arm, Open Label
9730303|NCT03066843|Experimental|Zero incubation with ALA (5-aminolevulinic acid)|Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
9730304|NCT03066843|Experimental|One hour incubation with ALA (5-aminolevulinic acid)|Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
9730305|NCT03057964|Experimental|PDL (Pulsed Dye Laser) and Fractional Photothermolysis|
9730306|NCT03057964|No Intervention|Control|
9730307|NCT03039114|Experimental|Parsaclisib + Hexal and Gazyvaro|
9730308|NCT03022461||Ongoing HM3 CE Mark study patients|The study will include the ongoing HM3 CE Mark study patients that have consented to continue the long term follow-up data collection.
9730309|NCT02979587|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
9730310|NCT02979574|Active Comparator|Electro-Acupuncture (EA) Procedure|Participants will receive 10 treatment of EA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
9730311|NCT02979574|Active Comparator|Battle Field Acupuncture (BFA) Procedure|Participants will receive 10 treatment of BFA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
9730312|NCT02979574|Active Comparator|Wait List Control (WLC) Usual Care Procedure|Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
9730313|NCT02964039|Experimental|Error reduction|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error reduction mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
9730314|NCT02964039|Experimental|Error augmentation|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error augmentation mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
9730315|NCT02964039|Sham Comparator|Activity matched control|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in transparent mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
9730316|NCT02960555|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.
9730317|NCT02930889|Experimental|Prostate Artery Embolization|Prostate Artery Embolization is a surgical procedure to relieve symptoms of Benign Prostatic Hyperplasia (BPH). Embolizing particles are injected into a target blood vessel to occlude blood flow.
9730318|NCT02924818|Experimental|Chronic Obstructive Pulmonary disease (COPD)|
9730319|NCT02924818|Experimental|Cystic Fibrosis (CF)|
9730320|NCT02924818|Experimental|bronchiectasis|
9730321|NCT02924818|Experimental|Interstitial lung disease (ILD)|
9730322|NCT02924818|Experimental|controls|
9730323|NCT02922036|Experimental|Treatment|WiSE System therapy ON with Guideline Directed Medical Therapy
9730324|NCT02919618|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to a region of the heart determined by EP-guidance, using noninvasive electrical mapping combined with anatomic imaging.
9730325|NCT02906657|Experimental|Medication reconciliation|Medication reconciliation involving a pharmacist using electronic pharmaceutical records
9730326|NCT02906657|No Intervention|Control|Usual Care
9730327|NCT02894398|Experimental|Palbociclib+AI or Fulvestrant|Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
9730328|NCT02852057|Experimental|Subjects Receiving Lenses|All subjects who meet inclusion criteria will receive lenses loaded with timolol maleate and dorzolamide hydrochloride.
9730329|NCT02844946|Experimental|ACT on Life|One day workshop aimed at providing Veterans with new tools and skills needed to pursue valued goals and directions in the face of life's challenges. Mindfulness, acceptance, values clarification, and goal-setting will be taught.
9730330|NCT02844946|No Intervention|Treatment as Usual|Veterans will continue receiving care as usual.
9730331|NCT02843087||NW vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730332|NCT02843087||NW C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730333|NCT02843087||Ob vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730334|NCT02843087||Ob C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730335|NCT02843087||GDM vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730336|NCT02843087||GDM C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730337|NCT02843087||T2D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730338|NCT02843087||T2D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9781241|NCT01144299|Experimental|Fluarix Adult Group|Subjects aged 18 to 60 years received one dose of Fluarix™.
9781242|NCT01144299|Experimental|Fluarix Elderly Group|Subjects aged > 60 years received one dose of Fluarix™.
9781243|NCT01144338|Experimental|Exenatide Once Weekly|
10200179|NCT04922840|No Intervention|Usual care|Control group participants receive the same treatment as usual care; CVD risk assessment including lifestyle advice (heart-healthy diet, regular exercise, weight management and non-smoking) and relevant medication. Control group participants are invited to a physiotherapist-led theoretical and practical HIIT session following study completion.
10200180|NCT04893187|Experimental|Part 1: Single Dose Escalation SSS17|Escalating doses of SSS17, single dose administration
10200181|NCT04893187|Placebo Comparator|Part 1: Single Dose Escalation matching Placebo|Escalating doses of matching placebo, single dose administration
10200182|NCT04893187|Experimental|Part 2: Multiple Dose Escalation SSS17|Escalating doses of SSS17, multiple dose administration
10200183|NCT04893187|Placebo Comparator|Part 2: Multiple Dose Escalation matching Placebo|Escalating doses of matching placebo, multiple dose administration
9730339|NCT02843087||T1D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730340|NCT02843087||T1D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
9730341|NCT02810197|Experimental|Exposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
9730342|NCT02810197|Experimental|unexposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
9730343|NCT02734537|Experimental|Arm A (IMRT)|Patients undergo IMRT QD 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
9730344|NCT02734537|Experimental|Arm B (IMRT, cisplatin)|Patients undergo IMRT QD 5 days a week and receive cisplatin IV over 1-2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
9730345|NCT02728388|Experimental|PDT Treatment|"Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.~16 to 24 hours post study drug treatment, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes)."
9730346|NCT02710734|Experimental|CRT|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3
9730347|NCT02710734|Experimental|Surveillance|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance
9730348|NCT02710734|Experimental|Intravesicle therapy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3
9730349|NCT02710734|Experimental|Radical Cystectomy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy
9730350|NCT02675114|Active Comparator|Surgical aortic valve replacement (SAVR)|
9730351|NCT02675114|Experimental|Transcatheter aortic valve replacement (TAVR)|
9730352|NCT02615054||treated with trastuzmab no cardiac effects|
9730353|NCT02615054||treated with trastuzmab with cardiac effects|
9730354|NCT02615054||healthy volunteers no cancer treatment|
9730355|NCT02611024|Experimental|Lurbinectedin Escalation Group|Irinotecan 75 mg/m^2 as a 90-min (-5-min/+30-min) intravenous (i.v.) infusion, followed by Lurbinectedin with starting dose of 1.0 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min [-5-min/+30-min] i.v. infusion)
9730356|NCT02611024|Experimental|Irinotecan Escalation Group|Starting dose of Irinotecan 15 mg/m^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 3.0 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion followed by Irinotecan alone on Day 8 (at the same dose as Day 1 and as a 90-min [-5-min/+30-min] i.v. infusion).
9730357|NCT02611024|Experimental|Intermediate Escalation Group|Starting dose of Irinotecan 50 mg/m^2 as a 90-min (-5-min/+30-min) i.v. infusion, followed by Lurbinectedin 2.6 mg/m^2 as a 60-min (-5-min/+20-min) i.v. infusion. No Irinotecan dose will be administered on Day 8 in this group.
9730358|NCT02609880|Experimental|Cognitive Behavioral Therapy|This group will receive Cognitive Behavioral Therapy to optimize sleep, pain, and mood in women with gynecologic cancers. The therapy will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
9730359|NCT02609880|Placebo Comparator|Psychoeducation|This group will receive Psychoeducation which is aimed at providing information, resources, and non-specific support related to adapting well to cancer. The education will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
9730360|NCT02588885|Experimental|Trauma-sensitive Care|Participants will attend 7, one-hour psychotherapy sessions, which will be concurrent with trauma-sensitive care at physical therapy appointments.
9730361|NCT02564796|Placebo Comparator|Control|Group II (non-treatment group): Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
9730362|NCT02564796|Experimental|Epoetin alfa and iron supplements|Group I (treatment group): Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
9730363|NCT02562716|Experimental|Arm I (mFOLFIRINOX, surgery)|Patients receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive 5-fluorouracil IV over 46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin, irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or unacceptable toxicity.
10200184|NCT04893187|Experimental|Part 3: Treatment Sequence 1 (A to B)|The subjects in the first cycle received oral administration of SSS17 on an empty stomach, and subjects in the second cycle received oral administration of SSS17 after a high-fat meal
9730364|NCT02562716|Experimental|Arm II (gemcitabine, nab-paclitaxel, and surgery)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride treatment in the absence of disease progression or unacceptable toxicity.
9730365|NCT02560129||ICU Survivors|ICU survivors will be seen in a MICU Recovery Clinic where Questionnaires, Physical and Cognitive Function assessments will be measured
9730366|NCT02558010|Experimental|Methadone Group|Patients will receive a total of 0.2mg/kg IV methadone intraoperative (0.1mg / kg preincision and 0.1mg/kg prior to emergence) with a maximum dosing of 20 mg.
9730367|NCT02558010|Active Comparator|Control Group|Patient will receive normal saline placebo initially, then morphine prior to emergence.
9730368|NCT02502006|Experimental|High Dose|During each treatment phase, subjects will receive celecoxib (200 mg by mouth twice daily), naproxen (500 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
9730369|NCT02502006|Experimental|Low dose|During each treatment phase, subjects will receive celecoxib (100 mg by mouth twice daily), naproxen (250 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
9730370|NCT02481245|Experimental|Bipolar I and Bipolar II Disorder|30 currently depressed patients with DSM-IV bipolar I or bipolar II disorder who are currently taking an adequate dose of an FDA-approved anti-manic medication will receive Bezafibrate treatment.
9730371|NCT02477384|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
9730372|NCT02477384|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
9730373|NCT02427724|Active Comparator|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
9730374|NCT02427724|Active Comparator|lidocaine 7%/tetracaine 7% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
9730375|NCT02427724|Placebo Comparator|placebo vehicle|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
9730376|NCT02393794|Experimental|Romidepsin (8mg/m2) + Cisplatin (75mg/m2)|Romidepsin 8mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
9730377|NCT02393794|Experimental|Romidepsin (10mg/m2) + Cisplatin (75mg/m2)|Romidepsin 10mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
9730378|NCT02393794|Experimental|Romidepsin (12mg/m2) + Cisplatin (75mg/m2)|Romidepsin 12mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
9730379|NCT02393794|Experimental|Romidepsin Dose Expansion|Romidepsin maximum tolerated dose (MTD) from Phase I IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle Nivolumab 360mg on day 1 of each 21 day cycle
9730380|NCT02323165||Burns and Wound Care|Blood samples will be taken to detect and identify a molecular detection of bacteria in the bloodstream. In addition, data will be collected from the standard of care blood samples and compared.
9730381|NCT02316951||single-arm study group|Study participants will be adult patients recovering from orthopedic surgery. The study group will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room.
9730382|NCT02307630|Experimental|PET Imaging using 124I-Humanized 3F8|124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
9730383|NCT02289781||Zirconia posterior crowns|Monolithic zirconia crowns which are polished and non-glazed
9730384|NCT02289781||Metal-Ceramic posterior crowns|Metal-supported glass-ceramic veneered crowns which are polished and non-glazed
9730385|NCT02276066|Active Comparator|Inhospital group at day 14|This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
9781244|NCT01144338|Placebo Comparator|Placebo|
9781245|NCT01144364|Experimental|1|
9781246|NCT01144377|Experimental|180 mg LY2541546 Q4W + Placebo|"LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
9781247|NCT01144377|Experimental|180 mg LY2541546 Q2W|LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
9730386|NCT02276066|Other|Released from hosptial prior to day 14|This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
9730387|NCT02263508|Experimental|Phase 1b;|Phase 1b: talimogene laherparepvec and pembrolizumab (MK-3475)
9730388|NCT02263508|Experimental|Phase 3 Arm 1;|Phase 3 Arm 1: talimogene laherparepvec and pembrolizumab (MK-3475)
9730389|NCT02263508|Experimental|Phase 3 Arm 2;|Phase 3 Arm 2: placebo and pembrolizumab (MK-3475)
9730390|NCT02211131|Other|Surgery|Surgical resection of melanoma tumor lesion(s)
9730391|NCT02211131|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec for 6 doses followed by surgical resection of melanoma tumor lesion(s).
9730392|NCT02152254|Active Comparator|Arm A: Targeted Therapy|Personalized treatment, targeted therapy against the alteration based on molecular profiling.
9730393|NCT02152254|Experimental|Arm B: Standard-of-Care Therapy|Standard-of-Care treatment not selected on basis of alteration analysis.
9730394|NCT02056132||Cystic Fibrosis patients.|Patients with Cystic Fibrosis. Results of Exhaled Breath Condensate lab.
9730395|NCT02056132||Control Subjects|Individuals without Cystic Fibrosis or signs of current respiratory infection. Results of Exhaled Breath Condensate lab.
9730396|NCT02047513|Experimental|perioperative nab-paclitaxel/gemcitabine|neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
9730397|NCT02047513|Experimental|adjuvant nab-paclitaxel/gemcitabine|Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
9730398|NCT02043847|Experimental|Cohort 1Total Marrow Irradiation (TMI) 3Gy|3Gy with standard high dose melphalan prior to autologous stem cell rescue
9730399|NCT02043847|Experimental|Cohort 2 Total Marrow Irradiation (TMI) 6Gy|6Gy with standard high dose melphalan prior to autologous stem cell rescue
9730400|NCT02043847|Experimental|Cohort 3 Total Marrow Irradiation (TMI) 9Gy|9Gy with standard high dose melphalan prior to autologous stem cell rescue
9730401|NCT01976286|Active Comparator|Salicylic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
9730402|NCT01976286|Active Comparator|Glycolic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
9730403|NCT01976260|Active Comparator|Fractional Radiofrequency|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
9730404|NCT01976260|Active Comparator|1550-nm Fractional Photothermolysis|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
9730405|NCT01954576|Experimental|NovoTTF therapy|Patients undergo NovoTFF therapy at least 18 hours daily for 6 months (bevacizumab-naive) or 4 months (bevacizumab-refractory). Treatment may continue for up to 2 years in patients experiencing CR, PR, or SD.
9730406|NCT01944566|Experimental|heavy armpit odour|subjects with heavy armpit odour
9730407|NCT01943695|Experimental|Aerobic Training During Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training an intensity of at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy. VO2peak will be determined by the CPET performed at baseline. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
9730408|NCT01943695|Experimental|Aerobic Training After Chemotherapy|The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training at an intensity 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy. VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients. For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
9781248|NCT01144377|Experimental|270 mg LY2541546 Q2W|LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
10200185|NCT04893187|Experimental|Part 3: Treatment Sequence 2 (B to A)|The subjects in the first cycle received oral administration of SSS17 after a high-fat meal, and the subjects in the second cycle received oral administration of SSS17 on an empty stomach
10200186|NCT04891198|Experimental|Subjects with TMB-H/TMB-L|Subjects receive KN035 400 mg Subcutaneously on Day 1 of every 4-week cycle (Q4W)
9730409|NCT01943695|Experimental|Continuous Aerobic Training|The ultimate goal is for participants to complete 3 exercise sessions week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy. For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.
9730410|NCT01943695|Experimental|General Physical Activity Group|Patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, consultation with a staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to record type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress, and answer questions.
9730411|NCT01913912|Active Comparator|Lisdexamfetamine dimesylate (LDX)|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the optimal dose of LDX will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking LDX at the DRUG unit.
9730412|NCT01913912|Placebo Comparator|Sugar pill|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the placebo will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking placebo at the DRUG unit.
9730413|NCT01803854||Gulf War Era Veterans|All Veterans who served in the uniformed services during 1990-1991 who signed consent forms, completed a survey, and provided a blood sample are included in the cohort.
9730414|NCT01799265|Active Comparator|Transcend followed by REMstar|The patient will receive treatment with Transcend during the first night sleep study, followed by treatment with the REMstar on the second night.
9730415|NCT01799265|Active Comparator|REMstar followed by Transcend|The patient will receive treatment with REMstar during the first night sleep study followed by treatment with Transcend on the second night.
9730416|NCT01775644||Metastatic Colorectal Cancer Participants|"Administration of treatment will be as used in normal daily routine under local labelling in 4 subgroups- participants with liver and/or lung metastases, potentially resectable after a response to a systemic therapy and clinically operable; participants with tumor related symptoms, risks for complications or fast progression for whom quick proliferation control is needed; asymptomatic participants (indolent tumor) without the option of a metastases resection (no pressure for remission) for whom the aim of the therapy is proliferation control and participants without classification."
9730417|NCT01733433|Experimental|taped ankle|Subjects will be taped in at the ankle for a series of exercises.
9730418|NCT01729858||Metal-Ceramic|Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.
9730419|NCT01729858||Ceramic-Ceramic|Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.
9730420|NCT01725633|Other|Progressive Stretching Group|
9730421|NCT01725633|Experimental|Nonlinear Aerobic Training|
9730422|NCT01639937||1|Subjects with palliated congenital heart disease including, but not limited to, d TGA, ccTGA, single ventricles, hypoplastic left heart syndrome and tricuspid atresia will be recruited
9730423|NCT01620203||Control|Matched group of control infants without diagnosis of intracranial hemorrhage
9730424|NCT01620203||Intracranial Hemorrhage|Group of preterm infant with diagnosis of intracranial hemorrhage.
9730425|NCT01541345|Active Comparator|Control Group (A)|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland). These course of action is well documented in the literature and standard procedures.
9781249|NCT01144377|Experimental|270 mg LY2541546 Q12W + Placebo|"LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
10200187|NCT04875052|Active Comparator|Standard ACL Rehabilitation|Patients will complete a 20-week supervised, progressive rehabilitation protocol directed by physical therapists at 1 of 3 participating clinics. While the specific rehabilitation exercises and techniques used for a given patient may vary depending on clinician preference/experience and patient responsiveness and progress, the general rehabilitation protocol will be standardized and follow current best practices emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control consistent with the Multicenter Orthopaedics Outcomes Network (MOON) rehabilitation protocol.
10200188|NCT04875052|Experimental|Whole Body Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to whole body vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
9730426|NCT01541345|Experimental|Test group (B)|The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group. In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
9730427|NCT01529996|Experimental|YAG laser|
9730428|NCT01529996|Active Comparator|Pulse Dye Laer|
9730429|NCT01484093|Experimental|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|This is a phase I/phase II multi-institution trial. The phase I part of the trial will determine the MTD of cytarabine. The phase II part of the trial will examine the efficacy of the proposed regimen by evaluating the 3-year event-free survival (EFS) in patients with untreated mantle cell lymphoma. All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR.
9730430|NCT01472081|Experimental|Arm S: Nivolumab + Sunitinib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons"
9730431|NCT01472081|Experimental|Arm P: Nivolumab + Pazopanib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons"
9730432|NCT01472081|Experimental|Arm I-1: Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons~Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons"
9730433|NCT01472081|Experimental|Arm I-3: Nivolumab + Ipilimumab|"Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
9730434|NCT01472081|Experimental|Arm IN-3: Nivolumab+Ipilimumab|"Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
9730435|NCT01470105||pts bone metastases|This is a prospective, cross sectional, human use study conducted using patients with bone metastases requiring orthopaedic stabilization. Though this is an observational study, blood sampling, the SF-36 questionnaire, and ECOG performance status, and correlative studies will be performed.
9730436|NCT01367002|Active Comparator|Carboplatin/Paclitaxel|Chemotherapy
9730437|NCT01367002|Experimental|Trastuzumab|Monoclonal antibody
9730438|NCT01309672|Experimental|Abiraterone acetate + prednisone|"Abiraterone, 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); to be taken daily~Prednisone, 5 mg, oral, 5 mg twice daily"
9730439|NCT01257763|Experimental|Study device|The study device is a transdermal microneedle array designed to introduce microscopic channels into the skin. The study device arm will receive application of this device.
9730440|NCT01257763|Sham Comparator|Sham device|The sham device will be very similar in appearance to the study device. The sham device arm will receive application of this device.
9730441|NCT01161641|Experimental|ODSH at 0.125 mg/kg/h|First cohort of 3 subjects to be administered the lowest dose of ODSH.
9730442|NCT01161641|Experimental|ODSH at 0.250 mg/kg/h|Second cohort of 3 subjects to receive the medium dose of ODSH
9730443|NCT01161641|Experimental|ODSH at 0.375 mg/kg/h|Third and last cohort of subject to receive the high dose of ODSH.
9730444|NCT01131169|Experimental|relapsed multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
9730445|NCT01131169|Experimental|high-risk multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
9730446|NCT01067196||Observation and quality of life|Central Nervous System Tumors
9730447|NCT00974870|Experimental|needling treatment|Needling treatment applied to half of the face at each study visit
9730448|NCT00974870|No Intervention|Control|No treatment applied to half of the face
9730449|NCT00882791||Historical Arm|266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
9730450|NCT00882791||Prospective Arm|300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
9730451|NCT00882505|Experimental|Vitamin D supplement|Receive vitamin D supplements.
9730452|NCT00882505|Placebo Comparator|Placebo|Receive placebo pills
9730453|NCT00882505|No Intervention|Tanning bed user|Regular tanning bed users will be assessed for their vitamin D levels.
9730454|NCT00871013|Experimental|MEL-VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, Etoposide
9730455|NCT00774345|Experimental|Experimental: 1|Lenalidomide po qd on days 1-28 of a 28 day cycle
9730456|NCT00774345|Placebo Comparator|Placebo Comparator: 2|Placebo capsules given orally on days 1-28 of a 28 day cycle
9730457|NCT00735657|Active Comparator|Group 1|Control
9730458|NCT00735657|Active Comparator|Group 2|Block with short needle
9730459|NCT00510055|Experimental|A|scars receive subdermal manipulation ONLY
9730460|NCT00510055|Experimental|B|scars receive subdermal manipulation AND injection of a filler
9730461|NCT00467233|Experimental|1|Laser Treatment
9730462|NCT00467233|Experimental|2|Acid peel
9730463|NCT00457951|Experimental|Open Label|Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
9730464|NCT00457951|Placebo Comparator|0.9% Sodium Chloride|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
9730465|NCT00457951|Active Comparator|Randomized, Blinded, ODSH Arm|Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.
9730466|NCT00345943||Adolescents with Bulimia Nervosa or subclinical BN|Adolescents with Bulimia Nervosa or subclinical Bulimia Nervosa
9730467|NCT00345943||Healthy control adolescents|Healthy control adolescents
9730468|NCT00258427|Experimental|Marrow Isolex|Bone marrow processed using Isolex300i
9730469|NCT00258427|Experimental|USB arm|No processing
9730470|NCT00258427|Experimental|Marrow Clinimacs|Bone marrow processed using CliniMACS system
9730471|NCT00258427|Experimental|Sibling without CliniMacs|Sibling donor without the use of CliniMACS system
9730472|NCT00250341|Active Comparator|Advair|
9730473|NCT00250341|Experimental|QVAR|
9730474|NCT03723889||PDA|Evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
9730475|NCT03723889||noPDA|No evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
9730476|NCT03723668||OPTN data system|In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
9730477|NCT03723668||CRISTAL registry|In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
9730478|NCT03723486||Roux-en-Y gastric bypass surgery (RYGB)|Morbidly obese patients undergoing gastric bypass surgery
9730479|NCT03723278||Healthy individuals|Young, male and healthy volunteers without any significant disease
9730480|NCT03722810|Active Comparator|Active comparator: patient interview|This intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.
9730481|NCT03722810|Sham Comparator|Sham comparator: document|In this intervention, the student's allocated GP teacher will give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher.
9730482|NCT00000125|No Intervention|Observation|Close Observation.
9730483|NCT00000125|Other|Treatment|Participants treated with commercially available topical ocular hypotensive eye drops.
9730484|NCT00000134|Experimental|intravenous foscarnet|intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
9730485|NCT00000134|Active Comparator|intravenous ganciclovir|intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
9730486|NCT00000134|Active Comparator|combination therapy|combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
9730487|NCT00000135|Experimental|MSL-109|The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.
9730488|NCT00000135|Placebo Comparator|Placebo|Placebo administered intravenous infusion every 2 weeks 60 mg.
9730489|NCT00000136|Experimental|Foscarnet|The induction dose for foscarnet is 60 mg/kg every 8 hours. Full dose maintenance therapy for foscarnet is 90 mg/kg/day
9730490|NCT00000136|Experimental|Ganciclovir|The induction dose for ganciclovir is 5 mg/kg every 12 hours. Full dose maintenance therapy for ganciclovir is 5 mg/kg every 24 hours, 7 days a week.
9730491|NCT00000142|Experimental|treatment deferral|"IV (in the vein) treatment deferred until retinitis progressed, either:~5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks, or~5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
9730492|NCT00000142|Experimental|Cidofovir (low dose)|5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks
10200189|NCT04875052|Experimental|Local Muscle Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to local muscle vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
10200190|NCT04870125|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
10200191|NCT04870125|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
10200192|NCT04865497|Experimental|High dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
10200193|NCT04865497|Experimental|Low dose Group|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
10200194|NCT04865497|Other|Adjuvant-free Group|Adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
10200195|NCT04865497|Other|Control Group|Haemophilus b Conjugate Vaccine,10μg/dose
9664978|NCT05237726|Active Comparator|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will receive Enoxaparin 40 mg q24 hours as pharmacological VTE prophylaxis
9664979|NCT05237726|Active Comparator|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will receive Enoxaparin 30 mg q12 hours as pharmacological VTE prophylaxis
9664980|NCT05236868|Experimental|Seltorexant|Participants will receive a single oral dose of seltorexant. At 2 hours after oral dosing, participants will receive 14C-seltorexant as an intravenous (IV) infusion over 15 minutes.
9664981|NCT05236530|Experimental|Cohort 1|Each participant will receive a single oral dose of the 4-probe substrate cocktail consisting of midazolam, repaglinide, dextromethorphan and metformin in the morning of Day 1 of Period 1. In Period 2, participants will receive ganaplacide and lumefantrine combination orally once daily (q.d.) in the morning on Days 1 through 3, with a single oral dose of the 4-probe substrate cocktail co-administered on Day 3.
9664982|NCT05236530|Experimental|Cohort 2|Each participant will receive a single oral dose of the 2 probe substrate cocktail consisting of rosuvastatin and dolutegravir in the morning on Day 1 of Period 1. In Period 2, participants will receive ganaplacide and lumefantrine combination orally q.d. in the morning on Days 1 through 3, with a single oral dose of the 2 probe substrate cocktail co-administered on Day 3.
9664983|NCT05233774|Placebo Comparator|Placebo|Group 1 will receive four infusions of Placebo on Day 0, Week 4, Week 8, and Week 12.
9664984|NCT05233774|Experimental|Lomecel-B Dose 1|Group 2 will receive an infusion of Lomecel-B at a dose of 25 x 10^6 cells (25M) on Day 0, followed by Placebo infusions at Week 4, Week 8, and Week 12.
9664985|NCT05233774|Experimental|Lomecel-B Dose 2|Group 3 will receive four infusions of 25M Lomecel-B on Day 0, Week 4, Week 8, and Week 12.
9664986|NCT05233774|Experimental|Lomecel-B Dose 3|Group 4 will receive four infusions of Lomecel-B at a dose of 100 x 10^6 cells (100M) on Day 0, Week 4, Week 8, and Week 12.
9664987|NCT05231993|Active Comparator|Active comparator|"All women ages <41, women ages ≥41 with TZ1 and TZ2, and women ages ≥41 with a desire for further childbearing Clinical management and follow-up according to the national screening guidelines published in 2017 (same as for the comparator group, see below).~Women with TZ3 and women ages ≥41 with no desire for further childbearing a. Referral to (diagnostic) excision. The depth of the diagnostic excision will be clinically determined in the trial. It should be with the intent to treat but no so extensive that the risk for side effects increases.~The excision should include a cervical abrasion and endometrial sampling."
9664988|NCT05231993|Placebo Comparator|Placebo comparator|"Clinical management and follow-up according to the national screening guidelines published in 2017:~Colposcopy with biopsy within 3 months, endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~Colposcopy after 12 months if the first colposcopy and biopsies are normal~Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
9664989|NCT05231772|Experimental|Probiotics|Patients in the Test arm will receive Saccharomyces boulardii (Saccharomyces), (Enterol), Biocodex Ltd, France, registration number LP-000622 from 21.09.2011 at a dose of 250 mg 2 times a day for 3 months.
9664990|NCT05231772|Placebo Comparator|Placebo|Patients in the Placebo arm will receive the placebo at a dose of 250 mg 2 times a day for 3 months.
9664991|NCT05231525|Experimental|WiTOF|
9664992|NCT05231525|Active Comparator|TOFscan|
9664993|NCT05231200|Active Comparator|Control Arm- Current management|NICUs in the control arm can continue conducting QI activities relevant to current practice and current standard of care, but without receiving the interventions until they transition to the intervention arm.
9664994|NCT05231200|Experimental|Intervention Arm- Collaborative Quality implementation Strategies|The study intervention is a constellation of collaborative QI strategies: 1) QI Team Building; 2) QI Education; 3) Implementation of 2 standardized practice care bundles (Respiratory Care, and Nutritional Care); 4) QI mentoring; and 5) Collaborative networking.
9664995|NCT05230940|Experimental|TURKOVAC|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
9664996|NCT05230940|Active Comparator|CoronaVac|The dose of the CoronaVac vaccine will be 3 μg/0.5 mL. It will be administered by injection to the left deltoid muscle of the upper arm, two doses are given 28 days apart.
9664997|NCT05230147|Experimental|Spinal cord stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define the stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. Stimulation is initiated within 2 min before tilting the table. Then verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
9664998|NCT05230147|Sham Comparator|Sham stimulation|"Before tilt testing, adhesive patches are applied to subjects' back skin. Single stimuli are delivered to the patches in order to define stimulation threshold under the guidance of neuromyography. An investigator says loudly: I am initiating high-frequency stimulation. No stimulation is initiated. Two minutes after, verticalization of the table 45 degrees is performed, and the test is continued for 15-30 min. Beat-to-beat blood pressure recording is carried out and 10 min after blood pressure complete stabilization the test is ended."
10200196|NCT04855357|Experimental|Smoke-free home permanent supportive housing (PSH) resident intervention + Staff Intervention|Study staff will deliver a one hour, one-on-one counseling to PSH residents that includes: (1) a step-by-step guide on how to voluntarily adopt a smoke-free home, (2) information on second hand smoke (SHS) and third-hand smoke, alternative combustible tobacco and nicotine product use, cannabis-tobacco co-use, effects of SHS on kids and pets,(3) a worksheet on calculating personal costs related to tobacco use, and (4) pledges to designate one's home smoke-free. At follow-up assessments, the study team will ask participants whether they had a chance to view the intervention materials in between visits and will offer an opportunity for participants to discuss conflicts that they had experienced around smoke-free home adoption and will provide strategies to address these roadblocks.
9730493|NCT00000142|Experimental|Cidofovir (high dose)|5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
9730494|NCT00000143|Experimental|Ganciclovir implant and oral ganciclovir|Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
9730495|NCT00000143|Experimental|Cidofovir IV (Intravenous)|cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
9730496|NCT00000371|Experimental|D-Cycloserine|Subjects were given 50 mg/day of D-Cycloserine for 24 weeks
9730497|NCT00000371|Placebo Comparator|Placebo|Participants were given 50 mg/day of Placebo for 24 weeks.
9730498|NCT00000378|Active Comparator|sertaline|patients randomized to sertraline 12 week trial does up to 200mgs
9730499|NCT00000378|Active Comparator|nortriptyline|patients randomized to nortriptyline dose adjusted to therapeutic level
9730500|NCT00000392|Active Comparator|Peptide T|Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
9730501|NCT00000392|Placebo Comparator|Placebo|Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
9730502|NCT00000479|Experimental|1|Vitamin E (600 IU every other day) and aspirin (100 mg every other day)
9730503|NCT00000479|Experimental|2|Vitamin E (600 IU every other day) and placebo
9730504|NCT00000479|Experimental|3|Aspirin (100 mg every other day) and placebo
9730505|NCT00000479|Placebo Comparator|4|Placebo and placebo
9730506|NCT00000575|Active Comparator|1 Budesonide|Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
10200197|NCT04855357|Other|Wait-List Control (Usual Care) then crossover to Smoke-free home PSH resident intervention|The current standard of care includes no interventions for smoke-free home adoption or referrals to smoking cessation resources. Wait-list group receives Smoke-Free Home (SFH) intervention after intervention group complete 6-month follow-up
10200198|NCT04853654|Experimental|Selective training|selective training on lower extremity for 3 days/week
10200199|NCT04853654|Experimental|Downhill walking|downhill walking training on the treadmill for 2 days/week
10200200|NCT04853654|Experimental|Uphill walking|uphill walking training on the treadmill for 2 days/week
10200201|NCT04847310|Experimental|Group 1|
10200202|NCT04847310|Experimental|Group 2|
9730507|NCT00000575|Active Comparator|2 Nedocromil|Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
9730508|NCT00000575|Placebo Comparator|3 Placebo|Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.
9730509|NCT00000620|Experimental|Glycemia Trial: intensive control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels <6.0%.
9730510|NCT00000620|Active Comparator|Glycemia Trial: standard control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.
9730511|NCT00000620|Experimental|BP Trial: intensive control|Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to <120 mmHg.
9730512|NCT00000620|Active Comparator|BP Trial: standard control|Open label administration of multiple anti-hypertensive agents to maintain SBP level <140 mm Hg.
10200203|NCT04847310|Active Comparator|Group 3|
10200204|NCT04846907||Healthcare personnel working in pediatric intensive care units during COVID-19 pandemic|Physicians, registered nurses, nurse technicians, physical therapists and other professionals; on duty, routine staff or fellow/residents working in participants PICU
10200205|NCT04845347|Experimental|Bright Light Therapy|
10200206|NCT04845347|Sham Comparator|Dim Light Therapy|
9730513|NCT00000620|Experimental|Lipid Trial: fenofibrate|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
9730514|NCT00000620|Placebo Comparator|Lipid Trial: placebo|Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
9730515|NCT00001151|Experimental|Drug treatment|1,25-Dihydroxycholecalciferol 5 ug orally per day for 2 years
9730516|NCT00001213|Experimental|Cysteamine topical solution|Cysteamine topical solution administered hourly while awake in both eyes
9730517|NCT00001262|Experimental|Copper histidine|
9730518|NCT00001304|Experimental|PTH 1-34|All patients received twice daily synthetic Human Parathyroid Hormone 1-34.
9730519|NCT00001304|Experimental|Calcitriol & Calcium|All patients received twice daily Calcitriol and Calcium 1000mg divided into four doses daily.
9730520|NCT00001305|Experimental|Growth Hormone|Treatment of children with types III and IV osteogenesis imperfecta with Humatrope
9730521|NCT00001566|Experimental|Peptide vaccine/autologous T cell transplant/indinavir therapy|Patients receive oral indinavir sulfate 350 mg/m^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10^6 injection; harvested autologous T cells (minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
9781250|NCT01144377|Placebo Comparator|Placebo Comparator Q2W|Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
9730522|NCT00001575|Experimental|Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)|"10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).~Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body"
9730523|NCT00001586|Experimental|Low-Intermediate Risk B-Cell Pts|Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered. Eligible to donate cells.
9730524|NCT00001586|Experimental|Intermediate-high Risk B-Cell Pts|Previously untreated intermediate or high risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients requiring chemotherapy. Rituximab 375 mg/m^2 by infusion on day 1, cycle 1 followed by fludarabine on day 2-6, 25 mg/m^2 day x 5 days administered as an intravenous push or intravenous piggyback over 10-30 minutes, repeated every 28 days.
9730525|NCT00001596|Active Comparator|Pirfenidone|Subjects received pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
9730526|NCT00001596|Placebo Comparator|Placebo|Subjects received placebo (3 pills), three times daily.
9730527|NCT00001656|Active Comparator|Olanzapine|
9730528|NCT00001656|Active Comparator|Clozapine|
9730529|NCT00001703|Experimental|Group A-VHL peptide and ISA-51 adjuvant|Patients are vaccinated with 1000 micrograms of the mutant Von Hipple-Lindau (VHL) peptide administered subcutaneously along with ISA-51 adjuvant (Montanide ISA-51 adjuvant, Incomplete Freund's adjuvant) and injected subcutaneously every four weeks for a total of four vaccinations.
9730530|NCT00001723|Placebo Comparator|Placebo|Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
9730531|NCT00001723|Experimental|Orlistat|Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
9730532|NCT00001832|Experimental|Abl Cells in culture|"Peripheral blood mononuclear cells (PBMC) and/or tumor infiltrating lymphocytes (TIL) obtained by apheresis or lesion excision to be cloned and expanded in the lab.The patients underwent an apheresis and/or an excision of their tumor.~They didn't receive any drugs."
9730533|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 30 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730534|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 60 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730535|NCT00001832|Experimental|Abl Cells IV+Low Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730536|NCT00001832|Experimental|Abl Cells IV+High Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730537|NCT00001832|Experimental|Abl Cells IV + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730538|NCT00001832|Experimental|Abl Cells IA + MTD (prior cells IV on 6)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
9730539|NCT00001832|Experimental|Abl Cells IA + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
9730540|NCT00001832|Experimental|Abl Cells IA+MTD IL-2 (MART-1 reactive)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
9730541|NCT00001832|Experimental|Abl Cells IV + MTD IL-2 no GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730542|NCT00001832|Experimental|Abl Cells IV+MTD IL-2 no GCSF|"Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
9730543|NCT00001832|Experimental|Abl Cells IV+MTD IL-2|"Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
9730544|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730545|NCT00001832|Experimental|Abl Cells IV + SQ|Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730546|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF (no reactivity)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
9730547|NCT00001849|Experimental|Patients with Cushing Syndrome|Patients receive various types of radiologic or nuclear medicine scans to identify tumor
9730548|NCT00001880|Experimental|Stem Cell Transplantation in Patients With Progressive and Incurable Metastatic Solid Tumors|Cyclosporin beginning day -4 then stem cells given on Day 0 followed by intravenous Methotrexate on days +1, +3, and +6.
9730549|NCT00001941|Experimental|Phase I - 2 mg/kg cohort|2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2
9730550|NCT00001941|Experimental|Phase I - 4 mg/kg cohort|4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
9730551|NCT00001941|Experimental|Phase I - 6 mg/kg cohort|6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
9730552|NCT00001941|Experimental|Phase I - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
9730553|NCT00001941|Experimental|Phase II - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
9730554|NCT00001962|Experimental|Daclizumab in participants with a bone marrow failure syndrome|daclizumab, 1 mg/kg, will be given for a total of 5 intravenous infusions. These subjects may be diagnosed with moderate aplastic anemia, pure red cell aplasia, Diamond Blackfan anemia, relapse and refractory severe aplastic anemia will receive treatment. The subjects will be seen and receive the daclizumab infusion biweekly during the treatment period.
9730555|NCT00001984|Experimental|Alemtuzumab and DSG|The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.
9730556|NCT00002525|Experimental|Perioperative 5-FU|"Within 24 hours of the colon resection, patients receive perioperative fluorouracil intravenously (IV) over 24 hours for 7 days.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
9730557|NCT00002525|Active Comparator|No perioperative 5-FU|"Patients receive no perioperative fluorouracil.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
9730558|NCT00002540|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
9730559|NCT00002540|Active Comparator|Prostate Screening|Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.
9730560|NCT00002558|Experimental|chemotherapy administered with G-CSF and PBSC support|The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.
9730561|NCT00002597|Experimental|Neoadjuvant TAS + RT|Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
9730562|NCT00002597|Other|Radiation therapy alone|Radiation therapy alone
10200207|NCT04839354|Experimental|Arginine Hydrochloride|Arginine is a nutritional supplement in parenteral form
10200208|NCT04839354|Placebo Comparator|Placebo|Normal saline
10200209|NCT04834076||Cancer patients|50 cancer patients referred to the Oncology Department, Faculty of medicine, Sohag University.
10200210|NCT04834076||Healthy controls|50 healthy controls will be recruited in the study.
10200211|NCT04832477|Other|Stigma Counseling for PrEP Access|Behavioral counseling
10200212|NCT04823247||Tildrakizumab|Patients diagnosed with moderate-to-severe plaque psoriasis who require systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor in real-world clinical practice, following the routine clinical practice on each patient country, will be observed for 24 months.
10200213|NCT04821609|Experimental|Resistance training group|Twice a week sessions supervised and group, during 12 weeks
9730563|NCT00002601|Experimental|Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT|"Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.~Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused"
9730564|NCT00002651|Active Comparator|Consolidation arm I|Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
9730565|NCT00002651|Experimental|Consolidation arm II|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.
9730566|NCT00002766|Experimental|"ARA-C/High-Dose Mitoxantrone(All-2)"|See detail description
9730567|NCT00002766|Active Comparator|"Standard Vincristine/Prednisone (L-20)"|See detail description
9730568|NCT00002842|Experimental|Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin|Patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks
9730569|NCT00002850|Experimental|Ciprofloxacin or ofloxacin|"Quinolone:~Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours."
9730570|NCT00002850|Experimental|TMP-SMX|TMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
9730571|NCT00002850|No Intervention|No prophylaxis|The patient will receive no prophylactic antibiotics.
9730572|NCT00002931|Experimental|HD Chemo and Auto Stem Cells|
9730573|NCT00003138|Active Comparator|Supportive Care|Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of >= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
9730574|NCT00003138|Experimental|Erythropoietin|Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.
9730575|NCT00003199|Experimental|Arm I|See Detailed Description.
9730576|NCT00003222|Experimental|Peptides pulsed on dendritic cells|4 melanoma peptides pulsed on monocyte-derived dendritic cells
9730577|NCT00003222|Experimental|Peptides in GMCSF-in-adjuvant|4 melanoma peptides administered as an emulsion with GM-CSF and Montanide ISA-51 adjuvant.
9730578|NCT00003224|Experimental|Group 1: peptide 946 plus QS-21|100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
9730579|NCT00003224|Experimental|Group 2. p946 plus IFA|100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
9730580|NCT00003224|Experimental|Group 3: p946 plus Tet-p plus QS-21|100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
9730581|NCT00003224|Experimental|Group 4. p946, Tet-p plus IFA|100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
9730582|NCT00003224|Experimental|Group 5: p946/Tet-p plus QS-21|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
9730583|NCT00003224|Experimental|Group 6. p946/Tet-p plus IFA|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
9730584|NCT00003270|Experimental|Arm 1|Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0
9730585|NCT05235100|Experimental|Apatinib arm|Apatinib 500mg QD, used 2 weeks prior to IMRT, concurrent with pre-operative IMRT, and 1 month after end of IMRT
10200214|NCT04821609|No Intervention|Control Group|The control group will follow the usual physical therapy management, which does not include resistance training
10200215|NCT04817787|Placebo Comparator|LoEx+Placebo|"Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions while receiving placebo.~Drug: Low Intensity Exercise + Placebo~Low Intensity Exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo."
10200216|NCT04817787|Placebo Comparator|HiEx+Placebo|"Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions while receiving placebo.~Drug: High Intensity Exercise + Placebo~High Intensity Exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo."
10205067|NCT04119375|Active Comparator|Control|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
9730586|NCT05235087|Experimental|Bovine Atelocollagen Skin Sensitization Test|Volunteer cohort tested for hypersensitivity towards intradermal injection of bovine atelocollagen.
9730587|NCT05235074|Experimental|Dose escalation and dose expansion|The dose-escalating phase of the phase I trial of OH2 injection is divided into two dose groups (10^6 CCID50/mL and 10^7 CCID50/mL).It will be administered by Ommaya reservoir injection, and the total amount of each dose in each dose group should not exceed 2ml according to the size of the tumor cavity.
9730588|NCT05235048|Placebo Comparator|Standard of care control|Tooth extraction and spontaneous healing
9730589|NCT05235048|Experimental|Socket seal with CT graft|Tooth extraction and socket sealing with autologous connective tissue graft
9730590|NCT05235048|Experimental|Socket seal with CT graft and bone replacement graft|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket
9730591|NCT05235048|Experimental|Tooth extraction and socket sealing and BRG with membrane|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket and positioning of collagen membrane
9730592|NCT05235035||health care professionals|Staff from the department of anesthesia and general resuscitation and thoracic cardiac pediatric with patient contact that regularly works in shifts including night shifts
9730593|NCT05234996|Active Comparator|virtual reality|In The VRE arm, patients will use Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics. During the entire experience, an operator dedicated to patient care will be present to allow the most possible comfortable experience.
9730594|NCT05234996|Active Comparator|control arm|In control arm, patients will entertain themselves with conventional means such as listening to music, watching a mobile program, reading newspapers, books, magazines or also doing nothing, according to the patient's preferences
9730595|NCT05234983|Experimental|LifeFirst SWASTH brief advice intervention|"Described in the Intervention Description section"
9730596|NCT05234983|No Intervention|Control: Educational pamphlets|In lieu of the intervention, participants will receive a high-quality evidence-based pamphlet tobacco cessation pamphlet created by the NSF team for low-SES audiences in Mumbai. After all data has been collected, community healthcare settings in the control arm will have the opportunity to receive the intervention.
9730597|NCT05234957|Active Comparator|Asymmetric bilateral lateral rectus recession (A-BLR)|The amount of bilateral lateral rectus recession is asymmetrically divided between both eyes, with 2mm more recession in the non-dominant eye.
9730598|NCT05234957|Active Comparator|Symmetric bilateral lateral rectus recession (S-BLR)|The amount of bilateral lateral rectus recession is equally divided between both eyes.
9730599|NCT05234944|Experimental|Intervention|A CDCES trained by the research team will deliver the intervention via HIPAA compliant telehealth platform. There will be 2 sessions within approx 2 weeks of routine medical appointments over 1 year. Prior to each session, participants will complete an assessment of T1D-specific health-related quality of life, which will generate a summary report for each person that lists aspects of quality of life that are going well and aspects that are potential areas for improvement. The CDCES will review the reports with the participants, focusing on building on areas of strength and teaching brief behavioral strategies or resources to address aspects of quality of life that could be improved. Strategies may include stress management, problem-solving techniques, goal-setting, strategies to seek social support, or other brief behavioral skills. The CDCES will also offer information about relevant resources and will provide referrals for mental health support as needed.
9730600|NCT05234918|Experimental|(Kedo S plus file study group)|Group1: Kedo S plus file study group (The teeth will be instrumented by Kedo S plus file)
9730601|NCT05234918|Experimental|(Kidzo-file study group)|Group2: Kidzo file study group (The teeth will be instrumented by Kidzo file)
9730602|NCT05234918|Experimental|(Manual K-file control group)|Group3: Manual K-file control group (The teeth will be instrumented by Manual K-file)
9730603|NCT05234905|Experimental|Recombinant human adenovirus type 5+ Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×10^12vp (3 injections) on day 1, 1.0×10^12vp (2 injections) on day 4.~② Tumor maximum diameter >5cm but ≤10cm, 3.0×10^12vp (6 injections) on day 1 and 2.0×10^12vp (4 injections) on day 4.~③ Tumor maximum diameter >10cm, 4.5×10^12vp (9 injections) on day 1 and 3.0×10^12vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
9730604|NCT05234892||EVAR group|All consecutive eligible patients submitted to EVAR by Alto Endovascular AAA implantation will be included in analysis. Patients will be submitted to EVAR procedures on the basis of their own preferences, anatomical features, and operators experience.
9730605|NCT05234866||Phase I (Feasibility Study)|
9730606|NCT05234866||Phase II (Prospective Study)|
9730607|NCT05234853|Experimental|"Monotherapy classic 3+3 design dose escalation and expansion"|
9730608|NCT05234840|Active Comparator|Triamcinolone group|Patients were placed in the prone position. Transforaminal triamcinolone injections were performed under a C-arm fluoroscopy.
9730609|NCT05234840|Experimental|Platelet-rich plasma|Patients were placed in the prone position. Transforaminal PRPinjections were performed under a C-arm fluoroscopy.
9730610|NCT05234827|Experimental|Virtual Reality|VR sessions include a device (XBOX 360) and motion sensor (Kinect) and LED (tv screen) with speakers attached. Height of the device is 1m while tv screen is placed 2.5m away, motion sensor is placed 1.2m away from the patient, play area should be 1.8m wide and long. Instruction to play game is provided to each patient. Before starting each training session, the device was adjusted to correctly follow the movements of each patient. VR session includes games by Kinect Adventures (Microsoft games studios, Washington, US) which include minigames in which patients participated these mini games are 20000 Leaks, Curvy Creek, Rally Ball and Reflux Ridge.
9730611|NCT05234827|Active Comparator|Control|Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing
10200217|NCT04817787|Active Comparator|LoEx+Metformin|"Subjects randomly assigned to this group will participate in the same 3 supervised training sessions and 2 unsupervised training sessions, but they will be provided Metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not find out whether or not they are on Metformin until after the study is complete. If their doctor needs to know, the people doing this study can find out.~Drug: Low Intensity Exercise + Metformin~Low Intensity Exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo."
10200218|NCT04817787|Active Comparator|HiEx+Metformin|"Subjects randomly assigned to this group will participate in the same HiEx 3 supervised training sessions and 2 unsupervised training sessions, but they will be provided Metformin.~Drug: High Intensity Exercise + Metformin~High Intensity Exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo."
9730612|NCT05234814|Active Comparator|Control group|The control group was given the Traditional Chinese Medicine auricular acupuncture point buried seeds therapy.
9730613|NCT05234814|Experimental|Observation group|The observation group was given the auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.
9730614|NCT05234801||DARCO™ Headed Cannulated Screw|Patients who received a device from the DARCO™ Headed Cannulated Screw family of devices during routine lower limb surgery.
9730615|NCT05234801||ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|Patients who received a device from the ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System family of devices during routine lower limb surgery.
9730616|NCT05234801||ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|Patients who received a device from the ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module family of devices during routine lower limb surgery.
9730617|NCT05234801||CHARLOTTETM Multi-Use Compression (MUC) Screw System|Patients who received a device from the CHARLOTTETM Multi-Use Compression (MUC) Screw System family of devices during routine lower limb surgery.
10200219|NCT04816916|Experimental|AXA1665 53.8 g per day|AXA1665 administered orally TID
10200220|NCT04816916|Placebo Comparator|Matching placebo|Placebo administered orally TID
9730618|NCT05234788|Experimental|TransRadial access|Patients in this group are thus treated using a TRA approach
9730619|NCT05234788|Active Comparator|TransFemoral Access|Patients in this group are thus treated using a TFA approach.
9730620|NCT05234762|Experimental|ES-481|Week 1 - 25 mg qd (2 x 25 mg capsule in the mornings Days 1 to 7 in Treatment Period 1 and Days 44 to 50 in Treatment Period 2) Week 2 - 50 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 8 to 14 in Treatment Period 1 and Days 51 to 57 in Treatment Period 2) Week 3 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 15 to 21 in Treatment Period 1 and Days 58 to 64 in Treatment Period 2) Week 4 - 75 mg bid (2 x 25 mg capsule in the mornings and 2 x 25 mg capsules in the evening on Days 22 to 28 in Treatment Period 1 and Days 65 to 71 in Treatment Period 2)
10200221|NCT04816162|Placebo Comparator|Control group|21 ml of normal saline 0.9% will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively.
10200222|NCT04816162|Active Comparator|ketofol group|21 ml of a mixture of (ketamine and propofol) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
10200223|NCT04816162|Active Comparator|dexmedetomidine group|21 ml of a mixture of (dexmedetomidine diluted with normal saline 0.9%) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
10200224|NCT04809831|Active Comparator|Trial Group - Biorepair Peribioma Toothpaste + Mousse|Domiciliary oral hygiene with Biorepair Peribioma Toothpaste in association with Peribioma Mousse twice a day until T2 session.
10200225|NCT04809831|Active Comparator|Control Group - Curasept Toothpaste (chlorhexidine 0,2%)|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%) twice a day until T2 session.
10200226|NCT04807842|Other|Active product|
10200227|NCT04807842|Placebo Comparator|Placebo|
10200228|NCT04806217|Experimental|¨Patients with multiple sclerosis|"Patients :~With multiple sclerosis~Aged of 18 and over~Recruited during their consultation in the adult outpatient unit or neurological unit or during a hospitalization."
10200229|NCT04805528|Experimental|Experimental: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS) Therapy|Six (6) small electrodes will be placed on specific points of the body using adhesive pads. These electrodes are connected to the ALTENS device, which will send controlled, low-level electrical impulses through the skin and into the tissue underneath.
10200230|NCT04800510|No Intervention|NoCDO|Participants will be evaluated without a CDO.
10200231|NCT04800510|Experimental|CDO-A|The first design variant will be designated CDO-A.
10200232|NCT04800510|Experimental|CDO-B|The second design variant will be designated CDO-B.
10200233|NCT04800510|Experimental|CDO-C|The third design variant will be designated CDO-C.
10200234|NCT04800484|Experimental|Arm 1:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Soft, Short Firm, NoAFO
9730621|NCT05234762|Placebo Comparator|Placebo|Placebo will be dosed at the same quantity and frequency as ES-481 just as Placebo HPMC capsules
10200235|NCT04800484|Experimental|Arm 2:|Testing Order: Clinical AFO, Tall Soft, Tall Firm, Short Firm, Short Soft, NoAFO
10200236|NCT04800484|Experimental|Arm 3:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Tall Firm, Short Firm, NoAFO
10200237|NCT04800484|Experimental|Arm 4:|Testing Order: Clinical AFO, Tall Soft, Short Soft, Short Firm, Tall Firm, NoAFO
10200238|NCT04800484|Experimental|Arm 5:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Tall Firm, Short Soft, NoAFO
10200239|NCT04800484|Experimental|Arm 6:|Testing Order: Clinical AFO, Tall Soft, Short Firm, Short Soft, Tall Firm, NoAFO
10200240|NCT04800484|Experimental|Arm 7:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Soft, Short Firm, NoAFO
10200241|NCT04800484|Experimental|Arm 8:|Testing Order: Clinical AFO, Tall Firm, Tall Soft, Short Firm, Short Soft, NoAFO
10200242|NCT04800484|Experimental|Arm 9:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Tall Soft, Short Firm, NoAFO
10200243|NCT04800484|Experimental|Arm 10:|Testing Order: Clinical AFO, Tall Firm, Short Soft, Short Firm, Tall Soft, NoAFO
10200244|NCT04800484|Experimental|Arm 11:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Tall Soft, Short Soft, NoAFO
10200245|NCT04800484|Experimental|Arm 12:|Testing Order: Clinical AFO, Tall Firm, Short Firm, Short Soft, Tall Soft, NoAFO
10200246|NCT04800484|Experimental|Arm 13:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Short Firm, Tall Firm, NoAFO
10200247|NCT04800484|Experimental|Arm 14:|Testing Order: Clinical AFO, Short Soft, Tall Soft, Tall Firm, Short Firm, NoAFO
10200248|NCT04800484|Experimental|Arm 15:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Short Firm, Tall Soft, NoAFO
10200249|NCT04800484|Experimental|Arm 16:|Testing Order: Clinical AFO, Short Soft, Tall Firm, Tall Soft, Short Firm, NoAFO
10200250|NCT04800484|Experimental|Arm 17:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Soft, Tall Firm, NoAFO
10200251|NCT04800484|Experimental|Arm 18:|Testing Order: Clinical AFO, Short Soft, Short Firm, Tall Firm, Tall Soft, NoAFO
10200252|NCT04800484|Experimental|Arm 19:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Tall Firm, Short Soft, NoAFO
10200253|NCT04800484|Experimental|Arm 20:|Testing Order: Clinical AFO, Short Firm, Tall Soft, Short Soft, Tall Firm, NoAFO
10200254|NCT04800484|Experimental|Arm 21:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Short Soft, Tall Soft, NoAFO
10200255|NCT04800484|Experimental|Arm 22:|Testing Order: Clinical AFO, Short Firm, Tall Firm, Tall Soft, Short Soft, NoAFO
10200256|NCT04800484|Experimental|Arm 23:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Firm, Tall Soft, NoAFO
10200257|NCT04800484|Experimental|Arm 24:|Testing Order: Clinical AFO, Short Firm, Short Soft, Tall Soft, Tall Firm, NoAFO
10200258|NCT04787965||ONGENTYS|Opicapone 50 mg capsule once daily for 6 months
10200259|NCT04785690|Experimental|CureSight|eye-tracking-based
10200260|NCT04785690|Active Comparator|Patching|occlusive deprivation
10200261|NCT04770272|Experimental|Arm A|2 weeks Atezolizumab monotherapy before biopsy, followed by a 12-week therapy with Paclitaxel + Carboplatin+ Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
10200262|NCT04770272|Active Comparator|Arm B|12-week therapy with Paclitaxel + Carboplatin + Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
10200263|NCT04765345||Vision Cohort 1|"~25 participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter 10 degrees or more in every meridian of the central field.~The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date."
10200264|NCT04765345||Vision Cohort 2|"~15 participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 [approximate Snellen equivalent 20/100 - 20/400] or (visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter less than 10 degrees in any meridian of the central field).~The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging.~The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date."
10200265|NCT04728139|Active Comparator|patients with colorecta cancer|
10200266|NCT04728139|No Intervention|healthy individuals|
10200267|NCT04717635|Experimental|Canakinumab|All participants receive canakinumab (ACZ885) as open-label study medication. Participants are administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed is 300 mg.
10200268|NCT04716946|Experimental|Participants with Early-stage Non-Small Cell Lung Cancer|Participants will be diagnosed with Stage I-IIIA NSCLC and will be ineligible for surgery and will have any level of PD-L1
10200269|NCT04716075|Experimental|Acalabrutinib 2x100mg oral capsule +alloSCT|Acalabrutinib administered 2x100mg p.o. daily for 3-6 months before alloSCT +acalabrutinib administered 2x100mg p.o. daily for 9 months after alloSCT
10200270|NCT04713358|Experimental|Nalmefene group|for the nalmefene group, immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
10200271|NCT04713358|Placebo Comparator|Control group|Intravenous injection of normal saline 1ml immediately after surgery
10200272|NCT04700137|Active Comparator|Caring Contacts + Introductory Phone Call (CC+)|"Healthcare provider and staff participants who are randomized to both caring text messages and an introductory phone call.~Adult and adolescent participants who are randomized to both caring text messages and an introductory phone call."
9730622|NCT05234697||Morning group|Surgery performed during 08:00 to 12:00
9730623|NCT05234697||Afternoon group|Surgery performed during 14:00 to 18:00
9730624|NCT05234684|Experimental|Orelabrutinib+ R-CHOP|Participants will receive 150 mg of oral orelabrutinib once daily with R-CHOP on day 1 of each cycle (21 days).
9730625|NCT05234684|Placebo Comparator|Placebo+ R-CHOP|Participants will receive 150 mg placebo once daily with R-CHOP on day 1 of each cycle (21 days).
9730626|NCT05234671|Experimental|Exercise group|The exercise group will perform a supervised combined (e.g., aerobic and resistance training) 12-week exercise programme, twice per week adjunct to the patient's standard care.
9730627|NCT05234671|No Intervention|Control group|The control group will not perform the exercise programme and will receive only the standard care.
9730628|NCT05234658|Experimental|PHIT|
9730629|NCT05234658|Experimental|PHITAH|
9730630|NCT05234658|Active Comparator|Biobrane|
9730631|NCT05234658|Active Comparator|Autograft|
9730632|NCT05234645|Experimental|Younger group|Fifteen participants, between 18 and 35 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
9730633|NCT05234645|Experimental|Older group|Fourteen participants, between 55 and 75 years of age. Participants are not pregnant; are healthy and suffering from no chronic diseases with the potential to influence vascular function; non-smoker; sedentary (defined via the completion of the international physical activity questionnaire; IPAQ); and were not consuming regularly probiotic-containing products. Additionally, a medical questionnaire was completed to exclude anyone with overt chronic disease.
9730634|NCT05234632|Experimental|PICO 14 Any Wound|Any wound treated with PICO 14. For closed Surgical incisions this will be for 14 days post surgery and with a 30 day follow up. For chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
9730635|NCT05234632|Experimental|PICO 14 Closed Incisions|Any Closed incision treated with PICO 14, for closed Surgical incisions this will be for 14 days post-surgery and with a 30 day follow up.
9730636|NCT05234632|Experimental|PICO 14 Chronic/Dehisced Surgical Wounds|Any Chronic/Dehisced Surgical wound treated with PICO 14, for chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
9730637|NCT05234619|Active Comparator|Group one ( lidocaine or control LE ) Early deflation|Patients in group one (lidocaine or control group LE = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) then distal tourniquet deflation occurs after 20 minutes.
9730638|NCT05234619|Active Comparator|Group two ( lidocaine , ketorolac LKE) Early deflation|Patients in group two (lidocaine ketorolac LKE = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) plus ketorolac 0.5mg/kg (maximum 30mg) then distal tourniquet deflation occurs after 20 minutes.
9730639|NCT05234619|Active Comparator|Group three ( lidocaine Or control LL ) Late deflation|Patients in group three (lidocaine or control group LL = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) then distal tourniquet deflation occurs after 40 minutes.
9730640|NCT05234619|Active Comparator|Group four ( lidocaine , ketorolac LKL ) Late deflation|Patients in group four (lidocaine ketorolac LKL = 20): will receive 2% lidocaine 3mg/kg (maximum 200 mg) plus ketorolac 0.5mg/kg (maximum 30mg) then distal tourniquet deflation occurs after 40 minutes.
9730641|NCT05234580|Experimental|PA9159 10 μg|Fifty subjects will be randomly assigned to receive 10 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 5 μg/spray; Spray Bottle B: 0 μg/spray.
9730642|NCT05234580|Experimental|PA9159 20 μg|Fifty subjects will be randomly assigned to receive 20 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 0 μg/spray; Spray Bottle B: 10 μg/spray.
9730643|NCT05234580|Experimental|PA9159 40 μg|Fifty subjects will be randomly assigned to receive 40 μg of PA9159 Nasal Spray for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 10 μg/spray; Spray Bottle B: 10 μg/spray.
9730644|NCT05234580|Placebo Comparator|Placebo|Fifty subjects will be randomly assigned to receive placebo Nasal Spray without active of PA9159 for 14 days. Subjects will be administered two vials of drug (spray bottle A and spray bottle B) once daily in the morning, one spray each in the left and right nostril, in the order of first spray A and then spray B. Spray Bottle A: 0 μg/spray; Spray Bottle B: 0 μg/spray.
9781251|NCT01144403|Experimental|Rituximab|Rituximab, 375 milligram per meter square (mg/m^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).
9781252|NCT01144442|Experimental|HIPC Treatment|
9781253|NCT01144455|Active Comparator|Gemcitabine|Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle
9781254|NCT01144455|Experimental|240 mg/m2 TH-302 + Gemcitabine|"TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
9781255|NCT01144455|Experimental|340 mg/m2 TH-302 + Gemcitabine|"TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
9781256|NCT01144494|Active Comparator|Intraocular pressure lowering drug|Eyedrops for lowering intraocular pressure
9781257|NCT01144494|Placebo Comparator|Artificial Tears|Lubricated eye drops
9781258|NCT01144598||Turkish patients with rheumatoid arthritis|
9781259|NCT01144624|Experimental|1|"AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1):~AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2)"
9730645|NCT05234554|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
9730646|NCT05234554|Placebo Comparator|Vehicle Ophthalmic Solution|
9730647|NCT05234515||Patients with intestinal failure or an enterocutaneous fistula undergoing elective surgery.|Adult patients with a diagnosis of intestinal failure (IF) or an enterocutaneous fistula (ECF) undergoing planned surgery in our unit.
9730648|NCT05234502|Experimental|Group-1 (Ketogenic diet)|Group-1 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with an anthracycline. And simultaneously with standard neoadjuvant therapy containing taxane (12 weeks), KD will be planned for Group-1
9730649|NCT05234502|Other|Group-2 (Adequate and balanced healthy diet)|Group-2 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with anthracycline and taxane (12 weeks).
9730650|NCT05234489|Active Comparator|Low Dosage Group|This group will receive the lower dose (75mg) of the investigational product.
9730651|NCT05234489|Active Comparator|High Dosage Group|This group will receive the higher dose (150mg) of the investigational product.
9730652|NCT05234411||Observational group|Eligible participants will be female patients aged 13 years or older, with regular menstrual cycle, who have been undergoing a KDT for at least 3 months and thus previously diagnosed with Drug resistant epilepsy or GLUT1DS.
9730653|NCT05234398||Naïve patients|"This study involve non-responder solid organ transplanted patients after an adapted vaccinal scheme (i.e. 3 doses or more of mRNA vaccines).~Patients included in Group 1 are naïve patients; there have never received anti-SARS Cov2 monoclonal antibodies.~They will have additional blood and saliva samplings during their study visits, which are included in their usual medical follow-up."
9730654|NCT05234398||Switched patients|"This study involve non-responder solid organ transplanted patients after an adapted vaccinal scheme (i.e. 3 doses or more of mRNA vaccines).~Patients included in Group 2 have previously received anti-SARS Cov2 monoclonal antibodies.~They will have additional blood and saliva samplings during their study visits, which are included in their usual medical follow-up."
9730655|NCT05234372|Experimental|Treatment received intervention at enrollment|Participants received mobile phone delivered intervention at enrollment. The intervention had a duration of 4 weeks. Each week participants received two text messages inviting them to view a short video (Monday) and brief written content (Wed). Each week, the material consisted of a culturally tailored theme related to COVID-19 vaccination. Participants also received information on how to get vaccinated.
9730656|NCT05234372|Other|Control|Wait-list control. No intervention during month 1. Received the intervention at Month 2. Each week, during the first month, participants received a text with a count down of how many days were left to begin the intervention.
9730657|NCT05234359||CHILD Cohort Study|"CHILD Cohort Study, a general population cohort of 3500 families (n~12,000) with children born in BC, AB, MB and ON between 2009-12. CHILD has dense longitudinal data (pregnancy to children aged 5-8 years) on physical and mental health, emotional wellbeing, child behaviour problems, and parenting stress, providing the powerful opportunity to identify and study changes in these parameters during the pandemic. CHILD participants have also granted permission for data linkage, providing the opportunity to link study data with administrative health data including clinical diagnoses, hospitalization and medication use. In this grant, the investigators will monitor SARS-CoV-2 seroprevalence among CHILD families and collect information about how they are experiencing the COVID-19 pandemic over the next 12 months.~Interventions - Diagnostic Testing via home kit at 2 timepoints:~Blood sample, Saliva sample, Stool sample"
9730658|NCT05234346|Experimental|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
9730659|NCT05234346|Placebo Comparator|Placebo|
9730660|NCT05234333||Patients presenting a malaise after the vaccination by any vaccine|
9730661|NCT05234333||Patients presenting any other adverse event after the vaccination by any vaccine|
9730662|NCT05234307|Experimental|Treatment (PBF-1129, nivolumab)|Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9730663|NCT05234281|Other|Low back pain|Adults with chronic low back pain and at least 4 months of decreased work participation. Intervention as for all groups but with the use of GLADRyg back rehabilitation principles.
9730664|NCT05234281|Other|Chronic Obstructive Pulmonary Disease (COPD)|Adults with COPD (FEV1<80%). Intervention as for all groups but with added pulmonary rehabilitation focus.
9730665|NCT05234281|Other|Diabetes type 2|Adults with type 2 diabetes and diabetes-related challenges including dysglycaemia, diabetic complications and/or weight issues. Intervention as for all groups but with added focus on how to make useful microchoices in terms of lifestyle.
9781260|NCT01144624|Placebo Comparator|2|
9730666|NCT05234281|Other|Mixed anxiety/depression|"Young adults (18-35 years) with mixed anxiety/depression. Intervention as for all groups but with added focus on acceptance and commitment therapy, behavioral analysis, metacognitive therapy and physical activity."
9730667|NCT05234281|Other|Post COVID-19|Adults who have persistant fatigue and/or dyspnea following infection with COVID-19.
9730668|NCT05234268|Experimental|Manual Cervical Traction|The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion.
9730669|NCT05234268|Experimental|Passive Accessory Intervertebral Movements|Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension. Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra.
10200273|NCT04700137|Active Comparator|Caring Contacts (without phone call) (CC)|"Healthcare provider and staff participants who are randomized to only caring text messages.~Adult and adolescent patient participants who are randomized to only caring text messages."
10200274|NCT04699136|Experimental|Cardiovascular disease|
9730670|NCT05234268|Experimental|Active Strength Training|The progression of exercises will be done using different colours of Thera-band indicating varied resistance
9730671|NCT05234242||stationary/inpatient|
9730672|NCT05234242||ambulatory/outpatient|
9730673|NCT05234216|Experimental|Comfort Group|Centers evaluating patients after surgery requiring postoperative opioid treatment with an ICU comfort scale.
9730674|NCT05234216|Other|Pain Group|Centers evaluating patients, after surgery requiring postoperative opioid treatment, with a pain numerical verbal scale in the postoperative care service.
9730675|NCT05234190|Experimental|Treatment group|
9730676|NCT05234164|Experimental|EXIST 6F NiTi Stent System FLEX|Stent implantation of lesions in the SFA graded with Fanelli 1 and 2, and lesions in the P1 segment of the proximal popliteal artery.
9730677|NCT05234164|Experimental|EXIST 6F NiTi Stent System PULL|Stent implantation of lesions in the SFA graded with 3 and 4.
9730678|NCT05234125|Active Comparator|Intervention arm|Sleep hygiene practices and cognitive-behavioral principles
9730679|NCT05234125|Placebo Comparator|Attention control|Training about pregnancy issues
9730680|NCT05234112|Experimental|Uganda, India, Bangladesh|hrHPV self-test, followed by VIA inspection for hrHPV-positive women.
9730681|NCT05234112|Experimental|Slovakia|hrHPV self-test, followed by Pap-smear for cytology
9730682|NCT05234086|Active Comparator|Advanced Healing|Activities related to wound washing, microbiological load control, care of peri-ulcer tissue and application of wound healing products in accordance to condition of the ulcer
9730683|NCT05234086|Experimental|InbioDerm + C plus advanced healing|For patient who are assigned treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section and through an enzymatic process with cell proliferation, skin cells will be obtained that will be integrated into de the InbioDerm+C, then will be apply to the patients with the advanced wound healing every fourteen days in accordance application program.
10200275|NCT04696952|Experimental|TS-142 10 mg|Period in which subjects received TS-142 10 mg
10200276|NCT04696952|Experimental|TS-142 20 mg|Period in which subjects received TS-142 20 mg
10200277|NCT04696952|Experimental|Zopiclone 7.5 mg|Period in which subjects received Zopiclone 7.5 mg
10200278|NCT04696952|Experimental|Placebo|Period in which subjects received placebo
9730684|NCT05233995|Experimental|Intervention group|The patients included in the experimental group will be operated on, performing the resection of the intestinal segment affected by the dehiscence, the sectioned intestinal ends will be left without anastomosis, and open abdomen therapy will be established. After surgery, the patient will be cared for in the intensive care unit where intensive resuscitation will be carried out in order to improve the general conditions of the patient. After 48 ± 24 hours, a second surgical procedure will be performed where local conditions will be evaluated and the possibility of performing a delayed anastomosis will be evaluated.
9730685|NCT05233995|Active Comparator|Control group|The patients included in the control group will be operated on with a resection of the affected intestinal segment and a stoma with or without associated mucosal fistula will be performed at the same surgical time. After the procedure, the patient will be cared for in the intensive care unit in order to improve the general conditions of the patient.
10200279|NCT04696653|Other|Comprehensive unit based safety (CUSP) intervention arm|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
10200280|NCT04676802|Experimental|NSAIDS|Following surgery will receive NSAID capsules following surgery. Will take online and phone surveys.
10200281|NCT04676802|Experimental|Opioids|Following surgery will receive opioid capsules following surgery. Will take online and phone surveys.
10200282|NCT04676282||Survey 1 Statin - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm.
10200283|NCT04676282||Survey 1 Stain - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may lack benefit.
10200284|NCT04676282||Survey 1 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
9781261|NCT01144637|Experimental|Group 1|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
9781262|NCT01144637|Experimental|Group 2|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
9730688|NCT05233943||Parkinson's patients|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
9730689|NCT05233943||Healthy control group|"The cognitive function of Parkinson's patients will be assessed using the Standardized Mini Mental Test  .~The spinal posture will be evaluated using IDIAG M360 Spinal Mouse  .~Parkinson's patients' spinal position sense will be assessed using a repositioning error test with J-TECH medical, Salt Lake City, USA Dual Digital Inclinometer.~Dynamic and static components of the balance function will be evaluated with 'four square step tests' and 'stand on one leg' tests respectively"
10200285|NCT04676282||Survey 1 PPI - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm.
10200286|NCT04676282||Survey 1 PPI - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may lack benefit.
9730692|NCT05233891||Breast reconstruction after breast cancer|Women who have had/have breast cancer and will have/have had a breast reconstruction.
9730693|NCT05233891||Breast reduction|Women who have had/will have a breast reduction due to breast hypertrophy.
9730694|NCT05233878||Cohort group|Patients over 18 with a confirmed diagnosis of one or multiple cervical paragangliomas
9730695|NCT05233865|Experimental|Water condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing and walking conditions when in a pool.
9730696|NCT05233865|Active Comparator|Land condition|Participants blood pressure, heart rate and self-reported symptoms (such as dizziness) will be collected multiple times during sitting, standing, and walking conditions when on land.
9730697|NCT05233813|Experimental|ABM intervention group|The intervention group received three, 45-min group exercise lessons for 12 weeks. The group exercise lessons were taught by two experienced instructors.. Each participant in the intervention group received a Fitbit (Model InspireHR) activity tracker to self-monitor their daily PA, 5 days per week for 12 weeks.
9730698|NCT05233813|No Intervention|Comparison group|The comparison group continued their usual activities.
9730699|NCT05233748|Experimental|Stochastic Resonance (SR)|During this condition, participants will walk on the treadmill while receiving SR stimulation at their individual optimal intensity (SR) with and without visual perturbations.
9730700|NCT05233748|No Intervention|No Stochastic Resonance (noSR)|During this condition, participants will walk on the treadmill while receiving no SR stimulation (noSR) with and without visual perturbations.
9730701|NCT05233735|Other|topical treatment|Topical Betamethasone for the Treatment of Vitiligo Disease
9730702|NCT05233735|Experimental|Enhanced Transcutaneous Delivery|Enhanced Transcutaneous Delivery of Topical Betamethasone after a treatment with Tixel device for the Treatment of Vitiligo Disease
9730703|NCT05233722|Placebo Comparator|Post-exercise insulin sensitivity following placebo administration|Young healthy males will ingest placebo (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
9730704|NCT05233722|Experimental|Post-exercise insulin sensitivity following Rapamycin administration|Young healthy males will ingest Rapamycin (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
9730705|NCT05233709|Other|OTf + FeSO4|OTf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with apo-Ovotransferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
9730706|NCT05233709|Other|Lf+ FeSO4|Lf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with lactoferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
9730707|NCT05233709|Other|FeSO4|FeSO4 - This is the control arm where Ferrous sulfate will be given in the form of a solution that will be spread on bread with butter and honey, as a breakfast meal
9730708|NCT05233683|Experimental|Caudal block and circumcision with Plastibell,|Caudal block will be performed with 0.75ml/kg of 0.25% bupivacaine containing 1 mic/kg dexmedetomidine. Circumcision will be done using plastibell. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
9730709|NCT05233683|Experimental|Caudal block and circumcision with conventional dissection method|Caudal block will be performed with 0.75ml/kg of 0.25% bupivacaine containing 1 mic/kg dexmedetomidine. Circumcision will be done using the conventional dissection method. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
9730710|NCT05233683|Active Comparator|Dorsal penile nerve block plus ring block and circumcision with Plastibell|Dorsal penile nerve block plus ring block with 0.25% bupivacaine. Circumcision will be done using plastibell.
9781263|NCT01144637|Experimental|Group 3|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
10200287|NCT04676282||Survey 1 PPI - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm and lack benefit.
9730711|NCT05233683|Active Comparator|Dorsal penile nerve block plus ring block and circumcision with conventional dissection method|Dorsal penile nerve block plus ring block with 0.25% bupivacaine. Circumcision will be done using the conventional dissection method
9730712|NCT05233657|Experimental|JX11502MA 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received JX11502MA capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water.
9730713|NCT05233657|Placebo Comparator|Placebo 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg|Participants received placebo capsule 0.25mg、0.5mg、1mg、2mg、3mg、6mg、8mg orally administration once, once on an empty stomach in the morning, with about 240ml of warm water..
9730714|NCT05233631||T-EUS Patients|Any patient who has undergone clinically indicated and/or standard of care T-EUS procedures from October 2014 - June 2022.
9730715|NCT05233618|Experimental|Tagraxofusp (escalating doses)|IV tagraxofusp on days 1-3 of cycles 1-4 and days 1-2 of additional cycles for up to 9 cycles (some participants could receive more if considered in their best interest)
9730716|NCT05233605||Exposed to Dexmedetomidine during ICU stay|Dexmedetomidine has been administered in accordance with its MA (at least 24 hours continuously with a starting dose of 0.7 µg/kg/h and then adjusted to sedation scores between 0.4 and 1.1 µg/kg/h), as part of care, prior to inclusion in the protocol
9730717|NCT05233605||Non exposed to Dexmedetomidine during ICU stay|This group is unexposed to Dexmedetomidine during ICU stay.
9730718|NCT05233579|Experimental|Sulforaphane 1 Tablet|Participants are taking 1 tablet per day. All participants will start with 1 tablet and continue with 1 tablet for 2 weeks before increasing dose.
9730719|NCT05233579|Experimental|Sulforaphane 2 Tablets|Participants will increase dosage to 2 tablets per day after 2 weeks from the start of study participation. Participants will continue to take 2 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 1 tablet.
9730720|NCT05233579|Experimental|Sulforaphane 3 Tablets|Participants will increase dosage to 3 tablets per day at 4 weeks from the start of study participation. Participants will continue to take 3 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 2 tablets.
9730721|NCT05233579|Experimental|Sulforaphane 4 Tablets|Participants will increase dosage to 4 tablets per day at 6 weeks from the start of study participation. Participants will continue to take 4 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 3 tablets.
9730722|NCT05233579|Experimental|Sulforaphane 5 Tablets|Participants will increase dosage to 5 tablets per day at 8 weeks from the start of study participation. Participants will continue to take 5 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 4 tablets.
9730723|NCT05233579|Experimental|Sulforaphane|Participants will increase dosage to 6 tablets per day at 10 weeks from the start of study participation. Participants will continue to take 6 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 5 tablets.
9730724|NCT05233553||post-COVID-patients|
9730725|NCT05233540||Locally advanced or synchronous metastatic anal cancer treated with induction chemotherapy|Patients with newly diagnosed anal cancer who by standard of care are eligible for induction chemotherapy prior to definitive CRT or radiotherapy alone (RT) will be screened according to inclusion- and exclusion criteria. Patients eligible for induction chemotherapy will be patients with locally advanced or synchronous metastatic anal cancer.
10200288|NCT04676282||Survey 2 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
10200289|NCT04676282||Survey 2 Statin - Cardiologist|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin previously started by a cardiologist.
10200290|NCT04676282||Survey 2 Statin - Daughter Preference|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's adult daughter prefers for her to continue the medication.
10200291|NCT04676282||Survey 2 Statin - Husband Stroke|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's husband previously had a stroke after he stopped his statin.
10200292|NCT04676282||Survey 2 Statin - Flier|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient saw an educational flier about strokes in the waiting room.
10200293|NCT04676282||Survey 2 Statin - Difficulty Maintaining Lifestyle Changes|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient recognizes that they have had difficulty exercising and eating healthier foods.
10200294|NCT04668950|Experimental|Fluvoxamine|Start fluvoxamine 50mg capsule once, then 100mg twice daily. May reduce dose for tolerability reasons. Will be followed in the RCT for approximately 15 days.
10200295|NCT04668950|Placebo Comparator|Placebo|Start placebo one capsule, twice daily. May reduce dose for tolerability reasons. Will be followed in RCT for approximately 15 days.
10200296|NCT04641871|Experimental|Sym021+Sym022 [ARM A]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
10200297|NCT04641871|Experimental|Sym021+Sym023 [ARM B]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
10200298|NCT04641871|Experimental|Sym021+Sym023+irrinotecan|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
9730726|NCT05233514|Experimental|Aerobic exercise group (AEM)|The AEM group performed aerobic exercise three times a week for 12 weeks in addition to Metformin treatment.
9730727|NCT05233514|Active Comparator|Metformin group (M)|The M group received Metformin only
9730728|NCT05233501|Sham Comparator|non-surgical perıodontal treatment|
9730729|NCT05233501|Experimental|non-surgical treatment+ low level laser therapy|
9730730|NCT05233488|Experimental|Low US dose|Pulsed US, 1 W/cm2, 10% duty cycle.
9730731|NCT05233488|Experimental|Intermediate US dose|Pulsed US, 1 W/cm2, 50% duty cycle.
9730732|NCT05233488|Experimental|High US dose|Pulsed US, 3 W/cm2, 10% duty cycle.
9730733|NCT05233488|Experimental|Higher US dose|Pulsed US, 3 W/cm2, 50% duty cycle.
9730734|NCT05233475|Active Comparator|Control group (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
9730735|NCT05233475|Experimental|Intervention Group (EUC + GAIN Lite)|"GAIN Lite:~GAIN Lite in an add-on to EUC, and consists of one face-to-face group meeting where participants and (if wanted) their closest relative will receive extended information about post-concussion symptoms, reassurance on the usually benign course, and advice on adaptive symptom management such as gradually resuming premorbid activities and avoiding excessive rest and 'all-or-nothing' behaviour. This education will be followed up by up to three individual video- or phone sessions over a period of 2 months. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
9730736|NCT05233462|Active Comparator|control group|"intrathecal administration of a solution containing~bupivacaine 10 mg~morphine 100 micrograms~sufentanil 3 micrograms"
9730737|NCT05233462|Experimental|individualized group|"intrathecal administration of a solution containing~bupivacaine 0.05 mg per cm of patient's height~morphine 100 micrograms~sufentanil 3 micrograms"
9730738|NCT05233423|Experimental|Intervention Group|The patients in the intervention group were applied 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
9730739|NCT05233423|No Intervention|Control Group|The patients in the control group were applied 9 times of cold gel in the form of 20 minutes of application and 40 minutes of rest after surgery.
10200299|NCT04639505||ELISA|ELISA kit detecting the serum AMH level
9730741|NCT05233384||Patients with hereditary dysfibrinogenemia|Patient, male or female, aged over 18, with confirmed hereditary dysfibrinogenemia
9730742|NCT05233371||Infants at high risk of developmental delay|
9730743|NCT05233358|Experimental|HAIC combined with regorafenib and immune checkpoint inhibitors|Subjects received FOLFOX regimen HAIC treatment, within 2 weeks of regorafenib (28 days as a cycle, 80-160 mg qd regorafenib orally on days 1-21) and immune checkpoint inhibitors (continue treatment according to the original plan, 1 cycle every 3 weeks) treatment. HAIC treatment was repeated every 3 weeks for a maximum of six cycles.
9730744|NCT05233358|Active Comparator|TACE combined with regorafenib and immune checkpoint inhibitors|Choose traditional precise cTACE or dTACE treatment, and receive regorafenib within 2 weeks (28 days as a cycle, 80-160mg qd regorafenib orally on d1-21) and immune checkpoint inhibitors (continue treatment according to the original plan, every 3 weeks as a cycle) treatment. CT or MRI examination was repeated 4-6 weeks after the operation to evaluate whether there were active lesions. If there were still active lesions, one repeat TACE could be performed, and the number of TACE was less than 3 times.
9730745|NCT05233345|Experimental|Experimental group: web based occupational therapy program|"Web-based occupational therapy classes were carried out as 5 sessions per week, each session lasting 1 hour, for 3 weeks. In total, 15 sessions were performed during the study period.~Group activities were performed through the Zoom application by means of a video camera. Included painting and cake making together, sports activities to be performed simultaneously with the movements shown by the researcher, memory games, and games that can be played with the group, such as the categories game. Sports activities were performed in the last 15 minutes of group activities, 5 days a week, in order to increase the physical activity level of children whose physical activities decreased during the lockdown period at home.~Also, all study participants continued taking classes from the EBA program as part of their routine education plan while taking occupational therapy program. EBA program is online classes given by government on local television."
9781264|NCT01144637|Placebo Comparator|Group 4|Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
10200300|NCT04639505||Chemiluminescence|CLIA method detecting the serum AMH level
10200301|NCT04638647|Experimental|Secukinumab s.c.|Participants will be started on 75 mg, 150 mg or 300 mg s.c. Q4W depending on what dose the participant was receiving in the parent trial (for trials with i.v. formulation the starting dose will be 300 mg s.c.). The study medication dose may be modified basedu pon clinical need, the judgement of the investigator and health authority guidelines (if applicable). For pediatric participants, the dose should not be increased beyond the maximum dose evaluated in the respective weight category in the parent protocol.
10200302|NCT04631471|Active Comparator|Ibudilast|Increasing dose of Ibudilast up to 100mg/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
10200303|NCT04631471|Placebo Comparator|Placebo|Increasing dose of matched placebo containing mannitol instead of ibudilast up to 10 pills/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
10200304|NCT04602598|Experimental|Zanubrutinib|Zanubrutinib orally at a dose of 80mg BID for 24 weeks
9785321|NCT01248962|Experimental|Standard 30-minute infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatin containing chemotherapy regimen.
9730746|NCT05233345|No Intervention|Control Group|There are no interventions except EBA which all study participants are already taking classes from as part of their routine education plan. EBA program is online classes given by government on local television. This program is out of our study.
9730747|NCT05233332|Experimental|phase IIa: HL-085 in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085
9730748|NCT05233332|Experimental|phase IIa: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
9730749|NCT05233332|Experimental|phase IIa: HL-085+Vemurafenib in Subjects With RAS or other BRAF-Mutated or MEK1/2-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
9730750|NCT05233332|Experimental|phase IIb: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
9730751|NCT05233293|Experimental|SpyGlass group|ERCP plus SpyGlass plus RFA group
9730752|NCT05233293|Active Comparator|Cytobrush Group|ERCP plus Cytobrush plus RFA group
9730753|NCT05233254|Experimental|Patients with L4-5 disc herniation|In the light of the reference research, it was estimated that it could reach an effect size of 0.6 according to the sample size measurement made with at least 80% power and 0.05 margin of error, and 18 individuals with LDH (9 men, 9 women) were planned to participate in this study. Since data loss was predicted to be 20%, it was decided to include a total of 22 patients for the study.
9730754|NCT05233241|Experimental|Patients with acute drug-induced interstitial nephritis|Patients with acute drug-induced interstitial nephritis
9730755|NCT05233228|Experimental|Automated Treatment|Consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos.
9730756|NCT05233228|Active Comparator|Standard Care|Consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of nicotine replacement therapy (transdermal patches).
9730757|NCT05233215|Experimental|GROW Support Program|"Patient participants will fill out questionnaires about emotional and physical health with responses used to develop an individualized survivorship plan conducted through 1x monthly virtual or in-clinic check-ins as well as GROW support meetings as needed for 6 months.~Caregiver participants will fill out questionnaires used to develop patient individualized survivorship plan and participate in 1x monthly check-in meetings with patients or separately for 6 months."
9730758|NCT05233202|Experimental|LEVOSIMEDAN|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
9730759|NCT05233202|Placebo Comparator|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin <48H before anesthetic induction.
9730760|NCT05233189|Experimental|"With the MOOC Childhood cancer, living well, after"|Quantify the impact of the MOOC's membership on the CCS knowledge about LTFU adapted to the medical history of patients and measure how this MOOC can improve the LTFU care of each CCS.
9730761|NCT05233189|Active Comparator|"Without the MOOC Childhood cancer, living well, after"|Quantify the impact of the MOOC's non-membership on the CCS knowledge about LTFU adapted to the medical history of patients and measure how this MOOC can improve the LTFU care of each CCS.
9730762|NCT05233124|Active Comparator|Dual antiplatelet therapy|Acetyl salicylic acid, 100mg once a day + clopidogrel 75mg, once a day.
9730763|NCT05233124|Experimental|Antiplatelet monotherapy + low dose anticoagulant|Clopidogrel 75mg + Rivaroxaban 75mg
9730764|NCT05233072|Other|Fracture|Patients with a fracture of the upper neck of the femur
9730765|NCT05233072|Other|Control|Patients with no fracture of the upper neck of the femur
9730766|NCT05233059|Active Comparator|Walking|The walking group will receive a tailored FitEx for endometrial cancer survivors, including cancer specific newsletters.
9730767|NCT05233059|Experimental|Walking Plus Yoga|The walking group will receive a tailored FitEx for endometrial cancer survivors with yoga cuing and yoga-based newsletters.
9730768|NCT05233046|Experimental|Impact of Nourish Carolina - Control Group|Group A - nutrition (one time/week) and mental health counseling (biweekly) for 12 weeks
9730769|NCT05233046|Experimental|Impact of Nourish Carolina - Study Group|Group B - nutrition ( one time/week) and mental health counseling (biweekly)with Nourish Carolina for 12 weeks
9730770|NCT05233020|Experimental|Robotic|Fifteen patients undergo rVHR operation.
9730771|NCT05233020|Experimental|hybrid|Fifteen patients undergo hybrid operation.
9730772|NCT05233007||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
9730773|NCT05232994|Experimental|combination metformin and esomeprazole|Combination 2 g of oral extended release metformin, in divided doses and Esomeprazole 20mg daily until delivery.
9730774|NCT05232994|Placebo Comparator|placebo|Placebo arm
9730775|NCT05232968|Experimental|Elderly volunteers participating in the long-term exercise program|Elderly volunteers will be recruited from participants in the long-term exercise program (ongoing since 2017) at the Center of Physical Activity BMC SAS in Bratislava.
9730776|NCT05232968|No Intervention|Elderly sedentary volunteers|Control population will be recruited from the sedentary elderly, who dropped out from the exercise program ≥2 years prior entering this study and do not exercise on regular basis.
9730777|NCT05232968|Experimental|Elderly volunteers participating in the short-term exercise program|Elderly volunteers will follow 4-month of aerobic-strength training intervention and exercise induced effects on mild cognitive impairment will be determined afterwards.
9730778|NCT05232864|Experimental|Secukinumab|Secukinumab 300 mg solution for s.c. injection in a 2mL Pre-Filled Syringe (PFS)
9730779|NCT05232812|Experimental|Administration of 3-[11C]-OHB|All participants will first be injected with 200 MBq 3-[11C]-OHB followed by an oral ingestion of 100 MBq 3-[11C]-OHB.
10200305|NCT04585269|Experimental|Bright IDEAS-YA|Intervention consists of six 45-minute one-on-one sessions between a patient and a trainer, who teaches the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach and worksheets. In addition, participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer Network (NCCN) adolescent and young adult patient guidelines.
9730782|NCT05232773||Experimental group|"Enrolled patients will undergo supervised rehabilitation treatment for rotator cuff repair according to a standardized protocol (5 days/week) and will undergo clinical, kinematic and shoulder muscle strength assessments to collect data useful to define objective criteria for progression between rehabilitation phases. Assessment will be performed at four different times.~The clinical evaluation of the shoulder is carried out through the Constant-Murley Score (CMS).~Pain will be assessed through the visual analogical scale (VAS). Kinematic assessment (shoulder ROM, scapula-humeral rhythm, movement smoothness, movement speed) will be assessed through magneto-inertial measurements units (M-IMU).~The maximal voluntary isometric contraction (MVIC) of shoulder flexor, abductor and rotator cuff muscles of the affected limb will be measured by the Chronojump Boscosystem® Force Sensor Kit"
9730783|NCT05232773||Healthy subjects|Healthy subjects will undergo evaluations with the same timing as patients in the Experimental group.
9730784|NCT05232760||SUPERA peripheral stent system|
9730785|NCT05232747||Study|Participants' pain level and pain-related behaviors will be questioned.
9730786|NCT05232721||Fecal Immunochemical Test|People in this group will detect hemoglobin in stool before colonoscopy by the new instrument
9730787|NCT05232695||metabolically healthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have only high waist circumference without any other metabolic syndrome criteria.
9730788|NCT05232695||metabolically unhealthy obese individuals|Individuals who have a body mass index equal or higher than 30 kg/m2, no medication usage, who have more than one metabolic syndrome criteria (as defined below) including high waist circumference.
9730789|NCT05232656|No Intervention|Pre-intervention|"Usual care on three general medicine units.~Patients/caregivers do no have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
9730790|NCT05232656|Experimental|Post-intervention|Patients/caregivers have access to the pre-discharge preparation checklist. Providers have access to patient safety dashboard.
9730791|NCT05232643||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants administered oral anticoagulants (OAs)
9730792|NCT05232643||Cohort 2|Non-valvular atrial fibrillation (NVAF) participants not administered oral anticoagulants
9730793|NCT05232617||Rheumatological rehabilitation training|
9730794|NCT05232604|Experimental|Aerobic exercise group (AE)|The session training will be divided into a warm-up, main exercise period, and cool-down, with a total duration of 60 minutes (guided by a PT). The training will be performed on a cycle ergometer, three times per week for 12 weeks. The duration of the main AE will be between 30-45 minutes and the intensity will be based on the maximal heart rate (HRmax), heart rate reserve (HRR), and the Borg Rating of Perceived Exertion Scale (Borg Scale), which will be monitored. The intensity of the AE program will be progressively increased according to each patient's response and tolerance but will be standardized as much as possible: 1) first two weeks, low to moderate intensity (60% HRmax or 9-11 on the Borg scale); 2) 2-6 weeks, moderate-intensity (55-70% HRmax or 12-14 on the Borg scale), and 3) last 6 weeks, high intensity interval training (HIT) (75-90% HRmax or 15-17 on the Borg scale; 4 min*4 times HIT followed by 3 min of 70%HRmax in between) will be targeted per literature endorsements.
9730795|NCT05232604|Active Comparator|Neck motor control exercise group|The treatment will consist of a 12-week progressive exercise program targeted to the neck flexor and extensor muscles supervised by a physical therapist (PT). This exercise protocol has been successfully tested in subjects with NP. Low load craniocervical exercises (nodding) will be performed at early stages (first 6 weeks) guided by visual feedback from a pressure unit. Higher-load neck exercises will be performed at later stages (last 6 weeks). During the first month, subjects will receive 30-45 min of MCTF three times per week, in the second month twice per week, and in the third month once per week. This duration of treatment is commonly used in clinical settings and has proven to be sufficient to improve muscle function, clinical, and brain outcomes.
9730796|NCT05232591||1|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
9730797|NCT05232591||2|GCF samples will be taken from the collateral teeth (healthy teeth) of the teeth diagnosed with chronic apical periodontitis.
9730798|NCT05232552|Experimental|anlotinib|3 cycles of anlotinib (12mg, d1-14)was given concurrently with docetaxel plus cisplatin chemotherapy as induction , then 2 additional cycles of anlotinib concurrent with definitive chemoradiation (IMRT with conccurent cisplatin)
9730799|NCT05232539|Active Comparator|Lamellar corneal transplantation type DMEK|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
9730800|NCT05232539|Active Comparator|Deep sclerectomy with implantation of subchoroidal implant Esnoper Clip|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
9730801|NCT05232539|Active Comparator|Pars plana vitrectomy with epiretinal membrane peeling|50 operations, procedure will be randomly divided into 2 subgroups of 25 patients with and without the use of iOCT during the operation.
9730802|NCT05232526|Experimental|Mental imagery (MI) and exercise program|MI will start immediately when the sample is going to start the exercise program. The intervention group will undergo 24 sessions of imagery, starting from the 1st exercise program session. Participants of the intervention group will undergo a 45-minute imagery session sitting in a quiet place after the end of every exercise program session. The content of every imagery session is alike with the content of the exercise program session. That means that every session includes imagery of the same exercises of the exercise program performed earlier by the subject in the Day Center. Sessions are identical for all subjects of the intervention group. The total duration of the physiotherapy exercise program will be 24 sessions, 2 times/week, duration of 45 minutes each session, 3 months (12 weeks).
9730803|NCT05232526|Placebo Comparator|Exercise program|The total duration of the physiotherapy exercise program will be 24 sessions, 2 times/week, duration of 45 minutes each session, 3 months (12 weeks).
9730804|NCT05232513|Experimental|Hand massage group|The group that received hand massage for 10 minutes before cataract surgery
9730805|NCT05232513|No Intervention|Control group|standard care group
9730806|NCT05232461|Active Comparator|PrimeC ER Fasted|Single dose PrimeC-ER (748 mg), administered following an overnight fast of at least 10 hours.
9730807|NCT05232461|Active Comparator|PrimeC ER Meal|Single dose PrimeC-ER (748 mg), administered at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours.
9730808|NCT05232461|Active Comparator|Marketed ciprofloxacin and celecoxib|Single dose of 750 mg of ciprofloxacin 200 mg of celecoxib, co-administered following an overnight fast of at least 10 hours.
9730809|NCT05232448|No Intervention|Control Group|Data collection forms will be applied to the students in the control group first. They will then continue their normal education.
9730810|NCT05232448|Experimental|Intervention Group|Data collection forms will be applied to the students in the intervention group first. Afterwards, cognitive-behavioral therapy training will be implemented as four modules, lasting 1 month in total.
9730811|NCT05232435|Experimental|pilate group|will receive pilate exercise(1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist) and standard treatment (stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) for 12 sessions(3 sessions/week) over a period of four weeks.
9730812|NCT05232435|Experimental|MET|will receiveMET treatment for hamstring and erector spinae and standard treatment(stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) for 12 sessions (3 sessions/week)over a period of four weeks.
9730813|NCT05232435|Active Comparator|control group|will receive standard treatment(stretch hamstring , stretch lower back , strength abdominal muscles and electrical heat pad) only for 12 sessions (3 sessions/week) over a period of four weeks.
9730814|NCT05232422|Experimental|Yoga-Intervention Group|This arm will participate in a hatha yoga course for a time period of 8 weeks with a frequency of at least 3 up to 5 times per week. Further they will participate in the pre- as well as the post-tests before and after the intervention.
9730815|NCT05232422|No Intervention|Waiting Control Group|For the first 8 weeks of the study this group will not receive any intervention. After the second measurement is completed they will get the possibility to participate in a hatha yoga course as well. Further they will participate in the pre- as well as the post-tests around the same time as the Yoga-Intervention group.
9730816|NCT05232409|Experimental|Zeaxanthin Monotherapy|Zeaxanthin administered orally on daily basis.
9730817|NCT05232409|Experimental|Zeaxanthin plus Pembrolizumab|Zeaxanthin administered orally on daily basis in addition to intravenous pembrolizumab infused every 42 days at fixed dose of 400 mg.
9730818|NCT05232383|Active Comparator|Wp|
9730819|NCT05232383|Active Comparator|Wn|
9730820|NCT05232383|Active Comparator|Gn|
9730821|NCT05232383|Active Comparator|Gp|
9730822|NCT05232383|Active Comparator|Rp|
9730823|NCT05232383|Active Comparator|Rn|
9730824|NCT05232370|No Intervention|Control Group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to control group (Without losartan or enalapril)"
9730825|NCT05232370|Experimental|Enalapril group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to Enalapril group"
9730826|NCT05232370|Experimental|Losartan group|"Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.~Randomly assigned to Losartan group"
9781265|NCT01144663|Experimental|Nimenrix 3 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 3 primary doses of Nimenrix™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 3, 4 and 12 months of age.
9781266|NCT01144663|Experimental|Nimenrix 2 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Nimenrix™ vaccine at 2 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
9781267|NCT01144663|Active Comparator|Menjugate Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Menjugate® vaccine at 2 and 4 months of age, followed by a booster dose of Menjugate® vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
9781268|NCT01144663|Active Comparator|NeisVac-C Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of NeisVac-C™ vaccine at 2 and 4 months of age, followed by a booster dose of NeisVac-C™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
9781269|NCT01144715|Experimental|Hand Mentor Therapy|Use of the Hand Mentor (TM) Stroke Therapy Device at home for 8 weeks
9781270|NCT01144715|Active Comparator|Control|Self administered home therapy program
9781271|NCT01144949|Active Comparator|silodsosin|
9781272|NCT01144949|Placebo Comparator|placebo|
9781273|NCT01145001|Active Comparator|Active Nicotine Patch and Contingency Management|Subjects in this group will receive Contingency Management and active nicotine patch
9781274|NCT01145001|Active Comparator|Nicotine Patch with no Contingency Management|Subjects in this group will receive active nicotine patch without contingency management for abstinence
9781275|NCT01145001|Placebo Comparator|Placebo patch and Contingency Management|Subjects in this group will receive a placebo transdermal patch and contingency management
9781276|NCT01145001|Placebo Comparator|Placebo Patch and no Contingency Management|Subjects in this group will receive a placebo patch and will not receive contingency management
9781277|NCT01145053||Treatment|
9781278|NCT01145066|Experimental|borage and echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
9781279|NCT01145066|Active Comparator|fish oil|Croda 18:12 fish oil
9781280|NCT01145066|Placebo Comparator|corn oil|
9730827|NCT05232331|No Intervention|Control|This group will receive non-surgical periodontal treatment, however they will not receive any modification to their diet
9730828|NCT05232331|Experimental|Intervention|This group will receive non-surgical periodontal treatment, and also as a treatment of interest, will receive the indication to consume ~ 350 mg of nitrate from vegetables, as well as an accompaniment to achieve this objective.
9730829|NCT05232305|Experimental|People with type 2 diabetes who eat bread with pomegranate crust - Experimental Group|"Individuals with type 2 diabetes who met the inclusion criteria and participated in the study will divided into two groups by Specialist Akkız Zuhal ÖZTAŞ and Specialist Doctor Emel ŞENOL, and they will be asked to consume the breads produced (in the preliminary study) produced as a standard (n=15) and with the addition of pomegranate peel (n=15) for eight weeks.~The individuals participating in the study will be asked not to change their eating habits, physical activity habits, and drug treatments during the study period. Each individual participating in the study will be provided with the required amount of bread during the study and will be contacted weekly by Zeynep ÇAMLIK, a specialist dietitian, to verify whether they consume bread regularly."
9730830|NCT05232305|No Intervention|No intervention - Control Group|Individuals with type 2 diabetes will not eat pomegranate crust bread
9730831|NCT05232292|Active Comparator|Vaccinated|vaccinated ACS & CHF patients over 65 years
9730832|NCT05232292|No Intervention|Not vaccinated|not vaccinated ACS & CHF patients over 65 years
9730833|NCT05232279|Experimental|Testofen 300mg|Testofen in capsule form - taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
9730834|NCT05232279|Experimental|Testofen 600mg|Testofen in capsule form - taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
9730835|NCT05232279|Placebo Comparator|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
9730836|NCT05232266|Experimental|Caralluma fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
9730837|NCT05232266|Placebo Comparator|Placebo comparator capsule - Microcrystalline cellulose|A comparator capsule taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
9730838|NCT05232253|Experimental|Neurogenic Bladder Patient|Patients with neurogenic bladder
9730839|NCT05232227|Active Comparator|Standard regimen Primaquine single dose over 14 days|The standard regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 3.5 mg/kg divided over 14 days (0.25mg/kg/day)
9730840|NCT05232227|Experimental|Treatment regimen Primaquine double dose over 14 days|The treatment regimen consists of administering Chloquine Phosphate 10 mg/kg on days 1 and 2, and 5 mg/kg on day 3 plus Primaquine Phosphate 7 mg/kg divided over 14 days
9730841|NCT05232214||short eyes|Axial length under 22.5 mm
9730842|NCT05232214||long eyes|Axial length under 25.5 mm
9730843|NCT05232188|Experimental|22French (Fr)|After renal access, dilatation is provided up to 22Fr with a dilatator set, and fragmentation is started with a 19Fr nephroscope.
9730844|NCT05232188|Experimental|28F|After renal access, dilatation is provided up to 28Fr with a dilatator set, and fragmentation is started with a 25Fr nephroscope.
9730845|NCT05232175|Experimental|Part I (Allergy assessment) - ALT-BB4|
9730846|NCT05232175|Placebo Comparator|Part I (Allergy assessment) - 0.9%NaCl|
9730847|NCT05232175|Experimental|Part II-A (PK assessment)|
9730848|NCT05232175|Experimental|Part II-B (Safety assessment) - ALT-BB4|
9730849|NCT05232175|Placebo Comparator|Part II-B (Safety assessment) - 0.9% NaCl|
9730850|NCT05232149|Experimental|Lower Dose|Orelabrutinib is a white, round, uncoated tablet
9730851|NCT05232149|Experimental|Higher Dose|Orelabrutinib is a white, round, uncoated tablet
9730852|NCT05232123|Placebo Comparator|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
9730853|NCT05232123|Experimental|Cannabidiol 25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
9730854|NCT05232123|Experimental|Cannabidiol 50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
9730855|NCT05232123|Experimental|Cannabidiol 200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
9730856|NCT05232084|Active Comparator|Group 30 = 30 ml of Erector spinae plane block group|In group 30 ml, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
9730857|NCT05232084|Active Comparator|Group 20 = 20 ml of Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
9730858|NCT05232045||Automated urinary output collection system group (tight monitoring of urine output)|
9730859|NCT05232045||Manual urinary output collection system group (routine monitoring of urine output)|
9730860|NCT05231967||Atrial fibrillation recurrence|Atrial fibrillation recurrence one month after cardioversion
9730861|NCT05231967||Sinus rhythm continue|Sinus rhythm continue one month after cardioversion
9730862|NCT05231928|Experimental|Argon Laser Iridoplasty|Argon Laser is applied to the anterior iris surface after pharmacological miosis and instillation of ocular surface anesthetic using YAG capsulotomy lens or Abraham Iridotomy lens as auxiliary lenses. Laser is applied at sites and with parameters that are tailored for each case according to exact iris configuration, iris colour and pupil diameter.
9730863|NCT05231915|Other|HOXB13 c.853delT mutation|Mutation is detected using Next Generation Sequencing (NGS) technique
9730864|NCT05231889|Placebo Comparator|Below the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located below the shoulder
9730865|NCT05231889|Active Comparator|Above the shoulder vascular anomaly|If the standard J-tip guidewire does not cross a vascular anomaly located above the shoulder
9730866|NCT05231863||Observational Group|Patients receive TKIs after T-DM1 progression.
9730867|NCT05231850|Experimental|Tislelizumab|Tislelizumab
9730868|NCT05231837|No Intervention|Usual Fee Structure and Usual Outreach|Park usual fee structure and usual publicity, marketing and outreach will be tracked as a control comparison group for the study. Only St Paul parks (n=4 of a total of 16) are allocated to this condition.
9730869|NCT05231837|Experimental|Fee Waiver|Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment.
9730870|NCT05231837|Experimental|Fee Waiver Plus Intensive Outreach|"Parks randomly assigned to the Intensive Outreach and Fee Waiver:~Intensive Outreach consists of the formation and activity of a community advisory group who will engage with neighborhood community partners to support parents in the neighborhood to enroll their child and support the child's participation in the park youth sports programs offered at the neighborhood park and recreation center. Program marketing and materials and registration will be offered in both Spanish and English. Program coaches will be supported with technical assistance from study staff to implement the park youth sports program with high fidelity and with high communication and engagement with enrolled youth and their parents.~Fees for youth sports programs will be waived in this condition. Youth who enroll in youth sports programs in parks that are randomly assigned to this condition will pay no fee for program enrollment."
9730871|NCT05231798||Down Syndrome|Adults between 18-55 with Down Syndrome.
9730872|NCT05231759||Navigable Percutaneous Plasma Disc Decompression (L'DISQ)|The L'DISQ (U&I Co., Uijeongbu, Korea) is one of the minimally invasive disc decompression procedures which was introduced in 2011. The L'DISQ uses a navigable tip and flexible handle allowing resection of the posterolateral or posterior median disc tissue without thermal damage.
9730873|NCT05231733|Experimental|SPX-101|A total of up to 27 patients will be enrolled in this study. Subjects will receive SPX-101 by IV infusion in 60-minutes（±15 minutes）on Day 1 of the first cycle (3 weeks), and will be evaluated for DLTs in 3 weeks (DLT window). After the first cycle, subjects will continue the treatment at the assigned dose level.
9730874|NCT05231681|Experimental|Eye Concealer|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer
9730875|NCT05231655||Bladder Cancer|
9730876|NCT05231655||Kidney Cancer|
9730877|NCT05231655||Melanoma|
9730878|NCT05231655||Sarcoma|
9730879|NCT05231655||Glioblastoma|
9730880|NCT05231655||Head and Neck Cancer|
9730881|NCT05231642|Experimental|Low GI|Consumption of standardised low-GI mixed-macronutrient breakfast-based meal followed by a standardised low-GI mixed-macronutrient lunch meal 4 hours later.
9730882|NCT05231642|Experimental|High GI|Consumption of a standardised high-GI mixed-macronutrient breakfast-based meal followed by a standardised high-GI mixed-macronutrient lunch meal 4 hours later.
9730883|NCT05231577|Experimental|Experimental: Patients in Group 0 undergo 7.5fr ultra-fine ureteroscopy|
9730884|NCT05231577|Experimental|Experimental: Patients in Group 2 undergo 9.2fr ureteroscopy|
9730885|NCT05231538|Experimental|Neurodevelopmental Therapy|The treatment group received neurodevelopment treatment lasting for 3 months (3sessions per week). Additionally, for this study, the NDT programme included passive stretching of the lower limb muscles (e.g. hamstrings, gastrocsoleus), followed by techniques of reducing spasticity and facilitating more normal patterns of movement while working on motor functions. In each session, exercises included patients sustaining themselves on their forearms and hands, sitting, crawling, semi-kneeling, and in standing positions supported by the Physical therapist until tone reduction achieved. Balance and corrective reactions were developed by using a CP ball and tilt board.
9730886|NCT05231538|Active Comparator|Routine Physical Therapy|The control group underwent the exercises (stretching, passive range of motion, and active range of motion).
9730887|NCT05231512|Experimental|Individuals living with post-Covid-19 respiratory symptoms|Live virtual music therapy interventions for people experiencing difficulties breathing after having had COVID-19 (diagnosed or presumed).
9730888|NCT05231499||healthy volunteers|
9730889|NCT05231499||immunocompromised subjects|
9730890|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 1|"This arm is the first group composed of four childrens who will do the CO-OP. CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.~The four patients will begin the sessions one week apart each."
9730891|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 2|"This arm is the second group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
9730892|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 3|"This arm is the third group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
9730893|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 4|"This arm is the fourth group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
9730894|NCT05231486|Experimental|Cognitive Orientation to daily Occupational Performance 5|"This arm is the fifth group composed of four others childrens who will do the CO-OP.~CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas The four patients will begin the sessions one week apart each."
9730895|NCT05231460|Active Comparator|narcotic regimen with TAP block|Patient will receive Tap Block and will be administered the Narcotic Pain Regimen post-operatively
9730896|NCT05231460|Active Comparator|narcotic regimen with no TAP block|Patient will not receive TAP block and will be administered the Narcotic Pain Regimen post-operatively
9730897|NCT05231460|Active Comparator|non-narcotic regimen with TAP block|Patient will receive Tap Block and will be administered Non-narcotic Pain Regimen post-operatively
9730898|NCT05231460|Active Comparator|non-narcotic regimen with no TAP block|Patient will not receive TAP block and will be administered Non-narcotic Pain Regimen post-operatively
9730899|NCT05231434|Active Comparator|Control protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. Hydration will not be allowed throughout the protocol
9730900|NCT05231434|Experimental|Hydration protocol|The control protocol will consist of an initial 10 minutes of rest, followed by 90 minutes of aerobic activity and 60 minutes of the final recovery. In this protocol, volunteers will be hydrated with mineral water from the 15th minute of exercise until the end of recovery
9730901|NCT05231421||Low-income smokers|Interested participants will first complete a screening survey asking about their demographic information and checking whether are eligible for this study. If eligible, participants will read a consent statement. Only those who give consent would be allowed to proceed. If participants agree to be in this study, they will continue to participate in the study and schedule a time for focus group discussion.
9730902|NCT05231369|Experimental|ChulaCov19 BNA159 mRNA vaccine|
9730903|NCT05231369|Active Comparator|ChulaCov19-US|
9730904|NCT05231369|Active Comparator|Comirnaty|
9730905|NCT05231356||2|group 1 with positive signs group 2 with negative signs
9730906|NCT05231330|Experimental|silver nanoparticles|
9730907|NCT05231330|Active Comparator|silverdiamine fluoride|
9730908|NCT05231330|No Intervention|no medicament|
9730909|NCT05231317|Experimental|Experimental: Plant-based diet|Diet rich in fruit and vegetables (42% carbohydrates, 17.2% fibres; 15% proteins and 43% fats).
9730910|NCT05231317|Active Comparator|Active Comparator: Western diet|Diet Rich in Processed Foods (48% carbohydrates, 10.4% fibres; 14% proteins and 39% fats).
9730911|NCT05231291||Young Adults|"Skinfold thickness (SFT) at multiple marked sites on biceps, triceps, subscapular and suprailiac areas using a Harpenden Caliper (Baty, UK) for the non-dominant side.~Hand grip strength measurement Jamar Hydraulic Dynamometers (Hydraulic Hand Dynamometer Fabrication Enterprises Inc, NY) was used as the evaluation tool for measuring grip.~The handgrip measurement was carried out as per the recommendations laid by The National Institute of Health Research (NIHR).~The T score for hand grip strength was also calculated. Also the mean predicted handgrip strength for given height was calculated foe the given height Trunk muscle strength testing was done. An analogue hydraulic push-pull dynamometer (Model: FEI-12-0394) was used to evaluate. The trunk extensor and flexor muscle strength was evaluated using and was recorded in pounds (lbs.)."
9730912|NCT05231265||Patients with Low Back Pain|
9730913|NCT05231239|Active Comparator|Active tDCS|tDCS will be applied for 20 min with 2 mA
9730914|NCT05231239|Placebo Comparator|Placebo tDCS|tDCS will be applied for only 20 sec, monatge will be left on the head for 20 min
9730915|NCT05231226|Experimental|Immediately CR group|Immediately open non-IRA after successful emergency PCI of IRA in STEMI patients with MVD
9730916|NCT05231226|Active Comparator|Staged (within 45 days) CR group|Strategy of opening non-IRA by stages after emergency PCI of IRA in STEMI patients with MVD
9730917|NCT05231148|Other|infected non united fractures|patient of any age and any sex with infected non united fractures of long or short bones
9730918|NCT05231109|Other|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The exercise program was arranged 3 times a day for 6 months, and each exercise was 10 repetitions. The patients were called for physiotherapist control once every 2 weeks.
9730919|NCT05231083|Experimental|Arm A - 20Hz Stimulation|Transcutaneous stimulation of the genital nerves at 20Hz
9730920|NCT05231083|Experimental|Arm B - 60Hz Stimulation|Transcutaneous stimulation of the genital nerves at 60Hz
9730921|NCT05231044|Experimental|KX01 Ointment 1%|KX01 Ointment 1% is applied topically once daily for 5 consecutive days on face or scalp
9730922|NCT05231044|Placebo Comparator|Placebo|Vehicle Ointment is applied topically once daily for 5 consecutive days on face or scalp
9730923|NCT05231031|Active Comparator|Aerobic exercise|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks
9730924|NCT05231031|Experimental|Aerobic, Breathing exercises , and relaxation training|This group received continuous aerobic exercise only in the form of walking on a treadmill 3 sessions/week for 6 weeks in addition to breathing exercises and relaxation training for the same period
9730925|NCT05231005|Experimental|4th dose BNT162b2 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (30 microgram) of the BNT162b2 vaccine
9730926|NCT05231005|No Intervention|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
9730927|NCT05230979|Experimental|Normal weight|People with normal weight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
9730928|NCT05230979|Experimental|Overweight|People with overweight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
9730929|NCT05230979|Experimental|Glycemic index|Determination of glycemic index under the ISO 26642:2010.
9730930|NCT05230966|No Intervention|Group 1- angina pectoris|Patients with acute coronary syndrome; angina pectoris (chest pain with negative troponin T with or without changes in electrocardiographic findings);
9730931|NCT05230966|No Intervention|Group 2 - angina pectoris + STEMI+ PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
9730932|NCT05230966|Active Comparator|Group 3 - without angina pectoris + STEMi + RIC + PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention during which it's carried out remote ischemic conditioning (RIC)
9730933|NCT05230966|No Intervention|Group 4 - without angina pectoris + STEMI + PCI|Patients with acute myocardial infarction with ST-segment elevation, < 6 hours from the onset of chest pain and without preceding symptoms of angina pectoris with primary percutaneous coronary intervention.
9730934|NCT05230966|Active Comparator|Group 5 - healthy + RIC|healthy volunteers of the same age and sex, whose samples will be taken after the RIC procedure
9730935|NCT05230953|Experimental|4th dose mRNA1273 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (50microgram) of the mRNA1273 vaccine
9730936|NCT05230953|No Intervention|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
9730937|NCT05230953|Experimental|4th dose BNT162b2 vaccine|The outcomes will be compared to those participating in study IRB-8980-21, with a similar protocol, initiated 1 week earlier.
9730938|NCT05230927||Chronic Heart Failure|
9730939|NCT05230927||Chronic Obstructive Pulmonary Disease|
9730940|NCT05230914|Experimental|NCCT|NCCT and CTA will be used to screen patients for endovascular treatment
9730941|NCT05230914|Active Comparator|CTP|NCCT, CTA, and CTP will be used to screen patients for endovascular treatment
9730942|NCT05230901|Other|Control group|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care
9730943|NCT05230901|Experimental|Spironolactone|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.)
9730944|NCT05230901|Experimental|Spironolactone + Dihydralazine|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.) + Dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg / d p.o. in fast acethylators, confirmed by genetic testing)
9730945|NCT05230875||Patients participating in the therapeutic education program|Patients participating in an educational program on Inflammatory Bowel Disease (IBD) including a specific discussion on intimacy and sexuality .
9730946|NCT05230875||Patients control (not participating in the therapeutic education program)|A control group (at the rate of two controls for one case) will be made up of IBD patients routinely followed in the gastroenterology department.Those patients will not participate in the therapeutic education program.
9730947|NCT05230849|Active Comparator|control group|conventional physiotherapy treatment
9730948|NCT05230849|Experimental|dry needling treatment|group that includes a dry needling treatment on the tibialis anterior and posterior muscles.
9730949|NCT05230836|Experimental|30 kilohertz|Alternating current stimulation at 30 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
9730950|NCT05230836|Experimental|40 kilohertz|Alternating current stimulation at 40 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
9730951|NCT05230836|Experimental|50 kilohertz|Alternating current stimulation at 50 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
9730952|NCT05230836|Sham Comparator|Sham stimulation|Sham stimulation via transcutaneous, 15 minutes each intervention, following the same procedures as 30, 40 and 50kHz HFAC groups.
9730953|NCT05230823|Experimental|Intervention|The intervention consists of a traditional 12-week outpatient CR program with added weekly behavioural weight loss classes.
9730954|NCT05230797|Experimental|zinc-oxide propolis|Propolis is a natural resinous mixture produced by honeybees from substances collected from parts of plants, buds, and exudates. The essential principle compounds responsible for biological activities are polyphenols, aromatic acids, and diterpenic acids. Numerous biological properties of propolis have been reported including cytotoxic, antiherpes, free radical scavenging, antimicrobial, and anti-HIV activities The antibacterial effect of propolis is bactericidal by inhibiting their mobility. Propolis kills the fungi and also inhibits the growth of the viruses.
9730955|NCT05230797|Active Comparator|zinc-oxide eugenol|Zinc oxide-eugenol cement (ZOE) has been used as a root canal filling material for primary teeth and has long been the material of choice of pediatric dentists worldwide, although it fails to meet the ideal requirements of root canal filling material for primary teeth due to limited antimicrobial action, and a slower rate of resorption than the roots of the primary teeth. Studies report that the success rate of ZOE ranges from 65% to 86% so it's materials of choice if primary teeth are not nearing exfoliation.
9730956|NCT05230784|Experimental|HEPA Air Purifier|
9730957|NCT05230784|Placebo Comparator|EGAPA Air Purifier|
9730958|NCT05230758|Experimental|Metformin|Oral metformin will be administered approximately 500mg/m2/day for 1 week and increased to 1000mg/m2/day for 15 weeks. Doses will be rounded to increments of half tablets (250mg, 500mg, 750mg and 1000mg).
9730959|NCT05230758|Placebo Comparator|Placebo|Oral placebo will be administered approximately 500mg/m2/day for 1 week and increased to 1000mg/m2/day for 15 weeks. Doses will be rounded to increments of half tablets (250mg, 500mg, 750mg and 1000mg).
9730960|NCT05230745|Experimental|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
9730961|NCT05230732|Experimental|Experimental|Active LLTS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks.
9730962|NCT05230732|Sham Comparator|Control arm|Sham LLTS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks.
9730963|NCT05230706|No Intervention|Control (CBL)|The control group was kept under normal room light conditions (CBL) 24 hours a day (level of illumination was 275.82±14 lux during the day and 145.28±14 lux at night).
9730964|NCT05230706|Experimental|Experimental (LDC)|The experimental group were allocated to alternating light/darkness conditions as follows: from 07:00 to 19:00 hours the subjects were kept under normal room light conditions; from 19:00 to 07:00 of the following day the conditions were modified by placing the patient under an acrylic cephalic helmet (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm). The helmet was covered with surgical cloth (green or blue) folded to 50x60cm rectangles, leaving the frontal part open in order to maintain an adequate air flow. This intervention exposed infants in the experimental group to light at 25 lux for 12 hours every day, while during daytime the cloth was removed in order for study subjects to be exposed to regular room lighting.
9730965|NCT05230654|Experimental|fosaprepitant|Patients received intravenous Ganisetron plus dexamethasone followed by fosaprepitant infusion
9730966|NCT05230654|Placebo Comparator|Placebo|Patients received intravenous Ganisetron plus dexamethasone followed by normal saline
9730967|NCT05230615||Patients with type 2 diabetes|once-daily oral semaglutide in a real-world adult population with type 2 diabetes
9730968|NCT05230602|Experimental|Study Group|The participants will fill the study scales and will be instructed to eat the tzabar fruit twice a day for two weeks
9730969|NCT05230602|No Intervention|Control Group|The participants will fill the study scales and will be instructed not to change their diet for two weeks
9730970|NCT05230589||Patients with type 2 diabetes|once-daily oral semaglutide in a real-world adult population with type 2 diabetes
9730971|NCT05230576||Deep learning training cohort|2/3 of the enrolled patients and their corresponding carotid artery dynamic scan images and expert diagnosis results were randomly selected as the training cohort for deep learning.
9730972|NCT05230576||Deep learning validation cohort|The carotid artery dynamic scan images and expert diagnosis results of the remaining 1/3 patients were used as a validation cohort to evaluate the overall diagnostic accuracy of the deep learning model.
9730973|NCT05230563|No Intervention|Control Group|Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images
9730974|NCT05230563|Experimental|"Experimental Group - with the aid of Taihao lung CT decision support system"|"Participating clinicians will perform lung nodule detection on 200 cases of lung low-dose computed tomography images with the aid of Taihao lung CT decision support system"
9982418|NCT05243732|Experimental|Preferred Music Listening|Participants in the preferred music listening group will receive personalised playlists based on music tracks or albums or genres suggested by the participant in the pre-intervention survey. Participants will be advised to select music that uplifts and helps them to relax and to avoid music that may trigger a negative emotion or make them feel sad. The music playlists will be generated using participants' preferred music streaming platform, for which they have an existing account.
9982419|NCT05243732|Active Comparator|Mindfulness Listening|Participants in the mindfulness listening group, will receive playlists created on the streaming platform they are subscribed to. Participants in the mindfulness group will be informed mindful music will have relaxing background music with spoken instructions to help achieve mindfulness by relaxing the mind and body.
9982420|NCT05243199|Experimental|Sacubitril/Valsartan|
9982421|NCT05243199|Active Comparator|Irbesartan|
9730979|NCT05230485|Experimental|Higher CPAP|CPAP level will be 2 cmH2O higher than pre-extubation measured mean airway pressure
9730980|NCT05230485|Active Comparator|Equivalent CPAP|CPAP level will be equal to the pre-extubation measured mean airway pressure
9730981|NCT05230472|Active Comparator|simvastatin group|68 patients who had a ventilator associated pneumonia received simvastatin
9730982|NCT05230472|No Intervention|control group|68 patients who had a ventilator associated pneumonia not received simvastatin
9730983|NCT05230459|Experimental|LION-101 Cohort 1|
9730984|NCT05230459|Experimental|LION-101 Cohort 2|
9730985|NCT05230459|Placebo Comparator|Placebo (Cohorts 1 and 2)|
9982422|NCT05242692|Experimental|S-ketamine|S-ketamine (50 mg, 2 ml) is diluted to 50 ml (1 mg/ml) with 48 ml normal saline;
9982423|NCT05242692|Active Comparator|Dexmedetomidine|Dexmedetomidine (200 ug, 2 ml) is diluted to 100 ml (2 ug/ml) with 98 ml normal saline;
9982424|NCT05242692|Placebo Comparator|Normal saline|Control group only contains 50 ml normal saline in light of blindness
9982425|NCT05242653|Experimental|cotton swab|
9982426|NCT05242653|Active Comparator|balanced salt solution (BSS)|
9982427|NCT05241730|Experimental|Low GI|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
9982428|NCT05241730|Active Comparator|High GI|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
9982429|NCT05241730|Experimental|Low Carb High Fat|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
9982430|NCT05241561|Experimental|Cabozantinib|
9982431|NCT05241470|Active Comparator|Low Dose ST-100 Ophthalmic Solution|Low Dose ST100-001 Ophthalmic solution, 20mg/ml
9982432|NCT05241470|Active Comparator|High Dose ST-100 Ophthalmic Solution|High Dose ST100-001 Ophthalmic Solution, 50mg/ml
9982433|NCT05241470|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (vehicle)
10200306|NCT04585269|No Intervention|Enhanced Usual Care|Participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer network (NCCN) adolescent and young adult patient guidelines.
9730986|NCT05230446|Other|Percutaneous Coronary Intervention|Interventional comparitor, compared to an optimal performance goal of 7% MACCE resulted from past CABG results
9730987|NCT05230433|Experimental|High-fat Metabolic Challenge|Participants will consume a high-fat agent one time, at the second study visit.
9730988|NCT05230186||On-Treatment Solid Tumor Responder (Tumor Biopsy)|Research tumor tissue biopsy collected at any one time point while responding to ICI therapy (radiographic regression of lesion). Tumor biopsy and companion blood sample.
9730989|NCT05230186||Pre and On-Treatment Solid Tumor Responder (Tumor Biopsy)|Tumor tissue collection prior to beginning ICI therapy (optional biopsy). If and when there is a response to ICI therapy, a second research tumor tissue biopsy is collected. Tumor biopsy and companion blood sample.
9730990|NCT05230186||On-Treatment Solid Tumor Responder (Surgical Removal Tumor)|Collection of excess tumor tissue in patients who are responding to ICI therapy and are scheduled for Surgical resection of residual disease. Excess tissue provided.
9730991|NCT05230186||Post-Treatment of patients with Melanoma who develop vitiligo|Up to 5 patients treated for melanoma that develop vitiligo - Skin Tissue Biopsy obtained at any point in time from any skin site with vitiligo (selected sites only). Tissue biopsy
9730992|NCT05230186||On-Treatment Responder (Previously Frozen Tumor Tissue)|Previously Cryopreserved Tissue obtained from a Biobank or Tissue Repository, collected from patients when they were responding to ICI Therapy (clinical data required).
9730993|NCT05228327|Active Comparator|Occlusal Splint Group|Only occlusal splint was made for this patients.
9730994|NCT05228327|Active Comparator|Masticatory muscle injection group|Only intramuscular injection was applied to this patients. Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points.
9730995|NCT05228327|Active Comparator|Occlusal splint and masticatory muscle injection combination group|Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points. Patients were started to use their occlusal splints in the evening of the injection day.
9730996|NCT05228327|No Intervention|Control group|16 healthy volunteers was involved. Not given any treatment to these volunteers.
9730997|NCT05224375|Experimental|Treatment|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.
9730998|NCT05223036|Experimental|Arm I (OCA)|Patients receive OCA PO QD for 6 months in the absence of unacceptable toxicity.
9730999|NCT05223036|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months in the absence of unacceptable toxicity.
9731000|NCT05212753|Active Comparator|Conventional Physical Therapy Group|The conventional physical therapy group will receive Transcutaneous Electrical Nerve Stimulation (TENS) and hot pack application.
9731001|NCT05212753|Active Comparator|Stabilization Group|The stabilization group will receive lumbar stabilization exercises and the conventional physical therapy program. That program includes lumbar stabilization exercises including activation of the transverses abdominals (TA) and multifidi muscles.
9731002|NCT05212753|Active Comparator|Breathing Exercise Group|The breathing exercise group will receive breathing exercises including sleep hygiene, and the stabilization group program. Breathing exercises include diaphragmatic breathing and pursed-lip.
9731003|NCT05212740|Experimental|Corticosteroid|The participants will receive prednisolone for four weeks.
9731004|NCT05212740|Active Comparator|Exercise|The participants will receive joint mobilization techniques, stretching and home exercise.
9731005|NCT05212467|Active Comparator|AIR-program|• The Amygdala and insula retraining program consists of novel brain retraining approaches focused on hypothetically interrupting and retraining the conditioned defensive hyper-stimulation of the sympathetic nervous system and aspects of the immune system by the amygdala and insula, to bring the brain and body back to homeostasis. It includes supportive techniques such as breathing, meditation, and neurolinguistic programming. The patients are invited to an online program of video session and eight weekly 2 h webinar sessions followed by three monthly sessions. The patients are assigned to do daily homework that takes approximately 15 to 20 min to complete
9731006|NCT05212467|Active Comparator|HUS Internet therapy|The HUS internet therapy for bodily stress syndromes (iHUSbss) includes psychoeducation about autonomic nervous system and of the effects of patient's own thinking and action on the nervous system. The exercises aim at relaxing the body, at novel ways to observe the symptoms, and at developing acceptance and self-compassion. The program includes exercises that are done regularly in everyday life.
9731007|NCT05212467|Placebo Comparator|Treatment as usual|The patients may have appointments with their physician, physiotherapist, or another health professional, and they may attend group interventions. If possible, medication is kept the same during the intervention and three months afterwards. If there is need to change the medication during the trial, the changes will be recorded. Appointments with health professionals and attendance in group interventions are monitored.
9731008|NCT05212194|Other|Post spinal puncture headache|the patients who developed post spinal puncture headache
9731009|NCT05211986|Active Comparator|Cohort A|Participants will receive twice weekly intramuscular (im) administration of IMM01 STEM for 4 weeks with a dose of 225μg.
9731010|NCT05211986|Active Comparator|Cohort B|Participants will receive twice weekly intramuscular (im) administration of IMM01 STEM for 4 weeks with a dose of 450μg.
9731011|NCT05211986|Active Comparator|Cohort C|Participants will receive twice weekly intramuscular (im) administration of IMM01 STEM for 4 weeks with a dose of 900μg.
9731012|NCT05211570|Experimental|AB8939|AB8939 administered as a single agent
9731013|NCT05211570|Experimental|AB8939 plus azacitidine|AB8939 administered in combination with azacitidine
9731014|NCT05211154|Experimental|Diclofenac Potassium (soluble)|50 mg diclofenac potassium taken orally once
9731015|NCT05211154|Active Comparator|Rimegepant|75 mg rimegepant taken orally once
9781281|NCT01145183|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
9781282|NCT01145183|Placebo Comparator|Placebo|Matched placebo daily dosing.
9781283|NCT01145222|Experimental|A. Remimazolam (CNS 7056)|"Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
9781284|NCT01145222|Experimental|B. Remimazolam (CNS 7056)|"Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
9781285|NCT01145222|Experimental|C. Remimazolam (CNS 7056)|"Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
9781286|NCT01145222|Active Comparator|D. Midazolam|"Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses"
9781287|NCT01145352||Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
9781288|NCT01145391|No Intervention|Control|Patients receive usual care.
9781289|NCT01145391|Active Comparator|Intervention|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
9781290|NCT01145417|Experimental|Pregabalin (Lyrica)|
9781291|NCT01145482|Experimental|insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
9781292|NCT01145482|Placebo Comparator|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
9781293|NCT01145508|Experimental|Arm A (vaccine therapy and chemotherapy)|Patients receive rilimogene-galvacirepvec SC on day 1 of course 1 and fowlpox-PSA-TRICOM vaccine SC on days 15, 29, 43, and 57 of course 1. Beginning on day 85 (day 1 of course 2), patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment with docetaxel and prednisone repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9781294|NCT01145508|Active Comparator|Arm B (docetaxel, prednisone)|Patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9781295|NCT01145547|Active Comparator|low glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.
9781296|NCT01145547|Active Comparator|high glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.
9781297|NCT01145560|Experimental|1|AZD9773 250/50 units/kg
9781298|NCT01145560|Experimental|2|AZD9773 500/100 units/kg
9781299|NCT01145560|Placebo Comparator|3|
9781300|NCT01145625|Experimental|5% MTF|5% Minoxidil Topical Foam
9781301|NCT01145625|Active Comparator|2% MTS|2% Minoxidil Topical Solution
9781302|NCT01145638|Experimental|iron isomaltoside 1000|Iron isomaltoside intravenously as bolus or infusion
9781303|NCT01145638|Active Comparator|iron sulphate|oral iron sulphate twice a day
9781304|NCT01145755|Experimental|AZD2066|
9781305|NCT01145755|Placebo Comparator|Placebo|
9781306|NCT01145755|Active Comparator|Duloxetine|Duloxetine
9781307|NCT01145833|Active Comparator|Immediate treatment group|The immediate treatment group begins the 5-month treatment immediately after baseline assessment.
9781308|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group serves as the control group. This group starts treatment 5 months after the baseline assessment. No intervention is involved during this 5-month waiting period. After 5 months, the delayed group is assessed for the second time and then begins the 5-month treatment.
9781309|NCT01145885|Experimental|BI 6727|BI 6727 cycles in every 21 days
9781310|NCT01145898||Glaucoma patients|Patients with Glaucoma
9781311|NCT01146054|Experimental|SBRT and Gemzar|Before stereotactic Body Radiotherapy (SBRT) 3-5 gold fiducials are placed by endoscopic ultrasound or CT guidance. A simulation FDG-PET/CT (Fludeoxyglucose (18F) - Positron emission tomography/Computerized tomography) scan will be used for treatment planning purposes (standard free-breathing CT and respiratory-correlated 4-D (4 dimensional) pancreatic protocol CT). Patients are treated by either respiratory gated (Trilogy, Elekta, Novalis) or by respiratory tracking (CyberKnife). SBRT is delivered in 5 fractions of 6.6 Gy by LINAC-based or CyberKnife based radiotherapy over a five-day period. Gemcitabine, cycles should resume/start up to 4 weeks following SBRT on a 3-week on, 1-week off schedule. Initial follow up is at 4, 6, 9 and 12 months and then for years 2-5 is every 3-6 months.
9731016|NCT05210842||Lumen apposing metal stent|All patients who had a lumen-proximating stent implanted are included.
9731017|NCT05210543||Anaphylactic reaction (observational)|Patients who experienced an anaphylactic reaction will be observed
9731018|NCT05210088|Experimental|PHASE 1- Dose escalation protocol|"4-step dose-escalation protocol with increasing doses of intermittent hypoxia and continuous reassessment of safety criteria (primary endpoint).~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored: 90% for stage 1 (n=1 patient), 85% for stage 2 (n=3 patients), 80% for stage 3 (n=3 patients), 75% for stage 4 (n=3 patients)."
9731019|NCT05210088|Active Comparator|PHASE 2 - Intermittent hypoxia group|"Group exposed to an intermittent hypoxic stimulus (n=20, target pulsed saturation in dioxygen 75%).~The device used is a gas mixer already in use in the unit and used in current clinical practice and research in our team (Altitrainer®, Sport and Medical TEChnologies S.A. (SMTEC S.A.), Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the FiO2 will be set individually to achieve the targeted level of desaturation."
9731020|NCT05210088|Sham Comparator|PHASE 2 - Sham (Normoxia) group|Normoxia group (n=10, FiO2 = 21%). The same setting will be used as in the Intermittent hypoxia group, but subjects will breathe ambient air throughout the conditioning procedure.
9731021|NCT05209503|Experimental|AccuFFRangio Group|STEMI patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.
9731022|NCT05209503|Active Comparator|Angiography Group|The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis > 70% based on angiographic results.
9731023|NCT05209477|Other|Lung ultrasound|"n patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio < 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~baseline, in supine position under protective ventilation after two minute of recruitment maneuver in pressure controlled ventilation at 1 hour following prone positioning application"
9731024|NCT05209165|Experimental|Semaglutide|
9731025|NCT05209165|Placebo Comparator|Placebo|
9731026|NCT05209074|Experimental|Ivosidenib+mFOLFIRINOX|
9731027|NCT05208684|Experimental|Breast stimulation|A 30-minute stimulation with moderate intensity by an electric milk pump (Elvie Pump) will be performed.
9731028|NCT05208424||Normal glycemia|100 patients without evidence of dysglycemia.
9731029|NCT05208424||Prediabetes|100 patients with evidence of pre-diabetes defined as hemoglobin A1C (HbA1c) 5.7-6.4% with or without fasting plasma glucose (FPG) of 100 mg/dL to 125 mg/dL.
9731030|NCT05208424||Diabetes|100 patients without evidence diabetes defined as hemoglobin HbA1c > 6.4% with or without FPG >125 mg/dL.
9731031|NCT05208385|Other|Standard umbilical trocar incision closure (UC)|standard umbilical trocar incision closure
9731032|NCT05208385|Active Comparator|Video-assisted umbilical trocar incision closure (UCVA))|video-assisted umbilical trocar incision closure
9731033|NCT05208034|No Intervention|single-dose group|Women in single-dose group were administered a single-dose of intramuscular methotrexate as 50 mg/m2 on day-zero (the start of treatment).
9731034|NCT05208034|Experimental|two-dose group|Women allocated to two-dose group were administered intramuscular methotrexate as 50mg/m2 at day-zero and 7 while measurement of β-hCG was ordered at day-14.
9731035|NCT05208021|Experimental|Intervention group|"Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program was applied to the intervention group"
9731036|NCT05208021|No Intervention|Control Group|Only data collection was carried out. No attempt was made by the researcher during the study
9731037|NCT05207124||Botulinum toxin injection group|onabotulinumtoxinA
9731038|NCT05206630|Experimental|Embedded ED Physical Therapy|An ED physical therapist will be embedded with the primary treatment team to evaluate patients presenting with low back pain at the beginning of the overall treatment course. The physical therapist will utilize a clinical protocol that matches the patient's history and exam findings to an appropriate treatment classification consisting of directional preference exercises, manual traction, stabilization exercises, non-thrust manipulation/mobilization, and/or psychologically informed rehabilitation. The embedded PT intervention will supplement any usual care performed by the treating physician.
9731039|NCT05206630|No Intervention|Usual Care|Usual care consists of any ED testing or treatment not involving an ED physical therapist in accordance with the treating physician's usual and customary practice. This could include diagnostic imaging, patient education and reassurance, and administration and/or prescribing of analgesic medications.
9731040|NCT05206526|Experimental|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
9731041|NCT05206526|Active Comparator|Control|12 weeks of home-based training, without supervision, to perform 3 time per week composed by ten total body exercise.
9731042|NCT05204849|Active Comparator|Active irrigation and aspiration|Patients randomized to IRRAflow will receive a ventricular catheter with active irrigation and aspiration.
9731043|NCT05204849|Active Comparator|Standard passive external ventricular drainage|Patients randomized to passive external ventricular drainage will receive a standard EVD.
9731044|NCT05203796|Experimental|Experimental group: Dry eye disease patients (n=12)|"Patient needs to visit site at least 7 times(Screening, Baseline, wk1, wk2, wk3, wk4, wk5). From baseline visit, patients wear our clinical trial device 30mins per day for 5wks(2Hz stimulation). All other procedures during clinical trial the are the same.~Intervention: Device: Transcutaneous pulsed electrical stimulation"
9731045|NCT05203796|Sham Comparator|Comparison group: Dry eye disease patients (n=12)|"Patient needs to visit site at least 7 times(Screening, Baseline, wk1, wk2, wk3, wk4, wk5). From baseline visit, patients wear our clinical trial device 30mins per day for 5wks(sham stimulation). All other procedures during clinical trial the are the same.~Intervention: Device: Sham device"
9731046|NCT05203276|Experimental|Envafolimab+ Endostar Group|Envafolimab（300mg，SC，Q3W，d1） Endostar（210mg，CIV 72h，Q3W，d1-3）
9731047|NCT05203198|No Intervention|1. No adolescent modules + no parent modules|No adolescent nor parent modules will be offered to the participant.
9731048|NCT05203198|Experimental|2. Adolescent behavioral activation modules only|Adolescent behavioral activation modules only
9731049|NCT05203198|Experimental|3. Adolescent cognitive-behavioral therapy modules only|Adolescent cognitive-behavioral therapy modules only
9731050|NCT05203198|Experimental|4. Adolescent interpersonal therapy modules only|Adolescent interpersonal therapy modules only
9731051|NCT05203198|Experimental|5. Adolescent behavioral activation modules + cognitive-behavioral therapy modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules
9731052|NCT05203198|Experimental|6. Adolescent behavioral activation modules + interpersonal therapy modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules
9731053|NCT05203198|Experimental|7. Adolescent cognitive-behavioral therapy modules + interpersonal therapy modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
9731054|NCT05203198|Experimental|8. Full Adolescent program only|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules
9731055|NCT05203198|Experimental|9. Parent program modules only|Parent program modules
9731056|NCT05203198|Experimental|10. Adolescent behavioral activation modules + parent program modules|Adolescent behavioral activation modules Parent program modules
9731057|NCT05203198|Experimental|11. Adolescent cognitive-behavioral therapy modules + parent program modules|Adolescent cognitive-behavioral therapy modules Parent program modules
9731058|NCT05203198|Experimental|12. Adolescent interpersonal therapy modules + parent program modules|Adolescent interpersonal therapy modules Parent Program
9731059|NCT05203198|Experimental|13. Adolescent behavioral activation + cognitive-behavioral therapy + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Parent program modules
9731060|NCT05203198|Experimental|14. Adolescent behavioral activation + interpersonal therapy + parent program modules|Adolescent behavioral activation modules Adolescent interpersonal therapy modules Parent program modules
9731061|NCT05203198|Experimental|15. Adolescent cognitive-behavioral therapy + interpersonal therapy + parent program modules|Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
9731062|NCT05203198|Active Comparator|16. All adolescent + parent program modules|Adolescent behavioral activation modules Adolescent cognitive-behavioral therapy modules Adolescent interpersonal therapy modules Parent program modules
9731063|NCT05203159|Experimental|ocean sound|The group that will listen to the ocean sound
9731064|NCT05203159|Active Comparator|control group|The group that will not listen to sound
9982434|NCT05241158|Active Comparator|Group A|Group A: Counselling group Patients were given a briefing about the procedure; the use of local anesthetic along with potential benefits and side effects of the drug. The steps of the endoscopy procedure (gastroscopy or colonoscopy) were explained in detail including the position, intubation, biopsy or intervention wherever applicable, extubation and post-procedure observation period in the recovery room. Detailed instructions were provided regarding post-procedural care, introduction of diet & follow-up.
10205068|NCT04119375|Experimental|SMS-Only|"Patients in the SMS reminder group will receive a single, medication reminder SMS once daily at their indicated treatment time. The reminder message will read Please take the medication on time consistent with messages used by Liu and colleagues (2015)."
9731065|NCT05202964||Tolerance and adherence to oral antibiotics in patients managed for BJI|Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery
9731069|NCT05202158|Active Comparator|Irrigation + Genta|Patients treated with gentamicin in irrigation fluid during RIRS
9731070|NCT05202158|Sham Comparator|Irrigation|Patients treated only irrigation fluid during RIRS
9731071|NCT05202041|Experimental|AccuFFRangio Group|NSTE-ACS patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.
9731072|NCT05202041|Active Comparator|Angiography Group|The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis > 70% based on angiographic results.
9731073|NCT05202028|Experimental|Classic abdominal massge|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Classic abdominal massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
9731074|NCT05202028|Experimental|Connective tissue massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
9731075|NCT05202028|Experimental|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
9731076|NCT05201768||INDIVIDUALS WITH ALZHEIMER|balance and gait will be evaluated survey questions will be asked
9731077|NCT05201768||HEALTHY INDIVIDUALS|balance and gait will be evaluated survey questions will be asked
9731078|NCT05201742|Active Comparator|Inspiratory muscle trainer|Inspiratory muscle trainer group - Inspiratory muscle training was performed.
9731079|NCT05201742|Active Comparator|Incentive spirometer|Incentive spirometer group - Incentive spirometry was performed.
9731080|NCT05201690|Experimental|VV116 200 mg Group|VV116 200 mg Group
9731081|NCT05201690|Experimental|VV116 400 mg Group|VV116 400 mg Group
9731082|NCT05201690|Experimental|VV116 600 mg Group|VV116 600 mg Group
9731083|NCT05201690|Placebo Comparator|Placebo|VV116 Matching placebo tablets; Multiple doses
9731084|NCT05201391|Experimental|"Eat Right Now (ERN) mobile application"|Participants in this single-arm trial will receive the ERN app as the intervention.
9731085|NCT05199493|Experimental|Angiotensin II|Intravenous infusion of max. 80 ng/kg/min Angiotensin II (titrated for each individual patient by effect) over 12 h after start of infusion
9731086|NCT05199493|Placebo Comparator|Control|Intravenous infusion placebo (matched infusion volume) over 12 h after start of infusion
9731087|NCT05198752|Experimental|Neoantigen mRNA Personalised Cancer|This study is a 3+3 dose escalation design. Participants will receive a total of 6 cycles of SW1115C3 every 21 days.
9731088|NCT05196854|Other|Group 1: Standard Blood Pressure measurement at home|Standard home blood pressure measurement at home
9731089|NCT05196854|Experimental|Group 2. Hypnosis script prior to Home Blood Pressure measurement|Participant listens to a pre-recorded hypnosis script (approx 5 mins long) prior to standard home blood pressure measurement.
9731090|NCT05196295|Experimental|Hydrogen capsules|Participants will be allocated by doctors and receive either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
9731091|NCT05195814||Effectiveness of tofacitinib|Participants receiving tofacitinib will be included to assess the effectiveness of tofacitinib overall and stratified by key variables of interest
9731092|NCT05192148|Experimental|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
9731093|NCT05191615|Experimental|Intervention Group|"The proposed study will be implemented as an intervention study at two levels within the organization, managerial and registered nurses. The intervention comprises three major phases: a pre-intervention phase, an implementation-intervention phase, and a post-intervention phase. The interventions will be provided face-to-face by trained interventionists. At baseline, all participants will complete questionnaires and get labs completed, blood pressure checked, and weight/height measured.~Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work."
9731094|NCT05191615|No Intervention|Control Group|Participants randomized to the control group will complete the baseline questionnaires and lab tests at baseline and three follow-up times. Lab values will be collected using the current standard of care and American Heart Association (AHA) guidelines (2019).
9731095|NCT05190302||Phase I - Patients undergoing regional anesthesia with a block allowing a neurostimulation.|The investigators propose to conduct a single-blind, prospective observational study on all eligible patients undergoing regional anesthesia with a peripheral nerve block allowing a neurostimulation.
9731096|NCT05189847||Patients with MFA|Patients with MFA confirmed by ultrasound examination, ABI or using clinical and medical history data.
9731097|NCT05189847||Patients with a history of established isolated coronary artery disease|The criterion for inclusion of patients in the present study is the diagnosed ischemic heart disease.
9731098|NCT05189106|Experimental|Baricitinib|Baricitinib 2mg administered by mouth once daily for the first 8 weeks, followed by baricitinib 4mg administered by mouth once daily for 16 weeks.
9731099|NCT05188170|Experimental|Niclosamide 250 mg/m2 /day divided BID|
9731100|NCT05188170|Experimental|Niclosamide 500 mg/m2 /day divided BID|
9731101|NCT05188170|Experimental|Niclosamide 800 mg/m2 /day divided BID|
9731102|NCT05188170|Experimental|Niclosamide 1200 mg/m2 /day divided BID|
9731103|NCT05187533|Other|Mild dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
9731104|NCT05187533|Other|Moderate dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
9731105|NCT05187533|Other|Severe dry eye disease|Osteopathic protocol of sphenopalatine ganglion stimulation
9731106|NCT05187455|Experimental|Renal transplantation(S group)|n=17,CLCR≤30ml/min
9731107|NCT05187455|Experimental|the control group|n=17, CLCR≥80ml/min
9731108|NCT05184777|Experimental|Patients undergoing ovarian stimulation for IVF/ICSI|90 patients undergoing ovarian stimulation for IVF/ICSI; Low, average and high responders will be included in equal proportions, in order to cover the widest range of hormonal values (30 blood and saliva samples per ovarian stimulation point will be taken for determination of progesterone and oestradiol).
9731109|NCT05184777|Experimental|Patients for embryo transfer (ET) undergoing hormonal replacement therapy|30 patients for embryo transfer (ET) undergoing hormonal replacement therapy. These patients will only have a progesterone determination in their blood and saliva samples on the day of ET.
9731110|NCT05182866|Experimental|Single Arm|ASP-1929 640 mg/m^2 treatment by intravenous (IV) infusion followed approximately 24 hours later by illumination (also termed as photoimmunotherapy [PIT]) of tumor(s) using the PIT690 Laser System with a 690 nm light dose of 50 J/cm^2 for superficial illumination and 100 J/cm of fiber length for interstitial illumination.
9731111|NCT05181722|Active Comparator|Intervention group|The study participants in this group will receive support from the patient navigator as part of this study.
9731112|NCT05181722|No Intervention|Usual care group|The study participants in this group will receive the usual care per the institutional protocol.
9731113|NCT05179837|Experimental|Optical coherence tomography (OCT) probe|After consent, the endoscopist will perform a standard of care colonoscopy. If a polyp is found, then OCT will be used to image that polyp. Patients with polyps, regardless of number found, will have either one tubular adenoma (NICE type 2) imaged OR one hyperplastic polyp (NICE type 1) imaged. If no polyps are found, then one area of normal mucosa will be imaged. If on the rare chance a malignant appearing colonic tumor (NICE type 3) is found, this and no other polyps will be imaged with OCT.
9731114|NCT05179304|Experimental|Oncoplastic technique with a droplet-shaped glandular flap|
9731115|NCT05178797|Experimental|K-tapping and exercise (Group A)|Group A will be given kinesiology taping technique and exercise therapy
9731116|NCT05178797|Active Comparator|Compression decongestive therapy (Group B )|Group B will be given compression decongestive therapy (manual lymphatic drainage, short stretch bandage and exercise therapy)
9731119|NCT05174455|Experimental|Treatment (Niraparib)|Patients receive niraparib PO QD. Cycles repeat every 28 days for 15 months in the absence of disease progression or unacceptable toxicity.
9731120|NCT05172349|Experimental|LV-Visio-AMTRIX|Sutureless amniotic membrane supported by a biological ring positioned by the investigator during patients' hospital visits.
9731121|NCT05170516|Experimental|Experimental Group A|In experimental group A, 4°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
9731122|NCT05170516|Experimental|Experimental Group B|In experimental group B, 10°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
9731123|NCT05170516|Active Comparator|Control Group A|In control group A, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 4 °C saline irrigation on one side.
9731124|NCT05170516|Active Comparator|Control Group B|In control group B, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 10 °C saline irrigation on one side.
9731125|NCT05165810|Active Comparator|Arm 1: standard ART initiation + government-based HIV care + routine adherence support|Participants randomized to Arm 1 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
9731126|NCT05165810|Experimental|Arm 2: same-day ART + government-based HIV care + routine adherence support|Participants randomized to Arm 2 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
9731127|NCT05165810|Experimental|Arm 3: standard ART initiation + community-based HIV care + routine adherence support|Participants randomized to Arm 3 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
9731128|NCT05165810|Experimental|Arm 4: standard ART initiation + government-based HIV care + enhanced adherence support|Participants randomized to Arm 4 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
9731129|NCT05165810|Experimental|Arm 5: same-day ART initiation + community-based-based HIV care + routine adherence support|Participants randomized to Arm 5 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
9731130|NCT05165810|Experimental|Arm 6: same-day ART initiation + government-based-based HIV care + enhanced adherence support|Participants randomized to Arm 6 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
9731131|NCT05165810|Experimental|Arm 7: standard ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 7 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
9731132|NCT05165810|Experimental|Arm 8: same-day ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 8 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
9731133|NCT05164640|Other|assessment of coronary physiology|"This is a prospective, multicentric, non-randomized , single-arm , open label clinical study.~Included patients will be studied with invasive functional tests performed during index coronary angiography. These will include FFR, instantaneous Wave-Free Ratio (iFR), Resting Ful-Cycle Ra-tio (RFR), CFR, IMR and provocative Acetylcholine test.~After the diagnosis of vasospastic angina (VSA) or coronary microvascular dysfunction (CMD) is made, a stratified medical therapy will then be initiated according to the results of physiological assessment according to ESC guidelines and recent EAPCI expert consensus document ."
9982435|NCT05241158|Active Comparator|Group B|Group B: Video group Patients in the visual aid group (video group) were provided with the same information mentioned in intervention group A. In addition to that, patients watched a 2 minutes video of the respective procedure. Video showed the animation of a gastroscopy or colonoscopy procedure with a voice over explaining all the steps of the procedure in addition to the pre and post-procedure precautions to be observed.
9731136|NCT05160766|Active Comparator|Comirnaty-Comirnaty-Comirnaty|Participants are already fully vaccinated with 3x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
9781312|NCT01146275|Other|Participants in the Pilot study 31GB0601|"This is an additional safety follow up 7-years post treatment, for subjects enrolled in a pilot study using a previous formulation of Macrolane for breast augmentation.~Radiological breast examinations - MRI of breast, mammography and ultrasound of breast"
9731137|NCT05160766|Active Comparator|Spikevax-Spikevax-Spikevax|Participants are already fully vaccinated with 3x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
9731138|NCT05160766|Active Comparator|Vaxzevria-Vaxzevria-Spikevax|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Spikevax (mRNA-1273) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
9731139|NCT05160766|Active Comparator|Vaxzevria-Vaxzevria-Comirnaty|Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
9731140|NCT05160766|Active Comparator|Spikevax-Spikevax-Comirnaty|Participants are already fully vaccinated with 2x Spikevax (mRNA-1273) and 1x Comirnaty (BNT162b2) when entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
9731141|NCT05160766|Active Comparator|Comirnaty-Comirnaty-Spikevax|Participants are already fully vaccinated with 2x Comirnaty (BNT162b2) and 1x Spikevax (mRNA-1273) entering the trial, only the 4th dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial.
9731142|NCT05159401|Experimental|"the first group: the method of vibroacoustic lung massage using the BARK VibroLUNG device"|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
9731143|NCT05159401|Experimental|the second group:the method of oscillating REР therapy using Acapella DH Green|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
9731144|NCT05159401|Experimental|the third group:the method of hardware stimulation of cough (Comfortable cough Plus)|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
9731145|NCT05159401|Experimental|the fourth group:classical manual chest massage with percussion|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
9731146|NCT05158478|Experimental|Subject glucometer measurement|
9731147|NCT05158439|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
9731148|NCT05157932|Experimental|Talk Test|Virtual Cardiac Rehab + Exercise prescription based on the Talk test.
9731149|NCT05157932|Experimental|Cardiopulmonary Exercise Test|Virtual Cardiac Rehab + Exercise prescription based on the CPET results.
9731150|NCT05155826|No Intervention|standard care (control group)|Patient benefit the standard care during the placement of Cook's balloon (standard care).
9731151|NCT05155826|Experimental|standard care and virtual reality (experimental group)|Patient benefit the standard care during placement of Cook's balloon (standard care) with the use of a virtual reality.
9731152|NCT05154760|Active Comparator|one on one video conference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of one on one interviews with video conference method once a week.
9731153|NCT05154760|Active Comparator|group videoconference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of group interviews with video conference method once a week.
9731154|NCT05154006|Active Comparator|Active Control (Information only)|Women in the active control group receive instruction on safe carrying behaviors (reduce carried weight & use safe lifting techniques) and information about benefits when performing the behavior and reducing strain on the pelvic floor.
9781313|NCT01146288|Experimental|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
10200307|NCT04582370|Experimental|Theater program|"The design of the 10-week theater program is based on the principles of acting as written and practiced by Constantin Stanislavski in his revolutionary text on acting: An Actor Prepares [Stanislavsky C, 1989]. The exercises target concentration, voice, physical skills, emotion memory, observation, and dramatic analysis and include 3 components: 1. Preparation for the Actor (which involves relaxation , collaboration, movement, posture, and vocality; 2. Learning the Components of the Repeatable Acting Process (which involves physicality, attention, and concentration); and 3. Synthesizing Components into Characterization (which involves creativity and emotional expression).~Each of these components will be addressed during each of 20 sessions through the use of group warm ups, group ensemble exercises, and group recitations. Participants will perform physical, mental, and emotional exercises similar to those given to beginning acting students in traditional theater schools."
10200308|NCT04582370|No Intervention|Wait-list control|During the study period, the control group will not receive any type of intervention. However, they will be offered the same theater program experience after the primary data collection period ends.
10200309|NCT04572880|Active Comparator|Trabeculectomy|
10200310|NCT04572880|Active Comparator|XEN®|
10200311|NCT04572880|Active Comparator|Preserflo®|
10200312|NCT04562896|No Intervention|No Device|Participants will be evaluated without a CDO.
10200313|NCT04562896|Experimental|CDO-A|The first design variant will be designated CDO-A
10200314|NCT04562896|Experimental|CDO-B|The second design variant will be designated CDO-B
10200315|NCT04562896|Experimental|CDO-C|The third design variant will be designated CDO-C
10200316|NCT04558502|Experimental|minocycline-based bismuth quadruple regimen for 14 days|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
9731155|NCT05154006|Experimental|Individual promotion of self-efficacy|"The group Individual promotion of self-efficacy receives the same instructions and information on safe carrying behavior as the control group.~Additionally, this group will receive behavior change techniques (Michie et al., 2013) to increase self-efficacy (psychological activities to increase self-confidence / belief in own capability to reduce risks of carrying loads with own behavior)."
9731156|NCT05154006|Experimental|Promotion of self-efficacy + social support|"The group Promotion of self-efficacy + social support receives the same instructions for safe carrying behavior as the control group. The intervention will also include the same behavior change techniques to promote self-efficacy.~Additionally, a social partner from the same or neighboring household will be involved in the intervention activities. The partner will participate in the intervention activities and will be instructed to provide emotional, practical and informational social support."
9731157|NCT05153174|Experimental|2 tablets of Sulforaphane|Participants will be given 2 extra strength tablets per day
9731158|NCT05153174|Experimental|4 tablets of Sulforaphane|Participants will be given 4 extra strength tablets per day
9731159|NCT05153174|Experimental|6 tablets of Sulforaphane|Participants will be given 6 extra strength tablets per day
9731160|NCT05153148|Experimental|NDI-034858 study drug - Dose 1|NDI-034858 study drug will be orally administered QD for 12 weeks
9731161|NCT05153148|Experimental|NDI-034858 study drug - Dose 2|NDI-034858 study drug will be orally administered QD for 12 weeks
9731162|NCT05153148|Experimental|NDI-034858 study drug - Dose 3|NDI-034858 study drug will be orally administered QD for 12 weeks
9731163|NCT05153148|Placebo Comparator|Placebo|Placebo will be orally administered QD for 12 weeks
9731164|NCT05151562|Experimental|Virtual Music Therapy|Participants will attend two 30 minutes long virtual music therapy sessions per week for 8 weeks using Zoom.
9731165|NCT05150002|Experimental|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
9731166|NCT05149807|Experimental|SHR-1701 + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
9731167|NCT05149807|Placebo Comparator|Placebo + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
9731168|NCT05149313|Experimental|Lebrikizumab|Lebrikizumab administered subcutaneously (SC), 250 milligram (mg) dose once every two weeks (Q2W) in the induction period for 16 weeks. Participants achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab 250 mg once every four weeks (Q4W) after Week 20 up to Week 36. Participants not achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16 and 18, followed by 1 injection of lebrikizumab 250 mg Q2W after Week 20 up to Week 52.
9731169|NCT05149313|Placebo Comparator|Lebrikizumab-matching Placebo|Lebrikizumab-matching Placebo administered SC, 250 mg dose, Q2W in the induction period for 16 weeks. Participants will receive 2 injections each of 250 mg lebrikizumab-matching placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab- matching placebo 250 mg Q4W after Week 20 up to Week 36.
9731170|NCT05147129||Postmenopausal with vulvar lichen sclerosus|Includes postmenopausal patients with clinically-active vulvar lichen sclerosus, as determined by biopsy or examination by a vulvar specialist
9731171|NCT05147129||Postmenopausal without vulvar lichen sclerosus|Includes postmenopausal patients without vulvar lichen sclerosus
9731172|NCT05146648|Active Comparator|Real AMPS|AMPS therapy consists of mechanical stimulations applied to two specific points on both feet: the tip of the big toe (hallux) and the first metatarsal joint.
9731173|NCT05146648|Sham Comparator|Sham AMPS|AMPS therapy applied to two non-specific points on both feet.
9731174|NCT05145023||Development of the CARD-SARC (n=20)|"Interviews: 6-20 participants (depending of data saturation) will be recruited using a convenience sampling strategy.~Field-testing: 20 participants using a convenience/consecutive sampling strategy."
9731175|NCT05145023||Validation of the CARD-SARC (n=100)|The CS-specialist centres (Barts Health NHS Trust and Royal Papworth Hospital NHS Foundation Trust) have a cohort of 60-70 potential candidates in each site. The estimated sample size for the Pilot-testing is 100 study participants, considering previous sarcoidosis studies including PROMs, with less than 10% population declining participation or failing to complete their questionnaires.
9731176|NCT05140564|Experimental|STEADY intervention group|
9731177|NCT05140564|No Intervention|Treatment as usual group (control)|
9731178|NCT05139745|Experimental|Histological evaluation of BTL-899 device´s effect on fat tissue|This group will be treated with 100% of the treatment parameter settings
9731179|NCT05139745|Sham Comparator|Sham treatment|This group will be treated with 5% of the treatment parameter settings
9731180|NCT05139277|Experimental|CONVIVO system|During tumor resection, study investigators trained in the use of the system will determine when the CONVIVO imaging system will be used for in vivo¬ imaging. At this point 5 mg/kg of fluorescein will be administered intravenously by an anesthesia provider over one minute.Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique.
10200317|NCT04558502|Active Comparator|clarithromycin-based bismuth quadruple regimen for 14 days|Esomeprazole 20 mg,clarithromycin 500 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
10200318|NCT04558502|Experimental|minocycline-based bismuth quadruple regimen for 10 days|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 10 days.
10200319|NCT04550455|Experimental|Cladribine Tablets|All participants will receive cladribine tablets according to the current United States Federal Food and Drug Administration (FDA) package guidelines.
10200320|NCT04534517|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age will be recruited. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
10200321|NCT04517123|No Intervention|Control - Usual Care|Usual Care
10200322|NCT04517123|Experimental|Intervention - Prone Positioning|Prone Positioning
10200323|NCT04508075|Experimental|SARS-CoV-2 Vaccine|Participants receive 2 doses of SARS-CoV-2 Inactivated Vaccine with 14 days interval, intramuscularly
10200324|NCT04508075|Placebo Comparator|Placebo|Participants receive 2 doses of placebo with 14 days interval, intramuscularly
9731181|NCT05139277|Other|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
9731182|NCT05138679||Acute lower limb ischemia|Patients with acute lower limb ischemia (older than 18 years)
9731183|NCT05135702|Experimental|Sodium Propionate First|Subjects in this arm will consume 500mg sodium propionate powder twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of placebo twice daily.
9731184|NCT05135702|Placebo Comparator|Placebo First|Subjects in this arm will consume a placebo twice daily for four weeks, mixed into their food/drink. This is followed by four weeks of 500mg sodium propionate powder, twice daily.
9731185|NCT05135650|Experimental|Prevention (Sotrovimab)|Patients receive sotrovimab IV over 30 minutes within 1-7 days prior to the start of pre-transplant conditioning.
9731186|NCT05133999||Preterm infants|infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight
9731187|NCT05133154|Other|Patients with low-grade glioma|Group 1
9731188|NCT05133154|Other|Patients with high-grade glioma|Group 2
9731189|NCT05133154|Other|Patients undergoing brain surgery for a non-tumor disease|Group 3
9731190|NCT05133076|Active Comparator|Active arm|
9731191|NCT05133076|Placebo Comparator|Placebo arm|
9731192|NCT05130190|Other|RF Treatment|At the time of the subject's trans-abdominal or laparoscopic hysterectomy, the ProVu System will be used to apply RF treatment to one or two adenomas, focal areas of adenomyosis, or diffuse adenomyosis.
9731193|NCT05126277|Experimental|Arm 1 - ianalumab s.c. q4w|ianalumab s.c. q4w in addition to standard of care (SoC)
9731194|NCT05126277|Experimental|Arm 2 - ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
9731195|NCT05126277|Placebo Comparator|Arm 3 - placebo s.c. q4w|Placebo s.c. q4w in addition to SoC
9731196|NCT05125952|Experimental|Acute Respiratory Failure|Patients with acute respiratory failure managed with pressure-support ventilation.
9731197|NCT05125068|Experimental|Arm A|AT-1501 10mg/kg Arm A will receive 10 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions.
9731198|NCT05125068|Experimental|Arm B|AT-1501 5mg/kg Arm B will receive 5 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions
9731199|NCT05124834|Experimental|Subject glucometer measurement|Blood glucose measurement BGM for personal use
9731200|NCT05124171|Experimental|Comirnaty® (Pfizer-BioNTech)|Length of use : 1 day
9731201|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|Length of use : 1 day
9731202|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|Length of use : 1 day
9731203|NCT05120895||Mevalotin|Korean menopausal women aged 50 years or more who required treatment of dyslipidemia and received Mevalotin® tablets.
9781314|NCT01146288|Experimental|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
9781315|NCT01146379|Experimental|Low Movement Dose, 3200 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
9781316|NCT01146379|Experimental|Medium Movement Dose, 6400 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
9781317|NCT01146379|Experimental|High Movement Dose, 9600 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
9785322|NCT01248962|Experimental|extended 3-hour infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatincontaining chemotherapy regimen.
10200325|NCT04505735||Normal Control|Adults with no history of memory complaints, diagnosis of MCI, or dementia from a physician
9785323|NCT01249027||Observational|Single arm prospective, observational, single-arm, open-label, multicenter, postapproval registry study using XIENCE V® Everolimus Eluting Coronary Stent System (EECSS).
9731204|NCT05118919|Experimental|Active|
9731205|NCT05118919|Placebo Comparator|Placebo|
9731206|NCT05118451|Experimental|3d reconstruction visualization model to guide preoperative planning and surgery|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
9731207|NCT05118451|No Intervention|Based on high-quality thin slice CT images to guide preoperative planning and surgery.|All patients in this study were operated by the medical team whose main members were the medical team leader, and all patients underwent anatomic hepatectomy. The main points of anatomic hepatectomy are summarized as follows :(1) determine and mark the boundary of liver segment according to ischemia line or staining. (2) The postoperative liver section should fully expose the iconic veins and vessels. (3) The initial part of Glisson's pedicle of the target liver segment was severed. Tissue was taken from the surgical margins of all patients and sent to frozen sections for examination. Routine pathological examinations were performed on all resected liver after surgery. Postoperative patients were treated with relevant perioperative symptomatic treatment, and blood routine examination, liver function and coagulation function were detected on the 1st, 3rd and 5th day after surgery.
9731208|NCT05113043||Ischemic stroke|Young patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
9731209|NCT05113043||Hemorrhagic stroke|Young patients who suffered from acute hemorrhagic stroke within 12 hours for the first time before entry into the study.
9731210|NCT05113043||Healthy Controls|Healthy young people
9731211|NCT05107466|Other|Cochlear implant, good performer|40 adults (>18 y/o) with Cochlear implants at least 6 months post implantation who score >60% on the clinically administered speech understanding score AZBIO (Arizona Bioindustry Association sentence test).
9731212|NCT05107466|Other|Cochlear implant, poor performer|40 adults (>18 y/o) with Cochlear implants at least 6 months post implantation who score <60% on the clinically administered speech understanding score AZBIO.
9731213|NCT05106218|Experimental|SurroundScope|For laparoscopic camera system, the SurroundScope, 270-degree angle videoscope (270Surgical, Israel) is used
9731214|NCT05106218|Active Comparator|Standard laparoscope|For laparoscopic camera system, the Standard laparoscope that is in a standard use at the medical center is used
9731215|NCT05103085||Experimental|Patient undergoing digestive endoscopy and aged 50 years and over
9731216|NCT05103046|Experimental|Dose Finding as Monotherapy - Part 1|UCT-03-008 Dose Finding
9731217|NCT05103046|Experimental|Expansion as Monotherapy - Part 2|UCT-03-008 RP2D Expansion
9731218|NCT05098912|Active Comparator|Manual acupuncture|"The subjects/population of this study is woman at age 30-50 who meet the inclusion criteria. Subjects group with manual acupuncture treatment will be treated with 6 session of manual acupuncture at:~From the superior of zygomatic arch through ST 2 to LI 20 bilaterally using a needle size of 0.25 x 60 mm From the inferior of zygomatic arch through SI 18 to ST 4 bilaterally using a needle size of 0.25 x 60 mm From ST 7 to ST 4 bilaterally using a needle size of 0.25 x 60 mm Along the nasolabial crease through ST 4 to the bilateral EXHN-8 using a needle size of 0.25 x 40 mm"
9785324|NCT01249092|Experimental|Pentoxifylline 400 mg TID|This study is an open label pilot with only one arm.
9785325|NCT01249118|Experimental|Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
9731219|NCT05098912|Active Comparator|Thread embedding acupuncture|"The subjects/population of this study is woman at age 30-50 who meet the inclusion criteria. Subjects group with thread embedding acupuncture group treatment will be treated with 1 session of thread embedding acupuncture at:~From the superior of zygomatic arch through ST 2 to LI 20 bilaterally using a gauge and length of the needle of 31G x 50 mm From the inferior of zygomatic arch through SI 18 to ST 4 bilaterally using a gauge and length of the needle of 31G x 50 mm From ST 7 to ST 4 bilaterally using a gauge and length of the needle of 31G x 50 mm Along the nasolabial crease through ST 4 to the bilateral EXHN-8 using a gauge and length of the needle of 31G x 30 mm"
9731220|NCT05098080|Experimental|HutrukinTM|At least three healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), three subjects will be administered HutrukinTM.
9731221|NCT05096117|Experimental|Active Medication|
9731222|NCT05096117|Placebo Comparator|Matching Placebo|
9731223|NCT05094856||Effect of volume expansion by albumin on the correction of peripheral tissue hypoperfusion|Effect of volume expansion by albumin on the correction of peripheral tissue hypoperfusion by measuring the proportion of patients who normalized their cutaneous re-coloring time (CRT) measured at the index level, defined by a value <3 seconds at H1. The clinical measurement method has been standardized in the participating departments and has been used for several years in clinical practice.
9731224|NCT05094856||Effect of volume expansion by saline on the correction of peripheral tissue hypoperfusion|Effect of volume expansion by saline on the correction of peripheral tissue hypoperfusion by measuring the proportion of patients who normalized their cutaneous re-coloring time (CRT) measured at the index level, defined by a value <3 seconds at H1. The clinical measurement method has been standardized in the participating departments and has been used for several years in clinical practice.
9731225|NCT05093296|Experimental|Oxytocin + Naltrexone|"All patients will receive 50mg Naltrexone daily (NTX, oral tablet) in the course of standard in-patient treatment. In the experimental group, patients will receive a single dose of 24 I.U. oxytocin nasal spray at two study visits during in-patient treatment:~Visit 2 - First Application of Oxytocin 40 minutes prior to a combined stress- and alcohol cue-exposure during visit 2~Visit 3 - Second Application of Oxytocin 40 minutes prior to an fMRI-based assessment of alcohol cue-reactivity"
9731226|NCT05093296|Active Comparator|Placebo + Naltrexone|"All patients will receive 50mg Naltrexone daily (NTX, oral tablet) in the course of standard in-patient treatment. In the comparator group, patients will receive a placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin) at two study visits during in-patient treatment:~Visit 2 - First Application of Placebo 40 minutes prior to a combined stress- and alcohol cue-exposure during visit 2~Visit 3 - Second Application of Placebo 40 minutes prior to an fMRI-based assessment of alcohol cue-reactivity"
9731227|NCT05089227|Experimental|"intervention group"|
9731228|NCT05089227|Active Comparator|"standard group"|
9731229|NCT05088395|Other|"Cohort 1: SENOLOC"|"Detecting residual disease after surgery is absolutely crucial in oncology, as this detection could allow the personalisation of post-operative treatments based on the presence of residual disease.~The laboratory wishes to develop a new technique for the detection of circulating tumour DNA, based on the recognition of translocation fragments in circulating DNA by shallow whole genome sequencing. This is an original approach, which to our knowledge has not been tested so far with the envisaged bioinformatics approach and could potentially be more sensitive than the techniques currently used to detect residual disease after surgical removal of localised (non-metastatic) breast cancer.~The analysis will therefore focus on the search for tumour chromosomal translocations, which will need to be differentiated from possible germline chromosomal translocations. The collection of constitutional DNA is therefore planned in this cohort."
9731230|NCT05088395|Other|"Cohort 2: Immuno-TNBC "|"The aim for this cohort is to study the role that variations in circulating tumour DNA might have as a marker associated with response during chemoimmunotherapy.~A fresh biopsy (subsequently stored frozen) is required for mutational profiling analysis (which will be used to track circulating tumour DNA in the blood). In addition, it will be used to analyse currently recognised biological tissue factors of response to chemoimmunotherapy (PD-L1 labelling, mutational load, ...) and to identify possible associations with circulating tumour DNA variations.~Constitutional DNA analysis is necessary for the determination of point mutations present in the tumour (to be differentiated from polymorphisms present at the constitutional level), as the determination of these mutations is essential to monitor circulating tumour DNA and will therefore be collected."
9731231|NCT05088395|Other|"Cohorte 3: Trans-TNBC"|"The objective of this cohort is the development of new plasma tests, for example based on the detection of chromosomal translocations of circulating tumor DNA.~The hypothesis is that these tests would allow the detection of relapse, the prediction of treatment efficacy and the monitoring of treatment efficacy at different stages of cancer in patients with triple-negative breast cancer, either in the non-metastatic phase with planned neo-adjuvant treatment, or in the metastatic phase. The number of inclusions between these 2 populations (neo-adjuvant and metastatic) will be monitored at the operational level to avoid an excessive imbalance towards one group."
9731232|NCT05085860|Experimental|Moderate Intensity Continuous Training (MICT)|Participants will do 3 sessions of moderate-intensity continous exercise training over 7 days
9731233|NCT05085860|Experimental|High Intensity Interval Training (HIIT)|Participants will do 3 sessions of high-intensity interval training over 7 days
9731234|NCT05085860|No Intervention|Rest|Participants will abstain from doing moderate- to high-intensity interval training over 7 days
10200326|NCT04505735||Adults with Mild Cognitive Impairment|Adults with cognitive decline verified by a study partner or cognitive impairment verified by the study physician. The cognitive decline has had limited impact on functional activities; general cognition and functional performance are sufficiently preserved such that a diagnosis of dementia cannot be made by the enrolling physician
10200327|NCT04504773|Experimental|Virtual Reality Exposure Therapy|Participants will receive a single session of exposure therapy to address specific phobia that includes the use of virtual reality exposures.
10200328|NCT04497402||female COVID19 patients|Females with COVID19 disease
10200329|NCT04497402||male COVID19 patients|Males with COVID19 disease
10200330|NCT04497402||female matched COVID19-free patients|Free from disease COVID19 Females matched.
10200331|NCT04497402||male matched COVID19-free patients|Free from disease COVID19 males matched.
10200332|NCT04494646|Experimental|Bardoxolone Methyl|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
10200333|NCT04494646|Placebo Comparator|Placebo|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
10200334|NCT04486066|Experimental|Mindfulness-Based Stress Reduction (MBSR)|In MBSR, participants meet for 2 hours per week for 8 weeks in a video group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
10200335|NCT04486066|Experimental|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 sessions in a video group format, while retaining all essential elements.
10200336|NCT04486066|Other|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
10200337|NCT04485104|Experimental|Standard of care (SOC) plus GWP42003-P|
10200338|NCT04485104|Active Comparator|SOC|
10200339|NCT04479267|Experimental|Treatment (polatuzumab vedotin, R-CHP)|Patients receive prednisone PO, prednisolone IV, or methylprednisolone IV on days 1-5. Patients also receive rituximab IV, polatuzumab vedotin IV over 30-90 minutes, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9665002|NCT05229055|Active Comparator|Intranasal ketamine|Ketamine solution 250 mg/5ml was used. It was applied intranasally using a nasal spray pump whereeach spray delivered approximately 0.4 ml of solution corresponding to 20 mg of ketamine. After initial evaluation, each patient having the inclusion criteria receives one pulverisation (0.4 ml) per nostril of ketamine corresponding to a total dose of 20 mg of ketamine. Ketamine dosing was based on previous reports of intranasal ketamine use in ED patients, doses ranged from 0.45mg/kg to 1.25mg/kg (9).
9665499|NCT05040841|Experimental|Condition 13|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S2/Peer: Enhanced peer group support."
9665500|NCT05040841|Experimental|Condition 14|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; S1/Text: Weekly check-in text messages."
9665501|NCT05040841|Experimental|Condition 15|"Includes 3 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient."
9665502|NCT05040841|Experimental|Condition 16|"Includes 5 interventions:~M1/OTR: Outreach to patient due to unsuppressed VL test result; M2/PRM: Pharmacy refill monitoring (PRM) + outreach to the patient; M3/EAM: Electronic adherence monitoring (EAM) + outreach to the patient; S1/Text: Weekly check-in text messages; S2/Peer: Enhanced peer group support."
9665503|NCT05040698|Experimental|Open Label Fostamatinib|Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1
9665504|NCT05040308|Active Comparator|Participants in PrEP and MAT programs|Integrated PrEP and MAT program
9665505|NCT05040308|Active Comparator|Participants in PrEP and NSP programs|Integrated PrEP and NSP program
9665506|NCT05039008|Experimental|Blood flow restriction group|"The intervention will last 4 weeks, with a periodicity of 3 weekly sessions (34). In total there will be 12 sessions lasting between 15 and 30 minutes.~The exercises will be: squats, knee extension and heel elevation (performing 4 sets of 15 repetitions with 30 seconds of rest between sets)."
9665507|NCT05039008|No Intervention|Control group|The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients.
9665508|NCT05036278|Experimental|Damoctocog alfa-pegol prophylaxis regimens|"Prophylaxis regimens:~Participants with a high risk score (> 4) continue on prophylaxis 2x/week (40 IU/kg/dose).~Participants with a medium risk score (2 to 4) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose).~Participants with a low risk score (< 2) will switch after 4 weeks to prophylaxis Q5D (50 IU/kg/dose) and then after 4 weeks to a less frequent (e.g. Q7D) regimen (60 IU/kg/dose)."
9665509|NCT05035797|Active Comparator|CaRe-ECMO group|Patients in the CaRe-ECMO group will be treated with usual care, ECMO therapy, and cardiopulmonary rehabilitation program.
9665510|NCT05035797|Placebo Comparator|Control group|Usual care and ECMO therapy
9665511|NCT05035602||Oesophagectomy|Patients who have undergone oesophageal cancer resection.
9665512|NCT05035602||Gastrectomy|Patients who have undergone gastric cancer resection.
9665513|NCT05035602||Control group|A cohort consisting of healthy controls who have not been diagnosed with, or have undergone treatment for oesophageal or gastric cancer.
9665514|NCT05032846|Experimental|Ultrasound Guided Laparoscopic Ovarian Cystectomy|During surgical resection of the ovarian cyst, a clinician with experience of ultrasound and laparoscopy will perform an ultrasound scan during surgery to resect cyst tissue only and preserve healthy ovarian tissue.
9665515|NCT05032846|Active Comparator|Laparoscopic Ovarian Cystectomy|A laparoscopic ovarian cystectomy will be performed without ultrasound guidance. This is currently standard clinical practice.
9665516|NCT05032196|Experimental|WVE-003 (Dose A) or placebo|
9665517|NCT05032196|Experimental|WVE-003 (Dose B) or placebo|
9731235|NCT05082311||Patients with Pheochromocytoma/Paraganglioma (secretory, extra adrenal pheochromocytoma)|"Patients included in this cohort (n=50) are those who are diagnosed of Pheochromocytoma / Paraganglioma, willing to consent for the study and not on α-blockade at the time of recruitment into study, while can be on any other anti hypertensives~Patients in this group, besides the usual evaluation of Pheochromocytoma / Paraganglioma, will also undergo detailed cardiac and vascular evaluation, which will be done at diagnosis, at 7- 10 days of α-blockade, and 7 days, 3 and 6 months post adrenalectomy/ Paraganglioma excision The cardiovascular evaluation includes 2D-echocardiography, speckle tracking Echo (for measuring global longitudinal strain), serum NT-proBNP estimation and flow mediated vasodilatory studies by Doppler Ultrasonography of the brachial artery to assess the endothelial dependent and smooth muscle dependent vasodilatory responses"
9731236|NCT05082311||Essential Hypertensive Groups|This is a contemporary age- and gender-matched control group This group includes 10 newly detected (within 3 months) Essential Hypertensive patients, who will undergo treatment with standard anti- HT medications Cardiac evaluation will be done at baseline and after 3 months of anti hypertensive medications
9731237|NCT05082311||Healthy Individuals|This is a contemporary age- and gender-matched control group This group includes 10 Healthy individuals (normal in physical examination, ECG , Echo), that include hospital staff nurses, technicians, doctors whom would be requested to volunteer Cardiac evaluation will be done at the start of study and after 6 months
9731238|NCT05080504||Study Population|Subjects with implanted CardioMEMS who are actively managed through Columbia University Medical Center will be enrolled.
9731239|NCT05077761|Experimental|High-intensity laser therapy|77 participants will receive active high-intensity laser therapy interventions on hamstring muscle to improve the flexibility of muscle
9731240|NCT05077761|Sham Comparator|Sham High-intensity laser therapy|77 participants will receive sham high-intensity laser therapy on hamstring muscle
9731241|NCT05075876|Experimental|Group 1 (SP-01-K)|Application of SP-01 manufactured by Site K (SP-01-K) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site A (SP-01-A) for 6 days
9731242|NCT05075876|Active Comparator|Group 2 (SP-01-A)|Application of SP-01 manufactured by Site A (SP-01-A) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site K (SP-01-K) for 6 days
9731243|NCT05074550|Experimental|PPMX-T003|This drug should be administered within 48 hours after the phlebotomy. In addition, as a dose escalation design, 4 doses of 0.25 mg/kg, 0.4 mg/kg, 0.64 mg/kg, and 1 mg/kg are administered to the same subject, when the next phlebotomy required during observation period after the 1st administration.
9731244|NCT05074381|Experimental|Dry needling|A single dry needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into skin surface, fascia,into the muscle tissue at the MTrP location of the M. Obliquus Capitis Inferior, and will move the needle up and down to elicit local twitch responses.In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
9731245|NCT05074381|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying in prone position. A trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated. Afterwards, a rotational muscle energy technique will be applied to the atlanto-axial level.
9731246|NCT05071586|Experimental|Children diagnosed with stroke/brain bleed|Male and females aged 8 to 17 with established diagnosis of stroke/brain bleed who are US residents.
9731247|NCT05067621|Experimental|Receive treatment|Semaglutide (Wegovy) pen is a subcutaneous injection
9731248|NCT05067621|Placebo Comparator|Placebo|The placebo pen is almost exactly the same as the Wegovy subcutaneous injection except it does not contain the active ingredient, Semaglutide.
9731249|NCT05059301|Experimental|RSVPreF3_Grp1 Group|Participants receive 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at Day 1 and are followed up until the study end (Month 6).
9731250|NCT05059301|Experimental|RSVPreF3_Grp2 Group|Participants receive 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at Day 1 and are followed up until the study end (Month 6).
9731251|NCT05059301|Experimental|RSVPreF3_Grp3 Group|Participants receive 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1 and are followed up until the study end (Month 6).
9731252|NCT05059236|Experimental|Darolutamide+ADT|Participants will receive darolutamide plus ADT in the ARASEC treatment arm. The control arm for the study will be derived from the participants treated with ADT alone in the CHAARTED trial using a matching approach
9731253|NCT05057169|Experimental|BNT162b2 third dose after two doses of BNT162b2|
9731254|NCT05057169|Experimental|CoronaVac third dose after two doses of BNT162b2|
9731255|NCT05057169|Experimental|BNT162b2 third dose after two doses of CoronaVac|
9731256|NCT05057169|Experimental|CoronaVac third dose after two doses of CoronaVac|
9731257|NCT05045170|Experimental|propofol group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with propofol sedation
9731258|NCT05045170|Experimental|dexmedetomidine group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia with dexmedetomidine sedation
9665518|NCT05032196|Experimental|WVE-003 (Dose C) or placebo|
9665519|NCT05032196|Experimental|WVE-003 (Dose D) or placebo|
9665520|NCT05030454|Experimental|CT-guided stereotactic adaptive radiotherapy|-Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
9665521|NCT05029999|Experimental|Cohort A|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
9665522|NCT05029999|Experimental|Cohort B|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle starting on cycle 2 until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 1 and 2 only."
9665523|NCT05029999|Experimental|Cohort C|"PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle until toxicity or progression.~CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle starting on cycle 2 until toxicity or progression for up to 24 months.~CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 days cycles 2 and 3 only."
9665524|NCT05028946|Experimental|Cohort 1: Foralumab Dose Level 1|Participants will receive foralumab enteric coated capsules at dose level 1, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
9665525|NCT05028946|Experimental|Cohort 2: Foralumab Dose Level 2|Participants will receive foralumab enteric coated capsules at dose level 2, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
9665526|NCT05028946|Experimental|Cohort 3: Foralumab Dose Level 3|Participants will receive foralumab enteric coated capsules at dose level 3, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
9665527|NCT05028946|Experimental|Cohort 4: Foralumab Dose Level 4|Participants will receive foralumab enteric coated capsules at dose level 4, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
9665528|NCT05028660||Cohort 1|At least 76 patients with MIBC and elected for NAC
9665529|NCT05027802|Experimental|Palovarotene Chronic/Flare-Up Regimen|"Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment.~Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days."
9665530|NCT05026112||DCM with MSF (MSF+)|Patients with dilated cardiomyopathy and midwall septal fibrosis identified in a previous cardiac MRI scan
9665531|NCT05026112||DCM without MSF (MSF-)|Patients with dilated cardiomyopathy but without midwall septal fibrosis on previous cardiac MRI scan
9665532|NCT05026112||Control - MSF+|Control healthy volunteers (HV) to the MSF+ cohort
9665533|NCT05026112||Control - MSF-|Control healthy volunteers (HV) to the MSF- cohort
9665534|NCT05023057|Experimental|Multidomain intervention|The participants in the intervention arm will receive all five components of the intervention: (1) monitoring and management of metabolic and vascular risk factors; (2) cognitive training and social activity; (3) physical exercise; (4) nutritional guidance; and (5) motivational training.
9665535|NCT05023057|No Intervention|Control|At baseline, the participants in the control group will meet a study doctor, be prescribed medication when necessary, and receive educational booklets corresponding to their risk factors and a booklet on lifestyle guidelines to prevent dementia. They will receive usual care during the study period and be informed that they could participate in the multidomain intervention program after this study end.
9665536|NCT05019222|Experimental|Arm 1) Sevoflurane group|Sevoflurane based inhalation anesthesia
9665537|NCT05019222|Active Comparator|Arm 2) Remimazolam group|Remimazolam based total intravenous anesthesia
9665538|NCT05018728|Experimental|Voxelotor|Children with sickle cell anemia taking voxelotor for 12 weeks.
9665539|NCT05017740|Active Comparator|ICSI|
9665540|NCT05017740|Active Comparator|PICSI|
9665541|NCT05013996|Experimental|Intervention|Patients randomized to the experimental (MIDSA groupe) will be treated according to the usual methods of each of the centers (CMP / CRIAVS / private practitioners, etc.) completed with the Multidimensional Inventory of Development, Sex, and Aggression-MIDSA groupe Multidimensional Inventory of Development, Sex, and Aggression-inventory tool.
9665542|NCT05013996|Active Comparator|Control|Patients randomized to the control group will be treated according to the usual methods of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
9665543|NCT05013190||Participants With Multiple Myeloma (MM)|Participants diagnosed with MM (Newly Diagnosed Multiple Myeloma [NDMM]) using IMWG criteria and received a bortezomib-based triple-drug regimens for more than 2 cycles as initial therapy will be treated with ixazomib based regimens strictly following NINLARO® label will be observed prospectively for 24 months.
9665544|NCT05010746|Experimental|MV replacement with Innovalve MR system|MV replacement with Innovalve MR system
9731259|NCT05045170|Placebo Comparator|control group|patients with American Society of Anesthesiologists (ASA) I-II, Montreal cognitive assessment test≥26, trauma surgery under spinal anesthesia without sedation
9731260|NCT05042934|Experimental|Treatment (lurbinectedin, fine-needle aspiration, irinotecan)|Patients receive lurbinectedin IV over 60 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo fine-needle aspiration on days 2-6 of cycle 1. Beginning in cycle 2, if the biopsy shows suppression of NR0B1, then patients receive irinotecan IV over 1 hour on the day of maximum NR0B1 suppression on cycle 2. If the duration of NR0B1 suppression from lurbinectedin alone exceeds 48 hours, or if the duration of NR0B1 suppression from lurbinectedin and irinotecan exceeds 48 hours and is longer than that seen with lurbinectedin alone, then patients may receive a second dose of irinotecan during the extended period of NR0B1 suppression.
9731261|NCT05037968|Experimental|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side
9731262|NCT05037968|Active Comparator|Trinity Evolution|Trinity Evolution is a cryopreserved, viable cellular allograft containing cancellous bone and demineralized cortical bone designed for surgical use, applied per spine level at the contralateral side.
9731263|NCT05034939|Active Comparator|FLEX Vessel Prep System followed with PTA (TEST arm)|FLEX Vessel Prep System is used to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion. Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
9731264|NCT05034939|Active Comparator|PTA only (CONTROL arm)|Standard Balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding instructions for use. Once advanced to the lesion, the balloon should be inflated according to the site's standard of care.
9731265|NCT05034627|Experimental|Treatment (calaspargase pegol-mknl, cobimetinib)|Patients receive calaspargase pegol-mknl IV over 1 hour on day 1 and cobimetinib PO QD on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9731266|NCT05032690|Experimental|Treatment B: Bosutinib four 25 mg capsule after meal|Bosutinib four 25 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1
9731267|NCT05032690|Active Comparator|Treatment A: Bosutinib 100 mg capsule after meal (active comparator)|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1
9731268|NCT05032690|Experimental|Treatment A: Bosutinib 100 mg capsule after meal (experimental)|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 2
9731269|NCT05032690|Active Comparator|Treatment C: Bosutinib 100 mg capsule after fasting|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours for comparison 2
9731270|NCT05032105|Experimental|Intervention|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
9731271|NCT05027204|Experimental|Docetaxel combined with Nivolumab|"Phase Ib: The eligible patients with SCCHN will received Docetaxel for Injection (Albumin-bound) 75 mg/m^2 or 100 mg/m^2 sequentially in combination with Nivolumab 360 mg to evaluate safety and efficacy and explore RP2D.~Phase II: According to the RP2D determined in the phase Ib study, patients will be treated with Docetaxel for Injection (Albumin-bound) combined with Nivolumab until participants meet the criteria for termination or withdrawal criteria, for a maximum of 2 years."
9731272|NCT05025605|Experimental|80 Micrograms|Sublingual film containing 80 micrograms Dexmedetomidine
9731273|NCT05025605|Experimental|120 Micrograms|Sublingual film containing 120 micrograms Dexmedetomidine
9731274|NCT05025605|Placebo Comparator|Placebo|Sublingual Placebo film
9731275|NCT05023070|Experimental|Test condition 1|Cannabidiol 200 mg with standard meal
9731276|NCT05023070|Experimental|Test condition 2|Cannabidiol 400 mg with standard meal
9731277|NCT05023070|Experimental|Test condition 3|Epidiolex 400 mg with standard meal
9731278|NCT05023070|Experimental|Test condition 4|Cannabidiol 400 mg with high fat meal
9731279|NCT05022862|Active Comparator|Usual Care|Participants will receive routine (non-study directed) medical care for latent tuberculosis infection according to published guidelines, including medication, nurse case management, Tuberculosis health education, and toxicity assessments.
9731280|NCT05022862|Active Comparator|Video Directly Observed Therapy alone|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, however treatment will be viewed by video directly observed therapy (video-DOT)
9731281|NCT05022862|Experimental|Video Directly Observed Therapy plus Financial Incentives|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, as well as treatment viewed by video DOT. This arm will also earn financial contingent incentives. Participants will receive incentive payments when a submitted video is monitored by a staff member and deemed valid. If a participant fails to submit a video on a medication day or if a submitted video is deemed invalid (i.e., not the correct person or no appropriate ingestion of medication), the participant will not receive the scheduled incentive amount that day and the daily incentive value will be decreased.The participant will have opportunities the next day to again resume adherence. After taking the medication again for one week, participants will earn a reduced incentive until they adhere to the medication schedule for a week.
9731282|NCT05022615||Mild Non-Proliferative Diabetic Retinopathy (NPDR)|Presence of at least one retinal microaneurysm or hemorrhage as determined by clinician.
9731283|NCT05022615||Moderate NPDR|Increasing hemorrhages and microaneurysms as well as cotton wool spots, venous beading (VB) or Intraretinal microvascular abnormalities (IRMA) to a mild degree as determined by clinician
9731284|NCT05022615||Severe NPDR|"4-2-1 rule-that is, one has severe NPDR if hemorrhages or microaneurysms, or both, appear in all four retinal quadrants; venous beading appears in two or more retinal quadrants; or prominent IRMAs are present in at least one retinal quadrant as determined by clinician."
9731285|NCT05022615||Proliferative Diabetic Retinopathy (PDR)|Neovascularization, either on or within one disc diameter (DD) of the optic disc (NVD) or elsewhere in the retina (NVE); a preretinal hemorrhage (PRH); or vitreous hemorrhage (VH) as determined by the clinician.
9731286|NCT05018273|Experimental|VB10.NEO 3 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 3 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
9731287|NCT05018273|Experimental|VB10.NEO 6 mg in combination with Atezolizumab 1200 mg|"VB10.NEO 6 mg will be administered by IM injection for an induction course Q3W (4 doses) followed by maintenance doses Q6W (6 doses) and Q12W (5 doses).~Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of 21 day cycles."
9731288|NCT05015634|Active Comparator|Active Arm|Patients will be discharged from the hospital with the telemedicine package. If the patient develops possible cardiac symptoms and seeks medical attention, the data provided by the telemedicine package will be acted upon, as appropriate, by the trial cardiology team. With remote follow up over the phone at 3, 6 and 9 months.
10200340|NCT04478279|Experimental|Dose Escalation|This cohort only patients diagnosed with locally advanced or metastatic melanoma, carcinoma or sarcoma of any tumor type who are refractory or intolerant to all available therapies. ST101 will be administered intravenously (IV), initially once per week.
10200341|NCT04478279|Experimental|Dose Expansion HR+ Breast|This cohort must have progressed after 1-2 hormone based therapies. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
10200342|NCT04478279|Experimental|Dose Expansion Melanoma|This cohort must have Melanoma that has progressed after/or on treatment with an immune checkpoint inhibitor (CPI) and have received 1-2 prior lines of therapy for their advanced/metastatic disease. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
10200343|NCT04478279|Experimental|Dose Expansion GBM|Primary (de novo) GBM that has recurred or progressed (per modified RANO criteria) after 1 standard treatment regimen. Standard therapy is defined as maximal surgical resection, radiotherapy, and concomitant temozolomide with radiotherapy or adjuvant chemotherapy with temozolomide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
9731289|NCT05015634|Placebo Comparator|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
9731290|NCT05014282|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with Florida Quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
9731291|NCT05014282|Experimental|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
9731292|NCT05014230|Other|Treatment as Usual|Opioid medication, as prescribed in routine care
9731293|NCT05014230|Experimental|Open Label Placebo + Treatment as Usual|Opioid medication, as prescribed in routine care + Honest placebos
9731294|NCT05013424|Experimental|OnabotulinumtoxinA|Participants will receive one dose of OnabotA X administered as 5 injections to the corrugator and procerus muscles on Day 1.
9731295|NCT05012722||Decompensated Heart Failure with reduced ejection fraction (HFrEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFrEF)
9731296|NCT05012722||Decompensated Heart Failure with Preserved ejection fraction (HFpEF)|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e stable (HFpEF)
9731297|NCT05012722||Acute Kidney Injury in patients with Chronic Kidney Disease stage 3a,3b or 4|Pulse wave velocity to be measured during hospitalisation phase and repeated 4 weeks after when participant is in a stable state i.e. stable Chronic Kidney Disease stage 3a, 3b and 4
9731298|NCT05010265||Use of advanced neurotechnologies to detect consciousness and predict recovery|Treating clinicians, family members (caregivers) and patients recovering from a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
9731299|NCT05006872|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
9731300|NCT05006872|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
10200344|NCT04478279|Experimental|Dose Expansion CRPC|CRPC that has progressed after previous treatment with taxanes, abiraterone and enzalutamide/apalutamide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
10200345|NCT04475809|Placebo Comparator|Group C|high intra-abdominal pressure
10200346|NCT04475809|Active Comparator|Group L|low intra-abdominal pressure
10200347|NCT04475809|Active Comparator|Group LR|low intra-abdominal pressure with pulmonary recruitment maneuver group
10200348|NCT04475809|Active Comparator|Group LS|low intra-abdominal pressure with intraperitoneal saline infusion group
10200349|NCT04471597|Placebo Comparator|Control group|patients will receive 5ml of normal saline 0.9% topically 15 min before the expected end of surgery.
10200350|NCT04471597|Active Comparator|bupivacaine group|patients will receive 5ml of bupivacaine 0.5% topically 15 min before the expected end of surgery.
9731301|NCT05006482|Active Comparator|Arm I (usual care)|Patients and caregivers receive routine survivorship follow-up care at their doctor's office for 5 visits over 12 months.
9731302|NCT05006482|Experimental|Arm II (GEMS intervention)|Patients and caregivers participate in GEMS consultation over 1 hour that includes discussion of results and recommendations from geriatric assessment. Patients also participate in survivorship health education sessions over 75 minutes twice weekly for 4 weeks. Patients also participate in EXCAP program, which includes daily walking and resistance exercises.
9731303|NCT05006378|Placebo Comparator|Placebo Capsule|
9731304|NCT05006378|Experimental|Chamomile Tea|Subjects will consume three servings of chamomile tea throughout the day for the one-week treatment period. Each tea serving will be prepared using 3 grams of chamomile tea steeped in hot water according to the study protocol.
9731305|NCT05006378|Experimental|Chamomile Extract Capsule|Subjects will consume three chamomile capsules throughout the day for the one-week treatment period. Each capsule consists of 500 milligrams of a chamomile extract that has been standardized to 1.2% apigenin content.
9731306|NCT05006326|Experimental|68Ga-PSMA PET/MR|The investigators selected patients with a high clinical suspicion of HCC, or patients with confirmed HCC without tumour-related treatment who were to be biopsied or surgically resected to obtain pathological results. Patients signed an informed consent form and underwent 68Ga-PSMA PET/MR imaging (or PET/CT imaging if the patient had a contraindication to MR imaging).
9731307|NCT05005507|Experimental|Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks for 24 weeks plus NA treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly for 24 weeks.
9731308|NCT05005507|Experimental|Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil, or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from Week 12 till Week 24.
9731309|NCT05005507|Experimental|Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a|Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from baseline till Week 12.
9731310|NCT05004987|Active Comparator|Escitalopram (ESC)|
9731311|NCT05004987|Placebo Comparator|Placebo (PBO)|
9731312|NCT05004805|Experimental|Methylene blue Arm|The intervention is carried out in addition to the standard treatment. Administered Intervention is topical application of 0.02% Methylene blue solution in the form of repeated nasopharyngeal irrigation. The investigational drug is equipped with a spray nozzle to perform three administrations into both lower nasal passages. After three administrations on each side, it is recommended to take a deep breath so that the injected solution is distributed along the nasopharynx and oropharynx every 4 hours (5-6 times a day with a break for sleep). Duration is the period of stay of the subject, as long as there is no need for non-invasive or invasive mechanical ventilation. If the subject refuses further treatment in a hospital but does not withdraw consent to participate in the study, they should continue to take study drug after discharge from hospital, but not later than the date of the follow-up visit.
9731313|NCT05004805|Placebo Comparator|Saline solution Arm|The intervention is carried out in addition to the standard treatment. Adminestered Intervention is saline solution in the form of repeated nasopharyngeal irrigation. Dosage form, dosage, frequency and duration of intervention are the same.
9731314|NCT05004675|Experimental|lerodalcibep|300 mg SC dosed monthly
9731315|NCT05004675|Active Comparator|inclisiran|284 mg SC dosed Day 1 and Day 90
9731316|NCT05003830||AD group|Patients who meet the core clinical diagnostic criteria for Alzheimer's disease as defined by NIA-AA for mild cognitive decline or probable Alzheimer's disease.
9731317|NCT05003830||Healthy control group|Age-matched subjects, who are healthy and have no clinically significant related abnormalities in their physical examinations, laboratory tests, vital signs, or ECG. In addition, no first-degree family history of early-onset AD or other neurodegenerative diseases related to dementia.
9731318|NCT05000164|Experimental|Market Product|Eligible subjects will be dispensed the study lenses in a bilateral fashion and will be in the treatment for approximately 5 weeks.
9731319|NCT04996264|Experimental|Varespladib-methyl|"Varespladib-methyl is an immediate-release (IR), oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.~Scaled pediatric doses of varespladib-methyl are supplied as 50 mg IR capsules for oral administration.~Adult subjects will receive an initial loading dose of 500 mg (2 × 250 mg oral tablet) varespladib-methyl upon randomization, followed by dosing with 250 mg varespladib-methyl (1 × 250 mg oral tablet) approximately 12 hours later, and subsequent twice daily (BID) dosing with 1 × 250 mg varespladib-methyl oral tablets for the remainder of the 7-day treatment period. Tablets may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation.~Pediatric subjects (5 to < 18 years) will be administered doses of varespladib-methyl determined by allometric scaling, provided as 50 mg capsules. Age-appropriate capsules may be administered via naso- or orogastric tubes in patients requiring mechanical ventilation."
9785326|NCT01249118|Experimental|Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
10200351|NCT04462419||Diagnostic (18F-fluciclovine, PET/MRI imaging)|Patients receive fluciclovine IV and undergo brain dynamic PET/MRI imaging over 50 minutes.
10200352|NCT04459416|Experimental|Usual Care plus Acupuncture|Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. to prevent severe pain. If acupuncture does not prevent severe pain, the participant will receive opioid medication as backup pain relief.
10200353|NCT04459416|Active Comparator|Usual Care|Will receive only the usual pain management approach, which includes opioid medication when needed for severe pain, according to the routine guidelines for their care.
9731320|NCT04996264|Placebo Comparator|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an immediate-release capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~The dosing of placebo will match that of varespladib-methyl."
9731321|NCT04994080|Experimental|Treatment group A/B|
9731322|NCT04994080|Placebo Comparator|Treatment group C|
9731323|NCT04987281|Experimental|Device feasibility (bronchoscopy, CT, indocyanine green)|During standard of care surgical resection, patients undergo robotic bronchoscopy and CT. Patients also receive indocyanine green via injection.
9731324|NCT04987216|Experimental|PODEYE TORIC IOL Implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC
9731325|NCT04986540|Experimental|Cohort 1|A single subcutaneous injection of SHR-1906/placebo dose 1 in healthy subjects
9731326|NCT04986540|Experimental|Cohort 2|A single subcutaneous injection of SHR-1906/placebo dose 2 in healthy subjects
9731327|NCT04986540|Experimental|Cohort 3|A single subcutaneous injection of SHR-1906/placebo dose 3 in healthy subjects
10200354|NCT04450043|Experimental|Run In|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
10200355|NCT04450043|Experimental|Intervention|Participants will receive a 5-session psychoeducational intervention, focused on skills to enhance post-treatment quality of life with attention to (a) managing expectations, (b) coping with uncertainty, (c) self-managing residual symptoms and (d) strengthening social support.
9731328|NCT04986540|Experimental|Cohort 4|A single subcutaneous injection of SHR-1906/placebo dose 4 in healthy subjects
9731329|NCT04986540|Experimental|Cohort 5|A single subcutaneous injection of SHR-1906/placebo dose 5 in healthy subjects
9731330|NCT04978246||Study Group|The study group consists of 50 individuals aged 18-50 years who have received a positive COVID-19 RT-PCR test in the past 60 days.
9731331|NCT04978246||Control Group|The control group consists of 50 healthy individuals aged 18-50 years who have not had COVID-19.
9731332|NCT04975880|Other|Hemodialysis Treatments|All subjects will receive hemodialysis treatments using the SC+ machine for all phases of the trial including in-clinic training, transition, and in the home setting.
9731333|NCT04974671|Experimental|Stereotactic Body Radiation Therapy|
10200356|NCT04450043|Active Comparator|Control|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
10200357|NCT04438590|Experimental|Kelulut Honey|"Medical Grade Kelulut Honey which will be in 2 doses.~The first would be diluted to 800 ml of water, and the second dose in 400ml of water."
9731336|NCT04973072|No Intervention|Control|Participants in this arm will not receive any intervention.
9731337|NCT04973072|Experimental|One large reward|Participants in this arm will receive S$300 if they reach the PBF goal at the end of 12 weeks.
9731338|NCT04973072|Experimental|Small wins|Participants in this arm will receive cash rewards capped by S$300, depending on which intermediate goals they reach and the PBF at the end of the 12 weeks.
9731339|NCT04969003|Active Comparator|Transgender male (TM)|~90-second video of depressed transgender male
9731340|NCT04969003|Active Comparator|Cis-gender male (CM)|~90-second video of depressed cis-gender male
9731341|NCT04969003|Active Comparator|Transgender female (TF)|~90-second video of depressed transgender female
9731342|NCT04969003|Active Comparator|Cis-gender female (CF)|~90-second video of depressed cis-gender female
9731343|NCT04968938|Experimental|MDMA-assisted therapy|Two sessions of MDMA-assisted therapy with flexible dose of MDMA from 80 mg initial dose and optional supplemental dose half that of initial dose 1.5 to 2 hours later
9731344|NCT04968028|Experimental|ACAF|Participants underwent anterior decompression of Anterior Controllable Antedisplacement and Fusion
9731345|NCT04968028|Experimental|Laminoplasty|Participants underwent posterior decompression of Laminoplasty
9731346|NCT04965220|Experimental|ATC|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
10200358|NCT04438590|Active Comparator|Carborie|Carborie Load which will be 100g of carbohydrate in 800 ML of water and 50g of carbohydrate in 400ml of water.
10200359|NCT04433806|Experimental|Intervention|25 subjects, all referred to community based program for weight loss at ExercisAbilities
10200360|NCT04421313|Experimental|Rhumatoid Arthritis|The patients with Rheumatoid arthritis receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
10200361|NCT04421313|Placebo Comparator|Control Subjects|The patients with Control Subjects receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
10205069|NCT04119375|Experimental|Social Behavior Change Communication (SBCC)|"Patients assigned to this intervention will have access to a mobile health platform that provides reminders, information and motivation - designed with behaviorally-informed strategies - but no follow up support from a human beyond what the standard of care allows. Further details of the intervention can be found in the study protocol section.~The intervention will send automated motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. Clinicians can view individual or aggregate patient histories to leverage limited resources."
9731347|NCT04965220|Experimental|Primary brain tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
9731348|NCT04965220|Experimental|CRC(KRAS mutant)|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
9731349|NCT04965220|Experimental|other solid tumor|HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)
9731350|NCT04962594|Experimental|Experimental formulas (EF) group|Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) supplemented with pre- and probiotic(s)
9731351|NCT04962594|Active Comparator|Control formulas (CF) group|Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) not supplemented
9731352|NCT04962594|Active Comparator|Breastfed (BF) group|Breast milk
9731353|NCT04961437||Patients with de novo acute respiratory failure|"The following tests will be performed as part of the research (these tests are usually performed as part of routine care but not routinely and comprehensively):~A diaphragmatic ultrasound in the half-seated position. Diaphragmatic excursion and thickening fraction will be measured in the right hemi-diaphragm.~A 10-minute reference acquisition. They will be performed at inclusion, H2, H4 and H48."
9731354|NCT04956263|Experimental|Treatment A|YG1699 10 mg
9731355|NCT04956263|Experimental|Treatment B|YG1699 25 mg
9731356|NCT04956263|Active Comparator|Treatment C|Dapagliflozin 10 mg
9731357|NCT04954677|Experimental|Participates being subjected to capsule endoscopy (AI-box assistant)|In this group ,Participates will be subjected to magnet controlled capsule endoscopy with AI-box assistant.
9731358|NCT04954677|No Intervention|Participates being subjected to capsule endoscopy|In this group ,Participates will be subjected to magnet controlled capsule endoscopy without AI-box assistant.
9731361|NCT04949243||People who use the self administered SARs-CoV-2 antigen testing kits|
9731362|NCT04949165|Experimental|Iron Supplementation|
9731363|NCT04949165|No Intervention|Control|
9731364|NCT04946305||Lutathera|Patients administered Lutathera by prescription
9731365|NCT04945655|Experimental|Arm 1: component 1 + component 2 + component 3|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2) + Access to vaccination at school (component 3)
9731366|NCT04945655|Experimental|Arm 2: component 1 + component 2|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2)
9731367|NCT04945655|Experimental|Arm 3: component 1 + component 3|Adolescents and parents' education and motivation at school (component 1) + Access to vaccination at school (component 3)
9731368|NCT04945655|Experimental|Arm 4: component 1|Adolescents and parents' education and motivation at school (component 1)
9731369|NCT04945655|Experimental|Arm 5: component 2|General practitioners' training (component 2)
9731370|NCT04945655|No Intervention|Arm 6: Control|No intervention
9731371|NCT04943497||ribociclib + AI/fulvestrant|Patients administered ribociclib + AI/fulvestrant by prescription AI: Aromatase inhibitor
9731372|NCT04943497||aplelicib + fulvestrant|Patients administered aplelicib + fulvestrant by prescription
9731373|NCT04943497||mono endocrine therapy|Patients administered mono endocrine therapy by prescription
9731374|NCT04943497||chemotherapy|Patients administered chemotherapy by prescription
9731375|NCT04939714|Experimental|Psychoeducational Intervention|Caregivers receiving the psychoeducational intervention immediately.
9731376|NCT04939714|No Intervention|Waitlist|Caregivers on a waitlist to receive the psychoeducational intervention after a waiting period of 8 weeks.
9731377|NCT04937166|Experimental|DSP107 monotherapy and in combination with azacitidine or azacitidine plus venetoclax.|"DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study.~Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle.~Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards."
9731378|NCT04928950|Experimental|Adults undergoing TEMLA|Adults undergoing TEMLA (Transcervical Extended Mediastinal Lymphadenectomy) take Oral Activated Charcoal (OAC) dissolved in apple juice a night before the surgery
9731379|NCT04927637||Orthopedic Infection|Subjects who have undergone previous orthopaedic trauma surgery and have developed and infection will be assessed for protocol inclusion criteria. Patients who meet all inclusion criteria and no exclusion criteria will be administered a single dose 2.5-5 mg/kg ICG dose intravenously ideally 24h prior to surgical debridement. Fluorescent images will be obtained pre and post irrigation and debridement
9731380|NCT04925895|Experimental|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization (DSTM) is a soft tissue mobilization technique use to treat tight spasm using progressive muscle activation.
9731381|NCT04925895|Active Comparator|Proprioceptive neuromuscular facilitation stretching|PNF stretching technique, a type of flexibility training that is effective in improving muscle flexibility and restore functional ranges using a wide array of techniques.
9731382|NCT04924933|Experimental|Patients (Epilepsy group)|Patients with drug-resistant focal epilepsy in whom an accelerated long-term forgetting is suspected (presence of a subjective memory complaint and absence of objective deficit in memory tests conducted in the frame of a routine comprehensive neuropsychological assessment)
9731383|NCT04924933|Active Comparator|Healthy volunteers (control group)|Age-matched healthy volunteers
9731384|NCT04924244|Active Comparator|No Music|No music will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
9731385|NCT04924244|Experimental|Music Therapy|Music of the subject's preferred genre will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
9731386|NCT04924036|Other|Glycopyrronium Cloths then Placebo|Participants that are randomized to Glycopyrronium cloths for 4 weeks, then 2 week wash out, then cross over to placebo cloths for 4 weeks.
9731387|NCT04924036|Other|Placebo then Glycopyrronium Cloths|Participants that are randomized to placebo cloths for 4 weeks, then 2 week wash out, then cross over to Glycopyrronium cloths for 4 weeks.
9731388|NCT04920539|Experimental|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
9731389|NCT04920539|Placebo Comparator|Placebo|Placebo (saline solution) administered intravenously.
9731390|NCT04919382|Experimental|Cohort I (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9731391|NCT04919382|Experimental|Cohort II (atezolizumab, temozolomide)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive temozolomide PO QD on days 1-14 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9731392|NCT04907643|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
9731393|NCT04907643|Experimental|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
9731394|NCT04907643|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
9731395|NCT04900831||Group 1|
9731396|NCT04899544|Experimental|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|A 16-week center-based PRT intervention (PRT-C) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
9731397|NCT04899544|Experimental|Home-Based Pivotal Response Treatment (PRT) Intervention (PRT-H)|A 16-week home-based PRT intervention (PRT-H) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
9731398|NCT04899544|No Intervention|Treatment As Usual (TAU)|This is a control group that consists of children who are receiving treatment as usual (TAU) for a 16-week period. These families will be invited to participate in PRT after completing the 16-week TAU phase.
9781318|NCT01146379|Experimental|Individual Maximum High Movement Dose|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
9781319|NCT01146457|Placebo Comparator|Placebo|
9781320|NCT01146457|Active Comparator|Morphine 25|
9731399|NCT04896476|Experimental|EchoMark|All subjects will undergo a physician exam prior an arteriovenous fistula creation per the institution's standard of care. After the fistula creation is completed, but prior to closure, the EchoMark will be implanted under the outflow vein.
9731400|NCT04892667|Other|Patients with lymphoma (Hodgkin's or non Hodgkin's)|
9731401|NCT04889560|Experimental|Experimental group|Experimental group receives Home CoRe (Home CoRe Group)
9731402|NCT04889560|Other|Control group|Control group receives CoRe software (CoRe Group)
9731403|NCT04883788||Pandemic group|Patients undergone hip and knee replacement during pandemic period (June-december 2020)
9731404|NCT04883788||Pre-pandemic group|Patients undergone hip and knee replacement during the pre-pandemic period (january-march 2020)
9731405|NCT04882735|Experimental|Acoramidis HCI 800 mg (two 400mg tablets)|TTR stabilizer administered orally twice daily (BID)
9731406|NCT04881409|Experimental|nasal high-flow|Patient with AECOPD is treated with NHF.
9731407|NCT04881409|Active Comparator|non-invasive ventilation|Patient with AECOPD is treated with NIV
9731408|NCT04873232|Experimental|Engensis|Patients who have received Engensis in protocol VMDN-003-2
9731409|NCT04873232|Placebo Comparator|Placebo|Patients who have received Placebo in protocol VMDN-003-2
9731410|NCT04873050|Experimental|Semaglutide Pen Injector (Ozempic)|Weekly injections of semaglutide for 8 months total (2 months of titration; 6 months of full dose- 1mg/week)
9731411|NCT04873050|Sham Comparator|Placebo|Weekly injections of placebo for 8 months total
9731412|NCT04871568|Active Comparator|Right subclavian vein catheterization|The temporary central dialysis catheter is placed in the right subclavian vein.
9731413|NCT04871568|Active Comparator|Right internal jugular vein catheterization|The temporary central dialysis catheter is placed in the right internal jugular vein.
9731414|NCT04871503|Experimental|HIFEM+RF (HR)|The HR group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with mild heating of the muscles.
9731415|NCT04871503|Experimental|HIFEM (H)|The H group will receive a treatment with the intensities of the magnetic field just below the patient's tolerance threshold without the use of radiofrequency.
9731416|NCT04869670|Experimental|G-POEM|
9731417|NCT04869670|Sham Comparator|Sham procedure|
9731418|NCT04867174|Placebo Comparator|Control Arm|No messaging about COVID-19 vaccination
9731419|NCT04867174|Experimental|Emotional message|Participants view an emotional video from the state of California about getting back to normal.
9731420|NCT04867174|Experimental|Safety and effectiveness message|Participants view a video with information about the safety and effectiveness of the COVID-19 vaccines
9731421|NCT04867174|Experimental|Consequences message|Participants view a video with information about the consequences of not getting vaccinated against COVID-19.
9731422|NCT04864743|Experimental|Arm 1-ADVATE+FRSW117(25 IU/kg)|Subjects received two treatments: 25 IU/kg ADVATE in the first period, followed by 25 IU/kg FRSW117 in the second period, with a washout period before each treatment.
10200362|NCT04420546|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to be more physically active (We want you to plan to increase your level of physical activity). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted not to be physically active and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
9731423|NCT04864743|Experimental|Arm 2-ADVATE+FRSW117( 50 IU/kg)|Subjects received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW117 in the second period, with a washout period before each treatment.
9731424|NCT04863313|Experimental|Group receiving the probiotic capsules|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
9731425|NCT04863313|Placebo Comparator|Group receiving the placebo capsules|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
9731426|NCT04858360|Experimental|Study group|
9731427|NCT04857164|Experimental|Pembrolizumab combined with Chemotherapy|"Chemotherapy regimen* is as follows, selected by the investigator, 3 weeks (21 days) is a cycle，combined with pembrolizumab 200 mg intravenously on day 1, every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated(Less than or equal to 35 cycle)~*1) Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2) 2)Cisplatin(25 mg/m2,d1-d3) + albumin-bound paclitaxel(260 mg/m2) 3)Carboplatin(AUC5) + Albumin-bound Paclitaxel(260 mg/m2)"
9731431|NCT04855851|Experimental|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|Subjects will receive 6 PAIN NEUROSCIENCE EDUCATION (PNE) sessions and 12 weeks (3 times/week) of STRENGTH TRAINING (ST)
9731432|NCT04855851|Active Comparator|USUAL CARE|The subjects of this group will receive Usual Care. In Spain, the treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients, and recommendation of aerobic and flexibility exercise
9731433|NCT04853108||Remote Monitoring of COVID-19|Patients with COVID-19 who completed acute clinical monitoring of at least 30 days from symptom onset or positive COVID-19 test.
9731434|NCT04853056|Experimental|Virtual Reality Group|watching the application by wearing virtual glasses to the child during the peripheral IV line insertion
9731435|NCT04853056|Experimental|Cold Vibration Group|Buzzy, connecting and operating 5 cm above the area to be inserted peripheral IV line
9731436|NCT04853056|No Intervention|Control group|Standart care
9731437|NCT04852003|Experimental|SHR0410 Injection|
9731438|NCT04852003|Placebo Comparator|Placebo for SHR0410 Injection|
9731439|NCT04852003|Active Comparator|Morphine|
10200363|NCT04420546|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
9731443|NCT04847973|Experimental|12 weeks of medically-tailored meals (MTMs)|12 weeks of home-delivered medically-tailored meals (MTMs), prepared and delivered by the non-profit Community Servings. The MTM has be developed specifically for patients with heart failure, with an approximate protein intake range of 1.1-1.5 g/kg body weight/day and a maximum of 2000 mg sodium/day.
9731444|NCT04847973|Experimental|12 weeks of protein supplementation shakes|Participants will receive 1 bottle of Ensure Max Protein shake every day (any flavor option without caffeine, daily for 12 weeks) to take in addition to their standard diet, without MTM delivery.
9731445|NCT04845035|Experimental|BFM + Tyrosine Kinase Inhibitor|This study has 2 cohorts: participants aged 18 - 59 years and participants aged 60 or more years. Both cohorts receive the same study intervention with dosage adjusted for age. Participants receive the Berlin-Frankfurt-Münster (BFM) protocol plus dasatinib during a two-phase induction and a delayed re-induction. Participants receive the BFM protocol plus ponatinib during post-induction consolidations and maintenance.
9731446|NCT04843332|No Intervention|Usual Oncology Care|This arm is the control group. They will receive usual oncology care from their regular oncologist and care team with no change in their care plan or treatment as a result of the intervention. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
9731447|NCT04843332|Experimental|Community Health Worker Intervention|This arm is the treatment group. Patients randomized into the intervention will be assigned a community health worker who will contact the patient to begin the intervention. They will receive usual oncology care from their regular oncologist and care team but will also receive supplemental support and health education from a community health worker. The lay health worker will assist patients in ensuring that patients discuss the following with their cancer care teams: 1) precision medicine 2) cancer diagnosis and treatment plan 3) adherence to treatments and 3) goals of care and 4) symptom burden. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
9731448|NCT04836468|Experimental|Experimental group|Application of Magnetic Tape transversely over the vertebral levels of L4 and L5
9731449|NCT04836468|Placebo Comparator|Placebo group|Application of kinesiology tape transversely over the vertebral levels of L4 and L5
9731450|NCT04836455|Experimental|The Real Cost vaping prevention ads - Health effects theme|
9731451|NCT04836455|Experimental|The Real Cost vaping prevention ads - Addiction theme|
9731452|NCT04836455|Other|Neutral vaping ads|
9731453|NCT04829240|Experimental|Intervention condition|Modular cognitive-behavioral anxiety intervention tailored to and personalized for Veterans
9731454|NCT04829240|Active Comparator|Control condition|Usual care anxiety treatment
9731455|NCT04825756|Experimental|Treatment Group|A total of up to 80 child/caregiver dyads will be enrolled in the study, anticipating that 40 dyads will complete the 10 week intervention. An equine assisted therapy called Reining in Anxiety for children with anxiety and their caregivers.
9731456|NCT04824703|Active Comparator|Conservative oxygen therapy|"Spo2 alarm limit will be set as follow: - upper limit 94% and lower limit 88%~If spo2 >94% Unless fio2 is 0.21%, decrease fio2 by 0.10% at intervals no longer than 5 minutes till spo2 = 94%~If spo2 within target Decrease fio2 0.05% at intervals no longer than 30 min till fio2 0.21% reached or spo2 = 88 %~If spo2 < 88 % return to previous spo2 that achieve target spo2.~if an arterial blood gas demonstrate that the PaO2 is < 60 mmHg FiO2 will increased if clinically appropriate irrespective of the SpO2 reading ( target po2 60-100 mmhg )~During intubation, airway suction, tracheostomy, bronchoscopy, transportation outside of the ICU for radiological or other investigations or for procedures or operations, other critical situations such as hemodynamic collapse, patients will receive standard (non-study)treatment.~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
9731457|NCT04824703|Placebo Comparator|Liberal oxygen therapy|"Spo2 target > 95%~No specific measures will be taken to avoid high fio2 or high po2~Use of upper alarm limit for spo2 will be prohibited~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
9731458|NCT04816708|Active Comparator|Arm 1: Intervention group (access to LIFT mindfulness app)|Participants randomized to the intervention arm will be provided access to LIFT app's daily mobile mindfulness therapy for 30 days.
9781321|NCT01146457|Active Comparator|Morphine 50|
9781322|NCT01146457|Active Comparator|Morphine 75|
9781323|NCT01146457|Active Comparator|Morphine 100|
10200364|NCT04420455|Experimental|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
10200365|NCT04419337|Experimental|Active arm|metformin+pioglitazone+an SGLT2 inhibitor
10200366|NCT04419337|Active Comparator|Control arm|metformin + DPP4 inhibitors
10200367|NCT04410796|Experimental|Osimertinib alone|All patients will receive osimertinib 80mg orally daily. Subjects randomized to Arm A may be dispensed osimertinib for 2 cycles from Cycle 4 onward.
10200368|NCT04410796|Experimental|Osimertinib plus Carboplatin and Pemetrexed|All patients will receive osimertinib 80mg orally daily. Patients receive Carboplatin (AUC 5 IV q 3 weeks) and Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles followed by pemetrexed maintenance from cycle 8 onwards.
10200369|NCT04380701|Experimental|BNT162a1 (P/B) - Part A 18-55 years of age|Escalating dose levels
10200370|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 18-55 years of age|Escalating dose levels
10200371|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-55 years of age|Escalating dose levels
10200372|NCT04380701|Experimental|BNT162c2 (P/B) - Part A 18-55 years of age|Escalating dose levels
9982436|NCT05240729|Active Comparator|Retroclavicular|Retroclavicular approach to the infraclavicular region, the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will then be inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip will be constantly seen, until it will be positioned posterior to the axillary artery.
9982437|NCT05240729|Active Comparator|Costoclavicular|A new approach to the infraclavicular block The ultrasound transducer will be placed parallel and inferior to the clavicle and angled cephalad to optimize the ultrasound view. The block needle will be inserted in-plane from a lateral to medial direction into the costoclavicular space and the entire drug will be deposited in this location
10200373|NCT04380701|Experimental|BNT162c2 (prime only) - Part A 18-55 years of age|Single dose
10200374|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 56-85 years of age|Escalating dose levels
10200375|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 56-85 years of age|Escalating dose levels
10200376|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohorts 11 to 13)|Escalating dose levels
10200377|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohort 14)|Biomarker (B cell and plasma cell immunity)
10200378|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 3 weeks|
10200379|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 4.5 weeks|
10200380|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 6 weeks|
10200381|NCT04364854|Other|No Therapy 6 weeks|
10200382|NCT04327466|Experimental|Osciflow|Crossover sequence of experimental treatment and active comparator.
10200383|NCT04327466|Active Comparator|Highflow|Crossover sequence of experimental treatment and active comparator.
10200384|NCT04324554||MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
10200385|NCT04318717|Experimental|Pembrolizumab + Hypofractionated radiation therapy|"Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).~Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy."
10200386|NCT04304755|Experimental|Investigational Medical Product : Zoledronic acid|Zoledronic acid 5 mg IV at baseline and after 26 weeks.
9665545|NCT05010148|Placebo Comparator|Placebo|Patients will be administered D5 water intravenously at the same infusion rate (ml/hr) as the intervention group for 48 hours after major spinal surgery.
9665546|NCT05010148|Experimental|Intervention-Intravenous Lidocaine Infusion|Will be administered intravenous lidocaine at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery.
9665548|NCT05008055|Experimental|Capivasertib monotherapy|Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
9665549|NCT05007028|Experimental|Nitrous Oxide|Active Drug: EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide)
9665550|NCT05007028|Placebo Comparator|Medical air|Control Drug: Medical air : 78% N2 / 22% O2
9665551|NCT05006976|Active Comparator|NSAC health only|Treatment as usual (TAU) at NSAC, following a digital survey of health problems and the provision of a condensed report of this survey to clinician prior to consultation.
9665552|NCT05006976|Experimental|NSAC health + MBW|Treatment as usual (TAU) at NSAC, following a digital survey of health problems as well as Motivation, Barriers for return to work and Work environment (MBW), and the provision of a condensed report of this survey to clinician prior to consultation.
9665553|NCT05005676|Experimental|adductor pollicis AP|Measurement site: M.adductor pollicis of both arms.
9665554|NCT05005676|Experimental|Corrugator supercilii CS|Measurement site: M. corrugator supercilii at both sides
9665555|NCT05004896|Experimental|Ketamine|Four infusions of ketamine will be administered over two weeks. The first two infusions will be dosed at 0.5mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.5 mg/kg to 0.75 mg/kg, depending on clinical response to first two infusions.
9665556|NCT05004896|Active Comparator|Midazolam|Four infusions of midazolam will be administered over two weeks. The first two infusions will be dosed at 0.02mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.02 mg/kg to 0.03 mg/kg, depending on clinical response to first two infusions.
9665557|NCT05003115|No Intervention|Standard of Care|Standard of Care
9665558|NCT05003115|Experimental|Intervention|Motivational interviewing intervention
9665559|NCT05002322|Experimental|intervention health facilities|Health facilities implement the optimization of the cascade under research team support and continuous supervision
9665560|NCT05002322|No Intervention|Control|Health facilities implement the optimization of the cascade and maintain supervision without research team support
9665561|NCT04999956|Experimental|dynamic navigation|
9665562|NCT04999956|Sham Comparator|freehand|
9665563|NCT04999904|Experimental|Uneven Treadmill Arm|Uneven Treadmill Intervention with up to twelve sessions over approximately six weeks and Standard of Care Physical Therapy with an 18 month follow-up period
9665564|NCT04999904|Active Comparator|Control Arm|Standard of Care Physical Therapy over approximately six weeks with an 18 month follow-up period
9665567|NCT04996173|Placebo Comparator|Control|Bronchoscopic Balloon Dilation with Radial Cuts
9665568|NCT04996173|Active Comparator|Intervention|Bronchoscopic Balloon Dilation with Radial Cuts & truFreeze Spray Cryotherapy
9665569|NCT04991805||Benralizumab|Patients who have received Benralizumab.
9665570|NCT04991805||Other biologics|Patients who have received non benralizumab biologics.
9665571|NCT04991805||Non-biologic|Patients who have received non biologic drug.
9731459|NCT04816708|No Intervention|Arm 2: Control waitlist group (delayed access to LIFT mindfulness app)|Control participants will not receive access to the LIFT app daily mobile mindfulness therapy during study period. They may have access to LIFT app daily mobile mindfulness therapy after completion of the study period.
9731460|NCT04810598|Experimental|Group 1: Participants With Normal Renal Function|Participants with normal renal function will receive single dose of venetoclax on Day 1.
9731461|NCT04810598|Experimental|Group 2: Participants With End Stage Renal Disease|Participants with end stage renal disease (ESRD) will receive single dose of venetoclax on Period 1 Day 1 and Period 2 Day 1 (Each period is 3 days separated by 7-day washout period).
9731462|NCT04809714|Active Comparator|Routine Post-operative Physical Therapy|The control group will undergo routine post-op and undergo a modified version of the graduated therapy protocol.
9731463|NCT04809714|Experimental|Routine Physical Therapy + Blood Flow Restriction and Neuromuscular Electrical Stimulation (NMES)|The intervention group will start with a Delfi tourniquet system cuff set on a limb occlusion pressure (LOP) of 60-100%. The intervention group will also use a neuromuscular electrical stimulation device at therapeutic level in addition to BFR.
9731464|NCT04802720|Experimental|ERT-C: Emotion Regulation Therapy for Cancer Caregivers|Emotion Regulation Therapy for Cancer Caregivers (ERT-C) is an 8-session intervention that builds upon the foundations of CBT-C and addresses earlier motivational processing components of the caregivers context while targeting earlier and later components of internal distress and resultant maladaptive behavioral coping.
9731465|NCT04802720|Experimental|CBT-C: Cognitive Behavioral Therapy for Cancer Caregivers|Cognitive Behavioral Therapy (CBT-C) is an evidence-based psychotherapeutic approach that is grounded in the cognitive model that purports that a person's emotional, behavioral, and physiological reactions to a situation is based on their appraisal of that situation. The focus of therapy is on changing cognitions and beliefs about a situation and altering automatic behavioral responses evoked by that perception. CBT-C aims to improve emotion regulation by challenging and changing unhelpful cognitions and behaviors and improving personal coping strategies.
9731466|NCT04802720|Experimental|Training case group|Will be assigned to receive ERT-C only and will not complete questionnaires.
9731467|NCT04796922|Experimental|Treatment Group A|Participants will be administered with parsaclisib in combination with investigator choice of rituximab or obinutuzumab.
9731468|NCT04796922|Placebo Comparator|Treatment Group B|Participants will be administered with placebo in combination with investigator choice of rituximab or obinutuzumab
9731469|NCT04795076|Placebo Comparator|Standard formula|Feeding the infant or child with the regular formula which is prepared with standard concentrations
9731470|NCT04795076|Active Comparator|Nutrient-dense formula|Feeding the infant or child with the nutrient-dense formula which is prepared by concentrating regular formula.
9731471|NCT04792008|Experimental|YQ23 Single dose|Two-third of randomized patients will receive YQ23 as active treatment
9731472|NCT04792008|Placebo Comparator|Placebo Single dose|One-third of randomized patients will receive matching placebo
9731473|NCT04791709|Experimental|HOLA Group|Participants in this group will receive a multicomponent intervention for 16 weeks.
9731474|NCT04790513|Experimental|LIB003 (lerodalcibep)|300 mg SC Q4W
9731475|NCT04790513|Active Comparator|evolocumab|420 mg SC Q4W
9731476|NCT04790513|Active Comparator|alirocumab|300 mg SC Q4W
9731477|NCT04789863|Other|Intervention group|Intervention group (IG) patients will receive usual care plus the SMILe-ICM (see below) when they come to their planned follow-up appointments at the University Hospital Basel. Thus, while IG participants will receive the same number of follow-up appointments as CG participants (depending on their state of health), they will also receive the SMILe-ICM, i.e., tailored self-management and behavioural support delivered by the combination of totally 12 face-to-face meetings with a Care Coordinator (CC) and the SMILeApp. The personal meetings with the CC will last around 40-90 minutes. The first three of them will occur during the initial alloSCT hospitalization, and the other nine will occur in the outpatient setting, beginning with biweekly and expanding to bi-monthly intervals until one year post-alloSCT.
9731478|NCT04789863|Other|Control group|"see Intervention section"
9731479|NCT04786210|Experimental|Site A of keloid scar|One half of keloid scarring on a single subject
9731480|NCT04786210|Experimental|Site B of keloid scar|One half of keloid scarring on a single subject
9781324|NCT01146496|Active Comparator|Storage container|Ultraviolet light resistant plastic in-ground pesticide storage container
9731481|NCT04785456|Experimental|Active TBS|"Daily, 4-week, 5-days per week treatment sessions, each consisting of:~First, intermittent TBS (iTBS) over the L-DLPFC: triplet 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, (600 pulses per session, total duration of 3 min 9 s), then continuous TBS (cTBS) over the R-DLPFC as 40 s uninterrupted bursts (600 pulses). Intensity at 120% resting motor threshold (RMT)."
9731482|NCT04785456|Sham Comparator|Sham TBS|Daily, 4-week, 5-days per week treatment sessions. The sham coil will generate auditory and somatosensory (vibratory) stimuli identical to the active stimulation.
9731483|NCT04782778|Active Comparator|Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
9731484|NCT04782778|Active Comparator|Ultrasound Guided Supraclavicular Block|US-guided supraclavicular block with 1 mg/kg Bupivacaine (%0,25)
9731485|NCT04781517||Short-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments less than 3 was divided into Short-segment group(200).
9731486|NCT04781517||Long-segment group|Lumbar degenerative diseases' patients,whose lumbar fixed segments no less than 3 was divided into Long-segment group(200).
9731487|NCT04777656|Experimental|CDED/Modulen™IBD®|Strategy combining CD exclusion diet plus Modulen™IBD® on top of ongoing maintenance therapy.
9731488|NCT04777656|Active Comparator|Unrestricted food access|Stop CDED and Modulen™IBD®, but continue maintenance therapy with unrestricted food access.
9731489|NCT04777656|Other|Not randomized|Patient not in remission at M2 or refusing randomisation
9731490|NCT04774575|No Intervention|routine group|Patients will follow a standard clinical follow-up based on kidney allograft function (serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria) and a surveillance allograft biopsies performed at 3 and 12 months after transplantation (M3 and M12). Visits with biopsies for clinical indication are left to the appreciation of the investigator
9731491|NCT04774575|Experimental|biomarker guided follow-up|"Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed.~Visits with biopsies for clinical indication are left to the appreciation of the investigator"
9731492|NCT04773639|Experimental|Multi-Modal Acceptance and Commitment Therapy (M-ACT)|M-ACT consists of five 2-hour group sessions (plus booster) that alternate with self-paced online modules and check-ins that participants complete on their own, between the group sessions. The intervention addresses distress associated with coping with metastatic cancer and supports engagement in advance care planning. The intervention is based on Acceptance and Commitment Therapy, an intervention model that aims to help people cope with life challenges and difficult thoughts/feelings in a manner that helps them to live fuller and more meaningful lives.
9731493|NCT04773639|Other|Control: Usual Care|Patients in the control arm will have access to usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request. After completion of study procedures, including FU, the UC participants will be offered M-ACT free of cost.
9731494|NCT04771169|Experimental|Vestibular Training Group|This Group will receive vestibular Adaptation and Balance exercises
9731495|NCT04771169|Active Comparator|Virtual Reality Group|This Group will receive virtual reality training by using exergaming.
9731496|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 1)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 1 administered with a DPI.
9731497|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 2)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 2 administered with a DPI.
9731498|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI(Dose 3)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 3 administered with a DPI.
9731499|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 4)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 4 administered with a DPI.
9731500|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 5)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 5 administered with a DPI.
9731501|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 6)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 6 administered with a DPI.
9781325|NCT01146496|No Intervention|Control|
9781326|NCT01146561|Experimental|Tanezumab 20 mg|
9731502|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 7)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 7 administered with a DPI.
9731503|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI|An additional cohort of healthy volunteers will receive a single inhaled dose of AZD4604 administered with a DPI.
9731504|NCT04769869|Placebo Comparator|Part 1a (SAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
9731505|NCT04769869|Experimental|Part 1b: AZD4604 for intravenous administration|Healthy volunteers will receive a single IV dose of AZD4604 administered as a 20 minute infusion.
9731506|NCT04769869|Experimental|Part 1b: AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604.
9731507|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 8)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
9731508|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 9)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
9731509|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 10)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
9731510|NCT04769869|Placebo Comparator|Part 2 (MAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
9731511|NCT04769674|Experimental|STAR intervention|Each research participant will receive individual 30-minute therapy sessions two times per week for fifteen weeks. Fifteen weekly ten-minute consultations with the teacher will also be conducted for each participant.
9731512|NCT04766892|Experimental|mavacamten (MYK-461)|
9731513|NCT04763512|Experimental|Intact Cow's Milk Protein Formula Group (CMFG)|All enrolled subjects will be fed Stage 1 CMF libitum for 4 months. Thereafter, they will discontinue study formula and complete the study.
9731514|NCT04763512|Experimental|Partially Hydrolysed Whey Formula Group (pHFG)|All enrolled subjects will be fed Stage 1 pHF libitum for 4 months. Thereafter, they will switch to Stage 2 pHF at age 6 months (Study Month 4) and to Stage 3 pHF at age 12 months (Study Month 9) and continue until age 18 months (Study Month 15). Thereafter, they will discontinue study formula and complete the study.
9731515|NCT04763447|Experimental|OMA withdrawal attempt|
9731516|NCT04763447|Active Comparator|OMA continuation|
9731517|NCT04761861|Experimental|Vildagliptin|Vildagliptin 50 mg tablet daily
9731518|NCT04761861|Placebo Comparator|Placebo|Placebo tablet daily
9731519|NCT04761094||Insulin pump|All patient treated with insulin pump.
9731520|NCT04758234|Experimental|LY3549492 (Part A)|LY3549492 administered orally as single ascending doses.
9731521|NCT04758234|Experimental|LY3549492 (Part B)|LY3549492 administered orally as multiple ascending doses.
9731522|NCT04758234|Placebo Comparator|Placebo|Placebo administered orally.
9731523|NCT04756271|Experimental|Health-care workers|Healthy health-care workers at Zagazig University Hospital who opt by their free well to administer 2 doses of SARS-Cov-2 inactivated vaccine at 0 and 21 days. Blood samples will be withdrawn from them to investigate the immune response to the given vaccine
9731524|NCT04754204||Patients indicated for Mobile Cardiac Telemetry Monitoring|Patients indicated for Mobile Cardiac Telemetry Monitoring while meeting inclusion/exclusion criteria and enrolled in sequential manner.
9731525|NCT04752098|Other|premature infants and full term infants|"The study visits will be at ≥3 time points at ages: within the first 28 days after birth, 2 months, 3 months, and, if still hospitalized, at 4 months and at 6 months.~The ultrasound machine to the nursery or neonatal intensive care unit at a scheduled time.~The appropriate ultrasound probe will be placed on the infant's tibia and a miniature hydrophone near the probe. A series of ultrasound measurements will be obtained and the ultrasound data will be saved for offline processing.~The Investigators will repeat the measurement in 3 locations of the infant's tibia.~Each ultrasound measurement takes a few seconds. The complete ultrasound study will take about 15 minutes at each visit.~All procedures will be conducted in the nursery or neonatal intensive care unit to ensure infant safety.~The ultrasound measurement for full-term infants can be done in ultrasound lab."
9731526|NCT04750733||Multiple Sclerosis|Ambulatory MS patients
9731527|NCT04749966||Emergency services staff|Emergency Services staff recruited from the Ambulance, Police, and Fire and Rescue Services.
9731528|NCT04749823|Experimental|Blended treatment program|The blended treatment program will consist of a combination of specific active exercises of the neck and general aerobic exercises. This contains a program of 12 weeks, including 9 supervised online sessions supplemented with 1 to 3 individual home exercises sessions without supervision per week, with a total of 3 sessions/week.
9731529|NCT04749823|Active Comparator|Specific strength exercise program|This group will receive an exercise program with specific strength exercises of the neck muscles. Within a 12-week period, patients will receive 9 online treatment sessions under supervision and 1 to 3 additional home exercise sessions without supervision, with a total of 3 sessions/week..
9731530|NCT04749823|Active Comparator|General aerobic exercise program|This control group will perform general aerobic exercises. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
9731531|NCT04742608||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples on the day of surgery following anesthesia but prior to incision and at the first routine blood test following surgery. Patients who undergo remnant ablation after total thyroidectomy with radioactive iodine have an additional blood sample collected. Patients also undergo collection of tissue samples following surgical resection of thyroid nodule or thyroid cancer. Patients' medical records are also reviewed.
9781327|NCT01146561|Placebo Comparator|Placebo|
10200387|NCT04304755|Placebo Comparator|Placebo: NaCl 0,9%|100 ml 0.9% NaCl IV at baseline and after 26 weeks.
10200388|NCT04297592|Active Comparator|Group A - antibiotic group|Patients will be given 7-days of an oral antibiotic (either cephalexin or doxycycline) to be started after completion of standard perioperative intravenous antibiotics following primary hip or knee arthroplasty
10200389|NCT04297592|No Intervention|Group B - no additional antibiotic|No antibiotics will be prescribed following standard perioperative IV antibiotics following primary hip or knee arthroplasty.
9731532|NCT04739930|Experimental|Bone Marrow Aspiration Group|A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.
9731533|NCT04739930|Sham Comparator|Control|The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation.
9731534|NCT04739189|Experimental|Obese adolescent|
9731535|NCT04738591|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
9731536|NCT04738591|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
9731537|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for two weeks.|
9731538|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for two weeks.|
9731539|NCT04735393|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID for four weeks followed by BID for 11 months.|
9731540|NCT04735393|Placebo Comparator|Vehicle Ophthalmic Solution QID for four weeks followed by BID for 11 months.|
9731541|NCT04729023|Experimental|Combined surgery group|In this group, all eligible patients will receive pars plana vitrectomy combined with phacoemulsification cataract surgery.
9731542|NCT04729023|Active Comparator|Subsequent surgery group|In this group, all eligible patients will receive pars plana vitrectomy first. And a subsequent phacoemulsification will be systematically performed 6 months after the PPV surgery.
9731543|NCT04725825|Experimental|Dry needling|"A single dry needling session will be performed on the dominant painful trapezius muscle, with the patient lying in prone position. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down (fast-in, fast-out technique) in three different directions.~In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct."
9731544|NCT04725825|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
9731545|NCT04721717||People with SCI|People with paraplegia and quadriplegia
9731546|NCT04721314|Experimental|Lower rate set to a higher, personalized backup heart rate (myPACE)|Patients randomized to this group will have their pacemaker lower heart rate setting programmed to a personalized lower rate based on a resting heart rate algorithm.
9731547|NCT04721314|Active Comparator|Lower rate left at 60 beats-per-minute|Patients randomized to this group will have their pacemaker lower heart rate setting left at or programmed to the conventional pacemaker lower rate setting of 60bpm.
10200390|NCT04289870|Experimental|Innoventric Trillium™ Stent Graft Single Arm|Single-arm, open label, multi-center study
10200391|NCT04287556||Population in risk of MH|Patient with hypermetabolic response of skeletal musculature by causes related with Malignant Hyperthermia in the literature.
10200392|NCT04284319|Experimental|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
10200393|NCT04273022|Experimental|SCT Group|Fifteen SCT subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
9731548|NCT04721262||Patients prescribed Ferumoxytol for iron deficiency anemia|Patients with iron deficiency anemia are commonly prescribed Ferumoxytol periodically as part of their standard clinical care. Multiple studies have characterized the efficacy and safety of Ferumoxytol in the treatment of iron deficiency anemia. Patients prescribed Ferumoxytol for iron-deficiency anemia typically include otherwise healthy women with heavy menstrual periods, patients with inflammatory bowel disease, and patients with chronic kidney disease. Such patients make ideal candidates for characterizing the effects of Ferumoxytol on novel imaging devices by obviating a medically unnecessary injection of the contrast agent.
9731549|NCT04719377|Experimental|Powerme midline catheter|Powerme midline catheter
9731550|NCT04719377|Sham Comparator|peripheral intravenous catheter|BD Pegusas peripheral intravenous catheter
9731551|NCT04718350|Active Comparator|Intravenous administration of Levosimendan at a dosage of 6 mcg/kg after induction of anesthesia|in this group, 6 mcg/kg of levosimendan will be administered intravenously after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
9731552|NCT04718350|Active Comparator|Inhalational administration of Milrinone at a dosage of 50 mcg/kg after induction of anesthesia|in this group, 50 mcg/kg of milrinone will be administered via inhalation after anesthesia induction, aiming at prevention of pulmonary hypertension post bypass
10200394|NCT04273022|Active Comparator|Control Group|Five healthy subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
9731553|NCT04714710|Experimental|Potassium canrenoate|Potassium canrenoate 200mg diluted in SODIUM CHLORIDE SOLUTION 0.9%
9731554|NCT04714710|Placebo Comparator|Placebo (SODIUM CHLORIDE SOLUTION 0.9%)|SODIUM CHLORIDE SOLUTION 0.9%
9731555|NCT04714281|Other|Hemodiafiltration HDF|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
9731556|NCT04713072|Experimental|ABY-035 40 mg|40 mg ABY-035 SC
9731557|NCT04713072|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
9731558|NCT04713072|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 16 weeks
9731559|NCT04713033|Experimental|Experiment 1|Experiment 1 (Aim 1) will utilize a 16-channel sEMG array to characterize cervical-cranial muscle activity networks in typical speakers at baseline and after a vocal loading task. Flexible laryngoscopy will be performed to exclude any existing pathology and confirm eligibility in the healthy control group. Aim 2 will quantify how cervical muscle networks are perturbed in patients with two different types of dysphonia and examine if standard-of-care treatment restores cervical-cranial muscle networks to more typical states.
9731560|NCT04713033|Experimental|Experiment 2|In Experiment 2 (Aim 2), the study will measure muscle networks in patients with muscle tension dysphonia before and after a course of voice therapy. Patients with muscle tension dysphonia represent an intact but potentially maladaptive network.
9731561|NCT04713033|Experimental|Experiment 3|In Experiment 3 (Aim 2), the study will measure patients with unilateral vocal old paralysis, representing a neurologically impaired network, before and after a vocal fold medialization procedure.
9731562|NCT04711915|Active Comparator|0.1 mg/kg DMT|0.1 mg/kg DMT administered intravenously
9731563|NCT04711915|Active Comparator|0.3 mg/kg DMT|0.3 mg/kg DMT administered intravenously
10200395|NCT04271072||Study|"Parturients that underwent cesarean delivery and is POSITIVE for the composite outcome of either:~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), and/or~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
10200396|NCT04271072||Control|"Parturients that underwent cesarean delivery and is NEGATIVE for the composite outcome of both:~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), AND~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
9731566|NCT04708626||Extended Cohort: Patients tested for any neuronal antibody in the Swedish population|All patients tested for any neuronal antibody in serum or CSF between 2015 and 2019 in Sweden.
9731567|NCT04708626||Core Cohort: Patients with a positive neuronal antibody test belonging to the Uppsala-Örebro region|All patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or cerebrospinal fluid between 2015-2019.
9731568|NCT04705974|Experimental|Fascia iliaca block|ultrasound-guided fascia iliaca block with predetermined dose of 0.4% ropivacaine will be performed.
9731569|NCT04705974|Experimental|Femoral nerve block|ultrasound-guided ultrasound-guided femoral nerve block with predetermined dose of 0.4% ropivacaine will be performed.
9731570|NCT04705974|Experimental|Pericapsular nerve group block (PENG block)|ultrasound-guided ultrasound-guided pericapsular nerve group block with predetermined dose of 0.4% ropivacaine will be performed.
9731571|NCT04705038|Experimental|Educational Intervention|Participants in this arm undergo a short educational session about orchiectomy. They will also be asked to complete questionnaires.
9731572|NCT04705038|No Intervention|No Intervention|"Participants that decline the education session will continue with routine care of their cancer.~They will also be asked to complete questionnaires."
9731573|NCT04700280|Experimental|GLPG3970|Participants will receive GLPG3970 tablet, orally, once daily for 12 weeks.
9731574|NCT04700280|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
9731575|NCT04698434|Active Comparator|0.5mg/kg esketamine group|0.5mg/kg esketamine group will be given a single intravenous 0.5mg/kg esketamine
9731576|NCT04698434|Active Comparator|.75mg/kg esketamine group|0.75mg/kg esketamine groupwill be given a single intravenous 0.75mg/kg esketamine
9731577|NCT04698434|Active Comparator|1.0mg/kg esketamine group|1.0mg/kg esketamine group will be given a single intravenous 1.5mg/kg esketamine
9781328|NCT01146600|Experimental|Random Group A|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
10200397|NCT04258020|Experimental|Experimental: alternating BiPAP and HFNC|Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation
10200398|NCT04258020|No Intervention|Historical Control: standard of care|A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.
10200399|NCT04254419|Experimental|NK cell infusion|"For source PBMCs from the patient, up to 3ml/kg (maximum 150ml) of heparinized peripheral blood will be drawn. NK cell product will be manufactured by a GMP facility. Once the NK cell goes through the appropriate procedures, it will undergo a lot release testing and cryopreservation by day 14 for infusion.~If NK cells fail to meet release criteria or are insufficient in number for the dose level assigned, collection of PBMCs may be repeated up to 2 additional times.~Duration of study therapy is up to 12 weeks and nine doses of NK cells."
10205070|NCT04119375|Experimental|Keheala|"An automated system sends motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. If a patient fails to correctly verify her compliance, the system automatically alerts the support-sponsor, who then intervenes with a supportive dialogue. Clinicians can view individual or aggregate patient histories to leverage limited resources.~Further details of the intervention can be found in the study protocol section."
9731578|NCT04696575|Experimental|Treatment (lamivudine, chemoimmunotherapy)|"INDUCTION: Patients receive lamivudine PO QD on days 1-28. Patients also receive carboplatin IV over 30-60 minutes and atezolizumab IV on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lamivudine PO QD on days 1-28 and atezolizumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Patients who are not eligible for atezolizumab as outlined in exclusion criteria or who refuse to receive atezolizumab may still be treated in this study with carboplatin and etoposide as the IV drug component, in addition to lamivudine orally administered."
9731579|NCT04694807|Experimental|Group-based Cognitive Behavioural Therapy|A group delivered treatment format of CBTgrief (12 sessions).
9731580|NCT04694807|Active Comparator|Individually delivered Cognitive Behavioural Therapy|An individual delivered treatment format of CBTgrief (12 sessions).
9731581|NCT04681430|Experimental|convalescent plasma (CP)|Administration of 2 units of CP (neutralizing anti-SARS-CoV-2 antibody titer of at least 1:160) on day 1
9731582|NCT04681430|Other|Standard of Care|Standard of care allowed
9731583|NCT04681430|Experimental|Camostat Mesilate|Tablets 600 mg per day in 3 doses over 7 days
9731584|NCT04681430|Placebo Comparator|Placebo camostat|Placebo Tablets in 3 doses over 7 days (blinded)
9731585|NCT04678882|Experimental|Dupilumab|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
9731586|NCT04678882|Placebo Comparator|Placebo|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
9731587|NCT04677816|Experimental|Vitamin D Supplementation Group - Deficient Levels|Along with standard of care neoadjuvant chemotherapy treatments and procedures, participants will receive oral 50,000 international units of Vitamin D3 supplementation at the initiation of chemotherapy once a week.
9731588|NCT04677816|Active Comparator|Observational Arm - Vitamin D at Normal Levels|Standard of care neoadjuvant chemotherapy
9731589|NCT04674774|Experimental|tegoprazan based bismuth quadruple therapy group|tegoprazan based bismuth quadruple therapy group
9731590|NCT04674774|Active Comparator|PPI based bismuth quadruple therapy group|PPI based bismuth quadruple therapy group
9731591|NCT04672512|Experimental|SAD Cohort A CORT125329|Participants will receive a single dose of CORT125329 30 mg lipid capsule formulation 1 in the fasted state on Day 1
9731592|NCT04672512|Experimental|SAD Cohort B CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 in the fasted state on Day 1. The dose will be determined after review of safety, tolerability, and PK data from SAD Cohort A.
9731593|NCT04672512|Experimental|SAD Cohorts C through H CORT125329|Participants will receive a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
9731594|NCT04672512|Placebo Comparator|SAD Cohorts A through H Placebo|Participants will receive a single dose of placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 in a dose escalation format. The dose, formulation, and prandial state for each placebo cohort will match that used in the corresponding CORT125329 cohort.
9731595|NCT04672512|Experimental|MAD Cohorts A through D CORT125329|Participants will receive CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency (once- or twice-daily), formulation, and prandial state for each cohort will be determined after review of safety, tolerability, and PK data from previous cohorts.
9731596|NCT04672512|Placebo Comparator|MAD Cohorts A through D Placebo|Participants will receive placebo matching CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Days 1 through 14 in a dose escalation format. The dose, dose frequency, formulation, and prandial state for each cohort will match that used in the corresponding CORT125329 cohort.
9731597|NCT04672512|Experimental|Pharmacodynamic (PD) Effect Cohort|Participants will receive a single dose of prednisone 25 mg in the fasted or fed state on Day 1 of Period 1. The prandial state for the Period 1 treatment will be determined after review of safety and tolerability data from the SAD Cohorts. After a 7-day washout period, participants will receive a single dose of prednisone 25 mg and a single dose of CORT125329 lipid capsule formulation 1 or 2 in the fasted or fed state on Day 1 of Period 2. The formulation and dose level of CORT125329 treatment in Period 2 will be determined after review of safety, tolerability, and PK data from the SAD cohorts. The prandial state for treatment in Period 2 will be the same used in Period 1.
9781329|NCT01146600|Experimental|Random Group B|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
9781330|NCT01146613|Active Comparator|Varenicline|Varenicline Tartrate
9781331|NCT01146613|Placebo Comparator|Sugar Pill|
9781332|NCT01146665|Experimental|Computer-based PAF|Standard medical care followed by computer-based personalized assessment feedback (PAF).
9781333|NCT01146665|Sham Comparator|Computer-based sham|Standard medical care followed by a computer-based sham.
9781334|NCT01146704|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
9781335|NCT01146704|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
9781336|NCT01146782|Experimental|Treatment|Treatment with the Attune Sleep Apnea System
9785327|NCT01249118|Experimental|Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion|Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
9785820|NCT01260584|Experimental|Prasugrel|Prasugrel 10 mg film-coated tablet daily dose × 10 days. To maintain blinding, placebo film-coated tablets matching clopidogrel in appearance will be given daily × 10 days to subjects in the prasugrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
9731598|NCT04656925|Experimental|Contingency management A-B-A|All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods.
9731599|NCT04655352||Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by MB40 intervention
9731600|NCT04651218|No Intervention|control|sedentary control group watches TV between being assessed for outcome measures
9731601|NCT04651218|Experimental|exercise|exercise treatment performs exercise between being assessed for outcome measures
9731602|NCT04650217|Active Comparator|L-DOPA + Exercise|N=20 subjects assigned to L-DOPA + Exercise will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive exercise training 4 times a week (exercise)
9731603|NCT04650217|Active Comparator|LDOPA + Control|N=20 subjects assigned to L-DOPA + Control will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive a stretching and toning regime (Control).
9731604|NCT04650217|Placebo Comparator|Placebo + Exercise|N=20 subjects assigned to Placebo + Exercise will receive placebo three times daily and also will receive exercise training 4 times a week (exercise).
9731605|NCT04650217|Placebo Comparator|Placebo + Control|N=20 subjects assigned to Placebo + Control will receive placebo three times daily and also will receive a stretching and toning regime (Control).
9731606|NCT04650074|Active Comparator|LIDOCAINE 20 mg|4 injections (on day 1, day 7, day 14, day 30) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).
9731607|NCT04650074|Experimental|LIDOCAINE 20 mg + KETAMINE 20 mg|4 injections (on day 1, day 7, day 14, day 30) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).
9731608|NCT04650074|Experimental|LIDOCAINE 20 mg + KETAMINE 40 mg|4 injections (on day 1, day 7, day 14, day 30) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).
9731609|NCT04649905||Surgical Treatment|
9731610|NCT04649905||Nonoperative Treatment|
9731611|NCT04649879|Experimental|Convalescent plasma treatment|"Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions.~If steroid therapy has not already been initiated, betamethasone 3 mg daily will be given concomitantly with steroid therapy or longer if clinically indicated but for a maximum of 10 days."
9731612|NCT04649879|Active Comparator|Control|Standard of care for COVID-19 patients.
9731613|NCT04647058|Active Comparator|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
9731614|NCT04647058|Experimental|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
9731615|NCT04644952||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
9731616|NCT04644367|Experimental|Tai Chi group|The Tai Chi (TC) group will receive or be taught TC in a class size consisting of about 5-12 students. Classes will be taught by a TC master with more than 4 years of experience practicing either Yang or Wu style TC. The participants will be allowed to practice TC at home and during their leisure time so long as they keep an activity log of their daily TC practice. This monitoring form (i.e. activity log or journal) will be distributed to all members of this group and collected weekly.
9731617|NCT04644367|Active Comparator|Regular Physical Activity (control) group|The regular physical activity (control) group will be asked to maintain or engage in at least 60 minutes of regular physical activity. The participants will be instructed as to the type of regular PA that they may engage in. These types of PA include: walking, cleaning or performing chores inside the home, and/or climbing the stairs. No restriction will be made to limit others forms of physical activity; individuals in the control group will be permitted to engage in organized sports, instructor-led class such as boxing, dance, etc. to ensure the participant recruitment process is feasible. Similar to the TC group, participants in this group will be asked to complete an activity log (or journal) that will be collected weekly to monitor their regular PA levels.
9731618|NCT04641195|Placebo Comparator|Placebo- Placebo|Participants in the PLACEBO-PLACEBO group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
9731619|NCT04641195|Experimental|Vitamin D- Placebo|Participants in the VITAMIN D-PLACEBO group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and daily placebo zinc supplements.
9731620|NCT04641195|Experimental|Placebo-Zinc|Participants in the PLACEBO-ZINC group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and actual daily zinc supplements.
9731621|NCT04641195|Experimental|Vitamin D- Zinc|Participants in the VITAMIN D-ZINC group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and actual daily zinc supplements.
9731622|NCT04635670|Placebo Comparator|Placebo|Soluble powder for oral use twice daily
9731623|NCT04635670|Active Comparator|Active|The investigational product is soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
9785821|NCT01260584|Active Comparator|Clopidogrel|Clopidogrel 75 mg film-coated tablet daily dose x 10 days To maintain blinding, placebo film-coated tablets matching prasugrel in appearance will be given daily × 10 days to subjects in the clopidogrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
10205071|NCT04107961|Experimental|Vaccine arm|Vaccine in 1 ml, single dose
10205072|NCT04107961|Placebo Comparator|Placebo|1 ml normal saline , single dose
10205073|NCT04107727|Experimental|Quizartinib|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days"
9731624|NCT04634539|Experimental|Gemcitabine + Nab-paclitaxel + L-glutamine|For the dose-finding portion of this study, all subjects will receive a combination of L-glutamine, gemcitabine, and nab-paclitaxel which will be preceded by a 1-week (+/- 1 day) administration of L-glutamine. This 1-week administration of L-glutamine will facilitate measurement of baseline and post-glutamine monotherapy plasma metabolite levels prior to addition of gemcitabine and nab-paclitaxel. The combination therapy will be administered over 28-day cycles during the treatment period until disease progression, treatment intolerance, or withdrawal from the study. Patients are expected to be on treatment for 12 cycles.
9731625|NCT04634110|Experimental|Patients with ALK+ NSCLC and brain metastases|Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib.
9731626|NCT04628949|Experimental|aScope™ Duodeno endoscope and aBox™ Duodeno|Eligible subjects who are undergoing non-emergent, clinically indicated ERCP using aScope™ Duodeno endoscope and aBox™ Duodeno.
9731627|NCT04623593|Active Comparator|ACDF|Anterior cervical discectomy and fusion.
9731628|NCT04623593|Experimental|ACDA|Anterior cervical discectomy with arthroplasty.
9731629|NCT04620239|Experimental|padeliporfin VTP|"Induction Treatment phase:1-3 padeliporfin VTP treatments provided 4 weeks (28 +/-3 days) apart.~Maintenance Treatment Phase: Repeated maintenance VTP treatments during this period will be provided for patients who show evidence of tumor recurrence that is deemed treatable."
9731630|NCT04619979||preoperative anxiety group|
9731631|NCT04619979||Non-preoperative anxiety group|
9731632|NCT04618523|Experimental|Artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days for children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
9731633|NCT04618523|Experimental|Artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
9731634|NCT04617860|Experimental|WVE-120102 (Dose A)|
9731635|NCT04617847|Experimental|WVE-120101 (Dose A)|
9731636|NCT04616066|Experimental|Dates Arm|Consumption of Khalas dates (3 dates =30g undried dates) twice daily (phytoestrogen content 329ug/100g)
9731637|NCT04616066|Experimental|Raisins Arm|Consumption of Raisins (30g twice daily, phytoestrogen content of 9.6ug/100g)
9731638|NCT04613674|Experimental|Arm A|
9731639|NCT04613674|Experimental|Arm B|
9731640|NCT04610762||(Ex) Drug users recognized at-risk population of infection with Hepatitis C virus|
9731641|NCT04610710|Active Comparator|Operation|Operation for severe endometriosis
9731642|NCT04610710|Active Comparator|Fertility treatment|Fertility treatment for women with severe endometriosis.
9731643|NCT04608266|Experimental|Camostat mesylate|Camostat mesylate, oral administration 600mg/day
9731644|NCT04608266|Placebo Comparator|Placebo|Placebo tablets, oral administration
9731645|NCT04608149||Subjects treated with Carpediem system|All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.
9731646|NCT04607317|Experimental|Exercise Intervention|Participants in this arm will be enrolled in a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day). Participants will meet weekly 1:1 with a trained health coach via a Webex platform. Weekly exercise goals will be tailored to the individual's abilities and specific barriers. Coaching will utilize social cognitive theory and self-determination theory to develop self-efficacy for sustainable behavior change.
9731647|NCT04607317|Active Comparator|Control|Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks. They will continue to wear the Garmin activity tracker and can view their activity but will not be given an exercise program. They will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
9731648|NCT04606992|Experimental|CELS resection|All patients included in the study will be in this arm
9731649|NCT04605939|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated lievr fibrosis for 68Ga-DOTA-FAPI PET/MR imaging.
9731650|NCT04601064|Experimental|Collaborate Care (CC) Model|For patients randomized to the CC arm, in addition to the provider being alerted to the positive Mental Health and Substance Use Disorder screener, the patient will also be assigned to a peer case manager (P-CM). The P-CM will provide longitudinal care for the patient as part of their care management case load. The collaborative care support team will include the P-CM, a consultant addiction psychiatrist and the patient's HIV provider who will implement a stepped care program consisting of: 1) an initial assessment, determination of and implementation of an individualized care plan to provide; 2) psychosocial and medication adherence support; 3) evidence-based brief intervention incorporating motivational interviewing informed strategies; 4) measurement-based care for Mental Health and Substance Use Disorder provided directly by the HIV primary care provider or in collaboration with specialty Mental Health and Substance Use Disorder services.
9731651|NCT04601064|No Intervention|Usual Care (UC)|For patients randomized to the UC referral arm, the patient's HIV provider will receive an electronic alert of the patient's positive screen for a Mental Health and Substance Use Disorder. The patient will not be contacted by the P-CM. The provider, at their discretion, will initiate referral to the psychiatry service available onsite. For patients with Substance Use Disorder, providers refer to the in-clinic Substance Use Disorder treatment program that is managed by a nurse practitioner with Substance Use Disorder care experience. Once referred, the patient is seen by the nurse practitioner (separate from the HIV provider) who manages prescription of and assessment of adherence to buprenorphine, including monitoring of urine toxicology results with support from an addiction counselor. The Bartlett Clinic runs 2 substance use groups weekly and has processes for referral to a higher level of Substance Use Disorder care at offsite Substance Use Disorder treatment programs.
9731652|NCT04599816|Active Comparator|levosimendan administration at a dose of 3 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 3 mcg/kg after anesthesia induction
9731653|NCT04599816|Active Comparator|levosimendan administration at a dose of 6 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 6 mcg/kg after anesthesia induction
9731654|NCT04599816|Active Comparator|levosimendan administration at a dose of 12 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 12 mcg/kg after anesthesia induction
9731655|NCT04599777|Experimental|TACE-Sor-Tis|TACE combined with sorafenib and tislelizumab.
9731656|NCT04599257|Experimental|Hip and thigh circumference changes|"The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits. All of the study subjects will receive the treatment with the subject device.~At the baseline visit, MRI imaging will be performed; the subject's weight and hip and thigh circumference will be recorded. Photos of the treated area will be taken.~The treatment administration phase will consist of four (4) treatments, delivered once a week. The applicator of the device will be applied over the treatment area. The device will induce visible muscle contractions along with heating of the subcutaneous fat.~At the last therapy visit, the subject's weight and hip and thigh circumference will be recorded, and photos of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire to fill in."
9731657|NCT04597450|Experimental|Lu AG06466|
9731658|NCT04597450|Placebo Comparator|Placebo|
9731659|NCT04595851|Other|Pharmacist Coordinated care Oncology Model (PCOM)|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and primary care pharmacists.
9731660|NCT04595422|Experimental|Call center staff (educational intervention)|Participants undergo training consisting of a 60-minute educational session.
9731661|NCT04595422|Experimental|Callers substudy (LCS educational materials, questionnaire)|Participants are referred to lung cancer screening educational materials. Participants also complete questionnaires at 1 week and 6 months after referral to educational materials.
9731662|NCT04591366|Active Comparator|Control|Standard skin prep prior to procedure will be performed and an adhesive iodine-infused barrier dressing will be applied post procedure but prior to taking the culture swab and closing the incision.
9731663|NCT04591366|Experimental|Intervention|Standard skin prep prior to procedure plus an adhesive iodine-infused barrier dressing prior to incision, post procedure a culture swab will be taken and the incision closed.
9731664|NCT04589624|Active Comparator|Arm I ( Health Volunteer MRI)|Healthy volunteers undergo MRI over 30 minutes.
9731665|NCT04589624|Experimental|Arm II (Thyroid Cancer Patient hpMRI)|Patients with thyroid cancer undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
10200400|NCT04251715|Experimental|mFOLFIRINOX, Floxuridine-DEX, mFOLFIRI|"Treatment Period 1 - mFOLFIRINOX for 4 cycles (cycle = 14 days) Cycle 1~Oxaliplatin 85 mg/m2 intravenously (iv) over 2 hours~Folinic acid 400 mg/m2 iv over 2 hours~Irinotecan 165 mg/m2 iv over 90 minutes~Fluorouracil 400 mg/m2 iv bolus after folinic acid~Fluorouracil 2,400 mg/m2 continuous infusion over 46 hours~Dosages on Cycle 2, 3, and 4 will be reduced by 25% Treatment Period 2 - HAI delivery of floxuridine + mFOLFIRI for 2 cycles (cycle = 28 days)~Floxuridine-DEX (with heparin and saline) - 0.12 mg/kg/day; via HAI pump, adjusted for weight and flow rate~mFOLFIRI on Day 15~Irinotecan 180 mg/m2 iv over 30 minutes to 1 hour~Folinic acid 400mg/m2 iv over 30 minutes to 1 hour~5-FU 1000 mg/m2 continuous infusion over 46 hours"
9731666|NCT04588129|Experimental|LB-102 50 mg, single dose Cohort 1|LB-102 (n Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
9731667|NCT04588129|Experimental|LB-102 100 mg, single dose Cohort 2|LB-102 (n Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
9731668|NCT04588129|Experimental|LB-102 75 mg, single dose Cohort 3|LB-102 (n Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
9731669|NCT04588129|Experimental|LB-102 100 & 50 mg, multiple dose Cohort 4|LB-102 (n Methyl amisulpride) formulated capsule will be administered orally once daily for four days in 4 subjects; 2 subjects @ 100 mg and 2 subjects @ 50 mg.
9731670|NCT04584801||Part A|"Development Phase Any adult (≥18 years old) who has been diagnosed with COPD guide GOLD criteria (FEV1/FVC ratio post bronchodilator <0.70)~Cohort A (N=50): COPD stage 1~Cohort B (N=50): COPD stage 2~Cohort C (N=50): COPD stage 3~Cohort D (N=50): COPD stage 4~Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history of ≥10 pack-years (20 cigarettes smoked per day for 1 year)"
9731671|NCT04584801||Part B|"Validation Phase~Cohort A (N=50): COPD stage 1~Cohort B (N=50): COPD stage 2~Cohort C (N=50): COPD stage 3~Cohort D (N=50): COPD stage 4~Cohort E (N=50): Suspected COPD"
9731672|NCT04583072||Non-Hispanic White/Caucasian men|Self-identified as White Non-Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
9731673|NCT04583072||African/Black men|Self-identified as African or Black men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
9731674|NCT04583072||Hispanic White/Caucasian men|Self-identified as White Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
9731675|NCT04583072||Asian men|Self-identified as Asian men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
9731676|NCT04582669|Placebo Comparator|Sodium Chloride 0.9%|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
9731677|NCT04582669|Active Comparator|Intralesional Triamcinolone 10 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
9731678|NCT04582669|Experimental|Intralesional Triamcinolone 20 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
9731679|NCT04582669|Experimental|Intralesional Triamcinolone 40 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
9731680|NCT04581798||OSA|Patients with OSA confirmed by polysomnography, aged 35-65
9731681|NCT04581798||Non-OSA|Patients without OSA aged 35-65
9731682|NCT04567407|Experimental|Bilateral erector spinae blocks|All enrolled patients will have bilateral erector spinae blocks (with catheters for postoperative local anesthetic infusion) placed by the by a member of the clinical regional anesthesia team (under the supervision of a member of the research team) in a sterile fashion after the cardiac surgical procedure is completed. Postoperative continuous infusion of local anesthetic (ropivacaine) via the nerve block catheter is initiated and managed by the Acute Pain Service (per standardized, clinical weight-based protocols).
9731683|NCT04566289||PiCSO treatment group|PiCSO treatment as per IFU
9731684|NCT04562246||PCR positive subjects|Patients who receive positive test result from RT-PCR for SARS-CoV-2.
9731685|NCT04561128|Experimental|SHR-1819|Experimental: SHR-1819
9731686|NCT04561128|Placebo Comparator|Placebo|Placebo comparator: placebo
9731687|NCT04559334|Other|open label|All participants will receive Tetrasodium EDTA Catheter Lock Solution (KiteLock™ 4% Sterile Catheter Lock Solution)
9731688|NCT04557280|Experimental|Treatment A: liquid formulation via auto-injector|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an auto-injector forming an integral ready-to-use single-dose drug delivery system.
9731689|NCT04557280|Experimental|Treatment B: liquid formulation via syringe|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe.
9731690|NCT04557280|Experimental|Treatment C: lyophilizate-based formulation via syringe|Selatogrel will be administered as a reconstituted lyophilizate-based formulation for injection.
9731691|NCT04556305|Experimental|Mind - BrainHQ cognitive training intervention|The Mind intervention uses the evidence-based BrainHQ computerized cognitive training program. BrainHQ focuses on improving memory, attention, sensory function, and working memory, and has demonstrated efficacy in improving memory among healthy older adults and adults with heart failure. BrainHQ is tailored to the individual, and program difficulty automatically progresses based on performance. Training occurs during three 30-minute sessions per week, for a total of 36 hours. Participants will complete the BrainHQ program on an iPad tablet, which will be provided to them.
9785822|NCT01260649|Experimental|ketamine|ketamine (0.5 mg/kg) followed by anesthetic agent titrated to sedation and succinylcholine titrated to muscle relaxation Right unilateral ECT at 5-6x seizure threshold three times a week
9731692|NCT04556305|Experimental|Move - lifestyle physical activity intervention|"The Move intervention is a 24-week evidence-based program based on social cognitive theory. It was originally developed for midlife women and successfully maintained increased physical activity. It has since been tailored for older women with CVD to prevent or delay cognitive decline, and includes: (1) education on the importance of lifestyle physical activity for brain health, (2) increasing lifestyle physical activity while considering CVD, and (3) including a goal for increasing Fitbit active minutes (≥ 3 METs or moderate-intensity physical activity) to ensure participants are obtaining the beneficial aerobic fitness effects during periods of lifestyle physical activity. Core elements include a personal lifestyle physical activity goal and five group meetings."
9731693|NCT04556305|Experimental|MindMoves - cognitive training and lifestyle physical activity|Participants who are assigned to this condition will complete both the Move lifestyle physical activity program and the Mind BrainHQ cognitive training intervention simultaneously for 24 weeks (see Move and Mind descriptions). Participants will receive both a Fitbit and iPad tablet to complete the combined MindMoves intervention.
9731694|NCT04556305|No Intervention|Usual Care|Participants in the usual care group do not receive any Mind- or Move-related intervention, and will receive their usual care from their cardiology provider.
9731695|NCT04554719|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated malignant tumors who have completed 18F-FDG PET/CT imaging, focusing on malignant tumors with poor results of FDG PET/CT imaging, such as brain tumors, liver tumors, digestive system tumors and peritoneal, greater omentum, and mesenteric metastatic tumors. Patients undergo 68Ga-DOTA-FAPI PET/MR imaging within one week.
9731696|NCT04553744||Observational (survey)|Participants complete an online survey over 5-10 minutes asking how they would manage lymph node basins in the extremity sarcoma.
9731697|NCT04553107|Experimental|Deprescribing Intervention|
9731698|NCT04553107|Active Comparator|Usual Care|
9731699|NCT04551495|Experimental|Single Arm|Subjects will receive four 28-day cycles of letrozole 2.5 mg daily in combination with entrectinib 600 mg daily. Pre-menopausal women will receive goserelin 3.6 mg every 28 days.
9731700|NCT04548817||Neurocutaneous Melanocytosis|Participants will have Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement
9731701|NCT04548310||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
9731702|NCT04548310||Healthy group|Healthy individuals without chronic disease
9731703|NCT04548297||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
9731704|NCT04548297||Healthy group|Healthy individuals without chronic disease
9731705|NCT04548206|Experimental|Pilates training|60 minutes of Pilates training will be performed for 8 weeks.
9731706|NCT04548206|Placebo Comparator|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
9731707|NCT04547400||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
9731708|NCT04547400||Healthy group|Healthy individuals without chronic disease
9731709|NCT04545580|Placebo Comparator|Treatment period: Placebo|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with matching placebo.
9731710|NCT04545580|Experimental|Treatment period: BAY1817080|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with BAY1817080.
9785823|NCT01260649|Placebo Comparator|placebo|"IV saline, followed by anesthestic agent titrated to sedation and succinylcholine titrated to muscle relaxation.~Right unilateral ECT at 5-6x seizure threshold three times a week"
9731711|NCT04542850|Other|Moderate group and Severe Group|Moderate group and Severe group - . Both groups will be administered 5-aminolevulinic acid (5-ALA) is a natural delta amino acid widely present in nature that can be found in common food. 5-ALA combined with sodium ferrous citrate (SFC) produces the nutritional dietary supplement 5-ALA-Phosphate + SFC (5-ALA + SFC).
9731712|NCT04541810||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
9731713|NCT04541290|Experimental|Treatment|Women with stage 1-2 lymphedema due to breast cancer treatment
9731714|NCT04540887|Experimental|Treatment|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (whole body mat), B. Pad (targeted pelvic mat), and Control Unit. The participant will lay the B. Body mat on any flat surface (i.e. floor, bed, reclining chair, etc.) and lie down on the mat with the smaller B. Pad placed directly over their pelvic area. Then, the participant will turn the PEMF device on using the attached control unit, which has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a four-week period. As this is a single-group assignment, all participants will be given the PEMF device.
9731715|NCT04539808|Experimental|Treatment (mFOLFIRINOX, chemotherapy)|"mFOLFIRINOX REGIMEN: Oxaliplatin intravenously (IV) over 2 hrs, leucovorin calcium IV over 2 hrs, and irinotecan hydrochloride IV over 90 minutes on day 1. Also receive fluorouracil IV over 46 hrs starting on day 1. Repeats every 14 days for up to 4 cycles. Those with response and no disease progression may receive an additional 2 months.~GA REGIMEN: Those with disease progression or toxicity to mFOLFIRINOX switch to GA regimen comprising gemcitabine hydrochloride IV over 30-60 mins and nab-paclitaxel IV over 30-40 mins on days 1, 8, and 15. Repeats every 28 days for 2 cycles.~LOSARTAN: Cycle 1 day 1, start losartan potassium orally once daily until end of RT.~RT/SURGERY: Short-course RT for 10 fractions over 5 days weekly or long-course RT with 15-25 fractions over 5 days weekly along with oral capecitabine twice daily on Monday-Friday or fluorouracil IV over 5-7 days weekly until completion of RT. Patients then undergo surgery 1-4 weeks following RT"
9731716|NCT04536103||Cleveland Clinic Foundation (CCF) Volunteers|The group will be used for evaluating differences between standard T1rho and T2 imaging vs accelerated T1rho and T2 imaging techniques that will be developed from this study.
9731717|NCT04536103||Traveling Volunteers|The group will be recruited at CCF and be scanned at CCF, University of California San Francisco, University of Kentucky and Albert Einstein College of Medicine.
9731718|NCT04536103||ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).
9731719|NCT04536103||Group Matched to ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).Traveling Volunteers share the same inclusion and exclusion criteria as this group, therefore subjects can participate the study and serve as subjects within both groups
9731720|NCT04535505||pertussis test population|People with clinical diagnosis of suspected pertussis in outpatient and ward in the Children's Hospital of Fudan University will be collected as study subjects. Their nasopharyngeal swabs will be collected. Bordetella isolation culture and identification method is the gold standard, and the new CPA platform based on CRISPR technology is the method to be tested. Diagnostic values of this research platform would be detected.
9731721|NCT04530773|Experimental|GROUP1|
9731722|NCT04530773|Experimental|GROUP2|
9731723|NCT04530773|Experimental|GROUP3|
9731724|NCT04530773|Experimental|GROUP4|
9731725|NCT04530773|Experimental|GROUP5|
9731726|NCT04530175||patients with hemodialysis|patient treated with intermittent hemodialysis for chronic renal failure
9731727|NCT04529707|Experimental|Sleep Intervention|All participants will engage in a 10-week, parent mediated sleep intervention with weekly education sessions.
9731728|NCT04527393|Experimental|individualized opioid analgesia regimen group|The dose of oral morphine for patients in the individualized group is determined according to the results of fentanyl test.
9731729|NCT04527393|Active Comparator|conventional opioid analgesia regimen group|Patients in the conventional group are given routine dose of oral morphine.
9731730|NCT04524325|Active Comparator|Trans men|transgender men taking physiologic doses of testosterone for gender affirming hormone therapy
9731731|NCT04524325|No Intervention|control|cisgender women not receiving testosterone and with normal sex hormone levels
9731732|NCT04522557|Experimental|Experimental: Participants with breast cancer enrolled in grou|
9982438|NCT05240729|Active Comparator|Classic|Infraclavicular brachial plexus block (ICPB) ultrasound probe will be placed near the lower edge of the clavicle, and a transverse view of the subclavian artery and vein will be visualized. Using a needle guide, the needle will be advanced under real-time ultrasound guidance, and local anaesthetic will be injected near the subclavian artery, 15 mm medially and 15 mm laterally to the artery. The extent of sensory and motor block will be evaluated at 30 minutes after the injection
9982439|NCT05240196|No Intervention|Control|participant will receive standard care only
9731737|NCT04521413|Experimental|A1: Monotherapy Escalation|Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
9731738|NCT04521413|Experimental|A2: Monotherapy Biomarker|Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.
9731739|NCT04521413|Experimental|A3: Monotherapy Expansion|Dose expansion arm with CFI-402411 at its recommended phase 2 dose.
9731740|NCT04521413|Experimental|B1: Combination Escalation|Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
9731741|NCT04521413|Experimental|B2: Combination Expansion|Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
9731742|NCT04520633||control level stable|severe asthma for which the control level is stable (variation in ACT score <3 between M0 and M6) contributing to the test-retest
9731743|NCT04520633||biologic initiation|introduction or modification of biotherapy at M0
9731744|NCT04519411|Experimental|Intubated pediatric patients with COVID-19 respiratory failure|
9731745|NCT04515784|Experimental|Active|Active arm- START-PTSD
9731746|NCT04515784|No Intervention|Control|Control arm
9731747|NCT04513171|Experimental|Y-shape pegylated somatropin low dose|
9731748|NCT04513171|Experimental|Y-shape pegylated somatropin middle dose|
9731749|NCT04513171|Experimental|Y-shape pegylated somatropin high dose|
9731750|NCT04513171|Active Comparator|Norditropin-1|
9731751|NCT04513171|Experimental|Y-shape pegylated somatropin optimal dose|
9731752|NCT04513171|Active Comparator|Norditropin-2|
9731753|NCT04513067|Experimental|Stage 1: Single agent|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels of 20, 30, 60, 90 and 120 mg/kg will be evaluated.
9731754|NCT04513067|Experimental|Stage 2: Combination Therapy|Intravenous weekly dose of YQ23 for 6 weeks with an ascending dose levels from 20 mg/kg to the MTD obtained from Stage 1 in combination of a fixed dose of 200 mg intravenous pembrolizumab given on the same day following YQ23 administration and every 3 weeks thereafter.
9731755|NCT04512053|Experimental|TAS-303|
9731756|NCT04512053|Placebo Comparator|Placebo|
9731757|NCT04509024|Experimental|Incidental training|Participants undergo novel non-linguistic incidental category learning training.
9731758|NCT04509024|Active Comparator|explicit training|Participants undergo traditional explicit language learning.
9731759|NCT04508062|Active Comparator|pectopexy group|this group will only have pectopexy operation
9731760|NCT04508062|Active Comparator|Pectopexy and uterosacral ligaments plication group|this group will have pectopexy operation with bilateral uterosacral ligaments plication
9731761|NCT04506073|Experimental|MSC+placebo|2 treatment doses + 1 placebo 3 months apart
9731762|NCT04506073|Experimental|MSC|3 treatment doses 3 months apart
9731763|NCT04506073|Placebo Comparator|Placebo|3 placebo doses 3 months apart
9731764|NCT04506008|Experimental|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy followed by immediate surgical resection
9731765|NCT04505969||SCD patients and healthcare professionals|
9731766|NCT04505163|Active Comparator|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Standard cryoballoon pulmonary vein isolation alone using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
9731767|NCT04505163|Experimental|Cryoballoon PVI + Posterior Wall Isolation|Cryoballoon pulmonary vein isolation in conjunction with posterior wall isolation using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
9731768|NCT04504864|Experimental|low-dose aspirin|Management policy is to use 50 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 50mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke. But this dose is rarely used clinically, especially in East Asia area.
9731769|NCT04504864|Active Comparator|conventional-does aspirin|Management policy is to use 100 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 100mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke, and this dose is widely used clinically.
9731770|NCT04502810|Experimental|High-level laser therapy|Real high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
9731771|NCT04502810|Sham Comparator|Sham High-level laser therapy|Sham high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
9731772|NCT04501276|Experimental|Part A : Dose escalation of ADG116 monotherapy|
9731773|NCT04501276|Experimental|Part B : Dose escalation of ADG116 combined with anti PD1 drug|
9731774|NCT04501276|Experimental|Part C : Dose escalation of ADG116 combined with ADG106|
9731775|NCT04500600||Observational (questionnaire)|Patients complete an online questionnaire over 10 minutes regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
9731776|NCT04500132|Experimental|EC-18 Arm|EC-18 QD
9731777|NCT04500132|Placebo Comparator|Placebo Arm|Placebo EC-18 QD
9731778|NCT04497155||Prehospital norepinephrine|Trauma patients that received norepinephrine in the prehospital setting or in the resuscitation unit .
9731779|NCT04497155||Prehospital no norepinephrine|Trauma patients that did not receive norepinephrine in the prehospital setting or in the resuscitation unit.
9731780|NCT04496999|Experimental|Midostaurin with HDM201 dose escalation.|Midostaurin 50mg bid d1-28 (morning, evening) and HDM201
9785824|NCT01260662|Active Comparator|Propofol|Deep sedation using propofol
9785825|NCT01260662|Experimental|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
9785826|NCT01260662|Experimental|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
9982440|NCT05240196|Other|Binaural music|Participants will listen to binaural music whilst having a routine mammogram
9731781|NCT04496713|No Intervention|Telemedicine - Phone|Patients will continue with their telephone-based telemedicine visit as scheduled. There will be no change to their care. Patients will receive a survey by mail about the visit.
9731782|NCT04496713|Experimental|Telemedicine - Audio/Video|Patients will be given an internet-connected tablet to have their upcoming visit with their physician by audio/video. A survey can be completed on the tablet. The devices will be sent back to the research time after their single use.
9731783|NCT04493320|Experimental|L-DOPA, Then Placebo|"Step 1 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1 week taper period.~Step 2 (3 Weeks): Participants will receive L-DOPA matching placebo tablets daily.~Participants will then enter a 1-week taper period."
9731784|NCT04493320|Experimental|Placebo, Then L-DOPA|"Step 1 (3 Weeks): Participants will receive 3 L-DOPA matching placebo tablets daily. Participants will then enter a 1-week taper period.~Step 2 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1-week taper period."
9731785|NCT04491968|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
9731786|NCT04491968|Other|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
9731787|NCT04490941|Experimental|Intervention group|
9731788|NCT04490941|Other|Control group|
9731789|NCT04490369||Group 1- short interval|Less than or equal to six minutes between receiving sedation and the start of the procedure
9731790|NCT04490369||Group 2- long interval|Greater than or equal to seven minutes between receiving sedation and the start of the procedure
9731791|NCT04489667|Other|+STEP Implementation|All patients will receive +STEP as new standard of care at their clinic. This intervention will include staff training, PROs as part of routine care to screen for substance use and mental health disorders, and telemedicine for health care delivery.
9731792|NCT04483505|Experimental|Rogaratinib + palbociclib + fulvestrant|
9731793|NCT04474301||Observational (survey administration)|Patients complete a survey over 10 minutes.
9731794|NCT04474145|Active Comparator|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
9731795|NCT04474145|Active Comparator|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
9731796|NCT04468529|Experimental|Investigational drug group|Injectable Neucardin + standard basic therapeutic medication
9731797|NCT04468529|Placebo Comparator|Placebo group|placebo + standard basic therapeutic medication
9731798|NCT04466137|Experimental|YPEG-rhG-CSF 2mg|YPEG-rhG-CSF 2mg
9731799|NCT04466137|Experimental|YPEG-rhG-CSF 33μg/kg|YPEG-rhG-CSF 33μg/kg
9731800|NCT04466137|Active Comparator|Positive Control Group|rhG-CSF/PEG-rhG-CSF
9731801|NCT04463914|Other|Group A- Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
9731802|NCT04463914|Experimental|Group B- Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
9827898|NCT02472405|Active Comparator|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
9827899|NCT02472405|No Intervention|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
9731803|NCT04463914|Experimental|Group C- Moodivate + EHR|Participants randomized to the Moodivate + EHR condition will receive similar instructions as those randomized to Moodivate, but will also be instructed that their PCP will have access to metrics related to their app utilization and may choose to follow-up with them regarding treatment utilization and response. The PCP for each participant randomized to this condition will be provided EHR access to Moodivate metrics which will include metrics related to change in mood, frequency of app utilization, and frequency of activity completion. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
9731804|NCT04461678|Experimental|screening population|
9731805|NCT04459013||Patient of the orthodontic consultation|
9731806|NCT04454489|Experimental|Quad-shot palliative radiotherapy and Immunotherapy|Systemic therapy (ICI) and radiotherapy will be administered according to the standard of care, according to the treating medical oncologist and radiation oncologist, respectively
9731807|NCT04443348|Experimental|Group A (No RT Boost)|No RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy.There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
9731808|NCT04443348|Experimental|Group B (Low Dose RT Boost)|Low-dose RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
9731809|NCT04443348|Experimental|Group C (High Dose RT Boost)|High-dose RT boost plus pembrolizumab followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
9731810|NCT04442347|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
9731811|NCT04442347|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
9731812|NCT04442061|Active Comparator|Active transcranial magnetic stimulation|excitatory TMS will be applied to the right posterior STS
9731813|NCT04442061|Sham Comparator|Sham transcranial magnetic stimulation|The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue
9731814|NCT04440982|Experimental|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015
9731815|NCT04440982|No Intervention|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
9731816|NCT04438174|Experimental|Amniotic Fluid Injection|Processed Amniotic Fluid. Dose is 1ml/5cm2; Route: injected directly into wound; Limited to two injections. The wound will then be dressed according to standard of care.
9731817|NCT04438174|Active Comparator|Standard of Care Wound Treatment Regimen|Primary dressings are variable and based on the moisture content and microorganism load. In general, wounds respond differently to various topical treatments. Through our clinical practice, we have found that wounds plateau with the same topical for greater than 4 weeks, hence changing antimicrobial topical helps to manage the bacterial overgrowth. We will start with our application of our slurry, a 1:1:1 ratio of Nystatin ointment, Mupirocin Ointment, and Bacitracin Ointment. This slurry will be applied directly to the cleansed wound, followed by silver gauze/foam product to all wounds. Types of silver product- site and comfort predict use of Restore, Mepilex-AG, or Mepitel-AG. If allergies to the above slurry occurs, we will use medical honey with or without bacitracin. If ointment related rash present with transition to silver product only or silver product plus medical honey.
9731818|NCT04437303|Active Comparator|Continuation of oral anticoagulants|
9731819|NCT04437303|Active Comparator|Interruption of oral anticoagulants|
9731820|NCT04436068|Experimental|Outpatients with known or suspected hydrocephalus|
9731821|NCT04436068|Experimental|Outpatients with other known or suspected neurological condition|
9731822|NCT04435431|Experimental|Mesdopetam dose 1|Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
9731823|NCT04435431|Experimental|Mesdopetam dose 2|Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
9731824|NCT04435431|Experimental|Mesdopetam dose 3|Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
9731825|NCT04435431|Placebo Comparator|Placebo|Placebo capsule, 1 capsule b.i.d. for 84 days
9731826|NCT04434729|Experimental|Fetal embolization of vein of Galen malformation|This is a single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.
9731827|NCT04426630|Other|mHealth|Heart failure patients enrolled in the mHealth program
9731828|NCT04426318|Experimental|Healthy Minds Program Foundations Training|"Healthy Minds Program (HMP) Description:~The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Richard Davidson, PhD. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose."
9731829|NCT04426318|No Intervention|Wait-list control|Participants assigned to the wait-list control will not receive treatment for the intervention and follow-up period. They will be provided access to the HMP Foundations training after completing follow-up testing.
9731830|NCT04414787|Active Comparator|Intervention|PCplanner intervention during hospitalization
9731831|NCT04414787|No Intervention|Usual care control|Usual care
9731832|NCT04413786|Experimental|oxytocin group|male subjects with oxytocin treatment
9731833|NCT04413786|Placebo Comparator|placebo group|male subjects with placebo treatment
9731834|NCT04408937|Experimental|tropifexor AM 200 micrograms and Placebo (PM)|Tropifexor 200 μg (AM) and Placebo (PM) once daily each
9731835|NCT04408937|Experimental|tropifexor PM 200 micrograms and Placebo (AM)|Tropifexor 200 μg (PM) and Placebo (AM) once daily each
9731836|NCT04408092|Experimental|GM-CSF treatment at second-look surgery arm|Newly diagnosed patients with EPN who have a subtotal resection at initial presentation and are without evidence of metastatic tumor will be enrolled in this stratum. Total patient population in this stratum will be 10 patients. It should be noted that prior experience suggests that about 1/3 of newly presenting patients still have residual tumor after the initial surgery
9731837|NCT04408092|Experimental|GM-CSF treatment at recurrence arm.|"EPN patients with a first regional relapse and without evidence of metastatic tumor will be enrolled in this stratum. Total patient population will be 10 patients.~Patients with a first recurrence will have the recurrence confirmed by the local institutional neuro-radiologists. They will have the entire neuro-axis scanned and a spinal tap performed (where safe) to exclude metastatic tumor. They will then receive 5 days of GM-CSF and then proceed to surgery if deemed clinically indicated by the treating physician"
9731838|NCT04404400|Experimental|Active|For CIRCI patients: hydrocortisone + fludrocortisone therapy.
9731839|NCT04404400|Placebo Comparator|Placebo|For CIRCI patients: hydrocortisone placebo + fludrocortisone placebo
9731840|NCT04401267|Experimental|Intensive Antihypertensive Therapy|Patients will begin Intensive antihypertensive therapy to achieve the targeted blood pressure (targeted to the 50-75th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
9982441|NCT05240196|Other|Non-binaural music|Participants will listen to non-binaural music whilst having a routine mammogram
9731841|NCT04401267|Active Comparator|Conventional Antihypertensive Therapy|Patients will begin Conventional antihypertensive therapy to achieve the targeted blood pressure (targeted to the 90-95th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
9731842|NCT04400383|Experimental|AB011 Injection|AB011 Injection treatment. This phase 1 trial will include two stages, a single treatment stage and a Combo treatment stage.
9731843|NCT04394624|Experimental|Ramucirumab + SAR408701|Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.
9731844|NCT04388332||Retrospective|20 patients that received one or two level ACDF structural allograft with plates with autograft and /or allograft comprised of cancellous and/or corticocancellous bone chips.
9731845|NCT04388332||Prospective|20 patients who are receiving Tritanium C as standard of care.
9731846|NCT04382391|Experimental|gammaCore Sapphire® (nVNS) plus standard of care|Subjects will be administered study treatment with the nVNS device 3 times per day (prophylaxis) and also as needed for acute respiratory symptoms.
9731847|NCT04382391|Active Comparator|standard of care alone|Will receive standard of care therapies to treat CoViD-19 infection and symptoms
9731848|NCT04381650|Experimental|Dose Escalation: TAK-981 + Pembrolizumab (fixed dose)|Escalating doses of TAK-981 with starting dose of 40 mg, intravenous (IV) infusion, on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle and pembrolizumab 200 mg, IV infusion, as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle until RP2D is determined (for a maximum of 24 months).
9731849|NCT04381650|Experimental|Dose Expansion Phase: Cohort A: Non-squamous NSCLC|TAK-981 at RP2D as IV infusion in participants with non-squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731850|NCT04381650|Experimental|Dose Expansion Phase: Cohort B: Cervical Cancer|TAK-981 at RP2D as IV infusion in participants with cervical cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731851|NCT04381650|Experimental|Dose Expansion Phase: Cohort C: MSS-CRC|TAK-981 at RP2D as IV infusion in participants with microsatellite stable colorectal cancer (MSS-CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731852|NCT04381650|Experimental|Dose Expansion Phase: Cohort D: Cutaneous Melanoma|TAK-981 at RP2D as IV infusion in participants with Cutaneous melanoma on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731853|NCT04381650|Experimental|Dose Expansion Phase: Cohort E: Squamous NSCLC|TAK-981 at RP2D as IV infusion in participants with Squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731854|NCT04381650|Experimental|Dose Expansion Phase: Cohort F: Small Cell Lung Cancer|TAK-981 at RP2D as IV infusion in participants with Small cell lung cancer on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731855|NCT04381650|Experimental|Dose Expansion Phase: Cohort G: HNSCC|TAK-981 at RP2D as IV infusion in participants with head and neck squamous cell carcinoma (HNSCC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731856|NCT04381650|Experimental|Dose Expansion Phase: Cohort H: MSI-H/dMMR CRC|TAK-981 at RP2D as IV infusion in participants with microsatellite instability, high levels/ mismatch-repair-deficient colorectal cancer (MSI-H/dMMR CRC) on Days 1, 4, 8 and 11 or Days 1 and 8 or Days 1, 8 and 15 in each 21-day Treatment Cycle up to disease progression or 24-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks on Day 1 of 21-day Treatment Cycle for a maximum of 24 months.
9731857|NCT04378959|Experimental|Lidocaine patch first|This group will receive up to 3 lidocaine patches for 4 weeks, followed by placebo patches after a 1-3 week washout period.
9731858|NCT04378959|Placebo Comparator|Placebo patch first|This group will receive up to 3 placebo patches for 4 weeks, followed by lidocaine patches after a 1-3 week washout period.
9731859|NCT04371250||Youth|Assessed group
9731860|NCT04369859||pregnant women with COVID-19|Pregnant women who have tested positive for COVID-19
9731861|NCT04361851|Experimental|Single Arm|Pembrolizumab and Daratumumab
9731862|NCT04360928|Experimental|Lake Effect Zero Degree Splinting Group|These patients will be randomized to receive the Lake Effect Zero Degree Splint. Patients will follow the same standardized postoperative rehabilitation protocol.
9731863|NCT04360928|Sham Comparator|Standard Hinged Knee Brace|These patients will be randomized to receive a standard hinged knee brace. Patients will follow the same standardized postoperative rehabilitation protocol.
9731864|NCT04358393|Experimental|APG-115 monotherapy|Monotherapy given in part 1
9982442|NCT05239494|Experimental|Dailies Total1|All participants will be asked to wear Dailies Total1 for the duration of this study.
9731865|NCT04358393|Experimental|APG-115 + 5-azacitidine combination|Combination therapy given in part 2
9731866|NCT04352179|Experimental|Virtual Education Simulation|All participants will have access to the virtual education simulations.
9731867|NCT04351269||CanGaroo Envelope|Patients who received a CanGaroo Envelope with their CIED implantation.
9731868|NCT04351269||TYRX Envelope|Patients who received a TYRX Envelope with their CIED implantation.
9731869|NCT04351269||No Envelope|Patients who had their CIED implanted with no envelope.
9731870|NCT04347486|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
9731871|NCT04347486|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
9731872|NCT04347486|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
9731873|NCT04347486|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) on reappearance of T2 by Train-of-Four stimulation
9731874|NCT04346381|Experimental|camrelizumab combined with famitinib|Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.
9731875|NCT04343521|Experimental|Targeted Indoor Residual Spraying (TIRS)|All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, epidemiological and entomological evaluation will occur in the center of each cluster
9731876|NCT04343521|No Intervention|Control|Routine Aedes-borne virus (ABV) prevention and control, no Targeted Indoor Residual Spraying (TIRS)
9731877|NCT04341441|Active Comparator|Study Drug - Daily Dose|The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
9731878|NCT04341441|Active Comparator|Study Drug - Weekly Dose|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria.
9731879|NCT04341441|Active Comparator|Placebo|All treatment groups will receive placebo pills to have the patients take 2 pills a day. The randomized placebo arm will receive placebo pills made to resemble the daily dosing of HCQ. Similarly, the once a week treatment arm will receive placebo pills for the days not on HCQ medication.
9731880|NCT04341441|Active Comparator|Non-Randomized Active Comparator|A non-randomized comparator group will be enrolled in the study comprising of healthcare workers and first responders who are chronically on oral hydroxychloroquine as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.
9731881|NCT04340752|Experimental|Group 1:ICG 7.5 mg|Subjects in this group are randomized to receive 7.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
9731882|NCT04340752|Experimental|Group 2:ICG 12.5 mg|Subjects in this group are randomized to receive 12.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
9731883|NCT04340752|Experimental|Group 3: ICG 25 mg|Subjects in this group are randomized to receive 25 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
9731884|NCT04339413|Experimental|Gantenerumab|Participants will continue receiving open-label gantenerumab by subcutaneous (SC) injection every four weeks (Q4W) up to Week 208.
9731885|NCT04338698|Active Comparator|Control Intervention|Hydroxychloroquine
9731886|NCT04338698|Experimental|Comparator 1|Azithromycin
9731887|NCT04338698|Experimental|Comparator 2|Oseltamivir
9731888|NCT04338698|Experimental|Comparator 3|Hydroxychloroquine + Azithromycin
9731889|NCT04338698|Experimental|Comparator 4|Hydroxychloroquine + Oseltamivir
9731890|NCT04338698|Experimental|Comparator 5|Oseltamivir + Azithromycin
9731891|NCT04338698|Experimental|Comparator 6|Hydroxyquinine + Oseltamivir + Azithromycin
9731892|NCT04338698|No Intervention|Observational Cohort|Non-consenting to randomization
9731893|NCT04331938|Experimental|Open Label Arm|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion. This will be performed on both sides. Patients will be asked to rate their pain pre- and 30 minutes post-procedure on a scale of 0-10. Patients will also be asked to rate their nausea and photophobia on a similar scale. Patients will be reevaluated at 24 hours and 48 hours post procedure.
9731894|NCT04326738|Placebo Comparator|normal saline (N) group|N group received corresponding intravenous normal saline of 1ml·kg-1.
9731895|NCT04326738|Active Comparator|midazolam (M) group|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam.
9731896|NCT04311320|Experimental|Low-Resource Oxygen Blender|This is a single-arm study. All participants will receive respiratory support using the investigational device.
9731897|NCT04305769|Placebo Comparator|Alanyl-glutamine 0g|
9731898|NCT04305769|Experimental|Alanyl-glutamine 4g|
9731899|NCT04305769|Experimental|Alanyl-glutamine 24g|
9731900|NCT04305769|Experimental|Alanyl-glutamine 44g|
9731901|NCT04305041|Experimental|Pembrolizumab + Quavonlimab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus quavonlimab IV plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
9731902|NCT04305041|Experimental|Pembrolizumab + Quavonlimab + Lenvatinib|Participants will receive pembrolizumab IV plus quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
9731903|NCT04305041|Experimental|Pembrolizumab + all-trans retinoic acid (ATRA)|Participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days for a total treatment duration of up to approximately 2 years
9731904|NCT04304469||women|women consulting for domestic violence
9731905|NCT04303169|Experimental|Pembrolizumab + Vibostolimab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
9731906|NCT04303169|Experimental|Pembrolizumab + V937|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus V937 intratumorally (IT) at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
9731907|NCT04303169|Experimental|Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
9731908|NCT04303169|Experimental|Pembrolizumab + MK-4830|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus MK-4830 IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
9731909|NCT04300920|Experimental|N-acetylcysteine|600 mg oral N-acetylcysteine (NAC) three times daily for 24 months.
9731910|NCT04300920|Placebo Comparator|Placebo|Placebo tablet three times daily for 24 months.
9731911|NCT04293523||Hemophilia A patients|All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.
9731912|NCT04288427|Experimental|Finasteride Treatment|Patients who are eligible will be given 5ARI therapy, Finasteride, for medical management of Benign Prostatic Hyperplasia (BPH) symptoms. Only patients with lower urinary tract symptoms (LUTS) as assessed by AUA urinary symptom score > than 8, (suggestive of moderate LUTS) prostate size > 40cc, no prostate nodule/tenderness/firmness and increased PSA between 4-10ng/ml requiring prostate biopsy will be enrolled. Then, they will have prostate MRIs/needle biopsies and blood/urine collection followed by treatment with Finasteride (standard of care). They will be followed in urology clinic for assessment of LUTS every 6 months and Finasteride responsiveness at the 12-month time point. Prostate biopsy samples will be evaluated for SRD5A2 gene expression/methylation, hormonal androgen/estrogen levels (which will be repeated in blood samples). Prostate MRIs will assess size/inflammatory changes at the start and 3-year time points.
9731913|NCT04282668|Experimental|TAS1440|TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
9731914|NCT04282668|Experimental|TAS1440 + ATRA|TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
9731915|NCT04274894|Experimental|AndroGel|Participants will receive AndroGel 1.62% once daily
9731916|NCT04273425||Study cohort (Confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Those who receive a positive diagnosis will be followed up upon completion of first-line treatment, and questionnaire data and blood samples collected again."
9731917|NCT04273425||Control cohort (non-confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.~Samples from patients who receive a negative myeloma diagnosis will be used as negative controls."
9731918|NCT04263090|Experimental|Rigosertib + Nivolumab|Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients
9731919|NCT04260984|Active Comparator|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
9731920|NCT04260984|Active Comparator|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
9731921|NCT04258852|Experimental|Low Strength, High Strength|
9731922|NCT04258852|Experimental|High Strength, Low Strength|
9731923|NCT04258293||Patients|Patients on prolonged corticosteroid therapy (more than three months)
9731924|NCT04255381|Experimental|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Use Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system
9731925|NCT04254159|Experimental|Neuromuscular Electrical Stimulation Group|Asthma Education Aerobic Exercise Quadriceps Strengthening by superimposed NMES
9731926|NCT04254159|Active Comparator|Control Group|Asthma Education Aerobic Exercise Quadriceps Strengthening
9731927|NCT04250363|Experimental|M5717|Participants will receive single ascending oral dose of M5717 powder in capsule after DVI of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
9731928|NCT04250363|Placebo Comparator|Placebo|Participants will receive placebo matched to M5717 after DIV of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
9731929|NCT04248127|Experimental|Honey sweetened yogurt|1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.
9731930|NCT04248127|Placebo Comparator|Sugar sweetened yogurt|Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.
9731931|NCT04236141|Experimental|Polatuzumab Vedotin plus BR|
9731932|NCT04236141|Active Comparator|Placebo plus BR|
9731933|NCT04229836|Experimental|Tildrakizumab|Participants will receive subcutaneous (SC) injection of tildrakizumab 100 milligrams (mg).
9731934|NCT04229381|Experimental|Supportive Care (physical therapy, muscle relaxation)|Patients participate physical therapy sessions consisting of cardiovascular and resistance training exercises in person or online and also undergo progressive muscle relaxation sessions once weekly for up to 12 weeks.
9731935|NCT04227977|Experimental|Treatment|JuxtaFlow
9731936|NCT04226599|Experimental|Dissolve AVF Group|This group treated with Peripheral scoring drug balloon.Dissolve AVF
9731937|NCT04226599|Active Comparator|PTA Group|This group treated with plain balloon catheter.Armada 35
9731938|NCT04216563|Experimental|Treatment (asciminib)|Patients receive asciminib PO BID for up to 36 months while receiving standard of care dasatinib or nilotinib in the absence of disease progression or unacceptable toxicity. Patients may continue to receive asciminib after 36 months at the discretion of investigator.
9731939|NCT04214730|Experimental|Combination of NK with chemotherapy group|Patients will receive NK treatments combined with Chemotherapy.
9731940|NCT04214730|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
9731941|NCT04210557|Experimental|TMS to insula|"This study will recruit 30 clinical voice hearers (P+H+). They will complete two parallel forms of the conditioned hallucinations task (with different visual and auditory stimuli) on two occasions, separated by a week.~TMS and sham will be delivered in a randomized counterbalanced order. Hypothesis: Inhibiting the insula will decrease prior over-weighting. If this computational perturbation is responsible for conditioned hallucinations, then ameliorating it with TMS that increases insula engagement will decrease conditioned hallucination responses. Furthermore, the prior weighting parameter will be reduced following active TMS compared with sham."
9731942|NCT04210557|Experimental|TMS to cerebellum|This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.
9731943|NCT04210037|Experimental|APG-1252 160 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
9731944|NCT04210037|Experimental|APG-1252 240 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
9731945|NCT04210037|Experimental|APG-1252 80 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
9731946|NCT04203927|Active Comparator|Empagliflozin + insulin infusion|vascular measurements in overnight fasted state and during insulin infusion
9731947|NCT04203927|Active Comparator|Empagliflozin + mixed meal|vascular measurements in overnight fasted state and 2 hours after mixed meal 10kcal/kg body weight ( 55% Cho, 30%Fat, 20% Pro)
9731948|NCT04201431|Experimental|Group 1|Up to 12 volunteers in Group 1 will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at 1, 2 and 12-18 months prior to blood-stage CHMI 2-4 weeks after the third vaccination.
9731949|NCT04201431|Experimental|Group 2|If fewer than 8 volunteers complete the study in Group 1, then new volunteers will be recruited into Group 2, to make up a total of 10 to 12 volunteers who complete 3 vaccinations and CHMI between Groups 1 and 2. Group 2 volunteers will receive three doses of the PvDBPII 50ug/Matrix M1 50ug candidate vaccine at monthly intervals, prior to blood-stage CHMI 2-4 weeks after the third vaccination.
9731950|NCT04201431|Experimental|Group 3|Up to 6 volunteers from Group 1 will receive a fourth dose of PvDBPII 50ug/Matrix M1 50ug, at 5 months post the third dose, prior to a second CHMI 2-4 weeks later.
9731951|NCT04200066|Experimental|Experimental Arm|This arm will combine maprotiline with temozolomide and tamoxifen to determine the maximum tolerated dose.
9731952|NCT04194164|Experimental|Fluid intake app|Participants in this arm will use the fluid intake app to help them decrease interdialytic fluid intake. Participants will take a survey to assess the efficacy of the fluid app..
9731953|NCT04190082||Group Control|Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
9731954|NCT04190082||Group BIS|Group who maintain deep sedation using Bispectral Index (BIS) score.
9731955|NCT04185337|Experimental|Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)|Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.
9731956|NCT04183712|Experimental|target therapy with GEMOX|Target therapy
9731957|NCT04183712|Active Comparator|conventional chemotherapy|The patients wil receive conventional chemotherapy(GEMOX).
9731958|NCT04182763|Experimental|CoA-Z dose 1|6 months of CoA-Z at the highest assigned dose followed by 18 months of CoA-Z at dose 2
9731959|NCT04182763|Experimental|CoA-Z dose 2|6 months of CoA-Z at the medium assigned dose followed by 18 months of CoA-Z at dose 2
9731960|NCT04182763|Experimental|CoA-Z dose 3|6 months of CoA-Z at the lowest assigned dose followed by 18 months of CoA-Z at dose 2
9731961|NCT04182763|Placebo Comparator|Placebo|6 months of placebo, followed by 18 months of CoA-Z at dose 2 (medium dose)
9731962|NCT04182763|Experimental|Open-label arm|Up to 24 months of CoA-Z at dose 2
9731963|NCT04180813||Subjects with Diabetes Mellitus, Type 2|
9731964|NCT04177823|Experimental|Chinese participants with relapsed/refractory multiple myeloma|Participants will be administered belantamab mafodotin 2.5 mg/kg or 3.4 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle over 30 minutes. Participants will be treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.
9827900|NCT02472457|Placebo Comparator|Free Diet|No dietary restrictions
9827901|NCT02472457|Active Comparator|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
9827902|NCT02472522|Placebo Comparator|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
9827903|NCT02472522|Experimental|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
9827904|NCT02472652|Other|Abilify Maintena|Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month period to determine if there is any significant sexual functioning improvement.
9827905|NCT02472730|Experimental|Cap Assisted Colonoscopy|The distal attachment cap is affixed to the colonoscope before every colonoscopy in this arm.
9827906|NCT02472730|No Intervention|Standard Colonoscopy|Standard colonoscopy without the distal attachment cap is performed in this arm.
9827907|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
9827908|NCT02472795|Experimental|Cenerimod 0.5 mg (Part A)|Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
9827909|NCT02472795|Experimental|Cenerimod 1 mg (Part A)|Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
9827910|NCT02472795|Experimental|Cenerimod 2 mg (Part A)|Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
9827911|NCT02472795|Experimental|Cenerimod 4 mg (Part B)|Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
9827912|NCT02472795|Placebo Comparator|Matching placebo (Part A and B)|Capsules of matching placebo taken orally once daily for 12 weeks.
9827913|NCT02472847|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
10200401|NCT04249739|Experimental|CapeOx+Pembrolizumab(HER2 negative)|"<Cohort A>: HER2 negative patients CapeOx+Pembrolizumab therapy (N=78)~Cycle 1 CapeOX~Cycle 2 up to Cycle 8 CapeOX + pembrolizumab therapy~Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy~CapeOx + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~Cycle: Day 1 through Day 21)"
10200402|NCT04249739|Experimental|Cape/Cis+Trastuzumab+Pembrolizumab (HER2 positive )|"Cape/Cis+Trastuzumab+Pembrolizumab therapy (N=15)~Cycle 1 Capecitabine + cisplatin (Cape/Cis)~Cycle 2 up to Cycle 8 Cape/Cis + Trastuzumab + pembrolizumab therapy~Cycle 9 up to Cycle 35 Capecitabine + Trastuzumab + pembrolizumab therapy~Cape/Cis + Trastuzumab + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~Cycle: Day 1 through Day 21)"
9827914|NCT02472847|Active Comparator|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
9827915|NCT02472886|Experimental|LDV/SOF|Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
9827916|NCT02472886|Experimental|LDV/SOF Coinfected with HIV-1|Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
9827917|NCT02472886|Experimental|LDV/SOF+RBV Retreatment|Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
9827918|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
9827919|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
9827920|NCT02473250|Experimental|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
9827921|NCT02473289|Experimental|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
9827922|NCT02473289|Placebo Comparator|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
9827923|NCT02473367|Experimental|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
9827924|NCT02473393|Experimental|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
10200403|NCT04237116|Experimental|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
10200404|NCT04237116|Placebo Comparator|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
9731965|NCT04177797|Experimental|Toripalimb|Single arm, non randomized, open label study.The patients will receive Toripalimb concurrently caboplatin and paclitaxel treatment.
9731966|NCT04171167|Active Comparator|Frequently treated acute rhino sinusitis|Does not meet the European position paper criteria of CRS: asymptomatic periods in between and no objective findings when entering the study.
9731967|NCT04171167|Active Comparator|CRSsNP|Meets the European position paper criteria of CRS. Zinreich modification of Lund-Mackey scoringing: Opacification score < 21 and obstruction score 0-8. No visible nasal polyps in endoscopy
9731968|NCT04171167|Active Comparator|Severe CRSsNP and CRSwNP|Meets the European position paper criteria of CRS and not included in the first two groups.
9731969|NCT04171167|No Intervention|Healthy volunteers|No nasal symptoms or complaints. No interventions done.
9731970|NCT04160546|Experimental|Ponatinib plus ASA treatment|Patients will be treated with ponatinib 15 mg/day plus 100 mg/day ASA for 104 weeks. After that, ponatinib and ASA will be stopped.
9731971|NCT04159688|Experimental|Alcohol Challenge|Alcohol Challenge, I.V. infusion, 60 mg/dL in 6% saline (v/v), Given once
9731972|NCT04158648|Experimental|Emicizumab|Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.
9731973|NCT04155749|Experimental|ARM 1|Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma
9731974|NCT04155749|Experimental|Arm 2|Phase 1 Study of Bivalent BCMA-Specific Adapter (SPRX001) and Universal CAR-Modified T cell (ARC-T Cells) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9731975|NCT04155541||VIZIMPRO(dacomitinib hydrate)|Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)
9781337|NCT01146795|Experimental|Carboplatin, Paclitaxel, and Bevacizumab|"Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab.~After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill all criteria to be considered eligible for surgical exploration: 1) ≥50% reduction in pretreatment cancer antigen 125 (CA-125) and 2) No medical contraindications to surgery.~After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4."
9781338|NCT01146808|Experimental|ADV plus hepatitis B vaccination|Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
9781339|NCT01146834|Experimental|Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
9781340|NCT01146834|Experimental|Arm B: VELCADE & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection
9781341|NCT01146834|Experimental|Arm C: CYCLOPHOSPHAMIDE & G-CSF|High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
9781342|NCT01146834|Experimental|Arm D: PLERIXAFOR & G-CSF|G-CSF is given for ten (+/- two) consecutive days starting on day 1 at a dose of 10 micrograms/kg/day. Plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5. Both G-CSF and plerixafor are continued daily until collection is complete. Pheresis will commence for everyone on Day 5 regardless of ANC status.
9781343|NCT01146834|Experimental|Arm E: PLERIXAFOR, VELCADE, & G-CSF|"Bortezomib at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- wo) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day.~Plerixafor is given on day 12, approximately 11 hours prior to stem cell collection attempt and is continued daily until collection is complete. Pheresis will commence for everyone on Day 13 regardless of ANC status."
9781344|NCT01146860|Experimental|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
9781345|NCT01146860|Placebo Comparator|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days
9785827|NCT01260688|Experimental|Arm I|Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9731976|NCT04141774|Active Comparator|Passive FES|Subjects randomized to this control group will be asked to participate in a passive FES intervention or non-EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, and functional electric stimulation (FES) treatment.
9731977|NCT04141774|Experimental|Active FES|Subjects randomized to this experimental group will be asked to complete the active FES intervention which include EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, functional electric stimulation (FES) treatment, and EEG.
9731978|NCT04134390|Experimental|Cabozantinib|Cabozantinib 40 mg p.o. once daily in 28-day cycles.
9731979|NCT04134000|Experimental|Atezolizumab + BCG|"Ten patient will be enrolled in first cohort, starting on level 0 (DL 0) receiving BCG 1 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w).~The next level of dose in case is necessary is BCG 1/2 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w)"
9731980|NCT04131647|Active Comparator|Weight Maintenance|Heart Healthy nutrition, walking, resistance band exercise
9731981|NCT04131647|Experimental|Weight Maintenance + Intermittent Fasting|Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
9731982|NCT04127838|Experimental|Low Vision Occupational Therapy|The anticipated low vision occupational therapy intervention strategy includes training participants to compensate for their vision more effectively for increased participation in ADLs and IADLs.
9731983|NCT04124341|Experimental|Epidural Prefrontal Cortical Stimulation (EpCS)|Stereotactically implanted bilateral EpCS
9731984|NCT04116671|Experimental|Neuromechanical Gait Assist|All participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance.
9731985|NCT04113759|Placebo Comparator|Control Group|The control group will receive sham BFR, in which a non-occlusive pressure is applied with the cuff. The exercises performed will be identical to the BFR group.
9731986|NCT04113759|Experimental|BFR Postoperative Rehabilitation|The experimental group will receive BFR postoperative rehabilitation, which will involve performing a series of blood flow restriction exercises identical to the control group.
9731987|NCT04109079|Experimental|No axillary treatment|Patients in this arm will not receive axillary treatment (axillary lymph node dissection or axillary radiotherapy). Supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
9731988|NCT04109079|Active Comparator|Axillary treatment|Patients in this arm will receive axillary treatment. Axillary treatment can be axillary lymph node dissection or axillary radiotherapy.
9731989|NCT04100577|Experimental|TNT PISP intervention|Participants in TNT PISP intervention group will come to once monthly educational support group sessions and will be additionally enrolled in the community based doula program where they will receive 1 on 1 doula and lactation support throughout their pregnancy, delivery, and postpartum period. They will receive prenatal care clinical visits on their own with their prenatal care provider. In phase 2 of the study, participants will be offered on site prenatal care once per month.
9731990|NCT04100577|No Intervention|Control|Participants in control group will have no enhanced prenatal care support. They will attend visits on their own with their prenatal care provider and participation in this research study will not interfere with the prenatal care.
9731991|NCT04095143||New onset of stage ≥2 acute kidney injury|"Either:~A ≥ 2-fold increase in serum creatinine OR~A serum creatinine ≥ 354 μmol/L with evidence of a minimum increase of 27 μmol/L OR~Urine output < 6.0 mL/kg over the preceding 12 hours OR~Initiation of RRT for severe acute kidney injury less than 72 hours before recruitment"
9731992|NCT04094207|Placebo Comparator|Control group|Equivalent Placebo will be given
9731993|NCT04094207|Experimental|Pentoxifylline group|Pentoxifylline will be given orally at 800 mg a day for 8 weeks
9785828|NCT01260688|Experimental|Arm II|Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9731994|NCT04086030|Sham Comparator|Sham Postoperative Rehabilitation|Patients in this group will complete the standardized postoperative rehabilitation program with sham BFR, which is pressure of 20 mmHG. Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set. The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
9731995|NCT04086030|Experimental|BFR Postoperative Rehabilitation|Assigned intervention of BFR where exercises are performed with BFR at 80% limb occlusion pressure (LOP). Patients in this group will undergo blood flow restriction (BFR) training during their postoperative rehabilitation program (use an inflatable cuff that prevents blood flow from flowing out of the leg while patients perform physical therapy exercises). Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set.16 The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
9731996|NCT04081779|Active Comparator|Arm I (patient-generated SCP)|Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).
9731997|NCT04081779|Experimental|Arm II (patient-generated SCP, educational counseling)|Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.
9731998|NCT04080544|Experimental|Follow up DLBS participants|Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
10200405|NCT04234464|Experimental|A/B - Treatment with BDA MDI 160/180 followed by treatment with Placebo MDI|Subjects randomized to receive a single dose of BDA MDI 160/180 in treatment period 1, and a single dose of Placebo MDI in treatment period 2.
10200406|NCT04234464|Experimental|B/A - Treatment with Placebo MDI followed by treatment with BDA MDI 160/180|Subjects randomized to receive a single dose of Placebo MDI in treatment period 1, and a single dose of BDA MDI 160/180 in treatment period 2.
10200407|NCT04234334|Experimental|Egg intake|Consumption of 2 eggs with spinach daily for breakfast for 4 weeks
10200408|NCT04234334|Experimental|Egg Subsitute|Consumption of 2 egg substitutes daily for breakfast for 4 weeks
9732003|NCT04074616|Experimental|High Dose|
9732004|NCT04074616|Other|Control|Low dose TTNS
9732005|NCT04072783|Other|Patients with craniosynostosis|Patients with craniosynostosis will undergo pre - and post-operative imaging studies. The surgery will be performed for these patients as standard of care. They will also be tested fro neurodevelopment.
9732006|NCT04071470|Active Comparator|Standard of Care|Standard of care for pregnant women at risk of HIV seroconversion includes couples counseling and access to PrEP (women) and ART (men)
9732007|NCT04071470|Experimental|Storytelling Intervention|Participants in this group will receive the same services as those in the SOC but will also be provided three storytelling sessions for themselves and their families as a way to educate and de-stigmatize PrEP services.
9732008|NCT04069819|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 6 week plus placebo tablet twice daily for 6 weeks
9732009|NCT04069819|Experimental|Cilostazol group|Escitalopram 20 mg tablet once daily for 6 week plus Cilostazol 50mg tablet twice daily for 6 weeks
9732010|NCT04066374|Experimental|Treatment Arm|Intrathoracic placement of neurostimulation device
9732011|NCT04063657|Active Comparator|External fixation|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in external fixator until the patient is deemed clinically appropriate for definitive surgical fixation.
9732012|NCT04063657|Active Comparator|Splinting|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in a short leg splint until the patient is deemed clinically appropriate for definitive surgical fixation.
9732013|NCT04058795|Experimental|Cancer Distress Coach (CaDC)|Participants in this group will get the mHealth CaDC app, which will give them tools based on cognitive behavioral therapy principles to manage their stress.
9732014|NCT04058795|Experimental|CaDC and mCoaching|Participants in this group will get both the CaDC app and weekly clinician support.
9732015|NCT04058795|Experimental|mCBT|Participants in this group will get 8-sessions with a therapist to receive cognitive behavioral therapy (CBT).
9732016|NCT04058795|No Intervention|Control|Participants in this group can use mental health services commonly available to all cancer patients at their local medical facility but will not receive access to the CaDC app.
9732017|NCT04057807|Experimental|Patients receiving endotoxin|The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
9732018|NCT04057807|No Intervention|control|
9785829|NCT01260701|Experimental|Treatment (CLOSED TO ACCRUAL 05/01/13)|Patients receive Akt inhibitor MK2206 PO every other day on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10200409|NCT04230824|Active Comparator|Pre-workout plus and Protein recovery plus|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
10200410|NCT04230824|Placebo Comparator|Placebo|Non-caloric powder mixed with water and consumed within 30 minutes prior to exercise and within 15 minutes after exercise
10200411|NCT04230824|No Intervention|Control|This arm will receive no intervention
10200412|NCT04230434|Experimental|Safety Plan Intervention|The Safety Plan Intervention (SPI) performed in ED or in ambulatory appointment
10200413|NCT04228965|Other|Co-Use Group|Cannabis and tobacco co-use group.
10200414|NCT04228965|Active Comparator|Tobacco Only Group|Tobacco only group.
9732019|NCT04051216|Experimental|Supportive Care|Caregivers receive the Roadmap information system loaded on an Apple iPad® for use during the inpatient hospitalization of CART therapy. The Roadmap information system consists of 5 modules personalized to the CART patient: laboratory studies, medications, clinical trial enrollment, healthcare providers, and criteria for discharge. Patients wear an activity monitoring device on days 0-100. Patients wear the device as long as they can each day to monitor physical activity level, sleep/wake patterns, skin temperature, heart rate and respiratory rate.
9732020|NCT04047810|Experimental|Subjects with Advanced Chronic Obstructive Pulmonary Disease|Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)
9732021|NCT04042623|Experimental|Treatment with AVB-S6-500|Patients will receive AVB-S6-500 by intravenous infusion every 2 weeks for total of 6 doses.
9732022|NCT04038567|Experimental|High dose / therapist attention / introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and an introductory call from a therapist.
9732023|NCT04038567|Experimental|High dose / therapist attention / no introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and no introductory call from a therapist.
9732024|NCT04038567|Experimental|High dose / app attention / introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
9732025|NCT04038567|Experimental|High dose / app attention / no introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
9732026|NCT04038567|Experimental|Standard dose / therapist attention / introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and an introductory call from a therapist.
9732027|NCT04038567|Experimental|Standard dose / therapist attention / no introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and no introductory call from a therapist.
9732028|NCT04038567|Experimental|Standard dose / app attention / introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
9732029|NCT04038567|Experimental|Standard dose / app attention / no introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
9732030|NCT04036058|Experimental|Intervention|Enact universal gloving practices
9732031|NCT04036058|No Intervention|Control|Continue standard of care gloving practices
9732032|NCT04035590|Active Comparator|With drain|Patients undergo mastectomy with flap fixation and low vacuum drainage.
9732033|NCT04035590|Experimental|No drain|Patients undergo mastectomy with flap fixation and low vacuum drainage is omitted.
9732034|NCT04028284|Active Comparator|Group 1|In Group 1 (control), the staff anesthesiologist will follow the traditional technique for US-guided thoracic epidural insertion. Briefly, the anesthesiologist will use the US to identify and mark the appropriate spot for placement of the thoracic epidural catheter. The US probe is then placed at rest and the anesthesiologist will proceed with thoracic epidural needle insertion following standard techniques.
9732035|NCT04028284|Active Comparator|Group 2|In Group 2 (intervention), the staff anesthesiologist will use the HoloLens tool to assist with the traditional technique as described above for Group 1. In combination with the US, a hologram image of the trajectory towards the epidural space will be generated, thereby mitigating the need to walk off the lamina. The holographic system will mark the appropriate spot for placement of the thoracic epidural catheter. Then, the needle will be inserted following the holographic trajectory overlaid on the patient's back.
9732036|NCT04024059|Experimental|Buprenorphine Adherence and Opiate Abstinence|Participants will receive financial incentives for buprenorphine use and opiate abstinence.
9732037|NCT04024059|Experimental|Buprenorphine Adherence Only|Participants will receive financial incentives for buprenorphine use.
9732038|NCT04024059|No Intervention|Control|Participants will not receive any intervention.
9732039|NCT04020887|No Intervention|Observation Phase|In the first three months of this proof-of-concept study, a telemedicine center for the PACU will monitor patients assigned to PACU bays. Both telemedicine center clinicians and nurses caring for patients in these PACU bays will independently record information on patient physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness (based on the modified Aldrete scale). During this phase of the study, clinicians in the telemedicine center will not communicate with clinicians in the PACU (nurses or physicians), unless there was a patient safety event.
9732040|NCT04020887|Experimental|Interaction Phase|In the three months following the observation phase, clinicians in the telemedicine center will interact with clinicians and patients in the two designated PACU bays using audio-visual technology. The clinicians in the telemedicine center will continue to document information on physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness.
9732041|NCT04017468|Active Comparator|Treatment Arm|The powdered vancomycin will be placed subcutaneously over the closed muscle fascia (suprafascially) at the end of the surgery during wound closure.
9732042|NCT04017468|No Intervention|Control Arm|The control group receiving only a standard preoperative antimicrobial prophylaxis administered intravenously.
9732043|NCT04017039|No Intervention|Phase 1|Phase I is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 6.5 hr/night (short sleep)
9732044|NCT04017039|Experimental|Phase 2|Phase II is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep less than 6.5 hr/night (Specific Aims 3).
9732045|NCT04016415|Experimental|Mindfulness Based Stress Reduction|
9732046|NCT04016415|Active Comparator|Stress Management Education|
9732047|NCT04015739|Experimental|Bevacizumab, Olaparib and Durvalumab|Single arm study
9732048|NCT04008134|No Intervention|Standard recommendation (ORS)|Participants received the standard recommendation on oral rehydration solution use
9732049|NCT04008134|Experimental|mHealth with no home visits|Participants received the health facility delivery of CHoBI7, plus bi-weekly mHealth (voice and text) reminders for 12 months
9732050|NCT04008134|Experimental|mHealth with home visits|Participants received the health facility delivery of CHoBI7, plus two home visits and bi-weekly mHealth (voice and text) reminders for 12 months
9732051|NCT03994484|Experimental|HA121-28 tables|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
9732052|NCT03992950|Experimental|Cricoid pressure|Cricoid pressure is applied in the anesthetized state and during video laryngoscopy
9732053|NCT03992950|Experimental|Paratracheal pressure|Paratracheal pressure is applied in the anesthetized state and during video laryngoscopy
9732054|NCT03990792|Experimental|e-predictD intervention|In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).
9732055|NCT03990792|Active Comparator|m-Health control|In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.
9732056|NCT03985878|Experimental|Eteplirsen|Participants will receive eteplirsen via IV infusions, once weekly, for up to 284 weeks.
9732057|NCT03978728||ECMO patients|Patients with ECMO support
9732058|NCT03974503|Experimental|Exposure, Relaxation, and Rescripting Therapy (ERRT)|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately one hour per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, sleep behavior modification, Progressive Muscle Relaxation, diaphragmatic breathing, exposure to the trauma-nightmare, rescription, and treatment maintenance planning.
9732059|NCT03974503|Active Comparator|Sleep and Nightmare Management|This treatment protocol has amounts of therapist contact, handouts, and homework between sessions equivalent to those in ERRT. The protocol contains psychoeducation about sleep disturbances and trauma-related nightmares, including their distressing nature, chronicity, and impact on sleep and daytime functioning. Additionally, basic sleep behavior modification are presented. No nightmare content or rescripting will be explicitly discussed, and the diaphragmatic breathing techniques will be omitted from this protocol.
9732060|NCT03972969|Experimental|In-person exercise group|facility-based structured exercise program
9732061|NCT03972969|Experimental|Remote exercise group|home-based structured exercise program
9732062|NCT03972969|Active Comparator|Control group|health education
9732063|NCT03971162|Experimental|Group A|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 3 months. Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
9732064|NCT03971162|Experimental|Group B|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 6 months.Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
9732065|NCT03969680|Experimental|BMSCs plus PRP group|Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
9732066|NCT03969680|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
9732067|NCT03967626|Experimental|Cerebral temperature target|CCT performed by the external cooling device with cerebral temperature target, measured by a intracranial sensor (coupled to the intracranial pressure device)
9785830|NCT01260883|Experimental|ketorolac 1 mg/kg|ketorolac 1 mg/kg iv given by 10 min infusion
9982443|NCT05238155||Orthotopic Liver Transplantation recipients prior to protocol implementation date|Orthotopic Liver Transplantation recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid.
9732068|NCT03967626|Active Comparator|Systemic temperature target|CCT performed by the external cooling device with systemic temperature target, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).
9732069|NCT03959696|Active Comparator|Notification only arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening.
9732070|NCT03959696|Experimental|Training and Notification arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening and will complete a two-hour shared decision making communication skills training course that includes case studies, interactive exercises, and lecture content.
9732071|NCT03956940|Experimental|Intplex test|In vitro diagnostic device
9732072|NCT03952299|Active Comparator|Oral administration|"Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. The current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.~Post-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital."
9732073|NCT03952299|Experimental|Transdermal administration|Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed.
9732074|NCT03952078|Experimental|CPI-818 Dose Escalation|Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for >2 months or if dose determined to be unsafe.
9732075|NCT03952078|Experimental|CPI-818 Dose Expansion phase|"Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.~CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for > 2 months."
9732076|NCT03948763|Experimental|V941 Monotherapy|V941(mRNA-5671/V941) administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles
9732077|NCT03948763|Experimental|V941 + Pembrolizumab|V941(mRNA-5671/V941) administered IM Q3W for 9 cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles
9732078|NCT03948464|Experimental|Slow release oral morphine (SROM)|Daily witnessed ingestion of SROM (24-hour formulation) for 24 weeks as per provincial and national guidelines for opioid use disorder.
9732079|NCT03948464|Active Comparator|Methadone|Daily witnessed ingestion of methadone for 24 weeks as per provincial and national guidelines for opioid use disorder.
9732080|NCT03945565|Active Comparator|FiO2 0.3|Patients allocated to this group are going to receiving FiO2 of 0.3 during surgery
9732081|NCT03945565|Active Comparator|FiO2 0.8|Patients allocated to this group are going to receiving FiO2 of 0.8 during surgery
9732082|NCT03945305|Experimental|RIC+ antihypertensive treatment|Baseline blood pressure and heart rate are measured 2 times a day for 3 days. And then the blood pressure and heart rate are measured before and after remote ischemic conditioning. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 30±2 days.
9732083|NCT03941730|Experimental|Treatment (estradiol)|Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9732084|NCT03933384|Active Comparator|Tenofovir alafenamide group|Study subjects will receive tenofovir alafenamide 25 mg/tab once daily for 3 years (144 weeks).
9732085|NCT03933384|Active Comparator|Entecavir group|Study subjects will receive entecavir 0.5 mg/tab once daily for 3 years (144 weeks).
9732086|NCT03928587|Experimental|Active|A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
9732087|NCT03928587|Placebo Comparator|Placebo|An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
9732088|NCT03920826|Experimental|tACS stimulation group|NEXALIN ADI transcranial alternating current stimulator
9732089|NCT03920826|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
9732092|NCT03913130|Experimental|Drug QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
9732093|NCT03913039||transperineal protocol|"Transperineal biopsy approach with avoidance of rectal flora~MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~Multi-antibiotic prophylaxis~Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
9732094|NCT03913039||Traditional biopsy|"Transrectal approach~Standard 12-core template~Surgeon-specific antibiotic prophylaxis~Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
9732095|NCT03911388|Experimental|HSV G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
9732096|NCT03907969|Experimental|Core Module: AZD7648 Monotherapy|AZD7648 will be administered orally on an empty stomach
9732097|NCT03907969|Experimental|Combination Module 1: AZD7648 + PLD|AZD7648 will be administered in combination with Pegylated liposomal doxorubicin (PLD)
9732098|NCT03901469|Experimental|Experimental: ZEN003694 in Combination with Talazoparib|ZEN003694 will be administered orally once daily with Talazoparib orally once daily in 28-day cycles, enrolling TNBC patients. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2
9732099|NCT03899987|Experimental|Arm I (aspirin, interferon alpha, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7. Patients also receive recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV over 2 hours on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24..
9732100|NCT03899987|Experimental|Arm II (aspirin, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7 and rintatolimod IV over 2 hours on days 1-3,and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24.
9732101|NCT03899987|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy about 4 weeks after enrollment.
9732102|NCT03892993|Experimental|Supportive care (decision aid)|Participants use decision aid and complete questionnaires.
9732103|NCT03889067|Experimental|Combination of Challenge Agents|"Wild-Type Quailes Strain Salmonella Typhi: Quailes Typhoid toxin knock out strain in a 1:1 ratio at a dose of 1-5 x 10^4CFU~All participants will receive the same intervention in a given group for challenge (dose reduction may occur for later participants depending on the results from the first six participants)"
9732104|NCT03887377|Experimental|Breast receiving botulinum toxin|"Following reconstruction one horizontal incisional wound will be selected to receive a series of botulinum toxin injections along the wound.~Injection abobotulinum toxin at time of surgery, single injection time with 30 gauge needle superficially, dosage determined by length of scar 5-15U per cm"
9732105|NCT03887377|Placebo Comparator|Breast receiving placebo|The other breast will be injected with bacteriostatic normal saline in a similar fashion to the other breast. The injector will be blinded to the contents of the syringe.
9785831|NCT01260883|Active Comparator|ketorolac 0.5 mg/kg|ketorolac 0.5 mg/kg iv given by 10 min infusion
9732106|NCT03884712|Experimental|CalmiGo Recipients|This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
9732107|NCT03882047|Experimental|Mometasone furoate nasal spray|Participants receive 200 mcg of mometasone furoate nasal spray and fluticasone propionate placebo matching nasal spray once daily.
9732108|NCT03882047|Active Comparator|Fluticasone propionate nasal spray|Participants receive 200 mcg of fluticasone propionate nasal spray and mometasone furoate placebo matching nasal spray once daily.
9732109|NCT03882047|Placebo Comparator|Placebo nasal spray|Participants receive mometasone furoate placebo matching nasal spray and fluticasone propionate placebo matching nasal spray once daily.
9732110|NCT03879772|Experimental|MFNS 25 mcg QD|Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
9732111|NCT03879772|Experimental|MFNS 100 mcg QD|Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
9732112|NCT03879772|Experimental|MFNS 200 mcg QD|Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
9732113|NCT03879772|Active Comparator|BDP 84 mcg BID|Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
9732114|NCT03879772|Placebo Comparator|Placebo|Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
9732115|NCT03873402|Experimental|Nivolumab + ipilimumab|
9732116|NCT03873402|Experimental|Nivolumab + ipilimumab placebo|
9732117|NCT03871465|Experimental|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
9732118|NCT03871465|Experimental|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
9785832|NCT01260883|Sham Comparator|placebo|placebo group received D5W 10 min infusion
9785833|NCT01260896|Experimental|Investigational Test Product|150 mg Venlafaxine Hydrochloride Extended-Release Capsules
9732119|NCT03871465|Experimental|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
9732120|NCT03861559|Experimental|mometasone furoate nasal spray|Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
9732121|NCT03861559|Placebo Comparator|placebo nasal spray|Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.
9732122|NCT03860233|Experimental|Visit 1 Randomization|At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
9732123|NCT03860233|Experimental|Visit 2 Crossover Randomization|At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
9732124|NCT03855228|Experimental|MFNS 200 µg + Loratadine 10 mg|Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
9732125|NCT03855228|Active Comparator|MFNS 200 µg|Daily administration of 200 µg of MFNS plus oral placebo tablet.
9732126|NCT03855228|Active Comparator|Loratadine 10 mg|Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
9732127|NCT03855228|Placebo Comparator|Placebo|Daily administration of placebo nasal spray plus oral placebo tablet.
9732128|NCT03855189|Experimental|Mometasone Furoate (MF)|Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
9732129|NCT03855189|Active Comparator|Beclomethasone Dipropionate (BDP)|Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
9732130|NCT03855189|Placebo Comparator|Placebo|Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
9732131|NCT03845543|Experimental|Luminor-14 paclitaxel eluting balloon|Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
9732132|NCT03842670|Active Comparator|Cognitive-Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
9732133|NCT03842670|Active Comparator|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
9732134|NCT03840200|Experimental|Ipatasertib + Rucaparib|A Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer. There will be a 7-day run-in period with ipatasertib alone prior to Cycle 1, Day 1. After the completion of the ipatasertib run-in period, participants will begin Cycle 1, Day 1 of the ipatasertib and rucaparib combination treatment. Each cycle has 28 days. Participants will be split into 4 cohorts: Dose Level 1 group - 300 mg ipatasertib once daily (QD) + 400 mg rucaparib twice daily (BID), Dose Level 2a: 300 mg ipatasertib QD + 600 mg rucaparib BID, Dose Level 2b: 400 mg ipatasertib QD + 400 mg rucaparib BID, Dose Level 3: 400 mg ipatasertib QD + 600 mg rucaparib BID
9732135|NCT03840200|Experimental|Part 2: Ipatasertib + Rucaparib|A Dose-Expansion Phase (Part 2) - The recommended dose identified in Part 1 (highest dose level of ipatasertib and rucaparib with an acceptable safety profile and less than one-third of participants experience a dose limiting toxicity) will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
9785834|NCT01260896|Active Comparator|Reference Listed Drug|150 mg Effexor® XR Extended-Release Capsules
9732136|NCT03835702|No Intervention|Usual care with non-sleep provider|Participant will continue the follow up for sleep apnea with the non-sleep provider
9827925|NCT02473393|Experimental|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
9827926|NCT02473393|Experimental|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
9827927|NCT02473393|Experimental|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
9827928|NCT02473471|Experimental|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
9827929|NCT02473471|No Intervention|control side|No intervention in the other side of maxilla (control side)
9732137|NCT03835702|Experimental|SAM Clinic Intervention|Participants will attend a sleep apnea management group based intervention to improve PAP adherence.
9827930|NCT02473510|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
9827931|NCT02473510|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
9827932|NCT02473614|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
9732138|NCT03833180|Experimental|Zilovertamab vedotin Schedule 1: Q1/3W|Participants will be administered escalating doses of zilovertamab vedotin at 0.50, 1.00, 1.50, 2.25, 2.50, 2.75, and 3.00 mg/kg IV on Day 1 of repeated 21-day cycles (Q1/3W).
9732139|NCT03833180|Experimental|Zilovertamab vedotin Schedule 2: Q2/3W|Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1 and 8 of repeated 21-day cycles (Q2/3W).
9732140|NCT03833180|Experimental|Zilovertamab vedotin Schedule 3: Q3/4W|Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1, 8, and 15 of repeated 21-day cycles (Q3/4W).
9732141|NCT03830918|Experimental|Arm A (temozolomide, niraparib, atezolizumab)|Patients receive temozolomide PO QD on days 1-5 and niraparib PO QD on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
9732142|NCT03830918|Active Comparator|Arm B (atezolizumab)|Patients receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
9732143|NCT03828994|Experimental|TECH-PN|Participants receive community health nurse visits, text-messaging support, additional testing and field based visits with a nurse practitioner.
9732144|NCT03828994|No Intervention|TECH-N|Participants receive enhanced standard of care with community health nurse visits and text-messaging support.
9732145|NCT03828292|Experimental|Part 1: Belantamab mafodotin Monotherapy|
9732146|NCT03828292|Experimental|Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone|
9732147|NCT03828292|Experimental|Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone|
9732148|NCT03810651|Other|Renal tumors|Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
9732150|NCT03787303|Experimental|Triiodothyronine (T3)|Following discontinuation of L-thyroxine (T4), triiodothyronine (T3) will be initiated at a 3:1 ratio. The dose will be titrated by the investigator to maintain levels of free T4 < 50% of normal range while maintaining a euthyroid state. Triiodothyronine (T3) tablets for oral administration will be prescribed once or twice daily depending on the total dose. Treatment duration will be approximately 9 months during which time the subjects will continue to be treated and monitored as usual for their metastatic breast cancer. During the study period and at the conclusion of the study period, there will be continuous evaluations of the disease status and thyroid status with the option of resuming the original thyroid replacement or continuation of the triiodothyronine (T3).
9732151|NCT03786692|Experimental|Arm A|Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab
9732152|NCT03786692|Active Comparator|Arm B|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab
9732153|NCT03784625|Experimental|therapeutic dose activity (level 1)|[131]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)
9732154|NCT03784625|Experimental|therapeutic dose activity (level 2)|[131]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)
9732155|NCT03784625|Experimental|therapeutic dose activity (level 3)|[131]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)
9732156|NCT03784625|Experimental|therapeutic dose activity (level 4)|[131]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)
9781346|NCT01146873|Active Comparator|Group 1: Lopinavir/ritonavir (LPV/r)|Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.
9781347|NCT01146873|Experimental|Group 2: Efavirenz (EFV)|Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.
9781348|NCT01146873|Active Comparator|Group D: Stavudine (D4T)|Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily
9781349|NCT01146873|Experimental|Group A: Abacavir (ABC)|Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.
9781350|NCT01146912|Experimental|Text message vaccine reminders|Receipt of text message vaccine reminders
9781351|NCT01146912|Active Comparator|automated phone call from clinic|Receipt of automated phone call from clinic
9781352|NCT01146951|Experimental|Rufinamide (E2080)|
9781353|NCT01146951|Placebo Comparator|Placebo|
9781354|NCT01147055|Experimental|1|There should be at least 14-day washout period between treatment A and B.
9785328|NCT01249131|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
9732157|NCT03776643|Experimental|ILT-101 (ld-IL2)|Subcutaneous injections of ILT-101
9732158|NCT03776643|Placebo Comparator|placebo|Subcutaneous injections of placebo
9732159|NCT03771469|Experimental|Questionnaires and sleep studies|Caregivers of patients meeting eligibility criteria will be invited to participate. If they agree to participate, baseline SRBD-PSQ, OSA-18, and PedsQL questionnaires along with written informed consent forms will be mailed to them along with their standard scheduling paperwork. Caregivers will be asked to review the consent form and complete the questionnaires and bring the paperwork to clinic on the day of their visit. Sleep study testing will also be ordered prior to their visit so that it can be scheduled within a month of the initial clinic visit and again three months later.
10200415|NCT04211675|Other|Treatment|"The planned therapy will involve 6 cycles of 21 days each consisting of irinotecan, temozolomide, dinutuximab, and sargramostim (Cycle 1), or irinotecan, temozolomide, dinutuximab, sargramostim, and natural killer (NK) cells (Cycles 2-6).~Treatment cycles will be repeated every 21 days based upon disease response and toxicity criteria. Tumor response will be assessed after Cycles 2, 4 and 6. Patients who do not experience dose-limiting toxicities and achieve complete response, partial response or stable disease may continue to receive the assigned therapy for as many cycles as are possible with the number of NK cells manufactured.~Patients will be assigned an initial NK cell dose level at time of registration. If the NK cell dose is tolerated, intra-patient dose escalation will occur at cycle 4 and cycle 6."
10200416|NCT04208815|Experimental|MPL-rich dairy beverage|Daily consumption of 100 g of dairy powder containing 5.3 g MPL for 4 weeks
10200417|NCT04208815|Placebo Comparator|Control dairy beverage|Daily consumption of 100 g of dairy powder containing 0.3 g MPL for 4 weeks
10200418|NCT04204122|Experimental|Arm 1: Eye treated with Vigamox|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
10200419|NCT04204122|Placebo Comparator|Arm 2: Eye treated with placebo|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
10200420|NCT04202705|Experimental|SYD1875|5T4-targeting Antibody-Drug Conjugate
10200421|NCT04198805|Active Comparator|Vitamin E (1000 mg)|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months.
10200422|NCT04198805|Active Comparator|DHA EE (1.89 g)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months).
9732160|NCT03771261|Placebo Comparator|WL-Control|Weight loss intervention (WL-Control; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein~0.8g/g/d.
9732161|NCT03771261|Active Comparator|WL-Protein|High-protein weight loss intervention (WL-Protein; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of > 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from eggs or egg protein powder that will be provided to WL-Protein participants.
9732162|NCT03769285|Experimental|Nicotinamide|
9732163|NCT03769285|Placebo Comparator|Placebo|
9732164|NCT03768492|Experimental|Caffeine Based Cream|caffeine based cream during and for 4 weeks following radiation
9732165|NCT03768492|Placebo Comparator|Placebo|placebo cream during and for 4 weeks following radiation
9732166|NCT03765463|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 4 two-hour sessions in an intensive format.
9732167|NCT03764631||subjects with Type 2 Diabetes mellitus|
9732168|NCT03764072|Placebo Comparator|Placebo|Participants received placebo matched to VX-150 for 2 days.
9732169|NCT03764072|Experimental|VX-150 - Dose Level 1|Participants received VX-150 1500 milligrams (mg) as first dose, followed by VX-150 750 mg every 12 hours (q12h) for 2 days.
9732170|NCT03764072|Experimental|VX-150 - Dose Level 2|Participants received VX-150 1000 mg once daily (qd) for 2 days.
9732171|NCT03764072|Experimental|VX-150 - Dose Level 3|Participants received VX-150 500 mg q12h for 2 days.
9732172|NCT03764072|Experimental|VX-150 - Dose Level 4|Participants received VX-150 500 mg as first dose, followed by VX-150 250 mg q12h for 2 days.
9732173|NCT03764072|Experimental|VX-150 - Dose Level 5|Participants received VX-150 250 mg qd for 2 days.
9732174|NCT03761030|Experimental|L-DOPA Arm|Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa (37.5 mg carbidopa/150mg levodopa twice daily and placebo once daily) for one week, and finally increase to 112.5mg carbidopa/450mg levodopa (37.5 mg carbidopa/150mg levodopa three times daily and no placebo) for the final six weeks. Each subject assigned to the L-DOPA arm will be titrated to 450mg L-DOPA unless they cannot tolerate higher doses, in which case subjects will have their dosage reduced to the maximum tolerable dose
9732175|NCT03761030|Placebo Comparator|Placebo Arm|Subjects assigned to the placebo arm will take placebo oral tablet three times daily throughout the study.
9732176|NCT03754114|Active Comparator|ICP only|ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
9732177|NCT03754114|Active Comparator|ICP + PbtO2|ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
9781355|NCT01147068|Experimental|PanBlok 135µg No Adjuvant|135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
9781356|NCT01147068|Experimental|PanBlok 45µg No Adjuvant|45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
9785835|NCT01260922|Experimental|Investigational Test Product|Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
10200423|NCT04198805|Active Comparator|DHA EE (1.89 g) and Vitamin E (1000 mg)|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months.
9732178|NCT03753945|Experimental|DBS electrode placement|"Participants in this study will be patients who have already undergone surgery for implantation of DBS electrodes.~Patients who have already undergone surgery for implantation of DBS electrodes and patients for whom the treating physicians recommends (based on clinical grounds) a spine MRI (cervical, thoracic or lumbar) shall be recruited for the study.This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician."
9732179|NCT03750292|Experimental|HEPAirX air filter|
9732180|NCT03750292|Placebo Comparator|Control air filter|
9732181|NCT03747120|Active Comparator|Arm A: THP|"Arm A: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
9732182|NCT03747120|Experimental|Arm B: THP-K|"Arm B: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
9732183|NCT03747120|Experimental|Arm C: TH-K|"Arm C: Paclitaxel weekly x12 + Trastuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
9732184|NCT03745521||X-linked Hypophosphatemia (XLH)|Hypophosphatemic Rickets/osteomalacia
9732185|NCT03745144|Experimental|First Cladribine, Then Placebo|Participants will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.
9732186|NCT03745144|Experimental|First Placebo, Then Cladribine|Participants 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.
9732187|NCT03736720|Experimental|Treatment (liposomal irinotecan, leucovorin, fluorouracil)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin IV over 30 minutes, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 28 days for in the absence of disease progression or unacceptable toxicity.
9732188|NCT03734588|Experimental|SPK-8016|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
9732189|NCT03717961|Experimental|" BTX-A group"|"BOTOX® solution~Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~BOTOX 100 UNITES (Allergan, Courbevoie, France, and São Paulo, Brazil) Single injection schedule of BOTOX® in both hands, diluted in 2 ml of sterile serum saline, with a dosage of 50 UI (1 ml) by hand. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site)~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
9732190|NCT03717961|Placebo Comparator|Placebo group|"Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~Sterile saline solution Single injection schedule of 2 ml (1 ml by hand) of serum saline, in both hands. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site).~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer of the lidocaine cream.~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
9732191|NCT03711799|No Intervention|Resource Only Group|Families randomized to the resource only condition will have access to training materials in web-based and paper formats. The will receive the internet address to access web-based trainings, handouts and materials, including instructions for each activity and they will receive a binder that includes the information that is available on line so they can access the information even if they do not have internet access. Families in the resource only condition will not have access to a peer coach through the program. They will not have access to the on-line support community.
9732192|NCT03711799|Experimental|Peer Coaching Group|Families randomized to peer coaching will receive assistance with navigating the training program and accessing the system from a trained peer parent coach. Peer coaches will, as much as possible, be culturally and language-matched with the participant family.
9785836|NCT01260922|Active Comparator|Reference Listed Drug|Aricept® 10 mg Orally Disintegrating Tablets
9732193|NCT03708328|Experimental|Dose Escalation Part A: Once Every 2 Weeks (Q2W)|RO7121661 will be administered in treatment cycles once every 2 weeks (Q2W). Dose escalation will be carried out according to a modified continual reassessment method (mCRM) with escalation with overdose control (EWOC) design.
9732194|NCT03708328|Experimental|Expansion Part B1: Metastatic Melanoma Cohort|This cohort will comprise participants with checkpoint inhibitor (CPI) experienced, second line and beyond metastatic melanoma. The starting dose of RO7121661 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
9732195|NCT03708328|Experimental|Expansion Part B2: NSCLC Cohort 1|This cohort will comprise participants with CPI and platinum experienced, second or third line PD-L1 positive non-small cell lung cancer (NSCLC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
9732196|NCT03708328|Experimental|Expansion Part B3: NSCLC Cohort 2|This cohort will comprise participants with PD-L1 high, cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
9732197|NCT03708328|Experimental|Expansion Part B4: SCLC Cohort|This cohort will comprise participants with CPI naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to, standard therapy. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
9732198|NCT03708328|Experimental|Expansion Part B5: ESCC Cohort|This cohort will comprise participants with CPI-naïve esophageal squamous cell carcinoma (ESCC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
9732199|NCT03703375|Experimental|Administration of Oral Azacitidine (CC-486)|Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
9732200|NCT03703375|Active Comparator|Investigator's choice therapy - Romidepsin|Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
9732201|NCT03703375|Active Comparator|Investigator's choice therapy - Gemcitabine|Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
9732202|NCT03696069||Patients treated with immunotherapy and BRAF/MEK inhibitors|
9732203|NCT03677986|No Intervention|Usual Care|Participants in this group will be referred to receive office-based buprenorphine treatment
9732204|NCT03677986|Experimental|Video DOT+|Participants in this group will be referred to receive office-based buprenorphine treatment and will receive financial incentives for taking their daily buprenorphine dose.
9732205|NCT03674645|Experimental|MRI|MRI exam performed on 200 healthy volunteers
9732206|NCT03658954|Active Comparator|Advice|Participants receive only web-based sleep hygiene advice
9732207|NCT03658954|Experimental|Advice + Self-monitoring|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring
9732208|NCT03658954|Experimental|Advice + Self-monitoring + Feedback|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring + sleep/alcohol data feedback
9732209|NCT03658694|Experimental|Conventional rTMS - study 1|In study 1 patients were randomly allocated to receive conventional repetitive transcranial magnetic stimulation (10Hz).
9732210|NCT03658694|Experimental|Sham rTMS - study 1|In study 1 patients were randomly allocated to receive sham repetitive transcranial magnetic stimulation.
9732211|NCT03658694|Experimental|Conventional rTMS - study 2|In study 2, after the end of the first trial will be allocated to receive conventional of repetitive transcranial magnetic stimulation (10Hz).
9732212|NCT03658694|Experimental|Patterned rTMS - study 2|In study 2, after the end of the first trial will be allocated to receive patterned of repetitive transcranial magnetic stimulation (Theta-burst).
9732213|NCT03656081|Placebo Comparator|Itraconazole & inhaled placebo|Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
9732214|NCT03656081|Experimental|Itraconazole & inhaled Ambisome®|Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
9732215|NCT03652285|Experimental|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
9732216|NCT03647800|Experimental|PART 1 Dose Escalation - 10 dose cohorts|CD123 and CD3 epsilon bispecific antibody
9732217|NCT03647800|Experimental|PART 2 Dose expansion - 5 cohorts|90 patients, 18/cohort in 5 dose expansion cohorts, will receive the recommended dose of APVO436 determined from Part 1
9732218|NCT03647657|Experimental|Entresto second|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
9732219|NCT03647657|Experimental|Entresto first|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
9732220|NCT03645564|Active Comparator|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
9732221|NCT03645564|No Intervention|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
9781357|NCT01147068|Experimental|PanBlok 45µg and GLA 1.0µg, SE 2%|45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
9781358|NCT01147068|Experimental|PanBlok 15µg and GLA 1.0µg, SE 2%|15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
9781359|NCT01147068|Experimental|PanBlok 7.5µg and GLA 1.0µg, SE 2%|7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
9732222|NCT03645408|Experimental|Exenatide then Placebo|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a 5 mcg dose of immediate release exenatide on the day of the first alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Subjects in this arm then received a sham injection on the day of the second alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
9732223|NCT03645408|Experimental|Placebo then Exenatide|This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a sham injection on the day of the first alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Subjects in this arm then received a 5 mcg dose of immediate release exenatide on the day of the second alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.
9732224|NCT03639935|Experimental|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
9732225|NCT03630055|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
9732226|NCT03630055|No Intervention|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
9732227|NCT03623828|Experimental|Apomorphine treatment|"Treatment by apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: 5-days titration phase (increasing doses from 0 to 4 mg/h), 7 days of maintenance at 4 mg/h and 18 days of maintenance phase with possible increase up to 6 mg/h if well tolerated.~Two days before the initiation of apomorphine, domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects. It will be maintained at least 7 days before an optional tapering off in the absence of nausea of vomiting."
9732228|NCT03619044|Other|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
9732229|NCT03618979|Experimental|PPP treatment|Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
9732230|NCT03618979|Experimental|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
9732231|NCT03618979|Experimental|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
9732232|NCT03605706|Experimental|SHR-1210|SHR-1210+FOLFOX4
9732233|NCT03605706|Experimental|CONTROL|SHR-1210+Placebo
9732234|NCT03599141|Active Comparator|Depression Management|8 weekly group sessions
9732235|NCT03599141|Experimental|Trust-building Self-management Together|8 weekly group sessions
9732236|NCT03596801|Experimental|Group 1: RSV 6120/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^6.0 plaque-forming units (PFUs) of RSV 6120/∆NS1 vaccine at Day 0.
9732237|NCT03596801|Experimental|Group 1: RSV 6120/F1/G2/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^5.8 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
9732238|NCT03596801|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of placebo at Day 0.
9732239|NCT03596801|Experimental|Group 2: RSV 6120/∆NS1 Vaccine|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS1 vaccine at Day 0.
9785837|NCT01260948|Experimental|Investigational Test Product|Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg
9732240|NCT03596801|Experimental|Group 2: RSV 6120/F1/G2/∆NS1|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
9732241|NCT03596801|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of placebo at Day 0.
9732242|NCT03595657|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
9732243|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
9732244|NCT03586609|Experimental|Treatment (cladribine, cytarabine, venetoclax, azacitidine)|See Detailed Description.
9732245|NCT03582436||Prospective cohort|Kidney transplantation
9732246|NCT03578809|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo matched to MEDI6012 on Day 1 prior to pPCI followed by a second inpatient dose on Day 3 by IV push.
9732247|NCT03578809|Experimental|Cohort A: MEDI6012|Participants will receive loading dose of MEDI6012 300 mg on Day 1 prior to pPCI followed by a second inpatient dose of MEDI6012 150 mg on Day 3 by IV push.
9732248|NCT03578809|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo matched to MEDI6012 on Day 1 prior to pPCI followed by a second inpatient dose on Day 3, and outpatient maintenance doses on Days 10, 17, 24, and 31 by IV push.
9732249|NCT03578809|Experimental|Cohort B: MEDI6012|Participants will receive loading dose of MEDI6012 300 mg on Day 1 prior to pPCI followed by a second inpatient dose of MEDI6012 150 mg on Day 3, and outpatient maintenance doses of MEDI6012 100 mg on Days 10, 17, 24, and 31 by IV push.
9732250|NCT03573401|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Photodynamic therapy (PDT)"
9732251|NCT03573401|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
9732252|NCT03571204|Active Comparator|Group 1: ART prior to 3BNC117 + 10-1074 in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
9732253|NCT03571204|Placebo Comparator|Group 1: ART prior to placebo treatment in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given normal saline intravenously. Subjects received two separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
9732254|NCT03571204|Experimental|Group 2: 3BNC117 + 10-1074 in HIV-1 subject|Subjects who were not on anti-retroviral therapy (ART) during primary HIV-1 infection within the past 2 years. Subjects were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
9732255|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
9732256|NCT03569215||IVF/ICSI failure|These patients had prolonged infertility with one or more failure of IVF/ICSI cycles
9732257|NCT03569215||Prolonged infertility only|These patients had prolonged infertility without any trials of IVF/ICSI cycles
9732258|NCT03565913|Experimental|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
9732259|NCT03565913|Active Comparator|CaAcS|Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
9732260|NCT03561896|Experimental|IGRT|Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
9732261|NCT03561896|Experimental|SRS|Stereotactic Radiosurgery of the resection cavity (SRS)
9732262|NCT03553576|Experimental|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL)
9732263|NCT03553576|Experimental|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL).
9732264|NCT03546686|Experimental|Treatment Arm|Ipilimumab + Nivolumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery Nivolumab
9732265|NCT03545607|Experimental|MultiStem|1.2 billion cells
9732266|NCT03545607|Placebo Comparator|Placebo|
9732267|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
9732268|NCT03528642|Experimental|Treatment (telaglenastat, temozolomide, RT)|Patients receive telaglenastat PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
9732269|NCT03523156|Active Comparator|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
9785838|NCT01260948|Active Comparator|Reference Listed Drug|Aricept® Orally Disintegrating Tablets, 10 mg
9785839|NCT01261000|Experimental|Pegvisomant|
9732270|NCT03523156|Experimental|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
9732271|NCT03523091|Experimental|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
9732272|NCT03523091|Experimental|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
9732273|NCT03519009|Experimental|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
9732274|NCT03519009|No Intervention|Usual Care Control|Counseling and referrals to employment and treatment programs.
9732275|NCT03503474||CDI cases|
9732276|NCT03503474||CDI negative controls|
9732277|NCT03497689|Experimental|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Intravenous (IV) or subcutaneous (SC) treprostinil induction followed by transition to oral treprostinil
9732278|NCT03493711||Breast Fed|Exclusively breastfed for first 3 months of life
9732279|NCT03493711||Milk-based fomula fed|Exclusively on Similac Advance Formula for at least 1 month prior to visit
9732280|NCT03492125|Experimental|low dose|MS-533
9732281|NCT03492125|Experimental|mid low dose|MS-533
9732282|NCT03492125|Experimental|mid high dose|MS-533
9732283|NCT03492125|Experimental|high dose|MS-533
9732284|NCT03484936|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
9732285|NCT03484936|Placebo Comparator|Sham RIC+Standard medical treatment|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
9732286|NCT03476317|Experimental|Group 1-Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
9732287|NCT03476317|Placebo Comparator|Group 1-Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
9732288|NCT03476317|No Intervention|Group 2|Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.
9732289|NCT03472989|Active Comparator|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
9732290|NCT03472989|Sham Comparator|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
9732291|NCT03472989|Active Comparator|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
9732292|NCT03472989|Active Comparator|Usual care|Only standardized information and custom made foot orthosis
9732293|NCT03472274|Active Comparator|Cisplatin-based neoadjuvant chemotherapy|"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:~Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin"
9732294|NCT03472274|Experimental|Durvalumab plus Tremelimumab|Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks
9732295|NCT03467542|Experimental|dAVF treatment|PHIL® Liquid Embolic System
9732296|NCT03451409|Active Comparator|OCD Proband|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
9732297|NCT03451409|Active Comparator|OCD Siblings|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
9732298|NCT03451409|Active Comparator|Healthy Controls|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
9781360|NCT01147068|Experimental|PanBlok 3.8µg and GLA 1.0µg, SE 2%|3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
9781361|NCT01147068|Placebo Comparator|Placebo|0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
9732299|NCT03446989|Experimental|Case management|Those who did not agree to participate in the NLCM were enrolled into the control group and received the standard care: visits to their RA physicians on a regular basis with health education administered by a ward nurse during each visit. The education sessions lasted for approximately 15 minutes and consisted of consultation about disease symptoms, related treatments, and disease management.
9732300|NCT03445520|No Intervention|Transition Passport Comparison Group|This group will only receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide.
9732301|NCT03445520|Experimental|Intervention Coaching Group|This group will also receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide. This group will also receive coaching support to implement these resources. The coach will be a member of the research team who will introduce the resources to the family, briefly teach them fundamental information about the transition process, provide brief coaching phone calls, and help parents identify an appropriate person at the school or district who can work with them to complete the Student Snapshot. This group will also use ParentSquare to enhance and encourage communication between parent and members of the child's school team.
9732302|NCT03445494|Experimental|Brace|After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night
9732303|NCT03445494|Experimental|Normal sling|After surgery the patient must wear the normal sling for two weeks
9732304|NCT03445481|Experimental|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
9732305|NCT03442582||Afluria|Afluria exposure in pregnancy
9732306|NCT03442556|Experimental|Treatment (docetaxel, carboplatin, rucaparib camsylate)|"INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9732307|NCT03436654|Experimental|ADT + Apalutamide|
9732308|NCT03436654|Experimental|ADT + Apalutamide + Abiraterone Acetate + Prednisone|This arm is no longer being assigned to subjects.
9732309|NCT03436654|Experimental|Apalutamide, SBRT, Radiation|
9732310|NCT03434158|Experimental|Olaparib|600 mg/day
9732311|NCT03425201|Experimental|Niraparib plus Cabozantinib|"Patients will receive niraparib and cabozantinib p.o. once daily in 28-day cycles.~In phase I, patients will be accrued to each dose level in cohorts of 6 patients. Escalation will continue until a dose-limiting toxicity (DLT) is observed or the highest dose-level is reached.~In phase II study patients will receive niraparib p.o. once daily and cabozantinib p.o. once daily in 28-day cycles at doses recommended in the phase I study.~If niraparib or cabozantinib need to be interrupted due to toxicity, patient can continue only with the other drug."
9732312|NCT03421808|Experimental|SYNC TMS|Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
9732313|NCT03421808|Active Comparator|Non-Sync TMS|Patients will receive daily left prefrontal transcranial Magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will NOT be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm. This is the way conventional TMS is delivered now and is FDA approved.
9732314|NCT03419585|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
9732315|NCT03419585|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
9732316|NCT03416153|Active Comparator|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy)
9732317|NCT03416153|Experimental|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
9732318|NCT03408340|Experimental|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
9732319|NCT03408340|Active Comparator|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
9732320|NCT03397238||Non-metastatic TC|blood withdrawal, bone marrow aspiration
9732321|NCT03397238||Metastatic TC|blood withdrawal, bone marrow aspiration
9732322|NCT03397238||MNG surgery|blood withdrawal, bone marrow aspiration
9732323|NCT03397238||MNG RAI treatment|blood withdrawal
9732324|NCT03397238||Healthy volunteers|blood withdrawal
9732325|NCT03397004|Active Comparator|doxycycline Hyclate|subjects will be treated with a 6-month course of doxycycline oral capsule at a dose of 100mg twice daily
9732326|NCT03397004|Placebo Comparator|Placebo|subjects will be given a placebo oral capsule twice daily for 6-months
9732327|NCT03391960|Other|Disinfecting barrier cap|"In the participating wards, disinfecting barrier cap was used on every needless connector used for accessing CVC IV lines.~Compliance with disinfecting barrier cap was observed weekly."
9732328|NCT03389698|Active Comparator|Heatlthy Control Group|cognitively normal (CN) subjects in two age groups: young(20-40) and old (65-85)
9732329|NCT03389698|Active Comparator|Amnestic mild cognitive impairment (aMCI)|32 participants who have aMCI.
9732330|NCT03386487|Active Comparator|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
9982444|NCT05238155||Orthotopic Liver Transplantation recipients after protocol implementation date|Over the last several years, there have been changes made to this protocol, and the current protocol now suggests consideration for the omission of the antimetabolite at discharge if there is a donor-recipient age discrepancy that is greater than 30 years. This change was made with the intention to reduce the risk of GVHD, given that a greater disparity in donor-recipient age may put these patients at a higher risk for GVHD.
9732331|NCT03386487|Placebo Comparator|Placebo|Subjects will be randomized to placebo
9732332|NCT03383419|Experimental|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
9732333|NCT03362190|Experimental|Cohort 1|Zimura dosage 1 + Lucentis 0.5 mg
9732334|NCT03362190|Experimental|Cohort 2|Zimura dosage 2 + Lucentis 0.5 mg
9732335|NCT03362190|Experimental|Cohort 3|Zimura dosage 3 + Lucentis 0.5 mg
9732336|NCT03362190|Experimental|Cohort 4|Zimura dosage 4 + Lucentis 0.5 mg
9732337|NCT03354520|Active Comparator|Tailored Videos|
9732338|NCT03354520|Active Comparator|Standard Videos|
9732339|NCT03354520|Active Comparator|OSA Treatment|
9732340|NCT03347929|Experimental|Naproxen|Naproxen 500 mg twice daily
9732341|NCT03347929|Placebo Comparator|Placebo|Placebo 1 tablet twice daily
9732342|NCT03346668|Experimental|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
9732343|NCT03338790|Experimental|nivolumab + rucaparib|Specified dose on specified days
9732344|NCT03338790|Experimental|nivolumab + docetaxel + prednisone|Specified dose on specified days
9732345|NCT03338790|Experimental|nivolumab + enzalutamide|Specified dose on specified days
9781362|NCT01147107|Experimental|Raltegravir based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
9781363|NCT01147107|Active Comparator|Efavirenz based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
9781364|NCT01147172|Experimental|Elevess|Gel implant (dermal filler) composed of hyaluronan produced by Streptococcus equi (bacterial fermentation) that is cross-linked and suspended in phosphate buffered saline with 0.3% lidocaine HCl and 0.1% sodium metabisulfite
9781365|NCT01147250|Placebo Comparator|Placebo|Placebo matched to lixisenatide once daily (QD) up to end of treatment.
9781366|NCT01147250|Experimental|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment.
10200424|NCT04198805|Placebo Comparator|Placebo|Matching soybean oil placebo (3 capsules) of all arms daily for 6 months.
10200425|NCT04184791|Experimental|Deep Brain Stimulation(DBS) OFF Medication|Subthalamic-DBS in the Levodopa OFF state.
10200426|NCT04184791|Experimental|Deep Brain Stimulation(DBS) ON Medication|Subthalamic-DBS in the Levodopa ON state.
10200427|NCT04183868|Experimental|Empagliflozin|"Eligible patients (meeting all inclusion criteria) will be randomized to receive empagliflozin in addition to existing metformin background therapy (daily dose of ≥1.500 mg, which has to remain unchanged throughout the study) for 26 weeks.~At the end of 26 weeks of treatment, subjects belonging to empagliflozin arm will be shifted to glimepiride treatment."
10200428|NCT04183868|Active Comparator|Glimepiride|"Eligible patients will be randomized to receive glimepiride (starting dose: 2 mg daily) treatment arm, can undergo to up-titration of glimepiride to a maximum of 6 mg/day, if they experience fasting plasma glucose (FPG) levels > 112 mg/dl (6,2 mmol/l) at scheduled visit at 6th week or at any later scheduled visit.~Whereas, glimepiride-treated patients experiencing recurrent hypoglycemic episodes should down-titrate glimepiride to a dose, considered as appropriate by Investigator.~Hypoglycemic events are defined as symptoms suggestive of low blood glucose confirmed by self monitored blood glucose (SMBG) < 56 mg/dl (3,1 mmol/l).~Severe hypoglycemia is defined as any hypoglycemic episode requiring the assistance of another party for recovery.~At the end of 26 weeks of treatment, subjects belonging to glimepiride arm will be shifted to treatment with empagliflozin for 26 weeks."
10200429|NCT04161755|Experimental|Pancreatic Cancer|Radiologically resectable primary pancreatic tumors
10200430|NCT04122690|Experimental|Partnered Dance Aerobic Exercise|Partnered Dance-Aerobic Exercise (PDAE) is an adapted form of Argentine tango, aka Adapted tango. Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
9732346|NCT03332797|Experimental|Dose Escalation: GDC-9545|During dose escalation, postmenopausal participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).
9732347|NCT03332797|Experimental|Dose Escalation: Cohort B0: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose lower than the MTD or MAD determined in single-agent dose escalation, in combination with the label-recommended dose of palbociclib.
9732348|NCT03332797|Experimental|Dose Expansion: Cohort A1: GDC-9545 Dose 1|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 1).
9732349|NCT03332797|Experimental|Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 1) in combination with an approved LHRH agonist.
9732350|NCT03332797|Experimental|Dose Expansion: Cohort A3: GDC-9545 Dose 2|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 2).
9732351|NCT03332797|Experimental|Dose Expansion: Cohort A4: GDC-9545 Dose 2 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 2) in combination with an LHRH agonist.
9732352|NCT03332797|Experimental|Dose Expansion: Cohort A5: GDC-9545 Dose 3|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 3).
9732353|NCT03332797|Experimental|Dose Expansion: Cohort B1: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib.
9732354|NCT03332797|Experimental|Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib and an approved LHRH agonist.
9732355|NCT03332797|Experimental|Dose Expansion: Cohort C1: GDC-9545 Dose 2 +/- Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2) as a single agent for 14 days, followed by treatment with either GDC-9545 (Dose 2) plus palbociclib or GDC-9545 (Dose 2) alone for the duration of the study, as determined by the investigator.
9732356|NCT03332797|Experimental|Dose Expansion: Cohort C2: GDC-9545 Dose 2 + Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2), in combination with the label-recommended dose of palbociclib.
9732357|NCT03332797|Experimental|Dose Expansion: Cohort X: GDC-9545 Dose 3|GDC-9545 will be administered at a pre-defined dose level (Dose 3) to postmenopausal participants currently receiving clinical benefit with GDC-0927 or GDC-0810 on Studies GO29656 (NCT02316509) or GO29642 (NCT01823835), respectively, upon completion of their studies.
9732358|NCT03321760|Experimental|Run-In Dose 1|10 Gy dose delivered to the primary tumor & 10 Gy to the hilar (N1) node over 5 fractions
9732359|NCT03321760|Experimental|Run-In Dose -1|10 Gy dose delivered to the primary tumor & 9 Gy to the hilar (N1) node over 5 fractions
9982445|NCT05237310|Active Comparator|Standard Colonoscopy followed by CAD-EYE|Subjects will undergo standard colonoscopy immediately followed by CAD-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
9982446|NCT05237310|Active Comparator|CAD-EYE followed by Standard Colonoscopy|Subjects will undergo CAD-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
9982447|NCT05237310|Active Comparator|Standard Colonoscopy followed by combined CAD-EYE and G-EYE colonoscopy|Subjects will undergo standard colonoscopy immediately followed by combined CAD-EYE and G-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
9982448|NCT05237310|Active Comparator|Combined CAD-EYE and G-EYE colonoscopy followed by Standard Colonoscopy|Subjects will undergo combined CAD-EYE and G-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session).
9982449|NCT05236790|Experimental|Artificial intelligence for real-time detection and monitoring of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. Patients will undergo colonoscopies using the CAD-eye ans Scale-eye. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
9982450|NCT05236491|Experimental|Moderna Spikevax|Participants will receive one (1) intramuscular injection of 0.5 mL (100 mcg) of the Moderna Spikevax vaccine.
9982451|NCT05236491|Experimental|AstraZeneca Vaxzevria|Participants will receive one (1) intramuscular injection of 0.5 mL of the AstraZeneca Vaxzevria vaccine.
9982452|NCT05236491|Experimental|Novavax NVX-CoV2373|Participants will receive one (1) injection of the Novavax NVX-CoV2373 vaccine.
9982453|NCT05236387||Intent to Treat group|All patients meeting entrance criteria, injected with 99m Tc-TM, and having one or more lymph nodes removed for which the pathologist confirms the type (lymph node versus non-lymph node) and contents (e.g., tumor cells) of the excised tissues will comprise the intent-to-treat population (ITT). This definition also carries over to the lymph nodes; i.e., nodes used for the ITT analysis must come from patients included in the ITT population. The ITT population will serve as the analysis population for all efficacy endpoints, unless indicated otherwise in the description of analyses.
9982454|NCT05236153|Other|RV mapping|Participants will undergo a sinus rhythm electroanatomic RV substrate map prior to TPVR.
9982455|NCT05236023|No Intervention|Control group|Group receiving care as usual before the intervention takes place
9732360|NCT03321760|Experimental|Run-In Dose -2|10 Gy dose delivered to the primary tumor & 8 Gy to the hilar (N1) node over 5 fractions
9732361|NCT03321760|Experimental|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
9732362|NCT03311503|Experimental|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
9732363|NCT03309150|Experimental|M6620 Monotherapy or Combination Therapy|
9732364|NCT03304717|Experimental|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
9732365|NCT03304717|Experimental|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for 6 months.
9732366|NCT03297775||Evidence of interstitial lung disease|"Subjects who screen positive for ILD will be followed annually until study closure.~Assessments are as follows:~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic - Assessment for airways disease, interstitial lung abnormalities~Genetic - DNA, RNA~Biologic - Serum, Plasma, Sputum"
9732367|NCT03297775||No evidence of interstitial lung disease|"Subjects who screen negative for ILD will be followed five years after the initial screen and re-screened with a chest CT scan to check for evidence of new lung disease.~Assessments are as follows:~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic - Assessment for airways disease, interstitial lung abnormalities~Genetic - DNA, RNA~Biologic - Serum, Plasma, Sputum"
9732368|NCT03292029|Other|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
9732369|NCT03289299|Experimental|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
9732370|NCT03282656|Experimental|Treatment arm|open-label, non-randomized, single center, pilot and feasibility, single arm cohort study of a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with lentiviral vector containing a short-hairpin RNA targeting BC11A.
9732371|NCT03272685|Experimental|Very Low Nicotine Content Cigarettes|Very low nicotine content cigarettes (0.4 mg/g nicotine; 9 mg of tar)
9732372|NCT03272685|Active Comparator|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (15.8 mg/g nicotine; 9 mg of tar)
9732373|NCT03265366|Experimental|ABPA|15 patients with ABPA
9732374|NCT03265366|Active Comparator|Severe asthma|12 patients with severe asthma
9732375|NCT03254355|Experimental|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
9732376|NCT03254355|No Intervention|Waiting-list control group|12 weeks of weekly full-body relaxation massage
9732377|NCT03253120|Other|Patient|Patients will drink 5dl of water.
9982456|NCT05236023|Experimental|Intervention group|Group receiving a new model of care based on zero separation and couplet care
9982457|NCT05235893|Experimental|Reflexology Group|The newborns who have applied Reflexology to soles three minutes before and during 5-7 minutes of painful procedure by a physiotherapist, certificated in reflexology.
9982458|NCT05235893|Active Comparator|Sucrose Group|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
9982459|NCT05235893|Active Comparator|Kangaroo Care Group|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
9732378|NCT03253120|Other|Healthy volunteer|Healthy volunteers will drink 5dl of water.
9732379|NCT03252522|Experimental|Intervention|Capsules of broad spectrum micronutrients: a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants.
9732380|NCT03252522|Placebo Comparator|Placebo|Capsules of inactive placebo.
9982460|NCT05235893|Active Comparator|Music Group|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
9982461|NCT05235893|No Intervention|Control Group|Control arm
9982462|NCT05235815|Experimental|Sonoanatomy and retro SCTL compartment block|"During phase 1, ten healthy human volunteers will be involved. A bilateral ultrasound scan will be performed in the paravertebral region to describe the sonoanatomy of the retro SCTL compartment.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block."
9982463|NCT05235763|Placebo Comparator|Control|A sham activity coach will be installed on the Optilogg system, slightly changing its appearance.
9732381|NCT03252522|Experimental|Open Label|All participants have the option to participate in an 8-week, naturalistic, open label follow-up in which the child will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
9732382|NCT03250767||Integra Titan Modular Shoulder System 2.5|
9732383|NCT03245320||TITAN™ Total Shoulder System Generation 1.0|Integra TITAN™ Total Shoulder System Generation 1.0
9732384|NCT03235544|Experimental|Cohort 1: Treatment A (Exposed to Ibrutinib)|"Participants received parsaclisib 20 mg tablets, orally, once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to 52 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group."
9732385|NCT03235544|Experimental|Cohort 1: Treatment B (Exposed to Ibrutinib)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to 116 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group."
9732386|NCT03235544|Experimental|Cohort 2: Treatment A (Bruton's Tyrosine Kinase Inhibitor Naïve)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 20 mg QW for up to approximately 145 weeks.~Participants who had not received a BTK inhibitor previously were included in this group."
9732387|NCT03235544|Experimental|Cohort 2: Treatment B (Bruton's Tyrosine Kinase Inhibitor Naïve)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to approximately 136 weeks.~Participants who had not received a BTK inhibitor previously were included in this group."
9732388|NCT03225833|Experimental|WVE-120101 (Dose A) or placebo|
9732389|NCT03225833|Experimental|WVE-120101 (Dose B) or placebo|
9732390|NCT03225833|Experimental|WVE-120101 (Dose C) or placebo|
9732391|NCT03225833|Experimental|WVE-120101 (Dose D) or placebo|
9732392|NCT03225833|Experimental|WVE-120101 (Dose E) or placebo|
9732393|NCT03223155|Experimental|Sequential Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.
9732394|NCT03223155|Experimental|Concurrent Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).
9732395|NCT03217201|Experimental|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
9732396|NCT03217201|Active Comparator|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
9732397|NCT03217201|Experimental|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
9732398|NCT03217201|Active Comparator|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
9732400|NCT03198494|Experimental|Acoustic 1Hz Stimulation|1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.
9732401|NCT03198494|Sham Comparator|Sham Background Noise|Background noise applied via headphones and downloadable phone application during sleep every night.
9732402|NCT03198494|No Intervention|Baseline Seizure Monitoring|No use of sound system; Patients record seizures in a diary.
9732403|NCT03195400||CC Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 obese CC adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20.
9732404|NCT03195400||TT Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 TT subjects will be enrolled in this group. An anticipated 50 obese TT adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will be enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20
9732405|NCT03192462|Experimental|Group A (Closed to New Patient Enrollment)|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
9732406|NCT03192462|Experimental|Group B (Closed to New Patient Enrollment)|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
9732407|NCT03192462|Experimental|Group C (Closed to New Patient Enrollment)|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
9732408|NCT03182179|Experimental|O-P sequence|Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.
9732409|NCT03182179|Experimental|P-O sequence|Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.
9732410|NCT03177421|Experimental|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
9732411|NCT03177421|Other|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
9732412|NCT03167242|Experimental|Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
9732413|NCT03167242|Experimental|Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 800 mg and LUM-SDF 960 mg
9732414|NCT03167242|Experimental|Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
9732415|NCT03167242|Experimental|Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 days|Participants received KAF156 200 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
9732416|NCT03167242|Experimental|Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
9732417|NCT03167242|Experimental|Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
9732418|NCT03167242|Active Comparator|Part A - Cohort 7: Coartem|Participants received Coartem twice daily via oral administration for 3 days
9732419|NCT03167242|Experimental|PK Run-in Cohort: KAF 200 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 200 mg and LUM-SDF 960 mg
9732420|NCT03167242|Experimental|Part B - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
9732421|NCT03167242|Experimental|Part B - Cohort 2: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
9732422|NCT03167242|Experimental|Part B - Cohort 3: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
9732423|NCT03167242|Active Comparator|Part B - Cohort 4: Coartem|Participants received Coartem twice daily via oral administration for 3 days
9732424|NCT03164473|Experimental|Rituximab|"pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)~plus orally placebo-azathioprine for 24 months"
9732425|NCT03164473|Active Comparator|Azathioprine|"standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months~plus 4 placebo-rituximab infusions given every 6 months for 18 months"
9732426|NCT03163264|Experimental|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
9732427|NCT03163264|Active Comparator|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
9732428|NCT03161431|Experimental|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
9732429|NCT03161431|Experimental|Combination therapy: SX-682 dose escalation with pembrolizumab|SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
9732430|NCT03153280|Experimental|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
9732431|NCT03147612|Experimental|Treatment (chemotherapy, ponatinib, blinatumomab)|See Detailed Description.
9732432|NCT03144674|Experimental|Cohort 1- Closed to Further enrollment|Participants who have received prior ibrutinib.
9732433|NCT03144674|Experimental|Cohort 2|Participants who have not received a prior BTK inhibitor.
9732434|NCT03142958|Other|Integra® Cadence™ Total Ankle System|
9982464|NCT05235763|Experimental|Intervention|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
9732437|NCT03137537|Experimental|Ivabradine|"Ivabradine will be administered for a total of 6 weeks~Ivabradine is taken orally twice daily~Dosage will be adjusted according to physician determination"
9732438|NCT03137537|Placebo Comparator|Placebo Oral Tablet|"Placebo will be administered for a total of 6 weeks~Placebo is taken orally twice daily~Dosage will be adjusted according to physician determination"
9732439|NCT03137095||Breast Cancer Patient Participants|Female breast cancer patients receiving chemotherapy
9732440|NCT03137095||Healthy, age-matched, female participants|Healthy, female, age-matched participants
9732441|NCT03126890||Linezolid TDM (prospective)|Adult patients received linezolid at NTUH. This prospective cohort study will draw blood from every patient to measure the linezolid blood concentration. After blood concentration analysis by high pressure liquid chromatography (HPLC), the investigator will report the concentration to clinicians and dose adjustment is judged by clinician (not the investigators).
9732442|NCT03126890||Linezolid observation (retrospective)|Adult patients received linezolid at NTUH.
9732443|NCT03126019|Experimental|Treatment A: Parsaclisib 20 mg QD for 8 Weeks Followed by 20 mg QW|Participants received parsaclisib 20 mg once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to approximately 52 weeks.
9732444|NCT03126019|Experimental|Treatment B: Parsaclisib 20 mg QD for 8 Weeks Followed by 2.5 mg QD|Participants received parsaclisib 20 mg QD for 8 weeks followed by 2.5 mg QD for up to approximately 52 weeks.
9732445|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
9732446|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
9732447|NCT03113383|Experimental|Primary Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
9732448|NCT03113383|Experimental|Expanded Selection Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
9732449|NCT03113253|Experimental|Tranexamic Acid|"Patient will receive:~1g of tranexamic acid by slow intravenous injection~1g of tranexamic acid by syringe pump during 8 hours"
9732450|NCT03113253|Placebo Comparator|Placebo|"Patient will receive:~10 mL of 0.9% sodium chloride by slow intravenous injection~48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
9732451|NCT03111992|Experimental|Arm A|Dose escalation of single agent CJM112
9732452|NCT03111992|Experimental|Arm B|Dose escalation of CJM112 in combination with a fixed dose of PDR001
9732453|NCT03111992|Experimental|Arm C|Dose escalation of LCL161 in combination with a fixed dose of PDR001
9732454|NCT03101891|Experimental|Serial amnioinfusions with isotonic fluid|Patients will undergo amnioinfusions with isotonic fluid every 2-12 days.. A spinal needle will be used to perform the infusion. The latest infusions will begin is 26 weeks gestation. Standard postnatal care will occur at a RAFT center.
9732455|NCT03101891|No Intervention|Expectant|Patients will be observed serially by ultrasound, fetal echocardiogram and MRI. Standard postnatal care will occur at a RAFT center.
9732456|NCT03101046|Other|Group1: Arm A (standard arm) + Arm B (experimental arm)|"Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization.~Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization."
9732457|NCT03101046|Other|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having <5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)
9732458|NCT03097107|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks
9732459|NCT03097107|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks
9732460|NCT03097107|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks
9732461|NCT03097107|Placebo Comparator|Placebo|Placebo tablet orally once a day for 12 weeks
9732462|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
9732463|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
9732464|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
9732465|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
9732466|NCT03078426|Experimental|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
10200431|NCT04122690|Active Comparator|Walking Aerobic Exercise|Walking Aerobic Exercise (WAE) Participants in WAE will receive equivalent dose, volume, frequency, intensity and duration of exercise to the PDAE group. The investigators will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The investigators will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention.
9732467|NCT03078426|Experimental|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
9732468|NCT03078426|Experimental|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
9732469|NCT03078426|Experimental|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
9732470|NCT03078218|No Intervention|Before period group|Strictly observational in order to assess the current screening strategy as it is conducted in real life
9732471|NCT03078218|Experimental|After period group|Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards
9732472|NCT03059173|Experimental|Myo-Inositol + Levomefolic acid|The experimental group will receive the dietary supplement: 4 g of MYO + 0.736 mg of 5-MTHF, glucosamine salts per day per os (in 2 bags per day) in addition to the standard therapy (Clomiphene Citrate).
9732473|NCT03059173|Placebo Comparator|Placebo|The control group will receive the standard therapy ( Clomiphene Citrate) and a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
9732474|NCT03058627|No Intervention|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
9732475|NCT03058627|Experimental|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis > 90% or FFR ≤ 0.80 in vessels ≥ 2.5 mm in diameter .
9732476|NCT03057106|Active Comparator|Durvalumab and Tremelimumab|Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses
9732477|NCT03057106|Active Comparator|Platinum based chemotherapy + Durvalumab + Tremelimumab|"4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)~Followed by:~Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD"
9732478|NCT03031587|Experimental|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
9732479|NCT03028896|No Intervention|standard|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
9732480|NCT03028896|Experimental|rotational|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
9732481|NCT03015129|Experimental|Durvalubmab|Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
9732482|NCT03015129|Experimental|Durvalubmab + Tremelimumab|Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
9732483|NCT03013491|Experimental|CX-072|Monotherapy CX-072
9732484|NCT03013491|Experimental|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
9732485|NCT03013491|Experimental|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
9732486|NCT03013491|Experimental|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
10200432|NCT04118387|Active Comparator|acetazolamide|To determine the effect of dampening chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to PAP plus each intervention alone or placebo in reducing CAHI and the CO2 reserve during sleep in Veterans with CSA.
10200433|NCT04118387|Active Comparator|zolpidem|To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.
10200434|NCT04118387|Active Comparator|buspirone|To determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with CSA compared to PAP plus placebo.
9732487|NCT03013491|Experimental|CX-072 expansion|Monotherapy CX-072
9732488|NCT03010163|Active Comparator|Health Fair + Pedometer|Participants will get free weight, height, waist, and blood pressure testing at health fairs stationed at NYC taxi garage bases and airport taxi holding lots. Health fair staff will follow up with participants who need to see a doctor due to a high blood pressure reading or other unusual result that needs a physician follow-up. All participants will be given a pedometer with instructions on how to use it to track their daily step counts. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
9781367|NCT01147302|Experimental|C1 Esterase Inhibitor (Human)|Subjects were to receive C1 esterase inhibitor intravenously at a rate of approximately 1 mL per minute as tolerated. Subjects were to receive a total of 7 doses over a 2-week period: an initial IV infusion of 5000 U (not to exceed 100 U/kg) on Day 1, followed by 2500 U (not to exceed 50 U/kg) IV on Days 3, 5, 7, 9, 11, and 13
9781368|NCT01147302|Placebo Comparator|Normal Saline|placebo infused as above
10200435|NCT04116645||Group 1|singleton pregnancies
9732489|NCT03010163|Experimental|Health Fair, Pedometer + Text Messaging|In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
9732490|NCT03010163|Experimental|Health Fair, Pedometer, Social Network Support|Each participant in this group will receive the health fair services with general follow-up along with a pedometer with instructions on how to use the device to track daily step counts. Additionally, participants in this group will be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given a social network guide to train their family and/or friends on how to best motivate the participants . Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
9732491|NCT03010163|Experimental|Health Fair, Pedometer, Text Msg, Social Network Support|Participants in this group will receive the health fair service with general follow-up, along with a pedometer with instructions on how to use the device to track daily step counts. Participants will also receive daily healthy living advice through encouraging text messages about walking through text messages sent by our staff to participants' cellular phones. Participants will also be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given tools to train their family and/or friends on how to best motivate the drivers. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
9732492|NCT03008369|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
9732493|NCT03003533|Experimental|SPK-8011|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
9732494|NCT02988271|Experimental|Group I (meditation)|Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
9732495|NCT02988271|Active Comparator|Group II (waitlist control)|Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
9732496|NCT02984241|Active Comparator|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
9732497|NCT02984241|Active Comparator|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
9732498|NCT02984241|Active Comparator|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
9732499|NCT02978326|Experimental|Part A: SAGE-217 15/20 mg Oral Solution|Participants received SAGE-217, 15 milligrams (mg), oral solution, twice daily (BID) for first 2 days followed by SAGE-217, 15 or 20 mg, oral solution, BID, starting on Day 3 for up to 14 days as tolerated.
9732500|NCT02978326|Placebo Comparator|Part B: Placebo|Participants received SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
9732501|NCT02978326|Experimental|Part B: SAGE 217 30 mg Capsules|Participants received SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
9732502|NCT02970929|Experimental|SEP-363856|SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
9732503|NCT02963493|Experimental|melphalan flufenamide (melflufen) + dexamethasone|Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (20 mg for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.
9732504|NCT02947503|Active Comparator|Metformin on top of usual care|"Metformin TEVA 850 mg (1-3 times daily) added to usual care from start of the diagnosis GDM.~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: metformin TEVA 850 mg (1-3 times daily) on top of usual care."
9732505|NCT02947503|No Intervention|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: usual care."
9732506|NCT02940171||Early surgery|Early Excision of full thickness burn First excision surgery of full -thickness burn performed within 48 hours from burn injury
9732507|NCT02940171||Late surgery|Late Excision of full thickness burn First excision surgery of full -thickness burn performed after 48 hours from burn injury
9732508|NCT02930902|Active Comparator|Arm A (pembrolizumab, paricalcitol)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each course and paricalcitol IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
10200436|NCT04116645||Group 2|Twin pregnancies
10200437|NCT04114812|Experimental|Blended learning|Participants in the blended learning group will be taught abdominal ultrasound by an e-learning platform and practical near-peer tutoring classes over 16 weeks, summing up to 5 hours of e-learning and 16 hours of near-peer tutoring classes.
10200438|NCT04114812|Active Comparator|Standard course|Participants in the standard course or control group will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training.
9732509|NCT02930902|Experimental|Arm B (pembrolizumab, paricalcitol, chemotherapy)|Patients receive pembrolizumab and paricalcitol as in Arm A. Patients also receive gemcitabine hydrochloride IV over 30 minutes and nab-paclitaxel IV over 30-40 minutes on days 1, 8, and 15 of course 1 in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
9732510|NCT02926521|No Intervention|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
9732511|NCT02926521|Active Comparator|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
9732512|NCT02926521|Active Comparator|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
9732513|NCT02926521|Active Comparator|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
9732514|NCT02921555|Experimental|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
9732515|NCT02921555|Active Comparator|prednisone|A decreasing conventional course of oral prednisone
9732516|NCT02920996|Experimental|NSCLC (Met Exon 14 Mutation)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
9732517|NCT02920996|Experimental|Solid Tumor (NTRK1,2,3 Rearrangement)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
9732518|NCT02899078|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9732519|NCT02895373|Experimental|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
9732520|NCT02895373|Placebo Comparator|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
9732521|NCT02885337|Active Comparator|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
9732522|NCT02885337|Experimental|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with patients at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
9732523|NCT02873975|Experimental|Homologous Repair (HR) Deficiency Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with homologous repair (HR) deficiency on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
9732524|NCT02873975|Experimental|Replicative Stress Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with advanced solid tumors exhibiting replicative stress on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
9732525|NCT02873975|Experimental|CCNE1 Amplification Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with CCNE1 amplification on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
9732526|NCT02869789|Experimental|Nivolumab in combination with Ipilimumab|Specified dose on specified days
9732527|NCT02861417|Experimental|Group I (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
9732528|NCT02861417|Experimental|Group II (matched donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.
9732529|NCT02861417|Experimental|Group III (haploidentical donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score > 3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
9732530|NCT02861417|Experimental|Group IV (matched donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score >3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
9732531|NCT02861417|Experimental|Group V (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
9732532|NCT02861417|Experimental|Group VI (matched or haploidentical transplant, chemotherapy)|Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
9732533|NCT02855268|Experimental|lademirsen (SAR339375)|Eligible participants will receive subcutaneous injection every week for 48 weeks
9732534|NCT02855268|Placebo Comparator|Placebo|Eligible participants will receive subcutaneous injection every week for 48 weeks
9732535|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
9732536|NCT02837471|Experimental|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
9732537|NCT02837471|No Intervention|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
9732538|NCT02834065|Active Comparator|Deep Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius
9732539|NCT02834065|Active Comparator|Low Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius
9732540|NCT02834065|Active Comparator|Moderate Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius
9732541|NCT02800317|Experimental|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
9732542|NCT02797951|Experimental|Galcanezumab|Participants received 300 milligram (mg) Galcanezumab administered subcutaneously (SC) up to once a month.
9732543|NCT02788591|Other|Proton Pump Inhibitor (PPI) Therapy|2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
9732544|NCT02788591|Other|Sucralfate|4x daily Sucralfate slurry, 1g, for 8 weeks
9732545|NCT02785471|Active Comparator|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
9732546|NCT02785471|Experimental|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health & Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
9732547|NCT02777593|Other|Zone 2 Aortic aneurysm - CLOSED TO ENROLLMENT|Zone 2 Aortic Aneurysm
9732548|NCT02777593|Other|Zone 2 Non-aneurysm aortic lesions|Includes dissection, traumatic transection and other isolated lesion types
9732549|NCT02776982|Other|Research procedures|Participants enrolled in study will have confocal endomicroscopy, research biopsies, mucosal impedance, and Bravo ambulatory pH capsule performed at the time of clinically indicated endoscopy.
9732550|NCT02772588|Experimental|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
9732551|NCT02766478|Experimental|Genistein|Participants with and without diabetes will receive 60 mg/day oral genistein (30 mg taken twice daily) for 12 weeks.
9732552|NCT02766478|Placebo Comparator|Placebo|Participants with and without diabetes will receive placebo taken twice daily for 12 weeks.
9732553|NCT02753751|No Intervention|Usual Care|No alert will be fired.
9732554|NCT02753751|Experimental|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
9982465|NCT05235737|Active Comparator|Treatment arm 1|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) plus adjuvant Pembrolizumab (16 cycles q3w, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 of body surface area (BSA) daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
9732555|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 2.5 mg|1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve low-density lipoprotein- cholesterol (LDL-C) goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg
9732556|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 5.0 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.
9732557|NCT02744989|Experimental|Active tDCS|Stimulation will be performed using an tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). The anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's Areas (BA) 8, 9, 10, and 46, depending on the patient). The cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day for 5 consecutive weekdays. The twice daily sessions will be separated by at least 2 hours.
9732558|NCT02744989|Sham Comparator|Sham tDCS|
9732559|NCT02741271|Experimental|MF/F MDI 100/10 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks.
9732560|NCT02741271|Active Comparator|MF MDI 100 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.
9732561|NCT02741245|Active Comparator|Ezetimibe 10 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
9732562|NCT02741245|Active Comparator|Rosuvastatin 2.5 mg|1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
9732563|NCT02741245|Active Comparator|Rosuvastatin 5.0 mg|2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
9732564|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 2.5 mg|1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
9732565|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 5.0 mg|1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
9732566|NCT02728050|Experimental|Treatment (sorafenib, G-CLAM)|See Detailed Description.
9732567|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
9732568|NCT02707939||Controls|Patients with no developmental diagnoses
9732569|NCT02705963|Experimental|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
9781369|NCT01147341|Placebo Comparator|placebo|Placebo (0.9% sodium chloride) given as 2 subcutaneous (sc) injections at weeks 0, 2, and 4, followed y 1 sc injection given an weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
9781370|NCT01147341|Active Comparator|active treatment with Cimzia|400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 0, 2, and 4, followed by 1 sc injection at weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
9781371|NCT01147380|Experimental|Small dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells( mainly NK cells) is between 10 and 100 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate. Patient of this arm receive small dose of liver NK cell inoculation as described.
9781372|NCT01147380|Experimental|Large dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells(mainly NK cells) is between 100 and 1000 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate.Patient of this arm receive large dose of liver NK cell inoculation as described.
9781373|NCT01147406|Experimental|Active|N6022
9781374|NCT01147406|Placebo Comparator|Placebo|Placebo
9781375|NCT01147458|Experimental|PF-04191834 followed by placebo|PF-04191834 600 mg BID dose followed by matched placebo plus naproxen placebo.
9781376|NCT01147458|Experimental|Placebo followed by PF-04191834|Placebo followed by 600 mg BID dose of PF-04191834 plus naproxen placebo.
9781377|NCT01147458|Experimental|PF-04191834+Naproxen followed by Naproxen|PF-04191834 600 mg BID + Naproxen 500 mg BID followed by Naproxen 500 mg BID plus PF-04191834 placebo
9781378|NCT01147458|Experimental|Naproxen followed by PF-04191834+Naproxen|Naproxen 500 mg BID followed by PF-04191834 600 mg BID + Naproxen 500 mg BID
9785840|NCT01261052|Active Comparator|FMPD/APD intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the first 13 hours, the original artificial pancreas algorithm FMPD, will be used to control the subject's blood glucose. After 13 hours, the adaptive component or APD will be used to control the subject's blood glucose for the remaining 20 hours.
9732570|NCT02688608|Experimental|Pembrolizumab|200 milligrams of Pembrolizumab will be given intravenously every 3 weeks.
9732571|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
9732572|NCT02676752||Skin/soft tissue elasticity assessment|Participants will be evaluated for LEF status using the HN-LEF Grading Criteria and neck range of motion using the Cervical Range of Motion Device. Participants also complete study questionnaires, including VHNSS and LSIDS-H&N. Participants undergo ultrasound shear wave elastography over 20-25 minutes. Participants' cancer disease and treatment information will be gathered from their medical records.
9732573|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant|150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
9732574|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab|150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
9732575|NCT02675231|Active Comparator|8 mg/kg Trastuzumab + Standard of Care Chemotherapy|8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
9732576|NCT02665377|Active Comparator|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
9732577|NCT02665377|Placebo Comparator|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
9732578|NCT02662257|Active Comparator|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
9732579|NCT02662257|Experimental|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
9732580|NCT02653248|Experimental|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
9732581|NCT02653248|Experimental|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
9732582|NCT02653248|Experimental|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
9732583|NCT02650401|Active Comparator|Extracranial solid tumors harboring NTRK1/2/3,|"Arm closed for further enrollment~ROS1, ALK non-gene fusion molecular alterations~Oral entrectinib (RXDX-101)"
9732584|NCT02650401|Active Comparator|CNS tumors harboring- NTRK1/2/3, ROS1, ALK|"Arm closed for further enrollment~molecular alterations, including gene fusions~Oral entrectinib (RXDX-101)"
9732585|NCT02650401|Active Comparator|Neuroblastoma|"Arm closed for further enrollment~Oral entrectinib (RXDX-101)"
9732586|NCT02650401|Active Comparator|Non-neuroblastoma, extracranial solid tumors|"Arm closed for further enrollment~harboring - NTRK1/2/3, ROS1, ALK gene fusions~Oral entrectinib (RXDX-101)"
9732587|NCT02650401|Active Comparator|Any participant unable to swallow capsules|"Arm closed for further enrollment~Any participant who otherwise meet all other eligibility criteria~Oral entrectinib (RXDX-101)"
9732588|NCT02650401|Active Comparator|Expansion: CNS tumors harboring NTRK1/2/3, ROS1|"gene fusions~Oral entrectinib (RXDX-101)"
9732589|NCT02650401|Active Comparator|Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1|"NTRK 1,2,3 and ROS1 fusions~Oral entrectinib (RXDX-101)"
9732590|NCT02648477|Experimental|Cohort 1 (pembrolizumab, doxorubicin hydrochloride)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV on day 1. Treatment repeats every 3 weeks for 6 courses, and then continues for up to 24 months with pembrolizumab alone in the absence of disease progression or unacceptable toxicity.~Patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
9732591|NCT02648477|Experimental|Cohort 2 (pembrolizumab, anti-estrogen therapy)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and an aromatase inhibitor (exemestane, anastrozole, or letrozole) PO QD on days 1-21. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.~In both arms, patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
9732592|NCT02634268|Active Comparator|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
9732593|NCT02634268|No Intervention|Usual Care|Participants continue with usual diet and exercise activities as they desire
9732594|NCT02626507|Experimental|Gedatolisib ER+/HER2- Breast Cancer|"Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.~Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.~Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles~Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
9732595|NCT02611206|Experimental|Open Label rTMS|All participants who qualify will undergo 6 weeks of open-label rTMS.
9732596|NCT02605967|Experimental|Spartalizumab 400 mg Q4W|anti-PD1 humanized monoclonal antibody. Participants treated with spartalizumab who remained on spartalizumab
9732597|NCT02605967|Active Comparator|Chemotherapy|commonly used chemotherapy as per investigator's choice
9732598|NCT02590809|Experimental|Treatment group|20 patients
9732599|NCT02590809|Placebo Comparator|Placebo group|20 patients
9732600|NCT02584634|Experimental|Group A|ALK negative Non-Small Cell Lung Cancer
9732601|NCT02584634|Experimental|Group B|ALK positive Non-Small Cell Lung Cancer
9732602|NCT02581137|Experimental|Prevention (extended-release metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9732603|NCT02570503|Experimental|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
9732604|NCT02570503|Placebo Comparator|Placebo|0.9% Sodium Chloride- 100ml
9732605|NCT02564068|Experimental|Oxytocin Only|Subjects will come in for one visit, and will receive only oxytocin
9732606|NCT02564068|Experimental|Oxytocin & Placebo Crossover|Subjects will come in for two visit: They will receive either placebo or oxytocin on visit 1 and the other intervention of visit 2. Subjects will be blinded as to which drug they are receiving on which visit.
9732607|NCT02563431|Active Comparator|SP-ED|Classic use
9732608|NCT02563431|Experimental|4P-ED|Literature update
9732609|NCT02553265|Placebo Comparator|Placebo|Matching placebo
9732610|NCT02553265|Experimental|Low-Dose Carbidopa|
9732611|NCT02553265|Active Comparator|High-Dose Carbidopa|
9732612|NCT02550288|Active Comparator|Ezetimibe 10 mg|1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
9732613|NCT02550288|Active Comparator|Atorvastatin 10 mg|1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
9732614|NCT02550288|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
9732615|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
9732616|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks
9732617|NCT02546661|Experimental|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:~The investigator believes it is in the patient's interest to receive durvalumab;~The patient consents to the continued treatment;~It is clinically appropriate for the patient to continue on durvalumab treatment;~The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
9732618|NCT02546661|Experimental|Module A: MEDI4736 (durvalumab) + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
9732619|NCT02546661|Experimental|Module B: MEDI4736 (durvalumab) + Olaparib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
9732620|NCT02546661|Experimental|Module C: MEDI4736 (durvaluamb) + AZD1775|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
9732621|NCT02546661|Experimental|Module D: MEDI4736 (durvalumab) monotherapy|MEDI 4736 (durvalumab) will be given by IV infusion once every 4 weeks.
9732622|NCT02546661|Experimental|Module E: MEDI4736 (durvalumab) + Vistusertib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
9732623|NCT02546661|Experimental|Module F: MEDI4736 (durvaluamb) + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV MEDI4736 (durvalumab) begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and MEDI4736 is given once every 4 weeks.
9732624|NCT02546661|Experimental|Module G: MEDI4736 + Selumetinib|
9732625|NCT02546492|Experimental|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
9732626|NCT02543320|Experimental|Supportive care (neurofeedback)|Beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training QID TIW for up to 6 treatments. Patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training.
9732627|NCT02510040||Convergence insufficiency|Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
9732628|NCT02510040||Divergence insufficiency|Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
9732629|NCT02510040||Small-angle hypertropia|Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
9732630|NCT02499328|Experimental|Part A1: AZD9150 / MEDI4736|Patients allocated in cohort of arm A1 (AZD9150/MEDI4736 will be evaluated for DLT until an MTD is achieved.
9732631|NCT02499328|Experimental|Part A2: AZD5069 / MEDI4736|Patients allocated in cohort of arm A2 (AZD5069/MEDI4736 will be evaluated for DLT until an MTD is achieved.
9732632|NCT02499328|Experimental|Part B1:AZD9150+MEDI4736:PDL1 pretreated|Patients in arm B1 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
9732633|NCT02499328|Experimental|Part B2:AZD5069+MEDI4736:PDL1 pretreated|Patients in arm B2 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
9732634|NCT02499328|Experimental|Part B3: AZD9150+MED4736:naiive 2L|Patients in arm B3 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
9732635|NCT02499328|Experimental|Part B4:AZD5069+MEDI4736:naiive patients|Patients in arm B4 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
9732636|NCT02499328|Experimental|Part B5: AZD9150 in naiive patients|Patients in arm B5 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
9732637|NCT02499328|Experimental|Part B6:AZD5069 in naiive patients|Patients in arm B6 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
9732638|NCT02499328|Experimental|Part A3: AZD5069/MEDI4736|Patients allocated in cohort of arm A3 (AZD5069/MEDI4736) will be evaluated for DLT and viability as alternate dosing option for Phase 2 studies
9732639|NCT02499328|Experimental|Part A4: AZD9150/Treme/MEDI4736|Patients allocated in cohort of arm A4 (AZD9150/treme/MEDI4736) will be evaluated for DLT and MTD
9732640|NCT02499328|Experimental|Part A5: AZD5069/Treme/MEDI4736|Patients allocated in cohort of arm A5 (AZD5069/treme/MEDI4736) will be evaluated for DLT and MTD.
9732641|NCT02499328|Experimental|Part A6: AZD9150/MEDI4736|Patients allocated in cohort of arm A6 (AZD9150/MEDI4736) will be evaluated for safety, PK and PD.
9732642|NCT02499328|Experimental|Part A7: AZD5069/MEDI4736|Patients allocated in cohort of arm A7 (AZD5069/MEDI4736) will be evaluated for safety, PK and PD.
9732643|NCT02499328|Experimental|Part B7: AZD9150+MEDI4736: naiive 1L|Patients in Arm B7 will be evaluated for efficacy until disease progression and then followed up for safety and survival
9732644|NCT02499328|Experimental|Part B8: AZD9150 (every other week)+MEDI4736: naive 1L|Patients in Arm B8 will be evaluated for efficacy until disease progression and then followed up for safety and survival
9732645|NCT02492269|Experimental|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
9732646|NCT02492269|Placebo Comparator|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
10200439|NCT04103879|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen.~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
10200440|NCT04093362|Experimental|TAS-120|TAS-120 tablets, oral; 21-day cycle
10200441|NCT04093362|Active Comparator|Cisplatin/Gemcitabine|"• On Days 1 and 8 of a 21-day cycle, patients will receive:~Cisplatin 25 mg/m2 in 1000 mL 0.9% saline by intravenous (I.V.) infusion over 1 hour, followed by 500 mL 0.9% saline over 30 minutes; and~Gemcitabine 1000 mg/m2 in 250-500 mL 0.9% saline by I.V. infusion over 30 minutes, beginning after completion of the cisplatin and saline infusions."
10200442|NCT04089514||Adalimumab Therapy|Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy
10200443|NCT04088071||Patients with atrial fibrillation|Subjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
9732647|NCT02470377|Experimental|Real Transcranial Magnetic Stimulation|After determination of the motor threshold, the TMS coil will be positioned at predetermined locations over the brain using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses (repetitive TMS) at 1Hz up to 10Hz or in theta burst mode will be delivered at one or more locations over the head, depending on the brain location under study (brain locations determined by MRI data).
9732648|NCT02470377|Active Comparator|Active Control Transcranial Magnetic Stimulation|An active comparator not at the target of interest will be used for the study.
9732649|NCT02469753|Experimental|Patients treated with anti-TNF and continuous daily NSAIDs|
9732650|NCT02469753|Active Comparator|Patients treated with anti-TNF and NSAIDs on demand|
9732651|NCT02467153|Experimental|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
9732652|NCT02467153|Placebo Comparator|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
10200444|NCT04086758|Experimental|Zolbetuximab|Participants will receive a loading dose-1 of zolbetuximab on Day 1 of Cycle 1, consists of 21 days, followed by subsequent lower dose-2 every 3 weeks until they meet the discontinuation criteria.
9732653|NCT02464904|Experimental|Cryotherapy|Cryospray and biopsies
9732654|NCT02464904|Other|Control|Biopsies
9732655|NCT02463981|Experimental|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
9732656|NCT02463981|Sham Comparator|sham control|Sham control group receives sham neurofeedback from a large control brain region.
9732657|NCT02460224|Experimental|Phase 1: LAG525 1 mg/kg Q2W|Single-agent LAG525 1 mg/kg Q2W
9732658|NCT02460224|Experimental|Phase 1: LAG525 3 mg/kg Q2W|Single-agent LAG525 3 mg/kg Q2W
9732659|NCT02460224|Experimental|Phase 1: LAG525 5 mg/kg Q2W|Single-agent LAG525 5 mg/kg Q2W
9732660|NCT02460224|Experimental|Phase 1: LAG525 10 mg/kg Q2W|Single-agent LAG525 10 mg/kg Q2W
9732661|NCT02460224|Experimental|Phase 1: LAG525 15 mg/kg Q2W|Single-agent LAG525 15 mg/kg Q2W
9732662|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W|Single-agent LAG525 240 mg Q2W
9732663|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q2W|Single-agent LAG525 400 mg Q2W
9732664|NCT02460224|Experimental|Phase 1: LAG525 3 mg/kg Q4W|Single-agent LAG525 3 mg/kg Q4W
9732665|NCT02460224|Experimental|Phase 1: LAG525 5 mg/kg Q4W|Single-agent LAG525 5 mg/kg Q4W
9732666|NCT02460224|Experimental|Phase 1: LAG525 10 mg/kg Q4W|Single-agent LAG525 10 mg/kg Q4W
9732667|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q4W|Single-agent LAG525 400 mg Q4W
9732668|NCT02460224|Experimental|Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
9732669|NCT02460224|Experimental|Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W|Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
9732670|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W|Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
9732671|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
9732672|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W|Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
9732673|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
9732674|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
9732675|NCT02460224|Experimental|Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
9732676|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W|Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
9732677|NCT02460224|Experimental|Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
9732678|NCT02460224|Experimental|Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
9732679|NCT02460224|Experimental|Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
9732680|NCT02460224|Experimental|Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
9732681|NCT02460224|Experimental|Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
9732682|NCT02460224|Experimental|Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W|Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
9732683|NCT02460224|Experimental|Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1
9732684|NCT02460224|Experimental|Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W|Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1
9732685|NCT02460224|Experimental|Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W|Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1
9732686|NCT02460159|Experimental|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
9732687|NCT02460159|Experimental|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
9732688|NCT02459457|Active Comparator|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4
9732689|NCT02459457|Active Comparator|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2
9732690|NCT02459457|Active Comparator|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2
9732691|NCT02457910|Experimental|Taselisib 2 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
9732692|NCT02457910|Active Comparator|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib
9732693|NCT02457910|Experimental|Taselisib 4 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
9732694|NCT02457910|Experimental|Taselisib 6 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
9732695|NCT02457910|Experimental|Taselisib 8 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
9732696|NCT02457910|Experimental|Enzalutamide + Taselisib|Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive Taselisib PO QD starting on day 1 of cycle 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9732697|NCT02457910|Experimental|Cross-Over|Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD
9732698|NCT02411253|Experimental|rhIL-2|"0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,~1MIU/day for adults.~Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351,~Regimen B injections every week between D15 and D351"
9732699|NCT02411253|Placebo Comparator|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351~Regimen B injections every week between D15 and D351"
9732700|NCT02407236|Placebo Comparator|Induction Study - Placebo Intravenous (IV)|Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
9732701|NCT02407236|Experimental|Induction Study - Ustekinumab 130 milligram (mg) IV|Participants will be randomized to receive single dose of ustekinumab 130 mg as IV infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
9732702|NCT02407236|Experimental|Induction Study - Ustekinumab 6 mg/kg IV|Participants will be randomized to receive ustekinumab approximating 6 mg/kg of body weight, as intravenous infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
9732703|NCT02407236|Other|Induction Study- Placebo- Nonresponsders at Week 8|Participants without clinical response to placebo at Week 8 will receive a single IV infusion of ustekinumab approximating 6mg/kg along with matching subcutaneous (SC) placebo (to maintain the blind). Participants in clinical response at Week 16 will be eligible to enter Maintenance study and will be randomized.
9732704|NCT02407236|Other|Induction study-Ustekinumab Nonresponders at Week 8|Participants without clinical response to ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 will receive a single dose of ustekinumab 90 mg subcutaneously along with matching placebo intravenously (to maintain the blind). Participants in clinical response at Week 16 (that is, delayed responders) will be eligible to enter Maintenance study, but will not be randomized.
9732705|NCT02407236|Placebo Comparator|Maintenance Study - Placebo Subcutaneous (SC)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.
9732706|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 12 weeks|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 12 weeks, beginning Week 0 of Maintenance study through Week 44.
9732707|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44.
9732708|NCT02407236|Other|Maintenance Study - Placebo IV - Responder - Placebo SC|Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
9732709|NCT02407236|Other|Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w|Participants without clinical response to induction treatment ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 but in clinical response at Week 16 after receiving Induction Ustekinumab at week 8 (delayed responders) will receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
9732710|NCT02397083|Experimental|Arm I (LIUD)|Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.
9732711|NCT02397083|Experimental|Arm II (LIUD, everolimus)|Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
9732712|NCT02386774|Other|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
9732713|NCT02386774|Other|diabetic patients|
9732714|NCT02370706|Experimental|Dose Escalation Arm 1|
9732715|NCT02370706|Experimental|Dose Escalation Arm 2|
9732716|NCT02370706|Experimental|Dose Escalation Arm 3|
9732717|NCT02370706|Experimental|Dose Expansion Arm 1|
9732718|NCT02370706|Experimental|Dose Expansion Arm 2|
9732719|NCT02370706|Experimental|Dose Expansion Arm 3|
9732720|NCT02320435|Experimental|Pertuzumab (Single-Agent or Combination Therapy)|Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.
9732721|NCT02320396|Experimental|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
9732722|NCT02320396|Placebo Comparator|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
9732723|NCT02299505|Experimental|ceritinib 450 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 450 mg (3×150 mg/capsule) administered in the morning immediately (within 30 minutes)following a low-fat meal.
9732724|NCT02299505|Experimental|ceritinib 600 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 600 mg (4×150 mg/capsule) administered in the morning immediately (within 30 minutes) following a low-fat meal.
9732725|NCT02299505|Active Comparator|ceritinib 750 mg on an empty stomach|Oral ceritinib QD (21 days/ cycle) at a dose of 750 mg (5×150 mg/capsule) administered in the morning on an empty stomach (i.e., fasted from food and drink except water)
9732726|NCT02282345|Experimental|Treatment (talazoparib)|"Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice.~This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib."
9732727|NCT02281864|Other|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
9732728|NCT02281864|Experimental|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
9732729|NCT02251262|Experimental|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
9732730|NCT02250014|Experimental|Arm I (cryotherapy, sargramostim)|Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously on days 1, 3, 5, 8, 10, and 12.
9732731|NCT02250014|Active Comparator|Arm II (cryotherapy, standard of care)|Patients undergo cryotherapy on day 0.
9732732|NCT02235701|Experimental|aldoxorubicin|
9732733|NCT02235688|Experimental|aldoxorubicin|
9732734|NCT02230410|Experimental|focal cryo ablation|Subjects with residual barrett's esophagus (less than 3 cm) post ablation will under go one CryoBalloon Focal Ablation treatment
9732735|NCT02212262||Multiple Myeloma Patients|Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only.
9732736|NCT02212262||Healthy subjects|Healthy subjects and multiple myeloma patients will undergo a blood draw
9732737|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
10205074|NCT04107727|Placebo Comparator|Placebo|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
10205075|NCT04107077|Experimental|Drug Administration Period|
9732740|NCT02115074|Experimental|Fluvastatine Celebrex|dose escalation for Fluvastatine
9732741|NCT02100800|Experimental|COPD Group|30 patients with diagnosis of COPD
9732742|NCT02100800|Sham Comparator|Control Group|10 volunteers with extrapulmonary neoplasia
9732743|NCT02083835||post-surgical patients|post-surgical patients > 18 years
9732744|NCT02083835||pediatric patients post-op day 1|pediatric patients <18 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
9732745|NCT02070549|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9732746|NCT02066636|Experimental|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
9732747|NCT02066636|Experimental|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until 1 year (52 weeks).~Discontinue treatment and at progression, retreatment allowed"
9732748|NCT02053246|Experimental|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
10205076|NCT04101630||Participants with Pulmonary Hypertension|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
10205077|NCT04101630||Healthy Volunteers|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
9732749|NCT02045381||MRI group|Patient receives one research MRI prior to radiation treatment.
9732750|NCT02029430|Experimental|aldoxorubicin|Subjects will receive either 100 or 150 mg/m2 (75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group.
9732751|NCT02014844|Experimental|aldoxorubicin|Subjects will receive either 250 mg/m2 or 350 mg/m2 aldoxorubicin IV.
9732752|NCT02005471|Active Comparator|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter squared (mg/m^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
9732753|NCT02005471|Experimental|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
9732754|NCT02005471|Experimental|Bendamustine + Rituximab Crossover Substudy|Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
9732755|NCT02005471|Experimental|Venetoclax + Rituximab Re-Treatment|Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
9732756|NCT01980940|Experimental|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
9732757|NCT01980940|Experimental|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
9732758|NCT01980940|Experimental|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
9732759|NCT01980940|Experimental|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
9732760|NCT01980940|Experimental|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose [OD]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
9732761|NCT01980940|Other|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
9732762|NCT01980940|Experimental|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
9732763|NCT01980940|Placebo Comparator|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
9732764|NCT01923298|Experimental|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
9732765|NCT01918033|Experimental|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
9732766|NCT01918033|Experimental|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
9732767|NCT01918033|Placebo Comparator|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
10200445|NCT04052685|Experimental|Selective removal to soft dentin (SRSD)|The patients in SRSD group will be randomized into two subgroups as Group A and Group C. After caries removal to soft dentin calcium silicate based material (Biodentine) will be applied in Group A while will not be applied in Group C prior to placement of the resin composite restoration. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel.Carious tissue at the periphery of the cavity will be prepared to hard dentin using round tungsten carbide burs and/or an excavator, while soft carious dentin will remain in the pulpal aspect of the cavity to prevent pulp exposure. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration.
10200446|NCT04052685|Active Comparator|Selective removal to firm dentin (SRSD)|Procedures will be done using local anesthesia. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel. Caries tissue in the periphery including the enamel-dentinal junction will be removed using round tungsten carbide burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries tissue will be removed until hard or leathery dentin remains. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration. Restoration will be performed after caries removal to firm dentin and placement of calcium silicate based material (Biodentine).
10200447|NCT04051112|Experimental|SCB-313|
10200448|NCT04048122|Active Comparator|Standard of Care (Control Group)|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
10200449|NCT04048122|Experimental|MC4PD Strategy Training|This treatment focuses on improving functional performance by enhancing the generation and use of strategies-which can be internal (e.g., self-talk, planning) or external (e.g., checklist, alarm)-to circumvent cognitive processing limitations caused by PD. It uses a standardized approach across and within sessions for all clients while being tailored to each client's cognitive problems and goals.
10200450|NCT04047290|Experimental|AK112|AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)
9732768|NCT01916980|Experimental|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
9732769|NCT01916980|Experimental|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
9732770|NCT01916967|Experimental|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
9732771|NCT01916967|Experimental|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
9732772|NCT01916967|Placebo Comparator|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
9732773|NCT01910402|Experimental|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
9732774|NCT01910402|Active Comparator|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
9732775|NCT01893320|Experimental|Vosaroxin + Decitabine|"The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).~Following the phase I portion, patients in phase II receive the following induction:~Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I.~Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I."
9732776|NCT01870401|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
9732777|NCT01870401|Active Comparator|PTA Catheter|Standard Uncoated PTA Catheter
9732778|NCT01869218||Pre-treatment tumor biopsies|Patients who meet eligibility criteria will undergo a fresh tumor biopsy and collection of research blood samples. Archived tumor specimens will also be obtained and analyzed. At the time of disease progression, fresh tumor biopsies and blood samples will be collected in patients who have evaluable pre-biopsy specimens and who are eligible to be screened for another study.
9732779|NCT01867606|Experimental|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
9732780|NCT01867606|Placebo Comparator|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
10200451|NCT04035668|Experimental|LOU064 Dose 1|high orally
10200452|NCT04035668|Experimental|LOU064 Dose 2|high orally
10200453|NCT04035668|Experimental|LOU064 Dose 3|middle orally
10200454|NCT04035668|Experimental|LOU064 Dose 4|low orally
10200455|NCT04035668|Placebo Comparator|Placebo|0 mg orally
9732781|NCT01857063|Experimental|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
9732782|NCT01857063|Experimental|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
9732783|NCT01854268|Experimental|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
9732784|NCT01852812|Experimental|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
9732785|NCT01852812|Experimental|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
9732786|NCT01852812|Experimental|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
9732787|NCT01844986|Experimental|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
9732788|NCT01844986|Placebo Comparator|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
9732789|NCT01828021|Experimental|margetuximab|Monotherapy of Anti-HER2 monoclonal antibody
9732790|NCT01796145|Experimental|TACE|
9732791|NCT01796145|Experimental|Systemic Therapy|
9732792|NCT01796145|Experimental|Surgery|
9732793|NCT01775046||DTA patients|160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.
9732794|NCT01770067|Experimental|Infected CIED and Infection-Prone Patients Prior to CIED Implantation|Administration of high-dose antibiotics (CITA)
9732795|NCT01770067|Active Comparator|Infected CIED extraction|Extraction of infected CIED
9732796|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 500/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9732797|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 700/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9732798|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 900/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9732799|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 75/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9732800|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 100/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9732801|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2)125/300 μg for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9732802|NCT01709318|Active Comparator|NuvaRing®|Participants will receive NuvaRing® (etonogestrel-ethinyl estradiol [ENG-EE] 120/15 μg) for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9732803|NCT01706835|Experimental|Aldoxorubicin|Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
9732804|NCT01698918|Experimental|Everolimus+letrozole/exemestane (first line and second line treatment)|Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)
10200456|NCT04032041||Group 1: Healthy Able-bodied Individuals (Completed)|Healthy able-bodied individuals with no history of lower extremity trauma.
9732805|NCT01692444||COPD|15 patients with COPD from 1 to 4 according to the GOLD 2011
9732806|NCT01692444||Non smoker Control|15 patients without COPD and no smoking history
9732807|NCT01692444||Smoker Control|15 patients without COPD but a smoking history
9732808|NCT01673620|Experimental|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg combination tablet administered orally once daily for 2 weeks
9732809|NCT01673620|Placebo Comparator|Placebo|Matching placebo tablet administered orally once daily for 2 weeks
9732810|NCT01673438|Experimental|Aldoxorubicin plus doxorubicin|Aldoxorubicin dosages of 175, 240, and 320 (doxorubicin equivalents of 130, 180, and 240 mg/m2) will be administered as a 30 minutes IVI on Day 1 of each cycle. In addition 35 mg/m2 of doxorubicin HCl will be administered as an IVI over > 3 minutes no later than 3 hours, but no more than 6 hours before the start of aldoxorubicin infusion.
9732811|NCT01660243|Active Comparator|MT-9938 2.5μg|
9732812|NCT01660243|Active Comparator|MT-9938 5μg|
9732813|NCT01660243|Active Comparator|MT-9938 10μg|
9732814|NCT01660243|Placebo Comparator|Placebo|
9732815|NCT01651533|Experimental|Experimental: Mental Practice Group|
9732816|NCT01651533|Active Comparator|Active Comparator: Active Control Group|
9732817|NCT01631851|Experimental|Cognitive behavior therapy|
9732818|NCT01618656|Active Comparator|PF-04457845|2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
9732819|NCT01618656|Placebo Comparator|Placebo (sugar pill)|1/3 of subjects will be randomized to placebo
9732820|NCT01617187|Experimental|Asenapine 2.5 mg BID|
9732821|NCT01617187|Experimental|Asenapine 5 mg BID|
9732822|NCT01617187|Active Comparator|Olanzapine 15 mg QD|
9732823|NCT01617187|Placebo Comparator|Placebo BID|
9732824|NCT01611883|Experimental|Ezetimibe|10 mg oral dose once daily for 24 weeks
9732825|NCT01611883|Placebo Comparator|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks
9732826|NCT01572675||Group Arcoxia®|Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
9732827|NCT01572675||Group Celebrex®|Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
9732828|NCT01554163|Experimental|Etoricoxib 30 mg|Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.
9732829|NCT01554163|Active Comparator|Celecoxib 200 mg|Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.
9732830|NCT01502371|Experimental|MF MDI 50 mcg BID|Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.
9732831|NCT01502371|Experimental|MF MDI 100 mcg BID|Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
9732832|NCT01502371|Experimental|MF MDI 200 mcg BID|Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
9732833|NCT01502371|Active Comparator|MF DPI 100 mcg QD|Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.
9732834|NCT01502371|Placebo Comparator|Placebo|Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
9732835|NCT01490190|Experimental|NuvaRing|
9781379|NCT01147471|Active Comparator|Operative rib fixation|"Randomized subjects will be operated upon within 72 hours of ventilation (early fixation) to stabilize the stove-in segment. Where all fractured ribs are accessible and the number of fractured ribs is few, stabilization of all fractured ribs would be the goal. However, where fractured ribs are in areas difficult to access, enough ribs, based on surgeon judgment, would be fixed to stabilize the stove-in segment. Post-operatively, the patients would receive the standard of care, similar to what is outlined for the non-operative arm.~Operative fixation will be accomplished utilizing the MatrixRIB Fixation System (Synthes CMF, West Chester, PA, USA) according to the device's instructions for use. Sites will obtain the product based on their medical center's normal purchasing practices."
9781380|NCT01147471|No Intervention|Non-operative arm|"Randomized subjects to receive standard of care therapy for blunt thoracic trauma (as per each participating institution's own protocols):~a. Ventilatory support b.Timing of extubation (removal from ventilator): c.Analgesia: institution should provide adequate analgesia utilizing available resources including oral, parenteral, epidural, local nerve blocks etc., d.Chest physical therapy, e.Postural drainage, f.Incentive spirometry - after extubation."
9781381|NCT01147497|Experimental|misoprostol|Misoprostol 400mcg taken buccally 2 hours prior to IUD insertion visit
9781382|NCT01147497|Placebo Comparator|placebo|Pill that is identical to the study drug in appearance, taste, and smell, taken buccally 2 hours prior to IUD insertion visit
9781383|NCT01147601|Active Comparator|Topical 0.5% Timolol|Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
9781384|NCT01147601|Placebo Comparator|Placebo|Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily
9781385|NCT01147627|Active Comparator|Exenatide|
9781386|NCT01147627|Active Comparator|Premixed insulin analog|
9781387|NCT01147627|Active Comparator|pioglitazone|
9781388|NCT01147640|Experimental|CXA 101/tazobactam and metronidazole|
9781389|NCT01147640|Active Comparator|meropenem with matching saline placebo|
9781390|NCT01147744|Experimental|GSK2190915 10mg and placebo|GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
9781391|NCT01147744|Experimental|GSK2190915 30mg and placebo|GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
9781392|NCT01147744|Experimental|GSK2190915 100mg QD and placebo|GSK2190915 100mg (1 x 100mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
9781393|NCT01147744|Experimental|GSK2190915 300mg QD and placebo|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
9781394|NCT01147744|Active Comparator|Fluticasone propionate 100mcg and placebo|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS and two placebo tablets in the morning and one placebo capsule in the evening
9781395|NCT01147744|Active Comparator|Montelukast 10mg and placebo|Montelukast 10mg (1 x 10mg capsule) once daily in the evening and two placebo tablets in the morning and inhaled placebo twice daily via ACCUHALER/DISKUS
9732836|NCT01473108|Experimental|Finerenone (20 mg solution)|3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
9732837|NCT01473108|Experimental|Finerenone (10 mg solution)|3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
9732838|NCT01473108|Experimental|Finerenone (5 mg solution)|3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
9732839|NCT01473108|Experimental|Finerenone (20 mg as tablets)|3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
9732840|NCT01473108|Experimental|Finerenone (2.5 mg solution)|3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
9732841|NCT01471340|Experimental|Mometasone Furoate/Formoterol MDI BID|MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
9732842|NCT01471340|Active Comparator|Mometasone Furoate MDI BID|MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)
9732843|NCT01462370|Experimental|Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
9732844|NCT01462370|Experimental|Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
9732845|NCT01436253||Croatian participants with hyperlipidemia|Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
9732846|NCT01414192||Ezetimibe monotherapy without prior treatment|Enrolled participants who had no prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
9732847|NCT01414192||Ezetimibe monotherpay with prior treatment|Enrolled participants with prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
9732848|NCT01414192||Ezetimibe plus statin|Enrolled participants who were being coadministered ezetimide (Ezetrol®) and another prescription statin.
9732849|NCT01414192||Ezetimibe/simvastatin|Enrolled participants who were receiving ezetimibe and simavastatin fixed dose combination tablet (Inegy®).
9732850|NCT01410825|Experimental|Gene transfer|Open label single arm study
9732851|NCT01390415||Losartan 50 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 50 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
9732852|NCT01390415||Losartan 100 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 100 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
9732853|NCT01381679||All participants|Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.
9732854|NCT01379989|Active Comparator|Carboplatin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
9732855|NCT01379989|Experimental|Trabectedin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
9732856|NCT01370603|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 40 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
9732857|NCT01370603|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/40 mg, placebo to ezetimibe, and placebo to atorvastatin.
9732858|NCT01370590|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 20 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
9732859|NCT01370590|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/20 mg, placebo to ezetimibe, and placebo to atorvastatin.
9732860|NCT01368185||All Participants|Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
9732861|NCT01349907|Experimental|Asenapine/Asenapine|Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
9732862|NCT01349907|Experimental|Placebo/Asenapine|Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
9732863|NCT01345786|Experimental|Commercial NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
9732864|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch A), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
9732865|NCT01345786|Experimental|Commercial NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
9732866|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch B), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
10200457|NCT04032041||Group 2: Individuals Requiring AFO Use (Recruiting)|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
10200458|NCT04027348|Experimental|Treatment (octreotide, dexamethasone, metoclopramide)|IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.
9732867|NCT01345656|Experimental|Arm 1|
9732868|NCT01345656|Experimental|Arm 2|
9732869|NCT01345656|Experimental|Arm 3|
9732870|NCT01345656|Experimental|Arm 4|
10200459|NCT04013802|Experimental|HLA-matched VSTs|"Partially HLA-matched VSTs will be thawed and given by intravenous injection. Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused with agreement of the principal investigator, patient and/or guardian and the treatment team~Additional doses may be from the same donor or a different donor based on available cell lines and patient/disease factors. Decision to switch to a different donor can be made by the principal investigator based on factors that include sequential treatment of different viral infections, concerns for immune escape of the targeted virus and/or availability of a better matched or otherwise superior VST line. Additional treatments will only be given following the agreement of the patient, treating physician, and investigator. This process can be repeated as needed."
10200460|NCT03972865|Experimental|Participants of the race|Participants of the race are healthy triathlete volunteers who will participate in August 2019 in the Embrun (EmbrunMan) long-distance triathlon (Ironman)
10200461|NCT03941509|No Intervention|Control|All facilities will receive usual care during the control phase of the trial.
10200462|NCT03941509|Experimental|Antimicrobial stewardship|Implementation of the nurse-led bundled antimicrobial stewardship intervention
10200463|NCT03921580|Placebo Comparator|Control Canned Tuna|Control Canned Tuna
10200464|NCT03921580|Experimental|Enriched Canned Tuna Variety 1|Enriched Canned Tuna Variety 1: Wakame fiber
10200465|NCT03921580|Experimental|Enriched Canned Tuna Variety 2|Enriched Canned Tuna Variety 2: Polyphenols
10200466|NCT03916770|Active Comparator|whole body vibration|WBV(whole body vibration) will be applied to interventional group for 4 weeks, 3 days a week, a total of 12 sessions while standing upright with the WBV powerplate pro5 device.(Vibration frequency: 30Hz, amplitude: 2.2 mm at progressively increasing duration)
9732871|NCT01345656|Placebo Comparator|Arm 5|
9732872|NCT01345656|Active Comparator|Arm 6|
9732873|NCT01337505|Experimental|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 doxorubicin equivalents of 165, 260, and 325 mg/m2)will be administered as a 30 minute IVI on Day 1 of each cycle.
9732874|NCT01309230|Experimental|Vigil™|intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)
9732875|NCT01306929|Experimental|pridopidine|45mg bid
9732876|NCT01294696||All Enrolled Participants|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
9732877|NCT01277822|Experimental|Losartan/amlodipine Treatment Arm|One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.
10200467|NCT03916770|Sham Comparator|Sham whole body vibration|The sham WBV will be applied to the Control group. A WBV device with 99.5% weakened amplitude will be used for sham WBV. (Application duration of the sham WBV will be same as WBV in the treatment group ).
10200468|NCT03901053|Experimental|AB|Participants in this arm will receive the Reaktiv AFO made by FabTech Systems LLC first, then the PhatBrace AFO by Bio-Mechanical Composites Inc. second.
10200469|NCT03901053|Experimental|BA|Participants in this arm will receive the PhatBrace AFO by Bio-Mechanical Composites Inc. first, then the Reaktiv AFO made by FabTech Systems LLC second.
10200470|NCT03852316|Experimental|Click Device|Each subject (females 14 years of age and older) will perform a self-collection vaginal swab for the Click device and be randomized to a particular order for three vaginal swab collections (performed by Health Care Providers (HCP) as defined by state/local regulatory authorities) for comparator methods. N=1750
10200471|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 40%|
10200472|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 80%|
10200473|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 40%|
10200474|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 80%|
10200475|NCT03840447|Experimental|Chronic Disease Self-Management programme|
10200476|NCT03832946|Experimental|A. GB0139 3 mg once a day|Inhalation of GB0139
10200477|NCT03832946|Placebo Comparator|B. Placebo once a day|Inhalation of Placebo
10200478|NCT03832829|Experimental|Indirect restorations with SR Nexco|Large posterior defects with at least one or more cuspal coverage in molars will be restored using the materials listed (SR Nexco). Procedures will be done using local anesthesia. The procedure, starts with removal of caries or defective restorations and coronal relocation of the the margins using flowable composite with maximum thickness 1 to 1.5 mm and followed by resin composite build-up. Defined principles of morphology driven preparation technique will be followed Impression making, fabrication of indirect restoration with SR Nexco and adhesive cementation will be completed according to manufacturer's instructions.
9732878|NCT01277822|Active Comparator|Amlodipine Treatment Arm|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.
9732879|NCT01273259|Experimental|200 mg /day arm|
9732880|NCT01273259|Experimental|25 mg/day arm|
9732881|NCT01261247|Experimental|Arm I|Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9732882|NCT01244763|Experimental|Cohort A: Roxadustat Tiered, Weight Based Dosing TIW|Participants will receive roxadustat capsules, administered orally 3 times weekly (TIW) for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kilograms (kg)], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 60, 100, and 140 milligrams [mg] roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL.
9732883|NCT01244763|Experimental|Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW|Participants will receive roxadustat capsules orally for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kg], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 60, 100, and 140 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to 2 times a week (BIW) at the time of the initial Hb response.
9732884|NCT01244763|Experimental|Cohort C: Roxadustat at 50 mg TIW|Participants will receive roxadustat capsules at 50 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
9732885|NCT01244763|Experimental|Cohort D: Roxadustat at 100 mg TIW|Participants will receive roxadustat capsules at 100 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
9732886|NCT01244763|Experimental|Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW|Participants will receive roxadustat capsules for 24 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kg], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 70, 100, and 150 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from BIW to 1 time a week (QW) at the time of the initial Hb response.
9732887|NCT01244763|Experimental|Cohort F: Roxadustat at 70 mg BIW then QW|Participants will receive roxadustat capsules at 70 mg for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to BIW at the time of the initial Hb response. Then after >8 weeks of stable Hb, dose frequency will be reduced from BIW to QW.
9732888|NCT01212926|Experimental|analysis of myocardial deformation in 2D strain|
9732889|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
9732890|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
9732891|NCT01208207|Experimental|etoricoxib 90 mg/etoricoxib 90 mg|The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
9732892|NCT01208207|Active Comparator|naproxen 1000 mg/naproxen 1000 mg|The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II
9732893|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
9732894|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
9732895|NCT01208181|Experimental|Etoricoxib 90 mg|The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
9732896|NCT01208181|Placebo Comparator|Placebo|The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
9732897|NCT01206517|Experimental|Cohort 1|Participants 10 or 11 years of age
9732898|NCT01206517|Experimental|Cohort 2|Participants 10 or 11 years of age
9732899|NCT01206517|Experimental|Cohort 3a-d|"Cohort 3a: Participants 10 or 11 years of age~Cohort 3b: Participants 12 or 13 years of age~Cohort 3c: Participants 14 or 15 years of age~Cohort 3d: Participants 16 or 17 years of age"
9732900|NCT01196832||Chronic obstructive pulmonary disease patients|"COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.~Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis."
9732901|NCT01196832||Control group|Subjects without any history of lung disease and with normal lung function testing
9732902|NCT01190267|Experimental|Asenapine|All enrolled participants receive open-label asenapine 2.5 mg twice daily (BID) on Day 1-3, which is increased to 5.0 mg BID on Day 4 (dose can be increased earlier at the investigator's discretion). Asenapine dosing is flexible for the remainder of the 26-week open-label drug administration period, and can be adjusted to either 2.5 mg or 5.0 mg BID at the investigator's discretion, based on tolerability and/or symptomatology.
9732903|NCT01190254|Experimental|Asenapine 2.5 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks.
9732904|NCT01190254|Experimental|Asenapine 5.0 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
9732905|NCT01190254|Placebo Comparator|Placebo|Participants receive placebo asenapine tablets sublingually BID for 8 weeks.
9732906|NCT01154036|Experimental|Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg|Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
9732907|NCT01154036|Active Comparator|Phase I: Atorvastatin 20 mg|Atorvastatin 20 mg tablet once daily for 6 weeks
9732908|NCT01154036|Active Comparator|Phase I: Rosuvastatin 10 mg|Rosuvastatin 10 mg tablet once daily for 6 weeks
9732909|NCT01154036|Experimental|Phase II: EZ 10mg+Atorva 10mg|Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
9732910|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [A]|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
9732911|NCT01154036|Active Comparator|Phase II: Atorva 40mg|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
9732912|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [R]|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
9732913|NCT01154036|Active Comparator|Phase II: Rosuvastatin 20mg|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase
9732914|NCT01101464|Experimental|Asenapine Sequence 1|
9732915|NCT01101464|Experimental|Asenapine Sequence 2|
9732916|NCT01098071|Experimental|mometasone furoate nasal spray|
9732917|NCT01077830||Ezetimibe/Simvastatin 10/40 mg|Participants who received Ezetimibe/Simvastatin 10/40 mg in the base study
9732918|NCT01077830||Placebo|Participants who received placebo in the base study
9732919|NCT01070966||VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)
9732920|NCT01070966||VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)
9732921|NCT01070966||VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)
9732922|NCT01070966||VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)
9732923|NCT01070953||EZETROL® 10 mg|Participants with Hypercholesterolemia treated with EZETROL®
9732924|NCT01035112|Experimental|Magnetic Resonance Imaging (MRI) of Breast Cancer|Contrast-enhanced magnetic resonance imaging (MRI) using the standard department of Radiology MRI screening procedures. The duration of scanning may be variable, but will not exceed 90 minutes.
9732925|NCT01030341|Experimental|CGMS and insulin pump|Continuous glucose monitoring in conjunction with insulin pump
9732926|NCT00979901|Experimental|1|montelukast
9732927|NCT00979901|Experimental|2|loratadine
9732928|NCT00979901|Placebo Comparator|3|placebo
9732929|NCT00979901|Experimental|4|montelukast/loratadine
10200479|NCT03798691|Active Comparator|Anti-TNF monotherapy|Patients with IBD on Anti-TNF monotherapy will be given the shingrix vaccine. Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
10200480|NCT03798691|Active Comparator|Vedolizumab|"Patients with IBD on vedolizumab monotherapy will be given the shingrix vaccine.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
10200481|NCT03790553|Active Comparator|50.4Gy|Total radiotherapy dose of 50.4Gy.
9732933|NCT00963599|Experimental|1|montelukast/loratadine
9732934|NCT00963599|Experimental|2|loratadine
9732935|NCT00963599|Experimental|3|montelukast
9732936|NCT00963599|Placebo Comparator|4|placebo
9732937|NCT00954915|Experimental|teplizumab|Anti CD-3 monoclonal antibody
9732938|NCT00953680|Active Comparator|losartan /HCTZ combination tablet|single dose losartan 100 mg/HCTZ 12.5 mg combination tablet
9732939|NCT00953680|Active Comparator|losartan tablet + HCTZ capsule|Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule
9732940|NCT00945035|Active Comparator|A|Etoricoxib, 20% tablet
9732941|NCT00945035|Active Comparator|B|Etoricoxib, 30% tablet
9732942|NCT00943852|Active Comparator|1|losartan 100 mg
9732943|NCT00943852|Active Comparator|2|ISMN 60 mg
9732944|NCT00943852|Active Comparator|3|losartan 100 mg + ISMN 15 mg
9732945|NCT00943852|Active Comparator|4|losartan 100 mg + ISMN 60 mg
9732946|NCT00943852|Placebo Comparator|5|Placebo
9732947|NCT00927953|Experimental|MGAWN1|30 mg/kg single intravenous infusion of MGAWN1
10200482|NCT03790553|Experimental|61.2Gy|Total radiotherapy dose of 61.2Gy.
10200483|NCT03789318|Active Comparator|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (CA-008 5 mg): the surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
9732948|NCT00927953|Placebo Comparator|Placebo - Normal Saline|single intravenous infusion of saline placebo
9732949|NCT00909389||Filipino Patients with Hypercholesterolemia|
9732950|NCT00870051||AAA patients|Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry
9732951|NCT00867048|Experimental|Early ART|Initiate ART immediately following randomization
9732952|NCT00867048|Active Comparator|Deferred ART|Defer ART until the CD4+ count declines to <350 cells/cu mm or AIDS develops
9732953|NCT00820027|Experimental|Etoricoxib 90 mg|Participants received etoricoxib 90 mg once daily, matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
9732954|NCT00820027|Experimental|Etoricoxib 120 mg|Participants received etoricoxib 120 mg once daily, matching placebo to etoricoxib 90 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
9732955|NCT00820027|Active Comparator|Ibuprofen 1800 mg|Participants received ibuprofen 600 mg every 8 hours, matching placebo to etoricoxib 120 mg once daily, and matching placebo to etoricoxib 90 mg once daily for 7 days.
9732956|NCT00820027|Placebo Comparator|Placebo|Participants received matching placebo to etoricoxib 90 mg and matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen every 8 hours for 7 days.
9732957|NCT00816114||Chronic Myelogenous Leukemia|All CML patients in any phase of the disease that received imatinib treatment outside of MDACC clinical trials and has had at least one MDACC clinic visit.
9732958|NCT00788710|Experimental|Etoricoxib 120 mg|etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
9732959|NCT00788710|Experimental|Etoricoxib 90 mg|etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
9732960|NCT00788710|Placebo Comparator|Placebo|Placebo- 3 tablets once daily
9732961|NCT00783224|Placebo Comparator|Mometasone Furoate Placebo (PLAMF)|Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
9732962|NCT00783224|Placebo Comparator|Fluticasone Propionate Placebo (PLAFP)|Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
9732963|NCT00783224|Experimental|Mometasone Furoate (MF)|Mometasone furoate nasal spray 200 μg/day(QD)
9732964|NCT00783224|Active Comparator|Fluticasone Propionate (FP)|Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
9732965|NCT00780403|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
9732966|NCT00780403|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
9732967|NCT00779116|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
9732968|NCT00779116|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
9732969|NCT00778700|Placebo Comparator|Vehicle Cream|Vehicle cream, applied topically, once daily from Day 1 to Week 12.
9732970|NCT00778700|Experimental|Ruxolitinib Phosphate 0.5% Cream|Ruxolitinib phosphate 0.5% cream, applied topically, once daily from Day 1 to Week 12.
9732971|NCT00778700|Experimental|Ruxolitinib Phosphate 1.0% Cream|Ruxolitinib phosphate 1.0% cream, applied topically, once daily from Day 1 to Week 12.
9732972|NCT00778700|Experimental|Ruxolitinib Phosphate 1.5% Cream|Ruxolitinib phosphate 1.5% cream, applied topically, once daily from Day 1 to Week 12.
9732973|NCT00764478|Experimental|Asenapine 5 mg BID|Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
9732974|NCT00764478|Experimental|Asenapine 10 mg BID|Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
9732975|NCT00764478|Placebo Comparator|Placebo BID|Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days
9732976|NCT00762580||Prospective|Patients with full thickness rotator cuff tears being treated with physical therapy
9732977|NCT00761527||Participants with allergic rhinitis or idiopathic urticaria|Outpatient pediatric participants (ages 6 months-11 years) in the Philippines with a diagnosis of allergic rhinitis or chronic idiopathic urticaria.
9732978|NCT00757627|Experimental|1|Etoricoxib
9732979|NCT00756938|Experimental|Losartan potassium 0.1 to 1.4 mg/kg|Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
9732980|NCT00756938|Experimental|Losartan potassium 0.3 to 1.4 mg/kg|Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
9732981|NCT00756938|Experimental|Losartan potassium 0.7 to 1.4 mg/kg|Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
9732982|NCT00746590|Experimental|1|
9732983|NCT00745992||Fungal infections|"Patients with invasive fungal infections; and~Patients who receive PO or IV voriconazole for more than 3 days"
9732984|NCT00730132||New Statin|Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
9732985|NCT00730132||Statin Dose Titration|Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
9732986|NCT00730132||Ezetimibe added to existing statin|Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment
9732987|NCT00728416|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
9732988|NCT00728416|Placebo Comparator|Arm 2|Matching placebo nasal spray
9732989|NCT00724477||Subjects treated with INEGY|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY
9732990|NCT00723736||Pediatric Patients|Those with allergic rhinitis or chronic idiopathic urticaria.
9732991|NCT00705081||Not previously treated|subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy
9732992|NCT00705081||Previously treated with statin|subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy
9732993|NCT00704769||1|Children with a history of perennial allergic rhinitis
9732994|NCT00704535||Subjects with hypercholesterolemia|Subjects with hypercholesterolemia that are using Ezetimibe either alone or in combination with a statin
9732995|NCT00694369|Experimental|1|etoricoxib 90 mg
9732996|NCT00694369|Experimental|2|etoricoxib 120 mg
9732997|NCT00694369|Active Comparator|3|ibuprofen 2400 mg
9732998|NCT00694369|Active Comparator|4|acetaminophen 2400 mg/codeine 240 mg
9732999|NCT00694369|Placebo Comparator|5|Matching Placebo
9733000|NCT00671528|Experimental|QUADRIDERME® cream|QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
9733001|NCT00671528|Active Comparator|Betamethasone and Gentamicin|Combination of betamethasone diproprionate cream and gentamicin sulfate cream
9733002|NCT00671528|Active Comparator|Betamethasone|Betamethasone diproprionate cream
9733003|NCT00667823|Experimental|ACT-064992|ACT-064992
9733004|NCT00652327|Experimental|Ezetimibe + Statin|
9733005|NCT00652327|Active Comparator|Double Statin|
9733006|NCT00604500|Experimental|MF/F MDI 100/10 mcg BID with dose counter|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
9733007|NCT00582257||High Genetic Risk:|"Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.~Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.~Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer."
9733008|NCT00582257||Low Genetic Risk: Closed to Accrual|"Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort.~Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone."
9733009|NCT00568178|Experimental|Losartan Double-Blind Base Study (12-weeks)|"Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo)."
9733010|NCT00568178|Active Comparator|Amlodipine Double-Blind Base Study (12-weeks)|Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
9733011|NCT00568178|Experimental|Losartan Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
9733012|NCT00568178|Active Comparator|Enalapril Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
9733013|NCT00549848|Experimental|HD PEG|"Participants randomized to receive higher dose PEG-asparaginase during the continuation phase.~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
9733014|NCT00549848|Active Comparator|CD PEG|"Participants randomized to receive conventional dose PEG-asparaginase during the continuation phase..~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
9733015|NCT00545844|Experimental|1|montelukast sodium
9733016|NCT00511433|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
9733017|NCT00511433|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
9733018|NCT00511355|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
9733019|NCT00511355|Active Comparator|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets (LNG-EE), 150 mcg LNG and 30 mcg EE
9733020|NCT00511342|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC
9733021|NCT00511342|Active Comparator|LNG-EE|Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC
9733022|NCT00511199|Experimental|NOMAC-E2|"Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive"
9733023|NCT00511199|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
9733024|NCT00491504|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg total dose (2 sprays each nostril)
9733025|NCT00491504|Placebo Comparator|Placebo|Placebo (2 sprays each nostril)
9733026|NCT00468312|Experimental|Mometasone Furoate Nasal Spray (MFNS)|200 mcg daily
9733027|NCT00468312|Placebo Comparator|Placebo|Two sprays in each nostril in the morning
9733028|NCT00453063|Experimental|MFNS 200 mcg QD|
9733029|NCT00453063|Placebo Comparator|Placebo|
9733030|NCT00447603|Active Comparator|Losartan 50 mg|Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
9733031|NCT00447603|Active Comparator|Losartan 100 mg|Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
9733032|NCT00447603|Experimental|Losartan 50 mg/HCTZ 12.5 mg|Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
9733033|NCT00447603|Experimental|Losartan 100 mg/HCTZ 12.5 mg|Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks
9733034|NCT00442351|Experimental|Asmanex Twisthaler|
9733035|NCT00442351|Placebo Comparator|Placebo inhaler|
9733036|NCT00423488|Experimental|Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg|Participants were instructed to take one 10-mg ezetimibe tablet and one simvastatin placebo tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
9733037|NCT00423488|Active Comparator|Ezetimibe Placebo + Simvastatin 40 mg|Participants were instructed to take one ezetimibe placebo tablet and one simvastatin 20-mg tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
9733038|NCT00413972|Experimental|Vytorin 10/10|Ezetimibe 10 mg with Simvastatin 10 mg
9733039|NCT00413972|Experimental|Vytorin 10/20|Ezetimibe 10 mg with Simvastatin 20 mg
9733040|NCT00413972|Experimental|Vytorin 10/40|Ezetimibe 10 mg with Simvastatin 40 mg
9733041|NCT00413972|Placebo Comparator|Placebo|
9733042|NCT00413062|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
9733043|NCT00413062|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
9733044|NCT00391170|Experimental|Dexamethasone oral rinse in stem cell transplant participants|Dexamethasone 0.01% (0.5mg/5 mL) oral rinse solution in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
9733045|NCT00391170|Placebo Comparator|Placebo oral rinse in stem cell transplant participants|Placebo oral rinse in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
9733046|NCT00359138|Experimental|Desloratadine 5 mg tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
9733047|NCT00359138|Active Comparator|Desloratadine placebo tablet + Levocetirizine 5 mg capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
9733048|NCT00359138|Placebo Comparator|Desloratadine placebo tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
9733049|NCT00350701|Experimental|androgel 5g|androgel 5g
9733050|NCT00350701|Experimental|androgel 10g|androgel 10g
9733051|NCT00350701|Placebo Comparator|placebo|placebo
9733052|NCT00335816|Experimental|Group 1 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
9733053|NCT00335816|Experimental|Group 2 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1-2. Treatment repeats every 14 days for 2 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
9733054|NCT00335816|Experimental|Group 3 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 4 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
9733055|NCT00335816|Experimental|Group 4 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 6 courses. After the last week of post- radiation chemotherapy, patients undergo standard surgical resection. Patients then receive 3 additional courses of FOLFOX-6 chemotherapy or other chemotherapy off study as directed by the physician.
9733056|NCT00319449|Experimental|Ezetimibe 10 mg|Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
9733057|NCT00319449|Placebo Comparator|Placebo 10 mg|Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
9733058|NCT00305344|Active Comparator|Cord Blood|Umbilical Cord Blood
9733059|NCT00289887|Experimental|1|Losartan
9733060|NCT00289887|Placebo Comparator|2|Placebo
9733061|NCT00281320|Experimental|Asenapine 2-10 mg BID|Dose titration from 2 mg to 5 mg to 10 mg twice daily (BID)
9733062|NCT00281320|Experimental|Asenapine 5-10mg BID|Dose titration from 5 mg to 10 mg BID
9733063|NCT00276016|Experimental|Phenylephrine, Pseudoephedrine, Placebo|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules."
9733064|NCT00276016|Experimental|Pseudoephedrine, Placebo, Phenylephrine|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
9733065|NCT00276016|Experimental|Placebo, Phenylephrine, Pseudoephedrine|"Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
9733066|NCT00276016|Experimental|Phenylephrine, Placebo, Pseudoephedrine|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
9733067|NCT00276016|Experimental|Pseudoephedrine, Phenylephrine, Placebo|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules."
9733068|NCT00276016|Experimental|Placebo, Pseudoephedrine, Phenylephrine|"Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
9781396|NCT01147744|Placebo Comparator|Placebo Comparator|Two GSK2190915 placebo tablets once daily in the morning, montelukast placebo capsule once daily in the evening and fluticasone propionate placebo twice daily via ACCUHALER/DISKUS
9781397|NCT01147809|Active Comparator|Eltrombopag|Drug: eltrombopag olamine thrombopoietin receptor agonist
9781398|NCT01147809|Placebo Comparator|Placebo|Other: Placebo Placebo tablets with no active pharmaceutical ingredient
9781399|NCT01147848|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks
9781400|NCT01147848|Active Comparator|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks
9781401|NCT01147874|No Intervention|psoriatic arthritis (PsA) questionnaire|
10200484|NCT03789318|Placebo Comparator|Placebo for Cohort 1|"Cohort 1:~Placebo comparator is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
10200485|NCT03789318|Active Comparator|CA-008 10 mg (0.1 mg/mL)|Cohort 2 (CA-008 10 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
10200486|NCT03789318|Active Comparator|CA-008 15 mg (0.15 mg/mL)|Cohort 3 (CA-008 15 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).
9781402|NCT01147900|Experimental|Boostrix-REF Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
9781403|NCT01147900|Experimental|Boostrix-US Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
9781404|NCT01147900|Experimental|Boostrix-INV Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
9781405|NCT01147926|Placebo Comparator|Placebo|Placebo
9781406|NCT01147926|Active Comparator|Prucalopride|1 milligram (mg) or 2 mg
9781407|NCT01148017|Experimental|ACWY - 4|Subjects who had previously received 4 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their first year of life are administered one booster dose of the same vaccine at 60 months of age.
9781408|NCT01148017|Experimental|ACWY - 2|Subjects who had previously received 1 or 2 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their second year of life, are administered one booster dose of the same vaccine at 60 months of age.
9781409|NCT01148017|Other|Naïve - 40|Control subjects, age-matched with the intervention groups subjects (40 months of age), to receive 1 optional dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
9781410|NCT01148017|Active Comparator|Naïve - 60|Control subjects, age-matched with the intervention groups subjects (60 months of age), are administered one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
9781411|NCT01148225|Other|Adalimumab|Participants received open label (OL) adalimumab 40 mg by subcutaneous (SC) injection every other week (eow) until the final visit.
9781412|NCT01148420|Experimental|DMPA & MPA|150 mg intramuscularly received DMPA and two 10 mg tablets of MPA every 8 hours for 3 days
9781413|NCT01148459|Experimental|Group A|Infants enrolled to this group will receive 3 doses of the experimental vaccine.
9781414|NCT01148459|Active Comparator|Group B|Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
9733069|NCT00265343|Experimental|1|asenapine
9827933|NCT02473614|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
9982466|NCT05235737|Active Comparator|Treatment arm 2|n=12 evaluable patients - neoadjuvant Pembrolizumab (2 doses, 200mg each) on top of standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
9982467|NCT05235737|No Intervention|Treatment arm 3|n=12 evaluable patients - standard chemo-radiotherapy (Stupp protocol: radiotherapy 60Gy over 6 weeks, 2 Gy per daily fraction Mo-Fri setting plus Temozolomide 75mg/m2 BSA daily during radiotherapy and six cycles post-radiotherapy of 150-200mg/m2 for 5 days in each 28-day cycle)
9982468|NCT05234775|Experimental|LIB003 (lerodalcibep) Process 1|300 mg LIB003 Process 1 drug product administered SC
9982469|NCT05234775|Active Comparator|LIB003 (lerodalcibep) Process 2|300 mg LIB003 Process 2 drug product administered SC
10205523|NCT05205811|Experimental|Combination zonisamide and bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with zonisamide (100 mg daily). The combination of zonisamide and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
9665581|NCT04989686||Cyclosporine A|"Males and females <18 years of age~Greater than 5 kg~Receiving cyclosporine A as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of cyclosporine A for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
9665582|NCT04989686||Tacrolimus|"Males and females <18 years of age~Greater than 5 kg~Receiving tacrolimus as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of tacrolimus for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
9665583|NCT04989686||Sirolimus|"Males and females <18 years of age~Greater than 5 kg~Receiving sirolimus as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of sirolimus for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
9665584|NCT04989660|Experimental|Treatment Group|6% aqueous phenol, 1.5 mL per target site
9665585|NCT04989660|Placebo Comparator|Placebo Group|Isotonic saline, 1.5 mL per target site
9665586|NCT04987944|Experimental|BHV3500|Zavegepant 150 mg BID
9665587|NCT04987944|Placebo Comparator|Placebo|Matching placebo 150 mg BID
9665588|NCT04985084|Experimental|The intervention group|A 4-week dietary behavioral intervention provided by a registered nurse who has received nutrition training.
9665589|NCT04985084|Other|Usual care|General dietary advice provided by the ward nurses.
9665590|NCT04981171|Experimental|Electro-thumbtack Needle Therapy (ETN) group|Electro-thumbtack needles (0.25×2 mm) will be inserted into acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, turn on the device to produce a proper electric stimulation that the participant can tolerate.
9665591|NCT04981171|Sham Comparator|Sham Electro-thumbtack Needle Therapy (ETN) group|Sham electro-thumbtack needles (0.25×0.2 mm) which are specially produced have blunt tips instead of sharp needle tip. They will be taped on acupoints of Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) after sterilization. Then apply the gel electrodes and stimulation devices, produce a minimal level of electric stimulation for 30 seconds before turning off the device.
9665592|NCT04979858|No Intervention|Control Group|The subjects will choose their own mask and masking practices.
9665593|NCT04979858|Experimental|Treatment Group|The treatment group will receive and use the focal mask.
9665594|NCT04978831|Experimental|Respiratory exercise device group|
9665595|NCT04978831|Experimental|Reading aloud group|
9665596|NCT04978831|No Intervention|Control group|
9665597|NCT04978818|Active Comparator|Vaxelis|165 infants will be randomized to the Vaxelis group, which is licensed for primary vaccination at 2, 4 and 6 months of age.
9665598|NCT04978818|Active Comparator|PedvaxHIB arm|165 infants will be randomized to the PedvaxHIB group, which is licensed for primary vaccination at 2 and 4 months of age.
9666438|NCT04518410|Placebo Comparator|Placebo (IM)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
9666439|NCT04518410|Experimental|Camostat|Administered as oral tablets.
9666440|NCT04518410|Placebo Comparator|Placebo (oral tablets)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
9666441|NCT04518410|Experimental|BMS 986414 + BMS 986413|Administered as subcutaneous (SC) injections.
9666442|NCT04518410|Placebo Comparator|Placebo (SC injections)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
9666443|NCT04518410|Experimental|SAB-185 (Lower dose)|Administered by IV infusion.
9666444|NCT04518410|Experimental|SAB-185 (Higher dose)|Administered by IV infusion.
9666445|NCT04518410|Active Comparator|Casirivimab + Imdevimab (Phase III only)|Administered by IV infusion
9733070|NCT00265343|Active Comparator|2|olanzapine
9733071|NCT00264147|Experimental|Period I: 1|etoricoxib
9733072|NCT00264147|Experimental|Period I: 2|etoricoxib
9733073|NCT00264147|Experimental|Period I: 3|etoricoxib
9733074|NCT00264147|Experimental|Period I: 4|etoricoxib
9733075|NCT00264147|Placebo Comparator|Period I: 5|Placebo
9733076|NCT00264147|Experimental|Period II: 1|etoricoxib
9733077|NCT00264147|Active Comparator|Period II: 2|diclofenac
9733078|NCT00202878|Experimental|ezetimibe/simvastatin|One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
9733079|NCT00202878|Active Comparator|simvastatin|One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.
9733080|NCT00174265|Experimental|asenapine|
9733081|NCT00174265|Active Comparator|olanzapine|
9733082|NCT00159783|Experimental|Asenapine|Asenapine 5-10 mg twice daily for 40 weeks
9733083|NCT00159783|Active Comparator|Olanzapine|Olanzapine 5-20 mg once daily for 40 weeks
9665599|NCT04978363|No Intervention|Arm 1. NONE|Participants will be tested while wearing no boot and no assistive device.
9733084|NCT00114101|Experimental|Arm I (melphalan, autologous PBSCT, lenalidomide)|Beginning between day 100-110, patients receive lenalidomide PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
9733085|NCT00114101|Placebo Comparator|Arm II (melphalan, autologous PBSCT, placebo)|Beginning between day 100-110, patients receive placebo PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
9733086|NCT00092677|Experimental|EZ/Simva 10/40 mg|Ezetimibe 10 mg + Simvastatin 40 mg
9733087|NCT00092677|Placebo Comparator|Placebo|
9733088|NCT00090259|Experimental|Losartan 50 mg|50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
9665600|NCT04978363|Experimental|Arm 2. BOOT|The first intervention condition tested is a walking boot only on the subject's right lower extremity.
9665601|NCT04978363|Experimental|Arm 3. HFC+BOOT|The second intervention condition tested is a Hands Free Crutch (HFC) with the walking boot, both worn on the subject's right lower extremity.
9665602|NCT04978363|Experimental|Arm 4. SAC+BOOT|The third intervention condition tested is standard axillary crutches (SAC) with the walking boot worn in non-weight bearing on the subject's right lower extremity.
9733089|NCT00090259|Experimental|Losartan 150 mg|Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan
9733090|NCT00003298|Experimental|Experimental Arm|Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of daily intravenous bolus leucovorin calcium and fluorouracil for 5 days. Chemotherapy is repeated 4-6 weeks later for the first 4 days of week 1 and the last 3 days of week 5 of radiation therapy given 5 days a week for 5 weeks. Patients receive two more courses, 4 weeks apart, of fluorouracil and leucovorin calcium for 5 days 4-6 weeks after completing radiation treatment.
9733091|NCT00003377|Other|Radiation therapy plus concurrent weekly chemotherapy|
9733092|NCT00003389|Experimental|Arm A (ABVD)|Arm A (ABVD): Patients receive doxorubicin (25 mg/m²), bleomycin (10 u/m²), vinblastine (6 mg/m²), and dacarbazine (375 mg/m²) intravenously (IV) on days 1 and 15. Courses repeat every 28 days. Patients are restaged after 4 courses. Patients who are in complete remission receive 2 additional courses. Patients with a partial response or less are evaluated after 6 courses, and if there is an ongoing response, patients may receive 2 additional courses for a total of 8. If no ongoing response is observed, patients are removed from the study. All patients with massive mediastinal disease, regardless of stage, receive radiotherapy 2-3 weeks after completion of chemotherapy.
9733093|NCT00003389|Active Comparator|Arm B (Stanford V)|Arm B (Stanford V): Patients receive Stanford V chemotherapy comprising doxorubicin (25 mg/m²) and vinblastine (6 mg/m²) IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; vincristine (1.4 mg/m²) and bleomycin (5 u/m²) IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; mechlorethamine (6 mg/m²) IV on day 1 of weeks 1, 5, and 9 (if mechlorethamine is unavailable, may substitute with cyclophosphamide [375 mg/m²] IV); etoposide (60 mg/m²) IV on days 1 and 2 of weeks 3, 7, and 11; and oral prednisone (40 mg/m²) every other day of weeks 1-9 followed by a taper. All patients with bulky disease receive radiotherapy 2-3 weeks after completion of chemotherapy.
9733094|NCT00003404|Experimental|Adjuvant Radiotherapy|Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.
9733095|NCT00003453|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733096|NCT00003456|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733097|NCT00003457|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733098|NCT00003459|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached.
9733099|NCT00003460|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9982470|NCT05234424|Active Comparator|THRIVE 40 L/min|40 L/min with 100% oxygen for 10 minutes.
9982471|NCT05234424|Experimental|THRIVE 100 L/min|100 L/min with 100% oxygen for 10 minutes.
9982472|NCT05234229||covagrip women in immediate post partum|women in immediate post partum
9982473|NCT05234229||Caregivers|health care personnel
9982474|NCT05233982|Experimental|OLAPARIB|
10200487|NCT03789318|Placebo Comparator|Placebo for Cohorts 2 and 3|"Cohorts 2 & 3:~Placebo comparator in each cohort is identical in appearance to the investigational product, containing the same excipients as the active comparator.~The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg)."
10200488|NCT03781414|Active Comparator|Arm 1|Control/Standard of Care: TAC + MMF + Corticosteroids
10200489|NCT03781414|Experimental|Arm 2|CFZ533 dose A + MMF + Corticosteroids
10200490|NCT03781414|Experimental|Arm 3|CFZ533 dose B + MMF + Corticosteroids
10200491|NCT03780179|Experimental|MMRvaxpro|
10200492|NCT03780179|Placebo Comparator|Placebo|
10200493|NCT03774875|Experimental|Apremilast 30 mg|Participants will take apremilast 30 mg tablets orally twice a day for up to 52 weeks.
10200494|NCT03774875|Placebo Comparator|Placebo / Apremilast 30 mg|Participants will take placebo tablets orally twice a day for 16 weeks. After week 16, participants will be switched to receive apremilast 30 mg twice daily until Week 52.
10200495|NCT03773952|Experimental|Oral 5-ASA + PBF-677 200 mg|Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
10200496|NCT03773952|Placebo Comparator|Oral 5-ASA + Placebo oral Capsules|Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
9665603|NCT04978363|Experimental|Arm 5. HFC|The fourth intervention condition tested is the Hands Free Crutch worn on the subject's right lower extremity without the walking boot.
9665604|NCT04978363|Experimental|Arm 6. SAC|The fifth and last intervention condition tested is standard axillary crutches with the subject non-weight bearing on the right lower extremity without the walking boot.
9665607|NCT04976153|Experimental|aSMDC|Autologous skeletal muscle derived cells for the treatment of urge fecal incontinence
9665608|NCT04976153|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product
9665609|NCT04974619||Aim 1 Only: Online Survey group|Spanish speaking young Latino men who have sex with men (YLMSM), ages 18-26 (approximately 130 in PR and approximately 130 in FL) will be asked to complete a Qualtrics survey.
9665610|NCT04974619||Aim 2 Only: Interview group|Individual interviews will be conducted with key healthcare stakeholders (i.e.,healthcare clinical leadership, providers and staff, community-based organization staff)
9665611|NCT04974619||Aim 3 Only: Focus Groups|Each site will host 4-6 focus groups with Spanish speaking young Latino men who have sex with men (YLMSM). The total participants will be 24 with 12 participants per site. When focus groups are not feasible, they will be replaced by individual interviews.
9665612|NCT04974333|Experimental|Mobile health application|"Participants assigned to the intervention group will use a mobile application on their smart phones that will assist the patients with their diabetes control, provide and update information on their clinical history, offer a monitoring their nutritional and physical activity habits as well as anthropometric measurements, provide recommendations how to improve on nutritional habits and physical activity behavior, assist in planning and reminding on clinical appointments.~The duration of the intervention will be 12 months. Each patient will be invited to follow-up visits and measurements each three months (month 3, month 6, month 9 and month 12)."
9665613|NCT04974333|No Intervention|Standard care|Participants assigned to the control arm will continue their regular standard diabetes care without mobile health technology assistance.
9665614|NCT04972890|Placebo Comparator|Control group|with 2cc saline/NaCl 0,9% solution once at baseline
9665615|NCT04972890|Experimental|Stem Cell Group|with umbilical cord stem cells 15x10^6 cells in 2 cc saline/NaCl 0,9% solution once at baseline
9665616|NCT04972721||Questionnaire survey|Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.
9665617|NCT04971863||Clareon Monofocal IOL|Patients bilaterally implanted with the Clareon monofocal IOL
9665618|NCT04971863||Asqelio Monofocal IOL|Patients bilaterally implanted with the Asqelio monofocal IOL
9665621|NCT04970433|Experimental|Electroacupuncture (EA)|Acupoint regimen: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation using an EA apparatus, with a pair of electrodes connecting acupoints LI4 with PC6, and another pair of electrodes connecting ST36 with SP6. EA stimulation will last for 15 min with a continuous wave of 2 Hz and a current intensity of 0.1-1 mA.
9665622|NCT04970433|Active Comparator|Laser acupuncture (LA)|Participants allocated to the LA group will receive LA therapy at the same acupoints used in EA group. The laser will be applied to each point for 40 seconds, which delivered 3 J of energy at each of the acupoints.
9665623|NCT04970433|Sham Comparator|Sham laser acupuncture (SLA)|Participants in the control group will receive sham LA treatment without any laser output. The acupuncture points, application duration, and total number of treatments are the same as those in the LA group.
9665624|NCT04969237||healthy subjects 2019|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
9665625|NCT04969237||healthy subjects 2020|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
9665626|NCT04969237||healthy subjects 2021|subjects with diseases not influencing vitamine D values without substitution nor post-COVID
9665627|NCT04969237||post-COVID subjects 2021|subjects with diseases not influencing vitamine D values without substitution with diagnosed post-COVID syndrome
9665628|NCT04966910|Experimental|Stay Connected|Menu-driven set of strategies to combat loneliness, anxiety and depression in older adults
9665629|NCT04966910|Active Comparator|Treatment as usual|Treatment as usual in these practice settings typically includes regular check-in calls and offering resources and referrals
9665630|NCT04966741|Experimental|Setmelanotide|Investigational product: Setmelanotide,10 mg/mL in a sterile solution for Subcutaneous (SC) injection
9733100|NCT00003468|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733101|NCT00003469|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733102|NCT00003470|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733103|NCT00003471|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733104|NCT00003472|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733105|NCT00003473|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733106|NCT00003474|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733107|NCT00003475|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733108|NCT00003476|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733109|NCT00003477|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733110|NCT00003483|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733111|NCT00003487|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733112|NCT00003492|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733113|NCT00003498|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733114|NCT00003499|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733115|NCT00003508|Experimental|Arm: Experimental: Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733116|NCT00003509|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733117|NCT00003511|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733118|NCT00003526|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733119|NCT00003531|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733120|NCT00003535|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733121|NCT00003537|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9733122|NCT00003590|Experimental|Hydroxyurea|
9733123|NCT00003631|Experimental|Arm I|(0-1 adverse prognostic factors): Patients receive ifosfamide by 24 hour infusion on day 2. Carboplatin is administered on day 2. Etoposide IV is administered once daily on days 1-3. Patients then receive filgrastim (G-CSF) subcutaneously or IV on days 5-12. Patients receive another course of ICE chemotherapy 2-3 weeks after the first course.
9733124|NCT00003631|Experimental|Arm II|(2 adverse prognostic factors): Patients receive the first course of ICE as in Arm I
9733125|NCT00003631|Experimental|Arm III|Arm III (3 adverse prognostic factors): Patients receive cyclophosphamide IV daily for 2 days, then G-CSF beginning on day 4 until blood stem cells are collected
9733126|NCT00003641|Other|Observation|Patients undergo observation for 4 weeks.
9733127|NCT00003641|Experimental|Interferon Alfa-2b|Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
9733128|NCT00003644|Experimental|Carboplatin, paclitaxel, low dose paclitaxel|carboplatin, paclitaxel followed by low dose paclitaxel 4 weeks later
9733129|NCT00003644|Active Comparator|Carboplatin, paclitaxel|carboplatin, paclitaxel
9733130|NCT00003645|Experimental|Arm I - Leuprolide + Flutamide|Arm I: Patients receive leuprolide intramuscularly once every 3 months and oral flutamide three times daily for 1 year.
9733131|NCT00003645|No Intervention|Arm II - No Treatment|Arm II: Patients receive no initial treatment.
9733132|NCT00003659|Experimental|intermediate or high risk chronic lymphocytic leukemia|This is a single-arm open-label pilot study designed to assess the antileukemic activity of a regimen containing sequential administration of fludarabine, high-dose cyclophosphamide, and rituximab.
9733133|NCT00003702|Experimental|Arm I (methotrexate)|Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
9733134|NCT00003702|Experimental|Arm II (dactinomycin)|Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
9733135|NCT00003782|Experimental|Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel|Doxorubicin + Cyclophosphamide, then Docetaxel
9733136|NCT00003782|Experimental|Arm 2: Doxorubicin + Docetaxel|Doxorubicin + Docetaxel
9733137|NCT00003782|Experimental|Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide|Doxorubicin + Docetaxel + Cyclophosphamide
9733138|NCT00003816|Experimental|Regimen 1|Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
9733139|NCT00003816|Experimental|Regimen 2|Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
9733140|NCT00003816|Experimental|Regimen 3|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
9733141|NCT00003816|Experimental|Regimen 4|Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
9733142|NCT00003816|Experimental|Regimen 5|Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
9733143|NCT00003816|Experimental|Regimen 6|Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
9733144|NCT00003816|Experimental|Regimen 7|Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
9733145|NCT00003816|Experimental|Regimen 8|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
9733146|NCT00003816|Experimental|Regimen 9|Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
9733147|NCT00003820|Experimental|Rituximab 375 mg/m2 per week|"375 mg/m2 rituximab by IV infusion weekly. The initial course of treatment is 4 weeks.~Subjects who achieve an objective response or stable disease after the initial course (4 weeks) were permitted to continue additional 4-week cycles of treatment, for 3 additional courses starting every 6 months (ie, at 6; 12; and 18 months)."
9733148|NCT00003830|Active Comparator|Arm I: Conventional axillary dissection|Sentinel node resection immediately followed by axillary dissection
9733149|NCT00003830|Experimental|Arm II: Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.
9733150|NCT00003869|Experimental|Arm I (CAI)|Patients receive oral carboxyamidotriazole daily.
9733151|NCT00003869|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo daily
9733152|NCT00003875|Experimental|Treatment (chemo, stem cell rescue, interleukin therapy)|"PREPARATIVE REGIMEN: Patients receive busulfan IV over 2 hours or PO every 6 hours on days -7 to -4 and etoposide IV on day -3.~STEM CELL INFUSION: Patients undergo autologous or syngeneic PBSC rescue on day 0.~POST-TRANSPLANT ALDESLEUKIN THERAPY: Beginning 30-100 days after transplant, patients receive low-dose aldesleukin SC daily for 12 weeks."
9733153|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
9733154|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
9733155|NCT00003896|Experimental|Paclitaxel/cisplatin/Liposomal Doxorubicin|paclitaxel, cisplatin and liposomal doxorubicin
9733156|NCT00003901|Experimental|Surgery|"All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed.~Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods.~Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years."
9733157|NCT00003907|Experimental|Hepatocellular carcinoma|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
9733158|NCT00003907|Experimental|Neuroendocrine hepatic metastases|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
9733159|NCT00003910|Experimental|Methotrexate (Cy if no response to MTX)|MTX given orally at 10 mg/m2 in divided doses once weekly. Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days. Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule.
9733160|NCT00004031|Active Comparator|CHOP/CHOP-R x 3|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cycles
9733161|NCT00004031|Experimental|CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.
9733162|NCT00004054|Experimental|Hormones and RT|Androgen suppression (AS) (Luteinizing hormone releasing hormone agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]). AS will continue for a total of 24 months from initiation of all treatment. Oral anti-androgen will be discontinued at the end of radiation therapy (RT).
9733163|NCT00004054|Experimental|Hormones and RT plus Chemotherapy|AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) and estramustine phosphate sodium, etoposide, paclitaxel, and warfarin [Coumadin®]. AS will continue for a total of 24 months from initiation all treatment. Oral antiandrogen will be discontinued at the end of RT.
9733164|NCT00004088|Experimental|HD chemotherapy followed by PBPC Rescue|Patients receive high-dose (HD) melphalan intra-venously (IV) on day -1. Peripheral blood progenitor cells (PBPCs) are reinfused on day 0. Filgrastim (G-CSF) is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive IV high-dose busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBPCs are reinfused on day 0 and G-CSF is administered IV or subcutaneously (SC) daily until blood counts recover.
9733165|NCT00004092|Experimental|Arm I (ACT) (closed to accrual as of 4/6/2006)|Patients receive doxorubicin IV over 24 hours on days -9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV over 24 hours on day -2. PBSC are reinfused on days -2 and 0. G-CSF is administered beginning on day 0 and continuing until blood counts recover.
9733166|NCT00004092|Active Comparator|Arm II (STAMP V)|Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm I.
9733167|NCT00004124|Active Comparator|bicalutamide, goserelin|androgen deprivation
9733168|NCT00004124|Experimental|bicalutamide, goserelin, mitoxantrone, prednisone|androgen deprivation plus mitoxantrone, prednisone
9733169|NCT00004143|Experimental|Campath SCT for hemoglobinopathies|Campath, Chemo and/or TBI Allo SCT
9733170|NCT00004143|Experimental|Campath SCT for Bone Marrow Failure|Campath, Chemo and/or TBI Allo SCT
9733171|NCT00004146|Experimental|Treatment (RT and CAI)|"Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for survival.~Other: pharmacological study, radiation therapy"
9733172|NCT00004228|Experimental|A0 (localized disease Stg I/II) Modified CCG BFM|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Doxorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Methotrexate, Intrathecal Methotrexate)
9733173|NCT00004228|Experimental|A1 (Disseminated, No CNS - CCG mod BFM w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, prednisone, Methotrexate, Intrathecal Methotrexate)
9733174|NCT00004228|Experimental|A2 (Disseminated, No CNS - CCG mod BFM w/ intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
9733175|NCT00004228|Experimental|B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
9733176|NCT00004228|Experimental|B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
10200497|NCT03771716|Experimental|African Dance|This is the experimental group. Dance classes will be held 3 times per week for 1 hour. Participants will learn traditional Africana dance moves and sequences.
10200498|NCT03771716|Active Comparator|African Cultural Immersion|This is the active control group. Participants will participate in a variety of educational activities related to African Culture, including traditional cooking, lectures, crafts, music and films. They will meet 3 times per week for the same duration as the Dance group. However, they will not participate in aerobic activity during the classes, and most activities will be conducted in a seated position.
10200499|NCT03767101|Experimental|TAU + Positive mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented positive mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a happy, positive situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities and feelings in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
10200500|NCT03767101|Active Comparator|TAU + Neutral mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented neutral mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a all-day, non-emotional provoking situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
10200501|NCT03767101|Other|Treatment as usual|In all conditions the first eight sessions of treatment are focused. No additional intervention is conducted at the start of therapy sessions. Standard cognitive behavioral therapy is conducted during the whole treatment sessions.
10200502|NCT03755297|Other|Rheumatoid arthritis|Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
10200503|NCT03755297|Other|Osteoarthritis|Control patients and Blood sample analysis of patients treated as standard care
10200504|NCT03755297|Other|Rheumatoid arthritis with JAK/STAT inhibitors|Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care
10200505|NCT03724942|Experimental|Brexpiprazole|
9733177|NCT00004228|Experimental|B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
9733178|NCT00004228|Experimental|B1 (Disseminated CNS-) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
9733179|NCT00004259|Experimental|Radiation therapy + temozolomide (TMZ)|Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles
9733180|NCT00004259|Active Comparator|RT + BCNU/CCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles
9733181|NCT00004259|Experimental|Pilot Arm #1: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles
9733182|NCT00004259|Experimental|Pilot Arm #2: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles
9733183|NCT00004412|Other|Standard local care dressing|Each subject provided his/her own dressing e.g,standard local care includes cleaning, saline irrigation, dressing changes only for 8 weeks twice a week.
9733184|NCT00004412|Experimental|Arginine Butyrate|Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.
9733185|NCT00004412|Other|Crossover|Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.
9733186|NCT00004418|Experimental|Glyceryl trierucate/glyceryl trioleate|Treatment of all enrolled participants. Dosage form is a liquid oil taken orally. Dose is to provide 20% of daily calories. Daily for duration of trial
9982475|NCT05233150|Experimental|PriCARE/CARIÑO plus Usual Care|Caregiver-child dyads assigned to the PriCARE/CARIÑO plus usual care group will receive the PriCARE/CARIÑO intervention within 4 months of randomization plus usual care. The intervention will last 6 weeks. Each group, administered by 1-2 trained mental health professionals, will have approximately 4-10 caregiver participants and will meet weekly for 6 weeks. Each of the 6 sessions is approximately 80 minutes. Caregivers are expected to practice the skills they learn with their children between sessions.
9982476|NCT05233150|No Intervention|Usual care|Caregiver-child dyads assigned to the usual care group will receive usual care and will not be aware of being in a group of about 8-10 recently-enrolled subjects.
10200506|NCT03681041||Pancreatic injury|Patient diagnosed with pancreatic trauma by surgery, computed tomography, Endoscopic retrograde cholangiopancreatography (ERCP) and Magnetic resonance cholangiopancreatography (MRCP) were included
9666446|NCT04517149|Experimental|4D-125 Dose Exploration|"Dose 1 and Dose 2~4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1. The contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent."
9666447|NCT04517149|Experimental|4D-125 Dose Expansion|4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1 in both adults and pediatric participants. For adult participants only, the contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent.
9666448|NCT04517149|Other|Observational|Natural History
9666449|NCT04516694|No Intervention|Control|Usual care reflects the standard treatment currently provided to T1D patients. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
9666450|NCT04516694|Experimental|Gain-framed incentive|"Participants will start off with nothing at the beginning of the treatment period. For each day that participants' meet goals, value will be added to their incentive balance.~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
9666451|NCT04516694|Experimental|Loss-framed incentive|"Participants will start off at the maximum incentive balance at the beginning of the treatment period and for each day that participants' fail to meet goals, value will be subtracted from their incentive balance over the 12-week.~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
9666452|NCT04516161||Radium-223 dichloride (Xofigo, BAY88-8223)|Patients with mCRPC who received treatment of Ra-223.
9666455|NCT04512456|Experimental|Active HIV-infected patients|Exercise training
9666456|NCT04512456|No Intervention|Inactive HIV-infected patients|No intervention.
9666457|NCT04512456|No Intervention|Healthy subjects|No intervention.
9733187|NCT00004445|Experimental|Implanted Neuroprosthesis|"Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.~Interventions include:~Procedure/Surgery Rehabilitation/Exercise~Device includes:~IRS-8 Stimulating Electrodes External Controller"
9733188|NCT00004500|Experimental|Lucinactant|Lucinactant via bronchoaveolar lavage
9733189|NCT00004500|Other|Standard Care|Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
9733190|NCT00004547|Experimental|Peritoneal mesothelioma|Patients with peritoneal mesothelioma suffer with intractable ascites but have a very surface oriented tumor which usually does not invade into organs and cause organ dysfunction. The main source of symptoms and cause of death is intractable ascites.
9733191|NCT00004547|Experimental|Low grade mucinous adenocarcinoma|Low grade mucinous adenocarcinoma also includes low grade mucinous neoplasms of borderline malignant potential. Patients with low grade mucinous adenocarcinoma can have prolonged survival with debulking surgery alone. The majority of patients with truly malignant disease will die of complications from intraperitoneal progression of tumor within 2 to 5 years. The tumors are often surface oriented within the peritoneal cavity without metastases to other distant sites. The most common origin for this type of tumor is the appendix and ovary.
9733192|NCT00004547|Experimental|Adenocarcinoma of gastrointestinal origin|Adenocarcinoma of gastrointestinal origin also includes other than low grade mucinous. Aggressive gastrointestinal adenocarcinomas such as gastric, small bowel, and colon cancer , tend to be more invasive into tissues and can more readily metastasize to distant sites. The cause of death is usually directly related to intraperitoneal progression of tumor. It is a more difficult group of patients to treat with intraperitoneal therapy because of the aggressive and invasive nature of the tumors.
9733193|NCT00004562|Active Comparator|Optimal Medical Therapy Only (MED)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification
9733194|NCT00004562|Experimental|Percutaneous Coronary Intervention (PCI)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting
9733195|NCT00004563|Experimental|Cylophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
9733196|NCT00004563|Placebo Comparator|Placebo|Matching gel caps at a dose of 25 mg
9733197|NCT00004635|Experimental|Thalidomide|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received thalidomide orally 200 mg a day. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received the placebo for thalidomide once a day.
9733198|NCT00004635|Experimental|Placebo|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received placebo for thalidomide. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received thalidomide 200 mg once a day.
9733199|NCT00004732|Active Comparator|Carotid Artery Endarterectomy (CEA)|Carotid endarterectomy is surgery to remove plaque buildup that causes narrowing (stenosis) in the carotid artery.
9733200|NCT00004732|Active Comparator|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) is a procedure used to open narrowed carotid arteries. During the procedure, a small, expandable wire tube called a stent is permanently inserted into the carotid artery.
9781415|NCT01148511|Experimental|Treat and Extend|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.
9982477|NCT05232006|Experimental|Niraparib|PARP-inhibitor, Niraparib Dosage : starting 300 mg/day for patients with body weight ≥77kg and platelet counts ≥ 150 000/µl or 200 mg when body weight inferior to 77kg and/or platelet counts ≤ 150 000/µl and > 100 000/µl Pharmaceutical form : 100 mg capsules Posology : single dose daily Route of administration : oral Administration procedures : oral, daily single dose Duration of treatment : 12 cycles of 28 days each
9665631|NCT04965454|Experimental|Tested with Biomarkers|For this single arm study, all enrolled subjects will undergo diagnostic testing with FCH PET/CT and genomic liquid biopsy before treatment involving an immune checkpoint inhibitor agent. A fluorine-18 fluorodeoxyglucose (FDG) PET/CT may also be performed before treatment and after 8 weeks if the pre-treatment FCH PET/CT shows low or heterogeneous tumor uptake.
9665632|NCT04964778|Experimental|Arm1: SKED© only first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 1 will be in the following order: SKED© only; SKED©+OSS-II©; SKED©+Vacuum mattress; SKED©+foam padding
9665633|NCT04964778|Experimental|Arm 2: SKED©+Vacuum mattress first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 2 will be in the following order: SKED©+Vacuum mattress; SKED©+OSS-II©; SKED©+foam padding, SKED© only
9665634|NCT04964778|Experimental|Arm 3: SKED©+OSS-II© first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 3 will be in the following order: SKED©+OSS-II©;SKED©+Vacuum mattress; SKED© only; SKED©+foam padding
9665635|NCT04964778|Experimental|Arm 4: SKED©+foam padding first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 4 will be in the following order: SKED©+foam padding, SKED©+Vacuum mattress; SKED© only; SKED©+OSS-II
9665637|NCT04962568|Experimental|NHF-NIV|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
9665638|NCT04962568|Experimental|NIV-NHF|Subjects will start with NHF. If all measurements are done, subjects will change to NIV. Same measurements will done.
9665639|NCT04962087|Experimental|Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
9665640|NCT04962087|No Intervention|Psychoeducation Control|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia.
9665641|NCT04962087|Experimental|Health enSuite Insomnia - Deprescribing|All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
9665642|NCT04962087|No Intervention|Psychoeducation Control - Deprescribing|Participants allocated to the Control group will receive a version of the Health enSuite Insomnia app that contains a static psychoeducation module. It will contain information related to insomnia and its treatment. Topics covered will include a brief description of cognitive behavioural therapy for insomnia and information about the benefits of medication de-prescribing for those in Trial 2.
9665643|NCT04960787|Active Comparator|Group I (usual care)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
9665644|NCT04960787|Experimental|Group II (financial navigation intervention)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients also meet with CENTS counselor and PAF case manager over approximately 1 hour every month for 6 months (with each group). Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
9665645|NCT04960124|Experimental|Part 1: Cohort 1 (JNJ-42847922)|Participants with normal hepatic function will receive Dose 1 of JNJ-42847922 on Day 1.
9733201|NCT00004859|Active Comparator|Arm A (Paclitaxel + Carboplatin + RT)|"Induction chemotherapy dosing: Paclitaxel, 225 mg/m² (3 hour infusion) Day 1. Carboplatin, area under the plasma drug concentration versus time curve (AUC) =6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1~Concurrent chemotherapy / radiotherapy dosing: Paclitaxel, 45 mg/m2, administered weekly during radiotherapy over one hour. Carboplatin, AUC=2, 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy~Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV"
9733202|NCT00004859|Experimental|Arm B (Paclitaxel + Carboplatin + RT+ Thalidomide)|"paclitaxel, carboplatin, and radiotherapy are same as those in Arm A.~thalidomide: Induction chemotherapy dosing, oral daily, starting Day 1 for 24 months or until disease progression. Concurrent chemotherapy / radiotherapy dosing, oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg."
9733203|NCT00004888|Experimental|Arm I (combination chemotherapy)|"Patients receive doxorubicin hydrochloride liposome IV over 30 minutes followed by docetaxel IV over 1 hour. Treatment is repeated every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive maintenance therapy of docetaxel IV over 1 hour either weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
9733204|NCT00004888|Experimental|Arm II (combination chemotherapy, trastuzumab)|"Patients receive trastuzumab IV over 90 minutes on day 1, with subsequent doses over 30 minutes. Patients receive doxorubicin HCl liposome IV over 30 minutes followed by docetaxel IV over 1 hour on day 2 of course 1, followed by subsequent doses on day 1 of each course. Antibody therapy continues weekly and chemotherapy every 3 weeks for 8 courses.~Patients may receive maintenance therapy of trastuzumab IV over 30 minutes weekly followed by docetaxel IV over 1 hour weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
9733205|NCT00004978|Experimental|rIL-2|Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.
9733206|NCT00004978|No Intervention|No rIL-2|Control arm uses anti-HIV medication of choice without rIL-2.
9733207|NCT00004980|Experimental|active rTMS|1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
9733208|NCT00004980|Placebo Comparator|sham stimulation|Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
9733209|NCT00005044|Experimental|TAS x 8 weeks|Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
9733210|NCT00005044|Experimental|TAS x 28 weeks|TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
9733211|NCT00005047|Experimental|Arm I: M-VAC x 3|Patients with altered (+) p53, reconsented to randomization, randomized to three cycles of MVAC
9733212|NCT00005047|No Intervention|Arm II: Observation|Patients with altered (+) p53, reconsented to randomization, randomized to observation
9733213|NCT00005047|No Intervention|Arm III: Observation|Patients with unaltered (-) p53
9733214|NCT00005047|No Intervention|Arm IV: Observation|Patients with altered (+) p53, patients did not consent to randomization
9733215|NCT00005669|Active Comparator|1 - Metformin HCL|Subjects receive metformin plus a weight loss program
9733216|NCT00005669|Placebo Comparator|2 - Placebo|Subjects receive placebo plus a weight loss program
9733217|NCT00005803|Experimental|Treatment (tandem transplantation)|See Detailed Description
9733218|NCT00005879|Placebo Comparator|Placebo|Placebo
9733219|NCT00005879|Experimental|Arzoxifene|LY353381, 20 mg daily
9733220|NCT00005901|Active Comparator|Pamidronate every 3 months for 3 years|Subjects who received Pamidronate every 3 months for 3 years.
9733221|NCT00005901|Active Comparator|Pamidronate every 6 months for 3 years|Subjects who received Pamidronate every 6 months for 3 years.
9733222|NCT00005906|Experimental|Octreotide|Patients with lymphangioleiomyomatosis and lymphatic tumors, ascites or pleural effusions who are symptomatic will receive subcutaneous injections of octreotide starting at a dose of 100 micrograms per day. Doses will be gradually increased to a maximum of 800 micrograms per day, two months after enrollment, if there is no response to lower doses.
9733223|NCT00005908|Experimental|Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine|Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
9733224|NCT00005908|Experimental|Dose B-Cohort 2-Arm 2 Reduced dose-Docetaxel & Capecitabine|Docetaxel 60 mg/m^2 intravenous day 1, capecitabine 937.5 mg/m^2 orally twice daily day 2-15 for 4 cycles
9781416|NCT01148511|Active Comparator|Treat and Observe|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.
9733225|NCT00005937|Experimental|Antithymocyte globulin & cyclosporine|Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.
9733226|NCT00005947|Active Comparator|sipuleucel-T|
9733227|NCT00005947|Placebo Comparator|Placebo|
9733228|NCT00005957|Active Comparator|Standard Breast Irradiation|
9733229|NCT00005957|Experimental|Breast Radiation plus regional radiation|regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
9733230|NCT00006011|Experimental|Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)|Patients receive doxorubicin IV over 30 minutes immediately followed by cisplatin IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) SC or pegfilgrastim on days 2-11.
9733231|NCT00006011|Experimental|Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)|Patients receive doxorubicin and cisplatin as in arm I, paclitaxel IV over 3 hours on day 2, and G-CSF SC or pegfilgrastim on days 3-12. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
9733232|NCT00006046|Experimental|Hu3S193 10 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
9733233|NCT00006046|Experimental|Hu3S193 25 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
9733234|NCT00006046|Experimental|Hu3S193 50 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
9733235|NCT00006046|Experimental|Hu3S193 100 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
9733236|NCT00006046|Experimental|Hu3S193 200 mg/m2|Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
9733237|NCT00006099|Experimental|Intraperitoneal (IP) Infusion of 111In-hu3S193|"Hu3S193 was administered intraperitoneally at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In.~Patients received 10 mCi 99mTc-sulphur colloid IP administered in 500 ml of normal saline to assure the absence of any loculation or heterogeneous distribution of radioactivity in the peritoneal cavity. A paracentesis catheter was inserted and the hu3S193 was diluted in 100 mL of 5% human serum albumin and administered as a continuous intraperitoneal infusion over 30 minutes. This was followed immediately by 900 mL of normal saline."
9733238|NCT00006099|Experimental|Intravenous Infusion of 111In-hu3S193|Hu3S193 was to be administered intravenously at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In, diluted in 100 mL of 5% human serum albumin and administered over a 30 minute period.
9733239|NCT00006101|Experimental|eflornithine|500mg/d for 12 months
9733240|NCT00006101|Placebo Comparator|Placebo|placebo for 12 months
9733241|NCT00006110|Experimental|Neo-adjuvant Herceptin with or without radiation|Chemotherapy followed by Taxol plus Herceptin followed by surgery followed by radiation (or no radiation) followed by additional Herceptin
9733242|NCT00006110|Experimental|Non-Herceptin with or without radiation|Chemotherapy followed by Taxol followed by surgery followed by radiation (or no radiation)
9733243|NCT00006151|Experimental|Accu Drops (AD&C)|The experimental group (N=30) will be prescribed active Accu Drops (AD&C) plus behavioral therapy.
9733244|NCT00006151|Placebo Comparator|Placebo|The control condition (N=30) will be prescribed placebo Accu Drops (PD&C) plus behavioral therapy.
9733245|NCT00006156|Experimental|Control|Control for FSH stimulation test
9733246|NCT00006156|Experimental|Drug: FSH|FSH Stimulation Test
9733247|NCT00006164|Experimental|1|Peg-interferon alfa-2a 90 mcg/week
9982478|NCT05231408|Experimental|Training Group|Training group will receive high-intensity interval aerobic exercise training on treadmill accompanied by physiotherapist for 8 weeks.
9982479|NCT05231408|Sham Comparator|Control Group|Breathing exercises will be given to control group as a home program for 8 weeks.
10200507|NCT03672929|No Intervention|Full cohort|Prospective non Controlled to Document long term performance of Allofit IT Shell in combination with the Longevity® Liner when used in primary total hip arthroplasty.
10200508|NCT03672929|Other|Subgroup RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years and will only be conducted on 40 patients.
10200509|NCT03672916||Patients who received the Allofit IT with BIOLOX delta|Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the BIOLOX delta Taper Liners
10200510|NCT03646461|Experimental|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
10200511|NCT03646461|Experimental|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
10200512|NCT03644615|Experimental|Mindfluness and usual care|
10200513|NCT03644615|Other|Usual Care|
10200514|NCT03631004|Experimental|olanzapine tablets|PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
9665646|NCT04960124|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with mild hepatic impairment will receive Dose 1 of JNJ-42847922 on Day 1.
9665647|NCT04960124|Experimental|Part 1: Cohort 3 (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 2 of JNJ-42847922 on Day 1.
9665648|NCT04960124|Experimental|Part 2: Cohort 4 (Optional) (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 1 (depending on the results of Cohort 3) of JNJ-42847922 on Day 1.
9665649|NCT04960124|Experimental|Part 2: Cohort 5 (Optional) (JNJ-42847922)|Participants with severe hepatic impairment will receive Dose 2 or Dose 3 (depending on the results of Part 1) of JNJ-42847922 on Day 1.
9665650|NCT04956406|Experimental|MIAKTR|MIAKTR is an acronym that defines Motivational Interviewing for Adult Kidney Transplant Recipients
9665651|NCT04956406|Active Comparator|Control Group|routine care
10200515|NCT03631004|Placebo Comparator|Starch tablets|PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
9665653|NCT04955652|Active Comparator|Standard of Care|A health maintenance topic, actionable sidebar item, and a single-click best practice alert are presented.
9665654|NCT04955652|Experimental|Silent Best Practice Alert|A health maintenance topic and an actionable sidebar item are presented. The best practice alert is set to be silent and will not appear in the patient's chart.
9665655|NCT04953962|Experimental|Arm 1: CBP501 (25) + Cisplatin + Nivolumab|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
9665656|NCT04953962|Experimental|Arm 2: CBP501 (16) + Cisplatin + Nivolumab|CBP501 16mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
9665657|NCT04953962|Experimental|Arm 3: CBP501 (25) + Cisplatin|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously.
9665658|NCT04953962|Experimental|Arm 4: Cisplatin + Nivolumab|Cisplatin 60mg/m2 will be administered as infusion and then Nivolumab 240mg will be administered.
9665659|NCT04952727|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
9665660|NCT04952727|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
9665661|NCT04952727|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months
9665662|NCT04952727|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
9665663|NCT04951986|Experimental|High dose Rifampicin plus Levofloxacin|Standard TB treatment plus additional Rifampicin 35 mg/kg/day PLUS Levofloxacin for 14 days
9665664|NCT04951986|Experimental|Prednisone|Prednisone 1.5 mg/kg for 14 days
10200516|NCT03625245|Placebo Comparator|Control Yogurt|Control yogurt
10200517|NCT03625245|Experimental|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
10200518|NCT03625245|Experimental|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
10200519|NCT03621358|Placebo Comparator|Control Gummy|Control gummy with free flavour (without encapsulating)
10200520|NCT03621358|Experimental|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
10200521|NCT03621358|Experimental|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
10200522|NCT03615664|Experimental|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
10200523|NCT03613662|Experimental|SP-102|SP-102
10200524|NCT03556345|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
10200525|NCT03550287|Experimental|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
10200526|NCT03550287|Placebo Comparator|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
10200527|NCT03538002|No Intervention|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
10200528|NCT03538002|Experimental|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
9733248|NCT00006164|Active Comparator|2|Standard of care followup
9982480|NCT05231395|Experimental|Inspiratory Muscle Training Group|Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
9982481|NCT05231395|Sham Comparator|Control Group|Control group will be given breathing exercises as a home program for 8 weeks.
9982482|NCT05231304||Total Talus Replacement|
9982483|NCT05231304||Total Ankle Total Talus Replacement|
9982484|NCT05231304||Total Ankle Total Talus Replacement + Subtalar Fusion|
9982485|NCT05231304||Total Talus Replacement + Subtalar Fusion|
9982486|NCT05230043||Suicide Attempters using Violent Means|A violent suicidal act is any suicidal act conducted with any means except for medication overdose or superficial wrist cutting.
9982487|NCT05230043||Patient Control|
9982488|NCT05230043||Healthy Controls|
9982489|NCT05230043||Suicide Attempters not using Violent Means|
9982490|NCT05227222|Experimental|PEP-device|Positive expiratory pressure device: continuous treatment with PEP-device breathing air for 20 minutes followed by 10 minutes rest and assessment. Inspiration through nose/mouth, expiration through device.
9982491|NCT05227222|No Intervention|spontaneous recovery|Control group: Resting and breathing air for 20 + 10 minutes.
9982492|NCT05227170|Experimental|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (1 serving of GoodBelly fermented oat drink) once daily for 8 weeks
9982493|NCT05227170|Placebo Comparator|Heat-killed placebo control|Subjects will consume 1 serving of GoodBelly fermented oat drink that has been treated to heat kill all Lp299v once daily for 8 weeks
9982494|NCT05226468|Experimental|NEI-01|Single Arm
9665665|NCT04951986|Active Comparator|Standard TB treatment|High dose rifampicin/levofloxacin comparator
9665666|NCT04951986|Placebo Comparator|Placebo|Prednisone comparator
9665669|NCT04951154|Other|Participants with Suspected Lung Cancer|Eligible participants with suspected lung cancer will be enrolled and undergo diagnostic and research bronchoscopic biopsies and research blood sample collection for biomarker analysis. Those participants who proceed to surgical resection will have additional research samples taken from the resected tumor and additional research blood samples drawn for biomarker analyses at the resection visit and at the post-operative follow up visit. Participants will then be followed clinically for two years for evidence of recurrence or until participants with confirmed lung cancer recurrence, whichever occurs earlier.
9665670|NCT04950192||Prospective Observational|Prospective observational subjects undergoing planned cardiac procedures utilizing image guidance
9665671|NCT04950114|Experimental|120 mg Dose Cohort|Participants who received GFB-887 or placebo at dose level 2 (120 mg) in GFB-887-201 will receive the same daily dose level upon enrollment. Participants who received GFB-887 or placebo at dose level 1 in GFB-887-201 will receive GFB-887 at the dose level 2 (120mg).
9665672|NCT04950114|Experimental|360 mg Dose Cohort|Participants who received GFB-887 or placebo at dose level 3 (360 mg) in GFB-887-201 will receive the same daily dose level upon enrollment
9665673|NCT04950010|Experimental|High-Intensity Interval Training (HIIT)|Breast cancer survivors randomized to HIIT will participate in a high-intensity interval training program for 8 weeks.
9665674|NCT04950010|Active Comparator|Moderate-Intensity Exercise (MOD)|Breast cancer survivors randomized to MOD will participate in a moderate-intensity aerobic exercise program for 8 weeks.
9665675|NCT04950010|No Intervention|Usual Care (UC)|Individuals randomized to UC will be instructed to continue standard cancer care and engage in habitual lifestyle behaviors.
9665676|NCT04948554|Experimental|Cohort 1 Arm A|Open-label ACE 1334-once every two weeks, Dose 1 + SOC
9665677|NCT04948554|Experimental|Cohort 1 Arm B|Open-label ACE 1334-once every four weeks, Dose 2 + SOC
9665678|NCT04948554|Experimental|Cohort 2 Arm A|Open-label ACE 1334-once every two weeks, Dose 3 + SOC
9665679|NCT04948554|Experimental|Cohort 2 Arm B|Open-label ACE 1334-once every four weeks, Dose 4 + SOC
9665680|NCT04948554|Experimental|Cohort 3 Arm A|Open-label ACE 1334-once every two weeks, Dose 5 + SOC
9665681|NCT04948554|Experimental|Cohort 3 Arm B|Open-label ACE 1334-once every four weeks, Dose 6 + SOC
9665682|NCT04948554|Experimental|Phase 2 Arm A (Dose 1)|Double-blind/placebo-controlled ACE 1334-once every x weeks xx mg/kg +SOC
9665683|NCT04948554|Experimental|Phase 2 Arm B (Dose 2)|Double-blind/placebo-controlled ACE 1334-once every x weeks yy mg/kg +SOC
9665684|NCT04948554|Placebo Comparator|Phase 2 Placebo + SOC|Placebo to match ACE-1334 + SOC
9665902|NCT04823273|Experimental|Interruptive alert|In addition to general improvement changes, subjects exposed to the interruptive alert arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. In contrast to the in-line help text arm, this arm includes an interruptive alert that appears when the user selects the transfusion order. This alert offers users the option to remove the order which results in no-blood product ordered. Alternatively, users may continue to order blood and are asked to select the reason for proceeding with the intended order.
9733249|NCT00006170|Experimental|Bupropion and Weight Concerns intervention|Bupropion SR and a weight concerns psychosocial intervention
9733250|NCT00006170|Active Comparator|Placebo and Weight Concerns|A matched placebo administered on same schedule as bupriopion and a weight concerns psychosocial intervention for smoking cesstion
10200529|NCT03525886|Experimental|NBI-74788 Dose Group 1|NBI-74788 administered orally for 14 consecutive days.
10200530|NCT03525886|Experimental|NBI-74788 Dose Group 2|NBI-74788 administered orally for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 2 will be dosed in parallel with Group 3.
10200531|NCT03525886|Experimental|NBI-74788 Dose Group 3|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 3 will be dosed in parallel with Group 2.
10200532|NCT03525886|Experimental|NBI-74788 Dose Group 4|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days.
10200533|NCT03513250|Experimental|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
10200534|NCT03513250|Placebo Comparator|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
10200535|NCT03496675|Other|Standard care|Participants receive standard care as locally available. The components of standard care are recorded.
10200536|NCT03496675|Experimental|Group Music Therapy (GMT)|"GMT is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~In line with usual practice, and as appropriate in local contexts, residents of a unit allocated to GMT may be divided into smaller groups (e.g. around 5 participants)."
9666458|NCT04511988|Experimental|Experimental|blood sample (20 ml) and biopsy
9666459|NCT04511767||ASD group|the autism spectrum disorder group
9666460|NCT04511767||GDD group|the global developmental disorder group
9666461|NCT04511767||LD group|the language disorder group
9666462|NCT04509700|Experimental|parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
9666463|NCT04509700|Experimental|parsaclicib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
9666464|NCT04509700|Experimental|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
9666465|NCT04509700|Experimental|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
9666466|NCT04509609||LGMD 2E with a genetic diagnosis|Any patient affected by LGMD 2E with a genetic diagnosis
9666467|NCT04506970||Intrauterine Growth Restriction|Pregnant women carrying a fetus identified with intrauterine growth restriction during the third trimester (>28 weeks gestation)
9666468|NCT04506970||Normal pregnancy|Pregnant women identified with an uncomplicated pregnancy during the third trimester (>28 weeks), matched for fetal sex and gestational age with women enrolled in the IUGR group.
9666469|NCT04505371|No Intervention|Control - Standard Care|The control intervention is referral to standard evidence-based cessation services available nationally to Veterans, including the National VA Quitline and SmokefreeVET texting program.
9666470|NCT04505371|Experimental|Intervention - Wellness Intervention for Smokers with HIV|The experimental WISH intervention is an HIV-specific comprehensive wellness program designed to offer integrated phone and text counseling regardless of readiness to quit.
10200537|NCT03496675|Experimental|Recreational Choir Singing (RCS)|"RCS is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~RCS may be conducted in larger groups (e.g. with all residents of the unit in one group)."
9666472|NCT04502394|Experimental|Cohort 1 (R/R DLBCL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
9666473|NCT04502394|Experimental|Cohort 2 (R/R CLL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
9666474|NCT04495959||68Ga-HTK03149 PET/MRI DWB scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
9666475|NCT04495556||Typical|Patients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
10200538|NCT03496675|Experimental|GMT + RCS|Group Music Therapy and Recreational Choir Singing are both provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
10200539|NCT03478826||ILD|250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
10200540|NCT03478826||Healthy|100 healthy participants as a control group.
10200541|NCT03478826||Pneumonia|25 patients with pneumonia as a control group.
9733251|NCT00006170|Active Comparator|Bupropion and standard smoking cessation|Bupropion SR and a time and attention controlled smoking cessation intervention
9733252|NCT00006170|Placebo Comparator|Placebo and standard smoking cessation|A matched placebo administered on same schedule as bupriopion and a time and attention controlled smoking cessation intervention
9781417|NCT01148524|Other|rMenB06|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 6 months) and placebo (at 1 and 2 months) in V72P10 study had a blood draw.
9781418|NCT01148524|Other|rMenB0|Subjects who had received 1 dose of rMenB+OMV-NZ (at 0 month) and 3 doses of placebo (at 1, 2 and 6 months) in V72P10 study had a blood draw.
9781419|NCT01148524|Other|rMenB016|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 6 months) and 1 dose of placebo (at 2 months) in V72P10 study had a blood draw.
9781420|NCT01148524|Other|rMenB01|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 1 month) and placebo (at 2 and 6 months) in V72P10 study had a blood draw.
9781421|NCT01148524|Other|rMenB026|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 2 and 6 months) and 1 dose of placebo (at 1 month) in V72P10 study had a blood draw.
9781422|NCT01148524|Other|rMenB02|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 2 months) and placebo (at 1 and 6 months) in V72P10 study had a blood draw.
9781423|NCT01148524|Other|rMenB012|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 2 months) and 1 dose of placebo (at 6 months) in V72P10 study had a blood draw.
9781424|NCT01148524|Other|rMenB6|Subjects who had received 1 dose of rMenB+OMV-NZ (at 6 months) and 3 doses of placebo (at 0, 1 and 2 months) in V72P10 study had a blood draw.
9781425|NCT01148524|Other|Naive|An additional study group of naïve subjects that served as a baseline comparator for assessing antibody persistence in the vaccine groups and had blood draw for serological analyses at the time of enrollment.
9781426|NCT01148537|Experimental|BTDS|Buprenorphine transdermal patches 5, 10, 20, and 2 * 20 mcg/h.
9781427|NCT01148537|Placebo Comparator|Placebo TDS|Matching placebo transdermal patches 5, 10, 20 and 2 * 20.
9781428|NCT01148537|Active Comparator|Moxifloxacin|Moxifloxacin hydrochloride 400 mg tablets
9781429|NCT01148563|No Intervention|Standard Care|The Standard Care group will continue regular LSU HCSD disease management care for heart failure patients with no additional intervention.
9781430|NCT01148563|Active Comparator|Tele-health Monitoring Group|The tele-monitoring intervention group will have the continual standard care from their physician plus the tele-health monitoring. The tele-health monitor will collect the following data: weight, blood pressure, pulse oximetry, pulse rate, & patient responses to disease-specific questions regarding changes in state of health for 6 months.
9781431|NCT01148693|Active Comparator|gentamicin|adding 10mg gentamicin to every 10 ml of contrast media
9781432|NCT01148693|Placebo Comparator|Placebo|Identical placebo
9781433|NCT01148745|Other|ferumoxytol|FDA approved drug
9781434|NCT01148771|Experimental|Ertapenem 1 gram intravenous (IV) 5 minute bolus|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 5 minute IV bolus.
9781435|NCT01148771|Active Comparator|Ertapenem 1 gram IV 30 minute infusion|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 30 minute infusion (i.e., the standard dose).
9781436|NCT01148810|Placebo Comparator|Placebo|
9781437|NCT01148810|Experimental|BAF312|
9781438|NCT01148836|Experimental|Coenzyme Q 10 and Pulmonary Hypertension|PAH subjects to take Co-Q daily for three months
9781439|NCT01148836|Experimental|Coenzyme Q 10 and Normal Controls|Normal controls to take Co-Q daily for three months
9781440|NCT01148862|Other|Group A|Group A will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature activated
9781441|NCT01148862|Other|Group B|Group B will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature deactivated
9781442|NCT01148940||White women with Hb AA|White pregnant and postpartum women with Hb AA
9781443|NCT01148940||Black women with Hb AA|Black pregnant and postpartum women with HbAA
9781444|NCT01148940||Black women with Sickle Trait|Black pregnant and postpartum women with HbAS
9781445|NCT01148979|Experimental|Adjunct Lisdexamfetamine (Vyvanse)|Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
9781446|NCT01148979|Placebo Comparator|Adjunct Placebo|Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
9781447|NCT01149057|Experimental|Single Arm|
9781448|NCT01149096|Active Comparator|Arm I (conventional bone marrow harvest)|Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
9781449|NCT01149096|Experimental|Arm II (filgrastim, bone marrow harvest)|Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
9733253|NCT05347914|Experimental|Mindfulness|
9733254|NCT05347901||Health Control|Health children with age and sex paired with experimental group
9733255|NCT05347901||Kawasaki Disease|KD patients, with no congenital heart disease, metabolic disease or Immune deficiency disease.
9733256|NCT05347875|No Intervention|Control Group|Activities of Daily Living App
9733257|NCT05347875|Experimental|Experimental Group|ICanWALK© App
9733258|NCT05347862|Other|Control group|Usual standard advice to practice physical activity as an important measure to promote health benefits.
9733259|NCT05347862|Experimental|Physical Activity Promotion|The intervention will consist of telephone calls and text messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants.
9733260|NCT05347849|Experimental|BPL-003 arm|
9733261|NCT05347849|Placebo Comparator|Placebo arm|
9733262|NCT05347836||Children diagnosed to have T1DM with a minimum duration of five years|
9733263|NCT05347836||Healthy children|
9733264|NCT05347810|Experimental|Study group|All participants in the study will receive the same investigational treatment (application of prolonged repetitive forces) and provide continuous comfort ratings.
9733265|NCT05347797|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue. The KRAS Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
9733266|NCT05347784||Patients without postoperative complications|
9733267|NCT05347784||Patients with postoperative complications|
9733268|NCT05347771|Experimental|Dupilumab|"Participants between 12-17 years of age, will receive an initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week (Q2W).~Participants between 6-11 years of age will not complete a loading dose and will receive injections based on their body weight:~Participants with a body weight of 15 kg to less than 30 kg, will receive 100mg Q2W.~Participants with a body weight of 30 kg or more, will receive 200 mg Q2W."
9733269|NCT05347771|Placebo Comparator|Placebo|"Participants between 12-17 years of age, will receive an initial dose of placebo (two injections) followed by a placebo injection given every other week (Q2W).~Participants between 6-11 years of age will not receive an initial loading dose of placebo and will receive injections Q2W based on their body weight."
9733270|NCT05347758|Experimental|Group A|Drug: HRS-7535
9733271|NCT05347758|Placebo Comparator|Group B|Drug: Placebo
9733272|NCT05347745|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx (US) instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE), colorectal cancer (CRC) tissue
9733273|NCT05347719|Experimental|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions led by a trained healthcare provider. Post-intervention, the experimental group will receive treatment as usual.
9733274|NCT05347719|No Intervention|Wait List Control|Participants will engage in treatment as usual during the baseline period. After the experimental group completes the MBCT intervention, the wait list control group will complete the MBCT intervention.
9733275|NCT05347706|Experimental|AAF-fed group|Amino Acid-Based Formula(NeocateⓇ; Nutricia, London, UK)
9733276|NCT05347706|Experimental|EHF-fed group|Extensively Hydrolyzed Formula(AlfareⓇ; Nestle, Netherlands)
9733277|NCT05347693|Experimental|Sodium Zirconium Cyclosilicate (SZC)|Participants discharged with SZC, as per local label, to manage HK until the end of the outpatient phase
9733278|NCT05347693|Active Comparator|Local standard of care (SoC)|Participants discharged with SoC, as per local practice, to manage HK until the end of study.
9733279|NCT05347680|Active Comparator|intubating laryngeal Tube Suction|Fiberoptic Intubation through intubating laryngeal Tube Suction
9733280|NCT05347680|Active Comparator|Ambu AuraGain Laryngeal Mask|Fiberoptic Intubation through Ambu AuraGain Laryngeal Mask
9733281|NCT05347667|Experimental|Pre-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the follicular phase of the menstrual cycle (pre-ovulation).
9733282|NCT05347667|Experimental|Post-Ovulation Unilateral Resistance Exercise|One leg will undergo 2 sessions of unilateral resistance exercise during the luteal phase of the menstrual cycle (post-ovulation).
9733283|NCT05347654|Active Comparator|Standard strategy|Local treatment with silver sulphadiazine and tulle from day 0 to day 8. From the 9t h day and until healing, the dressings are made with tulle, every 48 hours.
9733284|NCT05347654|Experimental|Strategy incorporating a poly-absorbent dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
9733285|NCT05347641|Experimental|Penpulimab combined with RMA was used for first-line treatment of PCNSL|One course of treatment was performed every 21 days. After 3 courses, patients underwent cranial MR+ whole-body enhanced CT for disease assessment. Patients who did not achieve partial response (PR) were withdrawn, and patients who achieved PR or complete response (CR)/uncertain CR (CRu) were given 3 courses of treatment.
9733286|NCT05347628|Experimental|PLB1004|PLB1004 given alone as monotherapy.
9733287|NCT05347615||EDOF|Eye after EDOF lens Implantation
9733288|NCT05347615||Monofocal|Eye after Monofocal lens Implantation
9733289|NCT05347602|Other|Phase 1: double-blinded placebo-controlled Supplement vs Placebo|Phase 1 (8 weeks): Supplement and Placebo groups ingested 3 oz of Supplement and Placebo per day respectively for the first four weeks as a loading dose, and then switched to 2 oz per day for weeks 5 - 8. This phase was double-blinded.
9733290|NCT05347602|No Intervention|Washout Phase|"Phase 2 (4 weeks): Both groups underwent a month-long wash out period, during which they did not ingest any of the Supplement or Placebo. This lasted from weeks 9-12. This phase was not double-blinded as all participants and the researchers were aware of the wash-out procedure."
9733291|NCT05347602|Active Comparator|Phase 3: Supplement|Phase 3 (8 weeks): Both groups took the Supplement at 3 oz per day as a loading dose for four weeks (weeks 13 - 16), and then 2 oz per day for the final four weeks (weeks 17 - 20). This phase was open labeled, as all participants and the researchers were aware that all participants were ingesting the Supplement.
9733292|NCT05347589|Experimental|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|
9733293|NCT05347589|Active Comparator|post isometric relaxation of the Quadratus lumborum|
9733294|NCT05347576|Experimental|sequence 1|Period 1- A single dose of 4 tablets(CKD-501 1T, D759 1T, D150 1T, D029 1T) under fed condition Period 2- A single dose of 2 tablets(CKD-393(2) 2T) under fed condition
9733295|NCT05347576|Experimental|sequence 2|Period 1- A single dose of 2 tablets(CKD-393(2) 2T) under fed condition Period 2- A single dose of 4 tablets(CKD-501 1T, D759 1T, D150 1T, D029 1T) under fed condition
9733296|NCT05347563||Children with acute respiratory failure|All patient with acute respiratory failure admitted to the Paediatric Intensive Care Unit requiring oxygenation or ventilatory support.
9733297|NCT05347550|No Intervention|Control - No graduated compression stockings|In those centres randomised to the control arm, participants will not receive Graduated Compression Stockings (GCS).
9733298|NCT05347550|Experimental|Intervention - The provision of graduated compression stockings|Centres randomised to the intervention arm, which is the current standard of care, will consist of participants receiving Graduated Compression Stockings (GCS). Clinical staff (e.g. theatre support workers) will issue stockings to all patients who are scheduled to undergo short-stay surgery. Participants will be instructed to wear their stockings just before undergoing the surgical procedure and to remove the stockings as soon as they are ambulant (i.e. after the procedure).
9733299|NCT05347537|Experimental|Mulligan mobilization|Group A will be treated with only mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
9733300|NCT05347537|Active Comparator|Mulligan mobilization with clamshell exercise|Group B will be treated with mulligan's mobilization with movement and clamshell exercises.
9733301|NCT05347524||Case arm - Gastric cancer with peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants with peritoneal metastasis.
9733302|NCT05347524||Control arm - Gastric cancer without peritoneal metastasis|Baseline blood samples will be collected from gastric cancer participants without peritoneal metastasis.
9733303|NCT05347498|Experimental|Treatment group A|HR091506 tablets + placebo of febuxostat tablets
9733304|NCT05347498|Active Comparator|Treatment group B|febuxostat tablets + placebo of HR091506 tablets
9664770|NCT05285267|Active Comparator|Parent-Child Activities|"Families assigned to the active control group will participate in weekly parent-child open house where the parents will be permitted to meet with other parents in the meeting room and the children will be invited to attend an open gym. There will be no formal curriculum for the parent meetings, but the facilitator will be available to inform the parents of community resources (e.g., mentorship programs) and a resources table will be made available of community activities and referrals in the same manner as the other two groups."
9733305|NCT05347485|Experimental|Ciltacabtagene Autoleucel (Cilta-cel)|Eligible participants will receive bridging therapy (that is, anti-plasma cell directed treatment) based on participant's clinical status and timing of availability of cilta-cel (JNJ-68284528) along with lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square [mg/m^2] intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants will receive a single IV infusion of cilta-cel (JNJ-68284528) at a total targeted dose of 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg).
9517989|NCT03301064|Experimental|Intervention Condition: MET/SBCM|The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
9733306|NCT05347472|Experimental|Experimental group|In this group, women will receive the smartphone application intervention that will include daily physical therapy exercises program
9733307|NCT05347472|Placebo Comparator|Control group|In this group, women will receive the sham application that includes information and general advice about UI only
9733308|NCT05347459||New Antidiabetic|Type 2 diabetic patients receiving either SGLT2 inhibitors and/or DPP-4 inhibitors
9733309|NCT05347459||Traditional Antidiabetic|Type 2 diabetic patients treated with metformin
9733310|NCT05347459||Control|Healthy non-diabetic patients
9733311|NCT05347446|Active Comparator|Hybrid ESD|Hybrid ESD is a modified ESD technique that uses snare-assisted resection as part of the procedure. With hybrid ESD, a circumferential mucosal incision followed by limited submucosal dissection is performed. Following this, a snare is placed around the lesion, slowly closed to allow resection by traversing the submucosal space
9733312|NCT05347446|Active Comparator|Non-Hybrid ESD|A partial or complete circumferential mucosal incision will be performed to expose the submucosa around and underneath the polyp. Endoscopic resection will then proceed via conventional ESD, submucosal tunneling or pocket technique.
9733313|NCT05347433||Tube baby pregnancy group|18-24-week pregnant women with in vitro fertilization
9733314|NCT05347433||Spontaneous pregnancy group|18-24-week pregnant women with spontaneous
9733315|NCT05347420||Diabetic peripheral neuropathy|Patients with diabetic peripheral neuropathy
9733316|NCT05347420||non diabetic peripheral neuropathy|Patient without diabetic peripheral neuropathy
9733317|NCT05347407||Control|Healthy Patients
9733318|NCT05347407||Parkinson's Disease|Patients diagnosed with Parkinson's disease
9733319|NCT05347407||At risk for PD|Defined as REM sleep behavior disorder, known genetic risk factor, and/or first degree relatives with PD
9733320|NCT05347407||Dementia with Lewy Bodies|Patients diagnosed with Dementia with Lewy Body Disease
9733321|NCT05347407||Multiple System Atrophy|Patients diagnosed with Multiple System Atrophy
9733322|NCT05347394|Experimental|Part A: VX-708|Participants will be randomized to receive a single dose of different dose levels of VX-708.
9733323|NCT05347394|Placebo Comparator|Part A: Placebo|Participants will receive placebo matched to VX-708.
9733324|NCT05347394|Experimental|Part B: VX-708|Participants will be randomized to receive multiple doses of different dose levels of VX-708. The dose levels will be determined based on the data from Part A.
9733325|NCT05347394|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to VX-708.
9733326|NCT05347381|Experimental|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
9733327|NCT05347368|Other|Control group (conventional therapy)|
9733328|NCT05347368|Experimental|Primal Reflex release Technique|
9733329|NCT05347355|Experimental|Spencer technique along with conventional treatment|
9733330|NCT05347355|Experimental|Gongs Mobilization along with conventional treatment|
9733331|NCT05347329|Placebo Comparator|Control Arm 1:|Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient), administered orally once daily on empty stomach with plenty of water.
9733332|NCT05347329|Experimental|Experimental Arm 2 (400 mg Tongkat Ali+ 200 mg Maca):|The content of 2 capsules of Tongkat Ali Maca (600 mg of active ingredient), Plus is equally distributed and inserted into 3 capsules size 1 (low dose), administered orally once daily with plenty of water.
9733333|NCT05347329|Experimental|Experimental Arm 3 (600 mg Tongkat Ali+ 300 mg Maca):|The content of 3 capsules of Tongkat Ali Maca Plus (900 mg of active ingredient), is equally distributed and inserted into 3 capsules size 1 (high dose), administered orally once daily with plenty of water.
9733334|NCT05347316|Experimental|Colchicine|0.5 mg of colchicine daily for 12 months
9733335|NCT05347316|No Intervention|Placebo|Follow-up for 12 months
9733336|NCT05347303|Experimental|Experimental group|The experimental group (EG) after taking initial measurements and signing their informed consent will be subjected to an 8-week intervention plan with 2 sessions per week where they will receive 1 MTOH and 1 Foam roller on discontinuous days. MTOH consists of first evaluating the structures that have restrictions, whether soft tissues or joints, to later be treated with a specific manual technique. For this, evaluation methods based on Kaltenborn are used when it comes to joints and Pilat when focusing on soft tissues. Interventions will not exceed 20 minutes per subject. For the foam roller, subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
9733337|NCT05347303|Active Comparator|Control group|After taking measurements, they will perform 2 foam roller sessions per week following the same indications expressed in the experimental group.
9733338|NCT05347290|Experimental|Lead Apron + Rampart IC, M1128|Consented providers will perform catherization procedures utilizing both lead apron and Rampart system. Radiation will be measured by dosimeters worn by the providers.
9733339|NCT05347290|Experimental|Rampart M1128 IC, Only|Consented providers will perform catherization procedures utilizing only the Rampart system. Radiation will be measured by dosimeters worn by the providers.
9733340|NCT05347290|Active Comparator|Lead Apron Only|This is the control group. Consented providers will perform catherization procedures utilizing only the lead apron and ancillary shields (lead skirt, vest, thyroid collar (all at least 0.5mm Pb) with use of under table lead per lab operating policy and mobile suspended lead-acrylic shield and lead glasses). Radiation will be measured by dosimeters worn by the providers.
9733341|NCT05347277||OCB positive|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as negative for the presence of CSF OCB
9733342|NCT05347277||OCB negative|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as positive for the presence of CSF OCB
9733343|NCT05347264|Experimental|massage gun|15 to 20 minutes along with hot pack.
9733344|NCT05347264|Experimental|transverse friction massage|15 to 20 minutes along with hot pack.
9733345|NCT05347251|Experimental|Group A|Cervicothoracic mobility program
9733346|NCT05347251|Other|Group B|Conventional Treatment
9733347|NCT05347238||Dopamine Units|Units who have standardized their practice with the use of Dopamine as a first line agent.
9733348|NCT05347238||Norepinephrine Units|Units who have standardized their practice with the use of Norepinephrine as a first line agent.
9733349|NCT05347225|Experimental|Nemtabrutinib|Participants receive nemtabrutinib at specified dose orally once daily (QD) until progressive disease (PD) or discontinuation.
9733350|NCT05347212|Experimental|Nivolumab+Relatlimab|nivolumab 480 mg IV plus relatlimab 480 mg IV every 4 weeks for up to 2 years
9733351|NCT05347199|Placebo Comparator|Healthy Volunteers Placebo|placebo pill at two time points
9733352|NCT05347199|Active Comparator|Healthy Volunteers Amisulpride|amisulpride pill at two time points
9733353|NCT05347199|Active Comparator|MDD Patients Placebo|placebo pill at two time points
9733354|NCT05347199|Experimental|MDD Patients Amisulpride|amisulpride pill at two time points
9733355|NCT05347186|Experimental|Systematic corrective exercises and non-biomechanical functional exercises|
9733356|NCT05347186|Other|Non biomechanical functional exercises.|
9733357|NCT05347173|No Intervention|Bupivacaine group (B gp)|Patients will receive 2.5 ml hyperbaric bupivacaine (0.5%) plus 0.5 ml normal saline
9733358|NCT05347173|Active Comparator|Bupivacaine-Dexmedetomidine group (BD gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 10 µg Dexmedetomidine in 0.5 mL normal saline
9733359|NCT05347173|Active Comparator|Bupivacaine-Nalbuphine group (BN gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 1 mg Nalbuphine in 0.5 mL normal saline
9733360|NCT05347160|Experimental|calcium hydroxide : group 1|Immature permanent molars with immature root filled by ca(oh)2
9733361|NCT05347160|Experimental|biodentine : group 2|clinically and radiographically evaluate BIODENTINE effect on permanent molars with immature root
9733362|NCT05347160|Experimental|platelet rich fibrin : group 3|filling of permanent molars with immature root by platelet rich fibrin
9733363|NCT05347147|Experimental|Presendin|2.0 mg
9733364|NCT05347147|Placebo Comparator|Placebo|
9733365|NCT05347134|Active Comparator|SKB264|5 mg/m2, IV (in the vein) on day 1 and Day 15 of each 28 day cycle.
9733366|NCT05347134|Active Comparator|Eribulin or Capecitabine or Gemcitabine or Vinorelbine|"Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21day cycle.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle."
9733367|NCT05347121||difficult airway|
9733368|NCT05347095|Experimental|Group 1: Guselkumab|Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.
9733369|NCT05347095|Experimental|Group 2: Guselkumab|Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
9733370|NCT05347095|Experimental|Group 3: Placebo|Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
9733371|NCT05347082|Experimental|Vitamin D|All the participants received 8000 IU of vitamin D orally, once a day, for four weeks.
9733372|NCT05347069|Active Comparator|Aspirin|Aspirin 100 mg/day
9733373|NCT05347069|Active Comparator|No Aspirin|No Aspirin
9733374|NCT05347056||Vertebral Body Tethering Group|Vertebral Body Tethering applied to the lumbar region, with or without fusion to the thoracic region
9733375|NCT05347056||Selective Thoracic Fusion Group|selective thoracic fusion was applied, no intervention was applied to the lumbar region
9733376|NCT05347043|Experimental|Intervention|All patients will undergo both the MoCA test and the standardized neuropsychological evaluation Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
9733377|NCT05347030|Experimental|Acupuncture Group|"The acupuncture points are: EX-B3, BL18, BL20, BL21, GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40, SP6.~After piercing 15-35mm into the skin, the needles will be gently rotated and lifted three times to achieve a sense of sourness, distention, and heaviness (de qi). For EX-B3, BL18, BL20, and BL21, withdrawn afterward immediately. For GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40 and SP6, The needles will be maintained for 30 minutes."
9733378|NCT05347030|Sham Comparator|Sham Acupuncture Group|"sham acupoints are located at a horizontal distance of 10 mm to those points used in the acupuncture group, and no manipulation was carried out after piercing the skin for 1-2mm to avoid de-qi sensation.~For sham EX-B3, BL18, BL20, and BL21, withdraw immediately after piercing. For sham GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40 and SP6, The needles will be maintained for 30 minutes after puncture."
9733379|NCT05347017|Experimental|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using HCL acid as demineralized dentin block graft and inserted in the extraction socket
9733380|NCT05347017|Active Comparator|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non-restorable teeth, then autogenous bone block will be harvested from the maxillary tuberosity and reshaped and inserted in the extraction socket
9733381|NCT05347004|Experimental|BI 425809 fed state (Test, T) then BI 425809 fasting state (Reference, R)|
9733382|NCT05347004|Experimental|BI 425809 fasting state (Reference, R) then BI 425809 fed state (Test, T)|
9733383|NCT05346991|Experimental|Intervention arm|Implementation of the Tobacco-Free Teachers, Tobacco Free Society program in government schools in Bihar, India
9733384|NCT05346991|No Intervention|Control arm|Delayed intervention - control arm schools receive the program after all data collection is complete
9733385|NCT05346978|Experimental|Nasturtium (NT)|5g freeze-dried nasturtium leaf powder ; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
9733386|NCT05346978|Placebo Comparator|Placebo (PLC)|3g collagen colored with green pigment used in the food industry; Each participant was supplemented with 15 grams of freeze-dried nasturtium leaf powder (NT) or placebo (PLC) per wk during 4 wk. Each participant received 3 envelopes per wk with 5 g NT each or 3 g PLC. In total each participant was given 24 envelopes (12 NT and 12 PLC) packaged in the same way to be indistinguishable from each other. The participants were instructed to take three days at wk one NT or PLC envelope diluted in 300 ml (about 10.14 oz) in chilly water in a bottle provided for the study
9781450|NCT01149148|Active Comparator|Intervention INVOS Cerebral Oximetry Monitoring|Intervention will be initiated if rSO2 drops > 20% from baseline or rSO2 declines below 50%.
10200542|NCT03436563|Experimental|Treatment (M7824)|Patients receive M7824 IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity (Cohorts A,B, and C) or for six doses in patients with detectable circulating tumor DNA (ctDNA) following resection of all known liver metastases (Cohort D).
10200543|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced (> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
9733389|NCT05346952|Experimental|TQB2450 injection + carboplatin + pemetrexed|TQB2450 injection：1200 mg, Intravenous drip d1； carboplatin ：Area Under Curve 5mg/mL/min，Intravenous drip d1；Pemetrexed: 500mg/m2，Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to TQB2450 injection（1200 mg, Intravenous drip d1）+Pemetrexed（500mg/m2，Intravenous drip d1）+ Anlotinib (10mg, peros every day, d1-14) . The regimen is repeated every 3 weeks until the disease progresses.
9733390|NCT05346952|Active Comparator|TQB2450 injection + Anlotinib + Pemetrexed|Tilelizumab: 200 mg, Intravenous drip d1;carboplatin : AUC 5mg/mL/min, Intravenous drip d1；Pemetrexed: 500mg/m2, Intravenous drip d1.The above schemes are repeated every three weeks. After 4 cycles, the regimen is changed to Tilelizumab (200 mg, Intravenous drip d1)+Pemetrexed (500mg/m2，Intravenous drip d1).The regimen is repeated every 3 weeks until the disease progresses.
9733391|NCT05346939|Experimental|Senior high school athletes in Taiwan|"In the first year, we would verify the relation between wearable device and motion analysis and its validity and reliability at stage I (n=15). And we are going to observe the effect of dynamic taping in lower limb biomechanics of high-school soccer or basketball athletes (n=50) at stage II.~In the second year, we would recruit high school soccer and basketball athletes to examine the effect of dynamic taping in lower limb biomechanics under fatigue (n=50)."
9733392|NCT05346926|Experimental|3D-printed cast|Treatment of distal radius fracture with 3D-printed forearm cast.
9733393|NCT05346926|Active Comparator|Conventional cast|Treatment of distal radius fracture with conventional plaster cast.
9733394|NCT05346913|Experimental|Caregivers of Persons with Spinal Cord Injury (mTBI)|
10200544|NCT03431090|Experimental|CliniMACS Isolation|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
9733396|NCT05346874|Experimental|SOX-TACiE|Preoperative transcatheter arterial chemoinfusion and embolism alternated with intra-venus chemotherapy.
9733397|NCT05346861|Active Comparator|Trastuzumab plus chemotherapy|
9733398|NCT05346861|Experimental|Pyrotinib in combination with Trastuzumab plus chemotherapy|
9733399|NCT05346848|Experimental|Experimental Arm A: combination of radiotherapy and darolutamide|Patients with unfavorable intermediate risk prostate cancer will be treated with darolutamide for a maximum of 6 months combined with external beam radiotherapy
9733400|NCT05346848|Other|Standard Arm B: combination of radiotherapy and androgen deprivation therapy|Patients with unfavorable intermediate risk prostate cancer will be treated with androgen deprivation therapy (ADT) as per market authorization combined with external beam radiotherapy
9733401|NCT05346822|Experimental|integrated rehabilitation program for total knee arthroplasty|the intervention was performed in one KMUH affiliated facility
9733402|NCT05346822|No Intervention|normal total knee arthroplasty clinical pathway|no integrated rehabilitatoin program for total knee arthroplasty patients with our conventional clinical pathway
9733403|NCT05346809|Experimental|Group 1|Subjects will receive the study drug Isatuximab in addition to standard procedures for transplant
9733404|NCT05346809|Experimental|Group 2|Subjects will receive standard procedures for transplant.
9733405|NCT05346796|No Intervention|Control|Group that will receive written survivorship care information.
9733406|NCT05346796|Experimental|Intervention|Group that will be provided access to the survivorship care plan-personal health record tool.
9733407|NCT05346783|Experimental|TJO-083 [Part 2]|1 drop 3 times a day
9733408|NCT05346783|Placebo Comparator|Placebo of TJO-083 [Part 2]|1 drop 6 times a day
9733409|NCT05346783|Active Comparator|Diquas-s Ophthalmic solution 3% 0.4mL [Part 2]|1 drop 6 times a day
9733410|NCT05346770||Individual Patient|Each case will represent one individual patient and patient case. The cases may not be related and may cover different clinical practice areas.
9733411|NCT05346757|Other|miRFec test|The miRFec test corresponds to the combination of fecal hemoglobin concentration and fecal miRNA expression
9733412|NCT05346744|Experimental|Zirconia|10 crowns made of zirconia from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
9733413|NCT05346744|Experimental|Celtra Duo|10 crowns made of Celtra Duo from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
9733414|NCT05346744|Experimental|e.max CAD|10 crowns made of e.max CAD from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
10200545|NCT03406156|Experimental|Obinutuzumab +/- bendamustine then obinutuzumab + venetoclax|"Debulking Period: Obinutuzumab with or without bendamustine (bendamustine administered in participants with high tumor load as described in the protocol) during the debulking period (up to 6 cycles).~Treatment Period: Venetoclax + obinutuzumab regimen initiated when participant achieves low tumor burden during debulking period, or if the participant has not achieved low tumor burden status after 6 cycles of debulking, the participant may proceed to venetoclax per the discretion of the treating provider after discussion with the study physician. During this regimen period, participants to receive obinutuzumab in combination with venetoclax for 5 months then venetoclax therapy alone to continue for a total duration of up to 53 weeks."
10200546|NCT03378219||Cohort 1|Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
9733415|NCT05346744|Experimental|Lici UPCERA|10 crowns made of Lici from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
9733416|NCT05346744|Experimental|Enamic|10 crowns made of Enamic from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
9733417|NCT05346744|Experimental|Runci UPCERA|10 crowns made of Runci from 10 individual were milled, post-processed and occlusal adjusted in patients' mouth.
9733418|NCT05346731|Active Comparator|Control group|"Weight category 30-40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg)~Weight category > 40 kg will receive:~dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
9733419|NCT05346731|Experimental|Olanzapine|"Weight category 30-40 kg will receive:~dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (80 mg), olanzapine (2.5 mg)~Weight category > 40 kg will receive: dexamethasone (5 mg/m2), ondansetron (0.15 mg/kg), aprepitant (125 mg), olanzapine (2.5 mg for <55 kg, 5 mg for >55 kg) Note: aprepitant at a dose of 80 mg/day. applied for another 2 days, regardless of the number of days of chemotherapy."
9733420|NCT05346718|Experimental|Sequence A: Exposure to no pollen (placebo), then to first pollen concentration|Participants are first exposed to no pollen, then challenged with the first pollen concentration, and finally all following concentrations.
9733421|NCT05346718|Experimental|Sequence B: Exposure to first pollen concentration, then to no pollen (placebo)|Participants are first challenged with the first pollen concentration, then with no pollen, and finally with all following concentrations.
9733422|NCT05346705|Experimental|Tongue/soft palate muscle control function training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
9733423|NCT05346705|Experimental|Soft palate muscle group vocal resistance training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
9733424|NCT05346705|Placebo Comparator|Simple tongue extension, cheek drumming/voice training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
9733425|NCT05346692|Active Comparator|Arm I (Pain Survey)|Patients complete pain survey via text message daily for 10 days after surgery. Patients also complete telephone interview 2 weeks after surgery.
9733426|NCT05346692|Experimental|Arm 2 (Mindfulness Intervention)|Patients complete mindfulness intervention via text message daily for 10 days after surgery. Patients also complete telephone interview 2 weeks after surgery.
9733427|NCT05346666|Active Comparator|Control Group|Group 1 received the conventional treatment for Status Epilepticus including propofol (loading dose is 3 to 5 mg/kg with maintenance of 1 to 15 mg/kg/h), phenobarbital (initial loading dose is 5 to 15 mg/kg over 1 hour. Infusion rates can be maintained at 0.5 to 15 mg/kg/h), and midazolam (a loading dose of 0.2 mg/kg is given with maintenance doses ranging between 0.05 and 2.0 mg/kg/h).
9733428|NCT05346666|Experimental|Tocilizumab Group|Group 2 received the same treatment in group 1 in addition to tocilizumab that was initiated at a dose of 4mg/kg administered twice monthly with 1-week intervals for 3 months. A monthly dose (8mg/kg) of tocilizumab was added if needed.
9733429|NCT05346653|Active Comparator|SGLT2i|Participants will be treated with a SGLT2i during their ICU stay. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
9733430|NCT05346653|Active Comparator|No SGLT2i|Participants will not be treated with a SGLT2i during their ICU stay. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
9733431|NCT05346627|Other|mitochondrial myopathy|Patient affected by mitochondrial myopathy, with genetic confirmation of mitochondrial DNA mutation
9781451|NCT01149148|Active Comparator|Standard of Care|Blinded cerebral oximetry monitoring with no intervention in surgical procedures and anesthesia without deviation from standard of care.
9733432|NCT05346614|Experimental|Active lifestyle intervention|Individuals in the active intervention group will undergo diabetyping (diabetes type 2 phenotyping: glucose, and C-peptide responses to a glucose challenge). Based on the diabetype, individuals will receive recommendations to follow either a calorie-restricted (500kcal deficit minimum) low carbohydrate or a modified Mediterranean diet for a period of 18 weeks (total intervention is 24 weeks). Secondly, individuals will follow a personalized exercise program. Guidance and coaching (individual and small group) will be given via mobile app and digital platform. Individuals will receive real-time feedback based on their diet, exercise, and glucose levels (via continuous glucose monitoring for 4 weeks). Medications will be slowly withdrawn over the intervention period, with a focus on the first phase of the intervention.
9733433|NCT05346614|No Intervention|Usual care group|Individuals in the usual care group will receive standard diabetes care.
9733434|NCT05346601|Other|Chiauranib(In the fasting state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet
9733435|NCT05346601|Other|Chiauranib(In the high fat diet state)|Experimental: Chiauranib Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state
9733436|NCT05346588|Active Comparator|Propofol total intravenous anesthesia (TIVA)|No administration of inhaled agent.
9733437|NCT05346588|Active Comparator|Inhaled volatile general anesthesia|Must administer inhaled agent.
9733438|NCT05346575|Active Comparator|Usual Care|Participants randomized to this arm will receive the usual obesity care, but will complete assessments every 6 months.
9733439|NCT05346575|Experimental|TOTAL intervention|Participants randomized to this arm will watch the TOTAL intervention video and participate in 1:1 motivational sessions every 6 months. Participants will also complete assessments every 6 months.
9733440|NCT05346562|Experimental|Cannabidiol, then Placebo|Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks. After two week washout, participant receives Placebo for five weeks (matching Cannabidiol tablets)
9733441|NCT05346562|Experimental|Placebo, then Cannabidiol|Participant receive placebo tablets (matching Cannabidiol pills) for five weeks. After two week washout, Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks.
9733442|NCT05346549|Experimental|High energy|"Child will be given a high energy drink: sugar free ribena squash (2kcal/100ml) plus a weighed amount of super soluble maxijul. Super Soluble Maxijul is a powdered carbohydrate energy source, which can be mixed with sweet or savoury foods/ liquids. It is safe for use in both children and adults that require fortification with a high or readily available carbohydrate. It is flavourless and tasteless offering little to no change in taste, flavor and texture of food being added to. It supplies 380 kcal energy per 100g powder. The amount given will supply 10% of the child's daily energy requirements per Kg - for example a 3-year old child weighing about 16 kg requires approximately 1300 kcal/day. Hence the high energy drink will supply the child with 130kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat standardized weighed buffet lunch of known energy content suitable for their age, chosen in consultation with the parents."
9733443|NCT05346549|Experimental|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink: sugar free ribena squash containing 2kcal per 100ml.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of weighed buffet foods as above."
9733444|NCT05346536|Experimental|Metastatic pancreatic cancer treatment-naive patients|Newly diagnosed major patients with metastatic pancreatic cancer, naïve of any treatment for metastatic disease
9733445|NCT05346523|Experimental|Usual Care + CDDS usage|Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual but with support of the CDDS.
9733446|NCT05346523|No Intervention|Usual Care|Patients presenting to the ER and included in the study during the ER's intervention period will be treated and diagnosed by the ER physicians as usual without support of the CDDS.
9733447|NCT05346510|Experimental|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS.
9733448|NCT05346510|Experimental|pALND Group|pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.
9733449|NCT05346510|Experimental|SLNB Group|SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
9733450|NCT05346497||Bentall|Patients who underwent Bentall procedure for ATAAD
9733451|NCT05346497||David|Patients who underwent David procedure for ATAAD
9733452|NCT05346497||ARR|Patients who underwent aortic root reconstruction procedure except Bentall and David procedure for ATAAD
9733453|NCT05346484|Experimental|CF33-hNIS IT Administration Monotherapy|
9733454|NCT05346484|Experimental|CF33-hNIS IV Administration Monotherapy|
9733455|NCT05346484|Experimental|CF33-hNIS IT Administration in Combination with Pembrolizumab|
9733456|NCT05346484|Experimental|CF33-hNIS IV Administration in Combination with Pembrolizumab|
9733457|NCT05346471|Other|Acute posterior fossa lesions|Subjects will receive additional multimodal infratentorial neuromonitoring
9733458|NCT05346458|Experimental|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients with coronary heart disease and undergoing coronary physiology investigations (pressure wire measurements) will have additional coronary pressure and flow measurements using the iKOs rapid-exchange microcatheter and iKOr console.
9733459|NCT05346445|Active Comparator|Fluoxetine group|Participants received fluoxetine, 20 mg tablets, once a day for six months.
9733460|NCT05346445|Experimental|Citalopram group|Participants received citalopram, 20 mg tablets, once a day for six months.
9733461|NCT05346432|Experimental|PS23|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
9733462|NCT05346432|Experimental|heat-treated PS23|PS23 heat-treated, 2 caps daily use.
9733463|NCT05346432|Placebo Comparator|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
9733464|NCT05346419|Experimental|Postmenopausal Osteopenia-osteoporosis patients|All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.
9733465|NCT05346406|Active Comparator|Peripherally Inserted Central Catheter|
9733466|NCT05346406|Experimental|Long Peripheral Catheter|
9733467|NCT05346393|Experimental|TIPS group|TIPS implant (transjugular intrahepatic portosystemic shunt)
9733468|NCT05346393|Active Comparator|Control group|Standard medication therapy with terlipressin and albumin
9733469|NCT05346380|Experimental|During Minimally Invasive Pulmonary Segmentectomy (Group 2)|
9733470|NCT05346380|Experimental|During Minimally Invasive Esophagectomy (Group 1)|
9733471|NCT05346367|Active Comparator|SRT (stereotactic radiotherapy)|stereotactic radiotherapy in 1 or 3 fractions of 8 Gy up to 15-24 Gy
9733472|NCT05346367|Experimental|fSRT (hypofractionated stereotactic radiotherapy)|hypofractionated stereotactic radiotherapy in 5 fractions of 7 Gy up to 35 Gy. Brain stem metastases 5 fractions of 6 Gy up to 30 Gy
9733473|NCT05346354|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive weight-based dosing of ravulizumab IV for a total of 50 weeks of treatment.~During the Extension Period, participants will continue to receive weight-based dosing of ravulizumab IV for up to 104 weeks."
9733474|NCT05346341|Experimental|Minimally invasive techniques|
9733475|NCT05346328|Experimental|Single Group Assignment|This study adopts an open research design and selects patients with refractory HER2-positive unresectable locally advanced or metastatic breast cancer who have failed previous ADC drug treatment. The patients who met the enrollment conditions were treated with injection of A166.
9733476|NCT05346302|Active Comparator|Pneumococcal (PPSV23) vaccine|PNEUMOVAX 23 is a clear, colorless solution. Each 0.5-mL dose of vaccine contains 25 micrograms of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative under the supervision of a licensed pharmacist.
9733477|NCT05346302|Active Comparator|Typhoid (inactivated) vaccine|Typhoid vaccine is a clear, colorless solution. Each dose of 0.5 mL is formulated to contain 25 mcg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7 ± 0.3), 4.150 mg of Sodium Chloride, 0.065 mg of Disodium Phosphate, 0.023 mg of Monosodium Phosphate, and 0.5 mL of Sterile Water for Injection under the supervision of a licensed pharmacist.
9733478|NCT05346302|Placebo Comparator|Saline|Saline will be purchased commercially and compounded under the supervision of a licensed pharmacist in sterile syringes for administration of the placebo group.
9733479|NCT05346289||Women|
9733480|NCT05346289||Men|
9733481|NCT05346276|Experimental|68Ga-DOTA-hLAG-3 PET/CT|Each subject receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
9733482|NCT05346263|Experimental|Experimental Group|Patients in experimental group will be adapted to Intermittent Abdominal Pressure Ventilation (IAPV). Abdominal ventilation replaces part of usual ventilation (non invasive ventilation with mouthpiece or nasal-pillow)
9733483|NCT05346263|Active Comparator|Control Group|Patients in control group continue with usual ventilation (NIV through mouthpiece or nasal-pillow)
9733484|NCT05346250||Non exercise program|Subjects receive 12 month lifestyle education alone.
9733485|NCT05346250||Moderate intensity exercise program|Subjects receive 12 month moderate exercise.
9733486|NCT05346250||Vigorous intensity exercise program|Subjects receive 6 month vigorous exercise and subsequent 6 month moderate exercise
9733487|NCT05346237||Adult laryngectomised patients|Patients who have undergone total laryngectomy and completed minimal their 12-month period without disease after surgery and post-operative treatments such as radiotherapy or chemotherapy
9733488|NCT05346224|Experimental|Treatment group|"Neoadjuvant:~HLX11 trastuzumab docetaxel~Adjuvant:~doxorubicin cyclophosphamide trastuzumab HLX11"
9733489|NCT05346224|Active Comparator|Control group|"Neoadjuvant:~Perjeta trastuzumab docetaxel~Adjuvant:~doxorubicin cyclophosphamide trastuzumab HLX11/Perjeta"
9733490|NCT05346211|Experimental|Curcumin Single|"The Single dose group will consume 1 placebo sachet and one curcumin sachet per day.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~The placebo is a sachet containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
9733491|NCT05346211|Experimental|Curcumin Double|"The double dose group will consume two sachets per day of curcumin.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
9733492|NCT05346211|No Intervention|Placebo|"Placebo sachets containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Participants will consume two sachets per day.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
9733493|NCT05346198|Experimental|Subjects will receive CART-BCMA|"Biological: CART-BCMA Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CART-BCMA.~During CART-BCMA production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CART-BCMA product, subjects will receive treatment with CART-BCMA therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CART-BCMA administered by intravenous (IV) injection."
9733494|NCT05346159||turner syndrome group|
9733495|NCT05346159||control group|
10200547|NCT03378219||Cohort 2|Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
10200548|NCT03378219||Cohort 3|Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
10205078|NCT04086017|Experimental|Reiki teaching|Reiki Master will perform the teaching and attunement process for Level 1 Reiki and teach the caregiver(s) how to complete a simple 10-minute Reiki session with the patient and a 10-minute self-Reiki session for the caregiver(s). The Reiki Master will explain that Reiki sessions can be given whenever the patient and caregiver feel it is appropriate, but sessions should be at minimum twice per 24-hour period for at least 10 minutes with at least two hours between sessions. Reiki sessions may be more frequent than twice per day and/or longer than 10 minutes. Self-Reiki sessions should be performed daily for at least 10 minutes but maybe more frequent and/or longer in length. Each family caregiver will receive a copy of the book. The patient and caregiver will wear a Holter monitor continuously for 48 hours beginning when the caregiver(s) are trained in Reiki to measure HRV, a valid measure for stress.
9733501|NCT05346107|Experimental|PldCHP---Nab-PHP|he patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
9733502|NCT05346081||Patients with underlying lung disease|
9733503|NCT05346081||Healthy subjects|
9733504|NCT05346068|Experimental|Study Device|
9733505|NCT05346068|Active Comparator|Control Device|
9733506|NCT05346055|Other|Engage Prism 2.0|Engage Prism is a 9-week program that integrates Engage- a form of behavioral talk therapy treating depression, and guided use of Prism technology- a software that aims to improve social support and interaction of older adults.
9733507|NCT05346042||Confirmed Covid-19|All adult COVID-19 patients and health care workers tested positive in the 7 participating hospitals identified between the end of February 2020 and December 2021.
9733508|NCT05346029|No Intervention|Standard of care|Patients will be followed-up according to standard clinical practices
9733509|NCT05346029|Experimental|Lifestyle intervention|Patients will undergo a 12 week lifestyle intervention (physical therapy and nutritional assessment)
9733510|NCT05346003|Experimental|Intervention Group|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. he BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human CPR mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a CPR mock-up in a home environment, and after blended e-learning, they will be able to perform CPR iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice CPR in a real simulation model two weeks after the blended e-learning.
9733511|NCT05346003|No Intervention|Control Group|In the pretest, all students will be given a BLS knowledge test, followed by e-learning blended with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class. Two weeks after the blended e-learning, all students will practice CPR in a real simulation model. Psychomotor skills will be recorded in the evaluation form.
9733512|NCT05345990|Experimental|Hepatitis B immunoglobulins|"20 patients treated in two cohorts for 12 weeks with hepatitis B Immunoglobulins (HBIG, Hepatect®CP/ Zutectra®).~Cohort A:~10 HBsAg positive, HBeAg-negative patients being treated with anti-HBV nucleotide or nucleoside analogous (NAs) for at least 12 months before screening. HBV-DNA should be below the lower limit of detection at screening. HBsAg should be positive and below 100 IU/ml.~Cohort B:~10 HBsAg positive, HBeAg-negative patients untreated with NAs for at least 12 months before screening. Patients with HBV-DNA levels below 2000 IU/ml and ALT < 1.5 times upper the limit of normal. HBsAg should be positive and below 100 IU/ml.~Trial duration: A recruiting period of approximately 6 months is planned. The total time per patient to complete all study visits is approximately 40 weeks including:~an 28 day screening period~an 12 week treatment period~an 24 week follow-up period"
9733513|NCT05345977|Experimental|Unified Protocol|The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
9733514|NCT05345964|Active Comparator|Single-dose experimental group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
9733515|NCT05345964|Placebo Comparator|Single-dose control group|5mg,15mg,30mg,60mg,90mg,120mg,150mg and 180mg need to complete a single-dose clinical study. The first two dose groups had 4 subjects in each group (3 received GST-HG151 and 1 received placebo，randomly assigned), and the rest are 10 ubjects in each group (8 received GST-HG151 and 2 received placebo， randomly assigned)
9733516|NCT05345964|Active Comparator|Multi-dose experimental group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
9733517|NCT05345964|Placebo Comparator|Multi-dose control group|According to the results of the SAD, it is planned to carry out multiple-dose studies in 2 to 3 dose groups. Continuous administration, 12 subjects in each group(10 received GST-HG151 and 2 received placebo， randomly assigned)
9733518|NCT05345964|Active Comparator|Food Impact Study Group A|According to the results of the SAD, it is planned to select 1 dose group，10 subjects(8 received GST-HG151 and 2 received placebo， randomly assigned)，two cycles, crossover
9733519|NCT05345964|Active Comparator|Food Impact Study Group B|According to the results of the SAD, it is planned to select 1 dose group，8 subjects，two cycles, crossover
9733520|NCT05345951|Experimental|e-PBI+|The e-PBI+ is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens, with additional content on cannabis use.
9733521|NCT05345951|Experimental|e-PBI|the e-PBI is an electronic handbook developed by the PI to guide parents in discussing drinking, behaviors, and consequences with their teens.
9733522|NCT05345951|No Intervention|e-AC|The e-AC is the attention matched control. They will receive general university-related materials to read, sections on parent and family resources (e.g., message from administrators, getting involved, academic calendar), advising, money matters, financial aid, campus life (arts, entertainment, housing, etc.), health and safety (health, counseling services, alcohol and drug laws). It is equivalent to the e-PBI+ and e-PBI on length of content and time to read. This group will not receive an intervention.
9733523|NCT05345938|Experimental|Mitoxantrone Hydrochloride Liposome Injection|"Stage 1: Subjects with R/R AML will receive one of three dose-escalation (30 mg/m^2, 36 mg/m^2, 40 mg/m^2) Mitoxantrone Hydrochloride Liposome, IV, on day 1 of each 28-day cycle (q4w).~Stage 2: Subjects with R/R AML or unfit AML will receive one dose Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 6 cycles."
9733524|NCT05345925|Experimental|Experimental group|Eligible subjects instrumented for CNT testing
9733525|NCT05345912|Experimental|Cohort 1|Subjects received 125 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 125 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
9733526|NCT05345912|Experimental|Cohort 2|Subjects received 250 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 375 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
9733527|NCT05345912|Experimental|Cohort 3|Subjects received 125 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 750 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
9733528|NCT05345899|Other|chronic rheumatism|Population of patients followed for chronic inflammatory rheumatism in remission or lupus in low activity, with chronic residual pain
9733529|NCT05345886|Experimental|Hippotherapy|The experimental group will receive 30 minutes of hippotherapy once a week for 12 weeks.
9733530|NCT05345886|No Intervention|Control|The control group will receive its rehabilitation care
9733531|NCT05345873|Experimental|SCTV01E Group|one dose of SCTV01E, intramuscular
9733532|NCT05345873|Active Comparator|mRNA-1273|one dose of mRNA-1273, intramuscular
9733533|NCT05345860|Experimental|TNBC with high risk or MRD+|"TNBC patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
9733534|NCT05345860|Experimental|HER2+ with high risk or MRD+|"HER2+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
9733535|NCT05345860|Experimental|ER+ with high risk or MRD+|"ER+ patients with clinical high risk or post-operation 1st MRD tested positive.~It's possible that this arm will be divided into many sub-arms considering the different kinds of intensive adjuvant therapies and the adopting of MRD strategy."
9733536|NCT05345860|Experimental|TNBC with low risk and MRD-|"TNBC patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
9733537|NCT05345860|Experimental|HER2+ with low risk and MRD-|"HER2+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
9827934|NCT02473640|Experimental|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
9835736|NCT02752776|Experimental|Secukinumab|All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.
9733538|NCT05345860|Experimental|ER+ with low risk and MRD-|"ER+ patients with low clinical risk and post-operation 1st MRD tested negative.~It's possible that this arm will be divided into many sub-arms considering the different kinds of standard adjuvant therapies and the adopting of MRD strategy."
9733539|NCT05345847|Experimental|1- Active Surveillance|Active surveillance with rescue corticosteroids
9733540|NCT05345847|Active Comparator|2- Early initiation of steroid (Standard)|Early intervention with high-dose steroids
9733541|NCT05345834|No Intervention|Usual Care|Participants will participate in usual prenatal care throughout the duration of study.
9733542|NCT05345834|Experimental|Patient Navigation and treatment|"In the patient navigation arm, women who do not meet diagnostic criteria (Group 2a) can participate in: (1) group-based CBT preventative intervention; (2) peer support group (virtual); or (3) both. Women in the threshold risk group, meeting diagnostic criteria for depression/anxiety (Group 2b) at baseline can participate in: (1) individual CBT treatment (2) peer support group (virtual) (3) both~Prevention group includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Individual treatment includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations."
9733543|NCT05345821||primary augmentation group|Women undergoing primary breast augmentation with Silimed® smooth surface Breast Implant.
9733544|NCT05345821||secondary (revision) augmentation group|Women undergoing secundary or revision breast augmentation with Silimed® smooth surface Breast Implant.
9733545|NCT05345808|Other|Formulated Posterior Sub Tenon Triamcinolone|All the eyes received single dose 40 mg of Triamcinolone Acetonide (TA) and VISCOAT which is 20 mg sodium chondroitin sulphate and 15 mg sodium hyaluronate (0.5 ml) through posterior subtenon route using NAGATA subtenon canula.
9733546|NCT05345795||SSc-ILD patients|
9733547|NCT05345782|Active Comparator|Laparoscopic Hypo gastric Neural Plexus Block|laparoscopy for diagnosis of the causes of chronic pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the sacral promontory then30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) are injected.
9733548|NCT05345782|Active Comparator|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block|laparoscopy for diagnosis and conventional surgical treatment of the causes of pelvic pain then injecting 5 ml normal saline for hydro dissection of the retroperitoneal space at the level of the promontory followed by 30 ml (14 ml Marcaine +14 ml normal saline+2ml betamethasone) then injecting 5 ml ( 2.5 marcaine+1ml betamethasone +1.5 ml normal saline) 2 cm away from the cervix at the uterosacral ligament on each sides.
9733549|NCT05345769|Experimental|Phase I- All|Subjects with neovascular AMD
9733550|NCT05345756|Experimental|Intraoral Protraction Technique|using intraoral appliance composed of modified lingual arch and miniscrews for indirect anchorage for maxillary protraction after Alt-RAMEC protocol using hybrid expander
9733551|NCT05345756|Active Comparator|Extraoral Protraction Technique|using facemask for maxillary protraction after ALT-RAMEC protocol
9733552|NCT05345743||Positive AIR-test|Patients with a positive intraoperative AIR-test result
9733553|NCT05345743||Negative AIR-test|Patients with a negative intraoperative AIR-test result
9785841|NCT01261052|Active Comparator|APD only intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the entire study, the adaptive component or APD will be used to control the subject's blood glucose.
9733554|NCT05345730||Mitral valve insufficiency patients undergoing mitral valve repair surgery|The research population consists of mitral valve insufficiency patients scheduled for elective surgical mitral valve repair (N=20) according to the current European guideline criteria. These patients will undergo a cardiac MRI scan 2 weeks prior to surgery and 3 months after surgery.
9733555|NCT05345717|Experimental|Patients treated with belatacept and proteasome inhibitor|Highly sensitized patients will be treated with belatacept and proteasome inhibitor and monitored for decreasing calculated Panel of Reactive Antibodies (cPRA) and suitable kidney donor base don negative crossmatch
9733558|NCT05345691|Experimental|Bmab 1000|
9733559|NCT05345691|Active Comparator|Prolia®:|
9733560|NCT05345665|Other|Echography|For the neuronal blockade of the patient, anesthesiologists used an echography.
9733561|NCT05345665|Other|Neurostimulation|For the neuronal blockade of the patient, anesthesiologists used neurostimulation.
9733562|NCT05345665|Other|Active mobilization|For the neuronal blockade of the patient, anesthesiologists used active mobilization.
9733563|NCT05345639|Experimental|TTP group (= Transversus Thoracic Plane block = Deep PIP = Deep parasternal intercostal plane block)|At the end of the surgery, realisation of a bilateral transverse thoracic block. (20ml of Naropeine 0.2%, each side) Followed by standard analgesic treatment.
9733564|NCT05345639|Experimental|PSB group (=ParaSternal Block = Superficial PIP = Superficial parasternal intercostal plane block)|"At the end of the surgery, realisation of a bilateral parasternal block (20ml of Naropeine 0.2%, each side).~Followed by standard analgesic treatment."
9733565|NCT05345639|Sham Comparator|Control group|Standard analgesic treatment alone (without LRA) .
9733566|NCT05345613|Experimental|Tranexamic Acid group|standard solution for injection with TXA and without adrenaline
9733567|NCT05345613|Placebo Comparator|Standard therapy group|standard solution for injection including adrenaline
9733568|NCT05345600|Experimental|MILTA|The MILTA® uses photons which are emitted with low intensity in the visible and near infrared combining 5 physical principles to reduce pain
9733569|NCT05345600|Placebo Comparator|placebo|
9733570|NCT05345587|Experimental|Prolife group|scheduled consultation with the hospital clinical pharmacist, therapeutic follow-up and collection of clinical information by the patient via the THESS monitoring system
9733571|NCT05345587|No Intervention|Standard care|
9733572|NCT05345574|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
9733573|NCT05345574|Active Comparator|remifentanil infusion group|remifentanil of 0.05 ㎍/kg/h during induction, followed by remifentanil infusion (0.05-0.3 ㎍/kg/h) during the surgery
9733574|NCT05345561||Pregnant women|Women with higher risk of FNAIT
9733575|NCT05345548|Experimental|Cold Pressor test|
9733576|NCT05345535|Experimental|Study group|Participants of study group will perform 45 minutes of trampoline exercises. Evaluations are going to be done immediately before and after trampoline session.
9733577|NCT05345535|Experimental|Control group|Participants of control group will perform 45 minutes of walking. Evaluations are going to be done immediately before and after walking session.
9733578|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg as the low dose group.
9733579|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg as the middle dose group.
9733580|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg as the high dose group.
9733581|NCT05345509|Active Comparator|Aricept Tablet|Aricept Tablet, QD, PO
9733582|NCT05345509|Experimental|IVL3003 (A mg)|SC, Single Dose
9733583|NCT05345509|Experimental|IVL3003 (B mg)|SC, Single Dose
9733584|NCT05345509|Experimental|IVL3003 (C mg)|SC, Single Dose
9733585|NCT05345496||WORKERS GROUP|44 physiotherapists with a history of at least 1 painful episode of work-related thumb pain in the last 3 months will be enrolled.
9733586|NCT05345496||STUDENT GROUP|44 physiotherapy students in their first academic year will be enrolled.
9733587|NCT05345470|Placebo Comparator|0 grams of chia seeds|3 cookies (30 grams)
9733588|NCT05345470|Experimental|3 grams of chia seeds|3 cookies (30 grams)
9733589|NCT05345470|Experimental|5 grams of chia seeds|3 cookies (30 grams)
9733590|NCT05345470|Experimental|7 grams of chia seeds|3 cookies (30 grams)
9733591|NCT05345457|Experimental|Antibiotics|Patients randomized into the treatment (i.e., antibiotics) arm of the study will be treated with a seven-day course of oral azithromycin and amoxicillin. Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days). Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
9733592|NCT05345457|No Intervention|No antibiotics|Patients randomized into the control (i.e., no antibiotics arm) will be managed according to standard of care practices for previable PPROM desiring of expectant management.
9733593|NCT05343195|Active Comparator|Control group|"Conventional physiotherapy was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program:~1-2 week: 20 min. of active exercise in lying position (e.g.: hip flexion, extension, abduction) with the goal to improve hip range of motions, strengthen muscles. Various equipment was used (slippery base, elastic bands, foam roller, gymnastic ball etc.). + gait training exercise within the bars (10 min);~3 week: 20 min. of active exercise in lying position + stationary bicycle / treadmill (10 min)."
9733594|NCT05343195|Experimental|Task oriented exercise group|"Task oriented exercise program was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program included:~1 week: active exercise in lying position (15 min) + task-oriented exercise (15 min);~2 week: active exercise in lying position (10 min) + task-oriented exercise (20 min);~3 week: stationary bicycle / treadmill (10 min) + task-oriented exercise (20 min).~Task oriented exercise included:~walking backwards, sideways, high kneels (on the instable bases);~walking with alternate speed (physiotherapist give the instruction when to walk faster / slower);~Sit and stand from the chair (standing up to reach for the ball held by the physiotherapist);~step onto the step (after stepping to reach the ball held by the physiotherapist);~walk with the obstacles (obstacle course);~Catch and throw the ball while standing on an unstable base."
9733595|NCT05343117||Palbociclib based-therapy as initial endocrine therapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy as initial endocrine therapy from August 1, 2018 to December 31, 2023.
9733596|NCT05343117||Palbociclib based-therapy after chemotherapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy after chemotherapy from August 1, 2018 to December 31, 2023.
9733597|NCT05337917||Case|Injury to digital nerve: thumb, digit II radial side, digit V ulnar side
9733598|NCT05337917||Control|Injury to digital nerve: digit II ulnarside, dig III, dig IV dig V radial side.
10200549|NCT03375918|Other|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
10200550|NCT03375918|Other|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
9733601|NCT05337228|Experimental|IN-C006 Peri inj.|IN-C006 Peri inj. 1904 mL
9733602|NCT05337228|Active Comparator|RPN301|RPN301 2020 mL
9733603|NCT05336383|Experimental|Radiation Therapy|Radiation treatment will be to bony or soft tissue plasmacytomas in up to five radiation treatment fields to 10-20Gy (or equivalent dose in 2Gy fractions of 10-21Gy
9733604|NCT05335486|Experimental|RELEARN - Intervention|Participants will be asked to attend eight sessions of RELEARN neurofeedback with an approximate duration of 45 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention
9733605|NCT05335486|No Intervention|Standard treatment control|Participants will be asked to attend eight sessions with no intervention and serve as no-treatment controls with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention
9733606|NCT05335408|Experimental|Vario-group|Patients in this group recieve the Acunex Vario IOL bilaterally during the cataract surgery.
9733607|NCT05335408|Active Comparator|Vivity-group|Patients in this group recieve the Alcon Acrysof IQ Vivity IOL bilaterally during the cataract surgery.
9733608|NCT05335109|Experimental|Xenon|
9733609|NCT05335109|Placebo Comparator|Oxygen|
10200551|NCT03375918|Other|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
10200552|NCT03375918|Other|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
10200553|NCT03375918|Other|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
9733610|NCT05334706|Experimental|Vaccination|Single arm, vaccination with 9vHPV in a 3-dose regimen (Day 1, Month 2, Month 6).
9785842|NCT01261325|Placebo Comparator|Placebo|Matching placebo tablets administered twice daily
9785843|NCT01261325|Experimental|Brivaracetam 100 mg/ day|Brivaracetam 50 mg/ day administered twice daily.
9785844|NCT01261325|Experimental|Brivaracetam 200 mg/ day|Brivaracetam 100 mg/ day administered twice daily
9733611|NCT05334459||Intervention|"Operable, postmenopausal ER/PR positive and Her2 neu (-), oligometastatic dnMBC patients~Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc)~o ER / PR /Her2 /Ki67 study~Collection of CTC.~Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~o Denosumab, Biphosphonate for bone metastasis~RT to metastatic side (if visible). Continue Systemic therapy~12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~ST will be continued until progression and/or unmanageable toxicity.~Radiologic evaluation every 3-6-month based on institutional practice."
9733612|NCT05334433|Experimental|Local anesthesia injection with the comfort in jet (Needless system)|A needle-less injection approach will be used to administer the local anesthetic solution
9733613|NCT05334433|Active Comparator|Local anesthesia injection with needle injection (conventional technique).|A conventional aspirating syringe fitted with 27-gauge long needles will be used to administer the local anesthetic solution.
9733614|NCT05333549|Experimental|Usual care plus istradefylline|Participants will receive usual care, and in addition, will be asked to take istradefylline daily for 26 weeks.
9982495|NCT05226455|Experimental|venetoclax + azacitidine +/- donor lymphocyte infusion|"Venetoclax alone during 28 days followed by venetoclax + azacitidine +/- donor lymphocyte infusion (maximum 12 cycles).~Venetoclax: Phase I: 4 dose levels: 50, 100, 200, 400 mg/d, starting dose at 100 mg ; Phase II: dose defined in the phase I.~Azacitidine 75 mg/m²/d or 50 mg/m²/d (if allohematopoietic stem cell transplantation relapse < 4 months) x 5 days (on D1 to D5 of 28 days cycle)."
9733616|NCT05333458|Experimental|Arm I (atezolizumab, selienexor)|Patients receive atezolizumab IV over 30-60 minutes on day 8 of cycle 1, and then on day 1 of subsequent cycles. Patients also receive selinexor PO QW on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9733617|NCT05333458|Experimental|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 8 of cycle 1, and then on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
9733618|NCT05332444|Experimental|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
9733619|NCT05332444|Active Comparator|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
9982496|NCT05226390|Experimental|1 x 107 IU/dose MVA-SARS-2-ST|All Participants will receive a single booster dose of 1 x 107 IU MVA-SARS-2-ST in 0.5 mL as inhalation (total inhaled volume 0.5 mL)
9982497|NCT05226325|Active Comparator|G0.2|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.2 mcg/kg/hour
9733622|NCT05328804|Experimental|rhTPO|rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days.
9733623|NCT05328804|Experimental|Herombopag|Herombopag will be taken orally at 5 mg daily for 28 days.
9733624|NCT05328804|Experimental|Herombopag in combination of rhTPO|Herombopag will be taken orally at 5 mg daily for 28 days，while rhTPO will be injected subcutaneously at 300 u/kg daily for 14 days
9733625|NCT05328037||Acute diarrhea cases|Children with acute diarrhea defined as at least 3 loose or watery stools per day for at least 3 consecutive days and up to 10 consecutive days
9733626|NCT05328037||Chronic diarrhea cases|Children with chronic diarrhea defined as 3 or more loose or liquid stools per day for at least 4 weeks
9733627|NCT05328037||Controls|Children without fever or signs of infection or ongoing diarrhea
9982498|NCT05226325|Active Comparator|G0.4|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.4 mcg/kg/hour
9982499|NCT05226325|Active Comparator|G0.6|(33) patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minutes followed by infusion at the rate of 0.6 mcg/kg/hour
9982500|NCT05225168|Active Comparator|laparoscopic burch colposuspension group|this group will only have laparoscopic burch colposuspension
9982501|NCT05225168|Active Comparator|Minisling Suburethral Sling group|this group will only have Minisling Suburethral Sling
10200554|NCT03372460|Active Comparator|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
10200555|NCT03372460|Sham Comparator|Sham Stimulation|Sham tDCS will include a 30-second ramp up to 1mA, 30 seconds of stimulation at 1mA, followed by a 30-second ramp down to off. The device will remain off for the remainder of the session. This process will be used for each of the 6 sessions during a 2 week period.
10200556|NCT03368963|Experimental|Treatment (Nal-IRI, TAS-102)|Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Cycles repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
10200557|NCT03365063|Experimental|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
10200558|NCT03365063|No Intervention|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
10205079|NCT04086017|No Intervention|Usual care|Patients and caregivers will complete all measures expected of the intervention cohort including daily symptom checklist for 10 days. The patient and caregiver will wear a Holter monitor for the first 48 hours of study participation to measure heart rate variability (HRV), a valid measure for stress. The patient and/or caregiver may opt out of the Holter monitor if requested and still participate in the rest of the study.
9982502|NCT05225051|Experimental|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)|presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
9733633|NCT05326373|Active Comparator|Healthy Group|Subjects without gingivitis (</= 3 bleeding sites) will use stannous fluoride toothpaste
9733634|NCT05326373|Active Comparator|Unhealthy Group|Subjects with gingivitis (>/= bleeding 20 sites) will use stannous fluoride toothpaste
9733635|NCT05324683||Study population (cohort)|No study arms; one patient population will be observed.
9733636|NCT05322993|Active Comparator|With artificial intelligence (AI)|Use of GI Genius artificial intelligence device during colonoscopy.
9733637|NCT05322993|Active Comparator|Without artificial intelligence|Use of standard colonoscopy equipment without GI Genius.
9733638|NCT05322954|Experimental|Oral Psilocybin|Psilocybin with psychological support: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
9733639|NCT05322928|Experimental|Engagement in daily occupations|The experimental contents will include 1-hour video appointments with an occupational therapist a week in four weeks and a maintenance phase of similar session format every second week in two months.
9733640|NCT05321576|Active Comparator|erector spinae plane block group|Before this process, it will be produced from the bupivacaine plan, which will be made by entering unilaterally 3 cm lateral in the ultrasound to be made from a work section that will be made before the shipment and by lidocaine.
9733641|NCT05321576|Active Comparator|control group|give opiod in this group of patients
9733642|NCT05320133|Experimental|JWC group|Jinghua Weikang Capsule containing quadruple therapy.
9733643|NCT05320133|Active Comparator|Control group|Bismuth-containing quadruple therapy.
9733644|NCT05317949|Experimental|Integrated neuromuscular training program group|Integrated neuromuscular training program group will perform exercise in three major domains
9733645|NCT05317949|Active Comparator|General fitness exercises program group|General fitness exercises program group will perform general fitness exercises
9733646|NCT05317728|Experimental|FAIOL|FA09200 IOL implanted in the first eye and FA10266 IOL implanted in the second eye during cataract surgery (contralateral implantation)
9733647|NCT05317728|Active Comparator|Monofocal|Monofocal IOL implanted in both eyes during cataract surgery (bilateral implantation)
9733648|NCT05315336|Experimental|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
9733649|NCT05315115|Experimental|Experimental group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
9733650|NCT05315115|Sham Comparator|Control group|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor.No spinal adjustment will be performed during any control intervention.
9733651|NCT05312710|Experimental|APG-157|Two pastilles (100 mg) taken three times a day (i.e. before meal time).
9733652|NCT05312255|Experimental|Module A (strength training, behavioral intervention)|Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 6 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 6 months.
9733653|NCT05312255|Experimental|Module B (intermittent fasting)|Patients undergo intermittent fasting for 1 month. This consists of restricting all eating to a consecutive 8-hour time period each day followed by 16 consecutive hours of not eating.
9733654|NCT05312255|Experimental|Module C Group I (propranolol)|Patients receive propranolol PO BID for 3 months.
9733655|NCT05312255|Active Comparator|Module C Group II (propranolol)|Patients continue receiving beta-blocker regimen as per SOC for 3 months.
9733656|NCT05312255|Experimental|Substudy Arm I (strength training, behavioral intervention)|Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 3 months. After 3 months, patients then cross-over and complete Arm II intervention.
9733657|NCT05312255|Experimental|Substudy Arm II (behavioral intervention, strength training)|Patients wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 3 months. After 3 months, patients then cross-over and complete Arm I intervention.
9733658|NCT05311839|Experimental|Thera band exercises group|received graded Thera band exercises for 5 days per week for eight weeks in addition to the conventional physical therapy program.
9733659|NCT05311839|Experimental|conventional physiotherapy program group|received a conventional physical therapy program.
9733660|NCT05309291|Experimental|Theranova 400 Dialyzer|1 week, 1 session in mid-week HD therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
9733661|NCT05309291|Active Comparator|FX 800 Dialyzer|1 week, 1 session in mid-week HDF therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
9733662|NCT05306418|Experimental|Mim8|52-week treatment period with a part 1 and part 2, where all participants receive Mim8 prophylaxis
9733663|NCT05301192|Experimental|Angiotensin-(1-7)|Participants will receive intravenous angiotensin-(1-7) at one study visit for 110 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 80 minutes. Infusion rates will be calculated for each participant based on body mass.
9733664|NCT05301192|Placebo Comparator|Saline|Participants will receive intravenous saline at one study visit for 110 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each participant based on body mass.
9733665|NCT05300776|Experimental|M-ROSE combined with mNGS group|The bronchoalveolar lavage fluid (BALF) of patients undergoes M-ROSE analysis and decide whether the samples are qualified, whether they indicate bacterial infection and identify pathogens, and the qualified samples are sent for mNGS analysis. The individualized anti-infection treatment is comprehensively guided according to the results of M-ROSE, mNGS and clinical examinations.
9733666|NCT05300776|No Intervention|mNGS group|BALF samples were directly sent for mNGS analysis, and anti-infective treatment was guided according to clinical examinations.
9733667|NCT05298579|Experimental|Group A|"Yoga exercises applied by video-conference method accompanied by a physiotherapist.~Evaluations and yoga exercises will be applied to the participants in this group through the Zoom program. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes, at a time determined jointly by the physiotherapist and the participant (Table 1). Before starting the program, an informative broadcast will be made to the participants and groups of 6-8 people will be formed."
9733668|NCT05298579|Active Comparator|Group B|"Yoga exercises performed asynchronously accompanied by videos. Exercise videos will be broadcast to the participants in this group through the YouTube program. The shooting of the exercise videos will be completed in advance and uploaded to a channel opened on YouTube. All posts made in this channel will only be open to individuals participating in the research during the duration of the study. Yoga exercises were created with reference to studies in the literature. It will be applied for 8 weeks, 3 days a week and 40-45 minutes. Participants will be able to access the exercise videos at a time they want (Table 2). Participants will be encouraged to achieve weekly targeted training sessions and to keep an exercise diary."
9733669|NCT05296421|Experimental|Basic science (uniformly-labeled [13C]glucose)|Patients receive uniformly-labeled [13C]glucose IV over 10 minutes and then over up to 120 minutes until time of biopsy. Patients then undergo surgery and biopsy per standard of care.
9733670|NCT05296187|Active Comparator|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
9733671|NCT05296187|Placebo Comparator|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
9733672|NCT05294835|Experimental|Ketamine Infusion|subanesthetic ketamine infusion (0.5mg/kg) over 2-3 weeks
9733673|NCT05294107|Experimental|Group Crohn's disease|4 additional biopsies for 30 patients with Crohn's disease
9733674|NCT05294107|Experimental|Group ulcerative colitis|4 additional biopsies for 30 patients with ulcerative colitis
9733675|NCT05294107|Active Comparator|Group No MICI|4 additional biopsies for 30 patients out of Inflammatory Disease Chronic Bowel Disease
9733676|NCT05292755|Experimental|Carboxymethylcellulose (CMC) Artificial Tears|Refresh brand artificial tears containing 0.5% carboxymethylcellulose will be self-administered three times a day in each eye by the participants for 1 week in the experimental arm.
9733677|NCT05292755|Placebo Comparator|Preservative-free, CMC-free Artificial Tears|Systane brand artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be self-administered three times a day in each eye by the participants for 1 week in the control arm.
9733678|NCT05290753|Other|Prokinetic use in accelerate healing of urgent intestinal anastomosis|Prikinetic agents administered immediately post operative and time of stay at hospital twice daily
9982503|NCT05225051|Experimental|symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)|symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)
9982504|NCT05225051|Experimental|human control cell lines, Unmutated Huntingtin|human control cell lines, Unmutated Huntingtin
9982505|NCT05224752||healthcare workers at MRMC|healthcare workers at MRMC
9982506|NCT05224583||Simultaneous Liver-Kidney Transplant patients population at MDMC|Consecutive SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).
9733683|NCT05288166|Experimental|Abemaciclib + Abiraterone + Prednisone/Prednisolone|Abemaciclib plus (+) abiraterone + prednisone/prednisolone administered orally.
9733684|NCT05288166|Active Comparator|Placebo + Abiraterone + Prednisone/Prednisolone|Placebo + abiraterone + prednisone/prednisolone administered orally.
9982507|NCT05224297||breast|
9982508|NCT05224297||thorax|
9982509|NCT05224297||skin|
9733688|NCT05278663|Experimental|Cohort 1: E6742 100 mg or Placebo|Participants will receive E6742 100 milligram (mg) tablet or E6742-matched placebo tablet, orally, twice daily for up to 85 days.
9733689|NCT05278663|Experimental|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg tablets (two tablets of each 100 mg) or E6742-matched placebo tablets, orally, twice daily for up to 85 days.
9785845|NCT01261338|Experimental|olestra|Non-absorbable fat administered in the form of 24 potato crisps per day (12 each with mid-day and evening meal) providing approximately 15g/day of olestra.
9982510|NCT05224297||abdomen|
9982511|NCT05224297||skull|
9982512|NCT05224297||head and neck|
9982513|NCT05224297||pelvis male|
9982514|NCT05224297||pelvis female|
9733690|NCT05277896|Active Comparator|Ketamine Group|Patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
9733691|NCT05277896|Active Comparator|Etomidate Group|Patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). In this pragmatic trial, treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
9733692|NCT05277168|Experimental|Single Arm|Single Arm : SHR-A1904
9733693|NCT05273060|No Intervention|Standard of Care Nasal Reconstruction Planning|Subjects undergoing nasal reconstruction will have standard planning for procedure.
9733694|NCT05273060|Experimental|3D Nasal Reconstruction Planning|Subjects undergoing nasal reconstruction will have 3D planning utilized by the surgical team for the procedure.
9733695|NCT05272033|Active Comparator|GROUP TEAS|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at PC-5, PC-6, and ST-36 with an electronic acupuncture device.
9733696|NCT05272033|Sham Comparator|Sham TEAS|In the sham TEAS group, the gel electrodes will be applied at the same anatomical points without stimulation.
9733697|NCT05270694|Experimental|COVID-19 Testing|The cohort participants will be exposed to a public health messaging campaign and provided with at-home tests to improve acceptability and access to COVID-19 testing.
9982515|NCT05224297||extremities|
9733699|NCT05266092||Participants with chronic kidney disease undergoing hemodialysis|
9733700|NCT05266092||Participants with chronic kidney disease, not in dialysis|
9733701|NCT05266092||Participants with chronic kidney disease undergoing peritoneal dialysis|
9733702|NCT05266092||Healthy participants|
9733703|NCT05266014|Experimental|tinlarebant|Daily, oral administration of one tinlarebant.
9733704|NCT05265715|Experimental|Low AGE dietary intervention|"Patients will complete a food frequency questionnaire, & if found to have a high AGE diet at baseline, will then begin the study the 24-week low AGE dietary intervention. Patients will complete a 3 day food record prior to receiving remotely delivered education on AGEs on how to adhere to a low AGE diet by the study dieticians prior to starting. This session will provide education on dietary AGE & how to prepare & choose low AGE meals~Subsequent sessions with the dieticians will be conducted remotely & will be 30-60 minutes in duration, with the exception of sessions scheduled for weeks when a study blood draw is required, when visits with the dietician may occur in person. These sessions will occur at the following schedule: weekly during the first 2 months (8 sessions), every other week during the next 2 months (4 sessions, aka step down sessions), monthly for the remaining 2 months (2 sessions)~3 day food records will be collected at 12 & 24 weeks, in addition to baseline."
9733705|NCT05264714|Experimental|Chronic Cluster Headache Subjects|Subjects with chronic cluster headaches will track their headaches for a one-week baseline headache diary. After establishing the baseline headache frequency, severity, and abortive medicine use, subjects will be asked to start their first dose of rimegepant with their next moderate to severe cluster headache.
9733706|NCT05262088||newborns|Assessment of the motor repertoire in children aged 0 to 5 months and its relationship with prenatal and perinatal factors and the results of neurological development in the second year of life.
9733707|NCT05258175|Experimental|Kinesio taping muscle facilitation technique along with standardized physiotherapy protocol|"On the diaphragmatic muscle, muscle facilitation technique will be applied from proximal to distal with 10-15% tension when the participant is standing and exhaled out and the body is in extension. The base of the tape will be about 1 inch below the xiphoid area.~Then the one tail of tape applied with 10% tension on the rib cage with maximum deep inspiration followed by expiration and the other tail of tape will be applied to the subcostal area in forward bending position while taking deep breath with arms adduct and being crossed.~The tape will be changed on every fifth day and assessment will be done at baseline and 2nd week of intervention Total number of sessions: 3"
9785846|NCT01261338|Placebo Comparator|Vegetable oil|Absorbable fat administered in the form of 12 potato crisps per day (6 each with mid-day and evening meal) in order to match the caloric intake provided by the crisps with Olestra.
9835737|NCT02752802|Active Comparator|Treatment|The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
9982516|NCT05224193||Paediatric Patients with Inflammatory Bowel Disease|
9733708|NCT05258175|Active Comparator|Standardized physiotherapy protocol|"Pursed lip breathing exercise: Patient instructed to breathe through nose and inspiration should be slowly and expiration is done through mouth by pursing the lips slowly such that if flame is held in front, then the flame should be bended but not blow off. 3 sets a day for 15 days.~Diaphragmatic breathing exercise: Patient sitting comfortably, with knees bent and shoulders, head and neck relaxed. Patient will be instructed to place one hand on upper chest and the other just below your rib cage. Breathe in slowly through nose so that stomach moves out against your hand. 3 sets a day for 15 days.~Deep breathing exercise: Patient instructed to take slow and deep breaths, inhaling through the nose and exhaling through the mouth. Participant is asked to place their hand on their abdomen and expand their abdomen to lift their hand during inhalation. 3 sets a day for 15 days."
9733710|NCT05254756|Active Comparator|Traditional plastic 2-blade disposable speculum|Patients assigned to this arm will be evaluated using the traditional plastic 2-blade disposable speculum
9733711|NCT05254756|Experimental|5-petal Bouquet speculum|Patients assigned to this arm will be evaluated using the 5-petal Bouquet speculum
9733712|NCT05254743|Experimental|Pirtobrutinib|Administered orally.
9733713|NCT05254743|Experimental|Ibrutinib|Administered orally.
9733714|NCT05254184|Experimental|Patients With NSCLC|All participants will receive the intervention.
9733715|NCT05253807|Experimental|Cohort A: Squamous NSCLC|Participants with squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
9733716|NCT05253807|Experimental|Cohort B: Non-squamous NSCLC|Participants with non-squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
9733717|NCT05253794|Experimental|Colchicine|Colchicine 0.6mg PO daily for 6 months
9733718|NCT05253794|Placebo Comparator|Placebo|Placebo tablet daily for 6 months
9733719|NCT05252689|Active Comparator|monolithic zirconia single posterior crowns with deep chamfer finish line|monolithic zirconia single posterior crowns with deep chamfer finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
9733720|NCT05252689|Experimental|monolithic zirconia single posterior crowns with vertical finish line|monolithic zirconia single posterior crowns with vertical finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
9733721|NCT05251818|Active Comparator|Acupressure grubu|"The first thing after the operation is to apply the thumb tool for approximately seven minutes, with 15 seconds of preparation and 1.5 minutes of application at each point of the LI4 and TH6 acupuncture points (the equivalent of working each point).The second application will be repeated three hours after the first application, with the same procedure.~By the researcher, hourly monitoring will be done until the bowel sounds of the puerperant are heard, and the puerperant will be followed up until the gas and defecation output. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
9733722|NCT05251818|Active Comparator|Control Group|"No application will be made to the control group.. From the first postoperative hour, the researcher will follow the bowel sounds every hour until the first bowel sounds of the patient are heard.~Postpartum women will be followed until gas and defecation are released. The gas and defecation time of the puerperants will be questioned every 12 hours, and the information will be obtained by making a phone call with those who are discharged without defecation."
9733723|NCT05244304|Experimental|Tinlarebant|5 mg tablet taken orally once a day
9733724|NCT05244304|Placebo Comparator|Placebo|Placebo tablets for tinlarebant 5 mg are prepared similarly but use microcrystalline cellulose, NF, in place of the active drug substance and will be identical in size and appearance.
9733725|NCT05240170|Experimental|RIRS group|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
9733726|NCT05240170|Experimental|SWL group|The medical records of all patients who underwent SWL at our institution in the past five years will be reviewed. Patients with renal rotation or position anomalies, as defined by NCCT and/or IVU, will be included for possible study participation.
9982517|NCT05223972|Experimental|Scoliosis Treatment Group|For the scoliosis group treatment include schroth theraphy
9835738|NCT02752802|Active Comparator|Control|The control group will include standard of care for diagnostic coronary angiograms.
9982518|NCT05223972|Experimental|Lyon Treatment|For the scoliosis group treatment include Lyon theraphy..
9982519|NCT05220904|Placebo Comparator|Placebo Comparator:placebo practice+spectacles|Patients will take placebo practices with spectacles every two days.
9982520|NCT05220904|Experimental|Experimental： perceptual learning practice+spectacles|Patients will take perceptual learning practices with spectacles every two days.
9733732|NCT05237349|Experimental|envafolimab plus chemotherapy|Envafolimab:300mg,sc,d1,Q3W; Chemotherapy:SOX(Oxaliplatin，130mg/m2, iv,d1,Q3W + S-1，40mg/m2, op,bid,d1-14,Q3W).
9733733|NCT05229523||1/Children with diparetic and hemiparetic cerebral palsy|1/Children with diparetic and hemiparetic cerebral palsy aged 7-18 years with the Communication Function Classification System (CFCS) level ≤ 3 and Extended Gross Motor Function Classification System (GMFCS-E&R) level ≤ 2
9733734|NCT05223491|Experimental|En Bloc|The bladder tumour will be resected en bloc and removed in total, if possible.
9733735|NCT05223491|Active Comparator|Conventional TURB|The bladder tumour will be removed by conventional piecemeal resection.
9733736|NCT05221840|Experimental|Arm A: Durvalumab and Oleclumab|Durvalumab on Day 1 of each 28-day cycle + Oleclumab on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months
9733737|NCT05221840|Experimental|Arm B: Durvalumab and Monalizumab|Durvalumab + Monalizumab on Day 1 of each 28-day cycle for up to 12 months. Placebo infusion will be administered on Day 15 of cycles 1 and 2 only
9733738|NCT05221840|Active Comparator|Arm C: Durvalumab and Placebo|Durvalumab on Day 1 of each 28-day cycle + Placebo on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months
9733739|NCT05219513|Experimental|Parts I-III: Dose-escalation of RO7443904|The dose-escalation of RO7443904 and glofitamab will take place every three weeks (Q3W) with obinutuzumab pre-treatment.
9733740|NCT05219513|Experimental|Part IV: Dose-expansion of RO7443904|Part IV of this study will evaluate selected dose levels of RO7443904 in combination with glofitamab from Parts I-III in a Q3W regimen with obinutuzumab pre-treatment.
9733741|NCT05217537|Experimental|Cohort 1 (adolescents)|12 to < 18 years of age
9733742|NCT05217537|Experimental|Cohort 2 (children)|8 to < 12 years of age
9733743|NCT05214534||Experimental|Retrospective analysis of the correlation between SuPAR measurement and patient outcome after hospitalization
9982521|NCT05220488||Asthma Group|Asthma Group
9982522|NCT05220488||Healthy Group|Healthy Group
9733746|NCT05213039||1/Children with diparetic and hemiparetic cerebral palsy|1/Children with diparetic and hemiparetic cerebral palsy whose Gross Motor Function Classification System (GMFCS) Level ≤ 2 will be evaulated by two different observers.
9982523|NCT05219435|Experimental|Nivolumab plus Ipilimumab|Patients will receive maintenance therapy with 4 cycles of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg every three weeks (Q3W)(induction phase) followed by Nivolumab 480 mg every 4 weeks (Q4W)(consolidation phase) until unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
9733748|NCT05211284|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (72 weeks)
9733749|NCT05211284|Placebo Comparator|Placebo Arm|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (72 weeks).
9733750|NCT05209828||pfmmedical port implantation|Port implantation for continous vascular access.
9733751|NCT05201456||Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite pressure monitoring single use flexible scope, real-time pressure monitoring technology, which will provide surgeons with intraluminal pressure data in the kidneys and ureter.
9733752|NCT05201456||Non-Pressure Monitoring|Subjects in this cohort will undergo ureteroscopic procedure using LithoVue Elite Non-pressure monitoring single use flexible scope.
9733753|NCT05201157|Active Comparator|Acupressure group|Acupressure will be applied to ST36, LI4 and SP6 points.The Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled by women once on the post-op 0th day and once on the post-op 2nd day, a total of 2 times.
9733754|NCT05201157|Active Comparator|Control Group|No application will be made to this group, and the Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled in 2 times in total, once on the post-op 0th day and once on the post-op 2nd day.
9733755|NCT05199441|Experimental|Dihydroxydibutylether group|This group takes dihydroxydibutylether for 8 weeks.
9733756|NCT05199441|Placebo Comparator|Control group|This group takes placebo for 8 weeks.
9733757|NCT05198674|Experimental|Main Cohort: Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
9733758|NCT05198089|Experimental|Arm I (MyInspiration)|Patients use MyInspiration for spiritual and/or religious guidance for 30 days.
9836233|NCT02777021||Inpatient Management Patients|Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
9982524|NCT05219396||mobile bearing (MB)|
9982525|NCT05219396||medial congruent (MC)|
9982526|NCT05219396||posterior stabilized (PS)|
9733759|NCT05192343|Experimental|Virtual Reality Glasses|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, before and during the HSG procedure, the Virtual Reality Glasses application group watched a video with a nature view with glasses.Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure. The women included in the Virtual Reality Glasses intervention group were made to watch a video with a nature view for 15 minutes before and during the HSG procedure. Each woman was shown the same video.
9733760|NCT05192343|Experimental|Music|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, a nature-based sound was played to the women in the music group before and during the HSG shooting.Listening to nature-based sound was performed for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes.
9733761|NCT05192343|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography.
9733762|NCT05192330|Experimental|Virtual Reality Glasses|"After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale(pain and nursing satisfaction) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were applied, the nurse gave Virtual Reality Glasses for 30 minutes.~Glasses was be given put on before the process starts and training was be given to continue watching the video while wearing the glasses.The women included in the Virtual reality application group will be shown a video with a nature view during the procedure.~Every woman will be shown the same video."
9733763|NCT05192330|Experimental|Therapeutic Touch|"Applied therapeutic touch intervention on their hands for 30 minutes to help patients feel comfortable during the procedure.The researcher started the application by taking an appropriate hand of the patient between his hands and held it for 30 minutes. The researcher's fingers are closed, not clasped, and his hand is placed on the participant's hand.~The researcher held her hand steady without touching or rubbing it. In addition, the researcher did not use gloves."
9733764|NCT05192330|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (virtual reality or Therapeutic Touch) was performed. Both groups were re-evaluated using the same scales after the intrauterine insemination. Within 5 minutes of completing the procedure, participants were asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale, anxiety scale and satisfaction scale.
9733765|NCT05191017|Experimental|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with enzalutamide until the recommended Phase 2 combination dose (RP2cD) is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
9733766|NCT05191017|Experimental|Phase 2|"NUV-422 will be administered orally at the RP2cD in combination with enzalutamide.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-422."
9982527|NCT05219136|Active Comparator|Conventional Fasting Group|In this parallel group, subjects are performed a conventional fasting protocol which requires 6-8h fasting for solid, 2h for clear liquids.
9982528|NCT05219136|Experimental|Modified Fasting Group|"In this test group, a new protocol of 4h fasting for rice porridge, 2h for clear liquids is applied to subjects.~The rice porridge is commercially available (New Rice Porridge®, Charm Kitchen Food Co., Ltd., Q/NBBD0001S). The volume is 300ml, with the energy as 105kJ per 100g, and it can be eaten after being heated or at room temperature."
9982529|NCT05218057|Active Comparator|Thulium-fibre laser (TFL)|The laser used in this group for surgical procedure ureteroscopic lithotripsy will be the Olympus SOLTIVETM Premium SuperPulsed laser system with a 365micron laser fibre. The laser pulse setting will be 1J x 10Hz, short pulse duration (adjusted up to 600microseconds).
9733770|NCT05186818|Experimental|CK-3773274 up to 20 mg|Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 24 weeks
9733771|NCT05186818|Placebo Comparator|Placebo to match CK-3773274|Patients will receive placebo for up to 24 weeks
9733772|NCT05186051|Experimental|ZYIL1 Capsule|subject will receive 50 mg twice daily (BD) dose for 7 days
9733774|NCT05185492||Cardiogenic shock cohort|Primary diagnosis of Cardiogenic Shock at the time of index evaluation. The clinical and hemodynamic criteria used to diagnose Cardiogenic Shock will be those as defined in the Society for Cardiovascular Angiography and Interventions clinical expert consensus statement on the classification of cardiogenic shock.
9733775|NCT05185024|Experimental|Ferrous Sulfate Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
9733776|NCT05185024|Experimental|>Your< Iron Forte Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
9733777|NCT05185024|Experimental|>Your< Iron Forte Liquid|35 mg of elemental iron, 0.7 mg vitamin B6 and 1.25 mcg vitamin B12 per one dosing (5 ml).
9733778|NCT05182775|Experimental|experimental group|This trial is a prospective study without a control group. It is planned to recruit 15 patients with IgA nephropathy. The experimental group received fecal bacteria transplantation through FMT capsule. The researchers will judge the effectiveness and safety of fecal bacteria transplantation in the treatment of IgA nephropathy by observing the changes of monitoring indicators before and after fecal bacteria transplantation and during follow-up. Donor screening and FMT capsule preparation were completed by Dongyuan Yikang company (www.dongyuanyikang. com).The patients participating in the trial took 16 Enterobacteriaceae capsules on day 1, day 8 and day 15 respectively as a course of treatment. The researchers will collect stool samples from patients one day before taking the medicine, one week after the last taking the medicine and one month after the last taking the medicine, and analyze the intestinal flora by sequencing
9733779|NCT05180227|Placebo Comparator|Without Stimulation|Participant will complete an orthostatic challenge without transcutaneous stimulation.
9733780|NCT05180227|Active Comparator|With Stimulation|Participant will complete an orthostatic challenge with transcutaneous stimulation.
9733781|NCT05180136|Experimental|Rice bran extract group|This group takes rice bran extract for 8 weeks.
9733782|NCT05180136|Placebo Comparator|Control group|This group takes a placebo for 8 weeks.
9733783|NCT05176873|Experimental|Single dose of DZD8586|Single dose of DZD8586
9733784|NCT05176873|Placebo Comparator|Single dose of Placebo|Single dose of Placebo
9733785|NCT05174468||Screen-eligible Subjects|High-risk for lung cancer population who meet the USPSTF eligibility. One 10-L breath sample will be collected from each subject. During breath collection, subjects will be asked to exhale into a portable breath sampling device through a single use filter. Subjects will not be contacted to donate additional/serial breath specimens after the initial breath samples. Subjects will fill out a medical questionnaire and medical records will also be reviewed to extract low-dose CT scan (LDCT) screening results and any additional tumour-related information including histologic subtype, tumor stage, and sites of disease.
9733786|NCT05171647|Experimental|M+P (Arm A)|Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
9733787|NCT05171647|Experimental|R-GemOx (Arm B)|Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.
9982530|NCT05218057|Active Comparator|Holmium: yttrium-aluminum-garnet (Ho: YAG)|The laser used in this group for surgical procedure ureteroscopic lithotripsy will be the Lumenis VersaPulse® PowerSuiteTM 100W laser system with a 365micron laser fibre. The laser pulse setting will be 1J x 10Hz. Pulse duration is not adjustable in this machine (up to 600microseconds).
9982531|NCT05217849|Experimental|Tai Chi|Participants will engage in 60-minute Tai Chi classes twice a week for 12 weeks. The classes will be live-streamed over the internet. Tai Chi is an ancient Chinese system of gentle physical exercise and stretching. It involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
9982532|NCT05217849|Experimental|Gentle, Mindful Movement|Participants will engage in a gentle, mindful movement class twice a week for 12 weeks. The classes will be one hour long and will be live-streamed over the internet. The mindful movement classes will combine elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
9982533|NCT05217849|Active Comparator|Health and Wellness Education|Participants will engage in bi-weekly 60 minute sessions of Health and Wellness Education classes. The classes will be held on-line for 12 weeks.
9982534|NCT05216978|Experimental|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~After consent procedures, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
9982535|NCT05215678||INKA participants|Individuals eligible and accepting participation in the INKA trial (NCT05172843)
9982536|NCT05215678||n-INKA participants|Individuals eligible and declining participation in the INKA trial (NCT05172843)
9982537|NCT05215418|Experimental|VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)|Week 1: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Week 2: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Week 3: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 4-8: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
9982538|NCT05215418|Active Comparator|Phentermine 30mg|Weeks 1-8: Phentermine 30mg oral capsule, once daily
9982539|NCT05215418|Placebo Comparator|Placebo|Weeks 1-8: Placebo oral capsule, once daily
9982540|NCT05215262|Experimental|T.A.K.E. Steps Motivational Interviewing Intervention|Four MI intervention sessions, 1:1 with participant and health coach.
9733798|NCT05169944|Experimental|Treatment (Magrolimab)|Each participant will receive magrolimab intravenously (IV) at a priming dose of 1 mg/kg during Cycle 0, followed by either 30 mg/kg or 45mg mg/kg dose weekly for eight weeks (Cycles 1 and 2), followed by either 30 mg/kg or 45 mg/kg dose every two weeks for the remainder of the study.
9733799|NCT05168865|Experimental|PCOS women will receive letrozole ovarian stimulation.|Polycystic ovarian disease (PCOS) women undergoing frozen embryo transfer (FER) will use Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
9733800|NCT05168865|Active Comparator|PCOS women will receive Estradiol and Progesterone (hormonal endometrial preparation).|PCOS women will use daily Cetorelix acetate 0.25 mg injections for 5 days from day 1-3 of the menstrual follow or after progesterone (P4) withdrawal bleeding. They will commence daily oral Estradiol Valerate (E2) 2 mg twice daily for 5 days starting from day 3 of the menstrual flow or after P4 withdrawal bleeding, then-after three times daily. When endometrial thickness reaches 7 mm or more, the dose of E2 will be reduced to 4 mg/ day. Women will start using vaginal micronized P4 100 mg three times daily starting from 8PM. After 48 hours of starting the vaginal P4, oral Dydrogesterone 10 mg three times daily will commence.
9733801|NCT05167734|No Intervention|Control (Standard of Care) Group|Subjects will receive standard clinical care for the treatment of anemia while in the ICU.
9733802|NCT05167734|Experimental|Anemia Treatment Bundle|The intervention arm is multi-faceted with 3 primary components: 1) Optimized phlebotomy, defined by minimal volume draws and closed-loop blood sampling, all performed by a dedicated phlebotomy team independent from the treatment team; 2) Decision support aids, including visual and electronic alerts reminding the care team to minimize non-essential laboratory testing and mitigate patient-specific bleeding risk; and 3) Pharmacologic anemia treatment with a single dose of IV iron and/or subcutaneous erythropoietin (given immediately following enrollment) targeted to 2 broad groups: 1) anemias responsive to iron supplementation alone (i.e. acute blood loss, iron deficiency) and 2) anemias requiring erythropoietic stimulation (e.g. anemia of inflammation, anemia of renal disease).
9733803|NCT05166460|Experimental|Surgery utilizing the Kidney Skinn cooling device|All patients in Part A, and those randomized to the Kidney Skinn arm in Part B, will receive transplant surgery in the traditional fashion with the exception that the renal allograft will be placed in the cooling device at the initiation of the vascular anastomosis. Cold saline irrigation flowing through the device will be used to maintain renal hypothermia for the duration for the vascular anastomosis. After the vascular clamps are released, the device will be removed.
9733804|NCT05166460|No Intervention|Standard transplant surgery practice|Standard transplant surgery per site practice
9733805|NCT05165498||Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures|Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures who will have placed a thoracic epidural catheter to manage their perioperative analgesia.
9733806|NCT05164705|Active Comparator|Intermittent Hypoxia|Participant will visit our center 2-4 times per week for three weeks to receive Acute Intermittent Hypoxia.
9733807|NCT05164705|Sham Comparator|Sham Intermittent Hypoxia|Participants will visit our center 2-4 times per week for three weeks to receive Sham Intermittent Hypoxia.
9733808|NCT05163041|Experimental|BT7480 monotherapy dose escalation|Participants will receive increasing doses of BT7480. It is expected that approximately 40 patients will participate in this dose escalation arm.
9733809|NCT05163041|Experimental|BT7480 and nivolumab dose escalation|Participants will receive increasing doses of BT7480 and standard dose of nivolumab. It is expected that approximately 12 patients will participate in this dose escalation arm.
9733810|NCT05163041|Experimental|BT7480 monotherapy dose expansion|Participants will receive a selected dose of BT7480. It is expected that approximately 20 patients will participate in this dose expansion arm in Phase 1 plus an additional 45 patients in Phase 2.
9733811|NCT05163041|Experimental|BT7480 and nivolumab dose expansion|Participants will receive a selected dose of BT7480 and standard dose of nivolumab. It is expected that approximately 20 patients will participate in this dose expansion arm in Phase 1 plus an additional 45 patients in Phase 2.
9733812|NCT05163041|Experimental|BT7480 monotherapy in patients with renal insufficiency|Participants will receive a selected dose of BT7480. It is expected that approximately 12 patients will participate in this dose confirmation arm.
9733813|NCT05160363|Experimental|PYR and PQP Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - <65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - <75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg
9733814|NCT05160363|Placebo Comparator|PYR and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - <65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Matched placebo for piperaquine (3 or 4 tablets based on body weight)
9733815|NCT05160363|Placebo Comparator|PQP and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - <75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg Matched placebo for pyronaridine (3 or 4 tablets based on body weight)
9733816|NCT05160363|Sham Comparator|Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Matched placebo for pyronaridine (3 or 4 tablets dependent on body weight) and matched placebo piperaquine (3 or 4 tablets dependent on body weight)
9733817|NCT05158582|Experimental|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|The modified exercise group will perform 12 exercises.
9733818|NCT05158582|Active Comparator|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercises program will perform conventional exercises.
9982541|NCT05215262|Active Comparator|Standard of Care|Standard of Care control visit with primary care physician (PCP)
9982542|NCT05214885||the ccRCC patient group|The age and gender of patients are not limited. The patient was preliminarily diagnosed as renal carcinoma by imaging examination and finally diagnosed as clear cell renal cell carcinoma by pathology.
9733819|NCT05158062|Experimental|pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib|Participants will continue treatment period up to 6 cycles and enter maintenance period after treatment period. Study treatment will be continued until progressive disease (PD) based on RECIST 1.1, death, unacceptable toxicity, or participant withdrawal from the study.
9733820|NCT05157633||Controls|Children without eating difficulties
9733821|NCT05157633||Patients|Children with eating difficulties
9982543|NCT05214885||the healthy control group|The age and sex of the healthy control group were matched with that of ccRCC patient group. There was no tumor in the kidney or other parts of the body, and no tumor in the blood system. The healthy control group did not have any renal benign diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. There are no inflammatory diseases in other parts of the body. The functions of the liver, kidney, and heart were normal.
9982544|NCT05214885||the benign kidney disease group|The age and sex of this group were matched with that of ccRCC patient group. The patient did not have any tumor but had one of the benign kidney diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. The functions of the liver and heart were normal.
9733826|NCT05151432|Experimental|Pulsed US + Exercise Group|Twenty subjects will receive PUT, plus an exercise program.
9733827|NCT05151432|Experimental|Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PEMF, plus an exercise program.
9733828|NCT05151432|Experimental|Pulsed US + Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PUT, PEMF, plus an exercise program.
9733829|NCT05151432|Experimental|Sham + Exercise group|Twenty subjects will receive sham PEMF and sham PUT plus exercises program.
9733834|NCT05147909|Experimental|Sodium Phosphate (NaPO4) then sodium chloride (NaCl)|Participants will be asked to take 2 capsules daily of Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) ) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d). Then, participants will be asked to take 2 capsules of Sodium Chloride (NaCl, containing a total of 372mg of sodium) to match Na content to Sodium Phosphate without extra Pi daily for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d).
9733835|NCT05147909|Experimental|NaCl then NaPO4|Participants will be asked to take 2 capsules daily of Sodium Chloride (NaCl, containing a total of 372mg of sodium) for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d). Then, participants will be asked to take 2 capsules of Sodium Phosphate daily for 4 weeks Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d).
9733836|NCT05138458|Experimental|Cohort 1 and Cohort 2|MT-101
9733837|NCT05138458|Experimental|Cohort 3|MT-101 preceded by conditioning (lymphodepleting) chemotherapy
9733838|NCT05137418|Experimental|3-5 years old age group|500 participants aged 3-5 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
9733839|NCT05137418|Experimental|6-11 years old age group|500 participants aged 6-11 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
9733840|NCT05136053|Experimental|Part A: Lu AG22515|Participants will receive a single intravenous (IV) infusion of Lu AG22515.
9733841|NCT05136053|Placebo Comparator|Part A: Placebo|Participants will receive a single IV infusion of placebo matching to Lu AG22515.
9733842|NCT05136053|Experimental|Part B: Lu AG22515 and Immune System Activator|Participants will receive a single IV infusion of Lu AG22515 and a subcutaneous (SC) injection of immune system activator 14 days prior to and 14 days following the start of Lu AG22515 IV infusion.
9733843|NCT05136053|Placebo Comparator|Part B: Placebo and Immune System Activator|Participants will receive a single IV infusion of placebo matching to Lu AG22515 and an SC injection of immune system activator 14 days prior to and 14 days following the start of placebo IV infusion.
9733844|NCT05132582|Experimental|Tucatinib + trastuzumab + pertuzumab|Tucatinib + trastuzumab + pertuzumab
9733845|NCT05132582|Active Comparator|Placebo + trastuzumab + pertuzumab|Placebo + trastuzumab + pertuzumab
9733846|NCT05130229|Experimental|Sleep Well Bee Well|Sleep program to help toddlers sleep better
9733847|NCT05130229|Placebo Comparator|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
9733848|NCT05125016|Experimental|Module 1- Monotherapy|REGN4336
9733849|NCT05125016|Experimental|Module 2-Combo Therapy|REGN4336 + Cemiplimab
9733850|NCT05123482|Experimental|Sub-Study 1 AZD8205 Monotherapy|"Sub-Study 1 has two parts:~Part A : The aim is to determine the safety, tolerability, Recommended Phase 2 Dose(RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205.~Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205 as monotherapy in select solid tumors."
9733851|NCT05114798|Experimental|Time Restricted Eating (TRE)|During the active weight loss period, the TRE group will be instructed to eat ad libitum from 11:00am - 7:00pm daily and fast from 7:00pm - 11:00am. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.
9733852|NCT05114798|Active Comparator|Calorie Restriction (Cal-R)|Cal-R subjects will be instructed to restrict energy intake by 25% of their baseline total energy expenditure (TEE) daily. Subjects will meet with a study dietitian for a 60-min one-on-one session to develop individualized weight loss meal plans to help them adhere to their calorie restriction goal. Meal plans will include portion sizes and food lists that are consistent with their food preferences and prescribed calorie levels for weight loss. Food scales will be provided to help with food portioning. Cal-R subjects will meet with the dietitian every week throughout the weight loss period to review intervention adherence and modify the meal plans as needed. Subjects will be asked to maintain their baseline level of physical activity. At the beginning of the weight maintenance phase, total energy needs will be reassessed. Subjects will be instructed to consume 100% of energy needs split between 3 meals every day.
9733853|NCT05114798|No Intervention|Control|Controls will be instructed to maintain their weight throughout the 12 m trial and to not change eating or physical activity habits. Controls will not receive dietary counseling. Controls will visit the research center monthly for outcome measurements.
9733854|NCT05112965|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
9733855|NCT05111353|Experimental|Arm 1: Vaccine given after neoadjuvant chemotherapy and surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, 22, 50, and 78 beginning approximately 1 month after surgery."
9733856|NCT05111353|Experimental|Arm 2: Vaccine given after neoadjuvant chemotherapy but before surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, and 22 during the chemotherapy holiday, and Days 50 and 78 post-operatively."
9982545|NCT05213390|Experimental|Dora follow-up phone call|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards. The entire conversation will be supervised by a clinician. This clinician will be able to interrupt the call at any point if the system fails, the patient struggles to interact with it, or DORA does not collect sufficient information from the patient. The clinician will record a clinical assessment which will be compared to the DORA assessment.
9982546|NCT05213338|Experimental|wear-documentation|Theramon
9982547|NCT05213338|No Intervention|controls|No microchip
9982548|NCT05212922|Experimental|YH001 + Toripalimab|This study will include two cohorts of up to 40 subjects each treated with RP2D dose of YH001 in combination with 240 mg Toripalimab to assess the antitumor activity and safety/tolerability.
9982549|NCT05212142|Sham Comparator|Traditional intervention: verbal education|
9982550|NCT05212142|Experimental|New intervention: verbal education, visual aids, and motivational interviewing|
9733863|NCT05102214|Experimental|Phase 1a dose-escalation stage|Phase 1a uses the Bayesian optimal interval (BOIN) design, to investigate the safety and determine the MTD of HLX301. Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 15 mg/kg are planned for dose finding. Intra-patient dose escalation is not permitted. Enrollment will continue until a maximum of 30 patients are enrolled.
9733864|NCT05102214|Experimental|Phase 1b dose-expansion stage|Patients with NSCLC will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX301. Phase 1b dose expansion will include 20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
9733865|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort A|20 per-protocol treated patients with non-small cell lung cancer (NSCLC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
9733866|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort B|20 per-protocol treated patients with gastric/esophagogastric junction adenocarcinoma (GC/EGJ), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
9733867|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort C|20 per-protocol treated patients with head and neck squamous cell carcinoma (HNSCC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
9733868|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort D|20 per-protocol treated patients with urothelial carcinoma (UC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
9733869|NCT05098938|Experimental|Acyclovir 50mg buccal tablet treatment group|
9733870|NCT05098938|Placebo Comparator|Matching placebo group|
9982551|NCT05211960|Experimental|Treatment|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness. Participants will receive a premium account for 1 year; the current study will evaluate outcomes over 3 months. The intervention will be delivered concurrently with treatment as usual which includes standard psychosocial care as participants are referred to their respective programs.
9733872|NCT05094102|Experimental|Axillary Surgery|Breast cancer patients undergoing SLN biopsy (n=20) or axillary lymph node dissection (n=5) will be enrolled to undergo standard of care axillary reverse mapping (ARM) using isosulfan blue dye. Participants will also receive ICG injection with visualization through the OnLume Imaging System to allow comparison of blue dye versus ICG lymphatic identification.
10205080|NCT04065386|Active Comparator|Active taVNS|"Patients will receive 5 days of transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the cymba conchae, the active localization.~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and a neurophysiological assessment (128/256 channels EEG and electrocardiograph) the first and last day of stimulation."
9733875|NCT05092347|Experimental|REGN5459|REGN5459 escalating dose
9733876|NCT05092347|Experimental|REGN5458|REGN5458 escalating dose
9733877|NCT05079360|Experimental|Sabizabulin Treatment Group|Subjects in the Sabizabulin Treatment Group will receive sabizabulin 32mg each day by mouth until disease progression is observed and confirmed by BICR.
9733878|NCT05079360|Active Comparator|Control Treatment Group|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
9733884|NCT05078827|Active Comparator|Comparator Arm|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
9733885|NCT05078827|Experimental|Arms and Interventions|Test Product (A): Fluorouracil Cream, 5% of Encube Ethicals Pvt. Ltd., India
9733886|NCT05078827|Placebo Comparator|Placebo Arm|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
9733887|NCT05075824|Experimental|Crovalimab|Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.
9733888|NCT05075824|Placebo Comparator|Placebo|Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.
9982552|NCT05211362|Experimental|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
9982553|NCT05211362|Active Comparator|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
9733891|NCT05067777|Experimental|Arm I (SMT)|Patients receive SMT over 45 minutes once weekly for 6 weeks.
9733892|NCT05067777|Sham Comparator|Arm II (LT)|Patients receive LT over 45 minutes once weekly for 6 weeks.
9733893|NCT05067777|Active Comparator|Arm III (waitlist)|Patients receive no intervention for 6 weeks.
9733894|NCT05065411|Experimental|Enobosarm Combination Group|"Enobosarm Combination Group will receive enobosarm 9 mg each day by mouth (QD), and abemaciclib will administered by mouth at a dose of 150 mg BID.~Stage 2 Subjects in the Enobosarm Combination Group will receive enobosarm 9 mg QD each day by mouth and abemaciclib 150 mg BID by mouth until disease progression is observed and confirmed by BICR."
9733895|NCT05065411|Active Comparator|Control Treatment Group|Control Treatment Group will receive a non-steroidal AI, a non-steroidal or steroidal (exemestane with or without everolimus), AI OR fulvestrant approved for the treatment of metastatic breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The decision of which comparator treatment will be used will be made prior to randomization.
9733897|NCT05061966|Active Comparator|Online Resource website|The comparator is a website that includes a list of freely available web-based resources for sexual and gender minority youth.
9733898|NCT05061966|Experimental|immi|The intervention is a novel and scalable web application designed to provide sexual and gender minority youth with tools for affirming their identity and coping with minority stress.
9733899|NCT05060081|Experimental|Pilates exercise program group|Pilates exercise program group will perform five exercises.
9733900|NCT05060081|Active Comparator|Traditional plank exercise program group|Traditional plank exercise program group will perform five exercises.
9733901|NCT05055063|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
9733902|NCT05054725|Experimental|RMC-4630 and sotorasib, Safety Run-in|"Safety Run-In:~RMC-4630 and sotorasib"
9733903|NCT05054725|Experimental|RMC-4630 and sotorasib, Expansion|"Dose Expansion:~RMC-4630 and sotorasib"
9733904|NCT05053607|Other|1. Single Arm Cohort Receiving Digital Health Coaching|"All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.~Participants have the option to participate in a one time interview about their treatment experience."
9733907|NCT05051566|Experimental|LY3502970 Prototype (Part A)|Multiple doses of LY3502970 prototype administered orally.
9733908|NCT05051566|Experimental|LY3502970 Reference (Part A)|Multiple doses of LY3502970 reference administered orally.
9733909|NCT05051566|Experimental|LY3502970 Prototype (Part B)|Multiple doses of LY3502970 prototype administered orally.
9733910|NCT05051566|Experimental|LY3502970 Reference (Part B)|Multiple doses of LY3502970 reference administered orally.
9733911|NCT05051566|Active Comparator|Esomeprazole (Part B)|Multiple doses of Esomeprazole (Proton Pump Inhibitor) administered orally.
9733915|NCT05050084|Experimental|Arm I (RT)|Patients undergo RT using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity.
9733916|NCT05050084|Experimental|Arm II (RT, ADT)|Patients undergo RT as Arm I. Patients also receive ADT consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days.
9733917|NCT05050084|Experimental|Arm III (RT, ADT)|Patients receive treatment as in Arm II.
9733918|NCT05050084|Experimental|Arm IV (RT, ADT, darolutamide)|Patients receive RT and ADT as in Arm II. Patients also receive darolutamide PO BID on days 1-90. Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
9733919|NCT05048797|Experimental|Arm 1|Trastuzumab Deruxtecan (T-DXd)
9733920|NCT05048797|Active Comparator|Arm 2|Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)
9982554|NCT05209841|Experimental|Catheter sealing with low dose heparin|Catheters will be sealed with 3mL of Fibrillin Ⓡ (heparin 20UI/mL)
9982555|NCT05209841|Active Comparator|Catheter sealing with normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
9982556|NCT05209035|Active Comparator|Trazodone|
9982557|NCT05209035|Placebo Comparator|Placebo|
9982558|NCT05207280|Experimental|Noradrenaline plus Terlipressin|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours. Solution for infusion (Intravenous). And: Terlipressin with dose 1 mg every 6 hours diluted in a 50 mL serum to pass in 15-30 minutesin injectable solution. Intravenous (diluted in a 50 mL serum to pass in 15-30 minutes)
9982559|NCT05207280|Placebo Comparator|Noradrenaline plus placebo|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours in solution for infusion (Intravenous), and placebo with solution in vial with the same external appearance as terlipressin. 1 mg every 6 hours, diluted in a 50 mL serum to pass in 15-30 minutes in injectable solution Route of administration: Intravenous, diluted in a 50 mL serum to pass in 15-30 minutes
9733927|NCT05039619|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1, Day 14, Week 24, Week 26 and Week 52. Participants with a body weight of 45 kg or more will receive the 1000 mg dose. Participants with a body weight below 45 kg will receive a weight adjusted dose of 20 mg/kilogram (kg).
9733928|NCT05039619|Placebo Comparator|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1, Day 14, Week 24, Week 26 and Week 52.
9733929|NCT05038735|Experimental|Alpelisib plus fulvestrant|Alpelisib 300 mg orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15, and on Day 1 on every Cycle thereafter, in a 28 days cycle.
9733930|NCT05038735|Placebo Comparator|Alpelisib-matching placebo plus fulvestrant|Alpelisib-matching placebo orally once daily on a continuous dosing schedule, in a 28-day cycle + fulvestrant 500 mg as intramuscular injection on Cycle 1 Day 1 and 15 and on Day 1 on every Cycle thereafter, in a 28 days cycle. Participants who have disease progression per RECIST v1.1 as assessed by BIRC will have the option to crossover to be treated with alpelisib plus fulvestrant
9733931|NCT05038514|Experimental|music therapy|Music therapy intervention, bluetooth headphones will be applied in the intensive care unit and will be disinfected after the application. The intervention consists of a 30-minute, single-session, nature-based music concert. the music concert is calibrated by the audiologist (60 decibels). During nature-based music listening, patients will be asked to close their eyes, rest and follow the sound flow.
9733932|NCT05038514|No Intervention|control|The control group will be given the prone position and music therapy will not be applied.
9733933|NCT05036668|Experimental|ABO809|Participants will receive ABO809 at a single oral dose of 1x10^4 oocysts. Other doses such as 1x10^6 oocysts may be considered to optimize the model
9982560|NCT05207085|Experimental|Valbenazine|Participants randomized1:1 to receive valbenazine
9982561|NCT05207085|Placebo Comparator|Placebo|Participants randomized 1:1 to receive placebo
9982562|NCT05205772|Experimental|medial prefrontal cortex - control site - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
9982563|NCT05205772|Experimental|medial prefrontal cortex - dorsolateral prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
9982564|NCT05205772|Experimental|dorsolateral prefrontal cortex - medial prefrontal cortex - control site|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the control site.
9733939|NCT05030584|Active Comparator|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
9733940|NCT05030584|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily.
9733950|NCT05025826|Experimental|Phycocare|PHYCOCARE during 12 cycles of 14 days from day -3 before oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months) From D-3 to D14 before cycle 1 chemotherapy: patient will take Phycocare From D1 to D14 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Phycocare On days of chemotherapy the patient does not take Phycocare
9733951|NCT05025826|Placebo Comparator|Placebo|"Placebo during 12 cycles of 13 days from day -3 before cycle 1 of oxaliplatin based chemotherapy until 3 months after the last dose of oxaliplatin (9 months).~From D-3 to D13 before cycle 1 chemotherapy: patient will take Placebo From D1 to D13 of cycle 2 chemotherapy and further chemotherapy cycles : patient will take Placebo.~On days of chemotherapy the patient does not take Placebo"
9733952|NCT05023850|Active Comparator|Group TLIP|"Patients will receive a Thoracolumbar Plane Block (TLIPB) under ultrasound guidance while under general anesthesia.~Intervention: Patients will receive a TLIPB with 20mls 0.25% Bupivicaine bilaterally."
9733953|NCT05023850|Experimental|Group ESP|"Patients will receive an Erector Spinae Plane Block (ESPB) under ultrasound guidance while under general anesthesia.~Intervention: Procedure: Patients will receive an ESPB with 20 ml 0.25% Bupivacaine bilaterally."
9982565|NCT05205772|Experimental|dorsolateral prefrontal cortex - control site - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
9982566|NCT05205772|Experimental|control site - medial prefrontal cortex - dorsolateral prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex.
9982567|NCT05205772|Experimental|control site - dorsolateral prefrontal cortex - medial prefrontal cortex|Participants first undergo transcranial magnetic stimulation to the control site. After a 3 week washout period, participants then undergo transcranial magnetic stimulation to the dorsolateral prefrontal cortex. After a 3 week washout period, participants undergo transcranial magnetic stimulation to the medial prefrontal cortex.
9982568|NCT05205382|Experimental|JUUL pods with 5% nicotine concentration|All participants will complete a lab visit where they will use 5% nicotine JUUL pods ad libitum for up to 60 minutes.
9982569|NCT05205382|Experimental|JUUL pods with 3% nicotine concentration|All participants will complete a lab visit where they will use 3% nicotine JUUL pods ad libitum for up to 60 minutes.
9982570|NCT05205382|Experimental|JUUL compatible pods with 0% nicotine concentration|All participants will complete a lab visit where they will use 0% nicotine JUUL compatible pods ad libitum for up to 60 minutes.
9733966|NCT05016310|Experimental|High Vit D|High Dose Vitamin D
9733967|NCT05016310|Active Comparator|SOC Vit D|Standard of Care Vitamin D
9982571|NCT05205369|Experimental|Yi Jin Bang group|Participants in this group will perform a 10-week home-based Yi Jin Bang exercise program.
9982572|NCT05205369|Experimental|Usual exercise therapy group|Participants in this group will perform a 10-week home-based usual exercise therapy program.
9982573|NCT05205369|No Intervention|Waitlist control group|Participants in the waitlist control group will be informed that they will receive either Yi Jin Bang training or exercise therapy after ten weeks have passed. This will be done only for motivational reasons and not for evaluation.
9982574|NCT05203978||Virtual reality colonoscopy|using virtual reality with glasses and sound no anaesthesia
9982575|NCT05203978||General anaesthesia colonoscopy|gold standard
9982576|NCT05202899|Experimental|Sugammadex Group|rocuronium-induced general anesthesia，use of sugammadex antagonism
9733974|NCT05010122|Experimental|Treatment (decitabine, cedazuridine, venetoclax, gilteritib)|"INDUCTION (CYCLE 1): Patients receive decitabine and cedazuridine PO QD on days 1-5, venetoclax PO QD on days 1-28, and gilteritinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity~CONSOLIDATION (CYCLES 2-24): Patients receive decitabine and cedazuridine PO QD on days 1-5, gilteritinib PO QD on days 1-28, and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (CYCLES 24+): Patients receive gilteritinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9982577|NCT05202899|No Intervention|Control Group|general anesthesia without rocuronium
10205081|NCT04065386|Placebo Comparator|Sham taVNS|"Patients will receive 5 days of transcutaneous auricular vagal nerve stimulation (taVNS) bilaterally, at the ear lobe, the sham localization.~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and a neurophysiological assessment (128/256 channels EEG and electrocardiograph) the first and last day of stimulation."
10205082|NCT04065074|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
9733978|NCT05007392|Experimental|Drug: Dotinurad + Febuxostat Matched Placebo|Participants will receive one dotinurad 1 mg tablet and one febuxostat 20 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then one dotinurad 2 mg tablet and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two dotinurad 2 mg tablets and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
9733979|NCT05007392|Active Comparator|Drug: Febuxostat + Dotinurad Matched Placebo|Participants will receive one febuxostat 20 mg tablet and one dotinurad 1 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then two febuxostat 20 mg tablets and one dotinurad 2 mg matched placebo tablet, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two febuxostat 20 mg tablets and two dotinurad 2 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
9733980|NCT05005806|Active Comparator|Omega 3 soft gel|participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
9733981|NCT05005806|Placebo Comparator|placebo|placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
10205083|NCT04042116|Experimental|Phase 1b: Dose Escalation|- Up to 50 patients with advanced solid tumor
10205084|NCT04042116|Experimental|Phase 1b: Food Effect Cohort|- Approximately 16 evaluable patients with an advanced, metastatic solid tumor will be enrolled
9733984|NCT04989595||Women_Kyleena|
9733985|NCT04989595||Women_Jaydess|
10205085|NCT04042116|Experimental|Phase 2: Expansion Cohort - Endometrial Cancer|"Recurrent endometrial carcinoma at least 1 prior platinum-based chemotherapy regimen~Up to 10 patients who have progressed on treatment with 1 prior PD-(L)1 inhibitor administered as monotherapy will be allowed to enroll"
9733986|NCT04989595||Women_Mirena|
9733988|NCT04980222|Experimental|Glofitamab + R-CHOP Immunochemotherapy|"Participants will receive step-up doses of glofitamab, starting on Day 8 of Cycle 3 (2.5 mg), Day 15 of Cycle 3 (10 mg), then 30 mg glofitamab will be given every three weeks (Q3W) onwards, on Day 8 of Cycles 4-6 and on Day 1 of Cycles 7-10. (cycle length = 21 days)~Participants will receive rituximab, cyclophosphamide, doxorubicin, and vincristine Q3W on Day 1 of Cycles 1-6. Prednisone or prednisolone will be administered daily (QD) on Days 1-5 of Cycles 1-6. (cycle length = 21 days)"
9982578|NCT05202873||Short Stem (Compress)|Compress megaprosthesis
9982579|NCT05202873||Long Stem (conventional)|Conventional long stem megaprosthesis
9982580|NCT05202509|Experimental|obicetrapib 10mg|one 10mg tablet, once daily.
9982581|NCT05202509|Placebo Comparator|Placebo|one placebo tablet, once daily
9733996|NCT04973605|Experimental|Part 1 Dose Escalation|Dose-escalation and de-escalation to determine maximum tolerated dose (MTD)
9733997|NCT04973605|Experimental|Part 2 Cohort Expansion|There will be 5 expansion cohorts to further evaluate the safety and efficacy of BGB-11417
9733998|NCT04972968|Experimental|ABBV-154 Dose A|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
9733999|NCT04972968|Experimental|ABBV-154 Dose B|Participants in this group will receive dose B of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
9734000|NCT04972968|Experimental|ABBV-154 Dose C|Participants in this group will receive dose C of ABBV-154 SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
9734001|NCT04972968|Placebo Comparator|Placebo|Participants will receive placebo SC eow for 52 weeks. In addition, participants will receive a glucocorticoid oral tablet taper.
9982582|NCT05202405|Experimental|Sequence A|Period 1 : Reference Drug(AD-221A and AD-221B) Period 2 : Test Drug(AD-221)
9982583|NCT05202405|Experimental|Sequence B|Period 1 : Test Drug(AD-221) Period 2 : Reference Drug(AD-221A and AD-221B)
9982584|NCT05202379|Experimental|SAD cohort 1A|first dose level with 6 active and 2 placebo healthy participants
9982585|NCT05202379|Experimental|SAD cohort 1B|second dose level with 6 active and 2 placebo healthy participants
9982586|NCT05202379|Experimental|SAD cohort 1C|third dose level with 6 active and 2 placebo healthy participants; food-effect cohort
9982587|NCT05202379|Experimental|SAD cohort 1D|fourth dose level with 6 active and 2 placebo healthy participants
9982588|NCT05202379|Experimental|MAD cohort 2A|first dose level with 6 active and 2 placebo healthy participants dose x 14 days
9982589|NCT05202379|Experimental|MAD cohort 2B|second dose level with 6 active and 2 placebo healthy participants dose x 14 days
9982590|NCT05202379|Experimental|MAD cohort 3B|third dose level with 6 active and 2 placebo healthy participants dose x 14 days
9734011|NCT04961567|Experimental|BIIB059 High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of BIIB059, subcutaneously (SC), every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
9734012|NCT04961567|Experimental|BIIB059 Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of BIIB059, SC Q4W, up to Week 48 with an additional dose at Week 2.
9734013|NCT04961567|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive BIIB059 matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
9734014|NCT04959266|Experimental|Arm A|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with itraconazole.
9734015|NCT04959266|Experimental|Arm B|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with rifampicin.
9734016|NCT04959266|Experimental|Arm C|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with omeprazole.
9982591|NCT05201404|Experimental|Namodenoson (CF102)|Namodenoson 25 mg orally BID, until disease progression or unacceptable adverse events
9982592|NCT05201404|Placebo Comparator|Placebo|Matching placebo orally BID, until disease progression or unacceptable adverse events
9982593|NCT05199714|Experimental|Fiasp-and-pramlintide fully automated system (8μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
9982594|NCT05199714|Active Comparator|Fiasp-alone with carbohydrate-matched boluses|The Fiasp-alone intervention will have a 14 hour duration. During which, carbohydrate counting will inform insulin bolus doses based on insulin to carbohydrate ratios.
9982595|NCT05199714|Experimental|Aspart-and-pramlintide fully automated system (10μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
9982596|NCT05199714|Experimental|Fiasp-and-pramlintide fully automated system (10μg)|Fiasp and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 10μg of pramlintide.
9982597|NCT05199714|Experimental|Aspart-and-pramlintide fully automated system (8μg)|Aspart and pramlintide artificial pancreas with no meal announcement. Ratio of 1 unit of insulin for 8μg of pramlintide.
9982598|NCT05199389|Experimental|PBM1 group|The patients allocated to the first PBM-group will receive six PBM sessions of 6 J/cm² over three weeks (2x/week).
9982599|NCT05199389|Experimental|PBM2 group|The patients allocated to the first PBM-group will receive six PBM sessions of 8 J/cm² over three weeks (2x/week).
10200559|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - PILOT|"Proactive Psychiatry Consultation and Case Management is:~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
10205086|NCT04042116|Experimental|Phase 2: Expansion Cohort - Ovarian Cancer|"Recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma~At least 2 prior chemotherapy regimens which at least 1 must have been platinum-doublet chemotherapy~Up to 10 subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma who have progressed within 6 months after completing first-line platinum-based chemotherapy will be allowed to enroll"
9982600|NCT05196451|Active Comparator|Short-time rehabilitation|The intervention consists of an individualized numbers of outpatient encounters (min. 2, max. 8) with medical doctors and physiotherapists at Kysthospitalet, Stavern, Norway. The encounters aim to foster a rehabilitation process based upon principles from Cognitive Behavioral Therapy (CBT)
9734029|NCT04949490|Experimental|Group A, BNT162b2s01 30 µg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) will receive one booster injection of BNT162b2s01 on Day 1. Day 1 (baseline in this trial) must occur ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
9734030|NCT04949490|Experimental|Group A, BNT162b2 30 µg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) will receive one booster injection of BNT162b2 (Comirnaty) on Day 1. Day 1 (baseline in this trial) must occur ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
9734031|NCT04949490|Experimental|Group B, BNT162b2 30 µg (2 doses)|Trial participants in either the trial BNT162-01 (excluding transplant participants from Cohort 13) or BNT162-04 who did not receive the full two vaccinations of 30 μg BNT162b2 (Comirnaty) will be offered two injections of 30 μg BNT162b2 (Comirnaty) as per the conditional marketing authorization on Day 1 and Day 21. Day 1 (baseline in this trial) must occur ≥12 weeks after receiving the last BNT162 candidate vaccine in the respective parent BNT162-01 or BNT162-04 trial.
9734032|NCT04949490|Experimental|Group B transplant subjects, BNT162b2 30 µg (2 doses)|Transplant trial participants from Cohort 13 of the trial BNT162-01 will receive one injection of 30 μg BNT162b2 (Comirnaty) on Day 1 which will be followed 3 to 7 months afterward by a second injection of BNT162b2 (Comirnaty). Day 1 (baseline in this trial) must occur ≥12 weeks after receiving the last BNT162 candidate vaccine in the parent BNT162-01 trial.
9982601|NCT05196451|No Intervention|Care as usual|
9982602|NCT05195489|Experimental|Active Intervention|Family members participate in Connectors by phone and receive a packet of resources
9982603|NCT05195489|No Intervention|Comparison|Family members receive a pack of resources
9982604|NCT05194397|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 16 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
9982605|NCT05194397|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 16 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 16 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 16 wks."
9982606|NCT05194397|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
9982607|NCT05194397|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions including: aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strength training exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo"
9982608|NCT05193903|Experimental|Intervention: Simulation|Interactive information tools
9982609|NCT05193903|Other|Control: Text|Standard text-based information
9734042|NCT04939272|Experimental|Treatment (copanlisib hydrochloride, venetoclax)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
9982610|NCT05192707||Healthy Volunteers|TcPO2 measurement in the upper limb of healthy volunteers
9982611|NCT05192707||Patients with arterial disease in the upper limb and wound|Patients with arterial disease in the upper limb and wound (retrospective setting, research on data)
9982612|NCT05191537|Experimental|spinal mobilization with arm movement|conventional treatment and of spinal mobilization with arm movement
9982613|NCT05191537|Active Comparator|positional SNAGs|conventional treatment and positional SNAGs
9734048|NCT04935229|Experimental|SD-101|3 weekly doses of SD-101 given via hepatic artery infusion over 2 cycles
9982614|NCT05191485||Patients of decision making need assessment|"We will conduct semi-structured interviews with target patients and patients' representatives to assess their decisional needs. Decisional needs including difficult decision type /timing, unreceptive decisional stage, decisional conflict (uncertainty), inadequate knowledge & unrealistic expectations, unclear values, inadequate support & resources, and Personal & clinical needs. All interviews will be conducted one-to-one or one-to-many (including families) and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For patients, aiming for diversity regarding age, sex, education level and annual household income. All participants should be Chinese-speaking."
9982615|NCT05191485||Other stakeholders of decision making need assessment|"We will conduct semi-structured interviews with other stakeholders to assess their decisional needs. All interviews will be conducted one-to-one and be audio-recorded for further analysis. Written informed consent will be obtained prior to each interview.~Nonrandom purposive sampling will be used to select key respondents to conduct in depth interview. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For other stakeholders (including thoracic surgeons, nurses, psychoanalyst, hospital administrators, molecular testing company staffs and insurance company staffs), region, seniority, position, and attitude toward both molecular testing and SDM are considered. All participants should be Chinese-speaking."
9984626|NCT03895827|Experimental|Recovery Initiation and Management after Overdose (RIMO)|Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.
9734059|NCT04925479|Experimental|Asciminib|"This arm consists of 2 groups:~The pediatric formulation group where the dose is based on body weight (1.3mg/kg)~The adult formulation group where participants will receive a flat dose of 40mg BID"
9734066|NCT04916197|Experimental|Dexmedetomidine prolonged group|Dexmedetomidine 0.1~1.0 μg/kg/h for 24h after patients finished mechanical thrombectomy and returned to ICU. Maintain Ramsay score 2-3.
9734067|NCT04916197|Placebo Comparator|placebo group|Placebo（Equal dose of saline）24h after patients finished mechanical thrombectomy and returned to ICU. If Ramsay Sedation score was 1, midazolam was given 0.02 ~ 0.1mg/kg. If the dose of midazolam was more than 0.2mg/kg within 1 hour after operation, the Ramsay Sedation score was still 1, propofol was given to maintain sedation.
9734070|NCT04912869|Experimental|Crovalimab|Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.
9734071|NCT04912869|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching Placebo.
9734072|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
9734073|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
9734074|NCT04912063|Experimental|Lemzoparlimab + Azacitidine in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
9734075|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
9734076|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
9734077|NCT04912063|Experimental|Lemzoparlimab Monotherapy in AML (Japan Only Escalation)|Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
9734078|NCT04912063|Experimental|Lemzoparlimab Monotherapy in MDS (Japan Only Escalation)|Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
9734079|NCT04910568|Experimental|Single-Agent Cevostamab (Arm A)|"Cohort A1S is a safety run-in arm evaluating Cevostamab administered in 28-day cycles on a modified weekly schedule.~Upon completion, Cohort A1E, an expansion cohort may be opened. Participants will be treated with single-agent cevostamab administered in 28-day cycles on a modified weekly schedule."
9734080|NCT04910568|Experimental|Cevostamab plus Pomalidomide and Dexamethasone (Pd) (Arm B)|"Participants will be treated with cevostamab monotherapy during a 21-day period prior to the start of pomalidomide treatment (cevostamab pre-phase).~Cohort B1S is a safety run-in arm evaluating cevostamab and Pd administered in 28-day cycles every 2 weeks (Q2W) followed by every 4 weeks (Q4W) schedule.~Upon completion, Cohort B1E, an expansion cohort may be opened. It will follow the same Q2W/Q4W dosing schedule as Cohort B1S."
9734081|NCT04910568|Experimental|Cevostamab plus Daratumumab and Dexamethasone (Dd) (Arm C)|"Cohort C1S is a safety run-in arm evaluating cevostamab and Dd administered in 21 day cycles from Cycle(C)1 - C8 every 3 weeks (Q3W) and 28-day cycles from C9 onwards Q4W.~Upon completion, Cohort C1E, an expansion cohort may be opened. It will follow the same Q3W/Q4W dosing schedule as Cohort C1S."
10205087|NCT04042116|Experimental|Phase 2: Expansion Cohort - Clear Cell Cancer|"Recurrent, metastatic clear cell carcinoma of ovarian, fallopian tube, primary peritoneal or endometrial origin~At least 1 prior platinum- and taxane-based chemotherapy regimen"
9982616|NCT05191485||Participants of cognitive debriefing/alpha tests|The purpose of Alpha test is to test the understandability of Decision Aid for Lung Cancer Molecular Testing version 1.0 (DA_LCMT 1.0). All debriefing interviews will be conducted one-on-one with structured probing questions. Participants will be encouraged to comment on DA_LCMT 1.0 and give recommendations to replace any unclear wording. At the start, the interviewer will explain the aim of the study and the procedures of the cognitive debriefing to participants. Then a paper-based DA_LCMT 1.0 will be given to participants, and sufficient time will be guaranteed to allow them to read DA_LCMT 1.0. The cognitive debriefing interview will start afterwards, and participants will answer questions probing questions asked by interviewers about DA_LCMT 1.0. Each cognitive debriefing interview will last for about 20 minutes. DA_LCMT 2.0 will be generated after the completion of the cognitive debriefing (Alpha test).
9982617|NCT05191485||Patients of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
9734085|NCT04901507|Experimental|The Voutia System|The Voutia System oral irrigation device
9734086|NCT04899310|Experimental|mRNA-3705|Treatment Period (during the Dose Optimization Stage and the Optional Dose Expansion Stage): 1 of up to 5 possible doses of mRNA-3705, administered intravenously (IV), once every 2 to 4 weeks (q2W to q4W), depending on participant's weight for up to 10 doses over approximately 40 weeks.
9982618|NCT05191485||Clinician of Field testing /β tests|"Then the investigators will conduct the field testing (Beta test) with patient and clinician facing the decision in real time. The purpose of Beta test is to test the usability of DA_LCMT 2.0 in real-world setting. Clinician and patients will use the DA_LCMT 2.0 for real-time decision making. The conversation of decision progress will be audio-recorded. After the decision is made by patients, structured interview will be conducted and audio-recorded separately between clinician and patients. All the field testing interviews will conducted one-on-one and written informed consent will be obtained prior to each interview. Each field testing interview will last for about 20 minutes."
9982619|NCT05190471|Experimental|Relapsed/Refractory AML - BP1002 monotherapy|BP1002 monotherapy dose escalation
9982620|NCT05190471|Experimental|Relapsed/Refractory AML - BP1002 in combination with decitabine|BP1002 single dose in combination with decitabine
9982621|NCT05189834|Other|Treatment sequence A|"Patients will follow the following treatment sequence:~Treatment with Gelsectan® (30 days)~Washout period (15 days)~Treatment with placebo (30 days)"
10205088|NCT04042116|Experimental|Phase 2: Expansion Cohort - Cervical Cancer|"Persistent or recurrent cervix cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology~At least 1 prior regimen of platinum-based chemotherapy, with or without bevacizumab, for metastatic disease"
10205089|NCT04037462|Experimental|Lead in Dexamethasone followed by immunotherapy|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
10205090|NCT04031820|Active Comparator|unipolar cup|550 patients will receive a total hip arthroplasty with a unipolar cup.
9734094|NCT04895241|Experimental|BIIB059 High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of BIIB059, subcutaneously (SC) every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
9734095|NCT04895241|Experimental|BIIB059 Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of BIIB059, SC Q4W, up to Week 48 with an additional dose at Week 2.
9734096|NCT04895241|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive BIIB059 matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
10205091|NCT04031820|Active Comparator|Dual Mobility cup|550 patients will receive a total hip arthroplasty with a dual mobility cup.
10205092|NCT04017390|Experimental|Arm 1: Theraworx Foam alone|Theraworx foam only
9734099|NCT04889924|Experimental|Axillary radiotherapy without lymphadenectomy|Axillary radiotherapy (level I and II) + level III and supraclavicular +/- internal mammary chain without lymphadenectomy
9734100|NCT04889924|Active Comparator|Axillary lymph node dissection|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
10205093|NCT04017390|Active Comparator|Arm 2: Theraworx Foam and night splint|Theraworx foam with a night time splint
10205094|NCT04017390|Placebo Comparator|Arm 3: Placebo foam alone|Placebo foam alone
9734104|NCT04883398||Breast cancer survivors|Breast cancer survivors ages 50-70 with AJCC stages 0-3 breast cancer who are at least 1 year post-treatment (including surgery, radiation, and chemotherapy, with or without current endocrine therapy)
9734105|NCT04883398||Healthy controls|Healthy controls ages 50-70 with no history of cancer.
9734114|NCT04872101|Experimental|Delgocitinib 20 mg/g|Twice-daily topical application for 16 weeks
9734115|NCT04872101|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
9734116|NCT04871711|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for 16 weeks
9734117|NCT04871711|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
9982622|NCT05189834|Other|Treatment sequence B|"Patients will follow the following treatment sequence:~Treatment with placebo (30 days)~Washout period (15 days)~Treatment with Gelsectan® (30 days)"
9982623|NCT05188287|Experimental|HealthyCells|"The HealthyCells app will have the following features:~Smoking status assessments with facial recognition: Participants will initiate a smoking status assessment and CO breath sample submission using the iCOquit® Smokerlyzer® TWICE per day. To verify the participant's identity while they complete their CO breath sample, we will use Microsoft Face API.~Daily step counter and sedentary behavior prompts: A Google OS smartwatch will be used to monitor participants' activity, and the HealthyCells app will deliver an activity prompt when they have been sedentary for 30 minutes, which will be experienced as noise and vibration on the phone and watch. Also, a text-based reminder message will appear on the phone and watch along with a personalized tip for reducing sedentary time.~Motivational messages for smoking cessation and physical activity. TWICE per day, the HealthyCells app will send messages to encourage users to remain quit and become more active."
9734120|NCT04868968|Experimental|DFV890|DFV890
9982624|NCT05187364|Experimental|COPE Therapy Arm|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE)
9982625|NCT05186922|Experimental|CM326 55 mg, once every two weeks (Q2W)|55mg for 6 doses, every 2 weeks, subcutaneous (SC)
9734123|NCT04866472|Other|Video Laryngoscope and GlideRite Ridgid Stylet|
9734124|NCT04866472|Experimental|Video Laryngoscope and TCI Articulating Introducer|
9982626|NCT05186922|Experimental|CM326 110 mg, once every two weeks (Q2W)|110mg for 6 doses, every 2 weeks, subcutaneous (SC)
9982627|NCT05186922|Experimental|CM326 110 mg, once every four weeks (Q4W)|110mg for 3 doses, every 4 weeks, subcutaneous (SC)
9982628|NCT05186922|Experimental|CM326 220 mg, once every two weeks (Q2W)|220mg for 6 doses, every 2 weeks, subcutaneous (SC)
9982629|NCT05186922|Experimental|CM326 220 mg, once every four weeks (Q4W)|220mg for 3 doses, every 4 weeks, subcutaneous (SC)
9734129|NCT04862663|Experimental|Capivasertib Plus Palbociclib and Fulvestrant|Capivasertib Plus Palbociclib and Fulvestrant
9734130|NCT04862663|Placebo Comparator|Placebo Plus Palbociclib and Fulvestrant|Placebo Plus Palbociclib and Fulvestrant
9734131|NCT04853355|Experimental|Spironolactone Treatment|Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).
9982630|NCT05186922|Placebo Comparator|Placebo|Placebo for 6 doses, every 2 weeks, subcutaneous (SC) and placebo for 3 doses, every 4 weeks, subcutaneous (SC)
9982631|NCT05186337|Experimental|Experimental|Functional Remediation for Older-Age Patients With Bipolar Disorder (FROA-BD)
9982632|NCT05186337|No Intervention|Control|The control group (42 patients) will not receive any type of add-on psychotherapy.
9982633|NCT05184387||Prospective epidemiological cohort|Urban and suburban population of healthy subjects aged 18-55 years, not vaccinated against influenza
9982634|NCT05182827|Experimental|Euthymic patients with history of suicide attempt (suicide attempters)|Currently euthymic patients with at least one lifetime major depressive episode and a history of suicide attempts
9982635|NCT05182827|Experimental|Euthymic patients without any history of suicide attempt (affective controls)|Currently euthymic patients with at least one lifetime major depressive episode and with no history of suicide attempts
10205095|NCT04017390|Other|Arm 4: Placebo foam and night splint|Placebo foam with a night time splint
10205096|NCT03997097|Experimental|sildenafil|• Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day (t.i.d.), as defined in the marketing authorization indicated for PAH in adolescent and adult patients, and for a period of 6 months.
10205097|NCT03997097|Placebo Comparator|placebo|• Patients in the group 2 will receive a placebo (t.i.d.), for the same period of 6 months. To guarantee the double blind, capsules will be similar in size and colour and will be differentiated only by a vial number regarding to the randomization list
10205098|NCT03993678|Experimental|Ablation + IP-001|"Ablation + IP-001 will be administered every 4 weeks for up to 6 treatment visits.~Trial treatment will stop in case of tumor progression according to RECIST 1.1 or iRECIST or unacceptable toxicity.~In all cases, toxicity assessment will continue for at least 100 days after discontinuing the last treatment of Ablation + IP-001 or until resolution of Ablation + IP-001-associated toxicity."
10205099|NCT03992703||Standard strategy|This group has been treated with antibiotic susceptibility testing on a conventional Mueller-Hinton medium with reading after 24 hours of incubation (Period 1: from July 1, 2015 to December 31, 2016)
10205100|NCT03992703||Rapid strategy|This group has been treated with antibiotic susceptibility testing on a rapid Mueller-Hinton medium after 8 hours of incubation (period 2: January 1, 2017 to June 30, 2018)
9734146|NCT04842747|Experimental|9mg of VERU-111 Oral daily|9mg of VERU-111
9734147|NCT04842747|No Intervention|Placebo Capsule once daily|Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital.
9734149|NCT04839315|Other|mRNA COVID19 vaccines|mRNA-based COVID19 vaccines
9734150|NCT04837196|Experimental|Phase 1 ASP7517 Monotherapy Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses.
9734151|NCT04837196|Experimental|Phase 1 ASP7517 + Pembrolizumab Dose Escalation|Participants will receive ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks starting from Cycle 1 Day 1. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
9734152|NCT04837196|Experimental|Phase 2 ASP7517 Monotherapy Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses
9734153|NCT04837196|Experimental|Phase 2 ASP7517 + Pembrolizumab Dose Expansion|Participants will receive RP2D of ASP7517 on Day 1 of each 28-day cycle for up to 6 doses in combination with up to 4 doses of pembrolizumab administered every 6 weeks. Pembrolizumab monotherapy may be extended up to a total of 17 doses for qualifying participants.
9734155|NCT04828343|Experimental|Cohort 1 <50 kg|Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
9734156|NCT04828343|Experimental|Cohort 2 <50 kg|Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
9734157|NCT04828343|Experimental|Cohort 3 >=50 kg|Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
9734158|NCT04828343|Experimental|Cohort 4 >=50 kg|Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
9982636|NCT05182346|Experimental|Acupressure of classical acupoints|Acupressure is applied on four acupoints: Pressure was applied to large intestine 10 (LI10) (large intestine meridians): It is located on the dorsal radial side of the forearm, 2 Cun below the transverse cubital crease. Hegu (large intestine meridians, LI 4): It is in the middle of the 2nd metacarpal bone on the radial side. TE5 (Triple energizer): It is located 2 cun proximal to the dorsal wrist crease between the radius and the ulna. SI3 (small intestine meridians): It is located at the ulnar end of the distal palmar crease proximal to the 5th metacarpal phalangeal joint. These acupoints are commonly used in the treatment of cervical myofascial pain syndrome.
9982637|NCT05182346|Experimental|Ischemic compression release of myofascial trigger points|Ischemic compression was gradually applied pressure to the trigger point with your thumb. The patient will likely feel referred pain in a question mark pattern (along the back of the neck, around the side of the head, and then a focused pain right behind the eye). Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points will be treated. Then apply a few effleurage strokes to flush out the area and follow up with a passive stretch to the muscle.
9984627|NCT03895710||Sleep-deprived group|i. Self-reported time in bed (period from bedtime to get-up time) during school days of <8 hours per day ii. Self-perceived insufficient sleep during school days
9734162|NCT04822350||Locally advanced or metastatic urothelial carcinoma patients treated with avelumab|
9984628|NCT03895710||Normal sleep group|i. Self-reported time in bed during school days of >=8 hours per day ii. Self-perceived sufficient sleep during school days
9734165|NCT04817761|Experimental|Calaspargase pegol (S95015)|
9734170|NCT04813991|Experimental|Arm 1 - Ibuprofen Breakthrough|600 mg Ibuprofen for breakthrough pain.
9734171|NCT04813991|Active Comparator|Arm 2 - Oxycodone Breakthrough|5 mg of Oxycodone for breakthrough pain.
9734173|NCT04807439||SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
9982638|NCT05180773|Active Comparator|Bromocriptine Treatment Arm|100 Women in the Treatment Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of bromocriptine administered orally as 2.5 mg twice daily for 2 weeks then 2.5mg once daily for 6 weeks. Women not on clinical anticoagulation will also receive prophylactic anticoagulation with rivaroxaban 10 mg once daily for 8 weeks while on bromocriptine.
9982639|NCT05180773|Placebo Comparator|Placebo Arm|100 Women in the Placebo Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of a placebo administered orally twice daily for 2 weeks then once daily for 6 weeks. Women not on clinical anticoagulation will not receive rivaroxaban but will instead receive a second placebo for 8 weeks.
9982640|NCT05180773|Other|Breastfeeding Observational Cohort|Up to 50 women meeting all other criteria but excluded from REBIRTH due to an intent to continue to breastfeed will be enrolled in an observational cohort. They will receive guideline directed medical therapy with no additional interventions and will have the same follow up and assessment of myocardial recovery by echocardiogram at 6 and 12 months post entry as women in the randomized trial.
9982641|NCT05180240|Experimental|CardiolRx|"Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
9734183|NCT04797767|Experimental|Treatment (CLAG-M, venetoclax)|Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days 1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone, and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression or unacceptable toxicity.
9734185|NCT04787237|Experimental|Vestibulart socket therapy and immediate implants|A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted . A flexible cortical membrane shield that is made of cortical bone of heterologous origin was introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a membrane tack or a micro screw to the alveolar bone apical to the base of the socket . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
9734186|NCT04787237|Active Comparator|Buser's technique and early implant placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks was followed. Then an open flap implant surgery using a triangular flap design was cut. Implant was then placed under the crest of the palatal bone. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone conditioned medium (BCM) added to bioss bone granules to activate it.
9734187|NCT04784221|Experimental|Radiation by protontherapy associated to nanoparticles injection|
9734194|NCT04762277|Experimental|Spesolimab|
9734195|NCT04762277|Placebo Comparator|Placebo|
9734197|NCT04754607|Experimental|Low-level laser therapy group|"Low Level Laser Therapy (LLLT): Low-level laser therapy will be applied to the cases in addition to LT4 hormone replacement therapy.~LLLT group will be treated using a continuous wave GaAIAs type diode laser (Intelect® Mobile Laser, Model No: 2779, Production Year: 2016; Chattanooga Group) device in the treatment area of 0.07 cm2. Continuous mode at 850 nm wavelength, 100 mW output power,1.43 W/cm2 power density and 28.57 J / cm2 energy density will be used."
9734198|NCT04754607|Sham Comparator|Sham Group|Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
9734199|NCT04754529|Experimental|Supportive care (yoga)|Patients receive online yoga intervention QW for 12 weeks.
9982642|NCT05180240|Placebo Comparator|Placebo|"Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
9982643|NCT05180097|Active Comparator|GDP|
9982644|NCT05180097|Active Comparator|Brentuximab vedotin + Pembrolizumab|
9734203|NCT04745689|Experimental|AZD2811 + Durvalumab|"Induction:~Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin & Etoposide)~Maintenance:~AZD2811 + Durvalumab"
9734204|NCT04742595|Experimental|Treatment (SARS-COV-2 specific cytotoxic T cells)|Patients receive SARS-COV-2 specific cytotoxic T lymphocytes IV over 30 minutes on day 1. Treatment may repeat every 14 days at investigators' discretion if patient fails to respond, the infection reoccurs, until the viral load becomes negative or until complete resolution of clinical and radiological signs.
9982645|NCT05175911||premature infants|premature infants less than 31 weeks of gestation or weighting less than 1300 g
9982646|NCT05175794||Cohort 1|Participants that test positive for Mycobacterium tuberculosis (M.tb) with rifampicin resistance will be enrolled in Cohort 1 (n=880).
9982647|NCT05175794||Cohort 2|Participants that test positive for M.tb that are rifampicin susceptible with isoniazid mono-resistance will be enrolled in Cohort 2 (n=400).
9982648|NCT05175365|Experimental|Dance|Patients allocated to this group will attend dance classes for patients with Parkinson's disease given once a week over a 4-month period for a total of 16 dance sessions.
9734209|NCT04740918|Active Comparator|Arm A: Trastuzumab Emtansine and Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor.
9734210|NCT04740918|Experimental|Arm B: Trastuzumab Emtansine and Atezolizumab|Atezolizumab 1200 mg IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.
9982649|NCT05175365|No Intervention|Control|The control group will receive its rehabilitation care.
9982650|NCT05173142|Experimental|dose escalation phase of HMPL-453 monotherapy or combination therapy|HMPL-453 monotherapy or combination therapy
9982651|NCT05173142|Experimental|indication specific dose expansion phase of HMPL-453 combination therapy|HMPL-453 combined with chemotherapy or anti-PD-1 antibody, in patients with IHCC, G/GEJ, or UC harboring specific FGFR gene alterations
9734214|NCT04729712|Active Comparator|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive an erector spinae block with catheter insertion under ultrasound guidance under general anaesthesia. This regional anaesthesia procedure will be performed by an Anaesthesiologist with experience in performing this block.
9734215|NCT04729712|Experimental|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Patient's will be randomised to this arm of the study. This group will receive a paravertebral block with catheter insertion under under thoracoscopic guidance. This regional anaesthesia procedure will be performed at the start of the operation by a surgeon with experience in performing this block.
9734216|NCT04729608|Experimental|Batiraxcept+Pac|Combination of batiraxcept and Pac
9734217|NCT04729608|Placebo Comparator|Placebo+Pac|Placebo-controlled arm with Pac
9982652|NCT05171348|Experimental|CM326 55mg Q2W|55mg for 6 doses, SC, Q2W
9982653|NCT05171348|Experimental|CM326 110mg Q2W|110mg for 6 doses, SC, Q2W
9734220|NCT04727528|Experimental|Open-label correction phase (up to 48 hours)|"All eligible patients will receive SZC 10 g TID for up to 48 hours. Patients with POCT (Point-of-Care-Test) K+ ≥5.1 mmol/L after 24 hours will continue on SZC 10 g TID for another 24 hours. Patients who achieve normokalemia (defined as POCT K+ between 3.5 and 5.0 mmol/L inclusive) after receiving SZC 10 g TID for up to 48 hours will proceed to randomization.~Patients with POCT K+ <3.5mmol/L at any time during the open-label phase will be withdrawn from study treatment and will be followed per protocol."
9836234|NCT02777086|Experimental|StaySafe|Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about once per week.
9982654|NCT05171348|Experimental|CM326 220mg Q2W|220mg for 6 doses, SC, Q2W
9734221|NCT04727528|Experimental|Randomized, placebo controlled phase (Day 2 or 3 to Day 29)|Patients will be randomized to SZC 10 g QD or placebo 10 g QD. The dose of SZC/placebo will be titrated by increasing or decreasing the dose by 5 g increments at 1-week intervals to between 5 g every other day (QOD) and 15 g QD of the randomized phase to maintain normokalemia by POCT K+.
9734222|NCT04721015|Experimental|Part 1: ABBV-637 Monotherapy|Participants will receive escalating doses of ABBV-637 in 28-day cycles.
9734223|NCT04721015|Experimental|Part 2a: ABBV-637 + Docetaxel|Participants will receive escalating doses of ABBV-637 in combination with docetaxel in 28-day cycles.
9734224|NCT04721015|Experimental|Part 2b: ABBV-637 + Docetaxel|Participants will receive ABBV-637 at dose determined in Part 2a in combination with docetaxel in 28-day cycles.
9734225|NCT04721015|Experimental|Part 3a: ABBV-637 + Osimertinib|Participants will receive escalating doses of ABBV-637 in combination with osimertinib in 28-day cycles.
9734226|NCT04721015|Experimental|Part 3b: ABBV-637 + Osimertinib|Participants will receive ABBV-637 at dose determined in Part 3a in combination with osimertinib in 28-day cycles.
9982655|NCT05171348|Experimental|CM326 220mg Q4W|220mg for 3 doses, SC, Q4W
9982656|NCT05171348|Placebo Comparator|Placebo|Placebo
9982657|NCT05170230|Active Comparator|intracapsular myomectomy Terlipressin injection|intracapsular myomectomy Terlipressin injection in women undergoing laparoscopic myomectomy procedure
9982658|NCT05170230|Active Comparator|intracapsular myomectomy Carbetocin injection|intracapsular myomectomy Carbetocin injection in women undergoing laparoscopic myomectomy procedure
9982659|NCT05170230|Placebo Comparator|intramyometrial saline|intracapsular myomectomy saline injection in women undergoing laparoscopic myomectomy procedure
9734232|NCT04715646|Experimental|Brivaracetam|LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day.
9982660|NCT05168735|Experimental|Intravenous Ketamine + Mindfulness Exercises|
9982661|NCT05168735|Active Comparator|Intravenous Ketamine + Academic Exercises|
9982662|NCT05168579|Experimental|Deliberate practice|Trainees will be paired with a coach, and will meet, once per week for thirty minutes, over a three week period. During the training session, coach-trainee dyads will play a puzzle video game, and will discuss contextual cues that should inform triage decisions. At the completion of the three weeks, trainees will complete a semi-structured, debriefing interview and a virtual simulation to assess triage performance.
9982663|NCT05168579|No Intervention|Control|Participants in the control group will complete a virtual simulation.
9982664|NCT05167929|Experimental|Intervention Group|
9982665|NCT05167929|Experimental|Intervention PLUS Group|
9982666|NCT05167929|Active Comparator|Comparison Group|
9982667|NCT05167435|Experimental|Group A (Intervention)|"Myofascial release (Following Cross-hand release techniques of myofascial release in a manner of 2 minutes approach:~Cross-Hand Release of Back [For Thoracolumbar Fascia] Cross-Hand Release of the Lumbosacral Junction [L5-S1] Cross-Hand Release of Lateral low back area [for quadratus lumborum]) will be provided with conventional therapy including stretching exercises (Stretching of Latissimus Dorsi [10 seconds hold, 10 reps, 2 sets], Quadratus Lumborum Stretching [10 seconds hold, 3 reps, 1 set bilaterally], Lower Back Stretching [10 seconds hold, 10 reps, 2 sets], Hamstring Stretching [10 seconds hold, 10 reps, 2 sets bilaterally], Tensor Fasciae Latae Stretching [10 sec hold, 10 reps, 2 sets bilaterally] with duration rest will be of thirty seconds after five minutes) and Thermotherapy will be given for 20 minutes"
9982668|NCT05167435|Active Comparator|Group B (Control)|Posterior-anterior glide: Grade 1-4 [depending on tolerance] (120 oscillations per minute x 3 sets, Duration of rest between each set: 30 seconds) will be provided with the same conventional therapy as in Group A (Intervention)
9982669|NCT05166746|Active Comparator|Clindamycin + LACTIN-V (L.crispatus)|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
9982670|NCT05166746|Active Comparator|Clindamycin + placebo LACTIN-V|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V placebo (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
9982671|NCT05166746|Placebo Comparator|Placebo clindamycin + placebo LACTIN-V|Matching clindamycin placebo 2 times per day for 7 days followed by LACTIN-V placebo (Osel Inc.) until completion of the clinical pregnancy scan at week 7-9.
10205101|NCT03980730|Experimental|Azeliragon|Azeliragon 5mg capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
10205102|NCT03980730|Placebo Comparator|Placebo|Matching placebo capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
9734247|NCT04697628|Experimental|Tisotumab vedotin|Tisotumab vedotin monotherapy
9734248|NCT04697628|Active Comparator|Chemotherapy|Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
9734249|NCT04696354|Other|Interrogation Arm|patients will first be evaluated with MPV (limited to 3 views). The prescribed course of treatment based on the MPV results will be documented and patients will then be evaluated using IVUS. A treatment plan based on IVUS results will be compared with the MPV guided treatment plan and any differences will be documented. Any patients determined to still require venous stenting based on IVUS results will be stented accordingly using IVUS to guide stent placement.
9734250|NCT04696354|Other|Deferred Interrogation Arm|"Deferred Interrogation Guidelines for this study are as follows:~Mandate:~• Continued compression therapy/stockings as prescribed.~Allow:~Periodic leg elevation.~Sclerotherapy under ulcer bed.~Recommend mechanical debridement as needed.~Wound biopsy if evidence of infection.~Systemic antibiotics if patient is diagnosed with an infection, avoid prophylactic prescription.~Pain management medication (Pentoxifylline/Trental) allowed but not recommended~Topical antimicrobial as needed.~Prohibit:~Negative pressure systems.~Artificial and/or autologous skin grafting within first 3 months after randomization and within the first 3 months for subjects that crossover from deferred interrogation to the interrogation arm."
10205103|NCT03979885|Other|Goal-Directed Incentives|
10205104|NCT03979885|Other|Outcome-Based Incentives|
10205105|NCT03979885|Other|Enhanced Usual Care|
9982672|NCT05165875|Other|Randomized: Steroid injection|1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.
9982673|NCT05165875|Other|Randomized: Splint|a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks
9984629|NCT03894202||Ultra-early aneurysm treatment|Ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping within the initial twenty-four hours.
9984630|NCT03894202||Non-ultra-early aneurysm treatment|Non-ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping after the initial twenty-four hours.
9984631|NCT03887624|Experimental|Experimental group|Ethosuximide(2 weeks) + Escitalopram (4 weeks)
9984632|NCT03887624|Placebo Comparator|Control group|Placebo(2 weeks)+Escitalopram(4 weeks)
9984633|NCT03883594|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
9734261|NCT04674306|Experimental|α-lactalbumin and zymosan|"Participants will be treated with successively higher doses of α-lactalbumin and zymosan in a traditional 3 + 3 phase I trial design. Treatment will involve a course of 3 vaccinations given every 2 weeks. Participants will be enrolled sequentially into 1 of 5 different dose levels each comprised of cohorts of 1-6 participants until the MTD has been identified (intra-patient dose escalation not permitted), after which the MTD will be expanded to 6 participants. Successively lower doses will be expanded to 6 participants until the lowest DL associated with immune response has been expanded.~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan~DL2: 100 mcg a-lactalbumin + 10 mcg Zymosan~DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan~DL4: 500 mcg a-lactalbumin + 30 mcg Zymosan~DL5: 500 mcg a-lactalbumin + 50 mcg Zymosan"
9734262|NCT04674111|Experimental|Vortex Feasibility Study (Vortex FIH)|Vortex - First in Human Study to Evaluate the Feasibility, Safety, Clinical and Technical Success of the Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System)
9734263|NCT04671667|Experimental|Arm A (pembrolizumab, IMRT, PBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo IMRT or PBRT QD for a total of 30 fractions in the absence of disease progression or unacceptable toxicity.
9734264|NCT04671667|Active Comparator|Arm B (cisplatin, carboplatin, IMRT, PBRT)|Patients receive cisplatin or carboplatin IV on day 1. Treatment repeats every 7 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo IMRT or PBRT QD for a total of 30 fractions in the absence of disease progression or unacceptable toxicity.
9734265|NCT04671667|Experimental|Arm C (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity.
9984634|NCT03883412|Experimental|Exercise Alone|16 weeks of treatment
9984635|NCT03883412|Experimental|Liraglutide alone|16 weeks of treatment
9984636|NCT03883412|Experimental|Exercise + Liraglutide|16 weeks of treatment
9984637|NCT03883191|Experimental|Mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
9734270|NCT04665921|Experimental|SGN-STNV|SGN-STNV monotherapy
9984638|NCT03883191|Placebo Comparator|Placebo powder|Taking 1 pack of placebo powder three times a day before meals for three months.
9984639|NCT03880565|Experimental|ECMO Facilitated Resuscitation|Regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, patients will enter the Cardiac Catheterization Laboratory (CCL) for expeditious VAECMO initiation, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
9734273|NCT04661761|Experimental|stimulated salivary flow rate|stimulated salivary flow rate determined in a crossover design: first using Paraffin Pellets from Aurosan GmbH; thereafter using Chewing wax from the Saliva-Check Buffer from GC Europe
9734274|NCT04661358|Experimental|Fenofibrate 160-mg|
9734275|NCT04661358|Placebo Comparator|Placebo|
9734276|NCT04658784|Experimental|Intervention|Receives posterior colporrhaphy closure using standardized technique with 2-0 V-Loc 90TM, Medtronic
9734277|NCT04658784|Active Comparator|Control|Receives posterior colporrhaphy closure using standardized technique with conventional 2-0 PDS® Ethicon
9984640|NCT03880565|Other|Standard ACLS Resuscitation|Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI, and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
9734284|NCT04647253|Experimental|AGENT DCB|Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
9734285|NCT04647253|Active Comparator|Commercially available, PTCA Dilation Catheter|
9734289|NCT04644276|Active Comparator|Mask with Mask Adhesive/Arm 1|Patients will be randomized to AF531 if they receive mask adhesive with mask on the first study night then the mask without mask adhesive(Performatrak) on the second study night.
9734290|NCT04644276|Placebo Comparator|Mask without Mask Adhesive/Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then they will receive the mask with the mask adhesive on the second study night.
9982674|NCT05163860||Youth|TGGD youth age 12-17 will answer a survey regarding demographics (gender identity, sex assigned at birth, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism, degree of family conservatism/liberalism, ethnicity), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (ADO-BED, previous Eating Disorder diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (ARQ), adequacy of physical activity (PACE+), bodyweight (BMI, BMI%ile, %mBMI), and previously diagnosed psychiatric and neurodevelopmental disorders
9982675|NCT05163860||Young Adults|TGGD young adults age 18-25 will answer a survey regarding demographics (gender identity, sex assigned at birth, country of residence, ethnicity, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (SCOFF, ADO-BED, previous ED diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (RRBQ), bodyweight (BMI), malnutrition risk (MST), and previously diagnosed psychiatric and neurodevelopmental disorders.
9982676|NCT05163860||Parents|Parents of TGGD youth will answer a survey with information regarding demographics (religion, degree of religiosity, degree of conservatism/liberalism, country of residence, ethnicity, gender identity, sex assigned at birth, sexual orientation, education, marital status, household size, income), anxiety (GAD-7), depression (PHQ-9), family gender environment (FGE), food insecurity (HVS), height and bodyweight (BMI).
9982677|NCT05163457||aged of 75 and more living at home|"aged of 75 and more living at home group: patients aged of 75 and more living at home"
9982678|NCT05162768|Experimental|Elamipretide|0.75 mL of 80mg/mL solution of elamipretide for a single daily SC dose of 60mg elamipretide
9982679|NCT05162768|Placebo Comparator|Placebo|0.75 mL of 80mg/mL solution of matching placebo for a single daily SC dose of 60mg
9982680|NCT05162599|Experimental|Diagnostic study, experimental evaluative cross-sectional study|Evaluate the performance of the Cardiags Trimod medical device, compared to a reference examination, echocardiography, for the detection of heart murmurs Verification of the performance of the Cardiags Trimod medical device compared to a reference examination (ECG, Cardiologist interpretation) for the detection of rythm abnormalities Verification of the repeatability of measurements Verification of safety and suitability for use Verification of acceptability
9984641|NCT03877458|Experimental|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
9984642|NCT03877458|Experimental|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
9734300|NCT04619797|Experimental|Tiragolumab+Atezolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with tiragolumab in combination with atezolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab in combination with atezolizumab and pemetrexed on Day 1 of each 21-day cycle.
9734301|NCT04619797|Placebo Comparator|Placebo+Pembrolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with placebo in combination with pembrolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo in combination with pembrolizumab and pemetrexed on Day 1 of each 21-day cycle.
9984643|NCT03877458|Placebo Comparator|Placebo group|Taking 1 Placebo capsule at bed time everyday for three months.
9984644|NCT03876652|Experimental|DDD-CLS|Patients with a pacemaker programmed in DDD-CLS mode
9734307|NCT04603001|Experimental|Dose Escalation Arm A (Monotherapy)|Patients not requiring a strong CYP3A4 inhibitor.
9734308|NCT04603001|Experimental|Dose Escalation Arm B (Monotherapy)|Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.
9734309|NCT04603001|Experimental|Cohort 1|Patients with R/R AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.
9734310|NCT04603001|Experimental|Cohort 2|Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.
9734311|NCT04603001|Experimental|Cohort 3|Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation,
9734312|NCT04603001|Experimental|Cohort 4|Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.
9734313|NCT04602546|Active Comparator|Sevoflurane alone|"Sevoflurane will be administered in steps to achieve a loss of consciousness via a tight-face mask by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until MOAA/S scales at values less than 2 is reached.~The equilibration time for each targeted concentration will be approximately 12 minutes to maintain a constant ETSEVO. The BIS™ value, MOAA/S score and picture recall test will be assessed when the patient is awake and at the different ETSEVO concentrations.~ETSEVO is decreased by the same steps until consciousness is regained."
9836235|NCT02777086|No Intervention|Comparison|Participants are asked to complete baseline, 3-month and 6-month surveys but are not asked to complete StaySafe sessions or other alternate activities.
9734314|NCT04602546|Active Comparator|Sevoflurane with Remifentanil Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, an initial IV bolus of remifentanil will be given followed by the start of an infusion. Approximately within 7 minutes, the infusion rate of remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml.~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of less than 2 is reached.~ETSEVO is decreased by the same steps until consciousness is regained."
9734315|NCT04602546|Active Comparator|Sevoflurane with Fentanyl Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of fentanyl of 2 ng/mL, an initial IV bolus of fentanyl will be given followed by the start of an infusion. Approximately within 10 minutes, the infusion rate of fentanyl may be adjusted to maintain the effect-site concentration of fentanyl of 2 ng/ml.~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of equal to or less than 2 is reached.~ETSEVO is decreased by the same steps until consciousness is regained."
9734316|NCT04602546|Active Comparator|Desflurane Group|"Due to desflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to desflurane. Once correct LMA placement has been confirmed, there will be an equilibrium time of approximately 15-20 minutes to allow the effect site concentration of propofol to reach a level consistent with a pharmacodynamic effect of consciousness as measured by a MOAA/S score of 2 or 3. Desflurane will then be administered via a tight-face mask at the targeted end-tidal concentration (ETDES) of 2, 5, 7, 8, 9, 10 %, or higher until an MOAA/S score of less than 2 is reached.~The BIS™ value will be correlated with desflurane ETDES concentration. ETDES is decreased by the same steps until consciousness is regained."
9734317|NCT04602546|Active Comparator|Isoflurane Group|"Due to isoflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to isoflurane.Isoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness (MOAA/S of 0,1) by increasing the end-tidal concentration of Isoflurane (ETISO). Targeted concentration for ETISO are 0.25, 0.5, 0.75, 1, 1.5% or higher until MOAA/S scales at values less than 2 is reached.~The BIS™ value will be correlated with desflurane ETISO concentration. ETISO is decreased by the same steps until consciousness is regained."
9982681|NCT05162313|Other|all patients undergoing tracheal intubation procedure|"In current practice, the endotracheal intubation procedure includes the systematic use of the capnometer, which is immediately connected to the tube after its insertion by direct laringoscopy. Confirmation of the correct tube positioning is established by color change of the capnometer from violet to yellow. Then, the colorimetric capnometer is usually removed before connecting the endotracheal tube to the flow-sensor of the ventilator.~For the purpose of our study, after the tube insertion the care provider will connect in line both the capnometer and the ventilator flow-sensor to the tracheal tube."
9982682|NCT05162118|Experimental|Single Arm|"Intratumoral injection of VG161 - 1.5*10^8 on D1 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2, D3 + Nivolumab on D8, D22"
9781452|NCT01149343|Experimental|GSK2302025A Cohort 1|Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
9984645|NCT03876652|Active Comparator|DDD-R|Patients with a pacemaker programmed in DDD-R mode
9982683|NCT05161780|Active Comparator|Normal Saline|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the normal saline group using a random number generator.
9982684|NCT05161780|Experimental|Lactated Ringer's Irrigation|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the lactated reinger group using a random number generator.
9982685|NCT05161260|Experimental|Yoga Breathing (YB)|A first production version of a mobile application that guides users through proscribed yoga breathing exercises.
9734323|NCT04594824||Term neonates|
9734324|NCT04594824||Preterm neonates|
9982686|NCT05161260|Experimental|Attention Control|A first production version of a mobile application that guides users through an attention control activity, presented as methods for mindfulness.
9982687|NCT05159310|Other|Cast|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
9982688|NCT05159310|Other|Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
9982689|NCT05158556|Experimental|myofascial release technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. deep pressure will be applied and glided medially towards the thoraco-lumbar region.ins
9982690|NCT05158556|Experimental|Instrument Assisted Soft Tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
9734330|NCT04579380|Experimental|Tucatinib + Trastuzumab (+ Fulvestrant)|Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
9982691|NCT05157971|Experimental|Treatment (venetoclax, C10403 regimen)|See Detailed Description
9734332|NCT04577599|Other|Single Arm|Mobile Low-dose Computed Tomography (LDCT) Screening
9982692|NCT05155917|Experimental|basal insulin and insulin pump|Subjects in the intervention group received insulin glargine sc (0.25 U/kg body weight) within 6 h of initiation of iv insulin infusion, as close to initiation of iv insulin as possible.
9982693|NCT05155917|No Intervention|insulin pump|Patients in the control group did not receive placebo injections.
9984646|NCT03876080|Experimental|Dry needling|Dry needling intervention to the gastrocnemius muscle trigger point
9984647|NCT03876080|Sham Comparator|Sham needling|Sham dry needling intervention to the gastrocnemius muscle trigger point
9734337|NCT04572295|Experimental|Part 1 Dose Escalation: E7090 + Fulvestrant or Exemestane|Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 milligram (mg), intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later, or along with exemestane 25 mg tablet, orally, once daily in 28 days cycle. Each cycle length equals to (=) 28 days.
9734338|NCT04572295|Experimental|Part 2 Monotherapy: E7090|Participants will receive E7090 tablets, orally, once daily in 28 days cycle. Each cycle length =28 days.
9734339|NCT04572295|Experimental|Part 3 Dose Expansion: E7090 + Fulvestrant|"Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 mg, intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later. Each cycle length =28 days.~The dose of E7090 for Part 3 in combination with fulvestrant will be determined based on the safety, tolerability, pharmacokinetic (PK), and biomarker data obtained from Part 1."
9984648|NCT03875339|Active Comparator|Navigator Arm|Examination of adherence to follow-up with a navigator.
9734341|NCT04569032|Experimental|CD30-negative Cohort|Participants with CD30 expression level < 1%
9734342|NCT04569032|Experimental|CD30-positive Cohort|Participants with CD30 expression level ≥1% to < 10%
9734344|NCT04565665|Experimental|Phase II Arm I (mesenchymal stem cells)|Patients receive MSCs as in the Pilot study.
9734345|NCT04565665|Active Comparator|Phase II Arm II (standard of care)|Patients receive standard of care.
9734346|NCT04565665|Experimental|Pilot study (mesenchymal stem cells)|Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
9734351|NCT04552899|Experimental|PRM-151|Participants will receive intravenous (IV) infusions of PRM-151 over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
9734352|NCT04552899|Placebo Comparator|Placebo|Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
9982694|NCT05154929|Other|Control arm|Participants in the control group will be provided a smartwatch and home blood pressure monitor. They will also be provided with general instructions on how to download and install a physical activity and diet regulation applications (apps) available to the general public. They will still be asked to perform the blood pressure monitoring at regularly scheduled time periods, but do not receive the intervention components notifications in myBPmyLife app developed for the experimental group.
9982695|NCT05154929|Experimental|Dietary plus physical activity JITAI|Participants in the experimental group will be provided a smarthwatch and home blood pressure monitor. They will then receive the myBPmyLife app that includes push notifications to promote increased physical activity and improve low sodium food choices. The app also provides goal setting for weekly step count and information on low-sodium food choices, as well as feedback on achieving the goals using a dashboard with visualization tools within the mobile application.
9982696|NCT05154708||Patient Group - Phase 1|15 to 30 patients are expected in Phase 1 for the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
9982697|NCT05154708||Health Professionals Group - Phase 1|15 to 30 healthcare professionals are expected to participate in Phase 1 regarding the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
9982698|NCT05154708||Patient Group - Phase 2|50 à 60 patients were expected to test a systematic electronic assessment
9734358|NCT04533763|Experimental|Mindful Living (ML)|Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.
9734359|NCT04533763|Active Comparator|Healthy Lifestyles (HL)|Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.
9982699|NCT05153291|Experimental|Bachmann's bundle area pacing|Lead placement in Bachmann's bundle area
9734366|NCT04525183|Experimental|Run In|"Recruit up to 5 patients who meet eligibility criteria to participate in the run-in period of the study~Participants will receive a 6-week Acceptance and Commitment Therapy (ACT) intervention (REVITALIZE)."
9734367|NCT04525183|Experimental|Enhanced Usual Care (EUC)|Participants randomized to EUC will receive educational materials developed by the National Comprehensive Cancer Network (NCCN) about fatigue and exercise during cancer treatment.
9734368|NCT04525183|Experimental|REVITALIZE ACT Intervention|Participants randomized to the REVITALIZE acceptance and commitment therapy (ACT) will receive 6 weekly sessions lasting approximately 60-75-minutes over a 6-8 week period, delivered face-to-face using iPads, computers or tablets, and a HIPAA-compliant platform (Zoom for Healthcare). If participants have difficulty connecting to the platform, telephone sessions are permitted.
9734369|NCT04520659|Experimental|Group 1: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
9734370|NCT04520659|Placebo Comparator|Group 1: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
9734371|NCT04520659|Experimental|Group 2: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
9734372|NCT04520659|Placebo Comparator|Group 2: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
9734375|NCT04508010|Experimental|IVR survey|Participants will receive an IVR survey
9734376|NCT04508010|Experimental|CATI survey|Participants will receive a CATI survey
9734377|NCT04506931|Experimental|Short Message Service (SMS) survey|Participants will receive an SMS survey
9734378|NCT04506931|Experimental|Interactive Voice Response (IVR) survey|Participants will receive an IVR survey
9734379|NCT04506931|Experimental|Computer Assisted Telephone Interviews (CATI) survey|Participants will receive a CATI survey
9734380|NCT04506918|Experimental|IVR survey|Participants will receive an IVR survey
9734381|NCT04506918|Experimental|SMS survey|Participants will receive an SMS survey
9734382|NCT04504669|Experimental|Monotherapy|Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years.
9734383|NCT04504669|Experimental|Combination Therapy|Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years.
9734384|NCT04502862|Experimental|Dupilumab|2 x dupilumab injections as loading dose on Day 1, followed by 1 dupilumab maintenance dose injection every 2 weeks (Q2W) during 12 weeks
9734385|NCT04502862|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 12 weeks
9982700|NCT05153291|Active Comparator|Right atrial appendage pacing|Lead placement in the right atrial appendage
9982701|NCT05150041|Active Comparator|iPRo2 only (Control group)|- The Control group will go through target lifestyle coaching including diet and exercise and they will undergo 24 weeks of follow-up period.
9734388|NCT04499924|Experimental|Phase 2 Arm|Tucatinib + trastuzumab + ramucirumab + paclitaxel
9734389|NCT04499924|Experimental|Arm 3A|Tucatinib + trastuzumab + ramucirumab + paclitaxel
9734390|NCT04499924|Active Comparator|Arm 3B|Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
9734391|NCT04499924|Experimental|Arm 3C|Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
9734392|NCT04499508|Experimental|Treatment with Optima Balt Coils|The APPLY study is a single-arm prospective study which means that everyone enrolled in the clinical trial will be/has been treated with the Optima Balt Coils.
9982702|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week treatment (Treatment group 1)|Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.
9982703|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week on /3 weeks off (2cycles) (Treatment 2)|- Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
9734395|NCT04496830|Experimental|Relapsing Remitting Multiple Sclerosis|"Blood sample collection~Vital signs, weight, height and BMI.~Complete neurological examination documented in NeurEx (recorded with an iPAD).~Clinical data questionnaire~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~Optical Coherence Tomography (OCT)~CSF Analysis"
9734396|NCT04496830|Experimental|Progressive Multiple Sclerosis|"Blood sample collection~Vital signs, weight, height and BMI.~Complete neurological examination documented in NeurEx (recorded with an iPAD).~Clinical data questionnaire~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).~Optical Coherence Tomography (OCT)~CSF Analysis"
9734397|NCT04496830|Experimental|Non-Inflammatory Neurological Diseases|"Clinical data questionnaire~CSF Analysis"
9734398|NCT04496830|Experimental|Other Non-Inflammatory Neurological Diseases|"Clinical data questionnaire~CSF Analysis"
9982704|NCT05149326|Experimental|Experimental arm|
9982705|NCT05149326|Placebo Comparator|Control arm|
9982706|NCT05148286|Active Comparator|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1~2h for initial fluid resuscitation.
9982707|NCT05148286|Placebo Comparator|Control|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice.
9982708|NCT05147103|Experimental|Duration Trials|Six different durations (three intermittent and three continuous) of LIFU application will be tested across six study sessions. Response recorded using TMS and EMG.
9734404|NCT04485858|Experimental|CorNeat KPro|Intraocular implantation of the CorNeat KPro
9984649|NCT03875339|No Intervention|Non-Intervention Arm|Examination of adherence to follow-up without a navigator.
9734406|NCT04472598|Experimental|Navitoclax + Ruxolitinib|Participants will receive Navitoclax in combination with Ruxolitinib
9734407|NCT04472598|Active Comparator|Placebo for Navitoclax + Ruxolitinib|Participants will receive placebo for Navitoclax and Ruxolitinib
9734408|NCT04469920|Experimental|Group 1- mild hepatic impairment without evidence of PHT|Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points
9734409|NCT04469920|Experimental|Group 2- mild hepatic impairment with evidence of PHT|Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points
9734410|NCT04469920|Experimental|Group 3-moderate hepatic impairment|Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points
9734411|NCT04469920|Experimental|Group 4- severe hepatic impairment|Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)
9734412|NCT04469920|Experimental|Group 5-cholestatic liver disease|Subjects with cholestatic liver disease
9734413|NCT04469920|Experimental|Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH|Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH
9734414|NCT04469920|Experimental|Group 7- normal hepatic function|Subjects with normal hepatic function
9734415|NCT04468815|Experimental|Treatment A: BMS-986278 suspension, fasted|
9734416|NCT04468815|Experimental|Treatment B: BMS-986278 tablet, fasted|
9734417|NCT04468815|Experimental|Treatment C: BMS-986278 tablet, fed|
9734418|NCT04468815|Experimental|Treatment D: BMS-986278 tablet + esomeprazole capsule, fasted|
9734422|NCT04449874|Experimental|Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)|"Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.~Participants with select solid tumors will be treated with GDC-6036 PO QD in Stage II."
9734423|NCT04449874|Experimental|Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab.
9734424|NCT04449874|Experimental|Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)|Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab.
9734425|NCT04449874|Experimental|Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)|Participants with solid tumors will receive GDC-6036 in combination with bevacizumab.
9734426|NCT04449874|Experimental|Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)|Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib.
9734427|NCT04449874|Experimental|Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO in Stage II."
9734428|NCT04449874|Experimental|Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)|"Participants with solid tumors will receive GDC-6036 in combination with inavolisib PO in Stage I.~Participants with select solid tumors will be treated with GDC-6036 in combination with inavolisib PO in Stage II."
9982709|NCT05144542|Active Comparator|Group A (usual brand cigarettes)|Participants smoke their usual brand of cigarettes for 26 weeks. Participants use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day for up to 182 days. Participants complete questionnaires over 50 minutes and undergo collection of urine sample at 1, 6, 12, and 26 weeks, and collection of blood samples at 6, 12, and 26 weeks. Participants may also undergo measurement of CO levels at 1, 6, 12, and 26 weeks.
9734430|NCT04447898|Experimental|Low dose|10 μg + Montanide™ ISA 51 VG
9734431|NCT04447898|Experimental|High dose|50 μg + Montanide™ ISA 51 VG
9982710|NCT05144542|Experimental|Group B (e-cigarettes)|Participants vape e-cigarettes for 26 weeks. Participants use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day for up to 182 days. Participants complete questionnaires over 50 minutes and undergo collection of urine sample at 1, 6, 12, and 26 weeks, and collection of blood samples at 6, 12, and 26 weeks. Participants may also undergo measurement of CO levels at 1, 6, 12, and 26 weeks.
9982711|NCT05144438||Pregnant women or woman in desire for conception|Towseek test : hair taking different questionnaires : environmental questionnaire, compliance questionnaire
9982712|NCT05144152||Average risk CRC screening group|Subjects with average risk of CRC require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms
9734435|NCT04446507|Experimental|Group 1|Subjects in severe renal impairment group will be enrolled and dosed consecutively (i.e. first 8 subjects of group 1 will receive 2 mg dose, followed by another 8 subjects who will receive 4 mg dose).
9734436|NCT04446507|Experimental|Group 2|Subjects (Normal renal function eGFR ≥90) will be matched according to age (± 10 years), sex, and weight (± 10 kg) with participants in Group 1 (Severe renal impairment not on HD) on a one to one basis based on demographic characteristic. Here, 8 participants will be administered single dose of 2 mg Saroglitazar Magnesium and 8 participants will be administered single dose of 4 mg Saroglitazar Magnesium.
9982713|NCT05142267|Other|Adults with chronic non-cancer low back pain|
9982714|NCT05142072|Experimental|vitamin D film|Prepared intranasal films containing vitamin D3 by the investigators and administered to the right nostril with the aid of an ENT surgeon
9982715|NCT05142072|Other|control group|No devices will be added
9982716|NCT05140785|Experimental|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional MRI sequences and biopsies in addition to the standard of care.
9982717|NCT05139940||Pilot Group to calibrate the operating points for AI algorithms (Estimated Enrollment up to 500)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
9982718|NCT05139940||Main Cross Sectional Group (Estimated Enrollment 1932 minus the volume in pilot)|"Diagnostic Test: TB AI algorithm performance in detecting active TB.~Diagnostic Test: TB diagnosis from sputum and urine (Smear microscopy, Xpert MTB RIF/ultra, Lipoarabinomannan (LAM) and mycobacterial culture)~Diagnostic Test: Abnormal/Normal AI algorithm to detect abnormal/normal CXRs.~Diagnostic Test: Radiologist evaluation of CXRs for active TB, abnormal/normal.~Diagnostic Test: Labs: Hemoglobin level, HIV status, CD4 count."
9982719|NCT05139290|Experimental|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
9982720|NCT05138848|Experimental|Time in Bed Restriction|Time in Bed (TIB) restriction of 85% of habitual TIB.
9982721|NCT05138848|Active Comparator|Control|No change of time in bed, but prescribed sleep schedule based on observed average sleep and wake times.
9982722|NCT05138029|Experimental|Anti-VEGF treatment group|Visual acuity and center thickness of the macula
9982723|NCT05138029|Experimental|Inner limiting membrane stripping group|Visual acuity and center thickness of the macula
9982724|NCT05138029|Experimental|Glucocorticoid treatment group|Visual acuity and center thickness of the macula
9734457|NCT04435600|Experimental|Part 1: Risankizumab Dose A|Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
9734458|NCT04435600|Experimental|Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Risankizumab Dose A or B based on body weight for 24 weeks."
9734459|NCT04435600|Experimental|Part 2: Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare.~Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4)."
9734460|NCT04435600|Experimental|Part 3: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
9734461|NCT04435600|Experimental|Part 4: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
9982725|NCT05137899|Experimental|Neoadjuvant Atezolizumab/Bevacizumab|• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles
9982726|NCT05137899|Experimental|Neoadjuvant SBRT|• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day
9982727|NCT05137119|No Intervention|Methicillin-resistant staphylococcus aureus (MRSA) - Standard Therapy Arm (backbone therapy)|"Vancomycin or Daptomycin - Standard Therapy Arm~Either intravenous vancomycin dosed as per Australian Therapeutic Guidelines: This includes a loading dose of 25 mg/kg (up to 3000mg) if considered appropriate by the treating clinician, initial maintenance dosing at 15-20 mg/kg q12h, with subsequent adjustment to maintain area under the concentration-time curve (AUC) of 400 to 600 mg.hr/L OR trough levels at 10-20 mg/L, and the initial level taken 48-72 hours after the initiation of the first dose. Daptomycin 8-10mg/kg per day intravenously. The choice of vancomycin or daptomycin will be at the clinician's discretion. Dosing will be based on renal function."
9982728|NCT05137119|Experimental|Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy)|"Vancomycin or Daptomycin (Standard Therapy) + Beta-Lactam (β-lactam) Arm~In addition to standard treatment an intravenous β-lactam will be added for the first 7 calendar days following randomisation (day 1 being the day of randomisation - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous cefazolin 2g every 8 hours. For patients with renal impairment the intravenous cefazolin administration doses will be adjusted."
9982729|NCT05137119|No Intervention|Methicillin-susceptible staphylococcus aureus (MSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
9982730|NCT05137119|Experimental|Methicillin-susceptible staphylococcus aureus (MSSA) - Interventional Arm (backbone therapy)|"Cefazolin - Interventional Arm~Intravenous cefazolin 2g every 6 or 8 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous cefazolin administration dose will be adjusted."
9734471|NCT04420819|Experimental|IPC-LOP|this group will carry out the baseline assessments, perform the ischemic preconditioning using exactly the limb occlusion pressure , then perform post-IPC assessments and start the excentric exercise, and the post-exercise assessments will take place immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
9734472|NCT04420819|Experimental|IPC-40%|this group will carry out baseline assessments, perform IPC using 40% more occlusion than LOP, then perform assessments after IPC protocol and start EE, and post exercise assessments will take place immediately after the end of EE and will be repeated in 24h, 48h, 72h and 96h.
9734473|NCT04420819|Placebo Comparator|IPC-10mmHg:|this group will perform baseline assessments, perform occlusion-perfusion intervention with 10 mmHg restriction characterizing the placebo, then perform post-IPC assessments and initiate EE, and post-exercise assessments will take place immediately after completion of EE and if will repeat in 24h, 48h, 72h and 96h.
9734474|NCT04420819|No Intervention|CONTR|this group will carry out the baseline assessments, immediately after starting the EE, and the post-exercise assessments will happen immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
9982731|NCT05137119|No Intervention|Penicillin-susceptible staphylococcus aureus (PSSA) - Standard Therapy Arm (backbone therapy)|"Flucloxacillin or cloxacillin - Standard Therapy Arm~Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted."
9734492|NCT04404283|Experimental|Experimental Arm|Brentuximab vedotin + lenalidomide + rituximab
9734493|NCT04404283|Active Comparator|Control Arm|Placebo + lenalidomide + rituximab
9982732|NCT05137119|Experimental|Penicillin-susceptible staphylococcus aureus (PSSA) - Interventional Arm (backbone therapy)|"Benzylpenicillin - Interventional Arm~Intravenous benzylpenicillin 1.8g (3 million units) every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with critical illness the intravenous benzylpenicillin administration doses will be adjusted."
9982733|NCT05137119|No Intervention|No adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|"No adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA~Participants with either MRSA or MSSA or PSSA will have no adjunctive therapy in combination with their backbone therapy arm."
9982734|NCT05137119|Experimental|Adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm|Adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Intravenous clindamycin (or lincomycin) 600mg every 8 hours for 5 days. No dosage adjustment is needed to renal impairment.
9982735|NCT05137119|No Intervention|Continue intravenous antibiotic therapies (backbone +/- adjunctive therapy) - standard of care arm|"Backbone therapy arm for MRSA or MSSA or PSSA +/- adjunctive therapy will continue on intravenous antibiotic treatment for the length of time as per usual standard of care.~Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised if not eligible then eligibility will be assess again at Day 14(+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
9982736|NCT05137119|Experimental|Switch to oral antibiotics at trial day 7 (+/- 2 days) or Day 14 (+/- 2 days) if eligible.|"Switch from intravenous backbone antibiotic for MRSA or MSSA or PSSA to oral antibiotics at the treating clinicians discretion on trial Day 7 (+/- 2 days) or trial Day 14 (+/- 2 days).~Participants eligibility is assessed at Day 7 (+/- 2 days). If eligible will be randomised, if not eligible then eligibility will be assessed again at Day 14 (+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain."
9982737|NCT05136287||Diabetes mellitus 2 patients with obesity|Patients that meet criteria to start treatment with GLP-1 receptor agonists (dulaglutide; exenatide; liraglutide; lixisenatide )
9982738|NCT05135533|Experimental|Portable Neuromodulation Stimulator|
9982739|NCT05135533|Sham Comparator|Sham|
9982740|NCT05135481|Active Comparator|CONTROL GROUP|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function.
9982741|NCT05135481|Experimental|STUDY GROUP|"Management in group 2 will include increased lactation care both during hospital stay and post discharge.~Increased lactation care will consist of:~individual consultations on how to properly attach the baby to the breast (at least 3 meetings during hospitalization with personnel trained in lactation counselling), regular (at least once a week) contact with a breastfeeding consultant as part of a closed group on social media or by phone, if necessary (expressed by the mother or based on a referral by a member of the lactation team) an outpatient appointment at the breastfeeding clinic."
9982742|NCT05135325|Experimental|No-blood-type message|This group will receive a message that does not mention the patient's blood type, or that the patient's blood type is in short supply.
9982743|NCT05135325|Experimental|Blood-type message|This group will receive a message that mentions the patient's blood type and that states their blood type is in short supply.
9982744|NCT05135325|No Intervention|Shortage control|This group will not receive a message.
9734507|NCT04390672|Experimental|SUPRAFLEX Cruz|Percutaneous Coronary Intervention with the SUPRAFLEX Cruz Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
9734508|NCT04390672|Active Comparator|SYNERGY|Percutaneous Coronary Intervention with the SYNERGY EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with an bioabsorbable polymer coating.
9734509|NCT04390139|Experimental|Treatment A|Wharton-Jelly mesenchymal stromal cells on D1 and D3
9734510|NCT04390139|Placebo Comparator|Treatment B|Placebo on D1 and D3
9982745|NCT05135325|No Intervention|No-shortage control|This group will not receive a message.
9982746|NCT05135039|Experimental|Lifestyle interventions + Canagliflozin|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of canagliflozin 100mg.
9734513|NCT04373785|Experimental|NG101m and standard treatment|"Concomittant therapy:~Radiation therapy, oral temozolomide, and oral NG101m~Adjuvant therapy:~Oral temozolomide and oral NG101m"
10205524|NCT05205811|Experimental|Bupropion with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with placebo zonisamide. The combination of placebo and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
9734518|NCT04368130|Experimental|SIGNAL|"Program to explore the feasibility and acceptability of a smartphone-based real-time behavioral anomaly detection system (SIGNAL).~Patients will download the adapted Beiwe app onto their smartphones for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
9734525|NCT04356989||Rivaroxaban|Adult NVAF patients with renal impairment, who are prescribed with rivaroxaban to prevent stroke or non-central nervous system (CNS) systemic embolism (SE).
9734534|NCT04347421|Experimental|Krill oil group|This group takes Krill oil for 12 weeks
9734535|NCT04347421|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
9982747|NCT05135039|Placebo Comparator|Lifestyle interventions + Placebo|Subjects were instructed on diet and exercise and advised to make lifestyle changes while they were given daily oral doses of placebo 100mg.
9982748|NCT05129943|Active Comparator|active distraction group|local anesthesia with video game using VR device
9982749|NCT05129943|Active Comparator|passive distraction group|local anesthesia with cartoon video using VR device
9734539|NCT04340531|Experimental|Arm I (early arm)|Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 13-24. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
9734540|NCT04340531|Active Comparator|Arm II (delayed arm)|Female smokers receive usual care during months 13-24. Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 25-36. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
9734541|NCT04340193|Experimental|Nivolumab + Ipilimumab + TACE|TACE (Trans-arterial ChemoEmbolization)
9734542|NCT04340193|Experimental|Nivolumab + TACE|
9734543|NCT04340193|Active Comparator|TACE|
9982750|NCT05129709|Experimental|"My Health Priorities Identification Program"|"The intervention, the My Health Priorities Identification Program consists of four self-directed, web-based modules intended to guide patients with MCCs in identifying their own health priorities. These priorities can then be used to guide discussions with family caregivers and clinicians regarding specific goals and preferences that they wish to guide future treatment decisions. Most models of palliative care have been developed based on white middle-class populations and may not apply to African Americans (AA) who have a very different cultural value set."
9982751|NCT05129332|Experimental|Vaginal Dilator Intervention|Patients assigned to the vaginal dilator group will be provided the device, vaginal moisturizer, an adherence calendar, and standardized verbal and written instructions from a trained health professional to apply the moisturizer and use the dilator for 15 minutes daily. Standard medical grade vaginal dilators and pure Vitamin E oil will be provided for each study participant. They have the option of purchasing a dilator and/or moisturizer of a similar nature if they choose to.
9982752|NCT05129332|Other|Control (Vaginal Moisturizer Only)|Patients assigned to vaginal moisturizer alone will receive pure Vitamin E oil and similar standardized instructions on daily use and an adherence calendar. They will apply a dime-sized amount of Vitamin E oil every day. They have the option of purchasing their own moisturizer if they choose to.
9982753|NCT05128903|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive Translocation Protein (TSPO) Positron Emission Tomography (PET) for longitudinal, quantitative assessment of brain neuroinflammation following whole brain radiation therapy.
9982754|NCT05128591|Experimental|Arm A-Rivaroxaban|Period 1 : Reference Drug(AD-1091) Period 2 : Test Drug(AD-109)
9982755|NCT05128591|Experimental|Arm B-Rivaroxaban|Period 1 : Test Drug(AD-109) Period 2 : Reference Drug(AD-1091
9734552|NCT04323800|Experimental|High titer anti-SARS-CoV-2 plasma|Participants with High titer anti-SARS-CoV-2 plasma.
9734553|NCT04323800|Active Comparator|SARS-CoV-2 non-immune plasma|Participants with SARS-CoV-2 non-immune plasma.
9734554|NCT04323774|No Intervention|Aim 1-Part 1 Stakeholder Interview|"This arm will focus on finding the best format for the study intervention (called AYA-RISE) whether AYA-RISE is easy to use; and whether patients, family caregivers, and providers find AYA-RISE acceptable.~The research study procedures include:~Using and reviewing AYA-RISE~Participating in audio-recorded, 30-minute interviews"
9734555|NCT04323774|Experimental|Aim 1-Part 2|"This arm is a pilot study of the study intervention (called AYA-RISE).~The activities involved in this part of the study are:~Baseline Questionnaire~Using and reviewing AYA-RISE~Follow-up Questionnaire~Brief interviews to get feedback on AYA-RISE"
9734556|NCT04323774|Active Comparator|Aim 2-Genetic Counseling|"The names of the study activities involved in this study are:~Baseline Questionnaire~Follow-up Questionnaire~Medical record review~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
9734557|NCT04323774|Experimental|Aim 2- Genetic Counseling with AYA-RISE|"The names of the study activities involved in this study are:~Baseline Questionnaire~Follow-up Questionnaire~Medical record review~Using the study intervention, AYA-RISE~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
9734558|NCT04323774|No Intervention|Aim 3 Semi-structured interviews|Each site will conduct 30-minute interviews with patients, caregivers, and providers, and site principal investigators.
9734570|NCT04304183||slow transit constipation|patients diagnosed with slow transit constipation had undergone surgery.
9665903|NCT04822662|Experimental|Experimental Group: Epilepsy education program|The training prepared for epilepsy will be held in 3 main modules and 5 sessions with two weeks intervals. Each session will last 25 minutes. Trainings will be given to adolescents and their parents online.
9982756|NCT05128201|Experimental|System treatment plus consolidative radiotherapy and Maintenance treatment|4-6 Cycles System chemotherapy (Camrelizumab , Gemcitabine and cisplatin or nedaplatin) ; And local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F) and Maintenance of Camrelizumab (total 2 years; from first cycles of System chemotherapy to last cycles of miantenance of camrelizumab)
9982757|NCT05127681|Experimental|severe hemophilia A or B patients|30 patients with severe hemophilia A or B (Factor (F)VIII or Factor IX (FIX)≤ 1%) aged 20 to 60 years will be included in this study.
9665904|NCT04822662|No Intervention|Control Group|The control group will receive standard epilepsy treatment without any training intervention. The group did not receive any other intervention.
9665905|NCT04822025|Experimental|High Dose|High-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
9665906|NCT04822025|Experimental|Mid Dose|Mid-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
9665907|NCT04820764|Experimental|CardioMech Mitral Valve Repair System (MVRS)|
9665908|NCT04820686|Experimental|VBR + AB-729 + SOC NrtI|Participants with cHBV will receive VBR + AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up.
9665909|NCT04820686|Other|VBR + SOC NrtI|Participants with cHBV will receive VBR + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment will be used as a reference regimen.
9665910|NCT04820686|Other|AB-729 + SOC NrtI|Participants with cHBV will receive AB-729 + SOC NrtI for 48 weeks followed by 48 weeks in follow-up. This treatment will be used as a reference regimen.
9665911|NCT04819997|Experimental|Supportive care (videoconference, questionnaire, survey)|Patients participate in 5 videoconference sessions over 30 minutes each over 6 weeks focused on worry management skills, values-based goal setting, and brief mindfulness-based practices, then complete patient workbook activities after each session over 15-20 minutes per day. Patients also complete a survey over 8 minutes at 6 weeks, an exit interview at 7 weeks, and questionnaires over 25 minutes each at baseline, 6 weeks, and 10 weeks.
9665912|NCT04819269|Active Comparator|Tivanisiran sodium ophthalmic solution|
9665913|NCT04819269|Placebo Comparator|Vehicle ophthalmic solution|
9665914|NCT04817670|Experimental|Cohort 1a|Subjects receive VIT-2763 30mg daily during the 8 weeks of treatment (Part A and Part B)
9665915|NCT04817670|Experimental|Cohort 1b|Subjects receive VIT-2763 30mg daily during the first 4 weeks of the treatment (Part A) followed by 60mg daily for other 4 weeks (Part B).
9665916|NCT04817670|Experimental|Cohort 2a|Subjects receive VIT-2763 60mg daily during the 8 weeks of treatment (Part A and Part B)
9665917|NCT04817670|Experimental|Cohort 2b|Subjects receive VIT-2763 60mg daily during the first 4 weeks of the treatment (Part A) followed by 120 mg daily for other 4 weeks (Part B).
9665918|NCT04817670|Placebo Comparator|Cohort 3|Subjects randomised to placebo during Part A continue unchanged during Part B.
9665919|NCT04817267|Experimental|reSET-O + Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU plus the reSET-O app.
9665920|NCT04817267|No Intervention|Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU only (no use of the reSET-O app).
9665921|NCT04817228|Experimental|EX-02 Gel|The powder of EX-02 (8.1 g in each unit) should be reconstituted with 20 g sterile water for injection (WFI) to obtain 5% EX-02. EX-02 5% gel will be topically applied on a wound surface of up to 80 cm2 for 24±3 hours, up to 8 consecutive applications
9665923|NCT04813614|Experimental|STYLAGE M Lidocaine|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into and/or around the lip mucosa by linear threading injection, multipoint injection, or a combination of both techniques with needle or cannula.~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
9982758|NCT05127681|Other|healthy men|"Data of healthy men, matching in age- height-weight-ethnicity and smoking-matched with patient will be collected. These data are already available at the Institut national de la santé et de la recherche médicale (INSERM) research unit associated."
9982759|NCT05124977|Experimental|Experimental group|Antimicrobial stewardship based on daily clinical assessment of clinical cure (experimental group). Discontinuation of antibiotic therapy antibiotics if criterions of clinical cure (regression of tracheal secretions, regression of temperature, improvement of PaO2/FiO2 ratio, absence of hemodynamic failure) of confirmed VAP are met. In the intervention group, intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
9734577|NCT04288362|Experimental|Intervention Group|
9734578|NCT04288362|Active Comparator|Control Group|
9982760|NCT05124977|Other|Control group|Standard management: duration of appropriate antibiotic therapy for confirmed VAP according to guidelines. In the control group, intensivists will perform clinical assessment daily, but a minimum duration of 7 days, as highly recommended of antibiotic therapy will be mandatory whatever the clinical cure.
9982761|NCT05124925|Experimental|Treatment Arm|Ianalumab 300 mg subcutaneous monthly
9982762|NCT05123560||women attending first-trimester ultrasound|All women attending their first-trimester ultrasound and meeting the inclusion criteria will be invited to participate
9734582|NCT04279925|Experimental|Locally-made Miniplate and screw|Locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia.
9734583|NCT04279925|Active Comparator|Imported Miniplate and screw|Biomet® miniplate 1.5 and screw 1.5 produced by Biomet, included in the Lorenz® Plating System Midface.
9734584|NCT04279522|Experimental|Group 1 - active stimulation|
9734585|NCT04279522|Placebo Comparator|Group 2 - sham stimulation|
9734586|NCT04278989|Active Comparator|Anti-tumor B|1,200 mg three times a day.
9734587|NCT04278989|Placebo Comparator|Placebo|Placebo taken three times a day.
9982763|NCT05121701|Active Comparator|Videolaryngoscopy|The patients were intubated with the C-MAC PM-Karl Storz Video laryngoscope.
9982764|NCT05121701|Active Comparator|Laryngoscopy|The patients were intubated with the Macintosh laryngoscope.
9982765|NCT05121519|Experimental|Avoid|Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
9982766|NCT05121519|Experimental|Consume|Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
9734592|NCT04266301|Experimental|MBG453 + Azacitidine|Participants will receive MBG453 plus Azacitidine
9734593|NCT04266301|Placebo Comparator|Placebo + Azacitidine|Participants will receive Placebo plus Azacitidine
9982767|NCT05120544|Active Comparator|EXTEND-Monitoring|Participants randomized to EXTEND-Monitoring receive mobile monitoring devices to facilitate chronic disease self-management, including a glucose meter and test strips, a BP cuff, a home scale, and an accelerometer. Mobile monitoring data are transferred Duke University Health System (DUHS). Participants can review data and trends within the device apps and modify self-management practices accordingly. The EXTEND-Monitoring group continues chronic disease care with their existing providers during the study, and are instructed at baseline to address management questions via their primary clinics' established avenues (as would be the case for any patient using mobile monitoring in clinical practice).
9734595|NCT04261751||Clinicians|Physicians, Nurses, or Respiratory Therapists will be taking the Clinician Questionnaire electronically.
10205525|NCT05205811|Placebo Comparator|Placebo with e-cigarette|After the first week of e-cigarette use (JUUL), participants will be given placebo bupropion with placebo zonisamide. The combination of these placebos will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).
9734597|NCT04256486|Experimental|Family DSMES|
9734598|NCT04256486|Experimental|Wait List|
9734599|NCT04254263|Experimental|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
9734600|NCT04254263|No Intervention|No Pyrotinib|Observation follow-up
9734601|NCT04251442|Experimental|Study Group|The study group will have soft tissue balance performed with the use of IOS.
9734602|NCT04251442|No Intervention|Control Group|Control group patients will have soft tissue balance performed manually, with final soft tissue balance values measured using IOS, while the surgeon will remain blinded to those values.
9734603|NCT04248257|Experimental|PeACE peer coaching arm|Behavioral, PeACE, PeACE consists of 3 streamlined 30-minute psychosocial telephone counseling sessions delivered by a well-trained peer coach. Coaches are lay YARs from HBOC families demonstrating good knowledge, communication skills, and protocol mastery.
9734604|NCT04248257|Active Comparator|Community peer coaching arm|Behavioral, usual care, Participants in the usual care arm will receive navigation to peer support with a range of community groups who provide these services.
10205526|NCT05205798|Experimental|Participants|Food consumption using plates with a diameter of 23 cm first then using plates with a diameter of 31 cm
9734608|NCT04238780|Active Comparator|ESP( Erector Spinae Plane Block)|After induction parturient in the ESPB underwent bilateral ESPB at the level of T7 using a linear ultrasound (US) transducer.
9734609|NCT04238780|Sham Comparator|control group|Control group
9734614|NCT04234399||Group|All patients receiving SOC imaging and Axumin PET scans.
9734617|NCT04227847|Experimental|Part A|SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
9734618|NCT04227847|Experimental|Part B|SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
9734619|NCT04227847|Experimental|Part C|SEA-CD70 expansion cohort in relapsed/refractory AML
9734620|NCT04225117|Experimental|Cohort 1: HR+/HER2- breast cancer|"Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.~HR+/HER2- = Hormone receptor-positive/ human epidermal growth factor receptor 2-negative"
9734621|NCT04225117|Experimental|Cohort 2: Triple negative breast cancer (TNBC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
9734622|NCT04225117|Experimental|Cohort 3: Squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
9734623|NCT04225117|Experimental|Cohort 4: Non-squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
9734624|NCT04225117|Experimental|Cohort 5: Head and neck cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
9734625|NCT04225117|Experimental|Cohort 6: Gastric or GEJ or esophageal cancer|"Participants enrolled into Cohort 6 will be reallocated based on disease type and histology into Cohorts 7 or 8.~GEJ= gastroesophageal junction"
9734626|NCT04225117|Experimental|Cohort 7: Gastric adenocarcinoma or esophageal adenocarcinoma (EAC) or GEJ adenocarcinoma|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
9734627|NCT04225117|Experimental|Cohort 8: Esophageal squamous cell carcinoma (ESCC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
9982768|NCT05120544|Experimental|EXTEND-Nursing|For EXTEND-Nursing, participants receive mobile monitoring devices to facilitate chronic disease self-management as for EXTEND-Monitoring. Additionally, these data are transferred Duke University Health System (DUHS) for use as part of a nurse-delivered intervention combining mobile monitoring, self-management support, and medication management. Each intervention component is administered by clinical registered nurses (RNs) from Duke Primary Care (DPC) or Duke Endocrinology. For EXTEND-Nursing's medication management component, RNs work in conjunction with a PharmD study clinician affiliated with the participant's clinic. The PharmD determines whether medication changes are needed, and prescribes accordingly. The RNs deliver EXTEND-Nursing via scheduled telephone encounters throughout the 12-month intervention. The initial encounter frequency is every two weeks, but may be extended to every four weeks for patients achieving treatment goals.
9982769|NCT05120388|Experimental|Dietary addition of extra virgin olive oil|WHO diet with a daily addition of extra virgin olive oil
9982770|NCT05120388|No Intervention|No addition of extra virgin Olive Oil|WHO diet
9734631|NCT04221477|Experimental|Obinutuzumab|"Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit.~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
9734632|NCT04221477|Placebo Comparator|Placebo|"Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone.~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
9734633|NCT04219696|Active Comparator|1 session|Participants will complete one 45-minute session of reactive balance training. Participants will experience 40-60 perturbations during this session. Participants will also complete 5 45-minute 'traditional' balance training sessions.
9734634|NCT04219696|Experimental|3 sessions|Participants will complete three 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session. Participants will also complete 3 45-minute 'traditional' balance training sessions.
9734635|NCT04219696|Experimental|6 sessions|Participants will complete six 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session.
9734636|NCT04218565|Experimental|Golimumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
9982771|NCT05120193|Experimental|Sphere-9 Catheter|Sphere-9™ Mapping and Ablation Catheter; Affera Mapping System; Affera Ablation System
9734639|NCT04216290|Experimental|Step I, Arm C (durvalumab, radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice weekly for 6 weeks; cisplatin IV over 30-60 minutes for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
9734640|NCT04216290|Active Comparator|Step I, Arm D (radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice weekly for 6 weeks; cisplatin IV over 30-60 minutes for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
9734641|NCT04216290|Experimental|Step II, Arm E (durvalumab)|Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1. Cycles repeat every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
9734642|NCT04216290|Active Comparator|Step II, Arm F (observation)|Patients previously randomized to Arm D who achieve clinical CR or clinical benefit, or patients previously randomized to Arm C with no clinical CR or clinical benefit undergo observation.
9734647|NCT04200053|Experimental|Reflexology massage|Reflexology massage
9734648|NCT04200053|Experimental|Reflexology massage and passive music|Reflexology massage and passive music
9734649|NCT04200053|No Intervention|Control|Control
9734650|NCT04197986|Experimental|Infigratinib 125 mg|Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
9734651|NCT04197986|Placebo Comparator|Placebo|Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
9734652|NCT04193176|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
9734653|NCT04193176|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
9734654|NCT04191499|Experimental|Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib, palbociclib, and fulvestrant.
9734655|NCT04191499|Placebo Comparator|Placebo + Palbociclib + Fulvestrant|Participants will receive placebo, palbociclib, and fulvestrant.
9734656|NCT04189757|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
9734657|NCT04178174|Experimental|SABR boost and de-escalated chemoradiation|SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.
9734658|NCT04178174|Active Comparator|Standard chemoradiation|The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.
9734659|NCT04168372|Experimental|High fructose meal, with fructose label|2-13C fructose incorporated into a meal with high fructose content
9734660|NCT04168372|Experimental|High fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with high fructose content
9734661|NCT04168372|Experimental|Low fructose meal, with fructose label|2-13C fructose incorporated into a meal with low fructose content
9734662|NCT04168372|Experimental|Low fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with low fructose content
9982772|NCT05120193|Active Comparator|THERMOCOOL SMARTTOUCH SF|THERMOCOOL SMARTTOUCH® SF Catheter; SMARTABLATE® System; CARTO® 3 System
9734664|NCT04161599|Experimental|Oral + Parenteral prophylaxis + Mechanical Bowel Preparation|"Drug: Extra dosage - cefuroxime (750mg) I.V~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Sodium picosulfate, magnesium oxide, citric acid anhydrous 15.08 g oral An oral laxative for bowel cleansing (2 doses) the day before surgery.~Drug: Metronidazole 1 g Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
9734665|NCT04161599|Active Comparator|Oral + Parenteral prophylaxis|"Drug: Extra dosage - cefuroxime (750mg) I.V In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Metronidazole 1 gr Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
9734666|NCT04157088|Experimental|Participants treated with darolutamide|
9734667|NCT04157088|Experimental|Participants treated with enzalutamide|
9734668|NCT04153760|Active Comparator|Aspirin|Aspirin 81 mg daily for six weeks post-randomization (postpartum)
9734669|NCT04153760|Placebo Comparator|Placebo|Placebo daily for six weeks post-randomization (postpartum)
9734670|NCT04150029|Experimental|MBG453+Venetoclax +Azacitidine|Patients will receive MBG453 in combination with Venetoclax and Azacitidine
9734671|NCT04148911|Experimental|Atezolizumab plus Nab-Paclitaxel|Participants will receive Atezolizumab via intravenous (IV) infusion on Days 1 and 15 of every 28-day cycle in combination with Nab-Paclitaxel on Days 1, 8, and 15 (individually selected by the investigator) until disease progression, or unacceptable toxicity, additionally until loss of clinical benefit as determined by the investigator or participant decision to discontinue treatment.
9734672|NCT04147819|Experimental|Dose escalation of BAY2701439|The target population consists of participants with advanced HER2-expressing/amplified breast, gastric or gastroesophageal cancer.
9982773|NCT05119998|Experimental|IBI325 and sintilimab combination does-escalation|
9734673|NCT04147819|Experimental|HER2 overexpressing breast cancer|Dose expansion of BAY2701439
9734674|NCT04147819|Experimental|HER2 low expressing breast cancer|Dose expansion of BAY2701439
9734675|NCT04147819|Experimental|Other HER2 overexpressing advanced carcinomas|Dose expansion of BAY2701439
9982774|NCT05119998|Experimental|IBI325 monotherapy does-escalation|
9982775|NCT05119556|No Intervention|Standard of Care|Participants will receive standard of care for COPD management per local guidance. In addition, they will receive 4-weekly phone calls for 13 weeks post discharge to inquire about health status and exacerbations.
9982776|NCT05119556|Active Comparator|Video Telehealth Pulmonary Rehabilitation|In addition to standard of care, participants will be asked to participate in rehabilitation sessions administered at home via live videoconferencing for approximately 60 minutes a session, three times a week. A total of 36 sessions will be planned to be completed by week 13 post-discharge. Exacerbations and health status will be ascertained every 4-weeks for 13 weeks.
9734677|NCT04142437||GI|adult patients with gastrointestinal (GI) cancer
9734678|NCT04142437||H&N|adult patients with head and neck (H&N) cancer
9734679|NCT04142437||STS|adult patients with soft tissue sarcoma (STS)
9734680|NCT04142437||CNS|adult patients with primary central nervous system (CNS) cancer
9734681|NCT04142437||Lung|adult patients with lung cancer
9734682|NCT04142437||Melanoma|adult patients with melanoma
9734683|NCT04142437||Pediatric|all pediatric patients regardless of tumor type will be enrolled under this cohort
9734684|NCT04142437||other|patients with other tumor types
9734685|NCT04142021||patients with 3-vessel disease with or without left main|Patients with 3-vessel disease with or without left main involvement referred to CABG treatment based on coronary angiography.
9982777|NCT05119335|Experimental|Phase 1 dose escalation|Phase 1 is designed to determine the maximum tolerated dose and/or identify the recommended Phase 2 dose of NKT2152 as a single agent administered orally once daily in ccRCC patients
9982778|NCT05119335|Experimental|Phase 2 dose expansion|Phase 2 will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 as a single agent administered orally once daily in ccRCC patients
9734688|NCT04134936|Experimental|Arm A|Tafasitamab in addition to R-CHOP
9734689|NCT04134936|Experimental|Arm B|Tafasitamab plus lenalidomide in addition to R-CHOP
9734690|NCT04131036||Arm A|Male patients with severe Hemophilia A who use prophylaxis with IV factor VIII concentrate with intended trough >1%.
9734691|NCT04131036||Arm B|Male patients with severe Hemophilia A who use prophylaxis with SQ emicizumab.
9982779|NCT05118906|Experimental|BP1.4979|15 mg BID active treatment
9734693|NCT04110145|Experimental|Cohort 1 (Linaclotide 18 μg)|Linaclotide 18 microgram (μg), capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
9734694|NCT04110145|Experimental|Cohort 2 (Linaclotide 36 μg)|Linaclotide 36 μg, capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
9734695|NCT04110145|Experimental|Cohort 3 (Linaclotide 72 μg)|Linaclotide 72 μg, capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
9734696|NCT04110145|Experimental|Final Cohort (Linaclotide 72 μg)|Linaclotide at the highest dose tested/determined to be safe (72 μg), capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
9734697|NCT04110145|Placebo Comparator|Placebo Pooled|Matching placebo, orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period pooled from Cohorts 1, 2, 3, and Final Cohort.
9734698|NCT04109911|Experimental|Fermented oyster extract group|This group takes fermented oyster extract for 12 weeks
9734699|NCT04109911|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
9734700|NCT04109391|Experimental|Test Product|IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles
9734701|NCT04109391|Active Comparator|Reference Therapy|IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles
9982780|NCT05118906|Placebo Comparator|Placebo|matching placebo
9734707|NCT04101422|No Intervention|Development of Augmented Reality (AR) Application|Investigators will collaborate with an AR software specialist to develop AR stimuli that are embedded within a basic digital application.
9734708|NCT04101422|Experimental|Pilot Testing of AR Application|AR stimuli (smoking, e.g, cigarette, ashtray, lighter; and non-smoking, e.g., pen, notebook, eraser) will be piloted on a small group of smokers to receive feedback and modify as needed. Participants will answer questions from a 10 point Likert scale that will asses urge from 1 (absolutely no urge to smoke) to 10 (strongest urge to smoke) and reality/co-existence (how realistic the item looks, and it's integration into the environment), from 1 (Not at all) to 10 (Very Much). Participants will then be asked additional open-ended questions about the quality of the images following the ratings of the images.
9734709|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 1: Cue Reactivity|142 study participants will attend 1st lab based session that will test cue-reactivity. Participant will be randomized to view either AR images, or in vivo items first. Order of presentation of items will also be randomized within the type (AR or in vivo).Session 1 should last under 1 hour.
9734710|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 2: Extinction|Participants will be randomized into either the extinction or control group. 28 trials of AR cues will be presented for each group. Both groups will receive the same neutral cue in Trial 1 (to establish baseline urge) and the same smoking cue in Trial 2 (for pre-test cue-reactivity). The extinction group will receive smoking cues for trials 3-26, whereas the control group will receive neutral cues. Both groups will receive matched smoking cues for trial (27) followed by matched neutral cues for the final trial (28), for post-test cuereactivity. Each cue will be presented for 1 minute and will be shown 4 times in trials 3-26. Following each cue, participants will complete the single-item measure of urge. Following the final trial (28) for both groups, participants will be presented with one of their own cigarettes and asked to take at least one puff. Latency to smoke will later be determined using time stamps on the video recording. Session 2 is expected to last 1.25 hours.
9734711|NCT04101422|Experimental|Testing AR Application|20 Participants will be instructed to use the AR app that presents smoking-related stimuli (cigarette, ashtray, lighter) in locations/situations where they typically smoke with the goal of at least 5 uses per day for 7 days. Usage and rating data will be collected in real-time. Participants will also be asked to rate their urge to smoke on the smartphone app at selected times. Participants will then return to the lab to provide additional feedback on the app, answer questions related to smoking behavior, and receive an in-person interview on their perceptions of the app as a potential cessation tool. Participants will use the smart phone application for 7 days.
9734712|NCT04100733|Active Comparator|Control|Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.
9734713|NCT04100733|Experimental|Intervention|Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.
9734714|NCT04100018|Experimental|Arm A: Nivolumab + docetaxel + prednisone|
9734715|NCT04100018|Placebo Comparator|Arm B: Placebo + docetaxel + prednisone|
9982781|NCT05118815|Active Comparator|Conventional straight esthetic abutment|After implant surgery, 30 patients will have a 3 mm high conventional straight esthetic abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N.
9982782|NCT05118815|Experimental|Slim (New Slim) transepithelial abutment|After surgery, 30 patients will have a 3 mm high transepithelial New Slim abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N
9982783|NCT05117346|Experimental|To Establish the Safety and Efficacy of CARDIX-101 in Chronic Bradycardia Patients|"Treatment Regimen: A total of 20±4 chronic bradycardia subjects with a heart rate (H.R.) average of less than 60 bpm will be enrolled in the study (6±3/cohort). A clinical study period of 14±2-days is planned for each enrollment of patients.~Route of Administration: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment."
9982784|NCT05116319||Chinese people with no known history of diabetes|
9734731|NCT04095273|Experimental|Dose escalation of Elimusertib|2 dose levels of Elimusertib are planned
9734732|NCT04095273|Experimental|Dose expansion cohort 1a of Elimusertib|Participants with advanced hormone-receptor-positive, Human epidermal growth factor receptor 2 negative breast cancer (HER2-negative BC), known to be positive for Ataxia-telangiectasia mutated (ATM) loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known microsatellite instability-high (MSI-H) cannot be included
9734733|NCT04095273|Experimental|Dose expansion cohort 1b of Elimusertib|Participants with advanced hormone-receptor-positive, HER2-negative BC, known to be DDR deficiency biomarker-positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
9734734|NCT04095273|Experimental|Dose expansion cohort 2a of Elimusertib|Participants with advanced Colorectal cancer (CRC) known to be positive for ATM loss and/or ATM deleterious alterations who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
9734735|NCT04095273|Experimental|Dose expansion cohort 2b of Elimusertib|Participants with advanced CRC, known to be DDR deficiency biomarker -positive (except ATM loss/mutation) who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
9734736|NCT04095273|Experimental|Dose expansion cohort 3 of Elimusertib|Participants with advanced Gastric/gastroesophageal junction cancer (GC/GEJ) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
9734737|NCT04095273|Experimental|Dose expansion cohort 3a of Elimusertib|Participants with advanced GC/GEJ cancer and without DDR deficiency alterations as described above. Variants of unknown significance (VUS) of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
9734738|NCT04095273|Experimental|Dose expansion cohort 4 of Elimusertib|Participants with advanced Non-small cell lung cancer (NSCLC) known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
9734739|NCT04095273|Experimental|Dose expansion cohort 4a of Elimusertib|Participants with advanced NSCLC and without DDR deficiency alterations as described above. VUS of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
9734740|NCT04095273|Experimental|Dose expansion cohort 5 of Elimusertib|Participants with advanced pancreatic cancer, known to be DDR deficiency biomarker-positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
9734741|NCT04095273|Experimental|Dose expansion cohort 5a of Elimusertib|Participants with advanced pancreatic cancer and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
9734742|NCT04095273|Experimental|Dose expansion cohort 6 of Elimusertib|Participants with advanced Metastatic castration-resistant prostate cancer (mCRPC), known to be DDR deficiency biomarker positive (incl. ATM mutation) and/or positive for ATM loss who have not received prior treatment with immunotherapy. Participants with known MSI-H cannot be included.
9734743|NCT04095273|Experimental|Dose expansion cohort 6a of Elimusertib|Participants with advanced mCRPC and without DDR deficiency alterations as described above, who have not received prior treatment with immunotherapy. VUS of the DDR gene alterations are eligible. Participants with known MSI-H cannot be included.
9734744|NCT04095052|Experimental|Methyl Folate|Participants will receive a capsule containing 1,000 mcg methyl folate and microcrystalline cellulose orally once per day for 15 days.
9734745|NCT04095052|Placebo Comparator|Placebo|Participants will receive a microcrystalline cellulose capsule orally once per day for 15 days.
9982785|NCT05114616|Experimental|Sleep Study and Daytime MWT|Health volunteers completing one overnight sleep study followed by daytime MWT. The sleep study will include standard surface electrodes as well as EEGBuds. Participants will be asked to wear Ellcie Healthy glasses, concurrent with the EEGBuds, during each MWT trial.
9836236|NCT02777125|Active Comparator|Albuterol by Metered Dose Inhaler|Albuterol administered via MDI and spacer device with weight and severity based dosing. For weight less than 20 kg: mild and moderate disease 540mcg of albuterol per dose. For weight greater than or equal to 20 kg: mild disease 540 mcg of albuterol per dose and moderate disease 1080 mcg of albuterol per dose.
9982786|NCT05112991|Experimental|Envafolimab + Lenvatinib|Subjects receive lenvatinib daily and envafolimab once at the start of each 4-week treatment cycle.
9982787|NCT05112991|Experimental|Envafolimab|Subjects receive lenvafolimab once at the start of each 4-week treatment cycle.
10200560|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - Randomized Trial|"Proactive Psychiatry Consultation and Case Management is:~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
10200561|NCT03360695|Active Comparator|Enhanced Usual Care (EUC) - Randomized Trial|Study staff will send a templated email to the treating oncologist at enrollment informing the oncologists of the psychiatric diagnosis and available psychosocial services. Study staff will also inform the patient and caregiver of available psychosocial services.
9734749|NCT04091464|Experimental|TRAIN-BW|1x/week for 8 weeks + home exercise program
9734750|NCT04091464|Active Comparator|TRAIN-FW|1x/week for 8 weeks + home exercise program
9734751|NCT04088305|Experimental|Study group|Patients of study group will accept vancomycin strategies decided by a serum trough concentration model.
9734752|NCT04088305|No Intervention|Control group|Patients of control group will accept vancomycin dosages decided by attending physician.
9982788|NCT05111327|Experimental|Intervention|Students in the interventional groups will receive structured simulation guideline
9982789|NCT05111327|No Intervention|Control|Students in the control groups will receive standard treatment.
9734755|NCT04085900||Screening cohort|All participants will be tested for EBV associated biomarkers, including EBNA1/IgA, VCA/IgA, BNLF2b/IgG et al. And in males, EBV-DNA will be tested.Screening positive people will be followed up annually. And screening negative are invited to retest every four year.
9734756|NCT04084574|Experimental|Behavioral Diet Counseling|Groups of 4-6 participants will attend 12 weekly dietitian-led counseling sessions and receive coaching on practical strategies to enhance DASH diet adherence and reduce daily sodium intake.
9734757|NCT04084574|Other|Standard of Care|Participants will meet one-on-one with the study dietitian for a single 30- minute encounter and be advised to limit daily sodium intake per current clinical practice guidelines for hypertension in patients with CKD. Educational handouts and tip sheets about practical strategies to reduce dietary sodium will be distributed.
9734758|NCT04079504|Active Comparator|Ligation|Ligation of indirect inguinal hernia sac in inguinal hernioplasty patients
9734759|NCT04079504|Experimental|Non-ligation|Non-Ligation of Indirect inguinal hernia sac/ simple inversion/reduction of indirect inguinal hernia sac in inguinal hernioplasty patients
9982790|NCT05110508|Experimental|Physical Activity Self-Regulation|Participants will receive multiple weekly text messages. Texts will contain wear reminders, encouragements, congratulatory content, and behavior change messages based on the Garmin data. Some text message content asks for a response from the participant to help tailor later messages for behavior change support.
9982791|NCT05109806|Experimental|Experimental group|Problem prevention therapy will be given as per intervention. a group of parents will be included for a group session for narration of their problems in relevance to health related quality of life .After the assessment the next session the solution to these problems would be given to them.
9734762|NCT04073784|Experimental|Gemcitabine combined with Apatinib and Toripalimab|Subjects receive Apatinib for oral administration, 250mg, once a day, gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) and Apatinib 250mg once a day maintenance for the remainder of the study or until documented PD.
9734763|NCT04066244|Other|Cohort 1|Dose 1 of BLZ945
9734764|NCT04066244|Other|Cohort 2|Dose 2 of BLZ945
9734765|NCT04066244|Other|Cohort 3|Dose 3 of BLZ945
9734766|NCT04066244|Other|Cohort 4|Dose 4 of BLZ945
9734767|NCT04066244|Other|Cohort 5|Dose 5 of BLZ945
9734768|NCT04062851|No Intervention|GRV group|Gastric residuals will be checked prior to feeds
9734769|NCT04062851|Experimental|NO GRV group|Gastric residuals will not be checked prior to feeds
9982792|NCT05109806|Other|control group|for this group only a general education regarding disease will be conducted and no further interventions will be provide to them .
9982793|NCT05109676|Experimental|Patients having embryo transfert|Patients benefit from the usual treatment for frozen embryo transfer with a preparatory cycle of the artificial endometrium: 150 µg of percutaneous estradiol for approximately 11 days and 200 mg of progesterone morning and evening to be taken vaginally for 2 days in case of embryo transfer at day 2 stage, 3 days in case of embryo transfer at day 3 stage, 5 days in case of day 5 embryo transfer or 6 days in case of day 6 embryo transfer.
9982794|NCT05108883|No Intervention|standard care arm|decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment and usual protocols
9982795|NCT05108883|Experimental|MR-proADM guided arm|decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment, usual protocols and MR-proADM levels
9982796|NCT05108493|Experimental|Dry needling and home exercise|"The experimental intervention will consist of 3 sessions of dry needling of the lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).~Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
10200562|NCT03345823|Experimental|Group A - Arm A|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose B.
10200563|NCT03345823|Experimental|Group A - Arm B|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose C.
9734782|NCT04042961|Experimental|Reactive balance training|
9734783|NCT04042961|Active Comparator|Aerobic and strength training|
9982797|NCT05108493|Active Comparator|Home exercise|"Range of motion, stretching exercises, ulnar and radial deviation, forearm pronation, supination, elbow extensor, and flexor strengthening exercises will be given to all participants.~The exercise program will be performed for 10 repetitions 2 times a day. All participants will be advised to continue the exercise program for 12 weeks."
9734788|NCT04036435|Experimental|BMS-986165|
9982798|NCT05107401|Experimental|Crowdsourced Intervention|The digital crowdsourced intervention will be presented to participants in the intervention arm.
9982799|NCT05107401|No Intervention|Standard of Care|Standard HIV informational materials currently used by the Kazakhstan Ministry of Health will be presented to participants in the control arm.
9982800|NCT05105802|Experimental|Mindfulness Intervention|MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal. Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
9734792|NCT04032704|Experimental|Ladiratuzumab Vedotin|SGN-LIV1A monotherapy
9734793|NCT04032106|Active Comparator|Group A (standard HPV information)|Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.
9734794|NCT04032106|Experimental|Group B (Outsmart HPV, unidirectional vaccine reminders)|Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
9734795|NCT04032106|Experimental|Group C (Outsmart HPV, interactive vaccine reminders)|Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
10200564|NCT03345823|Experimental|Group A- Arm C|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive placebo.
10200565|NCT03345823|Experimental|Group B - Arm A|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose B.
10200566|NCT03345823|Experimental|Group B - Arm B|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose C.
9734799|NCT04024956|Experimental|Sealing Device|Sealing Device applied in hepatic resection or distal pancreatectomy
9734800|NCT04024488|Experimental|TI-CBT Intervention Arm|In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.
9734801|NCT04024488|Active Comparator|Discussion Control Arm|Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.
9734802|NCT04018261|Experimental|Activated T-Lymphocytes|Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.
10200567|NCT03345823|Experimental|Group B - Arm C|This is a long-term extension group with 240 weeks which includes participants who complete group A.
10200568|NCT03293667|Other|Exploratory arm|
10200569|NCT03269474||Experimental Group|Blood and tissue specimen will be collected from subjects with an EB diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.
9734806|NCT04008355|Experimental|60mg/day/84 days|Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
9734807|NCT04008355|Experimental|80mg/day/10 days followed by 50mg/day/74 days|Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.
9734808|NCT04008355|Placebo Comparator|Placebo/84 days|Patients randomized in this arm will receive placebo solution once daily during 84 days.
9734809|NCT04003779|Other|Participant stability with various room configurations|Single-arm. Ergonomically exploring patient stability moving around various configurations of a hospital room.
10200570|NCT03269474||Control Group|Blood and tissue specimen will be collected from healthy subjects with non-EB. Tissue specimen will be collected from an inconspicuous skin area.
10200571|NCT03248388|Experimental|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
10200572|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
10200573|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
10200574|NCT03232736||Healthy Control|Individuals free of cardiovascular disease and not on any medications to treat a cardiovascular-related condition
10200575|NCT03232736||LVAD Group|Individuals with history of advanced heart failure who are supported by left ventricular assist devices
10200576|NCT03229382|Experimental|Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22|
10200577|NCT03227211||COPD exacerbated patients admitted|No specific intervention
10200578|NCT03208530|Experimental|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
9982801|NCT05105802|Active Comparator|Cognitive Sham Application + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. We consider this arm as active as participants will be assigned to a cognitive sham app (cognitive math game) delivered via the same app (same main interface as the mindfulness intervention). However, they will not take part in the MBI program for the first 4 weeks. On a daily basis, participants will be asked questions about their stress and emotions and about their symptoms.
9734811|NCT03997799|Experimental|uniportal transcervical approache|Uniportal lobectomy with complete lymphadenectomy - transcervical approach with elevation of the sternum
9734812|NCT03997799|Experimental|uniportal intercostal approache|Uniportal lobectomy with complete lymphadenectomy - intercostal approache
9982802|NCT05105048|Experimental|mRNA-1647|CMV-seronegative or CMV-seropositive participants will receive mRNA-1647 vaccine by intramuscular (IM) injection in a 0-, 2-, and 6-month schedule.
9982803|NCT05105048|Placebo Comparator|Placebo|CMV-seronegative or CMV-seropositive participants will receive placebo matching to mRNA-1647 vaccine by IM injection in a 0-, 2-, and 6-month schedule.
9982804|NCT05103358|Experimental|Arm A: Pathogenic inactivating TSC1 alterations|
9734816|NCT03986866|No Intervention|No Video|Patients are not shown the informational video on the safe usage of opioids.
9734817|NCT03986866|Experimental|Video|Patients are shown an informational video on the safe usage of opioids.
9982805|NCT05103358|Experimental|Arm B: Pathogenic inactivating TSC2 alterations|
10200579|NCT03194308|Other|HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
10200580|NCT03158688|Active Comparator|Kd - Carfilzomib and Dexamethasone|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles."
9982806|NCT05103124|Experimental|Hydral|The participants will be asked to rinse their mouth five times a day with the experimental product. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
9982807|NCT05103124|Placebo Comparator|Placebo|The participants will be asked to rinse their mouth five times a day with the placebo comparator. After one month, the administration will be stopped and the patients will be asked to fulfill the questionnaires mentioned in the methods section (XQ, QLQ-C30, QLQ HN35)
9982808|NCT05102747|Experimental|Hypofractionated SRT (stereotactic radiotherapy)|
9982809|NCT05102747|Active Comparator|Historical single-dose SRS (stereotactic radiosurgery)|
9982810|NCT05102513|Experimental|Unilateral Cleft Lip Repair with the New Hybrid Technique|
9982811|NCT05102513|Active Comparator|Unilateral Cleft Lip Repair with the Millard II Technique|
10200581|NCT03158688|Experimental|KdD - Carfilzomib, Dexamethasone and Daratumumab|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.~Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only."
10200582|NCT03152786|Experimental|Group I (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
10200583|NCT03152786|Active Comparator|Group II (no treatment)|Patients receive no treatment prior to standard of care prostatectomy.
10200584|NCT03130036|Experimental|No risk of disease|Subjects with no identifiable risk of Alzheimer's Disease
10200585|NCT03130036|Experimental|Asymptomatic|Asymptomatic subjects with increased risk of Alzheimer's disease
10200586|NCT03130036|Experimental|Early Alzheimer's or Mild Cognitive Impairment|Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)
10200587|NCT03127215|Experimental|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
10200588|NCT03127215|Other|Arm C: Physician's choice|Physician's choice
10200589|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
10200590|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
10200591|NCT03103321|Experimental|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
10200592|NCT03103321|Experimental|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
10200593|NCT03103321|Experimental|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
10200594|NCT03103321|Active Comparator|Arm D (usual care)|Patients undergo usual care.
9734832|NCT03975647|Experimental|Tucatinib + T-DM1|Tucatinib + T-DM1
9734833|NCT03975647|Active Comparator|Placebo + T-DM1|Placebo + T-DM1
9982812|NCT05101148|Experimental|selumetinib single arm|This is a sequential study consisting of a screening period lasting up to 28 days, a 28 day (1 cycle) treatment period (T1) in a fed state, a 7 day washout period, a further 1 cycle treatment period (T2) in a fasted state and an extension to T2 until results from the primary analysis are available. During Treatment Period 1 and 2 all participants will receive selumetinib (25 mg/m2 bid). If a third treatment period (T3) is required, participants will enter a 7 day washout period followed by a treatment period in a fed state at an adjusted dose for 3 cycles.
9982813|NCT05099536|Experimental|3D011-08|
9982814|NCT05099471|Experimental|Venetoclax / Rituximab|"Cycle 1 (28-days cycle) Stepwise dose escalation of Venetoclax in all patients with a target dose of 800 mg/d QD PO.~Day 1-7: Venetoclax 200 mg/d QD PO Day 8-14: Venetoclax 400 mg/d QD PO Day 15-28: Venetoclax 800 mg/d QD PO~Cycle 2-12:~Day 1: Rituximab 375 mg/m2 IV Day 1-28: Venetoclax 800 mg/d QD PO"
9734837|NCT03970330|Experimental|Low-Dose Naltrexone|12-week intervention period of 4.5 mg daily naltrexone in combination with standard treatment of 5-15 mg daily norethindrone acetate
9734838|NCT03970330|Placebo Comparator|Placebo|12-week intervention period of daily placebo in combination with standard treatment of 5-15 mg daily norethindrone acetate
9982815|NCT05099471|Active Comparator|Dexamethasone / Rituximab / Cyclophosphamide|"Cycle 1-6:~Day 1: Dexamethasone 20 mg PO Day 1: Rituximab 375 mg/m2 IV Day 1-5: Cyclophosphamide 100 mg/m2 BID PO~Cycle 7-12:~Day 1: Rituximab 375 mg/m2 IV"
9982816|NCT05099289|Experimental|AtaCor EV-ICD Lead System|Subjects inserted with the AtaCor EV-ICD Lead Model AC-7000
9982817|NCT05098145|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood cells and delivered as a single infusion with a nonmyeloablative conditioning regimen.
9982818|NCT05097170||1|patients under the age of 65
9982819|NCT05097170||2|patients above the age of 65
9982820|NCT05096494|Experimental|SP-103|One SP-103 transdermal system is worn 12 hours per day for 28 days on the lower back.
9982821|NCT05096494|Placebo Comparator|Placebo|One placebo transdermal system is worn for 12 hours per day for 28 days on the lower back
9982822|NCT05096052|Experimental|ProLectin M|Active chewable tablets containing galectin inhibitor complex carbohydrate
9734847|NCT03952598|Experimental|1/Arm 1|Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS)
9982823|NCT05096052|Placebo Comparator|PLACEBO|Placebo chewable tablets not containing galectin inhibitor complex carbohydrate
9982824|NCT05094037|Experimental|Treatment group|Patients will be given additional counseling
9982825|NCT05094037|Active Comparator|Control group|Patients will be given standard of care.
9982826|NCT05093595|No Intervention|Group A|The tracheal tube was routinely fixed with a teeth pad and adhesive tape (3M).
9982827|NCT05093595|Experimental|Group B|The tracheal tube was fixed by the trans-nasal Silicone Foley Catheter (SFC) and adhesive tape.
9734854|NCT03935893|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic gastric/esophagogastric, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal squamous cell, Merkel cell, cancers refractory to systemic therapy, and those with deficient mismatch repair and/or microsatellite instability cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused through a central vein catheter and administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
9734855|NCT03933696|Active Comparator|Active Lighting Intervention|"The TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, TLI will allow us to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The investigators will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater).~The lighting intervention will be in place for 24 weeks"
9734856|NCT03933696|Placebo Comparator|Placebo Lighting Intervention|The placebo condition light source will be a warm yellow - white (2700 - 3000 K) source providing 50 -100 lux at the eye. The lighting intervention will be in place for 24 weeks.
9734857|NCT03933306|Placebo Comparator|Placebo+routine blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is managed according to routine practice.
9734858|NCT03933306|Experimental|Dexmedetomidine+routine blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is managed according to routine practice.
9734859|NCT03933306|Experimental|Placebo+goal-directed blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
9734860|NCT03933306|Experimental|Dexmedetomidine+goal-directed blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
9982828|NCT05093244|Experimental|SeQuent Please ReX|Drug coated balloon (DCB) catheter.
9734862|NCT03928808|Experimental|FMT for SE-AN|Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.
9982829|NCT05093244|Active Comparator|Plain old balloon angioplasty (POBA)|
9982830|NCT05092932||Normal Control Data|"Normal adults with no history of neuromusculoskeletal disease will be recruited for this study. Participants will be independent walkers (no walking aid needed) and will not have needed a walking aid for injury over the past 5 years.~Participants will walk 200 m under 4 randomized conditions: non-weightbearing ambulation using crutches, a walker, a wheeled knee walker, and unaided walking. An in-shoe sensor will measure stance limb plantar force, a stopwatch will time each walk, perceived exertion will be reported using the BORG CR-10 scale, and device preference will be identified."
9982831|NCT05092451|Experimental|Cyclophosphamide|Cyclophosphamide is dosed per adjusted body weight for patients weighing > 20% above their ideal body weight using the calculation.
9982832|NCT05092451|Experimental|CAR.70/IL15-transduced CB-NK cells|Patients will receive a single flat dose of CAR-NK.
9982833|NCT05092451|Experimental|Fludarabine phosphate|Fludarabine is dosed using actual body weight.
9982834|NCT05092009||All patiens|There is only one arm in this trial
9982835|NCT05090345||Biorepository trial of children and adolescents/young adults (AYA)|undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
9734871|NCT03914469|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
9734872|NCT03914469|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
9982836|NCT05090085|Active Comparator|3M Scotchbond MultiPurpose, etch and rinse adhesive|O.I. will clean the labial surface of the tooth with polishing paste and brush Roughening of the surface may be needed by the diamond point The tooth will be isolated by a rubber dam. Apply etchant for 30 s for enamel and 15 s for dentin. Rinse thoroughly with water for 15 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist. Active application of consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 20 s. Light curing of all resin materials was performed using (3M Elipar Curing Light) delivering 1100 mW/cm2.
9982837|NCT05090085|Experimental|DMSO application before 3M Scotchbond MultiPurpose, etch and rinse adhesive|The same steps of the comparator group with an additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 50% DMSO/H2O solutions on etched-dentin followed by 30 seconds of air drying then apply adhesive.
9982838|NCT05090033||Part I study cohort|Retrospective data analysis of up to 3500 de-identified participants contributing onboarding and adherence data via the MSGo Kesimpta Patient App.
9734876|NCT03902301|Active Comparator|Dietary group|A diet based on general recommendations for people with insulin resistance for 20 weeks.
9734877|NCT03902301|Experimental|Lactobacillus rhamnosus group|Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.
9734878|NCT03898934|Experimental|Vitamin D group|These patients will receive 6000IU daily for 8 weeks then 2000IU maintenance till pregnancy or end of study
9734879|NCT03898934|Placebo Comparator|Placebo group|These group will receive placebo for the same periods of study group
9982839|NCT05090033||Part II study cohort|Up to 100 participants responding to PROs via the MSGo Patient App
9982840|NCT05089825|Active Comparator|Receive routine instructions|Participants will receive routine instructions included in the myLAB Box Clinical Laboratory Improvement Amendments (CLIA) certified collection kit
9982841|NCT05089825|Active Comparator|Telehealth Visit|Participants will have a telehealth-based instructional visit and receive routine instructions included in the myLAB Box commercially available, CLIA certified collection kit
9982842|NCT05089331||Participants will be recruited from the GERFHS/ROSE Study|Participants will be recruited who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study/Recovery and Outcomes from Stroke study, who live in the area of University of Cincinnati, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, Baptist Health Louisville and Houston Methodist. The participant's age must be18 years or greater. The participant or legal representative must be able to provide informed consent, and the racial/ethnic category of participants should be Caucasian, African American or Hispanic.
9982843|NCT05089019|Experimental|Selpercatinib (Test)|Selpercatinib given orally on days 1 and 15.
9982844|NCT05089019|Active Comparator|Selpercatinib (Reference)|Selpercatinib given orally on days 1 and 15.
9734886|NCT03884556|Experimental|Arm 1, Single Agent|TTX-030
9734887|NCT03884556|Experimental|Arm 2, Anti-PD-1 Combination|TTX-030 plus pembrolizumab
9734888|NCT03884556|Experimental|Arm 4, Chemotherapy Combination|TTX-030 plus gemcitabine plus nab-paclitaxel
10200595|NCT03102554|Experimental|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands 17 years old or younger will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
10200596|NCT03079869|Other|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
10200597|NCT03033875|Experimental|Tele-Savvy Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program immediately.
10200598|NCT03033875|Other|Attention Control Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Healthy Living Education Program. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
10200599|NCT03033875|No Intervention|Usual Care Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to continue to receive care through whatever arrangement has been in place. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
10200600|NCT03000153|Experimental|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
10200601|NCT03000153|No Intervention|therapy as usual|In this arm, clients will have therapy as usual.
9734898|NCT03868670|Experimental|Responsive Neurostimulation|Surgical arm. Patients expected to receive treatment.
9734903|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose A|Resected participants are administered with Pancrelipase dose A. At week 1,5, or 9, participants who meet dose modification criteria will be administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
9734904|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose B|Resected participants are administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
9734905|NCT03859869|Experimental|Non-Resected Participants Receiving Pancrelipase Dose B|Non-resected participants are administered with Pancrelipase dose B.
9982845|NCT05088928|Experimental|Interventional Arm|Ecru (Apixaban )Tablets
9982846|NCT05088928|Active Comparator|Comparator/control|Rivascot (Rivaroxaban)
9734908|NCT03851588|Active Comparator|Supplementary dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
9734909|NCT03851588|Placebo Comparator|Placebo dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
10200602|NCT02993900|Experimental|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
9734910|NCT03849378|Experimental|Sargassum Horneri Extract group|This group takes Sargassum Horneri Extract for 12 weeks.
9734911|NCT03849378|Placebo Comparator|Placebo group|This group takes Placebo Extract for 12 weeks.
9982847|NCT05087771|Active Comparator|Oral naltrexone|patients will receive a 30 day supply of oral naltrexone 50 mg daily at hospital discharge. This medication was FDA approved in 1984 for the treatment of alcohol use disorder
9982848|NCT05087771|Experimental|injectable naltrexone|patient will receive 360 mg injection of naltrexone prior to hospital discharge
9982849|NCT05087030|Experimental|RGB-14-P (Main period)|Randomized participants will receive subcutaneous (SC) injection of RGB-14-P, on Day 1 of Treatment periods 1 and 2.
9982850|NCT05087030|Active Comparator|Prolia® (Main period)|Randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment periods 1 and 2.
9982851|NCT05087030|Experimental|RGB-14-P (Transition period)|Re-randomized participants will receive SC injection of RGB-14-P, on Day 1 of Treatment period 3.
9982852|NCT05087030|Active Comparator|Prolia® (Transition period)|Re-randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment period 3.
9982853|NCT05087030|Experimental|RGB-14-P (Continued till transition period)|Randomized participants will continue to receive SC injection of RGB-14-P from the main period till Day 1 of Treatment period 3.
9982854|NCT05084859|Experimental|CRPC (Castration Resistant Prostate Cancer) - SM08502 + Abiraterone/Prednisone|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC.~Subjects will recieve increasing doses of SM08502 with fixed doses of Abiraterone/Prednisone to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502 in subjects with advanced CRPC. Approximately 20 subjects will be enrolled."
9982855|NCT05084859|Experimental|NSCLC (Non-Small Cell Lung Cancer) - SM08502 + Docetaxel|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced NSCLC.~Subjects will recieve increasing doses of SM08502 with fixed doses of docetaxel to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM0850 in subjects with advanced NSCLC. Approximately 20 subjects will be enrolled."
9984650|NCT03874988|Experimental|Portion-Controlled Meals|Participants will receive prepackaged food, delivered biweekly to their home over the course of 13 weeks, with costs covered by the grant. Depending on their calorie goals, participants will drink and eat a mix of shakes and entrees each day, plus up to five fruits and vegetables. HMR entrees and shakes are formulated to provide recommended levels of macronutrients, vitamins, sodium, fat, cholesterol and fiber and fortified to meet at least 100% of the recommended daily allowance for essential vitamins and minerals.
10200603|NCT02983071|Experimental|Once-Daily G1T38 Dosing|G1T38 (lerociclib) orally (once daily) in combination with fulvestrant.
10200604|NCT02983071|Experimental|Twice-Daily G1T38 Dosing|G1T38 (lerociclib) orally (twice daily) in combination with fulvestrant.
9734924|NCT03820310|Experimental|Experimental group|traditional therapy plus autologous Tcm cellular immunotherapy.
9734925|NCT03820310|No Intervention|control group|traditional therapy alone, such as radiotherapy or chemotherapy.
10200605|NCT02939313|Experimental|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
10200606|NCT02939313|Experimental|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
10200607|NCT02939313|Sham Comparator|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
10200608|NCT02935595|Experimental|Ketamine|Slow infusions of ketamine will take place over a time period of 40 minutes.
10200609|NCT02887248|Experimental|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
10200610|NCT02866812|Experimental|patient with endovascular treatment for intracranial aneurysm|
10200611|NCT02864862|Active Comparator|Immediate implant|Immediate implant alone
10200612|NCT02864862|Active Comparator|Immediate implant combined with SCTG|Subepithelial connective tissue graft (SCTG)
10200613|NCT02864862|Active Comparator|Immediate implant combined with ADM|Acellular dermal matrix (ADM)
10200614|NCT02849990|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
10200615|NCT02819752|Experimental|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
9734926|NCT03817801|Experimental|non-slip element (NSE) predilation|In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.
9734927|NCT03817801|Active Comparator|non-compliant (NC) balloon predilation|In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.
9734928|NCT03812874|Experimental|PTX-9908 Injection group|IV injection.
9734929|NCT03812874|Placebo Comparator|Placebo/Vehicle group|IV injection
9982856|NCT05084859|Experimental|CRC (Colorectal Cancer) - SM08502 + FOLFIRI/Panitumumab|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRC.~Subjects will recieve increasing doses of SM08502 with fixed doses of FOLFIRI/Panitumumab to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502. Subjects that have RAS wild type tumors will receive FOLFIRI and panitumumab with SM08502 (n=15). Subjects that have RAS mutant tumors will receive FOLFIRI with SM08502 (n=15)."
9982857|NCT05082740||Women with a family history of breast cancer|This women are register to the Family History Risk and Prevention clinic and have taken part in the original FH-Risk study. These women will be given the opportunity to learn of their revised breast cancer risk estimate.
9982858|NCT05082480|Experimental|Hyaluronic acid (HA)|Hyaluronic acid (HA)
9982859|NCT05082480|Placebo Comparator|Saline|Saline
9982860|NCT05082233|Experimental|SHR7280 tablets|Treatment group A: oral SHR7280 tablets; 300mg bid p.o.; Treatment group B: oral SHR7280 tablets; 200mg bid p.o.; Treatment group C: oral SHR7280 tablets; 200mg qd p.o.; Treatment group D: oral SHR7280 tablets; 400mg bid p.o.; as an alternative.
9734935|NCT03810339|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
9982861|NCT05081843|Active Comparator|Usual Health Education Curriculum|Students will receive the school's usual health education curriculum.
9982862|NCT05081843|Experimental|Usual Health Education Curriculum plus Intervention|Students will receive the school's usual health education curriculum. Students will also receive the intervention. Delivery of the intervention (i.e., timing, frequency) will be determined by discussing the results of the Aim 1 focus groups with teachers and administrators.
9982863|NCT05081609|Experimental|Part 1 Dose Escalation: TransCon IL-2 β/γ|TransCon IL-2 β/γ in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D
9982864|NCT05081609|Experimental|Part 2 Dose Escalation: TransCon IL-2 β/γ with Pembrolizumab|TransCon IL-2 β/γ with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D
9982865|NCT05081609|Experimental|Part 3 Dose Expansion: TransCon IL-2 β/γ with SOC Chemotherapy|TransCon IL-2 β/γ with SOC Chemotherapy using the RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination
9734941|NCT03798639|Experimental|Arm I (nivolumab, radiation therapy)|Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
9835739|NCT02752880|Experimental|YH1 group|YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
9982866|NCT05080959|Experimental|CPL-01|CPL-01 200mg, 400mg, 600mg
9734942|NCT03798639|Active Comparator|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes at week 0. Treatments repeat every 2 weeks for nivolumab and 6 weeks for ipilimumab for up to 1 year in the absence of disease progression or unacceptable toxicity.
9982867|NCT05080959|Experimental|Naropin|150mg
9982868|NCT05080959|Experimental|Placebo|30mL normal saline (0.9%)
9982869|NCT05080699|Experimental|Peptamen Intense in obese home enteral nutrition patients after stroke|Subjects currently enrolled in Mayo Clinic Home Enteral Nutrition (HEN) program and anticipated to require tube feedings to provide 90% or more of feeding needs will be placed on a Peptamen Intense VHP for up to 12 weeks.
10200616|NCT02819752|Experimental|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
10200617|NCT02817347|Experimental|YH1177 (4/0.5%+0.1%)|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
10200618|NCT02817347|Experimental|YH1177 (8/1.0%+0.1%)|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
10200619|NCT02817347|Experimental|YH1177-D (2/0.25%)|piperacillin 2% + tazobactam 0.25%
10200620|NCT02817347|Experimental|YH1177-D (4/0.5%)|piperacillin 4% + tazobactam 0.5%
10200621|NCT02817347|Experimental|YH1177-D (8/1.0%)|piperacillin 8% + tazobactam 1.0%
10200622|NCT02800824|Experimental|Budesonide rectal foam|
10200623|NCT02800824|Active Comparator|Uceris rectal foam|
10200624|NCT02780401|Experimental|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
10200625|NCT02773524|Experimental|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
10200626|NCT02773524|Placebo Comparator|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
10200627|NCT02760498|Experimental|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously (IV) every 2 weeks (Q2W).
9982870|NCT05078762|Experimental|iVR|The intervention group will train on a bronchoscopy simulator in an iVR environment with Virtual Reality Goggles (HTC IVE Pro Eye, HTC corporation, Taiwan) while using the bronchoscopy simulator.
9734945|NCT03792880|Active Comparator|Control arm|Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment
9734946|NCT03792880|Experimental|Intervention arm|Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program
9982871|NCT05078762|No Intervention|Non iVR|The control group will train on a bronchoscopy simulator without VR goggles.
9982872|NCT05076045|Experimental|Personal sound amplification products|Speech perception will be evaluated using personal sound amplification products.
9982873|NCT05076045|No Intervention|Control|Speech perception will be evaluated without using hearing devices.
9734950|NCT03783689|Active Comparator|Group 1 (Treatment)|Subjects in Group 1 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
9734951|NCT03783689|Sham Comparator|Group 2 (Control)|Subjects in Group 2 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Subjects will then have the option to crossover and receive stimulation therapy.
9982874|NCT05075408|Experimental|Nemolizumab 30 mg|
9982875|NCT05075408|Experimental|Nemolizumab 60 mg|
9982876|NCT05075408|Placebo Comparator|Placebo|
9982877|NCT05075122|Experimental|Vaccination arm|Pembrolizumab flat dose iv every 3 weeks + UV1 vaccination (UV1 plus GM-CSF/Sargramostim as adjuvant per vaccination)
9734954|NCT03780894|Experimental|Experimental treatment|The active treatment consists of intravenous injection of 2g of fibrinogen concentrate, 1g of tranexamic acid, 2 red bood cells concentrate O Rh(D) negative (Banc de Sang i Teixits, Barcelona, Spain), and crystalloids at pre-hospital phase of care.
9734955|NCT03780894|Active Comparator|Standard treatment|Patients in the control arm will be treated according the existing protocols based on crystalloids and tranexamic acid administration.
9734956|NCT03775486|Experimental|Durvalumab/Olaparib Combination Therapy|"Durvalumab/Olaparib Combination Therapy:~Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)"
9734957|NCT03775486|Experimental|Durvalumab Monotherapy|Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
9835740|NCT02752880|Placebo Comparator|placebo group|The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
9982878|NCT05075122|Other|Calibration arm|Pembrolizumab flat dose iv every 3 weeks
9982879|NCT05074771|Experimental|ARC intellicare|"Study participants will use ARC intellicare at home, to carry out usability tests and a collection of useful data in order to optimise the system. After enrolment and training session, patients will receive an ARC unit to be used autonomously for the following 30 days.~45 minutes 5 days / week for 4 weeks of personalized training will be carried out by the enrolled subjects: 4 weekly sessions will be unsupervised, while one will be supervised remotely by a therapist in telepresence, thanks to the integrated audio-video channel."
9982880|NCT05074056|Experimental|Ketorolac|A double-blinded number of children will get one dose of intravenous 0.5 mg/kg (max dose 30mg) ketorolac intraoperatively.
9982881|NCT05074056|Placebo Comparator|Placebo|A double-blinded number of children will get one dose of intravenous placebo intraoperatively.
9982882|NCT05071833|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
9982883|NCT05071833|Experimental|Peppermint oil|50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
9982884|NCT05069922|Active Comparator|Fresh Frozen Plasma|At 6-8 hours, Initiate FFP infusion
9982885|NCT05069922|Active Comparator|Albumin|At 7 hours, Initiate 5% Albumin infusion
9982886|NCT05068908||Low-impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be low-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, quantitative sensory testing (QST) using a standard protocol, endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
9734958|NCT03774160|Experimental|Generacion Actual|Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.
9734959|NCT03774160|No Intervention|Comparison|No intervention is implemented in the comparison arm.
9734960|NCT03774134||CME group|The CME group consisted of patients, who underwent elective CME for sigmoid colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2014.
9734961|NCT03774134||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for sigmoid adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
9982887|NCT05068908||High- impact chronic painful temporomandibular disorder (TMD) cases|Participants whose chronic painful TMD is determined to be high-impact. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, quantitative sensory testing (QST) using a standard protocol, endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
10200628|NCT02760498|Experimental|Group 2|Patients with unresectable locally advanced CSCC. Cemiplimab administered IV Q2 weeks.
9734964|NCT03769090|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
9734965|NCT03769090|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
9734966|NCT03769090|Active Comparator|AS MDI (PT007) 90 µg|
9734967|NCT03763162|Experimental|Treatment (daratumumab, bortezomib, dexamethasone, ixazomib)|Patients receive daratumumab IV over 3.5-6.5 hours on days 1, 8, and 15, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV over 15 minutes on days 1, 8, and 15 and PO on days 2, 4, 5, 9, 11, 12, and 16. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive daratumumab IV over 3.5 hours on days 1 and 15 of cycles 4-7 and day 1 of subsequent cycles, ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO once weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10200629|NCT02760498|Experimental|Group 3|Patients with metastatic CSCC to distant sites or lymph nodes. Cemiplimab administered IV Q3 weeks.
10200630|NCT02760498|Experimental|Group 4|Patients with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] Cemplimab administered IV Q4 weeks.
9734970|NCT03762694|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|12 sessions acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization.
9734971|NCT03762694|No Intervention|Wait-list control|No treatment except routine care will be given at the first 6 weeks, followed by 12 sessions treatment as Acupuncture group.
9734972|NCT03754660|Experimental|Untreated patients (Part A and Part B)|"Part A: Untreated PAH and CTEPH patients will be enrolled to test 5 ascending doses of BAY1237592 with 4 patients per dose group up to a maximum dose of 4000 µg.~Part B: The highest safe, well tolerated and effective dose of Part A will be tested in further untreated patients."
9734973|NCT03754660|Experimental|Monotherapy (Part B)|The highest safe, well tolerated and effective dose chosen from Part A will be tested in pre-treated patients with any kind of monotherapy for PAH/CTEPH.
9734974|NCT03754660|Experimental|Combined therapy (Part B)|The highest safe, well tolerated and effective dose from Part A will be tested in pre-treated patients with any kind of double combination treatment for PAH/CTEPH.
9734975|NCT03752996|Experimental|ACURATE TF™ Aortic Valve System|ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .
9734976|NCT03752216|Experimental|NIRAPARIB|Oral Niraparib Daily
9734977|NCT03751124|Experimental|Relugolix plus E2/NETA|Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
9734978|NCT03751124|Placebo Comparator|Placebo tablets and capsules|"Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.~Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns."
10200631|NCT02760498|Experimental|Group 6|Patients with advanced CSCC (metastatic [nodal or distant] or locally advanced) who received cemiplimab IV Q3W for at least 27 weeks without experiencing disease progression, will have the option to receive cemiplimab by subcutaneous (SC) injection Q3W (first 12 patients) or Q6W (next ≥ 6 patients) basis.
10200632|NCT02742311|Active Comparator|transforaminal endoscopic discectomy|
10200633|NCT02742311|Active Comparator|interlaminar endoscopic discectomy|
10200634|NCT02732509||Lean|Body mass index less than 25 kg/m2
10200635|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
10200636|NCT02673151|Experimental|68Ga-PSMA-11 PET/CT|Patients receive 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11). Participant will be injected IV with 3 to 7 millicurie (mCi) of 68Ga-PSMA-11. Beginning 50 to 100 minutes later, a low-dose computed tomography (CT) scan will be obtained from vertex to mid thighs; followed by a static positron emission tomography (PET) scan over the same .
10200637|NCT02653092|Active Comparator|Aim 1|"Reproduction of the reproductive phenotype of obesity in Normal Weight Women (NWW) by:~infusing insulin and free fatty acids (FFAs) in short term experiments and measuring gonadotropin pulsatility and pituitary GnRH response; and~inducing a chronic model of the reprometabolic syndrome by administering a eucaloric diet that is relatively high in pro-inflammatory omega-6 fatty acids and low in anti-inflammatory omega-3 fatty acids (high fat diet; HFD) for one month while monitoring gonadotropin pulsatility and daily urinary reproductive hormone excretion."
10200638|NCT02653092|Experimental|Aim 2|Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production.
9982888|NCT05068908||Pain-free controls|Participants without chronic painful TMD. Visits include a standardized clinical examination using the Diagnostic Criteria for TMD (DC/TMD) protocol, psychosocial questionnaires completion, quantitative sensory testing (QST) using a standard protocol, endogenous pain modulation (EPM) testing and a multi-modal Magnetic Resonance Imaging (MRI) data acquisition.
9982889|NCT05068505|Experimental|Community health worker delivered multicomponent intervention|The study will employ a closed cohort stepped wedge cluster randomized design. There will be a sequential crossover of clusters from the control to the intervention arms and the order of the cross over will be randomly determined. This study will be conducted in 21 clusters within Nakaseke district. Each cluster will consist of 4-5 villages. We plan to rollout the intervention in two clusters per month and one cluster in the final month.
9982890|NCT05068505|No Intervention|Control|All clusters will be observed under both the intervention and control arm through sequential crossover.
9982891|NCT05067582|Placebo Comparator|Placebo Capsules|1 capsule twice daily
9982892|NCT05067582|Experimental|L1-79 200 mg or 300 mg Capsules|1 capsule twice daily
9982893|NCT05067439|Other|Period 1|In Period 1, all the participants will receive single doses of the probe drugs, including caffeine 100 mg, efavirenz 50 mg and omeprazole 10 mg, together on Day 1.
9982894|NCT05067439|Other|Period 2|In Period 2, participants will receive abrocitinib 200 mg once daily (QD) on Day 1-10, single dose of omeprazole on Day 2 and single dose of probe drugs together on Day 8.
9982895|NCT05067127|Experimental|Group 1: Pegcetacoplan administration|Subcutaneous infusion of 20mL (1080 mg), twice weekly (for adults or adolescents >50kg), and the three other weight-based doses either of 10mL (540mg), 12mL (648mg), or 15mL (810mg)
9982896|NCT05067127|Placebo Comparator|Group 2: Placebo administration|Subcutaneous infusion of either 10mL, 12mL, 15mL, or 20mL, twice weekly
9982897|NCT05066009|Experimental|Prescribed medication followed by drug holiday|Participants will complete the study assessments on a day when they take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they do not take the medication.
9734990|NCT03735095|Experimental|Treatment (porfimer sodium, EBUS, and photodynamic therapy)|Patients receive porfimer sodium IV over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes.
9982898|NCT05066009|Experimental|Drug holiday followed by prescribed medication|Participants will complete the study assessments on a day when they do not take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they take their medication as prescribed.
9982899|NCT05064319|Experimental|Group A - Gabapentin|
9982900|NCT05064319|Placebo Comparator|Group B - Placebo|
9982901|NCT05064241|Experimental|Virtual Advisory Board|Participants have access to a genetic counselor to answer their questions on accessing genetic medicine.
9734995|NCT03730454|Experimental|Group A. Transanastomotic Tube|Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.
9734996|NCT03730454|Experimental|Group B. No Transanastomotic Tube|Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.
9734997|NCT03722407|Experimental|Ruxolitinib|All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.
9982902|NCT05064241|No Intervention|Virtual Peer-to-Peer Discussion Board|Participants answer each others' questions on the topic of accessing genetic medicine.
9982903|NCT05064176|Experimental|Reconstructive lymphatic surgery|"The intervention treatment is reconstructive lymphatic surgery and consists of the application of lymphovenous anastomosis (LVA), lymph node transfer (LNT) or a combination of both. The choice of reconstructive technique(s) is determined by the surgeon and is based on the algorithm for reconstructive lymphatic surgery of lymphoedema.~Additionally, all patients receive usual care (i.e. maintenance decongestive lymphatic therapy)"
9982904|NCT05064176|Active Comparator|No surgery|All patients receive usual care (i.e. maintenance decongestive lymphatic therapy)
10200639|NCT02593175|Experimental|Treatment (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 30 minutes and paclitaxel IV over 30 minutes on days 1, 8, and 15. Patients also receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10200640|NCT02589600|Experimental|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
10200641|NCT02589600|Placebo Comparator|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
10200642|NCT02567578|Experimental|YH12852 0.1 mg|twice daily for 4 weeks
9735006|NCT03696160|Experimental|Biktarvy|"Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection.~Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018.~Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF).~Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food."
9735007|NCT03696160|Experimental|Symtuza|"Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.~Symtuza® received marketing authorisation valid throughout the EU in September 2017.~Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)~Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food."
9735008|NCT03691064||LUTATHERA|Treated per labeled LUTATHERA dosing regimen.
9982905|NCT05064137|Experimental|Curodont Repair® ( monomeric self - assembling peptide P11-4 )|Self assembling peptide P11-4 as Curodont Repair® can remineralize WSLs in a deeper manner than fluoride by guided enamel regeneration by forming a three-dimensional matrix within the subsurface body of an initial carious lesion to which calcium and phosphate ions found in natural saliva can bind and build de novo hydroxyapatite crystals.
10200643|NCT02567578|Experimental|YH12852 0.25 mg|twice daily for 4 weeks
10200644|NCT02567578|Experimental|YH12852 0.5 mg|twice daily for 4 weeks
10200645|NCT02567578|Placebo Comparator|Placebo|twice daily for 4 weeks
10200646|NCT02523274|Placebo Comparator|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
10200647|NCT02523274|Experimental|Resveratrol 500 mg/day + exercise|500 mg/day resveratrol taken orally in combination with exercise
9735015|NCT03685461|Other|Arm 1: Audible ECochG Response Off|Arm 1: Audible ECochG Response Off This condition is identical to the current standard-of-care for conventional CI surgery used worldwide. The surgeon will perform his or her electrode insertion without ECochG monitoring. Minute manipulations of the electrode are a normal part of conventional electrode insertion; manipulations such as redirecting the insertion vector or slowing down insertion speed will be made, as deemed necessary by the surgeon. A full electrode insertion will be performed, as appropriate. The ECochG responses will be recorded, but the surgeon will be blinded to this information during surgery.
9827935|NCT02473718|Experimental|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
10200648|NCT02523274|Experimental|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
10200649|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
10200650|NCT02467270|Experimental|Cohort A: Ponatinib 45 mg|Ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
10200651|NCT02467270|Experimental|Cohort B: Ponatinib 30 mg|Ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
10200652|NCT02467270|Experimental|Cohort C: Ponatinib 15 mg|Participants received ponatinib 15 mg orally once daily up to data cut-off: 31 May 2020 in each 28 day Cycle.
10200653|NCT02464553|Experimental|Group A|1x periradicular therapy in one intervertebral space, corresponding with pain radiating dermatome
10200654|NCT02464553|Experimental|Group B|2x periradicular therapy in two intervertebral spaces, the first corresponding with pain radiating dermatome the second according magnetic resonance visualization where stenosis is situated
10200655|NCT02452554|Experimental|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
10200656|NCT02449148|Experimental|Intermittent Calorie Restriction|2 days per week fasting with 25 % energy intake and 5 days per week at 100% energy intake
10200657|NCT02449148|Experimental|Continuous Calorie Restriction|daily energy intake of 80 %
10200658|NCT02449148|No Intervention|Healthy Nutrition|general advice on healthy nutrition
10200659|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
10200660|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
9735016|NCT03685461|Experimental|Arm 2: Audible ECochG Response On|This condition will have the audible ECochG response on and available to the surgeon. In this condition, the surgeon perform a conventional electrode insertion while listening to the running ECochG signal for drop in amplitude (suggesting impending trauma). If no drop is detected, insertion will proceed to the full electrode length according to the standard-of-care. If an ECochG amplitude drop is observed, the surgeon will place this observation in its clinical context and evaluate insertion parameters, (i.e., insertion vector, insertion speed, etc.), customary practice with conventional CI surgery, but here supplemented by the ECochG response. In the case of an ECochG amplitude drop that does not recover, the standard-of-care practice of achieving a full electrode insertion will be followed.
9982906|NCT05064137|Experimental|Clinpro white varnish® ( Tricalcium Phosphate Fluoride Varnish, 5% F- )|Tri-calcium phosphate can be hydrolyzed rapidly to form calcium hydroxyapatite (HAp). The processes of hydrolysis and formation of HAp are accelerated by the presence of NaF ions as in case of Clinpro white varnish®. Moreover, the HAp formed by such hydrolysis tends to have a greater uptake of fluoride than conventional HAp.
9982907|NCT05064137|Active Comparator|Voco-profluorid® fluoride varnish (5% sodium fluoride)|Fluoride varnish is the gold standard for treating WSLs.
9735019|NCT03656562|Experimental|Cohort 1 VAY736|multiple doses of VAY736, s.c.
9735020|NCT03656562|Placebo Comparator|Cohort 1 VAY736 Placebo|multiple doses of matching placebo s.c. until week 29. Multiple doses of VAY736, s.c from week 29 until week 53.
9735021|NCT03656562|Experimental|Cohort 2 CFZ533|multiple doses of CFZ533, i.v.
9735022|NCT03656562|Placebo Comparator|Cohort 2 CFZ533 Placebo|multiple doses of matching placebo i.v. until week 29. Multiple doses of CFZ533, i.v. from week 29 until week 53.
9982908|NCT05063097||CCU patients|All consecutive patients over 18 years admitted to the CCU.
9982909|NCT05063045|Experimental|smart-cloth|Participants receive smart-cloth assisted home nursing care
9982910|NCT05063045|No Intervention|routine care|This group receive routine care
9982911|NCT05062590|Experimental|Group Intervention|Experimental: Group 1 The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
9982912|NCT05062590|No Intervention|Group control|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations
9735028|NCT03646123|Experimental|Part A: A+AVD|Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
9735029|NCT03646123|Experimental|Part B: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
9735030|NCT03646123|Experimental|Part C: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
9735031|NCT03639623|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
9735032|NCT03636269|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
9735033|NCT03636269|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
9735034|NCT03629483|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
9735035|NCT03629483|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
9735036|NCT03622788|Experimental|Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)|"CONDITIONING REGIMEN: Patients receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.~TRANSPLANT: Patients undergo PBSCT IV over 30-60 minutes on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7."
9982913|NCT05059743|Experimental|[14C]-Larotinib|Patients will receive single dose of [14C]-Larotinib (Suspension, 350mg/100μCi).
9982914|NCT05058690|Experimental|Individuals who had a CCTA as part of their clinical care|Approximately 90 individuals who had a CCTA as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable;
9982915|NCT05058690|Experimental|Individuals who had a chest CT as part of their clinical care|Approximately 90 individuals who had a chest CT as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable.
9982916|NCT05057364|Experimental|Heart Smart Group|Receives Heart Smart Intervention
9735041|NCT03608631|Experimental|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
9982917|NCT05057026||Adult mental health support program|The investigators will evaluate the Impact of an Adult mental health support program on stigmatization and confidence of medical residents working with people with mental health concerns. The intervention will be delivered to approximately 30 residents from the University of Dalhousie family medicine residency program from the 2021-2022 academic year. The training will be delivered by resident groups. The first group will receive the PSP training October - November 2022. The second will receive the training November 2021 to February 2022. The third will take the training March to May 2022. Each group will include approximately 10 residents.
9982918|NCT05055986||CBCT Dicom files of patients|CBCT Dicom files of patients will be used for measurements of mandibular bone volume by open-source software.
9982919|NCT05055726|Experimental|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|"Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A., is assigned to the patients for radiation-induced oromucositis.~The patients take at home 15 ml (1 tablespoon) of concentrated or diluted (with water) mouthwash 2-3 times a day, but not more than 5 times a day, washing the mouth and throat for 20-30 seconds, according to the Investigator's indications and the local product's SmPC.~In Hungary, the therapy should started with diluted product (15 ml of water + 15 ml of concentrated solution). After that, gargling can be continued with 15 ml (1 tablespoon) of concentrated mouthwash, generally 2-3 times a day, but not more than 5 times a day.~In Poland, the solution is used 2 to 3 times daily; at a single time, it should be used approximately 15 ml of concentrated or diluted mouthwash with a small amount of water and wash the mouth and throat for 20 to 30 seconds."
9982920|NCT05053022|Experimental|Microneedling with Skinpen Precision System|"Skinpen precision system will be used in accordance with the instructions in the IFU on the treatment area. A numbing cream will be applied at least 20-30 minutes before the Skinpen Precision system treatment is done. The affected areas will be treated at depths of up to 2.50mm. Treatment depth will be recorded for each treatment at every visit.~Subjects will be dispensed with the Blue Lizard sunscreen and trained on proper use."
9982921|NCT05052528|Experimental|Dose level 1 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily and cyclophosphamide IV over 60 minutes daily on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
9982922|NCT05052528|Experimental|Dose level 2 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
9735054|NCT03595059|Experimental|Escalation 1a: ABBV-155|Participants will be administered ABBV-155 (various doses).
9735055|NCT03595059|Experimental|Escalation 1b: ABBV-155 + paclitaxel or docetaxel|Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel .
9735056|NCT03595059|Experimental|Expansion 2a: ABBV-155 in SCLC|Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).
9735057|NCT03595059|Experimental|Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer|Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.
9735058|NCT03595059|Experimental|Expansion 2b: ABBV-155 + docetaxel in NSCLC|Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.
9735059|NCT03588702|Experimental|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
9982923|NCT05052528|Experimental|Dose level 3 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -3 to -5 and cyclophosphamide IV over 60 minutes daily on day -5. Patients also receive CD19 CAR T cells IV on day 0.
9735061|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
9735062|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
9982924|NCT05052528|Experimental|Dose level 4 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on day -5. Patients also receive CD19 CAR T cells IV on day 0.
9735064|NCT03564938|Experimental|Regorafenib (Stivarga, BAY 73-4506)|Patients with metastatic colorectal cancer
9735065|NCT03563131|Active Comparator|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
9735066|NCT03563131|Active Comparator|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
9982925|NCT05052528|Experimental|Dose level 5 (fludarabine, cyclophosphamide, CD19 CAR T)|Patients receive fludarabine phosphate IV over 30 minutes daily on days -5 to -1 and cyclophosphamide IV over 60 minutes daily on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
9982926|NCT05052528|Experimental|Dose level 6 (rituximab, fludarabine, cyclophosphamide, CAR T)|Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -1, and cyclophosphamide IV over 60 minutes on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
9982927|NCT05051150|Active Comparator|epinephrine 0.03 mcg|
9735070|NCT03553810|Experimental|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
9735071|NCT03553810|Active Comparator|Controlled Arm|Valsartan 40mg once a day
9735072|NCT03539094|Experimental|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
9735073|NCT03539094|No Intervention|Western diet|The subjects randomized to this group will eat a standard western style diet.
9982928|NCT05051150|Active Comparator|epinephrine 0.05 mcg|
9982929|NCT05051150|Active Comparator|epinephrine 0.07 mcg|
9982930|NCT05045313|Experimental|The DDI of DBPR108 and Warfarin Sodium Tablets|Subjects will receive a single dose of Warfarin sodium 5 mg on Day 1, then take DBPR108 100 mg once-daily on Day 15 through Day 26 and a single dose of Warfarin sodium 5 mg on Day 19.
9982931|NCT05045313|Experimental|The DDI of DBPR108 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take DBPR108 100 mg once-daily on Day 6 through Day 15 and a single dose of Digoxin 0.25 mg on Day 10.
9982932|NCT05045313|Experimental|The DDI of DBPR108 and Probenecid Tablets|Subjects will receive a single dose of DBPR108 100 mg on Day 1, then take Probenecid 500 mg twice-daily on Day 5 through Day 9 and a single dose of DBPR108 100 mg on Day 7.
9982933|NCT05045157|Experimental|percutaneous A1 pulley release with corticosteroid injection|
9982934|NCT05045157|Active Comparator|corticosteroid injection alone|
9982935|NCT05044572|Experimental|Open chain kinetic exercises|
9982936|NCT05044572|Experimental|Forward head posture correction exercises|
9982937|NCT05044156||Case group|vaginal candidiasis
9982938|NCT05044156||Control group|healty women
10200661|NCT02427568|Placebo Comparator|Placebo with therapy|Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.
10200662|NCT02427568|Active Comparator|MDMA-assisted therapy (125 mg)|125 mg 3,4-methylenedioxymethamphetamine (MDMA) administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg MDMA.
10200663|NCT02359175|Active Comparator|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
9982939|NCT05041855|Experimental|Community based childhood obesity intervention|A novel family-inclusive childhood obesity treatment program consisting of 12 family group sessions delivered in English and Spanish by health educators at community recreation centers, followed by three group booster sessions occurring every 6 months.
10200664|NCT02359175|Active Comparator|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
10200665|NCT02332577|Experimental|Pristinamycin + Placebo|Pristinamycin: 500 mg tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days Amoxicillin Placebo: capsule, 2 capsules x 3 /day for 7 to 9 days.
10200666|NCT02332577|Active Comparator|Amoxicillin + Placebo|Amoxicillin: 500 mg capsule, 2 capsules x 3/day for 7 to 9 days Pristinamycin Placebo: tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days.
10200667|NCT02323698|Active Comparator|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine then AIH
10200668|NCT02323698|Active Comparator|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo then AIH
9835741|NCT02752958|Experimental|stannous fluoride|This was a non-comparative design study, all the participants applied dentifrice containing stannous fluoride for 1 timed minute, twice daily (morning and evening) for 24 weeks.
9735093|NCT03538093|Experimental|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
9735094|NCT03538093|Experimental|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
9735095|NCT03538093|Experimental|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
9982940|NCT05041855|Active Comparator|Primary care based childhood obesity intervention|A healthy lifestyle counseling intervention delivered by trained primary care providers and health educators at visits occurring every 3 months.
9982941|NCT05035225|Experimental|Specialty Pharmacy Patient|Patients who have been prescribed at least one selected specialty medication
9982942|NCT05035030|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 72 weeks.
9735100|NCT03531463|Active Comparator|Operative treatment|"Operative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles.~Rehabilitation with standardized physiotherapy guideline and self exercise protocol"
9735101|NCT03531463|No Intervention|Non-Operative treatment|Rehabilitation with standardized physiotherapy guideline and self exercise protocol
9735102|NCT03527264|Experimental|Cohort 1A|Nivolumab during Chemo/RT with whole pelvic RT
9735103|NCT03527264|Experimental|Cohort 1B|Nivolumab during Chemo/RT with extended field
9735104|NCT03527264|Experimental|Cohort 2|Chemoradiation followed by Nivolumab Maintenance
9735105|NCT03527264|Experimental|Cohort 3|Nivolumab during chemoradiation and then as maintenance
9735106|NCT03523897|Active Comparator|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
9735107|NCT03523897|Active Comparator|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
9735108|NCT03523351|Active Comparator|Standard of care|Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT).
9835742|NCT02753075|Experimental|Experimental Oral Rinse 1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
9735109|NCT03523351|Experimental|Selective radiation to ≤5 highest risk bone metastases|Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) &/or disease with posterior element involvement.
9982943|NCT05034432|Experimental|Intra-Op Prophylactic VT ablation|Subjects will get ablation procedure as needed if they were determined to be refractory to medical antiarrhythmic control should undergo catheter-based electrophysiology study and ablation on LVAD support
9982944|NCT05034432|Active Comparator|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
9982945|NCT05033652|No Intervention|Standard strategy|
9982946|NCT05033652|Experimental|Warning KD strategy|
9982947|NCT05032885|Experimental|A|48-72 hours after hospital admission, following the baseline assessment of the patient, they will begin to receive physiotherapy treatment with respiratory techniques and motor training, adapted at all times to the clinical situation of the patient, until hospital discharge. If the patient's clinical condition worsens, treatment will be temporarily suspended until the patient improves to allow resumption of treatment.
9735115|NCT03519308|Experimental|Arm A|
9735116|NCT03519308|Experimental|Arm B|
9982948|NCT05032885|No Intervention|B|48-72 hours after admission to the hospital, after the patient's baseline assessment, the patient will not receive physiotherapy and the usual referral to the Rehabilitation Service for physiotherapy treatment of hospitalized patients will be followed, if the patient's physician considers it necessary and requests it.
9982949|NCT05032872|Experimental|Social Exergame Treatment Group|The treatment group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the full version of the Go&Grow fitness app for 6 weeks.
9982950|NCT05032872|Active Comparator|Control Group|The control group will wear a Fitbit step counter for 8 weeks. In addition, participants will use the Go&Grow fitness app without the social features for 6 weeks.
9982951|NCT05032742|Experimental|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
9982952|NCT05032742|No Intervention|Standard of care|Caregiver participants will receive an informational brochure describing ways to support one's adolescent during detention and community reentry and any other usual care.
9982953|NCT05032703|Experimental|Arm ergometer|Children in group I will receive strength-endurance protocol of arm ergometer for 30 minutes in addition to the conventional physical therapy program for 30 minutes, per session, three times a week, for three consecutive months.
9982954|NCT05032703|Experimental|Trunk stabilization exercise|Children in group II will receive trunk stabilization exercises for 30 minutes in addition to the conventional physical therapy program for 30 minutes, per session, three times a week, for three consecutive months.
9982955|NCT05032508|Experimental|xylocaine|
9982956|NCT05032508|Placebo Comparator|Placebo|
9982957|NCT05031637|Experimental|treatment by night-time BP|titrate drug treatment in the evening against night home blood pressure monitoring (HBPM) SBP (aiming SBP of <120 mmHg; intervention group)
9982958|NCT05031637|Other|treatment by daytime BP|Usual care - titrate drug treatment in the morning against HBPM SBP (aiming SBP of <135 mmHg; control group)
9982959|NCT05030922|Experimental|Diet intervention|Follow up of both mother and offspring 20 years after allocation to an antiatherogenic diet during pregnancy.
9982960|NCT05030922|No Intervention|Control|Follow up of both mother and offspring 20 years after allocation to control group during pregnancy.
9982961|NCT05030194|Experimental|Order 1 - Oral Nicotine product - ZYN and Electronic Cigarettes|Participants will use each product for up to a 30 minute interval But will also be permitted to stop use before the end of the 30-minute ad lib use period
10200669|NCT02323698|Active Comparator|Caffeine/SHAM|Subjects with chronic, motor-incomplete SCI receive Caffeine then SHAM
9735132|NCT03483038|Experimental|Liposomal irinotecan with FOLFOX|Subjects will receive 8 cycles and each cycle is 14 days.
10200670|NCT02323659|Active Comparator|Methotrexate arm|Patients assigned to receive methotrexate
10200671|NCT02323659|Active Comparator|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
10200672|NCT02318277|Experimental|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
10200673|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
10200674|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
10200675|NCT02296801|Active Comparator|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
10200676|NCT02296801|Experimental|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
10200677|NCT02296801|Experimental|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
9735141|NCT03475342|Active Comparator|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
9735142|NCT03475342|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
9735143|NCT03473847|Experimental|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
9735144|NCT03473847|Experimental|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
9735145|NCT03473847|Experimental|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
9735146|NCT03473847|Experimental|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
9735147|NCT03473223|Experimental|CSL112|Apolipoprotein A-I [human]
9735148|NCT03473223|Placebo Comparator|Placebo|25% albumin solution diluted to 4.4%
9735149|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
9735150|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
9735151|NCT03467724|Active Comparator|Fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
9735152|NCT03467724|No Intervention|No fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
9735153|NCT03467516|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
9735154|NCT03449602|Experimental|Mini-thoraoscopy|The mini-thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 5.5 mm and a working channel diameter of 3.5 mm.
9735155|NCT03449602|Active Comparator|Conventional rigid thoracoscopy|The rigid thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 10 mm and channel internal diameter of 5 mm.
9735158|NCT03447314|Experimental|Part 1a: 50ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 50 nanogram (ng) intravenously (IV) on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3174998 24 milligram (mg) administered at 3-week intervals (Q3W) via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
9735159|NCT03447314|Experimental|Part 1a: 100ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
9735160|NCT03447314|Experimental|Part 1a: 150ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
9735161|NCT03447314|Experimental|Part 1a: 200ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
9735162|NCT03447314|Experimental|Part 1a: 250ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
9735163|NCT03447314|Experimental|Part 1b: 50ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
9735164|NCT03447314|Experimental|Part 1b: 100ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
9735165|NCT03447314|Experimental|Part 1b: 150ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
9735166|NCT03447314|Experimental|Part 1b: 200ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
9735167|NCT03447314|Experimental|Part 1b: 250ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
9735168|NCT03447314|Experimental|Part 1c: 50ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
9735169|NCT03447314|Experimental|Part 1c: 100ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
9735170|NCT03447314|Experimental|Part 1c: 150ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
9735171|NCT03447314|Experimental|Part 1c: 200ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
9735172|NCT03447314|Experimental|Part 1c: 250ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
9735173|NCT03447314|Experimental|Part 2a: GSK1795091 + 24 mg GSK3174998|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3174998 24 mg.
9735174|NCT03447314|Experimental|Part 2b: GSK1795091 + 80 mg GSK3359609|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3359609 80 mg.
9735175|NCT03447314|Experimental|Part 2c: GSK1795091 + 200 mg Pembrolizumab|Participants will be administered GSK1795091 at a dose identified in Part 1 along with pembrolizumab 200 mg.
10200678|NCT02296801|Experimental|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
10200679|NCT02296801|Other|Combined Groups B+D+C|Combined data
10200680|NCT02283853|Experimental|BG00012|Participants will receive the recommended dose of 240 mg orally, twice a day
10200681|NCT02283853|Active Comparator|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
9982962|NCT05030194|Experimental|Order 2 - Electronic Cigarettes and Oral Nicotine product|Participants will use each prodcut for up to 30 minutes but will also be permitted to stop use before the end of the 30-minute ad lib use period
9982963|NCT05030051|Experimental|SkinPen Precision System|This proof of concept study is being conducted over the course of 60 days followed by a 3-month post-treatment visit to assess the efficacy and tolerability of the Sponsor's SkinPen device when used to treat men and women with signs of aging on the dorsum of the hands. Overall assessment of clinical outcome and safety will be based on the evaluation of pre- and post-treatment photos comparing baseline to final visit. The subject's assessment of satisfaction will also be evaluated at Visit 3 and Visit 4. Finally, both the clinician's and subject's assessment will be characterized using a clinician assessment scale at the 3 month post-treatment visit.
9982964|NCT05028790|Other|Single vision contact lens|Subjects will wear a single vision soft contact lens during the study visit
9982965|NCT05028790|Other|Multifocal contact lens|Subjects will wear a multifocal soft contact lens during the study visit
9982966|NCT05027217||Standard ICU Arm (Main study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU prior to the COVID-19 surge in the country, who are invasively mechanically ventilated for more than 12 hours. We will include medical, surgical, trauma and neurological/neurosurgical patients who are COVID-19 negative.
9982967|NCT05027217||COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from patients admitted with a confirmed diagnosis of acute respiratory failure due to COVID-19 infection.
9982968|NCT05027217||Non-COVID19 ICU arm (COVID-19 sub-study)|We will retrospectively collect data from adults (≥18 years) admitted to a participating ICU who are invasively mechanically ventilated for more than 12 hours. We will include data from medical, surgical, trauma and neurological/neurosurgical patients who are not admitted for COVID-19.
10200682|NCT02192762|Experimental|Withdrawal regulation training|Withdrawal coping skills
10200683|NCT02192762|Active Comparator|Relaxation training|Relaxation skills instruction
10200684|NCT02183558|Experimental|OGTT by randomization|Women without risk factors for GDM are offered OGTT in gestational week 28
10200685|NCT02183558|Experimental|OGTT by indication|Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28
10200686|NCT02176668|Experimental|Cohort1-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
10200687|NCT02176668|Experimental|Cohort1-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal
10200688|NCT02176668|Experimental|Cohort1-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
9735194|NCT03422653|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
9735195|NCT03422653|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
10200689|NCT02176668|Experimental|Cohort1-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
10200690|NCT02176668|Experimental|Cohort2-YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
10200691|NCT02176668|Experimental|Cohort2-YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
9735196|NCT03419468|Experimental|1|iPad administration of Self Geriatric Assessment Measure (SGAM)
9735197|NCT03419468|Active Comparator|2|Paper survey administration of Self Geriatric Assessment Measure (SGAM)
9735198|NCT03418792|Experimental|Parotid-Sparing Head & Neck Radiation|Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head & neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
9982969|NCT05027087|Experimental|Treatment|Participants receive the blueberry gummy supplement
9982970|NCT05027087|Placebo Comparator|Placebo|Participant receive the placebo gummy supplement
9735201|NCT03410823|Experimental|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
9982971|NCT05026710|Experimental|Silicone (Coloplast Imajin Hydro) ureteral stent|
9982972|NCT05026710|Experimental|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).|
9982973|NCT05024305|Experimental|Dose Escalation Cohort|Four dose levels of TWP-102 injection will be tested by BOIN study design.
9982974|NCT05024305|Experimental|Dose Expansion Cohort|Once the effective doses have been determined, two expansion cohorts will be opened to evaluate the efficacy and safety in one or two tumors.
9735206|NCT03404388|Experimental|Experimental|Balance Training
9735207|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
9735208|NCT03400371||Controls|People without a lifetime history of seizures.
9982975|NCT05023135||Subjects with Thermal Burn Injury|An initial imaging with the DV-SSP would be completed at the Study Site within 72 hours of suffering a thermal burn injury.
9982976|NCT05020574|Experimental|Cohort A: Standard antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - Prescribed standard postoperative antibiotics to take for at least 7 days post-operatively
9982977|NCT05020574|No Intervention|Cohort B: No antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - No antibiotics post-operatively, unless patient develops clinical evidence of infection
9982978|NCT05018117|Experimental|Young (18-28 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
9982979|NCT05018117|Experimental|Old (60-85 years) participants - nicotine gum|6 mg nicotine gum, one time before fMRI measurements
9982980|NCT05018117|Placebo Comparator|Young (18-28 years) participants - placebo gum|placebo gum, one time before fMRI measurements
9982981|NCT05018117|Placebo Comparator|Old (60-85 years) participants - placebo gum|placebo gum, one time before fMRI measurements
9982982|NCT05016297|Experimental|baricitinib 4mg per day + HCQ 200mg twice a day|On the basis of the HCQ treatment before, patients in this group will be added on baricitinib 4mg once a day.
9982983|NCT05016297|Active Comparator|HCQ 200mg twice a day|Patients in this group will be given HCQ 200mg twice a day for 12 weeks. Patients who has no response to HCQ treatment alone at week 12 will be switched to baricitinib + HCQ group and added on baricitinib 4mg per day until the end of the study (week 24).
9982984|NCT05015439|Experimental|Cannabidiol|Participants will receive cannabidiol, starting at 100 mg twice daily, and increased to 200 mg twice daily by week 3. This arm will last six weeks.
9982985|NCT05015439|Placebo Comparator|Placebo|Participants will receive six weeks of placebo.
9982986|NCT05012826|Experimental|Osteopathic Manipulative Treatment (OMT)+ Physiotherapy (PT) Group|Participants in this group will receive OMT in addition to the same interventions of PT group for the same 2- month period. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
9982987|NCT05012826|Active Comparator|Physiotherapy Group (PT)|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 2 months. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council. the treatment provided will be registered on each participant's clinical notes and a summary of main interventions will be reported.
10200692|NCT02176668|Experimental|Cohort2-YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
10200693|NCT02176668|Experimental|Cohort2-YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
10200694|NCT02176668|Experimental|Cohort3-YH4808 OF 200|"(Partial cross over design)~7 days repeat administration of YH4808 Old Formulation 200mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before dinner~7 days repeat administration of YH4808 Old Formulation 200mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before bed"
10200695|NCT02176668|Experimental|Cohort3-YH4808 OF 400|"(Partial cross over design)~7 days repeat administration of YH4808 Old Formulation 400mg before bed, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before dinner~7 days repeat administration of YH4808 Old Formulation 400mg before dinner, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 400mg before bed"
10200696|NCT02143063|Active Comparator|standard care|standard care
10200697|NCT02143063|Active Comparator|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
9735227|NCT03374137||obinutuzumab|Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.
10200698|NCT02143063|Experimental|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
10200699|NCT02073097|Experimental|rituximab, combination chemotherapy, carfilzomib|"Participants receive (every 21 day cycle):~Rituximab IV over at least 90 minutes on day 2~Carfilzomib IV over 30 minutes on days 1, and 2~Cyclophosphamide IV over 30-60 minutes on day 3~Doxorubicin hydrochloride IV over 3-5 minutes on day 3~Vincristine sulfate IV over 1 minute on day 3~Prednisone PO on days 3-7 any time~Pegfilgrastim day 4~Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6~Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
9735230|NCT03367247|Experimental|Bolster|"Bolster provides participants with longitudinal nursing support across care settings,~A smartphone-based symptom management app,~A print and web-based symptom management toolkit,~Advance care planning to ensure that the patient receives care that is congruent with her informed preferences~BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks~Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
9735231|NCT03367247|Other|Enhanced Discharge Planning (EDP)|"Medication education,~Self-management strategies for symptoms,~Skills training,~A list of red flag symptoms and numbers for who to call"
9735239|NCT03361033||Medulloblastoma|Participants who are survivors of pediatric medulloblastoma and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
9735240|NCT03361033||Other Brain Tumors|Participants who are survivors of other pediatric brain tumors (excluding medulloblastoma and craniopharyngioma), who have not been treated with craniospinal irradiation (CSI), and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
9982988|NCT05012241||Czech patients with multiple sclerosis|Czech patients with multiple sclerosis will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test. Video of their performance will be obtained.
9982989|NCT05011123|Experimental|Group 1|1 injection of vYF vaccine at Day 1
9982990|NCT05011123|Active Comparator|Group 2|1 injection of Stamaril vaccine at Day 1
9982991|NCT05010759|Experimental|Ablation Arm|Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
9982992|NCT05009394|Active Comparator|Targeted Muscle Reinnervation (TMR)|In this surgical procedure, the residual peripheral nerve is transferred to an available muscle in the stump that has been deinnervated from its native nerve. The surgical procedure includes three core steps: preparation of the residual nerve; motor nerve identification from the targeted muscle; and coaptation. To prepare the residual nerve, the surgeon identifies the injured nerve that has developed a painful neuroma and cuts the nerve back to healthy fascicles. Next, the surgeon dissects the motor nerve to a nearby target and thereby denervates a native muscle. Lastly, the injured nerve where the neuroma was excised is transferred and coapted to the newly severed motor nerve stump innervating the targe muscle. The surgery time is approximately 2-3 hours and it takes place in the hospital. The patient can leave the hospital the same day.
9982993|NCT05009394|Active Comparator|Regenerative Peripheral Nerve Interface (RPNI)|The RPNI procedure involves construction of a residual peripheral nerve split into several nerve fascicles and implanted into free skeletal muscle grafts. The surgeon first identifies the injured nerve and excises the terminal neuroma. Then, this peripheral nerve is transected into several intraneural fascicles. Next, autologous muscle grafts are harvested from a healthy donor site and the transected nerve endings are placed in the middle part of each muscle graft, in parallel to the muscle fibres. The muscle graft is wrapped around the distal transected nerve ending and anchored by epimysial sutures, and an RPNI is created. This is repeated for each group of fascicles obtained from splitting a transected nerve. The surgery time is approximately 2-3 hours and it takes place in the hospital. The patient can leave the hospital the same day.
9982994|NCT05009394|Active Comparator|Standard neuroma treatment, neuroma transposition|The standard neuroma treatment, also called neuroma transposition, includes excision of the terminal neuroma and burying the nerve into an adjacent deep muscle. As in the TMR and RPNI procedure, the surgeon starts with finding the injured nerve and excises the terminal neuroma into healthy fascicles. Next, the surgeon identifies a deep nearby muscle which is away from joint motion and has limited output opportunities for the nerve. The nerve is then channelled inside to the deep muscle without applying any tension on it and secured by sutures. The surgery time is approximately 1-2 hours and it takes place in the hospital. The patient can leave the hospital the same day.
9982995|NCT05008341|Experimental|Solriamfetol|Participants will receive a single oral dose of solriamfetol 150 mg with 240 mL water at 0 hour on the morning of Day 1, 2 hours after completion of a light breakfast.
9982996|NCT05007847|Active Comparator|Active|Participants randomised to the active arm will be provided with an AW Series 4 on Day 0 for the duration of the study. They shall undergo an education and training session to ensure technical competency of heart rhythm recording and familiarity with the recommended recording schedule for the duration of the study. Participants will also be given the contact details for a dedicated email mailbox for the duration of the study through which they can submit remote transmissions of ECG data.
9982997|NCT05007847|No Intervention|Control|Participants in the control arm will be advised to continue with the standard of care and advised to contact their direct clinical team or primary care physician should they experience any symptoms of concern (palpitations, dizziness, collapse). They will be contacted by the study team at 6 and 12 months for clinical assessment (symptoms, hospitalisation data, further stroke events, mortality).
9982998|NCT05007561|Experimental|Naltrexone|50mg naltrexone HCL once daily for seven days by mouth
9982999|NCT05007561|Placebo Comparator|placebo|sugar pill once daily for seven days by mouth
9983000|NCT05003804|Experimental|STMC-103H Part A1|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
9735255|NCT03320330|Experimental|Treatment (pepinemab)|Patients receive pepinemab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
9983001|NCT05003804|Placebo Comparator|Placebo Part A1|Once daily dosing with one capsule of placebo mixed with milk, formula, or a milk product for 28 days
9983002|NCT05003804|Experimental|STMC-102H Part A2|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
9983003|NCT05003804|Placebo Comparator|Placebo Part A2|Once daily dosing with one capsule of placebo mixed with milk, formula or a milk product for 28 days
9983004|NCT05003804|Experimental|STMC-103H Part B|Once daily dosing with one capsule of STMC-103H mixed with breastmilk, formula or a milk product for 28 days
9983005|NCT05003804|Placebo Comparator|Placebo Part B|Once daily dosing with one capsule of placebo mixed with breastmilk, formula or a milk product for 28 days
9983006|NCT05003687|Experimental|Part A: Single Dose of Lu AG06474 or Placebo|Participants will receive single oral dose of Lu AG06474 or placebo.
9735277|NCT03288480|Other|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
9735284|NCT03275103|Experimental|Arm A: Single Step Dose Escalation for Cevostamab|Study drug will be administered intravenously on a 21-day cycle. The step-up dose will be given on Cycle 1 Day 1 and the target dose will be given on C1D8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
9735285|NCT03275103|Experimental|Arm B: Double Step Dose Escalation for Cevostamab|In Cycle 1, participants will receive 2 step-up doses and a target dose. The step-up dose will be given on Cycle 1 Day 1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
9735286|NCT03275103|Experimental|Arm C: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
9735287|NCT03275103|Experimental|Arm D: Double Step Dose Expansion for Cevostamab|The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
9735288|NCT03275103|Experimental|Arm E: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
9735289|NCT03275103|Experimental|Arm F: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
9735290|NCT03275103|Experimental|Arm G: Double Step Dose Expansion for Cevostamab|The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
9735291|NCT03275103|Experimental|Arm H: Triple Step Dose Escalation for Cevostamab|In Cycle 1, participants will receive 3 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 2-4, 8, and 9-11. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
9735292|NCT03275103|Experimental|Arm I: Triple Step Dose Expansion for Cevostamab|The triple step dose expansion stage of the study may use the dosing and assessment schedule from the triple step dose escalation arm in Cycle 1, based on data from Arm H.
9735293|NCT03275103|Experimental|Arm J: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
9735294|NCT03271151|Experimental|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
9735295|NCT03271151|Placebo Comparator|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
9983007|NCT05003687|Experimental|Part B: Repeated Dose of Lu AG06474 and Food Interaction|"Participants will receive a single oral dose of Lu AG06474 in each dosing period (Period 1, 2, and 3) in the following sequence:~Sequence B1: Fed - Fasting- Fasting~Sequence B2: Fasting- Fed - Fasting~Sequence B3: Fasting- Fasting - Fed"
9983008|NCT05003674|Experimental|Adults cochlear implant recipients receiving alternative stimulation strategy|ACE strategy, 8 maxima, alternative mode
9735298|NCT03265405|Active Comparator|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
9735299|NCT03265405|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
9735300|NCT03265405|No Intervention|Observation|The subjects with sarcoidosis who do not have any indication for immunosuppressive treatment will be observed and monitored. If any treatment requiring indication arises during the observed period, the subjects will be randomized to one of the above study groups
9983009|NCT05003674|Active Comparator|Adults cochlear implant recipients receiving Standard-of-Care stimulation strategy.|ACE strategy, 8 maxima, monopolar mode.
9983010|NCT05003622|Experimental|encorafenib|Encorafenib hard capsule will be orally self-administered. A fixed-flat dose of 300 mg (4 x 75 mg) Per Oral (PO) encorafenib will be administered once-daily (QD).
9983011|NCT05002738|Experimental|Overall Cohort|Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days
9983012|NCT05001724|Experimental|Cohort 1: KN046 plus Lenvatinib RP3D.|Experimental arm: Cohort 1: KN046 5mg/kg every 2 weeks + lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
9983013|NCT05001724|Experimental|Cohort 2: Lenvatinib RP3D|Cohort 2 lenvatinib RP3D every day until progressive disease or unacceptable toxicity.
9983014|NCT05001724|Active Comparator|Docetaxel|Active Comparator: docetaxel 75 mg/m² every 3 weeks until progressive disease or unacceptable toxicity.
9983015|NCT05001594|No Intervention|Usual care+ Sham device|"Each participant will go through the normal rehabilitation process that follows ACL reconstruction+ a sham device used in the same was as the intervention group.~The sham device will look the same, will gave the same pressure around the leg, but will not vibrate."
9983016|NCT05001594|Experimental|Usual care+ knee vibratory device|Each participant will go through the normal rehabilitation process that follows ACL reconstruction. Additionally, each participant will receive the active device that applies non-invasive vibrational stimulation to the leg for two months, and will be asked to wear it during ambulation for at least an hour per day.
9983017|NCT05001594|No Intervention|Normative data|"Healthy participants will go through one session of the full protocol (excluding blood tests):~Questionnaires (IKDC, TSK, GAD-7).~Biomechanical analysis during walking, stair ambulation, and hoping.~Quadriceps and Hamstring strength testing"
9983018|NCT04999735||Patients with FSHD|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
9983019|NCT04999735||Healthy controls|CHDR Monitoring Remotely (MORE) Withings Steel HR Withings Body+ scale Withings Blood Pressure Monitor
9983020|NCT04998110|Experimental|Supportive Care Intervention|The supportive care intervention arm will receive their usual ambulatory longitudinal nephrology care integrated with ambulatory supportive care through monthly supportive care visits over six months.
9983021|NCT04998110|No Intervention|Usual Care Control|The usual care control arm will be seen at the discretion of their nephrologist, or receive their usual dialysis if on dialysis.
9983022|NCT04997759|Experimental|Neostigmine group|This group will administered neostigmine for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
9735314|NCT03240536|Experimental|Intervention Group|Ordering physicians who have referred to a rheumatologist in the St. Joseph's rheumatology clinic randomized to the intervention group will receive a brief Choosing Wisely form (for education of guidelines) faxed with the referral notice. At one and two years all ordering physicians will receive by fax a three question survey.
9735315|NCT03240536|No Intervention|Control Group|Ordering physicians who have referred to rheumatologists in the control group will not receive the Choosing Wisely form. At one and two years all ordering physicians will receive by fax a three question survey.
9983023|NCT04997759|Experimental|Sugammadex group|This group will administered Sugammadex for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
9735317|NCT03234881|Active Comparator|MOVE! (virtual)|Weight management delivered as Treatment-as-Usual
9735318|NCT03234881|Experimental|MOVE!+gshCBT (virtual)|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
9827936|NCT02473718|No Intervention|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
9735321|NCT03228537|Experimental|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.~SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo EPP or PD. Patients who undergo EPP will then undergo RT.~MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
9983024|NCT04997694|Experimental|Active Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form, Temperature Comfort Perception Scale- The form was recorded in the Shivering Level Diagnosis Form Filling.Before anesthesia was given, heating was performed with the 3M Bair Hugger Model 775 Heating Unit, which has an active heating system, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
9983025|NCT04997694|Experimental|Pasive Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form ,Vital Signs Follow-up Form, Temperature Comfort Perception Scale. The form was recorded in the Shivering Level Diagnosis Form . Before anesthesia was given, heating was performed with a wool blanket, which is a passive heating method, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
9983026|NCT04997694|No Intervention|Control Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form , Temperature Comfort Perception Scale The form was recorded in the Shivering Level Diagnosis Form the participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form , Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
9983027|NCT04997161|Experimental|SZC arm with enhanced dietary advice|Participants will continue taking Sodium Zirconium Cyclosilicate (SZC), which can be titrated up or down to maintain S-K+ in the range 3.5-5.5 mmol/L; participants will also receive enhanced nutritional advice to consume fruit and vegetables. Advice will be provided by dietitians at study visits and by Noom app between visits.
9983028|NCT04997161|Other|SoC arm with standard dietary advice|SZC will be withdrawn and participants will receive SoC as per site practice, including dietary K+ restriction. Dietary advice will be given by dietitians at study visits and by Noom app between study visits.
9983029|NCT04997057|Other|Probiotics mixture|Daily supplementation with a mixture of probiotics for 12 weeks
9983030|NCT04996693|Other|Scanner 1|Imaging performed on scanner 1: Photon-Counting Detector CT
9983031|NCT04996693|Other|Scanner 2|Imaging performed on scanner 2: Energy-Integrating Detector CT (128-slice)
9983032|NCT04996693|Other|Scanner 3|Imaging performed on scanner 3: Energy-Integrating Detector CT (20-slice)
9983033|NCT04995484|Experimental|Belzutifan in participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single oral 80 mg dose of belzutifan.
9983034|NCT04995484|Experimental|Belzutifan in participants with normal hepatic function|Participants with normal hepatic function will receive a single oral 80 mg dose of belzutifan.
9983035|NCT04994600||EFA_1st_phase|Exploratory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of Charite intensive care units
9983036|NCT04994600||CFA_2nd_phase|Confirmatory factor analysis group. All staff members (physicians, specialist nurses, respiratory therapists) of collaborating intensive care units.
9983037|NCT04994522|Experimental|Belzutifan in Participants with ESRD|Participants with ESRD will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1), followed by a ≥7 day washout period. Participants receive another single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 2).
9983038|NCT04994522|Experimental|Belzutifan in Healthy Participants|Participants in the healthy matched control group will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1).
9983039|NCT04991948|Experimental|CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab|
9984651|NCT03874988|Experimental|Enhanced Self-Monitoring|Participants will be encouraged to self-monitor 4 specific behaviors daily: 1) measuring their food; 2) measuring their physical activity; 3) recording their food, drink, and physical activity; and 4) monitoring their weight. To achieve this aim, participants will attend a single group-based educational session at baseline during which they will be provided the self-monitoring equipment (scale and Garmin vivofit) and receive training about how to use the Lilypad scale and smartphone food tracking app.
9984652|NCT03874988|Experimental|GLB-SCI|The content and delivery format of the developed GLB SCI lifestyle intervention program is subject to change based on guidance of the SCI Consumer Group. Therefore, this section provides a general description of the GLB AIM (lifestyle intervention program adapted for impaired mobility). The content of the GLB AIM core meetings include a mix of in-person (4) and telephone (9) sessions. The initial meeting is conducted in person, with one in-person sessions delivered each month, and the intervening weeks delivered by telephone. To achieve weight loss, participants will be encouraged to follow daily calorie and fat gram goals to achieve a .5 to 1 pound weight loss over the 13 weeks. Participants will also be encouraged to gradually increase their physical activity to ultimately achieve 150 weekly minutes.
9735355|NCT03175744|Experimental|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
9735356|NCT03175744|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
9984653|NCT03874988|Experimental|GLB-SCI+|The final multicomponent GLB SCI+ will include combining specific intervention strategies identified from the previous 3 interventions as effective and usable. If all 3 strategies yield evidence in support of being included, the combined intervention would encompass (1) providing prepackaged foods for a specified period of time to facilitate greater initial weight loss, (2) encouraging enhanced self-monitoring of food, physical activity, and weight using devices and apps along with social support, and (3) delivering the further adapted GLB SCI in a group-based format to teach skills helpful in making lifestyle changes.
10200700|NCT02017964|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on days 1, 15, and 29; cyclophosphamide IV over 1 hour on days 1-3; methotrexate IV over 24 hours on days 15 and 29; etoposide IV over 60-120 minutes on days 43-45; and carboplatin IV over 1 hour on days 43-45. Treatment repeats every 63 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CONTINUATION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on day 1, cyclophosphamide IV over 1 hour on days 1-3, etoposide IV over 60-120 minutes on days 21-23, and carboplatin IV over 1 hour on days 21-23. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity."
10200701|NCT01968785|Active Comparator|Radiation dose 25 Gy|• 25 Gy: Subjects will be treated with beta radiation dosage of 25 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
10200702|NCT01968785|Active Comparator|Radiation dose 50 Gy|• 50 Gy: Subjects will be treated with beta radiation dosage of 50 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
9735360|NCT03172897|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
9735361|NCT03172897|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
10200703|NCT01956110|Experimental|A|Follitropin Delta (FE 999049)
10200704|NCT01956110|Active Comparator|B|Follitropin Alfa (GONAL-F)
10200705|NCT01777802||Prostate Cancer|Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy
10200706|NCT01777802||Breast Cancer|Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy
10200707|NCT01777802||Lung Cancer|Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy
10200708|NCT01777802||Melanoma Cancer|Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy
10200709|NCT01648023|Experimental|Randomization to LC OR ONCOZENE Bead with Gem-Cis or Gem-Carbo|Transarterial Chemoembolization (LC or ONCOZENE Bead) with Gem-Cis or Gem-Carbo
10200710|NCT01648023|Active Comparator|Randomization to Gem-Cis or Gem-Carbo|Gem-Cis or Gem-Carbo alone
9735369|NCT03141177|Experimental|Doublet|Nivolumab and Cabozantinib
9735370|NCT03141177|Active Comparator|Monotherapy|Sunitinib
9735371|NCT03141177|Experimental|Triplet|"Nivolumab, Ipilimumab, Cabozantinib~*Enrollment to the triplet arm was discontinued by protocol amendment"
9735372|NCT03117049|Experimental|ONO-4538 group|"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
9735373|NCT03117049|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
9735377|NCT03102723|Experimental|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
9735378|NCT03102723|Placebo Comparator|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
9983040|NCT04990817|Experimental|Average American Diet With SoFAS Replaced With Avocado|Average American diet with foods that provide the equivalent of 1 medium to large avocado per day. It is anticipated that energy from avocado would replace 12-15% of daily energy, roughly half from solid fats and half from added sugars (SoFAS).
9983041|NCT04990817|Placebo Comparator|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
9983042|NCT04990778|Experimental|Treatment (eprenetapopt, venetoclax)|Patients receive eprenetapopt IV over 6 hours on days 1-4 and venetoclax PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9983043|NCT04990479|Experimental|Cohort 1a|Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.
9735383|NCT03097575|Experimental|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
9735384|NCT03095742|Placebo Comparator|Low MAP|Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
9735385|NCT03095742|Active Comparator|High MAP|High mean arterial pressure. 30 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
9735386|NCT03094026|Experimental|Intervention|The arm will begin the Lumosity program at enrollment in the study.
9735387|NCT03094026|Active Comparator|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
9983044|NCT04990479|Experimental|Cohort 2a|Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.
9983045|NCT04990479|Experimental|Cohort 2b|Cohort 2b: 12 patients with stage IV NSCLC (PDL1≥ 50%).
9983046|NCT04989075|No Intervention|Control group|The control group will continue its usual oral hygiene practice.
9735394|NCT03080896|Active Comparator|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
9735395|NCT03080896|Experimental|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
9835743|NCT02753075|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
9735398|NCT03075696|Experimental|Part I: Dose Escalation|Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
9735399|NCT03075696|Experimental|Part II: Dose Escalation|"In each treatment regimen, participants will receive obinituzumab (Gpt) 1000 milligrams (mg) IV infusion on Day -7 (pre-treatment); or 2000 mg either administered on Day -7, or split into two 1000 mg doses on Days -1 and -7. The first glofitamab IV infusion will be given on Day 1 of Cycle 1 and a total of 12 cycles will be administered.~Monotherapy, glofitamab as a single agent: ascending doses of glofitamab administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with ascending doses of glofitamab on Day 1 of every 3 week cycle until either the MTD/OBD is defined.~Step-up dosing: Q3W, participants will receive an initial low dose of glofitamab on C1D1, followed by a higher dose on C1D8; the total dose in C1 will not exceed the previously determined MTD. Higher doses may be explored from C2 or later cycles."
9735400|NCT03075696|Experimental|Part III: Dose Expansion|"Part III will start once MTD/OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment), followed by glofitamab at a fixed dose regimen or step-up dose regimen on a Q2W or Q3W dosing schedule as determined in Part II. A total of 12 cycles will be administered.~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with glofitamab at the dosing regimen determined in Part II."
9735401|NCT03066050||SMR MV Repair|This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
9735402|NCT03066050||MV Replacement|This group of patients had been randomized in the SMR study to mitral valve replacement.
9735403|NCT03066050||MMR MV Repair|This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
9735404|NCT03066050||CABG|This group of patients had been randomized in the MMR study to receive CABG
9983047|NCT04989075|Experimental|Oral prophylactic intervention|For the study group, the oral prophylactic intervention will consist of provision of specfic package including soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
9983048|NCT04987957|Experimental|Experimental group|"4 music genres with expert opinion will be presented to the preference of the participants in the intervention group, these types of music; Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music. The music is instrumental, 70 decibels and non-verbal. Participants will listen to a genre they choose and download to their mobile phones once for 5 days for 15 minutes. They will listen to the music in the environment they live in, at a time convenient for them, at the desired volume level and with headphones in accordance with the determined therapy program.~At the beginning of the research, an Introductory Questionnaire will be applied to all participants. Trait Anxiety Inventory will be administered before music therapy on the 1st day of the study and after the music therapy application on the 5th day."
9983049|NCT04987957|No Intervention|Control group|No application will be made to the participants in the control group, and the data collection tools will be applied with the same frequency as in the intervention group.
9983050|NCT04987762|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily in the morning
9735413|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
9735414|NCT03056872||AnxD+AUD-Cognitive Behavioral Therapy (CBT)|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
9735415|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
9735416|NCT03056872||Healthy Controls|Community sample
9835744|NCT02753075|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
9735424|NCT03046121|Experimental|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
9735425|NCT03046121|No Intervention|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
9983051|NCT04987164||Feminabiane CBU Consumers|Group of consumers of Feminabiane CBU : 2 tablets of Feminabiane CBU® every day, to be swallowed with a glass of water.
9983052|NCT04987164||Control group|Control group of non consumers of Feminabiane CBU
9983053|NCT04986358|Other|Patient cohorte|Cohort of patients who will benefit from surgical management of their Hallux Valgus with post-operative follow-up at 2 years
9735429|NCT03035890|Experimental|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
9983054|NCT04986046|Active Comparator|Fruit and vegetable prescription|Fruit and vegetable incentive program
9983055|NCT04986046|Experimental|Fruit and vegetable prescription + Home Plate Lite|Fruit and vegetable incentive program + asynchronous, electronic resources delivered over six weeks
9983056|NCT04986046|Experimental|Fruit and vegetable prescription + Virtual Home Plate|Fruit and vegetable incentive program + 45-minute, virtual, small-group classes twice weekly for six weeks
9983057|NCT04983394|Experimental|Virtual Realty|Participants will play a motion-controlled video game with Microsoft XBox One Kinect for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance exercises
9983058|NCT04983394|Active Comparator|Conventional|Participants will do aerobic exercises for 30 minutes, three days a week, for 8 weeks and lower and upper extremity stretching, strengthening and endurance
9983059|NCT04981158|Placebo Comparator|control group, group I|standard general anesthetic (GA) technique
9735437|NCT03023813|Experimental|Intervention|Individualized preventive care recommendations will be distributed to subjects.
9735438|NCT03023813|No Intervention|Control|Usual care
9735439|NCT03023813|Experimental|Development Phase|Non-randomized receipt of individualized preventive care recommendations
9983060|NCT04981158|Active Comparator|Epidural /GA using TET group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using tolerable endotracheal tube (TET)
9983061|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - telemedicine self exam before face-to-face evaluation|First care will be performed via telemedicine with a clinical physician, guiding self-examination guided by telemedicine. After the remote consultation, a face-to-face evaluation will be performed with an orthopedist, according to institutional protocol.
10200711|NCT01561651|Experimental|Left Atrial Appendage Occlusion Group|Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.
10200712|NCT01561651|No Intervention|No Left Atrial Appendage Occlusion Group|Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.
9735444|NCT03018080|Experimental|Cohort A|Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. Starting with cycle 3 and subsequent cycles, pembrolizumab will be given as an IV infusion over 30 minutes before paclitaxel on day 1 every 21 (+/- 3) days.
9735445|NCT03018080|Experimental|Cohort B|Pembrolizumab will be given as an IV infusion on day 1 before paclitaxel every 21 (+/- 3) days. Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days.
9735446|NCT03012984|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
9735447|NCT03012984|Placebo Comparator|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
9735448|NCT03009890|Experimental|Open reduction internal fixation|Surgical open reduction internal fixation (ORIF)
9735449|NCT03009890|Active Comparator|Plaster immobilization|Standard local hospital protocol for cast treatment
10200713|NCT01460264||exposed|current daily smokers 100 cigarettes or more during lifetime
10200714|NCT01460264||unexposed|current non-smokers
10200715|NCT01443637||Coronary CT Angiography (CCTA)|Patients included in the CONFIRM Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
10200716|NCT01404754|Placebo Comparator|Lactose (Inactive Placebo)|Participant receives inactive placebo during day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
10200717|NCT01404754|Active Comparator|3,4-methylenedioxymethamphetamine|Participant receives 125 mg MDMA possibly followed by 62.5 mg MDMA during a day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
10200718|NCT01335581|Experimental|Laser treatment|Laser treatment and microdermabrasion and topical lightening agent regimen
10200719|NCT01335581|Active Comparator|Control|Microdermabrasion and topical lightening agent regimen
10200720|NCT01209923|Experimental|Body composition testing|Body composition tested using bioelectrical impedance (BC1) and the DEXA or hydrostatic weighing methods.
10200721|NCT01083433|No Intervention|Standard Diabetes Care|Patients will attend diabetes clinic as usual, once every 3 months.
10200722|NCT01083433|Experimental|Intensive Diabetes Clinic|Patients will attend diabetes clinic on a monthly basis for 4 months in a row. Each patient will have a 30 minute visit with a physician, 30 minutes dedicated to diabetes education, and 45 minutes with a child psychologist.
10200723|NCT01083433|Experimental|Intensive Diabetes Clinic plus CGM|Patients in this group will include all procedures as listed for group 2 (intensive diabetes clinic) in addition to wearing a continuous glucose monitor for 3-5 days each month. Patients will also have an additional 30 minutes with a psychology graduate student dedicated to adherence with the CGM.
10200724|NCT01063751|Other|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell
10200725|NCT00882895|Experimental|Allogeneic Transplant|"TLI - 80 cGy on days -14, -11, -10, -9, -8, -7, -4, -3, -2, -1~Anti-thymocyte globulin (ATG) 1.5 mg/kg on days -11, -10, -8, -7~Solumedrol - 1 mg/kg on days -11, -10, -9, -8, -7~Tacrolimus - beginning on day -3 with starting dose of 0.3 mg/kg PO BID. Will be continued per institutional guidelines.~Stem cell infusion - day 0~Mycophenolate mofetil (MMF) - beginning on day 0 with dose of 15 mg/kg PO (5-10 hours after transplant)"
10200726|NCT00867178|Experimental|Treatment (vorinostat, isotretinoin, chemotherapy)|See Detailed Description
10200727|NCT00787176|Active Comparator|Group A|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient is positioned for epidural placement. Oxytocin management continued as per protocol.
10200728|NCT00787176|Experimental|Group B|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
10200729|NCT00787176|Active Comparator|Group C|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
10200730|NCT00787176|Experimental|Group D|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
9983062|NCT04981002|Active Comparator|Adult patients with orthopedic complaints - only face-to-face evaluation|Face-to-face care with an orthopedist, according to institutional protocol.
9735453|NCT02993822|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
9735454|NCT02993822|Experimental|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
9735455|NCT02993822|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
9735456|NCT02993822|Placebo Comparator|Placebo|Placebo to match tablet, once daily for 12 weeks
9983063|NCT04980976|Active Comparator|Conventional blind insertion technique.|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
9983064|NCT04980976|Experimental|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique to advance into esophagus under direct vision.
9983065|NCT04978324|Experimental|Autogenous Growth Factors Left Side|5-8mm pockets on the left side of the mouth will receive insertion of small treatment after deep cleaning. The right side of the mouth will receive deep cleaning only, the standard of care.
9983066|NCT04978324|Experimental|Autogenous Growth Factors Right Side|5-8mm pockets on the right side of the mouth will receive insertion of small treatment after deep cleaning. The left side of the mouth will receive deep cleaning only, the standard of care.
9983067|NCT04977349|Experimental|Wind Musicians|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assesment. And the manual therapy from the Active Comparator group.
9983068|NCT04977349|Active Comparator|Wind musicians|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, Sternocleidomastoid (ECOM), masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
9983069|NCT04977180|Experimental|Treatment arm (beta blocker and ACE inhibitor)|Participants will receive a beta blocker (either metoprolol or carvedilol) and an ACE inhibitor (lisinopril) at standard doses based on tolerance starting from when they start induction therapy for AML through 90 days after the first day of the last cycle of therapy that includes an anthracycline (whether that is in the induction, re-induction, or consolidation phase of treatment). They will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
9983070|NCT04977180|No Intervention|Standard Clinical Care|Participants will receive standard clinical care, but will also undergo regular assessments via ECG/EKG and echocardiogram, and to measure troponin levels
9735473|NCT02972840|Experimental|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
9735474|NCT02972840|Placebo Comparator|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
9735477|NCT02957019|Experimental|L19-IL2 + RTX|"Phase I (Dose definition):~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.~Phase II (Activity Evaluation):~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
9781453|NCT01149343|Experimental|GSK2302025A Cohort 2|Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
9735478|NCT02951338|Active Comparator|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
9735479|NCT02951338|Experimental|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
9735480|NCT02948660|Other|acute consciousness disorders group|"Duration time of coma <= 3 weeks.~This group will receive sleep EEG monitoring,EEG-reactivity test, serum melatonin and orexin level testing, and Zolpidem Tartrate Tablets or melatonin treatment."
9735481|NCT02948660|Other|prolonged disorders of consciousness group|"age ≥ 18 years;~presence of UWS or MCS on admission;~time since onset > 4 weeks;~no history of neurodegenerative or psychiatric diseases.~This group will receive EEG-reactivity test, zolpidem tartrate tablets treatment."
9735482|NCT02942355|Experimental|Cohort A: First-line therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
9735483|NCT02942355|Experimental|Cohort B: Maintenance therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
9983071|NCT04974567||Women recently diagnosed with breast cancer who have not undergone any treatment.|Tear sample collection
9983072|NCT04972110|Experimental|Phase Ib Dose Escalation|Multiple dose levels of RP-3500 for oral administration in combination with Niraparib and/or Multiple dose levels of RP-3500 for oral administration in combination with Olaparib
9735486|NCT02938793|Experimental|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.
9735487|NCT02938416|Experimental|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
9735488|NCT02938416|Active Comparator|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
9983073|NCT04972110|Experimental|Phase 2 Expansion Cohorts|Expansion cohort with RP-3500 + Niraparib and/or Expansion cohort RP-3500 + Olaparib
9983074|NCT04970914|Experimental|Anlotinib+Penpulimab|
9983075|NCT04969471|Experimental|Thrombectomy Arm|enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot
9983076|NCT04969471|Experimental|Conventional Treatment Arm|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
9735491|NCT02931058|Active Comparator|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
9735492|NCT02931058|Active Comparator|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
9735493|NCT02931058|Active Comparator|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
9983077|NCT04968808|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after percutaneous coronary intervention (PCI) for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
10200731|NCT00352534|Experimental|Nephrectomy and re-evaluation (very low-risk disease)|Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.
10200732|NCT00352534|Experimental|Nephrectomy, chemotherapy (standard-risk, stg I or II)|Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.
10200733|NCT00352534|Experimental|Nephrectomy/biopsy, chemotherapy (standard-risk, stage III)|Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.
9735498|NCT02924441|Experimental|Right Breast Lidocaine and calming music|Group 1 - right breast lidocaine & calming music
9735499|NCT02924441|Experimental|Right Breast Lidocaine and no music|Group 2 - right breast lidocaine & no calming music
9735500|NCT02924441|Experimental|Left Breast Lidocaine and calming music|Group 3 - left breast lidocaine & calming music
9735501|NCT02924441|Experimental|Left Breast Lidocaine and no music|Group 4 - left breast lidocaine & no calming music
10200734|NCT00033293|Experimental|Arm I (chemotherapy, immunoglobulin therapy)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hr on day 0. Treatment repeats every 4 wks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 mths and then every other day for 7-15 mths.~Patients receive therapeutic immune globulin IV on days -2 and -1, at wks 4, 8, 12, 16, 20, and 24, and then at mths 8, 10, and 12 after therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with no response after 6 months go off treatment. In case of progression of opsoclonus-myoclonus-ataxia (OMA) during evaluation, patient will be switched to another steroid, corticotropin-releasing hormone (ACTH)."
10200735|NCT00033293|Active Comparator|Arm II (chemotherapy, observation)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.~Patients do not receive therapeutic immune globulin. Patients with unresponsive opsoclonus-myoclonus-ataxia syndrome after 2 months or progression after 6 months may cross over to arm I."
10200736|NCT05193435|Experimental|Pelvic floor exercise group|Pelvic floor exercises for muscle fiber types I and II will performed 3 days a week for 8 weeks
10200737|NCT05193435|Active Comparator|Stabilization exercise group|Lumbar spinal stabilization exercises will performed 3 days a week for 8 weeks
10200738|NCT05193422|Active Comparator|Phase I: No mask|"Participants, without wearing a face mask, will undergo the following:~Measurement of peak nasal inspiratory flow~Cardiopulmonary exercise testing (CPET) with an ergometric bike at 30% of their predicted maximum workload (Wmax) for 4 minutes, 50% of Wmax for 2 minutes and 70% of Wmax for 1 minute, with continuous oxygen saturation (SpΟ2), heart rate (HR), end-tidal CO2 (EtCO2) and respiratory rate (RR) monitoring.~Spirometry and measurement of nPIF immediately after CPET.~Discomfort assessment using a special scale"
10200739|NCT05193422|Experimental|Phase II: Face mask|"Following nPIF measurement, participants will be asked to wear a standard surgical face mask. A temperature and humidity sensor will also be placed inside the mask. Will follow:~Resting phase, 6 minutes. SpO2, HR, EtCO2 and RR will be monitored.~CPET at 30% of Wmax for 4 minutes, 50% Wmax for 2 minutes and 70% Wmax for 1 minute. SpO2, HR, EtCO2 and RR will be continuously monitored.~Spirometry and measurement of nPIF immediately after CPET.~Discomfort assessment."
10200740|NCT05193383|Experimental|Imaginal exposure|Exposure to mental imagery including a fearful stimulus (spider) and corresponding scenes including a neutral stimulus (leaf)
9735502|NCT02924324|Active Comparator|Propofol First, then Propofol & Ropivacaine|1st Bone Marrow procedure (BM) Intervention A: propofol first. Then second BM procedure with propofol & ropivacaine
9735503|NCT02924324|Experimental|Propofol and Ropivacaine First, then Propofol|1st BM procedure: Intervention B: propofol & ropivacaine first. Then second BM procedure with propofol
9735504|NCT02914171|Experimental|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
9735505|NCT02914171|Other|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
9983078|NCT04968808|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after percutaneous coronary intervention (PCI) for IRA (during index PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
9735511|NCT02907398||ADHERE|This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
9735512|NCT02907398||CONTROL|This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
9735513|NCT02901041|Experimental|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
9735514|NCT02901041|Active Comparator|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
9735515|NCT02890485|Experimental|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
9735516|NCT02890485|Experimental|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
9735517|NCT02890485|Sham Comparator|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
9735518|NCT02890485|Sham Comparator|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
9735519|NCT02890485|Active Comparator|Control|Receives only standard physical therapy treatment.
10200741|NCT05193383|Experimental|In vivo exposure|Exposure to video clips including a fearful stimulus (spider) and corresponding clips including a neutral stimulus (leaf)
10200742|NCT05193370|Experimental|angiotensin II (intervention)|For patients randomized to the intervention group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, angiotensin II will be started at a dose of 20 ng/kg/min (recommended starting dose in package insert). Thereafter, angiotensin II and norepinephrine will both be titrated according to the schema in UNM Hospitals Nursing Department Titration Guideline. Angiotensin II treatment will be capped at 72h, at which point (if a second vasopressor is still needed) the patient will be started on an alternative agent.
10200743|NCT05193370|Active Comparator|vasopressin (standard of care)|In patients randomized to the control group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, vasopressin will be used at a fixed dose of 0.04 units/min and norepinephrine will be titrated per usual standard of care (as also outlined in the UNM Hospitals Nursing Department Titration Guideline).
10200744|NCT05193357|Experimental|home-based IPC device|Participants used a device produced by Maxstar Corp. (Gimpo, South Korea), which specializes in pneumatic compression appliance manufacture. The IPC device (UAM-9306NB) was cleared by National Institute of Medical Device Safety Information (NIDS) of Korea (approval number: 18-4745). This device consists of a six-chamber pneumatic sleeve and a gradient-sequential pneumatic pump.
10200745|NCT05193344|Experimental|Digital solution group|Participants will be instructed to download a remote symptom monitoring and lifestyle-changing mobile application to which they will have access for 12 months. The program aims to provide remote symptom monitoring by having participants enter data (on diet, exercise, weight, etc) and answer questionnaires via the SidekickHealth platform, and to empower positive lifestyle changes. Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm.
10200746|NCT05193344|Active Comparator|Standard of care - control group|All participants in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF. After the baseline measurements and data collection, there will be scheduled visits to a health care provider at 3, 6, and 12 months.
10205106|NCT03979040|Experimental|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
10205107|NCT03979040|Active Comparator|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant?s principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and MDD (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
10205108|NCT03975621|Experimental|Immediate Intervention|The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months. Patients will receive the tablet, a pedometer and an exercise band. Patients will use Nurse AMIE while receiving weekly phone calls from a patient navigator. After 90 days of the intervention observation will take place for 90 days, the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
10205109|NCT03975621|Experimental|Delayed Intervention|The delayed intervention group will receive the intervention 3 months after consent (6 months of intervention with 3 months delay total of 9 months); the patient will then follow the same pattern as listed above. The only difference is we will ask the delayed intervention group to wear a FitBit device for 1 week following consent in order to gain baseline data as to their activity/movement.
10205110|NCT03970252|Experimental|Treatment (nivolumab, mFOLFIRINOX)|Patients receive nivolumab IV over 60 minutes on day 1. Patients also receive fluorouracil IV over 10 minutes and over 46 hours, irinotecan hydrochloride IV over 90-120 minutes, leucovorin calcium IV over 120 minutes, and oxaliplatin IV over 120 minutes on days 1 and 15. Treatments repeat every 28 days for 3-6 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients with resectable disease undergo surgery. Within 8-12 weeks after surgery, patients with successful resection may receive 6 additional cycles of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin in the absence of disease progression or unacceptable toxicity.
10205111|NCT03970200|Active Comparator|No investigational product|Participants who receive the antibiotics usually prescribed for C diff infection.
9983079|NCT04968522|Placebo Comparator|Placebo comparator 2|Participants will be allocated a randomly allocated sequence of treatment. The randomisation will be in two-week pairs - so the order of treatment (A) and placebo (P) to be randomly assigned within each two-week cycle (over 8 weeks). Placebo will be matched in dose to their stimulant dose at enrolment to the trial as determined and titrated by their primary paediatrician. This dose will remain constant for the course of the trial (8 weeks). Placebo will be orally administered, unless this is not possible for clinical reasons.
10200747|NCT05193318|Experimental|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
10200748|NCT05193292|Experimental|Camrelizumab combined with trastuzumab and chemotherapy|Camrelizumab: 200mg, iv, 21d for a treatment cycle Trastuzumab: 8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle Chemotherapy will either be XELOX, mFOLFOX6, FOLFIRI, mXELIRI or mIRIS
9735523|NCT02880891|Experimental|splinted|splinted crown
9735524|NCT02880891|No Intervention|non-splinted|single crown
9781454|NCT01149343|Experimental|GSK2302025A Cohort 3|Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
10200749|NCT05193227|Experimental|Treatment (ST-01)|Peri-neural injection and incisional deposition of ST-01
10200750|NCT05193227|Active Comparator|Control (Standard of Care)|Incisional deposition of Lidocaine HCl Injection USP Xylocaine® or Bupivacaine HCl Injection USP Marcaine®
10200751|NCT05193214|Experimental|609A UPS|The 609A single-drug regimen (200mg Q3W) was used to treat unresectable or advanced undifferentiated pleomorphic sarcoma to evaluate the safety and effectiveness of 609A.
10200752|NCT05193201|Experimental|Cohort 1 : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
10200753|NCT05193201|Experimental|Cohort 2 : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.|The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.
10200754|NCT05193188|Experimental|Anlotinib combined with PD-1 monoclonal antibody|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off; PD-1 monoclonal antibody，PD-1 inhibitor，Intravenous injection，once 3 week.
10200755|NCT05193188|Active Comparator|Anlotinib monotherapy|Anlotinib, a multi-target tyrosine kinase inhibitor，oral，12mg/10mg/8mg，2 weeks on and 1 week off.
10200756|NCT05193175|Experimental|Prolonged sitting|Uninterrupted sitting for 6 hours.
10200757|NCT05193175|Experimental|Sitting interrupted with standing|Sitting interrupted with 5 minutes of static standing every 30 minutes for 6 hours.
10200758|NCT05193175|Experimental|Sitting interrupted with light stepping|Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.
10200759|NCT05193162||Pancreatic ductal adenocarcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200760|NCT05193162||Chronic pancreatitis|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200761|NCT05193162||Pancreatic serous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200762|NCT05193162||Pancreatic mucinous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200763|NCT05193162||Intraductal papillary mucinous tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200764|NCT05193162||Pancreatic neuroendocrine tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200765|NCT05193162||Pancreatic acinar cell carcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200766|NCT05193162||Solid pseudopapillary tumor of pancreas|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
10200767|NCT05193162||Blank paraffin section|
10200768|NCT05193149|Experimental|16 wk IMT + 12 wk exercise|16 weeks of IMT, 3/week, 3 sets of 15 repetitions, intensity up to 70% of MIP using a pressure threshold device PLUS 12 weeks of aerobic exercise training including cycling, walking, elliptical, starting in week 5, 3/week, up to 50min per session, moderate intensity
10200769|NCT05193149|Experimental|4 wk IMT + 12 wk exercise|4 weeks of IMT, 3/week, 3 sets of 15 repetitions, intensity up to 70% of MIP using a pressure threshold device PLUS 12 weeks of aerobic exercise training including cycling, walking, elliptical, starting in week 5, 3/week, up to 50min per session, moderate intensity
10200770|NCT05193149|Sham Comparator|4 wk SHAM + 12 wk exercise|4 weeks of SHAM training, 3/week, 3 sets of 15 repetitions, intensity up of 10% of MIP using a pressure threshold device PLUS 12 weeks of aerobic exercise training including cycling, walking, elliptical, starting in week 5, 3/week, up to 50min per session, moderate intensity
10200771|NCT05193110|Other|CAD/CAM PEEK sub-periosteal implant retaining maxillary fixed prosthesis|4 PEEK sub-periosteal implants were surgically placed for patients demonstrated sever bone loss especially in the posterior region which complicate conventional implant placement for full arch prosthesis.The PEEK framework was fabricated by CAD/CAM method
9735525|NCT02866344|Experimental|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
9735526|NCT02866344|Active Comparator|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
9983080|NCT04968522|Experimental|Stimulant|"The stimulants used in the trial are commercially available and will be used in accordance with the approved labelling. Participants must be on a stable dose of stimulant medication for at last 1 month prior to the study. The dose is individualized and titrated by treating primary paediatrician. This will represent the starting dose for the trial, and this will remain stable through the course of the 8-week trial. This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. Based on pilot data from this group, psychostimulant medications prescribed in this population may include:~Methylphenidate IR~Methylphenidate LA~Dexamphetamine~Children will take the required number of capsules to match the total prescribed dose (e.g. 30mg Ritalin LA is 3x10mg capsules)."
9983081|NCT04968405|Other|Single Arm|Intervention with a 510k cleared shoulder arthroplasty device
9983082|NCT04968236|Experimental|Deep dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a deep dry needling technique to the latent trigger point and make 10-12 incisions.
9983083|NCT04968236|Experimental|Superficial dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a superficial dry needling technique to the latent trigger point. Once the needle is placed in the subcutaneous cellular tissue, we manipulate the needle by twisting it until an unpleasant response is provoked. We keep the needle for 5 minutes
9983084|NCT04968236|Experimental|Passive muscle stretching|With the patient positioned in the supine position, the pelvis stabilized with a strap and the lower extremity where we are going to apply the rectus femoris muscle stretch placed outside the table, we perform a passive stretching technique, increasing hip extension and knee flexion until the patient feels the tension. The position is held for 60 seconds.
9983085|NCT04967677||Czech healthy occupational therapy students|Czech healthy occupational therapy students will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test. Video of their performance will be obtained.
9983086|NCT04966559|Placebo Comparator|Placebo treatment|"Film-coated matched placebo-tablets consisting of:~Core:~Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
9983087|NCT04966559|Active Comparator|Naldemedine treatment|"Film-coated matched active-tablets consisting of:~Core:~Naldemedine Tosylate (0,2 mg) Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
9983088|NCT04966247||Patients with Aortic Arch Pathology|Patients undergoing aortic arch surgery for aortic arch pathologies, such as aortic aneurysm and aortic dissection.
9983089|NCT04965402|Experimental|Panel 1: Dose 1|
9983090|NCT04965402|Experimental|Panel 2: Dose 2|
9983091|NCT04965402|Placebo Comparator|Placebo|
9735543|NCT02828917|Experimental|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
9735550|NCT02807454|Experimental|Daratumumab Plus Durvalumab Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward"
9735551|NCT02807454|Experimental|Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward~oral POM at 4mg/day on days 1 to 21~oral/IV dex at 40mg/day (>75 years old) or 20mg/day (>75 years old) on days 1, 8, 15 and 22"
9781455|NCT01149343|Experimental|GSK2302025A Cohort 4|In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.
9983092|NCT04964934|Experimental|AZD9833 + palbociclib or abemaciclib|The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment) or abemaciclib (PO, twice daily, 150,100 or 50 mg) + anastrozole placebo ( PO, once daily) or letrozole placebo ( PO, once daily)
9735554|NCT02795104|Experimental|ARM I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
9735555|NCT02795104|Experimental|ARM II (TIDVD, PN)|Educational Intervention-DVD & Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
9735556|NCT02795104|Experimental|ARM III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
9983093|NCT04964934|Active Comparator|Anastrozole or letrozole + palbociclib or abemaciclib|The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125,100 or 75 mg for 21 consecutive days followed by 7 days off treatment) or abemaciclib (PO, twice daily, 150,100 or 50 mg) + AZD9833 placebo (PO, once daily)
9983094|NCT04961801|Experimental|Acalabrutinib in combination with tacrolimus and methotrexate|"Phase I: To determine the maximum tolerated dose (MTD) of Acalabrutinib in combination with tacrolimus and methotrexate for Phase II.~Phase II: To determine if acalabrutinib in combination with tacrolimus and methotrexate is safe and effective in reducing acute GVHD rate."
10200772|NCT05193110|Other|Injection molding PEEK sub-periosteal implant retaining maxillary fixed prosthesis|4 CAD/CAM PEEK sub-periosteal implants were surgically placed for patients demonstrated sever bone loss especially in the posterior region which complicate conventional implant placement for full arch prosthesis.The PEEK framework was fabricated by injection molding technique method.
10200773|NCT05193006||peritoneal malignant mesothelioma of grade 1|peritoneal malignant mesothelioma of grade 1
10200774|NCT05193006||peritoneal malignant mesothelioma of grade 2|peritoneal malignant mesothelioma of grade 2
10200775|NCT05193006||peritoneal malignant mesothelioma of grade 3|peritoneal malignant mesothelioma of grade 3
10200776|NCT05192993|Experimental|visual motor integration group|participants in the experimental group will receive visual motor integration program
9983095|NCT04961281|Active Comparator|Dexmeditomidine group|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
9983096|NCT04961281|Active Comparator|triamcinolone group|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
9983097|NCT04956887|Experimental|Intervention|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
9983098|NCT04956887|Placebo Comparator|Placebo|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning.
9983099|NCT04955431|Placebo Comparator|Normal Sleep (with 250 ug/m^3 PM2.5)|Participants will have a normal sleep opportunity the night prior to reporting to the lab for the simulated firefighting session (250 ug/m^3 PM2.5 with moderate intensity exercise).
9983100|NCT04955431|Experimental|Restricted Sleep (with 250 ug/m^3 PM2.5)|Participants will have a restricted sleep opportunity (~4 hours) the night prior to reporting to the lab for the simulated firefighting session (250 ug/m^3 PM2.5 with moderate intensity exercise).
9983101|NCT04954131|Experimental|SCB-2019 vaccine|Investigational SCB-2019 vaccine contains 30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants, in each 0.5 mL dose
9983102|NCT04954131|Placebo Comparator|Placebo|Saline solution (0.9%)
9983103|NCT04951037|Experimental|Fully Asynchronous Online Savvy Program|Family caregivers of PLWD taking part in a fully asynchronous online caregiver education program.
10200777|NCT05192993|Active Comparator|Handwriting intervention group|participants in the experimental group will receive handwriting intervention program.
10200778|NCT05192993|Active Comparator|visual motor integration and Handwriting intervention group|participants in the group will receive visual motor integration program and handwriting intervention program.
10200779|NCT05192980|Other|Peripheral neuroblastic tumors (ganglioneuroma, ganglioneuroblastoma and neuroblastoma)|
10200780|NCT05192967|Experimental|Experimental 1|"The training program determined to the experimental group was applied with video. Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
10200781|NCT05192967|Experimental|Experimental 2|"The training program determined to the experimental group was applied with video.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
10200782|NCT05192967|Other|Control 1|"The training program determined to the control group was applied with classical method.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
9735574|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
10200783|NCT05192967|Other|Control 2|"The training program determined to the control group was applied with classical method.~Training program content:~Knowledge, attitude, skills about COVID-19~Approach to the COVID-19 positive case~Communication skills~Psychological resilience"
9781456|NCT01149369|Active Comparator|Aprepitant|Aprepitant 125 mg per day
9781457|NCT01149369|Placebo Comparator|Aprepitant-placebo|Placebo aprepitant 125mg per day
9781458|NCT01149421|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
9781459|NCT01149421|Experimental|0.75 milligram (mg) LY2189265|LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
9781460|NCT01149421|Placebo Comparator|Placebo|Placebo: subcutaneous (SC), once weekly (QW)
9781461|NCT01149434|Experimental|Pharmacokinetic Arm|Patients going on Pharmacokinetic arm will receive JI-101 & Everolimus (4 patients only)
9735576|NCT02753127|Experimental|Napabucasin plus FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
9735577|NCT02753127|Active Comparator|FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
9735578|NCT02746081|Experimental|BAY1436032|"Dose escalation: Patients with any type of IDH1-R132X-mutant solid tumor may be eligible for enrollment. A minimum of 3 patients per cohort will be treated. If dose limiting toxicities (DLTs) occur, Bayesian dose-DLT modeling will be performed to help guide dosing decisions and to identify the maximum tolerated dose (MTD). If the MTD is not reached, a recommended phase II dose (RP2D) will be chosen based on available safety, tolerability, PK, PD and clinical efficacy data.~Dose expansion: The dose and schedule that was determined to be most appropriate in the dose escalation part of the study, which may be the MTD and / or the RP2D, will be used. Cohorts will consist of patients with the following IDH-R132X-mutant tumor types: (1) anaplastic glioma; (2) glioblastoma; (3) intrahepatic cholangiocarcinoma; (4) tumor types other than those in Cohorts 1-3."
9735579|NCT02745821|Experimental|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
9735580|NCT02745067|Other|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
9735581|NCT02744430|Active Comparator|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
9735582|NCT02744430|Placebo Comparator|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
10200784|NCT05192941|Experimental|Inclisiran sodium 300 mg s.c. + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~Inclisiran sodium 300 mg s.c.~Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
10200785|NCT05192941|Placebo Comparator|Corresponding placebo + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~Inclisiran sodium 300 mg s.c.~Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
9781462|NCT01149434|Experimental|Pharmacodynamic arm|Patients going on the Pharmacodynamic study will receive JI-101 only.
9781463|NCT01149460|Experimental|Valacyclovir|Test 1000 mg Tablet
9781464|NCT01149460|Active Comparator|Valtrex|Reference Listed Valacyclovir 1000 mg Tablet
9781465|NCT01149473|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
10200786|NCT05192928|Experimental|All Patients using the Ripple Health Smart Pill Cap|In this single-arm trial, all patients will be using the Ripple Health Smart Pill Cap as a method of medication administration
10200787|NCT05192902|Experimental|Student-administered|
10200788|NCT05192902|Placebo Comparator|Dentist-administered|
10200789|NCT05192876||Data Base of Patient Records 2000-2025|Analysis of outcomes and adverse events
10200790|NCT05192824|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39
10200791|NCT05192824|Experimental|Orthokeratology lenses group 1|Subjects wearing orthokeratology lenses of 5mm optical zone.
10200792|NCT05192824|Experimental|Orthokeratology lenses group 2|Subjects wearing orthokeratology lenses of 5.5mm optical zone.
10200793|NCT05192824|Experimental|Orthokeratology lenses group 3|Subjects wearing orthokeratology lenses of 6mm optical zone.
10200794|NCT05192824|Experimental|Orthokeratology lenses group 4|Subjects wearing orthokeratology lenses of 6mm optical zone and the increased height of peripheral reverse curve.
10200795|NCT05192811|Experimental|probiotic K56|Probiotic capsule (lactobacillus paracasei K56 10^9CFU) 1capsule/day , for 60days
10200796|NCT05192811|Placebo Comparator|placebo|placebo capsule(maltodextrin, 1capsule/day, 60days
10200797|NCT05192785|No Intervention|Control group|"In the control group, patients who met the sampling criteria filled out the Consent and Information Forms with the researcher, and the breathing and coughing exercises, and early mobilization and pain control practices that were part of the routine clinical procedure were continued.~Arterial and venous oxygen saturation values and vital signs were measured and recorded at the end of the first, second and third postoperative days on the Application Information form. The researchers and clinic nurses were responsible for the execution of applications and the follow-up and monitoring of the pulmonary rehabilitation care throughout the hospitalization of the patient."
10205112|NCT03970200|Experimental|Upper gastrointestinal FMT|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given by mouth in capsules or through a tube that goes into your stomach/intestines if you already have one (upper delivery). You will not be assigned to this group if you cannot take any medications either by mouth or through a tube safely, as determined by your doctor
9735585|NCT02721381|Experimental|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
9735586|NCT02721381|Experimental|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
9735587|NCT02721381|No Intervention|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
9735588|NCT02720445|Experimental|Nicotine Transdermal Patch|150 participants will wear nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment
9735589|NCT02720445|Placebo Comparator|Placebo Patch|150 participants will wear matching placebo patches during waking hours.
9983104|NCT04949633|Experimental|Induction of labor|women randomized in the experimental group will be admitted to the labor ward to undergo induction of labor with intra-veinous oxytocin and early amniotomy. Oxytocin will be administered according to the French guidelines for induction of labor. Maximum oxytocin used should not exceed 10 UI.
9735591|NCT02713022||Breast Cancer|DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
9735592|NCT02713022||Prostate Cancer|DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
9983105|NCT04949633|Active Comparator|Second cervical ripening|"women randomized in the control group will undergo a second cervical ripening lasting a maximum of 24 hours with either:~Vaginal slow releasing system of dinoprostone PROPESS® which is inserted in the vagina, against the cervix and left in place during 24 hours.~Oral misoprostol (ANGUSTA®) 25 µg every 2 hours, 8 times (maximum dosage should not exceed 200µg). Tablets will be given one at the time by midwives.~Vaginal gel of dinoprostone (2 mg PROSTINE®) every 6 hours, maximum dose of 6 mg.~The choice of the cervical ripening agent will depend of the local protocol of the participating maternity unit. The choice between ANGUSTA®, PROPESS® and PROSTINE® will be made by investigators of each participating unit at the beginning of the trial.~At the end of the second cervical ripening procedure women not in labor will be transferred to the labor ward for induction of labor with oxytocin."
9983106|NCT04947475|Experimental|Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program|There are two objectives to the Brief Intervention. First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder.
9983107|NCT04947384||Patients with moderate mitral valve disease, undergoing interventions|Patients with established WHO-2 diagnosis of PH undergoing open and interventional mitral valve procedures.
9983108|NCT04947384||Patients undergoing mitral valve interventions without pulmonary hypertension|Patients with no PH undergoing open and interventional mitral valve procedures. This group will serve as a control.
9735597|NCT02707029||Persons, with or without pain disorders|Adults and adolescents with or without pain disorders.
9983109|NCT04947384||Patients with precapillary pulmonary hypertension scheduled for right heart catheterization|Patients with established diagnosis of WHO-1-4 groups of PH undergoing right heart catheterization. This group will serve as a control.
9983110|NCT04943900|Experimental|Part 1A: Monotherapy (BMS-986416)|
9983111|NCT04943900|Experimental|Part 1B: Combination Therapy (BMS-986416 + Nivolumab)|
9983112|NCT04942210|Experimental|vYF|1 injection of vYF at Day 1
9983113|NCT04942210|Active Comparator|YF-VAX|1 injection of YF-VAX at Day 1
9983114|NCT04941664|Other|Levobupivacaine|Superior trunk nerve block will be done under ultrasound guidance to patients scheduled for shoulder surgeries. Local anesthetic agent (0.5% levobupivacaine) 8ml will be injected at the superior trunk of the brachial plexus in order to produce surgical anesthesia or analgesia for shoulder surgeries.
9984654|NCT03873467|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
9735612|NCT02686697|Experimental|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
9735613|NCT02686697|Placebo Comparator|Placebo|matching placebo
9735615|NCT02674958|Active Comparator|Aspirin|Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
9735616|NCT02674958|No Intervention|No aspirin|No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
9983115|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide in separate syringes|Participants will up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks treatment with cagrilintide and semaglutide administered as separate injections. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination). Followed by a 38 days follow-up period.
9983116|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide combined in DV3384 device|Participants will be up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks of treatment with cagrilintide and semaglutide administered using the DV3384 manual syringe. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination. Followed by a 38 days follow-up period.
9983117|NCT04940078|Experimental|Part B: Cagrilintide and semaglutide combined in DV3384 device|Participants will receive a single injection of Cagrilintide 0.25 mg/semaglutide 0.25 mg using the DV3384 manual syringe followed by a 28 days follow-up period.
9983118|NCT04939701|Experimental|Phase 1 ASP0739 Monotherapy Dose Escalation|Participants with R/R solid tumors known to express NY-ESO-1 will receive ASP0739 on day 1 of each 28-day cycle for up to 6 doses, to determine the Recommended Phase 2 Dose (RP2D).
9983119|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Safety Lead-in|Participants with R/R SS, MRCL or ovarian cancer will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses in combination with receiving 4 doses of pembrolizumab every 6 weeks starting on Cycle 1 Day 1 to determine the RP2D of ASP0739 with pembrolizumab. An additional 13 doses of pembrolizumab may be available for qualifying participants.
9735622|NCT02668562|Experimental|Early CABG|Patients to undergo early CABG
9735623|NCT02668562|Active Comparator|Delayed CABG|Patients to undergo delayed CABG
10200798|NCT05192785|Experimental|Incentive Spirometry Group|"The patients who met the sampling criteria were given consent and information forms in the preoperative period from their admission to the clinic by the researcher and the incentive spirometry (IS) application along with respiratory and cough exercises was explained, demonstrated and performed.~In addition, all postoperative patients underwent a pain assessment using the visual analogue scale (VAS) pain scale every 4-6 hours every day prior to incentive spirometry implementation, and pain control was provided based on the results (with paracetamol and opioids in the clinical routine). The patients whose pain levels were moderate and low continued the incentive spirometry application. Arterial and venous oxygen saturation values and vital signs were measured and recorded at the end of the first, second and third days postoperatively on the Application Information form."
10200799|NCT05192759|Experimental|TBS Group|Participants will receive active transcranial magnetic stimulation (TMS) daily for 1 week
10200800|NCT05192746|Experimental|"group A Control group"|"Twenty two patients will receive conventional treatment hot pack and exercise (control group).~."
10200801|NCT05192746|Experimental|"group BExtracorporeal shock wave group:"|Twenty two patients will receive Radial Extra corporeal Shock Wave Therapy plus conventional treatment hot pack and exercise.
10200802|NCT05192746|Experimental|"Group CHigh power pain threshold ultrasound group:"|Twenty two patients will receive High-Power Pain Threshold Ultrasound therapy plus conventional treatment hot pack and exercise
10200803|NCT05192720|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 100 ml/day orally for 1 month. The intervention solution is given in a neutral plastic container
10200804|NCT05192720|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 100 ml/day orally for 1 month. The placebo solution is given in a neutral plastic container (same as for intervention/experimental solution).
10200805|NCT05192681|Experimental|Tislelizumab arm|Tislelizumab: 200 mg, intravenous infusion, administered on the 1st day of each cycle, every 3 weeks Docetaxel: 60-75mg/m2 administered on the 1st day of each cycle, every 3 weeks Treatment until the disease progresses or intolerable side effects appear.
10200806|NCT05192668|Experimental|Quiet time care|Reduce noise and centralize medical or nursing operations in the NICU
10200807|NCT05192668|No Intervention|Routine nursing care|Perform routine nursing care for the VLBWIs in the NICU
10200808|NCT05192655||HNSCC-patients treated with primary radio(chemo)therapy (R(C)T)|Patients, older than 18 years, with diagnosed HNSCC, attending the Department of Radiooncology and Radiotherapy at Charité for a treatment with curative intension (R(C)T) . All patients received as pretherapeutic diagnostic method a 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging.
10200809|NCT05192655||HNSCC-patients treated with primary surgery|Patients, older than 18 years, with diagnosed HNSCC, attending the Department of Oral and Maxillofacial Surgery or ENT Department at Charité for a treatment with curative intension ( primary surgery +/- combined with adjuvant (R(C)T)). All patients received as pretherapeutic diagnostic method a 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging.
10200810|NCT05192616||iCover covered stent|Percutaneous transluminal angioplasty (PTA)
10200811|NCT05192590|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs). Control arm physicians will continue to have access to standard of care diagnostic tools, but not the CDMT test results.
10200812|NCT05192590|Experimental|Educational Materials and CDMT Test Results (Intervention 1)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results whether they select it or not. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
10205113|NCT03970200|Experimental|Lower gastrointestinal FMT|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given through the rectum by an enema (lower delivery).
9735632|NCT02659241|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5. Patients then undergo standard of care laparoscopy. Patients may also receive adavosertib PO QD on days 8-12, 15-19, and 22-26 for up to 28 days based on surgery schedule.
9983120|NCT04939701|Experimental|Phase 2 ASP0739 Monotherapy Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer and other solid tumors known to express NY-ESO-1 (melanoma, NSCLC-adenocarcinoma, squamous cell, and ESCC) will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses.
9983121|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer will receive RP2D of ASP0739 with pembrolizumab on day 1 of each 28-day cycle for up to 6 doses, in combination with 4 doses of pembrolizumab administered every 6 weeks. An additional 13 doses of pembrolizumab may be available for qualifying participants.
9983122|NCT04939610|Experimental|Phase 1: Dose Escalation|Up to 30 patients with solid tumors.
9983123|NCT04939610|Experimental|Phase 1: RP2D Expansion Cohort|Up to 20 patients with solid tumors.
9983124|NCT04939610|Experimental|Phase 2: Specific Solid Tumors|Cohorts of up to 40 patients each with Advanced or Solid Tumors
9983125|NCT04938440||Prescribers of Instanyl®|Healthcare professionals (Oncologists, oncoradiologists, anaesthesiologists, pain management prescribers, palliative care prescribers, internal medicine prescribers and other specialties) who are current and potential prescribers of Instanyl® will be assessed before and after the implementation of the updated EMs via web-based survey questionnaire.
10205114|NCT03969134|Active Comparator|Vaccine arm|ChAd63 KH 7.5x1010 vp, single dose, by IM injection
9735639|NCT02647619|Active Comparator|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
9735640|NCT02647619|Active Comparator|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
10205115|NCT03969134|Placebo Comparator|Placebo|Normal Saline, single dose, by IM injection
10205116|NCT03968679|Experimental|Unilateral elective nodal irradiation|Exclusion of contralateral neck from elective nodal irradiation, based on results of SPECT/CT and (in case of contralateral drainage) contralateral sentinel node procedure.
10205117|NCT03963063|Active Comparator|Non Goal-directed Care Group|
10205118|NCT03963063|Experimental|Goal-directed Care Group|
10205119|NCT03960476|Experimental|Access to Web-Based Intervention|All study participants will be given access to the web-based study intervention, PlanYourLifespan.org.
10205120|NCT03954509||semi-structured interview|"Screening and inclusion of patients hospitalized or seen in day hospital to conduct semi-structured interviews according to the interview grid. This interview schedule was established after review of the literature and identification of primary and secondary objectives.~Identification of key ideas through content analysis of the interviews conducted and based of the anchored theory.~This step is performed until the results are saturated (approximately 15 patients). The principle of saturation is based on the fact that from a threshold, the diversity of the elements collected decreases. Much more than an end signal, this principle is a methodological guarantee since it allows the possibility of comparing divergent or contradictory data and thus validating the data."
9983126|NCT04938388|Active Comparator|Oral Semaglutide (OS) with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the OS dose will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the OS tablet whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
9983127|NCT04938388|Placebo Comparator|Oral Semaglutide (OS) Placebo with Enhanced Lifestyle Care (organic vegetables)|"Participants will start at a 3 mg dose of OS matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the Placebo will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the Placebo will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of Placebo will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit. If participants report moderate-to-severe nausea or vomiting, the Placebo will be maintained or decreased at the study physician's discretion.~Participants will be instructed to swallow the matched OS Placebo whole (not crushed, cut or chewed) in the morning, in a fasted state, with up to 120 mL of plain water, at least 30 minutes before any other food, beverage, or oral medication."
9983128|NCT04936074|Experimental|Muscle preserving selective laminectomy (L-group)|Muscle-preserving selective laminectomy (18) with a posterior midline incision and dissection through the nuchal fascia. The spinous processes are split in the midline using a high-speed burr/ultrasound knife and without disturbing the deep extensor muscles on either side. Angulating away from the midline, the spinous processes are divided at their bases. Laminectomy is performed with a width no more than 2-3 mm wider than the dural borders. The facet joints are not exposed. Finally, the split spionous processes are sutured together. No collar or restrictions will be used in either group.
9983129|NCT04936074|Active Comparator|Laminectomy with instrumented fusion (LF-group)|Laminectomy with instrumented fusion (33) with a midline incision over the appropriate levels defined as the same levels as the extension of laminectomy plus one level above and below but not extending beyond C3-C7 (34). Soft tissue dissection and retraction is performed to identify osseous landmarks. Special care is taken to spare muscle attachments on C2 and C7. Spinal instrumentation is performed with lateral mass or pedicle screws (C3-C7) combined with rod fixation. Laminectomy is performed with a width not extending more than 2 mm outside the dural borders. Facet joint injury should be avoided. Special care is taken to spare the C7 spinous process and distal half of C7 lamina (35). The sagittal alignment is corrected before spinal fixation. No collar or restrictions will be used in either group.
9983130|NCT04935723|Experimental|EFFECT OF REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the reiki/sham reiki group were taken to a quiet single room and reiki/sham reiki was applied for approximately 25-30 minutes. will be applied. Reiki application will be applied by a researcher who has Reiki I and Reiki II level training.
9735662|NCT02602457|Experimental|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
9735663|NCT02602457|Experimental|High-Intensity Interval Training|High-Intensity Interval Training
9983131|NCT04935723|Placebo Comparator|EFFECT OF SHAM REIKIN ON ANXIETY, FEAR, PAIN AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|According to randomization, the patients in the sham reiki group were taken to a quiet single room and sham reiki was applied for approximately 25-30 minutes. will be applied. Sham Reiki will be applied by a health professional who has not received Reiki training.
9735688|NCT02538744|Placebo Comparator|placebo|placebo po 1x/day from day -12 through 4
9735689|NCT02538744|Active Comparator|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
9983132|NCT04935723|No Intervention|ANXIETY, FEAR PAIN LEVELS AND LIFE FINDINGS OF ABDOMINAL SURGERY PATIENTS|The control group will be given routine post-operative care without any intervention and the data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
9983133|NCT04935697|Experimental|nVNS|nVNS treatment will be applied three times daily. One treatment is defined as 2 consecutive stimulations: one, 2-minute stimulation on the side of the neck followed by a second, 2-minute stimulation on the same side of the neck. The treatment will be done 3 times per day (morning, mid-day and 1 hour before bed at night), every day, until patient is discharged from the hospital or requires mechanical ventilation. Patient will record the time they administered these treatments. If the patient is unable to do this, a research staff member who has been trained on the device can assist. Will also receive SOC for TBI.
9983134|NCT04935697|Other|SOC only|Patients will be managed according to the institutional best practices and SOC for TBI.
9983135|NCT04935619|Other|Non-Contingency Reinforcement Group|Subjects assigned to the NCR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will not receive contingency monetary reinforcement at Day 28 of the study.
9983136|NCT04935619|Experimental|Contingency Reinforcement Group|Subjects assigned to the CR group with self-reported abstinence verified by urinary THC-COOH level <20 ng/ml will receive contingency monetary reinforcement at Day 28 of the study.
9983137|NCT04935008|Experimental|Effect of recruitment maneuver on intracranial pressure|A recruitment maneuver will be performed in patients with decreased oxygen saturation due to atelectasis by applying 30 cm H2O positive pressure support for 30 seconds. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver.
9983138|NCT04933188||control|Lean health controls with a BMI<25kg/m2
9983139|NCT04933188||overweight|patients with a BMI of 25-30kg/m2
9983140|NCT04933188||obesity|patients with a BMI of over 30kg/m2
9983141|NCT04931836|Experimental|Experimental Group|Participants in this group will complete the physical activity intervention.
9983142|NCT04931836|No Intervention|Control Group|Participants in this group will be asked to maintain their normal level of physical activity.
9983143|NCT04931264|Experimental|YuWell YE660D and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE660D Electronic Sphygmomanometer (YuWell YE660D) and with Desk Mercury Sphygmomanometer.
9983144|NCT04930406||Historical control group|
9983145|NCT04930406||Intervention group|
9735704|NCT02519985|Experimental|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
9983146|NCT04926246|Experimental|Part 1: T1|T1: Test Product M, under fasted conditions
9983147|NCT04926246|Experimental|Part 1: T2|T2: Test Product N, under fasted conditions
9983148|NCT04926246|Experimental|Part 1: T3|T3: Test Product O, under fasted conditions
9983149|NCT04926246|Experimental|Part 1: T4|T4: Test Product O, under fed conditions
9983150|NCT04926246|Experimental|Part 1: R1|R1: Reference Product X, under fasted conditions
9983151|NCT04926246|Experimental|Optional Part 2: R2|R2: Reference Product Y, under fasted conditions
9983152|NCT04926246|Experimental|Optional Part 2: T5|T5: Test Product P, under fasted conditions
9983153|NCT04926246|Experimental|Optional Part 2: T6|T6: Test Product P, under fed conditions
9983154|NCT04926246|Experimental|Optional Part 2: T7|T7: Test Product Q, under fasted conditions
9983155|NCT04926246|Experimental|Optional Part 3: R3|R3: Reference Product Z, under fasted conditions
9983156|NCT04926246|Experimental|Optional Part 3: T8|T8: Test Product S, under fasted conditions
9983157|NCT04926246|Experimental|Optional Part 3: T9|T9: Test Product S, under fed conditions
9983158|NCT04926246|Experimental|Optional Part 3: T10|T10: Test Product U, under fasted conditions
9983159|NCT04925882|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levopubivacaïne for the realization of the erector spinae plane block."
9983160|NCT04925882|Placebo Comparator|Placebo|"The Placebo group corresponds to the reference group, that is to say that it will consist of patients who benefit from an injection of physiological serum for the realization of the erector spinae plane block."
9983161|NCT04925752|Experimental|Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF|"Participants will receive the following for at least 52 weeks:~Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~Oral LEN 600 mg on Days 1 and 2"
9983162|NCT04925752|Experimental|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:~SC LEN placebo every 26 weeks~Oral F/TDF 200/300 mg once daily~PTM Oral LEN on Days 1 and 2"
9983163|NCT04925752|Experimental|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.~Participants randomized to F/TDF will receive SC LEN 927 mg on OLE Day 1, OLE Week 26, and OLE Week 52 and will also receive oral LEN 600 mg on OLE Days 1 and 2."
9983164|NCT04925752|Experimental|PK Tail Coverage Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.~Additionally, participants that prematurely discontinue the study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase are also eligible to transition to the PK Tail Coverage Phase.~Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks beginning 26 weeks after the last injection of LEN."
9983165|NCT04919564|Experimental|Furosemide|Low dose continuous furosemide 2 mg/hour for a period of 12 hours since anesthetic induction
9983166|NCT04919564|Placebo Comparator|Control|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
9983167|NCT04918823|Other|Single arm|All subjects will receive Restasis in this study
9983168|NCT04918147|Experimental|Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper.~Elotuzumab: 10 mg/kg administered once weekly, intravenously (IV push or bolus), per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
9983169|NCT04918147|Experimental|Cohort 1b: Elotuzumab-Three-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.~Elotuzumab: 10 mg/kg administered as referenced above, intravenously (IV push or bolus), per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
9984655|NCT03873467|Other|Wait-List Control|The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
10200813|NCT05192590|Experimental|Educational Materials and CDMT Test Results when Selected (Intervention 2)|Participants will care for the same set of CPV patients as the control arm, but will be educated on and will receive the CDMT test results only if they select it. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
10200814|NCT05192577|Experimental|Study group|
9735725|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
9735726|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
10200815|NCT05192564|Experimental|EX Group|Conventional rehabilitation treatment plus exercise intervention under the supervision of exercise specialists two non-consecutive days per week for eight weeks.
9735727|NCT02497534||Affected with Friedreich's ataxia|Friedreich's ataxia patients aged 8 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
9735728|NCT02497534||Healthy controls|Health controls aged 8 to 70 (inclusive). Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and an optional blood draw.
9735729|NCT02497534||Carriers of Friedreich's ataxia|An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia. No assessments are to be conducted. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
10200816|NCT05192564|Active Comparator|AC Group - ATTENTION CONTROL GROUP|Conventional rehabilitation treatment at home with unsupervised exercise intervention
10200817|NCT05192551||Plenvu|A new type of low-volume bowel-prep recently approved and introduced in the Swedish market. The dose is 500 ml x 2, The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
10200818|NCT05192551||Laxabon|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
10200819|NCT05192551||Vistaprep|A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
10200820|NCT05192551||Movprep|A standard median volume bowel-prep, used for a long time in Sweden. The dose is 1000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
10200821|NCT05192525|Experimental|mChemotherapy group|"The intervention group participants will adopt an app mChemotherapy to self-manage their symptoms under nurse-led supervision for six weeks."
10200822|NCT05192525|No Intervention|Control group|"Participants in control group will receive routine care, with no use of mChemotherapy during six weeks. Routine care is composed of a pre-chemotherapy visit and two follow-up visits. Through the Official WeChat platform, the patients in control group will be informed about the chemotherapy regimen, and chemotherapy-related symptoms and how to deal with them, during the pre-chemotherapy visit. The control group will have two scheduled visits by telephone with the follow-up nurse. Patients will be given a phone number for consulting the follow-up nurse should they have questions related to their symptoms, or concerns related to the chemotherapy. Patients in the control group cannot access the mChemotherapy until they have completed the pilot study."
10200823|NCT05192486|Experimental|Study treatment|Patients receive GNC-038 as intravenous infusion for one cycle. Participants with no intolerable AEs could continue for another three cycles. Participants with a clinical benefit after four cycles' treatment could also receive additional treatment for another four cycles at the same dose level
9983170|NCT04918147|Experimental|Cohort 2: Arm A- Elotuzumab (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).~Forty-two participants will receive elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.~Elotuzumab: 10 mg/kg administered as referenced above, intravenously (IV push or bolus), per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
9983171|NCT04918147|Placebo Comparator|Cohort 2: Arm B-Placebo (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).~Twenty-one participants will receive placebo for elotuzumab on days 0,7, 14, 21, then weeks 5,7,9 and 11 (three-month regimen), and the prescribed 10-week prednisone taper.~Placebo for elotuzumab: Administered on same schedule as elotuzumab described in Cohort 2 Arm A: intravenously (IV push or bolus), per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that involves daily doses by mouth, per protocol. Dosage in milligrams (mgs)."
9983172|NCT04918069|Experimental|Capsaicin|2g of 0.075% topical capsaicin ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
9983173|NCT04918069|Placebo Comparator|Placebo|2g of topical placebo ointment applied four times daily (preferably to the abdomen) for the first five days of chemotherapy
9983174|NCT04917588|Experimental|Saypha® FILLER HQ|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma HQ Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
9983175|NCT04917588|Active Comparator|Saypha® FILLER C1|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma C1 Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
9983176|NCT04916977||FD patients|
9983177|NCT04916236|Experimental|Phase I - Dose-escalation|This is a single-center open-label phase I dose-finding study (3+3 classical design) evaluating the RP2D of RMC-4630 in combination with LY3214996. Based on the safety, tolerability, and PK and PD data from the dose-finding stage of the study, a RP2D will be defined for the expansion phase.
9983178|NCT04916236|Experimental|Phase Ib|The phase Ib expansion cohort study is intended to further characterize the safety, tolerability and PK/PD of the selected dose of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC. Furthermore, it will explore the clinical activity of RMC-4630 in combination with LY3214996 in patients with advanced KRASm PDAC.
9983179|NCT04914949||ESRD Patients|ESRD patients will wear the Alio SmartPatch on top of their newly created vascular access
9983180|NCT04914611||HBsAg Positive|Patients with chronic hepatitis B infection as defined by HBV surface antigen positive
9983181|NCT04911335|Experimental|phase 2 open intervention|All patients assisted by the palliative care center (hospice and home) will receive the oral hygiene protocol and the propolis-based product. The oral hygiene protocol will be applied starting from the day of taking care of the patient in the service and until discharge / death. Administration of the study product will be continued for 2 weeks or stopped sooner if the patient loses the ability to swallow.
9735746|NCT02460198|Experimental|Cohort A - Pembrolizumab 200 mg|Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 52 cycles (up to approximately 3 years).
9735747|NCT02460198|Experimental|Cohort B - Pembrolizumab 200 mg|Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 52 cycles (up to approximately 3 years).
9983182|NCT04910932|Experimental|Breathing Exercises group|Breathing exercises will be applied via teleconference by a physiotherapist 1 day a week. Individuals will perform exercises by themselves at their homes on the remaining 6 days of the week. Exercise program will be applied for 4 weeks. Individuals will also be informed about COVID-19 for once at baseline.
9983183|NCT04910932|Other|Control group|Individuals will be informed about COVID-19 for once at baseline.
9983184|NCT04910776|Experimental|Avalglucosidase alfa|Administered intravenously every 2 weeks
9983185|NCT04910607||Patient|Participating patients will be recruited from the Specialised Obesity Centres =CSO (CHU and Follow-up and rehabilitation care (SSR), as well as patient associations) to fill in a questionnaire and take part in an interview (varied panel representative of the target population in terms of place of residence, socio-professional category, sex and age).
9983186|NCT04910607||Professional|Medical and paramedical staff involved in the partner CSOs will also be asked to participate in a semi-structured interview.
9983187|NCT04909983|Experimental|Intervention|Medical Device, an occlusive patch for 3 days.
9983188|NCT04909983|Active Comparator|Control|Standard of Care
9983189|NCT04909372|No Intervention|No labelling|Food products without any label in the virtual supermarket.
9983190|NCT04909372|Experimental|Environmental labelling|Food products with an environmental label in the virtual supermarket.
9983191|NCT04908826|Active Comparator|Group A (standard cholangiography during surgery)|All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
9735770|NCT02421939|Experimental|Gilteritinib|Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.
9735771|NCT02421939|Active Comparator|Salvage Chemotherapy|Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days, etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
9983192|NCT04908826|Active Comparator|Group B (cholangiography with iv administration of icg prior to surgery)|All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).
9983193|NCT04908826|Active Comparator|Group C (cholangiography with direct administration of icg to the bile duct system during surgery)|All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
9983194|NCT04908371|Active Comparator|Selective Trunk Block (SeTB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. After identifying the three trunks of the brachial plexus, ultrasound guided selective trunk block will be done using local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 20ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
9983195|NCT04908371|Active Comparator|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC-BPB)|Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove. The unique sonomorphology of the C7 transverse process will be used as the key anatomical landmark to identify the individual elements of the brachial plexus. Under ultrasound guidance, local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 30ml) will be injected at the interscalene groove and at the supraclavicular fossa in order to anesthetize the whole upper limb.
9983196|NCT04907825|Experimental|Pharmacist Intervention Arm|Pharmacist to prescribe/monitor/manage oral anticoagulation therapy for atrial fibrillation stroke prophylaxis (under collaborative practice agreement with participants primary care provider) in accordance with ACC/AHA/HRS Guidelines.
9983197|NCT04907825|Active Comparator|Enhanced Usual Care Control Arm|Pharmacist to notify primary care provider that patient has 'actionable' atrial fibrillation and provide current medication list.
9983198|NCT04906746|Experimental|Dosing Regimen for Ruxolitinib|"Level 1: Ruxolitinib 0 MG po bid for 1 month~Level 0: Ruxolitinib 10 MG po bid for 1 month~Level -1: Ruxolitinib 15 MG po bid for 1 month"
9983199|NCT04906135|Experimental|Usher Syndrome|Adult and pediatric cochlear implant users with Usher syndrome
9735780|NCT02410733|Experimental|Lipo-MERIT|7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts
9983200|NCT04906135|Active Comparator|Idiopathic Hearing Loss|Adult and pediatric cochlear implant users with idiopathic hearing loss
9983201|NCT04904575|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levobupivacaine for the realization of the erector spinae plane block."
10200824|NCT05192447|Experimental|Intervention Group = Exercise Group|EG will perform complementary cognitive and physical training (120 min./5/per week during study observation)
10200825|NCT05192447|No Intervention|Control Group|CG will be provided with normal hospital care during RT and next will conduct a normal daily activity at home.
10200826|NCT05192395|Experimental|Group A|fed state: period 1) DWJ15251, period 2) DWP16001 and DWC2021011 fased state: period 3) DWJ15251, period 4) DWP16001 and DWC2021011
10200827|NCT05192395|Experimental|Group B|fed state: period 1) DWP16001 and DWC2021011, period 2) DWJ15251 fased state: period 3) DWP16001 and DWC2021011, period 4) DWJ15251
10200828|NCT05192382|Experimental|Paltusotine|
10200829|NCT05192382|Placebo Comparator|Placebo|
9983202|NCT04904575|Placebo Comparator|Placebo|"The placebo group corresponds to the reference group, that is to say that it will consist of patients who will benefit from an injection of physiological serum for the realization of the erector spinae plane block."
9983203|NCT04902248|Experimental|Over-the-scope clips|"The OTSC® System Set is an instrument for flexible endoscopy~The OTSC® System Set consists of an applicator cap with a mounted OTSC® clip, thread, thread retriever and a hand wheel for clip release.~The OTSC® clip is delivered by means of an applicator cap mounted to the tip of gastroscopes or colonoscopes. The clip is released by tightening the thread with the hand wheel.~The OTSC® clip for flexible endoscopy is a superelastic Nitinol device for compression and approximation of tissue in the digestive tract"
9983204|NCT04902248|Experimental|angiographic embolization|"The procedure was performed in the angiographic suite and under local anaesthetics to the patient's groin. The celiac and then gastroduodenal artery or the left gastric artery was selectively cannulated depending on ulcer location.~Coils were deposited distal to the bleeding point. Gel foam particles were then packed into the artery and its collaterals. This was followed by further coils deposited in its proximal portion until complete cessation of arterial flow. Our protocol requested empiric embolisation of the artery even in the absence of active contrast extravasation or a pseudoaneurysm."
9983205|NCT04897425|Experimental|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"The participant can choose between one, two, or five interventions per week depending on their availability.~Steps of each intervention:~Pain Evaluation: Numeric Rating Scale (NRS)~Functional Assessments (1st, 5th, 10th, and last sessions)~Preparation:~Locate participant in a comfortable position for training (comfortable chair, about a meter distance to the screen, pleasant arm position)~Placement of the surface electrodes~Positioning of the feedback wearable device over the affected body part~Placement of the brain modulation cap~Treatment modalities:~Motor training~Sensory training~Sensorimotor training~Assessments~Step 4 is repeated for different phantom movements, initially one at a time, progressing to several joints simultaneously. A treatment session lasts 2 hours."
9983206|NCT04897217|Active Comparator|Megestrol Acetate Arm - Control Arm|Megestrol Acetate 160 mg by mouth daily
9983207|NCT04897217|Experimental|Levonorgestrel IUD - Comparison Arm|Levonorgestrel intrauterine device with 52 mg progestin (Releases 20mcg/daily)
9983208|NCT04896827||Chronic pain|Patients with chronic pain (n=100)
9983209|NCT04896827||Healthy participants|Healthy participants (n=144)
9983210|NCT04896645|Experimental|Patients 8 to <19 years of age with a diagnosis of asthma|Patients 8 to <19 years of age with a diagnosis of asthma as ICD-9 code 493 or ICD-10 code J45 seen in the allergy clinic at CHLA who have an albuterol rescue inhaler already prescribed and access to a personal smartphone will be eligible for recruitment.
9983211|NCT04896541|Experimental|AZD7442|Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
9983212|NCT04896541|Experimental|placebo|Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
9983213|NCT04895579|Experimental|Copanlisib (30-60mg iv)|Patients in the group will receive Durvalumab at 10mg/kg (IV infusion on days 1 and 15, q28 days or 1500mg day 1 q28d). They will also receive Copanlisib ranging from 30mg to 60mg (IV infusion on days 1 and 15, q 28 days).
9983214|NCT04895514|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of gamma-irradiated preserved corneal tissue
9983215|NCT04894786|Experimental|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization & Sleeper Stretch
9735838|NCT02308202|Active Comparator|doxazosin|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive doses of study medication as over-encapsulated doxazosin XL or placebo dosed once in the morning. Study medication will be initiated as one capsule of doxazosin XL 4 mg or placebo given in the morning. The dose will be titrated up to 16 mg/d doxazosin XL or placebo as follows: Days 1-4: 4mg, Days 5-8: 8mg, Day 9-12: 12 mg, Days 13-16: 16 mg.
9735839|NCT02308202|Active Comparator|perindopril|Subjects will be randomized to receive either perindopril 16mg or placebo for 8 days. Participants will receive doses of study medication as over-encapsulated perindopril or placebo dosed once in the morning.
9735840|NCT02308202|Placebo Comparator|placebo|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive placebo for doxazosin XL for 16 days and placebo for perindopril for 8 days.
9735841|NCT02297698|Experimental|Trastuzumab + NeuVax|Patients randomized to this arm will receive vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) (NeuVax vaccine) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumbab to overlap with the PVS. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
9781466|NCT01149473|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
9781467|NCT01149486|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
9781468|NCT01149486|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
9735842|NCT02297698|Active Comparator|Trastuzumab + GM-CSF|Patients randomized to this arm will receive inoculations of GM-CSF (250 μg) administered in an identical manner to those receiving nelipepimut-S/GM-CSF (NeuVax). Patients will be blinded as to whether they are receiving nelipepimut-S/GM-CSF or GM-CSF alone. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
9983216|NCT04894786|Active Comparator|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique and Sleeper Stretch
9983217|NCT04894435|Active Comparator|Group 1: Moderna, Moderna - 28 Days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9735848|NCT02260869|Active Comparator|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
9735849|NCT02260869|Active Comparator|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
9983218|NCT04894435|Active Comparator|Group 2: Moderna, Moderna - 112 days apart|"Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983219|NCT04894435|Active Comparator|Group 3: Moderna, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9984656|NCT03872427|Experimental|Treatment (telaglenastat hydrochloride)|Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9735856|NCT02255838|Experimental|Disposable bronchoscope first (aScope IV), then Reusable bronchoscope (Storz 8402 2x)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
9735857|NCT02255838|Active Comparator|Reusable bronchoscope first (Storz 8402 2x), then Disposable bronchoscope (aScope IV)|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
9781469|NCT01149512||LAGB patients in Weight Wise Program|All patients seen within the Weight Wise program and selected for surgical management, who have undergone LAGB will be included in this analysis.
9781470|NCT01149538|Experimental|Choline Bitartrate|Choline Bitartrate supplementation
9983220|NCT04894435|Active Comparator|Group 4: Moderna, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983221|NCT04894435|Active Comparator|Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983222|NCT04894435|Active Comparator|Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983223|NCT04894435|Active Comparator|Group 7: Pfizer/BioNTech, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9781471|NCT01149538|Placebo Comparator|Placebo|Placebo for choline bitartrate supplementation
9781472|NCT01149616|Active Comparator|Intervention|Dexamethasone 8mg iv x 1
9781473|NCT01149616|Placebo Comparator|Placebo|placebo
9781474|NCT01149655|Experimental|Phase 1|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
9781475|NCT01149655|Experimental|Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
9781476|NCT01149655|Placebo Comparator|Phase 3|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
9781477|NCT01149681|Experimental|Arm one|
9781478|NCT01149733|Experimental|Tamsulosin|0.4 mg Capsule
9781479|NCT01149733|Active Comparator|Flomax®|0.4 mg Capsule
9781480|NCT01149759|Experimental|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks.
9781481|NCT01149772|Experimental|ACCESS|Medically ill patients received six-sessions of cognitive behavioral therapy tailored to their unique needs. Patients received 2 core modules and 3 elective modules. Elective modules focused on physical health, cognitive restructuring, behavioral activation, and relaxation. The six session was a wrap up that everyone received. Patients also had the option to receive 2 follow-up booster sessions to aid in maintenance of skills learned.
9781482|NCT01149772|No Intervention|Enhanced Usual Care|Patients in this arm received feedback about their physical and emotional health functioning and were still able to receive usual primary care services.
9781483|NCT01149785|Experimental|1|There should be at least 14-day washout period between treatment A and B.
9781484|NCT01149863|Experimental|Plerixafor 17 hours prior to apheresis|Dosing of plerixafor will occur at 3PM (1500 hours).
9781485|NCT01149876|Experimental|Nu Skin Product|
9781486|NCT01149876|Experimental|Nu Skin product with galvanic spa system|
9781487|NCT01149876|Active Comparator|Tretinoin cream 0.05|
9781488|NCT01149876|Placebo Comparator|over the counter moisturizer|
9781489|NCT01150097|Experimental|Everolimus + reduced tacrolimus|Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.
9781490|NCT01150097|Experimental|Tacrolimus elimination|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.
9781491|NCT01150097|Active Comparator|Tacrolimus control|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.
9781492|NCT01150123|Experimental|5 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant
9781493|NCT01150123|Experimental|20 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.
9781494|NCT01150123|Experimental|5 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
9781495|NCT01150123|Experimental|20 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
9781496|NCT01150123|Experimental|5 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59
9781497|NCT01150123|Experimental|20 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59
9983224|NCT04894435|Active Comparator|Group 8: Pfizer/BioNTech, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983225|NCT04894435|Active Comparator|Group 9: Astra Zeneca, Moderna - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983226|NCT04894435|Active Comparator|Group 10: Astra Zeneca, Moderna - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983227|NCT04894435|Active Comparator|Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983228|NCT04894435|Active Comparator|Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart|"Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days.~Vaccine-exposed participants will only be blinded to, and receive, the second injection."
9983229|NCT04894435|Active Comparator|Group 1b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
9735871|NCT02210078|Experimental|Treatment (allogeneic CMV-specific cytotoxic T-lymphocytes)|Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes IV. Patients with partial response, stable disease, or progressive disease may receive an additional dose of allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes at a minimum of 2 weeks from the first infusion.
9735872|NCT02207712|Active Comparator|Standard Arm|Those receiving only their prescribed ranibizumab treatment only
9735873|NCT02207712|Experimental|Intervention Arm|Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
9983230|NCT04894435|Active Comparator|Group 2b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
9983231|NCT04894435|Active Comparator|Group 3b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
9983232|NCT04894435|Active Comparator|Group 4b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
9983233|NCT04894435|Active Comparator|Group 5b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
9983234|NCT04894435|Active Comparator|Group 6b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
9983235|NCT04894435|Active Comparator|Group 7b|Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.
9735880|NCT02191306||HIV Positive Patients (Study Group)|
9735881|NCT02191306||Non HIV Positive Patients (Control)|
9983236|NCT04894435|Active Comparator|Group 8b|Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.
9983237|NCT04892797||Covid-19+|Hospitalized patients with Covid-19 infection confirmed by PCR test
9983238|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
9983239|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 250mg/m2|Eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 250 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
9735888|NCT02164942||Single Arm|Specimen Collection
9735900|NCT02151526|Experimental|LentiGlobin BB305 Drug Product|Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.
9735904|NCT02141438||Radium-223 dichloride (Xofigo, BAY88-8223)|Single-arm cohort observational study with CRPC patients with bone metastasis treated with Radium-223.
9983240|NCT04890613|Experimental|Main Study Cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with histologically confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation will be enrolled to receive CX-5461 at a dosing concentration of 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
9983241|NCT04890613|Experimental|Exploratory cohort patients receiving CX-5461 at 325mg/m2|After confirming the dose of 250mg/m2 to be safe and tolerable, eligible patients with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation will be enrolled to receive CX-5461 at a dosing concentration of 325 mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle.
9984657|NCT03869515||chILD|The chILD syndrome exists when a child with DLD has had the common causes of DLD excluded as the primary diagnosis and has at least three of the following four criteria: (1) respiratory symptoms (e.g., cough, rapid and/or difficult breathing, or exercise intolerance); (2) respiratory signs (e.g., resting tachypnea, adventitious sounds, retractions, digital clubbing, failure to thrive, or respiratory fail- ure); (3) hypoxemia; and (4) diffuse abnormalities on CXR or a CT scan.
9984658|NCT03869515||Control|Healthy subjects were recruited from participants of an ongoing prospective birth cohort study: 'The Pulmonary Function Assessment for Bronchopulmonary Dysplasia (BPD) and Recurrent Lower Respiratory Tract Infections (LRTI) in Chinese Children'. Exclusion criteria were major birth defects, upper airway pathology, cardiac or neurological diseases, failure to thrive, a history of severe respiratory disease with intensive care unit admission, previous physician-diagnosed LRTI, gestational age (GA) <37 weeks or birthweight (BW) <2.5 kg.
9735913|NCT02119468|Experimental|Treatment (3mg MLN9708)|Patients receive 3mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9735914|NCT02119468|Experimental|Treatment (4mg MLN9708)|Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9983242|NCT04890236|Experimental|Treatment (duvelisib)|Patients receive duvelisib PO BID for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion.
9983243|NCT04888858|Experimental|Epidural Analgesia|All subjects will be given epidural analgesia to treat their labor pain. As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
9983244|NCT04886817|No Intervention|Control|The control group participants in this study will not receive any intervention as is the current standard of clinical care for excess sugary drink consumption. They will receive monthly check-in reminders from research staff to promote engagement and retention and will participate in data collection visits at baseline, 3 and 6 months.
9983245|NCT04886817|Experimental|Intervention|"Intervention group participants will receive a 6-month behavioral intervention with the following components:~A water promotion toolkit that includes water bottles, water flavor infusers, stickers to decorate bottles, and a children's book about water consumption, as well as instructions for other intervention components (how to view video, download app, and prepare for calls)~A 5-minute educational video that introduces parents to healthy drink choices for the family.~Ready, Set Gulp! A smartphone application for families that will help all family members track their beverage intake, find out how much water and sugar they are consuming, set goals, compete for points, answer quiz questions and create new recipes for flavor infused water.~A series of 14 interactive voice response phone calls to parents over 6 months that educate parents on topics relevant to improving family drink choices."
9983246|NCT04886479|Experimental|Daily Disposable Silicone Hydrogel Contact Lens|Subjects will be randomized to wear Daily Disposable Silicone Hydrogel Contact Lens in one eye and will be patched for 3 hours with the contralateral eye remain open.
9983247|NCT04886479|Active Comparator|Habitual Daily Disposable Hydrogel Contact Lens|Subjects will be randomized to wear Daily Disposable Hydrogel Contact Lens in one eye and will be patched for 3 hours with the contralateral eye remain open.
9983248|NCT04886479|Active Comparator|Non-lens wearers|Subjects with no previous history of contact lens wear
9983249|NCT04886284|Experimental|Ertapenem|Ertapenem 1g IV daily infused over 2 hours x 5 days
9983250|NCT04886284|Placebo Comparator|Placebo|Saline placebo infused daily over 2 hours x 5 days
9983251|NCT04884243|Placebo Comparator|CBT-006|
9983252|NCT04884243|Experimental|2.5% CBT-006|
9983253|NCT04884243|Experimental|10% CBT-006|
9983254|NCT04883281|Active Comparator|Involved Nodal Radiotherapy with conventional margins w or w/o chemotherapy|If a patient loses a significant amount of weight on treatment, or the tumor contour changes substantially, repeat CT simulation and re-planning is allowed in the CM arm. However, the gross tumor volume may not be reduced due to tumor shrinkage. The original extent of disease must be included in the replanned GTV.
9735938|NCT02106572|Experimental|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900
9735939|NCT02106572|Active Comparator|Mitomycin C|intravesical instillation of Mitomycin C
9983255|NCT04883281|Experimental|Involved Nodal Radiotherapy with marginless Daily Adaptive Radiotherapy w or w/o chemotherapy|Patients in the ML/DART Arm will have their radiation plan adapted with every fraction. The adaptation process will be performed automatically on the Varian Ethos adaptive therapy software under the supervision of the treating physician.
9983256|NCT04882696|No Intervention|usual care with bare feet|patients will be treated barefoot during their stay
9983257|NCT04882696|Experimental|specific care with anti-slip socks|Patients in this group will wear non-slip socks
9983258|NCT04881825|Experimental|once-weekly glepaglutide|All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)
9983259|NCT04881175|Experimental|FlexSure Applicator|The TempSure FlexSure applicator will be used on the abdomen or flanks.
9983260|NCT04880538||Asymptomatic patients for any motility disorder|
9983261|NCT04880538||Patients with gastrointestinal dysmotility|
9984659|NCT03867682|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 administered on Day 5 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
9984660|NCT03867643||Hepatitis B vaccine booster|Children with anti-HBs at a level of<10mIU/mL or [10,100) mIU/mL before booster.
9984661|NCT03867643||Observation|Children with anti-HBs at a level of >100mIU/mL or [10,100) mIU/mL before booster.
9983262|NCT04879823|Experimental|Dexamethasone|"IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup.~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
9735951|NCT02024360|Experimental|patient navigation|Patient navigator visits home to encourage health eating, active living and parental skill building
9983263|NCT04879823|Placebo Comparator|Placebo|"An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
9983264|NCT04878120|Active Comparator|Standard Hybrid Closed Loop Control (USS Virginia)|Use of Standard Hybrid Closed Loop Control
9983265|NCT04878120|Experimental|Hybrid Closed Loop Control (USS Virginia) with Smart Bolus Calculator Informed by SI|Use of Hybrid Closed Loop Control with Enhanced Prandial Dosing
9983266|NCT04876703|Experimental|Excite group (Group A)|The experimental group (Group A) will receive standard motor retraining of the affected upper extremity in addition to functional electrical stimulation provided by means of Xcite system 4 days per week for 30 minutes for two weeks.
9983267|NCT04876703|Active Comparator|Standard motor training group (Group B)|The control group (Group B) will receive standard motor retraining of the upper extremity.
9983268|NCT04875429|Experimental|Aortic abdominal aneurysm|
9735967|NCT01960530|No Intervention|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
9735968|NCT01960530|Other|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
9735969|NCT01960530|Experimental|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
9735970|NCT01960530|Active Comparator|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
9781498|NCT01150123|Experimental|5 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59
9735971|NCT01960530|Active Comparator|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
9735972|NCT01960244||hypercholesterolemia|familial hypercholesterolemia
9735973|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
9735974|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
9735975|NCT01954875||healthy controls|healthy subjects as controls
9983269|NCT04875221|Experimental|Experimental neurofeedback arm|The experimental arm will be able to view a feedback display that informs them of the strength of connectivity between the target regions. In both arms, feedback signals will be relayed back to the participant in the scanner through visualization software as a thermometer that increases or decreases as the extent to which the neural target model dominates (in other words, as the strength of directed connectivity between regions increases).
9983270|NCT04875221|Sham Comparator|Sham-control neurofeedback arm|Participants in the sham-control arm will receive yoked sham neurofeedback signal (or fake signal), corresponding to a replayed feedback signal from a successful participant in the experimental group in order to ensure similar motivational states and following standard methods.
9735978|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
9735979|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
9983271|NCT04874350|Experimental|LPCN 1148|Oral LPCN 1148 capsules, administered as BID.
9983272|NCT04874350|Placebo Comparator|Placebo|Oral matching placebo capsules, administered as BID.
9983273|NCT04872439||Antibody isolation|
9983274|NCT04871815|Experimental|Treatment of COVID19 Long Haulers with sodium pyruvate nasal spray|This is a single arm, open label study. All subjects will be provided a log for monitoring symptoms associated with Long COVID and asked to record symptom severity using a likert scale for one week. All subjects will then use N115 sodium pyruvate nasal spray 3x daily for an additional week and continue to log their symptoms.
9983275|NCT04870333|Active Comparator|Niclosamide|"INN: Niclosamide Ethanolamine Chemical name (IUPAC): 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide.2 aminoethanol CAS registry number: 1420-04-8 Lab code: UNI911~The IMPs niclosamide Nasal Spray 1% and matching Nasal Spray Placebo will be provided in 20 mL amber glass vials with nasal spray pumps, containing 8.5 mL of the respective solution, delivering 140 μL per spray shot. It is an isotonic and euhydric aqueous solution with red colour."
9983276|NCT04870333|Placebo Comparator|Placebo niclosamide|Placebo to match niclosamide will be supplied, stored, labelled, dispensed and dosed as for the active formulation. The placebo product is formulated to have the same appearance as the active solution.
9735986|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
9735987|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
9983277|NCT04870333|Active Comparator|Ciclesonide|"Chemical name (IUPAC): 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacycloicosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate CAS registry number: 141845-82-1~It is a pressurised solution, intended for inhalation use and commercialised under the brand Alvesco. The recommended dose of ciclesonide is 160μg once daily, which leads to asthma control in the majority of patients. However, this may be increased if necessary to 320μg twice daily, in severe asthma."
9983278|NCT04870333|Placebo Comparator|Placebo ciclesonide|Matched placebo contains the same solvent and propellant as the active product but no drug substance.
9983279|NCT04870333|Experimental|Sotrovimab|Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion Colourless or yellow to brown, liquid solution 20 mM histidine, 7% sucrose (w/v), 0.04% PS80 (w/v), 5 mM L-methionine at pH 6.0
9983280|NCT04870333|Placebo Comparator|Placebo sotrovimab|This will be in the form of 0.9% sodium chloride 50mL for infusion and will be sourced from commercially available stock by the site. It may be procured and stored as per sites usual procedures and only requires handling as an IMP upon dispensing and labelling.
9736007|NCT01892722|Experimental|Fingolimod|Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
9736008|NCT01892722|Active Comparator|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
9736009|NCT01892722|Experimental|Fingolimod-Younger Cohort|The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2)
9736011|NCT01881308|Active Comparator|Stable dose TNF inhibitor|Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
9736012|NCT01881308|Experimental|Stepdown and withdrawal of TNF inhibitor|Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
9736013|NCT01881308|Active Comparator|Stable dose synthetic DMARD|Stable dose of synthetic DMARDs, either monotherapy or combination therapy.
9736014|NCT01881308|Experimental|Synthetic DMARD dose reduction|Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).
9736015|NCT01881308|Other|ARCTIC follow-up|Patients are treated according to the ARCTIC treatment schedule based on disease activity.
9983281|NCT04869449|Experimental|Ketoconazole|Participants will be taking 400 mg of the study drug (two 200 mg tablets) by mouth twice a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation) and in the evening after their biopsy or surgery (after the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
9983282|NCT04867954||Healthy volunteers|7 healthy participants will be recruited.
9983283|NCT04867954||Patients with small, low-risk GEV|7 patients with small, low-risk Gastroesophageal varices (GEV) will be recruited.
9983284|NCT04867954||Patients with large, high-risk GEV|7 patients with large, high-risk Gastroesophageal varices (GEV) will be recruited.
9983285|NCT04867954||Patients scheduled for screening or surveillance esophagogastroduodenoscopy (EGD)|"100 patients diagnosed with cirrhosis and scheduled for screening or surveillance esophagogastroduodenoscopy (EGD) procedure will be recruited. Participants will complete a single research visit, lasting approximately 2 hours, that will include the following procedures:~Participants will fast for 12 hours prior to arriving.~An IV will be placed and a blood sample collected (~11 mL, if necessary).~All participants will undergo research MRI lasting approximately 1.5 hours"
9983286|NCT04867954||Obese patients|20 obese patients will be recruited
9983287|NCT04867317|Active Comparator|Growth Hormone Replacement Therapy|Recombinant Human Growth Hormone
9983288|NCT04867317|Placebo Comparator|Placebo|Placebo
9983289|NCT04867018||Orthopaedic Trauma, Pediatrics and Joint Patients|Patients will have an additional 9ml of blood drawn during their normal course of care for this study up to 4 times. Intraoperatively, we will request a tissue sample of the debrided injured muscle from the area where the surgeon is operating. There will be no additional tissue sample taken during the surgery, but what is removed in the normal course of the operation will be used for analysis in our study.
9983290|NCT04867018||Healthy Volunteer|Blood will be taken from healthy, nonpregnant adults who weigh at least 110 pounds. All volunteers will have a single blood draw of 100ml at the time of consent.
9983291|NCT04866550||Connected tablet|Patients aged over 60, living at home, with heart failure and / or chronic obstructive pulmonary disease, potentially requiring care cross-border (France and Belgium).
9983292|NCT04866147||Chronic postsurgical pain patients|Patients who undergo various common surgical procedures
9983293|NCT04862871|No Intervention|Healthy Controls|A cohort (n=10) of participants will be recruited who do not have any neurological conditions and are age and sex-matched to participants in Arms 2 and 3.
9983294|NCT04862871|No Intervention|Chronic Widespread Pain|A cohort (n=10) of participants who have not yet begun the exercise program and are currently on the waitlist for the exercise program at the PPRC
9983295|NCT04862871|Active Comparator|Chronic Widespread Pain - Exercise|A cohort (n=10) of participants who have completed the exercise program at the PPRC. These individuals will be evaluated the day of their last treatment visit
9983296|NCT04862741|Experimental|NX-13 250mg IR|Oral
9983297|NCT04862741|Experimental|NX-13 500mg IR|Oral
9983298|NCT04862741|Experimental|NX-13 500mg MR|Oral
9983299|NCT04862741|Placebo Comparator|Placebo|Oral
9983300|NCT04862676|Experimental|Experimental Arm:single|Repeated treatments with hyperbaric oxygen on Days 0, +1 and +2 of high-dose therapy melphalan and autologous transplants.
9983301|NCT04862533|Experimental|Beta-alanine + PFMT|Participants will ingest an active supplement containing beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
9983302|NCT04862533|Experimental|Placebo + PFMT|Participants will ingest a placebo supplement containing no beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
9983303|NCT04861610|Experimental|Brief mindfulness based program|A four session program, each last for 2.5 hours. Brief mindfulness exercises promote stress reduction, with an introduction of mindfulness to caregivers and home practice is encouraged with guidance.
9983304|NCT04861610|Active Comparator|Psychoeducation|A four session program, each last for 2.5 hours. It promotes the coping and problem solving of caregivers. Brief home application included.
9983305|NCT04861610|No Intervention|Treatment-as-usual|
9983306|NCT04861025||Users Group|Patients admitted to any Hospitalization Unit belonging to Geriatrics Department
9983307|NCT04861025||Health Professionals Group|All health professionals working at some Hospitalization Unit belonging to CSAPG Institution
9983308|NCT04860271|Active Comparator|Filiform Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 6 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first treatment, after the third treatment, after the sixth treatment and at 2 weeks after the sixth treatment.
9983309|NCT04860271|Active Comparator|Press Needle|Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 3 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first needle placement, after replacing the first sets of needles, after removing the third sets of needles and at 2 weeks after removing the third sets of needle.
9983310|NCT04859829||Patients with autoimmune dysmotility receiving IVIG infusions|
9983311|NCT04859829||Patients with autoimmune dysmotility without IVIG infusions|
9983312|NCT04859764|Experimental|Reparel Sleeve Group|Reparel sleeve and corticosteroid injection
9983313|NCT04859764|Placebo Comparator|Placebo Sleeve Group|Placebo sleeve and corticosteroid injection
9983314|NCT04859699|No Intervention|Control Group|This arm will include schools and the enrolled families assigned as the control group, who will not receive the COVID-19 Health Education Comic Books and video intervention until the end of the school year.
9983315|NCT04859699|Active Comparator|COVID-19 Comic Books|This arm will include schools that are randomized to receive an intervention of Health Education comic books focused on the benefits of COVID-19 topics such as masking, social distancing and COVID-19 testing.
9983316|NCT04857281|Experimental|nVNS device|Candidates who, after the screening period are eligible to receive the nVNS device.
9983317|NCT04857099||Macular edema|
9736075|NCT01742299|Experimental|imatinib mesylate|The starting dose of imatinib should be the same as the last dose that was given in the parent imatinib study (400 mg/day to 600 mg/day). After this, the dose of imatinib is based on the investigator's judgment.
9736076|NCT01737060|Active Comparator|Angular stable plate Philos|Open Reduction and Osteofixation with Philos plate and TiCron cerclages
9736077|NCT01737060|Experimental|Reverse Total Shoulder Artroplasty|Intervention group
9983318|NCT04856865|Experimental|Arm 1|
9983319|NCT04856865|Experimental|Arm 2|
9983320|NCT04856696|Experimental|combined non-invasive PGT-A & PGT-A|Infertility women who underwent both non-invasive PGT-A and PGT-A
9983321|NCT04856696|Experimental|non-invasive PGT-A|Infertility women who underwent non-invasive PGT-A only
9983322|NCT04856696|Active Comparator|PGT-A|Infertility women who underwent PGT-A only
9983323|NCT04854278||Pilot study|Pilot study with 22 cases, no intervention
9983324|NCT04854278||Baseline measurement|Baseline measurement of +/- 100 cases, no intervention
9983325|NCT04854278||Post measurement|Post measurement of +/- 100 cases after implementation of a Massive Open Online Course
9736086|NCT01726179|Experimental|Resin infiltration|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Control. Teeth in this arm are treated by the resin infiltration technique using Icon (DMG, Germany) according to manufactures´ instructions. In addition patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
9736087|NCT01726179|Other|Control|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Resin infiltration. Teeth randomized into this arm do not recieve any special treatment except general oral nonivasiv treatment (flossing and brushing). Patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
9736089|NCT01716806|Experimental|Part A: Brentuximab Vedotin in HL Patients|
9736090|NCT01716806|Experimental|Part B: Brentuximab Vedotin + Dacarbazine in HL Patients|
9736091|NCT01716806|Experimental|Part C: Brentuximab Vedotin + Bendamustine in HL Patients|
9736092|NCT01716806|Experimental|Part D: Brentuximab Vedotin + Nivolumab in HL Patients|
9736093|NCT01716806|Experimental|Part E: Brentuximab Vedotin in HL Patients|
9736094|NCT01716806|Experimental|Part F: Brentuximab Vedotin in PTCL Patients|
9983326|NCT04854031||Cochlear Implant Recipients|30 participants who lost their hearing and received one or two cochlear implants as adults will participate in this study. We will include unilaterally and bilaterally implanted individuals listening with their everyday hearing configuration. Individuals with residual acoustic hearing better than 60 dBA at any audiometric frequency will be excluded. Participants will range in age between 19 and 80 years old, although most are expected to be within 50 - 75 years of age.
9983327|NCT04853459|Experimental|Retention|After Border modeling by traditional and light cure. Amount of force required to dislodge.
9983328|NCT04853459|Experimental|Vestibular depth measurement|Casts By using Ney Surveyor
9983329|NCT04851847|Experimental|MatrixflexTM resorbable collagen membrane|Experimental arm using the Matrixflex Resorbable Collagen Membrane for treatment of periodontal intrabony defects
9983330|NCT04851847|Active Comparator|control group membrane|Control arm using the Comparator Xenograft Resorbable Collagen Membrane or treatment of periodontal intrabony defects
9983331|NCT04849741|Experimental|ION373|ION373 will be administered by intrathecal bolus (ITB) injection once every 12 weeks through Week 109.
9983332|NCT04849741|Placebo Comparator|Placebo|Matching placebo will be administered by ITB injection once every 12 weeks through Week 109.
9983333|NCT04849637|Experimental|Standard of care plus adjunctive virgin coconut oil supplementation|Standard of care plus virgin coconut oil
9983334|NCT04849637|No Intervention|COVID-19 Standard of care treatment|Standard of care
9983335|NCT04848480|Experimental|Insulin icodec + insulin aspart|insulin icodec once a week in combination with 2-4 times daily injections of insulin aspart at meal times
9983336|NCT04848480|Active Comparator|Insulin degludec + insulin aspart|insulin degludec once a day in combination with 2-4 times daily injections of insulin aspart at meal times
9983337|NCT04846322|Other|ED delirium & dementia screening & outpatient referral|Routine ED screening for delirium and memory problems with referral for outpatient assessment of cognitive impairment.
9983338|NCT04844593||Participants With CD|Participants with CD diagnosed with or without CPF will be identified from EMRs through medical language application program interface (API) software. The AI will apply NLP and machine learning to identify and analyse text information in EMRs and thereby, extract medical information. The study will consist of two sequential phases: Phase 1 (validation process) and Phase 2 (data collection and NLP).
9983339|NCT04844554|Experimental|Group 1 - 3.0 mA active HD-tDCS|HD-tDCS with 3.0 milliamperes (mA) of intensitive
9983340|NCT04844554|Experimental|Group 2 - Sham HD-tDCS|Sham HD-tDCS
9983341|NCT04843800|Experimental|Acupuncture|The acupuncture treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. The acupuncture treatment protocol will be semi standardized according to usual practice. All patients will be treated with a selection of local and distant points, comprising 10 minutes of insertion time, 30 minutes of needle retention and manipulation to achieve de qi (an irradiating feeling) if possible.
9983342|NCT04843800|Experimental|Chiropractic|The chiropractic treatments will consist of one 20-minute session weekly, for 3 consecutive weeks. The Diversified technique is one of the most commonly practiced techniques by chiropractors. In the treatment of low back pain, this technique involves the application of a quick (high-velocity), short (low-amplitude) thrust (adjustment) to the lombo-pelvic area.
9983343|NCT04843800|Experimental|Waiting list and Therapeutic Massage|The therapeutic massage treatments will consist of one 45-minute session weekly, for 3 consecutive weeks. A technique called Fascial Release will be used. Tension related to back pain is believed to be present not only in the back but also in various parts of the body such as the legs, through the connection of fascia, the membrane that surrounds the muscles. The purpose of this treatment is to reduce the tension connected to the lower back.
9736116|NCT01636544|Experimental|contralateral healthy tissue biopsy|
9983344|NCT04843527|Active Comparator|FreeStyle Libre|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System to manage their diabetes.
9983345|NCT04843527|Active Comparator|FreeStyle Libre plus food logging|Subjects will be randomized to use the FreeStyle Libre Flash Glucose Monitoring System and a food logging smartphone application to manage their diabetes.
9983346|NCT04843436|Experimental|Symani|Patients treated with Symani for any indications expressed in Inclusion/Exclusion criteria
9983347|NCT04842786|Experimental|Coconut oil at 5 mg/Kg body weight twice daily|Coconut oil (Parachute Brand) is a marketed product that is routinely used for daily massage after birth for infants in India. An amount of 5 mg/Kg body weight will be applied twice daily by the health care provider from enrollment until discharge, or until day of life 28, whichever occurs first.
9983348|NCT04842786|No Intervention|No intervention|Subjects assigned to this arm will have their skin gently stroked twice daily for the time that would be required to apply an oil. This will simulate the stroking received by the intervention arm subjects. This will occur from enrollment until discharge, or until day of life 28, whichever occurs first.
9983349|NCT04840056||Intestinal Metaplasia|patient with history of histologically proven gastric intestinal metaplasia
9983350|NCT04840056||Atrophic gastritis|patient with history of histologically proven atrophic gastritis
9983351|NCT04839770|Experimental|Axonpen|Subjects will receive minimally invasive endoscopic surgery using the Axonpen™ system for early hematoma evacuation (within 48 hours post-ictus).
9983352|NCT04839705|Other|WEB Aneurysm Embolization Device|WEB Aneurysm Embolization Device The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
9983353|NCT04837534|Experimental|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
9983354|NCT04837534|Experimental|SMS and phone call reminder group:|In this group after the children have been examined, treatment plan and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol
9983355|NCT04837534|No Intervention|Routine standard care group|In this group, the children will undergo ocular examination, and treatment plan. They will be discharged from the department and advised accordingly including a routine follow-up schedule as per hospital protocol.
9983356|NCT04837495|Active Comparator|Stellate Ganglion block group|will include 20 patients: each one will receive 10 ml lidocaine 2% right stellate ganglion block (RSGB) under sonar guidance
9983357|NCT04837495|No Intervention|Control group|will include 20 patients: a control group
9983358|NCT04837040|Experimental|Paltusotine|
9983359|NCT04837040|Placebo Comparator|Placebo|
9983360|NCT04835402|Experimental|Intervention|Day 1: Pembrolizumab 400mg Day 10: Irreversible electroporation Day 42/84/126/168: Pembrolizumab 400mg
9983361|NCT04834648|Experimental|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
9983362|NCT04834648|No Intervention|Control Arm|General Counseling, which included saying you need to visit the hospital and you have involvement in the eyes due to diabetes, providing a health education leaflet.
9983363|NCT04829305|Experimental|Low dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 1).
9983364|NCT04829305|Experimental|Medium dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 2).
9983365|NCT04829305|Experimental|High dose of SHR2285|The subjects will receive a single dose of SHR2285 (cohort 3).
9983366|NCT04829084|Experimental|Intervention Arm|Health education
9983367|NCT04829084|No Intervention|Control Arm|No health education
9983368|NCT04825873||Cohort 1|Participants with non-small cell lung cancer (NSCLC)
9983369|NCT04825873||Cohort 2|Participants with squamous cell carcinoma of head and neck (SCCHN)
9984662|NCT03866902|Experimental|Nutrition and Physical Activity Intervention|"Classes for the intervention mothers will be run by a bilingual interventionist and will last 105 minutes weekly for 12 weeks and then monthly for 6 months.~Classes for intervention group children will be 105 minutes weekly for 12 weeks and then monthly for 6 months."
9781499|NCT01150123|Experimental|20 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59
9983370|NCT04823663||BSC Product Use|"Subject fulfilling one of the following conditions:~a. prospectively scheduled for a procedure involving i. use of a BSC EP Ablation product or BSC Capital Equipment product or ii. a BSC CRM product implant or b. retrospectively enrolled no more than 10 days after the index procedure and and all data necessary for appropriate reporting of all past visits is available and complete including i. the procedure where being diagnosed or treated with at least 3 separate BSC EP Ablation products/components or BSC Capital Equipment products/components or ii.the BSC CRM product implant."
9983371|NCT04820972|Experimental|E-STAR group|
9983372|NCT04820972|No Intervention|traditional group|
9983373|NCT04818957|Experimental|Vitamin D Oral Thin Film (OTF)|Study subjects will receive vitamin D OTF for a maximum of 12 weeks.
9983374|NCT04817579|Active Comparator|Conventional visual shade matching|Patients requiring single crown in the esthetic zone treated with Conventional visual shade matching (Ivoclar Classic shade guide)
9983375|NCT04817579|Experimental|Spectrophotometer|Patients requiring single crown in the esthetic zone treated with Spectrophotometer (Vita Easy Shade)
9983376|NCT04817579|Experimental|Digital photography combined with eLABor_aid shade analyzing software.|Patients requiring single crown in the esthetic zone treated with Digital photography combined with eLABor_aid shade analyzing software.
9983377|NCT04817007|Experimental|Part 1A: BMS-986158 + Ruxolitinib|
9983378|NCT04817007|Experimental|Part 1B: BMS-986158 + Fedratinib|
9983379|NCT04817007|Experimental|Part 2A: BMS-986158 + Ruxolitinib|
9736182|NCT01516216|Active Comparator|Chemotherapy + Standard Dose Vitamin D|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 400 IU vitamin D3 orally once daily~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
9736183|NCT01516216|Active Comparator|Chemotherapy + Higher Dose|"FOLFOX-bevacizumab: intravenously on Day 1 (+/- 7 days) of every two-week cycle per institutional standards + 8000 IU daily x 2 weeks as loading dose, followed by 4000 IU daily as maintenance dose.~Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons."
9983380|NCT04817007|Experimental|Part 2B1: BMS-986158 + Fedratinib|
9781500|NCT01150123|Placebo Comparator|Placebo|Subjects received 2 injections of placebo administered 1 month apart
9781501|NCT01150357|Experimental|Low Dose Aliskiren|Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than < 50 kg received 6.25 mg; ≥50 kg and < 80 kg received 12.5 mg and ≥ 80 kg and ≤ 150 kg received 25 mg of aliskiren.
9983381|NCT04817007|Experimental|Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable|
9983382|NCT04816175|Experimental|Treatment Intervention|All children will receive 3-5 weeks of intensive neuromotor Acquire therapy, an operant conditioning, play based therapy that maximizes therapeutic movements, attention, and engagement.
9983383|NCT04815720|Experimental|pepinemab + pembrolizumab|Pepinemab will be administered at 20 mg/kg (with possible dose modifications to 15 mg/kg or 10 mg/kg, if the initial 20 mg/kg dose of pepinemab is determined not to be well tolerated) in combination with a fixed dose of 200 mg pembrolizumab, administered in separate IV infusions, Q3W.
9983384|NCT04815525||Normal finding|Colonoscopy finding normal
9983385|NCT04815525||Hyperplastic polyps|Colonoscopy finding of hyperplastic polyps
9983386|NCT04815525||Low-risk adenomas|Colonoscopy finding of low-risk adenomas
9983387|NCT04815525||High-risk adenomas|Colonoscopy finding of high-risk adenomas
9983388|NCT04813120|Experimental|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
9983389|NCT04813120|Experimental|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
9983390|NCT04813120|Experimental|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
9983391|NCT04813120|Active Comparator|Traditional MT using a mirror box|The following common categories of upper-limb movements and actions will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movements, and (c) object manipulation.
9983392|NCT04810988|Active Comparator|Unsupported|"Participants in this arm will receive a 12-week Unified Protocol intervention delivered via the same web platform. Each week, participants will complete the following content:~depression survey,~anxiety survey,~information about their symptom change over time,~psychoeducational text~practice exercises,~home practice instructions,~writing exercise,~home practice worksheets.~In the first week, participants will receive an emailed welcome message followed by a link to the first week's content. For every following week, participants will receive an email at the start of the week with automatically generated feedback on intervention usage, behavior change, and symptom change, as well as the link to the new week's intervention content."
9983393|NCT04810988|Experimental|Partially Supported|Participants in the partially supported arm will receive all aspects of the intervention described above, with no differences between arms for the first seven weeks of the intervention (Modules 1-6). Participants will be introduced to their study therapist in week 8, at the start of Module 7 via email. During Module 7 (exposure; weeks 8-11), participants will receive four video therapy sessions. Session content will be based on principles of exposure therapy (developing a personalized exposure hierarchy, live demonstrations of exposure exercises, in-session exposure practices, post-exposure processing, home practice assignments, and therapist feedback).
9983394|NCT04809064|Experimental|Arthroscopic Bankart repair with remplissage of Hill-Sachs lesion/rehabilitation|Arthroscopic Bankart repair surgery with remplissage of Hill-Sachs lesion and post-operative rehabilitation.
9983395|NCT04809064|Experimental|Open Bankart/rehabilitation|Open Bankart surgery and post-operative rehabilitation.
9983396|NCT04809064|Experimental|Latarjet/rehabilitation|Latarjet surgical procedure and post-operative rehabilitation.
9983397|NCT04805255||Hypofractionated Stereotactic Radiotherapy (HF-SRT)|"A prospective cohort study addressing both neurocognitive outcome measures and oncological endpoints will be carried out for treating newly-diagnosed brain oligometastases with a pre-defined course of hypofractionated stereotactic radiotherapy (HF-SRT) in cancer patients with a fair/satisfactory performance status.~Either a limited number of brain metastases or oligometastatic brain disease refers to that the number of brain metastatic lesions (both post-resected and intact) at enrollment should be limited to three or fewer and that the greatest diameter of any metastatic lesion (either a tumor bed post-surgical resection or an intact brain metastasis) should be no more than 4 cm."
9983398|NCT04803877|Experimental|Regorafenib and Nivolumab|
9983399|NCT04801641|Placebo Comparator|Placebo|Placebo
9983400|NCT04801641|Experimental|Low-Dose Nabilone|pms-nabilone titrated to 2 mg daily
9983401|NCT04801641|Experimental|High-Dose Nabilone|pms-nabilone titrated to 6 mg daily
9983402|NCT04800744|Experimental|Lavender Peppermint Elequil Aromatab|Participants will have a lavender peppermint elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new treatment elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
9983403|NCT04800744|Active Comparator|Sweet Almond Oil Elequil Aromatab|Participants will have a sweet almond oil active comparator elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new active comparator elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
9983404|NCT04800718|Experimental|Door-to-door screening|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
9983405|NCT04800718|No Intervention|Routine awareness activities,Control Arm|The control arm VC will continue its routine awareness activities & health talk sessions in the community.
9983406|NCT04800302|Experimental|Continuous QLB group|U/S-guided continous QLB III
9983407|NCT04800302|Active Comparator|Single dose QLB group|U/S-guided single dose QLB III
9983408|NCT04800302|Active Comparator|Morphine group|IV Morphine
9983409|NCT04800276|Experimental|APA with consideration of ischemia localization|
9983410|NCT04800276|Experimental|APA without consideration of ischemia localization|
9983411|NCT04795700|Experimental|The intervention group|Patients in the intervention group receiving the 8 weeks MSC intervention sessions.
9983412|NCT04795700|No Intervention|The control group|No interventions except conventional care were performed for the control group.
9983413|NCT04794075|Experimental|Experimental group with the therapeutic education and nursing support program|In addition to the conventional oncology follow-up, patients will participate in an initial educational assessments day.
9983414|NCT04794075|No Intervention|Control group|Patients will have the conventional oncology follow-up.
9983415|NCT04792970|Active Comparator|Talc instilled via tunneled pleural catheter combined with standard daily drainage|This arm consists of eligible participants who are randomized to the Talc arm and would receive Talc therapy instilled into the pleural catheter.
9983416|NCT04792970|No Intervention|Standard daily drainage|This arm consists of eligible participants who are randomized to control group and would not receive any intervention.
9983417|NCT04791813||Exposure group|group of surgically treated unilateral cleft lip and palate Egyptian children aged 9_12years
9983418|NCT04791813||Control group|group of healthy Egyptian children aged 9_12years
10200830|NCT05192356|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348(3) - A single oral dose of 1 tablet under fasting condition"
10200831|NCT05192356|Experimental|Sequence 2|"Period 1: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348(3) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
10200832|NCT05192317|Experimental|Arm Sollievo Fisiolax|Sollievo Fisiolax
10200833|NCT05192317|Placebo Comparator|Arm Placebo|Placebo
10200834|NCT05192304|Experimental|0.2mg single dose|single dose of TPN-672 0.2mg, 2 subjects
10200835|NCT05192304|Experimental|0.3mg single dose|single dose of TPN-672 0.3mg, 12 subjects（9 for TPN-672, 3 for placebo）
10200836|NCT05192304|Experimental|0.4mg single dose|single dose of TPN-672 0.4mg, 12 subjects（9 for TPN-672, 3 for placebo）
10200837|NCT05192304|Experimental|0.5mg single dose|single dose of TPN-672 0.5mg, 12 subjects（9 for TPN-672, 3 for placebo）
10200838|NCT05192304|Experimental|0.6mg single dose|single dose of TPN-672 0.6mg, 12 subjects（9 for TPN-672, 3 for placebo）
10200839|NCT05192304|Experimental|0.7mg single dose|single dose of TPN-672 0.7mg, 12 subjects（9 for TPN-672, 3 for placebo）
10200840|NCT05192278|Active Comparator|Group 20 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 10 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 7 ml saline 0.9% (total 20 ml with bupivacaine 0.25%).
10200841|NCT05192278|Active Comparator|Group 30 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 15 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 12 ml saline 0.9% (total 30 ml with bupivacaine 0.25%).
10200842|NCT05192213|Experimental|Intervention|"1,5 g of vitamin C every 6 hours + 200 mg of thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death"
10200843|NCT05192213|Placebo Comparator|Control|"Placebo 1 for vitamin C every 6 hours + Placebo 2 for thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death"
10200844|NCT05192044|Experimental|Group A|Fast track Care (Enhanced recovery after)pancreatico-duodenectomy
10200845|NCT05192044|Active Comparator|Group B|Conventional Care pancreatico-duodenectomy.
10200846|NCT05192018|Experimental|Group A|This group will have their ileostomy reversed after 3 weeks from the index operation. All procedures were performed by the same senior surgeons. The duration of the operation was noted and the ease of reversal of stoma and closure of abdominal wall were assessed on ascale of 0-10 (0 = difficult, 10 = easy) by the operating surgeons.
10200847|NCT05192018|Active Comparator|Group B|This group will be discharged home after the primary colorectal surgery with a defunctioning ileostomy and brought back after an interval of 3 months ,or after completion of their adjuvant therapy, for reversal. All procedures were performed by the same senior surgeons. The duration of the operation was noted and the ease of reversal of stoma and closure of abdominal wall were assessed on ascale of 0-10 (0 = difficult, 10 = easy) by the operating surgeons.
10200848|NCT05191992|Experimental|experimental|The group will receive CPR training with the e-learning method and will learn skills with a handmade mannequin.
10200849|NCT05191979|Active Comparator|Blood volume interactions with cardiovascular adaptations|Individual differences in the time course and relationship between cardiovascular (central and peripheral) adaptations to long-term aerobic training and the concomitant blood volume changes.
10200850|NCT05191979|Active Comparator|Sex differences|Evaluate differences between genders and hormonal factors influencing individual differences (high vs. low responders) - hypothesizing that female have a blunted cardiovascular response to long-term aerobic training.
10200851|NCT05191927||female group|all are female
10200852|NCT05191927||male group|all are male
10200853|NCT05191914|Experimental|chidamide + fulvestrant|
10200854|NCT05191888|Active Comparator|14-day vonoprazan high-dose two-in-one therapy|vonoprazan 20mg bid and amoxicillin 750mg qid
10200855|NCT05191888|Active Comparator|14-day vonoprazan triple therapy|vonoprazan 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid
9983419|NCT04791761|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Families will receive an opioid disposal education document.
9983420|NCT04791761|Experimental|Opioid pain control + Disposal Pouch|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary or by email/mail if no appointment was scheduled. Half of the families randomized to the opioid group will be further randomized to receive an opioid disposal bag + an opioid disposal education document. The pouch is a drug deactivation disposal pouch to dispose the opioid at home.
9983421|NCT04791761|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary or by email/mail if no appointment was scheduled.
9983422|NCT04790201|Experimental|Friendship Bench Delivered by Professional Counselor|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a professional counselor. Individuals enrolled in this arm will receive 6 weekly counseling sessions per the adapted FB protocol (Aim 1).
9983423|NCT04790201|Experimental|Friendship Bench Delivered by Lay Counselor|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a trained lay counselor. Individuals enrolled in this arm arm will receive 6 weekly counselling sessions per the adapted FB protocol (Aim 1).
9983424|NCT04790201|Active Comparator|Enhanced Usual Care|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Enhanced usual care will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care.
9983425|NCT04789096|Experimental|PD-L1 positive|"Participants will receive:~Tucatinib (oral) at a dose of 300 mg BD on day 1-21 of each 21-day cycle~Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle (or 400 mg IV every 6 weeks)~Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle."
9983426|NCT04789096|Experimental|PD-L1 negative|"Participants will receive:~Tucatinib (oral) at a dose of 300 mg BD on day 1-21~Capecitabine (oral) at a dose of 1000 mg/m^2 BD on day 1-14 of each 21-day cycle~Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle (or 400 mg IV every 6 weeks)~Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle."
9983427|NCT04786717|Experimental|core muscle training|Training the endurance of the core muscle.
9983428|NCT04786717|Experimental|movement control training|Based from the initial test, the subjects will receive lumbar movement control exercise. They will perform each lumbar movement control exercise in different position.
9983429|NCT04786717|Experimental|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, and the subjects will practice the real movement in the rest of 7 times.
9983430|NCT04786093|Active Comparator|Stereotactic Ablative Radiotherapy (SAbR) Arm plus Durvalumab arm|SAbR with each radiation treatment fraction delivered every other day
9983431|NCT04786093|Experimental|Personalized Ultra-fractionated Stereotactic Radiotherapy (PULSAR) plus Durvalumab arm|PULSAR with each radiation treatment fraction delivered every 4 weeks
9984663|NCT03866902|Active Comparator|English for Second Language Intervention|"Mothers in the control group will receive English as a Second Language (ESL) classes taught by professional ESL teachers; they will receive the same number of contacts and time as the intervention group mothers for 105 minutes weekly for 12 weeks and 105 minutes monthly for 6 months.~Children in the control group will be read to and color with crayons 105 minutes weekly for 12 weeks and then 105 minutes monthly for 6 months."
9984664|NCT03864536|No Intervention|No-contact control|No-contact control
9983432|NCT04784065|Active Comparator|Treatment arm with control orthosis|
9983433|NCT04784065|Experimental|Treatment arm with experimental orthosis|
9983434|NCT04783376|Active Comparator|Arm 1 (usual treatment)|intervention A
9983435|NCT04783376|Active Comparator|Arm 2(splitted bolus dose, fast-acting insulin only)|intervention B
9983436|NCT04783376|Active Comparator|Arm 3 (splitted bolus dose, fast acting insulin before the meal and regular insulin after the meal)|intervention C
9983437|NCT04783285|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving CS or to a control group receiving treatment as usual. Participants in the intervention group will participate in two CS sessions per week for 16 weeks besides their treatment as usual. The sessions will be based on the existing protocol.
9983438|NCT04783285|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment: social interaction activities, stimulation of personal skills, and any prescribed psychotic-specific medication.
9983439|NCT04779489|Experimental|PULSAR|Eligible patients will receive next-generation stereotactic radiotherapy (PULSAR) 30-36 Gy in 3 fractions to the bladder and targetable, pathologically enlarged lymph nodes
9983440|NCT04779242|Experimental|Omadacycline|Omadacycline 100 mg IV; Omadacycline 300 mg PO (2 x 150 mg tablets); QD Dosing; 7-10 day duration.
9983441|NCT04779242|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg IV; Moxifloxacin 400 mg tablets; QD Dosing; 7-10 day duration
9983442|NCT04777071|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11 IV then undergo PET/CT over 2-3 minutes per bed position at baseline. Patients receiving systemic therapy undergo an additional 68Ga-PSMA-11 PET/CT scan 6 weeks after initiating therapy.
9983443|NCT04776798|Experimental|Biomechanical Taping|"Anti pronation taping will apply bilaterally with Dynamic Tape®. The tape will attach to the dorsal aspect of the foot.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
9983444|NCT04776798|Placebo Comparator|Placebo Taping|"Placebo Taping will apply bilaterally to each individual in the control group by the same physiotherapist, without any effect on increased pronation.~A home-based exercise program will apply in the first session. Printouts showing the exercises will give to the patients. Exercises will be done at home for 4 weeks, 5 d/w."
9983445|NCT04773067|Experimental|UB-612|A proprietary high-precision designer S1-RBD protein based vaccine incorporating Th/CTL peptides to activate T cells.
9983446|NCT04773067|Placebo Comparator|Placebo|Normal saline 0.9%.
9983447|NCT04772885|Experimental|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
9983448|NCT04772885|Experimental|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
9983449|NCT04772885|Experimental|Food Effect Cohort in healthy subjects|Healthy Volunteer SAD subject cohorts (up to 2) will return for a second treatment period and will receive the same treatment which was originally allocated, but in the fed state.
9983450|NCT04772885|Experimental|Multiple dose cohort in HS and AD patients|A single cohort of up to 20 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 14 days.
9983451|NCT04772560|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
9983452|NCT04772560|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
9983453|NCT04770922||Pediatric ALL patients on 6-mercaptopurine|Pediatric ALL patients treated with 6-mercaptopurine who did not experience neutropenia.
9983454|NCT04770922||Pediatric ALL patients on 6-mercaptopurine with neutropenia|Pediatric ALL patients treated with 6-mercaptopurine who experienced neutropenia.
9983455|NCT04768868|Other|IMP7068|"Part 1: Dose Escalation~The study will begin with open-label dose escalation in IMP7068 monotherapy treatment to determine the Maximum tolerated dose (MTD)~Part 2: Dose Expansion The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage. A total of 100 patients each with advanced solid tumor who has exhausted available treatment options will be evaluated."
9983456|NCT04768829|Active Comparator|Placebo group|Nystatin ear drops formulations prepared as intervention except for the addition of Moringa prepared using biodegradable polymers in aseptic condition and tested for sensitivity
9983457|NCT04768829|Experimental|Moringa group|Moringa ear drops prepared using biodegradable polymers in aseptic condition and tested for sensitivity
9983458|NCT04767022|Experimental|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
9983459|NCT04767022|Active Comparator|SeQuent® Please NEO|Paclitaxel Coated PTCA Balloon Catheter
9983460|NCT04764474|Experimental|Treatment|All patients will be administered HMPL-306 orally QD
9983461|NCT04763980|Active Comparator|Cohort A (survey, genetic testing)|Patients complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may also undergo genetic testing.
9983462|NCT04763980|Experimental|Cohort B (educational session, survey, genetic testing)|Patients participate in educational session with health coach over 60 minutes. Patients also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may undergo genetic testing.
9983463|NCT04760912|Experimental|Experimental group general anesthesia without rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring. After induction with Propofol and Sufentanil ( doses adjusted according to weight and age) anesthesia was maintained with sevorane. Muscle strength measured on three occasions with Yamar dinamometar for hand grip strength, before induciran to anesthesia and immediate after Salingeru from anesthesia, then again measured in first 24 hours.
9736342|NCT01175655|Experimental|MSC|
9983464|NCT04760912|Active Comparator|Active comparator: general anesthesia with rocuronium|30 patient ASA classification 1-2 for general anesthesia. Standard anesthesia monitoring with train-of-four (TOF). After induction with Propofol and Sufentanil (doses adjusted according to weight and age) and rocuronium 0,6 mg per kg, anesthesia maintained with sevorane. Muscle strength neasured with Yamar dinamometar for hand grip strength before induction to anesthesia and immediate after awakening from anesthesia, then again measured in first 24 hours.
9983465|NCT04760691|Active Comparator|Pre-Exposure Prophylaxis (PrEP) only|Truvada one tablet by mouth daily
9983466|NCT04760691|Experimental|PrEP plus Gonadotropin Releasing Hormone (GnRH) Agonist|Truvada one tablet by mouth daily Leuprolide 11.25 milligrams (mg) intramuscular (im) injection once
9983467|NCT04760691|Experimental|PrEP plus Low Dose Estrogen|Truvada one tablet by mouth daily Estradiol 1 milligram by mouth daily x 2 weeks
9983468|NCT04760691|Experimental|PrEP plus High Dose Estrogen|Truvada one tablet by mouth daily Estradiol 6 milligrams (mg) by mouth daily x 2 weeks
9983469|NCT04760691|Experimental|High Dose Estrogen|Estradiol 6 mg by mouth daily x 2 weeks
9983470|NCT04758702|Experimental|GROUP 1|L-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
9983471|NCT04758702|Experimental|GROUP 2|H-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
9983472|NCT04758702|Experimental|GROUP 3|A surgical stent will be delivered to cover the surgical site and apply pressure on the wound site.
9983473|NCT04758208||Healthy CALIPER Participants|Healthy community children and adolescents recruited through the CALIPER initiative as well as healthy children and adolescents recruited from outpatient clinics at the Hospital for Sick Children through the CALIPER initiative. Blood samples from these participants will be tested on the Mindray BC-6800Plus device to measure hematology parameters and establish reference intervals.
9983474|NCT04755530|Active Comparator|Regular whole milk|Substitution of a part of the habitual diet with 400 g/day of regular whole milk
9983475|NCT04755530|Experimental|Yogurt with live bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with life bacteria
9983476|NCT04755530|Experimental|Yogurt with inactivated bacteria|Substitution of a part of the habitual diet with 400 g/day of yogurt with inactivated bacteria
9983477|NCT04755530|Experimental|Acidified whole milk|Substitution of a part of the habitual diet with 400 g/day of acidified whole milk
9983478|NCT04753528|Experimental|Group A|Personalized stimulation parameters and amplitude
9983479|NCT04753528|Experimental|Group B|Personalized stimulation amplitude
9983480|NCT04753528|Active Comparator|Group C|Non-personalized stimulation
9983481|NCT04752722|Experimental|Phase 1|Dose escalation phase
9983482|NCT04752722|Experimental|Phase 2|"Cohort 1: Recommended Phase 2 dose (RP2D) with eligible BCG-unresponsive NMIBC patients, up to 4 cycles of treatment with EG-70~Cohort 2: RP2D with eligible high-risk NMIBC patients who have been incompletely treated with BCG or are BCG-naïve"
9983483|NCT04749732|Experimental|WalkingPad plus Psychological Intervention - PsyWPad Group|The participants in Experimental Group 1 will receive a prescription of an HBET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
9983484|NCT04749732|Experimental|WalkingPad plus Virtual Assistant - CyberWPad Group|The participants in Experimental Group 2 will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a virtual assistant that will give motivational support.
9983485|NCT04749732|Active Comparator|Paper WalkingPad group - PaperWPad Group|The participants in the Active Control Group will receive a prescription of an HbET consisting of a walking plan with a duration greater than 30 min per session, frequency of at least three sessions per week, use of near-maximal pain during training as claudication pain endpoint, with the support of a behavioral motivational intervention delivered by a health psychologist.
9983486|NCT04748445||All participants|
9983487|NCT04745299|Experimental|Single cycle administration group|Study drug injections twice in a 26-day interval followed by three times comparator injections every three months.
9516847|NCT03311672|Experimental|Cohort 2 - Immunotherapy with Stereotactic Radiation|Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
9516848|NCT03311633|Experimental|3 week percutaneous pinning group|Percutaneous pinning time will be for three weeks and short cast immobilization for six weeks.
9983488|NCT04745299|Experimental|Multiple administation group|Study drug injections twice in a 26-day interval followed by repeated three times study drug injections every three months.
9736390|NCT01143454||1. Adult index cases and relatives|Enrolled with a known or suspected pathology that may be associated w/cardiovascular dysfunction or risk w/suspected atypical presentation, heritable disorder, or genetic predisposition.
9736391|NCT01143454||2. Child index case and child relatives|Children over 1 year of age who is affected with diseases/disorders (index cases), or who is a relative of a person who is affected with diseases/disorders.
9736392|NCT01143454||3. Healthy adult volunteers|Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.
9983489|NCT04745299|Placebo Comparator|Control group|Comparator injections twice in a 26-day interval followed by three times comparator injections every three months.
9983490|NCT04744285|Active Comparator|Condition 1 (normal cigarettes)|Participants receive regular package cigarettes for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection.
9983491|NCT04744285|Experimental|Condition II (cigarettes with neutral message)|"Participants receive cigarettes with neutral message Nothing about this product's color or name means that it will protect a smoker from the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection."
9983492|NCT04744285|Experimental|Condition III (cigarettes with compensation message)|"Participants receive cigarettes with compensation message This product has a ventilated filter. Filter vents increase how deeply a smoker inhales without them knowing, which can increase the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
9984665|NCT03864536|Active Comparator|Psychoeducation control|Receives general psychoeducation on dementia prevalence, prognosis, and risk factors,
9983493|NCT04744285|Experimental|Condition IV cigarettes with blocking message|"Participants receive cigarettes with blocking message This product has a ventilated filter. Be sure not to block the vent holes with your fingers or lips, which can increase the health risks of smoking for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
9983494|NCT04743791|Active Comparator|Dupilumab|Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.
9983495|NCT04743791|Placebo Comparator|Placebo|Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.
9983496|NCT04743479||New Onset Diabetes|"New Onset Diabetes must meet one of the following criteria:~Documented diabetes diagnosed within the past 3 years.~Definite new-onset diabetes based on recent fasting blood glucose (FBG) values ≥126 mg/dl (7.0 mmol/L) or Hemoglobin A1c (HbA1c) ≥ 6.5%. All glycemic parameters must be measured in an outpatient setting."
9983497|NCT04743479||Familial pancreatic cancer|"Familial pancreatic cancer must meet one of the following criteria:~≥ 2 blood relatives with pancreatic cancer (includes 1st-3rd degree relatives)~One 1st degree relative with PDAC diagnosed before age 60"
10200856|NCT05191888|Active Comparator|14th Rabeprazole reverse mixed therapy|first 7 days rabeprazole 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid and metronidazole 500mg bid Next 7 days rabeprazole 20mg bid and amoxicillin 1gm bid
10200857|NCT05191875|Experimental|group 1 of stage I|14-day therapy：Saccharomyces boulardii. 500mg b.i.d
10200858|NCT05191875|No Intervention|group 2 of stage I|Observe for one month before treatment
10200859|NCT05191875|Other|stage 2|14-day therapy：Ilaprazole. 5mg b.i.d Doxycycline. 0.1g b.i.d Furazolidone. 0.1g b.i.d Colloidal Bismuth Tartrate . 220mg b.i.d
10200860|NCT05191862|Other|Sequence 1|Treatment RTRT
10200861|NCT05191862|Other|Sequence 2|Treatment TRTR
10200862|NCT05191849|Other|Small Cell Lung Cancer receiving chemotherapy|
10200863|NCT05191836|Experimental|Pulpotomy in primary mandibular molars by using video game distraction.|
10200864|NCT05191836|Experimental|Pulpotomy in primary mandibular molars by using audio visual distraction.|
9736416|NCT01099982||Advanced Heart Failure Therapy Group|Patients diagnosed with end stage heart failure undergoing either VAD implantation or heart transplantation.
10200865|NCT05191836|Other|Pulpotomy in primary mandibular molars without using any type of distraction aids|
10200866|NCT05191823|Experimental|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
10200867|NCT05191823|Placebo Comparator|Placebo|Corn oil supplement
10200868|NCT05190900|Experimental|Experimental|We will measure the stabilometric variables before and after the performance of a neuromeningeal mobilisation.
10200869|NCT05189483|Experimental|Albumin-bound paclitaxel plus camrelizumab therapy arm|Enrolled patients will receive the following treatment: 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) and 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks.
10200870|NCT05183776|Experimental|Study patients|study patients will receive holmium radioembolization using a novel administration device.
10200871|NCT05173857|Active Comparator|Drug Eluting Balloon (DEB)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Drug Eluting Balloon Technology.~Drug: Paclitaxel (PTX). Name of Device: Advance PTX"
10200872|NCT05173857|Placebo Comparator|Plain Old Balloon Angioplasty (POBA)|"Percutaneous Angioplasty in dysfunctional arteriovenous access, using Plain Old Balloon Angioplasty.~Drug: None. Name of Device: Advance LP (Low Profile)"
10200873|NCT05173272|Experimental|Experimental: NACT+CCRT|Patients will be treated with 2 cycles of neoadjuvant chemotherapy (Cisplatin 50 mg/m^2 d2 q 21+ Paclitaxel 135 mg/m^2 d1 q 21). After that, weekly cisplatin 30mg/m^2 for 4 or 5 weeks is administered concomitant with external beam radiotherapy (45-50Gy) in 1.8 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes. The primary cervical tumor is the boosted, using brachytherapy, with an additional 30-40 Gy using either image guidance or to point A (in low dose-rate equivalent dose), for a total point A dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
10200874|NCT05173272|Experimental|Experimental: CCRT alone|weekly cisplatin 30mg/m^2 for 4 or 5 weeks is administered concomitant with external beam radiotherapy (45-50Gy) in 1.8 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes. The primary cervical tumor is the boosted, using brachytherapy, with an additional 30-40 Gy using either image guidance or to point A (in low dose-rate equivalent dose), for a total point A dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
10200875|NCT05172661|Experimental|Integrated training model|"Participants in this group will accept postural and cognitive training at the same time, e.g. naming animals while standing on the foam.~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
10200876|NCT05172661|Experimental|Consecutive training model|"Participants in this group will accept postural and cognitive training separately and for identical durations (both 30 minutes).~Each training session will last for 70 minutes, twice a week, and 12 sessions in total."
10200877|NCT05172206|Active Comparator|Symptom-focused Rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
10200878|NCT05172206|Other|Usual Care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
9736417|NCT01099982||Normal Hearts Group|Control samples will be obtained from individuals undergoing other types of cardiac surgery during which it is routine to discard some tissue intraoperatively.
9983498|NCT04743479||Inherited syndromes associated with pancreatic cancer|"Family history includes with inherited syndromes associated with pancreatic cancer ( ≥ 2 blood relative, includes 1st-3rd degree relatives).~Inherited syndromes must meet one of the following criteria:~Hereditary pancreatitis~Familial atypical multiple mole and melanoma syndrome~Hereditary nonpolyposis colon cancer~Peutz-Jeghers syndrome~Hereditary breast and ovarian cancer syndromes"
9983499|NCT04743479||Pancreatic Cystic Neoplasm|Pancreatic Cystic Neoplasm, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), which are defined by endoscopic ultrasound or serial imaging.
9983500|NCT04743479||Chronic pancreatitis|Chronic pancreatitis, defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist.
9983501|NCT04743284||tele-assessment|The balance evaluations will be applied by the tele-assessment method.
9983502|NCT04743284||face-to-face assessment|The balance evaluations will be applied by the face-to-face assessment method in a clinical setting
9516849|NCT03311633|Active Comparator|6 week percutaneous pinning group|Percutaneous pinning time will be for six weeks and also short cast immobilization.
9516850|NCT03311620|Other|Endobronchial ultrasound transbronchial needle aspirate|
9516851|NCT03311607|Other|Cohort treated with AmBisome 15 mg/kg|280 patients, receiving AmBisome
9983503|NCT04742751|Experimental|Treatment|Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With Metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
9516852|NCT03311594|Experimental|Low Alcohol Consumption and No Pain Induction|Condition 1: Low alcohol consumption Condition 2: No pain group
9736433|NCT01067209||Diabetic/Obese Gastric bypass patients|Subjects with obesity including those with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery.
9736434|NCT01062451|Placebo Comparator|Placebo|
9736435|NCT01062451|Active Comparator|Perindopril|
9736436|NCT01062451|Active Comparator|Candesartan|
9983504|NCT04741425|Experimental|REST intervention|There will be one session of online antenatal breastfeeding talk, 5 sessions of daily online postnatal individualized breastfeeding coaching, and 7 weekly postnatal telephone follow-ups.
9983505|NCT04741425|No Intervention|Usual care|"Standard antenatal and postnatal care provided by midwives and lactation consultants in the hospitals through by Zoom or by online self-learning through watching videos and reading pamphlets. Participants can also attend other breastfeeding talks or breastfeeding support groups provided by the non-governmental organizations for maternal care.~After delivery, mothers will be taught about baby care at bedside. Breastfeeding skills will also be taught and assessed by the midwives and lactation consultants individually or in group-based breastfeeding talk in the postnatal ward.~Upon discharge, a breastfeeding and postnatal hotline will be provided to all women for advices, and a telephone follow-up will be arranged for all the mothers within 3 to 4 days after delivery by midwives or lactation consultants. The mother-baby dyads will be suggested to follow up in MCHCs for baby growth and breastfeeding support."
9983506|NCT04740879|Experimental|Intervention|"The Intervention condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful immediately after randomization to group."
9983507|NCT04740879|Other|Waitlist Control|"The Waitlist Control condition will be provided with access to the 4-week online Mindfulness-Based Cognitive Therapy course Be Mindful approximately 4 months after randomization to group."
9983508|NCT04738448|Experimental|Art Therapy Group|
9983509|NCT04738201|Active Comparator|Control group|Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active - resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle.
9983510|NCT04738201|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
9983511|NCT04737096|Experimental|tDCS+DAOIB|
9983512|NCT04737096|Placebo Comparator|tDCS+placebo|
9983513|NCT04736355|Experimental|DAOIB|oral, for 24 weeks
9983514|NCT04736355|Placebo Comparator|Placebo|oral, for 24 weeks
9983515|NCT04734613|Experimental|Tai Chi intervention|Tai Chi exercise intervention provided twice a week for one hour for 12 weeks
9983516|NCT04734613|Active Comparator|self management|self management program provided 6 sessions (one hour per session) for 12 weeks
9983517|NCT04732481||interventional group|passive leg lift test
9983518|NCT04732481||control group|no intervention (SOC)
9983519|NCT04731688|Experimental|Weight Maintenance Group|Individuals in this group will receive all aspects of the Provider Directed Group plus a comprehensive behavioral fat mass loss intervention with food provision. Individuals in this group will be provided foods to eat to support weight maintenance and loss of body fat throughout pregnancy. They will be asked to attend two behavioral counseling sessions at the beginning of the study to help learn the program and set goals. They will return for brief visits with a lifestyle counselor every two weeks until 20 weeks gestation and at least once a month until delivery. Individuals will be provided a scale to help keep track of weight during pregnancy.
9781502|NCT01150357|Experimental|Mid dose|Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 37.5 mg; ≥50 kg and < 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.
9983520|NCT04731688|No Intervention|Provider Directed Group|Individuals in this group will receive what is standard practice by their prenatal care providers during pregnancy. In addition, individuals in this group will be asked to attend a brief session at the time of randomization to familiarize with the study and what is expected. They will also be provided with materials describing healthy behaviors in pregnancy.
9983521|NCT04729816|Experimental|Dietary Intervention|All participants will stay weight stable while undergoing 5 phases of a dietary intervention that lasts 62 days.
9983522|NCT04727970|Experimental|Tricaprilin|Tricaprilin will be administered for 5-21 days. The total daily dose (individual per subject up to a maximum of 10g/kg/day) will be split into 4 doses administered orally, approximately every 6 hours.
9983523|NCT04727736|Experimental|18F-DCFPyL + PET imaging|"Participants will receive a single dose of 18F-DCFPyL and undergo a PET imaging study.~(The PET imaging may be repeated at a later date if the biopsy of the lesion is negative and if the lesion is present on follow-up imaging.)"
9983524|NCT04723953|Experimental|Acute myocardial infarction patient group|
9983525|NCT04723108|Experimental|Virtual reality arm|Participants will be asked to use virtual reality during their infusion for a duration of at least 10 minutes.
9983526|NCT04720196|Experimental|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 5 daily sessions (on consecutive week days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
9983527|NCT04720196|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
9983528|NCT04717401|Experimental|Strain-counterstrain Group A|Strain Counterstrain (SCS) is a passive positional technique which aims to relieve musculoskeletal pain and dysfunction by indirect manipulation .
9983529|NCT04717401|Experimental|Muscle Energy Technique Group B|MET is a gentle manual therapy for the restricted mobility of the spine and extremities and is an active procedure in which the corrective force is regulated by the patient, not the clinician. This technique requires the patient to perform voluntary muscle contractions of varying intensity, in a specific direction, while the clinician uses a counter-force that does not allow movement to occur The physiological mechanism underlying SCS is unknown though. It has hypothesized that muscle tone inhibition occurs by stimulation of the target muscle's Golgi tendon organ by physical approximation of muscle origin and insertion.
9983530|NCT04716101|Experimental|Patients with nonspecific low back pain|Patients will be randomized to receive either a massage technique or a sham massage technique.
9983531|NCT04716101|Active Comparator|Asymptomatic volunteers|Similarly, the volunteers will be randomized to receive either a massage technique or a sham massage technique.
9983532|NCT04715516|Experimental|alcohol brief intervention + lifestyle health promotion|"The intervention arm will receive 4 minutes of alcohol brief intervention, and 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight), to increase knowledge of how to improve women's health and reduce breast cancer risk. Alcohol and lifestyle information will be delivered by way of an animation on an iPad. Participant responses to questions about current alcohol use will branch to personalised feedback consistent with level of alcohol consumption (i.e. drinking within or above current Australian Alcohol Guidelines).~Take-home pamphlets - a pamphlet summarising the alcohol information presented during the animation, and a pamphlet on nutrition to maintain a healthy weight, will be provided."
9983533|NCT04715516|Other|lifestyle health promotion, not inclusive of alcohol information|"The control arm will receive 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight) to increase knowledge of how to improve women's health and reduce breast cancer risk, not inclusive of alcohol information. Lifestyle information will be delivered by way of an animation on an iPad.~Take-home pamphlet - a pamphlet on nutrition to maintain a healthy weight will be provided."
9983534|NCT04713046|Experimental|Allogeneic bone marrow transplant|non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
9983535|NCT04713046|Experimental|CD8-depleted donor lymphocyte infusion (DLI) per dose escalation scheme|CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
9983536|NCT04712604|Experimental|MSOS Group|The participants in this group will receive the MSOS Intervention for 4 consecutive weeks.
9983537|NCT04710641|Experimental|MTL-CEBPA in combination with sorafenib|Intravenous infusion of MTL-CEBPA 130mg/m2 given once every 3 weeks. Oral sorafenib 400mg twice a day will commence C1D8.
9983538|NCT04710641|Active Comparator|Sorafenib alone|Oral sorafenib 400mg twice a day commencing Day1
9983539|NCT04709653|Experimental|Intervention Group|Occupational-based nursing program
9983540|NCT04709653|Experimental|Control Group|Routine nursing care
9983541|NCT04707664|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
9983542|NCT04707664|Placebo Comparator|Placebo Arm|Day 1 - 5: Placebo treatment in addition to standard of care for COVID-19
9983543|NCT04706767|Experimental|Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of Recovery|
9983544|NCT04706767|Experimental|Effect of Dexmedetomidine infusion on Quality of Recovery|
9983545|NCT04706767|Experimental|Effect of Lidocaine infusion on Quality of Recovery|
9983546|NCT04706767|Experimental|Effect of saline infusion on Quality of Recovery|
9983547|NCT04706481||Healthy Control|Healthy subjects who have provided consent for specimen collection
9983548|NCT04706481||Cancer or Other Diseases|Diseased subjects who have provided consent for specimen collection
9983549|NCT04706468|Experimental|40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
9983550|NCT04706468|Experimental|80 mg TG-1000|Participants received 80 mg of TG-1000 orally on Day 1 and 40 mg of placebo on Day 3.
9983551|NCT04706468|Experimental|40 mg TG-1000+40 mg TG-1000|Participants received 40 mg of TG-1000 and 40 mg of placebo orally on Day 1 and 40 mg of TG-1000 on Day 3.
9516853|NCT03311594|Experimental|Low Alcohol Consumption and Pain Induction|Condition 1: Low alcohol consumption Condition 2: Pain group
9983552|NCT04706468|Placebo Comparator|Placebo|Participants received 80 mg of placebo orally on Day 1 and 40 mg of placebo on Day 3.
9983553|NCT04705298|Placebo Comparator|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
9983554|NCT04705298|Experimental|Prebiotic|Oligofructose-enriched inulin 4 grams daily for ≤ age 6; or 8 grams daily for >6 years
9983555|NCT04704700|Active Comparator|patient with inspace device|
9983556|NCT04704700|Placebo Comparator|patient without inspace device|
9983557|NCT04702139|Active Comparator|patient with game-ready splint|Installation of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
9983558|NCT04702139|Placebo Comparator|patient with standard splint|Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
9983559|NCT04702113|No Intervention|Conventional Therapy (Controls)|Treatment with clopidogrel and no pre-emptive genotyping
9983560|NCT04702113|Experimental|Genotype-guided therapy (experimental)|"Treatment with clopidogrel 75 mg daily for non-carriers~Treatment with ticagrelor 90 mg twice daily for carriers"
9983561|NCT04701827|Experimental|Intervention group|AWARE intervention
9983562|NCT04701827|No Intervention|Control group|Treatment as usual (consisting of the standard out-patient mental health service routines in The Capital Region of Denmark)
9983563|NCT04700215|Active Comparator|Group 01 Effectiveness of BiPAP in reducing post CABG pulmonary complications|Bilevel positive airway pressure device after every 6 hours
9983564|NCT04700215|Active Comparator|Group 02 Effectiveness of IS in reducing post CABG pulmonary complications|Incentive spirometry for 15 minutes after every 4 hours
9983565|NCT04699656|Experimental|Plazomicin Injection|plazomicin (30-minute IV infusion at 2.5 mg/kg) single dose given before IHD and single dose given after IHD
9983566|NCT04698304||Group A：TASC C lesion group|Multiple stenoses or occlusions totaling >15cm or recurrent stenoses or occlusions that need treatment after endovascular interventions (300 cases)
9983567|NCT04698304||Group B：TASC D lesion with common femoral artery involved|Chronic total occlusions >20cm with common femoral artery involved (100 cases)
9983568|NCT04698304||Group C：TASC D lesion with proximal popliteal artery involved|Chronic total occlusions >20cm with proximal popliteal artery involved (300 cases)
9983569|NCT04698304||Group D：TASC D lesion with distal popliteal artery involved|Chronic total occlusions >20cm with distal popliteal artery involved (200 cases)
9983570|NCT04698304||Group E：TASC D lesion with popliteal artery and proximal trifurcation vessels involved|Chronic total occlusion of popliteal artery (P1-3 segment) with proximal trifurcation vessels involved (100 cases)
9983571|NCT04698174|Experimental|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|
9983572|NCT04698174|Experimental|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|
9983573|NCT04698174|Active Comparator|Standard Photorefractive keratectomy (PRK)|
9983574|NCT04698070|Active Comparator|Standard|RUTF 130-200 kcal/kg/day for children with nutritional edema or MUAC < 115 mm or WHZ <-3 and RUSF 500 kcal/d for children 6-23 months with WHZ between -2 and -3 Z and MUAC 115-124 mm.
9983575|NCT04698070|Experimental|OptiMA|RUTF 170 kcal/kg/d for children with nutritional edema or MUAC < 115 mm; 125 kcal/kg/d for MUAC 115-119 mm and 75 kcal/kg/d for MUAC 120-124 mm.
9983576|NCT04698070|Experimental|ComPAS|RUTF 1000 kcal/d for children with nutritional edema or MUAC < 115 mm and 500 kcal/day for MUAC 115-124 mm.
9983577|NCT04697810|Experimental|Namodenoson|Namodenoson capsules orally 25 mg every 12 hours for 36 weeks
9983578|NCT04697810|Placebo Comparator|Placebo|Matching placebo capsules orally 25 mg every 12 hours for 36 weeks
9983579|NCT04697719|Experimental|Aspirin 81mg, Then Aspirin 325mg|After a 3 week placebo run-in period, participants first receive Aspirin 81mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 325mg capsule daily for another 3 weeks.
9983580|NCT04697719|Experimental|Aspirin 325mg, Then Aspirin 81mg|After a 3 week placebo run-in period, participants first receive Aspirin 325mg capsule daily for 3 weeks. After a placebo washout period of 3 weeks, they then receive Aspirin 81mg capsule daily for another 3 weeks.
9983581|NCT04693364||Observational (questionnaire, 3D breast model, discussion)|Patients complete questionnaire over 5 minutes about difficulties in making decision about breast cancer treatment, then participate in a consultation with regular care doctor and study doctor/study staff using the 3D breast model. Patients then complete questionnaires over 5-10 minutes about their opinions on the breast model and different breast surgical treatment options available.
9983582|NCT04691557|Experimental|Intervention Group|The intervention group receives the YoungAsthma developing for the smartphone or tablet additionally usual nursing care.
9983583|NCT04691557|Active Comparator|Control Group|The control group receives the usual nursing care.
9983584|NCT04691037||CCTA|
9983585|NCT04690686|Experimental|LW-02 device immunopheresis combined with atezolizumab|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus atezolizumab 1200 milligrams (mg) q3w until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first [N=8]
9983586|NCT04690686|Experimental|LW-02 device immunopheresis combined with weekly paclitaxel|LW-02 column immunopheresis treatments ~3x/week for 16 weeks plus paclitaxel 80 mg/m2 /week × 6 followed by 2 weeks rest until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
9983587|NCT04690686|Experimental|LW-02 device immunopheresis|LW-02 column immunopheresis treatments ~3x/week for 16 weeks alone until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. [N=8]
9983588|NCT04690439|Experimental|Group A|Group A will receive first PBM + manual lymphatic drainage for 9 weeks (2 sessions/week), followed by 9 weeks only manual lymphatic drainage.
9983589|NCT04690439|Active Comparator|Group B|Group B will first receive only manual lymphatic drainage for 9 weeks, followed by the combination of PBM and manual lymphatic drainage for 9 weeks (2x/week).
9983590|NCT04688866||Pregnant women with cervical insufficiency (Cases)|Pregnant women with a shortened (<25 mm) or dilated cervix in the second trimester (or late first trimester)
9983591|NCT04688866||Pregnant women without cervical insufficiency (Controls)|Pregnant women with a normal-length (>= 25 mm) and closed cervix in the second trimester (or late first trimester)
9983592|NCT04688411|Other|MED-Go app Intervention|Participants will use MED-Go app intervention for a total of 12 weeks
9983593|NCT04688411|No Intervention|Control Arm|Standard of care
9516854|NCT03311594|Experimental|Moderate Alcohol Consumption and No Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: No pain group
9983594|NCT04687046||Cohort 1 JUVÉDERM VOLUX® with 3D Imaging|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 1 will have follow-up on-site visits, including 3D imaging, at Months 1, 3, 6, and 12.
9983595|NCT04687046||Cohort 2 JUVÉDERM VOLUX®|Treatment will be determined according to the physician's experience and Directions for Use. Cohort 2 will have follow-up on-site visits at Months 1 and 3 and follow-up telephone calls at Months 6 and 12.
9983596|NCT04685369||Active smokers with wet AMD|
9983597|NCT04682977|Experimental|IPROACTIF|12 weekly sessions. First two sessions focus on comprehensive assessment of physical and executive functioning, assessment of home safety and accessibility, assessment of ADL/IADL competence and performance in context; information in these areas is used by the interventionist to collaboratively identify three patient-centered goals. Goal planning is followed by 10 treatment sessions. Treatment sessions focus on chronic disease education, problem solving issues related to disease management by modifying daily routines, recommendations for embedding physical activity in everyday tasks, and environmental modifications or activity adaptations to increase ADL/IADL independence.
9983598|NCT04682977|Other|Usual care|Participants in the control group will receive usual services which might include primary care and prescription medications for chronic disease management.
9983599|NCT04682626|Experimental|VD3 group|"Dietary Supplement: Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg once weekly for 8 weeks.~."
9983600|NCT04682626|No Intervention|Control group|none has been administered
9983601|NCT04680793|Other|EDS Patients|No intervention during the control period (9 weeks) and then experimental during the rehabilitation stage (9 weeks).
9983602|NCT04680065|Experimental|Active Treatment|
9736561|NCT00588315||skin lesions|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
9736562|NCT00588315||normal skin|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
9983603|NCT04680065|Sham Comparator|Placebo Surgery|
9983604|NCT04679818|Active Comparator|Control Group|Clinicians will be blinded to PMD-200 NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when.
9983605|NCT04679818|Active Comparator|PMD-200 NOL group|Clinicians will titrate fentanyl to keep PMD-200 NOL under 25 - always using good clinical judgement for individual patients
9983606|NCT04677621|Experimental|Nurse Telehealth Intervention|Allocated to tele-intervention
9983607|NCT04677621|Active Comparator|Standard Deep Brain Stimulation (DBS)|Allocated to conventional approach
9983608|NCT04676607|Experimental|treatment group|SHR7390
9983609|NCT04676425|Experimental|Hepatic Impairment|Participants with hepatic impairment will receive a single dose of MK-8189 4 mg orally on Day 1.
9983610|NCT04676425|Experimental|Healthy|Healthy participants will receive a single dose of MK-8189 4 mg orally on Day 1.
9736571|NCT00519818|Experimental|Cortef and Chronocort|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days followed by Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
9983611|NCT04675411|Other|usual care|After a fall leading to hip fracture, patients are cared for by orthopedists and receive internal fixation or arthroplasty. Consultations for internal medicine care are occasionally made depending on the patient's condition. During the first 1 to 2 days after surgery, nurses teach patients how to exercise while still in bed, using caution while changing their position. Pain-relief medications and antibiotics are also administered (for 2-3 days). The first day after surgery, physical therapy usually starts with rehabilitation training only on patients receiving arthroplasty. The average hospital stay is 5 to 7 days. After hospital discharge, very few patients use in-home or community rehabilitation or are admitted to a 2-week subacute rehabilitation unit. Patients usually come back to the clinic around 1, 3, 6, and 12 months after hospital discharge. However, adherence to this follow-up schedule is poor. Telephone follow-ups are seldom used.
9983612|NCT04675411|Experimental|Smart Care Model|"The smart care model (SCM) will contain the components of geriatric assessment, continuous rehabilitation, and discharge planning.~Sensors will be installed in bedrooms and living areas of the patient's home to receive signals from the smart clothing. Instant alerts and feedbacks from research nurses to family caregivers about the patient's condition and activity level will be provided."
9983613|NCT04674514|Experimental|Arm A (Single agent)|Dose escalation APG-2575 at 3 dose levels 3+3 design.
9983614|NCT04674514|Experimental|Arm B (combo)|Dose escalation APG-2575 at 3 dose levels in combination with Rd, 3+3 design.
9983615|NCT04672941||COPD patients|COPD patients switching from Tiotropium monotherapy to dual therapy with Tiotropium bromide plus Olodaterol
9983616|NCT04672538|Experimental|Low transition to High Vt protocol|This arm of the study will begin with lower tidal volumes at higher respiratory rates for initial hemodynamic measurements. They will then be transitioned to the higher tidal volume at lower respiratory rate condition for repeat hemodynamic measurement.
9983617|NCT04672538|Experimental|High transition to Low Vt protocol|This arm of the study will begin with higher tidal volumes at lower respiratory rates for initial hemodynamic measurements. They will then be transitioned to the lower tidal volume at higher respiratory rate condition for repeat hemodynamic measurement.
9983618|NCT04670965||E-PRF/rhBMP-2 (similar ratios)|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
9983619|NCT04670965||E-PRF/ACS/rhBMP-2|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
9736605|NCT00381641|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity
9983620|NCT04670965||rhBMP-2/E-PRF|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
9983621|NCT04670965||E-PRF only|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
9983622|NCT04669899|Experimental|Stage 1, Dose Escalation: JTX-8064 monotherapy dose escalation|Dose Escalation, Stage 1 JTX-8064 Monotherapy. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies
9983623|NCT04669899|Experimental|Stage 2, Dose Escalation: JTX-8064 in combination with pimivalimab|Dose Escalation, Stage 2: JTX-8064 in combination with pimivalimab. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies
9983624|NCT04669899|Experimental|Stage 3 Expansion: JTX-8064 monotherapy (Ovarian)|Cohort will enroll subjects with advanced/metastatic PD-1/PD-L1 (PD-(L)1)-naïve, platinum-resistant ovarian cancer
9983625|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (ccRCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced clear cell renal cell carcinoma (ccRCC)
9983626|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (TNBC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced triple negative breast cancer (TNBC)
9983627|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (HNSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, PD-L1+ head and neck squamous cell carcinoma (HNSCC)
9983628|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (Ovarian)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, platinum resistant ovarian cancer
9983629|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (NSCLC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced non-small cell lung cancer (NSCLC)
9983630|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (cSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced cutaneous squamous cell carcinoma (cSCC)
9983631|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (UPS & LPS)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS)
9983632|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (PD-(L)1i-experienced HNSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with PD-(L)1i-experienced HNSCC
9983633|NCT04669834|Other|group A|Patients in this group will receive a traditional therapeutic knee rehabilitation program based on a recent systematic review in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators using clamshell exercise . No emphasis will be placed on stabilizing the core musculature before initiating any of those exercises.
9983634|NCT04669834|Experimental|group B|Patients in this group will receive the same program as group (A) plus core stability exercise , but the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
9983635|NCT04669249|Experimental|PROCare|Technology-enabled, reward-based recovery platform
9983636|NCT04669249|No Intervention|Control|Treatment-as-Usual
9984666|NCT03864536|Experimental|Psychoeducation + CogRx|Receives same general psychoeducation on dementia and will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
9984667|NCT03864419|Experimental|Cohort I (pediatric BL)|Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
9983637|NCT04669067|Experimental|TL-895 combined with KRT-232|"TL-895 will be administered orally, twice a day (BID) continuously starting on Day 1 in a 28-day cycle.~KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle."
9983638|NCT04667572|Experimental|Pulsed 5mW/cm2|5mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 36 minute total treatment time
9983639|NCT04667572|Experimental|Pulsed 8mW/cm2|8mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 22 minute and 30 seconds total treatment time
9983640|NCT04665622|Other|Fronto-temporal Dementia|10 subjects
9983641|NCT04665622|Other|Alzheimer's Dementia|20 subjects
9983642|NCT04665622|Other|Parkinson's Disease|20 subjects
9983643|NCT04665622|Other|Healthy volunteers|20 subjects
9983644|NCT04663087|Experimental|Treatment with XSTAT|Participants randomized to the treatment arm will be treated using the study device - XSTAT.
9983645|NCT04663087|Other|Standard Care|Participants assigned to the control group receive standard prehospital care, consisting of direct pressure/dressings.
9983646|NCT04662489|Active Comparator|Control arm. Pulmonary vein isolation|Pulmonary vein isolation with ablation.
9983647|NCT04662489|Experimental|Treatment arm. Radial ablation|Pulmonary vein isolation plus radial ablation of rotational activity sites.
9983648|NCT04662190|Active Comparator|Control grup|Conventional surgery.
9983649|NCT04662190|Experimental|Intervention group|Surgery planned, simulated and guided by 3D printing.
9983650|NCT04661540|Experimental|Auxora|"Auxora will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours; After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
9983651|NCT04661540|Placebo Comparator|Placebo|"Placebo will be given as a continuous infusion:~Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours. After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours"
9983652|NCT04660240|Active Comparator|Abluminus Sirolimus Eluting Stent System (ASES)|The Abluminus sirolimus eluting stent manufactured by Envision and distributed by Concept Medical.
9983653|NCT04660240|Experimental|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|The Orsiro sirolimus eluting stent manufactured by Biotronik.
9983654|NCT04658888|Experimental|Modified letter with self-sampling request card|This group will receive a modified letter telling the participant they are out of date with their cervical cancer screening. They will also receive information on the self-sampling kit and will be provided a card that they can send back to the study team in order to have a kit sent to their house. The kit will include a pre-paid mailer so that it can be sent back to the lab for testing. The result will then be shared with the participant.
9983655|NCT04658888|No Intervention|Standard letter|Participants will receive a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
9983656|NCT04658498|Experimental|Usual Care (UC)|Intermittent spontaneous breathing periods
9983657|NCT04658498|Experimental|UC + High-intensity inspiratory muscle training (HI-IMT)|
9983658|NCT04658498|Experimental|UC + Low-intensity inspiratory muscle training (LI-IMT) (sham IMT)|
9983659|NCT04658342||Oral Cancer Patients|
9983660|NCT04656236|Experimental|Intervention|3 hours of continuously intravenous infusion of 3-hydroxybutyrate.
9983661|NCT04656236|Placebo Comparator|Control|3 hours of continuously intravenous infusion of saline (NaCl).
9983662|NCT04655391|Experimental|Chapter 1 (glasdegib, decitabine, venetoclax)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD on days 1-28,decitabine IV over 1 hour on days 1-5, and venetoclax PO QD on days 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9983663|NCT04655391|Experimental|Chapter 2 (glasdegib, gilteritinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and gilteritinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9984668|NCT03864419|Experimental|Cohort II (DLBCL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
9983664|NCT04655391|Experimental|Chapter 3 (glasdegib, bosutinib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and bosutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9983665|NCT04655391|Experimental|Chapter 4 (glasdegib, ivosidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9983666|NCT04655391|Experimental|Chapter 5 (glasdegib, enasidenib)|"MOLECULAR DIAGNOSIS SEGMENT: Patients receive glasdegib PO QD for at least 14 days until their AML TAC recommendation is made and they are either consented to a treatment arm in the Treatment Segment or go off study.~TREATMENT SEGMENT: Patients receive glasdegib PO QD and enasidenib PO QD on days 1-28 .Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
9983667|NCT04655378||Acute Rheumatoid Purpura|
9983668|NCT04655378||Rheumatoid Purpura in Remission|
9983669|NCT04655378||Controls|Without infection, inflammatory or auto-immune pathology
9983670|NCT04654546|Experimental|Abdominal scans|Participants who performed an abdominal CT exam up to one month prior to the experimental ultrasound exam.
9983671|NCT04653961|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro Decision Support System-MDI algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 2.5 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
9983672|NCT04652609|Experimental|PRESIONA|An adapted therapeutic exercise program using blood flow restriction cuff perfomed during chemotherapy treatment. 24-36 sessions of 1 hour multimodal components: aerobic, strength and fascial release exercises. Frequency will be adapted to the recovery status of each patient.
9983673|NCT04652609|No Intervention|Control group|Patients undergoing usual medical treatment
9983674|NCT04652414|Experimental|Prednisone|Patients randomized to the intervention arm will receive prednisone 50mg PO daily for 7 days.
9983675|NCT04652414|Placebo Comparator|Placebo|Patients will receive matching placebo PO daily for 7 days.
9983676|NCT04648579|Experimental|Hillrom|The intervention involves an automated vital signs document system consisting of a mobile medical device for measuring vital signs (CSM / Hillrom) that collects and analyzes data acquired at the bedside to be sent to a remote data processing point (Digital Control Station), using Hillrom Connecta software.
9983677|NCT04648579|Active Comparator|Control|Hospital usual care.
9983678|NCT04647682||One single group study|Patients aged 75 years and over Hospitalized in a French covid-19 geriatric unit Positive Covid-19 infection made by Real-time Polymerase Chain Reaction Covid-19 or suspected on thoracic lesions on computerized tomography.
9983679|NCT04647513|Experimental|Art Filler Fine Lines (forehead)|Injection of Art Filler Fine Lines in Forehead wrinkles
9983680|NCT04647513|Experimental|Art Filler Fine Lines (upper lip)|Injection of Art Filler Fine Lines in upper lip wrinkles
9983681|NCT04647513|Experimental|Art Filler Fine Lines (cheek folds)|Injection of Art Filler Fine Lines in cheek folds
9983682|NCT04647513|Experimental|Art Filler Fine Lines (crow's feet)|Injection of Art Filler Fine Lines in crow's feet
9983683|NCT04647513|Experimental|Art Filler Universal (lips volume)|Injection of Art Filler Universal in lips
9983684|NCT04647513|Experimental|Art Filler Universal (nasolabial folds)|Injection of Art Filler Universal in nasolabial folds
9983685|NCT04647513|Experimental|Art Filler Lips (lips volume)|Injection of Art Filler Lips in lips
9983686|NCT04647513|Experimental|Art Filler Lips (very deep nasolabial folds)|Injection of Art Filler Lips in very deep nasolabial folds
9983687|NCT04645576|Other|Midface zone|Injection in the mid-facial areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
9983688|NCT04645576|Other|Temple|Injection in the temples (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
9983689|NCT04645576|Other|Jaw-line|Injection in the jaw-line areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
9983690|NCT04645576|Experimental|Chin|The chin will only receive one injection of Art Filler Volume.
9983691|NCT04644159||Housolds|Pupils, teachers and non-teaching staff who attended schools of the city during the 2019-2020 school year and members of their households
9983692|NCT04644159||Subjects hospitalized or residing in health care facilities|Residents and patients from retirement homes and long-term care units
9983693|NCT04644159||Staff of health care institutions|Staff of health care institutions
9983694|NCT04641702|Experimental|Pharmacologic challenge|Measurement of esophageal response toatropine using functional lumen imaging probe (FLIP)
9983695|NCT04640792|No Intervention|Common Colonoscopy (Group A)|Patients will be examined with Conventional Colonoscopy (CC)
9983696|NCT04640792|Experimental|Magentiq Eye Assisted Colonoscopy (Group B)|Patients will be examined with Magentiq Eye Assisted Colonoscopy (MEAC)
9983697|NCT04640636|Experimental|Ketamine|Ketamine hydrochloride 0.5 mg/kg IM single injection
9983698|NCT04640636|Active Comparator|midazolam|Midazolam 0.06 mg/kg IM single injection
9983699|NCT04640376|Experimental|Paracetamol UNIFLASH 125mg|1 sachet Paracetamol UNIFLASH 125mg + 2 placebo capsule
9983700|NCT04640376|Placebo Comparator|Placebo|1 Placebo sachet + 2 placebo capsule
9983701|NCT04640376|Active Comparator|Paracetamol 500mg|1 Placebo sachet + 1 placebo capsule + 1 capsule Panadol 500mg
9983702|NCT04640376|Active Comparator|Paracetamol 1000mg|1 Placebo sachet + 2 capsules Panadol 500mg
9983703|NCT04640025|Experimental|itacitinib|Participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. Participants who are receiving ruxolitinib under parent protocol INCB39110-209 may continue to receive it as described in that protocol.
9983704|NCT04636879|Experimental|• Group 1. Positive expectation|"Dry needling is a very effective tool used in the treatment of nonspecific neck pain, which we hope will reduce your neck pain."
9983705|NCT04636879|Active Comparator|• Group 2. Neutral Expectation|"Dry needling is an indicated tool used in the treatment of nonspecific neck pain, but its efficacy is unknown."
9983706|NCT04636879|Active Comparator|• Group 3. Negative Expectation|"Dry needling is not a very effective treatment tool for nonspecific neck pain, so we expect your neck pain to increase a bit."
9983707|NCT04636801|Experimental|CHF6001 1600µg|
9983708|NCT04636801|Experimental|CHF6001 3200µg|
9983709|NCT04636801|Placebo Comparator|CHF6001 Placebo|
9983710|NCT04635683|Experimental|Treatment (lenalidomide, umbralisib, ublituximab)|Patients receive lenalidomide PO QD on days 1-21 and umbralisib PO QD on days 1-28. Beginning in cycle 2, patients also receive ublituximab IV over 90 minutes to 4 hours on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial or complete response after cycle 6 continue treatment of lenalidomide PO QD and umbralisib PO QD for 12 additional cycles, and ublituximab IV on day 1 of subsequent even cycles (8, 10, 12, 14, 16, and 18). Patients with stable disease after cycle 6 may continue on treatment for an additional 12 cycles at the discretion of the investigator.
9983711|NCT04634266|Experimental|Experimental intervention|Transcatheter tricuspid valve treatment (TTVT) plus optimal medical therapy (OMT)
9983712|NCT04634266|No Intervention|Control intervention|OMT for severe tricuspid regurgitation in right-sided heart failure
9983713|NCT04632498|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
9983714|NCT04632498|No Intervention|Wait-list Control (WL)|Patient Control receiving no treatment
9983715|NCT04632498|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
9983716|NCT04632225|Active Comparator|Engensis|64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
9983717|NCT04632225|Placebo Comparator|Placebo|32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
9983718|NCT04631926|Other|Hip Muscle Exercises|Hip Muscle Exercises
9983719|NCT04626882|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
9983720|NCT04626882|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after PCI for IRA (during primary PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
9983721|NCT04625101|Experimental|NBI-827104|NBI-827104 administered orally for 13 weeks.
9983722|NCT04625101|Placebo Comparator|Placebo|Placebo administered orally for 13 weeks.
9983723|NCT04623372|Experimental|suture|
9983724|NCT04623372|Experimental|Directed wound healing|
9983725|NCT04622735|Experimental|FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
9983726|NCT04622735|Active Comparator|Paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
9983727|NCT04622735|Active Comparator|Nefopam hydrochloride 30 mg (X2)|Each dose: 2 tablets (included in masking capsule)
9983728|NCT04621916|Active Comparator|Emicizumab + FVIII weekly|In addition to emicizumab prophylaxis,participants will receive non-prophylactic exposure to FVIII concentrates through weekly 50 IU/kg ±10% doses - the choice of FVIII concentrate is at the discretion of the PI.
9983729|NCT04621916|Active Comparator|Emicizumab only|Participants will only receive emicizumab prophylaxis.
9983730|NCT04621682|Active Comparator|Non technical skills and check list|10 hours of training in non-technical skills and checklists in high Fidelity simulation
9983731|NCT04621682|Active Comparator|check list|Control: 10 hours of standard training with checklists in high Fidelity simulation
9983732|NCT04619121|Experimental|Treatment with real NIR-tPBM on top of standing pharmacotherapy|NIR t-PBM to the dorsolateral prefrontal cortex, bilaterally and simultaneously, 20 minutes a day, for 8 consecutive weeks.
9516855|NCT03311594|Experimental|Moderate Alcohol Consumption and Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: Pain group
9516856|NCT03311594|Placebo Comparator|Placebo Alcohol Consumption and No Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: No pain group
9983733|NCT04619121|Sham Comparator|Sham device on top of standing pharmacotherapy|Sham device with neglectable energy to the dorsolateral prefrontal cortex, bilaterally and simultaneously, 20 minutes a day, for 8 consecutive weeks.
9983734|NCT04619056|Experimental|Cohort 1|CEB-01 with total SN-38 dose: 9 mg
9983735|NCT04619056|Experimental|Cohort 2|CEB-01 with total SN-38 dose: 18 mg
9983736|NCT04619056|Experimental|Cohort 3|CEB-01 with total SN-38 dose: 36 mg
9983737|NCT04618458|Experimental|Intervention Arm|Eligible overweight/obese children and their overweight/obese parent (N=20 families) will receive the same telehealth diabetes prevention intervention based on Power to Prevent and delivered by a trained lifestyle coach. Families will meet weekly for 11-weeks (60-min sessions), and then monthly (60-min sessions) for 4 pilot behavioral reinforcement maintenance sessions (15 sessions total). Participants will meet in their respective groups (n=5 families per group) via videoconference using Wi-Fi-enabled tablets with cellular connectivity for the entire intervention. Sessions will consist of nutrition and physical activity behavior change strategies (20 min), problem solving and decision-making skills to circumvent barriers to behavioral change (20 min), and family goal setting and action planning (20 min). Assessment measures will be collected from the child and parent participants at baseline, 12-weeks (post-intervention), and 30-weeks (follow-up).
9983738|NCT04617080|Active Comparator|SUPRACOR Regular|
9983739|NCT04617080|Experimental|SUPRACOR Strong|
9983740|NCT04616846|No Intervention|Control cohort|
9983741|NCT04616846|Experimental|Infected cohort|
9983742|NCT04614987||Participants undergoing CAR T transfusion|Participants will undergo baseline examination followed by evaluations between Days 3 and 5 post-transfusion, on Day 30 post-transfusion date (PTD), PTD 90, and PTD 180. At baseline this will include plasma testing, lumbar puncture (voluntary), neuroimaging (voluntary) and neuropsychiatric performance testing (voluntary). Between post-transfusion Day 3 and day 5, participants will undergo repeat exam, plasma testing, lumbar puncture (voluntary), and neuroimaging (voluntary). Day 30 testing will again test all modalities, including serum, CSF/lumbar puncture (voluntary), brain imaging (voluntary), and formal neuropsychiatric performance testing (voluntary). Finally, Day 90 and 180 will repeat serum testing, brain imaging, and formal neuropsychological performance testing.
9983743|NCT04614766|Experimental|Combination Therapy|Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow. The drug administration is individualized to each participant.
9983744|NCT04614766|Active Comparator|Lutathera® only|Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
9983745|NCT04614597||Three-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 2, 3, and 4 months of age, collected two blood samples and laboratory test results were available.
9983746|NCT04614597||Two-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 4 and 8-11 months of age, collected two blood samples and laboratory test results were available.
9983747|NCT04614142|Experimental|Experimental: Glecaprevir/pibrentasvir for HCV+ kidney transplant recipient|"Glecaprevir (100mg) / pibrentasvir (40mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor.~Subject will receive first dose on day 3 (+/- 2 days) post-kideny transplantation and continue daily for 8 weeks."
9983748|NCT04614064|Experimental|COPD patients|As per inclusion and exclusion criteria for COPD patients
9983749|NCT04614064|Experimental|Healthy volunteers|As per inclusion and exclusion criteria for healthy volunteers
9983750|NCT04613882|Experimental|Soft Toric Custom Made contact lenses|Subjects will be randomized to wear Soft Toric custom made contact lenses for 30 minutes in one eye with other eye patched.
9983751|NCT04613882|Active Comparator|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lens for 30 minutes in one eye with other eye patched
9983752|NCT04613882|Active Comparator|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
9983753|NCT04613739|Experimental|Insurance navigation|The intervention group will be offered access to AAFA's insurance chat bot and navigation services. Navigation will be provided through AAFA's existing online patient community platform that provides assistance with clinical, educational and financial questions and includes secure, personal messaging capabilities that will be supplemented with telephonic outreach.
9983754|NCT04613739|No Intervention|Wait-list controls|Control subjects will be offered the chat bot after completion of data collection for the intervention group (after completion of the four-month follow-up surveys)
9983755|NCT04613050|Active Comparator|Group A (Respiratory Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive respiratory training for 6 weeks.
9983756|NCT04613050|Active Comparator|Group B : (Aerobic Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive aerobic training for 6 weeks
9983757|NCT04613050|No Intervention|Group C : (control group)|It will include 20 patients of both sexes, recovered from COVID-19 infection on medical drugs only will receive no exercise as control group.
9983758|NCT04609124||Intervention group:|Patients (n=35) fasting for 8 hours and received 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
9983759|NCT04609124||Control group:|Patients (n=35) fasting for 8 hours and received intravenous 10 mL saline 0.9% as placebo
9983760|NCT04607850|Experimental|Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^7 pfu)
9983761|NCT04607850|Experimental|Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
9983762|NCT04607850|Experimental|Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10) vp and MVA-HPV (1 x 10^8 pfu)
9983763|NCT04607850|Experimental|Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
9983764|NCT04607850|Experimental|Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^7 pfu)
9983765|NCT04607850|Experimental|Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^8 pfu)
9983766|NCT04607850|Experimental|Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^8 pfu)
9983767|NCT04607850|Experimental|Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^8 pfu)
9983768|NCT04607850|Placebo Comparator|Group 6 Placebo Saline|Sodium Chloride (0.9%)
9983769|NCT04607226|Experimental|Active tVNS - 2 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 2 Hz stimulation frequency
9983770|NCT04607226|Experimental|Active tVNS - 8 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 8 Hz stimulation frequency
9983771|NCT04607226|Experimental|Active tVNS - 30 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 30 Hz stimulation frequency
9983772|NCT04607226|Experimental|Active tVNS - 100 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 100 Hz stimulation frequency
9983773|NCT04607226|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
9983774|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Hydration Gatorade:|
9983775|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Hydration CarbRich Beverage|
9516857|NCT03311594|Experimental|Placebo Alcohol Consumption and Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: Pain group
9983776|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Analgesia Adjunct|
9983777|NCT04606264|No Intervention|Major Abdominal: No Preoperative Oral Analgesia Adjunct|
9983778|NCT04606264|Active Comparator|Major Abdominal: Neuraxial Analgesia|
9983779|NCT04606264|Active Comparator|Major Abdominal: Regional Analgesia|
9983780|NCT04606264|Active Comparator|Major Abdominal: PONV Prophylaxis Perphenazine|
9983781|NCT04606264|Active Comparator|Major Abdominal: PONV Prophylaxis Aprepitant|
9983782|NCT04606264|Active Comparator|Major Abdominal: Primary Anesthetic Volatile Agent|
9983783|NCT04606264|Active Comparator|Major Abdominal: Primary Anesthetic TIVA|
9983784|NCT04606264|Active Comparator|Major Abdominal: Fluid Therapy Stroke Volume Optimization|
9983785|NCT04606264|Active Comparator|Major Abdominal: Fluid Therapy Maintain Euvolemia|
9983786|NCT04606264|Active Comparator|Major Abdominal: Analgesia Adjuncts Ketamine|
9983787|NCT04606264|Active Comparator|Major Abdominal: Anesthesia Adjuncts Lidocaine|
9983788|NCT04606264|Active Comparator|Major Abdominal: Anesthesia Adjuncts Ketamine and Lidocaine|
9983789|NCT04606264|No Intervention|Major Abdominal: No Anesthesia Adjuncts|
9983790|NCT04606264|Active Comparator|Major Abdominal: Intraoperative Opioid|
9983791|NCT04606264|No Intervention|Major Abdominal: No Intraoperative Opioid|
9983792|NCT04606264|Active Comparator|Major Abdominal: Postoperative Oral Analgesia Adjunct|
9983793|NCT04606264|No Intervention|Major Abdominal: No Postoperative Oral Analgesia Adjunct|
9983794|NCT04606264|Active Comparator|Orthopedic: Preoperative Oral Hydration Gatorade|
9983795|NCT04606264|Active Comparator|Orthopedic: Oral Hydration CarbRich Beverage|
9983796|NCT04606264|Active Comparator|Orthopedic: Preoperative Oral Analgesia Adjunct Gabapentin|
9983797|NCT04606264|No Intervention|Orthopedic: No Preoperative Oral Analgesia Adjunct|
9983798|NCT04606264|Active Comparator|Orthopedic: Neuraxial Analgesia|
9983799|NCT04606264|Active Comparator|Orthopedic: Regional Analgesia|
9983800|NCT04606264|Active Comparator|Orthopedic: PONV Prophylaxis Perphenazine|
9983801|NCT04606264|Active Comparator|Orthopedic: PONV Prophylaxis Aprepitant|
9983802|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic Volatile Agent|
9983803|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic Spinal|
9983804|NCT04606264|Active Comparator|Orthopedic: Fluid Therapy Stroke Volume Optimization|
9983805|NCT04606264|Active Comparator|Orthopedic: Fluid Therapy Maintain Euvolemia|
9983806|NCT04606264|Active Comparator|Orthopedic: Analgesia Adjuncts Ketamine|
9983807|NCT04606264|Active Comparator|Orthopedic: Intraoperative Opioid|
9983808|NCT04606264|No Intervention|Orthopedic: No Intraoperative Opioid|
9983809|NCT04606264|Active Comparator|Orthopedic: Postoperative Oral Analgesia Adjunct|
9983810|NCT04606264|No Intervention|Orthopedic: No Postoperative Oral Analgesia Adjunct|
9983811|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic TIVA (Propofol)|
9983812|NCT04605172||Lockdown Group|newborn born prematurely during confinement (1st March - 1st June 2020)
9983813|NCT04605172||Control group|newborn born prematurely in comparative years over the same period (1st March - 1st June from 2015 to 2019)
9983814|NCT04604691|Experimental|Blinatumomab Treatment|
9983815|NCT04604665|Experimental|High frequency postural change|"Repositioning or rotation of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency. It has to be performed on each patient between an interval less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to the right lateral, supine, left lateral, supine, or prone position to supine position. The repositioning will be provided until a patient is discharged from ICU, die or begin ambulation. When providing each repositioning, avoid dragging the patient, the shear, and the friction to increase UPP risk. This must be applied to avoiding massage. Patients in any position should use pressure-reducing items such as pillows."
9983816|NCT04604665|Active Comparator|Conventional care|Repositioning or rotation of patients hospitalized will be the conventional or usual care. Units in this group are not going to receive any intervention. Will be only observed in their current intervention of repositioning.
9983817|NCT04604132|Experimental|Derazantinib|In Substudies 1 and 3.1, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib.
9983818|NCT04604132|Experimental|Derazantinib-paclitaxel-ramucirumab|In Substudies 2 and 3.2, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-paclitaxel-ramucirumab in combination.
9983819|NCT04604132|Experimental|Derazantinib-atezolizumab|In Substudy 3.3, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-atezolizumab in combination.
9516858|NCT03311594|Placebo Comparator|Control and No Pain Induction|Condition 1: No alcohol consumption Condition 2: No pain group
9983820|NCT04604132|Active Comparator|Standard of care|In Substudy 3.4, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive the Standard of Care drugs paclitaxel-ramucirumab in combination.
9983821|NCT04602494|Experimental|Varenicline|Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
9983822|NCT04602494|Placebo Comparator|Placebo|Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
9983823|NCT04601740||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
9983824|NCT04601454|Experimental|Spinal Cord Stimulation|Enrolled subjects are implanted with a spinal cord stimulation system that is activated and programmed to on-label parameters.
9983825|NCT04598321|Experimental|Planned Therapy|Talazoparib monotherapy as 1 mg capsule orally on a daily basis for three cycles, defined as a 21-day period, prior to surgery. Volunteers will continue treatment to complete three cycles, unless disease progression or unacceptable toxicity occurs.Volunteers who complete neoadjuvant treatment with talazoparib should undergo surgical cytoreduction within three weeks of their last dose of talazoparib. All volunteers should then undergo standard of care adjuvant therapy using carboplatin and paclitaxel. For volunteers, who agree to continue talazoparib as maintenance therapy, treatment should begin three weeks (+/- 2 weeks) from the end of adjuvant chemotherapy or after cytoreductive surgery alone.
9983826|NCT04597593||ADR Group|ISTH bleeding scale Major Bleeding
9983827|NCT04597593||Control Group|No ADR, No Treatment Failure
9983828|NCT04597593||Treatment Failure Group|Recurrent MI, Ischemic stroke, Other thromboembolic disorders
9983829|NCT04594590||Patients with SLC25A46 deficiency|Male and female patients from age 2 to age 65 with clinically confirmed SLC25A46 mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
9983830|NCT04594525|Experimental|Perinatal women receiving Low intensity psychosocial interventions|One Arm (Intervention): Will receive baseline assessment (personal characteristics) and standard psychological distress screening tools Plus WHO-low intensity psychological interventions through Telemental health.
9983831|NCT04594525|No Intervention|Participants-Perinatal women (pregnant women and post-partum) not receiving intervention|One Arm (Control): baseline assessment (personal characteristics) and standard psychological distress screening tools without the WHO-low psychological intervention through Telemental health.
9983832|NCT04591067||Hip Dysplasia group|Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
9983833|NCT04589377|Experimental|Mindfulness Training|Participants receive 20 minutes of mindfulness training per day for five continuous days (Monday through Friday). Training is delivered remotely to participants' computers and smartphones.
9983834|NCT04589377|No Intervention|No-Training|Participants do not receive training. On Monday and Friday, they listen to a 20 minute audiobook to match for time.
9983835|NCT04587193|Experimental|PD participants|Subjects will participate in a total of 10 walking sessions, twice per week for 5 weeks, while wearing a robotic-assist gait training device. There will also be 3 additional visits for assessments at: baseline (up to 1 prior to treatment), post (1 week after last treatment), and final (4-6 weeks after last treatment).
9983836|NCT04583995|Experimental|Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
9983837|NCT04583995|Placebo Comparator|Cohort 1: Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
9983838|NCT04583995|Experimental|Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
9983839|NCT04583995|Placebo Comparator|Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
9983840|NCT04583501|Experimental|Omalizumab|Ex vivo exposure of excised human surgical polyp tissue to omalizumab.
9983841|NCT04580979||Patients with ferredoxin reductase deficiency|Male and female patients from age 2 to age 65 with clinically confirmed FDXR mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
9983842|NCT04580654|Experimental|CSL312 (Cohort 1a, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
9983843|NCT04580654|Experimental|CSL312 (Cohort 1b, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
9983844|NCT04580654|Experimental|CSL312 (Cohort 2, high dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
9983845|NCT04580654|Experimental|CSL312 (Cohort 3, low dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
9983846|NCT04580654|Experimental|CSL312 (Cohort 4, high dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
9983847|NCT04580602||ADR Group|Major Bleeding BARC Bleeding Criteria Type 2,3,5
9983848|NCT04580602||Control Group|No ADR or treatment failure, case-control matched to experimental groups
9983849|NCT04580602||Treatment Failure Group|Major Adverse Cardiovascular Events (MACE)
9983850|NCT04580381||Standard Interval Dosing (SID)|Patients continuing Natalizumab treatment with standard interval dosing defined as > 11 infusions per year
9983851|NCT04580381||Extended Interval Dosing (EID)|Patients switching to extended interval dosing defined as ≤ 10 infusions per year
9516859|NCT03311594|Experimental|Control and Pain Induction|Condition 1: No alcohol consumption Condition 2: Pain group
9983852|NCT04579848|Active Comparator|Methotrexate|"Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.~Additional Folic acid 1mg prescribed daily."
9983853|NCT04579848|Placebo Comparator|Placebo|"3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.~Additional Folic acid 1mg prescribed daily."
9983854|NCT04579250|Experimental|Group 1|20 mcg IM at Day 0
9983855|NCT04579250|Experimental|Group 2A|60 mcg IM at Day 0 and Week 16
9983856|NCT04579250|Experimental|Group 2B|60 mcg IM at Day 0 and Week 16
9983857|NCT04579159|Other|only control group|To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
9983858|NCT04578080|Experimental|Anodal-tDCS & PT|"Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere.~Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
9983859|NCT04578080|Active Comparator|Sham-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area of affected hemisphere, Cathodal on the supraorbital area of affected hemisphere. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity.
9983860|NCT04577547|Experimental|Dietary Guidelines (DGA) diet with weight loss (WL) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with Physical Activity Guidelines for Americans (PAGA)-recommended exercise
9983861|NCT04577547|Experimental|DGA diet with WL & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with no exercise
9983862|NCT04577547|Experimental|DGA diet weight maintenance (WM) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with PAGA-recommended exercise
9983863|NCT04577547|Experimental|DGA diet WM & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with no exercise
9983864|NCT04577547|Experimental|Western diet with WL & exercise|Western-type menu to provide a calorie level to promote weight loss with PAGA-recommended exercise
9983865|NCT04577547|Experimental|Western diet with WL & no exercise|Western-type menu to provide a calorie level to promote weight loss with no exercise
9983866|NCT04577547|Experimental|Western diet WM exercise|Western-type menu to provide a calorie level to promote weight maintenance with PAGA-recommended exercise
9983867|NCT04577547|Experimental|Western diet WM no exercise|Western-type menu to provide a calorie level to promote weight maintenance with no exercise
9983868|NCT04575792||C group|C group: control group, children who do not practice oral habits.
9983869|NCT04575792||E group|E group: exposed group, children who practicing oral habits.
9983870|NCT04575337||AD group|Dementia is diagnosed according to the 2011 NIA-AA criteria.
9983871|NCT04575337||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
9983872|NCT04575337||pre-MCI group|β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment; not up to MCI or cognitive impairment.
9983873|NCT04575337||Other neurodegenerative diseases|Frontotemporal Dementia; or Parkinson's disease
9983874|NCT04575337||Cognitive normal group|Individuals are with normal cognitive function and ≥ 60 years old.
9983875|NCT04574219|Other|Feasibility/Acceptability|This arm will be used to assess the feasibility and acceptability of using FaceTime during induction.
9983876|NCT04574219|Other|Coaching prior to surgery|
9516860|NCT03311581|Experimental|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
9983877|NCT04574219|Other|Coaching day of surgery|
9983878|NCT04573972|Active Comparator|Regular incentive|During the two-week intervention period, the standard incentive group will earn $2 per day when they meet their step goal, and this reward is earned regardless of whether they walk alone or with others.
9983879|NCT04573972|Experimental|Social Incentive|During the two-week intervention period, he social incentive group will earn $1 per day when they meet their step goal and an additional $1 if they walk 2,000 steps together with another study participant.
9983880|NCT04571632|Active Comparator|Immediate treatment arm:|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1, approximately 2 hours after the last SBRT fraction, intratumoral injection of ipilimumab (Yervoy®, 50mg/10mL solution) at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) and avelumab (Bavencio®, 200mg/10mL solution) at maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) will be performed. Subject will also receive a standard 200mg (fixed dose) intravenous infusion of pembrolizumab (Keytruda®, 100 mg/4mL solution).~On day 2, autologous, non-substantially manipulated CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be intratumorally administered. Previously cryopreserved CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be thawed before administration.~On day 21 and every 21 days thereafter, IT injection of ipilimumab and avelumab and IV pembrolizumab at the same dose as on day 1 will be performed. Treatment will be discontinued upon disease progression"
9983881|NCT04571632|Active Comparator|Contemporary control arm|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1 and every + 21 days thereafter, subjects will receive a standard 200mg (fixed dose) IV pembrolizumab (Keytruda®, 100 mg/4mL solution) dose.~On disease progression, intratumoral administration as in the immediate-treatment arm will be conducted. Thus, intratumoral injection of ipilimumab at a maximum total dose of 10 mg and avelumab at maximum total dose of 40 mg will be performed. Administration of pembrolizumab at a dose of 200 mg will be continued.~Tumor response assessments by whole body PET/CT will be scheduled in week 12 and every 12 weeks thereafter during the treatment phase; . Baseline scan will be performed during screening period Procurement of tumor tissue by fine needle aspirates will be performed at the time of every intra-tumoral study drug administration"
9983882|NCT04566172|Experimental|Prehabilitation program|Patient undergoing thoracic or upper abdominal surgery as part of their regular medical care will be approached. Participants will receive a prehabilitation program that includes an inspiratory muscle training that they will do leading up to the day of their surgery.
9983883|NCT04564612|Experimental|Part 1|Participants will receive single oral dose of BIIB091 on Day 1 of each study period, in fasted state, for up to 5 periods. There will be a minimum 7-day washout between Day 1 of each study period.
9983884|NCT04564612|Experimental|Part 1B|Participants will be randomized to receive single oral or 2 oral doses for divided daily doses of BIIB091 on Day 1 of Period 1, in fasted state or single oral dose of BIIB091 on Day 1 of Period 1, in fed state. Participants will receive single oral dose of BIIB091 on Day 1 of Period 2, in fasted state. Participants will receive single or two divided oral dose(s) of BIIB091 on Day 1 of Periods 3 and 4, in fasted or fed state. There will be a minimum 7-day washout between Day 1 of each study period.
9983885|NCT04564612|Experimental|Part 2|Participants will receive single oral dose of BIIB091 on Day (D) 1 of Period (P) 1 in fasted/fed state; then itraconazole 100 milligram (mg) capsules (cap), orally, twice daily (BID) for 1 day (D -4) of P2, in fed state; then itraconazole 100 mg cap, orally, once daily (QD) for 2 days (D -3, -2) of P2, in fed state; then itraconazole 100 mg cap, orally, QD for 1 day (D -1) of P2, in fasted/fed state; then combination of itraconazole 100 mg cap, orally and BIIB091, orally on 5th day (D 1) of P2, in fasted/fed state; then itraconazole 100 mg cap, orally on 6th day (D 2) of P2, in fed state; then rabeprazole 20 mg tablets (tab), orally, BID for 3 days (D -3, -2, and -1) of P3 in fed state; then combination of rabeprazole 20 mg tab, orally and BIIB091, orally, on 4th day (D 1) of P3 in fasted/fed state. Minimum 7-day washout between dose of BIIB091 in P1 and 1st dose of itraconazole in P2; minimum 10-day washout between final dose of itraconazole in P2 and 1st dose of rabeprazole in P3.
9983886|NCT04564612|Experimental|Part 3|Participants will receive BIIB091, orally, QD or BID for at least 7 days in fasted or fed state.
9983887|NCT04563026|Experimental|DUR-928 (30 mg)|
9983888|NCT04563026|Experimental|DUR-928 (90 mg)|
9983889|NCT04563026|Placebo Comparator|(Placebo) Sterile Water for Injection|
9781503|NCT01150357|Experimental|High dose|Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 150 mg; ≥50 kg and < 80 kg received 300 mg and ≥ 80 kg and ≤ 150 kg received 600 mg of aliskiren.
9781504|NCT01150461|Experimental|losartan|Losartan 50 mg b.i.d.
9781505|NCT01150461|Placebo Comparator|placebo|Placebo b.i.d.
9781506|NCT01150474|Experimental|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
9781507|NCT01150474|Placebo Comparator|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
9781508|NCT01150500|Experimental|Drug Eluting Stent|Up to two lesions in two separate target vessels may be treated under this protocol. The lesions should be amenable to treatment with at least one 2.25 mm stent, a second lesion could be treated with any stent from 2.25 to 3.5 mm.
9781509|NCT01150760||Alvimopan Users|
9781510|NCT01150760||Matched controls|
9781511|NCT01150838|Experimental|Propofol administration|"For each of the 6 groups, propofol 2 mg/kg will be administered to first subject. The propofol dose will move separately for each of the 6 groups, and be increased by 0.3 mg/kg for the next subject if intubation score is not excellent and decreased by 0.3 mg/kg if intubation score is excellent. This dosing scheme will be continued until there are 6 crossovers as described above."
9781512|NCT01150903||PDE5 inhibitor prescription|
9781513|NCT01150903||Age-matched Control|
9781514|NCT01150981|Experimental|Rosiglitazone|One 8mg capsule daily for 6 weeks.
9781515|NCT01150981|Placebo Comparator|Placebo|One capsule daily for 6 weeks.
9781516|NCT01151020|Experimental|Arm 1|Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
9781517|NCT01151046|Experimental|MM-121 (SAR256212) + exemestane|
9781518|NCT01151046|Placebo Comparator|Placebo + exemestane|
9781519|NCT01151085||Voriconazole|Subjects who are treated with voriconazole
9781520|NCT01151098|Experimental|BTDS 5, 10 or 20|Buprenorphine transdermal patch
9781521|NCT01151137|Experimental|Dronedarone|Dronedarone 400 mg twice a day until the CSED
9781522|NCT01151137|Placebo Comparator|placebo|Placebo (for Dronedarone) twice a day until the CSED
9781523|NCT01151189|Placebo Comparator|Placebo|The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
9781524|NCT01151189|Experimental|MVA85A/AERAS-485|MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
9781525|NCT01151215|Experimental|1|AZD8931 40mg (bd) plus anastrozole 1mg (od)
9781526|NCT01151215|Experimental|2|AZD8931 20mg (bd) plus anastrozole 1mg (od)
9781527|NCT01151215|Placebo Comparator|3|Placebo (bd) plus anastrozole 1mg (od)
9737045|NCT00006178|Experimental|Sirolimus and Thymoglobulin|Thymoglobulin (Sangstat), a FDA-approved polyclonal rabbit-IgG antithymocyte preparation, will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.
9737046|NCT00006184|Experimental|Recipient - Chemotherapy Group|Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and granulocyte colony stimulating factor (GCSF) followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.
9737047|NCT00006184|Other|Donor - Vaccine Generation Group|3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2), and third injection (week 6) with Id-KLH (Anti-idiotype-keyhole limpet hemocyanin) (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination.
9737048|NCT00006227|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
9737049|NCT00006237|Active Comparator|Arm I|Patients receive interferon alfa IV on days 1-5 of weeks 1-4 followed by interferon alfa subcutaneously (SC) on days 1, 3, and 5 of weeks 5-52 in the absence of disease progression or unacceptable toxicity.
9737050|NCT00006237|Experimental|Arm II|Patients receive cisplatin IV over 30 minutes followed by vinblastine IV on days 1-4. Patients also receive dacarbazine IV over 1 hour on day 1, interleukin-2 IV over 96 hours on days 1-4, and interferon alfa SC on days 1-5, 8, 10, and 12. In addition, patients receive filgrastim (G-CSF) SC on days 6-15. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
9737051|NCT00006244|Experimental|Treatment (immunotherapy)|Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
9737052|NCT00006289|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
9737053|NCT00006289|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
9737054|NCT00006305|Active Comparator|Revascularization and Insulin Providing (IP)|Prompt revascularization with intensive medical therapy and insulin providing glycemic control strategy
9737055|NCT00006305|Active Comparator|Revascularization and Insulin Sensitizing (IS)|Prompt revascularization with intensive medical therapy and insulin sensitizing glycemic control strategy
9737056|NCT00006305|Active Comparator|Medical Therapy and Insulin Providing (IP)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin providing glycemic control strategy
9737057|NCT00006305|Active Comparator|Medical Therapy and Insulin Sensitizing (IS)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin sensitizing glycemic control strategy
9737058|NCT00006389|Experimental|Treatment|Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1 hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
9737059|NCT00006392|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
9737060|NCT00006392|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
9737061|NCT00006392|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
9737062|NCT00006392|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamine E placebo and selenium placebo daily for 7-12 years
9516861|NCT03311581|Active Comparator|Sevoflurane group|sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
9516862|NCT03311568|Experimental|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
9737063|NCT00006400|Active Comparator|Hydroxyurea|Participants will receive hydroxyurea.
9737064|NCT00006400|Placebo Comparator|Placebo|Participants will receive placebo.
9737065|NCT00006409|Experimental|School-based intervention|TAAG health education included six lessons in each of 7th and 8th grades designed to enhance behavioral skills known to influence physical activity. TAAG physical education classes promoted moderate-vigorous physical activity for at least 50% of class time and encouraged teachers to promote physical activity outside of class. In conjunction with community partners, programs that were promoted outside of school included Dance Dance Revolution, after-school step aerobics class, before-school open gym, basketball camp, touch football, and weekend canoe programs. TAAG promotions used a social marketing approach to promote awareness of and participation in activities through media and promotional events.
9737066|NCT00006409|No Intervention|Control group|
9737067|NCT00006411|Active Comparator|1|cornea assigned from donor age group <66.0 years
9737068|NCT00006411|Active Comparator|2|cornea assigned from donor age group >= 66.0 years
9737069|NCT00006489|Active Comparator|Naltrexone alone|Naltrexone alone
9737070|NCT00006489|Active Comparator|Naltrexone with CBT for PTSD|Naltrexone with CBT for PTSD
9737071|NCT00006489|Active Comparator|Placebo with CBT for PTSD|Placebo with CBT for PTSD
9737072|NCT00006489|Placebo Comparator|Placebo alone|Placebo alone
9737073|NCT00006604|Experimental|Step I: Group 1|"Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
9737074|NCT00006604|Experimental|Step I: Group 2|"Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
9737075|NCT00006604|Experimental|Step I: Group 3|"Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 415 mg/m2, 520 mg/m^2; Final Dose: 520 mg/m^2"
9737076|NCT00006604|Experimental|Step I: Group 4|"Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 520 mg/m^2, 620 mg/m^2; Final Dose: 620 mg/m^2"
9737077|NCT00006604|Experimental|Step I: Group 5|"Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
9737078|NCT00006604|Experimental|Step I: Group 5a|"Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
9737079|NCT00006604|Experimental|Step I: Group 6|"Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
9737080|NCT00006604|Experimental|Step I: Group 7|"Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
9737081|NCT00006604|Experimental|Step I: Group 8|"Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
9737082|NCT00006721|Active Comparator|Arm I (CHOP only)|"Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day~1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02)"
9737083|NCT00006721|Experimental|Arm II (CHOP + rituximab)|Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141.
9737084|NCT00006721|Experimental|Arm III (CHOP + tositumomab)|Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141.
9737085|NCT00006903|Experimental|Treatment (fulvestrant)|Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
9737086|NCT00007020|Other|Cholic Acid|
9737087|NCT00007345|Experimental|Peripheral T-cell Lymphoma (PTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
9737088|NCT00007345|Experimental|Cutaneous T-cell Lymphoma (CTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
9737089|NCT00007475|Experimental|Plasma Exchange + Cyclophosphamide|"Procedure/Surgery: Plasma exchange A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.~Drug: Cyclophosphamide For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months."
9737090|NCT00007644|Other|Radical Prostatectomy|Surgical removal of the prostate
9737091|NCT00007644|No Intervention|Watchful Waiting|Closely watching, waiting and treating symptoms if and when cancer progresses
9737092|NCT00008138|Experimental|chemo/debulking surgery/IP chemo|neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)
9737093|NCT00008385|Placebo Comparator|Arm I|Participants receive an oral yeast placebo as in arm II.
9737094|NCT00008385|Experimental|Arm II|Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
9737095|NCT00009737|Experimental|Capecitabine|Participants received capecitabine 1250 milligram per square meter (mg/m ^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).
9737096|NCT00009737|Active Comparator|5-Fluorouracil + Leucovorin|Participants received leucovorin 20 mg/m ^ 2 followed by 5-fluorouracil at 425 mg/m ^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).
9737097|NCT00009945|Experimental|Arm 1: Clodronate|Patient receives 2 tablets once daily for 3 years.
9737098|NCT00009945|Placebo Comparator|Arm 2: Placebo|Patient receives 2 tablets once daily for 3 years.
9737099|NCT00010257|Experimental|Paclitaxel plus Carboplatin|Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle
9737100|NCT00010374|Experimental|NeuRx DPS|Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.
9737101|NCT00010439|Experimental|1 Alendronate for 12 months|Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.
9737102|NCT00010803|Placebo Comparator|Placebo|Placebo 1 pill twice a day
9737103|NCT00010803|Active Comparator|Ginkgo biloba|Ginkgo biloba EGb761 120 mg twice daily
9737104|NCT00011986|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
9737105|NCT00011986|Experimental|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
9737106|NCT00011986|Experimental|Arm III|Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
9737107|NCT00011986|Experimental|Arm IV|Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.
9737108|NCT00011986|Experimental|Arm V|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
9737109|NCT00012012|Experimental|Radiation therapy plus cisplatin|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin.
9737110|NCT00012012|Experimental|Radiation therapy plus cisplatin and amifostine|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin and amifostine trihydrate.
9737111|NCT00012298|Experimental|Treatment (radiolabeled monoclonal antibody therapy)|Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
9737112|NCT00013611|No Intervention|Antiretroviral therapy alone|
9737113|NCT00013611|Experimental|Proleukin plus antiretroviral therapy|
9737114|NCT00014222|Active Comparator|Arm 1: CEF|6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid
9737115|NCT00014222|Active Comparator|Arm 2: EC/T|6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
9737116|NCT00014222|Active Comparator|Arm 3: AC/T|4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
9737117|NCT00014495|Experimental|bismuth Bi 213 monoclonal antibody M195 & cytarabine|"Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD.~Patients are followed twice weekly for 4 weeks and then monthly for 3 months"
9737118|NCT00014911|Experimental|Islet Transplantation|All study participants
9737119|NCT00015457|Experimental|cervical dystonia|cervical dsytonia patinets
9737120|NCT00016354|Experimental|benzoylphenylurea|
9737121|NCT00016718|Experimental|Age Group 1: 90 days to < 3 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
9737122|NCT00016718|Experimental|Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
9516863|NCT03311568|Experimental|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
9983890|NCT04562597|Placebo Comparator|Dose Response Curve Placebo|5-10 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
9983891|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 50 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
9516864|NCT03311568|Experimental|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
9737123|NCT00016718|Experimental|Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
9737124|NCT00016913|Experimental|Neo-Adj ChemoTx + ablation prior to RT|Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m^2 intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77.4 gray [Gy] in 1.8-Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.
9516865|NCT03311568|Experimental|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
9516866|NCT03311529|Experimental|Applied Relaxation|
9516867|NCT03311529|No Intervention|usual care|
9737125|NCT00017563|Experimental|Docetaxel, Mitoxantrone, Conventional Surgery|"Drug: Docetaxel-35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.~Drug: Mitoxantrone-Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.~Procedure/Surgery: Conventional Surgery- Prostatectomy will be scheduled 2-4 weeks after the last dose of chemotherapy"
9737126|NCT00018031|Experimental|1|Weekly Injection of peginterferon alfa-2b and weight based ribavirin (1-1.2g/day) for 48 weeks
9737127|NCT00019604|Experimental|Radiofrequency ablation in liver cancer|This trial is designed to gain experience with the use of ablation devices with liver tumors. Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.
9737128|NCT00019682|Experimental|Arm I (aldesleukin)|Patients receive aldesleukin IV over 15 minutes every 8 hours for 12 doses. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
9737129|NCT00019682|Experimental|Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)|Patients receive gp100 antigen emulsified in Montanide ISA-51 SC on day 1. Patients also receive aldesleukin as in Arm I beginning on day 2. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
9737130|NCT00021229|Experimental|Imatinib mesylate|
9737131|NCT00021255|Experimental|Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)|Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
9781528|NCT01151280|Experimental|WallFlex Biliary Fully Covered Stent|All eligible patients entered into the study will be treated with a WallFlex Biliary Fully Covered Stent
9781529|NCT01151345|Experimental|diltiazem|
9781530|NCT01151371|Experimental|narafilcon B daily disposable 4 weeks|narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks
9983892|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 100 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
9983893|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 150 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
9983894|NCT04562597|Experimental|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteine dose is identified, 10-15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.
9983895|NCT04562597|Placebo Comparator|Placebo|10-15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.
9737132|NCT00021255|Experimental|AC followed by Docetaxel + Herceptin (AC→TH)|Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
9737133|NCT00021255|Experimental|Docetaxel + Carboplatin + Herceptin (TCH)|Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
9737134|NCT00021541|Experimental|Tipifarnib (R11577)-Arm I|Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737135|NCT00021541|Placebo Comparator|Placebo-Arm II|Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.
9737136|NCT00022490|Experimental|Cytarabine/ Imatinib Mesylate|
9737137|NCT00022516|No Intervention|No-CM|No further chemotherapy following standard adjuvant chemotherapy.
9737138|NCT00022516|Experimental|CM-Maintenance|12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)
9737139|NCT00022633|Experimental|gemcitabine, paclitaxel|
9737140|NCT00022659|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9737141|NCT00022672|Experimental|trastuzumab + anastrozole|Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
9737142|NCT00022672|Active Comparator|anastrozole|1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
9737143|NCT00022698|Experimental|Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )|Participants will receive capecitabine (Xeloda) 1000 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
9737144|NCT00022698|Experimental|Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)|Participants will receive capecitabine 900 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
9737145|NCT00023309|Experimental|Lamivudine and adefovir|
9737146|NCT00023309|Active Comparator|Adefovir|
9737147|NCT00023322|Experimental|Peginterferon Alpha-2a|Patients with hepatitis D virus (HDV) infection are treated with pegylated alpha interferon therapy for 3 years. The dose of the drug is 180 mcg/week.
9737148|NCT00023452|Active Comparator|Daily Isoniazid|Isoniazid (INH) daily for 9 months (240 to 270 total doses).
9737149|NCT00023452|Experimental|Weekly Isoniazid / Rifapentine|Isoniazid / Rifapentine (RPT/INH) weekly for 3 months (11 to 12 total doses) given by Directly Observed Therapy (DOT)
9737150|NCT00023595|Active Comparator|H01: Medication|Medical therapy alone to treat Coronary Artery Disease
9983896|NCT04562194|Other|Intervention|NeVa Stent Retriever
9737151|NCT00023595|Active Comparator|H01: Medication + CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
9737152|NCT00023595|Active Comparator|H02: Medication+CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
9737153|NCT00023595|Active Comparator|H02: Medication+CABG+SVR|CABG plus Medication and Surgical ventricular reconstruction (SVR)
9737154|NCT00023673|Experimental|Phase I: 75.25 Gy/36 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 75.25 Gy given in 36 fractions (2.15 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
9737155|NCT00023673|Experimental|Phase I: 74 Gy/37 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
9737156|NCT00023673|Experimental|Phase I: 70 Gy/35 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 70 Gy given in 35 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
9737157|NCT00023673|Experimental|Phase II: 74 Gy/37 fx + chemotherapy|Phase II: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
9737158|NCT00023712|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9737159|NCT00023764|Experimental|Arm I|Patients receive an infusion of bortezomib (dose of 1.8 mg/m2) over 3-5 seconds once weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response lasting at least 6 months may receive retreatment.
9737160|NCT00024102|Active Comparator|Standard Chemotherapy|"Patient/Physician choice of cyclophosphamide + MTX + 5-FU~OR~Cyclophosphamide + doxorubicin"
9737161|NCT00024102|Experimental|Capecitabine|Treatment with capecitabine
9737162|NCT00024167|Experimental|Induction regimen A|Doxorubicin IV over 24 hours day 1; Oral ketoconazole 3 x daily on days 1-7 of weeks 1, 3, and 5; Vinblastine IV over 30 minutes Day 1, oral Estramustine 3 x daily on Days 1-7 of weeks 2, 4, and 6.
9737163|NCT00024167|Experimental|Induction regimen B|Oral Prednisone 2 x daily on days 1-21 (days 1-14 of course 5 only) and Docetaxel IV over 1 hour Day 1.
9737164|NCT00024167|Experimental|Consolidation arm I|Doxorubicin IV over 24 hours once weekly for 6 weeks + Strontium-89 IV once at beginning of chemotherapy.
9737165|NCT00024167|Experimental|Consolidation arm II|Doxorubicin as in Consolidation arm I.
9737166|NCT00024258|Experimental|Arsenic Trioxide|"Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2-3 months for 1 year and then annually thereafter."
9737167|NCT00025155|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR.
9737168|NCT00025233|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9737169|NCT00025259|Experimental|Arm I (Patients off-therapy before callback-Induction only)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
9737170|NCT00025259|Experimental|Arm II (RER with CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
9781531|NCT01151371|Active Comparator|nelfilcon A daily disponsable 1 week|nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week
9781532|NCT01151371|Active Comparator|lotrafilcon B daily wear, monthly replacement, 4-weeks|lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks
9983897|NCT04561648|Experimental|High Dose of Unfractionated Heparin|100 IU/Kg of Unfractionated Heparin
9737171|NCT00025259|Experimental|Arm III (RER with CR [ABVE-PC])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
9737172|NCT00025259|Experimental|Arm IV (RER with less than CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
9737173|NCT00025259|Experimental|Arm V (RER with PD)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
9737174|NCT00025259|Experimental|Arm VI (SER [DECA, ABVE-PC, IFRT])|Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, and cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 and 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 and G-CSF SC beginning on day 3 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
9737175|NCT00025259|Experimental|Arm VII (SER [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
9737176|NCT00025506|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737177|NCT00025662|Experimental|RFT5-SMPT-dgA Isolex system|RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin used in allogeneic stem cell transplantation (SCT) in older patients with hematologic malignancies using a graft manipulation process
9737178|NCT00025883|Experimental|Metreleptin|subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.
9737179|NCT00026208|Experimental|Stanford V-C + Low-dose Radiotherapy|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.~Radiotherapy = 20 Gy modified involved field radiotherapy"
9737180|NCT00026208|Experimental|Stanford V-C only|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide."
9737181|NCT00026221|Experimental|Arm I (monoclonal antibody and biological therapy)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive low-dose interferon alfa (IFN-alpha) SC on days 1-14.
9737182|NCT00026221|Experimental|Arm II (monoclonal antibody)|Patients receive bevacizumab as in arm I.
9737183|NCT00026221|Experimental|Arm III (monoclonal antibody and biological therapy)|Patients receive bevacizumab as in arm I. Patients also receive high-dose IFN-alpha SC on days 1, 3, 5, 8, 10, and 12.
9737184|NCT00026494|Experimental|Temozolomide and Vinorelbine|Patients will be treated with vinorelbine on days 1 and 8 of each cycle; temozolomide will be administered on days 1 to 7 and 15 to 21 of each cycle. The dose level of temozolomide will be given at a dose of 150 mg/m2/day. A cycle will be defined as 28 days of treatment.
9737185|NCT00026793||Kaposi's Sarcoma|Adult patients with biopsy-proven cutaneous Kaposi's sarcoma. Some participants received interleukin-12 and liposomal doxorubicin. However, the therapy was administered on a different protocol and was not part of this study.
9737186|NCT00027378|Experimental|1|fluoxetine plus Treatment As Usual (TAU)
9737187|NCT00027378|Placebo Comparator|2|placebo plus Treatment As Usual (TAU)
9737188|NCT00027560|Experimental|TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES|This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
9737189|NCT00027846|No Intervention|GTR1 Differentiated Histology Supratentorial (Group 1)|Patients undergo observation.
9983898|NCT04561648|Active Comparator|Standard Dose of Unfractionated Heparin|5000 IU of Unfractionated Heparin.
9516868|NCT03311516|Experimental|Group A|Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
9516869|NCT03311516|Other|Group B|Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
9516870|NCT03311490|Experimental|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
9737190|NCT00027846|Experimental|Radiation (Group 2)|Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.
9737191|NCT00027846|Experimental|Sub-Total Resection Any Histology or Location (STR) (Group 3)|Patients receive an initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.
9737192|NCT00028002|Experimental|Arm I|Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
9737193|NCT00028093|Experimental|Pefinterferon+Ribavirin|Patients with chronic hepatitis C virus (HCV) infection genotype 1 peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
9737194|NCT00028093|Active Comparator|Peginterferon|patients with chronic hepatitis C virus (HCV) infection genotype 1 were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
9737195|NCT00028262|Experimental|Drug: Cystagon and N-acetylcysteine|
9737196|NCT00028769|Experimental|Hormone therapy, estramustine, etoposide and paclitaxel|Hormone therapy (leuprolide, bicalutamide, nilutamide, goserelin, flutamide), estramustine, etoposide and paclitaxel
9737197|NCT00029107|Other|Immediate treatment|Patients receive treatment with four weekly infusions of rituximab 375mg/m2 immediately following randomization.
9737198|NCT00029107|Other|Delayed treatment|Patients treated with standard therapy (corticosteroids, plasma exchange, etc.). After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.
9737199|NCT00029146|Experimental|Surgical group|Assigned to undergo extracranial-intracranial arterial bypass in addition to best current practice medical therapy
9737200|NCT00029146|Active Comparator|Non-surgical group|Receives best current practice medical therapy
9737201|NCT00029172|Experimental|Nurse Case management|
9737202|NCT00029536|Experimental|Catamenial Epilepsy: Progesterone Lozenges|Subjects with catamenial epilepsy received 200 mg progesterone lozenges
9737203|NCT00029536|Placebo Comparator|Catamenial Epilepsy: Placebo Lozenges|Subjects with catamenial epilepsy received matched placebo lozenges
9737204|NCT00029536|Experimental|Noncatamenial Epilespy:Progesterone Lozenges|Subjects without catamenial epilepsy received 200 mg progesterone lozenges
9737205|NCT00029536|Placebo Comparator|Noncatamenial Epilespy: Placebo Lozenges|Subjects without catamenial epilepsy received matched placebo lozenges
9737206|NCT00030147|Experimental|Raloxifene|Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks
9737207|NCT00030147|Experimental|Rimostil|Rimostil (phytoestrogen) 1000 mg twice a day and placebo skin patch for eight weeks
9737208|NCT00030147|Active Comparator|Transdermal estradiol|17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks
9737209|NCT00030147|Placebo Comparator|Placebo|Placebo skin patch and placebo tablets for eight weeks.
9737210|NCT00030264|Experimental|Methotrexate & Vinblastine|Methotrexate and Vinblastine will be given once a week for the first 26 weeks and then every two weeks for the next 26 weeks or until disease progression (whichever occurs first).
9737211|NCT00030823|Experimental|Vaccine|Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.
9737212|NCT00030901|Active Comparator|L-selenomethionine|L-selenomethionine (Selenium)one tablet by mouth daily for 3 years.
9737213|NCT00030901|Placebo Comparator|L-selenomethionine placebo|L-selenomethionine placebo one tablet by mouth daily for 3 years
9737214|NCT00030992|Experimental|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
9737215|NCT00031447|Placebo Comparator|Placebo|
9737216|NCT00031447|Experimental|Acyclovir|
9737217|NCT00031460|Experimental|Acyclovir|
9737218|NCT00031460|Placebo Comparator|Placebo|
9737219|NCT00031486|Experimental|Valacyclovir|
9737220|NCT00031486|Placebo Comparator|Placebo|
9737221|NCT00031551|Experimental|Main Study: Etanercept Mouthwash|Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
9737222|NCT00031551|Placebo Comparator|Main Study: Placebo Mouthwash|Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
9737223|NCT00031551|No Intervention|Pilot Study|Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.
9737224|NCT00031590|Experimental|Study Treatment|"All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide [IV and oral]) which will be given in the following order: AABAABAAB (total of 54 weeks)."
9737225|NCT00031694|Experimental|Treatment (paclitaxel, bryostatin 1)|Patients receive paclitaxel IV over 1 hour on day 1 followed by bryostatin 1 IV over 1 hour on day 2 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9737226|NCT00032487|Active Comparator|Standard glycemic control|Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs
9737227|NCT00032487|Experimental|Intensive glycemic control|Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1
9737228|NCT00032591|Active Comparator|Arm 1|Patient Self-Testing (PST) of prothrombin time by international normalized ratio (PT-INR or INR) with weekly testing
9737229|NCT00032591|Other|Arm 2|High quality anticoagulation management (HQACM) with conventional monthly testing
9737230|NCT00032630|Other|Arm 1|Coronary artery bypass - on-pump
9737231|NCT00032630|Other|Arm 2|Coronary artery bypass - off-pump
9781533|NCT01151410|Experimental|Aliskiren|Patients will receive one of the following doses based on the their weight: Low weight (≥20 to <50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to <80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
9781534|NCT01151410|Active Comparator|Enalapril|Patients will receive one of the following doses based on their weight: Low weight (≥20 to <50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to <80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
9781535|NCT01151423|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
9781536|NCT01151423|Placebo Comparator|Placebo|Placebo once daily
9781537|NCT01151436|Experimental|hyaluronic acid|
9781538|NCT01151449|Experimental|Treatment (gamma-secretase/Notch signalling pathway inhibitor)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9781539|NCT01151540|Experimental|Rufinamide|Ralfinamide was administered orally twice daily after breakfast and dinner. Participants on placebo in Study 304 were titrated over to rufinamide within 2 weeks during the Conversion Period. As a general rule, the dose of rufinamide at the end of the Conversion Period was maintained throughout the Maintenance Period.
9781540|NCT01151579|Active Comparator|Levalbuterol 0.63|Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
9781541|NCT01151579|Active Comparator|Levalbuterol 1.25|Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.
9781542|NCT01151618|Experimental|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
9781543|NCT01151761|Experimental|SBRT, Chemo and Liver Transplantation|The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU
9781544|NCT01151813|Active Comparator|Varenicline|Varenicline, oral administration for 1 week
9781545|NCT01151813|Placebo Comparator|Placebo|Placebo, oral administration for 1 week
9781546|NCT01151852|Experimental|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
9781547|NCT01151852|Placebo Comparator|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
9983899|NCT04561154|Experimental|patient hospitalized between march 1 and june 30, 2020|patient hospitalized between march 1 and june 30, 2020
9737232|NCT00033371|Active Comparator|Arm I: Celecoxib and Placebo|Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
9737233|NCT00033371|Experimental|Arm II: Celecoxib and Eflornithine|Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
9737234|NCT00033514|Experimental|treatment|please see intervention description
9737235|NCT00033540|Experimental|Capecitabine + Gemcitabine|Capecitabine 650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days; Gemcitabine 1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1, 8, every 21 days
9737236|NCT00033631|Active Comparator|70.2 Gy|70.2 Gy 3D-CRT/IMRT
9737237|NCT00033631|Experimental|79.2 Gy|79.2 Gy 3D-CRT/IMRT
9737238|NCT00033657|Experimental|Cisplatin / Irinotecan / Radiation therapy (Arm A)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
9737239|NCT00033657|Experimental|Paclitaxel / Cisplatin / Radiation therapy (Arm B)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles."
9737240|NCT00033917|Active Comparator|1|indomethacin
9737241|NCT00033917|Placebo Comparator|2|placebo
9737242|NCT00035555|Experimental|Belatacept: More intensive (MI) regimen|The MI regimen was designed to achieve projected serum trough concentrations of belatacept of approximately 20 μg/mL through Day 99, and approximately 5 μg/mL through Day 183 (10 mg/kg on Days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, and 169). After Day 169, patients were reallocated and dosed to achieve projected trough serum concentrations of approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 197). Those patients who received belatacept every 8 weeks received placebo infusions on scheduled treatment dates between infusions of active drug to maintain the blind between treatment regimens. Patients initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the patient was able to tolerate medications by mouth. Corticosteroids given daily.
9737243|NCT00035555|Experimental|Belatacept: Less intensive (LI) regimen|The LI regimen was designed to achieve projected trough serum concentrations of belatacept of approximately 20 μg/mL through Day 29, and approximately 5 μg/mL through Day 99 (10 mg/kg on Days 1, 15, 29, 57 and 85). After Day 85, these subjects were reallocated and dosed to achieve projected trough serum concentrations of either approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 113). Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
9737244|NCT00035555|Experimental|Cyclosporine regimen|The initial daily dose was 7±3 mg/kg. Subsequent doses were adjusted to maintain a predefined range of serum concentrations: 1st month, target level 150-400 ng/mL; after 1st month, target level of 150-300 ng/mL. Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
9737245|NCT00035815|Active Comparator|IGF-1|Insulin like growth factor, type 1 will be given 0.05 mg per kg body weight subcutaneously twice daily
9737246|NCT00035815|Placebo Comparator|Placebo|Placebo arm
9516871|NCT03311490|No Intervention|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
9737247|NCT00035932|Active Comparator|I|"ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice~ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
9737248|NCT00035932|Active Comparator|II|"ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice~ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
9737249|NCT00035932|Active Comparator|III|"LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice~LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
9737250|NCT00036270|Experimental|exemestane|
9737251|NCT00036270|Experimental|tamoxifen + exemestane|
9737252|NCT00036569|Experimental|Interferon Alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
9737253|NCT00036738|Experimental|Treatment (allogeneic nonmyeloablative HSCT)|See Detailed Description
9737254|NCT00037830|Active Comparator|Early-Start Group|Subjects were randomized to receive GM1 ganglioside for 24 weeks.
9737255|NCT00037830|Placebo Comparator|Delayed-Start Group|Subjects were randomized to receive placebo for 24 weeks.
9737256|NCT00037830|No Intervention|Comparison Group|A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.
9737257|NCT00038103|Active Comparator|1.|
9737258|NCT00038103|Experimental|2.|
9737259|NCT00038467|Active Comparator|B|
9737260|NCT00038467|Experimental|A|
9737261|NCT00038610|Experimental|Hyper-CVAD + Imatinib|Imatinib 600 mg orally days 1-14, course 1, & 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 & 11; & Dexamethasone 40 mg IV or orally daily days 1-4 & 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
9737262|NCT00038649|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
9737263|NCT00038857|Experimental|CD34 PBPC|CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m^2 Fludarabine over 4 days on days -6, -5, -4, -3 and 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
9737264|NCT00038948|Active Comparator|A|Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression
9737265|NCT00038948|Active Comparator|B|Continued calcineurin inhibitor therapy
9737266|NCT00039130|Experimental|Rituximab with High Intensity Chemotherapy|Cycle1: Cyclophosphamide 100 mg/m^2/day (d) IV (d 1-5), Prednisone 60 mg/m^2/d oral (d 1-7), Allopurinal 300 mg/d oral (d 1-14) Cycle 2, 4 & 6 (21 day): Ifosfamide 800 mg/m^2/d (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 25 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Cytarabine 1000 mg/m^2/d over 2 h (d 4-5), Etoposide 80 mg/m^2.d over 1 h (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 50 mg/m^2 d 8 cycle 2 only, 375 mg/m^2/d (d 10, 12 cycle 2, d 8 cycle 4 & 6) Cycle 3, 5 & 7 (21 day): Cyclophosphamide 200 mg/m^2/day (d) IV (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 50 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Doxorubicin 25 mg/m^2/d (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 375 mg/m^2/d (d 8)
9737267|NCT00039195|Experimental|Induction R-CHOPac Therapy for patients with B-Cell Lymphoma|Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.
9737268|NCT00039377|Experimental|Treatment (imatinib mesylate, chemotherapy, PBSCT)|See Detailed Description.
9737269|NCT00039741|Experimental|PI/1K|Two NRTIs plus a PI with a regimen change recommended at when viral load reaches 1000 copies/ml or higher
9737270|NCT00039741|Experimental|NNRTI/1K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 1,000 copies/ml or higher
9737271|NCT00039741|Experimental|PI/30K|2 NRTIs plus 1 PI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
9737272|NCT00039741|Experimental|NNRTI/30K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
9737273|NCT00039871|Experimental|Overall study population|
9737274|NCT00040365|Experimental|Amifostine|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
9737275|NCT00040443|Experimental|CX516|CX516 - 900 mg
9737276|NCT00040443|Placebo Comparator|Placebo|Placebo
9737277|NCT00040664|Experimental|2 to 5 years (FPV/RTV)|Two to five years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
9737278|NCT00040664|Experimental|6 to 11 years (FPV/RTV)|Six to twelve years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
9737279|NCT00040664|Experimental|12 to 18 years (FPV/RTV)|Twelve to Eighteen years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
9737280|NCT00040742|Placebo Comparator|Placebo|Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
9737281|NCT00040742|Experimental|0.5g ginger|Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
9737282|NCT00040742|Experimental|1.0g ginger|Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
9737283|NCT00040742|Experimental|1.5g ginger|Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
9737284|NCT00040846|Experimental|Treatment (dose-escalation of alemtuzumab, HSCT)|"CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 2 hours on days -8 to -5 and fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~HSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156."
9737285|NCT00040937|Experimental|treatment arm|thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
9737286|NCT00041067|Experimental|Trastuzumab, docetaxel, vinorelbine and filgrastim|Trastuzumab, docetaxel, vinorelbine and filgrastim
9737287|NCT00041080|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily on days 1-28.
9737288|NCT00041080|Experimental|Arm II (tamoxifen)|Patients receive oral tamoxifen twice daily on days 1-28.
9737289|NCT00041119|Active Comparator|Arm I (CA for 4 courses)|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9737290|NCT00041119|Experimental|Arm II (CA for 6 courses [closed to accrual 12/15/2007])|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9737291|NCT00041119|Experimental|Arm III (paclitaxel for 4 courses)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9737292|NCT00041119|Experimental|Arm IV (paclitaxel for 6 courses [closed 12/15/2007])|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9737293|NCT00041132|Experimental|Hyper-CVAD + MTX/Ara-C + Rituximab|"21-day cycles of Hyper-CVAD and high-dose methotrexate/cytarabine are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.~Hyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and filgrastim 5 ug/kg on days 8-21.~Methotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21."
9737294|NCT00041392|Active Comparator|Magnesium|100 mg/kg magnesium
9737295|NCT00041392|Placebo Comparator|0.9 % saline|100 mg/kg 0.9 % saline
9737296|NCT00041470|Experimental|Weekly paclitaxel, vinorelbine and GCSF|"Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.~Paclitaxel weekly. Dose levels:~50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2~Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:~20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2~Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.~G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily"
9737297|NCT00041717|Active Comparator|fampridine-SR 50mg/day|
9737298|NCT00041717|Placebo Comparator|Placebo|
9737299|NCT00041756|Placebo Comparator|Placebo|Placebo tablet
9737300|NCT00041756|Experimental|25 mg PG-530742|25 mg PG-530742
9737301|NCT00041756|Experimental|50 mg PG-530742|50 mg PG-530742
9737302|NCT00041756|Experimental|100 mg PG-530742|100 mg PG-530742
9737303|NCT00041756|Experimental|200 mg PG-530742|200 mg PG-530742
9737304|NCT00041938|Active Comparator|aspirin|Aspirin: 325 mg per day
9737305|NCT00041938|Active Comparator|warfarin|Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75
9737306|NCT00042224|Experimental|1 ECT plus clozapine|Electroconvulsive therapy ECT plus clozapine for 8 weeks
9737307|NCT00042224|Active Comparator|2 Clozapine|Clozapine for 8 weeks
9737308|NCT00042432|Experimental|cinacalcet (AMG 073)|
9737309|NCT00042432|Placebo Comparator|Placebo|
9737310|NCT00042666|Experimental|LY317615|500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles
9737311|NCT00042939|Active Comparator|Irinotecan/Docetaxel|"Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. This constituted a cycle of treatment. Patients were evaluated after 2 cycles."
9737312|NCT00042939|Experimental|Irinotecan/Docetaxel/Cetuximab|"Patients received Cetuximab intravenously once a week for 6 weeks. On day 1 of cycle 1 only, an initial dose of 400 mg/m² (over 120 minutes) was administered. Thereafter, a once-a-week maintenance dose of 250 mg/m² (infused over 60 minutes), was given. The infusion rate never exceeded 5 ml/minute.~On the day of the initial dose, the administration of Cetuximab was followed by the administration of docetaxel, after a 60-minute observation period. (The observation period was 30 minutes following maintenance doses.) Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Cetuximab was administered once a week for 6 consecutive weeks. A cycle of treatment was 6 weeks."
9737313|NCT00042991|Experimental|Treatment (gefitinib and radiation therapy)|"Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.~Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose."
9737314|NCT00043186|Placebo Comparator|Placebo|Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.
9737315|NCT00043186|Experimental|Denosumab 6 mg every 3 months|Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
9737316|NCT00043186|Experimental|Denosumab 14 mg every 3 months|Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
9737317|NCT00043186|Experimental|Denosumab 30 mg every 3 months|Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.
9737318|NCT00043186|Experimental|Denosumab 14 mg every 6 months|Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
9737319|NCT00043186|Experimental|Denosumab 60 mg every 6 months|Participants received denosumab 60 mg SC every 6 months until Month 42.
9737320|NCT00043186|Experimental|Denosumab 100 mg every 6 months|Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
9737321|NCT00043186|Experimental|Denosumab 210 mg every 6 months|Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.
9737322|NCT00043186|Active Comparator|Alendronate 70 mg|Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.
9737323|NCT00043550|Experimental|1 Sertraline/Venlafaxine|Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8
9737324|NCT00043550|Active Comparator|2 Supportive Expressive Therapy|Participants will receive supportive-expressive psychotherapy.
9737325|NCT00043550|Placebo Comparator|3 Pill Placebo|Participants receive placebo.
9737326|NCT00043979|Experimental|Arm 1- Sibling Donors|Donors (n = 30) were matched first degree relatives who were eligible to donate peripheral blood stem cells.
9737327|NCT00043979|Experimental|Arm 2 - Recipients|Recipients (n=30) were enrolled to receive peripheral blood stem cells (PBSC) and receive either cyclosporine or tacrolimus and sirolimus for graft versus host disease (GVHD) prophylaxis.
9737328|NCT00044005|Experimental|Lurasidone 20 mg|Lurasidone 20 mg oral tablet
9737329|NCT00044005|Experimental|Lurasidione 40 mg|Lurasidone 40 mg oral tablet
9737330|NCT00044005|Experimental|Lurasidone 80mg|Lurasidone 80mg oral tablet
9737331|NCT00044044|Experimental|Lurasidone 20 mg|Lurasidone 20 mg tablets
9737332|NCT00044044|Experimental|Lurasidone 40 mg|Lurasidone 40 mg tablets
9737333|NCT00044044|Experimental|Lurasidone 80 mg|Lurasidone 2 40 mg tablets
9737334|NCT00044044|Active Comparator|Haloperidol 10mg|Haloperidol 10mg tablets
9737335|NCT00044044|Placebo Comparator|Placebo|Matching Placebo to Lurasidone and Haloperidol
9737336|NCT00044083|Placebo Comparator|Placebo Arm|Placebo one week
9737337|NCT00044083|Active Comparator|Tolcapone Arm|Tolcapone one week
9737338|NCT00044213|Active Comparator|EDTA + high dose vitamin|Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
9737339|NCT00044213|Placebo Comparator|EDTA + high dose vitamin placebo|Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
9737340|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin|Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
9737341|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin placebo|Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.
9737342|NCT00044512|Experimental|Sorafenib 400 mg b.i.d.|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
9737343|NCT00044655|Active Comparator|Stay on baseline medication prescribed|Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
9737344|NCT00044655|Active Comparator|Switch per study protocol|Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
9737345|NCT00045032|No Intervention|Observation Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
9737346|NCT00045032|Experimental|Herceptin 1-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
9737347|NCT00045032|Experimental|Herceptin 2-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
9737348|NCT00045110|Experimental|Phase 1 Dose Escalation|"Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~erlotinib hydrochloride given orally~Other: pharmacological study."
9737349|NCT00045110|Experimental|Phase 2 recurrent malignant gliomas and nonprogressive GBM|"Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose (150mg/day.~patients requiring surgery treated 7 days prior to tumor removal (150mg/day)~PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)~erlotinib hydrochloride given orally~Other: pharmacological study, laboratory biomarker analysis."
9737350|NCT00045162|Active Comparator|1|
9737351|NCT00045162|Active Comparator|2|
9737352|NCT00045305|Experimental|Arm I|"Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses.~Transplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient.~Acute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD."
9737353|NCT00045435|Experimental|Treatment (nonmyeloablative donor PBSC transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive CSP PO BID on days -3 to 56 with taper to day 77. Patients also receive MMF PO BID on days 0-27."
9737354|NCT00045487|Experimental|OSI-774|
9737355|NCT00045630|Experimental|Gemcitabine, Paclitaxel, Carboplatin|Gemcitabine, Paclitaxel, Carboplatin followed by surgery
9737356|NCT00045708|Experimental|Group A [Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
9983900|NCT04560582||Kidney Transplant Patients with Failed Allograft|All participants are assigned to a single cohort of kidney transplant patients with failed allograft requiring dialysis.
9737357|NCT00045708|Experimental|Group B [No Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
9737358|NCT00045708|Experimental|Group C [MTD-Phase 2)|"Maximum tolerated Dose (MTD-Phase 2) - subjects treated at dose determined by Group B~Drug: ixabepilone~Other Names:~BMS-247550 epothilone B lactam Ixempra Given IV"
9737359|NCT00045734|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study/ laboratory biomarker analysis"
9737360|NCT00045942|Experimental|PKC412 (Core)|Participants received 75 mg PKC412 three time daily (tid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
9737361|NCT00045942|Experimental|FLT3 mutated PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
9737362|NCT00045942|Experimental|FLT3 mutated PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
9737363|NCT00045942|Experimental|FLT3 wild type PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
9737364|NCT00045942|Experimental|FLT3 wild type PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
9737365|NCT00045942|Experimental|FLT3 mutated PKC412 dose escalation|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
9737366|NCT00045942|Experimental|FLT3 mutated PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
9737367|NCT00045942|Experimental|FLT3 wild type PKC412 dose escalation (E2)|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
9737368|NCT00045942|Experimental|FLT3 wild type PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
9737369|NCT00046228|Experimental|001|Abciximab; reteplase; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
9737370|NCT00046228|Experimental|002|abciximab; reteplase placebo; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
9737371|NCT00046228|Experimental|003|abciximab placebo; reteplase placebo, abciximab, abciximab placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
9737372|NCT00046566|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
9737373|NCT00046566|Experimental|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
9737374|NCT00046566|Placebo Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
9737375|NCT00046839|Experimental|Phase I: Celecoxib 200mg BID + RT|"COX-2 Inhibitor: Celecoxib 200 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
9737376|NCT00046839|Experimental|Phase I: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
9737377|NCT00046839|Experimental|Phase II: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
9737378|NCT00046891|Experimental|Ginkgo Biloba|120 mg per day (60 mg BID)
9737379|NCT00046891|Placebo Comparator|Placebo|1 tablet BID
9737380|NCT00046930|Experimental|Zosuquidar|Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
9737381|NCT00046930|Active Comparator|Placebo|Induction treatment with daunorubicin, cytarabine and placebo (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
9737382|NCT00047008|Other|Standard fractionation RT + cisplatin|Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.
9737383|NCT00047008|Experimental|Accelerated fractionation RT + cisplatin|Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.
9737384|NCT00047060|Experimental|Stem Cell Transplant Therapy With Campath-1H|Recipients received a nonmyeloablative preparative regimen of alemtuzumab 30mg iv three times a week for two weeks followed by fludarabine 25mg/m2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x106 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).
9737385|NCT00047320|Experimental|Radiation Therapy (CR from Induction)|Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC > 750/L and platelets > 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.
9737386|NCT00047385|Experimental|Low-Dose CT|
9737387|NCT00047385|Experimental|Chest X-ray|
9737388|NCT00047463|Active Comparator|CPAP active comparator|continuous positive airway pressure (CPAP)
9737389|NCT00047463|Placebo Comparator|CPAP Placebo|Placebo-CPAP
9737390|NCT00047619|Experimental|Pulsatile lavage group|pulsatile lavage therapy
9737391|NCT00047619|Sham Comparator|Sham lavage group|sham pulsatile lavage
9737392|NCT00047697|Experimental|Donepezil HCl|Donepezil HCL 5 mg and 10 mg
9737393|NCT00047697|Placebo Comparator|Placebo|Placebo
9737394|NCT00047879|Other|Glioblastoma multiforme stratum|Glioblastoma multiforme is one of the most common and aggressive types of brain tumor.
9737395|NCT00047879|Other|Anaplastic Glioma Stratum|Anaplastic glioma is a type of brain tumor that develops from star-shaped glial cells that support nerve cells. Anaplastic oligodendroglioma is a malignant type of brain tumor sensitive to treatment with chemotherapy and radiotherapy.
9737396|NCT00048035|Experimental|Cohort 1 (RO0503821 [0.25/150 1x/week])|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) intravenously (IV) using a dose conversion factor of 0.25/150 microgram (mcg)/kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 62.50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9737397|NCT00048035|Experimental|Cohort 2 (RO0503821 [0.25/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.25/150 mcg/kg of the previous weekly ESA dose, (equal to 62.50% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9737398|NCT00048035|Experimental|Cohort 3 (RO0503821 [0.4/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9737399|NCT00048035|Experimental|Cohort 4 (RO0503821 [0.4/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9737400|NCT00048035|Experimental|Cohort 5 (RO0503821 [0.6/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9737401|NCT00048035|Experimental|Cohort 6 (RO0503821 [0.6/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9737402|NCT00048048|Experimental|Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) at a dose of 0.15 microgram per kilogram (mcg/kg) subcutaneously (SC) once every week to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737403|NCT00048048|Experimental|Cohort 2 (RO0503821, 0.3 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every week to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737404|NCT00048048|Experimental|Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737405|NCT00048048|Experimental|Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every two week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737406|NCT00048048|Experimental|Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every two week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737407|NCT00048048|Experimental|Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.2 mcg/kg SC once every two week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737408|NCT00048048|Experimental|Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.45 mcg/kg SC once every three week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737409|NCT00048048|Experimental|Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)|Eligible participants will be receiving RO0503821 at a dose of 0.9 mcg/kg SC once every three week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737410|NCT00048048|Experimental|Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.8 mcg/kg SC once every three week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
9737411|NCT00048061|Active Comparator|Ibandronate 2.5 mg|Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
9737412|NCT00048061|Experimental|Ibandronate 50/50 mg|Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
9737413|NCT00048061|Experimental|Ibandronate 100 mg|Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
9737414|NCT00048061|Experimental|Ibandronate 150 mg|Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
9737415|NCT00048074|Experimental|1|oral placebo daily and IV ibandronate 2 mg q 2 mo
9737416|NCT00048074|Experimental|2|oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
9737417|NCT00048074|Experimental|3|oral placebo daily and IV ibandronate 3 mg q 3 mo
9737418|NCT00048165|Experimental|Daclizumab|Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram [mg/kg] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
9516872|NCT03311477|Experimental|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
9516873|NCT03311464|Experimental|Arm A|Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).
9737419|NCT00048165|Placebo Comparator|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.
9737420|NCT00048347|Experimental|Avonex|Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks
9737421|NCT00048542|Experimental|Double-Blind Adalimumab + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received adalimumab plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
9737422|NCT00048542|Placebo Comparator|Double-Blind Placebo + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received placebo plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
9737423|NCT00048542|Experimental|Double-Blind Adalimumab|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received adalimumab, but no concomitant MTX treatment, during the Double-Blind Phase.
9737424|NCT00048542|Placebo Comparator|Double-Blind Placebo|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received placebo, but no concomitant MTX treatment, during the Double-Blind Phase.
9737425|NCT00048542|Experimental|OLE BSA Adalimumab + MTX|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), concomitantly with MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
9737426|NCT00048542|Experimental|OLE BSA Adalimumab|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), but not MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
9737427|NCT00048542|Experimental|OLE FD Adalimumab + MTX|Subjects received adalimumab concomitantly with MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
9737428|NCT00048542|Experimental|OLE FD Adalimumab|Subjects received placebo without concomitant MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
9737429|NCT00048568|Experimental|Abatacept + Methotrexate|Short Term: Abatacept was dosed by weight with participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.
9737430|NCT00048568|Active Comparator|Placebo + Methotrexate|Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.
9737431|NCT00048568|Experimental|Abatacept + Methotrexate Open Label|Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.
9737432|NCT00048581|Active Comparator|Abatacept|Short Term Portion of Study
9737433|NCT00048581|Placebo Comparator|Placebo|Short Term Portion of Study
9737434|NCT00048581|Active Comparator|Abatacept (Long Term)|"Long Term Portion of Study:~All participants receive Active Drug"
9737435|NCT00048724|Experimental|PegIntron|PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up
9737436|NCT00048724|No Intervention|Untreated Control|
9737437|NCT00048737|Experimental|90Y Zevalin in ASCT|Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
9737438|NCT00048815|Active Comparator|citalopram|Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.
9737439|NCT00048815|Experimental|St. John's Wort|Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.
9737440|NCT00048815|Placebo Comparator|Placebo|Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.
9737441|NCT00048932|Active Comparator|Double-blind abatacept|Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants > 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period
9737442|NCT00048932|Placebo Comparator|Double-blind Placebo|Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.
9737443|NCT00048932|Active Comparator|Open-label Abatacept|Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.
9737444|NCT00048997|Experimental|Prophylactic cranial irradiation (PCI)|Radiation therapy
9737445|NCT00048997|Other|Observation|Observation
9737446|NCT00049036|Experimental|Arm I|Patients receive rituximab intravenously (IV) over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
9737447|NCT00049036|Experimental|Arm II|Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
9737448|NCT00049127|Experimental|Phase II (Group 1)|Patients receive imatinib mesylate PO, at the MTD determined in phase I, BID for 4 weeks.
9737449|NCT00049127|Experimental|Phase II (Group 2)|Patients receive standard-dose imatinib mesylate PO BID for 4 weeks.
9737450|NCT00049257|Experimental|Treatment|Please see intervention descriptions
9737451|NCT00049322|Experimental|Arm I-bevacizumab|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization at a dose of 10 mg/kg. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
9737452|NCT00049322|No Intervention|Arm II-chemoembolization|chemoembolization as part of standard of care
9737453|NCT00049504|Experimental|Treatment (nonmyeloablative HSCT)|"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35."
9781548|NCT01152021|Active Comparator|Dexmedetomidine Group|Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
9737454|NCT00049517|Experimental|Standard Daunorubicin Then Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
9737455|NCT00049517|Experimental|High-dose Daunorubicin Then Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
9737456|NCT00049517|Experimental|Standard Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
9785329|NCT01249131|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
9737457|NCT00049517|Experimental|High-dose Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
9737458|NCT00049517|Active Comparator|Standard Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
9737459|NCT00049517|Experimental|High-dose Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
9737460|NCT00049530|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
9737461|NCT00049543|Experimental|Arm I (gefitinib)|Patients receive gefitinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
9737462|NCT00049543|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
9781549|NCT01152021|Active Comparator|Propofol Group|Propofol bolus at an initial dose of 1 mg/kg over 1 minute then up to two additional 1 mg/kg boluses may be administered (total 3 mg/kg) - each over a one (1) minute interval, waiting 30 seconds after completion of each bolus to reassess sedation level. Once a minimum Ramsey Sedation Score 4 is achieved, an infusion at 125 mcg/kg/min is initiated. It may be titrated to 300 mcg/kg/min. If there is movement or awakening the patient may be rebolused with no more than 2 doses of Propofol at 1 mg/kg over 1 minute, in the same dosing manner as described above, waiting 30 seconds between doses. If adequate sedation is not achieved, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg.
9781550|NCT01152112|Experimental|Treatment, Office Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in an office setting
9781551|NCT01152112|Experimental|Treatment, Hospital Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
9781552|NCT01152190|Experimental|5 milligrams (mg) Tadalafil|
9781553|NCT01152190|Placebo Comparator|Placebo|
9781554|NCT01152294|No Intervention|Control|Group not receiving the decision aid (DVD and booklet)
9781555|NCT01152294|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
9781556|NCT01152307|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
9781557|NCT01152307|No Intervention|Control|Group not receiving the decision aid (DVD/booklet)
9781558|NCT01152359|Experimental|Arm 1|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
9785330|NCT01249131|Experimental|Treatment B first, then Treatment A, followed by Treatment C|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
9737463|NCT00049673|Experimental|Arm I|Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.
9737464|NCT00049673|No Intervention|Arm II|Patients undergo observation.
9737465|NCT00049842|Experimental|PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)|PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up
9737466|NCT00049842|No Intervention|Untreated Control|
9737467|NCT00050011|Experimental|Zoledronic Acid upfront|Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
9737468|NCT00050011|Experimental|Zoledronate delayed-start|In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
9737469|NCT00050089|Active Comparator|No ARDFP+Standard-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Standard-ART
9737470|NCT00050089|Active Comparator|No ARDFP+Mega-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Mega-ART
9737471|NCT00050089|Active Comparator|ARDFP+Standard-ART|Antiretroviral Drug-Free Period (ARDFP) and Standard-ART
9737472|NCT00050089|Active Comparator|ARDFP+Mega-ART|Antiretroviral Drug-Free Period (ARDFP) and Mega-ART
9737473|NCT00050167|Experimental|Weekly Paclitaxel (WP)|Weekly Paclitaxel (WP) for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles
9737474|NCT00050167|Experimental|Docetaxel and Capecitabine (DX)|Docetaxel + Capecitabine (DX) days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.
9737475|NCT00050622|Placebo Comparator|No Treatment|No Medication, No Behavior Modification (BMOD)
9737476|NCT00050622|Active Comparator|Low Dose Medication Only|0.15 mg/kg methylphenidate (MPH), No BMOD
9737477|NCT00050622|Active Comparator|Medium Dose Medication Only|0.3 mg/kg MPH, No BMOD
9737478|NCT00050622|Active Comparator|Higher Dose Medication Only|0.6 mg/kg MPH, No BMOD
9737479|NCT00050622|Active Comparator|Low Intensity BMOD Only|Placebo, Low Intensity BMOD
9737480|NCT00050622|Active Comparator|Low Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, Low Intensity BMOD
9737481|NCT00050622|Active Comparator|Low Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, Low Intensity BMOD
9737482|NCT00050622|Active Comparator|Low Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, Low Intensity BMOD
9737483|NCT00050622|Active Comparator|High Intensity BMOD Only|Placebo, High Intensity BMOD
9737484|NCT00050622|Active Comparator|High Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, High Intensity BMOD
9737485|NCT00050622|Active Comparator|High Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, High Intensity BMOD
9737486|NCT00050622|Active Comparator|High Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, High Intensity BMOD
9737487|NCT00050778|Active Comparator|Interferon Beta-1a|
9737488|NCT00050778|Experimental|Alemtuzumab 12 mg|
9737489|NCT00050778|Experimental|Alemtuzumab 24 mg|
9737490|NCT00050960|Experimental|bexarotene with carboplatin and paclitaxel|
9737491|NCT00050960|Experimental|carboplatin and paclitaxel|
9737492|NCT00050986|Experimental|Temozolomide and R115777|
9737493|NCT00051168|Experimental|Travatan|Travoprost (0.004%)
9737494|NCT00051311|Other|Donor|Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
9737495|NCT00051311|Experimental|Recipient|Recipients will receive induction chemotherapy (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.
9737496|NCT00051363|Active Comparator|Active CPAP|Active Continuous Positive Airway Pressure (CPAP)
9737497|NCT00051363|Placebo Comparator|Sham CPAP|Sham Continuous Positive Airway Pressure (CPAP)
9737498|NCT00051558|Experimental|A|Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
9737499|NCT00051558|Active Comparator|B|Alendronate 10 mg/day oral plus injection placebo, 36 months
9737500|NCT00051636|Experimental|Zoledronic Acid and Placebo to Risedronate|Participants received zoledronic acid 5 mg intravenous infusion one dose, 60 days of oral placebo to risedronate, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
9737501|NCT00051636|Active Comparator|Risedronate and Placebo to Zoledronic Acid|Participants received 60 days of oral risedronate 30 mg, one intravenous infusion of placebo to zoledronic acid, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
9737502|NCT00052078|Active Comparator|Sertraline|Participants received sertraline for 12 weeks.
9737503|NCT00052078|Active Comparator|CBT|Participants received cognitive behavioral therapy for 12 weeks
9737504|NCT00052078|Active Comparator|SRT + CBT|Participants received both sertraline and CBT for 12 weeks.
9737505|NCT00052078|Placebo Comparator|Placebo|Participants received a placebo pill for 12 weeks.
9737506|NCT00052429|Experimental|High-Dose Radiation Therapy Plus Chemotherapy|"Phase I~Radiotherapy: Patients receive radiotherapy once daily 5 days a week for 6 weeks beginning on day 1.~Concurrent chemotherapy: Patients receive cisplatin IV over 20-30 minutes on days 1-5 and 22-26.~Adjuvant chemotherapy: Approximately 2-5 weeks after the completion of radiotherapy, patients receive fluorouracil IV continuously on days 1-4 and cisplatin IV over 20-30 minutes on days 1-5 and 22-26. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. In the absence of dose-limiting toxicity in 1 whole cohort of patients, study proceeds to phase II. Phase II~Patients are treated as in phase I. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter."
9737507|NCT00052442|Experimental|135 mg/m^2 Pralatrexate 1/2 weeks|Pralatrexate (PDX) 135 mg/m^2 administered as an intravenous (IV) infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.
9737508|NCT00052442|Experimental|30 mg/m^2 Pralatrexate 3/4 weeks|PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.
9737509|NCT00052442|Experimental|30 mg/m^2 Pralatrexate 6/7 weeks|PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
9737510|NCT00052442|Experimental|45 mg/m^2 Pralatrexate 6/7 weeks|PDX 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
9737511|NCT00052442|Experimental|270 mg/m^2 Pralatrexate 2/4 weeks|PDX (270 mg/m^2) administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.
9737512|NCT00052715|Experimental|poly-ICLC Newly diagnosed GBM|"Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy~Intramuscular injection~Drug Poly-ICLC"
9737513|NCT00052910|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil (5-FU) IV on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
9737514|NCT00052910|Experimental|Arm II|Patients receive epirubicin IV over 3-15 minutes and cisplatin IV over 1 hour on day 1 and 5-FU IV continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
9737515|NCT00052962|Other|Arm 1 Surgery + post op chemotherapy|"Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~Post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-fluorouracil (5-FU), every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
9737516|NCT00052962|Other|Arm 2 Surgery + HIPEC|"Arm 2 Surgery + Continuous hyperthermic peritoneal perfusion (CHPP/HIPEC) + post op dwell + post op chemotherapy~Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin~post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluorouracil (5FU) 800 mg/m^2 and paclitaxel 125 mg/m^2~post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-FU, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
9737517|NCT00053014|Experimental|treatment|patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27
9737518|NCT00053352|Experimental|Arm I|"Patients enrolled with gonadal tumors of stage II or greater or extragonadal tumors of any stage receive cisplatin IV over 90 minutes & etoposide IV over 90 minutes days 1-3 and bleomycin sulfate IV over ≥ 10 minutes day 1. Treatment repeats every 3 weeks, 3 courses (weeks 0,3 & 6).~After completion of compressed induction chemotherapy, patients with no change in disease status or disease progression are removed from study. Patients with no evidence of disease receive no further therapy. Patients with a partial response or abnormal tumor markers proceed to conventional surgery (second-look) and/or 3 more courses of compressed consolidation chemotherapy.~After surgery, patients with pathologic complete response and have normal tumor markers receive no further therapy. Patients who remain with a partial response after surgery receive compressed consolidation chemotherapy.~Patients receive cisplatin, etoposide, and bleomycin as induction chemotherapy in weeks 10,13, & 16."
9737519|NCT00053352|No Intervention|Arm 2|"Patients who are enrolled with stage I gonadal tumors receive no further anticancer therapy until evidence of tumor recurrence or the diagnosis of a second malignant neoplasm.~Observation only for recurrence or development of an SMN"
9737520|NCT00053365|Experimental|Treatment (irofulven)|Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
9737521|NCT00053417|Placebo Comparator|1|Placebo control, twice a day (b.i.d.)
9737522|NCT00053417|Experimental|2|10 milligram (mg) fampridine b.i.d.
9737523|NCT00053417|Experimental|3|15 mg fampridine b.i.d.
9737524|NCT00053417|Experimental|4|20 mg fampridine b.i.d.
9737525|NCT00053482|Experimental|Group 1: ACAM2000|Participants will receive dose 1 of the ACAM2000 smallpox vaccine
9737526|NCT00053482|Experimental|Group 2: ACAM2000|Participants will receive dose 2 of the ACAM2000 smallpox vaccine
9737527|NCT00053482|Experimental|Group 3: ACAM2000|Participants will receive dose 3 of the ACAM2000 smallpox vaccine
9737528|NCT00053482|Experimental|Group 4: ACAM2000|Participants will receive dose 4 of the ACAM2000 smallpox vaccine
9737529|NCT00053482|Active Comparator|Group 5: Dryvax®|Participants will receive dose 1 of Dryvax® smallpox vaccine.
9737530|NCT00053495|Experimental|Group 1: ACAM2000 Dose 1|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units (PFU)/mL on Day 0.
9737531|NCT00053495|Experimental|Group 2: ACAM2000 Dose 2|Participants will receive a single dose of ACAM2000 smallpox vaccine, 2.0x10-8th plaque-forming units/mL on Day 0.
9737532|NCT00053495|Experimental|Group 3: ACAM2000 Dose 3|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0
9737533|NCT00053495|Experimental|Group 4: ACAM2000 Dose 4|Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0
9737534|NCT00053495|Active Comparator|Group 5: Dryvax® Vaccine|Participants will receive a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0
9737535|NCT00053677|Placebo Comparator|Naltrexone|17 weeks of double-blind Naltrexone. Subjects were randomized into one of these three conditions (if they weren't randomized to placebo): naltrexone 50mg/day, 100mg/day, 150mg/day. To minimize nausea, treatment for all subjects was initiated at 25mg/day naltrexone for two days, then the dose was increased to 50mg/day. At week 3, subjects were randomly assigned to 50mg/day continued at that dose, while subjects who were randomized to naltrexone 100mg/day or 150mg/day were raised to the higher doses.
9737536|NCT00053677|Placebo Comparator|Placebo|Subjects who were assigned to placebo in the 17 week double-blind phase.
9737537|NCT00053703|Active Comparator|olanzapine|oral olanzapine 5-20mg per day for up to 52 weeks
9737538|NCT00053703|Active Comparator|risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
9737539|NCT00053703|Active Comparator|molindone|oral molindone from 10-140mg/daily for up to 52 weeks
9737540|NCT00053846|Experimental|buspirone hydrochloride|buspirone hydrochloride
9737541|NCT00053846|Placebo Comparator|Placebo|Placebo
9737542|NCT00053898|Active Comparator|Group 1|tamoxifen 20 mg/day and an anastrozole look-alike placebo for 5 years
9737543|NCT00053898|Experimental|Group 2|anastrozole, 1 mg/day and an tamoxifen look-alike placebo for 5 years
9737544|NCT00053989|Experimental|All patients|All patients enrolled on study
9737545|NCT00054028|Experimental|Treatment (suramin and paclitaxel)|"PHASE I: Patients receive low-dose suramin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive adjusted doses of suramin until a target dose is determined. The suramin target dose is defined as the dose at which at least 5 of 6 patients achieve the target plasma concentration of 10-50 uM over the duration when paclitaxel levels are therapeutic.~PHASE II: Patients receive paclitaxel in combination with the target dose of suramin as above."
9737546|NCT00054132|Experimental|Treatment (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9737547|NCT00054275|Experimental|Erlotinib Plus Docetaxel|
9737548|NCT00054327|Experimental|Regimen A|Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.
9737549|NCT00054327|Experimental|Regimen B-1|Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..
9737550|NCT00054327|Experimental|Regimen B-2|Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.
9737551|NCT00054327|Experimental|Regimen C|Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.
9737552|NCT00054327|Experimental|Regimen B-3|Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.
9737553|NCT00054327|Experimental|Regimen D|Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.
9737554|NCT00054353|Experimental|Related Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
9737555|NCT00054353|Experimental|Unrelated Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
9737556|NCT00054639|Experimental|Treatment (oblimersen sodium and monoclonal antibody therapy)|Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
9737557|NCT00054665|Experimental|Part A: PS-341 Alone|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
9737558|NCT00054665|Experimental|Part B: PS-341 & EPOCH|"PS-341: level 1: 0.5 mg/m^2 intravenous (IV) days 1, 4; level 2: 1.0 mg/m^2 IV days 1, 4; level 3: 1.5 mg/m^2 IV days 1, 4; level 4: 1.7 mg/m^2 IV days 1, 4.~EPOCH: Etoposide: 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion; Doxorubicin: 10 mg/m^2 day CIV days 1-4, 96 hour infusion; Vincristine: 0.4 mg/m^2 day CIV days 1-4, 96 hour infusion; Cyclophosphamide: 750 mg/m^2 day IV day 5 bolus; Prednisone: 60 mg/m^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycles every 21 days."
9737559|NCT00054691|Experimental|Iressa (ZD1839)|Iressa (ZD1839) 250 mg by mouth daily.
9737560|NCT00054704|Experimental|Riluzole|Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
9737561|NCT00054704|Placebo Comparator|Placebo|Placebo pills resembling 50 mg riluzole tables were dispensed either once or twice a day. Dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
9737562|NCT00054717|Other|Tipranavir(TPV)/low dose ritonavir(r)|
9737563|NCT00054717|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
9737564|NCT00054756|Experimental|Thyrotropin Releasing Hormone|Subjects receiving TRH (Thyrotropin Releasing Hormone)
9737565|NCT00054847|Active Comparator|Saphenous Vein Graft|Saphenous Vein Graft
9737566|NCT00054847|Active Comparator|Radial Artery Graft|Radial Artery Graft
9737567|NCT00055237|Experimental|Cohort 1: Pts with HIV-associated Kaposi's Sarcoma|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
9737568|NCT00055237|Experimental|Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
9737569|NCT00055471|Experimental|ZD4054 10 mg|1 x 10 mg oral tablets once daily
9737570|NCT00055471|Experimental|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
9737571|NCT00055471|Experimental|ZD4054 22.5 mg|2 x 10 mg + 1 x 2.5 mg oral tablets once daily
9737572|NCT00055497|Placebo Comparator|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
9737573|NCT00055497|Experimental|Double-blind adalimumab 40 mg every other week (eow)|Double-blind adalimumab 40 mg eow by subcutaneous injection
9737574|NCT00055497|Experimental|Double-blind adalimumab 40 mg every week (ew)|Double-blind adalimumab 40 mg every week by subcutaneous injection
9737575|NCT00055497|Experimental|Open-label adalimumab 40 mg|Open-label adalimumab 40 mg eow or ew by subcutaneous injection
9737576|NCT00055601|Experimental|Pelvic RT + paclitaxel + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with paclitaxel and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with paclitaxel and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
9737577|NCT00055601|Experimental|Pelvic RT + fluorouracil + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with fluoruracil and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with fluoruracil and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
9737578|NCT00055692|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
9737579|NCT00056160|Experimental|CC-5013/Dex|CC-5013 (lenalidomide) plus oral high-dose dexamethasone
9737580|NCT00056160|Experimental|Placebo/Dex|Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
9737581|NCT00056316|Experimental|Behavioral Skills Training|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
9737582|NCT00056316|Active Comparator|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
9737583|NCT00056407|Placebo Comparator|Placebo Arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
9737584|NCT00056407|Experimental|dustasteride arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
9737585|NCT00056472|Active Comparator|olanzapine/sertraline combination|sertraline plus olanzapine
9737586|NCT00056472|Placebo Comparator|olanzapine plus placebo|olanzapine (5 - 20mg/day) plus placebo
9737587|NCT00056498|Active Comparator|Active|Participants assigned to risperidone
9737588|NCT00056498|Placebo Comparator|Placebo|Participants assigned to placebo
9737589|NCT00056550|Experimental|Recombinant Human Antithrombin (rhAT) infusion|Loading and continuous infusion dose of rhAT to target and maintain an AT activity level > 80% and < 120% of normal.
9737590|NCT00056563|Active Comparator|1|Deep Brain Stimulation
9737591|NCT00056563|Active Comparator|2|Best Medical Therapy
9737592|NCT00056862|Experimental|Low-dose pegIFN/standard-dose RBV|Patients receive a lower dose of peginterferon alfa-2a (90 mcg per week) and standard dose of ribavirin (800 mg/d) for chronic hepatitis C, genotype 2/3, for 24 weeks.
9737593|NCT00056862|Active Comparator|Standard-dose PegIFN/RBV|Patients receive the standard, recommended doses of peginterferon alfa-2a (180 mcg per week) and ribavirin (800 mg/d) for chronic hepatitis c, genotype 2/3, for 24 weeks.
9737594|NCT00057330|Experimental|Herpes Simplex Virus Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
9737595|NCT00057330|Experimental|Havrix Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
9737596|NCT00057551|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
9737597|NCT00057551|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
9737598|NCT00057551|Active Comparator|Medication Only|Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine
9737599|NCT00057577|Experimental|Cognitive therapy plus medications|Participants will receive antidepressant medication plus cognitive therapy
9737600|NCT00057577|Experimental|Medications alone|Participants will receive maintenance of antidepressant medication alone
9737601|NCT00057681|Experimental|1|Participants will receive treatment with lithium for 8 to 16 weeks
9737602|NCT00057681|Experimental|2|Participants will receive treatment with valproate for 8 to 16 weeks
9737603|NCT00057681|Experimental|3|Participants will receive treatment with risperidone for 8 to 16 weeks
9737604|NCT00057746|Active Comparator|Arm I|Prophylactic cranial irradiation, 2.5 Gy fx
9737605|NCT00057746|Experimental|Arm II|Prophylactic cranial irradiation, 2.0 Gy fx
9737606|NCT00057746|Experimental|Arm III|Prophylactic cranial irradiation, 1.5 Gy fx
9737607|NCT00057785|Experimental|IMRT +/- chemotherapy|Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+
9737608|NCT00057811|Experimental|Group B (chemotherapy, protective therapy, monoclonal antib.)|Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
9737609|NCT00057811|Experimental|Group C (Chemotherapy, monoclonal antibody therapy)|Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.
9737610|NCT00057837|Experimental|PET (Topotecan/Etoposide/Cisplatin/G-CSF)|Patients receive topotecan intravenously (IV) over 30 minutes on days 1-3; etoposide IV over 60 minutes immediately followed by cisplatin IV over 60 minutes on days 8-10; and filgrastim (G-CSF) subcutaneously daily beginning on day 11 and continuing until blood counts recover.
9737611|NCT00057837|Experimental|PIE (Irinotecan/Cisplatin/Etoposide)|Patients receive irinotecan IV over 90 minutes and cisplatin IV over 60 minutes on days 1 and 8 and oral etoposide twice daily on days 3 and 10 of each cycle.
9737612|NCT00057863|Experimental|Treatment (paclitaxel, oxaliplatin)|Patients receive paclitaxel IV over 3 hours and oxaliplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9737613|NCT00057876|Active Comparator|Gemcitabine|
9737614|NCT00057876|Experimental|Gemcitabine + Radiation|
9737615|NCT00057941|Experimental|Arm I (anastrozole, gefitinib)|Patients receive oral anastrozole and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737616|NCT00057941|Experimental|Arm II (fulvestrant, gefitinib)|Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737617|NCT00057954|Experimental|Transplant|Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).
9737618|NCT00058019|Experimental|Treatment (chemotherapy)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.
9737619|NCT00058058|Experimental|MRI Evaluation of Contralateral Breast|The cohort is a distinct population of women at high risk for breast carcinoma: women with a recent (within 60 days) personal diagnosis of breast cancer who will have MRI to evaluate the contralateral breast.
9737620|NCT00058123|Experimental|Poly-ICLC Recurrent gliomas|"Poly-ICLC 20ug/kg 3 times a week 4 week cycles (Monday-Wednesday-Friday)~Intramuscular injection~Drug Poly-ICLC"
9737621|NCT00058214|Experimental|Treatment (perifosine)|Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.
9737622|NCT00058240|Experimental|Arm I|Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
9737623|NCT00058370|Experimental|histologic proof of medulloblastoma|This is a single-arm study of post-operative radioimmunotherapy (intrathecal 131-I-3F8), reduced-dose craniospinal radiation therapy (1800 cGy), primary site boost (to 5400 cGy) via IMRT and standard chemotherapy.
9737624|NCT00058422|Experimental|R-CHOP and Ibritumomab Tiuxetan (Zevalin)|"Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.~Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
9737625|NCT00058825|Experimental|Stem Cell Transplant|Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
9737626|NCT00059202|Placebo Comparator|Placebo|Placebo tablet that is identical (size, color, etc) to experimental ursodeoxycholic acid tablet.
9737627|NCT00059202|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid 28-30 mg/kg/day
9737628|NCT00059215|Experimental|Prasugrel (CS-747) 40 mg LD/7.5 mg MD|Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days
9737629|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/10 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days
9737630|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/15 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days
9737631|NCT00059215|Active Comparator|Clopidogrel|Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.
9737632|NCT00059228|Experimental|Estradiol|Experimental
9737633|NCT00059228|Placebo Comparator|Placebo|Placebo comparator
9737634|NCT00059332|Experimental|Magnesium Sulfate|Magnesium sulfate (Mg) was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. The bolus-loading dose consisted of 4 grams Mg in 54 ml normal saline. The maintenance infusion contained 16 grams Mg diluted in 240 ml 0.9% normal saline, infused at 10 ml/hr for 24 hours. Paramedics in the field initiated the bolus-loading dose, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose.
9737635|NCT00059332|Placebo Comparator|Normal saline|Normal saline was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. Paramedics in the field initiated the bolus-loading dose of 54 ml normal saline, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose at 10 ml/hr for 24 hours.
9737636|NCT00059475|Experimental|Adj-2 MART-1: 27-35|melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).
9737637|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 27-35|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)
9737638|NCT00059475|Experimental|Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).
9737639|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)
9737640|NCT00059475|Experimental|Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4|melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).
9737641|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)
9737642|NCT00059475|Experimental|Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).
9737643|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)
9737644|NCT00059787|Experimental|Paclitaxel, carboplatin, erlotinib|Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
9737645|NCT00059839|Experimental|Standard APO with Vincristine (Arm I )|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV over 15 minutes, vincristine sulfate (1.5 mg/m2 (maximum dose 2 mg)) IV, and methotrexate intrathecally (age-adjusted dosing) (IT) on day 1 and oral prednisone (40 mg/m2/day) three times daily and oral mercaptopurine (225 mg/m2) once daily on days 1-5. In courses 4 and 5, patients receive doxorubicin (30 mg/m2), vincristine sulfate (1.5 mg/m2 (Maximum dose 2 mg)), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3. In courses 6-15, patients receive vincristine sulfate (1.5 mg/m2), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3 and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
9737646|NCT00059839|Experimental|Consolidation with Vinblastine|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV, methotrexate (age adjusted dosing) IT, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) IV over 1 minute on days 1, 8, and 15. In courses 4 and 5, patients receive doxorubicin hydrochloride (30 mg/m2) IV, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) as in arm II (courses 1-3). In courses 6-15, patients receive prednisone (120 mg/m2/day) and mercaptopurine (225 mg/m2) as in arm I, vinblastine sulfate (4 mg/m2) IV as in arm II (courses 1-3), and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
9737647|NCT00060008|Experimental|18FDG-PET scan and MR perfusion|Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.
9737648|NCT00060333|Experimental|Treatment (adjuvant radiation therapy)|Within 8 weeks after surgical resection, patients undergo radiation therapy twice weekly over approximately 2.5 weeks for a total of 5 fractions in the absence of disease progression or unacceptable toxicity.
9737649|NCT00060346|Experimental|Rituximab + CHOP|"Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by:~Cyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily"
9737650|NCT00060424|Experimental|Treatment (enzyme inhibitor, transplant, GVHD prophylaxis)|NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and TBI on day 0. TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclosporine PO every 12 hours on days -3 to 180 with taper on day 56 and mycophenolate mofetil PO every 12 hours on days 0-27.
9737651|NCT00060528|Experimental|no GM|No granulocyte macrophage colony stimulating factor (GM-CSF) was given
9737652|NCT00060528|Experimental|Rec-hGM|Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine. Given subcutaneously (s.c.) at site of vaccine.
9737653|NCT00060528|Experimental|rF-GM (10^7pfu)|recombinant fowlpox GM-CSF was given on day one at 10^7 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
9737654|NCT00060528|Experimental|rF-GM (10^8)|recombinant fowlpox GM-CSF was given on day one at 10^8 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
9737655|NCT00060606|Experimental|Prenatal Surgery Group|Fetal surgery to close spina bifida defect prior to 26 weeks of gestation with delivery by C-Section at approximately 37 weeks of gestation.
9737656|NCT00060606|Active Comparator|Postnatal Surgery Group|Standard postnatal closure of the spina bifida defect when the baby is medically stable, usually within 48 hours of birth by C-section.
9737657|NCT00060840|Active Comparator|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)
9737658|NCT00060840|Placebo Comparator|Nitrogen|Nitrogen (N2) administered at 40 ppm.
9737659|NCT00060944|Experimental|Yondelis weekly schedule|Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
9737660|NCT00060944|Experimental|Yondelis once every 3 weeks schedule|Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.
9737661|NCT00061048|Experimental|Campath-1H|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week.
9737662|NCT00061373|Experimental|MRI Selected Patients|"Patients are eligible for the MRI arm if all clinical and all MRI inclusion and exclusion criteria are met.~A single dose of aspirin 81 mg orally (or rectal dose equivalent), a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide."
9737663|NCT00061373|Experimental|non-MRI Selected Patients|"Patients are eligible for the non-MRI arm if all clinical inclusion-exclusion criteria are met, if MRI is contraindicated or if MRI compromises iv tPA delivery within 3-hours of symptom onset.~A single dose of aspirin 81 mg orally (or rectal dose equivalent) and a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide.~--------------------------------------------------------------------------------"
9737664|NCT00061633|Experimental|Telavancin|
9737665|NCT00061633|Active Comparator|Standard of care for cSSSI|cSSSI - complicated skin and skin structure infections
9737666|NCT00061893|Experimental|Combination chemotherapy|Metastatic Ewing Sarcoma - 14-cycle study building on conventional tx (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, ifosfamide, etoposide) and adding two antiangiogenic agents: the vinca alkaloid vinblastine and the cyclooxygenase-2 inhibitor celecoxib. Refer to the Interventions section for dosages, method of delivery and frequency of administration.
9737667|NCT00061932|Experimental|Stratum 1 (previously untreated)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8.
9737668|NCT00061932|Experimental|Stratum 2 (previously treated)|(closed to accrual as of 9/19/2006): Patients receive bortezomib as in stratum 1.
9737669|NCT00061945|Experimental|Treatment (alemtuzumab and combination chemotherapy)|See detailed description.
9781559|NCT01152359|Active Comparator|Arm 2|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
9781560|NCT01152385|Experimental|high|AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
9781561|NCT01152385|Experimental|Middle|AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
9781562|NCT01152385|Experimental|low|AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
9781563|NCT01152385|Placebo Comparator|4|
9781564|NCT01152437|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
9781565|NCT01152437|Active Comparator|Cetuximab|Patients receive cetuximab intravenously once a week, every week
9781566|NCT01152450|Experimental|Tiotropium daily dose q.d.|two actuations delivered via Respimat® inhaler
9781567|NCT01152450|Experimental|Tiotropium half daily dose b.i.d.|two actuations delivered via Respimat® inhaler
9781568|NCT01152450|Placebo Comparator|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
9781569|NCT01152515|No Intervention|Control|stopping of propofol and remifentanil infusion
9984669|NCT03864419|Experimental|Cohort III (Adult BL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
9781570|NCT01152515|Active Comparator|Remifentanil|stopping of propofol and maintenance of remifentanil infusion
9781571|NCT01152554|Experimental|SSRI/Serotonin/SNRI + TC-5214 1-4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
9781572|NCT01152554|Placebo Comparator|SSRI/Serotonin/SNRI + placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
9781573|NCT01152580|Placebo Comparator|Sugar pill|
9781574|NCT01152580|Active Comparator|melatonin|
9781575|NCT01152697|Experimental|Patient Noncompliance|There was only one arm for this study.
9785331|NCT01249131|Experimental|Treatment B first, then Treatment C, followed by Treatment A|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
9737670|NCT00062010|Experimental|IFN-alpha, 13-CRA, paclitaxel|Interferon alpha: 6 million U/m2 on days 1 and 2 of each week for 6 weeks of an 8-week cycle 13-cis-retinoic acid: 1 mg/kg on days 1 and 2 of each week for 6 weeks of an 8-week cycle Paclitaxel: 75 mg/m2 on day 2 of each week for 6 weeks of an 8-week cycle
9737671|NCT00062374|Experimental|Treatment (preoperative chemotherapy)|"Neoadjuvant chemotherapy: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1, 8, 22, and 29. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Within 4 weeks after completion of neoadjuvant chemotherapy, patients undergo radical subtotal or total gastrectomy with lymph node dissection."
9737672|NCT00062439|Experimental|Etoposide, Cisplatin, Thoracic RT, Surgery, Docetaxel|
9737673|NCT00062647|Experimental|Telavancin|
9737674|NCT00062647|Active Comparator|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram/12 hours or nafcillin, oxacillin, or cloxacillin 2 Gram/6 hours (IV) intravenously
9737675|NCT00062738|Experimental|nortriptyline|drug
9737676|NCT00062738|Experimental|paroxetine|drug
9737677|NCT00062738|Placebo Comparator|placebo|placebo
9737678|NCT00062764|Experimental|Pioglitazone|
9737679|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
9737680|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
9737681|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
9737682|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
9737683|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant
9737684|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group C)|Patients receiving CTLs following allogeneic stem cell transplant
9737685|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
9737686|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
9737687|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
9737688|NCT00063154|Experimental|Pertuzumab|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.
9737689|NCT00063258|Active Comparator|Chemotherapy + Tarceva|
9737690|NCT00063258|Active Comparator|Chemotherapy Alone|
9737691|NCT00063362|Experimental|Lithium + divalproex + lamotrigine|
9737692|NCT00063362|Placebo Comparator|Lithium + divalproex + placebo|
9737693|NCT00063570|Experimental|A|
9737694|NCT00063570|Experimental|B|
9737695|NCT00063622|Active Comparator|1|Pioglitazone
9737696|NCT00063622|Active Comparator|2|Vitamin E
9737697|NCT00063622|Placebo Comparator|3|Placebo Pioglitazone or Placebo Vitamin E
9737698|NCT00063635|Active Comparator|1|Metformin, 500 mg, twice daily
9737699|NCT00063635|Active Comparator|2|Vitamin E, 400 IU, twice daily
9737700|NCT00063635|Placebo Comparator|3|Matching placebo
9737701|NCT00063882|Experimental|EBRT + Brachytherapy|External beam radiation therapy (EBRT) and transperineal interstitial permanent brachytherapy (100/110)
9737702|NCT00063882|Active Comparator|Brachytherapy Only|Transperineal interstitial permanent brachytherapy (125/145)
9737703|NCT00063934|Experimental|Treatment (oblimersen, doxorubicin, docetaxel)|"PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6 interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13 or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at the MTD as in phase I.~Patients with resectable tumors after 6 courses undergo surgical resection."
9737704|NCT00063986|Experimental|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
9737705|NCT00063999|Active Comparator|Arm I (doxorubicin hydrochloride, cisplatin, paclitaxel)|Patients receive doxorubicin hydrochloride IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
9737706|NCT00063999|Experimental|Arm II (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
9781576|NCT01152788|Active Comparator|rIL-21|
9781577|NCT01152788|Active Comparator|Dacarbazine|
9984670|NCT03864419|Experimental|Cohort IV (MCD)|Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
9737707|NCT00064025|Experimental|Treatment (medroxyprogesterone)|"Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.~A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays."
9737708|NCT00064038|Experimental|Arm I|Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737709|NCT00064038|Active Comparator|Arm II|Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
9737710|NCT00064077|Experimental|Arm I (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
9737711|NCT00064077|Experimental|Arm II (vinorelbine, cisplatin)|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
9737712|NCT00064077|Experimental|Arm III (gemcitabine, cisplatin)|Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
9737713|NCT00064077|Experimental|Arm IV (topotecan, cisplatin)|Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
9737714|NCT00064259|Experimental|Treatment (oblimersen sodium)|"Phase I: Patients receive oblimersen IV continuously on days 1-7, fluorouracil IV continuously on days 4-8, and cisplatin IV on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 12 patients are treated at the MTD.~Phase II: Patients receive treatment as in phase I with oblimersen at the MTD."
9737715|NCT00064298|Experimental|Arm I - JuicePlus|Patients receive oral fruit and vegetable extracts twice daily.
9737716|NCT00064298|Placebo Comparator|Arm II - Control|Patients receive oral placebo twice daily.
9737717|NCT00064337|Experimental|Treatment|"MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70.~Mobilization and SC Collection:~MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis.~Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection).~Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion >/= 3.5 x 10^6 CD34+ cells/kg IV Day 0.~Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year."
9737718|NCT00064350|Experimental|Induction then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease."
9737719|NCT00064350|Placebo Comparator|Induction then Placebo then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm."
9737720|NCT00064350|Other|Induction, not randomized|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.~Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study."
9737721|NCT00064662|Other|Burch|The Burch colposuspension
9737722|NCT00064662|Other|Sling|Pubovaginal sling, using autologous rectus fascia
9737723|NCT00064701|Experimental|Tacrolimus|Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
9737724|NCT00064701|Active Comparator|Tacrolimus Modified Release|Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
9737725|NCT00064701|Active Comparator|Cyclosporine|Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
9737726|NCT00064753|Experimental|High Dose Multivitamin|Multivitamin with increased folic acid, vitamin B6 and vitamin B12
9737727|NCT00064753|Active Comparator|Low Dose Multivitamin|Multivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
9737728|NCT00064792|Placebo Comparator|OraPlus|
9737729|NCT00064792|Active Comparator|Simvastatin Susp|
9737730|NCT00064844|Placebo Comparator|Nicotine patch plus placebo gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
9737731|NCT00064844|Active Comparator|Nicotine patch plus active gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
9737732|NCT00064987|Experimental|Group 1 (FSH)|Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
9737733|NCT00064987|Active Comparator|Group 2 (GnRH)|Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.
9737734|NCT00065065|Experimental|Rosiglitazone|4 mg of rosiglitazone taken twice daily for 12 weeks.
9737735|NCT00065065|Placebo Comparator|placebo|Identical in appearance to study drug taken twice daily for 12 weeks.
9737736|NCT00065156|Experimental|Lenalidomide|
9737737|NCT00065260|Experimental|r-ATG /cyclosporine|A randomized trial of rabbit anti-thymocyte globulin (r-ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
9737738|NCT00065260|Experimental|Alemtuzumab (Campath-1H)|A randomized trial of rabbit anti-thymocyte globulin (ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
9737739|NCT00065429|Experimental|BB-10901, 5mg/m2 - Phase I|
9737740|NCT00065429|Experimental|BB-10901, 10 mg/m2 - Phase I|
9737741|NCT00065429|Experimental|BB-10901, 20 mg/m2 - Phase I|
9737742|NCT00065429|Experimental|BB-10901, 40 mg/m2 - Phase I|
9737743|NCT00065429|Experimental|BB-10901, 60 mg/m2 - Phase I & Phase II|Phase I and Phase II were consecutive and sequential. Different patients received the 60mg/m2 dose in Phase I and in Phase II.
9737744|NCT00065429|Experimental|BB-10901, 67.5 mg/m2 - Phase I|
9737745|NCT00065429|Experimental|BB-10901, 75 mg/m2 - Phase I|
9737746|NCT00065442|Placebo Comparator|APC-Placebo|
9737747|NCT00065442|Active Comparator|Sipuleucel-T|
9737748|NCT00065468|Active Comparator|A|
9737749|NCT00065468|Experimental|B|
9737750|NCT00065468|Experimental|C|
9737751|NCT00065507|Experimental|A1|
9737752|NCT00065507|Active Comparator|A2|
9737753|NCT00065806|Experimental|1|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
9781578|NCT01152814|Experimental|Arm 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
9737754|NCT00065806|Placebo Comparator|2|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
9737755|NCT00066066|Placebo Comparator|Scaling and root planing alone|Full mouth scaling and root planing (SRP) alone plus a placebo pill taken twice daily for 2 weeks.
9737756|NCT00066066|Active Comparator|SRP + Metronidazole|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 days
9737757|NCT00066066|Active Comparator|SRP + MET + Amoxicillin + Doxycycline|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 d and Amoxicillin (AMOX) 500 mg tid for 14 days and local drug delivery of Doxycycline (TET LDD) in pockets >4mm
9737758|NCT00066170|Experimental|Group 1.|Xyrem + Modafinil Placebo
9737759|NCT00066170|Placebo Comparator|Group 2:|Xyrem Placebo + Modafinil Placebo
9737760|NCT00066170|Active Comparator|Group 3|Xyrem Placebo + Modafinil at established dose
9737761|NCT00066170|Experimental|Group 4:|Xyrem + Modafinil at established dose
9737762|NCT00066222|Experimental|Radiation Therapy + Chemotherapy|Accelerated high dose thoracic radiation therapy (RT) with concurrent cisplatin/etoposide chemotherapy, followed by 2 cycles of adjuvant cisplatin/etoposide chemotherapy
9737763|NCT00066365|Experimental|Group 1 (unilateral recurrence) - Sargramostim and thoractomy|Patients receive initial inhalation therapy inhaled sargramostim (GM-CSF) twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure thoracotomy on day 22. Beginning on day 29, or as soon as possible thereafter, patients begin post-thoracotomy inhalation therapy for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
9737764|NCT00066365|Experimental|Group 2 (bilateral recurrence) - Sargramostim and thoractomy|Patients may be enrolled on study either before or after the first thoracotomy procedure. For the first thoracotomy, patients undergo surgical procedure unilateral thoracotomy. Patients receive initial inhalation therapy inhaled GM-CSF, as soon as possible after recovery from first thoracotomy, twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure contralateral thoracotomy on day 22. Beginning on day 29, or as soon as possible, patients begin post-thoracotomy inhalation therapy as above for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
9737765|NCT00066469|Experimental|Cyclophosphamide, prednisone, rituximab|Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease
9737766|NCT00066573|Experimental|Exemestane|Patients receive oral exemestane (25 mg) once daily for 5 years.
9737767|NCT00066573|Active Comparator|Anastrozole|Patients receive oral anastrozole (1 mg) once daily for 5 years.
9737768|NCT00066677|Experimental|rhuMAB-VEGF|bevacizumab 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks until disease progression, unacceptable toxicity or patient preference.
9737769|NCT00066677|Experimental|rhuMAB-VEGF and Docetaxel|rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and 15 of each 28 day cycle. Treatment continued until evidence of disease progression, unacceptable toxicity, or patient preference.
9737770|NCT00066690|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
9737771|NCT00066690|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
9737772|NCT00066690|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
9737773|NCT00066703|Active Comparator|T+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
9737774|NCT00066703|Experimental|E+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
9737775|NCT00066729|Experimental|NY-ESO-1b peptide with Montanide® ISA-51|Patients received NY-ESO-1b peptide mixed with Montanide® ISA-51 by subcutaneous injections, once every 3 weeks (weeks 1, 4, 7, 10, and 13) for a total of 13 weeks.
9737776|NCT00066742|Experimental|Treatment (tirapazamine, cisplatin, etoposide)|"CHEMORADIOTHERAPY: Patients receive tirapazamine IV over 1 hour on days 1, 8, 10, 12, 29, 36, 38, and 40; cisplatin IV over 1 hour on days 1, 8, 29, and 36; and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning on day 1 of chemotherapy, patients undergo thoracic radiotherapy once daily 5 days a week for 7 weeks.~CONSOLIDATION CHEMOTHERAPY: Within 28 days after completion of radiotherapy, patients with stable or responding disease receive cisplatin IV over 1 hour on days 1 and 22 and etoposide IV over 1 hour on days 1-3 and 22-24.~Treatment continues in the absence of disease progression or unacceptable toxicity."
9737777|NCT00066781|Experimental|Cohort I (closed to accrual 11/17/05)|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9737778|NCT00066781|Experimental|Cohort II|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9737779|NCT00066937|Experimental|Nortriptyline Oral Capsule/CBT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.
9737780|NCT00066937|Experimental|Benztropine Oral Product/CBT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.
9737781|NCT00066937|Experimental|Nortriptyline Oral Capsule/Disease MGT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.
9737782|NCT00066937|Active Comparator|Benztropine Oral Product/Disease MGT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.
9737783|NCT00067002|Experimental|Double Cord Blood Transplant Group|Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.
9737784|NCT00067002|Experimental|One Expanded Cord Blood Transplant Group|One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.
9737785|NCT00067028|Experimental|Clofarabine + Ara-C|"Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.~Ara-C Starting dose: 1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
9737786|NCT00067028|Experimental|Clofarabine + Idarubicin|"Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.~Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
9737787|NCT00067028|Experimental|Clofarabine + Idarubicin + Ara-C|"Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.~Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
9737788|NCT00067236|Experimental|PG-116800 tablet|PG-116800 tablet (200 mg) taken twice daily for 90 days
9737789|NCT00067236|Placebo Comparator|Placebo tablet|Placebo tablet taken twice daily for 90 days
9737790|NCT00067470|Placebo Comparator|Placebo|
9737791|NCT00067470|Active Comparator|rhASB|
9737792|NCT00067808|Active Comparator|Decitabine 10 mg/m^2 IV|10 mg/m^2 intravenous (IV) over 1 hour daily for 10 days
9737793|NCT00067808|Active Comparator|Decitabine 20 mg/m2 IV|20 mg/m2 IV over 1 hour daily for 5 days
9737794|NCT00067808|Active Comparator|Decitabine 20 mg/m2 SQ|20 mg/m2 subcutaneous (SQ) daily for 5 days
9737795|NCT00067990|Experimental|Losartan 100mg|Losartan 100 mg per day to be started within three months of transplantation and continuing treatment for five years.
9737796|NCT00067990|Placebo Comparator|Placebo|No intervention with continuing follow-up for five years.
9737797|NCT00068107|Experimental|Relagal|All participants received Relagal administered weekly
9737798|NCT00068237|Experimental|Surgery + Transfer + Radiation|Submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes followed by post-operative radiation therapy.
9737799|NCT00068250|Experimental|Phase I: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
9737800|NCT00068250|Experimental|Phase I: Temozolomide 150 mg|Rituximab, methotrexate, temozolomide 150 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
9737801|NCT00068250|Experimental|Phase I: Temozolomide 200 mg|Rituximab, methotrexate, temozolomide 200 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
9737802|NCT00068250|Experimental|Phase II: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
9737803|NCT00068341|Experimental|Arm I (neoadjuvant therapy)|see intervention description
9737804|NCT00068341|Experimental|Arm II (neoadjuvant therapy)|please see intervention description
9737805|NCT00068341|Experimental|HER2/neu negative patients|please see intervention description
9737806|NCT00068367|Experimental|Arm I (OSI-774)|"Drug: erlotinib hydrochloride~Other Names:~OSI-774 150 mg per day, daily until disease progression"
9737807|NCT00068380|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9737808|NCT00068393|Experimental|Doxorubicin/Gemcitabine|Doxorubicin was given at 50 mg/m² by IV slow push, followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life. Cycles were repeated every 2 weeks.
9737809|NCT00068406|Experimental|Treatment (conventional surgery, radiation therapy, cisplatin)|"Patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin IV over 30 minutes on day 1. Treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity.~Six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). Patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. Patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin."
9737810|NCT00068419|Experimental|Treatment (enzyme inhibitor therapy, anti-estrogen therapy)|Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
9737811|NCT00068445|Experimental|Arm I - lamotrigine|"Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks. Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
9737812|NCT00068445|Other|Arm II - placebo|"Patients receive oral placebo once daily for 2 weeks and then twice daily for 8 weeks.~Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
9737813|NCT00068575|Experimental|Postoperative Chemoradiation Regimen|Postoperative Cisplatin 30 mg/m^2 intravenous (IV) weekly for 6 doses, Interferon Alfa-2b 3 million units subcutaneous (SQ) on Monday, Wednesday and Friday days 1-19 and 29-45 for 17 total doses, and 5-fluorouracil (5-FU) 175 mg/m2/day by continuous intravenous infusion days 1-19 and 29-45 with concurrent Radiation Treatment.
9737814|NCT00068588|Experimental|Treatment (GTI-2040, capecitabine)|Patients receive GTI-2040 IV continuously on days 1-15 of the first course and days 1-14 of all subsequent courses. Patients also receive oral capecitabine twice daily on days 2-15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9737815|NCT00068601|Active Comparator|Standard Chemotherapy|Patients receive cyclophosphamide-containing chemotherapy alone.
9737816|NCT00068601|Experimental|Chemotherapy Plus Goserelin|Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
9737817|NCT00068692|Experimental|Group I, Arm I|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
9737818|NCT00068692|Experimental|Group I, Arm II|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 8 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
9781579|NCT01152996|Experimental|Vortioxetine|Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.
9781580|NCT01153009|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
9737819|NCT00068692|Experimental|Group I, Arm III|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 1 hour on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 8 weeks for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
9737820|NCT00068692|Experimental|Group II, Arm I|"Patients receive irinotecan, leucovorin calcium, and fluorouracil as in group 1, arm I for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
9737821|NCT00068692|Experimental|Group II, Arm II|"Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in group 1, arm II for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
9737822|NCT00068692|Experimental|Group II, Arm III|Patients receive leucovorin calcium and fluorouracil as in group 1, arm III for 1 course. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III. Treatment continues in the absence of disease progression or unacceptable toxicity.
9737823|NCT00068718|Experimental|Treatment (DLI)|Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
9737824|NCT00068770|Active Comparator|p450 ( +EIASD)|"on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine)~celecoxib and radiation therapy will be adminstered with this arm"
9737825|NCT00068770|Active Comparator|nonp450 (-EIASD)|"not on p450 inhibitor (Patients either NOT taking anti-seizure drugs or ones that are known to not significantly influence the hepatic drug-metabolizing enzymes - including gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine,topiramate, zonisamide and filbamate.~celecoxib and radiation therapy will be adminstered with this arm"
9737826|NCT00068822|Experimental|Vertebroplasty|Participants will receive percutaneous vertebroplasty
9737827|NCT00068822|Placebo Comparator|Control Group|Participants will receive sham vertebroplasty without PMMA
9737828|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine)|Patients in the 2-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
9737829|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
9737830|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)|Patients in the 2-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
9737831|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.
9737832|NCT00069108|Experimental|XELOX|Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m^2 intravenous (IV) infusion over 2 hours (every 3 weeks [Day 1]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).
9737833|NCT00069108|Active Comparator|FOLFOX-4|Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin [LV] and 5-fluorouracil [5-FU] combination). Oxaliplatin was administered as an 85 mg/m^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m^2 over 2 hours followed by 5-FU, given as 400mg/m^2 bolus injection over 2-4 minutes, and then as a 600 mg/m^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).
9781581|NCT01153009|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
10200879|NCT05172102|Experimental|study group|"Will receive diaphragmatic breathing with pursed lips as (breathing exercise), They will instruct to perform 3 different conditions will be registered: (1) 6 min of quiet breathing (3 sets of 2 min each), defined as spontaneous breathing pattern; (2) 6 min of diaphragmatic breathing (3 sets of 2 min each); and (3) 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).~For aerobic exercises: Will include the following exercises: walking, cycling, running and intermittent running. The exercises will perform for 18-60 minutes for 1-2 sets per week.~For resistance exercises: Will include the following 8 exercises: shoulder press, biceps curl, triceps curl, bench press, leg squats, leg press, leg curl and toe raise. The exercises will perform for 60 minutes for 2-3 sets per week."
10200880|NCT05172102|No Intervention|control group|not receiving any exercises
9737834|NCT00069121|Active Comparator|5-Fluorouracil/Leucovorin (5-FU/LV)|Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).
9737835|NCT00069121|Experimental|Capecitabine in Combination with Oxaliplatin (XELOX)|Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).
9737836|NCT00069160|Experimental|Pts who received docetaxel on day 1, 8, & tariquidar day 8,22|Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
9737837|NCT00069160|Experimental|Pts who received docetaxel on days 1, 8, & tariquidar day 1,22|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.
9737838|NCT00069264|Experimental|E7389|
9737839|NCT00069329|Experimental|NOMID treatment arm|All patients enrolled received daily doses of subcutaneous injection of increased doses of anakinra starting at 0.5mg/kg/day up to a maximum 10mg/kg/day to achieve disease remission.
9737840|NCT00069576|Active Comparator|Nutritional counseling & self blood glucose monitoring|Within one week of enrollment, women in the treatment group receive formal nutritional counseling and will be instructed on the technique of self blood glucose monitoring using a memory-based reflectance meter.
9737841|NCT00069576|No Intervention|No treatment|This group will not receive any specific dietary therapy except for written information concerning general nutritional recommendations for normal pregnancy.
9737842|NCT00069641|Experimental|Idursulfase weekly (0.5 mg/kg)|
9737843|NCT00069641|Experimental|Idursulfase every other week (0.5 mg/kg)|
9737844|NCT00069641|Placebo Comparator|Placebo|
9737845|NCT00069784|Experimental|Insulin glargine + omega-3 polyunsaturated fatty acids|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of omega-3 polyunsaturated fatty acids once daily"
9737846|NCT00069784|Experimental|Insulin glargine + placebo|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of placebo once daily"
9737847|NCT00069784|Experimental|Standard care + omega-3 polyunsaturated fatty acids|• One capsule of omega-3 polyunsaturated fatty acids once daily
9737848|NCT00069784|Placebo Comparator|Standard care + placebo|• One capsule of placebo once daily
9737849|NCT00069823|Experimental|Esomeprazole|Proton pump inhibitor of gastric acid
9737850|NCT00069823|Placebo Comparator|Placebo for esomeprazoe|Placebo
9737851|NCT00069953|Experimental|ChemoRT and selective surgery|Induction therapy of fluorouracil, cisplatin, paclitaxel, and pegfilgrastim OR filgrastim, then chemoradiotherapy of concurrent cisplatin and fluorouracil with external beam radiotherapy (RT), followed by selective salvage therapy.
9737852|NCT00070070|Experimental|Cohort 1|"HLA-A2 Status Positive, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
9737853|NCT00070070|Experimental|Cohort 2|"HLA-A2 Status Positive, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
9781582|NCT01153009|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
9781583|NCT01153009|Active Comparator|Duloxetine 60 mg|Duloxetine 30 mg capsules, orally, once daily for one week then duloxetine 60 mg, capsules, orally, once daily for 7 weeks, then duloxetine 30 mg capsules, once daily, for one week.
9737854|NCT00070070|Experimental|Cohort 3|"HLA-A2 Status Negative, Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 10E6 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 10E5 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
9737855|NCT00070070|Experimental|Cohort 4|"HLA-A2 Status Negative, No Previous BCG Therapy; All patients underwent skin testing with the purified protein derivative (PPD) test.~NY-ESO-1 protein, 75 mcg, was administered by intradermal injection every week for 6 weeks. TICE®-strain BCG, 1 x 106 viable units in Purified Protein Derivative (PPD) negative patients and 1 x 105 viable units in PPD positive (induration greater than or equal to 10 mm) patients, were mixed with each protein vaccination for the first 2 weeks only. For the last 4 weeks GM-CSF, 100 mcg, was mixed with NY-ESO-1 protein given once a week for 4 weeks, intradermally. GM-CSF alone was given subcutaneously on the day prior to the administration of the co-mixture (NY-ESO-1 Protein/GM-CSF) and for 3 days after."
9737856|NCT00070109|Experimental|Trabectedin 1.3 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. A cohort of 6 patients will be enrolled at the 1.3 mg/m2 dose level.
9737857|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Six toxicity-evaluable patients are assigned this treatment.
9737858|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 to assess efficacy in Ewing sarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
9737859|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 - assess efficacy in rhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
9737860|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 - assess efficacy in nonrhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
9781584|NCT01153269||HIV-infected patients with hepatitis co-infection|HIV-infected patients with co-infections of Hepatitis B or Hepatitis C
9781585|NCT01153321|Experimental|1|Oral treatment
9781586|NCT01153321|Placebo Comparator|2|Oral treatment
9781587|NCT01153347|Experimental|SSRI/Serotonin/SNRI+ TC-5214 0.5 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.5 mg BID
9983901|NCT04558931|Experimental|A - Isatuximab/CellProtect|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~CellProtect will be given IV infusion at the dose of 3x10^7 cells/kg day 29 , 43 and 3-10x10^7 on day 57.~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
9984671|NCT03858621|Experimental|fentanyl NOL guided|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
9737861|NCT00070135|Experimental|Treatment (fludarabine, busulfan, allogeneic PBSC)|"PREPARATIVE REGIMEN: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and busulfan IV over 2 hours 4 times per day (every 6 hours) on days -4 and -3.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO or IV BID on days -2 with taper between days 90-120, and stopping by days 150-180. Patients also receive methotrexate IV on days 1, 3, 6, and 11 and rabbit antithymocyte globulin IV over 4-6 hours on days -4 through -2.~ALLOGENEIC PBSC: Patients undergo allogeneic PBSC transplant on day 0. Patients then receive filgrastim SC daily beginning on day 12 and continuing until blood counts recover."
9737862|NCT00070291|Experimental|Cyclosporine|High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.
9737863|NCT00070317|Experimental|Diagnostic|Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.
9737864|NCT00070941|Experimental|SAM-e|40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo escitalopram.
9737865|NCT00070941|Active Comparator|Escitalopram|40 subjects receiving oral escitalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.
9737866|NCT00070941|Placebo Comparator|Placebo Comparator|20 subjects receiving oral placebo escitalopram and placebo SAM-3 daily in two divided doses.
9737867|NCT00071006|Experimental|Single arm study|
9737868|NCT00071032|Experimental|Liberal (10 g/dL) Transfusion Strategy|Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
9737869|NCT00071032|Active Comparator|2|Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
9737870|NCT00071058|Experimental|Surgery plus chemotherapy|"Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.~Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3."
9737871|NCT00071110|Experimental|1|Electroacupuncture (EA).
9737872|NCT00071110|Placebo Comparator|2|Sham
9781588|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 2 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 2 mg BID
9781589|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
9781590|NCT01153347|Placebo Comparator|SSRI/Serotonin/SNRI + Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
9781591|NCT01153425|Active Comparator|Teriparatide (Forteo)|20 µg of Teriparatide will be self-injected subcutaneously once a day for 12 months and an MRI at 3T ('Virtual Bone Biopsy') will be performed at 0 and 12 months.
9781592|NCT01153425|Active Comparator|Zoledronic Acid (Reclast)|5 mg of zoledronic Acid will be administered intravenously at baseline and 12 months and an MRI at 3T ('Virtual Bone Biopsy) will be performed at 0 and 12 months.
9781593|NCT01153503|Active Comparator|Ketorolac 30 mg, IV + TAP block|"Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
9781594|NCT01153503|Active Comparator|TAP block|"Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery~First 24-h Postoperative: IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
9781595|NCT01153503|No Intervention|Ketorolac 30 mg|"Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
9781596|NCT01153581|Experimental|Ganirelix acetate|Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
9781597|NCT01153581|Experimental|17β-Oestradiol, E2|The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
9781598|NCT01153581|Experimental|Progesterone|The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
9781599|NCT01153620|Placebo Comparator|Ringer's Solution|
9781600|NCT01153620|Active Comparator|Lavasept 0.04%|
10200881|NCT05171322||All patients|All patients included were set up with the WARD monitoring devices.
10200882|NCT05171205|Experimental|Spinal cord stimulation(SCS) implantation|"Phase I:~C2-4 is selected as the puncture location. Percutaneous puncture is performed under X-ray guidance. One or two electrodes are placed in the patient's epidural cavity, and the electrode position is adjusted intraoperatively by the patient's feedback of the current stimulation position until the current can cover the entire area.~An extension lead is connected, an external temporary stimulator is attached, and the patient decides whether to proceed to full implantation in phase II after 7-10 days of phase I testing experience.~Phase II:~The complete SCS system is implanted under local anesthesia or epidural anesthesia after successful testing. A subcutaneous capsular bag is usually created in the lower abdomen and the implanted electrodes are connected to the pulse generator through a connecting wire in the subcutaneous tunnel."
9737873|NCT00071396|Experimental|Campath-1H + Rituximab|"Campath 15 mg/day continuous intravenous (IV) infusion x 6 days, then twice a week for 3 weeks as 30 mg injection under skin to complete 4 week treatment course.~Rituximab 375 mg/m^2 IV infusion day 1, then 500 mg/m^2 on days 8, 15 + 22."
9737874|NCT00071487|Placebo Comparator|Placebo plus SOC|
9737875|NCT00071487|Experimental|Belimumab 1 mg/kg plus SOC|
9737876|NCT00071487|Experimental|Belimumab 4 mg/kg plus SOC|
9737877|NCT00071487|Experimental|Belimumab 10 mg/kg plus SOC|
9737878|NCT00071513|Experimental|CAST-T/HSTS|The CAST-T/HSTS condition combined the Brief Intervention and 12 school based small group sessions which taught skills to enhance personal control (to manage depression, anger, stress), self-esteem, decision making and interpersonal communications. HSTS skills groups were held in the spring of 8th grade with 4 one-on-one booster sessions delivered to the students as 9th graders by HSTP leaders; parents also participated in 4 sessions. HSTS objectives are: 1) to increase the acquisition of coping skills competencies by teaching and practicing strategies taught; 2) to increase social support resources by building a supportive network; 3) to increase the youth's engagement in positive social activities; and 4) to motivate parents to increase their support via parent educational sessions.
9737879|NCT00071513|Active Comparator|Brief Intervention|Brief Intervention: After each youth and parent completed baseline questionnaires the youth participated in a 1 on 1 standardized clinical follow-up with a trained clinician (blind to study condition) to review areas of concern, based on questionnaire responses including stressors at school, home, and with peers, level of support available and how to access support. The teen and clinician then planned a feedback call to parents, allowing teens to shape requests for support from parents as well as understand exactly what information would be shared with parents. Feedback call to parents reviewed concerns and made recommendations for services as needed. A similar procedure was followed after each assessment for all participants who indicated a risk of clinical depression or self-harm.
9737880|NCT00071721|Experimental|1|
9737881|NCT00071721|Placebo Comparator|2|
9737882|NCT00071760|Experimental|Arm A - 4weeks - less than 2 years old (FPV/RTV bid)|"Cohort 2A - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)~Cohort 1A - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)"
9737883|NCT00071760|Experimental|Arm B- 4weeks - less than 2 years old (FPV bid)|"Cohort 2B - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)~Cohort 1B - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)"
9737884|NCT00071799|Experimental|Azacitidine|Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
9737885|NCT00071799|Active Comparator|Conventional Care|Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
9737886|NCT00071812|Placebo Comparator|Placebo plus SOC|
9737887|NCT00071812|Experimental|Belimumab 1 mg/kg plus SOC|
9737888|NCT00071812|Experimental|Belimumab 4 mg/kg plus SOC|
9737889|NCT00071812|Experimental|Belimumab 10 mg/kg plus SOC|
9737890|NCT00071890|Active Comparator|Interleukin 2 group|HAART (standard of care) and three cycles of IL-2
9737891|NCT00071890|Active Comparator|Control group|HAART alone
9737892|NCT00071981|Experimental|Arm I (12MP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising 12 melanoma peptides restricted by Class I MHC (12MP) emulsified with sargramostim (GM-CSF) and Montanide ISA-51 (incomplete Freund's adjuvant) or Montanide ISA-51 VG (ISA-51) intradermally (ID) and subcutaneously (SC) on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
9737893|NCT00071981|Experimental|Arm II (12MP/Tet)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
9737894|NCT00071981|Experimental|Arm III (12MP/6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 6 melanoma helper peptides (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
9737895|NCT00071981|Experimental|Arm IV (6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising melanoma helper peptide vaccine (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
9737896|NCT00072176|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737897|NCT00072189|Experimental|Treatment (7-hydroxystaurosporine)|Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9737898|NCT00072280|Experimental|Chemotherapy plus possible surgery|"Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.~(See Interventions section for drug dosage and administration details.)"
9737899|NCT00072280|Experimental|Surgery only|Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.
9737900|NCT00072293|Active Comparator|Axillary Dissection|Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
9737901|NCT00072293|Experimental|No Axillary Dissection|Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
9737902|NCT00072384|Experimental|Treatment (chemotherapy, surgery)|Patients receive liposomal vincristine sulfate IV over 1 minute on day 1 and carboplatin IV over 1 hour and etoposide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 3 and continuing until blood counts recover. Patients receive subtenon carboplatin to each group C or D eye on day 0 or 1prior of courses 2-4 only. Treatment repeats every 28 days for 6 courses in the absence of occurrence of extraocular retinoblastoma or a second malignancy. Beginning with course 3 of systemic chemotherapy, patients undergo local ophthalmic therapy comprising local laser surgery and/or cryosurgery on day 1.
9737903|NCT00072449|Experimental|Rituximab monotherapy|Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
9737904|NCT00072475|Experimental|Vatalanib|Adult patients with MDS receive treatment with vatalanib.
9737905|NCT00072514|Experimental|Treatment|Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
9737906|NCT00072566|Experimental|Treatment (bevacizumab, cyclophosphamide)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737907|NCT00072761|Active Comparator|Transfusion Group|Participants allocated to the transfusion arm will receive blood transfusion therapy every 4-6 weeks for 36 months.
9737908|NCT00072761|No Intervention|Observation Group|Participants allocated to the observation arm will be treated according to standard care and will receive a quarterly physical examination by a study hematologist for 36 months.
9737909|NCT00073008|Other|lapatinib|Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.
9737910|NCT00073021|Active Comparator|Asacol 2.4 g/day|Asacol (2.4 g/day)
9737911|NCT00073021|Experimental|Asacol 4.8 g/day|Asacol (4.8 g/day)
9737912|NCT00073073|Experimental|Exemestane|exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects.
9737913|NCT00073307|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.
9737914|NCT00073307|Placebo Comparator|Placebo|Placebo tablets matching in appearance were to be orally administered twice a day.
9737915|NCT00073333|Active Comparator|1|Social skills training and exposure
9737916|NCT00073333|Active Comparator|2|Exposure treatment
9737917|NCT00073333|Placebo Comparator|3|Placebo
9983902|NCT04558931|Active Comparator|B - Isatuximab|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
9737918|NCT00073528|Placebo Comparator|Placebo + Letrozole 2.5 mg|Letrozole (2.5 mg once daily orally) with Placebo (which matched with Lapatinib tablet)
9737919|NCT00073528|Experimental|Lapatinib 1500 mg + Letrozole 2.5 mg|Lapatinib (1500 mg once daily orally) with Letrozole (2.5 mg once daily orally)
9737920|NCT00073749|Experimental|Inotuzumab ozogamicin|Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2
9737921|NCT00073918|Experimental|Treatment (radio labeled monoclonal antibody, chemotherapy)|"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.~CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.~AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0."
9737922|NCT00073957|Experimental|Y-90 Ibritumomab Tiuxetan|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab and central nervous system prophylaxis with Cytarabine or liposomal cytarabine
9737923|NCT00074035|Experimental|Pentostatin|treatment of pts with refractory graft vs host disease
9737924|NCT00074152|Active Comparator|Arm I|Patients receive radiotherapy* within 6 months after surgery.
9737925|NCT00074152|Experimental|Arm II|Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.
9737926|NCT00074165|Experimental|All subjects|
9737927|NCT00074269|Experimental|treatment|
9737928|NCT00074282|Experimental|Arm A (PCR)|"Treatment consisted of 6 cycles of pentostatin, cyclophosphamide, and rituximab (PCR) given every 28 days.~Rituximab administered as follows: For the first infusion, all patients receive 100 mg dose (regardless of weight/BSA). For subsequent infusions, all patients receive rituximab 375 mg/m2.~Pentostatin and cyclophosphamide administered as follows: Pentostatin given at 4 mg/m2 either as an IV push or IV over 10-30 minutes in 250 mL NS or D5W on day 1 every 4 weeks of cycles 1-6. Cyclophosphamide given at 600 mg/m2 IV over 30-60 minutes in 250 mL NS on day 1 every 4 weeks of cycle 1-6."
9737929|NCT00074282|Experimental|Arm B (Alemtuzumab: CR, nPR)|Patients who achieved a confirmed CR or nPR, were registered to receive Alemtuzumab (Arm B). When the patient was registered to Arm B, the drug was administered three times a week for four weeks. The dose was 30 mg per dose. A twelve-week treatment-free period had to elapse before CAMPATH-1H began following completion of PCR for Arm B patients
9983903|NCT04558593||active surveillance|220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
9737930|NCT00074282|Experimental|Arm C (Alemtuzumab: PR, <PR, PD)|For those patients not achieving a CR or nPR (thus patients either achieved PR, SD, or PD), Alemtuzumab (Arm C) was administered three times a week for eighteen weeks at a dose of 30 mg TIW. For PR, SD and PD patients, the timing of CAMPATH-1H was left to the discretion of the investigator, and treatment could begin earlier but no less than two weeks and no longer than eight weeks after the completion of the last PCR course. Patients determined to have PD during treatment with PCR did not need to complete all 6 cycles of PCR to go on to Arm C, however, completing a minimum of 2 cycles was required.
9737931|NCT00074308|Experimental|Arm I|Patients receive oral imatinib mesylate once or twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737932|NCT00074412|Experimental|2A|For infants: extended treatment with NVP
9737933|NCT00074412|Placebo Comparator|2B|For infants: extended treatment with NVP placebo
9737934|NCT00074490|Experimental|Arm IVD cohort 1 (Th2 DLI)|Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive)
9737935|NCT00074490|Experimental|Arm IVD cohort 2 (conventional DLI)|Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with unmanipulated donor T-cells on day 14 (single T- cell DLI in patients with low CD4 count between 100 and 200 inclusive)
9737936|NCT00074490|Experimental|Arm IVD cohort 3 (multiple Th2 DLI)|Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300)
9737937|NCT00074490|Experimental|Arm IVA (12-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine by mouth twice a day (PO BID) on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14.
9737938|NCT00074490|Experimental|Arm IVB (6-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
9737939|NCT00074490|Experimental|Arm IVC (6-day expanded Th2 DLI and High-Dose Sirolimus)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
9737940|NCT00074581|Experimental|1|Participants will begin ART in addition to receiving HIV primary care
9737941|NCT00074581|Experimental|2|"Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.~Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible."
9737942|NCT00074711|Active Comparator|Calcium Phosphate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
9737943|NCT00074711|Active Comparator|Calcium Carbonate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
9737944|NCT00074802|Experimental|Paroxetine Continuation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine for 16 additional weeks.
9737945|NCT00074802|Experimental|Paroxetine with CBT Augmentation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine plus cognitive behavioral therapy (CBT) for 16 additional weeks.
9737946|NCT00074815|Experimental|MedMgmt+CBT|Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.
9737947|NCT00074815|Experimental|MedMgmt+I-CBT|Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.
9737948|NCT00074815|Active Comparator|MedMgmt Only|Participants will receive the intervention SRI medication management with a psychiatrist
9737949|NCT00074958|Experimental|Fabrazyme|1.0 mg/kg of Fabrazyme given to the patients every 2 weeks
9737950|NCT00074984|Placebo Comparator|Placebo|Patients randomized to placebo
9737951|NCT00074984|Active Comparator|Fabrazyme (agalsidase beta)|Patients randomized to Fabrazyme (agalsidase beta).
9737952|NCT00075023|Experimental|Thalidomide gel|Thalidomide gel 20 mg applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
9737953|NCT00075023|Experimental|Placebo|Placebo gel with no Thalidomide applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
9737954|NCT00075088|Experimental|Electrocardiogram (ECG) Intervention|Patients randomized to the experimental group had their ECGs printed out in the target ED with an audible voice alarm. Print-out of the pre-hospital ECG in the target ED was the intervention.
9737955|NCT00075088|Other|Routine Clinical Practice|Control patients had an ECG conducted after hospital arrival, as was the standard of care in the county.
9737956|NCT00075218|Placebo Comparator|B|
9737957|NCT00075218|Active Comparator|A|
9737958|NCT00075270|Experimental|Arm 1|Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
9737959|NCT00075270|Placebo Comparator|Arm 2|Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo
9737960|NCT00075335|Experimental|AMD 3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
9737961|NCT00075400|Experimental|Treatment (imatinib mesylate)|Patients receive imatinib mesylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9737962|NCT00075478|Experimental|Arm I (chemotherapy, TBI, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
9737963|NCT00075478|Active Comparator|Arm II (TBI, transplant, GVHD prophylaxis)|Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
9737964|NCT00075504|Experimental|triapine, gemcitabine|Triapine IV over 4 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15, repeat every 28 days
9737965|NCT00075582|Experimental|Regimen I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)
9737966|NCT00075582|Experimental|Regimen II (chemotherapy, radiotherapy, surgery)|Patients receive VAC chemotherapy and radiation therapy as in regimen I and VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy). Some patients do not receive radiation therapy; some start it at week 13 and some at week 24. Some patients have conventional surgery (second-look) at Week 13 (closed to accrual as of 9/23/2011).
9737967|NCT00075725|Active Comparator|Arm I|Patients in arm I receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
9737968|NCT00075725|Active Comparator|Arm II|Patients in arm II will receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
9983904|NCT04558593||surgery|110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
9737969|NCT00075725|Experimental|Arm III|"Patients in arm III will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks."
9737970|NCT00075725|Experimental|Arm IV|"Patients in arm IV will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks."
9737971|NCT00075764|Active Comparator|Arm I|Patients receive oral anastrozole once daily on days 1-28.
9737972|NCT00075764|Experimental|Arm II|Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.
9737973|NCT00075803|Active Comparator|Fluconazole|The dose of fluconazole is 400 mg by mouth or intravenous drip.
9737974|NCT00075803|Experimental|Voriconazole|The dose of oral voriconazole is 200 mg twice daily. When voriconazole must be given intravenously, it will be given at a dose of 200 mg every 12 hours for the duration of intravenous therapy.
9737975|NCT00075816|Active Comparator|Bone Marrow Transplant|Allogeneic bone marrow transplantation
9737976|NCT00075816|Active Comparator|Blood Stem Cell Transplant|Peripheral blood stem cell transplantation
9737977|NCT00075829|Active Comparator|Auto transplants plus Therapy|One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.
9737978|NCT00075829|Active Comparator|Auto transplants|One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.
9737979|NCT00075829|Active Comparator|Auto and Allo transplants|One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.
9737980|NCT00075881|Experimental|Treatment (bortezomib)|"INDUCTION TREATMENT: Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TREATMENT: Patients who complete induction treatment without progressive disease receive bortezomib IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~REINDUCTION TREATMENT: Patients who progress while on maintenance treatment receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
9737981|NCT00075946|Active Comparator|Arm A: Rituximab Retreatment|Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
9737982|NCT00075946|Experimental|Arm B: Rituximab Scheduled|Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
9737983|NCT00076024|Other|Docetaxel + Placebo|Docetaxel + Placebo
9737984|NCT00076024|Experimental|Docetaxel + AG-013736|Docetaxel + AG-013736
9737985|NCT00076050|Experimental|1|Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.
9737986|NCT00076050|Placebo Comparator|2|Participants will receive placebo daily over 2 years.
9737987|NCT00076102|Experimental|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
9737988|NCT00076219|Experimental|Intensive renal replacement therapy|In the intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 6 times per week, and continuous venovenous hemodiafiltration was provided at 35 mL/kg/hour.
9737989|NCT00076219|Active Comparator|Less-intensive renal replacement therapy|In the less-intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 3 times per week, and continuous venovenous hemodiafiltration was provided at 20 mL/kg/hour.
9737990|NCT00076245|Experimental|1 Light therapy|
9737991|NCT00076245|Experimental|2 Cognitive behavioral therapy|
9737992|NCT00076245|Experimental|3 Light therapy plus cognitive behavioral therapy|
9737993|NCT00076245|No Intervention|4 Control|
9737994|NCT00076258|Experimental|SSRI+ LD|A low dose aerobic exercise (LD) augmentation intervention to SSRI
9737995|NCT00076258|Experimental|SSRI+ PHD|A public health dose of aerobic exercise (PHD) augmentation intervention to SSRI
9737996|NCT00076336|Experimental|Telbivudine 600 mg|Participants received Telbivudine 600 mg and a matching lamivudine placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
9737997|NCT00076336|Active Comparator|Lamivudine 100 mg|Lamivudine 100 mg and a Telbivudine matching placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
9737998|NCT00076570|Experimental|Sirolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to sirolimus monotherapy and followed up for 4 years.
9737999|NCT00076570|Active Comparator|Tacrolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to tacrolimus monotherapy and followed up for 4 years.
9738000|NCT00076622||Randomized to drug continuation|Participants assigned to continue current antidepressant medication
9738001|NCT00076622||Randomized to drug discontinuation|Participants assigned to discontinue current antidepressant medication (no antidepressant medication)
9738002|NCT00076622||Participant preference to continue drug|Chose to continue antidepressant medication
9738003|NCT00076622||Participant preference to discontinue drug|Chose to discontinue antidepressant medication (no antidepressant medication)
9738004|NCT00076687|Experimental|1|
9738005|NCT00076687|Experimental|2|
9738006|NCT00076687|Placebo Comparator|3|
9738007|NCT00076752|Experimental|Autologous HSCT in SLE|"Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).~SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion."
9738008|NCT00076804|Experimental|1|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
9738009|NCT00076804|No Intervention|2|Self administration of ARVs
9738010|NCT00076999|Experimental|TPV/r 290/115 mg/m^2|TPV and RTV oral solution low dose
9738011|NCT00076999|Experimental|TPV/r 375/150 mg/m^2|TPV and RTV oral solution high dose
9738012|NCT00077064|No Intervention|Observation|Clinical observation
9738013|NCT00077064|Experimental|Captopril|Captopril
9738014|NCT00077207|Experimental|Treatment (carboplatin, vincristine sulfate, temozolomide)|Induction therapy: Patients receive carboplatin IV (175/m2) over 1 hour on days 1, 8, 15, and 22; vincristine IV (1.5 mg/m2) on days 1, 8, 15, 22, 29, and 36; and oral temozolomide (200 mg/m2) on days 43-47. Four weeks after the completion of induction therapy, patients achieving stable or responding disease proceed to maintenance therapy. Maintenance therapy: Patients receive carboplatin (175/m2) and temozolomide (200 mg/m2) as in induction therapy and vincristine IV ((1.5 mg/m2) day 1 of weeks 10,11,12. Treatment repeats every 10 weeks for a total of 6 courses in the absence of disease progression.
9738015|NCT00077376|Experimental|Treatment (trastuzumab, ixabepilone, carboplatin)|"Induction therapy: Patients receive trastuzumab (Herceptin®) IV over 30 minutes* on days 1, 8, 15, and 22 and ixabepilone IV over 1 hour and carboplatin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of unacceptable toxicity.~NOTE: *Trastuzumab is given over 90 minutes on day 1 of course 1 (induction therapy) only.~Maintenance therapy: Patients receive trastuzumab IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
9738016|NCT00077610|Experimental|RO0503821 (1x/2 Weeks)|Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (<8000, 8000-16000, >16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.
9738017|NCT00077610|Experimental|RO0503821 (1x/4 Weeks)|Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (<8000, 8000-16000, >16000 IU/Week) administered during the week preceding the switch to the study drug.
9738018|NCT00077610|Active Comparator|Epoetin (1-3x/Weeks)|Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.
9738019|NCT00077623|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
9738020|NCT00077623|Experimental|RO0503821 (1x/4 Weeks)|Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of<8000, 8000-16000, or >16000 IU/week administered during the week preceding the switch to the study drug.
9738021|NCT00077623|Active Comparator|Epoetin Reference|Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .
9738022|NCT00077636|Experimental|1|
9738023|NCT00077636|Experimental|2|
9738024|NCT00077649|Active Comparator|PEG-IFN Alfa-2a 180 μg +Ribavirin 1200 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
9738025|NCT00077649|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 1600 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
9738026|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1200 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered po daily in split doses for 48 weeks
9738027|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1600 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1600 mg of ribavirin (200 mg/tablet) administered po daily in split doses for 48 weeks.
9738028|NCT00077675|Experimental|Telavancin|
9738029|NCT00077675|Active Comparator|Standard of care for cSSSI|cSSSI - comlicated skin and skin structure infections
9738030|NCT00077766|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants will be administered with RO0503821 ([methoxy polyethylene glycol-epoetin beta] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
9738031|NCT00077766|Active Comparator|Darbepoetin (1x/1-2 Weeks)|Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.
9738032|NCT00077857|Experimental|1250 mg/m^2 capecitabine + docetaxel|1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
9738033|NCT00077857|Experimental|825 mg/m^2 capecitabine + docetaxel|825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
9738034|NCT00077922|Experimental|LMB-2 in chronic lymphocytic leukemia|40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.
9738035|NCT00077974|Experimental|1|
9738036|NCT00078286|Experimental|Sertraline|Participants will take sertraline for 12 weeks
9738037|NCT00078286|Placebo Comparator|Placebo|Participants will take placebo for 12 weeks
9738038|NCT00078325|Experimental|1|Armodafinil 250 mg/day
9738039|NCT00078325|Experimental|2|Armodafinil 150 mg/day
9738040|NCT00078325|Placebo Comparator|3|Placebo
9738041|NCT00078338|Experimental|Rebif®|
9738042|NCT00078338|Active Comparator|Copaxone®|
9738043|NCT00078377|Experimental|1|Armodafinil 250 mg
9738044|NCT00078377|Experimental|2|Armodafinil 150 mg
9738045|NCT00078377|Placebo Comparator|3|Placebo
9738046|NCT00078403|Experimental|Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.
9738047|NCT00078403|Experimental|Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).
9738048|NCT00078403|Experimental|Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)|At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA <600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly & RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA >=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.
9738049|NCT00078559|Experimental|Alemtuzumab|
9983905|NCT04554121|Experimental|Brain Basics|Brain Basics is a cognitive remediation intervention that emphasizes training in early auditory processing.
9738050|NCT00078715|Experimental|Yohimbine then Placebo|Participants are randomized to receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep. After 8 days they receive placebo administered over 3 minutes during REM sleep.
9738051|NCT00078715|Experimental|Placebo then Yohimbine|Participants are randomized to receive placebo administered over 3 minutes during REM sleep. After 8 days they receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
9738052|NCT00078728|Experimental|Family-based anxiety prevention program|Participants will complete an 8 session (1 session/week), cognitive behavioral therapy-based, family prevention program to be administered by a trained clinician, after randomization to the study. The prevention program will include 3 booster sessions that take place after the first 8 sessions.
9738053|NCT00078728|Active Comparator|Evaluation only|Waitlist control group. Participants in this group will receive general information (in the form of a printed packet) about anxiety after randomization to the study. Families in this group will complete all study evaluations and will then be offered the option of participating in the prevention program. Families who accept will begin the prevention sessions and will receive the same CBT-based, family-based prevention program as the other treatment arm.
9738054|NCT00078754|Experimental|A|Participants will to receive treatment with fluoxetine for 12 weeks
9738055|NCT00078754|Experimental|B|Participants will to receive treatment with divalproex for 12 weeks
9738056|NCT00078754|Placebo Comparator|C|Participants will to receive treatment with placebo for 12 weeks
9738057|NCT00078767|Experimental|TF-CBT + sertraline|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus Sertraline provided in dosage titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 50mg/day to a maximum dosage of 150 mg/day
9738058|NCT00078767|Active Comparator|TF-CBT +placebo|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus placebo identical to Sertraline, provided in pill form and titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 1 to 3 pills/day (identical in appearance to 50 to 150mg/day of Sertraline)
9738059|NCT00078819|Placebo Comparator|Placebo|"Participants received placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
9781601|NCT01153633|Active Comparator|Prontosan Wound Solution and Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
9983906|NCT04554121|Active Comparator|Brain Training|Brain Training is a cognitive remediation intervention that targets a range of cognitive abilities
9738060|NCT00078819|Experimental|Etanercept|"Participants received 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
9738061|NCT00078897|Active Comparator|Selenium|Participants receive oral selenium 200 mcg once daily.
9738062|NCT00078897|Placebo Comparator|Placebo|Participants receive oral placebo once daily.
9738063|NCT00078949|Experimental|Salvage arm I|Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
9738064|NCT00078949|Experimental|Salvage arm II|Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
9738065|NCT00078949|Experimental|Maintenance arm I|Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
9738066|NCT00078949|No Intervention|Maintenance arm II|Patients undergo observation only.
9738067|NCT00079001|Experimental|Zoledronic acid + androgen deprivation therapy|4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).
9738068|NCT00079001|Active Comparator|Placebo + androgen deprivation therapy|Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.
9781602|NCT01153633|Placebo Comparator|Normal Saline and Placebo Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
10200883|NCT05170906|Experimental|Experimental Group|"The subject will be placed on a stretcher with the torso uncovered. Once the spectroscopy helmet is in place, a recording of the resting activity will be started, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation on the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure on the pectoral area in the pattern of the reflex swing locomotion complex in its first phase. For this, the subject will be placed in supine decubitus aligned with respect to the axial axis, with the arms alongside the body, the lower extremities in extension and the head extended with a rotation of approximately 30º to one side of the stimulation. Manual stimulation pressure will be exerted in the space between the 6th-7th or 7th-8th ribs below the mammary line, with a force of about 2 kg."
9781603|NCT01153672|Experimental|Treatment (enzyme inhibitor therapy, AI sensitization therapy)|Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
9781604|NCT01153685|Experimental|Fluviral A Group|Subjects aged between 18 and 60 years who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
9781605|NCT01153685|Experimental|Fluviral B Group|Subjects over 60 years of age who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
9781606|NCT01153698||patients after hip or knee replacement|
9781607|NCT01153711|Experimental|BI 1744 10 mcg|solution for oral inhalation
9781608|NCT01153711|Experimental|Ketoconazole 400 mg|tablet
9781609|NCT01153724|Experimental|Olodaterol|
9781610|NCT01153724|Experimental|Olodaterol + Fluconazole|
9781611|NCT01153763|Other|All patients|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
9781612|NCT01153815|Placebo Comparator|placebo|Sodium chloride
9781613|NCT01153815|Experimental|GSK1358820(Botulinum Toxin Type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
9781614|NCT01153841|Experimental|Synflorix Group|Subjects receiving Synflorix™(GSK 1024850A) co-administered along with Infanrix hexa™.
10200884|NCT05170906|Sham Comparator|Control Group|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg"
9781615|NCT01153841|Active Comparator|Control Group|Subjects receiving Infanrix hexa™ vaccine alone.
9781616|NCT01153893|Experimental|Synflorix/Infanrix primed Group|Subjects previously primed with the Synflorix™ vaccine in the primary study 110521 (NCT00678301) received a booster dose of the Synflorix™ vaccine co-administered with a booster dose of the Infanrix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
10200885|NCT05170321||patients undergoing knee arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent knee arthroplasty and was recorded in HQMS were included in this group
10200886|NCT05170321||patients undergoing hip arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent hip arthroplasty and was recorded in HQMS were included in this group
9738069|NCT00079040|Experimental|Treatment (cisplatin, etoposide, bevacizumab)|"Chemotherapy: Patients receive cisplatin IV over 30-60 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Bevacizumab therapy: Beginning concurrently with chemotherapy, patients receive bevacizumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 17 courses (1 year) in the absence of disease progression or unacceptable toxicity."
9738070|NCT00079183|Experimental|Sirolimus|Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician. Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is started. Topical therapy, including psoralen and UVA irradiation (PUVA), glucocorticoid creams, topical tacrolimus, oral beclomethasone, topical azathioprine and ophthalmic glucocorticoids may be given at the discretion of the managing physician in consultation with the transplant center.
9738071|NCT00079274|Experimental|Arm A (combination chemotherapy)|Patients received oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
9738072|NCT00079274|Experimental|Arm B (combination chemotherapy)|Patients received irinotecan IV over 2 hours on day 1 and leucovorin calcium and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
9738073|NCT00079274|Experimental|Arm C (combination chemotherapy)|Patients received the same treatment as in arm A for 6 courses followed by the same treatment as in arm B for 6 courses (total of 12 courses). Treatment continues in the absence of unacceptable toxicity or recurrent disease.
9738074|NCT00079274|Experimental|Arm D (combination chemotherapy, monoclonal antibody)|Patients received cetuximab IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
9738075|NCT00079274|Experimental|Arm E (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and irinotecan, leucovorin calcium, and fluorouracil as in arm B. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
9738076|NCT00079274|Experimental|Arm F (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and chemotherapy as in arm C.
9738077|NCT00079274|Other|Arm G (Locally directed therapy)|Patients determined to have mutated KRAS (or KRAS not evaluable) were assigned to an event monitoring arm in which adjuvant therapy was determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification was the responsibility of the treating oncologists.
9738078|NCT00079326|Experimental|Treatment (trastuzumab, ixabepilone)|Patients receive trastuzumab IV over 30-90 minutes and ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9781617|NCT01153893|Experimental|Synflorix/Infanrix unprimed Group|Unprimed subjects from the primary study 110521 (NCT00678301), not previously vaccinated with any pneumococcal vaccine, received a 2-dose catch-up vaccination of Synflorix™ vaccine at 15-21 and 17-23 months of age and a booster dose of Infanrix™ vaccine co-administered with the first dose of Synflorix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
9781618|NCT01153958|Experimental|Colposeptine (A)|
9738079|NCT00079339|Experimental|Treatment (radiation therapy and tipifarnib)|"PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity."
9738080|NCT00079391|Experimental|allogeneic hematopoietic SCT|allogeneic hematopoietic stem cell transplantation (SCT) using Nexell Isolex system
9738081|NCT00079417|Experimental|Vincristine Sulfate and Carboplatin and surgery|Patients receive chemoreduction comprising carboplatin IV (Pts < 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts < 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.
9738082|NCT00079677|Experimental|1|Armodafinil 150 mg/day
9738083|NCT00079677|Placebo Comparator|2|Placebo
9738084|NCT00079781|Active Comparator|Treatment Group|Group of subjects who have undergone RNS® System implantation who are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the blinded Evaluation Period. Stimulation is enabled during the first month post-implant and may continue throughout the subject's participation in the study.
9738085|NCT00079781|Sham Comparator|Sham Group|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the blinded Evaluation Period. Stimulation is enabled after transition into the Follow-Up Period (5th month post-implant) and may continue for the remainder of the subject's participation in the study.
9738086|NCT00079781|Other|Open Label Group|Group of subjects who have undergone RNS® System implantation who were not randomized or blinded to therapy status during the Evaluation Period. Stimulation may have been enabled during the first month post-implant and may have continued throughout the subject's participation in the study.
9738087|NCT00079937|Experimental|Omalizumab|Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
9738088|NCT00079937|Placebo Comparator|Placebo|Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
9738089|NCT00080119|Experimental|HIVneg/INH|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
9738090|NCT00080119|Placebo Comparator|HIVneg/PL|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
9738091|NCT00080119|Experimental|HIVpos/INH|HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
9738092|NCT00080119|Placebo Comparator|HIVpos/PL|HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
9738093|NCT00080223|Experimental|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
9738094|NCT00080288|Experimental|1|Armodafinil 150 mg/day
9738095|NCT00080288|Placebo Comparator|2|Placebo
9738096|NCT00080301|Experimental|A|
9738097|NCT00080301|Active Comparator|B|
9738098|NCT00080470|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
9738099|NCT00080470|Sham Comparator|2|No Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
9738100|NCT00080483|Experimental|1|Testosterone transdermally 5 g a day and somatropin subcutaneously 2 µg/kg body weight a day
9738101|NCT00080483|Active Comparator|2|AndroGel transdermally 5 g a day for two years
9738102|NCT00080535|Experimental|LMB-2 for cutaneous Tcell lymphoma|30 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with cutaneous T-cell lymphoma, a group of lymphoproliferative disorders characterized by malignant CD4+ T-lymphocytes which localize tot he skin on initial presentation.
9738103|NCT00080899|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9738104|NCT00080912|Experimental|Arm I|Patients receive single-fraction radiotherapy (8 Gy) on day 1.
9738105|NCT00080912|Active Comparator|Arm II|Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
9738106|NCT00080938|Experimental|Temozolomide and Radiation|Temozolomide:administered orally. Radiation: whole brain radiation therapy
9738107|NCT00081159|Experimental|HAT, Doxorubicin, Zoledronate + Strontium chloride|Arm I: Hormonal ablative therapy (HAT) comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses; and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1.
9738108|NCT00081159|Experimental|HAT, Doxorubicin + Zoledronate|Arm II: HAT, doxorubicin, and zoledronate as in arm I. HAT comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses.
9738109|NCT00081263|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib once daily for 14-18 weeks.
9738110|NCT00081263|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for 14-18 weeks.
9738111|NCT00081289|Experimental|Neoadjuvant chemoradiation with irinotecan|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1200mg/m^2/day 5 days/week during RT, and irinotecan 50 mg/m^2 IV for 1 hour days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
9738112|NCT00081289|Experimental|Neoadjuvant chemoradiation with oxaliplatin|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1650mg/m^2/day 5 days/week during RT, and oxaliplatin 50 mg/m^2 IV for 2 hours days 1, 8, 15, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
9738113|NCT00081328|Experimental|1|Metformin alone
9738114|NCT00081328|Experimental|2|Metformin + Rosiglitazone
9738115|NCT00081328|Experimental|3|Metformin + Lifestyle Program
9738116|NCT00081458|Placebo Comparator|placebo|Placebo injectable subcutaneously daily into the thigh or abdomen
9738117|NCT00081458|Experimental|2|teduglutide 0.05 mg/kg/d
9738118|NCT00081458|Experimental|3|teduglutide 0.1 mg/kg/d
9738119|NCT00081497|Experimental|Fabrazyme 1.0 mg/kg every 2 weeks|This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.
9738120|NCT00081653|Experimental|1|
9738121|NCT00081653|Active Comparator|2|
9738122|NCT00081731|Active Comparator|Optimal Medical Therapy|Optimal anti-hypertensive therapy
9738123|NCT00081731|Experimental|Stenting|Stent procedure plus optimal anti-hypertensive therapy
9738124|NCT00081770|Experimental|PegIntron 1.5 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
9738125|NCT00081770|Experimental|PegIntron 1.0 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
9781619|NCT01153958|Active Comparator|Metronidazole (B)|
9781620|NCT01153971|Experimental|1|
9738126|NCT00081770|Active Comparator|PEGASYS 180 ug/wk Plus COPEGUS|PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up
9738127|NCT00081861|Experimental|Avastin + Rituximab|Avastin 10 mg/kg given intravenously every 2 weeks for 4 doses, and Rituximab 375 mg/m^2 intravenously weekly for 8 doses.
9738128|NCT00081939|Experimental|Study Treatment|Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects > 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.
9738129|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 1 - Every 28 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days."
9738130|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 2 -Every 21 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
9738131|NCT00082173|Experimental|1|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
9738132|NCT00082173|Placebo Comparator|2|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks
9738133|NCT00082329|Experimental|G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers|Participants received subcutaneous injection of G-CSF (10 mcg/kg/day) for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
9738134|NCT00082342|Active Comparator|real transcranial direct current stimulation (tDCS)|
9738135|NCT00082342|Sham Comparator|sham transcranial direct current stimulation (tDCS)|
9738136|NCT00082355|Experimental|Alteplase (r-tPA)|Patients with DVT of lower extremity will receive up to 4 treatments low dose (<10 mg/day) intraclot injections of alteplase. Intention is to evaluate safety and efficacy of this treatment, and durability of outcomes (for 6 months)in 25 patients.
9738137|NCT00082368|Experimental|PET (positron emission imaging) Imaging with Tc-94m Sestamibi|PET sestamibi scans followed by tariquidar and repeat imaging
9738138|NCT00082381|Experimental|Exenatide Arm|exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
9738139|NCT00082381|Active Comparator|Insulin Glargine Arm|subcutaneous injection, once daily; forced titration to target blood glucose level
9738140|NCT00082407|Experimental|Exenatide Arm|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
9738141|NCT00082407|Active Comparator|Biphasic Insulin Aspart Arm|subcutaneous injection, twice daily; titration to target blood glucose level
9738142|NCT00082433|Experimental|A|
9738143|NCT00082433|Active Comparator|B|
9738144|NCT00082628|Placebo Comparator|Period I: Placebo|Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.
9738145|NCT00082628|Experimental|Period I: Serostim® 4 mg|Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.
9738146|NCT00082628|Experimental|Period II: Serostim® 4 mg to Placebo|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.
9738147|NCT00082628|Experimental|Period II: Serostim® 4 mg to Serostim® 2 mg|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.
9738148|NCT00082628|Experimental|Period II: Placebo to Placebo/Serostim® 4 mg|All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
9738149|NCT00082641|Experimental|Arm I|Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).
9738150|NCT00082641|Experimental|Arm II|Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.
9781621|NCT01153984|Experimental|Erlotinib|Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
9738151|NCT00082758|Experimental|Disease Measurable by Standard Criteria(hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute.~hu14.18-Interleukin-2 fusion protein : Given IV"
9738152|NCT00082758|Experimental|Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology.~hu14.18-Interleukin-2 fusion protein : Given IV"
9738153|NCT00082758|Experimental|Disease Identified by BM Immunohistochemistry Only|"Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (>5 neuroblastoma cells per 1,000,000 nucleated marrow cells).~hu14.18-Interleukin-2 fusion protein : Given IV"
9738154|NCT00082810|Experimental|Treatment (tipifarnib, fulvestrant)|Patients receive fulvestrant intramuscularly on day 1 and oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity*.
9738155|NCT00082888|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738156|NCT00083122|Experimental|Group 1|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9738157|NCT00083122|Experimental|Group 2|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9738158|NCT00083174|Other|Exemestane|one 25 mg tablet daily in am
9738159|NCT00083226|Experimental|Treatment (doxorubicin+bortezomib)|Patients receive doxorubicin IV over 5-15 minutes on days 1 and 8. Patients also receive bortezomib at a dose of 1.3 mg/m^2 IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with no disease progression may continue to receive bortezomib alone in the absence of disease progression or unacceptable toxicity.
9738160|NCT00083382|Experimental|Thalidomide + Bisphosphonate|200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy
9738161|NCT00083551|Active Comparator|Thalidomide|Thalidomide 400 qod during induction.100 mg qd between transplants, post transplant pat. 200 mg qd. During year one of maintenance therapy pt will take 100mg of Thal qod and 50 mg of thal qod during second year of maintenance
9738162|NCT00083551|Active Comparator|No Thalidomide|During induction, consolidation, and maintenance steps patient receives no thalidamide
9738163|NCT00083616|Experimental|Panitumumab|Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.
9738164|NCT00083720|Experimental|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
9738165|NCT00083889|Active Comparator|2|
9738166|NCT00083889|Experimental|1|
9738167|NCT00084084|Experimental|Agalsidase alfa (Cohort 1)|Cohort 1: Patients who completed TKT023.
9738168|NCT00084084|Experimental|Agalsidase Alfa (Cohort 2)|Cohort 2: Treatment-naive patients.
9738169|NCT00084136|Experimental|ZDV/3TC+EFV|ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
9738170|NCT00084136|Experimental|ddI+FTC+ATV|ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
9983907|NCT04551963|Experimental|Zanubrutinib + Moderate CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg twice daily (BID) + fluconazole (days 4 - 10), zanubrutinib 320 mg once daily (QD) (days 13 - 19), zanubrutinib 80 mg BID + diltiazem (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
9738171|NCT00084136|Experimental|TDF/FTC+EFV|TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz
9738172|NCT00084149|Experimental|Cyclosporin|Cyclosporin arm (Arm A) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily, 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily, and liquid cyclosporin A (CsA) (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
9738173|NCT00084149|Experimental|No Cyclosporin|The No Cyclosporin arm (Arm B) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily and 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily for all 48 weeks
9738174|NCT00084266|Experimental|1|Subjects receiving linezolid for the treatment phase of the study
9738175|NCT00084266|Active Comparator|2|Subjects receiving vancomycin for the treatment phase of the study
9738176|NCT00084318|Experimental|RT + cisplatin + cetuximab|Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
9738177|NCT00084318|Experimental|RT + docetaxel + cetuximab|Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.
9738178|NCT00084383|Experimental|GVAX pancreatic cancer vaccine|"5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination"
9738179|NCT00084409|Experimental|Arm I|Patients receive oral iloprost twice daily for 6 months in the absence of unacceptable toxicity.
9738180|NCT00084409|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months in the absence of unacceptable toxicity.
9738181|NCT00084487|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9738182|NCT00084552|Active Comparator|Arm I|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
9738183|NCT00084552|Experimental|Arm II|Patients undergo IMRT with dose restriction to erectile tissue once daily 5 days a week for approximately 7.5 weeks.
9738184|NCT00084617|Experimental|Treatment (oxaliplatin, irinotecan, capecitabine)|Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on days 1, 8, 15, and 22 and oral capecitabine twice daily on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9738185|NCT00084682|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738186|NCT00084747|Experimental|bortezomib|
9738187|NCT00084838|Experimental|Multi-agent Intrathecal and Systemic CT with RT (mod IRS III)|"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)~Induction Chemotherapy: CT backbone of the IRS-III regimen [vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.~Radiation Therapy: Pts w/ M0 dz OR M+ dz aged <3y received focal RT (3D conformal or intensity-modulated delivery). Pts >3y w/ M+ dz rcvd craniospinal irradiation.~Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively."
9738188|NCT00084864|Experimental|Stage 1, Arm I|Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
9738189|NCT00084864|Experimental|Stage 1, Arm II|No study drugs before surgery.
9738190|NCT00084864|Experimental|Stage 1 Arm 3|Patients receive oral dexamethasone once daily on days 1-4.
9738191|NCT00084864|Experimental|Stage 1, Arm 4|Patients receive oral calcitriol once daily on days 2-4.
9738192|NCT00084929|Experimental|CT Colonography|CT colonography conducted during the same assessment as colonoscopy.
9738193|NCT00085098|Experimental|Regimen A (radiotherapy only)|Within 52 days of surgery, patients will undergo standard-dose radiation therapy 5 days a week for approximately 5-6 weeks.
9738194|NCT00085098|Experimental|Regimen B (chemotherapy plus radiotherapy)|"Courses 1 and 2: Patients receive carboplatin IV over 1 hour on days 1 and 2 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for 2 courses.~Within 3 weeks of completing chemotherapy, patients with CR undergo low-dose radiation therapy 5 days a week for 5 weeks. Patients with MRD, a PR, or SD receive chemotherapy courses 3 and 4 as outlined below.~Courses 3 and 4: Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour on days 2 and 3, and filgrastim (G-CSF), subcutaneous (SC) or IV beginning on day 4 and continuing until blood counts recover.~Treatment repeats every 21 days for 2 courses. Patients achieving a CR or MRD proceed to reduced-dose radiotherapy. Patients with a PR, SD, or progressive disease (PD) are restaged and may undergo standard radiation therapy as in regimen A. Reduced-dose radiation therapy: Within 6 weeks of starting course 4, patients undergo lower-dose radiation therapy once daily on days 1-5 for 5 weeks"
9738195|NCT00085254|Experimental|Arm 1 (Safety Run In)|"INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Doses of cilengitide: 500mg, 1000mg and 2000mg~Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
9738196|NCT00085254|Experimental|Phase II (Arm1-500mg)|"INITIATION COURSE: Patients receive cilengitide (500mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (500mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide, Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
9738197|NCT00085254|Experimental|Phase II (Arm 2 -2000mg)|"INITIATION COURSE: Patients receive cilengitide (2000mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (2000mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~cilengitide,Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
9738198|NCT00085293|Experimental|Treatment|Starting dose 6 mg/m^2 Decitabine intravenous (IV) over 1 hour on days 1-5 and 8-12 of weeks 1 and 2 (course 1). Week 3, Iodine I 131 (131I) scanning using thyrotropin alfa injections. Participants whose scan do not demonstrate iodine uptake continue suppressive thyroid hormone therapy but no further study therapy; these participants who do show uptake undergo thyroid hormone withdrawal on weeks 4-8 and second course of decitabine (as in course 1) on weeks 7 and 8, with 131I therapy on week 9.
9738199|NCT00085410|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
9738200|NCT00085423|Experimental|IL-2, CTX, fludarabine, GM-CSF|Aldesleukin (IL-2), cyclophosphamide, fludarabine phosphate, sargramostim
9983908|NCT04551963|Experimental|Zanubrutinib + Strong CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg QD + voriconazole (days 4 - 10), zanubrutinib 320 mg QD (days 13 - 19), zanubrutinib 80 mg QD + clarithromycin (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
9738201|NCT00085436|Experimental|Vaccine, Aldesleukin-2, Interferon-a|All patients will be treated with autologous tumor cell vaccine administered into inguinal lymph nodes via ultrasound guidance in addition to systemic IL-2 and recombinant interferon alfa. Two cycles of induction IL-2/IFNα-2a followed by 3 cycles of maintenance IL-2 + IFNα-2a.
9738202|NCT00085540|Experimental|Phase 1 Dose Escalation - Romidepsin|"Patients receive FR901228 (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation two dose levels:~Romidepsin (depsipeptide): 13.3mg/m2 and 17.7mg/m2~Pharmacokinetics"
9738203|NCT00085540|Experimental|Phase 2 Dose from Phase 1 - Romidepsin|"Patients receive FR901228 (romidepsin) as in phase I at dose level 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity~Romidepsin (depsipeptide): 13.3mg/m2"
9738204|NCT00085566|Experimental|Everolimus (RAD-001) and Gefitinib|"•Phase I: Patients receive oral everolimus on day 1 and oral gefitinib once daily on days 8-21. Beginning on day 22, patients receive oral everolimus once weekly and oral gefitinib once daily. Treatment with the combination continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~•Phase II (prostate cancer patients only) (closed to accrual as of 10/19/2006): Patients receive oral everolimus (at the MTD determined in phase I) once weekly and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
9738205|NCT00085644|Experimental|Adalimumab|
9738206|NCT00085644|Placebo Comparator|Placebo|
9738207|NCT00085709|Experimental|Post-consolidation GO|Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
9738208|NCT00085709|Other|Post-consolidation observation|Patients receive no additional therapy. Patients are observed at days 30 and 60 after randomization.
9738209|NCT00085709|Active Comparator|Induction 7+3|Standard induction regimen of 7 days of Ara-C (cytosine arabinoside) and 3 days of daunomycin
9738210|NCT00085709|Active Comparator|Induction 7+3+GO|Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C and 3 days of daunomycin
9738211|NCT00085839|Experimental|Erlotinib|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
9738212|NCT00085839|Active Comparator|Standard Chemotherapy|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
9738213|NCT00085917|Active Comparator|Standard dose arm|Pegylated interferon alfa -2a STANDARD DOSE Pegasys 180ug/week
9738214|NCT00085917|Experimental|Double dose arm|Double dose pegylated interferon with weight based Ribavirin
9738215|NCT00086047|Experimental|Coping Skills|Patients will receive 8 weeks of behavioral training in pain coping strategies
9738216|NCT00086047|Active Comparator|Education|Patient will receive 8 weekly sessions of education about fibromyalgia syndrome.
9738217|NCT00086138|Experimental|1|Participants will receive sertraline at a target dose of 100mg daily.
9738218|NCT00086138|Placebo Comparator|2|Participants will receive placebo matched to sertraline
9738219|NCT00086190|Active Comparator|paroxetine|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
9738220|NCT00086190|Active Comparator|venlafaxine extended release|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
9738221|NCT00086190|Placebo Comparator|placebo|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
9738222|NCT00086281|Experimental|1|Xyrem 9 grams given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later
9738223|NCT00086281|Active Comparator|2|Zolpidem 10 mg + placebo were given at bedtime and placebo given 2.5 to 4 hours later.
9738224|NCT00086281|Experimental|3|Xyrem 9 g + modafinil 200 mg (Xyrem 9 g was given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later; modafinil was given at 8 am on the morning of Xyrem treatment).
9738225|NCT00086281|Placebo Comparator|4|Placebo was given at bedtime and again 2.5 to 4 hours later.
9738226|NCT00086307|Active Comparator|Pramipexole|Patients receive pramipexole and placebo. The dosage of pramipexole is 0.125 milligrams (mg) three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
9738227|NCT00086307|Active Comparator|Escitalopram|Patients receive escitalopram and placebo. The dosage of escitalopram is 10 milligrams (mg) per day.
9781622|NCT01154010|Active Comparator|Active Device|"ActiPatch, a device that emits a low frequency energy called pulsed electromagnetic field (PEMF), will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids."
9738228|NCT00086307|Experimental|Escitalopram and Pramipexole|Patients receive escitalopram and pramipexole. The dosage of escitalopram is 10 milligrams (mg) per day. The dosage of pramipexole is 0.125 mg three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
9738229|NCT00086346|Active Comparator|A|
9738230|NCT00086346|Active Comparator|B|
9738231|NCT00086385|Active Comparator|Brief Treatment|"Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT)~Brief Counseling - The counseling intervention consisted of five 90-minute group meetings.~There was no further treatment during Weeks 12-52."
9738232|NCT00086385|Experimental|Extended NRT|"Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT.~Counseling Treatment - This is identical to the Brief Counseling described above."
9738233|NCT00086385|Experimental|Tailored/No Extended NRT|This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
9738234|NCT00086385|Experimental|Extended Tailored Counseling + NRT|Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).
9738235|NCT00086411|Experimental|1: Bup+MM|bupropion and MM counseling with placebo patch
9738236|NCT00086411|Experimental|2 Bup+Mayo|bupropion and Mayo counseling with placebo patch.
9738237|NCT00086411|Placebo Comparator|3 Patch+MM|patch and MM counseling with placebo pills
9738238|NCT00086411|Experimental|4 Patch+Mayo|patch and Mayo counseling with placebo pills
9738239|NCT00086450|Active Comparator|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
9738240|NCT00086450|Experimental|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
9738241|NCT00086502|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg
9738242|NCT00086502|Placebo Comparator|Placebo|Placebo
9738243|NCT00086515|Experimental|Sitagliptin 100 mg|The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.
9738244|NCT00086515|Placebo Comparator|Placebo / Glipizide 5 mg|The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.
9738245|NCT00086580|Experimental|Combination Arm (FluCAM)|
9738246|NCT00086580|Active Comparator|Fludarabine Alone|
9738247|NCT00086619|Experimental|constant dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a constant dose of 30 mcg/day.
9738248|NCT00086619|Experimental|ascending dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a dose that ascends at 6 month intervals (20-30-40 mcg/day).
9738249|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg once a day|One 100 mg pentosan polysulfate sodium capsule in the morning and 1 matching placebo capsule in the afternoon and evening for 24 weeks
9738250|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg three times a day|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning afternoon and evening) for 24 weeks
9738251|NCT00086684|Placebo Comparator|Placebo|Placebo One placebo capsule 3 times a day (morning afternoon and evening) for 24 weeks
9738252|NCT00086957|Experimental|ZD1839, Trastuzumab and Docetaxel|
9738253|NCT00086996|Experimental|Chemo Plus RT, Surgery, Chemo|neoadjuvant fluorouracil, oxaliplatin and radiation therapy followed by conventional surgery and adjuvant fluoruracil and oxaliplatin
9738254|NCT00087022|Experimental|Arm I|Patients receive monoclonal chimeric antibody cG250 (synonym names: Rencarex®, girentuximab, and WX-G250) IV over 15 minutes once weekly for 24 weeks.
9738255|NCT00087022|Placebo Comparator|Arm II|Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
9738256|NCT00087126|Experimental|Topotecan|Topotecan weekly
9738257|NCT00087139|Experimental|Arm I|"Patients are stratified according to prior chemotherapy (none vs 1 prior taxane-containing regimen vs 2 prior cytotoxic regimens).~Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9738258|NCT00087152|Experimental|Imatinib Mesylate & Capecitabine|
9738259|NCT00087438|Experimental|Stereotactic body radiation therapy (SBRT)|20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
9738260|NCT00087516|Active Comparator|Sitagliptin 100 mg/100 mg|Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
9738261|NCT00087516|Active Comparator|Sitagliptin 200 mg/200 mg|Phase A and B: Oral tablets of sitagliptin 200 mg q.d
9738262|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 100 mg|Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
9738263|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 200 mg|Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.
9738264|NCT00087529|Experimental|1|
9738265|NCT00087529|Placebo Comparator|2|
9738266|NCT00087555|Experimental|2|Sodium oxybate 6.0 g per day.
9738267|NCT00087555|Placebo Comparator|3|Placebo (one of two doses matching active treatment by volume).
9738268|NCT00087555|Experimental|1|Sodium oxybate 4.5 g per day.
9738269|NCT00087568|Experimental|Non-Responders|Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day [(mg/day), < or >=75 kilogram (Kg) body weight, respectively], orally in divided doses for 60 weeks.
9738270|NCT00087568|Experimental|Non-Tolerators|Participants will receive Pegasys 180 µg subcutaneously (SC) once a week and ribavirin 1000 or 1200 mg/day (< or >=75 kg body weight, respectively) orally in divided doses for 36 weeks.
9738271|NCT00087594|Experimental|Direct Observed Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at the clinic as: subcutaneous peginterferon alfa-2a 180 microgram (mcg) (once in a week) for 24 weeks for Genotype 2 or 3 (G2/3), and for 48 weeks for Genotype 1 (G1); oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
9738272|NCT00087594|Experimental|Self-Administration Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at home as: subcutaneous peginterferon alfa-2a 180 mcg (once in a week) for 24 weeks for G2/3, and for 48 weeks for G1; oral ribavirin 800 mg/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
9738273|NCT00087607|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants received Peginterferon alfa-2a (40 kD) [Pegasys] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin [Copegus] 1000 or 1200 milligram (mg)/day), orally, [according to body weight, lesser than or greater than/equal to (< or >/=) 75 kilogram (kg), respectively] twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
9738274|NCT00087607|Active Comparator|Peginterferon Alfa-2b + Ribavirin|Participants received Peginterferon alfa-2b (12 kD) [PEG-Intron] at a dosage of 1.5 μg/kg SC once weekly plus Ribavirin [Rebetol] 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
9738275|NCT00087633|Experimental|1|
9738276|NCT00087633|No Intervention|2|
9738277|NCT00087646|Experimental|1|
9738278|NCT00087646|Experimental|2|
9738279|NCT00087646|Experimental|3|
9738280|NCT00087646|Active Comparator|4|
9738281|NCT00087672|Experimental|CC-5013|
9738282|NCT00087685|Experimental|RAD001|RAD001 10 mg by mouth Daily
9738283|NCT00087698|Experimental|A|chemotherapy, surgery then chest radiation x 54 gray (Gy)
9738284|NCT00088153|Experimental|Physiologic estrogen replacement|"Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month).~Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study"
9738285|NCT00088153|Placebo Comparator|Placebo|Placebo patches or pills
9738286|NCT00088166|Experimental|I|Patients will take hCRF (XERECEPT) 2mg/day and open label-dexamethasone they are currently taking.
9738287|NCT00088166|Placebo Comparator|II|Patient will receive placebo hCRF and any open-label dexamethasone that they are currently taking
9738288|NCT00088205|Experimental|A|
9738289|NCT00088218|Active Comparator|Clofarabine|Clofarabine intravenous (IV) 30 mg/m^2 daily times 5 days
9738290|NCT00088218|Active Comparator|Clofarabine Plus Ara-C|Clofarabine IV 30 mg/m^2 daily times 5 days + Ara-C 20 mg/m^2 subcutaneously daily times 14 days.
9738291|NCT00088374|Experimental|Von Hippel-Lindau (VHL) associated renal tumors|
9738292|NCT00088413|Experimental|All Cohorts: Colorectal, Non-Colorectal, Breast, and Ovarian|All cohorts receive the same intervention (Cohort 1: Colorectal arm, non-colorectal cancers; Cohort 2: breast cancer; Cohort 3: ovarian cancers)
9781623|NCT01154010|Placebo Comparator|Placebo Device|Patients wear the PEMF placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
9781624|NCT01154088|Experimental|Group A|
9781625|NCT01154088|Experimental|Group B|
9781626|NCT01154088|Active Comparator|Group C|
10200887|NCT05170321||patients undergoing shoulder arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent shoulder arthroplasty and was recorded in HQMS were included in this group
9738293|NCT00088452|Active Comparator|Ethosuximide|"Ethosuximide~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup~Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)"
9738294|NCT00088452|Active Comparator|Lamotrigine|"Lamotrigine~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets~Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower)."
9738295|NCT00088452|Active Comparator|Valproic acid|"Valproic acid~Frequency and Duration: twice a day, every day for the duration of the study treatment~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.~Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)"
9738296|NCT00088465|Experimental|Intramuscular Olanzapine Depot|Intramuscular (IM) olanzapine depot flexible dosing and flexible interval
9738297|NCT00088530|Experimental|Experimental Arm|Pixantrone (BBR2778)
9738298|NCT00088530|Active Comparator|Comparator Arm|To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone
9738299|NCT00088595|Experimental|Pasireotide|
9738300|NCT00088621|Experimental|Lurasidone 80 mg tablet|Lurasidone 80mg oral tablet taken once a day
9738301|NCT00088634|Experimental|Lurasidone|80 mg AM dosing once daily
9738302|NCT00088634|Placebo Comparator|Placebo|
9738303|NCT00088699|Experimental|Ketamine, Then Placebo|Ketamine and placebo infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg.
9738304|NCT00088699|Experimental|Placebo, Then Ketamine|Placebo and Ketamine infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg
9738305|NCT00088881|Experimental|Treatment|"R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients with progressive disease go off study.~Zevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Radiation therapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy."
9738306|NCT00088907|Active Comparator|Arm I (docetaxel and placebo)|Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
9738307|NCT00088907|Experimental|Arm II (docetaxel and gefitinib)|"Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.~ZD1839 (Iressa, gefitinib) will be given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.~In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression."
9738308|NCT00088985|Experimental|Dendritic Cell Vaccine|Dendritic Cells: Dosage: 20 x 106 dendritic cells (DCs) given per treatment Vinorelbine:25 mg/m2 will be administered i.v biweekly Trastuzumab: 6mg/Kg administered by i.v. biweekly
9738309|NCT00089011|Experimental|Arm I (nonmyeloablative conditioning with fludarabine and TBI)|Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
9738310|NCT00089011|Experimental|Arm II (nonmyeloablative conditioning with TBI)|Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.
9738311|NCT00089024|Experimental|treatment|see interventions
9738312|NCT00089076|Experimental|Treatment (ipilimumab)|"PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive MDX-010 as in phase I at the MTD."
9738313|NCT00089102|Experimental|Gemcitabine + Irinotecan|
9984672|NCT03858621|No Intervention|fentanyl standard analgesia|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following the heart rate and mean arterial blood pressure variations.
9738314|NCT00089284|Experimental|Rituxan and 90Yttrium-Zevalin plus MGd|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
9738315|NCT00089297|Experimental|Cetuximab/Paclitaxel/Carboplatin|"Induction: Cetuximab (C225) 400 mg/m2 at wk 1 then 250 mg/m2 for 5 weeks. Paclitaxel (P) 90 mg/m2 IV and carboplatin (C) AUC = 2 IV were given weekly.~Restaging biopsy of primary site scheduled at wk 7. Concurrent chemoradiation: Radiation therapy at 200cGy/d/5 wks for a total of 50Gy and C225 at 250 mg/m2/wk. P following C225 at 30 mg/m2/wk and C following P at AUC = 1/week. Patients with a negative biopsy continued concurrent therapy to complete radiation (68-72Gy).~Restaging biopsy of primary site: Patients with positive biopsy at wk 7 or patients without a clinical complete response at the primary site after induction therapy had re-biopsy at wk 14. If the biopsy was negative, the patients continued concurrent therapy to complete radiation (68-72 Gy). If positive, resection of the primary site was done.~Additional concurrent chemoradiation: C225 at 250mg/m2/wk IV followed by P 30mg/m2/wk IV followed by C AUC = 1/wk and RT for 3 wks."
9738316|NCT00089479|Experimental|1|
9738317|NCT00089479|Active Comparator|2|
9738318|NCT00089505|Experimental|NVP/NVP|For participants who had SD NVP exposure prior to study entry. FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
9738319|NCT00089505|Experimental|NVP/LPV_r|For participants who had SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
9738320|NCT00089505|Experimental|NoNVP/NVP|For participants who did NOT have SD NVP exposure prior to study entry.FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
9738321|NCT00089505|Experimental|NoNVP/LPV_r|For participants who did NOT have SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
9738322|NCT00089544|Experimental|Cohort A (chemotherapy, radiation, thalidomide, surgery)|Patients receive doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients receive G-CSF subcutaneously beginning on days 4, 25, and 46 and continuing until blood counts recover. Patients undergo radiotherapy once daily on days 7-11, 14-18, 21, 28-32, 35-39, and 42. Patients receive oral thalidomide once daily on days 7-21 and 26-42. Patients undergo surgical resection between days 84 and 98. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 12 months in the absence of unacceptable toxicity.
9738323|NCT00089544|Experimental|Cohort B (thalidomide, radiation, surgery)|Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity.
9738324|NCT00089583|Experimental|2 - 18 yrs old (FPV/RTV BID)|Cohort 1B - 2 - less than 6yrs old (FPV/RTV BID) Cohort 2 - 6 to less than 12 yrs old (FPV/RTV BID) Cohort 3 - 12 - 18 yrs old (FPV/RTV BID) Cohort 4 - 2 - 18 yrs (FPV/RTV BID)
9738325|NCT00089583|Experimental|2 - less than 6yrs old (FPV BID)|Cohort 1A - 2 - less than 6yrs old (FPV BID)
9738326|NCT00089609|Experimental|Main cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days. Thalidomide 200 mg by mouth daily throughout the cycle. Prednisone 10 mg by mouth daily throughout the cycle. Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
9738327|NCT00089609|Experimental|Expansion cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes and Bevacizumab 15 mg/kg intravenously was given for 2 cycles. After two cycles Prednisone 10 mg by mouth daily and Thalidomide 200 mg by mouth daily was added.
9738328|NCT00089635|Experimental|Panitumumab|Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons.
9738329|NCT00089648|Experimental|1|
9738330|NCT00089661|Experimental|AMG 162 / Denosumab|
9738331|NCT00089661|Placebo Comparator|Placebo|
9738332|NCT00089674|Experimental|AMG 162|
9738333|NCT00089674|Placebo Comparator|Placebo|
9738334|NCT00089752|Active Comparator|Active Treatment|Continuous Positive Airway Pressure Treatment
9738335|NCT00089752|Placebo Comparator|Sham/Placebo Treatment|Ineffective sham continuous positive airway pressure device with leak in interface to <1.0 cm H2O and resistance in motor to simulate normal operating noise and no compensation for leak.
9738336|NCT00089778|Experimental|Grp A-Measurable metastatic disease (no immediate aldesleukin)|"Patients who do not need or are ineligible for treatment with interleukin-2 (IL-2) and patients who have previously had IL-2 therapy.~A3 FGF-5 (Fibroblast growth factor 5): 172-176/217-220 peptide - two 1 ml injections in the anterior thigh deep subcutaneous tissue within 2c of each other."
9738337|NCT00089778|Experimental|Grp B - Measurable metastatic disease that require aldesleukin|"Patients who require immediate treatment with IL-2. A2 FGF-5: 117-126 peptide + HD (high dose) IL-2 (prior cycle 1)- two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.~720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses)."
9738338|NCT00089778|Experimental|Grp C - High-risk loco-regional disease|"Patients whose cancer has been surgically removed but who are at risk for recurrence and local disease and who are seeking experimental adjuvant therapy.~A2 FGF-5: 117-126 peptide (adjuvant); A3 FGF-5: 172-176/217-220 peptide (adjuvant)"
9738339|NCT00089843|Active Comparator|2|Placebo Actonel (risedronate) and active testosterone patch
9738340|NCT00089843|Active Comparator|3|Active Actonel (risedronate) and active testosterone patch
9738341|NCT00089843|Active Comparator|4|Active Actonel (risedronate) and placebo testosterone
9738342|NCT00089843|Placebo Comparator|1|Placebo testosterone patch and placebo Actonel (risedronate)
9738343|NCT00089973|Experimental|SB-715992|Females with advanced or metastatic breast cancer were administered Ispinesib
9738344|NCT00090051|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
9738345|NCT00090051|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
9738346|NCT00090064|Experimental|MDMA-assisted therapy|Participants will receive an initial dose of 125 mg MDMA orally followed 2 to 2.5 hours later by a second dose of 62.5 mg MDMA during two 8-hour long blinded therapy sessions.
9738347|NCT00090064|Placebo Comparator|Placebo with therapy|Participants will receive an initial dose of 125 mg placebo orally followed 2 to 2.5 hours later by a second dose of 62.5 mg placebo during two 8-hour long blinded therapy sessions.
9738348|NCT00090103|Active Comparator|dutasteride|dutasteride 0.5mg once daily
9738349|NCT00090103|Experimental|Combo|Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily
9738350|NCT00090103|Active Comparator|tamsulosin|tamsulosin 0.4mg once daily
9738351|NCT00090220|Experimental|qHPV Vaccine in Base Study|Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
9738352|NCT00090220|Placebo Comparator|Placebo in Base Study|Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1
9738353|NCT00090233|Experimental|1|RotaTeq
9738354|NCT00090233|Placebo Comparator|2|Placebo
9738355|NCT00090285|Experimental|qHPV Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
9738356|NCT00090285|Placebo Comparator|Placebo|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
9738357|NCT00090363|Placebo Comparator|Placebo|Matching placebo oral tablet once daily, with best supportive care
9738358|NCT00090363|Experimental|ZD4054 10 mg|ZD4054 10 mg oral tablet once daily, with best supportive care
9738359|NCT00090363|Experimental|ZD4054 15 mg|ZD4054 15 mg oral tablet once daily, with best supportive care
9738360|NCT00090402|Placebo Comparator|Fish Oil Placebo & Lipoic Acid Placebo|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram placebo-lipoic acid per day. Placebo fish oil capsules consisted of soybean oil flavored with lemon flavor and 5% fish oil to match fish oil capsules. LA placebo contained no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate.
9738361|NCT00090402|Active Comparator|Fish Oil Only|Three 1-gram fish oil concentrate capsules in triglyceride form (675 milligrams DHA and 975 milligrams EPA), 2 in the morning and 1 in the evening, plus one 600 milligram placebo-lipoic acid (containing no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate) per day.
9738362|NCT00090402|Experimental|Fish Oil Plus Lipoic Acid|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram lipoic acid (LA) capsule in the racemic form per day.
9738363|NCT00090493|Experimental|MAGE-A3 and NY-ESO-1 Immunotherapy|Treatment will consist of receiving peptide vaccinations as a shot just under the skin (subcutaneous). Peptides are small pieces of proteins. We have chosen to vaccinate with peptides derived from cancer proteins found in myeloma and other cancers. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
9738364|NCT00090519|Experimental|Ruboxistaurin|32 milligrams (mg) once daily (QD) oral for up to 36 months
9738365|NCT00090519|Placebo Comparator|Placebo|QD oral for up to 36 months
9738366|NCT00090545|Experimental|First Stage - disease progression|"The first stage was to rule out the probability of 4 month progression free survival.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
9738367|NCT00090545|Experimental|Second Stage - increased accrual|"Due to prostatic specific antigen and radiographic discordance during the first stage, the protocol was amended to allow accrual to a second stage.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
9738368|NCT00090584|Experimental|Combination therapy|Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication (tolterodine) and behavioral training.
9738369|NCT00090584|Active Comparator|Drug therapy alone|Women assigned to this arm received 10 weeks of anti-cholinergic medication (tolterodine), only.
9738370|NCT00090610|Experimental|Arm 1 - Combination Therapy|Docetaxel 30mg/m2 mg IV on Days 1 and 8, in combination with carboplatin AUC 6 IV on Day 1, repeated every 21 days X 6 cycles or until disease progression
9738371|NCT00090610|Experimental|Arm 2 - Sequential Therapy|Docetaxel 30mg/m2 IV on Days 1 and 8, repeated every 21 days for 6 cycles until disease progression. Once subjects have completed 6 cycles of docetaxel, they receive carboplatin AUC 6 IV every 21 days for 6 cycles or until disease progression.
9738372|NCT00090753|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.
9738373|NCT00090753|Active Comparator|Comparator ESA|Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.
9738374|NCT00090766|Experimental|Valganciclovir Age Group <= 2 Years|Eligible participants aged <= 2 years received valganciclovir up to maximum of 900 milligrams (mg) once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * body surface area (BSA) * creatinine clearance (CrCLS).
9738375|NCT00090766|Experimental|Valganciclovir Age Group >2 to <12 Years|Eligible participants aged >2 to <12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
9738376|NCT00090766|Experimental|Valganciclovir Age Group >= 12 Years|Eligible participants aged >= 12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
9738377|NCT00090779|Active Comparator|IT arm|IT (immediate treatment) arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily
9738378|NCT00090779|No Intervention|DT arm|DT (deferred treatment) arm participants received no treatment
9738379|NCT00090844|Experimental|triptorelin|GnRH analogue (triptorelin) during chemotherapy
9738380|NCT00090844|No Intervention|no triptorelin|No GnRH analogue (triptorelin) during chemotherapy
9738381|NCT00090857|Experimental|Letrozole|Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
9738382|NCT00090857|Placebo Comparator|Placebo|Participants in this arm received 1 tablet per day which contained the inert ingredients from the letrozole tablet, for a duration of 12 months; followed by an optional 5 years of letrozole.Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
9738383|NCT00090987|Experimental|Imatinib mesylate|Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months
9738384|NCT00091026|Experimental|Arm I (cetuximab, gemcitabine hydrochloride, bevacizumab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22; gemcitabine IV over 30 minutes on days 1, 8, and 15; and bevacizumab IV over 30-90 minutes on days 1 and 15.
9738385|NCT00091026|Experimental|Arm II (gemcitabine hydrochloride, bevacizumab, erlotinib)|Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26.
9738386|NCT00091169|Experimental|Arm I|Patients receive oral levocarnitine (L-carnitine) twice daily on weeks 1-4.
9738387|NCT00091169|Placebo Comparator|Arm II|Patients receive oral placebo twice daily on weeks 1-4.
9738388|NCT00091260|Experimental|revlimid|lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
9738389|NCT00091390|Experimental|External Beam Radiotherapy and High Dose brachytherapy boost|
9738390|NCT00091442|Experimental|DOXIL and docetaxel combination therapy|DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
9738391|NCT00091442|Active Comparator|Docetaxel monotherapy|Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
9738392|NCT00091507|Experimental|1 -- GIK|GIK = glucose-insulin-potassium; In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin; infused at 1.5 ml/kg/hour for a total of 12 hours.
9738393|NCT00091507|Placebo Comparator|2 -- Placebo|Dextrose 5%, infused at 1.5 ml/kg/hour for total of 12 hours.
9738394|NCT00091572|Experimental|A|"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (7 days on / 7 days off continuously)"
9738395|NCT00091572|Active Comparator|B|dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks
9738396|NCT00091793|Experimental|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
9738397|NCT00091793|Placebo Comparator|Placebo|Placebo given day 1, month 6, month 12 and month 18
9738398|NCT00091819|Experimental|Telavancin|
9738399|NCT00091819|Active Comparator|Vancomycin|
9738400|NCT00091832|Experimental|Denosumab 60 mg every 12 weeks|Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
9738401|NCT00091832|Experimental|Denosumab 120 mg every 4 weeks|Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
9738402|NCT00091832|Experimental|Denosumab 180 mg every 4 weeks|Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
9738403|NCT00091832|Active Comparator|IV bisphosphonates every 4 weeks|Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.
9738404|NCT00091832|Experimental|Denosumab 180 mg every 12 weeks|Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
9738405|NCT00091832|Experimental|Denosumab 30 mg every 4 weeks|Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
9738406|NCT00091949|Active Comparator|Pioglitazone|pioglitazone
9738407|NCT00091949|Placebo Comparator|Placebo|inactive substance
9738408|NCT00091962|Experimental|Depressed Intervention|Telephone-based, nurse-delivered Collaborative Care program for depression; Involving: Psychoeducation; workbook for depression self-care; initiation or adjustment of antidepressant pharmacotherapy prescribed under their PCPs' direction; referral to mental health specialist
9738409|NCT00091962|Active Comparator|Depressed Usual Care|"Usual care for depression; feedback of the depression finding by the study team"
9738410|NCT00091962|No Intervention|Non-Depressed Control Group|Non-depressed control group
9738411|NCT00092417|Experimental|1|Higher Potency Dose
9738412|NCT00092417|Experimental|2|Lower Potency Dose
9738413|NCT00092443|Experimental|RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)|"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)~administered 28 to 70 days apart."
9738414|NCT00092443|Placebo Comparator|Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
9738415|NCT00092456|Experimental|RotaTeq™ Lot 1|~8.81 X 10^7 IU/Dose of RotaTeq™
9738416|NCT00092456|Experimental|RotaTeq™ Lot 2|~8.01 X 10^7 IU/Dose of RotaTeq™
9738417|NCT00092456|Experimental|RotaTeq™ Lot 3|~6.91 X 10^7 IU/Dose of RotaTeq™
9738418|NCT00092456|Placebo Comparator|Placebo|
9738419|NCT00092495|Experimental|1|100% Formulation qHPV Vaccine
9738420|NCT00092495|Experimental|2|60% Formulation qHPV Vaccine
9738421|NCT00092495|Experimental|3|40% Formulation qHPV Vaccine
9738422|NCT00092495|Experimental|4|20% Formulation qHPV Vaccine
9738423|NCT00092521|Experimental|1|V501
9738424|NCT00092521|Placebo Comparator|2|Placebo
9738425|NCT00092521|Experimental|3|HPV 16 Monovalent Vaccine
9738426|NCT00092534|Experimental|Quadrivalent Human Papillomavirus (HPV) Vaccine|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
9738427|NCT00092534|Placebo Comparator|Placebo|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
9738428|NCT00092547|Experimental|qHPV Vaccine in Base Study|Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
9738429|NCT00092547|Placebo Comparator|Placebo in Base Study|Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
9738430|NCT00092547|Experimental|qHPV Vaccine in Extension Study|Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.
9738431|NCT00093015|Active Comparator|Active|
9738432|NCT00093015|Placebo Comparator|Placebo|
9738433|NCT00093041|Experimental|Zalutumumab 0.15 mg/kg|
9738434|NCT00093041|Experimental|Zalutumumab 0.5 mg/kg|
9738435|NCT00093041|Experimental|Zalutumumab 1 mg/kg|
9738436|NCT00093041|Experimental|Zalutumumab 2 mg/kg|
9738437|NCT00093041|Experimental|Zalutumumab 4 mg/kg|
9738438|NCT00093041|Experimental|Zalutumumab 8 mg/kg|
9738439|NCT00093145|Experimental|Albumin-bound paclitaxel, Carboplatin + Herceptin|Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.
9738440|NCT00093379|Experimental|Capecitabine + Oxaliplatin + XRT|Capecitabine (825 mg/m^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m^2, Days 1, 8, 22, 29) during the duration of radiation therapy only. Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44. The final dose of radiation therapy determined by the T stage of the primary tumor. Radiotherapy = XRT.
9738441|NCT00093470|Experimental|Arm A (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738442|NCT00093470|Other|Arm B (clinical observation)|Patients undergo observation only.
9738443|NCT00093496|Experimental|Treatment (chemotherapy)|Patients are stratified according to gemcitabine hydrochloride therapy (gemcitabine hydrochloride-naive/no prior exposure to gemcitabine hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure to gemcitabine hydrochloride as a single agent with disease progression while on treatment). Patients receive tanespimycin IV over 2 hours on days 1 and 8 during course 1 and days 2 and 9 during subsequent courses and gemcitabine hydrochloride IV over 30 minutes on day 7 during course 1 and days 1 and 8 during subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
9738444|NCT00093756|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|"PHASE I: Cohorts of 3-6 patients receive escalating doses of study medications until the maximum tolerated dose (MTD) is determined. PHASE II: Patients receive as in phase I at the MTD. Patients also undergo radiotherapy as in phase I.~3-dimensional conformal radiation therapy bortezomib: Given IV paclitaxel: Given IV carboplatin: Given IV"
9738445|NCT00093782|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR or PR receive 2 additional courses beyond CR or PR.
9738446|NCT00093795|Active Comparator|Group 1: TAC X 6|Doxorubicin, cyclophosphamide, and docetaxel.
9738447|NCT00093795|Active Comparator|Group 2: AC X 4 then P X 4|Doxorubicin, cyclophosphamide, and paclitaxel
9738448|NCT00093795|Experimental|Group 3: AC X 4 then PG X 4|Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
9738449|NCT00093808|Experimental|capecitabine + vinorelbine + trastuzumab|"Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
9738450|NCT00093847|Experimental|1 Oral SAMe Tosylate|Participants receiving the oral SAMe tosylate
9738451|NCT00093847|Placebo Comparator|2 Oral Placebo Pill Twice Daily|Participants receiving placebo
9781627|NCT01154101|Active Comparator|Cohort 2 - 500mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 2 will commence after Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 2 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
9781628|NCT01154101|Active Comparator|Cohort 3 - 1000mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 3 will commence after Cohort 2 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 3 will be administered four SRT2104 capsules at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
9984673|NCT03857984|Experimental|Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
9738452|NCT00093964|Experimental|Cilengitide 500 Milligram (mg)|
9738453|NCT00093964|Experimental|Cilengitide 2000 mg|
9738454|NCT00094055|Experimental|Axitinib [AG-013736]|
9738455|NCT00094094|Experimental|Axitinib|AG-013736 is a vascular endothelial growth factor [VEGF] inhibitor
9738456|NCT00094107|Experimental|Axitinib [AG-013736]|
9738457|NCT00094172|Experimental|Atorvastatin|80 mg/day
9738458|NCT00094172|Placebo Comparator|Placebo|Once daily.
9738459|NCT00094211||Low Walkability/Low Income|Participants reside in a low walkability, low income neighborhood
9738460|NCT00094211||Low Walkability/High Income|Participants reside in a low walkability, high income neighborhood
9738461|NCT00094211||High Walkability/Low Income|Participants reside in a high walkability, low income neighborhood
9738462|NCT00094211||High Walkability/High Income|Participants reside in a high walkability, high income neighborhood
9738463|NCT00094302|Placebo Comparator|Placebo|Placebo of spironolactone
9738464|NCT00094302|Experimental|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
9738465|NCT00094328|Other|Bicalutamide with Anastrozole|Bicalutamide in combination with Anastrozole
9738466|NCT00094445|Experimental|Curcumin|Oral curcumin daily for eight weeks, starting dose 8 gm per day.
9738467|NCT00094458|Experimental|003|infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
9738468|NCT00094458|Experimental|001|infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
9738469|NCT00094458|Experimental|002|infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
9738470|NCT00094497|Active Comparator|EDP-M|etopodide, doxorubicin, cisplatin and mitotane
9738471|NCT00094497|Active Comparator|Sz-M|streptozotocin and mitotane
9738472|NCT00094536|Experimental|Extended Treatment Regimen|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
9738473|NCT00094575|Active Comparator|Arm 1|Standard Open Repair of Abdominal Aortic Aneurysm
9738474|NCT00094575|Active Comparator|Arm 2|Endovascular Repair of Abdominal Aortic Aneurysm
9738475|NCT00094653|Active Comparator|1|Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
9738476|NCT00094653|Experimental|2|MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
9738477|NCT00094653|Active Comparator|3|MDX-010 (ipilimumab) + Placebo
9738478|NCT00094757|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg
9738479|NCT00094757|Experimental|Sitagliptin 200 mg|Sitagliptin 200 mg
9738480|NCT00094757|Placebo Comparator|Placebo/Pioglitazone|Placebo/Pioglitazone
9738481|NCT00094770|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
9738482|NCT00094770|Active Comparator|Glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
9738483|NCT00094809|Active Comparator|Pegfilgrastim|6 mg pegfilgrastim
9738484|NCT00094809|Placebo Comparator|Placebo|6 mg placebo
9835745|NCT02753400|Experimental|Emixustat hydrochloride|"Week 1- Four tablets (2 placebo, 2 emixustat HCl Strength A)~Week 2- Four tablets (2 placebo, 2 emixustat HCl Strength B)~Week 3- Four tablets (2 placebo, 2 emixustat HCl Strength C)~Week 4- Four emixustat HCl tablets (Strength C)~All tablets are administered orally once daily. After week 4, all subjects will be held at a stable dose for the remainder of the 12-week dosing regimen."
9738485|NCT00094835|Experimental|Paclitaxel + Carboplatin + Motesanib|Chemotherapy naïve participants received paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by intravenous (IV) infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort and up to 125 mg once daily was used in subsequent cohorts. A cycle was defined as the 3 weeks plus the time to recover from toxicity, if encountered.
9738486|NCT00094835|Experimental|Panitumumab + Motesanib|Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.
9738487|NCT00094835|Experimental|Panitumumab + Paclitaxel + Carboplatin + Motesanib|"Chemotherapy naïve participants received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by IV infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter.~Participants were enrolled in this arm once a safe and tolerable dose of motesanib was established."
9738488|NCT00094861|Placebo Comparator|Placebo|"Participants received a single intravenous (IV) dose of placebo administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
9738489|NCT00094861|Experimental|Palifermin|"Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy (administered for 6 to 7 weeks) was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 IV infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
9738490|NCT00094887|Experimental|Inhaled Nitric Oxide|Participants receive Inhaled nitric oxide (INO)
9738491|NCT00094887|Placebo Comparator|Placebo|Participants receive Nitrogen gas
9738492|NCT00094900|Experimental|IL-1 Trap|
9738493|NCT00095056|Experimental|Sitagliptin|Participants in the Sitagliptin treatment sequence will receive sitagliptin in Phase A and placebo to glipizide in Phase B.
9738494|NCT00095056|Placebo Comparator|Placebo|Participants in the Placebo treatment sequence will receive placebo to sitagliptin in Phase A and glipizide in Phase B.
9738495|NCT00095121|Placebo Comparator|Placebo (PLB)|Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
9738496|NCT00095121|Experimental|Adefovir Dipivoxil (ADV)|Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
9738497|NCT00095147|Active Comparator|Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])|Days 1-365
9738498|NCT00095147|Active Comparator|Infliximab + MTX (DB)|Days 1-365
9738499|NCT00095147|Placebo Comparator|Placebo + MTX (DB)|Days 1-197
9738500|NCT00095147|Experimental|Placebo + MTX switched to abatacept + MTX (DB)|Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365
9738501|NCT00095147|Experimental|Abatacept (open-label)|Days 365 to 729 All participants receive Active Drug
9738502|NCT00095173|Active Comparator|Abatacept|Double Blind Period
9738503|NCT00095173|Placebo Comparator|Placebo|Double Blind Period
9738504|NCT00095173|Experimental|Abatacept - Open Label|
9738505|NCT00095199|Experimental|Cetuximab & Pemetrexed|
9738506|NCT00095199|Active Comparator|Pemetrexed|
9738507|NCT00095199|Experimental|Cetuximab & Docetaxel|
9738508|NCT00095199|Active Comparator|Docetaxel|
9738509|NCT00095212|Active Comparator|1 Transdermal Testosterone (Patch)|300 micrograms applied twice a week
9738510|NCT00095212|Placebo Comparator|2 Placebo Patch (identical in appearance)|placebo patch (0 micrograms of testosterone)applied twice a week
9738511|NCT00095238|Active Comparator|1|
9738512|NCT00095238|Placebo Comparator|2|
9738513|NCT00095303|Experimental|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
9738514|NCT00095303|Active Comparator|Treatment as Usual (TAU)|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
9738515|NCT00095498|Experimental|Denosumab 180 mg|Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
9738516|NCT00095498|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
9738517|NCT00095498|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections on Day 1 and at Month 6.
9738518|NCT00095563|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
9738519|NCT00095576|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
9738520|NCT00095576|Placebo Comparator|Placebo|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.
9738521|NCT00095628|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9738522|NCT00095836|Experimental|Gefitinib 250mg|
9738523|NCT00095875|Experimental|Arm I|Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
9738524|NCT00095875|Experimental|Arm II|Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
9738525|NCT00095940|Experimental|Treatment (surgery, lapatinib)|"Molecular Biology Phase: Patients randomized to receive lapatinib prior to surgery receive oral lapatinib twice daily for 7-14 days. Surgery is performed after 7-14 days of lapatinib treatment. For patients randomized to not receive lapatinib, surgery is performed within 3 weeks of registration. After surgical resection, all molecular biology participants start lapatinib treatment within 10 days post-surgery. The first dose of lapatinib post-surgery initiates course 1. Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.~Lapatinib Continuation/Phase II: Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity."
9738526|NCT00095979|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9738527|NCT00096018|Experimental|Dose escalation|Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days
9738528|NCT00096031|Experimental|Cetuximab|250 mg/m^2 on days 1, 8, 15, and 22 of every 28-day cycle.
9738529|NCT00096044|Experimental|Oral Lenalidomide|Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
9738530|NCT00096109|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9738531|NCT00096122|Experimental|Arm I|See Detailed Description
9738532|NCT00096135|Experimental|CNS Patients-Treatment (combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
9738533|NCT00096135|Experimental|Testicular Relapse Patients (Combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
9785332|NCT01249131|Experimental|Treatment C first, then Treatment A, followed by Treatment B|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
9738534|NCT00096161|Experimental|pentostatin, DLI, mycophenolate mofetil, cyclosporine|"Group I (pentostatin, DLI): Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.~Group II (pentostatin, DLI, mycophenolate mofetil, cyclosporine): Patients receive treatment as in group I. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD."
9738535|NCT00096174|Experimental|Cisplatin, C225, Radiation|"Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.~Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.~Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months."
9738536|NCT00096226|Experimental|Chemoradiation, Surgery, Chemotherapy|Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks. Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions. Followed by an assessment to determine whether patient will undergo a resection or not. Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
9738537|NCT00096265|Active Comparator|Arm I|Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
9738538|NCT00096265|Experimental|Arm II|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9738539|NCT00096265|Experimental|Arm III|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
9738540|NCT00096278|Active Comparator|Arm I (mFOLFOX6)|Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
9738541|NCT00096278|Experimental|Arm II (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
9738542|NCT00096356|Active Comparator|Arm 1 - CoQ10 & Vitamin E|CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.
9738543|NCT00096356|Placebo Comparator|Arm 2 - Placebo & Vitamin E|Placebo-Vitamin E 100 mg/day in 3 doses
9738544|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
9738545|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, No prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
9738546|NCT00096447|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738547|NCT00096460|Active Comparator|Autologous Transplant|Cyclophosphamide and Rituximab with Filgrastim conditioning and chemotherapy or radiation therapy prior to autologous Hematopoietic Stem Cell Transplant (HSCT). Rituximab maintenance therapy following HSCT.
9738548|NCT00096460|Active Comparator|Allogeneic Transplant|Non-myeloablative conditioning regimen followed by allogeneic Hematopoietic Stem Cell Transplant (HSCT). Graft-versus-Host Disease (GVHD) Prophylaxis therapy following HSCT.
9738549|NCT00096486|Experimental|Gefitinib and Everolimus (RAD001)|"Phase I: Patients receive oral everolimus once on day 1. Beginning on day 8, patients receive oral gefitinib once daily. Beginning on day 22, patients receive oral everolimus once daily. Both drugs are then given concurrently for the rest of the treatment. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.~Phase II: Patients receive oral everolimus at the MTD determined in phase I and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
9738550|NCT00096538|Experimental|valganciclovir|Patients receive oral valganciclovir twice daily for 3 weeks and then once daily for 21 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed for 1 month after completion of therapy. Patients with responding disease are followed monthly for up to 1 year.
9738551|NCT00096785|Active Comparator|A1|
9738552|NCT00096785|Active Comparator|A2|
9738553|NCT00096941|Experimental|Pertuzumab|Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.
9738554|NCT00096954|Experimental|Omalizumab|Omalizumab (Xolair) administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
9738555|NCT00096954|Placebo Comparator|Placebo|Placebo administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
9738556|NCT00096993|Placebo Comparator|Placebo + gemcitabine|Participants received placebo intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles).
9738557|NCT00096993|Active Comparator|Pertuzumab + gemcitabine|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Participants received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond. In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles
9738558|NCT00097253|Experimental|Lavender|
9738559|NCT00097253|Experimental|Citrus|
9738560|NCT00097253|Placebo Comparator|Water|
9738561|NCT00097370|Experimental|mepolizumab|750mg Intravenous, monthly and individual dosing schedule
9738562|NCT00097448|Other|1|Nineteen days of oral prednisone
9738563|NCT00097448|Experimental|2|Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks
9738564|NCT00097500|Experimental|Exenatide Arm|Exenatide and Metformin
9738565|NCT00097500|Active Comparator|Insulin Glargine Arm|Insulin Glargine and Metformin
9738566|NCT00097539||Participants With Growth Disorders|Participants initiating therapy with Genentech GH products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) for the treatment of pediatric growth disorders as determined by their physician and who have consented to participate in the NCGS will be enrolled in the study and will be followed throughout their course of treatment, or until withdrawal from the NCGS.
9738567|NCT00097591|Experimental|Prasugrel|Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to clopidogrel once daily
9738568|NCT00097591|Active Comparator|Clopidogrel|Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to prasugrel once daily
9738569|NCT00097669|Active Comparator|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug)|Active Treatment Arm: VITATOPS study tablet (folate 2 mg, B6 25 mg, B12 500 ug). Taken daily for the duration of the study.
9738570|NCT00097669|Placebo Comparator|Placebo Tablet|Placebo Treatment Arm: The placebo tablet will have the same appearance, taste and texture as the vitamin preparation and contains excipients, coating and coating aids.
9738571|NCT00097695|Experimental|Icatibant- Randomized|Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.
9738572|NCT00097695|Placebo Comparator|Placebo-Randomized|Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.
9738573|NCT00097695|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
9738574|NCT00097695|Experimental|Untreated Patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )
9738575|NCT00097721|Experimental|E7389|
9738576|NCT00097773|Placebo Comparator|Cycled TOBI & placebo|Tobramycin inhalation solution and oral placebo for six consecutive quarterly cycles
9738577|NCT00097773|Active Comparator|Cycled TOBI & oral ciprofloxacin|Tobramycin solution for inhalation and oral ciprofloxacin for six consecutive quarterly cycles.
9738578|NCT00097773|Placebo Comparator|Culture based TOBI & placebo|Tobramycin solution for inhalation and oral placebo administered only when quarterly respiratory cultures are found positive for Pa.
9738579|NCT00097773|Active Comparator|Culture based TOBI & oral cipro|Tobramycin solution for inhalation and oral ciprofloxacin administered only when quarterly respiratory cultures are found positive for Pa.
9738580|NCT00097786|Experimental|Valsartan 160 mg + nateglinide 60 mg|For the first 2 weeks of treatment, patients took the combination of nateglinide 30 mg (3 times daily, ante cibum [ac] before meals) and valsartan 80 mg (once daily [od] in the morning). After 2 weeks, patients were up-titrated to nateglinide 60 mg ac and valsartan 160 mg od.
9738581|NCT00097786|Experimental|Valsartan 160 mg + nateglinide placebo|For the first 2 weeks of treatment, patients took valsartan 80 mg capsules (once daily [od] in the morning). After 2 weeks, patients were up-titrated to 160 mg valsartan od. Patients also received nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals).
9738582|NCT00097786|Experimental|Nateglinide 60 mg + valsartan placebo|For the first 2 weeks of treatment, patients took nateglinide 30 mg tablets (3 times daily, ante cibum [ac] before meals). After 2 weeks, patients were uptitrated to 60 mg nateglinide ac. Patients also received valsartan placebo capsules (once daily [od] in the morning).
9738583|NCT00097786|Placebo Comparator|Placebo|Patients took 3 nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals) and 1 valsartan placebo capsule (once daily [od] in the morning).
9738584|NCT00097981|Active Comparator|Thalidomide + dexamethasone|
9738585|NCT00097981|Experimental|Thalidomide + dexamethasone + DOXIL|
9738586|NCT00098020|Experimental|Isotretinoin|Subjects will be treated with Isotretinoin.
9738587|NCT00098059|Experimental|Famciclovir, pediatric oral formulation|single-arm
9738588|NCT00098254|Experimental|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
9738589|NCT00098293|Experimental|1|
9738590|NCT00098293|Active Comparator|3|
9738591|NCT00098293|Experimental|2|Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
9738592|NCT00098306|Experimental|1|
9738593|NCT00098306|Experimental|2|
9738594|NCT00098306|Experimental|3|
9738595|NCT00098345|Experimental|Caprelsa (vandetanib) 300 mg|Daily oral dose of Caprelsa (vandetanib) 300mg
9738596|NCT00098371|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for > 6 months after completion of treatment may receive 6 additional courses of flavopiridol.
10200888|NCT05170321||patients undergoing ankle arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent ankle arthroplasty and was recorded in HQMS were included in this group
10200889|NCT05170321||patients undergoing elbow arthroplasty in Hospital Quality Monitoring System in China|Patients who underwent elbow arthroplasty and was recorded in HQMS were included in this group
10200890|NCT05169008|Experimental|Vaccine Group|2000 participants，1000 children aged 6-12 years and 1000 adolescents aged 13-17 years, Ad5-nCoV + Ad5-nCoV-IH, 56 days interval. Intramuscular injection and nebulized inhalation.
10200891|NCT05168527|Experimental|experimental group|This is an opened single-arm phase 2 study， the study drug includes Fruquintinib combine with Paclitaxel Injection and Gemcitabine.
9738601|NCT00098670|Experimental|Treatment (alemtuzumab, rituximab, fludarabine phosphate)|"Patients receive induction therapy comprising rituximab IV over 4 hours on days 1, 3, and 5 of course 1 and day 1 of all subsequent courses and fludarabine IV over 30 minutes on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression.~Approximately 4 months after completion of induction therapy, patients achieving a partial response, nodular partial response, or stable disease receive consolidation therapy comprising alemtuzumab subcutaneously on days 1-3. Treatment repeats weekly for up to 6 courses in the absence of disease progression."
9738602|NCT00098722|Experimental|1|
9738603|NCT00098722|Placebo Comparator|2|
9738604|NCT00098722|Experimental|3|
9738605|NCT00098748|Experimental|1|
9738606|NCT00098748|Experimental|2|
9738607|NCT00098748|Experimental|3|
9738608|NCT00098774|Experimental|Intensive Combination Chemo & Immunotherapy|"Induction Cycles 1-3: Methotrexate 8gm/m^2 days 1 & 15; Leucovorin 100 mg/m^2 days 2 & 16; Rituximab 375 mg/m^2 days 3, 10, 17 & 24 of cycle 1, days 3 & 10 of cycle 2; Temozolomide 150 mg/m^2/day PO days 7-11~Induction Cycle 4: Temozolomide 150 mg/m^2/day PO days 7-11; Methotrexate 8gm/m^2 day 15; Leucovorin 100 mg/m^2 day 16~Consolidation Cycle 5: Methotrexate 8gm/m^2 days 1; Leucovorin 100 mg/m^2 days 2; Temozolomide 150 mg/m^2/day PO days 7-11~Consolidation Cycle 6: Cytarabine 2 g/m^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m^2/day starting day 14 until ANC recovers (>= 500 for 2 consecutive days or >= 1500 for one day)"
9738609|NCT00098787|Experimental|Arm A (High TS, IROX/bev)|Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
9738610|NCT00098787|Experimental|Arm B (High TS, FOLFOX/bev)|Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
9738611|NCT00098787|Experimental|Arm C (Low or intermediate TS, FOLFOX/bev)|Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.
9738612|NCT00098813|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.
9738613|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab once weekly|Four weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 8, 15, 22. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
9738614|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab twice weekly|Eight 8 twice-weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 4, 8, 11, 15, 18, 22 & 25. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
9738615|NCT00098865|Experimental|Thalidomide and Temozolomide|"Thalidomide:~Oral thalidomide on days 1-28 of a 28 day cycle initiated at 3 mg/kg and increased to maximum dose of 24 mg/kg or 1000 mg as tolerated.~Temozolomide:~Oral temozolomide on days 1-5 of 28 day cycle given at 200 mg/m2 or 150 mg/m2 for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal radiation.~Patients were treated for 6 cycles unless disease progression or excessive toxicity. Treatment could continue beyond 6 cycles if absent disease progression"
9738616|NCT00098956|Experimental|Treatment (topotecan hydrochloride, UCN-01)|Patients receive topotecan IV over 30 minutes on days 1-5 and UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR receive 2 additional courses beyond CR or PR.
9738617|NCT00099021|Experimental|Prevention (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.
9738618|NCT00099047|Experimental|Arm I (celecoxib)|Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
9738619|NCT00099047|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
9738620|NCT00099268|Experimental|Carbidopa/levodopa/entacapone|Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
9738621|NCT00099268|Active Comparator|Immediate release carbidopa/levodopa|Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
9738622|NCT00099359|Experimental|A|Standard of care ( Zidovudine only)
9738623|NCT00099359|Experimental|B|Standard of care (Zidovudine) plus Nevirapine
9738624|NCT00099359|Experimental|C|Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir
9738625|NCT00099372||Abdominal Sacral Colpopexy with no Burch colposuspension|Participants had an Abdominal Sacral Colpopexy without Burch colposuspension for treatment of pelvic organ prolapse
9738626|NCT00099372||Abdominal Sacral Colpopexy with Burch Colposuspension|Participants had an Abdominal Sacral Colpopexy with Burch colposuspension for treatment of pelvic organ prolapse
9738627|NCT00099632|Experimental|7-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
9738628|NCT00099632|Experimental|21-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
9738629|NCT00099632|Experimental|7-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
9738630|NCT00099632|Experimental|21-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
9738631|NCT00099632|Experimental|7-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
9738632|NCT00099632|Experimental|21-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r
9738633|NCT00099983|Active Comparator|Risperidone|1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
9738634|NCT00099983|Placebo Comparator|Sugar Pill|Placebo 1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
9738635|NCT00100048|Experimental|600 mg monotherapy|MK0518 600 mg twice daily
9738636|NCT00100048|Experimental|400 mg monotherapy|MK0518 400 mg twice daily
9738637|NCT00100048|Experimental|200 mg monotherapy|MK0518 200 mg twice daily
9738638|NCT00100048|Experimental|100 mg monotherapy|MK0518 100 mg twice daily
9738639|NCT00100048|Placebo Comparator|placebo monotherapy|Placebo to MK0518 twice daily
9738640|NCT00100048|Experimental|600 mg combo therapy|MK0518 600 mg + tenofovir + lamivudine
9738641|NCT00100048|Experimental|400 mg combo therapy|MK0518 400 mg + tenofovir + lamivudine
9738642|NCT00100048|Experimental|200 mg combo therapy|MK0518 200 mg + tenofovir + lamivudine
9738643|NCT00100048|Experimental|100 mg combo therapy|MK0518 100 mg + tenofovir + lamivudine
9738644|NCT00100048|Active Comparator|EFV combo therapy|efavirenz + tenofovir + lamivudine
9738645|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg twice per day in a blinded capsule.
9738646|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine)75 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg twice per day in a blinded capsule.
9738647|NCT00100165|Placebo Comparator|placebo|Patient receives placebo twice per day in a blinded capsule.
9738648|NCT00100178|Experimental|MMF and DBZ|DZB given by intravenous infusion (1 mg/kg)at baseline and 2 weeks later, and MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years.
9738649|NCT00100178|Experimental|MMF Alone|MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years and saline intravenous infusions given at baseline and two weeks later.
9738650|NCT00100178|Placebo Comparator|Placebo|Placebo pills given daily for two years and saline intravenous infusions given at baseline and two weeks later.
9738651|NCT00100230|Experimental|1.|Oral Docosahexaenoic acid, dosage based on body weight
9738652|NCT00100230|Placebo Comparator|2|corn/soy oil placebo; oil not containing DHA...dosage based on body weight
9781629|NCT01154101|Active Comparator|Cohort 1 - 250mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 1 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff.~Dosing for Cohort 2 will not commence until Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee."
9835746|NCT02753400|Placebo Comparator|Placebo|Four placebo tablets are administered orally once daily for 12 weeks; Subjects in the placebo group will be mock-titrated on the same schedule as those in the active arm.
9835747|NCT02753413|Experimental|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
9738653|NCT00100659|Active Comparator|Pegylated interferon/ribavirin|"Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.~Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets."
9738654|NCT00100659|Placebo Comparator|Pegylated interferon/placebo|Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).
9738655|NCT00100698|Active Comparator|1|recombinant human growth hormone subcutaneously once a day
9738656|NCT00100698|Placebo Comparator|2|placebo subcutaneously once a day
9738657|NCT00100789|Experimental|gemcitabine paclitaxel combination|
9738658|NCT00100802|Experimental|Surgery, Chemoradiotherapy, Rest, Maintenance, FUP|Patients must begin therapy within 31 days of surgery. Chemoradiotherapy = Radiation Therapy Dose: 54.0 Gy with a Boost of 5.4 Gy Temozolomide 90mg/m2/day daily for 42 days. Maintenance consists of 6 treatment cycles of combo chemotherapy with lomustine and temozolomide. Maintenance will begin 4 weeks following radiation. Five days of temozolomide (day 1 - 5) and one dose of lomustine (day 1) followed by 36 days of rest = 1 treatment cycle.
9738659|NCT00100841|Experimental|Treatment (combination chemotherapy)|Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
9738660|NCT00100932|Experimental|1|E7389 28 day cycle
9738661|NCT00100932|Experimental|2|E7389 21 day cycle
9738662|NCT00101010|Experimental|Rituximab - Combination Chemotherapy|Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide IV over 1-1½ hours, Pegylated doxorubicin HCl liposome 40 mg/m^2 IV over 1 hour, Vincristine 2 mg IV, day 1, & oral Prednisone 40 mg/m^2 days 1 - 5; Filgrastim (G-CSF) 5 mcg/kg subcutaneously (SC) once daily beginning day 6 continuing until blood counts recover OR Pegfilgrastim 6 mg SC once on day 6 (24 hours after chemotherapy). Treatment repeats every 21 days for up to 8 courses.
9738663|NCT00101036|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738664|NCT00101101|Experimental|Vaccine and Conventional Therapy|"Patients were treated with 3-6 cycles of chemotherapy +/- rituximab, with type and duration at the discretion of the individual clinician.~Chemotherapy: 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.~Patients who achieve a partial or complete response after completion of chemotherapy proceed to autologous tumor cell-based vaccine therapy.~Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2.~Treatment continues in the absence of disease progression or unacceptable toxicity."
9738665|NCT00101166|Experimental|Vaccine Therapy|Treatment consisted of intradermal vaccine injections at 28-day intervals for a total of 3 immunizations. Injections were performed on Days 1, 29, and 57.
9738666|NCT00101283|Experimental|Pemetrexed/Carboplatin|Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle.
9738667|NCT00101283|Experimental|Pemetrexed/Gemcitabine|Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
9738668|NCT00101361|Active Comparator|1|oxandrolone
9738669|NCT00101361|Placebo Comparator|2|placebo
9738670|NCT00101400|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
9738671|NCT00101413|Experimental|Sorafenib|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
9738672|NCT00101452|Experimental|S-adenosyl-l-methionine (SAMe)|A natural substance
9738673|NCT00101452|Active Comparator|2. Escitalopram|A selective serotonin reuptake inhibitor (SSRI)
9738674|NCT00101452|Placebo Comparator|3. placebo|Sugar pill- contains no active ingredients
9738675|NCT00101582|Experimental|Palifermin|Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course.
9738676|NCT00101582|Placebo Comparator|Placebo|Participants received a single IV dose of placebo three days before the start of radiotherapy, and then 7 once weekly placebo doses during a 7-week radiotherapy/chemotherapy course.
9738677|NCT00101647|Experimental|1|
9738678|NCT00101660|Experimental|Dasatinib, 70 mg twice daily (BID)|Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.
9738679|NCT00101686|Experimental|Modified Bolus 5-FU/LV with Irinotecan|
9738680|NCT00101686|Experimental|FOLFIRI + bevacizumab|
9738681|NCT00101686|Experimental|miFL + bevacizumab|
9738682|NCT00101686|Experimental|Infusional 5-FU/LV with Irinotecan|
9738683|NCT00101686|Other|Oral Capecitabine with Irinotecan|
9738684|NCT00101816|Experimental|1|
9738685|NCT00101868|Experimental|Discharge communication software|Computerized-Physician-Order-Entry software application to facilitate communication at time of hospital discharge to patients, retail pharmacists, community physicians. Software had required fields, pick lists, standard drug doses, alerts, reminders, online reference information. Software prompted discharging physician to enter pending tests, order tests after discharge. Hospital physicians used software on day of discharge to generate four documents automatically: personalized letter to outpatient physician, legible prescriptions, and legible discharge order
9738686|NCT00101868|Active Comparator|Usual care discharge process|Hospital physicians and ward nurses completed handwritten discharge forms on the day of discharge. The forms contained blanks for discharge diagnoses, discharge medications, medication instructions, post discharge activities and restrictions, post discharge diet, post discharge diagnostic and therapeutic interventions, and appointments. Patients received handwritten copies of the forms, one page of which also included medication instructions and prescriptions
9738687|NCT00101907|Experimental|Panitumumab + Gem/Cis|Panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
9738688|NCT00101907|Experimental|50 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 50 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
9738689|NCT00101907|Experimental|75 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
9738690|NCT00101907|Experimental|100 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 100 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
9738691|NCT00101907|Experimental|125 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 125 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
9738692|NCT00101907|Experimental|75 mg BID AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally twice daily (BID) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
9738693|NCT00101933|Experimental|1|Active Stimulation
9738694|NCT00101933|Sham Comparator|2|No Stimulation
9738695|NCT00102063|Active Comparator|Aripiprazole 10 mg/day Group|Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
9738696|NCT00102063|Active Comparator|Aripiprazole 30 mg/day Group|Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
9738697|NCT00102063|Placebo Comparator|Placebo Group|Participants were given a single pill administered once daily
9738698|NCT00102440|Experimental|Febuxostat 80 mg QD|
9738699|NCT00102440|Experimental|Febuxostat 120 mg QD|
9738700|NCT00102440|Active Comparator|Allopurinol 300 mg QD|
9738701|NCT00102518|Experimental|NCT00102063 and NCT00110461 Subjects|All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).
9738702|NCT00102531|Experimental|Cisplatin liposomal 24 mg/m2|Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles.
9738703|NCT00102531|Experimental|Cisplatin liposomal 36 mg/m2|The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2
9738704|NCT00102687|Experimental|Aza-5|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days on a 28 day cycle.
9738705|NCT00102687|Experimental|Aza-5-2-2|Azacitidine administered subcutaneously at 75mg/m^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.
9738706|NCT00102687|Experimental|Aza-5-2-5|Azacitidine administered subcutaneously at 50mg/m^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.
9738707|NCT00102687|Experimental|Maintenance Aza 5 days q 4 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 4 weeks.
9738708|NCT00102687|Experimental|Maintenance Aza 5 days q 6 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 6 weeks.
9738709|NCT00102804|Experimental|Pemetrexed and Best Supportive Care|
9738710|NCT00102804|Placebo Comparator|Placebo and Best Supportive Care|
9738711|NCT00102960|Experimental|Deferred therapy Arm|"Zidovudine: First Line Regimen: Given twice daily at a dose of 240 mg/m^2 of body surface area. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
9738712|NCT00102960|Experimental|Early therapy for 40 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2~Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
9738713|NCT00102960|Experimental|Early therapy for 96 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
9738714|NCT00103012|Experimental|Effect of G. Biloba on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba).
9738715|NCT00103012|Experimental|Effect of Echinacea on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Echinacea purpurea).
9738716|NCT00103012|Experimental|Effect of P. ginseng on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Panax ginseng).
9738717|NCT00103116|Experimental|Autologous dendritic cell cancer vaccine|Open label nonrandomized
9738718|NCT00103142|Experimental|PANVAC-V + PANVAC-F + DC|Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic cells (DC). Patients then receive autologous DC loaded with vaccinia-CEA-MUC-1-TRICOM (PANVAC-V) vaccine subcutaneously (SC) and intradermally (ID) on day 1 and autologous DC loaded with fowlpox-CEA-MUC-1-TRICOM (PANVAC-F) vaccine SC and ID on days 28, 56, and 84.
9738719|NCT00103142|Experimental|PANVAC-V + PANVAC-F + GM-CSF|Patients receive PANVAC-V SC on day 1 and PANVAC-F SC on days 28, 56, and 84. Patients also receive sargramostim (GM-CSF) SC into the same injection site once daily on days 0-3, 28-31, 56-59, and 84-87.
9738720|NCT00103194|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738721|NCT00103207|Experimental|Cetuximab|Cetuximab was given as a weekly intravenous (IV) infusion (over 60 minutes) at 250 mg/m2 from week 2 onwards after an initial loading dose of 400 mg/m2 (over 120 minutes) on week 1 until disease progression or unacceptable toxicity. The infusion rate of cetuximab could not exceed 5 mL/min. Each cycle will be 28 days in length. To prevent a hypersensitivity reaction, all patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) by IV (over 30-60 minutes) prior to the first dose of cetuximab. Premedication might be administered prior to subsequent doses, but at the investigator's discretion, the dose of diphenhydramine (or a similar agent) was reduced.
9738722|NCT00103259|Experimental|Arm I (bortezomib, irinotecan hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
9738723|NCT00103259|Experimental|Arm II (bortezomib)|Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I.
9738724|NCT00103285|Experimental|Group 0 Induction Therapy|All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) < 0.1% OR MRD >= 0.1% and < 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD >= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.
9738725|NCT00103285|Active Comparator|Group 1-SR-low ALL, Arm I (combination chemotherapy)|Patients receive standard consolidation therapy, standard interim maintenance therapy, and standard delayed intensification (DI) therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years
9738726|NCT00103285|Experimental|Group 1-SR-low ALL, arm II (combination chemotherapy)|Patients receive experimental consolidation therapy, experimental interim maintenance therapy, and standard DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
9738727|NCT00103285|Active Comparator|Group 2-SR-avg ALL, arm I (combination chemotherapy)|Patients receive standard consolidation therapy, standard interim maintenance therapy, and standard DI therapy as in group 1, arm I, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
9738728|NCT00103285|Experimental|Group 2-SR-avg ALL, arm II (combination chemotherapy)|Patients receive standard consolidation therapy, augmented interim maintenance therapy, augmented DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
9738729|NCT00103285|Active Comparator|Group 2-SR-avg ALL, arm III (combination chemotherapy)|Patients receive intensified consolidation therapy, standard interim maintenance therapy, and standard DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
9738730|NCT00103285|Active Comparator|Group 2-SR-avg ALL, arm IV (combination chemotherapy)|Patients receive intensified consolidation therapy, augmented interim maintenance therapy, and augmented DI therapy, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
9738731|NCT00103285|Experimental|Group 3-SR-high ALL, combination chemotherapy|Patients receive intensified consolidation therapy, augmented interim maintenance therapy (2 courses), and augmented DI therapy (2 courses), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
9738732|NCT00103311|Experimental|Arm I|Patients receive SB-715992 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738733|NCT00103311|Experimental|Arm II|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9738734|NCT00103376|Experimental|Part A: Velcade|Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Part B (Velcade + antiandrogen). If the patient has a partial response or stable disease, he will start Part B after at least a 7-day break.
9738735|NCT00103376|Experimental|Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist|Patient will start Part B after completing Part A or may be enrolled to part B only.
9738736|NCT00103402|Experimental|Alfuzosin|10 mg of alfuzosin once daily for 12 weeks
9738737|NCT00103402|Placebo Comparator|Placebo|10 mg of an identical-looking placebo once daily for 12 weeks
9738738|NCT00103506|Active Comparator|VELCADE (bortezomib) monotherapy|Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
9738739|NCT00103506|Experimental|DOXIL/CAELYX in combination with VELCADE (bortezomib)|Bortezomib (VELCADE) 1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
9738740|NCT00103610|Experimental|G-CSF plus plerixafor|
9738741|NCT00103610|Placebo Comparator|G-CSF plus placebo|
9738742|NCT00103662|Experimental|G-CSF plus plerixafor|
9738743|NCT00103662|Placebo Comparator|G-CSF plus placebo|
9738744|NCT00103740|Experimental|Zoledronic acid and placebo to risedronate|Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
9738745|NCT00103740|Active Comparator|Risedronate and placebo to zoledronic acid|Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
9738746|NCT00103844|Experimental|1|Active Comparator
9738747|NCT00103844|Experimental|2|Active Comparator
9738748|NCT00103857|Experimental|1|MK0431 100 mg q.d.
9738749|NCT00103857|Active Comparator|2|Metformin 500 mg b.i.d.
9738750|NCT00103857|Active Comparator|3|Metformin 1000 mg b.i.d.
9738751|NCT00103857|Experimental|4|Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
9738752|NCT00103857|Experimental|5|Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
9738753|NCT00103857|Placebo Comparator|6|Placebo/Metformin 1000 mg b.i.d.
9738754|NCT00103857|Experimental|7|Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.
9738755|NCT00104052|Experimental|PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).
9738756|NCT00104104|Experimental|15 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks
9738757|NCT00104104|Experimental|30 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.
9738758|NCT00104234|Other|rhASB/rhASB|N-acetylgalactosamine 4-sulfatase
9738759|NCT00104234|Other|Placebo/rhASB|
9738760|NCT00104299|Experimental|Rituximab|
9738761|NCT00104299|Active Comparator|Control Group|
9738762|NCT00104416|Placebo Comparator|Placebo|
9738763|NCT00104416|Experimental|lamotrigine (LAMICTAL) extended-relesase|
9738764|NCT00104520|Placebo Comparator|Placebo (pooled two times a day [BID]/three times a day [TID])|
9738765|NCT00104520|Experimental|AZLI (pooled two times a day [BID]/three times a day [TID])|
9738766|NCT00104572|Experimental|(Androgel) testosterone gel|17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
9738767|NCT00104572|Experimental|anastrozole (Aromatase inhibitor)|14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
9738768|NCT00104572|Placebo Comparator|placebo|13 participants will receive a placebo tablet and placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
9738769|NCT00104637|Active Comparator|Sildenafil / Placebo|Sildenafil first, followed by washout, followed by placebo
9738770|NCT00104637|Placebo Comparator|Placebo / Sildenafil|Placebo first, followed by washout, followed by Sildenafil
9738771|NCT00104650|Active Comparator|IV Bisphosphonates q 4 weeks|This is an open-label randomization to receive IV bisphosphonate (administered per package insert) every 4 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will receive AMG 162 180mg (SC) every 4 weeks.
9738772|NCT00104650|Experimental|180 mg AMG 162 (SC) q 12 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 12 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 12 weeks.
9738773|NCT00104650|Experimental|180 mg AMG 162 (SC) q 4 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 4 weeks during the treatment phase. If subject is enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 4 weeks.
9738774|NCT00104676|Active Comparator|Arm I|Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
9738775|NCT00104676|Experimental|Arm II|Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.
9738776|NCT00104858|Experimental|Treatment|"Patients receive a conditioning regimen comprising fludarabine IV on days -4 to -2 and rituximab IV on days -3, 10, 24, and 38.~Patients undergo single fraction low-dose TBI on day 0. After completion of TBI, patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive rituximab IV on days 10, 24, and 38.~Patients receive an immunosuppressive regimen comprising cyclosporine PO BID on days -3 to 56 followed by a taper to day 180 (related recipients) or on days -3 to 100 followed by a taper to day 180 (unrelated recipients). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related recipients) or TID on days 0-40 followed by a taper to day 96 (unrelated recipients)."
9738777|NCT00104871|Experimental|Bortezomib|Bortezomib 1.3 mg/m^2 intravenous (IV) at over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses.
9738778|NCT00104884|Experimental|Depsipeptide|Depsipeptide is administered as a 4-hour IV infusion weekly in doses of 13 mg/m^2 for 3 weeks. Repeat cycle every 28 days until unacceptable toxicity or disease progression.
9738779|NCT00105001|Active Comparator|Arm I (MMF and tacrolimus)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD.
9738780|NCT00105001|Experimental|Arm II (MMF and tacrolimus alternate schedule)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD.
9738781|NCT00105001|Experimental|Arm III (MMF, tacrolimus, and sirolimus)|Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80.
9738782|NCT00105027|Active Comparator|CRVO Observation|
9738783|NCT00105027|Active Comparator|CRVO 1 mg dose triamcinolone acetonide|
9738784|NCT00105027|Active Comparator|CRVO 4 mg dose triamcinolone acetonide|
9738785|NCT00105027|Active Comparator|BRVO standard care|
9738786|NCT00105027|Active Comparator|BRVO 1 mg dose triamcinolone acetonide|
9738787|NCT00105027|Active Comparator|BRVO 4 mg dose triamcinolone acetonide|
9738788|NCT00105066|Placebo Comparator|Placebo|placebo
9738789|NCT00105066|Experimental|Metformin|Metformin 850 mg twice daily
9738790|NCT00105079|Experimental|saquinavir/ritonavir|saquinavir mesylate 1000 mg twice daily (BID) + ritonavir 100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
9738791|NCT00105079|Active Comparator|lopinavir/ritonavir|lopinavir/ritonavir 400/100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
9738792|NCT00105157|Experimental|1|MK0518 200 mg
9738793|NCT00105157|Experimental|2|MK0518 400 mg
9738794|NCT00105157|Experimental|3|MK0518 600 mg
9738795|NCT00105157|Placebo Comparator|4|Placebo
9738796|NCT00105183|Active Comparator|EZ-2053|Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)
9738797|NCT00105183|Placebo Comparator|Placebo|USP 0.9% sodium chloride solution
9738798|NCT00105183|Active Comparator|EZ-2053 5mg/kg|Anti-human-T-Lymphocyte Immune Globulin, Rabbit
9738799|NCT00105196|Experimental|A1|
9738800|NCT00105196|Placebo Comparator|A2|
9738801|NCT00105235|Experimental|Alemtuzumab|Liver transplant, with two in-patient infused doses of alemtuzumab; followed by maintenance immunotherapy with cyclosporine, mycophenolate mofetil, and/or tacrolimus; with possible immunosuppression withdrawal
9738802|NCT00105443|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
9738803|NCT00105443|Placebo Comparator|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.
9738804|NCT00105469|Experimental|AzaSite|1.0% azithromycin in DuraSite
9738805|NCT00105469|Active Comparator|Tobramycin|0.3% tobramycin
9738806|NCT00105482|Experimental|Naltrexone, Transdermal Nicotine|Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
9738807|NCT00105482|Placebo Comparator|Placebo Naltrexone, Transdermal Nicotine|Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
9738808|NCT00105508|Experimental|Sarizotan|
9738809|NCT00105508|Placebo Comparator|Placebo|
9738810|NCT00105521|Placebo Comparator|Placebo|Participants will receive placebo matched to sarizotan tablet orally twice daily up to Week 12.
9738811|NCT00105521|Experimental|Sarizotan 2 milligrams per day (mg/day)|Participants will receive sarizotan 2 milligrams (mg) per day (given in 2 divided daily doses) up to Week 12.
9738812|NCT00105521|Experimental|Sarizotan 4 mg/day|Participants will receive sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.
9738813|NCT00105521|Experimental|Sarizotan 10 mg/day|Participants will receive sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.
9738814|NCT00105534|Experimental|AzaSite|
9738815|NCT00105534|Sham Comparator|Vehicle|
9738816|NCT00105586|Experimental|Escitalopram (1)|Escitalopram
9738817|NCT00105586|Placebo Comparator|Placebo (2)|Placebo
9738818|NCT00105989|Experimental|A|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
9738819|NCT00105989|Placebo Comparator|B|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks
9738820|NCT00106002|Experimental|A|
9738821|NCT00106028|Placebo Comparator|Placebo Daily|placebo tablet, once a day for one year then for two years open label risedronate
9738822|NCT00106028|Experimental|Risedronate Daily|risedronate tablet, once a day for one year then for two years open label risedronate once a day
9738823|NCT00106080|Experimental|Intervention|Audit and Feedback
9738824|NCT00106080|No Intervention|Control|Usual care
9738825|NCT00106106|Placebo Comparator|Placebo|For subjects randomized to placebo control, placebo doses were given every 8 hours.
9738826|NCT00106106|Experimental|Acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
9738827|NCT00106119|Active Comparator|Liothyronine and Levothyroxine|Hypothyroid patients treatment with Levothyroxine and Liothyronine in 2 crossover, randomized phases
9738828|NCT00106184|Experimental|Adult Study Group 1|Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
9738829|NCT00106184|Experimental|Adult Study Group 2|Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
9738830|NCT00106184|Experimental|Adult Study Group 3|Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
9738831|NCT00106184|Experimental|Adult Study Group 4|Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
9738832|NCT00106184|Experimental|JDM Study Group 1|Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
9738833|NCT00106184|Experimental|JDM Study Group 2|Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
9738834|NCT00106249|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
9738835|NCT00106249|Sham Comparator|Sham rTMS|Placebo Repetitive Transcranial Magnetic Stimulation (rTMS)
9738836|NCT00106353|Experimental|1.0|
9738837|NCT00106392|Experimental|Tacrolimus|Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
9738838|NCT00106392|Placebo Comparator|Placebo|Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.
9781630|NCT01154127|Experimental|NVA237 followed by Placebo|"Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days~Period 2: Matching placebo via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
9738839|NCT00106535|Experimental|Tocilizumab 4 mg/kg + Methotrexate|Tocilizumab 4 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
9738840|NCT00106535|Experimental|Tocilizumab 8 mg/kg + Methotrexate|Tocilizumab 8 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
9738841|NCT00106535|Placebo Comparator|Placebo + Methotrexate|Placebo intravenously (IV) every 4 weeks plus methotrexate (MTX) 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
9738842|NCT00106639|Experimental|CP-690,550 15 mg BID|
9738843|NCT00106639|Experimental|CP-690,550 30 mg BID|
9738844|NCT00106639|Active Comparator|tacrolimus|
9738845|NCT00106704|Experimental|Sitagliptin|Sitagliptin 10 mg tablet daily for 54 weeks
9738846|NCT00106704|Placebo Comparator|Placebo/ Pioglitazone|Placebo tablet daily for 24 weeks followed by Pioglitazone tablet daily for 30 weeks
9738847|NCT00106938|Active Comparator|1|"CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
9738848|NCT00106938|Active Comparator|2|"CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
9738849|NCT00106964|Active Comparator|1|Standard dose (20 mcg) of Hepatitis B vaccine.
9738850|NCT00106964|Active Comparator|2|40 mcg of Hepatitis B vaccine
9738851|NCT00106964|Active Comparator|3|20 mgc of Twinrix
9738852|NCT00107042|Active Comparator|1|Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
9738853|NCT00107042|Experimental|2|Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
9738854|NCT00107120|Experimental|Escitalopram|Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks
9738855|NCT00107120|Placebo Comparator|2|Placebo once daily for up to 8 weeks
9738856|NCT00107172|Active Comparator|Arm I|Patients undergo open or thoracoscopic sublobar resection comprising either a wedge resection or anatomical segmentectomy.
9738857|NCT00107172|Experimental|Arm II|Patients undergo surgery as in arm I. Patients also undergo intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
9738858|NCT00107198|Experimental|Surgery or combination chemotherapy, with/without radiotherapy|"Patients receive doxorubicin hydrochloride 50 mg/m2 IV over 10-30 minutes and cyclophosphamide 800 mg/mg2 IV over 1 hour on day 1, vincristine sulfate 1.4 mg/m2 IV (2.8 mg maximum) over 1 minute on days 1 and 8, and prednisone 40 mg/m2/day PO or IV two or three times daily on days 1-7. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve CR after 3 courses of therapy proceed to follow-up. Patients who do not achieve a CR proceed to involved-field radiation therapy (IFRT).~IFRT: Beginning within 3 weeks after completion of combination chemotherapy, patients undergo IFRT once daily, 5 days a week for 2.8 weeks (14 treatments)."
9738859|NCT00107276|Experimental|cyclophosphamide and capecitabine|cyclophosphamide orally days 1-14 and capecitabine orally days 15-21 for 8 cycles of 21 days each
9738860|NCT00107380|Experimental|R-CHOP x 8 with I-131 Tositumomab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 cycles~Unlabeled Anti-B1 Antibody 450 mg IV Day 170 Dosimetric dose 35 mg IV Day 170~Unlabeled Anti-B1 Antibody 450 mg IV Day 177 Therapeutic dose 35 mg IV Day 177"
9781631|NCT01154127|Experimental|Placebo followed by NVA237|"Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days~Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
9781632|NCT01154140|Experimental|A|
9781633|NCT01154140|Active Comparator|B|
9781634|NCT01154153|Placebo Comparator|Placebo|"placebo during the screening phase and~placebo during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
9781635|NCT01154153|Experimental|TAA-AQ|"placebo during the screening phase and~TAA-AQ (Nasacort AQ) during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
9781636|NCT01154166|Experimental|ReQuip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
9781637|NCT01154166|Placebo Comparator|Placebo|Placebo
9835748|NCT02753413|Active Comparator|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
9738861|NCT00107536|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9738862|NCT00107575|Active Comparator|Standard treatment (ST)|Standard smoking cessation treatment (ST)
9738863|NCT00107575|Experimental|ST-BI|Standard treatment plus a brief alcohol intervention
9738864|NCT00107653|Experimental|Latino|Participants received peginterferon alfa-2a 180 microgram (mcg)/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day, which was taken orally in split doses for 48 weeks. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day (400 mg in the morning and 600 mg in the evening). Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day (600 mg in the morning and 600 mg in the evening).
9738865|NCT00107653|Experimental|Non-Latino White|Participants received peginterferon alfa-2a 180 mcg/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day which was taken orally in split doses. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day. Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day for 48 weeks.
9738866|NCT00107744|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
9738867|NCT00107744|Active Comparator|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
9738868|NCT00107744|Active Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
9738869|NCT00107783|No Intervention|Control|No treatment
9738870|NCT00107783|Experimental|Nitisinone-treated|Subjects received nitisinone 2 mg orally, once daily.
9738871|NCT00107900|Experimental|15mg BID|15mg edoxaban administered twice daily (BID)
9738872|NCT00107900|Experimental|30mg QD|30mg edoxaban administered once daily (QD)
9738873|NCT00107900|Experimental|30mg BID|30mg edoxaban administered twice daily (BID)
9738874|NCT00107900|Experimental|60mg QD|60mg edoxaban administered once daily (QD)
9738875|NCT00107900|Experimental|60mg BID|60mg edoxaban administered twice daily (BID)
9738876|NCT00107900|Experimental|120mg QD|120mg edoxaban administered once daily (QD)
9738877|NCT00107952|Experimental|Telavancin|
9738878|NCT00107952|Active Comparator|Vancomycin|
9738879|NCT00107978|Experimental|Telavancin|
9738880|NCT00107978|Active Comparator|Vancomycin|
9738881|NCT00107991|Experimental|Treatment arm|Open-label treatment with etanercept 50 mg/week subcutaneous injection
9738882|NCT00108069|Experimental|GBM (Glioblastoma multiforme)|
9738883|NCT00108069|Experimental|AG (Anaplastic glioma)|
9738884|NCT00108082|Experimental|Carvedilol CR|Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study. (In the protocol, carvedilol CR was referred to as carvedilol modified-release [MR].)
9738885|NCT00108082|Experimental|Atenolol|Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
9738886|NCT00108082|Experimental|Lisinopril|Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
9738887|NCT00108160|Active Comparator|Mupirocin Ointment [Treatment]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
9738888|NCT00108160|Placebo Comparator|Polyethylene Glycol Ointment [Placebo]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
9738889|NCT00108277|Experimental|Raise CO2|Raise CO2 - biofeedback-assisted breathing training to raise baseline pCO2
9738890|NCT00108277|Active Comparator|Lower CO2|Lower CO2 - biofeedback-assisted breathing training to lower baseline pCO2
9738891|NCT00108277|No Intervention|Waitlist|Waitlist - treatment as usual
9738892|NCT00108303||Diagnostic|A diagnostic was performed
9738893|NCT00108355|Active Comparator|Albumin (Control group)|"After LVP, patients in this group received:~Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)"
9738894|NCT00108355|Experimental|Vasoconstrictor (Study Group)|"After LVP, patients in this group received:~Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose"
9738895|NCT00108485|Active Comparator|Extended release niacin|Extended release niacin 1500-2000 mg daily versus placebo comparator
9738896|NCT00108485|Placebo Comparator|Placebo|Placebo tablets
9738897|NCT00108524|Experimental|Low Carbohydrate Ketogenic Diet|Participants receive dietary counseling over 48 weeks aimed at helping them to lower starch and sugar intake.
9738898|NCT00108524|Active Comparator|Low-Fat Diet plus Orlistat|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake, and additionally receive Orlistat taken 3 times daily.
9738899|NCT00108550|Experimental|1|Gabapentin 300 mg orally three times daily up to a maximum of 1200 mg orally three times daily for 12 weeks
9738900|NCT00108550|Sham Comparator|2|Inert placebo capsules identical in size and shape to the experimental capsules, one to three capsules taken orally three times daily for 12 weeks
9738901|NCT00108628|Experimental|Arm 1|Imagery Rehearsal Therapy
9738902|NCT00108628|Active Comparator|Arm 2|Sleep and Nightmare Management
9738903|NCT00108732|Experimental|Treatment (vaccine therapy)|"Patients receive vaccinia-PSA-TRICOM vaccine SC on day 1 and sargramostim (GM-CSF) SC on days 1-4 during weeks 1-4. Beginning in week 5, patients receive fowlpox-PSA-TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Treatment with fowlpox-PSA-TRICOM vaccine and GM-CSF repeats every 4 weeks for 3 courses (weeks 5-16). Beginning in week 17, patients receive fowlpox-PSA-TRICOM vaccine and GM-CSF as above every 12 weeks in the absence of clinical or biochemical disease progression or unacceptable toxicity.~Patients with biochemical or clinical disease progression receive androgen ablation therapy comprising oral bicalutamide once daily for 1 month and goserelin SC once every 4 weeks in addition to fowlpox-PSA-TRICOM vaccine and GM-CSF. Treatment continues in the absence of further clinical or biochemical disease progression."
9738904|NCT00108745|Experimental|Arm I (paclitaxel poliglumex)|Patients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9738905|NCT00108745|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9738906|NCT00108745|Other|Arm III (observation)|Patients receive no further anticancer treatment until evidence of disease progression.
9738907|NCT00108862|Experimental|Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of tuberculosis (TB) treatment.
9738908|NCT00108862|Active Comparator|Deferred ART|The intervention is the strategy of initiating ART after 8 to 12 weeks of TB treatment.
9738909|NCT00108953|Experimental|Sorafenib + Doxorubicin|"Sorafenib + Doxorubicin -- combination therapy: Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
9738910|NCT00108953|Active Comparator|Placebo + Doxorubicin|"Placebo + Doxorubicin -- monotherapy: Sorafenib (Nexavar, BAY43-9006) matching placebo tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
9738911|NCT00109005|Experimental|Cohort 1 - 25 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks
9738912|NCT00109005|Experimental|Cohort 2 - 5 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks
9738913|NCT00109031|Active Comparator|Palifermin 60 µg/kg for 3 days|Palifermin 60 µg/kg plus placebo to match the total volume equivalent to a 180 µg/kg dose on the 3 days prior to fractionated total body irradiation (fTBI) and palifermin 60 µg/kg on Days 0, 1 and 2 after peripheral blood progenitor cell transplantation (PBPC). Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
9738914|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -1|Palifermin 180 μg/kg on Day -1 and matched placebo on Days -2 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
9738915|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -2|Palifermin 180 μg/kg on Day -2 and placebo on Days -1 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
9738916|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -3|Palifermin 180 μg/kg on Day -3 and placebo on Days -1 and -2 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
9738917|NCT00109343|Experimental|1|Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)
9738918|NCT00109343|Experimental|2|Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)
9738919|NCT00109343|Experimental|3|Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)
9738920|NCT00109473|Experimental|Growth Hormone plus cortecosteroid|Growth Hormone (nutropin AQ 0.075 mg/kg/day subcutaneously daily)
9738921|NCT00109473|Active Comparator|Cortecosteroids alone|Cortecosteroid therapy as prescribed by the referring gastroenterologist
9738922|NCT00109577|Placebo Comparator|2|Placebo comparator, 6 placebo capsules three times a day
9738923|NCT00109577|Experimental|1|nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.
9738924|NCT00109590|Experimental|Arm A: LPV/r x 7d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and BID for 7 days postpartum, ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally twice daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 7 days postpartum, LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 7 days postpartum.
9738925|NCT00109590|Experimental|Arm B: no LPV/r|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum.
9738926|NCT00109590|Experimental|Arm C: LPV/r x 30d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum,LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 30 days postpartum.
9738927|NCT00109707|Experimental|CML-CP With Prior Imatinib Only|Imatinib-resistant / intolerant PH+ CML-CP patients
9738928|NCT00109707|Experimental|CML-AP With Prior Imatinib Onl|Imatinib-resistant / intolerant PH+ CML-AP patients
9738929|NCT00109707|Experimental|CML-CP|Imatinib-resistant / intolerant PH+ CML-CP patients
9738930|NCT00109733|Experimental|Standard dose group|0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
9738931|NCT00109733|Experimental|High dose group|0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
9738932|NCT00109772|Experimental|lenalidomide|10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.
9738933|NCT00109772|Placebo Comparator|Placebo|Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.
9738934|NCT00109837|Experimental|Induc x2, Consol, Maint|Induc 1: Allopurinol; Daunorubicin; Vincristine; Prednisone; asparaginase; Bactrim Induc 2: Allopurinol; cytarabine; Dexamethasone; filgrastim; mitoxantrone; Methotrexate; leucovorin Consol: Cyclophosphamide; cytarabine; 6-mercaptopurine; Methotrexate; filgrastim Maint:Course 1: 6-mercaptopurine; Methotrexate Course 2: Vincristine; doxorubicin; Dexamethasone Course 3: Cyclophosphamidee; thioguanine; cytarabine Course 4: 6-mercaptopurine; methotrexate
9738935|NCT00109850|Experimental|Treatment|Cetuximab+Cisplatin+Irinotecan followed by radiation therapy (RT) in Cycle 3.
9738936|NCT00109876|Experimental|Treatment (RFA therapy)|A radiofrequency electrode is placed by CT guidance into the target tumor. Patients undergo RFA directly to the tumor for up to 12 minutes to obtain an intratumoral temperature > 60° C. Patients may receive 3 RFA treatments (a total of 36 minutes) to obtain the target temperature.
9738937|NCT00109928|Experimental|PEGS Treatment|VP-16 (Etoposide) 40 mg/m2 IV Days 1-4 Methyl Prednisolone 250 mg IV Days 1-4 Cisplatin 25 mg/m2 IV Days 1-4 Gemcitabine 1,000 mg/m2 IV Day 1
9738938|NCT00109967|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 only of courses 3, 5, 7, 9, and 11. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of course 3, patients undergo reevaluation. Patients achieving a CR or an unconfirmed CR (CRu) receive 2 additional courses of treatment for a total of 5 courses. Patients achieving a PR or stable disease continue study treatment as outlined above for up to 12 courses. Patients achieving a PR or stable disease who subsequently achieve a CR or CRu between courses 3 and 10 receive 2 additional courses of treatment.
9738939|NCT00110019|Experimental|Arm I (paclitaxel, carboplatin, sorafenib tosylate)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive sorafenib tosylate PO BID (approximately every 12 hours) on days 2-19.
9738940|NCT00110019|Active Comparator|Arm II (carboplatin, paclitaxel, placebo)|Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.
9738941|NCT00110084|Experimental|Nab-paclitaxel/Gemcitabine|
9738942|NCT00110136|Experimental|St. John's Wort|Patient given one 300mg St. John's Wort tablet three times per day
9738943|NCT00110149|Experimental|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
9738944|NCT00110214|Experimental|Arm I|Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1. Patients also receive oral prednisone once daily on days 1-21.
9738945|NCT00110214|Experimental|Arm II|Patients receive docetaxel and prednisone as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
9738946|NCT00110266|Experimental|ICL670|Evaluate the safety and tolerability of deferasirox 20 mg/kg/day over one year in patients with MDS
9738947|NCT00110305|Experimental|TMC278 25 mg|Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
9738948|NCT00110305|Experimental|TMC278 75 mg|Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
9738949|NCT00110305|Experimental|TMC278 150 mg|Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
9738950|NCT00110305|Active Comparator|Efavirenz|Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
9738951|NCT00110357|Active Comparator|Group A|1-12 years old
9738952|NCT00110357|Active Comparator|Group B|13-18 years old
9738953|NCT00110396|Experimental|Rebif New Formulation Cohort|
9738954|NCT00110461|Active Comparator|1|Aripiprazole 10 mg tablet
9738955|NCT00110461|Active Comparator|2|Aripiprazole 30 mg tablet
9738956|NCT00110461|Placebo Comparator|3|Placebo
9738957|NCT00110513|Experimental|Recombinant Human Antithrombin (rhAT) Infusion|Intravenous infusion of rhAT.
9738958|NCT00110617|Experimental|Deferasirox (ICL670)|Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.
9738959|NCT00110617|Experimental|Deferoxamine (DFO) then ICL670|Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.
9738960|NCT00110812|No Intervention|No IL-2|Participants will receive no aldesleukin or HAART
9738961|NCT00110812|Experimental|IL-2 without ART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level. Some Group 2 participants may take part in additional cycles of aldesleukin if they meet certain study criteria.
9781638|NCT01154192|Experimental|PCOS group|Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
9781639|NCT01154192|Experimental|Normal group|Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
9738962|NCT00110812|Experimental|IL-2 with pericycle HAART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.
9738963|NCT00110890|No Intervention|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
9738964|NCT00110890|Other|Cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet may occur based on iPTH values.
9738965|NCT00110994|Experimental|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine|Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
9738966|NCT00110994|Active Comparator|Placebo + Dacarbazine|Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
9738967|NCT00111007|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die [twice daily]) on Study Days 2 to 19 + Paclitaxel (225 mg/m^2 iv [Intravenous]) and Carboplatin (AUC [area under the curve] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
9738968|NCT00111007|Active Comparator|Carboplatin/Paclitaxel (C/P)|Placebo, 2 tablets bid on Study Days 2-19 + Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
9738969|NCT00111228|Experimental|Continuous use of the Guardian RT|Continuous use of the Guardian RT group
9738970|NCT00111228|Experimental|Bi-weekly use of the Guardian RT (once every 2 weeks)|Bi-weekly use of the Guardian RT (once every 2 weeks) group
9738971|NCT00111228|Active Comparator|Control group. SMBG monitoring|Control group. SMBG monitoring group
9738972|NCT00111475|Experimental|Part A: Romiplostim 0.2 µg/kg|Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
9738973|NCT00111475|Experimental|Part A: Romiplostim 0.5 µg/kg|Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
9738974|NCT00111475|Experimental|Part A: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
9738975|NCT00111475|Experimental|Part A: Romiplostim 3 µg/kg|Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
9738976|NCT00111475|Experimental|Part A: Romiplostim 6 µg/kg|Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
9738977|NCT00111475|Experimental|Part A: Romiplostim 10 µg/kg|Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
9738978|NCT00111475|Placebo Comparator|Part B: Placebo|Participants received placebo subcutaneously once a week for 6 weeks.
9738979|NCT00111475|Experimental|Part B: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
9738980|NCT00111475|Experimental|Part B: Romiplostim 3.0 µg/kg|Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
9738981|NCT00111475|Experimental|Part B: Romiplostim 6.0 µg/kg|Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.
9738982|NCT00111657|Experimental|pegloticase|"All study participants received intravenous pegloticase at dose of 8 mg, administered every 21 days for a maximum of 5 doses.~There was no control group for this open label study."
9738983|NCT00111761|Experimental|Part 1: Panitumumab + IFL|Panitumumab (2.5 mg/kg once weekly for up to 48 weeks or until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan, 5-fluorouracil (5-FU)and leucovorin (IFL chemotherapy regimen)
9738984|NCT00111761|Experimental|Part 2: Panitumumab + FOLFIRI|Panitumumab (2.5 mg/kg once weekly until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan/5-FU/leucovorin chemotherapy (the FOLFIRI regimen)
9738985|NCT00111800|Placebo Comparator|Placebo|Participants received oral dose of matching placebo capsule to denagliptin (DEN) once daily in the morning, 30 minutes (min) prior to breakfast during the main phase 12-weeks treatment period. Participants who were randomized to placebo in the main phase 12-weeks treatment period received oral dose of DEN 2.5 milligram (mg) once daily in the morning, 30 min prior to breakfast during the extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of placebo to the participants.
9738986|NCT00111800|Experimental|DEN 2.5 mg|Participants received oral dose of DEN 2.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 2.5 mg to the participants.
9738987|NCT00111800|Experimental|DEN 7.5 mg|Participants received oral dose of DEN 7.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 7.5 mg to the participants.
9738988|NCT00111800|Experimental|DEN 15 mg|Participants received oral dose of DEN 15 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 15 mg to the participants.
9738989|NCT00111800|Experimental|DEN 30 mg|Participants received oral dose of DEN 30 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 30 mg to the participants.
9738990|NCT00111800|Experimental|DEN 45 mg|Participants received oral dose of DEN 45 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 45 mg to the participants.
9738991|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.7 mg/m^2|Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
9738992|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.9 mg/m^2|Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
9738993|NCT00111813|Experimental|vorinostat 300 mg + bortezomib 1.3 mg/m^2|Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
9738994|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 0.9 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
9738995|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.1 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
9738996|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.3 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
9738997|NCT00111839|Active Comparator|Pemetrexed Alone|Participants will receive pemetrexed 50 milligrams per square meter (mg/m^2) intravenous (IV) infusion every 3 weeks until disease progression (PD) or the occurrence of unacceptable toxicity.
9738998|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 800 mg per Week|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 800 milligrams (mg) IV infusion once every week. Treatment will continue until PD or the occurrence of unacceptable toxicity.
9738999|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 1600 mg IV infusion every 3 weeks. Treatment will continue until PD or the occurrence of unacceptable toxicity.
9739000|NCT00111917|Experimental|Infliximab|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
9739001|NCT00111917|Placebo Comparator|Placebo|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
9739002|NCT00112047|Active Comparator|EFV+CBV|Participants in this group received EFV 600 mg once daily + Combivir ([CBV]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla ([ATR]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
9739003|NCT00112047|Experimental|EFV+FTC+TDF|Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF [TDF]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada ([TVD] the fixed-dose combination pill containing FTC/TDF [200/300 mg] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
9739004|NCT00112112|Active Comparator|FluMist|The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
9739005|NCT00112112|Placebo Comparator|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
9739006|NCT00112125|Experimental|Optimizer System + Optimal medical treatment|Optimizer System implanted and cardiac contractility modulation therapy activated.
9739007|NCT00112125|No Intervention|Optimal medical treatment|Treatment with optimal medical therapy only.
9739008|NCT00112151|Experimental|LowT+Resistance Training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
9739009|NCT00112151|Experimental|LowT+No Resistance training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~No exercise program"
9739010|NCT00112151|Experimental|HighT+Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
9739011|NCT00112151|Experimental|HighT+No Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~No exercise program"
9739012|NCT00112151|Active Comparator|Placebo+Resistance Training|"Placebo Group applies two 2.5 gm placebo packets~1 year standard Progressive Resistance Training(PRT) program"
9739013|NCT00112151|Placebo Comparator|Placebo+No Resistance Training|"Placebo group applies two 2.5 gm placebo packets~No exercise program"
9739014|NCT00112242|Experimental|1. Melan-A ELA|500 mcg Melan-A ELA analog peptide + 1 ml Montanide ISA-51
9739015|NCT00112242|Experimental|2. Melan-A ELA + NY-ESO-1b + MAGE-A10|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51
9739016|NCT00112242|Experimental|3. Melan-A ELA + NY-ESO-1b + MAGE-A10 + CpG|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 + 2.5 mg CpG-7909/PF-3512676
9739017|NCT00112242|Experimental|4. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676"
9739018|NCT00112242|Experimental|5. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG+ IL-2|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2"
9739019|NCT00112294|Active Comparator|Cetuximab+Taxane+Carboplatin (C/T/C)|Cetuximab was administered at an initial dose (Week 1) of 400 mg/m^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
9739020|NCT00112294|Active Comparator|Taxane+Carboplatin (T/C)|A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
9739021|NCT00112359|Placebo Comparator|Placebo three times a day (TID)|
9739022|NCT00112359|Experimental|AZLI 75 mg three times a day (TID)|
9739023|NCT00112385|Active Comparator|Etanercept|Subjects randomized to Etanercept will be provided with syringes contain 50 mg and will be injected subcutaneously once a week for 52 weeks.
9739024|NCT00112385|Placebo Comparator|Placebo|Subjects will be given syringes containing placebo. Injections will be given subcutaneously, one time per week for 52 weeks.
9739025|NCT00112437|Placebo Comparator|Placebo|
9739026|NCT00112437|Experimental|Odanacatib 3 mg|
9739027|NCT00112437|Experimental|Odanacatib 10 mg|
9739028|NCT00112437|Experimental|Odanacatib 25 mg|
9739029|NCT00112437|Experimental|Odanacatib 50 mg|
9739030|NCT00112463|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
9739031|NCT00112489|Experimental|Taxol-Carbo|Paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC = 6 IV over 30 minutes every 21 days until disease progression or adverse effects prohibit further therapy
9739032|NCT00112502|Active Comparator|Arm I: TMZ|Oral Temozolomide (TMZ) 150 mg/m^2 once daily on days 1-7 and 15-21.
9739033|NCT00112502|Experimental|Arm II: TMZ + Thalidomide|Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).
9739034|NCT00112502|Experimental|Arm III: TMZ + Isotretinoin|Temozolomide as in Arm I and oral Isotretinoin 40 mg/m^2 twice daily on days 1-21.
9739035|NCT00112502|Experimental|Arm IV: TMZ + Celecoxib|Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.
9739036|NCT00112502|Experimental|Arm V: TMZ + Thalidomide + Isotretinoin|Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.
9739037|NCT00112502|Experimental|Arm VI: TMZ + Thalidomide + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.
9739038|NCT00112502|Experimental|Arm VII: TMZ + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
9739039|NCT00112502|Experimental|Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
9739040|NCT00112593|Experimental|Treatment (allogeneic hematopoietic stem cell transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD."
9739041|NCT00112671|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9739042|NCT00112723|Experimental|Treatment (alvocidib)|"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I."
9739043|NCT00112736|Experimental|Phase 1 (erlotinib & temsirolimus)|"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.~pharmacological study: Correlative studies"
9739044|NCT00112736|Experimental|Phase 2 temsirolimus MTD & erlotinib|"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.~PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.~therapeutic conventional surgery: Undergo surgical resection~laboratory biomarker analysis: Correlative studies"
9739045|NCT00112827|Experimental|Arm I|See Detailed Description
9739046|NCT00112866|Experimental|Group I (high-dose cilengitide) 2000mg|"Preoperative Treatment: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1. (High dose 2000mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity."
9739047|NCT00112866|Experimental|Group II (low-dose cilengitide) 500mg|"Preoperative Treatment: Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1. (500mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity"
9739048|NCT00112905|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
9739049|NCT00112918|Active Comparator|FOLFOX4|"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Observation only."
9739050|NCT00112918|Experimental|FOLFOX4 + Bv|"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
9739051|NCT00112918|Experimental|XELOX+Bv|"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
9739052|NCT00112957|Experimental|rV- and rF-NY-ESO-1|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10^7 PFU) on Day 1, followed by subcutaneous injections of rF-NY-ESO-1 (7.41 × 10^7 PFU) on Days 29, 57, 85, 113, 141, and 169 or until observation of treatment-related ≥ grade 3 toxicity or disease progression.
9739053|NCT00113022|Experimental|Org 24448|Blinded, active experimental compound
9739054|NCT00113022|Placebo Comparator|Placebo|Blinded placebo
9739055|NCT00113087|Active Comparator|Enalapril|Enalapril (angiotensin converting enzyme inhibitor)
9739056|NCT00113087|Placebo Comparator|Placebo|Placebo (Ora-Plus and Ora-Sweet)
9739057|NCT00113217|Experimental|Bevacizumab|10 mg/kg intravenous (IV) Day 1 of 14-day cycle.
9739058|NCT00113230|Experimental|Avastin|Capecitabine, Avastin (RHUMAB VEGF/Bevacizumab) And Radiotherapy
9739059|NCT00113269|Experimental|Alemtuzumab High-Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
9739060|NCT00113269|Active Comparator|Conventional High-Risk Patients|Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
9739061|NCT00113269|Experimental|Alemtuzumab Low- Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
9739062|NCT00113269|Active Comparator|Conventional Low-Risk Patients|Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
9739063|NCT00113295|Active Comparator|Paroxetine CR and Placebo|Eleven individuals were randomized to plaecbo augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly titrated up to a maximum of 62.5 mg/day by week 10. Individuals who did not achieve remission and were randomized into the placebo group received placebo augmentation of continued paroxetine CR at the week 10 dose level.
9739064|NCT00113295|Experimental|Quetiapine and continued paroxetine CR|Eleven individuals were randomized to quetiapine augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly tirated up to a maximum of 62.5 mg/day by week 10. Individuals who did not receive remission and were randomized to receive quetiapine started at 25 mg at bedtime for the first week, then flexibly dosed based on response and tolerability to a maximum of 200 mg BID by week 16.
9739065|NCT00113321|Experimental|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
9739066|NCT00113334|Experimental|ABT-510 (Thrombospondin)|Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.
9739067|NCT00113360|Experimental|RAD001 plus Depot Octreotide|RAD001 at 5 or 10 milligrams orally once a day plus Octreotide Depot 30 milligrams intramuscularly once every 28 days.
9739068|NCT00113373|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9739069|NCT00113425|Experimental|Laser Therapy|V-Beam laser, Candela Corp., 595 nm wavelength
9739070|NCT00113425|No Intervention|Control|Untreated
9739071|NCT00113490|Experimental|motavizumab (MEDI-524) 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
9739072|NCT00113490|Active Comparator|palivizumab 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
9739073|NCT00113516|Experimental|1|
9739074|NCT00113529|Experimental|Sunitinib + Gefitinib|"Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib"
9739075|NCT00113555|Experimental|Experimental|Open Label Study, ACT (Adjustable Continence Therapy)
9739076|NCT00113568|Experimental|XP12B (tranexamic acid tablets)|
9739077|NCT00113607|Experimental|DOXIL + trabectedin|Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
9739078|NCT00113607|Active Comparator|DOXIL|Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.
9739079|NCT00113763|Experimental|Panitumumab plus best supportive care|Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
9739080|NCT00113763|Other|Best Supportive Care|Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.
9739081|NCT00113841|Experimental|Curcumin|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
9739082|NCT00113841|Experimental|Curcumin + Bioperine|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.
9739083|NCT00113880||1|5-8 years of age, estimated to be approximately 4,000 new FluMist vaccinees per season
9739084|NCT00113880||2|9-17 years of age, estimated to be approximately 5,000 new FluMist vaccinees per season
9739085|NCT00113880||3|18-49 years of age, estimated to be approximately 6,000 new FluMist vaccinees per season.
9739086|NCT00114114|Experimental|Group 1: 0 g/day|Zoladex plus Placebo Testosterone (T) gel
9739087|NCT00114114|Experimental|Group 2: 1.25 g/day|Zoladex plus 1.25 g/day T gel
9739088|NCT00114114|Experimental|Group 3: 2.5 g/day|Zoladex plus 2.5 g/day T gel
9739089|NCT00114114|Experimental|Group 4: 5 g/day|Zoladex plus 5 g/day T gel
9739090|NCT00114114|Experimental|Group 5: 10* g/day|Zoladex plus 10* g/day T gel. *Note that the 10 g/day dose was reduced to 7.5 g/day part-way through the trial
9739091|NCT00114114|Experimental|Group 6: Placebo/Placebo (PBO/PBO)|Placebo Zoladex plus Placebo T gel (controls)
9739092|NCT00114127|Placebo Comparator|Duloxetine 60mg + Placebo for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
9739093|NCT00114127|Active Comparator|Duloxetine 120mg for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
9739094|NCT00114127|Active Comparator|Duloxetine 60mg/day for 6 Weeks|In Phase 1 all participants entered an open trial.
9739095|NCT00114140|Experimental|Temozolomide + Radiation Therapy (RT)|Daily temozolomide plus concurrent radiotherapy followed by temozolomide
9739096|NCT00114166|Active Comparator|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle until disease progression or adverse effects prohibit further therapy
9739097|NCT00114166|Active Comparator|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle until disease progression or adverse effects prohibit further therapy
9739098|NCT00114218|Experimental|Treatment (gemcitabine hydrochloride, docetaxel)|Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
9739099|NCT00114231|Experimental|Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)|"Patients undergo high-dose external beam radiotherapy once daily and receive capecitabine PO BID on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive oxaliplatin IV over 2 hours on days 1, 8, 22, and 29.~Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo local excision of the tumor. Patients with T3 disease or positive resection margins after local excision undergo radical resection of the rectum and receive additional chemotherapy and/or radiotherapy at the discretion of the physician."
9739100|NCT00114244|Experimental|Arm I (sorafenib tosylate)|Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
9739101|NCT00114244|Experimental|Arm II (sorafenib tosylate, gemcitabine hydrochloride)|Patients receive 400 mg oral sorafenib as in Arm I and 1000 mg/m2 gemcitabine IV over 100 minutes on days 1, 8, and 15.
9739102|NCT00114504|Experimental|Simvastatin group|Patients with FDG-positive plaque who received simvastatin and diet therapy
9739103|NCT00114504|No Intervention|Control group|Patients FDG-positive plaque who received diet therapy alone
9739104|NCT00114517|Active Comparator|17B-estradiol|Oral 17B-estradiol 1 mg daily
9739105|NCT00114517|Placebo Comparator|Placebo|Matched placebo oral 17B-estradiol daily
9739106|NCT00114530|Experimental|mHSCT|Myeloablative Hematopoietic Stem Cell Transplant (mHSCT) Participants will first have hematopoietic stem cells removed from their blood. They then will receive high doses of chemotherapy and radiation to eliminate their developed and presumably abnormal immune system, followed by autologous stem cell transplantation to reintroduce the purified stem cells to re-establish their immune system.
9739107|NCT00114530|Experimental|cyclophosphamide|"Cyclophosphamide (CY) Participants will receive high doses of intravenous cyclophosphamide. The dose being used in this study is about 50% higher than that commonly used by most physicians to treat many other autoimmune diseases.~Administration of 12 monthly pulses of high-dose intravenous cyclophosphamide (an initial dose of 500 mg/m^2, followed by 11 doses of 750 mg/m^2)."
9739108|NCT00114634|Experimental|Egg yolk preparation with cholesterol|Dietary cholesterol in the form of liquid egg yolk
9739109|NCT00114634|Placebo Comparator|Egg yolk preparation without cholesterol|"No dietary cholesterol supplementation (egg substitute) Papetti Foods Better 'n Eggs egg substitute"
9739110|NCT00114738|Experimental|EPOCH-R + Bortezomib|Combo chemo etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-Rituxan (R) + Bortezomib (B)
9739111|NCT00114738|Experimental|"Bortezomib window"|Bortezomib alone
9739112|NCT00114738|Active Comparator|Bortezomib maintenance|Bortezomib maintenance
9739113|NCT00114738|Other|Observation|At the beginning of part C patients are randomized to receive bortezomib maintenance or observation without bortezomib.
9739114|NCT00114777|Active Comparator|Cyclosporin A|
9739115|NCT00114777|Experimental|Belatacept Less Intensive Regimen (LI)|
9739116|NCT00114777|Experimental|Belatacept More Intensive Regimen (MI)|
9739117|NCT00114959|Experimental|Homoharringtonine + Imatinib Mesylate|Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous infusion daily on Days 1-5 of each 4 week treatment cycle, and imatinib mesylate (Gleevec) by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML.
9739118|NCT00114972|Experimental|PCI with DES|
9739119|NCT00114972|Active Comparator|CABG (coronary artery bypass graft)|Coronary Artery Bypass Graft
9739120|NCT00115037|Experimental|Phase 1 Liberal Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 5 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
9739121|NCT00115037|Experimental|Phase 1 Stringent Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 2 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
9739122|NCT00115037|Experimental|Phase 2 nalt and tele for responders|Phase 2: Naltrexone and telephone counseling for responders.
9739123|NCT00115037|Experimental|Phase 2 nalt, MM and CBI for NR|Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
9739124|NCT00115037|Placebo Comparator|Phase 2 placebo, MM and CBI for NR|Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR)
9739125|NCT00115037|Experimental|Phase 2 naltrexone for responders|Phase 2: Naltrexone and TAU for phase 1 responders.
9739126|NCT00115063|Experimental|1|"Intensive Medical Intervention including Low Calorie Liquid Diet, Weight loss medications, Group Behavioral Therapy and a Tool Box approach"
9739127|NCT00115063|Active Comparator|2|Access to Weight Loss Informational Website sponsored by the Mayo Clinic
9739128|NCT00115076|Experimental|psoriasis|moderate to severe plaque psoriasis
9739129|NCT00115297|Experimental|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
9739130|NCT00115297|Placebo Comparator|Placebo|Participants who are 2 to 3 years old received 5-mg montelukast placebo tablets and participants who are 12 months to 2 years old received 4-mg montelukast placebo granules.
9739131|NCT00115336|Active Comparator|1-Intravenous ketorolac and oral placebo|Intravenous ketorolac and oral placebo
9739132|NCT00115336|Active Comparator|2-Intravenous placebo and oral ibuprofen|Intravenous placebo and oral ibuprofen
9739133|NCT00115349|Experimental|L1/DFO|Deferoxamine (DFO) and deferiprone (L1) combination therapy
9739134|NCT00115349|Active Comparator|DFO|Deferoxamine (DFO) monotherapy
9739135|NCT00115739|Experimental|Imatinib|Patients will be treated with Imatinib (Gleevec) 400 mg two times a day for eight weeks after which radiologic imaging will be obtained to assess response. Patients who attained a complete response will be treated with four additional weeks of Imatinib. Patients who attain a partial response or stable disease will be treated until a complete response is attained, or until disease progression. All patients with progression of disease will be taken off the study. Patients continuing on the study, will undergo radiologic imaging every eight weeks following their initial response assessment. All patients will be followed until death.
9739136|NCT00115765|Active Comparator|Oxaliplatin and bevacizumab without panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.
9739137|NCT00115765|Experimental|Irinotecan and bevacizumab plus panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
9739138|NCT00115765|Active Comparator|Irinotecan and bevacizumab without panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W alone
9739139|NCT00115765|Experimental|Oxaliplatin and bevacizumab plus panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
9739140|NCT00115778|Experimental|First IVIG, then Placebo|Study participants will receive three doses of IVIG given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of placebo over 12 weeks.
9739141|NCT00115778|Experimental|First Placebo, then IVIG|Study participants will receive three doses of 0.1% albumin solution (placebo) given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of IVIG over 12 weeks.
9739142|NCT00115804|Experimental|Fluoxetine|All eligible patients were started on Fluoxetine at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
9739143|NCT00115869|No Intervention|No-intervention control|
9739144|NCT00115869|Experimental|Social influences school-based smoking prevention curriculum|
9739145|NCT00115934|Active Comparator|MBTS|Blalock-Taussig pulmonary artery shunt
9739146|NCT00115934|Active Comparator|RVPAS|Right ventricular to pulmonary artery shunt
9739147|NCT00116168|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
9739148|NCT00116168|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
9739149|NCT00116168|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
9739150|NCT00116168|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
9739151|NCT00116207|Experimental|ORAL ANTIOXIDANT|Allopurinol (300mg daily), ALA (600mg twice daily) nicotinamide (750 mg twice daily) Given orally These drugs were given together as a combination and not as individual treatment.
9739152|NCT00116207|Placebo Comparator|Placebo|Placebo administered twice daily.
9739153|NCT00116272||Etanercept-Exposed|Pregnant women with a current diagnosis of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsoA) or psoriasis (PsO) who used etanercept in the first trimester of pregnancy for any length of time.
9739154|NCT00116272||Diseased Controls|Pregnant women with a current diagnosis of RA, JRA, AS, PsA, or PsO who did not use etanercept or any tumor necrosis factor (TNF) antagonist during pregnancy.
9739155|NCT00116272||Non-Diseased Historical Comparison|Pregnant women not diagnosed with RA, JRA, AS, PsoA, or PsO who did not use etanercept or any TNF antagonist at any time in pregnancy and were not exposed to any known human teratogen during pregnancy. This cohort consists of historical controls enrolled in other pregnancy outcome studies selected to match pregnant women in the exposed cohort.
9739156|NCT00116337|Experimental|Expiratory Muscle Stimulator|Procedure/Surgery: spinal cord stimulation to restore cough
9739157|NCT00116428|Experimental|NAVISTAR® THERMOCOOL® Catheter|
9739158|NCT00116428|Active Comparator|Antiarrhythmic drug|
9739159|NCT00116558|Experimental|Early NIPPV Intervention|Participants with >80% predicted forced vital capacity (FVC).
9739160|NCT00116558|Active Comparator|Standard of Care NIPPV|Participants with 50-74% predicted forced vital capacity (FVC).
9739161|NCT00116558|Active Comparator|Standard of Care NIPPV and Nutritional Monitoring|Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.
9739162|NCT00116584|Other|heliox|heliox-driven nebulizations for children with moderate to severe bronchiolitis
9739163|NCT00116584|Other|oxygen|oxygen-driven nebulizations for children with moderate to severe bronchiolitis
9739164|NCT00116649|Experimental|Aldara 5%|Aldara® (imiquimod) cream, 5% supplied in 250 mg single-use packets.
9739165|NCT00116688|Experimental|Romiplostim|Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.
9739166|NCT00116753|Active Comparator|Degarelix 240@40/240@40 (1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9.
9739167|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9.
9739168|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,4,7,10)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10.
9739169|NCT00116779|Experimental|Degarelix 60mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.
9739170|NCT00116779|Experimental|Degarelix 80mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.
9739171|NCT00116805|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
9739172|NCT00116805|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
9739173|NCT00116831|Active Comparator|Glipizide|oral anti-diabetic medication
9739174|NCT00116831|Experimental|rosiglitazone maleate|oral anti-diabetic medication
9739175|NCT00116844|Experimental|Sequence 1: VALTREX 1 g once daily, Placebo|VALTREX 1 g once daily, Placebo
9739176|NCT00116844|Experimental|Sequence 2: Placebo, VALTREX 1 g once daily|Placebo, VALTREX 1 g once daily
9739177|NCT00116857|Active Comparator|Sertraline/omega-3 supplement|
9739178|NCT00116857|Placebo Comparator|Sertraline/corn oil|
9739179|NCT00117143|Experimental|Romiplostim|Participants will receive a maximum of 2 administrations of romiplostim by subcutaneous injection, the first on day 1 of the study and the second on day 15 or 22 depending on the participant's platelet count. Romiplostim doses to be tested were 30, 100, 300, and 500 μg.
9739180|NCT00117156|Experimental|Fludarabine and Rituximab|"Fludarabine:~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles~Rituximab:~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts > 10x10^9/L~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles."
9739181|NCT00117286|Experimental|Degarelix (60 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 60 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
9739182|NCT00117286|Experimental|Degarelix (80 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 80 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
9739183|NCT00117312|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
9739184|NCT00117312|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
9739185|NCT00117312|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
9739186|NCT00117312|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
9739187|NCT00117325|Experimental|GW685698X|GW685698X
9739188|NCT00117507|Experimental|Deferasirox|Participants received deferasirox 20mg/kg/day OD for 12 months. Deferasirox was taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets was dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
9739189|NCT00117559|Experimental|TEL-CBT|Telehealth, problem solving based treatment provided over the telephone
9739190|NCT00117559|No Intervention|Treatment as Ususal|Control group, no treatment provided
9739191|NCT00117572|Active Comparator|Induction plus chemoradiotherapy|"Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (75 mg/m2, day 1), cisplatin (75 mg/m2, day 1), and 5-fluorouracil (750 mg/m2/day, days 1-5). Total duration of 6 weeks.~Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks."
9739192|NCT00117572|Active Comparator|Chemoradiotherapy|Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks.
9739193|NCT00117585|Other|Treatment Phase 1|Stepped intervention consisting of treatment phase 1, 2 and 3. Subjects whose orthostatic hypotension is resolved after treatment phase 1 will not receive new treatments (phase 2 and 3)
9739194|NCT00117598|Experimental|A|
9739195|NCT00117598|Experimental|B|
9739196|NCT00117598|Active Comparator|C|
9739197|NCT00117637|Experimental|First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg|Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression (= first intervention period, 5.7 months [median] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months [median]) on a continuous basis.
9739198|NCT00117637|Active Comparator|First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg|Interferon (IFN) α-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months [median]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period.After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months [median]).
9739199|NCT00117676|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
9739200|NCT00117676|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
9739201|NCT00117793|Active Comparator|Arm 1|Current clinical practice
9739202|NCT00117793|Experimental|Arm 2|Novel socket system
9739203|NCT00117806|Experimental|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury
9739204|NCT00117806|Placebo Comparator|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
9739205|NCT00117845|Experimental|Denileukin Diftitox in ATL|Denileukin Diftitox in adult T-cell leukemia (ATL) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
9739206|NCT00117949|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
9739207|NCT00117949|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
9739208|NCT00117949|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
9739209|NCT00117949|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
9739210|NCT00117962|Experimental|Std Tx + Pemetrexed|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on days 1, 22, 43, and 64. Patients also undergo thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
9739211|NCT00117962|Experimental|Std Tx + Pemetrexed and Cetuximab|Patients receive pemetrexed disodium, carboplatin, and thoracic radiotherapy as in arm I. Patients also receive cetuximab IV over 2 hours on day 1 and then IV over 1 hour on days 8, 15, 22, 29, 36, and 43.
9739212|NCT00117988|Experimental|Arm I|Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease regression after completion of 8 courses may receive 2 additional courses of treatment beyond their maximal response. After completion of study treatment, patients are followed every 3 months until disease progression.
9739213|NCT00118040|Experimental|Arm I (lower dose genistein)|Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
9739214|NCT00118040|Experimental|Arm II (higher dose genistein)|Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
9739215|NCT00118040|Placebo Comparator|Arm III (placebo)|Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
9739216|NCT00118092|Experimental|Treatment (tanespimycin)|Patients receive 17-N-allylamino 17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
9739217|NCT00118131|Experimental|Docetaxel and Cisplatin|"A cycle is defined as an interval of 28 days.~Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).~Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).~Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15."
9739218|NCT00118144|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1 and 8.
9739219|NCT00118157|Experimental|Treatment (lapatinib, tamoxifen)|Patients receive lapatinib ditosylate PO daily and tamoxifen citrate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9739220|NCT00118209|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy~Cyclophosphamide 750 mg/m^2 IV on Day 1~Doxorubicin 50 mg/m^2 IV on Day 1~Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1~Prednisone 40 mg/m^2/day PO on Days 1-5~filgrastim or pegfilgrastim as defined in the protocol~Required ancillary medications is administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6."
9739221|NCT00118209|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment:~Cycle 1 Doses:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy~Doxorubicin 10 mg/m^2/day CIVI on Days 1-4~Etoposide 50 mg/m^2/day CIVI on Days 1-4~Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)~Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions)~Prednisone 60 mg/m^2 PO BID on Days 1-5~Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.~Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.~Required ancillary medications are administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6."
9739222|NCT00118248|Experimental|Treatment (chemotherapy)|Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9739223|NCT00118274|Experimental|Arm I|Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
9739224|NCT00118274|Experimental|Arm II|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
9739225|NCT00118274|Experimental|Arm III|Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
9739226|NCT00118274|Experimental|Arm IV|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
9739227|NCT00118287|Experimental|Treatment (chemotherapy, chemoprotection)|Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
9739228|NCT00118352|Experimental|Treatment (chemotherapy, TBI, transplant)|"NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 6 hours once daily on days -6, -5, and -4 OR days -5 and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.~ALLOGENEIC PBSCT: After completion of TBI, patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 12 hours on days -3 to 180 followed by a taper until day 365 in the absence of GVHD. Beginning 4-6 hours after completion of allogeneic PBSCT, patients receive mycophenolate mofetil PO every 8 hours on days 0 to 100 followed by a taper until day 156 in the absence of GVHD."
9739229|NCT00118365|Placebo Comparator|Arm II (placebo)|Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
9739230|NCT00118365|Experimental|Arm I (eflornithine and sulindac)|Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
9739231|NCT00118378|Experimental|Modafinil|Participants will take modafinil for 4 weeks.
9739232|NCT00118378|Placebo Comparator|Placebo|Participants will take placebo for 4 weeks.
9739233|NCT00118404|Experimental|1|Participants received acute phase and continuation phase cognitive therapy
9739234|NCT00118404|Placebo Comparator|2|Participants received acute phase cognitive therapy and continuation phase pill placebo
9739235|NCT00118404|Active Comparator|3|Participants received acute phase cognitive therapy and continuation phase fluoxetine
9739236|NCT00118417|Experimental|1|Participants in phase II will receive sertraline, or an equivalent medication, up to 100 mg plus a placebo pill. Participants in phase III will receive the same medication with cognitive behavioral therapy.
9739237|NCT00118417|Experimental|2|Participants in phase II will receive sertraline, or equivalent medication, up to 200 mg. Participants in phase III they will receive the same medication with flexible clonazepam augmentation.
9739238|NCT00118430|Experimental|Stepped Care|Stepped care group
9739239|NCT00118430|Active Comparator|Usual Care|Treatment as usual group
9739240|NCT00118430|No Intervention|No Treatment|Participants without depression group
9739241|NCT00118482|Experimental|fludrocortisone acetate|
9739242|NCT00118482|Placebo Comparator|Placebo|
9739243|NCT00118534|Experimental|Arm 1|Integration of smoking cessation therapy with PTSD therapy.
9739244|NCT00118534|Active Comparator|Arm 2|Per standard of care, patients are referred to a smoking cessation clinic for their smoking cessation therapy.
9739245|NCT00118716|Experimental|FSC 100/50 mcg BID|Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days
9739246|NCT00118716|Experimental|FP 100 mcg BID|Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.
9739247|NCT00118742|Experimental|CellCept + CNI (tacrolimus or cyclosporine)|
9739248|NCT00118742|Active Comparator|CellCept + sirolimus|
9739249|NCT00118755|Experimental|1|
9739250|NCT00118755|Active Comparator|2|
9739251|NCT00118898|Experimental|EFV, FTC/TDF, and placebo ABC/3TC|Participants will receive EFV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
9739252|NCT00118898|Experimental|EFV, ABC/3TC and placebo FTC/TDF|Participants will receive EFV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
9739253|NCT00118898|Experimental|RTV-boosted ATV, FTC/TDF, and placebo ABC/3TC|Participants will receive RTV-boosted ATV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
9739254|NCT00118898|Experimental|RTV-boosted ATV, ABC/3TC, and placebo FTC/TDF|Participants will receive RTV-boosted ATV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
9739255|NCT00118911|Experimental|Cognitive-Behavioral Therapy|Participants will receive cognitive-behavioral therapy following our protocol.
9739256|NCT00118911|Active Comparator|Relaxation with Educational Support|Applied relaxation plus educational support (RES).
9739257|NCT00119015|Placebo Comparator|Fluticasone propionate + Placebo|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Placebo - 10 mg po daily for 2 weeks"
9739258|NCT00119015|Active Comparator|Fluticasone propionate + Montelukast|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Montelukast - 10 mg po daily for 2 weeks"
9739259|NCT00119041|Experimental|Telemedicine CBOC|"Designated CBOC's were involved in the intervention phase where their Diabetes Mellitus (DM) patients were asked to participate in a telemedicine visit.~The Behavioral: The Diabetes Treatment Satisfaction Questionnaire given during this phase along with the Behavioral: Diabetes Empowerment Scale and the Behavioral: CBOC's undergo half-day joint-clinics via teleconference."
9739260|NCT00119041|No Intervention|Control CBOC|The CBOC's not involved in the intervention phase had their patients not be involved in the telemedicine visit, but traditional education.
9739261|NCT00119041|No Intervention|Provider Interviews|Qualitative interviews with providers
9739262|NCT00119106|Experimental|tenofovir disoproxil fumarate|Participants in the Tenofovir arm will receive daily oral tenofovir
9739263|NCT00119106|Placebo Comparator|Placebo|Participants in the Placebo are will receive daily oral placebo
9739264|NCT00119158|Placebo Comparator|placebo|Placebo cream
9739265|NCT00119158|Active Comparator|pimecrolimus cream|
9739266|NCT00119262|Experimental|Arm I (combination chemotherapy, 18 courses of bevacizumab)|See detailed description.
9739267|NCT00119262|Active Comparator|Arm II (combination chemotherapy, 22 courses of bevacizumab)|See detailed description.
9739268|NCT00119379|Experimental|uridine supplementation|NucleomaxX 36 grams TID every other day
9739269|NCT00119379|Active Comparator|Switch to Tenofovir|Switch of AZT or d4T to Tenofovir Disoproxil Fumarate
9739270|NCT00119392|Experimental|Treatment (90Y ibritumomab tiuxetan, hematopoietic transplant)|See Detailed Description
9739271|NCT00119678|Active Comparator|Abatacept + Prednisone|Double Blind Period
9739272|NCT00119678|Placebo Comparator|Placebo + Prednisone|Double Blind Period
9739273|NCT00119678|Experimental|Abatacept|Open Label
9739274|NCT00119847|Experimental|PCI+MED|Percutaneous Coronary Intervention (PCI) with angioplasty and stenting of the infarct-related artery and optimal medical therapy
9739275|NCT00119847|Experimental|MED|Optimal medical therapy alone
9739276|NCT00120250|Experimental|Eszopiclone|Subjects received 3mg eszopiclone nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of placebo, followed by another 1 week washout.
9739277|NCT00120250|Placebo Comparator|Placebo|Subjects received placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of 3mg eszopiclone, followed by another 1 week washout.
9739278|NCT00120289|Experimental|Combination Therapy|Extended release niacin plus simvastatin
9739279|NCT00120289|Active Comparator|Monotherapy|Simvastatin alone
9781640|NCT01154192|Experimental|Oligomenorrhea group|Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
9781641|NCT01154218|Experimental|1|"All subjects will receive four treatments in one of the indicated orders:~A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A"
9781642|NCT01154231||Nonacog Alfa (Genetical Recombination)|
10200892|NCT05166811|Active Comparator|75 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 75 mg/kg arm, this will be accomplished by mixing 37.5 mL of IVMg (80 mg/mL) with 2.5 mL of sterile water for a final concentration of 75 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
9781643|NCT01154283|Active Comparator|Bi-level, standard, NIPPV|Standard NIPPV with both an inspiratory and expiratory positive airway pressure.
9781644|NCT01154283|Experimental|IPAP-only, NIPPV|NIPPV with only inspiratory positive airway pressure, no expiratory positive airway pressure
10200893|NCT05166811|Active Comparator|50 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 50 mg/kg arm, this will be accomplished by mixing 25 mL of IVMg (80 mg/mL) with 15 mL of sterile water for a final concentration of 50 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
10200894|NCT05166811|Placebo Comparator|Placebo|For the placebo arm, 40 mL of 0.9% sodium chloride solution will be drawn into a polyvinylchloride container identical in appearance to the containers used for the IVMg arms. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
10200895|NCT05166720|Experimental|NIDCAP care|The training core group was formed by the project team. After a one-month clinical unified training on the best evidence of NIDCAP for the VLBW nursing professional group, the best evidence of NIDCAP was applied to the intervention group.
10200896|NCT05166720|No Intervention|routine nursing care|routine nursingPerform routine care for NICU infants according to the nursing routine of each hospital
9781645|NCT01154296|Experimental|Rapid HIV Testing w/ Counseling (Group 1)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.
9781646|NCT01154296|No Intervention|Rapid HIV Testing & Information Only (Group 2)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.
9781647|NCT01154322|Experimental|Pediatric mask|
9781648|NCT01154335|Experimental|Dose Level 1|"combination of OSI-906 and everolimus~OSI-906: 50 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
9781649|NCT01154335|Experimental|Dose Level 2|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 10mg Daily, cycle-28 days"
9781650|NCT01154335|Experimental|Dose Level 2a|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
9781651|NCT01154452|Experimental|Arm I (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
9781652|NCT01154452|Experimental|Arm II (vismodegib and gamma-secretase inhibitor RO4929097)|Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
9781653|NCT01154634|Experimental|First 5 mg, then placebo, then 16 mg, then 40 mg|period 1: AZD2516 5 mg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD2516 16 mg, period 6: washout, period 7: AZD2516 40 mg.
9781654|NCT01154634|Experimental|First 40 mg, then 16 mg, then placebo, then 5 mg|period 1: AZD2516 40 mg, period 2: washout, period 3: AZD2516 16 mg, period 4: washout, period 5: placebo, period 6: washout, period 7: AZD2516 5 mg.
9781655|NCT01154634|Experimental|First 16 mg, then 5 mg, then 40 mg, then placebo|period 1: AZD2516 16 mg, period 2: washout, period 3: AZD2516 5 mg, period 4: washout, period 5: AZD2516 40 mg, period 6: washout, period 7: placebo.
9781656|NCT01154634|Experimental|First placebo, then 40 mg, then 5 mg, then 16 mg|period 1: placebo, period 2: washout, period 3: AZD2516 40 mg, period 4: washout, period 5: AZD2516 5 mg, period 6: washout, period 7: AZD2516 16 mg
9739280|NCT00120406|Experimental|1|Zilver® PTX™ Drug Eluting Vascular Stent
9739281|NCT00120406|Active Comparator|2|Angioplasty
9739282|NCT00120523|Experimental|1|Pimecrolimus
9739283|NCT00120523|Active Comparator|2|Topical corticosteroids
9739284|NCT00120627|Experimental|Arm 1: Mantram + Usual Care|Mantram Repetition Program for PTSD delivered in this study as 6-week, 90-minute per week that targeted PTSD symptoms. It was offered as an adjunct to usual care consisting of medication and case-management.
9739285|NCT00120627|Active Comparator|Arm 2: Usual Care alone|Usual care alone is defined as receiving 6 weeks of medication and case management, as needed by each patient. No group meetings.
9739286|NCT00120874|Experimental|Group 1|Individualized Management including caregiver training and Memantine
9739287|NCT00120874|Active Comparator|Group 2|Only Memantine
9739288|NCT00121134|Experimental|Group A|Bevacizumab Alone
9739289|NCT00121134|Experimental|Group B|Bevacizumab with cyclophosphamide and methotrexate
9739290|NCT00121134|Experimental|Group C|capecitabine, 14 days on/7 days off scheduling, and bevacizumab
9739291|NCT00121134|Experimental|Group D|capecitabine 7 days on/7 days off scheduling, and bevacizumab
9739292|NCT00121173|Experimental|Low dose|"3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.~Genetic (recombinant DNA vaccine)"
9739293|NCT00121173|Experimental|Intermediate dose|3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
9739294|NCT00121173|Experimental|High dose|3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
9739295|NCT00121186|Experimental|Nonmyeloablative allogeneic stem cell transplant|Patients are given fludarabine 30 mg/m^2 on days -6 to -2 and melphalan 70 mg/m^2 on days -3 and -2, then transplanted with donor peripheral blood stem cells or harvested bone marrow stem cells on day 0. Patients are then given post-transplant immunosuppression consisting of tacrolimus 0.06 mg/kg/day on days -3 to 100 and methotrexate 5 mg/m^2 on days 1, 3, and 7.
9739296|NCT00121199|Experimental|Treatment (CHOP, rituximab, bevacizumab)|Patients receive rituximab IV, bevacizumab IV over 30-90 minutes, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1. Patients also receive oral prednisone on days 1-5. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
9739297|NCT00121225|Experimental|Arm I|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
9739298|NCT00121238|Experimental|Experimental treatment: cilengitide|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. After 3 courses, patients undergo evaluation. Patients achieving a complete prostate-specific antigen (PSA) response (i.e., PSA < 0.2 ng/mL) receive 2-3 additional courses of therapy. Patients with partial PSA response or stable disease continue treatment indefinitely in the absence of disease progression or unacceptable toxicity. Patients demonstrating disease progression by CT scan, MRI, or bone scan are removed from the study.
9739299|NCT00121251|Experimental|Sorafenib + Gemcitabine + Capecitabine|Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.
9739300|NCT00121485|Experimental|HeartMate II|Implantation of HeartMate II LVAS
9739301|NCT00121485|Active Comparator|HeartMate XVE|Implantation of HeartMate XVE LVAS
9739302|NCT00121641|Experimental|Saxagliptin 2.5 mg (A)|Metformin 500-2000 mg (as needed for rescue)
9739303|NCT00121641|Experimental|Saxagliptin 5 mg (B)|Metformin 500-2000 mg (as needed for rescue)
9739304|NCT00121641|Experimental|Saxagliptin 10 mg (C)|Metformin 500-2000 mg (as needed for rescue)
9739305|NCT00121641|Placebo Comparator|Placebo (D)|Metformin 500-2000 mg (as needed for rescue)
9739306|NCT00121641|Experimental|Open-Label Treatment Cohort (Direct Enrollees) (E)|"Saxagliptin 10 mg~Metformin 500-2000 mg (as needed for rescue)"
9739307|NCT00121667|Experimental|Saxagliptin + Metformin (A)|Pioglitazone 15-45 mg (as needed for rescue)
9739308|NCT00121667|Experimental|Saxagliptin + Metformin (B)|Pioglitazone 15-45 mg (as needed for rescue)
9739309|NCT00121667|Experimental|Saxagliptin + Metformin (C)|Pioglitazone 15-45 mg (as needed for rescue)
9739310|NCT00121667|Placebo Comparator|Placebo+ Metformin (D)|Pioglitazone 15-45 mg (as needed for rescue)
9739311|NCT00121719|Experimental|1|
9739312|NCT00121810|Experimental|1|
9739313|NCT00121810|Active Comparator|2|
9739314|NCT00121836|Experimental|1|
9739315|NCT00121992|Active Comparator|Arm A: FAC|FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
9739316|NCT00121992|Experimental|Arm B: TAC|TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
9739317|NCT00122109|Experimental|Videoteleconferencing AMT|"The experimental arm is the group condition that received the AMT treatment intervention via a videoteleconferencing modality as compared to the control condition which is the traditional face-to-face modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
9781657|NCT01154673|Experimental|Intensive HAART|"Patients in this arm will receive the following HAART regimen:~Raltegravir 400 mg BID + Maraviroc 150mg BID + emtricitabine 200mg /tenofovir 300mg QD + lopinavir 400 mg/ritonavir 100mg BID for 96 weeks"
9781658|NCT01154673|Placebo Comparator|Placebo Arm|Placebo (in place of raltegravir and maraviroc) will be added to standard HAART (Emtricitabine 200mg /tenofovir 300mg QD + Lopinavir 400 mg/ritonavir 100mg BID) for 48 weeks and then offered open label Raltegravir and Maraviroc after 48 weeks
9739318|NCT00122109|Active Comparator|Face to Face AMT|"The control arm is the group condition that received the AMT treatment intervention via a traditional face-to-face modality as compared to the experimental condition which is the videoteleconferencing modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
9739319|NCT00122135|No Intervention|Patients without Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who did not receive the VI prior to their physician clinic encounter
9739320|NCT00122135|Experimental|Patients with Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who completed the VI prior to their physician clinic encounter
9739321|NCT00122187|Experimental|Electronic Consult System|A new consult system designed to automatically send a gastroenterology consult request for patients with positive fecal occult blood testing (FOBT+) results
9739322|NCT00122187|No Intervention|Usual Care|The usual and customary procedures for addressing FOBT+ results: primary care physicians continued to be responsible for follow up of FOBT+ results.
9739323|NCT00122278|Experimental|Dexamethasone|Dexamethasone 10 mg
9739324|NCT00122278|Placebo Comparator|Placebo|Placebo Dexamethasone, 10 mg
9739325|NCT00122317|Experimental|Eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
9739326|NCT00122369|Experimental|Self-hypnotic Relaxation|A research assistant displayed defined behaviors of empathic attention and read to the patient a self-hypnotic relaxation script. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
9739327|NCT00122369|No Intervention|Standard Care|Patients received the routine standard treatment which included application of lidocaine as local anesthetic. This is not considered a unique intervention in terms of the trial. Omitting local anesthetic actually would have been an intervention deviating from routine care.
9739328|NCT00122369|Active Comparator|Empathic Attention|A research assistant displayed defined behaviors of empathic attention. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
9739329|NCT00122382|Active Comparator|ABA + MTX|abatacept 10 mg/kg intravenous (IV) + methotrexate
9739330|NCT00122382|Active Comparator|Placebo (PLA) + MTX|placebo IV + methotrexate
9739331|NCT00122447|Active Comparator|Anti-inflammatory agent|Aspirin (ASA)
9739332|NCT00122447|Active Comparator|Angiotensin receptor blocker (ARB)|Olmesartan (ARB)
9739333|NCT00122447|Active Comparator|Antioxidant|Alpha lipoic acid (ALA)
9739334|NCT00122447|Placebo Comparator|Placebo|Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day
9739335|NCT00122460|Experimental|Cetuximab Plus Chemotherapy|
9739336|NCT00122460|Active Comparator|Chemotherapy alone|
9739337|NCT00122681|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.
9739338|NCT00122681|Active Comparator|Havrix Group|Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrix™-based investigational formulation) at Months 0, 1 and 6.
9739339|NCT00122954|Experimental|Fish oil concentrate|Fish oil concentrate
9739340|NCT00122954|Placebo Comparator|Placebo oil|Placebo oil
9739341|NCT00122980|Active Comparator|1|Hydroxyurea and phlebotomy
9739342|NCT00122980|Active Comparator|2|Transfusion and chelation
9739343|NCT00123110|Experimental|1|metformin pill plus placebo injection
9739344|NCT00123110|Experimental|2|leuprolide injection plus placebo pill
9739345|NCT00123110|Placebo Comparator|3|placebo pill plus placebo injection
9739346|NCT00123123|Placebo Comparator|Placebo (Vehicle Control)|Delivered Twice a day
9739347|NCT00123123|Experimental|0.12% chlorhexidine gluconate oral rinse|Delivered twice a day
9739348|NCT00123123|Experimental|0.12% chlorhexidine oral rinse|Delivered once a day, placebo once a day
9739349|NCT00123162|Experimental|Sildenafil Citrate|A single vaginal dose of Viagra 100 mg.
9739350|NCT00123162|Placebo Comparator|Placebo|A single vaginal dose of placebo.
9739351|NCT00123409|Experimental|Telephone Disease Management|Telephone based disease management or counseling used to promote a reducution in alcohol misuse
9739352|NCT00123409|Placebo Comparator|Usual Care|Usual Care
9739353|NCT00123422|Experimental|Breathing retraining|Exercise training with computerized training program
9739354|NCT00123422|Experimental|Heliox|Exercise training with helium oxygen combination
9739355|NCT00123422|Active Comparator|Exercise|Exercise training
9739356|NCT00123474|Experimental|1|
9739357|NCT00123474|Experimental|2|
9739358|NCT00123474|Experimental|3|
9739359|NCT00123474|Experimental|4|
9739360|NCT00123487|Experimental|dasatinib Twice a Day (BID)|70 mg dasatinib twice a day (BID)
9739361|NCT00123487|Experimental|dasatinib Once a Day (QD)|140 mg dasatinib once a day (QD)
9739362|NCT00123604|Experimental|Carvedilol|Carvedilol, orally, 25 mg, twice daily for five months
9739363|NCT00123604|Active Comparator|Metoprolol|Metoprolol, orally, 200 mg, twice daily for five months.
9739364|NCT00123630|Placebo Comparator|placebo|placebo group
9739365|NCT00123630|Experimental|omalizumab|Xolair group
9739366|NCT00123643|Experimental|Rosiglitazone|
9739367|NCT00123643|Active Comparator|Glyburide|
9739368|NCT00123682|Experimental|Arm 1 - proactive, intensive counseling|Proactive outreach to counseling; multi-session counseling from California Smokers' Helpline
9739369|NCT00123682|Experimental|Arm 2 - reactive, intensive counseling|Reactive outreach to counseling; multi-session counseling from California Smokers' Helpline
9739370|NCT00123682|Experimental|Arm 3 - proactive, self-help|Proactive outreach to engage smoker in treatment; mailed self-help materials
9739371|NCT00123682|Experimental|Arm 4 - reactive, self-help|Reactive approach to engaging smoker in treatment; mailed self-help materials
9739372|NCT00123955|Experimental|1|Spironolactone
9739373|NCT00123955|Placebo Comparator|2|Placebo
9739374|NCT00124020|Experimental|Telavancin|
9739375|NCT00124020|Active Comparator|Vancomycin|
9739376|NCT00124072|Active Comparator|Simvastatin 20 mg + folic acid and B12|Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
9739377|NCT00124072|Active Comparator|Simvastatin 80 mg + folic acid and B12|Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
9739378|NCT00124072|Active Comparator|Simvastatin 20 mg + placebo|Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
9739379|NCT00124072|Active Comparator|Simvastatin 80 mg + placebo|Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
9739380|NCT00124176|Experimental|1|Nebulized levalbuterol 10mg/hr given continuously
9739381|NCT00124176|Active Comparator|2|Racemic albuterol 20mg/hr given continuously
9739382|NCT00124449|Active Comparator|1|
9739383|NCT00124449|Placebo Comparator|2|
9739384|NCT00124462|Other|Realignment to Placebo|Realigning knee brace and custom orthodic- A valgus brace, customized functional orthotic for neutral foot position and motion control footwear.
9739385|NCT00124462|Other|Placebo to Realignment|Non realigning knee brace and flat orthodic- A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
9739386|NCT00124514|Experimental|Triptorelin T1|Triptorelin Pamoate 25 μg/kg body weight
9739387|NCT00124514|Experimental|Triptorelin T2|Triptorelin Pamoate 50 μg/kg body weight
9739388|NCT00124514|Experimental|Triptorelin T3|Triptorelin Pamoate 75 μg/kg body weight T3
9739389|NCT00124514|Experimental|Triptorelin T4|Triptorelin Pamoate 100 μg/kg body weight T4
9739390|NCT00124514|Placebo Comparator|Placebo|Normal Saline
9739391|NCT00124579|Experimental|bortezomib with thalidomide and dexamethasone|bortezomib with thalidomide and dexamethasone
9739392|NCT00124618|Experimental|cetuximab/Radiation|Cetuximab (C225) and Radiation
9739393|NCT00124657|Experimental|Patients with High-Grade/Low-Grade Glioma|Patients with newly diagnosed high-grade glioma (excluding those originating in the brain stem) and unfavorable low-grade glioma who are ≥ 3 years and <26 years of age. Patients receiving enzyme-inducing anticonvulsants (EIACs) are not eligible for this study. Patients with spinal cord tumors will be eligible for the Phase I and Phase II component of this study, but they will not be taken into consideration to estimate PFS in the Phase II component of this trial because of their notoriously worse prognosis. Patients receive erlotinib hydrochloride.
9517235|NCT03308175|Experimental|modified inclined fixed anterior bite plane|"In modified inclined fixed anterior bite plane,the modification is that some indentations will be done in the acrylic part where the lower anteriors will fit such that mandible will be held in a more forward position. These indentations will be relieved lingually to overcome it's flaring effect on mandibular incisors .The inclined plane will be 60 degrees to occlusal plane.~Functional bite will be taken to position the mandible in the proper position forward.~Bite taken edge-to-edge for appliance construction. Mounting upper and lower casts on simple hinge articulator for construction of modified flat fixed anterior bite plane"
9739394|NCT00124709|Experimental|1|Pimecrolimus
9739395|NCT00124709|Active Comparator|2|Corticosteroid
9739396|NCT00124735|Experimental|Rocuronium bolus maintenance|Rocuronium bolus maintenance
9739397|NCT00124735|Experimental|Rocuronium continuous infusion maintenance|Rocuronium continuous infusion maintenance
9739398|NCT00124748|Experimental|Imatinib 400 mg|Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.
9739399|NCT00124748|Experimental|imatinib 800 mg|Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
9739400|NCT00124917|Experimental|Radiation Therapy|Radiation to tumor area as per protocol
9739401|NCT00124943|Experimental|10 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 10 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesion) or balloon angioplasty (in-stent restenosis lesions).
9739402|NCT00124943|Experimental|22 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 22 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
9739403|NCT00124943|Experimental|35 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 35 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
9739404|NCT00124943|Experimental|45 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 45 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
9739405|NCT00124982|Experimental|Open-label Abatacept (ABA)-Previous User|In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
10200897|NCT05166317||Liver Cirrhosis|All the consecutive patients of cirrhosis admitted to Intensive care unit of Hepatology department of ILBS.
9739406|NCT00124982|Experimental|Open-label ABA-Current User|In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
9739407|NCT00124982|Experimental|Long-term ABA|Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
9739408|NCT00125034|Experimental|Cetuximab Plus FOLFOX-4|
9739409|NCT00125034|Active Comparator|FOLFOX-4 Alone|
9739410|NCT00125138|Experimental|Melperone HCl - 20 mg|
9739411|NCT00125138|Experimental|Melperone HCl - 40 mg|
9739412|NCT00125138|Experimental|Melperone HCl - 60 mg|
9739413|NCT00125138|Placebo Comparator|Placebo|
9739414|NCT00125164|No Intervention|Untreated|Observational Group
9739415|NCT00125164|Experimental|40 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
9739416|NCT00125164|Experimental|80 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 80 μg/kg BID
9739417|NCT00125164|Experimental|120 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 120 μg/kg BID
9739418|NCT00125190|Experimental|rhIGF-1 QD|Subjects received subcutaneous injection (SC) injections of rhIGF-1 once a day.
9739419|NCT00125242|Experimental|Semantic Feature Analysis (SFA)|Word retrieval treatment for aphasia.
9739420|NCT00125242|No Intervention|Participants for Stimuli Development|Non-brain-injured participants provided data for development of treatment stimuli.
9739421|NCT00125359|Experimental|1|All eligible patients will receive continuous daily oral erlotinib 150mg with daily bexarotene oral capsules 400mg.
9739422|NCT00125372|Experimental|Erlotinib and Bexarotene|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.
9739423|NCT00125515|Placebo Comparator|Placebo|Placebo plus oral naltrexone
9739424|NCT00125515|Active Comparator|Memantine 30 mg bid|Memantine 30 mg bid plus oral naltrexone
9739425|NCT00125515|Active Comparator|Memantine 15 mg bid|memantine 15 mg bid plus oral naltrexone
9739426|NCT00125528|Experimental|1|D-cycloserine 50mg bid/100mg bid/200 mg bid
9739427|NCT00125528|Placebo Comparator|2|placebo
9739428|NCT00125593|Placebo Comparator|Placebo|Placebo = Arm 1. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 1 patients taking 2 tablets (placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) during the first year. After the first year, all Arm 1 patients took one tablet (placebo simvastatin plus ezetimibe tablet).
9739429|NCT00125593|Active Comparator|Simvastatin 20mg plus Ezetimibe 10mg|Simvastatin 20mg plus ezetimibe 10mg = Arm 2. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 2 patients taking 2 tablets during the first year (active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet). After the first year, all Arm 2 patients took one tablet (active simvastatin 20mg plus ezetimibe 10mg tablet).
9739430|NCT00125593|Other|Simvastatin 20mg|Simvastatin 20mg alone = Arm 3. After 1 year, those initially allocated to Arm 3 were re-randomized to simvastatin 20mg plus ezetimibe 10mg (Arm 3b) daily or placebo (Arm 3a). A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with Arm 3 patients taking 2 tablets (a placebo simvastatin plus ezetimibe tablet with an active simvastatin tablet) during the first year. After the first year, all Arm 3a and Arm 3b patients took one tablet (active or placebo simvastatin plus ezetimibe tablet).
9739431|NCT00125619|Active Comparator|Arm 1: Therapist assisted|Therapist assisted locomotor training (partial body-weight supported)
9739432|NCT00125619|Experimental|Arm 2: Robot-assisted|Robot-assisted locomotor training (partial body-weight supported)
9739433|NCT00125658|Active Comparator|Control|FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
9739434|NCT00125658|Experimental|Experimental|POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
9739435|NCT00125762|Experimental|Single Arm undergoing FibroScan|Single arm active comparison of biopsy to vibration controlled elastography
9739436|NCT00125788|Experimental|investigational product|L-glutamine
9739437|NCT00125788|Placebo Comparator|placebo|maltodextrin
9739438|NCT00125853|Experimental|atenolol 25mg daily|atenolol 25mg daily
9739439|NCT00125853|Active Comparator|nebivolol 2.5mg daily|nebivolol 2.5mg daily
9739440|NCT00125931|Experimental|Pentazocine/Talwin|Talwin NX
9739441|NCT00125957|Experimental|Wellbutrin first, then Placebo|Subjects randomly assigned to the Wellbutrin then Placebo group will receive 100mg BID of Wellbutrin at the first visit following intake (Week 0).Subjects will be increased to 150mg Wellbutrin BID at Week 1 unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of bupropion qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on Wellbutrin 100mg BID. At Week 4, subjects will cross-over to placebo and will continue to take placebo until Week 8.
9739442|NCT00125957|Experimental|Placebo first, then Wellbutrin|Subjects randomly assigned to the Placebo then Wellbutrin group will receive placebo until Week 4 when they will cross-over to active drug. At Week 4, subjects will be assigned 100mg Wellbutrin BID. At Week 5, Subjects will be increased to 150mg Wellbutrin BID unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of Wellbutrin qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on bupropion 100mg BID. Subject will continue on the assigned dosage until Week 8 of study.
9739443|NCT00126113|Experimental|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
9739444|NCT00126113|Other|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
9739445|NCT00126126|Experimental|EBAR Program|Evidence Based Amputee Rehabilitation Program (rehabilitation program based on performance of the Amputee Mobility Predictor
9739446|NCT00126126|No Intervention|Wait List Control|Wait List Control Group
9739447|NCT00126191|Experimental|Low Risk|"Low-risk patients receive 3 cycles of regimen A.~Regimen A:~Rituximab (375 mg/m^2) on Days 1 and 3. Cyclophosphamide (800 mg/m^2) on days 1 and 2. Vincristine (1.4 mg/m^2) on days 1 and 10. Doxorubicin (50 mg/m^2) on Day 1. Methotrexate (3000 mg/m^2) on Day 10. Intrathecal Cytarabine (50mg) will be given on Day 1 and intrathecal methotrexate (12mg) will be given on Days 1 and 10.~Leucovorin on days 11 and 12.~Rituximab is given on Days 1 and 3 in cycle 1, and on Day 1 of all other cycles."
9739448|NCT00126191|Experimental|High Risk|"High-risk patients receive 4 alternating cycles of regimens A and B (A-B-A-B).~Regimen A (as described earlier).~Regimen B:~Rituximab (375mg/m^2) on Day 1. Ifosfamide (1500mg/m^2) on Days 1-5. Mesna (275 mg/m^2) on Days 1-5. Etoposide (60mg/mg^2) on Days 1-5. Cytarabine (2 gm/m^2) twice a day on Days 1 and 2. Intrathecal methotrexate (12mg) on Day 5, and intrathecal methotrexate (50mg) on Day 3 (also on Day 1 for patients with central nervous system involvement)."
9739449|NCT00126425|Experimental|123I-mIBG (meta-iodobenzylquanidine|Single dose
9739450|NCT00126438|Experimental|123I-mIBG (meta-iodobenzylguanidine)|Single dose
9739451|NCT00126490|Experimental|Treatment (bevacizumab, aldesleukin)|Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11. Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
9739452|NCT00126503|Experimental|Treatment (bevacizumab and sorafenib tosylate)|"Phase I: Patients receive sorafenib PO twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of sorafenib and bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive sorafenib PO once daily on days 1-28 and bevacizumab IV over 90 minutes on days 1 and 15 at the MTD in the absence of disease progression or unacceptable toxicity."
9739453|NCT00126555|Experimental|Stratum I (Gefitinib, Radiotherapy, Surgery)|"Resectable Strata: Induction Gefitinib (60 days), Surgery followed 3-6 weeks later by daily Radiotherapy 5 days a week for approximately 6-7 weeks then after 4 weeks restart Maintenance Gefitinib for up to additional 12 months post radiation.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
9739454|NCT00126555|Experimental|Stratum II (Gefitinib, Radiotherapy/Surgery)|"Unresectable Strata: Concomitant Radiation/Gefitinib and post-radiation (or post-surgery if surgery is indicated) Gefitinib. Daily Radiotherapy 5 days a week for approximately 6-7 weeks concurrent with Maintenance Gefitinib dose daily up to 12 months.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
9739455|NCT00126568|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9739456|NCT00126581|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9739457|NCT00126581|Experimental|Arm II (erlotinib hydrochloride, paclitaxel, carboplatin)|Patients receive erlotinib hydrochloride as in arm I. Patients also receive paclitaxel IV over 1-3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of treatment, patients may continue to receive erlotinib hydrochloride alone as above.
9739458|NCT00126594|Experimental|Sorafenib Tosylate|Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.
9739459|NCT00126594|Experimental|Sorafenib Tosylate, Recombinant interferon alfa-2b|Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
9739460|NCT00126737|Active Comparator|Arm 1|Group assigned to both a Weight Control Nutritional Program and home-based exercise program (Ex+WC).
9739461|NCT00126737|Active Comparator|Arm 2|Group assigned to a Weight Control Nutritional Program (WC).
9739462|NCT00126737|Active Comparator|Arm 3|Group assigned to a home-based exercise program (Ex).
9739463|NCT00126737|No Intervention|Arm 4|Usual care and non- specific health information (C).
9739464|NCT00126750|Other|Arm 1|
9739465|NCT00127036|Experimental|XELOX + Bevacizumab|Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
9739466|NCT00127036|Experimental|XELIRI + Bevacizumab|Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
9739467|NCT00127062|Experimental|Asthma|Asthma patients ranging from mild to severe
9739468|NCT00127062|Other|Healthy Non-Smokers|
9739469|NCT00127101|Experimental|Cohort 1|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
9739470|NCT00127101|Experimental|Cohort 2|Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
9739471|NCT00127101|Experimental|Cohort 2a|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter[2] daily x 7 days per week
9739472|NCT00127101|Experimental|Cohort 2b|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter[2] daily x 7 days per week
9739473|NCT00127101|Experimental|Cohort 6|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
9739474|NCT00127101|Experimental|Cohort 7|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week [150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)
9739475|NCT00127166|Experimental|Montelukast/Salmeterol|Period I - Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
9739476|NCT00127166|Experimental|Salmeterol/Montelukast|Period I - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
9739477|NCT00127192|Placebo Comparator|1|Placebo QD 12-week
9739478|NCT00127192|Experimental|2|25 mg QD 12-week
9739479|NCT00127192|Experimental|3|50 mg QD 12-week
9739480|NCT00127192|Experimental|4|100 mg QD 12-week
9739481|NCT00127192|Experimental|5|200 mg QD 12-week
9739482|NCT00127205|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.
9739483|NCT00127205|Active Comparator|Arm II|Patients receive oral clodronate once daily for 35 months.
9739484|NCT00127205|Experimental|Arm III|Patients receive oral ibandronate once daily for 35 months.
9739485|NCT00127218|Experimental|1|any statin plus niacin
9739486|NCT00127218|Placebo Comparator|2|any statin plus placebo
9739487|NCT00127231|Experimental|1 Brief Intervention|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
9739488|NCT00127231|Active Comparator|2 Standard Care Arm|
9739489|NCT00127413|Experimental|Cognitive Behavioral Therapy - Pain|Cognitive Behavioral Therapy targeting chronic pain
9739490|NCT00127413|Experimental|Cognitive Behavioral Therapy-Integrated|Integrated treatment for comorbid chronic pain and PTSD
9739491|NCT00127413|Experimental|Cognitive Processing Therapy - PTSD|Cognitive Processing Therapy for PTSD
9739492|NCT00127413|Other|Treat as Usual|Participants received care for pain and PTSD as usual from their Primary care provider
10200898|NCT05166031|Active Comparator|bOPV dose|Naïve infants to receive two doses of bOPV at 2 and 3 months of age.
10200899|NCT05166031|Active Comparator|nOPV2 dose|Naïve infants to receive two doses of nOPV2 at 2 and 3 months of age.
10200900|NCT05166031|Experimental|bOPV + nOPV2 dose|Naïve infants to receive two doses of nOPV2 and bOPV at 2 and 3 months of age.
10200901|NCT05159245|Experimental|Alectinib|For patients with a molecular tumor profile that can potentially be targeted by alectinib.
10200902|NCT05159245|Experimental|Cobimetinib|For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.
10200903|NCT05159245|Experimental|Vismodegib|For patients with a molecular tumor profile that can potentially be targeted by vismodegib.
10200904|NCT05159245|Experimental|Trastuzumab+Pertuzumab|For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.
10200905|NCT05159245|Experimental|Entrectinib|For patients with a molecular tumor profile that can potentially be targeted by entrectinib.
9739493|NCT00127439|Experimental|Robotic Assisted Locomotor Training|A robotic stepping device in concert with a body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. The robotic device provides the appropriate kinematics associated with standing and stepping.
9739494|NCT00127439|Experimental|Manually Assisted Locomotor Training|A body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. Therapists and trainers promote the appropriate kinematics associated with standing and stepping.
9739495|NCT00127530|Placebo Comparator|Placebo- sugar pill|Placebo control
9739496|NCT00127530|Experimental|Fampridine-SR|10 milligram (mg) tablet b.i.d.
9781659|NCT01154699|Experimental|Usual Care first, then Bilevel PAP|"Subjects will begin the study by continuing their usual care for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period. After a Washout Period of an additional 4 weeks of usual care, they will then start Bilevel PAP therapy for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests."
9781660|NCT01154699|Experimental|Bilevel PAP first, then Usual Care|"Subjects will begin the study by starting on Bilevel PAP for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests. After a 4 week Washout Period of usual care, they will start a Usual Care period for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period."
9781661|NCT01154751|Other|Device SUPERA Stent|SUPERA Interwoven Self-Expanding Nitinol Stent System
9781662|NCT01154816|Experimental|Arm I (neuroblastoma- measurable)|Patients with measurable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781663|NCT01154816|Experimental|Arm II (Neuroblastoma- MIBG evaluable)|Patients MIBG evaluable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781664|NCT01154816|Experimental|Arm III (rhabdomyosarcoma)|Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781665|NCT01154816|Experimental|Arm IV (osteosarcoma)|Patients with osteosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781666|NCT01154816|Experimental|Arm V (Ewing sarcoma/peripheral PNET)|Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781667|NCT01154816|Experimental|Arm VI (non-RMS soft tissue sarcoma)|Patients with non-RMS soft tissue sarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781668|NCT01154816|Experimental|Arm VII (hepatoblastoma)|Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781669|NCT01154816|Experimental|Arm VIII (malignant germ cell tumor)|Patients with malignant germ cell tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781670|NCT01154816|Experimental|Arm IX (Wilms tumor)|Patients with Wilms tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781671|NCT01154816|Experimental|Arm X (acute lymphoblastic leukemia)|Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781672|NCT01154816|Experimental|Arm XI (acute myelogenous leukemia)|Patients acute myelogenous leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781673|NCT01154816|Experimental|Arm XII (rhabdoid malignancy)|Patients with rhabdoid malignancy receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9781674|NCT01154985|Placebo Comparator|Placebo|3x placebo capsules TID
9781675|NCT01154985|Experimental|EPA-E 1800 mg/day|2x EPA-E 300 mg capsules + 1placebo capsule TID
9781676|NCT01154985|Experimental|EPA-E 2700 mg/day|3x EPA-E 300 mg capsules TID
9781677|NCT01155011|Experimental|MIPARC intervention|"Eleven Continuing Care Retirement Communities were randomized to either the MIPARC intervention or an attention-control condition. The intervention focused on increasing light to moderate PA.~The MIPARC study intervenes on four levels: individual (pedometer self monitoring, educational materials and monthly counseling calls, support), interpersonal (monthly group educational sessions and peer mentoring), environment (walking signage prompts, tailored environmental resources, step counts)and policies (review of on-site activity opportunities and walkability, recommendations for policy change and peer led advocacy)to increase the activity levels of residents.~For the first 3 months, intervention participants will engage in either a group educational session, phone counseling call, or a peer led session, on a rotating basis."
10200906|NCT05159245|Experimental|Atezolizumab|For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.
10200907|NCT05159245|Experimental|Vemurafenib|For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.
10200908|NCT05159245|Experimental|Regorafenib|For patients with a molecular tumor profile that can potentially be targeted by regorafenib.
9739497|NCT00127608|Experimental|Varicella Group|Subjects aged between 0 and 16 years of age, with clinically-diagnosed primary varicella disease.
9739498|NCT00127660|Experimental|Menu: calories=yes, value pricing=no|There were calories listed on the menu, but no value pricing was in place.
9739499|NCT00127660|Experimental|Menu: calories=yes, value pricing = yes|There were calories listed on the menu, AND value pricing was in place.
9739500|NCT00127660|Experimental|Menu: calories=no, value pricing = no|Calories were not listed on the menu, and value pricing was not in place.
9739501|NCT00127660|No Intervention|Menu: calories=no, value pricing = yes|CONTROL CONDITION: calories were not listed on the menu, and value pricing WAS in place.
9739502|NCT00127712|Experimental|Amiodarone|Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
9739503|NCT00127712|No Intervention|No treatment|Patients in this group receive no intervention
9739504|NCT00127790|Active Comparator|CBT for Insomnia (CBT-I)|Cognitive-Behavioral Therapy for Insomnia (CBT-I)consisting of 10 individual sessions and including sleep education, sleep restriction therapy, stimulus control therapy, sleep hygiene, cognitive therapy, relaxation training and relapse prevention.
9739505|NCT00127790|Active Comparator|CBT for Pain (CBT-P)|Cognitive-Behavioral Therapy for Pain (CBT-P)consisting of 10 individual sessions and including pain education, pacing strategies, problem solving, goal setting, cognitive therapy, relaxation training and relapse prevention.
9739506|NCT00127790|Experimental|CBT for Insomnia & Pain (CBT-I/P)|Combined Cognitive-Behavioral Therapy for Insomnia & Cognitive-Behavioral Therapy for Pain (CBT-I/P)over 10 individual sessions.
9739507|NCT00127790|No Intervention|Wait-List Control (WL)|Waitlist Control condition (WL) with no contact during the intervention period.
9739508|NCT00127803|Placebo Comparator|Placebo|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28, and 56, respectively.
9739509|NCT00127803|Experimental|Low dose vaccine|Participants will receive a 2 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively.
9739510|NCT00127803|Experimental|Medium dose vaccine|Participants will receive a 10 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
9739511|NCT00127803|Experimental|High dose vaccine|Participants will receive a 50 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
9739512|NCT00127842|Other|Etanercept|Open-label etanercept administered by subcutaneous injection at a dose of 50 mg/week for 24 months.
9739513|NCT00127855|Experimental|MenHibrix Formulation 1 Group|Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
9739514|NCT00127855|Experimental|MenHibrix Formulation 2 Group|Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
9739515|NCT00127855|Experimental|MenHibrix Formulation 3 Group|Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
9739516|NCT00127855|Active Comparator|Menjugate Group|Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
9739517|NCT00127855|Active Comparator|ActHIB Group|Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
9739518|NCT00127933|Experimental|HER2-NEU Positive|
9739519|NCT00127933|Experimental|HER2-NEU Negative|
9739520|NCT00128102|Experimental|Vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
9739521|NCT00128102|Placebo Comparator|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
9739522|NCT00128180|Active Comparator|Active|Methylprednisolone
9739523|NCT00128180|Placebo Comparator|Placebo|Placebo
9739524|NCT00128193|Experimental|A1-Ramping (MLSA-LAM)|5 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
9739525|NCT00128193|Experimental|C1-Target Population|80 subjects to receive: 1.0 mcg of MLSA-LAM, 1.0 mcg of MLCwA and 2TU Purified Protein Derivative/RT-23.
9739526|NCT00128193|Experimental|C-1b-Target Population (Low Dose)|80 subjects to receive: 0.1 mcg MLSA-LAM, 0.1 mcg MLCwA, 2 TU Purified Protein Derivative/RT-23.
9739527|NCT00128193|Experimental|B2-Full-Scale (MLCwA)|45 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
9739528|NCT00128193|Experimental|B1-Full-Scale (MLSA-LAM)|45 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
9739529|NCT00128193|Experimental|A2-Ramping (MLCwA)|5 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
9739530|NCT00128206|Active Comparator|B|isoniazid (INH) (900 mg orally) given twice weekly for 9 months
9739531|NCT00128206|Active Comparator|A|rifampin (600 mg orally) given daily for 4 months
10200909|NCT05159245|Experimental|Apalutamide|For patients with a molecular tumor profile that can potentially be targeted by apalutamide.
9739532|NCT00128219|Experimental|GBS III-TT|A single dose of GBS III-TT vaccine administered intramuscularly (IM) containing 50 mcg of GBS III capsular polysaccharide and 32 mcg of tetanus toxoid.
9739533|NCT00128219|Active Comparator|Td|The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.
9739534|NCT00128401|Active Comparator|D-Cycloserine|An antibiotic, d-cycloserine (DCS) was given to one group and the group is evaluated to see if the drug boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.
9739535|NCT00128401|Placebo Comparator|Placebo|Another group was given the placebo and tested for effectiveness of cognitive behavior therapy (CBT) for social anxiety.
9739536|NCT00128661|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
9739537|NCT00128661|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
9739538|NCT00128713|Active Comparator|1|Lower Dose Prophylactic Platelets
9739539|NCT00128713|Active Comparator|2|Medium Dose Prophylactic Platelets
9739540|NCT00128713|Active Comparator|3|Higher Dose Prophylactic Platelets
9517236|NCT03308162|Experimental|Group Intervention|Cognitive behavioral experiential group therapy for health behavior change
9517237|NCT03308136|Experimental|subcutaneous anesthesia group (group A)|
9517238|NCT03308136|Active Comparator|muscle anesthesia group (group B)|
9517239|NCT03308123||Health Care Professionals|Health care professionals
9739541|NCT00128830|Experimental|Etravirine + 2 antiretrovirals|
9739542|NCT00128921|Experimental|Velcade, Cohort A|Treatment: 1.3 mg/m^2
9739543|NCT00128921|Experimental|Velcade, Cohort B|Treatment: 1.0 mg/m^2
9739544|NCT00128921|Experimental|Velcade, Cohort C|Treatment: 0.7 mg/m^2
9739545|NCT00129116|Experimental|Menhibrix F1/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
9739546|NCT00129116|Experimental|Menhibrix F2/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
9739547|NCT00129116|Experimental|Menhibrix F3/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
9739548|NCT00129116|Experimental|Menitorix/Infanrix-penta Group|Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
9739549|NCT00129116|Active Comparator|Menjugate/Infanrix-hexa Group|Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
9739550|NCT00129129|Experimental|MenHibrix Group|Subjects in the Group were followed during the entire study period, from Day 0 up to study end 6 months post fourth dose vaccinationDuring Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of Menhibrix™ co-administered with Pediarix™ and Prevnar™ (at Day 0 and Months 2 and 4). During Fourth-Dose Phase (Study 102015), subjects primed with 3 doses of Menhibrix™ during the Primary Phase received one dose of Menhibrix™ and one concomitant dose of Prevnar™ at Month 10-13. During Primary Phase, Menhibrix™ was administered intramuscularly (IM) in the right upper thigh, and Pediarix™ and Prevnar™ IM in the left upper and lower thighs, respectively. During Fourth-Dose Phase, Menhibrix™ was administered by the same route and at the same site as during Primary Phase, and Prevnar™ was administered IM in the left upper thigh.
9739551|NCT00129129|Active Comparator|ActHIB Group|During Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of ActHIB™ vaccine co-administered with the Pediarix™ and Prevnar™ vaccines (at Day 0 and Months 2 and 4). Subjects in this Group were followed from Day 0 up to Month 10-13 solely. During Fourth-Dose Phase (Study 102015), these subjects were followed as subjects either in the ActHIB/MenHibrix Group or in the ActHIB/ActHIB Group, receiving then one dose of either Menhibrix™ or ActHIB™ concomitantly with one dose of Prevnar™. During Primary Phase, ActHIB™ was administered intramuscularly (IM) in the right upper thigh, and the Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively.
10200910|NCT05159245|Experimental|Abemaciclib|For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.
9739552|NCT00129129|Active Comparator|Menomune Group|Subjects in the Group were followed solely during the period of Primary Phase (Study 101858), up to Month 10. Subjects in the Group, aged 3-5 years at enrolment, received one dose of Menomune™ at Day 0. Menomune™ was administered subcutaneously in the left deltoid region.
9739553|NCT00129129|Experimental|ActHIB/Menhibrix Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase (study 101858) and received at Month 10-13 a fourth dose of Menhibrix™ and a concomitant fourth dose of Prevnar™. Menhibrix™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
9739554|NCT00129129|Experimental|ActHIB/ActHIB Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
9739555|NCT00129220|Experimental|Olanzapine|olanzapine: 5 to 20 mg per day for 6 weeks
9739556|NCT00129220|Active Comparator|Haloperidol|haloperidol: 2.5 to 10 mg per day for 6 weeks
9739557|NCT00129220|Placebo Comparator|Placebo|placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks
9739558|NCT00129246|Active Comparator|Bupropion only|The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).
9739559|NCT00129246|Experimental|Naltrexone +Bupropion|The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).
9739560|NCT00129259|Experimental|Anti-CD3 mAb Plus Diabetes Standard of Care Treatment|"Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 [Cycle 1] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)[Cycle 2]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
9739561|NCT00129259|Active Comparator|Diabetes Standard of Care Treatment|"Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
9739562|NCT00129272|Active Comparator|Bupropion (Wellbutrin-SR)|Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
9739563|NCT00129272|Placebo Comparator|Matching Placebo|Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
9739564|NCT00129285|Experimental|Low Dose Modafinil|Low Dose Modafinil 200 mg daily
9739565|NCT00129285|Experimental|High Dose Modafinil|High dose modafinil 400 mg daily
9739566|NCT00129285|Placebo Comparator|Placebo|Placebo
9739567|NCT00129311|Experimental|1|Selegiline
9739568|NCT00129311|Placebo Comparator|2|Placebo
9739569|NCT00129376|Experimental|Doxorubicin+cyclophosphamide - Docetaxel|Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).
9739570|NCT00129389|Active Comparator|Arm A: FAC|FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.
9739571|NCT00129389|Experimental|Arm B: FAC-wP|FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)
9739572|NCT00129441|Experimental|Merck L-830982|
9739573|NCT00129441|Placebo Comparator|Sugar pill|
9739574|NCT00129467|Experimental|methylphenidate + SSRI|During the 18-day blind treatment period, subjects will be prescribed methylphenidate 5-10 mg twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram. Subjects who respond to methylphenidate treatment will have the option of continuing on methylphenidate, up to 15 mg bid, and an antidepressant in the 6 week open label portion of the study.
9739575|NCT00129467|Placebo Comparator|Placebo + SSRI|During the 18-day blind treatment period, subjects will be prescribed placebo 1-2 capsules twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram.
9739576|NCT00129480|Experimental|Assistance with Pain Treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers
9739577|NCT00129480|No Intervention|Treatment as usual|Treatment as usual
9739578|NCT00129545|Experimental|WATCHMAN|Implant of WATCHMAN Left Atrial Appendage Closure Technology
9739579|NCT00129545|Active Comparator|Warfarin control|Subjects are treated with current standard of care Oral Anticoagulation Therapy with Warfarin
9739580|NCT00129545|Other|Roll-in|Implant of WATCHMAN Left Atrial Appendage Closure Technology. Up to 3 non-randomized subjects per site, these subjects were not included in the primary analysis.
9739581|NCT00129623|Experimental|1|
9739582|NCT00129623|Placebo Comparator|2|
9739583|NCT00129649|No Intervention|control group|This group received usual care and did not receive a telephone reminder
9739584|NCT00129649|Active Comparator|telephone reminder group|This group received a telephone reminder for their clinic appointment
9739585|NCT00129701|Experimental|Patients attending|Patients recruited to have a telephone consultation and then at the next appointment a face-to-face appointment
9739586|NCT00129727|Experimental|Phase II|Paclitaxel carboplatin bevacizumab
9739587|NCT00129740|Experimental|Nilotinib|400 mg orally twice daily
9739588|NCT00129766|Active Comparator|palivizumab|15 mg/kg administered intramuscularly for 5 monthly doses
9739589|NCT00129766|Experimental|motavizumab (MEDI-524)|15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses
9739590|NCT00129935|Active Comparator|Arm A: EC-T|Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
9739591|NCT00129935|Experimental|Arm B: ET-X|Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
9739592|NCT00129961|Experimental|1|Conversion to a sirolimus-based regimen
9739593|NCT00129961|Active Comparator|2|Continuation of a CNI-based regimen
9739594|NCT00129987|Experimental|Nurse group|An initial consultation of up to 45 min offered either by a practice based primary care nurse, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
9739595|NCT00129987|Experimental|Lay educator group|An initial consultation of up to 45 min offered either by a lay educator, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
9739596|NCT00130039|Experimental|cilostazol|cilostazol 100mg bid plus placebo of clopidogrel
9739597|NCT00130039|Active Comparator|Clopidogrel|clopidogrel 75mg qd and matching placebo of cilostazol
9739598|NCT00130117|Experimental|r-metHuLeptin|r-metHuLeptin administered subcutaneously.
9739599|NCT00130117|Placebo Comparator|Oral Contraceptive Pills (OCPs)|PLACEBO
9739600|NCT00130208|Experimental|Sulodexide|Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
9739601|NCT00130208|Placebo Comparator|Placebo|All patients will be on standard of care ACE or ARBs.
9739602|NCT00130247|Experimental|2EHRZ/2HR arm|Daily treatment with isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.
9739603|NCT00130247|Active Comparator|2EHRZ/4HR arm|Daily treatment with Isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.
9739604|NCT00130286|Experimental|rhGH + rosi|Recombinant human growth hormone + rosiglitazone
9739605|NCT00130286|Experimental|rhGH placebo + rosi|Placebo for recombinant human growth hormone + rosiglitazone
9739606|NCT00130286|Experimental|rhGH + rosi placebo|Recombinant human growth hormone + placebo for rosiglitazone
9739607|NCT00130286|Placebo Comparator|Double placebo|Placebo for recombinant human growth hormone + placebo for rosiglitazone
9739608|NCT00130442|Experimental|Arm 1- PI-88 plus dacarbazine|PI-88 (muparfostat) 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
9739609|NCT00130442|Active Comparator|Arm 2- dacarbazine alone|dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
9739610|NCT00130520|Experimental|open label|
9739611|NCT00130533|Experimental|Xeloda (capecitabine)|1000 mgrs/m2 twice a day, tablets, 8 cycles
9739612|NCT00130533|No Intervention|Observation|Observation. No intervention.
9739613|NCT00130637|Experimental|Daclizumab|IV daclizumab
9739614|NCT00130689|Other|Cetuximab|Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.
9739615|NCT00130728|Experimental|erlotinib HCl + bevacizumab|oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
9739616|NCT00130728|Placebo Comparator|erlotinib HCl + placebo|oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
9739617|NCT00130780|Active Comparator|A|Pre-surgical Treatment with Bevacizumab plus Chemotherapy
9739618|NCT00130780|Active Comparator|B|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
9739619|NCT00130793|Experimental|zoster vaccine live (Oka/Merck) refrigerated formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose-urea (PGSU) stabilizer (~45,000 plaque-forming units [PFU]), 1 subcutaneous 0.65-mL injection
9739620|NCT00130793|Active Comparator|zoster vaccine live (Oka/Merck) frozen formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose (PGS) stabilizer (~57,000 PFU), 1 subcutaneous 0.65-mL injection
9739621|NCT00130832|Experimental|1|RotaTeq and OPV concomitantly
9739622|NCT00130832|Experimental|2|RotaTeq and OPV on staggered schedule
9739623|NCT00130923|Experimental|Risperidone Long Acting|Risperidone Long Acting; aka Risperdal Consta; injectable form
9739624|NCT00130923|Active Comparator|Oral Risperidone|Oral Risperidone; aka Risperdal; oral form
9739625|NCT00131248|Other|Anti-reflux Medications, then Placebo (group 1)|"3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.~All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
9739626|NCT00131248|Other|Placebo, then Anti-reflux Medications|"3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.~All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
9739627|NCT00131352|Experimental|Synvisc|Participants with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL hylan G-F 20 (Synvisc).
9739628|NCT00131352|Placebo Comparator|Saline Control|Participants (control group) with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL phosphate buffered saline.
9739629|NCT00131365|Experimental|ExAblate MRgFUS|Treatment with the ExAblate 2000 system Version 4.1
9739630|NCT00131378|Experimental|Male on GH|"Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
9739631|NCT00131378|Placebo Comparator|Male on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
9739632|NCT00131378|Experimental|Female on GH|"Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
9739633|NCT00131378|Placebo Comparator|Female on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
9739634|NCT00131456|Active Comparator|Venlafaxine|Venlafaxine
9739635|NCT00131456|Placebo Comparator|Placebo|Placebo
9739636|NCT00131469|Active Comparator|Teriparatide (FORTEO)|Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
9739637|NCT00131469|Placebo Comparator|Placebo|Daily SQ placebo for 18 months
9739638|NCT00131508|Experimental|2|Glutamine
9739639|NCT00131508|Placebo Comparator|1|
9739640|NCT00131573|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
9739641|NCT00131573|Sham Comparator|2|No stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
9739642|NCT00131664|Active Comparator|Avandamet|Avandamet 2 mg / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily over 6 months
9739643|NCT00131664|Active Comparator|Avandia and Amaryl|Avandia + Amaryl 4 mg + 1 mg once daily titration up to 8 mg + 2 mg once daily over 6 months
9739644|NCT00131664|Active Comparator|Metformin|Metformin 500 mg twice daily titration up to 1000 mg twice daily over 6 months
9739645|NCT00131677|Active Comparator|active immediate|participants in this arm start study product immediately upon enrollment
9739646|NCT00131677|Placebo Comparator|placebo immediate|participants in this arm start study product immediately upon enrollment
9739647|NCT00131677|Active Comparator|active delayed|persons in this arm start study product 9 months after enrollment
9739648|NCT00131677|Placebo Comparator|placebo delayed|participants in this arm start study product nine months after enrollment
9739649|NCT00131885|Placebo Comparator|Levonorgestrel 1.5 with Placebo Herb|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a placebo herb daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
9739650|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took St. John's Wort (SJW) 900 mg a Day orally for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
9739651|NCT00131885|Active Comparator|Levonorgestrel 2.25 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules three times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 2.25 mg
9739652|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 1500 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules five times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
9739653|NCT00131911|Experimental|Group A (patients with carcinoid tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
9739654|NCT00131911|Experimental|Group B (islet cell and other neuroendocrine tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
9739655|NCT00131937|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9739656|NCT00132002|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9739657|NCT00132028|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
9739658|NCT00132041|Other|All Patients|patients with cirrhosis undergoing solitary or repetitive percutaneous RFA treatment sessions for the treatment of HCC.
9739659|NCT00132132|Experimental|Intervention|This is a long term randomized controlled study looking at the effect of a Behavioral program on BMI in a population 10-20years old with a BMI greater than or equal to 85%. The intervention is a Behavioral education program which meets monthly for 4 hour session and includes exercise, education, empowerment and incentives. Both groups are referred to a dietician. The primary outcome is change in BMI and the secondary outcome is improvement in fasting metabolic parameters (lipid panel, insulin, glucose).
9739660|NCT00132132|No Intervention|Standard of Care/Control|Education on physical activity and nutrition in a primary care office setting
9739661|NCT00132301|Active Comparator|Arm 1: Docetaxel and Prednisone|Chemotherapy after radical prostatectomy
9739662|NCT00132301|No Intervention|Arm 2: Standard of care|Standard of care
9739663|NCT00132314|Experimental|Arm 1|long-acting injectable risperidone
9739664|NCT00132314|Active Comparator|Arm 2|oral antipsychotic medication
9739665|NCT00132678|Experimental|001|Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
9739666|NCT00132678|Placebo Comparator|002|Placebo Matching placebo intramuscular (IM) injection every 2 weeks
9739667|NCT00132691|Active Comparator|1|Immunosuppressant medication implant
9739668|NCT00132691|Active Comparator|2|Systemic corticosteroids with immunosuppressant drugs as needed
9739669|NCT00132730|Experimental|MK-0873 2.5 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
9739670|NCT00132730|Experimental|MK-0873 1.25 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
9739671|NCT00132730|Experimental|MK-0873 0.75 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
9739672|NCT00132730|Placebo Comparator|Placebo|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)
9739673|NCT00132730|Experimental|MK-0873 2.5 mg + Usual Care|Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
9739674|NCT00132730|Active Comparator|Usual Care|Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
9739675|NCT00132769|Experimental|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
9739676|NCT00132769|Placebo Comparator|Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
9739677|NCT00132808|Experimental|Zoledronic Acid 2x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
9739678|NCT00132808|Experimental|Zoledronic Acid 1x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
9739679|NCT00132808|Placebo Comparator|Placebo|Placebo given at randomization and Month 12
9739680|NCT00132964|Active Comparator|Immobilizaton device|Below Knee walking cast
9739681|NCT00132964|Experimental|Immobilization device|Removable ankle brace
9739682|NCT00133575|Experimental|Group E: ACAM3000 MVA 10^7 ID|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intradermal route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
9739683|NCT00133575|Experimental|Group F: ACAM3000 MVA 10^8 IM|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
9739684|NCT00133575|Experimental|Group D: ACAM3000 MVA 10^8 SC|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via subcutaneous route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
9739685|NCT00133575|Experimental|Group B: ACAM3000 MVA 10^7 IM|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
9517240|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
9739686|NCT00133575|Experimental|Group A: ACAM3000 MVA 10^6 ID|10 subjects to receive ACAM3000 MVA dose 10^6 tissue culture infectious dose 50 (TCID50) via intradermal (ID) route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
9739687|NCT00133575|Experimental|Group C: ACAM3000 MVA 10^7 SC|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via subcutaneous (SC) route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
9739688|NCT00133705|Experimental|Mifepristone|Mifepristone 5 MG capsule taken once daily by mouth
9739689|NCT00133705|Placebo Comparator|Inert capsule|Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth
9739690|NCT00133809|Experimental|Islet Transplant|All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
9739691|NCT00133952|Experimental|Ruboxistaurin|32 mg taken orally daily for up to 48 months
9739692|NCT00133952|Placebo Comparator|Placebo|Taken orally daily for up to 48 months
9739693|NCT00133978|Experimental|Glutamine|Glutamine supplementation
9739694|NCT00133978|Experimental|Antioxidants|Antioxidant supplementation
9739695|NCT00133978|Experimental|Glutamine + Antioxidants|Glutamine and antioxidant supplementation
9739696|NCT00133978|Placebo Comparator|Placebo|Non-isonitrogenic, iso-caloric placebo solution
9739697|NCT00133991|Experimental|R-CVP + HiCy|Protocol intervention consists of two fifteen-day cycles of cyclophosphamide (Cy), vincristine (V), prednisone (P), rituximab (R), with filgrastim support. CNS intervention consists of three days of cytarabine and hydrocortisone and one day of methotrexate (with leucovorin support) for each cycle. After those two cycles, rituximab and high-dose cyclophosphamide (HiCy) will be given.
9739698|NCT00134004|Experimental|Mini-haplo Transplant|Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
9739699|NCT00134017|Experimental|Bone marrow transplant|Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis
9739700|NCT00134043|Experimental|Arm I|Patients receive oral suberoylanilide hydroxamic acid (SAHA) twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are then evaluated for disease response. Patients achieving a complete response receive an additional 2 courses of SAHA. Patients achieving stable disease or a partial response receive 4 additional courses of SAHA.After completion of study treatment, patients are followed within 4 weeks.
9739701|NCT00134056|Active Comparator|Arm I: placebo|Patients receive docetaxel and prednisone as in arm I. Patients also receive oral placebo once daily on days 1-21. Treatment repeat every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral placebo treatment for up to 52 weeks.
9739702|NCT00134056|Experimental|Arm II: atrasentan hydrochloride|Patients receive docetaxel IV over 1 hour on day 1. Patients also receive oral atrasentan and oral prednisone once daily on days 1-21. Treatment repeats every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral atrasentan treatment for up to 52 weeks.
9739703|NCT00134082|Experimental|Immunotherapy|All participants received two days of rituximab, then four days of high-dose cyclophosphamide followed by filgrastim. Participants then received six doses of KGEL vaccine over 24 weeks interspersed with four additional doses of rituximab.
9739704|NCT00134381|Active Comparator|active drug|bilateral comparison of green tea constituent
9739705|NCT00134381|Placebo Comparator|placebo|bilateral comparison of placebo vehicle
9739706|NCT00134563|Experimental|Teriflunomide 7 mg|Teriflunomide 7 mg once daily for 108 weeks
9739707|NCT00134563|Experimental|Teriflunomide 14 mg|Teriflunomide 14 mg once daily for 108 weeks
9739708|NCT00134563|Placebo Comparator|Placebo|Placebo (for teriflunomide) once daily for 108 weeks
9517241|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
9739709|NCT00134719|Experimental|MenHibrix Group|Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
9739710|NCT00134719|Active Comparator|ActHIB + Meningitec Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
9739711|NCT00134719|Active Comparator|ActHIB/PedvaxHIB Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.
9739712|NCT00134784|Experimental|Assess [123I]B-CIT SPECT imaging|To assess[123I]B-CIT SPECT imaging in early Parkinson's disease subjects on placebo compared to early verses later Levodopa. Subjects on Levodopa 150mg/day, Levodopa 300 mg/day, and Levodopa 600 mg/day will be assessed.
9739713|NCT00134901|Experimental|Memantine|Memantine
9739714|NCT00134901|Placebo Comparator|Placebo|Placebo
9781678|NCT01155011|Active Comparator|Health Education Control|The control group received an active health education intervention. The education curriculum will involve both lectures and mailed materials. The lectures were delivered to match the MIPARC intervention schedule. Sessions included information on general health and healthy aging. Physical activity was not discussed in these sessions but participants received information on the benefits of PA. Control participants also received health check phone calls to match the individual attention paid to participants in the MIPARC intervention sites.
9781679|NCT01155024|Other|Traditional Socket First, then DM Socket|Initial fitting of a traditional diagnostic prosthetic socket in first intervention period and initial fitting of a direct manufactured prosthetic socket in the second intervention period
9781680|NCT01155024|Other|DM Socket First, then Traditional Socket|Initial fitting of a direct manufactured prosthetic socket in first intervention period and initial fitting of a traditional diagnostic prosthetic socket in the second intervention period
9739715|NCT00135226|Active Comparator|Aspirin + Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.
9739716|NCT00135226|Active Comparator|Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.
9739717|NCT00135226|Active Comparator|Placebo Aspirin + Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.
9739718|NCT00135226|Active Comparator|Placebo Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.
9739719|NCT00135330|Experimental|Exenatide Arm|
9739720|NCT00135330|Experimental|Exenatide plus Rosiglitazone Arm|
9739721|NCT00135330|Experimental|Rosiglitazone Arm|
9739722|NCT00135356|Active Comparator|Switch arm|
9739723|NCT00135356|Active Comparator|Control Arm|
9739724|NCT00135694|Experimental|Immunosuppression Withdrawal|Subjects may randomize to this group at 12 to 24 months after transplantation. This is followed by tapered withdrawal of calcineurin inhibitor-based immunosuppression therapy over the course of 1 year.
9739725|NCT00135694|Active Comparator|Immunosuppression Maintenance|Liver transplant, followed by maintenance doses of continuous calcineurin inhibitor-based immunosuppression therapy.
9739726|NCT00135707|Experimental|Dietary Supplement/Vitamins|1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.
9739727|NCT00135707|Placebo Comparator|Placebo for Vitamin C and Vitamin E|Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.
9739728|NCT00135798|Experimental|LADR Treatment, Genotypes 1,4,6|Subjects randomized to low accelerating dose regimen (LADR) treatment
9739729|NCT00135798|No Intervention|Standard care|Subjects randomized to Standard Care group, Genotypes 1,4,6
9739730|NCT00135798|Experimental|LADR treatment, Genotypes 2,3|Subjects randomized to low accelerating dose regimen (LADR) treatment.
9739731|NCT00136084|Experimental|HDAC (High-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for HDAC.
9739732|NCT00136084|Experimental|LDAC (Low-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for LDAC.
9739733|NCT00136214||Interferon Treated Group|Group treated with PEG-Interferon and ribavirin and undergoing MR brain and neuropsychiatric tests
9739734|NCT00136214||Non-treated cohort control|Group undergoing MR brain and neuropsychiatric tests
9517242|NCT03308110|Other|Relative Bioavailability Cohort|Relative Bioavailability cohort
9739735|NCT00136318|Active Comparator|Escitalopram|After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
9739736|NCT00136318|Placebo Comparator|Placebo|After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
9739737|NCT00136357|Experimental|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
9739738|NCT00136357|No Intervention|Delayed Intervention|Comparison group not receiving intervention until after the initial intervention was completed.
9739739|NCT00136604|Experimental|ACAC GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccines at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
9739740|NCT00136604|Experimental|ACHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9739741|NCT00136604|Experimental|HibACPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9739742|NCT00136604|Experimental|HibHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
9739743|NCT00136604|Experimental|CC GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix + Meningitec vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
9739744|NCT00136695|Experimental|anastrozole|anastrozole
9739745|NCT00136695|Placebo Comparator|placebo|placebo
9739746|NCT00136760|Experimental|1|Contingent reinforcement plus bupropion
9739747|NCT00136760|Experimental|2|Contingent reinforcement plus placebo
9739748|NCT00136760|Experimental|3|Non-contingent reinforcement plus bupropion
9739749|NCT00136760|Placebo Comparator|4|Non-contingent reinforcement plus placebo
9739750|NCT00136812|No Intervention|enhanced usual care control|NRT during hospitalization with brief advice to stay quit once discharged
9517243|NCT03308084|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
9739751|NCT00136812|Experimental|stage-tailored intervention|NRT during hospitalization with brief advice to stay quit once discharged plus a computer-delivered stage-tailored smoking cessation intervention with manual and counseling plus 10-weeks of nicotine patch available post-hospitalization
9739752|NCT00136838|Experimental|Neutral Cue first, then Active Cue|"Each participant receives two consecutive interventions.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue."
10200911|NCT05159245|Experimental|Selpercatinib|For patients with a molecular tumor profile that can potentially be targeted by selpercatinib.
9739753|NCT00136838|Experimental|Active Cue first, then Neutral Cue|"Each participant receives two consecutive interventions.~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue"
9739754|NCT00136916|Experimental|Inhaled Insulin|Inhalable short-acting insulin
9739755|NCT00136916|Active Comparator|Subcutaneous insulin|
9739756|NCT00136955|Experimental|irinitecan/cisplatin|experimental arm consists of patients who receive irinotecan/cisplatin
9739757|NCT00137046|Active Comparator|Subcutaneous Insulin|
9739758|NCT00137046|Experimental|Inhaled Insulin|
9739759|NCT00137111|Other|1|
9739760|NCT00137111|Other|2|
9739761|NCT00137267|Experimental|Arm 1|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
9739762|NCT00137267|Active Comparator|Arm 2|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
9739763|NCT00137280|Experimental|Collaborative Chronic Illness Care Model|Collaborative Chronic Illness Care Model: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
9739764|NCT00137280|No Intervention|Usual Care|Usual Care
9739765|NCT00137423|Experimental|SU011248 (sunitinib)|Single-arm study
9517244|NCT03308084|Placebo Comparator|IV dexamethasone|Standard systemic (IV) dexamethasone only
9517245|NCT03308071|Experimental|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
9739766|NCT00137436|Experimental|A|SU011248 in combination with docetaxel and prednisone
9739767|NCT00137449|Experimental|A|
10200912|NCT05149534|Experimental|Active TMS/WET|Active repetitive transcranial magnetic stimulation completed prior to written exposure therapy
10200913|NCT05149534|Sham Comparator|Sham TMS/WET|Sham repetitive transcranial magnetic stimulation completed prior to written exposure therapy
10200914|NCT05149365|Experimental|Sitagliptin Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will receive Sitagliptin combined with Standard prophylaxis regimen for GVHD of Alternative Donor HSCT.
10200915|NCT05149365|Active Comparator|Standard Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will only receive Standard prophylaxis regimen for GVHD of Alternative Donor HSCT
10200916|NCT05147324|Experimental|"MyPlan - Individualized Eating Pattern"|All youth enrolled in the study will receive the 6-month MyPlan behavioral intervention. Youth will be paired with a dietitian to individualize the eating plan and receive support in setting and refining action plans focused on adhering to the five eating behavior goals that define the eating plan.
10200917|NCT05146388|No Intervention|Pre-Implementation - Usual Care|In pre-implementation phase, patient e-Rxs will be generated by the EHR in the usual fashion.
9739768|NCT00137631|Experimental|Many Men, Many Voices (3MV) Intervention|Receive 6-session intervention immediately after baseline assessment and randomization
9739769|NCT00137631|No Intervention|Wait list comparison|Receive intervention after 6-month delay (wait list control group)
9739770|NCT00137839|Experimental|Erlotinib|Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.
9739771|NCT00137969|Experimental|Rituximab 1000 mg + prednisone|Participants will receive rituximab 1000 mg intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
9739772|NCT00137969|Placebo Comparator|Placebo + prednisone|Participants will receive placebo intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
9739773|NCT00138034|Active Comparator|Percutaneous coronary intervention (PCI)|Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months
9739774|NCT00138034|Other|Dual antiplatelet therapy|Aspirin and clopidogrel for at least 6 months
9739775|NCT00138125|Experimental|Arm I|see intervention description for details
9739776|NCT00138203|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9739777|NCT00138294|Experimental|Intervention Cities|Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.
9517246|NCT03308071|No Intervention|Usual care|These patients will be enrolled in the study and usual care will be provided.
9739778|NCT00138294|Active Comparator|Comparison Cities|Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites will received their influenza vaccines (live attenuated or inactivated influenza vaccines) by the local healthcare providers.
9739779|NCT00138424|Experimental|Cidofovir|32 subjects will be randomized to 1 of 3 possible cohorts. Cohort I will receive dose 0.25 mg/kg; Cohort II will receive 0.5 mg/kg, Cohort III will receive 1.0 mg/kg. Maximum tolerated dose is to be determined.
9739780|NCT00138424|Placebo Comparator|Placebo|16 subjects to receive placebo.
9739781|NCT00138645|Experimental|MicroDiet|Participants randomized to the MicroDiet group (1200 kcal/day) will be instructed by a Registered Dietitian to consume (one shake and 3 cookies; 240 kcal) for two meals each day for Months 1 through 3. They will be provided with meal plans for the meal that they do not replace with MicroDiet. During Months 4 through 6, participants in the MicroDiet group will be instructed to replace one meal per day with MD (the energy content of the meal plan will still be 1200 kcal/day). Participants will also be encouraged to eat or drink MD for snacks. The rest of the diet will consist of healthy foods, as outlined above. To help participants adhere to the MicroDiet regimen, they will meet with a registered dietitian for one hour at Week 0 and 30 minutes at Weeks 2 and 4, and every month thereafter.
9739782|NCT00138645|Active Comparator|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet. The Healthy Diet will consist of the same foods that are used in the meal plans for the MicroDiet group. The Healthy Diet group will be instructed not to use meal replacements such as shakes (e.g., Slim Fast®), nutrition bars (e.g., Balance Bar®), or portion-controlled meals (e.g., Healthy Choice entrees).
9739783|NCT00138671|Active Comparator|Subcutaneous Insulin|
9739784|NCT00138671|Experimental|Inhaled Insulin|
9739785|NCT00139399|Active Comparator|Saphenous vein|Saphenous vein aortocoronary bypass graft
9739786|NCT00139399|Experimental|Radial artery|Radial artery aortocoronary bypass graft
9739787|NCT00139477|Experimental|Diet/Exercise only, then Diet/Exercise plus Metformin|Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).
9739788|NCT00139477|Active Comparator|Diet/Exercise plus Metformin, then Diet/Exercise only|Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).
9739789|NCT00139659|Experimental|Inhaled Insulin|
9739790|NCT00139659|Active Comparator|Subcutaneous Insulin|
9739791|NCT00139776|Active Comparator|Celecoxib - Continuous use|
9739792|NCT00139776|Active Comparator|Celecoxib - Intermittent use|
9739793|NCT00139997|Experimental|LED phototherapy device|Litebook treatment devices: LED phototherapy device, used for 30 min before 8 am
9739794|NCT00139997|Placebo Comparator|Inactivated Negative Ion Generator|Equivalent exposure to inactivated negative ion generator
9739795|NCT00140140|Experimental|Part 1: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.
9739796|NCT00140140|Experimental|Part 2: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
9739797|NCT00140140|Experimental|Part 2: 90 mg ABI-007 + 20 mg vinorelbine|Weekly intravenous infusion of 90 mg/m^2 ABI-007, followed by an infusion of 20 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
9739798|NCT00140205|Experimental|Fed state or fasting state|"1-day fed studies with administration of r-metHuLeptin at three different doses (0.01 mg/kg, 0.1 mg/kg, 0.3 mg/kg). All subjects participated in 3 studies in the fed condition (Part A) and 3 separate 72-hour fasting studies.~Intervention administered was-r-metreleptin in 3 different doses"
9739799|NCT00140231|Active Comparator|Metreleptin|r-metHuLeptin self-administered subcutaneously
9739800|NCT00140231|Placebo Comparator|Placebo|Placebo, administered in same method as active arm.
9739801|NCT00140244|Active Comparator|r-MetHuLeptin|r-MetHuLeptin SubQ once daily
9739802|NCT00140244|Placebo Comparator|Placebo|SubQ once daily
9739803|NCT00140413|Experimental|Treatment Group 1: Receiving GH Treatment|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with growth deceleration were assigned to the GH treatment group in accordance with standard of care. Subjects with normal growth were randomized to treatment or to control (no intervention). The intervention was Nutropin AQ. The starting dose was calculated as 0.3 mg/kg/wk and subsequently modified based on observed length/height velocity and serum IGF-I levels.
9739804|NCT00140413|No Intervention|Treatment Group 2: Control|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with normal growth were randomized to treatment or to control. The control group received no intervention; however, control subjects were switched (crossed over) to the GH replacement group if, during the course of the study, they met criteria for growth deceleration.
9739805|NCT00140426|Placebo Comparator|placebo|double blind study of risperidone for anorexia nervosa. this is the subject group that receives placebo.
9739806|NCT00140426|Active Comparator|risperidone|Study is double blind, placebo controlled. This is the subject group on active medication
9739807|NCT00140556|Experimental|ChemoRadiotherapy|Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva
9739808|NCT00140621|Experimental|Agalsidase Beta|Agalsidase beta 1 milligram per kilogram (mg/kg) intravenously once every 2 weeks up to 156 weeks.
9739809|NCT00140842||Obese girls|The inclusion criteria will be girls 12-18 years of age. According to the Centers for Disease Control and Prevention, the definition of obesity is a BMI higher than the 95th percentile for age and sex, and that of overweight is a BMI between the 85th and 95th percentiles. Cases will be defined as having a body mass index (BMI) greater than the 95th percentile for age according to the 2000 Centers for Disease Control and Prevention growth charts.
9739810|NCT00140842||Normal-weight girls|
9739811|NCT00140855|Experimental|ipilimumab|Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.
9739812|NCT00141037|Active Comparator|Steroid-Based Immunosuppression|Subjects will receive prednisone immunosuppression (10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40kg and 1.5 mg/kg/day in subjects weighing >40 kg) and proceed with a prednisone taper according to the trial's protocol.
9739813|NCT00141037|Experimental|Steroid-Free Immunosuppression|Subjects will receive extended daclizumab induction until the sixth month post-transplant (2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11 and months 4, 5, and 6).
9739814|NCT00141102|Experimental|A|
9739815|NCT00141102|Active Comparator|B|
9739816|NCT00141115|Experimental|Levetiracetam|Levetiracetam 1500 mg BID
9739817|NCT00141219|Experimental|1|
9739818|NCT00141219|Placebo Comparator|2|
9739819|NCT00141271|Active Comparator|20-40mg BID arm|
9739820|NCT00141271|Active Comparator|60-80mg bid arm|
9739821|NCT00141271|Placebo Comparator|Placebo|
9739822|NCT00141297|Experimental|PD-0332991|
9739823|NCT00141453|Experimental|1|Olmesartan medoxomil tablets 10mg to 40 mg
9739824|NCT00141453|Placebo Comparator|2|Matching placebo tablets
9781681|NCT01155050|Active Comparator|Tele-health Home Monitoring|Participants will use the tele-health monitoring equipment to measure daily weight.
9739825|NCT00141518|Experimental|Duodopa Naïve|Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
9739826|NCT00141518|Experimental|Duodopa Non-naïve < 2 Years|Duodopa non-naïve participants treated with Duodopa for < 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
9739827|NCT00141518|Experimental|Duodopa Non-naïve ≥ 2 years|Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
9739828|NCT00141726|Experimental|etanercept treatment|Etanercept for lung injury
9739829|NCT00141739|Experimental|GVHD prophylaxis|GVHD prophylaxis with etanercept
9739830|NCT00141765|Experimental|Myeloablative Chemotherapy with Stem Cell Rescue|Myeloablative Chemotherapy, followed by stem cell rescue
9739831|NCT00141778|Placebo Comparator|Placebo|matched placebo pills daily beginning 4-7 days before surgery and continuing through discharge
9739832|NCT00141778|Experimental|Ramipril|Ramipril daily (2.5mg, increased to 5mg) beginning 4 to 7 days before surgery and continuing through discharge
9739833|NCT00141778|Experimental|Spironolactone|Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge
9739834|NCT00141921|Experimental|Etanercept|Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
9739835|NCT00142116|Experimental|Thalidomide and Rituximab|"Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later."
9739836|NCT00142168|Experimental|CC-5103 (Lenalidomide) and Rituximab|Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
9739837|NCT00142298|Experimental|telbivudine|telbivudine 600 mg p.o. daily for 104 weeks.
9739838|NCT00142415|Experimental|Cohort 1, 30 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 30 mCi/m^2 of 177-Lu.
9739839|NCT00142415|Experimental|Cohort 2, 40 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 40 mCi/m^2 of 177-Lu.
9739840|NCT00142415|Experimental|Cohort 3, 50 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 50 mCi/m^2 of 177-Lu.
9739841|NCT00142415|Experimental|Cohort 4, 60 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 60 mCi/m^2 of 177-Lu.
10200918|NCT05146388|Experimental|Post-Implementation - EHR-Based Approach|
10200919|NCT05138731||Stable angina (SA)|Typical chronic exersive angina pectoris attacks, lasting several minutes to more than 10 minutes, 3-5 minutes in most cases, generally not more than 30 minutes. The pain disappeared after rest or taking nitrates, and the pain degree, frequency, duration, nature and inducing factors did not change in the last 1-3 months.
9739842|NCT00142415|Experimental|Cohort 5, 70 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 70 mCi/m^2 of 177-Lu.
9739843|NCT00142415|Experimental|Cohort 6, 65 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 65 mCi/m^2 of 177-Lu.
9739844|NCT00142454|Experimental|Imiquimod + NY-ESO-1|Patients applied topical imiquimod followed by vaccination with intradermal injections of the NY-ESO-1 protein.
9739845|NCT00142506|Active Comparator|1|radiotherapy with hormones, questionaire assessments
9739846|NCT00142506|Placebo Comparator|2|radiotherapy without hormones, questionaire assessments
9739847|NCT00142597|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
9739848|NCT00142597|Sham Comparator|Sham Treatment|Sham acupuncture is used.
9739849|NCT00142792|Active Comparator|A. Cyclic stim|"Preprogrammed cycles of finger and thumb flexor and extensor stimulation (and flexor stimulation if deemed necessary by the PI) repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Uses NMES device with EMG-triggered and Cyclic capabilities"
9739850|NCT00142792|Active Comparator|B. Sensory stim|"Sensory-only electrical stimulation. The stimulation will be cyclic in nature but intensity will be set to a level that can be felt by the patient but not sufficient to cause muscle contraction.~Uses NMES device with EMG-triggered and Cyclic capabilities"
9739851|NCT00142792|Active Comparator|C. EMG-Triggered|"EMG-Triggered electrical stimulation. Subjects in this group will attempt to extend their affected wrist and fingers in response to an audio cue. They will be rewarded with stimulation to cause full hand opening once they have generated EMG sufficient to reach a preset threshold level.~Uses NMES device with EMG-triggered and Cyclic capabilities"
9739852|NCT00142818|Experimental|Naltrexone plus modafinil|Nal + Mod
9739853|NCT00142818|Experimental|Naltrexone|Nal
9739854|NCT00142818|Experimental|Modafinil|Mod
9739855|NCT00142818|Placebo Comparator|Placebo|Placebo
9739856|NCT00142909|Experimental|Drug: Lofexidine|"Lofexidine: Study medication~Participants will receive daily lofexidine and the dosing will be initiated at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject."
9739857|NCT00142909|Placebo Comparator|Drug: Placebo|"Placebo pill.~Participants will receive daily placebo and will follow the same scheduled delivery as those in the intervention for 12 weeks."
9739858|NCT00142935|Experimental|Pre-Release Initiation MMT|Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
9739859|NCT00142935|Experimental|Post Release Initiation of MMT|Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
9739860|NCT00142935|Active Comparator|Standard of Care Plus|Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
9739861|NCT00143247|Experimental|Exubera® (inhaled insulin)|Open label, no comparator
9739862|NCT00143312|Experimental|1|
9739863|NCT00143390|Experimental|1|
9739864|NCT00143390|Experimental|2|
9739865|NCT00143403|Experimental|1|
9739866|NCT00143403|Active Comparator|2|
9739867|NCT00143455|Experimental|B|
9739868|NCT00143455|Experimental|A|
9739869|NCT00143507|Experimental|Ivabradine|
9739870|NCT00143507|Placebo Comparator|Placebo|
9739871|NCT00143598|Active Comparator|Active ECS|Active Elastic Compression Stockings (ECS) 30-40 mm Hg compression at the ankle.
9739872|NCT00143598|Placebo Comparator|Placebo ECS|Placebo stockings with identical appearance to Active ECS and with < 5 mm Hg compression at the ankle.
9739873|NCT00143819|Active Comparator|1|bilateral comparison
9739874|NCT00143819|Placebo Comparator|2|bilateral comparison
9739875|NCT00143845|Experimental|Immunosuppression Taper|Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).
9739876|NCT00144027|No Intervention|Control|The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
9739877|NCT00144027|Experimental|Antipsychotic adherence intervention|Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.
9739878|NCT00144170|Other|Tipranavir(TPV)/low dose ritonavir(r)|
9739879|NCT00144170|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
9739880|NCT00144300|Active Comparator|Mirapex|Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines
9739881|NCT00144300|Active Comparator|Requip|Requip tablets three times daily (TID) dosing according to manufacturer's guidelines
9739882|NCT00144391|Experimental|Transdermal Testosterone Gel|Transdermal Testosterone Gel (2 mg per pump), 2 pumps per day for 6 months
9739883|NCT00144391|Placebo Comparator|Placebo|Placebo 2 pumps per day for 6 months
9739884|NCT00144781|Active Comparator|1|0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.
9739885|NCT00144781|Active Comparator|2|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.
9739886|NCT00144781|Active Comparator|3|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
9739887|NCT00144781|Active Comparator|4|1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
9739888|NCT00144963|Experimental|VSLI|Vincristine Sulfate Liposomes Injection (VSLI)
9739889|NCT00145041|Experimental|VSLI|Single armed study; all subjects received VSLI
9739890|NCT00145145|Experimental|MAGE-3.A1 Peptide mixed with CpG 7909|Patients were vaccinated every two weeks on six occasions. On each vaccination day, the MAGE-3.A1 peptide (300 mcg) mixed with CpG 7909 (5 mg) was administered twice intradermally (10% of the dose each) and twice subcutaneously (40% of the dose each) in the arms and thighs.
9739891|NCT00145249|Active Comparator|Standard Therapy|Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
9739892|NCT00145249|Experimental|Fluconazole Low Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
9739893|NCT00145249|Experimental|Fluconazole High Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
9739894|NCT00145327|Experimental|Zoledronic Acid 6|Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
9739895|NCT00145327|Placebo Comparator|Zoledronic Acid 3 Placebo 3|Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
9739896|NCT00145327|Experimental|Placebo 3 Zoledronic Acid 3|Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.
9739897|NCT00145418|Experimental|1|Oxaliplatin + Docetaxel as first line therapy of Stage IV or IIIB unresectable non-small cell lung cancer. The primary objective of the trial is to determine the response rate by RECIST criteria to the combination of oxaliplatin and docetaxel in patients with previously untreated NSCLC.
9739898|NCT00145574|Experimental|high dose colesevelam|colesevelam HCl 3.750 g
9739899|NCT00145574|Experimental|Low dose colesevelam|Low dose colesevelam 1.875 g
9739900|NCT00145574|Placebo Comparator|placebo|placebo comparator
9781682|NCT01155050|No Intervention|Self-Directed Group|Participants will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss.
9781683|NCT01155050|Active Comparator|TrestleTree Telephone Coaching|Participants will speak to Trestletree health coaches for 15 to 60 minutes each session. During these sessions, the coaches will identify the participant's stage of change and intervene accordingly. The telephone calls will be centered on weight loss.
9781684|NCT01155050|Active Comparator|Home monitoring + telephone coach|System to track stage of change in weight loss.
9781685|NCT01155063||Main Group|Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy
9781686|NCT01155141|Experimental|No arms|There are no arms to this study. All patients receive drug (H.P. Acthar Gel)
9781687|NCT01155154|Active Comparator|clindamycin|clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
9781688|NCT01155154|Active Comparator|cepahlexin|
9781689|NCT01155154|Placebo Comparator|Placebo|
9781690|NCT01155167|Placebo Comparator|Placebo|
9781691|NCT01155167|Experimental|Topical dilator|
9781692|NCT01155180|Experimental|Leptin|We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
9781693|NCT01155180|Placebo Comparator|Placebo|We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
9781694|NCT01155193||Palivizumab|Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season.
9781695|NCT01155219|Experimental|Geltim LP®|Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
9781696|NCT01155219|Active Comparator|Xalatan®|Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
10200920|NCT05138731||Unstable angina (UA）|Including resting angina (attack at rest, the duration is usually >20 minutes), primary angina (usually the first symptoms within 1-2 months, very light physical activity can be induced, at least CCSIII level), worsening angina (angina gradually increases on the basis of relatively stable labor angina. More severe pain, longer or more frequent pain, at least grade I increase according to THE CCS classification, at least GRADE II CCSI). TNI was negative, routine electrocardiogram may have transient ST segment depression, T wave low flat or inverted.
9739901|NCT00145587|Other|1|
9739902|NCT00145600|Experimental|Unfavorable Risk, Group 2|Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
9739903|NCT00145600|Experimental|Favorable Risk|Favorable Risk arm in patients with Hodgkin's Disease (n=91).
9739904|NCT00145600|Experimental|Intermediate Risk|Intermediate Arm in patients with Hodgkins's disease (n=46).
9739905|NCT00145600|Experimental|Unfavorable Risk, Group 1|Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).
9739906|NCT00145626|Experimental|Study Participants|"Participants who meet the eligibility criteria for this study. Donor cells will be obtained using the Miltenyi Biotec CliniMACS device.~Interventions: Chemotherapy and antibodies, allogeneic stem cell transplantation."
9739907|NCT00145795|Experimental|Kaletra + Current Dual NRTI Backbone|Patients in this arm received Kaletra in addition to their current Dual NRTI Backbone.
9739908|NCT00145795|Active Comparator|Current Regimen|Patients in this study arm continued their current regimen.
9739909|NCT00145977|Experimental|Experimental|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
9739910|NCT00145977|Active Comparator|Control|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
9739911|NCT00146172|Experimental|Neratinib 40 mg|
9739912|NCT00146172|Experimental|Neratinib 80 mg|
9739913|NCT00146172|Experimental|Neratinib 120 mg|
9739914|NCT00146172|Experimental|Neratinib 180 mg|
9739915|NCT00146172|Experimental|Neratinib 240 mg|
9739916|NCT00146172|Experimental|Neratinib 320 mg|
9739917|NCT00146172|Experimental|Neratinib 400 mg|
9739918|NCT00146172|Experimental|Neratinib 320 mg MTD|
9739919|NCT00146328|Experimental|Group 1|Patients With Varying Degrees of Tipranavir Treatment Experience
9739920|NCT00146328|Experimental|Group 2|Highly Tipranavir Treatment Experienced Patients
9739921|NCT00146328|Experimental|Group 3|Tipranavir Treatment Naive Patients
9739922|NCT00146640|Experimental|MR Prednisone|Participants will receive MR prednisone at bed time and placebo matching to IR prednisone in the morning. Total duration of double blind treatment will be 12 weeks.
9739923|NCT00146640|Active Comparator|IR Prednisone|Participants will receive IR prednisone in the morning and placebo matching to MR prednisone at bed time. Total duration of double blind treatment will be 12 weeks.
9739924|NCT00146757|Experimental|Aldurazyme (rhIDU) 100 U/kg ONLY every week|Patients received Aldurazyme (recombinant human alpha-L-iduronidase (rhIDU)) once per week at a dose of 100 Units/kg (approximately 0.58 mg/kg) for up to 52 weeks - labeled dose.
9739925|NCT00146757|Experimental|Aldurazyme (rhIDU) 100-200 U/kg every week|After receiving 100 Units/kg dose of Aldurazyme (rhIDU) for the first 25 weeks, patients enrolling after January 1, 2004 were eligible to receive an increased dose of 200 Units/kg from Week 26 onwards if the patient's urinary glycosaminoglycan (uGAG) levels were >200µg/mg creatinine at Week 22.
9739926|NCT00146770|Active Comparator|Placebo/Aldurazyme|Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
9739927|NCT00146770|Active Comparator|Aldurazyme/Aldurazyme|Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.
9739928|NCT00146848|Active Comparator|DDD-40|DDD-40 for this trial is the comparator arm. Even though patients are receiving a CRT-D device, atrial support pacing in this arm will be limited as the device will not pace unless the rate falls below 40 bpm.
9739929|NCT00146848|Active Comparator|DDDR-40|DDDR-40 programming will initiate atrial support pacing if the rate falls below 40 bpm or if atrial support is needed in response to increased activity.
9739930|NCT00146848|Active Comparator|DDD-70|Atrial support pacing in this arm will be delivered when the rate falls below 70 bpm.
9739931|NCT00147017||Smokers|All subjects had a smoking history of >15 pack years
9739932|NCT00147017||Ex-smokers|Ex-smokers had ceased smoking for >6 months.
9739933|NCT00147017||Emphysema lung transplant|The emphysema subjects were all undergoing lung transplants.
9739934|NCT00147030|Active Comparator|cooled|Whole body mild induced hypothermia for 72 hours, starting by 6 hours of age, in addition to standard intensive care. After 72 hours of cooling, rewarming by a maximum of 0.5 degree C / hour to normothermia.
9739935|NCT00147030|No Intervention|non-cooled|Standard intensive care
9739936|NCT00147043|Experimental|Autologous Stem Cells|
9739937|NCT00147069||Controls|Non-smoking control subjects without lung disease
9739938|NCT00147069||Asthmatics|Non-smokers patients with asthma
9739939|NCT00147069||Non-COPD smokers|Current smokers without airways obstruction, FEV1 >80% predicted
9739940|NCT00147069||COPD smokers|Patients with COPD and cigarette smokers
9739941|NCT00147082||COPD|Patients with COPD - no intervention
9739942|NCT00147082||Smokers without COPD|Smokers without COPD - no intervention
9739943|NCT00147082||Non-smokers|Non-smokers with no history of respiratory disease - no intervention
9739944|NCT00147199|Experimental|Inhaled treprostinil|0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
9739945|NCT00147199|Placebo Comparator|Placebo|Placebo inhalation solution for use in ultrasonic nebulizer
9739946|NCT00147212|Experimental|1|ET-743
9739947|NCT00147225|Experimental|1 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~Adriamycin - Ifosfamide (AI) regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
9739948|NCT00147225|Experimental|3 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
9739949|NCT00147225|Experimental|10 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
9739950|NCT00147225|Experimental|10 mcg/kg Pre/Post Chemotherapy|"Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
9739951|NCT00147225|Experimental|5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
9739952|NCT00147225|Experimental|10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"10 mcg/kg AMG 531 + Pre/Pre/Post/Post Chemotherapy Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
9739953|NCT00147251|No Intervention|SANDS Control Group|Standard Treatment for blood pressure and cholesterol
9739954|NCT00147251|Active Comparator|SANDS Intervention Group|FDA approved drugs to treat blood pressure and cholesterol
9739955|NCT00147316|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
9739956|NCT00147446|Experimental|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
9739957|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
9739958|NCT00147498|Experimental|5 mg BID|CP 690,550 5 mg BID
9739959|NCT00147498|Experimental|15 mg BID|CP 690,550 15 mg BID
9739960|NCT00147498|Experimental|30 mg BID|Oral tablets administered at a dose of 30 mg BID for 6 weeks
9739961|NCT00147498|Placebo Comparator|Placebo|Placebo
9739962|NCT00147537|Experimental|Phase 2 (Arms A & B)|CP-751,871 + paclitaxel + carboplatin
9739963|NCT00147537|Experimental|Phase 1b|"Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin~Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib"
9739964|NCT00147745|Experimental|1|colesevelam 3.8g administered daily for 12 weeks
9739965|NCT00147745|Placebo Comparator|2|Colesevelam matching placebo for 12 weeks
9739966|NCT00147745|Active Comparator|3|open-label Insulin Glargine for 12 weeks
9739967|NCT00147823|Experimental|Vitoss with bone marrow aspirate|Addition of Vitoss to the bone marrow aspirate
9739968|NCT00147823|Active Comparator|Vitoss Alone|vitoss alone
9739969|NCT00147966|Experimental|ritxumab|all patients get treatment
9739970|NCT00148109|Active Comparator|EGFR positive|The EGFR positive group will be conducted in a 2-stage minimax trial design to determine the rate of four-month progression free survival in this patient population treated with cetuximab
9665715|NCT04933474|Experimental|Skills-based VR Therapy|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
9665716|NCT04931862|Experimental|WVE-004 (Dose A) or placebo|
9665717|NCT04931862|Experimental|WVE-004 (Dose B) or placebo|
9665718|NCT04931862|Experimental|WVE-004 (Dose C) or placebo|
9665719|NCT04931862|Experimental|WVE-004 (Dose D) or placebo|
9665720|NCT04931017|Experimental|Cohort A (metformin ER)|Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity.
9665721|NCT04931017|Active Comparator|Cohort B (metformin ER with waiting period))|Participants receive no intervention for 26 weeks, then cross-over to Cohort A.
9665722|NCT04927884|Experimental|All subjects|Sacituzumab plus chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK)
9665723|NCT04926675|Experimental|Combined intervention|Participants accessing one-to-one psychological therapy from the IAPT service will be asked if they have any money worries affecting their mental health. Suitable participants will be offered one-to-one support from a money advisor, who they will access in tandem to their therapy.
9665724|NCT04924517|Experimental|Extended Evening Fasting|Participants will eat between 8am-4pm
9665725|NCT04924517|Active Comparator|Control|Participants will eat between 8am-8pm
9665726|NCT04923139||Japanese VTE patients including Ca-VTE patients|Include a large number of adult VTE patients (including Ca-VTE patients) prescribed rivaroxaban who visited facilities covered by the MDV database
9665727|NCT04922853|Experimental|2 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have TME operation after reevaluation and randomization.
9665728|NCT04922853|Other|4 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have two more cycles chemotherapy and TME operation after reevaluation and randomization.
9665729|NCT04922281|Active Comparator|ICM-guided Management|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
9665730|NCT04922281|Placebo Comparator|Conventional Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
9665731|NCT04921787|Active Comparator|Low Intensity|MOUD training and support through the use of educational materials.
9665732|NCT04921787|Experimental|High Intensity|MOUD training and support through the use of educational materials in addition to practice facilitation.
9665733|NCT04919980|Experimental|Treatment|MV replacement with Innovalve MR system
9665734|NCT04919018||Primary Ciliary Dyskinesia (PCD)|Subjects with a confirmed diagnosis of PCD
9665735|NCT04919018||Primary Immune Deficiency (PID)|Subjects with a confirmed diagnosis of PID
9665736|NCT04916132||Peolpe with T2DM and albuminuria|Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome.
9665737|NCT04915833|Experimental|Patients for CRC screening and diagnostic colonoscopy|Consecutive patients >45 years of age submitted for diagnostic colonoscopy
9665738|NCT04915352|Experimental|Adult dust mite allergenic rhinitis patients|Nasal Provocation Test administration (725 Dermatophagoides pteronyssinus (5.000 SBE/ml) dosage form: Lyophilisate and solvent for nasal drops, suspension dosage and frequency: 3 nasal sprays at 3 different concentrations per year: 50, 500 and 5000 SBE / ml for 3 years Duration: 36 months
9665739|NCT04914416|Placebo Comparator|Verum T1|
9665740|NCT04914416|Experimental|Verum T2|
9665741|NCT04914416|Experimental|Verum T3|
9665742|NCT04914416|Experimental|Verum T4|
9665743|NCT04914416|Experimental|Verum T5|
9665744|NCT04914416|Experimental|Verum T6|
9665745|NCT04914416|Experimental|Verum T7|
9665746|NCT04914416|Experimental|Verum T8|
9665747|NCT04914416|Experimental|Verum T9|
9665748|NCT04914416|Experimental|Verum T10|
9665749|NCT04914416|Experimental|Verum T11|
9665750|NCT04914416|Experimental|Verum T12|
9665751|NCT04914416|Experimental|Verum T13|
9665752|NCT04914416|Experimental|Verum T14|
9665753|NCT04914416|Experimental|Verum T15|
9665754|NCT04914416|Experimental|Verum T16|
9665755|NCT04914416|Placebo Comparator|Verum T17|
9665756|NCT04914182|Experimental|LASER|In the intervention group, the laser will be applied to the points of the edges of the lesion, with a distance of one centimeter between them. The laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
9665757|NCT04914182|Sham Comparator|CONTROL|In the control group, the sham laser will be applied the exact same way as the real laser, to the points of the edges of the lesion, with a distance of one centimeter between them. The sham laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
9665758|NCT04910685|Experimental|(Part 1) BLU-263 Dose 1 + BSC|Patients will receive best supportive care (BSC) and Dose 1 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
9665759|NCT04910685|Experimental|(Part 1) BLU-263 Dose 2 + BSC|Patients will receive best supportive care (BSC) and Dose 2 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
9739971|NCT00148109|Active Comparator|EGFR Negative|The EGFR negative group will help us explore the possibility of benefit of cetuximab in a patient whose tumor does not express or minimally expresses EGFR. If benefit in progression-free survival or in another surrogate such as tumor response or a molecular event is seen in this group it would provide rationale to study this group further in subsequent trials
9739972|NCT00148122|Experimental|Arm 1|Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, &15)
9739973|NCT00148317|Experimental|Treatment Arm|
9739974|NCT00148343|Experimental|ODFS|Odstock Dropped-Foot Stimulator (ODFS)
9739975|NCT00148343|Active Comparator|Standard of Care (inc. AFO)|Conventional Standard of Care (which may include a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) [Traditional Physical Therapy Treatment]
9739976|NCT00148668|Active Comparator|Arm 1|Herceptin/navelbine
9739977|NCT00148668|Active Comparator|Arm 2|Taxotere/carboplatin/herceptin
9739978|NCT00148759|Active Comparator|adult male subjects|LPV/r 800/200 mg once daily
9739979|NCT00148759|Experimental|Adult female subjects|LPV/r 800/200 mg once daily
9739980|NCT00148798|Experimental|Cetuximab plus chemotherapy|cetuximab + cisplatin + vinorelbine
9739981|NCT00148798|Active Comparator|Chemotherapy alone|cisplatin + vinorelbine alone
9739982|NCT00148941|Experimental|SB213503 lot 1 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 1 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
9739983|NCT00148941|Experimental|SB213503 lot 2 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 2 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
9739984|NCT00148941|Experimental|SB213503 lot 3 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 3 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
9739985|NCT00148941|Active Comparator|Infanrix + IPOL + M-M-R Group|Subjects aged 4 to 6 years received a dose of Infanrix and a dose of IPOL vaccines separately and a dose of M-M-R II vaccine. Infanrix was administered by deep intramuscular injection in the upper left deltoid. IPOL was administered subcutaneously in the lower right deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid.
9739986|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Boston Scientific|VITALITY 2 ICD
9739987|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Medtronic|Selected Medtronic family ICD
9739988|NCT00149214|Experimental|A: Pemetrexed Plus Doxorubicin, Followed by Docetaxel|
9739989|NCT00149214|Active Comparator|B: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel|
9739990|NCT00149227|Active Comparator|Non-ARB|'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
9739991|NCT00149227|Experimental|Valsartan|Valsartan add-on treatment
9739992|NCT00149396|Experimental|Safety and antitumor effects of NV1020|"Stage 1: Four escalating dose cohorts of NV1020 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, and 1x10^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.~Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy."
9739993|NCT00149630|Experimental|Disulfiram, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
9739994|NCT00149630|Active Comparator|Placebo, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
9739995|NCT00149643|Active Comparator|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
9739996|NCT00149643|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
9739997|NCT00149669|No Intervention|Work Plus Naltrexone Prescription|Participants were prescribed naltrexone, but were not be required to ingest it to work. Participants could work and earn money, independent of whether or not they continued to take naltrexone.
9739998|NCT00149669|Experimental|Work Plus Naltrexone Contingency|Participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose (employment-based reinforcement of naltrexone ingestion).
9739999|NCT00149734|Experimental|Ondansetron followed by placebo|Participants will take ondansetron then placebo plus an atypical antipsychotic drug
9740000|NCT00149734|Experimental|Placebo followed by Ondansetron|Participants will take placebo then ondansetron plus an atypical antipsychotic drug
9740001|NCT00149747|Experimental|Exercise training|Group based exercise training. Two weekly classes including aerobic endurance physical activity and strength and flexibility training, and up to three home-based sessions of similar composition of aerobic endurance, strength and flexibility training.
9740002|NCT00149747|Placebo Comparator|2|Attention-control of exposure to study staff. Weekly general health education classes conducted in group sessions.
9740003|NCT00149799|Experimental|Escitalopram|In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
9740004|NCT00149799|Placebo Comparator|Placebo|Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)
9740005|NCT00149825|Experimental|MED+CBTI|Escitalopram plus Cognitive Behavioral Therapy for Insomnia
9740006|NCT00149825|Active Comparator|MED+CTRL|Escitalopram plus Pseudo-desensitization Therapy for Insomnia
9740007|NCT00149838|Experimental|Active prefrontal rTMS phase1|Phase I participants receiving rTMS
9740008|NCT00149838|Placebo Comparator|Sham rTMS phase 1|Phase I participants receiving sham stimulation
9740009|NCT00149838|Experimental|rTMS extension|rTMS. Phase II participants, all of whom did not meet remission requirements after phase 1. They all receive active open label rTMS
9740010|NCT00149838|Experimental|Open label antidepressant regimen|All patients who met remission who were then transitioned to medications after the TMS trial was completed.
9740011|NCT00149890|Experimental|With Intraoperative Steroids|Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
9740012|NCT00149890|Active Comparator|Without Intraoperative Steroids|No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.
9740013|NCT00149994|Experimental|Cyclosporine A|Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; > 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.
9781697|NCT01155284|Experimental|Sitagliptin and Lansoprazole|Sitagliptin 50mg co-administered with Lansoprazole 30mg. Subjects age 11-17 years at Visit 2 will take 1 capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 capsules of each once daily
9740014|NCT00149994|Active Comparator|Tacrolimus|Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; > 6 months: range of 5-10 ng/ml is recommended.
9740015|NCT00150345|Experimental|Early treatment|Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (< 38.0 °C) for 7 days with neutrophil counts < 500/µL, or if the patient is afebrile (< 38.0 °C) for 2 days with neutrophil counts > 500/µL.
9740016|NCT00150345|Other|Deferred treatment|"Treatment with voriconazole (for dosage see early treatment arm) is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment."
9740017|NCT00150462|Experimental|CFZ 1.2 mg/m²|Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740018|NCT00150462|Experimental|CFZ 2.4 mg/m²|Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740019|NCT00150462|Experimental|CFZ 4.0 mg/m²|Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740020|NCT00150462|Experimental|CFZ 6.0 mg/m²|Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740021|NCT00150462|Experimental|CFZ 8.4 mg/m²|Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740022|NCT00150462|Experimental|CFZ 11.0 mg/m²|Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740023|NCT00150462|Experimental|CFZ 15.0 mg/m²|Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740024|NCT00150462|Experimental|CFZ 20.0 mg/m²|Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740025|NCT00150462|Experimental|CFZ 27.0 mg/m²|Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
9740026|NCT00150462|Experimental|CFZ 20/27 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
10200921|NCT05138731||Acute non-ST-segment elevation myocardial infarction （NSTEMI）|Patients with elevated troponin accompanied by one or more of the following conditions: electrocardiogram showed new ST segment depression or T wave flatness or inversion; Persistent ischemic chest pain; Echocardiography showed abnormal segmental ventricular wall activity. Abnormal coronary angiography.
10200922|NCT05138731||Acute ST-segment elevation myocardial infarction （STEMI）|Troponin was elevated, and ECG showed ST segment arcuate back elevation, accompanied by one or more of the following conditions: persistent ischemic chest pain; Echocardiography showed segmental abnormal ventricular wall activity; Abnormal coronary angiography.
9740027|NCT00150462|Experimental|CFZ 20/27 mg/m² + DEX|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
9740028|NCT00150592|Experimental|SPD503 (Guanfacine HCl)|
9740029|NCT00150592|Placebo Comparator|Placebo|
9740030|NCT00150618|Experimental|SPD503 (Guanfacine HCl) (1 mg)|
9740031|NCT00150618|Experimental|SPD503 (2 mg)|
9740032|NCT00150618|Experimental|SPD503 (3 mg)|
9740033|NCT00150618|Experimental|SPD503 (4 mg)|
9740034|NCT00150618|Placebo Comparator|Placebo|
9740035|NCT00150800|Experimental|Brivaracetam|Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.
9740036|NCT00150813|Experimental|Levetiracetam|Subjects received open-label Levetiracetam.
9740037|NCT00150969|Experimental|phyloquinone|5 mg Vitamin K1
9740038|NCT00150969|Placebo Comparator|placebo|
9740039|NCT00151281|Experimental|Study Treatment Arm|
9740040|NCT00151320|Experimental|Arm 1|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles~Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule."
9740041|NCT00151372|Experimental|Treatment Adherence Intervention|In the Treatment Adherence Intervention group, a study therapist regularly meets with subjects in order to identify obstacles to depression and chronic obstructive pulmonary disease treatment adherence and to help the participant overcome those obstacles.
9740042|NCT00151372|Active Comparator|Enhanced Care|In the Enhanced Care group, physicians providing aftercare will be informed in writing of the patients' diagnosis but will receive no clinical instructions by the research team.
9740043|NCT00151411|Experimental|Metformin|Metformin
9740044|NCT00151411|Placebo Comparator|Placebo|Placebo
9740045|NCT00151476||Celecoxib - Routine Medical Care|800 mg total daily dosing
9740046|NCT00151476||Control Group - Routine Medical Care|Observation of subjects treated with routine medical care
9740047|NCT00151775|Experimental|Period 2|"For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old."
9740048|NCT00151775|Experimental|Period 3|Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
9740049|NCT00151775|Experimental|Period 4|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
9740050|NCT00151814|Experimental|Olmesartan|Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.
9740051|NCT00151892|Experimental|SPD476|Mesalazine
9740052|NCT00151892|Active Comparator|Asacol|
9740053|NCT00151996|Experimental|Methylphenidate + SPD503|
9740054|NCT00151996|Experimental|Amphetamine + SPD503|
9740055|NCT00152009|Experimental|SPD503 (Guanfacine HCl) (2 mg)|
9740056|NCT00152009|Experimental|SPD503 (3 mg)|
9740057|NCT00152009|Experimental|SPD503 (4 mg)|
9740058|NCT00152009|Placebo Comparator|Placebo|
9740059|NCT00152464|Experimental|Levocetirizine (LCTZ)|0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.
9740060|NCT00152464|Placebo Comparator|Placebo (PBO)|Placebo was administered as oral drops twice daily.
9740061|NCT00152516|Experimental|Levetiracetam|
9740062|NCT00152763|Experimental|Cognitive Behavior Therapy - males|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the males.
9740063|NCT00152763|Experimental|Cognitive Behavior Therapy - females|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the females.
9740064|NCT00152763|Active Comparator|Usual Cardiac Care - Males|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was just for males randomized.
9740065|NCT00152763|Active Comparator|Usual Cardiac Care - females|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was for females randomized.
9740066|NCT00152971|Experimental|Dabigatran Dose 1|low dose regimen taken once daily
9740067|NCT00152971|Experimental|Dabigatran Dose 2|high dose regimen taken once daily
9740068|NCT00152971|Active Comparator|Enoxaparin|30 mg subcutaneously twice daily
9740069|NCT00153062|Placebo Comparator|Aggrenox, Clopidogrel placebo, Micardis|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis (80mg) qd
9740070|NCT00153062|Placebo Comparator|Aggrenox placebo, clopidogrel,, Micardis|Clopidogrel (75mg) qd; Aggrenox placebo bid, Micardis (80mg) qd
9740071|NCT00153062|Placebo Comparator|Aggrenox, clop placebo, micardis placebo|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis placebo qd
9740072|NCT00153062|Placebo Comparator|Aggrenox plcebo, clop, micardis placebo|Clopidogrel (75mg) qd, Aggrenox placebo bid, Micardis placebo qd.
9740073|NCT00153166|Experimental|Patients with PAD (Including diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
9740074|NCT00153166|Active Comparator|PAD (Excluding Diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
9740075|NCT00153166|Active Comparator|Healthy Controls|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
9740076|NCT00153179|Active Comparator|1|Acipimox treatment for 7 days
9740077|NCT00153179|Placebo Comparator|2|placebo treatment for 7 days
9740078|NCT00153803|Experimental|1|Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
9740079|NCT00153803|Placebo Comparator|2|Matched Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
9740080|NCT00153816|Experimental|Full Factorial Placebo|subjects in 2X2 factorial design; randomized to daily placebo
9740081|NCT00153816|Experimental|Full Factorial Calcium|subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate
9740082|NCT00153816|Experimental|Full Factorial Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1000 IU vitamin D3
9740083|NCT00153816|Experimental|Full Factorial Calcium Plus Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate and 1000 IU vitamin D3
9740084|NCT00153816|Experimental|Two Arm Placebo|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily placebo
9740085|NCT00153816|Experimental|Two Arm Vitamin D|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily 1000 IU vitamin D3
9740086|NCT00153842|Experimental|Bexarotene|Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
9740087|NCT00153920|Experimental|bortezomib|Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.
9740088|NCT00154063|Placebo Comparator|Placebo|During the Titration Phase, placebo was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
9740089|NCT00154063|Experimental|E2007|During the Titration Phase, perampanel was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
9740090|NCT00154102|Experimental|Cetuximab Plus FOLFIRI|
9740091|NCT00154102|Active Comparator|FOLFIRI Alone|
9740092|NCT00154284|Active Comparator|Everolimus (Certican) with Cyclosporine (Neoral) Continuation|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. After randomization the target trough range remained at 3 - 8 ng/mL in the cyclosporine (Neoral) continuation groups for a period of 9 months. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
9781698|NCT01155284|Placebo Comparator|Placebo|Sitagliptin Placebo and Lansoprazole placebo capsules will be administered. Subjects age 11-17 years at Visit 2 will take 1 placebo capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 placebo capsules of each once daily
9781699|NCT01155323|Active Comparator|etafilcon A/omafilcon A|etafilcon A contact lenses will be worn during the first week and omafilcon A contact lenses will be worn during the second. Lenses were replaced daily
9740093|NCT00154284|Experimental|Everolimus (Certican) with Cyclosporine (Neoral) Withdrawal|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. Therefore, patients were randomized to cyclosporine withdrawal over a period of 1 month (±1 week) in study A2419 (NCT00154284) and over 3 months (±1 week) in study A2423 (NCT00170807). After randomization, final target trough range for everolimus was 8 - 12 ng/mL. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
9740094|NCT00154297|Active Comparator|Immediate Everolimus|Patients received Everolimus starting within 48 hours of kidney transplant through to the end of the study, administered orally twice a day. Dose was adjusted in order to maintain a trough level between 3-8 ng/mL.
9740095|NCT00154297|Experimental|Delayed Everolimus|Patients received Everolimus 4 weeks after kidney transplant until the end of the study, administered orally twice a day. The dose was adjusted in order to maintain a trough level between 3-8 ng/mL. Patients received mycophenolic acid until everolimus was initiated.
9740096|NCT00154310|Experimental|Everolimus + Mycophenolate sodium|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued throughout the first year. Cyclosporine withdrawal started from Month 4.5 post-transplant.
9740097|NCT00154310|Active Comparator|Cyclosporine + Mycophenolate sodium|Cyclosporine tablets orally twice a day to achieve protocol specific target levels and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
9740098|NCT00154375|Experimental|Imatinib mesylate + hydroxyurea (HU)|Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
9740099|NCT00154375|Active Comparator|Hydroxyurea alone|1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
9740100|NCT00154466|Experimental|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2.
9740101|NCT00154466|No Intervention|postinfarction patients|those in the nontraining group continued their usual lifestyle
9740102|NCT00154466|Placebo Comparator|healthy controls|Age-, weight-, and height-matched subjects without cardiovascular risk factors were selected as healthy controls.
9740103|NCT00156013|Experimental|1|Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.
9740104|NCT00156247|Experimental|etanercept with acitretin|open-label
9740105|NCT00156390|Experimental|1|echo-guided LV lead placement
9740106|NCT00156390|Other|2|LV lead placement as per standard of care (without echo-guidance)
9740107|NCT00156533|Placebo Comparator|Placebo|QHS dosing with placebo (i.e. nightly dose)
9740108|NCT00156533|Active Comparator|QHS Zolpidem|QHS dosing with 10mg of zolpidem (i.e. nightly dose)
9740109|NCT00156533|Experimental|Intermittant Zolpidem|Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed
9740110|NCT00156533|No Intervention|Control|Monitor only condition (no placebo, no drug).
9781700|NCT01155323|Active Comparator|omafilcon A/etafilcon A|omafilcon A contact lenses will be worn during the first week and etafilcon A contact lenses will be worn during the second. Lenses were replaced daily.
10200923|NCT05138731||normal coronary artery （NCA）|symptoms of chest pain and no stenosis in coronary arteries (such as myocardial bridging, reflux esophagitis, intercostals neuralgia, cervical spondylopathy, and unexplained chest pain)
10200924|NCT05138731||nonobstructive coronary atherosclerosis （NOCA）|stenosis < 50% in coronary arteries
10200925|NCT05138731||healthy volunteers|Healthy control subjects who had no significant systemic diseases (e.g. ischemic heart disease, hypertension,diabetes,cancer, pulmonary disease, or infectious diseases) were recruited from Physical Examination Center of Ningxia Medical University General Hospital
10200926|NCT05137028|Experimental|Otago Exercise|Otago Exercise Group
10200927|NCT05135494|Experimental|Experimental Group|Experimental Group: Inspiratory Muscle Training + rehabilitation program
10200928|NCT05135494|Other|Control Group|Control Group: rehabilitation program
10200929|NCT05135468|Experimental|CU-40102 Spray|0.25% (2.275mg/mL) Finasteride
10200930|NCT05135468|Placebo Comparator|Placebo for CU-40102 Spray|Placebo Spray
10200931|NCT05134610|No Intervention|Control|Standard of care for pre- and post-op pulmonary care
10200932|NCT05134610|Experimental|OPEP Therapy|14 days pre- and and post-op OPEP device usage
10200933|NCT05133297|Experimental|Sequence 1|TLL018 tablets, 1piece,BID
10200934|NCT05133297|Experimental|Sequence 2|TLL018 tablets, 2pieces, BID
10200935|NCT05133297|Experimental|Sequence 3|TLL018 tablets, 3pieces, BID
10200936|NCT05133297|Active Comparator|Sequence 4|TOFA tablets, 1pieces, BID
10200937|NCT05131308||Detachable embolization coils group|Patients who have an intervention for leak closure with detachable embolization coils
10200938|NCT05131308||Vascular plugs/septal occluders group|Patients who have an intervention for leak closure with vascular plugs/CSO
10200939|NCT05131308||RF Ablation group|Patients who have an intervention for leak closure with Radio Frequency Ablation (RFA)
9740111|NCT00156715|Experimental|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
9740112|NCT00156819|Active Comparator|Fluticasone|Participants continued fluticasone (100 microgram twice daily) treatment.
9740113|NCT00156819|Experimental|Montelukast|Participants were changed to Montelukast (5 or 10 mg each night).
9740114|NCT00156819|Experimental|Fluticasone plus salmeterol|Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
9740115|NCT00156910|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
9740116|NCT00156910|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
9740117|NCT00156923|Experimental|Medisorb naltrexone 380 mg|
9740118|NCT00156923|Experimental|Medisorb naltrexone 190 mg|
9740119|NCT00156936|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
9740120|NCT00156936|Experimental|Oral naltrexone to Medisorb naltrexone 380 mg (VIVITROL)|
9740121|NCT00157014|Experimental|Tacrolimus - Adult|Adults: 0.05 - 0.10 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
9740122|NCT00157014|Active Comparator|Cyclosporine - Adult|Adults: 3-5 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
9740123|NCT00157014|Experimental|Tacrolimus - Pediatric|Pediatrics: 0.05 - 0.30 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
9740124|NCT00157014|Active Comparator|Cyclosporine - Pediatric|Pediatrics: 6 - 10 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
9740125|NCT00157157|Experimental|Single Arm - All Participants|All subjects enrolled in the study who meet the eligibility criteria.
9740126|NCT00157196|Experimental|Tecemotide(L-BLP25)+Cyclophosphomide+best standard of care|
9740127|NCT00157209|Experimental|Tecemotide (L-BLP25) plus Best Supportive Care (BSC)|
9740128|NCT00157209|Active Comparator|Best Supportive Care (BSC) Alone|
9740129|NCT00157248|Experimental|dabigatran etexilate, 150 mg once daily|dosage used at study start
9740130|NCT00157248|Experimental|dabigatran etexilate, 150 mg twice daily|dosage used at study start
9740131|NCT00157248|Experimental|dabigatran etexilate, 300 mg once daily|dosage used at study start
9740132|NCT00157248|Experimental|dabigatran etexilate, 300 mg twice daily|dosage used at study start
9781701|NCT01155336|Experimental|Lovaza®|Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
9781702|NCT01155336|Placebo Comparator|Corn Oil|The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
9781703|NCT01155466|Experimental|Preladenant 2 mg|Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks
9781704|NCT01155466|Experimental|Preladenant 5 mg|Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks
9781705|NCT01155466|Experimental|Preladenant 10 mg|Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks
9781706|NCT01155466|Placebo Comparator|Placebo|Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks
9781707|NCT01155466|Active Comparator|Rasagiline 1 mg|Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks
9781708|NCT01155479|Experimental|Preladenant 2 mg|Preladenant 2 mg oral tablet and placebo for rasagiline taken in the morning (AM) followed by preladenant 2 mg oral tablet taken in the evening (PM) for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
9740133|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 1|GM-CSF, Sargramostim 250 μg/m^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
9740134|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 2|GM-CSF, sargramostim 150 μg/m^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m^2 per day if applicable based on toxicity and white blood cell count.
9740135|NCT00157820|Active Comparator|SC true|Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
9740136|NCT00157820|Experimental|SC sim|Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
9740137|NCT00157820|Experimental|DC true|Dual chamber ICD initially programmed as a DDED (''DC true arm'').
9740138|NCT00157950|Experimental|Gardasil™|Gardasil™ 3 dose regimen
9740139|NCT00157950|Placebo Comparator|Placebo|Gardasil™ matching placebo 3 dose regimen
9740140|NCT00158054|Experimental|Intervention Condition (INT)|Enhanced depression care: Participants assigned to INT condition will be given an information brochure describing the intervention. This description will include an overview of the two elements of treatment (Problem Solving Therapy (PST), pharmacotherapy), the choice that the participant has for which element of treatment they will receive, and the stepped care aspect of treatment.
9740141|NCT00158054|Other|Usual Cardiologic Care Condition (UCC)|Referred depression care: Participants assigned to the usual cardiologic care condition (UCC) condition will be scheduled for their next follow-up visit and thanked for their time.
9740142|NCT00158184|Active Comparator|Rx Opioid Abusers|Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
9740143|NCT00158184|Active Comparator|Rx Opioid Non-Abusers|Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.
9740144|NCT00158197|Experimental|continuous voucher schedule|Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
9740145|NCT00158197|Experimental|intermittent predictable schedule|Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
9740146|NCT00158197|Experimental|intermittent unpredictable schedule|Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, & F for 12 wks and complete measures 1x/wk.
9740147|NCT00158197|No Intervention|standard|Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
9740148|NCT00158223|Placebo Comparator|placebo|Participants will receive encapsulated placebo made to match active drug
9740149|NCT00158223|Experimental|pimozide|Participants will receive pimozide flexible dosing
9740150|NCT00158249|Placebo Comparator|placebo|matched capsules
9740151|NCT00158249|Experimental|citicoline|2 gm/day
10200940|NCT05123820|Experimental|ACT-1014-6470, Midazolam and Omeprazole|"Treatment Period A (Day 1 to Day 2) The plan is that all participants will receive treatment A and then treatment B.~A single oral dose of midazolam 2 mg and a single oral dose of omeprazole 20 mg on Day 1.~Treatment Period B (Day 8 to Day 11)~A single oral dose of 100 mg ACT-1014-6470, a single oral dose of 20 mg omeprazole, and a single oral dose of 2 mg midazolam on Day 8."
10200941|NCT05121220|Experimental|fixed mandibular lingual rectangular retainer 0.673 x 0.268 mm|0.673 x 0.268 mm 8-stranded wire Bond A Braid (Reliance Orthodontic Products, USA) will be bonded in mandible canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
10200942|NCT05121220|Experimental|fixed mandibular lingual round retainer 0.40 mm|0.40 mm round 6-stranded wire (Forestadent, Germany) will be bonded on 6 mandibular frontal teeth, canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
10200943|NCT05121220|Active Comparator|removable mandibular retainer|Group without fixed retainer will be wearing removable thermoplastic vacuum-formed Essix retainer
10200944|NCT05113745|Experimental|AXS-12 (reboxetine)|"Up to 24 weeks in open-label period~Up to 4 weeks in randomized double-blind period"
10200945|NCT05113745|Placebo Comparator|Placebo|Up to 4 weeks in randomized double-blind period
9740152|NCT00158262|Experimental|Propranolol|Following the occurrence of an acute psychologically traumatic event, an initial dose of short-acting propranolol 40 mg orally then one hour later, long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
9740153|NCT00158262|Placebo Comparator|Placebo|Following the occurrence of an acute psychologically traumatic event, an initial dose of placebo-matching short-acting propranolol 40 mg orally then one hour later, placebo-matching long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of placebo-matching long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
9740154|NCT00158379|Experimental|Paclitaxel|
9740155|NCT00158600|Active Comparator|alglucosidase alfa|Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
9740156|NCT00158600|Placebo Comparator|Placebo|Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
9740157|NCT00158743|Active Comparator|Digoxin immune fab|Digibind treatment plus standard of care
9740158|NCT00158743|Placebo Comparator|placebo (sodium chloride)|
9740159|NCT00158756|Experimental|Tritanrix™-HepB+Rotarix™ Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
9740160|NCT00158756|Experimental|Tritanrix™-HepB+Placebo Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
9740161|NCT00158756|Active Comparator|Zilbrix™+Rotarix™ Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
9740162|NCT00158756|Active Comparator|Zilbrix™+Placebo Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
9740163|NCT00158756|Active Comparator|Triple Antigen™+Engerix™-B Group|Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.
9740164|NCT00158860|Experimental|Valaciclovir|Participants received double blinded treatment of oral dose of Valacyclovir 1 g given as 2 x 500 mg caplets QD for 6 months (24 weeks).
9740165|NCT00158860|Placebo Comparator|Placebo|Participants received double blinded treatment of oral dose of matching placebo to Valacyclovir 1 gram (g) given as 2 x 500 milligram (mg) caplets once daily (QD) for 6 months (24 weeks).
9740166|NCT00158925|Experimental|EASYTRAK EPI Lead|Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.
9740167|NCT00159250|Experimental|Low dose|Low dose of AVI-4658
9740168|NCT00159250|Experimental|High dose|High dose of AVI-4658
9665760|NCT04910685|Experimental|(Part 1) BLU-263 Dose 3 + BSC|Patients will receive best supportive care (BSC) and Dose 3 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
9665761|NCT04910685|Placebo Comparator|(Part 1) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily until completion of Part 1
9665762|NCT04910685|Experimental|(Part 2) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for approximately 24 weeks
9740169|NCT00159263|Placebo Comparator|Placebo|placebo
9740170|NCT00159263|Experimental|Formoterol|Oxis(®) 12 μg
9740171|NCT00159263|Experimental|Budesonide low dose|Pulmicort(®) 200 μg
9740172|NCT00159263|Experimental|Budesonide high dose|Pulmicort(®) 800 μg
9740173|NCT00159263|Experimental|Budesonide/formoterol combination single|single 100/6 μg SYM100
9740174|NCT00159263|Experimental|Budesonide/formoterol combination double|double 200/12 μg SYM200
9740175|NCT00159419|Active Comparator|Alendronate|1 mg/kg po qd rounded to nearest 10 or 20 mg dose
9740176|NCT00159419|Active Comparator|Pamidronate|3 mg/kg IV q4 months
9740177|NCT00159432|Experimental|Oxaliplatin, followed by Bevacizumab with Capecitabine|oxaliplatin 85 mg/m2 q 14 days, followed by bevacizumab 5 mg/kg q 14 days, with capecitabine 750 mg/m2 bid daily
9740178|NCT00159822|Experimental|1|
9740179|NCT00159874|Experimental|Sildenafil high dose|As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
9740180|NCT00159874|Experimental|Sildenafil Low dose|
9740181|NCT00159874|Experimental|Sildenafil medium dose|As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
9740182|NCT00159913|Experimental|Sildenafil Low dose|
9740183|NCT00159913|Experimental|Sildenafil Medium dose|
9740184|NCT00159913|Experimental|Sildenafil High dose|
9740185|NCT00159913|Placebo Comparator|Placebo|
9740186|NCT00159965|Active Comparator|sertraline|flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
9740187|NCT00159965|Placebo Comparator|placebo|flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
9740188|NCT00160199|Experimental|1|
9740189|NCT00160199|Active Comparator|2|
9740190|NCT00160251|Active Comparator|Arm 1A: PegIntron (PEG) + Ribavirin (RBV)|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is undetected, PEG + RBV will continue for another 36 weeks.
9740191|NCT00160251|Active Comparator|Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is detectable, BOC 400 mg TID will be added for 36 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
9740192|NCT00160251|Experimental|Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
9740193|NCT00160251|Experimental|Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
9740194|NCT00160251|Experimental|Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
9740195|NCT00160251|Experimental|Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
9740196|NCT00160251|Experimental|Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
9517275|NCT03307746|Active Comparator|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
9781709|NCT01155479|Experimental|Preladenant 5 mg|Preladenant 5 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 5 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
9740197|NCT00160251|Experimental|Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800|By first protocol amendment to P03659, this non-randomized arm is added. A single dose of PEG is given first, followed 1 week later by PEG + BOC 800 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
9740198|NCT00160251|Experimental|Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800|By second protocol amendment to P03659, participants from all arms except Arm 1A will be rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.
9740199|NCT00160524|Experimental|Certolizumab Pegol|400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.
9740200|NCT00160615|Experimental|Levetiracetam|Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).
9740201|NCT00160641|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
9740202|NCT00160654|Experimental|Levetiracetam|Subjects received open-label Levetiracetam.
9740203|NCT00160667|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day.
9740204|NCT00160667|Experimental|Brivaracetam 200 mg/day|Brivaracetam 200 mg/day (100 mg administered twice a day).
9740205|NCT00160667|Experimental|Brivaracetam 400 mg/day|Brivaracetam 400 mg/day (200 mg administered twice a day).
9740206|NCT00160680|Experimental|Continuous Treatment|5 mg of Levocetirizine (LCTZ) was taken orally once a day.
9740207|NCT00160680|Experimental|On Demand Treatment|5 mg of Levocetirizine (LCTZ) was taken whenever needed.
9740208|NCT00160693|Experimental|Certolizumab Pegol|
9740209|NCT00160706|Experimental|Certolizumab Pegol|3-dose induction regimen of Certolizumab Pegol 400 mg at Weeks 0, 2, 4. Subsequently continue on 4-weekly treatment with Certolizumab Pegol 400 mg until Week 360.
9740210|NCT00161213|Experimental|Gemcitabine and Imatinib|
9740211|NCT00161382|Experimental|Intervention Group|HIV, STD, and pregnancy prevention curriculum
9740212|NCT00161382|Experimental|Control Group|Standard sexual education curriculum
9740213|NCT00161473|Active Comparator|prazosin|
9740214|NCT00161473|Placebo Comparator|placebo (inert substance)|
9740215|NCT00161616|Active Comparator|A|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage +surgical fixation
9740216|NCT00161616|Other|B|Standard of Care: Surgical fixation only
9740217|NCT00162032|Other|Children (Ages 4-11)|Children 4-11 years of age, intervention Sestamibi
9740218|NCT00162032|Other|Adolescents (Ages 12-16)|Adolescents 12-16 years of age, intervention Sestamibi
9740219|NCT00162097|Experimental|EFV600mg Participants With Mild Hepatic Impairment|
9740220|NCT00162097|Experimental|EFV600mg Participants With Moderate Hepatic Impairment|
9740221|NCT00162097|Experimental|EFV600mg Participants With Severe Hepatic Impairment|
9740222|NCT00162097|Active Comparator|EFV600mg Participants With Normal Hepatic Function|
9740223|NCT00162123|Experimental|First reinduction: Ipilimumab, 0.3 to 10 mg/kg|Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
9740224|NCT00162123|Experimental|First reinduction: Ipilimumab, 3 to 10 mg/kg|Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
9740225|NCT00162123|Experimental|First reinduction: Ipilimumab, 10 to 10 mg/kg|Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
9740226|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 0.3 mg/kg|Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
9740227|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 3 mg/kg|Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
9740228|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 10 mg|Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
9740229|NCT00162123|No Intervention|Follow-up|Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
9740230|NCT00162136|Experimental|A1|
9740231|NCT00162266|Experimental|Abatacept (10 mg/Kg) - Open Label|
9740232|NCT00162266|Experimental|Abatacept (2 mg/kg) - Double blind|
9740233|NCT00162266|Experimental|Abatacept (10 mg/kg) - Double blind|
9740234|NCT00162266|Experimental|Placebo - Double blind|
9740235|NCT00162981|Experimental|Clobazam Low Dose|
9740236|NCT00162981|Experimental|Clobazam High Dose|
9740237|NCT00163020|Active Comparator|1 Test Group (170HP)|Test Group will receive weekly doses of 170HP via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
9740238|NCT00163020|Placebo Comparator|2 - Control (Normal Saline)|Control Group will receive weekly doses of placebo (NS) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
9740239|NCT00163189|Experimental|Somatropin|
9740240|NCT00163215|Experimental|Somatropin|
9740241|NCT00163293|Placebo Comparator|Placebo|
9740242|NCT00163293|Active Comparator|Ciclesonide 100 µg|Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
9740243|NCT00163293|Active Comparator|Ciclesonide 200 µg|Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
9740244|NCT00163657|Active Comparator|tacrolimus and cyclosporine|immunosuppressant treatment regimens the intervention is antirejection treatment with the above labeled drugs tacrolimus and cyclosporine
9740245|NCT00163657|Active Comparator|MMF, tacrolimus and cyclosporine|immunosuppressant treatment regimensthe intervention is antirejection treatment with the above labeled drugs MMF tacrolimus and cyclosporine
9740246|NCT00163657|Active Comparator|daclizumub, MMFand tacrolimus|immunosuppressant treatment regimens
9740247|NCT00165646|Experimental|1|
9740248|NCT00165646|Experimental|2|
9740249|NCT00165646|Placebo Comparator|3|
9740250|NCT00165672|Experimental|1|
9740251|NCT00165672|Experimental|2|
9740252|NCT00165698|Active Comparator|1|
9740253|NCT00165698|Active Comparator|2|
9740254|NCT00165841|Placebo Comparator|Placebo|
9740255|NCT00165841|Experimental|Rabeprazole 20 mg|
9740256|NCT00165958|Experimental|Punch excision|
9740257|NCT00165958|Active Comparator|Traditional excision|
9740258|NCT00166036|Experimental|Atorvastatin 10MG|
9740259|NCT00166036|Experimental|Pravastatin 80mg|
9740260|NCT00166114|Active Comparator|Escitalopram|
9740261|NCT00166114|Active Comparator|Desipramine|
9740262|NCT00166166|Experimental|Healthy Controls|Healthy subjects had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
9740263|NCT00166166|Experimental|Risk Factors|Non-hypertensive subjects with cardiovascular risk factors had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
9740264|NCT00166205|Experimental|Gastric Band|Single-arm study, all subjects banded.
9740265|NCT00166296|Experimental|Escitalopram|Escitalopram, 15 mg/day
9740266|NCT00166296|Placebo Comparator|Placebo pill|Placebo
9740267|NCT00166361|Experimental|Memokath 051 Ureteral Stent|Subjects assigned to this arm received a Memokath 051 Ureteral Stent.
9740268|NCT00166361|Active Comparator|JJ Stent|Subjects assigned to this arm received a JJ stent.
9740269|NCT00166439|Experimental|Treatment (ROAD)|The treatment regimen included oxaliplatin with rituximab, cytarabine, and dexamethasone (ROAD); specifically, rituximab 375 mg/m^2 IV on days 1, 8,15, and 22 (cycle 1 only); dexamethasone 40 mg PO/IV days 2-5; oxaliplatin 130 mg/m^2 IV over 2 hours on day 2; cytarabine 2000 mg/m^2 IV in 250 mL of D5W over three hours x two doses on days 2-3. The second dose of cytarabine was to be given no sooner than 12 hours after the first dose and no later than 24 hours after the conclusion of the first dose. This permitted outpatient administration if desired. Patients were provided pegfilgrastim 6 mg SC on day 4. A cycle was 21 days.
9740270|NCT00166517|Experimental|1|RotaTeq
9740271|NCT00166517|Placebo Comparator|2|Placebo
9740272|NCT00166712|Active Comparator|Group 1: Alemtuzumab + TAC + MMF|Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
9740273|NCT00166712|Active Comparator|Group 2: Alemtuzumab + Sirolimus + MMF|"Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor.~If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil."
9740274|NCT00167102|Experimental|Alefacept|
9740275|NCT00167102|Placebo Comparator|Placebo|
9740276|NCT00167180|Active Comparator|CML|Patients with Chronic Myelogenous Leukemia (CML) who have failed or refused Gleevec(TM) therapy and will receive Donor Lymphocyte Infusion.
9740277|NCT00167180|Active Comparator|Non-CML or CML that Relapsed after Donor Lymphocyte Infusion|Patients with non-CML or CML who have failed Donor Lymphocyte Infusion (DLI) and will receive induction chemotherapy plus DLI.
9740278|NCT00167206|Experimental|HSCT Patients|Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)
9740279|NCT00167245|Experimental|Topiramate|topiramate capsules dose titrated up to 300 mg daily
9740280|NCT00167245|Placebo Comparator|Placebo|placebo capsules identical in appearance to the topiramate capsules
9740281|NCT00167310|Experimental|1|Eicosapentaenoic acid (omega-3 fatty acid, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
9740282|NCT00167310|Placebo Comparator|2|Placebo (soy bean oil, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
9740283|NCT00167388|No Intervention|group 1|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be NPO during the PRBC transfusion
9740284|NCT00167388|Active Comparator|group 2|Babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
9740285|NCT00167388|No Intervention|group 3|All babies >1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
9740286|NCT00167388|Experimental|group 4|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
9740287|NCT00167414|Experimental|Hypofractionated Stereotactic Body Radiation Therapy|Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
9740288|NCT00167544|Experimental|1|1. Tapering dose of hydrocortisone every 12 h over 7 day period
9740289|NCT00167544|Placebo Comparator|2|2. Identical-appearing saline placebo
9740290|NCT00167661|Experimental|Campath 1-H|Campath 1-H
9740291|NCT00167778|Experimental|Arm 1|Novel prosthetic pylon
9740292|NCT00167778|Active Comparator|Arm 2|rigid pylon
9740293|NCT00167934|Placebo Comparator|Placebo|50% of participants will receive placebo
9740294|NCT00167934|Experimental|Experimental|50% of participants will receive Depakote ER
9740295|NCT00168038|Experimental|IgPro10|
9740296|NCT00168064|Active Comparator|1 (PG - NM (MCH) 0.02%)|PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
9740297|NCT00168064|Active Comparator|2 (AP - MCH(NM) 0.02%)|AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF
9740298|NCT00168103|Experimental|C1-INH 10 U/kg bw|10 Units (U)/kg body weight (bw) dose
9740299|NCT00168103|Experimental|C1-INH 20 U/kg bw|20 U/kg bw dose
9740300|NCT00168103|Placebo Comparator|Placebo|
9740301|NCT00168298|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
9740302|NCT00168298|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
9740303|NCT00168298|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
9740304|NCT00168311|Experimental|Active Treatment|Bilateral high frequency (10 Hertz) rTMS
9740305|NCT00168311|Sham Comparator|Sham rTMS|Bilateral Sham rTMS
9740306|NCT00168324|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
9740307|NCT00168324|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
9740308|NCT00168324|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
9740309|NCT00168337|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
9740310|NCT00168337|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
9740311|NCT00168337|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
9740312|NCT00168389|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
9740313|NCT00168389|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
9740314|NCT00168389|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
9740315|NCT00168428|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
9740316|NCT00168428|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
9740317|NCT00168454|Placebo Comparator|Placebo|Placebo (normal saline) injected into detrusor on Day 1
9740318|NCT00168454|Experimental|BOTOX 50 U|botulinum toxin Type A 50 U injected into detrusor on Day 1
9740319|NCT00168454|Experimental|BOTOX 100 U|botulinum toxin Type A 100 U injected into detrusor on Day 1
9740320|NCT00168454|Experimental|BOTOX 150 U|botulinum toxin Type A 150 U injected into detrusor on Day 1
9740321|NCT00168454|Experimental|BOTOX 200 U|botulinum toxin Type A 200 U injected into detrusor on Day 1
9740322|NCT00168454|Experimental|BOTOX 300 U|botulinum toxin Type A 300 U injected into detrusor on Day 1
9740323|NCT00168805|Experimental|dabigatran etexilate 220 mg|220 mg once daily
9740324|NCT00168805|Experimental|dabigatran etexilate 150 mg|150 mg once daily
9740325|NCT00168805|Active Comparator|enoxaparin|40 mg once daily
9740326|NCT00168818|Experimental|dabigatran etexilate 75 mg|daily dose 150 mg once daily, half a dose on the day of surgery
9740327|NCT00168818|Experimental|dabigatran etexilate 110 mg|daily dose 220 mg once daily, half a dose on the day of surgery
9740328|NCT00168818|Active Comparator|enoxaparin|40 mg once daily
9740329|NCT00168831|Other|Tiotropium Respimat 5mcg (Tio R5)|
9740330|NCT00168831|Other|Tiotropium Respimat 10mcg (Tio R10)|
9740331|NCT00168831|Other|Placebo|
9740332|NCT00168844|Other|Tiotropium Respimat 5mcg (Tio R5)|
9740333|NCT00168844|Other|Tiotropium Respimat 10mcg (Tio R10)|
9740334|NCT00168844|Other|Placebo|
9740335|NCT00169104|Active Comparator|1|Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg IV weeks 3 through 14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13 and G-CSF at 5 mcgm/kg SQ daily Monday through Friday weeks 3-14.
9740336|NCT00169104|Placebo Comparator|2|Subjects will receive ten doses of a placebo injection SQ daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg weeks 3-14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13, and G-CSF at 5 mcgm/kg SQ daily Monday through Fridays weeks 3-14.
9740337|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
9740338|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
9740339|NCT00169442|Experimental|HB Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine (with HepB at birth), received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
9740340|NCT00169442|Experimental|Tritanrix-HepB Kft.+Hiberix Group|Healthy male and female infants who were primed with Tritanrix™-HepB Kft. and Hiberix™ vaccines, were boosted with Tritanrix™-HepB Kft. vaccine administered intramuscularly into the right upper thigh and Hiberix™ vaccine, administered intramuscularly into the left upper thigh, at 15-18 months of age.
9740341|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
9740342|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
9740343|NCT00170157|Experimental|Arm I|Patients receive either leuprolide acetate intramuscularly (IM) or goserelin subcutaneously (SC) on days 0, 28, and 56. Patients also receive oral flutamide three times daily or oral bicalutamide once daily. Treatment with antiandrogen (AA) therapy continues for 3 months (3-4 months for patients who initiated AA therapy <= 21 days prior to enrollment) in the absence of disease progression or unacceptable toxicity. Patients receive ipilimumab IV over 90 minutes on day 7 (within 7-28 days post-initiation of AA therapy for patients who initiated AA therapy <= 21 days prior to enrollment) of AA therapy.
9740344|NCT00170157|Active Comparator|Arm II|Patients receive AA therapy as in arm I. Patients may crossover to arm II in the case of disease progression.
9740345|NCT00170625|Experimental|Hycamtin|
9740346|NCT00170846|Active Comparator|Group A: No RAD|Calcineurin Inhibitors (CNI) ± Mycophenolate Acid (MPA)/Azathioprine (AZA) ± Steroids
9740347|NCT00170846|Experimental|Group B : CNI Withdrawal|Initiation of everolimus (8-12 ng/mL) with discontinuation of CNI. Everolimus(RAD001) 4 mg initial daily dose.
9517276|NCT03307746|Active Comparator|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
9517277|NCT03307733|No Intervention|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
9740348|NCT00170846|Experimental|Group C: CNI Reduction|Initiation of everolimus (3-8 ng/mL) with reduction by 70-90% in CNI blood levels. Everolimus (RAD001) 3 mg initial daily dose.
9740349|NCT00170950|Experimental|Benazepril/amlodipine|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
9740350|NCT00170950|Active Comparator|Benazepril/hydrochlorothiazide|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
9740351|NCT00171054|Experimental|Valsartan 320 mg|
9740352|NCT00171054|Experimental|Amlodipine 10 mg|
9740353|NCT00171158|Experimental|Imatinib Mesylate (STI571)|Participants initially received STI571 capsules or tablets, orally, initially once daily (400 mg) or (600 mg). The dosage was escalated from 400 mg to 600 mg and from 600 mg to 800 mg, on an individual basis as per the investigator's judgement. Treatment continued until death, or the development of intolerable toxicity, or the participant was considered not to benefit from treatment, whichever came first.
9781710|NCT01155479|Experimental|Preladenant 10 mg|Preladenant 10 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 10 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
9781711|NCT01155479|Placebo Comparator|Placebo|Placebo for preladenant and placebo for rasagiline taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).
9781712|NCT01155479|Active Comparator|Rasagiline|Rasagiline 1 mg oral capsule and placebo for preladenant taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
9781713|NCT01155531|Experimental|Telenzepine - Group A|Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine
9781714|NCT01155531|Experimental|Sertraline plus Telenzepine - Group B|Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine
9781715|NCT01155531|Experimental|Sertraline plus Telenzepine - Group C|Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine
9781716|NCT01155531|Experimental|Sertraline plus Telenzepine - Group D|Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine
9781717|NCT01155570||Humira|Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.
9781718|NCT01155583|Experimental|Arm A - Azacitidine/Lenalidomide/Dexamethasone|"Dose Level (DL) 1 - Azacitidine 30mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 40mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 3 - Azacitidine 30mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 4 - Azacitidine 40mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 5 - Azacitidine 50mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR > 60 ml/min) receive azacitidine subcutaneously 1 or 2x per weekly and oral Dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
9781719|NCT01155583|Experimental|Arm B - Chronic Kidney Disease (CDK) Cohort|"DL (-1) - Azacitidine 30mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 1 - Azacitidine 40mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 50mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR 30-59 ml/min Chronic Kidney Disease (CKD)) receive azacitidine subcutaneously 1 or 2x per weekly and oral dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
9781720|NCT01155661|Experimental|LY2216684 (edivoxetine) + SSRI|
9517278|NCT03307733|Active Comparator|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
9517279|NCT03307720|Active Comparator|Poor responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
9740354|NCT00171210|Experimental|Deferasirox|All participants received Deferasirox (ICL670) orally once a day. Dosage based on body weight.
9740355|NCT00171223|Experimental|All Participants With Chronic Myeloid Leukemia|Participants received STI571, capsules or tablets, orally, once a day at a dose of 400 mg. During the Core Phase of the study, participants received STI571 daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study, and they continued STI571 for as long as the therapy was beneficial or until death, intolerable toxicity or the decision to discontinue by the investigator, whichever came first. (Maximum duration on study was approximately 14 years).
9740356|NCT00171249|Experimental|Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg|Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
9740357|NCT00171249|Experimental|Lymphoid Blast Crisis 400 mg|Participants with lymphoid blast crisis received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
9740358|NCT00171249|Experimental|Acute Lymphoblastic Leukemia 400 mg|Participants with acute lymphoblastic leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
9740359|NCT00171249|Experimental|Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg|Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
9740360|NCT00171249|Experimental|Lymphoid Blast Crisis 600 mg|Participants with lymphoid blast crisis received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
9740361|NCT00171249|Experimental|Acute Lymphoblastic Leukemia 600 mg|Participants with acute lymphoblastic leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
9740362|NCT00171249|Experimental|Acute Myeloid/Myelogenous Leukemia 600 mg|Participants with acute myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
9740363|NCT00171301|Experimental|Deferasirox|Deferasirox was given orally once daily (10 to 20 mg/kg) to participants 2 years and older based on participant's body weight.
9740364|NCT00171314|Experimental|Upfront Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
9740365|NCT00171314|Experimental|Delayed Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
9740366|NCT00171340|Experimental|Upfront Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
9740367|NCT00171340|Experimental|Delayed Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
9740368|NCT00171704|Experimental|Letrozole|2.5 mg once daily (q.d.)orally for 5 years
9740369|NCT00171704|Experimental|Tam-Let|20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.
9740370|NCT00171730|Experimental|Pasireotide s.c. Overall|Participants received pasireotide as a daily subcutaneous (s.c) injection, every 12 hours at 9:00 AM and 9:00 PM at the dose at which the biochemical control was achieved (either 200, 400, or 600 microgram (μg)) for as long as the participant benefited from the treatment, and there were no safety or tolerability concerns (median duration of 22.7 months).
9740371|NCT00171873|Experimental|Octreotide LAR (Long Acting Release)|Octreotide LAR 30 mg intramuscularly every 28 days
9740372|NCT00171873|Placebo Comparator|Placebo|Placebo - Sodium chloride intramuscularly every 28 days
9740373|NCT00171925|Experimental|Zoledronic acid (ZOL446)|Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
9740374|NCT00171925|No Intervention|Control|No treatment with study medication.
9740375|NCT00171951|Experimental|Pasireotide 600 μg BID SC or Ramp up Dose 900 μg BID SC|Participants received pasireotide 600 micrograms (μg) twice daily (BID) subcutaneously (SC) to achieve or maintain urinary free cortisol (UFC) normalization. If UFC levels were increased at any time, participants received 900 μg BID SC, until no safety or tolerability concerns were observed as per investigators assessment. If the participant was unable to tolerate the 900 μg BID, dosing of 600 μg three times a day was given.
9740376|NCT00172042|Experimental|Zoledronic acid|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
9740377|NCT00172042|Other|Control|No investigational treatment. If a participant developed bone metastases, treatment was started with Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks until 24 months from the date of study entry had elapsed.
9517280|NCT03307720|Experimental|Poor responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
9740378|NCT00172185|Experimental|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d teduglutide subcutaneous injection
9740379|NCT00172185|Experimental|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d teduglutide subcutaneous injection
9740380|NCT00174187|Experimental|Somatropin|
9740381|NCT00174252|Experimental|Genotonorm (Somatropin)|
9740382|NCT00174291|Experimental|Somatropin|
9740383|NCT00174382|Experimental|1|
9740384|NCT00174447|Experimental|A1|
9740385|NCT00174460|Active Comparator|Treatment Arm|
9740386|NCT00174460|No Intervention|Control Arm|
9740387|NCT00174785|Experimental|Dronedarone 400mg bid|Dronedarone 400mg tablets twice daily (bid)
9740388|NCT00174785|Placebo Comparator|Placebo|matching placebo tablets
9740389|NCT00174915|Experimental|Febuxostat 80 mg QD|
9740390|NCT00174915|Experimental|Febuxostat 120 mg QD|
9740391|NCT00174915|Experimental|Febuxostat 240 mg QD|
9740392|NCT00174915|Active Comparator|Allopurinol QD|
9740393|NCT00174915|Placebo Comparator|Placebo QD|
9740394|NCT00174941|Experimental|1|
9740395|NCT00174941|Experimental|2|
9740396|NCT00174941|Experimental|3|
9740397|NCT00174954||1|Volumes/measurements of tophi determined by serial MRIs
9740398|NCT00174967|Placebo Comparator|Placebo QD|
9665763|NCT04910685|Placebo Comparator|(Part 2) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily once daily for approximately 24 weeks
9665764|NCT04910685|Experimental|(Part 3) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablet in an open-label fashion for up to 5 years.
9665765|NCT04910685|Experimental|(Part M) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for the duration of participation in the study.
9740399|NCT00174967|Experimental|Febuxostat 40 mg QD|
9740400|NCT00174967|Experimental|Febuxostat 80 mg QD|
9740401|NCT00174967|Experimental|Febuxostat 120 mg QD|
9740402|NCT00175006||Tophi Participants|
9740403|NCT00175019|Experimental|Febuxostat 80 mg QD|
9740404|NCT00175019|Experimental|Febuxostat 120 mg QD|
9740405|NCT00175019|Active Comparator|Allopurinol QD|
9740406|NCT00175825|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
9740407|NCT00175825|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day
9740408|NCT00175825|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
9740409|NCT00175825|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
9740410|NCT00175877|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
9740411|NCT00175916|Experimental|Brivaracetam|Flexible dosing, can up and down titrate as needed.
9740412|NCT00176202|Active Comparator|Risperidone|Risperidone is an antimanic medication and is a second generation antipsychotic
9740413|NCT00176202|Active Comparator|Divalproex sodium|Divalproex sodium is an antiepileptic medication and is a mood stabilizer
9740414|NCT00176228|Experimental|lamotrigine|The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg. Increasing the medication to final dose will take 8 weeks and the response on full and tolerable dose is further monitored for response over 6 weeks. Therefore, this is a 18-26 week trial (2 to 12 weeks=screening and wash out; 8 weeks=dosing; 6 weeks=acute trial period on full dose).
9740415|NCT00176254|Experimental|Induction chemotherapy and radiation|Induction chemotherapy with low dose radiation
9740416|NCT00176306|Experimental|Levofloxacin|Patients receiving levofloxacin 750mg IV
9740417|NCT00176423|Experimental|galantamine|galantamine, 24mgs, p.o., qday
9740418|NCT00176423|Placebo Comparator|placebo|placebo, 3 tablets, p.o., qday
9740419|NCT00176462|Experimental|Arm 1 Standard Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin
9740420|NCT00176462|Experimental|Arm 2 High Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C
9740421|NCT00176592|Active Comparator|Betaseron|Betaseron 250 micrograms SQ every other day and Triple-Dose Gadolinium at each MRI
9740422|NCT00176592|Active Comparator|Copaxone|Copaxone 20 mg daily SQ and Triple-Dose Gadolinium at each MRI
9740423|NCT00176605|Experimental|Arm 1 (Etoposide + Cyclophosphamide)|Therapy will be divided into 4 cycles. Each cycle will be composed of 6 weeks of therapy. Total duration of therapy is 24 weeks. Administration of etoposide (50 mg po qd) and cyclophosphamide (50 mg po qd) will alternate in 21 day intervals. Starting with etoposide, patients will receive 21 days of therapy, upon completion of etoposide therapy patients will then receive 21 days of cyclophosphamide therapy. Therapy will continue in this alternating manner for 24 weeks. Week 1 of each cycle, begins with etoposide; Week 4 of each cycle, begins with cyclophosphamide.
9740424|NCT00176644|Experimental|Transdermal estradiol|
9740425|NCT00176800|Experimental|1|Paclitaxel is administered intravenously over 1 hour on Days 1, 8, 15, and 22. Cisplatin will then be administered intravenously over 1 hour on Days 1 and 22. Radiation treatments will be given twice/day, on Days 1-5, 8-12 and 15-19. The subject's esophagus will be surgically removed on approximately Day #50. Approximately 4-6 weeks after surgery, the subject will start taking Tetrathiomolybdate, for 2 years or until treatment is no longer working to control your cancer. The subject will have blood drawn weekly while he/she is receiving chemotherapy and radiation prior to their surgery. 4-6 weeks after their surgery (when the subject starts taking Tetrathiomolybdate), a blood test will be performed every other week for 2 times, and monthly thereafter. When the level of copper has been lowered sufficiently an additional blood test and a baseline chest x-ray will be obtained. Additional blood will be drawn and tested every 6 months for the first 2 years.
9740426|NCT00176826|Experimental|Intent-To-Treat|Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
9740427|NCT00176839|Experimental|Treatment Arm|Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0.
9740428|NCT00176852|Other|RIC Bu/Flu (A) (discontinued)|Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.
9740429|NCT00176852|Experimental|MA Bu/Cy (B)|Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC >2500 x 2 days.
9740430|NCT00176852|Experimental|RIC Cy/Flu/TBI (A2)|Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.
9740431|NCT00176865|Active Comparator|Arm 1 - Matched sibling donor|Stem Cell Transplant: human leukocyte antigen (HLA) genotypic matched sibling donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
9740432|NCT00176865|Active Comparator|Arm 2 - Matched unrelated donor|Stem Cell Transplant: HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
9740433|NCT00176865|Active Comparator|Arm 3 - Mismatched double cord donors|Stem Cell Transplant: two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord) and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
9740434|NCT00176878|Experimental|Bone Marrow Failure Disorders|Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
9740435|NCT00176891|Experimental|Laronidase ERT Treatment|Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
9740436|NCT00176904|Experimental|Treated Patients|All patients treated with protocol regimen (chemotherapy and surgery).
9740437|NCT00176917|Experimental|Treatment Arm|All patients treated with chemotherapy and transplantation.
9740438|NCT00176930|Experimental|PBSC: No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
9740439|NCT00176930|Experimental|Marrow : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
9740440|NCT00176930|Experimental|UCB : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
9740441|NCT00176930|Experimental|UCB : No TBI/Bu/Cy/ATG|Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
9740442|NCT00176930|Experimental|PBSC|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
9740443|NCT00176930|Experimental|Marrow|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
9740444|NCT00176930|Experimental|UCB|Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
9740445|NCT00176930|Experimental|Co-Enroll From MT0403|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)
9517281|NCT03307720|Active Comparator|Normo responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
9740446|NCT00177047|Experimental|Chemotherapy and Transplant Treatment|Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.
9740447|NCT00177164|Active Comparator|1|Oral Risperidone followed by Long acting Risperidone injections (Consta)
9740448|NCT00177164|Active Comparator|2|Oral second generation antipsychotic agents other than clozapine or risperidone (olanzapine, quetiapine, ziprasidone, aripiprazole)
9740449|NCT00177216|Experimental|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
9740450|NCT00177216|Experimental|Excitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
9740451|NCT00177216|Placebo Comparator|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
9740452|NCT00177255|Experimental|Docetaxel + Capecitabine|"Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.~Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days. Cycle 2 will begin on day 22."
9740453|NCT00177294|Experimental|1|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly interpersonal psychotherapy (IPT)
9740454|NCT00177294|Active Comparator|2|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly depression care management(DCM) without interpersonal psychotherapy (IPT)
9740455|NCT00177307|Experimental|Oxaliplatin, Capecitabine, and Bevacizumab|
9740456|NCT00177671|Experimental|1|"escitalopram plus donepezil (DNP)in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation donepezil.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
9740457|NCT00177671|Placebo Comparator|2|"escitalopram plus placebo (PBO) in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of venlafaxine or duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
9740458|NCT00178126|Active Comparator|Segmented Foam Cushion|Receive seating assessment, wheelchair and seat cushion representing the standard of care in nursing homes
9740459|NCT00178126|Experimental|Skin Protection Cushion|Receive seating assessment, wheelchair and cushion meeting CMS code for Skin Protection Wheelchair Cushion
9740460|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraaticulary Only|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Intraaticular Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter"
9740461|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Patellar Tendon Site|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Patellar Tendon Site Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter"
9740462|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%; Intraarticular and Patellar Tendon Sites~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter"
9740463|NCT00178178|Placebo Comparator|Drug: Placebo|"Breg Pain Care 3000 Catheter with Placebo~Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter"
9740464|NCT00178191|Experimental|200 units Botox|200 units Botulinum-A toxin
9740465|NCT00178191|Experimental|300 units Botox|300 units Botulinum-A toxin
9740466|NCT00178191|Placebo Comparator|Placebo|Placebo
9740467|NCT00178256|Experimental|1st dose cohort 15mg/m2 taxol plus RT|"15 mg/m2 Paclitaxel On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.~On Monday, Tuesday, Wednesday, Thursday, Friday Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible"
9740468|NCT00178256|Experimental|2nd dose cohort20 mg/m2 taxol plus daily RT|
9740469|NCT00178256|Experimental|3rd Dose Cohort --25mg/m2 taxol plus RT|
9740470|NCT00178256|Experimental|Phase II Arm --20mg/m2 taxol plus RT|
9740471|NCT00178399|Experimental|Stereotactic body radiation therapy|
9740472|NCT00178464|Experimental|Aspirin|One-arm study
9740473|NCT00178503|Placebo Comparator|MPH Trial-Placebo|24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase
9740474|NCT00178503|Active Comparator|MPH Trial: Low Dose|24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
9740475|NCT00178503|Active Comparator|MPH Trial: Med Dose|24 Participants with ASD-ADHD underwent 1 week at a medium dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
9740476|NCT00178503|Active Comparator|MPH Trial: High Dose|24 Participants with ASD-ADHD underwent 1 week at a high dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
9740477|NCT00178633||Bariatric Surgery|Procedures were not part of the trial. Patients already undergoing these clinical procedures agreed to analysis and follow-up for research purposes. All patients had one of two different types of procedures, but outcome analyses did not distinguish between the two procedures.
9740478|NCT00178646|Experimental|1 - Low Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline
9740479|NCT00178646|Active Comparator|2 - High Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 50 units per 1 ml of preservative-free normal saline
9740480|NCT00178646|Other|3 - High Volume, Low Dose|Botox (onabotulinumtoxinA), 75 units prepared as 25 units per 1 ml of preservative-free normal saline
9740481|NCT00178711|Active Comparator|hypothermia|Induction and maintenance of moderate hypothermia to 33 degrees celsius achieved within 2.5 hours of injury and maintained for 48 hours.
9740482|NCT00178711|No Intervention|control|treated at normothermia
9740483|NCT00178919|Experimental|Autonomic Failure Patients|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in Patients with Autonomic Failure.
9740484|NCT00178919|Experimental|Controls and hypertensives|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in normal volunteers and hypertensive subjects.
9740485|NCT00179010|Experimental|Adenosine then Adenosine Mono Phosphate (AMP)|Intrarterial infusion of adenosine then same subject switch to AMP one month apart.
9740486|NCT00179010|Experimental|Adenosine Mono Phosphate (AMP) then adenosine|Intrarterial infusion of AMP then same subject switch to Adenosine one month apart.
9740487|NCT00179309|Experimental|Arm I - PANVAC + docetaxel|Patients receive vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine subcutaneously (SC) once and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) SC once daily for 4 days in week -2. Patients also receive fowlpox-CEA-MUC-1-TRICOM vaccine SC once and GM-CSF SC once daily for 4 days in weeks 1, 5, and 9. Patients also receive docetaxel intravenous (IV) over 30 minutes once weekly in weeks 1-3, 5-7, and 9-11. After week 12, patients with no disease progression continue with docetaxel once weekly for 3 weeks followed by 1 week of rest and fowlpox-CEA-MUC-1-TRICOM vaccine plus GM-CSF every 4 weeks until disease progression.
9740488|NCT00179309|Experimental|Arm II - Docetaxel alone|Patients receive docetaxel as in arm I. After week 12, patients with disease progression discontinue docetaxel and receive vaccinia-carcinoembryonic antigen (CEA)- mucin 1(MUC-1)-triad of costimulatory molecules (TRICOM) vaccine, fowlpox-CEA-MUC-1-TRICOM vaccine, and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) as in arm I until further disease progression. Patients with no disease progression after week 12 continue with docetaxel as in arm I until disease progression.
9740489|NCT00179413|Active Comparator|PEG-Intron|PEG-Intron 0.5mcg/kg once a week SC
9740490|NCT00179413|Active Comparator|Colchicine|0.6mg twice a day
9740491|NCT00179478|Experimental|Immediate Treatment Group|Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
9740492|NCT00179478|Active Comparator|Delayed Treatment Group|Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation
9740493|NCT00179517|Experimental|depotestosterone plus anastrozole (T-A)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes an oral tablet of anastrozole 1 mg daily for the duration of the study. This group is referred to as the depotestosterone plus anastrozole (T-A) group.
9740494|NCT00179517|Placebo Comparator|depotestosterone plus placebo (T-P)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes 1 matching placebo oral tablet daily for the duration of the study. This group is referred to as the depotestosterone plus placebo (T-P) group.
9740495|NCT00179621|Placebo Comparator|Placebo|Placebo matching to active study arms.
9740496|NCT00179621|Experimental|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
9740497|NCT00179621|Experimental|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
9740498|NCT00179647|Other|Lenalidomide 5-25 mg, w/wo dexamethasone|single-arm, open-label, lenalidomide, 5-25 mg, 21/28 days, with/without dexamethasone
9740499|NCT00179660|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
9740500|NCT00179673|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
9740501|NCT00179777|Experimental|Hydrolysed infant formula|Hydrolysed infant formula
9740502|NCT00179777|Placebo Comparator|Nonhydrolysed infant formula|Nonhydrolysed cow's milk based infant formula
9740503|NCT00179959|Active Comparator|Treatment|Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths
9740504|NCT00179959|Placebo Comparator|Placebo|Intranasal petrolatum ointment treatment and plain water baths
9740505|NCT00179998|Active Comparator|Recombinant Human DNase (Pulmozyme) then Placebo|once daily nebulized rhDNAse
9740506|NCT00179998|Placebo Comparator|Placebo (Nebulized Saline) then rhDNase|once daily nebulized vehicle
9740507|NCT00180271|Experimental|CRT-D|CRT-D: Cardiac resynchronization therapy with defibrillation.
9740508|NCT00180271|Active Comparator|ICD|ICD: Implantable cardioverter defibrillator
9740509|NCT00180297|Experimental|Mid septal site location|RV lead is placed at mid septum.
9740510|NCT00180297|Active Comparator|Apical site location|RV lead is placed in apical position
9740511|NCT00180323|Experimental|Renewal CRT (CRT ICD)|Single arm study only. All patients will undergo advanced echocardiographic examination pre-operative, pre-discharge after implantation and at 3 and 6-months follow-up. AV-delay optimization will be performed using aortic VTI (Velocity Time Integral) measured by continuous wave Doppler in a modified 4-chamber view. During optimisation aortic VTI will be measured at different heart rates reached by increasing atrial pacing 10, 20 and 30 beats above intrinsic heart rate (IHR).
9740512|NCT00180479|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
9740513|NCT00180479|Active Comparator|2|TAXUS® EXPRESS2™Paclitaxel Eluting Coronary Stent System
9740514|NCT00180661||Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
9740515|NCT00180661||Moderate Asthma|Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
9740516|NCT00180661||Mild Asthma|Asthma patients on steps 1 of asthma treatment (steroid naive).
9740517|NCT00180674|Experimental|Warfarin anticoagulation|Anticoagulated with warfarin to maintain an INR of 2-3 between 8 and 16 weeks (treatment period).
9740518|NCT00180687|Sham Comparator|Control|No intraperitoneal therapeutics (No nebulised Bupivacaine)
9740519|NCT00180687|Placebo Comparator|IP Aerosolized Normal Saline|Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
9740520|NCT00180687|Experimental|Nebulised Bupivacaine intraperitoneally|Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
9740521|NCT00180687|Active Comparator|Injected Bupivacaine intraperitoneally|Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
9740522|NCT00180713|Placebo Comparator|Arm 1: Control|Placebo tablet once daily
9740523|NCT00180713|Experimental|Arm 2: Experimental|Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
9740524|NCT00181155|Experimental|Allopurinol|One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
9740525|NCT00181155|Placebo Comparator|Placebo|One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
9740526|NCT00181168|Experimental|Euthyroid Group|Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.
9740527|NCT00181168|No Intervention|Hypothyroid Group|Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.
9740528|NCT00181207|Experimental|Active|Pneumatic Compression Device used twice daily for 20 minutes each time for 12 weeks
9740529|NCT00181207|Placebo Comparator|Sham|Device looked and sounded like a pneumatic compression device, but was not inflating nor deflating.
9740530|NCT00181285|Sham Comparator|Sham high frequency chest wall oscillation|Sham high frequency chest wall oscillation
9740531|NCT00181285|Active Comparator|Active high frequency chest wall oscillation|Active high frequency chest wall oscillation
9740532|NCT00181363|Experimental|Mamma board|use of the mamma board during radiotherapy
9740533|NCT00181610|Active Comparator|1|Placebo group normal saline twice per day
9740534|NCT00181610|Active Comparator|2|Recombinant human prolactin 60 mcg/kg every 12 hours
9740535|NCT00181610|Active Comparator|3|Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours
9740536|NCT00181623|Experimental|recombinant human prolactin treatment|Open label twice daily recombinant human prolactin
9740537|NCT00181714|Experimental|OROS MPH|Single arm- open treatment with extended duration methylphenidate (OROS MPH)
9740538|NCT00181766|Experimental|Strattera (atomoxetine)|
9740539|NCT00181844|Experimental|Lamotrigine|
9740540|NCT00181883|Experimental|Quetiapine|"2.5 - 5.0mg/kg PO BID quetiapine~Other Names:~Seroquel"
9781721|NCT01155726|Active Comparator|Nelfilcon A, Masked, Unmasked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
9781722|NCT01155726|Active Comparator|Nelfilcon A, Masked, Partially Masked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
9781723|NCT01155726|Active Comparator|Etafilcon A, Masked, Unmasked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
9781724|NCT01155726|Active Comparator|Etafilcon A, Masked, Partially Masked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
9781725|NCT01155778|Experimental|10 mg rhHNS|10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
9781726|NCT01155778|Experimental|45 mg rhHNS|45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
9781727|NCT01155778|Experimental|90 mg rhHNS|Given IDDD as a 45 mg dose every 14 [±2 days] for a monthly total of 90 mg for 6 months
9781728|NCT01155830||Infants with CHD|Infants with Congenital Diaphragmatic Hernia (CHD)
9781729|NCT01155830||Infants with sepsis|Infants who are culture positive for sepsis and require vasopressor support
9781730|NCT01155830||Infants treated with ECMO|Infants suffering cardiopulmonary failure significant enough to require heart/lung bypass treatment with extracorporeal membrane oxygenation (ECMO)
9781731|NCT01155869|Experimental|XR-NTX|Depot naltrexone (Vivitrol) 380 mg. IM monthly
9781732|NCT01155869|Active Comparator|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
9781733|NCT01155999|Experimental|T1225|
9781734|NCT01155999|Active Comparator|Tobramycin|
9781735|NCT01156012|Experimental|T2345|One drop of T2345
9781736|NCT01156012|Active Comparator|Prostaglandin|One drop
9781737|NCT01156051|Experimental|Guanfacine Extended-Release Tablets|Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
9781738|NCT01156051|Placebo Comparator|Placebo comparator|Placebo control
9781739|NCT01156116|Active Comparator|Continuous positive airway pressure|2 weeks of continuous positive airway pressure (CPAP) treatment which includes wearing the CPAP mask for 8 hours each night
9781740|NCT01156116|Placebo Comparator|Placebo|2 weeks of oral administration of a placebo tablet 30min before bedtime
9781741|NCT01156142|Experimental|Arm I|Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
9781742|NCT01156142|Placebo Comparator|Arm II|Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.
9781743|NCT01156311|Experimental|Glatiramer acetate (GA) and dimethyl fumarate|Participants taking a stable dose of GA for at least 12 months prior to the study remain on that dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
9781744|NCT01156311|Experimental|Interferon beta (IFNβ) and dimethyl fumarate|Participants taking a stable dose of one of the IFNβ products for at least 12 months prior to the study remain on that product and dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
9781745|NCT01156363|Experimental|Single Arm|
9781746|NCT01156376|Experimental|PO-019|Formula 12027-019 Mouthwash
9781747|NCT01156376|Experimental|PO-020|Formula 12027-020 Mouthwash
9781748|NCT01156376|Active Comparator|PO-116-A|Cool Mint Listerine
9781749|NCT01156480|Experimental|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
9740541|NCT00181961|Experimental|Maca Root 1500mg|Patients receiving 1500mg of maca root
9740542|NCT00181961|Experimental|Maca Root 3000mg|Patients receiving 3000mg of maca root
9740543|NCT00182000|Active Comparator|Seromycin|
9740544|NCT00182000|Placebo Comparator|Placebo|
9740545|NCT00182078|Placebo Comparator|Placebo|Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
9740546|NCT00182078|Experimental|Sertraline|Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.
9740547|NCT00182091|Active Comparator|AcroGHD Randomized to Growth Hormone|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to growth hormone. This is an interventional arm.
9740548|NCT00182091|Placebo Comparator|AcroGHD Randomized to Placebo|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to placebo. This is an interventional arm.
9740549|NCT00182091|No Intervention|AcroGHS|
9740550|NCT00182091|No Intervention|Active Acromegaly|
9740551|NCT00182325|Experimental|personalized web prenatal information|Personalized health information for pregnancy through personal health record
9740552|NCT00182325|Active Comparator|general web prenatal information|General pregnancy health related websites
9740553|NCT00182689|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9740554|NCT00182754|Experimental|Arm I|Patients receive octreotide subcutaneously (SC) once on day 1.
9740555|NCT00182754|Placebo Comparator|Arm II|Patients receive placebo SC once on day 1.
9740556|NCT00182767|Experimental|Treatment (ixabepilone and doxorubicin)|Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.
9740557|NCT00182793|Experimental|Arm I|Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®). One day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation. No more than 7 weeks later, patients proceed to course 2. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
9740558|NCT00182793|Experimental|Arm II|Patients undergo stem cell collection. Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
9740559|NCT00183092|Experimental|quinacrine|
9740560|NCT00183092|Placebo Comparator|placebo|
9740561|NCT00183170|Experimental|Alcohol then Placebo|Participants report for their first dosing night where they receive several alcohol drinks. After a wash out period of 1 week they then return and receive several placebo drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
9740562|NCT00183170|Experimental|Placebo then Alcohol|Participants report for their first night where they receive several placebo drinks. After a wash out period of 1 week they then return and receive several alcohol drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
9740563|NCT00183196|Active Comparator|1|Naltrexone plus placebo
9740564|NCT00183196|Active Comparator|2|naltrexone + gabapentin
9740565|NCT00183196|Sham Comparator|3|Placebo plus placebo
9740566|NCT00183248|Experimental|DBMCs|Kidney transplantation, followed by immunotherapy given along with kidney donor Donor bone Bone marrow Marrow stem cell Cells (DBMCs) infusions
9740567|NCT00183248|Active Comparator|Control Group|Kidney transplantation, followed by immunotherapy
9740568|NCT00183274|Active Comparator|Open-Label Group|6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
9740569|NCT00183274|Active Comparator|Double-Blind Drug Group|6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
9740570|NCT00183274|Placebo Comparator|Double-Blind Placebo Group|6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
9740571|NCT00183274|Active Comparator|Double-Blind Drug-After-Drug Group|6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
9740572|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Drug Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
9740573|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Placebo Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
9740574|NCT00183339|Placebo Comparator|Placebo|Placebo, liquid solution flexible dose 0.5 to 5ml every morning (AM)
9740575|NCT00183339|Experimental|fluoxetine|Fluoxetine, 20mg/5ml solution, flexible dose 0.5 to 5ml every AM
9740576|NCT00183391|Active Comparator|Atomoxetine|Participants will receive treatment for ADHD with the non-stimulant atomoxetine
9740577|NCT00183391|Active Comparator|Methylphenidate|Participants will receive treatment for ADHD with the stimulant methylphenidate
9740578|NCT00183430|Experimental|1|Participants will receive treatment with prazosin plus psychotherapy
9740579|NCT00183430|Placebo Comparator|2|Participants will receive treatment with placebo plus psychotherapy
9740580|NCT00183443|Placebo Comparator|DVP + placebo|Participants will receive divalproex ER at a therapeutic dose, plus placebo
9740581|NCT00183443|Active Comparator|DVP + Quetiapine|Participants will receive divalproex ER at a therapeutic dose, plus quetiapine up to 800 mg
9740582|NCT00183443|Active Comparator|DVP + Lithium|Participants will receive divalproex ER at a therapeutic dose, plus lithium at a therapeutic blood level
9740583|NCT00183456|Experimental|Intervention Condition: CHAT|Participants received the program over the course of five small group sessions and one individual session based on a harm reduction philosophy. Participants were trained as Peer Mentors and were encouraged to talk to their family, friends, and sex partners about a range of sex risk reduction options.
9740584|NCT00183456|Active Comparator|Comparison Condition: Standard of Care|The comparison condition consisted of one group session. The session focused on HIV and STIs transmission and risk reduction information.
9740585|NCT00183456|No Intervention|Network Participants|Index participants generated a list of network members during their baseline visits and were asked to recruit eligible network members into the study. These network participants completed study interviews but did not participate in the intervention.
9740586|NCT00183456|No Intervention|Non-randomized Baseline index participants|This arm includes those index participants that did not show up for randomization or did not recruit a network member were thus not eligible to be randomized into a study condition.
9740587|NCT00183469|Active Comparator|lamotrigine plus divalproex ER|Participants will take active lamotrigine and active divalproex ER
9740588|NCT00183469|Placebo Comparator|lamotrigine plus placebo divalproex ER|Participants will take active lamotrigine and placebo
9740589|NCT00183625|Active Comparator|Risperidone Plus Supported Employment|
9740590|NCT00183625|Active Comparator|Olanzapine Plus Supported Employment|
9740591|NCT00183625|Active Comparator|Risperidone+Supported Employment+Skills|
9740592|NCT00183625|Active Comparator|Olanzapine+Supported Employment+Skills|
9740593|NCT00183677|Experimental|Escitalopram|Participants will receive open treatment with escitalopram.
9740594|NCT00183729|Experimental|Memantine (1)|Memantine for 12 weeks
9740595|NCT00183729|Placebo Comparator|Placebo (2)|Placebo for 12 weeks
9740596|NCT00183794|Experimental|Arm 1|Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks.
9740597|NCT00183872|Experimental|Arm 1 - Irinotecan and Docetaxel|Irinotecan given day 1 and 8 every 21 days Docetaxel given day 1 and 8 every 21 days
9740598|NCT00184002|Experimental|DR-COP|"On cycle 1 patients receive Doxil 40 mg/m2 iv day 1 over a minimum of 60 min., Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min., Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5.~On cycle 2 until study completion patients receive Doxil 40 mg/m2 iv day 1, Rituxan 375 mg/m2 iv day 1, Cyclophosphamide 750 mg/m2 iv day 1, Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5~1 cycle = 21 days.~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
9740599|NCT00184028|Experimental|Arm 1|On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days.
9740600|NCT00184054|Experimental|Arsenic Trioxide (ATO) Plus Ascorbic acid|"Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period.~Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given"
9740601|NCT00184093|Experimental|Gemcitabine weekly x 6 wks with concurrent external radiation|Gemcitabine 350 mg/m2 IV weekly x 6 weeks with concurrent external radiation
9740602|NCT00184548|Experimental|rFVIIa, Blunt Trauma|
9740603|NCT00184548|Placebo Comparator|Placebo, Blunt Trauma|
9740604|NCT00184548|Experimental|rVIIa, Penetrating Trauma|
9740605|NCT00184548|Placebo Comparator|Placebo, Penetrating Trauma|
9740606|NCT00184600|Experimental|Insulin detemir (basal insulin)|Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.
9781750|NCT01156480|Placebo Comparator|Placebo|Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
9740607|NCT00184600|Active Comparator|Insulin aspart (prandial insulin)|Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.
9740608|NCT00184600|Active Comparator|Biphasic insulin aspart 30 (biphasic insulin)|Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.
9740609|NCT00184717|Experimental|0.033 mg / NN-220|In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
9740610|NCT00184717|Experimental|0.067 mg / NN-220|In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
9740611|NCT00184717|No Intervention|No treatment|No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
9740612|NCT00184717|Experimental|No treatment --> 0.033 mg|In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
9740613|NCT00184717|Experimental|No treatment --> 0.067 mg|In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
9740614|NCT00185211|Experimental|Initial IFNB-1b (Interferon beta-1b)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
9740615|NCT00185211|Experimental|Initial Placebo|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
9740616|NCT00185380|Experimental|LCS12|Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
9740617|NCT00185380|Experimental|LCS16|Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
9740618|NCT00185380|Active Comparator|IUS20 (Mirena)|Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro
9740619|NCT00185458|Experimental|LNG IUS|Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
9740620|NCT00185588|Experimental|Stage 1 Dose Exploration 0 - Gemcitabine 700 + vatalanib 1250|Gemcitabine 700 mg/m2 + vatalanib 1250 mg daily
9740621|NCT00185588|Experimental|Stage 1 Dose Exploration 1 - Gemcitabine 850 + vatalanib 1250|Gemcitabine 850 mg/m2 + vatalanib 1250 mg
9740622|NCT00185588|Experimental|Stage 1 Dose Explrtion2 - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
9740623|NCT00185588|Experimental|Stage 2 Dose Expansion - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
9740624|NCT00185614|Experimental|Auto- then Allo-HCT|Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue [ie, autologous hematopoietic cells transplant (Auto-HCT)]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 & Day 0, to a target of > 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV & diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.
9740625|NCT00185640|Experimental|Non-myeloablative transplantation|Pre-transplant total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) infusion with Day 0 allogeneic hematopoietic cell transplant (HCT), followed by post-transplant immunosuppression by cyclosporine and mycophenolate mofetil.
9740626|NCT00185679|Experimental|Haploidentical Allogeneic Transplant Using CliniMACS System|The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
9740627|NCT00185692|Experimental|Transplantation of CD34+ cells|"Week #1: Total Lymphoid Inrradiation (TLI) 120 cGy + Anti-thymocyte Globulin (ATG) 1.5 mg/kg + Solumedrol 1.0 mg/kg Daily for 5 days.~Week #2: TLI 120 cGy (3 days a week, double on the 4th day) 5 days of CSP (oraly) one day after TLI was started. 3 days of MMF 4 days after TLI was started."
9740628|NCT00185731|Experimental|80 mg Atorvastatin|Atorvastatin, 80 mg tablet, will be taken orally by the patient daily, beginning on study day 1.
9740629|NCT00185900|Active Comparator|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate.
9740630|NCT00185900|Active Comparator|Nifedipine|Preterm labor treatment with Nifedipine.
9740631|NCT00185965|Experimental|Lymphoma, B-cell low-grade (BCL)|Recurrent low-grade B-cell lymphoma patients (at least one prior treatment failure)
9740632|NCT00185965|Experimental|Mycosis fungoides (MF)|"Mycosis fungoides patients must have failed or have been intolerant of at least 1 topical or 1 systemic treatment~Recurrent mycosis fungoides patients (at least one prior failure of topical or systemic treatment)"
9740633|NCT00186017|Experimental|Olanzapine/Zyprexa|Olanzapine/Zyprexa 2.5 mg up to 8 per day for 1 week
9740634|NCT00186017|Placebo Comparator|Placebo|Placebo was taken in the same manner as olanzapine with up to 8 per day for 1 week
9740635|NCT00186043|Experimental|Quetiapine/Seroquel|Quetiapine/Seroquel up to 800 mg/day
9740636|NCT00186043|Placebo Comparator|Placebo|Placebo
9740637|NCT00186056|Experimental|Mifepristone|Patients received mifepristone for 6 days
9740638|NCT00186056|Placebo Comparator|placebo|Patients received placebo for 6 days
9740639|NCT00186069|Active Comparator|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by 2 grams per hour
9740640|NCT00186069|Placebo Comparator|Normal Saline|Normal Saline 4 gram bolus, followed by 2 grams per hour
9740641|NCT00186121|Experimental|Anastrozole + Goserelin|Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.
9740642|NCT00186186|Experimental|Depakote ER|Depakote ER up to 1500 mg/day
9740643|NCT00186446|Experimental|Bupropion|
9740644|NCT00186485|Experimental|Right Sided Low Frequency Unilateral TMS|1Hz unilateral TMS delivered to the right DLPFC using the MagStim device
9740645|NCT00186498|Placebo Comparator|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
9740646|NCT00186498|Experimental|memantine|Patients receive memantine starting the day before ECT begins and while receiving ECT
9740647|NCT00186537|Active Comparator|fenofibrate|160 mg daily for 12 weeks
9740648|NCT00186537|Active Comparator|rosiglitazone|4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
9740649|NCT00186537|Active Comparator|calorie restricted diet|calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
9740650|NCT00186628|Experimental|Prophylactic Rituximab|Rituximab will be infused after a non-myeloablative transplantation regimen of total lymphoid irradiation (TLI) + anti-thymoglobulin (ATG), with the intention of reducing chronic graft-vs-host disease (cGvHD)
9740651|NCT00186875|Other|Treatment|Participants receive chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplant, and natural killer cell transplant as outlined in the Interventions section, including etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase.
9740652|NCT00186901|Placebo Comparator|1A|Nutritional counseling + placebo
9740653|NCT00186901|Experimental|1B|Nutritional counseling + supplementation with calcium, 1000mg/day + vitamin D, 800 units/day, for a 2 year period
9740654|NCT00187096|Experimental|Stratum 1|"Stratum 1 (AML in complete remission)~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0"
9740655|NCT00187096|Experimental|Stratum 2|"Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0."
9740656|NCT00187135|Active Comparator|1|Fentanyl-1mcg/kg in 3 ml of Normal Saline
9740657|NCT00187135|Active Comparator|2|Fentanyl - 0.5 mcg/kg in 3 ml normal saline
9740658|NCT00187135|Placebo Comparator|3|normal saline
9740659|NCT00187200|Active Comparator|Simultaneous VV Pacing|Programmed to simultaneous biventricular pacing
9740660|NCT00187200|Active Comparator|Sequential VV Pacing|Programmed to sequential biventricular pacing
9740661|NCT00187226|Other|Stratum 1|Ependymoma, craniopharyngioma, low-grade glioma
9740662|NCT00187226|Other|Stratum 2|High-grade glioma
9740663|NCT00187278|Active Comparator|RV Pacing|Standard Pacemaker implant
9740664|NCT00187278|Experimental|Biventricular Pacing|Biventricular Pacemaker implant
9983909|NCT04551430|Experimental|Cohort A: Cabozantinib|Patients randomized to Cohort A will take cabozantinib at a dose of 60 mg by mouth once each day of each 28-day cycle. At time of progression, patients will continue on cabozantinib daily but will reduce their dose to 40 mg. They will cross over into Cohort B and initiate treatment.
9740665|NCT00187369|Other|Caesarean Section|delivery by CS
9740666|NCT00187369|Other|Vaginal Birth|delivery by VB
9740667|NCT00187486|Experimental|Temodar plus Tarceva plus Radiation Therapy|Single arm phase-2 experimental treatment of newly diagnosed patients with Glioblastoma with Temodar plus Tarceva plus Radiation Therapy
9740668|NCT00187655|Other|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
9740669|NCT00187681|Experimental|OCT1-variant Group|Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin
9740670|NCT00187681|Experimental|OCT1-reference Group|Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin
9740671|NCT00187720|Experimental|OCT2-variant Group|Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
9740672|NCT00187720|Experimental|OCT2-reference Group|Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.
9740673|NCT00187876|Active Comparator|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts.
9740674|NCT00187876|Experimental|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
9740675|NCT00187889|Active Comparator|Eplerenone|Eplerenone 25 mg (1 pill)daily for 1 week then uptitrated to 50 mg (2 pills)daily for 15 weeks.
9740676|NCT00187889|Placebo Comparator|Placebo or sugar pill|Placebo blinded as 25 mg tablet once daily for 1 week then uptitrated to 2 pills daily for 15 weeks.
9740677|NCT00189098|Placebo Comparator|placebo|
9740678|NCT00189098|Active Comparator|Sulfamethoxazole-trimethoprim|
9740679|NCT00189137|Active Comparator|doxorubicin and ifosfamide|
9740680|NCT00189137|Experimental|gemcitabine and docetaxel|
9740681|NCT00189202|Experimental|Sirolimus, steroid avoidance arm|Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
9740682|NCT00189228|Experimental|xolair|This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.
9740683|NCT00189306|Experimental|Aldara|Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
9740684|NCT00189423|Experimental|1|Active compression decompression cardiopulmonary resuscitation (ACD-CPR) with an impedance threshold device (ITD)
9740685|NCT00189423|Active Comparator|2|Conventional standard cardiopulmonary resuscitation (S-CPR)
9740686|NCT00189436|Active Comparator|Treatment with Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
9740687|NCT00189436|Active Comparator|Usual care|Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
9740688|NCT00189462|Active Comparator|Montelukast|Treatment with montelukast for 4 months (4 mg per day)
9740689|NCT00189462|Placebo Comparator|Placebo|Treatment with placebo for 4 months
9740690|NCT00189475|Active Comparator|Montelukast|Treated for 4 months with montelukast 4 mg per day
9740691|NCT00189475|Placebo Comparator|Placebo|Treated for 4 months with placebo
9740692|NCT00189488|Experimental|Palifermin|Palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and 180 μg/kg administered once prior to transplant and at least 96 hours from last palifermin dose of 60 μg/kg. Participants received conditioning therapy starting at least 24 hours after the last 60 μg dose of palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the 180 μg/kg dose of palifermin on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
9740693|NCT00189488|Placebo Comparator|Placebo|Placebo to palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and placebo to palifermin 180 μg/kg once prior to transplant and at least 96 hours from previous placebo to palifermin 60 μg/kg dose. Participants received conditioning therapy starting at least 24 hours after the last 60 μg/kg dose of placebo to palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the dose of placebo to palifermin 180 μg/kg on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
9740694|NCT00189540|Active Comparator|Active Group|4.0 mg AMG0001 via intramuscular injections on days 0, 14, and 28
9740695|NCT00189540|Placebo Comparator|Placebo Group|Placebo (saline) via intramuscular injections on days 0, 14, and 28
9740696|NCT00190671|Experimental|Pemetrexed 600 mg/m2|
9740697|NCT00190671|Experimental|Pemetrexed 1800 mg/m2|
9740698|NCT00190684|Experimental|Atomoxetine|Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.
9740699|NCT00190749|Experimental|Olanzapine|
9740700|NCT00190749|Active Comparator|Risperidone|
9740701|NCT00190775|Experimental|Atomoxetine|Atomoxetine 40 milligrams (mg) once daily (QD) for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
9740702|NCT00190775|Placebo Comparator|Placebo|Placebo is administered once daily (QD), orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
9740703|NCT00190983|Experimental|Pemetrexed|
9740704|NCT00191100|Experimental|1|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week~Two week rest period with no chemotherapy or radiation~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles"
9740705|NCT00191100|Active Comparator|2|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week"
9740706|NCT00191113|No Intervention|Control|Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
9740707|NCT00191113|Experimental|Humatrope|Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
9740708|NCT00191139|Experimental|Gemcitabine|
9740709|NCT00191139|Experimental|Gemcitabine plus Docetaxel|
9740710|NCT00191152|Experimental|Gemcitabine + Docetaxel|
9740711|NCT00191152|Active Comparator|Capecitabine + Docetaxel|
9740712|NCT00191165|Experimental|1|Doubled dosage
9740713|NCT00191165|Active Comparator|2|In-label dosage
9740714|NCT00191191|Experimental|Pemetrexed 500 mg/m2|Pemetrexed 500 mg/m2
9740715|NCT00191191|Experimental|Pemetrexed 1000 mg/m2|Pemetrexed 1000 mg/m2
9740716|NCT00191269|Experimental|A|Dose Level 1 - 1000 mg/m2
9740717|NCT00191269|Experimental|B|Dose Level 2 - 1250 mg/m2
9740718|NCT00191282|Experimental|1|Postprandial: Premeal insulin lispro +/- bedtime NPH
9740719|NCT00191282|Active Comparator|2|Fasting: NPH/insulin glargine or human insulin 30/70
9740720|NCT00191308|Experimental|Pemetrexed + Cisplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs~Cisplatin: 75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs"
9740721|NCT00191334|Experimental|A|
9740722|NCT00191386|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
9740723|NCT00191451|Experimental|HER2+|Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin.
9740724|NCT00191451|Experimental|HER2- (Taxane-)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients).
9740725|NCT00191451|Experimental|HER2- (Taxane+)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients).
9740726|NCT00191477|Experimental|A|
9740727|NCT00191477|Placebo Comparator|B|
9740728|NCT00191646|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 milligrams per meter square (mg/m^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles
9740729|NCT00191646|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel 175 milligrams per meter square (mg/m^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles
9740730|NCT00191724|Experimental|1|
9740731|NCT00191724|Experimental|2|
9740732|NCT00191724|Experimental|3|
9740733|NCT00191724|Experimental|4|
9740734|NCT00191724|Placebo Comparator|5|
9740735|NCT00191789|Experimental|Gemcitabine+Doxorubicin+Cisplatin+Surgery|"Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).~Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision."
9781751|NCT01156532||Adalimumab Treatment in Participants with Psoriasis|Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate.
9781752|NCT01156571|Experimental|cangrelor|"Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered."
9781753|NCT01156571|Active Comparator|clopidogrel|"Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm."
9781754|NCT01156597|Active Comparator|Pioglitazone Group|This is a baseline versus treatment study comparing subjects on pioglitazone to a matched group of subjects treated with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level
9781755|NCT01156597|No Intervention|Comparator Group|This group of subjects will be maintained on standard treatment with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level as group treated with pioglitazone.
9781756|NCT01156675|Experimental|FLEXUS™ Interspinous Spacer|
9781757|NCT01156675|Active Comparator|XSTOP® Interspinous Spacer|
9740736|NCT00191815|Experimental|Gemcitabine + Cisplatin|
9740737|NCT00191854|Experimental|Gemcitabine + Paclitaxel|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles."
9740738|NCT00191854|Experimental|Gemcitabine + Carboplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles."
9740739|NCT00191854|Experimental|Gemcitabine + Cisplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.~cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles"
9740740|NCT00191906|Experimental|Atomoxetine first, then Placebo|Atomoxetine, 1.2 mg/kg/day, by mouth (PO) for 4 weeks, 2 week washout period and cross-over to placebo, every day (QD), PO for 4 weeks
9740741|NCT00191906|Experimental|Placebo first, then Atomoxetine|Placebo, every day (QD), by mouth (PO) for 4 weeks, 2 week washout period and cross-over to atomoxetine 1.2 mg/kg/day, PO for 4 weeks
9740742|NCT00191906|No Intervention|Normal Control|Normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population.
9740743|NCT00191906|No Intervention|Reading Disordered Control|The reading disordered control group is comprised of children with reading disorder who receive standard remedial teaching therapy.
9740744|NCT00191945|Experimental|Atomoxetine|atomoxetine: 0.5 mg/kg/day every day (QD),by mouth (PO) for 2 weeks, 1.2 - 1.4 mg/kg/day QD, PO for 10 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year
9740745|NCT00191945|Placebo Comparator|Placebo|placebo every day (QD), by mouth (PO) for 12 weeks,then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year (open-label extension)
9740746|NCT00191984|Experimental|Pemetrexed + Irinotecan|
9740747|NCT00192023|Experimental|Atomoxetine|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO) for 1 week, 1.2 mg/kg/day QD, PO for 7 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
9740748|NCT00192023|Placebo Comparator|Placebo|placebo, daily (QD), by mouth (PO) for 8 weeks, then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
9740749|NCT00192036|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).~Cisplatin: 80 mg/m2, IV, every 21 days x 5 cycles.~Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."
9740750|NCT00192075|Experimental|A+FFG|Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid
9740751|NCT00192075|Active Comparator|A+FOLFOX 4|Avastin + Oxaliplatin + 5-Fluorouracil (5FU)/Folinic Acid
9740752|NCT00192114|Experimental|Enzastaurin HCl|
9740753|NCT00192296|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
9740754|NCT00192296|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
9740755|NCT00192296|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
9740756|NCT00192296|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
9740757|NCT00192504|Experimental|Motavizumab, 3 mg/kg as a single intravenous dose|Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0
9740758|NCT00192504|Experimental|Motavizumab, 15 mg/kg as a single intravenous dose|Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0
9740759|NCT00192504|Experimental|Motavizumab, 30 mg/kg as a single intravenous dose|Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0
9740760|NCT00192504|Placebo Comparator|Placebo, as a single intravenous dose|Placebo, as a single intravenous dose administered on Day 0
9740761|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Induction Treatment|Participants will receive 12 weeks of induction therapy with PEG-IFN alfa-2a (Pegasys), 360 micrograms (mcg) subcutaneous (SC) once weekly, along with ribavirin, 1000 or 1200 milligrams (mg) orally daily in divided doses. Thereafter, the dose of PEG-IFN alfa-2a will be reduced to 180 mcg SC once weekly and the ribavirin dose maintained for the remaining 36 weeks of treatment.
9740762|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Standard Treatment|Participants will receive 48 weeks of standard therapy with PEG-IFN alfa-2a, 180 mcg SC once weekly, along with ribavirin, 1000 or 1200 mg orally daily in divided doses.
9740763|NCT00193037|Experimental|Liposomal Doxorubicin|Liposomal doxorubicin 40 mg/m2 by 1 hour IV infusion repeated every 28 days.
9740764|NCT00193037|Experimental|Docetaxel|Weekly docetaxel 36 mg/m2 by 30 minute IV infusion on days 1, 8, and 15 of the 28 day cycle
9740765|NCT00193050|Experimental|Intervention|"In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles~Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.~After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.~After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines."
9740766|NCT00193063|Experimental|Intervention|All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.
9740767|NCT00193128|Experimental|Cohort 1|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
9740768|NCT00193128|Experimental|Cohort 2|"Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
9740769|NCT00193180|Experimental|Intervention|All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beginning concurrently with the first dose of docetaxel; however, after the first 15 patients were treated it became evident that this imatinib dose was not tolerable, and subsequent patients received imatinib mesylate 400 mg orally daily.
9740770|NCT00193206|Experimental|Intervention|Patients were treated with 6 doses of neoadjuvant gemcitabine 2000 mg/m2, epirubicin 50 mg/m2, and albumin-bound paclitaxel 175 mg/m2 intravenously administered at 14-day intervals. Following neoadjuvant chemotherapy, patients underwent either mastectomy or breast conservation surgery; pathologic response to treatment was assessed. Postoperatively, patients received 4 doses of gemcitabine 2000 mg/m2 with albumin-bound paclitaxel 220 mg/m2 at 14-day intervals. Pegfilgrastim 6 mg was administered subcutaneously on day 2 following each dose of chemotherapy.
9740771|NCT00193258|Experimental|Intervention|"In the phase I portion:~Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course~Erlotinib 150 mg orally daily~Imatinib 300 mg orally daily or 400 mg orally daily~In the phase II portion:~Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle~Erlotinib 150 mg orally daily~Imatinib 400 mg orally daily"
9740772|NCT00193375|Experimental|Intervention|Patients received carboplatin [area under the concentration-versus-time curve of 5 intravenously (IV) day 1 every 3 weeks x 4), irinotecan (50mg/m2 IV days 1 and 8 every 3 weeks x 4], and radiation (1.8 Gy daily to a total of 61.2 Gy beginning with the 3rd cycle). Cycles 3 and 4 were 28 days each; with restaging after 4 cycles. Patients without progressive disease received bevacizumab (10 mg/kg IV every 14 days x 10).
9740773|NCT00193453|Experimental|Intervention|Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d).
9740774|NCT00193492|Active Comparator|Rituximab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). Patients who have objective response or stable disease at week 12 reevaluation will receive 4 additional doses of rituximab (375 mg/m2) administered in months 3 (week 12), 5, 7, and 9.
9740775|NCT00193492|Experimental|Rituximab/Bevacizumab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
9740776|NCT00193596|Experimental|Regimen A|"Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1~Carboplatin area under the curve (AUC) 6.0 IV, day 1~Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10~Regimen A was repeated at a 21-day interval"
9740777|NCT00193596|Experimental|Regimen B|"Irinotecan 100 mg/m2 IV, days 1 and 8~Gemcitabine 1000 mg/m2 IV, days 1 and 8~Regimen B was repeated at a 21-day interval"
9740778|NCT00193609|Experimental|Oxaliplatin/Capecitabine|All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
9740779|NCT00194012|Active Comparator|Aripiprazole-Randomized Phase|Patients randomly assigned to aripiprazole received medication in pill form with dosing at 2mg, 5mg, 7mg, 10mg, 12mg or 15mg depending on their response.
9740780|NCT00194012|Placebo Comparator|Placebo-Randomized Phase|Patients randomly assigned to placebo received pills/dosing made to look identical to the aripiprazole.
9740781|NCT00194025|Experimental|valproate|All participants received open-label, add-on valproate.
9740782|NCT00194077|Active Comparator|Aripiprazole|Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
9740783|NCT00194077|Placebo Comparator|Placebo|in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks
9740784|NCT00194116|Experimental|Divalproex Sodium ER|
9740785|NCT00194116|Placebo Comparator|Placebo|
9740786|NCT00194129|Experimental|Lithium plus Divalproex|Patients assigned to the combination group were continued on lithium and blinded divalproex.
9740787|NCT00194129|Placebo Comparator|Lithium plus placebo|Patients assigned to lithium monotherapy underwent divalproex-placebo substitution at a rate of 250 mg decrements every week until discontinued.
9740788|NCT00194532|Experimental|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
9740789|NCT00194532|Active Comparator|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
9740790|NCT00194610|Experimental|Botox injection|Subjects were injected with Botulinum toxin A in a mix of 50 U diluted in 2 cubic centimeters of normal saline. With the subjects in the dorsal lithotomy position, one injection of 25 international units was given into the bladder neck at the 3 o'clock position and another of 25 international units was given into the 9 o'clock position
9740791|NCT00194610|Placebo Comparator|Normal saline|Subjects were injected in the bladder neck with 1 cubic centimeter normal saline into the 3 o'clock and 6 o' clock positions in the perineum, while in the dorsal lithotomy position
9740792|NCT00194675|Active Comparator|Testosterone gel + oral placebo|Testosterone 1% gel 7.5 topical daily + placebo dutasteride orally daily
9740793|NCT00194675|Active Comparator|Testosterone gel + oral dutasteride|Testosterone 1% gel 7.5 topical daily + dutasteride 0.5 mg orally daily
9740794|NCT00194779|Experimental|Treatment (neoadjuvant therapy, adjuvant therapy)|See Detailed Description.
9740795|NCT00194792|Experimental|Treatment (hormone therapy and chemotherapy)|See detailed description
9740796|NCT00194896|Active Comparator|rosiglitazone|Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
9740797|NCT00194896|Active Comparator|glyburide|Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.
9740798|NCT00194987|Experimental|IVIG x 2|IVIG 2 g/kg/wk divided into 2 infusions per week for women with a fetus affected by FNAIT
9740799|NCT00194987|Experimental|IVIG x 1 + prednisone|IVIG 1 g/kg/wk in 1 infusion per week + prednisone 0.5 mg po daily for women with a fetus affected by FNAIT
9740800|NCT00195013|Experimental|Glutamine|10 grams three times a day (orally) for four days and then stop
9740801|NCT00195013|Placebo Comparator|Placebo|10 grams three times a day (orally) for four days and then stop
9740802|NCT00195039|Experimental|All patients|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
9740803|NCT00195260|Experimental|Dose escalation|Dose finding study of monotherapy bosutinib in patients with advanced solid tumors.
9740804|NCT00195260|Experimental|Colorectal Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
9740805|NCT00195260|Experimental|Pancreatic Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
9740806|NCT00195260|Experimental|Non-Small Cell Lung Cancer (NSCLC)|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
9740807|NCT00195273|Experimental|1|Sirolimus + Daclizumab + Mycophenolate + Corticosteroids
9740808|NCT00195273|Active Comparator|2|Cyclosporine + Mycophenolate + Corticosteroids
9740809|NCT00195338||1|This is an open label, observational study.This is a post-marketing surveillance study in rheumatology practice patients in Luxemburg.Rheumatologists will be asked to document safety and adherence to therapy of Enbrel when given to adults with active rheumatoid arthritis.All patients initiated with Enbrel will be observed.
9740810|NCT00195351|Active Comparator|A|
9740811|NCT00195351|Active Comparator|B|
9740812|NCT00195403||1|
9740813|NCT00195429|Experimental|Sirolimus + Tacrolimus|
9740814|NCT00195429|Active Comparator|Sirolimus + Prednisone|
9740815|NCT00195442||A|Patients with Hemophilia A
9740816|NCT00195494|Active Comparator|1a|Etanercept + Methorexate for Period 1 (first 12 months) and Period 2 (Second 12 months)
9740817|NCT00195494|Active Comparator|1b|Etanercept + Methotrexate for Period 1 (First 12 months) and Etanercept alone for Period 2 (Second 12 months)
9740818|NCT00195494|Active Comparator|2a|Methotrexate alone in Period 1 (First 12 months) and etanercept + Methotrexate in Period 2 (Second 12 months)
9740819|NCT00195494|Active Comparator|2b|Methotrexate alone in Period 1 (First 12 months) and Methotrexate alone in Period 2 (Second 12 months)
9517282|NCT03307720|Experimental|Normo responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
9517283|NCT03307720|Active Comparator|High responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
9740820|NCT00195624|Experimental|Relapsed severe aplastic anemia|Subjects diagnosed with relapsed severe aplastic anemia
9740821|NCT00195624|Experimental|Refractory severe asplastic anemia|Subjects diagnosed with refractory severe aplastic anemia
9740822|NCT00195624|Experimental|Relapse after Alemtuzumab|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit.
9740823|NCT00195650|Experimental|Adalimumab|Open-label adalimumab 40 mg
9740824|NCT00195663|Experimental|Adalimumab|Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.
9740825|NCT00195663|Experimental|Adalimumab + methotrexate|Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
9740826|NCT00195663|Experimental|Methotrexate|Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
9740827|NCT00195676|Other|Adalimumab|
9740828|NCT00195702|Experimental|DB adalimumab 20 mg ew|Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
9740829|NCT00195702|Experimental|DB adalimumab 40 mg eow|Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
9740830|NCT00195702|Placebo Comparator|DB placebo ew|Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
9740831|NCT00195702|Experimental|DB adalimumab 20 mg ew/OL adalimumab 40 mg eow|Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
9740832|NCT00195702|Experimental|DB adalimumab 40 mg eow/OL adalimumab 40 mg eow|Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
9740833|NCT00195702|Experimental|DB placebo ew/OL adalimumab 40 mg eow|Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
9740834|NCT00195819|Experimental|Adalimumab|
9740835|NCT00195819|Placebo Comparator|Placebo|
9740836|NCT00196105|Experimental|6 mm Zilver|6 mm Nitinol Zilver Stent
9740837|NCT00196105|Experimental|10 mm Zilver|10 mm Nitinol Zilver Stent
9740838|NCT00196105|Active Comparator|10 mm Wallstent|10 mm Stainless Steel Wallstent
9740839|NCT00196313|Experimental|1 levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablet|
9740840|NCT00196313|Placebo Comparator|2|
9740841|NCT00196326|Experimental|DR-1011|Participants were instructed to take, by mouth, one tablet daily for four 91-day cycles.
9740842|NCT00196716|Experimental|Fabrazyme|Open-label study. Patients received 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months.
9740843|NCT00196937|Experimental|Cervarix (15-25 Years) Group|Women aged 15 to 25 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
9740844|NCT00196937|Experimental|Cervarix (26-45 Years) Group|Women aged 26 to 45 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
9740845|NCT00196937|Experimental|Cervarix (46-55 Years) Group|Women aged 46 to 55 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
9740846|NCT00196976|Experimental|GSK134612A Form1 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
9740847|NCT00196976|Experimental|GSK134612A Form2 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
9740848|NCT00196976|Experimental|GSK134612A Form3 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
9740849|NCT00196976|Experimental|GSK134612A Form4 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
9740850|NCT00196976|Active Comparator|Control (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer's Meningitec™ conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
9740851|NCT00196976|Experimental|GSK134612A Form1 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
9517284|NCT03307720|Experimental|High responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
9740852|NCT00196976|Experimental|GSK134612A Form2 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
9740853|NCT00196976|Experimental|GSK134612A Form3 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
9740854|NCT00196976|Experimental|GSK134612A Form4 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
9740855|NCT00196976|Active Comparator|Control (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).
9740856|NCT00196976|Experimental|GSK134612A Form1 (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
9740857|NCT00196976|Active Comparator|Control (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
9740858|NCT00196976|Experimental|GSK134612A Form1 (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.
9740859|NCT00196976|Active Comparator|Control (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, did not receive any booster vaccination.
9740860|NCT00197002|Active Comparator|Havrix Group|Healthy male or female subjects, 15 months of age, who received Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Day 0 and at Month 6-9.
9740861|NCT00197002|Experimental|Havrix+Prevnar Group|Healthy male or female subjects, 15 months of age, who received Havrix® and Prevnar™ vaccines co-administered intramuscularly in the right and left anterolateral thighs, respectively, at Day 0 and Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Month 6-9.
9740862|NCT00197002|Active Comparator|Prevnar Havrix Group|Healthy male or female subjects, 15 months of age, who received Prevnar™ vaccine administered intramuscularly in the left anterolateral thigh, at Day 0 and Havrix® vaccine, administered intramuscularly in the right anterolateral thigh, at Day 30 and at Month 7-10.
9740863|NCT00197015|Active Comparator|HAV Group|Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)
9740864|NCT00197015|Experimental|HAV+MMR+V Group|Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9
9740865|NCT00197015|Active Comparator|MMR+V→HAV Group|Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)
9740866|NCT00197028|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of RTS,S/AS02D at days 14, 44 and 74 and a 3-dose vaccination course of TETRActHib™ vaccine at days 0, 30 and 60. The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
9740867|NCT00197028|Active Comparator|Engerix-B Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine at days 14, 44 and 74 and a 3-dose of TETRActHib™ vaccine at days 0, 30 and 60. The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
9740868|NCT00197054|Experimental|VACC 1 (RTS, S/AS01B)|RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
9740869|NCT00197054|Experimental|VACC 2 (RTS, S/AS02A)|RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
9740870|NCT00197054|Active Comparator|Rabipur (Rabies) Vaccine|Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
9740871|NCT00197106|Active Comparator|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg
9740872|NCT00197106|Other|fluticasone propionate 2 x 100 mcg|fluticasone propionate 2 x 100 mcg
9740873|NCT00197119|Active Comparator|Group Twinrix Adult|Subjects received Twinrix™ Adult (720/20) in a 0, 6 month schedule in the primary study.
9517285|NCT03307707||Heart Failure (HF)|subjects with a Left Ventricular Ejection Fraction (LVEF) <50% or LVEF >50% and E/e'>10.
9517286|NCT03307707||No Heart Failure (NHF)|subjects with LVEF>50%
9740874|NCT00197119|Active Comparator|Group Twinrix Junior|Subjects received Twinrix™ Junior (360/10) in a 0, 1, 6 month schedule in the primary study.
9740875|NCT00197145|Experimental|GW873140|
9740876|NCT00197184|Experimental|Twinrix Junior|Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).
9740877|NCT00197184|Active Comparator|Twinrix Adult|Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).
9740878|NCT00197236|Active Comparator|Havrix Group|Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.
9740879|NCT00197236|Experimental|Infanrix + ActHIB→Havrix Group|Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30 and a second dose of Havrix at Month 7-10.
9740880|NCT00197236|Active Comparator|Havrix + Infanrix + ActHIB Group|Subjects received one dose of Havrix co-administered with Infanrix and ActHIB vaccines at Day 0 followed by a second dose of Havrix at Month 6-9.
9740881|NCT00197392|Experimental|Bactiseal TM EVD|Bactiseal External Ventricular Drainage System.
9740882|NCT00197392|Active Comparator|Standard EVD Catheter|Standard External Ventricular Device system
9740883|NCT00197496|Experimental|BWSTT|Body weight supported treadmill training
9740884|NCT00197496|No Intervention|Usual care|Usual care
9740885|NCT00198029|Experimental|Pilot Study of Hylan G-F 20|32 Subjects have received Synvisc Injections and followed for 6 months.
9740886|NCT00198042|Experimental|Surgical Reconstruction of the ACL|
9740887|NCT00198081|Experimental|Surgical Candidate|COX-2 Inhibitor 6-8 weeks prior to surgery
9740888|NCT00198081|Experimental|Medical Candidate|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
9740889|NCT00198107|Placebo Comparator|1 Placebo|Participants will take placebo
9740890|NCT00198107|Active Comparator|2 Aripiprazole|Participants will take aripiprazole
9740891|NCT00198107|Active Comparator|3 Aripiprazole + D-cycloserine|Participants first will take aripiprazole then will also take D-cycloserine
9740892|NCT00198133|Experimental|Pemetrexed|Pemetrexed infusion once every 21 days (one cycle).
9740893|NCT00198822|Experimental|1|Weekly oral supplement with 7000 µg retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy
9740894|NCT00198822|Experimental|2|Weekly oral supplement with 42 mg of beta-carotene from early pregnancy through 12 weeks following termination of pregnancy
9740895|NCT00198822|Placebo Comparator|3|Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy
9740896|NCT00199381|Experimental|Single Arm|Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
9740897|NCT00199797|Experimental|huA33 antibody plus chemotherapy|"huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.~Starting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.~Oxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.~The doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as a bolus infusion and 600mg/m2 as a continuous infusion.~A complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
9740898|NCT00199836|Experimental|Patients with Cancer Expressing NY-ESO-1 or LAGE-1 Antigen.|NY-ESO-1b peptide, 100 μg mixed with 1 mg CpG 7909 and 0.5mL of Montanide® ISA-51 was administered to patients with cancer expressing NY-ESO-1 or LAGE-1 antigen. The injections were given subcutaneously beginning on week 1 and repeated every three weeks for 4 injections total. There was a 3 week follow-up period after the last injection. In the absence of toxicity and progressive disease (PD), a second cycle was offered to patients who received 4 vaccinations.
9740899|NCT00199849|Experimental|Cohort 1|"4 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device. The 4 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 4 X 1 µg PMEDs in close proximity.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
9740900|NCT00199849|Experimental|Cohort 2|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as 8 X 1 µg PMEDs.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > Grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
9740901|NCT00199849|Experimental|Cohort 3|"8 µg NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine~NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.~The 8 µg dosage of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered as a cluster dosage of 4 doses (day 1, 3, 5, 8) as 2 X 1 µg PMEDs per day.~The vaccine was administered in weeks 1, 5, and 9 of Cycle 1. In the absence of > grade 3 toxicity and in the absence of progressive disease requiring other treatment or the presence of NY-ESO-1 immunity, patients could receive an additional cycle of vaccinations of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine."
9517287|NCT03307694||MAC-SWEI, standard SWEI, ultrasound|Participants in this group will receive all three imaging techniques
9517288|NCT03307694||Standard SWEI, ultrasound|Participants in this group will receive two imaging techniques
9740902|NCT00199875|Experimental|Cohort 1 (0.2 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.2 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
9740903|NCT00199875|Experimental|Cohort 2 (0.3 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.3 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
9740904|NCT00199875|Experimental|Cohort 3 (0.4 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.4 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
9740905|NCT00199875|Experimental|Cohort 4 (0.45 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.45 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
9740906|NCT00199875|Experimental|Cohort 5 (0.55 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.55 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
9740907|NCT00199888|Experimental|124I-cG250|Patients who were scheduled for surgical resection of renal masses received a single intravenous (IV) dose of 10 mg of 5 milliCurie (mCi) /10 mg 124I-cG250. Patients underwent Positron-Emission Tomography/Computed Tomography (PET/CT) imaging of the whole body on at least 2 occasions: once following injection and once immediately prior to surgical resection. Patients were scheduled for surgical resection of their renal masses on day 8.
9740908|NCT00199901|Active Comparator|Vaccine|NY-ESO-1 ISCOMATRIX® vaccine
9740909|NCT00199901|Placebo Comparator|Adjuvant Alone|ISCOMATRIX® adjuvant alone
9740910|NCT00199914|Experimental|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
9740911|NCT00199914|Sham Comparator|control|continuous sham shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
9740912|NCT00200161|Active Comparator|Metronomic Therapy Cohort|Concurrent temozolomide and radiotherapy plus lose dose of temozolomide
9740913|NCT00200161|Experimental|Dose-Dense Therapy Cohort|Concurrent temozolomide and radiotherapy plus high dose of temozolomide
9740914|NCT00200343|Experimental|Ursodeoxycholic acid 150mg / day|
9740915|NCT00200343|Experimental|Ursodeoxycholic acid 600mg / day|
9740916|NCT00200343|Experimental|Ursodeoxycholic acid 900mg / day|
9740917|NCT00200356|Experimental|Edaravone|
9740918|NCT00200356|Active Comparator|Ozagrel|
9740919|NCT00200785|Active Comparator|Garlic powder in ambient water|high allicin
9740920|NCT00200785|Experimental|garlic powder in boiling water|no allicin
9740921|NCT00200850|Active Comparator|Low dose SLIT|Low dose SLIT
9740922|NCT00200850|Active Comparator|High dose SLIT|High dose SLIT
9740923|NCT00200850|Placebo Comparator|Placebo|Placebo
9740924|NCT00200902|Active Comparator|MED|"For medication treatment, three different types were utilized and assigned specifically to each subject depending on their condition:~MED 1: Venlafaxine XR. MED 2: Duloxetine (Cymbalta) MED 3: Escitalopram (Lexapro)"
9740925|NCT00200902|Placebo Comparator|Placebo (PBO)|Subjects enrolled will receive interpersonal clinical interaction (ICI) along with a placebo treatment (Interaction and assessment as in ICI plus double blinded treatment with placebo tablets).
9740926|NCT00200902|Other|Interpersonal Clinical Interaction (ICI)|Subjects assigned to the interpersonal clinical interaction (ICI) will undergo a one-week waiting period after the initial assessment. Visits will involve a session with a research nurse that will be approximately 20 minutes in length; visits at baseline, end of lead-in, and 1, 2, 4, and 8 weeks also will include a brief (5-10 minutes) meeting with a physician.
9740927|NCT00200967|Experimental|B16 Arg/Arg|B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
9740928|NCT00200967|Experimental|B16 Gly/Gly|B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
9740929|NCT00201006|Experimental|Face-to-face counseling|26 biweekly face-to-face group counseling sessions
9740930|NCT00201006|Experimental|Telephone Counseling|26 biweekly telephone counseling sessions
9740931|NCT00201006|Active Comparator|Mail contact|26 biweekly newsletters with weight management advice
9740932|NCT00201123|Placebo Comparator|Standard Treatment|Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
9740933|NCT00201123|Experimental|Aerosol Interferon-gamma|Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
9740934|NCT00201123|Experimental|Subcutaneous Interferon-Gamma|Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
9740935|NCT00201201|Experimental|Education|PEP-NG targeted and tailored education intervention
9740936|NCT00201201|Other|Control|Control, intervention is care as usual.
9740937|NCT00201240|Experimental|CD34+ selection with CliniMACS device|T cell depletion using Miltenyi device
9740938|NCT00201409|Experimental|1|Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).
9740939|NCT00201409|Placebo Comparator|2|Participants will be randomized to receive placebo.
9740940|NCT00201448|Active Comparator|Placebo (hepatitis A)|Placebo group
9740941|NCT00201448|Experimental|Towne vaccine|Towne vaccine given at 3000 pfu/subject
9517289|NCT03307681|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
9517290|NCT03307681|Experimental|Baked potato with skin|Baked russet potato
9740942|NCT00201643|Active Comparator|1 Test group|Receive 2nd Course = Study drug (betamethasone or dexamethasone)
9740943|NCT00201643|Placebo Comparator|2 - Control|Placebo group = received placebo course
9740944|NCT00201734|Experimental|Arm I|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, carboplatin IV over 1-2 hours on day 1, and capecitabine PO BID on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9740945|NCT00201760|Experimental|Arm 1 Gemcitabine/Cisplatin/Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
9740946|NCT00201760|Active Comparator|Arm 2 Gemcitabine / Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
9740947|NCT00201773|Experimental|Exemestane & Celecoxib|Patients will receive exemestane 25 mg orally per day for 8 weeks. Starting in the 9th week, patients will receive celecoxib 400 mg orally twice per day for 8 weeks in addition to exemestane.
9740948|NCT00201825|Experimental|Docetaxel and Capecitabine|
9740949|NCT00201838|Experimental|Arm I|Patients received entanercept 25 mg subcutaneously twice weekly with gemcitabine.
9740950|NCT00201838|Active Comparator|Arm II|Patients with pancreatic cancer for which treatment with gemcitabine as a single agent is planned will be asked to participate in this trial as a control group.
9740951|NCT00201851|Active Comparator|Immediate surgery|Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
9740952|NCT00201851|Experimental|Scheduled surgery|Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
9740953|NCT00201851|Other|Immediate Surgery - nonrandomized|Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
9740954|NCT00201864|Experimental|single-arm study|Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
9740955|NCT00201877|Experimental|Velcade and Rituximab|"Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14"
9740956|NCT00202449|Experimental|1|Prazosin
9740957|NCT00202449|Active Comparator|2|Paroxetine
9740958|NCT00202449|Placebo Comparator|3|Placebo
9740959|NCT00202644|Experimental|A|
9740960|NCT00202644|Active Comparator|B|
9740961|NCT00202722|Active Comparator|Remifentanil IVPCA|Bolus dose steps of 0.15 microgr/kg, with a 2-min lock-out time
9740962|NCT00202839|Experimental|24-Week Treatment|Genotype 1 hepatitis C virus [HCV] subjects treated for a total of 24 weeks, during the pilot treatment program (immediately before randomization)
9740963|NCT00202839|Active Comparator|48-Week Treatment|Genotype 1 HCV subjects treated for a total of 48 weeks: 24 weeks during the pilot treatment program (immediately before randomization) plus 24 weeks during the extended treatment program (immediately after randomization)
9740964|NCT00202930|Other|Rituximab|Single Arm
9740965|NCT00203021|Experimental|Glatiramer Acetate: Delayed Start|Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW). The treatment continued for up to 288 months.
9740966|NCT00203021|Experimental|Glatiramer Acetate: Early Start|Participants who were originally randomized to the glatiramer acetate 20 mg group in the 01-9001 and/or the 01-9001E studies continued to receive glatiramer acetate 20 mg SC injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg TIW. The treatment continued for up to 288 months.
9740967|NCT00203047|Active Comparator|GA + Placebo|Glatiramer acetate (GA) 10mg as a subcutaneous injection daily, plus a placebo to mimic prednisone given daily.
9740968|NCT00203047|Experimental|GA + Prednisone|Glatiramer acetate (GA) 20mg daily as a subcutaneous injection, plus 1250 mg of prednisone daily.
9740969|NCT00203203|Experimental|Stem Cell Therapy|Subject is randomized to receive Stem Cell Therapy (intramyocardial injection of stem cells) via NOGA mapping.
9740970|NCT00203203|Other|Control, then Stem Cell Therapy|"Subject is randomized to receive a NOGA mapping and no injections at time of active enrollment.~At 6 months, subject is offered stem cell therapy."
9740971|NCT00203216|Experimental|Levatiracetam|Subject titrated open-label study drug to maximally tolerated dose: maximum: 3000 mg. per date. (minimum allowed daily dose to remain in study: 1000)
9740972|NCT00203229|Placebo Comparator|Placebo|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
9740973|NCT00203229|Active Comparator|Lamotrigine|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
9740974|NCT00203242|Experimental|Depacon IV and Depakote ER|Subjects will be treated in this single arm study with 2 consecutive days of IV Depacon followed by oral Depakote ER for a total of 1000 mg of Depacon and 1000 mg of Depakote ER each day.
9740975|NCT00203268|Experimental|Treatment with dihydroergotamine mesylate (DHE-45)|Subjects who treated a moderate to severe migraine 2 and 4 hours after the onset of throbbing headache pain
9740976|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and saline|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
9517291|NCT03307681|Experimental|Mashed potato served hot|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
9517292|NCT03307681|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
9740977|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and triamcinolone 40 mg|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
9740978|NCT00203307|Other|Olanzapine then Placebo|Olazepam
9740979|NCT00203307|Other|Placebo then olanzapine|
9740980|NCT00203411|Experimental|Bevacizumab Plus Capecitabine|Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.
9740981|NCT00203424|Experimental|Erlotinib + Bevacizumab|Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
9740982|NCT00203476|Active Comparator|Statin with Niacin|Niacin dose range of 500-1500mg (average 888mg)
9740983|NCT00203476|Active Comparator|Statin with Colestipol|Colestipol dose range 5-15gm (average 9.5gm)
9740984|NCT00203476|Active Comparator|Statin with Ezitimibe|Ezitimibe 10mg (average 10mg)
9740985|NCT00203502|Experimental|Intervention: Dtx Cyclophosphamide Bev|Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg
9740986|NCT00203892|Experimental|A: CEA peptide 10mcg|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
9740987|NCT00203892|Experimental|B: CEA peptide 100 mcg|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
9740988|NCT00203892|Experimental|C: CEA peptide 1000mcg|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
9740989|NCT00203931|Active Comparator|Cetuximab|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
9740990|NCT00203931|Experimental|Cetuximab and Pemetrexed|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2.
9740991|NCT00203996|No Intervention|Aim 1: Placebo|One of the 3 treatment arms in Aim 1: Placebo. No subjects were randomized to this arm.
9740992|NCT00203996|Experimental|Aim 1: Pioglitazone|One of the 3 treatment arms in Aim 1: Pioglitazone. No subjects were randomized to this arm.
9740993|NCT00203996|Experimental|Aim 1: Leuprolide + Estrogen/Progestin|One of the 3 treatment arms in Aim 1: depot leuprolide plus estrogen/progestin replacement. No subjects were randomized to this arm.
9740994|NCT00203996|Experimental|Aim 2: PCOS + SDB|One of the 2 study groups in Aim 2: Women with polycystic ovary syndrome (PCOS) and sleep disordered breathing (SDB) were treated with 8 weeks of continuous positive airway pressure (CPAP).
9740995|NCT00203996|Experimental|Aim 2: Matched Controls|One of the 2 study groups in Aim 2: Women who were of similar age to those in the PCOS+SDB group were treated with 8 weeks of continuous positive airway pressure (CPAP). The recruitment of control subjects for this protocol was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria. As a consequence, the sample size of control subjects was insufficient to allow for any meaningful conclusions to be drawn. Statistical analyses were not possible due to insufficient sample size.
9740996|NCT00203996|Experimental|Aim 3: REM frag - SWS supp - Baseline|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Slow wave sleep (SWS) suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
9740997|NCT00203996|Experimental|Aim 3: REM frag - Baseline - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
9740998|NCT00203996|Experimental|Aim 3: Baseline - REM frag - SWS supp|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
10200946|NCT05109208|Experimental|Ultrasound viscoelastography (UVE) in radical proctectomy recovery|Subjects undergoing radical prostatectomy for prostate cancer disease as standard of care will have a ultrasound vibroelastography performed before surgery, 3 months, 6 months and 9 months post-prostatectomy.
9517293|NCT03307681|Experimental|Meal skipping|No food given
9517294|NCT03307668|Experimental|CaReS-1S|
9517295|NCT03307668|Active Comparator|Microfracture|
9517296|NCT03307655|Experimental|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
9740999|NCT00203996|Experimental|Aim 3: SWS supp - REM frag - Baseline|"Each subject was assessed under three experimental conditions in the following order.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
9741000|NCT00203996|Experimental|Aim 3: Baseline - SWS supp - REM frag|"Each subject was assessed under three experimental conditions in the following order.~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed."
9741001|NCT00204373|Experimental|single group|This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
9741002|NCT00204932|Active Comparator|CLA treatment|The group randomized to Conjugated Linoleic Acid (CLA) treatment at 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA; and 22% safflower oil for 6 months
9741003|NCT00204932|Placebo Comparator|Placebo|The group randomized to control received 4 g/d of safflower oil.
9741004|NCT00205179|Experimental|Novasoy treated|100mg/day soy isoflavones
9741005|NCT00205179|Placebo Comparator|Placebo|100mg/day matching placebo
9741006|NCT00205374|Active Comparator|Cidofovir|"Cidofovir (Vistide) is a commercially available agent approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The drug is not FDA approved for the treatment of RRP at this time. However, recent case reports have been encouraging with regard to the effectiveness of the agent in the treatment of RRP. The FDA has granted this study a safe to proceed designation with IND 58,481."
9741007|NCT00205374|Placebo Comparator|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
9741008|NCT00205504|Active Comparator|Obese women with metabolic syndrome|
9741009|NCT00205504|Active Comparator|Obese women without metabolic syndrome|
9741010|NCT00205504|Active Comparator|lean women without metabolic syndrome|
9741011|NCT00205660|Other|Stayers|Subjects are randomized to stay on their current antipsychotic.
9741012|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
9741013|NCT00205699|Active Comparator|aripiprazole|Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.
9741014|NCT00205699|Active Comparator|olanzapine|Participants in this group will be randomized to flexibly-dosed treatment with olanzapine.
9741015|NCT00205699|Active Comparator|risperidone|Participants in this group will be randomized to flexibly-dosed treatment with risperidone.
9741016|NCT00205712|Placebo Comparator|Ketamine plue saline|Ketamine without dexmedetomidine
9741017|NCT00205712|Experimental|Ketamine plus dexmedetomidine|Ketamine infusion plus dexmedetomidine
9741018|NCT00205777|Active Comparator|A|
9741019|NCT00205777|Placebo Comparator|B|
9741020|NCT00205803|Experimental|13vPnC|
9741021|NCT00205803|Active Comparator|7vPnC|
9741022|NCT00205855|Experimental|Precision SCS|Precision SCS. Patients who receive Precision Spinal Cord Stimulator (SCS) Stimulus system
9741023|NCT00205881|Active Comparator|1|Bilaterally Implanted with HiRes 90K device.
9741024|NCT00206076|Experimental|1|mycophenolate mofetil monotherapy
9741025|NCT00206076|Active Comparator|2|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
9741026|NCT00206102|Experimental|1|Quetiapine fumarate
9741027|NCT00206102|Active Comparator|2|Risperidone
9741028|NCT00206323|Placebo Comparator|placebo/sugar pill|Placebo or sugar pill
9741029|NCT00206323|Active Comparator|Topiramate|Topiramate 25 mg to 200 mg
9741030|NCT00206336|Experimental|topiramate|Topiramate open label
9741031|NCT00206427|Experimental|Intervention|Intervention/Lapatinib (GW572016)
9741032|NCT00206440|Experimental|Esomeprazole|Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
9741033|NCT00206440|Placebo Comparator|Sugar pill|Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.
10200947|NCT05108077|Experimental|Cytokine-induced killer cells|Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
10200948|NCT05108077|Active Comparator|Control|Patients with metastatic tumors of the urogenital area receiving standard treatment
10200949|NCT05106985|Experimental|ApplTree Reminder app|Following a randomised baseline period, each participant will use the ApplTree reminder app for 22 days to support adherence to goal-related tasks
9741034|NCT00206518|Experimental|A: Taxotere/Docetaxel|Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity.
10200950|NCT05103631|Experimental|CATCH T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 (CATCH T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
10200951|NCT05103527|Experimental|Non-operated Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with no history of knee surgery
10200952|NCT05103527|Experimental|Surgically Repaired Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with history of surgical repair of the knee
10200953|NCT05099835|Active Comparator|Botulinum Toxin|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
10200954|NCT05099835|Active Comparator|steroid|injected 10 mL of 0.25% bupivacaine with triamcinolonacetonide 4 mg/ml
10200955|NCT05094466|Experimental|Arm I (parent intervention)|Parents receive health coaching sessions over 50-60 minutes monthly for 6 months. Parents also receive navigation sessions with a lay LHW monthly for 6 months and church-based peer support monthly for 6 months.
10200956|NCT05094466|Experimental|Arm II (family intervention)|Family members receive health coaching sessions over 50-60 minutes monthly for 6 months. Family members also receive navigation sessions with a LHW monthly for 6 months and church-based peer support monthly for 6 months.
10200957|NCT05094466|Active Comparator|Arm III (delayed comparison)|Participants receive a handbook that includes core content from the parent and family interventions, but without individual support from coaches, LHWs or the church.
10200958|NCT05084066|Experimental|Experimental group|20 patients with PAD and claudication
10200959|NCT05084066|Sham Comparator|Control group (sham)|20 patients with PAD and claudication
10200960|NCT05078671|Active Comparator|Standard olaparib|Olaparib 300mg twice daily
10200961|NCT05078671|Experimental|Boosted olaparib|Olaparib 100mg twice daily + cobicistat 150mg twice daily
10200962|NCT05077800|Experimental|Safety Run-In: FOLFIRINOX + 9-ING-41 + Losartan|"The study will begin with a Safety Run-In phase to establish the side effects from the study treatment to its safety before beginning the main part of the study, six (6) participants will receive 1-2 cycles of:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~9-ING-41 on days on days 1, 3, 8, and 11 of every 14-day cycle~Losartan daily of every 14-day cycle."
10200963|NCT05077800|Experimental|FOLFIRNINOX|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy, participants will receive FOLFIRINOX as follows:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~For Maintenance therapy, participants will receive FOLFIRINOX as follows:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX until further disease progression"
10200964|NCT05077800|Experimental|FOLFIRINOX + Losartan|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Losartan daily up to 12 cycles (24 weeks)~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + Losartan until further disease progression"
10200965|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle up to 12 cycles (24 weeks)~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~For Complete Therapy Round 2, repeat of initial complete therapy until further disease progression"
10200966|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41 + Losartan|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle~Losartan daily~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + 9-ING-41+ Losartan until further disease progression"
10200967|NCT05074134|Experimental|[14C]-TNP-2092|
9741035|NCT00206518|Experimental|B: AC Adriamycin/Cytoxan|In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks.
9741036|NCT00206726|Experimental|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.
9741037|NCT00207090|Experimental|Ixabepilone + rifampin|
9741038|NCT00207142|Active Comparator|Switch|ATV 400 mg + 2 NRTIs (TBD), ATV once daily, NRTIs (TBD)
9741039|NCT00207142|Active Comparator|Continuation|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
9741040|NCT00207142|Other|Rescue|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
9741041|NCT00207714|Experimental|Golimumab (CNTO 148) with Methotrexate (MTX)|
9741042|NCT00207714|Experimental|Infliximab with MTX|
9741043|NCT00207714|Placebo Comparator|Placebo with MTX|
9741044|NCT00207740|Experimental|CNTO 148 (golimumab)|
9741045|NCT00207740|Placebo Comparator|Placebo|
9741046|NCT00207883||Landmark|Procedure/Surgery: Use of landmarks for central line placement
9741047|NCT00207883||Ultrasound guided|Procedure/Surgery: Use of ultrasound for central line placement
9741048|NCT00208026|Experimental|Pimecrolimus 1% Cream|Treatment with drug/Elidel. Single arm-open-label treatment arm. A Pilot Study of the Efficacy and Safety of Pimecrolimus Cream 1% for the Treatment of Netherton Syndrome:
9741049|NCT00208091|Experimental|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
9741050|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Sacrificed|PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
9741051|NCT00208325|Active Comparator|PFC Sigma RP PCL Sacrificed|PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
9741052|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Retained|PFC Sigma Fixed Bearing Total Knee System with PCL Retained
9741053|NCT00208325|Active Comparator|PFC Sigma RP PCL Retained|PFC Sigma Rotating Platform Total Knee System with PCL Retained
9741054|NCT00208494|Active Comparator|A|Ceramic-on-metal total hip implant
9741055|NCT00208494|Active Comparator|B|Metal-on-metal total hip implant
9741056|NCT00208507|Active Comparator|Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System|Total hip replacement with a 28 mm ceramic head and liner.
9741057|NCT00208507|Active Comparator|Pinnacle™ Acetabular Cup with Marathon® Polyethylene|Total hip replacement with 28 mm ceramic head with a polyethylene liner.
9741058|NCT00208767|Active Comparator|Valsartan|Valsartan titrated up to 320 mg orally daily
9741059|NCT00208767|Placebo Comparator|Placebo|Patients received a placebo instead of Valsartan
9741060|NCT00208949|Active Comparator|G-CSF(Granulocyte Colony-Stimulating Factor )|Single use of G-CSF(Granulocyte Colony-Stimulating Factor ) G-CSF 7.5 µg/kg twice a day
9741061|NCT00208949|Active Comparator|Granulocyte CSF+Granulocyte Macrophage CSF|Combined use of G-CSF(Granulocyte Colony-Stimulating Factor ) and GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) (G-CSF 7.5 µg/kg / GM-CSF 7.5 µg/kg.)
9741062|NCT00208975|Active Comparator|Fludarabine and Mitoxantrome followed by GM-CSF and Rituximab|"Initial patients (n=9) received fludarabine (25 mg/m2 IV) and mitoxantrone (10 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m2 IV) and cyclophosphamide (250 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8. All patients received dditional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
9741063|NCT00209092|Active Comparator|Sequential Therapy|Docetaxel will be given at 100mg/m^2 intravenous Day 1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).
9741064|NCT00209092|Active Comparator|Concurrent Therapy|Docetaxel will be given at 50mg/m^2 Intravenous Day1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
9741065|NCT00209170|Experimental|Beating the Blues CBT + Escitalopram|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with the selective serotonin reuptake inhibitor (SSRI) antidepressant, escitalopram (10 mg taken orally once or twice daily) for 6 months
9741066|NCT00209170|Active Comparator|Beating the Blues CBT + Placebo|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with placebo (taken orally one to two tablets daily) for 6 months
9741067|NCT00209274|Experimental|1|Percutaneous mitral valve repair using MitraClip implant. The calculated sample size was 186 patients in the device arm
9741068|NCT00209274|Active Comparator|2|Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.
9741069|NCT00209339|Experimental|MitraClip|Percutaneous mitral valve repair (MitraClip Implant)
9741070|NCT00209417|Active Comparator|Iodixanol 320-Arm 1|Iodixanol 320 mg I/mL
9741071|NCT00209417|Active Comparator|Iopamidol 300-Arm 2|Iopamidol 300 mg I/mL
9741072|NCT00210106|Experimental|Intraoperative radiofrequency ablation (IRFA)|IRFA treatment, either with or without resection, was performed at laparotomy within 28 days of inclusion in the study. The type of IRFA current generator and probes, and whether or not resection was performed, was at the discretion of the surgeon.
9741073|NCT00210119|Experimental|Imatinib mesylate|Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.
9741074|NCT00210184|Experimental|Irinotecan associated to fluorouracil and leucovorin|"On D1, as a single 90-minute intravenous infusion diluted in 250 ml of saline (sodium chloride a 9 ‰), or isotonic glucose, at a dose of 180 mg/m2. Dosage adjustments are provided in case of severe toxicity.~Then 5FU/ folinic acid: 400 mg/m2 of 5-FU as an IV bolus followed by a continuous 2400 mg/m2 infusion over 46 hours with 400 mg/m2 of folinic acid or 200 mg/m2 of l-folinic acid as a 2-hour infusion before 5-FU administration.~Doses of 5-FU are adjusted according to clinical tolerance. Resume on D15 for 6 months"
9741075|NCT00210353|Active Comparator|ARM A|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment; two weeks rest; chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
9741076|NCT00210353|Experimental|ARM B|rituximab 375 mg/m2 iv, d1, d8, d15, d22 chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment two weeks rest chlorambucil 6 mg/m2 os daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
9741077|NCT00210353|Experimental|ARM C (Since April 2006)|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
9741078|NCT00210470|Experimental|IRX-2 Regimen|The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin, zinc supplementation, and omeprazole.
9741079|NCT00210626|Active Comparator|PROCRIT|
9741080|NCT00210626|Placebo Comparator|Placebo|
9741081|NCT00210639||Levofloxacin-treated cohort|Participants receiveing levofloxacin in previous levofloxacin studies will be observed.
9741082|NCT00210639||Comparator-treated cohort|Participants receiveing comparator in previous levofloxacin studies will be observed.
9741083|NCT00211081|Experimental|Open Label|
9741084|NCT00211172|Experimental|Beta-blocker adherence after an AMI|Patients received two mailings about the importance of beta blocker use.
9741085|NCT00211172|No Intervention|Usual care|Patients received usual care.
9741086|NCT00211185|Experimental|Denileukin diftitox in combination with CHOP|Unblinded denileukin diftitox at 18 micrograms/kilogram/day (ug/kg/d) was administered intravenously (IV) on Days 1 and 2 of each 21-day cycle. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was administered on Day 3 of each 21-day cycle. On Day 4 of each 21-day cycle, pegfilgrastim (a granulocyte colony-stimulating factor (G-CSF)) was started as a prophylaxis to prevent neutropenia. After completion of two 21-day cycles, participants were evaluated for clinical response. Two 21-day cycles with denileukin and CHOP were repeated followed by response evaluations after each set of two 21-day cycles with intent to treat for 6 cycles, with a maximum of 8 cycles.
9741087|NCT00211237|Experimental|Balloon Kyphoplasty (BKP)|The subjects assigned to this group will undergo the treatment with Balloon kyphoplasty for their painful VCFs.
9741088|NCT00211237|Active Comparator|Non Surgical Management|The subjects in this group will undergo the non-operative treatments aimed at alleviation of back pain and restoration of decreased function associated with VCFs.
9741089|NCT00211510|Experimental|Paradigm 722 sensor augmented pump|subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring
9741090|NCT00211510|Active Comparator|Paradigm 715 insulin pump|subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin
9741091|NCT00211536|Experimental|MiniMed Implantable insulin Pump (MIP)|The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill procedure performed 180 days post implant, any insulin remaining in the pump will be removed and the pump will be refilled with Medtronic MiniMed Implantable Pump Human Recombinant Insulin.
9741092|NCT00211536|No Intervention|Subcutaneous insulin arm (SC)|The control group will remain on their current pre-study subcutaneous insulin therapy of either Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII - external insulin pump). The SC group will not be restricted to the type of insulin used, or be required to change or modify their current diabetes therapy for the purpose of the study.
9741093|NCT00211692|Active Comparator|Group A consensus interferon+rbv 52 wks|Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
9741094|NCT00211692|Experimental|Group B CIFN variable duration|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)
9741095|NCT00211757|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.
9741096|NCT00211757|Experimental|Divalproex Sodium|Subjects will receive the study drug, divalproex sodium.
9741097|NCT00211809|Experimental|Body dysmorphic disorder|Participants with body dysmorphic disorder
9741098|NCT00211887|Active Comparator|Interferon beta 1-a|"Active Interferon B1a Weekly vs. Placebo Glatiramer Acetate~Interferon b-1a (IFN) intramuscularly weekly"
9741099|NCT00211887|Active Comparator|glatiramer acetate|"Placebo Interferon B1a Weekly vs. Active Glatiramer Acetate~Glatiramer acetate 20mg daily"
9741100|NCT00211887|Active Comparator|IFN and GA|Active Interferon B1a Weekly and Active Glatiramer Acetate
9741101|NCT00212134|Active Comparator|aphakic contact lens|"Contact lens correction of aphakia~INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly."
9741102|NCT00212134|Experimental|aphakic intraocular lens|"Intraocular lens implantation~INTERVENTION: At the time of surgery to remove the cataractous natural lens, an intraocular lens was implanted to correct the large hyperopic refractive error induced by the cataract surgery."
9741103|NCT00212264|Experimental|Behavioral Therapy|Behavioral Therapy (Pelvic floor muscle training, bladder control strategies)
9741104|NCT00212264|Experimental|Behavioral Therapy Plus Technologies|Behavioral therapy plus technologies (home pelvic floor electrical stimulation and biofeedback)
9741105|NCT00212264|Placebo Comparator|Placebo Comparator|No treatment control
9741106|NCT00212355|Experimental|NPC-02|zinc acetate
9741107|NCT00212446|Experimental|Electrical Intervention|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
9741108|NCT00212758|Active Comparator|Low- Standard GH dose|This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
9741109|NCT00212758|Active Comparator|Standard-Low GH dose (7 Days)|This arm will receive Standard dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Standard dose GH will be 0.5 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the Low dose of Nutropin AQ (GH) at 0.025 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
9741110|NCT00213135|Experimental|Cladribine 5.25 mg/kg|
9741111|NCT00213135|Experimental|Cladribine 3.5 mg/kg|
9741112|NCT00213135|Placebo Comparator|Placebo|
9741113|NCT00213148|Active Comparator|Clomiphene Citrate 50 Milligram (mg)|
9741114|NCT00213148|Active Comparator|Clomiphene Citrate 100 mg|
9741115|NCT00213148|Experimental|Anastrozole 1 mg|
9741116|NCT00213148|Experimental|Anastrozole 5 mg|
9741117|NCT00213148|Experimental|Anastrozole 10 mg|
9741118|NCT00213239|Experimental|Propofol 4 mg/kg group|First patient in this arm will receive a bolus of propofol 4 mg/kg followed by remifentanil 0.5 mcg/kg. Subsequent patients randomized to this arm will receive propofol 4 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
9741119|NCT00213239|Experimental|Propofol 2 mg/kg group|First patient in this arm will receive a bolus of propofol 2 mg/kg followed by remifentanil 1 mcg/kg. Subsequent patients randomized to this arm will receive propofol 2 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
9741120|NCT00213980|No Intervention|Observation|Observation only for 12 months
9741121|NCT00213980|Active Comparator|Zoledronate|Zoledronate
9741122|NCT00214019|Placebo Comparator|Placebo Diskus|Placebo comparator
9741123|NCT00214019|Experimental|Salmeterol Diskus 50 mcg twice per day|Salmeterol Diskus 50 mcg twice per day
9741124|NCT00214019|Experimental|Placebo diskus, fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
9741125|NCT00214019|Experimental|Salmeterol, Fluticasone|Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day
9741126|NCT00214045|Active Comparator|Flexible Cystoscopy|Flexible Cystoscopy
9741127|NCT00214045|Active Comparator|Rigid Cystoscopy|Rigid Cystoscopy
9781758|NCT01156701||Cohort1: Prophylaxis with untreated index|"Individuals are eligible to be included in the prophylaxis with untreated index cohort if they are at least 5 years old and have at least 6 months of continuous enrollment, and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family identifier code has had a medical visit (outpatient, inpatient or emergency room (ER) visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
9781759|NCT01156701||Cohort2: Prophylaxis with treated index|"Individuals are eligible to be included in the prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
9741128|NCT00214097|Experimental|Level 1|64.7 Gy/22 fractions of 2.94 Gy
9741129|NCT00214097|Experimental|Level 2|58.08 Gy/16 fractions of 3.63 Gy
9741130|NCT00214097|Experimental|Level 3|51.6 Gy/12 fractions of 4.3 Gy
9741131|NCT00214136|Experimental|1|prostate radiation to 70Gy, lymph nodes to 56Gy
9741132|NCT00214201|No Intervention|1|Standard of Care CNI immunosuppression
9741133|NCT00214201|Experimental|2|Calcineurin inhibitor withdrawal
9741134|NCT00214383|Experimental|CHESS + Case Mgt|Case Management (with monthly support calls) and CHESS services were available for a 12 month intervention period. Support calls refer to check in calls by a nurse to the parents to see how the child is doing. CHESS services include access to a website with information on asthma management, discussion groups and a case manager. The website also include a management tool for asthma symptoms check in, and the case manager used the information entered to tailor the homepage to individual clients.
9741135|NCT00214383|No Intervention|Control|Control-usual care. Usual care refers to the manner in which clients generally manage their asthma.
9741136|NCT00214422|Experimental|Arm 1- 5040cGy to the lymph nodes|5040Gray (cGy) to the lymph nodes
9741137|NCT00214422|Experimental|Arm 2 - 5400cGy to the lymph nodes|5400Gray (cGy) to the lymph nodes
9741138|NCT00214422|Experimental|Arm 3 - 5900cGy to the lymph nodes|5900Gray (cGy) to the lymph nodes
9741139|NCT00214461|Placebo Comparator|Placebo Vaccine Group|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28 and 56, respectively.
9741140|NCT00214461|Experimental|Low Dose Vaccine Group|Participants will receive a dose of vaccine containing of 2 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
9741141|NCT00214461|Experimental|Medium dose vaccine group|Participants will receive a dose of vaccine containing of 10 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
9741142|NCT00214461|Experimental|High dose vaccine group|Participants will receive a dose of vaccine containing of 50 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
9741143|NCT00214487|Experimental|Bifocal Contact Lenses|Use of bifocal contact lenses to control the progression of myopia
9741144|NCT00214487|Placebo Comparator|Control|Single vision soft contact lenses
9741145|NCT00214526|Experimental|Alair Group|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
9741146|NCT00214526|Active Comparator|Control Group|Conventional therapy with ICS+LABA.
9741147|NCT00214539|Experimental|Treatment|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
9741148|NCT00214539|Active Comparator|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
9741149|NCT00214786|Experimental|Islet Cell Transplantation|Allogenic islet cell transplantation
9741150|NCT00214890|Active Comparator|Tenofovir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
9741151|NCT00214890|Active Comparator|Abacavir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
9741152|NCT00214903||1|New users of oral continuous combined HRT containing drospirenone
9741153|NCT00214903||2|New users of oral continuous combined HRT containing other progestagens
9741154|NCT00215137|Experimental|Open Label Escitalopram 10-20 mg/daily|Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
9741155|NCT00215137|Placebo Comparator|Randomizationn Placebo 10-20 mg daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
9741156|NCT00215137|Active Comparator|Randomization Escitalopram 10-20 mg/daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
9741157|NCT00215150|Other|Open Label Treatment|8 weeks of open label treatment with sertraline
9741158|NCT00215150|Other|Randomization Ziprasidone|8 weeks of treatment with sertraline augmented with ziprasidone
9741159|NCT00215150|Other|Randomization Placebo|8 weeks of treatment with sertraline augmented by placebo
9741160|NCT00215540|Experimental|SURFAXIN High Dose|SURFAXIN (lucinactant) at 175 mg/kg
9741161|NCT00215540|Experimental|SURFAXIN Low Dose|SURFAXIN (lucinactant) at 90 mg/kg
9741162|NCT00215540|Placebo Comparator|Placebo|Sham air using 3.0 mL/kg volume of air
9741163|NCT00215553|Experimental|A.1 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours.
9741164|NCT00215553|Experimental|A.2 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
9741165|NCT00215553|Experimental|A.3 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
9741166|NCT00215553|Experimental|A.4 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
9741167|NCT00215553|Experimental|B.1 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
9741168|NCT00215553|Experimental|B.2 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
9741169|NCT00215553|Other|B.3 SoC|Received standard ARDS management and ICU care (Standard of Care [SOC]). Included, but was not limited to, support with oxygen, conventional mechanical ventilation, sedations, and paralysis.
9741170|NCT00215644|Experimental|Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab|
9741171|NCT00215644|Active Comparator|ECX Only|
9741172|NCT00215657|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
9741173|NCT00215657|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
9741174|NCT00215657|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
9741175|NCT00215657|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
9741176|NCT00215657|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
9741177|NCT00215657|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
9741178|NCT00215657|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
9741179|NCT00215657|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
9741180|NCT00215683|Experimental|Degarelix 80 mg|Participants who completed the CS12 study in the Degarelix 80 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
9741181|NCT00215683|Experimental|Degarelix 120 mg|Participants who completed the CS12 study in the Degarelix 120 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
9741182|NCT00215683|Experimental|Degarelix 160 mg|Participants who completed the CS12 study in the Degarelix 160 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
9741183|NCT00215930|Experimental|Double Agent Chemotherapy|Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of ERCC1 and RRM1.
9741184|NCT00215943|Active Comparator|VAD Treatment|"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one cycle of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle."
9741185|NCT00215943|Active Comparator|Thalidomide and Dexamethasone Treatment|Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.
9741186|NCT00216060|Experimental|Experimental Arm|Daily oral risedronate combined with androgen deprivation
9741187|NCT00216060|Placebo Comparator|Placebo Arm|daily oral placebo combined with androgen deprivation
9741188|NCT00216086|Experimental|Investigational Treatment|"Irinotecan 200 mg/m2 IV, day 1~Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid~EUS~Neoadjuvant Chemotherapy~Preoperative Radiation~Surgery~Adjuvant Chemotherapy (at discretion of treating physician)"
9741189|NCT00216099|Experimental|Investigational Treatment|"Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle~Oral Folic Acid, once per day for 7 days preceding pemetrexed dose, continued daily, and for 21 days after the last dose of pemetrexed.~Vitamin B12, 1000ug intramuscular injection 7 days preceding pemetrexed dose, and every three cycles thereafter on the same day of pemetrexed administration"
9741190|NCT00216125|Other|Pre-Randomization|Prior to randomization patients received Cisplatin 50 mg/m^2 days 1,8,29,36 + Etoposide 50 mg/m^2 days 1-5, 29-33 + Radiation 5940 cGy (180 cGy/day). Patients with CR, PR or SD with manageable toxicity were randomized to either Docetaxel arm or Observation only arm.
9741191|NCT00216125|Active Comparator|Consolidation Docetaxel|Docetaxel 75 mg/m^2 q3wk X 3 cycles.
9983910|NCT04551430|Experimental|Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Patients randomized to Cohort B will take cabozantinib at a dose of 40 mg by mouth once each day. Nivolumab will given IV at a dose of 3 mg/kg over approximately 30 minutes every 3 weeks for 4 doses, followed by 480 mg over approximately 30 minutes every 4 weeks until treatment discontinuation. Ipilimumab will be given IV at a dose of 1 mg/kg over approximately 30 minutes every 3 weeks for 4 doses.
9741192|NCT00216125|No Intervention|Observation Only|Patients were followed for Observation.
9741193|NCT00216203|Experimental|Investigational Treatment|Pemetrexed + cetuximab for patients with recurrent non-small cell lung cancer.
9741194|NCT00216320|Experimental|WalkAide|Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
9741195|NCT00216320|Active Comparator|Ankle Foot Orthosis|Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
9741196|NCT00216320|Other|No Crossover|Subjects wear AFO for entire 12 weeks with no crossover
9741197|NCT00216476|Experimental|001|Risperidone Long Acting Injectable (LAI) 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
9741198|NCT00216476|Active Comparator|002|Quetiapine Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
9741199|NCT00216476|Other|003|Aripiprazole 10-30 mg oral once daily for 104 weeks
9741200|NCT00216671|Experimental|001|early initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
9741201|NCT00216671|Active Comparator|002|routine initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
9741202|NCT00216736|Placebo Comparator|1|This group received intravenous phenothiazine treatment for migraine (dosing at physician discretion) plus placebo. Patients and clinicians were blinded.
9741203|NCT00216736|Experimental|2|This group received intravenous phenothiazine migraine treatment (dosage at physician discretion) plus oral dexamethasone 8mg at time of emergency department discharge. Patients and clinicians were blinded.
9741204|NCT00217022|Active Comparator|Budesonide|9 mg daily
9741205|NCT00217022|Placebo Comparator|Placebo|three tablets daily
9741206|NCT00217087|Other|Endoscopic Mucosal Resection|Patients will undergo endoscopic mucosal resection at time of endoscopy if indicated.
9741207|NCT00217087|Other|Photodynamic Therapy|Patients will have endoscopic mucosal resection with photodynamic therapy.
9741208|NCT00217399|Experimental|Treatment|"PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.~PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I."
9741209|NCT00217425|Experimental|Treatment (A-CHOP followed by MA)|Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 [max. 2 mg]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
9741210|NCT00217438|Experimental|Arm I (high dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine IV over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
9741211|NCT00217438|Active Comparator|Arm II (low dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:~Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
9741212|NCT00217464|Experimental|Fulvestrant|Fulvestrant will be provided as 250 mg in 5 mL as a pre-tilled syringe. Fulvestrant will be administered as 500 mg, that is, 2 injections of 5 mL, one into each buttock im on day 0. A single 250 mg in 5 mL injection will be administered on day 14 followed by a single 250 mg in 5 mL dose on day 28 and monthly thereafter.
9741213|NCT00217490|Experimental|Computer Only|Dietary Counseling delivered by interactive computer program, without the addition of individual counseling provided by a health counselor. This arm tested a completely automated counseling program that did not include personalized behavioral counseling provided by a study staff member.
9741214|NCT00217490|Experimental|Counseling only|In this arm, dietary counseling was delivered by nutritionist, and this counseling did not include use of an automated, computer program.
9741215|NCT00217490|Experimental|Combined|In this arm, participants received dietary counseling delivered using both the automated computer program and additional counseling by a study nutritionist. That is, this arm combined the intervention programs delivered in the other two active intervention arms.
9741216|NCT00217490|Active Comparator|Physical Activity-computer|Participants assigned to this arm did not receive nutrition counseling, but they were provided physical activity counseling delivered by computer only.
9741217|NCT00217581|Experimental|Docetaxel, Oxaliplatin & Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
9741218|NCT00217594|Experimental|Alemtuzumab|Patients received a 1-mg test dose of alemtuzumab, and the following day, alemtuzumab was administered at 10 mg/dose intravenously for 10 days
9741219|NCT00217620|Experimental|sorafenib|sorafenib
9741220|NCT00217672|Experimental|Bevacizumab + Docetaxel|"docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.~Bevacizumab: 15 mg/kg IV every 3 weeks. Subjects continue on study until disease progression, unacceptable toxicity, or withdrawal of patient consent."
9741221|NCT00217672|Active Comparator|docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
9741222|NCT00217724|Experimental|Glutamine Arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral glutamine three times daily for 4 days.
9741223|NCT00217724|Placebo Comparator|Placebo arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral placebo three times daily for 4 days.
9741224|NCT00217971|Active Comparator|Dronabinol|Dronabinol: 20mg bid for a daily maximum dose of 40mg.
9741225|NCT00217971|Placebo Comparator|Placebo|placebo
9741226|NCT00218023|Experimental|Modafinil plus MI, CM, and CBT|"The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
9741227|NCT00218023|Experimental|Levodopa/Carbidopa plus MI, CM, and CBT|"Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
9741228|NCT00218023|Experimental|Naltrexone HCl plus MI, CM, and CBT|"Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
9741229|NCT00218023|Placebo Comparator|Placebo plus MI, CM, and CBT|"Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
9741230|NCT00218062|Experimental|D-Amphetamine 60mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. d-Amphetamine sustained release (SR) (Dexedrine Spansules) started at 15 mg (day 1-2), increased to 30mg (day3; 15mg, BID), 45mg (day4; 15mg, TID), and 60mg (day5; 15mg bid plus 30mg qd). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
9741231|NCT00218062|Experimental|Modafinil 400mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. Modafinil started at 200mg (day1) and increased to 400mg (days2-5). A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
9741232|NCT00218062|Experimental|Modafinil 200mg + D-Amphetamine 30mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. For the combination condition, dosages of modafinil and d-amphetamine were escalated to one-half of that for the single medication conditions. A 5-day dose reduction schedule occurred at week 17.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
9741233|NCT00218062|Placebo Comparator|Placebo + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance.~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
9741234|NCT00218257|Active Comparator|Progesterone|200mg progesterone twice daily
9741235|NCT00218257|Placebo Comparator|Placebo|Placebo twice daily
9741236|NCT00218296|Active Comparator|Usual Care Group|Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
9741237|NCT00218296|Experimental|Reduction Group|Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.
9741238|NCT00218335|Experimental|Intervention Condition|Participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
9741239|NCT00218335|Active Comparator|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
9741240|NCT00218387|Experimental|200mg Modafinil|200mg Modafinil
9741241|NCT00218387|Experimental|400mg Modafinil|400mg Modafinil
9741242|NCT00218387|Placebo Comparator|Matching Placebo|Matching Placebo
9741243|NCT00218426|Active Comparator|ONP + DNI|Oral naltrexone placebo (ONP) + Depot Naltrexone Implant (DNI) 1000 mg
9741244|NCT00218426|Active Comparator|ON + DNIP|Oral naltrexone (ON) 50 mg + Depot Naltrexone placebo Implant (DNIP)
9741245|NCT00218426|Placebo Comparator|ONP + DNIP|Oral placebo naltrexone + placebo naltrexone implant
9741246|NCT00218439|Experimental|1|Active medication for 4 weeks followed by placebo for 4 weeks
9741247|NCT00218439|Experimental|2|Placebo for 4 weeks followed by active for 4 weeks
9741248|NCT00218465|Experimental|GW468816|Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial
9741249|NCT00218465|Placebo Comparator|Placebo|Placebo, 200 mg/day, for a 5-week trial
9741250|NCT00218491|Experimental|1200mg N-Acetylcysteine|1200mg N-Acetylcysteine
9741251|NCT00218491|Experimental|2400mg N-Acetylcysteine|2400mg N-Acetylcysteine
9741252|NCT00218491|Placebo Comparator|Matching Placebo|Matching Placebo
9741253|NCT00218543|Experimental|Atomoxetine|Atomoxetine
9741254|NCT00218634|Experimental|CBT-AD|Cognitive behavioral therapy for adherence and depression
9741255|NCT00218634|Active Comparator|ETAU|Enhanced treatment as usual
9741256|NCT00219141|Experimental|Aliskiren 300 mg|Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan placebo. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan placebo. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
9741257|NCT00219141|Active Comparator|Losartan 100 mg|Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
9741258|NCT00219141|Experimental|Aliskiren/losartan 300/100 mg|Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
9741259|NCT00219284|Experimental|Immediate switch|Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
9741260|NCT00219284|Active Comparator|Delayed switch|Patients were switched 4 weeks after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
9741261|NCT00219349|Experimental|Escitalopram|12 weeks of open label escitalopram, 10-20 mg/day (after 14 weeks of cognitive behavioral therapy
9741262|NCT00219544|Experimental|1|
9741263|NCT00219544|Experimental|2|
9741264|NCT00219544|Experimental|3|
9741265|NCT00219544|Placebo Comparator|4|
9741266|NCT00219557|Active Comparator|Gemcitabine|
9741267|NCT00219557|Experimental|Axitinib [AG-013736] plus gemcitabine|
9741268|NCT00220636|Experimental|Aripiprazole|Aripiprazole 5 to 30 mg/day
9741269|NCT00220701|Experimental|escitalopram|Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
9741270|NCT00220701|Placebo Comparator|Placebo|inactive comparator
9741271|NCT00220727|Experimental|Group 1|Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.14 mL/kg/min)
9741272|NCT00220727|Experimental|Group 2|Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.08 mL/kg/min)
9741273|NCT00220740|Experimental|Group 1|IGIV-C
9741274|NCT00220740|Placebo Comparator|Group 2|
9741275|NCT00220779|Experimental|Group 1|IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
9741276|NCT00220779|Experimental|Group 2|IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
9741277|NCT00220779|Placebo Comparator|Group 3|placebo (0.1% albumin) 4 ml/kg bw/infusion
9741278|NCT00220805|Experimental|Group 1|
9741279|NCT00220805|Placebo Comparator|Group 2|
9741280|NCT00220961|Placebo Comparator|Placebo|Placebo tablet similar to pioglitazone tablet
9741281|NCT00220961|Active Comparator|Pioglitazone|Pioglitazone tablet similar to placebo tablet
9741282|NCT00221104|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
9741283|NCT00221104|No Intervention|No intervention|Patient has no intervention.
9741284|NCT00221117|Active Comparator|Conventional Occupational Therapy (COT)|Conventional Occupational Therapy pertaining to hand function represents the current best practice activities against which the FET was compared. The COT included the following: (a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; (b) task-specific, repetitive functional training; (c) strengthening and motor control training using resistance to available arm motion to increase strength; (d) stretching exercises; (e) electrical stimulation applied primarily for muscle strengthening (this was neither FES nor FET, but electro muscular stimulation); (f) practice of activities of daily living (ADLs) including self-care where the upper extremities were used as appropriate; and (g) caregiver training.
9741285|NCT00221117|Experimental|Neuroprosthesis-FES Therapy|The FES Therapy began by designing stimulation protocols to generate power (circular grip and lateral pinch) and precision (opposition with 2 and 3 fingers) grasps on demand. The stimulation sequence (protocol) for power and precision grasps was developed for each patient individually using the Compex Motion electric stimulator. Compex Motion is a fully programmable transcutaneous (surface) stimulator that uses self-adhesive surface electrodes.
9741286|NCT00221195|Other|On-demand first|Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
9741287|NCT00221195|Other|Prophylaxis first|Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug
9741288|NCT00221299|Active Comparator|Group1a-rhPTH&RIS-Placebo(Y1)&RIS(Y2)|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - re-randomized to risedronate (35mg/wk) tablets for second year.
9741289|NCT00221299|Active Comparator|Group1b-rhPTH&RisendronatePlacebo|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - continue on risedronate placebo tablets for second year.
9741290|NCT00221299|Active Comparator|Group2-rhPTH&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
9741291|NCT00221299|Active Comparator|Group3-rhPTH-Placebo&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), placebo SC injections of normal saline daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
9741292|NCT00221338|Experimental|Gabapentin|Double blind, placebo controlled
9741293|NCT00221338|Placebo Comparator|Placebo|Double blind
9741294|NCT00221403|Active Comparator|Valproate (VPA)|VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to achieve a blood level of 80-100 lg/mL. An independent, unblinded study psychiatrist adjusted VPA doses to achieve a therapeutic level
9741295|NCT00221403|Active Comparator|Risperidone|Risperidone was administered in liquid form matched for taste and color to the placebo. Medications were administered in a double-blinded manner on a twice-daily basis.
9741296|NCT00221403|Placebo Comparator|Placebo|The placebo was administered in liquid form, matched for taste and color with the active comparator.
9741297|NCT00222105|Experimental|1|Doxil, Thalidomide, Dexamethasone
9741298|NCT00222131|Placebo Comparator|1|Placebo
9741299|NCT00222131|Active Comparator|2|Esomeprazole
9741300|NCT00222729|Experimental|Pemetrexed & Bevacizumab|
9741301|NCT00223080|Active Comparator|Vaccine|ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
9741302|NCT00223080|Placebo Comparator|Placebo|ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
9741303|NCT00223236|Active Comparator|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
9741304|NCT00223236|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
9741305|NCT00223496|Experimental|Aripiprazole|Aripiprazole open-label in doses ranging from 5-30mg QD adjunct to Divalproex 500-2500mg QD.
9741306|NCT00223652|Experimental|Arm 1 - Telephone CBT|Telephone cognitive behavioral therapy
9741307|NCT00223652|No Intervention|Arm 2 - Treatment as Usual|Treatment as usual control.
9741308|NCT00223665|Experimental|Intermittent Androgen Suppression (IAS)|"Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.~Flutamide dosed as 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.~Leuprolide Acetate dosed as 7.5mg intramuscular (IM) injections once per month for a total of 9 months."
9741309|NCT00223678|Active Comparator|1|pt will switch from calcineurin inhibitor (CYA, prograf) to Rapamycin
9741310|NCT00223678|No Intervention|2|Patient will remain on calcineruin inhibitor
9741311|NCT00223704|Experimental|HOE 140|Bradykinin receptor antagonist
9741312|NCT00223704|Active Comparator|Aminocaproic Acid|Antifibrinolytic
9741313|NCT00223704|Placebo Comparator|Placebo|Placebo
9741314|NCT00223795|Active Comparator|Single point cane|People with knee osteoarthritis underwent gait analysis with a cane
9741315|NCT00223795|No Intervention|No cane|Patients with knee osteoarthritis undergo gait analysis without a cane
9741316|NCT00223808|Experimental|Robot-Low|low-dose mechanically-assisted upper limb therapy
9741317|NCT00223808|Experimental|Robot-High|high-dose mechanically-assisted upper limb therapy
9741318|NCT00223808|Active Comparator|Control|additional traditional therapy
9741319|NCT00223821|Active Comparator|Drug Therapy Aone|Oxybutynin chloride, extended-release, individually-titrated
9741320|NCT00223821|Experimental|Drug Therapy + Behavioral Training|Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
9741321|NCT00223977|Experimental|Sodium ferric gluconate complex 125 mg|125 mg sodium ferric gluconate weekly x 8 weeks
9741322|NCT00223977|Experimental|Sodium ferric gluconate complex 250 mg|250 mg sodium ferric gluconate complex weekly x 4 weeks
9741323|NCT00223977|Active Comparator|Oral iron|325 mg ferrous sulfate three times daily x 8 weeks
9741324|NCT00223990|Experimental|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
9741325|NCT00223990|Active Comparator|RabAvert (rabies vaccine)|RabAvert vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
9741326|NCT00224016|Experimental|Oxybutynin Transdermal System|Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
9741327|NCT00224016|Active Comparator|Oral oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
9741328|NCT00224029|Experimental|Oxybutynin transdermal system|Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing
9741329|NCT00224042|Experimental|IV iron|
9741330|NCT00224042|Active Comparator|oral iron|
9741331|NCT00224055|Experimental|IV iron|Sodium ferric gluconate
9741332|NCT00224055|Active Comparator|oral iron|ferrous sulfate
9741333|NCT00224107|Experimental|Silodosin|Silodosin 8 mg once daily with food
9741334|NCT00224107|Placebo Comparator|placebo|Matching Placebo capsule once daily with food
9741335|NCT00224120|Experimental|Silodosin|Silodosin 8 mg/Day with food
9741336|NCT00224120|Placebo Comparator|Placebo|Matching placebo capsule once daily with food
9741337|NCT00224133|Experimental|Silodosin|Silodosin 8 mg per day with food
9741338|NCT00224289|Other|1|All participants will be taking Latanoprost; This study compares efficacy within age groups.
9741339|NCT00224484|Experimental|GD2-AS04 GROUP|Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
9741340|NCT00224484|Active Comparator|HAVRIX GROUP|Female subjects aged 10-17 years, who received 3 doses of Havrix, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
9741341|NCT00224484|Placebo Comparator|SALINE GROUP|Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
9741342|NCT00224770|No Intervention|Medical Management|Standard of care medical management as per American Heart Association (AHA) guidelines.
9741343|NCT00224770|Active Comparator|MISTIE Surgical Management|"Minimally invasive surgery (MIS) with clot lysis with recombinant tissue plasminogen activator (rt-PA).~MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours, in addition to best medical care.~This includes 54 intent-to-treat patients, and excludes 27 pilots."
9741344|NCT00224770|Active Comparator|ICES Surgical Management|"Intraoperative stereotactic CT-Guided Endoscopic Surgery~Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative-targeting arm as MISTIE arm. Best medical care was provided, but no rt-PA was administered.~This includes 14 intent-to-treat patients, and excludes 4 pilots."
9781760|NCT01156701||Cohort3: No prophylaxis with untreated index|"Individuals are eligible to be included in the no prophylaxis with untreated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
9781761|NCT01156701||Cohort4: No prophylaxis with treated index|"Individuals are eligible to be included in the no prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza(HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received zanamivir (Relenza) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza"
9781762|NCT01156714|Other|Arm 1: Treadmill Training|Treadmill training with aerobic exercise
9781763|NCT01156714|Other|Arm 2: Memory Training|Memory training with computerized memory program
9781764|NCT01156714|Other|Arm 3: Treadmill and Memory Training|Combination of treadmill training and computerized memory program
9781765|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 100mg QD (AM)|FP 100mcg BID plus GSK2190915 100mg QD (AM)
9781766|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 300mg QD (AM)|FP 100mcg BID plus GSK2190915 300mg QD (AM)
9781767|NCT01156792|Active Comparator|FP 100mcg BID plus montelukast 10mg QD (PM)|FP 100mcg BID plus montelukast 10mg QD (PM)
9781768|NCT01156792|Active Comparator|FP 100mcg BID plus placebo BID|FP 100mcg BID plus placebo BID
9781769|NCT01156792|Active Comparator|FP/SAL 100/50mcg BID plus placebo BID|FP/SAL 100/50mcg BID plus placebo BID
9781770|NCT01156805|Experimental|Educational intervention, Control|Experimental, intervention group has received specific educational training to improve food habits and physical activity during the period of the study.
9781771|NCT01156805|No Intervention|Educational program|No intervention has been made.
10200968|NCT05071677||Observational (survey, interview)|Patients participate in a standard of care treatment planning meeting over 3 hours with members of the multidisciplinary treatment team including, the oncologist, radiologist, oncology surgeon, and social worker. Patients then complete surveys over 20 minutes and within 30 days later. Some patients may participate in interviews over 30 minutes.
10200969|NCT05070585|Experimental|Isothiocyanate Rich Juice|The juices will contain 37,5g isothiocyanate rich sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
10200970|NCT05070585|Placebo Comparator|Placebo Juice|The juices will contain 37,5g alfalfa sprouts and be delivered frozen to the subjects. The subjects will be instructed to consume two juices per day.
10200971|NCT05059223|Experimental|AXS-12 (reboxetine)|Up to 5 weeks
10200972|NCT05059223|Placebo Comparator|Placebo|Up to 5 weeks
10200973|NCT05054504|Other|Intervention|The primary intervention is a multi-phase, mixed methods, implementation research study that will investigate the feasibility and acceptability of the limited introduction of ultrasound via the Butterfly iQ device into routine ANC service delivery at health center level in Blantyre, Malawi. The study will occur in three phases: 1) Training, 2) Iterative Service Delivery, and 3) Final Evaluation.
10200974|NCT05053347|Experimental|Flaxseed oil|Flaxseed oil capsule, 5g/d(ALA2.5g/d)
10200975|NCT05053347|Placebo Comparator|Corn oil|Corn oil capsule, 5g/d
10200976|NCT05051969|Experimental|Remote Mindfulness-Based Stress Reduction Program|Mindfulness- Based Stress Reduction classes
10200977|NCT05050773||Nicorandil group|Patients who are prescribed with Nicorandil with or without other concomitant medication
10200978|NCT05050773||Non-Nicorandil group|Patients who are prescribed with antianginal drugs except Nicorandil
10200979|NCT05049083|Experimental|Treatment group A|
10200980|NCT05049083|Experimental|Treatment group B|
10200981|NCT05045014||Patient group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task. In addition, X-ray images taken during routine follow-ups will be used to determine the location, type of curvature and Cobb angle of the scoliosis. The degree of rotation will be measured with a mobile application called Scoliodetector. Quality of life is planned to be evaluated with the Scoliosis Research Society-22 questionnaire.
9517297|NCT03307655|Experimental|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
9741345|NCT00224874|Experimental|Etanercept|Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept
9741346|NCT00224874|Experimental|Mycophenolate Mofetil|Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil
9741347|NCT00224874|Experimental|Denileukin Diftitox|Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox
9741348|NCT00224874|Experimental|Pentostatin|Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin
9741349|NCT00224887|Experimental|in home nutrition counseling|In-home family-based behavioral counseling using in-person and video interventions delivered by community health advisors
9741350|NCT00224887|Active Comparator|standard nutrition education curriculum|standard nutrition education curriculum consisting of video and lesson plans based on USDA Food Guide pyramid
9741351|NCT00224952||Patients receiving Carbamazepine or Valproic Acid|
9741352|NCT00225017|Experimental|A|"ARM A: Switch current PI to atazanavir 400 mg once daily plus current > 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) for 24 weeks.~Subjects currently on ritonavir (RTV) (400 mg BID or greater) or RTV-boosted PI (<400 mg/day) , or tenofovir (TDF) as backbone NRTI therapy, will switch to ATV 300 mg boosted with RTV 100mg once daily."
9741353|NCT00225017|Active Comparator|B|ARM B: Continue current antiretroviral regimen (single or RTV-boosted PI plus > 2 NRTIs) for 24 weeks
9741354|NCT00225147|Experimental|100 IU/kg rhC1INH|100 IU/kg Recombinant human C1 inhibitor
9741355|NCT00225147|Experimental|50 IU/kg rhC1INH|50 IU/kg Recombinant human C1 inhibitor
9741356|NCT00225147|Placebo Comparator|Saline|
9741357|NCT00225212|Experimental|Rituximab after ASCT|Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.
9741358|NCT00225251|Experimental|bupropion XL|Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
9741359|NCT00225251|Placebo Comparator|Placebo|Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day
9741360|NCT00225277|Experimental|Pioglitazone QD|
9741361|NCT00225277|Active Comparator|Glimepiride QD|
9741362|NCT00225420|Other|Single Arm Intervention|Single Arm Intervention where after enrollment (or prior to enrollment but before starting radiotherapy) patients will initially receive leuprolide acetate (Lupron®) intramuscular (IM). Patients will begin adaptive external-beam radiation therapy 2-3 months following the initiation of hormonal therapy. Each patient receives a dose of docetaxel at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight weeks.
9741363|NCT00225498|Experimental|1|ziprasidone
9741364|NCT00225498|Active Comparator|2|risperidone or olanzapine
9741365|NCT00225732|Active Comparator|intravenous ibuprofen|
9741366|NCT00225732|Placebo Comparator|normal saline|
9741367|NCT00225758|Experimental|1|Subjects will continue on their prior endocrine therapy with the addition of lapatinib at 1500 mg once daily for 26 weeks or longer.
9741368|NCT00225784|Experimental|Cetuximab, Gemcitabine, RT|weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy
9741369|NCT00226239|Experimental|Head and neck cancer patients|Induction chemotherapy consists of 3 cycles of cisplatin 75 mg/m^2, on day 1, docetaxel 75 mg/m^2, on day 1, and cetuximab weekly days 1,8,15, repeated every 21 days (cetuximab dose is 400 mg/m^2 on day 1 and 250 mg/m^2 on subsequent weekly treatments). After 3 cycles of induction, patients receive standard radiation 70 Gy/200 cGy/daily, 5 days/week with concurrent weekly cisplatin 30 mg/m^2 and cetuximab 250 mg/m^2. After completing radiation therapy, patients receive cetuximab weekly as maintenance therapy for 6 months (see section 5 for detailed treatment plan and dose modifications)
9741370|NCT00226499|Experimental|MMRV Group|Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
9741371|NCT00226499|Experimental|OKAH Group|Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.
9741372|NCT00226499|Active Comparator|MMR Group|Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
9741373|NCT00226577|Experimental|Pre-Surgery Chemotherapy|
9741374|NCT00226590|Experimental|Combined Therapy|In this trial we adopted the approach of using both induction and concurrent chemotherapy together with TRT planned conformally to a tumor dose of 74 Gy.
9741375|NCT00226655|Experimental|I|All patients will receive hCRF (XERECEPT) 2mg/day
9741376|NCT00226811|Experimental|A|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
9741377|NCT00226941|Experimental|Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)~Oxaliplatin 100 mg/m², Days 2 and 23"
9741378|NCT00226941|Experimental|Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85|"Cetuximab 250 mg/m² / week~Capecitabine 700 mg/m²~Radiotherapy (XRT)~Oxaliplatin 85 mg/m², Days 2 and 23"
9741379|NCT00226941|Experimental|Group A - Cetuximab + Capecitabine-800 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)"
9517298|NCT03307642|No Intervention|SLIV + usual communication|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV
9741380|NCT00226941|Experimental|Group B - Cetuximab + Capecitabine-1000 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 1000 mg/m²~Radiotherapy (XRT)"
9741381|NCT00227019|Experimental|bevacizumab+ pemetrexed|pemetrexed (500 mg/m² IV) + bevacizumab (15 mg/kg IV). In addition to Vitamin B12 + Folate + Dexamethasone
9741382|NCT00227266|Placebo Comparator|Cohort 1a|Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
9741383|NCT00227266|Active Comparator|Cohort 1b|Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.
9741384|NCT00227266|Experimental|Cohort 2|Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
9741385|NCT00227344|Experimental|1|Catheter ablation
9741386|NCT00227344|Active Comparator|2|Antiarrhythmic drugs
9741387|NCT00227370|Active Comparator|1|Valganciclovir 900 mg QD for 9 months post lung transplant.
9741388|NCT00227370|Placebo Comparator|2|placebo for 9 months post lung transplant
9741389|NCT00227539|Experimental|Neoadjuvant therapy, PET scan and surgery|
9741390|NCT00227591|Experimental|Treatment (lenalidomide, prednisone)|For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28 and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Patients with stable or responding disease after course 3 receive oral lenalidomide alone once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9741391|NCT00227617|Experimental|FOLFOX with Bevacizumab|"Starting on Day 1, administered every two weeks:~5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes"
9741392|NCT00227721|Experimental|Docetaxel & Gemcitabine hydrochloride|Docetaxel, 40 mg/m2, 30 min IV infusion on Days 1 and 8, of a 21 day cycle Gemcitabine hydrochloride, 800mg/m2 30 min IV infusion on Days1 and 8, of a 21 day cycle
9741393|NCT00227760|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9741394|NCT00227877|No Intervention|Control - New England, USA|"Control participants will receive care as usual from their provider"
9741395|NCT00227877|Experimental|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
9741396|NCT00227877|No Intervention|Control - Prague, CZR|"Control participants will receive care as usual from their provider"
9741397|NCT00227877|Experimental|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
9741398|NCT00227903|Experimental|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
9741399|NCT00227903|Active Comparator|Brief Advice|Advice and education
9741400|NCT00227994|Experimental|Galantamine|Galantamine for 12 weeks
9741401|NCT00227994|Experimental|Donepezil|Donepezil for 12 weeks
9741402|NCT00228384|Active Comparator|Gore VIABAHN Endoprosthesis|
9741403|NCT00228384|Active Comparator|Bare Nitinol Stent (BNS)|
9741404|NCT00228423|Active Comparator|75mg Clopidogrel|75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
9741405|NCT00228423|Placebo Comparator|Placebo|Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
9741406|NCT00228553|Experimental|1|Armodafinil 100 to 250 mg/day
9741407|NCT00228813|Other|Granulocyte Colony Stimulating Factor (G-CSF) stimulation|Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.
9741408|NCT00228917|Experimental|ACAC_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study ( NCT00317187) are boosted in the current study with one dose of the same vaccines at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
9741409|NCT00228917|Experimental|ACHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9741410|NCT00228917|Experimental|HibACPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9741411|NCT00228917|Experimental|HibHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of the same vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9741412|NCT00228917|Experimental|ACAC_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccines at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
9741413|NCT00228917|Experimental|ACHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9741414|NCT00228917|Experimental|HibACPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9741415|NCT00228917|Experimental|HibHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
9741416|NCT00228943|Experimental|Acute tryptophan depletion|Full-strength tryptophan depletion
9741417|NCT00228943|Active Comparator|Control|Half-strength tryptophan depletion drink used as a control
9741418|NCT00229619|Experimental|Rituximab (Rituxan)|This is a non-randomized, off label, pilot study of humanized anti CD20 rituximab (Rituxan®) in patients with moderate aplastic anemia, pure red cell aplasia or Diamond-Blackfan anemia who have either failed to respond to at least one prior course of immunosuppressive therapy (PRCA/DBA patients only)or who have relapsed disease after prior immunosuppressive therapy (PRCA/DBA patients only).
9741419|NCT00229658||Type 1|Patients with type 1 diabetes
9741420|NCT00229658||Type 2|Patients with type 2 diabetes
9741421|NCT00229723|Placebo Comparator|1|Radiation + cisplatin; followed by placebo as maintenance therapy
9741422|NCT00229723|Experimental|2|250 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
9741423|NCT00229723|Experimental|3|500 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
9741424|NCT00229723|Experimental|4|gefitinib 250 mg + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
9741425|NCT00229723|Experimental|5|gefitinib 500 mg + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
9741426|NCT00229723|Placebo Comparator|6|placebo + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
9741427|NCT00229723|Placebo Comparator|7|placebo + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
9741428|NCT00229957|Experimental|Intervention|Intervention
9741429|NCT00229957|No Intervention|Control|Control group received usual care in primary care.
9741430|NCT00230009|No Intervention|Assessment only|
9741431|NCT00230009|Experimental|Brief intervention session|
9741432|NCT00230022|Experimental|Brief computer-delivered intervention|A 20-minute interaction with software designed to partially replicate the experience of a brief motivational intervention with a therapist or health care professional. Included decisional balance, normed feedback, and optional goal-setting.
9741433|NCT00230022|No Intervention|Assessment only|Participants in this arm only completed assessment section, same as intervention group, but then was done.
9741434|NCT00230048|No Intervention|Assessment only|
9741435|NCT00230048|Experimental|Brief intervention|
9741436|NCT00230100|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
9741437|NCT00230100|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
9741438|NCT00230126|Active Comparator|A erlotinib 150 mg|erlotinib 150 mg/day cycles 1 - 3
9741439|NCT00230126|Experimental|B erlotinib modified according to weight|erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
9741440|NCT00230178|Experimental|Arm A|Rasburicase alone given as a single agent for 5 days
9741441|NCT00230178|Experimental|Arm B|Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
9741442|NCT00230178|Active Comparator|Arm C|Oral allopurinol alone given as a single agent for 5 days
9741443|NCT00230282|Experimental|Fludarabine, cytoxan, then alemtuzumab|Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.
9741444|NCT00230737|Experimental|A|Melatonin 0.4 mg
9741445|NCT00230737|Experimental|B|Melatonin 4.0 mg
9741446|NCT00230737|Placebo Comparator|C|
9741447|NCT00230802|Active Comparator|2 tablet increase|Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)
9741448|NCT00230802|Active Comparator|3 tablet increase|Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).
9741449|NCT00230971|Active Comparator|A|
9741450|NCT00230971|Active Comparator|B|
9741451|NCT00231114|Experimental|Alair|Treatment of airways with the Alair System
9741452|NCT00231114|Sham Comparator|Sham|Sham treatment of airways
9741453|NCT00231179|Experimental|Home visiting Intervention|Home visiting intervention group.
9741454|NCT00231179|Placebo Comparator|Control|Control condition did not receive any services.
9741455|NCT00231283|Experimental|1|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
9741456|NCT00231309|Other|single arm|
9741457|NCT00231413|Active Comparator|HPV-16/18 Group|Female subjects who received 3 doses of the HPV-16/18 L1 AS04 vaccine intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
9741458|NCT00231413|Experimental|HPV-TETRA A Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 1 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
9741459|NCT00231413|Experimental|HPV-TETRA B Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 2 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
9741460|NCT00231413|Experimental|HPV-TETRA C Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 3 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
9741461|NCT00231413|Experimental|HPV-TETRA D Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 4 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
9741462|NCT00231413|Experimental|HPV-TETRA E Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 5 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
9741463|NCT00231413|Experimental|HPV-TETRA F Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 6 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
9741464|NCT00231465|Experimental|Taxotere® (Docetaxel) + ZD1839 (IRESSA®)|"Patients will receive Taxotere at 75 mg/m2 given IV over 60 minutes on day 1 of a three week cycle.~ZD1839 will be administered orally at 250mg daily starting on day one, concurrently with the Taxotere."
9741465|NCT00231478|Experimental|1|
9741466|NCT00231478|Experimental|2|
9741467|NCT00231777|Experimental|1|40 mg MK0517 IV
9741468|NCT00231777|Active Comparator|2|4 mg ondansetron IV
9741469|NCT00231816|Experimental|Concomitant|Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4
9741470|NCT00231816|Experimental|Nonconcomitant|Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4
9741471|NCT00231842|Experimental|Ifosfamide with or without cisplatin|Participants with surgically staged carcinosarcoma (CS) with no gross residual disease were initially administered ifosfamide (1.2 g/m2/day for 5 days) with cisplatin (20 mg/m2/day for 5 days) every 3 weeks for 3 cycles followed by pelvic external beam RT and brachytherapy followed by 3 additional cycles of ifosfamide (1.0 g/m2/day) with cisplatin with cisplatin (20 mg/m2/day for 5 days) evrey 3 weeks. cisplatin added toxicity without additional efficacy, so mid-study, cisplatin was eliminated.
9741472|NCT00231868|Experimental|A|Drug:Carboplatin and Paclitaxel and Radiation: Pelvic Radiation Therapy
9741473|NCT00231894|Active Comparator|Pioglitazone and life-style group|Pioglitazone (30-45 mg/daily) plus life-style diet group
9741474|NCT00231894|Placebo Comparator|Placebo and life style group|Placebo capsules daily plus life-style diet group
9741475|NCT00232180|Active Comparator|Eplerenone arm|Eplerenone administered on top of background standard heart failure therapy
9741476|NCT00232479|Experimental|arm 1|single arm study evaluating the efficacy of neoadjuvant taxotere, herceptin and carboplatin given in a dose dense fashion
9741477|NCT00232505|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.
9741478|NCT00232505|Experimental|Cetuximab and Carboplatin|Patients receive cetuximab as in arm I and carboplatin IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9741479|NCT00232544|Experimental|TLC-CPAP|A telephone-linked communication (TLC) system for promoting adherence to continuous positive airway pressure (CPAP)
9741480|NCT00232544|Placebo Comparator|TLC-Control|A TLC system for providing general health education
9741481|NCT00232557|Experimental|TLC-Asthma|Telephone-based home education and asthma monitoring
9741482|NCT00232557|Active Comparator|TLC-health education|Telephone-based home education
9741483|NCT00232583|Active Comparator|Metfomin and Insulin|Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration
9741484|NCT00232583|Active Comparator|Metformin, Pioglitazone and Glyburide|Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration
9741485|NCT00232596|Placebo Comparator|Placebo|
9741486|NCT00232596|Experimental|Retigabine|
9741487|NCT00232739|Experimental|1|
9741488|NCT00233064|Active Comparator|1|Liquid Palivizumab
9741489|NCT00233064|Active Comparator|2|Lyophilized Palivizumab
9741490|NCT00233103|Experimental|Sertraline|Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg).
9741491|NCT00233103|Placebo Comparator|Placebo|Placebo for 10 weeks.
9741492|NCT00233324|Experimental|Surfactant and Low Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturation of 85% to 89%
9741493|NCT00233324|Experimental|Surfactant and High Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturationof 91% to 95%
9741494|NCT00233324|Experimental|CPAP and Low Oxygen|Administration of continuous positive airway pressure (CPAP) and supplemental oxygen with target saturation of 85% to 89%
9741495|NCT00233324|Experimental|CPAP and High Oxygen|Administration of continuous positive airway pressure (CPAP)and supplemental oxygen with target saturation of 91% to 95%
9741496|NCT00233402|Active Comparator|Standard White Light Cystoscopy|
9741497|NCT00233402|Experimental|Standard White Light and Hexvix Fluorescence Cystoscopy|
9741498|NCT00233454|Experimental|Midostaurin|100 mg midostaurin twice daily as oral capsules
9741499|NCT00233480|Experimental|active treatment|atorvastatin 10mg QD x 3 months
9741500|NCT00233480|Placebo Comparator|placebo|matched placebo QD x 3 months
9741501|NCT00233519|Experimental|Cohort 1- Two Escalating Doses of Iplex|0.5 and 1.0 mg/kg/day
9741502|NCT00233519|Active Comparator|Cohort 2 - Three Escalating Doses of Iplex|0.5, 1.0, and 2.0 mg/kg/day
9741503|NCT00233948|Experimental|Arm I|Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9741504|NCT00233987|Experimental|High-dose therapy plus tandem transplant|Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.
9741505|NCT00234039|Experimental|Intravesical Gemcitabine|
9741506|NCT00234052|Experimental|Treatment Arm|Carboplatin + pemetrexed + bevacizumab
9741507|NCT00234065|Experimental|1|cilostazol
9741508|NCT00234065|Active Comparator|2|Aspirin
9741509|NCT00234078|Experimental|0.5% OPC-12759|0.5% OPC-12759 (rebamipide) ophthalmic suspension
9741510|NCT00234078|Experimental|1% OPC-12759|1% OPC-12759 (rebamipide) ophthalmic suspension
9741511|NCT00234078|Experimental|2% OPC-12759|2% OPC-12759 (rebamipide) ophthalmic suspension
9741512|NCT00234078|Placebo Comparator|placebo|placebo of OPC-12759 (rebamipide) ophthalmic suspension
9741513|NCT00234286|Experimental|Arm 1|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
9741514|NCT00234494|Experimental|Single Group Assignment|Cisplatin + Gemcitabine + Bevacizumab
9741515|NCT00234533|Experimental|NutropinAq 10 mg/2 mL (30 IU)|"Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:~GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight~TS patients: up to 0.05 mg/kg bodyweight~CRI patients: up to 0.05 mg/kg bodyweight~Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.~The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening."
9741516|NCT00234832|Experimental|Sibutramine|Subjects were randomized to receive sibutramine 10 mg once daily (QD) during the Treatment Period after a 6-week Lead-in Period
9741517|NCT00234832|Placebo Comparator|Placebo|Subjects were randomized to receive placebo QD during the Treatment Period after a 6-week Lead-in Period
9741518|NCT00234832|Experimental|Lead-in sibutramine|All subjects received 10 mg sibutramine QD during a 6-week Lead-in Period
9741519|NCT00234884||Adalimumab|RA patients in treatment with commercial adalimumab
9741520|NCT00235391|Experimental|Deferasirox|Deferasirox was administered orally once a day, 30 minutes prior to breakfast. Dosage was based on participant's body weight. Starting dose was determined by the frequency of blood transfusions and recommended initial daily dose of deferasirox is 20 mg/kg body weight for patients receiving blood transfusion, 10 mg/kg for patients receiving less frequent transfusion/exchange transfusion and 30 mg/kg for patients receiving more frequent blood transfusions.
9741521|NCT00235443|Experimental|1|Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day
9741522|NCT00235456|Active Comparator|80% perioperative oxygen|Perioperative supplemental oxygen: Patients were randomly assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
9741523|NCT00235456|Placebo Comparator|30% perioperative oxygen|Standard oxygen: Patients were randomly assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
9781772|NCT01156844|Experimental|Indacaterol 37.5 µg (twice a day)|"Indacaterol 37.5 µg twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9781773|NCT01156844|Experimental|Indacaterol 75 µg (once a day)|"Indacaterol 75 µg once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9781774|NCT01156844|Experimental|Indacaterol 150 µg (every other day)|"Indacaterol 150 µg every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 µg inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9781775|NCT01156844|Placebo Comparator|Placebo|"Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9781776|NCT01156987|Experimental|Healthy Volunteers|Five healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.
9781777|NCT01156987|Experimental|Breast Cancer Patients|40 breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.
9741524|NCT00235495|Active Comparator|Albumin (ALB)|Albumin (human albumin, 25% solution, 2.0 g/kg), infused intravenously over a period of 2 hours
9741525|NCT00235495|Placebo Comparator|Saline|Saline (isotonic solution), 8 ml/kg, infused intravenously over a 2-hour period
9741526|NCT00235547|Active Comparator|contraception-Immediate start|contraception after abortion and before leaving the clinic, observed by clinic staff
9741527|NCT00235547|Active Comparator|Contraception-Delayed start|instructed to begin contraception the first Sunday after leaving the clinic
9741528|NCT00235573|Experimental|Vitamin B12 supplement|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12 were administered 6 hours apart.
9741529|NCT00235716|Experimental|Arm 1|2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
9741530|NCT00235716|Experimental|Arm 2|20 mg per day of memantine plus placebo for dl-alpha-tocopherol
9741531|NCT00235716|Experimental|Arm 3|Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
9741532|NCT00235716|Placebo Comparator|Arm 4|Matching placebos for dl-alpha-tocopherol and memantine
9741533|NCT00235755|Placebo Comparator|Placebo|
9741534|NCT00235755|Experimental|Retigabine 600 mg|
9741535|NCT00235755|Experimental|Retigabine 900 mg|
9741536|NCT00235833|Experimental|Adalimumab 40 mg eow|
9741537|NCT00235872|Experimental|Adalimumab 40 mg every other week (eow)|
9741538|NCT00235989|Active Comparator|ET: IFNB-1b 250 mcg => 250 mcg|Extension Treatment 250 mcg continued
9741539|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 250 mcg|Extension Treatment 500 mcg reduced to 250 mcg
9741540|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 500 mcg|Extension Treatment 500 mcg continued
9741541|NCT00235989|Experimental|ET: IFNB-1b 250 mcg => 500 mcg|Extension Treatment 250 mcg increased to 500 mcg
9741542|NCT00236080|Experimental|1|PROVIGIL 200 mg/day
9741543|NCT00236080|Experimental|2|Armodafinil 250 mg/day
9741544|NCT00236080|Experimental|3|Armodafinil 200 mg/day
9741545|NCT00236080|Experimental|4|Armodafinil 150 mg/day
9741546|NCT00236080|Placebo Comparator|5|Placebo
9741547|NCT00236184|Placebo Comparator|Placebo|Oral placebo tablet
9741548|NCT00236184|Experimental|Rabeprazole sodium 10 mg|oral rabeprazole 10 mg enteric-coated tablet
9741549|NCT00236197|Experimental|1|
9741550|NCT00236197|Placebo Comparator|2|
9741551|NCT00236899|Experimental|A: Docetaxel and Gemcitabine (Tri-weekly)|Docetaxel and Gemcitabine (Tri-weekly)
9741552|NCT00236899|Experimental|B: Paclitaxel and Gemcitabine (Tri-weekly)|Paclitaxel and Gemcitabine (Tri-weekly)
9741553|NCT00236899|Experimental|C: Docetaxel and Gemcitabine (Weekly)|Docetaxel and Gemcitabine (Weekly)
9741554|NCT00236899|Experimental|D: Paclitaxel and Gemcitabine (Weekly)|Paclitaxel and Gemcitabine (Weekly)
9741555|NCT00236938|Experimental|Group A|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
9741556|NCT00236938|Active Comparator|Group B|Stable erythropoietin (EPO) dose and no supplemental iron.
9741557|NCT00236951|Active Comparator|Venofer + erythropoietin (responders)|
9741558|NCT00236951|Active Comparator|erythropoietin only (responders)|
9741559|NCT00236951|Active Comparator|Venofer+erythropoietin(non-responders)|
9741560|NCT00236951|Active Comparator|erythropoietin only (non-responders)|
9741561|NCT00236977|Experimental|Venofer|iron sucrose injection
9741562|NCT00236977|Active Comparator|Ferrous Sulfate|oral iron
9741563|NCT00237042|Active Comparator|Self Management|Dental hygienist-delivered pain self-management treatment
9741564|NCT00237042|Experimental|Targeted Self Management|Dental hygienist-delivered pain self-management treatment with a focus on menstrual cycle-related changes in pain and other symptoms
9741565|NCT00237042|Experimental|Continuous Oral Contraceptives|"Oral contraceptive (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months with no spacer pills."
9741566|NCT00237185|Experimental|imatinib mesylate 400 mg|400 mg once daily
9741567|NCT00237185|Experimental|imatinib mesylate 600 mg|600 mg once daily
9741568|NCT00237458|Experimental|Lacosamide|Open-label active treatment
9741569|NCT00237666|Experimental|Ziprasidone|Ziprasidone monotherapy, 20-60 mg BID.
9741570|NCT00237692|No Intervention|Arm 1|Control group - a group of hypertensive patient who receive usual care
9741571|NCT00237692|Experimental|Arm 2|Nurse Behavioral intervention with Home BP Telemonitoring Nurse-administered tailored behavior intervention
9741572|NCT00237692|Experimental|Arm 3|Nurse Medication Management with Home BP Telemonitoring -- Nurse administer medication management according to hypertension decision support system
9741573|NCT00237692|Experimental|Arm 4|Nurse Combined intervention with Home BP Telemonitoring - Combination of the nurse administered tailored behavioral & medication management interventions
9741574|NCT00237718|Active Comparator|ALA and Vitamin E|600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months
9741575|NCT00237718|Placebo Comparator|Placebo|placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months
9741576|NCT00237744|Experimental|Wrist/Hand FES + Whole Arm Motor Learning|Subjects > 6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning training and FES of the wrist/hand.
9741577|NCT00237744|Experimental|Shoulder/Elbow Robotics + Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning and shoulder/elbow robotics.
9741578|NCT00237744|Experimental|Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function who received whole arm motor learning training without addition of FES or Robotics
9741579|NCT00237770|Placebo Comparator|Arm 1|Placebo control (normal saline) is employed on a separate visit during procedure.
9741580|NCT00237796|Experimental|ARM 1|Cognitive Behavioral Social Skills Training (CBSST)
9741581|NCT00237796|Active Comparator|ARM 2|Goal Focused Supportive Contact (GFSC)
9741582|NCT00237809|Experimental|Drug and control CRT|D-serine/control
9741583|NCT00237809|Experimental|Drug and CRT|D-serine/cog rehab
9741584|NCT00237809|Experimental|Placebo Drug and Placebo CRT|Placebo/control
9741585|NCT00237809|Experimental|Placebo Drug and CRT|Placebo/cog rehab
9741586|NCT00238108|Experimental|1|Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
9741587|NCT00238108|Placebo Comparator|2|Placebo
9741588|NCT00238121|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9741589|NCT00238238|Active Comparator|Arm I - rituximab|Patients receive rituximab IV on days 1, 8, 15, and 22.
9741590|NCT00238238|Experimental|Arm II - lenalidomide|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9741591|NCT00238238|Experimental|Arm III - lenalidomide and rituximab|Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.
9741592|NCT00238264|Experimental|Treatment (radiotherapy)|Patients undergo reduced-field conformal radiation therapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
9741593|NCT00238303|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9741594|NCT00238303|Experimental|Stratum 2 (undergoing surgery)|Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses. Patients then undergo surgery to remove the tumor. Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9741595|NCT00238355|Experimental|Voriconazole plus Caspofungin|
9741596|NCT00238433|Experimental|Filgrastim/Melphalan/Thiotepa|"Biological/Vaccine: filgrastim~5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) > 1500 for 2 consecutive days.~Drug: busulfan~3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.~Drug: melphalan~50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.~Drug: thiotepa~250 mg/m2/day/iv on days -3 and -2 Procedure/Surgery: bone marrow ablation with stem cell support~The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.~Procedure/Surgery: peripheral blood stem cell transplantation~Performed 36-48 hours following last chemotherapy dose."
9741597|NCT00238615|Experimental|Chemotherapy+Radiation+Surgery|"Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.~Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.~No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation~Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support."
9741598|NCT00239005|Active Comparator|Mycophenolate Mofetil (MMF)|250 mg capsules or 500 mg tablets of mycophenolate mofetil. Daily dose decided by physician, was taken morning and evening.
9741599|NCT00239005|Experimental|Enteric-Coated Mycophenolate Sodium (EC-MPS )|Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium. Daily dose decided by the physician, was taken morning and evening.
9741600|NCT00239226|Experimental|1. IAS pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (1) includes patients with Delta CTos >50 ms and randomized IAS pacing.~IAS Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
9741601|NCT00239226|Experimental|2. IAS pacing-control group|"(Delta CTos<50ms)~Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (2) includes patients with Delta CTos <50 ms and randomized IAS pacing.~IAS Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
9781778|NCT01157065|Experimental|AL-78898A|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
9781779|NCT01157065|Active Comparator|Lucentis|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
9741602|NCT00239226|Active Comparator|3. RAA Pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (3) includes patients with Delta CTos >50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
9741603|NCT00239226|Active Comparator|4. RAA Pacing - control group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (4) includes patients with Delta CTos <50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
9741604|NCT00239356|Experimental|AI|
9741605|NCT00239577|Experimental|DENGUE FORMULATION 17A GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Dengue vaccine Formulation 17a, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
9741606|NCT00239577|Experimental|DENGUE FORMULATION 17B GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 17b, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6, and one booster dose approximately 5-12 months after the second dose.
9741607|NCT00239577|Experimental|DENGUE FORMULATION 19 GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 19, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6 and one booster dose approximately 5-12 months after the second dose.
9741608|NCT00239577|Placebo Comparator|PLACEBO GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Placebo, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
9741609|NCT00239590|Experimental|Testosterone|oral testosterone undecanoate, 80mg twice daily (Andriol Testocaps, Organon, The Netherlands) for 8 weeks
9741610|NCT00239590|Placebo Comparator|Placebo|identical to active medication, taken in an identical way to the active arm
9741611|NCT00239642|Experimental|Venofer (0.5 mg/kg)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
9741612|NCT00239642|Experimental|Venofer (1.0 mg/kg)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
9741613|NCT00239642|Experimental|Venofer (2.0 mg/kg)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
9741614|NCT00239681|Experimental|Rosuvastatin|Rosuvastatin 20 mg once daily
9741615|NCT00239681|Placebo Comparator|Placebo|Placebo once daily
9741616|NCT00239733|Experimental|1|Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.
9741617|NCT00239837|Experimental|Middle School Success Intervention (MSS)|Middle School Success Intervention (MSS): Participants receive the preventative intervention
9741618|NCT00239837|No Intervention|Foster Care Services as Usual|Foster Care Services as Usual: Participants continue with usual foster care
9741619|NCT00239928|Experimental|EYE001|
9741620|NCT00240071|Experimental|Avastin|The patient will continue the same hormonal therapy used prior to study enrollment but will combine it with Avastin.
9741621|NCT00240097|Experimental|Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
9517299|NCT03307642|Active Comparator|SLIV + usual communication + text|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV plus a series of text messages informing them about the usual communication for SLIV
9741622|NCT00240097|Experimental|Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
9741623|NCT00240110|Placebo Comparator|Lithium carbonate add on Placebo|Lithium carbonate started and stabilized then participants randomized to placebo
9741624|NCT00240110|Experimental|Lithium carbonate add on Valproate|Lithium carbonate started and stabilized then participants randomized to Valproate
9741625|NCT00240162|Experimental|PTK787/ZK 222584|Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.
9741626|NCT00240331|Experimental|Rosuvastatin 10mg|
9741627|NCT00240331|Placebo Comparator|Placebo|matching Placebo
9741628|NCT00240487|Active Comparator|Nitric oxide first|Subjects will be randomized to receive Nitric Oxide (NO) immediately after study entry, given at 10 parts per million (ppm) for the first 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide (NO) will be turned off and subjects will receive no intervention (no nitric oxide) for the next 4 hours of study participation. During this time, all subjects will receive standard clinical are. Blood gases will be monitored once an hour for 4 hours.
9741629|NCT00240487|Active Comparator|Delayed nitric oxide|Subjects will be randomized to receive no intervention (no nitric oxide) for he first 4 hours of study participation. During this time, all subjects will receive standard clinical care. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide will be turned on and subjects will receive 10 ppm of nitric oxide for the next 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours.
9741630|NCT00240526|Experimental|Engerix 4D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
9517300|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohorts 1-3|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 treatment given to 3 cohorts of 4 patients as 1 of 3 doses, 400mg, 800mg and 1200 mg.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
9741631|NCT00240526|Experimental|Engerix 3D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
9741632|NCT00240526|Experimental|Engerix 4D|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.
9741633|NCT00240526|Experimental|Engerix 3D Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6.
9741634|NCT00240539|Experimental|HBsAg(+) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
9741635|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 4 doses of Engerix™ in the primary study.
9741636|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 5-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 5 doses of Engerix™ in the primary study.
9741637|NCT00240539|Experimental|HBsAg(-) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen negative [HBsAg(-)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
9741638|NCT00240981|Experimental|Treatment|
9741639|NCT00240981|Placebo Comparator|Placebo|
9741640|NCT00240994|Experimental|Alemtuzumab (Campath)|In this open-label, single-arm trial , participants will be administered a 0.3 mg/kg dose of alemtuzumab (Campath) intravenously one day prior to kidney transplantation and one day post kidney transplantation. Participants will then receive a maintenance immunosuppressive regimen of tacrolimus and mycophenolate mofetil (MMF) for 8 to 12 weeks, followed by sirolimus and MMF until 24 months post transplantation.
9741641|NCT00241176|Experimental|Aripiprazole|
9741642|NCT00241280|Active Comparator|Control|etafilcon A contact lens being worn 7 days/6 nights.
9741643|NCT00241280|Experimental|Test|galyfilcon A contact lens being worn 7 days/6 nights.
9741644|NCT00241358|Active Comparator|Subcutaneous (SC) Treatment Plan - Donor|"Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
9741645|NCT00241358|Experimental|Intravenous (IV) Treatment Plan - Donor|"Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis~Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
9741646|NCT00241358|Other|Recipients|"Conditioning Regimen~Cyclophosphamide 60mg/kg/day on Days -3 and -2~TBI 550cGy on Day -1~GVHD prophylaxis~*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100~PBSC transplant on Day 0"
9741647|NCT00241631|Placebo Comparator|Placebo|Inhaled Theophylline placebo capsule, then placebo, then active Theophylline
9741648|NCT00241631|Active Comparator|Steroid|Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline
9741649|NCT00241644|Experimental|Rotarix 3-Dose Group|Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
9741650|NCT00241644|Experimental|Rotarix 2-Dose Group|Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
9741651|NCT00241644|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.
9741652|NCT00241839|Active Comparator|A|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated.
9741653|NCT00241839|Placebo Comparator|B|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, a Placebo,matched in appearance to Allopurinol, was added daily for 8-10 weeks, at which time testing was repeated.
9781780|NCT01157078|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
9781781|NCT01157078|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
9741654|NCT00241904|Active Comparator|Comprehensive Intervention Group|The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration with the CHW, tailored the intervention plan, conducted the intervention including lifestyle modification counseling and medication titration and prescription, consulted with the physician, and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension (HBP), hyperglycemia, ACE, and β-blocker therapy were developed for this study based on current guidelines and standards of care.
9741655|NCT00241904|Active Comparator|Less Intensive Intervention Group|Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. Patients and their providers in the received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the AHA/ACC Guidelines for Secondary Prevention.
9741656|NCT00241969|Experimental|Behavioral and Nutrition Treatment|The behavioral and nutrition treatment combines individualized nutritional counseling that targeted increasing energy and fat intake and parent training in behavioral child-management skills based on social learning theory to improve meal-time behaviors.
9741657|NCT00241969|Active Comparator|Education and Attention Control|The education and attention control treatment provides education and served as a behavioral placebo in terms of controlling for attention and contact frequency provided. Families are provided with information including general nutrition, enzyme therapy, respiratory infection control, and typical child development anticipatory guidance and safety for preschool- aged children.
9741658|NCT00242216|Active Comparator|Atazanavir oral once daily|HIV treatment
9741659|NCT00242216|Active Comparator|Fosamprenavir oral once daily|HIV treatment
9741660|NCT00242385|Experimental|ARALAST Fr. IV-1|60 mg/kg
9741661|NCT00242385|Active Comparator|ARALAST|60mg/kg
9741662|NCT00242502|Experimental|Bevacizumab + Erlotinib|Bevacizumab 10 mg/kg intravenous every 14 days, repeat cycle every 28 days; Erlotinib 150 mg orally every day continuous dosing.
9741663|NCT00242567|Experimental|Early Group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing at Baseline.
9741664|NCT00242567|Experimental|Delayed group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing no sooner than 12 months after their baseline visit, and not until they have had three rises in PSA level from Baseline, one of which must be a least 10 ng/mL greater than the baseline Serum Prostate-specific Antigen (PSA) level.
9741665|NCT00242580|Experimental|Verteporfin and Triamcinolone 1 mg|Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
9741666|NCT00242580|Experimental|Verteporfin and Triamcinolone 4 mg|Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
9741667|NCT00242580|Active Comparator|Verteporfin and Pegaptanib|Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.
9665766|NCT04910685|Experimental|PK Groups (Dose 2 or Dose 3)|Patients will receive best supportive care (BSC) and Dose 2 or Dose 3 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally for the duration of participation in the study.
9665767|NCT04909996|Experimental|Group A: Sentinox treatment performed 3 times/day for 5 days (as add-on to the standard therapy)|
9665768|NCT04909996|Experimental|Group B: Sentinox treatment performed 5 times/day for 5 days (as add-on to the standard therapy)|
9665769|NCT04909996|No Intervention|Group C: no Sentinox treatment; only the standard therapy will be performed|
9665770|NCT04909970|Experimental|Self hypnosis|Self-hypnosis program associated to usual practice of stress management
9665771|NCT04909970|Other|control group (waiting list)|Usual practice of stress management. This group will practice self-hypnosis after the intervention group has practiced self-hypnosis (waiting list).
9665772|NCT04909112|Other|group 1: patients with Sjogren's syndrome|Patients with Sjogren's syndrome
9665773|NCT04909112|Other|group 2: patients without sicca syndrome|Patients without sicca syndrome
9665774|NCT04907058|Experimental|Treatment with CO2|Patients were treated with an effective lowest concentration of CO2 delivered by the novel CO2 supply system.
9665775|NCT04903262|Experimental|ECCO2R|"Patients will be treated with standardized ventilation: constant flow, assist/control; VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45. ECCO2R blood flow between 1000 and 1500 mL/min. Anticoagulation with unfractionated heparin to a target aPTT of 1.5 - 2.0x baseline. Target: maintain PaCO2 at baseline value ± 20% of baseline settings with a VT = 6 mL/kg provided that pH remains ≥ 7.30. Following 2-hour run-in time, VT will be reduced to 5 mL/kg. Sweep gas will be initiated and VT decreased to 4.5 then 4 mL/kg, and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cmH2O. Respiratory rate progressively decreased to a minimum of 12 bpm (eventual increases in sweep gas flow). If PaCO2 > 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT."
9665776|NCT04903262|No Intervention|Standard of care|"Patients will be treated with standardized ventilation: constant flow, assist/control; VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to low PEEP/ high FiO2 table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45."
9665777|NCT04900038|Experimental|Blinded GSK3640254 100 mg + unblinded DTG|Participants will receive blinded GSK3640254 100 mg + unblinded DTG through at least Week 24 (double blind phase). The participants will receive optimal dose of GSK3640254 after the optimal dose has been selected by study 208379. The participants will receive optimal dose of unblinded GSK3640254 and unblinded DTG once both conditions are met: GSK3640254 optimal dose has been selected AND the study has reached Week 24 primary endpoint.
9665778|NCT04900038|Experimental|Blinded GSK3640254 150 mg + unblinded DTG|Participants will receive blinded GSK3640254 150 mg + unblinded DTG through at least Week 24 (double blind phase). The participants will receive optimal dose of GSK3640254 after the optimal dose has been selected by study 208379. The participants will receive optimal dose of unblinded GSK3640254 and unblinded DTG once both conditions are met: GSK3640254 optimal dose has been selected AND the study has reached Week 24 primary endpoint.
9665779|NCT04900038|Experimental|Blinded GSK3640254 200 mg + unblinded DTG|Participants will receive blinded GSK3640254 200 mg + unblinded DTG through at least Week 24 (double blind phase). The participants will receive optimal dose of GSK3640254 after the optimal dose has been selected by study 208379. The participants will receive optimal dose of unblinded GSK3640254 and unblinded DTG once both conditions are met: GSK3640254 optimal dose has been selected AND the study has reached Week 24 primary endpoint.
9665780|NCT04900038|Active Comparator|Blinded 3TC 300 mg + unblinded DTG|Participants will receive blinded 3TC 300 mg capsules + unblinded DTG through at least Week 24 (double blind phase). The participants will receive unblinded 3TC 300 mg tablets + unblinded DTG once both conditions are met: GSK3640254 optimal dose has been selected by study 208379 AND the study has reached Week 24 primary endpoint.
9665781|NCT04898543|Experimental|Cohort 1: Subjects newly diagnosed|Cohort 1: Subjects newly diagnosed with high-risk solid tumors who have not received treatment.
9665782|NCT04898543|Experimental|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors|Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies.
9665783|NCT04898179||Telecare group|"When discharged, patients will be followed at home by a telecare nursing and specialist teleconsultation program for 3 months. The key element of the program will be a structured nurse-managed telephone support and, when necessary, video consultations, to follow patients, for the first month. During these contacts, the nurse will conduct a standardized interview enquiring about the general clinical condition of the patient. In the case of any symptom or problem, the patient will be able to call the service. At the end of the third month, patients will contact again to check their clinical condition and to close the program. Patients will be provided with a pulse oximeter to measure O2 saturation.~At the start and end of the program, patients were administered the SF-12 quality of life questionnaire."
9741668|NCT00242619|Experimental|Rosiglitzone|This group includes all 12 subjects who received rosiglitazone. Rosiglitazone was administered in addition to current antidepressant and/or mood-stabilizing medication at a dose of 4 mg/day for the first 4 weeks, with subsequent increase in dose to 9 mg/day for the remaining 8 weeks of the 12-week trial.
9741669|NCT00242632|Experimental|ApoE Non-Carriers|Subjects in this group did not carry the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
9741670|NCT00242632|Experimental|ApoE Carriers|Subjects in this group carried the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
9741671|NCT00242658|Experimental|Tailored Physical Activity Intervention Group|Four feedback reports aimed to increase physical activity.
9741672|NCT00242658|No Intervention|No Tailored Physical Activity Intervention Group|General reports on preventive screening based on responses to preventive screening questions.
9741673|NCT00242684||Group 1|older patients admitted to a TCU unit
9741674|NCT00242710|Experimental|1|BZA 20mg/CE 0.625
9741675|NCT00242710|Experimental|Arm 2|BZA 20mg/CE 0.45
9741676|NCT00242710|Active Comparator|Arm 3|CE 0.45mg/MPA1.5mg
9741677|NCT00242710|Placebo Comparator|Arm 4|Placebo
9741678|NCT00243022|Experimental|Arm I (intervention)|Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
9741679|NCT00243022|Active Comparator|Arm II (control)|Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
9741680|NCT00243061|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9741681|NCT00243074|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9741682|NCT00243152|Active Comparator|Lamotrigine to Placebo Crossover|The drug lamotrigine will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
9741683|NCT00243152|Active Comparator|Placebo to Lamotrigine Crossover|The placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, the drug lamotrigine (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
9741684|NCT00243191|Other|imatinib mesylate|
9665784|NCT04898179||Control group|The patients in the control group will be followed by their general practitioner and they will be contacted after three months to check their clinical condition.
9665785|NCT04896918||Cohort of adult client of public dental clinics in Region Stockholm|Tobacco use (cigarette smoking and/or snus use) will be considered as exposure. Information on tobacco use will be extracted by public dental clinic records in Stockholm Region (October 2015-January 2020). Any diagnosis of COVID-19, hospitalization, receiving intensive care, and death because of COVID-19 will be examined as outcomes. Diagnoses of COVID-19 will be obtained through record linkage with health care registers of inpatient and outpatient care (February 2020-August 2021).
9665786|NCT04896008|Placebo Comparator|Placebo plus background PAH therapy|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy
9665787|NCT04896008|Experimental|Sotatercept plus background PAH therapy|Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy
9665788|NCT04895280|Other|Group 1 (marcaine)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine
9665789|NCT04895280|Experimental|Group 2 (ketorolac)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
9665790|NCT04895280|Other|Group 3 (kenalog)|4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1. Group 3 is standard of care
9665791|NCT04894890||secukinumab|Patients administered secukinumab by prescription
9665792|NCT04894734|Experimental|EES on|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES on. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.
9665793|NCT04894734|Placebo Comparator|EES off|Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES off. Both the patient and the provider will be formally blinded to treatment assignment. Only the biostatistician and programming team will be unblinded to treatment assignments.ES off. Those in the EES off category will have their EES turned on at the 9-month timepoint.
9665794|NCT04893681|Experimental|Fluoridated bottle water|5-gallon bottles containing water from the New Bern Water Resources Division's Black Creek aquifer which contains naturally-occurring fluoride in a concentration of approximately 0.8 mg/L F
9665795|NCT04893681|Placebo Comparator|Non-fluoridated bottled water|5-gallon bottles containing water from the North Lenoir Water Corporation's Black Creek aquifer which contains a negligible concentration of fluoride.
9665796|NCT04892459|Experimental|heterologous boost arm with Ad5 vectored vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3~6 months.
9665797|NCT04892459|Active Comparator|homogeneous boost arm with inactive vaccine|Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3~6 months.
9665798|NCT04892459|Experimental|heterologous regimen with Ad5 vectored vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1~3 months.
9665799|NCT04892459|Active Comparator|homogeneous regimen arm with inactive vaccine|Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1~3 months.
9665800|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Daratumumab)|"Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) will receive magrolimab as per protocol and daratumumab 1800 mg subcutaneously (SC) or 16 milligrams per kilogram (mg/kg) intravenously (IV) on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days).~."
9665801|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days).
9665802|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days).
9665803|NCT04892446|Experimental|Safety Run-in Cohort (Magrolimab+Bortezomib+Dexamethasone)|"Bortezomib + Dexamethasone may be initiated based on the preliminary safety and efficacy of the Carfilzomib + Dexamethasone cohort.~Participants with relapsed/refractory multiple myeloma who have had 1 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and carfilzomib 1.3 mg/m^2 on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward (Maximum of 8 cycles in those who have previously received bortezomib) and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 to 9 and then Days 1, 8, and 15 from Cycle 10 and onward. (Cycle 1=35 days, All other Cycles=28 days)."
9665804|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Daratumumab)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and daratumumab 1800 mg SC or 16 mg/kg IV on Days 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and Days 1 and 15 (every 2 weeks) until Cycle 6 (total of 8 doses) followed by Day 1 (every 4 weeks) for subsequent cycles. (Cycle 1=35 days, All other Cycles=28 days).
9741685|NCT00243230|Experimental|Double-Blind - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized antiretroviral therapy (ART) regimen containing a ritonavir-boosted protease inhibitor (PI/r) for 48 weeks.
9741686|NCT00243230|Experimental|Double-Blind - Vicriviroc 20 mg|Vicriviroc 20 mg QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
9741687|NCT00243230|Placebo Comparator|Double-Blind - Placebo|Placebo QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks.
9741688|NCT00243230|Experimental|Open-label - Vicriviroc 30 mg|Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized ART regimen containing a ritonavir-boosted protease inhibitor (PI/r) for up to 45 months.
9741689|NCT00243243|Experimental|rFVIIa|intravenous administration of rFVIIa (Novoseven; 90 micrograms/kg, IV push, given at start of first surgical incision and again at 1 hr after start of surgery)
9741690|NCT00243243|Placebo Comparator|Control|intravenous administration of placebo (sterile water, IV push, given at first surgical incision and again at 1 hr after start of surgery)
9741691|NCT00243269|Sham Comparator|1|Expectancy neutral handout and expectancy neutral tape
9741692|NCT00243269|Experimental|2|Expectancy enhancing handout and expectancy neutral tape
9741693|NCT00243269|Experimental|3|Expectancy neutral handout and expectancy enhancing tape
9741694|NCT00243269|Experimental|4|Expectancy enhancing handout and expectancy enhancing tape
9741695|NCT00243386|Active Comparator|1|Standard prophylaxis
9741696|NCT00243386|Experimental|2|PK-driven prophylaxis
9741697|NCT00243412|Experimental|Arm A: 500 mg Rituximab|"Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18).~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
9741698|NCT00243412|Experimental|Arm B: 1000 mg Rituximab|"Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered.~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion.~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
9741699|NCT00243503|Experimental|A|
9741700|NCT00243659|Experimental|A|
9741701|NCT00243659|Experimental|B|
9741702|NCT00243841|Experimental|Radiation Treatment Arm :A|Patients with a score of Childs A Will receive 3 fractions of radiation over 5-10 days
9741703|NCT00243841|Experimental|Radiation Treatment Arm: B|Patients with a score of Childs B will receive 5 fractions of radiation over 2-6 weeks.
9741704|NCT00243919|Active Comparator|Early Locomotor Training Program|body weight supported training program with treadmill
9741705|NCT00243919|Active Comparator|Late Locomotor Training Program|body weight supported training program with treadmill
9741706|NCT00243919|Active Comparator|Early Home Exercise Program|a non-specific low intensity exercise program
9741707|NCT00243932|Experimental|2,700 mg CoQ10|
9741708|NCT00243932|Placebo Comparator|placebo|
9741709|NCT00243932|Experimental|1,800 mg CoQ10|
9741710|NCT00244101|Active Comparator|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
9741711|NCT00244101|Experimental|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
9741712|NCT00244101|Experimental|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
9741713|NCT00244140|Experimental|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
9741714|NCT00244140|Experimental|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
9741715|NCT00244374|Experimental|AIC, Hepatitis A & B vaccine|Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC), for administration of viral hepatitis immunizations at Month 1, 2, 6.
9741716|NCT00244374|Experimental|AIC, Outreach, Hepatitis A & B vaccine|AIC + outreach: Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC)) for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
9741717|NCT00244374|Experimental|SEP, Hepatitis A & B vaccine|SEP only: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6.
9741718|NCT00244374|Experimental|SEP, Outreach, Hepatitis A & B vaccine|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
9741719|NCT00244621|Experimental|1|0.05 mg/kg Atacand oral liquid dose
9741720|NCT00244621|Experimental|2|0.20 mg /kg Atacand oral liquid dose
9741721|NCT00244621|Experimental|3|0.40 mg /kg Atacand oral liquid dose
9741722|NCT00244712|Experimental|ABC/3TC|The intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo +lopinavir/ritonavir.
9741723|NCT00244712|Active Comparator|TDF/FTC|The intervention is a regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
9741724|NCT00244751|Experimental|GI262570 0.5 mg|Participants received GI262570 0.5 milligrams (mg) tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
9741725|NCT00244751|Experimental|GI262570 1.0 mg|Participants received GI262570 1.0 mg tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
9741726|NCT00244751|Placebo Comparator|Placebo|Participants received matching placebo tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
9741727|NCT00244764|Experimental|Pazopanib|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
9741728|NCT00244764|Placebo Comparator|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
9741729|NCT00244855|Other|No previous treatment|Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
9741730|NCT00244855|Other|Previous treatment|Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
9741731|NCT00244881|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9741732|NCT00244933|Experimental|Gemcitabine, genistein (Novasoy), Tumor biopsy|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
9741733|NCT00244985|Experimental|Arm 1: Rituximab and Doxorubicin HCI Liposome|Patients receive rituximab IV over 3-8 hours on day 1 and doxorubicin HCl liposome IV over 1-3 hours on day 3
9741734|NCT00245011|Experimental|Samarium-153|Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.
9781782|NCT01157117|Experimental|Omalizumab/milk OIT|Participants receive blinded omalizumab injections every 2 to 4 weeks through Month 16 and unblinded omalizumab injections thereafter until the Month 28 desensitization oral food challenge (OFC). Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk OFC and discontinue omalizumab injections. If they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
9781783|NCT01157117|Placebo Comparator|Placebo for omalizumab/milk OIT|Participants receive blinded placebo for omalizumab injections every 2 to 4 weeks through Month 16; after unblinding the injections are discontinued. Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk oral food challenge (OFC); if they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
9781784|NCT01157117|No Intervention|Untreated control|Participants did not receive any study intervention but provided regular blood draws at specific study time points to allow mechanistic comparisons with the participants in the other two groups who did receive study intervention.
9781785|NCT01157169|Experimental|Investigational Test Product|Buprenorphine 8 mg Sublingual Tablets
9781786|NCT01157169|Active Comparator|Reference Listed Drug|Subutex® 8 mg Sublingual Tablets
9781787|NCT01157182|Experimental|Investigational Test Product|Estradiol/Norethindrone acetate 1/0.5 mg Tablets
9781788|NCT01157182|Active Comparator|Reference Listed Drug|Activella® 1/0.5 mg Tablets
9781789|NCT01157234|Active Comparator|Nebivolol|Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
9781790|NCT01157234|Active Comparator|Metoprolol|Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
9781791|NCT01157351|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
9781792|NCT01157351|Active Comparator|002|aripiprazole flexible dosing as prescribed by the study doctor for 15 months
9781793|NCT01157351|Active Comparator|003|haloperidole flexible dosing as prescribed by the study doctor for 15 months
9781794|NCT01157351|Active Comparator|004|olanzapine flexible dosing as prescribed by the study doctor for 15 months
9781795|NCT01157351|Active Comparator|005|paliperidone flexible dosing as prescribed by the study doctor for 15 months
9781796|NCT01157351|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 15 months
9741735|NCT00245037|Experimental|Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)|Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
9741736|NCT00245050|Experimental|Pyridoxine|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.
9741737|NCT00245050|Placebo Comparator|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo twice 100 mg daily on days 1-28.
9741738|NCT00245063|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9741739|NCT00245102|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9741740|NCT00245219|No Intervention|Health Tracking (control)|Participants assigned to the health-tracking condition received usual care and did not attend any meetings.
9741741|NCT00245219|Experimental|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
9741742|NCT00245219|Experimental|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
9741743|NCT00245466|Experimental|Degarelix 80/80 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
9741744|NCT00245466|Experimental|Degarelix 40/40 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 40 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
9741745|NCT00245466|Experimental|Degarelix 80 + 20|In the main study (FE200486 CS02; NCT00819247) one loading dose of degarelix 80 mg was given on Days 0. Maintenance doses of 20 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
9741746|NCT00245518|Experimental|Isoflavone|Isoflavone
9741747|NCT00245518|Placebo Comparator|Placebo|
9741748|NCT00245557|No Intervention|Healthy Controls|Healthy Controls undergo MRI and neuropsychological testing
9741749|NCT00245557|Experimental|Depressed|Depressed subjects receive experimental drug
9741750|NCT00245583|Experimental|Topiramate|25mg to 300mg daily dose
9741751|NCT00245583|Placebo Comparator|Placebo|placebo equivalent tablets
9741752|NCT00245635|Experimental|Fluoxetine|Fixed/flexible dosing regimen of fluoxetine based on weight of subject and reaction to dosage, varying between 10mg and 80mg tablets once a day.
9741753|NCT00245635|Placebo Comparator|Placebo|Placebo tablets will be given 1/day for the duration of the study with a dosing schedule equivalent to that of the drug.
9741754|NCT00245765|Placebo Comparator|Placebo|Subcutaneous injections of Placebo every 2 weeks
9741755|NCT00245765|Experimental|Certolizumab Pegol 200 mg|Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter
9741756|NCT00245765|Experimental|Certolizumab Pegol 400 mg|Subcutaneous injections of 400 mg every 2 weeks
9741757|NCT00245856|Experimental|Treatment of Upper Extremity DVT|Participants received dalterparin followed by warfarin or received dalterparin monotherapy for the treatment of upper extremity DVT
9741758|NCT00246012|Experimental|Intetumumab 3 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
9741759|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs. If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
9741760|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs.
9781797|NCT01157351|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 15 months
9781798|NCT01157351|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 15 months
9781799|NCT01157364|Other|bimatoprost 20 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
9741761|NCT00246012|Experimental|Dacarbazine + intetumumab 5 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with stable disease (SD) or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 milligram per meter-square (mg/m^2) intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
9741762|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
9741763|NCT00246012|Experimental|Dacarbazine + placebo [Phase 2]|Placebo will be administered intravenously over a period of 2 hr (±15 minutes). Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue with 10 mg/kg intetumumab alone.
9741764|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
9741765|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
9741766|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
9741767|NCT00246025|Experimental|Dabigatran etexilate 110 mg|Dabigatran etexilate 110 mg capsule, once a day, oral administration
9741768|NCT00246025|Experimental|Dabigatran etexilate 150 mg|Dabigatran etexilate 150 mg capsule, once a day, oral administration
9741769|NCT00246025|Experimental|Dabigatran etexilate 220 mg|Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration
9741770|NCT00246025|Placebo Comparator|Placebo|matching placebo capsule, once a day, oral administration
9741771|NCT00246090|Experimental|1|
9741772|NCT00246129|Active Comparator|Campath-Tacrolimus|Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
9741773|NCT00246129|Experimental|Daclizumab-Tacrolimus-Mycophenolate|Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy
9741774|NCT00246259|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following initiation of Risperidone LAI, and for a maximum of 3 weeks following a dose increase.
9741775|NCT00246259|Active Comparator|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg. Participants will be switched to another oral therapy as per Investigator's discretion.
9741776|NCT00246324|Experimental|Single Arm|Interferon beta 1a, oral doxycycline
9741777|NCT00246337|Placebo Comparator|Placebo|Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
9741778|NCT00246337|Experimental|MK0974 25 mg|MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741779|NCT00246337|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741780|NCT00246337|Experimental|MK0974 100 mg|MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741781|NCT00246337|Experimental|MK0974 200 mg|MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741782|NCT00246337|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741783|NCT00246337|Experimental|MK0974 400 mg|MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741784|NCT00246337|Experimental|MK0974 600 mg|MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741785|NCT00246337|Active Comparator|Rizatriptan 10 mg|Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
9741786|NCT00246376|Placebo Comparator|1|Subjects receive lifestyle advice and placebos for Niaspan and Tricor
9741787|NCT00246376|Experimental|2|Diet, exercise, and two placebos
9741788|NCT00246376|Experimental|3|Diet, exercise, Niaspan, and placebo
9741789|NCT00246376|Experimental|4|Diet, exercise, placebo, and Tricor
9741790|NCT00246376|Experimental|5|Diet, exercise, Niaspan, and Tricor
9741791|NCT00246441|Experimental|Paroxetine|Active medication containing the drug Paroxetine
9741792|NCT00246441|Placebo Comparator|Placebo|A Placebo medication that appears just like the active medication but does not contain placebo
9741793|NCT00246519|Experimental|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
9741794|NCT00246519|Experimental|Hydrochlorothiazide (HCTZ)|HCTZ 12.5 mg then HCTZ 25 mg if BP < 120/70, then add atenolol 50 mg if BP < 120/70, then atenolol 100 mg if BP < 120/70.
9741795|NCT00246571|Experimental|A|
9741796|NCT00246571|Active Comparator|B|
9741797|NCT00246740|Placebo Comparator|Placebo oral tablet|Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
9741798|NCT00246740|Experimental|Periostat|Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
9741799|NCT00246753|Other|Single Arm Trial|Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.
9741800|NCT00246805|Experimental|1. VRS ON|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.~This arm (1) is randomized to Function Ventricular Rate Stabilization ON."
9741801|NCT00246805|No Intervention|2. VRS OFF|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.~This arm (2) is randomized to Function Ventricular Rate Stabilization OFF."
9741802|NCT00247273|Active Comparator|1|5 mg risedronate, once daily for 2 years
9741803|NCT00247273|Experimental|2|150 mg risedronate taken once a month for 2 years
9741804|NCT00247377|Active Comparator|Laparoscopic Gastric Bypass|Subject undergoes Laparoscopic Gastric Bypass
9741805|NCT00247377|Active Comparator|LAP-BAND|Subject undergoes LAP-BAND procedure
9741806|NCT00247416|Other|1 No Dex|No Dexamethasone
9741807|NCT00247416|Experimental|2 Dex|Dexamethasone
9741808|NCT00247611|Other|Control|Participants will receive the control condition
9741809|NCT00247611|Experimental|Intervention|Participants will receive the LifeWindows Intervention sessions
9741810|NCT00247624|Experimental|A|Participants will receive treatment with eszopiclone and fluoxetine
9741811|NCT00247624|Active Comparator|B|Participants will receive treatment with placebo and fluoxetine
9741812|NCT00247676|Experimental|A|
9741813|NCT00247728|No Intervention|Untreated Control|Untreated control arm
9741814|NCT00247728|Experimental|160 mg PI-88/Day|PI-88 160 mg/day SC injection
9741815|NCT00247728|Experimental|250 mg PI-88/Day|PI-88 250 mg/day SC injection
9741816|NCT00247962|Experimental|A|
9741817|NCT00247962|Active Comparator|B|
9741818|NCT00248040|Experimental|reparixin group - continuous infusion|"Continuous iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.772 mg/kg/h was administered for12 hours."
9741819|NCT00248040|Experimental|reparixin group - intermittent infusion|"Intermittent iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.244 mg/kg was administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were administered over a total period of 22.5 hours."
9741820|NCT00248040|Placebo Comparator|placebo infusion|Continuous/intermittent iv infusion of a volume/schedule matched saline into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
9741821|NCT00248170|Experimental|Letrozole|2.5 mg by mouth (p.o.) once daily
9741822|NCT00248170|Active Comparator|Anastrozole|1 mg p.o. once daily
9741823|NCT00248495|Experimental|Neoadjuvant chemotherapy|Patients receive pemetrexed disodium IV over 10 minutes followed by cisplatin IV over approximately 1 hour on day 1. Treatment repeats every 21 days for 3 courses
9741824|NCT00248534|Experimental|IV Rituximab|"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.~Induction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide [TMZ] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression"
9517301|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohort 4|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 dose will be either one of 3 doses 400mg, 800mg and 1200 mg based on interim analyses of safety data and tumour response at WEEK 6 of 3 dose cohorts of 12 total patients. The Safety Steering Committee will inform on dose for cohort expansion.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
9741825|NCT00248547|Active Comparator|Aprepitant|
9741826|NCT00248547|Placebo Comparator|sugar pill|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
9741827|NCT00248560|Experimental|Gemcitabine, docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
9741828|NCT00248612|Experimental|Venlafaxine & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
9741829|NCT00248612|Active Comparator|Placebo & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
9741830|NCT00248612|Active Comparator|Venlafaxine & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
9741831|NCT00248612|Placebo Comparator|Placebo & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
9741832|NCT00248625|Active Comparator|N-acetylcysteine (NAC)|Eligible children were adaptively allocated by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive days
9741833|NCT00248625|Placebo Comparator|placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive
9741834|NCT00248638|Active Comparator|Glutamine dipeptide|Glutamine dipeptide supplemented nutrition to be given to participants.
9741835|NCT00248638|Placebo Comparator|standard|Participants given standard nutrition without glutamine dipeptide
9741836|NCT00248651|Active Comparator|Amitriptyline|Amitriptyline capsule (50 mg) plus a placebo escitalopram tablet will be taken at night half an hour before bedtime. To maximize patient tolerability, in the first 2 weeks the dose of amitriptyline will be 25 mg and then the dose will be increased to 50 mg, but the 25 mg and 50 mg capsules will be indistinguishable to maintain blinding.
9741837|NCT00248651|Active Comparator|Escitalopram|Escitalopram tablet (10 mg) plus a placebo amitriptyline capsule will be taken by mouth at night half an hour before bedtime for 12 weeks.
9741838|NCT00248651|Placebo Comparator|Placebo|Placebo escitalopram tablets and placebo amitriptyline capsules will be taken by mouth half an hour before bedtime for 12 weeks.
9741839|NCT00248781|Experimental|Arm 1|exercise
9741840|NCT00248781|Other|Arm 2|health education
9741841|NCT00248794|Experimental|CRT + Skills Training|"The intervention is call Cognitive Remediation Therapy (CRT) with a skill development group. Participants receive 15 weeks of cognitive training (with intake, 15 and 30 week assessment). This intervention is reliant upon didactic exchanges between trainer and participant, minimizing error, and behavioral modeling with the goal of developing better meta-cognitive skills. Procedures include paper and pencil activities (memory, planning and cognitive flexibility training) which are organized by difficulty. Sessions are organized to have a discussion between the trainer and the participant about the task and strategies, trainer modeling with articulation of strategy a participant attempts the task, talking aloud the steps, and finally the participant practices the task covertly. The trainer has the role of error catcher and model. All subjects randomized to this condition also are receiving the weekly skills group (SDG)offered to participants in all experimental conditions."
9741842|NCT00248794|Experimental|ICBCR and Skills Training|This intervention is Individualized Computer Based Cognitive Remediation (ICBCR) and skills development group (SDG). Participants receive 15 weeks of computerized training (with intake, 15 and 30 week assessments). This intervention relies upon intense, frequent, repetition of tasks being made incrementally more challenging. Computer tasks are organized so that the initial trials are easily completed and more challenging levels are then attempted. Parameters such as duration of task, task speed, and intra-task variables all be are manipulated. A trainer will be present at each session to help set up the computer tasks and answer questions. Besides the first two sessions that will be orientation sessions, the trainer has little involvement during the training sessions. The role of the trainer is to help organize, support, and provide feedback to each participant. All subjects randomized to this condition also are receiving the weekly skills group (SDG).
9741843|NCT00248794|Experimental|Skills Group Control|The control intervention is call the skills development group (SDG) and is augmented with up to five individual contacts with research staff. The Skills Group (SDG) control is standard care group which will receive 15 weeks of the skills development group (SDG) similar to that offered as a clinical service at the VA Medical Center. During the 15 weeks participants will attend 1.5 hours of skills group per week. The 15 sessions will include skills training related to: a) cooking and food preparation, b) negotiating the local transportation system, c) shopping, and d) planning leisure activities. The training activities are a blend of didactic learning, modeling and finally in vivo practice. Participants in this group will also be offered up to five weekly contacts with staff to balance out factors related to meeting with staff in the other conditions.
9741844|NCT00248807|Placebo Comparator|ARM 1|Head-up tilt maneuver without drug in subjects with spinal cord injury
9741845|NCT00248807|Placebo Comparator|ARM 3|Head-up tilt maneuver without drug in able-bodied controls
9741846|NCT00248807|Active Comparator|ARM 2|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in subjects with spinal cord injury
9741847|NCT00248807|Active Comparator|ARM 4|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in able-bodied controls.
9741848|NCT00248833|Experimental|1) 25ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
9741849|NCT00248833|Experimental|2) 25ug Group B Meningococcal 44/76 MOS NOMV 5D with adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D with AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
9741850|NCT00248833|Experimental|3) 50ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 50ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
9741851|NCT00249002|Experimental|ABI-007|ABI-007 35 mg/m^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21
9741852|NCT00249288|Experimental|Folate|Participants will receive a 2 mg/ day dose of folate, for 12 weeks
9741853|NCT00249288|Placebo Comparator|Placebo|Participants will receive a 2 mg/ day dose of placebo, for 12 weeks
9741854|NCT00249379|Experimental|Acamprosate|Subjects randomized to receive acamprosate
9741855|NCT00249379|No Intervention|No medication|No medication intervention (subjects do not receive acamprosate), but do receive Building Social Networks counseling
9741856|NCT00249444|Active Comparator|Mirtazapine|Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
9741857|NCT00249444|Placebo Comparator|Placebo|placebo
9741858|NCT00249470|Experimental|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
9741859|NCT00249470|Other|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
9741860|NCT00249496|Active Comparator|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
9741861|NCT00249496|Experimental|Contingency Management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
9741862|NCT00249613|Experimental|Women-Only|Substance abuse treatment program for women only
9741863|NCT00249613|No Intervention|Mixed-Gender|Substance abuse treatment program for both women and men
9741864|NCT00249769|Experimental|LJEV then MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.
9741865|NCT00249769|Experimental|LJEV and MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.
9741866|NCT00249769|Experimental|MV then LJEV|Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.
9741867|NCT00249795|Experimental|Irbesartan|150 mg for 2 weeks, then up-titrated to 300 mg up to final follow-up visit
9741868|NCT00249795|Placebo Comparator|Placebo|Matching placebo up to final follow-up visit
9741869|NCT00249808|Experimental|Efalizumab|
9741870|NCT00249821|Experimental|Saizen® 0.057 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than [<] -2 SDS or greater than [>] -2 SDS)
9741871|NCT00249821|Experimental|Saizen® 0.035 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (< -2 SDS or > -2 SDS)
9741872|NCT00249834|Experimental|Gonal-f 112.5 IU|
10200982|NCT05045014||Control group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task.
9741873|NCT00249834|Experimental|Gonal-f 37.5 IU|
9741874|NCT00249834|Experimental|Gonal-f 75 IU|
9741875|NCT00249834|Experimental|Gonal-f 150 IU|
9741876|NCT00249834|Experimental|Gonal-f 187.5 IU|
9741877|NCT00249834|Experimental|Gonal-f 225 IU|
9741878|NCT00249834|Experimental|Gonal-f 262.5 IU|
9741879|NCT00249834|Experimental|Gonal-f 300 IU|
9741880|NCT00249873|Experimental|Clopidogrel + ASA|Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
9741881|NCT00249873|Placebo Comparator|Placebo + ASA|Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
9741882|NCT00250276|Experimental|Cervarix Lot1 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 1 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
9741883|NCT00250276|Experimental|Cervarix Lot2 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 2 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
9741884|NCT00250276|Experimental|Cervarix Lot3 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 3 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
9741885|NCT00250276|Experimental|Cervarix Low Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine manufactured lower scale-80L according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
9741886|NCT00250432|Active Comparator|1|50 mg intravenous (IV) infusion (diluted with 9% saline) administered daily (following a 70-mg IV loading dose on Day 1), over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
10200983|NCT05034497|Experimental|Dose Escalation for Cohorts 1-3|"Each participant will receive a single 5cc administration of 186RNL.~At each dose level, a minimum of three to a maximum of six participants will be enrolled.~If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.~The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below:~COHORT ACTIVITY Cohort 1 (6.6 mCi) Cohort 2 (13.2 mCi) Cohort 3 (26.4 mCi)"
10200984|NCT05026736|Experimental|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue to receive treatment at the discretion of the treating physician.
10200985|NCT05017831|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
10200986|NCT05017831|Experimental|FBT w/ Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of FBT over six months. The first 9 sessions of FBT will be preceded by adolescent-focused CRT.
10200987|NCT05016960|Experimental|Sleep-SMART|Sleep-SMART intervention
10200988|NCT05013827||Company representatives|
10200989|NCT05011812|Experimental|Part 1, Treatment A|Dose level 1 of PBI-0451
10200990|NCT05011812|Experimental|Part 1, Treatment B|Dose level 2 of PBI-0451
10200991|NCT05011812|Experimental|Part 1, Treatment C|Dose level 3 of PBI-0451
10200992|NCT05011812|Experimental|Part 1, Treatment D|Dose level 4 of PBI-0451
10200993|NCT05011812|Experimental|Part 2, Treatment E|PBI-0451 =/< Dose level 1
10200994|NCT05011812|Experimental|Part 2, Treatment F|PBI-0451 =/< Dose level 2
10200995|NCT05011812|Experimental|Part 2, Treatment G|PBI-0451 =/< Dose level 3
10200996|NCT05011812|Experimental|Part 2, Treatment H|PBI-0451 =/< Dose level 4
9741887|NCT00250432|Experimental|2|150 mg intravenous (IV) infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
9741888|NCT00250484|Active Comparator|Transcranial Magnetic Stimulation|Active treatment with TMS for 10 days.
9741889|NCT00250484|Sham Comparator|Sham Transcranial Magnetic Stimulation|Patients will receive no active TMS/treatment.
9741890|NCT00250497|Experimental|New Moves Intervention Group|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
9741891|NCT00250497|No Intervention|control group|Girls in the control group participated in an all-girls physical education class but did not receive additional components offered in the intervention such as individual coaching.
9741892|NCT00250588|Experimental|Problem solving + care coordination|Problem solving skills training and asthma care coordination
9741893|NCT00250588|Experimental|Asthma care coordination|Asthma care coordination
9741894|NCT00250588|Active Comparator|Wait-list control|Usual care
9741895|NCT00250679|Active Comparator|Formoterol 12 ųg 2x/day|
9741896|NCT00250679|Experimental|Arformoterol 15 ųg 2x/day|
9741897|NCT00250679|Experimental|Arformoterol 25 ųg 2x/day|
9741898|NCT00250705|Other|Adolescent Conduct Disorder Males|All subjects were male and had a diagnosis of conduct disorder. All subjects were offered treatment with aripiprazole.
9741899|NCT00250835|Experimental|Chemotherapy, Celecoxib, and Radiation|"Oxaliplatin weekly at 50 mg/m2 given intravenously over two hours for the duration of radiation.~Capecitabine: on the days of radiation at 850 mg/m2 orally twice a day [1700 mg/m2/day] (Monday through Friday during radiation therapy).~Celecoxib at 200 mg orally twice a day throughout the duration of radiation without a break."
9741900|NCT00250926|Experimental|Bortezomib, Dexamethasone, Rituximab|A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.
9741901|NCT00251004|Experimental|Low-dose Everolimus Group|"1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
9741902|NCT00251004|Experimental|High-dose Everolimus Group|"3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
9741903|NCT00251004|Active Comparator|Control Group|"1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
9741904|NCT00251225|Experimental|Hormone Refractory Prostate Cancer|Gleevec + Docetaxel: Daily Oral Gleevec in Combination with Every-Three-Week Intravenous Docetaxel
9741905|NCT00251238|Experimental|Ginkgo biloba extract EGb 761|Receiving daily Ginkgo biloba extract EGb 761
9741906|NCT00251238|Placebo Comparator|Placebo|Receiving daily placebo
9741907|NCT00251303|Experimental|riluzole|Active drug put into 10-mg capsule form,,prepared by Clinical Center Pharmacy. Dose up to 120 mg daily, divided. Brand name Rilutek.
9741908|NCT00251303|Placebo Comparator|placebo|Placebo Capsules designed to mimic active drug capsules
9741909|NCT00251316|Experimental|Lithium Carbonate|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive lithium capsules.
9741910|NCT00251316|Placebo Comparator|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
9741911|NCT00251589|Experimental|Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion
9741912|NCT00251589|Experimental|Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
9741913|NCT00251589|Experimental|Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
9741914|NCT00251589|Experimental|Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.
9741915|NCT00251641|Experimental|Infliximab|
9741916|NCT00251641|Active Comparator|Methotrexate|
9741917|NCT00251693|Experimental|Dexlansoprazole MR 60 mg QD|
9741918|NCT00251693|Experimental|Dexlansoprazole MR 90 mg QD|
9741919|NCT00251693|Active Comparator|Lansoprazole 30 mg QD|
9741920|NCT00251719|Experimental|Dexlansoprazole MR 60 mg QD|
9741921|NCT00251719|Experimental|Dexlansoprazole MR 90 mg QD|
9741922|NCT00251719|Active Comparator|Lansoprazole 30 mg QD|
9741923|NCT00251745|Experimental|Dexlansoprazole MR 60 mg QD|
9741924|NCT00251745|Experimental|Dexlansoprazole MR 90 mg QD|
9741925|NCT00251745|Placebo Comparator|Placebo|
9741926|NCT00251758|Experimental|Dexlansoprazole MR 60 mg QD|
9741927|NCT00251758|Experimental|Dexlansoprazole MR 90 mg QD|
9741928|NCT00251758|Placebo Comparator|Placebo|
9741929|NCT00251862|Experimental|Decision aid plus YourDiseaseRisk|Patients viewed the decision aid and completed the Your Disease Risk risk assessment tool prior to visit with their primary care provider.
9741930|NCT00251862|Experimental|Decision aid alone|Patient's viewed decision aid only prior to a visit with their primary care provider.
9741931|NCT00251862|Sham Comparator|III|Standard care
9741932|NCT00251927|Active Comparator|1|Surgery
9741933|NCT00251927|Experimental|2|Esomeprazole (NEXIUM) therapy
9741934|NCT00252057|Experimental|Re-engineered hospital discharge|"Participants received the Re-Engineered Hospital Discharge, a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist."
9741935|NCT00252057|No Intervention|Standard hospital discharge|Participants received the routine, standard hospital discharge.
9741936|NCT00252187|Active Comparator|B-type Natriuretic Peptide (BNP)|BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
9741937|NCT00252187|Placebo Comparator|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
9741938|NCT00252239|Active Comparator|1|tenecteplase
9741939|NCT00252239|Active Comparator|2|tissue plasminogen activator, tPA
9741940|NCT00252382|Experimental|Treatment with 48 mg/m2 of SNS-595|Patients are treated with 48 mg/m2 of the drug SNS-595 injection once every 21 days for up to 6 cycles as a second -line therapy to patients with advanced non-small cell lung cancer (NSCLC)
9741941|NCT00252499|Placebo Comparator|Placebo Arm|matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd
9741942|NCT00252499|Experimental|Rosiglitazone Arm|rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd
9741943|NCT00252499|Experimental|Fenofibrate Arm|micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid
9741944|NCT00252512|Experimental|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are negative, they receive a chance to draw tokens from a bowl. Some tokens are social reinforcement. Others have monetary value.
9741945|NCT00252512|Placebo Comparator|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
10200997|NCT05011812|Experimental|Part 3, Treatment J|PBI-0451 + ritonavir (a CYP450 3A inhibitor)
10200998|NCT05011812|Experimental|Part 3, Treatment K|PBI-0451 + ritonavir
10200999|NCT05011812|Experimental|Part 3, Treatment L|"PBI-0451 dose TBD~+ midazolam (a sensitive CYP450 3A substrate)"
10201000|NCT05011812|Experimental|Part 1, Treatment M|Dose level 2 of PBI-0451 with food
10201001|NCT05011812|Experimental|Part 2, Treatment I|PBI-0451 =/< Dose level 5
10201002|NCT05011812|Experimental|Part 1, Treatment N|Dose Level 5 of PBI-0451
10201003|NCT05011526|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
10201004|NCT05011526|Experimental|AZD1222|ChAdOx1 nCoV-19 vaccine
10201005|NCT05009160||Patients with Multiple Sclerosis (PwMS)|PwMS will download the dreaMS App and will follow the study schedule.
10201006|NCT05009160||Healthy Control Persons (HC)|HC will download the dreaMS App and will follow the same study schedule as PwMS.
9741946|NCT00252538||Group 1|Research participants are: 1) male or female, 2) age 18 or older, 3) chronically infected with the hepatitis C virus, 4) candidates for interferon therapy, 4) not on antidepressant treatment , and 5) not currently abusing any substances such as alcohol or intravenous drugs, or having abused in the past 6 months
9741947|NCT00252564|Experimental|Bev-FOLFOX|"(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via T connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.~Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU~Dosing on Days 1 and 15 of each 28-day cycle"
10201007|NCT05007873|Experimental|Treatment (dasatinib, decitabine and cedazuridine)|"Patients receive dasatinib PO QD on days 1-28. Beginning cycle 4, patients also receive decitabine and cedazuridine PO QD on days 1-3. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days for up to 12 years in the absence of disease progression or unacceptable toxicity."
10201008|NCT04995042|Experimental|SHR7280 Does Escalation and Expansion|
9741948|NCT00252564|Experimental|FOLF-CB|"(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.~Cetuximab --> bevacizumab --> LV --> bolus 5-FU --> infusional 5-FU"
9741949|NCT00252577||Group 1|Veterans with bipolar disorder
9741950|NCT00252590|Experimental|Health Motivational Feedback|Personalized health-related feedback
9741951|NCT00252590|Active Comparator|Health Education|Non-personalized didactic health-related education
9741952|NCT00252590|Active Comparator|Control - treatment as usual|No added treatment control
9741953|NCT00252629|Active Comparator|Therapeutic nasal CPAP|Comparing change of veterans reported outcomes before and after 3 weeks treatment of therapeutic nasal CPAP with the change on sham nasal CPAP.
9741954|NCT00252629|Sham Comparator|Sham nasal CPAP|Comparing change of symptoms and veterans reported outcomes before and after treatment of 3 weeks on sham nasal CPAP with the change on therapeutic nasal CPAP
9741955|NCT00252694|Experimental|candesartan|candesartan cilexetil 32 mg once daily
9741956|NCT00252694|No Intervention|placebo|control
9741957|NCT00252720|Experimental|candesartan|candesartan cilexetil 32 mg once daily
9741958|NCT00252720|No Intervention|placebo|control
9741959|NCT00252733|No Intervention|1|Placebo
9741960|NCT00252733|Experimental|2|candesartan cilexetil
9741961|NCT00252967|Placebo Comparator|Placebo|Placebo taken daily
9741962|NCT00252967|Experimental|Atorvastatin|Atorvastatin at a dose of 80 mg daily
9781800|NCT01157364|Other|bimatoprost 15 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
9781801|NCT01157364|Other|bimatoprost 10 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
9781802|NCT01157364|Other|bimatoprost 6 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
9781803|NCT01157364|Other|bimatoprost 15 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
9781804|NCT01157364|Other|bimatoprost 10 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
9781805|NCT01157377|Experimental|AGN-214868 total dose 500 ng|AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
9781806|NCT01157377|Experimental|AGN-214868 total dose 1000 ng|AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
9781807|NCT01157377|Experimental|AGN-214868 total dose 2000 ng|AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
9781808|NCT01157377|Experimental|AGN-214868 total dose 6000 ng|AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
9781809|NCT01157377|Experimental|AGN-214868 total dose 18000 ng|AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
9781810|NCT01157377|Experimental|AGN-214868 total dose 60000 ng|AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
9781811|NCT01157377|Placebo Comparator|Placebo to AGN-214868|Placebo to AGN-214868 injected into the bladder on Day 1.
9781812|NCT01157416|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
9781813|NCT01157416|Placebo Comparator|Placebo plus CBT|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
9781814|NCT01157429|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
9781815|NCT01157429|Placebo Comparator|Placebo pill|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
9781816|NCT01157676|Active Comparator|Open cystectomy|Open cystectomy performed using an incision made just above or at the level of umbilicus to the pubic symphysis.
9781817|NCT01157676|Active Comparator|Robotic assisted radical cystectomy|Robotic assisted Radical Cystectomy (RARC) is accomplished by a robot assisted laparoscopic approach.
9785333|NCT01249131|Experimental|Treatment C first, then Treatment B, followed by Treatment A|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
9785334|NCT01249261|Placebo Comparator|Placebo/Risedronate|Placebo years 1-5, Risedronate 5mg/day years 6 & 7, no drug year 8
9741963|NCT00253370|Experimental|BAY 43-9006, docetaxel, cisplatin|Patients receive oral BAY 43-9006 400mg twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9741964|NCT00253435|Experimental|All the patients enrolled in the study|"This is a single arm study. The following description applies to all the patients who are enrolled in the study:~On Day -21, patients receive 131I-MIBG infusion.~On Day -7, Day -6, Day -5, patients receive Carboplatin, Etoposide, Melphalan.~On Day -4, patients receive Carboplatin, Etoposide.~On Day -3, Day -2, Day -1, patients rest.~On Day 0, patients receive peripheral blood stem cell infusion.~Dosing of Carboplatin, Etoposide and Melphalan is based upon whole body dosimetry (cGy) estimates.~Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0.~Local radiation therapy is to be given to previously non-irradiated primary and metastatic sites of disease."
9741965|NCT00253630|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9741966|NCT00253643|Experimental|Arm I (FO, GT catechin extract)|Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day
9741967|NCT00253643|Experimental|ArmII (FO placebo, GT catechin extract)|Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day
9741968|NCT00253643|Experimental|Arm III (FO, GT placebo)|Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day
9741969|NCT00253643|Placebo Comparator|Arm IV (FO placebo, GT placebo)|Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day
9741970|NCT00253708|Experimental|massage|"Patients received 3 massage therapy visits from massage therapists in initial week with a duration of 15-45 minutes.NOTE: Intervention 'management of therapy complications' has not been included in any Arm/Group Descriptions.~Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment"
9741971|NCT00253708|Active Comparator|no-touch control|Patients received 3 no-touch therapy visits from massage therapists who provided no-touch without healing intention.Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
9741972|NCT00253708|No Intervention|Usual care|Patients did not receive visits from massage therapists. Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
9741973|NCT00253747|Active Comparator|Osmotic-Release Methylphenidate|
9741974|NCT00253747|Placebo Comparator|Placebo|
9741975|NCT00253890|Active Comparator|Trazodone|50-150mg (50mg capsules) at bedtime for 90 days
9741976|NCT00253890|Placebo Comparator|Placebo|1-3 capsules at bedtime for 90 days
9741977|NCT00254072|Active Comparator|Smaller Stapler|3.5 mm Circular Stapler
9741978|NCT00254072|Active Comparator|Larger Stapler|4.8 mm Circular Stapler
9741979|NCT00254163|Active Comparator|Fludarabine, Cyclophosphamide, and Rituximab|Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle)
9741980|NCT00254163|Experimental|Pentostatin, Cyclophosphamide, and Rituximab|Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)
9741981|NCT00254293|Placebo Comparator|Group 1 (weight < 60 kg)|
9741982|NCT00254293|Placebo Comparator|Group 2 (weight < 60 kg)|
9741983|NCT00254293|Placebo Comparator|Group 3 (weight 60-100 kg)|
9741984|NCT00254293|Placebo Comparator|Group 4 (weight > 100 kg)|
9741985|NCT00254293|Placebo Comparator|Group 5 (weight > 100 kg)|
9741986|NCT00254293|Experimental|Abatacept|Long Term
9741987|NCT00254397|Experimental|gp100 + Leuprolide|Group IA: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
9741988|NCT00254397|Experimental|gp100 - No Leuprolide|Group IB: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
9741989|NCT00254397|Experimental|gp100 + MAGE-3 + Leuprolide|Group IIA: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
9741990|NCT00254397|Experimental|gp100 + MAGE-3 - No Leuprolide|Group IIB: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
9741991|NCT00254410|Experimental|FCM-R + Pegylated Filgrastim|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6. Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6. Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6. Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6. Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
9741992|NCT00254462|Experimental|atomoxetine and parent training|atomoxetine capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
9741993|NCT00254462|Placebo Comparator|placebo and parent training|matching placebo capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
9741994|NCT00254488|Experimental|Lithium (LI)|Participants will receive 9 weeks of treatment with lithium
9741995|NCT00254488|Experimental|Divalproex (DV)|Participants will receive 9 weeks of treatment with divalproex
9741996|NCT00254501|Active Comparator|Usual Care plus out-of-pocket cost waiver|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
9741997|NCT00254501|Experimental|EMPOWER|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
9741998|NCT00254540|Experimental|SU-011248 capsule|
9741999|NCT00254566|Experimental|1|
9742000|NCT00254566|Active Comparator|2|
9742001|NCT00254592|Experimental|AC with GM-CSF and Carboplatin/Nab-Paclitaxel|"Doxorubicin and cyclophosphamide (AC) administered intravenously every 14 days up to a total of 4 cycles, with GM-CSF on days 4-13, depending on tumor response.~Two weeks after the completion of AC, weekly doses of carboplatin/nab-paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. Subjects who receive 4 cycles of AC will receive 9 doses of nab-paclitaxel and subjects who receive 2 cycles of AC will receive 12 weeks of nab-paclitaxel. In addition, subjects will receive trastuzumab weekly (12-16) doses if they are Her-2 positive and bevacizumab (6-8) doses every 2 weeks if they are Her-2 negative. Each clinic visit will last approximately ½ hour."
9742002|NCT00254982|Experimental|Group 1 (high-need)|Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
9742003|NCT00254982|Experimental|Group II (low-need)|Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
9742004|NCT00254995||Menactra Vaccine Recipients|Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
9742005|NCT00254995||Age-Matched Control|Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente
9742006|NCT00255008|Active Comparator|Genotype 1 SEA PEG-IFN/RIB 48 w|Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy
9742007|NCT00255008|Active Comparator|Genotype 1 Caucasian PEG-IFN/RIB 48 w|Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
9742008|NCT00255008|Experimental|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
9742009|NCT00255008|Active Comparator|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
9742010|NCT00255034|Active Comparator|24 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks
9742011|NCT00255034|Experimental|48 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks
9742012|NCT00255047|Experimental|Study Group 1: DAPTACEL®, ActHIB®, and IPOL®|Participants will receive 3 doses of DAPTACEL®, ActHIB®, and IPOL® at Months 2, 4, and 6, respectively
9742013|NCT00255047|Experimental|Study Group 2: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
9742014|NCT00255047|Experimental|Study Group 3: DTaP-IPV and ActHIB®|Participants will receive 3 doses of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively
9742015|NCT00255047|Experimental|Study Group 4: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
9742016|NCT00255086|Experimental|Memantine|10mg Memantine
9742017|NCT00255086|Placebo Comparator|Control|10 mg Placebo pill
9742018|NCT00255125|Placebo Comparator|Arm Placebo|Placebo
9742019|NCT00255125|Experimental|Arm Soy Supplement|Soy Supplement
9742020|NCT00255151|Experimental|Dexlansoprazole MR 60 mg QD|
9742021|NCT00255151|Experimental|Dexlansoprazole MR 90 mg QD|
9742022|NCT00255151|Placebo Comparator|Placebo|
9742023|NCT00255164|Experimental|Dexlansoprazole MR 60 mg QD|
9742024|NCT00255164|Experimental|Dexlansoprazole MR 90 mg QD|
9742025|NCT00255164|Placebo Comparator|Placebo|
9742026|NCT00255177|Placebo Comparator|Placebo|
9742027|NCT00255177|Active Comparator|150 mg daily|
9742028|NCT00255177|Active Comparator|300mg daily|
9742029|NCT00255177|Active Comparator|300mg twice daily|
9742030|NCT00255190|Experimental|Dexlansoprazole MR 60 mg QD|
9742031|NCT00255190|Experimental|Dexlansoprazole MR 90 mg QD|
9742032|NCT00255346|Experimental|Acute myeloid leukemia (AML)|Dasatinib 70 mg orally twice daily.
9742033|NCT00255346|Experimental|MDS/CMML|Dasatinib 70 mg orally twice daily.
9742034|NCT00255346|Experimental|HES/CEL|Dasatinib 70 mg orally twice daily.
9742035|NCT00255346|Experimental|Primary myelofibrosis (PMF)|Dasatinib 70 mg orally twice daily.
9742036|NCT00255346|Experimental|Systemic Mastocytosis (SM)|Dasatinib 70 mg orally twice daily.
9742037|NCT00255684|Experimental|Conditioning therapy followed by TBI|Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
9742038|NCT00255723|Experimental|Cytoreductive chemotherapy group 1|Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
9742039|NCT00255723|Experimental|Cytoreductive chemotherapy group 2|Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.
9742040|NCT00255801|Experimental|Doxil and Targretin® (bexarotene)|Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
9742041|NCT00255840|Active Comparator|A|Study-specified Antiretroviral regimen under care of HIV-trained medical doctor
9781818|NCT01157845|Experimental|Laboratory assay|
9742042|NCT00255840|Active Comparator|B|Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse
9742043|NCT00255944|Experimental|Youthnet messages on Facebook|Participants will receive internet-based messages from the Youthnet program
9742044|NCT00255944|Active Comparator|Messages on Facebook about current events|Participants will receive internet-based messages from the control program
9742045|NCT00255970|Experimental|Regenafil graft|Regenafil
9742046|NCT00255970|Active Comparator|DFDBA|Demineralized Freeze Dried Bone Allograft
9742047|NCT00256126|Experimental|Turner Syndrome (TS)|
9742048|NCT00256126|Experimental|Growth Hormone Deficiency (GHD)|
9742049|NCT00256204|Experimental|1mg rasagiline|1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
9742050|NCT00256204|Experimental|2mg rasagiline|2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
9742051|NCT00256204|Placebo Comparator|Placebo|Each arm is followed by 36 weeks of placebo
9742052|NCT00256217|Experimental|Anastrozole|
9742053|NCT00256243|Experimental|Chemotherapy with GM-CSF|"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6)~This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.~Patients who are her-2 overexpressors by FISH will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination has been found to be synergistic in advanced breast cancer with improved clinical outcome."
9742054|NCT00256282|Experimental|Docetaxel & Vinorelbine + Sargramostim|Docetaxel, Vinorelbine, and Sargramostim
9742055|NCT00256308|Experimental|Oxaliplatin|Oxaliplatin-70mg/m2 IV over 120 min once a week during radiation. Radiation-200 centigray (cGy) per day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday.
9742056|NCT00256451|Experimental|ALC and NAL|alcohol and active naltrexone
9742057|NCT00256451|Active Comparator|Sham ALC and NAL|"sham alcohol and active naltrexone"
9742058|NCT00256451|Placebo Comparator|placebo pill and ALC|placebo naltrexone and alcohol
9742059|NCT00256451|Placebo Comparator|placebo pill and Sham ALC|placebo naltrexone and placebo (non-alcoholic) alcohol
9742060|NCT00256698|Active Comparator|1|Anastrozole
9742061|NCT00256698|Experimental|2|Anastrozole + Fulvestrant
9742062|NCT00256724|Sham Comparator|Sham ITD|sham Impedance Threshold Device
9742063|NCT00256724|Active Comparator|active ITD|active impedance threshold device
9742064|NCT00256750|Active Comparator|Cyclosporine (CsA)|
9742065|NCT00256750|Experimental|Belatacept LI (less intensive)|
9742066|NCT00256750|Experimental|Belatacept MI (more intensive)|
9742067|NCT00256776|Experimental|Thal + Dex + Velcade|
9742068|NCT00256776|Active Comparator|Thal + Dex|Standard treatment
9742069|NCT00256854|Experimental|Ropinirole cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 2 mg controlled release for Restless Legs Syndrome (CR-RLS) in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 1 mg IR at bedtime and continued to receive the same till the end of Week 4.
9742070|NCT00256854|Experimental|Ropinirole cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 2 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
9742071|NCT00256854|Experimental|Ropinirole cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 2 mg IR at bedtime and continued to receive the same till the end of Week 4.
9742072|NCT00256854|Experimental|Ropinirole cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
9742073|NCT00256854|Experimental|Ropinirole cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 4 mg IR at bedtime and continued to receive the same till the end of Week 4.
9742074|NCT00256854|Experimental|Ropinirole cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
9742075|NCT00256997|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
9742076|NCT00256997|Active Comparator|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
9742077|NCT00257010|Experimental|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
9742078|NCT00257166|Experimental|Ziprasidone oral capsules|
9742079|NCT00257166|Placebo Comparator|Placebo|
9742080|NCT00257192|Placebo Comparator|2.0|
9742081|NCT00257192|Active Comparator|1.0|
9742082|NCT00257309|Active Comparator|Thrombolysis|Weight adjusted tenecteplase bolus + Unfrationated heparin
9742083|NCT00257309|Active Comparator|Primary angioplasty|Primary angioplasty
9742084|NCT00257322|Experimental|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250ug/m^2 SQ QD with a cap of 500mcg SQ QD
9742085|NCT00257556|Experimental|Menotrophin|
9742086|NCT00257556|Active Comparator|Follitropin alfa|
9742087|NCT00257608|Experimental|1|
9742088|NCT00257608|Placebo Comparator|2|
9742089|NCT00257660|Experimental|1|Drug: abobotulinumtoxinA (Dysport®)
9742090|NCT00257660|Placebo Comparator|2|Placebo
9742091|NCT00257686|Experimental|Pitavastatin 1 mg|Pitavastatin 1 mg once daily
9742092|NCT00257686|Active Comparator|Pravastatin 10 mg|Pravastatin 10 mg once daily
9742093|NCT00257686|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
9742094|NCT00257686|Active Comparator|Pravastatin 20 mg|Pravastatin 20 mg once daily
9742095|NCT00257686|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
9742096|NCT00257686|Active Comparator|Pravastatin 40 mg|Pravastatin 40 mg once daily
9742097|NCT00257725|Experimental|ADHD Treatment Group|Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.
9742098|NCT00257894|Experimental|Baclofen condition|Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
9742099|NCT00257894|Placebo Comparator|Placebo condition|Placebo capsules identical to active medication, 3/day for 12 days.
9742100|NCT00257920|Active Comparator|A|
9742101|NCT00257920|Active Comparator|B|
9742102|NCT00257933|Active Comparator|1|High dose prednisolone
9742103|NCT00257933|Experimental|2|Lower dose prednisolone alternating with placebo
9742104|NCT00258011|Experimental|Aldurazyme (laronidase) treatment|Patients received weekly infusions of JC0498 (laronidase) at an intravenous dose of 100 Units/kg (0.58 mg/kg) body weight for up to 73 weeks.
9742105|NCT00258128|Experimental|Treatment|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the salsalate 4.0 g/d arm.
9742106|NCT00258128|Placebo Comparator|Placebo|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the placebo arm.
9742107|NCT00258154|Experimental|1|RotaTeq/Infanrix Hexa
9742108|NCT00258154|Placebo Comparator|2|Placebo/Infanrix Hexa
9742109|NCT00258180|Experimental|severe autoimmune enteropathy|Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
9742110|NCT00258206|Experimental|rituximab + cyclophosphamide|Rituximab 375 mg/m^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m^2 once each during months 3, 6, 9, and 12
9742111|NCT00258310|Experimental|Capecitabine|Surgery, chemotherapy and/or radiotherapy, prior to administration of Capecitabine 1000mg/day for one year.
9742112|NCT00258349|Experimental|Arm I|Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive a 90-minute infusion of trastuzumab in week 1.
9742113|NCT00258362|Experimental|Patients with Endometrial Cancer|Patients with advanced or current endometrial cancer receiving treatment with induction docetaxel/carboplatin, radiation (Weekly, 5 days/week over 6-7 weeks, tailored 4500 cGy) and followed by 3 courses of consolidation docetaxel (75 mg/m^2 on Day 1 of each course) /carboplatin (Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles).
9742114|NCT00258440|Active Comparator|Weekly Procrit (epoetin alfa) dosing|Weekly dosing schedule subjects will get the study drug once every week until the end of the study.
9742115|NCT00258440|Experimental|Interval Dosing (epoetin alfa) PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who consented to pharmacokinetic testing
9742116|NCT00258440|Experimental|Interval Dosing (epoetin alfa) Non PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who did not consent to pharmacokinetic testing.
9742117|NCT00258674|Active Comparator|Medicare Claims Feedback|Practices randomised to the Medicare Claims Feedback arm received period feedback on their performance on selected diabetes quality of care measures as reflected in the claims data for their diabetes patients.
9742118|NCT00258674|Experimental|Medicare Claims+Medical Record Feedback|Practices randomised to the Medicare Claims + Medical Record Review Feedback arm received periodic feedback on their performance on selected diabetes quality of care measures as reflected in both the Medicare claims for the diabetes patients AND review/audit of their diabetes patients' medical records.
9742119|NCT00258674|Experimental|Medicare Claims+Medical Chart Review+DRN|In addition to the performance data from both Medicare Claims data and from review of patients' medical records, practices randomised to the Medicare Claims + Medical Record review + Diabetes Resource Nurse (DRN) had a diabetes resource nurse assigned to them, who was available to provide diabetes education and care-coordination type services for their diabetes patients.
9742120|NCT00258817|Experimental|Influenza Virus Vaccine Naïve|Subjects have never received Influenza virus vaccine in the past
9742121|NCT00258817|Experimental|Influenza Virus Vaccine-primed|Subjects have received Influenza virus vaccine in the past
9742122|NCT00258830|Experimental|Age 18 to 59 years|Participants aged 18 to 59 years at enrollment.
9742123|NCT00258830|Experimental|Age 60 years and older|Participants aged 60 years and older at enrollment.
9742124|NCT00258856|Experimental|Menactra® Group 1|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination.
9742125|NCT00258856|Experimental|Menactra® Group 2|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination.
9742126|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 3|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination.
9742127|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 4|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination.
9742128|NCT00258895|Experimental|DAPTACEL Primed|Participants received Daptacel in Study P3T06.
9742129|NCT00258895|Experimental|Pentacel Primed|Participants received Pentacel in Study P3T06
9742130|NCT00258960|Other|Caelyx,Cyclophosphamide,Trastuzumab|Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)
9742131|NCT00259012|Active Comparator|Low dose|
9742132|NCT00259012|Active Comparator|High dose|
9742133|NCT00259090|Active Comparator|1|Anastrozole Monotherapy
9742134|NCT00259090|Experimental|2|Fulvestrant Monotherapy
9742135|NCT00259090|Experimental|3|Anastrozole + Fulvestrant
9742136|NCT00259272|Experimental|A|
9742137|NCT00259285|Experimental|A|
9742138|NCT00259298|Experimental|Teriparatide|Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy
9742139|NCT00259610|Active Comparator|1|methotrexate (MTX) + etanercept
9742140|NCT00259610|Active Comparator|2|methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
9742141|NCT00259610|Active Comparator|3|methotrexate (MTX) or MTX + Etanercept
9742142|NCT00259610|Active Comparator|4|methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
9742143|NCT00259740|Experimental|Denosumab|
9742144|NCT00259857|Experimental|1 Alendronate, Calcium, Vitamin D|Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.
9781819|NCT01157897|Experimental|Cohort 1: 15 μg VMP001|15ug VMP001 per vaccination on days -1 or 0, 28, and 84. P. vivax sporozoite challenge on day 98.
9781820|NCT01157897|Experimental|Cohort 2: 30 μg VMP001|30ug VMP001 per vaccination on days 14, 42, and 84. P. vivax sporozoite challenge on day 98.
9742145|NCT00259857|Placebo Comparator|2 Placebo, Calcium and Vitamin D|Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).
9742146|NCT00260065|Experimental|1|
9742147|NCT00260195|Experimental|School-based cognitive behavioral support group|Ten group lessons facilitated by a teacher or school counselor that focuses on psycho-education, development of a trauma narrative, approaching trauma-related situations, social problem solving, and cognitive skills.
9742148|NCT00260195|No Intervention|Wait-list control group|Waiting list
9781821|NCT01157897|Experimental|Cohort 3: 60 μg VMP001|60ug VMP001 per vaccination on days 28, 56, and 84. P. vivax sporozoite challenge on day 98.
9781822|NCT01157897|Other|Control|No Vaccinations given for controls. P. vivax sporozoite challenge on day 98.
9781823|NCT01158118|Experimental|Arm 1 - Donor|"Days 1-5: Mobilization with 5 mcg/kg/day GM-CSF (first 4 donors were mobilized with 10 mcg/kg GM-CSF then changed to 5 mcg/kg for remaining donors)~Day 5: Mobilization with 320 mcg/kg plerixafor IV~Day 5: Leukopheresis~If PBSC collected are not adequate, then donor will be mobilized with GM-CSF and plerixafor IV on day 6 and have leukopheresis collection on day 6."
9742149|NCT00260208|Active Comparator|Cyclosporin A|"The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges.~Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by the center was to be given to all patients enrolled in the trial from this center."
9742150|NCT00260208|Active Comparator|Tacrolimus|"Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges.~Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by center was to be given to all patients enrolled in trial from this center."
9742151|NCT00260429|Experimental|AA4500 0.58 mg|
9742152|NCT00260429|Placebo Comparator|placebo|
9742153|NCT00260533|Experimental|1|Atomoxetine
9742154|NCT00260533|Placebo Comparator|2|Placebo
9742155|NCT00260689|Experimental|Horse ATG/CsA taper|h-ATG (Anti-thymocyte globulin (horse)) + 6 months CsA (Cyclosporine) followed by an 18 month CsA taper
9742156|NCT00260689|Experimental|Rabbit ATG/CsA|r-ATG (Anti-thymocyte globulin (rabbit)) + 6 months CsA (Cyclosporine)
9742157|NCT00260689|Experimental|Alemtuzumab|Alemtuzumab administered for 10 days
9742158|NCT00260832|Experimental|A|Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
9742159|NCT00260832|Active Comparator|B|
9781824|NCT01158118|No Intervention|Arm 2 - Recipient|"Conditioning Regimens~fludarabine and busulfan +/- thymoglobulin~fractionated total body irradiation and cyclophosphamide~busulfan and cyclophosphamide~single dose total body irradiation and cyclophosphamide~Day -2 = GvHD prophylaxis~Day 0 or +1 = PBSC transplant~Day +7 until neutrophil engraftment = G-CSF 5 ug/kg/day"
9781825|NCT01158157|Other|Vaccination|This study was a single arm study. All eligible subjects received ACAM2000.
9781826|NCT01158222|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
9781827|NCT01158261||Vascular Surgery Subjects Treated with EVICEL|
9781828|NCT01158378|Active Comparator|DuraSeal Dural Sealant System|
9781829|NCT01158378|Experimental|Adherus Dural Sealant System|
9781830|NCT01158404|Experimental|LY900009|"Dose escalation phase: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Dose confirmation phase: 30 mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
9781831|NCT01158521|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
9781832|NCT01158534|Experimental|Arm I|Patients receive oral celecoxib twice daily and recombinant interferon alpha-2b subcutaneously, once daily, 5 times a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9781833|NCT01158573||Healthy non-asthmatic obese adults|Healthy non-asthmatic obese adults
9781834|NCT01158573||Healthy non-asthmatic non-obese adults|Healthy non-asthmatic non-obese adults
9781835|NCT01158573||Asthmatic obese adults|Asthmatic obese adults
9781836|NCT01158573||Asthmatic non-obese adults|Asthmatic non-obese adults
9781837|NCT01158651|Experimental|RAD001 (Everolimus) Active Therapy|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
9781838|NCT01158703|Active Comparator|clopidogrel|aspirin and clopidogrel
9781839|NCT01158703|Placebo Comparator|sugar pill|aspirin and placebo
9781840|NCT01158716|Active Comparator|Remote Ischemic Preconditioning|
9781841|NCT01158716|No Intervention|Control|
9781842|NCT01158820|Placebo Comparator|Placebo|midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
9781843|NCT01158820|Active Comparator|dexmedetomidine and ketamine|dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand
9781844|NCT01158885|Experimental|Single Arm|"A maximum of two courses of the following regimen will be administered.~Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.~Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.~Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.~Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients."
9742160|NCT00260962|Placebo Comparator|Placebo|Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
9742161|NCT00260962|Experimental|Olanzapine Plus Day Hospital|After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
9742162|NCT00261040|Active Comparator|Minimally Invasive Surgery (MIS)|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
9742163|NCT00261040|Sham Comparator|Standard Surgery|The standard way an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision
9742164|NCT00261443|Placebo Comparator|A1|/Active Comparator
9742165|NCT00261443|Experimental|A2|
9742166|NCT00261495|Active Comparator|Oxycodone|
9742167|NCT00261495|Experimental|OROS hydromorphone HCl|
9742168|NCT00261716|Experimental|IPS and VOMI|Individual Placement and Support (IPS), a form of evidence-based supported employment with 4 sessions of manualized vocationally-oriented motivational interviewing (VOMI) prior to each course of job searching
9742169|NCT00261716|Active Comparator|IPS and IE|Individual placement and support (IPS), a form of evidence-based supported employment with 4 sessions of education about schizophrenia/schizoaffective disorder (IE), as appropriate, prior to each course of job searching
9742170|NCT00261833|Experimental|Zemaira®|
9742171|NCT00261833|Placebo Comparator|Placebo|
9742172|NCT00261846|Experimental|SKI-606|
9742173|NCT00261950|Experimental|Cinacalcet|All subjects were enrolled into the single arm to receive Cinacalcet. There was no comparator arm.
9742174|NCT00262002|Experimental|UK234+ (MenACWY Ad+ at 2, 3, 4 m)|Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age in the UK group. A fourth dose of MenACWY Ad+ was given at 12 months of age.
9742175|NCT00262002|Experimental|UK24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.
9742176|NCT00262002|Experimental|UKMenC (Menjugate at 2, 4 m)|Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.
9742177|NCT00262002|Experimental|CA246+ (MenACWY Ad+ at 2, 4, 6 m)|Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age of the Canadian group (Prevnar at 6 months was optional and was given if available).One subgroup of subjects was given a reduced dose (1/5) of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.
9742178|NCT00262002|Experimental|CA24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (1/5) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
9742179|NCT00262002|Experimental|UK24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.
9742180|NCT00262002|Experimental|CA24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
9742181|NCT00262028|Experimental|MenACWY-CRM (2-10 years)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
9742182|NCT00262028|Experimental|MenACWY-CRM (12-23 months)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
9742183|NCT00262028|Active Comparator|MenACWY-PS (2-10 years)|Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine
9742184|NCT00262028|Experimental|MenACWY-CRM+PnC (12-15 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC
9742185|NCT00262028|Experimental|MenACWY-CRM+DTaP (16-23 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP
9742186|NCT00262041|Experimental|MenACWY-CRM(Ad+)|Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
9742187|NCT00262041|Experimental|MenACWY-CRM(Ad-)|Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
9742188|NCT00262041|Active Comparator|MenACWY- PS|Subjects received one single dose of the polysaccharide vaccine.
9742189|NCT00262067|Experimental|Bevacizumab + chemotherapy|Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
9742190|NCT00262067|Placebo Comparator|Placebo + chemotherapy|Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
9742191|NCT00262080|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
9742192|NCT00262080|Placebo Comparator|Placebo|Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
9742193|NCT00262119|Active Comparator|Control Group|PM programming according to actual clinical practice
10201009|NCT04994457||Adults with Glaucoma or Suspected Glaucoma|Adults with Glaucoma or Suspected Glaucoma, who have previously had standard automated perimetry (SAP) and will receive virtual reality visual field (VRVF) as part of the standard of care
9742194|NCT00262119|Active Comparator|MVP Only|PM programming according to actual clinical practice + MVP algorithm ON
9742195|NCT00262119|Active Comparator|DDDRP|PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
9742196|NCT00262223|Active Comparator|1) Seeking Safety + Sertraline|Seeking Safety + Sertraline
9742197|NCT00262223|Placebo Comparator|2) Seeking Safety + Placebo|Seeking Safety + Placebo;
9742198|NCT00262301|Experimental|"100 IU/kg rhC1INH"|100 IU/kg recombinant human C1 inhibitor
9742199|NCT00262301|Placebo Comparator|Saline|Saline solution
9742200|NCT00262509|Experimental|Egress Badge Performance|Blind subjects are walked into a building to a specific location, and then are asked to find their way out of the building.
9742201|NCT00262509|No Intervention|Baseline Egress Performance|Blind subjects are walked into a building to a particular location and then asked to find their way out of the building.
9742202|NCT00262522|Experimental|LPV/r 800/200 mg QD Tablet|
9742203|NCT00262522|Experimental|LPV/r 800/200 mg QD SGC (Through Week 8)|
9742204|NCT00262522|Active Comparator|LPV/r 400/100 mg BID Tablet|
9517302|NCT03307603|Experimental|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
9517303|NCT03307590|Active Comparator|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
9742205|NCT00262522|Active Comparator|LPV/r 400/100 mg BID SGC (Through Week 8)|
9742206|NCT00262600|Active Comparator|Dabigatran dose 2|twice a day
9742207|NCT00262600|Active Comparator|Warfarin|once a day
9983911|NCT04551430|Experimental|Crossover from Cohort A to Cohort B: Cabozantinib + Nivolumab + Ipilimumab|-Participants who cross-over from Cohort A into Cohort B will initiate treatment with nivolumab at a dose of 3 mg/kg IV over approximately 30 minutes and ipilimumab at a dose of 1 mg/kg IV over approximately 30 minutes. Nivolumab and ipilimumab will be given every 3 weeks for 4 doses. Nivolumab will then be continued at a dose of 480 mg IV over approximately 30 minutes every 4 weeks, with cabozantinib to continue at 40 mg every day.
9742208|NCT00262600|Active Comparator|Dabigatran dose 1|twice a day
9742209|NCT00262639|Experimental|I|2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.
9742210|NCT00262639|Placebo Comparator|II|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
9742211|NCT00262730|Experimental|Treatment Arm|"RT + TMZ 6wks, followed by~poly ICLC, temozolomide, radiation: radiation therapy"
9742212|NCT00262743|Experimental|polyphenon E|Designed to assess toxicity, treatment response, and pertinent laboratory measurements in patients with previously untreated, asymptomatic, Rai Stage 0-II CLL.
9742213|NCT00262821|Active Comparator|Arm I (cisplatin)|Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
9742214|NCT00262821|Experimental|Arm II (cisplatin, tirapazamine)|Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.
9742215|NCT00262834|Experimental|Arm I|Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
9742216|NCT00262847|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
9742217|NCT00262847|Experimental|Arm II (placebo, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
9742218|NCT00262847|Experimental|Arm III (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
9742219|NCT00262860|Experimental|Bortezomib, Gemcitabine Hdrochloride|
9742220|NCT00262873|Experimental|Bortezomib|
9785335|NCT01249261|Active Comparator|Risedronate|Risedronate 5mg years 1-7, no drug year 8
10201010|NCT04994457||Visual Field Naive Adults|Visual Field Naive Adults will receive SAP and VRVF
10201011|NCT04994457||Children with Glaucoma or Suspected Glaucoma|Children with Glaucoma or Suspected Glaucoma, who have previously had SAP and will receive VRVF as part of the standard of care
10201012|NCT04994457||Visual Field Naive Children|Visual Field Naive Children will receive SAP and VRVF
9742221|NCT00262925|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone."
9742222|NCT00262951|Experimental|Pancreatic Adenocarcinoma Patients|Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).
9742223|NCT00262964|Experimental|NAFLD-Niacin|Subjects, having previously diagnosed with NAFLD, were given Niacin for 16 weeks. The dosage was 500mg/day for week 1, 1000mg/day for week 2, 1500mg/day for week three and 2000mg/day for weeks 4 through 16.
9742224|NCT00262964|No Intervention|Control|Subjects were found to have intrahepatic triglyceride levels below the threshold for Non-Alcoholic Fatty Liver Disease (NAFLD). For this study that threshold was set at 10% intrahepatic triglyceride content as determined by magnetic resonance spectroscopy. These control subjects did not participate in any intervention. Only baseline features were characterized for this arm.
9742225|NCT00262964|Experimental|NAFLD-fenofibrate|Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
9742226|NCT00262964|Placebo Comparator|NAFLD-placebo|These subjects were diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) and received an 8 week course of a placebo pill. Their baseline characteristics were averaged into the overall NAFLD baseline characteristics along with the baseline data for the two intervention groups.
9742227|NCT00263211|Experimental|Plavix and Aspirin|Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
9742228|NCT00263211|No Intervention|Observation only|Observation by treating physician
9742229|NCT00263328|Active Comparator|Treatment group 1|Standard of care
9742230|NCT00263328|Experimental|Treatment group 2|Treatment group 2 also receives mycophenolate mofetil
9742231|NCT00263328|Experimental|Treatment group 3|Treatment group 3 does not receive mycophenolate mofetil
9742232|NCT00263562|Experimental|Steroid arm|Receipt of methyprednisolone pulse dose: 15mg/kg to a maximum of 1 gram; following this, the patients also received a steroid taper with oral prednisone:Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
9517304|NCT03307590|Active Comparator|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
9742233|NCT00263562|Placebo Comparator|Comparison Group|Patients receiving usual care, with receipt of placebo (saline in lieu of intravenous methylprednisolone infusion or a number of placebo pills equivalent in number to what would have been received for the prednisone.
9742234|NCT00263575|Experimental|sublingual fentanyl tablet|
9742235|NCT00263588|Experimental|single arm|750 mg lapatinib administered orally twice daily
9742236|NCT00263666|Experimental|Rotarix Group|Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
9742237|NCT00263666|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
9742238|NCT00263757|Experimental|Therapeutic Positive Airway Pressure|Subjects randomized to this arm received nightly Adaptive Servo-Ventilation during sleep for 12 months.
9742239|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management for 12 months as prescribed by their cardiologist.
9742240|NCT00263887|Experimental|Group 1|Prolastin
9742241|NCT00263887|Placebo Comparator|Group 2|
9742242|NCT00264004|Experimental|1|30 mg AZD2171
9742243|NCT00264004|Experimental|2|45 mg AZD2171
9742244|NCT00264238|Experimental|Memantine open label|All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.
9742245|NCT00264290|Experimental|Valganciclovir|900mg PO qd
9742246|NCT00264290|Placebo Comparator|Placebo|900mg PO qd
9742247|NCT00264303|Experimental|Levocetirizine|Levocetirizine, once daily, 4 week duration
9742248|NCT00264303|Active Comparator|Desloratadine|Desloratadine, once daily, 4 week duration
9742249|NCT00264381|Active Comparator|Ibuprofen|Ibuprofen 800mg tid X 7 days + additional 7 days determined by protocol
9742250|NCT00264498|Active Comparator|1|Gemcitabine + Carboplatin
9742251|NCT00264498|Experimental|2|Gefitinib
9742252|NCT00264537|Experimental|Group 1: Placebo + Methotrexate|Placebo subcutaneous injections (SC) every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 50 mg SC injections every 4 weeks from Week 28 up to 5 years; Golimumab - Dr's discretion after unblinding (in participants receiving methotrexate plus placebo), 50 mg SC injections every 4 weeks up to 5 years; Golimumab- Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9742253|NCT00264537|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; placebo capsules weekly from Week 0 for up to 5 years (unless early escape at Week 28); Methotrexate - if early escape, 10 to 20 mg weekly from Week 28 up to 5 years; Methotrexate - Dr's discretion after unblinding (in participants receiving golimumab plus placebo) 10 to 20 mg weekly for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9742254|NCT00264537|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 28 for up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9785336|NCT01249274|Placebo Comparator|Placebo|Matched placebo pills to be taken twice daily
9742255|NCT00264537|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9742256|NCT00264550|Placebo Comparator|Group 1: Placebo + Methotrexate|Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9742257|NCT00264550|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9742258|NCT00264550|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9742259|NCT00264550|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
9742260|NCT00264576|Experimental|cTIV|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
9742261|NCT00264576|Active Comparator|TIV|Received one dose of egg-derived trivalent vaccine (TIV).
9742262|NCT00264641|Experimental|High RAS activity|10 healthy men were characterized by having high basal RAS activity.
9742263|NCT00264641|Experimental|Low RAS activity|10 healthy men were characterized by having either a low basal RAS activity.
9742264|NCT00264797|Active Comparator|Methylphenidate|
9742265|NCT00264797|Placebo Comparator|Methylphenidate (Placebo)|
9742266|NCT00264810|Active Comparator|Treatment Group (stimulation ON)|Group of subjects that have undergone RNS® System implantation that are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the Blinded Evaluation Period. Stimulation is enabled during the Stimulation Optimization Period (second month post-implant) and may continue throughout the subject's participation in the study.
9742267|NCT00264810|Sham Comparator|Sham Group (stimulation OFF)|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the Blinded Evaluation Period. Stimulation is enabled after transition into the Open Label Period (sixth month post-implant) and may continue for the remainder of the subject's participation in the study.
9742268|NCT00264849|Experimental|OAT + Omalizumab|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.
9742269|NCT00264849|Active Comparator|Optimized Asthma Treatment (OAT)|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.
9742270|NCT00264875|Experimental|1|
9742271|NCT00265083|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
9742272|NCT00265083|Placebo Comparator|001|Golimumab (CNTO 148); placebo SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
9742273|NCT00265083|Experimental|002|golimumab 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
9742274|NCT00265096|Experimental|002|golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
9742275|NCT00265096|Experimental|001|Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
9742276|NCT00265096|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
9742277|NCT00265109|Other|open label|Open-label trial; all participants received levetiracetam
9742278|NCT00265122|Experimental|Population 1: Placebo SC followed by ustekinumab SC|Placebo injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
9742279|NCT00265122|Experimental|Population 1: Ustekinumab SC followed by Placebo SC:|Ustekinumab 90 mg injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
10201013|NCT04994457||Remote Care Arm|Glaucoma or Suspected Glaucoma participants, who have previously had SAP and will receive VRVF at their home
9742280|NCT00265122|Experimental|Population 1: Placebo IV followed by ustekinumab IV|Placebo given as 1 intravenous (IV) infusion at Week 0 during Intervention Period 1 and ustekinumab 4.5 mg/kg given as one IV infusion at Week 8 during Intervention Period 2.
9742281|NCT00265122|Experimental|Population 1: Ustekinumab IV followed by Placebo IV:|Ustekinumab 4.5 mg/kg given as one intravenous(IV) infusion at Week 0 during Intervention Period 1 followed by placebo given as one IV infusion at Week 8 during Intervention Period 2.
9742282|NCT00265122|Experimental|Population 2: Ustekinumab SC|Ustekinumab 90 mg injected subcutaneously (SC) once a week at Weeks 0-3 during Intervention Period 1. No intervention given during Intervention Period 2.
9742283|NCT00265122|Experimental|Population 2: Ustekinumab IV|Ustekinumab 4.5 mg given as one intravenous (IV) infusion at Week 0 during Intervention Period 1. No intervention given during Intervention Period 2.
9742284|NCT00265148|Experimental|Rosiglitazone|4 mg once a day for 1 month increasing to 8 mg once a day (Extended Released Tablets)
9742285|NCT00265148|Other|Placebo|Placebo dummy to match
9742286|NCT00265200|Experimental|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
9742287|NCT00265239|Active Comparator|1|Edaravone Group
9742288|NCT00265239|No Intervention|2|Placebo Group
9742289|NCT00265317|Experimental|A|
9742290|NCT00265317|Active Comparator|B|
9742291|NCT00265330|Experimental|Open|
9742292|NCT00265382|Other|Open|
9742293|NCT00265395|Active Comparator|Standard therapy|Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.
9742294|NCT00265395|Experimental|Extended therapy|Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.
9742295|NCT00265473|Experimental|Allogeneic Islets of Langerhans|Islet infusion
9742296|NCT00265512|Active Comparator|Telephone Case Monitoring Aftercare|Telephone Case Monitoring Aftercare
9742297|NCT00265512|Active Comparator|Continuing Care as Usual|Continuing Care as Usual
9742298|NCT00265538|No Intervention|Arm 1 (Pure Control Group)|Pure control (no intervention letter);
9742299|NCT00265538|No Intervention|Arm 2 (Contaminated Control Group)|Intervention control (patient does not receive intervention letter, but provider sees other patients who may bring in letter);
9742300|NCT00265538|Experimental|Arm 3 (Intervention Group A)|Intervention group A (the intervention is a letter only mailed to the subject); This intervention group receives an educational letter, which is the intervention. It is an educational intervention only.
9742301|NCT00265538|Experimental|Arm 4 (Intervention Group B)|Intervention group B (intervention letter A + financial incentive for discussion w/ provider and 6 month copay reimbursement); This group receives the same educational intervention as Group A, but also receives the Financial incentive, which is an added intervention.
9742302|NCT00265538|Experimental|Arm 5 (Intervention Group C)|Intervention group C (intervention letter A, financial incentive for discussion w/ provider + copay reimbursement, PLUS reminder phone call 1-3 days prior to primary care visit). This group receives the same intervention as Group B, but with the added intervention of a reminder phone call to test whether additional prompting is needed to make the intervention more effective.
9742303|NCT00265564|Active Comparator|Seeking Safety|Seeking Safety is a manualized, empirically supported, cognitive behavioral therapy that treats substance use disorders and comorbid PTSD. Participants assigned to the Seeking Safety arm attend two one hour sessions of group therapy for 12 weeks.
9742304|NCT00265564|Active Comparator|Usual Care|Usual Care Condition. Patients randomized to usual care will receive standard outpatient SUD treatment.
9742305|NCT00265616|Active Comparator|1|propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
9742306|NCT00265616|Active Comparator|2|thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
9742307|NCT00265759|Experimental|Arm I|Patients receive oral exemestane once daily for up to 16-18 weeks.
9742308|NCT00265759|Experimental|Arm II|Patients receive oral letrozole once daily for up to 16-18 weeks.
9742309|NCT00265759|Experimental|Arm III|Patients receive oral anastrozole once daily for up to 16-18 weeks.
9742310|NCT00265785|Experimental|Pemetrexed|pemetrexed
9742311|NCT00265850|Active Comparator|Arm A: FOLFOX or FOLFIRI + bevacizumab|Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
9742312|NCT00265850|Experimental|Arm B: FOLFOX or FOLFIRI + cetuximab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
9785337|NCT01249274|Experimental|Progesterone|100 mgs progesterone twice daily
9785338|NCT01249365|Experimental|HPV vaccine|Healthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
9742313|NCT00265850|Experimental|Arm C: FOLFOX or FOLFIRI + cetuximab + bevacizumab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
9742314|NCT00265889|Experimental|Poor Risk|Primary progressive, recurrent, or resistant relapse patients
9742315|NCT00265889|Experimental|Good Risk|First recurrence patients
9742316|NCT00265941|Active Comparator|RT + cisplatin|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin
9742317|NCT00265941|Experimental|RT + cisplatin + cetuximab|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab
9742318|NCT00265980|No Intervention|Weight initial|Subjects undergo studies at their usual body weight which is used as a baseline against which to compare subjects following weight loss with or without leptin repletion.
9742319|NCT00265980|Placebo Comparator|Weight -10% placebo|Subjects are studied while at a 10% reduced body weight and receiving placebo injections for 5 weeks.
9742320|NCT00265980|Experimental|Weight -10% leptin|Subjects are studied while at a 10% reduced body weight and receiving leptin injections for 5 weeks.
9742321|NCT00266032|Experimental|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
9742322|NCT00266032|Experimental|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
9742323|NCT00266032|Active Comparator|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
9742324|NCT00266110|Experimental|Dendritic Cell Vaccine|Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion
9742325|NCT00266227|Experimental|Arm A: Rituximab Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.
9742326|NCT00266227|Placebo Comparator|Arm B: Placebo Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by retreatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/week methotrexate.
9742327|NCT00266279|Experimental|Treatment with Study Drugs|Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
9742328|NCT00266409|Experimental|Panic: Niravam+SSRI/SNRI|Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI
9742329|NCT00266409|Experimental|Panic: SSRI/SNRI alone|Panic Disorder: Newly prescribed SSRI or SNRI alone
9742330|NCT00266409|Experimental|GAD: Niravam+SSRI/SNRI|Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI
9742331|NCT00266409|Experimental|GAD: SSRI/SNRI alone|Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone
9742332|NCT00266630|Experimental|Olanzapine Monotherapy|"Olanzapine extension for Study BMAC patients who completed Visit 8.~Patients received olanzapine 5-20 mg for 18 weeks."
9742333|NCT00266630|Experimental|Olanzapine + Mood Stabilizer|"Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5.~Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks.~Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks."
9742334|NCT00266656|Experimental|Experimental 1 Control|"No drug administration in B9R-US-GDFG (NCT00406926).~Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given."
9742335|NCT00266656|Experimental|Experimental 2 Humatrope|Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
9742336|NCT00266695|Experimental|Ruboxistaurin|
9742337|NCT00266708|Experimental|Risedronate|subjects received Risedronate for one year
9742338|NCT00266708|Placebo Comparator|subjects received placebo|subjects received placebo for 1 year
9742339|NCT00266799|Experimental|Pegylated liposomal doxorubicin|
9742340|NCT00266799|Active Comparator|Capecitabine|
9742341|NCT00266812|Experimental|Chemotherapy with temozolomide and radiotherapy|
9742342|NCT00266812|Active Comparator|Radiotherapy alone|
9742343|NCT00266825|Experimental|DHA capsules|DHA capsules
9742344|NCT00266825|Placebo Comparator|Placebo capsules|Placebo capsule
9742345|NCT00266851|Active Comparator|Azithromycin|Active adjunctive treatment
9742346|NCT00266851|Placebo Comparator|Placebo|Adjunctive placebo
9742347|NCT00266851|Other|Observational Cohort|Eligible participants who declined randomization, offered enrollment in parallel, open-label azithromycin treatment arm
9742348|NCT00266864|Experimental|Testosterone Replacement Therapy|Subjects with Low Testosterone (Hypogonadal) Receive Testosterone Transdermal System (Androderm 5 mg patch)
9742349|NCT00266864|No Intervention|No Intervention|Subjects with normal testosterone levels (eugonadal) participated in identical outcome measurements at parallel time points.
9785339|NCT01249404|Experimental|Dysport® 1000 U, IM|1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
9742350|NCT00266877|Experimental|Prior Tarceva or Iressa With EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening
9742351|NCT00266877|Experimental|Prior Tarceva or Iressa w/o EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening
9742352|NCT00266877|Experimental|No Prior EGFR Tyrosine Kinase Inhibitor Treatment|HKI-272 administered to patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, < or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)
9742353|NCT00267007|Experimental|001|PROCRIT 40 000 IU QW Epoetin alpha (PROCRIT) 40 000 IU every week (QW) for 18 weeks (IV or SC)
9742354|NCT00267007|Placebo Comparator|002|Placebo Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
9742355|NCT00267020|Experimental|Enzastaurin+Gemcitabine|
9742356|NCT00267020|Active Comparator|Gemcitabine|
9742357|NCT00267046|Experimental|Palifermin|"Palifermin + Chemotherapy (Adriamycin (Doxorubicin)+ Ifosfamide (AI) or Adriamycin (Doxorubicin) + Cisplatin (AP) Regimen); Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
9742358|NCT00267046|Placebo Comparator|Placebo|"Placebo + Chemotherapy (AI or AP Regimen);~AI = Doxorubicin (Adriamycin) + Ifosfamide:~A single dose placebo prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
9742359|NCT00267059|Experimental|Lenalidomide|
9742360|NCT00267085|Experimental|CML Vaccine|Imatinib mesylate subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
9742361|NCT00267098|Experimental|Biventricular pacing|
9742362|NCT00267098|Active Comparator|Right ventricular pacing|
9742363|NCT00267111|Experimental|Amethocaine gel 4% Group|1 g of topical amethocaine gel 4%
9742364|NCT00267111|Placebo Comparator|Placebo Group|
9742365|NCT00267150|Experimental|1|
9742366|NCT00267189|Active Comparator|Reduced CNI dose + everolimus ± steroids|Reduced CNI dose + everolimus (1.5 mg twice daily (b.i.d)) ± steroids
9742367|NCT00267189|Experimental|CNI continuation ± MPA/AZA ± Steroids|Standard CNI dose ± MPA/AZA ± steroids
9742368|NCT00267202|Placebo Comparator|Placebo|The dose of placebo was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
9742369|NCT00267202|Experimental|Omalizumab|The dose of omalizumab was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
9781845|NCT01158924|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
9781846|NCT01158950|Experimental|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
9781847|NCT01158950|Placebo Comparator|Placebo|Drug: Placebo for tolcapone administered at study visit
9781848|NCT01158976|Experimental|DHA supplementation|
9781849|NCT01158976|Placebo Comparator|Soybean Oil|
9781850|NCT01159015|Experimental|KetoNaph|KetoNaph Ophthalmic Solution
9781851|NCT01159015|Placebo Comparator|Vehicle|Vehicle of KetoNaph Ophthalmic Solution
9781852|NCT01159054|Experimental|This study has only one arm.|Blood sample and scan results to be compared before and after intervention in each subject.
9781853|NCT01159067|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
9781854|NCT01159171|Experimental|1|
10201014|NCT04994457||Ptosis Arm|Patients diagnosed with Ptosis, brow ptosis, or dermatochalasis, will receive a specialized version of VRVF and SAP, specifically to detect ptosis
9781855|NCT01159262|Experimental|Dexmedetomidine 0.05 mcg/kg|Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
10201015|NCT04994093||COLON CANCER|This cohort will consist of 100 patients with Colon Cancer.
9781856|NCT01159262|Experimental|Dexmedetomidine 0.1 mcg/kg|Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
9781857|NCT01159262|Experimental|Dexmedetomidine 0.2 mcg/kg|Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
9781858|NCT01159431|Experimental|Active|
9781859|NCT01159431|Other|Control|
10201016|NCT04993716||Cohort|Patient present in the SAU after an extra-hospital cardiac arrest
9785340|NCT01249404|Experimental|Dysport® 1500 U, IM|1500 U, I.M., on day 1 (single treatment cycle)
9742370|NCT00267293|Active Comparator|A|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg)
9742371|NCT00267293|Experimental|B|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg)
9742372|NCT00267293|Experimental|C|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate dose of Acetaminophen (15 mg/kg)
9742373|NCT00267631||At Risk Body Weight|Children with a BMI greater and equal to 85%
9742374|NCT00267631||Normal Body Weight|Children with a BMI of 25 to 75%
9742375|NCT00267644||Hydrated patients|Group 1 (n=63) were pediatric patiens that wer hydrated.
9742376|NCT00267644||Dehydrated Group|Group 2 (n=13) were pediatric patients that were dehydrated.
9742377|NCT00267670|Experimental|Pentoxifylline|400mg PO TID
9742378|NCT00267670|Placebo Comparator|Placebo|1 pill PO TID
9742379|NCT00267696|Experimental|Gemcitabine/carboplatin/bevacizumab|A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.
9742380|NCT00267748|Experimental|C|
9742381|NCT00267748|Experimental|A|
9742382|NCT00267774|Experimental|FFR guided PCI|
9742383|NCT00267774|Active Comparator|Angio-guided PCI|
9742384|NCT00267865|Experimental|Rituximab, High-Dose Methotrexate & Leucovorin Treatment|Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.
9742385|NCT00267956|Experimental|CNTO1275 (ustekinumab)|Group 1: Patients will receive CNTO 1275 63 mg at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive placebo to maintain the blind.
9742386|NCT00267956|Placebo Comparator|Placebo|Group 2: Patients will receive placebo at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive CNTO 1275 63 mg.
9742387|NCT00267969|Experimental|ustekinumab 45 mg|Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
9742388|NCT00267969|Experimental|ustekinumab 90 mg|Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
9742389|NCT00267969|Placebo Comparator|Placebo|Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.
9742390|NCT00268242|Experimental|Gemcitabine + Mitoxantrone|Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m^2/day I.V. on days 1, 2, and 3.
9742391|NCT00268346|Experimental|ZD1839|
9742392|NCT00268437|Experimental|Pemetrexed/Carboplatin|Pemetrexed+Carboplatin+Radiation
9742393|NCT00268762|Experimental|Intervention|Argatroban IV Infusion 1 mcg/kg/min for 48 hours
9742394|NCT00268892|Experimental|Degarelix 240/240@40(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (40 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (40 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
9742395|NCT00268892|Experimental|Degarelix 240/240@60(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
9742396|NCT00268892|Experimental|Degarelix 240/240@60(1-4-7-10)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 4, 7, 10) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
9742397|NCT00268905|Experimental|1|
9742398|NCT00268905|Experimental|2|
9742399|NCT00268905|Experimental|3|
9742400|NCT00268983|Experimental|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
9742401|NCT00268983|Active Comparator|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
9742402|NCT00268996|Experimental|Subjects with ACS and evidence of MN:SB-480848|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
9742403|NCT00268996|Placebo Comparator|Subjects with ACS and evidence of MN: placebo|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
9742404|NCT00268996|Experimental|Non-ACS and ACS subjects without evidence of MN: SB-480848|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
9742405|NCT00268996|Placebo Comparator|Non-ACS and those ACS subjects without evidence of MN: placebo|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
9742406|NCT00269113|Experimental|1|
9742407|NCT00269113|Active Comparator|2|
9742408|NCT00269152|Experimental|A: Pemetrexed + Cisplatin|
9742409|NCT00269152|Experimental|B: Pemetrexed + Carboplatin|
9742410|NCT00269399|Experimental|Rifaximin Treatment Arm|rifaximin 400mg taken 3 times a day
9742411|NCT00269399|Active Comparator|Vancomycin Comparator Arm|vancomycin 125mg taken 4 times a day
9785341|NCT01249404|Placebo Comparator|Placebo|I.M., on day 1 (single treatment cycle)
9785342|NCT01249417|Experimental|Dysport 10 U/Kg|10 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
9742412|NCT00269477|Experimental|Menactra® Vaccine Group 1|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
9742413|NCT00269477|Experimental|Menactra® Vaccine Group 2|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination
9742414|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 3|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
9742415|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 4|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination.
9742416|NCT00269633|Placebo Comparator|Red Light Box 657 nm|Red Light Box 657 nm
9742417|NCT00269633|Active Comparator|Blue Light Box 467 nm|Blue Light Box 467 nm
9742418|NCT00269919|Experimental|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 2 years.
9742419|NCT00270205|Experimental|A: 0.1 mg DNA/participant vaccination at weeks 1,7,13|Participants receiving three separate low-dose vaccinations of LC002 (0.1 mg DNA/participant, 0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
9984674|NCT03857074|Experimental|Open Label, Green Light Exposure|This is a single-center, open label, pilot feasibility study. Patients with epilepsy will be exposed to a narrow band of green light at low intensities (1-10 cd/m2). The investigators will record 30 minutes of scalp EEG prior to the light exposure and 30 minutes of scalp EEG recording post-light exposure. The number of epileptic spikes per minute at baseline will be compared to epileptic spike count per minute post-treatment, to determine whether green light exposure effectively decreases the number of epileptic spikes, in patients with ≥1 epileptic spike per minute at baseline.
9517305|NCT03307551|Active Comparator|CLADS group|Anaesthesia will be induced and maintained with Propofol administered by CLADS. Its administration rate will be controlled by a feedback loop facilitated by BIS monitoring. A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
9742420|NCT00270205|Experimental|B|Participants receiving three separate vaccinations of LC002 placebo (0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
9785343|NCT01249417|Experimental|Dysport 15 U/Kg|15 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
9742421|NCT00270205|Experimental|C: 0.4 mg DNA/participant vaccination at weeks 1, 7, 13|Participants receiving three separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
9742422|NCT00270205|Experimental|D|Participants receiving three separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
9742423|NCT00270205|Experimental|E: 0.4 mg DNA/participant vaccination at weeks 0,1,6,7,12,13|Participants receiving six separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
9742424|NCT00270205|Experimental|F|Participants receiving six separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
9742425|NCT00270231|Active Comparator|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
9742426|NCT00270231|Placebo Comparator|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
9742427|NCT00270257|Experimental|Long term medication assisted treatment (LT-MAT)|Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
9742428|NCT00270257|Experimental|Short term medication assisted treatment (ST-MAT)|Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
9742429|NCT00270296|Experimental|Trizivir (TZV) Arm|Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
9742430|NCT00270296|Experimental|Kaletra Arm|Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
9742431|NCT00270296|Experimental|Nevirapine (NVP) Arm|Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
9742432|NCT00270634|Active Comparator|Low Dose Voclosporin|Low dose voclosporin
9742433|NCT00270634|Active Comparator|Mid Dose Voclosporin|Mid Dose Voclosporin
9742434|NCT00270634|Active Comparator|High Dose Voclosporin|High Dose Voclosporin
9742435|NCT00270634|Active Comparator|Tacrolimus|Standard Dose Tacrolimus
9742436|NCT00270790|Experimental|AMIFOSTINE +CARBOPLATIN, TAXOL +RT|EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.
9742437|NCT00270842|Placebo Comparator|Education Control Group|Education group that is the control group for the study. Is a 10 week course with diverse health education topics.
9742438|NCT00270842|Experimental|Functional Balance Training|Exercise group that participated in functional balance training
9742439|NCT00270842|Experimental|Tai chi|Exercise Group that participated in tai chi training classes
9742440|NCT00270855|Other|Arm Crank Ergometer|Upper body Cycle ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
9742441|NCT00270855|Other|FESLCE|Functional Electrical Stimulation Leg Cycle Ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
9742442|NCT00270894|Experimental|Neoadjuvant therapy|Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments.
9742443|NCT00270998|Experimental|Intravaginal Pessary|Pessary restores continence by stabilization of the proximal urethra and urethrovesical junction, facilitating pressure transmission to the proximal urethra.
9742444|NCT00270998|Experimental|Behavioral Therapy|Pelvic floor muscle training and exercise which includes strong contraction of the pelvic floor muscles to prevent incontinence by occluding the urethra and regular practice can improve pelvic muscle support.
9742445|NCT00270998|Experimental|Pessary combined with behavioral therapy|Combination of the explanations above.
9742446|NCT00271024|Experimental|Male Naltrexone|50 mg Naltrexone tablet
9742447|NCT00271024|Experimental|Female Naltrexone|Females receiving either naltrexone (50 mg)
9742448|NCT00271024|Placebo Comparator|Male Placebo|Males receiving Placebo (sugar pill)
9742449|NCT00271024|Placebo Comparator|Female Placebo|Females receiving placebo (sugar pill)
9742450|NCT00271154|Placebo Comparator|CRT OFF|Cardiac Resynchronization Therapy (CRT) turned OFF in conjunction with optimal medical therapy
9742451|NCT00271154|Active Comparator|CRT ON|Cardiac Resynchronization Therapy (CRT) turned ON in conjunction with optimal medical therapy
9742452|NCT00271219|Experimental|Buprenorphine|Buprenorphine
9742453|NCT00271219|Active Comparator|Methadone|Methadone
9742454|NCT00271375|Experimental|Arm 1: Caring for you, Caring for me Educational Intervention|Educational Intervention
9742455|NCT00271375|Experimental|Arm 2: Caring for you, caring for me + social worker|Educational + Social Work Intervention
9742456|NCT00271375|Placebo Comparator|Arm 3: Control group usual care|Control group usual care
9742457|NCT00271505|Experimental|Avastin + Docetaxel + Carboplatin|Avastin 15 mg/kg intravenously (IV) every 3 weeks. Docetaxel 75 mg/m2 IV every 3 weeks. Carboplatin AUC 6 IV every 3 weeks.
9742458|NCT00271570|Active Comparator|Second Dose of IVIG (2g/kg)|Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg)
9742459|NCT00271570|Experimental|Infliximab (5mg/kg)|Remicade (5mg/kg) single dose
9742460|NCT00271596|Experimental|Citalopram|20mg daily citalopram
9742461|NCT00271596|Placebo Comparator|Placebo|Matching daily placebo
9742462|NCT00271609|Other|Anaplastic Glioma (AG)|Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mixed oligoastrocytoma Malignant astrocytoma (not otherwise specified) 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
9742463|NCT00271609|Other|Glioblastoma Multiforme (GBM)|Glioblastoma multiforme Gliosarcoma 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
9742464|NCT00271739|Experimental|Telemedicine case management|Telemedicine visits conducted by a registered nurse (RN) with remote monitoring of blood pressure (BP) and blood glucose through the use of a telemedicine home unit (HTU).
9742465|NCT00271739|Active Comparator|Usual care|usual care by primary care provider
9742466|NCT00271856|Experimental|0|Mindfulness Based Stress Reduction (MBSR)
9742467|NCT00271856|Active Comparator|1|HIV education/self-management workshop
9742468|NCT00272038|Experimental|Tarceva|Tarceva 150 mg QD
9742469|NCT00272168|Experimental|Arm 1: MPROVE|The Maryland Program for Vocational Effectiveness (MPROVE)
9742470|NCT00272168|Active Comparator|Arm 2: Control|Supportive Treatment for SMI (control)
9742471|NCT00272311|Active Comparator|1|81 mg Aspirin
9742472|NCT00272311|Active Comparator|2|162 mg Aspirin
9742473|NCT00272311|Active Comparator|3|325 mg Aspirin
9742474|NCT00272311|Active Comparator|4|650 mg Aspirin
9742475|NCT00272311|Active Comparator|5|1300 mg Aspirin
9742476|NCT00272337|Active Comparator|1|81 mg Aspirin
9742477|NCT00272337|Active Comparator|2|162 mg Aspirin
9742478|NCT00272337|Active Comparator|3|325 mg Aspirin
9742479|NCT00272337|Active Comparator|4|650 mg Aspirin
9742480|NCT00272337|Active Comparator|5|1300 mg Aspirin
9742481|NCT00272779|Active Comparator|Atazanavir (ATV) + Ritonovir (RTV)|Participants were administered an oral dose of ATV 300 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of ATV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
9742482|NCT00272779|Active Comparator|Lopinavir (LPV) + RTV|Participants were administered an oral dose of LPV 400 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of LPV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
9742483|NCT00272792|Experimental|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
9742484|NCT00272792|Placebo Comparator|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
9742485|NCT00272844|Experimental|Cholesterol supplementation|
9742486|NCT00272961|Placebo Comparator|placebo|
9742487|NCT00272961|Experimental|ARM 1|
9742488|NCT00272961|Experimental|ARM 2|
9742489|NCT00272961|Experimental|ARM 3|
9742490|NCT00272961|Experimental|ARM 4|
9742491|NCT00272987|Experimental|Cohort 1|Participants received: paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily
9742492|NCT00272987|Experimental|Cohort 2|Participants received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily.
9742493|NCT00272987|Experimental|Cohort 3|Participants in this arm received 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 750 mg PO
9742494|NCT00273052|Experimental|Carvedilol Phosphate modified release formulation|
9742495|NCT00273052|Active Comparator|metoprolol succinate|
9742496|NCT00273182||Cohort|Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
9742497|NCT00273364|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG
9742498|NCT00273364|Active Comparator|Standard therapy for MS|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)
9742499|NCT00273754|Placebo Comparator|Placebo|Saline
9742500|NCT00273754|Active Comparator|Caffeine|Caffeine benzoate
9742501|NCT00273793|Experimental|1|Shaping intervention for hard-to-treat smokers
9742502|NCT00273793|Active Comparator|2|fixed criterion intervention for hard-to-treat smokers
9742503|NCT00273793|Other|3|Non contingent incentives available to hard to treat smokers
9742504|NCT00273793|Experimental|4|Ascending incentives values used in Smokers with Early Success
9742505|NCT00273793|Active Comparator|5|fixed value incentives are used in Smokers with Early Success
9742506|NCT00273793|Other|6|Non contingent incentives are available to Smokers with Early Success
9742507|NCT00273858||etanercept|Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC).
9742508|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
9742509|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
9742510|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID|gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
9742511|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID + Imiquimod|gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.
9742512|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
9742513|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
9742514|NCT00274261|Experimental|A|C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
9742515|NCT00274261|Active Comparator|B|Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
9742516|NCT00274287|Experimental|GM-CSF|Once patients have finished receiving the chemotherapy and no signs of disease progression they may receive GM-CSF as outlined in the protocol
9742517|NCT00274456|Experimental|ABI-007 300 mg/m^2 q3w|ABI-007 300 mg/m^2 administered once every third week (q3w).
9742518|NCT00274456|Experimental|ABI-007 100 mg/m^2 weekly|ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
9742519|NCT00274456|Experimental|ABI-007 150 mg/m^2 weekly|ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
9742520|NCT00274456|Active Comparator|Docetaxel 100 mg/m^2, q3w|Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).
9742521|NCT00274469|Experimental|1|Fulvestrant
9742522|NCT00274469|Active Comparator|2|Anastrozole
9742523|NCT00274625|Experimental|1|Surgisis Gold Graft
9742524|NCT00274625|Active Comparator|2|Control
9742525|NCT00274651|Experimental|Arm A|PXD101 1000 mg/m2 once daily for 5 days every 21 days
9742526|NCT00274651|Experimental|Arm B|PXD101 1000 mg/m2 once daily for 5 days every 21 days
9742527|NCT00274716|Experimental|High BMI:MK-0736 2mg→Placebo|Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
9742528|NCT00274716|Experimental|High BMI:MK-0736 7mg→Placebo|Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
9742529|NCT00274716|Experimental|High BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
9742530|NCT00274716|Placebo Comparator|High BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
9742531|NCT00274716|Experimental|Low BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
9742532|NCT00274716|Placebo Comparator|Low BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
9742533|NCT00274742|Experimental|Blinatumomab|Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.
9742534|NCT00274768|Experimental|Capecitabine|26 patients received the pre-defined starting dose of capecitabine of 3,000 mg orally daily given in two divided doses. Two thirds of the patients received either the same dose or a 500 mg lower dose compared to what would have been administered with a commonly used body surface area (BSA)-dosing schedule (2,000 mg/m2 with rounding down to nearest 500 mg multiple).
9742535|NCT00274781|Experimental|ATO + GO|Arsenic Trioxide 0.25 mg/kg D1-5 Week 1/Twice Weekly W2-12 + Gemtuzumab Ozogamicin 3 mg/m^2 D8 for 1 or 2 Cycles of 12 Weeks each
9742536|NCT00274846|Experimental|Intent-to-Treat|All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10^7/kg.)
9742537|NCT00274924|Experimental|Group I (PET negative)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
9742538|NCT00274924|Experimental|Group II (PET positive)|Patients receive R-ICE comprising rituximab IV on day 1, ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day 2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously once daily starting on day 4 and continuing until blood counts recover. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9742539|NCT00274937|Experimental|Stratum I - AJCC Stages I-IIa|Patients undergo radiation therapy 5 days a week for 8 weeks. Patients also receive amifostine trihydrate subcutaneously on the same days they undergo radiation therapy.
9742540|NCT00274937|Experimental|Stratum II - AJCC Stages IIb-IV|Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiation therapy and receive amifostine trihydrate as in stratum I. Patients also receive 3 courses of cisplatin as before.
9742541|NCT00275002|Experimental|O6-BG and TMZ|O6-benzylguanine (O6-BG) and temozolomide (TMZ)
9742542|NCT00275028|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9742543|NCT00275262|Experimental|LAD 11.25 mg 3 Month Depot|Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
9742544|NCT00275262|Placebo Comparator|Placebo Comparator|Three intramuscular injections of matched placebo administered approximately 3 months apart.
9742545|NCT00275275|Experimental|1|Conversion factor of Mirapex to Requip 24-Hour of 1:3. This was a switch study in which the conversion factor was being investigated to assist in the conversion from Mirapex to Requip PR. In this group, the dose of Requip PR was 3 times the dose of Mirapex.
9742546|NCT00275275|Experimental|2|Conversion factor of Mirapex to Requip 24-Hour of 1:4
9742547|NCT00275275|Experimental|3|Conversion factor of Mirapex to Requip 24-Hour of 1:5
9742548|NCT00275301|Experimental|Open-label Olanzapine.|Open-label Olanzapine.
9742549|NCT00275392|Experimental|Vestibular Rehabilitation|vestibular exercises plus standard balance and gait exercises
9742550|NCT00275392|Placebo Comparator|Placebo|placebo exercises plus standard balance and gait exercises
9742551|NCT00275509|Experimental|Thymoglobulin|Thymoglobulin was administered as 1.5 mg/kg prior to reperfusion followed by 6 post-operative doses on days 1 through 6.
9742552|NCT00275509|Experimental|Daclizumab|Daclizumab was administered as 2 mg/kg prior to reperfusion followed by 1 mg/kg every other week for 8 weeks post-operatively (4 post-operative doses).
9742553|NCT00275561|Experimental|Fluticasone|Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks
9742554|NCT00275561|Placebo Comparator|Placebo|Placebo inhaler swallowed bid for 6 weeks
9742555|NCT00275821|Experimental|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|
9742556|NCT00275821|Experimental|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|
9742557|NCT00275821|Active Comparator|Ranibizumab 0.3 mg monthly|
9742558|NCT00275834|Experimental|A|Zonisamide 400 mg
9742559|NCT00275834|Experimental|B|Zonisamide 200 mg
9742560|NCT00275834|Placebo Comparator|C|matching placebo
9742561|NCT00276094|Experimental|Ospemifene 30 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 30 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
9742562|NCT00276094|Experimental|Ospemifene 60 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
9742563|NCT00276094|Placebo Comparator|Placebo tablets and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of placebo each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
9742564|NCT00276159|Experimental|852A Treatment|Patients receiving at least one dose of 852A.
9785344|NCT01249417|Placebo Comparator|Placebo|Total volume to be injected per lower limb - 2ml. Either one or both lower limbs can be treated.
9742565|NCT00276250|Experimental|Efalizumab Followed by Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received efalizumab-based immunosuppression regimen after islet-cell transplantation. During the course of the study, efalizumab was withdrawn from the US market due to safety concerns. The protocol was subsequently amended to alter the immunosuppressive regimen to abatacept for these participants.
9742566|NCT00276250|Experimental|Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received abatacept immunosuppresion regimen after islet-cell transplantation.
9742567|NCT00276250|Experimental|Belatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received Belatacept immunosuppresion regimen after islet-cell transplantation.
9742568|NCT00276380|Experimental|EGb761®|"EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).~The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
9742569|NCT00276380|Placebo Comparator|Placebo|"6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).~The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
9742570|NCT00276406|Experimental|Pyridostigmine|Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
9742571|NCT00276406|Placebo Comparator|Placebo|Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.
9742572|NCT00276549|Experimental|Gemcitabine and Docetaxel i|
9742573|NCT00276614|Experimental|Velcade|Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle. A 10 day-rest period (Days 12-21) with no Velcade will follow the 2 weeks of treatment in each cycle. one cycle = 21 days
9742574|NCT00276744|Experimental|Arm 1|"PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.~Capecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks~PART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration."
9742575|NCT00277095|Experimental|ProACT (Adjustable Continence Therapy)|Implantation with ProACT (Adjustable Continence Therapy), Single Arm
9742576|NCT00277212|Experimental|A1|Phase 1: Single-Blind Treatment, Lamotrigine + Aripiprazole ; Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole
9742577|NCT00277212|Placebo Comparator|A2|Phase 2 Double-Blind Treatment: Lamotrigine + Placebo
9742578|NCT00277355|Experimental|Minocycline|Minocycline (3:1 randomization) 100 mg capsules taken by mouth twice daily, 200 mg per day total for 18 months treatment duration.
9742579|NCT00277355|Placebo Comparator|Matching placebo|Sugar pill manufactured to mimic minocycline, 1 capsule taken by mouth twice daily for 18 months treatment duration.
9742580|NCT00277394|Experimental|innohep®|innohep® 175 anti-Xa IU/kg once daily
9742581|NCT00277394|Active Comparator|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
9781860|NCT01159535|Active Comparator|MBRP|The Mindfulness Based Relapse Prevention (MBRP) intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include mindfulness practices targeting craving, Negative affect, and reactivity, as well as discussion about how to implement practice into high-risk situations and in daily life.
9781861|NCT01159535|Active Comparator|Relapse Prevention (RP)|The RP intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include discussions of personal high-risk situations, coping skills assessment, and exercises to evaluate expectancies, self-efficacy, and craving.
9781862|NCT01159535|Active Comparator|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
9781863|NCT01159574|Experimental|all patients|"ClaPd therapy:~Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.~Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day."
9781864|NCT01159600|Experimental|BI 10773 Arm 2|BI 10773 once daily high dose
9781865|NCT01159600|Placebo Comparator|Placebo|Placebo matching BI 10773
9781866|NCT01159600|Experimental|BI 10773 open-label|BI 10773 once daily high dose open label
9781867|NCT01159600|Experimental|BI 10773 Arm 1|BI 10773 once daily low dose
9781868|NCT01159665|Experimental|PPV 5-30 minutes after injection|Primary Pars Plana Vitrectomy 5 to 30 minutes after 125µg of ocriplasmin intravitreal injection
9781869|NCT01159665|Experimental|PPV 31-60 minutes after injection|Primary Pars Plana Vitrectomy 31 to 60 minutes after 125µg of ocriplasmin intravitreal injection
9781870|NCT01159665|Experimental|PPV 2-4 hours after injection|Primary Pars Plana Vitrectomy 2 to 4 hours after 125µg of ocriplasmin intravitreal injection
10201017|NCT04989309|Experimental|Experiment 2. Phonetic precision disrupted by TMS|"Experiment 2 tests the influence of temporary disruption of activity within the left or right temporal cortex on the speed and precision of phonetic decisions compared to vertex stimulation. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Immediately following stimulation pulses, participants will perform a visual analog scale (VAS) phonetic rating task on tokens from the four continua, embedded in speech-shaped noise. To control for the possibility that TMS leads to a generalized deficit in categorization, a control task will involve categorization of visual objects on a morphed dog to cat object continuum. (We expect this task to be unaffected by TMS). The variables of interest are the steepness of the categorization curve, mean reaction time to all items on the continuum, and the difference in reaction time for boundary vs. endpoint tokens."
10201018|NCT04989309|Experimental|Experiment 3. Phonetic ambiguity in continuous speech|"Experiment 3 is designed to test whether left vs. right temporal lobe stimulation selectively disrupts processing of naturally-occurring phonetic ambiguity as compared to vertex stimulation (control). Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Stimuli will be nonsense sentences produced clearly or in a casual register. By-sentence phonetic ambiguity is estimated by the proximity of each token to other vowels belonging to different categories. Sentences will be embedded in speech-shaped noise to increase difficulty. Participants will listen to each sentence, then respond whether a visually-presented probe word appeared in the sentence (BRASS?). Dependent variables are accuracy and reaction time on this probe verification task."
10201019|NCT04989309|Experimental|Experiment 6: Disruption of talker-specific phonetic learning using TMS.|"Experiment 6 is designed to test whether disruption of activity in left or right temporal regions (vs. vertex control) using TMS interferes with talker-specific learning. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). The study uses a training paradigm where one talker's speech is manipulated to always have relatively short voice onset times (VOTs) for voiceless stops (e.g., /k/ in coal) and another to have relatively long VOTs. Immediately after stimulation, listeners will undergo a training trial where they identify sounds as mapping to Talker 1 or Talker 2's voice, and to the word (e.g. gain vs. cane). At test, listeners hear two VOT variants and are asked which is more typical of that talker's speech. The dependent variable is the accuracy of reporting which variant is typical of the talker."
10201020|NCT04983953||Abnormal|A patient diagnosed with intracranial haemorrhage after a brain CT scan
10201021|NCT04983953||Normal|A normal person or a patient not diagnosed with intracranial haemorrhage after a brain CT scan
10201022|NCT04983927||Ischemic stroke positive|Patients diagnosed with acute ischemic stroke after a brain CT scan
10201023|NCT04983927||Ischemic stroke negative with other brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan, but has been diagnosed with other brain diseases.
10201024|NCT04983927||Ischemic stroke negative and no brain disease|Patients who has not been diagnosed with acute ischemic stroke after a brain CT scan and has not been diagnosed with other brain diseases.
10201025|NCT04971408|Other|control|passive heat stress x1 visit then no intervention for 8 weeks. participants continue regular exercise habits as usual.
10201026|NCT04971408|Experimental|Passive heat stress|After arm 1, passive heat stress 3x/week x8 weeks.
10201027|NCT04962737|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
10201028|NCT04953143|Experimental|Pilot|"Inpatient longitudinal palliative care intervention that includes the following domains:~Therapeutic relationship: Developing trust and credibility with patients and their families~Symptom management: Proactive symptom management for common advanced liver disease symptoms including pain, fatigue, anorexia, breathlessness, depression and anxiety~Coping with illness: Introduction of strategies to improve adjustment and meaning in life; bolstering caregiver coping~Prognostic awareness and illness understanding: Assessing patients' level of prognostic awareness and discussing strategies to help patients cope with uncertainty~Treatment decision-making: Supporting patients and caregivers in their medical decision-making and assessing their values in decision-making~End-of-life care: Review/discuss selection of healthcare proxy, preferences for end-of-life care"
10201029|NCT04952467|Experimental|Drug: (14C)-XEN1101|Subjects will receive oral 14C-XEN1101 under fed conditions.
10201030|NCT04947644|Active Comparator|Thoracic epidural analgesia group|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
10201031|NCT04947644|Experimental|Ultrasound guided continuous erector spinae plane block group|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
10201032|NCT04944849||digital gamer group|Individuals with computer use more than 14 hours a week were included in this group.
10201033|NCT04944849||player group|Individuals with computer use less than 14 hours a week were included in this group.
9742582|NCT00277524||Overall|All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled.
9742583|NCT00278109|Experimental|PBI with Concurrent Chemotherapy|Phase I Single Arm study of PBI with concurrent chemotherapy. Primary endpoint is radiation toxicity. The intervention is partial breast radiation with doxorubicin and cyclophosphamide.
9742584|NCT00278148|Experimental|Dose Level A|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level A: 50 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
9742585|NCT00278148|Experimental|Dose Level B|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level B: 100 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
9742586|NCT00278148|Experimental|Dose Level C|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level C: 150 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
9742587|NCT00278161|Experimental|R-HiCy|Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.
9742588|NCT00278200|Experimental|EBV Seronegative|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were negative for Epstein-Barr Virus (EBV) at baseline.
9742589|NCT00278200|Experimental|EBV Seropositive|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were positive for Epstein-Barr Virus (EBV) at baseline.
9742590|NCT00278395|Experimental|Arm I|Patients receive oral vorinostat (SAHA) twice daily on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may have the option of continuing treatment beyond 52 weeks at the discretion of the investigator.
9742591|NCT00278473|Experimental|Meta-Cognitive Therapy|Cognitive behavioral group. Cognitive behavioral therapy focuses on changing patterns of thinking and behavior. Each group consists of 6 to 8 members and sessions are led by a psychologist.
9742592|NCT00278473|Active Comparator|Supportive Therapy|Social support problem-solving group. Social support problem-solving focuses on general support, problem solving, and information sharing. Each group consists of 6 to 8 members and sessions are led by a psychologist.
9742593|NCT00278512|Experimental|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant will be performed on eligible patients
9742594|NCT00278512|Experimental|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed on eligible patients
9742595|NCT00278525|Experimental|stem cell trasplantation|intervention as stem cell transplantation after conditioning regimen
9742596|NCT00278525|Active Comparator|standard of care|medication as standard of care will be given
9742597|NCT00278538|Experimental|Hematopoietic Stem Cell Transplant Regimen 2|Autologous Hematopoietic Stem Cell Transplantation: Rituximab, rATG and Cyclophosphamide regimen
9742598|NCT00278564|Experimental|Hematopoietic stem cell transplantation|Intervention as hematopoietic stem cells transplantation after conditioning regimen: Autologous hematopoietic stem cells will be injected after conditioning regimen
9742599|NCT00278629|Experimental|Hematopoietic Stem Cell Transplantation in CIDP|Autologous hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide 200 mg/kg/intravenously(IV), rATG(thymoglobulin) 5.5 mg/kg/IV and rituximab 1000mg/IV.
9742600|NCT00278655|Experimental|Hematopoietic stem cell transplantation|All participants will undergo hematopoietic stem cell transplantation after receiving conditioning regimen.
9742601|NCT00278863|Active Comparator|S-1|
9742602|NCT00278863|Active Comparator|Capecitabine|
9742603|NCT00278876|Experimental|imatinib mesylate|patients receiving adjuvant imatinib mesylate
9742604|NCT00278889|Active Comparator|1|Bevacizumab + FOLFOX
9742605|NCT00278889|Experimental|2|AZD2171 + FOLFOX
9742606|NCT00278954|Other|Gammaplex|Gammaplex
9742607|NCT00278993|Active Comparator|1|With stratification
9742608|NCT00279201|Active Comparator|Insulin glargine|Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
9742609|NCT00279201|Experimental|Lispro Low Mix|Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
9742610|NCT00279201|Experimental|Lispro Mid Mix prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
9742611|NCT00279201|Experimental|Lispro Low Mix prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
9742612|NCT00279201|Active Comparator|Basal bolus prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
9742613|NCT00279201|Active Comparator|Basal bolus prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
9742614|NCT00279305|Experimental|Rituximab Intravenous Infusion|Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
9742615|NCT00279305|Placebo Comparator|Placebo Intravenous Infusion|Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.
9742616|NCT00279500|Experimental|single arm study|Argus 16 Retinal Stimulation System-single arm study.
10201034|NCT04943484||Gastric cancer|Male and female subjects, over 18 years of age, with histological diagnosis of locally advanced gastric carcinoma (AGC), surgically resectable, without evidence of distant metastases (cT2-T4a; N0-3; M0) for which a surgical intervention with curative purposes is indicated both as a first treatment and following preoperative neoadjuvant chemotherapy
9742617|NCT00279591|Active Comparator|Continuous Blood Pressure Monitoring|Patients received continuous blood pressure monitoring the entire time they were in med flight to the hospital.
9742618|NCT00279591|Placebo Comparator|Standard of care blood pressure monitoring|Patients received the normal standard of care for blood pressure monitoring during the course of the med flight to the hospital.
9742619|NCT00279708|Active Comparator|Intervention Arm (Atorvastatin)|Atorvastatin: Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
9742620|NCT00279708|Placebo Comparator|Control Arm (Placebo)|Placebo: In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study: Placebo vs. Atorvastatin
9742621|NCT00279812|Placebo Comparator|Placebo|Placebo
9742622|NCT00279812|Experimental|50ug selenium enriched yeast|50ug/d selenium enriched yeast (containing 60% selenomethionine)
9742623|NCT00279812|Experimental|100ug selenium enriched yeast|100ug/d selenium enriched yeast (containing 60% selenomethionine)
9742624|NCT00279812|Experimental|200ug selenium enriched yeast|200ug/d selenium enriched yeast (containing 60% selenomethionine)
9742625|NCT00279812|Experimental|Control onion|3 meals/wk containing un-enriched onions equivalent to 4ug/d Se
9742626|NCT00279812|Experimental|Enriched onion|3 meals/wk containing enriched onions equivalent to 50ug/d Se
9742627|NCT00279916|Active Comparator|Triamcinolone acetonide|"Triamcinolone acetonide nasal spray; Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms) for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms) for 6 weeks duration."
9742628|NCT00279916|Sham Comparator|Placebo|"Placebo nasal spray; Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily for 6 weeks duration."
9742629|NCT00280059|Experimental|1|
9742630|NCT00280059|Active Comparator|2|
9742631|NCT00280150|Experimental|Cohort 1|Bevacizumab 10 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
9742632|NCT00280150|Experimental|Cohort 2|Bevacizumab 10 mg + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
9742633|NCT00280150|Experimental|Cohort 3|Bevacizumab + Erlotinib 150 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
9742634|NCT00280150|Experimental|Phase II|Bevacizumab + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
9742635|NCT00280241|Experimental|FLUDARABINE, CYCLOSPHOSPHAMIDE AND RITUXIMAB|
9742636|NCT00280293|Placebo Comparator|1|Placebo
9742637|NCT00280293|Active Comparator|2|LAmotrigine
9742638|NCT00280384|Active Comparator|E2014 (Botulinum toxin type B)|
9742639|NCT00280384|Placebo Comparator|E2014 (Botulinum toxin type B) Placebo|
9742640|NCT00280397|Experimental|1|
9742641|NCT00280566|Experimental|Ziprasidone|Active treatment, double-blind, randomized arm
9742642|NCT00280566|Placebo Comparator|Placebo|Placebo treatment, double-blind, randomized arm
9742643|NCT00280683|Active Comparator|Arginine|Enrolled subjects will take L-arginine orally, at 0.1 g/kg/day. Subjects will take three to four 1 g capsules (based on weight) of L-arginine twice daily for three months. L-arginine capsules were obtained from Jarrow Pharmaceuticals.
9742644|NCT00280683|Placebo Comparator|Placebo|Enrolled subjects took three to four placebo capsules that matched color and size of the intervention twice daily for three months. Matching placebo capsules were obtained from Jarrow Pharmaceuticals.
9742645|NCT00280735|Other|Single Arm Trial|adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles
9742646|NCT00280748|Other|Single Arm Study|Single Arm Study
9742647|NCT00280826|Experimental|Efalizumab|
10201035|NCT04933149|Experimental|Ketamine Infusion Group|Subjects will receive ketamine infusion during their planned surgery and postoperatively.
10201036|NCT04933149|No Intervention|Standard of Care Group|Subjects will receive general anesthesia as standard of care during their planned surgery
10201037|NCT04917107|Experimental|Qigong First|Participants in this group will complete the 12-week Qigong intervention first and then the 12-week observation period.
9742648|NCT00281021|Experimental|Erlotinib and Digoxin|Erlotinib plus Digoxin
9742649|NCT00281099|Active Comparator|VVI 40 pacing|Backup ventricular pacing (VVI) at 40 beats per minute
9742650|NCT00281099|Active Comparator|MVP pacing|Managed ventricular pacing (MVP) at 60 beats per minute
9742651|NCT00281463|Experimental|Pushrim Activated Power Assist Wheelchair|Participants will be asked to propel both their own chair and a pushrim activated power assist wheelchair on a computer controlled wheelchair dynamometer.
9742652|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 3 weeks|260 mg/m^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks
9742653|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 2 weeks|260 mg/m^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks
9742654|NCT00281528|Experimental|130 mg/m^2 ABI-007 weekly|130 mg/m^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks
9742655|NCT00281580|Placebo Comparator|Placebo|Placebo once daily for eight weeks
9742656|NCT00281580|Experimental|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
9742657|NCT00281580|Experimental|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
9742658|NCT00281580|Experimental|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
9742659|NCT00281580|Experimental|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
9742660|NCT00281580|Experimental|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
9742661|NCT00281580|Active Comparator|Amlodipine 10 mg|Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
9742662|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 2.5|Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
9742663|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 5|Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
9742664|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 10|Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
9742665|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 2.5|Telmisartan 40 / Amlodipine 2.5 for eight weeks
9742666|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 5|Telmisartan 40 / Amlodipine 5 for eight weeks
9742667|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
9742668|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 2.5|Telmisartan 80 / Amlodipine 2.5 for eight weeks
9742669|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 5|Telmisartan 80 / Amlodipine 5 mg for eight weeks
9742670|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
9742671|NCT00281632|Experimental|Pazopanib|800 mg GW786034 administered orally on a daily basis.
9742672|NCT00281671|Placebo Comparator|Placebo|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
9742673|NCT00281671|Experimental|Nesiritide|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
9742674|NCT00281684|Experimental|Placebo|Eligible participants received a single dose of SB705498 matching placebo capsules (4 placebo capsules) via oral route and were followed up to a maximum of 14 days.
9742675|NCT00281684|Experimental|SB705498 400 mg|Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a maximum of 14 days.
9742676|NCT00281684|Experimental|SB705498 1000 mg|Eligible participants received a single dose of SB705498 1000 mg capsules (2 x 200 mg capsules plus 2 x 300 mg capsules) via oral route and were followed up to a maximum of 14 days.
9742677|NCT00281684|Experimental|Co-Codamol|Eligible participants received a single dose of Co-codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via oral route and were followed up to a maximum of 14 days.
9742678|NCT00281697|Experimental|Standard chemotherapy + bevacizumab|Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
9742679|NCT00281697|Placebo Comparator|Standard chemotherapy + placebo|Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
9742680|NCT00281827|Experimental|Treatment Arm|Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.
9742681|NCT00281840|Experimental|bevacizumab with docetaxel and radiation therapy|
9742682|NCT00281918|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
9742683|NCT00281918|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
9742684|NCT00281957|Experimental|Arm I (sorafenib, temsirolimus)|Patients receive oral sorafenib twice daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
9742685|NCT00281957|Experimental|Arm II (sorafenib, tipifarnib)|Patients receive oral sorafenib as in arm I and oral tipifarnib twice daily on days 1-21
9742686|NCT00282048|Experimental|AG-013736 (axitinib)|AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity
9742687|NCT00282087|Other|gemcitabine/docetaxel then doxorubicin|Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).
9742688|NCT00282113|Active Comparator|ProBioPlus|
9742689|NCT00282113|Active Comparator|Culturelle|
9742690|NCT00282113|Placebo Comparator|Placebo|
9742691|NCT00282152|Active Comparator|ODT|Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary.
9742692|NCT00282152|Experimental|DBS+ODT|"Subjects receive bilateral subthalamic nucleus (B-STN) DBS and continue to take optimal drug therapy as prescribed by their treating neurologist.~B-STN DBS: Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for mid- and advanced PD. DBS is not approved for early stage PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.~Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary."
9742693|NCT00282243|Experimental|Tacrolimus MR|"After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study.~Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons."
9781871|NCT01159665|Experimental|PPV 24 hours (+2 hours) after injection|Primary Pars Plana Vitrectomy 24 hours (+2 hours)after 125µg of ocriplasmin intravitreal injection
9742694|NCT00282256|Experimental|Tacrolimus MR|Participants continued to receive their stable twice daily dose of tacrolimus twice daily on Day 1 through Day 7 and on Day 8 were converted to tacrolimus modified release (MR) once-daily in the morning for 7 days on a 1:1 (mg:mg) basis for their total daily dose. Patients who completed the 2-week pharmacokinetic treatment period were eligible to continue receiving tacrolimus MR as part of the extension treatment period of the study. The extended treatment period began on Day 15 and consisted of a single dose of tacrolimus MR once every morning through the end of the study.
9742695|NCT00282295|Experimental|Boostrix + Menactra Group|Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.
9742696|NCT00282295|Experimental|Boostrix-Menactra Group|Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
9742697|NCT00282295|Experimental|Menactra-Boostrix Group|Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
9742698|NCT00282308|Experimental|Rituximab + methotrexate (Group A)|Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
9742699|NCT00282308|Active Comparator|Methotrexate (Group B)|Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
9742700|NCT00282334|Experimental|Home blood pressure telemonitoring|
9742701|NCT00282334|No Intervention|Conventional blood pressure monitoring|
9742702|NCT00282347|Experimental|Rituximab|Participants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
9742703|NCT00282347|Placebo Comparator|Placebo|Participants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
9742704|NCT00282412|Experimental|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA
9742705|NCT00282438|Experimental|Autologous hematopoietic stem cell transplantation|Autologous stem cells will be injected after conditioning
9742706|NCT00282438|Experimental|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
9742707|NCT00282464|Active Comparator|Ziprasidone 20 and 60mg|For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
9742708|NCT00282464|Placebo Comparator|Placebo|
9742709|NCT00282568|Experimental|Tacrolimus Modified Release|Participants were enrolled into the study on their stable twice-daily (bid) dose of tacrolimus on Day 1 and continued to receive a stable bid dose of tacrolimus through Day 7. Participants then converted to Tacrolimus Modified Release (MR), administered once daily at an equivalent dose to the patient's previous stable total daily dose of tacrolimus. Participants who completed the 4-week pharmacokinetic treatment period with tacrolimus MR could continue receiving tacrolimus MR as part of the extended treatment period of the study. Dose adjustments were allowed in order to maintain tacrolimus trough concentrations within the target range of 5 to 15 ng/mL and for clinical reasons.
9742710|NCT00282672|Sham Comparator|LGD Sham Procedure first then LGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) receive proton pump inhibitor (PPI) with dose of Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
9742711|NCT00282672|Active Comparator|LGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
9781872|NCT01159665|Experimental|PPV 7 days (+1 day) after injection|Primary Pars Plana Vitrectomy 7 days (+1 day)after 125µg of ocriplasmin intravitreal injection
9742712|NCT00282672|Sham Comparator|HGD Sham Procedure first then HGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) with proton pump inhibitor (PPI) dose: Esomeprazole 40 mg BID.~At 12 month, subjects crossover to receive radiofrequency ablation."
9742713|NCT00282672|Active Comparator|HGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
9742714|NCT00282815|Active Comparator|1|CPAP
9742715|NCT00282815|Sham Comparator|2|sham CPAP (placebo)
9742716|NCT00282828|Experimental|Sertraline & Clonazepam|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of clonazepam up to 3.0mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 0.5mg of clonazepam per day in order to remain in the study."
9742717|NCT00282828|Experimental|Venlafaxine|"Phase I non-responders randomized to this group switched to venlafaxine with flexible titration up to 225 mg per day.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 75 mg venlafaxine per day in order to remain in the study."
9742718|NCT00282828|Experimental|Sertraline & Placebo|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of placebo.~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 1 capsule of placebo per day in order to remain in the study."
9742719|NCT00282841|Experimental|All stroke code patients|After written informed consent Code Stroke patients will undergo a contrast-enhanced transcranial ultrasound study to visualize the intracranial arteries. To do so, an ultrasound contrast agent (Definity) will be administered intravenously and transcranial ultrasound will be applied via the temporal bone window on both sides. Goal is to visualize and assess the intracranial arteries bilaterally. This includes the following vessel segments on both sides: middle cerebral artery (M1,M2,M3 segments), anterior cerebral artery (A1,A2 segments), posterior cerebral artery (P1,P2 segments), internal carotid artery (C1/2,C3/4 segments).
9742720|NCT00282919|Experimental|Azithromycin plus chloroquine|Single Arm, Open label study
9742721|NCT00282971|Experimental|Inhaled Insulin|Inhaled insulin plus oral therapy
9742722|NCT00282971|Other|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
9742723|NCT00282984|Placebo Comparator|placebo|
9742724|NCT00282984|Experimental|varenicline|
9742725|NCT00283049|Experimental|Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)|Arm 1: Insulin glargine administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
9742726|NCT00283049|Experimental|Insulins + Metformin (MET) + Thiazolidinedione (TZD)|Arm 2: Insulin glargine administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
9742727|NCT00283049|Experimental|Insulins + Metformin (MET) + Sulfonylurea (SU)|Arm 3: Insulin glargine administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added arms after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
9742728|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)|Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
9742729|NCT00283062|Active Comparator|Leuprolide Acetate - Immediate Treatment (I-HT)|Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
9742730|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.
9742731|NCT00283062|Active Comparator|Leuprolide Acetate - Deferred Treatment (D-HT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.
9742732|NCT00283075|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
9742733|NCT00283244|Active Comparator|Arm A|Patients receive gemcitabine hydrochloride 1200mg/m2 IV on days 1 and 8. Patients with progressive disease may cross over to arm B.
9742734|NCT00283244|Experimental|Arm B|Patients receive oral erlotinib hydrochloride 150mg p.o. daily on days 1-21.
9742735|NCT00283244|Experimental|Arm C|Patients receive gemcitabine hydrochloride 1000mg/m2 IV on days 1 and 8 and erlotinib hydrochloride 100mg p.o. daily
9742736|NCT00283283|Experimental|Male, Age 18 -49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
9742737|NCT00283283|Experimental|Male, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
9984675|NCT03845270|Experimental|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
9742738|NCT00283283|Experimental|Female, Age 18 - 49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
9742739|NCT00283283|Experimental|Female, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
9742740|NCT00283283|Experimental|Male, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
9984676|NCT03837431||CL suspicion|Individuals presenting with clinical suspicion of CL
10201038|NCT04917107|Experimental|Observation First|Participants in this group will complete the 12-week observation period first and then the 12-week Qigong intervention.
9742741|NCT00283283|Experimental|Male, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
9742742|NCT00283283|Experimental|Female, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
10201039|NCT04916847||children with controlled HIV|Children over 0 days and under 16 years old, with controlled HIV
9742743|NCT00283283|Experimental|Female, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
9742744|NCT00283296|Experimental|Endeavor Wheelchair|Participants will receive an introduction to the Endeavor wheelchair, and will complete the Activities of Daily Living Course with their own personal wheelchair and with the Endeavor chair.
9742745|NCT00283387|Experimental|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
9742746|NCT00283387|Placebo Comparator|Placebo|Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
9742747|NCT00283400|Active Comparator|dosage tier 1|0.625 g/kg 25% human albumin
9742748|NCT00283400|Active Comparator|dosage tier 2|1.25 g/kg 25% human albumin
9742749|NCT00283400|Active Comparator|dosage tier 3|1.875 g/kg 25% human albumin
9742750|NCT00283400|Active Comparator|dosage tier 4|2.5 g/kg 25% human albumin
9742751|NCT00283439|Experimental|Single Arm: AMG 531 Dose-Escalating Cohort Study|
9742752|NCT00283504|Experimental|all patients received Xolair/active drug|One arm:active drug
9742753|NCT00283595|Active Comparator|1|Treatment with rHGH
9742754|NCT00283595|Placebo Comparator|2|Treatment with Placebo
9742755|NCT00283686|Active Comparator|Study A, Arm 1|Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
9742756|NCT00283686|Active Comparator|Study A, Arm 2|Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
9742757|NCT00283686|Placebo Comparator|Study A, Arm 3|Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
9742758|NCT00283686|Placebo Comparator|Study A, Arm 4|Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg
9742759|NCT00283712|Experimental|Infliximab|"Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
9742760|NCT00283712|Placebo Comparator|Placebo Comparator|"Participants are randomized to receive intravenous infusions of placebo (5 mg/kg comprised of a white lyophilized powder reconstituted in 10 mL of Sterile Water for Injection, USP) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
9742761|NCT00283803|Experimental|IAS and Exisulind|Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
9742762|NCT00283816|Active Comparator|1|metformin
9742763|NCT00283816|Placebo Comparator|0|placebo
9742764|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 50mg|
9742765|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 100mg|
9742766|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 200mg|
9742767|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 400mg|
9742768|NCT00283842|Placebo Comparator|Placebo|
9742769|NCT00283933|Experimental|Migalastat|Migalastat 150 milligrams (mg) was administered orally QOD during the 24-week treatment period and then during the optional 24-week extension period.
9742770|NCT00284050|Experimental|Ranibizumab 0.3 mg|Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
9742771|NCT00284050|Experimental|Ranibizumab 0.5 mg|Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
9742772|NCT00284050|Sham Comparator|Sham injection|Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
9781873|NCT01159665|No Intervention|PPV without injection|Control Arm, no ocriplasmin intravitreal injection
9781874|NCT01159691||Neupro|Routine treatment as per approved label in Europe/ in accordance with the terms of the local marketing authorization for Neupro® transdermal patch.
9742773|NCT00284089|Experimental|Group A: Ranibizumab 0.3 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.
9742774|NCT00284089|Experimental|Group A: Ranibizumab 0.5 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.
9742775|NCT00284089|Experimental|Group B: Ranibizumab 0.3 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.
9742776|NCT00284089|Experimental|Group B: Ranibizumab 0.5 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.
9742777|NCT00284141|Experimental|aflibercept 4.0 mg/kg|Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.
9742778|NCT00284154|Experimental|Intervention|Patients received vinflunine 320 mg/m2 every 21 days as a 15- to 20-minute infusion.
9742779|NCT00284180|Experimental|HER2 Negative Intervention|Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes, repeated every 21 days
9742780|NCT00284180|Experimental|HER2 Positive Intervention|Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/kg, followed by 6 mg/kg IV on day 1 of each subsequent cycle, repeated every 21 days. If no grade 3/4 adverse events were encountered after the first cycle of vinflunine/trastuzumab, the dose of vinflunine could be escalated to 320 mg/m2.
9742781|NCT00284518|Experimental|botulinum toxin Type A 300 U|Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.
9742782|NCT00284518|Experimental|botulinum toxin Type A 200 U|Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.
9742783|NCT00284518|Experimental|botulinum toxin Type A 100 U|Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.
9742784|NCT00284518|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) transperineal or transrectal injection on Day 1.
9742785|NCT00284557|Experimental|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
9742786|NCT00284557|Active Comparator|Health education materials only|Those allocated to Group 2 were provided with a standardized packet of health education materials addressing the recommended items from the expert committee guidelines (e.g., dietary recommendations using the Food Guide Pyramid and the Traffic Light Diet, a general prescription to increase physical activity to 60 minutes daily). They were also given a community resource list that provides contact and program information for community-based obesity treatment activities in their area.
9742787|NCT00284739|Experimental|Alteplase|Multiple Alteplase injection into the abscess collection to improve percutaneous drainage
9742788|NCT00284739|Placebo Comparator|Saline|Multiple normal saline injection into the abscess collection to improve percutaneous drainage
9781875|NCT01159743||Efavirenz|HIV-infected patients on initial antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
9781876|NCT01159743||Lopinavir / Ritonavir|HIV-infected patients on initial antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
9781877|NCT01159769|Experimental|Olopatadine 0.2%|1 drop self-administered in each eye once daily in the morning for 7 days
9781878|NCT01159912|Experimental|Fluticasone Furoate OD and Placebo BID|Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
9781879|NCT01159912|Active Comparator|Fluticasone Propionate BID and Placebo OD|Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
9781880|NCT01159912|Placebo Comparator|Placebo only BID|Placebo inhalation powder twice daily for 24 weeks
9742789|NCT00284934|Active Comparator|Standard dose EC-MPS|Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
9742790|NCT00284934|Experimental|High EC-MPS|Patients received 1440 mg/day (720 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) tapered to reach a trough blood level target contained between 2 and 4.5 ng/mL within 15 days after randomization at the most. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
9742791|NCT00285012|Placebo Comparator|placebo|
9742792|NCT00285012|Experimental|varenicline|
9742793|NCT00285207|Placebo Comparator|Placebo|Placebo administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
9742794|NCT00285207|Experimental|A007|0.25% A007 administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
9742795|NCT00285246||Group 1|Army Reserve and National Guard soldiers deploying to a hazardous deployment from Fort Dix, NJ and Camp Shelby, MS
9742796|NCT00285467|Experimental|Doxercalciferol|doxercalciferol 1 mcg capsule orally daily for 3 months. This is a form of vitamin D that does not require activation by enzymes in the liver and kidney.
9742797|NCT00285467|Active Comparator|Cholecalciferol|cholecalciferol 4000 IU capsule orally daily for one month, then 2000 IU capsule daily orally for 2 months. this form of vitamin D requires activation by cells of the body.
9742798|NCT00285584|Active Comparator|Bupropion|Participants in this arm received bupropion.
9742799|NCT00285584|Placebo Comparator|Placebo|Participants in this arm received placebo that looked identical to the active comparator medication.
9742800|NCT00285649|Experimental|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
9742801|NCT00285649|Experimental|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
9742802|NCT00285649|Active Comparator|Usual Medical Care|Usual Medical Care, Active Comparator, advice, exercises and medications
9742803|NCT00285779|Placebo Comparator|Placebo injection|patients receive normal saline injection twice weekly for weeks 1-12
9742804|NCT00285779|Experimental|Etanercept|patients receive etanercept injection twice weekly for weeks 1-12.
9742805|NCT00285818|Active Comparator|Mifepristone|Patients receive mifepristone one day before and for 5 additional days after starting ECT
9742806|NCT00285818|Placebo Comparator|Placebo Oral Capsule|Patients receive a placebo capsule one day before and for 5 additional days after starting ECT
9742807|NCT00285857|Experimental|Lovastatin 80 mg/day|Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.
9742808|NCT00286078|Experimental|Treatment|Active occipital nerve stimulation (stimulation on)
9742809|NCT00286078|Sham Comparator|Control|Sham occipital nerve stimulation from activation to 12 weeks post-activation. Active occipital nerve stimulation from 12 weeks post-activation on.
9742810|NCT00286091|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
9742811|NCT00286091|Experimental|Denosumb|Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
9742812|NCT00286156|Experimental|1|Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
9517306|NCT03307551|Active Comparator|Manual group|Anaesthesia will be induced and maintained with propofol administration by an intravenous infusion pump. Its administration rate will be controlled manually to maintain a target BIS of 50 during induction and maintenance of anaesthesia.
9742813|NCT00286156|Experimental|2|Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
9742814|NCT00286156|No Intervention|3|Standard Care
9742815|NCT00286182|Experimental|Erythropoietin alpha|Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
9742816|NCT00286182|Placebo Comparator|Placebo|Placebo consists of saline injections.
9742817|NCT00286221|Experimental|Supratentorial PCA fentanyl|
9742818|NCT00286221|Active Comparator|Supratentorial PRN fentanyl|
9742819|NCT00286221|Experimental|Infratentorial PCA fentanyl|
9742820|NCT00286221|Active Comparator|Infratentorial PRN fentanyl|
9742821|NCT00286234|Placebo Comparator|1|Dual placebo
9742822|NCT00286234|Experimental|2|niaspan
9742823|NCT00286234|Experimental|3|lovaza
9742824|NCT00286234|Experimental|4|combined therapy
9742825|NCT00286325|Experimental|Treatment Rituximab|Open label study all subjects treated with rituximab
9742826|NCT00286429|Placebo Comparator|Insulin|
9742827|NCT00286429|Experimental|Alogliptin 12.5 mg QD|
9742828|NCT00286429|Experimental|Alogliptin 25 mg QD|
9742829|NCT00286442|Experimental|Alogliptin 12.5 mg QD|
9742830|NCT00286442|Experimental|Alogliptin 25 mg QD|
9742831|NCT00286442|Placebo Comparator|Metformin|
9742832|NCT00286455|Experimental|Alogliptin 12.5 mg QD|
9742833|NCT00286455|Experimental|Alogliptin 25 mg QD|
9742834|NCT00286455|Placebo Comparator|Placebo QD|
9742835|NCT00286468|Experimental|Alogliptin 12.5 mg QD|
9742836|NCT00286468|Experimental|Alogliptin 25 mg QD|
9742837|NCT00286468|Active Comparator|Placebo|
9742838|NCT00286494|Active Comparator|Placebo|
9742839|NCT00286494|Experimental|Alogliptin 12.5 mg QD|
9742840|NCT00286494|Experimental|Alogliptin 25 mg QD|
9742841|NCT00286728|Experimental|Arm 1|Intensive referral to dual-focused self-help groups
9742842|NCT00286728|No Intervention|Arm 2|Usual care
9742843|NCT00286741|Experimental|Medical group visits|Medical group visits
9742844|NCT00286741|No Intervention|Treatment as Usual control|control
9742845|NCT00286754|Experimental|Stage-matched intervention (SMI)|Stage-matched intervention (SMI)
9742846|NCT00286754|Active Comparator|Health Education Intervention (HEI)|Health Education Intervention (HEI)
9742847|NCT00286754|No Intervention|Usual Care (UC)|Usual Care (UC)
9742848|NCT00286949|Other|Atomoxetine (Strattera)|Open-Label Uncontrolled Active Drug Intervention, No comparator
9742849|NCT00287053|Experimental|Placebo|Divalproex Sodium
9742850|NCT00287053|Placebo Comparator|Placebo Comparator|Placebo Comparator
9742851|NCT00287079|Experimental|Rebif®|
9742852|NCT00287079|Other|No Treatment|
9742853|NCT00287118|Experimental|Efalizumab|
9742854|NCT00287222|Experimental|1 - Bevacizumab/Erlotinib|Subjects will be treated with bevacizumab and erlotinib
9742855|NCT00287287|Experimental|Lenalidomide (Revlimid)|Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.
9742856|NCT00287339|Experimental|1|40mg Esomeprazole BID
9742857|NCT00287339|Placebo Comparator|2|placebo capsules
9742858|NCT00287365|Experimental|1-ozone|Mildly asthmatic subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects
9742859|NCT00287469|Experimental|20mcg Recombinant HEV|20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
9742860|NCT00287469|Placebo Comparator|Placebo|PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
9742861|NCT00287586|Active Comparator|Testosterone|Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
9742862|NCT00287586|Placebo Comparator|Placebo|Participants received placebo-matching testosterone gel daily for 3 years.
9742863|NCT00287690|Experimental|Genistein|Supro drink once daily for 3 days
9742864|NCT00287690|Placebo Comparator|Placebo|Drink identical to Supro but containing no genistein, once daily for 3 days
9742865|NCT00287716|Active Comparator|2403 mg/day pirfenidone|Active arm 1, 2403 mg/day pirfenidone dose group.
9742866|NCT00287716|Active Comparator|1197 mg/day pirfenidone|Active arm 2, 1197 mg/day pirfenidone.
9742867|NCT00287716|Placebo Comparator|placebo|Placebo equivalent.
9742868|NCT00287729|Active Comparator|2403 mg/day pirfenidone|2403 mg/day pirfenidone dose group.
9742869|NCT00287729|Placebo Comparator|placebo|Placebo equivalent.
9742870|NCT00287872|Experimental|Bortezomib and Thalidomide|The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
9742871|NCT00287989|Experimental|150 PRE|Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2
9742872|NCT00287989|Experimental|1,500 PRE|Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2
9742873|NCT00287989|Experimental|1,500 POST|Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.
9742874|NCT00288015|Experimental|Bevacizumab|Bevacizumab treatment until disease progression or intolerance
9742875|NCT00288054|Experimental|Cetuximab + Radiotherapy (no Docetaxel)|
9742876|NCT00288054|Experimental|Cetuximab + Radiotherapy + Docetaxel|
9742877|NCT00288067|Experimental|Treatment (fenretinide, rituximab)|"PHASE I: Patients receive fenretinide PO BID on days 1-5. Treatment repeats weekly for at least 4 weeks in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive fenretinide PO BID on days 1-5 in weeks 1-8 and rituximab IV once weekly in weeks 5-8. Treatment continues in the absence of disease progression or unacceptable toxicity."
9742878|NCT00288366|Active Comparator|1|aripiprazole (Abilify)
9742879|NCT00288366|Active Comparator|2|ziprasidone (Geodon)
9742880|NCT00288509|Experimental|Dysport|250-1000 units
9742881|NCT00288574|Experimental|fluoxetine|fluoxetine up to 80 mg per day
9742882|NCT00288574|Placebo Comparator|Placebo|Placebo
9742883|NCT00288587|Active Comparator|Ultrafiltration|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
9742884|NCT00288587|Active Comparator|Usual & Customary|Patients treated with conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
9742885|NCT00288600|Experimental|Experimental group|Intravenous Immunoglobulin
9742886|NCT00288600|Placebo Comparator|CONTROL GROUP|Normal Saline solution
9742887|NCT00288626|Experimental|MS Treatment|Autologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.
9742888|NCT00288704|Placebo Comparator|Placebo|Some subjects were treated with Placebo in the Study. This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
9781881|NCT01159938|Experimental|T2DM, albuminuria but normal kidney function|
9781882|NCT01159938|No Intervention|Healthy participants|
9781883|NCT01159938|Experimental|T2DM, normal urinary albumin excretion rate (UAER)|
9517307|NCT03307538|Experimental|Stereotactic body radiation therapy|
9742889|NCT00288704|Active Comparator|rilonacept 160 mg|"If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B).~Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg."
9742890|NCT00288704|Other|Open-Label rilonacept 160 mg|"After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week.~Study drug is administered as a 2.0 mL subcutaneous injection once a week."
9742891|NCT00288860|Experimental|Telephone Monitoring|Biweekly monitoring and support by telephone (up to 6 calls over 3 months) as augmentation to mental health care as usual.
9742892|NCT00288860|Active Comparator|Treatment-As-Usual|Mental health Treatment As Usual, potentially including case management, pharmacotherapy, and individual and/or group psychotherapy.
9742893|NCT00288886|Experimental|Contracts, Prompts and Reinforcement arm|Participants were provided with contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
9742894|NCT00288886|Active Comparator|Control Arm|Participants were provided with routine care- they did not receive contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
9742895|NCT00288912|Active Comparator|Health Education Intervention|Health Education Intervention
9742896|NCT00288912|No Intervention|Usual Medical Care|Usual Medical Care
9742897|NCT00288912|Experimental|Osteoarthritis Self-Management|Osteoarthritis Self-Management
9742898|NCT00289016|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque forming units (PFU)/mL injected into 1 or more tumors with maximum total volume of 4 mL (up to 2 mL per tumor). Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks for up to 15 weeks. After the initial 8 doses, if indications of biological activity were observed, treatment could continue for up to 16 additional doses.
9742899|NCT00289094|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System
9742900|NCT00289094|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Retaining Knee System
9742901|NCT00289107|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform Cruciate Substituting Knee System
9742902|NCT00289107|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Substituting Knee System
9742903|NCT00289120|Experimental|Cola beverage|Subjects will be given 500cc of Cola twice daily.
9742904|NCT00289120|Placebo Comparator|Deionized water|Subjects will be given 500cc of deionized water.
9742905|NCT00289133|Active Comparator|GVF|Gamma Vacuum Foil polyethylene tibial insert
9742906|NCT00289133|Active Comparator|P.F.C.|Cross-linked polyethylene tibial insert
9742907|NCT00289185|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of the RTS,S/AS02D vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
9742908|NCT00289185|Active Comparator|Engerix-B Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh..
9742909|NCT00289198|Experimental|Fluticasone furoate|Participants were instructed to administer two sprays into each nostril once daily every morning of fluticasone furoate 110 μg
9742910|NCT00289198|Placebo Comparator|Placebo|Participants were instructed to administer two sprays into each nostril once daily every morning of placebo
9742911|NCT00289211|Experimental|C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV). If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
9742912|NCT00289211|Placebo Comparator|Placebo|Matching placebo (saline) administered IV. If there was no response to treatment 60 minutes after the first dose, a second placebo (saline) dose could be administered.
9742913|NCT00289289|Active Comparator|On-Off|Subjects have intervention pacing features turned On according to randomization assignment in the first crossover period then Off in the second period.
9742914|NCT00289289|Active Comparator|Off-On|Subjects have intervention pacing features turned Off according to the randomization assignment for the first crossover period and then On in the second period.
9742915|NCT00289289|No Intervention|Non-randomized|Subjects that did not have device recorded episodes of atrial tachycardia/atrial fibrillation during the 3 month observation period post-implant did not qualify for randomization but were continued to be followed in the study. There were no programming requirements and symptom activations were not collected.
9742916|NCT00289315|Experimental|Arm 1|Primary (Environmental) Prevention of Weight Gain
9742917|NCT00289315|Experimental|Arm 2|Primary (Envrironmental) and Secondary (Behavioral) Weight Gain Prevention Program
9742918|NCT00289315|Experimental|Arm 3|Control - no Environmental or Behavioral Program intervention
9742919|NCT00289341|Placebo Comparator|Placebo|12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
9742920|NCT00289341|Experimental|DC/LNCaP|12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
9742921|NCT00289458|Experimental|Aquatic Education|Exercise combined with education
9742922|NCT00289458|Experimental|Aquatic|
9742923|NCT00289458|Placebo Comparator|Control|
9742924|NCT00289471||Cognitive Screening|Cognitive screening
9742925|NCT00289536|Experimental|Low Dose|
9742926|NCT00289536|Experimental|Medium Dose|
9742927|NCT00289536|Experimental|High Dose|
9781884|NCT01160198|Experimental|ferrous bisglycinate chelate 1 OD|ferrous bisglycinate chelate 1 tablet daily
9742928|NCT00289653|Experimental|single open-label treatment arm|Adult smokers willing to quit were treated with escalating doses of transdermal nicotine patch (Nicoderm) and brief counselling if they continued to smoke over a 9-week treatment period.
9742929|NCT00289718|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the long term follow-up."
9742930|NCT00289731|Experimental|Twinrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received combined Twinrix™ (720/20) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule.
9742931|NCT00289731|Active Comparator|Engerix-B+Havrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of Engerix™-B (20 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Havrix™ (1440 EL.U) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
9742932|NCT00289731|Active Comparator|HB VAX PRO+Vaqta Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of HB VAX PRO™ (10 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Vaqta™ (50 IU) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
9742933|NCT00289744|Experimental|Twinrix Group|Subjects who received 2 doses (at Day 0 and Month 6) of Twinrix in the primary study (208127/076)
9742934|NCT00289744|Experimental|Engerix-B Additional Dose (Adult)|Subjects aged 16 years and above who received an additional dose of EngerixTM-B (adult dose).
9742935|NCT00289744|Experimental|Engerix-B Additional Dose (Pediatric)|Subjects under the age of 16 years who received an additional dose of EngerixTM-B (pediatric dose).
9742936|NCT00289757|Experimental|Havrix Group|"Subjects who received 2 doses of Havrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Havrix Group for data analyses during the long term follow-up."
9742937|NCT00289770|Experimental|Group A|Was vaccinated with Lot A in the primary study.
9742938|NCT00289770|Experimental|Group B|Was vaccinated with Lot B in the primary study.
9742939|NCT00289770|Experimental|Group C|Was vaccinated with Lot C in the primary study.
9742940|NCT00289783|Experimental|Menhibrix A Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
9742941|NCT00289783|Experimental|Menhibrix B Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot B co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
9742942|NCT00289783|Experimental|Menhibrix C Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
9742943|NCT00289783|Experimental|Menhibrix Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A, B or C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
9742944|NCT00289783|Active Comparator|ActHIB Group|Subjects were primed with 3 doses of ActHIB co-administered with Pediarix and boosted with 1 dose of PedvaxHIB, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. ActHIB, PedvaxHIB vaccines were administered intramuscularly in the right upper thigh and Pediarix vaccine in the left upper thigh. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
9742945|NCT00289848|Experimental|1|sitagliptin 100 mg
9742946|NCT00289848|Placebo Comparator|2|placebo
9742947|NCT00289900|Experimental|MK-0524B 2g/20 mg|Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
9517308|NCT03307512|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
9742948|NCT00289900|Experimental|MK-0524B 2g/40mg|Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
9742949|NCT00289900|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg, orally, once daily for 12 weeks
9742950|NCT00289900|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg, orally, once daily for 12 weeks
9742951|NCT00289900|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg, orally, once daily for 12 weeks
9742952|NCT00289900|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg, orally, once daily for 12 weeks
9742953|NCT00289913|Experimental|VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
9742954|NCT00289913|Experimental|PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
9742955|NCT00289913|Experimental|VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
9742956|NCT00289913|Experimental|PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ was administered.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
9742957|NCT00289913|Experimental|VAQTA™/VAQTA™ (Stage 2)|"Day 1: The first dose of VAQTA™ was administered.~Week 24: The second dose of VAQTA™ was administered."
9742958|NCT00289978|Experimental|Fingolimod 1.25 mg|
9742959|NCT00289978|Experimental|Fingolimod 0.5 mg|
9742960|NCT00289978|Placebo Comparator|Placebo|
9742961|NCT00289991|Active Comparator|Itraconazole|
9742962|NCT00289991|Experimental|Voriconazole|
9742963|NCT00290147|Experimental|1.0 mg of D1ME100 vaccine|1.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
9742964|NCT00290147|Experimental|5.0 mg of D1ME100 vaccine|5.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
9742965|NCT00290186|Experimental|Hyperbaric Oxygen Treatment (HBO)|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
9742966|NCT00290186|Active Comparator|Hyperbaric Air Treatment (HBA)|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
9742967|NCT00290199|Experimental|Transcervical Foley Catheter|
9742968|NCT00290199|No Intervention|No Foley|
9983912|NCT04549155|Experimental|Network-guided TMS|The study comprises one arm of five sessions. In Day 1 (~1.5 hr session), participants fill forms, complete a neuropsychological test battery (NIH Toolbox, NACC UDS, BDI), and provide a saliva sample to be banked for future APOE genotype determination. On Day 2 (~1 hr session), subjects will perform an initial MRI scanning session. In this session, MRI, RSFA, DWI, and fMRI are collected so they can be used for network-based targeting. In Days 3-5 (each comprising a ~2.5 hr session) a few days later participants will undergo combined TMS-fMRI sessions. In the scanner, participants complete four fMRI runs: 2 runs using either a network-based or standard target location, counterbalanced across participants. Active and Sham TMS trials are intermixed within each run.
9983913|NCT04548245||Term|
9742969|NCT00290238|Experimental|PNT|
9742970|NCT00290238|Sham Comparator|TENS|
9983914|NCT04548245||Preterm|
9983915|NCT04544475|Experimental|Investigational|
9742971|NCT00290290|Active Comparator|povidone-iodine|preoperative skin preparation with povidone-iodine
9742972|NCT00290290|Experimental|chlorhexidine-alcohol|preoperative skin preparation with scrub and paint technique
9742973|NCT00290329|Experimental|Group A|
9742974|NCT00290342|Experimental|Infanrix-IPV Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' combined Infanrix™-IPV (DTPa-IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral thigh.
9742975|NCT00290342|Active Comparator|Infanrix + IMOVAX Polio Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' Infanrix™ (DTPa) vaccine co-administered with Sanofi-Pasteur's IMOVAX Polio® (IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral sides of opposite thighs.
9742976|NCT00290355|Experimental|GSK 249553 Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of GSK 249553 vaccine, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
9742977|NCT00290355|Placebo Comparator|Placebo Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of placebo, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
9742978|NCT00290433|Experimental|HCVIDDOXIL Regimen|"Cycle 1: Cyclophosphamide by vein two times a day on Days 1,2, and 3. Mesna by vein nonstop over Days 1 through 3. Pegylated liposomal doxorubicin by vein over 1 hour on Day 2. Vincristine by vein on Days 4 and 11. Dexamethasone by mouth on Days 1 through 4 and 11 through 14.~Cycle 2: Methotrexate by vein over 2 hours on Day 1 and over 22 hours on day 1. Cytarabine by vein twice a day on Days 2 and 3."
9742979|NCT00290472|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.
9742980|NCT00290498|Experimental|Arm A|R-HCVAD + R-MTX/Ara-C ((Rituximab-HCVAD (rituximab, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) alternating with Rituximab-Methotrexate-Cytarabine))
9983916|NCT04544475|Active Comparator|Standard of Care|
9742981|NCT00290498|Active Comparator|Arm B|"R-CHOP ((Rituximab-CHOP (Rituximab, cyclophosphamide, vincristine, and prednisone))~No longer recruiting for this study arm."
9781885|NCT01160198|Active Comparator|ferrous ascorbate|ferrous ascorbate, 1 tablet daily
10201040|NCT04916847||children with hematologic Malignancy treated by conventional chemotherapy|Children over 0 days and under 16 years old, with Hematologic Malignancy treated by conventional chemotherapy
9742982|NCT00290537|Experimental|Part One: ZD6474|First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks.
9742983|NCT00290537|Experimental|Part Two A: ZD6474 300 mg|Second part of study where participants randomized to receive 300 mg of ZD6474 daily (group A)
9742984|NCT00290537|Experimental|Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel|Second part of study where participants randomized to receive 100 mg of ZD6474 daily plus carboplatin AUC 6.0 IV over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks (group B).
9742985|NCT00290589|Experimental|Intramuscular methylprednisolone acetate|Methylprednisolone acetate 160mg intramuscular injection
9742986|NCT00290589|Placebo Comparator|Placebo|Placebo intramuscular injection
9742987|NCT00290615|Experimental|Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab|"Capecitabine - oral administration of 850 mg/m2 every 12 hours on days 1-14. Oxaliplatin - IV administration of 130 mg/m2 over 2 hours on day 1 of a cycle. Bevacizumab- IV administration of 7.5 mg/kg over 30-90 minutes on day 1 of a cycle.~Cetuximab at an initial dose of 400 mg/m2 over 120 minutes and subsequently 250 mg/m2 over 60 minutes on day 1 of a cycle.~Cycles are 21 days."
9742988|NCT00290654|Experimental|Lumpectomy with Brachytherapy|Patients with ductal carcinoma in situ (DCIS, a non-invasive form of breast cancer) treated with standard lumpectomy/brachytherapy following by radiation using the MammoSite (FDA approved a balloon-catheter device placed in the lumpectomy cavity through which high dose radiation is delivered). Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient.
9742989|NCT00290693|Experimental|CapTere (Capecitabine + Docetaxel)|Capecitabine + Docetaxel (Taxotere)
9742990|NCT00290706|Experimental|Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds|Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
9742991|NCT00290732|Experimental|Intraductal arm|Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.
9742992|NCT00290732|Active Comparator|Intravenous arm|Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.
9742993|NCT00290745|Experimental|tamoxifen or letrozole|tamoxifen or letrozole work in treating women with ductal carcinoma in situ
9781886|NCT01160198|Experimental|ferrous bisglycinate chelate 2 OD|ferrous bisglycinate chelate 2 tablets daily
9781887|NCT01160211|Experimental|Lapatinib plus trastuzumab plus aromatase inhibitor|Experimental
9781888|NCT01160211|Active Comparator|trastuzmab plus aromatase inhibitor|Active Comparator
9781889|NCT01160211|Active Comparator|lapatinib plus aromatase inhibitor|Active Comparator
9781890|NCT01160237|Experimental|Group A|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
9781891|NCT01160237|Experimental|Group B|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
9781892|NCT01160237|Active Comparator|Group C|Subjects not previously vaccinated with a vaccine against the pandemic H1N1 strain
9781893|NCT01160289|Experimental|1 milligram (mg) LY2452473 + 5 mg tadalafil|
9781894|NCT01160289|Experimental|5 mg LY2452473 + 5 mg tadalafil|
9781895|NCT01160289|Experimental|5 mg LY2452473 + placebo|
9781896|NCT01160289|Active Comparator|10 mg tadalafil + placebo|
9781897|NCT01160289|Active Comparator|5 mg tadalafil + placebo|
9781898|NCT01160354|Experimental|Plerixafor 240 mcg/kg + Clofarabine|"Plerixafor 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before hour IV administration of Clofarabine fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).~Phase II: Plerixafor at the highest dose tolerated in Phase I.~Plerixafor was dose-escalated in a 3+3 design, starting at 240 mcg/kg, and proceeding to dose levels of 320 mcg/kg, and 400 mcg/kg."
10201041|NCT04916847||Children with inflammatory bowel disease treated by anti-TNF at least 6 weeks|Children over 0 days and under 16 years old, with inflammatory bowel disease treated by anti-TNF
10201042|NCT04916847||Children with idiopathic juvenile arthritis|Children over 0 days and under 16 years old, with idiopathic juvenile arthritis treated by methotrexate:
10201043|NCT04916847||Children treated by renal transplantation|Children over 0 days and under 16 years old, treated by renal transplantation from more than 3 months:
9781899|NCT01160380|Experimental|Armodafinil|The patients receive armodafinil for all 56 days of the study.
9781900|NCT01160380|Placebo Comparator|Placebo-First|These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
9781901|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Melanoma|"Patients with metastatic melanoma Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
9781902|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Renal Cell|"Patients with metastatic renal cancer Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
9781903|NCT01160458|Experimental|IMC-A12 Monotherapy in Patients|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
9785345|NCT01249625|Active Comparator|N95 Respirator|The investigators are comparing specific N95 respirator against specific medical masks.
9785346|NCT01249625|Active Comparator|Medical/surgical mask|The investigators are comparing medical/surgical masks against the N95 respirator.
9742994|NCT00290771|Experimental|Imatinib 600 mg + hydroxyurea 1000 mg|Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.
9742995|NCT00290771|Experimental|Imatinib 1000 mg + hydroxyurea 1000 mg|Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.
9742996|NCT00290810|Experimental|Treatment (monoclonal antibody therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9742997|NCT00290888|Active Comparator|ACR|Arthroscopic rotator cuff repair without acromioplasty
9742998|NCT00290888|Experimental|ACR-A|Arthorscopic rotator cuff repair with acromioplasty
9742999|NCT00291018|Experimental|ProDisc-C|ProDisc-C total disc replacement device intended to treat single level SCDD in the cervical spine from C3-C7
9743000|NCT00291018|Active Comparator|Control|ACDF
9743001|NCT00291135|Experimental|1|Oral Letrozole 2.5 mg daily for six months
9743002|NCT00291161|Experimental|Partners in Dementia Care|"PDC is telephone-based care consultation intervention jointly delivered by care consultants in the VA and local Alzheimer's Association. The steps in care consultation included 1) Assessment of medical and non-medical care needs; 2) Development of a care plan that addresses needs of patients and caregivers; 3) on-going monitoring of the status, progress, and barriers encountered; and 4) Reassessment of care needs for patients and caregivers.~PDC assisted families by: 1) providing disease-related education and information, 2) offering emotional support and coaching, 3) linking families to medical and non-medical services and resources, and 4) mobilizing and organizing the informal care network."
9743003|NCT00291161|No Intervention|Usual Care|Patients and caregivers at the three control VA settings were given a packet of educational materials on dementia and usual-care community resources.
9743004|NCT00291187|Placebo Comparator|Placebo|Take orally 30 minutes prior to bedtime.
9743005|NCT00291187|Experimental|20 mg VEC-162|20 mg taken orally 30 minutes prior to bedtime.
9743006|NCT00291187|Experimental|50 mg VEC-162|50 mg taken orally 30 minutes prior to bedtime.
9743007|NCT00291187|Experimental|100 mg VEC-162|100 mg taken orally 30 minutes prior to bedtime.
9743008|NCT00291226|Experimental|Glycine|Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing > 100 kg were limited to a total daily dose of 80 g daily. Glycine was dispensed under IND 33,515 (DCJ).
9743009|NCT00291226|Placebo Comparator|Placebo Group|Placebo was dispensed as a proprietary formulations developed by Glytech, Inc, consisting of microencapsulated sucrose. Recommended administration of the sprinkles was to spoon them onto pudding or applesauce and swallow them with minimal chewing. Since earlier product testing by Glytech revealed that a few individuals did not like the somewhat granular texture of the sprinkles, subjects could switch to a second Glytech placebo formulation, consisting of proprietary pre-flavored sugar powders to be dissolved in 8 ounces of water.
9743010|NCT00291317|Experimental|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD).
9743011|NCT00291330|Experimental|dabigatran etexilate 150 mg|twice daily
9743012|NCT00291330|Active Comparator|warfarin (INR 2-3)|prn to maintain INR (2-3)
9743013|NCT00291343|Experimental|TRITANRIX™-HEPB/HIB-MENAC +MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses of Tritanrix™-HepB/Hib-MenAC vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one booster dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
9743014|NCT00291343|Active Comparator|TRITANRIX™-HEPB/HIBERIX™+MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses Tritanrix™-HepB/Hiberix™ vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
9743015|NCT00291447|Experimental|Cohort 1|Patients received a single infusion of 5 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
9743016|NCT00291447|Experimental|Cohort 2|Patients received a single infusion of 10 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
9743017|NCT00291447|Experimental|Cohort 3|Patients received a single infusion of 20 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
9743018|NCT00291447|Experimental|Cohort 4|Patients received a single infusion of 40 mg/m2 111In-ch806 on Day 0 and followed for 30 days post infusion.
9743019|NCT00291499|Active Comparator|Chondroitin 4&6 sulfate (Condrosulf)|
9743020|NCT00291499|Placebo Comparator|placebo|
9743021|NCT00291577|Experimental|1|
9743022|NCT00291642|Placebo Comparator|Placebo (PBO)|A single dose of placebo was administered orally on Day 1.
9785347|NCT01249651|Other|1|One arm: esomeprazole 40 mg
9517309|NCT03307512|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
9517310|NCT03307499|Experimental|Treatment|NeoPatch
9785348|NCT01249664|Experimental|Arm 1|
9743023|NCT00291642|Experimental|Levocetirizine (LCTZ) 2.5 mg|A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
9743024|NCT00291642|Experimental|Levocetirizine (LCTZ) 5 mg|A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
9743025|NCT00291642|Experimental|Cetirizine (CTZ) 5 mg|A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
9743026|NCT00291642|Experimental|Cetirizine (CTZ) 10 mg|A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.
9743027|NCT00291655|Experimental|Levetiracetam (LEV)|
9743028|NCT00291668|Experimental|Certolizumab pegol 200 mg|Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
9743029|NCT00291668|Experimental|Certolizumab pegol 400 mg|Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
9743030|NCT00291668|Placebo Comparator|Placebo|Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.
9743031|NCT00291694|Active Comparator|1|Oral Celecoxib 400 mg twice daily for 12 months
9743032|NCT00291694|Placebo Comparator|2|Matched blinded placebo twice daily for 12 months
9743033|NCT00291876|Experimental|Havrix Group|Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.
9743034|NCT00292045|Experimental|NY-ESO-1 protein + CpG 7909|Patients received immunization with intradermal injections of the NY-ESO-1 protein combined with CpG 7909.
9743035|NCT00292162|Active Comparator|medical therapy|Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin
9743036|NCT00292162|Active Comparator|Radiofrequency ablation (RFA)|Isolation of the pulmonary veins using radiofrequency ablation
9743037|NCT00292188|Experimental|Active|
9743038|NCT00292188|Placebo Comparator|Placebo|
9743039|NCT00292227|Experimental|Rotigotine|Rotigotine Patch
9743040|NCT00292227|Placebo Comparator|Placebo|Placebo patch
9517311|NCT03307486||Gestational diabetes|Women diagnosed with GDM according to the IADPSG criteria, either by abnormal fasting plasma glucose or by abnormal oral glucose tolerance test.
9517312|NCT03307473||e-bike|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
9743041|NCT00292318|Active Comparator|Arm 1|Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
9743042|NCT00292318|Experimental|Arm 2|Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
9743043|NCT00292370|Other|Arm 1: Open Label (OL) Paroxetine|Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
9743044|NCT00292370|Placebo Comparator|Arm 2 OL Paroxetine + DB Placebo|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
9743045|NCT00292370|Experimental|Arm 3: OL Paroxetine + DB Quetiapine|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
9743046|NCT00292461|Active Comparator|zonisamide|tablet
9743047|NCT00292461|Active Comparator|lamotrigine|tablet
9743048|NCT00292591|Active Comparator|cholecalciferol-400 IU|Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
9743049|NCT00292591|Experimental|cholecalciferol 2000 IU|Experimental group receiving 2000 IU total vitamin D3/day.
9983917|NCT04544241|Experimental|Clergy Wives and Widows|We will provide cancer survivorship and caregiving leadership education and activities for African American Clergy Wives and Widows by creating an educational partnership program aimed towards church-based health education on cancer survivorship and caregiving
9743050|NCT00292591|Experimental|cholecalciferol 4000 IU|Experimental group receiving 4000 IU/day cholecalciferol
9743051|NCT00292942|Experimental|2 mg/kg Intravenous Artesunate|2 mg/kg of Intravenous artesunate
9743052|NCT00292942|Experimental|4 mg/kg Intravenous Artesunate|4 mg/kg of Intravenous artesunate
9743053|NCT00292942|Experimental|8 mg/kg Intravenous Artesunate|8 mg/kg of Intravenous artesunate
9743054|NCT00292942|Placebo Comparator|Placebo|Mannitol (200 mg/vial) diluted in phosphate buffer and delivered in an equivalent volume by subject's weight as artesunate.
9743055|NCT00292981|Experimental|C1 Esterase Inhibitor|
9743056|NCT00293020|Experimental|1|BEMA Fentanyl
9743057|NCT00293033|Placebo Comparator|Placebo|Placebo
9743058|NCT00293033|Experimental|BEMA™ Fentanyl|BioErodible MucoAdhesive (BEMA) Fentanyl
9517313|NCT03307460|Experimental|uPAR PET/MRI|68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
9743059|NCT00293059|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo
9743060|NCT00293059|Placebo Comparator|Placebo|Matching placebo to be taken orally daily
9743061|NCT00293202|Active Comparator|Etanercept 25 mg|Etanercept 25 mg injection twice a week
9743062|NCT00293202|Placebo Comparator|Saline|Saline injection twice a week
9743063|NCT00293215|Experimental|Cohort 1 (1.0 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m^2 on Day 1 of subsequent 21-day cycles.
9743064|NCT00293215|Experimental|Cohort 2 (2.6 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m^2 on Day 1 of subsequent 21-day cycles.
9743065|NCT00293241|Other|MVP ON|Managed Ventricular Pacing programmed on
9743066|NCT00293241|Other|MVP OFF|Managed Ventricular Pacing programmed off: conventional pacing
9743067|NCT00293254|Experimental|1|raltegravir potassium
9743068|NCT00293254|Placebo Comparator|2|Placebo
9743069|NCT00293267|Experimental|1|raltegravir potassium
9743070|NCT00293267|Placebo Comparator|2|Placebo
9743071|NCT00293293|Active Comparator|Chemotherapy Alone|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
9743072|NCT00293293|Experimental|Standard Chemotherapy + CAM|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.
9743073|NCT00293384|Experimental|Aprepitant, Dexamethasone, Cytoxan & Kytril|"Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.~Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.~Days 2 & 3: Aprepitant 80 mg once daily in the morning."
9743074|NCT00293397|Experimental|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|Patients undergo DEB-TACE procedures utilizing LC Beads, polyvinyl alcohol microspheres with diameters of 100-300um or 300-500um, which are loaded with 100mg of doxorubicin hydrochloride and mixed with an equal volume of nonionic contrast media.
9743075|NCT00293423|Experimental|Phase 1: Vaccine|Patients received 25 micrograms of HSPPC-96 bi-weekly or weekly for the first 4 vaccinations followed by biweekly injections.
9743076|NCT00293423|Experimental|Phase 2: Vaccine|Treatment consisted of 25 mcg of HSPPC-96 weekly for at least 4 weeks, followed by biweekly injections (pending vaccine availability) for up to 52 weeks from the date of surgical resection.
9743077|NCT00293462|Active Comparator|Arm I: GM-CSF Group (GG)|Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
9743078|NCT00293462|Active Comparator|Arm II: Salt & Soda Group (SS)|Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
9743079|NCT00293462|Active Comparator|Arm III: Salt & Soda Switched to GM-CSF (SG)|Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
9743080|NCT00293540|Active Comparator|A|Surgical oophorectomy in history-estimated mid-luteal phase of menstrual cycle plus Tamoxifen
9743081|NCT00293540|Active Comparator|B|Surgical oophorectomy in history-estimated mid-follicular phase of menstrual cycle plus Tamoxifen
9743082|NCT00293579|Experimental|Pemetrexed|pemetrexed 500 mg/m2 administered iv, every three weeks, for 6 cycles
9743083|NCT00293709||Patients with Psoriatic Arthritis|
9743084|NCT00293722||Patients with Psoriatic Arthritis|
9743085|NCT00293813|Placebo Comparator|3|Placebo for denosumab and placebo for alendronate
9743086|NCT00293813|Experimental|1|denosumab and placebo for alendronate
9743087|NCT00293813|Active Comparator|2|Placebo for denosumab and alendronate
9743088|NCT00294047|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
9743089|NCT00294047|Placebo Comparator|Aluminium Hydroxide Group|Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
9785349|NCT01249664|Sham Comparator|Arm 2|
9785350|NCT01249833|Active Comparator|Oseltamivir|Added to standard of care for influenza
9743090|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Standard asthma therapy including oral corticosteroids, albuterol, education and discharge instructions.
9743091|NCT00294398|Experimental|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
9743092|NCT00294515|Experimental|Valganciclovir up to 100 days|Valganciclovir for up to 100 days post kidney transplant
9743093|NCT00294515|Active Comparator|Valganciclovir up to 200 days|Valganciclovir for up to 200 days post kidney transplant
9743094|NCT00294554|Active Comparator|Active Memantine|Memantine tablets, formulated in appearance to match the placebo comparator, were initiated at 5 mg daily and advanced by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
9743095|NCT00294554|Placebo Comparator|Placebo Oral Tablet|Placebo tablets were formulated to match active 5mg memantine tablets. Dosing same as the active comparator with initiation at 5 mg daily and advancing by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
9743096|NCT00294632|Experimental|Lenalidomide + Rituximab|Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks
9743097|NCT00294645|Active Comparator|Control|Transtelephonic monitoring at 2 month intervals
9743098|NCT00294645|Active Comparator|Remote|Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals
9743099|NCT00294658|Active Comparator|Thymectomy plus prednisone|Procedure: Extended Transsternal Thymectomy plus prednisone treatment
9743100|NCT00294658|Placebo Comparator|Prednisone alone|Drug: prednisone alone protocol
9743101|NCT00294671|Active Comparator|Diflunisal|Diflunisal 250 mg po bid
9743102|NCT00294671|Placebo Comparator|Placebo|Placebo 1 po bid
9743103|NCT00294684|Experimental|Corticosteroids|
9743104|NCT00294684|Placebo Comparator|Placebo|
9743105|NCT00294723|Experimental|Lira 1.8|Liraglutide 1.8 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.8 mg once daily in the extension periods (weeks 52-195).
9743106|NCT00294723|Experimental|Lira 1.2|Liraglutide 1.2 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.2 mg once daily in the extension periods (weeks 52-195).
9743107|NCT00294723|Active Comparator|Glimepiride - 1|Glimepiride 8 mg once daily + liraglutide placebo 200 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
9743108|NCT00294723|Active Comparator|Glimepiride - 2|Glimepiride 8 mg once daily + liraglutide placebo 300 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
9743109|NCT00294762|Experimental|Erlotinib|150 mg erlotinib daily
9743110|NCT00294762|Experimental|Erlotinib + chemotherapy (intercalated)|carboplatin AUC 6 on Day 1 to 21 days, paclitaxel 200 mg/m2 on Day 1 to 21 days, erlotinib 150 mg Days 2-15 for 4 cycles then erlotinib 150 mg daily until progression, withdrawal of consent, or unacceptable toxicity
9743111|NCT00295009|Active Comparator|1-Level Fusion|Spinal fusion at a single lumbar level.
9743112|NCT00295009|Experimental|1-Level ProDisc|Total disc replacement with the ProDisc device at one spinal lumbar level.
9743113|NCT00295009|Active Comparator|2-Level Fusion|Spinal fusion at two adjacent lumbar levels.
9743114|NCT00295009|Experimental|2-Level ProDisc|Total disc replacement with the ProDisc device at two adjacent lumbar levels.
9743115|NCT00295009|Experimental|1-level ProDisc (non-randomized)|Total disc replacement with the ProDisc device for non-randomized subjects at one spinal lumbar level.
9743116|NCT00295009|Active Comparator|2-Level ProDisc (Continued Access)|Total disc replacement with the ProDisc device for non-randomized subjects at two spinal lumbar levels (only followed out to 24 months)
9743117|NCT00295022|Placebo Comparator|Placebo (PBO)|Placebo was administered orally on Days 1 and 2.
9743118|NCT00295022|Experimental|Montelukast (MLKT)|10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
9743119|NCT00295022|Experimental|Levocetirizine (LCTZ)|5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.
9743120|NCT00295061|Experimental|1 Alpha-1 MP|Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP
9743121|NCT00295061|Active Comparator|2 Prolastin|Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP
9743122|NCT00295503|Experimental|1|cisplatin, pemetrexed, and bevacizumab
9743123|NCT00295620|Experimental|Arm A: Anastrozol|1 mg per day for 2 years
9743124|NCT00295620|Experimental|Arm B: Anastrozol|1 mg per day for 5 years
9743125|NCT00295633|Experimental|Saxagliptin plus open-label TZD (A)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
9743126|NCT00295633|Experimental|Saxagliptin plus open-label TZD (B)|"Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
9743127|NCT00295633|Placebo Comparator|Placebo plus open-label TZD (C)|"Placebo PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)"
9743128|NCT00295750|Experimental|degarelix 240/160 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
9743129|NCT00295750|Experimental|degarelix 240/80 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
9743130|NCT00295750|Active Comparator|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.
9743131|NCT00295854|Experimental|MN-001|
9743132|NCT00295854|Placebo Comparator|MN-001 once daily|placebo tablets
9743133|NCT00295867|Experimental|Zoledronic Acid|Patients women with early stage breast cancer and evidence of occult malignant cells in bone marrow aspirates following adjuvant chemotherapy will receive zoledronic acid (Zometa) 4mg, given intravenously over 15 minutes, once a month for two years.
9743134|NCT00295880|Experimental|Transplant Patients|Patients receiving umbilical cord blood transplantation.
9743135|NCT00295932|Experimental|Arm I|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9743136|NCT00295932|Experimental|Arm II|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9743137|NCT00296036|Experimental|Arm I (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
9743138|NCT00296036|Experimental|Arm II (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
9743139|NCT00296036|Experimental|Arm III (closed to accrual as of 10/24/2007)|Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
9743140|NCT00296036|Placebo Comparator|Arm IV (closed to accrual as of 10/24/2007)|Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
9743141|NCT00296036|Experimental|Arm V|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
9743142|NCT00296036|Placebo Comparator|Arm VI|Patients receive placebo cream applied to palms and soles twice daily on days 1-21.
9743143|NCT00296140|Other|self management of PSD symptoms|
9743144|NCT00296140|Other|screening and treatment of PSD|
9743145|NCT00296192|Placebo Comparator|Placebo 1|Placebo nasal spray 1 - 4 puffs
9743146|NCT00296192|Experimental|Rotigotine 1|Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)
9743147|NCT00296192|Experimental|Rotigotine 2|Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)
9743148|NCT00296192|Experimental|Rotigotine 3|Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)
9743149|NCT00296192|Experimental|Rotigotine 4|Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)
9743150|NCT00296231|Experimental|Nasal High Frequency Ventilation|Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.
9743151|NCT00296244|Other|Steroid -free immunosuppression|Study group - Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
9743152|NCT00296244|Other|Steroid containing immunosuppression|Control group- Basiliximab, Tacrolimus, EC-MPA, steroids
9743153|NCT00296296|Active Comparator|Cyclosporin|Patients receive cyclosporin (dose-adjusted to pre-established targets) as immunosuppressive calcineurin inhibitor (CNI) and Diabetes Education / Management (therapeutic adjustment to target American Diabetes Association (ADA) criteria)
9743154|NCT00296296|Active Comparator|Tacrolimus|Patients receive tacrolimus (dose-adjusted to pre-established targets) as CNI and Diabetes Education / Management (therapeutic adjustment to target ADA criteria)
9743155|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine|Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
9785351|NCT01249833|No Intervention|Standard of care alone|Standard of care for influenza
9743156|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine, Cisplatin|iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
9743157|NCT00296335|Active Comparator|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
9743158|NCT00296335|Experimental|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
9743159|NCT00296374|Experimental|1|Rosuvastatin 10 mg
9743160|NCT00296374|Experimental|2|Rosuvastatin 40 mg
9743161|NCT00296374|Active Comparator|3|Atorvastatin 80 mg
9743162|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)|Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD
9743163|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol (FSC)|FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD
9743164|NCT00296491|Active Comparator|Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)|Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD
9743165|NCT00296491|Active Comparator|Montelukast (MON)|Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD
9743166|NCT00296517|Placebo Comparator|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
9743167|NCT00296517|Experimental|Bupropion SR|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
9743168|NCT00296647|Active Comparator|patch|
9743169|NCT00296647|Active Comparator|nicotine lozenge|
9743170|NCT00296647|Active Comparator|bupropion|
9743171|NCT00296647|Active Comparator|patch + lozenge|
9743172|NCT00296647|Active Comparator|buproion + lozenge|
9743173|NCT00296725|Experimental|fluoxetine / Imipramine|fluoxetine or Imipramine
9743174|NCT00296816|Experimental|Oxaliplatin/Docetaxel/Bevacizumab|Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery
9743175|NCT00297037|Active Comparator|1|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
9743176|NCT00297037|Placebo Comparator|2|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
9743177|NCT00297102|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
9743178|NCT00297102|Placebo Comparator|Placebo|once daily
9743179|NCT00297115|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
9743180|NCT00297115|Placebo Comparator|Placebo|once daily
9743181|NCT00297167|Experimental|EUR-1008 (APT-1008) First, Then Placebo|
9743182|NCT00297167|Experimental|Placebo First, Then EUR-1008 (APT-1008)|
9743183|NCT00297232|Experimental|Natalizumab|300 mg intravenous (IV) infusions once every 4 weeks for up to 480 weeks
9743184|NCT00297427|Experimental|Acupuncture|Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
9743185|NCT00297427|Sham Comparator|Sham acupuncture|Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.
9743186|NCT00297479|Experimental|Mindfulness-Based Treatment Group (MBAT)|MBAT is 6 weeks of nicotine patch therapy; a Self-help guide; and In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence.
9743187|NCT00297479|Active Comparator|Standard Care Group|Standard Care Group (ST) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
9743188|NCT00297479|Active Comparator|Usual Care Group|Usual Care (UC) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
9743189|NCT00297492|Experimental|Gradual reduction|Intervention: Reduction Phone Counseling. Intervention: Pre-Quit Nicotine Lozenges. Intervention: Post-Quit Nicotine Lozenges.
9743190|NCT00297492|Active Comparator|Abrupt cessation|Intervention: Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
9743191|NCT00297492|Active Comparator|Minimal intervention|Intervention: Minimal Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
9743192|NCT00297596|Experimental|Intervention|Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days.
9743193|NCT00297648|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg
9743194|NCT00297778|Experimental|pramipexole|A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
9743195|NCT00297778|Placebo Comparator|placebo|Placebo (matching) tablets
9743196|NCT00297830|Experimental|Active Zoledronic Acid & Placebo Alendronate|Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
9743197|NCT00297830|Experimental|Placebo Zoledronic Acid & Active Alendronate|Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.
9781904|NCT01160484|Experimental|DVD-R single arm|"Dose schematic of Dexamethasone + Bortezomib + Pegylated Liposomal Doxorubicin + Lenalidomide (DVD-R) Therapy:~Dexamethasone*- 40 mg IV Bortezomib**- 1.0 mg/m2 IV Push Pegylated Liposomal Doxorubicin*- 4.0 mg/m2 IV Lenalidomide***- 10 mg PO~Per 28 Day Cycle~Intravenous infusion (IV) Days 1, 4, 8 and 11 ** Intravenous push (IVP) Days 1, 4, 8 and 11 *** Per Orem (PO) Days 1-14"
9781905|NCT01160614|Experimental|ORF Tablets|ORF Tablets
9781906|NCT01160640|Placebo Comparator|Ceftriaxone/Doxycycline/Placebo Oral Cap|ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo oral capsule PO bid x 14 days
9781907|NCT01160640|Active Comparator|Ceftriaxone, Doxycycline, Metronidazole|ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days
9781908|NCT01160744|Experimental|IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin|IMC-1121B + Pemetrexed + Carboplatin [Area Under the Concentration Time Curve 6 (AUC 6)] or Cisplatin
9781909|NCT01160744|Active Comparator|Pemetrexed + Carboplatin (AUC 6) or Cisplatin|Pemetrexed + Carboplatin (AUC 6) or Cisplatin
9781910|NCT01160744|Experimental|IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin|IMC-1121B + Gemcitabine + Carboplatin [Area Under the Concentration Time Curve 5 (AUC 5)] or Cisplatin
9781911|NCT01160744|Active Comparator|Gemcitabine + Carboplatin (AUC 5) or Cisplatin|Gemcitabine + Carboplatin (AUC 5) or Cisplatin
9781912|NCT01160770|Experimental|Clobazam|
9781913|NCT01160822|Experimental|Part A: Canakinumab|In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.
9781914|NCT01160822|Placebo Comparator|Part A: Placebo|Participants received a single intra-articular injection of canakinumab-matching placebo.
9781915|NCT01160822|Experimental|Part B: Canakinumab|Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
9781916|NCT01160822|Placebo Comparator|Part B: Placebo|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
9743198|NCT00297882|Active Comparator|1 Artemether-Lumefantrine (AL)|Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days.
9743199|NCT00297882|Active Comparator|2 Amodiaquine-Artesunate (AQ-AS)|Study group 2. Subjects in this group received treatment with Amodiaquine-Artesunate. Children received a co-administered combination of 30 mg/kg Amodiaquine (AQ) plus 4 mg/kg Artesunate (AS) daily for 3 days.
9743200|NCT00298038|Experimental|Rifaximin|Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
9743201|NCT00298038|Placebo Comparator|Placebo|Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
9743202|NCT00298090||StO2 values|StO2 monitoring
9743203|NCT00298155|Active Comparator|Group 1|Goserelin + dutasteride
9743204|NCT00298155|Active Comparator|Group 2|Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
9743205|NCT00298155|Active Comparator|Group 3|Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
9743206|NCT00298233|Active Comparator|Standard Dose oseltamivir adult cohort|All participants >= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
9743207|NCT00298233|Active Comparator|Double Dose oseltamivir Adult cohort|All participants >= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
9743208|NCT00298233|Active Comparator|Standard Dose Oseltamivir child cohort|All participants <15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
9743209|NCT00298233|Active Comparator|Double Dose Oseltamivir child cohort|All Participants <15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
9743210|NCT00298272|Experimental|Double-blind/Open Label Rituximab|"The double-blind rituximab treatment group received rituximab 500 mg by intravenous (IV) infusion on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to rituximab infusion, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
9781917|NCT01160822|Active Comparator|Part B: Naproxen|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.
9983918|NCT04543812|Experimental|PBF-1681 (ferric citrate)|PBF-1681 (ferric citrate) will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
9983919|NCT04543812|Placebo Comparator|Placebo|Matching placebo will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
9743211|NCT00298272|Other|Double-blind Placebo/Open Label Rituximab|"The double-blind placebo treatment group received saline solution IV on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to each infusion of placebo, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
9743212|NCT00298363|Experimental|Tenofovir DF|TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
9743213|NCT00298363|Experimental|FTC/TDF|FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
9743214|NCT00298363|Experimental|Entecavir|ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD
9743215|NCT00298389||Non smokers|Non smokers included no history of respiratory or allergic disease, normal baseline spirometry
9743216|NCT00298389||Smokers|Smoking history of at least 10 pack years
9743217|NCT00298389||COPD|Patients with stable COPD
9743218|NCT00298558|Active Comparator|Memory Training|Memory training focused on verbal episodic memory. Participants were taught mnemonic strategies for remembering lists and sequences of items, text material, and main ideas and details of stories and other text-based information.
9743219|NCT00298558|Active Comparator|Reasoning Training|Reasoning training focused on the ability to solve problems that follow a serial pattern. Participants were taught strategies to identify the pattern or sequence required to solve a problem.
9743220|NCT00298558|Active Comparator|Speed of Processing Training|Speed of processing training focused on visual search and the ability to identify and locate visual information quickly in a divided attention format. Participants practiced increasingly complex speeded tasks on a computer.
9743221|NCT00298558|Placebo Comparator|Control|This group did not complete any cognitive training interventions
9743222|NCT00298610|Experimental|Artesunate and Malarone|Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
9743223|NCT00298766|Experimental|1|VELCADE
9743224|NCT00298831|Experimental|Sugammadex|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was administered. At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg MK-8616 was administered.
9743225|NCT00298896|Experimental|SNS-595|SNS-595; 48 mg/m2 administered IV once every 21 days for up to 6 cycles.
9743226|NCT00299000|Other|Naglazyme, 1.0 mg/kg|Dose comparison
9743227|NCT00299000|Other|Naglazyme, 2.0 mg/kg|Dose Comparison
9743228|NCT00299104|Experimental|Rituximab (0.5 g x 2) + Methotrexate|Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
9743229|NCT00299104|Experimental|Rituximab (1.0 g x 2) + Methotrexate|Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
9743230|NCT00299104|Placebo Comparator|Placebo + Methotrexate|"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks."
9743231|NCT00299130|Active Comparator|Placebo + methotrexate (MTX)|"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
9743232|NCT00299130|Experimental|Rituximab 2 x 0.5 g + MTX|"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
9743233|NCT00299130|Experimental|Rituximab 2 x 1.0 g + MTX|"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
9743234|NCT00299156|Experimental|Oral Clofarabine|10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
9743235|NCT00299182|Experimental|1 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
9743236|NCT00299182|Experimental|3 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
9517314|NCT03307447|Experimental|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
9743237|NCT00299182|Experimental|10 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
10201044|NCT04916847||Children attending consultation|"Children over 0 days and under 16 years old, without immunodepression or chronic inflammation attending consultation for :~preoperative assessment~-congenital abnormalities of the kidney and urinary tract:~Nephropathies without renal impairment (eDFG > 45mL/min/1.73m2)~Non-inflammatory intestinal (polyposis, Chronic intestinal pseudo-obstruction, short bowel syndrome) or pancreatic (hereditary pancreatitis) pathologies This group of children will be a control group (age matched healthy children, non-immunosuppressed)."
10201045|NCT04915534|Other|Women - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
9743238|NCT00299182|Placebo Comparator|Placebo (Arm A & Arm B) with Chemotherapy|"Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy~Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
9743239|NCT00299182|Experimental|1 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
9743240|NCT00299182|Experimental|3 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
9743241|NCT00299182|Experimental|10 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
9743242|NCT00299221|Active Comparator|Monotherapy|Tacrolimus alone
9743243|NCT00299221|Active Comparator|Combination therapy|tacrolimus with mycophenolate mofetil
9743244|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR)|Follicular
9743245|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL)|Diffuse Large B-cell Lymphoma
9743246|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY)|Refractory Aggressive NHL
9743247|NCT00299546|Placebo Comparator|Group 1: Placebo|Placebo Subcutaneous (SC) injections every 4 weeks (wks) thru Wk 20 (unless early escape at Wk 16); Golimumab - if early escape, 50 mg SC injections from Wk 16 up to 5 yrs; Golimumab - 50 mg SC injections beginning Wk 24 up to 5 yrs (unless early escape); Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
9743248|NCT00299546|Experimental|Group 2: Golimumab 50 mg|Golimumab 50 mg SC injections every 4 wks from Wk 0 up to 5 yrs (unless early escape at Wk 16); Golimumab - if early escape, 100 mg SC injections every 4 wks beginning Wk 16 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
9743249|NCT00299546|Experimental|Group 3: Golimumab 100 mg|Golimumab 100 mg SC injections every 4 wks from Wk 0 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50 mg. Duration of the blinded period will be until the week-24 database lock.
9743250|NCT00299689|Experimental|Intervention|Single-arm: Ontak
9743251|NCT00299702|Active Comparator|002|
9743252|NCT00299702|Experimental|001|
9743253|NCT00299741|Experimental|1|Sunitinib
9743254|NCT00299975|Experimental|MaZiRenWan (MZRW) Low dose|MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
9743255|NCT00299975|Experimental|MaZiRenWan (MZRW) Median dose|MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
9743256|NCT00299975|Experimental|MaZiRenWan (MZRW) High dose|MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
9743257|NCT00299988|Experimental|IVIG|ivig
9743258|NCT00299988|Placebo Comparator|Placebo|
9743259|NCT00300053|Experimental|CLBS14: Low-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 1 x 10^5 (=100000) cells/kg bodyweight
10201046|NCT04915534|Other|Men - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
10201047|NCT04915534|Other|Women - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
10201048|NCT04915534|Other|Men - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
10201049|NCT04904601|Active Comparator|Experimental Group: Kale|This group will be given one scoop of powder of (Kale) three times a day for a total of 10g/day for 6 weeks.
10201050|NCT04904601|Placebo Comparator|Placebo Group: Green Peas|This group will be given one scoop of powder of (Green Peas) three times a day for a total of 10g/day for 6 weeks.
10201051|NCT04894071|Experimental|QA102 group|
10201052|NCT04894071|Placebo Comparator|Placebo group|
9743260|NCT00300053|Experimental|CLBS14: High-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 5 x 10^5 (=500000) cells/kg bodyweight
9743261|NCT00300053|Placebo Comparator|Placebo injection|10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma
9743262|NCT00300235||1|200 subjects ages 5 to 9.9 years with a diagnosis of HbSS/HbSβ0
9743263|NCT00300235||2|400 subjects ages 10 to 14.9 years with a diagnosis of HbSS/HbSβ0
9743264|NCT00300235||3|400 subjects ages 15 to 24.9 years with a diagnosis of HbSS/HbSβ0
9743265|NCT00300235||4|400 subjects over the age of 25 with a diagnosis of HbSS/HbSβ0
9743266|NCT00300235||5|250 subjects age 15 and older with a diagnosis of HbSC or HbSβ+
9743267|NCT00300274|Experimental|everolimus 1.5 mg|Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
9743268|NCT00300274|Experimental|everolimus 3.0 mg|"Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.~Randomization of new patients in this arm was prematurely stopped as of 27 March 2008 due to high mortality rate, as per Data Monitoring Committee."
9743269|NCT00300274|Active Comparator|mycophenolate mofetil|Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.
9743270|NCT00300365|Experimental|Active Pioglitazone + Open-Label Niacin|Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
9743271|NCT00300365|Placebo Comparator|Placebo +Open-Label Niacin|Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin
9743272|NCT00300391|Experimental|haloperidol|Once diagnosed as delirious, randomized to haloperidol 5 mg IV
9743273|NCT00300391|Placebo Comparator|placebo|once diagnosed as delirious, received 5 mg saline placebo
9743274|NCT00300430|Active Comparator|A|20 mg drug and ABT-335
9743275|NCT00300430|Active Comparator|B|40 mg drug and ABT 335
9743276|NCT00300430|Active Comparator|C|40 mg drug and ABT-335
9743277|NCT00300456|Active Comparator|A|ABT-335 + 20 mg simvastatin
9743278|NCT00300456|Active Comparator|B|ABT-335 + 40 mg simvastatin
9743279|NCT00300456|Placebo Comparator|C|ABT-335 monotherapy
9743280|NCT00300456|Placebo Comparator|D|20 mg simvastatin monotherapy
9743281|NCT00300456|Placebo Comparator|E|40 mg simvastatin monotherapy
9743282|NCT00300456|Placebo Comparator|F|80 mg simvastatin monotherapy
9743283|NCT00300469|Active Comparator|A|ABT-335 + 20 mg atorvastatin
9743284|NCT00300469|Active Comparator|B|ABT-335 + 40 mg atorvastatin
9743285|NCT00300469|Placebo Comparator|C|ABT-335 monotherapy
9743286|NCT00300469|Placebo Comparator|D|20 mg atorvastatin monotherapy
9743287|NCT00300469|Placebo Comparator|E|40 mg atorvastatin monotherapy
9743288|NCT00300469|Placebo Comparator|F|80 mg atorvastatin monotherapy
9743289|NCT00300482|Active Comparator|A|ABT-335 + 10 mg rosuvastatin
9743290|NCT00300482|Active Comparator|B|ABT-335 + 20 mg rosuvastatin
9743291|NCT00300482|Placebo Comparator|C|ABT-335 monotherapy
9743292|NCT00300482|Placebo Comparator|D|10 mg rosuvastatin monotherapy
9743293|NCT00300482|Placebo Comparator|E|20 mg rosuvastatin monotherapy
9743294|NCT00300482|Placebo Comparator|F|40 mg rosuvastatin monotherapy
9743295|NCT00300495|Experimental|1 - Amiodarone|Perioperative amiodarone
9743296|NCT00300495|Active Comparator|2 - Control|Control arm, standard care with no perioperative amiodarone
9743297|NCT00300677|Experimental|voriconazole|voriconazole twice daily
9743298|NCT00300742|Experimental|Topiramate|Drug: Topiramate Other Name for Topiramate: Topamax
9743299|NCT00300755|Active Comparator|1|Arm 1- Low Dose pantoprazole
9743300|NCT00300755|Active Comparator|2|Arm 2- Medium Dose pantoprazole
9743301|NCT00300755|Active Comparator|3|Arm 3- High Dose pantoprazole
9743302|NCT00300781|Experimental|Neratinib 240 mg, with prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
9743303|NCT00300781|Experimental|Neratinib 240 mg, no prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
9743304|NCT00300885|Experimental|Sorafenib + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
9743305|NCT00300885|Active Comparator|Placebo + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
9743306|NCT00301028|Experimental|Cetuximab + Carboplatin/Paclitaxel|Cetuximab beginning weekly dose 400 mg/m^2 intravenous (IV), and 250 mg/m^2 weeks 2-6; Weekly Carboplatin area under the curve (AUC) 2 and Paclitaxel 135 mg/m^2 for 6 courses.
9743307|NCT00301067|Experimental|Cohort 1 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.2 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
9743308|NCT00301067|Experimental|Cohort 2 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.3 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
9743309|NCT00301067|Experimental|Cohort 3 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
9743310|NCT00301067|Experimental|Expansion - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
9743311|NCT00301366|Experimental|Alpha-1 Proteinase Inhibitor (Human), modified process|Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.
9743312|NCT00301418|Experimental|Tarceva (Erlotinib)|
9743313|NCT00301756|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9743314|NCT00301808|Experimental|Cisplatin, Docetaxel & Radiation Therapy|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43; Docetaxel 75 mg/m2 on day 1 of each cycle; Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
9743315|NCT00301821|Experimental|Epratuzumab + Rituximab + CHOP|One arm open label.
9743316|NCT00301834|Experimental|Single arm - conditioning and transplant|Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m*2 on day +1, 10 mg/m*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.
9743317|NCT00301873|Experimental|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
9743318|NCT00301964|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
9743319|NCT00302003|Experimental|Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim|Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 & 2, Vincristine sulfate IV (1.4 mg/m2 [max 2.8 mg]) Days 1 & 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 & 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.
9743320|NCT00302042|Experimental|1: Brief Counseling Plus Group Lifestyle|Brief counseling plus group diabetes prevention in community
9743321|NCT00302042|Active Comparator|2: Brief Counseling Alone|Brief Counseling for pre-diabetes alone
9743322|NCT00302055|Active Comparator|one-on-one lifestyle|Clinical referral to diabetes prevention lifestyle intervention at School of Medicine campus
9743323|NCT00302055|Experimental|group-based community lifestyle|Clinical referral to group diabetes prevention lifestyle intervention program in community
9743324|NCT00302068|Experimental|1|Supervised aerobic exercise, three times per week for 16 weeks.
9743325|NCT00302068|Active Comparator|2|Sertraline (Zoloft), for 16 weeks.
9743326|NCT00302068|Placebo Comparator|3|Placebo control, for 16 weeks.
9743327|NCT00302081|Active Comparator|PEG2b 1.5/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks
9743328|NCT00302081|Experimental|PEG 2b 1.0/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks
9743329|NCT00302081|Experimental|PEG2b 1.5/R (16 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks
9743330|NCT00302107|Active Comparator|Arm 1|Mirtazapine
9743331|NCT00302107|Placebo Comparator|Arm 2|Placebo
9743332|NCT00302133|Experimental|Naltrexone add on to valproate|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks add on to valproate
9743333|NCT00302133|Placebo Comparator|Placebo add on to valproate|Placebo comparator one capsule daily for 12 weeks add on to valproate
9743334|NCT00302159|Experimental|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
9743335|NCT00302211|Experimental|DB inhaled iloprost 6x/day|inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the double blind period
9743336|NCT00302211|Experimental|DB inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4×/day plus inhaled placebo 2x/day plus sildenafil with or without bosentan during the double blind period
9743337|NCT00302211|Placebo Comparator|DB inhaled placebo 6x/day|Inhaled placebo 6×/day plus sildenafil with or without bosentan during the double blind period
9743338|NCT00302211|Experimental|OL inhaled iloprost 6x/day|Inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
9743339|NCT00302211|Experimental|OL inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4 times per day (4×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
9743340|NCT00302328|No Intervention|macular hole operation no peeling|
9743341|NCT00302328|Active Comparator|Macular hole operation ICG peeling|
9743342|NCT00302328|Experimental|Macular hole operation TB peeling|
9743343|NCT00302458|Experimental|OROS-MPH + OROS-MPH|OROS-Methylphenidate Will be administered during the first part of the day, and again during the separate part of the day.
9743344|NCT00302458|Experimental|IR MPH + IR MPH|Immediate release methylphenidate will be administered in the first part of the day followed by Immediate release methylphenidate in the second part of the day.
9743345|NCT00302458|Placebo Comparator|Plabebo + Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
9743346|NCT00302458|Experimental|OROS MPH+ IR MPH|Concerta will be administered in the first part of the day, followed by Immediate Release Methylphenidate in the second part of the day.
9743347|NCT00302458|Experimental|IR MPH + OROS MPH|Immediate release Methylphenidate will be administered in the first part of the day, followed by Concerta in the second part of the day
9743348|NCT00302718|Experimental|Physician-level incentives|Examines the effect of physician-level financial incentives on hypertension quality of care
9743349|NCT00302718|Experimental|Practice-level incentives|Examines the effect of practice-level financial incentives on hypertension quality of care
9743350|NCT00302718|Experimental|Physician- and practice-level incentives|Examines the effect of physician- and practice-level financial incentives on hypertension quality of care
9743351|NCT00302718|No Intervention|No incentives (control)|Physician participants in this arm received only audit and feedback performance reports as did the participants in the intervention arms.
9743352|NCT00302731|Active Comparator|1 equine estrogens m-progesteroneacetate|Menopausal women in first seven years of menopause randomized to arm 1 receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
9743353|NCT00302731|Experimental|2 estradiol estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 2 estradiol .5mg, estriol 2.0mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
9743354|NCT00302731|Experimental|4 estradiol progesterone|Menopausal women in first seven years of menopause randomized to arm 4 estradiol 0.5 mg, progesterone 100 mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
9743355|NCT00302731|Experimental|3 estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 3 estriol 2.5mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
9743356|NCT00302848||Users of Drospirenone (DRSP)|
9743357|NCT00302848||Users of Levonorgestrel (LNG)|
9743358|NCT00302848||Users of other oral contraceptives (OCs)|
9743359|NCT00302952|Experimental|Lovastatin|Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D&C Yellow #10, FD&C Blue #1, and Yellow #6 were added as dyes.
9743360|NCT00302952|Placebo Comparator|Placebo|Participants are randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188.
9743361|NCT00303069|Experimental|V710 5 μg|V710 S. aureus vaccine
9743362|NCT00303069|Experimental|V710 30 μg|V710 S. aureus vaccine
10201053|NCT04893161|Other|belimumab|All patients with SLE receive belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48. The patients who had SRI-4 response at week 48 were divided into response group and the patients without SRI-4 response at week 48 were divided into no response group.
9743363|NCT00303069|Experimental|V710 90 μg|V710 S. aureus vaccine
9743364|NCT00303069|Placebo Comparator|Placebo|Placebo
9743365|NCT00303108|Experimental|Arm 1|Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.
9743366|NCT00303316|Experimental|DTacP IPV HepB PRP-T Combined Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.
9743367|NCT00303316|Active Comparator|PENTAXIM™ and ENGERIX B® Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)
9743368|NCT00303329|Experimental|Deferasirox|Deferasirox daily oral dose between 5-40 mg/kg/day
9743369|NCT00303446|Active Comparator|Dutasteride|Dutasteride 0.5 mg/day
9743370|NCT00303446|Placebo Comparator|Placebo|Matched placebo
9743371|NCT00303459|Experimental|A|Bosentan
9743372|NCT00303459|Placebo Comparator|B|Placebo
9743373|NCT00303472|Experimental|Part A: 300 µg romiplostim|Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
9743374|NCT00303472|Experimental|Part A: 700 µg romiplostim|Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
9743375|NCT00303472|Experimental|Part A: 1000 µg romiplostim|Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
9743376|NCT00303472|Experimental|Part A: 1500 µg romiplostim|Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
9743377|NCT00303472|Experimental|Part B: 750 µg romiplostim SC QW|Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
9743378|NCT00303472|Experimental|Part B: 750 µg romiplostim SC Q2W|Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.
9517315|NCT03307434|Experimental|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
9743379|NCT00303472|Experimental|Part B: 750 µg romiplostim IV Q2W|Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.
9743380|NCT00303485|Experimental|Ibandronate|Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
9743381|NCT00303485|Placebo Comparator|Placebo|Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.
9743382|NCT00303602|Experimental|A|Sublingual orally disintegrating olanzapine (SODO)
9743383|NCT00303602|Active Comparator|B|Oral olanzapine
9743384|NCT00303628|Active Comparator|Arm I|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses.
9743385|NCT00303628|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I.
10201054|NCT04890028|Experimental|F-DOPA PET/CT|Drug: 18 F-DOPA Radiation: F-DOPA PET CT
10201055|NCT04877054|Experimental|Intervention Arm|Intervention sessions will occur ~once per week, with all 4 sessions being completed within 4-8 weeks. Each session will include an education and motivational interviewing (MI) component.
10201056|NCT04877054|Active Comparator|Education only Arm|Participants in the education-only control arm will receive one education session. The education session will occur via telephone or telehealth. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
10201057|NCT04876794|Experimental|Arm 1|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
10201058|NCT04871165||Oncohematological patient group|Patients with prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
10201059|NCT04871165||Healthy control group|Subjects without prior diagnosis of oncohematological disease vaccinated with SARS-CoV-2 vaccine.
10201060|NCT04857385|Active Comparator|Terumo TR Band|Physical standard of care radial hemostasis device.
10201061|NCT04857385|Experimental|StatSeal|Potassium-ferrate based chemical hemostasis device.
10201062|NCT04857385|Experimental|Axiostat|Chitosan based biological hemostasis device.
10201063|NCT04842006|Experimental|TNT + precision|
10201064|NCT04842006|Active Comparator|Conventional|
9743386|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - short schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 40mg/m^2), cyclophosphamide (administered on Day -15 only), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
9743387|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - extended schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 35mg/m^2), cyclophosphamide (administered on Days -15 and -16), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
9743388|NCT00303719|Experimental|High Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
9743389|NCT00303719|Experimental|Standard Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
9743390|NCT00303823|Experimental|Arm I|Patients receive oral green tea extract once daily for 16 weeks in the absence of unacceptable toxicity.
9743391|NCT00303823|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 16 weeks in the absence of unacceptable toxicity.
9743392|NCT00303862|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
9743393|NCT00303901|Experimental|cryosurgery|cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
9743394|NCT00303953|Experimental|Arm I|"Patients will receive an infusion of PXD101 once a day for 5 days. Treatment may repeat every 3 weeks for up to 2 years. Some patients will also undergo core biopsy and blood collection for laboratory studies before and after treatment.~After finishing treatment, patients will be evaluated every 3-6 months for up to 3 years."
9743395|NCT00303966|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9743396|NCT00303979||Cohort A (longitudinal)|Longitudinal Cohort: Approximately 15,000 patients followed at baseline, 12 months and 24 months
9743397|NCT00303979||Cohort B (6 Month)|6 Month Cohort: Approximately 10,000 patients reviewed at single time point
9743398|NCT00303979||Cohort C (18 Month)|18 Month Cohort: Approximately 10,000 patients reviewed at single time point
9743399|NCT00304031|Active Comparator|Conventional adjuvant TMZ|Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.
9743400|NCT00304031|Experimental|Dose-dense adjuvant TMZ|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.
9743401|NCT00304031|Other|No adjuvant TMZ (not randomized )|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.
9743402|NCT00304083|Experimental|Chemotherapy and local control by radiotherapy and surgery|Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.
9743403|NCT00304083|Experimental|Chemotherapy and local control by surgery|Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.
9743404|NCT00304096|Experimental|Stratum 1: Receiving Hormone Therapy|Patients treated with 9 peptide vaccine who received hormone therapy
9743405|NCT00304096|Experimental|Stratum 2: Not receiving hormone therapy|Patients receiving 9 peptide vaccine who did not receive hormone therapy
9743406|NCT00304161|Active Comparator|Atomoxetine|Participants will receive 40-80mgs of atomoxetine orally once daily.
9743407|NCT00304161|Placebo Comparator|Placebo|Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.
9743408|NCT00304187|Experimental|Erythromycin|Subjects with Bulimia Nervosa will take erythromycin.
9743409|NCT00304187|Placebo Comparator|Placebo|Participants will take matched placebo.
9743410|NCT00304265|Experimental|6th Dose Pertussis Vaccine Group|Participants received 6th dose of pertussis vaccine
9983920|NCT04543682|Experimental|First intervention group (0.125 ng/kg/min Iloprost)|The first intervention group will receive open reduction and internal fixation with an angular stable plate (PHILOS, Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.125 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter will be inserted during the surgical procedure. Infusion of Iloprost will start 24hrs post-operatively and the dose will be delivered over 24h.
9743411|NCT00304265|Experimental|5th Dose Pertussis Vaccine Group|Participants received 5th dose of pertussis vaccine
9743412|NCT00304278|Experimental|RADPLAT and Tarceva|"All patients will receive RADPLAT and Tarceva:~Drug: Erlotinib (Tarceva)~150 mg daily X 7 weeks~Other Names:~Tarceva~Drug: Intra-arterial Cisplatin (PLAT)~1 dose (150 mg/sq) per week X 4 weeks~Other Names:~Cisplatin~Radiation: Radiation Therapy (RAD)~5 days per week X 7 weeks"
9743413|NCT00304356|Other|active drug|500 mg nitazoxanide bid given to patient
9743414|NCT00304512|Experimental|Migalastat Low Dose 50 mg|Migalastat 50 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
9743415|NCT00304512|Experimental|Migalastat Middle Dose 150 mg|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
9743416|NCT00304512|Experimental|Migalastat High Dose 250 mg|Migalastat 250 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
9743417|NCT00304707|Experimental|2|participants in this arm receive bupropion
9743418|NCT00304707|Placebo Comparator|1|placebo
10201065|NCT04840836||Telehealth-supported LARC provision|"Patients who receive care at the SBHC provide informed consent for care, as well as record review for quality assurance purposes. Analyses will include female patients who have a reproductive health visit, which includes contraceptive counseling, contraceptive management, or contraceptive method initiation, during the study period. Patients who have a telehealth consultation with a SBHC medical provider for LARC services (conservatively estimated n=113) will be considered enrolled patients once the data are extracted from the EHR."
9743419|NCT00304746|Active Comparator|testosterone gel|AndroGel (1% testosterone transdermal gel), 2.5 g to 10 g daily
10201066|NCT04830852||Recovery Group|Participants aged 21 years and younger and enrolled within 12 weeks after acute infection or positive test. These participants will attend study visits at baseline, every 3 months for the first 6 months, and subsequently every 6 months for a total of 3 years.
9743420|NCT00304746|Placebo Comparator|placebo gel|Placebo gel
9743421|NCT05267847|Experimental|Cryotherapy during inferior alveolar nerve block|
9743422|NCT05267847|Active Comparator|Inferior alveolar nerve block|
9743423|NCT05267808||Obstructive sleep apnea patients eligible for DISE|Patients with obstructive sleep apnea (AHI>=5) will be included in the study. Subjects should be eligible for drug-induced sleep endoscopy as the next step in their clinical path.
9781918|NCT01160848|Other|Part 1|Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
9781919|NCT01160848|Other|Part 2|For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
9781920|NCT01161043|Experimental|Sensor|All subjects that wear sensors (all subjects)
9781921|NCT01161121|Experimental|Adenosine then Regadenoson|Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.
9781922|NCT01161160|Experimental|AREPANRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
9781923|NCT01161160|Experimental|PANDEMRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Pandemrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
9781924|NCT01161160|Experimental|AREPANRIX GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
9781925|NCT01161173||Erlotinib|Participants received erlotinib (Tarceva) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. The recommended daily dose of erlotinib is 150 mg orally once daily.
10201067|NCT04830852||Convalescent Group|Participants aged 21 years and younger and enrolled more than 12 weeks after acute infection or positive test. These participants will attend study visits at baseline and subsequently every 6 months for a total of 3 years.
9781926|NCT01161225|Experimental|peer-led asthma self-managment program|
9781927|NCT01161225|Active Comparator|Adult-led asthma self-management program|
9743424|NCT05267795|Experimental|Operationalization|The experiment used a 2x2 within-subjects design in which participants either listened to music or underwent a silent control period and either performed an active foot tapping task, or a passive control task with no movement resulting in four experimental trial types: (a) Music Active (music with tapping); (b) Music Passive (music without tapping); (c) Silence Active (silence with tapping); and (d) Silence Passive (silence without tapping). The allocation of the music excerpts to the task (active, passive) was random, and the order of the four experimental trial types was counterbalanced.
9743425|NCT05267769|Experimental|Verum|AP707 single dose oromucosal application
9743426|NCT05267743|Experimental|Tegoprazan 50mg QD|Tegoprazan 50mg tablet, once daily, oral administration
9743427|NCT05267743|Active Comparator|Lansoprazole 30mg QD|Lansoprazole 30mg capsule, once dauly, oral administration
9743428|NCT05267730|Experimental|Modern board and card games group|"Conectar Jugando Game Program: The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Kaleidos Junior (Albertarelli, 1997), Sherlock Express (Kermarrec, 2019), Alles Kanone! (Knizia, 2007), Halli Galli (Shafir, 1990), Bananazul (Warsch, 2019), Blurble (Bernard, 2013), La Morada Maldita (Ortiz, 2020), Dice Academy (Gobert, 2019) and Streams (Itsubaki, 2011). Play sessions will be held in subgroups of 3-5 children within the class group. In each session, each subgroup will play two games. The games used in the program have an average duration of approximately 20-30 minutes (filler games).~All subgroups will play all games in the program the same number of times with the same rules. The game program will be the same in all participating centers to guarantee the homogeneity of its implementation"
9743429|NCT05267730|No Intervention|Wait-list group|Wait-list. They will do the usual classes without modern board games. At the end of the postintervention evaluation, the Conectar Jugando Game Program will be implemented under the same conditions as the experimental group.
9743430|NCT05267717||Control/Normal (no-pessary) group|"All participants will must meet the criteria in order to be eligible: a singleton gestation, pregnant women recruited between 18+0 - 24+6 weeks of gestation, maternal age ≥18 years, the ability to sign approved consent form to participate in the study.~Moreover for a normal cohort are being enrolled only asymptomatic pregnant women with no risk factors for spontaneous preterm birth"
9743431|NCT05267717||Pessarry group|"All participants will must meet the criteria in order to be eligible: a singleton gestation, pregnant women recruited between 18+0 - 24+6 weeks of gestation, maternal age ≥18 years, the ability to sign approved consent form to participate in the study.~Moreover both for a pessary cohort additional cohort-specific criteria need to be met. Those are: suspected short cervix and confirmotian with transvaginal ultrasound - TVUS (CL < 3rd percentile at gestational age at measurement) according to Salomon at al."
9743432|NCT05267704|Experimental|VR Arm|Pediatric patients age 5-17 using the VR headset during renal biopsy.
9743433|NCT05267691||sun-protected|All patients with basal cell carcinoma in a sun protected body site
9743434|NCT05267691||sun-exposed|All patients with basal cell carcinoma in a sun exposed body site
9743435|NCT05267678||Pregnant women with history of recurrent miscarriage|
9743436|NCT05267665|Experimental|BFI|Family members in this arm receive the 2-session BFI intervention.
9743437|NCT05267665|No Intervention|No BFI|Family members in this arm do not receive the BFI sessions
9743440|NCT05267587|Experimental|Hypofractionated Stereotactic Radiosurgery prior to resection|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected on Days 1-3 (3 consecutive days). If there are additional non index brain metastasis, they will be treated with standard stereotactic radiosurgery at the time of fSRS. Participants will then undergo stereotactic craniotomy for surgical resection of the index metastasis within 5 days following completion of fSRS.
9743441|NCT05267535|Experimental|Piromelatine 20 mg|Piromelatine 20 mg tablets once daily taken before going to bed, preferably between 2100h and 2300h, and after food consumption.
9743442|NCT05267535|Placebo Comparator|Placebo|Matched placebo tablets, with identical features to the piromelatine tablets, will be used as control treatment
9743443|NCT05267522|Experimental|Egg Diet|Egg diet, contains 2 eggs per day and limits saturated fat to 6% of energy intake. Cholesterol intake is 600mg/day. Protein and carbohydrate levels will be maintained at 20% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
9743444|NCT05267522|Active Comparator|Egg-free Diet|Egg-free diet, limits cholesterol to 300 mg/day (no eggs) with saturated fat intake at 12% of energy intake. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
9743445|NCT05267522|Active Comparator|Control Diet|Comparator diet based on the average Australian diet, limited to 1 egg per week, with saturated fat intake at 12% of energy intake. Cholesterol intake is 600 mg/day. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
9743446|NCT05267457||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
9781928|NCT01161329|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
9517316|NCT03307434|Active Comparator|control group|control group is composed of athletes will be continued their regular training
9743447|NCT05267457||Healthy pregnant women|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
9743448|NCT05267418|Active Comparator|automated nasal oxygen titration with FreeO2 alone|The participant received automated nasal oxygen titration administered by a closed loop system (FreeO2) during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). The objective of this system is maintain SpO2 a the pre-specified target level (94% in this study) with an automatic adjustment of oxygen flow second by second.
9743449|NCT05267418|Active Comparator|automated nasal oxygen titration with FreeO2 with high-flow nasal O2 therapy|In addition to nasal oxygen titration administered by a closed loop system (FreeO2), the participant received high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula during the 3-min CSST and endurance shuttle walking test.
9743450|NCT05267418|Active Comparator|Fixed-flow oxygen therapy|The participant received oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT). In patients already on home oxygen, the O2 flow during exercise was set at 1 L/min above the usual flow used at home .
9743451|NCT05267392|Experimental|Durvalumab|All subjects enrolled in the study will receive open-label neoadjuvant durvalumab 1500 mg followed by standard of care RT/RCT
9743452|NCT05267379||PEP patients|Patients who develop PEP
9743453|NCT05267379||Control cohort|Patients who do not develop PEP
9743454|NCT05267366|Experimental|Chemothreapy with PD-1 inhibitor and bevacizumab|PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Carboplatin 5 AUC /cisplatin 75 mg/m2, iv day 1 Pemtrexed 500 mg/m2, iv day 1 Bevacizumab 15 mg/m2, iv day 1 as induction therapy every 21 days a cycle for 4 cycles, PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Bevacizumab 15mg/m2, iv day 1 every 21 days a cycles as maintenance treatment for 31 cycles or 2 years.
9743455|NCT05267366|Active Comparator|Chemothreapy with PD-1 inhibitor|PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Carboplatin 5 AUC /cisplatin 75 mg/m2, iv day 1 Pemtrexed 500 mg/m2, iv day 1 as induction therapy every 21 days a cycle for 4 cycles, PD-1 inhibitor (pembrolizumab) 200mg iv day 1 every 21 days a cycles as maintenance treatment for 31 cycles or 2 years.
9743456|NCT05267353|No Intervention|Usual care|All patients received care as usual. Patients receive wound care and pain management post-surgery. Before RT, generally advising to do neck stretch and mouth opening exercises. Telephone follow-up was not provided to usual care group. Furthermore, patients in usual care group went to receive physical therapy were free to do. During the follow-up period, well-trained research nurses (assessors) recorded their physical therapy sections.
9743457|NCT05267353|Experimental|Exercise intervention programs|Based on our previous literature review, we will have two major parts of exercises in our intervention: (1) Upper Body Exercise (stretching in shoulder and neck, and mouth-opening); and (2) General Physical Function Training.
9743458|NCT05267340|Experimental|Experimental: TARA Training|"Behavioral: Training for Awareness, Resilience, and Action (TARA)~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)"
9743459|NCT05267340|Active Comparator|Control: Psycho-Education|"Behavioral: Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components"
9743460|NCT05267314|No Intervention|standard therapy|standard therapy
9743461|NCT05267314|Experimental|exerciser and standard therapy|exerciser and standard therapy
9743462|NCT05267301|Experimental|AlmgaPL|New consumers of iwi self-elected to start taking 2 capsules a day with 1000 mg of AlmegaPL, containing 250 mg of eicosapentaenoic acid (EPA), 150 mg polar lipids and 15 mg chlorophyll.
9743463|NCT05267288|Experimental|afatinib plus bevacizumab|afatinib 40mg oral continually bevacizumab 15mg/kg, iv day 1, every 21days until disease progression, untolerated toxicities of patient death.
9743464|NCT05267275|Experimental|extended resection with splenic flexure mobilization|
9743465|NCT05267262|Experimental|Cohort 1(Alport Syndrome Patients)|R3R01 administered orally as 200 mg tablets twice daily for the first 7 days, followed by 100 mg twice daily for the remaining 77 days
9743466|NCT05267262|Experimental|Cohort 2(Focal Segmental Glomerulosclerosis Patients)|R3R01 administered orally as 200 mg tablets twice daily for the first 7 days, followed by 100 mg twice daily for the remaining 77 days
9743467|NCT05267249|Experimental|Autotransplantation|Autotransplantation and apicoectomy of mature teeth
9743468|NCT05267223||Individuals with Paraplegia|After screening the participants according to the inclusion/exclusion criteria, informed consent will be obtained from all the selected participants. Their demographic details will be obtained and asked for their comfortable time for the interview. Data will be collected by in-depth face to face, semi- structured interviews. Audio/video recording of the interview will be taken & it will be written in English and will be transcribed verbatim also manual notes will be prepared for their analysis after the interview is conducted
10201068|NCT04830852||Healthy contacts|Individuals (aged ≤21 years) without a diagnosis of SARS-CoV-2 infection or current symptoms suggestive of COVID-19 will serve as a control group and will attend visits for evaluations and sample collection at baseline and every 12 months for a total of 3 years.
10201069|NCT04830852||Parents/guardians of participants|Parents or guardians of participants in all cohorts will also be enrolled for limited participation to complete questionnaires about how the family is impacted by the participant's health and SARS-CoV-2.
10201070|NCT04810520||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
9743469|NCT05267197||3D Telemedicine|Clinical consultation conducted with 3D Telemedicine
9743470|NCT05267197||2D Telemedicine|Clinical consultation conducted with 2D Telemedicine
10201071|NCT04810520||Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed without tele-supervision.
10201072|NCT04809246|No Intervention|Standard of care|The first group (n=240) of participants enrolled in the study will be assigned to the control period to receive the standard of care.
10201073|NCT04809246|Experimental|'One-stop-shop' intervention|Following the control period, the second group (n=300) of participants enrolled in the study will be assigned to the intervention period to receive the 'one-stop-shop' intervention.
10201074|NCT04797715|Experimental|AXS-05|Up to 26 weeks in double-blind period
9743473|NCT05267171|Experimental|Intervention group|
9743474|NCT05267171|No Intervention|Control group|
9743475|NCT05267145|Experimental|the blood storage bag contains blood preservation solution III|a blood storage bag containing blood preservation solution III preserves the washed RBC
9743476|NCT05267145|No Intervention|empty blood bag to store washed RBC|an empty blood storage bag preserves the washed RBC
9743477|NCT05267132|Experimental|Kindness to Others with Reflection|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others and will also complete a reflection component. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day. At the end of each intervention week, they will be asked to reflect upon their experience of performing kind acts for others.
9743478|NCT05267132|Active Comparator|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
9743479|NCT05267132|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
9743480|NCT05267119||Hijab|Women wearing hijab whose scalp sample was taken for microbiome analysis
9743481|NCT05267119||No hijab|Women not wearing hijab whose scalp sample was taken for microbiome analysis
9743482|NCT05267093|Experimental|Acupuncture group|
9743483|NCT05267093|Placebo Comparator|Sham acupuncture group|
9743484|NCT05267067|Active Comparator|manual respirtory exercises|Using manual traditional respiratory exercises.
9743485|NCT05267067|Active Comparator|Respiratory exercises with respiratory pressure meter|Using pressure respiratory meter in exercises.
9743486|NCT05267054|Experimental|Cohort 1 (participants with PD-L1 positive on the surface of tumor cells)|participants will receive ociperlimab in combination with tislelizumab
9743487|NCT05267054|Experimental|Cohort 2 (participants with PD-L1 negative on the surface of tumor cells|participants will receive ociperlimab in combination with rituximab
9743488|NCT05267028||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
9743489|NCT05267028||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
9743490|NCT05267015|Active Comparator|coronally advanced flap with connective tissue graft|After randomization a subepithelial connective tissue graft along with coronally advanced flap is applied to one maxillary quadrant to cover the recession.
9743491|NCT05267015|Experimental|coronally advanced flap with platelet rich fibrin membranes|After randomization platelet rich fibrin membranes along with coronally advanced flap are applied to the other maxillary quadrant to cover the recession.
9743492|NCT05267002|Experimental|Suture removal at 1 week|Cutaneous nylon suture removal of half of the split-scar at one week.
9743493|NCT05267002|Experimental|Suture removal at 2 weeks|Cutaneous nylon suture removal of half of the split-scar at two weeks.
9743494|NCT05266989||Fibromyalgia|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
10201075|NCT04797715|Placebo Comparator|Placebo|Up to 26 weeks in double-blind period
10201076|NCT04784806|Experimental|Consumption of ground beef|Consuming 106g of cooked ground beef (85% lean) to deliver 20g of protein.
10201077|NCT04784806|Experimental|Consumption of ground pork|Consuming 118g of cooked ground pork (72% lean) to deliver 20g of protein.
10201078|NCT04784806|Experimental|Consumption of tofu burger|Consuming 113g of cooked tofu to deliver 20g of protein.
10201079|NCT04784806|Experimental|Consumption of Beyond Meat burger|Consuming 113g of Beyond Meat burger to deliver 20g of protein.
10201080|NCT04760808||AIS group|
10201081|NCT04760808||Control Group|
10201082|NCT04748861|Experimental|Indoor Cycling (IC)|Participants will engage in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) 3x/week (minimum 90 minutes/week) for 18 months.
10201083|NCT04748861|No Intervention|Usual and Customary Care (UCC)|Participants engage in their habitual level of physical activity.
10201084|NCT04735185|Active Comparator|Intradiscal autologous stem cells|Participants in this arm will have autologous stem cells harvested through bone marrow aspiration. The stem cells that were harvested will be processed and injected into affected intradiscal spaces in the lumber spine.
10201085|NCT04735185|Active Comparator|Intradiscal corticosteroid and local anesthetic|Participants in this arm will receive an intradiscal injection of the steroid methylprednisolone and the local anesthetic bupivacaine into affected intradiscal spaces in the lumber spine.
10201086|NCT04693806|Experimental|Continuous CO2 Level|embryos will remain in a single incubator set at a continuousCO2 level
10201087|NCT04693806|No Intervention|Sequential CO2 Level|Current standard of care
10201088|NCT04688944||patients|(1) age ≥ 45 years, (2) diagnosed LSS through a combination of clinical history, physical examination and radiological changes showing spinal canal stenosis on magnetic resonance imaging
10201089|NCT04688944||healthy people|(1) age ≥ 45 years; (2) without chronic low back pain (LBP)
10201090|NCT04688905||Dyspnea explained by heart failure with preserved ejection fraction|All patients fulfilling invasive criteria for heart failure with preserved ejection fraction
9743495|NCT05266989||Healthy Controls|All participants will randomly participate through three tDCS conditions (1mA, 2mA and sham)
9743496|NCT05266976|Experimental|Resistance Exercise|Participants will perform total body resistance training 3x per week for 10 weeks. Each exercise session will last approximately 1 hour.
9743497|NCT05266976|Experimental|Endurance Exercise|Participants will complete 60 minutes of stationary cycling 3x per week at 70-80% of maximal heart rate for 10 weeks.
9743498|NCT05266950|Experimental|CI-135 CAR-T|chimeric antigen receptor T cell treatment
9743499|NCT05266937|Experimental|Single Arm|Single-arm study with the primary objective of providing preliminary evidence on the efficacy of atezolizumab plus carboplatin plus nab-paclitaxel as first-line therapy in metastatic triple-negative PD-L1 positive breast cancer patients as evaluated by % 2years OS.
9743500|NCT05266924|Experimental|Test group|Foligraf 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen Follicle Stimulating Hormone (Human Recombinant) manufactured by Bharat Serums and Vaccines Ltd
9743501|NCT05266924|Active Comparator|Reference group|Gonal-f Recombinant Human Follicle Stimulating Hormone
9743502|NCT05266898|Experimental|Gardasil-9 recipients|Participants receive 3-dose Gardasil-9 vaccine series.
9743503|NCT05266885||Male and Female|(37 male, 63 female)
9743504|NCT05266872||PD patients|Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism)
9743505|NCT05266872||Healthy controls|Gender- and age-matched healthy controls
9743506|NCT05266859|Active Comparator|Group I- Calcium hydroxide (Control)|"Group I will receive Calcium hydroxide . Calcium hydroxide is a gold standard medicament for the pulpotomy in deciduous teeth. It has antibacterial effects and widely used to disinfect the root canals.~This group will act as a control"
9743507|NCT05266859|Experimental|Group II- MTA (Experimental)|Group II will receive MTA (Mineral Trioxide Aggregate). MTA is a calcium silicate based highly biocompatible material that is commonly used for pulpotomies in deciduous teeth along with the regenerative procedures in permanent and deciduous teeth
9743508|NCT05266859|Experimental|Group III- PRF (Experimental)|Group III will receive PRF. PRF is platelet-rich fibrin that is a biocompatible product derived from patient's own blood. It is formed by centrifugation of the blood of the patient. It provides the growth factors and promotes regeneration of the pulp
9743509|NCT05266833|No Intervention|Control|Students in the control class received regular class instruction during the 5 weeks. This instruction did not deviate from regular instruction that was provided to all classes, including the intervention classes. During the intervention period, control group students completed the assessments once per week. The control class is considered a treatment-as-usual active control.
9743510|NCT05266833|Experimental|Self-Paced Breathing|The self-paced slow diaphragmatic breathing intervention provided guidance for participants to breathe at a slower pace than normal with brief, organic pauses after each inhale and exhale, and with exhales longer than inhales. Participants were guided to breathe at their own pace while following these principles of longer exhales and brief pauses after each inhale/exhale. They were invited to slow their pace when ready, both during each 5-minute session and over the course of the 5 weeks.
9743511|NCT05266833|Experimental|Guide-Paced Breathing|The guide-paced slow diaphragmatic breathing intervention comprised slow breathing with all exhales twice as long as the inhales; e.g., a 3-second inhale was followed by a 6-second exhale. Participants were instructed to breathe in sync with the guided pace. The breathing pace slowed over the 5 weeks: for weeks 1-2, the breath pattern comprised a 3-second inhale followed by a 6-second exhale; for weeks 3-4, the timing was 4 and 8, respectively; and was 5 and 10 for the last week.
9743512|NCT05266820|Experimental|TAS-102+Thalidomide|Thalidomide 100mg PO BID+TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
9743513|NCT05266820|Active Comparator|TAS-102|TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
9743514|NCT05266807|Experimental|SoC + oral Fecal Microbiota Transplantation|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days, followed 24h later by one oral FMT (15 capsules administered at D1 and 15 capsules at D2), and a second oral FMT depending on recurrent CDI severity.
9743515|NCT05266807|Active Comparator|SoC|Antibiotic (vancomycin 125 mg 4 times daily or fidaxomicin 200 mg 2 times daily, as initially prescribed per SoC) for 10 days.
9743516|NCT05266794|No Intervention|Control|25 hemodialysis patients who received their routine therapy only.
9743517|NCT05266794|Active Comparator|Selenium|23 hemodialysis patients who received Selenium 200µg once daily with their routine therapy just after the dialysis sessions for 3 months.
9743518|NCT05266794|Active Comparator|Alpha Lipoic acid|20 hemodialysispatients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
9743519|NCT05266781||Open surgical repair|Aneurysmectomy and aortic reconstruction with a surgical graft
9743520|NCT05266781||Endovascular repair|Off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR
9743521|NCT05266768|Experimental|IBI346|Single arm
9743522|NCT05266755|Placebo Comparator|Patiens who will receive stanrdar care after hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge the standar following we are doing now in our hospital
9743523|NCT05266755|Active Comparator|Patiens who will receive FLS following after the hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge a FLS following, multidisciplinary, with a web and mobile app aplication
9743524|NCT05266742|Experimental|END|Use of web based education
9743525|NCT05266742|No Intervention|END free|patient witout of web based education
9743526|NCT05266716|Experimental|Primary Arm|The study will involve a total of approximately 48 individuals enrolled during a six-week period as participants in the field test of the Affect digital therapeutic platform
9743527|NCT05266703|Other|Isotopically labelled iron sulfate 15mg|
9743528|NCT05266690|Experimental|Sequence 1|Roquette Glucidex 40 - Roquette Glucidex 2 - Pharmacosmos Dextran 10 - Promitor 70
9743529|NCT05266690|Experimental|Sequence 2|Roquette Glucidex 2 - Promitor 70 - Roquette Glucidex 40 - Pharmacosmos Dextran 10
9743530|NCT05266690|Experimental|Sequence 3|Promitor 70 - Pharmacosmos Dextran 10 - Roquette Glucidex 2 - Roquette Glucidex 40
9743531|NCT05266690|Experimental|Sequence 4|Pharmacosmos Dextran 10 - Roquette Glucidex 40 - Promitor 70 - Roquette Glucidex 2
9743532|NCT05266677|Experimental|EXPL|Liquid oral supplement comprising a blend of glycerides at certain proportions
9743533|NCT05266677|Other|CTRL|Liquid oral supplement comprising glycerides used in current formulas
9743534|NCT05266664||preterm|preterm infants gestational age less than 32 weeks
9743535|NCT05266664||healthy controls|healthy term infants
9743536|NCT05266651|Active Comparator|tadalafil group|5 mg of Tadalafil on daily bases for one month duration
9743537|NCT05266651|Placebo Comparator|placebo group|the patients will receive oral tablets without any active substance for one month
9743538|NCT05266599|Active Comparator|MTA Fillapex group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. MTA Fillapex sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
9743539|NCT05266599|Active Comparator|AH Plus group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. AH Plus sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
9743540|NCT05266573|Experimental|Exercise Participants with Limited Mobility|"The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components:~Warm Up: Walking which is progressively increased from 6 to 15 minutes. Dual task activity is introduced as tolerated by the participants. Participants are able to utilize assistive devices and there were additional supports provided.~Stretching, Strengthening and Balance Activities: Gradual progression of activities and repetitions for 30 minutes that are tailored by the exercise instructor to each participant. Exercises are led by the trainer and performed at the balance bar, in a chair, or in standing. Task oriented activities included items such as: weight shifting, forward/backward/side stepping, squats, forward/backward/side leg raises, toe raises, seated trunk rotations, sit to stand, forward trunk bending, arm rotations, and marching.~Walk/Obstacle Course: The final 6 to 15 minutes included challenged walking through an obstacle course."
9743541|NCT05266560|Active Comparator|Propofol injection group (1.5mg/kg)|The patients in the propofol group were given intravenous injection of propofol 1.5 mg/kg and succinylcholine 1 mg/kg in turn, and the interval between each drug administration was 1 minute, and electroconvulsive therapy was performed after the patients were anesthetized.
9743542|NCT05266560|Experimental|Ciprofol injection group(0.4mg/kg)|The patients in the ciprofol group were given intravenous injection of ciprofol 0.4 mg/kg and succinylcholine 1 mg/kg in turn. The interval between each drug administration was 1 minute, and the patients received electroconvulsive therapy after anesthesia.
9743543|NCT05266547||OCT guided group|
9743544|NCT05266547||angiography guided group|
9743545|NCT05266534|Active Comparator|intramyometrial Terlipressin injection in women undergoing open myomectomy|intramyometrial Terlipressin injection
9743546|NCT05266534|Active Comparator|intramyometrial Carbetocin injection in women undergoing open myomectomy|intramyometrial Carbetocin injection
9743547|NCT05266534|Placebo Comparator|intramyometrial saline injection in women undergoing open myomectomy procedure|intramyometrial saline injection in women
9743548|NCT05266521|Experimental|zLock Facet Locking Implant System|Device: zLOCK Facet Stabilization System zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
9983921|NCT04543682|Experimental|Second intervention group (0.25 ng/kg/min Iloprost)|The second intervention group will also receive open reduction and internal fixation with an angular stable plate (PHILOS, Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.25 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. Infusion will start 24hrs post-operatively and the dose will be delivered over 24h.
9983922|NCT04543682|Other|Control intervention group|Control intervention: Patients will receive the standard of care procedure for such fractures, i.e. standard of care open reduction and internal fixation with an angular stable plate (PHILOS).
9743551|NCT05266443|Placebo Comparator|Irritable bowel syndrome with normal mood receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be supplemented with placebo drinks.
9743552|NCT05266443|Active Comparator|Irritable bowel syndrome with normal mood receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be given lactobacillus-containing cultured milk drinks.
9743553|NCT05266443|Placebo Comparator|Irritable bowel syndrome with subthreshold depression receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be supplemented with placebo drinks.
9743554|NCT05266443|Experimental|Irritable bowel syndrome with subthreshold depression receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be given lactobacillus-containing cultured milk drinks.
9743555|NCT05266430||Case Group|Patients with primary Choroidal Melanoma and Indeterminate Lesions who have received AU-011 in a previous Aura sponsored clinical trial
9743556|NCT05266430||Control Group|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
9743557|NCT05266391||group 1|patients who received US-guided subacromial corticosteroid injections
9743558|NCT05266391||group 2|patients who underwent blind subacromial corticosteroid injections
9743559|NCT05266378|Experimental|Block group|The group undergoing PECs block
9743560|NCT05266378|Placebo Comparator|Control group|The group not receiving PECs block
9743561|NCT05266352|Experimental|Supervised exercise group|The group received the supervised exercise program
9743562|NCT05266352|Active Comparator|Home exercise group|The group received the home exercise program
9743563|NCT05266313|Experimental|Oncosexology program|Several workshops before and after the radical prostatectomy
9743564|NCT05266313|No Intervention|Usual care|Usual care of the urology department for patients with prostate cancer
9743565|NCT05266300||Retrospective|Historic group. Patients treated in the historic control group did not receive DPYD-genotype before treatment with fluorouracil, capecitabine, tegafur. They received standard start doses of 5-FU, capecitabine, tegafur.
9743566|NCT05266300||Prospective|"Participants enrolled in the prospective group will give a blood sample for immediate DPYD genotyping. Once the results from these tests are in, the treating oncologist have immediate access to the participant's genetic test results and can make dosing decisions/changes to the participant's chemotherapy prescription. The recommended starting doses for 5-FU, capecitabine, tegafur are.~No DPYD-gene variant = normal starting dose (100%)~1 DPYD-gene variant (heterozygous) = Reduced starting dose (50%) Homozygous for 1 DPYD variant or compound heterozygous (>1 variants) = Treatment with 5-FU, capecitabine, tegafur is not recommended ."
9743567|NCT05266287|Experimental|Investigational supplement|Participants in this arm will take a supplement containing 2'-fucosyllactose (2'-FL)
9743568|NCT05266287|Placebo Comparator|Placebo supplement|Participants in this arm will take a placebo supplement
9743569|NCT05266274|Experimental|The Treatment of Recurrent AML After Transplantation|
9743570|NCT05266261|Active Comparator|Non-diabetes|postmenopausal women with normal glucose tolerance
9743571|NCT05266261|Experimental|diabetes|postmenopausal women with type 2 diabetes
9743572|NCT05266235|Experimental|Withings WBS08 and 12-lead reference ECG|The electrodes of the 12-lead ECG will be set up on the participants, before they step on withings WBS08 to have ECGs simultaneously recorded by the study device and the control device
9743573|NCT05266196|Experimental|Single agent|Single agent seclidemstat, as assigned per parent protocol
9743574|NCT05266196|Experimental|TC Combination|Combination of seclidemstat with topotecan and cyclophosphamide, as assigned per parent protocol
9743575|NCT05266170||Normal adults|aerobic and anaerobic exercises
9743576|NCT05266157|Active Comparator|Usual care|"Skin care, exercise and compression stocking:~The patient has to wear custom-made compression thigh stocking(s) in case of unilateral/ bilateral swelling of the leg and has to wear a bermuda in case of swelling of the midline region. The patient continues the skin care and continues/ restarts exercise therapy with the home physical therapist 2 times a week. Frequency of exercises is gradually decreased: M1-3 2x/w, M4-6 1x/w, M7-9 1x/M; M10-12 only self-exercises."
9743577|NCT05266157|Experimental|Additional manual lymph drainage|"Usual care + manual lymph drainage. Manual lymph drainage is performed by the home physical therapist. Every session lasts for 30 minutes.~Frequency of manual lymph drainage is gradually decreased: M1-3 2x/w, M4-6 1x/w, M7-9 1x/M; M10-12 only self-MLD."
9743578|NCT05266144||atrial fibrillation|Atrial fibrillation patients who underwent radiofrequency ablation in Peking Union Medical College Hospital.
9743579|NCT05266118||Former ICU patients|Participants is former ICU patients, immediately after transferred from ICU to a hospital ward. At least one of these criteria is needed for the participation in the study: ICU stays > 24 hours; ventilatory support; transferals to other ICU < 24 hours; continuous infusion of vasoactive substances. In addition, to be included, the patients must be more than 18 years of age; understand and be able to write and read Norwegian; be able to communicate verbally; not have a manifest cognitive deficit; and not being readmitted to ICU < 72 hours
9743580|NCT05266105|Experimental|Dose Escalation|This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily with Palbociclib in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
9743581|NCT05266105|Experimental|Dose Expansion|This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 in combination with Palbociclib and estimates preliminary data of anti-tumor efficacy
9781929|NCT01161329|Experimental|Intervention group|Exercising two times/week according to the High-Intensity Functional Exercise Program (HIFE) in groups of 5-7 patients in combination with motivational discussions.
9781930|NCT01161407|Placebo Comparator|Placebo|Placebo control for calcium carbonate, given in same capsule form as the calcium carbonate, 3 times per day with meals.
9743582|NCT05266079|Experimental|Syndrome differentiation treatment(GMBHDHT, TWBXD,SG,LWDHP and EZP, YGP and LZP)|"Syndrome differentiation treatment group of participants will be given medication by syndrome differentiating from qualified TCM Practitioners. TCM Practitioners will base on the syndrome of the participants to evaluate and modify the prescription after each assessment.~Liver and Kidney Yin Deficiency syndrome use Gan Mai Bai He Di Hung Tang(GMBHDHT);~Non Interaction Between Heart and Kidney syndrome use Tian Wang Bu Xin Dan(TWBXD);~Liver Stagnation and Qi Stagnation syndrome use Shugan Granules(SG);~Kidney Yin Deficiency syndrome use Liu Wei Di Huang Pill and Er Zhi Pill(LWDHP and EZP) ;~Spleen and Kidney Yang Deficiency syndrome use You Gui pill and Li Zhong pill addition and subtraction(YGP and LZP).~Each dose will be prepackaged in two identical foil sachets. Participants will be instructed to drink one sachet of granules dissolved in 200 mL of warm water twice daily."
9743583|NCT05266079|Experimental|Fixed formula treatment|Fixed formula treatment Group will be given the standard formula Er-Xian decoction consisting of six herbs. The dosages of each herb were standardized according to the latest Chinese Medicine Recipe Dictionary (1997). The standard formula Er-Xian decoction are in the form of water-soluble granules. Each dose contains 11.8g and prepackaged in two identical foil sachets. Participants were instructed to drink one sachet of granules dissolved in 200 mL of warm water twice daily.
9743584|NCT05266066|Experimental|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care and no antibiotic therapy for VAT. Antibiotics will be prescribed if other infections and/or organ dysfunction ensues (especially shock) or there is progression to pneumonia
9743585|NCT05266066|Active Comparator|7 day antibiotic course for VAT|Patients will receive standard care and 7 day course of antibiotic therapy for VAT.
9743586|NCT05266053|Experimental|Treatment Group|This group will have a PICO negative pressure wound treatment device applied to their surgical wound site.
9743587|NCT05266053|Other|Control Group|Standard Intervention. This group will have a standard wound dressing (gauze, bandage) applied to their surgical wound site.
9743588|NCT05266040|Experimental|valacyclovir group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
9743589|NCT05266040|Placebo Comparator|Control group|250 patients presenting with pain and a diagnosis of acute apical abscess will be recruited for the VEII preoperative pain and VEIII postoperative pain and clinical/radiographic healing phases of the clinical trial.
9743590|NCT05266027|Experimental|Experimental Group|Nalbuphine Sebacate (Naldebain) intramuscular injection
10201091|NCT04688905||Dyspnea not explained by heart failure with preserved ejection fraction|All patients not fulfilling invasive criteria for heart failure with preserved ejection fraction
10201092|NCT04688541|Active Comparator|First standard Foley catheter than Optitip catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Standard Foley catheter Study period 2 = Optitip catheter"
9743591|NCT05266027|Placebo Comparator|Placebo Group|Placebo medication intramuscular injection
9743592|NCT05266001|Active Comparator|GM-CSF|Intravenous GM-CSF 125 mcg/m2/day x 7 days
9743593|NCT05266001|Placebo Comparator|Placebo|Intravenous placebo x 7 days
9743594|NCT05265988|Experimental|Meridian|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
9743595|NCT05265975|Experimental|ATG-010|Enrolled patients will be treated with dosage groups. Dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time; The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
9781931|NCT01161407|Active Comparator|Calcium Carbonate (Phosphate Binder)|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium.
9781932|NCT01161420|Experimental|Inspire Therapy|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
9781933|NCT01161446|Experimental|Home Testing|
9781934|NCT01161446|No Intervention|Standard Testing|
9781935|NCT01161472|Experimental|4mg fesoterodine|
9781936|NCT01161472|Experimental|fesoterodine 8mg|
9781937|NCT01161472|Active Comparator|1mg alprazolam|
9781938|NCT01161472|Placebo Comparator|Placebo|
9781939|NCT01161498|Active Comparator|Radiation/Cisplatin|Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
9781940|NCT01161498|Experimental|Talimogene Laherparepvec + Radiation/Cisplatin|The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63. Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
9781941|NCT01161524|Experimental|Perampenal (Core Study)|Participants received perampanel 2 mg per day and up-titrated weekly in 2-mg increments to a target dose range of 8 to 12 mg per day.
9781942|NCT01161524|Placebo Comparator|Placebo (Core Study)|Participants received matching placebo tablets once a day (6 tablets of placebo).
10201093|NCT04688541|Active Comparator|First Optitip catheter than standard Foley catheter|"Each participant is given the 2 trial catheters for successive periods of 4 weeks (+ up to 7 days) for each treatment period:~Study period 1 = Optitip catheter Study period 2 = Standard Foley catheter"
10201094|NCT04677413|Experimental|Phase I Dose Cohorts|"DOSE LEVEL 1 : 30 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 2 : 35 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 3 : 40 Gy (tumor)/ 25 Gy (pelvis)"
10201095|NCT04666389|Placebo Comparator|Control group|No statins being used for prevention
10201096|NCT04666389|Active Comparator|Low-dose statin therapy|Atorvastatin 40 mg
10201097|NCT04666389|Active Comparator|High-dose statin therapy|Atorvastatin 80 mg
10201098|NCT04652882|Experimental|Tasimelteon|
10201099|NCT04652882|Placebo Comparator|Placebo|
9743596|NCT05265962|Experimental|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
9743597|NCT05265949|Experimental|diet+physical activity|diet+physical activity
9743598|NCT05265949|Experimental|diet|diet
9743599|NCT05265949|Experimental|physical activity|physical activity
9743600|NCT05265949|No Intervention|control|control
9743601|NCT05265936|Active Comparator|Guidewire through DJ stent|Patients who underwent lithotripsy after guidewire insertion through a previously placed double j stent.
9743602|NCT05265936|Sham Comparator|DJ stent remove + guidewire|Patients who underwent lithotripsy after double j stent removal and guidewire placement.
9743603|NCT05265923|Experimental|CM310|CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)
9743604|NCT05265923|Placebo Comparator|Placebo|"Double blind treatment period : Placebo~Maintenance treatment period : CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)"
9743605|NCT05265910|Active Comparator|Pataday® Once Daily Relief Extra Strength and Placebo tablet|Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and Placebo tablet will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
9743606|NCT05265910|Active Comparator|Tears Naturale® II and Claritin® Tablet 24-Hour|Tears Naturale® II will be administered bilaterally and Claritin® Tablet 24-Hour (loratadine 10 mg) will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.
9743607|NCT05265897|No Intervention|Usual Care|Brief form letter with lung cancer screening results
9743608|NCT05265897|Experimental|CAQ|"Usual care, plus Commonly Asked Questions after Lung Cancer Screening informational document (CAQ)"
9743609|NCT05265884|Experimental|Group A (Kinesio taping group)(Experimental group):|This group includes 30 patients who will receive Kinesiotaping, in additional to traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
9743610|NCT05265884|Active Comparator|Group B (control group)|This group includes 30 patients who will receive traditional treatment only (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for 1 month.
9743611|NCT05265871||Refractory chronic cough|Subjects would be performed induced sputum test, ATP and capsaicin cough provocation test.
9743612|NCT05265871||Healthy control|Subjects would be performed induced sputum test, ATP and capsaicin cough provocation test.
9743613|NCT05265858||Patients with hip osteoarthritis|Patients with hip osteoarthritis who will undergo total hip arthroplasty
9743614|NCT05265845|Experimental|Intervention|Interactive text messages that include goal setting, tailored feedback, and skills training.
9743615|NCT05265845|Active Comparator|Control|Text4Baby
9743616|NCT05265819|Active Comparator|Group A|Group A: Control group No intervention was provided for 12 weeks except thyroid hormone replacement therapy
9743617|NCT05265819|Experimental|Group B|Group B: Exergaming exercise The volunteers carried out 36 exergaming sessions
9743618|NCT05265819|Experimental|Group C|Group C: Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
9743619|NCT05265819|Experimental|Group D|Group D: Exergaming exercises and Mediterranean diet Exergaming exercises are used in addition to Mediterranean diet
9743620|NCT05265806|Experimental|Intranasal oxytocin|Participants will be randomly assigned to the administration of oxytocin intranasal spray (24 IU).
9743621|NCT05265806|Experimental|Oral oxytocin|Participants will be randomly assigned to the administration of oxytocin lingual spray (24 IU).
9743622|NCT05265806|Placebo Comparator|Placebo|Participants will be randomly assigned to the administration of placebo.
9743623|NCT05265793|Experimental|Camrelizumab Combined With Apatinib|"Apatinib tablets: 250mg qd.po, 4 weeks as a cycle, continuous medication until disease progression, death or intolerable toxicity;~Camrelizumab: administered intravenously with a fixed dose of 200mg, administered intravenously (without preventive medication), each infusion for 30min (no less than 20min, no more than 60min), administered once every two weeks until disease progression, death or intolerable toxicity. The maximum period is 2 years.~The curative effect was evaluated every 8 weeks."
9743624|NCT05265780|Experimental|kinesiotape|kinesiotaping group
9743625|NCT05265780|Sham Comparator|control|sham group
9743626|NCT05265767|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|Autologous gene modified peripheral blood stem cell transplantation for patients with severe hemophilia A (FVIII <1%).
9743627|NCT05265026|Experimental|Exercise Intervention Arm|The high intensity interval exercise sessions per week of 38 minutes. Exercise will be performed on ergometerbikes.
9743628|NCT05265026|No Intervention|No Intervention|No lifestyle changes
9743629|NCT05262803|No Intervention|Standard-of-care DAPT|Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and prasugrel or ticagrelor for 6 months followed by ASA monotherapy.
9743630|NCT05262803|Experimental|Genotype-guided DAPT|DAPT according to CYP2C19*2/*3-genotyping for 6 months followed by ASA monotherapy.
9743631|NCT05262803|Experimental|Shorter genotype-guided DAPT|DAPT according to CYP2C19*2/*3-genotyping for 3 months followed by ASA monotherapy.
9743632|NCT05261360|Experimental|SF-MSC-EX Treatment Group (Experimental group's left knees)|The left knee will receive 1 million cells/kg SF-MSC-EX (Synovial fluid mesenchymal stem cell-derived exosome) by intra-articular injection method.
9743633|NCT05261360|Experimental|SF-MSC Treatment Group (Experimental group's right knees)|The right knee will receive 1 million cells/kg SF-MSC (Synovial fluid-derived mesenchymal stem cell) by intra-articular injection method.
9743634|NCT05261360|No Intervention|Control Group|Participants who received no treatment were defined as the control group.
9743635|NCT05251363|Other|Solia S LBB lead|
9743636|NCT05246384|Experimental|Part I (dose escalation) RP7214 + Azacitidine|Participants will receive RP7214 orally in combination with Azacitidine in a 28-day cycle. The dose levels will be escalated until MTD/a recommended Phase 2 dose (RP2D) has been identified.
9743637|NCT05246384|Experimental|Part II (dose expansion) RP7214 + Azacitidine|Participants will receive RP7214 orally at the MTD/RP2D in combination with Azacitidine in a 28-day cycle.
9743638|NCT05245409|Experimental|Stress|Individuals under various degrees of stress
9743639|NCT05242887||Older adults hospitalized in acute geriatric units|Response to a questionnaire
9743640|NCT05242679|Experimental|Myofascial Release Group|Participants were treated with a conventional physiotherapy program along with myofascial release with a tennis ball.
9743641|NCT05242679|Active Comparator|Conventional Physiotherapy Group|A conventional physiotherapy program was provided including range of motion/flexibility exercises, strength training, postural control, functional mobility exercises, lower limb functional exercises, and gait training.
9743642|NCT05242341|Experimental|app use teaching|"Intervention includes teach the subjects one-on-one to use the My Health Bank for 30 minutes (such as download, register, test, find information, etc.), and provide pre-recorded 1-minute instructional videos for viewing when needed at home. The intervention group also accepts to follow the use of My Health Bank app at home every two weeks for a period of two months. Both groups will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety (prohibited medicines and concomitant medications)."
9743643|NCT05242341|No Intervention|B|will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety
9743644|NCT05242094|Active Comparator|Group 1|Traditional Pulmonary Rehabilitation
9743645|NCT05242094|Experimental|Group 2|Pulmonary Rehabilitation in Virtual Reality
9743646|NCT05240781|Active Comparator|Zotarolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable Coronary Artery Disease (CAD) and Acute Coronary Syndrome (ACS) patients undergoing elective PCI.
9743647|NCT05240781|Experimental|Sirolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable CAD and ACS patients undergoing elective PCI.
9743648|NCT05238519|Experimental|Motivational Interview|Motivational interview arm will receive a message to schedule a follow up motivational interview via telephone or video after the baseline survey as well as follow up surveys.
9743649|NCT05238519|No Intervention|Usual Care|Usual care arm will receive baseline and follow up surveys only.
9743650|NCT05237596||Prescription-grade Crystalline Glucosamine Sulfate Group (pCGS Group)|pCGS Group includes patients treated with pCGS (Dona®, VIATRIS), in sachets of powder for oral solution, at the dose of 1500 mg glucosamine sulfate once daily, for a total period of 6 consecutive months according to the approved indication for knee OA, in addition to conventional therapy for HOA.
9743651|NCT05237596||Control Group|Control Group includes patients treated with conventional therapy alone for at least 6 consecutive months.
10201100|NCT04652505||Observational (questionnaires)|Patients complete 3 questionnaires online over 15 minutes regarding coping strategies that may have been used, mental health and physical well-being in the past month, and if they have been following certain behaviors which the WHO has recommended during the coronavirus pandemic, such as regular hand washing and social distancing.
10201101|NCT04645186||Calcium Phosphate Cement (CPC)|Evaluation of CPC in long bone & extremities
9743652|NCT05237050|Experimental|Sound therapy associated with relaxation|
9743653|NCT05237050|Active Comparator|Relaxation alone|
9743654|NCT05236036|Experimental|Group 1 (TMZ, MMF)|Patients who have already undergone surgery or biopsy followed by chemoradiation receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9743655|NCT05236036|Experimental|Group 2 (TMZ, MMF, radiation therapy)|Patients with unmethylated glioblastoma who have already undergone surgery or biopsy receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Starting at the same time as TMZ and MMF administration, patients also receive radiation therapy daily, 5 days per week, for 6 weeks.
10201102|NCT04644536||Granules in long bone & extremities|Filling of post-traumatic or surgically created bone defects
10201103|NCT04644536||Wedges in long bone & extremities|Osteotomies with fixation
10201104|NCT04644536||HA paste in long bone & extremities|Filling of post-traumatic or surgically created bone defects
10201105|NCT04644536||Granules in Spine|Spinal cage filling
10201106|NCT04644536||HA paste in Spine|Spinal cage filling
10201107|NCT04635631|Experimental|talazoparib|1 mg QD
10201108|NCT04627974||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
10201109|NCT04614168|Active Comparator|Group 1 - Standard Care|This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
10201110|NCT04614168|Experimental|Group 2- Automated insulin delivery and low carbohydrate diet|This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
10201111|NCT04610827|Active Comparator|Ferrous sulfate daily|Subject will take 3 mg/kg oral iron in the morning
10201112|NCT04610827|Active Comparator|Ferrous sulfate twice daily|Subjects will take 1.5 mg/kg oral iron twice daily
10201113|NCT04610827|Active Comparator|Ferrous sulfate every other day|6 mg/kg oral iron every other day in the morning
10201114|NCT04595474||Study Cohort|533 adult subjects with type 1 diabetes with no secondary causes of fatty liver
10201115|NCT04589195|Experimental|Mindfulness Training (MT) Group|Participants will receive four weeks of MT.
10201116|NCT04589195|Active Comparator|Wait List MT Group|Participants will receive four weeks of MT training after a five week washout period.
10201117|NCT04584970|Experimental|Virtual reality device|Participants will be offered a virtual reality (VR) device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
10201118|NCT04584970|Active Comparator|iPad device|Participants will be offered an iPad device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
10201119|NCT04580407|Experimental|TAK-672|TAK-672 will be administered at an initial dose of 200 U/kg with intravenous infusion at a rate of 1-2 mL/min. Subsequent doses will be determined based on the post-infusion factor VIII activity (FVIII:C) achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer (when available)
10201120|NCT04576936|Experimental|AIRVO Device|All participants are assigned to this single-arm: Enrolled participants will be given a MyAIRVO2 Device and device stand, and asked to use their device daily, for 12 months
10201121|NCT04559139|Active Comparator|Arm I (surgery, adjuvant therapy)|Within 4 weeks of randomization, patients undergo surgery to remove part of the liver, the lymph nodes around the liver, and possibly the bile ducts. Patients then receive gemcitabine IV over 30 minutes and cisplatin IV over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
10201122|NCT04559139|Experimental|Arm II (neoadjuvant therapy, surgery, adjuvant therapy)|Patients receive gemcitabine IV over 30 minutes and cisplatin over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Approximately 4-8 weeks after completion of chemotherapy, patients whose disease has not spread to other places in the body (metastasized), then undergo surgery as in Arm I. Patients with successful surgery then resume treatment with gemcitabine IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10201123|NCT04553419|Experimental|Cephalexin|Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
10201124|NCT04553419|Placebo Comparator|Placebo|The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks
10201125|NCT04536038|No Intervention|Opt-in|Patients randomized to opt-in framing will be instructed to visit the Way to Health website to enroll in the study, or to call or email the study coordinator with questions or for assistance in enrolling.
10201126|NCT04536038|Experimental|Opt-out|Patients randomized to opt-out framing will receive an email that frames participation in the study as part of the standard of care, and will be informed that a study coordinator will be calling them in the coming days to start enrollment in the study unless they opt out of participation.
9743656|NCT05236036|Experimental|Group 3 (TMZ, MMF, radiation therapy)|Patients who have already undergone surgery or biopsy receive TMZ PO QD on days 1-5 of each cycle and MMF PO BID. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Starting at the same time as TMZ and MMF administration, patients also receive radiation therapy daily, 5 days per week, for 6 weeks.
9743657|NCT05236036|Experimental|Group S (pre-surgical MMF, TMZ)|Patients planning to undergo surgery receive MMF PO BID and TMZ PO QD for 5 days prior to surgery in the absence of disease progression or unacceptable toxicity.
9743658|NCT05235698||Patients with long COVID diagnosis|Ophthalmological examinations performed as part of the care Addition of GlycoCheck for the study
9743659|NCT05235633||Comparison cohort|Children and adolescents at the end of acute treatment for leukemia and non-Hodgkin lymphoma without any exercise intervention
9743660|NCT05226884||Clareon IOL Group|Patients with bilateral implantation of Clareon IOLs.
9743661|NCT05226884||Eyhance IOL Group|Patients with bilateral implantation of EyhanceIOLs.
9743662|NCT05225129|Experimental|Training Group|Resistance training will be applied to the training group, equivalent to 30% of 1 maximum repetition with blood flow restricted exercise for 8 weeks , 2 days in a week.
9743663|NCT05225129|No Intervention|Control Group|Resistance training will be applied to the control group, equivalent to 30% of 1 maximum repetition without blood flow restriction for 8 weeks , 2 days in a week.
9743664|NCT05223413|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning (RIC): Patients will undergo weekly RIC during the entire span of the chemotherapy period. Each RIC session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation
9743665|NCT05223413|Sham Comparator|simulated RIPC (Sham)|Control group (Sham): Patients will undergo weekly simulated RIC (sham) during the entire span of the chemotherapy period. Each sham session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation.
9743666|NCT05217498|Experimental|Istradefylline+low oxygen training|"Drug: Nourianz Other Names: KW6002, Istradefylline~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first low oxygen therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
9743667|NCT05217498|Active Comparator|Placebo+low oxygen training|"This is a placebo counterpart to the istradefylline drug.~Participants enrolled in this study arm will ingest a 20mg placebo tablet/day containing dextrose starting 14 days prior to the first low oxygen therapy (LOT) and continuing for 14 additional days. Participants will consume a total of 28 placebo tablets.~Other: low oxygen training Other Names: therapeutic intermittent hypoxia, acute intermittent hypoxia~Participants will breathe 15 episodes/session of acute low oxygen via an automated air generator system (4 sessions/week x 2 weeks). During the 90-second episodes of low oxygen, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
9743668|NCT05217498|Active Comparator|Istradefylline+SHAM|"Drug: Nourianz Other Names: KW6002, Istradefylline~This is a SHAM counterpart to low oxygen therapy.~Participants enrolled in this study arm will ingest a 20mg tablet/day containing istradefylline starting 14 days prior to the first SHAM therapy and continuing for 14 additional days. Participants will consume a total of 28 istradefylline tablets.~Participants will breathe 15 episodes/session of SHAM via an automated air generator system (4 sessions/week x 2 weeks). The system will fill reservoir bags attached to a non-rebreathing face mask. During the 90-second episodes of SHAM, air concentrations will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia) with 60-second room-air intervals (FIO2 0.21±0.02).~Throughout experimentation, blood pressure, respiratory rate, and heart rate will be monitored. We also will assess for changes in sleep quality and pain level."
9743669|NCT05215392|Experimental|Smartphone Application|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app.
9743670|NCT05215392|Active Comparator|Treatment As Usual|Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
9743671|NCT05211804||Treatment-naïve|15 patients not previously receiving anti-VEGF treatment for nAMD.
9743672|NCT05211804||Undergoing treatment|15 patients already undergoing treatment with anti-VEGF for nAMD.
9743673|NCT05211232|Experimental|GP combined with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for eight cycles after radiotherapy
9743674|NCT05211232|Placebo Comparator|GP combine with Placebo neoadjuvant therapy+CCRT+Placebo adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and Placebo(200mg) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) ,then followed by adjuvant therapy with Placebo(200mg) every three weeks for eight cycles after radiotherapy
9743675|NCT05206435|Active Comparator|Electronic Cigarettes|Participants in this arm are randomized to receive electronic cigarettes for the 6-week study period.
9743676|NCT05206435|Active Comparator|Nicotine Lozenges|Participants in this arm are randomized to receive nicotine lozenge for the 6-week study period.
9743677|NCT05206370|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
9743678|NCT05206370|Experimental|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
9743679|NCT05206370|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
9743680|NCT05201430|Experimental|A: FOLFOXIRI|Neoadjuvant chemotherapy with 3-4 cycles of FOLFOXIRI regimen, followed by surgery
9743681|NCT05201430|Experimental|B: CapeOX|Neoadjuvant chemotherapy with 2-3 cycles of CapeOX regimen, followed by surgery
9743682|NCT05199454|Experimental|Exercise training|Aerobic exercise training for 12 weeks, 3 times per week, 60 minutes per session.
9743683|NCT05199454|No Intervention|Control (standards of care)|This arm will receive brochures for healthy lifestyle recommendations. No intervention will be conducted.
9743684|NCT05192369|Experimental|Treatment A: Therapeutic Dose|Single oral dose of 12mg CTP-543
9743685|NCT05192369|Experimental|Treatment B: Supratherapeutic Dose|Single oral dose of 48mg CTP-543
9743686|NCT05192369|Placebo Comparator|Treatment D: Placebo|Single oral dose of 1 Placebo tablet
9743687|NCT05192369|Active Comparator|Treatment C: Positive Control|Single oral dose of 400mg Moxifloxacin
9743688|NCT05188560|Experimental|AOT+MI|participants who, in addiction to standard rehabilitation program after surgery, underwent a single pre-operative training session of action observation therapy associated with motor imagery.
9743689|NCT05188560|No Intervention|Control group|Participants who was not subjected to any pre-operative activity. They received standard rehabilitation program after surgery too.
9743690|NCT05187780||Group 1|Adolescents with Idiopathic Scoliosis who have 10⁰-24⁰ Cobb angles
9743691|NCT05187780||Group 2|Adolescents with Idiopathic Scoliosis who have 25⁰-40⁰ Cobb angles
9743692|NCT05187780||Group 3|Healthy adolescents without scoliosis as controls
9743693|NCT05185973|Experimental|"For-Baby powder supplement"|For-baby supplements provided as powder containing dry yeast powder, biovita mixed probiotics, synergy probiotics and other nutrients such as glucose, xylitol, chocolate powder, chocolate flavor powder, organic galactose oligosaccharide, chicory extract powder, vegetable Cream substitute, silicon dioxide, milk flavor powder, whole milk powder, zinc oxide, vitamin B12, vitamin B6, enzyme mixed preparation, vitamin C, organic alpha rice powder, folate 0.4mg, thiamine, leucin, isoleucin, valine, glutamine, and magnesium chloride.
9743694|NCT05185973|Placebo Comparator|Micronutrient powder|Micronutrient powder containing containing glucose 236.3mg, xylitol 150mg, chocolate powder 600mg, chocolate flavor powder 45mg, organic galactose oligosaccharide 60mg, chicory extract powder 60mg, vegetable Cream substitute 135mg, silicon dioxide 45mg, milk flavor powder 30mg, whole milk powder 75mg, zinc oxide 11.2mg, vitamin B12 2.6mg, vitamin B6 2mg, enzyme mixed preparation 2mg, vitamin C 1mg, organic alpha rice powder 1mg, folate 0.4mg, thiamine 0.5mg, and maltodextrin 1,541mg.
9743695|NCT05177367|Experimental|Sequential Variety, Small Portion|3 courses each consisting of a different food served in a small portion.
9743696|NCT05177367|Experimental|Sequential Variety, Large Portion|3 courses each consisting of a different food served in a large portion.
9743697|NCT05177367|Experimental|Simultaneous Variety, Small Portion|3 courses each consisting of 3 foods served in small portions.
9743698|NCT05177367|Experimental|Simultaneous Variety, Large Portion|3 courses each consisting of 3 foods served in large portions.
9743699|NCT05177367|Experimental|Single Food, Small Portion|3 courses each consisting of the same food served in a small portion.
9743700|NCT05177367|Experimental|Single Food, Large Portion|3 courses each consisting of the same food served in a large portion.
9743701|NCT05176977|Experimental|Peer Specialist - Whole Health Coaching (PS-WHC)|Participants will meet with a Peer Specialist for 18 sessions over 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist, and 2) a structured Whole Health Coaching curriculum.
9743702|NCT05176977|No Intervention|Enhanced Usual Care (EUC)|Usual PACT care plus Hot Spotter Analytics (consists of access to field-based dashboard that allows PACTS to identify homeless Veterans on their panels who were super-utilizers, and the hot spotter manual).
9743703|NCT05175573|Experimental|SuperNO2VA Et|Continuous positive airway pressure with end-tidal CO2 monitoring
9743704|NCT05175573|Active Comparator|Supplemental Oxygen Face Mask|
10201127|NCT04535674|No Intervention|Standard of Care|
10201128|NCT04535674|Experimental|Standard of Care + Asunercept 25 mg|
10201129|NCT04535674|Experimental|Standard of Care + Asunercept 100 mg|
10201130|NCT04535674|Experimental|Standard of Care + Asunercept 400 mg|
10201131|NCT04528108|Experimental|ZYZQ Group|ZYZQ group is the experimental group which is treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine for 3 months.
10201132|NCT04528108|Active Comparator|GXN Group|GXN group is the active Comparator group which is treated with Gong Xue Ning capsules for 3 months
10201133|NCT04527549|Experimental|Arm A (dabrafenib, trametinib, hydroxychloroquine)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10201134|NCT04527549|Active Comparator|Arm B (dabrafenib, trametinib, placebo)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10201135|NCT04526600|No Intervention|No fidget|
10201136|NCT04526600|Experimental|With fidget|The participant is given a specially designed fidget ball
10201137|NCT04521114|Experimental|Phase II: 700 mg PRO 140 SC weekly|"Drug: 700 mg leronlimab will be administered subcutaneously every week for 13 weeks.~Other names:~PRO 140"
10201138|NCT04521114|Placebo Comparator|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
10201139|NCT04520516|Experimental|tVNS active device|VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
10201140|NCT04520516|Sham Comparator|Sham tVNS device|Sham VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
10201141|NCT04516018|Experimental|Cold acclimation arm|An oral glucose tolerance test will be performed on day 1 of the study. The next day (day 2), subjects will be exposed to shivering thermogenesis for at least 1 hour. The day after, an oral glucose tolerance test will be performed (day 3). The following 9 days, subjects will be exposed daily to shivering thermogenesis for at least 1 hour (day 4-12). On the last day (day 13), an oral glucose tolerance test will be performed.
9743707|NCT05167396|Experimental|Healthy Controls (HC)|n=90
9743708|NCT05167396|Experimental|Clinical High Risk of Psychosis (CHRP)|n=30
9743709|NCT05167396|Experimental|First Episode Psychosis (FEP)|n=30
9743710|NCT05166564|Experimental|PROMED (Experimental Intervention 1)|A Protein Enriched Mediterranean Diet (PROMED) intervention. Participants will receive individually tailored resources to encourage adoption of a protein-enriched Mediterranean diet pattern.
9743711|NCT05166564|Experimental|PROMED-EX (Experimental Intervention 2)|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention. Participants will receive the same PROMED diet resources (Experimental Intervention 1) and an individually tailored exercise intervention.
9743712|NCT05166564|No Intervention|Control group|'Standard Care' - consisting of a general diet information sheet.
9743713|NCT05165485|Experimental|Revefenacin|Revefenacin DoseA administered with tiotropium placebo
9743714|NCT05165485|Active Comparator|Tiotropium|Tiotropium DoseB administered with revefenacin placebo
9743715|NCT05161546|Experimental|patients with bipolar disorder (BD)|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit.~Between day 23 and day 28 (after the second visit), patients will be offered to assess the retinal structure and microvascularization using Spectral Domain Optical Coherence Tomography (SD-OCT) and OCT-Angiography (OCT-A)."
9743716|NCT05161546|Active Comparator|healthy volunteers|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit."
9743717|NCT05156060|Experimental|Gabapentin plus Ketamine|Gabapentin and Ketamine will be taken 3 times per day.
9984677|NCT03836651|Active Comparator|Control Group|Following completion of baseline data collection, participants will be randomized to one of two groups. The research assistant will open a pre-assigned envelope in which group assignment was determined by a random number/block generator. The intervention is designed to complement guideline directed medical management. Therefore, both the intervention and control group will continue to be medically managed by their health care provider as usual. In order to avoid introducing the confound of extra attention paid to the intervention group, the control group will have the same visit and call schedule as the intervention group.
9743722|NCT05117034|Experimental|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
9743723|NCT05117034|Placebo Comparator|Placebo|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
9743724|NCT05098054|Experimental|Arm 1, Moderate HI: Soticlestat 300 mg|Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with moderate HI.
9743725|NCT05098054|Experimental|Arm 2, Severe HI: Soticlestat 300 mg or lower dose|Soticlestat 300 mg or lower, tablets, orally, once on Day 1 to participant with severe HI.
9743726|NCT05098054|Experimental|Arm 3, Normal hepatic function: Soticlestat 300 mg or lower dose|Soticlestat 300 mg or lower, tablets, orally, once on Day 1 to healthy participants.
9743727|NCT05092360|Experimental|Nemvaleukin and Pembrolizumab Combination|
9743728|NCT05092360|Experimental|Pembrolizumab|
9743729|NCT05092360|Experimental|Nemvaleukin|
9743730|NCT05092360|Active Comparator|Investigator's Choice|Options for protocol-specific Investigator's choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine. The Investigator will pre-select the Investigator's choice treatment before the randomization of each patient.
9743731|NCT05081934|Active Comparator|Treatment as usual, TAU|TAU: Interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial.
9743732|NCT05081934|Experimental|TAU + A-CRA|"Behavioral: A-CRA, a 12-14 weekly sessions long behavioral treatment for youth (ages 12-25) suffering from substance use disorder and co-occurring problems, i.e. criminal behavior. The aim is to increase constructive behavior that reduces the need of substances and creates a context where it is rewarding to stay sober. Individual functional analyses, goals and needs guides treatment planning and interventions.~TAU: interventions and treatments usually offered and delivered in institutional care. For example, Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. Further specification of TAU will be made in collaboration with the institutions included in the trial."
9743733|NCT05073133|Experimental|OAV101|A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes
9743734|NCT05058911|Experimental|Internet-delivered exposure-based cognitive behavior therapy (Exp-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
9743735|NCT05058911|Active Comparator|Internet-delivered traditional cognitive behavior therapy (T-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
9743736|NCT05035693|Experimental|PMCF MOVE-C|PMCF MOVE®_C is a single arm observational study with 170 patients.
9743737|NCT05031806|Experimental|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
9743738|NCT05031806|Experimental|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
9743739|NCT05031806|Experimental|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
9743740|NCT05031806|Placebo Comparator|Vehicle (eye drop formulation without aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
9743741|NCT05030324|Experimental|XC221 100 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally in the morning (between 7:00 and 11:00) and 1 tablet of placebo in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
9743742|NCT05030324|Experimental|XC221 200 mg|Subjects will receive 1 tablet of XC221, 100 mg tablets orally twice daily, in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
9743743|NCT05030324|Placebo Comparator|Placebo|Subjects will receive 1 tablet of placebo orally twice daily in the morning (between 7:00 and 11:00) and in the evening (between 19:00 and 23:00) regardless of food intake for 5 days
9743744|NCT05018091|Active Comparator|Group 1|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
9743745|NCT05018091|Active Comparator|Group 2|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
9743746|NCT05018091|Active Comparator|Group 3|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
9743747|NCT05016284|Experimental|JW-100|Subjects applying JW-100 cream twice daily at home (experimental group).
9743748|NCT05016284|Active Comparator|EUCRISA|Subjects applying EUCRISA® (Pfizer) product twice daily at home (comparator group).
9743749|NCT04998487|Experimental|LY3471851 (Abdomen)|LY3471851 administered subcutaneously (SC) into the abdomen.
9743750|NCT04998487|Experimental|LY3471851 (Thigh)|LY3471851 administered SC into the thigh.
9743751|NCT04982666|Experimental|Whole-Food, Plant-Based Diet Group|Subjects with a known diagnosis of Crohn's disease will follow a whole-food, plant-based diet for a total of 12 weeks
9743752|NCT04982666|Active Comparator|FODMAP Diet|Subjects with a known diagnosis of Crohn's disease will follow a FODMAP diet for a total of 12 weeks
9743753|NCT04980482|Experimental|Cohort A, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
9743754|NCT04980482|Experimental|Cohort A, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
9743755|NCT04980482|Experimental|Cohort B, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
9743756|NCT04980482|Experimental|Cohort B, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
9743757|NCT04976621|Experimental|Behavioral Activation (BA) intervention group|Participants in the BA group will receive BA treatment and treatment as usual. BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
9743758|NCT04976621|Other|Treatment as Usual Control Group|Participants in the Control group receive treatment as usual (TAU), which is usual care provided by the VA medical center.
9743759|NCT04974216|Experimental|R-Lena-Tafa|"12 cycles of 28 days. From C1 to C6 : rituximab + tafasitamab + lenalidomide and from C7 to C12: tafasitamab and lenalidomide~Patients with Progressive Disease or Stable Disease after 3 cycles should start a conventional chemotherapy (rituximab + cyclophosphamide + adriamycine + vincristine + prednisone R-miniCHOP) at Investigator's discretion according to local practices"
9743760|NCT04944992|Experimental|Efinopegdutide|Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.
9743761|NCT04944992|Active Comparator|Semaglutide|Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.
9743764|NCT04923542|Experimental|Phase 1: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. In the phase I portion, safety will be monitored initially by a 3+3 design. If unexpected neurologic toxicities are noted, the dose of radiation therapy will be modified.
9743765|NCT04923542|Experimental|Phase 2: Radiation Therapy and Abemaciclib|Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation at the phase 1 dose to sites of brain metastases or post-operative cavities with continued abemaciclib.
9743766|NCT04922983|Sham Comparator|Group I: Placebo isometric measure, no injection|Group I: no isometric yoga-like exercise, no injection given.
9743767|NCT04922983|Placebo Comparator|Group II Isometric yoga-like exercise, placebo injection given|Group II isometric yoga-like exercise, injection of preservative-free normal saline.
9743768|NCT04922983|Active Comparator|Group III: True isometric exercise, botulinum injection|Group III: Isometric yoga-like exercise, botulinum injection given
9743769|NCT04922983|Active Comparator|Crossover|After the three months, Arm I and Arm II patients will be given botulinum injections, and Group I will be given the proper yoga-like exercise. These two arms will constitute a further comparator with their own performances in the first 3 months of the study.
9743770|NCT04849988|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - Intramuscular injections into affected neck muscles.
9743771|NCT04849988|Experimental|ABP-450 - Medium Dose|ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.
9743772|NCT04849988|Experimental|ABP-450 - High Dose|ABP-450 High Dose - Intramuscular injections into affected neck muscles.
9743773|NCT04849988|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.
9743774|NCT04805216||Immunocompromised patients (study group)|People who are likely to have a suppressed immunity due to their haematological disorder or its treatment
9743775|NCT04805216||Immunocompetent volunteers (control group)|People without suppressed immunity
9743776|NCT04786964|Experimental|Cosibelimab|Participants receive cosibelimab 1200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by cosibelimab 1200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
9743777|NCT04786964|Active Comparator|Control|Participants receive pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pemetrexed 500 mg/m^2 IV Q3W until progression.
9743778|NCT04754321|Experimental|Arm A (pembrolizumab, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo salvage surgery during week 4. Beginning week 8, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 9. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
9743779|NCT04754321|Experimental|Arm B (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo low dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
9743780|NCT04754321|Experimental|Arm C (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
9743781|NCT04750226|Experimental|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 96 weeks.
9743782|NCT04740814|Experimental|Certolizumab pegol|Subjects in this arm will receive doses of certolizumab pegol for the treatment of Rheumatoid Arthritis, in accordance with the US label.
9743783|NCT04737772|Active Comparator|Standard Quitline Treatment As Usual (TAU)|State quitline treatment as usual
9743784|NCT04737772|Experimental|QL Marijuana Check-Up intervention (QL-MJCU).|Newly developed intervention for co-users of marijuana and tobacco.
9743785|NCT04729231|Active Comparator|Nasalis Sling Flap|
9743786|NCT04729231|Active Comparator|Lobed transposition flap|
9743787|NCT04729114|Experimental|Cohort 1|The starting dose will be 180 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
9743788|NCT04729114|Experimental|Cohort 2|Cohort 2 dose will be 360 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
9743789|NCT04729114|Experimental|Cohort 3|Cohort 3 dose will be 720 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
9743790|NCT04729114|Experimental|Cohort 4|Cohort 4 dose will be 1260 mg of PRL-02 depot (abiraterone decanoate for intramuscular injection)
9743791|NCT04729114|Experimental|Dose Expansion|The recommended Phase 2a dose will be a dose from the cohort dose escalation phase that does not exceed the maximum tolerated dose and adequately suppresses serum testosterone (i.e., to less than or equal to 1 ng/dL) over the course of treatment. More than one dose may be selected for investigation in Phase 2a of the study.
9743792|NCT04721171|Active Comparator|Intervention group|The Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
9743793|NCT04721171|Sham Comparator|Placebo Group|The sham is similar in appearance to the Bridge device but does not deliver any electrical stimulation and is a sham that is designed to look identical to the Bridge device. It is placed on the external ear at the beginning of the study and removed by the patient after 5 days.
9743794|NCT04717323|Experimental|Patients|Gait with and without pelvic assistance
9743795|NCT04717323|Experimental|Controls|Gait with no pelvic assistance
9743796|NCT04710784|Experimental|I-TEST Intervention Package|Each study site will begin in the baseline, pre-implementation phase, and then be randomized to implement the I-TEST intervention package for a duration of three months, followed by the post-implementation phase.
9743797|NCT04650607||Adverse event after injection of phages|patients having a BJI/PJI treated by injection of phages, with or without surgery
9743798|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
9743799|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
9743800|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 3|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
9743801|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 4|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
9743802|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 5|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
9743803|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
9743804|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
9743805|NCT04643457|Placebo Comparator|Part A: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
9743806|NCT04643457|Placebo Comparator|Part A: Subcutaneous Placebo arm|Subjects randomized to this arm will receive subcutaneous Placebo to maintain the blinding.
9743807|NCT04643457|Experimental|Part B: Intravenous UCB9741 arm|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
9743808|NCT04643457|Placebo Comparator|Part B: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
9743809|NCT04641507|Active Comparator|Tamsulosin treated group|83 patient with lower ureteric stone will take tamsulosin 0.4 mg once daily .Therapy will be given for a maximum of 4 weeks.
9743810|NCT04641507|Active Comparator|Tadalafil treated group|83 patients with lower ureteric stone will take tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
9743811|NCT04618744|Placebo Comparator|Placebo|Fish oil
9743812|NCT04618744|Experimental|ORMD-0801 (Insulin) capsule 8 mg BD|ORMD-0801 (insulin) capsule Dose: 8 mg BD Dosage Regimen: 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) Mode of Administration: Oral
9743813|NCT04617457|Experimental|NAPOX chemotherapy|NAPOX chemotherapy in 14-day cycles with the four IMPs given intravenously in the following order: nal-irinotecan, oxaliplatin, folinic acid and 5-fluouracil.
9743814|NCT04590534|Experimental|study Group A|patients will receive one capsule of [garcinia 500 mg and chromium 281 mg] 3 times daily for 12 weeks.
9743815|NCT04590534|Active Comparator|Active control Group B|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
9743816|NCT04590534|Placebo Comparator|Placebo Group C|patients will receive placebo 3 times daily for 12 weeks
9781943|NCT01161524|Experimental|Perampanel (Extension Phase)|During the Extension Phase, participants previously assigned to perampanel arm (Core Study) continued taking study medication at the dose achieved at the end of the Core Study once daily. Participants previously assigned to a placebo arm (Core Study) started perampanel dose at 2 mg/day and up-titrated weekly in 2-mg increments up to a maximum dose of 12 mg/day.
9781944|NCT01161537|Experimental|VX-770|"Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects."
9781945|NCT01161563|Active Comparator|Leuprolide acetate|Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area. Injection occurred either 6 months before or 6 months after injection of triptorelin pamoate suspension (Trelstar 22.5 mg) intramuscularly in the buttock.
9781946|NCT01161563|Active Comparator|Triptorelin pamoate|Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock. Injection occurred either 6 months before or 6 months after injection of polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) subcutaneously in upper or mid-abdominal area.
9781947|NCT01161628|Experimental|Rituxan|All patients receive Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
9743817|NCT04586660|Experimental|Surgically unsalvageable disease|Participants with surgically unsalvageable disease (eg, sacral, spinal Giant cell tumor of bone [GCTB], or multiple lesions including pulmonary metastases).
9743818|NCT04586660|Experimental|Surgically salvageable disease|Participants with surgically salvageable disease whose planned on-study surgery is associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy).
9743819|NCT04564846|Placebo Comparator|Placebo|Subjects will be administered a single capsule of placebo( fish oil); placebo will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
9743820|NCT04564846|Active Comparator|ORMD-0801|Subjects will be administered a single 8mg capsule of ORMD-0801; study medication will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
9743821|NCT04546711||Ketogenic Diet|"Baseline Assessments~Ketogenic diet intervention~3 and 6 month Assessments"
9743822|NCT04537936|Experimental|Meaning Centered Psychotherapy for Latinos (MCP-L)|
9743823|NCT04537936|Active Comparator|Control|
9743824|NCT04528212|Experimental|Group I|Glimepiride (4 mg) per Day
9743825|NCT04528212|Experimental|Group II|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
9743826|NCT04528212|Experimental|Group III|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
9743827|NCT04526106|Experimental|Part 1: Dose Escalation|Multiple doses of RLY-4008 for oral administration.
9743828|NCT04526106|Experimental|Part 2: Dose Expansion|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
9743829|NCT04524442|Experimental|GEP-NET|One dose of arginine/lysine solution administered intravenously over a 4-hour period
9743830|NCT04518969|No Intervention|Control|Standard medical therapy (ie: control group) : Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed……
9743831|NCT04518969|Experimental|Cytosorb|"CytoSorb therapy (ie: study group): Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed…… Plus patients will be on CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
9743832|NCT04511338|Experimental|Sequence AB: circuit A follow by circuit B|Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline Circuit (B) includes dialyzer with Endexo and the Streamline bloodline
9743833|NCT04511338|Experimental|Sequence BA: circuit B follow by circuit A|Circuit (B) includes dialyzer with Endexo and the Streamline bloodline Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline
9743834|NCT04498767|Active Comparator|Arm 1: Standard of Care + palliative RT|"Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).~Systemic therapy will be pre-specified based on the standard of care approach for that patient, and it may include cytotoxic, targeted, hormonal, or immunotherapy."
9743835|NCT04498767|Experimental|Arm 2: Standard of Care + SBRT|"The experimental arm consists of SBRT (and standard of care systemic therapy). Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size & location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.~Patients treated with prior or concomitant systemic therapy are eligible for this study. Use of chemotherapy regimens, targeted therapy or immunotherapy containing potent enhancers of radiation damage (e.g. gemcitabine, doxorubicin) can be postponed or interrupted for a duration of one month after radiation."
9743836|NCT04493931|Experimental|Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg|This is a fixed sequence (Sequence AB) cohort. Participants will receive gepotidacin 1500 milligrams (mg) single dose (SD) on Day 1 of Period 1 (Treatment A); and Cimetidine 400 mg 4 times daily on Days 1 through 4 of Period 2 and gepotidacin 1500 mg single dose (Treatment B). Gepotidacin will be administered 1 hour after the first dose of cimetidine on Day 2 of Period 2. There will be a washout of at least 3 days between Treatment A and Treatment B, and a follow-up visit 5 to 7 days after the last dose of cimetidine.
9743837|NCT04493931|Experimental|Cohort 2: Gepotidacin 1500 mg + Rifampicin 600 mg|This is a fixed sequence (Sequence CDE) cohort. Participants will receive gepotidacin 1500 mg single dose on Day 1 of Period 1 (Treatment C), rifampicin 600 mg (administered in the evenings) once daily for 7 days (Days 1 through 7 of Period 2, to elicit maximal enzyme induction) (Treatment D); and gepotidacin 1500 mg single dose administered in the morning on Day 8 and rifampicin 600 mg administered in the evening on Days 8 and 9 of Period 2 (Treatment E). There will be a washout of at least 3 days between Treatment C and Treatment D, and a follow-up visit 7 to 10 days after the last dose of rifampicin.
9743838|NCT04493931|Experimental|Cohort 3: Digoxin 0.5mg+Midazolam 2mg then Gepotidacin 3000mg|Participants will receive digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 1 on Day 1 then gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 2 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G). There will be a washout of at least 10 days between treatments. In Sequence 2, these regimens are reversed. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
9743839|NCT04493931|Experimental|Cohort 3: Gepotidacin 3000mg then Digoxin 0.5mg+Midazolam 2mg|Participants will receive gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 1 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G) followed by digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 2 on Day 1. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
9743840|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fed then fasted then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fed conditions in Period 1 (Treatment H), then a single dose of gepotidacin 1500 mg under fasted conditions in Period 2 (Treatment I), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
9743841|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fasted then fed then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fasted conditions in Period 1 (Treatment I), then a single dose of gepotidacin 1500 mg under fed conditions in Period 2 (Treatment H), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
9743842|NCT04493931|Placebo Comparator|Cohort 4: Placebo fed then fasted then fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fed conditions in Period 1, then a single dose of placebo under fasted conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
9743843|NCT04489173|Experimental|Treatment|Treatment with TAS102
9743844|NCT04487353|Experimental|Experiment Group|"The Labor Evaluation Information Scale (LEIS) was administered as a pre-test before applying to 30 students who had taken a course on childbirth. After the pre-test, the application was carried out with the Labor mechanism application developed with virtual reality technology (VRT-LMA). Immediately after the application, data were collected with the LEIS, sense of presence scale and cognitive load scale. Post-test was performed again with the Labor Evaluation Information Scale (LEIS) 5 weeks after the application."
9743845|NCT04487353|No Intervention|Control Group|"Before the theory training, the Assessment Knowledge Scale (LEIS) was administered as a pre-test to 31 students in the control group who had taken a course on obstetrics. After the pre-test, theory training including birth knowledge was given. Labor mechanism application developed with virtual reality technology (VRT-LMA) was not applied to the control group. After 4 hours of theoretical training, the final test was performed using LEIS. After 5 weeks, the last test was repeated."
9743846|NCT04480528|Experimental|BFRT Group|This group will receive physical therapy plus active BFRT.
9743847|NCT04480528|Sham Comparator|Standard of Care Group|This group will receive physical therapy plus sham BFRT.
9743848|NCT04479735|Experimental|VR goggle with venipuncture|Virtual reality goggles SamsungGearVR supplied by KindVR will be placed on patients at least 2 min prior to venipuncture. All patients will also receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture.
9743849|NCT04479735|No Intervention|no VR goggle with venipuncture|Patients will receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture but NO virtual reality goggles.
9743850|NCT04476511|Active Comparator|Slower Loading Dose|30.000IU cholecalciferol once weekly for ten weeks
9743851|NCT04476511|Active Comparator|Moderate Loading Dose|30.000IU cholecalciferol twice weekly for five weeks
9743852|NCT04468659|Experimental|A45 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 milligram per kilogram (mg/kg), administered as intravenous (IV) infusion, every two weeks from Week 0 to 6, then 10 mg/kg, administered as IV infusion, every two weeks from Week 8 to 94, and 10 mg/kg, administered as IV infusion, every four weeks from Week 96 to 216.
9743853|NCT04468659|Placebo Comparator|A45 Trial: Placebo|Participants will receive placebo (0.9 percent [%] sodium chloride solution), administered as IV infusion, every two weeks from Week 0 to 94, then every four weeks from Week 96 to 216.
9743854|NCT04468659|Experimental|A3 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 mg/kg, administered as IV infusion, every four weeks from Week 0 to 4, then 10 mg/kg, administered as IV infusion, every four weeks from Week 8 to 216.
9743855|NCT04468659|Placebo Comparator|A3 Trial: Placebo|Participants will receive placebo (0.9% sodium chloride solution), administered as IV infusion, every four weeks from Week 0 to 216.
9743856|NCT04458298|Experimental|Stage I: Cohort A: OP-101 2 mg/kg|Participants will receive a single intravenous (IV) infusion of OP-101 2 milligram per kilogram (mg/kg) on Day 1.
9743857|NCT04458298|Experimental|Stage I: Cohort B: OP-101 4 mg/kg|Participants will receive a single IV infusion of OP-101 4 mg/kg on Day 1.
9743858|NCT04458298|Experimental|Stage I: Cohort C: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Day 1.
9743859|NCT04458298|Placebo Comparator|Stage I: Cohort D: Placebo|Participants will receive a single IV infusion of matching placebo on Day 1.
9743860|NCT04458298|Experimental|Stage II: Cohort E: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Days 1 and 4.
9743861|NCT04458298|Placebo Comparator|Stage II: Cohort F: Placebo|Participants will receive a single IV infusion of matching placebo on Days 1 and 4.
9743862|NCT04456569|Experimental|GAE + Standard of Care|Participants in this arm will receive geniculate artery embolization and standard of care.
9743863|NCT04456569|No Intervention|Standard of Care|Participants in this arm will receive standard of care only.
9743864|NCT04456140|Experimental|Prevention (pre-genetic test counseling, genetic testing)|Patients watch a pre-recorded genetic counseling video and those who consent to genetic testing undergo collection of blood samples. Patients also complete surveys over 5-15 minutes each prior to receiving their genetic test results and following the receipt of genetic test results.
9743865|NCT04445662|Active Comparator|Control (n=200)|"Varenicline~Tobacco coaching~Saliva cotinine monitoring with fixed payments ($10) regardless of results"
9743866|NCT04445662|Experimental|Financial incentives (n=200)|"Varenicline~Tobacco coaching~Saliva cotinine monitoring with escalating payments ($25-70) for levels <30 ng/ml"
9743867|NCT04441229|Experimental|Treatment Group|Patients age 12-24 diagnosed with pediatric-onset Multiple Sclerosis
9743868|NCT04429607|Active Comparator|Erbium:YAG Laser|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
9743869|NCT04429607|Active Comparator|PDL plus Nd:YAG|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
9743870|NCT04429607|Active Comparator|ED&C treatment|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
9743871|NCT04429308|Active Comparator|Photodynamic Therapy|One upper arm will be exposed to blue light therapy
9743872|NCT04429308|Active Comparator|Chemical Peels|One upper arm will be exposed to Jessner's Solution AND 35% Trichloroacetic acid peel
9781948|NCT01161771||Patients with cataract and corneal astigmatism|Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
9781949|NCT01161862|Experimental|Bi-hormonal with meal-priming bolus|The first meal-priming bolus was solely based on weight (0.05 U/kg), after which meal-priming boluses were automatically adapted by the control system online targeting 75% of the anticipated insulin needed in the first four hours after the start of the meal
9781950|NCT01161862|Experimental|Bi-hormonal without meal-priming bolus|The insulin controller was entirely reactive to CGMG; there were no meal priming boluses and no meal announcements
9781951|NCT01162005|Experimental|Tacrolimus|Tacrobell
9743873|NCT04428034|Experimental|Learning Skills Together Intervention|Participants in the Learning Skills Together program will begin their participation with a one-on-one phone call with an interventionist, who will ensure the participant is prepared to to attend the group sessions (e.g., familiar with videoconference technology) and will help the participant to set individual goals. The caregiver participant will then attend 4, group-based sessions lasting approximately 1.5 hours each, to learn about common complex care tasks managed by family caregivers to someone with mid-stage Alzheimer's disease, such as managing behavioral symptoms of dementia, incontinence, nutrition, transferring, medication management, and more. Sessions will integrate interactive activities, such as videos, case studies, and discussions. Approximately four weeks later, caregivers will be asked to attend a group reflection session to discuss application of what was learned and progress in meeting individual goals.
9743874|NCT04421352|Experimental|low-dose radiation+CS1001|low-dose radiation+CS1001
9743875|NCT04417621|Experimental|LXH254 + LTT462|
9743876|NCT04417621|Experimental|LXH254 + trametinib|
9743877|NCT04417621|Experimental|LXH254 + ribociclib|
9743878|NCT04413617|Experimental|PF-06650833 + tofacitinib|
9743879|NCT04413617|Experimental|PF-06650833 + PF-06651600|
9743880|NCT04413617|Experimental|PF-06650833|
9743881|NCT04413617|Experimental|PF-06651600|
9743882|NCT04413617|Experimental|Tofacitinib|
9743883|NCT04410822||Patients enrolled|an age older than 18 years old and symptoms of FI according to Rome IV criteria.
9743884|NCT04407676|Experimental|Experimental|Patients eligible for an investigator initiated trial are given the standard PIS by email, and are also emailed a summary PIS and access to an online set of 10 video educational modules. They are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They then present for their standard of care consent visit.
9743885|NCT04407676|Placebo Comparator|Control|Patients eligible for an investigator initiated trial are given the standard PIS by email and are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They will then be emailed and are also emailed a summary PIS and access to an online set of 10 video educational modules. They will then perform the QuIC-A and QuIC-B again. They will then present for their standard of care consent visit.
9743886|NCT04389918|Experimental|Tality|Participants will receive TalityTM as their sole intake for nutritional purposes for a 4 week period.
9743887|NCT04381260||2016-2019 STEMI Registry|Retrospective data will be collected to develop a well-characterized registry of patients treated from 2016-2019 by any of 14 local rural EMS agencies and transported to a facility capable of performing Percutaneous Coronary Intervention. This registry will be used to determine the time to PCI performance for each of the EMS agencies. Time will be adjusted for patient distance from a PCI center using a linear mixed model with a random effect for center and a fixed effect for distance. This process will allow qualitative methods to identify organizational culture, structure, and clinical processes that impact STEMI care from the two highest and lowest performing rural EMS agencies. (n=750)
9743888|NCT04381260||Key Informant Interviews|After identifying the two highest and lowest performing rural EMS agencies in the 2016-2019 STEMI Registry, key employees from each of those agencies will be recruited to participate in semi-structured key informant interviews. The interviews will assess current clinical care, organizational culture and opportunities for improvement. (n=32)
9743889|NCT04381260||Stakeholder Surveys|Employees at all local EMS agencies will be invited to participate in stakeholder surveys to quantify each agency's use of the care strategies identified during Key Information Interviews. (n=240)
9781952|NCT01162096|Experimental|Transplantation|
9743890|NCT04380233|Experimental|Investigational Drug Group|A 8-weeks double-blind treatment period with a Proprietary Chinese Medicine (consists of 4 kinds of Chinese herbs at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
9743891|NCT04380233|Placebo Comparator|Placebo Group|A 8-weeks double-blind treatment period with Placebo Capsules (at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
9743892|NCT04370236|Placebo Comparator|Placebo + Standard of Care|Patients will receive placebo + standard medical care
9743893|NCT04370236|Experimental|INB03 + Standard of Care|Patients will receive INB03 + standard medical care
9743894|NCT04364763|Experimental|RBT-9 (90 mg)|RBT-9 (90mg) will be administered intravenously over a 120-minute period on Day 1.
9743895|NCT04364763|Placebo Comparator|Placebo|0.9% sodium chloride (normal saline) will be administered intravenously over a 120-minute period on Day 1.
9743896|NCT04364750|Experimental|Group A|"Participants in group A will undergo challenges in the order:~High-FODMAP beverage + placebo probiotic + L-Histidine~Low-FODMAP beverage + placebo probiotic + L-Histidine~High-FODMAP beverage + probiotic + L-Histidine~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
9743897|NCT04364750|Experimental|Group B|"Participants in group A will undergo challenges in the order:~Low-FODMAP beverage + placebo probiotic + L-Histidine~High-FODMAP beverage + probiotic + L-Histidine~High-FODMAP beverage + placebo probiotic + L-Histidine.~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
9743898|NCT04364750|Experimental|Group C|"Participants in group A will undergo challenges in the order:~High-FODMAP beverage + probiotic + L-Histidine~High-FODMAP beverage + placebo probiotic + L-Histidine~Low-FODMAP beverage + placebo probiotic + L-Histidine.~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
9743899|NCT04342572|Experimental|Intra-arterial injections of melphalan|-Participants will receive intra-arterial injections of melphalan Q4W for 3 cycles.
9743900|NCT04341948|Active Comparator|Group 1 (Treatment)|Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
9743901|NCT04341948|Sham Comparator|Group 2 (Control)|Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.
9743902|NCT04339426|Experimental|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)
9743903|NCT04338204||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
9743904|NCT04337723|Experimental|Intervention|Clinic participants will be taught how to do ABI testing and WIfI scoring to identify patients with PAD/DM disease for early vascular referral.
9743905|NCT04332198|Experimental|ALS patients|
9743906|NCT04330417|Experimental|EMG Glove Group|A total of 12 sessions of robot-assisted hand training for 6 consecutive weeks.
9743907|NCT04330417|Active Comparator|Control Group|A total of 12 session of standard hand therapy sessions in 6 consecutive weeks.
9743908|NCT04318197|Active Comparator|Global rehabilitation|2 hours of daily rehabilitation, 3 days per week during 4 weeks
9743909|NCT04318197|Experimental|Personalized rehabilitation|2 hours of daily rehabilitation including at least 2 times 20 minutes of electrostimulation on atrophied muscles, 3 days per week during 4 weeks
9743910|NCT04318197|No Intervention|Classic rehabilitation|40 minutes of rehabilitation, once a week during 4 weeks.
9743911|NCT04312503||COHORT A: Lurasidone|Patients treated with Lurasidone
9743912|NCT04312503||COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)|Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)
9743913|NCT04302428||Pediatric CF Patients|Pediatric patients ages 3 months to 3 years with CF identified via newborn screening.
9743914|NCT04298463||COHORT A: dalbavancin|Patients hospitalized for at teast two days affected by ABSSSI and treated with dalbavancin.
9743915|NCT04298463||COHORT B: lipo and glyco-peptid drugs|Patients hospitalized for at teast two days affected by ABSSSI and treated with vancomycin, teicoplanin or daptomycin.
9743916|NCT04282915|Active Comparator|Implementation as Usual|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme adapted by the Nepal Ministry of Health.
9743917|NCT04282915|Experimental|RESHAPE|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme, plus they will have co-facilitation by mental health service users providing recovery testimonials as well as aspirational figures presenting testimonies and conducting myth-busting sessions.
9743918|NCT04282720|Other|SurgiMend Mesh|"SurgiMend Mesh - FDA approved noncross-linked bovine dermis biologic mesh. SurgiMend Mesh will be used according to FDA approved recommendations for the use of abdominal wall hernia reinforcement.~SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend is specifically indicated for:~Hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias."
9743919|NCT04281654|Experimental|Ballroom Dance|The Dance group participants will take part in ballroom dance lessons twice/week for 45-minutes/session for 10 weeks
9743920|NCT04281654|Experimental|Ukulele|The Music group participants will take part in ukulele lessons twice/week for 45-minutes/session for 10 weeks
9743921|NCT04281654|Active Comparator|Control|The Control group participants will meet 2 times per week for 45-minutes/session for 10 weeks to participate in a social conversational group for 10 weeks
9743922|NCT04263441|Experimental|NICE Intervention|The proposed intervention will engage clients in the health care enrollment and navigation process in-person, at the time of the HIV testing event. Subjects will be asked to share thoughts on the satisfaction survey.
9743923|NCT04263441|No Intervention|Control Intervention|Subjects will be offered a handout on how to enroll in healthcare coverage This group will be provided with the site's standard healthcare enrollment and linkage to care, which is specific to the health care clinic they are visiting. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review. Subjects will be asked to share thoughts on the satisfaction survey.
9743924|NCT04262947|Active Comparator|Conventional Method|Placement of peripheral venous catheter using conventional methods
9743925|NCT04262947|Experimental|VeinViewer Visualization Only|Use of a VeinViewer to visualize the most suitable target. Once the target has been identified and marked, the device will be placed aside and the peripheral venous catheter will be placed using conventional methods
9743926|NCT04262947|Experimental|Constant Imaging with VeinViewer|Identification of the most suitable target and placement of a peripheral venous catheter under constant imaging with a VeinViewer
9743927|NCT04260854|Active Comparator|Bupivacaine HCl|Immediately prior to surgical wound closure, participants randomized to the bupivacaine arm will be injected with bupivacaine HCl along the closure site.
9743928|NCT04260854|Placebo Comparator|Saline|Immediately prior to surgical wound closure, participants randomized to saline, will receive saline injections along the closure site.
9743929|NCT04251351|Experimental|Arm 1|Paracetamol 15 mg/kg/dose 6 hourly for 72 hours
9743930|NCT04251351|Sham Comparator|Arm 2|Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.
9743931|NCT04248569|Experimental|DNAJB1-PRKACA peptide vaccine, Nivolumab, and Ipilimumab|
9743932|NCT04248192|Experimental|Donor Derived HIV-Specific T-cells (DD HST-NEETs)|Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
9743933|NCT04242147|Experimental|Bi-weekly Monotherapy Dosing Regimen|For the biweekly dose escalation cohorts, KD033 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).
9743934|NCT04242147|Experimental|Weekly Monotherapy Dosing Regimen|For the weekly dose escalation cohorts, KD033 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW).
9743935|NCT04239131|Other|All Patients|It is a single arm study. Skin prick testing and laboratory Tests are carried out on all patients in the same way
9743936|NCT04221750|Experimental|Lifestyle Therapy plus Metformin|Diet-induced weight loss and Exercise Training plus Metformin 1 gm bid
9743937|NCT04221750|Placebo Comparator|Lifestyle Therapy plus Placebo|Diet-induced weight loss and Exercise Training plus Placebo
9743938|NCT04221750|Active Comparator|Healthy lifestyle plus Metformin|Healthy lifestyle and Metformin 1 gm bid
9743939|NCT04220125|Experimental|Ketamine Group|Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
9743940|NCT04220125|Active Comparator|MIdazolam Group|Midazolam 0.045 mg/kg administered via intravenous catheter.
9743941|NCT04217902||People living with diabetes in Grenoble and Lyon areas|Eligible patients with type 1 or type 2 diabetes 1) during or after hospitalization for decompensation, ketoacidosis, or other emergency or elective interventions such as insulin pump installation, 2) followed in routine care in specialized diabetes services, 3) participating in patient associations.
9743942|NCT04217902||Health care professionals working in diabetes care in Grenoble|Health care professionals working with diabetes care in specialized services or ambulatory care.
9743943|NCT04213079|Experimental|Vestibulo-ocular reflex (VOR)|Treatment by re-adaptation of the vestibulo-ocular reflex (VOR) for participants with motion triggered MdDS
9743944|NCT04213079|Experimental|Habituation of velocity storage|Participants with motion triggered MdDS
9743945|NCT04209686|Experimental|All Participants|All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.
9743946|NCT04207944|Experimental|Sulindac|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Patients will continue drug for 3 years during follow-up.
9743947|NCT04207944|Placebo Comparator|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus placebo. Patients will continue placebo for 3 years during follow-up.
9743948|NCT04204863||SE patients|
9743949|NCT04204408|Experimental|Single dose (part 1) Mim8|Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.
9743950|NCT04204408|Placebo Comparator|Single dose (part 1) placebo|Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.
9743951|NCT04204408|Experimental|Multiple dose (part 2)|Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.
9743952|NCT04190849||Non-alcoholic fatty liver disease patients|Children (<18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.
9743953|NCT04184050|Experimental|Part 1 (Dose Escalation)|HPN217 is IV administered 1x weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.
9743954|NCT04184050|Experimental|Part 2 (Dose Expansion)|HPN217 is IV administered 1x weekly for about 1 hour. Doses will be determined from Part 1 (dose escalation)
9743955|NCT04177758|Placebo Comparator|Control|Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm.
9743956|NCT04177758|Experimental|Treatment|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
9743957|NCT04177680|Experimental|Omega-3 pentaenoic acid (MAT9001)|2g MAT9001 capsules twice daily with meals
9743958|NCT04177680|Active Comparator|Icosapent ethyl (Vascepa)|2g Vascepa capsules twice daily with meals
9743959|NCT04169074|Experimental|Treatment with abemaciclib|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery. Abemaciclib 150 mg PO twice daily on Days 1-21 (+7 days).
9743960|NCT04163731||stable patient, referred for a VO2 peak test|All stable patients above 18 years, referred for a VO2 peak test as part of their standard management in the Louis Pradel Hospital (Hospices Civils de Lyon, Lyon) and without acute clinical event in the last 3 months. All patients who accept to participate will undergo a self-questionnaire of 10 minutes.
9743961|NCT04161950||Tested device model (EG-UR5-S50 )|Tested device model: The EG-UR5 echoendoscope manufactured by SonoSscope Medical Crop. That used with the HD-500 image processor, HDL-500X light source and S50 ultrasonic processor.
9743962|NCT04161950||Compared device model (GF-UE260-ME2)|Compared device model: The GF-UE260 echoendoscope manufactured by Olympus and its compatible light source, image processor and ME2 ultrasonic processor.
9743963|NCT04157673|Experimental|Episodic Future Thinking introduced at 6 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 8-week period following a 6-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
9743964|NCT04157673|Experimental|Episodic Future Thinking introduced at 8 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 6-week period following a 8-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
9743965|NCT04157673|Experimental|Episodic Future Thinking introduced at 10 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 4-week period following a 10-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
9743966|NCT04157153|Experimental|Treatment|All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 36 monts.
9743967|NCT04145700|Experimental|Ramucirumab + Gemcitabine + Docetaxel|Ramucirumab, Gemcitabine and Docetaxel given intravenously (IV).
9743968|NCT04145700|Active Comparator|Gemcitabine + Docetaxel|Gemcitabine and Docetaxel given IV.
9743969|NCT04140344|Experimental|ARM 1: Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
9743970|NCT04140344|No Intervention|ARM 2: Control group|The control group will be given the standard post-op packet that includes detailed instructions on proper wound care and signs and symptoms of infection. They will not receive text messages. The same outcomes will be assessed in both groups through a 30-day post-operative phone call.
9743971|NCT04129619|Experimental|ORP-101 50 mg|ORP-101 (50 mg) once daily
9743972|NCT04129619|Experimental|ORP-101 100 mg|ORP-101 (100 mg), once daily
9743973|NCT04129619|Placebo Comparator|Placebo|Matching placebo, once daily
9743974|NCT04128722|Experimental|Sirolimus 1mg/mL|Application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation, the experimental intervention versus usual care (no treatment), the control condition.
9743975|NCT04128722|No Intervention|Control condition|Usual care, i.e. no intervention
9743976|NCT04123873|Experimental|Group A|"Paracetamol 1000 mg + Ibuprofen 400 mg administered orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus placebo (matching DXM) IV administered after induction of anaesthesia"
9743977|NCT04123873|Experimental|Group B|"Paracetamol 1000 mg and placebo (matching ibuprofen) orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
9743978|NCT04123873|Experimental|Group C|"Placebo (matching paracetamol) + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
9743979|NCT04123873|Experimental|Group D|"Paracetamol 1000 mg + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.~Plus DXM 24 mg IV after induction of anaesthesia"
9743980|NCT04118088|Experimental|Darvadstrocel|Participants who have previously received darvadstrocel would receive a single repeat dose of darvadstrocel 120 million cells (5 million cells/mL), by local injection into the fistula.
9743981|NCT04100109|Active Comparator|Polylactose|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing polylactose
9743982|NCT04100109|Active Comparator|Placebo|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing cellulose, which is an inert dietary fiber, and which will act as our placebo for this project.
9743983|NCT04098068|Experimental|MSI (Microsatellite Unstable) Negative with Mutator Phenotype|
9743984|NCT04096586|Active Comparator|Red juice|Subjects consume 8 fl oz of red juice daily for 8 weeks
9743985|NCT04096586|Experimental|Watermelon juice|Subjects consume 8 fl oz of watermelon juice daily for 8 weeks
9743986|NCT04089943|Experimental|Revascularization group|Participants will be randomized to either an endovascular or an open bypass procedure.
9743987|NCT04089943|Other|Control group|Healthy non-PAD participants will be recruited as control group
9743988|NCT04076150|Experimental|Patients Receiving Optimum TAV|Patients with symptomatic severe aortic stenosis that will be treated via transcatheter aortic valve implantation procedure
9743989|NCT04072445|Experimental|Treatment (trifluridine and tipiracil, irinotecan)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and irinotecan hydrochloride IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9743990|NCT04070027|Active Comparator|Total Hip Arthroplasty|A standard fast-track multimodal surgical program comprising patient information, optimised pain management, and early mobilisation. Total hip arthroplasty (THA) will be performed by experienced orthopaedic surgeons in accordance with the standard posterior surgical approach. Patients will receive standard postoperative rehabilitation consisting of either a standard leaflet with a hospital-specific home-based exercise program aimed at increasing hip muscle strength and range of motion or, if considered necessary, a referral to supervised hip-specific exercise therapy delivered at private physiotherapist clinics or municipal rehabilitation. Furthermore, postsurgical procedures will follow hospital-specific procedures ranging from no postsurgical control to postsurgical assessment of the hip and rehabilitation at the physiotherapy department (after six-weeks).
9743991|NCT04070027|Active Comparator|Progressive Resistance Training|"A 12-week supervised explosive-type progressive resistance training (PRT) program with two training sessions a week. All training sessions will be conducted in municipal rehabilitation centres with one-to-one supervision and ≥48 hours of rest in between sessions. The standardised PRT program will consist of warm-up on a stationary bicycle (10 min) followed by four lower extremity exercises (50 min). Exercises will be performed unilaterally with as full range of motion as possible in sets of three separated by 60 sec of rest in the following order: leg press, hip extension, hip flexion, and hip abduction. Patients will be instructed to complete the concentric phase of each repetition as fast as possible, maintain full extension for 1 sec, and perform the eccentric phase in 2-3 sec. Hip-related pain up to 5 rated on a Numerical Rating Scale (0-10) is considered acceptable during exercises. After the 12-weeks, patients will be offered three-months of optional unsupervised PRT."
9781953|NCT01162122|Experimental|aTIV|Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
9743992|NCT04061590|Experimental|Cohort A (pembrolizumab)|Patients receive 200mg pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
9743993|NCT04061590|Experimental|Cohort B (pembrolizumab, cisplatin pemetrexed)|Patients receive 200mg pembrolizumab IV over 30 minutes and chemotherapy (cisplatin/pemetrexed) IV on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
9743994|NCT04053803|Experimental|Open Label|
9743995|NCT04042753|Experimental|Pituitary Cancer|Participants will have a pituitary adenoma/carcinoma of any histology
9743996|NCT04041830|Experimental|NW (Normal Weight)|20 to 55 years old lean adults
9743997|NCT04041830|Experimental|OBESE|20 to 55 years old adults with obesity
9743998|NCT04033120||Cohort 1|"Cohort 1: Symptomatic hospitalized patients: 900 patients admitted to the participating hospitals whom doctors suspect to have an infection and will perform TmAg testing alongside routine diagnostics and the following additional diagnostics:~MycoF/lytic blood culture system~Fujifilm lateral flow urine lipoarabinomannan (LF-LAM) test for tuberculosis~Cryptotoccoal antigen in sera (CrAg) LFA for cryptococcosis~Histoplasma antigen in urine (HAg) LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a six-month follow up period"
9743999|NCT04033120||Cohort 2|"Cohort 2: Asymptomatic outpatients: 500 patients registered at the outpatient clinics at the participating hospitals whom doctors do not suspect of having an active infection and will perform TmAg testing alongside the following diagnostics:~CrAg LFA for cryptococcosis~HAg LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a twelve-month follow up period."
9744000|NCT04031833|Experimental|Phase 1a single ascending dose study|Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.
9744001|NCT04031833|Experimental|Phase 1b multiple day dosing|9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.
9744002|NCT04031833|Experimental|Phase 2 safety and tolerability|Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.
9744003|NCT04030169|Experimental|Experimental: MDMA-assisted psychotherapy|Two sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
9744004|NCT04027153|Experimental|Fee Arm|Participants in this arm will pay a fee (based on an income sliding scale) to have their medication delivered to their location of choice.
9744005|NCT04027153|Active Comparator|Standard of Care Arm|Participants in this arm will pick up their medication refill at the local clinic
9744006|NCT04024007||Dialysis patients|Intensive care dialysis patients (Continuous Venous Hemofiltration with citrate). Dialysis performed according to the standard indications of the service. Patients are dialysed with the prismaflex system on AN69ST membranes.
9781954|NCT01162122|Experimental|Licensed TIV|Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).
9781955|NCT01162135|Experimental|Open Label Pilot Study|
9781956|NCT01162239|Experimental|Extended Brief Contact|Following standard brief treatment, participants have monthly meetings with medical staff.
9781957|NCT01162239|Experimental|Extended Health Education|Following standard treatment, participants receive monthly counseling with content based on a health education model.
9781958|NCT01162239|Experimental|Extended Relapse Prevention plus varenicline|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.
9781959|NCT01162239|Experimental|Extended Relapse Prevention|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.
9781960|NCT01162317|Active Comparator|Arm 1: sham acupuncture|sham acupuncture
9781961|NCT01162317|Experimental|Arm 2: acupuncture|acupuncture
9781962|NCT01162343||Older Emergency Department Patients|Patients who were 65 years or older from the emergency department were enrolled.
9781963|NCT01162421|Experimental|Early Adalimumab|Participants in the Early Adalimumab arm will receive adalimumab and methotrexate at Baseline and every other week for study duration.
9781964|NCT01162421|Active Comparator|Standard of Care|Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.
9781965|NCT01162473|Active Comparator|Delayed Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 16 and continue thru Week 50. Total active participation will last 51 weeks.
9781966|NCT01162473|Active Comparator|Immediate Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 3 and continue thru Week 35. Total active participation will last 38 weeks.
9781967|NCT01162486|Active Comparator|Rifampin control|Rifampin + midazolam
9781968|NCT01162486|Experimental|RPT 1|RPT Cohort 1 - 5 mg/kg
9781969|NCT01162486|Experimental|RPT 2|RPT Cohort 2 - 10 mg/kg
9781970|NCT01162486|Experimental|RPT 3|RPT Cohort 3 - 15 mg/kg
9781971|NCT01162486|Experimental|RPT 4|RPT Cohort 4 - 20 mg/kg
9781972|NCT01162486|Experimental|RPT 5|RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed
9785352|NCT01249872|Active Comparator|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
9744007|NCT04022603|Experimental|Optiflow nasal googles|Oxygen provided by means of high throughput nasal googles (Optiflow, Fisher&Paykel- New Zealand).
9744008|NCT04022603|Active Comparator|Venturi mask|Oxygen provided by means of a Venturi mask.
9744009|NCT04019418|Placebo Comparator|No Carbohydrate Drink + Rest|Participants will consume the no carbohydrate drink (300ml water) followed by a rest session
9744010|NCT04019418|Active Comparator|No Carbohydrate Drink + Exercise|Participants will consume the no carbohydrate drink (300ml water) followed by an exercise session (75% VO2 max on a cycle ergometer)
9744011|NCT04019418|Active Comparator|Carbohydrate Drink + Rest|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by a rest session
9744012|NCT04019418|Experimental|Carbohydrate Drink + Exercise|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by an exercise session (75% VO2 max on a cycle ergometer)
9744013|NCT04016142|Experimental|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients~will be registered in the first part of the study at diagnosis and will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage (no progression during Part 1 of the study and no medical contra-indication to the study treatment)."
9744014|NCT04013399|Experimental|Continuous Positive Airway Pressure|Women will receive Continuous Positive Airway Pressure (CPAP) for one month.
9744015|NCT04013399|No Intervention|Control|Women will receive standard prenatal care.
9744016|NCT04011722|Experimental|Portico™ NG (Navitor) valve, FlexNav™ Delivery System|Portico ™ NG (Navitor) valve implantation with the new generation Portico NG (Navitor) valve (23mm, 25mm, 27mm and 29mm sizes), and the second-generation FlexNav Delivery system (small and large), Portico™ NG (Navitor) Loading System(s) (small and large).
9744017|NCT04011722|Experimental|Navitor Titan Valve|Navitor Titan Valve (35mm) implantation with the large FlexNav Delivery system and Navitor Loading System - LG+.
9744018|NCT04010175|Active Comparator|Control group|
9744019|NCT04010175|Experimental|Experimental group 1|Moderate frequency cognitive distance training
9744020|NCT04010175|Experimental|Experimental group 2|High frequency cognitive distance training
9744021|NCT04009291|Experimental|TransCon PTH 15 mcg|TransCon PTH 15 mcg delivered once daily by subcutaneous injection
9744022|NCT04009291|Experimental|TransCon PTH 18 mcg|TransCon PTH 18 mcg delivered once daily by subcutaneous injection
9744023|NCT04009291|Experimental|TransCon PTH 21 mcg|TransCon PTH 21 mcg delivered once daily by subcutaneous injection
9744024|NCT04009291|Placebo Comparator|Placebo|Placebo mimicking 15, 18, or 21 mcg of TransCon PTH delivered once daily by subcutaneous injection
9744025|NCT04005287|Placebo Comparator|Placebo Low Dose|WST-057 Matching placebo 2 mL volume
9744026|NCT04005287|Placebo Comparator|Placebo High Dose|WST-057 Matching placebo 4mL volume
9744027|NCT04005287|Experimental|Active Low Dose|WST-057 2mL volume
9744028|NCT04005287|Experimental|Active High Dose|WST-057 4mL volume
9744029|NCT03999554|Experimental|Low dose Sing2016 M2SR|Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29
9744030|NCT03999554|Experimental|Medium dose Sing2016 M2SR|Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29
9744031|NCT03999554|Experimental|High dose Sing2016 M2SR|High dose Sing2016 M2SR will be administered intranasally on days 1 and 29
9744032|NCT03999554|Active Comparator|Low dose Bris10 M2SR|Low dose Bris10 M2SR will be administered intranasally on days 1 and 29
9744033|NCT03999554|Placebo Comparator|Placebo|Saline will be administered intranasally on days 1 and 29
9744034|NCT03994653||Cases|Participants diagnosed with ovarian cancer
9744035|NCT03994653||Controls|Participants without ovarian cancer
9744036|NCT03982160|Experimental|L-arginine|Intravenous infusion of L-arginine (250-350 mg/kg) will be performed for 30 minutes.
9744037|NCT03982160|Placebo Comparator|Saline|Saline will be infused for 30 minutes
9744038|NCT03977467|Experimental|Arm A (Chemo + Atezolizumab)|In Arm A, patients with NSCLC will receive chemotherapy plus atezolizumab at a flat dose of 1200 mg intravenously (IV) every 3 weeks. Standard of care chemotherapy is defined as a platinum-doublet therapy (or triplet if bevacizumab is used) of the Investigator's choice.
9744039|NCT03977467|Experimental|Arm B (Atezolizumab and Tiragolumab)|In Arm B, patients with advanced solid tumors will be treated with atezolizumab at a flat dose of 1200 mg IV every 3 weeks in combination with tiragolumab at a flat dose of 600 mg IV every 3 weeks until progression or unacceptable toxicity.
9744040|NCT03973697|Experimental|Single dose of PMT|
9744041|NCT03973697|Experimental|Two doses of PMT|Administered within 24 hours
9744042|NCT03962400|Active Comparator|Control|Subjects will have warfarin dose determined in the usual fashion by a health care provider.
9744043|NCT03962400|Experimental|Treatment|Subjects will have warfarin dose determined using a reinforcement learning computer model.
9744044|NCT03957928|Active Comparator|Low fat cookies|Subjects consume 100 kcal of low fat cookies daily for 12 weeks.
9744045|NCT03957928|Experimental|Mango fruit|Subjects consume 100 kcal of mango fruit daily for 12 weeks.
9744046|NCT03953144|Experimental|Synapse 3D Lung Modelling + IC-GREEN Segmentectomy|Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Synapse 3D to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus
9744047|NCT03934567|Experimental|Abexinostat 80 mg bis in die (BID)|Experimental: Abexinostat 80 mg BID
9744048|NCT03917966|Experimental|SHR-1210+Docetaxel+nedaplatin|SHR-1210+Docetaxel+nedaplatin
9744049|NCT03917966|Experimental|SHR-1210+Apatinib|SHR-1210+Apatinib
9744050|NCT03908476|Experimental|Subjects using BurstDR SCS systems|Spinal cord stimulation with a Burst waveform.
9744051|NCT03908476|Experimental|Subjects using DRG systems|Dorsal root ganglion stimulation.
9744052|NCT03905525|Experimental|Cohort 1 /Arm A|CFZ533 dose 1
9744053|NCT03905525|Experimental|Cohort 1/Arm B|CFZ533 dose 2
9744054|NCT03905525|Experimental|Cohort 1/Arm C|CFZ533 dose 3
9744055|NCT03905525|Placebo Comparator|Cohort 1/Arm D|Placebo dose (up to week 24)
9744056|NCT03905525|Experimental|Cohort 1/Arm D1|CFZ533 dose 1 (from week 24)
9744057|NCT03905525|Experimental|Cohort 2/Arm E|CFZ533 dose 1
9744058|NCT03905525|Placebo Comparator|Cohort 2/Arm F|Placebo dose (up to week 24)
9744059|NCT03905525|Experimental|Cphort 2/Arm F1|CFZ533 dose 2 (from week 24)
9744060|NCT03890250|Sham Comparator|Sham group|Following the assessments, sham group will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer. In Sham training group, NMES will be applied to the same region after aerobic exercise, current frequency is 5 Hz, current transit time is 300 μs, 10 seconds warning, 30 seconds electrical stimulation in 20 seconds rest period. The rehabilitation program will be administered two days a week for 8 weeks under the supervision of a physiotherapist.
9744061|NCT03890250|Experimental|NMES group|"Following the assessments, both groups will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer.~After the aerobic exercise in NMES group, bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds."
9744062|NCT03880786|Experimental|PNE test lead|
9744063|NCT03879798|Experimental|DS-3201b and Irinotecan|The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan. Dose-Escalation, which enrolled a total of 12 patients at MSK, is completed. Phase 1 of this study determined that the highest and safest dose of DS-3201b in patients was 100 mg daily.
9744064|NCT03867487|Experimental|Study intervention|Empagliflozin 10 mg will be taken daily
9744065|NCT03867487|Placebo Comparator|Control arm|Placebo oral tablet will be taken daily
9744066|NCT03860610||Patient group 1 after THA|Patients who have already received a THA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
9744067|NCT03860610||Patient group 2 after TKA|Patients who have already received a TKA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
9744068|NCT03860610||Patient group 3 before THA|Patients with severe hip OA (N=30) scheduled to receive a THA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
9744069|NCT03860610||Patient group 4 before TKA|Patients with severe knee OA (N=30) scheduled to receive a TKA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
9744070|NCT03860610||Healthy control group|Age-matched healthy control subjects (N=30);Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
9744071|NCT03859700|Experimental|DBV712 250mcg|
9744072|NCT03844828|Experimental|POD FT IOL Implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT and POD F.
9744073|NCT03832257|Experimental|ECHO CT Intervention|Weekly video conference between hospitalist at Beth Israel and skilled nursing facilities.
9744074|NCT03832257|Other|Matched Non- Participating Facilities|Matched non-participating facilities
9744075|NCT03824249|Experimental|Spontaneous breathing|Performance of indirect calorimetry in spontaneously breathing children through the use of indirect calorimetry.
9744076|NCT03824249|Experimental|NIV-CPAP|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 centimeters of water (cmH2O). CPAP will be applied via single-limb circuit with intentional leak.
9744077|NCT03824249|Experimental|NIV-PS|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 cmH2O and Pressure support (PS) of 8 cmH2O. Non-invasive ventilation will be applied via single-limb circuit with intentional leak.
9744078|NCT03821844|Experimental|Music and Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
9744079|NCT03821844|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
9744080|NCT03809364|Experimental|START Together|Couples randomized to START Together will receive the manualized treatment to enhance women's medication adherence. The treatment is 5 sessions in length and conducted weekly. Sessions are 60 - 75 minutes. Couples have the option of completing up to 3 additional booster sessions. Total treatment therefore ranges between 5 to 8 sessions.
9744081|NCT03809364|No Intervention|Standard of Care (SOC)|Couples randomized to SOC will receive referrals to local HIV clinics to support medication adherence (for women) or other HIV-related issues (for men).
9744082|NCT03801304|Experimental|Atezolizumab associated with vinorelbine|"Atezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle.~Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg."
9744083|NCT03792841|Experimental|Part 1 Dose-exploration: acapatamab treatment|Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.
9744084|NCT03792841|Experimental|Part 1 Dose-expansion: acapatamab treatment|Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.
9744085|NCT03792841|Experimental|Part 2: acapatamab + Pembrolizumab|Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.
9744086|NCT03792841|Experimental|Part 3: acapatamab + Etanercept Prophylaxis|Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.
9744087|NCT03792841|Experimental|Part 4: acapatamab 24 Hour Monitoring|Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.
9744088|NCT03792841|Experimental|Part 5: acapatamab Outpatient Cohort|Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.
9744089|NCT03792841|Experimental|Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction|Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.
9744090|NCT03783416|Experimental|Ixazomib (NINLARO®)|Treatment will follow a 28-day cycle. Participants will take one Ixazomib (NINLARO) capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free week, in sequence, for the duration of the trial.
9744091|NCT03783416|Placebo Comparator|Placebo|Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
9744092|NCT03774992|Experimental|Orthokeratology|Subjects randomized to OKL in the CONTROL-study
9744093|NCT03774992|Experimental|Cross over|Subjects randomized to SVS in the CONTROL-study
9744094|NCT03765983|Experimental|Cohort A: single-arm, two stage, phase II cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter
9744095|NCT03765983|Experimental|Cohort B: a pre-surgical window cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter Surgical brain metastasis resection
9744096|NCT03752723|Experimental|combination with CPA, GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: CPA, GX-I7 and pembrolizumab"
9744097|NCT03752723|Experimental|combination with GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: GX-I7 and pembrolizumab (without CPA)"
9744098|NCT03740880|Active Comparator|Late trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
9744099|NCT03740880|Experimental|Early trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm
9744100|NCT03734692|Experimental|cisplatin + rintatolimod + pembrolizumab|Intraperitoneal (IP) cisplatin 50mg/m^2 solution with IP rintatolimod 200 mg solution and IV pembrolizumab 200 mg solution.
9744101|NCT03732352|Experimental|Treatment (18F-FDG PET, osimertinib)|Within days -28 to -4, patients receive fludeoxyglucose F-18 IV and after 60 minutes undergo PET scan over 15 minutes. After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9744102|NCT03722797||Unilateral Transtibial Amputation|Individuals with a unilateral, transtibial amputation.
9744103|NCT03722797||Controls|Healthy adults without a lower-limb amputation who have been matched to participants in the Unilateral Transtibial Amputation group based on age, sex, and body mass index.
9744104|NCT03721822|Experimental|Traditional Cigarette Smokers|Reported current cigarette smoking of at least 5 cigarettes per day, 5 days per week for the past 1 year with no history of e-cigarette use (cannabis or nicotine) or cannabis smoking during the 30 days prior to study enrollment
9744105|NCT03721822|Experimental|Non-Smokers|Reported non-smoking history or < 100 lifetime cigarettes, < 100 e-cigarette use episodes and < 100 lifetime cannabis use episodes
9744106|NCT03721822|Experimental|Nicotine Vapers|Reported current e-cigarette use of nicotine at least 5 days per week for the past year with no current combustible cigarette use, cannabis vaping or cannabis smoking during the 30 days prior to study enrollment
9744107|NCT03721822|Experimental|Cannabis Vapers|Reported current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking or nicotine vaping during the 30 days prior to study enrollment
9744108|NCT03721822|Experimental|Dual Smokers/Vapers|Reported current e-cigarette use of cannabis and/or nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 days prior to study enrollment
9744109|NCT03709914|Experimental|ZTI-01 Cohort 1 ≥ 6 to <12 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
9744110|NCT03709914|Experimental|ZTI-01 Cohort 2 ≥ 2 to <6 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
9744111|NCT03709914|Experimental|ZTI-01 Cohort 3a Birth to < 3 mos of age|ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
9744112|NCT03709914|Experimental|ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
9744113|NCT03709914|Experimental|ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
9744114|NCT03706053|Placebo Comparator|Placebo|Investigational pharmacy formulated placebo. In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group)
9744115|NCT03706053|Experimental|Midodrine Hydrochloride 10 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
9744116|NCT03706053|Experimental|Midodrine Hydrochloride 20 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
9744117|NCT03704922|Experimental|≤10 day Blood|Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events.
9744118|NCT03704922|Experimental|≥30 day Blood|Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events.
9744119|NCT03684811|Experimental|Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)|
9744120|NCT03684811|Experimental|Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)|
9744121|NCT03684811|Experimental|Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)|
9744122|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 2b)|
9744123|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 4b)|
9744124|NCT03651622|Experimental|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
9744125|NCT03651622|Experimental|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
9744126|NCT03651622|Experimental|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
9744127|NCT03644472|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
9744128|NCT03644472|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
9744129|NCT03643939|Experimental|High Flow Nasal Catheter|The HFNC (AIRVO2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
9744130|NCT03643939|Active Comparator|Non-invasive positive pressure ventilation|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.
9744131|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort A dose)|"Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab, as specified per protocol (Cohort A dose).~Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted."
9744132|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort B dose)|Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab as specified per protocol (Cohort B dose). Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.
9744133|NCT03617172|Experimental|Study Drug (Misoprostol)|
9744134|NCT03617172|Placebo Comparator|Placebo|
9744135|NCT03596203|Experimental|Treatment group|
9744136|NCT03587519|Experimental|Early ileostomy closure|Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
9744137|NCT03587519|Active Comparator|Late ileostomy closure|Late ileostomy closure will be performed 8 - 12 weeks after IPAA.
9744138|NCT03587272|Experimental|SUN regimen|"Alemtuzumab intravenously, low dose total body irradiation, Sirolimus~HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, SUN) can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD)."
9744139|NCT03570801|Experimental|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
9744140|NCT03570801|No Intervention|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
9744141|NCT03565744|Experimental|Group 1 - B'N Fit POWER|Participants enrolling in B'N Fit POWER afterschool program will be assigned to Group 1.
9744142|NCT03565744|No Intervention|Group 2 - Standard of Care|All other PS/MS-95 participants who completed the screening (approximately 50) will be in comparison Group 2
9744143|NCT03565744|No Intervention|Group 3 - Standard of Care|Participants at an additional school site completing the screening (approximately 100) will be in an additional comparison Group 3.
9744144|NCT03563716|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
9744145|NCT03563716|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
9744146|NCT03549650|Experimental|Pentosan Polysulfate Na 100Mg Cap|Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
9744147|NCT03549650|Placebo Comparator|Placebo oral capsule|Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.
9744148|NCT03533465|Experimental|Complicated Grief Treatment (CGT)|10 adults with CG who successfully completed Aim 1 and will also participate in open complicated grief treatment (CGT), during which they will complete additional subjective and objective sleep assessments.
9744149|NCT03518034|Active Comparator|Arm A|Participants receiving topical testosterone
9744150|NCT03518034|Placebo Comparator|Arm B|Participants receiving placebo
9744151|NCT03509909|Experimental|Hatha yoga|12- week group-based yoga class
9744152|NCT03509909|Active Comparator|Supportive physical activity|12-week group-based stretching and strengthening class
9744153|NCT03500328|Active Comparator|Early Aggressive Therapy|"Higher efficacy disease-modifying therapy (Early Aggressive Therapy) for treatment of multiple sclerosis~Early Aggressive Therapy choices and maximum allowable doses:~Natalizumab (Tysabri), 300 mg intravenously (IV) every 4 weeks~Alemtuzumab (Lemtrada), 12 mg IV daily for 5 days; 1 year later: 12 mg IV daily for 3 days~Ocrelizumab (Ocrevus), 300 mg IV every 2 weeks (for 2 doses) at initiation; subsequently, 600 mg IV every 6 months~Rituximab (Rituxan), 1000 mg IV every 2 weeks (for 2 doses); may repeat every 16-24 weeks~Cladribine (Mavenclad), 3.5 mg per kg body weight PO divided into 2 yearly treatment courses (1.75 mg per kg body weight each year); each yearly treatment course is divided into 2 treatment cycles; administer cycle dosage as 1 or 2 tablets once daily over 4-5 consecutive days~Ofatumumab (Kesimpta), 20 mg SC weekly for weeks 0, 1 and 2; 20 mg SC monthly starting at week 4"
9744154|NCT03500328|Active Comparator|Traditional Therapy|"First-line disease-modifying therapy (Traditional Therapy) for treatment of multiple sclerosis~Traditional Therapy choices and maximum allowable doses:~Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg subcutaneously (SC) daily, or 40 mg SC three times a week~Intramuscular interferon (Avonex), 30 mcg intramuscularly (IM) weekly~Subcutaneous interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC three times a week (Rebif)~Pegylated interferon (Plegridy), 125 mcg SC every 14 days~Teriflunomide (Aubagio), 14 mg orally (PO) daily~Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day~Diroximel fumarate (Vumerity), 462 mg PO twice a day~Monomethyl fumarate (Bafiertam), 190 mg PO twice a day~Fingolimod (Gilenya and generics), 0.5 mg PO daily~Siponimod (Mayzent), 1 mg PO daily or 2 mg PO daily~Ozanimod (Zeposia), 0.92 mg PO daily~Ponesimod (Ponvory), 20 mg PO daily"
9744155|NCT03493789|Experimental|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
9744156|NCT03488472|Experimental|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
9744157|NCT03476018|Placebo Comparator|Placebo|
9744158|NCT03476018|Experimental|0.2 microgram Z-100|
9744159|NCT03476018|Experimental|2 microgram Z-100|
9744160|NCT03476018|Experimental|20 microgram Z-100|
9744161|NCT03448458|Experimental|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
9744162|NCT03436680|Experimental|Group I (neurofeedback)|Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.
9744163|NCT03436680|Active Comparator|Group II (standard of care)|Participants receive standard of care.
9744164|NCT03422198|Experimental|Short course vaginal cuff brachytherapy|Patients undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
9744165|NCT03422198|Active Comparator|Vaginal cuff brachytherapy|Patients undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
9744166|NCT03419702|No Intervention|Control|No almonds
9744167|NCT03419702|Experimental|Experimental|Almonds
9744168|NCT03410992|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
9744169|NCT03410992|Placebo Comparator|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
9744170|NCT03410992|Experimental|Bimekizumab Escape arm|Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
9744171|NCT03409744|Experimental|evinacumab|
9744172|NCT03407417|Experimental|Fit Testing|Patients who self selected to receive FIT screening after interaction with the Application
9744173|NCT03407417|Active Comparator|Non-FIT testing|Patients who elected not to have FIT testing after interaction with the application
9744174|NCT03382951||Healthy children|Each study is an observational study with no group assignments and no control/placebo.
9744175|NCT03380221|Experimental|Watermelon|
9744176|NCT03380221|Active Comparator|Low fat cookies|
9744177|NCT03380195|Experimental|Watermelon juice|
9744178|NCT03380195|Active Comparator|Sport drink|
9744179|NCT03380195|Active Comparator|Sugar water|
9744180|NCT03380195|Placebo Comparator|Water|
9744181|NCT03373968|Experimental|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
9744182|NCT03366415|Experimental|Induction chemotherapy+IMRT+adjuvant chemotherapy|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), followed by gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles.
9744183|NCT03366415|Active Comparator|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 30 mg/m² every week.
9744184|NCT03315910|Experimental|Motivational Interviewing( MI) (Yes vs. No)|Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session.
9744185|NCT03315910|Experimental|Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)|Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
9744186|NCT03315910|Experimental|NRT Lozenge (Yes vs. No)|Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
9744187|NCT03315910|Experimental|Message Framing (Gain vs. Loss)|Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed).
9744188|NCT03267888|Experimental|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
9744189|NCT03248167|Experimental|Cannabidiol (CBD 600 mg daily)|6 weeks, such that both participants and study staff are blind to treatment condition.
9744190|NCT03248167|Placebo Comparator|Placebo|6 weeks, such that both participants and study staff are blind to treatment condition.
9744191|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
9744192|NCT03239015|Experimental|Targeted Drug Therapy Group|All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib. If no durggable target, PD-1/L1 inhibitor plus anti-angiogenic agent was used.
9744193|NCT03225404|Experimental|Experimental group|EPTE + EXER Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
9744194|NCT03225404|Experimental|Control group|
9744195|NCT03212404|Experimental|CK-301 (cosibelimab)|Part 1 - Dose Escalation; Part 2 - Dose Expansion
9744196|NCT03197935|Experimental|Atezolizumab and Chemotherapy|Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
9744197|NCT03197935|Placebo Comparator|Placebo and Chemotherapy|Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
9744198|NCT03161379|Experimental|CY, Nivolumab, GVAX, and SBRT|CY, Nivolumab, GVAX, and SBRT
9744199|NCT03138096|Experimental|Group 1 - five Pb(PfCS@UIS4)-infected mosquitoes|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
9744200|NCT03138096|Experimental|Group 2 - 25 Pb(PfCS@UIS4)-infected mosquito bites|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
9744201|NCT03138096|Experimental|Group 3 - 75 Pb(PfCS@UIS4)-infected mosquito bites|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
9744202|NCT03138096|Other|Group 4 - Infectivity control group of Phase 1|Infectivity control group of Phase 1
9744203|NCT03138096|Other|Group 5 - Infectivity control group of Phase 2|Infectivity control group of Phase 2
9984678|NCT03836651|Experimental|Intervention Group|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants assigned to the intervention group will receive dietary antioxidants as V8® Low Sodium 100% vegetable juice.
9984679|NCT03836625|No Intervention|Control|The control arm will receive standard CareConekta, which will track their mobility with no additional features.
10201142|NCT04512781|Active Comparator|Conventional Legacy Cannula Design (Control)|During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.
9744207|NCT03120780|Active Comparator|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
9744208|NCT03120780|Experimental|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
9744209|NCT03117699|Experimental|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.~Phase 1 :~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
9744210|NCT03117699|Experimental|Healthy volunteers|"Testing of a new device for seated-standing passages .~Phase 1 :~3 seated-standing passages without help~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
9744211|NCT03111758|Active Comparator|Geko Device|Neuromuscular Stimulator
9744212|NCT03111758|Active Comparator|IPCS|Intermittent Pneumotic Compression Stocking
10201143|NCT04512781|Experimental|Cannula Design Test #1 (Randomized)|During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.
10201144|NCT04512781|Experimental|Cannula Design Test #2 (Randomized)|During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.
10201145|NCT04505540|Active Comparator|Bridge Clinic|Medication assisted treatment supervised by addiction bridge clinic until stabilized in treatment.
10201146|NCT04505540|Active Comparator|Local Waivered Physcian|Medication assisted treatment supervised by local waivered physician.
10201147|NCT04504942|Experimental|Leronlimab 525mg|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
9744213|NCT03079921|Active Comparator|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
9744214|NCT03079921|Active Comparator|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
9744215|NCT03079921|Placebo Comparator|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
9744216|NCT03079921|No Intervention|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
9744217|NCT03079921|No Intervention|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
9744218|NCT03062358|Experimental|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
9744219|NCT03062358|Placebo Comparator|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
9744220|NCT03017131|Experimental|Treatment (decitabine, genetically modified T cells)|COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..
9744221|NCT03013933|Experimental|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil hydrochloride PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9744222|NCT03007238|Experimental|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
9744223|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
9744224|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
9744225|NCT02923726|Active Comparator|ATP and Shock|Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
9744226|NCT02923726|Experimental|Shock only|Once tachycardia has been detected and duration met, this group would receive shock therapy only.
9781973|NCT01162499|Experimental|Exendin-(9-39) first, then Vehicle|"After an overnight fast, an intravenous (IV) infusion of Exendin-(9-39) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1). The Exendin-(9-39) dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects.~The next day, all procedures will be repeated except subjects will receive an IV infusion of normal saline (vehicle) over 6 hours."
9785353|NCT01249872|Active Comparator|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
9744227|NCT02914314|Experimental|Perampanel up to 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 4 years of age, will receive perampanel oral suspension once a day in titration period starting at Week 0 at a dose of 0.50 mg per day (mg/day) titrated up to 4 mg/day (for participants taking non-EIAED) or up to 8 mg/day (for participants taking EIAED). Depending on participants clinical response, tolerability and investigator's decision, dose can be up titrated to 6 mg/day (for participants taking non-EIAED) and up titrated to 8 mg/day (for participants taking EIAED). Dose titration must not exceed 12 mg/day (non-EIAED) and 16 mg/day (EIAED). Participants will continue taking the perampanel oral suspension at dose level achieved at end of titration period through maintenance period of core study and maintenance period of extension phase (Up to Week 52).
9744228|NCT02855892|Placebo Comparator|Control Group|- Placebo, two-week interval, intradermal administration
9744229|NCT02855892|Experimental|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
9744230|NCT02855892|Experimental|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
9744231|NCT02855892|Experimental|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
9744232|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
9744233|NCT02832323|Other|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
9744234|NCT02823002|Experimental|Slow, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
9744235|NCT02823002|Experimental|Rapid, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
9744236|NCT02823002|Experimental|Slow, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
9744237|NCT02823002|Experimental|Rapid, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
9744238|NCT02823002|Experimental|Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
9744239|NCT02823002|Placebo Comparator|Non-Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
9744240|NCT02816580|Experimental|elderly subjects|
9744241|NCT02779257|Experimental|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
9744242|NCT02713854|Experimental|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
9744243|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
9744244|NCT02701153|Experimental|Treatment (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.
9744245|NCT02678351|Experimental|68Ga-PSMA PET/MRI|Patients receive 68Ga-PSMA-11 IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
9744246|NCT02660411|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
9744247|NCT02660411|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
9744248|NCT02648282|Experimental|Cyclophosphamide, Pembrolizumab, GVAX, SBRT|
9744249|NCT02633137|Experimental|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months. Patients will be followed on active follow up for three years after completion of therapy. After the active followup period, survival, relapse, and new anti-lymphoma therapy information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 6 months until death, loss to follow up or consent withdrawal, whichever comes first.
9744250|NCT02624518|Experimental|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
9744251|NCT02611570||Non-smokers at risk for lung cancer|"Non-smoking subjects with lung cancer family history~Non-smoking subjects with a given lung cancer risk other than lung cancer family history"
9785354|NCT01249872|Active Comparator|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
9744252|NCT02578732|Experimental|FOLFOXA|"Schema:~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~Antiemetics will be administered as per standard institutional policy."
9744253|NCT02530437|Experimental|Step I (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib PO for 7 days, followed by taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
9744254|NCT02530437|Experimental|Step II (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
9744255|NCT02501434|No Intervention|Control|Standard of Care
9744256|NCT02501434|Experimental|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
9744257|NCT02487147|Active Comparator|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
9744258|NCT02487147|Experimental|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
9744259|NCT02485860|No Intervention|standard dressings|
9744260|NCT02485860|Experimental|standard dressings with sterile honey|Melectis G
9744261|NCT02478255|Active Comparator|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
9744262|NCT02478255|Active Comparator|Healthy volunteers|
9744263|NCT02462421|Active Comparator|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
9744264|NCT02462421|Experimental|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
9744265|NCT02462421|Experimental|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
9744266|NCT02462421|Experimental|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
9744267|NCT02442414|Experimental|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
9744268|NCT02414477|Experimental|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
9744269|NCT02379819|Experimental|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
9744270|NCT02374424|Experimental|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
9744271|NCT02350465|Experimental|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
9744272|NCT02350465|Active Comparator|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
9744273|NCT02331498|Other|A Pazopanib|Open label study with one group
9744274|NCT02326129||Obese with Type 2 Diabetes|Obese adolescents with Type 2 Diabetes
9744275|NCT02326129||Obese without Type 2 Diabetes|Obese adolescents without Type 2 Diabetes
9744276|NCT02326129||Normal weight|Normal weight adolescents
9744277|NCT02272790|Experimental|Arm A (adavosertib + gemcitabine)|Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
9744278|NCT02272790|Experimental|Arm B (adavosertib + paclitaxel)|Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
9744279|NCT02272790|Experimental|Arm C/C2 (adavosertib + carboplatin)|"Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.~Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
9744280|NCT02272790|Experimental|Arm D (adavosertib + PLD)|Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
9744281|NCT02247232|Placebo Comparator|Placebo|
9744282|NCT02247232|Experimental|Z-100|
9744283|NCT02208362|Experimental|Stratum I (T lymphocytes intratumoral)|"CLOSED TO ACCRUAL 03/02/2018.~Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions."
9744284|NCT02208362|Experimental|Stratum II (T lymphocytes intracavitary)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intracavitary catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions
9744285|NCT02208362|Experimental|Stratum III (T lymphocytes intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intraventricular catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available.
9744286|NCT02208362|Experimental|Stratum IV (T lymphocytes intratumoral and intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
9744287|NCT02208362|Experimental|Stratum V (T lymphocytes intratumoral and intraventricular)|Patients receive IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
9744288|NCT02178410|Active Comparator|Vitamin D + fish oil|
9744289|NCT02178410|Active Comparator|Vitamin D + fish oil placebo|
9744290|NCT02178410|Active Comparator|Vitamin D placebo + fish oil|
9744291|NCT02178410|Placebo Comparator|Vitamin D placebo + fish oil placebo|
9744292|NCT02159560|Active Comparator|End holed catheter|Single holed, end holed epidural catheter
9744293|NCT02159560|Active Comparator|Three holed catheter|closed ended, three side holed epidural catheter
9744294|NCT01961531|Experimental|Accuboost APBI|28Gy delivered in 5 daily fractions
9744295|NCT01957176|Experimental|Cohort A|Cohort A consists of subjects who had completed their treatment with eltrombopag (ELT) during their participation in a parent study for Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 50 to 300 mg once daily (OD) for subjects of non- East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e. Japanese, Chinese, Taiwanese, Thai and Korean) will be 25 to 150 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
9744296|NCT01957176|Experimental|Cohort B|Cohort B consists of adult subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
9744297|NCT01957176|Experimental|Cohort C|Cohort C consists of pediatric subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
9744298|NCT01931852|Experimental|CMR-guided care|Participants in this group will receive a cardiac MRI
9744299|NCT01931852|Active Comparator|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
9744300|NCT01880541|Experimental|hypnosedation|hypnosedation
9744301|NCT01880541|Other|general anesthesia|general anesthesia
9744302|NCT01852890|Experimental|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
9785355|NCT01249872|Active Comparator|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
9744303|NCT01852890|Experimental|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
9744304|NCT01852890|Experimental|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
9744305|NCT01852890|Experimental|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
9744306|NCT01819831|Experimental|Preoperative proton radiation|Patients will receive 50 Gray equivalents (GyE) in 25 fractions with proton therapy, followed by surgery 4-8 weeks after completion of radiation.
9744307|NCT01773486|Active Comparator|Hesperidin|Subjects will receive oral hesperidin 500 mg/day
9744308|NCT01773486|Placebo Comparator|Placebo|subjects will receive matching placebo to hesperidin daily for 1 month
9744309|NCT01697371|Experimental|Proton Radiation|
9744310|NCT01693692|Experimental|TD-9855 Group 1|Group 1 to be dosed with TD-9855
9744311|NCT01693692|Experimental|TD-9855 Group 2|Group 2 to be dosed with TD-9855
9744312|NCT01693692|Placebo Comparator|Placebo|Group to be dosed with Placebo
9744313|NCT01685606|Experimental|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.
9744314|NCT01684904|Experimental|Proton radiation|Proton radiation
9744315|NCT01684397|Experimental|Treatment (pazopanib hydrochloride and bevacizumab)|Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.
9744316|NCT01665521|Experimental|HEART Pathway|The HEART Pathway will be used for real time clinical decision making. Physicians will receive care recommendations according to the HEART Pathway, based on HEART score and serial cardiac biomarkers. This will help physicians identify low-risk patients for early discharge with no objective cardiac testing.
9744317|NCT01665521|No Intervention|Usual Care|Conventional Care cardiac testing. Patients will undergo cardiac testing as determined by their treating physicians.
9744318|NCT01650350|Experimental|Low Dose Naltrexone|LDN, 5 mg/day-(1 cycle = 28 days).
9744319|NCT01650285|Experimental|Cabazitaxel and radiation|Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
9744320|NCT01595321|Experimental|SBRT and FOLFIRINOX|The first 6 patients will receive SBRT and FOLFIRINOX only.
9744321|NCT01595321|Experimental|Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX|The last 12 patients will receive cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX.
9744322|NCT01594372|Active Comparator|Laparoscopic Repair|Laparoscopic supracervical hysterectomy with sacropexy
9744323|NCT01594372|Active Comparator|Vaginal Repair|Vaginal hysterectomy with uterosacral colposuspension
9744324|NCT01556256|Experimental|Arm I (TMV)|See detailed description.
9744325|NCT01556256|Experimental|Arm II (TMV+P)|See detailed description.
9744326|NCT01552590|Active Comparator|Tolvaptan|Tablet, QD, 2 weeks
9744327|NCT01552590|Placebo Comparator|Placebo|Tablet, QD, 2 weeks
9744328|NCT01496664|Experimental|Result of combined CABG and PCI treatment|The registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.
9744329|NCT01345136|Experimental|RAD001 Treatment|All subjects will be given RAD001 for 1 year (12 months).
9744330|NCT01278225||EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
9744331|NCT01278225||Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
9744332|NCT01158417|Placebo Comparator|Placebo|Placebo tablets
9744333|NCT01158417|Experimental|Resveratrol 40 mg oral three times a day|Resveratrol
9744334|NCT01158417|Experimental|resveratrol 500 mg oral once daily.|Resveratrol
9744335|NCT01105884|Active Comparator|Group 1|
9744336|NCT01105884|Active Comparator|Group 2|
9744337|NCT01105884|Active Comparator|Group 3|
9744338|NCT01105884|Active Comparator|Group 4|
9744339|NCT01105884|Active Comparator|Group 5|
9744340|NCT01083771|Experimental|Olive Oil|At least 3 tablespoons of olive oil each day
9744341|NCT01000467|Active Comparator|2|Group 2(probucol 500mg BID)
9744342|NCT01000467|Active Comparator|1|Group 1(Probucol 250mg)
9744343|NCT01000467|Active Comparator|3|Group 3(Probucol 500mg once daily)
9744344|NCT00898755||Ancillary-Correlative (tissue sample collection)|"Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:~NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry"
9744345|NCT00869713|Other|primary vaccination with boost|Inactivated, Dried (TSI-GSD 200), RVF Vaccine
9744346|NCT00743197|No Intervention|Usual Care Group|USUAL CARE GROUP-therapy in this group will be no dictated medical therapy, but usual care, as dictated by their referring physician.
9744347|NCT00743197|Active Comparator|Medical Treatment Group|TREATMENT GROUP-therapy in this group will be conventional treatment for CAD but targeting endothelial function, which will include aspirin, ACE-inhibitor and statin therapy, and therapeutic lifestyle changes.
9744348|NCT00549978|Other|1|Two compartments with cross-over and parallel
9744349|NCT00549978|Other|2|Two compartments with cross-over and parallel
9744350|NCT00505466||Pre-Test Genetic Counseling + Genetic Sample|
9744351|NCT00434499|Active Comparator|placebo first|placebo first then crossover to EGCG
9744352|NCT00434499|Active Comparator|EGCG first|EGCG first then crossover to placebo
9744353|NCT00198328|Active Comparator|Surgery Control|Patients receive surgical excision of their tumor.
9744354|NCT00198328|Experimental|MedPulser EPT|Patients receive electroporation with injection of Bleomycin Sulfate.
9744355|NCT00198315|Active Comparator|Surgery Control|Patients will receive standard of care surgical removal of their tumor.
9744356|NCT00198315|Experimental|MedPulser EPT with Bleomycin|Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
9744357|NCT00304915|Experimental|Arm 1: Collaborative Care Intervention|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.
9744358|NCT00304915|No Intervention|Arm 2: Usual Care|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.
9744359|NCT00304954|Active Comparator|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
9744360|NCT00304954|Active Comparator|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
9744361|NCT00304954|Active Comparator|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
9744362|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
9744363|NCT00305006|Experimental|CIMT Intervention|Participants randomized to this arm were provided with 90 minutes of Constraint-Induced Movement Therapy (CIMT), which requires hand restraint and progression of unimanual tasks.
9744364|NCT00305006|Experimental|HABIT Intervention|Participants randomized to this arm were provided with 90 minutes of Hand-Arm Bimanual Intensive Therapy (HABIT), which requires that tasks are progressed bimanually.
9744365|NCT00305058|Experimental|Hydromorphone|0.0075 mg/kg IV hydromorphone
9744366|NCT00305058|Active Comparator|Morphine|0.05 mg/kg IV morphine
9744367|NCT00305084|Experimental|A|
9744368|NCT00305110|Experimental|2 mg IV hydromorphone|2 mg IV hydromorphone administered over 2-3 minutes
9744369|NCT00305162|Experimental|Cangrelor|placebo capsules (to match) + cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
9744370|NCT00305162|Active Comparator|Clopidogrel|clopidogrel capsules (600 mg) + placebo bolus & infusion (to match) + placebo capsules (to match) post infusion
9744371|NCT00305227|Experimental|Lactin-V|Vaginal capsule containing Lactobacillus crispatus in high concentration. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
9744372|NCT00305227|Placebo Comparator|Placebo|Vaginal capsule - placebo. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
9744373|NCT00305253|No Intervention|Pre-Intervention|The Pre-Intervention Phase served as the Control / Baseline group.
9744374|NCT00305253|Experimental|Post-Intervention|Intervention used in this phase and outcomes compared to the Pre-Intervention phase.
9744375|NCT00305448|Experimental|1|Fulvestrant 250 mg intramuscular injection
9744376|NCT00305448|Experimental|2|Fulvestrant 250mg (Plus 250mg Loading Regimen)
9744377|NCT00305448|Experimental|3|Fulvestrant 500 mg
9744378|NCT00305565|Other|Low Dose|
9744379|NCT00305565|Other|Medium Dose|
9744380|NCT00305565|Other|High Dose|
9744381|NCT00305578|Placebo Comparator|Placebo|Placebo daily
9744382|NCT00305578|Active Comparator|Memantine|Daily dose Memantine
9744383|NCT00305604|Active Comparator|1|sitagliptin
9744384|NCT00305604|Placebo Comparator|2|Placebo
9744385|NCT00305682|Active Comparator|Arm 1-Previous Autologous Transplant|Arm 1 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
9744386|NCT00305682|Active Comparator|Arm 2 - No Prior Autologous Transplant|Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
9744387|NCT00305682|Active Comparator|Arm 3 - Refractory Leukemia/Lymphoma|Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
9744388|NCT00305682|Active Comparator|Arm 4: MT2006-01 coenrolling patients|Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
9744389|NCT00305682|Active Comparator|Arm 5 - Previous Autologous Transplant|Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
9744390|NCT00305682|Active Comparator|Arm 6 - No prior autologous transplant|Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
9744391|NCT00305695|Experimental|Arm I (zoledroic acid)|Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.
9744392|NCT00305695|No Intervention|Arm II (clinical observation)|Patients are observed for 18 months after surgery.
9744393|NCT00305760|Experimental|Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab|
9744394|NCT00305773|Experimental|Arm I (once daily vorinostat)|Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
9744395|NCT00305773|Experimental|Arm II (thrice daily vorinostat)|Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
9744396|NCT00305864|Experimental|Phase I: MGd 3 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9744397|NCT00305864|Experimental|Phase I: MGd 4 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40.Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9785356|NCT01249872|Active Comparator|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
9744398|NCT00305864|Experimental|Phase I: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9744399|NCT00305864|Active Comparator|Phase II: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9744400|NCT00305877|Experimental|Arm I (cetuximab, gemcitabine, capecitabine, radiation)|Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions).
9744401|NCT00305877|Experimental|Arm II (bevacizumab, gemcitabine, capecitabine, radiation)|Patients receive bevacizumab IV over 60-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23. Patients also receive gemcitabine hydrochloride and capecitabine and undergo radiotherapy as in arm I.
9744402|NCT00305942|Experimental|1|"Topotecan 4mg/m2 IV on days 1, 8.~Carboplatin AUC=5 IV day 1 only .~- Cycles are repeated every 21 days for > 4 cycles of topotecan and carboplatin (maximum 6 courses). Restaging studies will be performed every 2 cycles (or 6 weeks.)"
9744403|NCT00306163|Active Comparator|1|Ciclesonide 160 µg
9744404|NCT00306163|Active Comparator|2|Fluticasone 100 µg
9744405|NCT00306189|Active Comparator|100 mg AMG 162|
9744406|NCT00306189|Active Comparator|60 mg AMG 162|
9744407|NCT00306189|Placebo Comparator|Placebo|
9744408|NCT00306189|Active Comparator|14 mg AMG 162|
9744409|NCT00306202|Experimental|Stratum 1 (Ph+ CP-CML)|Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
9744410|NCT00306202|Experimental|Stratum 2/3 (Ph+ ALL or AP/BP-CML)|Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
9744411|NCT00306202|Experimental|Stratum 4 (Ph- ALL/AML)|Participants with second or subsequent relapse of Ph- ALL or Ph- AML
9744412|NCT00306384|Experimental|Alogliptin 12.5 mg|Alogliptin 12.5 tablet, orally, once daily for up to 4 years.
9744413|NCT00306384|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablet, orally, once daily for up to 4 years.
9744414|NCT00306488|Experimental|OT-551 antioxidant eye drop|The fellow eye was treated with OT-551 antioxidant eye drops over the course of the study.
9744415|NCT00306527|Active Comparator|cTIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
9744416|NCT00306527|Active Comparator|cTIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
9744417|NCT00306527|Active Comparator|cTIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
9744418|NCT00306527|Active Comparator|cTIV\TIV (elderly)|Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
9744419|NCT00306527|Active Comparator|TIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
9744420|NCT00306527|Active Comparator|TIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
9744421|NCT00306527|Active Comparator|TIV\TIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
9744422|NCT00306527|Active Comparator|TIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
9744423|NCT00306592|Experimental|Natalizumab|All study participants in 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) received open label 300 mg intravenous (IV) natalizumab 60-minute infusion once every 4 weeks (28 days ±7 days) for up to 48 weeks. After 48 weeks, participants from 101-MS-322 (NCT00306592) entering study 101-MS-321 (NCT 00297232; considered the Long-Term Treatment Period of 101-MS-322) were continued on treatment from Week 52 through Week 480.
9785357|NCT01249872|Active Comparator|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
9744424|NCT00306670|Experimental|Rituximab|Patients will receive rituximab.
9744425|NCT00306670|Active Comparator|Oral cyclophosphamide|Patients will receive oral cyclophosphamide.
9744426|NCT00306787|Experimental|Famciclovir|Patients received Famciclovir 1000 mg (2 x 500 mg tablets) twice a day for one day. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions and the second dose approximately 12 hours later. Patients also received 1 valacyclovir placebo capsule, beginning with the first famciclovir dose, twice a day for 3 days, each taken about 12 hours apart.
9744427|NCT00306787|Active Comparator|Valacyclovir|Patients received Valacyclovir 500 mg capsule twice a day approximately 12 hours apart for 3 consecutive days. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions. On the first day patients also received 2 famciclovir placebo tablets taken with the first 2 doses of Valacyclovir.
9744428|NCT00306852|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C
9744429|NCT00306852|Active Comparator|Implant|Baerveldt Implant
9744430|NCT00306891|Experimental|Cediranib 45 mg Fed|Part A: Cediranib 45 mg Fed State
9744431|NCT00306891|Experimental|Cediranib 45 mg Fasted|Part A: Cediranib 45 mg Fasted State
9744432|NCT00306891|Experimental|Cediranib 45 mg Fixed Dose|Part B: Cediranib 45 mg Fixed Dose
9744433|NCT00306891|Experimental|Cediranib 30 - 90 mg Dose Escalation|Part B: Cediranib 30 - 90 mg Dose Escalation
9744434|NCT00306917|Active Comparator|1|DuoFix HA
9744435|NCT00306917|Active Comparator|2|Porocoat porous coated
9744436|NCT00306995|Experimental|SB218352_15 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
9744437|NCT00306995|Experimental|SB218352_8 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
9744438|NCT00306995|Experimental|SB218352_4 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
9744439|NCT00306995|Experimental|SB218352_2 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
9744440|NCT00306995|Experimental|SB218352_8AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
9744441|NCT00306995|Experimental|SB218352_4AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
9744442|NCT00306995|Experimental|SB218352_2AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
9744443|NCT00307034|Experimental|2-dose group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
9744444|NCT00307034|Experimental|Comparator group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-3-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
9744445|NCT00307047|Experimental|XIENCE V®|
9744446|NCT00307047|Active Comparator|TAXUS™ EXPRESS2™|
9744447|NCT00307086|Other|Autologous PBSCT|bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant (PBSCT)
9744448|NCT00307125|Experimental|Pilot Phase-Rituximab plus immunosuppression|"Enrollment into a Stage 2 pilot treatment study will occur after Stage 1. Adult Rituximab Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Rituximab Dosing (Subjects <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
9744449|NCT00307125|Placebo Comparator|Pilot Phase-Placebo plus immunosuppression|"Adult Placebo Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Placebo Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
9744450|NCT00307151|Experimental|Coh I: NVP|Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.
9744451|NCT00307151|Experimental|Coh I: LPV/r|Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.
9744452|NCT00307151|Experimental|Coh II: NVP|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen
9744453|NCT00307151|Experimental|Coh II: LPV/r|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen
9744454|NCT00307164|Active Comparator|NucleomaxX|Participants received NucleomaxX for 48 weeks
9744455|NCT00307164|Placebo Comparator|Placebo|Participants received NucleomaxX placebo for 48 weeks
9744456|NCT00307294|Experimental|thalidomide and doxil|Combination of Thalidomide and Doxil
9744457|NCT00307333|Experimental|1|Very low birth weight infants with their HRC index continuously displayed. Clinicians can utilize the HRC score to develop treatment plan.
9744458|NCT00307333|No Intervention|2|Very low birth weight infants for whom the HRC index is not displayed. Infants receive standard of care treatment.
9744459|NCT00307437|Placebo Comparator|Group I: Placebo|
9744460|NCT00307437|Experimental|Group II: Ustekinumab 45 mg|
9744461|NCT00307437|Experimental|Group III: Ustekinumab 90 mg|
9744462|NCT00307489|Experimental|1|TDF
9744463|NCT00307489|Experimental|2|FTC/TDF
9744464|NCT00307684|Experimental|001|open label PR OROS methylphenidate Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
9744465|NCT00307684|Experimental|002|double blind PR OROS methylphenidate 18 36 54 72 or 90 mg/day once daily for 4 weeks
9744466|NCT00307684|Placebo Comparator|003|double blind placebo matching placebo tablets once daily for 4 weeks
9744467|NCT00307736|Experimental|Chemotherapy and radiation|Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.
9744468|NCT00307801|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
9744469|NCT00307801|Placebo Comparator|Placebo|Matching placebo to be taken orally daily.
9744470|NCT00307931|Experimental|Certolizumab pegol|certolizumab pegol 400 mg
9744471|NCT00308061|Experimental|FMP1/AS02A Vaccine|500 uL of FMP1/AS02A is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
9744472|NCT00308061|Active Comparator|Imovax Rabies Vaccine|1 mL of Imovax Rabies Vaccine is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
9744473|NCT00308074|Experimental|Aripiprazole|aripiprazole monotherapy, begun at 2.5 mg or 5.0 mg based on clinical impression and severity of aggression and agitation. Dose to be adjusted in not more than 5 mg increments, weekly. The lowest effective dose will be used up to a maximum daily dose of 20 mg.
9744474|NCT00308087|Active Comparator|Rituximab|
9744475|NCT00308087|Experimental|Rituximab + Sargramostim|
9744476|NCT00308139|Experimental|Exenatide Once Weekly|Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
9744477|NCT00308139|Active Comparator|Exenatide Twice Daily|"subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device."
9744478|NCT00308230|Placebo Comparator|Normal Heart|Control Group with Normal Heart
9744479|NCT00308230|Active Comparator|Congenital Heart Disease|Tetralogy of Fallot, DTGA, CCTGA
9744480|NCT00308230|Active Comparator|Heart Failure|Left ventricular heart failure, no congestive heart disease
9744481|NCT00308282|Experimental|A|
9744482|NCT00308282|Placebo Comparator|B|
9744483|NCT00308308|Experimental|1|Technosphere Insulin
9744484|NCT00308308|Active Comparator|2|Rapid-acting analogue insulin plus basal insulin glargine
9744485|NCT00308555|Other|Cannabis|
9744486|NCT00308581|Experimental|Active 1|"Q4W regimen~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol"
9744487|NCT00308581|Experimental|Active 2|"Q2W regimen~- every 2 weeks: 400 mg Certolizumab Pegol"
9744488|NCT00308620|Experimental|Chloroquine|Chloroquine 205mg or 500mg orally once daily (Results pooled)
9744489|NCT00308620|Placebo Comparator|Placebo|Placebo once daily for 8 weeks
9744490|NCT00308711|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg over 24h
9744491|NCT00308711|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg over 24h
9744492|NCT00308711|Active Comparator|Cervidil 10 mg vaginal insert|Cervidil 10 mg over 24h
9744493|NCT00308737|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
9744494|NCT00308737|Other|Usual care|Usual care
9744495|NCT00308737|No Intervention|Non-diabetes|Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)
9744496|NCT00308750|Experimental|Enzastaurin/Pemetrexed/Carboplatin|
9744497|NCT00308750|Experimental|Pemetrexed/Carboplatin|
9744498|NCT00308750|Active Comparator|Docetaxel/Carboplatin|
9744499|NCT00308997|Experimental|1|Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
9744500|NCT00308997|Sham Comparator|2|sham rTMS to Wernicke's area and a right homologous area
9744501|NCT00309140|Experimental|Enzastaurin|
9744502|NCT00309166|Experimental|Cervarix Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
9744503|NCT00309166|Active Comparator|Engerix-B Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
9744504|NCT00309244|Experimental|TI + Insulin glargine|Technosphere® Insulin Inhalation Powder + insulin glargine
9744505|NCT00309244|Active Comparator|BPR 70/30|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
9744506|NCT00309387|Experimental|Centrum|multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
9744507|NCT00309387|Placebo Comparator|placebo|placebo pills. One tablet a day for the whole study duration.
9744508|NCT00309452|Active Comparator|Treatment as usual|Referral to community providers.
9744509|NCT00309452|Experimental|STEP Care|Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.
9744510|NCT00309465|Experimental|1|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
9744511|NCT00309465|Active Comparator|2|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
9744512|NCT00309465|Experimental|3|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
9744513|NCT00309608|Experimental|Linagliptin low dose|Patients receive Linagliptin low dose tablets once daily
9744514|NCT00309608|Experimental|Linagliptin medium dose|Patients receive Linagliptin medium dose tablets once daily
9744515|NCT00309608|Experimental|Linagliptin high dose|Patients receive Linagliptin high dose tablets once daily
9744516|NCT00309608|Placebo Comparator|Placebo|Patients receive tablets identical to those containing Linagliptin low, medium and high dose
9744517|NCT00309608|Active Comparator|Glimepiride|Patients receive Glimepiride tablets once daily
9744518|NCT00309738|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
9744519|NCT00309738|Active Comparator|Simvastatin 40 mg QD|Simvastatin 40 mg once daily
9744520|NCT00309751|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
9744521|NCT00309751|Active Comparator|Atorvastatin 20 mg QD|Atorvastatin 20 mg once daily
9744522|NCT00309777|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
9744523|NCT00309777|Active Comparator|Simvastatin 20 mg|Simvastatin 20 mg once daily
9744524|NCT00309777|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
9744525|NCT00309777|Active Comparator|Simvastatin 40 mg|Simvastatn 40 mg once daily
9744526|NCT00309842|Experimental|Unrelated UCBT for Blood Cancers|Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
9744527|NCT00309907|Experimental|Etanercept and corticosteroid therapy|Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.
9744528|NCT00309946|Experimental|Treatment (enzyme inhibitor therapy)|Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
9785358|NCT01250002|Active Comparator|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
10201148|NCT04504903|Experimental|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will participate in 12 weekly group sessions to discuss thoughts, feelings, and behaviors that promote work success in the community
10201149|NCT04504903|Active Comparator|Psychoeducation|Veterans in the control group will participate in 12 weekly group sessions in which they will learn more about their mental health conditions.
10201150|NCT04503733|Experimental|Q4W GMA301 IV injections (300 mg)|"Drug: Q4W GMA301 IV injections (300 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
10201151|NCT04503733|Experimental|Q4W GMA301 IV injections (600 mg)|"Drug: Q4W GMA301 IV injections (600 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
10201152|NCT04503733|Experimental|Q4W GMA301 IV injections (1000 mg)|"Drug: Q4W GMA301 IV injections (1000 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
9744529|NCT00309959|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9744530|NCT00310037|Experimental|Arm A maintenance therapy|Patients receive bortezomib 1.6 mg/m^2 IV on days 1, 8, 15, and 22 once daily for 4 weeks. There will be a 4 week rest period. One cycle is a total of 8 weeks. A total of 10 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
9744531|NCT00310037|Experimental|Arm B consolidation therapy|Patients receive bortezomib 1.3 mg/m^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
9744532|NCT00310050|Experimental|Pemetrexed in combination with concomitant radiotherapy|Patients will receive Pemetrexed plus Radiotherapy.
9744533|NCT00310076|Experimental|Chemo therapy followed by thalidomide|After cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
9744534|NCT00310310|Placebo Comparator|Usual Care|Usual sleep apnea and cpap care
9744535|NCT00310310|Experimental|Self-Management|sleep apnea self-management program - 4 sessions, group-based
9744536|NCT00310362|Experimental|Usual Care with nurse phone call|Usual Care--Nurses telephoned patients 7 days prior to appointment to remind patients about scheduled GI appointment and to answer any questions.
9744537|NCT00310362|Experimental|interactive voice response 3 days prior|Interactive voice response system was used to remind patients 3 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR3)
9744538|NCT00310362|Experimental|interactive voice response 7 days prior|Interactive voice response system was used to remind patients 7 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR7)
9744539|NCT00310375|Experimental|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets - 50mg, 100mg or 300mg
9744540|NCT00310401|Experimental|Albuterol|Albuterol sulfate 5 mg dissolved in normal saline administered every 4 hours by nebulization
9744541|NCT00310401|Placebo Comparator|Saline|Saline administered every 4 hours by nebulization
9744542|NCT00310427|Experimental|LY686017|Subjects received 50 mg of the NK1 antagonist LY686017 orally on a daily basis.
9744543|NCT00310427|Placebo Comparator|Placebo|Subjects received placebo orally on a daily basis
9744544|NCT00310440|Experimental|Bone graft substitute|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
9744545|NCT00310440|Active Comparator|Autologous Bone|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.
10201153|NCT04503733|Experimental|Q4W GMA301 IV injections (1800 mg)|"Drug: Q4W GMA301 IV injections (1800 mg) Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.~Other: Q4W placebo IV injections Placebo is indistinguishable from GMA301"
10201154|NCT04497415|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
10201155|NCT04497415|No Intervention|Assessment only|Control
9744546|NCT00310466|Active Comparator|Sublingual immunotherapy|sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
10201156|NCT04493242|Placebo Comparator|Placebo|Normal saline 100 mL
10201157|NCT04493242|Experimental|Experimental Dose 1|Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.
10201158|NCT04493242|Experimental|Experimental Dose 2|Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles.
10201159|NCT04488068|Experimental|Magnetic Stimulation|Patients will be subjected to TPMS.
10201160|NCT04488068|No Intervention|Sham TPMS|Patients will be subjected to sham TPMS
9744547|NCT00310466|Placebo Comparator|Placebo|placebo sublingual drops
9744548|NCT00310791|Placebo Comparator|Sugar Pill|Placebo (sugar pill); identical to treatment medication capsule
9744549|NCT00310791|Experimental|DHEA + Hormone replacement therapy (estrogen/progestin)|Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
9744550|NCT00310804|Experimental|cTIV_lot 1|
9744551|NCT00310804|Experimental|cTIV_lot 2|
9744552|NCT00310804|Experimental|cTIV_lot 3|
9744553|NCT00310804|Active Comparator|TIV group|
9744554|NCT00310817|Experimental|MenACWY-CRM(Ad+) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine with adjuvant (Ad+) on day 1 and second dose at 28 days or at 6 months or at 12 months after the first vaccination.
9744555|NCT00310817|Experimental|MenACWY-CRM(Ad-) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant (Ad-) on day 1 and second dose either at 28 days or at 6 months or at 12 months after the first vaccination.
9744556|NCT00310817|Experimental|MenACWY-CRM(Ad-) 36 to 59 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant on day 1 and second dose on day 169 or day 337.
9744557|NCT00310817|Active Comparator|MenACWY-PS (36 to 59 Months)|Subjects received one dose of MenACWY polysaccharide (PS) vaccine on day 1 and second dose of MenACWY-CRM conjugate vaccine without adjuvant on day 169 or day 337.
9744558|NCT00310856|Experimental|MenACWY-CRM_6-12 M|Subjects received 2 doses of MenACWY-CRM (1 dose at 6 and 12 months of age). Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
9744559|NCT00310856|Experimental|MenACWY-CRM_12 M|Subjects received 1 dose of MenACWY-CRM at 12 months of age. Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
9744560|NCT00310856|Experimental|MenC-CRM_12 M_MenACWY-CRM_18 M|"Subjects received 1 dose of MenC-CRM (at 12 months of age) and 1 dose of MenACWY-CRM (at 18 months of age).~Subjects also received routine vaccines: 1 dose of PCV7 (at 12 months), MMR+Varicella (at 13 months) and DTaP-Hib-IPV (at 18 months)"
9744561|NCT00311155|Experimental|1|"Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks"
9984680|NCT03836625|Experimental|Intervention|The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled >50 km from the study site for >7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.
10201161|NCT04485039|Other|ABCDE|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet."
9744562|NCT00311168|Experimental|VIP On, Then VIP Off|Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.
9744563|NCT00311168|Experimental|VIP Off, Then VIP On|Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.
9744564|NCT00311181|Experimental|2.5/3.5/4.5 ms defibrillation waveform|
9744565|NCT00311246|Experimental|An open-label|Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52
9744566|NCT00311311|Active Comparator|1|Tacrolimus + MMF + Steroids
9744567|NCT00311311|Experimental|2|Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
9744568|NCT00311363|Experimental|GEn (XP13512) 1200 mg|GEn (XP13512) 1200 mg
9744569|NCT00311363|Placebo Comparator|Placebo|Placebo
9744570|NCT00311376|Experimental|1|botulinum toxin Type A (200U)
9744571|NCT00311376|Experimental|2|botulinum toxin Type A (300U)
9744572|NCT00311376|Other|3|placebo; botulinum toxin Type A (200U)
9744573|NCT00311376|Other|4|placebo; botulinum toxin Type A (300U)
9744574|NCT00311402|Other|Aggrenox Capsule|
9744575|NCT00311402|Other|Acetylsalicylic Acid (ASA) 81 mg Tablet|
9744576|NCT00311584|Experimental|Disease measurable by CT or MRI scan (Irinotecan/Temozolomide)|Measurable by CT scan (Computed Tomography) or MRI scan (Magnetic Resonance Imaging). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9744577|NCT00311584|Experimental|Disease eval by bone marrow or MIBG (Irinotecan/Temozolomide)|Evaluation by bone marrow or MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9744578|NCT00311623|Active Comparator|Control group|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Receive no intervention on Days 1-14. Surgery performed on Day 15."
9744579|NCT00311623|Experimental|Low-dose Rapamycin (3mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
10201162|NCT04485039|Other|ACEBD|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate"
9785359|NCT01250002|Placebo Comparator|Placebo|Placebo will receive the same volume of saline infusion.
9785360|NCT01250054|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B multifocal contact lenses worn first, with comfilcon A multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
9744580|NCT00311623|Experimental|High-dose Rapamycin (6mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
9744581|NCT00311766|Placebo Comparator|1|Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
9744582|NCT00311766|Active Comparator|2|Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days
9744583|NCT00312195|Experimental|BTDS (5, 10 or 20)|Buprenorphine transdermal patch
9744584|NCT00312195|Placebo Comparator|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch
9744585|NCT00312208|Experimental|1|Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -> T)
9744586|NCT00312208|Experimental|2|Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
9744587|NCT00312221|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
9744588|NCT00312221|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
9744589|NCT00312221|Experimental|Oxycodone Immediate-Release (Oxy IR) 40 mg|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
9744590|NCT00312338|Experimental|Infected Patient treated with Vigamox|Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
9744591|NCT00312338|No Intervention|Healthy Subjects|Healthy Subjects receiving no treatment
9744592|NCT00312377|Active Comparator|1|Docetaxel monotherapy
9744593|NCT00312377|Experimental|2|Vandetanib + Docetaxel
9744594|NCT00312494|Placebo Comparator|Placebo|
9744595|NCT00312494|Experimental|Ziprasidone 20-40mg twice a day (BID)|
9744596|NCT00312494|Experimental|Ziprasidone 60-80mg BID|
9744597|NCT00312572|Experimental|BTDS10/20|Initial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
9744598|NCT00312572|Experimental|BTDS 20|Initial doses (Level 1) of BTDS 20.
9744599|NCT00312663|Experimental|10ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
9744600|NCT00312663|Experimental|50ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
9744601|NCT00312702|Experimental|10µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
9744602|NCT00312702|Experimental|50µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
9744603|NCT00312728|Experimental|bevacizumab|
9744604|NCT00312845|Experimental|Bortezomib + Rituximab|
9744605|NCT00312845|Active Comparator|Rituximab|
9744606|NCT00312858|Active Comparator|1|Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
10201163|NCT04485039|Other|ADBEC|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet"
9744607|NCT00312858|Active Comparator|2|Arm 2: ProQuad™ 0.5 mL injection (2 doses ~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.
9744608|NCT00312884|Active Comparator|Usual Care|Recieved usual hospital and community care
9744609|NCT00312884|Experimental|Intervention Arm|Recieved telemonitoring
9744610|NCT00312897|Placebo Comparator|corn oil|as stated
9744611|NCT00312897|Experimental|Omega 3 Fatty Acids|as stated
9744612|NCT00312923|Experimental|Policosanol|20 mg daily of policosanol
10201164|NCT04485039|Other|AEDCB|"Single oral dose of TPOXX 600 mg~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 500 mg lanthanum carbonate chewable tablet.~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 1334 mg calcium acetate~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 1600 mg sevelamer carbonate"
9744613|NCT00312923|Placebo Comparator|Placebo|20 mg of microcrystalline cellulose daily
9744614|NCT00313014|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
10201165|NCT04479917|Experimental|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg 2 tablets
9744615|NCT00313014|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
9744616|NCT00313014|Experimental|Oxycodone Immediate-Release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
9744617|NCT00313170|Experimental|1|Fulvestrant 250 mg (intramuscular injection 250 mg)
9744618|NCT00313170|Experimental|2|Fulvestrant 250 mg (+ 250 mg loading regimen)
9744619|NCT00313170|Experimental|3|Fulvestrant 500 mg (intramuscular injection 500 mg)
9744620|NCT00313209|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: salmeterol 50 μg, twice daily, inhaled"
9744621|NCT00313209|Placebo Comparator|Placebo|"Placebo~underlying medication: salmeterol 50 μg, twice daily, inhaled"
9744622|NCT00313300|Active Comparator|A1|
9744623|NCT00313300|Experimental|A2|
9744624|NCT00313300|Placebo Comparator|A3|
9744625|NCT00313300|Experimental|A4|
9744626|NCT00313313|Experimental|Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)|Metformin 500-2500 mg (as needed)
9744627|NCT00313313|Experimental|Saxagliptin 5 mg + Glyburide 7.5 mg (B)|Metformin 500-2500 mg (as needed)
9744628|NCT00313313|Placebo Comparator|Placebo + Glyburide 7.5 mg (C)|Metformin 500-2500 mg (as needed)
9744629|NCT00313443|Experimental|Amiodarone, long-term|Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings
9744630|NCT00313560|Experimental|Erlotinib and EBRT after pancreatectomy|"Adjuvant treatment with erlotinib 100 mg plus Capecitabine 800 mg/m2 PO BID (5 days on/ 2 days off regimen) and External Beam Radiation Therapy (EBRT) at doses of 50.4 Gy in 28 fractions after pancreatectomy (Dosing for capecitabine and erlotinib was amended after considering the toxicity profile of the first 6 patients).~Approximately 4-8 weeks after the conclusion of chemoradiation, it is recommended patients will continue treatment with 4 cycles of gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg."
9744631|NCT00313586|Experimental|Arm A (azacitidine)|Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
9744632|NCT00313586|Experimental|Arm B (azacitidine, entinostat)|Patients receive azacitidine as in Arm A and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
9744633|NCT00313612|Experimental|Treatment (oxaliplatin plus topotecan)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
9744634|NCT00313716|Active Comparator|Epo1 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger of 10gm/dl
9744635|NCT00313716|Active Comparator|Epo1 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
9744636|NCT00313716|Active Comparator|Epo2 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 10gm/dl
9983923|NCT04542564|Experimental|telemedicine group|The HT app (HealthCap) allows patients to record their home BP measurements (HBPM) and can automatically provide mean BP values from the previous 7 or 30 days. 1-2 week prior to a scheduled physician, HealthCap and a research assistant will remind patients to take dual BP readings both in the morning and evening for 1 week for doctors' management. The mean values of the 7-day home BP will be checked before the index consultation. If the home BP control was optimal (i.e. ≤135/85 mmHg), other important parameters will be checked automatically by a questionnaire in the app: (i) if they have good drug compliance and if they experienced any side effects,(ii) if they have symptoms suggestive of target organ damages such as chest pain or hemiplegia, and (iii) if they have any problem(s) that need to consult a physician. If no complaints are identified, the patient can collect medications directly from the clinic and the physician appointment will be deferred for 3 months
9983924|NCT04542564|Placebo Comparator|usual care|Patients in the usual care group will be asked to refrain from downloading or using any health care apps related to HT
9744637|NCT00313716|Active Comparator|Epo2 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
9744638|NCT00313716|Placebo Comparator|Placebo and TT10|Placebo administration and transfusion threshold 10 gm/dl
9744639|NCT00313716|Placebo Comparator|Placebo and TT7|Placebo administration and transfusion threshold 7 gm/dl
9785361|NCT01250054|Other|Comfilcon A /Lotrafilcon B|Comfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
9983925|NCT04542317|Experimental|REACH VN|A multi-component behavioral intervention to support family caregivers of persons with dementia. Participants will receive 4-6 sessions in-person or by phone over the course of 2-3 months.
9744640|NCT00313729|Experimental|Temozolomide|Temozolomide
9744641|NCT00313781|Experimental|A|For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
9744642|NCT00313781|Active Comparator|B|
9744643|NCT00313820|Active Comparator|Pregabalin|The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
9744644|NCT00313820|Placebo Comparator|Placebo|The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
9744645|NCT00313846|Experimental|BTDS|Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
10201166|NCT04479917|Experimental|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet+ Placebo 10mg tablet
10201167|NCT04479917|Experimental|TPN171H 20mg group|TPN171H 10mg 2 tablets + Placebo 5mg tablet
10201168|NCT04479917|Placebo Comparator|Placebo group|Placebo 5mg tablet+ Placebo 10mg 2 tablets
9744646|NCT00313846|Placebo Comparator|Placebo|Placebo to match BTDS 5, 10 or 20 mcg/h
9744647|NCT00313911|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
9744648|NCT00313911|Active Comparator|Group 2: Tritanrix-Hep B/Hib™+OPV|
9744649|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, prior IL-2|Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).
9744650|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, no prior IL-2|Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)
9744651|NCT00314132|Placebo Comparator|Placebo|All subjects received a single injection of placebo on Day 0.
9744652|NCT00314132|Experimental|ChimeriVax™ JE 4 log10 PFU Vaccine|All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
9744653|NCT00314145|Experimental|ChimeriVax™-JE|Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
9744654|NCT00314145|Active Comparator|JE-VAX®|Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.
9744655|NCT00314236|Experimental|Microfracture with BST-CarGel|BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
9744656|NCT00314236|Active Comparator|Microfracture without BST-CarGel|Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
9744657|NCT00314249|Placebo Comparator|Placebo|Placebo, oral administration, twice daily for 12 weeks
10201169|NCT04477837||direct oral anticoagulant (DOAC) No.1|Apixaban 5mg, oral, twice daily for at least four months
10201170|NCT04477837||direct oral anticoagulant (DOAC) No.2|Rivaroxaban 20mg, oral, once daily for at least four months
9744658|NCT00314249|Experimental|Milnacipran|Milnacipran 100mg/day (50mg BID [twice a day])
9744659|NCT00314262|Experimental|Erlotinib & Celecoxib|
9744660|NCT00314340|Active Comparator|extended-release morphine|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On one of three study dates, subjects received ER morphine tablets, 45 mg (Mallinckrodt Pharmaceuticals, St. Louis, MO). The dose of ER morphine sulfate (45 mg) was selected because of its approximate equianalgesic effect to the dose of hydrocodone-acetaminophen (30/925 mg)."
9744661|NCT00314340|Active Comparator|hydrocodone|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On the day of the study session, patients received hydrocodone 30 mg plus N-acetyl-para-aminophenol 975 mg (APAP;Qualitest Pharmaceuticals Inc, Huntsville, AL)."
9744662|NCT00314340|Placebo Comparator|placebo|Subjects received a placebo pill if randomized to this arm. Both opioid medications and the placebo were administered in identical capsules.
9744663|NCT00314366|Active Comparator|Stem Cell Therapy|Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter.
9744664|NCT00314366|Placebo Comparator|Control|"Placebo patients will receive injections of plasma (control) instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria.~At 6 months, subject is offered stem cell therapy and then followed for 12 months."
9744665|NCT00314574|Experimental|Xolair|"The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
9744666|NCT00314574|Placebo Comparator|placebo|"The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
9785362|NCT01250119|Experimental|Single Arm|
9744667|NCT00314795|Experimental|Peginesatide|"Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL."
9744668|NCT00314808|Experimental|Dronabinol|
9744669|NCT00314951|Experimental|fidaxomicin|Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin
10201171|NCT04477837||direct oral anticoagulant (DOAC) No.3|Edoxaban 60mg, oral, once daily for at least four months
9744670|NCT00314951|Active Comparator|Vancomycin|Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen).
9744671|NCT00315055|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|Participants will receive 3 vaccinations with Diphtheria (D) and tetanus (T) toxoids, acellular pertussis (2-component) (aP), recombinant Hepatitis B surface antigen (HBsAg), inactivated poliomyelitis virus (IPV), and Hemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T); One dose each at 2, 3, and 4 months of age.
9744672|NCT00315055|Active Comparator|Group 2: PENTAXIM™ and ENGERIX B® PEDIATRIC|Participants will receive 3 vaccinations with DTaP-IPV-PRP~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines. One dose each at 2, 3, and 4 months of age.
9744673|NCT00315120|Other|A (Active OMT and active (UST)|Subjects in this group received active osteopathic manipulation and active ultrasound physical therapy
9744674|NCT00315120|Other|B (Sham OMT and active UST)|Subjects in this group received sham osteopathic manipulation and active ultrasound physical therapy
9744675|NCT00315120|Other|C (Active OMT and sham UST)|Subjects in this group received active osteopathic manipulation and sham ultrasound physical therapy
9983926|NCT04542317|Placebo Comparator|Enhanced control|A single session focused on education about the nature of dementia.
10201172|NCT04477837||direct oral anticoagulant (DOAC) No.4|Dabigatran 150mg, oral, twice daily for at least four months
9744676|NCT00315120|Other|D (Sham OMT and sham UST)|Subjects in this group received sham osteopathic manipulation and sham ultrasound physical therapy
9744677|NCT00315146|Placebo Comparator|Hypocaloric diet (and placebo)|
9744678|NCT00315146|Active Comparator|Hypocaloric diet, resist. training to maximize power, placebo|
9744679|NCT00315146|Active Comparator|Hypocaloric diet and a PPAR- γ agonist (pioglitazone/Actos™)|
9744680|NCT00315146|Active Comparator|Hypocaloric diet,resistance training, pioglitazone/Actos™|
10201173|NCT04473807|Other|DASH-AF|Patients with history of highly symptomatic persistent or paroxysmal AF who are scheduled for sotalol therapy once in sinus rhythm will be enrolled in this study.
10201174|NCT04467021|Experimental|Arm A (intensive systolic blood pressure management)|Patients receive intensive systolic blood pressure management for 6 months. Patients receive increased blood pressure medication every 2 weeks while systolic blood pressure is 120 mmHg or higher. Patients also monitor blood pressure at home 1 day a week (4 times in 1 day) every 2 weeks, and upload the recorded blood pressure readings to the provider and to a central blood pressure monitoring team. Patients with changes in blood pressure medications monitor blood pressure readings on 3 days in 1 week (4 times in 1 day).
9744681|NCT00315302|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye
9744682|NCT00315302|Active Comparator|Atropine plus plano|Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye
9744683|NCT00315328|Active Comparator|Patching|Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and >4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
9744684|NCT00315328|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)
9744685|NCT00315341|Experimental|Buprenorphine/Nx|For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
9744686|NCT00315341|Active Comparator|Methadone|For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
9744687|NCT00315445|Placebo Comparator|Placebo|Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
9744688|NCT00315445|Active Comparator|OXY/APAP|5 mg oxycodone/325 mg acetaminophen tablets
9744689|NCT00315445|Experimental|BTDS|Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
9744690|NCT00315458|Experimental|BTDS|Buprenorphine transdermal patches 10 or 20 mcg/h
9744691|NCT00315458|Placebo Comparator|Placebo|Placebo to match buprenorphine transdermal patch 10 or 20
9983927|NCT04541186|Active Comparator|Main Study|The cohort will include subjects with SHTG without concurrent fibrate therapy and will consist of 5 treatment groups to compare 4 dose levels/regimens of BIO89-100 versus placebo.
10201175|NCT04467021|Active Comparator|Arm B (usual blood pressure management)|Patients receive standard blood pressure management for 6 months. Patients receive blood pressure medications per doctor's instruction. Patients also monitor blood pressure at home 1 day (4 times in 1 day) every 2 weeks, and upload the recorded blood pressures to a central monitoring team.
10201176|NCT04466592|Experimental|Supportive intervention|A research psychologist will support participants, promoting their competences in the recover of work and social activities, such as the compliance.
10201177|NCT04455620|Experimental|Part 1: BNT151|Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
10201178|NCT04452344|Active Comparator|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen 300 mg and a placebo pill.
10201179|NCT04452344|Active Comparator|Non-Opioid|Combination of ibuprofen 400 mg/acetaminophen 500 mg
10201180|NCT04452292|Active Comparator|No TP53/Rb1 Co-Mutation|HG-LCNEC tumor lacking the TP53/Rb1 co-mutation (non-small cell-like).
10201181|NCT04452292|Experimental|TP53/Rb1 Co-Mutation Present|HG-LCNEC tumor with the TP53/Rb1 co-mutation.
10201182|NCT04445220|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
9744692|NCT00315588|Experimental|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
9744693|NCT00315614|Experimental|Islet Transplantation and Bone Marrow|Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
9744694|NCT00315627|Experimental|islet transplantation|Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
9744695|NCT00315705|Experimental|clofarabine, etoposide, cyclophosphamide|"Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m^2, etoposide dosage from 75-100 mg/m^2, cyclophosphamide dosage from 340-440 mg/m^2.~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m^2, etoposide 100 mg/m^2 and cyclophosphamide 440 mg/m^2 delivered intravenously"
9744696|NCT00315731|Experimental|tositumomab and iodine I 131 tositumomab|Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy.
9744697|NCT00315822|Placebo Comparator|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
9744698|NCT00315822|Active Comparator|80% oxygen|Subject undergoing surgery will receive supplemental oxygen
9744699|NCT00315939|Experimental|Group A Order: SMBG, IBMF-1, IBMF-2|Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
9744700|NCT00315939|Experimental|Group B Order: IBMF-1, IBMF-2, SMBG|Group B began with Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.
9744701|NCT00316004|Experimental|7.5% hypertonic saline/6% dextran (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
9744702|NCT00316004|Experimental|7.5% hypertonic saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline
9744703|NCT00316004|Placebo Comparator|0.9% normal saline (NS)|250 ml intravenous bolus administration of 0.9% saline
9744704|NCT00316017|Experimental|1|7.5% hypertonic saline/6% Dextran-70 (HSD)
9744705|NCT00316017|Experimental|2|7.5% hypertonic saline (HS)
9744706|NCT00316017|Placebo Comparator|3|0.9% normal saline
9744707|NCT00316082|Experimental|Saxagliptin 2.5 mg QAM (A)|PLUS open-label metformin (as needed as rescue medication)
9744708|NCT00316082|Experimental|Saxagliptin 2.5 mg titrated to 5 mg QAM (B)|PLUS open-label metformin (as needed as rescue medication)
9984681|NCT03833713|Experimental|SMS Intervention|Once-weekly automated SMS dialogue sessions or micro-interventions and use behavior change techniques including self-monitoring with performance feedback and goal support
10201183|NCT04445220|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
10201184|NCT04445220|No Intervention|Case controls|Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants.
10201185|NCT04436744|Experimental|Giredestrant + Palbociclib|
10201186|NCT04436744|Active Comparator|Anastrozole + Palbociclib|
9744709|NCT00316082|Experimental|Saxagliptin 5 mg QAM (C)|PLUS open-label metformin (as needed as rescue medication)
9744710|NCT00316082|Experimental|Saxagliptin 5 mg QPM (D)|PLUS open-label metformin (as needed as rescue medication)
9744711|NCT00316082|Placebo Comparator|Placebo (E)|PLUS open-label metformin (as needed as rescue medication)
9744712|NCT00316121|Experimental|1|
9744713|NCT00316121|Active Comparator|2|
9744714|NCT00316173|Experimental|Single-arm|HYCAMTIN at a dose of 2.0 - 2.5mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1, every 21 days
9744715|NCT00316186|Experimental|Single arm, open label|
9744716|NCT00316199|Experimental|A|
9744717|NCT00316225|Experimental|Pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) every 21 days for 6 cycles
9744718|NCT00316264|Experimental|Motavizumab followed by Palivizumab|2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
9744719|NCT00316264|Experimental|Palivizumab followed by motavizumab|2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
9744720|NCT00316264|Experimental|Motavizumab control|5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
9744721|NCT00316277|Experimental|Buprenorphine/Nx with EMM|
9827937|NCT02473783|Experimental|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
9827938|NCT02473913|Experimental|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
9827939|NCT02473913|Placebo Comparator|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
9827940|NCT02473952|Experimental|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
9827941|NCT02473952|Placebo Comparator|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
9827942|NCT02473965|Experimental|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
9827943|NCT02473965|Placebo Comparator|Placebo|0.9% sodium chloride injection, USP or equivalent
9827944|NCT02474069|Active Comparator|Secukinumab Interval Shortening|
9827945|NCT02474069|Active Comparator|Secukinumab 4-weekly|
9827946|NCT02474082|Experimental|Secukinumab|Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
9827947|NCT02474082|Active Comparator|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
9827948|NCT02474199|Experimental|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10^6 darTregs (range 300-500 x10^6) infused intravenously (IV) over an approximate 20-30 minute interval
9827949|NCT02474355|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
9827950|NCT02474407|Experimental|diazepam nasal spray (DZNS)|One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
9827951|NCT02474407|Active Comparator|diazepam rectal gel (DRG)|A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
9827952|NCT02474498|Active Comparator|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
9827953|NCT02474498|Active Comparator|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
9827954|NCT02474498|Active Comparator|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
9827955|NCT02474589|Active Comparator|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
9827956|NCT02474589|Placebo Comparator|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
9827957|NCT02474901|Active Comparator|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
9827958|NCT02474901|Active Comparator|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
9827959|NCT02475031|Placebo Comparator|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
9827960|NCT02475031|Active Comparator|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
9827961|NCT02475070|Active Comparator|Vildagliptin first|Treatment with vildagliptin 50mg twice daily for two weeks followed by four weeks washout and then treatment with dapagliflozin 10mg once daily for two weeks
9827962|NCT02475070|Active Comparator|Dapagliflozin first|Treatment with dapagliflozin 10 mg once daily for two weeks followed by four weeks washout and then treatment with vildagliptin 50 mg twice daily for two weeks
9827963|NCT02475265|Experimental|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
9827964|NCT02475278|Experimental|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
9984682|NCT03833713|Active Comparator|SMS Assessments|Once-weekly SMS assessments related to their target risk behavior without receiving any feedback or goal support
9744722|NCT00316277|Active Comparator|Buprenorphine/Nx with SMM|
9744723|NCT00316303|Experimental|1|Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
9744724|NCT00316303|Placebo Comparator|2|Participants will receive enhanced treatment as usual.
9744725|NCT00316355|Active Comparator|Traditional CBT|Cognitive-behavioral therapy (CBT) that incorporates exposure with ritual prevention (EX/RP)
9744726|NCT00316355|Experimental|Stepped-Care CBT|Stepped-care CBT
9744727|NCT00316524|Experimental|GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive|vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
9744728|NCT00316524|Experimental|GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive|vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)
9744729|NCT00316524|Placebo Comparator|GP 3: two x Placebo, s.c., vaccinia naive|vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).
9744730|NCT00316524|Experimental|GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced|vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).
9744731|NCT00316589|Experimental|Healthy subjects|Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
9744732|NCT00316589|Experimental|HIV-infected, vaccinia-naive|Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
9744733|NCT00316589|Experimental|HIV-infected, vaccinia-experienced|Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
9983928|NCT04541186|Active Comparator|Fibrate Expansion Study|The cohort will include subjects with SHTG on stable background fibrate therapy and with a baseline MRI PDFF ≥6%, and will consist of 2 treatment groups comparing one dose regimen of BIO89 100 versus placebo.
9984683|NCT03833661|Experimental|M7824|
9744734|NCT00316602|Experimental|Healthy Participants|Healthy, vaccinia naive subjects without Atopic Dermatitis, receiving two doses of MVA-BN (IMVAMUNE)
9744735|NCT00316602|Experimental|Atopic Dermatitis Participants|"Vaccinia naive subjects with diagnosed Atopic Dermatitis. Diagnosed AD included subjects with either history of or subjects with currently active AD (defined as scoring AD [SCORAD] <= 30), receiving two doses of MVA-BN (IMVAMUNE)"
9744736|NCT00316693|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
9744737|NCT00316693|Active Comparator|Aimmugen Group|Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.
9744738|NCT00316706|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
9744739|NCT00316706|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix™ (hepatitis A vaccine [HAV]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
9744740|NCT00316719|Experimental|Adefovir Dipivoxil (ADV)|
9744741|NCT00316719|Active Comparator|Lamivudine (LAM)|
10201187|NCT04436198|Experimental|Treatment group: toric IOL plus capsular tension ring|
10201188|NCT04436198|Active Comparator|Control group: toric IOL only|
10201189|NCT04423068|Experimental|Overall Study|
10201190|NCT04422249|Experimental|laparoscopic middle hepatic vein guidance hemihepatectomy|In theory, the advantages of anatomical hemihepatectomy guided by middle hepatic vein are as follows: 1) correctly guiding the transecting plane of the liver parenchyma can reduce the cross-sectional area of the liver and avoid damaging the vascular ducts of the pre-cut liver. so as to reduce the residue of necrotic tissue without blood supply and reduce the occurrence of postoperative complications. 2) active anatomy and exposure of hepatic vein can avoid uncontrollable bleeding after passive injury of hepatic vein, and laparoscopic anatomy has obvious advantage in exposing hepatic vein. 3) it may reduce the early recurrence rate of hepatocellular carcinoma after operation.
9744742|NCT00316862|Experimental|Treatment (chemotherapy, chemoradiotherapy, surgery)|"INDUCTION CHEMOTHERAPY (COURSES 1-2): Patients receive cisplatin intravenously (IV) over 30 minutes and irinotecan hydrochloride IV over 30-90 minutes on days 1 and 8 of courses 1 and 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY (COURSES 3-4): Beginning 2 weeks after completion of induction chemotherapy, patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 1 and 8 of courses 3 and 4 and undergo radiotherapy daily 5 days a week in course 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo surgery to remove the tumor."
9744743|NCT00316888|Experimental|Arm I (closed to accrual as of 11/3/2008)|Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
9827965|NCT02475369|Other|PES, Then Placebo|Participants first received Pancreatic Enzyme Supplementation (PES) for 10 days. PES taken 6 times daily with gluten free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received placebo tablets (matching PES treatment) 6 times daily for 10 days.
9984684|NCT03832595|Active Comparator|Usual care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
9744744|NCT00316888|Experimental|Arm II (open to accrual on 8/18/2009)|Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
9744745|NCT00316914|Experimental|Ca/Mg|Patients receive calcium gluconate (Ca) and magnesium sulfate (Mg) IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
9744746|NCT00316914|Placebo Comparator|Placebo|Patients receive a placebo IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
9744747|NCT00317044|Experimental|Esomeprazole 40 mg twice daily|
9744748|NCT00317044|Experimental|Esomeprazole 40 mg once daily|
9744749|NCT00317044|Placebo Comparator|Placebo|
9744750|NCT00317109|Experimental|AC primed Group|
9744751|NCT00317109|Active Comparator|AC unprimed Group|
9744752|NCT00317226|Experimental|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
9744753|NCT00317239|Experimental|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
9744754|NCT00317239|Active Comparator|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
9744755|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 10ug|Subject vaccinated with 10 ug of FMP1/AS02A on days 0, 29 and 57
9744756|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 25 ug|Subject vaccinated with 25 ug of FMP1/AS02A on days 14, 42, and 70
9744757|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 50 ug|Subject vaccinated with 50 ug of FMP1/AS02A on days 28, 56 and 84
9744758|NCT00317473|Active Comparator|Imovax Rabies Vaccine|Subject vaccinated with Imovax Rabies Vaccine on corresponding FMP1/AS021 vaccination days
9744759|NCT00317603|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
9744760|NCT00317642|Experimental|clofarabine (IV formulation) and cytarabine|"Participants received clofarabine (40 mg/m^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)~Complete induction cycle = 5 consecutive days of treatment~Re-induction cycle = 5 consecutive days of treatment at the original or modified dose~Consolidation cycle = 4 consecutive days of treatment at the original or modified dose"
9744761|NCT00317642|Experimental|placebo and cytarabine|Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
9744762|NCT00317720|Experimental|Trastuzumab + RAD001|Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. Starting RAD001 dose 10 mg by mouth daily.
9744763|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject
9744764|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject light|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject Light
9744765|NCT00317941|Active Comparator|IFNB-1a 44 mcg (Rebif) via Rebiject II|Interferon beta-1a ([IFNB-1a] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II
9744766|NCT00318136|Experimental|Treated with Bevacizumab|
9744767|NCT00318149|Experimental|Fluarix 18-40 Y Group|Subjects (aged 18-40 years [Y]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
9744768|NCT00318149|Experimental|Fluarix ≥65 Y Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
9744769|NCT00318149|Experimental|Fluarix-AS25 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.
9744770|NCT00318149|Experimental|Fluarix-AS50 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.
9744771|NCT00318149|Experimental|Fluarix- AS01B Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.
9744772|NCT00318149|Experimental|Fluarix- AS01E Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.
9744773|NCT00318292|Experimental|PLA|Active preemptive local analgesia.
9744774|NCT00318292|Placebo Comparator|Placebo|Placebo for preemptive local analgesia.
9744775|NCT00318357||CRT in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued ot follow up the original CARE-HF CRT group patients."
9744776|NCT00318357||Control in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, almost all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued to follow up the original CARE-HF control group patients."
9744777|NCT00318370|Experimental|Far Only|Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
9984685|NCT03832595|Experimental|Intervention Arm|Patients will receive a care bundle
9983929|NCT04540198|Experimental|GamePlan4Care (GP4C)|Participants in this arm will have access to full functionality and content of the online system GamePlan4Care (GP4C) including educational resources, skills training, and support tailored to their unique caregiving needs. Additional individualized feedback will be automatically generated based on responses to online questions and will include links to relevant site educational/skill-building content. Participants will be assigned a Dementia Care Specialist who will facilitate caregiver interactions with the online material and provide skills training via telephone or web-video conference. Study participants assigned to GP4C will receive 9 automated emails and 4 phone calls over a 6-month period.
9984686|NCT03830476|Experimental|Acceptance- and Commitment therapy group|Experiment group that receives the treatment direct after the baseline measurement.
9984687|NCT03830476|Active Comparator|Treatment as usual|Comparison group that receives treatment as usual and the Navigator ACT intervention appr 6 months later.
10201191|NCT04422249|Active Comparator|laparoscopic traditional anatomic hemihepatectomy|According to textbooks and the views of some scholars at present, traditional anatomical hepatectomy (non-hepatic vein-guided anatomical hepatectomy) has the following advantages: 1) avoiding exposure of hepatic vein can reduce the probability of injury to the trunk of hepatic vein, thus reduce the risk of massive bleeding during operation; 2) the difficulty of operation is relatively low, and a better short-term and long-term effect can be obtained.
9744778|NCT00318370|Experimental|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
9744779|NCT00318409|Active Comparator|Bupropion|buproprion XL 300mg daily
9744780|NCT00318409|Placebo Comparator|Placebo|placebo 300mg daily
9744781|NCT00318461|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
9744782|NCT00318461|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
9744783|NCT00318461|Experimental|Lira 1.8 + Met|Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
9744784|NCT00318461|Active Comparator|Met Mono|Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
9744785|NCT00318461|Active Comparator|Met + Glim|Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo
9744786|NCT00318474|Active Comparator|Mycophenolate Mofetil (MMF)|Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
9744787|NCT00318474|Placebo Comparator|MMF Placebo|Subjects receive MMF placebo.
9744788|NCT00318565|Experimental|Navistar ThermoCool Catheter|
9744789|NCT00318591|Experimental|SpeediCath|hydrophilic-coated intermittent catheter
9744790|NCT00318591|Experimental|Conveen Uncoated|uncoated urinary intermittent catheter
9744791|NCT00318643|Experimental|Cohort 1: MMC plus Chemophase 20,000 U|Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
9744792|NCT00318643|Experimental|Cohort 2: MMC plus Chemophase 60,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
9744793|NCT00318643|Experimental|Cohort 3: MMC plus Chemophase 200,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
9744794|NCT00318643|Experimental|Cohort 4: MMC plus Chemophase 400,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
9744795|NCT00318643|Experimental|Cohort 5: MMC plus Chemophase 800,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
9744796|NCT00318708|Experimental|clarithromycin + fluticasone|clarithromycin 500 mg twice daily (Biaxin) + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
9744797|NCT00318708|Active Comparator|placebo + fluticasone|placebo clarithromycin twice daily + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
9744798|NCT00318812|Experimental|Heme Iron|Heme Iron Polypeptide 11mg PO tid for 6 months
9744799|NCT00318812|Active Comparator|Venofer|Venofer q month IV x 6 months
9744800|NCT00319020|Experimental|Bosentan|Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
9744801|NCT00319046|Experimental|Open-label miglustat|Oral administration of miglustat 100 mg t.i.d. for a period of 2 years
9744802|NCT00319098|Experimental|GSK1562902A Group|Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
9744803|NCT00319098|Active Comparator|Fluarix+Placebo Group|Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
9744804|NCT00319111|Experimental|Bosentan|Open label bosentan treatment
9744805|NCT00319254|Experimental|Advanced breast cancer|
9785363|NCT01250145|Experimental|LY333334 + placebo|"Part A:~Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, for 22 days~Part B:~Induction phase: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, 4 times a week for 3 weeks~Rest phase: 2 weeks with no patch application~Challenge phase: 80 microgram active patch given once for at least 6 hours"
9785364|NCT01250171|Experimental|Secukinumab 10 mg/kg|Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
10201192|NCT04410237|Experimental|Med-Jet|"The Med-Jet injector is a novel needle-free drug-delivery system, which we believe may be a solution to the impracticalities of ILTA for mild-to-moderate psoriasis. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region.12 The drug-delivery device is highly configurable allowing adjustable depth and volume parameters.12 In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas"
10201193|NCT04410237|Active Comparator|Traditional Syringe|TAC will be injected on a half-plaque while the control half of the plaque will be untreated. A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
9744806|NCT00319436|Experimental|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
9744807|NCT00319436|Active Comparator|Standard Parent Education for Substance Using Mothers|This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
9744808|NCT00319501|Placebo Comparator|Placebo|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
9744809|NCT00319501|Experimental|Diazepam|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
9744810|NCT00319553|Experimental|Adacel® Vaccine Group|
9744811|NCT00319553|Active Comparator|BOOSTRIX® Vaccine Group|
9744812|NCT00319592|Experimental|ChimeriVax™-JE|Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.
9744813|NCT00319592|Active Comparator|JE-VAX®|Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.
9744814|NCT00319644|Experimental|Minibal Arm|Using Mini bronchoalveolar lavage
9744815|NCT00319644|No Intervention|Tracheal Aspirates|standard of care for ICU.
9744816|NCT00319696|Experimental|Bosentan|Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter
9744817|NCT00319735|Experimental|Investigational Treatment|"Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose)~Cetuximab 250 mg/m2 IV over 60 minutes Day -7~Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36~Combined with radiation therapy for six weeks.~Surgery for esophageal resection after 6 to 8 week rest period.~Subjects who consent will provide tissue samples."
9744818|NCT00319748|Experimental|Intent-To-Treat|Patients treated with at least one dose - 852A subcutaneous injection.
9744819|NCT00319748|Experimental|Evaluable Cohort|Patients who received all 24 doses of 852A per protocol.
9744820|NCT00319956|Active Comparator|Azithromycin Group|Group receives azithromycin
9744821|NCT00319956|Placebo Comparator|Placebo Group|Group receives placebo
9744822|NCT00319982|Experimental|I- Diltiazem|Diltiazem- study medication
9744823|NCT00319982|Placebo Comparator|II- Placebo|Placebo Comparator
9744824|NCT00320112|Experimental|Reciprocal Diabetes Peer Support program|peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
9744825|NCT00320112|Other|Nurse Case Management|patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.
9744826|NCT00320190|Active Comparator|Dasatinib|Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
9744827|NCT00320190|Active Comparator|Imatinib|Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
9744828|NCT00320216|Placebo Comparator|Group I (Placebo)|Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
9744829|NCT00320216|Experimental|Group II (Ustekinumab 45 mg)|Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
9744830|NCT00320216|Experimental|Group III (Ustekinumab 90 mg)|Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
9744831|NCT00320216|Experimental|Group IV|Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
9744832|NCT00320216|Experimental|Group V|Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
9744833|NCT00320242|Active Comparator|1 mo baseline|1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
9744834|NCT00320242|No Intervention|2 month baseline|Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo
9744835|NCT00320255|Placebo Comparator|Cohort 1: Placebo|Participants received placebo tablets once daily
9744836|NCT00320255|Placebo Comparator|Cohort 1: Apixaban, 5 mg|Participants received apixaban as tablet, 5 mg, once daily
9744837|NCT00320255|Active Comparator|Cohort 1: Apixaban, 10 mg|Participants received apixaban as tablet, 10 mg, once daily
9744838|NCT00320255|Active Comparator|Cohort 1: Apixaban, 20 mg|Participants received apixaban as tablet, 20 mg, once daily
9744839|NCT00320255|Placebo Comparator|Cohort 2: Placebo|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
9744840|NCT00320255|Active Comparator|Cohort 2: Apixaban, 5 mg|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.
9744841|NCT00320281|Placebo Comparator|placebo|Normal saline injections were used for placebo injections. Injections were based on treatment plan determined in clinical setting by study PI and physical therapist. 25 cc syringe was used and amount of saline injected was unit based on muscles to be injected according to the treatment plan.
9744842|NCT00320281|Active Comparator|Botulinum toxin A|Botulism toxin A dosage was based on plan developed in clinical setting with study PI and physical therapist. Drug was dosed in 25 cc syringe,diluted with normal saline and injections occured based on treatment plan.
9744843|NCT00320372||1. 500 VNS Patients|VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
9744844|NCT00320372||2. 300 Non-VNS Patients|Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.
9781974|NCT01162499|Active Comparator|Vehicle first, then Exendin-(9-39)|"After an overnight fast, an intravenous (IV) infusion of normal saline (vehicle) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1).~The next day, all procedures will be repeated except subjects will receive an IV infusion of Exendin-(9-39) which will be started 1 hour prior to the meal challenge and continue for 5 hours. The dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects."
9781975|NCT01162551|Experimental|Sirolimus and Methotrexate|"Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days"
9781976|NCT01162733|Active Comparator|Study Drug 1|Vancomycin 15mg/kg
9781977|NCT01162733|Active Comparator|Study Drug 2|Vancomycin 30mg/kg
9781978|NCT01162863|Active Comparator|Lubiprostone 8 mcg BID|
9781979|NCT01162863|Active Comparator|Lubiprostone 24 mcg QD|
9781980|NCT01162863|Placebo Comparator|Placebo|
9984688|NCT03827759||septic arthritis (group A)|Patients with acute juvenile arthritis with suspicion of bacterial infection,confirmed on a bacteriological plan, either by culture of the articular liquid or by blood culture, or by molecular biology in the articular liquid;
9984689|NCT03827759||inflammatory arthritis (group B)|Patients with idiopathic juvenile arthritis
9744845|NCT00320385|Experimental|Arm 1: Lapatinib plus Trastuzumab|Lapatinib 1000mg once daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly
9744846|NCT00320385|Experimental|Arm 2: Lapatinib|Lapatinib 1500mg once daily
9744847|NCT00320411|Experimental|Lapatinb|Lapatinib 1500mg QD
9744848|NCT00320489|Experimental|Olanzapine Pamoate Depot|Olanzapine pamoate depot
9744849|NCT00320489|Active Comparator|Olanzapine|Oral olanzapine
9744850|NCT00320515|Experimental|A|
9744851|NCT00320528|Experimental|Pure ADHD|Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
9744852|NCT00320528|Experimental|ADHD+Internalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
9744853|NCT00320528|Experimental|ADHD+Externalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
9744854|NCT00320541|Active Comparator|paclitaxel plus bevacizumab (PB)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
9744855|NCT00320541|Experimental|paclitaxel plus bevacizumab plus gemcitabine (PB+G)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
9744856|NCT00320593|Active Comparator|Progressive addition lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
9744857|NCT00320593|Active Comparator|Single vision lenses (SVLs)|Single vision lenses
9744858|NCT00320606|Experimental|Immunosuppression Withdrawal|"Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results."
9744859|NCT00320671|Experimental|Participants will take aripiprazole|Participants will take aripiprazole
9744860|NCT00320671|Experimental|Participants will take risperidone|Participants will take risperidone
9744861|NCT00320710|Experimental|Zoledronic acid every (q) 4 weeks|Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
9744862|NCT00320710|Experimental|Zoledronic acid q 12 weeks|Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
9744863|NCT00320710|Experimental|Placebo / zoledronic acid|Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.
9744864|NCT00320749|Experimental|capecitabine, docetaxel, gemcitabine|Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.
9744865|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4|
9744866|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12|
9744867|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4|
9744868|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12|
9744869|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12|
9744870|NCT00320801|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h, applied for 7-day wear
9744871|NCT00320801|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h, applied for 7-day wear
9744872|NCT00321048|Experimental|ABC (Active Breathing coordinator)|Patients are randomized to ABC arm will receive radiation with ABC. Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the No ABC arm.
9744873|NCT00321048|No Intervention|No Active Breathing Coordinator|Patients randomized to the No ABC arm will receive radiation without ABC.Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the ABC arm.
9744874|NCT00321269|Active Comparator|Single Illness Managment|This intervention includes standard disease self-management coaching for heart failure and helps patients set goals for fluid management, restricted salt-intake, and medication adherence.
9744875|NCT00321269|Experimental|Comorbid Illness Management|This intervention includes the same self-management coaching found in the comparator arm, but also includes discussion of ways to cope and manage mood.
9744876|NCT00321373|Experimental|GSK1247446A-AS03 Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9744877|NCT00321373|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9744878|NCT00321373|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9744879|NCT00321464|Active Comparator|zoledronic acid|
9744880|NCT00321464|Experimental|denosumab|
9744881|NCT00321555|Experimental|LMB-2 to Treat Hairy Cell Leukemia|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
9744882|NCT00321594|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9744883|NCT00321620|Active Comparator|zoledronic acid|
9744884|NCT00321620|Experimental|denosumab|
9744885|NCT00321646|Experimental|chemotherapy|docetaxel and bevacizumab prior to prostatectomy
9744886|NCT00321672|Experimental|NGX-4010, 60 minutes|
9744887|NCT00321672|Experimental|NGX-4010, 30 minutes|
9744888|NCT00321672|Other|0.04% conc. capsaicin patch, 60 min.|
9744889|NCT00321672|Other|0.04% conc. capsaicin patch, 30 min.|
9744890|NCT00321685|Experimental|Treatment (bevacizumab and chemoradiotherapy)|See Detailed Description
9744891|NCT00321698|Experimental|Phase I Dose 1-4|"Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
9744892|NCT00321698|Experimental|Phase II MTD Dose|"Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
9744893|NCT00321711|Active Comparator|Dose level 1 500 AMG 531 (Part A - azacitidine)|500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
9744894|NCT00321711|Active Comparator|Dose level 1 750 AMG 531 (Part B - decitabine)|750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
9744895|NCT00321711|Active Comparator|Dose level 2 750 AMG 531 (Part A - azacitidine)|750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
9744896|NCT00321711|Placebo Comparator|Placebo (Part A - azacitidine)|Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
9744897|NCT00321711|Placebo Comparator|Placebo (Part B - decitabine)|Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
9744898|NCT00321737|Experimental|Dexlansoprazole MR 30 mg QD|
9744899|NCT00321737|Experimental|Dexlansoprazole MR 60 mg QD|
9744900|NCT00321737|Placebo Comparator|Placebo|
9744901|NCT00321763|Experimental|GSK1247446A Lot 1 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9744902|NCT00321763|Experimental|GSK1247446A Lot 2 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9744903|NCT00321763|Experimental|GSK1247446A Lot 3 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9744904|NCT00321763|Experimental|GSK1247446A Pooled Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
9744905|NCT00321763|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
9744906|NCT00321789|Experimental|Spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse developed a plan to support patient goal achievement.
9827966|NCT02475369|Other|Placebo, Then PES|Participants first received placebo tablets (matching PES) for 10 days. Placebo was taken 6 times daily with gluten-free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received PES tablets six times daily for 10 days.
9827967|NCT02475395|Experimental|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
9827968|NCT02475395|Experimental|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
9827969|NCT02475564|Placebo Comparator|placebo|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 1 pill of placebo (starch)
9827970|NCT02475564|Experimental|resveratrol|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol
9827971|NCT02475629|Experimental|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
9827972|NCT02475655|Experimental|Arm A: Ruxolitinib|Participants received ruxolitinib twice a day for 5 weeks. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
9827973|NCT02475655|No Intervention|Arm B: No Study Treatment|Participants did not receive any study treatment. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
9827974|NCT02475733|Experimental|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
9827975|NCT02475733|Active Comparator|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
9827976|NCT02475837|Active Comparator|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
9827977|NCT02475837|Placebo Comparator|Placebo intervention|"This arm will receive the matching placebo.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
9827978|NCT02475850|Other|Fall prevention standard of care|"An evidence-based patient-centered intervention that will combine elements of a multifactorial, risk factor-based, standardly-tailored fall prevention strategy developed at Yale, practice guidelines offered by the CDC's STEADI toolbox and the joint American Geriatrics Society/British Geriatrics Society guidelines, and ACOVE practice change approach"
9827979|NCT02475850|Other|Control|Usual fall prevention care
9827980|NCT02475954|Active Comparator|TH-CBT + Standard Care|Cognitive-behavioral therapy delivered via telehealth with a focus on decreasing depressive symptoms in Parkinson's Disease (PD).
9827981|NCT02475954|Other|Standard Care|VA standard care depression in Parkinson's Disease (PD)
9827982|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
9827983|NCT02476032|Experimental|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
9827984|NCT02476032|Active Comparator|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter & Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
9827985|NCT02476032|Sham Comparator|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
9827986|NCT02476175|Experimental|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
9744907|NCT00321789|No Intervention|Usual care|Couples assigned to this arm received educational materials at baseline and usual care thereafter, with no contact from the study interventionist.
9744908|NCT00321828|Experimental|Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab|Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
9744909|NCT00321854|Experimental|Early Pramipexole|Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
9744910|NCT00321854|Experimental|Delayed Pramipexole|Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
9744911|NCT00321893|Experimental|Arm I: Budesonide|Inhaled Budesonide 800 ug twice daily for 1 year
9744912|NCT00321893|Placebo Comparator|Arm II: Placebo|Inhaled placebo twice daily for 1 year
9744913|NCT00321906|Active Comparator|Azathioprine|(tacrolimus,azathioprine/prednisone)
9744914|NCT00321906|Active Comparator|Sirolimus|tacrolimus/sirolimus/prednisone
9744915|NCT00321919|Experimental|Early Epoetin Beta Therapy|Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hb level of 13-15 g/dL; with an individual Hb increase of at least 2 g/dL within approximately 3 months.
9744916|NCT00321919|Active Comparator|Late Epoetin Beta Therapy|Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to <10.5 g/dL had occurred in order to reach a target Hb of 10.5-11.5 g/dL.
9744917|NCT00321932|Active Comparator|Arm I (control)|Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
9744918|NCT00321932|Experimental|Arm II (treatment)|Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
9744919|NCT00321971|Experimental|PST-MCI/AD Caregiving|The experimental Intervention (PST-MCI/AD Caregiving) focuses on training in adaptive problem-solving attitudes and skills (Problem-Solving Therapy or PST). It was adapted from a manualized protocol for PST use in primary care. Our adaptation sought to enhance problem-solving skill levels of family caregivers as they began to face a variety of potential caregiving stressor.
9744920|NCT00321971|Active Comparator|NT-MCI/AD Caregiving|"The comparison Intervention (Caregiver Nutritional Training (NT-MCI/AD) was based on the United States Department of Health and Human Services (USDHHS) 2005 My Pyramid Dietary Guidelines for Americans over Age 50. We chose a nutrition-based comparison intervention because information about dietary practices is not likely to affect mental health outcomes. The NT intervention was matched to the PST-based intervention in terms of number and duration of sessions."
9744921|NCT00321984|Experimental|Dexlansoprazole MR 30 mg QD|
9744922|NCT00321984|Experimental|Dexlansoprazole MR 60 mg QD|
9744923|NCT00321984|Placebo Comparator|Placebo|
9744924|NCT00322023|Experimental|D-serine 30 mg/kg|D-serine 30 mg/kg
9744925|NCT00322023|Experimental|D-serine 60 mg/kg|D-serine 60 mg/kg
9744926|NCT00322023|Experimental|D-serine 120 mg/kg|D-serine 120 mg/kg
9744927|NCT00322049|Experimental|Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )|"Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;~DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection."
9744928|NCT00322049|Active Comparator|Cohort B: Control vaccines|Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine
9744929|NCT00322049|Experimental|Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )|Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years
9744930|NCT00322101|Experimental|Arm I (Nonmyeloablative regimen)|"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96."
9744931|NCT00322101|Experimental|Arm II (Myeloablative regimen)|"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.~Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.~Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.~TRANSPLANTATION: Patients undergo PBSC infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
9744932|NCT00322153|Placebo Comparator|Placebo|Oral administration, once daily.
9744933|NCT00322153|Active Comparator|Memantine ER|28mg, once daily. Oral administration for 24 weeks.
9744934|NCT00322231|Experimental|ZOSTAVAX™ / Placebo|Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)
9744935|NCT00322231|Experimental|Placebo / ZOSTAVAX™|Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)
9744936|NCT00322309|Experimental|Mirtazapine|"Mirtazapine administration as follows:~Days 1-4 15mg of mirtazapine daily Days 5-9 30mg of mirtazapine daily Days 10-78 45mg of mirtazapine daily Days 79-81 30mg of mirtazapine daily Days 82-84 15mg of mirtazapine daily"
9744937|NCT00322309|Placebo Comparator|Placebo- Sugar pill|Matched Placebo given daily days 1-84
9781981|NCT01163032|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
9744938|NCT00322335|Experimental|Menitorix/Pediarix Group|Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
9744939|NCT00322335|Active Comparator|Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group|Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
9744940|NCT00322335|Active Comparator|Infanrix hexa/Meningitec Group|Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
9744941|NCT00322348|Experimental|ZOLADEX 10.8 mg|ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
9744942|NCT00322348|Experimental|ZOLADEX 3.6 mg|ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
9744943|NCT00322374|Experimental|25 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
9744944|NCT00322374|Experimental|30 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
9744945|NCT00322374|Experimental|35 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 35 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
9744946|NCT00322387|Experimental|Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days.~Called 'Cohort A' in protocol, study report and publications."
9744947|NCT00322387|Experimental|Plerixafor AM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days.~Called 'Cohort B' in protocol, study report and publications."
9744948|NCT00322387|Experimental|Low CD34+ Count/ Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of >=10 cells/µL but <20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days.~Called 'Cohort C' in protocol, study report and publications."
9744949|NCT00322387|Experimental|Plerixafor After Chemo|"This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery.~Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached >= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms.~Called 'Investigational Cohort' in protocol, study report and publications."
9744950|NCT00322439||Etanercept|Participants received etanercept (Enbrel) treatment at the dose and regimen determined by the investigator and were evaluated for up to 5 years at 6-month intervals. During this period, participants may have discontinued etanercept therapy, may have switched to another anti-psoriatic therapy, may have used etanercept in combination with other anti-psoriatic therapies, or may have discontinued any or all antipsoriatic treatments.
9744951|NCT00322452|Experimental|1|gefitinib
9744952|NCT00322452|Active Comparator|2|Carboplatin/Paclitaxel
9744953|NCT00322465|Experimental|Doxycycline|Doxycycline 100 mg orally twice daily (2 pills/day = 200 mg/day) for 7 days plus placebo azithromycin orally single dose and placebo tinidazole.
9744954|NCT00322465|Experimental|Doxycycline + Tinidazole|Doxycycline 100 mg orally twice daily for 7 days plus placebo azithromycin single dose plus tinidazole 2 gm orally single dose (4 tablets at 500 mg each).
9744955|NCT00322465|Experimental|Azithromycin|Azithromycin 1 gram (gm) orally single dose (2 tablets at 500 milligrams (mg) each) plus doxycycline placebo twice daily for 7 days plus tinidazole placebo single dose.
9744956|NCT00322465|Experimental|Azithromycin + Tinidazole|Azithromycin 1 gm orally single dose (2 tablets at 500 mg each) plus doxycycline placebo twice daily for 7 days plus tinidazole single dose (4 tablets at 500 mg each).
9781982|NCT01163032|Placebo Comparator|placebo|Placebo capsules, PO daily for 6 months
9744957|NCT00322491|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
9744958|NCT00322491|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
9744959|NCT00322556|Experimental|IgPro10|See Intervention Description
9744960|NCT00322621|Experimental|Duloxetine|All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.
9744961|NCT00322777|Experimental|Spirituality Group|Arm where participants began the intervention (the Spirituality Teaching Program) upon recruitment for an 8 week period. Therefore, the program was initiated at week 1 of the trial.
9744962|NCT00322777|Active Comparator|Waitlist Control Group|Arm where participants began the intervention (the Spirituality Teaching Program) after an 8 week wait period. Therefore, the program was initiated at week 8 of the trial. Between week 1 and week 8, participants did not complete the program and were instructed to carry out their day to day activities as before.
9744963|NCT00322842|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
9744964|NCT00322842|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
9744965|NCT00322868|Experimental|Pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda
9744966|NCT00322881|Experimental|Carboplatin/Paclitaxel|Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
9744967|NCT00323063|Active Comparator|Arm I (Gemcitabine Hydrochloride)|Patients receive gemcitabine hydrochloride IV on days 3 and 10.
9744968|NCT00323063|Experimental|Arm II (Gemcitabine Hydrochloride + Imatinib)|Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.
9744969|NCT00323115|Experimental|Vaccine|
9744970|NCT00323193|Experimental|Arm 1|The intervention group completes approximately 8 individual level sessions with a MOVE specialist as well as approximately 8 group level intervention sessions.
9744971|NCT00323193|No Intervention|Arm 2|The control group offers basic information about diet and exercise every month for six months.
9744972|NCT00323258|Experimental|Intervention|Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
9744973|NCT00323258|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
9744974|NCT00323271|Experimental|Arm 1|Behavioral: Cognitive-behavior therapy
9744975|NCT00323271|Active Comparator|Arm 2|Interventional: Educational intervention
9744976|NCT00323284|Active Comparator|A--iStent plus Cataract Surgery|iStent plus Cataract Surgery
9744977|NCT00323284|Active Comparator|B--Cataract Surgery Only|Cataract Surgery only
9744978|NCT00323297|Placebo Comparator|placebo|
9744979|NCT00323297|Experimental|Active|
9744980|NCT00323310|Experimental|Gadobenate Dimeglumine|
9744981|NCT00323362|Experimental|Gemcitabine hydrochloride and imatinib mesylate|
9744982|NCT00323414|Active Comparator|Polyunsaturated fatty acid (Opti-EPA)|Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
9744983|NCT00323414|Placebo Comparator|Placebo|Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
9744984|NCT00323427|Experimental|Arm 1|Group Aural Rehabilitation session, two hours in length, approximately 6 participants plus Group Facilitator
9744985|NCT00323427|Active Comparator|Arm 2|Veterans receive new VA issued digital hearing aids per Standard VA Audiology Hearing Aid services
9827987|NCT02476357|Active Comparator|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
9744986|NCT00323453|Experimental|Experimental Arm|The experimental arm will undergo open appendectomy utilizing the Alexis® retractor (wound protection device utilized intraoperatively), followed by standardized wound closure.
9744987|NCT00323453|Placebo Comparator|Control Arm|Open appendectomy and standardized wound closure
9744988|NCT00323492|Experimental|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization
9744989|NCT00323492|Active Comparator|Maintain Baseline Regimen|Maintain baseline regimen
9744990|NCT00323492|Experimental|Delayed Truvada|Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
10201194|NCT04406649|Experimental|STS101|STS101 (dihydroergotamine nasal powder)
9744991|NCT00323492|Experimental|All Truvada|Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)
9744992|NCT00323557|Experimental|Pneumococcal Vaccine + GM-CSF|Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7.
9744993|NCT00323557|Experimental|Pneumococcal Vaccine Alone|First vaccine dose subcutaneously, Day 0.
9744994|NCT00323609|Active Comparator|Kyphoplasty|
9744995|NCT00323609|Active Comparator|Vertebroplasty|
9744996|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
9744997|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
9744998|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
9744999|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 of the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
9745000|NCT00323622|Active Comparator|Cohort 1-Prevnar-Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
9745001|NCT00323622|Active Comparator|Cohort 1-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
9781983|NCT01163097|Experimental|Palifermin 40 µg/kg and heparin IV infusion|Treatment A: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections and continuous heparin IV infusion
10201195|NCT04395157||Veterans engaged in VA mental health rehabilitation/recovery|Veterans must be within 6 weeks of discharge from or current receive mental health treatment services in a VA San Diego Healthcare System psychosocial rehabilitation and recovery center (PRRC), mental health residential rehabilitation treatment program (RRTP), general mental health outpatient treatment, or recent acute mental health inpatient hospitalization.
10201196|NCT04394884||COVID-19 -|will receive BTK therapy for other reasons
10201197|NCT04394884||COVID-19 + BTK|will receive BTK therapy
10201198|NCT04394884||COVID-19 + No BTK|will not receive BTK therapy
10201199|NCT04388475|Experimental|All patients|All patients enrolled in this study
10201200|NCT04359758|Experimental|Proactive Streamlined Genetic Education and Testing|Participants randomized to this arm will proactively receive genetic education print materials and the option to proceed directly with genetic testing.
10201201|NCT04359758|Active Comparator|Usual Care|Participants in this arm will be sent a referral letter recommending that they schedule a genetic counseling session and providing them with contact information to do so.
10201202|NCT04353791|Active Comparator|Experimental arm OST-122|24 subjects will be randomized to receive OST-122 orally daily for 28 days
10201203|NCT04353791|Placebo Comparator|Control arm Placebo|8 subjects will be randomized to receive placebo orally daily for 28 days
10201204|NCT04347239|Placebo Comparator|Placebo|
10201205|NCT04347239|Experimental|700mg Leronlimab|
10201206|NCT04345562|Active Comparator|Back and forth pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin prep over the suspected skin incision site for 30 sec - the first applicator will then be used in a back and forth pattern work up towards the upper edge of the surgical field. The first applicator will then be discarded. The second applicator will then again start at the expected site of the incision and again working inferiority until the lower edge of the surgical field is reached.
9745002|NCT00323622|Active Comparator|Cohort 2-Prevnar- Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
9745003|NCT00323622|Active Comparator|Cohort 2-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
9745004|NCT00323739|Experimental|Bevacizumab and RAD001|Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
9745005|NCT00323869|Experimental|Bevacizumab + carboplatin + gemcitabine|"Bevacizumab in combination with carboplatin and gemcitabine:~•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.~Carboplatin was administered before the gemcitabine infusion:~•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles~Bevacizumab was administered 1 hour after end of all chemotherapy infusions:~•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity"
9745006|NCT00323882|Experimental|MDX-010|
9745007|NCT00323960|Active Comparator|Methylprednisolone pulse (MPDN)+PDN+CSA|MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
9745008|NCT00323960|Active Comparator|MPDN+PDN+MTX|MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
9745009|NCT00323960|Active Comparator|MPDN+PDN|MPDN= methylprednisolone PDN= prednisone or equivalent
9745010|NCT00324038|Experimental|buprenorphine transdermal system|Buprenorphine transdermal 7 day analgesic patch
9745011|NCT00324038|Active Comparator|codeine paracetamol tablets|codeine paracetamol combination tablets
9745012|NCT00324116|Experimental|Active|
9745013|NCT00324155|Experimental|Arm A: Ipilimumab and Dacarbazine|In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
9745014|NCT00324155|Active Comparator|Arm B: Placebo and Dacarbazine|
9745015|NCT00324168|Active Comparator|1|
9745016|NCT00324168|Placebo Comparator|2|
9745017|NCT00324233|Active Comparator|SC|Speedicath (SC) catheter is a catheter for intermittent catherisation
9745018|NCT00324233|Experimental|SCCM|SpeediCath Compact Male (SCCM) is a compact catheter for intermittent catherisation to be used by males
9745019|NCT00324259|Active Comparator|Arm 1 (6 mg estradiol)|6 mg of estradiol daily (2 mg tid).
9745020|NCT00324259|Active Comparator|Arm 2 (30 mg estradiol)|30 mg of estradiol. (10 mg tid)
9745021|NCT00324272|Experimental|Groin dissection: sealant used.|
9745022|NCT00324272|Active Comparator|Groin dissection: no sealant used.|
9745023|NCT00324272|Experimental|Axillary dissection: sealant used.|
9745024|NCT00324272|Active Comparator|Axillary dissection: no sealant used.|
9745025|NCT00324350|Active Comparator|1|intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
9745026|NCT00324350|Active Comparator|2|standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
9745027|NCT00324415|Experimental|CMT with Radiation Therapy|"All patients will receive combined modality therapy (CMT) with 2 cycles of cisplatin and 5-FU chemotherapy, given concurrently with radiation therapy. CMT consists of:~Cetuximab 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose).~Cisplatin 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)~5-FU 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)"
9745028|NCT00324649|Experimental|Truvada|Truvada + NNRTI or PI.
9745029|NCT00324649|Active Comparator|Zidovudine/lamivudine|Zidovudine/lamivudine + NNRTI or PI.
9745030|NCT00324675|Active Comparator|Rosiglitazone|
9745031|NCT00324675|Placebo Comparator|placebo|
9745032|NCT00324701|Experimental|Telepsychology|therapy done at patients house
9745033|NCT00324701|Active Comparator|Face-to-face therapy|therapy delivered at the VAMC
9745034|NCT00324740|Experimental|Treatment (vorinostat and isotretinoin)|Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9745035|NCT00324753|Experimental|Intervention|Communication sheet
9745036|NCT00324753|Other|Control|Standard of care brochures
9745037|NCT00324857|Placebo Comparator|Arm 1/Attention Control|Subjects randomized to the attention control arm received a patient educational booklet about OA published by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This booklet provides a brief educational program that summarizes how to live with knee OA but does not specifically mention joint replacement
9745038|NCT00324857|Active Comparator|Arm 2/Decision Aid (DA)|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
9745039|NCT00324857|Active Comparator|Arm 3/ Motivational Interview (MI)|Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain
9745040|NCT00324857|Active Comparator|Arm 4/ DA and MI|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.~Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain"
9745041|NCT00324870|Experimental|Arm I|"Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I."
9745042|NCT00324896|Experimental|eszopiclone|eszopiclone. Those under 65yo received 3mg of eszoplicone ( or randomized to matching placebo)and those 65yo or older received 2mg of eszoplicone ( or randomized to matching placebo)taken each night at bedtime
9745043|NCT00324896|Placebo Comparator|placebo|Those randomly assigned to matching placebo, took their dose each night at bedtime
9745044|NCT00324961|Experimental|Single arm open label adefovir dipivoxil|adefovir dipivoxil once daily 10 mg orally
9745045|NCT00324987|Experimental|Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)|Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9745046|NCT00324987|Active Comparator|Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)|Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9781984|NCT01163097|Experimental|Palifermin 40 µg/kg|Treatment B: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections
9781985|NCT01163097|No Intervention|Control group without any treatment|Treatment C: control group without any treatment administered.
9781986|NCT01163149|Experimental|Cohort 1|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
9781987|NCT01163149|Experimental|Cohort 2|Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
9781988|NCT01163149|No Intervention|Concurrent Control|Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.
9785365|NCT01250171|Experimental|Canakinumab 10 mg/kg|Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period.
9745047|NCT00325039|Active Comparator|1|retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
9745048|NCT00325039|Active Comparator|2|"transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (in-to-out) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (out-to-in)."
9745049|NCT00325078|Experimental|Treatment|Study drug (TNFa inhibitor-infliximab or adalimumab) treated group.
9745050|NCT00325078|No Intervention|Observation|Subjects with IBD without TNFa inhibitor treatment
9745051|NCT00325130|Experimental|Group 1|Concomitant Administration
9745052|NCT00325130|Experimental|Group 2|Non-concomitant administration
9745053|NCT00325143|Experimental|Infanrix Hexa Group|Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
9745054|NCT00325156|Experimental|Group A|
9745055|NCT00325195|Experimental|q2 wks|8 mg pegloticase every 2 weeks
9745056|NCT00325195|Experimental|q4 wks|8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
9745057|NCT00325195|Placebo Comparator|placebo|placebo every 2 weeks
9745058|NCT00325234|Experimental|Pemetrexed/Carboplatin|"Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1.~Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg*min/mL. The cycle of treatment was 21 days."
9745059|NCT00325234|Active Comparator|Gemcitabine/Vinorelbine|Vinorelbine 30 mg/m^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
9745060|NCT00325403|Active Comparator|UT-15C (oral treprositnil)|Subjects receive UT-15C (oral treprostinil) twice daily.
9745061|NCT00325403|Placebo Comparator|Placebo|Subjects receive placebo (sugar pill) twice daily.
9745062|NCT00325416|Experimental|Age Group A - Melphalan and Topotecan plus Stem Cell Rescue|Participants 18 - 60 years of age. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
9745063|NCT00325416|Active Comparator|Age Group B - Melphalan and Topotecan plus Stem Cell Rescue|Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
9745064|NCT00325442|Active Comparator|Active|Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
9745065|NCT00325442|Placebo Comparator|Placebo Arm|Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
9745066|NCT00325468|Experimental|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
9745067|NCT00325598|Experimental|Cohort 1 (36 Gy)|36 Gy in 9 fractions BID x 4 1/2 treatment days
9745068|NCT00325598|Experimental|Cohort 2 (40 Gy)|40 Gy in 10 fractions BID over 5 treatment days
9745069|NCT00325754|Active Comparator|E-Cylinder|22-lb E-cylinder towed on a cart
9745070|NCT00325754|Active Comparator|Lightweight Cylinder|3.6-lb lightweight cylinder that can be carried
9745071|NCT00325780|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
9745072|NCT00325819|Active Comparator|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
9745073|NCT00325819|Placebo Comparator|Placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
9745074|NCT00325897|Active Comparator|Azithromycin, 250 mg|Macrolide Antibiotic (Azithromycin)
9745075|NCT00325897|Placebo Comparator|Placebo|Inactive
9745076|NCT00326001|Experimental|Gold tip catheter|Gold tip catheter
9745077|NCT00326001|Active Comparator|Platinum-iridium tip catheter|Platinum-iridium tip catheter
9745078|NCT00326118|Active Comparator|Meningitec + Hiberix Group|Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
9745079|NCT00326118|Experimental|Menitorix Group|Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
9745080|NCT00326170|Experimental|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.
9745081|NCT00326196|Active Comparator|PCI|Percutaneous coronary intervention
9745082|NCT00326196|Active Comparator|CABG|Coronary artery bypass graft (CABG)
9745083|NCT00326209|Experimental|Encapsulated Mesalamine Granules (eMG)|Participants will receive eMG 1.5 grams (4 capsules of eMG 0.375 grams each) QD orally in the morning for up to 24 months.
9745084|NCT00326417|Experimental|Cyclophosphamide 150mg|Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)
9745085|NCT00326417|Experimental|Cyclophosphamide 100mg|Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)
9745086|NCT00326417|Experimental|Cyclophosphamide 50mg|Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)
9745087|NCT00326417|Experimental|Fludarabine|Fludarabine only (no Cyclophosphamide administered)
9785366|NCT01250171|Placebo Comparator|Placebo|Patients received a single placebo infusion intravenously over a 2 hour period.
9745088|NCT00326495|Experimental|BAY 43-9006 & Cetuximab|BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID). Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2, followed by 250 mg/m^2 weekly starting on week 3
9983930|NCT04540198|Active Comparator|Resources4Care (R4C)|"Participants in this arm will receive access to Resources4Care (R4C), a feature-limited version GamePlan4Care system. R4C will serve as an online hub for articles and videos about Alzheimer's disease and dementia. Educational topics will included information on: 1) Alzheimer's Disease & Dementia, 2) Caregiving, 3) Caregiver Stress and 4) Home Safety. R4C will present a page on each topic with active links to two additional online sources on the same topic. Study participants assigned to R4C will receive two emails from their DCS encouraging the caregiver to review specific education materials. Each email will be followed by brief check-in calls (15-min each) at three months and five months after randomization."
10201207|NCT04345562|Active Comparator|Circular pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin over the suspected skin incision site for 30 sec - the applicator will then be moved in a circular pattern moving outwards form the incision site until approximately half of thee surgical field is cleaned. The second applicator will then be used to complete the surgical prep until the entire surgical field is prepped in accordance with the package instructions.
9745089|NCT00326599|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and oral AZD2171 once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. Patients achieving stable disease, partial response, or complete response after 6 courses of therapy receive AZD2171 alone as above. Treatment with AZD2171 repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9745090|NCT00326599|Active Comparator|Arm II|Patients receive gemcitabine and carboplatin as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9745091|NCT00326612|Active Comparator|Intranasal Midazolam 0.2mg/kg|GIve once for seizure longer than 5 minutes
9745092|NCT00326612|Active Comparator|Rectal Diazepam 0.3-0.5 mg/kg|Given once for seizure longer than 5 minutes
9745093|NCT00326625|Experimental|40 mg glatiramer acetate (GA)|Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.
9745094|NCT00326625|Placebo Comparator|Placebo|Pre-filled syringe of matching placebo, administered subcutaneously once a day.
9745095|NCT00326716|Experimental|Treatment|
9745096|NCT00326781|Active Comparator|Nicotine Nasal Spray|
9745097|NCT00326781|Active Comparator|Transdermal Nicotine patch|
9745098|NCT00326872|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
9745099|NCT00326885|Experimental|Catumaxomab|
9745100|NCT00326911|Experimental|cetuximab + bevacizumab + gemcitabine|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
9745101|NCT00326911|Active Comparator|cetuximab + bevacizumab|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
9745102|NCT00326924|Experimental|Biological|PRBCs that are less than 7 days old are considered 'fresh'.
9745103|NCT00326924|Experimental|Standard PRBCs|PRBCs 'stored' as per hospital policy.
9745104|NCT00326950|Experimental|1|
9745105|NCT00326963|Experimental|Enfuvirtide+PI+ARV's|"Eligible participants received Fuzeon® (enfuvirtide) 90 milligram (mg) subcutaneously (SC) two times a day (bid) for 24 weeks plus new protease inhibitor (PI) (darunavir/ritonavir) plus other investigator-choice antiretrovirals (ARVs). Participants selected their preferred injection device among the following three options: 27 gauge (G) ½ needle/syringe, 31G 8 millimeter (mm) needle/syringe or Biojector 2000 (B2000) needle-free injection device (NFID)."
9745106|NCT00327015|Experimental|Saxagliptin and Metformin (A)|PLUS open-label pioglitazone (as needed as rescue medication)
9745107|NCT00327015|Experimental|Saxagliptin and Metformin (B)|PLUS open-label pioglitazone (as needed as rescue medication)
9745108|NCT00327015|Experimental|Saxagliptin and Placebo (C)|PLUS open-label pioglitazone (as needed as rescue medication)
9745109|NCT00327015|Active Comparator|Metformin and Placebo (D)|PLUS open-label pioglitazone (as needed as rescue medication)
9745110|NCT00327171|Experimental|Aflibercept 2.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
9745111|NCT00327171|Experimental|Aflibercept 4.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
9745112|NCT00327340|Experimental|OGX-011 / mitoxantrone/prednisone|OGX-011 / mitoxantrone/prednisone: OGX-011 administered in combination with mitoxantrone and prednisone
9745113|NCT00327340|Experimental|OGX-011/docetaxel/prednisone|OGX-011/docetaxel/prednisone: OGX-011 administered in combination with docetaxel and prednisone
9745114|NCT00327444|Placebo Comparator|Placebo|"Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study."
9785367|NCT01250184|Active Comparator|Physical Therapy|Twelve sessions, 3 per week.
9827988|NCT02476357|Active Comparator|Control|Monopolar scalpel and ligature
9745115|NCT00327444|Experimental|Aflibercept|"Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study."
9745116|NCT00327470|Experimental|Open Label|
9745117|NCT00327717|Experimental|Zonisamide 100 mg tablet|
9745118|NCT00327717|Placebo Comparator|Placebo|
9745119|NCT00328016|Experimental|Device Guided Breathing|Individual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
9745120|NCT00328016|Placebo Comparator|Control Group|Control group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
9745121|NCT00328042|Experimental|Self-Management Workshop|
9745122|NCT00328042|Active Comparator|Information Only|
9745123|NCT00328094|Experimental|CII, Continuous Insulin Infusion|Continuous intravenous insulin infusion to control glucose to <150 mg/dL in patients undergoing open peripheral vascular bypass surgery
9745124|NCT00328094|Active Comparator|IIB, Intermittent insulin boluses|Intermittent intravenous insulin insulin boluses to a blood glucose target of <150mg/dL in patients undergoing peripheral vascular bypass surgery
9745125|NCT00328172|Placebo Comparator|Placebo|Placebo tablets matching BI 1356
9745126|NCT00328172|Experimental|BI 1356 0.5 mg|BI 1356 dose 1 once daily
9745127|NCT00328172|Experimental|BI 1356 2.5 mg|BI 1356 dose 2 once daily
9745128|NCT00328172|Experimental|BI 1356 5.0 mg|BI 1356 dose 3 once daily
9745129|NCT00328172|Active Comparator|Metformin|Metformin
9745130|NCT00328198|Experimental|Dose escalation|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
9745131|NCT00328198|Experimental|No escalation|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
9745132|NCT00328263|Experimental|1|Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.
9745133|NCT00328263|Placebo Comparator|2|placebo devoid of bacteria
9745134|NCT00328510|Experimental|GTC Frame|Participant undergoes SRT using a GTC frame to immobilize the participant's heading during radiation therapy
9745135|NCT00328510|Experimental|BrainLab thermoplastic mask|Participant undergoes SRT using the BrainLab thermoplastic mask to immobilize the participant's head during radiation therapy
9745136|NCT00328562|Experimental|Iressa and RT|"Iressa plus thoracic RT at the following dose levels:~Level 1: 42.0 Gy in 10 fractions of 4.2 Gy~Level 2: 50.4 Gy in 12 fractions of 4.2 Gy~Level 3: 63.0 Gy in 15 fractions of 4.2 Gy"
9745137|NCT00328614|Experimental|Samarium-153 (0.25 mCi/kg)|Cohort 1: Patients receive 0.25 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
9745138|NCT00328614|Experimental|Samarium-153 (0.5 mCi/kg)|Cohort 2: Patients receive 0.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
9745139|NCT00328614|Experimental|Samarium-153 (0.75 mCi/kg)|Cohort 3: Patients receive 0.75 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
9745140|NCT00328614|Experimental|Samarium-153 (1.0 mCi/kg)|Cohort 4: Patients receive 1.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
9745141|NCT00328614|Experimental|Samarium-153 (1.5 mCi/kg)|Cohort 5: Patients receive 1.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
9983931|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1010|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010. This was the first model evaluated in the study.
10201208|NCT04342364|Active Comparator|Slush nitrogen|oocytes are randomized to undergo vitrification utilizing slush nitrogen
9745142|NCT00328614|Experimental|Samarium-153 (2.0 mCi/kg)|Cohort 6: Patients receive 2.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
10201209|NCT04342364|Active Comparator|Liquid Nitrogen|oocytes are randomized to undergo vitrification utilizing liquid nitrogen which is the current standard of care
10201210|NCT04323293|Experimental|CPM - Cold Water Bath|
10201211|NCT04323293|Sham Comparator|CPM - SHAM|
9745143|NCT00328627|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
9745144|NCT00328627|Experimental|Alogliptin 12.5 + Placebo|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
9745145|NCT00328627|Experimental|Alogliptin 25 + Placebo|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
9745146|NCT00328627|Active Comparator|Placebo + Pioglitazone 15|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
9745147|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 15|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
9745148|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 15|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
9745149|NCT00328627|Active Comparator|Placebo + Pioglitazone 30|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
9745150|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 30|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
9745151|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 30|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
9984690|NCT03827759||control (group C)|Healthy children who are matched by the age and at the sex in the groups A and B, to analyze elements studied in the blood.
9827989|NCT02476422|Experimental|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
9827990|NCT02476422|Active Comparator|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
9827991|NCT02476448|Active Comparator|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
9827992|NCT02476448|Experimental|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
9827993|NCT02476448|Experimental|Phenazopyridine|Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
9827994|NCT02476448|Experimental|Sodium Fluorescein|Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
9827995|NCT02476565|Experimental|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
9827996|NCT02476565|Active Comparator|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
9827997|NCT02476578|Experimental|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
9827998|NCT02476578|No Intervention|Control|No email is sent.
9827999|NCT02476617|Experimental|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily [QD]) + dasabuvir (250 mg twice daily [BID]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
9828000|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
9828001|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
9828002|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
9828003|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
9828004|NCT02477020|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for up to 6 weeks. Dose may be titrated down to 10 mg/day, if intolerable.
9828005|NCT02477020|Placebo Comparator|Placebo|TAK-063 matching-placebo tablets, orally, once daily for up to 6 weeks.
9828006|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone Dose Escalation|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: 70 mg/m^2, 80mg/m^2, or 90 mg/m^2 given on days 1 and 2"
9828007|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone MTD|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: MTD given on days 1 and 2"
9828008|NCT02477319||Part A|"Cohort 1: Healthy Controls~Cohort 2: Partial CFTR function CF (class IV/V)~Cohort 3: Absent CFTR function CF (Class I/II)"
9828009|NCT02477319||Part B|CF patients who are homozygous for the F508del
9828010|NCT02477332|Experimental|QGE031 24 mg s.c. q4w|ligelizumab 24 mg injection subcutaneous every 4 weeks
9828011|NCT02477332|Experimental|QGE031 72 mg s.c. q4w|ligelizumab 72 mg injection subcutaneous every 4 weeks
9828012|NCT02477332|Experimental|QGE031 240 mg s.c. q4w|ligelizumab 240 mg injection subcutaneous every 4 weeks
9828013|NCT02477332|Active Comparator|Omalizumab 300 mg s.c. q4w|omalizumab 300 mg injection subcutaneous every 4 weeks
9828014|NCT02477332|Placebo Comparator|Placebo s.c. q4w|placebo injection subcutaneous every 4 weeks
9828015|NCT02477332|Experimental|QGE031 120 mg s.c. s.d.|ligelizumab 120 mg injection subcutaneous single dose
9828016|NCT02477423|Active Comparator|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
9828017|NCT02477423|Placebo Comparator|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
9828018|NCT02477527|Experimental|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
9983932|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1020|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020. This was the second model evaluated in the study.
9828019|NCT02477553|Experimental|Quantitative|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
9828020|NCT02477553|Active Comparator|Verbal|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
9828021|NCT02477605|Experimental|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
9828022|NCT02477605|Active Comparator|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
9828023|NCT02477670|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
9828024|NCT02477670|Experimental|AVP-786|AVP-786 dose 2 capsules administered twice a day over a 12-week period
9828025|NCT02477709|Experimental|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
9828026|NCT02477800|Experimental|Low Dose|Monthly intravenous (IV) infusion
9828027|NCT02477800|Experimental|High Dose|Monthly intravenous (IV) infusion
9828028|NCT02477839|Experimental|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
9828029|NCT02477839|Placebo Comparator|Placebo|Matching placebo syrup
9828030|NCT02478164|Experimental|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
9828031|NCT02478359|No Intervention|Standard Care|Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
9828032|NCT02478359|Experimental|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
9828033|NCT02478372|Active Comparator|Patient Controlled Epidural (PCEA)|A lumbar epidural was sited using a side-directed technique towards the side of surgery following establishment of the spinal blockade. Following the completion of the operation, patients received 4ml of 0.25% levobupivacaine prior to leaving the operating room. Thereafter they were connected to a PCEA pump (McKinley 545) with no background infusion. Patients could self-medicate with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes to control their pain until the following morning (post-operative day one) when it was stopped. Nurse-administered rescue top-ups of 4ml of 0.25% levobupivacaine were available for insufficient analgesia. The epidural catheter was removed on the morning of post-operative day two (POD2).
9828034|NCT02478372|Experimental|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine. 50ml injected following bone preparation prior to implant cementation perpendicular to the posterior femur through the posterior joint capsule in 10ml aliquots. 30ml proximal to the suprapatellar pouch down to the femur.100ml spread into subcutaneous tissues including; collateral and cruciate ligaments, fatty and connective tissue on the anterior aspect of the incision. A 16 gauge epidural catheter inserted via a medial portal, 20ml was injected via the catheter following closure of wound. Post-operatively, patients received boluses of 40ml ropivacaine 0.2% via the catheter using a mechanical McKinley 595 pump 4 hours after leaving theatre, at 22:00 and 08:00 on post-operative day one.
9828035|NCT02478398|Experimental|Short ragweed pollen allergen extract|Participants receive one sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
9828036|NCT02478398|Placebo Comparator|Placebo|Participants receive one placebo sublingual tablet, QD for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
9828037|NCT02478463|Experimental|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
9828038|NCT02478489|Experimental|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
9828039|NCT02478489|Active Comparator|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
9828040|NCT02478580|Experimental|Nuvigil|A single oral dose of Nuvigil at 150mg dose in preoperative area
9828041|NCT02478580|Placebo Comparator|Placebo|A single oral placebo will be given in preoperative area
9828042|NCT02478632|Active Comparator|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
9828043|NCT02478632|Experimental|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
9828044|NCT02478671|Experimental|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
9828045|NCT02479139|Placebo Comparator|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
9828046|NCT02479139|Experimental|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
9828047|NCT02479139|Experimental|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
9828048|NCT02479139|Experimental|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
9828049|NCT02479139|Experimental|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
9828050|NCT02479139|Experimental|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
9828051|NCT02479412|Experimental|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
9828052|NCT02479412|Experimental|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
9828053|NCT02479412|Experimental|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
9828054|NCT02479412|Experimental|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
9828055|NCT02479412|Experimental|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
9828056|NCT02479412|Experimental|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
9828057|NCT02479412|Experimental|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
9828058|NCT02479412|Experimental|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
9828059|NCT02479412|Experimental|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
9828060|NCT02479763|No Intervention|Conventional loss-of-resistance|
9828061|NCT02479763|Experimental|Waveform-confirmed loss-of-resistance|
9828062|NCT02479802|Experimental|Albumin|Plasma exchange with Albumin
9828063|NCT02479880|Other|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
9828064|NCT02479880|Other|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
9828065|NCT02480010|Experimental|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
9828066|NCT02480010|Experimental|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
9828067|NCT02480114|Active Comparator|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
9828068|NCT02480114|Experimental|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
9828069|NCT02480153|Experimental|PF-06410293|
9828070|NCT02480153|Active Comparator|Adalimumab|
9828071|NCT02480166|Experimental|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
9828072|NCT02480166|Experimental|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
9828073|NCT02480439|Experimental|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
9983933|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1021|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1021. This was the third model evaluated in the study.
9983934|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1012|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1012. This is the fourth model currently being evaluated in the study.
9828074|NCT02480439|Experimental|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
9745152|NCT00328627|Active Comparator|Placebo + Pioglitazone 45|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
9745153|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 45|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
9745154|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 45|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
9983935|NCT04538144||Younger participants|Individuals aged 18-39 years
9745155|NCT00328770|Experimental|Sirolimus based immunosuppression|Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
9745156|NCT00328783|Experimental|Active Breathing Coordinator|Patients breathe through the ABC device
9745157|NCT00328861|Experimental|NK Cells + IL-2: Melanoma|Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
9745158|NCT00328861|Experimental|NK Cells + IL-2: Renal Cell|Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
9745159|NCT00328926|Active Comparator|Luveris® 75 IU|
9745160|NCT00328926|Active Comparator|Luveris® 25 IU|
9745161|NCT00328926|Placebo Comparator|Placebo|
9745162|NCT00329030|Active Comparator|Rituxan/BEAM|Autologous transplantation using rituxan/BEAM
9745163|NCT00329030|Experimental|Bexxar/BEAM|Autologous transplantation using Bexxar/BEAM
9745164|NCT00329238|Experimental|Dabigatran|Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
9745165|NCT00329238|Active Comparator|Warfarin (INR of 2.0-3.0)|Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
9745166|NCT00329303|Experimental|Certolizumab Pegol (CZP) 200 mg|Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter.
9745167|NCT00329303|Experimental|Certolizumab Pegol (CZP) 400 mg|Subcutaneous injections of 400 mg every 2 weeks.
9745168|NCT00329407|Active Comparator|Topiramate Treatment|In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
9745169|NCT00329420|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
9745170|NCT00329420|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
9745171|NCT00329420|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
9745172|NCT00329433|Active Comparator|Heparin|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
9745173|NCT00329433|Experimental|Desirudin (Iprivask™)|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
9745174|NCT00329524|Sham Comparator|Active versus Sham Treatment|Subjects randomly assigned to active and sham TMS separated by one week interval.
9745175|NCT00329550|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
9745176|NCT00329550|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
9745177|NCT00329550|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
9745178|NCT00329602|Placebo Comparator|Double-blind for 12 to 26 Weeks|Double-blind (Ropinirole:Placebo) for 12 to 26 weeks
9745179|NCT00329602|Other|Open-label ropinirole for 40-Weeks|Open label ropinirole for 40 weeks
9785368|NCT01250184|Active Comparator|Lidocaine injection|Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
9983936|NCT04538144||Older participants|Individuals aged 65 years or older
9983937|NCT04537884|Experimental|Treatment with UBX1325|UBX1325, single intravitreal injection, ascending dose
9984691|NCT03824938|Experimental|Aspirin|Aspirin 650 mg capsule by mouth, single dose
9745180|NCT00329641|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|"Patients receive carboplatin IV and paclitaxel IV once on day 1 and oral sorafenib twice daily on days 2-19. Treatment repeats every 21 days for up to 6 courses.* After 6 courses, patients continue to receive oral sorafenib alone twice daily in the absence of disease progression or unacceptable toxicity.~[Note: *If sorafenib is discontinued prior to course 6, patients may continue to receive carboplatin and paclitaxel for up to 6 courses; if carboplatin and paclitaxel are discontinued prior to course 6, patients may continue to receive sorafenib alone twice daily on days 1-21 of each course in the absence of disease progression or unacceptable toxicity. ]"
9745181|NCT00329719|Experimental|Group I (sorafenib tosylate, temsirolimus)|Patients receive sorafenib tosylate and temsirolimus as in Phase I.
9745182|NCT00329719|Experimental|Group II (sorafenib tosylate, temsirolimus, surgery)|Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
9745183|NCT00329719|Experimental|Group III (sorafenib tosylate, temsirolimus, anti-VEGF)|Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
9745184|NCT00329745|Experimental|Rotarix Group|During the primary study (NCT00197210) subjects received two oral doses of Rotarix™ vaccine.
9745185|NCT00329745|Placebo Comparator|Placebo Group|During the primary study (NCT00197210) subjects received two oral doses of placebo.
9745186|NCT00329771||Episodic migraineurs|Eligible subjects with episodic migraine (with or without aura)
9745187|NCT00329784|Experimental|Peanut Consumption Group|Participants on this arm will consume peanut protein.
9745188|NCT00329784|No Intervention|Peanut Avoidance Group|Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.
9745189|NCT00329797|Experimental|Zoledronic Acid|Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
9745190|NCT00329797|Active Comparator|Control|Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
9745191|NCT00329836||Subjects with cluster headache|Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
9745192|NCT00329849|Experimental|MenACWY-CRM|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)
9745193|NCT00329849|Active Comparator|MenACWY-PS|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)
9745194|NCT00329901|Experimental|Tdap + MenACWY-CRM|Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
9745195|NCT00329901|Experimental|Tdap + saline|Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
9745196|NCT00329901|Experimental|MenACWY-CRM + saline|Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms
9745197|NCT00330161|Experimental|Treatment (vorinostat)|"Patients receive oral vorinostat (SAHA) once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) after 4 courses receive an additional 3 courses. All other patients may continue treatment in the absence of disease progression or unacceptable toxicity.~Blood samples are taken on day 15 of course 1, day 1 of course 2, during the last week of course 4, and at completion of study treatment. Blood is examined for interleukin (IL)-6, IL-6 receptor, and gp130 levels."
9745198|NCT00330174|Experimental|1|Acamprosate tablets
9745199|NCT00330174|Placebo Comparator|2|Matching placebo tablets
9745200|NCT00330187|Experimental|Bupropion SR + Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
9745201|NCT00330187|Active Comparator|Placebo + Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
9745202|NCT00330187|Active Comparator|Bupropion SR + No Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management is not provided in this arm.
9745203|NCT00330187|Placebo Comparator|Placebo + No Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management is not provided in this arm.
9745204|NCT00330343|Experimental|Naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
9745205|NCT00330382|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
9745206|NCT00330382|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily for 6 months
9781989|NCT01163162|Experimental|Paricalcitol|After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
9781990|NCT01163214|Experimental|Nerve Block|Preoperative femoral block with indwelling femoral catheter and a single shot sciatic block.
9745207|NCT00330421|Experimental|Group I (sarcomas of extremity, closed accrual as of 5/30/07)|Patients receive oral sorafenib twice daily on days 1-14. Patients undergo surgical resection of the tumor on approximately day 15. Once patients recover from surgery (and radiotherapy if indicated), patients who demonstrate a clinically and pathologically significant response (≥ 25% reduction in tumor size or ≥ 25% necrosis in the surgical specimen) may continue sorafenib as above for a maximum of 6 months in the absence of disease progression or unacceptable toxicity and at the discretion of the principal investigator. Biopsy tissue and blood samples are examined for biomarkers and interstitial fluid pressure (IFP) is measured at baseline and immediately before surgery.
9745208|NCT00330421|Experimental|Group II (metastatic or inoperable sarcomas)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
9745209|NCT00330460|Active Comparator|Alendronate|Subjects in this arm will receive active ALN and placebo denosumab
9745210|NCT00330460|Experimental|Denosumab|Subjects in this arm will receive active denosumab and placbo ALN
9745211|NCT00330551|Experimental|Long-acting injectible risperidone|Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
9745212|NCT00330551|Active Comparator|Oral risperidone|Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.
9745213|NCT00330564|Experimental|SU011248 (Sutent, Sunitinib Malate)|50 mg/day orally for 4 weeks
9745214|NCT00330668|Experimental|All rhIGF-1 Subjects|"All subjects entering MS306 began recombinant human insulin-like growth factor-1 (rhIGF-1) twice a day (BID) treatment. Each subject treated in MS301 had an MS306 starting dose that was based on their dose at the completion of MS301 (i.e. subcutaneous injections of rhIGF-1 at 40, 80, or 120 micrograms [μg]/ kilogram [kg] BID).~MS301 untreated control subjects were randomised in MS306 in a 1:1 ratio to a dose of either 80 or 120 μg/kg rhIGF-1 BID.~Following Protocol Amendment 1, all subjects received either 80 or 120 μg/kg rhIGF-1 BID until the implementation of Protocol Amendment 2.~Following Protocol Amendment 2, all subjects were first switched to receive subcutaneous injections of 160 μg/kg rhIGF-1 once a day (QD), followed by individual dose-escalation first to 200 μg/kg rhIGF-1 QD and subsequently to a targeted maximum dose of 240 μg/kg rhIGF-1 QD. Subjects were treated QD until the early termination of the study."
10201212|NCT04317326|Experimental|Life style modification|"Lifestyle modifications group (Control) will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 <55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88)"
10201213|NCT04317326|Active Comparator|Life style modificacion and automatic NIV(AVAPS-AE)|Automatic NIV: In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 20 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight. These parameters may be modified according to patient tolerance or non-compensated leak.
10201214|NCT04317326|Experimental|Life style modification and titrated NIV(S/T mode)|In-laboratory polysomnographic NIV titration will be performed according to published guidelines (Berry R et al JCSM 2010). In addition to lifestyle modification and oxygen (if required), home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel PAP with backup respiratory rate (BIPAP S/T mode). The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG.
9745215|NCT00330681|Experimental|1|MCI-186
9745216|NCT00330681|Placebo Comparator|2|Placebo of MCI-186
9745217|NCT00330733|Placebo Comparator|Placebo|Matching placebo
9745218|NCT00330733|Active Comparator|Salsalate Therapy|Salsalate
9745219|NCT00330759|Active Comparator|zoledronic acid|denosumab placebo with active zoledronic acid
9745220|NCT00330759|Experimental|denosumab|active denosumab with zoledronic acid placebo
9745221|NCT00330863|Experimental|Injectable|Participants assigned to receive long-acting injectable risperidone
9745222|NCT00330863|Active Comparator|Oral|"Participants assigned to receive oral atypical antipsychotic medication"
9984692|NCT03824938|Active Comparator|Acetaminophen|Acetaminophen 650 mg capsule by mouth, single dose
10201215|NCT04317326|Active Comparator|Life style modification and titrated CPAP|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines (SEPAR guideline or AASM guideline). In addition to lifestyle modification and oxygen (if required), home CPAP therapy at a fixed pressure will be initiated.
10201216|NCT04315181|Experimental|Oral opioid agonist|Participants will receive non-therapeutic experimental doses of active or placebo oral opioid agonist. Active opioid agonist/placebo will be administered once per session and will be administered orally.
9745223|NCT00330876|Experimental|Pitavastatin 2 mg QD|Pitavastatin 2 mg once daily
9745224|NCT00330876|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
9984693|NCT03824938|Placebo Comparator|Placebo|Placebo 650 mg capsule by mouth, single dose
9745225|NCT00330915|Experimental|A|
9745226|NCT00330928|Experimental|1|Subjects undergoing elective percutaneous coronary intervention
9745227|NCT00330967||Group 1|healthy subjects
9745228|NCT00330967||Group 2|healthy subjects different from group 1
9745229|NCT00331006|Experimental|Rituximab|Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks
9984694|NCT03823404|Experimental|COR388 80 mg bid|
9745230|NCT00331136|Experimental|Group A (Tablets)|Pyronaridine artesunate 6:2 mg/kg. The tablet strength is 48:16 mg oral PA, with the number of tablets depending on body weight.
9745231|NCT00331136|Experimental|Group B (Tablets)|Pyronaridine artesunate 9:3 mg/kg. The tablet strength is 72:24 mg oral PA, with the number of tablets depending on body weight.
9745232|NCT00331136|Experimental|Group C (Tablets)|Pyronaridine artesunate 12:4 mg/kg. The tablet strength is 96:32 mg oral PA, with the number of tablets depending on body weight.
10201217|NCT04315181|Experimental|Oral sedative|Participants will receive non-therapeutic experimental doses of active or placebo oral sedative. Active sedative/placebo will be administered once per session and will be administered orally.
9745233|NCT00331136|Experimental|Group D (Granules)|Pyronaridine artesunate 9:3 mg/kg. The sachet of granules strength is 60:20 mg PA, with the number of sachets depending on body weight, and is administered as a suspension with water.
9745234|NCT00331162|Active Comparator|1|Alemtuzumab
9745235|NCT00331162|Active Comparator|2|Anti-Thymocyte Globulin
9745236|NCT00331344|Experimental|Treatment (combination chemotherapy)|Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
9745237|NCT00331409|Experimental|Everolimus and Imatinib Mesylate|Everolimus: 2.5 mg daily by mouth Imatinib Mesylate: 600 mg daily by mouth
9745238|NCT00331422|Experimental|Patients Who Received Treatment|All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
9745239|NCT00331552|Experimental|Arm I|Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
9781991|NCT01163214|Active Comparator|Periarticular Injection|Injection combination prior to skin closure.
9781992|NCT01163253|Experimental|Active Treatment|"The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market.~All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion"
9781993|NCT01163266|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 8 weeks.
9781994|NCT01163266|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
9781995|NCT01163266|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
9781996|NCT01163279|Experimental|Cognitive Training|
9781997|NCT01163279|Active Comparator|Psychosocial Education|
9781998|NCT01163292||Adalimumab|Participants who continued adalimumab treatment after completion of Study NCT00870467 (M06-859)
9781999|NCT01163292||Non-Adalimumab|Participants who discontinued adalimumab treatment after completion of Study NCT00870467(M06-859)
9782000|NCT01163318||Adalimumab 40 mg/0.8 mL syringe for subcutaneous injection|Participants with rheumatoid arthritis who received adalimumab, per approved label
9782001|NCT01163461|Experimental|Immediate Treatment|individuals will receive 60 hours of speech therapy
9782002|NCT01163461|Experimental|Delayed Treatment|individuals will receive 60 hours of speech therapy after 6 week delay period
9782003|NCT01163474|Experimental|Arm 1 - All study participants|Evaluate video clinic visit prior to Face-to-Face usual care visit
9782004|NCT01163604|Experimental|Argatroban group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive continuous infusions of argatroban for 2 days before and 3 days after stenting, with accompanied aspirin and clopidogrel treatment.
9984695|NCT03823404|Experimental|COR388 40 mg bid|
9984696|NCT03823404|Placebo Comparator|Placebo bid|
10201218|NCT04315181|Experimental|Opioid agonist/sedative|Participants will receive non-therapeutic, experimental doses of active opioid agonist/placebo in combination with non-therapeutic, experimental doses of active sedative/placebo. Opioid/placebo and sedative/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid and sedative doses will be administered orally.
10201219|NCT04305314||Group 1: PRI > 70%|Compliance with the Enhanced Revovery protocol higher than 70%
10201220|NCT04305314||Group 2: PRI < 70%|Compliance with the Enhanced Revovery protocol lower than 70%
10201221|NCT04302740|Active Comparator|LEAP|Housing First plus LEAP
10201222|NCT04302740|No Intervention|Service-As-Usual|Housing First
10201223|NCT04294862|Experimental|TNP-2092 300mg IV|TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose
10201224|NCT04292106|Placebo Comparator|Placebo|
10201225|NCT04292106|Experimental|Red Spinach Extract (RSE)|
10201226|NCT04285086|Experimental|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
10201227|NCT04285086|Active Comparator|Anagrelide|Capsules, Daily, p.o.
10201228|NCT04277559|Active Comparator|Patient preferential music|The preference of the patients will be listened to preoperatively through the headphones.
10201229|NCT04277559|Active Comparator|Classical music|Classical music (Four Seasons from Vivaldi) will be listened to preoperatively through the headphones.
10201230|NCT04277559|Placebo Comparator|No music|the patients will not listen.
10201231|NCT04255199|Experimental|Intervention|Primary care and urgent care clinicians randomized to the intervention arm will receive two to three visits with a standardized patient instructor who will physicians how to facilitate patient acceptance of a watchful waiting strategy with regard to spinal imaging in the context of acute low back pain.
10201232|NCT04255199|Placebo Comparator|Control|Primary care and urgent care clinicians randomized to the control arm will receive a single visit with a standardized patient who simulates a visit with patient with acute low back pain but will deliver no instruction on patient communication or other content.
9828075|NCT02480439|Experimental|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
9828076|NCT02480582|Experimental|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
9828077|NCT02480582|Experimental|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
9828078|NCT02480582|Experimental|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
9828079|NCT02480582|Experimental|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\kg).
9828080|NCT02480582|Experimental|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\kg). Finally, after another washout period participants received no food.
9828081|NCT02480582|Experimental|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\kg).
9828082|NCT02480621|No Intervention|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
9828083|NCT02480621|Experimental|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
9828084|NCT02480712|Experimental|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
9835749|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 1b)|"Recommended Phase 2 dose (RP2D) will be determined from the below dose levels:~Dose level 1: PEGPH20 (3.0 microgram per kilogram (mcg/kg)) followed by eribulin mesylate (1.4 milligrams per square meter (mg/m^2)) or~Dose level 0: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.4 mg/m^2) or~Dose level -1: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.1 mg/m^2)~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; DLT was only observed from the first treatment cycle; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. Upon determination of the RP2D, study Phase 1b Expansion Part will proceed to confirm the RP2D, and thereafter Phase 2 part will proceed."
9835750|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 2)|Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
9835751|NCT02753595|Experimental|Eribulin mesylate (Phase 2)|Participants will receive eribulin mesylate at 1.4 mg/m^2.
9835752|NCT02753699|Experimental|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
9835753|NCT02753699|Experimental|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
9835754|NCT02753699|Experimental|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
9835755|NCT02753816|Experimental|Tranexamic Acid|1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
9835756|NCT02753816|Placebo Comparator|Placebo|Placebo given over 10 minutes into the vein once prior to surgery
9835757|NCT02753842|Experimental|Fitted, Then Thin, Then Standard Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
9835758|NCT02753842|Experimental|Fitted, Then Standard, Then Thin Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
9835759|NCT02753842|Experimental|Thin, Then Fitted, Then Standard Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
9828085|NCT02480764|Experimental|Azilsartan medoxomil 40 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
9828086|NCT02480764|Experimental|Azilsartan medoxomil 80 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
9828087|NCT02480764|Active Comparator|Valsartan 160 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.
9828088|NCT02480998|Experimental|IL-YANG Flu Vaccine QIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
9828089|NCT02480998|Active Comparator|IL-YANG Flu Vaccine TIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
9828090|NCT02481050|Experimental|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
9828091|NCT02481141|Active Comparator|5-ALA-SFC|"Study product administration will be as follows:~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
9828092|NCT02481141|Placebo Comparator|Placebo|"Study matching placebo administration will be as follows:~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
9828093|NCT02481206|Experimental|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
9828094|NCT02481206|No Intervention|Conventional Treatment|Conventional Treatment
9828095|NCT02481219|Active Comparator|Bowel preparation regimen -Control|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
9828096|NCT02481219|Experimental|Bowel preparation regimen-Test|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
9828097|NCT02481258|Experimental|Ataciguat (HMR1766)|200mg taken daily for 12 months
9828098|NCT02481258|Placebo Comparator|Matching Placebo|Taken Daily for 12 months
9828099|NCT02481297|Experimental|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
9828100|NCT02481297|Experimental|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
9828101|NCT02481375|Experimental|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.~Women will receive the multiple micronutrient with iron for 12 weeks."
9828102|NCT02481375|Active Comparator|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.~Women will receive the multiple micronutrient without iron for 12 weeks."
9828103|NCT02481375|Active Comparator|Iron only|"This formulation only has 60 mg elemental iron.~Women will receive iron for 12 weeks."
9828104|NCT02481375|Placebo Comparator|Placebo|"This formulation is a placebo.~Women will receive a placebo for 12 weeks."
9828105|NCT02481440|Experimental|hUC-MSC Transplantation|Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
9828106|NCT02481505|Experimental|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
9828107|NCT02481505|Experimental|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
9828108|NCT02481505|Experimental|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
9828109|NCT02481557|Experimental|Oxalate Salt Solution|Professionally applied
9828110|NCT02481557|No Intervention|No Treatment|No Treatment
9835760|NCT02753842|Experimental|Thin, Then Standard, Then Fitted Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
10201233|NCT04249167|Experimental|Treatment (cryoablation, atezolizumab, nab-paclitaxel)|Patients undergo cryoablation of the primary tumor over about 1 hour. After 2-3 weeks, patients receive atezolizumab IV on days 1 and 15 and nab-paclitaxel IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10201234|NCT04245423|Active Comparator|Augmented Usual Care (AUC)|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. Almost all practices have hired mental health clinicians, equivalent to the care managers in the investigators' collaborative care model, to treat mild and moderate depression and anxiety. These clinicians typically are licensed clinical social workers; a few are nurses or psychologists. No care managers have received systematic training in treating patients with OUD. The clinicians will retain their role and continue to treat and monitor patients with mental health conditions in these practices. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD. Patients are informed that the primary care practice provides both OUD and mental health treatment and are referred back to their provider for referral or to schedule care. A list of available community resources are available to the patient.
9745240|NCT00331630|Experimental|Treatment arm|30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9745241|NCT00331682|Experimental|Treatment (docetaxel and alvocidib)|Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9745242|NCT00331760|Other|Endometrial Cancer: IMRT|Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks.
9745243|NCT00331760|Other|Cervical Cancer: IMRT + Chemotherapy (cisplatin)|Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks and concurrent weekly cisplatin 40 mg/m^2 for five weeks.
9745244|NCT00331773|Active Comparator|Conventional 3D-CRT|Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
9745245|NCT00331773|Experimental|Hypofractionated 3D-CRT|Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions
9745246|NCT00331799|Active Comparator|1|Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
9745247|NCT00331864|Experimental|Ranibizumab|Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
9745248|NCT00332163|Experimental|Pre-emptive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy.
9745249|NCT00332163|Experimental|Reactive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required.
9745250|NCT00332202|Experimental|A|
9745251|NCT00332202|Placebo Comparator|B|
9745252|NCT00332241|Experimental|A1|Active Abilify
9745253|NCT00332241|Placebo Comparator|A2|
9745254|NCT00332332|Experimental|etanercept|Open label etanercept 50 mg twice weekly subcutaneously (SC) for 3 months followed by 50 mg twice a week week SC for 9 months, for a total treatment period of 12 months.
9745255|NCT00332462|Experimental|Cyclosporine (Sandimmun®)|Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
9745256|NCT00332488|Experimental|1|Technosphere Insulin
9745257|NCT00332488|Active Comparator|2|Metformin & Secretagogues
9745258|NCT00332488|Experimental|3|Technosphere & Metformin
9745259|NCT00332579|Active Comparator|A|Naltrexone
9745260|NCT00332579|Placebo Comparator|B|Placebo
9745261|NCT00332605|Experimental|Naltrexone plus N-Acetyl Cysteine|"Naltrexone tablets~N-Acetyl Cysteine: 600mg tablets, daily"
9745262|NCT00332605|Placebo Comparator|Placebo|
9745263|NCT00332644|Experimental|1|nicotine patch alone treatment
9745264|NCT00332644|Experimental|2|nicotine lozenge alone treatment
9745265|NCT00332644|Experimental|3|nicotine patch + lozenge combination treatment
9745266|NCT00332644|Experimental|4|bupropion alone treatment
9745267|NCT00332644|Experimental|5|bupropion + nicotine lozenge combination treatment
9745268|NCT00332644|Placebo Comparator|6|placebo control (no active medication) treatment
9745269|NCT00332696|Experimental|Octreotide|Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
9782005|NCT01163604|Experimental|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
9782006|NCT01163617|Experimental|Current/Physiolis Syringe|Self-injection using current syringe at Week 0 (Visit 1), self-injection using Physiolis syringe at Week 2 (Visit 2) (Phase A)
9828111|NCT02481596|Experimental|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
9828112|NCT02481596|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
9828113|NCT02481596|Active Comparator|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
9828114|NCT02481713|Experimental|MI condition|motivational interview condition
9828115|NCT02481713|Sham Comparator|CI condition|learning style interview condition
9828116|NCT02481869|Active Comparator|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
9828117|NCT02481869|Placebo Comparator|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
9828118|NCT02481934|Experimental|NKAE cells infusion + chemotherapy|Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
9828119|NCT02481947|Experimental|BLI400 Laxative|21 gm BLI400 powder
9828120|NCT02481947|Active Comparator|Lubiprostone|24 mcg capsule bid
9828121|NCT02482025|No Intervention|Usual care|Usual care delivered at VA Boston
9828122|NCT02482025|Active Comparator|SMMRT|Receives Usual Care PLUS SMMRT Intervention
9828123|NCT02482129|Experimental|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
9828124|NCT02482129|Active Comparator|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
9828125|NCT02482298|Experimental|Dose A|
9828126|NCT02482298|Experimental|Dose B|
9828127|NCT02482298|Placebo Comparator|Placebo|
9828128|NCT02482428|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
9828129|NCT02482428|Experimental|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
9828130|NCT02482428|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
9828131|NCT02482428|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
9828132|NCT02482428|Active Comparator|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
9828133|NCT02482571|Experimental|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
9828134|NCT02482610|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
9828135|NCT02482610|Experimental|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
9828136|NCT02482610|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
9745270|NCT00332696|Placebo Comparator|Placebo|Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
9745271|NCT00332709|Experimental|Letrozole|Letrozole orally 2.5 mg/day for 3 years
9745272|NCT00332709|Experimental|Letrozole + Zoledronic Acid|Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
9745273|NCT00332722|Active Comparator|Group 1- without steroid|Cervical Facet Joint Nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
9745274|NCT00332722|Active Comparator|Group 2 - with steroid|Cervical Facet Joint nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
9745275|NCT00332839|Active Comparator|Calcineurin Inhibitor (CNI) group|Participants received Cyclosporine A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids, or Tacrolimus A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids.
9745276|NCT00332839|Experimental|Certican group|Participants were switched in a step-wise fashion from the CNI based regimen to Everolimus (RAD001).
9745277|NCT00333138|Experimental|Fingolimod (FTY720) 1.25 mg/day|Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
9745278|NCT00333138|Placebo Comparator|Placebo/Fingolimod (FTY720)|Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
9745279|NCT00333138|Experimental|Fingolimod (FTY720) 5.0 mg/day|Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
9745280|NCT00333177|Experimental|Cog Remediation, risperidone injection|Participants will receive cognitive remediation training plus risperidone, administered via injection.
9745281|NCT00333177|Active Comparator|Healthy Behavior Training, risperidone injection|Participants will receive health behavior training plus risperidone, administered via injection.
9745282|NCT00333177|Experimental|Cog Remediation, oral risperidone|Participants will receive cognitive remediation training plus risperidone administered orally.
9745283|NCT00333177|Active Comparator|Healthy Behavior Training, oral risperidone|Participants will receive health behavior training plus risperidone administered orally.
9745284|NCT00333359|Experimental|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
9745285|NCT00333437|Experimental|Treatment|Mycophenolate Mofetil
9745286|NCT00333606|Experimental|Verum acupuncture|Acupuncture of specific acupuncture points
9745287|NCT00333606|Sham Comparator|Sham acupuncture|Acupuncture of non-specific acupuncture points
9745288|NCT00333619|Experimental|Nonpharmacological sleep intervention|The intervention will combine: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies.
9745289|NCT00333619|Active Comparator|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
9745290|NCT00333710|Experimental|Individual face-to-face contact|Individual face-to-face contact treatment
9745291|NCT00333710|Experimental|Individual telephone contact|Individual telephone contact treatment
9745292|NCT00333710|No Intervention|Control condition/treatment as usual|Control condition/treatment as usual
9745293|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus placebo|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
9745294|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
9745295|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
9745296|NCT00333788|Experimental|Certolizumab pegol 400 mg|400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
9745297|NCT00333801|Active Comparator|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited.
9745298|NCT00333801|Experimental|Individual Placement and Support (IPS)|Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.
9745299|NCT00333814|Active Comparator|1|Dexamethasone 350 µg
9745300|NCT00333814|Active Comparator|2|Dexamethasone 700 µg
9745301|NCT00333814|Sham Comparator|3|Sham
9745302|NCT00333840|Experimental|imatinib (STI571)|In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
9745303|NCT00333840|Active Comparator|IFN-a+Ara-C|In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
9745304|NCT00333866|Experimental|1|
10201235|NCT04245423|Experimental|Collaborative Care (CC)|"CC condition includes the following elements:~Personnel trained to assist with scheduling, reminders and referrals;~PCP trained and waivered to provide evidence-based pharmacotherapy for OUD;~Addictions psychiatrist with collaborative care expertise to provide treatment consultation and supervision in both OUD and mental health issues;~A care manager trained in evidence-based interventions for individuals with OUD and psychiatric disorders, who provides care in the primary care practice as part of the collaborative care team;~Measurement-guided care and treat-to-target practices, using validated measures of substance use, depression, anxiety as well as measures of adherence and side effects;~Electronic and in-person systematic communication regarding patient care among team members, facilitated by the electronic health record; and~Shared patient-provider decision making."
9745305|NCT00333866|Experimental|2|
9745306|NCT00333866|Experimental|3|
9745307|NCT00333866|Placebo Comparator|4|
9745308|NCT00333879|Other|Virtual Sound System|Efficacy of using a virtual sound system to simulate street crossing conditions.
9745309|NCT00333970|Experimental|cognitive remediation|cognitive remediation
9745310|NCT00333970|No Intervention|treatment as usual|treatment as usual
9745311|NCT00333983|Experimental|Arm 1|Robot Exercise Group
9745312|NCT00333983|Active Comparator|Arm 2|Traditional Upper Extremity Exercise Group
9745313|NCT00334074|Experimental|Clofarabine and Cytarabine|Five consecutive days of clofarabine 40 mg/m^2 IVI over 1 hour followed 4 hours later by cytarabine 1000 mg/m^2 IVI over 2 hours
9745314|NCT00334113|Experimental|Arm 1|Participants in this arm will meet with an exercise physiologist and obtain an exercise prescription for a walking program. In addition, they will recieve an intervention that will be delivered over an automated telephone system (TLC-PED). These automated phone calls with voice response and voice recognition capabilities will occur weekly over a 6 month period. During these calls, participants' physical activity will be monitored, new physical activities goals will be set, information about physical activity and the associated health benefits will be provided, and barriers to physical activity will be explored.
9745315|NCT00334113|No Intervention|Arm 2|"This is the treatment as usual condition. Participants in this condition will also have 2 sessions with an exercise physiologist and will receive an exercise prescription for a home based walking program. The will not receive the automated phone calls each week that are designed to motivate physical activity."
9745316|NCT00334204|Other|Measure Platelet Function Analyser -100 (PFA-100)|measuring Platelet Function Analyser (PFA)-100 test (an in vitro platelet function test, in addition to the rest of the routine/uusal clinical care)
9745317|NCT00334282|Placebo Comparator|placebo arm|matching placebo (800 mg tablet) once daily
9745318|NCT00334282|Experimental|pazopanib arm|Oral pazopanib tablet 800 mg once daily continuously
9745319|NCT00334542|Experimental|Simvastatin|Simvastatin 40 mg for 24-28 weeks
9745320|NCT00334633|Active Comparator|control|metronidazole 500 BID for 7 days
9745321|NCT00334633|Active Comparator|tinidazole 500|tinidazole 500 BID for 7 days
9745322|NCT00334633|Active Comparator|tinidazole 1 gm|tinidazole 1 gm BID for 7 days
9745323|NCT00334737|Experimental|Darbepoetin alfa injection|Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
9745324|NCT00334737|Active Comparator|erythropoietin alfa injection|Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
9745325|NCT00334737|Placebo Comparator|placebo/control|Sham injection
9745326|NCT00334802|Experimental|A|
9745327|NCT00334815|Experimental|Group 1 (cisplatin, etoposide, radiotherapy)|Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
9745328|NCT00334815|Experimental|Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
9745329|NCT00334815|Experimental|Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
9745330|NCT00334893|Experimental|Treatment (chemotherapy)|Patients receive eribulin mesylate IV over 15 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9782007|NCT01163617|Experimental|Physiolis/Current Syringe|Self-injection using Physiolis syringe at Week 0 (Visit 1), self-injection using current syringe at Week 2 (Visit 2) (Phase A)
10201236|NCT04245423|Experimental|Collaborative Care + Certified Recovery Specialist (CC+)|In addition to the collaborative care model described above, patients in the CC+ condition will have access to a Certified Recovery Specialist (CRS) to assist with treatment engagement and retention. A CRS is a person in the community who is in recovery and may share similar experiences and barriers that participants have faced. They will work with participants as a peer to help them coordinate information and needs with their providers. The CRS will take participants to their PCP appointments and any other appointments that they may have to help them engage and stay in care to remain healthy. They will also provide education and help participants work on their recovery goals. They will identify and support linkages to community resources and help participants identify barriers to full participation in their recovery and develop strategies to overcome those barriers.
10201237|NCT04238013|Active Comparator|Corticospinal Tract Excitability|During the Corticospinal Tract Excitability arm, corticospinal excitability will be assessed by measuring motor evoked potentials after transcranial magnetic stimulation pre-post each intervention in conjunction with other outcome measures.
10201238|NCT04238013|Active Comparator|Spinal Reflex Circuit Excitability|During the Spinal Reflex Circuit Excitability arm, spinal reflex circuit excitability will be assessed by measuring low frequency depression after Hoffmann-Reflex testing pre-post each intervention in conjunction with other outcome measures.
9745331|NCT00334958|Placebo Comparator|Placebo|For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily.
9745332|NCT00334958|Active Comparator|Rufinamide|For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
10201239|NCT04231396|Other|HA and CI Users using Audiobooks for Hearing Loss for Auditory Training|"study participants will be seen weekly for 12 weeks and will use the Audiobooks for HL App for the final 6 weeks using the App at least two hours per week on their own. The researcher will conduct 12 weekly in-home visits where the following will be done:~First 6 weeks:~• Partial BKB-SIN will be administered~Final 6 weeks:~Partial BKB-SIN will be administered~Conduct a comprehension test.~Address any usability issues the participant brings up.~Review and set new weekly goals Final session: Conduct Final Usability survey"
9745333|NCT00335140|Experimental|Rituximab + standard chemotherapy|Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.
9745334|NCT00335153|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances."
9745335|NCT00335257||1|Users of OCs containing DRSP
9745336|NCT00335257||2|Users of OCs containing other progestins
9745337|NCT00335283|Active Comparator|Lansoprazole|
9745338|NCT00335283|Placebo Comparator|Sugar Pill|
9745339|NCT00335322|Active Comparator|1|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
9745340|NCT00335322|Active Comparator|2|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
9745341|NCT00335322|Experimental|3|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
9745342|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA high dose|
9745343|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA low dose|
9745344|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA high dose|
9745345|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA low dose|
9745346|NCT00335478|Experimental|Daptomycin|
9745347|NCT00335504|Experimental|Arm I (atorvastatin calcium)|Patients receive oral atorvastatin once daily.
9745348|NCT00335504|Experimental|Arm II (sulindac)|Patients receive oral sulindac twice daily.
9745349|NCT00335504|Experimental|Arm III (oligofructose-enriched inulin)|Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.
9745350|NCT00335504|Placebo Comparator|Arm IV (placebo)|Patients receive an oral placebo twice daily.
9745351|NCT00335517|Experimental|10mg Depodur|
9745352|NCT00335517|Experimental|15mg DepoDur|
9745353|NCT00335556|Experimental|Surgery|Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
9782008|NCT01163617|Experimental|Current/Physiolis Autoinjector|Self-injection using current autoinjector at Week 0 (Visit 1), self-injection using Physiolis autoinjector at Week 2 (Visit 2) (Phase A)
9782009|NCT01163617|Experimental|Physiolis/Current Autoinjector|Self-injection using Physiolis autoinjector at Week 0 (Visit 1), self-injection using current autoinjector at Week 2 (Visit 2) (Phase A)
9745354|NCT00335556|Experimental|Treatment (UH-1)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
9745355|NCT00335556|Experimental|Treatment (window/UH-1)|Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
9745356|NCT00335556|Experimental|Treatment (UH-2)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
9745357|NCT00335556|Experimental|Treatment (regimen I)|Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
9745358|NCT00335556|Experimental|Treatment (regimen DD-4A)|Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
9745359|NCT00335725|Experimental|Fostimon|Fostimon is an highly purified FSH preparation.
9745360|NCT00335725|Active Comparator|Gonal-F|Gonal-F is a recombinant FSH preparation.
9745361|NCT00335738|Experimental|Group 1 (identified by central review as high risk)|Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
9745362|NCT00335738|No Intervention|Group 2 (identified by central review as not high risk)|Patients undergo observation periodically for at least 5 years.
9745363|NCT00335764|Experimental|Group 1|Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
9745364|NCT00335764|Experimental|Group 2|Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
9745365|NCT00335764|Experimental|Group 3|Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
9984697|NCT03815370|Placebo Comparator|Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
9745366|NCT00335829|Experimental|single arm, received bevacizumab and TACE|
9745367|NCT00335959|Experimental|Chemotherapy, Chemoradiation, Surgery|"Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy"
9745368|NCT00335972|Active Comparator|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
9745369|NCT00335972|Active Comparator|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
9745370|NCT00336024|Active Comparator|Arm I (induction+consolidation chemotherapy, autologous PBSC))|"Patients receive vincristine sulfate IV on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
9745371|NCT00336024|Experimental|Arm II (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine sulfate IV on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
9745372|NCT00336232|Experimental|Diet Intervention|28 day diet low vitamin K, 28 day diet high vitamin K
9745373|NCT00336284|Active Comparator|Home Monitoring|Home Monitoring programmed on.
9745374|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off.
9745375|NCT00336323|Active Comparator|1|Laser photocoagulation at baseline
9745376|NCT00336323|Experimental|2|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
9745377|NCT00336323|Experimental|3|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
9745378|NCT00336323|Experimental|4|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
9745379|NCT00336323|Experimental|5|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
9745380|NCT00336479|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
9745381|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
9745382|NCT00336479|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
9745383|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
9745384|NCT00336492|Experimental|002|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
9745385|NCT00336492|Experimental|001|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
9745386|NCT00336505|Active Comparator|Clarithromycin|
9745387|NCT00336505|Experimental|Cethromycin|
9745388|NCT00336544|Experimental|Cethromycin|
9745389|NCT00336544|Active Comparator|Clarithromycin|
9745390|NCT00336583|Experimental|Oxaliplatin, response|relapsed or refractory non-Hodgkin's lymphoma
9745391|NCT00336700|Experimental|Gemcitabine and Erlotinib|Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months
9745392|NCT00336817|Active Comparator|Myfortic Group|Subjects in the Myfortic arm will receive Myfortic 360mg or 720 mg BID for 90 days
9745393|NCT00336817|Active Comparator|CellCept Group|Subjects in the CellCept arm will receive CellCept 500mg or 1000mg BID for 90 days
9745394|NCT00336856|Experimental|IRINOTECAN AND CETUXIMAB|Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
9745395|NCT00336895|Experimental|Liver Transplant Subjects|All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.
9745396|NCT00337077|Experimental|Eribulin mesylate|Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9745397|NCT00337103|Experimental|1|
9745398|NCT00337103|Active Comparator|2|
9745399|NCT00337129|Experimental|eribulin mesylate|eribulin mesylate
9745400|NCT00337168|Experimental|Induc, ReInduc, Consol, clofarabine, cytarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
9745401|NCT00337181||Vaccine Group|Received vaccination in RV144
9828137|NCT02482675|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
9828138|NCT02482675|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
9828139|NCT02482675|Experimental|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
9828140|NCT02482675|Experimental|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
9828141|NCT02482805|Experimental|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
9828142|NCT02482805|Experimental|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
9828143|NCT02482805|Experimental|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
9828144|NCT02482870|Active Comparator|Macintosh|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a Macintosh laryngoscope.
9828145|NCT02482870|Active Comparator|KingVision|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a King Vision video laryngoscope.
9828146|NCT02482935|Experimental|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
9828147|NCT02482935|Experimental|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
9828148|NCT02483000|Experimental|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
9828149|NCT02483416||group 1|Group without 'remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
9828150|NCT02483416||group 2|Group with 'remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team
9828151|NCT02483520|Experimental|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
9828152|NCT02483520|Placebo Comparator|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
9828153|NCT02483572|Experimental|Functional Communication Training|Participants assigned to this condition will receive treatment immediately after assignment. The investigators will implement functional communication training (FCT) to teach the participant an appropriate request response, known as a functional communication response or FCR. FCT training will continue until the participant emits independent FCRs in at least 90% of the 30-s intervals and until destructive behavior decreases by 90% (relative to pre-treatment baseline) for two consecutive sessions.
9828154|NCT02483572|No Intervention|Waitlist-Control Condition|Participants assigned to the waitlist-control condition will not immediately receive services. These participants will be paired with an FCT-condition participant such that the no-treatment duration for these participants is yoked to the amount of time their respective FCT-condition participants receive services (e.g., most treatment last approximately 4 months, or 16 weeks); if Participant A finishes treatment in 16 weeks, Participant B will not receive treatment for at least 16 weeks for comparative measures). After the wait period, these participants will then receive the same services as those assigned to the immediate treatment (FCT Condition).
9828155|NCT02483585|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
9828156|NCT02483585|Experimental|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
9828157|NCT02483611|Experimental|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
9745402|NCT00337181||Placebo Group|Received placebo in RV144
9745403|NCT00337194|Experimental|Arm I (SGN-30, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
9745404|NCT00337194|Active Comparator|Arm II (placebo, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
9745405|NCT00337207|Experimental|Avastin|
9745406|NCT00337272|Placebo Comparator|1 (Placebo)|Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
9745407|NCT00337272|Active Comparator|2 (Ramelteon)|Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
9745408|NCT00337285|Experimental|1|
10201240|NCT04230265|Experimental|UniCAR02-T-CD123|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the recombinant antibody derivative TM123.
10201241|NCT04218656|Experimental|Group A|111 patients with intermittent claudication
10201242|NCT04218656|Experimental|Group B|48 patients with critical limb ischemia with pain at rest and/or foot ulcers
10201243|NCT04210869|Experimental|Experimental|Mixed nuts
10201244|NCT04210869|No Intervention|Control|No mixed nuts
10201245|NCT04198363|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
10201246|NCT04198363|Active Comparator|Esomeprazole 20 mg|Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
10201247|NCT04198090|Other|Sexual & Gender Minority (SGM) Competence Training|Personnel will be trained using a validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for Oncology.
10201248|NCT04186832|Active Comparator|Group I (pedometer)|Patients wear a pedometer for step count monitoring over 6 weeks.
10201249|NCT04186832|Experimental|Group II (FitBit)|Patients wear a FitBit for step count monitoring over 6 weeks.
10201250|NCT04176380|Experimental|Administration of RAPA-201 cells|
10201251|NCT04163484||Stable coronary artery disease|
10201252|NCT04163484||ST-elevation myocardial infarction|
10201253|NCT04163484||Non-ST-elevation myocardial infarction|
10201254|NCT04161157|Experimental|Pathways|Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma.
10201255|NCT04158882||Patients enrolled in differentiated service delivery models|
10201256|NCT04158882||Patients not enrolled in DSD models|
10201257|NCT04157426|Experimental|Ultrasound-guided percutaneous electrolysis|
10201258|NCT04157426|Active Comparator|ultrasound-guided dry needling|
10201259|NCT04156789||Sarcoidosis group|Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
10201260|NCT04156789||Control group|Control subjects have no sarcoidosis and will be sex, age (± 3 years), height (± 20 cm), and weight (± 15 kg) matched to sarcoidosis patients.
10201261|NCT04154644|Experimental|Cervical Cytology|100 women with abnormal cervical cytology will receive cryotherapy with the experimental CryoPop device
10201262|NCT04151225|Placebo Comparator|Participants receiving placebo|Participants will receive placebo loading dose followed by placebo for 12 weeks during Induction phase. Participants with clinical response at Week 12 will continue to receive placebo into a 40-weeks blinded maintenance period. Participants without a clinical response at Week 12 will receive a 450mg GSK2330811 SC loading dose at Week 12, followed by 150 mg SC every week from Week 13 until Week 23, followed by 150 mg SC every 2 weeks until Week 50.
10201263|NCT04151225|Experimental|Participants receiving GSK2330811 450mg loading dose/150mg Q1W|Participants will receive 450mg GSK2330811 SC as loading dose followed by 150 mg GSK2330811 Q1W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
10201264|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q2W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q2W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
10201265|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q4W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q4W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q4W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
10201266|NCT04151225|Experimental|Participants receiving GSK2330811 150mg Q8W|Participants will receive GSK2330811 SC 150 mg Q8W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q8W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
9745409|NCT00337350|Active Comparator|rosiglitazone|rosiglitazone 4mg/day
9745410|NCT00337350|Placebo Comparator|placebo|matched placebo for 4mg rosiglitazone
9745411|NCT00337428|Experimental|Group 1|Concomitant/CMF
9745412|NCT00337428|Experimental|Group 2|Non-Concomitant/CMF
9745413|NCT00337428|Experimental|Group 3|Concomitant/FMF
9745414|NCT00337428|Experimental|Group 4|Non-Concomitant/FMF
9745415|NCT00337467|Experimental|A1|
9745416|NCT00337571|Experimental|A1|5 mg
9745417|NCT00337571|Experimental|A2|10 mg
9745418|NCT00337571|Experimental|A3|15 mg
9745419|NCT00337571|Placebo Comparator|B1|
9745420|NCT00337610|Experimental|sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day|
9745421|NCT00337610|Placebo Comparator|sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day|
9745422|NCT00337662|Experimental|1|Olanzapine for Not Early Onset response (NEO) patients
10201267|NCT04148417|Experimental|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
9745423|NCT00337662|Active Comparator|2|Risperidone for Not Early Onset response (NEO) patients
9745424|NCT00337662|Active Comparator|3|Risperidone for Early Onset response (EO) patients
9745425|NCT00337727|Other|1|Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
9745426|NCT00337727|Other|2|Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
9745427|NCT00337779|Active Comparator|glatiramer acetate 40 mg|
9745428|NCT00337779|Active Comparator|glatiramer acetate 20 mg|
9745429|NCT00337818|Experimental|Cervarix New Process|Subjects aged 15 to 25 years received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process.
9745430|NCT00337818|Experimental|Cervarix Old Process Group|Subjects aged 15 to 25 years who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the old manufacturing process.
9745431|NCT00337818|Experimental|Cervarix Young/Lot 1 Group|Subjects aged 10 to 14 years, who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process (Lot 1).
9745432|NCT00337935|Experimental|Epoetin Alfa|
9745433|NCT00337935|Other|Group 2|Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
9745434|NCT00338039|Experimental|Chemotherapy + Chemoradation|Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
9745435|NCT00338286|Experimental|001|epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.
9745436|NCT00338286|Other|002|Standard supportive care (packed RBC transfusion) Per doctor prescription
9782010|NCT01163617|Experimental|Physiolis Autoinjector at 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at storage temperature (2° to 8°C) (Phase B)
9782011|NCT01163617|Experimental|Current Autoinjector 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at storage temperature (2° to 8°C) (Phase B)
9782012|NCT01163617|Experimental|Physiolis Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at room temperature (20° to 27°C) (Phase B)
9782013|NCT01163617|Experimental|Current Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at room temperature (20° to 27°C) (Phase B)
9782014|NCT01163643|Experimental|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension
9782015|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension
9782016|NCT01163643|Placebo Comparator|Vehicle|Vehicle twice daily (BID)
9782017|NCT01163643|Experimental|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension
9782018|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension in the morning|2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)
9782019|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension PM|Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.
9782020|NCT01163656|Active Comparator|Direct Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Miller Laryngoscope.
9782021|NCT01163656|Active Comparator|Glidescope Cobalt Video Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Glidescope Cobalt Video Laryngoscope.
9782022|NCT01163721|Experimental|Ranolazine|Participants were randomized to receive ranolazine for 12 weeks.
9782023|NCT01163721|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ranolazine for 12 weeks.
9782024|NCT01163747|Active Comparator|Methotrexate|Participants continued to receive their standard dose of methotrexate up to Week 8. From Week 8 participants also received 8 mg/kg tocilizumab intravenously every 4 weeks until Week 20. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
9745437|NCT00338598|Experimental|Glycine|Glycine, 0.8 gr per kg given in two daily doses
9745438|NCT00338598|Placebo Comparator|placebo|placebo will be administered.
9745439|NCT00338728|Experimental|Treatment (imatinib mesylate, letrozole)|Participants receive imatinib mesylate PO BID and letrozole PO QD for 8 weeks in the absence of disease progression or unacceptable toxicity.
9745440|NCT00338741||1|Rebif exposed pregnancies
9745441|NCT00338741||2|Non-Rebif exposed pregnancies
9745442|NCT00338806|Experimental|Interpersonal Psychotherapy-Prevention|Participants will receive interpersonal psychotherapy for prevention with adolescents
9745443|NCT00338806|Active Comparator|Educational and Clinical Monitoring|Participants will receive educational clinical monitoring
9745444|NCT00338884|Experimental|SUNITINIB MALATE.|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
9745445|NCT00338949|Active Comparator|Control|Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone
9745446|NCT00338949|Experimental|Switch|Participants who enter on risperidone or olanzapine and switch to ziprasidone
9745447|NCT00338962|Active Comparator|Paroxetine and naltrexone|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
9745448|NCT00338962|Active Comparator|paroxetine and placebo|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day.
9745449|NCT00338962|Active Comparator|Desipramine and naltrexone|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
9745450|NCT00338962|Active Comparator|Desipramine and placebo|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
9745451|NCT00338988|Experimental|Capecitabine + Oxaliplatin|Combination of intravenous (IV) oxaliplatin 100 mg/m^2 Day 1 and oral (PO) capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m2) on Days 1-14.
9745452|NCT00339040|Active Comparator|Arm A: QHPV|QHPV at week 0, 8, 24, 96.
9745453|NCT00339040|Other|Arm B: Placebo/QHPV|Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.
9745454|NCT00339079|Experimental|Cognitive Behavioral Therapy (CBT)|Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions.
10201268|NCT04144608|Experimental|Toripalimab Combined With Platinum-containing Dual-agent|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer
9745455|NCT00339079|Placebo Comparator|Placebo|Patients only received placebo pills accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
9745456|NCT00339079|Experimental|Fluoxetine|Patients only received the SSRI Fluoxetine. Medication was adminstered on a fixed-flexible dosing regimen, beginning at 10mg/day for 2 weeks, then 20 mg/day for 2 weeks, 40 mg/day for two weeks, 60 mg/day for 2 weeks, and 80 mg/day (the target dose) thereafter. This was accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
9745457|NCT00339079|Experimental|Combined CBT and Fluoxetine|Patients in this arm received both CBT and the fluoxetine medication. Both interventions were administered in the same way as when adminstered alone in the other arms.
9745458|NCT00339144|Experimental|Dasatinib (100 mg)|
9745459|NCT00339144|Experimental|Dasatinib (150 mg)|
9745460|NCT00339144|Experimental|Dasatinib (200 mg)|
9745461|NCT00339183|Experimental|Panitumumab Plus FOLFIRI|Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
9745462|NCT00339183|Active Comparator|FOLFIRI Alone|Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
9745463|NCT00339833|Experimental|Salsalate|Salsalate (3g/day) for 7 days
9745464|NCT00339833|Placebo Comparator|Placebo|Placebo
9745465|NCT00340379|Active Comparator|Ziprasidone|Subjects in this arm received ziprasidone with a placebo to maintain the blind
9745466|NCT00340379|Active Comparator|Sertraline/Haloperidol|Subjects in this arm received a combination of sertraline and haloperidol with a placebo to maintain the blind. Sertraline dosage was 150-200mg/day and haloperidol was 6-8mg/day based on tolerance.
9745467|NCT00340678|Experimental|Normoalbuminuria Losartan|Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
9745468|NCT00340678|Placebo Comparator|Normoalbuminuria Placebo|Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.
9745469|NCT00340678|Experimental|Microalbuminuria Losartan|Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
9745470|NCT00340678|Placebo Comparator|Microalbuminuria Placebo|Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.
9745471|NCT00340704|Experimental|1. Low dose group|
9745472|NCT00340704|Experimental|2. Medium dose group|
9745473|NCT00340704|Experimental|3. High dose group|
9745474|NCT00340834|Experimental|Fingolimod 1.25 mg|
9745475|NCT00340834|Experimental|Fingolimod 0.5 mg|
9745476|NCT00340834|Active Comparator|Interferon β-1a 30 µg|
9745477|NCT00342355|Active Comparator|AZT+DDI+EFV|Zidovudine,Didanosine,Efavirenz ( Zidovudine 600 mg once daily,Didanosine <60 kg/125 mg twice daily or >60kg/200 mg twice daily,Efavirenz 600 mg once daily)
9745478|NCT00342355|Active Comparator|AZT+DDI+r/LPV|Zidovudine,Didanosine,Lopinavir/Ritonavir(AZT 600 mg once daily,DDI 100 mg twice daily,r/LPV 400mg/100mg twice daily)
9745479|NCT00342355|Active Comparator|d4T+3TC+EFV|Stavudine,Lamivudine,Efavirenz(d4T 40 mg twice daily,3TC 300 mg once daily,EFV 600 mg once daily)
9745480|NCT00342355|Active Comparator|d4T+3TC+r/LPV|Stavudine,Lamivudine,Lopinavir/Ritonavir(d4T 40m mg twice daily,3TC 300 mg once daily,r/LPV 400mg/100mg twice daily)
9745481|NCT00342563|Experimental|Mecamylamine- Smoker|
9745482|NCT00342563|Placebo Comparator|Placebo-Smoker|
9745483|NCT00342563|Experimental|Mecamylamine- Non-Smoker|
9745484|NCT00342563|Placebo Comparator|Placebo-Non-Smoker|
9745485|NCT00342628|Experimental|Vi-rEPA plus DTP|Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
9745486|NCT00342628|Active Comparator|Hib-TT plus DTP|Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
9745487|NCT00342628|Active Comparator|EPI|DTP at 2,4 and 6 months
9745488|NCT00343044|Experimental|Treatment|Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
9745489|NCT00343083|Experimental|Cetuximab comparison for Head and Neck Cancer|"To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).~Both chemotherapy and radiation will be given on a weekly basis (see interventions for details)."
9745490|NCT00343252|Experimental|Teriparatide|Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
9745491|NCT00343252|Active Comparator|Risedronate|Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
9745492|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Paclitaxel 200 mg/m² on day 1 of every 3 week cycle~Carboplatin area under curve (AUC=6 min*mg/mL) on day 1 of every 3 week cycle~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
9745493|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Cycles 1-3:~Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles~Carboplatin AUC=6 min*mg/mL on day 1 of each 3 week cycle for the first 3 cycles~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
10201269|NCT04141085||Healthy volunteers without infertility|Healthy volunteers without a history of infertility who have regular menstrual cycles and whom have not had any intrauterine procedures performed in the last 90 days prior to participation in the study
10201270|NCT04141085||Infertile Patients|Infertile patients with a history of infertility but without concern for endometrial dysfunction as the cause of their infertility.
10201271|NCT04134013|Experimental|Nutrition and Chiropractic|LBP chiropractic adjustment per protocol and 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
10201272|NCT04134013|Active Comparator|Chiropractic Adjustment ONLY|LBP chiropractic adjustment per protocol
10201273|NCT04118361|Experimental|Patients with AVS isolated at emergencies|Enrollment of patients with AVS isolated at emergencies
10201274|NCT04118348|No Intervention|Passive Control|Will consist of no alerts and will serve to examine lipid panel screening rates given the current standard of care. After 6 months, providers in this (and other conditions) will receive the alert(s) with the best demonstrated success in increasing screening rates.
10201275|NCT04118348|Experimental|Best Practice Alert (BPA-only)|Will consist of a BPA that fires for providers during a visit with an eligible 9-11 year-old patient. This is an active opt-in alert wherein the provider must respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test. The BPA will include a recommendation to administer the screen in combination with existing scheduled bloodwork.
10201276|NCT04118348|Experimental|Health Maintenance Topic (HMT-only)|Will consist of an HMT in Epic that is present for providers at their visit with an eligible patient. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
10201277|NCT04118348|Experimental|BPA+HMT|Will consist of both the BPA and HMT presented simultaneously in Epic.
10201278|NCT04116489|Experimental|Wildlife Immersion Activity|We will use a crossover design in which each participant receives an introductory forest walk followed by 3 wildlife immersion activity experiences in different settings .
10201279|NCT04093466|Experimental|Treatment (CX1003)|Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).
10201280|NCT04070105|Active Comparator|Conventional Prosthetic Foot|In this condition, participants will walk with their standard prosthetic foot
10201281|NCT04070105|Experimental|CAESER Prosthetic Foot|In this condition, participants will walk with a new prosthesis with enhanced energy storage and return and increased range of motion. They will only wear this device in the lab for an approximately 4 hour period of time
10201282|NCT04066959|Experimental|Question Prompt List (QPL)|A QPL is a simple, inexpensive communication tool that is comprised of list of questions related to the physical and psychosocial aspects of an illness and treatment components about which patients may want to ask their diabetes care team during a routine diabetes clinic visit.
9983938|NCT04537871||Observational (physical assessment)|Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.
9745494|NCT00343382|Experimental|Arm I|Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
9745495|NCT00343382|Experimental|Arm II|Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
9745496|NCT00343382|Placebo Comparator|Arm III|Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
9745497|NCT00343382|Placebo Comparator|Arm IV|Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
9745498|NCT00343460|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
9745499|NCT00343460|Experimental|Arm II|Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
9745500|NCT00343460|Experimental|Arm III|Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
9745501|NCT00343512|Experimental|Therapeutic Intervention|
9745502|NCT00343564|Experimental|Phase 1 Dose Escalation|Phase 1 dose escalation without and with GCSF support
9745503|NCT00343564|Experimental|Phase 2 Fixed Dose|Phase 2 fixed dose based on Phase I findings stratified by NHL type
9745504|NCT00343642|Experimental|Active Fructo-oligosaccharide|"Subjects received an active fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.~The fructo-oligosaccharide supplement was administered orally in a powder form two teaspoons daily."
9745505|NCT00343642|Placebo Comparator|Placebo Fructo-oligosaccharide|Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.
9745506|NCT00343642|Active Comparator|Dietary Therapy|Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.
9745507|NCT00343785|Experimental|Treatment (conditioning regimen, transplant, GVHD prophylaxis)|Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
9745508|NCT00343863|Active Comparator|Dexamethasone + Ondansetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
9745509|NCT00343863|Experimental|Dexamethasone + Palonosetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
9745510|NCT00343889|Experimental|Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine|Participants received 3 doses of the DTaP-Hep B-PRP~T concomitantly with Oral Polio Vaccine (OPV), 1 dose each at 6, 10, and 14 weeks of age.
9745511|NCT00343889|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of Tritanrix-Hep B/Hib™ concomitantly with Oral Polio Vaccine (OPV) at 6, 10, and 14 weeks of age.
9745512|NCT00343915|Experimental|2-Dose Engerix|subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
9745513|NCT00343915|Active Comparator|3-Dose Engerix|subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.
9745514|NCT00344032|Experimental|Cervarix|Subjects who received 3 doses of HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) (at 0, 1, 6 months).
9828158|NCT02483611|Experimental|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
9828159|NCT02483611|Placebo Comparator|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
9828160|NCT02483676|Experimental|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
9828161|NCT02483676|Active Comparator|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
9828162|NCT02483975|Experimental|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
9828163|NCT02483975|Placebo Comparator|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
9828164|NCT02484092|Experimental|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer
9828165|NCT02484547|Experimental|Low Dose|Monthly intravenous (IV) infusions
9828166|NCT02484547|Experimental|High Dose|Monthly intravenous (IV) infusions
10201283|NCT04066959|Experimental|Motivation Enhancement System (MES)|MES is a brief, 2-session computer-delivered intervention to enhance intrinsic motivation for behavior change. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. Session 1 begins with psychoeducation describing optimal diabetes self-management, then youth motivation for diabetes self-management is assessed and followed by exercises designed to increase or reinforce his/her current motivational state (e.g., decisional balance) and build self-efficacy, (e.g., building on strengths and past success). Session 1 concludes with goal setting to promote autonomous diabetes self-management. Session 2 begins with an assessment of progress toward the behavioral goal and proceeds to build motivation and self-efficacy with exercises consistent with the youth's current motivational state. Session 2 concludes with goal setting to promote autonomous diabetes self-management.
10201284|NCT04066959|Experimental|Text Message Reminders (TXT)|Participants will receive 30 days of one-way text messages targeting one of three key daily diabetes care behaviors: monitoring blood glucose, insulin administration, or carbohydrate counting. Participants will set a reminder schedule, i.e., frequency and timing of text message reminders.
9828167|NCT02484651|No Intervention|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
9828168|NCT02484651|Experimental|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
9828169|NCT02484690|Active Comparator|Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
9828170|NCT02484690|Experimental|Arm B: Faricimab, 1.5 mg Q4W|Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
9828171|NCT02484690|Experimental|Arm C: Faricimab, 6 mg Q4W|Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
9828172|NCT02484690|Experimental|Arm D: Faricimab, 6 mg Every 4-8 weeks|Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
9828173|NCT02484690|Experimental|Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
9828174|NCT02484729|Experimental|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
9828175|NCT02484729|Placebo Comparator|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
9828176|NCT02484729|Experimental|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
9828177|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
9828178|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
9828179|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
9828180|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
9828181|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
9828182|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
9828183|NCT02484859|Active Comparator|remifentanil|Following an intravenous bolus dose of 0.5 µg/kg remifentanil administered just before the induction of anaesthesia, patients will receive an intravenous infusion of remifentanil at a dose of 0.25-0.5 µg/kg/min throughout the surgery. The rate of infusion will be adjusted to maintain a mean blood pressure within %70-80 of the baseline value. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
9983939|NCT04537624||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
9983940|NCT04537299|Experimental|Treatment Group|Subjects will receive treatment drug (Fisetin)
9745515|NCT00344032|Placebo Comparator|Placebo|Subjects who received 3 doses of Placebo (at 0, 1, 6 months).
10201285|NCT04066959|Experimental|QPL & MES|Participants will receive the QPL and MES interventions as described above.
10201286|NCT04066959|Experimental|QPL & TXT|Participants will receive the QPL and TXT interventions as described above.
10201287|NCT04066959|Experimental|MES & TXT|Participants will receive the MES and TXT interventions as described above.
9745516|NCT00344175|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
9745517|NCT00344175|Active Comparator|Simvastatin 40mg/80mg|Simvastatin 40 mg or 80 mg once daily
9745518|NCT00344305|Experimental|Cohort 1: Participants Between 6 to < 24 Months Age|Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
9745519|NCT00344305|Experimental|Cohort 2: Participants Between 24 to < 60 Months Age|Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
9745520|NCT00344318|Experimental|Synflorix 1 Group|Subjects aged 6-12 weeks from the Philippines receiving Synflorix™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ vaccines at 6, 10, 14 weeks of age.
9745521|NCT00344318|Experimental|Synflorix 2 Group|Subjects aged 6-12 weeks from Poland receiving Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 2, 4, 6 months of age.
9745522|NCT00344318|Active Comparator|Prevenar 1 Group|Subjects aged 6-12 weeks from the Philippines receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ at 6, 10, 14 weeks of age.
9745523|NCT00344318|Active Comparator|Prevenar 2 Group|Subjects aged 6-12 weeks from Poland receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ at 2, 4, 6 months of age.
9745524|NCT00344370|Experimental|Pitavastatin|Pitavastatin 4 mg QD
9745525|NCT00344370|Active Comparator|Atorvastatin|Atorvastatin 40 mg
9745526|NCT00344448|Experimental|Raptiva|At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.
9745527|NCT00344448|Placebo Comparator|placebo|Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.
9745528|NCT00344461|Experimental|Nevirapine, FTC, Tenofovir|Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
9745529|NCT00344500|No Intervention|Usual Care|Usual Care
9745530|NCT00344500|Active Comparator|Lifestyle Balance|Behavioral Weight Loss Program
9745531|NCT00344682|Experimental|memantine|memantine (5-20mg a day)
9745532|NCT00344682|Placebo Comparator|Placebo|placebo (5-20mg a day)
9745533|NCT00344773|Experimental|Gefitinib|Gefitinib 250mg tablet once daily
9745534|NCT00344968|Experimental|1|
9745535|NCT00344968|Experimental|2|
9745536|NCT00344968|Sham Comparator|3|
10201288|NCT04066959|Experimental|MES, QPL & TXT|Participants will receive the MES, QPL, and TXT interventions as described above.
10201289|NCT04066959|No Intervention|Standard Medical Care|Participants will receive standard medical care at one of two participating clinical sites. Clinical practices at these sites are consistent with the standards of T1D care recommended by the American Diabetes Association and will include diabetes clinic visits every 3-4 months for routine diabetes medical care provided by an endocrinologist and/or nurse practitioner.
9745537|NCT00345033|Experimental|1|Participants will take aripiprazole 15mg/day for 8 weeks.
9745538|NCT00345033|Placebo Comparator|2|Participants will take placebo for 8 weeks.
9745539|NCT00345046|Active Comparator|Pred Forte 1%|Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
9745540|NCT00345046|Active Comparator|EconoPred Plus 1%|EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
9745541|NCT00345046|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
9745542|NCT00345176|Active Comparator|Lutein/Zeaxanthin|lutein (10mg)/zeaxanthin (2 mg)
9745543|NCT00345176|Active Comparator|DHA/EPA|DHA (350 mg)/EPA (650 mg)
9745544|NCT00345176|Active Comparator|Lutein/Zeaxanthin + DHA/EPA|lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
9745545|NCT00345176|Placebo Comparator|Placebo/Control|Considered control because all participants received the AREDS formulation
9745546|NCT00345254|Experimental|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
9745547|NCT00345254|No Intervention|Untouched cord|The cord was untouched after delivery of the anterior shoulder and prior to extraction of the body.
9745548|NCT00345293|Experimental|DC/PC3 vaccine|3 subcutaneous injections of ex vivo-generated autologous dendritic cell vaccine: 1) pulsed with apoptotic PC3 cells; 2) pulsed with apoptotic PC3-M1 cells, and 3) pulsed with keyhole limpet hemocyanin (KLH, control antigen)
9745549|NCT00345332|Placebo Comparator|1|Placebo
9745550|NCT00345332|Experimental|2|Botox
9745551|NCT00345371|Active Comparator|Topiramate|Subjects will receive topiramate (in tablet form) up to 200 mg/day for 13 weeks.
9983941|NCT04537299|Placebo Comparator|Placebo Group|Subjects will receive placebo
10201290|NCT04057469|Experimental|Tulobuterol patch|
10201291|NCT04057469|Placebo Comparator|Placebo|
10201292|NCT04038580|Sham Comparator|Prescribed Laminated Socket|In this arm, participants will wear their clinically prescribed laminated socket. This period is approximately 2 weeks.
9745552|NCT00345371|Placebo Comparator|Placebo Oral Tablet|After randomization subjects will receive topiramate matched placebo (in tablet form), up to 200 mg/day for 13 weeks.
9745553|NCT00345384|Placebo Comparator|Normal Saline|One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
9745554|NCT00345384|Active Comparator|Dexmedetomidine|The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
9745555|NCT00345397|Experimental|Subjects Receiving PEC Tube|Percutaneous Endoscopic Colostomy Tube (PEC) Placement
9745556|NCT00345540|Experimental|NOV-002 plus Carboplatin|NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles.
9745557|NCT00345579|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
9745558|NCT00345579|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
10201293|NCT04038580|Experimental|Adjustable Sockets|In this condition, participants will be fitted with 3 different adjustable transfemoral sockets by a certified prosthetist. The order in which the sockets are fitted are randomized and the participant will spend approximately 4 weeks in each socket.
10201294|NCT04034381||Port-au-Prince metropolitan area|
9745559|NCT00345592|Experimental|Device managed arm|Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
9745560|NCT00345592|Active Comparator|Traditional arm|Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.
9745561|NCT00345605|Experimental|HDA|"High Dose Arm~Wash-out then 7 days of:~Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA"
10201295|NCT04034381||Other urban areas|
9745562|NCT00345605|Experimental|LDA|"Low Dose Arm~Wash-out followed by 7 days of:~Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA"
9745563|NCT00345631|Active Comparator|Manual Compression|Manual compression (MC)
9745564|NCT00345631|Experimental|Vascular Closure Device|Vascular Closure Device (VCD)
9745565|NCT00345683|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and a fourth dose of Menhibrix vaccine at 12-15 months of age in this study (study Month 10-13). Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
9745566|NCT00345683|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in this study (study Month 10-13). ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
9745567|NCT00345839|Experimental|Cinacalcet|
9745568|NCT00345839|Placebo Comparator|Placebo|
9745569|NCT00345865|Experimental|NHL with irradiation|Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
10201296|NCT04034381||Rural areas|
9745570|NCT00345865|Experimental|HL without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
9745571|NCT00345865|Experimental|NHL - HIV infected with irradiation|Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
9745572|NCT00345865|Experimental|NHL - HIV infected without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
9745573|NCT00345865|Experimental|NHL without radiation and cyclosporine|Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
9745574|NCT00345878|Experimental|Cervarix Group|Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.
10201297|NCT04021485|Other|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~Standardized neurological exam~Morphometric measurements including height, weight, head circumference~Blood pressure measurement~Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~Social Relativeness, using Social Relativeness Scale parental questionnaire,~Parental stress using PSI questionnaire"
10201298|NCT04020809|Experimental|Atezolizumab|Atezolizumab will be administered as 1200 mg intravenously on Day 1 every 3 weeks for 2 cycles.
9828184|NCT02484859|Active Comparator|tramadol + metoprolol|Just before the induction of anaesthesia, an intravenous infusion of 1 mg/kg of tramadol in 100 ml isotonic fluid will be started. The infusion will be completed in 30 minutes using a perfusor. Additionally, following the administration of the neuromuscular blocking agent, 0.1 mg/kg of intravenous metoprolol will be administered within 5 minutes.
9828185|NCT02484898||SEEQ™ MCT/ECM System|SEEQ™ MCT/ECM monitoring for the detection of non-lethal cardiac arrhythmias.
10201299|NCT04007796|Experimental|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
9828186|NCT02484911|Experimental|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
9828187|NCT02484911|Other|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
9828188|NCT02485158|Experimental|AMP, ALC, THC or Placebo 1|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
9828189|NCT02485158|Experimental|AMP, ALC, THC or Placebo 2|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
9828190|NCT02485301|Experimental|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
9828191|NCT02485301|Placebo Comparator|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
9828192|NCT02485353|Other|Vosaroxin and Cytarabine|
9828193|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 [12 ± 2 weeks]) with a 10-14 week interval between assessments.
9828194|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
9828195|NCT02485561|Active Comparator|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the Centers for Disease Control and Prevention Screen for Life campaign.
9828196|NCT02485561|Experimental|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
9828197|NCT02485561|Experimental|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
9828198|NCT02485704|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
9828199|NCT02485704|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
9828200|NCT02485717|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
9828201|NCT02485717|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
9983942|NCT04536480|Experimental|Control: 12 hour eating period|Control: Habitual daily eating period (no meal time restrictions)
9983943|NCT04536480|Experimental|Time Limited Eating|Time Limited Eating: 8-hour eating period (16 hours of daily fasting).
10201300|NCT04007796|Active Comparator|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
10201301|NCT04005209|Active Comparator|Pain management without ketamine infusion|Pain management without ketamine infusion. No other restrictions on pain management or medications.
10201302|NCT04005209|Experimental|Pain management with ketamine infusion|Pain management that includes a ketamine infusion. No other restrictions on pain management or medications.
10201303|NCT03961789||cohorte 1|patients undergoing opioid replacement therapy
10201304|NCT03953859||Gamete donors|healthy male and female game donors to undergo routine gamete donation process
10201305|NCT03953859||Infertile Couple|Couples undergoing routine IVF to treat their infertility
10201306|NCT03951870|Experimental|Mesolimbic Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects will participate in four fMRI-NF sessions, up-regulating activation of three mesolimbic reward nodes:~ventral tegmental area, and bilateral ventral striatum. ROIs are 5 mm spheres around peak activations in funcitonal localizer task (Monetary Incentive delay, reward anticipation contrast), within a predifned meta-analytic anatomical masks of the three regions.~anatomical masks: VTA (Midbrain): -4 -24 -10 Right Nac: 12 10 -4 Left Nac: -10 10 -6 Oldham, Stuart, et al. Human brain mapping (2018).~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
10201307|NCT03951870|Active Comparator|Control Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects will participate in four fMRI-NF sessions, up-regulating activation of regions comprising one of 4 control networks (5mm spheres around MNI coordinates):~Motor Imagery (Hétu, Sébastien, et al. Neurosci. & Biobehav Rev (2013)) R. Cerebellum: 32 -62 -28 L. Cerebellum: -32 -56 -30 L. Precentral Gyrus: -26 -2 58; Auditory imagery (McNorgan, Chris.Front in Human Neurosci 6 (2012)) R STG:64 -30 9 L IFG:-48 24 -5 L precentral Gyrus: -52 1 47; Arithmetic processing (Arsalidou, Marie, and Margot J. Taylor. Nuroimage (2011)) R. SPL: 29 -66 49 L. MFG (dlpfc): -45 32 29 L. precuneus: -28 -71 33; Spatial Navigation (Kühn, Simone, and Jürgen Gallinat. Human Brain Map. (2014)) R. hippocampus 26 -35 -11 L. hippocampus -26 -47 -9 L. Post. cingulate -15 -59 19~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
9828202|NCT02485834|Active Comparator|Arm A - surgery, chemotherapy and radiation therapy|Patients undergo surgery within 42 days of completion of pre-registration chemotherapy. Beginning within 49 days of surgery, patients receive 5-FU IV continuously and capecitabine PO BID on days 1-7, and undergo 3D-CRT or IMRT QD on days 1-5. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
9828203|NCT02485834|Experimental|Arm B - surgery, chemotherapy and FDG-PET|Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
9828204|NCT02485912|Active Comparator|Group 1|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. Both vaccinations are administered in the same arm.
9828205|NCT02485912|Active Comparator|Group 2|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.
9828206|NCT02485925|Experimental|Treatment group|THERMOCOOL® SMARTTOUCH™
9828207|NCT02485964|Other|Blood Draw Only|One time blood draw at time of consent; No treatment
9828208|NCT02486016|Experimental|Duragesic Reference Fentanyl TDS|Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
9828209|NCT02486016|Active Comparator|Apotex Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
9828210|NCT02486016|Active Comparator|Mylan Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
9828211|NCT02486211|Placebo Comparator|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
9828212|NCT02486211|Experimental|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
9828213|NCT02486263|Experimental|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
9828214|NCT02486263|Other|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
9828215|NCT02486302||Observation Group|
9828216|NCT02486328|Other|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
9828217|NCT02486328|Other|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
9828218|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 1|Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.
9828219|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 2|Participants with HCV GT1b received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT1a with compensated cirrhosis received 24-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT4 received 12-week treatment with the OBV/PTV/RTV formulation and ribavirin 200 mg tablets were administered orally per local label.
9828220|NCT02486406|Experimental|Mini tablet, 9-11 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
9828221|NCT02486406|Experimental|Mini tablet, 3-8 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
9984698|NCT03815370|Experimental|Device: ABRO™Binder Arm|Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
9745575|NCT00345878|Placebo Comparator|Placebo Group|Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.
9745576|NCT00345969|Active Comparator|Transdermal Testosterone gel (1%)|Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
9745577|NCT00345969|Placebo Comparator|Placebo gel|Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
9745578|NCT00346034|Experimental|1|
9745579|NCT00346073|Experimental|Boostrix Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
9745580|NCT00346073|Experimental|Adacel Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
9745581|NCT00346151|Experimental|Belatacept|Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.
9983944|NCT04535349|Other|No cardiac ATTR amyloidosis|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up."
9983945|NCT04535349|Other|Cardiac ATTR amyloidosis, no treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned.~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
9983946|NCT04535349|Other|Cardiac ATTR amyloidosis, treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis.~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
9984699|NCT03814850|Experimental|Treatment group: standard blood pressure cuff|A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.
9745586|NCT00346216|Experimental|celecoxib|subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
9745587|NCT00346216|Active Comparator|ibuprofen|subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
9745588|NCT00346216|Active Comparator|naproxen|subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
9745589|NCT00346268|Active Comparator|Morphine plus Parecoxib|
9745590|NCT00346268|Active Comparator|Morphine and Placebo|
9745591|NCT00346333|Experimental|Lutein plus 15,000 IU/d Vitamin A|Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
9745592|NCT00346333|Placebo Comparator|Control plus 15,000 IU/d Vitamin A|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
9745593|NCT00346398|Experimental|Oral mucosal immunoprophylaxis (OMIP)|Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
9745594|NCT00346398|Placebo Comparator|Placebo|Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
9745595|NCT00346476||Participants|Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
9745596|NCT00346632|Experimental|KW-2449|Treatment with ascending doses of KW-2449
9745597|NCT00346697|Experimental|LOVAZA|4 g/d of omega-3 fatty acid esters, plus dietary counseling
9745598|NCT00346697|Placebo Comparator|Placebo|Corn oil placebo, plus dietary counselling
9745599|NCT00346905|Experimental|Single Arm|Those receiving Enteryx treatment
9745600|NCT00347009|Other|Adefovir Dipivoxil|10mg once daily in patients with CHB related advanced fibrosis/cirrhosis.
9745601|NCT00347022|Experimental|Xenetix|The patient receive one injection of Xenetix 300 (300 mg of iodine/ml)
9745602|NCT00347022|Active Comparator|Visipaque|The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)
9745603|NCT00347269|Experimental|CALM Intervention|"Participant choice of:~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization"
9745604|NCT00347269|Active Comparator|Treatment as Usual (TAU)|Participants assigned to TAU with their primary care provider (PCP)
9745605|NCT00347360|Experimental|lisinopril|lisinopril
9745606|NCT00347360|Experimental|carvedilol|carvedilol controlled release formulation
9745607|NCT00347438|Experimental|Capecitabine|Capecitabine will be given at 1000mg/m2 twice daily for 2 weeks x 8 cycles, with a one-week pause in-between cycles.
9745608|NCT00347776|Active Comparator|Control|topical tetracycline
9745609|NCT00347776|Active Comparator|Intervention 1|oral azithromycin, single 1g dose to subject
9745610|NCT00347776|Active Comparator|Intervention 2|single oral azithromycin dose to subject and immediate family members
9745611|NCT00347919|Experimental|monotherapy arm|1500 mg (6 x 250 mg tablets) oral lapatinib once daily
9745612|NCT00347919|Experimental|Cohort 1 combination arm|1000 mg (4 x 250 mg tablets) of oral lapatinib and 400 mg (4 x 100 mg tablets) of oral pazopanib taken together once daily
9745613|NCT00347919|Experimental|Cohort 2 combination arm|1500 mg (6 x 250 mg tablets) of oral lapatinib and 800 mg (1 x 500 mg tablets plus 3 x 100 mg tablets) of oral pazopanib taken together once daily
9745614|NCT00347932|Experimental|ISV-403|0.6% ISV-403 ophthalmic suspension
9745615|NCT00347932|Placebo Comparator|Vehicle|Vehicle of ISV-403 ophthalmic suspension
9745616|NCT00347958|Experimental|Adacel vaccine group|Participants 15 to 69 years of age who received a dose of Adacel vaccine in one of three previous studies (Td501, or Td502, or Td505), revaccinated in Study Td518.
9745617|NCT00348140|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
9983947|NCT04534686|Experimental|CogXergaming|CogXergaming based cognitive-motor balance training will be delivered to group A using the commercially available Wii-Fit Nintendo and a mouse in conjunction with cognitive training. All participants will undergo 18 sessions of training in a tapering manner for six weeks with 60-90 minutes of training per session, i.e., 3 sessions each week till the 6th week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 to 6 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
9745618|NCT00348140|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
9745619|NCT00348140|Placebo Comparator|Arm 3|Placebo
9745620|NCT00348205|Experimental|Technolas 217z Zyoptix System|Bausch & Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software.
9745621|NCT00348283|Placebo Comparator|Double Blind|Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
9745622|NCT00348283|Other|Open Label|Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
9745623|NCT00348309|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
9745624|NCT00348309|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
9745625|NCT00348309|Placebo Comparator|Arm 3|Placebo
9745626|NCT00348348|Active Comparator|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5%
9745627|NCT00348348|Experimental|Besifloxacin Suspension|Besifloxacin hydrochloride ophthalmic suspension 0.6%
9745628|NCT00348374|Active Comparator|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
9745629|NCT00348374|Experimental|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
9745630|NCT00348595|Active Comparator|1|5mg/day Arm: one 5 mg active Revlimid capsule and one 25 mg matched placebo capsules PO QAM (every morning) (at approximately the same time) days 1-21 days (28-day cycles).
9745631|NCT00348595|Active Comparator|2|25 mg/day Arm: one 25 mg active Revlimid capsule and one 5 mg matched placebo capsule PO QAM (every morning) (at approximately the same time) days 1-21 (28 day cycles).
9745632|NCT00348673|Experimental|Stage 1|
9745633|NCT00348673|Experimental|Stage 2|
9785369|NCT01250184|Experimental|Lidocaine injection + physical therapy|Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
9983948|NCT04534686|Experimental|Matter of Balance Training|Participants in group B will undergo matter of balance training for 8 weeks (one session a week for 2 hours/day).
9828222|NCT02486588|No Intervention|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
9828223|NCT02486588|Experimental|General Weekly Message|10% cash back, general weekly message, standard monthly message
9828224|NCT02486588|Experimental|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
9828225|NCT02486588|Experimental|25 percent cash back|25% cash back, personal weekly message, standard monthly message
9828226|NCT02486588|Experimental|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
9828227|NCT02486588|Experimental|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
10201308|NCT03951870|Other|Natural history|"No brain manipulation (Assesment of natural history immune response).~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
10201309|NCT03945240|Experimental|Group 1 (Pinnacle, lower dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
9828228|NCT02486627|Experimental|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
9828229|NCT02486627|Active Comparator|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
9828230|NCT02486653|Experimental|Tamsulosin|
9828231|NCT02486653|Placebo Comparator|Placebo|
9828232|NCT02486692|Experimental|Phase II- Experimental Group|Participants were provided with instructions and a web link for accessing the AboutFace website after the baseline assessment.
9828233|NCT02486692|No Intervention|Phase II- Usual Care Group|Participants were provided with instructions and a web link for accessing some online PTSD education materials after the baseline assessment.
9828234|NCT02486757|Experimental|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
9828235|NCT02486796|Active Comparator|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
9828236|NCT02486796|Active Comparator|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
9828237|NCT02486939|Experimental|CHS-0214|CHS-0214 50 mg weekly
9828238|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
9828239|NCT02487030|Experimental|LDV/SOF 8 wk TN (Cohort 1, Group 1)|LDV/SOF for 8 weeks (treatment-naive (TN))
9828240|NCT02487030|Experimental|LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)|LDV/SOF+RBV for 8 weeks (treatment-naive)
9828241|NCT02487030|Experimental|LDV/SOF 12 wk TN (Cohort 1, Group 3)|LDV/SOF for 12 weeks (treatment-naive)
9828242|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)|LDV/SOF+RBV for 12 weeks (treatment-naive)
9828243|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 2)|Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
9828244|NCT02487030|Experimental|LDV/SOF 12 wk TE (Cohort 3, Group 1)|LDV/SOF for 12 weeks (treatment-experienced)
9828245|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)|LDV/SOF+RBV for 12 weeks (treatment-experienced)
9828246|NCT02487199|Experimental|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
9828247|NCT02487199|Experimental|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) for 12 weeks.
9828248|NCT02487225|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
9828249|NCT02487225|Placebo Comparator|Placebo|Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
9828250|NCT02487303|Active Comparator|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
9828251|NCT02487303|Active Comparator|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
9828252|NCT02487303|No Intervention|No acetaminophen|(group 3) no acetaminophen
9828253|NCT02487446|Experimental|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
9828254|NCT02487446|Experimental|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
9828255|NCT02487472||HZ cohort|All patients ≥ 50 years old with a HZ diagnosis (as the primary diagnoses and no earlier case of HZ) during approximately 6 months inclusion period will be included in the HZ cohort, until total study target is achieved.
9828256|NCT02487485|Experimental|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
10201310|NCT03945240|Experimental|Group 2 (Pinnacle, higher dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
9745634|NCT00348686|Experimental|Candesartan|Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.
9745635|NCT00348790|Experimental|Vatalanib|"Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.~Patients who are responding may remain on study treatment for 12 months."
9745636|NCT00348816|Experimental|Docetaxel (Single Arm)|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Prednisone 5mg twice a day Radical prostatectomy as standard of care Radiation therapy will be used as standard of care Post radiation Doxcetaxel
9745637|NCT00348881|Experimental|Group 1: DTaP-Hep B-PRP-T + OPV vaccine|Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
9745638|NCT00348881|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
9745639|NCT00348933|Experimental|1|Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.
9745640|NCT00348946|Active Comparator|Oxandrolone|Androgen oxandrolone: Oxandrolone, 0.6 > mg/kg/day, orally, for 2 years.
9745641|NCT00348946|Placebo Comparator|Placebo|An inactive substance.
9782025|NCT01163747|Experimental|Tocilizumab + Methotrexate|Participants received 8 mg/kg tocilizumab intravenously at Baseline (Day 1) and every 4 weeks up to Week 20, in addition to their standard dose of methotrexate. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
9782026|NCT01163760|Other|etafilcon A / ocufilcon D|etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable
9782027|NCT01163760|Other|oculfilcon D / etafilcon A|ocufilcon D contact lens worn first, etafilcon A contact lens worn second
9782028|NCT01163760|Other|ocufilcon D / ocufilcon D|ocufilcon D contact lens worn first and second
9782029|NCT01163760|Other|etafilcon A / etafilcon A|etafilcon A contact lens worn first and second
9782030|NCT01163786|Experimental|Bortezomib|Patients will Receive 2 4week cycles of Bortezomib. Each cycle will consist of weekly bortezomib with a 2 week interval between cycles.
9785370|NCT01250210|Experimental|AG200-15|Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
9785371|NCT01250210|Experimental|AG200|Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
9785372|NCT01250210|Experimental|AG200LE|Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
9785373|NCT01250379|Active Comparator|1|
9785374|NCT01250379|Experimental|2|
9785375|NCT01250418|Active Comparator|Ketamine Group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
9785376|NCT01250418|No Intervention|No ketamine|No ketamine added to anesthesia regimen
9785377|NCT01250509|Experimental|CALMM|Participants receiving the 'Craving and Lifestyle Management through Mindfulness' intervention, i.e. program that combines stress reduction with mindful eating practices.
9785378|NCT01250509|No Intervention|Waitlist Control|Participants were waitlisted for the intervention during the experimental phase.
9785379|NCT01250717|Experimental|Docetaxel Followed by Radical Prostatectomy|Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy
9785380|NCT01250730|Experimental|1.0|This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
9785381|NCT01250756|Experimental|1|Experimental
9785382|NCT01250756|Experimental|2|Active comparator
9785383|NCT01250769|Active Comparator|Manual Toothbrush 1|Manual Toothbrush used for 1 minute twice a day
9785384|NCT01250769|Active Comparator|Manual Toothbrush 2|Manual Toothbrush used for 2 minutes twice a day
9785385|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 1|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used once a day
9785386|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 2|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used twice a day
9785387|NCT01250834|Experimental|LY2189265 + Atorvastatin|"Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2.~Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3."
9785388|NCT01250873|Experimental|LY2216684/sertraline/LY2216684 + sertraline|"Period 1: LY2216684 18 milligram (mg) oral (po) dose on Days 1-3.~Period 2: Sertraline 50 mg po dose on Day 4 followed by sertraline 100 mg po dose on Days 5-10.~Period 3: LY2216684 18 mg po dose + sertraline 100 mg po dose on Days 11-13."
9785389|NCT01250899|No Intervention|Vitamin D Sufficient|HIV-infected men and women with HIV-1 viral load <200 copies/mL on stable ART and 25(OH)D level ≥30ng/mL receive no intervention.
9785390|NCT01250899|Experimental|Vitamin D Insufficient|HIV-infected men and women with HIV-1 viral load <200 copies /mL on stable ART and 25(OH)D level <30ng/mL receive 50,000 IU twice weekly for 5 weeks followed by 2000 IU daily to complete 12 weeks.
9785391|NCT01250925|Active Comparator|OPTI-FREE® RepleniSH®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
9785392|NCT01250925|Active Comparator|Clear Care®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
9785393|NCT01250925|Active Comparator|ReNu MultiPlus® MultiPurpose Solution|33 participants will be assigned to use this lens care regimen during the six-week assessment period
9785394|NCT01250977|Placebo Comparator|Placebo|Participants are instructed to take one placebo pill every night before going to bed with a glass of water for 28 days.
9745642|NCT00349336|Experimental|1|
9745643|NCT00349336|Experimental|2|
9745644|NCT00349349|Experimental|ofatumumab|Anti-CD20 antibody therapy
9745645|NCT00349388|Experimental|Asacol once a day dosing|Asacol total dose in mg/kg given once a day
9745646|NCT00349388|Active Comparator|Asacol BID/TID dosing|Asacol total dose split BID or TID
9745647|NCT00349466|Experimental|1|CF101 1 mg given orally every 12 hours for 12 weeks
9745648|NCT00349466|Placebo Comparator|2|Placebo given orally every 12 hours for 12 weeks
9745649|NCT00349622|Active Comparator|Ceftriaxone|"Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day."
9745650|NCT00349622|Placebo Comparator|Placebo|"One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day."
10201311|NCT03945240|Experimental|Group 3 (Phoenix)|Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply LLT.
10201312|NCT03945175|Experimental|Treatment|During the first two week lead-in, if the subject has a ≥30% decrease in the AISRS, they will not move into the 4-week treatment period of the study.
9745651|NCT00349713|Experimental|Cohort 1: 25ug FMP2.1 / AS02A|20 subject to receive 25ug of FMP2.1 vaccine in 0.25mL of GSK Biologicals' adjuvant AS02A
10201313|NCT03938194|Experimental|Aquablation|Surgery of benign prostatic hyperplasia by waterjet ablation
9745652|NCT00349713|Experimental|Cohort 2: 50ug FMP2.1 / AS02A|20 subjects to receive 50ug of FMP2.1 vaccine in 0.5mL of GSK Biologicals' adjuvant AS02A
9745653|NCT00349713|Active Comparator|Cohorts 1 and 2: Rabies vaccine (RabAvert)|"20 subjects to receive Rabies vaccine (RabAvert). 10 subjects from Cohort 1 and 10 subjects from Cohort 2~Rabies vaccine (RabAvert): RabAvert Rabies vaccine"
9745654|NCT00349752|Experimental|Certolizumab pegol 400 mg|Certolizumab pegol 400 mg
9745655|NCT00349752|Placebo Comparator|Placebo|Placebo
9745656|NCT00349778|Experimental|High-Dose Sequential Therapy|Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim
9745657|NCT00349908|Experimental|Group 1: Atherosclerosis Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
9745658|NCT00349908|Active Comparator|Group 2: Aneurysm Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
9745659|NCT00349921|Active Comparator|clonidine first, then adenosine|clonidine given in first injection adenosine given in second injection
9745660|NCT00349921|Active Comparator|adenosine first, then clonidine|adenosine given in first injection clonidine given in second injection
9745661|NCT00349921|Placebo Comparator|clonidine given first, then placebo|placebo
9745662|NCT00349921|Placebo Comparator|adenosine given first, then placebo|placebo
9745663|NCT00349973|Experimental|1|Dipyridamole
10201314|NCT03912064|Experimental|CD25/Treg-depleted DLI + Ipilimumab|"Ipilimumab is administered intravenously every 12 weeks~Patients will receive a defined dose of CD25hi Treg depleted DLI intravenoudsly"
10201315|NCT03911778||Sacrospinofixation|Patients with apical symptomatic prolapse ≥ II in the POP-Q classification and for whom sacrospinofixation with posterior isthmic BSC Mesh is planned
10201316|NCT03894540|Experimental|IPN60090|"Part 1: Dose escalation of IPN60090, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle"
10201317|NCT03894540|Experimental|IPN60090 in combination with pembrolizumab|"Part 1: Dose escalation of IPN60090 in combination with pembrolizumab, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose, starting with pharmacologically active dose identified in 1dose escalation of IPN60090 as a single agent, over a 21-day cycle in combination with 200 mg pembrolizumab given every 21 days (Day 1 of every cycle) as IV infusion"
10201318|NCT03894540|Experimental|IPN60090 in combination with paclitaxel|"Part 1: Dose escalation of IPN60090 in combination with paclitaxel, Part 2: Dose expansion~IPN60090 given as a BID oral dose, starting with pharmacologically active dose identified in dose escalation of IPN60090 as a single agent over a 21-day cycle in combination with 175 mg/m2 or 135 mg/m2 paclitaxel given every 21 days (Day 1 of every cycle) as IV infusion"
10201319|NCT03894540|Experimental|IPN60090 food effect|"Part 1: Food Effect of IPN60090~IPN60090 given as a single oral dose as a single agent at the recommended dose (RD) under fasting and fed conditions followed by IPN60090 given as a BID oral dose administered at the RD over a 21-day cycle."
10201320|NCT03892746|Active Comparator|Active tDCS + task oriented practice|
10201321|NCT03892746|Sham Comparator|Sham tDCS + task oriented practice|
10201322|NCT03886519|Active Comparator|BRAP (Bevel/rotate/advance procedure)|The BRAP procedure is a full-thickness beveled full-thickness incision
10201323|NCT03886519|Active Comparator|Trabut 3 mm|The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.
10201324|NCT03873675||Study group|Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.
10201325|NCT03863769||Lumbar Spinal Stenosis|Questionnaire, chiropractic treatment, and posture and performance testing.
10201326|NCT03828825|Experimental|Patent Foramen Ovale Closure|The percutaneous closure of Patent Foramen Ovale is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis.
10201327|NCT03826992|Experimental|Venetoclax and Vyxeos combination|"Venetoclax will be given orally on Days 1-21 per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 21 doses of venetoclax will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.~Venetoclax is given daily by mouth per assigned dose level."
10201328|NCT03816202||Sundt Carotid Shunt|Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt.
10201329|NCT03811821|Active Comparator|Biofeedback (BIO)|Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
10201330|NCT03811821|Active Comparator|Injection (INJ)|Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
10201331|NCT03809767|Experimental|CS1003 monoclonal antibody|
10201332|NCT03809247||Pancreatic cancer|such as Pancreatic ductal adenocarcinoma, Pancreatic acinar adenocarcinoma, and so on.
10201333|NCT03809247||Other pancreatic diseases|such as chronic pancreatitis, Intraductal papillary mucinous neoplasm (IPMN); Solid pseudopapillary tumors (SPT); Serous cystic neoplasm (SCN); Pancreatic neuroendocrine neoplasm (P-NN); Mucinous cystic neoplasm (MCN) and so on.
10201334|NCT03803280||Traditional care|Patients with major abdominal surgery without before a enhanced recovery program was stablished
10201335|NCT03803280||ERAS care|Patients with major abdominal surgery within a enhanced recovery program was stablished
10201336|NCT03785561||Exposed (intervention) group|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital.
10201337|NCT03785561||Unexposed (comparator) group|The unexposed group is defined as patients, diagnosed with a musculoskeletal disorder receiving standard clinical care at the outpatient osteoarthritis clinic at Bispebjerg and Frederiksberg Hospital. They are not currently enrolled in a health research study concerning their musculoskeletal disorder at Bispebjerg and Frederiksberg Hospital
9745664|NCT00349973|Active Comparator|2|Olanzapine
9745665|NCT00350025|Other|Cetuximab alone|Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy
10201338|NCT03775785|Experimental|tailored enteral nutrition|Tailored Human milk fortification procedure Tailored milk fortification will be done twice a day (8 am and 8 pm) for each following 12 hour nursing shift. Standard fortification will be added first. The remainder amount of protein, lipids and carbohydrates required to meet the recommended by ESPGHAN doses will be acheived by adding single ingrediant nutrients.
10201339|NCT03775785|No Intervention|standard enteral nutrition|Standard fortification will be added according to the unit protocol.
9745666|NCT00350025|Other|Cetuximab with Paclitaxel|Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.
9745667|NCT00350142|Experimental|Stereotactic Body Radiotherapy|Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.
9745668|NCT00350220|Active Comparator|1|High Hemoglobin group; goal Hb >13g/dl. 10cc/kg RBCs are transfused for any hemoglobin value under 13g/dl regardless whether clinical indication for transfusion exists.
10201340|NCT03760419|Active Comparator|Intervention Arm|Effectiveness of the EHR-based antibiotic decision support application for promoting guideline-concordant antibiotic prescribing in children presenting for emergency care will be evaluated in a pragmatic, cluster randomized crossover study conducted over a period of 18 months that includes two respiratory seasons. The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive standard of care management. All treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
10201341|NCT03760419|No Intervention|Control Arm|The investigator will conduct a randomized controlled trial comparing a prognostic tool (intervention arm) to usual care (control arm) over a period of 24 months. Randomization will occur at the patient level. Allocation to intervention or control will be based on medical record number (even vs. odd) and will be assigned automatically once a provider confirms the diagnosis of pneumonia via the radiology alert tool. All standard of care treatment options will be available and decision-making will not be restricted in any way in either group.
10201342|NCT03758417|Experimental|LCAR-B38M Chimeric Antigen Receptor T Cell|"Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).~In addition, participants will enroll in additional cohort to further characterize the safety profile and accumulate efficacy data of LCAR-B38M CAR-T cells."
10201343|NCT03751553|Experimental|obstetric gel group|they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel.
10201344|NCT03751553|No Intervention|no intervention group|they will receive the standard care during labor and delivery without the use of the obstetrical gel
10201345|NCT03742167|Experimental|Telemedicine|The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician.
9745669|NCT00350220|Active Comparator|2|Low Hb transfusion group; goal to not transfuse unless the Hb <9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
9745670|NCT00350272|Experimental|Elvucitabine, Efavirenz,Tenofovir|"Elvucitabine (blinded) 10 mg/day in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
9782031|NCT01163851|Experimental|PF-04950615 (RN316)|
10201346|NCT03742167|No Intervention|Control|The control arm will receive pediatric medical control physician consultation via telephone.
10201347|NCT03740529|Experimental|Phase I Dose Escalation (Pirtobrutinib Monotherapy)|Dose Escalation and determination of MTD; multiple dose levels of pirtobrutinib to be evaluated
9828257|NCT02487485|Placebo Comparator|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
9828258|NCT02487498|Experimental|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
9828259|NCT02487498|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
9828260|NCT02487563|Experimental|Experimental Group 1|Decitabine in combination with rhTPO.
9828261|NCT02487563|Experimental|Experimental Group 2|Decitabine
9828262|NCT02487563|Active Comparator|Control Group|Conventional treatment except decitabine.
9828263|NCT02487771|Placebo Comparator|Placebo Capsule|
9828264|NCT02487771|Experimental|DHA Capsule|
9828265|NCT02487810|Experimental|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
9828266|NCT02487810|Experimental|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
9828267|NCT02487966|Experimental|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
9828268|NCT02487966|Experimental|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
9828269|NCT02487966|Experimental|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
9828270|NCT02487966|Sham Comparator|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
9828271|NCT02488005|Experimental|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
9828272|NCT02488018|Experimental|Provision of experimental honeys|Eight experimental monofloral honeys and reference glucose
9828273|NCT02488070|Experimental|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
9828274|NCT02488109|Active Comparator|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
9828275|NCT02488109|Active Comparator|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
9828276|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
9828277|NCT02488317|Other|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
9828278|NCT02488317|No Intervention|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
9835761|NCT02753842|Experimental|Standard, Then Fitted, Then Thin Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
9745671|NCT00350272|Active Comparator|Lamivudine,Efavirenz,Tenofovir|"Lamivudine (blinded) 300 mg daily in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
9745672|NCT00350298|Experimental|GS-CDA1/MDX-1388|Biological: GS-CDA1/MDX-1388 One Intravenous dose
9745673|NCT00350298|Placebo Comparator|Placebo|Biological: normal saline (0.9% sodium chloride) One Intravenous dose
9745674|NCT00350337|Experimental|Pre-transfection F17|"4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine"
9745675|NCT00350337|Experimental|Post-transfection F17|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
9745676|NCT00350337|Experimental|Post-transfection F19|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
9745677|NCT00350337|Placebo Comparator|Placebo|A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine.
9745678|NCT00350363|Active Comparator|1 hour gatifloxacin|presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
9745679|NCT00350402|Active Comparator|High Intensity Muscle Strength Training|This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
9745680|NCT00350402|Sham Comparator|Sham MST|This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.
9745681|NCT00350519|Experimental|PROCRIT (epoetin alfa)|Participants will receive PROCRIT (epoetin alfa).
9745682|NCT00350519|Experimental|STANDARD THERAPY|Participants will receive standard of care.
9745683|NCT00350532|Active Comparator|Neuropathic Pain Subjects|Chronic Pain Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
9745684|NCT00350532|Active Comparator|Healthy Subjects|Healthy Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
9745685|NCT00350545|Experimental|rituximab + prednisone arm|Rituximab will be given as an IV fusion as initial treatment, followed by predisone (given during registration) which will be continued through-out trial and tapered off by physician. Cyclosporine A and tacrolimus will be used if chances of new diagnosis of chronic GVHD occur. Both drugs have no interaction with Rituxan, but will be tapered off after predisone is completely tapered.
9745686|NCT00350636|Experimental|Oxybutynin topical gel|Oxybutynin topical gel
9745687|NCT00350636|Placebo Comparator|Placebo topical gel|placebo topical gel
9745688|NCT00350727|Experimental|Combination|Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.
9745689|NCT00350779|Experimental|1|Sitagliptin
9745690|NCT00350779|Placebo Comparator|2|Placebo
9745691|NCT00350792|Experimental|Pemetrexed + Carboplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles.~Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."
10201348|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 3|CLL/SLL patients with no prior therapy.
10201349|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 1|Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
9745692|NCT00350870|Placebo Comparator|Placebo|Placebo (plus Cognitive Behavioral Therapy- CBT)
9745693|NCT00350870|Active Comparator|Disulfiram|Disulfiram (plus CBT)
9745694|NCT00350870|Placebo Comparator|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
9745695|NCT00350870|Active Comparator|Disulfiram plus Contingency Management|Disulfiram plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
9745696|NCT00351039|Experimental|Bevacizumab, Erlotinib, Pemetrexed|Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer
9745697|NCT00351273|Active Comparator|Azithromycin and Rifampin|Participants received Azithromycin and Rifampin
9745698|NCT00351273|Active Comparator|Doxycycline and Rifampin|Participants received Doxycycline and Rifampin
9745699|NCT00351273|Placebo Comparator|received placebo|Participants received placebo
9745700|NCT00351299|Experimental|Infusion of dexmedetomidine|infusion 0.3-0.7 dexmedetomidine
9745701|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
9745702|NCT00351351|Experimental|A|Cyberwand
9745703|NCT00351351|Active Comparator|B|Currently available lithotripsy technology
9745704|NCT00351377|Experimental|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.
9745705|NCT00351416|Experimental|Aromatase inhibitor EFP|"Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
9745706|NCT00351416|Experimental|Aromatase inhibitor LFP|"Letrozole administration (20 mg daily x 2) at follicle size of > 16 mm (LFP; late follicular phase) in cycle 2.~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
9745707|NCT00351468|Experimental|Eltrombopag|Open-label eltrombopag
9745708|NCT00351533|Experimental|1|Enteral fish oil
9745709|NCT00351533|Placebo Comparator|2|Enteral saline
9745710|NCT00351611|Experimental|Active|Active drug
10201350|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 4|CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
10201351|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 2|CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
10201352|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 5|WM patients treated with a prior BTK inhibitor-containing regimen.
10201353|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 6|MZL patients treated with a prior BTK inhibitor-containing regimen.
10201354|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 7|Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded. MCL without prior BTK inhibitor treatment is excluded. Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.
10201355|NCT03740529|Experimental|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax
9745711|NCT00351611|Placebo Comparator|Placebo|placebo comparator
9745712|NCT00351741|Experimental|High Frequency|Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation
9745713|NCT00351741|Active Comparator|Conventional|Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation
9745714|NCT00351819|Active Comparator|Androgel (testosterone gel)|Testosterone replacement therapy
9745715|NCT00351819|Placebo Comparator|Placebo|Placebo gel
9745716|NCT00351936|Active Comparator|Aripiprazole|aripiprazole 15mg/day
9745717|NCT00351936|Placebo Comparator|placebo|matched placebo for aripiprazole 15mg/day
9745718|NCT00352001|Experimental|Lenalidomide and Azacitidine|
9745719|NCT00352027|Experimental|All Participants|Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
9745720|NCT00352053|Experimental|OBR + Tenofovir DF|Tenofovir DF administered orally, one tablet daily without regard to meals
9745721|NCT00352053|Placebo Comparator|OBR + Tenofovir DF Placebo|Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
9745722|NCT00352105|Experimental|Concurrent Chemotherapy and ZD1839|
9782032|NCT01163916||Patients with RA, PsA and AS|Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) prescribed adalimumab as part of Routine Clinical Care in Russia.
9782033|NCT01163955|Other|Sitting in a chair|Sitting in a chair with back support and feet flat on the ground
9782034|NCT01163955|Other|Sitting on the Floor|Sitting on the floor without back support, crossed leg style
9782035|NCT01164007|Experimental|Dacarbazine + Bevacizumab|Participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease will receive dacarbazine and bevacizumab until disease progression, unacceptable toxicity, participant withdrawal, or physician decision to discontinue.
9782036|NCT01164098|Active Comparator|Rituximab|Participants will receive Rituximab post within 24 of Kidney Transplant
9782037|NCT01164098|No Intervention|No rituximab|Participants will not receive Rituximab within 24 hours of Kidney Transplant
9828279|NCT02488330|Experimental|Control and/or Onartuzumab treatment|Participants will receive treatment with either the control treatment (erlotinib, bevacizumab) and/or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first). All participants will continue on the same dose and schedule of control treatment as specified in their respective P-trial. The dose of onartuzumab will be calculated based on the participant's weight at the screening visit for the E-trial.
9828280|NCT02488681|Experimental|Micra Pacemaker Implant|Micra Pacemaker Implant
9828281|NCT02488824|Experimental|Warm Temperature Exposure in Tetraplegia|Subjects are persons with higher-level spinal cord injury, levels C3 to T4, and ASIA Impairment Scale (AIS) level A and B, ages 18-68 years. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
9828282|NCT02488824|Active Comparator|Warm Temperature Exposure in Able-Bodied|Subjects are able-bodied controls matched with participants with tetraplegia for age and gender. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
9828283|NCT02488915|Experimental|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
9828284|NCT02488980|Experimental|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
9828285|NCT02488980|Active Comparator|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
9828286|NCT02488980|Placebo Comparator|Placebo|Placebo
9828287|NCT02489045|Experimental|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
9828288|NCT02489110|Experimental|Webnovela|Caregivers will watch the Webnovela and read related information. The Webnovela is a short online Telenovela in Spanish, specifically designed for Hispanic caregivers on how to cope with dementia caregiving. A DVD will be available to participants without Internet access.
9828289|NCT02489110|Active Comparator|Control|Caregivers will be directed to existing web sites, such as NIA Alzheimer's and Dementia Resources in Spanish. Participants will receive related materials in Spanish language.
9828290|NCT02489123|Experimental|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
9828291|NCT02489227|Active Comparator|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
10201356|NCT03740529|Experimental|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
9828292|NCT02489227|Experimental|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
9828293|NCT02489279|Experimental|Active - SAC|Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
9828294|NCT02489279|Active Comparator|Control - Scrabble|"Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions."
9835762|NCT02753842|Experimental|Standard, Then Thin, Then Fitted Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
9835763|NCT02753881|Active Comparator|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
9835764|NCT02753881|Active Comparator|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
9835765|NCT02753920|Active Comparator|Retrograde fill voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via visual analog scale (VAS) scale (however this information will only be used for research purposes).~If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids <200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial."
9835766|NCT02753920|Active Comparator|Force of Stream (FAST) voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via VAS scale.~If VAS scale >/=50 (>/=50%) the catheter will remain out, patient is discharged home without measuring a PVR~If VAS scale is from 0-49 (=0-49%) a PVR will be checked via bladder scan. If PVR is <500cc, the patient will be discharged without a catheter; if PVR is >/=500cc, the patient will be discharged with a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days."
9835767|NCT02753946|Experimental|ZTI-01|6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
9835768|NCT02753946|Active Comparator|piperacillin tazobactam|4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)
9745723|NCT00352365|Experimental|Treatment (lenalidomide)|"INDUCTION THERAPY: Patients receive oral lenalidomide once daily on days 1-14, 1-21, or 1-28 (course 1). Patients undergo bone marrow biopsy on day 28 or 35 to assess treatment efficacy. Patients with stable or improving disease (i.e., a decrease in blast percentage) without progressive disease proceed to maintenance therapy.~MAINTENANCE THERAPY: Beginning within 42 days after completion of induction therapy, patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9745724|NCT00352417|Experimental|VIA-2291|
9745725|NCT00352417|Placebo Comparator|Placebo|Matching Placebo
9745726|NCT00352612|Placebo Comparator|cephalexin|
9745727|NCT00352612|Active Comparator|clindamycin|
9745728|NCT00352664|Active Comparator|Donepezil|Oral Donepezil 5 mg daily x 7 days
9745729|NCT00352664|Placebo Comparator|daily x 7 days|Placebo tablet daily x 7 days
9745730|NCT00352690|Other|Cohort 1 (first 12 eligible patients)|"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
9745731|NCT00352690|Experimental|Cohort 2 (remaining patients)|"Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
9745732|NCT00352755|Experimental|Peritonectomy + IP5FU + FOLFOX|"Surgical debulking with peritonectomy~IP 5FU 600 mg/m^2 over 30-60 minutes with patient rotating every 15 minutes. Repeated every 2 weeks for a total of 9 cycles.~FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy. Oxaliplatin 85 mg/m^2 over 2 hours with leucovorin at 400 mg/m^2 and IV 5-FU at 2400 mg/m^2 over 46 hours. Repeated every 2 weeks for a total of 8 cycles."
9745733|NCT00352781|Experimental|Nicotine Replacement + Behaviour Therapy|Nicotine Replacement Therapy as per monograph & behavioural intervention
9745734|NCT00352794|Experimental|Lenalidomide + Prednisone|Lenalidomide oral 10 mg daily/days 1-21 of 28 day cycle. Prednisone starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
9745735|NCT00352846|Experimental|Vitamin D + Calcium Carbonate|Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
9745736|NCT00352846|Experimental|Vitamin D + Calcium Carbonate + Zoledronic Acid|Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m^2 intravenous at baseline and 6 months.
9745737|NCT00352885|Experimental|Escitalopram|Participants will receive escitalopram and IL-2 treatment
9745738|NCT00352885|Placebo Comparator|Placebo|Participants will receive placebo and IL-2 treatment
9745739|NCT00352911|Active Comparator|VGX-410 (Mifepristone)|150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days
9745740|NCT00352911|Placebo Comparator|Placebo for VGX-410 (Mifepristone)|150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days
9745741|NCT00352976|Experimental|Treatment with TBI|Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.
9745742|NCT00353119|Placebo Comparator|Placebo then etanercept|Patients randomized to initiate the study with placebo for the first 12 weeks - Group 1 then crossed over to etanercept 50mg twice weekly for weeks 12 to 24
9745743|NCT00353119|Active Comparator|Etanercept|Patients randomized to etanercept - Group 2. Patients received etanercept 50 mg subcutaneously twice weekly for 24 weeks
9745744|NCT00353262|Experimental|1|
9745745|NCT00353301|Experimental|Erlotinib and Sirolimus|"Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day.~Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day."
9745746|NCT00353366||Cohort Group|Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
9745747|NCT00353418|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 800 mg|
9745748|NCT00353418|Active Comparator|PEG-IFN Alfa-2a 180 μg + Ribavirin 1000 or 1200 mg|
9745749|NCT00353431|Active Comparator|1|"Conventional insulin group:~In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician."
9745750|NCT00353431|Experimental|2|"Intensive insulin therapy algorithm:~The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake."
9745751|NCT00353496|Experimental|lanreotide (Autogel formulation)|
9745752|NCT00353496|Placebo Comparator|Placebo|
9745753|NCT00353522|Experimental|Dalcetrapib|Dalcetrapib 900mg po daily for 24 weeks
9745754|NCT00353522|Placebo Comparator|Placebo|Placebo po daily for 24 weeks
9745755|NCT00353652|Active Comparator|Study#1: chlorthalidone (CTD) first then spironolactone (SP)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months of chlorthalidone first (12.5-25 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with spironolactone (25-75 mg/d)without washout period for 3 months. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
9745756|NCT00353652|Active Comparator|Study #1: spironolactone (SP) first, then chlorthalidone (CTD)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months spironolactone first (25-75 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with chlorthalidone(12.5-25 mg/d) without washout period. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
9745757|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+ SP 2nd, CTD+IR 3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dosespironolactone (SP) 25 mg daily for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
9745758|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+IR 2nd, CTD+SP3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, followed by fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
9745759|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD alone 2nd, CTD+IR 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
9745760|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD+IR 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, then fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
9745761|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD alone 2nd, CTD+SP 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
9745762|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD+SP 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, followed by fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
9745763|NCT00353704|Active Comparator|Pregabalin|150 mg Pregabalin per orally about one hour before surgery
9745764|NCT00353704|Placebo Comparator|Placebo|One capsule of saccharose (placebo) was administered orally about one hour before surgery.
9745765|NCT00353834|Active Comparator|Glargine insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve fasting blood glucose of 100 mg/dl and avoid hypoglycemia.
9745766|NCT00353834|Experimental|Exenatide|Exenatide 5ug twice daily for 4 weeks followed by 10 ug twice daily for 8 weeks.
9745767|NCT00353873|Active Comparator|Fluticasone propionate (FLIXOTIDE™)|Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
9745768|NCT00353873|Experimental|Fluticasone propionate/salmeterol (SERETIDE™)|Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
9745769|NCT00353977|Experimental|ALVAC-CMV (vCP260) Vaccinated group|Patients who were vaccinated with ALVAC-CMV (vCP260)
9745770|NCT00354029|Placebo Comparator|Placebo|Saline 0,9%
9745771|NCT00354029|Active Comparator|S (+) Ketamine|
9745772|NCT00354107|Experimental|Treatment (monoclonal antibody therapy, chemotherapy)|"Patients receive monoclonal antibody SGN-30 IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV over 2 hours on days 1-3, carboplatin IV over 1 hour on day 1, and etoposide IV over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses** in the absence of unacceptable toxicity. Patients also receive intrathecal therapy comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).~Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below in the event of ≥ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ≤ 1 of 6 patients experience DLT will be used in a phase II study."
9745773|NCT00354159|Experimental|Treatment Arm|Physicians have access to device-based hemodynamic monitor information to guide patient management
9745774|NCT00354159|Placebo Comparator|Control Arm|Physicians do not have access to device-based hemodynamic monitor information to guide patient management
9745775|NCT00354172|Experimental|Treated Patients|All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
9745776|NCT00354224|Experimental|Oxaliplatin + Capecitabine|Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.
9745777|NCT00354341|Experimental|Group 1 (Early Epoetin Beta)|Along with their standard treatment participants will receive epoetin beta at a starting dose of 2000 International Units (IU) subcutaneously (SC) once weekly to reach and maintain target hemoglobin (Hb) between 13 and 15 grams per deciliter (g/dL), for 15 months. Epoetin beta doses will be adjusted according to individual participant's Hb level. Standard treatment will be as per investigator discretion.
9745778|NCT00354341|Active Comparator|Group 2 (No/Late Epoetin Beta)|Participants will receive their standard treatment for 15 months but no treatment for anemia correction unless Hb level will be less than (<) 10.5 g/dL on 2 consecutive visits of 2 weeks interval or the Hb level will be <10 g/dL on a single determination. In such cases participants could receive epoetin beta at a starting dose of 2000 IU SC once weekly to reach and maintain a target Hb level of 10.5 to 11.5 g/dL. Standard treatment will be as per investigator discretion.
9745779|NCT00354432|Active Comparator|Arm I - Placebo|Patients receive oral placebo pill and oral placebo powder once daily.
9745780|NCT00354432|Active Comparator|Arm II - Soy|Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
9745781|NCT00354432|Experimental|Arm III - Venlafaxine|Patients receive oral Venlafaxine pill and placebo powder once daily.
9745782|NCT00354432|Placebo Comparator|Arm IV - Soy + Venlafaxine|Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.
9745783|NCT00354484|Experimental|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
9745784|NCT00354484|Active Comparator|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
9745785|NCT00354601|Experimental|Weekly Docetaxel and Capecitabine|Weekly Docetaxel and Capecitabine
9745786|NCT00354640|Experimental|Anastrozole and Simvastatin|This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.
9745787|NCT00354679|Experimental|Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, & Surger|"Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.~Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.~Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months"
9745788|NCT00354744|Experimental|High Risk Rhabdomyosarcoma|Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
9745789|NCT00354770|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine
9745790|NCT00354770|Placebo Comparator|2|Placebo
9745791|NCT00354887|Experimental|Oxaliplatin + Capecitabine|Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.
9745792|NCT00354913|Experimental|Imatinib mesylate+hydroxyurea|All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis. Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.
9745793|NCT00354978|Experimental|FOLFIRI plus Bevacizumab|FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.
9745794|NCT00355030|Experimental|1|
9745795|NCT00355030|Experimental|2|
9745796|NCT00355056|Sham Comparator|Medical Management|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).
9745797|NCT00355056|Experimental|PFO Closure|Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.
9745798|NCT00355082|Experimental|lamotrigine 300|300 mg/day treatment
9745799|NCT00355082|Experimental|lamotrigine 250|250 mg/day treatment
9745800|NCT00355121|Experimental|Group 1|DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
9745801|NCT00355121|Experimental|Group 2|DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
9745802|NCT00355121|Experimental|Group 3|Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
9745803|NCT00355134|Experimental|Fingolimod 1.25 mg|"Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day."
9745804|NCT00355134|Experimental|Fingolimod 0.5 mg|Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
9745805|NCT00355134|Experimental|Placebo|"Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day."
9745806|NCT00355147|Experimental|Arm 1 Secondary Risk Factor Management|Patient Secondary Stroke Risk Factor Program including Stroke Self Management and Stroke Peer Support and Physician Stroke Guideline Adherence
9745807|NCT00355147|Placebo Comparator|Attention Control Group|Received Phone Calls from Staff to Control for Attention
9745808|NCT00355199|Experimental|R-HDS|R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.
9745809|NCT00355199|Active Comparator|R-CHOP|Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).
9745810|NCT00355264|Experimental|Single Arm on Active Drug|"5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels~Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes involved in recycling."
9745811|NCT00355342|Experimental|Salmeterol 50 mcg BID|Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication. DISCUS is registered trademark product of GlaxoSmithKline.
9745812|NCT00355342|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.
9745813|NCT00355368|Active Comparator|Succinylcholine|
9745814|NCT00355368|Active Comparator|Rocuronium|
9745815|NCT00355394|Placebo Comparator|Placebo|Standard care including intravenous fluid, but no metoclopramide.
9745816|NCT00355394|Active Comparator|Metoclopramide|Standard care including intravenous fluid PLUS metoclopramide.
9745817|NCT00355472|Experimental|1|KW-0761
9782038|NCT01164137|Experimental|Medication Reconciliation Intervention|Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
9782039|NCT01164137|No Intervention|Medication Reconciliation Non-Interven.|Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
9782040|NCT01164475|Experimental|Fixed Dose Plerixafor|10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by 20 milligram (mg) plerixafor SC injection (fixed dose) in evening of Day 4 (10 to 11 hours prior to first apheresis), and then 10 mcg/kg G-CSF SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of cluster of differentiation 34 (CD34+) stem cells (greater than or equal to [>=] 5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
9782041|NCT01164475|Active Comparator|Weight-Based Plerixafor|G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (>=5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
9782042|NCT01164501|Experimental|BI 10773 low dose|BI 10773 tablets once daily
9782043|NCT01164501|Experimental|BI 10773 high dose|BI 10773 tablets once daily
9782044|NCT01164501|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
9828295|NCT02489344|Experimental|GZ/SAR402671|Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).
9828296|NCT02489357|Experimental|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
9828297|NCT02489500|Active Comparator|melphalan|Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion
9828298|NCT02489500|Experimental|melphalan + Bortezomib|Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion
9828299|NCT02489630|Experimental|Ketamine|0.1 mg/kg ketamine + opiate analgesic
9828300|NCT02489630|Placebo Comparator|Placebo|0.1 mL/kg normal saline + opiate analgesic
9828301|NCT02489734|Experimental|low concentration (LC)|low concentration group
9828302|NCT02489734|Experimental|high concentration (HC)|high concentration group
9828303|NCT02489773||Group 1|HbA1c values ranged from 7.5% to 12% (or higher)
9828304|NCT02489773||Group 2|HbA1c values <7.5%
9828305|NCT02489799|Active Comparator|Intervention|Advance care planning video
9828306|NCT02489799|Placebo Comparator|Control|Control video - no advance care planning content
9828307|NCT02489968|Experimental|empagliflozin 10 mg + linagliptin 5 mg|patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
9828308|NCT02489968|Experimental|empagliflozin 10 mg|patient to receive a tablet containing low dose empagliflozin once daily
9828309|NCT02489968|Experimental|empagliflozin 25 mg + linagliptin 5 mg|patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
9828310|NCT02489968|Experimental|empagliflozin 25 mg|patients to receive a tablet containing high dose empagliflozin once daily
9828311|NCT02489981||Spiriva|Patients with severe persistent asthma
9828312|NCT02490293|Experimental|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
9828313|NCT02490293|Placebo Comparator|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
9828314|NCT02490371|Experimental|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
9828315|NCT02490371|Placebo Comparator|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
9828316|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
9828317|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
9828318|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
9828319|NCT02490631|No Intervention|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
9828320|NCT02490631|Experimental|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
9828321|NCT02490670|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
9828322|NCT02490670|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods.
9835769|NCT02754310|Active Comparator|Repeated scenarios|Participants in the repeated scenario group will learn the management of a pediatric asthma exacerbation on the same scenario repeated three times. The scenario is a pediatric moderate asthma exacerbation not responding to treatment, .
9984700|NCT03814850|Sham Comparator|Sham group: standard blood pressure cuff|The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.
9984701|NCT03813121|Experimental|midazolam intravenous infusion|single midazolam infusion (0.02 mg/kg over 20 minutes)
9745818|NCT00355615|Active Comparator|rosuva 5|rosuvastatin 5 mg
9745819|NCT00355615|Active Comparator|rosuva 10|rosuvastatin 10 mg
9745820|NCT00355615|Active Comparator|rosuva 20|rosuvastatin 20 mg
9745821|NCT00355615|Placebo Comparator|Placebo|Placebo
9745822|NCT00355615|Other|rosuva ol|rosuvastatin open label
9745823|NCT00355706|Active Comparator|Group I - without Steroids|Thoracic Facet Joint Nerve Blocks with Local Anesthetic(0.25% Bupivacaine)
9745824|NCT00355706|Active Comparator|Group II - with steroid|Thoracic Facet Joint Nerve Blocks with Local Anesthetic (0.25% Bupivacaine) and Sterioids(0.15 mg of non-particulate betamethasone)
9745825|NCT00355784|Other|Control|9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and their plasma growth hormone concentration was allowed to decline naturally.
9745826|NCT00355784|Experimental|Growth Hormone Treatment|8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received exogenous growth hormone treatment administered in 4 daily injections to mimic physiological growth hormone secretion throughout the 2-week overeating period.
9745827|NCT00355784|Experimental|High Growth Hormone Treatment|5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received a relatively high daily dose of growth hormone.
9745828|NCT00355797|Active Comparator|Closed Loop Stimulation (CLS)|Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
9745829|NCT00355797|Active Comparator|Standard Rate Adaptive Technology (R)|Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
9745830|NCT00355797|Active Comparator|Non-rate adaptive pacing (DDD)|Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.
9745831|NCT00355914|Active Comparator|Group 1 Without Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
9745832|NCT00355914|Experimental|Group 2 With Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
9745833|NCT00356031|Experimental|Bevacizumab, Radiation, and Surgery|Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)
9745834|NCT00356057|Active Comparator|1|Biventricular pacing group with Closed Loop Stimulation rate adaptation (Protos CLS device)
9745835|NCT00356057|Active Comparator|2|Biventricular pacing group with accelerometer based rate adaption (Stratos LV device)
9745836|NCT00356057|Active Comparator|3|Right Ventricular pacing group with accelerometer based rate adaption (Stratos LV device)
9745837|NCT00356122|Experimental|Docetaxel/Oxaliplatin/Bevacizumab|Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
9745838|NCT00356135|Experimental|Prasugrel 10/10 mg|Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
9745839|NCT00356135|Experimental|Clopidogrel 75/75 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
9745840|NCT00356135|Experimental|Prasugrel 60/10 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
9745841|NCT00356148|Active Comparator|Prophylaxis Group|patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
9745842|NCT00356148|No Intervention|No Prophylaxis Group|Patients who are BMI over 25 and do not receive antibiotic prophylaxis
9745843|NCT00356200|Experimental|Fluphenazine treated|Treated with fluphenazine
9745844|NCT00356200|Placebo Comparator|Placebo|Treated with Placebo
9745845|NCT00356265|Experimental|CKD|
9745846|NCT00356265|Active Comparator|Hypertension group|
9984702|NCT03813121|Placebo Comparator|placebo intravenous infusion|single placebo infusion (saline over 20 minutes)
9745847|NCT00356265|Active Comparator|Normotensive group|
9745848|NCT00356278|Experimental|A|Participants will receive VRE therapy and D-cycloserine
9745849|NCT00356278|Active Comparator|B|Participants will receive VRE therapy and alprazolam
9745850|NCT00356278|Placebo Comparator|C|Participants will receive VRE therapy and placebo
9745851|NCT00356304|Experimental|1|Participants will receive motivational interviewing in addition to their antidepressant therapy
9745852|NCT00356304|Active Comparator|2|Participants will receive treatment as usual
9745853|NCT00356369|Experimental|Nimenrix Group|Subjects receiving GSK Biologicals' meningococcal vaccine 134612
9745854|NCT00356369|Active Comparator|Mencevax Group|Subjects receiving Mencevax™ ACWY
9745855|NCT00356408|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
9745856|NCT00356434|Active Comparator|1|Patients will have the Kendall, A-V foot impulse pump, model 6060 applied to their lower extremities to prevent DVT
9745857|NCT00356434|Active Comparator|2|Patients will have the Kendall,sequential compression device, model 9525 applied to the lower extremities to prevent DVT
9782045|NCT01164579|Experimental|Tofacitinib (CP 690,550) 10 mg BID plus MTX|
9828323|NCT02490878|Experimental|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be treated as per treating MD."
9828324|NCT02490878|Experimental|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
9828325|NCT02491073||Eslicarbazepine acetate treated|
9828326|NCT02491073||Non-Eslicarbazepine acetate treated|
9828327|NCT02491359|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9828328|NCT02491437|Experimental|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
9828329|NCT02491437|Experimental|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
9828330|NCT02491463|Experimental|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
9828331|NCT02491463|Experimental|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
9828332|NCT02491463|Active Comparator|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
9828333|NCT02491463|Placebo Comparator|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
9828334|NCT02491671|Experimental|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
9828335|NCT02491671|Other|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
9828336|NCT02491684|Placebo Comparator|Placebo (matching)|Placebo, once daily inhalation for 14 days
9984703|NCT03813121|Experimental|ketamine intravenous infusion|single ketamine infusion (0.5 mg/kg over 20 minutes)
10201357|NCT03740529|Experimental|Phase 1 Dose Expansion (Pirtobrutinib Monotherapy)|Patients to receive the recommended Phase 2 dose of pirtobrutinib
10201358|NCT03728179|Experimental|Cohort 1|0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
10201359|NCT03728179|Experimental|Cohort 2|1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
10201360|NCT03728179|Experimental|Cohort 3a|1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
10201361|NCT03728179|Experimental|Cohort 4a|2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
10201362|NCT03728179|Experimental|Phase I b|Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib
10201363|NCT03728179|Experimental|Cohort 3b|1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
10201364|NCT03728179|Experimental|Cohort 4b|2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
10201365|NCT03725293|Active Comparator|Angiodynamics BioFlo Midline Catheter|Placement of clinically indicated Angiodynamics BioFlo midline catheter.
10201366|NCT03725293|Active Comparator|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
10201367|NCT03722459|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
10201368|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
10201369|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
10201370|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
10201371|NCT03692832|Experimental|Group L|40 patients undergoing laparoscopic hysterectomy
10201372|NCT03692832|Active Comparator|Group V|40 patients undergoing vaginal hysterectomy
10201373|NCT03690284|Active Comparator|Conventional Double Lumen Tube|Patient will be intubated with conventional double lumen endotracheal tube for single lung ventilation during thoracic surgery.
10201374|NCT03690284|Experimental|VivaSight Double Lumen Tube|Patient will be intubated with VivaSight double lumen endotracheal tube for single lung ventilation during thoracic surgery.
10201375|NCT03670277|Experimental|TEST arm|For subjects enrolled in the Test arm, the Test Soft Contact Lens will be bilaterally fitted to the subject's eyes. Endpoint measures will be collected over one eye only - Test Arm: OD only.
10201376|NCT03670277|Experimental|CONTROL arm|Subjects enrolled in the Control Arm will be established orthokeratology lens wearers. Endpoint measures will be collected over one eye only - Control Arm: Better OK fitted eyes based on investigator's judgement.
10201377|NCT03666533|Active Comparator|Active tDCS|active tDCS plus gait training
10201378|NCT03666533|Sham Comparator|Sham tDCS|sham tDCS plus gait training
10201379|NCT03663790|No Intervention|Control|No intervention
9828337|NCT02491684|Experimental|Interferon beta-1a|Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days
9828338|NCT02491788|Experimental|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
9828339|NCT02491788|Placebo Comparator|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
9828340|NCT02491892|Experimental|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
9828341|NCT02491892|Experimental|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
9828342|NCT02491944|Experimental|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of [14C]AZD9291
9828343|NCT02492100|Experimental|Multi-modality sexual dysfunction intervention|"- Patients in remission > 6 months after allogeneic bone marrow transplant~Patient Enrollment and Baseline Data Collection~First Intervention Visit:~Comprehensive assessment of sexual dysfunction~Normalization & Education~Therapeutic interventions~Referral to Sexual Health Clinic if applicable~Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
9828344|NCT02492451|Active Comparator|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
9828345|NCT02492451|Active Comparator|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
9828346|NCT02492451|No Intervention|Control group|Only IUI
9828347|NCT02492750|Experimental|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
9828348|NCT02492750|Active Comparator|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9828349|NCT02492763|Experimental|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
9828350|NCT02492763|Experimental|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
9828351|NCT02492763|Placebo Comparator|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
9828352|NCT02492763|Active Comparator|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
9828353|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
9828354|NCT02492841|Experimental|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
9828355|NCT02492841|Active Comparator|Calcium hydroxide|-material for pulp capping
9828356|NCT02492841|Experimental|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
9828357|NCT02492854|Active Comparator|Standard Sterile Gauze Dressings|In this arm, pts. will be randomized to receive standard sterile gauze dressing post-operatively.
9828358|NCT02492854|Experimental|PICO Negative Pressure Dressings|In this arm, pts. will be randomized to receive PICO single-use negative pressure dressings.
9828359|NCT02492958|Experimental|SA4Ag|Staphylococcus aureus 4-antigen vaccine
9828360|NCT02492958|Placebo Comparator|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
9828361|NCT02492984|Experimental|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
9828362|NCT02492997|Experimental|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
9828363|NCT02492997|Sham Comparator|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
9828364|NCT02493036|Experimental|High Dose SYN-010|42-mg SYN-010
9828365|NCT02493062|Experimental|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery. These women will undergo sonohysterogram.
9828366|NCT02493088||Antisocial personality|Individuals Diagnosed with Antisocial Personality Disorder
9828367|NCT02493127|Experimental|Standard PCS|Grip strength measurements and completes standard PCS
9828368|NCT02493127|Experimental|Positive PCS|Grip strength measurements and completes positively adjusted PCS
10201380|NCT03663790|Experimental|Foot Progression|Participants will visualize a desired foot progression angle bandwidth in real-time that they should target with their foot angle
10201381|NCT03663790|Experimental|Trunk Lean|Participants will visualize a desired trunk lean angle bandwidth in real-time that they should target with their trunk lean angle
10201382|NCT03636490|Experimental|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
10201383|NCT03632252|Experimental|Powered ankle prosthesis|We will use data from various sensors to optimize the amount of power provided by custom ankle ankle prosthesis. This is a single session study lasting about 4 hours.
10201384|NCT03626376|Placebo Comparator|Control|suppressive antiviral treatment
9835770|NCT02754310|Experimental|Varied scenarios|"Participants in the varied scenarios group will learn the management of a pediatric asthma exacerbation on three different scenarios: a moderate asthma exacerbation, a mild one, and a severe one, for the same length of time than the repeated scenarios group. In this group, there is a variation of scenarios."
10201385|NCT03626376|Active Comparator|Study Arm|oral acyclovir or oral valacyclovir
9745858|NCT00356525|Experimental|Less Than One Year: Pemetrexed|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
9745859|NCT00356525|Experimental|Less Than One Year: Pemetrexed + Gemcitabine|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
9745860|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Carboplatin|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
9745861|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Gemcitabine|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
9745862|NCT00356590|Other|1|
9745863|NCT00356603|Experimental|Sumatriptan|Sumatriptan
9745864|NCT00356759|Sham Comparator|12-weekly INR|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
9745865|NCT00356759|No Intervention|Standard management|Dosing warfarin every 4 weeks, all INRs true values
9745866|NCT00356811|Experimental|Single arm|Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
9745867|NCT00356863|Experimental|Explanation on cardiac rehabilitation|Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
9745868|NCT00356863|No Intervention|Usual care with no intervention|Patients recruited to the study received the usual care without any additional explanation on cardiac rehabilitation, and no effort to increase their awareness or the ward's awareness to cardiac rehabilitation was done.
9745869|NCT00356889|Experimental|Bevacizumab and Erlotinib Hydrochloride|"Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
9745870|NCT00356915|Experimental|Itraconazole tablets|Itraconazole 200 mg tablets
9745871|NCT00356915|Active Comparator|Itraconazole capsules|Two Itraconazole 100 mg capsules were taken daily.
9745872|NCT00356915|Placebo Comparator|Placebo tablets|The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
9745873|NCT00356993|Experimental|NRT + Behavioural Support|Nicotine Replacement Therapy plus Behavioural Intervention
10201386|NCT03626012|Experimental|Cohort 1: BIIB078 First Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
10201387|NCT03626012|Experimental|Cohort 2: BIIB078 Second Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
10201388|NCT03626012|Experimental|Cohort 3: BIIB078 Third Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
9745874|NCT00357006|Active Comparator|1|100 mcg Estradiol
9745875|NCT00357006|Active Comparator|2|200 mcg Estradiol
9745876|NCT00357006|Placebo Comparator|3|adjunctive transdermal placebo
9745877|NCT00357032|Experimental|Treatment (belinostat)|Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
9745878|NCT00357110|Active Comparator|1|Anastrozole monotherapy
9745879|NCT00357110|Experimental|2|Anastrozole + Fulvestrant
9745880|NCT00357162|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9745881|NCT00357214|Active Comparator|potassium bicarbonate|Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
10201389|NCT03626012|Experimental|Cohort 4: BIIB078 Fourth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
10201390|NCT03626012|Experimental|Cohort 5: BIIB078 Fifth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
10201391|NCT03626012|Experimental|Cohort 6: BIIB078 Sixth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
10201392|NCT03626012|Placebo Comparator|Cohorts 1-6: Placebo|Matching placebo will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days (Cohorts 1 through 3) and five maintenance doses on five later days (Cohorts 4 through 6).
10201393|NCT03624036|Experimental|brexucabtagene autoleucel (KTE-X19)|Participants will receive conditioning chemotherapy (fludarabine and cyclophosphamide), followed by the investigational treatment, brexucabtagene autoleucel (KTE-X19).
10201394|NCT03556358|Experimental|TX05 (trastuzumab)|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
9745882|NCT00357214|Active Comparator|Sodium bicarbonate|Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
9745883|NCT00357214|Active Comparator|Potassium chloride|Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
9745884|NCT00357214|Placebo Comparator|microcrystalline cellulose|Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
9745885|NCT00357331|Experimental|Potassium Citrate|Potassium Citrate 20 meq twice daily
9745886|NCT00357331|Placebo Comparator|Placebo|Placebo
9745887|NCT00357370|Experimental|Cohort 1|20 mg
10201395|NCT03556358|Active Comparator|Herceptin®|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
10201396|NCT03555578||Leuprorelin Acetate 11.25 mg|Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
9745888|NCT00357370|Experimental|Cohort 2 - Arm 1|10 mg
9745889|NCT00357370|Experimental|Cohort 2 - Arm 2|20 mg
10201397|NCT03539302|Experimental|Repeat dose inhaled flecainide acetate|One 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used.
9745890|NCT00357370|Placebo Comparator|Cohort 2 - Arm 3|
9745891|NCT00357396|Experimental|Chemo followed by DSCT|"Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.~Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bone marrow or T-cell depleted peripheral blood stem cell transplantation on day 0.~Graft-vs-host disease (GVHD) prophylaxis: Patients receive treatment according to institutional guidelines and are given treatment against infection.~After completion of study treatment, patients are followed periodically for at least 3 years."
9745892|NCT00357500|Experimental|5-drug metronomic antiangiogenic regimen|Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: < 20 kg at 100 mg; 20-50 kg at 200 mg; > 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
9745893|NCT00357552|Experimental|LPV/r monotherapy|Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
10201398|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization.
10201399|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on CEM) during hospitalization.
9745894|NCT00357656|Experimental|BI|Bolus infusion of rAHF-PFM
9745895|NCT00357656|Experimental|CI|Continuous infusion of rAHF-PFM
10201400|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Placebo|"Gemcitabine and Nab-paclitaxel is administered intravenously 3 times/cycle.~Placebo is administered orally on a daily basis"
10201401|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered intravenously once weekly."
10201402|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered orally on a daily basis"
10201403|NCT03490760|Experimental|Durvalumab plus Radiation Therapy|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
10201404|NCT03461159|Experimental|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
10201405|NCT03461159|Experimental|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
10201406|NCT03461159|Experimental|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
10201407|NCT03461159|Experimental|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
10201408|NCT03456726|Experimental|FL with EZH2 gene mutation|Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
10201409|NCT03456726|Experimental|DLBCL with EZH2 gene mutation|Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
10201410|NCT03446417|Experimental|Phase 1|Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
10201411|NCT03446417|Experimental|Phase 2|"MTD/RP2D in subjects:~Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.~Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis."
9782046|NCT01164579|Experimental|Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX|
10201412|NCT03436108||PCOS group|patients who have PCOS
10201413|NCT03436108||control group|patients who donnot have PCOS
10201414|NCT03433248|Experimental|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
10201415|NCT03433248|Experimental|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
10201416|NCT03433248|Active Comparator|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
10201417|NCT03417999|Experimental|Cohort 1|"Cohort 1A:~Dexmedetomidine 2 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo~Cohort 1B:~Dexmedetomidine 2 μg/kg~Under sedation with a natural airway~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo"
10201418|NCT03417999|Experimental|Cohort 2|"Dexmedetomidine 4 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo"
9745896|NCT00357734|Experimental|Gefitinib (ZD1839)|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
9745897|NCT00357760|Experimental|Arm A (higher dose of VEGF Trap)|Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9745898|NCT00357760|Experimental|Arm B (lower dose of VEGF Trap)|Patients receive a lower dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, the dose of ziv-aflibercept (VEGF Trap) may be escalated to the higher dose in Arm A.
9745899|NCT00357877|Placebo Comparator|Placebo Dental Coating|Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
9745900|NCT00357877|Active Comparator|Active Dental Coating|10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
9745901|NCT00357903|Other|1|
9745902|NCT00357955|Experimental|MEDIC|Multidisciplinary education and diabetes intervention for cardiac risk reduction
9745903|NCT00357955|No Intervention|usual care|usual care
9745904|NCT00357968|Experimental|Prasugrel to Clopidogrel|One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
10201419|NCT03364803||Participants with Cushing's Syndrome|
9745905|NCT00357968|Active Comparator|Clopidogrel to Prasugrel|One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
9745906|NCT00357994|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
9745907|NCT00357994|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
9745908|NCT00358007|Experimental|Cone Beam CT|
9745909|NCT00358150|Experimental|Eliglustat tartrate|
9745910|NCT00358215|Experimental|Darbepoetin alfa|Starting dose of 0.75 µg/kg subcutaneously every 2 weeks until hemoglobin concentrations reach 13.0 g/dL on 2 consecutive visits, then monthly dosing, titrated to achieve hemoglobin target of 13.0 g/dL, not to exceed 14.5 g/dL.
9745911|NCT00358215|Placebo Comparator|Placebo|Participants received dose and administration schedule (every 2 weeks or once a month) changes that simulated the changes for participants receiving darbepoetin alfa.
9745912|NCT00358332|Experimental|Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.|20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
9745913|NCT00358332|Experimental|Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
9745914|NCT00358332|Experimental|Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
9745915|NCT00358436|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
9745916|NCT00358436|Placebo Comparator|Placebo|Placebo by inhalation
9745917|NCT00358449|Experimental|Mepolizumab 0.55 mg/kg|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
9745918|NCT00358449|Experimental|Mepolizumab 2.5 mg/kg|Participants received mepolizumab 2.5 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
9745919|NCT00358449|Experimental|Mepolizumab 10 mg/kg|Participants received mepolizumab 10 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
9745920|NCT00358462|Active Comparator|Active azithromycin+placebo doxycycline|Active azithromycin (1g) and placebo doxycycline
10201420|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
10201421|NCT03348670|Experimental|Assess for COVID-19 Antigen Presentation Therapeutic Biologics Mix activity|"CoronaVac® Organism 1.0 mL~TICE® BCG Organism 50 MG"
10201422|NCT03307824|Experimental|IfabondTM|Use of the synthetic glue IfabondTM
10201423|NCT03307824|Active Comparator|sutures|Glue-Free Suture Technique
10201424|NCT03290781|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 25 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
10201425|NCT03290781|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 75 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
9745921|NCT00358462|Active Comparator|Active doxycycline+placebo azithromycin|Active doxycycline and placebo azithromycin
9745922|NCT00358501|Experimental|Defibrotide|Defibrotide treatment
9745923|NCT00358501|No Intervention|Historical Control|Historical control group
9745924|NCT00358579|Active Comparator|Adrenaline|
9745925|NCT00358579|Active Comparator|Vasopressin|
9745926|NCT00358644|Experimental|1|
9745927|NCT00358657|Experimental|Treatment (chemo, total-body irradiation, transplant)|See Detailed Description
9745928|NCT00358670|Active Comparator|Maintenance Infliximab|Infliximab 5 mg/kg by body weight every 8 weeks
9745929|NCT00358670|Experimental|Intermittent Infliximab|Infliximab 5 mg/kg by body weight at Weeks 0, 2, 6 and 14 following a 50% reduction in Psoriasis Area and Severity Index (PASI) from the Study P04271 Baseline
9745930|NCT00358735|Experimental|ActiveCare CECT|The ActiveCare CECT device is a mobile compression device used to prevent venous thromboembolic events, used after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery.
9745931|NCT00358735|Active Comparator|LMWH (Enoxaparin)|Enoxaparin (LMWH) will be used, following a protocol that is considered a standard of care for this patient population. 40mg QD for the remainder of the 10 days.
9745932|NCT00358826|Experimental|VIA-2291 25 mg|VIA-2291 25 mg
9745933|NCT00358826|Experimental|VIA-2291 50 mg|VIA-2291 50 mg
9745934|NCT00358826|Experimental|VIA-2291 100 mg|VIA-2291 100 mg
9745935|NCT00358826|Placebo Comparator|Placebo|Placebo
9745936|NCT00358917|Experimental|LPV/r 800/200 mg QD Tablet|
9745937|NCT00358917|Active Comparator|LPV/r 400/100 mg BID Tablet|
9745938|NCT00358956|Experimental|1|
9745939|NCT00359021|Experimental|001|TMC125 200 mg twice daily until commercially available
9745940|NCT00359073|Active Comparator|Montelukast|montelukast (10 mg everyday)
9745941|NCT00359073|Placebo Comparator|Placebo|Placebo comparator
9745942|NCT00359203|Placebo Comparator|Dual chamber pacemaker|Dual chamber pacemaker programmed ODO (switched OFF)
9745943|NCT00359203|Active Comparator|Dual chamber pacemeker|Medtronic dual chamber pacemaker programmed ON and with Rate Drope Response programmed ON
9745944|NCT00359294|Experimental|Zalypsis (PM00104)|
9745945|NCT00359424|Active Comparator|intravenous (IV) rt-PA alone|Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour.
9745946|NCT00359424|Experimental|Endovascular therapy|Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose (based on the location and extent of the blood clot) a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery.
9745947|NCT00359619|Active Comparator|Cervarix Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9745948|NCT00359619|Experimental|Cervarix 1 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 1 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9745949|NCT00359619|Experimental|Cervarix 2 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 2 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9745950|NCT00359619|Experimental|Cervarix 3 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 3 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9745951|NCT00359619|Experimental|Cervarix 4 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 4 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
10201426|NCT03290781|Placebo Comparator|Placebo|Participants will receive 25 mg or 75 mg ontamalimab or placebo matched to ontamalimab in the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive placebo matched to ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
9745952|NCT00359619|Experimental|Cervarix 5 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 5 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9745953|NCT00359619|Experimental|Cervarix 6 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 6 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9745954|NCT00359632|Experimental|Linezolid|Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
9745955|NCT00359632|Active Comparator|Matched control|Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
9745956|NCT00359736|Experimental|Sildenafil|Sildenafil 20 mg tid orally
9745957|NCT00359736|Placebo Comparator|Placebo|Identical Placebo 20 mg tid orally
9745958|NCT00359762|Experimental|Exenatide|
9745959|NCT00359762|Active Comparator|Glimepiride|
9745960|NCT00359801|Experimental|Exubera|
9745961|NCT00359801|Active Comparator|Usual Diabetes Care|
10201427|NCT03278873|Experimental|Biological-Low dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single low dose of either AAV - CNGB3 or AAV - CNGA3
10201428|NCT03278873|Experimental|Biological-medium dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single medium dose of either AAV - CNGB3 or AAV - CNGA3
9745962|NCT00359944|Experimental|AC-3933|AC-3933, 5mg twice daily
9745963|NCT00359944|Experimental|AC-3933, 20 mg twice daily|AC-3933, 20 mg twice daily
9745964|NCT00359944|Placebo Comparator|Placebo|Sugar Pill twice daily
9745965|NCT00359983|Experimental|MenHibrix 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
9745966|NCT00359983|Active Comparator|ActHIB 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
9745967|NCT00359983|Experimental|ActHIB 3-dose + MenHibrix 4th-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
9745968|NCT00360009|Active Comparator|STN DBS|Patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's disease (PD)
9745969|NCT00360009|Active Comparator|GPI DBS|Patients who underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi) to treat Parkinson's disease (PD)
9745970|NCT00360009|No Intervention|no DBS|non-DBS PD patient control group
9745971|NCT00360230|Experimental|SB257049 F2 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
9745972|NCT00360230|Experimental|SB257049 F1 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
10201429|NCT03278873|Experimental|Biological-high dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single high dose of either AAV - CNGB3 or AAV - CNGA3
10201430|NCT03274661|Experimental|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
10201431|NCT03263559|Experimental|Haploidentical Transplantation|A conditioning regimen with Hydroxyurea, rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, and Mesna will be administered prior to Haploidentical Bone Marrow Transplantation.
9745973|NCT00360230|Experimental|SB257049 F2 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
9745974|NCT00360230|Experimental|SB257049 F1 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
9745975|NCT00360230|Experimental|SB257049 F2 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
9745976|NCT00360230|Active Comparator|SB257049 F1 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
9745977|NCT00360230|Active Comparator|Rabipur 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
9745978|NCT00360243|Experimental|flibanserin 25 mg b.i.d|25 mg twice daily for 24 weeks
9745979|NCT00360243|Experimental|flibanserin 50mg qhs|50 mg taken once daily at bedtime for 24 weeks
9745980|NCT00360243|Experimental|flibanserin 50mg b.i.d.|50 mg twice daily for 24 weeks
9745981|NCT00360243|Placebo Comparator|placebo|twice daily for 24 weeks
9745982|NCT00360269|Experimental|Active|Atomoxetine plus Motivational Enhancement Therapy
9745983|NCT00360269|Placebo Comparator|Placebo|Placebo plus Motivational Enhancement Therapy
9745984|NCT00360282|Other|With Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
9745985|NCT00360282|Other|With Vertigo; Rizatriptan - Placebo|These subjects received Rizatriptan on visit 1 and placebo on visit 2.
9745986|NCT00360282|Other|Without Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
9745987|NCT00360282|Other|Without Vertigo; Rizatriptan-Placebo|This group received Rizatriptan on visit 1 and placebo on visit 2.
9745988|NCT00360308|Placebo Comparator|Placebo|matching E2007 and matching entacapone
9745989|NCT00360308|Active Comparator|E2007|2 mg once daily in the evening, Weeks 0→2 (2 weeks) and 4 mg once daily in the evening, Weeks 2→18.
9745990|NCT00360308|Active Comparator|Entacapone|200 mg with each dose of Levodopa.
9745991|NCT00360334|Experimental|1|
9745992|NCT00360334|Active Comparator|2|
9745993|NCT00360360|Experimental|Bevacizumab/Paclitaxel/Carboplatin/Erlotinib|Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily
9745994|NCT00360399|Active Comparator|Escitalopram|Participants will receive treatment with escitalopram for 12 weeks
9745995|NCT00360399|Active Comparator|Duloxetine|Participants will receive treatment with duloxetine for 12 weeks
9745996|NCT00360399|Active Comparator|CBT|Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks
10201432|NCT03263195||Women with HIV only|Pregnant women with HIV infection only
10201433|NCT03263195||Women with ZIKV only|Pregnant women with ZIKV infection only
10201434|NCT03263195||Women with HIV and ZIKV|Pregnant women with HIV and ZIKV infection
10201435|NCT03263195||Women without HIV or ZIKV|Pregnant women without HIV or ZIKV infection
10201436|NCT03263195||Infants of women with HIV only|Infants of women with HIV infection during pregnancy
9745997|NCT00360412|Experimental|E2007|During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.
9745998|NCT00360490|Experimental|Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
9745999|NCT00360490|Active Comparator|Medroxyprogesterone acetate (MPA)|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
9746000|NCT00360529|Experimental|fibanserin|flibanserin 50 mg q.h.s.
9746001|NCT00360529|Experimental|flibanserin|flibanserin 100 mg q.h.s.
9746002|NCT00360529|Placebo Comparator|placebo|placebo q.h.s.
9746003|NCT00360555|Experimental|flibanserin|flibanserin 25 mg b.i.d
9746004|NCT00360555|Experimental|flibanserin 50mg|flibanserin 50mg qhs/b.i.d
9746005|NCT00360555|Experimental|flibanserin 100mg|flibanserin 50mg b.i.d./100mg qhs
9746006|NCT00360555|Placebo Comparator|placebo|placebo comparator
9746007|NCT00360568|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).~Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances."
9746008|NCT00360672|Experimental|Revlimid|Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
9746009|NCT00360685|Other|TAC + MMF|Tacrolimus and Mycophenolate
9746010|NCT00360685|Other|TAC+MTX|Tacrolimus and Methotrexate
9746011|NCT00360698|Other|insulin glulisine+insulin glargine+metformin+glimepiride|Bolus arm
9746012|NCT00360698|Other|insulin glargine+metformin+glimepiride|Control arm
9746013|NCT00360724|Experimental|duloxetine (cymbalta)|Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
9746014|NCT00360724|Placebo Comparator|Placebo treatment|placebo treatment: treatment with placebo capsules that match active medication capsules
9746015|NCT00360828|Experimental|Irinotecan Treatment|Participants were given irinotecan at a fixed dose: [350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan] once every 21 days. Depending on how many side effects were experienced with the first cycle [first 21 days], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
9746016|NCT00360971|Experimental|Palifermin|Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients.
9746017|NCT00360971|Placebo Comparator|Placebo|Concurrent radiation therapy, cisplatin, and placebo followed by neck dissection for indicated patients.
9746018|NCT00361140|Experimental|AUC 6000|"Busulfan AUC Level 1: 6000 +/- 600 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
9746019|NCT00361140|Experimental|AUC 7500|"Busulfan AUC Level 2: 7500 +/- 750 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
10201437|NCT03263195||Infants of women with ZIKV only|Infants of women with ZIKV infection during pregnancy
10201438|NCT03263195||Infants of women with HIV and ZIKV|Infants of women with HIV and ZIKV infection during pregnancy
10201439|NCT03263195||Infants of women without HIV or ZIKV|Infants of women without HIV or ZIKV infection during pregnancy
10201440|NCT03256227|Experimental|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
9746020|NCT00361140|Experimental|AUC 9000|"AUC Level 3: 9000 +/- 900 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
9746021|NCT00361218|Other|open-label selective serotonin reuptake inhibitor (SSRI)|citalopram or escitalopram
9746022|NCT00361231|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|"The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.~Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.~Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects."
9746023|NCT00361257|Experimental|Arm 1: Minocycline|100 mg orally every 12 hours
9746024|NCT00361257|Placebo Comparator|Arm 2: Matching placebo|orally every 12 hours
9782047|NCT01164579|Active Comparator|Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk|
9782048|NCT01164644|Active Comparator|Arnica Montana|The subject will take twelve pills by mouth three times a day over four days.
9782049|NCT01164644|Placebo Comparator|Placebo|The subject will take twelve pills by mouth three times a day over four days.
9782050|NCT01164722|Experimental|Arm I: Infrared coagulator treatment|Infrared photocoagulation therapy. The infrared coagulator (IRC) contact tip is placed in direct contact with lesion under high-resolution anoscopy (HRA) guidance. Patients then undergo IRC ablation for 1.5 second pulses. IRC ablation is reapplied until the level of submucosal vessels are reached.
9746025|NCT00361270|Experimental|Arm 1 Hyp-8|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist without audio recordings
9746026|NCT00361270|Experimental|Arm 2 Hyp-8 w recordings|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist with audio recordings
9746027|NCT00361270|Experimental|Arm 3 Hyp-2 w recordings|Single-site study at MEDVA-Houston Behavioral: 2 weeks 1-hour hypnosis with hypnotherapist with audio recordings
9746028|NCT00361270|Active Comparator|Arm 4 BIO|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour EMG biofeedback without audio recordings
9746029|NCT00361283|Other|atorvastatin|80mg of atorvastatin given once daily for 16 weeks
9746030|NCT00361296|Experimental|K562/GM-CSF cell vaccine|Vaccinations of 1x10^8 cells are given to participants at weeks 0, 3, 6, 9, and 17.
9746031|NCT00361335|Experimental|Group I: 2mg/kg Golimumab + MTX|Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
9746032|NCT00361335|Experimental|Group II: 2mg/kg Golimumab only|IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
9746033|NCT00361335|Experimental|Group III: 4mg/kg Golimumab + MTX|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
9746034|NCT00361335|Experimental|Group IV: 4mg/kg Golimumab only|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
9746035|NCT00361335|Placebo Comparator|Group V: IV Placebo + MTX|IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
9746036|NCT00361374|Experimental|EPA|Eicosapentaenoic acid (EPA) Omega-3, 1g/day
9746037|NCT00361374|Experimental|DHA|Docosahexaenoic acid (DHA) Omega-3, 1g/day
9746038|NCT00361374|Placebo Comparator|Placebo|Placebo capsule (980mg soybean oil)
9746039|NCT00361439|Active Comparator|Mometasone|Mometasone intranasal steroid therapy daily for 2 weeks
9746040|NCT00361439|Placebo Comparator|Placebo|2 puffs of placebo spray in each nostril once daily
9746041|NCT00361504|Experimental|Tapentadol (CG5503)|Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
9746042|NCT00361504|Active Comparator|Oxycodone|Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.
9746043|NCT00361569|Experimental|1|
9746044|NCT00361569|Experimental|2|
9746045|NCT00361569|Placebo Comparator|3|
9746046|NCT00361569|Placebo Comparator|4|
9746047|NCT00361595|Experimental|open label|5 mg zoledronic acid in a single 15 minute IV
9746048|NCT00361634|Experimental|Etanercept|Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
9746049|NCT00361712|Experimental|Preemptive epidural analgesia|Parturients will receive epidural analgesia immediately upon arrival in the labor ward before onset of painful contractions (VAS<3).
9746050|NCT00361712|Active Comparator|Standard of care|Parturients with cervical dilatation and painful labor (VAS >5) will receive epidural analgesia as soon as possible
9746051|NCT00361842|Experimental|Irinotecan|
9746052|NCT00361972|Active Comparator|Lansoprazole therapy|Lansoprazole 30 mg orally twice daily
9746053|NCT00361972|Placebo Comparator|Placebo|placebo orally twice daily
9746054|NCT00362115|Experimental|Azilsartan Medoxomil 5 mg QD|
9746055|NCT00362115|Experimental|Azilsartan Medoxomil 10 mg QD|
9746056|NCT00362115|Experimental|Azilsartan Medoxomil 20 mg QD|
9746057|NCT00362115|Experimental|Azilsartan Medoxomil 40 mg QD|
9746058|NCT00362115|Experimental|Azilsartan Medoxomil 80 mg QD|
9746059|NCT00362115|Active Comparator|Olmesartan 20 mg QD|
9746060|NCT00362115|Placebo Comparator|Placebo QD|
9746061|NCT00362180|Experimental|Cohort A: mipomersen|Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
9746062|NCT00362180|Placebo Comparator|Cohort A: placebo|Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
9746063|NCT00362180|Experimental|Cohort D: mipomersen|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
9746064|NCT00362180|Placebo Comparator|Cohort D: placebo|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
9746065|NCT00362180|Experimental|Cohort E: mipomersen|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.
9746066|NCT00362180|Placebo Comparator|Cohort E: placebo|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.
9746067|NCT00362180|No Intervention|Cohort F: no intervention|A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.
9746068|NCT00362180|Experimental|Cohort G: mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
9746069|NCT00362180|Placebo Comparator|Cohort G: placebo followed by mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
9746070|NCT00362232|Experimental|Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
9746071|NCT00362232|Active Comparator|Enoxaparin 30 mg twice a day (bid)|Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
9746072|NCT00362297|Active Comparator|Standard dose|
9746073|NCT00362297|Experimental|High-dose|
9746074|NCT00362336|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
9746075|NCT00362336|Experimental|Group 2: CombAct-HIB™ + OPV|
9746076|NCT00362336|Active Comparator|Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)|
9746077|NCT00362375|Experimental|Healthy Love Workshop|Single-session, small-group HIV prevention intervention
9746078|NCT00362375|Active Comparator|HIV101|Single-session, small-group intervention providing facts regarding HIV/AIDS
9746079|NCT00362414|Experimental|Dual Growth Factor|All patients received erythropoietin and beta-hCG. This was the only treatment arm in the study, i.e., all enrollees received active therapy.
9746080|NCT00362440|Experimental|Leptin|Leptin replacement therapy
9746081|NCT00362440|Placebo Comparator|Pioglitazone or metformin|Diabetes treatment therapy
9746082|NCT00362453|Experimental|Tai Chi|The Tai Chi program was based on the classical Yang Style. Patients participated in 60-minute Tai Chi sessions twice a week for 12 weeks. Each session included warm up and review of Tai Chi principles and techniques; Tai Chi exercises; breathing techniques; and various relaxation methods. The classes were taught by a Tai Chi master with over 20 years' experience conducting Tai Chi Mind-Body exercise programs. Several modifications were developed to achieve the physical and mental goals of the study for knee OA, accommodate knee OA symptoms and limit dropouts. Subjects were instructed to practice Tai Chi at least 20 minutes a day at home and encouraged to maintain their usual physical activities, but not to participate in additional new strength training other than their Tai Chi exercises.
9746083|NCT00362453|Placebo Comparator|Wellness Education and Stretching|The wellness education and stretching program provided an active control for the attention being paid to the Tai Chi group. The control group attended two 60-minute class sessions per week for 12 weeks. Each session started with 40 minutes of didactic lessons on OA knowledge, nutrition, and physical and mental health education. The final 20 minutes consisted of stretching exercises involving the upper body, trunk and lower body, each stretch being held for 10 to 15 seconds. Participants were also instructed to practice at least 20 minutes of stretching exercises per day at home. They were encouraged to maintain their usual physical activities, but not to participate in additional strength and mind-body exercise programs other than their stretching exercise.
9746084|NCT00362466|Active Comparator|A|50-180 mg once daily (QD)
9746085|NCT00362466|Active Comparator|B|200-800 mg QD
9746086|NCT00362609|Active Comparator|Low dose|
9746087|NCT00362609|Active Comparator|High dose|
9746088|NCT00362648|Experimental|1|RotaTeq™
9746089|NCT00362648|Placebo Comparator|2|Placebo
9746090|NCT00362817|Experimental|Temozolomide & Intra-Arterial (IA) carboplatin|Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
9746091|NCT00362882|Experimental|Arm 1|Patients receive docetaxel IV over 60 minutes on day 1 and bortezomib IV over 3-5 seconds on days 1 and 8.
9746092|NCT00362882|Experimental|Arm 2|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 2 and 8.
9746093|NCT00363051|Experimental|Everolimus 10 mg|"Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day.~Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy.~Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day."
9746094|NCT00363077|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9746095|NCT00363077|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
10201441|NCT03256227|Active Comparator|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
10201442|NCT03251144|Experimental|Switch to E/C/FTC/TAF daily|"Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be~If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months.~If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
9746096|NCT00363129|Experimental|Arm I|Patients receive oral vitamin E twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
9746097|NCT00363129|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
9746098|NCT00363142|Active Comparator|FPV/r200|Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
9746099|NCT00363142|Experimental|FPV/r100|Fosamprenavir/ritonavir 1400/100mg QD
9746100|NCT00363168|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
9746101|NCT00363168|Experimental|B|0.5 mg/0.05 ml dose of ranibizumab
9746102|NCT00363246||Group 1|Older veterans who use a wheelchair for their primary means of mobility.
9746103|NCT00363298|Experimental|d-amphetamine|dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
9746104|NCT00363298|Sham Comparator|Sham comparison|caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
9746105|NCT00363311|Active Comparator|Dutasteride|Dutasteride 0.5mg
9746106|NCT00363311|Placebo Comparator|Placebo|Matching placebo
9746107|NCT00363415|Experimental|A|
9746108|NCT00363415|Active Comparator|B|
9746109|NCT00363467|Other|Autologous Hematopoietic Progenitor Cell Transplantation|G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
9746110|NCT00363480|Experimental|SFC 50/250 mcg|Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
9746111|NCT00363545|Experimental|Liquid Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
9746112|NCT00363545|Experimental|Lyophilized Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the lyophilized formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
9746113|NCT00363649|Experimental|Arm A|Patients will receive injections of interferon alfa and sargramostim once a day for 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm II.
9746114|NCT00363649|Experimental|Arm B|Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + sargramostim (Arm A).
9746115|NCT00363675|Experimental|All study participants|Children with hand burns
9746116|NCT00363766|Experimental|LY573636|
9746117|NCT00363779|Experimental|LGL Patients administered cyclosporine|Large Granular Lymphocyte Leukemia (LGL) is a low grade non-Hodgkins lymphoma characterized by tissue invasion of the marrow, spleen, and liver. Cyclosporine 5-10 mg/kg/day was administered as an oral preparation given every 12 hours. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml.
9746118|NCT00363805|Experimental|Green Tea|Patients receive green tea beverage and placebo capsules for 6 months.
9746119|NCT00363805|Experimental|Polyphenon E|Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.
9746120|NCT00363805|Placebo Comparator|Placebo|Patients receive placebo beverage and placebo capsules daily for 6 months.
9746121|NCT00363883|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9746122|NCT00363896|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
9746123|NCT00363896|Placebo Comparator|Placebo|Placebo once-daily via inhalation
9746124|NCT00364013|Experimental|FOLFOX + Panitumumab|Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
9746125|NCT00364013|Active Comparator|FOLFOX|Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
9746126|NCT00364130|Active Comparator|Active Low Magnitude Mechanical Stimulus|Active Low Magnitude Mechanical Stimulus
9746127|NCT00364130|Placebo Comparator|Inactive Low Magnitude mechanical Stimulus|Inactive, or placebo low magnitude mechanical stimulus
9746128|NCT00364156|Experimental|Extended Patch Treatment|Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
9746129|NCT00364156|Active Comparator|Standard Patch Treatment|Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.
9746130|NCT00364182|Experimental|A|
9746131|NCT00364182|Experimental|B|
9746132|NCT00364286|Experimental|Dasatinib|Dasatinib 50mg Orally twice daily.
9746133|NCT00364351|Active Comparator|1|Erlotinib
9746134|NCT00364351|Experimental|2|Vandetanib
9746135|NCT00364377|Active Comparator|Sitagliptin|People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.
9746136|NCT00364377|Placebo Comparator|Placebo|People with impaired fasting glucose randomized to treatment with placebo once daily.
9746137|NCT00364533|Placebo Comparator|003|Placebo Fixed Dose Matching placebo for 3 days
9746138|NCT00364533|Active Comparator|002|Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
9746139|NCT00364533|Experimental|001|Tapentadol IR (CG5503) Fixed Dose 50, 75, & 100 mg BID for 3 days
9746140|NCT00364533|Other|004|Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
9746141|NCT00364611|Experimental|Docetaxel and Bevacizumab|Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
10201443|NCT03228680|Experimental|Follitropin delta|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
9746142|NCT00364611|Experimental|Docetaxel, Bevacizumab and Trastuzumab|Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
9746143|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 months to < 6 months|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
9746144|NCT00364793|Experimental|EFV+ddI+FTC in patients >=6 months to < 2 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
9782051|NCT01164722|Active Comparator|Arm II: Expectant management|Patients receive standard of care and undergo clinical observation. After 12 months, patients may receive IRC ablation to all anal intraepithelial neoplasia lesions despite of their size.
9782052|NCT01164865|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
9782053|NCT01164865|Active Comparator|Clear Care|Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
9782054|NCT01164891|Experimental|Single Arm|
10201444|NCT03228680|Active Comparator|Follitropin beta|FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
10201445|NCT03226470|Experimental|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
10201446|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
10201447|NCT03196167|Experimental|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
10201448|NCT03196167|Placebo Comparator|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
10201449|NCT03192436|Active Comparator|Real Ultrasound|The subjects will receive real ultrasound intervention.
10201450|NCT03192436|Sham Comparator|Sham Ultrasound|The subjects will receive sham ultrasound intervention.
10201451|NCT03144206|Experimental|Hyperbaric Oxygen Group|Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period
10201452|NCT03144206|No Intervention|Standard of Care Group|Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period
10201453|NCT03112174|Experimental|Safety Run-in Period|"Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.~Safety run-in phase for the study is closed to further enrollment as of 07-Nov-2018."
10201454|NCT03112174|Experimental|Phase 3: Ibrutinb + Venetoclax|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
10201455|NCT03112174|Placebo Comparator|Phase 3: Ibrutinib + Placebo|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
10201456|NCT03112174|Experimental|Treatment-naive|"This open-label arm is designed to explore the efficacy and safety of the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL.~Approximately 75 subjects (of which ~25 subjects with TP53 mutation) will be enrolled and treated with ibrutinib and venetoclax."
10201457|NCT03097874|Experimental|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
9828369|NCT02493257|Experimental|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the mucosal atomizer device (MAD), 0.8 milliliters (mL) will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
9828370|NCT02493257|Placebo Comparator|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
9828371|NCT02493361|Experimental|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
9828372|NCT02493452|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
9828373|NCT02493452|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
9828374|NCT02493452|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
9828375|NCT02493517|Experimental|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
9828376|NCT02493517|Active Comparator|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
9828377|NCT02493608|Active Comparator|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
9828378|NCT02493608|Active Comparator|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
9828379|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
9828380|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
9828381|NCT02493660|Experimental|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
9828382|NCT02493660|Active Comparator|Tendon Repair|Arthroscopic partial repair of rotator cuff
9828383|NCT02493712|Experimental|High dose|High dose, twice a day for 6 weeks.
9828384|NCT02493712|Placebo Comparator|Placebo: C|Placebo, twice a day
9828385|NCT02493712|Experimental|Low dose|Low dose, twice a day for 6 weeks
9828386|NCT02493764|Experimental|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
9828387|NCT02493764|Active Comparator|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
9828388|NCT02493777|Experimental|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
9828389|NCT02493777|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
9828390|NCT02493855|Experimental|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
9828391|NCT02493855|Experimental|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
9828392|NCT02493855|Experimental|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
9828393|NCT02493868|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Direct-entry participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Open-label Induction Phase. Participants will initiate a new oral antidepressant on Day 1 of this phase. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to esketamine will self-administer intranasal esketamine (same dose) once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
9828394|NCT02493868|Experimental|Placebo Plus Oral Antidepressant|Optimization Phase: Transferred-entry participants will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to intranasal placebo will self-administer intranasal placebo once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
9828395|NCT02493946|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.
9828396|NCT02493946|Placebo Comparator|Placebo|The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.
9828397|NCT02494076|Experimental|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
9828398|NCT02494076|Sham Comparator|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
9828399|NCT02494102|Placebo Comparator|Placebo|Administered Placebo day of surgery immediately prior to general anesthesia and surgery
9828400|NCT02494102|Active Comparator|Intervention|Administered Modafinil 200mg day of surgery prior to general anesthesia and surgery
9828401|NCT02494180|Placebo Comparator|A: intravenous fentanyl, midazolam|group A will be given intravenous 0.1mg fentanyl and 5mg midazolam prior oocyte retrieval
9828402|NCT02494180|Placebo Comparator|B: intravenous pethidine, diazepam|group B will be given intravenous 25mg pethidine, 5mg diazepam prior oocyte retrieval
9828403|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
9828404|NCT02494323|Experimental|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
9828405|NCT02494336|Active Comparator|Trans-incisional rectus sheath block|rectus sheath block under direct visualization through the umbilical incision by the attending surgeon
9828406|NCT02494336|Active Comparator|Laparoscopic guided rectus sheath block|rectus sheath block under direct laparoscopic visualization by the attending surgeon
9828407|NCT02494401|Active Comparator|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
9828408|NCT02494401|Other|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
9828409|NCT02494518|Active Comparator|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
9828410|NCT02494518|Active Comparator|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike at your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
9828411|NCT02494518|Active Comparator|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of stroke education~45 minutes of upper extremity repetitive arm exercises"
10201458|NCT03097874|Experimental|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment plus Intensive Parental Coaching if weight milestones are not met by session 4.
10201459|NCT03082729|Other|Apremilast|Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.
10201460|NCT03077204|Other|BIO4 treatment|Patients undergoing 1 or 2-level Anterior Cervical Discectomy and Fusion (ACDF) spine surgery utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
10201461|NCT03062826||Patients with STEMI treated medically|Drug: dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) for at least 12 months.
10201462|NCT03033693|Other|The deep anesthesia group|
10201463|NCT03033693|Other|The light anesthesia group|
10201464|NCT03029611|Experimental|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. After completion of 3 cycles, patients then undergo cytoreductive surgery.
10201465|NCT03024996|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
10201466|NCT03024996|Placebo Comparator|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
9828412|NCT02494583|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
9828413|NCT02494583|Experimental|Pembrolizumab + SOC Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
9828414|NCT02494583|Placebo Comparator|Placebo + SOC Chemotherapy (SOC)|Participants receive placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
9828415|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
9828416|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
9828417|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
9828418|NCT02494713|Other|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
9828419|NCT02494778|Experimental|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
9828420|NCT02494817|Placebo Comparator|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
9835771|NCT02754427|Experimental|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
9835772|NCT02754427|Active Comparator|Education Group|Participants in the education group received the usual post-operative follow-up.
10201467|NCT02999438||Patients with hemodynamically significant heart disease|"Patients with either:~Single ventricle physiology s/p Fontan~Heart failure diagnosed by a cardiologist~Pulmonary hypertension diagnosed by cath"
10201468|NCT02999438||Controls|Healthy controls as defined in inclusion- exclusion criteria
10201469|NCT02969824|No Intervention|Usual Care Group|Following a brief period of physical and cognitive rest (typically1-7 days, depending on symptom severity and timing of spontaneous symptom abatement), the physician advises participants to increase their activity levels gradually with minimal head movement (predominantly involving a stationary bike) and progressively increase levels of exertion while remaining under the threshold of symptom exacerbation. Subsequently, exercise progressed to include a progression of head movements, visual and cognitive burdens, sport-specific activities, and heavy resistance, in that order, all below the symptom exacerbation threshold.
9828421|NCT02494817|Active Comparator|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
9828422|NCT02495025|Experimental|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
9828423|NCT02495025|No Intervention|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
9828424|NCT02495038|No Intervention|Intubating dose, Group I|"combined ED95 rocuronium and ED95 cisatracurium~ED95, dose causing on average 95% suppression of neuromuscular response."
9828425|NCT02495038|Experimental|10% reduction of combination of Esmeron® and Nimbex®, Group S|This arm reduced 10% of combined ED95 rocuronium and ED95 cisatracurium
9828426|NCT02495038|Experimental|20% reduction of combination of Esmeron® and Nimbex®, Group L|This arm reduced 20% of combined ED95 rocuronium and ED95 cisatracurium
9828427|NCT02495103|Experimental|Phase I Component - Vandetanib|Phase I Component
9828428|NCT02495103|Experimental|Phase II Component- Vandetanib/Metformin|Phase II Component
9828429|NCT02495168|Experimental|Generic Budesonide/Formoterol Fumarate Dihydrate|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
9828430|NCT02495168|Active Comparator|Symbicort (Budesonide/Formoterol Fumarate Dihydrate)|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
9828431|NCT02495168|Placebo Comparator|Placebo|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.
9828432|NCT02495233|Experimental|Gilteritinib 120mg + Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
9828433|NCT02495233|Experimental|Gilteritinib 80mg+ Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
9828434|NCT02495259|Experimental|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
9828435|NCT02495259|Active Comparator|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
9828436|NCT02495259|Active Comparator|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
10201470|NCT02969824|Experimental|Supervised Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Two of the sessions (i.e., first and mid-point) will be an in-person exercise sessions at the lab with a member of the research team while the remaining six sessions will be home-based exercise sessions with remote communication by phone (i.e., call or text) with a member of the research team. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
10201471|NCT02959502|Experimental|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
10201472|NCT02959502|Experimental|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
9828437|NCT02495389|Experimental|Mirabegron|Participants received mirabegron (Myrbetriq) daily for 12 weeks
9828438|NCT02495454|Experimental|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).~GA101-miniCHOP regimen:~Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
9828439|NCT02495467|Experimental|MED Placebo then MED2005|Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
9828440|NCT02495467|Experimental|MED2005 then MED Placebo|Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
9828441|NCT02495623|Active Comparator|Low Dose|21 mg SYN-010
9828442|NCT02495623|Active Comparator|High Dose|42 mg SYN-010
9828443|NCT02495623|Placebo Comparator|Placebo|Placebo
9828444|NCT02495779|Experimental|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
9828445|NCT02495831|Experimental|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
9828446|NCT02495831|Active Comparator|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
9828447|NCT02495844|Experimental|UCB0942|UCB0942/UCB0942
9828448|NCT02495844|Placebo Comparator|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
9828449|NCT02495857|Experimental|Hyaluronate Injectable Viscosupplement|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
9828450|NCT02495857|Active Comparator|Euflexxa IA injection|Euflexxa IA injection to the knee once weekly for 3 weeks
9828451|NCT02495857|Placebo Comparator|Placebo|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
9828452|NCT02495883|Other|Essential Tremor Group|Patients will be randomized to start in one of two treatment arms: 1) 50ml of 40% ethanol or 2) Propranolol SR 60-120mg. In patients who receive ethanol first, they will return for a second visit when they will receive Propranolol, and vice versa. Ethanol will be administered to participants diagnosed with Essential Tremor during the study visit, whereas patients receiving Propranolol SR will be administered daily over an estimated period of two weeks prior to the fMRI visit.
9828453|NCT02495883|No Intervention|Health Volunteer Group|Healthy Volunteers will receive no interventions.
9828454|NCT02495948|Other|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
9828455|NCT02495948|Other|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
9828456|NCT02496000|Placebo Comparator|Placebo Comparator|three identical capsules containing placebo
9828457|NCT02496000|Experimental|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
9828458|NCT02496000|Experimental|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
9828459|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
10201473|NCT02914977|Experimental|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
10201474|NCT02906137|Experimental|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:~15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~10 subjects will have both a gastroscopy and a coloscopy"
10201475|NCT02906137|Other|Uninfected-controls|"40 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:~10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~20 subjects will have both a gastroscopy and a coloscopy"
10201476|NCT02891798|Experimental|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
10201477|NCT02891798|Active Comparator|Bupivacaine Only (control arm)|Patients will receive a nerve block consisting of bupivacaine only.
10201478|NCT02886845||Chinese Breast Cancers|Woman with breast cancer that have been diagnosed in clinic
10201479|NCT02886845||healthy controls|Woman without breast cancer
10201480|NCT02870218|Active Comparator|0.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
10201481|NCT02870218|Active Comparator|1.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
10201482|NCT02870218|Active Comparator|2.50mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
9828460|NCT02496221|Experimental|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
9828461|NCT02496533|No Intervention|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
9828462|NCT02496533|Experimental|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
9828463|NCT02496702|Experimental|Training|"The intervention is done in the form of groups of 4-5 participants per set of tiles, with 2-3 set of tiles at a time. As more set can be used it is possible to make groups of more people. The training will consist of 1.5-3 minutes of training (depending on the game) on tiles and the rest while the other 2-3 participants train (4-6 minutes of break). Then the participants will train for 1.5-3 minutes again until each participant have received a total of 13 minutes of training.~The intervention will be done 2 times a week for 12 weeks, each session lasting 1 hour and each participant receiving 13 minutes of training each time (see training plan)."
9828464|NCT02496702|No Intervention|Control|No training.
9828465|NCT02496767|Placebo Comparator|Group 1 - Placebo|Day 1 through Week 48: 2 placebo tablets twice daily
9828466|NCT02496767|Experimental|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
9828467|NCT02496767|Experimental|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
9828468|NCT02496767|Experimental|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
9828469|NCT02496884|Experimental|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
9828470|NCT02496884|Experimental|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
9828471|NCT02496884|Placebo Comparator|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
9828472|NCT02496884|Placebo Comparator|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
9828473|NCT02497001|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
10201483|NCT02870218|Active Comparator|5.60mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
10201484|NCT02870218|Active Comparator|16.9mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
10201485|NCT02870218|Experimental|Halo G6 & Tribeca e-liquid|"Difference detection assessments.~Nicotine discrimination thresholds"
10201486|NCT02870218|Experimental|Spectrum Research Cigarette|"Difference detection assessments.~Nicotine discrimination thresholds"
10201487|NCT02864992|Experimental|Tepotinib|
9828474|NCT02497001|Experimental|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
10201488|NCT02859961|Experimental|PRO 140 SC 350 mg weekly injection (Group A)|PRO 140 350 mg (175 mg/mL) SC injections per week
10201489|NCT02859961|Experimental|PRO 140 SC 525 mg weekly injections (Group B)|PRO 140 525 mg (175 mg/mL) SC injections per week
10201490|NCT02859961|Experimental|PRO 140 SC 700 mg weekly injections (Group C)|PRO 140 700 mg (175 mg/mL) SC injections per week
10201491|NCT02855593||Physicians|Physicians who perform acupuncture
10201492|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
10201493|NCT02799485|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
10201494|NCT02769520|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
10201495|NCT02736318|Experimental|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
10201496|NCT02679781|Active Comparator|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
10201497|NCT02679781|Active Comparator|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
9828475|NCT02497001|Experimental|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
9828476|NCT02497001|Active Comparator|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
9828477|NCT02497040|Experimental|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
9828478|NCT02497040|Active Comparator|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
9828479|NCT02497040|Active Comparator|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
9828480|NCT02497235|Experimental|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
9828481|NCT02497287|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
9828482|NCT02497391|Experimental|Evacetrapib Reference (R)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
9828483|NCT02497391|Experimental|Evacetrapib Test 1 (T1)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
9828484|NCT02497391|Experimental|Evacetrapib Test 2 (T2)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
9828485|NCT02497404|Experimental|5 Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor.
9828486|NCT02497469|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
9828487|NCT02497469|Active Comparator|Adalimumab SC 160/80/40 mg|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
9828488|NCT02497755|Experimental|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
9828489|NCT02497781|Experimental|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
9828490|NCT02497781|Active Comparator|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
9828491|NCT02497937|Experimental|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
9828492|NCT02497976|Active Comparator|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
9828493|NCT02497976|Placebo Comparator|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
10201498|NCT02664337|Experimental|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
10201499|NCT02664337|Active Comparator|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
10201500|NCT02624869|Experimental|Evolocumab|Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.
10201501|NCT02614690|Active Comparator|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
10201502|NCT02614690|Active Comparator|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
10201503|NCT02614690|Active Comparator|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
10201504|NCT02611687|Experimental|pitolisant|tablet, oral, once a day.
10201505|NCT02611687|Placebo Comparator|placebo|tablet, oral, once a day.
9746145|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 2 years to < 3 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
9746146|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 years to <= 6 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
9746147|NCT00364819|Experimental|1|rituximab 1000 mg IV on days 1 and 15, given over 5 - 6 hours
9746148|NCT00364832|Experimental|Cohort A (0.4/150, 1x/ Week)|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) SC using a dose conversion factor of 0.4/150 microgram (mcg)/ kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746149|NCT00364832|Experimental|Cohort B (0.4/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746150|NCT00364832|Experimental|Cohort C (0.4/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746151|NCT00364832|Experimental|Cohort D (0.8/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746152|NCT00364832|Experimental|Cohort E (0.8/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746153|NCT00364832|Experimental|Cohort F (0.8/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746154|NCT00364832|Experimental|Cohort G (1.2/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9785395|NCT01250977|Experimental|Donepezil|Participants are instructed to take one 5mg pill (donepezil HCL [Aricept®]) every night before going to bed with a glass of water for 28 days.
9983949|NCT04530981|Experimental|Repaglinide 0.5 mg + Ripretinib 150 mg QD|A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.
10201506|NCT02598947|Experimental|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
10201507|NCT02598947|Sham Comparator|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
10201508|NCT02595424|Experimental|Arm A (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10201509|NCT02595424|Active Comparator|Arm B (cisplatin, carboplatin, etoposide)|Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10201510|NCT02585921|No Intervention|Health & Wellness|Following enrollment, participants will learn about health and wellness.
10201511|NCT02585921|Experimental|Organ Donation Video Education|Following recruitment, participants will watch and discuss videos about organ donation.
10201512|NCT02585921|Experimental|Organ Donation Discussion Education|Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
10201513|NCT02585921|Experimental|Both Video and Discussion Education|Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.
10201514|NCT02569242|Experimental|Nivolumab Arm|Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9828494|NCT02498067|Experimental|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
9828495|NCT02498236|Experimental|Oxytocin 6-84 IU|Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.
9828496|NCT02498236|Placebo Comparator|Placebo|Subjects will be administered intranasal placebo using the same spray volume as experimental condition
9828497|NCT02498418|Experimental|Generic Rifaximin 200 mg Tablets|Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
9828498|NCT02498418|Active Comparator|Xifaxan 200 mg Tablets|Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
9828499|NCT02498418|Placebo Comparator|Placebo|Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
9828500|NCT02498483|Experimental|Acetaminophen Arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
9828501|NCT02498483|No Intervention|Non-treatment Arm|Routine circumcision without acetaminophen.
9828502|NCT02498522|Experimental|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
9828503|NCT02498522|Placebo Comparator|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
9828504|NCT02498652|Experimental|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
9828505|NCT02498652|Experimental|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
9828506|NCT02498678|No Intervention|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
9828507|NCT02498678|Experimental|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
9828508|NCT02498769|Experimental|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
9828509|NCT02498769|Placebo Comparator|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
9828510|NCT02498821|Other|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
9828511|NCT02498821|Other|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
9828512|NCT02498834|Experimental|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
10201515|NCT02569242|Active Comparator|Active Comparator Arm （Docetaxel/Paclitaxel）|"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~OR~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
10201516|NCT02562872|Experimental|Cohort 1 Active DSM265|
10201517|NCT02562872|Placebo Comparator|Cohort 1 Placebo|
10201518|NCT02562872|Experimental|Cohort 2a Active DSM265|
10201519|NCT02562872|Placebo Comparator|Cohort 2a Placebo|
10201520|NCT02562872|Experimental|Cohort 2b Active DSM265|
10201521|NCT02562872|Placebo Comparator|Cohort 2b Placebo|
10201522|NCT02527044|Experimental|Functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered functional for score of 3."
9746155|NCT00364832|Experimental|Cohort H (1.2/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746156|NCT00364832|Experimental|Cohort I (1.2/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
9746157|NCT00364845|Active Comparator|Darbepoetin alfa|Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
9746158|NCT00364845|Placebo Comparator|Placebo|Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.
9746159|NCT00364858|Other|Q2 Cerezyme|Patients receiving Cerezyme one infusion every 2 weeks (Q2).
9746160|NCT00364858|Other|Q4 Cerezyme|Patients receiving Cerezyme one infusion every 4 weeks (Q4).
9746161|NCT00365053|Experimental|Treatment (belinostat)|Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9746162|NCT00365105|Active Comparator|Zoledronic acid|Zoledronic acid, vitamin D and calcium supplements.
9746163|NCT00365105|Experimental|Zoledronic acid + Radiopharmaceuticals|Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153.
9746164|NCT00365144|Experimental|Bevacizumab Plus Erlotinib Hydrochloride|"A treatment cycle is 21 days:~bevacizumab 15 mg/kg as a 60-90 min infusion once every 21 days, with erlotinib hydrochloride 150 mg by mouth daily"
9746165|NCT00365209|Experimental|2g (curcumin)|Patients receive 2 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
9746166|NCT00365209|Experimental|4g (curcumin)|Patients receive 4 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
9746167|NCT00365261|Active Comparator|eszopiclone|active drug
9746168|NCT00365261|Placebo Comparator|placebo|placebo
9746169|NCT00365274|Experimental|SGN-30 + Combination Chemotherapy|"Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.~SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, and vincristine IV over 15 minutes on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6-8 courses."
9746170|NCT00365300|Active Comparator|Pantoprazole|
9746171|NCT00365300|Placebo Comparator|Placebo|
9746172|NCT00365352|Experimental|XP13512 600MG|XP13512 600MG ONCE DAILY
9746173|NCT00365352|Experimental|XP13512 1200MG|XP13512 1200MG ONCE DAILY
9746174|NCT00365352|Placebo Comparator|Placebo|PLACEBO ONCE DAILY
9746175|NCT00365365|Experimental|Stratum 1 (AC->T + bevacizumab)|"HER2-negative participants administered~doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by~docetaxel (T) + bevacizumab for 4 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
9746176|NCT00365365|Experimental|Stratum 2 (TAC + bevacizumab)|"HER2-negative participants administered~docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
9746177|NCT00365365|Experimental|Stratum 3 (TCH + bevacizumab)|"All HER2-positive participants administered~docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by~bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
9746178|NCT00365378|Experimental|1|HPV 16 L1 VLP vaccine
9746179|NCT00365378|Placebo Comparator|2|Placebo
9746180|NCT00365391|Experimental|Treatment (monoclonal antibody, enzyme inhibitor)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA.
9746181|NCT00365417|Experimental|Doxorubicin+Cyclophosphamide+Bevacizumab|
9746182|NCT00365456|Experimental|PTH (1-84)|
9746183|NCT00365456|Active Comparator|Risedronate|
9746184|NCT00365508|Experimental|Arm I|Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.
9828513|NCT02498834|No Intervention|Control group|Standard of care will be used
9828514|NCT02499029|Experimental|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
9828515|NCT02499029|Placebo Comparator|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
9828516|NCT02499081|Experimental|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
9828517|NCT02499120|Experimental|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
9828518|NCT02499120|Active Comparator|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
9828519|NCT02499146|Experimental|Cohort 1|Combination therapy of palbociclib and letrozole
9828520|NCT02499159|Experimental|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
9828521|NCT02499159|Active Comparator|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
9828522|NCT02499172|Experimental|Cohort 1|Cohort 1: Women who were pregnant and received at least one dose of ShancholTM during the mass OCV vaccination campaign.
9828523|NCT02499172|No Intervention|Cohort 2|Cohort 2: Women who received at least one dose and who became pregnant after the mass vaccination campaign; hence their fetuses were not exposed to the vaccine.
9828524|NCT02499172|No Intervention|Cohort 3|Cohort 3: Women who were pregnant in Chikwawa District at the time of the vaccination campaign in Nsanje District, but who did not receive the vaccine during the campaign.
9828525|NCT02499172|No Intervention|Cohort 4|Cohort 4: Women who become pregnant in Chikwawa District after the vaccination campaign in Nsanje District, and who did not receive the vaccine during the campaign.
9828526|NCT02499263||Participants with Ulcerative Colitis (UC)|Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week per the Korean label in participants with active moderate-to-severe UC.
9828527|NCT02499380||Treatment|Patients treated with PneumRx Coil System
9828528|NCT02499406|Other|Skills group|Dialectical behavior therapy skills group
9828529|NCT02499497|Placebo Comparator|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
9828530|NCT02499497|Active Comparator|LY2452473 Dose 1|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
9828531|NCT02499497|Active Comparator|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
9828532|NCT02499497|Active Comparator|LY2452473 Dose 3|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
9828533|NCT02499575|Active Comparator|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
9828534|NCT02499575|Experimental|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
9828535|NCT02499692|Experimental|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
9828536|NCT02499770|Experimental|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
9828537|NCT02499770|Experimental|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
9828538|NCT02499783|Experimental|Placebo Induction Regimen|"Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24."
9828539|NCT02499783|Experimental|Adalimumab Induction Regimen|"Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24."
9828540|NCT02499952|Experimental|Experimental Arm|Pembrolizumab
9828541|NCT02500043|Experimental|TAS-102+BSC|Participants received 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
9828542|NCT02500043|Experimental|Placebo+BSC|Participants received 35 mg/m^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
9828543|NCT02500056|Active Comparator|OM group|Optilene LP mesh
9828544|NCT02500056|Active Comparator|UM group|Ultrapro mesh
9828545|NCT02500368|Experimental|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
9828546|NCT02500368|Active Comparator|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
9828547|NCT02500537|Experimental|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
9828548|NCT02500537|Experimental|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
9828549|NCT02500550|Experimental|ATIR101|
9828550|NCT02500602|Experimental|Doxazosin|Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
9828551|NCT02500602|Placebo Comparator|Placebo|Participants randomly assigned to placebo. Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
9828552|NCT02500628|Experimental|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
9828553|NCT02500628|Experimental|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
9828554|NCT02500641|Experimental|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
9828555|NCT02500641|Active Comparator|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl.~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
9828556|NCT02500706|Experimental|Mealtime faster-acting insulin aspart and insulin degludec|
9828557|NCT02500706|Active Comparator|Mealtime NovoRapid® and insulin degludec|
9828558|NCT02500706|Experimental|Postmeal faster-acting insulin aspart and insulin degludec|
9828559|NCT02500719|Experimental|Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement (prior to the implementing in our PTSD participant group) the application of our support vector machine based real-time functional magnetic resonance imaging (rt-fMRI) algorithm, which evaluates brain networks thought to mediate emotional arousal and presents them (in real time) to subjects to aide in volitional manipulation of arousal.
9828560|NCT02500719|Experimental|PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation of rt-fMRI guidance of brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
9828561|NCT02500732|Placebo Comparator|Placebo|Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
10201523|NCT02527044|Active Comparator|Non functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered non functional for scores of 0 to 2."
10201524|NCT02516969|Experimental|Stereotactic Body Radiotherapy|Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes <25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.
9746185|NCT00365508|Experimental|Arm II|Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).
9746186|NCT00365547|Experimental|Patients Treated With Topotecan and Avastin in NSCLC|Weekly topotecan hydrochloride and bi-weekly Avastin (bevacizumab) in patients with non-small cell lung cancer (NSCLC) who have failed prior systemic chemotherapy.
9746187|NCT00365599|Experimental|Vorinostat and Tamoxifen|As outlined in Intervention descriptions
9746188|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
9746189|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
9746190|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
9746191|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 225|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
9746192|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 450|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
9746193|NCT00365768|Experimental|Arm I: Glutamine|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
9746194|NCT00365768|Placebo Comparator|Arm II: Placebo|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
9746195|NCT00365794|Experimental|Single arm|Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.
9746196|NCT00365846|Experimental|Campath 1H induction w/ Sirolimus immunosuppression|Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,
9746197|NCT00365859|Experimental|De Novo|De novo participants (those who did not participate in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
9746198|NCT00365859|Experimental|Rollover Placebo|Participants who completed participation in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) on placebo treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
9746199|NCT00365859|Experimental|Rollover Aripiprazole|Participants who completed participation in protocol CN138-178 [NCT00332241] or CN138-179 [NCT00337571] on aripiprazole treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
9746200|NCT00365872|Experimental|EBRT + DC Injection + Resection|Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
9746201|NCT00365976|Placebo Comparator|1|Placebo
9746202|NCT00365976|Active Comparator|2|Eszopiclone
9746203|NCT00365989|Experimental|ExAblate Enhanced Sonication Test Arm|The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.
9746204|NCT00366028|Other|Organizational Model|Organizational Model: Participants in this arm of the study will receive information regarding the organizational model and work closely with the research team throughout the project to implement various aspects of the model. Participants in this arm of the study will be interviewed and participate in the data feedback portion of the study as well.
9746205|NCT00366028|Other|Data Feedback|Data Feedback Only: Participants in this arm will be interviewed periodically and participate in the data feedback portion of the study.
9746206|NCT00366249|Active Comparator|A|
9746207|NCT00366249|Active Comparator|B|
9746208|NCT00366275|Experimental|In vivo purging autotransplant|
9746209|NCT00366301|Placebo Comparator|Placebo pill|Placebo pill
9746210|NCT00366301|Active Comparator|Metformin Pill|Metformin pill
9746211|NCT00366301|Active Comparator|Insulin Glargine plus placebo pill|Insulin glargine plus placebo pill
9746212|NCT00366301|Active Comparator|Insulin Glargine plus metformin pill|Insulin Glargine plus metformin pill
9746213|NCT00366340|Experimental|1|13-valent pneumococcal conjugate vaccine
9746214|NCT00366340|Active Comparator|2|7-valent pneumococcal conjugate vaccine
9746215|NCT00366444|Experimental|1|
9746216|NCT00366444|Placebo Comparator|2|
9746217|NCT00366457|Other|Gemcitabine, Bevacizumab and Erlotinib|single-arm, no masking
9746218|NCT00366535|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive Placebo for 12 weeks and then Neurotropin for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
9746219|NCT00366535|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 12 weeks and then Placebo for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others
9746220|NCT00366548|Experimental|1|
9746221|NCT00366548|Active Comparator|2|
9746222|NCT00366626|Experimental|1.|Naltrexone one capsule a day
9746223|NCT00366626|Placebo Comparator|2|One capsule a day match to naltrexone
9746224|NCT00366678|Experimental|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
9746225|NCT00366678|Active Comparator|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine
9746226|NCT00366899|Experimental|1|13-valent pneumococcal conjugate vaccine
9746227|NCT00366899|Active Comparator|2|7-valent pneumococcal conjugate vaccine
9782055|NCT01164956|Experimental|M-P, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9782056|NCT01164956|Experimental|P-M, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9782057|NCT01164956|Experimental|P-M, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9782058|NCT01164956|Experimental|M-P, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9785396|NCT01250990|Active Comparator|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
10201525|NCT02507960|Other|Pilot Study|The patient will undergo a conventional CT simulation in supine position without the breast immobilization cup. The purpose of the CT simulation is-two-fold: 1) the investigators will see if the TB volume can be accurately delineated and if the TB volume is too large for Gamma Pod boost; and 2) the CT images are used for planning the patient's whole breast irradiation. If, after viewing the CT images and the patient is deemed a study candidate and consents, the participants will receive a second CT-sim and the Gamma Pod TB boost treatment on the same day as described below.
10201526|NCT02435433|Experimental|Ramucirumab|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
10201527|NCT02435433|Placebo Comparator|Placebo|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
10201528|NCT02435433|Experimental|Open Label Ramucirumab|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
10201529|NCT02435433|Experimental|Ramucirumab ME2 Cohort|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
9746228|NCT00367003|Experimental|Deep Brain Stimulation|Participants with treatment resistant depression will have a device implanted for deep brain stimulation.
9746229|NCT00367016|Experimental|Omalizumab|Subjects will receive subcutaneous Omalizumab for 6 months. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
9746230|NCT00367016|Experimental|Placebo|Subjects will receive subcutaneous placebo for 6 months. Prior to placebo administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
9746231|NCT00367133|Active Comparator|1|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
9746232|NCT00367133|Experimental|2|Intravitreal injection of 1mg of triamcinolone acetonide
10201530|NCT02435433|Placebo Comparator|Placebo ME2 Cohort|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
9746233|NCT00367133|Experimental|3|Intravitreal injection of 4mg of triamcinolone acetonide
9746234|NCT00367237|Experimental|Infliximab + methotrexate (IFX + MTX)|Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
9746235|NCT00367237|Active Comparator|Methotrexate (MTX)|Oral methotrexate (MTX) 15 mg/week
9746236|NCT00367341|Other|Escitalopram|
9746237|NCT00367341|Other|Cognitive Behavioral Therapy|
9746238|NCT00367380|Experimental|Group 1|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
9746239|NCT00367380|Experimental|Group 2|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
9746240|NCT00367380|Experimental|Group 3|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
9746241|NCT00367432|Experimental|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
9746242|NCT00367458|Experimental|Atorvastatin, then Placebo|Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.
9746243|NCT00367458|Experimental|Placebo, Then Atorvastatin|Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.
9746244|NCT00367484|Experimental|Rebif® (clone 484-39)|Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.
9746245|NCT00367601|Experimental|1|Bevacizumab + erlotinib; if no progressive disease observed, combination or single-agent treatment will continue until unacceptable toxicity or progressive disease.
9746246|NCT00367640|Experimental|100 IR|100 IR grass pollen allergen extract tablet
9746247|NCT00367640|Experimental|300 IR|300 IR grass pollen allergen extract tablet
9746248|NCT00367640|Experimental|500 IR|500 IR grass pollen allergen extract tablet
9746249|NCT00367640|Placebo Comparator|Placebo|Placebo tablet
9746250|NCT00367679|Experimental|Single Arm|800 mg pazopanib oral daily
9746251|NCT00367744|Active Comparator|Rosigitazone arm|Rosiglitazone active 4 mg BID
9746252|NCT00367744|Placebo Comparator|Placebo arm|Matching Placebo BID
9746253|NCT00367770|Experimental|Tracleer|The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
9746254|NCT00367835|Experimental|SPD503 (Guanfacine hydrochloride)|
9746255|NCT00367835|Placebo Comparator|Placebo|
9746256|NCT00367991|Active Comparator|A|recombinant human erythropoietin 200 U/kg IV daily for 3 days
9746257|NCT00367991|Placebo Comparator|B|Normal saline volume to match active treatment IV daily for 3 days
9746258|NCT00368069|Experimental|Keppra® XR|Keppra® extended release formulation -XR
9746259|NCT00368069|Placebo Comparator|Placebo|placebo
9746260|NCT00368108|Experimental|2 mg perampanel|The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
9746261|NCT00368108|Experimental|4 mg perampanel|The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
9746262|NCT00368108|Placebo Comparator|placebo|The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
9746263|NCT00368251|Placebo Comparator|Placebo|Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
9746264|NCT00368251|Experimental|Brivaracetam 5 mg/day|Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
9746265|NCT00368251|Experimental|Brivaracetam 150 mg/day|Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
10201531|NCT02430558|Experimental|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
10201532|NCT02426125|Experimental|Ramucirumab + Docetaxel|Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
10201533|NCT02426125|Placebo Comparator|Placebo + Docetaxel|Placebo IV plus docetaxel (75 mg/m²) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
9746266|NCT00368277|Experimental|Aliskiren-based regimen|Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg
9746267|NCT00368277|Active Comparator|Ramipril-based regimen|Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg
9746268|NCT00368290|Experimental|1|modafinil plus CBT
9746269|NCT00368290|Placebo Comparator|2|placebo plus CBT
9746270|NCT00368316|Experimental|S. sonnei conjugate vaccine|Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
9746271|NCT00368316|Experimental|S. flexneri 2a conjugate vaccine|Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa
9746272|NCT00368355|Experimental|CLINIMACS Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
9746273|NCT00368355|Experimental|ISOLEX Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
9746274|NCT00368459|Experimental|raloxifene|oral raloxifene 120 mg once daily
9746275|NCT00368459|Placebo Comparator|placebo|identical appearing oral placebo
9746276|NCT00368472|Experimental|Perampanel|Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study
9746277|NCT00368537|Active Comparator|1|Arm 1: Tigecycline
9746278|NCT00368537|Active Comparator|2|Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide
9746279|NCT00368550|Experimental|1|Oral sertraline, cognitive-behavioral counseling to maintain abstinence from alcohol
10201534|NCT02417142|Experimental|Experimental|Exenatide 2mg subcutaneous injection, once weekly
9746280|NCT00368550|Placebo Comparator|2|Placebo, cognitive-behavioral counseling to maintain abstinence from alcohol
9746281|NCT00368641|Experimental|Intervention|peritoneal dialysis
9746282|NCT00368641|No Intervention|Standard of Care|
9746283|NCT00368745|Active Comparator|Pregabalin|Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
9746284|NCT00368745|Placebo Comparator|Placebo|Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
9746285|NCT00368849|Experimental|40 milligram twice a day atomoxetine|Participants received 40 milligram twice a day atomoxetine for 4 weeks.
9746286|NCT00368849|Placebo Comparator|Twice a day matching placebo|Participants received twice a day matching placebo for 4 weeks.
9746287|NCT00368875|Experimental|vorinostat, paclitaxel, bevacizumab|Vorinostat BID on days 1-3, 8-10, and 15-17, paclitaxel IV over 1 hour on days 2, 9, and 16, bevacizumab IV over 30-90 minutes on days 2 and 16, repeat every 28 days.
9746288|NCT00368927|Experimental|Arm I|Patients receive oral sulindac twice daily for 6 months.
9746289|NCT00368927|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
9746290|NCT00368940|Experimental|PATH|Participants will receive PATH for 12 weeks
9746291|NCT00368940|Active Comparator|ST-CI|Participants will receive ST-CI for 12 weeks
9746292|NCT00368966|Experimental|1|
9746293|NCT00368966|Active Comparator|2|
9746294|NCT00368979|Active Comparator|Dutasteride|
9746295|NCT00368979|Placebo Comparator|Placebo|
9746296|NCT00368992|Experimental|Treatment (cetuximab, paclitaxel, bevacizumab)|"INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
10201535|NCT02417142|Placebo Comparator|Placebo|Placebo
10201536|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
10201537|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
10201538|NCT02387398|Experimental|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
10201539|NCT02387398|No Intervention|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
9746297|NCT00369122|Experimental|Treatment (radiation therapy, bevacizumab, cisplatin)|"Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45 Gy.~Some patients also undergo low-dose rate brachytherapy twice, 1-3 weeks apart, beginning >= 4 weeks after initiating EBRT or high-dose rate brachytherapy 5 times, >= 48 hours apart, beginning >= 2 weeks after initiating EBRT. EBRT and chemotherapy are halted on the day of high-dose rate brachytherapy. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 35."
9746298|NCT00369161|Active Comparator|Very low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
9746299|NCT00369161|Active Comparator|Low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
9746300|NCT00369226|Experimental|Bortezomib/Tacrolimus/Methotrexate post HSCT|
9746301|NCT00369278|Experimental|Intensified Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.
9746302|NCT00369278|Active Comparator|Standard Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.
9746303|NCT00369343|Experimental|A|
9746304|NCT00369343|Placebo Comparator|B|
9746305|NCT00369382|Active Comparator|1|Group 1: Continuation of CNI regimen
9746306|NCT00369382|Experimental|2|Group 2: (CNI-Free) Conversion to SRL-based regimen
9746307|NCT00369486|Active Comparator|1|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)
9746308|NCT00369486|Experimental|2|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
9746309|NCT00369486|Experimental|3|Anterior peribulbar injection of 20 mg triamcinolone
9746310|NCT00369486|Experimental|4|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
9746311|NCT00369486|Experimental|5|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
9746312|NCT00369512|Experimental|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
9746313|NCT00369564|Experimental|Arm I Glutamic Acid|Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
9746314|NCT00369564|Placebo Comparator|Arm II Placebo|Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
9746315|NCT00369577|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, single dose
9746316|NCT00369577|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
9746317|NCT00369577|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
9746318|NCT00369590|Experimental|All Study Patients|"Patients receive VEGF Trap (ziv-aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis."
9746319|NCT00369629|Experimental|Cohort 1|"Pemetrexed at a dose of 400 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
9746320|NCT00369629|Experimental|Cohort 2|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
9746321|NCT00369629|Experimental|Cohort 3|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1000 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
9746322|NCT00369629|Experimental|Cohort 4|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1200 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
9746323|NCT00369655|Experimental|Treatment (ziv-afibercept)|Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9746324|NCT00369668|Experimental|High Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; four 90-minute sessions/week for 2 weeks.
9746325|NCT00369668|Active Comparator|Low Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; two 90-minute sessions/week for 2 weeks.
9746326|NCT00369668|Active Comparator|Control|Bilateral training moving both arms coupled with sham neuromuscular electrical stimulation
9746327|NCT00369681|Experimental|R-ABVD|ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m^2 Cycles 2, 4, and 6 Day 1.
9746328|NCT00369707|Experimental|Bortezomib and Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
9746329|NCT00369746||Alcohol and major depression, citalopram|Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
9746330|NCT00369746||Major Depression, citalopram|Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
9746331|NCT00369785|Experimental|Arm I - Donepezil|Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
9746332|NCT00369785|Placebo Comparator|Arm II - Control|Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
9746333|NCT00369824|Experimental|Cervarix + Boostrix/Menactra Group|Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.
9746334|NCT00369824|Experimental|Cervarix + Menactra/Boostrix Group|Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.
9746335|NCT00369824|Experimental|Cervarix + Boostrix + Menactra Group|Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.
9746336|NCT00369824|Experimental|Boostrix/Cervarix Group|Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.
9746337|NCT00369824|Experimental|Menactra/Cervarix Group|Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.
9746338|NCT00369824|Experimental|Cervarix Group|Subjects received Cervarix at Months 0, 1 and 6.
9746339|NCT00369915|Experimental|Plac/Scop|Placebo then scopolamine
9746340|NCT00369915|Experimental|Scop/Plac|Scopolamine then placebo
9746341|NCT00369928|Placebo Comparator|Placebo|Placebo, oral dose, BID
9746342|NCT00369928|Experimental|25 mg PG-760564|25 mg BID, of oral PG-760564
9746343|NCT00369928|Experimental|100 mg PG-760564|100 mg BID, of oral PG-760564
9746344|NCT00369941|Experimental|MK-0518 400 mg b.i.d.|MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
9746345|NCT00369941|Active Comparator|Efavirenz 600 mg q.h.s.|Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
9746346|NCT00369967|Experimental|Quick start|Start contraceptive method (NuvaRing) day of enrollment
9746347|NCT00369967|Active Comparator|Traditional start|Start contraceptive method (NuvaRing) after next menses (per package insert)
9746348|NCT00370071|Experimental|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
9746349|NCT00370149|Active Comparator|Antibiotic-impregnated Catheters (M/R)|Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
9746350|NCT00370149|Placebo Comparator|Non-impregnated Catheter (C/S)|Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
9746351|NCT00370292|Experimental|Pemetrexed - Before Protocol Amendment|
9746352|NCT00370292|Experimental|Pemetrexed - After Protocol Amendment|
9746353|NCT05288101|Active Comparator|Control|Patients in CON group received a personalized diet and dry weight adjustment by BIVA. Anthropometrical, biochemical, dietary, QoL, handgrip strength (HGS) and bioimpedance measurements were performed. Malnutrition Inflammation Score (MIS) was applied
9746354|NCT05288101|Experimental|Supplemented|Patients in SUPL group received a simultaneous intervention consisting of a personalized diet, 245 mL/d ONS and dry weight adjustment through BIVA, Anthropometrical, biochemical, dietary, QoL, handgrip strength (HGS) and bioimpedance measurements were performed. Malnutrition Inflammation Score (MIS) was applied
9746355|NCT05288088||Tumor craniotomy patients|Patients undergoing elective brain tumor craniotomy
9746356|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant A|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant A in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
9785397|NCT01250990|Placebo Comparator|Placebo|Placebo tablet with 50 mg niacin for the first 4 weeks to maintain blinding of the study team and subjects, changed to pure placebo after that.
9746357|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant B|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant B in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
10201540|NCT02368886|Experimental|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
10201541|NCT02368886|Experimental|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
9746358|NCT05288075|Experimental|Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant C|Each subject will receive a single dose of 2 inhaled doses from Indacaterol/glycopyrronium Easyhaler product variant C in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
9746359|NCT05288075|Active Comparator|Ultibro® Breezhaler® 85/43 µg inhalation powder, hard capsule|Each subject will receive 2 capsules of Ultibro® Breezhaler® (=Indacaterol/glycopyrronium) as a single dose in one of the four periods (cross-over) with concomitant charcoal administration (Carbomix granules). The total dose is 170 µg of indacaterol and 86 µg glycopyrronium (delivered doses).
9746360|NCT05288049|Experimental|Intervention aiming to enhance cognitive reserve (CR)|The psychological intervention to enhance cognitive reserve (CR) will be conducted in a group format (6-8 individuals). Each session will last approximately 60 minutes. The full psychological intervention will have 12 sessions (1 per week) and will last three months. Moreover, to remind the participants of the contents of the intervention, a follow-up session will be held every two months between the last session of the psychological intervention and the 12-month assessment. Most of the tasks of the psychological intervention will use pen and paper with audiovisual support. However, some sessions will use mobile apps and virtual reality. Virtual reality will be implemented for each patient in the sessions focusing on mindfulness training. The contents of the sessions are adapted to the different ages of the attendees. Groups with adolescents and those with young adults will be run separately.
9746361|NCT05288049|Active Comparator|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention. After the 12-month assessment, subjects in the support group will be offered the intervention although this will be out of the scope of this study.
9746362|NCT05288036|Experimental|Proprioceptive Neuromuscular Rehabilitation group|PNF techniques; It is based on facilitating the responses of neuromuscular mechanisms by stimulating proprioceptors. It is a method used to improve active movement ability by increasing muscle strength, to increase muscle endurance, to improve stabilization at the point where the technique is applied within the movement pattern.
9746363|NCT05288036|Experimental|Progressive Resistance Exercise Group|Progressive resistance training (PRT) is a method for increasing muscle strength and endurance based on the determination of the amount of resistance appropriate for the individual. Free weights and resistance machines are used in the practice of this technique.To facilitate continued adaptation, training intensity (i.e. load) and training volume (i.e. number of sets) are progressively increased, and exercises are adjusted as indicated throughout the training regimen, to attenuate the onset of a plateau in physiological adaptation.
9746364|NCT05288036|Active Comparator|Control Group|This group was created to determine the amount of self-healing of the disease in the process. The approach was taken in a way that did not affect the outcome measures.
9746365|NCT05288010|Other|Active Group|Patients of the clinic receiving cannabis treatment for non cancer chronic pain, who have been invited to join the study and have agreed and consented to join study.
9746366|NCT05287997|Other|Baseline|Participants in this arm will be evaluated at 3 time periods. Initial pre-season visit, mid-season visit and end-of-season visit. Capillary blood sample collection will occur at each visit.
9746367|NCT05287997|Experimental|Concussion|Participants in this arm will transition from the baseline arm to the concussion arm if they experience a concussion during the course of the sporting season. They will be evaluated with 72 hours of the injury and then at 2-, 4-, and 12-weeks post-injury. Capillary blood sample collection will occur at each visit.
9746368|NCT05287958||Healthy|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
9746369|NCT05287958||ALS|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
9746370|NCT05287945|Experimental|Orellanine 0.05-4.9 mg/kg single intravenous administration following hemodialysis|
9746371|NCT05287932|Experimental|Intervention|Brief physical activity intervention including an initial 45-minute physical activity consultation, telephone support after 2 weeks (approx. 15-minute call), and provision of a pedometer, written information, and a physical activity diary. Embedded behaviour change techniques will include goal setting, self-monitoring, building self-efficacy and social support, and overcoming barriers.
9746372|NCT05287932|No Intervention|Wait-list control|The control group will not receive any active or placebo intervention during the 4-week study period. They will also not receive any trial contacts during this period. They will however continue to be able to access their usual care from primary, secondary, community, and social services. After the final (4-week) follow-up assessment, this group will receive the full physical activity intervention.
9746373|NCT05287919|Other|Control group|Patients received the standard physical therapy (SPT) programme only (passive mobilization) twice a day.
9746374|NCT05287919|Experimental|Low-frequency NMES group|Patients submitted to low-frequency NMES and SPT twice a day.
9746375|NCT05287919|Experimental|Medium-frequency NMES group|Patients submitted to medium-frequency NMES and SPT twice a day.
9746376|NCT05287880||Non-N0 stage|Patients with malignant lymph nodes.
9746377|NCT05287880||N0 stage|Patients without malignant lymph nodes.
9984704|NCT03811886|Experimental|Phase I: Natalizumab|"Traditional 3+3 design escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed a maximum dose of 300mg~Phase II treatment to continue if the participant has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS as defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If the participant has progressive disease after 6 cycles, they will be removed from the study."
9746378|NCT05287867|Experimental|Platelet treatment|A series of two treatments spaced 4 weeks apart that include platelet-rich plasma (PRP). platelet lysate (PL), and platelet poor plasma (PPP).
9746379|NCT05287867|Sham Comparator|Sham procedure|A series of two sham procedures spaced 4 weeks apart.
9746380|NCT05287854|Experimental|Local anesthesia + Virtual Reality|In addition to local standard anaesthesia, patients benefit from a virtual reality session during the operation using a virtual reality headset
9746381|NCT05287854|No Intervention|Local anesthesia alone|Patients benefit only from a local anaesthesia is provided according to the standard procedure
9746382|NCT05287841|Experimental|Batten graft, plus septoplasty and inferior turbinate reduction|In the intervention arm, a portion of the quadrangular cartilage of the nasal septum is also removed, but will be refashioned and re-implanted into the patient as an autologous batten graft. This will be performed together with standard septoplasty and turbinate reduction.
9746383|NCT05287841|Active Comparator|Septoplasty and inferior turbinate reduction alone|In the control arm, a portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty and turbinate reduction.
9746384|NCT05287815||1|experimental(30 people) groups health education will be given by making a home visit
9746385|NCT05287815||2|control(30 people) no intervention
9746386|NCT05287802|Active Comparator|Biodex Training (BT) group|Biodex Balance System features a platform that can move simultaneously in the anteroposterior (AP) or medio-lateral (ML) direction in 12 different levels of stability within a 20-degree range of inclination, as well as a locked position for static environments. For this platform, 1 represents the least stable level and 12 represents the most stable level. Interactive, game-like training modes are provided with the on-screen grid and score-keeping functions. Patients in the BT group performed exercises with the Balance SystemTM SD once a day, three days a week for 10 weeks under the physicians' supervision. Furthermore this group received closed kinetic chain exercises (CKCE) in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
9746387|NCT05287802|Active Comparator|Classical balance training group (CT group)|Patients in the CT group completed the exercise program once a day and three days a week during the 10-week period under the physicians' supervision. The exercises consisted of standing on one leg, tandem walking (heel-to-toe), balance board exercises, Romberg exercise, backward walking, and side-to-side stepping exercises. The total duration of these exercises was 20-30 minutes. Furthermore this group also received CKCE in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
9746388|NCT05287802|Active Comparator|Control group|Isometric home exercises, which can be considered the most basic and feasible strengthening program, were selected to compare the effects they had when added to the intervention groups and administered alone. All patients in the study performed isometric exercises for the quadriceps and hamstrings at home once a day, three days a week for 10 weeks. The exercises were performed as 10 repetitive cycles of six-second contractions and two-second rest periods. All patients were given a daily exercise chart to mark the home program, and adherence to the exercises was monitored weekly by telephone call.
9746389|NCT05287789|Experimental|Squatting position by footstool|"After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a footstool at the appropriate height on the water closet type toilet.~The patients used footstools in the hospital and throughout a week after discharge at home for defecation."
9746390|NCT05287789|No Intervention|Control Group|The control group received the routine care provided to all the patients in the clinic with no additional interventions.
9746391|NCT05287776|Experimental|15 patients with vitiligo subjected to NB-UVB|Patients will be subjected to NB-UVB sessions 3 times weekly. The UVB dosing scheme in the patients receiving only NB-UVB treatment entailed initial dosing at 0.5 J/cm2 with increasing increments by 0.3 J/cm 2 every other session until faint erythema occurs.
9746392|NCT05287737||Referred for Total pancreatectomy with islet autotransplantation|Followed up for up for 15 years after TPIAT.
9746393|NCT05287698|Experimental|Cold vapor group|Cold vapor will be applied to the experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtime-un600a-ultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
9785398|NCT01251042|Experimental|Sangvia and retransfusion|
9785399|NCT01251042|Sham Comparator|Sangvia and no retransfusion|
9785400|NCT01251146|Experimental|Bisoprolol|
9785401|NCT01251146|Active Comparator|Atenolol|
9746394|NCT05287698|No Intervention|Control group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service.
9746395|NCT05287685|Experimental|Screen media adapted School Readiness Parenting Program|Screen media adapted School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
9746396|NCT05287685|Active Comparator|Original School Readiness Parenting Program|Original School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
9746397|NCT05287659|Experimental|VLCKD group|patients followed a structured VLCKD protocol (800Kcal/die)
9746398|NCT05287659|Active Comparator|VLCKD and Physical Training group|patients followed a structured VLCKD protocol (800Kcal/die) combined with interval training (IT), two times a week
9746399|NCT05287659|Active Comparator|LCD and Leucine supplementation group|patients followed a LCD regimen (1000 kcal/day) with supplementation of 18 g whey proteins which 4.1 g of leucine
9746400|NCT05287646|Active Comparator|Suction Suspension First|The residual limb will be imaged during dynamic activities while participants use suction suspension first, then while participants use elevated vacuum suspension. Dynamic stereo x-ray will take place 4-weeks after socket fitting.
9746401|NCT05287646|Active Comparator|Elevated Vacuum Suspension First|The residual limb will be imaged during dynamic activities while participants use elevated vacuum suspension first, then while participants use suction suspension. Dynamic stereo x-ray will take place 4-weeks after socket fitting.
9746402|NCT05287633|Active Comparator|A : Proton Pump Inhibitors|Patients are given proton pump inhibitors tablets once a day
9746403|NCT05287633|Placebo Comparator|B: Placebo|Patients are given a placebo instead of proton pump inhibitors active drug
9746404|NCT05287607||Newborn Infants|Newborn infants delivered at study hospital and admitted to neonatal unit. Babies anticipated to stay for at least 5 days.
9746405|NCT05287594|Experimental|TRAINER|The TRAINER group will receive an integrated exercise program, led by a peer-trainer, including a neuromuscular warm-up and high intensity interval training at their respective fire stations 2 times per week for 6 weeks.
9746406|NCT05287594|No Intervention|Waitlist Control|The waitlist control group will not receive training during the course of the study, but will be offered the opportunity to receive the integrated exercise program after the study ends.
9746407|NCT05287581|Experimental|Experimental|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
9746408|NCT05287581|No Intervention|Waitlist Control|24-week waitlist control condition
9746409|NCT05287555|Active Comparator|Control|"Home non-invasive mask ventilation with prisma VENT device. Modem for the daily transmission of specific therapy parameters.~Standard care according to clinical standard (technical support by the provider and three hospital follow-up appointments after 2, 6 and after 12 months) with assessment of health status and NIV therapy settings.~Study specific: During visits, recording of HRQOL by SGRQ and S3NIV questionnaires, hospitalizaion and physician visits.~Therapy data from NIV device."
9746410|NCT05287555|Experimental|Telemonitoring|"Home non-invasive mask ventilation with prisma VENT device. Modem for the daily transmission of specific therapy parameters. An electronic feedback system provides patients with feedback and recommendations on their therapy based on the data submitted.~The study center regularly reviews and reacts to all therapy data and other information according to the remote care scheme of intervention.~Telemonitoring care patients also receive an SpO2 sensor for monitoring of oxygen saturation.~Ambulantory implementation of three blood gas analyses to check the health status after 2, 6 and 12 months. There are no regular routine inpatient stays.~Study specific: During visits, recording of HRQOL by SGRQ and S3NIV questionnaires, hospitalizaion and physician visits."
9785402|NCT01251276|Experimental|Modified Process Hepatitis B Vaccine in Base Study|Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
9746411|NCT05287542|Experimental|Hypnotic suggestion|During the first phase of the study, two groups will receive identical hypnotic inductions followed by targeted suggestion for one group and non-targeted suggestion for the other. The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
9746412|NCT05287542|Active Comparator|Mindfulness|The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
9746413|NCT05287542|No Intervention|No treatment|The passive control group receives no intervention
9746414|NCT05287529|Experimental|8-Week Yoga Class|Randomized to immediately begin an 8-week Yoga Class via Telehealth
9746415|NCT05287529|Active Comparator|Waitlisted for 8-Week Yoga Class|Randomized to start an 8-week Yoga Class via Telehealth 8-weeks from the start of the study.
9746416|NCT05287516|Experimental|Breakfast meal with 460 kcal|
9746417|NCT05287516|Active Comparator|Breakfast meal with 230 kcal|
9782059|NCT01164956|Experimental|M-P, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9782060|NCT01164956|Experimental|M-P, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9782061|NCT01164956|Experimental|P-M, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9782062|NCT01164956|Experimental|P-M, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
9782063|NCT01165021|Experimental|Pemetrexed + Cisplatin|
9782064|NCT01165047|Experimental|Nitric Oxide|80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM
9782065|NCT01165112|Experimental|Treatment (chemotherapy and monoclonal antibody therapy)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
9782066|NCT01165138|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
9782067|NCT01165138|Experimental|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily for 12 weeks
9782068|NCT01165138|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 12 weeks
9782069|NCT01165177|Experimental|GSK1437173A group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
9782070|NCT01165177|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
9782071|NCT01165203|Experimental|GSK1437173A Group|Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
9782072|NCT01165203|Placebo Comparator|Placebo Group|Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
9782073|NCT01165216|Experimental|Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
9782074|NCT01165216|Experimental|Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
9782075|NCT01165229|Experimental|Zoster vaccine group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
9782076|NCT01165229|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
9782077|NCT01165242|Experimental|Group A|Subjects were vaccinated with vaccine GSK134612 Lot A
9782078|NCT01165242|Experimental|Group B|Subjects were vaccinated with vaccine GSK134612 Lot B
9782079|NCT01165242|Active Comparator|Group C|Subjects were vaccinated with Menactra®
9782080|NCT01165281|Experimental|001|R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.
9782081|NCT01165281|Active Comparator|002|Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.
9782082|NCT01165307|Active Comparator|Medical Therapy|Subjects will be prescribed monthly packets of Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills. Subjects who are unable to tolerate oral contraceptive pills or are unwilling to take oral contraceptive pills will be prescribed naproxen sodium pills. The latter will be administered as follows; 500mg with onset of menses, then 250mg three times daily for the duration of the menses (or maximum of five days).
9746418|NCT05287503|Experimental|Ambroxol|"Ambroxol hydrochloride 200 mg tablets Dose: 1.2 g daily~Escalation scheme:~Day 1 - 5 200 mg 200 mg once a day Day 6 - 10 400 mg 200 mg twice a day Day 11 - 15 600 mg 200 mg three times a day Day 16 - 20 800 mg 400 mg twice a day Day 21 - 25 1000 mg 400 mg + 200 mg + 400 mg a day Day 26 - 365 1200 mg 400 mg three times a day"
9746419|NCT05287503|Placebo Comparator|Placebo|Excipients
9746420|NCT05287490|Experimental|treatment|
9746421|NCT05287451|Other|Risk-Reducing Salpingectomy-RRS|Can help to lower the risk of ovarian cancer with a delayed removal of 1.
9746422|NCT05287451|Other|Risk-Reducing Oophorectomy-RRO|Can help to lower the risk of ovarian cancer removing both fallopian tubes.
9746423|NCT05287451|Other|Risk-Reducing Salpingo-Oophorectomy-RRSO|Can help to lower the risk of ovarian cancer as well as the standard-of-care risk-reducing procedure involving the removal of the fallopian tubes and ovaries (risk-reducing salpingo-oophorectomy-RRSO)
9746424|NCT05287438|Active Comparator|Group A - Culture|Following local standard of care, treatment will be based on standard culture
9746425|NCT05287438|Experimental|Group B - NGS|Treatment will be based on NGS results reviewed by an infectious disease doctor
9746426|NCT05287425|Experimental|Gentamicin eye drops|4 drops daily in both eyes for 7 ± 1 days
9746427|NCT05287425|Experimental|Ciprofloxacin eye drops|4 drops daily in both eyes for 7 ± 1 days
9746428|NCT05287425|Active Comparator|Povidone eye drops unpreserved|4 drops daily in both eyes for 7 ± 1 days
9746429|NCT05287425|Active Comparator|Povidone eye drops preserved|4 drops daily in both eyes for 7 ± 1 days
9746430|NCT05287399|Experimental|ASC61 200 mg 1|ASC61 200 mg orally once
9746431|NCT05287399|Experimental|ASC61 200 mg 2|ASC61 200 mg orally twice daily
9746432|NCT05287399|Experimental|ASC61 300 mg|ASC61 300 mg orally twice daily
9746433|NCT05287399|Experimental|ASC61 400 mg|ASC61 400 mg orally twice daily
9746434|NCT05287399|Experimental|ASC61 600 mg|ASC61 600 mg orally twice daily
9746435|NCT05287386|Experimental|Pemigatinib|Selective FGFR1-3 inhibitor
9746436|NCT05287373|Active Comparator|PNS Therapy plus Conventional Medical Management|peripheral nerve stimulator plus conventional medical management
9746437|NCT05287373|Other|Conventional Medical Management|Control arm conventional medical management only
9746438|NCT05287334|Experimental|Voluntary blood donors|Voluntary blood donors undergoing standard blood donation while measuring electrical impedance of the chest .
9746439|NCT05287321|Experimental|Aspirin 100mg + Hydroxychloroquine 200mg|Aspirin 100mg 1T daily PO + Hydroxychloroquine 200mg 1T daily PO
9746440|NCT05287321|Active Comparator|Aspirin 100mg|Aspirin 100mg 1T daily PO
9746441|NCT05287282|Experimental|TECAR application|
9746442|NCT05287282|Active Comparator|selected abdominal exercises program|
9746443|NCT05287256|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
9746444|NCT05287256|Experimental|Oral administration of 10mg D-8-THC|Single acute administration of cannabis containing 10mg Delta-8-THC baked into a brownie
9746445|NCT05287256|Experimental|Oral administration of 20mg D-8-THC|Single acute administration of cannabis containing 20mg Delta-8-THC baked into a brownie
9746446|NCT05287256|Experimental|Oral administration of 40mg D-8-THC|Single acute administration of cannabis containing 40mg Delta-8-THC baked into a brownie
9746447|NCT05287256|Experimental|Oral administration of 20mg D-9-THC|Single acute administration of cannabis containing 20mg Delta-9-THC baked into a brownie
9746448|NCT05287256|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
9746449|NCT05287256|Experimental|Administration of vaporized 10mg D-8-THC|Single acute administration of placebo cannabis containing 10mg Delta-8-THC via commercial vaporizer
9746450|NCT05287256|Experimental|Administration of vaporized 20mg D-8-THC|Single acute administration of placebo cannabis containing 20mg Delta-8-THC via commercial vaporizer
9746451|NCT05287256|Experimental|Administration of vaporized 40mg D-8-THC|Single acute administration of placebo cannabis containing 40mg Delta-8-THC via commercial vaporizer
9746452|NCT05287256|Experimental|Administration of vaporized 20mg D-9-THC|Single acute administration of placebo cannabis containing 20mg Delta-9-THC via commercial vaporizer
9746453|NCT05287230|Experimental|Intervention|
9746454|NCT05287230|Other|Control|
9746455|NCT05287217|Active Comparator|Group 1: Scheduled pain control|Group 1 patients will be instructed to take 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 consecutive days after surgery regardless of whether they experience pain or not.
9746456|NCT05287217|Active Comparator|Group 2: Pain control as needed.|Group 2 patients will be instructed to take the 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 days after surgery only when needed to control pain.
9746457|NCT05287204||AKI-RRT|These patients are those with acute kidney injury requiring renal replacement therapy.
9746458|NCT05287204||Controls|Controls matched to AKI-RRT patients based on age within 10 years, sex, and ICU length of stay (within 2 days)
9746459|NCT05287191|Experimental|Experimental arm|Intravenous magnesium sulphate as first line followed by digoxin IV loading as second line and then amiodarone IV as third line treatments for fast AF
9746460|NCT05287191|Active Comparator|Standard of care arm|Intravenous amiodarone as compactor group intervention
9746461|NCT05287178|Experimental|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
10201542|NCT02368886|Experimental|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
9746462|NCT05287165|Experimental|IM96 CAR-T cells|
9746463|NCT05287139||Hospital Beneficência Portuguesa de SP - BP1|Patients from private institutions.
9746464|NCT05287139||Hospital Pérola Byington - HPB2|Patients from public institutions.
9746465|NCT05287126|Experimental|Etrasimod|
9746466|NCT05287113|Experimental|Treatment Group 1: Retifanlimab Monotherapy|Retifanlimab will be administered intravenously every 4 weeks. Placebos for INCAGN02385 and INCAGN02390 will be administered intravenously every 2 weeks.
9746467|NCT05287113|Experimental|Treatment Group 2: Retifanlimab + INCAGN02385|Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and Placebo for INCAGN02390 will be administered intravenously every 2 weeks.
9746468|NCT05287113|Experimental|Treatment Group 3: Retifanlimab + INCAGN02385 + INCAGN02390|Retifanlimab plus INCAGN02385 and INCAGN02390 will be administered intravenously. Retifanlimab will be administered intravenously every 4 weeks. INCAGN02385 and INCAGN02390 will be administered every 2 weeks.
9746469|NCT05287100|Experimental|Midodrine|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
9746470|NCT05287100|Active Comparator|Standard medical therapy|Standard medical therapy as per departmental protocol
9746471|NCT05287061|Experimental|Cardiac Rehabilitation (CR) + Multicomponent Psychological Program (MPP):|The patients who are assigned to this treatment arm will have access to a psychological intervention program, which will use techniques from the positive psychology and motivational interviewing to work on several modules: Health pills (phase I), CR in phase II identical to the standar, and MPP interspersed in Phase II of the conventional program. An individualized program will be included in this branch, which will be added to the follow-up carried out in primary care. It will contain a post-traumatic growth module, an emotion management module, and an intention consolidation module.
9746472|NCT05287061|No Intervention|Cardiac Rehabilitation (CR)|The patient will follow the usual process of cardiac rehabilitation.
9746473|NCT05287048||Patients with postmenopausal bleeding|Patients attending a gynaecology clinic for investigation of postmenopausal bleeding and undergoing a transvaginal ultrasound (TVUS).
9746474|NCT05287035|Active Comparator|Steroid injection|Dexamethasone will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
9746475|NCT05287035|Placebo Comparator|Saline solution|Saline will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
9746476|NCT05286996|Experimental|Iovera|Cryoneurolysis + standard of care: Usual intervention plus pre-operation Iovera treatment. Patients will receive local anaesthesia unilaterally to the affected knee prior to the treatment and then the anesthesiologist will administer the freezing cold therapy (Iovera device) to the affected knee.
9746477|NCT05286996|Placebo Comparator|Placebo|Placebo: Usual intervention plus pre-operation placebo. The placebo group will receive short-acting local anaesthesia injection unilaterally to the affected knee.
9746478|NCT05286983||K0 - baseline cohort|45 preterm infants and their parents (average number of patient admissions per 6 months during the last 5 years)
9746479|NCT05286983||K1 - 1st intervention cohort|All preterm infants and their parents enrolled during the first 6 months period after completion of the baseline cohort and who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746480|NCT05286983||K2 - 2nd intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746481|NCT05286983||K3 - 3rd intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746482|NCT05286983||K4 - 4th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746483|NCT05286983||K5 - 5th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9828562|NCT02500732|Active Comparator|Atomoxetine|Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
10201543|NCT02368886|Experimental|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
9746484|NCT05286983||K6 - 6th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746485|NCT05286983||K7 - 7th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746486|NCT05286983||K8 - 8th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746487|NCT05286983||K9 - 9th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746488|NCT05286983||K10 - 10th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
9746489|NCT05286970|Experimental|0.5mg AK115 SC|
9746490|NCT05286970|Experimental|1mg AK115or placebo SC|
9746491|NCT05286970|Experimental|3mg AK115or placebo SC|
9746492|NCT05286970|Experimental|10mg AK115or placebo SC|
9746493|NCT05286970|Experimental|30mg AK115or placebo SC|
9746494|NCT05286970|Experimental|60mg AK115or placebo SC|
9746495|NCT05286957|Experimental|Tislelizumab after Adjuvant Chemotherapy in MRD＋resected NSCLC|after Adjuvant Chemotherapy, MRD＋resected NSCLC Tislelizumab was given 200 mg IV Q3W; MRD- resected NSCLC was follow-up until recurrence
9746496|NCT05286944|Experimental|Mobile daily alarm|A mobile smartphone with functioning alarm system and solely owned by the patient. The alarm will be set by the second investigator to alert the participant between 6am - 10am (based on participant's preference) in the morning daily. A recorded dual-language (English and Malay version) tone for alarm mobile phone will be used. Apart from that participants are also counseled and educated about allergic rhinitis and are also asked to fill up self monitored adherence card to document their nasal steroid intake.
9746497|NCT05286944|No Intervention|Control|This group of participant will receive counseling and education regarding allergic rhinitis and the importance of compliance. Patients are also given a self monitored adherence card to document their nasal steroid intake.
10201544|NCT02354703|Experimental|ondansetron-responsive genotype|"ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
10201545|NCT02354703|Experimental|ondansetron--non-responsive genotype|ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
10201546|NCT02354703|Placebo Comparator|placebo--responsive genotype|"placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and carrying one of the following genotypes:~if European ancestry:~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT~HTR3A gene:~rs1150226:AG; or rs1176713:GG~HTR3B gene:~rs17619942:AC~If African ancestry:~HTR3B gene:~rs176744: CC or CA~SLC6A4 gene:~5-HTTLPR:LL, or rs25531:AA, or 5-HTTLPR + rs25531 (LALA genotype) or rs1042173:TT"
10201547|NCT02354703|Placebo Comparator|placebo--non-responsive genotype|placebo bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks and NOT carrying any of the responsive genotypes
10201548|NCT02350595|Experimental|Lean fish|Participants eat 750g of lean fish per week for 8 weeks.
10201549|NCT02350595|Experimental|Fatty fish|Participants eat 750g of fatty fish per week for 8 weeks.
10201550|NCT02350595|No Intervention|Control|Participants eat as normal, but avoid fish and seafood for 8 weeks.
10201551|NCT02340403|Experimental|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
10201552|NCT02340403|Other|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
10201553|NCT02307448|Active Comparator|PRP Group|Patients will receive weekly PRP treatments
10201554|NCT02307448|Placebo Comparator|Standard of Care|Patients will receive weekly standard of care.
9746498|NCT05286931|Experimental|N. gonorrhea (gyrA wildtype) -Ciprofloxacin Treatment Arm|Participants who are N. gonorrhea (NG) positive and gyrA WT, will receive ciprofloxacin 500 mg PO x 1.
9746499|NCT05286918|Experimental|The intervention (CRP-guided) group|"Standard usual care (following GOLD initiative, including bronchodilator, and systemic steroid).~The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to <5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
9746500|NCT05286918|No Intervention|The usual care (control) group|Patients in the control arm will be treated with usual care (GOLD initiative). No CRP would be measured.No CRP would be measured.
9746501|NCT05286905|Active Comparator|Patients who receive cephalomedullary nail|Patients who receive cephalomedullary nail
9746502|NCT05286905|Active Comparator|Patients who receive proximal femur locking plate|Patients who receive proximal femur locking plate
9746503|NCT05286892|Active Comparator|Control|Participants randomized to the control group will receive enhanced pre-release diabetes education with registered or licensed practical nurse-delivered diabetes education about medications and insulin administration supplemented with the literacy tailored diabetes education packets used in the principal investigator's prior research.
9746504|NCT05286892|Experimental|Intervention|Because eight avatars plus the educator avatar are allowed in the VE classroom at one time, we will cap enrollment for the feasibility study to allow for CHW and CDE training and the opportunity to work together during LIVE JustICE sessions. The DSMES will consist of six synchronous 1-hour education sessions and an hour support session for participants living in supervised community housing in the experimental group. We will run the six-week series sequentially a total of eleven times over 18 months. LIVE JustICE sessions will be held conveniently for participants, and days/times rotated if needed.
9746505|NCT05286866|Experimental|Low speed drilling without irrigation|The dental implants will be placed using a low-speed drilling technique without irrigation for the experimental group.
9746506|NCT05286866|Active Comparator|High speed drilling with irrigation|The dental implants will be placed using a high-speed drilling technique with irrigation for the control group.
10201555|NCT02203409||Laparoscopic ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
9746507|NCT05286801|Experimental|Treatment (atezolizumab, tiragolumab)|Patients receive atezolizumab IV over 60 minutes on day 1 and tiragolumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
9984705|NCT03809663|Placebo Comparator|Part A: Placebo|"Matching placebo administered via SC injection Q2W for a maximum of 52 weeks.~Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
9746509|NCT05286775|Experimental|Clinical treatment and Knee educational program|Medical knee treatment combined with knee educational educational program
9746510|NCT05286775|Active Comparator|Knee educational program|Knee educational program
9746511|NCT05286762|Active Comparator|18.75 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (18.75 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg and the following week they will be increased to their assigned dose of 18.75 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
9746512|NCT05286762|Active Comparator|25 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (25 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to their assigned dose of 25 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
9746513|NCT05286762|Active Comparator|37.5 mg CTx-1301 (dexmethylphenidate tablet)|Subjects who are randomized to active drug (37.5 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to 25 mg; at week 3 they will be increased to their assigned dose of 37.5 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.
9746514|NCT05286762|Placebo Comparator|Placebo|Subjects randomized to placebo will be on placebo for the full 5 weeks of the study.
9746515|NCT05286749|Active Comparator|Control|Participants take a workshop where they are provided education on standard-of-care for cervical cancer screening such as pap smear and HPV testing through clinician-collection methods using speculum and cervical swabs.
9746516|NCT05286749|Experimental|Intervention|Participants take a workshop where they are provided all the same education as control as well as additional education on self-collection for HPV-only testing using vaginal swab as an additional method.
9746517|NCT05286736||Early (untreated) Parkinson's Disease|Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria.
9746518|NCT05286736||Healthy Controls|Age- and sex-matched healthy controls.
9746519|NCT05286723|Experimental|Multicomponent Training|"Traditional training. 3 times a week~Warm-up:~Main work:~Aerobic training Strength training Balance and coordination training Return to calm"
9746520|NCT05286710|Experimental|modified access group|modified access: PMT was performed via distal calf venous access or contralateral femoral access
9746521|NCT05286710|Active Comparator|traditional access group|traditional access: PMT was performed via ipsilateral popliteal venous access
9746522|NCT05286684|Experimental|Study process|Consultation, Cerebral and medullary MRI, lumbar puncture, CSF sampling, blood sample, collection of breast fluid
9746523|NCT05286658|Experimental|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
9746524|NCT05286645|Active Comparator|real stimulation|Participants will receive active tDCS once daily for two weeks. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions.
9746525|NCT05286645|Placebo Comparator|sham stimulation|Participants will receive sham tDCS once daily for two weeks. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
9782083|NCT01165307|Active Comparator|Radiofrequency Endometrial Ablation|Subjects will undergo NovaSure® radiofrequency endometrial ablation within 4 weeks of randomization. The procedure will occur at any time during the menstrual cycle, without endometrial pre-treatment. Endometrial thinning will be carried out using suction curettage in 50% of the cases included in the ablation group. Random assignment for this treatment will be included in the overall randomization plan.
9746526|NCT05286619|Experimental|Pembrolizumab plus Platinum and Gemcitabine|Pembrolizumab 200 mg will be administered as 30-minute IV infusion Day 1 of every 3 weeks. Pembrolizumab will be administered first followed by the platinum and gemcitabine infusions. Cisplatin will be administered on Day 1 and 8 of each 3-weeks treatment cycle with a dose of 35 mg/m2 for 60 minutes. Carboplatin will be administered on Day 1 of each 3-weeks treatment cycle given as a dose of AUC 5 for 60 minutes. Gemcitabine will be administered on Day 1 and 8 of each 3-weeks treatment given as a dose of 1250 mg/m2 for 30 minutes. AEs associated with pembrolizumab exposure, including coadministration with additional compounds, may represent an immunologic aetiology. If one or all of the chemotherapy components is discontinued, subjects can continue with pembrolizumab up to the full 35 cycles.
9746527|NCT05286606||Focus groups|Health Care Professionals (HCP), facilitators, participants in the exercise program will be invited to participate in focus groups to comment on usability/acceptability.
9746528|NCT05286606||App users|Users of the exercise program with musculoskeletal conditions have been referred to the exercise program via the charities, all will be participating in a three-month program using the beta version of the app. They will be invited to participate in the program evaluation
9746529|NCT05286606||Facilitators|Facilitators of the exercise program: The facilitators for the virtual groups have been recruited equally by the charities and are working for GoodBoost to facilitate the exercise program for the app users. They will be invited to participate in the program evaluation
9983950|NCT04530006|Experimental|GBM Patients|"This cohort of patients will be asked to orally ingest 200mg dose of FDA approved drug amantadine hydrochloride. This will be done at the following timepoints:~Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
9983951|NCT04526925|Active Comparator|standard CPET|Standard CPET will be performed without in-line filter
9983952|NCT04526925|Experimental|standard CPET with in-line filter|An in-line filter will be placed on the mouthpiece during standard CPET
9983953|NCT04525755|Experimental|Varenicline (.5mg BID)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline (.5 mg, 60 tablets total), NRT, or not, with outcomes assessed through 12 weeks of follow-up. 324 participants will be enrolled in this group. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience.
9746534|NCT05286541|Experimental|Lateralized buccal cortex group with xenograft|the buccal cortical bone was osteotomized and separated to be fixed in a lateralized position at the desired distance and the gap filled with Xenograft
9746535|NCT05286541|Active Comparator|lateralized buccal cortex with autogenous particulate|the buccal cortex was lateralized same as in the interventional group but the gap filled with autogenous particulate
9746536|NCT05286515|Experimental|Hybrid Preoperative Physical Therapy (PT)|
9746537|NCT05286515|Active Comparator|Control Standard Physical Therapy (PT)|
9746538|NCT05286502||Adults 18 years old or older|
9746539|NCT05286489|Experimental|group A|Qigong exercise program twice weekly for 8 weeks postmastectomy in addition to traditional medical and physical therapy treatment.
9746540|NCT05286489|Other|group B|traditional medical and physical therapy treatment only .
9746541|NCT05286476|Experimental|group A|received Whole-body Vibration, pelvic floor exercise and static abdominal exercises interventions In addition to diet instructions
9746542|NCT05286476|Other|group B|received pelvic floor exercises and static abdominal exercises in addition to diet instructions only
9746543|NCT05286463|Experimental|group A|received low-intensity pulsed ultrasound using bee venom (BV) gel for 5 minutes for each session, three times a week, for three consecutive weeks postoperative and received regular medical care.
9746544|NCT05286463|Sham Comparator|group B|received low-intensity pulsed ultrasound using only plain gel without BV gel for 5 minutes for each session, three times a week, for three consecutive weeks postoperative and received regular medical care.
9746545|NCT05286437|Experimental|Intervention|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
9746546|NCT05286385|Active Comparator|CP1150|CP1150 will be used as the comparator device for speech perception testing in quiet.
9746547|NCT05286385|Experimental|CP1150 (modified firmware)|CP1150 Sound Processor with modified firmware.
9746548|NCT05286385|Experimental|CP1150 + FF|CP1150 Sound Processor with ForwardFocus.
9746549|NCT05286385|Experimental|CP1110|CP1110 is a BTE Sound Processor.
9746550|NCT05286359|Experimental|NxTekTM Malaria Plus Rapid Diagnostic Test (RDT) Devices|
9746551|NCT05286346|Experimental|Experimental group|Tenolid Tab
9746552|NCT05286346|Active Comparator|Control group|Viread Tab
9746553|NCT05286320|Experimental|Target-/Immuno-therapy for advanced HCC w PVTT Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
9746554|NCT05286307|Experimental|Participants receiving IPACK block|Patients in this study group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%). And receive the additional IPACK block performed using 20 mL of Bupivacaine (0.25%) injected into the interspace between the popliteal artery and capsule of the knee.
9746555|NCT05286307|No Intervention|Standard of care group|Patients in the control group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%).
9746556|NCT05286294|Experimental|Treatment|Fecal Microbiota Transplant (FMT)
9746557|NCT05286268||Study group|Patients with confirmed COVID-19 disease
9746558|NCT05286268||Control group|Healthy volunteers without any of the exclusion criteria
9746559|NCT05286255|Experimental|Allogeneic Mesenchymal Stromal Cell infusion|Intravenous infusion of 1.25-1.5 x 10^6 cells/kg with a maximal dose of 100 x 10^6 cells on days 1 and 3 after study enrollment.
9746560|NCT05286242||Healthy control|Healthy controls Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
9746561|NCT05286242||Disease control|"Disease controls (individuals with a qualifying autoimmune condition, but not treated with any immunomodulator).~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
9746562|NCT05286242||B-cell depleted|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with B-cell depleting anti-CD20 monoclonal antibodies.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
9746563|NCT05286242||Other immunomodulator|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with a non-CD20 monoclonal antibody immunomodulator to treat their disease.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
9746564|NCT05286216|Experimental|Experimental group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale will be applied before the intervention. The training will be in two modules and two different sessions. The effectiveness of the training will be evaluated by re-applying the scales 12 weeks and 24 weeks after the training."
9746565|NCT05286216|No Intervention|Control group|"Patient diagnosis form with CHB and related scales (Patient Diagnosis Form with Chronic Hepatitis B, Medication Adherence Report Scale-5), Medication Adherence Report Scale (MedTake Test), Chronic Liver Disease Quality of Life Scale 2.0 (Liver Disease Symptom Index 2.0 (LDSI 2.0), Health-Related Quality of Life Scale SF-12 (12 Item Short Form Health Survey) (Short Form 12 - SF 12), Patient Learning Needs Scale in the first evaluation, 12 weeks and 24 weeks later, the scales were re-applied and the education was improved. effectiveness will be evaluated."
9746566|NCT05286203|Active Comparator|Standard of Care|Patients enrolled in the trial and randomized to the standard of care (SOC) arm will undergo standard of care testing.
9746567|NCT05286203|Experimental|MDS|Patients enrolled in the trial and randomized to the MDS arm will undergo standard of care testing and MDS testing.
9746568|NCT05286177|Experimental|Volume-based EN|Volume-based EN algorithm arm.
9746569|NCT05286177|Active Comparator|Rate-based EN|Rate-based EN algorithm (standard of care).
9746570|NCT05286125|Active Comparator|erector spinae plane (ESP) block group ( (E) group)|Under aseptic conditions, a high frequency linear transducer will be placed on the spinous process at T8 level on the parasagittal plane and then slid 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle.
9746571|NCT05286125|Active Comparator|oblique subcostal transverse abdominis plane (TAP) block ( (T) group) )|Under aseptic conditions, the probe will be initially placed below the xyphoid process to view the linea alba, then directed obliquely down the costal margin while keeping the rectus abdominis muscle in view. The transverse abdominis muscle come into view below the rectus abdominis muscle. The probe will be advanced further until the semilunaris is viewed.
10201556|NCT01981551|Experimental|PF-03084014 in Desmoid Tumors/Aggressive Fibromatosis|PF-03084014 will be administered orally at 150 mg twice a day in 21-day cycles
10201557|NCT01977144|Other|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
9746572|NCT05286086|Sham Comparator|PREHAB-PREOP|PREHABILITATION BEFORE SURGERY
9746573|NCT05286086|Experimental|PREHAB-NEOADJ|PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY
9746574|NCT05286073|Experimental|Hyflex EDm|The canals were prepared and shaped with one file (25/~) and finished with 40/.04 using crown down technique. Torque controlled endodontic motor was used with a rotational speed of 500 rpm and torque of 2.5Ncm (25 Nm).
9746575|NCT05286073|Experimental|F6 SkyTaper|The canals were prepared and shaped with one file (25/~) and finished with 40/.04 using crown down technique. Torque controlled endodontic motor was used with a rotational speed of 500 rpm and torque of 2.5Ncm (25 Nm).
9746576|NCT05286073|Experimental|One Shape|Canals were prepared and shaped with single rotational file system One Shape with the sequence of Endoflare (12, 0.12), One G (18, 0.03) and One Shape (12.06) connected to endodontic motor with rotational speed of 400rpm and 4 Ncm torque as recommended by manufacturer.
9746577|NCT05286073|No Intervention|Control|In the control group, no endodontic instrumentation and shaping was done in the canals. Only the necrotic pulp tissue was extirpated from the canals with the help of barbed broaches and then the specimens were analyzed for fracture testing.
9746578|NCT05286060|Experimental|GX-188E+GX-I7+Pembrolizumab|The operable non-small cell lung carcinoma patients (resectable stage IIA~IIIB) GX-188E: 1st day of week 1,2,4 2mg, GX-I7 1st day of week 2, Keytruda:1st day of week 1,2,4 200mg
10201558|NCT01977144|No Intervention|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
10201559|NCT01442194||Fingolimod|non-interventional
10201560|NCT01442194||parallel cohort|non-interventional
10201561|NCT01223092||Patients undegoing infertility treatment|Male and female patients undergoing infertility treatment
10201562|NCT00796068|Experimental|Arm I (low risk for graft failure)|"Patients receive a conditioning regimen comprising fludarabine phosphate IV over 1 hour QD on days -6 to -2 and treosulfan IV over 120 minutes on days - 6 to -4. Patients undergo TBI on day -1. Patients then undergo donor UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour or PO 2-3 times daily on days -3 to 100, followed by a taper in the absence of GVHD. Patients also receive mycophenolate mofetil IV 3 times daily on days 0 to 40, followed by a taper in the absence of GVHD."
10201563|NCT00796068|Experimental|Arm II (high risk for graft failure)|Patients receive a conditioning regimen, TBI, donor UCBT, GVHD prophylaxis, and mycophenolate mofetil as in Arm I.
9746579|NCT05286034|Experimental|Intervention group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test, with access to a decision aid tool tailored to those with low education levels. This tool will be available via Chatbot platforms.
9746580|NCT05286034|No Intervention|Control group|Women randomized to this group will be sent screening reminder letters to perform HPV self-sampling test (Standard care)
9746581|NCT05286021||Supine group|Children undergoing surgery in the supine position using the Ambu Auragain
9746582|NCT05286021||Prone group|Children undergoing surgery in the prone position using the Ambu Auragain
9746583|NCT05286008|Placebo Comparator|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
9746584|NCT05286008|Experimental|Ropivacaine at high concentration|Before the induction of anesthesia, 0.375% Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
9746585|NCT05286008|Experimental|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
9746586|NCT05285995|Experimental|The music group|In the music group, on the basis of the routine preoperative care, the preferred music was selected from the music library as the intervention content on the day of surgery according to the preference of the children in the 1-day preoperative visit. If there was no preference, the music was played randomly. During the intervention, the same multimedia audio system (Wanderer EDIFIER R1700BT) was used to play music for 30-40 minutes, the volume was controlled at 35-80dB, and adjusted in time according to the feedback of the children.
9746587|NCT05285995|Experimental|The animation group|The children in animation group also chose their favorite cartoons as the intervention content on the basis of preoperative care. The same pad (Lenovo TB3-850F) was used to play pre-selected cartoons, and volume as the music group. During the intervention period, the children in intervention group were also accompanied by a nurse, who was also responsible for the implementation and maintenance of the intervention program.
9746588|NCT05285995|No Intervention|The control group|No interventions except routine preoperative visits and conventional care were performed for the control group.
9746589|NCT05285969|Experimental|Motivational interview|Motivation Interview program with standard care
9746590|NCT05285969|Active Comparator|Standard care group|Standard care
9746591|NCT05285956|Experimental|Intervention|Participants (n=90) will be provided free access to and asked to register for the consumer-based mobile meditation app, Calm, on their phone. Participants will then receive an email containing one year of free access to Calm. Participants will be asked to use Calm at least 10 minutes per day for 8 weeks. Women will be asked to use 10 sessions of specific pregnancy content for the first four weeks and then will have autonomy to use the app how they prefer for the remainder of the study period (with continued encouragement to use the pregnancy meditations)
9746592|NCT05285956|No Intervention|Control|Participants (n=90) will be asked to continue with usual care and complete survey measures at each time point.
9746593|NCT05285943|Active Comparator|Betamethasone cream|Patients will apply Betamethasone Valerate 0.1% cream to the irradiated area twice a day.
10201564|NCT00740181|Experimental|Chemotherapy|Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
10201565|NCT00591500||Control|The control group comprises patients with a first primary melanoma diagnosed in a twelve-month period.
9746594|NCT05285943|Active Comparator|Olive oil cream|Patients will apply prepared Olive Oil cream to the irradiated area twice a day.
9746595|NCT05285943|Placebo Comparator|Base cream|Patients will apply prepared base cream to the irradiated area twice a day.
9746596|NCT05285930|Experimental|group A|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
9746597|NCT05285930|Experimental|group B|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
9746598|NCT05285930|Sham Comparator|group C|received a noncontact low-frequency pulsed ultrasound delivered through only plain gel without BV gel at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
9746599|NCT05285917|Experimental|Weight Based Starting Dose 1|20 mg/kg starting dose Hydroxyurea
9746600|NCT05285917|Experimental|Weight Based Starting Dose 2|25 mg/kg starting dose Hydroxyurea
9746601|NCT05285917|Experimental|PK-guided starting dose|Individualized, PK-guided starting dose Hydroxyurea
9746602|NCT05285891|Experimental|Ocrelizumab+Placebo Arm|"Ocrelizumab (OCR) infusions at months 18 and 24 and then after month 24 switch to placebo infusions every 6 months.~Each OCR 600 mg infusion or placebo infusion will be given as a slow IV infusion over approximately 240 minutes (4 hours). An alternative shorter infusion is available for participants who did not experience a serious Infusion Related Reaction (IRR) with any previous OCR infusion, a shorter (2-hour) infusion of 600mg can be administered for subsequent doses."
9746603|NCT05285891|Experimental|Ocrelizumab Arm|Ocrelizumab (OCR) infusions every 6 months. Each OCR 600 mg infusion will be given as a slow IV infusion over approximately 240 minutes (4 hours). An alternative shorter infusion is available for participants who did not experience a serious IRR with any previous OCR infusion, a shorter (2-hour) infusion of 600mg can be administered for subsequent doses.
10201566|NCT00591500||Cases|Cases are patients diagnosed with a second or higher order primary in a six-year period.
10201567|NCT00468130|Experimental|Aripiprazole|Subjects in the experimental group will receive Aripiprazole
10201568|NCT00468130|Placebo Comparator|Placebo|Subjects in the control group will receive sugar pill
10201569|NCT00384111|Experimental|1|Participants will receive standard R-CVP followed by Zevalin Therapeutic Regimen (Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin).
9746604|NCT05285891|Placebo Comparator|Placebo Arm|600 mg of Placebo infusions every 6 months. Each infusion of placebo will be given as a slow IV infusion over approximately 240 minutes (4 hours). An alternative shorter infusion is available for participants who did not experience a serious IRR with any previous OCR infusion, a shorter (2-hour) infusion of 600mg can be administered for subsequent doses.
9746605|NCT05285878|Placebo Comparator|Placebo|Participants will take a placebo capsule daily for 3 months. Placebo will be methylcellulose encapsulated into an opaque closed gelatin capsule for blinding. Capsules will be placed in a labeled bottle, with the contents only identifiable by a code on the package label and only the compounding pharmacy and the unblinded pharmacist at Houston Methodist Investigational Drug Service will know the code definition.
9746606|NCT05285878|Active Comparator|Fingolimod|Participants will take a 0.5 mg fingolimod capsule each day for 3 months. The fingolimod capsule will be placed inside an opaque closed gelatin capsule without transformation of the manufacteror's fingolimod capsule. The fingolimod blinded product and the placebo capsule will be identical in size, color, appearance, and weight.
9746607|NCT05285865|Active Comparator|Conventional Treatment|Thrice a day ,Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
9746608|NCT05285865|Experimental|Scapular Mobilization|Thrice a day Scapular mobilization (SM) along with Conventional treatment
9746609|NCT05285852|Experimental|Dry Needling|For application of the Dry Needling the individual should be in the supine position. To facilitate the approach and adhesion of the Sternocleidomastoid Muscle, the person's neck is placed ipsilaterally in the slightly lateral flexed position. Consequently, the therapist identified the active Trigger Points in the Sternocleidomastoid Muscle and cleansed the surface using an antiseptic solution. Using the insertion pipe, the dry needle inserted into the muscle. For the separation of neurovascular structure from muscle belly the needle is carried out in an anterior-posterior direction. A compression of 90 secs with a cotton swab will be applied at the needling site immediately after removing the needle to reduce the intensity and duration of pain. The variables will then be measured immediately following the processing session. Six sessions of Dry Needling will be applied to each patient and there will be a gap of at least 48 hours between each session.
9746610|NCT05285852|Placebo Comparator|Placebo Dry Needling|Following identification of the trigger point in the muscle, the surface would be cleaned with an antiseptic solution. For placebo Dry Needling, which only causes a pricking sensation, a blunt needle will be applied to the trigger points without penetrating the skin after application of a certain pressure to the skin. The protocol will be applied six times, with a two-day pause between treatments. Like the intervention group, the variables will be measured immediately after the processing session.
9746611|NCT05285839|Experimental|Dupixent and Narrowband UVB|Dupixent and Narrowband UVB
9782084|NCT01165320|Experimental|Participants with Esophageal Candidiasis|Candida infection is strongly suspected based on clinical symptoms and the participant's clinical course, white moss (plaque) is observed on the esophageal mucosa, and therapy via intravenous infusion is judged to be suitable for the present episode of esophageal candidiasis. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 7 and 28 days, respectively.
9782085|NCT01165320|Experimental|Participants with Invasive Candidiasis|Candida infection is strongly suspected based on the presence of refractory fever not responding to an antibiotic agent, or clinical symptoms at the site of disease, or the participant's clinical course. In addition, at least 1 of the following criteria must be met: 1) Candida infection is strongly suspected based on radiographic imaging findings and positive serological test for fungus, 2) yeast is observed by direct microscopy or histopathological test of tissue biopsied from the site of disease, or 3) Candida species are observed by culture test of specimens sampled from the site of disease. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 56 days, respectively.
9782086|NCT01165320|Experimental|Participants with Aspergillosis|Aspergillus infection is strongly suspected based on clinical symptoms and the participant's clinical course, and characteristic radiographic imaging findings are observed. In addition, at least 1 of the following criteria must be met: 1) risk factors predisposing to an Aspergillus infection, 2) positive serological test for Aspergillus, 3) acute-branching mold with separated hyphae are observed by direct microscopy or histopathological test, or 4) Aspergillus species are observed by culture test. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 84 days, respectively.
9782087|NCT01165541|Active Comparator|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine XR 50-400mg
10201570|NCT00384111|Active Comparator|2|Participants will receive standard R-CVP.
10201571|NCT05197777|Active Comparator|Group 1 : conservator physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
9782088|NCT01165541|Experimental|Quetiapine XR and Mirtazapine|Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
9782089|NCT01165554|Experimental|[18F] Flutemetamol|
9782090|NCT01165684|Experimental|Step-wise|
9782091|NCT01165684|Active Comparator|Basal-bolus|
9782092|NCT01165775||Threatened pre term labor patients|Patients receiving betamethasone to minimize the complications of prematurity will monitor blood glucose levels using the Dexcom Seven Plus Continuous Glucose Monitoring System.
9782093|NCT01165840|Experimental|Dapsone|Dapsone 100 mg PO x 1 dose
9782094|NCT01165983|Placebo Comparator|Placebo|
9782095|NCT01165983|Experimental|Aliskiren|
9828563|NCT02500758|Experimental|Parachlorometaxylenol|Reducing bacterial load after preoperative surgical scrubbing using 3% PCMX. Both hands have been prepared by preparatory handwash.
9828564|NCT02500758|Active Comparator|Clorhexidine digluconate|Reducing bacterial load after preoperative surgical scrubbing using 4% CHG. Both hands have been prepared by preparatory handwash.
9828565|NCT02500836|Experimental|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
9828566|NCT02500836|Experimental|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
9828567|NCT02500836|Placebo Comparator|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
9828568|NCT02500979|Experimental|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
9828569|NCT02500979|Placebo Comparator|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
9828570|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
9828571|NCT02501161|Experimental|Insulin degludec/liraglutide QD + OAD(s)|
9828572|NCT02501161|Active Comparator|insulin glargine QD + OAD(s)|
9828573|NCT02501265|Active Comparator|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
9828574|NCT02501265|Active Comparator|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
9828575|NCT02501265|Experimental|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by >50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
9828576|NCT02501265|Experimental|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by >50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
9828577|NCT02501473|Experimental|Part 1: Local Radiation + G100 5μg/tumor|Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks.
9828578|NCT02501473|Experimental|Part 1: Local Radiation + G100 10μg/tumor|Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
9828579|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
9746612|NCT05285813|Experimental|AML MRD cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
9746613|NCT05285813|Experimental|MDS post-HMA failure cohort only|Each study cycle is 28 days. Vibecotamab by vein (IV) over about 2 hours On Days 1, 3, 5, 8, 15 and 22 of Cycle 1 and then on Days 1, 8, 15 and 22 of Cycles 2-4.
9746614|NCT05285787|Experimental|EPN-701, 10mg orally daily over 14 days|Single arm
9746615|NCT05285761|Experimental|paper brochure + smartphone application|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. They will also receive the new recommendations relating to complementary feeding through an educational device in the form of a smartphone application. This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd month until the 36th month of the child. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
9746616|NCT05285761|Active Comparator|paper brochure|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information (48 messages) contained in the health record and in connection with the general development.
9746617|NCT05285748|Experimental|Self-Paced Intensity Physical Activity|
9746618|NCT05285748|Active Comparator|Prescribed Moderate Intensity Physical Activity|
9746619|NCT05281588|Experimental|Micro-osteoperforations|Micro-osteoperforations- assisted upper incisors retraction
9746620|NCT05281588|No Intervention|Control|Upper incisors retraction not associated with any clinical intervention to accelerate tooth movement
9746621|NCT05278364|Experimental|Dose-escalation and Dose-expansion|SY-5007 will be given orally in ascending doses (escalation cohort), until the DLT or RP2D is reached. Up to 7-17 patients will then be enrolled in the expansion cohort at the recommended doses.
9746622|NCT05274022|Placebo Comparator|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits.
9746623|NCT05274022|Experimental|Standard of Care Physical Therapy Program with Speed Walking Intervention|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. Additionally, subjects will complete the speed walking intervention. Participants will perform at 2 minute warm up followed by 1 minute of walking at their fastest tolerable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing. The subjects will perform 4 cycles of this followed by a 2 minute cool down at the end.
9746624|NCT05268250|Experimental|R2D2 mHealth treatment for diabetes distress|This is a mHealth supported, cognitive behavioral treatment for parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program
9746625|NCT05268250|No Intervention|Standard Care Control|Parents and school-age children who were identified with clinically relevant levels of diabetes distress as part of a clinic screening program will receive local resources (print or electronic).
9746626|NCT05264909|Experimental|Transcranial Direct Current Stimulation TDCS|"Each subject will receive transcranial electrical stimulation at primary motor located in Cz based on the EEG 10-20 international system. The program include 18 sessions with a frequency of 3 times per week during 6 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 15 minutes with a current of 1.5 milliamp using 7x5 cm electrodes.~During the stimulation, the patient must simultaneously perform gait training for 30 minutes where the speed of each step is guided by the frequency of biaural rhythms and beats, constantly heard through hearing aids. Additionally, the length of the passage will be indicated by white stripes (50 cm long and 5 cm wide), placed perpendicular along a walkway of 6.5 m.~Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin problems and other possible side effects of tDCS."
9746627|NCT05264350|Experimental|Viiral® Nasal Spray group|The nasal spray to be administrated twice daily for 8 weeks.
9746628|NCT05264350|Active Comparator|Isotonic Saline Nasal Spray|The nasal spray to be administrated twice daily for 8 weeks.
9746629|NCT05263375|Experimental|MV replacement with Innovalve TMVR system|MV replacement with Innovalve TMVR system
9746630|NCT05261048|Experimental|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week.~The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal.~These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between.~Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300.~Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
9746631|NCT05261048|Placebo Comparator|Conventional Physical Therapy|"Patient will perform conventional physiotherapy in form of truncal exercises, which consist of upper and lower part of trunk in spine and sitting position for total 30 minutes and then participants will be asked to take some rest. In supine position, pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
9746632|NCT05260606||Patients with NSCLC who will have FDG PET/CT before and during ICI Tx|There is no difference from the treatment schedule performed in usual clinical setting except for an additional F-18 FDG PET/CT scan. Detailed plan of ICI treatment and patient management (dose, administration date, treatment period, and follow-up) follows the standard protocol of our institution in this study.
9746633|NCT05260593|Experimental|Group A (Vit. B12 Phonophoresis group)|Patients in group (A) will receive phonophoresis with Vitamin B12. Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
9746634|NCT05260593|Placebo Comparator|Group B (Placebo-Phonophoresis with Vitamin B12)|Patients in group (A) will receive placebo phonophoresis with Vitamin B12 gel. Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 gel will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
9746635|NCT05260580|Experimental|Two-hour sessions per week for 18 weeks|The classroom learning of study subjects and clinical care experience of in-service students are both very important in this intervention course. The teaching method will primarily focus on empowerment strategies, with support from the school's digital action learning platform for teaching-related activities.
9746636|NCT05259735|Experimental|Intervention|Clinical guideline-based management of T2DM by Ayurvedic practitioners. The clinical guideline will cover topics like diagnostic criteria, blood glucose targets, lifestyle advice, Ayurvedic medicines, monitoring and follow-up (including screening for complications and referral to specialists for complications management). The clinical guideline will make recommendations based on the best available evidence. Ayurvedic practitioners will have at least a 5½ year undergraduate medical degree in Ayurveda. Regular training will be provided to Ayurvedic practitioners (in groups) in the use of clinical guideline which will involve roleplaying and structured and instructive feedback to improve their performance. The trainings will be recorded on the Training Attendance Log and they will be provided a Training Certificate for completing the training.
9746637|NCT05259735|Active Comparator|Comparator|"Comparator: Currently, no standard clinical guideline is used by Ayurvedic practitioners to manage T2DM in Nepal. Thus, the comparator will be the usual management of T2DM (i.e., without any clinical guideline) by Ayurvedic practitioners.~Participants will continue their medications for other systemic diseases, if any."
9746638|NCT05258656|Experimental|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
9746639|NCT05258656|Placebo Comparator|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
9746640|NCT05258331|Experimental|Single Arm|CT303
9746641|NCT05257512|Experimental|Dose-escalation and Dose-expansion|SY-3505 will be given orally in ascending doses (escalation cohort), until the DLT or RP2D is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose.
9746642|NCT05256641|Experimental|Group I (acalabrutinib)|Beginning day 90, patients receive acalabrutinib PO QD and then PO BID once no longer on prophylactic antifungal (CYP34A inhibitors) until day 365 in the absence of disease progression or unacceptable toxicity.
9746643|NCT05256641|Experimental|Group II (acalabrutinib)|Beginning day 60, patients receive acalabrutinib PO QD and then PO BID from day 74 if there are no dose reductions until day 365 in the absence of disease progression or unacceptable toxicity.
9746644|NCT05256641|Experimental|Group III (acalabrutinib)|Beginning anytime between days 28-104, patients receive acalabrutinib PO BID until day 365 in the absence of disease progression or unacceptable toxicity.
9746645|NCT05255432||Group A|Selection of tasks
9746646|NCT05255432||Group B|Selection of tasks
9746647|NCT05250050|Experimental|Genotypic resistance guided therapy|After Helicobacter pylori drug resistance mutation gene detection, according to genotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
9746648|NCT05250050|Experimental|Phenotypic resistance guided therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to phenotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
9746649|NCT05250050|Active Comparator|Empiric therapy|Esomeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g bid (no penicillin allergy) OR tetracycline 0.5g qid (penicillin allergy) for 14 days
9746650|NCT05248321|Experimental|Extra treatment (ET) group|In the extra treatment (ET) group, standard endoscopic therapy will be performed to the bleeding peptic ulcer by local injection of diluted epinephrine 1:10 000 in combination with either heater probe coagulation, hemoclipping and/or rubber band ligation. Afterwards, we will apply 2g tranexamic acid powder via the endoscopy to the peptic ulcer before the end of endoscopic exam. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores <6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
9746651|NCT05248321|No Intervention|standard treatment (ST) group|In the standard treatment (ST) group, the endoscopic exam ends after standard endoscopic therapy. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores <6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
9746652|NCT05244681|Other|People with chronic non-specific neck pain|Group of people with chronic non-specific neck pain who agreed to participate in a semi-structured interview about their experience using an immersive virtual reality serious game at home
9746653|NCT05241795|Active Comparator|Group A: Knee exercises then Ankle exercises|Patients will receive a rehabilitation protocol starting with knee training followed by ankle training.
9746654|NCT05241795|Experimental|Group B: Ankle exercises then Knee exercises|Patients will receive a rehabilitation protocol starting with ankle training followed by knee training.
9746655|NCT05229406|Experimental|5-minute app usage|Participants will be asked to use the HMP app for 5-minutes per day.
9746656|NCT05229406|Experimental|15-minute app usage|Participants will be asked to use the HMP app for 15-minutes per day.
9746657|NCT05228457|Active Comparator|Active Transcranial Magnetic Stimulation|Active Intensive iTBS involves intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over the left dorsal lateral prefrontal cortex (L-DLPFC).
9746658|NCT05228457|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham Intensive iTBS involves using the coil's electric stimulation functionality that allows for the delivery of a brief electric pulse to the scalp simultaneous to the TMS pulse, which mimics the scalp sensation from active stimulation.
9746659|NCT05228015|Experimental|Experimental: IK-930 Single Agent Dose Escalation|
9746660|NCT05228015|Experimental|Experimental: IK-930 Single Agent Dose Expansion|
9746661|NCT05225935|Experimental|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
9746662|NCT05225935|Active Comparator|conventional VT ablation strategy|Catheter ablation performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
9746663|NCT05225805|Experimental|Group A|Group A will receive one dose of 150 mg lefamulin IV followed by one dose of 600 mg lefamulin oral
9746664|NCT05225805|Experimental|Group B|Group B will receive one dose of 600 mg lefamulin oral followed by one dose of 150 mg lefamulin IV
9746665|NCT05222399|Experimental|LY3871801 (Period 1)|LY3871801 solid dispersion suspension administered orally.
9746666|NCT05222399|Experimental|LY3871801 (Period 2)|LY3871801 crystalline freebase tablet administered orally.
9746667|NCT05220462|Experimental|Remimazolam|"White to off-white lyophilised powder, presented in a 12 mL clear glass vial with a grey bromobutyl stopper, fitted with an aluminium crimp and a blue plastic flip-off cap. Each 20 mg vial of remimazolam, will be reconstituted with sterile 0.9% NaCl solution to yield a 2.5 mg/mL solution for injection.~An initial dose of 5mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 2.5mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 2.5mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly, at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum dose of 40mg of remimazolam (16mL) will be set."
9746668|NCT05220462|Active Comparator|Midazolam|"Midazolam will be presented as a solution in a 5 mL ampoule. Each ampoule will contain 5 mg of midazolam, yielding a 1 mg/mL solution for injection.~Dosing of midazolam was based on local formulary and standard of care / local guidance. An initial dose of 2mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 1mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 1mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum of dose of 16mg of midazolam (16mL) will be set."
9746669|NCT05219955|Experimental|Active condition (SAMM Protocol)|The goal of the SAMM protocol is to increase morning activity engagement over a 6-week period. Participants in this condition will review their morning routine, and make a list of potential morning activities to add. They will choose one activity and develop a plan for doing it. Each day, participants are asked to track if they do the morning activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one.
9746670|NCT05219955|Active Comparator|Attention-matched supportive control condition|Participants in this condition will receive sessions in the same number and duration as the SAMM experimental condition. Therapists will create a comfortable environment by demonstrating interest, empathy, and acceptance without judgment. Caregivers will be encouraged to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials.
9746671|NCT05217914||r/r iNHL Patients: Copanlisib treatment|"The data in patients who received at least one dose of copanlisib before 01-May-2022 will be included for interim analysis. All study data collection will end in Q2 2024, or when the data collection of maximal 50 enrolled patients is completed, whenever comes first.~Subgroup analysis: r/r iNHL Patients: Copanlisib 2nd line treatment Subgroup analysis: r/r iNHL Patients: Copanlisib 3rd line treatment"
9746672|NCT05215938||Study I: Multi-organ sodium imaging with B1 field correction|"The scan will be performed in four area of interests (AOFs) to acquire sodium level signal form the thigh, heart, kidneys, and brain. Between each AOF the sodium receive coil will be moved to cover the specific organ. Determination of the sodium imaging method robustness is performed with a series of MRI sequences.~The scans at the four AOFs are repeated to evaluate repeatability. The scan time with repositioning of coils is approximately 15 min per station (total scan time 2 hours).~If needed the participants are able to have a break between scan stations."
9782096|NCT01165996|Experimental|Arm I: decitabine|INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts &lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
9785403|NCT01251276|Experimental|ENGERIX-B™ Vaccine in Base Study|Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
9785404|NCT01251315|Placebo Comparator|Placebo low dose|Placebo for low dose group given as a single dose.
9785405|NCT01251315|Active Comparator|N Acetyl cysteine, 600mg (low dose)|N-Acetyl Cysteine (NAC)600 mg (low dose) given as a single dose.
9785406|NCT01251315|Active Comparator|Proimmune 200(FT061452)|Proimmune 200(FT061452) low dose group 3000 mg given as a single dose.
9746673|NCT05215938||Study II: Circadian sodium level variation in the kidney measured with MRI|"Participation requires one full day at the MR Centre. MRI scans will be performed three times at the same day within the following time periods: 6.30-8.00 am. (before breakfast), 12.30-14-00 pm. (after lunch) and 21.00-22.00 pm. (after dinner). The scan time is expected to be 30-40 min at each scan (three scans are performed on one examination day), which requires a total scan time ~1½ hours.~Participants are not allowed to perform excessive physical exercise the day before and during the study day. Lighter physical exercise as walking, biking etc. is accepted. Alcohol consuming is not allowed the day before and during the study day. The participants can drink and eat as usual, but all fluid intake and urinations shall be documented in a liquid urination schedule. Blood pressure will be measured at each scan session and urine samples are collected just after each scan session to assess the osmolarity."
9746674|NCT05212441|Experimental|Group A (LED group)|This group includes 30 burned patients who will receive LED therapy in addition to their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
9746675|NCT05212441|Active Comparator|Group B (Control group)|This group includes 30 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
9746676|NCT05206955|Experimental|Tadalafil Group|Study participants will receive 10 mg of Tadalafil daily for 1 week, then 20 mg daily for 1 week, and finally 40 mg daily for 50 weeks for a total therapy time of 52 weeks. Tadalafil will be taken orally in capsule form once daily.
9746677|NCT05206955|Placebo Comparator|Placebo Group|Study participants will receive a placebo capsule that looks identical to the Tadalafil capsule. The placebo will be taken orally once daily for 52 weeks.
10201572|NCT05197777|Experimental|Group 2- tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated to physical task from functional activity of daily life. Functional task for the assessment of pain with high-tech tools for the implementation an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. The dummy will be set at the height of the hands in a constrained position for the arms, i.e. with elbows flexed at 60 degrees. Elbow angles will be adjusted in a static position with a manual goniometer. The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes. The elbow will be in a prolonged constraint position, undergoing repetitive movements, for 30 consecutive minutes. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat
10201573|NCT05197764||Children with spastic cerebral palsy|Children between 6 months and 9 years old.
10201574|NCT05197764||Typically developing children|Children between 6 months and 9 years old.
10201575|NCT05197764||Children with an acquired brain injury|Children between 1,5 years and 9 years.
10201576|NCT05197751|Experimental|3 µg dose cohort|3 µg MSP3-CRM-Vac4All/Alhydrogel®
9746683|NCT05189756|Experimental|Verum|Patients will receive 2 encapsulated capsules containing aprepitant 80mg to be ingested with a sip of water 2 hours before surgery and 24 hours after surgery. Surgery will follow our hospital enhanced recovery after surgery (ERAS) standard (general anaesthesia using volatile anaesthetics, intravenous dexamethasone 8mg and ondansetron 4mg for PONV prophylaxis).
9746684|NCT05189756|Placebo Comparator|Placebo|Patients will receive similar looking encapsulated capsules containing only placebo to be ingested with a sip of water 2 hours before surgery and 24 hours after surgery. Surgical and anaesthetic procedures are identical to the verum arm.
9746685|NCT05183282|Experimental|Tarsus Patch Group|All subjects will receive the Tarsus Patch to be worn and evaluated by the investigator in the clinic and to also be worn at home for 3 nights.
9746686|NCT05183035|Active Comparator|Arm A: Control Arm without Venetoclax|"During cycle 1 (each cycle is 42 days), participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5. Gemtuzumab 3 mg/m^2 will be given on Day 6 (only for participants with CD33 expression on leukemia blasts).~During cycle 2 participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5.~After cycle 2 participants are assessed for hematopoietic stem cell transplantation (HSCT) or azacitidine maintenance therapy."
9746687|NCT05183035|Experimental|Arm B: Experimental Arm with Venetoclax|"During cycle 1 (each cycle is 42 days), participants will receive 300 mg adult dose equivalent of venetoclax once on Day 1 followed by 600 mg adult dose equivalent of venetoclax on Days 2-21. Participants will also receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 8-12. Gemtuzumab 3 mg/m^2 will be given on Day 13 (only for participants with CD33 expression on leukemia blasts).~During cycle 2, participants will receive 600 mg adult dose equivalent of venetoclax on Days 1-21. Participants will receive 30 mg/m^2 of fludarabine followed by 2 g/m^2 of cytarabine on Days 1-5.~After cycle 2 participants are assessed for HSCT or azacitidine maintenance therapy in combination with venetoclax."
10201577|NCT05197751|Experimental|10 µg dose cohort|10 µg MSP3-CRM-Vac4All/Alhydrogel®
10201578|NCT05197751|Experimental|30 µg dose cohort|30 µg MSP3-CRM-Vac4All/Alhydrogel®
10201579|NCT05197738||High risk OSA|"Cohort of individuals found to sleep have scores categorized as High risk, on the Berlin questionnaire."
10201580|NCT05197738||Low risk OSA|"Cohort of individuals found to sleep have scores categorized as Low risk, on the Berlin questionnaire."
10201581|NCT05197738||Short sleepers|Cohort of individuals found to have average sleep duration of < 7 hours per night. Individuals who sleep on average less than 6 hours per night will further be sub-categorized as very short sleeprs.
10201582|NCT05197738||Long sleepers|Cohort of individuals found to have average sleep duration of >9 hours per night.
10201583|NCT05197738||Average lengths leepers|Cohort of individuals found to have an average sleep duration between 7 and 9 hours per night
10201584|NCT05197738||Regular sleepers|Cohort of individuals whose standard deviation of sleep duration falls within 1 standard deviation of their mean sleep duration.
10201585|NCT05197738||Irregular sleepers|Cohort of individuals whose standard deviation of sleep duration falls greater than 1 standard deviation of their mean sleep duration
10201586|NCT05197738||Severe insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as severe
10201587|NCT05197738||Moderate insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as moderate
9746688|NCT05175053|Experimental|Early RRT group|Patients who will undergo renal replacement therapy (RRT) within 6 hours of diagnosis of stage 2 acute kidney injury (AKI).
9746689|NCT05175053|Active Comparator|Delayed RRT group|Patients who will undergo renal replacement therapy (RRT) if one of the absolute indications for RRT is present.
9746690|NCT05171049|Experimental|Abelacimab|Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
9746691|NCT05171049|Active Comparator|Apixaban|Apixaban administered orally twice a day
9746692|NCT05169957|Experimental|Ipilimumab + Nivolumab + Stereotactic Body Radiation Therapy (SBRT)|Liver SBRT following the second cycle of ipilimumab + nivolumab, which will then be continued up to 4 total cycles prior to subsequent maintenance nivolumab for duration of clinical benefit and tolerance (standard of care systemic therapy)
9746693|NCT05168774|Experimental|Low Dose (20-30mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (20-30 mg) for 52 weeks
9746694|NCT05168774|Experimental|High Dose (40-60 mg)|Subjects will receive daily subcutaneous (SC) dosing of Elamipretide (40-60 mg) for 52 weeks
9746695|NCT05168150|No Intervention|Control Group No-expert mediated post hoc benchmark group|"30 participants. Individuals receive identical introductory information,same time, to perform, same scenarios as other groups.~Students receive their scores on 5 performance metrics compared to expert performance benchmarks. Scores are presented in the 5 minute breaks between tasks. Student goal is to be within the benchmark in all five metrics."
9746696|NCT05168150|Experimental|Experimental Group - Intelligent Continuous Expertise Monitoring System group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task, participants receive no feedback. For the subsequent 4 practice tasks participants will receive real-time auditory feedback instruction by the intelligent system. After each of the 5 attempts, a student takes a 5-minute break. During each of the 5 breaks the participants will be shown the errors they made during the task by the intelligent system regarding five performance metrics monitored. After seeing each error outline, the participant will be shown a video demonstration to learn how to expertly perform on each performance metric. On their 6th attempt they will perform on the realistic scenario without any feedback given."
9746697|NCT05168150|Experimental|Experimental Group In-person expert-mediated instruction group|"30 Participants. Introductory information provided on simulator and scenario. They perform 5 simple practice subpial tumor resections with 5 minutes per trial. On 6th attempt 13 minutes to perform a complex realistic scenario.~During first practice task participants receive no feedback. For the subsequent 4 practice tasks participants receive real-time auditory feedback instruction by in-person expert during the task. After each of the 5 tasks, students takes a 5-minute break. During each of the 5 breaks the in-person expert provides feedback to the participant based on their OSATS score assessment during the previous trial. If the expert feels it is appropriate the expert will demonstrate how to do the specific procedure which has been found to be a concern on the simulator themselves so the participant can understand how to improve their performance. On their 6th attempt they will perform on the realistic scenario without any feedback given."
9746698|NCT05165966|Experimental|Experimental Group-High-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with high-dosage of COVID-19 vaccine (Vero cell), Inactivated.
9746699|NCT05165966|Experimental|Experimental Group-Medium-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with medium-dosage of COVID-19 vaccine (Vero cell), Inactivated.
9746700|NCT05156827|Experimental|TB006|Participants will receive an intravenous (IV) infusion of TB006 1000 milligrams (mg) once weekly for 5 weeks.
9746701|NCT05156827|Placebo Comparator|Placebo|Participants will receive an IV infusion of normal saline once weekly for 5 weeks.
9746702|NCT05156268|Experimental|Pembrolizumab with Olaparib|Eligible patients will receive olaparib in combination with pembrolizumab. Olaparib will be administered orally at 300 mg every 12 hours. Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
9746703|NCT05155332|Experimental|Part 1 (Monotherapy): Arm A|Arm A: Intratumoral (i.t.) administration
9746704|NCT05155332|Experimental|Part 1 (Monotherapy): Arm B|Arm B: Intravenous (i.v.) administration
9746705|NCT05155332|Experimental|Part 1 (Monotherapy): Arm C|Arm C: i.t.+i.v. administration
9746706|NCT05155332|Experimental|Part 2 (Combination therapy): Arm D|Arm D: Intratumoral (i.t.) administration
9746707|NCT05155332|Experimental|Part 2 (Combination therapy): Arm E|Arm E: Intravenous (i.v.) administration
9746708|NCT05155332|Experimental|Part 2 (Combination therapy): Arm F|Arm F: i.t.+i.v. administration
9746709|NCT05154552|Experimental|group A/ routine physical therapy and PNF|"In group A, PNF based gait training (15 minutes) and conventional physical therapy (45 minutes) will be performed.~PNF exercises involved PNF pelvic patterns (pelvic interior elevation and posterior depression), PNF lower extremity D1 Flexion and PNF lower extremity D1 extension (Unilateral during 1st to 3rd week and bilateral from 4th week onwards). Exercises will progress from rhythmic initiation and then progress to slow reversal and agonistic reversal up to 6th week of therapy and continues until 12th week. Each exercise will be repeated for 10 to 20 times.~Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson's disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
9746710|NCT05154552|Active Comparator|group B/ routine physical therapy|"Conventional physical therapy (45 minute session) will be performed in group B.Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
9746711|NCT05147467|Experimental|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
9746712|NCT05146739|Experimental|Experimental: Treatment (uproleselan, fludarabine, cytarabine)|Patients receive uproleselan intravenously (IV) once daily (QD) over 20 minutes on day 1 and IV over 20 minutes twice daily (BID) on days 2-8, fludarabine IV QD over 30 minutes on days 2-6, and high dose cytarabine IV QD over 1-3 hours on days 2-6. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
9746713|NCT05145140|Active Comparator|Standardized Western Medicine Treatment Group|All participants undergo a similar treatment protocol for the diabetic foot, based on the Infectious Diseases Society of America (IDSA).
9746714|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL tablet+TNTL cream Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day. Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
9746715|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL tablet Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day.
9746716|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL cream Group|Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
9746717|NCT05143632|No Intervention|Intermittent NIBP monitoring|Oscillometric intermittent (3 mins) noninvasive blood pressure monitoring
9746718|NCT05143632|Experimental|ClearSight|Continuous non invasive hemodynamic monitoring
9746719|NCT05143502|Experimental|Montelukast Group|Patients in group A (interventional group) will be treated with fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 monthes and oral Prednisolone 40 mg/day for two weeks.
9746720|NCT05143502|Active Comparator|Control Group|Subjects in treatment group B will receive topical and systemic steroids in an identical regimen only.
9746721|NCT05142371|Experimental|Arm A (home-based exercise program)|Patients undergo home-based exercise program 3 times per week for 8 weeks. Patients complete questionnaires at baseline (before 1 week) and at weeks 9 and 17.
9746722|NCT05142371|Active Comparator|Arm B (current activities)|Patients complete questionnaires at baseline and at week 9 and 17. Patients continue maintaining current activities of daily living and do not participate in any exercise program. Patients may then participate in home-based exercise program 3 times per week for 8 weeks.
9746723|NCT05140993|Experimental|extended support|providing extended emotional and orientation support
9746724|NCT05140993|No Intervention|common practice|The hospital routine clinical standard- not providing extended emotional and orientation support
9746725|NCT05136482|No Intervention|Control|Participants will wear the cryocompression device for 30 mins without any cold or pressure being applied to the lower limb by the cuff.
9746726|NCT05136482|Experimental|Condition A|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 6℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
9746727|NCT05136482|Experimental|Condition B|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
9746728|NCT05136482|Experimental|Condition C|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 10℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
9746729|NCT05136482|Experimental|Condition D|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 12℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
9746730|NCT05135767|Active Comparator|Alcohol Use Disorder Only|Individuals in the Alcohol Use Disorder Only arm will meet criteria for alcohol use disorder but will not show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.
9785407|NCT01251315|Placebo Comparator|Placebo high dose|Placebo given to high dose group given as a single dose.
10201588|NCT05197738||No insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as low
9785408|NCT01251315|Active Comparator|N Acetyly cysteine, 1200mg (high dose)|N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
9785409|NCT01251315|Active Comparator|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
9785410|NCT01251354|Experimental|BN83495|
9785411|NCT01251367|Experimental|Dysport®|Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.
9785412|NCT01251380|Experimental|Dysport|Dysport was injected into either one or both lower limbs in up to 4 cycles of treatment, a minimum of 12 weeks apart and up to a maximum of 40 weeks apart. Doses varied from 5 Units (U)/Kg to 20 U/kg for one leg, or from 10 U/Kg to 30 U/kg for two legs, with a maximum dose of no more than 30 U/Kg overall, or 1000 U, whichever was reached first.
9785413|NCT01251393|Experimental|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
9785414|NCT01251393|Placebo Comparator|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
9785415|NCT01251536|Other|Arm B - standard dose of cetuximab|Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
9785416|NCT01251536|Experimental|Arm A - dose escalation of cetuximab|Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.
9785417|NCT01251575|Experimental|Treatment (fludarabine, transplant, immunosuppression)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.~IMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150."
9785418|NCT01251588||MACI|autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
9785419|NCT01251588||Microfracture|Microfracture treatment received in previous MACI00206 study
9785420|NCT01251614|Experimental|Adalimumab 0.4 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.
9785421|NCT01251614|Experimental|Adalimumab 0.8 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
9785422|NCT01251614|Active Comparator|Methotrexate|Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
9785423|NCT01251653||Afatinib and docetaxel|
9785424|NCT01251653||Afatinib and gemcitabine|
9785425|NCT01251744|Experimental|CMV Mothers' Group|Pregnant subjects with confirmed primary CMV infection.
9785426|NCT01251744|Experimental|CMV Newborns' Group|Offsprings of the CMV Mothers' Group, also tested for CMV infection, comprising infants that were live born.
9785427|NCT01251757|No Intervention|Usual Care (UC)|Participants in this arm received their usual care with no restrictions.
9785428|NCT01251757|Active Comparator|Interactive Voice Recognition (IVR)|automated phone calls
9785429|NCT01251757|Active Comparator|Enhanced IVR (IVR+)|automated phone calls & Educational mailings and follow-up for nonadherence
9785430|NCT01251770|Experimental|half saline|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
9785431|NCT01251770|Active Comparator|third saline|Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
9785432|NCT01251887|Experimental|Diet A: Low omega-3 (n-3) + High linoleic acid (LA)|Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks
9785433|NCT01251887|Experimental|Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks
10201589|NCT05197738||Increased social jet lag|Individuals who are more than 1 hour less or more of sleep on weekdays compared to average weekend sleep.
9785434|NCT01251887|Experimental|Diet C: High omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks
9785435|NCT01251965|Experimental|Ruxolitinib 50 mg BID|Phase I - Starting dose of Ruxolitinib 50 mg by mouth twice a day for 28 day cycle.
9785436|NCT01251965|Experimental|Ruxolitinib 100 mg BID|Phase I dose of Ruxolitinib 100 mg by mouth twice a day for 28 day cycle.
9785437|NCT01251965|Experimental|Ruxolitinib 200 mg BID|Phase I dose of Ruxolitinib 200 mg by mouth twice a day for 28 day cycle.
9785438|NCT01251978|Active Comparator|High dose Ranibizumab|6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
9785439|NCT01251978|Active Comparator|Standard Dose Ranibizumab|6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
9785440|NCT01252095|Experimental|PG545|
9785441|NCT01252134|Other|Synergi, then Biotrue, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
9785442|NCT01252134|Other|Synergi, then OTE, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
9785443|NCT01252134|Other|Biotrue, then OTE, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
9785444|NCT01252134|Other|Biotrue, then Synergi, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
9785445|NCT01252134|Other|OTE, then Biotrue, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
9785446|NCT01252134|Other|OTE, then Synergi, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
9785447|NCT01252186|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy in each 91-day cycle for a total of two 91-day cycles.
9785448|NCT01252186|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received 21 days of active combination tablets containing 150 µg LNG/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
9785449|NCT01252186|Active Comparator|28-day Desogestrel Oral Contraceptive|Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
9785450|NCT01252238|Placebo Comparator|Valsartan and Aliskiren|Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
9785451|NCT01252238|Experimental|Aliskiren|
9785452|NCT01252238|Placebo Comparator|Placebo Group|Only taking Amlodipine
9785453|NCT01252251|Experimental|RAD001 and pasireotide LAR|This study will be an open-label, single-arm, phase II study of RAD001 and pasireotide LAR.
9785454|NCT01252277|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
9785455|NCT01252290|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
9785456|NCT01252355|Experimental|Teriflunomide 7 mg + IFN-beta|Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.
9785457|NCT01252355|Experimental|Teriflunomide 14 mg + IFN-beta|Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.
9785458|NCT01252355|Placebo Comparator|Placebo + IFN-beta|Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.
9785459|NCT01252563||Amlodipine 10mg Tablet|Subjects taking Amlodipine 10mg Tablet.
9785460|NCT01252667|Experimental|Part 1 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
9785461|NCT01252667|Experimental|Part 1 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
9746731|NCT05135767|Active Comparator|Alcohol Associated Liver Disease + Alcohol Use Disorder|Individuals in the Alcohol Associated Liver Disease + Alcohol Use Disorder arm will meet criteria for alcohol use disorder and also show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.
9746732|NCT05134207|Experimental|oral carbohydrate solution|Oral carbohydrate solution was given orally to the experimental group as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the intervention.
9746733|NCT05134207|No Intervention|control|From 24:00 on the night before the surgical intervention, food and water intake was prohibited for the patients in the control group.
9746734|NCT05133973|Experimental|Cohort A|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 3x between days 01-07, on Days 21 and 28. There will be safety visit at Day 14.~Finger pricking at home use will be intensified during days 00-07."
9746735|NCT05133973|Experimental|Cohort B|"Subjects will wear 3 FiberSense systems (2x arm and 1x abdomen) and one comparator. The subjects will participate in six clinic in-house sessions on Day 00, 4x between days 07-14 and on Day 28. There will be safety visit at Day 21.~Finger pricking at home use will be intensified during days 07-14."
9746736|NCT05131230||CytoSorb group|
9746737|NCT05128006||In-person new VA dermatology patients|In-person dermatology patients that are new patients at three facilities
9746738|NCT05128006||New patient consultative Teledermatology users|New patient consultative Teledermatology users at three facilities
9746739|NCT05128006||New patient Mobile teledermatology users|New patient Mobile teledermatology users at three facilities
9746740|NCT05128006||In-person new patient in Community Care|In-person new patient in Community Care
9746741|NCT05127187||Detainees in an Administrative Detention Center|
9746742|NCT05126238|Experimental|Lithium|In preoperative period patients will take 300mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take 300mg of lithium carbonate 2 hours before surgery. After the surgery, patients will take 300mg of lithium carbonate in the afternoon and 300mg of lithium carbonate in the evening.
9746743|NCT05126238|Placebo Comparator|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take placebo 2 hours before surgery. After the surgery, patients will take placebo in the afternoon and in the evening.
9746744|NCT05125822|Experimental|Meal Replacement and Lifestyle Therapy|Participants in this study will have an 8-week meal replacement therapy period in which they are asked to reduce their BMI by 5% by following a prescribed eating regimen consisting of meal replacement shakes and/or frozen meals for breakfast and lunch. For dinner they will consume a pre-packaged frozen entree to be consumed with two servings of fruit and three servings of vegetables per day. Participants will also have lifestyle/behavioral modification counseling every 2 weeks throughout the entire study.
9746745|NCT05124301|Experimental|Perceptual learning|Reaching task in which visual information about target finger position is offset to induce a change in perception of the finger.
9746746|NCT05124301|Experimental|Motor learning|Reaching task in which visual information about reaching errors is offset to induce a movement change.
9746747|NCT05124301|Active Comparator|Control|Reaching task with accurate visual information.
9746748|NCT05121493|Active Comparator|Platelet Poor Plasma Tear|
9746749|NCT05121493|Experimental|Platelet Rich Plasma Tears|
9746750|NCT05116163|Experimental|Arm 1: Individuation Intervention plus implicit bias education|10 rheumatologists who will have 10 patient interactions each (100 patients total) recorded Rheumatologists will watch implicit bias training modules and then will be instructed to incorporate an individuation strategy into each of their clinical encounters.
9746751|NCT05116163|Active Comparator|Arm 2: Implicit bias education only|10 rheumatologists randomized and stratified by hospital and gender
9746752|NCT05113784|Experimental|Meplazumab for Injection|First dose: 0.2 mg/kg - Day 1; Second dose: 0.2 mg/kg - Day 8
9746753|NCT05113784|Placebo Comparator|Placebo|First dose: control - Day 1; Second dose: control -Day 8
9746754|NCT05110183|Experimental|electrical and optical hybrid stimulation stimulation|Patients with large tumors of the skull base, requiring a translabyrinthine craniotomy with sacrifice of their cochlea and vestibular system during the tumor resection may participate. A recording electrode will be placed on the round window, a cochleostomy will be created, and different Light delivery systems (LDSs) will be inserted into the cochlea. LDSs include angle polished optical fibers to determine the accuracy of the orientation of the radiation beam, and hybrid arrays of small optical sources and electrical contacts to evaluate electric-alone stimulation as a reference, and compare it to optic-alone and combined electrical and optical stimulation. Compound action potentials (CAPs) of the auditory nerve will be recorded.
9746755|NCT05109429|Experimental|No Craving|Each participant will attend three sessions where the participant will experience three distinct cue-induced craving tasks in a randomized fashion.
9746756|NCT05108831|Experimental|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
9746757|NCT05108831|No Intervention|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
9746758|NCT05105568|Experimental|Process-based therapy|
9746759|NCT05101759|Other|Geriatric Follow-up (Comprehensive Geriatric Assessment)|A systematic reassessment of geriatric parameters
9828580|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.
9828581|NCT02501473|Experimental|Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors|Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors [injectable lymphoma mass(es) ≥ 4 cm in total size] for up to 8 weeks.
9828582|NCT02501473|Experimental|Part 3: Local Radiation + G100 20μg/tumor|Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks.
9828583|NCT02501473|Experimental|Part 4: G100 20μg/tumor and pembrolizumab 200mg|Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.
9828584|NCT02501473|Experimental|Part 5: G100 + Rituximab 375mg/m^2|Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m^2 on Day 0 and then QW for up to 3 weeks.
9828585|NCT02501538|Experimental|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
9828586|NCT02501590||study|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
9828587|NCT02501590||control|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
9828588|NCT02501629|Experimental|Reslizumab 110 mg|Reslizumab was administered by subcutaneous injection (sc) in a dosage of 110 mg (1.0 mL) every 4 weeks for a total of six doses.
9828589|NCT02501629|Placebo Comparator|Placebo|Matching placebo was administered by subcutaneous injection (sc) 1.0 mL every 4 weeks for a total of six doses.
9828590|NCT02501642|Experimental|Concussion Coach group|"After informed consent and randomization, participants will complete baseline study measures and will receive an iPod touch® with the Concussion Coach Explorer version"
9828591|NCT02501642|Other|Treatment as usual|Treatment as usual
9828592|NCT02501811|Experimental|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
9828593|NCT02501811|Experimental|c-kit+ cells|Target dose of 5 million c-kit+ cells
9828594|NCT02501811|Experimental|Combination Cells (MSC and c-kit+ cells)|Target dose of 150 million MSCs and 5 million c-kit+ cells
9828595|NCT02501811|Placebo Comparator|Placebo (Plasmalyte A)|Plasmalyte A
9828596|NCT02501902|Experimental|Palbociclib + Nab-Paclitaxel|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
9828597|NCT02501928|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
9828598|NCT02501928|Experimental|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
9828599|NCT02501928|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
9828600|NCT02501928|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
9828601|NCT02502019|Experimental|HEMOBLAST|All subjects will have the investigational device implanted
9828602|NCT02502097|Experimental|Gefapixant>Placebo Pre-Amendment 3|Gefapixant 50 mg twice daily (BID) for 10 days, then 150 mg BID for 4 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
9828603|NCT02502097|Experimental|Placebo>Gefapixant Pre-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 10 days, then 150 mg for 4 days in Period 2
9828604|NCT02502097|Experimental|Gefapixant>Placebo Post-Amendment 3|Gefapixant 50 mg twice daily (BID) for 14 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
9828605|NCT02502097|Experimental|Placebo>Gefapixant Post-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 14 days in Period 2
9828606|NCT02502149|Experimental|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
9828607|NCT02502149|Experimental|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
9828608|NCT02502461|Sham Comparator|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
9828609|NCT02502461|Active Comparator|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
9746760|NCT05095844||Vaccinated|All individuals who have received a vaccine dose.
9746761|NCT05095597|Other|Umbilical cord PRP donors|"Women who are going to give birth to a healthy live newborn at the Hospital Universitario y Politécnico La Fe.~Donors will donate their umbilical cord blood to obtain the hUC-PRP. A total of 30±15 donors will be recruited."
9746762|NCT05095597|Experimental|Group B- Asherman with PRP treatment and estrogen therapy|Women with thin endometrium/endometrial atrophy and/or Asherman's syndrome with fertility problems and reproductive desires, desires that could be achieved by their participation in the present study. A total of 15 patients will be included; all of them will receive the investigational treatment as well as estrogen therapy.
9746763|NCT05095597|Other|Group A1- POI with PRP treatment and estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the investigational treatment as well as estrogen therapy.
9746764|NCT05095597|Other|Group A2- POI with estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. All of them will receive the estrogen therapy.
9746765|NCT05095597|Other|Group A3- POI without PRP treatment nor estrogen therapy|Women with premature ovarian failure (POI). A total of 10 patients will be included. None of them will receive either the investigational treatment nor estrogen therapy.
9746766|NCT05093049|Active Comparator|Bilateral gynecomastia surgery with Renuvion APR System right side|The gynecomastia surgery and Renuvion APR System use will be as per investigator's standard clinical practice. The Renuvion APR System will be used on the right side only. The treated side will be randomized and the patient and Independent Reviewer will be blinded as to which side of the chest received Renuvion.
9746767|NCT05093049|Active Comparator|Bilateral gynecomastia surgery with Renuvion APR System left side|The gynecomastia surgery and Renuvion APR System use will be as per investigator's standard clinical practice. The Renuvion APR System will be used on the left side only. The treated side will be randomized and the patient and Independent Reviewer will be blinded as to which side of the chest received Renuvion.
9746768|NCT05087264|Experimental|Indocyanine green injection|43 cases received preoperative intravenous injection of indocyanine green and radical resection of q-mc1 cervical cancer under pelvic autonomic nerve fluorescence development
9746769|NCT05087264|No Intervention|Not Indocyanine green injection|43 cases underwent routine surgery，not indocyanine green injection
9746770|NCT05082961|Other|X-ray photon therapy + biological samples|
9746771|NCT05082961|Other|Protontherapy + biological samples|
9746772|NCT05081492|Experimental|Treatment (CF33-hNIS-antiPDL1)|Patients receive CF33-hNIS-antiPDL1 IT on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9746773|NCT05075746||enVista Toric 0.9D intra ocular lens|
9746774|NCT05075746||enVista non-Toric (spherical) intra ocular lens|
9746775|NCT05075421||Group 1 (high marker)|Patients with elevated serum markers
9746776|NCT05075421||Group 2 (normal marker)|Patients with normal value of serum markers
9746777|NCT05075330|Experimental|Intervention|Participants who live in the Orange Mound community of Memphis. Billboards targeting stigma reduction were posted in the community for one month.
9746778|NCT05075330|No Intervention|Control|Participants who live in the Frayser community of Memphis. No billboards (intervention) were placed here.
9746779|NCT05069038|Experimental|Treatment|"The following drugs will be taken for six cycles:~Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days and 7 days off schedule (meaning: on Days 1-21 of each 28-day cycle).~Letrozole should be taken daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.~Goserelin is given as subcutaneous injection every 28 days at a dose of 3.6 mg. It is to be given on Day 1 of each cycle. Goserelin will only be administered to pre-menopausal subjects."
9746780|NCT05061316|Experimental|Nutrition intervention group|Participants will receive Nestlé Impact Advanced Recovery Immunonutrition two times daily for 5 days leading up to the date of surgery. Nestlé Impact Advanced Recovery will be administered either orally or through a feeding tube.
9746781|NCT05059600|Experimental|ZULRESSO®|Participants will administer ZULRESSO® in a home setting as a single, continuous, intravenous (IV) infusion for 60-hours (hrs) starting on Day 1.
9746782|NCT05057975|Experimental|Sunrise|Home Sleep Test, OSA diagnosis based on mandibular movements recording
9746783|NCT05057975|Active Comparator|PSG|Polysomnography, OSA diagnosis based on local scoring by center
9746784|NCT05056246|Experimental|Group 1: Japanese participants - AMG 133 low dose|Japanese participants will receive the low dose of AMG 133 administered via subcutaneous injection.
9746785|NCT05056246|Experimental|Group 2: Japanese participants - AMG 133 medium dose|Japanese participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
9746786|NCT05056246|Experimental|Group 3: Japanese participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
9746787|NCT05056246|Experimental|Group 4: Caucasian participants - AMG 133 medium dose|Caucasian participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
9746788|NCT05056246|Experimental|Group 5: Caucasian participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
9746789|NCT05046730|Experimental|Prospective Evaluation of the SFM Device|This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device
9746790|NCT05046730|Active Comparator|Retrospective Chart Review of Historical Controls|In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.
9746791|NCT05032352||Treatment Arm|"Treatment Arm 1: 4 cycles of adjuvant treatment with a standard NSCLC cisplatin-based doublet regimen or carboplatin-based regimen of physician choice.~Treatment 1A: other adjuvant therapy or combination of adjuvant therapies (targeted therapy, immunotherapy, or other)"
9746792|NCT05032352||Observation only|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
9746793|NCT05031585|Experimental|Intervention Group|Nasal lubricant spray
9746794|NCT05031585|Placebo Comparator|Placebo|Placebo spray
9782097|NCT01166126|Experimental|Treatment (temsirolimus and selumetinib)|"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).~As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.~The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments."
9782098|NCT01166139|Experimental|Nilotinib 400 mg twice daily|
9782099|NCT01166230||Patients with Ta/T1, randomized to white light cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
9782100|NCT01166230||Patients with Ta/T1 randomized to Hexvix cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
9782101|NCT01166282|Placebo Comparator|Double-blind Placebo EOW|Placebo for adalimumab every other week (eow) for 12 weeks.
9782102|NCT01166282|Experimental|Double-blind Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
9782103|NCT01166282|Experimental|Open-label Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.
9782104|NCT01166347|Experimental|HeartWare® VAS|Implant of HeartWare® Ventricular Assist System
10201590|NCT05197699||DMT-Treated Participants|MS participants who are receiving DMTs will be enrolled.
9782105|NCT01166347|Active Comparator|Control LVAD|Implant of FDA-approved LVADs approved for destination therapy
9782106|NCT01166373|Experimental|Enrollment video arm|Arm of subjects that will be shown a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
9782107|NCT01166373|No Intervention|No video intervention arm|This group of subjects will not view a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
9782108|NCT01166373|Experimental|ULS|Uterosacral Ligament Suspension was one of the randomized surgical treatments in the OPTIMAL study
9782109|NCT01166373|Experimental|SSLF|Sacrospinous Ligament Fixation was one of the randomized surgical treatments in the OPTIMAL study.
9782110|NCT01166373|Experimental|PMT|Perioperative Behavioral Therapy/Pelvic Muscle Training was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
9782111|NCT01166373|Other|Usual Care|No Perioperative Behavioral Therapy/Pelvic Muscle Training (i.e., usual care) was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
9782112|NCT01166438|Experimental|Botox A|A single intradetrusor injection of 100U botulinum toxin A (Botox A®) plus daily oral placebo tablets
9782113|NCT01166438|Active Comparator|Standardized Anticholinergic Regimen|A standardized 3-step anticholinergic regimen of daily oral solifenacin 5mg, solifenacin 10mg, and/or trospium chloride XR 60mg, as well as a single intradetrusor injection of saline (placebo). All subjects will begin on solifenacin 5 mg for 2 mo. If a subject's symptoms are not adequately controlled at 2 mo, she will be escalated to solifenacin 10mg, and similarly at 4 mo to trospium XR 60mg. If a subject's symptoms are adequately controlled on solifenacin 5 mg, she may continue that study medication for the entirety of the study (6 mo). Additionally, if a subject is dose-escalated to solifenacin 10mg at study mo 2 or 4, and her symptoms are adequately controlled, she may continue the solifenacin 10mg dose for the remainder of the study.
9782114|NCT01166568|Experimental|Implantation-Non Randomized|Subjects are not participants in the randomized sub-study. PresView Scleral Implants surgical placed in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
9782115|NCT01166568|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. PresView Scleral Implants surgical placed in the eye(s)Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
9782116|NCT01166568|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have PresView Scleral Implants surgically placed in the eye(s) and become part of the overall study experimental group.
9782117|NCT01166646|Experimental|Halobetasol Proprionate Lotion 0.05%|Subjects randomized to receive lotion
10201591|NCT05197699||Untreated Participants|MS participants who are receiving no DMT treatment or receiving only symptomatic treatment will be enrolled.
10201592|NCT05197686|Experimental|HFNC|
10201593|NCT05197686|Active Comparator|COT|
10201594|NCT05197634||Children with Autism Spectrum Disorder|The orofacial trauma history, dietary habits and lifestyle changes of children aged 3-14 years diagnosed with autism in Istanbul University Department of Child Psychiatry evaluated through a questionnaire to be applied to their families.
10201595|NCT05197634||Healthy children|The orofacial trauma history, dietary habits and lifestyle changes of healthy children aged 3-14 years applying to Istanbul University Faculty of Dentistry Department of Pediatric Dentistry will be evaluated through a questionnaire to be applied to their families.
10201596|NCT05197621||Vaccine Arm|Pregnant women who are planning to receive an mRNA COVID vaccine (Pfizer of Moderna), and/or a third booster vaccine, who consent to maternal blood collection before receipt of the vaccine and at 6 time points after receiving the vaccine and/or booster.
9746795|NCT05025787|Active Comparator|Active comparator|The active comparator in the trial is Celecoxib 100mg BID
9746796|NCT05025787|Experimental|100mg BID|The lower dose proposed in this Phase 2 trial (100mg BID), which provides 1/3 of the exposure to CNTX-6970 relative to the higher dose, will generate informative data on the dose-related effects of the compound.
9746797|NCT05025787|Experimental|300mg BID|The higher dose (i.e., 300mg BID) demonstrated good tolerability and safety, as well as over 90% inhibition of the binding of monocyte chemoattractant protein-1 to its CCR-2 receptor. Moreover, this dose produced nearly 90% binding inhibition at the CCR-5 receptor as well.
9746798|NCT05025787|Placebo Comparator|Placebo|Placebo
9746799|NCT05025475|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), transseptal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present), and rate of a recurrent neurologic embolic event in patients with cryptogenic stroke and PFO.
9746800|NCT05025475|Active Comparator|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials
9746801|NCT05020158|Experimental|Family Talk intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
9746802|NCT05018611|Experimental|LifeSkills Mobile|Access to LifeSkills Mobile app. Participants will complete 4 modules with 20 activities across 6 months. Participants can log in at their convenience but will not be able to access the next module until the previous module is completed.
9746803|NCT05018611|No Intervention|Standard of Care|HIV home testing every 6 months, information regarding sexual and other behaviors that potentiate one's risk for HIV infection, receipt of a fact sheet about PrEP and PEP and referrals to the local PrEP clinics, and sexually transmitted infection testing via an on-line location findings app.
9746804|NCT05016856|Active Comparator|Reminder Only Condition|To promote adherence, participants will receive generic reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone.
9746805|NCT05016856|Experimental|Smart Adherence Support Condition|To promote adherence, participants will receive reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone. In this condition, participants will receive adaptive and tailored reminders based on dynamic algorithms that deploy reminders in a way that considers participant preferences, days and times of previous successful assessments, the success of previous reminder attempts, and answers to brief questions contained within reminder prompts. Parameter weights for these variables will be adjusted dynamically over a 6-month assessment period to ensure that reminders are deployed when they are most likely to be acted upon.
9746806|NCT05013411||Healthcare workers|Healthcare workers with patient care experience and are willing to share their experience of current practices of obtaining patient observations.
9746807|NCT05005299|Experimental|Dose Level A|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11 to -6 (total venetoclax dose: 600mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
9746808|NCT05005299|Experimental|Dose Level B|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 to -6 (total venetoclax dose: 1100mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
9746809|NCT05005299|Experimental|Dose Level C|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10, 400mg daily administered on day -9 and 600mg daily administered on day -8 to -6 (total venetoclax dose: 2500mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
9746810|NCT05005299|Experimental|Dose Level B'|Subjects will receive receive short-course venetoclax on day -11 to -6 [venetoclax 100mg daily administered on day -11, followed by 200mg daily administered on day -10 and 400mg daily administered on day -9 to -6 (total venetoclax dose: 1900mg)], followed by intravenous fludarabine 30mg/m2 daily (day -5 to -3) and intravenous cyclophosphamide 750mg/m2 daily (day -5 to -3). Allogeneic stem cell infusion will occur on day 0.
9746811|NCT05005286||Group A|Lactating women with vaginal infection during pregnancy as confirmed by past medical records
9746812|NCT05005286||Group B|Lactating women without any vaginal infection during pregnancy
9746813|NCT04998422|Experimental|Part A: HG381 Monotherapy Dose Escalation Cohort|Subjects will receive HG381 IV at every one week intervals (Q1W). Escalating doses of HG381 will be evaluated by the traditional 3+3 design.
9746814|NCT04998422|Experimental|Part B: HG381 Monotherapy Dose Expansion Cohort|Subjects will be administered the recommended Phase 2 dose of HG381 IV Q1W established in Part A of the study.
9746815|NCT04991025|Experimental|Participants with resectable stage II-III lung cancers.|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
9746816|NCT04987307|Experimental|Efavaleukin alfa|
9746817|NCT04987307|Placebo Comparator|Placebo|
9746818|NCT04980599|Active Comparator|K56 very high dose -E1|Probiotic drink (lactobacillus paracasei K56 10^11CFU) 350ml/d , for 60days
9746819|NCT04980599|Placebo Comparator|control -E2|maltodextrin powder 1.5g/sachet , 3g/d for 60days
9746820|NCT04980599|Active Comparator|K56 high dose-E3|Probiotic powder 1.5g/sachet , 3.0g/d (lactobacillus paracasei K56 10^10cfu) , for 60days
9746821|NCT04980599|Active Comparator|K56 middle dose-E5|Probiotic powder 8.0g/sachet , 8g/d ( Lactobacillus paracasei K56 10^9cfu) , for 60days
9746822|NCT04980599|Active Comparator|K56 low dose -E7|probiotic k56 capsule, 2capsules/d ( Lactobacillus paracasei K56 10^7cfu) , for 60days
9746823|NCT04980599|Active Comparator|K56 middle dose-E9|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^9cfu) ,for 60days
9746824|NCT04980599|Active Comparator|K56 high dose-E1K|probiotic K56 capsule, 2capsules/d (Lactobacillus paracasei K56 10^10cfu), for 60days
9746825|NCT04980599|Active Comparator|K56 very high dose-E11|probiotic K56 capsule, 4capsules/d (Lactobacillus paracasei K56 10^11cfu) ,for 60days
9746826|NCT04978480||Stroke patients|patients with suspected severe acute stroke
9746827|NCT04976283|Active Comparator|Pioglitazone|The starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
9746828|NCT04976283|Active Comparator|Empagliflozin|The starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
9746829|NCT04976283|Active Comparator|Pioglitazone + Empagliflozin|The starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.
9746830|NCT04971187|Experimental|Treatment (bintrafusp alfa, pemetrexed, carboplatin/cisplatin)|Patients receive bintrafusp alfa IV over 1 hour on day 1 and pemetrexed IV over 10 minutes on day 1. Patients also receive carboplatin IV over 15 minutes or cisplatin IV over 6-8 hours at the physician's discretion on day 1 of cycles 1-4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9746831|NCT04963920|Experimental|SoC+CytoSorb treatment|patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines
9746832|NCT04963920|No Intervention|SoC|patients allocated to this group will receive only standard of care therapy according to applicable guidelines
9746833|NCT04961164|Experimental|Resistant Potato Starch|15g RPS mixed with water will be consumed twice per day during intervention
9746834|NCT04961164|Placebo Comparator|Corn Starch|15 g corn starch mixed with water will be consumed twice per day during intervention
9746835|NCT04952376|Active Comparator|Short message service (SMS)|Subjects will receive vaccine availability and appointment information via SMS.
9746836|NCT04952376|Experimental|Personalized text message|Subjects will receive vaccine availability and appointment information via a personalized message text from the primary care provider (PCP).
9746837|NCT04952376|Experimental|Interactive or 2-way SMS|Subjects will receive vaccine availability and appointment information via interactive 2-way SMS options.
9746838|NCT04947852|Experimental|Investigation Mask|Bi Level CPAP Mask
9746839|NCT04947852|Active Comparator|Comparator Mask|Bi Level CPAP Mask
9746840|NCT04946292|Experimental|Theory-derived intervention|Questionnaire will be used including the scales for three dominant theoretical models, Health Belief Model (HBM), Theory of planned behaviour (TPB) and Social Cognitive Theory (SCT). The theoretical model that best explains the health behaviours of the selected participants will be selected for designing oral health intervention.The theory-derived intervention will address the constructs/domains of the selected model(s) in the context of the three target behaviours (diet, toothbrushing and dental flossing).
9746841|NCT04946292|Active Comparator|Conventional health education|Participants will be randomly assigned to the control group, stratified by gender and education level. Allocation concealment will be ensured by using sealed opaque envelopes.
9746842|NCT04944901|Experimental|SB-121|"One dose of SB-121 daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral"
9746843|NCT04944901|Placebo Comparator|Placebo|"One dose of placebo daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral"
9746844|NCT04937751||Invasive fusariosis|
9746845|NCT04937751||Fusarium keratitis|
9746846|NCT04934696|Experimental|BMS-986166 + Oral contraceptive|
9746847|NCT04933448|Experimental|Prospective Intervention Group|Participants will receive standard of care for acute management of moderate to severe traumatic brain injury, together with a weight-based ketogenic diet added for up to fourteen days.
9746848|NCT04933448|No Intervention|Historical Control Group|Medical records of past TBI patients will be used as controls matched for age, gender, socioeconomic status (type of health care coverage including private insurance vs. government-funded coverage), lowest first 24 hour post-injury Glasgow Coma Score (GCS) (<8 or 8-12), and pre-injury school program (regular or special education).
9746849|NCT04930783|Experimental|CDX-301 + Neovax + Nivolumab|"Participants will undergo metastatic tumor biopsy with vaccine made from collected tissue.~Participants will receive Nivolumab at a flat dose every 4 weeks up to two years.~Participants will receive CDX-301 at a predetermined dose dependent on the number of participants previously enrolled for 5 days starting 2 days before the initiation of NeoVax. CDX-301 will then be administered at a predetermined dose dependent on the number of participants previously enrolled 2 days before and for 5 days coinciding with the administration of NeoVax on days 50 and 78."
9746850|NCT04927065|Experimental|Part A: mRNA-1273.211 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.211 on Day 1.
9746851|NCT04927065|Experimental|Part A: mRNA-1273.211 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211 on Day 1.
9746852|NCT04927065|Experimental|Part B: mRNA-1273 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.
9746853|NCT04927065|Experimental|Part C: mRNA-1273.617.2 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.
9746854|NCT04927065|Experimental|Part C: mRNA-1273.617.2 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.
10201597|NCT05197621||Sample Collection at Delivery Arm|Pregnant patients who have tested positive for COVID during their pregnancy or have a positive COVID test at the time of admission to Labor & Delivery, who consent to collection of maternal blood, cord blood, placenta, and breast milk samples, as well as neonatal blood and stool samples. Patients testing negative for COVID at the time of admission to Labor & Delivery can be enrolled in the study as controls.
9746855|NCT04927065|Experimental|Part D: mRNA-1273.213 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.
9746856|NCT04927065|Experimental|Part D: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
9746857|NCT04927065|Experimental|Part E: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
9746858|NCT04927065|Experimental|Part F Cohort 1: mRNA-1273.529 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.529 on Day 1.
9746859|NCT04927065|Experimental|Part F Cohort 1: mRNA-1273.529 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA.1273.529 on Day 1.
9746860|NCT04927065|Experimental|Part F Cohort 2: mRNA-1273.529 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.529 (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.
9746861|NCT04927065|Experimental|Part F Cohort 2: mRNA-1273.529 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.529 (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.
9746862|NCT04924400|Active Comparator|CHIP Program|GHP members randomized to the intervention arm will participate in the CHIP Program.
9746863|NCT04924400|Active Comparator|Usual Diabetes Care|GHP members assigned to the control arm will receive the routine standard of care for GHP members.
9746864|NCT04922216|Experimental|Condition 1|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + No Choice
9746865|NCT04922216|Experimental|Condition 2|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + Choice
9746866|NCT04922216|Experimental|Condition 3|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + No Choice
9746867|NCT04922216|Experimental|Condition 4|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
9746868|NCT04922216|Experimental|Condition 5|Core+Standard Diet Monitoring+Daily Activity Goal+Adaptive Timing+Standard Content+No Choice
9746869|NCT04922216|Experimental|Condition 6|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Standard Content + Choice
9746870|NCT04922216|Experimental|Condition 7|Core+ Standard Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
9983954|NCT04525755|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.
9746871|NCT04922216|Experimental|Condition 8|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Adaptive Content + Choice
9983955|NCT04525755|No Intervention|Control Group|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group.
9983956|NCT04519320|Other|SARS-COV 2 Patients|
10201598|NCT05197608|Experimental|Intervention - System Navigator|"The intervention group will be connected to a system navigator who is a trained staff member embedded within the primary health clinic team with a focus to address participant's biological, psychological and social needs.~Working with the System Navigator will mean:~Discussing patients' current health status and concerns~Receiving support on management of chronic diseases and mental health including connection to local resources e.g. counseling, harm reduction, crisis support services~Receiving information about benefits that they may be entitled to and learning about free services~Receiving help from the System Navigator on forms or letters that are required to access resources"
10201599|NCT05197608|Active Comparator|Tailored list of community resources|Control group will be provided a tailored list of community resources.
9746872|NCT04922216|Experimental|Condition 9|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + No Choice
9746873|NCT04922216|Experimental|Condition 10|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
9983957|NCT04519008|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
9983958|NCT04519008|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
9746874|NCT04922216|Experimental|Condition 11|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + No Choice
9746875|NCT04922216|Experimental|Condition 12|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
9746876|NCT04922216|Experimental|Condition 13|Core+Standard Diet Monitoring+Weekly Activity Goal+Adaptive Timing+Standard Content+No Choice
9746877|NCT04922216|Experimental|Condition 14|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Standard Content + Choice
9746878|NCT04922216|Experimental|Condition 15|Core + Standard Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
9746879|NCT04922216|Experimental|Condition 16|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content + Choice
9746880|NCT04922216|Experimental|Condition 17|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ No Choice
9746881|NCT04922216|Experimental|Condition 18|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ Choice
9746882|NCT04922216|Experimental|Condition 19|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
9746883|NCT04922216|Experimental|Condition 20|Core + Simplified Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
9746884|NCT04922216|Experimental|Condition 21|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
9746885|NCT04922216|Experimental|Condition 22|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ Choice
9746886|NCT04922216|Experimental|Condition 23|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
9746887|NCT04922216|Experimental|Condition 24|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ Choice
9983959|NCT04516577||Shanghai Pulmonary Hospital|Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.
9983960|NCT04516577||Peking Union Medical College Hospital|Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.
9983961|NCT04516577||Nanjing Drum Tower Hospital|The Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital has been focusing on the research of rare pulmonary diseases for many years.
9983962|NCT04516447|Experimental|Combination with carboplatin|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles (± 3 days), and (2) carboplatin 5 mg/mL*min intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle (± 3 days)
9983963|NCT04516447|Experimental|Combination with PLD|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles (± 3 days), and (2) PLD 50 mg/m^2 intravenously over 60 minutes every 4 weeks, on Day 1 of each 28-day cycle
9746888|NCT04922216|Experimental|Condition 25|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Standard Content+ No Choice
9746889|NCT04922216|Experimental|Condition 26|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
9746890|NCT04922216|Experimental|Condition 27|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
9746891|NCT04922216|Experimental|Condition 28|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
9746892|NCT04922216|Experimental|Condition 29|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
9746893|NCT04922216|Experimental|Condition 30|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ Choice
9746894|NCT04922216|Experimental|Condition 31|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
9983964|NCT04516447|Experimental|Combination with paclitaxel|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles, and (2) paclitaxel 80 mg/m^2 administered intravenously over 60 minutes (± 10 minutes) on Days 1, 8, and 15 of each 28-day cycle
9983965|NCT04516447|Experimental|Combination with gemcitabine|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles, and (2) gemcitabine 1000 mg/m^2 intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle
9983966|NCT04515628|Experimental|Period A: Rosuvastatin|
9983967|NCT04515628|Experimental|Period B: Branebrutinib|
9983968|NCT04515628|Experimental|Period C: Branebrutinib + Rosuvastatin and Branebrutinib|
9983969|NCT04515628|Experimental|Period D: Branebrutinib|
9983970|NCT04515498||CloudCath System|Patients with End Stage Renal Disease (ESRD) currently using home peritoneal dialysis
9983971|NCT04514562|Other|Intervention|NeVa Stent Retrievers
9746895|NCT04922216|Experimental|Condition 32|Core + Simplified Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content+Choice
9746896|NCT04921384|Experimental|Eptinezumab 300 mg|"Double-Blind Treatment Phase (at baseline): 300 mg eptinezumab by intravenous (IV) infusion.~For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion."
9746897|NCT04921384|Experimental|Eptinezumab 100 mg|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion.~For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion."
9746898|NCT04921384|Placebo Comparator|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion.~For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion."
9746899|NCT04919954|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 7 doses of tebipenem, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours following the last dose.
9746900|NCT04919954|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of tebipenem, followed by sampling of interstitial tissue fluid by a microdialysis probe inserted in a thigh over 8 hours following the last dose.
9746901|NCT04918173|Experimental|Atenativ treatment|Patients will receive a single intravenous infusion of Atenativ for PK analysis. Patients will receive a single intravenous dose followed by maintenance doses administered every 24 hours for approximately 2-7 days for surgical patients and approximately 5 days for parturients
9746902|NCT04901975|Experimental|Spironolactone|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation.~Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every ~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg.~Spironolactone administration will begin after the Fontan procedure in the hospital prior to discharge or at the first outpatient visit ~ 2 weeks after discharge."
9746903|NCT04901975|No Intervention|Observational|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
9746904|NCT04901975|No Intervention|Control|"The purpose of this study is to non-invasively characterize the fibrotic consequences of SV physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion (figure 1) along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.~Control subjects who are non-SV patients but who have normal heart function who are undergoing CMR for evaluation (eg patients undergoing CMR for vascular ring evaluation, family history of congenital heart disease but found to be normal, etc) will have study related MRI and CMR sequences performed."
9746905|NCT04899388|Active Comparator|PENG|"The patient is placed in the supine position. After sterilization of the skin and drapping, the low frequency convex probe of Sonosite M Turbo ultrasonography( FUJIFIM sonosite, Inc., Bothell, WA, USA) is placed..~A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly."
9782118|NCT01166646|Active Comparator|Halobetasol Proprionate Cream 0.05%|Subjects randomized to receive cream
9782119|NCT01166659|Experimental|CyPass Micro-Stent|Subjects receive the CyPass Micro-Stent
9782120|NCT01166750|Experimental|CD-ROM-treatment|
9782121|NCT01166750|Active Comparator|Wait-list Control Group|
9782122|NCT01166763|Experimental|high dose vitamin D3 (10,000 IU weekly)|Group/Cohort Label vitamin D3
9746906|NCT04899388|Active Comparator|ESPB|"The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%, 10 ml normal saline was administered leading to hydrodissection to confirm correct location. All LA was administered to this location between the transverse process and the erector spinae muscle"
9746907|NCT04899388|Placebo Comparator|control|Patients will receive opioids analgesia before spinal anesthesia in the form of intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between before positioning the patient for spinal anesthesia.
9746908|NCT04892186|Experimental|Myo-inositol|30 women with resistance insulin or glucose intolerance will receive myo-inositol 2g, orally, twice a day for 6 months.
9746909|NCT04892186|Active Comparator|Metformin|30 women with resistance insulin or glucose intolerance will receive metformin, orally, three times a day for 6 months
9746910|NCT04890769||Participants|Patients with exuding wounds
9746911|NCT04888468|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose-escalating
9746912|NCT04886999|Experimental|Inhaler A CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator."
9746913|NCT04886999|Active Comparator|Inhaler B CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator"
9746914|NCT04884763|Active Comparator|Arm A|Arm A: erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
9746915|NCT04884763|Placebo Comparator|Arm B|Arm B: placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
9746916|NCT04879875|Experimental|Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
9746917|NCT04879875|Experimental|Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
9746918|NCT04876274|Experimental|Intervention group|Patients in the intervention group received Taipei Medical University (TMU) line-oriented video education and care in addition to usual care
9746919|NCT04876274|No Intervention|Control group|Patients in the control group received usual care
9746920|NCT04873245|Active Comparator|Intensive Behavioral Program Arm|"Participants randomized to this arm of the study will receive intensive behavioral therapy.~Participants will receive 52 weekly sessions (50% in person and 50% virtual)."
9746921|NCT04873245|Active Comparator|Medication Arm|Participants randomized to this arm of the study will receive semaglutide and will receive behavioral therapy. Behavioral therapy will consist of 12 monthly sessions (50% in person and 50% virtual).
9746922|NCT04871854|Experimental|Svere infected Covid-19 control|Arm one confirmed sever COVID 19 infection admitted to ICU including with or without breast cancer patients comorbidity receive traditional therapy
9746923|NCT04871854|Active Comparator|sever infected Covid -19 pateints study|Arm two patients with confirmed sever COVID 19 infection admitted to ICU with or without breast cancer patients comorbidity tocilizumab
9746924|NCT04870164|Experimental|ensovibep dose 1 (infusion)|
9746925|NCT04870164|Experimental|ensovibep dose 2 (infusion)|
9746926|NCT04870164|Experimental|ensovibep dose 3 (infusion)|
9746927|NCT04870164|Placebo Comparator|placebo (infusion)|
9746928|NCT04870164|Experimental|ensovibep dose 4 (IV bolus)|
9746929|NCT04870164|Experimental|ensovibep dose 5 (IV bolus)|
9746930|NCT04870164|Experimental|ensovibep dose 6 (SC injection)|
9746931|NCT04870164|Experimental|ensovibep dose 7 (SC injection)|
9746932|NCT04870164|Experimental|ensovibep dose 8 (SC injection)|
9746933|NCT04870164|Experimental|ensovibep dose 9 (SC injection)|
9746934|NCT04870164|Experimental|ensovibep dose 10 (IM injection)|
9746935|NCT04870164|Experimental|ensovibep dose 11 (IM injection)|
9746936|NCT04870164|Experimental|ensovibep dose 12 (IM injection)|
9746937|NCT04870164|Experimental|ensovibep dose 13 (IM injection)|
9746938|NCT04865276|Active Comparator|Intervention|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
9746939|NCT04865276|Active Comparator|Control|Home visit by a Community Health Worker during which the participant is scheduled to attend the tobacco cessation program at the public health system
9746940|NCT04849871|Experimental|Arm S_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 20 Gy-1 fraction)|-External Beam APBI 20 Gy to surgical bed surface (7 Gy to 1 cm from surgical bed in 1 fraction)
9746941|NCT04849871|Experimental|Arm F_APBI (External Beam Accelerated Partial Breast Irradiation (APBI) 30 Gy-5 fractions)|-External Beam APBI 30 Gy in 5 fractions over 5 days.
9782123|NCT01166945|Placebo Comparator|Short Course|Short course (5 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination and placebo for next 9 days.
9782124|NCT01166945|Active Comparator|Long Course|Long course (14 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination given orally for 14 days.
9782125|NCT01166958|Active Comparator|Daily teriparatide (Forteo)|
9828610|NCT02502487|Placebo Comparator|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
9828611|NCT02502487|Experimental|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
9828612|NCT02502487|Experimental|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
9828613|NCT02502526|Experimental|CVS with 45° Balanced Tip|Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
9828614|NCT02502526|Active Comparator|CVS with 45° MFK Tip|Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
9828615|NCT02502526|Active Comparator|IVS with 45° MFK Tip|lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
9828616|NCT02502734|Experimental|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
9828617|NCT02502734|Experimental|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
9828618|NCT02502864|Experimental|Standard of Care + Surveys|Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
9828619|NCT02503085|Experimental|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
9828620|NCT02503085|Experimental|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
9828621|NCT02503085|Active Comparator|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
9828622|NCT02503085|Active Comparator|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
9828623|NCT02503202|Experimental|V920 Consistency Lot A|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
9828624|NCT02503202|Experimental|V920 Consistency Lot B|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
9828625|NCT02503202|Experimental|V920 Consistency Lot C|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
9828626|NCT02503202|Experimental|V920 High-dose Lot|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
9828627|NCT02503202|Placebo Comparator|Placebo to V920|Participants received a 1.0 mL intramuscular injection of placebo on Day 1
9828628|NCT02503215|Experimental|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
9828629|NCT02503254|Experimental|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
9828630|NCT02503254|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
9828631|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
9828632|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL EOM for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
9828633|NCT02503332|Sham Comparator|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
9828634|NCT02503332|Sham Comparator|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
9828635|NCT02503410|Active Comparator|Usual care|Subjects receive physical therapy for low back pain as typically prescribed in the clinic.
9828636|NCT02503410|Experimental|Interactive gaming|Subjects participate in an intervention combining usual care and home-based exercises using the Valedo system.
9828637|NCT02503501|Experimental|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
9828638|NCT02503501|Placebo Comparator|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
9828639|NCT02503540|Other|Aflibercept|Monthly aflibercept for 6 months and then every other month for 6 months.
9828640|NCT02503735|Other|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|10 patients with hepatitis C (HCV) and HCV-associated CKD that will receive 12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)
9828641|NCT02503787|Other|Open label treatment|Spinal Cord Stimulation (SCS)
9828642|NCT02503852|Experimental|Fat + High Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
9983972|NCT04513210||Changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital with changes in the ultrasound on admission, suggesting pneumonia.
9828643|NCT02503852|Experimental|Fat + Low Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
9828644|NCT02503852|Active Comparator|Fat Alone|Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
9828645|NCT02503852|Placebo Comparator|No Fat Control|Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
9828646|NCT02503865|Active Comparator|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
9828647|NCT02503865|Experimental|"Analimentary detoxication Weight loss"|Vegetables and salt diet
9828648|NCT02503865|No Intervention|Healthy people|64 healthy people
9828649|NCT02503982|Experimental|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
9828650|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.~There is no intervention."
9828651|NCT02504216|Experimental|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
9828652|NCT02504216|Placebo Comparator|Placebo|Rivaroxaban-placebo orally twice daily
9828653|NCT02504268|Experimental|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
9828654|NCT02504268|Active Comparator|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
9828655|NCT02504268|Placebo Comparator|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
9828656|NCT02504268|Placebo Comparator|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
9828657|NCT02504294|Other|Epoetin Hospira|Epoetin Hospira Arm
9828658|NCT02504294|Other|Standard of Care|Standard of care arm
9828659|NCT02504320|Experimental|Treatment Sequence ABDC|Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
9828660|NCT02504320|Experimental|Treatment Sequence DACB|Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
9828661|NCT02504320|Experimental|Treatment Sequence CDBA|Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
9828662|NCT02504320|Experimental|Treatment Sequence BCAD|Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
9828663|NCT02504424|Experimental|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
9828664|NCT02504502|Experimental|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
9828665|NCT02504502|Other|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
9828666|NCT02504541|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
9828667|NCT02504554|Experimental|Oral Group|This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
9746942|NCT04849052|Experimental|MASTERY Intervention|Participants will complete a positive psychology activity, work towards a physical activity goal, and use a stress reduction technique, then will complete weekly text message sessions. In the first six weeks, participants will review the activities they performed the prior week, be introduced to new material, choose activities to perform that week, and set a new physical activity goal during the text message sessions. In the final 6 weeks, participants will review progress towards prior goals, set new physical activity goals, and choose positive psychology and stress reduction skills to use that week. Finally, over the course of the program participants will complete three brief calls with a study trainer to discuss progress.
9746943|NCT04849052|Active Comparator|Attentional control|Participants will receive the same physical activity component noted in MASTERY along with added messages providing education and guidance about physical activity, from our past work. Control participants will not receive PP or midlife-related content.
9746944|NCT04847453|Experimental|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO QD on days 1-28, ixazomib citrate PO on days 1, 8 and 15, and dexamethasone PO on days 1, 8, 15 and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9746945|NCT04820673||Sarecycline|Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.
9746946|NCT04820478|Experimental|Beta Hydroxybutyrate Ester|3 x 10 g beta hydroxybutyrate ester per day, in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
9746947|NCT04820478|Placebo Comparator|Placebo|matching placebo, in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
9746948|NCT04818918||STEMI group|"Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery.~Absolute coronary flow and microvascular resistance will be measured in the LAD."
9746949|NCT04818918||Control group|"Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions <90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value >0.8).~Absolute coronary flow and microvascular resistance will be measured in the LAD."
9746950|NCT04816604|Experimental|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) over 72 weeks
9746951|NCT04802590|Experimental|Arm A|Ibrutinib (+ CD20Ab)
9746952|NCT04802590|Experimental|Arm B|Ibrutinib + Venetoclax (+CD20Ab)
9746953|NCT04801667|Experimental|Coronavac vaccine|Kidney transplant recipients receiving the coronavac vaccine
9746954|NCT04799990||Risankizumab|Participants will receive risankizumab as prescribed by their physician.
9746955|NCT04799990||Comparator Group 1|Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.
9746956|NCT04799990||Comparator Group 2|Participants will receive non-biologic systemic small molecules as prescribed by their physician.
9746957|NCT04796909|Experimental|Parent coaching|The parent-coaching intervention consists of up to 8 weekly/fortnightly sessions, and each session will last up to one hour.
9746958|NCT04796909|Active Comparator|Parent consultation|The parent consultations are given for up to 8 weekly/fortnightly sessions, and each session may last up to one hour.
9782126|NCT01166958|Active Comparator|Monthly cycles of teriparatide followed by raloxifene|
9746959|NCT04781855|Experimental|Part A (ipilimumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks for up to a total of 2 years.
9746960|NCT04781855|Experimental|Part B (ipilimumab, nivolumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 7 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and nivolumab, and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks and nivolumab every 4 weeks for up to a total of 2 years.
9746961|NCT04771221|Experimental|Main group|Patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
9746962|NCT04771221|Experimental|Control group 1|Patients with an early diagnosis of Gastroesophageal reflux disease
9746963|NCT04771221|Experimental|Control group 2|Patients without complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching.
9746964|NCT04770259|No Intervention|Control|The control group will have a nursing evaluation and then follow the surgeon's instructions in the current standard way until de surgery day. In that day the RN will be evaluate again these group. Then, this group will be followed within the hospital and the first, second and third month after discharge.
9746965|NCT04770259|Experimental|Intervention|The intervention group will have a nursing evaluation and then will attend an evaluation by geriatarics team, kinesiology and nutrition, where a plan of physical cardiovascular, nutritional and metabolic prehabilitation is delivered. On the day of surgery, the RN will evaluate this group again. Then, this group will be followed within the hospital and the first, second and third month after discharge.
9746966|NCT04743635|Experimental|Investigational Device Treatment|Cellulite can be treated across thighs and buttocks
9746967|NCT04737668|Other|Usual care|Pump refill will be performed as usual.
9746968|NCT04737668|Other|Virtual Reality|Children will play a commercially available VR game during pump refill
9746969|NCT04737668|Other|Distraction|Children will watch a commercial 360° music video on YouTube during pump refill
9746970|NCT04726501|Experimental|Low risk group|Ann Arbor stage IA or IIA without bulky disease.
9746971|NCT04726501|Experimental|Intermediate risk group|Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulk disease, and IA or IIA with bulk disease
9746972|NCT04726501|Experimental|High risk group|Ann Arbor stages III or IV with B symptoms
9746973|NCT04724304|Experimental|Healthy adults|Healthy adults will have blood flow to the heart evaluated using s Real-Time Myocardial Echocardiography (RTMPE) and magnetic resonance image (MRI) to the heart.
9746974|NCT04723394|Experimental|AZD7442|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 1 (n=up to approximately 850) will receive a single dose (× 2 IM injections) of 600 mg of AZD7442.
9746975|NCT04723394|Placebo Comparator|Placebo|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 2 (n=up to approximately 850) will receive saline placebo.
9746976|NCT04714866|Experimental|Interventional group|Cognitive behavioral therapy for ADHD
9746977|NCT04714866|No Intervention|waiting list group|No Intervention for the waiting list group
9746978|NCT04698915|Experimental|Arm A Active GC4711|
9746979|NCT04698915|Placebo Comparator|Arm B Placebo|
9746980|NCT04694560||CLL/SLL|Diagnosis of CLL or SLL confirmed by the enrolling institution
9746981|NCT04684238|Active Comparator|Drug: Midazolam|Midazolam for sedation in the ICU
9746982|NCT04684238|Experimental|Drug: Isoflurane|Volatile for sedation in the ICU
9746983|NCT04681443|Active Comparator|Successful treatment|Patients with successfully treated pilonidal sinus disease
9746984|NCT04681443|Active Comparator|Treatment failure|Pilonidal sinus disease patients with treatment failure
9746985|NCT04666272||dabrafenib in combination with trametinib as adjuvant treatment|Patients will be treated according to the China package insert for dabrafenib and trametinib. The approved starting doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) will be used.
9746986|NCT04660721|Experimental|sFilm-FS|
9746987|NCT04660721|Active Comparator|TACHOSIL®|
9746988|NCT04657146||Patients with suspected newly-diagnosed Glioblastoma (GBM)|Patients, ≥18 years of age, with newly diagnosed GBM, World Health Organization (WHO) Grade IV, undergoing gross total resection (defined as >90% of contrast enhancing volume removed on post-operative MRI) and collection of blood, bone marrow, and tumor.
9746989|NCT04656691|Experimental|Participants with COVID-19|Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.
9828668|NCT02504554|Experimental|Rectal Group|This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
9828669|NCT02504619|Experimental|CordIn|Transplantation of CordIn
9828670|NCT02504645|Active Comparator|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
9828671|NCT02504645|Placebo Comparator|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
9828672|NCT02504671|Experimental|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
9828673|NCT02504671|Experimental|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
9828674|NCT02504671|Experimental|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
9828675|NCT02504671|Experimental|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
9828676|NCT02504671|Experimental|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
9828677|NCT02504671|Placebo Comparator|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
9828678|NCT02504723|Experimental|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
9828679|NCT02504723|Active Comparator|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
9828680|NCT02504775|Experimental|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet [500 milligram (mg) of paracetamol] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
9828681|NCT02504775|Experimental|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
9828682|NCT02504827|Experimental|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
9828683|NCT02504892|Experimental|Birt-Hogg-Dube Syndrome|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
9828684|NCT02504892|Experimental|Sporadic chromophobe renal tumors|Sporadic chromophobe renal tumors
9828685|NCT02504931|Experimental|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
9828686|NCT02504931|Placebo Comparator|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
9828687|NCT02505269|Experimental|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:~- Participants will receive combination therapy:~Brentuximab Vedotin intravenously on predetermined days per cycle~Adriamycin intravenously on predetermined days per cycle~Dacarbazine intravenously on predetermined days per cycle"
9828688|NCT02505334|Experimental|Liraglutide 1.8 mg|The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
9983973|NCT04513210||No changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital without changes in the ultrasound on admission, suggesting pneumonia.
9746990|NCT04630561|Experimental|Intervention Group|Subjects will participate in a 15 minute postural intervention program 2-3 times per week
9746991|NCT04630561|No Intervention|Control Group|Subjects will NOT participate in any postural intervention.
9983974|NCT04512976|Experimental|24 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
9983975|NCT04512976|Experimental|30 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
10201600|NCT05197595|Experimental|Compassion condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
9746995|NCT04623541|Experimental|Epcoritamab in R/R CLL|R/R CLL: in both dose escalation and dose expansion phases. Patients in the dose expansion phase will be treated at the RP2D defined in the dose escalation phase.
9746996|NCT04623541|Experimental|Epcoritamab in RS|RS: only in dose expansion phase. Patients in the dose expansion phase will be treated at the RP2D defined in the dose escalation phase.
9746997|NCT04623320||NAFLD+T1DM+|Subjects with type 1 diabetes and ultrasound-defined NAFLD
9746998|NCT04623320||NAFLD-T1DM+|Subjects with type 1 diabetes without ultrasound-defined NAFLD
9746999|NCT04615299|Active Comparator|Auricular acupuncture|Auricular (Battlefield) acupuncture needles will be utilized in the test arm, location of needles and stickers will be placed according to 5 VA approved BFA auricular acupuncture points associated with PONV, pain, and anxiety respectively
10201601|NCT05197595|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extracurricular activity.
10201602|NCT05197582|Active Comparator|Tele-monitoring group|The researchers called the patients in the experimental group on the first day of the quarantine and explained the topics covered in the COVID 19 patient education booklet to the patients. Patient education and follow-up in quarantine took approximately 25-30 minutes for each patient in the experimental group. The patients in quarantine were followed up by the researchers two more times, on the 5th and 9th days of the quarantine. On the 10th and last day of the quarantine, post-test online questionnaires were sent to the patients for the second time, and the data collection phase was ended.
10201603|NCT05197582|No Intervention|Plasebo group|The patients in the control group were called by the researchers on the first day of the quarantine and asked to fill in the online pre-test forms. On the 10th day, the last day of the quarantine, the patients were called and the online post-test forms were sent for the second time, and the data were collected. There was no telephone follow up in the control group and the patients received only routine care in the home
10201604|NCT05197569|No Intervention|Control group|No intervention will be applied to the control group and the measurements will be recorded simultaneously.
9747000|NCT04615299|Sham Comparator|Sham acupuncture|The control arm will receive sham or placebo acupuncture via pressing of a blunt needle on the specified BFA locations and then application of adhesive stickers. In the control group simulating acupuncture, the needles will never enter the patients' skin and will give the impression to the patient that the procedure has taken place.
9747001|NCT04614779|Experimental|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) or higher dose (15 mg/kg bw, bid) for 24 or 48 weeks, according to the administration plan.~The dosage form is tablets."
9747002|NCT04610372|Active Comparator|standard|External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks
9747003|NCT04610372|Experimental|High dose rate brachytherapy|A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.
9747004|NCT04610372|Experimental|Permanent seed implant brachytherapy|A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate
9747005|NCT04610372|Experimental|Stereotactic body radiotherapy|36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.
9747006|NCT04603560|Experimental|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
9747007|NCT04603560|Experimental|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
9747008|NCT04603560|No Intervention|Control|No intervention will be provided to physicians in the control arm.
9747009|NCT04602299|Experimental|Set the minimum time of gastroscopy|
9747010|NCT04602299|No Intervention|Observe the procedure time of gastroscopy|
9747011|NCT04600141|Active Comparator|Group 1 - Therapeutic anticoagulation|"(I) intravenous UFH started at a dose of 18 IU/kg/h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value; OR~(II) subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours."
9747012|NCT04600141|Active Comparator|Group 2 - Prophylactic anticoagulation|"(I) subcutaneous UFH 5,000 IU every 8 hours; OR~(II) subcutaneous LMWH - enoxaparin 40 mg daily."
9747013|NCT04600141|Experimental|Group 3 - Therapeutic anticoagulation with tocilizumab|"(I) Intravenous UFH initiated at a dose of 18 IU / kg / h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value associated with 8 mg / kg / tocilizumab infusion / intravenous dose in a single dose; OR~Subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours associated with an infusion of tocilizumab 8 mg / kg / dose in a single dose."
9747014|NCT04600141|Experimental|Group 4 - Prophylactic anticoagulation with tocilizumab|"(I) subcutaneous UFH 5,000 IU every 8 hours associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose; OR~(II) subcutaneous LMWH - enoxaparin 40 mg daily associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose."
9747015|NCT04598165|Experimental|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
9747016|NCT04598165|No Intervention|No SMS Control|Control receiving standard of care.
9747017|NCT04596735||Patients undergoing general endotracheal anesthesia that will be extubated following the procedure|Patients 60 years of age and older undergoing general anesthesia and non-cardiac surgery will be observed by a member of the research team independent from the team caring for the patient at the time of emergence and extubation
9747018|NCT04596345||University students|"This group will include all those participants who declare to be attending a study program to get a higher education degree.~No intervention will be applied."
9747019|NCT04596345||Non-university-attending peers|"This group will include all those participants who are not attending a study program to get a higher education degree.~No intervention will be applied."
9747020|NCT04588272||2 liters|40 patients will receive O2 supply at rate of 2 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
10201605|NCT05197569|Experimental|Thyme oil group|After filling out the forms, thyme oil aromatherapy will be applied to the patients assigned to the experimental group .The oregano oil to be prepared must have a high carvacrol ratio. Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
10201606|NCT05197504||intervention|atezolizumab + bevacizumab
10201607|NCT05197478|Other|COVID 19 positive patients|COVID 19 positive patients receiving inpatient treatment were evaluated.
9747021|NCT04588272||4 liters|40 patients will receive receive O2 supply at rate 4 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
9747022|NCT04588272||6 liters|: 40 patients will receive O2 supply at rate 6 liters per minute and then cabnographic and other measures will be recorded through out the procedure.
9747023|NCT04585984|Placebo Comparator|Control|140 men will be taking a placebo once a day during 21 days prior to the start of the IVF/ICSI cycle.
9747024|NCT04585984|Experimental|Experimental|140 men will be taking the probiotic compound (50% of each probiotic: Lactobacillus rhamnosus and Bifidobacterium longum at a dose of 10^9 cfu/day) once a day for 21 days prior to the start of the IVF/ICSI cycle.
9747025|NCT04584255|Experimental|Arm A Triple Negative Breast Cancer (TNBC)|"Participants will be randomized 1:1 to treatment with the combination (Arm A)~Niraparib-Daily beginning with week 1, day 1~Dostarlimab-Once every three weeks beginning with week 1, day 1"
9747026|NCT04584255|Experimental|Arm B TNBC|"Participants will be randomized 1:1 to treatment with the combination (Arm B)~3-week lead-in of niraparib monotherapy followed by treatment with the combination~Niraparib Daily beginning with week 1, day 1~Dostarlimab Once every three weeks beginning with week 4, day 1"
9747027|NCT04584255|Experimental|Arm C ER+/HER2-|"exploratory cohort of estrogen receptor (ER) positive HER2-negative participants will be enrolled to Arm C.~Niraparib Daily beginning with week 1, day 1~Dostarlimab Once every three weeks beginning with week 1, day 1"
10201608|NCT05197452|Experimental|COVID-19 Testing|COVID-19 antigen and PCR Testing
10201609|NCT05197413|Experimental|Arrae Bloat supplement|"The Bloat capsules are a blend of 5 herbs and a fruit-based digestive enzyme that target the cause for IBS symptoms."
9747028|NCT04574895|Other|VTE risk prediction scores|Patients in the intervention arm will have their VTE risk prediction scores presented to the study team daily on weekdays via an automated report, which will list patients in descending order of risk severity for review by the VTE research team each weekday. Starting with the highest risk patients, the VTE research team will review each patient and clinical situation, and then the VTE research team will directly discuss risks/benefits of prophylactic anticoagulation with the admitting team. Patients with a risk score <2.5% will not be reviewed, and the investigators anticipate most of the intervention arm patients will fall into this category (based on our previous data, the investigators anticipate >90% of all patients will score <2.5%). The VTE risk report will be re-calculated based on updated EHR data every day at midnight.
9747029|NCT04574895|No Intervention|Standard of care|Patients randomized to the control arm will continue to receive current standard of care anticoagulation practice, which is at the discretion of the admitting team. In general, nearly no pediatric patients are offered prophylactic anticoagulation unless a previous VTE has been identified. This currently is at the discretion of the provider and no risk scoring is used. VTE risk prediction scores will be calculated and stored for analysis, these will not be visible to the study team in real time.
9747030|NCT04574843|Experimental|Embolization arm|Intervention: Embolization of middle meningeal artery Device: Onyx, squid, Phil
9747031|NCT04567277|Experimental|Early VPS|
9782127|NCT01166971|Experimental|ReSTOR +3|Bilateral Implantation of ReSTOR +3 Intraocular lenses after cataract extraction
9782128|NCT01166971|Active Comparator|Tecnis MF|Bilateral Implantation of Tecnis Multifocal Intraocular lenses after cataract extraction
9782129|NCT01166984|Experimental|AB103 7.5 µg/kg|AB103 7.5 µg/kg administered as a single IV infusion
9782130|NCT01166984|Experimental|AB103 37.5 µg/kg|AB103 37.5 µg/kg administered as a single IV infusion
10201610|NCT05197400|Active Comparator|supine|operation in the supine position
9782131|NCT01166984|Experimental|AB103 150 µg/kg|AB103 150 µg/kg administered as a single IV infusion
9782132|NCT01166984|Experimental|AB103 450 µg/kg|AB103 450 µg/kg administered as a single IV infusion
9782133|NCT01166984|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
9782134|NCT01166997|Experimental|Ultrasound accelerated thrombolysis|Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
9828689|NCT02505334|Active Comparator|Liraglutide 0.9 mg|The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
10201611|NCT05197400|Active Comparator|prone|operation in the prone position
10201612|NCT05197309|Active Comparator|Women with anorexia nervosa|adult women with anorexia nervosa who have been recently restored to normal weight
10201613|NCT05197309|Active Comparator|Women with no history of eating disorders|adult women with no history of eating disorders
10201614|NCT05197283|Experimental|Glucose as reference food|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
10201615|NCT05197283|Experimental|White bread|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
9747032|NCT04559932|Experimental|Intervention|The knowledge and self-efficacy pre-tests will be completed at the start of the course and the post-test will be completed after the course at the end of the day. Study participants will complete tests independently using paper and pencil. Six weeks and six months post course completion, the knowledge and self-efficacy tests will be completed using REDcap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases or via telephone as per participant preference. Study participants will be sent a link to complete the tests online for the subsequent study visits. Study participants will receive 2 reminder emails (1 week apart) and 1 reminder phone call after the email reminders (if applicable) to complete the tests. Monthly telephone calls by the RA will be made to review the HCP experience logs.
9747033|NCT04559932|No Intervention|Control|Study participants in the control arm will be offered complementary attendance in the Health Tech Junior enterostomy and vascular access competency based training course while awaiting their session. This is being done to minimize the potential confound of generalized improvements in self-efficacy that may occur as a result of participating in an 8 hour learning opportunity at SickKids. The control group will also complete the tracheostomy course during session 3 and 4 but this will occur outside the window of data collection for the study procedures. Data collection intervals as described above for the intervention group will be followed for the control group.
9747034|NCT04556266|Experimental|Cohort -1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10^4 cells/kg"
9747035|NCT04556266|Experimental|Cohort 1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 1 x 10^5 cells/kg"
9747036|NCT04556266|Experimental|Cohort II|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 2 x 10^5 cells/kg"
9747037|NCT04556266|Experimental|Cohort III|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT~Total T-Cell Dose: 4 x 10^5 cells/kg"
9747038|NCT04555096|Experimental|Active GC4419|Arm A
9747039|NCT04555096|Placebo Comparator|Placebo|Arm B
9747040|NCT04551352|Experimental|Part I: Single Participant Cohorts (IV)|Part I is a dose escalation in single participant cohorts. RO7293583 will be administered intravenously (IV) every three weeks (Q3W). The starting dose will be 0.045mg and the maximum dose explored will be 1.5mg.
9747041|NCT04551352|Experimental|Part II: Multiple Participant Cohorts (IV/SC)|Multiple ascending dose-escalation of RO7293583 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation will be determined by Part I and RO7293583 will be administered IV or SC every 3 weeks. Dose-escalation will be undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. Fractionated, step up or subcutaneous dosing may be implemented. The maximum dose explored will be 600mg IV and 160mg SC.
9747042|NCT04549363|Experimental|Participants undergoing IC|IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.
9747043|NCT04549363|Experimental|Participants undergoing SK|SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.
9747044|NCT04548713|Experimental|4% EDTA CVC Lock|Patients in this group will be given 4% EDTA as their CVC locking solution.
9747045|NCT04548713|Active Comparator|Standard of Care Saline CVC Lock|Patients in this group will be given standard of care saline as their CVC locking solution.
9747046|NCT04547998|Experimental|All Participants (within patient control)|All subjects will receive both RECELL and NV-UVB. Each subject will serve as their own Control, with a depigmented area receiving no RECELL treatment but receiving the same targeted NB-UVB as the investigational treatment area. Study treatment areas will be randomily assigned as Area A and Area B. Investigational treatment (RECELL) will be randomly allocated to either Area A or Area B.
9747047|NCT04541017|Experimental|Arm I (magrolimab, mogamulizumab), Phase Ib and Phase II|Patients receive magrolimab IV over 2-3 hours weekly during cycles 1-2, then Q2W during cycles 3-12. Patients also receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9747048|NCT04541017|Active Comparator|Arm II (mogamulizumab), Phase II|Patients receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who have received at least 2 full treatment cycles and have PD or have received at least 6 full treatment cycles and have SD may crossover to Arm I.
9747049|NCT04537247|Experimental|Open partial nephrectomy (Group A)|patients in this group will have open partial nephrectomy for their renal tumors.
9747050|NCT04537247|Experimental|Robotic partial nephrectomy (group B)|patients in this group will have robotic partial nephrectomy for their renal tumors.
9747051|NCT04536857||Parkinson's Disease|Subjects who have a PD diagnosis
9747052|NCT04536857||Multiple System Atrophy|Subjects who have an MSA diagnosis
9747053|NCT04536857||Progressive Superanuclear Palsy|Subjects who have a PSP diagnosis
9747054|NCT04536857||Age-matched controls|Subjects who do not have a diagnosed neurological disorder
9747055|NCT04528459|Active Comparator|Traditional fluoroscopy|Cohort 1 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using traditional fluoroscopy for insertion of the lag screw (current standard of care).
9747056|NCT04528459|Experimental|Stryker© ADAPT™ platform|Cohort 2 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using the Stryker© ADAPT™platform to assist with insertion of the lag screw.
9747057|NCT04527926|Experimental|STEPuP Intervention|STEPuP interventions
9747058|NCT04527926|Active Comparator|Usual Care|Standard of Care
9747059|NCT04526288|Active Comparator|Arm A (alloHCT)|Patients undergo alloHCT.
9747060|NCT04526288|Experimental|Arm B (CPX-351, alloHCT)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment may repeat for an additional cycle for a total of 2 cycles (on days 1 and 3 only of cycle 2) in the absence of disease progression or unacceptable toxicity. Within 60 days after completion of CPX-351, patients undergo alloHCT.
9747061|NCT04522739|Experimental|Spironolactone|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.
9747062|NCT04522739|Placebo Comparator|Placebo|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
9747063|NCT04517799|Experimental|cannabidiol|cannabidiol arm
9747064|NCT04517799|Placebo Comparator|placebo|placebo arm
9747065|NCT04517396|Experimental|Fenofibrate + Usual Care|The randomized intervention will be Fenofibrate, in combination with usual care. Dosing: 145 mg of Tricor or a dose-equivalent preparation
9747066|NCT04517396|Placebo Comparator|Placebo + Usual Care|The randomized intervention will a matching placebo, in combination with usual care.
9747067|NCT04504318|Experimental|Apixaban|Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.
9747068|NCT04504318|Active Comparator|Enoxaparin|Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.
9747069|NCT04503759||Foot and Ankle Surgery using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
9747070|NCT04498949|Experimental|Exprimental|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
9747071|NCT04498949|Active Comparator|Treatment as usual|Treatment as usual care, Recieve consulting not included unified protocol Recieve supportive cares
9747072|NCT04495972|Active Comparator|Experimental arm: Intestinimonas|Intestinimonas in capsules
9747073|NCT04495972|Placebo Comparator|Placebo arm: Placebo|Placebo in capsules
9747074|NCT04493567|Experimental|Part A: 1 x BMS-986036 via auto-injector or pre-filled syringe|
9747075|NCT04493567|Experimental|Part B: 2 x BMS-986036 via auto-injector or pre-filled syringe|
9747076|NCT04492553|Experimental|Testogel|All patients will be treated with Testogel. Starting dose is 1 sachet of gel daily applied to the skin of arms, thighs or abdomen. Dose adjustments are made after serum-levels of testosterone. All patients will be treated for a total of 52 weeks, unless they exit the study early because of side-effects or other reasons.
9828690|NCT02505542|Other|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
9747077|NCT04490356|Experimental|Legacy Intervention|Older adults who have successfully completed a lifestyle intervention (lost at least 3% body weight and increased short physical performance battery (SPPB) score by 1 point or 6-minute walk test (6MWT) by 50 meters) will be enrolled in a tele-nutrition and tele-exercise intervention.
9747078|NCT04480541|Experimental|Roadmap 2.0 + Fitbit Charge 3|"Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.~Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep."
9747079|NCT04479605||Patients with advanced cancer|Patient and caregiver coaching is facilitated by a booklet titled Our Cancer Care (Appendices E & F) that includes a Question Prompt List (QPL) and resources for a Values Affirmation Exercise (Appendices G & H). The QPL and Values Affirmation Exercises will be provided with a cover letter (Appendix I). The QPL consists of example questions to discuss with oncologists about diagnosis, prognosis, treatments, symptom management, transitions in care, self-care, family needs, and life goals. Patients and caregivers meet over video-conferencing with a study interventionist for one hour to review the QPL. The interventionist makes three follow-up phone calls to each dyad bi-weekly to evaluate use of the QPL.
9747080|NCT04479605||Caregivers|Caregivers will participate in three 45-minute sessions with the interventionist over the telephone or video-conferencing (per caregiver preference) approximately bi-weekly. These sessions take place while the patient and caregiver are completing the three follow-up dyadic sessions. Efforts will be made to schedule the caregiver support sessions during weeks that fall between dyadic coaching sessions to minimize intervention burden on caregivers (i.e., avoiding scheduling two sessions for the caregiver in the same week).
9747081|NCT04479605||Oncologists|The Oncologist training will be conducted online using Bridge, an internet-based platform designed to facilitate communication between instructors and learners. The training includes written information on and videos demonstrating target communication skills (Table 1) and knowledge acquisition checks. Five of the online modules are required and the remaining six modules are optional. The required modules are estimated to take oncologists approximately one hour to complete; the optional modules are estimated to take 90 minutes total (i.e., for all modules) to complete. Oncologists' logging history will be tracked in Bridge.
9747082|NCT04475640|Other|Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood or saliva sample for genetic testing.
9747083|NCT04471792|Experimental|Creatine monohydrate|Creatine Monohydrate will be given at a 5 day loading period (10g/day) followed by a maintenance phase (5 g/day). The objectives of the current trial are to investigate if creatine supplementation plus muscle stretching improves 6-minute walking distance and muscle oxygenation in patients with peripheral artery disease.
9747084|NCT04471792|Placebo Comparator|Cellulose|These participants will consume a fiber supplement in place of creatine monohydrate at a matched dose with muscle stretching.
9747085|NCT04464421|Experimental|Contingency management (CM)|Participants will receive physical rewards urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment (MAT)) during their first four visits after initiation of MAT.
9747086|NCT04464421|Experimental|BSM|BSM (Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion) participants will have one-on-one behavioral intervention sessions at each of the first four visits after initiation of MAT.
9747087|NCT04462562|Experimental|quantitative ultrasound imaging parameters|"quantitative ultrasound imaging parameters~tissue attenuation imaging (TAI) parameter~tissue scatter-distribution imaging (TSI) parameter~Hepatorenal index (semi-auto, EzHRI)"
9747088|NCT04458207|Experimental|Experimental group (EG), the immediate rehabilitation group|The experimental group will begin with the rehabilitation immediately after the first measurement of cognitive tests (pre-test). Three months after complete rehabilitation the first post-test (post-test 1) will be conducted on all participants. Participants will be recalled after about a year for a long-term follow up (post-test 2). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at different time points (i.e., pre-test, post-test 1 and post-test 2).
9747089|NCT04458207|Active Comparator|Control group (CG), the test-retest group|The control group will be tested with the cognitive tests two times (pre-test + post-test 1) at an interval of about three months or more inbetween tests and before the onset of the prosthodontic rehabilitation. Three months after complete rehabilitation the post-test (post-test 2) will be conducted on all participants. Further, participants will be recalled after about a year for a long-term follow up (post-test 3). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at these time points (i.e., pre-test, post-test 1, post-test 2 and post-test 3).
9747090|NCT04445428|Experimental|Intervention|Standard dose bivalent oral polio vaccine, 0.1ml, and information regarding prevention of COVID-19
9747091|NCT04445428|Other|Control|Information regarding prevention of COVID-19
9747092|NCT04439032||Spine Fusion using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be candidates for spinal fusion surgery after having failed conservative treatment or will have had spinal fusion surgery but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient.
9747093|NCT04434352|Active Comparator|Baseline Erectile Dysfunction|The first arm of the study will be those men with erectile dysfunction as defined by IIEF score. These men will either have PDE5i refractory or responsive erectile dysfunction. Subjects will receive either Sham treatment (no ultrasound energy delivered via a Sham probe) or LiSWT for erectile dysfunction. Follow up will occur at 1 month, 3 months, and 6 months following the end of treatment. Effectiveness will be measured by change in IIEF/SHIM score and EHS score. Each questionnaire is described in the trial description with a higher score indicating improved function.
9747094|NCT04434352|Active Comparator|Erectile Dysfunction-Penile Rehabilitation|The second population of patients will be those who are planning to undergo treatment for prostate cancer. In a similar manner, men will be randomized to either the Sham or active treatment groups. Men will be treated prior to undergoing definitive treatment for prostate cancer to assess the effectiveness in LiSWT as a means of erectile preservation prior to prostate cancer treatment.
9747095|NCT04434352|Active Comparator|Erectile Dysfunction Post-Prostate Cancer Treatment|The third population of patients will be those who have undergone treatment for prostate cancer. The investigators will compare IIEF scores and EHS scores in men who have undergone prostatectomy or radiation therapy. Again, there will be a sham and treatment group.
9747096|NCT04428164||Hospitalized patients|Any patient admitted to the study units (MDMC: 10ST; MCMC: A6; MMMC: A3; MRMC: 3Medical ) that do not have any of the exclusion criteria
9747097|NCT04428112|Experimental|Building Better Caregivers Workshop Group|Building Better Caregivers Workshop is a 6-week online self-management and skills building workshop. Participants receive the online workshop as soon as possible after randomization.
9747098|NCT04428112|Active Comparator|Attention Control Group|Participants will be offered the online workshop after the 12 month trial is completed if they so desire.
9747099|NCT04422431|Experimental|ALXN1840|Participants will receive ALXN1840.
9747100|NCT04421118||standard portal pressure gradient measurement and CT scan|"Procedure/Surgery:~Portal pressure gradient measurement and CT imaging examination. Three-dimensional models reconstructing and fluid dynamics simulation."
9747101|NCT04418765|Experimental|Eptinezumab 100 mg|
9747102|NCT04418765|Experimental|Eptinezumab 300 mg|
9747103|NCT04418765|Experimental|Placebo|
9747104|NCT04417179|Experimental|TAP block group|"the TAP block will be given by a high frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .~a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under direct ultrasound visualization, . After confirming the correct placement of the needle and the negative aspiration probe anaesthetic substance will be injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine(10) , and the dissection of the plane was observed. The block will be performed bilaterally."
9747105|NCT04417179|Experimental|ESP group|the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .A blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under strict aseptic precautions until the tip is deep to erector spinae muscle, The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally
9747106|NCT04415151|Experimental|Tofacitinib|Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
9747107|NCT04415151|Placebo Comparator|Placebo|Matching placebo will be administered.
9747108|NCT04410627|No Intervention|Standard of Care|
9747109|NCT04410627|Experimental|Standard of Care + HoPE|
9747110|NCT04400500||Suspected NSTEACS|Patients urgently admitted to the CCU with suspected NSTEACS
9747111|NCT04395196|Active Comparator|High-dose choline supplementation|2 g choline cation
9747112|NCT04395196|Placebo Comparator|Placebo|Placebo identical to active treatment in appearance, taste, and smell.
9747113|NCT04389242|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
9747114|NCT04389242|Experimental|app-based cognitive behavioral intervention|"Application-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
9747115|NCT04389242|Other|Wait-list control group|No intervention will be provided when the experimental groups are receiving services, but the access to the App-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
9747116|NCT04388800|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist."
9747117|NCT04388800|Experimental|app-based cognitive behavioral intervention|"App-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist"
9747118|NCT04388800|No Intervention|Wait-list control group|No intervention will be provided when the experimental group is receiving services, but the access to the app-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
9747119|NCT04375813|Active Comparator|Active Study Drug Group|Patients will be given 0.5mg eRapa (encapuslated rapamycin) orally each weekday (Monday-Friday) for one year.
9747120|NCT04375813|Placebo Comparator|Placebo Group|Patients will be given a placebo (visually identical to the eRapa (encapsulated rapamycin)) orally each weekday (Monday-Friday) for one year.
9747121|NCT04349436|Experimental|RP1, intra-tumoral injection, oncolytic virus|RP1 administered as an intra-tumoral injection every 2 weeks.
9747122|NCT04339036|Experimental|Oral CapTem + Y90 Radioembolization|"Capecitabine 750 mg/m2 twice daily orally for 14 days and temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles, to be continued until 1) disease progression or 2) intolerable toxicities.~Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4."
9747123|NCT04334915|Experimental|Arm A: Cenicriviroc Mesylate (CVC)|"Cenicriviroc mesylate (CVC) 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing antiretroviral (ARV) regimens.~For participants who are on an efavirenz (EFV)-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
9747124|NCT04334915|Placebo Comparator|Arm B: Placebo for CVC|"Placebo for CVC 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing ARV regimens.~For participants who are on an EFV-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
9747125|NCT04330742||0 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 0, at which time 0 mL of fluids will have been administered.
9747126|NCT04330742||250 mL crystalloid.|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 1, after the spinal has been placed and approximately 250 mL fluids has been administered.
9747127|NCT04330742||500 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 2, at which time 500 mL of fluids will have been administered.
9747128|NCT04330742||1000 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 3, at which time 1000 mL of fluids will have been administered.
9747129|NCT04316494|Experimental|Hydroxychloroquine|"Patients will be receive 400mg of Hydroxychloroquine (2 x 200mg) to take daily for 52 weeks. Hydroxychloroquine will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
9747130|NCT04316494|Placebo Comparator|Placebo|"Patients will be receive 400mg of Placebo (2 x 200mg) to take daily for 52 weeks. Placebo will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
9747131|NCT04315961|Experimental|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
9747132|NCT04314843|Experimental|Lenzilumab and Axicabtagene Ciloleucel|Phase 1: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab and axicabtagene ciloleucel on Day 0 to determine a recommended Phase 2 dose (RP2D) of lenzilumab. Phase 2: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab, at the RP2D, and axicabtagene ciloleucel on Day 0.
9747133|NCT04309942|Experimental|Guided Clinical Pharmacy Consultation group|Patients following either Revlimid - Velcade - Dexamethasone or Revlimid - Dexamethasone protocols with the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
9747134|NCT04309942|No Intervention|Standard group|Patients following either Revlimid - Velcade - Dexamethazone or Revlimid - Dexamethazone protocols but without the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
9747135|NCT04307446|Experimental|10 Minutes|Subject takes part in 10 minute VR experience
9747136|NCT04307446|Experimental|20 Minutes|Subject takes part in 20 minute VR experience
9747137|NCT04299113|Experimental|Treatment (vinorelbine, mocetinostat)|Participants receive mocetinostat in combination with vinorelbine
9747138|NCT04294264|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9747139|NCT04290897|Experimental|Supportive care (anhydrous enol-oxaloacetate)|Patients receive anhydrous enol-oxaloacetate PO BID for 8 weeks in the absence of worsening symptoms or unacceptable toxicity.
9747140|NCT04290351||Band ligation and phlebotonic group|"Patients with rubber band ligation and the prescribed anti hemorrhoidal drug will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
9747141|NCT04290351||Only phlebotonic group|"Patients who are prescribed the only 450mg of diosmin + 50mg of hesperidin as a treatment for bleeding internal hemorrhoids will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
9747142|NCT04288895|Experimental|Vortioxetine|flexible-dose
9747143|NCT04275726|Experimental|Myval THV Series|"Myval THV Series will include Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site.~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
9747144|NCT04275726|Active Comparator|Contemporary Valves|"Sapien THV Series will consist of Sapien 3/Sapien 3 Ultra THVs or any subsequent advanced version commercially available at the study site.~Evolut THV Series will include Evolut R/Evolut PRO THVs or any subsequent advanced version commercially available at the study site.~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
9747145|NCT04271202|Other|Treatment|Effects of galacenezumab (emgality) treatment (injectable 240 mg initial dose followed by 120 mg treatments 1 and 2 month later) on brain functioning.
9747146|NCT04267562|Other|Single-Arm, Open-Label Treatment with the Minitouch System|Eligible participants will undergo a single treatment (endometrial ablation) with the Minitouch System
9747147|NCT04259060|Active Comparator|Hydroxocobalamin with Butyrate|Subjects enrolled will take hydroxocobalamin capsules twice daily for 4 weeks. All subjects will take an oral butyrate dose of 120 mg twice daily for 4 weeks.
9747148|NCT04259060|Placebo Comparator|Placebo with Butyrate|Subjects enrolled will take placebo capsules twice daily for 4 weeks. All subjects will take an oral butyrate dose of 120 mg twice daily for 4 weeks.
9747149|NCT04253236|Experimental|Cohort 1|Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
9747150|NCT04253236|Experimental|Cohort 2|Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
9747151|NCT04252040|Experimental|Active tDCS with guided imagery|Subjects will receive 2 miliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
9747152|NCT04250662|Experimental|Active tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
9747153|NCT04250662|Experimental|Active tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes while remaining seated, no guided imagery will be provided.
9828691|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
9828692|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
9828693|NCT02505542|Placebo Comparator|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
9828694|NCT02505542|Other|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
9828695|NCT02505542|Other|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
9828696|NCT02505542|Other|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
9828697|NCT02505867|Experimental|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
9828698|NCT02505867|No Intervention|Control|No device provided
9828699|NCT02505919|Experimental|Treatment|AQUABEAM System
9828700|NCT02505919|Active Comparator|Control|Transurethral Resection of the Prostate (TURP)
9828701|NCT02505945|Active Comparator|Control Arm|Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
9828702|NCT02505945|Active Comparator|Treatment Arm|LINX Reflux Management System
9828703|NCT02506036|Active Comparator|Control then Social Cognitive Training|Patients assigned to this arm will first receive a control therapy on a laptop followed by the Brain HQ social-cognitive training.
9828704|NCT02506036|Experimental|Social Cognitive Training then Control|Patients assigned to this arm will first receive the Brain HQ social-cognitive training and then undergo a control therapy.
10201616|NCT05197283|Experimental|Regular spaghetti No 7|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
9828705|NCT02506114|Experimental|Arm A: PROSTVAC-V/F|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.
9828706|NCT02506114|Experimental|Arm B: Ipilimumab Monotherapy|Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.
9828707|NCT02506114|Experimental|Arm C: Combined PROSTVAC-V/F + Ipilimumab|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
9828708|NCT02506257|Experimental|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
9828709|NCT02506257|Experimental|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
9828710|NCT02506257|Experimental|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
9828711|NCT02506257|Placebo Comparator|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
9828712|NCT02506309|Experimental|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
9828713|NCT02506309|Active Comparator|TOT trans obturator tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
9828714|NCT02506634||Participants with upper gastrointestinal symptoms|Participants are stratified at baseline based on their main upper gastrointestinal symptoms and then evaluated for GERD using different methods (i.e., reflux esophagitis on endoscopy or positive acid exposure time (AET) on reflux monitoring). Patients would then be given Esomeprazole MUPS（ Multiple Unit Pellet System）20 mg bid for evaluating the ability of the PPI Test for GERD. According to the guidelines, the duraion of PPI treatment was 4 weeks and 8 weeks for endoscopy negative patients and patients has reflux esophagitis, respectively.
9835773|NCT02754440|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
9835774|NCT02754440|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
9835775|NCT02754440|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
9835776|NCT02754492|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
9747154|NCT04250662|Sham Comparator|Sham tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
9747155|NCT04250662|Sham Comparator|Sham tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject will remain seated, no guided imagery will be provided.
9747156|NCT04249778|Experimental|Dapagliflozin|Patients admitted with exacerbation of chronic heart failure by clinical and radiologic features randomized to receive 10 mg of dapagliflozin, once daily
9747157|NCT04249778|Placebo Comparator|Placebo|Patients admitted with exacerbation of chronic heart failure by clinical and radiologic features randomized to receive a placebo to match 10 mg of dapagliflozin, once daily
9747158|NCT04248491|Active Comparator|Emsella Chair Active Treatment|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
9747159|NCT04248491|Sham Comparator|Emsella Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (<10% power).
9747160|NCT04247126|Experimental|Group 1: Single Agent Dose Escalation|Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.
9747161|NCT04247126|Experimental|Group 2: SY-5609 + Fulvestrant|Participants with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.
9747162|NCT04247126|Experimental|Group 3: SY-5609 + Gemcitabine|Participants with PDAC will receive SY-5609 in combination with gemcitabine in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine at the recommended combination dose.
9747163|NCT04247126|Experimental|Group 4: SY-5609 + Gemcitabine + Nab-paclitaxel|Participants with PDAC will receive SY-5609 in combination with gemcitabine plus nab-paclitaxel in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety, tolerability, and preliminary clinical activity of SY-5609 in combination with gemcitabine plus nab-paclitaxel at the recommended combination dose.
9747164|NCT04239196|Experimental|tocilizumab and IV steroids combination|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months. Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).
9747165|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
9747166|NCT04230499|Experimental|Cohort 1|Cohort 1 will receive 0.5mg of eRapa every other day.
9747167|NCT04230499|Experimental|Cohort 2|Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.
9747168|NCT04230499|Experimental|Cohort 3|Cohort 3 will receive 0.5 mg of eRapa daily.
9747169|NCT04222751|Experimental|Stretch Group|Subjects assigned to this group will be instructed on how to wear the device to produce the appropriate amount of dorsiflexion (stretch). Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
9747170|NCT04222751|Placebo Comparator|No Stretch Group|Subjects assigned to this group will wear the splints but instructed to wear the device in a position that produces no stretch. Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
9747171|NCT04221542|Experimental|Part 1: AMG 509 Intravenous (IV) Monotherapy|"Part 1 will evaluate AMG 509 in participants with metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with novel hormonal therapy (NHT) and 1 to 2 prior taxanes.~The dose exploration phase of the study will estimate the MTD of AMG 509 using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).~RP2D may be identified based on emerging safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) data, as well as patient experience prior to reaching an MTD. Alternative dosing schedule(s) (including a third step dose) may be explored based on emerging efficacy, safety, PK data and patient experience.~During the dose expansion phase, individual cohorts of participants from China will be enrolled with a safety lead-in at 1 dose level below the MTD or RP2D followed by evaluation at the MTD or RP2D to confirm the safety, tolerability, MTD and/or RP2D of AMG 509 in Chinese participants."
9828715|NCT02506660|Active Comparator|Intravenous dexamethasone|Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
9828716|NCT02506660|Experimental|Perineural dexamethasone|Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
9828717|NCT02506673|Active Comparator|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
9828718|NCT02506673|Experimental|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
9828719|NCT02506816||Olaparib|Drug exposure has a limited duration 28 (+/- 5) days.
9828720|NCT02506868|Experimental|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
9828721|NCT02506868|Active Comparator|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
9828722|NCT02506881|Experimental|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
9828723|NCT02506881|Experimental|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
9828724|NCT02506881|Experimental|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
9828725|NCT02506881|Experimental|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
9828726|NCT02507011|Experimental|Carvedilol First|Crossover Design: Participants receive Carvedilol first and placebo second
9828727|NCT02507011|Placebo Comparator|Placebo First|Crossover Design: Participants receive placebo first and Carvedilol second
9828728|NCT02507219|Placebo Comparator|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
9828729|NCT02507219|Active Comparator|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
9828730|NCT02507219|Active Comparator|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
9828731|NCT02507297|Experimental|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
9828732|NCT02507297|No Intervention|TAU Group|Treatment as usual through obstetrics
9828733|NCT02507349|Active Comparator|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
9828734|NCT02507349|Active Comparator|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
9828735|NCT02507375|Experimental|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
9828736|NCT02507375|Experimental|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
9828737|NCT02507388|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
9828738|NCT02507388|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
9828739|NCT02507752||Rituximab|Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
9828740|NCT02508077|Experimental|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
9828741|NCT02508103|Experimental|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
9828742|NCT02508103|Experimental|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
9828743|NCT02508116|Experimental|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
9828744|NCT02508116|No Intervention|Control group|Antiplatelet therapy will be decided based on usual care
9747172|NCT04221542|Experimental|Part 2: AMG 509 Subcutaneous (SC) Monotherapy|"Part 2 will explore the safety, tolerability, and PK of AMG 509 SC dosing in participants with mCRPC who have been previously treated with NHT and 1 to 2 prior taxanes.~The dose exploration phase of Part 2 of the study will estimate the MTD of AMG 509 SC using a BLRM (Neuenschwander et al, 2008).~Recommended phase 2 dose for SC monotherapy may be identified based on emerging safety, efficacy, PK, and PD data, as well as patient experience prior to reaching an MTD."
9747173|NCT04221542|Experimental|Part 3: AMG 509 IV Monotherapy in Earlier Lines of Treatment|Part 3 will explore AMG 509 in participants with mCRPC who have received 1 prior NHT. This dose expansion will be conducted to confirm safety, PK, and PD of AMG 509 at the MTD or RP2D determined in Part 1 dose exploration, and to obtain further safety and efficacy data and correlative biomarker analysis.
9747174|NCT04221542|Experimental|Part 4: AMG 509 IV Combination Therapy|"Part 4 will explore the safety, tolerability, and PK of AMG 509 for participants with mCRPC who have received 1 prior NHT, at dose regimens previously determined to be safe and tolerable in Part 1, in combination with abiraterone (Part 4A) or enzalutamide (Part 4B). Part 4 consists of a dose exploration phase and a dose expansion phase.~This dose exploration study will estimate the MTD and/or RP2D of AMG 509 in combination with abiraterone or enzalutamide using a modified toxicity probability interval design."
9747175|NCT04210245|Experimental|Daily 0.3 mg dose|Administered by subcutaneous injection
9747176|NCT04210245|Experimental|Daily 1 mg dose|Administered by subcutaneous injection
9747177|NCT04210245|Experimental|Daily 3 mg dose|Administered by subcutaneous injection
9747178|NCT04210245|Placebo Comparator|Placebo|Administered by subcutaneous injection
9747179|NCT04200339||Adolescents|Adolescents between the ages of 12 and 17 years old (inclusive).
9747180|NCT04194060|Experimental|Enhanced recovery after surgery group|"ERAS GROUP~Tracheal intubation.~Short acting anesthetic agents,avoid opioid agents~Omental patch repair with placement of sub hepatic drain~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~Post operative nausea and vomiting prophylaxis.~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~Initiation of feeding-Oral sips on day 1, step up day 2 onward~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~Removal of urinary catheter-after weaning from the effect of general anesthesia.~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~Avoid opiod analgesics."
9747181|NCT04194060|Active Comparator|Conventional group|"CONVENTIONAL GROUP~Tracheal intubation~Short acting anesthetic agents, avoid opiod anesthesia agents.~Omental patch repair along with sub hepatic drain placement.~Post operative nausea and vomiting prophylaxis.~Ambulation-as per patients' own request.~Initiation of oral feed- after passage of 1st flatus.~Nasogastric tube removal-output <300ml/day with resolution of ileus.~Removal of urinary catheter- when patient sits on bed side/ambulate.~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~Patient will receive opiod analgesics.~I"
9747182|NCT04182516|Experimental|Dose Escalation Part|Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.
9747183|NCT04182516|Experimental|Dose Expansion Part - Epithelial Ovarian Cancer|Patients with gBRCA mutation and epithelial ovarian cancer.
9747184|NCT04182516|Experimental|Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.
9747185|NCT04182516|Experimental|Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.
9747186|NCT04182516|Experimental|Dose Expansion Part - CRPC|Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC).
9747187|NCT04182516|Experimental|Dose Expansion Part - Pancreatic Cancer|Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.
9983976|NCT04512976|Experimental|38 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
9983977|NCT04512716|Experimental|B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell Lym|Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma
9983978|NCT04511845|Experimental|Dose escalation cohort of SPYK04|Patients will receive SPYK04 at escalated dose.
9983979|NCT04511845|Experimental|Expansion part in NSCLC, ovarian cancer and other solid tumors|Patients will receive SPYK04 at the recommended dose.
9983980|NCT04511741||invasive mechanical ventilation|
9983981|NCT04511741||non invasive mechanical ventilation|
9983982|NCT04510129||head and neck squamous cell carcinoma (HNSCC)|
9983983|NCT04510129||non-small-cell lung cancer (NSCLC)|
9983984|NCT04510129||small cell lung cancer (SCLC)|
9983985|NCT04510129||urothelial carcinoma (UCC)|
9983986|NCT04510129||gastric or gastroesophageal junction adenocarcinoma|
9983987|NCT04510129||cervical cancer|
9983988|NCT04510129||esophageal squamous cell carcinoma (ESCC)|
9747201|NCT04163107|Experimental|Combination treatment of carfilzomib/dexamethasone/HCQ|
9747202|NCT04150341|Experimental|TD-8236 Dose A (low dose)|TD-8236 Dose A (QD x 14 days)
9983989|NCT04510129||triple-negative breast cancer (TNBC)|
9983990|NCT04510129||hepatocellular carcinoma (HCC)|
9983991|NCT04510129||renal cell carcinoma (RCC)|
9983992|NCT04510129||colorectal cancer (CRC)|
9983993|NCT04508647|Experimental|Treatment|Treatment-Naive Stage II (non-contiguous), Stage III, Stage IV FL + MZL will receive Ublituximab 900mg IV weekly x 4 doses. End of treatment assessment 8 weeks post last dose of single agent ublituximab will be performed. Patients who achieve less than a complete response will receive a combination of ublituximab AND umbralisib for a total of 12 cycles. (In the combination arm ublituximab will be administered on day 1,8 and 15 on cycle 1 and on day 1 on each cycle thereafter. Umbralisib will be administered at 800 mg daily for 12 cycles)
9828745|NCT02508194|Active Comparator|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
9828746|NCT02508194|Experimental|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
9828747|NCT02508207|Placebo Comparator|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
9828748|NCT02508207|Experimental|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
9828749|NCT02508259|Active Comparator|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
9828750|NCT02508259|Placebo Comparator|Saline|50 ml of saline by intravenous infusion over 30 minutes
9828751|NCT02508389|Experimental|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
9828752|NCT02508389|Experimental|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
9828753|NCT02508389|Placebo Comparator|Placebo|Placebo daily, prior to IMRT
9828754|NCT02508428|Active Comparator|Crosslinked Marathon polyethylene|The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
9828755|NCT02508428|Active Comparator|Noncrosslinked Enduron polyethylene|The standard, noncrosslinked Enduron polyethylene liners used for the primary total hip replacements in this study were manufactured from the same polyethylene resin as the crosslinked Marathon liners but never irradiated. Like the Marathon components, these liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. Based on the manufacturing methods, these liners would not have had free radicals at the time of implantation and did not incorporate antioxidants.
9828756|NCT02508480|Experimental|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
9828757|NCT02508480|Active Comparator|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
9828758|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 30 mg QD|"Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
9828759|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 60 mg QD|"Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
9828760|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 90 mg QD|"Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
9828761|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 135 mg QD|"Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
9828762|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 200 mg QD|"Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. ."
9828763|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 300 mg QD|"Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
9828764|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 400 mg QD|"Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.~Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
9828765|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 600 mg QD|"Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
9828766|NCT02508532|Experimental|Part 1 and Part 2 Avapritinib (formerly BLU-285) 300 mg or 400 mg QD|"Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
9828767|NCT02508636|Experimental|Combination Therapy: Enzalutamide, Leuprolide, Radiotherapy|"Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months.~Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks."
9828768|NCT02508649|Placebo Comparator|Placebo|
9828769|NCT02508649|Experimental|Selepressin 1|Starting dose 1.7 ng/kg/min
9828770|NCT02508649|Experimental|Selepressin 2|Starting dose 2.5 ng/kg/min
9828771|NCT02508649|Experimental|Selepressin 3|Starting dose 3.5 ng/kg/min
9828772|NCT02508649|Experimental|Selepressin 4|"Starting dose 5.0 ng/kg/min~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility."
9828773|NCT02508701|Other|Altruistic inside-dorm|"Altruistic & personal message with direct recommendation and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine"
9828774|NCT02508701|Other|Generic inside-dorm|"Generic message and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation"
9828775|NCT02508701|Other|Generic outside-dorm|"Generic message and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation"
9828776|NCT02508701|Other|Altruistic outside-dorm|"Altruistic & personal message with direct recommendation and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine"
9828777|NCT02508935|Experimental|XARTEMIS XR|All participants received XARTEMIS XR
9828778|NCT02509026|Experimental|Etanercept|etanercept 50 mg QW
9828779|NCT02509065|Active Comparator|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
9828780|NCT02509065|Experimental|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
9828781|NCT02509065|Experimental|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
9828782|NCT02509065|Experimental|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
9828783|NCT02509065|Experimental|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
9828784|NCT02509065|Experimental|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
9828785|NCT02509065|Experimental|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
9828786|NCT02509065|Experimental|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
9828787|NCT02509065|Experimental|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
9828788|NCT02509078|Active Comparator|Early Neuromuscular Blockade (NMB)|Patients will receive cisatracurium besylate for the first 48 hours of the trial.
9828789|NCT02509078|No Intervention|Control: No Routine Early NMB|Use of non-study NMB will be discouraged.
9828790|NCT02509117|Experimental|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
9828791|NCT02509117|Experimental|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
9828792|NCT02509117|Placebo Comparator|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
9828793|NCT02509117|Experimental|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
9828794|NCT02509117|Placebo Comparator|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
9828795|NCT02509156|Experimental|Allo-MSCs|Target dose of 100 million allo-MSCs
9828796|NCT02509156|Placebo Comparator|Placebo|Buminate solution
9828797|NCT02509481|Active Comparator|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
9828798|NCT02509481|Experimental|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
9828799|NCT02509585|Experimental|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
9828800|NCT02509624|Experimental|Moderate hepatic impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
9828801|NCT02509624|Experimental|Severe hepatic impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
9828802|NCT02509624|Experimental|Mild hepatic impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
9835777|NCT02754492|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
9983994|NCT04505319|Experimental|DEFINISSE CORE FILLER|"Cross linked sodium hyaluronate 25 mg/ml with 0,3% lidocaine hydrochloride will be inject during the first visit and a touch up after one month if indicated by the physician.~The filler will inject in the face."
10201617|NCT05197283|Experimental|Whole wheat spaghetti|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
10201618|NCT05197283|Experimental|High fiber - low carbohydrate spaghetti|Fourteen healthy, normal body weight adults (male: 6, female: 10) after 12hr fast, consumed 50g available carbohydrates from D-glucose, tested two times, in different visits as reference food; and 50g available carbohydrates from white bread, tested two times; and 50 gr available carbohydrates from spaghetti No7 types, regular, whole wheat and low carbohydrates - high fibre, tested once, in different visits, along with 300mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90 and 120min after food consumption. The first glucose and salivary insulin sample was taken exactly 15min after the first bite of food or drink.
10201619|NCT05197244|Experimental|Culinary Medicine Intervention|Participants will attend a 2-hour hands-on cooking class in additional to usual care.
10201620|NCT05197244|No Intervention|Control|Participants will receive usual care.
10201621|NCT05197218|Experimental|Healthy subjects|Prebiotic administration
10201622|NCT05197205|Experimental|sickle cell children group|A nasopharyngeal swab is taken during the consultation, with bacteriological analysis.
10201623|NCT05197205|No Intervention|control children group|healthy children control group (ACTIV network)
10201624|NCT05197192|Experimental|GAVe-Arm|Acalabrutinib plus Venetoclax plus Obinutuzumab plus (GAVe)
10201625|NCT05197192|Experimental|GVe-Arm|Obinutuzumab plus Venetoclax (GVe)
10201626|NCT05197179|Other|Single-dose A|A single dose A of FB2001 or placebo will be administered by intravenous (IV) infusion
10201627|NCT05197179|Other|Single-dose B|A single dose B of FB2001 or placebo will be administered by intravenous (IV) infusion
10201628|NCT05197179|Other|Multiple-dose A|Dose A of FB2001 or placebo will be administered by intravenous (IV) infusion once daily for 5 consecutive days
10201629|NCT05197179|Other|Multiple-dose B|Dose B of FB2001 or placebo will be administered by intravenous (IV) infusion once daily for 5 consecutive days
10201630|NCT05197127|Experimental|Device Walking Group|Twelve participants over 65 years old completed a total of twelve 30-minute gait training sessions over a period of 4-6 weeks using the GEMS-H. All gait training sessions were completed in the community spaces at a senior living community. Gait training included dynamic over-ground walking (both self-selected and fast-paced),variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
10201631|NCT05197114|Experimental|Intervention|There will be one arm to the study, and all participants will be receiving the intervention.
10201632|NCT05197101|Experimental|nulliparous women with estimated fetal weight ≥3500g at 39-40 weeks of gestation|
10201633|NCT05197088|Experimental|1 week of tamsulosin|1 week of tamsulosin tablet 400mcg once a night
10201634|NCT05197088|No Intervention|no additional medication|
9747203|NCT04150341|Experimental|TD-8236 Dose B (high dose)|TD-8236 Dose B (QD x 14 days)
9747204|NCT04150341|Placebo Comparator|Placebo|Placebo (QD x 14 days)
9747205|NCT04141657||Group 1 (0-17 years)|We will observe the treatment course in ICU pediatric patients, register adverse events (AEs) and serious adverse events (SAEs) if occur, and assess patient health status at the end of the performed therapy.
9747206|NCT04138173|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
9747207|NCT04138173|No Intervention|Usual care group|Usual care
9747208|NCT04137965||Testicular torsion group|Men having undergone surgery for testicular torsion between 01.01.2003 and 12.31.2012
9747209|NCT04137965||Control group|Men without knowledge of their fertility status and who have never had their semen analyzed
9747210|NCT04115839|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
9747211|NCT04115839|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 16 weeks.
9747212|NCT04115839|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
9747213|NCT04115839|Experimental|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 44 weeks.
9747214|NCT04115839|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 44 weeks.
9747215|NCT04110431|Experimental|LBBP group|In this arm, An right artrial (RA) lead and an implantable cardioverter defibrillator (ICD) lead are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed. If LBBP failed, a left ventricular(LV) pacing lead is implanted instead.
9747216|NCT04110431|Active Comparator|BivP group|In this arm, an RA lead , an ICD lead and a LV pacing lead are placed. If the implantation of LV pacing lead is unsuccessful due to unavailable coronary sinus branches(venae cordis magna or venae cordis media is not recommended), capture above 3.5V/0.5ms or refractory phrenic nerve stimulation,a LBBP lead is placed instead.
9747217|NCT04102007|Other|Risankizumab|Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab
9747226|NCT04080284|Experimental|Niraparib|"Oral niraparib~-Cohort - Uterine serous carcinoma"
9747227|NCT04078126|Experimental|Budesonide and formoterol fumarate (MDI BFF)|Subject treated with MDI BFF followed by washout period
9747228|NCT04078126|Active Comparator|Symbicort Turbuhaler|Subject treated with Symbicort followed by washout period
9747229|NCT04073446|Active Comparator|Dorsal Column (DC) Perception|Use of DC Perception based programming
9747230|NCT04073446|Active Comparator|Dorsal Root (DR) Perception|Use of DR Perception based programming
9747231|NCT04073446|Active Comparator|Dorsal Column (DC) Sub-perception|Use of DC sub-perception based programming
9747232|NCT04073446|Active Comparator|Dorsal Root (DR) Sub-perception|Use of DR sub-perception based programming
9747233|NCT04072107|Experimental|Arm I|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy + capecitabine AC. All patients will receive concurrent cisplatin (100 mg/m2) every 3 weeks, in a total of three cycles. All patients will receive low-dose metronomic capecitabine (650 mg/m2 bid, oral, d1-21, q3w) until disease progression, or intolerable toxicity or 6 months.
9747234|NCT04072107|Experimental|Arm II|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy and anti-PD-1 therapy (sintilimab) + anti-PD-1 therapy (sintilimab) AC. All patients will receive concurrent cisplatin (100 mg/m2) and sintilimab (200 mg, IV drop 30-60 min) every 3 weeks in a total of three cycles. All patients will receive adjuvant anti-PD-1 therapy (sintilimab, 200 mg, IV drop 30-60 min, q3w) in a total of nine cycles until disease progression, or intolerable toxicity or 6 months.
9747235|NCT04057742||Group A|30 participants with a positive virtual crossmatch (VXM) at the time of transplant will be monitored for 24 months and undergo protocol biopsies on months 3, 12, and 24 to detect subclinical rejection. Participants may also undergo clinically indicated biopsies for suspicion of rejection. AlloSure, AlloMap, immune cell phenotypes, and inflammatory cytokines will be measured at baseline (within 48 hours of transplant), 3 weeks, 6 weeks, 3 months (Standard of Care (SOC) biopsy), 6 months, 12 months (SOC biopsy), 24 months (SOC biopsy) and additionally at the time of any indication biopsy (5-8 time points/participant). Participants in this group will be monitored for 24 months per SOC. Paticipants will be offered the option of donating either 22.5 mL of blood (Allosure+AlloMap+cytokines) or 52.5 mL of blood (Allosure+AlloMap+cytokines+immune cell phenotyping) at each visit. Participants may change their donation volume from 22.5 mL to 52.5 mL at any point during the study.
9747236|NCT04057742||Group B|35 participants with De novo donor specific antibodies (dnDSA) will undergo a SOC biopsy within approximately three months to determine the incidence of Active Antibody Mediated Rejection (AMR). Immune cell phenotyping, AlloSure, and AlloMap will be measured at the time of the SOC biopsy (1 timepoint/patient). This is a single-time point study, unless participants are diagnosed with AMR and require treatment. In this case, they would be enrolled in group C (see below).
9747237|NCT04057742||Group C|35 additional participants with the diagnosis of Chronic Active Antibody Mediated Rejection (cAMR) will undergo standard of care therapy and be monitored for treatment response with a follow-up biopsy at three months. Immune cell phenotyping, AlloSure, and AlloMap will be used at baseline (prior to index biopsy) and 3 month (follow-up surveillance biopsy) (2 timepoints/participant). Participants in this group will be monitored per SOC for three months (time between the two biopsies).
9747238|NCT04056611|Experimental|Adult cohort: JNJ-53718678 or Placebo|Participants greater than or equal to (>=) 18 to less than or equal to (<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
9747239|NCT04056611|Experimental|Adolescent cohort: JNJ-53718678 or Placebo|Participants >=13 to <18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
9782135|NCT01166997|Active Comparator|Intravenous unfractionated heparin|Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
9782136|NCT01167023|Experimental|7.5 mg Prasugrel|Participants were to receive 7.5 milligrams (mg) of prasugrel orally, once daily if they weighed ≥60 kilograms (kg) and if pharmacodynamic (PD) measures indicated that the 5-mg prasugrel dose did not produce a steady-state PD response equivalent to inhibition of platelet activation (IPA) ≥25%. Because these criteria were not met, no participants received 7.5 mg of prasugrel.
9782137|NCT01167023|Placebo Comparator|Placebo|
9782138|NCT01167023|Experimental|5 mg Prasugrel|
9782139|NCT01167140|Experimental|Cryo-Touch II|
9782140|NCT01167153|Experimental|Valsartan/amlodipine|Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
9782141|NCT01167153|Active Comparator|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
9782142|NCT01167179|No Intervention|comparison group|Usual care Participants in the comparison group receive the usual care which consists of a 5 year medical routine control schedule based on the national guidelines, and - if appropriate - involvement of the dietician and the speech language therapist.During years one to five the routine control appointments are planned at a minimum of every 2, 3, 4, 6 and 12 months respectively. Most patients who undergo a total laryngectomy have additional contact with an oncology nurse during their 6-8 weekly medical control visits at the outpatient clinic for approximately the first year of follow-up. All other head and neck cancer patients have no structured follow-up contact with an oncology nurse.
9835778|NCT02754492|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections
9835779|NCT02754518|Other|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
9828803|NCT02509767|Experimental|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
9828804|NCT02509767|Other|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
9828805|NCT02509936|Active Comparator|Standard of Care Arm|In this arm enrolled children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement.
9828806|NCT02509936|Experimental|Home-based Education|In the intervention arm, children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement. In addition, they will receive monthly home visits from a community health promoter who will provide detailed dietary assessments and individualized dietary coaching and education to parents.
9828807|NCT02510001|Experimental|Dose Escalation Phase Cohort 1 Dose level 1|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
9828808|NCT02510001|Experimental|Dose Escalation Phase Cohort 2 Dose level 2|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
9828809|NCT02510001|Experimental|Dose Escalation Phase Cohort 3 Dose level 3|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle
9828810|NCT02510001|Experimental|Dose Escalation Phase Cohort 4 Dose level 4|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
9828811|NCT02510001|Experimental|Dose Escalation Phase Cohort 7 Dose level 5|Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
9828812|NCT02510001|Experimental|Dose Escalation Phase Cohort 13 Dose level 5a|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
9828813|NCT02510001|Experimental|Dose Expansion Phase|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.
9828814|NCT02510001|Experimental|Dose Escalation Phase Cohort 12 Dose level 5 (Interval dosing)|Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
9828815|NCT02510014|Experimental|Roll-over Subjects|Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
9828816|NCT02510014|Experimental|De Novo Subjects|Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.
9828817|NCT02510144|Active Comparator|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
9828818|NCT02510144|Experimental|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
9828819|NCT02510664|Experimental|Intervention|There is no control/comparator group for this pilot study - all participants receive the intervention
9828820|NCT02510794|Experimental|Port Delivery System with Ranibizumab 10mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 10-mg/mL ,approximately 0.2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 10-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
9828821|NCT02510794|Experimental|Port Delivery System with Ranibizumab 40mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 40-mg/mL, approximately 0.8 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 40-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
9835780|NCT02754570|Experimental|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension that are currently taking latanoprost
9747240|NCT04019249|Experimental|Experimental: Healthy Weight Coaching|Intervention: Healthy Weight Coaching.
9747241|NCT04014231||Observational (single wave assessment)|Patients undergo placement of a single wave application near the carotid region of the neck.
9747242|NCT04013061||Standard consultation|
9747243|NCT04013061||Pharmacist-anesthesiologist consultation|
9747244|NCT04011072|Active Comparator|Infrared treatment arm|Far infrared radiation will be given for 40 minutes on the skin above the patients fistula in each dialysis session for one year
9747245|NCT04011072|No Intervention|Control arm|The control group will not receive any intervention, but will be followed with the same data as the treatment group
9747246|NCT04009330||Adults in the Intensive Care Setting|Adults in the Intensive Care Setting
10201635|NCT05197036||LEGION Porous CR with Hydroxyapatite|Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR with HA femoral component (max 250 subjects)
9747247|NCT04008056||Patients undergoing chemotherapy|
9747248|NCT04004273|Experimental|Exercise|Participants randomised to the exercise training intervention will complete 24 moderate-intensity exercise training sessions over the subsequent six weeks (four times per week; ~50 min per session). Each week, one exercise training session will be supervised by the research team, whilst three sessions will be unsupervised but monitored objectively using a heart rate monitor.
9747249|NCT04004273|No Intervention|Control|Participants randomised to control will receive no interventions and will be requested to maintain their habitual lifestyle during the six week intervention phase
9747250|NCT04003272||Comprehensive Reverse Versa-Dial Titanium Glenosphere|Patients who have an allergy to typical cobalt chrome or other metal allergies had surgery to repair shoulder malfunction/disease.
9747251|NCT03997162||Observational (ERAS protocol)|Participants complete standard of care early recovery after surgery protocol beginning the day before surgery to day 6 after surgery.
9747252|NCT03997123|Experimental|Capivasertib + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Capivasertib: Oral tablets. 400 mg of Capivasertib (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
9747253|NCT03997123|Placebo Comparator|Placebo + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
9747254|NCT03993002|Active Comparator|Normoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 30-40"
9747255|NCT03993002|Active Comparator|Normoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 50-60"
9747256|NCT03993002|Active Comparator|Hyperoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40"
10201636|NCT05197036||LEGION Porous CR without Hydroxyapatite|Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR without HA femoral component (max 250 subjects)
9517317|NCT03307421|Other|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
9747257|NCT03993002|Active Comparator|Hyperoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60"
9747258|NCT03991923|Experimental|Non-ischemic heart preservation (NIHP)|Continous cold cardioplegic perfusion of hearts
9747259|NCT03991923|Active Comparator|Ischemic cold static storage (ICSS)|Standard preservation technique
10201637|NCT05197023|Experimental|SHR-1819 injection|
10201638|NCT05197023|Placebo Comparator|placebo|
10201639|NCT05197010|Experimental|Home-based exercise program|The subjects will receive 6 weeks of the home exercise program via a smartphone application. The home exercise program sets the exercise intensity to 3 levels (low, medium, and high) according to the disease and consists of 2 stretches, 3 strengthening and/or functional exercises, and a cool-down exercise. The exercise group applies a daily home exercise program (30min/day, 7days/week for 6 weeks).
10201640|NCT05197010|No Intervention|Exercise brochure|This group will be offered a brochure including number of exercises for back or knee.
10201641|NCT05196971|Experimental|HS-10345 84mg|Participants will self-administer intranasal HS-10345 84mg on Days 1, 4, 8, and 11 during the double-blind phase
10201642|NCT05196971|Placebo Comparator|Placebo|Participants will be self-administered on Days 1, 4, 8, and 11 during the double-blind phase
10201643|NCT05196906||Modified Broström operation group|Patients who accept a modified Broström operation
10201644|NCT05196906||Anatomic reconstruction operation group|Patients who accept an anatomic reconstruction
9828822|NCT02510794|Experimental|Port Delivery System with Ranibizumab 100mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 100-mg/mL, approximately 2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 100-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
9828823|NCT02510794|Active Comparator|Intravitreal Injection with Ranibizumab 0.5mg|Participants received ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
9828824|NCT02510820|Active Comparator|Synergi / comfilcon A|Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study.
9828825|NCT02510820|Active Comparator|Biotrue / comfilcon A|Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study.
9828826|NCT02511184|Experimental|Dose finding and dose expansion phases|Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
9828827|NCT02511236|Experimental|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
9828828|NCT02511236|Active Comparator|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
9828829|NCT02511379|Experimental|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
9828830|NCT02511431|Experimental|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
9828831|NCT02511431|Experimental|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
9828832|NCT02511431|Experimental|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
9828833|NCT02511431|Experimental|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
9828834|NCT02511431|Experimental|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
9828835|NCT02511431|Experimental|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
9828836|NCT02511535|Experimental|Allergic patients|Allergic patients receive TBE booster vaccination
9828837|NCT02511535|Experimental|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
9828838|NCT02511535|Active Comparator|Healthy controls|Healthy controls receive TBE booster vaccination
9828839|NCT02511561|Experimental|0.1 mL OTO-201|Ciprofloxacin
9828840|NCT02511561|Experimental|0.2 mL OTO-201|Ciprofloxacin
9828841|NCT02511561|Experimental|0.4 mL OTO-201|Ciprofloxacin
9828842|NCT02511587|Active Comparator|intra muscular application|intra muscular application of FSME-Immune vaccination
9828843|NCT02511587|Experimental|subcutaneous application|subcutaneous application of FSME-Immune vaccination
9828844|NCT02511678|Experimental|Cryoablation|All participants will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles within 14 days of screening. In the case of participants with multiple metastatic lesions involving bone, the most painful lesion is to be selected for cryoablation. If treatment could not be completed within 14 days of screening, the participant will be re-screened using the inclusion and exclusion criteria. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators.
9828845|NCT02511717|Sham Comparator|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
9828846|NCT02511717|Active Comparator|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
9747260|NCT03988569|Experimental|Intervention Group|Will view audiovisual decision aid (AVDA) and then have opportunity for questions with physician before signing consent forms
9747261|NCT03988569|No Intervention|Control Group|Will undergo standard verbal informed consent with physician before signing consent forms
9747262|NCT03984240|Experimental|Brain eloquent area glioma group|The brain eloquent area glioma will be diagnosed by MRI scan.
9747263|NCT03984240|Active Comparator|control group|Healthy volunteers without intracranial diseases.
9747264|NCT03983226|Experimental|Surgery|"Intervention:~Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib"
9747265|NCT03983226|Active Comparator|No surgery|Intervention: Drug: Platinum-based chemotherapy and Niraparib
9747266|NCT03950570|Experimental|Phase 1: Dose Escalation|"Advanced solid tumors or metastatic breast cancer: Treatment with a single oral agent, ORIN1001.~Relapsed, refractory metastatic breast cancer: Treatment with a combination of ORIN1001 and Abraxane."
9747267|NCT03950570|Experimental|Phase 2: Dose Expansion|Relapsed refractory metastatic breast cancer that are Triple negative, ER+ or HER2- and treated with a single agent (ORIN1001) or in combination with ORIN1001 and Abraxane.
9747268|NCT03949725|Experimental|Hans Kai program|
9747269|NCT03949725|No Intervention|Wait list control|
9747270|NCT03948347|Active Comparator|active|Active patients will receive liraglutide injections
9747271|NCT03948347|No Intervention|standard care/no intervention|standard care for stroke as per hospital protocol
9747272|NCT03944434|Experimental|single arm|"patients will receive anastrozole tablets (1 mg once daily) or letrozole tablets (2.5 mg once daily) + ribociclib tablets (600 mg day 1 to 21 in a 28 day cycle). Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, physician's decision, patient's refusal/consent withdrawal, or lost to follow-up.~A LHRH agonist (triptorelin 3,75 mg or leuprolide 3,75 mg or goserelin 3,6 mg, as injectable intramuscular (i.m.) or subcutaneous (s.c.) implant every 28 days) will be used in men."
9747273|NCT03932331|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
9747274|NCT03924635|Active Comparator|SYMBICORT as maintenance and reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 twice a day (BID) for maintenance and as needed (PRN) for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance and PRN for relief.
9983995|NCT04505020|Experimental|3D Print + Conventional imaging|Patients in this group allocation will receive a 3D reconstruction of their hip in addition to conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
9983996|NCT04505020|Other|Conventional Imaging|Patients in this group allocation will receive conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
9983997|NCT04503096|Experimental|High-dose accelerated rTMS|
9747275|NCT03924635|Active Comparator|SYMBICORT as maintenance, salbutamol as reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief.
9747276|NCT03924401|Experimental|Participants Receiving Abatacept|Pediatric participants who are undergoing URD HSCT for serious NMHD will receive 8 doses of abatacept in addition to conventional GVHD prophylaxis.
9747277|NCT03919188|Active Comparator|air temperature control (ATC)|Incubator control using air temperature control (ATC) method
9747278|NCT03919188|Active Comparator|skin servocontrol (SSC)|Incubator control using skin servocontrol method
10201645|NCT05196893|Experimental|Immediate Student Intervention Group|Eligible students who were randomized into an immediate intervention group, and received intervention from school staff who received specialized intervention training starting in the fall semester of the academic year. Students from two clusters of schools received staggered intervention (Cluster 1 starting in year 1, and Cluster 2 starting in year 2). School staff recorded details of intervention sessions in a case management tool, and administrative records were maintained by the school district, for evaluation purposes.
9828847|NCT02511730|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
9983998|NCT04502030|Experimental|Panzyga|
9983999|NCT04502030|Placebo Comparator|Placebo|
9984000|NCT04501978|Experimental|ACTIV-3 Drug plus SOC|Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC
9984001|NCT04501978|Placebo Comparator|Placebo plus SOC|The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
9984002|NCT04500795|Experimental|Embolization Group|Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
9747279|NCT03914703||EZ Pass Suture Passer|Patients who have surgery using the EZ Pass Suture Passer Instrument either in rotator cuff or soft tissue repair
9984706|NCT03809663|Experimental|Part A: Tezepelumab 210 mg|"Tezepelumab 210 mg administered via SC injection once every 4 weeks (Q4W) from Week 4 for a maximum of 52 weeks.~All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive a placebo at Week 2 to maintain blinding.~Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
10201646|NCT05196893|Experimental|Wait-list Student Intervention Group|Eligible students who were randomized into a wait-list intervention group, and received intervention from school staff who received specialized intervention training starting in the spring semester of the academic year. Students from two clusters of schools received staggered intervention (Cluster 1 starting in year 1, and Cluster 2 starting in year 2). School staff recorded details of intervention sessions in a case management tool, and administrative records were maintained by the school district, for evaluation purposes.
10201647|NCT05196893|No Intervention|Within School Student Control Group|Eligible students who were randomized into either the immediate or wait-list intervention groups, but did not receive intervention from school staff. This was used as a control group instead of an intended 3rd Cluster, which ultimately was not a comparable control based on enrollment and demographic characteristics.
9747280|NCT03914703||Precision Flexible Reamer|Patients who have surgery using the Precision Flexible Reamer Instrument in ACL repair
9747281|NCT03907475|Active Comparator|Arm I (durvalumab)|Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10201648|NCT05196880||ARM 1|Patients with negative clinical suspicion of Biofilm containing wounds(CSB-).
9747282|NCT03907475|Experimental|Arm II (gemcitabine hydrochloride, durvalumab)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 8 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who discontinue gemcitabine hydrochloride continue receiving durvalumab alone as in Arm I.
9747283|NCT03907475|Experimental|Arm III (pegylated liposomal doxorubicin, durvalumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9747284|NCT03907475|Experimental|Arm IV (capecitabine, durvalumab)|Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, and durvalumab IV over 60 minutes on days 8 of cycle 1, day 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9747285|NCT03907475|Experimental|Arm V (carboplatin, durvalumab)|Patients receive carboplatin IV over 30-60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9747286|NCT03907475|Experimental|Arm VI (paclitaxel, durvalumab)|Patients receive paclitaxel IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9747287|NCT03907475|Experimental|Arm VII (nab-paclitaxel, durvalumab)|Patients receive nab-paclitaxel IV over 30 minutes on day 1 and durvalumab IV over 60 minutes on day 8 of cycle 1, days 8 and 15 of cycle 2, day 8 of cycles 3, and day 1 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9747288|NCT03873805|Experimental|Treatment (PSCA CAR T cells)|Patients may receive lymphodepleting regimen including fludarabine IV on days -5 to -3 and cyclophosphamide IV on days -5 to -3 or on days -4 and/or -3. Patients then receive autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes IV over 10-15 minutes at day 0.
9747289|NCT03872492|Experimental|Patients with Major Depressive Disorder|"Patients will be followed for 12 weeks. Hospital visits will be made at week 2 and week 6 (Phase1) as well as week 8 and week 12 (Phase 2).~At the end of phase 1 if the patient is considered as an responder he will make one more visit at week 12.~If the patient is considered as non-responder, he will make 2 other visits: at week 8 and week 12.~Between each visit, the patient will perform REDRESS application assessments every day for My daily survey and every 3 days for the other assessments."
9747290|NCT03871959|Experimental|Pembrolizumab + Debio 1143|"Pembrolizumab : 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.~Debio 1143 : 3 escalating dose level (100 mg, 150 mg, 200 mg) administered daily for 14 days over a 21-day cycle period."
9747291|NCT03864614|Experimental|SAGE-217|
9747292|NCT03859024|Active Comparator|Standard Protocol|Patients will receive the historical standard for pain management, which may include narcotics during and after surgery. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
9747293|NCT03859024|Experimental|Enhanced Recovery Protocol|A combination regimen of acetaminophen, Celebrex and gabapentin pre-op, with 30 mL of 0.5% bupivacaine and 4 mg of dexamethasone given as a perineal nerve block at the time of urethroplasty surgery. Narcotics will be administered judiciously and ass seen fit by the anesthesia and/or surgical teams. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
9747294|NCT03858868|Experimental|Church and park-based intervention|Participants at intervention churches will be offered: texting intervention (messages about physical activity); peer leader training; walking groups; park-based fitness classes; sermons; participation in park advisory board; community advocacy.
9747295|NCT03858868|Other|Publicly available physical activity materials|Participants at control churches will be offered standard health educational materials (brochures, tip sheets, posters) about physical activity.
9747296|NCT03855020||observational cohort|Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
10201649|NCT05196880||ARM 2|Patients with positive clinical suspicion of Biofilm containing wounds(CSB+)
10201650|NCT05196841|Experimental|Experimental group|Anastatica Hierochuntica
10201651|NCT05196841|No Intervention|Control group|routine care
10201652|NCT05196828|Active Comparator|Arm 1 - Direct Roll-Over Extension|24-wks of Active neurostimulation - Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation; followed by 8-wks of No Intervention
10201653|NCT05196828|No Intervention|Arm 2 - Control Group|24-wks of No Intervention
9747297|NCT03854656|No Intervention|Control|Control group for 13 weeks (n=50). Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
9747298|NCT03854656|Experimental|Time-restricted eating|Time-restricted eating for 13 weeks (n=50). In addition to the intervention, participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
9747299|NCT03851458||Consumo de Opciones Mas Ideales De Alimento (COMIDA)|Participants will be placed in either individual or group interventions by convenience. Recruitment will be consecutive and participants will be placed in either intervention depending on what resource is available on a given day at the VDS, individual counselor or a group educator.
9747300|NCT03851458||SANOS|Conducting SANOS Focus Groups. We will conduct 3-5 focus groups (in Spanish) with 6-10 participants each, until saturation. Bilingual study staff will approach individuals visiting the VDS and VDS Mobile for potential participation. A brief screening questionnaire will be administered, and a BMI assessment conducted, to ascertain eligibility. Focus groups will be scheduled at the VDS Mobile unit at times convenient to participants. Participants will be verbally consented in Spanish, and will be apprised that their participation is purely voluntary and that their names will not be included in the final narrative. The 6-month follow-up and 24-hour dietary surveys can be done over phone . Study staff will access step counts (or obtain it through phone via the pedometer manual provided to the participant) and upload data onto the REDCap tracking tool. Staff may ask participants to report step counts captured by their personal devices (i.e., phone or smartwatch).
9747301|NCT03845517|Placebo Comparator|Placebo|Placebo
9747302|NCT03845517|Experimental|PF-06700841 15 mg|PF-06700841 15 mg
9747303|NCT03845517|Experimental|PF-06700841 30 mg|PF-06700841 30 mg
9747304|NCT03845517|Experimental|PF-06700841 45 mg|PF-06700841 45 mg
9747305|NCT03839394|Experimental|Educational pamphlets + telephone|
9747306|NCT03839394|Active Comparator|Educational pamphlets|
9747307|NCT03827798|Experimental|CFZ533|s.c.
9747308|NCT03827798|Experimental|LYS006|p.o.
9747309|NCT03827798|Placebo Comparator|Placebo to CFZ533|Matching placebo (s.c.)
9747310|NCT03827798|Placebo Comparator|Placebo to LYS006|Matching placebo (p.o.)
9747311|NCT03827798|Experimental|MAS825|s.c.
9747312|NCT03827798|Placebo Comparator|Placebo to MAS825|Matching placebo (s.c.)
9747313|NCT03827798|Active Comparator|LOU064 25mg|p.o.
9747314|NCT03827798|Active Comparator|LOU064 100mg|p.o.
10201654|NCT05196828|Active Comparator|[Not Yet Recruiting] Arm 3 - Delayed Extension|24-wks of Active neurostimulation - Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation; followed by 8-wks of No Intervention
9747315|NCT03827798|Placebo Comparator|Placebo to LOU064|Matching placebo p.o.
9747316|NCT03825341|Active Comparator|Arm 1 Liquid Hydroxyurea|In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be ~20 mg/kg/day or the infant's usual daily dose.
9747317|NCT03825341|Active Comparator|Arm 2 Hydroxyurea Oral Capsule|In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg
9747318|NCT03818607|Other|T (ABP 959) / R (eculizumab)|ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
9747319|NCT03818607|Other|R (eculizumab) / T (ABP 959)|Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2
9747320|NCT03812289|Experimental|Treatment (SBRT)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
9747321|NCT03810456|Active Comparator|iCBT|Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend.
10201655|NCT05196815|Experimental|The Royal Wolverhampton NHS Trust- New Cross Hospital|
10201656|NCT05196802|Experimental|mHeart.4u|The mHEART.4U intervention includes the use of an online Clinical Decision Support System (CDSS) for remote patient monitoring. According to the patient needs and profile, the CDSS will suggest a monitoring plan for the patient. The mHEART.4U kit will include mobile apps and wearables, such as heart rate, blood pressure, peripheral oxygen saturation (SpO2), sleep and step trackers, symptoms, lifestyle self-monitoring tools, medication reminders or motivational resources. The intervention length will be 6 months and will take into account the most recent guidelines on Cardiac Rehabilitation.
10201657|NCT05196802|No Intervention|Standard care|This arm will receive treatment and care according to the prevailing practice at each of the cardiac hospital units.
10201658|NCT05196750||Normal vaginal delivery|Maternal delivery of delivery via normal vaginal delivery
10201659|NCT05196750||Lower segment Caesarean section (LSCS)|Maternal delivery of delivery via lower segment Caesarean section (LSCS)
10201660|NCT05196724|Experimental|Mentalization Based Therapy (MBT)|MBT for foster carers is a 12 session therapeutic intervention that will be offered to foster families by municipal foster care consultants
10201661|NCT05196724|Active Comparator|Usual care|the control group will receive the usual care offered to foster families such as supervision
9747322|NCT03810456|Active Comparator|sCBT|Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks.
10201662|NCT05196711|Experimental|MAX-40070|MAX-40070 is a liniment with two dose specification: 0.5%, 2% (Weight/Volume). In SAD phase, MAX-40070 will be applied once in each cohort, and there will be 6 cohorts. For the first 2 cohorts, 0.5% MAX-40070 will be used. For the rest 4 cohorts, 2% MAX-40070 will be used. In MAD phase, MAX-40070 2% will be applied once daily for consecutive 14 days in each cohort.
10201663|NCT05196711|Placebo Comparator|Placebo|Placebo is a liniment with two dose specification: 0.5%, 2% (Weight/Volume) to match with active drug in 2:1 manner ( 6 active: 2 placebo in each cohort).
9747323|NCT03810456|No Intervention|TAU|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual.
9747324|NCT03809000|Active Comparator|Salvage Radiation Therapy + Standard ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog with or without 1-4 months of bicalutamide.
9747325|NCT03809000|Experimental|Salvage Radiation Therapy + Enhanced ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog + 24 months of enzalutamide.
9747326|NCT03797209||AXIOS Patient|
9747327|NCT03796195|Experimental|.5% Bupivacaine|Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
9747328|NCT03794583|Experimental|Inhaled Treprostinil Solution|Inhaled treprostinil solution (0.6 milligrams per milliliter [mg/mL], 6 mcg/breath) QID during waking hours.
9747329|NCT03770689|Experimental|Peposertib + Capecitabine + RT|
9747330|NCT03751631|Other|1-TR/PE, 2-TR, 3-PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
9747331|NCT03751631|Other|1-TR/PE, 2-PE, 3-TR|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
9747332|NCT03751631|Other|1-TR, 2-TR/PE, 3-PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
9747333|NCT03751631|Other|1-TR, 2-PE, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
9747334|NCT03751631|Other|1-PE, 2-TR/PE, 3-TR|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
9747335|NCT03751631|Other|1-PE, 2-TR, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
9747336|NCT03751098|Other|1-TR/PE, 2-Placebo, 3-Placebo|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
9747337|NCT03751098|Other|1-Placebo, 2-Placebo, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
10201664|NCT05196698|Experimental|High Flow Oxygen Therapy|
9747338|NCT03742037|Experimental|Cenerimod 0.5 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
9747339|NCT03742037|Experimental|Cenerimod 1 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
9747340|NCT03742037|Experimental|Cenerimod 2 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
9747341|NCT03742037|Experimental|Cenerimod 4 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will will be re-randomized in a double-blinded fashion in TP2 in a 1:1 ratio to placebo or cenerimod 2 mg."
9747342|NCT03742037|Placebo Comparator|Placebo|"Subjects will receive matching placebo once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
9747343|NCT03729869|Experimental|Progesterone Males|35 men will take 400 mg of progesterone a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
9747344|NCT03729869|Placebo Comparator|Placebo Males|35 men will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
9747345|NCT03729869|Experimental|Progesterone Female|35 women will take 200 mg of progesterone twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
9747346|NCT03729869|Placebo Comparator|Placebo Females|35 women will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
9747347|NCT03723798|Experimental|Group 1|SA001 Low dose
9747348|NCT03723798|Experimental|Group 2|SA001 Mid dose
9747349|NCT03723798|Experimental|Group 3|SA001 High dose
9747350|NCT03723798|Placebo Comparator|Placebo|Placebo
9747351|NCT03681678||fCO2 Laser Therapy Group|Women treated with the fCO2 laser
10201665|NCT05196698|Other|Long-Term Oxygen Therapy|Control arm
10201666|NCT05196685||Group Vertigo|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test scores of 1 and above will be sent to ENT
9747352|NCT03677141|Experimental|Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding|Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
9747353|NCT03677141|Experimental|Phase Ib: M-CHP-Pola Dose-Finding|Participants will receive M-CHP-Pola up to the RP2D.
9747354|NCT03677141|Experimental|Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort|Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
9747355|NCT03677141|Experimental|Phase II: M-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
9747356|NCT03677141|Active Comparator|Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
9747357|NCT03677141|Experimental|Phase II: M-CHOP 1L DLBCL|Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.
9747358|NCT03675412|Active Comparator|Glaucoma Patients|Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
9747359|NCT03675412|Active Comparator|Healthy controls|Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
9747360|NCT03673345|Experimental|Cohort 1A|0.25 mL dose of IIV-4 administered intramuscularly on days 0 and 28 of study year 1 and on day 0 of study year 2 in children 6-12 months of age who have not previously had an influenza infection or vaccination, n=20
9747361|NCT03673345|Experimental|Cohort 1B|0.25 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 after primary influenza infection in study year 1 in children 3-12 months of age, who have not previously had an influenza vaccination, n=20
9747362|NCT03673345|Experimental|Cohort 2A|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=60
9747363|NCT03673345|Experimental|Cohort 2B|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
9828848|NCT02511730|Active Comparator|FFDM Alone|Breast Images with FFDM alone
10201667|NCT05196685||Group control|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test score below 1
10201668|NCT05196659|No Intervention|CONTROL Group|"Regular current system of care~Treating physicians provided current cardiovascular disease management guidelines~Patients provided a leaflet (printed information) on healthy lifestyle"
10201669|NCT05196659|Active Comparator|INTERVENTION Group|"Electronic Health Record-Decision Support Software (EHR-DSS):~Electronic patient health record storage~Management prompts to the clinical team (following algorithms)~Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~Non-physician health worker-led continuity of care:~- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~Text-message based reminders for a healthy lifestyle~Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~Quarterly audit and feedback to the clinical team"
10201670|NCT05196646||(1) 5 preterm infants spontaneously breathing in-room air with no respiratory support|"Respiratory acoustic signals will be collected and compared with airflow measurements obtained using a pneumotachometer, i.e. the gold standard. Inclusion of these infants is necessary to demonstrate the reliability of the respiratory acoustic sensor in capturing airflow when compared to the gold standard pneumotachometer.~Data will be collected for 10 minutes."
10201671|NCT05196646||(2) 10 preterm infants spontaneously breathing in-room air with no respiratory support|"Respiratory acoustic signals will be collected and compared with airflow measurements obtained using a nasal temperature sensor. In addition, measurements of respiratory efforts will be obtained using respiratory inductive plethysmography, electrical activity of the diaphragm, and transthoracic impedance. The inclusion of these infants will allow for better description of the properties of the breath sounds in a stable cohort of infants, without interference from the CPAP noise.~Data will be collected for 3 hours."
10201672|NCT05196646||(3) 10 preterm infants on continuous positive airway pressure (CPAP) with cardiorespiratory events|"Respiratory acoustic signals will be collected. In addition, measurements of respiratory efforts will be obtained using respiratory inductive plethysmography, electrical activity of the diaphragm, and transthoracic impedance. The inclusion of infants on CPAP will allow for detection of both breath sounds and airflow coming from the transmitted CPAP pressure in a cohort of infants at higher risk of cardiorespiratory events.~Data will be collected for 3 hours."
10201673|NCT05196633|Experimental|Conventional physiotherapy, visual feedback training, rESWT|conventional physiotherapy (5 times/week), visual feedback training (5 times/week), radial extracorporeal shock wave therapy (once/week for 2 weeks)
10201674|NCT05196633|Sham Comparator|Conventional physiotherapy, visual feedback training, sham rESWT|conventional physiotherapy (5 times/week), visual feedback training (5 times/week), sham radial extracorporeal shock wave therapy (once/week for 2 weeks)
10201675|NCT05196620||EAUS|Patients with EAUS pre and postpartum
10201676|NCT05196594||Affected group by transthyretinal amyloidosis with cardiac involvement|collection of stools
10201677|NCT05196594||Affected group by transthyretinal amyloidosis without cardiac involvement|collection of stools
10201678|NCT05196594||healthy control group|collection of stools
10201679|NCT05196581|No Intervention|No intervation|
10201680|NCT05196581|Active Comparator|Experimental intervation one|
10201681|NCT05196581|Active Comparator|Experimental intervation two|
10201682|NCT05196568|No Intervention|control|no dietary intervention
10201683|NCT05196568|Experimental|DMD|administration of Fasting Mimicking Diet
9747364|NCT03673345|Experimental|Cohort 3A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2006 and 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=30
9747365|NCT03673345|Experimental|Cohort 3B|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2006 and 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
9747366|NCT03673345|Experimental|Cohort 4A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2003 and 2006, who have previously received 2 doses of influenza vaccine prior to the study, n=30
9747367|NCT03673345|Experimental|Cohort 4B|0.5 mL does of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2003 and 2006, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
9747368|NCT03672318|Experimental|CAR138 T cells|The first 3 subjects enrolled in the study will receive 5x10^6 CAR138 T-cells/m^2 via infusion. The number of cells for the infusion will be increased to 1x10^7 CAR138 T-cells/m^2 and then, 2.5x10^7 CAR138 T-cells/m^2, 5x10^7 CAR138 T-cells/m^2, 1x10^8 CAR138 T-cells/m^2 and 2x10^8 CAR138 T-cells/m^2 in subsequent cohorts of 3 subjects provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each subject to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another subject is allowed to enroll in the cohort.
9747369|NCT03658616|Experimental|WO3970|Formulation containing WO3979 for topical application
9747370|NCT03658616|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
9747371|NCT03650920|Experimental|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
9747372|NCT03644485|Experimental|Standard Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 1 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
9747373|NCT03644485|Experimental|Delayed Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 3 - 5 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
9747374|NCT03641027|Experimental|Increased physical activity|Increased physical activity daily before surgery. Standard care during hospital stay and continued training after discharge.
9747375|NCT03641027|Other|Standard care|Standard care
9747376|NCT03636503|Experimental|Rituximab +Utomilumab+Avelumab|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~Avelumab is administered intravenously over 1 hour once every 2 weeks"
9747377|NCT03636503|Experimental|Rituximab+Utomilumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
9747378|NCT03636503|Experimental|Rituximab+Avelumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Avelumab is administered intravenously over 1 hour once every 2 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
9747379|NCT03586635||Patients with Multiple Sclerosis|
9747380|NCT03580213|Experimental|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
9747381|NCT03580213|Experimental|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
9747382|NCT03580213|No Intervention|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
9747383|NCT03580213|No Intervention|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
9747384|NCT03568682|Experimental|Nutritional counseling + urban gardening|Participants in the intervention clinic will receive: 1) nutritional counseling from peer counselors in their clinic (approximately 4-5 sessions administered monthly); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (training workshop and monthly follow-up); and 3) a cooking and nutrition workshop facilitated by project nutritionists once garden produce are available.
9747385|NCT03568682|No Intervention|Usual care control|Participants in the control clinic will receive their usual care from the clinic. After 12 month follow-up, they will be offered the opportunity to receive the intervention.
9747386|NCT03561584|Active Comparator|Active Drug (Sulfasalazine)|
9747387|NCT03561584|Placebo Comparator|Placebo|
9747388|NCT03554083|Experimental|Arm A - CLOSED (vemurafenib, cobimetinib, atezolizumab)|"Patients receive vemurafenib PO BID on days 1-28 and cobimetinib PO QD on days 1-21. Patients also receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15 of cycles 2 and 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
9747389|NCT03554083|Experimental|Arm B - CLOSED (cobimetinib, atezolizumab)|Patients receive cobimetinib as in Arm A and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
9747390|NCT03554083|Experimental|Arm C (atezolizumab, tiragolumab)|"Patients with BRAF wild-type or BRAF mutant melanoma receive atezolizumab IV over 30-60 minutes and tiragolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
9747391|NCT03547518|Experimental|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
9747392|NCT03547518|Sham Comparator|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
9747393|NCT03530969|Experimental|GI/GU/Lymphoma Oncologists|Doctors specializing in treating gastrointestinal cancer (cancer of the stomach, pancreas, colon, etc.), genitourinary cancer (cancer of the genitals and urinary tract), and lymphoma (cancer affecting the blood and lymph nodes)
9747394|NCT03530969|Active Comparator|Participants with GI/GU/Lymphoma Cancer|Patients of the physicians in group 1
9747395|NCT03530969|Active Comparator|Caregivers of Participants with GI/GU/Lymphoma Cancer|Family members or caregivers of the patients in group 2
9747396|NCT03529071|Experimental|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
9747397|NCT03529071|No Intervention|Control|Individuals will not receive any intervention or surveys.
9747398|NCT03519347|Experimental|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
9747399|NCT03519347|Experimental|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
9747400|NCT03519347|Experimental|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
9747401|NCT03519347|Experimental|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
9747402|NCT03510104|Experimental|MRX-2843|MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
9747403|NCT03507686|Experimental|BIIB111|Participants will receive a single dose of sub-retinal injection of BIIB111 in each eye at Day 0 separated by an interval of <6 months, 6-12 months, or >12 months.
9747404|NCT03506334|Experimental|Pediatric Scoliosis Patients|Tether group
9747405|NCT03506334|Active Comparator|Pediatric Scoliosis Control Patients|Fusion (control) group
9747406|NCT03496623|Experimental|Inhaled Treprostinil|Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms [mcg]) 4 times daily (QID)
9747407|NCT03496623|Placebo Comparator|Placebo|Placebo delivered via an ultrasonic nebulizer for QID administration
9747408|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
9747409|NCT03459482|Experimental|Group 1 - True Food Elimination Diet|Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
9747410|NCT03459482|Sham Comparator|Group 2 - Sham Food Elimination Diet|"Group 2 (control group): Subjects will be given a Sham elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates."
9747411|NCT03459443|Experimental|Danicopan|Danicopan was to be administered to participants with C3G or IC-MPGN at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then the dosage was to be increased to 200 mg TID for the remainder of the study.
9747412|NCT03458117|Experimental|Talimogene Laherparepvec (T-VEC)|Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)
9747413|NCT03430700|Experimental|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
9747414|NCT03418675|Placebo Comparator|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
9747415|NCT03418675|Experimental|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
9747416|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
10201684|NCT05196555|Experimental|microscopic surgical repair of cleft palate with intravelar veloplasty (IVVP)|
9747417|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
9747418|NCT03375866|Active Comparator|Pretzels|
9747419|NCT03375866|Experimental|Mixed nuts|
9747420|NCT03367910|Experimental|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
9747421|NCT03361215||Atopic dermatitis|Patients with dermatologist-diagnosed atopic dermatitis, psoriasis or autoimmune skin disease.
9747422|NCT03361215||Controls|Healthy volunteers with no history of atopic, autoimmune or chronic inflammatory disease.
9747423|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
9747424|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
9747425|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
9747426|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
9747427|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
9747428|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
9747429|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
9747430|NCT03329690|Experimental|Parallel: DS-8201a|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
9747431|NCT03329690|Active Comparator|Parallel: Physician's Choice|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
9747432|NCT03329690|Other|Exploratory: Naïve HER2 IHC 2+/ISH-|A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
9747433|NCT03329690|Other|Exploratory: Naïve HER2 IHC 1+|A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.
9747434|NCT03320564|Experimental|Infiltration|Repeat F-18 FDG PET
9747435|NCT03306485||Patients with GERD symptoms refractory to PPI therapy|"Patients with proven GERD (gastro-esophageal reflux disease) off PPI (proton pump inhibitor) (Los Angeles grade B, C or D esophagitis and/or esophageal acid exposure > 5% on pH monitoring performed off PPI).~These patients have persistent heartburn and/or regurgitation despite double dose proton pump inhibitor. Patients are referred for esophageal high resolution impedance manometry and ambulatory 24-h pH-impedance monitoring on proton pump inhibitor."
9747436|NCT03303898|Other|asymptomatic carriers|
9747437|NCT03303898|Other|uninfected patient|
9747438|NCT03302234|Experimental|Pembrolizumab + Ipilimumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
10201685|NCT05196542|Experimental|mersilene tape arm (ETHICON, polyester 5mm double needle)|Group 1: patients with apical prolapse who will do Sacro hysteropexy using mersilene tape (polyester 5mm tape with double needle)
9747439|NCT03302234|Active Comparator|Pembrolizumab + Placebo|Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
9747440|NCT03284723|Experimental|PF-06804103|Study Treatment
9747441|NCT03284723|Experimental|PF-06804103+Combination Regimen|Study Treatment
9747442|NCT03282981|Experimental|Timolol|Timoptic-XE plus standard of care (SOC)
9747443|NCT03282981|Placebo Comparator|SOC plus non biologically active gel|SOC plus non biologically active gel (hydrogel as placebo medication)
9747444|NCT03278717|Experimental|Olaparib and Cediranib|"Patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
9747445|NCT03278717|Active Comparator|Olaparib|"Patients will receive oral olaparib 300mg BD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
10201686|NCT05196542|Other|polyproline mesh arm (ETHICON, polyprolene mesh)|Group 2: patients with apical prolapse who will do Sacro hysteropexy using poly-proline mesh
10201687|NCT05196529|Experimental|Inspiratory muscle training|The 8-week inspiratory muscle training protocol consists of using 80% of maximal inspiratory pressure (determined in lab), 3x per week, 6 sets of 6 repetitions. Each set will be separated by decreasing lengths of time over the 8 weeks starting at a 30 second interim. This totals 36 inhalations 3 times per week. Progress will be determined via weekly phone calls with the participants and progress will also be logged by participants over the 8 weeks.
9747446|NCT03238170|Experimental|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
9747447|NCT03235817|Experimental|Spontaneous ventilation|
9747448|NCT03235817|Experimental|Pressure support ventilation|
9747449|NCT03235817|Active Comparator|Pressure control ventilation|
9747450|NCT03233256|Experimental|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
9782143|NCT01167179|Experimental|nurse-led consultation|"Interventional care Year 1 follow-up: 2-monthly medical control visit + 30 minute nursing consultation, to a minimum of 6 in year 1. No restrictions with regard to cancer stage, site or treatment modality.~Intervention consist of standardised nursing consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. Goals: helping patients (and their partners) cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship."
9782144|NCT01167192|Experimental|Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation|"Cisplatin 75 mg/m^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.~Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.~Recommended mastectomy~Recommended adjuvant chemotherapy~-doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m2 for 14 days for 4 cycles)"
9782145|NCT01167257|Experimental|Experimental arm|"Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation~Liposome encapsulated botulinum toxin A'"
9782146|NCT01167257|Placebo Comparator|Control arm|"Normal saline 50 mL in single intravesical instillation~Normal saline instillation'"
9782147|NCT01167426|Active Comparator|20 mg/0.5 mL Glatiramer Acetate|Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).
9782148|NCT01167452|Experimental|Sulfamethoxazole/trimethoprim|2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
9782149|NCT01167504||Saliva Sample Collection|Saliva collection
9782150|NCT01167569|Active Comparator|A-Ascorbic Acid (Vitamin C)|Ascorbic Acid (Vitamin C) 10mg/kg x 2 in the operating room followed by Ascorbic Acid (Vitamin C) 5mg/kg every 4 hours x 48 hours.
9782151|NCT01167569|Placebo Comparator|B-5% Dextrose Water or Normal Saline|5% Dextrose Water or Normal Saline (placebo) x 2 in the operating room followed by 5 % Dextrose Water or NS (placebo) every 4 hours X 48 hours.
9782152|NCT01167582|Experimental|Liberal Transfusion Strategy|Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.
9782153|NCT01167582|Experimental|Restrictive transfusion strategy|"Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.~Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension."
9782154|NCT01167595|Experimental|PEP uP Protocol|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
9782155|NCT01167595|No Intervention|Standard Feeding Protocol|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
9782156|NCT01167608||People with Parkinson's disease|Individuals diagnosed with Parkinson's disease
9782157|NCT01167634|No Intervention|1|
9782158|NCT01167634|Experimental|2|Deposit contract with a 1:1 match
9782159|NCT01167634|Experimental|3|Deposit contract with a 2:1 match
9782160|NCT01167634|Experimental|Experimental 4|Deposit contract with no match
9782161|NCT01167712|Experimental|Arm I (adjuvant chemotherapy suboptimally debulked)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
9782162|NCT01167712|Experimental|Arm II (neoadjuvant chemotherapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
9782163|NCT01167829|Experimental|Acyline and oral testosterone|
9782164|NCT01167881|Experimental|BI 10773 dose plus metformin|Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
9782165|NCT01167881|Active Comparator|Glimepiride 1-4 mg plus metformin|Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.
10201688|NCT05196490||Micro-CT|Samples were scanned before and after air polishing with a high-resolution micro-CT device. The scanning conditions were 100 kVp; 100-mA, 0.5-mm Al/Cu filter; 13.1-μm pixel size; and rotation at 0.2 steps. According to the manufacturer's instructions, each sample was rotated 360°. The mean scanning time was around 1hour.
9747451|NCT03224819|Experimental|Exploration Phase|Dose finding phase of the study
9747452|NCT03224819|Experimental|Expansion Phase|Maximum Tolerated Dose identified by Exploration Phase administered to subjects
9747453|NCT03167554|Sham Comparator|Sham group|Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
9747454|NCT03167554|Experimental|Experimental group 1|Electrolysis application with monopolar needle.
9747455|NCT03167554|Experimental|Experimental group 2|Electrolysis application with bipolar needle.
9747456|NCT03165955|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
9747457|NCT03160456|Experimental|Transcutaneous electrical stimulation|The group of participants receiving continuous transcutaneous electrical stimulation will be trained on the device and settings will be recorded. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At each visit comfort, compliance and adverse reactions will be recorded. At 12-weeks, the patients will be invited for a repeat assessment including polysomnography during a night of electrical stimulation. Usage time of the device will be discussed with the patients and recorded.
9747458|NCT03160456|Active Comparator|Continuous positive airway pressure|Participants who will be randomized to the usual care group will be given their own CPAP device, as previously prescribed. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At the last visit, the patients will be studied during a repeat inpatient polysomnography and the initial assessment will be repeated.
9747459|NCT03133793|Placebo Comparator|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
9747460|NCT03133793|Active Comparator|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
9747461|NCT03133793|Active Comparator|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
9747462|NCT03133793|Experimental|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
9747463|NCT03130127|Experimental|Continuous infusion of terlipressin|In our clinical practice, continuous infusion of terlipressin is being employed.
9747464|NCT03130127|Active Comparator|Bolus infusion of terlipressin|Traditionally, a bolus infusion of terlipressin is recommended.
9747465|NCT03127774|Experimental|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
9747466|NCT03127267|Experimental|Masitinib (4.5) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d
9747467|NCT03127267|Experimental|Masitinib (6.0) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.
9747468|NCT03127267|Placebo Comparator|Placebo & Riluzole|Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.
9747469|NCT03125720|Experimental|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
9747470|NCT03125720|No Intervention|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
9747471|NCT03108131|Experimental|Treatment (cobimetinib, atezolizumab)|Participants receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9747472|NCT03107533||Video recording of clinical visit|Investigators will enroll patients from the Department of Orthopedic Surgery for enrollment. The shared decision group will provide staff for data analysis.
9747473|NCT03105713|Experimental|Patient Safety Checklist Intervention|The intervention to be administered is a patient safety checklist (two parts) for patients to be performed on paper or electronically: a) before admission to hospital, and b) under hospital stay (discharge)
9747474|NCT03105713|No Intervention|Controls|Patients do not receive the safety checklist intervention. Care as usual.
9747475|NCT03103542|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
9747476|NCT03086317|Active Comparator|Standard Catheter-Directed Thrombolysis|Participants randomized to this arm will receive standard catheter-directed thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
9747477|NCT03086317|Active Comparator|Ultrasound-Accelerated Thrombolysis|Participants randomized to this arm will receive ultrasound-accelerated thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
9747478|NCT03070340|Experimental|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
10201689|NCT05196490||CAD/CAM|The teeth surfaces were digitalized before and after air polishing with an intraoral scanner. The mean scanning time was around 10 second. The virtual images of the scanned teeth were saved in stereolithography (STL) format.
10201690|NCT05196477||Olokizumab treatment group|Subjects with the infection caused by SARS-CoV-2 who received olokizumab injection in addition to the standard therapy.
10201691|NCT05196477||Standard treatment group|Subjects with the infection caused by SARS-CoV-2 who received the standard therapy without monoclonal antibodies (mAbs).
10201692|NCT05196464|Other|VA primary care patients|VA primary care patients with psychological distress are being enrolled
10201693|NCT05196425|Other|Control group|
10201694|NCT05196425|Active Comparator|MS with optic neuritis|
10201695|NCT05196425|Active Comparator|Ms without optic neuritis|
10201696|NCT05196412|Experimental|Main study group|Normal subjects of at least 65 years of age
10201697|NCT05196412|Experimental|Endurance athlete group|Group consists of active endurance athletes of at least 50 years of age
10201698|NCT05196386|Experimental|Patient with targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
10201699|NCT05196386|Other|Patient without targeted pharmaceutical interview|No Specific information about treatment delivered by pharmacist
10201700|NCT05196373|Experimental|Part 1: Group 1|10ug Intrascar injection
10201701|NCT05196373|Experimental|Part 1: Group 2|20ug Intrascar injection
10201702|NCT05196373|Experimental|Part 1: Group 3|40ug Intrascar injection
10201703|NCT05196373|Experimental|Part 1: Group 4|60ug Intrascar injection
10201704|NCT05196373|Experimental|Part 1: Group 5|80ug Intrascar injection
10201705|NCT05196373|Experimental|Part 1: Group 6|100ug Intrascar injection
10201706|NCT05196360|Experimental|MAX-10181|tables
10201707|NCT05196347|Experimental|dapagliflozin + integrated CKD care program|"Subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip <20%.~In both arms, the integrated CKD care program includes CKD stage 4 and 5 education, diet counseling, bioimpedance and echocardiography measurements to control overhydration at 0-1 liter (by body composition monitor (BCM; Fresenius))"
10201708|NCT05196347|Active Comparator|integrated CKD care program|In both arms, the integrated CKD care program includes CKD stage 4 and 5 education, diet counseling, bioimpedance and echocardiography measurements to control overhydration at 0-1 liter (by body composition monitor (BCM; Fresenius))
10201709|NCT05196282||UC, Smoker|
10201710|NCT05196282||UC, Smoking cessation|
10201711|NCT05196282||UC, THS user|
10201712|NCT05196282||CD, Smoker|
10201713|NCT05196282||CD, Smoking cessation|
10201714|NCT05196282||CD, THS user|
10201715|NCT05196269|Experimental|Artificial Intelligence and Digital Health Arm|Using an Artificial Intelligence approach integrated in a cloud-based healthcare platform CANKADO to give the patient complete information about the proposed type of locoregional treatment and access to photographs and data of patients with similar characteristics previously treated with the same technique (using AI). All interaction will be through the CANKADO Platform
10201716|NCT05196269|Other|Control Comparator|The standard approach of proposing patients for locoregional treatment with or without printed or digital materials and hypothetic visualization of results
10201717|NCT05196256|Experimental|Dural Puncture Epidural group (DPE)|Dural puncture with a 25 Gauge needle, then placement of the epidural catheter (Tuohy 18 Gauge). The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractionated bolus of 20 mL will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
10201718|NCT05196256|Active Comparator|Epidural group (EP)|Placement of an epidural catheter through a 18 Gauge Tuohy needle. The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent boluses mode (PIB) and patient controlled epidural analgesia (PCEA); An initial fraction bolus of 20ml will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
10201719|NCT05196256|Active Comparator|Combined Spinal-Epidural group (CSE)|Spinal injection through a 25 Gauge needle of Levobupivacaine 2.5mg and Sufentanyl 2.5 mcg in a total volume of 2 mL, placing an epidural catheter through a Tuohy 18 Gauge needle. The epidural medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL. The epidural medication is administered on a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractioned bolus of 20 mL will be administered epidurally 30 min after the intrathecal injection, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20min, all along the dilatation and expulsion period.
10201720|NCT05196230|Experimental|Experimental Condition (360° Video)|The 360° video (experimental) group will be mailed a study tablet with the 360° video prior to the dental visit.
10201721|NCT05196230|Active Comparator|Control Condition (Social Story)|The treatment-as-usual (control) group will be mailed a study tablet with a social story prior to the dental visit.
10201722|NCT05196204|Experimental|Trunk-oriented task combined with functional electrical stimulation training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training combined with functional electrical stimulation.
10201723|NCT05196204|Active Comparator|Trunk-oriented task training group|This group will be formed with participants with spinal cord injury. This group will perform 12 weeks of trunk-oriented task training.
10201724|NCT05196204|No Intervention|Control group|Healthy participants will be recruited based on the age and sex of the participants with spinal cord injury to realize clinical, biomechanical and cortical evaluations
10201725|NCT05196191|Experimental|Viagenex Max|VIAGENEX Max graft will be placed in the incision at the end of surgery prior to closing.
10201726|NCT05196191|Active Comparator|Standard of care|Hibiclens wash will be performed.
9517366|NCT03306888|Experimental|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
9747479|NCT03063203|Experimental|Decitabine|"Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle~Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.~Cycle 3 and subsequent cycles: All patients will receive 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle"
9747480|NCT03057795|Experimental|Treatment (brentuximab vedotin, nivolumab)|Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
9747481|NCT03005379|Active Comparator|1|Fecal Microbiota Therapy (FMT)
9747482|NCT03005379|Placebo Comparator|2|Placebo
9747483|NCT02994498|Experimental|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
9747484|NCT02994498|Experimental|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
9747485|NCT02994498|Experimental|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
9747486|NCT02973126|Other|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
9747487|NCT02947685|Experimental|Arm A|Palbociclib 125 mg daily + AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt) until confirmed disease progression
9747488|NCT02947685|Active Comparator|Arm B|AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant) until confirmed disease progression
9747489|NCT02927769|Experimental|Nivolumab + brentuximab vedotin|
9747490|NCT02927769|Experimental|brentuximab vedotin + bendamustine|
9747491|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
9747492|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
9747493|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
9747494|NCT02887911||Healthy, atopic non-asthmatic|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
10201727|NCT05196178|Experimental|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
9747496|NCT02845882|Other|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
9747497|NCT02845882|Other|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
9747498|NCT02845882|Other|High risk group|Failure to qualify a PR, or >5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
9747499|NCT02843451|Experimental|Silymarin (Milk Thistle)|Each subject will have a 4 week treatment phase with milk thistle.
9747500|NCT02843451|Placebo Comparator|Placebo|4 week placebo phase before or after milk thistle phase depending on randomization.
9747501|NCT02795156|Experimental|Arm 1|Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
9747502|NCT02795156|Experimental|Arm 2|Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
9747503|NCT02795156|Experimental|Arm 3|Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
9747504|NCT02795156|Experimental|Arm 4|Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
9747505|NCT02782949|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
9747506|NCT02782949|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
9747507|NCT02772003|Experimental|Treatment (INO-8000, INO-9012, EP)|Patients receive INO-8000 IM and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by EP at day 0 and at weeks 4, 12, and 24.
10201728|NCT05196126|Active Comparator|Group A|According with ESC indications for elective pacemaker implantation due to SND will referred for PM implantation.
9828849|NCT02511782|Experimental|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
9828850|NCT02511782|Experimental|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
9828851|NCT02511782|Active Comparator|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
9828852|NCT02512042|Experimental|Brinzolamide 1% Ophthalmic suspension|Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd
9828853|NCT02512042|Active Comparator|Azopt® 1% Ophthalmic suspension|Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc
9828854|NCT02512068|Experimental|Trelagliptin 25 mg|Trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period I + II)
9828855|NCT02512068|Experimental|Placebo and Trelagliptin 25 mg|Placebo tablet, orally, once weekly before breakfast for up to Week 12 (Period I), followed by trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period II)
9828856|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
9828857|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
9828858|NCT02512276|Experimental|Telepharmacist intervention|Patients diagnosed with diabetes, hypertension, or hyperlipidemia exhibiting sub-optimal adherence to their medications [defined as combined (average of averages) proportion of days covered (PDC) < 80%] who also have poor or worsening disease control.
10201729|NCT05196126|Experimental|Group B|According with ESC indications for elective PM implantation due to SND will referred for ICM/ILR implantation or prolonged ECG monitoring. Within 4 weeks patient will be screened by interdisciplinary team and autonomic tests (including atropine tests) will be performed. Than, based on atropine tests, electrophysiologic study and extracardiac vagal nerve stimulation, final indication for cardioneuroablation will be established. Biatrial, binodal cardioneuroablation will be performed with anatomical approach with bilateral extra cardiac vagal nerve stimulation during general anesthesia. Than, patient will be closely monitored and indication for PM implantation will be verified.
10201730|NCT05196113|Experimental|sipIT|Participants receive education and a digital tool to monitor their fluid intake and remind them when they have lapsed in regular fluid intake.
10201731|NCT05196113|No Intervention|Control|Participants receive usual care (i.e., education about fluid intake guidelines and encouragement to meet those guidelines).
10201732|NCT05196100|Experimental|Confidence socket|Participants to receive a confidence socket system
10201733|NCT05196048||No Intervention|No Intervention
10201734|NCT05196022||G1|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant but will not opt for a cochlear implant.
10201735|NCT05196022||G2|Patients with bilateral severe to profound hearing loss that would qualify for reimbursement of en cochlear implant and receive a cochlear implant
10201736|NCT05196022||G3|Patients with a single-sided deafness in an acute setting
10201737|NCT05196022||G4|Patients with a single-sided deafness in a chronic setting
10205121|NCT03954509||questionnaires|"From the previous results: elaboration of a written questionnaire built according to the results obtained thanks to the previous interviews. In order to apply the simple correspondence factor analysis method, this questionnaire will be constructed on a Likert scale. The objective is twofold:~to reduce the observer's bias by considering both the literature reviews but also the points of view of patients to develop the questionnaire;~reach a larger patient population (more than 100 patients) compared to the previous qualitative analysis (15 patients planned), in order to generalize the results. This methodology combines both qualitative and quantitative study to minimize bias induced by both types of study.~Dissemination of the questionnaire and filling by the patient independently. The health professional who submitted the questionnaire will remain available to answer any questions the patient may have."
10205122|NCT03951961|Experimental|Midostaurin|50 mg Midostaurin bid for 12 months
10205123|NCT03949153|Experimental|Experimental arm|Single Nivolumab 240 mg infusion at D0, followed by cryotherapy using interventional radiology of metastatic lymphadenopathy at D1 and in situ injection with ipilimumab at D2.
10205124|NCT03947216|Experimental|PIMAVANSERIN|In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.
10205125|NCT03947216|Placebo Comparator|PLACEBO|In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.
10205126|NCT03945552|No Intervention|Control|Care as usual
10205127|NCT03945552|Experimental|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
9747508|NCT02742025|Other|Standard Care|"Patients randomized to this arm will have standard care with no extra interventions.~Intervention: Inclusion visit~Intervention: Coronarography on day 0"
9747509|NCT02742025|Experimental|HEARTLINK|"Patients randomized to this arm will participate in the HEARTLINK program, which includes a specific nurse consultation and telephone contact.~Intervention: Inclusion visit~Intervention: Nurse consultation~Intervention: Telephone contact~Intervention: Coronarography on day 0"
9747510|NCT02676765|Experimental|sublingual allergen tablets|Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.
9747511|NCT02676765|Placebo Comparator|Placebo|Subjects will be administered placebo sublingual tablets
9747512|NCT02669394|Experimental|Resistance Training (RT)|"The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
9747513|NCT02669394|Active Comparator|Stretching and Relaxation (CON)|"The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
9747514|NCT02662634|Experimental|Sequential, no radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
9747515|NCT02662634|Experimental|Concurrent, no radiation|"AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
9747516|NCT02662634|Experimental|Sequential, radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI"
9828859|NCT02512276|No Intervention|Usual care|Patients randomized to this arm will receive usual care.
9828860|NCT02512302|Experimental|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
9828861|NCT02512302|Experimental|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
9828862|NCT02512302|Active Comparator|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
9828863|NCT02512302|Active Comparator|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
9828864|NCT02512302|Active Comparator|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
9828865|NCT02512393|Experimental|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
9828866|NCT02512393|Sham Comparator|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
9828867|NCT02512419|Experimental|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on Social Cognitive Theory (SCT) and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals).
9828868|NCT02512419|Active Comparator|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
9828869|NCT02512575|Experimental|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).~In Part B: one cohort with a single dose"
9828870|NCT02512575|Placebo Comparator|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
9828871|NCT02512575|Experimental|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
9828872|NCT02512679|Other|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.~Drug to be given in combination of Busulfan, Campath and Fludarabine"
9828873|NCT02512679|Other|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
9828874|NCT02512679|Other|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
9828875|NCT02512679|Other|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
9828876|NCT02512783|Active Comparator|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
9828877|NCT02512783|Placebo Comparator|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
9828878|NCT02512809|Experimental|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
10201738|NCT05195957||rTAR|All consecutive patients undergoing bilateral robotic transversus abdominis release operation in the treatment of their ventral incisional hernia, are considered eligible for inclusion.
10201739|NCT05195957||oTAR|All consecutive patients undergoing bilateral open transversus abdominis release operation in the treatment of their ventral incisional hernia, are considered eligible for inclusion.
10201740|NCT05195944|Experimental|Semaglutide|In the Semaglutide Arm, participants will receive daily: 1 tablet of Semaglutide and 1 tablet of Sitagliptin placebo for 26 weeks. The dosages of Semaglutide are 3 mg, 7 mg, and 14 mg.
10201741|NCT05195944|Active Comparator|Sitagliptin|In the Sitagliptin arm, participants will receive daily: 1 tablet of 100 mg Sitagliptin and 1 tablet of Semaglutide placebo for 26 weeks.
10201742|NCT05195931||Preload and Afterload|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in preload (head-up tilt and saline infusion), and afterload (nitroprusside and phenylephrine infusion).
10201743|NCT05195931||Contractility|10 participants with heart failure who are supported by LVADs will undergo hemodynamic monitoring and observation while undergoing changes in contractility with adjustments in heart rate (by adjusting pacemaker), dobutamine infusion, and during exercise.
10201744|NCT05195905|Experimental|Physician-modified endografts|For this clinical protocol, endografts which are commercially available will be modified in a sterile fashion on a back-table in the operating room.
10201745|NCT05195827|Experimental|PRM125|PRM125
10201746|NCT05195788|Experimental|Intervention|Participants assigned to the Intervention group will undergo a cardiac rehabilitation program. The program will combine individualized aerobic and muscle strengthening exercises, comprising three sessions per week to be conducted in person at the EPIC center and at home, for a duration of three months. All sessions will be prepared by a certified kinesiologist.
9828879|NCT02512809|Experimental|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
9828880|NCT02512809|No Intervention|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
9828881|NCT02512861|Active Comparator|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
9828882|NCT02512861|Placebo Comparator|Placebo|Normal Saline
9828883|NCT02512874|Other|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, Dual-energy X-ray absorptiometry (DEXA) scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
9828884|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 1 (12 to 14 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.
9828885|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 2 (15 to 17 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.
9828886|NCT02512965|Active Comparator|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
9828887|NCT02512965|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
9828888|NCT02513095|Experimental|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
9828889|NCT02513095|No Intervention|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
9828890|NCT02513121|Active Comparator|Dietary modification|Low free sugar diet
9828891|NCT02513121|No Intervention|Observational Arm|Standard of care
9828892|NCT02513160|Experimental|Beclomethasone dipropionate BAI 320|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
9828893|NCT02513160|Experimental|Beclomethasone dipropionate BAI 640|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 640 mcg/day (80 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
9828894|NCT02513160|Active Comparator|Beclomethasone dipropionate MDI 320|"Beclomethasone dipropionate Metered Dose Inhaler (MDI) 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
9828895|NCT02513160|Placebo Comparator|Placebo|"Pooled breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) placebo groups. Participants were instructed to take 4 inhalations twice daily for 6 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
9828896|NCT02513212|Other|oxalate liquid, SnF2 paste, manual toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Manual toothbrush
9828897|NCT02513212|Other|oxalate liquid, SnF2 paste, power toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Power toothbrush
9828898|NCT02513446|Experimental|BI 1026706|Single dose
9828899|NCT02513446|Experimental|BI 1026706 + Itraconazole|7 days of itraconazole treatment combined with a single dose of 1026706 on day 4
9828900|NCT02513459|Experimental|Risankizumab|Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
9828901|NCT02513472|Experimental|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
9828902|NCT02513498|Experimental|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
9828903|NCT02513550|Experimental|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
10201747|NCT05195788|No Intervention|Control|Participants assigned to the control group will be encouraged to remain at the usual level of physical activity for the duration of the study. At the end of the study, they will gain free access to the same cardiac rehabilitation program provided to the intervention group.
9828904|NCT02513550|Experimental|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
10201748|NCT05195749|Experimental|COVID-19 Patients|Moderate to severe COVID-19 patients receiving SOC and '005.
10201749|NCT05195749|Placebo Comparator|Control|Moderate to severe COVID-19 patients receiving SOC and placebo.
10201750|NCT05195710|Experimental|Yttrium-90|Help to control the tumor(s) on the right side of the liver while the remaining left side of the liver, which is clear of cancer, grows.
10201751|NCT05195684|Other|single arm|entirely within-subject outcome variables
10201752|NCT05195645|Experimental|A-10mg/kg|Patients in arm A will receive doses of 10 mg/kg of Abatacept
9517367|NCT03306875|Experimental|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
9747517|NCT02662634|Experimental|Concurrent, radiation|"AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy choice of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI."
9747518|NCT02658279|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab 200 mg will be administered as an approximately 30 minute (-5/+10 mins) IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment in spite of increase in tumor size, provided the patient has no, or manageable, new neurologic symptoms, and at the discretion of treating physician. In that situation, tumor resection should be encouraged for the distinction between tumor progression and immunologic reactions. Patients undergoing surgical resection will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
9747519|NCT02656823|Other|ANKYLOS C/X 6.6 mm implants|ANKYLOS C/X 6.6 mm implants
9747520|NCT02616172|Experimental|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
9747521|NCT02599714|Experimental|Triplet Combination (Dose Finding)|Phase 1 triplet dose finding phase in 3-6 patients per cohort - approximately 30 patients depending on emerging data to determine the maximum tolerated dose (MTD) of the triplet.
9747522|NCT02599714|Experimental|Triplet Combination (Dose Expansion)|Additional patients will be enrolled at the dose determined in Part A.
10201753|NCT05195645|Experimental|B-20mg/kg|Patients in arm B will receive doses of 20 mg/kg of Abatacept
10201754|NCT05195645|Experimental|C-25mg/kg|Patients in arm C will receive doses of 25 mg/kg of Abatacept
9747525|NCT02539563|Active Comparator|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
9747526|NCT02539563|No Intervention|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
9747527|NCT02503722|Experimental|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9747528|NCT02491632|Experimental|Arm I (high-dose dexamethasone, physical activity)|Patients receive high-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
9747529|NCT02491632|Experimental|Arm II (low dose dexamethasone, physical activity)|Patients receive low-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
9747530|NCT02460484|Experimental|Cord Blood Infusion|Autologous cord blood infusion
9747531|NCT02448420|Experimental|Arm A: HER2-positive/Hormone receptor-negative (Recruitment Closed)|"Patients with hormone receptor-negative, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
9747532|NCT02448420|Experimental|Arm B1: HER2+/Hormone receptor-positive (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
9747533|NCT02448420|Experimental|Arm B2:HER+/HR+: trastuzumab + palbociclib +letrozole (Recruitment Closed)|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib + letrozole Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Letrozole: daily oral dose of 2.5 mg."
10201755|NCT05195619|Experimental|Cohort 1|metastatic NSCLC of any histology without any actionable oncogenic driver treated by SOC. Maintenance treatment with pemetrexed and/or maintenance/continuation of pembrolizumab, nivolumab or atezolizumab is allowed.
10201756|NCT05195619|Experimental|Cohort 2|metastatic NSCLC with actionable oncogenic driver such as EGFR mutation, ROS-1 or ALK rearrangement, currently receiving osimertinib, alectinib, lorlatinib or crizotinib as per SOC in each disease entity.
10201757|NCT05195554|Experimental|Intervention group|The intervention groups will involve a psycho-educational intervention and will consist of between 10 and 12 people led by two professionals, one of whom must be a psychologist, while the other may be any professional in the center (usually social workers).
10201758|NCT05195554|No Intervention|Control group|Participants in the control group will receive information on suicide and advice if the suicidal ideation increases.
10201759|NCT05195541|Experimental|Cohort A1|0.02mg/injection，2 injections
10201760|NCT05195541|Experimental|Cohort A2|0.04mg/injection，2 injections
10201761|NCT05195541|Experimental|Cohort B1|0.04mg/injection，4 injections
10201762|NCT05195541|Experimental|Cohort B2|0.075mg/injection，4 injections
10201763|NCT05195541|Experimental|Cohort C1|0.075mg/injection，6 injections
10201764|NCT05195541|Experimental|Cohort C2|0.15mg/injection，6 injections
9828905|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
9828906|NCT02513550|Experimental|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
9828907|NCT02513550|Experimental|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
9828908|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
9828909|NCT02513641|Experimental|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs per night) to moderate hypoxia (~2,400 meters) using the Hypoxico Altitude Training Systems device.
9828910|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
9828911|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
9828912|NCT02513745|Active Comparator|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
9828913|NCT02513745|Active Comparator|Refractive Cataract Suite (Verion + ORA)|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
9828914|NCT02513771|Active Comparator|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
9828915|NCT02513771|Placebo Comparator|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
9828916|NCT02513823|Experimental|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
9828917|NCT02513940|Experimental|Testosterone - progesterone - placebo|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
9828918|NCT02513940|Experimental|Testosterone - placebo - progesterone|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
9828919|NCT02513940|Experimental|Progesterone - testosterone - placebo|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
10201765|NCT05195541|Experimental|cohort X1|0.04mg/injection，20 injections
10201766|NCT05195541|Experimental|cohort X2|0.075mg/injection，20 injections
10201767|NCT05195541|Experimental|cohort X3|0.15mg/injection，20 injections
10201768|NCT05195541|Placebo Comparator|cohort X|0.15mg of placebo /injection，20 injections
10201769|NCT05195476|Experimental|Behavioral Treatment|Participants diagnosed with OCD will receive 16 sessions (1 hour long) of exposure and response prevention (Ex/RP) delivered twice weekly over the course of eight weeks.
10201770|NCT05195463|Experimental|First group|Core stabilization exercises
10201771|NCT05195463|Experimental|Second group|Combination of core stabilization and abdominal corset
10201772|NCT05195463|Experimental|Third group|Only abdominal corset
10201773|NCT05195437||Growth hormone treatment|Adolescents and young adults followed or having been followed by the endocrinology, gynecology and pediatric diabetology department of the Necker Enfants Malades hospital, who reached their final height and who have been treated with growth hormone due to short stature.
10201774|NCT05195411||Nephroblastoma with vena cava thrombosis|Children with nephroblastoma with vena cava thrombosis +/- atrial extension, cared between 1999 and 2019 in Parisian hospitals: Necker and Bicêtre.
10201775|NCT05195398|Experimental|A-tDCS|Participants randomized to tDCS will undergo 15- 30 minute sessions over 5 weeks of A-tDCS to the ipsilesional frontoparietal cortex while participating in computerized cognitive therapy (CCT).
10201776|NCT05195398|Active Comparator|Sham Intervention|Participants randomized to sham will undergo 15- 30 minute sessions over 5 weeks of a sham-intervention, also applied to the ipsilesional frontoparietal cortex, while participating in computerized cognitive therapy (CCT).
10205128|NCT03940105|No Intervention|Control|For 3 days during the control snack pattern, the participants will be asked to complete dietary recalls concerning their afternoon and evening snacking behavior. The participants will use the Automated Self-Administered 24-hour Recall (ASA24) system which was developed by the National Cancer Institute.
9747534|NCT02448420|Experimental|Arm C1: Palbociclib, trastuzumab and endocrine therapy|"HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy~Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Palbociclib: oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.~Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant, or Tamoxifen."
9747535|NCT02448420|Active Comparator|Arm C2: Treatment based of physician's choice|HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment based on physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab or endocrine therapy (Aromatase Inhibitor, Fulvestrant or Tamoxifen) in combination with trastuzumab.
10205129|NCT03940105|Active Comparator|Standard Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch.
9747537|NCT02432963|Experimental|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
9747538|NCT02432950|Experimental|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
9747539|NCT02422446|Experimental|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
9747540|NCT02422446|No Intervention|Control|Control group will not receive EPA
9747541|NCT02421133|Experimental|Transitional care program.|The transitional care program from hospital to home will be implemented at three steps: during the patient's stay in hospital, the day of the discharge and during 4 weeks after discharge.
9747542|NCT02421133|Other|standard care program|No intervention liable to affect the care provided to the patients, the organization of care or the practices of health care professionals will be implemented during the control period (time steps without intervention).
9747543|NCT02405676|Other|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
9747544|NCT02405676|Other|Risk group2|Not or incompletely resected stage I/II disease and LDH <2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
9747545|NCT02405676|Other|Risk group3|Stage III with high LDH < 4 times NL, or Stage I,II with LDH >=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
9747546|NCT02405676|Other|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
9747547|NCT02369770|Experimental|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
9747548|NCT02369770|Experimental|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
9747549|NCT02362451|Experimental|1/Lead-in T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|All patients to receive autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine before randomization
9747550|NCT02362451|Experimental|2/Active T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment|Autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine after randomization
9747551|NCT02362451|Placebo Comparator|3/Placebo|Autologous elutriated monocyte vaccine placebo after randomization
9747552|NCT02359799|Experimental|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
9747553|NCT02359799|Experimental|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
10205130|NCT03940105|Active Comparator|Large Package Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that the package sizes of all the foods are larger (though food amount remains the same).
9517368|NCT03306862|Experimental|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
9517369|NCT03306862|Experimental|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
9517370|NCT03306862|Placebo Comparator|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
9747554|NCT02349217|Experimental|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
9747555|NCT02349217|Active Comparator|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
9747556|NCT02342782|Experimental|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
9747557|NCT02338037|Experimental|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9747558|NCT02337634|Placebo Comparator|Placebo|Matched dosage of milk thistle daily.
9747559|NCT02337634|Active Comparator|Milk Thistle|Capsule form, 150mg BID to 300mg BID
9747560|NCT02336087|Experimental|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9747561|NCT02297672|Experimental|Breast seed implant|Stranded palladium seed interstitial radioactive seed implant to seroma with margin with 3 dimensional ultrasound and CT guidance
9747562|NCT02282020|Experimental|1/OLAPARIB|olaparib 300mg oral tablets; twice daily
9747563|NCT02282020|Active Comparator|2/CHEMOTHERAPY|Physician's choice single agent chemotherapy
9747564|NCT02277782|Active Comparator|No Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 0.05 ml of 0.9% normal saline.
9747565|NCT02277782|Experimental|Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 50 mcg preservative-free hydromorphone (0.05 ml)
9747566|NCT02271230|Experimental|Vitamin D and fish oil|2000 IU per day and 1 g per day of fish oil
9747567|NCT02271230|Placebo Comparator|Vitamin D alone|2000 IU Vitamin D and fish oil placebo
9747568|NCT02271230|Experimental|Fish oil (EPA/DHA) alone|1 g per day of fish oil and vitamin D placebo
10201777|NCT05195359|Active Comparator|Allocation to Sleep Improvement App|Participants will be instructed to engage with the Dein Schlaf. Dein Tag. smartphone app, log their behaviors in-app, and track their sleep daily for the duration of the study (12 weeks). Participants will be instructed to start the sleep tracking device via their iOS device before lying down in bed and turning off the lights to go to sleep. In the morning, participants will turn off the sleep tracking device as soon as they wake up and decide to leave the bed. Participants will also be instructed to complete a brief sleep diary using Survey Monkey. At the three time points (baseline, 6 weeks, and 12 weeks), participants will be instructed to complete online assessments on self-reported sleep quality, chronotype, and preventative health measures including physical activity, diet, psychosocial variables, occupational performance.
10205131|NCT03940105|Active Comparator|Variety Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that there is about twice as much snack variety (though food amount remains the same).
10205132|NCT03939520|Experimental|Combined therapy|
10205133|NCT03939520|Active Comparator|Switch monotherapy|
9747569|NCT02271230|Placebo Comparator|Fish oil and vitamin D placebo|Placebo for both vitamin D and fish oil
9747570|NCT02268448|Experimental|Clonidine|Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
9747571|NCT02268448|Experimental|Naltrexone|Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
9747572|NCT02235051|Experimental|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
9747573|NCT02235051|No Intervention|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
10205134|NCT03939520|Other|Control group|
9747574|NCT02180724|Experimental|Previously Treated/Naive|Previously treated, N=92 Treatment Naïve, N=14
9747575|NCT02112565|Experimental|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9747576|NCT02060630|Other|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
9747577|NCT02060630|Other|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
9747578|NCT02060630|Other|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
9747579|NCT02060630|Other|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
9747580|NCT02056704|No Intervention|Angiography|Evaluation by angiography only.
9747581|NCT02056704|Experimental|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
9747582|NCT02048150|Experimental|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
9747583|NCT02047591|Experimental|Relaxing-touch method|
9747584|NCT02047591|No Intervention|Usual care|
9747585|NCT02038777|Experimental|Monotherapy Cohort|PF-04449913 Monotherapy
9747586|NCT02038777|Experimental|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
9747587|NCT02038777|Experimental|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
9747588|NCT02038777|Experimental|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
9747589|NCT02038777|Experimental|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
9747590|NCT02038777|Experimental|Expansion Cohort of LDAC Combination for Efficacy|PF-04449913 in combination with LDAC to evaluate efficacy
10205135|NCT03935932|Experimental|baseline followed by intervention|Subjects randomized to perform baseline measurement of clearance on study day 2 and measurement of clearance with nasal delivery of heated and humidified air on day 3
9747591|NCT01996449|Active Comparator|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
9747592|NCT01996449|Active Comparator|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
9747593|NCT01992432||Single-group study: chemotherapy|Single-group study: chemotherapy
9747594|NCT01976962|Experimental|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
9747595|NCT01958190|Active Comparator|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
9747596|NCT01958190|Experimental|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
9747597|NCT01936831|Experimental|Group 1: Participants with a TB strain that has an inhA mutation|"Participants who meet Step 2 entry criteria will be randomized 1:1:1 to receive the following treatments for 7 days:~5 mg cohort: Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily~10 mg cohort: Isoniazid 10 mg/kg daily plus vitamin B6 ≥25 mg daily~15 mg cohort: Isoniazid 15 mg/kg daily plus vitamin B6 ≥25 mg daily"
9747598|NCT01936831|Experimental|Group 2: Participants with TB without inhA nor katG mutations|Participants who meet Step 2 entry criteria will receive Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily for 7 days
10205136|NCT03935932|Experimental|intervention followed by baseline|Subjects randomized to perform measurement of clearance with nasal delivery of heated and humidified air on day 2 and baseline measurement of clearance on study day 3
10205137|NCT03925077|Active Comparator|Movement to Music (M2M)|All M2M sessions are delivered using videos uploaded to a secure study website (the SCIPE website). Participants in M2M will have access to the website and attend three 60-minute M2M sessions per week for a total of 8 weeks. Each session provides rhythmic-based exercises that are choreographed to music to target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
10205138|NCT03925077|Active Comparator|Standardised Exercise Training (SET)|All M2M sessions are delivered using videos uploaded to the SCIPE website. Participants in SET will have access to the website and attend three 60-minute SET sessions per week for a total of 8 weeks. Each session provides traditional exercises that target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
10205139|NCT03925077|No Intervention|Attention Control (AC)|Participants in AC will not have access to any exercise videos. They will have access to the weekly educational articles on health and fitness, same as the ones received by the M2M and SET groups, through the SCIPE website.
10205140|NCT03920306|Experimental|Intervention|"Drug administration for the experimental arm includes:~AgNO3 applied to the fistula tract.~A topical adhesive of either 2-Octylcyanoacrylate glue (Dermabond), or Fibrin glue, or Histoacryl glue (Tissue Seal), will be applied over the fistula's aperture.~Oral anti-reflux therapy of either Pantoprazole 20-40mg PO OD, or Ranitidine 5-10mg/kg/day PO divided twice daily or 150mg PO BID, for either 4 weeks or until gastrocutaneous fistula tract closure, whichever comes first."
10205141|NCT03918642|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
9828920|NCT02513940|Experimental|Progesterone - placebo - testosterone|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
9828921|NCT02513940|Experimental|Placebo - testosterone - progesterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
9828922|NCT02513940|Experimental|Placebo - progesterone - testosterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
9828923|NCT02514044|Experimental|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
9828924|NCT02514044|Experimental|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
9828925|NCT02514044|Experimental|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
9828926|NCT02514044|Experimental|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
9828927|NCT02514044|Experimental|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
9828928|NCT02514044|Experimental|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
9828929|NCT02514070|Experimental|EPA-rich fish oil arm then DHA-rich fish oil arm|Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm
9828930|NCT02514070|Experimental|DHA-rich fish oil arm then EPA-rich fish oil arm|Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm
9828931|NCT02514122|Experimental|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
9828932|NCT02514122|Placebo Comparator|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
9828933|NCT02514174|Experimental|Afatinib|afatinib starting at 30 mg daily dose
9828934|NCT02514473|Experimental|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
9828935|NCT02514473|Placebo Comparator|Placebo|Matching placebo q12h
9828936|NCT02514551|Experimental|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.
9828937|NCT02514551|Active Comparator|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
9828938|NCT02514577|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
9828939|NCT02514577|Active Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
9828940|NCT02514746|Experimental|Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
9828941|NCT02514772|Experimental|GP2013 - proposed biosimilar rituximab|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration, two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
9828942|NCT02514772|Active Comparator|Originator rituximab - Rituxan ® or MabThera ®|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
9828943|NCT02514824|Experimental|Dose Level 1: MLN01283 3 mg (Phase 1)|"Phase 1 dose level 1 participants receive MLN01283 3 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
9828944|NCT02514824|Experimental|Dose Level 2: MLN01283 4 mg (Phase 1)|"Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
9828945|NCT02514824|Experimental|Dose Level 3: MLN01283 5 mg (Phase 1)|"Phase 1 dose level 3 participants receive MLN01283 5 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
9828946|NCT02514824|Experimental|MLN01283 RP2D (Phase 2)|"Phase 2 participants receive MLN01283 at the recommended phase 2 dose (RP2D) orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
9747599|NCT01936831|Experimental|Group 3: Participants with an MTB isolate with a katG mutation with or without an inhA mutation|Participants with an M. tuberculosis isolate with a katG mutation with or without an inhA mutation who meet Step 2 entry criteria will be randomized to receive either Isoniazid 15 mg/kg or 20 mg/kg daily, plus vitamin B6 ≥25 mg daily for 7 days.
9747600|NCT01927419|Experimental|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
9747601|NCT01927419|Experimental|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
9747602|NCT01924533|Experimental|Olaparib+ paclitaxel|olaparib + paclitaxel
9747603|NCT01924533|Placebo Comparator|Placebo+paclitaxel|placebo+ paclitaxel
9747604|NCT01915511||Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry
9747605|NCT01915511||Subjects with a non-IPF ILD diagnosis|Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype
9747606|NCT01856140|Experimental|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
9747607|NCT01856140|Active Comparator|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
9747608|NCT01773395|Active Comparator|GVAX|"GVAX vaccine~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points."
9747609|NCT01773395|Placebo Comparator|Placebo|"Placebo vaccine~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points."
9747610|NCT01759901|Experimental|Pringle|Intermittent vascular inflow occlusion applied during liver resection
9747611|NCT01759901|No Intervention|Non-Pringle|No vascular inflow occlusion applied during liver resection
9747612|NCT01750073|Experimental|Treatment (chemotherapy, surgery, post-operative therapy)|See Detailed Description
9747613|NCT01730833|Experimental|Treatment (pertuzumab, trastuzumab, nab-paclitaxel)|Patients receive pertuzumab IV over 30-60 minutes on day 1, trastuzumab IV over 30-90 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9747614|NCT01723839|Other|FCR with Lenalidomide|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity. If there are at least 5 CRs after 4 cycles of FCR plus lenalidomide the study will accrue an additional 35 subjects.
9747615|NCT01711879|Active Comparator|Aflibercept with Laser|A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
9747616|NCT01711879|Experimental|Aflibercept|2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
9747617|NCT01697267|Experimental|Rituximab Maintenance|Rituximab maintenance: 1g at 4, 8, 12, 16 & 20 months with standardised steroid taper
9747618|NCT01697267|Active Comparator|Azathioprine Maintenance|Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.
9747619|NCT01653223|No Intervention|control|untreated
9747620|NCT01653223|Experimental|short statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 7 days postoperatively.
9747621|NCT01653223|Experimental|long statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 6 months postoperatively.
9747622|NCT01571778|Experimental|Donning Gloves without Hand Hygiene|In this arm, healthcare workers will be assigned to don non-sterile gloves prior to patient contact WITHOUT first performing hand hygiene. Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
9747623|NCT01571778|No Intervention|Hand Hygiene before donning Non-Sterile Gloves|In this arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (This is usual,expected practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
9747624|NCT01528982|No Intervention|Control|Psychoeducation
9747625|NCT01528982|Active Comparator|Mindfulness|Mindfulness activity and psychoeducation
9747626|NCT01528982|Active Comparator|Cognition|Cognitive training and psychoeducation
9828947|NCT02514889|Active Comparator|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
9828948|NCT02514889|Experimental|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
9747627|NCT01527149|Experimental|Treatment (monoclonal antibody and combination chemotherapy)|"COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.~COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.~All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Eligible patients then undergo standard HDC-ASCT."
9747628|NCT01512407|Experimental|Hepatectomy plus TACE|Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
9747629|NCT01512407|No Intervention|Hepatectomy alone|
9747630|NCT01504789|Experimental|Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
9747631|NCT01504789|Experimental|Non-Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
9747632|NCT01504789|Active Comparator|Waitlist Group|Patients may choose to participate in the exercise program after 16-week assessment. After 4 months of exercise, all the follow-up tests repeated. Exercise recommendation then given, and all of the intervention materials.
9747633|NCT01494662|Active Comparator|Cohort 1|"Patients With Progressive Brain Metastases~Intervention: HKI-272 (Neratinib)340 mg orally, once daily."
9747634|NCT01494662|Active Comparator|Cohort 2|"Patients Who Are Candidates For Craniotomy.~Intervention: HKI-272 (Neratinib) 240 mg orally, once daily.~Surgical resection (biopsy).~Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib."
9747635|NCT01494662|Active Comparator|Cohort 3a/3b|"Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.~Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest."
9747636|NCT01494662|Active Comparator|Cohort 4a/4b/4c|"Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks."
9782166|NCT01167907|Experimental|0.2% ropivacaine|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
9747637|NCT01476839|Experimental|Treatment (radiolabeled monoclonal antibody, chemotherapy)|"DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0."
9747638|NCT01441687|Experimental|Arm I (PMU)|Patients receive digital rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then undergo a prostate biopsy.
9747639|NCT01441687|Experimental|Arm II (EPS)|Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.
9782167|NCT01167907|Placebo Comparator|Saline|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
9782168|NCT01168024|Experimental|CINCOR™ System Treatment|Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).
9782169|NCT01168024|Other|Standard of Care|The control group will receive a peri and post-procedural hydration rate.
9782170|NCT01168232|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9782171|NCT01168349||Cohort|
9782172|NCT01168401|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus Bivalent GI.1 and GII.4 VLP Vaccine, adjuvanted with 50 microgram (mcg) MPL and 500 mcg Al(OH)3, IM, on Days 0 and 28.
9782173|NCT01168401|Placebo Comparator|Saline|
9782174|NCT01168596|Placebo Comparator|sugar pill|Placebo tablet, 1 per day, duration is approximately 12 weeks.
9782175|NCT01168596|Active Comparator|rasagiline|Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
9782176|NCT01168674|Placebo Comparator|Sugar pill|Patients are randomized to a sugar pill (placebo), added to their current medications.
9782177|NCT01168674|Active Comparator|Ziprasidone|Patients are randomized to ziprasidone, added to their current medications.
9782178|NCT01168687|Experimental|Group A|Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
9782179|NCT01168687|Experimental|Group B|Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
9517371|NCT03306849||Regular menstrual cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
9782180|NCT01168726|Experimental|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
9782181|NCT01168726|Experimental|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
9782182|NCT01168726|Active Comparator|Alcohol Education|Educational information about harms associated with heavy drinking.
9782183|NCT01168856||Cohort|
9782184|NCT01168908|Experimental|Revatio (sildenafil)|This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
9782185|NCT01168908|Other|Placebo|This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
9782186|NCT01168934|Experimental|1|Each subject will receive single oral and IV doses of crizotinib separated by at least 14 days.
9782187|NCT01168973|Experimental|Ramucirumab + Docetaxel|
9782188|NCT01168973|Placebo Comparator|Placebo + Docetaxel|
9782189|NCT01168986|Active Comparator|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
9782190|NCT01168986|Active Comparator|Exercise|Participants perform an exercise to strengthen the deep neck flexors
9782191|NCT01168986|No Intervention|No intervention|Participants receive/perform no intervention
9782192|NCT01168999|Active Comparator|spinal manipulation|a spinal manipulation known to be effective in the treatment of low back pain for some individuals
9782193|NCT01168999|Placebo Comparator|sham spinal manipulation|a sham spinal manipulation intended to mimic the studied spinal manipulation
9747640|NCT01388920|Experimental|Tesamorelin 2 mg|Tesamorelin 2 mg/day
9747641|NCT01388920|Experimental|Tesamorelin 3 mg|Tesamorelin 3 mg/day
9747642|NCT01388920|Placebo Comparator|Placebo|Placebo
9747643|NCT01230346|Experimental|Arm I|Patients receive a culturally-informed adapted motivational interviewing telephone call.
9747644|NCT01230346|Experimental|Arm II|Patients participate in a controlled condition comprising a health habits intervention group.
9747645|NCT01230346|Active Comparator|Arm III|Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
9747646|NCT01164202|Placebo Comparator|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
9747647|NCT01164202|Experimental|Sunitinib|sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year
9747648|NCT01163357|Experimental|Group I (bortezomib, fludarabine phosphate, TMI, melphalan)|Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients also undergo TMI BID on days -9 to -7. If no DLT is observed in the first cohort, bortezomib IV will be added on days -6 and -3 for subsequent cohorts.
9747649|NCT01163357|Experimental|Group II (bortezomib, fludarabine phosphate, melphalan|Patients receive fludarabine phosphate IV and melphalan IV as in Stratum I. Patients also receive bortezomib IV on days -6, -3, 1, and 4.
9747650|NCT01088789|Other|Cohort 1|"Arm A: Vaccine only. Arm B receives vaccine as well as a single dose of intravenous cyclophosphamide. Arm C: In addition to Vaccine Cohort 3 receives a daily dose of metronomic cyclophosphamide orally.~Only patients from the J0810 study are eligible.~Closed to enrollment."
9747651|NCT01088789|Other|Cohort 2|"Cohort 2 receives vaccine as well as a single dose of intravenous cyclophosphamide. Vaccine-naïve cohort.~Closed to enrollment."
9747652|NCT01088789|Other|Cohort 3|"Cohort 3 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J1568 study are eligible."
9747653|NCT01088789|Other|Cohort 4|"Cohort 4 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J15237 study are eligible."
9747654|NCT01088789|Other|Cohort 5|"Cohort 5 receives vaccine as well as a single dose of intravenous cyclophosphamide.~Only participants from J1766 study are eligible."
9747655|NCT01030250||Under 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those under 65 years of age will be prospectively evaluated for outcome.
9747656|NCT01030250||Over 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those over 65 years of age will be prospectively evaluated for outcome.
9747657|NCT00977457|Experimental|Diagnostic (specimen collection)|Patients receive prostatic massage and undergo a digital rectal examination. Laboratory assessments are performed and blood samples are collected for molecular biology testing. On the day of the scheduled prostatectomy, a second blood collection is performed prior to surgery.
9747658|NCT00638898|Experimental|Arm I|See Detailed Description
9517372|NCT03306849||Normoandrogenic anovulation|Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
9747659|NCT00609791|Experimental|nab-paclitaxel|
9747660|NCT00577278|Experimental|Treatment (chemo, monoclonal antibody therapy, transplant)|REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
9747661|NCT00576979|Experimental|Treatment (radiation therapy, chemotherapy, transplant)|PREPARATIVE REGIMEN: Patients undergo IMRT using helical tomotherapy once or twice daily on days -10 to -6 or -10 to -7. Patients also receive etoposide IV on day -6 or -5 and cyclophosphamide IV on day -4 or -3. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplantation on day -1 or day 0.
9747662|NCT00554840|Active Comparator|varenicline|
9747663|NCT00554840|Placebo Comparator|placebo|
9747664|NCT00538031|Active Comparator|Arm I|Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9747665|NCT00538031|Experimental|Arm II|Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9747666|NCT00477958|Experimental|Geriatric Assessment Tool|
9747667|NCT00003656|Experimental|All subjects|Weekly ATRA-IV with recombinant interferon alfa
9747668|NCT00370331|Experimental|Treatment arm plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
9747669|NCT00370331|Placebo Comparator|placebo plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
9782194|NCT01168999|No Intervention|natural history|No intervention is provided to participants in this arm of the study
9747670|NCT00370396|Experimental|Synflorix-Synflorix Group|This group consisted of subjects previously vaccinated with the Synflorix™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
9747671|NCT00370396|Active Comparator|Prevenar-Prevenar Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Prevenar™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Prevenar™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
9747672|NCT00370396|Experimental|Prevenar-Synflorix Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
9747673|NCT00370552|Experimental|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|
9747674|NCT00370552|Experimental|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|
9747675|NCT00370552|Active Comparator|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|
9747676|NCT00370682|Experimental|T-DEN F17|Full Dose (0.5 mL) 0 and 6 months
9747677|NCT00370682|Experimental|T-DEN F19|Full Dose (0.5 mL) at 0 and 6 months
9747678|NCT00370682|Placebo Comparator|Placebo Comparator|0.5 mL sterile buffer at 0 and 6, subcutaneous injection
9747679|NCT00370838|Experimental|Levetiracetam|"Levetiracetam (Keppra) is used in one phase of this cross-over study.~The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
9747680|NCT00370838|Active Comparator|Clonidine|"Clonidine is used in one phase of this cross-over study.~The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
9747681|NCT00370994|Active Comparator|Caudal epidural injection|Caudal epidural with placement of catheter in sacral canal with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 0.9% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
9747682|NCT00370994|Active Comparator|Percutaneous adhesiolysis|Pecutaneous adhesiolysis and targeted placement of Racz catheter with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 10% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
9747683|NCT00371137|Placebo Comparator|1|
9747684|NCT00371137|Experimental|2|
9747685|NCT00371150|Experimental|Arm1|
9747686|NCT00371176|Experimental|D-Cycloserine|Brief imaginal exposure therapy plus DCS pill
9747687|NCT00371176|Placebo Comparator|Placebo|Brief imaginal exposure therapy plus Placebo pill
9747688|NCT00371254|Experimental|1|
9747689|NCT00371254|Experimental|2|
9747690|NCT00371267|Experimental|Arm 1: Telephone-delivered CBT|Telephone-delivered cognitive behavior therapy for pain management
9747691|NCT00371267|Active Comparator|Arm 2: Telephone patient education|Telephone-delivered patient education regarding management of chronic pain
9747692|NCT00371293|Active Comparator|1|Participants will receive CPAP therapy.
9747693|NCT00371293|Active Comparator|2|Participants will take part in a weight loss program.
9747694|NCT00371293|Experimental|3|Participants will receive CPAP therapy and take part in a weight loss program.
9747695|NCT00371345|Experimental|Dasatinib|Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).
9747696|NCT00371397|Experimental|Hatha yoga classes|Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
9747697|NCT00371397|Sham Comparator|Movement Control|Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
9747698|NCT00371397|No Intervention|Passive Video Control|Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
9747699|NCT00371436|Active Comparator|Progressive Audiologic Tinnitus Management (PATM)|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment."
9747700|NCT00371436|Other|Usual Care (UC)|Typical audiologic care that would be received in a VA Audiology Clinic.
9747701|NCT00371449||hearing aid users|hearing aid users
9747702|NCT00371540|No Intervention|I|Routine care in the clinic
9747703|NCT00371540|Experimental|II|Follow-up in clinic every 3 months, home visits monthly
9747704|NCT00371566|Experimental|Lapatinib|
9747705|NCT00371566|Placebo Comparator|Placebo|
9747706|NCT00371631|Other|Arm 1|insertion of E. coli coated catheter
9747707|NCT00371644|Experimental|Arm 1|Participants receive 12 biweekly sessions of Cognitive Processing Therapy (CPT).
9747708|NCT00371644|Active Comparator|Arm 2|Participants receive 12 biweekly sessions of Present Centered Therapy (PCT).
9747709|NCT00371683|Active Comparator|A1|+ placebo
9747710|NCT00371683|Experimental|A2|+ placebo
9747711|NCT00371761|Experimental|PegIntron|PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
9747712|NCT00371761|Active Comparator|Adefovir|Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
9747713|NCT00371787|Experimental|soft contact lens|
9747714|NCT00371787|No Intervention|non-lens wear|control group
9747715|NCT00371826|Experimental|Calcineurin Inhibitor (CNI) Withdrawal|"Every randomized patient in this group received~Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone~Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg/day~Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day"
9747716|NCT00371826|Experimental|Steroid Withdrawal|"Every randomized patient in this group received~Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day~Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg per day~Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120.~Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol"
9747717|NCT00371826|Active Comparator|CNI+MPA+ Steroid|"Patients randomized to this group received:~Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36."
9747718|NCT00371839|Active Comparator|Mild Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 20-39 decibels hearing level (dBHL)
9747719|NCT00371839|Active Comparator|Moderate Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 40-49 decibels hearing level (dBHL)
9747720|NCT00371839|Active Comparator|Moderate-Severe Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz greater than 50 decibels hearing level (dBHL)
9747721|NCT00371865|Active Comparator|Cognitive Behavioral Therapy|8 group-administered sessions of Cognitive-Behavioral Therapy
9747722|NCT00371865|Experimental|Acceptance-Based Therapy|8 group-administered sessions of Acceptance-based therapy
9747723|NCT00372060|Experimental|1|MK0431 + pioglitazone
9747724|NCT00372060|Placebo Comparator|2|Placebo/MK0431 + pioglitazone
9747725|NCT00372112|Active Comparator|100 mcg GW642444H|Twice daily in the morning.
9747726|NCT00372112|Active Comparator|400 mcg GW642444H|Twice daily in the morning.
9747727|NCT00372112|Active Comparator|50 mcg salmeterol|Twice daily.
9747728|NCT00372112|Placebo Comparator|placebo|Twice daily
9747729|NCT00372190|Experimental|Mesh surgery|Trocar guided tension free vaginal mesh insertion by Prolift mesh kit
9747730|NCT00372190|Active Comparator|Conventional vaginal surgery|Classical vaginal prolapse surgery (fascia plication)
9747731|NCT00372255|Experimental|Influsplit SSW® 2005/2006 6-9 years Group|Subjects aged 6 to 9 years who received 2 doses of Influsplit SSW® 2005/2006 vaccine at an interval of 4 weeks (Day 0 and Day 28 ± 2).
9747732|NCT00372255|Active Comparator|Influsplit SSW® 2005/2006 10-13 years Group|Subjects aged 10 to 13 years who received 1 dose of Influsplit SSW® 2005/2006 vaccine at Day 0.
9782195|NCT01168999|Placebo Comparator|Enhanced sham spinal manipulation|"a sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
9747733|NCT00372385|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
9747734|NCT00372385|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
9747735|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
9747736|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.
9747737|NCT00372411|Experimental|Arm 1|Robot-Assisted Therapy - MIT-MANUS System
9747738|NCT00372411|Active Comparator|Arm 2|Intensive Comparison Therapy
9747739|NCT00372411|Other|Arm 3|Usual Care
9747740|NCT00372424|Experimental|1|Combination of SU011248 (37.5 mg once daily [Schedule 2/1]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
9747741|NCT00372489|Experimental|Peginesatide|
9747742|NCT00372528|Experimental|pregabalin|open label treatment
9747743|NCT00372567|Experimental|A|
9747744|NCT00372567|Active Comparator|B|
9747745|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
9747746|NCT00372593|Experimental|Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome|Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, & 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
9747747|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
9782196|NCT01169038|Active Comparator|Antibiotics|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
9747748|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in ALL patients.|Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
9747749|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in AML patients.|Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
9747750|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in ALL patients.|Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
9747751|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in ALL patients.|Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
9747752|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in AML patients.|Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
9747753|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in AML patients|Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
9747754|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy - ambiguous lineage pt|Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
9747755|NCT00372697|Experimental|Octreotide 30 mg every 21 days|Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
9747756|NCT00372697|Experimental|Octreotide 60 mg every 28 days|Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
9747757|NCT00372775|Experimental|Sunitinib|
9747758|NCT00372905|Experimental|bortezomib, Ibritumomab tiuxetan, rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
9747759|NCT00372957|Placebo Comparator|Placebo|Participants received two capsules of matching placebo orally once daily in the morning with 150 milliliter (mL) of water at least 15 minutes prior to breakfast for 7 Days.
9747760|NCT00372957|Experimental|GW823093C 15 mg|Participants received one 15 milligrams (mg) of GW823093C capsule and one placebo capsule orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
9747761|NCT00372957|Experimental|GW823093C 30 mg|Participants received 30 mg (2x15 mg) of GW823093C capsules orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
9747762|NCT00372970|Active Comparator|Botulinum Toxin A|200 U of Botox injected endoscopically into pylorus
9747763|NCT00372970|Placebo Comparator|Placebo|saline into pylorus.
9747764|NCT00372996|Experimental|1|CP-751,871 + exemestane Treatment until progression or toxicity
9747765|NCT00372996|Active Comparator|2|
9747766|NCT00373113|Active Comparator|A|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
9747767|NCT00373113|Experimental|B|37.5 mg daily, continuous dosing
9747768|NCT00373256|Experimental|A|
9747769|NCT00373256|Active Comparator|B|
9747770|NCT00373269||Diabetic subject|Subjects with acute stroke, hyperglycemia and history of diabetes.
9747771|NCT00373269||Normoglycemic Control|Subjects with acute stroke and normal blood glucose.
9747772|NCT00373295|Experimental|Baclofen 60 mg, Placebo, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
9747773|NCT00373295|Experimental|Baclofen 90 mg, Placebo, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
9747774|NCT00373295|Experimental|Baclofen 60 mg, Baclofen 90 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
9747775|NCT00373295|Experimental|Baclofen 90 mg, Baclofen 60 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
9747776|NCT00373295|Experimental|Placebo, Baclofen 90 mg, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
9747777|NCT00373295|Experimental|Placebo, Baclofen 60 mg, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
9747778|NCT00373334|Experimental|1|
9747779|NCT00373334|Experimental|2|
9747780|NCT00373334|Sham Comparator|3|
9747781|NCT00373360|Experimental|1|
9747782|NCT00373386|Experimental|Growth Hormone|Growth hormone treatment 0.3 mg/kg/min
9747783|NCT00373399|Placebo Comparator|Inactive Marijuana (0, 1.8, or 3.9% THC)|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Inactive marijuana (0% THC) served as a placebo comparator. Participants received an inactive marijuana cigarette (0% THC; provided by NIDA) in 1 of the 3 outpatient sessions in randomized order.
9747784|NCT00373399|Experimental|Active Marijuana|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Participants received active marijuana cigarettes (1.8, or 3.9% THC; provided by NIDA) over 2 of 3 outpatient sessions in randomized order.
9747785|NCT00373425|Experimental|Erlotinib|Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
9747786|NCT00373425|Placebo Comparator|Placebo|Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
9747787|NCT00373490|Experimental|Vorinostat 600 mg|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
9747788|NCT00373490|Experimental|Vorinostat 400 mg|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
9747789|NCT00373529|Experimental|Clofarabine|Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
9747790|NCT00373685|Experimental|Celecoxib|dosing as per USPI label
9747791|NCT00373685|Active Comparator|NSAIDs|
9747792|NCT00373698|Experimental|Three Component Model|Three Component Model of Collaborative Care: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
9747793|NCT00373698|No Intervention|Usual Care|"Patients randomized to Usual Care will receive care as usual by VA clinicians."
9747794|NCT00373880|Experimental|Aripiprazole (15mg) + Cocaine|Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).
9747795|NCT00373880|Placebo Comparator|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)
9747796|NCT00373958|Experimental|13vPnC vaccine|
9747797|NCT00373958|Active Comparator|7vPnC vaccine|
9747798|NCT00374088|Placebo Comparator|Placebo|These patients receive a placebo infusion of D5W prior to and after surgery
9747799|NCT00374088|Experimental|N-Acetylcysteine|These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.
9747800|NCT00374127|Experimental|marijuana blunt|marijuana blunt (0%, 1.8%, or 3.6% THC)
9747801|NCT00374127|Experimental|marijuana cigarette|marijuana cigarette (0%, 1.8%, or 3.6% THC)
9747802|NCT00374140|Experimental|RAD001 (Everolimus)|RAD001 (Everolimus)10 mg by mouth daily without interruption
9747803|NCT00374231|Experimental|Immunosuppression|All the patients who enroll in this study will receive the same medications (tacrolimus, mycophenolate mofetil, and a short course of steroids) to prevent rejection of the liver transplant. All participants will be gradually taken off prednisone if they are 90 days or longer post liver transplant and have not had a rejection in the last 30 days.
9747804|NCT00374244|Placebo Comparator|1|placebo pimozide
9747805|NCT00374244|Active Comparator|2|active pimozide
9747806|NCT00374322|Placebo Comparator|Placebo|6 tablets daily for 12 months
9747807|NCT00374322|Experimental|Lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
9747808|NCT00374335|Other|infants with cutaneous hemangiomas|
9747809|NCT00374452|Experimental|ATHENA-CDS-HTN plus Guideline Link|ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines
9747810|NCT00374452|Other|Guideline Link Only|Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD) hypertension guidelines
9747811|NCT00374556|Experimental|Eszopiclone|Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks
9747812|NCT00374556|Placebo Comparator|Placebo|3mg placebo capsule, once daily at bedtime for 12 weeks
9747813|NCT00374803|Experimental|Mycophenolic Acid (Myfortic) Preload|Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
9747814|NCT00374803|Active Comparator|Mycophenolic Acid (Myfortic) Standard|Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
9747815|NCT00374842|Experimental|GSK1247446A Formulation 1 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a full dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9747816|NCT00374842|Experimental|GSK1247446A Formulation 2 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a half dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9747817|NCT00374842|Active Comparator|Fluarix Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9747818|NCT00374868|Experimental|Pemetrexed + Cisplatin|
9747819|NCT00374907|Experimental|Saxagliptin (A)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
9747820|NCT00374907|Placebo Comparator|Placebo (ST) / Metformin (LT) (B)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
9747821|NCT00375167|Experimental|Recovery Workbook Intervention|12-week Recovery Intervention: The intervention is a 12-week group-based intervention. The intervention is informed by the Recovery Workbook- a validated intervention for people with serious mental illness. The intervention includes 2 hour sessions for 12 weeks that focus on the following areas: Introduction to the intervention; Recovery; Knowledge and Control; Managing life stress; Enhancing personal meaning; Building personal support; and Setting personal goals. The total time period of the intervention is 24 hours. Participants in this arm also receive treatment as usual.
9782197|NCT01169064|Active Comparator|Silver-containing surgical dressing|Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
9782198|NCT01169064|Active Comparator|Cloth adhesive dressing|Soft cloth adhesive wound dressing
9747822|NCT00375167|No Intervention|Treatment as usual|The participants in the control arm will continue to receive treatment as usual. TAU is Assertive Community Treatment. Assertive Community Treatments are structured to meet set fidelity standards that are evidence-based. This arm did not receive any intervention.
9747823|NCT00375219|Experimental|omacetaxine|Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.
9747824|NCT00375427|Experimental|Every 3 months|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
9747825|NCT00375427|Experimental|Every 4 weeks|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.
9747826|NCT00375492|Experimental|Group A|
9747827|NCT00375492|Placebo Comparator|Group B|
9747828|NCT00375505|Experimental|Zometa|Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
9747829|NCT00375505|Placebo Comparator|Placebo|Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
9747830|NCT00375518|Active Comparator|1|Atorvastatin
9747831|NCT00375518|Placebo Comparator|2|placebo
9747832|NCT00375609|Experimental|Betrixaban 15 mg|Betrixaban 15 mg oral twice daily for 10 to 14 days
9747833|NCT00375609|Experimental|Betrixaban 40 mg|Betrixaban 40 mg oral twice daily for 10 to 14 days
9747834|NCT00375609|Experimental|Enoxaparin|Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days
9747835|NCT00375674|Experimental|A|
9747836|NCT00375674|Placebo Comparator|B|
9747837|NCT00375713|Experimental|Levocetirizine|Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
9747838|NCT00375713|Active Comparator|Cetirizine|Cetirizine + Levocetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
9747839|NCT00375752|Active Comparator|Letrozole|Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment
9747840|NCT00375752|Experimental|Zolendronic Acid + Letrozole|2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
9747841|NCT00375830|Experimental|Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Preliminary pilot assessment to confirm feasibility & improved diagnostic accuracy of the combined 18F-NaF CT & 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
9747842|NCT00375830|Experimental|Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Assessment to define the accuracy of the combined 18F-NaF CT & 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
9747843|NCT00375830|Experimental|Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan|Assessment to define the utility of 18F-NaF & 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.
9747844|NCT00375934|Experimental|1|
9747845|NCT00375934|Placebo Comparator|2|
9782199|NCT01169103|Experimental|recombinant human growth hormone|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
9782200|NCT01169103|Placebo Comparator|Placebo|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
9782201|NCT01169311|Experimental|HEEA Stapler|hemorrhoidopexy using Covidien EEA Hemorrhoid and Prolapse Stapling Set
9782202|NCT01169337|Experimental|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9782203|NCT01169337|Active Comparator|Arm B (observation)|Patients undergo observation until progression to symptomatic myeloma.
9747846|NCT00375973|Experimental|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
9747847|NCT00375973|Placebo Comparator|Placebo|Placebo comparator to Duloxetine
9747848|NCT00375999|Experimental|docetaxel and epirubicin|salvage docetaxel and epirubicin
9747849|NCT00376168|Experimental|prGCD 30 Units/kg|
9747850|NCT00376168|Experimental|prGCD 60 Units/kg|
9747851|NCT00376220|Experimental|1|"Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.~Other Names:~• Rilutek"
9747852|NCT00376220|Placebo Comparator|2|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
9747853|NCT00376246|Other|Group 1|1st group will receive Ezetimibe for 2 weeks followed by washout (no medication) period for 4 weeks and followed by placebo for 2 weeks.
9747854|NCT00376246|Other|Group 2|2nd group will receive Ezetimibe and placebo in reverse order with interspaced 4-week washout period.
9747855|NCT00376259|Experimental|Combination therapy|Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
9747856|NCT00376259|Active Comparator|Adefovir monotherapy|Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
9747857|NCT00376363|Active Comparator|Ahmed implant,1|Ahmed glaucoma drainage implant for intraocular pressure control
9747858|NCT00376363|Active Comparator|Baerveldt implant|Baerveldt glaucoma drainage implant for intraocular pressure control
9747859|NCT00376506|Experimental|Implanted Device|Implanted intramuscular neurostimulator device
9747860|NCT00376506|Active Comparator|External Device|External vibrotactile device
9747861|NCT00376532||ICD pacing or shock event|Subjects who experienced a device treatment, defined as a pacing event or a shock event
9747862|NCT00376532||No ICD pacing or shock event|Subjects who did not experience a treatment defined as a pacing event or a shock event
9747863|NCT00376558|Active Comparator|Contingency Management w/ CRA|Cocaine users: Contingency management w/ Community Reinforcement Approach
9747864|NCT00376558|No Intervention|Healthy Control|A group of healthy matched comparison subjects with no DSM-IV axis I Disorder was included; they were matched for cigarette smoking, gender, and ethnicity.
9747865|NCT00376597|Experimental|Arm I (lymphedema education)|Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.
9747866|NCT00376597|Experimental|Arm II (lymphedema education, physical therapy)|Description Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.
9747867|NCT00376675|Experimental|Arm I|Patients receive oral methylphenidate hydrochloride daily on days 1-28.
9747868|NCT00376675|Placebo Comparator|Arm II|Patients receive oral placebo daily on days 1-28.
9747869|NCT00376688|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9747870|NCT00376805|Experimental|All Treated Patients|All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.
9747871|NCT00376935|Placebo Comparator|1|Participants will receive palifermin placebo injection on Days 1, 2, and 3
9747872|NCT00376935|Experimental|2|Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
9747873|NCT00376935|Experimental|3|Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
9747874|NCT00376935|Experimental|4|Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
9747875|NCT00376948|Experimental|Novasoy®, Gemcitabine & Erlotinib|Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
9747876|NCT00376961|Experimental|R-CHOP + Velcade|6 21-day cycles of standard R-CHOP with 1.3 mg/m^2 Bortezomib given on days 1 and 4 of each cycle. This is followed by 8 3-month cycles of maintenance with 1.3 mg/m^2 Bortezomib on days 1, 4, 8 and 11 of each cycle.
9747877|NCT00377156|Active Comparator|Arm I|Patients undergo stereotactic radiosurgery (SRS)
9747878|NCT00377156|Experimental|Arm II|Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.
9747879|NCT00377234|Experimental|1|
9747880|NCT00377234|Active Comparator|2|
9747881|NCT00377260|Experimental|Amoxicillin-clavulanate|Reconstituted amoxicillin-clavulanate at 90/6.4 mg/kg/day in 2 divided doses for 10 days.
9747882|NCT00377260|Placebo Comparator|Placebo|Reconstituted placebo in 2 divided doses for 10 days.
9747883|NCT00377299|Experimental|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
9747884|NCT00377299|Placebo Comparator|Placebo|Placebo matching active medication.
9747885|NCT00377312|Experimental|Group 1|Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
9828949|NCT02515045|Active Comparator|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
9828950|NCT02515045|Active Comparator|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
9828951|NCT02515045|Active Comparator|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
9828952|NCT02515058|Experimental|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
9828953|NCT02515058|Active Comparator|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
9828954|NCT02515097|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
9828955|NCT02515097|Placebo Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
9828956|NCT02515253|Experimental|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
9828957|NCT02515253|Other|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
9835781|NCT02754661|Experimental|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.~Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
9835782|NCT02754661|Active Comparator|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
9835783|NCT02754674|Experimental|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
9835784|NCT02754674|Experimental|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
9835785|NCT02755090|Experimental|Nitrous oxide and IV saline|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
9835786|NCT02755090|No Intervention|Standard Care (IV Sedation and Oxygen)|Within the IV sedation group, women will receive 100mcg fentanyl and 2mg midazolam at least two minutes prior to initiation of the procedure. This group will also receive 100% oxygen by a scented face mask. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
9835787|NCT02755116|Experimental|Olanzapine|10mg pill
9835788|NCT02755116|Placebo Comparator|Placebo|
9835789|NCT02755129|Other|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:~Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test~Walking exercises - 4 Meter Gait Speed (4MGS) Test~Walking Exercises - Five Times Sit to Stand (FTSTS) Test~Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
9835790|NCT02755285|Experimental|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
10205142|NCT03918642|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
10205143|NCT03914495|Placebo Comparator|Placebo|Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.
9747886|NCT00377312|Experimental|Group 2|Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.
9747887|NCT00377364|Experimental|Acetaminophen|Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days.
9747888|NCT00377364|Placebo Comparator|Placebo|Participants will be given an identical appearing placebo (two 500 mg tablets) four times daily for 7 days.
9747889|NCT00377403|Experimental|Intervention Arm|Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
9747890|NCT00377403|Placebo Comparator|Symptomatic treatments only|Placebo for 10 days in addition to symptomatic treatments
9747891|NCT00377429|Experimental|catumaxomab|
9747892|NCT00377520|Experimental|Pemetrexed|
9747893|NCT00377572|Experimental|Omalizumab (Xolair) + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
9747894|NCT00377572|Placebo Comparator|Placebo + Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
9747895|NCT00377611|Experimental|FLUARIX 50-64 YEARS GROUP|Adult subjects aged between and including 50-64 years who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
9747896|NCT00377611|Experimental|FLUARIX 65+ YEARS GROUP|Elderly subjects aged 65 and over who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
9747897|NCT00377637|Experimental|Induction Phase: Mycophenolate mofetil|Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
9747898|NCT00377637|Active Comparator|Induction Phase: Cyclophosphamide|Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
9747899|NCT00377637|Experimental|Maintenance Phase: Mycophenolate mofetil|Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
9747900|NCT00377637|Active Comparator|Maintenance Phase: Azathioprine|Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.
9747901|NCT00377676|Experimental|Usual Diabetes Therapy plus placebo|Usual diabetes therapy plus placebo
9747902|NCT00377676|Experimental|Drug Cycloset|
9747903|NCT00377741|Experimental|1|
9747904|NCT00377819|Experimental|denosumab|
9747905|NCT00377819|Active Comparator|alendronate|
9747906|NCT00377832|No Intervention|1|
9747907|NCT00377832|Active Comparator|2|Acetaminophen 975 mg once
9747908|NCT00377858|Experimental|Insulin Lispro Mid Mixture|Insulin lispro mid mixture (MM) up to three times a day (TID)
9747909|NCT00377858|Active Comparator|Insulin Glargine|Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.
9747910|NCT00377962|Experimental|Everolimus + CNI reduction|Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level < 75 ng/mL or a tacrolimus trough level < 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.
9747911|NCT00377962|Active Comparator|Control|CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.
9747912|NCT00378014|Experimental|Everolimus|Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
9747913|NCT00378014|Active Comparator|Calcineurin Inhibitor (CNI)|Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
9747914|NCT00378079|Experimental|3|
9747915|NCT00378079|Active Comparator|1|
9747916|NCT00378079|Experimental|2|
9747917|NCT00378105|Experimental|lenalidomide, dexamethasone, bortezomib combination|In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.
9747918|NCT00378209|Experimental|lenalidomide, dexamethasone, bortezomib combination|Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.
9747919|NCT00378326|Experimental|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
9747920|NCT00378352|Placebo Comparator|Dose Escalation Safety|The objective of the first phase is to evaluate the safety of escalating doses of Epoetin alfa in patients with STEMIs.
9747921|NCT00378352|Placebo Comparator|Single Dose Efficacy|Single parenteral administration of 60000 U of epoetin alfa. The objectives of the second phase are to investigate the effects of the highest safe dose on infarct size, left ventricular remodeling and endothelial progenitor cells.
9747922|NCT00378508|Experimental|1|The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
9747923|NCT00378508|Placebo Comparator|2|Normal saline infusion
9747924|NCT00378534|Experimental|T Cell Depletion Transplant Participants|Participants with hematological malignancies received a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion at day 90.
9747925|NCT00378534|Other|Stem Cell Donors|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. The stem cell collection aspect of this protocol is not investigational.
9747926|NCT00378560|Placebo Comparator|1|Placebo
9747927|NCT00378560|Experimental|2|Vaccine
9747928|NCT00378573|Experimental|docetaxel, gemcitabine and bevacizumab|Single arm treatment with docetaxel, gemcitabine and bevacizumab
9747929|NCT00378599|Experimental|PEG-Intron plus Rebetol (RBV)|PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was >10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing <65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing >85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).
9747930|NCT00378703|Active Comparator|Arm A (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15.
9747931|NCT00378703|Experimental|Arm B (bevacizumab and temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and bevacizumab as in Arm A.
9747932|NCT00378703|Experimental|Arm C (bevacizumab and sorafenib tosylate)|Patients receive bevacizumab as in Arm A and sorafenib tosylate PO BID on days 1-5, 8-12, 15-19, and 22-26.
9747933|NCT00378703|Experimental|Arm D (sorafenib tosylate and temsirolimus)|Patients receive sorafenib tosylate PO BID on days 1-28 and temsirolimus as in Arm B.
9747934|NCT00378898|Active Comparator|EGD with proximal BRAVO capsule|Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
9747935|NCT00378898|Sham Comparator|EGD with sham BRAVO capsule placement|Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
9747936|NCT00379080|Experimental|Arm I - Feasibility|"Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~conventional surgery~oral tandutinib~Pharmacological study~Tissue samples"
9747937|NCT00379080|Experimental|Arm 2 - Dose Escalation (Phase 1)|"Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.~the starting dose for tandtinib is 500mg BID~oral tandutinib~Pharmacological study~Tissue samples"
9747938|NCT00379080|Experimental|Arm 3 - Phase 2|"Patients receive tandutinib as in phase I at the MTD determined in phase I.~600mg was the determined MTD in Dose Escalation~oral tandutinib~Pharmacological study~Tissue samples"
9747939|NCT00379145|Experimental|Trabectedin|Trabectedin IV over 24 hours every 3 weeks
9747940|NCT00379197|Experimental|Naltrexone|Naltrexone 50 mg will be taken orally once a day every day of a 28 day treatment course (cycle 1) and continue for another identical 28 day treatment (cycle 2) . PET scan will be performed after cycle 1 and cycle 2 complete.
9747941|NCT00379210|Experimental|1|"Meditation training group-- received Mindfulness Based Stress Management from the Penn Program for Stress Management.~The meditation practice initially emphasized attention to a single focus. For most concentrative exercises, this focus was the breath. The sensations of breathing were to be examined closely, and when attention wandered it was to be redirected back to the breath. In other exercises, the focus of attention was to be directed to sensations within specific body parts (body scan exercise) and sensations of walking (walking meditation). During the 5th week of classes, the mindfulness training was expanded to include some explicit training in receptive attention."
9747942|NCT00379210|Active Comparator|2|"Nutrition education group~An active comparison condition involving nutrition education was offered. This course matched the mindfulness course in all dimensions including course duration, homework, psychosocial support, and teacher expertise. The course was taught by a nurse who had expertise in nutrition and offered a program described in the book, Nutrition for Life by Lisa Hark."
9747943|NCT00379236|Experimental|EUFLEXXA™ Double-blind|Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
9747944|NCT00379236|Placebo Comparator|Placebo Double-blind|Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
9782204|NCT01169350|Experimental|Diagnostic (18F FDG and 18F FMISO PET/CT)|Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.
9747945|NCT00379236|Experimental|EUFLEXXA™ Open Label|All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.
9747946|NCT00379353|Active Comparator|Group 1: Thalidomide|100 mg capsules orally, once a day for 14 days
9747947|NCT00379353|Placebo Comparator|Group 2: Placebo|Two placebo capsules orally, once a day for 14 days.
9747948|NCT00379574|Experimental|Bortezomib + CHOP every 2 weeks|Bortezomib + CHOP(Cycloophosphamide, vincristine, doxorubicin,and predinisolone) every 2 weeks
9747949|NCT00379639|Experimental|Romidepsin / Gemcitabine|Participants were to receive 7, 10 or 12 mg/m^2 of romidepsin intravenously on either Days 1, 8 and 15 (Schedule A) or Days 1 and 15 (Schedule B) of each 28-day cycle, followed by 800 or 1000 mg/m^2 of gemcitabine. Subsequent doses of both drugs were based on treatment-related toxicities. The planned duration of study therapy was 6 cycles or until disease progression occurred. Patients who responded could continue beyond 6 cycles until disease progression or until a withdrawal criterion was met.
9747950|NCT00379769|Experimental|rosiglitazone in addition to background metformin|Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
9747951|NCT00379769|Experimental|rosiglitazone in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
9747952|NCT00379769|Active Comparator|Sulfonylurea in addition to background metformin|Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
9747953|NCT00379769|Active Comparator|Metformin in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
9747954|NCT00379795|Experimental|Ranibizumad 0.5 mg|Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
9747955|NCT00379808|Placebo Comparator|Placebo|1 lactose-containing capsule daily for 1 month
9747956|NCT00379808|Active Comparator|Montelukast 10 mg|1 montelukast 10 mg tablet (masked by capsule) daily for 1 month
9747957|NCT00379821|Experimental|CQ Monotherapy|N=160: treat with Chloroquine (CQ) alone.
9747958|NCT00379821|Experimental|CQ plus atovaquone proguanil|N=160: treat with CQ plus atovaquone proguanil.
9747959|NCT00379821|Experimental|CQ plus artesunate|N=160: treat with CQ plus artesunate.
9747960|NCT00379821|Experimental|CQ plus azithromycin|N=160: treat with CQ plus azithromycin.
9747961|NCT00379834|Active Comparator|Cosopt|Cosopt twice daily in both eyes
9747962|NCT00379899|Active Comparator|Control|Standard of care, without use of cinacalcet.
9747963|NCT00379912|Experimental|Investigational Arm A|Azacitidine + Erythropoietin
9747964|NCT00379912|Experimental|Investigational Arm B|Azacitidine
9747965|NCT00380029|Experimental|Erlotinib|erlotinib given before and after transurethral resection of a bladder tumor, TURBT
9747966|NCT00380068|Experimental|Ambrisentan|
9747967|NCT00380081|Experimental|placebo/zolpidem 3.5/zolpidem 1.75|
9747968|NCT00380081|Experimental|placebo/zolpidem 1.75/zolpidem 3.5|
9747969|NCT00380081|Experimental|zolpidem 3.5/placebo/zolpidem 1.75|
9747970|NCT00380081|Experimental|zolpidem 3.5/zolpidem 1.75/placebo|
9747971|NCT00380081|Experimental|zolpidem 1.75/placebo/zolpidem 3.5|
9747972|NCT00380081|Experimental|zolpidem 1.75/zolpidem 3.5/placebo|
9747973|NCT00380250|Experimental|Lubiprostone|8 mcg capsule twice daily (BID)
9747974|NCT00380250|Placebo Comparator|Placebo|Matching placebo capsule twice daily (BID)
9747975|NCT00380367|Experimental|Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)|Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.
9747976|NCT00380393|Experimental|GSK257049 Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
9747977|NCT00380393|Active Comparator|Rabipur Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
9747978|NCT00380588|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.~Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal."
9747979|NCT00380588|Experimental|Gemcitabine|Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
9747980|NCT00380692|Experimental|Atomoxetine|atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
9747981|NCT00380692|Placebo Comparator|Placebo|"placebo every day (QD), by mouth (PO) for 8 weeks~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks"
9747982|NCT00380718|Experimental|Pemetrexed|
9747983|NCT00380744|Experimental|Part A LY2189102 0.1 mg/kg/wk|"Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV)~Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV"
9747984|NCT00380744|Experimental|Part A LY2189102 0.3 mg/kg/wk|"Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV~Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV"
9747985|NCT00380744|Experimental|Part A LY2189102 1.0 mg/kg/wk|"Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV~Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV"
9747986|NCT00380744|Experimental|Part A LY2189102 2.5 mg/kg/wk|"Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV~Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV"
9747987|NCT00380744|Placebo Comparator|Placebo|IV, once weekly x 4 wks
9747988|NCT00380861|Active Comparator|PFC Sigma RP-F|PFC® Sigma™ RP-F knee implant is a posterior stabilized cemented component cemented that is implanted with a standard posterior stabilized surgical technique.
9747989|NCT00380861|Active Comparator|PFC Sigma RP|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System has a special insert that helps the knee move more like it did before the knee replacement.
9747990|NCT00380874|Experimental|1|flexible dosing
9747991|NCT00380874|Placebo Comparator|2|
9747992|NCT00380978|Active Comparator|early analgesia:combined-spinal epidural|
9747993|NCT00380978|Active Comparator|late analgesia (systemic)|
9747994|NCT00381004|Experimental|FCR + Sargramostim|Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.
9747995|NCT00381043|Active Comparator|1- Acamprosate|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
9747996|NCT00381043|Placebo Comparator|2 - Sugar Pill - Placebo|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
9747997|NCT00381095|Experimental|1|flexible dosing
9747998|NCT00381095|Placebo Comparator|2|
9747999|NCT00381238|Experimental|rosiglitazone|Extended Release Tablets
9748000|NCT00381303|Experimental|001|darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks
9748001|NCT00381550|Experimental|Arm I|Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9748002|NCT00381563|Other|Intervention to placebo|Participants will wear the patellofemoral realigning knee brace for 6 weeks, followed by the non-aligning knee brace for 6 weeks.
9748003|NCT00381563|Other|Placebo to intervetion|Participants will wear the non-aligning knee brace for 6 weeks, followed by the patellofemoral realigning knee brace for 6 weeks.
9782205|NCT01169467|Active Comparator|Standard-of-Care plus Precedex|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment.
9782206|NCT01169467|Placebo Comparator|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
9748004|NCT00381615|Experimental|rMenB|"Infants received 4 doses of recombinant meningococcal serogroup B (rMenB) vaccine without outer membrane vesicle (OMV-NZ) at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of Diphtheria Tetanus Pertussis-Haemophilus influenzae type b-Inactivated Polio Vaccine (DTaP-Hib-IPV) (at 2, 3, and 4 months) and Heptavalent Pneumococcal Conjugate (PC7) (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and Measles Mumps Rubella (MMR) (at 13 months)."
9748005|NCT00381615|Experimental|rMenB+OMV|"Infants received 4 doses of rMenB vaccine with OMV-NZ at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months)."
9748006|NCT00381615|Experimental|Routine|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine without OMV-NZ at 12 months of age."
9748007|NCT00381615|Experimental|Routine+OMV|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine with OMV-NZ at 12 months of age."
9748008|NCT00381628||Stable subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro.
9748009|NCT00381628||Exacerbating subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) at the beginning and end of treatment for a pulmonary exacerbation. These cells will be studied in vitro.
9748010|NCT00381628||Stable subjects with asthma|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the disease control group.
9748011|NCT00381628||Healthy volunteers|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the control group
9748012|NCT00381680|Active Comparator|Regimen A: Standard vincristine dosing|See detailed description.
9748013|NCT00381680|Experimental|Arm B: Randomized High Dose Vincristine regimen|See detailed description. Closed to accrual as of 09/2010).
9748014|NCT00381706|Experimental|Arm A (ECF + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab IV on days 1, 8 and 15. Patients receive epirubicin 50 mg/m^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m^2 IV over 60 minutes. On days 1-21, patients receive 5-fluorouracil 200 mg/m^2/day continuous IV infusion. Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
9748015|NCT00381706|Experimental|Arm B (IC + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1, 8 and 15. Patients receive cisplatin 30 mg/m^2 IV over 30 minutes on days 1 and 8 after cetuximab. Patients also receive irinotecan 65 mg/m^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
9748016|NCT00381706|Experimental|ARM C (FOLFOX + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m^2 IV over 120 minutes and leucovorin 400 mg/m^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration. Following leucovorin, patients will receive 5-fluorouracil 400 mg/m^2 IV bolus injection, then 5-fluorouracil 2400 mg/m^2 IV infusion over 46-48 hours. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
9748017|NCT00381797|Experimental|Arm I|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and fludeoxyglucose F 18 positron emission tomography at baseline and periodically during treatment."
9517373|NCT03306849||Hyperandrogenic anovulation|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
9748018|NCT00381810|Experimental|Rituximab 1000 mg|Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
9748019|NCT00381849|Active Comparator|Cystone then sugar pill|Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
9748020|NCT00381849|Placebo Comparator|Sugar pill then Cystone|Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
9748021|NCT00381849|Experimental|Open-label Cystone|All subjects will receive Cystone for 46 weeks in the open-label period.
9748022|NCT00381862|Experimental|Aprepitant and Palonosetron|
9748023|NCT00381888|Experimental|Patients Treated with Fondaparinux|Patients treated with at least one dose of Fondaparinux (2.5 mg subcutaneous, Days 1-28 by mouth).
9748024|NCT00381940|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy)|"Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy."
9748025|NCT00381966|Experimental|Robotic placement device|The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.
9748026|NCT00382018|Active Comparator|Group 1|Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.
9748027|NCT00382018|Experimental|Group 2|Patients continue to receive their current chemotherapy regimen without change.
9748028|NCT00382018|Active Comparator|Group 3, Arm I|Patients continue with their current chemotherapy regimen without change.
9748029|NCT00382018|Experimental|Group 3, Arm II|Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.
9748030|NCT00382031|Active Comparator|zalutumumab|Zalutumumab in combination with Best Supportive Care
9748031|NCT00382031|Other|Control|Best Supportive Care
9748032|NCT00382070|Experimental|Group 2 Letrozole|Patients receive oral letrozole once daily for up to 5 years.
9748033|NCT00382070|Placebo Comparator|Group 1 Placebo|Patients receive oral placebo once daily for up to 5 years.
9748034|NCT00382109|Experimental|Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors) and oral sirolimus (dose 2.5mg/m2/day - 4 mg max starting dose) daily starting on day 0 followed by a taper starting on day 180 through day 207.
9748035|NCT00382109|Active Comparator|Tacro-MTX GVHD Prophylaxis|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally (when able) daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors).
9782207|NCT01169493|Experimental|VVI-40 to RV DDD-40 to Bi-V DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
9782208|NCT01169493|Experimental|VVI-40 to Bi-V DDD-40 to RV DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
9782209|NCT01169493|Experimental|Bi-V DDD-40 to VVI-40 to RV DDD-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
9782210|NCT01169493|Experimental|Bi-V DDD-40 to RV DDD-40 to VVI-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
9782211|NCT01169493|Experimental|RV DDD-40 to VVI-40 to Bi-V DDD-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
9782212|NCT01169493|Experimental|RV DDD-40 to Bi-V DDD-40 to VVI-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
9782213|NCT01169519|Active Comparator|Sildenafil|Pharmacokinetic and hemodynamic evaluation following sildenafil administration
9782214|NCT01169532|Experimental|Treatment (ridaforolimus and vorinostat)|Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9782215|NCT01169558|Experimental|Bevacizumab|Bevacizumab will be administered in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum until disease progression or study completion.
9782216|NCT01169636|Experimental|Panobinostat MTD + ICE|Phase 1: Escalating Panobinostat dose with routine ICE Chemotherapy
9748036|NCT00382148|Experimental|1|
9748037|NCT00382174|Placebo Comparator|1|0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
9748038|NCT00382174|Active Comparator|2|3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
9748039|NCT00382265|Active Comparator|Tamsulosin|Tamsulosin 0.4mg PO qd for 28 days
9748040|NCT00382265|Placebo Comparator|Placebo|Placebo PO qd for 28 days
9748041|NCT00382291|Experimental|Regular Titration|Regular titration of Sertraline plus cognitive behavioral therapy. The titration schedule used a flexible upward titration from 25 mg/day to 200 mg/day over 9 weeks unless higher doses were not tolerated, after which the dosage was adjusted as a function of tolerability. If tolerated, maximum dose could be achieved in 5 weeks.
9748042|NCT00382291|Placebo Comparator|Placebo|Placebo plus cognitive behavioral therapy
9748043|NCT00382291|Experimental|Slow Titration|Slow titration of Sertraline plus cognitive behavior therapy. The titration schedule utilized a slower titration schedule relative to the RegSert arm. Unless unable to tolerate higher doses, children remained on 25mg/day for the first two weeks, 50mg/day from weeks 3-4, 75mg/day for weeks 5-6, 100mg/day for week 7, 150mg/day for week 8, and 200mg/day for week 9 until the end of the study.
9748044|NCT00382408|Experimental|Vaccine|Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
9748045|NCT00382408|Placebo Comparator|Placebo|Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
9748046|NCT00382590|Active Comparator|5-Aza + VPA|5-Azacytidine (5-Aza) 75 mg/m^2 subcutaneously daily + Valproic Acid (VPA) 50 mg/m^2 orally daily, each for 7 days
9748047|NCT00382590|Active Comparator|Ara-C|Low-Dose Ara-C 20 mg twice daily subcutaneously for 10 days.
9748048|NCT00382720|Experimental|TE (Taxotere and Eloxatin)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study."
9748049|NCT00382720|Experimental|TEF (Taxotere, Eloxatin and 5-FU)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study."
9748050|NCT00382720|Experimental|TEX (Taxotere, Eloxatin and Xeloda)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study."
9748051|NCT00382785|Experimental|moderated online support|12-week online support led by a healthcare professional
9748052|NCT00382785|Experimental|peer-led support|12-week online support group in a peer-led format
9748053|NCT00382824|Active Comparator|CoQ10|Half of the enrolled patients will be randomized into the the CoQ10 arm and will receive a dosage of 2400mg/day of Coenzyme Q10
9748054|NCT00382824|Placebo Comparator|Placebo|Half of the enrolled patients will be randomized into the the Placebo arm and will receive a matching dose of placebo that resembles the 2400mg/day dose of the CoQ10 arm.
9748055|NCT00382863|Experimental|Treatment|HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)
9748056|NCT00382863|Active Comparator|Control|Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)
9748057|NCT00382928|No Intervention|Standard of Care Group|Patients will receive standard of care measures in case of cardiac arrest. They will not receive AECD monitoring or intervention
9748058|NCT00382928|Experimental|AECD Monitoring + Standard of Care Group|Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital. Defibrillation of pulseless VT/VF by AECD.
9748059|NCT00382967|Experimental|Datscan Product|
9748060|NCT00382967|No Intervention|Control|
9748061|NCT00382993|Other|Combination Product - Placebo|Combination Product (sumatriptan and naproxen sodium) [Attack 1] followed by Placebo [Attack 2]
9748062|NCT00382993|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
9748063|NCT00383019|Experimental|Xalatan|
9748064|NCT00383019|Experimental|Xalacom|
9748065|NCT00383071|Active Comparator|Cohort 1|H5N1 vaccine - 90 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
9748066|NCT00383071|Active Comparator|Cohort 2|H5N1 vaccine - 120 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
9748067|NCT00383071|Active Comparator|Cohort 3|H5N1 vaccine - 180 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
9748068|NCT00383071|Active Comparator|Cohort 4|H5N1 vaccine - 180 mcg IM every 4 weeks x 2 doses, injection site randomized to either deltoid or gluteus Apheresis - if HAI titer above 1:160
9748069|NCT00383084|Experimental|1|Group 1 participants will take part in 30 minutes total of self-selected lifestyle physical activity throughout the day, 5 to 7 days per week. Twice a month, they will attend group sessions designed to help participants develop and maintain a more physically active lifestyle. Goal setting, self-monitoring, and pain management will be discussed at these sessions.
9748070|NCT00383084|Active Comparator|2|Group 2 participants will attend monthly fibromyalgia educational sessions, which will focus on understanding the symptoms of FM, learning to manage pain and fatigue, and developing self-help strategies.
9748071|NCT00383110||Group 1|Adults (age 18 or older) with type 2 diabetes.
9748072|NCT00383123|Experimental|Fluarix Group|"Subjects in this group received Fluarix™ and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
9748073|NCT00383123|Active Comparator|Fluzone Group|"Subjects in this group received Fluzone and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
9748074|NCT00383149|Experimental|Ixabepilone plus Cetuximab|All participants were administered ixabepilone at a starting dose of 32 mg/m^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m^2 IV over 1 hour).
9748075|NCT00383162|Other|Combination Product - Placebo|Combination product (sumatriptan and naproxen sodium) [Attack 1] followed by placebo [Attack 2]
9748076|NCT00383162|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
9748077|NCT00383188|Placebo Comparator|1|
9748078|NCT00383188|Experimental|2|
9748079|NCT00383188|Experimental|3|
9748080|NCT00383188|Experimental|4|
9748081|NCT00383188|Experimental|5|
9748082|NCT00383266|Experimental|Pemetrexed + Carboplatin|"Pemetrexed 500 mg/m^2 IV over 10 minutes~Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle~Each cycle will last 21 days."
9748083|NCT00383292|Experimental|Tasisulam|
9748084|NCT00383331|Experimental|A|
9748085|NCT00383331|Experimental|B|
9748086|NCT00383448|Experimental|Treated Patients|Patients receiving chemotherapy (Hydroxyurea, Alemtuzumab, Clofarabine, Melphalan), Hematopoietic Stem Cell Transplantation and radiation therapy (Total body Irradiation) mycophenylate mofetil and cyclosporine A.
9748087|NCT00383500|Experimental|Flexitouch device|Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)
9748088|NCT00383500|Experimental|Manual Lymphatic Drainage (MLD)|Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment
9748089|NCT00383500|No Intervention|Observational Control (no intervention)|Control group, no intervention. No Flexitouch or manual massage therapy
9748090|NCT00383565|Experimental|Arm I|Patients receive FR901228 IV over 4 hours on days 1, 8, and 15.
9748091|NCT00383643|Placebo Comparator|Placebo|Eligible subjects randomized to this arm received placebo as gelatin capsule and a liquid capsule to fully maintain the blind.
9748092|NCT00383643|Active Comparator|Zolpidem tartrate|Eligible subjects randomized to this arm received zolpidem as gelatin capsule and a placebo liquid capsule to fully maintain the blind.
9748093|NCT00383643|Active Comparator|Sodium oxybate|Eligible subjects randomized to this arm received placebo as gelatin capsule and a sodium oxybate capsule to fully maintain the blind.
9748094|NCT00383747|Active Comparator|Nicotine Patch|
9748095|NCT00383747|Placebo Comparator|Placebo Nicotine Patch|
9748096|NCT00383760|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV on days 1 and 8.
9748097|NCT00383786|Experimental|GR205171|selective neurokinin-1 receptor antagonist, fixed 5 mg dose every day, for 8 weeks.
9748098|NCT00383786|Placebo Comparator|placebo|sugar pill
9748099|NCT00383942|Active Comparator|Misoprostol|Patients randomized to this arm will receive 25 micrograms of misoprostol every four hours.
9748100|NCT00383942|Experimental|EASI Catheter|Patients randomized to this arm will receive extra amniotic saline infusion (EASI) administered via catheter
9748101|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
9748102|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 100 mg|
9748103|NCT00384033|Placebo Comparator|Placebo|
9748104|NCT00384033|Other|Duloxetine 60mg|Active control to assess assay sensitivity
9748105|NCT00384059|Experimental|1|13-valent pneumococcal vaccine
9748106|NCT00384059|Active Comparator|2|7-valent pneumococcal vaccine
9748107|NCT00384085|Experimental|Lantus/Apidra-3|Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
9748108|NCT00384085|Experimental|Lantus/Apidra-1|Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
9748109|NCT00384085|Experimental|Novolog Mix 70/30|Premixed insulin (Novolog® Mix 70/30) added to oral agents.
9748110|NCT00384176|Active Comparator|1|Bevacizumab + FOLFOX
9748111|NCT00384176|Experimental|2|Cediranib + FOLFOX
9748112|NCT00384189|Active Comparator|Ciclesonide 40 µg|Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
9748113|NCT00384189|Active Comparator|Ciclesonide 80 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
9748114|NCT00384189|Active Comparator|Ciclesonide 160 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
9748115|NCT00384189|Placebo Comparator|Placebo|Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
9748116|NCT00384241||Children|Children age 15-19, self reported as African American of European Origin, healthy non-smoker, with normal blood pressure, exposed to an activity to that results in induced stress
9748117|NCT00384241||Parents|Collection of buccal swab Parent of participants in the Children Arm
9748118|NCT00384332|Experimental|Arm 1|Orally disintegrating olanzapine
9748119|NCT00384332|Experimental|Arm 2|regular olanzapine
9748120|NCT00384397|Experimental|Group 1: Menactra® Vaccine|Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.
9748121|NCT00384397|Experimental|Group 2: Menactra® + MMRV|Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months
9748122|NCT00384397|Experimental|Group 3: Menactra® + PCV|Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months
9748123|NCT00384449|Experimental|Lucentis (ranibizumab)|Lucentis (ranibizumab)
9748124|NCT00384670|Experimental|Dengue and Japanese Encephalitis vaccine|1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5.
9748125|NCT00384748|Experimental|Tele-visit Group|TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
9748126|NCT00384748|Active Comparator|Usual Care Group|Patients randomized to the Usual Care group receive routine VA care, as directed by their physicians. Therapy services are tracked via a weekly diary for the entire 6 month study period. In this weekly diary, patients in both the usual care and intervention group will record receipt of therapy. Usual Care group will be asked whether they exercised, and if so how frequently. They will be administered telephone interviews at baseline, 3-and 6-months. The interview outcome measures are FONEFIM, Late-Life Function and Disability Instrument, Falls Self Efficacy Scale and Stroke Specific Patient Satisfaction with Care. In addition, sociodemographics, stroke severity, length of time since stroke onset, and depression at baseline will be measured.
9748127|NCT00384774|Experimental|Lasmiditan|Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
9748128|NCT00384774|Placebo Comparator|Placebo|Participants received intravenous infusion of placebo solution.
9748129|NCT00384813|Experimental|1: Home-based family intervention|Home-based family intervention
9748130|NCT00384813|Active Comparator|2: ETAU|Enhanced Treatment As Usual (1 home visit)
9748131|NCT00384839|Experimental|1|azacitidine for injectable suspension
9748132|NCT00384865|Active Comparator|Aspirin 81 mg + Simvastatin 40 mg|"Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months~Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months"
9748133|NCT00384865|Active Comparator|Aspirin 81 mg + Placebo|"Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
9748134|NCT00384865|Active Comparator|Placebo + Simvastatin 40 mg|"Placebo taken orally, once a day for 6 months~Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months"
9748135|NCT00384865|Placebo Comparator|Placebo + Placebo|"Placebo taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
9748136|NCT00384930|Placebo Comparator|1|placebo tablet
9748137|NCT00384930|Active Comparator|2|2.5 mg tadalafil tablet
9748138|NCT00384930|Active Comparator|3|5 mg tadalafil tablet
9748139|NCT00384930|Active Comparator|4|10 mg tadalafil tablet
9748140|NCT00384930|Active Comparator|5|20 mg tadalafil tablet
9517374|NCT03306836|Experimental|Standard dose group of Heparin Sodium|First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.
9748141|NCT00384956|Experimental|Azacitidine|Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
9748142|NCT00385008|Other|Arm 1|open-label active drug
9748143|NCT00385008|Other|Arm 2|open-label active drug
9748144|NCT00385138|Experimental|Cangrelor|cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
9748145|NCT00385138|Active Comparator|Clopidogrel|placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
9748146|NCT00385216|Active Comparator|Nicotine nasal spray|In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.
9748147|NCT00385216|Placebo Comparator|Placebo spray|In one sitting the subject will receive a placebo nasal spray (0 mg), one application.
9748148|NCT00385255|Experimental|BOOSTRIX+FLUARIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
9748149|NCT00385255|Experimental|FLUARIX BOOSTRIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
9748150|NCT00385268|Experimental|Active medication Acamprosate|1998mg/day for 8 weeks
9748151|NCT00385268|Placebo Comparator|Placebo|placebo pills for 8 weeks
9748152|NCT00385541|Active Comparator|A|Patients receive morphine 1mg/dose PCA for postsurgical pain; max 10 mg/hr; lockout 6 minutes.
9748153|NCT00385541|Active Comparator|B|Patients receive hydromorphone 0.2mg/dose PCA for postsurgical pain; max 10mg/hr; lockout 6 minutes.
9748154|NCT00385580|Experimental|1|
9748155|NCT00385580|Experimental|2|
9748156|NCT00385671|Active Comparator|Pregabalin|Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US & Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US & Germany) or 150 mg BID (Canada), PO for 10 weeks.
9748157|NCT00385671|Experimental|Duloxetine|Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
9748158|NCT00385671|Experimental|Gabapentin + Duloxetine|Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.
9748159|NCT00385684|Experimental|A1: hydrocodone/APAP w placebo PRN|This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
9748160|NCT00385684|Placebo Comparator|A2: placebo w hydrocodone/APAP PRN|This is a fully crossed study, each participant serves as his own control. Phase A: Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
9748161|NCT00385684|Active Comparator|B: Open label hydrocodone/acetaminophen|Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
9748162|NCT00385723|Experimental|1|1.25 g/d
9748163|NCT00385723|Experimental|2|2.496 g/d
9748164|NCT00385723|Placebo Comparator|3|
9748165|NCT00385736|Experimental|Adalimumab 80/40|
9748166|NCT00385736|Experimental|Adalimumab 160/80/40|
9748167|NCT00385736|Placebo Comparator|Placebo|
9748168|NCT00385788|Experimental|Gemcitabine + Fludarabine + Melphalan|Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
9748169|NCT00385788|Experimental|Fludarabine + Melphalan|Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
9748170|NCT00385801|Placebo Comparator|Placebo|Identical placebo tablets and injections
9748171|NCT00385801|Active Comparator|risperidone consta|Risperidone 1-2 mg tablets and Risperidone 25 mg injections
9782217|NCT01169636|Experimental|ICE Chemotherapy|Phase 2: Routine ICE Chemotherapy (Ifosfamide, Carboplatin, + Etoposide)
9782218|NCT01169636|Experimental|Panobinostat + ICE|Phase 2: Panobinostat with ICE Chemotherapy
9782219|NCT01169649|Experimental|islet cell carcinomas and carcinoid tumors|This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
9782220|NCT01169675|Experimental|BIBW 2992 low dose|patient receives low dose tablet BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
9748172|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (CNTO 328) (Part 1)|In Part 1, mitoxantrone 12 milligram per square meter (mg/m^2) will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kilogram (mg/kg) intravenously as a 2 hour-infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
9748173|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kg intravenously as a 2-hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
9748174|NCT00385827|Active Comparator|Mitoxantrone+Prednisone (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
9748175|NCT00385840|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9748176|NCT00385840|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9748177|NCT00385918|Experimental|Lokomat training|Subjects will receive active exercise treatment in the Lokomat device 3 times per week for 3 months. Each session will last approximately 45 minutes.
9748178|NCT00385918|Active Comparator|Home stretching then Lokomat training|Patients will participate in a home stretching program for 3 months. They will then be crossed over to an active Lokomat treatment for a subsequent 3 months.
9748179|NCT00385944|Experimental|Prasugrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
9748180|NCT00385944|Active Comparator|Clopidogrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
9748181|NCT00385996|Experimental|Erlotinib|Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
9748182|NCT00386009|Placebo Comparator|1|Placebo
9748183|NCT00386009|Active Comparator|2|tadalafil
9748184|NCT00386022|Experimental|Young postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
9748185|NCT00386022|Experimental|Older postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
9748186|NCT00386100|Placebo Comparator|Metformin|MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
9748187|NCT00386100|Active Comparator|Avandamet (Rosiglitazone maleate/metformin hydrochloride)|AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg
9748188|NCT00386152|Experimental|epoetin alfa (120,000 Units)|epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
9748189|NCT00386152|Experimental|epoetin alfa (80,000 Units)|epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
9748190|NCT00386152|Active Comparator|darbepoetin alfa (500 mcg)|darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
9748191|NCT00386243|No Intervention|Usual Care|Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.
9748192|NCT00386243|Experimental|Stepped Care|Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.
9748193|NCT00386256|Experimental|Health Buddy outpatient|Received home telehealth monitoring by Health Buddy
9748194|NCT00386256|Experimental|Telephone outpatient|
9748195|NCT00386256|Experimental|health buddy inpatient|
9748196|NCT00386256|Experimental|telephone inpatient|
9748197|NCT00386308|Experimental|1|
9748198|NCT00386308|Placebo Comparator|2|
9748199|NCT00386334|Placebo Comparator|Placebo|Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
9782221|NCT01169675|Experimental|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
9517375|NCT03306836|Active Comparator|Low dose group of Heparin Sodium|infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.
9517376|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
9517377|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
9748200|NCT00386334|Experimental|Eszopiclone|Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
9748201|NCT00386360|Placebo Comparator|Placebo|Placebo dose
9748202|NCT00386360|Experimental|Risedronate|35 mg risedronate, orally, once weekly
9748203|NCT00386425|Experimental|Standard therapy|24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
9748204|NCT00386425|Experimental|Alternative therapy:moderate protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
9748205|NCT00386425|Experimental|Alternative therapy:severe protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
9748206|NCT00386477|Experimental|Vag prep|Vagina cleansed prior to performing cesarean
9748207|NCT00386607|Experimental|Core Treatment|Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
9748208|NCT00386607|Experimental|Extension Treatment|"For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.~The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits."
9748209|NCT00386776|Experimental|'Computer-based medical history|A computer-based medical history to take in their homes via the Internet. The history is divided into 24 modules- family history, social history, cardiac history, pulmonary history, and the like.
9748210|NCT00386880||Subjects with episodic migraine with allodynia|These are subjects with episodic migraine with allodynia
9748211|NCT00386880||Subjects with episodic migraine without allodynia|Subjects with episodic migraine without allodynia
9748212|NCT00387010|Experimental|fentanyl buccal tablets|Successful dose strength for each participant was determined during a titration period of no more than 10 days. Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
9748213|NCT00387023|Experimental|Zevalin + Rituximab|Rituximab 250 mg/m^2 intravenous (IV) over 4-6 hours for 2 weeks, + Zevalin 5 millicurie (mCi)/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
9748214|NCT00387036|Other|1|Arm 1: drug, crossing over to Pbo comparator
9748215|NCT00387036|Other|2|Arm 2: Pbo comparator, crossing over to drug
9748216|NCT00387088|Other|Tiotropium|Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
9748217|NCT00387088|Other|Placebo|Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
9748218|NCT00387127|Experimental|Lapatinib|1500mg lapatinib orally daily
9748219|NCT00387127|Placebo Comparator|Placebo|orally daily
9748220|NCT00387335|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9748221|NCT00387348|Placebo Comparator|Placebo-Placebo|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
9748222|NCT00387348|Other|Placebo-Escitalopram|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
9748223|NCT00387348|Other|Escitalopram-Placebo|Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks
9748224|NCT00387426|Experimental|Arm I|Patients receive oral sunitinib malate once daily for 6 weeks.
9748225|NCT00387465|Experimental|Phase I - 30mg/m2 Azacitidine|Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
9748226|NCT00387465|Experimental|Phase I - 40mg/m2 Azacitidine|Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
9748227|NCT00387465|Experimental|Phase II Arm|Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9748228|NCT00387621|Experimental|Placebo First, then Nesiritide (Arm A)|In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
9782222|NCT01169675|Experimental|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
9782223|NCT01169675|Experimental|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
9748229|NCT00387621|Experimental|Nesiritide First, then Placebo (Arm B)|In the first intervention period the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
9517378|NCT03306810|Active Comparator|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
9748230|NCT00387647|Experimental|Azacitidine Treatment|Azacitidine 50 mg/m^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
9748231|NCT00387660|Experimental|Metastatic SCLC|Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
9748232|NCT00387660|Experimental|Relapsed SCLC|Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles
9748233|NCT00387712|Experimental|Velocity based treadmill training|6 month of progressive treadmill walking with treadmill speed gradually progressed to meet the training heart rate goals for moderate intensity aerobic exercise, when hemiparetic gait velocity can no longer be safely progressed, incline is added to achieve the heart rate training goals.
9748234|NCT00387712|Experimental|Duration based treadmill training|6 month of progressive treadmill walking with duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress.
9748235|NCT00387725|Experimental|Group A|20ug Experimental
9748236|NCT00387725|Experimental|Group 2|60ug Experimental
9748237|NCT00387725|Experimental|Group 3|200ug Experimental
9748238|NCT00387725|Active Comparator|Group 4|Active comparator
9782224|NCT01169675|Experimental|BIBW 2992 medium dose 6 day|patient receives medium BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
9782225|NCT01169675|Experimental|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
9782226|NCT01169701|Active Comparator|Tacrolimus|Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).
9782227|NCT01169701|Experimental|Everolimus|Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.
9782228|NCT01169779|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD up to Week 24.
9782229|NCT01169779|Placebo Comparator|Placebo|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, followed by 20 mcg QD up to Week 24.
9782230|NCT01169844|Experimental|AIN457/AIN457 3 mg/kg.|Participants who were treated with secukinumab 2x10 mg/kg during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
9782231|NCT01169844|Placebo Comparator|Placebo/AIN457 3 mg/kg.|Participants who were treated with placebo during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
9785462|NCT01252667|Experimental|Part 1 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
9785463|NCT01252667|Experimental|Part 2 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
9785769|NCT01259492|Experimental|Ritalin LA 40 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2, continued in same dose till week 9. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
9517379|NCT03306810|No Intervention|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
9517380|NCT03306797|Experimental|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
9517381|NCT03306797|Other|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
9748239|NCT00387751|Experimental|Arm I|Patients receive oral sorafenib tosylate on days 1-5, 8-12, 15-19, and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
9748240|NCT00387764|Experimental|pazopanib arm|This was a single arm study, therefore no control arm.
9748241|NCT00387790|Experimental|Arm I|Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9748242|NCT00387829|Active Comparator|1|Use of DuraGen Plus Adhesion Barrier Matrix as an adhesion barrier in the spine
9748243|NCT00387829|No Intervention|2|Control arm is surgery alone (no adhesion barrier)
9748244|NCT00387881|Placebo Comparator|Placebo|
9748245|NCT00387881|Experimental|Treximet|
9748246|NCT00387894|Experimental|erlotinib hydrochloride (Tarceva)|During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
9748247|NCT00387959|Experimental|Unrelated Donor Umbilical Cord Transplant|Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilixal Cord Blood
9748248|NCT00388037|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9748249|NCT00388154|Experimental|Gemcitabine + Cisplatin|Gemcitabine 900 mg/m^2 by vein (IV) over 1 hour on Day 1 and Day 8. Cisplatin 30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
9748250|NCT00388297|Experimental|Levothyroxine for Subclinical Hypothyroidism|100 µg of Levothryoxine for participants with subclinical hypothyroidism
9748251|NCT00388297|Placebo Comparator|Placebo for Levothyroxine - Subclinincal Hypothyroidism|Placebo for Levothyroxine for participants with subclinical hypothyroidism
9748252|NCT00388297|Experimental|Levothyroxine for Hypothyroxinemia - Hypothyroxinemia|50 µg of Levothyroxine for participants with hypothyroxinemia
9748253|NCT00388297|Placebo Comparator|Placebo for Levothyroxine|Placebo for Levothyroxine for participants with hypothyroxinemia
9748254|NCT00388349|Experimental|Gemcitabine + Autologous HCT|Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.
9748255|NCT00388362|Experimental|Sirolimus Therapy|Administration of Sirolimus and Prednisone
9748256|NCT00388414|Placebo Comparator|Placebo - sugar pill|
9748257|NCT00388414|Experimental|Duloxetine|
9748258|NCT00388453|Active Comparator|1|Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
9748259|NCT00388453|Experimental|2|subject is known to have GERD based on symptoms and previous positive response to PPI
9748260|NCT00388453|Experimental|3|subject is known to have EERD based on symptoms and previous positive response to PPI
9748261|NCT00388505|Experimental|Tobramycin inhalation powder (TIP)|Participants received four 28 mg capsules of tobramycin inhalation powder (TIP) delivered with the T-326 inhaler twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
9748262|NCT00388505|Active Comparator|Tobramycin solution for inhalation (TOBI)|Participants received one 300 mg (in 5 mL) ampoule of tobramycin solution for inhalation (TOBI) delivered with a nebulizer twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
9748263|NCT00388583|Experimental|Fluzone Intradermal (ID) Vaccine Group|Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine
9748264|NCT00388583|Active Comparator|Fluzone Intramuscular (IM) Vaccine Group|Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.
9748265|NCT00388674||A|
9748266|NCT00388674||B|
9748267|NCT00388726|Experimental|1|
9748268|NCT00388726|Active Comparator|2|
9748269|NCT00388804|Active Comparator|RT Group 1|Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
9748270|NCT00388804|Active Comparator|RT Group 2 + Hormone Therapy|Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)
9748271|NCT00388947||1|AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)
9748272|NCT00389064|Experimental|Quetapine XR|Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily.
9748273|NCT00389064|Placebo Comparator|Placebo|Matching placebo tablets orally administered once daily.
9748274|NCT00389168|Experimental|Irbesartan|Irbesartan per os titrated to 300 mg od, 48 weeks
9748275|NCT00389168|Active Comparator|Atenolol|Atenolol per os titrated to 100 mg od, 48 weeks
9748276|NCT00389207|Active Comparator|NVP bid|nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
9748277|NCT00389207|Experimental|NVP qd|nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
9748278|NCT00389207|Active Comparator|ATZ/r|ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
9748279|NCT00389324|Experimental|Immune Globulin Intravenous (Human)|Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
9748280|NCT00389441|Experimental|A|
9748281|NCT00389467|Active Comparator|1 Mechanical Embolectomy|Participants will be randomized to receive mechanical embolectomy treatment either with the Merci Retriever or Penumbra System and standard medical care or treatment with standard medical care alone.
9748282|NCT00389467|No Intervention|2|standard medical care
9748283|NCT00389493|Active Comparator|1|Participants will receive treatment with risperidone
9748284|NCT00389493|Active Comparator|2|Participants will receive exposure and ritual prevention therapy (EX/RP)
9748285|NCT00389493|Placebo Comparator|3|Participants will receive treatment with the placebo
9748286|NCT00389519|Placebo Comparator|Placebo|once per day
9748287|NCT00389519|Experimental|ramipril low dose|0.3125, 0.625, or 1.25 mg once a day, based on subject weight
9748288|NCT00389519|Experimental|ramipril mid dose|1.25, 2.5, or 5 mg once a day, based on subject weight
9748289|NCT00389519|Experimental|ramipril high dose|5, 10, or 20 mg once a day, based on subject weight
9748290|NCT00389532|Experimental|1|aged 19 to 59 years
9748291|NCT00389532|Experimental|2|aged ≥ 60 years
9748292|NCT00389597|Experimental|1 Level|Cervical artificial disc (investigational device) at 1 level compared with control procedure (ACDF) at one level
9748293|NCT00389597|Experimental|2 Level|Cervical artificial disc (investigational device) at 2 levels compared with control procedure (ACDF) at two levels
9748294|NCT00389818|Experimental|DR-COP|Single arm interventional study: all subjects receive DR-COP regimen.
9748295|NCT00389831|Placebo Comparator|Placebo|Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
9748296|NCT00389831|Experimental|Rotigotine Nasal Spray|Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
9748297|NCT00389857|Experimental|Influenza vaccine-naive group|Participants have never received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0 and Day 28, respectively.
9748298|NCT00389857|Experimental|Influenza vaccine-primed group|Participants have received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0.
9748299|NCT00389974|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
9748300|NCT00390013|Active Comparator|Gabapentin|Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
9748301|NCT00390013|Placebo Comparator|Placebo oral capsule|Placebo titration and dosing for total of 8 weeks (Cross over)
9748302|NCT00390182|Experimental|Single Arm|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy."
9748303|NCT00390221|Placebo Comparator|Placebo|Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
9748304|NCT00390221|Experimental|150 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
9748305|NCT00390221|Experimental|300 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
9748306|NCT00390234|Experimental|Treatment (ziv-aflibercept)|Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
9748307|NCT00390299|Experimental|Arm A (resection cavity administration)|Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
9748308|NCT00390299|Experimental|Arm B (intratumoral and resection cavity administration)|Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
9748309|NCT00390325|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.
9748310|NCT00390416|Experimental|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
9748311|NCT00390429|Experimental|Phase I, Group I (completed)|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride once on days 2, 9, and 16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
9748312|NCT00390429|Experimental|Phase I, Group II (completed)|Patients receive docetaxel as in group I and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
9748313|NCT00390429|Experimental|Phase II|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride at the MTD determined in group II of phase I once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then continue to receive erlotinib hydrochloride alone in the absence of disease progression or unacceptable toxicity.
9748314|NCT00390455|Experimental|Arm I (lapatinib)|Patients receive lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 and 15 of course 1 and on day 1 of each subsequent course. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9748315|NCT00390455|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 and fulvestrant as in Arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9748316|NCT00390468|Experimental|Tandutinib (MLN518)|500 mg twice daily, a small-molecule inhibitor of the type III receptor tyrosine kinases. Tandutinib (MLN518) previously known as CT53518.
9748317|NCT00390546|Experimental|Propranolol|Single dose of 0.5 mg/kg per dose and increased to 1.0 mg/kg per dose ITD for the second and subsequent doses.
9748318|NCT00390546|Experimental|Digoxin|First 2 doses at 0.010 mg/kg per dose TID, then 0.0035 mg/kg per dose TID for the third and subsequent doses
9748319|NCT00390559|Experimental|ActiveP/ActiveC|21 mg patch/Nicotine-containing cigarette
9748320|NCT00390559|Experimental|PlaceboP/ActiveC|0 mg patch/nicotine-containing cigarette
9748321|NCT00390559|Experimental|Active P/PlaceboC|21 mg patch/no nicotine cigarette
9748322|NCT00390559|Experimental|PlaceboP/PlaceboC|0 mg patch/no nicotine cigarette
9748323|NCT00390572|Experimental|Sleep Specialty Consultation|Participants randomized to receive a one-time sleep consultation at beginning of study
9748324|NCT00390572|No Intervention|Treatment as Usual|Participants randomized to receive a one-time sleep consultation after completing study procedures (after 10 month study wait-list period).
9748325|NCT00390611|Active Comparator|Paclitaxel/Carboplatin/Sorafenib|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV, Day 1 Sorafenib 400mg PO bid
9748326|NCT00390611|Active Comparator|Paclitaxel/carboplatin|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV
9748327|NCT00390689|Experimental|Pramipexole 0.25 mg once daily|Pramipexole 0.25 mg given once daily
9748328|NCT00390689|Experimental|Pramipexole 0.5 mg once daily|Pramipexole 0.5 mg given once daily
9748329|NCT00390689|Experimental|Pramipexole 0.75 mg once daily|Pramipexole 0.75 mg given once daily
9748330|NCT00390780|Active Comparator|Clotrimazole|Clotrimazole troches, 10 mg, 5 times per day for 14 days
9748331|NCT00390780|Experimental|miconazole Lauriad|Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days
9748332|NCT00390806|Experimental|topotecan plus radiation|topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
9748333|NCT00390806|Active Comparator|Whole brain radiation|Whole brain radiation 3 Gy/day for 10 days
9748334|NCT00390858|Experimental|Deferasirox|Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
9748335|NCT00390884|Experimental|Fluzone®-Primed Group|Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
9748336|NCT00390884|Experimental|Fluzone®-Naive Group|Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
9748337|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group I|Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)
9748338|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group II|Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
9748339|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group III|Infants born after a gestation period of more than 36 weeks (more than 258 days)
9748340|NCT00390949|Experimental|Intervention arm|Peer education with female sex workers and potential male clients. Strengthened syndromic management of STIs with community-based promotion activities
9748341|NCT00390949|No Intervention|Control|Standard of care
9748342|NCT00391027|Active Comparator|Insulin Glargine (Lantus®)|
9748343|NCT00391027|Active Comparator|Inhaled Human Insulin (Exubera®)|
9748344|NCT00391053|Experimental|Study Group 1|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1
9748345|NCT00391053|Experimental|Study Group 2|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2
9748346|NCT00391053|Experimental|Study Group 3|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3
9748347|NCT00391053|Active Comparator|Group 4|Participants will receive the Standard Fluzone® vaccine
9748348|NCT00391079|Experimental|A|
9748349|NCT00391079|Placebo Comparator|B|
9748350|NCT00391092|Experimental|1|
9748351|NCT00391092|Active Comparator|2|
9748352|NCT00391118|Experimental|A (Part A)|"Enzastaurin: 1125 milligram (mg) loading dose then 500 mg oral tablet, daily for six 21-day cycles or up to 3 years~Carboplatin: Area under the concentration time curve (AUC) 5 intravenous (IV), every (q) 21 days for six 21-day cycles~Paclitaxel:175 milligrams/square meter (mg/m²) IV, q21 days for six 21-day cycles"
9748353|NCT00391118|Placebo Comparator|B (Part B)|"Carboplatin: AUC5 IV, q21 days for six 21-day cycles~Paclitaxel: 175 mg/m², IV, q21 days for six 21-day cycles~Placebo: oral tablet"
9748354|NCT00391222|Experimental|001|Risperidone Long Acting Injectable (LAI) Intramuscular injections of risperidone LAI (25 37.5 or 50 mg) every 2 weeks and oral placebo daily
9748355|NCT00391222|Placebo Comparator|002|Placebo Intramuscular injections of placebo every 2 weeks and oral placebo daily
9748356|NCT00391222|Active Comparator|003|Olanzapine Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
9748357|NCT00391274|Experimental|Pemetrexed|
9748358|NCT00391274|Active Comparator|Docetaxel|
9748359|NCT00391365||Group 1|Subjects undergoing ankle arthrodesis (fusion) for treatment of ankle arthritis
9748360|NCT00391365||Group 2|Subjects undergoing ankle arthroplasty (replacement) for treatment of ankle arthritis
9748361|NCT00391391|Experimental|1|Split, Inactivated, Trivalent Influenza Vaccine
9748362|NCT00391391|Experimental|2|Split, Inactivated, Trivalent Influenza Vaccine
9748363|NCT00391391|Active Comparator|3|Split, Inactivated, Trivalent Influenza Vaccine
9748364|NCT00391391|Active Comparator|4|Split, Inactivated, Trivalent Influenza Vaccine
9748365|NCT00391443|Experimental|Bosentan|Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight > 40 kg) or bosentan 62.5 mg b.i.d. (if body weight < 40 kg)
9748366|NCT00391443|Placebo Comparator|Placebo|Subjects receive placebo matching the bosentan treatment regimen
9748367|NCT00391469|No Intervention|control treatment|
9748368|NCT00391586|Experimental|Erlotinib followed by chemotherapy|"Erlotinib: 150 mg orally once daily,~Platinum-based chemotherapy regimen selections include:~Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:~Docetaxel 75 mg/m2, D1~Docetaxel 35 mg/m2, D1,8,15~Paclitaxel 200-225 mg/m2, D1~Paclitaxel 80-100 mg/m2, D1,8,15~Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:~Etoposide 100 mg/m2 D1-3~Etoposide 200 mg/m2 orally D1-3~Pemetrexed 500 mg/m2, D 1~Irinotecan 50 mg/m2 D1,8,15~Other regimens:~Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8~Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1"
9748369|NCT00391599|Experimental|Study Group|a fleet enema (250 cc of sodium biphosphate 16 gr and sodium phosphate 6 gr per 100 cc) the night before cesarean section
9748370|NCT00391599|Active Comparator|Control Group|no preoperative intestinal preparation.
9748371|NCT00391625|Experimental|GA-GCB|15-60 U/kg every other week via intravenous infusion
9748372|NCT00391716|Experimental|gabapentin 900mg daily|900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
9748373|NCT00391716|Experimental|gabapentin 1800mg daily|1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
9748374|NCT00391716|Placebo Comparator|placebo daily|placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
9748375|NCT00391768|Experimental|oseltamivir (Tamiflu®)|
9748376|NCT00391807|Experimental|study drug|Norethindrone/Ethinyl Estradiol
9748377|NCT00391846|Other|Guided by NT-proBNP|Treatment guided by clinical symptoms and signs + NTproBNP
9748378|NCT00391846|Other|Not Guided by NT-proBNP|Treatment guided by clinical symptoms and signs
9748379|NCT00391872|Active Comparator|Clopidogrel|Oral treatment
9748380|NCT00391872|Experimental|Ticagrelor|Oral treatment
9748381|NCT00391898|Experimental|Levodopa/carbidopa/entacapone|
9748382|NCT00391898|Active Comparator|Levodopa/carbidopa|
9748383|NCT00391976|Experimental|Tobramycin 300 mg for 28 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
9748384|NCT00391976|Experimental|Tobramycin 300 mg for 56 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
9748385|NCT00392015|Experimental|Dose-escalation|NMRC-M3V-Ad-PfCA
9748386|NCT00392015|Experimental|Regimen-comparison|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
9748387|NCT00392041|Experimental|Eszopiclone|
9748388|NCT00392041|Placebo Comparator|Placebo|
9748389|NCT00392054|Experimental|Catheter Ablation|Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
9748390|NCT00392054|Active Comparator|Antiarrhythmic Drug Therapy|Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation
9748391|NCT00392171|Experimental|Temozolomide|Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
9748392|NCT00392210|No Intervention|Spontaneous Fill|
9748393|NCT00392210|Active Comparator|Retrograde Fill|
9748394|NCT00392223|Experimental|Treatment Group A|
9748395|NCT00392223|Experimental|Treatment Group B|
9748396|NCT00392236|Experimental|A|Participants will receive treatment as usual and a 2-way pager for 6 months
9748397|NCT00392236|Active Comparator|B|Participants will receive treatment as usual
9748398|NCT00392288|Placebo Comparator|Placebo MDI|double-blind
9748399|NCT00392288|Experimental|Ciclesonide MDI 40 µg BID|double-blind
9748400|NCT00392288|Experimental|Ciclesonide MDI 80 µg BID|double-blind
9748401|NCT00392379|Experimental|A|4 mg nicotine lozenges for 3 months
9748402|NCT00392379|Placebo Comparator|B|Placebo nicotine lozenges for 3 months
9748403|NCT00392392|Experimental|Intervention|Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.
9748404|NCT00392444|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
9748405|NCT00392496|Experimental|Arm I|This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
9748406|NCT00392665|Active Comparator|Erlotinib + Bevacizumab|erlotinib plus bevacizumab
9748407|NCT00392665|Active Comparator|Erlotinib + Sulindac|erlotinib plus sulindac
9748408|NCT00392678|Placebo Comparator|Placebo|Placebo, appearance matched to active drug
9748409|NCT00392678|Active Comparator|3 gram|Salsalate 3.0 grams daily, divided
9748410|NCT00392678|Active Comparator|3.5 gram|Salsalate 3.5 g daily, divided
9748411|NCT00392678|Active Comparator|4 gram|Salsalate 4.0 g daily, divided
9748412|NCT00392704|Experimental|Intervention|"All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.~One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
9748413|NCT00392769|Experimental|Cetuximab|400 mg/m^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m^2 IV over 60 minutes.
9748414|NCT00392782|Experimental|Natural Killer Cell Kir Epitope|
9748415|NCT00392808|Experimental|MENC-CRM/MENC-CRM|Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
9748416|NCT00392808|Experimental|MENC-CRM/MENC-TT|Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
9748417|NCT00392808|Experimental|MENC-TT/MENC-CRM|Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
9748418|NCT00392808|Experimental|MENC-TT/MENC-TT|Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine
9782232|NCT01169987||Participants Treated with Adalimumab|Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
9782233|NCT01170039|Active Comparator|Lubiprostone|
9782234|NCT01170039|Placebo Comparator|Placebo|
9828958|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
9828959|NCT02515305|Experimental|Test product|
9828960|NCT02515305|Active Comparator|Reference product|
9828961|NCT02515305|Placebo Comparator|Placebo product|
9828962|NCT02515331|Experimental|LHW090 100 mg|LHW090 100 mg once daily for 28 days
9828963|NCT02515331|Experimental|LHW090 200 mg|LHW090 200 mg once daily for 28 days
9828964|NCT02515331|Placebo Comparator|Placebo|Matching placebo to LHW090 oral dose for 28 days
9828965|NCT02515630|Experimental|Momelotinib|MMB for 24 weeks (± 7 days)
9828966|NCT02515656|Experimental|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
9828967|NCT02515656|Active Comparator|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
9828968|NCT02515669|Active Comparator|RO7239361|RO7239361 subcutaneous injections on specified days
9828969|NCT02515669|Placebo Comparator|Placebo|Placebo subcutaneous injections on specified days
9828970|NCT02515825||AMBIENCE|CADence System testing followed by coronary angiogram
9828971|NCT02515825||AMBIENCE plus R&R Substudy|CADence System testing for repeatibility and reproducibility (4x by 2 operators) followed by coronary angiogram
9828972|NCT02515890|Experimental|Dexmedetomidine Only|All subjects receive saline (control), followed by a dexmedetomidine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
9828973|NCT02515890|Experimental|Midazolam Only|Subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
9828974|NCT02515890|Experimental|Ketamine Only|All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
9828975|NCT02515890|Experimental|Saline/Midazolam/Saline/Ketamine|"All subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by ketamine infusion."
9828976|NCT02515890|Experimental|Saline/Ketamine/Saline/Midazolam|"All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by midazolam infusion."
9828977|NCT02515942|Experimental|CLG561|CLG561 10 mg, one IVT injection every 28 days for a total of 12 injections
9828978|NCT02515942|Experimental|CLG561+LFG316|CLG561 5mg + LFG316 5 mg, one IVT injection every 28 days for a total of 12 injections
9828979|NCT02515942|Sham Comparator|Sham Injection|One sham injection every 28 days for total of 12 sham injections
9828980|NCT02515994|Experimental|senofilcon C|JJVCI investigational contact lens daily wear replacement.
9828981|NCT02515994|Active Comparator|comfilcon A|Marketed contact lens daily wear replacement.
9828982|NCT02516046|Experimental|Flortaucipir PET Scan|
9828983|NCT02516098|Active Comparator|Hyoscine butylbromide SCT|
9828984|NCT02516098|Experimental|Hyoscine butylbromide|
9828985|NCT02516150|Experimental|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
9828986|NCT02516150|Active Comparator|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
9828987|NCT02516163|Other|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
9835791|NCT02755649|Experimental|Placebo QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
9517382|NCT03306771||Metabolic syndrome risk factors|Candidates for bariatric surgery who have metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
9748420|NCT00392834|Experimental|Regimen A (R-CODOX-M chemotherapy)|Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.
9748421|NCT00392834|Experimental|Regimen B (rituximab and IVAC chemotherapy)|Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.
9748422|NCT00392925|Experimental|Placebo and Metreleptin|Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
9748423|NCT00392925|Experimental|Pramlintide Acetate and Placebo|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
9748424|NCT00392925|Experimental|Pramlintide Acetate and Metreleptin|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
9748425|NCT00392925|Other|Lead-In Period|During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).
9748426|NCT00392951|Experimental|Sirolimus treatment|Sirolimus treatment
9748427|NCT00392990|Experimental|Alternating doxil/Magrath regimen & rituximab/Magrath regimen|Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
9748428|NCT00393029|Experimental|Patients with metastatic melanoma|Melanoma is a serious form of skin cancer that develops in the skin cells that make our skin color (melanocytes).
9748429|NCT00393029|Experimental|Patients with other metastatic cancers|
9748430|NCT00393042|Experimental|Focalin XR then Adderall XR|Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.
9748431|NCT00393042|Experimental|Adderall XR then Focalin XR|Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.
9748432|NCT00393094|Experimental|Bevacizumab & Irinotecan Patients|Bevacizumab - 10 mg/kg intravenous injection Irinotecan - 125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
9748433|NCT00393367|Placebo Comparator|Saline Placebo|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.
9828988|NCT02516202|Active Comparator|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
9828989|NCT02516202|Active Comparator|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
9828990|NCT02516202|Placebo Comparator|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
9828991|NCT02516306|Experimental|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
9828992|NCT02516306|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
9828993|NCT02516332|Experimental|Supervised Aerobic Exercise|Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
9828994|NCT02516332|Experimental|Lexapro|Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
10205144|NCT03914495|Active Comparator|Inulin|Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
10205145|NCT03906708||Premature Infants|Premature infants born between 24+0 and 36+6 weeks of gestation.
10205146|NCT03906292|Experimental|Asciminib 60mg QD|Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD
10205147|NCT03906292|Experimental|Asciminb 20 mg BID|Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID
10205148|NCT03906292|Experimental|Asciminib 40 mg QD|Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD
10205149|NCT03906292|Experimental|Asciminib 80 mg QD|Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD
10205150|NCT03906292|Experimental|Asciminib 80 mg QD monotherapy|Asciminib 80 mg QD as a single agent
10205151|NCT03891966|Active Comparator|Splint|
10205152|NCT03891966|Active Comparator|Soft Dressing|
9517383|NCT03306771||No metabolic Syndrome risk factors|Candidates for bariatric surgery who lack metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
10205153|NCT03891901|Experimental|Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid|Participants will receive 50 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
10205154|NCT03891901|Experimental|Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid|Participants will receive 100 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
10205155|NCT03891901|Experimental|Cohort 1c: Imatinib (200 mg) + Rifabutin + Isoniazid|Participants will receive 200 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
10205156|NCT03891901|Experimental|Cohort 1d: Imatinib (400 mg) + Rifabutin + Isoniazid|Participants will receive 400 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
10205157|NCT03891901|Experimental|Cohort 2a: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
10205158|NCT03891901|Experimental|Cohort 2b: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
10205159|NCT03860961|Active Comparator|Standard Survivorship Care Plan (SCP)|Practices review a SCP with patients and send it to the PCP during the last week of RT.
10205160|NCT03860961|Experimental|Enhanced Survivorship Care Plan (SCP)|Practices review a treatment plan with patient and send it to the PCP at the beginning of RT. Practices also review a SCP with patients and send it to the PCP during the last week of RT.
9748434|NCT00393367|Experimental|Budesonide Inhalaiton Suspension|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.
9748435|NCT00393380|Experimental|Parathyroid Hormone (teriparatide)|Parathyroid hormone after double umbilical cord blood transplant.
9748436|NCT00393458|Experimental|Indacaterol 300 μg plus placebo to formoterol|Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9748437|NCT00393458|Experimental|Indacaterol 600 μg plus placebo to formoterol|Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9748438|NCT00393458|Active Comparator|Formoterol 12 μg plus placebo to indacaterol|Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9748439|NCT00393458|Placebo Comparator|Placebo to indacaterol plus placebo to formoterol|Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9748440|NCT00393484|Experimental|Arm A|"Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)"
9748441|NCT00393484|Active Comparator|Arm B|"Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)"
9748442|NCT00393510|Active Comparator|Traditional Chinese Medicine|12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
9748443|NCT00393510|Placebo Comparator|Placebo|Placebo was made with starch and colouring materials. Given to patient orally twice a day
9748444|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose)."
9748445|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 2)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)"
9748446|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose)."
9748447|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 4)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose)."
9748448|NCT00393523|Experimental|5 µg Modified Process Hepatitis B Vaccine (Group 5)|"Participants did not receive a prior vaccination with a hepatitis B vaccine.~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine."
10205161|NCT03859193|No Intervention|Standard care|
10205162|NCT03859193|Experimental|Video|Participants will watch an Nutritional video at their second high risk visit
10205163|NCT03854331|Experimental|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
10205164|NCT03854331|No Intervention|Standard care|Danish antenatal standard care is 3 visits at the general practitioner, 5 midwife controls and 2 ultrasound scans
10205165|NCT03847519|Experimental|Safety Phase Part A|"Enroll subjects with metastatic squamous or non-squamous NSCLC who have become refractory or intolerant to standard therapy. ADXS-503 monotherapy will be evaluated at 2 planned escalating dose levels:~Dose level 1: 1e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~Dose level 2: 5e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
9748449|NCT00393705|Experimental|insulin lispro LM + insulin lispro MM|Three times per day subcutaneous injection of insulin lispro mid mixture (MM) with the possibility to change the evening injection of MM to insulin lispro low mixture (LM) if fasting blood glucose target is not achieved.
9748450|NCT00393705|Active Comparator|Insulin Biphasic Aspart 30/70 or Insulin Lispro LM|Twice daily subcutaneous injection of either insulin biphasic aspart 30/70 or insulin lispro low mixture (LM) (continuation of analogue formulation used before study enrollment).
9748451|NCT00393718|Experimental|Liraglutide|Liraglutide 0.9 mg + glibenclamide placebo
9748452|NCT00393718|Active Comparator|Glibenclamide|Glibenclamide 1.25-2.5 mg + liraglutide placebo
9748453|NCT00393796|Active Comparator|SUTENT|Study participants randomized to received SUTENT will receive a dose of 50 mg PO (capsules) as a single agent to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
9748454|NCT00393796|Placebo Comparator|Placebo|Study participants randomized to receive placebo will receive 50 mg/day PO (capsules) of an inactive substance to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
9748455|NCT00393848|Experimental|Experiment 2 - Experimental Group|
9748456|NCT00393848|No Intervention|Experiment 1 - Standard of care Group|
9748457|NCT00393848|Experimental|Experiment 1 - Experimental Group|
9748458|NCT00393848|Placebo Comparator|Experiment 2 - Placebo Group|
9748459|NCT00393861|Experimental|oxaliplatin & bevacizumab|
9748460|NCT00393874|Active Comparator|Medication|Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
9748461|NCT00393874|Active Comparator|Behavioral|"Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES)."
9748462|NCT00393874|Placebo Comparator|Placebo|Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.
9748463|NCT00393887|Experimental|1|Biodesign IHM Graft placement
9748464|NCT00393887|Active Comparator|2|Polypropylene mesh placement
9748465|NCT00393913||Continuous Positive Airway Pressure (CPAP)|Participants will use a CPAP machine if they are found to have sleep apnea.
9748466|NCT00393939|Experimental|A|
9748467|NCT00393939|Active Comparator|B|
9748468|NCT00393978|Placebo Comparator|Quetiapine and Placebo|Quetiapine and Placebo
9748469|NCT00393978|Active Comparator|Quetiapine and Topiramate|Quetiapine and Topiramate
9748470|NCT00394082|Experimental|ABI-007 plus Bevacizumab|ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
9748471|NCT00394095|Experimental|Topiramate Group|Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
9517384|NCT03306758|Experimental|Experimental: sodium bicarbonate|
9517385|NCT03306758|No Intervention|No Intervention|
9748472|NCT00394095|Placebo Comparator|Placebo Group|Sugar pill
9748473|NCT00394212|Experimental|1|Transoral suturing of the dilated gastrojejunostomy
9748474|NCT00394212|Sham Comparator|2|Sham Endoscopy (suturing not performed)
9748475|NCT00394251|Experimental|AC --> ABI-007|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
9748476|NCT00394251|Experimental|AC --> Taxol|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
9748477|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1200 mg|
9748478|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1400/1600 mg|
9748479|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1200 mg|
9748480|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg|
9782235|NCT01170065|Experimental|BIBF 1120 low qd|Low dose BIBF 1120 once daily
9782236|NCT01170065|Experimental|BIBF 1120 low bid|Low dose BIBF 1120 twice daily
9782237|NCT01170065|Experimental|BIBF 1120 medium bid|Intermediate dose BIBF 1120 twice daily
9748481|NCT00394329|Experimental|Daily ICS + Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
9748482|NCT00394329|Active Comparator|Daily ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
9748483|NCT00394329|Experimental|Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
9748484|NCT00394329|Placebo Comparator|Placebo|Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
9748485|NCT00394433|Experimental|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA)|Patients received bevacizumab 10 mg/kg IV on day 1 every 3 weeks while on study. Additionally, they received docetaxel 30 mg/m2 IV over 30 minutes, followed by cisplatin 25 mg/m2 IV over 30 minutes, followed by irinotecan 50 mg/m2 IV over 30 minutes on days 1 and 8 of each 3-week cycle until disease progression or unacceptable toxicity. Dose reductions were not permitted for bevacizumab although treatment could be held up to 2 months. If bevacizumab was discontinued, treatment with other agents could continue. When docetaxel, cisplatin, or irinotecan was held on day 1 of a cycle, all agents were held.
9748486|NCT00394524|Experimental|Computer assisted IV insulin infusion|Subjects in this group will receive continuous intravenous (IV) Insulin Infusion using glucommander computer guided system. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
9748487|NCT00394524|Active Comparator|Standard insulin infusion algorithm|Subjects in this group will receive Insulin using Standard insulin infusion algorithm. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
9748488|NCT00394589|Experimental|Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
9748489|NCT00394589|Experimental|Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
9748490|NCT00394589|Active Comparator|Control|Continuation of infliximab 3 mg/kg every 8 weeks
9748491|NCT00394654|Experimental|MEDI528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
9748492|NCT00394654|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
9748493|NCT00394706|Experimental|1|Use of Impedance Threshold Device (ITD)
9748494|NCT00394706|Sham Comparator|2|Sham ITD
9748495|NCT00394706|Other|3|Analyze early. Upon EMS (emergency medical services) arrival at the scene of a non-traumatic cardiac arrest, the EMS providers assess the cardiac rhythm as soon as possible. Approximately thirty seconds of CPR (cardiopulmonary resuscitation) may be done prior to an assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
9748496|NCT00394706|Other|4|Analyze late. Upon the EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is done prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
9748497|NCT00394771|Experimental|Low Dose DR-1031|42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
9748498|NCT00394771|Experimental|Midrange Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
9748499|NCT00394771|Experimental|High Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
9748500|NCT00394771|Active Comparator|Seasonale|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
9748501|NCT00394888|Other|Facial Hemangioma|Patients with large facial hemangioma.
9748502|NCT00394888|Other|Lumbosacral Hemangioma|Patients with lumbosacral hemangioma.
9748503|NCT00394888|Other|Multiple Hemangiomas|patients with multiple hemangiomas (>5)
9748504|NCT00394901|Placebo Comparator|Placebo|
9748505|NCT00394901|Experimental|Pregabalin 150mg/day|
9748506|NCT00394901|Experimental|Pregabalin 300mg/day|
9748507|NCT00394901|Experimental|Pregabalin 600mg/day|
9748508|NCT00394914|Experimental|Pleconaril|Participants will receive Pleconaril nasal spray 4 sprays per nostril twice daily (BID), 24 mg/day for 1 week during the Treatment Period for a total of 14 doses.
9748509|NCT00394914|Placebo Comparator|Placebo|Participants will receive placebo nasal spray 4 sprays per nostril BID for 1 week during the Treatment Period for a total of 14 doses.
9748510|NCT00394953|Experimental|MIRCERA|Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA [RO0503821]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of <40, 40-80, and >80 mcg, respectively.
9748511|NCT00394953|Active Comparator|Darbepoetin Alfa|Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.
9748512|NCT00395018|Experimental|entecavir|
9748513|NCT00395044|Experimental|Gabapentin|1200 mg/daily of Gabapentin
9828995|NCT02516332|Placebo Comparator|Placebo|Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.
9828996|NCT02516410|Experimental|VX-661/IVA|VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
9828997|NCT02516410|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
9828998|NCT02516592|Experimental|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. Capsules for inhalation
9828999|NCT02516592|Active Comparator|salmeterol/fluticasone 50/500 micrograms|salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder
9829000|NCT02516605|Experimental|LJN452|
9829001|NCT02516605|Placebo Comparator|Placebo|
9829002|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
9829003|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
9829004|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
9829005|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
9829006|NCT02517021|Experimental|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
9829007|NCT02517021|Active Comparator|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
9829008|NCT02517047|Experimental|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
9829009|NCT02517268|Active Comparator|Standard 7-Day Pathway|Patients follow the standard 7-day pathway following pancreaticoduodenectomy
9829010|NCT02517268|Experimental|Accelerated 5-Day Pathway|Patients follow the Whipple accelerated 5-day pathway following pancreaticoduodenectomy. The accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and enhanced physical therapy, multimodal pain control, dietary modifications, and increased and standardized phone contact by a nurse practitioner during the first week following hospital discharge.
9829011|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
9829012|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
9829013|NCT02517515|Experimental|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
9829014|NCT02517515|Experimental|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
9829015|NCT02517528|Experimental|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
9829016|NCT02517541|Experimental|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
9517386|NCT03306745|Experimental|Study group|"1 soft capsule/day containing 500mg omega-3 fatty acids~one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
9517387|NCT03306745|Placebo Comparator|Control group|200µg folic acid - two capsules per day
9748514|NCT00395044|Placebo Comparator|Placebo|1200mg/d of Placebo
9748515|NCT00395057|Experimental|AGN 211745 Solution 1000 ug|AGN 211745 Solution 1000 ug
9748516|NCT00395057|Experimental|AGN 211745 Solution 300 ug|AGN 211745 Solution 300 ug
9748517|NCT00395057|Experimental|AGN 211745 Solution 100 ug|AGN 211745 Solution 100 ug
9748518|NCT00395057|Active Comparator|Ranibizumab 500 ug|Ranibizumab 500 ug
9748519|NCT00395083|No Intervention|Group 1|Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
9748520|NCT00395083|Experimental|Group 2|The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.
9748521|NCT00395135|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
9748522|NCT00395135|Placebo Comparator|Matching Placebo BID|Matching placebo tablet each morning and evening
9748523|NCT00395161|Experimental|zinc selenium glutamine metoclopramide|metoclopramide, zinc, selenium, and glutamine
9748524|NCT00395161|Placebo Comparator|enteral whey protein and IV saline|saline, sterile water, whey protein
9748525|NCT00395226|Experimental|Zinc sulfate|220 mg of zinc sulfate
9748526|NCT00395226|Placebo Comparator|Lactose|270 mg lactose
9748527|NCT00395291|Experimental|MK-0677 then Placebo|MK-0677 and Placebo - All subjects were given MK-0677 for a 30 +/- 7 days and then they were given a placebo for 30 +/- 7 days.
9748528|NCT00395291|Experimental|Placebo then MK-0677|MK-0677 and Placebo - All subjects were given Placebo for a 30 +/- 7 days and then they were given MK-0677 for 30 +/- 7 days.
9748529|NCT00395304|Experimental|Sequence #1|fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
9748530|NCT00395304|Experimental|Sequence #2|fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
9748531|NCT00395304|Experimental|Sequence #3|fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
9748532|NCT00395304|Experimental|Sequence #4|fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
9748533|NCT00395304|Experimental|Sequence #5|fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
9748534|NCT00395304|Experimental|Sequence #6|fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol
9748535|NCT00395343|Experimental|1|sitagliptin
9748536|NCT00395343|Placebo Comparator|2|Placebo
9748537|NCT00395447||Straight-forward Device Replacement|Subject with a straight-forward device replacement without lead revisions or additions.
9748538|NCT00395447||Device Replacement with Upgrade|Subjects with a device replacement and planned lead upgrade, revision, or addition.
9748539|NCT00395460|Experimental|Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)|Participant received 0.1 mmol/kg BW Gadobutrol (= 0.1 mL/kg BW by intravenous injection at a rate of 1.0 mL/sec)
9748540|NCT00395460|Active Comparator|GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)|Participant received 0.1 mmol/kg BW Gadopentetate Dimeglumine (GD) (= 0.2 mL/kg BW by intravenous injection at a rate of 2.0 mL/sec
9748541|NCT00395486|Experimental|Rosuvastatin|
9748542|NCT00395486|Active Comparator|Atorvastatin|
9748543|NCT00395512|Experimental|Alogliptin 25 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
9748544|NCT00395512|Active Comparator|Pioglitazone 30 mg QD|Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
9748545|NCT00395512|Experimental|Alogliptin 25 mg QD+ Pioglitazone 30 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
9748546|NCT00395512|Active Comparator|Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
9748547|NCT00395538|Other|Biopsy|Subjects are randomized to have the second bone biopsy done 1,2, or 4 years after the start of PTH.
9748548|NCT00395629|Experimental|ICL670 (Deferasirox)|Three dose cohorts: 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day
9748549|NCT00395642|Experimental|HM with weight and BP remote monitoring|Device based Home Monitoring and weight and blood pressure remote monitoring
9748550|NCT00395694|Experimental|lamictal|
9748551|NCT00395733|Experimental|Gadobutrol, then Gadopentate dimeglumine|Period 1: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged; Period 2: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged
9748552|NCT00395733|Experimental|Gadopentate, dimeglumine then Gadobutrol|Period 1: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged; Period 2: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged
9748553|NCT00395746|Experimental|0.6 mg + SU|Liraglutide 0.6 mg + sulphonylurea
9748554|NCT00395746|Experimental|0.9 mg + SU|Liraglutide 0.9 mg + sulphonylurea
9748555|NCT00395746|Placebo Comparator|SU Mono - 1|Liraglutide placebo 0.6 mg + sulphonylurea
9748556|NCT00395746|Placebo Comparator|SU Mono - 2|Liraglutide placebo 0.9 mg + sulphonylurea
9748557|NCT00395850|Placebo Comparator|1|microcrystalline cellulose
9748558|NCT00395850|Experimental|2|disulfiram at 250 mg/day
9748559|NCT00395850|Experimental|3|Disulfiram at 375 mg/day
9748560|NCT00395850|Experimental|4|Disulfiram at 500 mg/day
9748561|NCT00395863|Active Comparator|MultiHance|0.5 M MultiHance at a single injection
9748562|NCT00395863|Active Comparator|Magnevist|0.5 M Magnevist at a single injection
9829017|NCT02517567|Other|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
9829018|NCT02517567|Other|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
9829019|NCT02517567|Other|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
9829020|NCT02517567|Other|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
9829021|NCT02517580|Experimental|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
9829022|NCT02517658|Active Comparator|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
9829023|NCT02517658|Experimental|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
9829024|NCT02517658|Experimental|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
9829025|NCT02517866|Experimental|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of <140/85 mmHg at Week 6.
9829026|NCT02517905|Experimental|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
9829027|NCT02517905|Placebo Comparator|Placebo|10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
9829028|NCT02517996|Experimental|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
9829029|NCT02517996|Placebo Comparator|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
9829030|NCT02518048|Active Comparator|LEO 90100 Aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
9829031|NCT02518048|Active Comparator|Betesil® 2.25 mg|Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )
9829032|NCT02518113|Experimental|LY3039478 + Dexamethasone (Adult)|"Part A: 50 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~75 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~100 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~125 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression."
9517388|NCT03306732|Active Comparator|Thiamine group|
9829033|NCT02518113|Experimental|LY3039478 + Dexamethasone (Pediatric)|"Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Part B of the study."
9829034|NCT02518113|Experimental|Phase 2: LY3039478 + Dexamethasone|"LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
9829035|NCT02518113|Placebo Comparator|Phase 2: Placebo + Dexamethasone|"Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
9829036|NCT02518191|Experimental|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
9829037|NCT02518191|No Intervention|None GnRHa group|Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.
9829038|NCT02518230|Other|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
9829039|NCT02518230|Other|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
9829040|NCT02518464|Experimental|Ticagrelor 90 mg twice per day|Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.
9829041|NCT02518490|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
9829042|NCT02518490|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
9829043|NCT02518620|Experimental|ALX-0061 150 mg q2w (+ MTX)|
9829044|NCT02518685|Experimental|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus Lifestyle Counseling
9517389|NCT03306732|Placebo Comparator|Placebo group|
9517390|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
9517391|NCT03306719||Control Group|Pregnant women without IAI
9748563|NCT00395876|Placebo Comparator|Placebo + Tenecteplase + Tenecteplase (PTT)|
9748564|NCT00395876|Experimental|Tenecteplase + Tenecteplase + Placebo (TTP)|
9748565|NCT00395967|Experimental|All Patients|Patients who were predicted to be unable to mobilize a minimum number of cells (≥2*10^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.
9748566|NCT00395993|Experimental|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
9748567|NCT00395993|Active Comparator|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
9748568|NCT00396032|Experimental|1|
9748569|NCT00396032|Placebo Comparator|2|
9748570|NCT00396084|Experimental|Gatifloxacin|10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.
9748571|NCT00396084|Active Comparator|Isoniazid|20 subjects to receive isoniazid 300 mg orally once daily for 7days.
9748572|NCT00396084|Experimental|Levofloxacin|10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.
9748573|NCT00396084|Experimental|Linezolid every 12 hours|10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.
9748574|NCT00396084|Experimental|Linezolid once daily|10 subjects to receive linezolid 600 mg orally once daily for 7days.
9748575|NCT00396084|Experimental|Moxifloxacin|10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.
9748576|NCT00396097|Active Comparator|Standard|Standard daily HGH treatment
9748577|NCT00396097|Active Comparator|Formula-based|Formula-based dose regimen
9748578|NCT00396162|Placebo Comparator|Placebo pill|Placebo pills on same schedule as active intervention.
9748579|NCT00396162|Active Comparator|Probiotic|L. rhamnosus R0011 strain
9748580|NCT00396201|Experimental|Participants with Hodgkin's Disease (HD)|Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
9748581|NCT00396253|Experimental|Tenecteplase|At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
9748582|NCT00396266|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
9748583|NCT00396266|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
9748584|NCT00396279|Experimental|Denosumab|Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.
9748585|NCT00396292|Experimental|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
9748586|NCT00396292|Active Comparator|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
9748587|NCT00396318|Experimental|Tenecteplase|
9748588|NCT00396331|Experimental|G-CSF plus Plerixafor|
9748589|NCT00396383|Experimental|Participants with Multiple Myeloma (MM)|Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
9748590|NCT00396409|Experimental|Depigold+Omalizumab|Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
9748591|NCT00396409|Experimental|Depigoid+Placebo|Depigoid® (grass/rye pollen 50/50) + Placebo
9748592|NCT00396565|Experimental|ER OROS paliperidone|Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
9748593|NCT00396565|Placebo Comparator|Placebo|
9748594|NCT00396565|Active Comparator|Olanzapine|
9782238|NCT01170065|Experimental|BIBF 1120 high bid|High dose BIBF 1120 twice daily
9748595|NCT00396591|Experimental|Aflibercept|Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
9748596|NCT00396630|Experimental|Rotarix Group|"All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
9748597|NCT00396630|Placebo Comparator|Placebo Group|"All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
9748598|NCT00396656|Experimental|Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)|"After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning."
9748599|NCT00396656|Experimental|Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan|"After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning."
9748600|NCT00396812|Experimental|Rituximab|
9748601|NCT00396877|Placebo Comparator|Placebo|
9748602|NCT00396877|Experimental|Clopidogrel 0.2 mg/kg/day|
9748603|NCT00396981|Active Comparator|Matrix 2® Coils|Matrix 2® Coils for endovascular aneurysm occlusion
9748604|NCT00396981|Active Comparator|GDC® Coils|GDC® Coils for endovascular aneurysm occlusion
9748605|NCT00397020|Experimental|1 Divalproex ER|Divalproex ER
9748606|NCT00397020|Active Comparator|2 Quetiapine Fumarate|quetiapine fumarate
9748607|NCT00397033|Experimental|002|Paliperidone ER 12mg/day paliperidone er for 6 weeks
9748608|NCT00397033|Experimental|001|Paliperidone ER 6mg/day paliperidone er for 6 weeks
9748609|NCT00397033|Placebo Comparator|003|Placebo Placebo for 6 weeks
9748610|NCT00397046|Experimental|Neratinib 80 mg|
9748611|NCT00397046|Experimental|Neratinib 160 mg|
9748612|NCT00397046|Experimental|Neratinib 240 mg|
9748613|NCT00397046|Experimental|Neratinib 320 mg|
9748614|NCT00397150|Experimental|Intervention|Peer-support for exclusive breastfeeding
9748615|NCT00397150|No Intervention|No intervention|No intervention
9748616|NCT00397189|Experimental|Circadin|
9748617|NCT00397189|Placebo Comparator|placebo|
9748618|NCT00397215|Experimental|GSK1562902A 1 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
9748619|NCT00397215|Experimental|GSK1562902A 2 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
9748620|NCT00397215|Experimental|GSK1562902A 3 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
9748621|NCT00397215|Experimental|GSK1562902A 4 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
9748622|NCT00397462|No Intervention|Control|No change to usual behavior
9748623|NCT00397462|Experimental|Low dose|Request that calf muscle pump stimulation be used less than four hours per day
9748624|NCT00397462|Experimental|High dose|Request that calf muscle pump stimulation be used at least four hours per day
9748625|NCT00397488|Experimental|Sunitinib|This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
9748626|NCT00397514||Congenital Heart Surgery Patients|Pacing protocol prior to patient's extubation with 20 min. of either conventional right ventricular (RV) or biventricular (BiV) pacing, preceded and followed by 10 min. of recovery time.
9748627|NCT00397540|Active Comparator|percutaneous ethanol injection therapy|Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
9748628|NCT00397540|Active Comparator|radiofrequency thermal ablation|Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
9748629|NCT00397579|Experimental|SL-401|Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
9782239|NCT01170091||Pramipexole|
9782240|NCT01170117|Placebo Comparator|Placebo|Control group receiving placebo
9782241|NCT01170117|Experimental|Olanzapine|Group receiving olanzapine
9748630|NCT00397631|Experimental|1|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
9748631|NCT00397631|Active Comparator|2|sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.
9748632|NCT00397813|Experimental|Arm A - Dose Level 1|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
9748633|NCT00397813|Experimental|Arm A - Dose Level 2|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
9748634|NCT00397813|Experimental|Arm A - Dose Level 3|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
9748635|NCT00397813|Experimental|Arm B - Dose Level 1|"Arm B - patients with MDS-RAEB or CMML Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
9748636|NCT00397813|Experimental|Arm B - Dose Level 2|"Arm B - patients with MDS-RAEB or CMML Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
9748637|NCT00397813|Experimental|Arm B - Dose Level 3|"Arm B - patients with MDS-RAEB or CMML Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
9748638|NCT00397839|Placebo Comparator|Placebo|
9748639|NCT00397839|Experimental|Ibandronate|
9748640|NCT00397878|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9748641|NCT00397891|Experimental|1|bapineuzumab 0.15 mg/kg or placebo
9748642|NCT00397891|Experimental|2|bapineuzumab 0.5 mg/kg or placebo
9748643|NCT00397891|Experimental|3|bapineuzumab 1.0 mg/kg or placebo
9748644|NCT00397904|Experimental|Cetuximab, Cisplatin, and Irinotecan|Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2.
9748645|NCT00397930|Experimental|Yoga Intervention (YOCAS)|Standardized Yoga for Cancer Survivors (YOCAS)
9748646|NCT00397930|Experimental|Standard Care Control Condition|Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.
9829045|NCT02518685|Sham Comparator|Control|Sham procedure plus Lifestyle Counseling
9829046|NCT02518919|No Intervention|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
9829047|NCT02518919|Experimental|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
9829048|NCT02518919|Experimental|Music Listening|Patients will listen to music of their choice using headphones during sedation
9829049|NCT02518971|Experimental|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
9829050|NCT02518971|Placebo Comparator|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
9829051|NCT02518997|Experimental|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
9829052|NCT02519023|Experimental|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
9829053|NCT02519023|Active Comparator|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
9829054|NCT02519036|Experimental|ISIS 443139 10 mg|Participants received ISIS 443139, 10 milligrams (mg), by intrathecal injection, on Study Days 1, 29, 57, and 85.
9829055|NCT02519036|Experimental|ISIS 443139 30 mg|Participants received ISIS 443139, 30 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
9517392|NCT03306693|Experimental|Emotional skills|3 group sessions where patients are going to learn how to identify, express and regulate their emotions
9829056|NCT02519036|Experimental|ISIS 443139 60 mg|Participants received ISIS 443139, 60 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
9829057|NCT02519036|Experimental|ISIS 443139 90 mg|Participants received ISIS 443139, 90 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
9829058|NCT02519036|Experimental|ISIS 443139 120 mg|Participants received ISIS 443139, 120 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
9829059|NCT02519036|Placebo Comparator|Placebo|Participants received placebo, by intrathecal injection, on Study Days 1, 29, 57, and 85.
9829060|NCT02519231|Active Comparator|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
9829061|NCT02519231|Placebo Comparator|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
9829062|NCT02519244|Experimental|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
9829063|NCT02519387|Experimental|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
9829064|NCT02519491|Active Comparator|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
9829065|NCT02519491|Active Comparator|Iphone assessment|iPhone assessment of radial and ulnar patency.
9829066|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
9829067|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
9829068|NCT02519595|Experimental|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
9829069|NCT02519595|Experimental|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
9829070|NCT02519595|Experimental|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
9829071|NCT02519621|Active Comparator|NPWT PRO without irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
9829072|NCT02519621|Active Comparator|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
9829073|NCT02519621|Active Comparator|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
9829074|NCT02519842|Experimental|Fosaprepitant Regimen Cycle 1|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
9829075|NCT02519842|Placebo Comparator|Control Regimen Cycle 1|Participants received a single dose of matched placebo for fosaprepitant IV on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
9748647|NCT00397943|Experimental|M72/AS01B Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
9748648|NCT00397943|Experimental|M72/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
9748649|NCT00397943|Active Comparator|Mtb72F/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
9748650|NCT00397943|Active Comparator|Non-adjuvanted Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
9748651|NCT00397943|Placebo Comparator|Control Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
9748652|NCT00397982|Experimental|Treatment (enzyme inhibitor, monoclonal antibody)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
9748653|NCT00398047|Experimental|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine andHematopoietic Growth Factors
9748654|NCT00398073|Experimental|mouse gp100 DNA via PMED|patients will be randomized to mouse gp100 DNA delivered via gold particles using the PowderMed delivery system (ND10, described above). Two actuations/day will be administered every two weeks for 4 months for a total of 16 actuations. Each actuation consists of 2 μg of plasmid DNA coated onto 1000 μg of gold. The total dose of plasmid DNA given will be 32 μg DNA on 16,000 μg gold.
9748655|NCT00398073|Experimental|mouse gp100 DNA injections intramuscularly|patients will be injected with 1000 μg of mouse gp100 plasmid DNA intramuscularly. Two injections/day will be administered every two weeks for 4 months (4000 ug of mouse gp100 plasmid/month) for 16 vaccinations.
9748656|NCT00398086|Experimental|100 mg/m^2|Participants received albumin-bound paclitaxel 100 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
9748657|NCT00398086|Experimental|125 mg/m^2|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
9748658|NCT00398086|Experimental|150 mg/m^2|Participants received albumin-bound paclitaxel 150 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
9748659|NCT00398112|Experimental|Arm I|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9748660|NCT00398138|Experimental|vaccine|Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 & 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 & -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time & placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) & the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response & have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
9748661|NCT00398320|Experimental|Bevacizumab (Avastin), Oxaliplatin (Eloxatin)|
9748662|NCT00398398|Experimental|Capecitbine, oxaliplatin, cetuximab|Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
9748663|NCT00398411|Experimental|Moxifloxacin|moxifloxacin 400 mg tablets once daily
9748664|NCT00398411|Placebo Comparator|Placebo|identical appearing placebo
9748665|NCT00398476|Active Comparator|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
9829076|NCT02519842|Experimental|Fosaprepitant Regimen Cycles 2-6|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) IV on Day 1 prior to chemotherapy plus a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 prior to chemotherapy and per product label or standard of care. Participants may also have received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
9829077|NCT02519855|Experimental|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
9829078|NCT02519855|Experimental|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
9829079|NCT02520089|Active Comparator|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
9829080|NCT02520089|Experimental|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
9829081|NCT02520284|Experimental|Andecaliximab Every 2 Weeks|Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
9829082|NCT02520284|Experimental|Andecaliximab Weekly|Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
9829083|NCT02520284|Placebo Comparator|Placebo|Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
9829084|NCT02520310|Experimental|AVJ-514|The AVJ-514 system
9829085|NCT02520388|Experimental|HLD200 (methylphenidate)|"Experimental: HLD200 (methylphenidate)~The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 3-weeks prior to testing."
9829086|NCT02520388|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 3-weeks prior to testing.
9829087|NCT02520414|Experimental|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
9829088|NCT02520518|Experimental|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
9829089|NCT02520518|Experimental|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
9829090|NCT02520518|Placebo Comparator|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
9829091|NCT02520518|Placebo Comparator|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
9829092|NCT02520531|Active Comparator|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
9829093|NCT02520531|Active Comparator|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
9829094|NCT02521181|Experimental|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
9829095|NCT02521181|Experimental|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
9748666|NCT00398476|Active Comparator|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
9748667|NCT00398567|Experimental|Part 1 - dose level 1 (160 mg)|All subjects receiving HKI-272 dose level 1 in combination with trastuzumab
9748668|NCT00398567|Experimental|Part 1 - dose level 2 (240 mg)|All subjects receiving HKI-272 dose level 2 in combination with trastuzumab
9748669|NCT00398567|Experimental|Part 2 - expanded MTD cohort|All subjects receiving HKI-272 in combination with trastuzumab
9748670|NCT00398632|Experimental|Duloxetine|Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
9748671|NCT00398866|Active Comparator|1|Bupivicaine (local anesthetic)
9748672|NCT00398866|Active Comparator|2|Corticosteroid (trimcinolone (Kenalog) 40 mg)
9748673|NCT00398866|Experimental|3|Synvisc
9748674|NCT00398918|Experimental|Zonisamide|
9748675|NCT00398918|Placebo Comparator|Placebo|
9748676|NCT00398983|Experimental|Decitabine 20 mg/m^2|20 mg/m^2 intravenous (IV) daily for 5 days
9748677|NCT00398983|No Intervention|No Study Drug|Continue current therapy.
9748678|NCT00399035|Placebo Comparator|FOLFOX + placebo Cediranib|FOLFOX + placebo Cediranib
9748679|NCT00399035|Placebo Comparator|Xelox + placebo Cediranib|Xelox + placebo Cediranib
9748680|NCT00399035|Experimental|FOLFOX + Cediranib|FOLFOX + Cediranib
9748681|NCT00399035|Experimental|XELOX + Cediranib|XELOX + Cediranib
9748682|NCT00399308|Active Comparator|Control|Multi-layer compression bandaging (Profore)
9748683|NCT00399308|Experimental|Celaderm, Bi-Weekly|Celaderm, bi-weekly applications, up to a maximum of four applications
9748684|NCT00399308|Experimental|Celaderm, Weekly|Celaderm, applied weekly, up to a maximum of four applications
9748685|NCT00399360|Placebo Comparator|Group 1|No Lifestyle Modification and Placebo
9748686|NCT00399360|Active Comparator|Group 2|Lifestyle Modification and Placebo
9748687|NCT00399360|Active Comparator|Group 3|No Lifestyle Modification and Metformin
9748688|NCT00399360|Active Comparator|Group 4|Lifestyle Modification and Metformin
9748689|NCT00399490|Experimental|1|
9748690|NCT00399529|Experimental|Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide|"Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.~Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously~Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study"
9748691|NCT00399568|Experimental|IV acetaminophen 1 g/100 mL solution|
9748692|NCT00399568|Placebo Comparator|IV Placebo 100 mL solution|
9748693|NCT00399763|Placebo Comparator|1|placebo plus individual cognitive behavioral therapy
9748694|NCT00399763|Experimental|2|atomoxetine plus individual cognitive behavioral therapy
9748695|NCT00399802|Active Comparator|Single IV infusion of ZA 4 mg|Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
9748696|NCT00399802|Experimental|Odanacatib 5 mg|Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.
9748697|NCT00399880|Experimental|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
9748698|NCT00399880|No Intervention|Usual care|
9829096|NCT02521181|Placebo Comparator|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
9829097|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
9829098|NCT02521259||normal BIS group|BIS range from 40 to 60
9829099|NCT02521376|Experimental|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
9829100|NCT02521376|Experimental|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
9829101|NCT02521376|Experimental|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
9829102|NCT02521766|Experimental|All HMIOL Cohort|HMIOL implantation with or without optic exchange
9829103|NCT02521766|Experimental|Cohort 1|HMIOL implantation with no optic exchange
9829104|NCT02521766|Experimental|Cohort 2|HMIOL implantation with optic exchange
9829105|NCT02521766|Other|Fellow Eye|IOL implantation per standard of care
9829106|NCT02521792|Experimental|Palovarotene|The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.
9829107|NCT02521870|Experimental|Dose Escalation Phase 1b|Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).
9829108|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 1)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
9829109|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 2)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
9829110|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 3)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
9829111|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 4)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
9829112|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 5)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
9829113|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 6)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
9829114|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 7)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.
9829115|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 8)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.
9829116|NCT02521948|Experimental|MANTA Vascular Closure Device|The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
9829117|NCT02521974|Experimental|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
9829118|NCT02522104|Experimental|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
9829119|NCT02522104|Experimental|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR > 130 mL/min/1.73m2 in women and GFR > 140 mL/min/1.73m2 in men.
9748699|NCT00399893|Experimental|Octreotide|Octreotide to be administered by subcutaneous injection three times daily while on study
9748700|NCT00399893|Placebo Comparator|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
9748701|NCT00400153|Experimental|COMBIVENT Respimat 20/100 mcg|
9748702|NCT00400153|Experimental|COMBIVENT CFC-MDI 36/206 mcg|
9748703|NCT00400153|Experimental|Ipratropium Respimat 20 mcg|
9748704|NCT00400179|Active Comparator|A|In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
9748705|NCT00400179|Active Comparator|B|In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
9748706|NCT00400205|Experimental|Recipients of Docetaxel, Cisplatin, 5-Fluorouracil|Participants with squamous cell carcinoma receiving chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil.
9748707|NCT00400400|Experimental|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium tablets taken orally twice a day (in the morning and in the evening) at a dose equimolar to the dose of mycophenolate mofetil the participant was taking prior to start of the study + Placebo to mycophenolate mofetil capsules taken orally twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
9748708|NCT00400400|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
9748709|NCT00400439|Experimental|dalcetrapib (RO4607381)|
9748710|NCT00400439|Placebo Comparator|placebo|
9748711|NCT00400517|Experimental|GM-CSF Injections and Oral Thalidomide|taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
9748712|NCT00400569|Experimental|Sunitinib Malate (SU011248) Treatment|Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
9748713|NCT00400634|Experimental|1|Intracerebral administration of CERE-120
9748714|NCT00400634|Sham Comparator|2|Sham Neurosurgery
9748715|NCT00400686|Experimental|Epoetin Alfa - 80,000 U sc|Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
9748716|NCT00400712|No Intervention|Control|natural progression post-stroke
9748717|NCT00400712|Experimental|Intervention|two weeks of goal directed intensive physical rehabilitation therapy at 6 months (and one year)
9748718|NCT00400764|Experimental|Phase Ib: Dulanermin 4 mg/kg|Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
9748719|NCT00400764|Experimental|Phase Ib: Dulanermin 8 mg/kg|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
9748720|NCT00400764|Active Comparator|Phase II: Rituximab|Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
9748721|NCT00400764|Experimental|Phase II: Combination Therapy|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
9748722|NCT00400764|Experimental|Phase II: Dulanermin|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
9748723|NCT00400803|Experimental|Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|Patients treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
9748724|NCT00400829|Experimental|Arm I|Patients receive 1.4 mg/m2 eribulin mesylate IV over 1-2 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9748725|NCT00400881|No Intervention|Continuous PAP (CPAP)|CPAP (continuous positive airway pressure). 5 cm H2O.
9748726|NCT00400881|Experimental|Automatic tube compensation (ATC)|ATC is a new mode of ventilation being compared with traditional one (CPAP). ATC is a mode of ventilation of the same device (mechanical ventilator), not a new device. The pressure in this modes varies according the mechanical parameters of the respiratory system that are automatically calculated by this mode. This is the intervention arm.
9748727|NCT00400946|Active Comparator|Intramuscular native E coli L-asparaginase (IM-EC)|Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
9748728|NCT00400946|Experimental|Intravenous PEG-asparaginase (IV-PEG)|Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
9748729|NCT00400985|Other|Implantable Device diagnostics|All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off
9748730|NCT00401102|Other|Interpersonal psychotherapy|All participants received interpersonal psychotherapy adapted for self-injury
9748731|NCT00401193|Experimental|1|
9748732|NCT00401193|Experimental|2|
9748733|NCT00401193|Placebo Comparator|3|
9748734|NCT00401245|Active Comparator|A|
9748735|NCT00401245|Active Comparator|B|
9748736|NCT00401245|Active Comparator|C|
9748737|NCT00401245|Active Comparator|D|
9748738|NCT00401245|Active Comparator|E|
9748739|NCT00401245|Active Comparator|F|
9748740|NCT00401245|Active Comparator|G|
9748741|NCT00401245|Placebo Comparator|H|
9748742|NCT00401258|Other|1|12-week, open-label trial of duloxetine in subjects with IBS.
9748743|NCT00401375|Experimental|MNTX 12 mg|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) as an intravenous (IV) infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
9748744|NCT00401375|Experimental|MNTX 24 mg|Participants will receive MNTX 24 mg as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
9748745|NCT00401375|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
9748746|NCT00401401|Experimental|Zalutumumab 4 mg/kg|Zalutumumab 8 weekly infusions
9748747|NCT00401401|Experimental|Zalutumumab 8 mg/kg|Zalutumumab 8 weekly infusions
9748748|NCT00401401|Experimental|Zalutumumab 12 mg/kg|Zalutumumab 8 weekly infusions
9748749|NCT00401401|Experimental|Zalutumumab 16 mg/kg|Zalutumumab 8 weekly infusions
9748750|NCT00401414|Experimental|Warfarin|We will develop a nomogram for warfarin dosing that uses rapid turnaround genetic testing and monthly nomogram modification (if necessary) to achieve effective and safe warfarin induction and maintenance. More than 70% of the time, we will maintain warfarin naïve patients within the target therapeutic range. The percent of time in the therapeutic range will be analyzed beginning 2 weeks after initiation of warfarin. Analyses will be stratified by the indication for anticoagulation.
9748751|NCT00401518|Experimental|ACADIA®|Investigational surgical treatment using the ACADIA Facet Replacement system
9748752|NCT00401518|Active Comparator|Control Instrumented PLF|Control surgical treatment using an instrumented posterolateral fusion
9748753|NCT00401531|Experimental|Group 1: DTaP IPV Hep B PRP T + Prevnar™|
9748754|NCT00401531|Active Comparator|Group 2: Infanrix hexa™ + Prevnar™|
9517393|NCT03306693|Sham Comparator|Relaxation and talking group|3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
9517394|NCT03306667|Experimental|Normal group|Healthy control subjects
9748755|NCT00401544|Experimental|Darbepoetin alfa 300 μg plus IV Iron|Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
9748756|NCT00401544|Experimental|Darbepoetin alfa 300 μg|Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
9748757|NCT00401544|Experimental|Darbepoetin alfa 500 μg|Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
9748758|NCT00401544|Active Comparator|Darbepoetin alfa 500 μg plus IV Iron|Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
9748759|NCT00401622|Experimental|OneTouch® Ultra®2 system|Test care group assigned to OneTouch® Ultra®2 system
9748760|NCT00401622|Active Comparator|Standard care|Control group receiving standard care with a traditional blood glucose monitoring system
9748761|NCT00401778|Active Comparator|1|RAD001 5 mg/day for 21 days sequentially.
9748762|NCT00401778|Active Comparator|3|RAD001 10 mg/day for 21 days sequentially.
9748763|NCT00401778|No Intervention|Control|Patients who are eligible for the study but choose not to receive RAD001 treatment.
9748764|NCT00401817|Experimental|Study Treatment Arm|Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1, and standard dose R-CHOP on day 3, for six 21-day cycles
9748765|NCT00401830|Placebo Comparator|Placebo|
9748766|NCT00401830|Experimental|Lacosamide|Lacosamide Tablet 400mg daily
9517395|NCT03306667|Experimental|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
9748767|NCT00401843|Experimental|Part 1: Siltuximab Plus Bortezomib|Siltuximab 6 milligram per kilogram (mg/kg) will be administered as intravenous infusion once every 2 weeks along with bortezomib 1.3 milligram per square meter (mg/m^2) during cycle 1.
9748768|NCT00401843|Experimental|Part 2: Bortezomib + Placebo|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
9748769|NCT00401843|Experimental|Part 2: Bortezomib + Siltuximab|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
9748770|NCT00401882|Active Comparator|Standard Of Care Drug Epinephrine|Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
9748771|NCT00401882|Active Comparator|IV Metoprolol instead Epinephrine|IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
9748772|NCT00401960|Experimental|Daptomycin adjunctive group|Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
9748773|NCT00401960|No Intervention|standard of care|Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician
9748774|NCT00401973|Experimental|Olanzapine|olanzapine plus behavioral information
9748775|NCT00401973|Experimental|Olanzapine + Amantadine|Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
9748776|NCT00401973|Experimental|Olanzapine + Metformin|Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
9748777|NCT00401986||Alair Treatment|Alair Treated subjects from PREDECESSOR STUDY (NCT00214539).
9748778|NCT00402025|Experimental|Talimogene Laherparepvec|Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
9748779|NCT00402051|Experimental|Pemetrexed + Cisplatin|
9748780|NCT00402051|Experimental|Pemetrexed + Carboplatin|
9748781|NCT00402103|Experimental|Aliskiren/Amlodipine|
9748782|NCT00402103|Experimental|Aliskiren/Amlodipine/HCTZ|
9748783|NCT00402116|Experimental|A|The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD). Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy. The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT). If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle. If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles. If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin. The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
9748784|NCT00402168|Experimental|A: Belatacept|
9748785|NCT00402168|Active Comparator|B: calcineurin inhibitor (CNI)-based immunosuppressive regimen|
9748786|NCT00402233|Other|Placebo|
9748787|NCT00402233|Other|Pramipexole 0.5 mg Tid|Pramipexole 0.5 mg tid (three times a day)
9748788|NCT00402233|Other|Pramipexole 0.5 mg Bid|Pramipexole 0.5 mg bid (bis in die (two times a day))
9748789|NCT00402233|Other|Pramipexole 0.75 mg Bid|Pramipexole 0.75 mg bid (bis in die (two times a day))
9748790|NCT00402246|Experimental|Remote Arm|Remote Management
9748791|NCT00402246|Active Comparator|In-office Arm|In-Office Care
9748792|NCT00402285|Active Comparator|lycopene supplement|Two 15mg lycopene capsules daily for 3 months.
9748793|NCT00402285|Active Comparator|fish oil supplement|1g fish oil capsule daily for 3 months.
9748794|NCT00402285|Placebo Comparator|placebo|placebos for lycopene and fish oil.
9782242|NCT01170208|Other|Group I|Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting and insulin dose software.
9748795|NCT00402298|Experimental|Full dose (125 mg) MDMA-assisted therapy|Participants will receive an initial dose of 125 mg MDMA followed 2.5 hours later by a supplemental dose of 62.5 mg MDMA during the course of two day-long therapy sessions.
9748796|NCT00402298|Active Comparator|Active Comparator (25 mg) MDMA-assisted therapy|Participants will receive an initial dose of 25 mg MDMA followed 2.5 hours later by a supplemental dose of 12.5 mg MDMA during the course of two day-long therapy sessions.
9748797|NCT00402324|Experimental|1|olanzapine and divalproex
9748798|NCT00402324|Placebo Comparator|2|placebo and divalproex
9748799|NCT00402337|Active Comparator|72 ug linaclotide acetate|
9748800|NCT00402337|Active Comparator|145 ug linaclotide acetate|
9748801|NCT00402337|Active Comparator|290 ug linaclotide acetate|
9748802|NCT00402337|Active Comparator|579 ug linaclotide acetate|
9748803|NCT00402337|Placebo Comparator|Matching Placebo|
9748804|NCT00402363|Experimental|omega-3-acid ethyl esters|
9748805|NCT00402363|Placebo Comparator|Placebo|
9748806|NCT00402597|Experimental|001|Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
9748807|NCT00402597|Experimental|002|Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
9748808|NCT00402597|Placebo Comparator|003|Placebo 1 placebo tablet twice daily for 6 months.
9748809|NCT00402649|Experimental|1|All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
9748810|NCT00402688|Active Comparator|001|levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
9748811|NCT00402688|Active Comparator|002|levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
9748812|NCT00402688|Active Comparator|003|levofloxacin 500mg tablet once daily for 4 weeks.
9748813|NCT00402714|Active Comparator|1|Extracorporeal photopheresis, pentostatin and total body irradiation
9748814|NCT00402714|Active Comparator|2|Pentostatin and total body irradiation
9748815|NCT00402727|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
9748816|NCT00402727|Active Comparator|PIP/TAZ-AMC|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
9748817|NCT00402779|Experimental|Erlotinib|Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.
9748818|NCT00402779|Placebo Comparator|Placebo|Balanced randomization: Placebo continuous administration for 1 year.
9748819|NCT00402831|Experimental|Intramuscular ProQuad®|Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
9748820|NCT00402831|Active Comparator|Subcutaneous ProQuad®|Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
9748821|NCT00402896|Experimental|ZD6474|300 mg/day orally for 10 weeks.
9748822|NCT00402987|Experimental|celecoxib 50 mg/50 mg|
9748823|NCT00402987|Experimental|celecoxib 100 mg/placebo|
9748824|NCT00402987|Experimental|celecoxib 100 mg/50 mg|
9748825|NCT00402987|Placebo Comparator|Placebo|
9748826|NCT00403117|Placebo Comparator|Placebo, Marijuana (0% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748827|NCT00403117|Experimental|Placebo, Marijuana (3.27% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748828|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748829|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748830|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748831|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748832|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9782243|NCT01170208|Other|Group II|Type 2 diabetes treated with basal-bolustherapy and insulin dose software.
9782244|NCT01170208|Other|Group III|Type 2 diabetes treated with biphasic insulin and insulin dose software.
9748833|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748834|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748835|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
9748836|NCT00403130|Experimental|Phase II 3-drug regimen|Gemcitabine + Paclitaxel + Bevacizumab
9748837|NCT00403234|Experimental|BTDS 10|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
9748838|NCT00403234|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
9748839|NCT00403234|Experimental|BTDS 30|Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
9748840|NCT00403234|Placebo Comparator|Placebo TDS|Placebo patches were similar to BTDS 10 and 20.
9517396|NCT03306667|Experimental|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
9748841|NCT00403260|Experimental|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
9748842|NCT00403260|Active Comparator|Mefloquine plus artesunate|Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
9782245|NCT01170221|Experimental|TR-701 FA|TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
9782246|NCT01170221|Active Comparator|Linezolid|Linezolid 600 mg tablets oral twice a day for 10 days
9782247|NCT01170247|Experimental|Intranasal Ketamine|
9782248|NCT01170247|Active Comparator|Intramuscular Ketamine|
9782249|NCT01170273|Placebo Comparator|Placebo Arm|placebo capsule
9782250|NCT01170273|Experimental|Cholecalciferol 4000 IU|cholecalciferol 4000 IU daily
9782251|NCT01170364|Experimental|Sibutramine|Participants in this arm receive sibutramine 15mg for one week followed by two weeks of placebo.
9782252|NCT01170364|Experimental|Placebo|Participants are prescribed two weeks of placebo, followed by one week of 15mg sibutramine.
9782253|NCT01170390|Other|All participants|A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
9782254|NCT01170390|Active Comparator|Aviane and Portia|A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
9782255|NCT01170390|Active Comparator|Aviane & Aviane|A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)
9782256|NCT01170533|Active Comparator|Omeprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
9782257|NCT01170533|Active Comparator|Pantoprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
9782258|NCT01170546|Experimental|KLCIR|plate-loaded kneeling leg curl with internal rotation
9782259|NCT01170546|Experimental|SP (Squat Press)|plate-loaded squat press
9782260|NCT01170546|Experimental|KLC (Kneeling Leg Curl)|plate-loaded kneeling leg curl
9782261|NCT01170598|Experimental|Exercise|
9782262|NCT01170663|Experimental|Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel|Ramucirumab (IMC-1211B) DP and Paclitaxel
9782263|NCT01170663|Placebo Comparator|Placebo and Paclitaxel|Placebo and Paclitaxel
9782264|NCT01170715|Experimental|Experimental Group|Enbrel (etanercept): started with self-injection of 50 mg subcutaneous twice weekly for 12 weeks, followed by self-injection of 50 mg subcutaneous weekly for 40 weeks.
9782265|NCT01170754|Experimental|PEG-3350 and Gatorade|255 miralax with 64 oz gatorade.
9517397|NCT03306667|Experimental|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
9782266|NCT01170754|Active Comparator|Golytely 4 Liters|Golytely 4 Liters
9782267|NCT01170884|Active Comparator|Combigan® + Lumigan®|COMBIGAN® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution) adjunctive to LUMIGAN® (bimatoprost 0.03% ophthalmic solution)
9782268|NCT01170884|Active Comparator|Lumigan®|LUMIGAN® (bimatoprost 0.03% ophthalmic solution) plus Gen Teal® Mild (hypromellose 0.2% eye drops) used for masking purposes
9782269|NCT01170949|Experimental|Miltefosine|
9782270|NCT01170949|Placebo Comparator|Placebo|
9782271|NCT01170962|Experimental|Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
9782272|NCT01170962|Experimental|Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
9782273|NCT01170962|Experimental|Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
9782274|NCT01170962|Experimental|Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
9517398|NCT03306654|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
9748843|NCT00403273|Experimental|A|Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
9748844|NCT00403273|Placebo Comparator|B|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
9748845|NCT00403390|Experimental|Brand name levothyroxine (Synthroid)|Dose previously demonstrated to normalize thyroid function given daily for 2 months
9748846|NCT00403390|Active Comparator|Generic formulation of Levothyroxine|Dosage previously determined to normalize thyroid function given daily for 2 months
9748847|NCT00403403|Placebo Comparator|Placebo+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
9748848|NCT00403403|Experimental|Bevacizumab+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
9748849|NCT00403455|Other|Paroxetine Arm|This is a single arm, single site, open-label clinical trial to treat veterans with PTSD. It is a 12-week trial to investigate the efficacy of paroxetine in reducing PTSD symptoms, with the primary outcome measure using CAPS. Genetic information is included to understand why some respond and some do not respond to paroxetine treatment.
9748850|NCT00403481|Experimental|Active treatment|Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
9748851|NCT00403494|Experimental|Sapropterin dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
9748852|NCT00403494|Placebo Comparator|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
9748853|NCT00403546|Experimental|High-Dose Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
9748854|NCT00403546|Placebo Comparator|Placebo, Standard Treatment Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
9748855|NCT00403754|Experimental|Placebo-Ind 150 μg-Ind 300 μg-Ind 600 μg-Salmeterol|"In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 μg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
9748856|NCT00403754|Experimental|Ind 150 μg-Ind 600 μg-Placebo-Ind 300 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 μg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
9782275|NCT01170962|Experimental|Arm 5: Placebo plus peginterferon alfa-2a and ribavirin|(prior partial responders only)
9782276|NCT01171118|Experimental|Sedation & Physostigmine & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
9748857|NCT00403754|Experimental|Ind 300 μg-Placebo-Ind 600 μg-Ind 150 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 300 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 μg capsules; and in treatment period 4: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation, device on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
9748858|NCT00403754|Experimental|Ind 600 μg-Ind 300 μg-Ind 150 μg-Placebo-Salmeterol|"In treatment period 1: patients received 2 indacaterol (Ind) 300 μg capsules; in treatment period 2: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
9748859|NCT00403767|Experimental|Rivaroxaban|
9748860|NCT00403767|Active Comparator|Warfarin|
9748861|NCT00403845|Experimental|Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg|In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9748862|NCT00403845|Experimental|Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg|In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9748863|NCT00403845|Experimental|Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg|In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9748864|NCT00403845|Experimental|Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo|In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9748865|NCT00404066|Experimental|Neoadjuvant Chemotherapy|Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
9748866|NCT00404079|Experimental|Glucosamine Sulphate|
9748867|NCT00404079|Placebo Comparator|Placebo|
9748868|NCT00404092|Experimental|1st cohort|70mg caspofungin 1x/day
9748869|NCT00404092|Experimental|2nd cohort|100mg caspofungin 1x/day
9748870|NCT00404092|Experimental|3rd cohort|150mg caspofungin 1x/day
9748871|NCT00404092|Experimental|4th cohort|200mg caspofungin 1x/day
9748872|NCT00404235|Experimental|paclitaxel + carboplatin|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.~After completion of study treatment, patients are followed periodically for up to 2 years."
9748873|NCT00404248|Active Comparator|With Enzyme-inducing antiseizure drugs (+EIASD)|"subjects on the +EIASD treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
9829120|NCT02522104|Experimental|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
9829121|NCT02522286|No Intervention|Usual Care|Standard clinical care in primary care offices
9829122|NCT02522286|Experimental|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
9748874|NCT00404248|Active Comparator|With Non enzyme-inducing antiseizure drugs (-EIASD)|"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
9748875|NCT00404352|Active Comparator|RNF 44 mcg three times weekly|
9748876|NCT00404352|Active Comparator|RNF 44 mcg once weekly and placebo twice weekly for blinding|
9748877|NCT00404352|Placebo Comparator|Placebo three times weekly|
9748878|NCT00404495|Experimental|Temozolomide + Irinotecan|
9748879|NCT00404547|Active Comparator|Alvesco|Alvesco 320mcg / Alvesco 640mcg
9748880|NCT00404547|Active Comparator|Usual Care|
9748881|NCT00404651|Experimental|Group 1|Participants receive vaccine Batch A
9748882|NCT00404651|Experimental|Group 2|Participants receive vaccine Batch B
9748883|NCT00404651|Experimental|Group 3|Participants receive vaccine Batch C
9748884|NCT00404651|Active Comparator|Group 4|Participants receive Infanrix hexa™
9748885|NCT00404755|Experimental|escitalopram|escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
9748886|NCT00404755|Experimental|bupropion|bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
9748887|NCT00404755|Experimental|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
9748888|NCT00404768|Experimental|Treatment|GSK221149A
9748889|NCT00404768|Placebo Comparator|Placebo|Placebo
9748890|NCT00404820|Experimental|Zoledronic acid 5 mg|Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year. The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
9748891|NCT00404820|Active Comparator|Alendronate 70 mg|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal. Patients were to remain in an upright position for 30 minutes after swallowing the tablet. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
9748892|NCT00404924|Placebo Comparator|1|Best Supportive Care
9748893|NCT00404924|Experimental|2|Vandetanib + Best Supportive Care
9748894|NCT00405275|Active Comparator|Arm 1|Etanercept and Methotrexate. Participants also received placebo hydroxychloroquine and sulfasalazine
9748895|NCT00405275|Active Comparator|Arm 2|Hydroxychloroquine, sulfasalazine and methotrexate. Participants also received placebo etanercept.
9748896|NCT00405288||Proctofoam-HC®|Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
9748897|NCT00405288||Control|Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
9748898|NCT00405353|Experimental|crossover treatment with Androgel|6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone
9748899|NCT00405509||Confirmed respiratory virus|
9748900|NCT00405509||Unconfirmed respiratory infection|
9748901|NCT00405522|Experimental|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|
9748902|NCT00405522|Experimental|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|
9748903|NCT00405548|Active Comparator|BNP (nesiritide)|BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
9748904|NCT00405548|Placebo Comparator|Placebo|Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
9748905|NCT00405587|Experimental|PLX4032|Open-label, sequential dose escalation
9829123|NCT02522286|Experimental|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
9748906|NCT00405639|Active Comparator|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
9748907|NCT00405639|Placebo Comparator|Placebo|Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
9748908|NCT00405652|Experimental|Enteric-coated Mycophenolate sodium|Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
9748909|NCT00405704|Active Comparator|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
9748910|NCT00405704|Placebo Comparator|Placebo|Cherry-flavored liquid suspension matched to active comparator.
9748911|NCT00405756|Experimental|MPR+R|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
9748912|NCT00405756|Experimental|MPR+p|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
9748913|NCT00405756|Other|MPp+p|Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
9748914|NCT00405821|Active Comparator|Acyclovir 400mg tablet twice daily|
9748915|NCT00405821|Placebo Comparator|Placebo tablet twice daily|
9748916|NCT00405912|Placebo Comparator|Placeo|Placebo pill was identical in appearance to the active medication.
9748917|NCT00405912|Experimental|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tablets, 3 times a day.
9748918|NCT00405912|Experimental|St. John's Wort-1800 mg/day|St. John's Wort - 600 mg 3 times per day
9748919|NCT00405938|Experimental|Bevacizumab/anastrozole|Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.
9748920|NCT00405938|Experimental|Bevacizumab/fulvestrant|Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
9748921|NCT00406029|Experimental|Preladenant 1 mg BID|Participants received preladenant 1 mg twice daily (BID) during the 12-week treatment period.
9748922|NCT00406029|Experimental|Preladenant 2 mg BID|Participants received preladenant 2 mg BID during the 12-week treatment period.
9748923|NCT00406029|Experimental|Preladenant 5 mg BID|Participants received preladenant 5 mg BID during the 12-week treatment period.
9748924|NCT00406029|Experimental|Preladenant 10 mg BID|Participants received preladenant 10 mg BID during the 12-week treatment period.
9748925|NCT00406029|Placebo Comparator|Placebo BID|Participants received preladenant matching placebo BID during the 12-week treatment period.
9748926|NCT00406107|Active Comparator|Pegaptanib Sodium 0.3mg (Macugen)|Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
9748927|NCT00406107|Active Comparator|Pegaptanib Sodium 1 mg (Macugen)|Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
9748928|NCT00406133|No Intervention|Standard intensive glucose monitoring|Patients in the control group were given blood glucose meters and test strips and asked to perform home blood glucose monitoring at least four times daily.
9748929|NCT00406133|Active Comparator|Continuous Glucose Monitoring (CGM)|Patients in the CGM group were instructed to use the CGM device on a daily basis and to verify the accuracy of the glucose measurement with a home blood glucose meter (provided by the study) before making management decisions (as per the regulatory labeling of the devices).
9748930|NCT00406276|Experimental|RAD001+Docetaxel|RAD001 in combination with Docetaxel.
9748931|NCT00406315|Other|A1|atypical antipsychotic for the treatment of schizophrenia
9748932|NCT00406354|Experimental|Atomoxetine Fast Titration|0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
9829124|NCT02522286|Experimental|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
9829125|NCT02522299|Experimental|GSK2269557 1000 microgram (mcg)|Subjects will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device.
9829126|NCT02522299|Placebo Comparator|Placebo via DISKUS|Subjects will receive 2 inhalations of placebo once daily for 84 days via DISKUS device.
9829127|NCT02522299|Experimental|GSK2269557 700 mcg|Subjects will receive 2 inhalations of GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
9829128|NCT02522299|Placebo Comparator|Placebo via ELLIPTA|Subjects will receive Placebo once daily for 84 consecutive days via ELLIPTA.
9829129|NCT02522325|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
9829130|NCT02522325|Experimental|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
9829131|NCT02522377|Experimental|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
9829132|NCT02522377|Active Comparator|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
9829133|NCT02522403|Active Comparator|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
9829134|NCT02522403|Experimental|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
9829135|NCT02522442|Experimental|Auto BiLevel Group|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
9829136|NCT02522442|Active Comparator|CPAP Group|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
9829137|NCT02522481|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
9829138|NCT02522494|Active Comparator|Intervention|Patients randomized to the intervention will view the video
9829139|NCT02522494|Other|Pamphlet alone|Patients randomized to the pamphlet alone will only receive the pamphlet
9829140|NCT02522624|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
9829141|NCT02522624|No Intervention|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
9829142|NCT02522728|Active Comparator|Triathlon CR|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
9829143|NCT02522728|Active Comparator|Triathlon PS|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
9829144|NCT02522767|Experimental|Mesalamine|4 g extended release granules (sachet)
9829145|NCT02522767|Placebo Comparator|Placebo|Matching placebo
9829146|NCT02522780|Experimental|Mesalamine|Mesalamine 2 g extended release granules (sachet), administered orally once daily (QD) for 6 months.
9829147|NCT02522780|Placebo Comparator|Placebo|Placebo matched to mesalamine extended release granules (sachet), administered orally QD for 6 months.
9829148|NCT02522845|Active Comparator|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
9829149|NCT02522845|No Intervention|No Compression|Patients randomised to this group will not be provided with any compression
9748933|NCT00406354|Experimental|Atomoxetine Slow Titration|0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
9748934|NCT00406354|Placebo Comparator|Placebo|matching placebo daily dose taken orally
9748935|NCT00406367|Experimental|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection"
9748936|NCT00406367|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
9748937|NCT00406393|Active Comparator|Tacrolimus/Methotrexate|Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.
9748938|NCT00406393|Experimental|Tacrolimus/Sirolimus|Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.
9748939|NCT00406419|Placebo Comparator|Placebo × 2 IV + MTX|Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
9748940|NCT00406419|Experimental|Ocrelizumab 200 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
9748941|NCT00406419|Placebo Comparator|Ocrelizumab 500 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
9748942|NCT00406640|Active Comparator|A|
9748943|NCT00406640|Active Comparator|B|
9748944|NCT00406653|Experimental|1|"4 arms for induction period~2 arms for maintenance period"
9748945|NCT00406653|Placebo Comparator|2|"4 arms for induction period~2 arms for maintenance period"
9748946|NCT00406653|Other|abatacept|1 arm for open-label extension phase
9748947|NCT00406692|Experimental|Zonisamide|In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study
9748948|NCT00406718|Experimental|PharmCAT|Participants will receive PharmCAT in addition to Treatment as usual, Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
9748949|NCT00406718|Active Comparator|Med-eMonitor|Participants will receive Med-eMonitor™ in addition to treatment as usual. Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
9748950|NCT00406718|Active Comparator|Treatment as Usual|Participants will receive standard treatment as usual which is medication management and limited case management provided by the CMHC.
9748951|NCT00406848|Experimental|Duloxetine|
9748952|NCT00406848|Placebo Comparator|Placebo|
9748953|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection"
9748954|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection"
9748955|NCT00407030|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection
9748956|NCT00407355|Active Comparator|RBZ 0.3|RBZ at the 0.3 mg dose intravitreal injection
9748957|NCT00407355|Active Comparator|RBZ 0.5|RBZ dose level .5 for ITV injection
9748958|NCT00407381|Experimental|Ranibizumab|Ranibizumab (RBZ) intravitreal injection alone
9748959|NCT00407381|Active Comparator|Laser|Laser photocoagulation
9748960|NCT00407381|Experimental|Laser with Ranibizumab|Laser following intravitreal injection of RBZ
9748961|NCT00407420|Experimental|Mandometer|Active intervention - one meal eaten per day off Mandometer
9748962|NCT00407420|Active Comparator|Control|Nutritional and activity advice alone
9748963|NCT00407485|Experimental|Treatment (ziv-aflibercept)|Patients receive 4 mg/kg VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
9748964|NCT00407511|Experimental|Pregabalin|
9748965|NCT00407537|Experimental|Caduet|Open label caduet added to usual care regimen followed by investigators.
9748966|NCT00407550|Experimental|Gemzar x2|Treat subjects with 2 dosings/cycle of Gemzar x6 cycles.
9748967|NCT00407550|Experimental|Gemzar x1|Treat subjects with 1 dosing/cycle of Gemzar x9 cycles.
9829150|NCT02522884|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections.
9829151|NCT02523196|Other|(HVPG) and HepQuant-SHUNT (HQ-Shunt)|"Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.~Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices."
9829152|NCT02523235|Active Comparator|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: …we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the [superior border of the] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
9829153|NCT02523235|Experimental|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
9829154|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
9829155|NCT02523599|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
9829156|NCT02523599|Placebo Comparator|Placebo|3 placebo implants
9829157|NCT02523690|Experimental|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
9829158|NCT02523690|Placebo Comparator|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
9829159|NCT02523924|Experimental|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
9829160|NCT02524054|Experimental|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
9829161|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
9829162|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
9829163|NCT02524106|Experimental|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
9829164|NCT02524106|Placebo Comparator|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
9829165|NCT02524119|Experimental|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
9829166|NCT02524145|Active Comparator|Healthy Seniors|"Fifteen healthy senior volunteers > 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) <30, with exercise histories of less than 3 days per week of aerobic exercise.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
9829167|NCT02524145|Experimental|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction > 0.50; and c) objective evidence of diastolic dysfunction.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
9829168|NCT02524145|Active Comparator|Healthy Young|"Fifteen volunteers <45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI <30.~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
9829169|NCT02524158|Experimental|Yoga|The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
9748968|NCT00407654|Experimental|Arm I|Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
9517399|NCT03306654|Placebo Comparator|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
9748969|NCT00407745|Placebo Comparator|matched placebo|
9748970|NCT00407745|Experimental|pregabalin|flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period
9748971|NCT00407797|Experimental|Pregabalin|
9748972|NCT00407888|Experimental|Arm I|Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
9748973|NCT00407966|Experimental|Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)|"Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.~Patients age 50 and over with core binding factor acute myeloid leukemia (AML) (e.g., t[8;21], inv[16], or t[16;16]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator."
9748974|NCT00408070|Experimental|I|This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
9748975|NCT00408200|Other|AAD:YES|Subjects receive membrane-active anti-arrhythmic medication after ablation. See intervention list below.
9748976|NCT00408200|Other|AAD:NO|Subjects do not receive membrane-active anti-arrhythmic medications after ablation.
9748977|NCT00408317|Experimental|Ultrase® MT20|
9748978|NCT00408317|Placebo Comparator|Placebo|
9748979|NCT00408408|Active Comparator|Arm 1A: Docetaxel then AC|Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
9748980|NCT00408408|Experimental|Arm 1B Docetaxel + Bev then AC + Bev|Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
9748981|NCT00408408|Experimental|Arm 2A: Docetaxel + Capecitabine then AC|Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
9748982|NCT00408408|Experimental|Arm 2B: Docetaxel + Cape + Bev then AC + Bev|Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
9748983|NCT00408408|Experimental|Arm 3A: Docetaxel + Gem then AC|Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
9748984|NCT00408408|Experimental|Arm 3B: Docetaxel + Gem + Bev then AC + Bev|Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
9748985|NCT00408421|Experimental|A|duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
9748986|NCT00408421|Placebo Comparator|B|placebo daily (QD), by mouth (PO) for 13 weeks
9748987|NCT00408434|Experimental|CS-7017|CS-7017 from 0.05 to 3.2 mg bid
9748988|NCT00408460|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
9748989|NCT00408499|Experimental|Erlotinib + Cetuximab|Daily erlotinib combined with weekly cetuximab
9748990|NCT00408564|Experimental|Gemcitabine,Oxaliplatin and Cetuximab|"Gemcitabine will be given on day 1 of every 2 week cycle. Oxaliplatin will be given day 2 of every 2 week cycle. Cetuximab will be given every week for 12 weeks.~After chemotherapy, patient will be assessed for resectability. Patients will have either surgery or daily radiation and capceitabine Monday-Friday for a total of 5 and a half weeks."
9748991|NCT00408590|Experimental|Experimental Arm|
9748992|NCT00408603|Experimental|All study patients|All patients will receive voreloxin injection
9748993|NCT00408629|Experimental|adalimumab group|
9748994|NCT00408629|Experimental|placebo group|
9748995|NCT00408681|Experimental|Arm I|Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
9748996|NCT00408694|Experimental|Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT)|"BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
9748997|NCT00408876|Experimental|Duloxetine 20 mg|duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
9748998|NCT00408876|Experimental|Duloxetine 60 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
9748999|NCT00408876|Experimental|Duloxetine 120 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
9749000|NCT00408876|Placebo Comparator|Placebo|placebo once a day (QD), by mouth (PO) for 13 weeks
9749001|NCT00408902|Experimental|TandutinibTreatment|Patients receive oral tandutinib 500 mg twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9749002|NCT00408928|Experimental|Bortezomib for Treatment of GHVD|To determine if bortezomib (VELCADE®) will successfully inhibit T-cell responses in clinically acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
9749003|NCT00408993|Experimental|Duloxetine|60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)
9749004|NCT00408993|Placebo Comparator|Placebo|Placebo every day (QD), by mouth (PO) for 12 weeks
9749005|NCT00409006|Experimental|Pemetrexed/Cisplatin/Gefitinib|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
9749006|NCT00409006|Experimental|Pemetrexed/Cisplatin|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
9749007|NCT00409175|Experimental|1.|Fx-1006A
9749008|NCT00409175|Placebo Comparator|2.|Placebo
9749009|NCT00409188|Experimental|Tecemotide (L-BLP25)|
9749010|NCT00409188|Placebo Comparator|Placebo|
9749011|NCT00409240|Experimental|MEDIC Intervention|Receives pharmacist-led behavioral and pharmacologic group intervention for cardiac risk reduction
9749012|NCT00409240|No Intervention|Usual Care|Patient continued on usual care
9749013|NCT00409292|Experimental|RAD001|"RAD001 was administered continuously at a dose of 10 mg daily by mouth until disease progression, unacceptable toxicity, or withdrawal of consent.~Four weeks of study drug was considered to be one cycle of treatment."
9749014|NCT00409409|Experimental|300 IR|300 IR grass pollen allergen extract tablet
9749015|NCT00409409|Placebo Comparator|Placebo|Placebo tablet
9749016|NCT00409539|Placebo Comparator|1|Placebo run-in phase. 2 week duration.
9749017|NCT00409539|Placebo Comparator|2|To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
9749018|NCT00409539|Experimental|3|20mg dose of SMP-986 to be taken once daily for 8 week duration.
9749019|NCT00409539|Experimental|4|40mg dose of SMP-986 to be taken for 8 week duration.
9749020|NCT00409539|Experimental|5|80mg dose of SMP-986 to be taken for 8 week duration.
9749021|NCT00409539|Experimental|6|120mg dose of SMP-986 to be taken for 8 week duration.
9749022|NCT00409565|Experimental|Cetuximab plus bevacizumab|Cetuximab plus bevacizumab
9749023|NCT00409578|Placebo Comparator|Placebo|Placebo tablets and capsules
9749024|NCT00409578|Experimental|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
9749025|NCT00409578|Experimental|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
9749026|NCT00409578|Experimental|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
9749027|NCT00409617|Experimental|Open Label|
9749028|NCT00409682|Active Comparator|Open-label adalimumab (Week 0 to Week 4)|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
9749029|NCT00409682|Active Comparator|Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
9749030|NCT00409682|Active Comparator|High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
9749031|NCT00409708|Active Comparator|1|
9749032|NCT00409708|Other|2|
9749033|NCT00409747|Experimental|Minocycline|
9782277|NCT01171118|Placebo Comparator|Sedation & Placebo & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
9782278|NCT01171118|Experimental|Sedation & Physostigmine & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
9782279|NCT01171118|Placebo Comparator|Sedation & Placebo & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
9782280|NCT01171183|Placebo Comparator|Placebo|
9782281|NCT01171183|Active Comparator|Carvedilol controlled release|controlled release carvedilol (Coreg CR) at 80 mg/day in once daily dosing
9782282|NCT01171521|Experimental|DermaClose Group|DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.
9782283|NCT01171612||Coronary Stent|Patients with coronary Bare Metal Stent (BMS) or Drug Eluting Stent (DES) undergoing noncardiac surgery
9782284|NCT01171625|Other|CEP Aortic Bioprothesis, model 3300TFX|
9782285|NCT01171677|Experimental|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
9782286|NCT01171677|No Intervention|Treatment as Usual|
9782287|NCT01171690|Experimental|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
9782288|NCT01171794|Active Comparator|ibuprofen|600mg ibu TID
9782289|NCT01171794|Placebo Comparator|placebo|visually identical
9782290|NCT01171820|Active Comparator|TAXUS® Liberté™|
9782291|NCT01171820|Active Comparator|XIENCE V® EECSS|
9782292|NCT01171924|Experimental|Arm A: 5 days/week schedule|
9782293|NCT01171924|Experimental|Arm B: 3 days/week schedule|
9829170|NCT02524158|No Intervention|Delayed Treatment Control - Usual Care|Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.
9749034|NCT00409825|Experimental|Part 1|Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 3, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 4: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.
9749035|NCT00409838|Experimental|Abatacept and Methotrexate|
9749036|NCT00409838|Placebo Comparator|Placebo and Methotrexate|(standard of care)
9749037|NCT00409838|Experimental|Abatacept - Open Label|Open-label extension phase
9749038|NCT00410046|Experimental|Etanercept (ETN)|Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
9749039|NCT00410059|Experimental|Erlotinib|Erlotinib 150 mg by mouth daily x 28 days.
9749040|NCT00410072|Experimental|TDF 0.5 mg|TDF=tenofovir
9749041|NCT00410072|Experimental|ETV 0.5 mg +TDF 300 mg|ETV=entecavir; TDF=tenofovir
9749042|NCT00410124|Experimental|RAD001 +BSC|The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
9749043|NCT00410124|Placebo Comparator|Placebo (plus BSC)|Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
9749044|NCT00410150|Experimental|Group 1 (Heliox-powered albuterol)|Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
9749045|NCT00410150|Active Comparator|Group 2 (Oxygen-powered albuterol)|Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.
9749046|NCT00410163|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
9749047|NCT00410163|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg
9749048|NCT00410189|Experimental|ZD6474|ZD6474 300 mg by mouth daily for 28 Days.
9749049|NCT00410202|Active Comparator|Entecavir|With the option of adding tenofovir at week 48. (This does not apply to Korea)
9749050|NCT00410202|Active Comparator|Adefovir + Lamivudine|
9749051|NCT00410202|Active Comparator|Entecavir + Adefovir|
9749052|NCT00410280|Other|1|
9749053|NCT00410384|Placebo Comparator|Placebo|Placebo
9749054|NCT00410384|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
9749055|NCT00410384|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
9749056|NCT00410410|Experimental|Abatacept (ABA)|"Induction Period; 3 arms for Cohort 1: ABA 30/~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at ~10 mg/kg), ABA ~10 mg/kg, ABA 3 mg/kg~Induction Period; 2 arms for Cohort 2: ABA 30/~10 mg/kg and Second Cohort ABA ~10 mg/kg~1 arm for maintenance period (ABA ~10 mg/kg)"
9749057|NCT00410410|Placebo Comparator|Placebo|"1 arm for induction period~1 arm for maintenance period"
9749058|NCT00410410|Other|abatacept|1 arm for open-label extension phase (ABA ~10 mg/kg)
9749059|NCT00410423|Experimental|Bortezomib 0.7mg/m^2|Bortezomib in combination with mitoxantrone, etoposide and cytarabine
9749060|NCT00410423|Experimental|Bortezomib 1.0mg/m^2|
9749061|NCT00410423|Experimental|Bortezomib 1.3mg/m^2|
9749062|NCT00410488|Active Comparator|Palonosetron - 1 Dose|"Arm 1: Palonosetron 0.25 mg intravenous (IV) for 1 dose (day 0).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
9749063|NCT00410488|Active Comparator|Palonosetron - 3 Doses|"Arm 2: Palonosetron 0.25 mg IV for 3 doses (days 0, 2, 4).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
9749064|NCT00410514|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
9749065|NCT00410514|Experimental|Mirabegron 50 mg|Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
9749066|NCT00410514|Experimental|Mirabegron 100 mg|Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
9749067|NCT00410605|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9749068|NCT00410761|No Intervention|1|Placebo vandetanib
9749069|NCT00410761|Experimental|2|Vandetanib
9749070|NCT00410813|Experimental|Arm I|Patients receive oral dasatinib once daily.
9749071|NCT00410813|Experimental|Arm II|Patients receive oral dasatinib twice daily.
9749072|NCT00410826|Experimental|Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer)|Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
9749073|NCT00410826|Active Comparator|Arm II (chemotherapy, radiotherapy)|Patients receive cisplatin and radiotherapy as in Arm I.
9749074|NCT00410891|Experimental|topical antibiotic|topical gatifloxacin 4 times per day
9749075|NCT00410904|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28 in course 1 and on days 1-21 in course 2 and all subsequent courses. Patients also receive pemetrexed disodium IV over 10 minutes on day 8 in course 1 and on day 1 in course 2 and all subsequent courses. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
9749076|NCT00411086|Experimental|Rituximab + GM-CSF|Rituximab 375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22. Sargramostim (GM-CSF) 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
9749077|NCT00411216|Experimental|exercises for gaze stabilization|Experimental group performed vestibular adaptation and substitution exercises
9749078|NCT00411216|Placebo Comparator|Control exercises|Saccadic eye movements against a Ganzfeld to prevent retinal slip error signal; no head movements
9749079|NCT00411398|Experimental|Memantine 5-20mg/d flexible dose|Memantine tablets 5-20mg/d flexible dose
9749080|NCT00411411|Placebo Comparator|Placebo|Placebo treatment, administered as tablets.
9749081|NCT00411411|Experimental|Januvia|Active treatment
9749082|NCT00411450|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.
9749083|NCT00411463|Experimental|Psychotherapy|Subjects randomized to the Psychotherapy arm will receive Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
9749084|NCT00411463|Experimental|Medication|Subjects randomized to the medication arm will receive the FDA approved medication Seroquel (quetiapine)
9749085|NCT00411554|Experimental|Sitagliptin 50 mg QD|sitagliptin 50 mg orally once daily (QD=once daily)
9749086|NCT00411554|Active Comparator|Voglibose 0.2 mg TID|voglibose 0.2 mg orally three times daily (TID= three times daily)
9749087|NCT00411619|Experimental|Everolimus|As this was a non-randomized, open-label, single arm study, all patients in the study received treatment with everolilmus
9749088|NCT00411632|Experimental|Bexarotene + Erlotinib|Bexarotene 400 mg/m^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days.
9749089|NCT00411645|Experimental|A|
9749090|NCT00411645|Placebo Comparator|B|
9749091|NCT00411671|Experimental|Sorafenib|Sorafenib 400 mg By Mouth Twice Daily for 28 Days.
9749092|NCT00411684|Experimental|CDB-2914|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CBD-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse
9749093|NCT00411749|Experimental|V501|"V501 vaccination Quadrivalent HPV (Types 6, 11, 16,~18) L1 VLP Vaccine Injection~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle [VLP] Type 6,~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6."
9749094|NCT00411749|Placebo Comparator|Placebo|Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen
9749095|NCT00411762|Experimental|PHY906 Administration|PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle
9749096|NCT00411788|Experimental|sirolimus and trastuzumab|Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
9749097|NCT00412061|Experimental|Octreotide+ Everolimus|Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
9749098|NCT00412061|Placebo Comparator|Octreotide+ Placebo|Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
9749099|NCT00412074|Active Comparator|Control 400 IU vitamin D3|400 IU vitamin D3/day given to lactating women and 400 IU vitamin D3/day given as oral supplement to infant in dyad
9749100|NCT00412074|Experimental|2400 IU vitamin D3 (cholecalciferol)|2400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 2000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
9749101|NCT00412074|Experimental|6400 IU vitamin D3 (cholecalciferol)|6400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 6000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
9749102|NCT00412087|Experimental|Cholecalciferol 2000 IU|Women at 12-16 weeks' gestation are enrolled into the study to receive 2000 IU/day vitamin D3 for one month. After the run-in dose, the subjects are randomized to one of two treatment groups: either 2000 or 4000 IU/day to be taken throughout pregnancy until delivery.
9749103|NCT00412087|Experimental|Cholecalciferol 4000 IU|Women are randomized to one of 2 treatment groups: 2000 or 4000 IU vitamin D3/day
9749104|NCT00412113|Active Comparator|Norvasc 5 mg|Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
9749105|NCT00412113|Experimental|Caduet 10/20mg|Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
9749106|NCT00412113|Active Comparator|Norvasc 10 mg|Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
9749107|NCT00412113|Experimental|Caduet 5/20mg|Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
9749108|NCT00412217|Experimental|Erlotinib|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
9749109|NCT00412217|Placebo Comparator|Placebo|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.
9749110|NCT00412243|Experimental|Clofarabine + Cyclophosphamide|Clofarabine 40 mg/m^2 daily for 3 Days + Cyclophosphamide starting 200 mg/m^2 every 12 hours for 3 days
9749111|NCT00412360|Experimental|Single Cord Blood Transplant|Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
9749112|NCT00412360|Experimental|Double Cord Blood Transplant|Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
9749113|NCT00412373|Experimental|001|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
9749114|NCT00412373|Experimental|003|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
9749115|NCT00412373|Placebo Comparator|002|Placebo for 6 weeks
9749116|NCT00412425|Active Comparator|2 Days Palonosetron|2 Days Palonosetron 0.25 mg intravenous (IV)
9749117|NCT00412425|Active Comparator|3 Days Palonosetron|3 Days Palonosetron 0.25 mg IV
9749118|NCT00412451|Experimental|Ocriplasmin 25µg|25µg ocriplasmin intravitreal injection versus sham injection
9749119|NCT00412451|Experimental|Ocriplasmin 75µg|75µg ocriplasmin intravitreal injection versus sham injection
9749120|NCT00412451|Experimental|Ocriplasmin 125µg|125µg ocriplasmin intravitreal injection versus sham injection
9749121|NCT00412451|Sham Comparator|sham injection|Sham injection
9749122|NCT00412516|Other|Group 1|JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month
9749123|NCT00412516|Experimental|Group 2|JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently
9749124|NCT00412516|Other|Group 3|Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month
9749125|NCT00412529|Experimental|Telbivudine|
9749126|NCT00412529|Active Comparator|Entecavir|
9749127|NCT00412542|Experimental|Thalidomide + CPT-11|Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.
9749128|NCT00412607|Experimental|NaviStar ThermoCool Catheter|
9749129|NCT00412737|Experimental|Oseltamivir|
9749130|NCT00412737|Placebo Comparator|Placebo|
9749131|NCT00412750|Experimental|LdT+ PEG-INF|Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
9749132|NCT00412750|Experimental|LdT Monotherapy|Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
9749133|NCT00412750|Active Comparator|PEG-INF Monotherapy|Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
9749134|NCT00412841|Experimental|Atorvastatin|Atorvastatin 40mg
9749135|NCT00412841|Placebo Comparator|Placebo|Tablets identical to atorvastatin 40mg
9749136|NCT00412867|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
9749137|NCT00412893|Experimental|Isavuconazole|Participants received a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they reached a treatment endpoint or for a maximum of 84 days.
9749138|NCT00412893|Active Comparator|Voriconazole|Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
9749139|NCT00412958|Experimental|Ocriplasmin 25µg|25µg of ocriplasmin intravitreal injection
9749140|NCT00412958|Experimental|Ocriplasmin 75µg|75µg of ocriplasmin intravitreal injection
9749141|NCT00412958|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
9749142|NCT00412958|Placebo Comparator|Placebo|Intravitreal injection of placebo
9749143|NCT00412971|Active Comparator|Hexvix cystoscopy group|
9749144|NCT00412971|Other|White light|Standard White light cystoscopy
9749145|NCT00412984|Active Comparator|1|
9749146|NCT00412984|Experimental|2|
9749147|NCT00413010|Placebo Comparator|Arm 2|
9749148|NCT00413010|Experimental|Arm 1|
9749149|NCT00413036|Experimental|lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
9749150|NCT00413049|Experimental|Valsartan/amlodipine 80/5 mg|
9749151|NCT00413049|Active Comparator|Amlodipine 5 mg|
9749152|NCT00413153|Active Comparator|1|Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
9749153|NCT00413153|Active Comparator|2|Kaletra (pre-study dose)
9749154|NCT00413166|Experimental|Induction ATRA + ATO + Idarubicin|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATRA 45 mg/m2 daily by mouth beginning day 1; ATO 0.15 mg/kg by vein daily beginning on day 1; Idarubicin 12 mg/m2 x 1 dose; Methylprednisolone 50 mg daily for 5 days starting on day 1."
9749155|NCT00413166|Experimental|Maintenance|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATO 0.15 mg/kg by vein over 2 hours Monday-Friday for 4 weeks, then a 4-week break. ATRA 45 mg/m2 by mouth every day for 2 weeks, followed by 2 additional weeks of no study drug. Continue ATRA until treatment with ATO complete."
9749156|NCT00413166|Experimental|Induction ATRA + ATO + GO|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO)~ATRA 45 mg/m2 daily po (in 2 divided doses) beginning day 1; ATO 0.15 mg/kg IV daily beginning on day 1; GO 9 mg/m2 on day 1 Methylprednisolone 50 mg daily for 5 days followed by rapid taper starting on day 1.~Theophylline 100mg p.o. bid days 1-3, 200 mg p.o. bid days 4-6, and 300 mg p.o. bid thereafter during periods when patient is receiving ATRA or ATO. Theophylline administration continues until therapy with ATO and ATRA is completed."
9749157|NCT00413192|Experimental|1|
9749158|NCT00413218|Experimental|Isavuconazole (ISA)|Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.
9749159|NCT00413218|Active Comparator|Caspofungin (CAS)/Voriconazole|Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.
9749160|NCT00413231|Experimental|Valiant Thoracic Stent Graft System|"160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.~There were no other arms for this study."
9749161|NCT00413244|Experimental|Androgel treatment|"Androgel 5 grams~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
9749162|NCT00413244|Placebo Comparator|Placebo|Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
9749163|NCT00413283|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
9749164|NCT00413283|Experimental|Romiplostim 250 μg|Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
9749165|NCT00413283|Experimental|Romiplostim 500 μg|Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
9829171|NCT02524418|Other|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
9829172|NCT02524561|Active Comparator|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
9517400|NCT03306654|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
9517401|NCT03306628|Experimental|Early Laser Therapy|a group which will receive laser therapy to one breast incision at the first post-operative visit
9749166|NCT00413283|Experimental|Romiplostim 750 μg|Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
9749167|NCT00413335|Active Comparator|1|Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
9749168|NCT00413335|Placebo Comparator|2|Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
9749169|NCT00413374|Other|Enoxaparin|
9749170|NCT00413400|Placebo Comparator|Placebo|
9749171|NCT00413400|Active Comparator|Etanercept|
9749172|NCT00413413|Experimental|Valsartan/amlodipine 80/5 mg|
9749173|NCT00413413|Active Comparator|Valsartan 80 mg|
9749174|NCT00413413|Active Comparator|Valsartan 160 mg|
9749175|NCT00413478|Experimental|5-Azacytidine|5-Azacytidine 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
9749176|NCT00413582|Active Comparator|1|Epidural analgesia
9749177|NCT00413582|Experimental|2|IV narcotic analgesia
9749178|NCT00413634|Experimental|Younger Participants (18-50 years)|
9749179|NCT00413634|Experimental|Elderly Participants (≥65 years)|
9749180|NCT00413660|Experimental|CP 690,550 1 mg BID|
9749181|NCT00413660|Experimental|CP 690,550 10 mg BID|
9749182|NCT00413660|Experimental|CP 690,550 15 mg|
9749183|NCT00413660|Experimental|CP 690,550 3 mg BID|
9749184|NCT00413660|Experimental|CP 690,550 5 mg BID|
9749185|NCT00413660|Experimental|CP-690,550 20 mg QD|
9749186|NCT00413660|Placebo Comparator|Placebo|Dummy tablets
9749187|NCT00413777|Experimental|Tolvaptan 45/15 mg/day orally for up to 4 years|Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
9749188|NCT00413777|Experimental|Tolvaptan 60/30 mg/day orally for up to 4 years|Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
9749189|NCT00413894|Experimental|1|
9517402|NCT03306628|Experimental|Late Laser Therapy|a group which will receive laser therapy to one breast incision 6 weeks after surgery
9749190|NCT00413920|Experimental|Without Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, but did not subsequently receive oral corticosteroids for the remainder of the study.
9749191|NCT00413920|Active Comparator|With Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
9749192|NCT00413959|Experimental|Velcade, Rituximab,Cyclophosphamide & Decadron|Velcade 375 mg/m^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
9749193|NCT00414011|Experimental|Moxifloxacin|Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
9749194|NCT00414011|Experimental|Gatifloxacin|Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
9749195|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 5 μg|Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
9749196|NCT00414050|Active Comparator|RECOMBIVAX HB™ Hepatitis B Vaccine|Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
9749197|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 10 μg|Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
9749198|NCT00414050|Active Comparator|ENGERIX-B®|Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.
9749199|NCT00414076|Active Comparator|Letrozole|Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks.
9749200|NCT00414076|No Intervention|Standard of Care|Patients receive no treatment. Follow up every 3 months.
9749201|NCT00414167|Experimental|1|Bupropion
9749202|NCT00414167|Placebo Comparator|2|Placebo
9749203|NCT00414206|Active Comparator|1% mecamylamine|
9749204|NCT00414206|Active Comparator|0.3% mecamylamine|
9749205|NCT00414206|Placebo Comparator|Placebo|
9749206|NCT00414271|Experimental|Docetaxel and Capecitabine in gastric cancer|Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
9749207|NCT00414310|Experimental|Decitabine|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.
9749208|NCT00414310|Experimental|Decitabine + Valproic Acid|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.
9749209|NCT00414388|Experimental|Single agent Sorafenib|Oral Single agent Sorafenib 400mg twice daily
9749210|NCT00414440|Experimental|Everolimus|Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).
9749211|NCT00414440|Placebo Comparator|Placebo|Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
9749212|NCT00414466|Placebo Comparator|Placebo (0mg/day)|Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
9749213|NCT00414466|Active Comparator|Gabapentin Low (1mg/day)|Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
9749214|NCT00414466|Active Comparator|Gabapentin Medium (6mg/day)|Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
9749215|NCT00414466|Active Comparator|Gabapentin High (30mg/day)|Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
9749216|NCT00414518|Experimental|Treatment interruption|Oral Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for 12 weeks followed by treatment interruption if CD4 count is 450 mm^3 or higher. When CD4 count is less than 350 mm^3 on two separate, consecutive measurements during treatment interruption, therapy will be resumed.
9749217|NCT00414518|Experimental|CD4 T cell guided therapy|Anti Retroviral Therapy initiated when AIDS-defining illness occurs or if CD4 count is confirmed at less than 350 mm^3 at two separate, consecutive measurements
9749218|NCT00414544|Experimental|CosmetaLife|Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
9749219|NCT00414544|Active Comparator|Restylane|Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
9749220|NCT00414596|Experimental|DRX Group|Patients using the device DRX9000™.
9749221|NCT00414609|Experimental|Aliskiren|"Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.~Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.~Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study."
9749222|NCT00414609|Placebo Comparator|placebo|Core study: placebo for 36 weeks once daily in the morning
9749223|NCT00414635|Other|Control Arm with Week 24 Crossover|Subjects randomized to the control arm will remain on daily dosing of the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily for 24 weeks. After 24 weeks of daily therapy subjects on this arm may be eligible to cross over to the experimental arm regimen of the coformulated single tablet of 600 mg efavirenz +300 mg tenofovir df +200 mg of emtricitabine on the 5/2 intermittent dosing treatment schedule for the remainder of the study.
9749224|NCT00414635|Experimental|5/2 Intermitent Treatment Arm|Subjects randomized to the 5/2 intermittent dosing treatment schedule regimen will be prescribed the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily, for 5 consecutive days per week followed by 2 days off of these medications, 600 mg efavirenz, 300 mg tenoforvir dt and 200 mg emtricitabine, for 48 weeks.
9782294|NCT01171963|Experimental|Rotarix Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Rotarix™ vaccine, liquid formulation, at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccines were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Rotarix™ vaccine. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Rotarix™ and OPV vaccines were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
9782295|NCT01171963|Placebo Comparator|Placebo Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Placebo at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccine were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Placebo. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Placebo and the OPV vaccine were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
9782296|NCT01171976|Experimental|TE Ranibizumab 0.5 mg and Laser|On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
9782297|NCT01171976|Experimental|TE Ranibizumab 0.5 mg alone|Patients received ranibizumab intravitreal injection therapy only.
9749225|NCT00414661||Study group|All enrolled subjects
9749226|NCT00414700|Experimental|ChondroCelect|
9749227|NCT00414700|Active Comparator|Microfracture|
9749228|NCT00414726|Active Comparator|NBO (Normobaric Oxygen)|Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
9749229|NCT00414726|Placebo Comparator|Room Air|Room Air, inhaled at 30-45L/min via a facemask for 8 hours
9749230|NCT00414765|Experimental|Aldesleukin|All participants were treated with aldesleukin 600,000 international units per kilogram [IU/kg] (0.037 milligram (mg)/kg) administered as a 15-minute intravenous (IV) infusion every 8 hours for a maximum of 14 doses for the first cycle (5-day cycle). Following 9 days of rest from therapy, the cycle was repeated for up to 14 doses (i.e., a total of up to 28 doses), if tolerated.
9749231|NCT00414817|Experimental|Automated Phone-Based Refill Reminders|Intervention Arm: Participants randomly assigned to this study arm may receive up to 8 automated phone calls from the BREATH EASY Medication Reminder Program over the course of the 19 month intervention period.
9749232|NCT00414817|No Intervention|Usual Care|"Usual Care: Participants randomly assigned to this arm received the same introductory letter as those in the intervention arm, giving them the opportunity to opt out, but were subsequently selected to be in the usual care study arm, and therefore, receive no intervention."
9749233|NCT00414908|Experimental|A|
9749234|NCT00414908|Placebo Comparator|B|
9517403|NCT03306602|Experimental|Bulk Fill Composite|In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps.
9749235|NCT00414960|Experimental|Enzastaurin|Treatment with enzastaurin 500 milligrams (mg) orally (po) once daily (QD) given as 4 tablets (125 mg each).
9749236|NCT00414960|Placebo Comparator|Placebo|Treatment with placebo po QD appearing identical to enzastaurin.
9749237|NCT00414973|Experimental|A|
9749238|NCT00414973|Active Comparator|B|
9749239|NCT00415051|Experimental|Single Group Assignment|RVF MP-12
9749240|NCT00415168|Experimental|Pemetrexed + Cisplatin|
9782298|NCT01171976|Active Comparator|PRN Ranibizumab 0.5 mg|Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.
9517404|NCT03306602|Active Comparator|Layered Composite|The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.
9749241|NCT00415194|Experimental|Pemetrexed/Cisplatin|"Pemetrexed 500 milligrams per meter square (mg/m^2) administered intravenously (IV) plus cisplatin 75 mg/m^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment.~Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
9749242|NCT00415194|Placebo Comparator|Placebo/Cisplatin|"Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m^2 on Day 1 every 21 days.~Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose.~Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
9749243|NCT00415363|Experimental|A|
9749244|NCT00415363|Placebo Comparator|B|
9749245|NCT00415493|Experimental|Order 1|Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation
9749246|NCT00415493|Experimental|Order 2|Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation
9749247|NCT00415506|Experimental|Scleritis|Subjects with Scleritis
9749248|NCT00415506|Experimental|Orbital Inflammation|Subjects with Orbital Inflammation
9749249|NCT00415519|Experimental|1|
9749250|NCT00415519|Placebo Comparator|2|
9749251|NCT00415532|Experimental|Romiplostim|Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10^9/L for up to 52 weeks.
9749252|NCT00415532|Other|Standard of Care|Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
9749253|NCT00415597|Experimental|ALO-01|Doses given once or twice daily
9749254|NCT00415610|Other|Tier 1|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
9749255|NCT00415610|Other|Tier 2|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
9749256|NCT00415610|Other|Tier 3|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
9749257|NCT00415636|Experimental|LY2603618 40 mg/m^2 (4.5-hour infusion)|LY2603618 40 milligrams per square meter (mg/m^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed.
9749258|NCT00415636|Experimental|LY2603618 40 mg/m^2 (1-hour infusion)|Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m^2 [4.5-hour infusion]), the LY2603618 40 mg/m^2 dose in Cohort 2 (LY2603618 40 mg/m^2 [1-hour infusion]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed.
9749259|NCT00415636|Experimental|LY2603618 70 mg/m^2|Beginning with Cohort 3 (LY2603618 70 mg/m^2), dose modifications were allowed. LY2603618 70 mg/m^2 was administered over the course of 1 hour.
9749260|NCT00415636|Experimental|LY2603618 105 mg/m^2|Cohort 4: LY2603618 105 mg/m^2 administered over the duration of 1 hour.
9749261|NCT00415636|Experimental|LY2603618 150 mg/m^2|Cohort 5: LY2603618 150 mg/m^2 administered over the duration of 1 hour.
9517405|NCT03306563|Experimental|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
9517406|NCT03306563|Active Comparator|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
9749262|NCT00415636|Experimental|LY2603618 195 mg/m^2|Cohort 6: LY2603618 195 mg/m^2 administered over the duration of 1 hour.
9749263|NCT00415857|Experimental|PR1 + Imatinib|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Continue receiving imatinib by mouth at the same dose received during the last 6 months. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
9749264|NCT00415857|Experimental|PR1 + Imatinib + Interferon|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
9749265|NCT00415870|Experimental|PACE|Received text messages and counseling calls
9749266|NCT00415870|No Intervention|Control|
9749267|NCT00415909|Experimental|TALL-104 + IM|TALL-104 cells and imatinib mesylate (IM) therapy
9749268|NCT00416078|Experimental|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
9749269|NCT00416078|Active Comparator|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
9749270|NCT00416182|Experimental|Pulmozyme|2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
9749271|NCT00416182|Placebo Comparator|placebo|2.5 mg/2mL placebo administered intranasally once daily
9749272|NCT00416195|Experimental|E2007|2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).
9749273|NCT00416195|Placebo Comparator|Placebo|Matching placebo once daily for 16 weeks (Days 1 to 112)
9749274|NCT00416312||Conventional & Patient-Specific Dosimetry|Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
9749275|NCT00416455|Experimental|Treatment (diagnostic scans, surgery, chemotherapy, radiation)|Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.
9749276|NCT00416494|Experimental|Initial Cohort|
9749277|NCT00416494|Experimental|Second cohort|
9749278|NCT00416520|Experimental|1|
9749279|NCT00416520|Placebo Comparator|2|
9749280|NCT00416520|Active Comparator|3|
9749281|NCT00416572|Experimental|Education Intervention|Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
9749282|NCT00416572|Experimental|Nutrition Education Intervention|Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
9749283|NCT00416572|No Intervention|Control Condition|Participants received care as usual.
9749284|NCT00416598|Experimental|Treatment (chemotherapy, PBSC or bone marrow transplantation)|See Detailed Description.
9749285|NCT00416624|Experimental|Epoetin alfa - 40000 units|40,000 Units
9749286|NCT00416624|Experimental|Epoetin alfa - 80000 units|80,000 Units
9749287|NCT00416624|Experimental|Epoetin alfa - 120000 Units|120,000 Units
9749288|NCT00416624|Experimental|Darbepoetin alfa***|500 mcg
9749289|NCT00416715|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
9749290|NCT00416793|Experimental|Treatment|Patients receive bortezomib IV on days 1, 4, 8, and 11 and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9749291|NCT00416884|Experimental|TBI, Campath, Fludarabine T-cell Deplete|(Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
9749292|NCT00416949|Experimental|Patient-specific 3D-RD Dosimetry|Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
9749293|NCT00417027|Active Comparator|2.5 mL bolused every 15 minutes|
9749294|NCT00417027|Active Comparator|5ml bolused every 30 minutes|
9749295|NCT00417027|Active Comparator|10ml bolused every 60 minutes|
9749296|NCT00417079|Active Comparator|Mitoxantrone + Prednisone|Mitoxantrone + Prednisone
9749297|NCT00417079|Experimental|Cabazitaxel + Prednisone|Cabazitaxel + Prednisone
9749298|NCT00417170|Experimental|Aliskiren 300 mg|Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
9749299|NCT00417170|Active Comparator|Amlodipine 5 mg|Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
9749300|NCT00417274|Experimental|Quinacrine|Uncontrolled treatment arm
9749301|NCT00417417|Experimental|Rilonacept|Rilonacept 320 mg subcutaneous at each treatment visit
9749302|NCT00417417|Sham Comparator|Placebo|Normal saline subcutaneously at each treatment visit.
9749303|NCT00417482|Other|Risperidone-risperidone|Risperidone for 16 weeks followed by risperidone for 16 weeks
9749304|NCT00417482|Other|Risperidone-Placebo|Risperidone for 16 weeks followed by placebo for 16 weeks
9749305|NCT00417482|Other|Placebo-Placebo|Placebo for 16 weeks followed by placebo for 16 weeks
9749306|NCT00417612|Experimental|1|Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
9749307|NCT00417612|Placebo Comparator|2|Participants given placebo capsule to match for comparison
9749308|NCT00417859|Active Comparator|TKA mobile|TKA mobile
9749309|NCT00417859|No Intervention|TKA|TKA fix
9749310|NCT00417885|Experimental|A|sunitinib + exemestane
9749311|NCT00417963|Experimental|stent placement in the carotid artery|placement of a bare metal stent for treatment of carotid artery stenosis
9749312|NCT00417976|Experimental|Bevacizumab|
9749313|NCT00417989|Experimental|722 sensor augmented pump|722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
9749314|NCT00417989|No Intervention|Multiple Daily Injections (MDI)|MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year
9749315|NCT00418015||Labor analgesia|Labor analgesia receiving fentanyl labor analgesia
9749316|NCT00418015||Cesarean delivery analgesia|Cesarean delivery analgesia consisting of spinal fentanyl and morphine
9749317|NCT00418028|Active Comparator|A Cint|Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
9749318|NCT00418028|Experimental|B Ccont|Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
9749319|NCT00418093|Experimental|Chemotherapy|All patients received oxaliplatin, gemcitabine, and bevacizumab
9749320|NCT00418184|Experimental|1|
9749321|NCT00418184|Placebo Comparator|2|
9749322|NCT00418262|Experimental|Atomoxetine HCL (Strattera)|Teatment of children with fetal alcohol syndrome and ADHD with Atomoxetine HCL (Strattera)
9749323|NCT00418314|Experimental|QuickOpt (Treatment)|Frequent optimization using QuickOpt to optimize the AV/PV and VV Delays.
9749324|NCT00418314|Active Comparator|Control|Empiric programming or one-time optimization using a non-IEGM method.
9749325|NCT00418379|Experimental|300 IR (4M)|300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
9749326|NCT00418379|Experimental|300 IR (2M)|300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
9749327|NCT00418379|Placebo Comparator|Placebo|Placebo tablet
9749328|NCT00418457|Active Comparator|General anesthesia and opioid|General anesthesia followed by opioid administration
9749329|NCT00418457|Active Comparator|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
9749330|NCT00418522|Active Comparator|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
9749331|NCT00418522|Experimental|Exubera|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
9749332|NCT00418561|Experimental|Cohort 1|Metazym (Recombinant human arylsulfatase A (rhASA)): 25 U/kg as a single dose - hereafter 50 U/kg
9749333|NCT00418561|Experimental|Cohort 2|100 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
9749334|NCT00418561|Experimental|Cohort 3|200 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
9749335|NCT00418574|Experimental|Abagovomab|
9749336|NCT00418574|Placebo Comparator|Placebo|
9749337|NCT00418665|Active Comparator|750 mcg AMG 531|750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
9749338|NCT00418665|Placebo Comparator|Placebo Part B|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
9749339|NCT00418665|Placebo Comparator|Placebo Part A|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
9749340|NCT00418665|Active Comparator|500 mcg AMG 531|500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
9749341|NCT00418665|Active Comparator|750 mcg AMG531 Part B|750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
9749342|NCT00418691|Active Comparator|Immediate Release (IR) Methylphenidate|10 mg by mouth (PO) twice daily for 4 Weeks
9749343|NCT00418691|Active Comparator|Sustained Release (SR) Methylphenidate|200 mg PO once daily for 4 Weeks
9749344|NCT00418691|Active Comparator|Modafinil|18 mg PO once daily for 4 Weeks
9749345|NCT00418717|Experimental|1|Arm 1: Period A-25mg BW; Arm 1: Period B-50mg QW
9749346|NCT00418886|Placebo Comparator|1|Placebo Vandetanib + Pemetrexed
9749347|NCT00418886|Experimental|2|Vandetanib + Pemetrexed
9749348|NCT00418938|Experimental|Arm A|FOLFIRI + Panitumumab
9749349|NCT00418938|Experimental|Arm B|FOLFIRI + Bevacizumab
9749350|NCT00418951|Experimental|Liposomal amphotericin B: 3 mg/kg|3 mg/kg intravenously (IV) three times per week
9749351|NCT00418951|Experimental|Liposomal amphotericin B: 9 mg/kg|9 mg/kg IV once per week
9749352|NCT00418951|Experimental|Voriconazole: 400 mg|400 mg oral twice daily day 1 followed by 200 mg twice daily
9749353|NCT00418964|Experimental|Single bundle hamstring|
9749354|NCT00418964|Experimental|Double bundle hamstring|
9749355|NCT00418964|Active Comparator|Bone patellar tendon bone|
9749356|NCT00418977|Experimental|Family Based Therapy|Participants will receive family based therapy (FBT)
9749357|NCT00418977|Active Comparator|Individual Supportive Psychotherapy|Participants will receive individual supportive psychotherapy (ISP)
9749358|NCT00419003|Experimental|Lamotrigine Pre-Treatment|Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
9749359|NCT00419003|Placebo Comparator|Placebo Pre-Treatment|2 hours prior to ketamine infusion each patient received three capsules of placebo identical in size, weight, appearance, and taste to the lamotrigine tablets. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
9749360|NCT00419094|Experimental|Keppra XR 1000 mg/day|1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
9749361|NCT00419094|Experimental|Keppra XR 2000 mg/day|2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
9749362|NCT00419120|Experimental|Neo-bladder construction|Surgical implantation of autologous neo-bladder construct
9749363|NCT00419159|Experimental|Everolimus (RAD001) 70 mg/week|
9749364|NCT00419159|Experimental|Everolimus (RAD001) 10 mg/day|
9749365|NCT00419263|Experimental|Peramivir 150 mg|
9749366|NCT00419263|Experimental|Peramivir 300 mg|
9749367|NCT00419263|Placebo Comparator|Placebo|
9749368|NCT00419315|Experimental|Alcohol Care Management|Care management for alcohol dependence delivered in primary care
9749369|NCT00419315|Active Comparator|Usual Care|Usual care included a referral to specialty addiction treatment
9749370|NCT00419341|Experimental|IgPro20|Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
9749371|NCT00419380|Active Comparator|dornase alfa (Pulmozyme®)|dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear.
9749372|NCT00419380|Active Comparator|Ofloxin|Ofloxin : 5 drops twice daily for 7 days to the affected ear.
9749373|NCT00419393|Experimental|Keppra XR (Levetiracetam XR)|1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
9749374|NCT00419445|Active Comparator|GTS21 25 mg tid/Placebo 25 mg tid|
9749375|NCT00419445|Active Comparator|GTS21 75 mg tid/Placebo 75 mg tid|
9749376|NCT00419445|Active Comparator|GTS21 150 mg tid/Placebo 150 mg tid|
9749377|NCT00419562|Experimental|Oral Insulin|7.5 mg oral insulin capsules given before breakfast on a daily basis.
9749378|NCT00419562|Placebo Comparator|Placebo|Placebo capsule designed to match appearance of treatment capsule
9749379|NCT00419666|Experimental|Calcitriol 3mcg/g|Participants receive calcitriol 3 micrograms per gram (mcg/g) ointment applied topically twice daily for 56 days.
9749380|NCT00419757|Active Comparator|Symbicort|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
9749381|NCT00419757|Active Comparator|Budesonide|budesonide HFA pMDI 160 μg x 2 actuations twice daily
9749382|NCT00419770|Experimental|B|Deferasirox
9749383|NCT00419770|Placebo Comparator|A|
9749384|NCT00419926|Experimental|Intensified Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
9749385|NCT00419926|Active Comparator|Standard Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
9749386|NCT00419952|Experimental|Symbicort|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
9749387|NCT00419952|Experimental|Budesonide|Budesonide HFA pMDI 160 ug x 2 actuations BID
9749388|NCT00420004|Experimental|LY2216684|"LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 3 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 3 mg/day; it could be increased 3 mg at a time (scheduled visit) to a maximum dose of 12 mg/day; or it could be decreased 3 mg at any time (scheduled or unscheduled visits) to a minimum dose of 3 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 3 mg/day and 6 mg/day of LY2216684 also received 1 LY2216684-matching placebo tablet + 2 escitalopram-matching placebo capsules. Participants on 9 mg/day and 12 mg/day of LY2216684 also received 2 escitalopram-matching placebo capsules."
9749389|NCT00420004|Placebo Comparator|Placebo|Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks.
9749390|NCT00420004|Active Comparator|Escitalopram|"Escitalopram: flexible dose of 10 or 20 milligram (mg), capsules, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 10 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 10 mg/day; it could be increased up to a maximum dose of 20 mg/day; or it could be decreased back to 10 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 10 mg/day of escitalopram also received 1 escitalopram-matching placebo capsule + 2 LY2216684-matching placebo tablets. Participants on 20 mg/day of escitalopram also received 2 LY2216684-matching placebo tablets."
9749391|NCT00420017|Experimental|Amiodarone|Intravenous amiodarone
9749392|NCT00420017|Other|Control|Control
9749393|NCT00420056|Experimental|PD-0332991|
9749394|NCT00420095|Active Comparator|1|Human insulin mix 30/70
9749395|NCT00420095|Experimental|2|Insulin lispro low mix
9749396|NCT00420147|Experimental|Wedged Orthosis|Subjects were given a wedged inshoe orthosis
9749397|NCT00420147|Placebo Comparator|Neutral Orthosis|Subjects were given a neutral inshoe orthosis.
9749398|NCT00420199|Active Comparator|Abatacept + Methotrexate (Double-blind period)|
9749399|NCT00420199|Placebo Comparator|Placebo + Methotrexate (Double-blind period)|
9749400|NCT00420212|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
9749401|NCT00420212|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
9749402|NCT00420212|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
9749403|NCT00420238|Experimental|A|
9749404|NCT00420238|Placebo Comparator|B|
9749405|NCT00420290|Active Comparator|Kineret|Interleukin-1 receptor antagonist
9749406|NCT00420290|Placebo Comparator|Placebo|
9749407|NCT00420303|Experimental|A|
9749408|NCT00420303|Placebo Comparator|B|
9749409|NCT00420316|Experimental|Rotarix Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
9829173|NCT02524561|Active Comparator|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
9829174|NCT02524561|Placebo Comparator|placebo|Placebo tablet, placebo patch, placebo progesterone
9835792|NCT02755649|Experimental|Dupilumab 300 mg Q2W + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
9835793|NCT02755649|Experimental|Dupilumab 300 mg QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
9836137|NCT02770612|Other|Post-cesarean delivery mothers|"Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.~After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session (intervention). The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with (primary outcome)~The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.~A chart review will be performed by physicians in the research group on participants to gather information on demographics, indications for surgery, etc."
9836138|NCT02770625|Experimental|ISU302|60 U/kg (once every 2 weeks for 6 months)
9836139|NCT02770820|Experimental|Treatment (autologous CD8 T cells)|Beginning 4 weeks after completion of last course of consolidation chemotherapy, patients receive autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes IV over 1-4 hours on day 0 and again after a minimum of 3 weeks. Beginning 6 hours after the second infusion of T cells, patients also receive aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity. Patients who have clinically benefitted from T cell therapy may receive additional infusions of T cells and aldesleukin at the discretion of the PI and the attending physician.
9836140|NCT02770846|Experimental|Immediate loading|Immediate loading of single dental implant in the anterior maxilla with temporary crown in central occlusion
9836141|NCT02770846|Active Comparator|Delayed loading|Delayed loading. 2-stage procedure with a 4 months healing period before fabrication of temporary crown.
9836142|NCT02771093|Experimental|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
9836143|NCT02771093|Experimental|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
9836144|NCT02771145|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
9836145|NCT02771210|Experimental|AIN457/Secukinumab|Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose was assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
9836146|NCT02771210|Placebo Comparator|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
9836147|NCT02771340|Experimental|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
9836148|NCT02771340|Experimental|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
9836149|NCT02771340|Experimental|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
9836150|NCT02771366|Experimental|Fermented Papaya Preparation, then granulated sugar|Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
9829175|NCT02524665|Experimental|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
9829176|NCT02524665|Active Comparator|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
9829177|NCT02524730|Other|Scorpio NRG CR Total Knee System|Primary total knee replacement
9829178|NCT02524769|Other|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
9829179|NCT02524847|Experimental|Methoxsalen with ECP|Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.
9829180|NCT02524977|Active Comparator|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
9829181|NCT02524977|Experimental|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
9829182|NCT02525055|Experimental|Infectious titre 1|6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50 of virus
9829183|NCT02525055|Experimental|Infectious titre 2|6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50 of virus
10201778|NCT05195359|No Intervention|Allocation to Tracking-only Control App|The tracking-only control app includes identical measurement and daily logging capabilities to the active comparator condition, but is stripped of all active sleep improvement content and features found in the Dein Schlaf. Dein Tag. app. Participants assigned to the control app condition will be instructed to log their behaviors in-app and track their sleep daily for the duration of the study (12 weeks). Participants will also be instructed to complete a brief sleep diary daily using Survey Monkey. At the three time points (baseline, 6 weeks, and 12 weeks), participants will be instructed to complete online assessments on self-reported sleep quality, chronotype, and preventative health measures including physical activity, diet, psychosocial variables, occupational performance.
9829184|NCT02525055|Experimental|Infectious titre 3|6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50 of virus
10201779|NCT05195346||People Living with HIV (PLHIV)|Thai people living with HIV, aged 18 or above, who are on Antiretroviral Therapy (ART)
9829185|NCT02525055|Experimental|Infectious titre 4|6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50 of virus
9829186|NCT02525055|Experimental|Infectious titre 5 (age 18 to 45 y)|6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
9829187|NCT02525055|Experimental|Infectious titre 5 (age 46 to 64 y)|16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
9829188|NCT02525094|Experimental|MEDI9929 280 mg|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
9829189|NCT02525094|Placebo Comparator|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
9829190|NCT02525133|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
9829191|NCT02525133|Placebo Comparator|Placebo|3 placebo implants
9829192|NCT02525263|Experimental|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
9829193|NCT02525471|Experimental|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 23 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
9829194|NCT02525523|Experimental|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
9829195|NCT02525523|Placebo Comparator|Placebo|Placebo enema, once daily for 6 weeks
10201780|NCT05195346||HIV Healthcare Providers|Thai healthcare providers, including but not limited to doctors, nurses, counsellors, lay providers, pharmacists, lab technicians, etc., who take care of any persons living with HIV. All aged 18 or above
9517407|NCT03306563|Sham Comparator|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
9749410|NCT00420316|Placebo Comparator|Placebo Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
9749411|NCT00420342|Experimental|0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
9749412|NCT00420342|Experimental|2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
9749413|NCT00420342|Active Comparator|1.5 mg MPA / 0.3 mg CEE (Prempro)|1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
9749414|NCT00420381|Experimental|A|
9749415|NCT00420407|Experimental|I|Vasopressin
9749416|NCT00420407|Placebo Comparator|2|bolus of NS (normal saline) followed by continuous infusion of NS, no vasopressin added
9749417|NCT00420420|Experimental|MK0249|
9749418|NCT00420420|Placebo Comparator|placebo|
9749419|NCT00420459|Experimental|Aripiprazole|
9782299|NCT01171989|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of GSK2202083A and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of GSK2202083A vaccine at Day 0 and of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
9782300|NCT01171989|Active Comparator|INFANRIX HEXA/MENJUGATE GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and 2 doses of Menjugate® vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with Menjugate® vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
9782301|NCT01171989|Active Comparator|INFANRIX HEXA/NEISVAC-C + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with NeisVac-C® vaccine at Day 0 and 1 dose of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
9782302|NCT01172067|Experimental|Quickopt Group|the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
9782303|NCT01172067|Active Comparator|Echocardiography group|the Echo Group patients will be optimized by Echo.
9782304|NCT01172145|Placebo Comparator|Cholinesterase inhibitor only|
9782305|NCT01172145|Experimental|Cholinesterase Plus Modafinil|
9782306|NCT01172184||Severe mitral regurgitation|Patients with severe mitral regurgitation are admitted for pre-operation cardiac catheterization and are willing to participate in this study.
9782307|NCT01172197|Active Comparator|Ropivacaine|Local anaesthetic bolus and infusion
9782308|NCT01172197|Active Comparator|Levobupivacaine|Local anaesthetic bolus and infusion
9782309|NCT01172275|Experimental|N-Acetylcysteine|N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
9782310|NCT01172275|Placebo Comparator|Placebo|Placebo effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
9782311|NCT01172288|Experimental|N-Acetylcysteine|NAC was titrated up to a maximum dose of 2400 mg over the course of 2 weeks. Subjects were assigned 600 mg twice a day for weeks 1-2, and then were assigned 1200 mg twice a day for the remainder of the 12 week study.
9782312|NCT01172288|Placebo Comparator|Placebo|Placebo: Subjects were assigned to take two capsules twice a day for weeks 1-2, and then were assigned 4 capsules twice a day for the remainder of the 12 week study.
9782313|NCT01172353|Experimental|sodium bicarbonate|hydration with sodium bicarbonate
9782314|NCT01172353|Active Comparator|saline|hydration with saline 1ml/Kg/h for 6 hours
9782315|NCT01172418|Active Comparator|Thymoglobulin and Daclizumab|Group I: Our standard steroid avoidance protocol, i.e., 3 daily doses of 1 mg/kg of Thymoglobulin®, the first to be infused at surgery, accompanied by 2 doses of anti-CD25 humanized monoclonal antibody, the first also to be given at surgery, and the second 2 weeks later. (controls)
9517408|NCT03306550|Active Comparator|aspirin arm|only take aspirin (100mg,qd) orally for 10 days treatment course
9782316|NCT01172418|Experimental|Thymoglobulin and Alemtuzumab|Group II: A new steroid avoidance protocol in which 1 dose of 1 mg/kg of Thymoglobulin® is to be infused at surgery followed by 1 dose of alemtuzumab (Campath-1H) at 0.3 mg/kg within 24 hours. No further antibody therapy will be used.
9782317|NCT01172522|Experimental|Fexofenadine left; placebo right|"Topical treatment active versus placebo.~Double blind randomized placebo controlled split face intrasubject comparison."
9782318|NCT01172522|Experimental|Fexofenadine right; placebo left|Split face double blind
9782319|NCT01172535|Experimental|Lopinavir/ritonavir|Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
9782320|NCT01172600|Active Comparator|Entonox|Patients will receive inhaled Entonox along with the interventional block they are scheduled.
9782321|NCT01172600|Placebo Comparator|Oxygen|Patients will receive inhaled oxygen along with the interventional block they are scheduled.
9782322|NCT01172639|Other|CoBRA classic high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Sulfasalazine 2g tablet by mouth, daily for 40 weeks~Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32"
9829196|NCT02525536|Experimental|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
9829197|NCT02525536|Experimental|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
9829198|NCT02525536|Experimental|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
9829199|NCT02525549|Experimental|Test product|Adapalene and Benzoyl Peroxide Gel
9829200|NCT02525549|Active Comparator|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
9829201|NCT02525549|Placebo Comparator|Placebo product|Placebo gel
9829202|NCT02525575|Experimental|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
9829203|NCT02525588|Active Comparator|Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)|Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis
9829204|NCT02525588|Active Comparator|Highly cross-linked polyethylene (X3)|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
9829205|NCT02525627|Active Comparator|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
9829206|NCT02525627|Active Comparator|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
9749420|NCT00420511|Experimental|Sitagliptin|Sitagliptin 100mg once a day (od) by mouth (po)
9749421|NCT00420511|Placebo Comparator|Placebo arm|Placebo once a day (od) by mouth (po)
9749422|NCT00420628|Experimental|Loteprednol/Tobramycin|0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension
9749423|NCT00420628|Placebo Comparator|Vehicle|Vehicle
9749424|NCT00420641|Experimental|GSK372475 Arm|GSK372475 1.0- 1.5 mg/day
9749425|NCT00420641|Experimental|Paroxetine Arm|Paroxetine 20-30 mg/day
9749426|NCT00420641|Other|Placebo|Placebo to Match
9749427|NCT00420745|Experimental|Rotarix Group|All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
9749428|NCT00420745|Placebo Comparator|Placebo Group|All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
9749429|NCT00420771|Experimental|Gabapentin|gabapentin treatment 1200 mg three times daily
9749430|NCT00420771|Placebo Comparator|Placebo|Placebo condition received pills identical in appearance to experimental arm.
9749431|NCT00420784|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
9749432|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
9749433|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
9749434|NCT00420784|Placebo Comparator|PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
9749435|NCT00420849|Experimental|Lenalidomide plus Dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
9749436|NCT00420927|Experimental|ADA+MTX/PBO+MTX (Arm 1)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
9749437|NCT00420927|Experimental|ADA+MTX/ADA+MTX (Arm2)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
9749438|NCT00420927|Experimental|ADA+MTX/OL ADA+MTX (Arm 3)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
9749439|NCT00420927|Experimental|PBO+MTX/PBO+MTX (Arm 4)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
9749440|NCT00420927|Experimental|PBO+MTX/OL ADA+MTX (Arm 5)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
10201781|NCT05195333|Experimental|First group|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient. You will be asked to do these exercises as home exercise with 10 repetitions 3 days a week, until the 34th week of pregnancy.
10201782|NCT05195333|Experimental|Second group|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy
10201783|NCT05195333|No Intervention|Third group|The participants will not be given any exercise program, they will be asked to continue their routine care.
10201784|NCT05195320|Experimental|Group Intervention|Participants will attend six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion. These skills are presented in sequence over the course of the intervention so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex. The culmination of developing these skills and participation in a peer group will assist individuals in increasing self-efficacy and overall QOL, well-being and participation. Participants will complete follow-up assessment at 18- and 30-weeks post-intervention.
10201785|NCT05195320|Placebo Comparator|Placebo|Participants will receive no intervention throughout the course of the study; however, the participants will be tested at 18- and 30-weeks participation in the study.
10201786|NCT05195307|Experimental|Music Group|Application Group Pregnant women in the application group were regularly listened to music for 20 minutes a day for 10 days. In addition, the pregnant women in the application group were trained by the researcher on preparing for normal delivery.
10201787|NCT05195307|No Intervention|Control Group|In the study, pregnant women in the control group were trained by the researcher on preparing for normal delivery.
10201788|NCT05195294|Experimental|LioCyx-M monotherapy|Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M).
10201789|NCT05195294|Experimental|LioCyx-M + lenvatinib combinational therapy|Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M) with daily intake of lenvatinib.
10201790|NCT05195281|Experimental|Repetition of EUS-FNA or FNB for RNA extraction|
9749441|NCT00420992|Experimental|ALO-01|Up to 80 mg twice a day (bid)
9749442|NCT00420992|Placebo Comparator|Placebo|Twice a day (bid)
10201791|NCT05195255|Experimental|Healthy subjects|Prebiotic administration
10201792|NCT05195216||individuals with cystic fibrosis|
9749443|NCT00421148|Experimental|Sugammadex 0.5 mg/kg|Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.
9749444|NCT00421148|Experimental|Sugammadex 1 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
9749445|NCT00421148|Experimental|Sugammadex 2 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.
9749446|NCT00421148|Experimental|Sugammadex 4 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.
9749447|NCT00421148|Placebo Comparator|Placebo|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.
9749448|NCT00421174|Experimental|Etanercept|Etanercept plus corticosteroids
9749449|NCT00421174|Active Comparator|Placebo|Placebo plus Corticosteroids
9749450|NCT00421304|Placebo Comparator|Placebo|Participants will receive a single intravenous (IV) dose of placebo matched to motavizumab on Day 0 of the study.
9749451|NCT00421304|Experimental|Motavizumab 30 mg/kg|Participants will receive a single IV dose of motavizumab 30 mg/kg on Day 0 of the study.
9749452|NCT00421304|Experimental|Motavizumab 100 mg/kg|Participants will receive a single IV dose of motavizumab 100 mg/kg on Day 0 of the study.
9749453|NCT00421343|Other|Treatment for osteoporosis and falls|calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention
9749454|NCT00421408|Experimental|Protein powder|Participants will receive a protein supplement daily (40 g whey protein supplement).
9749455|NCT00421408|Placebo Comparator|Placebo carbohydrate|Participants will receive a placebo supplement daily (40 g maltodextrin).
9749456|NCT00421603|Active Comparator|Adderall-XR and Topiramate|Adderall-XR (60 mg/day) and Topiramate (300mg/day)
9749457|NCT00421603|Placebo Comparator|Placebo|Placebo
9749458|NCT00421707|Experimental|GW876008|GW876008
9749459|NCT00421707|Placebo Comparator|Placebo|Placebo
9749460|NCT00421733|Active Comparator|Paricalcitol 1 mcg|One paricalcitol 1 mcg capsule and one matching placebo capsule per dose
9749461|NCT00421733|Active Comparator|Paricalcitol 2 mcg|Two paricalcitol 1 mcg capsules per dose
9749462|NCT00421733|Placebo Comparator|Placebo|Two placebo capsules per dose
9749463|NCT00421889|Experimental|Single arm|"Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle~Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle"
9749464|NCT00421928|Experimental|001|tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
9749465|NCT00421928|Active Comparator|002|oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
9749466|NCT00421928|Placebo Comparator|003|placebo matching placebo twice a day (BID) during 15 weeks
9749467|NCT00421993|Experimental|1|Adapalene/Benzoyl Peroxide Topical Gel
10201793|NCT05195216||healthy individuals|
9749468|NCT00421993|Active Comparator|2|Adapalene Topical Gel
9749469|NCT00421993|Active Comparator|3|Benzoyl Peroxide Topical Gel
9749470|NCT00421993|Placebo Comparator|4|Topical Gel Vehicle
9749471|NCT00422032|Experimental|15 mg/m^2 Clofarabine|Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days
9749472|NCT00422032|Experimental|30 mg/m^2 Clofarabine|Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days
9749473|NCT00422058|Placebo Comparator|Lira placebo/Lira 2.4 mg/Lira 3.0 mg|Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
9749474|NCT00422058|Experimental|Lira 1.2 mg/Lira 3.0 mg|Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
9749475|NCT00422058|Experimental|Lira 1.8 mg/Lira 3.0 mg|Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
9749476|NCT00422058|Experimental|Lira 2.4 mg/Lira 3.0 mg|Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
10201794|NCT05195203|Experimental|HS-10353|Capsules；Single dose: only one administration; Multiple doses: continuous administration for 7 days
10201795|NCT05195203|Placebo Comparator|Placebo|Capsules；Single dose: only one administration; Multiple doses: continuous administration for 7 days
10201796|NCT05195177|Experimental|Study group|
10201797|NCT05195138|Experimental|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education (MBDE) will be delivered in-person in a group of 10-14 participants during 8 weekly sessions followed by 2 bimonthly individual sessions. Sessions integrate Mindfulness-Based Stress Reduction and Diabetes Self-Management Education. MBDE will introduce breath awareness meditation, body scan, walking meditation, mindful yoga, and applying mindfulness to daily activities, as well as core areas from DSME. MBDE will include incremental goal setting to build participants' self-efficacy for diabetes self-management behaviors, mindful attention to diabetes self-management, and on development of social support in the group. Participants will complete daily home mindfulness exercises and self-monitoring of diabetes self-management behaviors.
9749477|NCT00422058|Experimental|Liraglutide 3.0 mg|Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
9749478|NCT00422058|Active Comparator|Orlistat|Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)
9749479|NCT00422084|Experimental|PA group|Pyronaridine artesunate (PA)
9749480|NCT00422084|Active Comparator|AL group|Arthemether lumefantrine (AL)
9749481|NCT00422097|Experimental|Ixabepilone, 5 mg/d|If none of first 3 participants experiences a dose-limiting toxicity (DLT) during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the maximum tolerated dose (MTD). If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
9749482|NCT00422097|Experimental|Ixabepilone, 10 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
9749483|NCT00422097|Experimental|Ixabepilone, 15 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
9749484|NCT00422097|Experimental|Ixabepilone, 20 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
9749485|NCT00422097|Experimental|Ixabepilone, 25 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
9749486|NCT00422097|Experimental|Ixabepilone, 30 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
9749487|NCT00422097|Experimental|Ixabepilone, 25 mg, with famotidine|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive famotidine, 40 mg on Day 1.
9749488|NCT00422097|Experimental|Ixabepilone, 25 mg, with food|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive a low-fat meal on Day 1.
9749489|NCT00422162|Experimental|Duloxetine Hydrochloride (60 mg)|"Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo"
9749490|NCT00422162|Experimental|Duloxetine Hydrochloride (120 mg)|"Up to Week 4: 60 mg every morning and 60 mg every evening, PO.~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose"
9749491|NCT00422201|Experimental|Prospective, open-label, study of mifepristone|Eligible subjects will start study treatment at the dose of 600 mg/day (given as one 200 mg tablet tid, per os). Total duration of treatment will not exceed 12 months. At the end of 12-month treatment, investigators may petition to extend treatment on a case-by-case basis.
9749492|NCT00422227|Active Comparator|1|Etanercept + Methotrexate
9749493|NCT00422227|Active Comparator|2|DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
9749494|NCT00422279|Experimental|supraalevolar|Bone inductive implant (Nobel Replace Tapered Groovy) placed in the supralveolar position
9829207|NCT02525653|Experimental|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
9829208|NCT02525718|Placebo Comparator|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
9829209|NCT02525718|Active Comparator|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
9829210|NCT02525744|Experimental|LY900014 7.5 Units (U)|Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods.
9829211|NCT02525744|Active Comparator|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
9829212|NCT02525744|Experimental|LY900014 15 U|Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods.
9829213|NCT02525744|Experimental|LY900014 30 U|Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.
9829214|NCT02525861|Experimental|Cohort I: GLASSIA (High-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
9829215|NCT02525861|Experimental|Cohort II: GLASSIA (Low-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
9829216|NCT02525874|Experimental|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
9829217|NCT02526160|Experimental|Burosumab 1 mg/kg|Burosumab 1 mg/kg administered subcutaneously (SC) every 4 weeks, for the duration of the study.
9829218|NCT02526160|Placebo Comparator|Placebo|Placebo administered SC every 4 weeks through Week 24, followed by burosumab 1 mg/kg, for the duration of the study.
9829219|NCT02526212|Experimental|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
9829220|NCT02526212|Active Comparator|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
9829221|NCT02526277|Active Comparator|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
9829222|NCT02526277|Active Comparator|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
9829223|NCT02526277|Active Comparator|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
9829224|NCT02526277|No Intervention|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
9829225|NCT02526290|Experimental|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
9829226|NCT02526524|Experimental|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
9829227|NCT02526524|Experimental|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
9829228|NCT02526524|Experimental|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
9829229|NCT02526524|Experimental|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
9829230|NCT02526524|Placebo Comparator|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
9829231|NCT02526524|Placebo Comparator|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
9829232|NCT02526524|Active Comparator|2000 mg Met IR|1000 mg metformin immediate-release twice daily
9829233|NCT02526550|Experimental|Imojev|Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
9829234|NCT02526654|Experimental|Glaucoma Subjects|Subjects with glaucoma were recruited based on characteristic glaucomatous disc damage and visual field changes. They will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
9829235|NCT02526654|Experimental|Healthy Controls|Subjects that do not have glaucoma and are recruited for testing will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
9829236|NCT02526667|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
9829237|NCT02526667|Placebo Comparator|Vehicle Cloth|Excipients on cloth
9829238|NCT02526667|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
9829239|NCT02526680|Experimental|Glaucoma Subjects|27 glaucoma subjects will be given the OrCam low vision aid device to use for 1 month.
9829240|NCT02526693|Other|Glaucoma Patients|Glaucoma patients recruited from Wills Eye Hospital Glaucoma Service will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
9829241|NCT02526693|Other|Healthy Controls|Healthy subjects with no eye diseases recruited from Wills Eye Hospital Glaucoma Service staff, family and friends will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
9829242|NCT02527148|Active Comparator|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
9829243|NCT02527148|Active Comparator|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
9829244|NCT02527161|Other|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
9829245|NCT02527265|Experimental|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
9829246|NCT02527343|Experimental|Placebo/Volanesorsen|"Randomized Period: Volanesorsen-matching placebo as SC, QW for Weeks 1-52. Participants who received volanesorsen-matching placebo in RT period and not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen-matching placebo in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Weeks 105-156). Participants not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
9829247|NCT02527343|Experimental|Volanesorsen|"Randomized Period: 300 mg of volanesorsen as SC, QW for Weeks 1-52. Participants who received 300 mg of volanesorsen in RT period and did not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Week 105-156). Participants who were not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
9829248|NCT02527421|Experimental|DFD01 Spray Group 1|DFD01 spray, twice daily, 15 days
9829249|NCT02527421|Experimental|DFD01 Spray Group 2|DFD01 spray, twice daily, 29 days
9829250|NCT02527512|Active Comparator|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
9829251|NCT02527512|Active Comparator|Normal Saline|Sterile sodium chloride (NaCl) solution
9829252|NCT02527694|Experimental|Flexible EMS Stretcher Cart Group|Patients in this group will be transported on the new flexible EMS stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
9829253|NCT02527694|No Intervention|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
9829254|NCT02528188|Active Comparator|NSAID|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
9829255|NCT02528188|Experimental|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks
9749495|NCT00422279|Experimental|Other|Bone inductive implant (Nobel Replace Tapered Groovy) placed in extraction socket
9749496|NCT00422292|Experimental|Menactra® at 9 and 12 Months|Participants will received Menactra® vaccination at 9 and 12 months of age.
9749497|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + MMRV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
9749498|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + PCV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
9749499|NCT00422292|Active Comparator|MMRV + PCV at 12 Months|Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
9749500|NCT00422383|Experimental|1|
9749501|NCT00422383|Experimental|2|
9749502|NCT00422383|Experimental|3|
9749503|NCT00422422|Experimental|Brivaracetam|
9749504|NCT00422448|Experimental|Nevi from participants|Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis
9749505|NCT00422461|Placebo Comparator|Placebo|
9749506|NCT00422461|Experimental|PF-00489791 20 mg titrated to 40 mg|
9749507|NCT00422461|Experimental|PF-00489791 4 mg|
9749508|NCT00422461|Experimental|PF-00489791 10 mg|
9749509|NCT00422513|Experimental|methoxy polyethylene glycol-epoetin beta|120-360 micrograms (iv) monthly, starting dose
9749510|NCT00422513|Active Comparator|Epoetin Alfa|As prescribed, (iv), 3 times weekly
9749511|NCT00422591|Experimental|Idarubicin + Cytarabine|Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
9749512|NCT00422656|Experimental|Perifosine|Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.
9749513|NCT00422695||HIV +|Groups divided according to CD4 counts
9749514|NCT00422695||Healthy Controls|HIV -ve subjects
9749515|NCT00422734|Placebo Comparator|1|Placebo
9749516|NCT00422734|Active Comparator|2|5 mg tadalafil
9749517|NCT00422799|Experimental|bortezomib and rituximab|bortezomib and rituximab
9749518|NCT00422812|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
9749519|NCT00422812|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
9749520|NCT00422812|Experimental|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
9749521|NCT00422812|Experimental|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
9749522|NCT00422903|Placebo Comparator|Letrozole plus placebo|Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery
9749523|NCT00422903|Experimental|Letrozole plus lapatininb|Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
9749524|NCT00423046|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals human papillomavirus [HPV]16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
9829256|NCT02528188|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks
9749525|NCT00423046|Active Comparator|Gardasil Group|Subjects received 3 doses of Gardasil® (Merck's human papillomavirus [HPV] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
9749526|NCT00423085|Placebo Comparator|Placebo|Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
9749527|NCT00423085|Experimental|rivastigmine 5 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
9749528|NCT00423085|Experimental|Rivastigmine 10 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
9749529|NCT00423098|Experimental|Standard dose|Mycophenolate sodium was administered orally in combination with a standard dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 1 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
9782323|NCT01172639|Other|CoBRA slim high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
9517409|NCT03306550|Active Comparator|salvianolate injection arm|only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
9517410|NCT03306550|Experimental|aspirin and salvianolate injection arm|take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
9749530|NCT00423098|Active Comparator|Low dose|Mycophenolate sodium was administered in combination with a reduced dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 0.5 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
9749531|NCT00423137|Placebo Comparator|Placebo - low dose|Twice daily (b.i.d.)
9749532|NCT00423137|Placebo Comparator|Placebo - high dose|Twice daily (b.i.d.)
9749533|NCT00423137|Experimental|BIBW2948 - low dose|Twice daily (b.i.d.)
9749534|NCT00423137|Experimental|BIBW2948 - high dose|Twice daily (b.i.d.)
9749535|NCT00423150|Experimental|Temozolomide|
9749536|NCT00423189|Active Comparator|Ranibizumab only|drug - intravitreal ranibizumab
9749537|NCT00423189|Experimental|40% fluence PDT/procedure|40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
9749538|NCT00423189|Experimental|20% fluence photodynamic therapy|20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
9749539|NCT00423267|Experimental|Posaconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
9749540|NCT00423267|Active Comparator|Fluconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months. Fluconazole treatment or placebo only occurred during Period A.
9749541|NCT00423293|Other|5-FU + Mitomycin + IMRT|5-FU + Mitomycin + IMRT
9749542|NCT00423319|Active Comparator|Apixaban, 2.5 mg BID plus placebo|Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
9749543|NCT00423319|Experimental|Enoxaparin, 40 mg QD plus placebo|Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
9749544|NCT00423332|Placebo Comparator|1|Cediranib placebo
9749545|NCT00423332|Experimental|2|Cediranib
9749546|NCT00423358|Active Comparator|vitamin D|ergocalciferol 50,000 IU Twice monthly
9749547|NCT00423358|Placebo Comparator|placebo|matching placebo tablet
9749548|NCT00423436|Experimental|IVR Assessment Plus Triage|Interactive Voice Response Telephone System (IVR) Plus Triage (Participants report symptoms to telephone system and doctor/nurse notified when symptom is severe) + Questionnaire
9749549|NCT00423436|Experimental|IVR Assessment Only|IVR (Phone calls twice weekly) + Questionnaire
9749550|NCT00423449|Experimental|Vorinostat + Gemcitabine + Platinum-based agent|
9749551|NCT00423605|Experimental|1|
9749552|NCT00423657|Experimental|Ceftaroline fosamil for Injection|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
9749553|NCT00423657|Active Comparator|IV Vancomycin plus IV Aztreonam|Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.
9749554|NCT00423670|Active Comparator|Arm 1. PEG +RBV for 48 Wks (Part I)|"Participants treated with PegIntron (1.5 μg/kg, once weekly [QW]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily [TID]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks."
9749555|NCT00423670|Experimental|Arm 2. PEG + RBV + BOC for 28 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
9517411|NCT03306524|Experimental|SIPPV_VG_0_08|SIPPV VG ventilation for 15 minutes slope time = 0.08 seconds inspiratory time = 0.40 seconds
9749556|NCT00423670|Experimental|Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
9749557|NCT00423670|Experimental|Arm 4. PEG +RBV + BOC for 48 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
9749558|NCT00423670|Experimental|Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
9749559|NCT00423670|Experimental|Arm 6. PEG + RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
9749560|NCT00423670|Experimental|Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
9749561|NCT00423670|Experimental|Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I)|"Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks."
9749562|NCT00423683|Experimental|1- Arixtra Alone|Arixtra Alone
9749563|NCT00423683|Active Comparator|2 Arixtra+ filter|Arixtra + filter
9749564|NCT00423722|Experimental|Hydration: Normal Saline (salt water)|Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily
9749565|NCT00423722|Placebo Comparator|Placebo: Lower Saline|Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
9749566|NCT00423735|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
9749567|NCT00423800|Experimental|Pegetron® - 24 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
9749568|NCT00423800|Active Comparator|Pegetron®- 48 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.
9749569|NCT00423813|Placebo Comparator|1|
9749570|NCT00423813|Experimental|2|
9749571|NCT00423852|Experimental|chemotherapy with Stem Cell Support|This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.
9749572|NCT00423878|Experimental|1|Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day
9749573|NCT00423878|Active Comparator|2|Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.
9749574|NCT00423891|Experimental|Arm 1: Entecavir|
9749575|NCT00423917|Experimental|fulvestrant + bevacizumab|"Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed every 3-6 months for 5 years."
9749576|NCT00423930|Experimental|IMRT + cisplatin + bevacizumab|This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.
9749577|NCT00423943|Experimental|D|modafinil
9749578|NCT00423943|Placebo Comparator|Placebo|placebo
9749579|NCT00424047|Experimental|CC-5013 plus dexamethasone|Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
9749580|NCT00424047|Experimental|Dexamethasone plus placebo|Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
9749581|NCT00424177|Experimental|eltrombopag|
9749582|NCT00424190|Experimental|Ceftaroline for Injection|
9749583|NCT00424190|Active Comparator|IV Vancomycin and IV Aztreonam|
9749584|NCT00424255|Experimental|Lapatinib+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus lapatinib 1500 mg once daily for 6 to 7 weeks, followed by lapatinib 1500 mg once daily for one year.~Chemoradiotherapy=total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of radiotherapy. Lapatinib is also given at 1500 mg once daily for 3-7 days prior to the start of chemoradiotherapy."
9749585|NCT00424255|Placebo Comparator|Placebo+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus placebo once daily for 6 to 7 weeks, followed by placebo once daily for one year.~Chemoradiotherapy = total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of treatment. Placebo is also given once daily for 3-7 days prior to the start of chemoradiotherapy."
9749586|NCT00424268|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: tiotropium 18 µg, once daily, inhaled"
9749587|NCT00424268|Placebo Comparator|Placebo|"Placebo~underlying medication: tiotropium 18 µg, once daily, inhaled"
9749588|NCT00424294|Active Comparator|Celecoxib|Celecoxib with placebo therapy.
9749589|NCT00424294|Other|Methotrexate|Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
9749590|NCT00424294|Experimental|CP-195,543|CP-195,543 and Celecoxib dual therapy.
9749591|NCT00424346|Experimental|Canakinumab 600 mg IV + 300 mg q2wk|Participants received canakinumab 600 mg intravenous (IV) loading dose on Day 1 and 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg every 4 weeks.
9749592|NCT00424346|Experimental|Canakinumab 300 mg q2wk|Participants received canakinumab 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
9829257|NCT02528214|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
9829258|NCT02528214|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
9829259|NCT02528253|Placebo Comparator|Placebo to Week 16; tanezumab 5 mg SC|
9829260|NCT02528253|Placebo Comparator|Placebo to Week 16, tanezumab 10 mg SC|
9829261|NCT02528253|Experimental|Tanezumab 5 mg SC|
9829262|NCT02528253|Experimental|Tanezumab 10 mg SC|
9829263|NCT02528253|Active Comparator|Tramadol PR oral|
9829264|NCT02528305|Experimental|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
9829265|NCT02528318|Experimental|50 mg/kg|"Lucinactant for inhalation 50 mg total phospholipids (TPL)/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
9829266|NCT02528318|Experimental|75 mg/kg|"Lucinactant for inhalation 75 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
9829267|NCT02528318|Experimental|100 mg/kg|"Lucinactant for inhalation 100 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
9829268|NCT02528318|Experimental|150 mg/kg|"Lucinactant for inhalation 150 mg TPL/kg with nCPAP~1 repeat dose will be allowed if repeat dosing criteria are met."
9829269|NCT02528318|Active Comparator|nCPAP alone|nCPAP therapy alone
9829270|NCT02528331|Experimental|rTMS and Cognitive Behavior Therapy|
9829271|NCT02528357|Experimental|Part 1A: GSK3174998 Monotherapy- Dose escalation|Participants will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
9829272|NCT02528357|Experimental|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Participants will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
9829273|NCT02528357|Experimental|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Participants will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
9829274|NCT02528370|Experimental|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
9829275|NCT02528370|No Intervention|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
9829276|NCT02528409|Placebo Comparator|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
9829277|NCT02528409|Experimental|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
9829278|NCT02528721|Experimental|Initial Diagnosis Subjects|Patients with clinical indication for H.pylori infection
9829279|NCT02528721|Experimental|Post Therapy Subjects|Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
9829280|NCT02528786|Other|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, [NCT01317797]) will have blood samples collected on Day 1.
9829281|NCT02528942|Experimental|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
9829282|NCT02529072|Experimental|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
9749593|NCT00424346|Experimental|Canakinumab 150 mg q4wk|Participants received canakinumab 150 mg subcutaneous injections every 4 weeks (q4wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
9749594|NCT00424346|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
9749595|NCT00424372|Experimental|pregabalin|
9749596|NCT00424385|Experimental|Arm 1|Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
9749597|NCT00424398|Experimental|Bepreve|Bepotastine Besilate Ophthalmic Solution 1.5%
9749598|NCT00424398|Placebo Comparator|Placebo|sterile ophthalmic solution
9749599|NCT00424398|Experimental|Bepotastine Besilate|sterile ophthalmic solution 1.0%
9749600|NCT00424463|Experimental|1|
9749601|NCT00424463|Placebo Comparator|2|
9749602|NCT00424476|Placebo Comparator|Placebo|Placebo
9749603|NCT00424476|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
10201798|NCT05195138|Active Comparator|Standard Diabetes Self-Management Education|Standard DSME will be delivered in-person, in a group setting with 10-14 participants per group. Standard DSME will be delivered by a certified diabetes educator in eight weekly sessions of 2 hours duration. Sessions will cover seven core content areas - healthy eating, physical activity, medication usage, self-monitoring, preventing and treating acute and chronic complications, healthy coping, and problem solving.
10201799|NCT05195086||Cyc group|
9749604|NCT00424476|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
9749605|NCT00424489|Experimental|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
9749606|NCT00424502|Experimental|1|
9749607|NCT00424515|Experimental|Treatment Arm|Imatinib
9749608|NCT00424528|Active Comparator|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
9749609|NCT00424528|Active Comparator|Tiotropium 18 mcg once daily|Tiotropium 18 mcg once daily/Placebo Inhalation Solution
9749610|NCT00424528|Experimental|Arformoterol /Tiotropium|Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
9749611|NCT00424554|Experimental|Temozolomide treatment|
9749612|NCT00424554|No Intervention|No treatment|
9749613|NCT00424593|Experimental|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
9749614|NCT00424593|Placebo Comparator|Placebo|every day (QD), by mouth (PO), 13 weeks
9749615|NCT00424619|Active Comparator|1|50 000 IU Vitamin D2
9749616|NCT00424619|Active Comparator|2|100 000 IU Vitamin D2
9749617|NCT00424619|Placebo Comparator|3|Placebo
9749618|NCT00424632|Experimental|Single arm dose escalation|
9749619|NCT00424749|Experimental|Rituximab|375 mg/m^2/week for 4 weeks
9749620|NCT00424762|Experimental|rosiglitazone|4mg titrated to 8mg daily
9749621|NCT00424762|Placebo Comparator|Placebo|blinded matching placebo treatment
10201800|NCT05195086||MMF group|
10201801|NCT05195060||COVID-19|Patients diagnosed with COVID-19
9517412|NCT03306524|Experimental|PSV_VG_0_08|PSV VG ventilation for 15 minutes slope time = 0.08 seconds maximum inspiratory time = 0.60 seconds
9749622|NCT00424827|Experimental|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
9749623|NCT00424840|Experimental|Bortezomib 1.3 mg/m2|Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
9749624|NCT00424840|Experimental|Bortezomib 1.6 mg/m2|Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
9749625|NCT00424840|Experimental|Bortezomib 1.8 mg/m2|Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
9749626|NCT00425061|Experimental|1|
9749627|NCT00425061|Experimental|2|
9749628|NCT00425061|Placebo Comparator|3|
9749629|NCT00425113|Experimental|Metronidazole|Metronidazole added to background TB treatment regimen during initial 2 months
9749630|NCT00425113|Placebo Comparator|Placebo|Placebo added to background TB treatment regimen during initial 2 months
9749631|NCT00425269|Experimental|Intervention|The intervention group was divided into nine subgroups of ten to twelve women who were offered six educational sessions, each lasting 2 h, during a 7 +- 1-month period. The main focus was on the physiological importance of blood glucose and its regulation by diet and physical activity, and on knowledge about the Pakistani lifestyle in Pakistan and Norway
9749632|NCT00425269|No Intervention|Control|One lesson recieved after post-test
9749633|NCT00425308|Active Comparator|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|Everolimus dose has been adjusted to reach in Group 2, assessment of everolimus dose/trough level (C0), between 6 and 10 ng/ml plus Enteric-coated Mycophenolate Sodium (EC-MPS) 720 mg/d (360mg the morning and 360 mg the evening) plus steroids
9749634|NCT00425308|Active Comparator|Everolimus + Cyclosporine|Everolimus dose has been adjusted to reach in Group 1, assessment of everolimus dose/trough level (C0), between 3 and 8 ng/ml plus Cyclosporine in which Group 1 dose adjusted to reach, assessment of Cyclosporine dosage and blood concentration (C2), between 200 and 450 ng/ml plus steroids
9749635|NCT00425373|Experimental|Valsartan + amlodipine 40/2.5 mg|
9749636|NCT00425373|Experimental|Valsartan + amlodipine 40/5 mg|
9749637|NCT00425373|Experimental|Valsartan + amlodipine 80/2.5 mg|
9749638|NCT00425373|Experimental|Valsartan + amlodipine 80/5 mg|
9749639|NCT00425373|Active Comparator|Valsartan 40 mg|
9749640|NCT00425373|Active Comparator|Valsartan 80 mg|
9749641|NCT00425373|Active Comparator|Amlodipine 2.5 mg|
9829283|NCT02529072|Experimental|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
9829284|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
9829285|NCT02529488|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
9829286|NCT02529553|Experimental|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
9829287|NCT02529995|Experimental|AZD9291 40 mg|Cohort 1: 40 mg once daily
9829288|NCT02529995|Experimental|AZD9291 80 mg|Cohort 2: 80 mg once daily
9829289|NCT02530125|Experimental|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
9829290|NCT02530151|Experimental|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
9829291|NCT02530151|Placebo Comparator|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
9829292|NCT02530242|Other|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
9829293|NCT02530242|Other|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
9829294|NCT02530281|Experimental|glycopyrronium|glycopyrronium Topical Wipes
9829295|NCT02530281|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
9829296|NCT02530294|Experimental|glycopyrronium|glycopyrronium Topical Wipes
9829297|NCT02530294|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
9829298|NCT02530385|Experimental|FMT|Active FMT capsules
9829299|NCT02530385|Placebo Comparator|Placebo|Placebo capsules
9829300|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
9829301|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
9829302|NCT02530476|Experimental|Phase I Group 1 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
9829303|NCT02530476|Experimental|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
9829304|NCT02530476|Experimental|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
9829305|NCT02530476|Experimental|Phase I Group 2 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle."
9829306|NCT02530515|Experimental|Treatment (ex vivo autologous lymph node lymphocytes)|Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.
9829307|NCT02530528|Experimental|2% CHG 1 min|single administration, 1 min application time
9829308|NCT02530528|Experimental|2% CHG 2 min|single administration, 2 min application time
9829309|NCT02530528|Experimental|2% CHG 3 min|single administration, 3 min application time
9829310|NCT02530528|Active Comparator|Comparator 2% CHG|Single administration, Marketed CHG
9829311|NCT02530541|Experimental|CHG 1 min|1 min application time
9829312|NCT02530541|Experimental|CHG 2 min|2 min application time
9829313|NCT02530541|Active Comparator|Comparator CHG|Marketed CHG
9829314|NCT02530554|Experimental|CHG Cloth|3 min application time
9829315|NCT02530554|Active Comparator|Comparator CHG|Marketed 2% CHG
9829316|NCT02530619|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9829317|NCT02530671|Active Comparator|Manual toothbrush|ADA reference manual toothbrush
9829318|NCT02530671|Experimental|Power toothbrush|Multi-directional power toothbrush
9829319|NCT02530905|Placebo Comparator|Placebo (double-blind dose titration)|Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.
9829320|NCT02530905|Experimental|SRP-4045 (double-blind dose titration)|Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.
9829321|NCT02530905|Experimental|SRP-4045 (open label extension period)|All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.
9517413|NCT03306524|Experimental|SIPPV_VG_0_16|SIPPV VG ventilation for 15 minutes slope time = 0.16 seconds inspiratory time = 0.40 seconds
9749642|NCT00425373|Active Comparator|Amlodipine 5 mg|
9749643|NCT00425373|Placebo Comparator|Placebo|
9782324|NCT01172639|Other|CoBRA avant-garde high risk group|"Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)~Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
9782325|NCT01172639|Other|CoBRA slim low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
9782326|NCT01172639|Other|Tight Step Up low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~No oral steroids allowed during the first year of the trial"
9782327|NCT01172808|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
9782328|NCT01172808|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
9782329|NCT01172808|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
9782330|NCT01172808|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
9782331|NCT01172821|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
9782332|NCT01172821|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
9782333|NCT01172821|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
9782334|NCT01172821|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
9782335|NCT01172847|Active Comparator|A|
9782336|NCT01172847|Active Comparator|B|
9782337|NCT01172847|Experimental|C|
9782338|NCT01172873|Active Comparator|DCS + Exposure and Response Prevention|Participants in this arm receive 10 twice-weekly 60-minute sessions of Exposure and Response Prevention (E/RP) therapy and 50mg of D-Cycloserine immediately after each therapy session. D-Cycloserine is only administered on days in which therapy sessions are held.
9782339|NCT01172873|Active Comparator|E/RP alone (no DCS administration)|Participants in this arm received twice-weekly 60 minute sessions of E/RP alone for a total of 10 sessions.
9782340|NCT01172938|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
9782341|NCT01172938|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
9782342|NCT01172938|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
9782343|NCT01172938|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
9782344|NCT01173016|Experimental|Laronidase After Transplantation|Patients with Mucopolysaccharidosis type IH (MPS I, Hurler syndrome) treated with a prior allogeneic transplant >2 years previously and treated with Laronidase weekly for 2 years after transplant.
9782345|NCT01173029||Resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was not achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure >/=130 mmHg or mean 24hr diastolic pressure >/=80mmHg) by non-investigation specialized hypertensive unit care, in spite of appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
9782346|NCT01173029||Pseudo-resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure <130 mmHg and mean 24hr diastolic pressure <80mmHg) by non-investigation specialized hypertensive unit care, with appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
9782347|NCT01173055|Experimental|Milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
9782348|NCT01173055|Experimental|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
9782349|NCT01173120|Experimental|Abatacept Combination Product (ACP)|Participants from the long-term period of study NCT00559585 who enrolled in the ACP substudy switched to administration of subcutaneous (SC) abatacept via the ACP for the duration of the substudy. Abatacept was administered SC using the ACP by the participant or caregiver on Substudy Day 1 and at weekly intervals thereafter. The ACP was a pre-filled liquid product device delivering 125 mg abatacept/device (125 mg/mL).
9782350|NCT01173159|Experimental|Omegaven|Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require Total Parenteral Nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.
9749644|NCT00425386|Experimental|Erlotinib and Sunitinib|"Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily~Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off"
9749645|NCT00425477|Experimental|Bexarotene + GM-CSF|BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.
9749646|NCT00425555|Experimental|Previously treated with oral bexarotene|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
9749647|NCT00425555|Experimental|No prior oral bexarotene treatment|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
9749648|NCT00425607|Experimental|Lonafarnib|All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity.
9749649|NCT00425672|Experimental|Arm I|Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9749650|NCT00425698|Active Comparator|intravenous erythropoietin|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
9749651|NCT00425698|Placebo Comparator|intravenous placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
9749652|NCT00425750|Experimental|Treatment|"Docetaxel (40 mg/m2) IV Infusion over 30 minutes every 3 weeks (Day 1 and 8 of 21 day cycle)except the first dose is held on Day 1 of Cycle 1.~Bortezomib (1.6mg/m2) IV 3-5 second push every 3 weeks (Day 1 and 8 of 21 day cycle).Bortezomib is given as a single agent only on Day 1 of Cycle 1."
9749653|NCT00425802|Other|treatment|This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) or bone marrow if PBSC collection not possible from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLC) and mantle cell non-Hodgkin's lymphoma (NHL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL).
9749654|NCT00425854|Experimental|BIBW 2992|high dose once daily
9749655|NCT00425945|Placebo Comparator|Placebo|Placebo delivered as four tablets matching the active product once daily orally.
9749656|NCT00425945|Active Comparator|Pine Bark Extract|Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
9749657|NCT00426127|Experimental|Docetaxel and Liposomal Doxorubicin Combined with Enoxaparin|Docetaxel 75 mg/m^2 + Doxil 30 mg/m^2 + Enoxaparin 1.5 mg/kg
9749658|NCT00426153|Active Comparator|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
9749659|NCT00426153|Placebo Comparator|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
9749660|NCT00426231|Experimental|Patient Navigator intervention|Patient Navigator intervention
9749661|NCT00426231|Active Comparator|Information control|Information control
9749662|NCT00426270|Experimental|Octagam 10% 1 g/kg/day|Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.
9749663|NCT00426283|Experimental|Flovent 1760 mcg|Fluticasone propionate 880 mcg twice daily for 3 months
9749664|NCT00426283|Placebo Comparator|Placebo|Placebo twice daily for 3 months
9749665|NCT00426361|Experimental|Cervarix Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.
9749666|NCT00426361|Experimental|Boostrix Polio → Cervarix Group|Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.
9749667|NCT00426361|Experimental|Cervarix + Boostrix Polio Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.
9749668|NCT00426517|Experimental|Matched related donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 10 mg/kg total dose given intravenously over 2 days
9749669|NCT00426517|Experimental|Matched unrelated donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
9749670|NCT00426517|Experimental|Matched unrelated donor stem cell transplant (MUD-non CGD)|Conditioning with ATG 40 mg/kg total dose over 4 days IV, Busulfan 5 mg/kg total dose over 2 days IV, and TBI 300 cGy in two fractions at day -2
9749671|NCT00426517|Experimental|Matched unrelated donor transplant (MUD-CGD) cord blood|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
9749672|NCT00426556|Experimental|Phase I - RAD001 5mg + PT, daily|Daily dosing schedule of EPT = Paclitaxel & Trastuzumab verolimus 5mg plus Paclitaxel plus Trastuzumab.
9749673|NCT00426556|Experimental|Phase I - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
9749674|NCT00426556|Experimental|Phase I - RAD001 30mg + PT, weekly|Weekly dosing schedule of Everolimus 30mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab.
9749675|NCT00426556|Experimental|Phase II - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
9749676|NCT00426660|Experimental|1|
9749677|NCT00426751|Active Comparator|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
10201802|NCT05195021|Experimental|Group 1 (conventional irrigation)|After finishing the mechanical instrumentation, each root canal was irrigated with 5 ml of 5.25% NaOCl using a 31-gauge needle positioned 2 mm shorter than the WL. To remove the smear layer, 5 ml of 17% ethylenediaminetetraacetic acid (EDTA) was used in each canal for 1 minute, and 5 ml of saline was then administered to neutralize all the residues.
10201803|NCT05195021|Experimental|Group 2 (EDDY)|In group 2, 1 ml of 5.25% NaOCl was agitated for 20 seconds three times with the EDDY tip positioned 2 mm shorter than the WL. The root canals were then irrigated with 2 ml of 5.25% NaOCl again. Subsequently, the EDDY tip was activated with short pumping movements, and 2 ml of 17% EDTA was activated for 30 seconds, as described above. The final irrigation followed the same procedures as in group 1.
10205166|NCT03847519|Experimental|Safety Phase Part B|"Enroll subjects with metastatic squamous or non-squamous NSCLC. ADXS-503 will be evaluated at 2 planned escalating dose levels in combination with a fixed dose of pembrolizumab:~Dose level 1: 1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~Dose level 2: 5e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
10205167|NCT03847519|Experimental|Efficacy Phase Part C|"Enroll subjects with metastatic squamous or non-squamous NSCLC.~1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
10205168|NCT03821935|Experimental|ABBV-151 Monotherapy|Various doses of ABBV-151 administered during dose escalation, followed by dose expansion of ABBV-151 administered at the Recommended Phase 2 Dose (RP2D).
10205169|NCT03821935|Experimental|ABBV-151 + Budigalimab Combination Therapy|Various doses of ABBV-151 plus budigalimab Dose A administered every 4 weeks (Q4W) during dose escalation, followed by dose expansion of ABBV-151 administered at the RP2D plus budigalimab Dose A administered Q4W.
10205170|NCT03804554||Patients taking nivolumab|
10205171|NCT03793010|Experimental|FX006|FX006 32mg
10205172|NCT03793010|Placebo Comparator|Normal Saline|Normal Saline
10205173|NCT03781219|Experimental|HL-085 plus Vemurafenib|HL-085 will be administered as BID with specified dose. And the Vemurafenib will be taken as the instruction in the label ( 960 mg, BID)
10205174|NCT03780322|Experimental|Armeo Spring Pediatric|This group will receive training with Armeo Spring Pediatric in 45 minute sessions, 3 times a week, for a total of 15 sessions
10205175|NCT03780322|Active Comparator|Conventional physical and occupational therapy|This group will receive combined physical and occupational therapy in 45 minute sessions, 3 times a week, for a total of 15 sessions.
10205176|NCT03779620|Experimental|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
10205177|NCT03776669|Active Comparator|LSG alone|"Intervention: laparoscopic sleeve gastrectomy alone.~LSG will be performed laparoscopically via a 5-port technique. The greater omentum is dissected by using the 5-mm laparoscopic LigaSure or Harmonic from 4 cm proximal to the pyloric ring to the angle of His. Sleeve calibration is done by a 36-French bougie inserted along the lesser curvature. Then the stomach is transected with sequential firings of linear green, gold, and blue 60 mm staplers starting about 4 cm proximal to the pylorus and ending approximately 2 cm distal to the left of the esophagus. The staple-line of the remnant gastric tube is oversewn with 3-0 V-Loc to prevent leakage and hemorrhage."
10205178|NCT03776669|Experimental|LSG + HHR|"Intervention: concomitant laparoscopic sleeve gastrectomy + hiatal hernia repair.~The surgical detail of LSG is the same as described in LSG alone arm, and the surgical detail of HHR is described as below.~The hiatus is approached from the right side of the EGJ, through the lesser omentum. The hiatal defect is repaired by 1-0 Surgilon interruptedly, and then a commercialized U-shaped Biodesign Hiatal Hernia Graft is placed to the EGJ to cover the posterior side but spare the anterior side of the hiatus. Care must be taken to avoid direct contact of mesh to the esophagus to avoid any unnecessary complication. After the mesh is appropriately placed and oriented, 2 ml of TISSEEL solution for sealant is applied all over the mesh for fixation."
10205179|NCT03768310|Experimental|CD19.CAR-multiVST for Group A|"Group A: Patients with no evidence of disease after having a bone marrow transplant.~T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
10205180|NCT03768310|Experimental|CD19.CAR-multiVST for Group B|"Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant.~Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
10205181|NCT03762122|Experimental|Rogaratinib|Rogaratinib is given at a dose of 600 mg twice daily in continuous 28-days cycles, without treatment breaks (except for toxicity management). Trial treatment is continued until evidence of tumor progression, unacceptable toxicity, consent withdrawal or withdrawal by the investigator.
10205182|NCT03759834|Experimental|Testing Arm|"There will only be one arm. The patient and investigator will initially be blinded to the on-off status of the electrode. The patient will thus serve as an internal control for testing. Once device integrity and possible benefit is confirmed, the patients will undergo non-tactile electrical stimulation to the bone of the inner ear (cochlear promontory) for short term relief of tinnitus via Cochlear promontory stimulation."
10205183|NCT03740997|Experimental|Patients with body weight ≥20 to ≤28 kg|In children weighing ≥20 to ≤28 kg, 0.1 or 0.2 mL of OPTISON per injection will be given in ascending order. The cumulative dose will not exceed 1.0 mL.
10205184|NCT03740997|Experimental|Patients with body weight >28 to ≤40 kg|If children weigh >28-≤40 kg, 0.2 or 0.3 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.5 mL.
10205185|NCT03740997|Experimental|Patients with body weight >40 kg|For children whose weight is >40 kg, 0.2 or 0.4 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.8 mL.
10205186|NCT03728556|Experimental|CS1001monoclonal antibody|
9749678|NCT00426751|Experimental|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
9749679|NCT00426764|Experimental|Romidepsin|Participants received romidepsin 14 mg/m^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.
9749680|NCT00426842|Experimental|Arm 1|Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.
9749681|NCT00426855|Experimental|Bendamustine and Bortezomib|Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
9749682|NCT00427011|Experimental|1|
9749683|NCT00427037|Placebo Comparator|Placebo|Placebo
9749684|NCT00427037|Active Comparator|Cholecalciferol|D3
9749685|NCT00427297|Experimental|NVP-containing|Infants randomized to this arm will receive nevirapine-containing HAART regimen
9749686|NCT00427297|Active Comparator|NVP-sparing|Infants randomized to this arm will receive nevirapine-sparing HAART
9749687|NCT00427336|Experimental|Fludarabine + Cyclophosphamide + ATG|Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day
9749688|NCT00427349|Experimental|AMG 706+Octreotide|"Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles."
9749689|NCT00427557|Experimental|Cellular Therapy with Cord Blood Cells|Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion
9749690|NCT00427648|Active Comparator|1|xylocaine
9749691|NCT00427648|Placebo Comparator|2|normal saline
9749692|NCT00427661|Other|AHCT in High Risk SCD|Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
9749693|NCT00427700|Active Comparator|Clomiphene|Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
9749694|NCT00427700|Experimental|Raloxifene|Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
9749695|NCT00427765|Experimental|Busulfan + Melphalan|Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days
9749696|NCT00427778|Experimental|Incontinence ring then no intervention|Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
9749697|NCT00427778|Experimental|No intervention then incontinence ring|Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
9749698|NCT00427791|Experimental|Etoposide + Total Body Irradiation + Rituximab|Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
9749699|NCT00427791|Experimental|Etoposide + Total Body Irradiation|Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
9517414|NCT03306524|Experimental|PSV_VG_0_16|PSV VG ventilation for 15 minutes slope time = 0.16 seconds maximum inspiratory time = 0.60 seconds
9749700|NCT00427804|Experimental|Calcitriol|Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
9749701|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
9749702|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
9749703|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 1|Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
9749704|NCT00427895|Experimental|13vPnC Cohort 3, Vaccination 1|Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
9749705|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 2|Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
9749706|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 2|Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
9749707|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 2|Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
9749708|NCT00427908|Experimental|Group A|All subjects received GSK Biolgicals' meningococcal vaccine 134612.
9749709|NCT00427908|Active Comparator|Group B|Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.
9749710|NCT00427921|Experimental|1|Open Label
9749711|NCT00427934|Placebo Comparator|2|
9749712|NCT00427934|Experimental|1|This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
9749713|NCT00427960|Active Comparator|rosuvastatin|rosuvastatin 5 mg
9749714|NCT00427960|Active Comparator|atorvastatin|atorvastatin 10 mg
9749715|NCT00427973|Experimental|AZD2171|Patients will receive AZD2171 (cediranib maleate) 30mg by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies. Laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, and pharmacological study will be performed.
9749716|NCT00427999|Experimental|STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane|STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks
9749717|NCT00428090|Experimental|Rosiglitazone|XR (extended release) oral tablets
9749718|NCT00428090|Other|Placebo|Placebo (Double-Dummy to Match)
9749719|NCT00428116|No Intervention|Interrupted HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
9749720|NCT00428116|Active Comparator|Continued HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.
9749721|NCT00428220|Experimental|A|"Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.~The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible."
9749722|NCT00428246|Active Comparator|1|1 mcg paricalcitol
9749723|NCT00428246|Active Comparator|2|2 mcg paricalcitol
9749724|NCT00428246|Placebo Comparator|3|Placebo
9749725|NCT00428298|Experimental|Active Treatment Valacyclovir|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
9749726|NCT00428298|Placebo Comparator|Placebo Treatment|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
9749727|NCT00428389|Experimental|Immediate Switch|Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
9749728|NCT00428389|Experimental|Delayed Switch|Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
9749729|NCT00428584|Experimental|1|interferon beta-1a
9749730|NCT00428584|Active Comparator|2|interferon beta-1b
9749731|NCT00428597|Experimental|A|
9749732|NCT00428597|Placebo Comparator|B|
9749733|NCT00428610|Experimental|LY573636|LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
9749734|NCT00428714|Experimental|Enzastaurin-Cohort 1|Chemo-naive participants who had androgen-independent prostate cancer with rising prostate-specific antigen (PSA) levels but no clinical or radiographic evidence of metastatic disease. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
9749735|NCT00428714|Experimental|Enzastaurin-Cohort 2|Participants with progressed, metastatic prostate cancer who had received prior treatment with a docetaxel-containing agent. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
9749736|NCT00428792|Experimental|Very light breakfast (VLB) then standard breakfast (SB)|Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
9749737|NCT00428792|Experimental|Standard breakfast (SB) then very light breakfast (VLB)|Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
9517415|NCT03306524|Experimental|SIPPV_VG_0_24|SIPPV VG ventilation for 15 minutes slope time = 0.24 seconds inspiratory time = 0.40 seconds
9829322|NCT02530996|Experimental|Placebo before BH4|Six SSc received oral placebo 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral BH4 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
9829323|NCT02530996|Experimental|BH4 before Placebo|Six SSc received oral BH4 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral placebo 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
9829324|NCT02531022|Active Comparator|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
9829325|NCT02531022|Experimental|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
9829326|NCT02531035|Placebo Comparator|Placebo|Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
9829327|NCT02531035|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
9829328|NCT02531113|Experimental|RPC1063 (Ozanimod)|
9829329|NCT02531321|Experimental|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
9829330|NCT02531321|Active Comparator|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
9829331|NCT02531373|Experimental|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
9829332|NCT02531373|Experimental|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
9829333|NCT02531373|Experimental|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
9829334|NCT02531373|Experimental|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
9829335|NCT02531373|Experimental|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
9829336|NCT02531373|Experimental|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
9829337|NCT02531373|Experimental|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
9829338|NCT02531373|Experimental|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
9829339|NCT02531373|Active Comparator|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
9829340|NCT02531438|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
9829341|NCT02531438|Active Comparator|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
9829342|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
9829343|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
9829344|NCT02531633|Experimental|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
9829345|NCT02531633|Placebo Comparator|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
9829346|NCT02531633|Placebo Comparator|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
10205187|NCT03728556|Placebo Comparator|CS1001 Placebo|
10205188|NCT03720366|Experimental|Arm 1: Administration of enasidenib and Arm 1 probes|Part 1: Subjects will receive prescribed doses of Arm 1 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 1 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
9749738|NCT00428844|Experimental|Daptomycin 6 mg/kg|Daptomycin (6 mg/kg every 24 hours [q24h]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
9749739|NCT00428844|Experimental|Daptomycin 8 mg/kg|Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
9749740|NCT00428844|Active Comparator|Comparator|Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
9749741|NCT00428922|Experimental|Trastuzumab, Bevacizumab, and Docetaxel|Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
9749742|NCT00428948|Experimental|Tolvaptan|Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
9749743|NCT00428948|Placebo Comparator|Placebo|Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
9749744|NCT00428974|Experimental|CF101 1 mg|
9749745|NCT00428974|Experimental|CF101 2mg|
9749746|NCT00428974|Experimental|CF101 4mg|
9749747|NCT00428974|Placebo Comparator|Placebo|
9749748|NCT00429104|Experimental|HER2+ Metastatic Breast Cancer|Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m^2 subcutaneously
9749749|NCT00429143|Experimental|Haploidentical Allogeneic Transplantation|Patients undergoing hematopoietic stem cell transplant from a partially matched related donor
9749750|NCT00429169|Active Comparator|Paroxetine|Participants will receive paroxetine for 8 weeks
9749751|NCT00429169|Active Comparator|Bupropion|Participants will receive bupropion for 8 weeks
9749752|NCT00429182|Experimental|High-dose chemotherapy|Carboplatin + Cyclophosphamide + Thiotepa
9749753|NCT00429273|Active Comparator|Group 1: Guan-Guan+Placebo|weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
9749754|NCT00429273|Active Comparator|Group 2: Placebo-Placebo+DMPH|weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
9749755|NCT00429273|Experimental|Group 3: Guan-Guan+DMPH (Comb)|weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH
9749756|NCT00429299|Active Comparator|Arm A|Chemotherapy plus trastuzumab
9749757|NCT00429299|Experimental|Arm B|Chemotherapy plus lapatinib
9749758|NCT00429299|Active Comparator|Arm C|Chemotherapy plus trastuzumab plus lapatinib
9749759|NCT00429364|Active Comparator|Atenolol|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.
9749760|NCT00429364|Active Comparator|Losartan|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).
9749761|NCT00429403|Experimental|Goserelin|3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
9749762|NCT00429403|No Intervention|No Goserelin|
9749763|NCT00429416|Experimental|LLME to Decrease GVHD Following HSC T|To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
9749764|NCT00429494|Experimental|Leuprolide Acetate|Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.
9749765|NCT00429507|Experimental|Samarium 153-EDTMP + Stem Cell Transplant|Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose. Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP. Questionnaires taking about 15 minutes to complete.
9749766|NCT00429572|Experimental|Allogeneic Transplantation|Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.
9749767|NCT00429585|Other|Randomized Treatment - Nail|Randomized Treatment - Nail
9749768|NCT00429585|Other|Randomized Treatment - Plate|Randomized Treatment - Plate
9749769|NCT00429663|Other|IM Nails|Reamed, Interlocking Intramedullary Nail - Randomized treatment
9749770|NCT00429663|Other|Plate Fixation|Locking Periarticular Plate - Randomized Treatment
9749771|NCT00429702|Experimental|Benadryl® Ativan® Decadron® (BAD) Pump|Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
9749772|NCT00429702|Active Comparator|Control Arm Saline|Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
9829347|NCT02531633|Experimental|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
9829348|NCT02531646|Experimental|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
9829349|NCT02531646|Experimental|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
9829350|NCT02531646|Experimental|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
9829351|NCT02531698|Experimental|Bivalent rLP2086|Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
9829352|NCT02531698|Other|Licensed pediatric hepatitis A vaccine|
9829353|NCT02531802|Experimental|Adult: ETVAX (Full)|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14
9829354|NCT02531802|Experimental|Adult: ETVAX (Full) + 10 ug dmLT|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
9829355|NCT02531802|Placebo Comparator|Adult: Placebo|Adult arm (18-45 year olds) receiving a placebo on days 0 and 14
9829356|NCT02531802|Experimental|24-59 months: ETVAX (1/4)|24-59 month old children receiving a quarter adult dose (2.5 x 10^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
9829357|NCT02531802|Experimental|24-59 months: ETVAX (1/2)|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
9829358|NCT02531802|Experimental|24-59 months: ETVAX (full)|24-59 month old children receiving a full adult dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
9829359|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 2.5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
9829360|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
9829361|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 10 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
9829362|NCT02531802|Placebo Comparator|24-59 months: Placebo|24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
9829363|NCT02531802|Experimental|12-23 months: ETVAX (1/4)|12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
9829364|NCT02531802|Experimental|12-23 months: ETVAX (1/2)|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
9829365|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 2.5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
9829366|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
9829367|NCT02531802|Placebo Comparator|12-23 months: Placebo|12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
9829368|NCT02531802|Experimental|6-11 months: ETVAX (1/8)|6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
9829369|NCT02531802|Experimental|6-11 months: ETVAX (1/4)|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
9829370|NCT02531802|Experimental|6-11 months: ETVAX (1/2)|6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
9829371|NCT02531802|Experimental|6-11 months: ETVAX (1/4) + 2.5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
9829372|NCT02531802|Experimental|6-11 month olds: ETVAX (1/4) + 5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
9829373|NCT02531802|Placebo Comparator|6-11 month olds: Placebo|6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
9829374|NCT02531867|Experimental|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
9829375|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Duragesic (192 h), Mylan (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained 0-192 h
9829376|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Mylan (192 h), Duragesic (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained for 0-192 h
9829377|NCT02532010|Active Comparator|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
9829378|NCT02532010|Active Comparator|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
9829379|NCT02532036|Experimental|Starter Group|Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
9829380|NCT02532036|Experimental|Group A|Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
9829381|NCT02532036|Experimental|Group B|Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
9829382|NCT02532179|Experimental|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
9829383|NCT02532283|Experimental|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
9829384|NCT02532283|Experimental|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
9829385|NCT02532374|Experimental|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
9829386|NCT02532465|Active Comparator|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
9829387|NCT02532465|Experimental|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
9829388|NCT02532517|Experimental|Enterprise|
9829389|NCT02532543|Active Comparator|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
9829390|NCT02532543|Active Comparator|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
9829391|NCT02532543|Active Comparator|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
9829392|NCT02532543|Active Comparator|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
9829393|NCT02532556|Experimental|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
9829394|NCT02532556|Experimental|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
9829395|NCT02532556|Experimental|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
9829396|NCT02532556|Experimental|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
9829397|NCT02532556|Experimental|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
9829398|NCT02532556|Experimental|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
9829399|NCT02532556|Experimental|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
9829400|NCT02532647|Experimental|Remimazolam|"Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
9829401|NCT02532647|Active Comparator|Midazolam|"Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
9829402|NCT02532647|Placebo Comparator|Placebo|"Placebo administered in double-blind manner.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
9829403|NCT02532764|Experimental|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
9829404|NCT02532764|Placebo Comparator|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
9829405|NCT02532855|Experimental|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
9829406|NCT02532855|Active Comparator|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
9829407|NCT02532933|Active Comparator|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
9829408|NCT02532933|Active Comparator|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
9829409|NCT02532972|Experimental|Cochlear Implant surgery|All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
9829410|NCT02532998|Experimental|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9749773|NCT00429793|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9749774|NCT00429949|Experimental|Dasatinib|"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.~In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle."
9749775|NCT00430183|Experimental|Arm A: docetaxel + LHRH agonist + surgical intervention|"Patients receive six cycles of docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.~Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol.~Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery."
9749776|NCT00430183|Other|Arm B: surgical intervention|All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery.
9749777|NCT00430248|Experimental|Febuxostat 40 mg QD|
9749778|NCT00430248|Experimental|Febuxostat 80 mg QD|
9749779|NCT00430248|Active Comparator|Allopurinol 200 mg or 300 mg QD|(dependent on renal function)
9749780|NCT00430300|Experimental|150mcg, 450mcg or 1350mcg|Active treatment given BID via a double pin monodose capsule inhaler device
9749781|NCT00430300|Placebo Comparator|Placebo|Placebo treatment given BID via a single pin monodose inhaler device
9749782|NCT00430352|Experimental|1|
9749783|NCT00430482|Experimental|1|Cognitive Behavioral Therapy
9749784|NCT00430482|Active Comparator|2|Individual Counseling
9749785|NCT00430495|Experimental|Atacicept 25 mg|
9749786|NCT00430495|Experimental|Atacicept 75 mg|
9749787|NCT00430495|Experimental|Atacicept 150 mg|
9749788|NCT00430495|Placebo Comparator|Placebo|
9749789|NCT00430521|Experimental|GSK1562902A V/I/6 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
9749790|NCT00430521|Experimental|GSK1562902A V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
9749791|NCT00430521|Experimental|GSK1562902A 2V/I/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.
9749792|NCT00430521|Experimental|GSK1562902A 2V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
9749793|NCT00430521|Experimental|GSK1562902A V/I/12 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
9749794|NCT00430521|Experimental|GSK1562902A V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
9749795|NCT00430521|Experimental|GSK1562902A 2V/I/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
9749796|NCT00430521|Experimental|GSK1562902A 2V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
9749797|NCT00430573|Experimental|DCS-augmented CBT-IC|D-cycloserine-augmented CBT-IC
9749798|NCT00430573|Placebo Comparator|Placebo-augmented CBT-IC|Placebo-augmented CBT-IC
9749799|NCT00430625|Experimental|VPRIV®-45 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
9749800|NCT00430625|Experimental|VPRIV®-60 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
9829411|NCT02532998|Experimental|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9749801|NCT00430638|Experimental|Treatment|Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
9749802|NCT00430638|Placebo Comparator|Placebo|Placebo tablets were taken once daily for 12 weeks
9749803|NCT00430677|Experimental|Abatacept 30 mg/kg+Corticosteroids+MMF|Short-term Period
9749804|NCT00430677|Experimental|Abatacept 10 mg/kg+Corticosteroids+MMF|Short-term Period
9749805|NCT00430677|Experimental|Placebo+Corticosteroids+MMF|Short-term Period
9749806|NCT00430677|Experimental|Abatacept 10mg/kg|Long-term Extension Period
9749807|NCT00430716|Experimental|Sildenafil High dose|
9749808|NCT00430716|Experimental|Sildenafil Low dose|
9749809|NCT00430716|Experimental|Sildenafil medium dose|
9749810|NCT00430716|Experimental|Sildenafil - Open label Phase|Open label extension from week 12 to week 24.
9749811|NCT00430755|Other|Inpatients of hospital|"All patients who were admitted to the departments of nephrology or cardiology in a tertiary hospital in Germany.~The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
9749812|NCT00430768|Experimental|Group 1 Low Dose|"rAAV1-CB-hAAT 6.9 x10e12 vector genomes (vg) administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
9749813|NCT00430768|Experimental|Group 2 Middle Dose|"rAAV1-CB-hAAT 2.2 x 10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
9749814|NCT00430768|Experimental|Group 3 High Dose|"rAAV1-CB-hAAT 6.0 x10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
9749815|NCT00430781|Experimental|Combination arm|Pazopanib plus lapatinib
9749816|NCT00430781|Active Comparator|Lapatinib monotherapy|Lapatinib
9749817|NCT00430781|Active Comparator|Pazopanib monotherapy|Pazopanib
9749818|NCT00430937|Experimental|Daptomycin|4 mg/kg intravenous (i.v.) once daily
9749819|NCT00430937|Active Comparator|Pooled Comparator|
9749820|NCT00430989|Other|70% Nitrous Oxide|General anaesthesia using 70% Nitrous Oxide with fraction of inspired oxygen at 30%
9749821|NCT00430989|Other|No Nitrous Oxide|General anaesthesia not containing Nitrous oxide with fraction of inspired oxygen at 30%
9749822|NCT00431041|Experimental|Solifenacin|Solifenacin succinate: 5 mg tablets, taken orally, once daily
9749823|NCT00431041|Active Comparator|Oxybutynin IR|Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day
9749824|NCT00431067|Experimental|BIBW 2992|BIBW 2992 (Afatinib) once daily until progression
9749825|NCT00431132|Experimental|Vagifem® 10 mcg|One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
9749826|NCT00431184|Active Comparator|Pentazocine then Lorazepam|In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
9749827|NCT00431184|Active Comparator|Lorazepam then Pentazocine|In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.
9782351|NCT01173211|Experimental|Arm 1: Fluarix®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluarix®.
9782352|NCT01173211|Experimental|Arm 3: Fluzone®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluzone®.
9782353|NCT01173211|Experimental|Arm 2: Agriflu®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Agriflu®.
9782354|NCT01173471|Experimental|1) AZD4017|Europe: 200 mg AZD4017
9782355|NCT01173471|Placebo Comparator|2) Placebo|Europe: placebo
9782356|NCT01173471|Experimental|3) AZD4017|USA: 800 mg AZD4017
9782357|NCT01173471|Placebo Comparator|4) Placebo|USA: placebo
9782358|NCT01173523|Experimental|Cohort A: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed > 60 days following initial chemotherapy completion.
9782359|NCT01173523|Experimental|Cohort B: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort B participants had not responded or had relapsed </= 60 days from the completion of initial chemotherapy.
9749828|NCT00431444|Active Comparator|Zoledronic Acid|Zoledronic acid 5 mg (single i.v. infusion) + daily oral placebo for 6 months (zoledronic acid group)
9749829|NCT00431444|Active Comparator|Raloxifene|Placebo (single i.v. infusion) + oral raloxifene 60 mg/day for 6 months (raloxifene group)
9749830|NCT00431496|Experimental|Cinacalcet|Cinacalcet was administered orally at a starting dose of 30 mg/day for 23 weeks. Possible sequential doses during the study were 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet occurred if the intact parathyroid hormone (iPTH) level from the previous study visit was > 31.8 pmol/L (300 pg/mL) unless the participant had either reached the maximum dose (180 mg/day), the serum corrected total calcium was < 2.1 mmol/L (8.4 mg/dL), or the participant experienced an adverse event that precluded a dose increase.
9749831|NCT00431626|Experimental|Laser TURP with dutasteride|Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
9749832|NCT00431626|Placebo Comparator|Laser TURP with placebo|Prior to and after standard treatment with laser TURP, placebo is applied to each patient
9749833|NCT00431847||Group 1|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
9749834|NCT00431847||Group 2|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.
9749835|NCT00431951|Experimental|ST-246|250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
9749836|NCT00431951|Placebo Comparator|placebo|Placebo to match ST-246
9749837|NCT00431964|Active Comparator|Active|azithromycin 250 mg tablets
9749838|NCT00431964|Placebo Comparator|Placebo|placebo tablets (matched to active drug in appearance)
9749839|NCT00432042|Experimental|ProQuad® + Infanrix® hexa|Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
9749840|NCT00432042|Active Comparator|ProQuad®|Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
9749841|NCT00432042|Active Comparator|Infanrix® hexa|Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
9749842|NCT00432159|Experimental|1-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level of the cervical spine, C3 to C7 inclusive.
9749843|NCT00432159|Active Comparator|1-level ACDF with plate|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at a single level of the cervical spine, C3 to C7 inclusive.
9749844|NCT00432159|Experimental|2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at two adjacent levels of the cervical spine, C3 to C7 inclusive.
9749845|NCT00432159|Active Comparator|2-level ACDF|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at two adjacent levels of the cervical spine, C3 to C7 inclusive.
9749846|NCT00432159|Experimental|Training: 1 & 2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level or multiple levels of the cervical spine, C3 to C7 inclusive. Training cohort.
9749847|NCT00432172|Active Comparator|Group 1 (Luminal A) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
9749848|NCT00432172|Experimental|Group 1 (Luminal A) Selective treatment|"Selective treatment:~Postmenopausal patients: exemestane x 6 months Premenopausal patients: goserelin x 6 months + exemestane x 6 months"
9749849|NCT00432172|Active Comparator|Group 2 (Basal) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
9749850|NCT00432172|Experimental|Group 2 (Basal) Selective treatment|Selective treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.
9749851|NCT00432237|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
9749852|NCT00432237|Experimental|MK0974 150 mg|MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
9749853|NCT00432237|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
9749854|NCT00432237|Placebo Comparator|Placebo|Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
9749855|NCT00432276|Experimental|Alogliptin 25 mg + Pioglitazone 30 mg add-on to Metformin|Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
9749856|NCT00432276|Active Comparator|Pioglitazone 45 mg add-on to Metformin|Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
9749857|NCT00432341|Experimental|BOTOX®|Botulinum toxin type A (BOTOX®)
9749858|NCT00432341|Active Comparator|Dysport®|Botulinum toxin type A (Dysport®)
9749859|NCT00432380|Experimental|PLACEBO-ROTARIX-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Month 1 and Month 2, and a single oral dose of placebo at Day 0. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
9749860|NCT00432380|Experimental|ROTARIX-PLACEBO-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Day 0 and Month 2, and a single oral dose of placebo at Month 1. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
9749861|NCT00432380|Placebo Comparator|PLACEBO GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 3 oral doses of placebo at Day 0, Month 1 and Month 2. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
9749862|NCT00432458|Experimental|Arm I: Thal/ZLD|Thalidomide (Thal) + Zolendronic acid (ZLD)
9749863|NCT00432458|Experimental|Arm II: ZLD|Zoledronic acid (ZLD)
9749864|NCT00432601|Experimental|Arm 1|Patients will receive Michigan Cancer Consortium decision aid.
9749865|NCT00432601|Active Comparator|Arm 2|Patients will receive National Comprehensive Cancer Network decision aid.
9749866|NCT00432666|Experimental|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
9749867|NCT00432666|Placebo Comparator|Placebo|
9749868|NCT00432679|Experimental|arm 1|study drug
9749869|NCT00432744|Active Comparator|CoenzymeQ10|CoenzymeQ10: patients will be randomized to receive CoenzymeQ10 in either Period #1 (Months 0-6) or Period #2 (Months 7-12).
9749870|NCT00432744|Placebo Comparator|Placebo|Placebo: patients will be randomized to receive placebo either ion Period #1 (months 1-6) or Period #2 (months 7-12).
9749871|NCT00432809|No Intervention|Medical therapy|Intensive medical therapy for diabetes
9749872|NCT00432809|Active Comparator|Gastric Bypass|Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
9749873|NCT00432809|Active Comparator|Sleeve Gastrectomy|Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy
9749874|NCT00432835|Active Comparator|Gastric Stimulation Days1-4/Sham5-8|The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days
9749875|NCT00432835|Active Comparator|Sham1-4/Gastric Stimulation Days5-8|The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.
9749876|NCT00432965|Experimental|VAC Therapy|Treatment of Diabetic Foot Ulcers with VAC Therapy
9749877|NCT00432965|Active Comparator|Moist Wound Therapy|Moist Wound Therapy (standard of care)
9749878|NCT00432991|Placebo Comparator|Saline Placebo|Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
9749879|NCT00432991|Experimental|IM Ephedrine|Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
9749880|NCT00433004|No Intervention|1|No advance supply of emergency contraception
9749881|NCT00433004|Active Comparator|2|Advance supply of emergency contraception is given
9749882|NCT00433017|Experimental|Verteporfin + Ranibizumab|Verteporfin (6 mg/m^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
9829412|NCT02532998|Experimental|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9749883|NCT00433017|Active Comparator|Ranibizumab Monotherapy|Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
9749884|NCT00433147|Experimental|Afegostat tartrate 25 milligrams (mg) once per day|Afegostat tartrate was administered orally during the 4-week treatment period.
9749885|NCT00433147|Experimental|Afegostat tartrate 150 mg once per day|Afegostat tartrate was administered orally once per day during the 4-week treatment period.
9749886|NCT00433147|Experimental|Afegostat tartrate 150 mg once every four days|Afegostat tartrate was administered orally once every 4 days during the 4-week treatment period.
9749887|NCT00433147|Experimental|Afegostat tartrate 150 mg once every seven days|Afegostat tartrate was administered orally once every 7 days during the 4-week treatment period.
9749888|NCT00433160|Experimental|Teriparatide|20 micrograms for 104 weeks
9749889|NCT00433160|Placebo Comparator|Placebo|Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks
9749890|NCT00433199|Placebo Comparator|Placebo|Placebo
9749891|NCT00433199|Experimental|T-Gel 1.62%|Testosterone (T) gel 1.62%
9749892|NCT00433290|Experimental|A|
9749893|NCT00433290|Placebo Comparator|B|
9749894|NCT00433329|Experimental|Bosentan|Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
9749895|NCT00433381|Experimental|Arm I (bevacizumab and temozolomide)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
9749896|NCT00433381|Experimental|Arm II (bevacizumab & irinotecan hydrochloride)|Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
9749897|NCT00433446|Experimental|CNTO 328|
9749898|NCT00433537|Experimental|VcR-CVAD induction followed by maintenance rituximab|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Maintenance rituximab: Beginning 4-8 weeks after completion of induction therapy, patients receive rituximab IV over 3-4 hours once weekly for 4 weeks. Treatment repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity."
9749899|NCT00433537|Experimental|VcR-CVAD induction followed by ASCT|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) SC or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~ASCT: After completion of induction therapy, patients who are eligible may have the option to receive consolidation therapy for autologous stem cell transplantation (off-study). These patients undergo stem cell harvest during courses 4, 5, or 6 of induction therapy."
9749900|NCT00433550|Experimental|Group 1 (6/6 UGT1A1 genotype)|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
9749901|NCT00433550|Experimental|Group 2 (6/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
9749902|NCT00433550|Experimental|Group 3 (7/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
9749903|NCT00433654|Active Comparator|MRI group|The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
9749904|NCT00433654|Other|Control group|The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.
9749905|NCT00433745|Experimental|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
9749906|NCT00433771|Experimental|WallFlex Biliary Fully Covered stent|Single arm, biliary stenting, using WallFlex Biliary Fully Covered stent
9749907|NCT00433836|Experimental|Valsartan 80 mg|
9749908|NCT00433836|Experimental|Valsartan 160 mg|
9749909|NCT00433836|Experimental|Valsartan 320 mg|
9749910|NCT00433836|Active Comparator|Enalapril 10 mg|
9749911|NCT00433836|Active Comparator|Enalapril 20 mg|
9749912|NCT00433836|Active Comparator|Enalapril 40 mg|
9749913|NCT00433914|Experimental|rMenB|6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
9749914|NCT00433914|Experimental|rMenB+OMV|6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
9829413|NCT02532998|Experimental|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9829414|NCT02532998|Experimental|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9829415|NCT02532998|Experimental|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9829416|NCT02532998|Experimental|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9829417|NCT02532998|Experimental|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
9829418|NCT02533063|Active Comparator|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
9829419|NCT02533063|Sham Comparator|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
9835794|NCT02755805|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
9835795|NCT02755805|Placebo Comparator|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
9835796|NCT02755818||control|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
9835797|NCT02755818||chronic renal disease (CKD3b)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
9835798|NCT02755818||chronic renal disease (CKD4)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
9835799|NCT02755818||chronic renal disease (CKD5)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
9835800|NCT02755831|Experimental|Sleep Study + CPAP group|Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
9835801|NCT02755831|Other|Standard Prenatal Care group|Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
9835802|NCT02755935|Experimental|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
9835803|NCT02756013|Experimental|Paclitaxel + Carboplatin|Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
9835804|NCT02756078|Active Comparator|Group 1 (TEST / CONTROL wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
9835805|NCT02756078|Active Comparator|Group 2 (CONTROL / TEST wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
9517416|NCT03306524|Experimental|PSV_VG_0_24|PSV VG ventilation for 15 minutes slope time = 0.24 seconds maximum inspiratory time = 0.60 seconds
9749915|NCT00433966|Active Comparator|Pharmacology Arm|"To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:~reduced rates of major bleeding events at 30 days~similar rates of major adverse ischemic cardiac events at 30 days~reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days."
9749916|NCT00433966|Active Comparator|Stent Arm|"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~reduced rates of target lesion revascularization for ischemia at 1 year~similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~lower rates of analysis segment binary angiographic restenosis at 13 months"
9749917|NCT00433992||ABC/3TC|HIV-infected subjects were given Abacavir-Lamuvidine
9749918|NCT00433992||TDF/FTC|HIV-infected patients were given tenofovir DF-emtricitabine
9749919|NCT00434018|Other|Wheelchair Skills Training Program|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
9749920|NCT00434018|Other|Basic Health Education|Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
9749921|NCT00434057|Other|Biopsied Pigmented Skin Lesions|Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto
9749922|NCT00434109|Experimental|Sunitinib Malate and Hepatic Artery Embolizations|Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
9749923|NCT00434122|Experimental|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
9749924|NCT00434122|Placebo Comparator|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
9749925|NCT00434148|Experimental|Pasireotide 600 ug|At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
9749926|NCT00434148|Experimental|Pasireotide 900 ug|At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
9749927|NCT00434161|Active Comparator|Palifermin before only|Subjects received palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses)
9749928|NCT00434161|Placebo Comparator|Placebo (suger pill)|Subjects received matched placebo before- and after-high dose chemotherapy
9749929|NCT00434161|Active Comparator|Palifermin before and after|Subjects received palifermin before- and after-high dose chemotherapy (total of 6 doses)
9749930|NCT00434213|Experimental|Methylphenidate Transdermal System|To characterize the dermal reactions seen with the use of DAYTRANA
9749931|NCT00434252|Placebo Comparator|Carboplatin+Paclitaxel+Placebo|
9749932|NCT00434252|Experimental|Carboplatin+Paclitaxel+Bevacizumab|
9749933|NCT00434278|Placebo Comparator|Placebo|
9749934|NCT00434278|Experimental|Dornase alfa|
9749935|NCT00434304|Experimental|Ropinirole PR/XR|
9749936|NCT00434330|Experimental|Cohort 1, Q4W, SC, No Transition|
9749937|NCT00434330|Experimental|Cohort 2, Q4W, IV, No Transition|
9749938|NCT00434330|Experimental|Cohort 3, Q4W, SC, Transition|
9749939|NCT00434330|Experimental|Cohort 4, Q4W, IV, Transition|
9749940|NCT00434330|Experimental|Cohort 5, Q4W, SC, Transition|
9749941|NCT00434330|Experimental|Cohort 6, Q4W, IV, Transition|
9749942|NCT00434356|Experimental|1|
9749943|NCT00434356|Placebo Comparator|2|
9749944|NCT00434421|Experimental|German Cockroach Allergen Dosing Group|Glycerinated German Cockroach Allergenic Extract
9517417|NCT03306524|Experimental|SIPPV_VG_0_32|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
9517418|NCT03306524|Experimental|PSV_VG_0_32|PSV VG ventilation for 15 minutes slope time = 0.32 seconds maximum inspiratory time = 0.60 seconds
9749945|NCT00434434|Experimental|1|
9749946|NCT00434434|Experimental|2|
9749947|NCT00434434|Placebo Comparator|3|
9517419|NCT03306524|Experimental|SIPPV_VG_0_40|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
9749948|NCT00434512|Experimental|SB732461 adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
9749949|NCT00434512|Experimental|SB732461 adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
9749950|NCT00434512|Experimental|SB732461 adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
9749951|NCT00434512|Experimental|SB732461 non-adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
9749952|NCT00434512|Experimental|SB732461 non-adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
9749953|NCT00434512|Experimental|SB732461 non-adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
9749954|NCT00434577|Experimental|GSK1437173A _LD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.
9749955|NCT00434577|Experimental|GSK1437173A _MD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
9749956|NCT00434577|Experimental|GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
9749957|NCT00434577|Placebo Comparator|Placebo + GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
9749958|NCT00434577|Active Comparator|GSK1437173A_MODIFIED GROUP|Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
9749959|NCT00434642|Experimental|Carboplatin and gemcitabine + bevacizumab|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
9749960|NCT00434642|Active Comparator|Carboplatin and gemcitabine + placebo|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.
9749961|NCT00434759|Active Comparator|SCP|SCP is a stepped-care program with a self-help module with minimal therapist contact (8 sessions) as first step, followed by therapist-guided intervention depending on status of remission (8 sessions up to a maximum of 16 sessions).
9749962|NCT00434759|Active Comparator|ST|A standard therapy which means a therapist-guided intervention with 16 sessions face-to-face therapy.
9749963|NCT00434876|Experimental|1|Quetiapine XR
9749964|NCT00434876|Placebo Comparator|2|Placebo
9749965|NCT00434954|Experimental|Exenatide Twice Daily (BID)|
9749966|NCT00434954|Active Comparator|Premixed Insulin Aspart Twice Daily (BID)|
9749967|NCT00434967|No Intervention|4|Placebo
9749968|NCT00434967|Active Comparator|2|Candesartan cilexetil
9749969|NCT00434967|Active Comparator|3|Hydrochlorothiazide (HCT)
9749970|NCT00434967|Experimental|1|Candesartan cilexetil + Hydrochlorothiazide Combination
9749971|NCT00434993|Active Comparator|Albuterol Sulfate|
9749972|NCT00434993|Placebo Comparator|Placebo|
9749973|NCT00435019|Experimental|insulin detemir|insulin detemir + insulin aspart
9749974|NCT00435019|Experimental|NPH insulin|NPH insulin + insulin aspart
9749975|NCT00435045|Active Comparator|atorvastatin arm|atorvastatin + placebo
9749976|NCT00435045|Experimental|Lovaza arm|Lovaza + atorvastatin
9749977|NCT00435162|Experimental|Low Dose|
9749978|NCT00435162|Experimental|Medium Dose|
9749979|NCT00435162|Experimental|High Dose|
9829420|NCT02533089|Experimental|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
9517420|NCT03306524|Experimental|PSV_VG_0_40|PSV VG ventilation for 15 minutes slope time = 0.40 seconds maximum inspiratory time = 0.60 seconds
9517421|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
9517422|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
9829421|NCT02533089|No Intervention|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
9517423|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
9517424|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
9517425|NCT03306472|Active Comparator|Arm A: Letrozole|Arm A: 15 days of Letrozole 2.5mg daily
9749980|NCT00435188|Experimental|Arm 1|Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
9749981|NCT00435188|No Intervention|Arm 2|Usual care
9749982|NCT00435370|Experimental|Tropisetron|Tropisetron (10mg/day) + risperidone(6mg/day)
9749983|NCT00435370|Placebo Comparator|Placebo|Placebo + risperidone (6mg/day)
9749984|NCT00435409|Experimental|A|
9749985|NCT00435409|Active Comparator|B|
9749986|NCT00435487|Experimental|A|
9749987|NCT00435487|Active Comparator|B|
9749988|NCT00435539|Experimental|ocriplasmin 75µg single injection|Ocriplasmin 75µg single injection versus sham injection
9749989|NCT00435539|Experimental|ocriplasmin 125µg single injection|Ocriplasmin 125µg single injection versus sham injection
9749990|NCT00435539|Experimental|ocriplasmin 175µg single injection|Ocriplasmin 175µg single injection versus sham injection
9749991|NCT00435539|Experimental|ocriplasmin 125µg multiple injections|Ocriplasmin 125µg multiple injections. Subjects who did not achieve resolution of VMT by the day 28 visit (i.e. non-responders) were given an open-label injection of ocriplasmin 125µg. Subjects who still did not achieve resolution of VMT by the day 56 visit were given a second open-label injection of ocriplasmin 125µg.
9749992|NCT00435539|Sham Comparator|sham injection|sham injection
9749993|NCT00435591|Experimental|Dose Regimen 1|Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule
9749994|NCT00435591|Experimental|Dose Regimen 2|Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule
9749995|NCT00435591|Experimental|Dose Regimen 3|Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag
9749996|NCT00435591|Experimental|Dose Regimen 4|Conivaptan loading dose (20mg) + 20mg/day continuous infusion conivaptan per premix bag
9749997|NCT00435812|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
9749998|NCT00435812|Active Comparator|Engerix-B|1.0 mL Engerix-B
9749999|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_24 Weeks|Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
9750000|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_24 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
9750001|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_48 Weeks|Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
9750002|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_48 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
9750003|NCT00435929|Experimental|1|
9750004|NCT00435929|Experimental|2|
9750005|NCT00435942|Experimental|1|Endovascular Treatment arm to be implanted with Relay device
9750006|NCT00435942|Active Comparator|2|Surgical Control, underwent open repair
9750007|NCT00435994|Other|Infants with viral lower respiratory infections|Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
9750008|NCT00435994|Other|Healthy Control|Healthy infants between the ages of 2-24 month
9750009|NCT00435994|Other|Bronchiolitis-Nasal wash only|Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only
9750010|NCT00436007|Experimental|GSK 257049 1 Group|"Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib, Polio Sabin™ and GSK 257049 vaccines at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ vaccines at Month 7.~The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania."
9750011|NCT00436007|Experimental|GSK 257049 2 Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, 3 doses of GSK 257049 vaccine at Months 0, 1 and 7, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. Stamaril™ was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
9750012|NCT00436007|Active Comparator|Tritanrix™ HepB/Hiberix™ Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
9517426|NCT03306472|Experimental|Arm B: Letrozole + Megestrol Acetate (40mg)|Arm B: 15 days of Letrozole 2.5mg daily + Megestrol acetate 40mg daily
9517427|NCT03306472|Experimental|Arm C: Letrozole + Megestrol Acetate (160mg)|Arm C: 15 days of Letrozole 2.5mg daily + Megestrol acetate 160mg daily.
9665957|NCT04788589|No Intervention|Control|"Informed consent~Randomization into groups~Sedation and ventilator weaning according to attending physicians~Pain scores and SBS score is noted every 6 hours for the first 24 hours, and every day for the next 24 hours until extubation.~Attending physicians assessed that subject could be weaned: pain scores, SBS score, WAT-1 score~Extubation. Researcher did not take part in the judgement of extubation."
9665958|NCT04786990|Experimental|Open-Label Treatment|"Subjects 6-11 years of age: 100 to 400mg SPN-812 (100 mg oral capsule)~Subjects 12-17 years of age: 100 to 600mg SPN-812 (100, 200 mg oral capsule)"
9665959|NCT04785950||Women with IUS|Women aged 18 to 35 years from Spain who chose to use any low-dose LNG-IUS marketed in Spain for the first time during routine clinical practice
9665960|NCT04785573|Active Comparator|Intervention group|Participants with metabolic disorders will be subjected to nutritional counsel and the intake of 1 soft gel capsule daily for a total of 3 months.
9665961|NCT04785573|No Intervention|Control group|Participants with metabolic disorders will be subjected to nutritional counsel for a total of 3 months.
9665962|NCT04783792|Experimental|ascorbic acid / phytochemical supplement|A mixture of active phenolic compounds with ascorbic acid
9665963|NCT04783792|Experimental|ascorbic acid|Ascorbic acid group
9665964|NCT04783662||Robust|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal to 0
9665965|NCT04783662||Pre Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is 1 or 2
9665966|NCT04783662||Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal or greater than 3
9665967|NCT04782271|Experimental|Single administration Low Dose once daily|1 treatment day
9665968|NCT04782271|Experimental|Single administration Middle Dose once daily|1 treatment day
9665969|NCT04782271|Experimental|Single administration High Dose once daily|1 treatment day
9665970|NCT04782271|Experimental|Single administration High Dose twice daily|1 treatment day
9665971|NCT04782271|Experimental|Multiple administrations Low Dose once daily|7 treatment days
9665972|NCT04782271|Experimental|Multiple administrations Middle Dose once daily|7 treatment days
9665973|NCT04782271|Experimental|Multiple administrations High Dose once daily|7 treatment days
9665974|NCT04782271|Experimental|Multiple administrations High Dose twice daily|7 treatment days
9665975|NCT04781816|Experimental|SAR443122|SAR443122 for 12 weeks
9665976|NCT04781816|Placebo Comparator|Placebo|Matching placebo
9665977|NCT04781179|Experimental|CM-II Technique|
9665978|NCT04781179|Placebo Comparator|Psychoeducation|
9665979|NCT04780425|Experimental|DESMOND|receive usual care plus a structured diabetes self-management education program delivered once over 6hours
9665980|NCT04780425|Active Comparator|USUAL CARE|Receive usual care as per standard treatment guidelines of ghana unstructured education during clinic visits for routine care
9665981|NCT04779957|Experimental|Tocilizumab|Evaluation of the use of Tocilizumab after allograft nephrectomy.
9665982|NCT04779008|Experimental|Experimental Group 1|Routine treatment + interventions:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) before surgery, then normal surgery, and RIPC was performed on the second day and Once RIPC/day after CABG for one year.
9750013|NCT00436046|Active Comparator|Group 1: 0.6 ml of IVV|30 subjects to receive 0.6 ml of inactivated influenza virus vaccine (IVV).
9750014|NCT00436046|Experimental|Group 3: 0.7 ml of IVV + 10M units of IFN|30 subjects to receive 0.7 ml of IVV containing 10M units of interferon (IFN).
9665983|NCT04779008|Experimental|Experimental Group 2|Routine treatment + interventions:Patients underwent a RIPC before surgery, and then normal medical procedures were performed with no additional intervention.
9665984|NCT04779008|No Intervention|Control group|routine treatment, no RIPC
9665985|NCT04777409|Experimental|Oral semaglutide 14 mg|Participants are given oral semaglutide once daily
9665986|NCT04777409|Placebo Comparator|Placebo (semaglutide)|Participants are given oral placebo once daily
9665987|NCT04777396|Experimental|Oral Semaglutide|Participants are given oral semaglutide once daily
9665988|NCT04777396|Placebo Comparator|Placebo (semagludtide)|Participants are given oral placebo once daily
9665989|NCT04777253|Experimental|Biofeedback method and Health-resort based rehabilitation|Health-resort based treatments supplemented with biofeedback training
9665990|NCT04777253|Other|Health-resort based rehabilitation|Control group - health-resort based treatments, without biofeedback training.
9665991|NCT04776161|No Intervention|Control|Patients in the control arm will not receive any intervention (but will receive electronic pill bottles to monitor their adherence).
9665992|NCT04776161|Experimental|Cue-Reward Intervention|Patients in this intervention arm will choose an event-based cue and receive reminder text messages reminding them of their cue. Additionally, a donation will be made to a local charity every time they take their medication.
9665993|NCT04776161|Experimental|Cue-Reward Intervention with possible intensification.|Patients in this intervention arm will choose an event-based cue. Additionally, a donation will be made to a local charity every time they take their medication. Those who show no improvement in adherence after 6 weeks will start receiving reminder text messages reminding them of their cue.
9665994|NCT04775771|Experimental|Animal Assisted Practice (Experimental) Group|
9665995|NCT04775771|No Intervention|Control Group|
9665996|NCT04775706|Experimental|HM15912 0.5 mg/kg Active|
9665997|NCT04775706|Placebo Comparator|Placebo|
9665998|NCT04771234|Experimental|Treatment group|The intervention consists of a self-guided digital tool to guide participants with chronic insomnia through sleep restriction and stimulus control procedures.
9665999|NCT04770532|Experimental|Insulin icodec|Insulin icodeg + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
9829422|NCT02533167|Experimental|skin to skin|skin to skin initiated on all consented CS while in the operating room
9829423|NCT02533180|Other|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
9829424|NCT02533375|Experimental|Participants receiving adalimumab|80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
9665805|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Pomalidomide+Dexamethasone)|Participants with relapsed/refractory MM who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab as per protocol and pomalidomide 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days).
9829425|NCT02533401|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared [mg/m^2] intravenously [IV]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
9829426|NCT02533427|Experimental|SOF/VEL/VOX + VOX|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX."
9829427|NCT02533453|Experimental|Bydureon|exenatide once weekly
9829428|NCT02533466|Experimental|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
9829429|NCT02533466|Placebo Comparator|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
9829430|NCT02533505|Active Comparator|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
9829431|NCT02533505|Placebo Comparator|Placebo of reference drug|Placebo of reference drug
9829432|NCT02533570|Experimental|Brentuximab vedotin|4 dose groups
9829433|NCT02533570|Placebo Comparator|Placebo|Matching placebo
9829434|NCT02533674|Experimental|gemcitabine plus PM060184|
9829435|NCT02533726|Experimental|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
9829436|NCT02533726|Active Comparator|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
9829437|NCT02533921|Other|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
9829438|NCT02533921|Active Comparator|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
9829439|NCT02533934|Experimental|Treatment with Sofosbuvir based HCV Therapy|Prospective and retrospective treatment for HCV
9829440|NCT02533999|Experimental|Surgical Instrument|"PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
9829441|NCT02533999|Active Comparator|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
9829442|NCT02534129|Experimental|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
9829443|NCT02534285|Sham Comparator|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
9829444|NCT02534285|Active Comparator|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
9829445|NCT02534324||High SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge < 180 mmHg
9750015|NCT00436046|Experimental|Group 2: 0.6 ml of IVV + 1M unit of IFN|30 subjects to receive 0.6 ml of IVV containing 1M units of interferon (IFN).
9750016|NCT00436163|Experimental|Peginterferon Alfa-2a|Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.
9750017|NCT00436215|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (sorafenib) + Bevacizumab
9750018|NCT00436280|Experimental|Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)|
9750019|NCT00436332|Experimental|Erlotinib and Bevacizumab|
9750020|NCT00436345|Experimental|Remifentanil|remifentanil
9750021|NCT00436345|Active Comparator|Propofol|Propofol infusion
9750022|NCT00436436|Experimental|O6-benzylguanine & Temozolomide in Glioblastoma|Patients receive O6-benzylguanine intravenous over 1 hour and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9750023|NCT00436475|Other|1|Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
9750024|NCT00436475|Other|2|Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
9750025|NCT00436475|Other|3|Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
9750026|NCT00436475|Other|4|Vitamin D3-Placebo plus Calcium-Placebo
9750027|NCT00436501|Experimental|Treatment (VEGF Trap, Docetaxel)|"Phase I (closed to accrual as of 3/14/2008): Patients receive VEGF Trap IV over 1 hour on day 1 of course 1. Patients then receive VEGF Trap IV over 1 hour and docetaxel IV over 1 hour on day 1 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 or 6 patients experience dose-limiting toxicity."
9750028|NCT00436501|Experimental|Phase II Treatment (VEGF Trap, Docetaxel)|Phase II (opened to accrual as of 5/9/2008): Patients receive VEGF Trap at the MTD determined in phase I and docetaxel as in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9750029|NCT00436553|Experimental|Verteporfin With Standard Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
9750030|NCT00436553|Active Comparator|Ranibizumab Monotherapy|Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
9750031|NCT00436553|Experimental|Verteporfin With Reduced Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
9750032|NCT00436605|Experimental|Treatment (kinase inhibitor therapy)|Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9750033|NCT00436618|Experimental|Relapsed aggressive non-Hodgkin lymphoma|Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
9750034|NCT00436618|Experimental|Relapsed indolent non-Hodgkin lymphoma|Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
9750035|NCT00436618|Experimental|Uncommon lymphomas|Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
9750036|NCT00436644|Experimental|Lapatinib + Topotecan|Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.
9750037|NCT00436748|Experimental|Darbepoetin Alfa QW|Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
9829446|NCT02534324||Severely high SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge >= 180 mmHg
9829447|NCT02534350|Experimental|Presatovir|Presatovir 200 mg (4 x 50 mg) on Day 1, followed by 100 mg (2 x 50 mg) from Day 2 to Day 14
9829448|NCT02534350|Placebo Comparator|Placebo|Placebo tablets for a total of 14 days
9829449|NCT02534493|Experimental|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
9829450|NCT02534883|Active Comparator|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
9829451|NCT02534883|Placebo Comparator|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
9829452|NCT02534896|Experimental|Treatment 1: Sunpharma1505 (Low dose) and Placebo|
9829453|NCT02534896|Experimental|Treatment II: Sunpharma1505 (High Dose) and Placebo|
9829454|NCT02534896|Active Comparator|Treatment III: Reference1505 and Placebo|
9829455|NCT02534935|Experimental|rLP2086 vaccine|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
9829456|NCT02534935|Active Comparator|Control|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
9829457|NCT02535000|Experimental|Group C (control)|subjects who will receive one capsule of placebo before the surgery and being repeated the next day
9829458|NCT02535000|Active Comparator|Group D (duloxetine)|subjects who will receive one capsule of duloxetine 60 mg before the surgery and being repeated the next day
9829459|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
9829460|NCT02535364|Experimental|JCAR015 (CD19-targeted CAR T cells)|JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.
9829461|NCT02535416|Experimental|ARC-520 Cohort 1|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine
9750038|NCT00436748|Experimental|Darbepoetin Alfa Q2W|Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
9750039|NCT00436852|Experimental|Measurable disease by CT or MRI scan (ABT-751 chemotherapy)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
9750040|NCT00436852|Experimental|Evaluable by I-MIBG scintigraphy (ABT-751)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
9750041|NCT00436904|Experimental|Alemtuzumab + Rituximab|Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
9750042|NCT00436917|Experimental|zoledronic acid|4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.
9750043|NCT00436956|Experimental|AZD2171 in Prostate Cancer|Cohort 1 (n=35) received 20 mg AZD2171 (Cediranib) orally daily. Cohort 2 (n=23) received prednisone 10 mg orally daily with 20 mg AZD2171.
9750044|NCT00436969|Active Comparator|Control|Subjects randomized to the control arm injection of prescribed anesthetic and corticosteroid, shall receive an equivalent volume (8 mL's).
9750045|NCT00436969|Experimental|Investigational|Subjects randomized to the active treatment in this study will receive a one-time dose of 8 mL's of Orthovisc derived from non-animal source bacterial fermentation, S. Equi.
9782360|NCT01173601|Experimental|12 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 12-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
9782361|NCT01173601|Experimental|18 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 1 week, followed by 18 mg, administered orally, once daily for 7 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 18-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
9782362|NCT01173601|Placebo Comparator|Placebo + SSRI|"Placebo: Tablet equivalent to LY2216684, administered orally, once daily (QD) for 11 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the placebo treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase. Participants who had received placebo were assigned to the abrupt DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
9782363|NCT01173653|Placebo Comparator|Standard EM Smoking Cessation Info|Patients discharged from ER receive pamphlet re: smoking cessation
9782364|NCT01173653|Active Comparator|Patients contact 1-800-QUIT-NOW before leaving ED|Prior the patient leaving the ED, the PI will assist the patient with contacting 1-800-QUIT-NOW, who will help patient to quit smoking.
9782365|NCT01173679|Other|dasatinib, rituximab, fludarabine|Single-arm, open-label
9782366|NCT01173692|Placebo Comparator|Placebo|Twice Daily Orally
9782367|NCT01173692|Experimental|Minocycline|100 mg Twice Daily Orally
9782368|NCT01173718|Experimental|GORE® ACUSEAL Vascular Graft|
9782369|NCT01173848|Active Comparator|Vitamin D2|Patients randomized to take vitamin D2
9782370|NCT01173848|Active Comparator|Vitamin D3|Patient's randomized to take Vitamin D3
9829462|NCT02535416|Experimental|ARC-520 Cohort 2A|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine
9829463|NCT02535416|Experimental|ARC-520 Cohort 2|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine
9750046|NCT00436982|Active Comparator|Cemented Triathlon total knee system|The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
9750047|NCT00436982|Active Comparator|Cemented Duracon total knee system|The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
9750048|NCT00437034|Experimental|Treatment (antiangiogenesis therapy)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9750049|NCT00437073|Experimental|lapatinib plus capecitabine|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
9750050|NCT00437073|Experimental|lapatinib + topotecan|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
9750051|NCT00437125|Experimental|Duloxetine|Participants received duloxetine 30 milligram (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg orally QD for 11 weeks
9750052|NCT00437203|Experimental|1|
9750053|NCT00437268|Experimental|enzastaurin + irinotecan + cetuximab|
9750054|NCT00437268|Active Comparator|irinotecan + cetuximab|
9750055|NCT00437281|Placebo Comparator|Placebo|
9750056|NCT00437281|Experimental|Pregabalin|
9750057|NCT00437294|Experimental|Capecitabine + Enzastaurin|
9750058|NCT00437294|Placebo Comparator|Capecitabine + Placebo|
9750059|NCT00437489|Active Comparator|Control|
9750060|NCT00437489|Experimental|Experimental|
9750061|NCT00437645|Experimental|Valsartan/amlodipine 160/5 mg|Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
9750062|NCT00437645|Active Comparator|Amlodipine 10 mg|Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
9750063|NCT00437658|Experimental|Elagolix 75 mg BID|Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
9750064|NCT00437658|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
9750065|NCT00437658|Active Comparator|DMPA-SC|Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.
9750066|NCT00437983|Active Comparator|PS-Omega3|Phosphatidylserine-Omega3, 300mg/day 15 wk
9750067|NCT00437983|Placebo Comparator|Placebo|Cellulose tainted with fishy odor, 3 capsules/day
9750068|NCT00438100|Active Comparator|Capecitabine arm|Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
9750069|NCT00438100|Experimental|S-1 arm|S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
9750070|NCT00438191||1|Subjects who wear the splint whenever the feel the need.
9750071|NCT00438191||2|Subjects who wear the splint whenever possible.
9750072|NCT00438204|Experimental|Bevacizumab, gemcitabine hydrochloride|"Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days~Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days~Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days."
9750073|NCT00438256|Experimental|Group 1|10 Radiation Sessions over 2 weeks
9750074|NCT00438256|Experimental|Group 2|5 Radiation sessions: 3 in week 1 and 2 in week 2
9750075|NCT00438256|Experimental|Group 3|5 Radiation sessions: 4 in week 1 and 1 in week 2
9750076|NCT00438256|Experimental|Group 4|5 Radiation Sessions in one week
9750077|NCT00438360|Active Comparator|Cyclosporine A|Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
9750078|NCT00438360|Placebo Comparator|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
9750079|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 1|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Wash-out up to 8 weeks~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
9750080|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 2|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
9750081|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 3|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
9750082|NCT00438399|Active Comparator|Corticosteroid 1-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
9750083|NCT00438399|Active Comparator|Corticosteroid 2-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
9750084|NCT00438399|Active Comparator|Corticosteroid 3-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
9750085|NCT00438451|Active Comparator|Levetiracetam|Levetiracetam
9750086|NCT00438451|Active Comparator|Carbamazepine|Carbamazepine
9750087|NCT00438451|Active Comparator|Lamotrigine|Lamotrigine
9750088|NCT00438464|Experimental|Arm I (Finasteride)|Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
9750089|NCT00438464|Placebo Comparator|Arm II (Placebo)|Placebo once daily for 4-6 weeks, then undergo prostatectomy.
9750090|NCT00438490|Experimental|recombinant human prolactin|Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
9750091|NCT00438490|Placebo Comparator|Placebo|Normal saline placebo subcutaneous injection
9750092|NCT00438633||Early Therapy|Subjects who begin therapy immediately after diagnosis of injury.
9750093|NCT00438633||Late Therapy|Subjects who delay therapy for 3 weeks after diagnosis of injury.
9750094|NCT00438659|Experimental|Mometasone|Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.
9750095|NCT00438659|Placebo Comparator|Placebo|Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm I.
9750096|NCT00438672|Active Comparator|Dequervains|The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.
9750097|NCT00438672|Active Comparator|Lateral Epicondylitis|
9750098|NCT00438672|Active Comparator|CMC Arthritis|The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.
9750099|NCT00438750|Experimental|Independent Home Exercises|Subjects who learn their therapy exercises from the surgeon and practice them independently at home.
9750100|NCT00438750|Experimental|Formal Therapy|Subjects who follow the conventional protocol of seeing a therapist to learn and guide them in their exercises.
9750101|NCT00438802|Experimental|alefacept|Determine both the maximum tolerated dose level as well as the optimal immunologic dose and toxicity.
9750102|NCT00438815|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
9750103|NCT00438854|Experimental|Dasatinib treatment|All patients were treated with dasatinib pills by mouth as treatment.
9750104|NCT00438880|Experimental|Arm I|See Detailed Description
9750105|NCT00438932|Active Comparator|Lanthanum Carbonate and Low Phosphorus Diet|25% of subjects will receive binders plus a phosphate restricted diet.
9750106|NCT00438932|Active Comparator|Lanthanum Carbonate and Unrestricted Phosphorus Diet|25% binders + unrestricted phosphate diet.
9750107|NCT00438932|Active Comparator|Placebo and Low Phosphorus Diet|25% placebo + phosphate restricted diet.
9750108|NCT00438932|Active Comparator|Placebo and Unrestricted Phosphorus Diet|25% placebo + unrestricted phosphate diet.
9750109|NCT00438971|Experimental|Duloxetine|
9750110|NCT00439140|Experimental|botulinum toxin Type A 200U|Botulinum toxin Type A 200U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
9750111|NCT00439140|Experimental|botulinum toxin Type A 300U|Botulinum toxin Type A 300U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 300U injection after a minimum of 12 weeks (if applicable).
9750112|NCT00439140|Other|Placebo/botulinum toxin Type A 200U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
9750113|NCT00439140|Other|Placebo/botulinum toxin Type A 300U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 300U injection (200U after discontinuation of 300U) after a minimum of 12 weeks (if applicable).
9750114|NCT00439179|Experimental|Cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
9750115|NCT00439179|Experimental|Cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
9750116|NCT00439179|Experimental|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
9750117|NCT00439179|Experimental|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
9750118|NCT00439218|Experimental|Subject Enrollments|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
9750119|NCT00439231|Experimental|Lenalidomide (Revlimid) subjects|Lenalidomide regimen testing to determine efficacy for CLL/ SLL subjects
9750120|NCT00439244|Active Comparator|Zoledronic acid plus teriparatide|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
9750121|NCT00439244|Experimental|Zoledronic acid|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion.
9750122|NCT00439244|Active Comparator|Placebo zoledronic acid plus teriparatide|Placebo zoledronic acid 100 mL intravenous (i.v.) (once at randomization) plus teriparatide 20 μg (daily subcutaneous injections administered concurrently through 52 weeks). Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
9750123|NCT00439270|Active Comparator|Dasatinib, 50 mg + Docetaxel, 60 mg/m^2|Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m^2.
9750124|NCT00439270|Active Comparator|Dasatinib, 50 mg + Doxetaxel, 75 mg/m^2|Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
9750125|NCT00439270|Active Comparator|Dasatinib, 70 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
9750126|NCT00439270|Active Comparator|Dasatinib, 100 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
9750127|NCT00439270|Active Comparator|Dasatinib, 120 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
9750128|NCT00439296|Experimental|Dose Level 1|"Treatment Dose of ABT-751 is 80 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
9750129|NCT00439296|Experimental|Dose Level 2|"Treatment Dose of ABT-751 is 100 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
9750130|NCT00439296|Experimental|Dose Level 3|"Treatment Dose of ABT-751 is 125 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
9750131|NCT00439296|Experimental|Dose Level 4|"Treatment Dose of ABT-751 is 150 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
9750132|NCT00439296|Experimental|Dose Level 5|"Treatment Dose of ABT-751 is 175 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
9750133|NCT00439296|Experimental|Dose Level 0|"Treatment Dose of ABT-751 is 65 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
9750134|NCT00439296|Experimental|Dose Level -1|"Treatment Dose of ABT-751 is 50 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
9750135|NCT00439309|Experimental|VascuSeal|Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
9750136|NCT00439309|Active Comparator|GELFOAM/THROMBIN|GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
9750137|NCT00439335|Experimental|H5 HA IM|Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.
9750138|NCT00439335|Experimental|H5 HA ID|Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.
9750139|NCT00439374|Active Comparator|17 alpha-hydroxyprogesterone caproate|250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
9750140|NCT00439374|Placebo Comparator|Placebo|Placebo oil given by weekly injection until 37 weeks gestation or delivery.
9750141|NCT00439413|Active Comparator|Selegiline Transdermal Patch|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received Selegiline Transdermal System, 6mg -20cm(2) patch, one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
9750142|NCT00439413|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received matched placebo 20cm(2) patch transdermal patch one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
9750143|NCT00439465|Other|Ex-vivo expanded effector cells|Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)
9750144|NCT00439517|Experimental|1|UFOX + Cetuximab
9750145|NCT00439517|Active Comparator|2|FOLFOX4 + Cetuximab
9750146|NCT00439556|Experimental|Treatment (chemotherapy, transplant, filgrastim, tacrolimus)|See Detailed Description
9750147|NCT00439608|Experimental|Treatment|Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
9750148|NCT00439647|Experimental|Zoledronic Acid|5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
9750149|NCT00439647|Placebo Comparator|Placebo|100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
9750150|NCT00439725|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 20 mg oral tablet once daily
9750151|NCT00439725|Placebo Comparator|Placebo|Participants were to receive matching placebo oral tablet once daily
9750152|NCT00439777|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
9750153|NCT00439777|Active Comparator|Enoxaparin/VKA|Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
9750154|NCT00439946|Experimental|treprostinil|IV treprostinil continuous infusion via Crono Five infusion pump.
9750155|NCT00440011|Experimental|1|
9750156|NCT00440011|Active Comparator|2|
9750157|NCT00440037|Experimental|AMG 531|
9750158|NCT00440050|Experimental|1.|DHA
9750159|NCT00440050|Placebo Comparator|2.|Placebo
9750160|NCT00440115|Experimental|High intensity disease management|High intensity disease management, free nicotine replacement therapy or bupropion
9750161|NCT00440115|Experimental|Low intensity disease management|Low intensity disease management, free nicotine replacement therapy or bupropion
9750162|NCT00440115|Other|Comparison group|Comparison group, free nicotine replacement therapy or bupropion
9750163|NCT00440180|Placebo Comparator|Group B|Placebo
9750164|NCT00440180|Experimental|Group A|Anastrozole
9750165|NCT00440193|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
9750166|NCT00440193|Active Comparator|Enoxaparin/VKA|Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
9750167|NCT00440232|Experimental|Frovatriptan|5.0 mg of Frovatriptan given as single dose
9750168|NCT00440232|Placebo Comparator|placebo|
9750169|NCT00440297|Experimental|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
9750170|NCT00440297|Active Comparator|ENGERIX-B™2|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
9829464|NCT02535416|Experimental|ARC-520 Cohort 3|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine
9829465|NCT02535416|Experimental|ARC-520 Cohort 4|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine
9829466|NCT02535416|Experimental|ARC-520 Cohort 5|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine
9829467|NCT02535416|Experimental|ARC-520 Cohort 6|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine
9829468|NCT02535416|Experimental|ARC-520 Cohort 7|Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine
9829469|NCT02535416|Experimental|ARC-520 Cohort 8|Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
9829470|NCT02535481|Experimental|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
9829471|NCT02535481|Experimental|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
9829472|NCT02535572|Experimental|FEAST|Patients will receive the FEAST form of ECT
9829473|NCT02535572|Active Comparator|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
9829474|NCT02535611|Active Comparator|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
9829475|NCT02535611|Placebo Comparator|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
9829476|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd|Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study
9829477|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd|Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study
9829478|NCT02535715|Experimental|ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd|One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study
9829479|NCT02535741|Other|Triathlon CR Total Knee System|Primary total knee replacement
9829480|NCT02535806|Experimental|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
9829481|NCT02535949|Experimental|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
9829482|NCT02535949|Experimental|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
9829483|NCT02535949|Placebo Comparator|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
9829484|NCT02536040|Experimental|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
9829485|NCT02536040|Placebo Comparator|Water|Topical application of fluoride free water to active cavity
9829486|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
9829487|NCT02536105|Placebo Comparator|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
9829488|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
9829489|NCT02536105|Active Comparator|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
9829490|NCT02536196|Experimental|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
9829491|NCT02536196|Active Comparator|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
9829492|NCT02536248|Experimental|Sitagliptin first, then Placebo|"Sitagliptin 100 mg/d for 6 weeks~Wash-out 14 days~Placebo for 6 weeks"
9829493|NCT02536248|Placebo Comparator|Placebo first, then Sitagliptin|"Placebo for 6 weeks~Wash-out 14 days~Sitagliptin 100 mg/d for 6 weeks"
9829494|NCT02536313|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
9829495|NCT02536313|Experimental|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
9829496|NCT02536404|Experimental|Etrasimod 2 mg|
9829497|NCT02536404|Active Comparator|Placebo|
9829498|NCT02536508|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
9750171|NCT00440310|Experimental|Litx + Chemotherapy|
9750172|NCT00440310|Active Comparator|Chemotherapy alone|
9750173|NCT00440401|Active Comparator|TachoSil®|
9750174|NCT00440401|Active Comparator|Standard Treatment|Standard Treatment of haemorrhage in cardiovascular surgery
9750175|NCT00440466|Experimental|001|epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
9750176|NCT00440466|Experimental|003|epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
9750177|NCT00440466|Experimental|002|epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
9750178|NCT00440505|Placebo Comparator|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
9750179|NCT00440505|Experimental|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
9750180|NCT00440505|Experimental|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
9750181|NCT00440518|Placebo Comparator|Placebo|Placebo
9750182|NCT00440518|Experimental|Lacosamide 100mg|100mg lacosamide
9750183|NCT00440518|Experimental|Lacosamide 300mg|300mg lacosamide
9750184|NCT00440557|Experimental|TIW: Epoetin alfa 3 injections Weekly/Once Weekly|Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
9750185|NCT00440557|Experimental|QW: Epoetin alfa once weekly|Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
9750186|NCT00440557|Experimental|Q2W: Epoetin alfa once every two weeks|Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
9750187|NCT00440596|Experimental|Mindfulness based stress reduction|Mindfulness based stress reduction
9750188|NCT00440596|Active Comparator|Progressive Muscle Relaxation|Progressive Muscle Relaxation
9750189|NCT00440700|Experimental|Patient-directed music|Patients select preferred music for listening through headphones whenever they like for as long as they like whenever feeling anxious, desire some rest and quiet time, or for listening enjoyment while mechanically ventilated in the ICU.
9750190|NCT00440700|Active Comparator|Headphones|Noise-canceling headphones only (no music) are applied by the patient to block out noise/sound in the ICU whenever desired.
9750191|NCT00440700|Other|Standard of Care|Patients receive usual care for the ICU and are encouraged to self-initiate rest periods twice daily.
9750192|NCT00440726|Experimental|Ph 1 Dose Escalation|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
9750193|NCT00440726|Experimental|Ph 2 Efficacy and Safety|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
9750194|NCT00440830|Experimental|Smokers-nicotine|Smokers who were treated with nicotine
9750195|NCT00440830|Experimental|Nonsmokers-nicotine|Nonsmokers who were treated with nicotine
9750196|NCT00440830|Placebo Comparator|Smokers-placebo|Smokers who were treated with placebo
9750197|NCT00440830|Placebo Comparator|Nonsmokers-placebo|Nonsmokers who were treated with placebo
9750198|NCT00440947|Other|Simplification|Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
9750199|NCT00440947|Other|Continuation|Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
9829499|NCT02536508|Experimental|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
9750200|NCT00440999|Experimental|pyronaridine artesunate|The tablet strength is 180:60 mg oral PA plus chloroquine-placebo. Depending on their body weight, patients receive 1 to 4 tablets once a day, for 3 days. The actual dose-level range covered by this regimen is 7.2: 2.4 mg/kg to 13.8:4.6 mg/kg pyronaridine artesunate.
9750201|NCT00440999|Active Comparator|chloroquine|"The tablet strength is 155 mg oral chloroquine plus PA-placebo.~Patients receive:~For adults: 620 mg (i.e. 4 tablets) on Days 0 and 1 and 310 mg (i.e. 2 tablets) on Day 2. For children: 10 mg/kg on Days 0 and 1 and 5 mg/kg on Day 2."
9750202|NCT00441012|Experimental|1|Modified process Hib/Hep B vaccine
9750203|NCT00441012|Active Comparator|2|COMVAX™
9750204|NCT00441064|Experimental|Diet Sequence Low/High Sodium|Patients on low sodium diet ( <= 100 mmol/day) for the first 4 weeks and high sodium (>= 200 mmol/day) diet for the next 4 weeks. [with Aliskiren 300 mg]
9750205|NCT00441064|Experimental|Diet Sequence High/Low Sodium|Patients on high sodium (>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( <= 100 mmol/day) for the next 4 weeks. [with Aliskiren 300 mg]
9750206|NCT00441090|Experimental|Avatrombopag tablets|"2.5, 5, 10 or 20 mg tablets~1 tablet taken orally once daily for 28 days"
9750207|NCT00441090|Placebo Comparator|Placebo tablet|"2.5, 5, 10, or 20 mg tablets~1 tablet taken orally once daily for 28 days"
9750208|NCT00441103|Experimental|Rebif® New Formulation (IFN-beta-1a, RNF)|
9750209|NCT00441103|Placebo Comparator|Placebo/RNF|
9750210|NCT00441116|Placebo Comparator|Dutasteride|Dutasteride
9750211|NCT00441129|Active Comparator|Conventional insulin pump therapy|Conventional insulin pump therapy or continuous subcutaneous insulin infusion (CSII)
9750212|NCT00441129|Experimental|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
9750213|NCT00441142|Active Comparator|Phase II: Arm A (Control Group: RT + TMZ)|"The Induction Phase:~Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given]."
9750214|NCT00441142|Experimental|Phase I + Phase II: Arm B (RT + TMZ + Vandetanib)|"The Induction Phase:~ZD6474 (Vandetanib) daily (to begin 5-7 days prior to starting participant's RT) Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given].~ZD6474 (Vandetanib) daily for the twelve (12) 28-day cycles of adjuvant temozolomide, with the option to continue until participant experiences an unacceptable toxicity or his/her tumor progresses."
9750215|NCT00441168|Active Comparator|VAD Treatment|vincristine in combination with adriamycin and dexamethasone
9750216|NCT00441168|Experimental|PAD Treatment|bortezomib in combination with adriamycin and dexamethasone
9750217|NCT00441259|Experimental|JE-CV Group|Participants will receive Japanese encephalitis chimeric virus vaccine (JE-CV)
9750218|NCT00441259|Active Comparator|MBDV Group|Participants will receive the mouse brain-derived vaccine (MBDV)
9750219|NCT00441285|Active Comparator|I. ABZ + ABZ Placebo + PZQ|Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
9750220|NCT00441285|Active Comparator|II.- ABZ + ABZ Placebo + PZQ Placebo|Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
9750221|NCT00441285|Active Comparator|III .- Albendazole + PZQ Placebo|"Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward."
9750222|NCT00441337|Experimental|0.3 mg/kg MDX-1106 drug|0.3 milligrams (mg) MDX-1106 drug (nivolumab) per kilogram (kg) of body weight (mg/kg) was administered in a single intravenous (IV) infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
9750223|NCT00441337|Experimental|1 mg/kg MDX-1106 drug|1 mg MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
9750224|NCT00441337|Experimental|3 mg/kg MDX-1106 drug|3 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
9750225|NCT00441337|Experimental|10 mg/kg MDX-1106 drug|10 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
9750226|NCT00441350|Active Comparator|OM 40|Olmesartanmedoxomil (OM)40 mg tablets.
9829500|NCT02536508|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)
9750227|NCT00441350|Experimental|OM/HCTZ 40/12.5|Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.
9750228|NCT00441363|Active Comparator|Bromocriptine Mesylate|Bromocriptine mesylate 0.8 mg
9750229|NCT00441363|Placebo Comparator|Placebo|Bromocriptine mesylate 0.8 mg matching placebo
9750230|NCT00441441|Experimental|Fluticasone propionate/salmeterol 100/50 HFA|Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
9750231|NCT00441441|Experimental|Fluticasone propionate 100mcg HFA|Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
9750232|NCT00441467|Experimental|Glufosfamide|Glufosfamide
9750233|NCT00441480|Active Comparator|Plant sterol esters|plant sterols esterified to fish oil fatty acids
9750234|NCT00441480|Placebo Comparator|placebo|Corn oil
9750235|NCT00441545|Experimental|1|Fosrenol (Lanthanum carbonate)
9750236|NCT00441545|Active Comparator|2|Sevelamer hydrochloride
9750237|NCT00441558|Experimental|flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
9750238|NCT00441584|Experimental|PegIntron plus Rebetol|PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks
9750239|NCT00441701|Experimental|Part 1: Navarixin 3 mg|Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) once daily (QD) for up to 12 weeks
9750240|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 3 mg|Cohort 1: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
9750241|NCT00441701|Experimental|Part 1: Navarixin 10 mg|Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
9750242|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 10 mg|Cohort 2: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
9750243|NCT00441701|Experimental|Part 1: Navarixin 30 mg|Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
9750244|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 30 mg|Cohort 3: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
9750245|NCT00441701|Experimental|Part 2: Navarixin 3 mg|Cohort 4: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
9750246|NCT00441701|Experimental|Part 2: Navarixin 10 mg|Cohort 4: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
9750247|NCT00441701|Experimental|Part 2: Navarixin 30 mg|Cohort 4: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
9750248|NCT00441701|Placebo Comparator|Part 2: Placebo to navarixin|Cohort 4: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
9750249|NCT00441727|Experimental|Esomeprazole 40 mg|Esomeprazole 40 mg
9750250|NCT00441727|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg
9750251|NCT00441727|Placebo Comparator|Placebo|Placebo
9750252|NCT00441766|Experimental|AGN 203818 3 mg|Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
9750253|NCT00441766|Experimental|AGN 203818 20 mg|Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
9750254|NCT00441766|Experimental|AGN 203818 60 mg|Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
9750255|NCT00441766|Placebo Comparator|Placebo|Part A: Placebo capsule every 12 hours for 4 weeks
9750256|NCT00441792|Experimental|Etomidate|
9750257|NCT00441792|Experimental|midazolam|
9750258|NCT00441883|Experimental|PF-03187207 and Latanoprost Vehicle|One drop of each, once daily in study eye for 28 days
9750259|NCT00441883|Active Comparator|Latanoprost 0.005% and PF-03187207 Vehicle|One drop of each, once daily in study eye for 28 days
9750260|NCT00441974|Experimental|Single arm adefovir dipivoxil|adefovir dipivoxil once daily orally 10 mg
9750261|NCT00442013|Experimental|Lansoprazole|Participants in this group will receive lansoprazole on a daily basis for 6 months. There are two doses of Lansoprazole solutab provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
9750262|NCT00442013|Placebo Comparator|Matching placebo|Participants in this group will receive a matching placebo on a daily basis for 6 months. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
9750263|NCT00442169|Experimental|Group 1: WN02 Low Dose (Part 1)|Low Dose in healthy adults in Part 1 against a placebo control.
9750264|NCT00442169|Experimental|Group 2: WN02 Medium Dose (Part 1)|Medium dose level in part one healthy subjects against a placebo control.
9750265|NCT00442169|Experimental|Group 3: WN02 High Dose (Part 1)|High dose level in part one healthy subjects against a placebo control
9750266|NCT00442169|Placebo Comparator|Group 4: Placebo (Part 1)|Participants will receive a single dose of saline in Part 1 on Day 0
9750267|NCT00442169|Experimental|Group 5: WNO2 High Dose (Part 2)|Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.
9750268|NCT00442169|Placebo Comparator|Group 6: Placebo (part 2)|Participants will receive a single dose of saline in Part 2 on Day 0
9750269|NCT00442286|Experimental|On|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
9750270|NCT00442286|Experimental|Off|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
9750271|NCT00442364|Experimental|1|Polidocanol (1%) Microfoam (Varisolve)
9782371|NCT01173874|Experimental|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
9782372|NCT01173874|No Intervention|Cognitive activity control group|This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
9782373|NCT01174004|Experimental|1|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
9782374|NCT01174004|Placebo Comparator|2|placebo, tablet, once daily by mouth for 6 weeks
9782375|NCT01174030|Experimental|CD07805/47 Gel 0.5% QD|
9782376|NCT01174030|Experimental|CD07805/47 Gel 0.18% QD|
9782377|NCT01174030|Experimental|CD07805/47 Gel 0.18% BID|
9782378|NCT01174030|Placebo Comparator|Vehicle Gel QD|
9782379|NCT01174030|Placebo Comparator|Vehicle Gel BID|
9782380|NCT01174043|Experimental|Erlotinib|
9782381|NCT01174082|Experimental|KLH Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
9782382|NCT01174082|Experimental|KLH-id Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
9782383|NCT01174082|Experimental|KLH Vaccine (Donor)|Donor Group 1: (non-specific vaccination) vaccinated with KLH only vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
9782384|NCT01174082|Experimental|Vaccine KLH-id (Donor)|Donor Group 2: (myeloma specific vaccination) vaccinated with KLH-id vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collections.
9782385|NCT01174160|Experimental|vernakalant HCl|vernakalant hydrochloride
9782386|NCT01174160|Placebo Comparator|placebo|placebo
9782387|NCT01174173|Experimental|Ranolazine|1000 mg PO BID
9782388|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin elevated|Spondylitis patients with elevated levels of fecal calprotectin. Patients are treated with adalimumab
9782389|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin normal|Spondylitis patients with normal levels of fecal calprotectin. Patients are treated with adalimumab.
9782390|NCT01174238|Experimental|Arm A|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. In addition patients enrolled in Arm A will also have FLT-PET scans.
9782391|NCT01174238|Experimental|Arm B|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. Patients enrolled in Arm B will not have FLT-PET scans.
9782392|NCT01174264|Experimental|Arm I (vismodegib on empty stomach)|Patients receive a single dose of vismodegib PO on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
9782393|NCT01174264|Experimental|Arm II (vismodegib after high fat meal)|Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
9782394|NCT01174264|Experimental|Arm III (vismodegib after low fat meal)|Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.
9782395|NCT01174342||Pregnant women|Healthy pregnant women
9782396|NCT01174446|Experimental|BAX 326|Recombinant factor IX (rFIX)
9782397|NCT01174446|Active Comparator|BeneFIX|Recombinant Factor IX (rFIX)
9782398|NCT01174459||Patient with Restless Legs Syndrome|
9782399|NCT01174550|Active Comparator|Functional diagnostic tests|Stress Echocardiogram Nuclear Stress Test Exercise Electrocardiogram
9782400|NCT01174550|Active Comparator|Anatomic diagnostic test|Coronary Angiography
9782401|NCT01174576|Experimental|caffeinated coffee|200 mL caffeinated coffee with 3 mg caffeine per kg body weight
9782402|NCT01174576|Experimental|decaffeinated coffee|200 mL decaffeinated coffee, same amount as caffeinated coffee
9782403|NCT01174576|Experimental|Water|200 mL, control intervention
9750272|NCT00442416|Experimental|RO0503821|Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) subcutaneously (SC) every month for eight months (6 months of titration period [TP] and two months of evaluation period [EP] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of >=10.0 gram per decilitre (g/dL) and <=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
9750273|NCT00442416|Active Comparator|Epoetin Alfa|Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.
9750274|NCT00442468||All participants|This is a cross-sectional, non-interventional study. All enrolled subjects were asked to complete a questionnaire and pulmonary function test to assess the prevalence of airflow obstruction.
9750275|NCT00442507|Experimental|1|Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects.
9750276|NCT00442572|Experimental|PEGASYS|Participants received 4 treatment cycles of continuous intermittent treatment with PEGASYS® (Peginterferon alfa-2a) . Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
9750277|NCT00442572|No Intervention|No Intervention|Participants were on non- specific anti-viral treatment.
9750278|NCT00442598|Experimental|Glufosfamide q21 days|1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycle
9750279|NCT00442598|Experimental|Glufosfamide q7 days low|1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
9750280|NCT00442598|Experimental|Glufosfamide q7 days high|1-hour infusion of glufosfamide at a dose of 2,500 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
9750281|NCT00442611|Experimental|Abatacept|Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
9750282|NCT00442611|Placebo Comparator|IV fluid|Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
9750283|NCT00442689|Experimental|1|oral contraceptive (35 mg ethinyl estradiol)
9750284|NCT00442689|Experimental|2|Flutamide 250 mg twice daily
9750285|NCT00442689|Placebo Comparator|3|Placebo
9750286|NCT00442702|Experimental|Mircera|Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
9750287|NCT00442702|Active Comparator|Darbepoetin alfa|Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
9750288|NCT00442767|Active Comparator|Rapid acting Insulin therapy - before meal|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal
9750289|NCT00442767|Experimental|Pre-meal Pramlintide and Post-meal Insulin therapy|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
9750290|NCT00442936|Experimental|Telcagepant 150 mg|Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
9750291|NCT00442936|Experimental|Telcagepant 300 mg|Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
9782404|NCT01174784|Experimental|Treatment|The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.
9782405|NCT01174823|Experimental|Bepotastine Besilate Ophthalmic Solution|
9750292|NCT00442936|Active Comparator|Zolmitriptan 5 mg|Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
9750293|NCT00442936|Placebo Comparator|Placebo|Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
9750294|NCT00442962|Experimental|EFV + FTC/TDF|Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300mg in pill form, taken orally, once daily), for 48 weeks
9750295|NCT00443053|Active Comparator|Fondaparinux 2.5mg|
9750296|NCT00443053|Placebo Comparator|Placebo|
9750297|NCT00443079|Experimental|Siliphos/Placebo|Received study medication first followed by placebo
9750298|NCT00443079|Experimental|Placebo/Siliphos|Received placebo first followed by study medicaiton
9750299|NCT00443118|Active Comparator|Neopuff TM with PEEP|Newborns ventilated for neonatal resuscitation using Neopuff TM with PEEP
9750300|NCT00443118|Active Comparator|Self Inflating Bag with PEEP|Newborns ventilated for neonatal resuscitation using Self Inflating Bag with PEEP valve attached
9750301|NCT00443118|Active Comparator|Self Inflating Bag without PEEP|Newborns ventilated for neonatal resuscitationusing Self Inflating Bag without PEEP valve attached
9750302|NCT00443209|Experimental|Telcagepant 280 mg/300 mg|Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
9750303|NCT00443209|Active Comparator|Rizatriptan 10 mg|Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
9750304|NCT00443261|Experimental|1 (SCCHN)|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Patients will receive Azacitidine and cisplatin.
9750305|NCT00443352|Experimental|Duloxetine|Duloxetine 120mg daily for 12 weeks.
9750306|NCT00443430|Active Comparator|Methotrexate Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone
9750307|NCT00443430|Active Comparator|Methotrexate-Etanercept-Prednisolone Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks
9750308|NCT00443456|Experimental|Single|
9750309|NCT00443534|Experimental|1|
9750310|NCT00443547||1-level|Patients needing a single level cervical fusion with Vectra-T
9750311|NCT00443547||2-level|Patients needing cervical fusion at two consecutive levels with Vectra-T
9750312|NCT00443547||3-level|Patients needing cervical fusion at three consecutive levels with Vectra-T
9750313|NCT00443547||4-level|Patients needing cervical fusion at four consecutive levels with Vectra-T
9750314|NCT00443560||Instrumental Vaginal Delivery (IVD)|Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
9750315|NCT00443560||Spontaneous Vaginal Delivery (SVD)|The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.
9750316|NCT00443599|Experimental|Insulin|Insulin was infused to target a blood glucose concentration of 80-110 mg/dL
9750317|NCT00443599|Active Comparator|Usual Care|Insulin was infused according to the discretion of the treating clinical team.
9750318|NCT00443651|Experimental|Rituximab 1000 mg (Stage I patients)|Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
9782406|NCT01174823|Placebo Comparator|Placebo|
9782407|NCT01175005||Fever and a central venous catheter|
9782408|NCT01175018|Experimental|Anakinra|Anakinra 100 mg injectable subcutaneously daily
9750319|NCT00443651|Experimental|Rituximab 500 mg (Stage II patients)|Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
9750320|NCT00443703|Experimental|1|Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
9750321|NCT00443703|Active Comparator|2|Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)
9750322|NCT00443729|Experimental|1|Raltegravir & Placebo
9750323|NCT00443729|Active Comparator|2|Lopinavir (+) Ritonavir & Placebo
9750324|NCT00443755|Active Comparator|Insulin Sensitizer Therapy|Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
9750325|NCT00443755|Placebo Comparator|Placebo|Placebo tablets were used to match the active comparator drugs and dosing regimen.
9750326|NCT00443781|Other|PD and F.A.D. diagnostic testing|
9750327|NCT00443820|Experimental|1|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
9750328|NCT00443820|Placebo Comparator|2|Vehicle (placebo) for 48 weeks
9750329|NCT00443820|Experimental|3|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
9750330|NCT00443820|Placebo Comparator|4|Vehicle (placebo) for 24 weeks
9750331|NCT00443846|Experimental|Group 1: Concomitant Administration|Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
9750332|NCT00443846|Active Comparator|Group 2: Sequential Administration|Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.
9750333|NCT00443872|Other|orally disintegrating selegiline|This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.
9750334|NCT00443898|Experimental|1|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
9750335|NCT00443898|Placebo Comparator|2|vehicle (placebo) applied once daily for 48 weeks
9750336|NCT00443898|Experimental|3|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
9750337|NCT00443898|Placebo Comparator|4|vehicle (placebo) applied once daily for 24 weeks
9750338|NCT00444028|Experimental|Cohort A: Inhaled Loxapine 0.625 mg or Placebo|Single 0.625 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
9750339|NCT00444028|Experimental|Cohort B: Inhaled Loxapine 1.25 mg or Placebo|Single 1.25 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
9750340|NCT00444028|Experimental|Cohort C: Inhaled Loxapine 2.5 mg or Placebo|Single 2.5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
9750341|NCT00444028|Experimental|Cohort D: Inhaled Loxapine 5 mg or Placebo|Single 5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
9750342|NCT00444028|Experimental|Cohort E: Inhaled Loxapine 10 mg or Placebo|Single 10 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
9750343|NCT00444067|Experimental|Spinal Sealant System|Spinal Sealant System
9750344|NCT00444067|Active Comparator|Standard of Care|Standard of care methods as an adjunct to sutured dural repair
9750345|NCT00444080|Active Comparator|Control Arm|Subjects undergoing trabeculectomy with the use of Mitomycin C
9750346|NCT00444080|Experimental|Treatment Arm|Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C
9750347|NCT00444106|Experimental|Artemether-lumefantrine (Coartem)|Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
9829501|NCT02536664||First-line Stratum|Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
9829502|NCT02536664||Relapsed/Refractory Stratum|Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
9829503|NCT02536781|Placebo Comparator|Placebol|Placebo
9829504|NCT02536781|Active Comparator|Anthocynin|Anthocyanin
9829505|NCT02536833|Experimental|0.03 mg SM04690|Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
9829506|NCT02536833|Experimental|0.07 mg SM04690|Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
9829507|NCT02536833|Experimental|0.23 mg SM04690|Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
9829508|NCT02536833|Placebo Comparator|Placebo|Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
9829509|NCT02536846|Experimental|Second Generation Antipsychotic Drug|Olanzapine; a single 2.5 mg dose PO daily followed by 5 mg dose PO daily for 14 days
9829510|NCT02536963||PVS Screening and reference examination|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit. They will then receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
9829511|NCT02536976|Experimental|Active treatment|mirabegron
9829512|NCT02536976|Placebo Comparator|Placebo|Matching placebo
9829513|NCT02537015|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new 13 mg Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
9829514|NCT02537431|Experimental|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
9829515|NCT02537444|Experimental|Regimen 1|Drug: acalabrutinib monotherapy
9829516|NCT02537444|Experimental|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
9829517|NCT02537522|Experimental|Test/Control - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 8.5 BC in right eye and Contact Lenses with 9.0 BC in left eye in a contralateral manner.
9829518|NCT02537522|Experimental|Control/Test - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 9.0 BC in right eye and Contact Lenses with 8.5 BC in left eye in a contralateral manner.
9829519|NCT02537522|Experimental|Test/Control - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 9.0 BC at Period 1 and Contact Lenses with 8.5 BC at Period 2 in a bilateral manner.
9829520|NCT02537522|Experimental|Control/Test - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 8.5 BC at Period 1 and Contact Lenses with 9.0 BC at Period 2 in a bilateral manner.
9829521|NCT02537574|Experimental|NTX/BUP|Oral naltrexone + sublingual buprenorphine
9829522|NCT02537574|Active Comparator|NTX/PBO-B|Oral naltrexone + sublingual placebo
9829523|NCT02537574|Placebo Comparator|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
9829524|NCT02537717|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
9829525|NCT02537717|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
9829526|NCT02537730|Active Comparator|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
9829527|NCT02537730|Active Comparator|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
9829528|NCT02537873|Experimental|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
9829529|NCT02537873|Placebo Comparator|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
9829530|NCT02537951|Experimental|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
9829531|NCT02537951|Active Comparator|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
9829532|NCT02537951|Active Comparator|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
9829533|NCT02538016|Other|Tolvaptan|
9829534|NCT02538029|Experimental|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
9829535|NCT02538029|Active Comparator|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
9829536|NCT02538042|Experimental|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
9829537|NCT02538042|Other|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
9829538|NCT02538094|Sham Comparator|Sham Stimulation First|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS first and then Anodal Stimulation second.
9829539|NCT02538094|Experimental|Anodal Stimulation First|Transcranial direct current stimulation using Anodal stimulation first over the area of interest and then Sham Stimulation second.
9829540|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
9829541|NCT02538341|Active Comparator|Zostavax (Zoster Vaccine Live)|Zostavax (zoster vaccine live) is used to prevent herpes zoster (HZ) virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active herpes zoster (HZ) vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
9829542|NCT02538341|Placebo Comparator|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
9829543|NCT02538354|Experimental|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
9829544|NCT02538354|Experimental|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
9829545|NCT02538419|Active Comparator|CPAP + Peer Support|"Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.~All participants will receive CPAP in addition to this intervention."
9829546|NCT02538419|Active Comparator|CPAP + Individual Education|"Participants randomized to this arm will receive individual support and education from a trained investigator.~All participants will receive CPAP in addition to this intervention."
9829547|NCT02538471|Experimental|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
9835806|NCT02756182|Experimental|Urodynamics with AC and WP|Patients underwent a conventional urodynamics study utilizing a single catheter technique
9782409|NCT01175018|Placebo Comparator|Placebo|0.67 ml of sodium chloride (NaCl) 0.9% solution
9782410|NCT01175031|Experimental|REMstar Auto with A-Flex|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be measured with REMstar Auto with A-Flex.
9782411|NCT01175031|Other|Manually Scored Polysomnography (PSG)|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be Manually Scored Polysomnography (PSG).
9782412|NCT01175083|Experimental|Tritanrix-HepB/Hib+Polio Sabin <6S Group|Children below (<) 6 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
9782413|NCT01175083|Active Comparator|Tritanrix-HepB/Hib+Polio Sabin <6NS Group|Healthy children, below (<) 6 months of age at time of enrolment, who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
9782414|NCT01175083|Experimental|Synflorix 7-11S Group|Children between 7-11 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
9782415|NCT01175083|Active Comparator|Synflorix 7-11NS Group|Healthy children between 7-11 months of age at time of enrolment, who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
9782416|NCT01175083|Experimental|Synflorix 12-23S Group|Children between 12-23 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
9782417|NCT01175083|Active Comparator|Synflorix 12-23NS Group|Healthy children between 12-23 months of age at time of enrolment, who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
9782418|NCT01175135|Experimental|PF-02545920 5 mg|
9782419|NCT01175135|Experimental|PF-02545920 15 mg|
9782420|NCT01175135|Placebo Comparator|Placebo|
9782421|NCT01175135|Active Comparator|Risperidone 3 mg|
9782422|NCT01175148|Experimental|Recipient - Atorvastatin to prevent GVHD|Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.
9782423|NCT01175148|Other|Donor - Atorvastatin conditioning for donors|Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.
9782424|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety)|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)
9782425|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)
9782426|NCT01175213|Experimental|IV treatment with IGSC, 10% only|Partial efficacy (trough levels of immunoglobulin G [IgG] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603
9782427|NCT01175226|Experimental|BTA798|
9782428|NCT01175226|Placebo Comparator|Placebo|
9782429|NCT01175317|Experimental|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
9782430|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
9782431|NCT01175343|Experimental|Treatment (RO4929097)|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected."
9782432|NCT01175369|No Intervention|Usual Care|Usual asthma care
9782433|NCT01175369|Experimental|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
9782434|NCT01175382|Active Comparator|Behavioral Treatment alone|Behavioral treatment is implemented in 4 clinic visits over a period of 6 weeks, followed by 6 weeks of combined behavioral + drug therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and daily bladder diaries, supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
9782435|NCT01175382|Active Comparator|Drug Therapy (Tolterodine + tamsulosin)|Drug therapy for 6 weeks implemented in a clinic visit with telephone follow-up at 3 weeks, followed by 6 weeks of combined drug + behavioral therapy. Participants in the drug group will receive an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
9829548|NCT02538523|Active Comparator|Erchonia FX-635|The Erchonia FX-635 is made up of 3 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
9829549|NCT02538523|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia FX-635 but does not emit any therapeutic light.
9829550|NCT02538614|Experimental|Phase 1b: Idelalisib + BI 836826|Participants will receive escalating dose of idelalisib at dose levels, 50 mg, 100 mg, and 150 mg + BI 836826 10 mg on Day 8, 50 mg on Day 9 and Day 15, and 100 mg on Day 22, every 2 weeks through Week 18, and every 4 weeks through Week 46. 2 dose combinations (highRP2D and lowRP2D) will be determined for further evaluations in Phase 2.
9829551|NCT02538614|Experimental|Phase 2 Idelalisib + BI 836826|Participants will be randomly assigned to receive 1 of the 2 dose combinations selected from Phase 1b.
9829552|NCT02538679|Placebo Comparator|PLACEBO|No TAP block performed
9829553|NCT02538679|Experimental|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
9829554|NCT02538679|Experimental|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
9829555|NCT02538783|No Intervention|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
9829556|NCT02538783|Experimental|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
9829557|NCT02538900|Experimental|Group 1|Low-intensity, self-paced walking exercise. Home based exercise.
9829558|NCT02538900|Experimental|Group 2|Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.
9829559|NCT02538900|Active Comparator|Group 3|Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.
9829560|NCT02538965|Experimental|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
9829561|NCT02539108|Experimental|Study Group 1|Participants at 6 months to < 36 months age at enrollment
9829562|NCT02539108|Experimental|Study Group 2|Participants at 3 years to < 9 years age at enrollment
9829563|NCT02539134|Experimental|Part 1, Cohort 1: TAK-935 100 mg QD|TAK-935 100 milligram (mg), solution, orally, once daily (QD) or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
9829564|NCT02539134|Experimental|Part 1, Cohort 2: TAK-935 300 mg QD|TAK-935 300 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
9829565|NCT02539134|Experimental|Part 1, Cohort 3: TAK-935 300 mg BID|TAK-935 300 mg, solution, orally, twice daily (BID) or TAK-935 placebo-matching solution, orally, BID for up to 10 days.
9829566|NCT02539134|Experimental|Part 1, Cohort 4: TAK-935 600 mg QD|TAK-935 600 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 10 days.
9829567|NCT02539134|Experimental|Part 1, Cohort 5: TAK-935 400 mg QD|TAK-935 400 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
9829568|NCT02539134|Experimental|Part 2, Cohort 6: TAK-935 Dose 1|TAK-935 first decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
9829569|NCT02539134|Experimental|Part 2, Cohort 7: TAK-935 Dose 2|TAK-935 second decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
9829570|NCT02539342|Experimental|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is >500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
9829571|NCT02539342|Active Comparator|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC >500 after nadir or oral mucositis resolves (whichever occurs later)
9829572|NCT02539368||CT-P13|biosimilar infliximab
9829573|NCT02539368||Remicade|infliximab
9750348|NCT00444106|Active Comparator|Atovaquone-proguanil (Malarone)|Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
9750349|NCT00444106|Active Comparator|Artesunate-mefloquine|Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.
9750350|NCT00444145|Experimental|Patients with documented GERD or laryngopharyngeal reflux|Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
9750351|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (initial phase)|
9750352|NCT00444275|Experimental|Esomeprazole 40 mg Once Daily (initial phase)|
9750353|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (Maintenance Phase)|
9750354|NCT00444275|Experimental|Esomeprazole 20 mg on Demand (Maintenance Phase)|
9750355|NCT00444275|Experimental|Antacid Treatment (Maintenance Phase)|
9750356|NCT00444457|Experimental|1|
9750357|NCT00444457|Experimental|2|
9750358|NCT00444457|Experimental|3|
9750359|NCT00444457|Active Comparator|4|
9750360|NCT00444535|Experimental|Oral lapatinib tablets in combination with IV bevacizumab|1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)
9750361|NCT00444587|Experimental|Trastuzumab + 2nd Line Chemotherapy|
9750362|NCT00444587|Active Comparator|Only Chemotherapy|
9750363|NCT00444600|Experimental|0.5mg Ranibizumab plus laser|
9750364|NCT00444600|Experimental|0.5 mg Ranibizumab plus deferred laser|
9750365|NCT00444600|Experimental|4 mg Triamcinolone plus laser|
9750366|NCT00444600|Active Comparator|Sham plus laser|
9750367|NCT00444626|Experimental|DGE|Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.
9750368|NCT00444626|Active Comparator|Restylane|Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
9750369|NCT00444678|Experimental|Cetuximab, Capecitabine and Oxaliplatin|
9750370|NCT00444795||1|patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
9750371|NCT00444795||2|patients diagnosed as advanced RCC
9750372|NCT00444795||3|patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
9750373|NCT00444821|No Intervention|Surveillance|
9750374|NCT00444821|Experimental|Early Endovascular Repair|
9750375|NCT00444912|Experimental|G-CSF plus plerixafor|Participants with CD20- lymphoma
9750376|NCT00444912|Experimental|G-CSF plus plerixafor and rituximab|Participants with CD20+ lymphoma
9750377|NCT00444925|Experimental|Fesoterodine|Tablets
9750378|NCT00444925|Placebo Comparator|Placebo|Tablets and capsules
9750379|NCT00444925|Active Comparator|Tolterodine|Capsules
9750380|NCT00444951|Experimental|Menactra® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
9750381|NCT00444951|Experimental|Mencevax® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.
9750382|NCT00444951|Experimental|Control group|Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
9750383|NCT00444964|Experimental|Primary Cohort|Nutropin AQ
9750384|NCT00445003|Experimental|Sham injection plus laser|Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
9750385|NCT00445003|Experimental|0.5mg Ranibizumab plus laser|Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
9750386|NCT00445003|Active Comparator|4-mg Triamcinolone Acetonide plus Laser|4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
9750387|NCT00445068|Experimental|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.
9750388|NCT00445146|Experimental|EVG+RTV|"EVG 85 mg or 150 mg + RTV + ARV regimen~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their ARV regimen will receive EVG 85 mg and all other participants will receive EVG 150 mg.~Some participants may receive EVG 300 mg during the course of protocol amendment 2."
9750389|NCT00445211|Active Comparator|Intra-Aortic balloon Pump with Heparin|Intra-Aortic Balloon Pump (IABP) with Heparin
9750390|NCT00445211|Active Comparator|Intra-Aortic balloon Pump without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin
9750391|NCT00445224|Experimental|Hip Progressive Resistive Exercises|Exercises targeting hip musculature such as hip abduction and hip external rotation that was progressed by increased resistance following typical progressive resistive exercise approach.
9829574|NCT02539459|Experimental|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
9829575|NCT02539511|Experimental|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
9829576|NCT02539511|Active Comparator|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
9829577|NCT02539654|Experimental|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
9829578|NCT02539797|Experimental|tDCS anodal stimulation|anodal stimulation
9829579|NCT02539797|Active Comparator|tDCS cathodal stimulation|cathodal stimulation
9829580|NCT02539797|Sham Comparator|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
9829581|NCT02539992|Active Comparator|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
9829582|NCT02539992|Active Comparator|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
9829583|NCT02539992|Active Comparator|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
9829584|NCT02540083|Experimental|Experimental: DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
9829585|NCT02540161|Experimental|non-bevacizumab failures - 18 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
9829586|NCT02540161|Experimental|bevacizumab failures - 18 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
9829587|NCT02540161|Experimental|non-bevacizumab failures - 24 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
9829588|NCT02540161|Experimental|bevacizumab failures - 24 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
9829589|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram [mcg/kg]) every 2 weeks (q2w) up to 9 months
9829590|NCT02540226|Active Comparator|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
9829591|NCT02540226|Experimental|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
9829592|NCT02540265|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
9829593|NCT02540265|Experimental|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
9829594|NCT02540265|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
9829595|NCT02540291|Experimental|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
9829596|NCT02540356|Experimental|Single-Route Arm|BAX69 administered weekly by intraperitoneal (IP) infusion only
9829597|NCT02540356|Experimental|Double-Route Arm|BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion
9835807|NCT02756351|Experimental|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
9835808|NCT02756351|Active Comparator|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
9750392|NCT00445224|Active Comparator|Quad Progressive Resistive Exercises|Exercises targeting quadriceps musculature such as quadriceps isometric setting, terminal knee extensions, and straight leg raises that was progressed by increased resistance following typical progressive resistive exercise approach..
9750393|NCT00445263|Experimental|Early Invasive strategy|Tirofiban and coronarography within 6 hours
9750394|NCT00445263|Active Comparator|Delayed invasive strategy|Coronarography after 6 hours
9750395|NCT00445302|Active Comparator|Normal renal function|Participants with normal renal function (creatinine clearance (CLcr) > 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
9750396|NCT00445302|Experimental|Mild renal impairment|Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
9750397|NCT00445302|Experimental|Moderate renal impairment|Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
9750398|NCT00445302|Experimental|Severe renal impairment|Participants have severe renal impairment (creatinine clearance (CLcr) < 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
9750399|NCT00445315|Experimental|2|
9750400|NCT00445315|Experimental|3|
9750401|NCT00445315|Experimental|1|
9750402|NCT00445315|Experimental|4|
9750403|NCT00445315|Placebo Comparator|5|
9750404|NCT00445328|Active Comparator|B|
9750405|NCT00445328|Experimental|A|
9750406|NCT00445341|Experimental|Flavopiridol in lymphoma patients|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
9750407|NCT00445432|Experimental|DB Adalimumab 40 mg eow|Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
9750408|NCT00445432|Placebo Comparator|Placebo eow|Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
9750409|NCT00445432|Experimental|OL Adalimumab 40 mg eow|Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
9750410|NCT00445458|Experimental|HKI-272 dose level 1|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
9750411|NCT00445458|Experimental|HKI-272 dose level 2|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
9750412|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm A|Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
9750413|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm B|Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
9750414|NCT00445484|Experimental|Group 1|Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
9750415|NCT00445484|Experimental|Group 2|Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
9750416|NCT00445549|Experimental|Vandetanib treatment|300 mg daily oral dose, 28 day cycle
9750417|NCT00445588|Experimental|Treatment|"Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study"
9750418|NCT00445601|Experimental|Arm I|Patients receive intravesical gemcitabine hydrochloride over 1 hour.
9750419|NCT00445601|Placebo Comparator|Arm II|Patients receive intravesical placebo over 1 hour.
9750420|NCT00445679|Experimental|A|DVS SR 50mg/day
9750421|NCT00445679|Experimental|B|DVS SR 100mg/day
9750422|NCT00445679|Experimental|C|DVS SR 200mg/day
9829598|NCT02540447|Experimental|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
9829599|NCT02540447|No Intervention|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
9829600|NCT02540538|Active Comparator|HB vaccine naive - HBVaxPro|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
9829601|NCT02540538|Experimental|HB vaccine naive - HBAI20|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
9829602|NCT02540538|Experimental|Non-responders - HBAI20|"Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180."
9829603|NCT02540629|No Intervention|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
9829604|NCT02540629|Experimental|After intervention|The main study phase was planned to begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable. However, because we could not continue our project in 2017, we changed after period. We included implementation period (2015) in after period. Therefore, final after period begins in January 2015 to December 2016.
9829605|NCT02540668|Experimental|Warfarin|Single oral dose of 15 mg warfarin on Day 1.
9829606|NCT02540668|Experimental|Lanabecestat + Warfarin|Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
9829607|NCT02540772|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
9829608|NCT02540772|No Intervention|No treatment|Patients in the control group only performed the baselines.
9829609|NCT02540850||CRC group|stage 0-IV CRC subjects
9829610|NCT02540850||precancerous disease group|subjects with adenoma or polyps
9829611|NCT02540850||other disease group|subjects with other bowel diseases, other cancers, and subjects with no evidence of disease
9829612|NCT02540954|Experimental|Aflibercept extended dosing|Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).
9829613|NCT02540954|Active Comparator|Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)|Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.
9829614|NCT02540993|Experimental|Finerenone (BAY94-8862)|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy
9829615|NCT02540993|Placebo Comparator|Placebo|Participants received matching placebo once daily in addition to standard of care therapy
9829616|NCT02541409|Active Comparator|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
9829617|NCT02541409|Active Comparator|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
9829618|NCT02541422|Active Comparator|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
9829619|NCT02541422|Placebo Comparator|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
9829620|NCT02541565|Experimental|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9835809|NCT02756364|Active Comparator|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).
9750423|NCT00445679|Active Comparator|D|Paroxetine 20mg/day
9750424|NCT00445692|Experimental|Treatment (clarithromycin, dexamethasone, lenalidomide)|"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.~NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks."
9750425|NCT00445705|Placebo Comparator|Placebo|Part A: Placebo every 12 hours for 4 weeks
9750426|NCT00445705|Experimental|AGN 203818 3 mg|Part A: 3 mg AGN 203818 every 12 hours for 4 weeks
9750427|NCT00445705|Experimental|AGN 203818 20 mg|Part A: 20 mg AGN 203818 every 12 hours for 4 weeks
9750428|NCT00445705|Experimental|AGN 203818 60 mg|Part A: 60 mg AGN 203818 every 12 hours for 4 weeks
9750429|NCT00445744|Experimental|Treatment (cyclophosphamide, busulfan, transplant)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11."
9750430|NCT00445770|Experimental|1|
9750431|NCT00445770|Experimental|2|
9750432|NCT00445770|Active Comparator|3|
9750433|NCT00445848|Experimental|Erlotinib and Bevacizumab|
9750434|NCT00445887|Experimental|Arm I (levonorgestrel)|Patients receive oral levonorgestrel once daily.
9750435|NCT00445887|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily.
9750436|NCT00445939|Experimental|Adalimumab 160 mg/80 mg|
9750437|NCT00445939|Experimental|Adalimumab 80 mg/40 mg|
9750438|NCT00445939|Placebo Comparator|Placebo|
9750439|NCT00445978|Experimental|Sapropterin dihydrochloride|2.5, 5, 10, 20 mg/kg/day of sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks, with an optional extension phase at the highest tolerated dose for up to a total of 2 years.
9750440|NCT00446030|Experimental|Stratum 1: TAC + Bevacizumab|"Human epidermal growth factor receptor-2 (HER2) negative participants stratified at registration, were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
9750441|NCT00446030|Experimental|Stratum 2: TCH + Bevacizumab|"HER2 positive participants stratified at registration, were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
9750442|NCT00446095|Experimental|fostamatinib|
9750443|NCT00446134|Experimental|Group 1: Drug|Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
9750444|NCT00446134|Experimental|Group 2: Drug|Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
9750445|NCT00446134|Experimental|Group 3: Drug|Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
9750446|NCT00446134|Active Comparator|Group 4: Drug|Oral ribavirin 800 mg/day (body weight <65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
9750447|NCT00446147|Placebo Comparator|Placebo|one tablet twice per day, which is identical to pyridoxine
9750448|NCT00446147|Experimental|Pyridoxine|100 mg twice per day
9750449|NCT00446199|Experimental|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
9750450|NCT00446199|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
9750451|NCT00446199|Experimental|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
9750452|NCT00446199|Placebo Comparator|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
9750453|NCT00446264|Experimental|islet transplantation|Each participant received up to three sequential fresh islet infusions within three months.
9750454|NCT00446290|Experimental|Docetaxel, Capecitabine and Oxaliplatin|
9750455|NCT00446446|Experimental|Panitumumab|articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.
9750456|NCT00446511|Experimental|CKD patients: Valsartan+enalapril|
9750457|NCT00446511|Active Comparator|CKD patients: Enalapril|
9750458|NCT00446511|Experimental|Non-CKD patients: Valsartan|
9750459|NCT00446511|Active Comparator|Non-CKD patients: Enalapril|
9750460|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 1|For the first 2 weeks, afegostat tartrate was administered orally at a dose of 225 milligrams (mg) once daily (QD) for 7 consecutive days, followed by no study medication for 7 consecutive days. After 2 weeks, participants then took 225 mg afegostat tartrate QD for 3 consecutive days, followed by no study medication for 4 consecutive days. This 3-days-on/4-days-off treatment regimen was followed for 22 weeks.
9750461|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 2|Afegostat tartrate was administered orally at a dose of 225 mg QD for 7 consecutive days, followed by no study medication for 7 consecutive days. This 7-days-on/7-days-off treatment regimen was followed for 24 weeks.
9750462|NCT00446563|Experimental|Amlodipine + Valsartan|Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
9750463|NCT00446563|Active Comparator|Losartan + Hydrochlorothiazide|Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
9750464|NCT00446641|Experimental|1 Cilostazol|100mg of Cilostazol twice a day
9750465|NCT00446641|Placebo Comparator|Placebo|matching placebo to cilostazol
9750466|NCT00446654|Experimental|CGC-11047 once every 2 weeks|16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
9750467|NCT00446654|Experimental|CGC-11047 once every four weeks|16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
9750468|NCT00446797|Active Comparator|Non-Selective NSAIDS|nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
9750469|NCT00446797|Experimental|Celecoxib|
9750470|NCT00446849|Experimental|MMX Mesalamine|
9750471|NCT00446966|Experimental|fish oil , corn oil|Highly purified pharmaceutical grade omega three polyunsaturated fatty acids
9750472|NCT00446966|Placebo Comparator|placebo|olive oil
9750473|NCT00446992|Experimental|Open Trial Group|The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
9750474|NCT00447005|Experimental|Open|
9750475|NCT00447057|Experimental|Pemetrexed (Nonsquamous)|Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
9750476|NCT00447057|Experimental|Pemetrexed + Erlotinib (Nonsquamous)|Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
9750477|NCT00447057|Experimental|Pemetrexed (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
9750478|NCT00447057|Experimental|Pemetrexed + Erlotinib (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
9750479|NCT00447083|Experimental|UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with UV. The dose of UV (time of exposure) will be progressively increased from 3 minutes to 9 minutes over the 6 visits to acclimate subjects to UV light. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive UVB tanning bed treatment first, then switch to the non-UVB treatment.
9750480|NCT00447083|Placebo Comparator|Non-UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with non-UV bulbs. The time of exposure will be progressively increased from 3 minutes to 9 minutes over the 6 visits to mirror UVB treatment. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive non-UVB tanning bed treatment first, then switch to the UVB treatment.
9750481|NCT00447083|Experimental|UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of UVB.
9750482|NCT00447083|Placebo Comparator|Non-UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of non-UVB exposure
9750483|NCT00447226|Experimental|Lapatinib Oral Tablets|
9750484|NCT00447226|Placebo Comparator|Placebo Control|
9750485|NCT00447265|Experimental|Etanercept|Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
9829621|NCT02541604|Experimental|Atezolizumab|Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams [mg]) on Day 1 of each 21-day cycle.
9829622|NCT02541669|Experimental|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
9829623|NCT02541669|Experimental|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
9829624|NCT02541669|Experimental|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
9829625|NCT02541669|Experimental|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
9829626|NCT02541669|Placebo Comparator|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
9829627|NCT02541812|Experimental|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
9829628|NCT02541812|Active Comparator|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
9829629|NCT02541864|Experimental|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
9829630|NCT02541864|Active Comparator|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
9829631|NCT02541903|Experimental|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
9829632|NCT02541942|Other|Collection of specimen|
9829633|NCT02542046||Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
9829634|NCT02542046||diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
9829635|NCT02542046||iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
9829636|NCT02542072|Active Comparator|comfilcon A|Participants were randomized to wear the comfilcon A lens pair for one month during the cross over study.
9829637|NCT02542072|Active Comparator|samfilcon A|Participants were randomized to wear the samfilcon A lens pair for one month during the cross over study.
9829638|NCT02542150|Experimental|acetate arm|IV acetate given during magnetic resonance scan
9829639|NCT02542150|Experimental|alcohol arm|jello shots given before magnetic resonance scan
9829640|NCT02542280|Experimental|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
9829641|NCT02542280|Active Comparator|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
9829642|NCT02542410|Active Comparator|Control|Norethindrone acetate 5 mg po daily x 6 months
9829643|NCT02542410|Experimental|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
9829644|NCT02542462|Active Comparator|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
9829645|NCT02542462|Active Comparator|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
9829646|NCT02542462|Active Comparator|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
9829647|NCT02542462|Active Comparator|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
9829648|NCT02542605|Other|PACAP-38 Challenge Agent|In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
9829649|NCT02542605|Placebo Comparator|Placebo|Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
9829650|NCT02542605|Experimental|Erenumab|Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
9829651|NCT02542631|Experimental|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
9829652|NCT02542631|Active Comparator|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
9829653|NCT02542761|Experimental|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
9829654|NCT02542761|Experimental|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
9829655|NCT02542865|Experimental|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
9829656|NCT02542865|No Intervention|Control Group|No treatment was administered
9829657|NCT02542943|Experimental|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
9829658|NCT02542943|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
9829659|NCT02542943|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
9829660|NCT02543203|Active Comparator|A/C - Reconnect, Then Coconut Oil Comparator|"Participants randomized to treatment order A/C, received Reconnect for 3-months each day, morning and evening. After a washout period of one-month, they received the Coconut Oil Comparator morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
9829661|NCT02543203|Sham Comparator|C/A - Coconut oil Blend, Then Reconnect|"Participants randomized to treatment order C/A received the Coconut Oil Comparator for 3-months each day, morning and evening. After a washout period of one-month, they received Reconnect morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
9829662|NCT02543294|Experimental|Anthracycline Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
9829663|NCT02543294|Experimental|Herceptin Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
9829664|NCT02543294|Experimental|Combination of Treatments Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
9829665|NCT02543346|Other|cetirizine hydrochloride|
9829666|NCT02543346|Placebo Comparator|placebo|
9829667|NCT02543398|Other|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
9829668|NCT02543398|Other|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
9829669|NCT02543437|Other|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
9829670|NCT02543528|Experimental|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
9829671|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
9829672|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
9829673|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
9829674|NCT02543554||Pre-intervention group|mechanically ventilated patients before implementation of ED lung protective ventilation
9829675|NCT02543554||Intervention group|mechanically ventilated patients after implementation of ED lung protective ventilation
9829676|NCT02543658|Experimental|Neostigmine|Intramuscular injection of neostigmine on the basis of conventional conservative treatment
9750486|NCT00447265|Placebo Comparator|Placebo|Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
9750487|NCT00447278|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
9750488|NCT00447278|Active Comparator|OEST|Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
9782436|NCT01175382|Experimental|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
9782437|NCT01175395|Experimental|IBI-20089/Lucentis|Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
9782438|NCT01175434|Experimental|School-Based Medication Group|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse will begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
9782439|NCT01175434|No Intervention|Usual Care Group|Children in the Usual Care group will not receive preventive medications delivered at school. These children will continue to receive all of their asthma care from their parents and primary care physicians.
9782440|NCT01175473|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD for up to Week 4.
9782441|NCT01175473|Active Comparator|Liraglutide|2-step initiation regimen of liraglutide: 0.6 milligram (mg) QD subcutaneously for 1 week, followed by 1.2 mg QD for 1 week, then 1.8 mg QD up to Week 4.
9782442|NCT01175590|Experimental|Besivance|besifloxacin ophthalmic suspension 0.6%
9782443|NCT01175590|Placebo Comparator|Vehicle|Vehicle of Besivance
9782444|NCT01175668|Experimental|NMS/Clonidine|
9782445|NCT01175668|Active Comparator|NMS/Phenobarbital|
9782446|NCT01175707|Experimental|Daptomycin|500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted
9782447|NCT01175707|Active Comparator|Vancomycin|Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician
9782448|NCT01175798|No Intervention|No treatment (standard of care)|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
9782449|NCT01175798|Experimental|Vitamin D repletion|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
9829677|NCT02543658|Other|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
9750489|NCT00447330|Experimental|1|
9750490|NCT00447382|Active Comparator|NN304|Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
9750491|NCT00447382|Experimental|NN729|Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
9750492|NCT00447499|Experimental|Somatuline Autogel (lanreotide acetate)|Somatuline Autogel (lanreotide acetate) Injection
9750493|NCT00447590|Experimental|LAP-BAND|All subjects who received the LAP-BAND System.
9750494|NCT00447694|Experimental|deferasirox every day for 77 weeks|Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed.
9750495|NCT00447772|Experimental|1|
9750496|NCT00447876|Experimental|Botulinum type A toxin (Dysport®)|
9750497|NCT00447876|Placebo Comparator|Placebo|
9750498|NCT00448019|Experimental|FCR + Bevacizumab|FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.
9750499|NCT00448123|Placebo Comparator|Placebo|Placebo
9750500|NCT00448123|Active Comparator|Tamsulosin|Intervention - Tamsulosin
9750501|NCT00448136|Experimental|1|
9750502|NCT00448136|Experimental|2|
9750503|NCT00448175|Experimental|Urgent PC treatment arm|
9750504|NCT00448201|Active Comparator|Methotrexate Only Arm|GVHD Prophylaxis with Methotrexate
9750505|NCT00448201|Active Comparator|2 Doses ATG + Methotrexate|GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate
9750506|NCT00448201|Active Comparator|2 Doses ATG|GVHD prophylaxis with 2 doses ATG
9750507|NCT00448201|Active Comparator|3 Doses ATG|GVHD prophylaxis with 3 doses ATG
9750508|NCT00448227|Experimental|Famciclovir|Famciclovir was administered orally as a suspension in OraSweet® on Day 1. Patients received a single, individualized dose between 25-200 mg based on body weight.
9750509|NCT00448279|Active Comparator|Chemotherapy Alone|Chemotherapy, schedule and dose at the investigator's discretion.
9750510|NCT00448279|Experimental|Chemotherapy, Trastuzumab|Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
9750511|NCT00448344|Experimental|Arm 1|Family-supported smoking cessation
9750512|NCT00448344|Other|Arm 2|Standard smoking cessation
9750513|NCT00448357|Experimental|GVHD prophylaxis|"Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine .~Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus."
9750514|NCT00448435|Active Comparator|SLM+FP First|SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).
9750515|NCT00448435|Active Comparator|SFC First|SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).
9750516|NCT00448435|Experimental|SFC|SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).
9829678|NCT02543723|Active Comparator|Nurse Coach Intervention|The nurse coach conducted an initial assessment with the participant and identified specific adherence strategies tailored to the participant's needs. The educational strategies include information about the patient's cancer treatment and expected outcomes; clear instructions about medication dosing schedule; what to do if a dose is missed or delayed; medication side effects and/or potential drug interactions; and review of cancer health literacy infographics. The behavioral skills and affective support strategies include coping strategies for side effects, skills for fitting medication regimen into daily routine, identifying a support network, communication skills for interacting with providers, and facilitating a positive perception for effective self-management experience. Patients received weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period.
9829679|NCT02543723|No Intervention|Control|Patients received standard of care.
9829680|NCT02543801|Active Comparator|Hip Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
9829681|NCT02543801|Active Comparator|Hip Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
9829682|NCT02543801|Active Comparator|Knee Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
9829683|NCT02543801|Active Comparator|Knee Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
9829684|NCT02543840|Experimental|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
9829685|NCT02543840|Placebo Comparator|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
9829686|NCT02543892|Experimental|Adult 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
9829687|NCT02543892|Placebo Comparator|Adult Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
9829688|NCT02543892|Experimental|Adult 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
9829689|NCT02543892|Placebo Comparator|Adult Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
9829690|NCT02543892|Experimental|Toddler 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
9829691|NCT02543892|Placebo Comparator|Toddler Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
9829692|NCT02543892|Experimental|Toddler 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
9829693|NCT02543892|Placebo Comparator|Toddler Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
9829694|NCT02543918|Experimental|Ixekizumab + Boostrix® + Pneumovax®23|"Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2."
9829695|NCT02543918|Other|Boostrix® + Pneumovax®23|Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
9829696|NCT02544074||eSAGE score of 10|Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
9829697|NCT02544074||eSAGE score of 11|Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
9829698|NCT02544074||eSAGE score of 12|Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
9829699|NCT02544074||eSAGE score of 13|Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
9829700|NCT02544074||eSAGE score of 14|Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
9829701|NCT02544074||eSAGE score of 15|Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
9829702|NCT02544074||eSAGE score of 16|Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
9829703|NCT02544074||eSAGE score of 17|Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
9829704|NCT02544074||eSAGE score of 18|Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
9829705|NCT02544074||eSAGE score of 19|Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
9829706|NCT02544074||eSAGE score of 20|Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
9829707|NCT02544074||eSAGE score of 21|Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
9829708|NCT02544074||eSAGE score of 22|Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
9829709|NCT02544074||eSAGE score of 9|Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
9829710|NCT02544074||eSAGE score of 8|Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
10201804|NCT05195021|Experimental|Group 3 (conventional irrigation and laser irradiation)|In group 3, final irrigation followed the same procedures as in group 1 and group 2. During the laser therapy, both the operator and the patient wore eyewear for protection. Laser irradiation was performed using a 980-nm diode laser (Medency Primo 10 W Diode Laser; Vicenza, Italy), coupled with optical fibre (200 µm). The settings were as follows: average power of 1.2 W with a low frequency of 50 Hz and energy of 12 J (each cycle) in pulsed mode, irradiation for 10 seconds, followed by a 10 second pause, which constituted one cycle. This cycle was applied four times to each root canal. The optical fibre tip was located at the WL. The root canals were then slowly (at a speed of 2 mm/s) irradiated from the apical to the coronal portion using a continuous helicoidal movement, with optical fibre tip contacting the root canal walls in one cycle for each power.
10201805|NCT05195021|Experimental|Group 4 (EDDY and laser irradiation)|In this group, after agitation using the EDDY (VDW) system was performed using the same procedures as in group 3, final irrigation and laser irradiation were done as in group 2.
10201806|NCT05194982|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
9750517|NCT00448448|Active Comparator|Brace|This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
9750518|NCT00448448|Active Comparator|Observation|Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.
9750519|NCT00448539|Experimental|Rufinamide (Rufinamide During Core Study)|
9750520|NCT00448539|Experimental|Rufinamide (Placebo During Core Study)|
9750521|NCT00448591|Experimental|1|
9750522|NCT00448630||Atypical Antispychotics (or second generation antipsychotics)|Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.
9750523|NCT00448669|Active Comparator|TDF-FTC,condoms,adh/risk counseling|Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
9750524|NCT00448669|Placebo Comparator|Placebo,condoms,adh/risk counseling|Eligible participants were randomized to the placebo arm and received placebo oral tablets that were visually identical to the TDF-FTC tablet and taken once daily. The placebo tablets contained no active ingredients. The ratio of randomization was 1:1. Participants randomized to the placebo arm received male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
9750525|NCT00448708|Experimental|Vascular Wrap and Graft|Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.
9750526|NCT00448708|No Intervention|Lifespan® ePTFE Vascular Graft|Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.
9750527|NCT00448747|Experimental|AEZS-130 ( formerly ARD-07)|A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test
9750528|NCT00448747|Active Comparator|L-ARG+GHRH|This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimulation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27-March-2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130
9750529|NCT00448760|Experimental|Neoadjuvant + Adjuvant Chemotherapy|
9750530|NCT00448812|Experimental|Alair Treatment|Subjects from PREDECESSOR STUDY (NCT00214526) treated with conventional therapy with ICS+LABA (inhaled corticosteroid + long-acting beta-agonist) plus Bronchial Thermoplasty with the Alair System.
9750531|NCT00448812|No Intervention|Control|Control group subjects from PREDECESSOR STUDY (NCT00214526).
9750532|NCT00448864|Experimental|Ecallantide - Low Dose Regimen|Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
9750533|NCT00448864|Experimental|Ecallantide - High Dose Regimen|Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 milliliters per hour (mL/hr) for 4 hours.
9782450|NCT01175811|Experimental|Premixed Insulin|Twice daily (before breakfast and lunch) insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension [LM50]) and once daily (before dinner) insulin lispro mix 25 (25% insulin lispro, 75% insulin lispro protamine suspension [LM25])
9750534|NCT00448864|Placebo Comparator|Placebo|Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
9750535|NCT00448916|Experimental|Pregabalin|Orally-administered pregabalin
9750536|NCT00449007|Active Comparator|1|fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
9750537|NCT00449007|Active Comparator|2|bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
9750538|NCT00449033|Experimental|Sorafenib (Nexavar, BAY43-9006) + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
9750539|NCT00449033|Placebo Comparator|Placebo + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
9750540|NCT00449072|Placebo Comparator|Placebo|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle~Placebo in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
9750541|NCT00449072|Active Comparator|TAA-AQ|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle~Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
9750542|NCT00449150|Experimental|Treatment Group A: CET 78 mg + 78 mg|"Treatment course 1: Cetrorelix 78 mg + 78 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: 26 mg CET(1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
9750543|NCT00449150|Experimental|Treatment Group B: CET 78 mg + 52 mg|"Treatment course 1: Cetrorelix 78 mg + 52 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: Placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
9750544|NCT00449150|Placebo Comparator|Treatment Group C: Placebo|"Treatment course 1:~Week 0: placebo (2 injections)~Week 2: placebo (1 injection)~Treatment course 2:~Week 26: placebo (2 injections)~Week 28: placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
9750545|NCT00449163|Experimental|Combination Chemotherapy and Bevacizumab|"Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:~Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;~Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;~Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;~Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29."
9750546|NCT00449176|Experimental|001|tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
9750547|NCT00449176|Active Comparator|002|oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
9750548|NCT00449176|Placebo Comparator|003|placebo matching placebo twice daily for 15 weeks
9750549|NCT00449540|Active Comparator|Active Transcranial Magnetic Stimulation (TMS) Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
9750550|NCT00449540|Sham Comparator|Sham TMS Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
9750551|NCT00449644|Experimental|TMC207 Stage 1|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
9750552|NCT00449644|Placebo Comparator|Placebo Stage 1|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
9750553|NCT00449644|Experimental|TMC207 Stage 2|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
9750554|NCT00449644|Placebo Comparator|Placebo Stage 2|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.
9782451|NCT01175811|Active Comparator|Basal-Bolus|Once daily (bedtime) insulin glargine and three pre-meal insulin lispro
9782452|NCT01175824|Experimental|Insulin lispro low mixture (LM)|Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
9750555|NCT00449670|Experimental|H5N1 Adjuvanted Group|Subjects received 2 doses of H5N1 adjuvanted split virus vaccine (lot 1, 2, 3 or 4) containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 during Primary Phase. A subset of these subjects (Boosted sub-cohort) received a single dose of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 during Booster Phase. The remaining subjects (Non-Boosted sub-cohort) received a single booster dose at Month 12 or 36 after initial priming in study 111443 (NCT00652743).
9750556|NCT00449670|Active Comparator|H5N1 Un-adjuvanted Group|Subjects received 2 doses of a H5N1 non-adjuvanted split virus vaccine containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 and two booster doses of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 and Month 6 + 21 days.
9750557|NCT00449696|Experimental|Gel-200|
9750558|NCT00449696|Placebo Comparator|PBS|
9750559|NCT00449748|Experimental|RAD001|Oral 10 mg daily for 30 days
9750560|NCT00449761|Experimental|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat was administered at the same time each morning, and with an 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue this treatment until an unacceptable toxicity that precludes further treatment was experienced, or until disease progression.
9750561|NCT00449787|Active Comparator|Sumatriptan|Sumatriptan 100 mg tablet
9750562|NCT00449787|Active Comparator|Naproxen|Naproxen 500 mg tablet
9750563|NCT00449865|Placebo Comparator|Placebo|
9750564|NCT00449865|Active Comparator|creatine|
9750565|NCT00449930|Experimental|1|Drug
9750566|NCT00449930|Active Comparator|2|Active comparator
9750567|NCT00449956|Experimental|1|combination of dorzolamide hydrochloride and timolol maleate
9750568|NCT00449956|Active Comparator|2|Concomitant use of dorzolamide hydrochloride and timolol maleate
9750569|NCT00449956|Active Comparator|3|timolol maleate
9750570|NCT00450073|Active Comparator|Vitamin D3|Vitamin D3=cholecalciferol 50,000 IU weekly
9750571|NCT00450073|Active Comparator|vitamin D2|The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks.
9750572|NCT00450073|Active Comparator|Sunlamp|The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks
9750573|NCT00450177|Experimental|Iron Group|Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
9750574|NCT00450177|Placebo Comparator|Placebo Group|Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
9750575|NCT00450190|Experimental|Saizen® E-Device|
9750576|NCT00450216|Experimental|1|HZT-501: Ibuprofen 800mg/famotidine 26.6mg
9750577|NCT00450216|Active Comparator|2|Ibuprofen 800mg
9750578|NCT00450242|Experimental|5% Lidocaine cream|5% topical lidocaine cream.
9750579|NCT00450242|Placebo Comparator|Placebo cream|
9750580|NCT00450255|Experimental|Arm I|Patients receive Aflibercept IV at 4 mg/kg over 1 hour on day 1. Treatment repeats every 14 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
9750581|NCT00450372|Experimental|ADI-PEG 20|
9750582|NCT00450385|Experimental|R-CHOP|"Patients will receive R-CHOP for 6 to 8 cycles:~Rituximab 375 mg/m2 on day 1~Cyclophosphamide 750 mg/m2 IV on day 1~Doxorubicin 50 mg/m2 on day 1~Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1~Prednisone 100 mg orally days 1-5, repeated every 21 days."
9750583|NCT00450411|Experimental|Brachytherapy|Prostate brachytherapy delivered using either 125-iodine (I-125) or 103-palladium (Pd-103)
9750584|NCT00450424|No Intervention|Counseling|Participants will be given one of two counseling interventions regarding MSI testing: standard counseling or a CD-ROM intervention.
9750585|NCT00450437|Active Comparator|Licensed Meningococcal Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
9750586|NCT00450437|Experimental|Novartis MenACWY Conjugate Vaccine|Novartis meningococcal ACWY conjugate Vaccine
9750589|NCT00450463|Active Comparator|Flutamide Alone|Patients receive flutamide orally 3 times a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising prostatic specific antigen (PSA) levels) without metastatic disease (as evidenced on scans), may receive vaccine treatment as defined in arm II beginning 4 weeks after flutamide therapy is discontinued.
9750590|NCT00450463|Experimental|Flutamide + Vaccine + Sargramostim|Patients receive flutamide orally 3 times a day on days 1-28. Patients also receive recombinant vaccinia PSA vaccine subcutaneously (SC) on day 1 of course 1 only and recombinant fowlpox PSA vaccine SC on day 1 of all subsequent courses. Patients receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising PSA levels), discontinue flutamide but may continue to receive vaccine treatment.
9750591|NCT00450580|Experimental|Arm A|Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
9750592|NCT00450580|Active Comparator|Arm B|Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
9750593|NCT00450619|Experimental|Arm A -EDTMP Alone|Patients receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg intravenous (IV) over 1 minute on day 8. Treatment repeats every 12 weeks in the absence of disease progression or unacceptable toxicity.
9750594|NCT00450619|Experimental|Arm B - 153SmEDTMP with vaccine|Patients receive recombinant vaccinia-TRICOM vaccine 2 x 10^8 PFU subcutaneously (SC) on day 1. Patients also receive recombinant fowlpox-TRICOM vaccine 1 x 10^9 PFU SC on days 15 and 29 and sargramostim (GM-CSF)100 mcg/injection SC x 4 days. Treatment with recombinant fowlpox-TRICOM vaccine and GM-CSF* repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg as in arm I.
9750595|NCT00450658|Experimental|1|HZT-501: Ibuprofen 800mg/Famotidine 26.6mg
9750596|NCT00450658|Active Comparator|2|Ibuprofen 800mg
9750597|NCT00450723|Experimental|Sentinel Lymph Node Biopsy|
9750598|NCT00450749|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.
9750599|NCT00450749|Experimental|Arm II (low-dose lycopene)|Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
9750600|NCT00450749|Experimental|Arm III (high-dose lycopene)|Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
9750601|NCT00450801|Experimental|R-MACLO-IVAM-T|Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.
9750602|NCT00450814|Experimental|Stage 1 (MV-NIS alone)|Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)
9750603|NCT00450814|Experimental|Stage 2 (MV-NIS and cyclophosphamide)|Patients receive cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)
9750604|NCT00450866|Experimental|Epothilone B|
9750605|NCT00451035|Experimental|Panobinostat (LBH589)|Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.
9750606|NCT00451048|Experimental|Arm I|Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
9750607|NCT00451178|Experimental|R-CHOP and Enzastaurin|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
9750608|NCT00451178|Active Comparator|R-CHOP|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
9750609|NCT00451191|Active Comparator|1|100 units botulinum toxin type A (BoNT/A)
9750610|NCT00451191|Active Comparator|2|300 units botulinum toxin type A (BoNT/A)
9750611|NCT00451204|Active Comparator|Estriol plus Copaxone injections QD|Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
9750612|NCT00451204|Placebo Comparator|Placebo plus Copaxone injections QD|Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.
9750613|NCT00451217|Experimental|Rocuronium + Sugammadex|After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
9750614|NCT00451217|Active Comparator|Rocuronium + Neostigmine|After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
9750615|NCT00451217|Experimental|Vecuronium + Sugammadex|After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
9750616|NCT00451217|Active Comparator|Vecuronium + Neostigmine|After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
9750617|NCT00451282|Experimental|Stepped Preventive Care|Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
9750618|NCT00451282|No Intervention|Treatment as usual|Medical and psychosocial care per usual hospital protocols, which may include social work support.
9750619|NCT00451321|Experimental|otelixizumab|
9750620|NCT00451451|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
9750621|NCT00451451|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
9750622|NCT00451451|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
9750623|NCT00451451|Active Comparator|Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)|Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
9750624|NCT00451555|Experimental|Enzastaurin + Fulvestrant|"Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.~Participants received enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 250 mg orally (BID) twice daily in a 28-day cycle.~Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter."
9750625|NCT00451555|Placebo Comparator|Fulvestrant + Placebo|Participants received fulvestrant: 500 mg, IM, day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression. Then, participants received placebo, oral, daily.
9750626|NCT00451698|Placebo Comparator|3|acyanotic placebo
9750627|NCT00451698|Experimental|4|acyanotic erythropoietin
9750628|NCT00451906|Experimental|Bevacizumab + Chemotherapy|Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.
9750629|NCT00451958|Experimental|Degarelix 80 mg / Degarelix 80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
9750630|NCT00451958|Experimental|Degarelix 160 mg / Degarelix 160 mg|"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
9750631|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 80 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
9750632|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 160 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
9750633|NCT00452114|Active Comparator|Assignment to In-Exsufflator Cough Assist Device|In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
9750634|NCT00452114|Active Comparator|Assignment to flutter valve device|flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily
9750635|NCT00452335|Experimental|Lubiprostone 12 mcg QD|Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (<6 years of age and able to swallow capsules) who are at least 12 kg body weight
9750636|NCT00452335|Experimental|Lubiprostone 12 mcg BID|Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight
9750637|NCT00452335|Experimental|Lubiprostone 24 mcg BID|Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight
9750638|NCT00452348|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
9750639|NCT00452348|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
9750640|NCT00452374|Experimental|Oxaliplatin, Fludarabine, Cytarabine + Rituximab|Starting dose oxaliplatin 17.5mg/m^2/day intravenous (IV) for 4 days; Fludarabine 30 mg/m^2 IV and Cytarabine 1 g/m^2 IV for two days, + Rituximab 375 mg/m^2 IV on Day 3, Cycle 1 then Day 1 following cycles.
9750641|NCT00452413|Experimental|Enzastaurin and erlotinib combination therapy|"Enzastaurin:~Phase 1, Dose Level 1: 500 milligram (mg) oral loading dose Day 1, 250 mg oral, daily Day 2-28, 28-day cycle until disease progression~Phase 1, Dose Level 2: 1125 mg oral loading dose Day 1, 500 mg oral, daily until disease progression~Phase 2: Dose determined from Phase 1, oral, daily, 28-day cycles until disease progression~Erlotinib:~• 150 mg, oral, daily, 28-day cycles until disease progression"
9750642|NCT00452426|Experimental|Sedation System|Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
9750643|NCT00452426|Active Comparator|Current Standard of Care|Site's current standard used for delivery of sedation
9750644|NCT00452439|Active Comparator|Actonel|Actonel (Risedronate) + Vitamin D + Calcium
9750645|NCT00452439|Placebo Comparator|Placebo|Placebo + Vitamin D + Calcium
9750646|NCT00452452|Experimental|A|
10201807|NCT05194943||1. UOC Chirurgia Bariatrica, Policlinico San Marco, Zingonia, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
10201808|NCT05194943||2. UOC di Chirurgia Bariatrica e Metabolica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
9750647|NCT00452530|Experimental|Apixaban, 2.5 mg BID + Placebo|Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
9750648|NCT00452530|Active Comparator|Enoxaparin, 40 mg QD + Placebo|Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
9750649|NCT00452543|Experimental|Escitalopram plus acamprosate|
9750650|NCT00452543|Placebo Comparator|Escitalopram plus placebo|
9750651|NCT00452673|Experimental|50 mg BID dasatinib + 825 mg/m^2 BID capecitabine|Twice a day (BID) for 2 weeks of a 3-week cycle
9750652|NCT00452673|Experimental|70 mg BID dasatinib + 825 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
9750653|NCT00452673|Experimental|70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
9750654|NCT00452673|Experimental|100 mg QD dasatinib + 1000 mg/m^2 BID capecitabine|2 weeks of a 3-week cycle
9829711|NCT02544074||eSAGE score of 6|Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
9829712|NCT02544074||eSAGE score of 7|Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
9829713|NCT02544074||eSAGE score of 5|Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
9829714|NCT02544074||eSAGE score of 4|Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
9829715|NCT02544074||eSAGE score of 3|Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
9829716|NCT02544074||eSAGE score of 2|Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
9829717|NCT02544113|Experimental|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 [after transplant], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
9829718|NCT02544113|Placebo Comparator|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
9829719|NCT02544152|Experimental|Lubiprostone|Participants receive 8 mcg lubiprostone capsules twice daily (BID)
9829720|NCT02544152|Placebo Comparator|Placebo|Participants receive 0 mcg capsules BID
9829721|NCT02544217|Experimental|Single Escalating|2 alternating groups receiving escalating single doses of active/placebo
9829722|NCT02544217|Experimental|Multiple Escalating|3 multiple escalating groups, receiving active/placebo
9829723|NCT02544321|Active Comparator|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
9829724|NCT02544321|Placebo Comparator|Placebo|4 weeks of placebo
9829725|NCT02544451|Experimental|Treatment Period 1: LUM/IVA to LUM/IVA|
9829726|NCT02544451|Experimental|Treatment Period 1: Placebo (PBO) to LUM/IVA|
9829727|NCT02544451|No Intervention|Treatment Period 1: Observational Cohort|
9829728|NCT02544451|Experimental|Treatment Period 2: LUM/IVA|
9829729|NCT02544607|Experimental|Ketamine + MRI|All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
9829730|NCT02544633|Experimental|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
9829731|NCT02544633|Experimental|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
9829732|NCT02544633|Experimental|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
9829733|NCT02544633|Experimental|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
9829734|NCT02544763|Experimental|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
9829735|NCT02544763|Experimental|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
9829736|NCT02544763|Placebo Comparator|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
9829737|NCT02544984|Placebo Comparator|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
9829738|NCT02544984|Experimental|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
9829739|NCT02545075|Experimental|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
9750655|NCT00452699|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
9750656|NCT00452699|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
9750657|NCT00452790|Experimental|A|
9750658|NCT00452790|Active Comparator|B|
9750659|NCT00452868|Experimental|Donepozil|Donepezil 5 milligrams a day for 6 weeks
9750660|NCT00453102|Experimental|Zevalin + Rituximab|Ibritumomab Tiuxetan (Zevalin) + Rituximab
9829740|NCT02545075|Experimental|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
9829741|NCT02545270|Experimental|Group 1: 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation after surgery is completed.
9829742|NCT02545270|Experimental|Group 2: 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation after surgery is completed.
9829743|NCT02545270|Experimental|Group 3: 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation after surgery is completed.
9829744|NCT02545322|Experimental|Adaptive Radiotherapy|"Follow-up CT scans during week 3 and week 5 of Treatment~Image-guided adaptive Radiotherapy arm:~Follow-up CT scans are performed on a conventional CT-simulator. Deformable Image Registration between the planning-CT and the follow-up CT (fCT) is done using a dedicated Software package. Delineations for target volumes and organs at risk are transferred to the fCT based on the Deformation vector fields calculated during deformable Image registration. Volumetric changes in target volumes and organs-at-risk are assessed. The initial treatment plan is transferred to the fCT scan. Dosimetric consequences of morphologic changes are analysed with the Focus on target dose coverage for the planning target volume. Adaption and plan re-optimisation are performed."
9829745|NCT02545504|Experimental|Andecaliximab|Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
9750661|NCT00453154|Experimental|Arm I (Combination Chemotherapy + Sunitinib Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m^2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start sunitinib at 150 mg on day 1, then 37.5 daily until disease progression."
9750662|NCT00453154|Active Comparator|Arm II (Combination Chemotherapy + Placebo Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start placebo at 150 mg on day 1, then 37.5 daily until disease progression."
9750663|NCT00453180|Experimental|1|Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.
9750664|NCT00453180|Placebo Comparator|2|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
9750665|NCT00453193|Experimental|Alemtuzumab + Pentostatin|Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
9750666|NCT00453310|Experimental|sunitinib malate|The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
9750667|NCT00453336|Experimental|Single Arm|
9750668|NCT00453349|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
9750669|NCT00453349|Active Comparator|Levofloxacin plus Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
9750670|NCT00453362|Experimental|Erlotinib|"Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.~After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans."
9750671|NCT00453388|Experimental|Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
9750672|NCT00453388|Experimental|Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
9750673|NCT00453388|Experimental|Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
9750674|NCT00453388|Experimental|Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
9750675|NCT00453895|Experimental|Sunitinib|"Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.~treatment will continue until progressive disease or unacceptable toxicity"
9750676|NCT00453921|Placebo Comparator|1|Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
9750677|NCT00453921|Active Comparator|2|Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
9750678|NCT00453921|Active Comparator|3|Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
9750679|NCT00453921|Active Comparator|4|Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
9750680|NCT00453973|Experimental|Maintenance Switch in Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study."
9750681|NCT00453973|Experimental|Treatment Initiation in Non-Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study."
9750682|NCT00453986|Experimental|Nimenrix A Group|subjects received 1 dose of Nimenrix™ Lot A at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
10201809|NCT05194943||3. UOSD Week Surgery, Chirurgia Bariatrica, Azienda Ospedale-Università di Padova, Padova, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
9750683|NCT00453986|Experimental|Nimenrix B Group|subjects received 1 dose of Nimenrix™ Lot B at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
9750684|NCT00453986|Experimental|Nimenrix C Group|subjects received 1 dose of Nimenrix™ Lot C at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
9750685|NCT00453986|Active Comparator|Mencevax ACWY Group|subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0. Mencevax™ ACWY vaccine was administered by subcutaneous injection in the non-dominant upper arm.
9750686|NCT00453986|Experimental|Nimenrix+Fluarix Group|subjects received 1 dose of Nimenrix™ Lot A co-administered with Fluarix™ vaccines at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm. Fluarix™ vaccine was administered by intramuscular injection in the deltoid region of the dominant arm.
9750687|NCT00453999|Experimental|Arm 1: Peramivir 200 mg|Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
9750688|NCT00453999|Experimental|Arm 2: Peramivir 400 mg|Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
9750689|NCT00453999|Experimental|Arm 3: Oseltamivir|Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
9750690|NCT00454051|Active Comparator|Omalizumab|Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
9750691|NCT00454051|Placebo Comparator|Placebo|Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.
9750692|NCT00454116|Placebo Comparator|1|FOLFIRI + placebo vandetanib
9750693|NCT00454116|Experimental|2|FOLFIRI + low dose vandetanib
9750694|NCT00454116|Experimental|3|FOLFIRI + high dose vandetanib
9750695|NCT00454142|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28."
9750696|NCT00454181|Experimental|IFN lozenges|500 IU Interferon-alpha lozenges for oral dissolution
9750697|NCT00454181|Placebo Comparator|placebo lozenges|200 mg lozenges containing anhydrous crystalline maltose
9750698|NCT00454194|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9750699|NCT00454194|Active Comparator|Arm II|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9750700|NCT00454207|Experimental|sildenafil citrate (UK-92,480)|sildenafil citrate 20 mg TID
9750701|NCT00454246|Experimental|methoxy polyethylene glycol-epoetin beta|"120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
9750702|NCT00454246|Active Comparator|Epoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
9750703|NCT00454246|Active Comparator|Darbepoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
9750704|NCT00454324|Experimental|Arm A|Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
9750705|NCT00454324|Experimental|Arm B|Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles
9750706|NCT00454363|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
9750707|NCT00454584|Experimental|CNTO 1275 45 mg|Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
9750708|NCT00454584|Experimental|CNTO 1275 90 mg|Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
9750709|NCT00454584|Active Comparator|Etanercept 50 mg|Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
9750710|NCT00454636|Experimental|Cisplatin / Capecitabine|Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
9750711|NCT00454636|Experimental|Epirubicin / Cisplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
9750712|NCT00454636|Experimental|Epirubicin / Oxaliplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
9829746|NCT02545504|Placebo Comparator|Placebo|Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
9829747|NCT02545543|Experimental|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
9829748|NCT02545543|Active Comparator|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
9829749|NCT02545608|Experimental|Restylane Vital in both hands|Open group used to develop a proper use of injection technique for Restylane Vital
9829750|NCT02545608|Other|Restylane Vital and No treatment|Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand
9829751|NCT02545907|Experimental|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:~Level -1 - 27mg/m2~Level 0 - 36mg/m2~Level 1 - 45mg/m2~Level 2 - 56mg/m2~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
9829752|NCT02545933|Experimental|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
9829753|NCT02545933|Experimental|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
9829754|NCT02545933|Active Comparator|DAPT|Aspirin in addition to prasugrel or ticagrelor
9829755|NCT02546193|Experimental|Outpatient Foley catheter (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the outpatient Foley catheter group (RCT design) or (B) chose the outpatient Foley catheter group (Modified Prospective study design).~Participants underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exams the evening before their scheduled induction in the Family Birth Center. A Foley catheter was placed for cervical ripening. After fetal monitoring, they were dismissed to home, to return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting."
9829756|NCT02546193|Active Comparator|Inpatient usual care (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the inpatient usual care group (RCT design) or (B) chose the inpatient usual care group (Modified Prospective study design). No participants in the modified Prospective study design were accrued due to screen failure.~Participants presented to the Family Birth Center in the evening for their scheduled induction of labor. They underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening commenced with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They remained in the inpatient setting throughout their entire labor induction course."
9829757|NCT02546323|Experimental|Rosuvastatin|20 mg tablets, Daily oral dose
9829758|NCT02546323|Placebo Comparator|Placebo|Matching placebo tablets
9829759|NCT02546362|Experimental|Cefaly active device|12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)
9829760|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
9666000|NCT04770532|Active Comparator|Insulin degludec|Insulin degludec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
9829761|NCT02546388|Experimental|Indium-111 Pentreotide (OctreoScan)|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
9829762|NCT02546388|Experimental|Gallium-68 DOTATATE|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.
9829763|NCT02546544|Other|Linsitinib|Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
9829764|NCT02546570|Experimental|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
9829765|NCT02546570|Experimental|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
9829766|NCT02546570|Experimental|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
9829767|NCT02546609|Experimental|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
9829768|NCT02546609|Experimental|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
9829769|NCT02546609|Placebo Comparator|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
9829770|NCT02546765|Experimental|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
9829771|NCT02546765|Experimental|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
9829772|NCT02546765|Active Comparator|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
9666001|NCT04770220|Experimental|ALZ-801|ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one table of ALZ-801 265mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265mg tablet BID.
9666002|NCT04770220|Placebo Comparator|Placebo|Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study
9829773|NCT02546765|Active Comparator|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
10201810|NCT05194943||4. Unita di Chirurgia dell'Obesità e Metabolica, Azienda Ospedaliero-Universitaria, Bologna, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
10201811|NCT05194943||5. UO Chirurgia Generale, Policlinico San Marco di Zingonia, Zingonia, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
10201812|NCT05194943||6. UOC Chirurgia Bariatrica e Metabolica, Ospedale San Carlo di Nancy , Roma, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
10201813|NCT05194943||7. Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria, Torino, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
10201814|NCT05194943||8. UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
9750713|NCT00454636|Experimental|Docetaxel / Cisplatin / Capecitabine|Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
9750714|NCT00454649|Experimental|Axitinib [AG-013736] + chemotherapy combination|"The following separate groups were included:~axitinib~plus carboplatin/paclitaxel in three different schedules~plus paclitaxel~plus docetaxel/carboplatin~plus docetaxel~plus capecitabine~plus gemcitabine/cisplatin~plus pemetrexed/cisplatin"
9750715|NCT00454779|Experimental|Arm 1|Panitumumab + Docetaxel + Cisplatin
9750716|NCT00454779|Other|Arm 2|control
9750717|NCT00454805|Active Comparator|2|Fulvestrant Monotherapy
9750718|NCT00454805|Experimental|3|AZD2171 + Fulvestrant
9750719|NCT00454818|Experimental|MYDICAR Very Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.
9750720|NCT00454818|Experimental|MYDICAR Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
9750721|NCT00454818|Experimental|MYDICAR Mid Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
9750722|NCT00454818|Experimental|MYDICAR High Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
9750723|NCT00454818|Placebo Comparator|Placebo infusion|A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.
9750724|NCT00454857||Patients with ITP|Participants with ITP and currently treated for ITP were followed prospectively for a period of 12 months.
9750725|NCT00454909|Experimental|Group A|Subjects aged 10 years (< 11 years) vaccinated with meningococcal vaccine GSK134612.
9750726|NCT00454909|Experimental|Group B|Subjects aged 11 to 25 years vaccinated with meningococcal vaccine GSK134612.
9750727|NCT00454909|Active Comparator|Group C|Subjects aged 11 to 25 years vaccinated with Menactra®.
9750728|NCT00454987|Experimental|Menitorix Group|Previously primed in infancy with Menitorix™ and Infanrix-IPV™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
9750729|NCT00454987|Active Comparator|Meningitec Group|Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
9750730|NCT00454987|Active Comparator|Meningitec+Hiberix Group|"Previously primed (according to the routine UK immunisation schedule) with 3 doses of a Meningitec™ conjugate vaccine and a Hiberix™ containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix-IPV™ and Menitorix™ at 40 to 43 months of age, intramuscularly in the deltoid region.~This group was added only at year 2 in UK (Meningitec+Hiberix Group) to comply with UK Hib Catch-up vaccination programme."
9750731|NCT00455013|Experimental|belatacept, mycophenolate mofetil (MMF)|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months; MMF 1g twice daily(bis in die, BID)
9750732|NCT00455013|Experimental|belatacept, sirolimus|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months;sirolimus 5 mg/day on Day 1 (day of transplant)and continued through Day 2, dosing to be adjusted to keep pre-dose C0 levels at 7-12 ng/mL for first 6 months, followed by 5 - 10 ng/mL until 12 months.
9750733|NCT00455013|Other|tacrolimus, MMF|(IMPs as comparator regimen)thymoglobulin 1.5mg/kg for 4 days; oral tacrolimus 0.1 mg/kg/day in 2 divided doses with initial targeted trough level of 8-12 ng/mL for Days 1 - 30 with dose reduction to achieve 12 hour trough target of 5-10 ng/mL for 12 months; MMF (mycophenolate mofetil) 1g BID.
9750734|NCT00455195|Experimental|Alglucosidase Alfa/Alglucosidase Alfa|Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
9750735|NCT00455195|Experimental|Placebo/Alglucosidase Alfa|Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.
9750736|NCT00455312|Experimental|Patients with DC|Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
9750737|NCT00455312|Experimental|Patients with SAA|Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
9750738|NCT00455429|Placebo Comparator|Placebo|
9750739|NCT00455429|Experimental|JNJ-26113100 (50 mg) once daily|
9750740|NCT00455429|Experimental|JNJ-26113100 (100 mg) once daily|
9750741|NCT00455429|Experimental|JNJ-26113100 (100 mg) twice daily|
9750742|NCT00455429|Experimental|JNJ-26113100 (250 mg) twice daily|
9750743|NCT00455455|Active Comparator|Optifree RepleniSH Multipurpose Disinfecting Solution|
9750744|NCT00455455|Active Comparator|ReNu Multiplus Multipurpose Solution|
9750745|NCT00455520|Placebo Comparator|Placebo|placebo matching placebo twice daily for 12 weeks
9750746|NCT00455520|Experimental|CG5503|CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks
9750747|NCT00455533|Experimental|A|
9750748|NCT00455533|Active Comparator|B|
9750749|NCT00455650|Active Comparator|Schizophrenia, Mecamylamine|
9750750|NCT00455650|Active Comparator|Schizophrenia, Varenicline|
9750751|NCT00455650|Placebo Comparator|Schizophrenia, Placebo|
9750752|NCT00455650|Active Comparator|Control, Mecamylamine|
9750753|NCT00455650|Active Comparator|Control, Varenicline|
9750754|NCT00455650|Placebo Comparator|Control, placebo|
9750755|NCT00455663|Experimental|Cognitive Adaptation Training|In home treatment using environmental supports such as signs, labels, alarms, checklists and the organization of belongings to bypass cognitive impairment, cue and sequence adaptive behavior and improve a wide range of functional outcomes.
9750756|NCT00455663|Experimental|Pharm-Cognitive Adaptation Training|Uses Supports from Cognitive Adaptation Training designed only to promote adherence to medication and treatment follow up.
9750757|NCT00455663|Active Comparator|Treatment As Usual|Medication follow up and limited case management provided by local mental health authority
9750758|NCT00455689|Experimental|Developed hot flashes|Subjects who developed hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
9750759|NCT00455689|Experimental|Did not develop hot flashes|Subjects who did not develop hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
9750760|NCT00455702|Experimental|D-cycloserine|50 mg d-cycloserine
9750761|NCT00455702|Placebo Comparator|Placebo|50 mg placebo
9750762|NCT00455741|Active Comparator|Young postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
9750763|NCT00455741|Active Comparator|Older postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
9750764|NCT00455858|Active Comparator|insulin detemir|
9750765|NCT00455923|Experimental|Seretide|Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
9750766|NCT00455923|Experimental|Flixotide|Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
9750767|NCT00455962|Active Comparator|African American women 18-35 yo|intervention: estradiol steroid infusion and progesterone steroid infusion
9750768|NCT00455962|Active Comparator|Caucasian women 18-35 yo|intervention: estradiol steroid infusion intervention: progesterone steroid infusion
9750769|NCT00455975|Experimental|Weekly Avastin|Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
9750770|NCT00455975|Experimental|Bi-weekly Avastin|Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity
9750771|NCT00456014|Experimental|1 - SSRI|Participants will receive standardized pharmacotherapy with the SSRI escitalopram over 8 weeks. Non-remitters after 8 weeks will be offered standardized pharmacotherapy with desipramine
9782453|NCT01175824|Active Comparator|Insulin glargine+insulin lispro|Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro
9750772|NCT00456092|Experimental|Apremilast 40 mg QD|"Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks.~The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication."
9750773|NCT00456092|Experimental|Apremilast 20 mg BID|Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
9750774|NCT00456092|Placebo Comparator|Placebo|Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.
9750775|NCT00456261|Experimental|Cohort A|Cohort A, will receive bevacizumab 10mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over 10 minutes followed by gemcitabine 1500 mg/m2 by vein over 30-60 minutes. This regimen will be given on day 1 and day 15 of each treatment cycle. Each cycle is 28 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 2 weeks as long as their disease does not worsen.
9750776|NCT00456261|Experimental|Cohort B|Cohort B, will receive bevacizumab 15mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over approximately 10 minutes followed by carboplatin AUC=5 by vein over 30-60 minutes. This regimen will be given on day 1 of each treatment cycle. Each cycle is 21 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 3 weeks as long as their disease does not worsen.
9750777|NCT00456300|Experimental|Exenatide 1.25 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
9750778|NCT00456300|Experimental|Exenatide 2.5 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
9750779|NCT00456300|Active Comparator|Insulin|Each subject received a baseline study with insulin alone
9750780|NCT00456365|Experimental|Pravastatin|Pravastatin
9750781|NCT00456365|Placebo Comparator|Placebo|Placebo
9750782|NCT00456495|Experimental|Subconjunctival ranibizumab|Patients will receive subconjunctival ranibizumab every 2-4 weeks.
9750783|NCT00456508|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
9750784|NCT00456521|Experimental|NB32|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
9750785|NCT00456521|Placebo Comparator|Placebo|Placebo with intensive group lifestyle modification counseling
9750786|NCT00456547||Postpartum hysterectomy|Women that require postpartum hysterectomy for post-delivery bleeding.
9750787|NCT00456547||Cesarean delivery case controls|Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy
9750788|NCT00456599|Experimental|Oxaliplatin & gemcitabine with radiation|This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
9750789|NCT00456625|Experimental|Group Engerix™-B|Subjects received a dose of Hepatitis B vaccine approximately 20 years after the primary neonatal vaccination
9750790|NCT00456755|Active Comparator|Shi-Bi-Lin|Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae, Radix) and 5 g Verbena officinalis L. (Verbenaceae, Herba).
9750791|NCT00456755|Placebo Comparator|Placebo|The placebo contained brown colored starch resembling the SBL powder
9750792|NCT00456807|Experimental|Cervarix Group|Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).
9750793|NCT00456807|Placebo Comparator|Placebo Group|Subjects who received 3 doses of placebo during the primary study (NCT00294047).
9750794|NCT00456846|Experimental|ABI-007|100 mg/m^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
9750795|NCT00456885|Placebo Comparator|Exenatide First|Started on Exenatide, 3 week washout, start placebo
9750796|NCT00456885|Experimental|Placebo First|Started on placebo, 3 week washout, start exenatide
9750797|NCT00457002|Experimental|Arm 1|"While hospitalized, Apixaban plus Placebo~Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC)~After hospital discharge, Apixaban~Apixaban (Tablets, Oral, 2.5 mg)"
9782454|NCT01175850|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
9750798|NCT00457002|Active Comparator|Arm 2|"While hospitalized, Enoxaparin plus Placebo~Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral)~After hospital discharge: Placebo~Placebo (Tablets, Oral)"
9750799|NCT00457015|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
9750800|NCT00457015|Placebo Comparator|Placebo|Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
9750801|NCT00457197|Placebo Comparator|Placebo|This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
9750802|NCT00457197|Active Comparator|Quetiapine|This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
9750803|NCT00457249|Experimental|Adacel Vaccine Group|
9750804|NCT00457249|Active Comparator|DECAVAC Vaccine Group|
9750805|NCT00457301||Control|
9750806|NCT00457366|Active Comparator|Quetiapine|Quetiapine is being used in an ER setting on agitated patients, being administered orally.
9750807|NCT00457366|Active Comparator|Haloperidol|"Haloperidol is being used in an ER setting on agitated patients, administered IM. This is being used in combination with lorazepam and cogentin. We are comparing the use of this cocktail to quetiapine alone."
9750808|NCT00457366|Active Comparator|Lorazepam|"Lorazepam is being used in an ER setting on agitated patients, administered IM.This is being used in combination with haloperidol, and cogentin. We are comparing the use of this cocktail to quetiapine alone."
9750809|NCT00457366|Active Comparator|Cogentin|"Cogentin is being used in an ER setting on agitated patients, administered IM.~This is being used in combination with haloperidol, and lorazepam. We are comparing the use of this cocktail to quetiapine alone."
9750810|NCT00457392|Experimental|1|
9750811|NCT00457392|Active Comparator|2|
9750812|NCT00457418|Experimental|PEG-Intron|"6 ug/kg/week, SC (first 8 weeks)~3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)"
9750813|NCT00457626|Experimental|Valsartan Open Label|Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.
9750814|NCT00457639|Experimental|Cholic Acid active capsules|Cholic Acid weight based dose for 6 months double-blind
9750815|NCT00457639|Placebo Comparator|Placebo for Cholic Acid|Placebo for Cholic Acid for 6 months double-blind
9750816|NCT00457665|Active Comparator|Nelfinavir (Viracept)|
9750817|NCT00457665|Active Comparator|Efavirenz (Sustiva)|
9750818|NCT00457691|Experimental|1|
9750819|NCT00457691|Placebo Comparator|2|
9750820|NCT00457730|Experimental|Duloxetine|subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
9750821|NCT00457730|Placebo Comparator|placebo|matched placebo medication
9750822|NCT00457743|Experimental|SU011248|25 , 50 or 75 mg/day of SU011248
9750823|NCT00457795|Experimental|brimonidine 0.1%|brimonidine 0.1%
9750824|NCT00457821|Experimental|Ivacaftor Group A|Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
9750825|NCT00457821|Experimental|Ivacaftor Group B|Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
9750826|NCT00457821|Experimental|Ivacaftor Group C|Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
9750827|NCT00457821|Placebo Comparator|Placebo|Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.
9750828|NCT00457977|Active Comparator|Pneumovax (PPSV23)|pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
9750829|NCT00457977|Active Comparator|Prevnar (PCV7)|diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose
9750830|NCT00458211|Experimental|Experimental|Open label change to ziprasidone
9750831|NCT00458237|Experimental|Ph I: Everolimus L1 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
9750832|NCT00458237|Experimental|Ph I: Everolimus L2 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
9750833|NCT00458237|Experimental|PhII: Everolimus MTD + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus at the MTD by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
9750834|NCT00458302|Experimental|darunavir monotherapy|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
9750835|NCT00458302|Experimental|darunavir + 2 NRTI|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
9750836|NCT00458341|Experimental|Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg|During Cycle 1, participants will receive ataluren at 4 mg/kg in the morning, 4 mg/kg at midday, and 8 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 10, 10, and 20 mg/kg) for Cycle 2.
9750837|NCT00458341|Experimental|Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg|During Cycle 1, participants will receive ataluren at 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 4, 4, and 8 mg/kg) for Cycle 2.
9750838|NCT00458393|Experimental|TDF/FTC|Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
9750839|NCT00458393|Placebo Comparator|Placebo|Drug. Daily oral placebo
9666003|NCT04769011|Experimental|Clinical, neuropsychological, neurophysiological, and genetic evaluations|Clinical, neuropsychological, neurophysiological, and genetic evaluations
9782455|NCT01175850|Active Comparator|Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
9782456|NCT01175902|Active Comparator|Arm 1|Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
9782457|NCT01175902|Active Comparator|Arm 2|Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day
9782458|NCT01175980|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9782459|NCT01176032|Experimental|Aliskiren|"Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
9782460|NCT01176032|Active Comparator|Lostaran|"Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
9782461|NCT01176058|Active Comparator|open label|
9782462|NCT01176240|Experimental|Droxidopa|droxidopa active drug
9782463|NCT01176240|Placebo Comparator|Placebo|Placebo matched control
9782464|NCT01176266|Experimental|Asfotase alfa|A total of 6 mg/kg/week of asfotase alfa administered by SC injection (either 1 mg/kg asfotase alfa 6 times per week, or 2 mg/kg asfotase alfa 3 times per week)
9782465|NCT01176292|Other|Rotating Platform High-Flex Cruciate Substituting TKA|
9782466|NCT01176292|Other|Rotating Platform Cruciate Substituting TKA|
9782467|NCT01176435|Active Comparator|0.76 mg/kg L-DOPA|Solution taken orally three times a day.
9782468|NCT01176435|Active Comparator|0.51 mg/kg L-DOPA|Solution taken orally three times a day.
9782469|NCT01176435|Placebo Comparator|Placebo|Solution taken orally three times a day.
9782470|NCT01176448|Experimental|Fractionated laser|This Arm is the section of scar that will be treated with Fractionated Laser
9782471|NCT01176448|Active Comparator|Dermabrasion|Dermabrasion is the gold standard for scar resurfacing and will be used as the control against which Fractionated Laser is compared.
9782472|NCT01176565|Active Comparator|Standard SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the standard BP reduction group will be to reduce and maintain SBP < 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm.~For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
9782473|NCT01176565|Active Comparator|Intensive SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the intensive BP reduction group will be to reduce and maintain SBP < 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm.~For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
9782474|NCT01176591|Experimental|Placebo Session 1, Aprepitant Session 2|Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.
9782475|NCT01176591|Placebo Comparator|Placebo Session 1, Placebo Session 2|Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.
9782476|NCT01176617|No Intervention|Conventional Monitoring Strategy|Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.
9782477|NCT01176617|Other|Reveal XT|Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
9782478|NCT01176773|Experimental|Juvéderm® Ultra Lip Injectable Gel|
9782479|NCT01176877|Other|keloid scar|Those with a diagnosis of keloid scar.
9782480|NCT01176916|Experimental|A|
9782481|NCT01176955|Experimental|Internet survey|Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.
9782482|NCT01176955|Placebo Comparator|Control|Subjects will receive standard-of-care treatment with the study medication, without internet surveys.
9782483|NCT01176968|Experimental|Eplerenone plus standard of care|
9750840|NCT00458406|Active Comparator|Bi-Flex|"Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Following a baseline polysomnography, subjects in this arm will undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will be randomized to Bi-Flex or CPAP, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
9750841|NCT00458406|Active Comparator|CPAP|"Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.~Subjects in this arm received standard continuous positive airway pressure (CPAP) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will randomized to CPAP or Bi-Flex, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
9750842|NCT00458484|Experimental|Series 1: Stereotactic radiosurgery|Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy.
9750843|NCT00458484|Experimental|Series 2: Stereotactic radiosurgery|Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each.
9750844|NCT00458705|Experimental|Combination therapy|Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.
9750845|NCT00458783|Active Comparator|Prolonged RBC storage|Transfusion with oldest available matching RBCs.
9750846|NCT00458783|Active Comparator|Short RBC storage|Transfusion with youngest available matching RBCs.
9750847|NCT00458822|Experimental|All Patients|All patients treated with Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients with Systemic Light-Chain (AL) Amyloidosis
9750848|NCT00458952|Experimental|Dose Escalation|Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.
9750849|NCT00459043|Active Comparator|1|Docetaxel Alone
9750850|NCT00459043|Active Comparator|2|Docetaxel with ZD6474
9750851|NCT00459056|Experimental|Carvediolol CR + Lisinopril, then Lisinopril + HCTZ|Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months.
9750852|NCT00459056|Active Comparator|Lisinopril + HCTZ, then Carvedilol CR + Lisinopril|Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and then were given Carvedilol CR + Lisinopril for the final three months.
9750853|NCT00459108|Experimental|Oral Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9750854|NCT00459134|Experimental|Arm I: ArginMax|ArginMax® 3 pills twice daily
9750855|NCT00459134|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo 3 pills twice daily
9750856|NCT00459186|Experimental|RAD001 Followed by RAD001 + Docetaxel|RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.
9750857|NCT00459290|Experimental|Mifepristone 200 mg PO daily|Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy.
9782484|NCT01176968|Placebo Comparator|Placebo plus standard of care|Matching placebo for eplerenone 25mg film coated tablets.
9782485|NCT01176981|Experimental|HDMTX|This is a single arm study. All subjects enrolled in the study will be in this arm.
9782486|NCT01177007|Experimental|TheraSphere|
9782487|NCT01177059|Other|Anti-HIV-1 Ribozyme (OZ1) transduced cells|OZ1 transduced cells Long term follow up of previously infused OZ1 transduced cells
9782488|NCT01177098|Experimental|bimatoprost/timolol formulation A|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
9782489|NCT01177098|Active Comparator|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
9782490|NCT01177137|Experimental|TRT|TRT includes treatment with a conventional sound generator (SG) and directive counseling (DC)
9750858|NCT00459303|Active Comparator|intraocular lens|patients with bilateral clinical significant cataract reisiceved cataract surgeries and recieved spherial intraocuar lens(SA60AT, Alcon) in one eye and aspherical intraocular lens(Tecnis Z9000, AMO)in the other respectively.
9750859|NCT00459316|Experimental|Group 1|Participants ≤11 to <25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
9750860|NCT00459316|Experimental|Group 2|Participants ≤11 to <25 years of age with CD4% at screening <15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
9750861|NCT00459316|Experimental|Group 3|Participants >=2 to <11 years of age with CD4% at screening ≥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
9750862|NCT00459342|Experimental|Arm I|Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9750863|NCT00459355|Experimental|Home Safety Toolkit|Intervention group receives home safety tool-kit with education and self-efficacy materials to promote competence to make home safety modifications.
9750864|NCT00459355|No Intervention|Conventional Safety Checklist|Comparison group received a conventional home safety checklist
9750865|NCT00459368|Experimental|I|In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
9750866|NCT00459368|Active Comparator|II|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
9750867|NCT00459381|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
9750868|NCT00459537|Experimental|Terbinafine|10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
9750869|NCT00459537|Active Comparator|Amorolfine|5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
9750870|NCT00459667|Experimental|IFNB-1b 500 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 500 mcg administered s.c. every other day (double blind)
9750871|NCT00459667|Experimental|IFNB-1b 250 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day (double blind)
9750872|NCT00459667|Experimental|IFNB-1b 250 mcg*|"Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day~*(Subjects who were administered Copaxone and subjects who had prematurely discontinued medication during BEYOND study.)"
9750873|NCT00459706|Experimental|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
9750874|NCT00459706|Experimental|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
9750875|NCT00459732|Placebo Comparator|Placebo Capsule|placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months
9750876|NCT00459732|Active Comparator|Zinc (25 mg/d)|25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months
9750877|NCT00459862|Experimental|Arm I|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
9750878|NCT00459875|Experimental|Sunitinib|The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
9750879|NCT00459953|Experimental|Extended treatment|extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
9750880|NCT00459953|No Intervention|Control group|Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact
9750881|NCT00459979|Experimental|Sunitinib|
9750882|NCT00460031|Experimental|Ketoconazole Plus Lenalidomide|
9750883|NCT00460109|Experimental|rituximab + denileukin diftitox|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients also receive denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment with denileukin diftitox repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9750884|NCT00460239|Experimental|Placebo|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750885|NCT00460239|Experimental|Morphine 15|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750886|NCT00460239|Experimental|Morphine 30|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750887|NCT00460239|Experimental|Buprenorphine 8|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750888|NCT00460239|Experimental|Buprenorphine 16|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750889|NCT00460239|Experimental|Buprenorphine 32|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750890|NCT00460239|Experimental|Buprenorphine 48|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750891|NCT00460239|Experimental|Buprenorphine 60|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
9750892|NCT00460265|Active Comparator|ARM 2|Arm 2 consists of Cisplatin and 5-FU
9750893|NCT00460265|Experimental|ARM 1|ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU
9750894|NCT00460408||Observational study, no comparator|Observational study of patients with AMD treated with Macugen, no comparator
9750895|NCT00460421|Experimental|Palifermin Dose Escalation|A 3 dose escalation design. Sucessive cohorts of patient (9 patients per group) will each be administered Palifermin as an IV bolus injection (40, 60 or 80 µg) once daily for 3 consecutive days before the start of conditioning regimen (chemotherapy and total body irradiation) and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
9750896|NCT00460434|Experimental|1|Tension-free Vaginal Tape (TVT) surgery
9750897|NCT00460434|Sham Comparator|2|Sham Tension-free Vaginal Tape (TVT) surgery
9750898|NCT00460525|Active Comparator|Rabies Vaccine|Rabies vaccine administered on Days 0, 30, and 60.
9750899|NCT00460525|Experimental|FMP2.1/AS02A|50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.
9750900|NCT00460551|Experimental|Zalutumumab 8 mg/kg|
9750901|NCT00460564|Active Comparator|High-Dose BTX|
9750902|NCT00460564|Placebo Comparator|High-Dose Placebo|
9750903|NCT00460564|Active Comparator|Low-Dose BTX|
9750904|NCT00460564|Active Comparator|Low-Dose Placebo|
9750905|NCT00460577|Active Comparator|Formoterol (Foradil®)|Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
9750906|NCT00460577|Active Comparator|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
9750907|NCT00460603|Active Comparator|B|bevacizumab 5 mg/kg every 2 weeks + FOLFOX
9750908|NCT00460603|Experimental|C|AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
9750909|NCT00460603|Experimental|A|AG-013736 5 mg bid starting dose + FOLFOX
9750910|NCT00460655|Active Comparator|BTX|
9750911|NCT00460655|Placebo Comparator|Placebo|
9750912|NCT00460746|Experimental|001|TMC125, Darunavir; RitonavirTMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
9750913|NCT00460798||Non-Interventional Study|
9750914|NCT00460811|Active Comparator|72 ug linaclotide acetate|
9750915|NCT00460811|Active Comparator|145 ug linaclotide acetate|
9750916|NCT00460811|Active Comparator|290 ug linaclotide acetate|
9750917|NCT00460811|Active Comparator|579 ug linaclotide acetate|
9750918|NCT00460811|Placebo Comparator|Matching Placebo|
9750919|NCT00460993|Experimental|Group 1|Lunesta Active drug (eszopiclone) 1 mg during 1st week of active drug. If sleep efficiency does not improve does increases to 2 mg for 2nd week of active drug administration.
9750920|NCT00460993|Placebo Comparator|Group 2|"Sugar pill packaged and supplied by Sepracor. One pill weeks one and two of intervention.~Weeks 3 and 4 this Placebo group crosses over to active drug. 1 mg week 3 increasing to 2mg week 4 if sleep efficiency does not improve."
9750921|NCT00461045|Experimental|MRZ 0.5 mg/m^2|Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
9750922|NCT00461097|Experimental|Egg Oral Immunotherapy (OIT)|Subjects ingest egg white solid (EWS) on Visit 1 (initial day dose escalation up to 50 mg), followed by a build-up phase (escalating daily egg doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects are on a maximally tolerated daily egg dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects are given a 5 gm Oral Food Challenge (OFC) using EWS to identify desensitized [1] subjects. Subjects/study staff are unblinded following this OFC and either continue on their egg OIT maintenance dose of 2 gm/day or are allowed to attempt escalation up to 2 gm/day for the remainder of the study (1-3 years). A 10 gm OFC to identify desensitized [1] subjects occurs at specified intervals under prescribed conditions (yrs 2 - 4). Subjects who pass this 1st 10 gm OFC stop study therapy for 4-6 wks, then have a 2nd 10 gm OFC. Subjects that pass this 2nd 10 gm OFC are considered tolerant [2], stop EWS dosing and add egg to their diet.
9750923|NCT00461097|Placebo Comparator|Control Group|Subjects ingest placebo (cornstarch) during Visit 1 (initial day of dose escalation up to 50 mg), followed by a build-up phase (escalating daily placebo doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects were on a maximally tolerated daily placebo dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects were given a 5 gm Oral Food Challenge (OFC) using egg white solid to identify desensitized [1] subjects. Subjects/study staff were unblinded following this initial 5 gm OFC. After unblinding, subjects discontinued further placebo dosing and continued on an egg-restricted diet. A 10 gm OFC was administered under prescribed conditions to subjects if their egg-specific serum IgE level was below 2 kUA/L. They were followed in the study up to 2 years. [1] Desensitized: Subject does not react to egg during OFC while taking daily doses of therapy. [2] Tolerant: Subject does not react to egg during OFC 4-6 wks after abstinence from egg consumption.
9750924|NCT00461123|Experimental|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
9782491|NCT01177137|Other|Partial TRT|Partial TRT includes treatment with a placebo sound generator (placebo SG) and directive counseling (DC).
9750925|NCT00461123|Placebo Comparator|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
9750926|NCT00461175||1|Mirena®
9750927|NCT00461175||2|Copper IUD
9750928|NCT00461253||1|Breast Cancer Cases
9750929|NCT00461253||2|Matched Controls for Breast Cancer Cases
9750930|NCT00461292|Experimental|1|botulinum toxin Type A (200U)
9750931|NCT00461292|Experimental|2|botulinum toxin Type A (300U)
9750932|NCT00461292|Other|3|placebo; botulinum toxin Type A (200U)
10201815|NCT05194943||9. UOC Chirurgia Generale & Bariatric Center of Excellence IFSO-EC, Latina, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
9750933|NCT00461292|Other|4|placebo; botulinum toxin Type A (300U)
9750934|NCT00461305|Experimental|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
9750935|NCT00461305|Experimental|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
9750936|NCT00461331|Active Comparator|Insulin 1|Either insulin Aspart or insulin Lispro were randomized to be insulin 1.
9750937|NCT00461331|Active Comparator|Insulin 2|Between insulin Aspart and insulin Lispro, the one that was not used as insulin 1 was then used as the second insulin for the second arm of the study.
9750938|NCT00461513||Intervention|The PCDM intervention will include evaluation of CHF care by the collaborative care team, with diagnostic and therapeutic treatment recommendations based on current ACC/AHA national clinical practice guidelines, daily telemonitoring and patient self-care support utilizing the VA telemonitoring system, and screening and treatment for comorbid depression. The Collaborative Care (CC) team at each site will consist of a primary care provider, cardiologist, and psychiatrist, who are local opinion leaders, as well as a nurse site coordinator and pharmacist. For a given intervention patient, there will be an initial assessment of care by the CC team following the enrollment visit. Each intervention patient will be re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients will have daily telemonitoring, and their care will be reviewed by the CC team if the telemonitoring data suggests clinical deterioration.
9750939|NCT00461513||Usual Care|Patients randomized to the usual care arm will continue to receive care at the discretion of their regular VA providers (for a given patient, this could include cardiology specialty care in addition to PCP care, participation in site-specific CHF programs such as CHF patient education classes, etc.), in direct continuity with the care they were receiving prior to enrollment. Patients in the usual care group will also be given information sheets that outline self-care for CHF, and will be provided with a scale, if needed, at the enrollment visit. Patients in the usual care group will have the same amount of interaction with the study team as the intervention patients (i.e. complete questionnaires at the same frequency; have the same study visits). PCPs of usual care patients will be notified of the results of all screening studies (patient survey results, lab tests) as we have done in previous studies.
9750940|NCT00461552|Active Comparator|Leptin|Leptin weight and gender based dose, sub-cutaneous, twice daily. Leptin versus placebo for entire 6 months double-blind.
9750941|NCT00461552|Placebo Comparator|Placebo|Placebo , sub-Q injection twice daily.
9750942|NCT00461591|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
9750943|NCT00461591|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
9750944|NCT00461630|Experimental|ER niacin/laropiprant|1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
9750945|NCT00461630|Active Comparator|Placebo|Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
9750946|NCT00461708|Experimental|Rash, Grade <2|Participants with a rash graded less than (<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
9750947|NCT00461708|Experimental|Rash, Grade ≥2|Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
9750948|NCT00461734|Active Comparator|RV Apex|
9750949|NCT00461734|Experimental|RV High Septum|
9750950|NCT00461773|Active Comparator|bevacizumab|brief exposure bevacizumab
9750951|NCT00461773|Active Comparator|bevacizumab and letrozole|brief exposure bevacizumab and letrozole
9750952|NCT00461786|Experimental|Pemetrexed|
9750953|NCT00461851|Experimental|Chemotherapy plus sorafenib|Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
9750954|NCT00461981|Experimental|FluMist, Influenza Virus Vaccine Live|FluMist, Influenza Virus Vaccine Live, Intranasal
9829774|NCT02546856|Active Comparator|Heart Failure (HF) cardiologist up-titration|Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
9829775|NCT02546856|Experimental|HF nurse up-titration|Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.
9829776|NCT02547012|Experimental|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
9829777|NCT02547012|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
9829778|NCT02547038|Experimental|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
9829779|NCT02547038|Active Comparator|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
9829780|NCT02547064|Active Comparator|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
9829781|NCT02547064|Experimental|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
9829782|NCT02547220|Experimental|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
9829783|NCT02547220|Placebo Comparator|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
9829784|NCT02547233|Experimental|LEO 43204 gel|Treatment once daily for 3 days
9829785|NCT02547233|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
9829786|NCT02547363|Experimental|LEO 43204|Treatment once daily for 3 days
9829787|NCT02547363|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
9829788|NCT02547428|Experimental|CTN SR First, Then Placebo|Participants received CTN SR tablets starting at a dose of 100 or 200 milligrams (mg) on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 1. The dose was decreased based on safety and tolerability based on Investigator's discretion, followed by a washout Period of 1 week followed by matching-placebo for up to 3 weeks in Period 2. The most common total daily dose (TDD) was 400 mg/day.
9829789|NCT02547428|Experimental|Placebo First, Then CTN SR|Participants received matching-placebo for up to 3 weeks in Period 1, followed by a washout Period of 1 week, followed by CTN SR tablets starting at a dose of 100 or 200 mg on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 2. The dose was decreased based on safety and tolerability based on Investigator's discretion. The most common TDD was 400 mg/day.
9829790|NCT02547454||CKD participants treated with Mircera|Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.
9829791|NCT02547623|Active Comparator|dexamethasone depot|dexamethasone depot 517 mcg
9829792|NCT02547623|Active Comparator|standard of care|prednisolone drops 1%
9829793|NCT02547649|Experimental|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
9829794|NCT02547649|Experimental|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
9829795|NCT02547649|Active Comparator|Prevnar 13®|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1
9829796|NCT02547714|Experimental|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
9829797|NCT02547766|Experimental|Anakinra Arm|All patients in this arm receive Anakinra in a pre-post design. That is, outcome markers are measured, the intervention (Anakinra) is applied, and the outcome markers are measured again at various intervals to determine effect.
9829798|NCT02547779|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
9829799|NCT02547779|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
9829800|NCT02547922|Experimental|Anifrolumab - Lower Dose|Anifrolumab - Lower Dose
9829801|NCT02547922|Experimental|Anifrolumab - Higher Dose|Anifrolumab - Higher Dose
9829802|NCT02547922|Placebo Comparator|Placebo|Placebo IV Q4W plus SOC
9829803|NCT02547935|Experimental|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
9829804|NCT02547935|Experimental|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
9829805|NCT02547935|Placebo Comparator|Placebo|Tablets administered orally once daily for 24 weeks
9829806|NCT02547974|Experimental|GSK3277513A F1 Group|Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
9829807|NCT02547974|Experimental|GSK3277513A F2 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
9829808|NCT02547974|Experimental|GSK3277513A F3 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
9829809|NCT02547974|Placebo Comparator|Placebo Group|Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
9829810|NCT02547987|Experimental|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
9829811|NCT02548078|Experimental|GSK3390107A+Nimenrix Group|Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
9829812|NCT02548078|Experimental|Nimenrix+GSK3390107A Group|Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
9829813|NCT02548156|Other|Test dentifrice|1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
9829814|NCT02548156|Other|Reference dentifrice|1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
9829815|NCT02548156|Other|Comparator dentifrice|1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
9829816|NCT02548312|Experimental|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
9829817|NCT02548312|Experimental|Review 1- competing interest statement 2|Variations of financial competing interest statements.
9829818|NCT02548312|Experimental|Review 1- competing interest statement 3|Variations of financial competing interest statements.
9829819|NCT02548312|Experimental|Review 1- competing interest statement 4|Variations of financial competing interest statements.
9829820|NCT02548312|Experimental|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
9829821|NCT02548312|Experimental|Review 2- competing interest statement 2|Variations of financial competing interest statements.
9829822|NCT02548312|Experimental|Review 2- competing interest statement 3|Variations of financial competing interest statements.
9829823|NCT02548312|Experimental|Review 2- competing interest statement 4|Variations of financial competing interest statements.
9517428|NCT03306459||1/PCOS|The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting >35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
9829824|NCT02548455|Experimental|Treatment|Subjects implanted with the Quartet 1457Q LV lead
9829825|NCT02548585|Placebo Comparator|Placebo|Participants will receive placebo (matched to either 100 micrograms [mcg], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
9829826|NCT02548585|Experimental|Cohort 1: MEDI0382 100 mcg|Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
9829827|NCT02548585|Experimental|Cohort 2: MEDI0382 150 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
9829828|NCT02548585|Experimental|Cohort 3: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
9829829|NCT02548585|Experimental|Cohort 4: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
9829830|NCT02548585|Experimental|Cohort 5: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
9829831|NCT02548585|Experimental|Cohort 6: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).
9829832|NCT02548650|Experimental|Patients with diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
9829833|NCT02548650|Active Comparator|Patients without diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
9829834|NCT02548728|Experimental|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
9829835|NCT02548728|Placebo Comparator|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
9829836|NCT02548910|Experimental|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
9829837|NCT02548910|No Intervention|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
9829838|NCT02548962|Experimental|Phase 1: Dose Finding|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
9829839|NCT02548962|Experimental|Phase 2: Treatment Arm A|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
9829840|NCT02548962|Experimental|Phase 2: Treatment Arm B|Placebo PO+ Pomalidomide PO+ Dexamethasone PO
9829841|NCT02549014|Experimental|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829842|NCT02549014|Experimental|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829843|NCT02549014|Experimental|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829844|NCT02549014|Experimental|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829845|NCT02549014|Experimental|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829846|NCT02549014|Experimental|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829847|NCT02549014|Experimental|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829848|NCT02549014|Experimental|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829849|NCT02549014|Experimental|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
9829850|NCT02549014|Experimental|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
9829851|NCT02549014|Placebo Comparator|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
9829852|NCT02549027|Experimental|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
9666004|NCT04768972|Experimental|ION363|ION363 will be administered by lumbar intrathecal (IT) bolus injection with 1 dose every 4-12 weeks, after a loading dose at 4 weeks, over a 61-week double-blind treatment period in Part 1 and every 12 weeks for 85 weeks in the open-label extension treatment period, aside from a loading dose administered 4 weeks after the first dose in Part 2.
9750955|NCT00461981|Active Comparator|TIV, Trivalent Inactivated Influenza Virus Vaccine|TIV, Trivalent Inactivated Influenza Virus Vaccine, Intramuscular
9750956|NCT00462020|Active Comparator|1|5 days of IV antibiotics after appendectomy
9750957|NCT00462020|Experimental|2|home on oral antibiotics to complete 7 days of treatment when tolerating PO's
9750958|NCT00462124|Other|Balloon|Implantation of a biodegradable balloon spacer (absorbable perirectal spacer)
9666005|NCT04768972|Placebo Comparator|Placebo|Placebo will be administered by lumbar IT bolus injection with 1 dose every 4-12 weeks over a 61-week double-blind treatment period.
9666006|NCT04767607||Breast cancer plus chemotherapy|Patients of the group will receive chemotherapy treatment.
9666007|NCT04767607||Breast cancer without chemotherapy|Patients of the group will not receive chemotherapy treatment.
9666008|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 1|
9666009|NCT04766476|Experimental|Active Treatment (BMS-963272) Dosing Regimen 2|
9666010|NCT04766476|Placebo Comparator|Placebo|
9666011|NCT04763330|Active Comparator|Enhanced Usual Care (EUC)|Active comparator (EUC only).
9666012|NCT04763330|Experimental|Active treatment plus EUC|Veterans randomized to this condition received the treatment plus EUC.
9666013|NCT04763317||AFFECTED|"Affected with PrCa < 70 years~Affected with metastatic castration resistant PrCa (mCRPC) at any age~Affected with PrCa and a family history defined as~two or more cases in family with one case < 70~three or more cases any age (FDR or SDR)"
9666014|NCT04763317||UNAFFECTED|"- Aged >30 and with a family history defined as::~FDR diagnosed < 70~2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed < 70 years~3 or more cases at any age (on same side of family)"
9666015|NCT04762680|Experimental|Phase 2 Cohort -SARS-CoV-2 vaccine Formulation 1|2 injections of SARS-CoV-2 vaccine Formulation 1 at Day 1 and Day 22
9666016|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 2|2 injections of SARS-CoV-2 vaccine Formulation 2 at Day 1 and Day 22
9666017|NCT04762680|Experimental|Phase 2 Cohort - SARS-CoV-2 vaccine Formulation 3|2 injections of SARS-CoV-2 vaccine Formulation 3 Day 1 and Day 22
9666018|NCT04762680|Experimental|Supplemental Cohort 1 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were previously vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
9666019|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine or SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
9666020|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Bivalent (D614 + B.1.351)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA or adenovirus-vector COVID-19 vaccine will receive 1 booster injection of bivalent (D614+B.1.351)-AS03 SARS-CoV-2 vaccine
9666021|NCT04762680|Experimental|Supplemental Cohort 2 - Booster Monovalent (D614)-AS03 SARS-CoV-2 vaccine|Participants who were vaccinated 4 to < 10 months prior with SARS-Cov-2 vaccine will receive 1 booster injection of monovalent (D614)-AS03 SARS-CoV-2 vaccine
9666022|NCT04762680|Active Comparator|Supplemental Comparator for Cohort 1 and 2 Boosters - Monovalent (D614)-AS03 SARS-CoV-2 vaccine|2 injections of monovalent (D614)-AS03 SARS-CoV-2 vaccine at Day 1 and Day 22 in previously unvaccinated, naïve participants
9666023|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 1|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
9666024|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 2|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
9666025|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 3|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
9666026|NCT04762680|Experimental|Cohort 2 - Booster Exploratory 4|Participants who were vaccinated 4 to < 10 months prior with an authorized mRNA COVID-19 vaccine will receive 1 booster injection of monovalent (B.1.351)-AS03 SARS-CoV-2 vaccine
9666027|NCT04762043|Experimental|MyoVoice Device|MyoVoice Device for individuals with total laryngectomy
9666028|NCT04761796||Professional flight members|
9666539|NCT04456959||Adult R/R ALL patients who have received InO|Relapsed/refractory ALL patients who are 18 years and over and initiated InO between 1st of June 2016 and date of data collection (to be confirmed). They will have accessed InO treatment via NHS commissioning, via the CUP, or via private purchase and will have at least 3 months follow up from the index date unless death occurs within that time.
9666542|NCT04453475|Experimental|Partial digital group: depression|"Burg~Online depression session as a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
9666543|NCT04453475|Experimental|Partial digital group: social work (social medicine)|"NOR~Online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
9666544|NCT04453475|Experimental|Partial digital group: depression + social work|"JUL~Online depression session as a flipped classroom and an online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
9666545|NCT04453475|Active Comparator|Control group: only digital training before rehabilitation|"MOE~Online tobacco cessation a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
9666546|NCT04452825|Experimental|Cancer and Aging: Reflections for Elders (CARE) Intervention|Session content and timing was developed and confirmed in our qualitative work (Expert Panel) and the CARE pilot study. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
9984003|NCT04500795|No Intervention|Control Group|All symptomatic patients (headache unresponsive to analgesic or neurological deficits including focal neurological deficits, deteriorated consciousness, headache, seizures, and other signs or symptoms suggestive of SDH as the cause) will undergo haematoma evacuation either by burr-hole drainage or craniotomy. Their response to treatment, neurological status, and CT scans will be monitored. Asymptomatic patients will be monitored radiologically (CT) every 2-4 weeks. The decision for surgical evacuation of haematoma will be based on CT findings (increasing haematoma size) and presentation of symptoms or neurological deficits. They remain in the control group should they refuse embolization of MMA. The size of haematoma will be measured continuously based on CT scans taken at times of presentation, 1-day, 1-week, 1-month, 3-month, and 6-month post-op. Size of haematoma, residual or recurrent will be measured for comparison to the Embolization Group.
9984004|NCT04496245|Active Comparator|Wait-list control|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
9666029|NCT04759690|Experimental|Action observation group|Action observation group consist of 19 randomly selected participants.Action observation + conventional balance exercise group
9666030|NCT04759690|Active Comparator|Exercise group|Exercise group is the control group.Consist of 19 randomly selected participants. the The participants will only do the conventional balance exercise.
9666031|NCT04759027||X-ray|Measurements of subacromial distance on standardized direct radiography
9666032|NCT04759027||ultrasound|Measurements of subacromial distance on ultrasound
9666033|NCT04758520|Experimental|Experimental|"Six subjects are involved in a single session of upper limb robotic-assisted therapy lasting about 3 hours and including:~passive mobilization of patient's upper arm along elementary shoulder movements:shoulder flexion/extension, adduction/ abduction in the frontal plane, horizontal adduction/ abduction, intra/extrarotation (Passive Mode);~passive mobilization of patient's upper arm along complex trajectories recorded from manual mobilization of the therapist (Learn&Replay Mode);~active mobilization, performed by the patient during rehabilitative functional tasks, relying only on gravity and friction compensations and tuneable assistance from the exoskeleton (Transparency Mode)."
9666034|NCT04757662|Experimental|Tadalafil|"Tadalafil will be given orally once daily for a total of 60 days at a weight-normalized dose as follows:~10 mg/day if weight ≤63.5 kg~15 mg/day if weight >63.5 kg and ≤104.3 kg~20 mg/day for weight >104.3 kg~Standard of care fractionated radiation therapy (RT) to 60 Gy in 30 daily fractions will be administered in this study.~Concurrent temozolomide (TMZ) will be administered as per standard of care, i.e., continuously (Monday through Sunday) from Day 1 of RT to the last day of RT at a daily oral dose of 75 mg/m^2 at the discretion of treating medical oncologist.~Adjuvant therapy will administered as per standard of care. Typically, this consists of adjuvant TMZ initiated 4 to 6 weeks after completion of RT for 6 cycles at 150-200 mg/m^2 PO per day on Days 1-5 of every 28-day cycle. Tumor-treating fields or Optune device (Novocure) as per routine clinical care during adjuvant TMZ is permitted at the discretion of the treating physician."
9666037|NCT04750408|Active Comparator|Oxygen use|Patients will use standard oxygen via face mask of nasal prongs as usual care.
9666038|NCT04750408|Experimental|NHF use|Patients will use NHF instead of oxygen. Oxygen will be supplemented via the NHF flow.
9666039|NCT04750070|Experimental|Dopamine arm|Children in the dopamine arm (Treatment plan A) will receive dopamine, 8 microgram/kg/min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
9666040|NCT04750070|Experimental|Adrenaline arm|Children in the adrenaline arm (Treatment plan B) will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
9666041|NCT04750070|Active Comparator|Blood transfusion arm|Children in the blood transfusion arm (Treatment plan C) will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
9666042|NCT04749992||Non-Dreamers|Experimental Group
9666043|NCT04749992||Dreamers|Comparison Group
9666044|NCT04748718|Experimental|Injury Prevention Arm|
9666045|NCT04748523|Active Comparator|Intervention group|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
9666046|NCT04748523|Placebo Comparator|Placebo group|arm to receive 15 to 30 mg of placebo for a period of 8 weeks.
9666050|NCT04744363|Experimental|AVT04 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
9666051|NCT04744363|Active Comparator|US Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
9666052|NCT04744363|Active Comparator|EU Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
9666053|NCT04743167|Active Comparator|Surgery|Patients undergoing surgery for endometriosis, after surgery, will receive indications for seeking for a natural pregnancy up to 12 months from the time of randomization
9666054|NCT04743167|Active Comparator|In Vitro Fertilization|Patients included in the IVF arm will undergo three complete cycles of IVF (i.e. three oocytes retrievals regardless of the number of embryo transfers)
9666055|NCT04741334||patients not in therapy with anticoagulants or antiplatelets drugs|Patients presenting in ED with mild head trauma and not in therapy with antiplatelets and/or anticoagulants
9666056|NCT04741334||patients in therapy with direct anticoagulant|Patients presenting in ED with mild head trauma and in therapy with direct anticoagulants
9984005|NCT04496245|Experimental|Initial treatment wtih OM85|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
9666057|NCT04741334||patients in therapy with oral anticoagulant (dicumarolics)|Patients presenting in ED with mild head trauma and in therapy with oral anticoagulants (dicumarols)
9666058|NCT04741334||patients in therapy with antiplatelet drugs|Patients presenting in ED with mild head trauma and in therapy with antiplatelets
9666059|NCT04740424|Experimental|FS222 Q4W|The initial cohorts will enroll sequentially as single participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design. Additional participants will be recruited into the PK/PD expansion cohorts at dose levels deemed safe during dose escalation. Once a tolerated dose has been established participants will be recruited into tumour-specific expansion cohorts.
9666060|NCT04738890|Experimental|MBCT-PCCFA plus TAU|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing, plus treatment as usual.
9666061|NCT04738890|Other|TAU control|Treatment as usual control group
9984006|NCT04495582||Non-Interventional Study group|Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
9984007|NCT04494295||AURORA|Aurora® Surgiscope used for MIS evacuation of supratentorial hematoma
9666064|NCT04738110||KCH patients|75 high grade glioma patients from KCH
9666065|NCT04738110||NHNN patients|75 high grade glioma patients from NHNN
9666066|NCT04737759|Experimental|Taking Care of Us|Taking Care of Us involves seven sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. The program is a communication-based, relationship-focused intervention that is strengths-based and fosters new skills to support couples managing heart failure. The goals of the program are to 1) target the couple with heart failure as a team; 2) increase shared appraisal within the couple; 3) improve communication skills within the couple; 4) improve collaboration within the couple and dyadic management of heart failure; 5) improve confidence within the couple; and 6) improve both individual and dyadic health and well-being.
9666067|NCT04737759|Active Comparator|SUPPORT|The SUPPORT program involves three sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. This arm is an educational intervention to support management of heart failure.
9666068|NCT04734028||PTRG-DES registry|After DES implantation, CAD patients were treated with DAPT with clopidogrel and aspirin. During hospitalization, their platelet function, genotype and inflammation biomarker were evaluated.
9666069|NCT04732195|Experimental|Pilocarpine microneedle patch|Participants will receive in their left forearm the microneedle patch. Upon application to skin, the MNs penetrate into the skin's upper layers and dissolve in the interstitial fluid to release the loaded drugs. MN patches are painless and can be administered with little or no training.
9666070|NCT04732195|Active Comparator|Pilocarpine Iontophoresis|Participants will receive in their right forearm the pilocarpine iontophoresis. Uses a gel disc containing Pilocarpine that drives the medication into the skin with a small electric current (iontophoresis) followed a 30-minute period of sweat collection.
9666071|NCT04731168|No Intervention|Control|
9666072|NCT04731168|Experimental|MAD|Patients will have a mandibular advancement device during the first postoperative night
9666073|NCT04730011|Experimental|Treatment Group|Patients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week.
9666074|NCT04729972|Experimental|NT-501 CNTF Implant|Participants from the NTMT-01/02 Extenstion study or participants from the NTMT-03 study which received an implant Studies with a CNFT implant in one eye will receive an implant in the fellow eye
9666075|NCT04728451|Active Comparator|Full-Time Spectacle Wear|Parents are asked to encourage their child to wear the spectacles full-time (all waking hours). A study staff member works closely with families throughout the child's participation to provide support and encouragement and to make suggestions on methods parents can use to maximize spectacle wear.
9984008|NCT04492410|Experimental|Experimental arm|screening using a rapid serological test with a drop of blood from a finger prick.
9666076|NCT04728451|Active Comparator|Ad-Lib Spectacle Wear|Parents are asked to encourage their child to wear the spectacles as much as possible for the initial 30 days after dispensing, and thereafter to continue to offer the spectacles to the child but not force the child to wear them if they resist or refuse. Limited support for parents is provided with regard to maximizing spectacle wear.
9666077|NCT04726891|Active Comparator|Continued M2M + SNS for 8 weeks|Participants who successfully watch and exercise at or above 40 minutes per week will continue doing M2M + SNS for the remaining 8 weeks of the study.
9666078|NCT04726891|Active Comparator|Augmented M2M + SNS + IBC for 8 weeks|Some participants with sub-optimal adherence in the first treatment stage will be randomized to one of two treatment groups in the second treatment stage. these participants will receive M2M plus social networking support augmented with individualized behavioral coaching. Individualized behavioral coaching involves a weekly coaching session to improve self-regulatory skills based on prior and individualized exercise prescription. The exercise prescriptions are determined by the coach and individual based on their current activity level and a 4-week goal. An example of tailoring the exercise prescribed involves setting a goal of completing the exercise routine one time for the upcoming week instead of three times. The coach will be trained in motivational interviewing to help the participant modify their exercise habits.
9666775|NCT04272840|Experimental|Low Glycemic Index|Standard care + Glycemic Index. Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record). Diabetes Canada and Dietitian's Canada resources on glycemic index will also be reviewed: the Glycemic Index Food Guide, Flip Cards, and Recipes.
9666776|NCT04272801|Experimental|Pre-operative endocrine therapy|All participants enrolled to the study will receive 3 months of pre-operative endocrine therapy (e.g. tamoxifen or aromatase inhibitors (AIs) such as letrozole, anastrozole, or exemestane). The choice and dose of endocrine therapy will be at the discretion of the treating medical oncologist.
9984009|NCT04484818|Active Comparator|Arm A (ADT, placebo)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive a placebo four times daily (QID) for 52 weeks in the absence of disease progression or unacceptable toxicity.
9750959|NCT00462228|Experimental|Memantine|Subjects will be titrated up to 20 mg of memantine per day for 12 weeks, followed by placebo for 12 weeks
9750960|NCT00462228|Placebo Comparator|Placebo|Subjects will be titrated up to 20 mg of placebo per day for 12 weeks, followed by memantine for 12 weeks
9750961|NCT00462280|Experimental|Two matched nevi group - Lovastatin|Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
9750962|NCT00462280|Placebo Comparator|Two Matched Nevi Group - Placebo|Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
9750963|NCT00462280|Experimental|One large nevi group - Lovastatin|Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
9750964|NCT00462280|Placebo Comparator|One Large Nevi Group - Placebo|Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
9750965|NCT00462306||Pregnant population|The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
9750966|NCT00462306||Non-Pregnant Population|The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery
9750967|NCT00462332|Experimental|High risk patientes|Category of risk will be defined according to biological features.
9750968|NCT00462332|Experimental|Low risk patients|Category of risk will be defined according to biological features.
9750969|NCT00462345|Experimental|Rituximab, Methotrexate|Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
9750970|NCT00462384|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
9750971|NCT00462423|Experimental|Single Arm, Open Label|Single Arm, Open Label trial of Abraxane and Avastin
9750972|NCT00462449|No Intervention|1|Individuals randomized into this group will only receive specialized therapy associated with this population.
9750973|NCT00462449|Experimental|2|In addition to appropriate therapy, this group will receive the FES device and be given instruction on how to complete specialized exercises utilizing this device.
9750974|NCT00462462|Experimental|1|Ethanol gel
9750975|NCT00462462|Active Comparator|2|Ethanol solution
9750976|NCT00462488|Active Comparator|Treatment Schedule A -|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 6 weeks. If free of disease at 12 weeks after the first instillation, the subject enters Maintenance dosing in which 30 mg of Vicinium is administered once per week for 3 weeks followed by 9 weeks of no therapy.~If the subject had histologically confirmed disease that is stage <T2, they repeat the Induction phase dosing. If the subject is free of disease, the subject enters the maintenance dosing phase of every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 51 (end-of-study [EOS])."
9782492|NCT01177137|Other|Standard of Care (SC)|The standard of care arm includes care as typically delivered in US military medical centers
9782493|NCT01177189|Other|Arm 1|Young healthy men and women aged 18-30
9782494|NCT01177189|Other|Arm 2|Older healthy men and women aged >70.
9782495|NCT01177228|Placebo Comparator|Placebo|Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
9782496|NCT01177228|Experimental|Vedolizumab 2 mg/kg|Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
9829853|NCT02549027|Experimental|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
9829854|NCT02549027|Experimental|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
9829855|NCT02549027|Experimental|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
9829856|NCT02549040|Experimental|Doravirine fixed sequence treatment|After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.
9829857|NCT02549196|Experimental|Cohort 1|Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
9829858|NCT02549196|Experimental|Cohort 2|Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
9829859|NCT02549196|Experimental|Cohort 1b|Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
9829860|NCT02549196|Experimental|Cohort 3c|Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.
9829861|NCT02549287|Experimental|SafeCare|SafeCare, an evidence-based home visiting program
9829862|NCT02549287|Active Comparator|Supportive Case Management|Child welfare services as usual
9829863|NCT02549339|Experimental|LEO 43204 gel|Treatment once daily for 3 days
9829864|NCT02549339|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
9829865|NCT02549352|Experimental|LEO 43204 gel|Treatment once daily for 3 days
9829866|NCT02549352|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
9829867|NCT02549365|Experimental|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
9829868|NCT02549365|Other|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
9829869|NCT02549508|Experimental|AutoCPAP with SensAwake On, then SenAwake Off|Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.
9829870|NCT02549508|Experimental|AutoCPAP with SensAwake Off, then SensAwake On|Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.
9829871|NCT02549573|Active Comparator|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
9829872|NCT02549573|Other|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
10201816|NCT05194943||10. UOC Chirurgia Generale, Ospedale Villa d'Agri, Potenza, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
10201817|NCT05194943||11. UOC di Chirurgia Generale e d'Urgenza, Presidio Ospedaliero ARNAS, Catania, Italy|All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
10201818|NCT05194930|Experimental|The ABC of Insomnia (Acceptance and the Behavioral Changes to|This is the new treatment arm that is being compared to CBT-I, standard treatment for insomnia.
9984010|NCT04484818|Experimental|Arm B (ADT, darolutamide)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive darolutamide QID for 52 weeks in the absence of disease progression or unacceptable toxicity.
9666779|NCT04263987|Active Comparator|Holmium Laser Enucleation of Prostate|Traditional holmium laser enucleation of the prostate as currently performed
9666780|NCT04263987|Experimental|Moses Holmium Laser Enucleation of Prostate|holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.
9666781|NCT04263181||Cohort 0|"-A technical run-in of 5 patients with any of the following:~Standard cytarabine/idarubicin induction, includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) & idarubicin 12 mg/m2 per day for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle.~Azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle~Decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter.~Azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
9666782|NCT04263181||Cohort 1|"Patients treated with cytarabine/idarubicin induction therapy~Patients will receive a standard cytarabine/idarubicin induction, which includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) and idarubicin 12 mg/m2 per day in 0.9% normal saline over 15-30 minutes for 3 consecutive days (Days 1-3). Other standard cytarabine-based induction protocols are allowed (e.g. cytarabine/daunorubicin or Vyxeos)."
9666783|NCT04263181||Cohort 2|"Patients treated with decitabine~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle."
9666784|NCT04263181||Cohort 3|"Patients treated with azacitidine~Patients will receive azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle"
9666785|NCT04263181||Cohort 4|"Patients treated with decitabine + venetoclax~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
9666786|NCT04263181||Cohort 5|"Patients treated with azacitidine + venetoclax~Patients will receive azacitidine 75 mg/m2/day as a 1-hour infusion or by subcutaneous injection on consecutive Days 1-7 or on day 1-5 and 8-9 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
9666787|NCT04259645|Active Comparator|Low Volume group|30 subjects randomized to Low Volume will receive unilateral Quadratus Lumborum block type II. Each block of 0.375% Bupivacaine x 20 ml
9666788|NCT04259645|Experimental|High Volume group|30 subjects randomized to High Volume will receive unilateral Quadratus lumborum block Type II. Each block of 0.375% Bupivacaine x 20 mL + Normal Saline Solution 20 mL
9666789|NCT04258358|Experimental|People living with dementia intervention group|"Long term care and support are provided in a dementia care friendly environment with emphasis on 'the person's home'. Each resident's home carries a registered address to symbolise the person's home. Based on needs and strengths, people living with dementia and their families are supported to choose the technology to enable the person's independence plus developing new and maintaining existing skills. Examples of supportive and assistive technology include mobile devices, memory clocks, gas and flood detectors, sensor mats and global positioning system trackers or safe return ornaments. Routine care follows a holistic integrated health and social care plan tailored to the needs of the person living with dementia.~Respite care provided in guesthouse facilities embody a similar approach only for a shorter period of time without assigning registered home addresses."
9666790|NCT04258358|No Intervention|People living with dementia control group|"People living with dementia in need of long-term rehabilitation or recovery for at least eight months; and people living with dementia in need of respite care for up to 14 days~People living with dementia will continue to use standard care. Standard care in this respect constitutes usual health and social care or any other nationally acceptable form of therapy that people living with dementia would seek to use."
9666791|NCT04258150|Experimental|Experimental|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 6 mg/kg (up to 480 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 (± 3 days) twice in total every 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Tocilizumab 8 mg/kg is given IV on day 1 (± 3 days) over 1-hour, repeated every 4 weeks. Tocilizumab infusion over 30 minutes is allowed after 5. infusion in the absence of infusion related events.
9666792|NCT04257578|Experimental|Treatment (acalabrutinib, axicabtagene ciloleucel)|Beginning up to 3 weeks and at least 24 hours prior to leukapheresis, patients receive acalabrutinib PO every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also receive axicabtagene ciloleucel IV at 36-96 hours after completion of lymphodepleting chemotherapy.
9666793|NCT04253587|Experimental|LabyrinthVR Trackers|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via participant ambulation wearing leg-position trackers.
9666794|NCT04253587|Experimental|LabyrinthVR Scoot|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
9666795|NCT04253587|Placebo Comparator|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
9666796|NCT04253587|Active Comparator|Coherence|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive rhythm training game.
9984011|NCT04482803|Experimental|Carbon nanoparticles labelled lymph nodes group|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes before NST.
9666797|NCT04251156|Experimental|Semaglutide|Once-weekly injections of gradually increased doses of semaglutide
9666798|NCT04251156|Placebo Comparator|Placebo (semaglutide)|Once-weekly injections of gradually increased doses of semaglutide placebo
9666800|NCT04250493|Experimental|MSA patient|Patients will be recruited at the French Reference Center for MSA.
9666801|NCT04250493|Other|Control|Healthy volunteer matched for age (+/- 5years) and sex with MSA patient.
9666802|NCT04246918|Placebo Comparator|Standard Treatment Group|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. This group would not receive any supplement other than the prescribed diet. Whey protein will be included in this group.
9666803|NCT04246918|Active Comparator|Intervention Arm|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
9666804|NCT04242199|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
9666805|NCT04242199|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
9666806|NCT04242199|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
9666807|NCT04239456|Experimental|Group A|Receive intervention 2 weeks after group assignment.
9666808|NCT04239456|Other|Group B|Wait List - Receive intervention 3 months after initial testing.
9666809|NCT04237025|Experimental|Nordic walking exercise group|Supervised Nordic walking exercise training 3 times per week for the first two weeks and 2 times per week for next four weeks (total 6 weeks). In addition to independent Nordic walking exercise twice weekly during intervention phase and three times weekly during the 3-month followup phase.
9666810|NCT04234867|Experimental|Dapagliflozin - Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of 250µg ACTH (Synacthen)
9666811|NCT04234867|Experimental|Dapagliflozin and Placebo Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of Placebo matching Synacthen
9666812|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of 250µg ACTH (Synacthen)
9666813|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Placebo Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of Placebo matching Synacthen
9666814|NCT04234204|Experimental|Fezolinetant group|Participants will receive fezolinetant once daily for 24 weeks.
9666815|NCT04234204|Placebo Comparator|Placebo group|Participants will receive matching placebo for 12 weeks, and then receive fezolinetant for 12 weeks once daily.
9666816|NCT04230356|Experimental|VSTs to Prevent|VSTs are given through an IV infusion 21 days after transplant to see if the VSTs will help prevent a viral infection.
9666817|NCT04230356|Experimental|VSTs to Treat|VSTs will be given only if a viral infection develops.
9666818|NCT04229940|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
9666819|NCT04229940|Active Comparator|No bridging|The hernia defect is left without closure prior to application of the mesh.
9666820|NCT04227756|Experimental|LSD-100|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
9666821|NCT04227756|Active Comparator|Psilocybin-20|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
9666822|NCT04227756|Active Comparator|Mescaline-300/500|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
9666823|NCT04227756|Placebo Comparator|Placebo|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
9666824|NCT04227730||group A|group A (+ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
9666825|NCT04227730||group B|group B (-ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
9666826|NCT04224545|Experimental|Colchicine|Colchicine 1 mg day
9666827|NCT04224545|Placebo Comparator|Placebo|Sugar pill
9666828|NCT04223830|Experimental|Exalt DScope 01B|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
9666829|NCT04221178||MRD-Negative Participants|
9666830|NCT04219163|Experimental|CLL-1.CAR|Group A
9666831|NCT04218591|Active Comparator|PRP|Intra-articular injection PRP
9666832|NCT04218591|Placebo Comparator|Saline|Intra-articular injection Saline
9750977|NCT00462488|Active Comparator|Treatment Schedule B|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 12 weeks followed by 1 week of no therapy.~If 13 weeks after the first instillation of Vicinium the subject is free of disease, they have a break from therapy before entering Maintenance dosing in which 30 mg of Vicinium is administered once weekly for 3 weeks followed by 9 weeks of no therapy. If the subject is free of disease, additional maintenance cycle(s) are repeated every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 57 (EOS)."
9750978|NCT00462501|Experimental|Chemotherapy and Bevacizumab With or Without Radiation|FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
9750979|NCT00462605|Experimental|Arm I|Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.
9750980|NCT00462644|Active Comparator|Etomidate|Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications
9750981|NCT00462644|Active Comparator|Fentanyl-Midazolam|Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.
9750982|NCT00462670|Placebo Comparator|1|0mg
9750983|NCT00462670|Experimental|2|15mg OPC-41061
9750984|NCT00462709|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 7 days.
9750985|NCT00462722|Placebo Comparator|Placebo pre and post exercise|placebo before and after musculoskeletal-loading exercise
9750986|NCT00462722|Experimental|Placebo pre and ibuprofen post exercise|placebo before and ibuprofen after musculoskeletal-loading exercise
9750987|NCT00462722|Experimental|Ibuprofen pre and placebo post exercise|ibuprofen before and placebo after musculoskeletal-loading exercise
9750988|NCT00462735|Experimental|Advanced Head and Neck Cancer|Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck
9750989|NCT00462761|Experimental|AC220|Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
9750990|NCT00462826|Experimental|Treatment (aflibercept)|Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9750991|NCT00462839|Experimental|Calibrated drapes viewed first|Caregivers were shown calibrated drape demonstrating level of blood and asked to estimate amount of blood in collection bag. These same individuals were then crossed over and shown non-calibrated drapes and asked to estimate the amount of blood they contained.
9750992|NCT00462839|Active Comparator|Non-calibrated drapes viewed first|Standard vaginal delivery drape (non-calibrated) was shown to caregiver who was asked to estimate amount of blood. These same individuals were then crossed over and shown calibrated delivery drapes and asked to estimate the amount of blood they contained.
9750993|NCT00462865|Experimental|Gemcitabine and Capecitabine and Avastin|Avastin administered concurrently with chemotherapy (Gemcitabine + Capecitabine) for six cycles followed by single agent Avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
9750994|NCT00462917|Experimental|Pleiotropic info, in-person disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed in-person during an APOE-based genetic risk assessment
9750995|NCT00462917|Experimental|AD-only info, phone disclosure|Alzheimer's disease risk information only is disclosed via telephone during an APOE-based genetic risk assessment
9750996|NCT00462917|Experimental|Pleiotropic info, phone disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed via telephone during an APOE-based genetic risk assessment
9750997|NCT00462917|Active Comparator|AD-only info, in-person disclosure|Alzheimer's disease risk information only is disclosed in-person during an APOE-based genetic risk assessment
9750998|NCT00462982|Experimental|Sunitinib|Patients will be treated with 50 mg daily for four out of every six weeks.
9750999|NCT00463047|Experimental|Fentanyl Buccal Tablets (FBT)|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
9751000|NCT00463047|Active Comparator|Oxycodone|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
9751001|NCT00463060|Experimental|Treatment|Participants treated with chemotherapy and radiotherapy
9751002|NCT00463151|Placebo Comparator|1|0mg rebamipide
9751003|NCT00463151|Experimental|2|60mg rebamipide
9751004|NCT00463151|Experimental|3|150mg rebamipide
9751005|NCT00463151|Experimental|4|300mg rebamipide
9782497|NCT01177228|Experimental|Vedolizumab 6 mg/kg|Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
9782498|NCT01177228|Experimental|Vedolizumab 10 mg/kg|Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.
9782499|NCT01177293|Active Comparator|treatment A - reference w/ water|
9782500|NCT01177293|Experimental|Treatment B - ODT (test) w/o water|
9751006|NCT00463229|Experimental|Interprofessional Team Approach|Participants in the experimental group will receive home care services from a team of professional service providers [Community Care Access Centre (CCAC) Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist] and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
9751007|NCT00463229|No Intervention|Usual Home Care Services|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessment and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessment with clients.
9751008|NCT00463346|Experimental|Acamprosate|Acamprosate
9751009|NCT00463346|Placebo Comparator|placebo|placebo
9751010|NCT00463385|Experimental|Prednisone|"Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants were discontinued from the study."
9751011|NCT00463385|Experimental|Pomalidomide|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase.~After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
9751012|NCT00463385|Experimental|Pomalidomide 2 mg + Prednisone|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
9751013|NCT00463385|Experimental|Pomalidomide 0.5 mg + Prednisone|"Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
9751014|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
9751015|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
9751016|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
9751017|NCT00463437|Active Comparator|Prevenar™ + Menitorix™|Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
9782501|NCT01177384|Experimental|Sitagliptin|Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily [t.i.d.])
9782502|NCT01177384|Placebo Comparator|Placebo|Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)
9782503|NCT01177410|Placebo Comparator|Placebo|
9984012|NCT04481412|Experimental|Study group|(33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
9984013|NCT04481412|Active Comparator|Control group|(33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.
9984014|NCT04480255|Active Comparator|Group 1: Standard of Care|Parents of infants born from date July 2020-December 2020
9984015|NCT04480255|Active Comparator|Group 2: NICU2HOME+ app|Parents of infants born from mid Jan 2021-May2021
9665003|NCT05229055|Active Comparator|subcutanous ketamine|Ketamine dosing by subcutanous route was based on previous reports use for post operative pain management. . The results of these reports revealed that low-dose ketamine 20-60 mg (0.5mg/kg for patients weighing 40-120 kg) showed an over all decrease in either the amount of opioid used or the amount of pain experienced (10, 11).For our study, we decided to chose a dose of 20mg of ketamine for all patients administered via 1ml insulin syringe once subcutaneously.
9665004|NCT05228184|Experimental|Treatment|Tirosint®-SOL (levothyroxine sodium) oral solution (IBSA Pharma Inc.) at the following strengths: 25, 37.5, 44, 50, 62.5, 75, 88, 100 mcg.
9665005|NCT05228184|Active Comparator|Control|Crushed levothyroxine sodium tablets
9665006|NCT05228106||Patients eligible for [68Ga]-PSMA-617-PET|All cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with a [68Ga]-PSMA-617 dose calculated depending on the characteristics of the PET tomograph and patient weight (maximum 370 MBq). 60-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.
9665007|NCT05226676|Experimental|Real rTMS group|Repetitive TMS at 20Hz frequency over the M1 will be performed for five consecutive days for 2 weeks (using 90% of the resting motor threshold/total of 500 pulses). The rTMS will be applied through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
9665008|NCT05226676|Sham Comparator|Sham group|Sham stimulation will be performed for five consecutive days for 2 weeks (using 90% of the resting motor threshold/total of 500 pulses). For the sham stimulation a sham coil will be used.
9665009|NCT05226637|Sham Comparator|Control group|"In addition to standard of care, with BoNTA injections, the randomly selected control group will be treated with a sham head to the flexor muscles of the upper extremity. The sham component made by the manufacturers is designed such that the internal pneumatic projectile is physically blocked from providing high energy impact with the contact surface, however the handset looks and sounds identical. In doing so, the sham head still actuates and makes the same sounds but produces no shockwave~ESWT will be apply on every candidate over the anterior region of the upper extremity injected with the BoNTA."
9665010|NCT05226637|Experimental|Experimental group with ESWT|"The randomly selected Study group will be comprised of patients who will receive the appropriate treatment with BoNTA in addition to actual ESWT (extra-corporeal shock wave therapy.~ESWT is an existing technology that uses a device that generates high intensity shockwaves. These shock waves are generated outside of the body (extra corporeal) but penetrate through the skin surface to underlying structures and tissue. ESWT has been historically used safely and for many years to treat common musculoskeletal (MSK) conditions.~For the purpose of the study these variables are standardized. We will treated with the Storz Duolith SD1 and we will use the D15 head 3000 number of shocks, 2.5 bar, 15 Hz over the same area of upper extremity described for the control group."
9665011|NCT05223257|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
9665012|NCT05223257|No Intervention|Control group|"Children will continue standard care for 8 weeks~Subject allocated to standard care group will have to continue what they normally do; they (if > 13 years) or their parents will have to fill a diary in which they will write the rehabilitative activities they do, specifying their intensity and whether these activities are more focused on the lower limbs or upper limbs."
9665013|NCT05220371|Experimental|Collagen|15g of collagen peptides ingested daily
9665014|NCT05220371|Placebo Comparator|Placebo|15g of Placebo ingested daily
9665017|NCT05219825|Experimental|Breathwork group|Treatment-seeking individuals with substance use disorders who will participate in the 1-week breathwork workshop.
9665018|NCT05219617|Experimental|Carisbamate 200 mg BID arm|"Age: 4 to <12y* Titration: 2 mg/kg BID Maintenance: 4 mg/kg BID~Age: ≥12 y Titration: 100 mg BID Maintenance: 200 mg BID"
9665019|NCT05219617|Experimental|Carisbamate 300 mg BID arm|"Age: 4 to <12y* Titration: 2.75 mg/kg BID Maintenance: 5.5 mg/kg BID~Age: ≥12 y Titration: 150 mg BID Maintenance: 300 mg BID"
9665020|NCT05219617|Placebo Comparator|Placebo matched to 200 mg BID arm|"Age: 4 to <12y* Titration: Volume equivalent to 2 mg/kg BID Maintenance: Volume equivalent to 4 mg/kg BID~Age: ≥12 y Titration: Volume equivalent to 100 mg BID Maintenance: Volume equivalent to 200 mg BID"
9665021|NCT05219617|Placebo Comparator|Placebo matched to 300 mg BID arm|"Age: 4 to <12y* Titration: Volume equivalent to 2.75 mg/kg BID Maintenance: Volume equivalent to 5.5 mg/kg BID~Age: ≥12 y Titration: Volume equivalent to 150 mg BID Maintenance: Volume equivalent to 300 mg BID"
9665022|NCT05218538||Learning e-cohort|Includes the entire population within Clalit Healthcare's electronic records database which spans from the year 2000 to 2021.
9665023|NCT05218538||FIB-4 score group|One of the two validation population invited to the clinic. The FIB-4 score group are individuals invited by their score.
9665024|NCT05218538||Model based group|"One of the two validation population invited to the clinic:~The Model based group are individuals invited by their predicted time-to-event to liver cirrhosis diagnosis."
9665025|NCT05217758|Experimental|Mifepristone|Glucocorticoid Receptor (GR) blockade using the generic drug mifepristone
9665026|NCT05217758|Placebo Comparator|Placebo|
9665027|NCT05217446|Experimental|Arm A: encorafenib, cetuximab and pembrolizumab|Participants receive encorafenib orally + cetuximab IV + pembrolizumab IV.
9829873|NCT02549859|Experimental|Deep Brain Stimulation (DBS)|All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.
9829874|NCT02550106|Experimental|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
9829875|NCT02550132|Experimental|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
9835810|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 4 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).
9835811|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 30 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).
9835812|NCT02756572|Experimental|Treatment (chemotherapy, HCT)|See Detailed Description
9835813|NCT02756624|Experimental|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
9835814|NCT02756624|Placebo Comparator|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
9835815|NCT02756637||Prognostic|Patients with NLR who completed curative therapy (surgery with or without chemo)
9835816|NCT02756637||Predictive|Patients with NLR who were assigned to a trial arm (chemo or no chemo)
9835817|NCT02756650|Experimental|Canakinumab|Canakinumab was administered monthly
9835818|NCT02756689|Active Comparator|Inpatient cervical Ripening|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
9835819|NCT02756689|Active Comparator|Outpatient cervical Ripening|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
9835820|NCT02756819||Azilsartan Medoxomil|Overweight or obese participants with hypertension who received azilsartan medoxomil tablets, orally, as prescribed by physician according to local summary of product characteristics (SmPC) were observed for approximately 6 months.
9835821|NCT02756832||Alogliptin Benzoate|Participants with diabetes mellitus type 2 (T2DM) who received alogliptin benzoate tablets, orally, as prescribed by physician according to Russian summary of product characteristics (SmPC) were observed for approximately 6 months.
9835822|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
9835823|NCT02756949|Experimental|Smartphone-enabled app for linkage to care|Participants in this arm are randomised to receive the smartphone application which provides direct access to HIV-related laboratory test results.
9835824|NCT02756949|No Intervention|Standard of care|Participants in this arm are randomised to receive standard of care services.
10201819|NCT05194930|Active Comparator|Cognitive-Behavioral Therapy for Insomnia|This is the standard treatment for insomnia that is being compared to the new treatment (ABCI).
10201820|NCT05194917|Experimental|OSMI|
9665028|NCT05217446|Active Comparator|Arm B: pembrolizumab|Participants receive pembrolizumab IV.
9782504|NCT01177410|Experimental|Mesalamine Granules 750 mg|
9782505|NCT01177410|Experimental|Mesalamine Granules 1500 mg|
9782506|NCT01177553|Active Comparator|Surgery Group|"Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.~Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures."
10201821|NCT05194917|Active Comparator|Control Motivational Message|
10201822|NCT05194917|No Intervention|Control Treatment as Usual|
10201823|NCT05194904|Active Comparator|group 1|ketorolac group: number = 30 patients , time : after intubation, dose 0.9 mg/kg
10201824|NCT05194904|Active Comparator|group 2|Dexmedetomidine group: number : 30 patients, time : after intubation, dose 1 μg/kg
10201825|NCT05194878|Experimental|Neoadjuvant chemotherapy|12 weeks of FOLFOXIRI neuoadjuvantly followed by surgery and adjuvant chemotherapy
10201826|NCT05194878|Active Comparator|Postoperative chemotherapy|surgery followed by 24 weeks of FOLFOX or CapeOX or Cape
10201827|NCT05194865||CMR viability study group|"Diagnostic Test: CMR Basic CMR data including LV and RV volumes, SWMA reported, EF and wall thinning will be collected.~SWMA from SSFP sequences will be reported and numbered according to the usual (1 normal, 2 hypokinetic, 3 akinetic, 4 dyskinetic, 5 aneurysmal).~Data of viability assessed with LGE imaging with scar measurement using standard deviation method with SD of 4-5 will be used.~AHA 17 segment model will be used as a reference for LV segmentation.~Viability scoring will be calculated for each segment based on the transmurality index, in a semiautomated method, with no scar given 0, 1-25% subendocardial scar given score 1, 25-50% given 2, 50-75% given 3, >75% as 4.~Wall thinning will be given 0 or 1 score for each segment, with 1 given for <6 mm thickness."
10201828|NCT05194865||direct revascularization group|Direct Coronary revascularization
10201829|NCT05194852|Active Comparator|group 1|Group I received ultrasound-guided hydrodilatation with corticosteroid, saline, and local anesthetic via posterior intra-articular approach
10201830|NCT05194852|Experimental|group 2|group II received the same ultrasound-guided hydrodilatation via anterior rotator interval approach
10201831|NCT05194826|Experimental|Fascia lata membrane|
9984707|NCT03809663|Experimental|Part A: Tezepelumab 280 mg|"Tezepelumab 280 mg administered via SC injection Q2W from Week 2 for a maximum of 52 weeks.~All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive their randomized dose of 280 mg Q2W from Week 2.~Participants defined as non-responders (those who did not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
9984708|NCT03809663|Experimental|Part A: Tezepelumab 420 mg|Tezepelumab 420 mg administered via SC injection Q2W for a maximum of 52 weeks.
9665029|NCT05216991||TetraGraph monitoring on dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
9665030|NCT05216991||TetraGraph monitoring on non-dominant hand|Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care
9665031|NCT05216770|Other|Spatial and temporal CNS pathophysiology of laryngeal dystonia and voice tremor|Simultaneous fMRI with EEG and MEG imaging will be used to examine neural dynamics during phonation.
9665032|NCT05216770|Experimental|Sensorimotor modulations on CNS pathophysiology of laryngeal dystonia and voice tremor|"Topical laryngeal block will be used to modulate somatosensory feedback from the laryngeal mucosa during speech production and examine associated changes in brain activity.~The role of auditory feedback processing on task-induced speech sensorimotor activity will be examined using MEG imaging during perturbing pitch or formants of auditory feedback, unpredictably during speech production, and examining the behavioral and neural correlates of the resulting within-trial compensation responses."
9665033|NCT05216770|Other|Motor learning and CNS pathophysiology of laryngeal dystonia and voice tremor|"Implicit learning of the production of motor sequences will be examined during simultaneous fMRI/EEG and MEG imaging.~Sensorimotor adaptation of speech production during MEG imaging will be examined during perturbing pitch or formants of auditory feedback consistently during speech production and examining the behavioral and neural correlates of the resulting across-trial adaptation responses."
9665034|NCT05214547|Experimental|Experimental Group|The patients received shock-wave exposure (energy flux density= 0.12 mJ/mm2, at 8 Hz), twice a week, for six weeks. Standard physiotherapy care was applied.
9665035|NCT05214547|Placebo Comparator|PlaceboGroup|In the placebo group, the device applicator was positioned in the same way as the experimental shock-wave group. The previously recorded 8 Hz pulsed shock wave sounds were played, as if the actual application was being performed, however the device itself was off during the session, and its pedal was not pressed. Standard physiotherapy care was applied.
9665036|NCT05213130|Experimental|Information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., as well as a clear reminder to inform donors that their blood has saved patient's life.
9665037|NCT05213130|No Intervention|Non-information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., but there will be no reminder to inform donors that their blood has saved patient's life.
9665038|NCT05212831|No Intervention|Standard of Care (SOC)|SOC is defined as the patient symptoms or complications based treatment.
9665039|NCT05212831|Experimental|Portable Oxygen Concentrator|"Inogen One® G4 Portable Oxygen Concentrator (POC) is used on a prescriptive basis by subjects requiring supplemental oxygen. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the subject.~Inogen One® G4 is designed to provide a flow of high purity oxygen. Inogen One® G4 may be used in home, institution, vehicle and various mobile environments."
9665040|NCT05212701|Experimental|Reparixin|Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) three times daily (total dose of 3600 mg/day) with no interruptions during each cycle.
9665041|NCT05212701|Placebo Comparator|Placebo|Masked placebo will be administered orally (2 tablets) three times daily with no interruptions during each cycle.
9751018|NCT00463476|Experimental|2-year olds|Healthy children 2 years of age (±3 months) who had previously received all vaccinations recommended under the Sri Lankan childhood immunization schedule according to their age. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12 and 13 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
9751019|NCT00463476|Experimental|5-year olds|Healthy children 5 years of age (±3 months) that met all other eligibility criteria. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12, 13, and 24 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
9751020|NCT00463567|Experimental|Indacaterol 150 µg (Continued Into Stage 2)|"In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
9751021|NCT00463567|Experimental|Indacaterol 300 µg (Continued Into Stage 2)|"In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
9751022|NCT00463567|Active Comparator|Tiotropium 18 µg (Continued Into Stage 2)|"Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
9751023|NCT00463567|Placebo Comparator|Placebo (Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
9751024|NCT00463567|Experimental|Indacaterol 75 µg (Not Continued into Stage 2)|"In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
9751025|NCT00463567|Experimental|Indacaterol 600 µg (Not Continued Into Stage 2)|"In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
9751026|NCT00463567|Active Comparator|Formoterol 12 µg (Not Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
9751027|NCT00463580|Experimental|Infliximab|Participants in this arm will receive an infusion of infliximab.
9751028|NCT00463580|Placebo Comparator|Placebo|Participants in this arm will receive an infusion of normal saline.
9751029|NCT00463606|Experimental|ABT-335 and Rosuvastatin Calcium|ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
9751030|NCT00463606|Active Comparator|ABT-335|ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
9751031|NCT00463606|Active Comparator|Rosuvastatin Calcium|Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks
9751032|NCT00463684|Experimental|All subjects|Healthy infants 9 months of age (plus or minus 2 weeks) that met the eligibility criteria. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV) and one dose of live, attenuated measles vaccine.
9751033|NCT00463788|Experimental|cisplatin and cetuximab|
9751034|NCT00463788|Active Comparator|cisplatin|
9751035|NCT00463801|Experimental|Daptomycin|350 mg of Daptomycin was supplied as sterile lyophilized powder in glass vials. Each vial was to be reconstituted with 7 mL of normal saline or water for injection, to give a 50 mg/mL drug concentration. Daptomycin was to be administered as a 30-minute intravenous infusion, once daily for at least 7 days, at the dose of 4 mg/Kg, up to a maximum of 14 days.
9984709|NCT03809663|Experimental|Part B: Placebo and Topical Corticosteroids Regimen|Matching placebo administered via SC injection Q2W with topical corticosteroids (TCS) for a maximum of 52 weeks.
10201832|NCT05194826|Active Comparator|Connective tissue graft both with xenogenic lamina membrane|
10201833|NCT05194813|Experimental|Hydrophilic sandblasted and acid-etched dental implants|
10201834|NCT05194813|Active Comparator|Conventional hydrophobic sandblasted and acid-etched dental implant|
10201835|NCT05194774||GT overgrowth group|pediatric patients with greater trochanter overgrowth
10201836|NCT05194683|Experimental|Letter Writing Arm|Relational letter writing intervention
10201837|NCT05194683|No Intervention|Control Arm|No intervention
10201838|NCT05194670|Experimental|Acunex Vario AN6V|Patient will receive the enhanced depth of focus IOL during cataract surgery
10201839|NCT05194670|Experimental|Acunex AN6|Patient will receive the monofocal IOL during cataract surgery
10201840|NCT05194657|Experimental|Acrysof IQ Vivity|Patient will receive the enhanced depth of focus IOL during cataract surgery
9751036|NCT00463840|Experimental|Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6|"Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours."
9751037|NCT00464087|Active Comparator|Heparin|Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
9751038|NCT00464087|Active Comparator|Bivalirudin|Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
9751039|NCT00464204|Experimental|Voluven® Arm|
9751040|NCT00464204|Active Comparator|0.9 % NaCl|
9751041|NCT00464269|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
9751042|NCT00464269|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
9751043|NCT00464269|Experimental|BRV 20mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
9751044|NCT00464269|Experimental|BRV 50mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.
9751045|NCT00464308|Active Comparator|001|Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
9751046|NCT00464308|Active Comparator|002|Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
9751047|NCT00464308|Active Comparator|003|Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
9751048|NCT00464334|Experimental|Placebo to V950/IMX 0 mcg|Participants receive Placebo to V950/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751049|NCT00464334|Experimental|Placebo to V950/IMX 16 mcg|Participants receive Placebo to V950/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751050|NCT00464334|Experimental|V950 0.5 mcg/IMX 0 mcg|Participants receive V950 0.5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751051|NCT00464334|Experimental|V950 0.5 mcg/IMX 16 mcg|Participants receive V950 0.5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751052|NCT00464334|Experimental|V950 0.5 mcg/IMX 47 mcg|Participants receive V950 0.5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751053|NCT00464334|Experimental|V950 0.5 mcg/IMX 94 mcg|Participants receive V950 0.5 mcg/IMX 94 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751054|NCT00464334|Experimental|V950 5 mcg/IMX 0 mcg|Participants receive V950 5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751055|NCT00464334|Experimental|V950 5 mcg/IMX 16 mcg|Participants receive V950 5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751056|NCT00464334|Experimental|V950 5 mcg/IMX 47 mcg|Participants receive V950 5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751057|NCT00464334|Experimental|V950 50 mcg/IMX 0 mcg|Participants receive V950 50 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751058|NCT00464334|Experimental|V950 50 mcg/IMX 16 mcg|Participants receive V950 50 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
9751059|NCT00464438|Experimental|1|
9751060|NCT00464438|Active Comparator|2|
9751061|NCT00464464|Active Comparator|1|cognitive-behavioral therapy
9751062|NCT00464464|No Intervention|2|standard medical care
9782507|NCT01177553|Active Comparator|Expectant Management Group|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
9782508|NCT01177709|Experimental|Metformin|
9782509|NCT01177722|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)|
9782510|NCT01177722|Experimental|Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)|
9782511|NCT01177722|Experimental|Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)|
9782512|NCT01177722|Active Comparator|Group 4: Active Control|
9782513|NCT01177735|Experimental|Pomalidomide|
9782514|NCT01177787|Active Comparator|zeltiq|Cryolipolysis had been done for 1 hour on ipsilateral thigh fat through Zeltiq machine.
9782515|NCT01177787|Sham Comparator|electrical stimulation|Lipolysis had been done for 30 minutes on controlateral thigh fat through amplitude modulated frequency.
9984710|NCT03809663|Experimental|Part B: Tezepelumab 420 mg and Topical Corticosteroids Regimen|Tezepelumab 420 mg administered via SC injection Q2W with TCS for a maximum of 52 weeks.
9751063|NCT00464490|No Intervention|Standard Hospital Ventilation Weaning Protocol|Control. Hospital weaning protocol
9751064|NCT00464490|Experimental|Dexmedetomidine for Extubation|Dexmedomidine infusion to facilitate extubation
9751065|NCT00464542|Other|Metronidazole|Observational before and after treatment Drug: Metronidazole 500 mg, taken by mouth, two times a day, 7 days
9751066|NCT00464620|Experimental|Dasatinib, 70 mg, twice daily|Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
9751067|NCT00464646|Experimental|1|"Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)~Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer"
9751068|NCT00464672|Experimental|Influenza virus vaccine|
9751069|NCT00464672|Active Comparator|Comparator influenza vaccine|
9751070|NCT00464685|Experimental|700 µg Dexamethasone Implant and Laser Photocoagulation|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
9751071|NCT00464685|Sham Comparator|Sham Implant and Laser Photocoagulation|Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
9751072|NCT00464698|Experimental|All Study Participants|Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)
9751073|NCT00464711|Other|Escitalopram|single arm
9751074|NCT00464737|Placebo Comparator|Placebo|Placebo
9751075|NCT00464737|Experimental|Rotigotine 4 mg|4 mg/24 hrs
9751076|NCT00464737|Experimental|Rotigotine 8 mg|8 mg/24 hrs
9751077|NCT00464815|Experimental|Group A|Subjects of 11-17 years of age who will receive GSK134612
9751078|NCT00464815|Active Comparator|Group B|Subjects of 11-17 years of age who will receive MencevaxTM ACWY
9751079|NCT00464945|Experimental|1|
9751080|NCT00464945|Active Comparator|2|
9751081|NCT00465088|Experimental|1|
9751082|NCT00465088|Experimental|2|
9751083|NCT00465101|Other|GreenLight HPS|
9751084|NCT00465179|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off.
9751085|NCT00465270|Experimental|Device|AMPLATZER PFO Occluder
9751086|NCT00465270|Active Comparator|Standard or Care - Medical Management|Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
9751087|NCT00465361|No Intervention|Baseline Performance|Observation of baseline performance
9751088|NCT00465361|Experimental|Post-intervention Performance|Observation of performance post-intervention
9751089|NCT00465530|Experimental|2|Saline plus Gentamycin
9751090|NCT00465530|Placebo Comparator|1|Saline
9751091|NCT00465569|Experimental|Active Treatment|Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
9751092|NCT00465569|Placebo Comparator|Placebo|
9751093|NCT00465595|Experimental|Low Dose First, High Dose Second|The Low-Dose-1st Group received the low dose of psilocybin on the first session and the high dose on the second session
9751094|NCT00465595|Experimental|High Dose First, Low Dose Second|The High-Dose-1st Group received the high dose of psilocybin on the first session and the low dose on the second session
9751095|NCT00465647|Experimental|≥ 28 Days to < 13 Months|infant and toddler
9751096|NCT00465647|Experimental|≥ 13 months to < 5 years|young child
9751097|NCT00465647|Experimental|≥ 5 years to < 12 years|older child
9751098|NCT00465647|Experimental|≥ 12 years to < 17 years|adolescent
9751099|NCT00465738|Experimental|incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 5.0 mL resulted in a dose of 20 units per 1.0 mL."
9751100|NCT00465738|Active Comparator|incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 mL sterile of NaCl 0.9% solution without preservatives. Dilution with 2.0 mL resulted in a dose of 50 units per 1.0 mL."
9751101|NCT00465816|Experimental|Nimenrix + Twinrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
9751102|NCT00465816|Active Comparator|Nimenrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
9751103|NCT00465816|Active Comparator|Twinrix Group|Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
9751104|NCT00465894|Active Comparator|Extended Release Tolterodine LA|An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
9751105|NCT00465894|Active Comparator|Intra Vaginal Estradiol Cream|For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.
9751106|NCT00465972|Placebo Comparator|Placebo|Placebo
9751107|NCT00465972|Active Comparator|2|Doxepin
9751108|NCT00465972|Active Comparator|3|Temazepam
9751109|NCT00465985|Experimental|Part I, Part II-arm1, & Part III|
9751110|NCT00465985|Placebo Comparator|Part II - arm 2|
9751111|NCT00466167|Other|Pramipexole ER|
9751112|NCT00466167|Other|Pramipexole IR|
9751113|NCT00466167|Placebo Comparator|Placebo|
9751114|NCT00466193|Experimental|Zolpidem 3.5mg|
9751115|NCT00466193|Placebo Comparator|Placebo|
9751116|NCT00466206|Experimental|3MP - Treatment Arm|Magnetic Mini-Mover Procedure using the Magnimplant and Magnatract
9751117|NCT00466310|Active Comparator|Aripiprazole for 4 weeks|Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
9751118|NCT00466310|Active Comparator|Risperidone for 4 weeks|Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
9751119|NCT00466310|Other|Healthy volunteers|Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.
9751120|NCT00466323|Experimental|FMPO Condition|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
9751121|NCT00466323|Active Comparator|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
9751122|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin|Regimen A: docetaxel 75 milligrams per square meter (mg/m^2), intravenous (IV) is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 milligrams (mg) oral (po), twice daily (BID) every day. In Cycle 1, enzastaurin is given as a loading dose of 1125 mg on the day prior to docetaxel and prednisone therapy, followed by enzastaurin 500 mg po, daily (QD) for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
9751123|NCT00466440|Placebo Comparator|docetaxel + prednisone + placebo|Regimen B: docetaxel 75 mg/m^2, IV is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, placebo is given as a loading dose on the day prior to docetaxel and prednisone therapy, followed by po, QD placebo for the remaining Period 2 (chemotherapy) and Period 3 (maintenance), until unblinding.
9751124|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin (modified Regimen A)|Modified Regimen A, including pharmacokinetic (PK) characterization: Participants were treated with a modified investigational regimen with no dose escalation: docetaxel 75 mg/m2, IV was administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, enzastaurin was given as a loading dose of 1125 mg starting on Day 4, followed by enzastaurin 500 mg po, QD for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
9751125|NCT00466505|Experimental|Therapeutic Intervention|
9751126|NCT00466661|Experimental|Acamprosate|666 mg p.o. TID
9751127|NCT00466661|Placebo Comparator|Placebo|Matching placebo
9751128|NCT00466687|Experimental|Therapeutic Intervention|"Tarceva and Avastin:~Tarceva: 150mg PO, days 1-28~Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course"
9751129|NCT00466752|Experimental|Treatment (enzyme inhibitor) 48hr stop|Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
9751130|NCT00466752|Experimental|Treatment (enzyme inhibitor) 24hr stop|tients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 day after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
9751131|NCT00466817|Experimental|Valganciclovir|Six months of oral Valganciclovir.
9751132|NCT00466817|Placebo Comparator|Placebo|Six weeks of oral Valganciclovir followed by placebo to complete the six month time period.
9751133|NCT00466921|Experimental|Lenalidomide|
9751134|NCT00466947|Experimental|Synflorix Group|Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
9751135|NCT00466947|Active Comparator|Control Group|Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.
9751136|NCT00466960|Experimental|Treatment (colony stimulating factor and chemotherapy)|"INDUCTION THERAPY: Patients receive GM-CSF SC once daily on days 16-26. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 14 days after last GM-CSF injection, patients receive GM-CSF SC once daily on days 1-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
9751137|NCT00467038|Other|Dialectical Behavior Therapy|Dialectical Behavior Therapy
9751138|NCT00467038|No Intervention|Healthy Controls|Healthy controls
9751139|NCT00467051|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
9751140|NCT00467077|Experimental|Gefitinib and PEG-IFNa Treatment|Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).
9751141|NCT00467259|Placebo Comparator|Placebo|28 cm² Placebo patch
9751142|NCT00467259|Experimental|Testosterone|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
9751143|NCT00467272|Experimental|Daptomycin|Daptomycin 6 mg/kg intravenous (IV) every 24 hours for at least 7-14 days, depending on the type of bacteria.
9751144|NCT00467285||Group 1|140 subjects with type 2 diabetes on pioglitazone.
9751145|NCT00467285||Group 2|140 subjects with type 2 diabetes not on pioglitazone.
9751146|NCT00467298|Experimental|Self-management|Novel intensive self-management education and exercise program of four weeks
9751147|NCT00467298|No Intervention|Usual care|Usual care- cardiac or pulmonary rehabilitation exercise program of 8 weeks duration
9751148|NCT00467350|Active Comparator|enema|Rectal enema containing mixture of milk and molasses
9751149|NCT00467350|Active Comparator|PEG 3350|Medication to be taken orally once each day for three consecutive days
9751150|NCT00467363|Active Comparator|Aspirin|81mg of low-dose aspirin plus 400micrograms of folic acid.
9751151|NCT00467363|Placebo Comparator|Placebo|400micrograms of folic acid.
9751152|NCT00467389|Experimental|Oral Placebo First|Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil
9751153|NCT00467389|Experimental|Donepezil First|Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo.
9751154|NCT00467519|Experimental|Group 1|DAPTACEL primed participants
9751155|NCT00467519|Experimental|Group 2|Pentacel primed participants
9751156|NCT00467558|Active Comparator|Naltrexone|Naltrexone 50mg-150mg by mouth per day.
9751157|NCT00467558|Placebo Comparator|Placebo|Placebo pills (1-3 pills daily) depending upon dose prescribed by study physician
9751158|NCT00467584|Active Comparator|High Dose Aspirin|High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
9751159|NCT00467584|Active Comparator|Low Dose Aspirin|Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
9751160|NCT00467584|Placebo Comparator|Placebo|Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks
9751161|NCT00467597||Group 1|
9751162|NCT00467610|Experimental|Panhematin|
9751163|NCT00467649|Experimental|Group A|
9751164|NCT00467649|Active Comparator|Group B|
10201841|NCT05194657|Experimental|Acrysof IQ|Patiet will receive the monofocal IOL during cataract surgery
10201842|NCT05194527||Patients with Acute Mesenteric Ischemia|Patients that are diagnosed with Acute mesenteric Ischemia
10201843|NCT05194527||Patient with another underlying disease/condition|Patients that are diagnosed not with acute mesenteric ischemia, but with a other underlying disease/condition
10201844|NCT05194475|Experimental|Thermogenic Ready-to-drink Beverage|Arm in which a thermogenic ready-to-drink beverage is ingested.
10201845|NCT05194475|Placebo Comparator|Placebo Ready-to-drink Beverage|Arm in which a placebo ready-to-drink beverage is ingested.
10201846|NCT05194462|Active Comparator|Pelvic Floor Physical Therapy (PFPT)|6 sessions of PFPT over a 12 week period with planned home exercises as per physical therapist's recommendation.
9751165|NCT00467779|Experimental|Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)|Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
9751166|NCT00467779|Experimental|Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)|Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
9751167|NCT00467779|Experimental|Stage 2: Cobimetinib Expansion (21/7 Schedule)|Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
9751168|NCT00467779|Experimental|Stage 2 A: Cobimetinib Expansion (14/14 Schedule)|Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
9751169|NCT00467779|Experimental|Stage 3: Cobimetinib+Midazolam+Dextromethorphan|Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
9751170|NCT00467818|Active Comparator|Omega 3 fatty Acids, drug|Omega 3 Fatty acids will be dispensed to subjects in the active experimental group of the study.
9751171|NCT00467818|Placebo Comparator|Placebo|The placebo will be dispensed to subjects in the control group
9751172|NCT00467831|Experimental|Multi-Drug Regimen|Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
9751173|NCT00467844|Experimental|1|1 mg GTx-024
9751174|NCT00467844|Experimental|2|3 mg GTx-024
9751175|NCT00467844|Placebo Comparator|3|Placebo
9751176|NCT00467857|Active Comparator|InteguSeal* and standard surgical preparation solutions|InteguSeal* microbial skin sealant was applied to surgical sites prior to incision after standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
9751177|NCT00467857|Other|Standard surgical skin preparation alone|Prior to incision, standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
9751178|NCT00467870|Experimental|1|750 mg dose of testosterone undecanoate
9751179|NCT00467870|Experimental|2|1000 mg dose testosterone undecanoate
9751180|NCT00467896|Experimental|Iloprost|The study enrolled patients who were already using iloprost (10 µg/mL) standard dose (5 µg) delivered by I-neb® Adaptive Aerosol Delivery (AAD) System with Power Disc-6 (PD-6) without any safety or tolerability concerns, thereby facilitating a direct comparison with the Power Disc-15 (PD-15). The single arm design allowed each patient to serve as his/her own control.
9751181|NCT00467961|Experimental|Miltenyi system transplant recipients|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression
9751182|NCT00468052|Active Comparator|fentanyl|fentanyl bolus 1ug.kg-1
9751183|NCT00468052|Experimental|dexmedetomidine|dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1
9751184|NCT00468104|Active Comparator|Alteplase, Placebo- intapleural instillation|Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
9751185|NCT00468104|Active Comparator|Placebo, Alteplase -2nd arm|If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days
10201847|NCT05194462|Active Comparator|Biofeedback device|Pericoach® by Analytica is a vaginal device with recommendation for daily use during the 12 week period.
10201848|NCT05194462|Other|Comparator|Women who decline randomization but agree to participate in the comparator arm will be asked to complete the questionnaires at baseline, 3-months and 1-year. They will have no in-person follow up or intervention and will receive the usual postpartum care as determined by their obstetrician.
10201849|NCT05194449|Experimental|Comfort Talk® App (Cft) Group|Mobile app with elements of relaxation, self-hypnosis, and reframing of distress
10201850|NCT05194449|Placebo Comparator|Placebo Group|Mobile app with white noise choices having the same looks and functionality as the active Comfort Talk® 1st app
10201851|NCT05194423|Experimental|Tricuspid Valve Replacement System via jugular vein|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system via jugular vein will be included in this arm.
10201852|NCT05194371||Definitive (chemo)radiotherapy|
9751186|NCT00468143|Experimental|Adderall Extended Release First|This group was treated with Adderall extended release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall immediate release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
9751187|NCT00468143|Experimental|Adderall Immediate Release First|This group was treated with Adderall immediate release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall extended release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
9751188|NCT00468169|Experimental|A: Cetuximab+FHX|Cetuximab [250mg/m2 (day 1, weekly x10)] + FHX (5-FU [CI: 600mg/m2/day; days 0-5 (120h total) every other week x5], Hydroxyurea [500 mg PO BID, days 0-5 (=11 doses), every other week x5] and twice-daily radiation [150 cGy per fraction - days 1-5, every other week x5 (70-72 Gy total dose)]). Total duration is 10 weeks.
9751189|NCT00468169|Experimental|B: Cetuximab + PX|Cetuximab [250 mg/m2 (day 1, weekly x7)] + PX (Cisplatin [100mg/m2 (week 1 & 4 on day 1 (or 2))], Accelerated fraction radiotherapy with concomitant boost [AFX-CB (72 Gy/42 F/6 W) (3-D or IMRT based)]). Total duration: 7 weeks.
9751190|NCT00468208|Experimental|1|Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
9751191|NCT00468286|Experimental|A|Treatment group A: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
9751192|NCT00468286|Experimental|B|Treatment group B: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
9751193|NCT00468299|Active Comparator|Misoprostol and placebo|Women in this arm receive placebo and misoprostol 800 mcg buccally
9751194|NCT00468299|Experimental|Mifepristone and misoprostol|Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally
9751195|NCT00468481|Experimental|Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)|1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
9751196|NCT00468481|Active Comparator|Drospirenone (DRSP)/Ethinylestradiol (EE)|1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks
9751197|NCT00468546|Placebo Comparator|Placebo Plus Methotrexate|Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
9751198|NCT00468546|Experimental|Rituximab plus Methotrexate|Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
9751199|NCT00468559|Experimental|Open Label Esomeprazole|This is an open label, run-in phase. All patients received Esomeprazole.
9751200|NCT00468559|Experimental|Double Blind Esomeprazole|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
9751201|NCT00468559|Placebo Comparator|Double Blind Placebo|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
9751202|NCT00468585|Experimental|1 Capecitabine and Bevacizumab|The Phase II trial has a Simon mini-max two-stage design. Twenty-seven patients will be enrolled to the first stage of the Phase II trial, with a target accrual of 40 patients. The treatment dose of capecitabine as determined in the Phase I portion of this trial will be administered orally in two divided doses daily on Days 1 through 7 and Days 15 through 21 in a 28 day cycle. Phase II patients will receive bevacizumab 10 mg/kg intravenously every 2 weeks concurrently with oral capecitabine. Patients will be evaluated for toxicity between Days 3 to 5 (complete blood count only), Day 8, Day 15, and Day 22 during cycle #1. Thereafter, toxicity will be assessed on Days 1 and 15. Efficacy will be assessed with every other week physical examination and radiographic scans of measurable disease every 12 weeks.
9751203|NCT00468650|Active Comparator|Open label|Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
9751204|NCT00468676|Active Comparator|B|Treatment as usual
9751205|NCT00468676|Experimental|A|Case management intervention
9751206|NCT00468728|Active Comparator|1|Vancomycin
9751207|NCT00468728|Experimental|2|PAR-101/OPT-80
9751208|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
9751209|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
9751210|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
9751211|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
9751212|NCT00468845|Experimental|1|
9751213|NCT00468845|Experimental|2|
9751214|NCT00468845|Placebo Comparator|3|
9751215|NCT00468858|Experimental|T-DEN-Post-Transfection F17|Post-Transfection F17, full dose
9751216|NCT00468858|Experimental|T-DEN-Post-Transfection F19|Post-Transfection F19, full dose
9751217|NCT00468858|Placebo Comparator|Placebo|Control
9751218|NCT00468910|Experimental|Arm I|Patients receive oral acetylsalicylic acid (aspirin) once daily.
9751219|NCT00468910|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
9751220|NCT00469014|Active Comparator|Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 30 mg/m^2 intravenous (IV) Daily + Fludarabine 30 mg/m^2 IV Daily; + Clofarabine 10 mg/m^2 IV Daily; Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
9751221|NCT00469014|Experimental|Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 20 mg/m^2 IV + Fludarabine 20 mg/m^2 IV Daily + Clofarabine 20 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
9751222|NCT00469014|Experimental|Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 10 mg/m^2 IV Daily + Fludarabine 10 mg/m^2 IV Daily + Clofarabine 30 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
9751223|NCT00469014|Experimental|Arm 4: Busulfan + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 40 mg/m^2 IV Daily + Clofarabine 40 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
9751224|NCT00469079|Active Comparator|1|Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
9751225|NCT00469079|Experimental|2|Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
9751226|NCT00469079|Experimental|3|Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
9751227|NCT00469092|Experimental|BIAsp 30|
9751228|NCT00469092|Active Comparator|Glargine|
9751229|NCT00469144|Experimental|Fixed-Dose Busulfan + Fludarabine|Busulfan Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
9751230|NCT00469144|Experimental|Adjusted Dose Busulfan + Fludarabine|Busulfan Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
9751231|NCT00469209|Active Comparator|No Bortezomib|Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
9751232|NCT00469209|Active Comparator|Bortezomib 1.0 mg/m^2|Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
9751233|NCT00469209|Active Comparator|Bortezomib 1.5 mg/m^2|Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
9751234|NCT00469274|Active Comparator|Antibiotic PEP|Subjects who did receive PEP following pertussis exposure
9751235|NCT00469274|No Intervention|No PEP|Subjects who did not receive PEP following pertussis exposure
9751236|NCT00469391|Experimental|GI Sleeve|medical device that mimics gastric bypass mechanism for weight-loss
9751237|NCT00469391|Sham Comparator|Sham Control|
9751238|NCT00469456|Active Comparator|1|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
9829876|NCT02550210|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
9829877|NCT02550743|Experimental|Dose 1|BYL719, capectabine and radiation Dose BYL719: 200mg/day
9829878|NCT02550743|Experimental|Dose 2|BYL719, capectabine and radiation Dose BYL719: 250mg/day
9829879|NCT02550743|Experimental|Dose 3|BYL719, capectabine and radiation Dose BYL719: 300mg/day
9829880|NCT02550743|Experimental|Dose -1|BYL719, capectabine and radiation Dose BYL719: 150mg/day
9829881|NCT02550795|Placebo Comparator|Control|administration of 0.9% normal saline 10ml
9829882|NCT02550795|Active Comparator|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
9829883|NCT02550795|Active Comparator|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
9829884|NCT02550873|Experimental|PRM-151 10mg / kg|Dosing Every 4 Weeks
9829885|NCT02550873|Placebo Comparator|Placebo|Dosing Every 4 weeks
9829886|NCT02550938|Experimental|7 Aligner Cohort weartime 1|Seven Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
9829887|NCT02550938|Experimental|7 Aligner Cohort weartime 2|Seven Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
9829888|NCT02550938|Experimental|12 aligner cohort weartime 1|Twelve Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
9829889|NCT02550938|Experimental|12 aligner cohort weartime 2|Twelve Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
9829890|NCT02551055|Experimental|MLN1117 300 mg + Alisertib|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
9829891|NCT02551055|Experimental|MLN1117 600 mg + Alisertib|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
9829892|NCT02551055|Experimental|MLN1117 300 mg + Paclitaxel|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
9829893|NCT02551055|Experimental|MLN1117 600 mg + Paclitaxel|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
9829894|NCT02551055|Experimental|MLN1117 300 mg + TAK-659|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 [NCT02000934]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
9829895|NCT02551055|Experimental|MLN1117 200 mg + Docetaxel|MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
9829896|NCT02551055|Experimental|MLN1117 300 mg + Docetaxel|MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
9829897|NCT02551094|Active Comparator|colchicine|0.5 mg tablet of colchicine taken once a day
9829898|NCT02551094|Placebo Comparator|colchicine placebo|0.5 mg tablet of placebo taken once a day
9829899|NCT02551159|Experimental|Monotherapy|MEDI4736 monotherapy.
9829900|NCT02551159|Experimental|Combination Therapy|MEDI4736+Tremelimumab combination therapy
9829901|NCT02551159|Active Comparator|Standard of Care|Standard of Care treatment
9829902|NCT02551224|Experimental|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
9829903|NCT02551224|Experimental|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
9829904|NCT02551432|Experimental|Paclitaxel pembrolizumab|"PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,~Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,~Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
9829905|NCT02551653|Experimental|[11C]-GSK2256098|Subjects will receive single IV bolus injection of [11C]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of [11C]-GSK2256098 with maximum [11C]-GSK2256098 mass <=10 microgram (mcg).
9829906|NCT02551666|Active Comparator|Tai Chi exercise intervention|Participants will perform 30-minute Tai Chi sessions (Yang Short form) 3 times a week for 4 weeks.
9829907|NCT02551666|Experimental|Balance recovery training|Participants will practice balance recovery on a modified treadmill for approximately 30-minutes per session, 3 sessions a week for 4 weeks.
9829908|NCT02551692|Placebo Comparator|NRT|
9829909|NCT02551692|Placebo Comparator|VAR|
9829910|NCT02551692|Placebo Comparator|PLAC|
9829911|NCT02551731|Experimental|Cannabidiol Oral Solution: 20 or 40 mg/kg/day BID|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
9829912|NCT02551744|Active Comparator|proton pump inhibitor group|Pantoprazole Tab 40mg qd for 6 monthrs.
9829913|NCT02551744|Experimental|histamine-2 receptor antagonist group|famotidine Tab 40 mg qd for 6 months.
9829914|NCT02551757|Experimental|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
9829915|NCT02551757|Sham Comparator|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
9829916|NCT02551770|Active Comparator|Test (with Emdogain)|Scaling and root planing with Emdogain
9829917|NCT02551770|Other|Control (without Emdogain)|Scaling and root planing without Emdogain
9829918|NCT02551809|Experimental|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
9829919|NCT02551809|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
9829920|NCT02551809|Placebo Comparator|Placebo|Subjects will receive 7 doses of placebo.
9829921|NCT02551822|Active Comparator|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
9829922|NCT02551822|Active Comparator|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
9829923|NCT02551874|Experimental|Saxagliptin/Dapagliflozin/Metformin|Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
9829924|NCT02551874|Active Comparator|Insulin Glargine, Lantos/Metformin|Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
9829925|NCT02551887|No Intervention|Usual Care|Usual Care Only
9829926|NCT02551887|Active Comparator|Automated Reminder|Reminder
9829927|NCT02551887|Experimental|Automated Reminder Plus Script|Provider sees both reminder and script.
9829928|NCT02552121|Experimental|Tisotumab vedotin (HuMax-TF-ADC)|
9829929|NCT02552147|Experimental|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
9829930|NCT02552147|Experimental|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
9829931|NCT02552212|Experimental|Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
9751239|NCT00469456|Placebo Comparator|2|Placebo oral administration twice daily for 12 weeks
9751240|NCT00469508|Active Comparator|Modafinil|Modafinil 400mg oral dose taken daily for 12 weeks
9751241|NCT00469508|Placebo Comparator|Placebo|Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks
9751242|NCT00469833|Experimental|Arm 1|Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).
9751243|NCT00469859|Experimental|Group 1 (Lestaurtinib dose 50 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
9829932|NCT02552212|Placebo Comparator|Placebo|Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.
9829933|NCT02552225|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
9829934|NCT02552225|Placebo Comparator|placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
9829935|NCT02552238|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
9984016|NCT04478123|Experimental|romiplostim|"Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.~Regardless of the conditioning regimen received, all patients will receive romiplostim 3.0 mcg/kg SC on Day +1 and romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated until platelet count is >50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. No patient will receive more than six doses of romiplostim, even if platelets have not corrected by Day +42."
9829936|NCT02552303|Active Comparator|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
9984711|NCT03807921|Experimental|Warfarin|"Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.~Aspirin will be administered 100 mg daily."
9665044|NCT05210790|Experimental|Rusfertide|Rusfertide (32 Weeks) - Rusfertide (124 Weeks Open-label)
9665045|NCT05210790|Experimental|Placebo|Placebo (32 Weeks) - Rusfertide (124 Weeks Open-label)
9665048|NCT05207059|Experimental|Study Arm|The intervention will comprise four modules, namely the HELMS Journey, HELMS Model, HELMS Lifestyle and HELMS Community. The HELMS Journey will provide anticipatory guidance for both HELMS and routine clinic visits. The HELMS Model will deliver the 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management') care plan, detailed below. The HELMS Lifestyle will provide lifestyle support in terms of healthy eating through the 6P tool ('Portion', 'Proportion', 'Pleasure', 'Phase', Physicality', 'Psychology'), physical activity, sleep and mental well-being. Finally, the HELMS Connection will provide community support and improve engagement with the program.
9665049|NCT05206565|Experimental|Autologous with TRAM/DIEP flaps, with neurotization|Autologous with TRAM/DIEP flaps, with neurotization
9665050|NCT05206565|No Intervention|Autologous with TRAM/DIEP flaps, without neurotization|Autologous with TRAM/DIEP flaps, without neurotization
9665051|NCT05205499|Experimental|IBS|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
9665052|NCT05203835|Experimental|Placebo and acebilustat|Participants will take acebilustat and placebo over a period of 9 months.
9665053|NCT05203679|Experimental|Arm of BBM-H901|1×10^13 vg/kg, Single-dose treatment
9665054|NCT05202418|Experimental|Biofeedback Enhanced Treatment|Participants in this group will participate in biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. They will complete questionnaires before and after each session to measure autonomic reactivity in response to stress induction and coping strategies.
9665055|NCT05202418|No Intervention|Wait-list control|Participants randomized to the wait-list control group will complete the same measures of lifetime stress, autonomic reactivity, depression, anxiety. The identical treatment will be offered to control participants after the 6-week time point.
9665056|NCT05201755|Other|A|"Investigators will evaluate the diameter of the basilica vein and venous flow-velocity after 5 minutes of breathing at room air. Investigators will collect basic vital parameters (heart rate, blood pressure, pulsoximetry).~Afterwards, the investigators will administer CPAP through a helmet, with the straps placed under the armpits. After 5 minutes, the investigators will collect again ultrasound data (venous diameter of basilica vein, flow-velocity) and basic vital parameters (heart rate, blood pressure, pulsoximetry).~Then the CPAP helmet will be tied to the bed and the armpit straps removed. After 5 minutes the investigators will collect ultrasound data and basic vital parameters as in the steps before (venous diameter, flow-velocity, heart rate, blood pressure, pulsoximetry). After this three steps, the protocol ends."
9665057|NCT05201755|Other|B|Same interventions and measurements as A, in different order (breathing room air, then with a CPAP helmet tied to the bed, then with a CPAP helmet fastened with armpit straps).
9665058|NCT05201755|Other|C|Same interventions and measurements as A, in different order (breathing with a CPAP fastened with armpit straps, breathing with a CPAP helmet tied to the bed and breathing at room air).
9665059|NCT05201755|Other|D|Same interventions and measurements as A, in different order (breathing with a CPAP helmet tied to the bed, breathing with a CPAP helmet fastened with armpit straps and breathing at room air).
9665060|NCT05200286|Experimental|Severe renal impairment|120 mg olorofim
9665061|NCT05200286|Active Comparator|Normal renal function|120 mg olorofim
9665062|NCT05200221||Donafenib|Patients with uHCC taking donafenib in clinical treatment
9665063|NCT05197725|Experimental|Mask intervention|Communities randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use. Every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people. In arms randomized to school promotion, secondary school children will also be encouraged to wear masks both inside and outside of school.
9665064|NCT05197725|No Intervention|Control|Control individuals will receive no masks or behavior change communication.
9665067|NCT05195632|Experimental|Treatment arm (Safety Lead-in and Pivotal arm)|Encorafenib will be administered as a fixed, flat oral dose of 450 mg QD in combination with binimetinib as a fixed, flat oral dose of 45 mg BID.
9665068|NCT05193500|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
9665069|NCT05193500|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
9665070|NCT05192798|Active Comparator|Group of albumin-bound paclitaxel|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks).
9829937|NCT02552303|Placebo Comparator|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
9829938|NCT02552303|Active Comparator|Armodafinil|Medication (armodafinil) only, without CBTI.
9829939|NCT02552303|Placebo Comparator|Placebo|Placebo only, without CBTI.
9829940|NCT02552316|Other|NB-UVB Phototherapy|NB-UVB phototherapy is a therapy which uses ultraviolet B (UVB) light directed at the skin. This type of light therapy is given through the use of phototherapy booths which contain fluorescent tubes that emit UVB light. Booths used for phototherapy look similar to commercial tanning booths. NB-UVB phototherapy affects psoriasis by causing changes to the cells of the skin and producing a local effect by reducing the number of certain types of skin cells which have an impact on psoriasis formation.
9829941|NCT02552355|Experimental|Metformin/Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin.
9829942|NCT02552355|Placebo Comparator|Placebo/Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo.
9829943|NCT02552355|Active Comparator|Metformin/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin
9829944|NCT02552355|Active Comparator|Placebo/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.
9829945|NCT02552368|Experimental|IpsiHand|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
9829946|NCT02552732|Experimental|NHF with or without Oxygen|NHF with or without oxygen will be delivered to COPD patients using myAIRVO™ 2 for 30 days post hospital discharge
9829947|NCT02552810|Active Comparator|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
9829948|NCT02552810|Active Comparator|Steam clean|Abutment cleaning by steam clean device.
9829949|NCT02552888|Experimental|treatment|Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.
9829950|NCT02552888|Placebo Comparator|Placebos|identical placebos.
9829951|NCT02552966|Experimental|UESAD|Upper Esophageal Sphincter Assist Device
9829952|NCT02553135|Experimental|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
9829953|NCT02553317|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
9829954|NCT02553317|Placebo Comparator|Placebo|Placebo once daily
9829955|NCT02553330|Experimental|Ruxolitinib Phosphate Cream|"Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks;~Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks."
9829956|NCT02553330|Placebo Comparator|Placebo Cream|Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
9829957|NCT02553395|Experimental|Phenacite contact lens|Study Test Contact Lens
9829958|NCT02553395|Active Comparator|comfilcon A contact lens|Control Contact Lens
9829959|NCT02553421|Experimental|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
9829960|NCT02553421|Experimental|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
9751244|NCT00469859|Experimental|Group 2 (Lestaurtinib: Dose 62.5 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
9751245|NCT00469898|Experimental|Therapeutic Intervention|Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
9751246|NCT00469911|Experimental|Magnetic Resonance Spectroscopy|Patients will have Magnetic Resonance Spectroscopy to measure in vivo accumulation of triglycerides in myocardial tissue
9751247|NCT00469911|Experimental|Ex vivo heart biopsy|Patients will have their normal routine clinical heart biopsy of myocardial heart tissue.
9751248|NCT00470054|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9751249|NCT00470093|Experimental|Interleukin-6 and Interferon-α|Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.
9782516|NCT01177800|Experimental|Infliximab|5 milligram per kilogram (mg/kg) infusion (a fluid or a medicine delivered into a vein by way of a needle) of infliximab administered intravenously (into a vein) at Week 0, 2 and 6 followed by maintenance regimen of 5 mg/kg infliximab at Week 14 and 22. Placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial infusion), matched to infliximab will be given at Week 10, 12 and 16. Total duration of treatment will be 26 weeks.
9782517|NCT01177800|Experimental|Placebo|Placebo infusion, matched to infliximab will be given intravenously at Week 0, 2 and 6. At Week 10, 12 and 16, participants will receive 5 mg/kg infliximab intravenously. Placebo infusion will be again given at Week 14 and 22. Total duration of treatment will be 26 weeks.
9782518|NCT01177813|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose tablets once daily
9782519|NCT01177813|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose tablets once daily
10201853|NCT05194345|Experimental|Autism Eats nutrition intervention|Autism Eats intervention lessons (10 lessons + 2 booster sessions) integrate ASD-specific feeding strategies such as repeated exposures, food chaining, and making regular mealtime routines and behaviorally-focused nutrition content and activities utilizing goal setting, healthy meal planning, monitoring progress, strategies to overcome barriers, and creating healthy home food environment. The early intervention (EI) providers will be trained to implement the lessons. EI providers are well-trained to use personalized intervention and coaching approach in their EI services, which will be applied to Autism Eats activities as well. Each intervention lesson will take 25-30 minutes within one hour EI services, and parent-child dyads will participate in the intervention as part of their regular EI services. The Autism Eats lesson manual will be provided to the EI providers and the parent handbook will be distributed to the parent participants.
9782520|NCT01177813|Placebo Comparator|Placebo|Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
9782521|NCT01177813|Active Comparator|Sitagliptin 100 mg|Patients receive Sitagliptin 100 mg tablets once daily
9782522|NCT01177813|Experimental|BI 10773 high dose open label|Patients receive BI 10773 high dose tablets open label once daily
9782523|NCT01177943|Experimental|Atomoxetine Oral Solution|
9782524|NCT01177943|Active Comparator|Atomoxetine Capsule Formulation|
9782525|NCT01177956|Experimental|Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)|
9782526|NCT01177969|Experimental|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
9782527|NCT01177969|Placebo Comparator|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
9782528|NCT01178073|Active Comparator|Combination ambrisentan + tadalafil|ambrisentan + tadalafil
9782529|NCT01178073|Active Comparator|Monotherapy ambrisentan|ambrisentan
9782530|NCT01178073|Active Comparator|Monotherapy tadalafil|tadalafil
9782531|NCT01178086||Participants With CLL|Participants with CLL who are being treated with intravenous (IV) rituximab in combination with chemotherapy, will be observed for 24 months including 6-month treatment period.
9782532|NCT01178099|Experimental|Prasugrel|Participants received a single 10 milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants<60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).
9782533|NCT01178125|Experimental|DR-102|desogestrel/ethinyl estradiol 0.15/0.02 mg for 21 days then ethinyl estradiol 0.01 mg for 7 days
9782534|NCT01178138|Other|Prazosin effects on methamphetamine|Randomized placebo controlled trial of prazosin effects on methamphetamine
9829961|NCT02553421|Experimental|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
9665071|NCT05192798|Experimental|Group of albumin-bound paclitaxel combined with apatinib|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks)+ apatinib mesylate tablet (500 mg, orally, once daily, every 3 weeks).
9829962|NCT02553499|Experimental|MK-1248|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to ~3 months).
9829963|NCT02553499|Experimental|MK-1248 + Pembrolizumab|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to ~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~24 months).
9829964|NCT02553538|Experimental|Patient Navigation Intervention|Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
9829965|NCT02553538|No Intervention|Standard of Care - No Intervention|Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
9829966|NCT02553629|Active Comparator|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
9829967|NCT02553629|Experimental|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
9829968|NCT02553746|Experimental|Ultrasound|
9829969|NCT02553746|Active Comparator|Landmarks|
9829970|NCT02553772|Experimental|OM3 Tear|Carboxymethylcellulose based eye drop [Omega-3 (OM3) Tear] administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
9829971|NCT02553772|Active Comparator|REFRESH OPTIVE® ADVANCED|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
9829972|NCT02553798|Experimental|Glycopyrronium|Glycopyrronium Topical Wipes
9829973|NCT02553915|Placebo Comparator|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
9829974|NCT02553915|Experimental|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
9829975|NCT02553915|Experimental|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
9829976|NCT02553915|Experimental|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
9829977|NCT02553928|Experimental|Memantine (once daily)|Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
9829978|NCT02553928|Experimental|Memantine (twice daily)|Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally
9829979|NCT02554019|Experimental|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
9829980|NCT02554019|Placebo Comparator|Placebo|Placebo administered by IV infusion 8 times
9829981|NCT02554279|Experimental|menotropin|menotropins for injection
9829982|NCT02554279|Active Comparator|recombinant FSH|
9829983|NCT02554435|Active Comparator|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
9829984|NCT02554435|Experimental|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
9829985|NCT02554474|Active Comparator|Immediate Group|Time spent in Moderate/Vigorous Physical Activity (MVPA) was measured with a SenseWear Mini sensor over a 7-day period. The mean time was calculated in bouted MVPA per day. A bout is defined as >= 10 consecutive minutes or more at the level of >= 3 METs (i.e., the lower bound of MVPA), with allowance for interruption of up to two minutes below the threshold.
9829986|NCT02554474|Placebo Comparator|Delay Group|Time spent in sedentary activity was measured with a SenseWear Mini sensor over a 7-day period. The mean daily time spent in sedentary activity was calculated with an energy expenditure of <=1.5 METs, occurring in bouts of >= 20 minutes during waking hours.
9829987|NCT02554513|Active Comparator|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
9829988|NCT02554513|Active Comparator|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
9829989|NCT02554682|Other|Sexual Health|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to sexual health at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
9665072|NCT05192798|Experimental|Group of albumin-bound paclitaxel combined with bevacizumab|Albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks) + bevacizumab (7.5mg/kg, intravenous infusion, once every 3 weeks).
9829990|NCT02554682|Other|Alcohol Prevention|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to alcohol prevention at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
9665073|NCT05192109|Active Comparator|Addressed|Children participate via video in an interaction with an experimenter who uses the word to be learned.
10201854|NCT05194345|Active Comparator|We Can! enhanced usual care control|Enhanced usual care (EUC) control group materials are from the evidence-based materials that are already developed and available online (in both English and Spanish): https://www.nhlbi.nih.gov/health/educational/wecan/index.htm. We will download one to two handouts and email early intervention providers to distribute them to parent-child dyads. Materials will be distributed each week for 10 weeks and additional monthly handouts for two months after the first 10 weeks (parallel to the intervention schedule).
10201855|NCT05194332|Experimental|LIFUP sonication to the amygdala|
9665074|NCT05192109|Experimental|Overheard|Children watch via video while an experimenter uses the word to be learned in an interaction with another experimenter.
9665075|NCT05192031|Experimental|Smoking cessation support|
9665076|NCT05192031|No Intervention|Usual care|
9665077|NCT05191225|Experimental|Rapid infusion group|After the administration of intravenous premedication (usually dexchlorpheniramine 5 mg IV and paracetamol 1 g IV), rituximab will be administered at standard dose (375 mg/m2 diluted in 250 ml of saline) administered in one hour, divided into: 10 first minutes at 450 mg/hour, and 50 minutes later at 720 mg/hour.
9665078|NCT05191225|Experimental|Ultrarapid infusion group|After the administration of intravenous premedication, the dose of rituximab will be administered at standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
9665079|NCT05191225|Experimental|Ultrarapid plus infusion group|After the administration of oral premedication, the dose of rituximab will be administered at the standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.
9665080|NCT05191056|Placebo Comparator|Placebo drink|
9665081|NCT05191056|Experimental|MelaGene drink|
9665082|NCT05189496|Experimental|hyperbaric oxygen therapy group|30-40 times hyperbaric oxygen therapy
9665083|NCT05189496|No Intervention|control group|No hyperbaric oxygen therapy
9665084|NCT05189275|Experimental|Cannabidiol 40 mg (CBD40)|Subjects consume beverages with 40mg of CBD.
9665085|NCT05189275|Experimental|Cannabidiol 20 mg (CBD20)|Subjects consume beverages with 20mg of CBD.
9665086|NCT05189275|Experimental|Cannabidiol 0 mg (CBD0)|Subjects consume beverages with 0mg of CBD.
9665087|NCT05189275|Placebo Comparator|Placebo Beverage (PLAC)|Subjects consume calorie matched beverages with 0 CBD.
9665088|NCT05187325||myofascial trigger point and disc displacement with reduction|the participants have myofascial trigger points in master muscle and also temporomandibular joint disc displacement with reduction.
9665089|NCT05187325||disc displacement with reduction|the participants have only temporomandibular joint disc displacement with reduction.
9665090|NCT05187117|Experimental|Open Label Pilot|"The Open Label Pilot (Phase 4) will include testing the CAPABLE Family intervention with 6 individuals with MCI or early-stage dementia. At least 5 of the 6 older adults will be required to have a family member involved. Assuming all have a family member involved (though one may not), 12 participants will be enrolled in the open label pilot.~Open label pilot participants will be asked to provide feedback halfway through the intervention and at the end via phone conversations with the research study team, allowing the study team to make changes accordingly."
9665091|NCT05187117|Experimental|Randomized Control Pilot - Intervention Arm|After the open label pilot, 17 older adults (and if available, care partners) will be randomized to the CAPABLE Family intervention. They will be assessed at baseline, after the 4 month intervention, and after the waitlist control arm.
9665092|NCT05187117|Active Comparator|Randomized Control Pilot - Waitlist Control Arm|The waitlist control group, 17 older adults and if available, care partners, will receive the intervention after they have served as controls to the immediate treatment group, ensuring all participants have access to the intervention.
9665093|NCT05185921|Experimental|Cognitive-behavioral therapy virtual|The intervention will be provided by 2 psychotherapists. The total of sessions will be eight carried out weekly, for 2 to 3 months. They will also receive standard treatment, i.e. psychiatric management with or without drugs.
9665094|NCT05185921|No Intervention|Control|They will only receive standard treatment, i.e. psychiatric management with or without drugs.
9665095|NCT05185427||Participants with pulse oximetry readings|The research team will take a reflectance measurement on the same location that the most recent pulse oximetry measurement was taken. In addition, a reflectance measurement will be taken bilaterally for the nailbed, dorsal and ventral side of the digits, dorsal and ventral side of the hand, dorsal and ventral side of the forearm, lower leg, foot, and either side for the ear. The most recent pulse oximetry and arterial oxygen saturation readings will be accessed through the electronic medical records, those readings are generally conducted simultaneously and will provide comparison. The duration anticipated for an individual participant's participation is 1 day.
9665096|NCT05185167|Experimental|Desflurane Group|Desflurane 1,0 minimum alveolar concentration will be administered during anesthesia maintenance
9665097|NCT05185167|Experimental|Propofol Group|Propofol 6 mg//kg/hour will be administered during anesthesia maintenance
9665098|NCT05185089|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet once daily for 4 weeks
9665099|NCT05185089|Experimental|Orvepitant 60mg|Orvepitant 60mg tablet once daily for 4 weeks
9665100|NCT05185089|Placebo Comparator|Placebo|Placebo tablet once daily for 4 weeks
9665101|NCT05182931|Experimental|BRAFv600E mutant radioiodine refractory thyroid cancer|"Prior to commencing interventional treatment, participants will commence a low iodine diet and undergo thyroxine withdrawal and commence T3 replacement from day -27. On day -5 they will receive an oral dose of 124I (40MBq/1.08 mCi) with imaging at 24 hours (+/-6) post dose and a second imaging assessment within 120 hours.~Participants will receive Dabrafenib (oral, 150mg BD) and Trametinib (oral, 2mg OD) from day 1-30.~A second oral dose of I124 will be administered at day 24 followed by imaging at the same interval as baseline.~Participants achieving >20Gy tumour uptake of I124 will be administered 6GBq (3.3Gy/GBq) 131I, I131 wb scan and SPECT/CT will be performed within 24 hours and at hospital discharge.~Participants who do not achieve >20Gy tumour update of I-124 will move into follow up.~Follow up will occur every 12 weeks for 12 months."
9666833|NCT04217499||Patients with pelvic ring fractures|This retrospective study will be carried out on the data of patients who have received treatment or followed for a pelvic ring fracture, in the Orthopedic Surgery department of the Paris Saint-Joseph Hospital Group between January 2015 and September 2019.
9751250|NCT00470106|Active Comparator|Cognitive Remediation|cognitive remediation
9751251|NCT00470106|Experimental|Social Cognitive Skills Training|social cognitive skills training
9751252|NCT00470106|Active Comparator|Hybrid Intervention|combined social cognitive and cognitive remediation training
9751253|NCT00470106|Other|Skills Training|control training
9666834|NCT04216719|Experimental|OCM-RISE|Opioid court team provided external facilitation to generate action plans to develop and roll out or improve practice of the county opioid court.
9666835|NCT04211246|Active Comparator|Standard group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2.
9666836|NCT04211246|Experimental|ORI group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2 and ORI
9666837|NCT04210687|Active Comparator|Trapeziectomy|Standard simple trapeziectomy, no pins.
9666838|NCT04210687|Active Comparator|trapeziometacarpal limited excision|Trapeziometacarpal limited excision; Narrow pseudarthrosis of the trapeziometacarpal joint.
9666839|NCT04208997|Experimental|Continuation of antiarrhythmic drugs|Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
9666840|NCT04208997|No Intervention|Discontinuation of antiarrhythmic drugs|Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.
9666841|NCT04207788|Experimental|Intervention|HIP-REP programme offers elderly with hip fracture add on activity-focused interventions.
9666842|NCT04207788|Active Comparator|Usual care|The elderly with hip fracture in the control group will receive usual care.
9666843|NCT04206787||Patients with non-small cell lung cancer (NSCLC)|
9666844|NCT04201873|Experimental|Group A (pembrolizumab, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
9666845|NCT04201873|Active Comparator|Group B (placebo, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
9666846|NCT04199403||Single Group|
9666847|NCT04196335|Experimental|single-arm|
9666848|NCT04187768||Healthy Group|Healthy volunteers will donate a sample of blood to be used as controls
9666849|NCT04187768||NSCLC Group|Patients with advanced NSCLC will have blood collected prior to treatment and after completing 3 cycles of immune checkpoint therapy. . If a patient is noted to have progressive disease after 2 cycles of treatment, a sample will be collected after the 2nd cycle. If a patient is noted to have pseudoprogression (determined at the discretion of the treating physician), an additional sample may be collected after 3 cycles of therapy.
9666850|NCT04184895|Experimental|ASP2390 Low Dose (Cohort 1)|Participants will receive a low dose of ASP2390 once weekly for a total of 12 doses. After all participants in cohort 1 complete 4 doses of treatment, the overall safety and tolerability of the dose will be evaluated by the Dose Escalation Committee (DEC).
9666851|NCT04184895|Placebo Comparator|Placebo Low Dose (Cohort 1)|Participants will receive a low dose of matching Placebo once weekly for a total of 12 doses.
9666852|NCT04184895|Experimental|ASP2390 High Dose (Cohort 2)|Participants will receive a high dose of ASP2390 once weekly for a total of 12 doses. The dose for cohort 2 may be adapted after the DEC evaluates emergent safety and tolerability data.
9666853|NCT04184895|Placebo Comparator|Placebo High Dose (Cohort 2)|Participants will receive a high dose of matching Placebo once weekly for a total of 12 doses.
9666854|NCT04183699|Experimental|MRI targeted + systematic random biopsy|
9666855|NCT04182490|Active Comparator|3000-mg cohort|LMN-101, six 500-mg capsules orally three times daily for 14 days (n=21)
9666856|NCT04182490|Placebo Comparator|Placebo cohort|Placebo, six 500-mg capsules orally three times daily for 14 days (n=21)
9666857|NCT04182386||rPVE|Right portal vein embolization. All patients subjected to selective right portal vein embolization prior to planned hepatobiliary surgery.
9666858|NCT04182386||rPVE+S4|Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery.
9666859|NCT04175600|Experimental|Selexipag|Participants will receive selexipag based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Selexipag will be uptitrated during the first 12 weeks until the participants reaches the individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline body-weight category is achieved. Uptitration is followed by a maintenance period after Week 12 until end of treatment (EOT), at the maximum tolerated dose.
9666860|NCT04175600|Placebo Comparator|Placebo|Participants will receive matching placebo based on the body weight on Day 1 and will continue thereafter with twice daily dosing.
9751254|NCT00470158|Experimental|combined iron and zinc|Iron and zinc together
9751255|NCT00470158|Experimental|Separate iron and zinc|Iron and zinc on separate days
9751256|NCT00470158|Experimental|iron alone|Iron
9751257|NCT00470158|Experimental|zinc alone|Zinc
9751258|NCT00470158|Placebo Comparator|placebo|
9751259|NCT00470184|Experimental|Chemo|Oxaliplatin 85 mg/m2 will be administered IV on days 1, 15 and 29. Capecitabine 1250 mg/m2 will be administered in 2 divided daily doses P0 or via enteral tube, on radiation days only (Monday- Friday/ weekly). Capecitabine will be continued until the final dose of radiotherapy
9751260|NCT00470262|Other|Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD|Treatment with pioglitazone and fenofibrate in subjects with pre diabetes
9751261|NCT00470262|Other|Fenofibrate 145 mg PO QD|Treatment with fenofibrate in subjects with pre diabetes
9751262|NCT00470275|Experimental|Cytarbine|Cytarabine IV every 12 hours days 1-5 of 21 day cycle. Response evaluation after 6 cycles of therapy.
9751263|NCT00470301|Experimental|Arm I|Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide
9751264|NCT00470366|Experimental|Paclitaxel, Ifosfamide, and Cisplatin|-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.
9751265|NCT00470392|Other|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
9751266|NCT00470392|Other|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
9751267|NCT00470418|Other|NIC5-15|Subjects with Alzheimer's Disease
9751268|NCT00470418|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease
9751269|NCT00470470|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
9751270|NCT00470535|Experimental|Arm 1 - Oral Erlotinib hydrochloride|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity
9751271|NCT00470548|Experimental|Phase I: Abraxane and Alimta|Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days.
9751272|NCT00470548|Experimental|Phase II: Abraxane and Alimta|Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days.
9751273|NCT00470600|Placebo Comparator|Normal Saline|250 milliliters normal saline as a placebo comparator was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
9751274|NCT00470600|Experimental|Intravenous ibuprofen|800 mg of intravenous ibuprofen diluted in 250 milliliters normal saline was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
9751275|NCT00470626|Experimental|1|Vena Cava Filter
9751276|NCT00470717|Other|Phone calling|Weekly telephone call. There are not two arms to the study. The primary intervention is phone calling weekly to assess ability to complete phone call and obtain feeding data.
9751277|NCT00470834|Experimental|Arm 1|50 mg bicalutamide and 3.5 mg Dutasteride (IP)
9751278|NCT00470834|Placebo Comparator|Arm 2|50 mg bicalutamide and placebo
9751279|NCT00470847|Other|Lapatinib,Whole Brain Radiation,Herceptin|Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly
9751280|NCT00471068|Experimental|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
9751281|NCT00471068|Active Comparator|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
9751282|NCT00471081|Experimental|Group A|Single dose GSK134612.
9751283|NCT00471081|Experimental|Group B|Two doses of GSK134612.
9751284|NCT00471107|Sham Comparator|Sham TDCS|
9751285|NCT00471107|Experimental|Surface-anodal direct current|0.08 mA/cm2
9751286|NCT00471107|Active Comparator|Surface-cathodal direct current|0.08 mA/cm2
9751287|NCT00471146|Experimental|A|
9751288|NCT00471146|Active Comparator|B|
9751289|NCT00471237|No Intervention|Placebo|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
9751290|NCT00471237|Active Comparator|Alendronate|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
9751291|NCT00471237|Active Comparator|Teriparatide|Open-label arm. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
9751292|NCT00471237|Experimental|Ronacaleret|4 arms, 100mg, 200mg, 300mg, 400mg. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study.
9751293|NCT00471276|Experimental|1|
9751294|NCT00471315|No Intervention|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
9751295|NCT00471328|Experimental|Nilotinib|400mg twice daily in core and extension phases of the study.
9751296|NCT00471328|Active Comparator|Control/cross-over to Nilotinib|"In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm.~Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression."
9751297|NCT00471354|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD), by mouth (PO), starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
9751298|NCT00471380|Active Comparator|Crossover group ABB|"3 period, 2 treatment cross-over model:~Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)"
9751299|NCT00471380|Active Comparator|Crossover group BAA|"3 period, 2 treatment cross-over model:~Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)."
9751300|NCT00471445|Experimental|ketamine/amitriptyline NP-H cream|Patients apply 4 grams amitriptyline (4%) and ketamine (2%) hydrochloride topical analgesic cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
9751301|NCT00471445|Placebo Comparator|Placebo Cream|Patients apply a placebo cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
9751302|NCT00471497|Experimental|nilotinib 300mg bid (investigating arm)|
9751303|NCT00471497|Experimental|Nilotinb 400 mg bid (investigating arm)|
9751304|NCT00471497|Experimental|imatinib 400mg QD (control arm)|
9751305|NCT00471536|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9751306|NCT00471705|Experimental|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
9751307|NCT00471705|Active Comparator|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
9751308|NCT00471705|Experimental|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
9751309|NCT00471718|Experimental|Phase I/II: Chemotherapy ABT-751|"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.~Phase II: Patients receive ABT-751 twice daily"
9751310|NCT00471848|Experimental|Treatment Arm|Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent
9751311|NCT00471887|Experimental|Treatment-Single Arm|See intervention descriptions
9751312|NCT00472030|Experimental|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
9751313|NCT00472030|Active Comparator|Prednisone|The control arm of the study will receive standard prednisone therapy to a maximum dose of 0.5 mg/kg/day.
9751314|NCT00472056|Experimental|BEAM + Standard Rituximab|"Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Standard Rituximab: 375 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0."
9751315|NCT00472056|Experimental|BEAM + High Rituximab|"BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~High Dose Rituximab: 1000 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0"
9751316|NCT00472199|Experimental|Pramipexole|4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
9751317|NCT00472199|Placebo Comparator|Placebo|4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
9751318|NCT00472290|Experimental|Open Label Romiplostim (formerly AMG 531)|
9751319|NCT00472303|Placebo Comparator|Matching Placebo after Tapentadol in Titration Phase|Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
9751320|NCT00472303|Active Comparator|Morphine Controlled Release|Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
9751321|NCT00472303|Experimental|Tapentadol Prolonged Release|Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses.
9751322|NCT00472420|Experimental|1|
9751323|NCT00472446|Experimental|cervical block before surgery|bilateral superficial cervical block, placed before surgery (just before skin incision)
9751324|NCT00472446|Placebo Comparator|placebo cervical block before surgery|placebo bilateral superficial cervical block with saline, placed before surgery (just before skin incision)
9751325|NCT00472446|Experimental|cervical block after surgery|bilateral superficial cervical block, placed after surgery (just after skin closure)
9751326|NCT00472446|Placebo Comparator|placebo cervical block after surgery|placebo bilateral superficial cervical block with saline, placed after surgery (just after skin closure)
9751327|NCT00472576|Experimental|Placebo then MK-0657|Double-blind crossover administration of placebo then MK-0657 (4-8 mg/day)
9751328|NCT00472576|Experimental|MK-0657 then Placebo|Double-blind crossover administration of MK-0657 (4-8 mg/day) then placebo
9751329|NCT00472641|Experimental|Ziprasidone/Geodon|Ziprasidone/Geodon up to 320 mg per day
9751330|NCT00472732||1|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
9751331|NCT00472732||2|Healthy males or females without known medical or metabolic disorder (control group)
9751332|NCT00472797|Active Comparator|1|Rebif New Formulation - Non Titrated
9751333|NCT00472797|Active Comparator|2|Rebif New Formulation - Titrated
9751334|NCT00472849|Experimental|OFAR (Phase I)|Oxaliplatin starting dose 30 mg/m^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
9751335|NCT00472849|Experimental|OFAR MTD (Phase II)|Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
9751336|NCT00473083|Experimental|Arm 1: Prophylactic Treatment|Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
9782535|NCT01178216|Experimental|Rituxan|All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
9782536|NCT01178268|Active Comparator|XIENCE V EECSS|Patients who will receive this stent.
9782537|NCT01178268|Active Comparator|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
9984712|NCT03807921|Active Comparator|Aspirin only|Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.
9751337|NCT00473083|Experimental|Arm 2: Reactive Treatment|"Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:~Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade~Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.~Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.~Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln."
9751338|NCT00473083|Experimental|Arm 3: No Treatment Unless Severe (Grade 3)|This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
9751339|NCT00473265|Experimental|PTH(1-84)|100mcg of PTH1-84 every other day, every day, or every three days
9751340|NCT00473330|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
9751341|NCT00473330|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
9751342|NCT00473330|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
9751343|NCT00473382|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
9751344|NCT00473382|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
9751345|NCT00473382|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
9751346|NCT00473434|Experimental|001|Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks
9751347|NCT00473512|Experimental|Abiraterone acetate|Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
9751348|NCT00473564|Experimental|TORS Candidates|Participants who consented to undergo transoral robotic-assisted surgery using the da Vinci® Robotic System
9751349|NCT00473590|Experimental|Bortezomib + bevacizumab|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
9751350|NCT00473590|Active Comparator|Bortezomib + placebo|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
9751351|NCT00473642|Experimental|1|Standard Fluence Photodynamic Therapy combined with ranibizumab
9751352|NCT00473642|Experimental|2|Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab
9751353|NCT00473642|Active Comparator|3|Ranibizumab monotherapy
9751354|NCT00473668|Experimental|TRITANRIX-HEPB/HIBERIX KFT. GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
9751355|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX LD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
9751356|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX HD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
9751357|NCT00473694|Experimental|rocuronium+sugammadex|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 post-tetanic counts (PTC) and after the last dose of rocuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
9751358|NCT00473694|Active Comparator|rocuronium+neostigmine|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 PTC and after the last dose of rocuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
9751359|NCT00473694|Experimental|vecuronium+sugammadex|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
9751360|NCT00473694|Active Comparator|vecuronium+neostigmine|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
9751361|NCT00473746|Experimental|Phase I Dose Escalation|
9751362|NCT00473746|Experimental|Phase II Dose Treatment|
9751363|NCT00473824|Experimental|Civacir Treated|Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
9751364|NCT00473824|No Intervention|Observational Control|Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir].
9751365|NCT00473837|Active Comparator|Treatment|Subjects initially treated with Co-arthemeter, and then continued on weekly chloroquine till day 90
9751366|NCT00473837|Placebo Comparator|Control|Subjects initially treated with Co-arthemeter, and then continued on weekly placebo till day 90
9751367|NCT00473876|Active Comparator|1|Receiving Metformin for 4 months
10201856|NCT05194306|Experimental|Perla® Cold Preservation solution|Perla® is a Cold Preservation Solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient.
9751368|NCT00473876|Placebo Comparator|2|Matched Placebo for 4 months
9751369|NCT00473889|Experimental|1|vorinostat; IV paclitaxel; IV carboplatin
9751370|NCT00473889|Placebo Comparator|2|Placebo; IV paclitaxel; IV carboplatin
9751371|NCT00474045|Experimental|Insulin detemir|Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
10201857|NCT05194280||Robotic-assisted group|Group of patients that underwent a robotic-assisted donornephrectomy
10201858|NCT05194280||Hand-assisted laparoscopic group|Group of patients that underwent a hand-assisted laparoscopic donornephrectomy.
10201859|NCT05194254|Experimental|ASD|people with Autism Spectrum Disorders
10201860|NCT05194254|Active Comparator|TD|Typical Development) group of people
10201861|NCT05194241|Experimental|One MORE|
10201862|NCT05194241|No Intervention|Waitlist Control|
10201863|NCT05194228|Experimental|Group 1|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Fixed schedule Slider first
10201864|NCT05194228|Experimental|Group 2|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Fixed schedule Likert first
10201865|NCT05194228|Experimental|Group 3|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Random schedule Slider first
10201866|NCT05194228|Experimental|Group 4|$1 Payment per EMA 2 EMAs per day 15 questions per EMA Random schedule Likert first
10201867|NCT05194228|Experimental|Group 5|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Fixed schedule Slider first
10201868|NCT05194228|Experimental|Group 6|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Fixed schedule Likert first
10201869|NCT05194228|Experimental|Group 7|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Random schedule Slider first
10201870|NCT05194228|Experimental|Group 8|$1 Payment per EMA 2 EMAs per day 25 questions per EMA Random schedule Likert first
10201871|NCT05194228|Experimental|Group 9|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Fixed schedule Slider first
10201872|NCT05194228|Experimental|Group 10|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Fixed schedule Likert first
10201873|NCT05194228|Experimental|Group 11|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Random schedule Slider first
10201874|NCT05194228|Experimental|Group 12|$1 Payment per EMA 4 EMAs per day 15 questions per EMA Random schedule Likert first
10201875|NCT05194228|Experimental|Group 13|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Fixed schedule Slider first
10201876|NCT05194228|Experimental|Group 14|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Fixed schedule Likert first
10201877|NCT05194228|Experimental|Group 15|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Random schedule Slider first
10201878|NCT05194228|Experimental|Group 16|$1 Payment per EMA 4 EMAs per day 25 questions per EMA Random schedule Likert first
10201879|NCT05194228|Experimental|Group 17|Payment by % EMAs 2 EMAs per day 15 questions per EMA Fixed schedule Slider first
9829991|NCT02554682|No Intervention|Sexual Health & Alcohol Control Group|Parents of teens between the ages of 14 and 15 will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 4 to 5 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from both the sexual health and alcohol prevention groups.
9829992|NCT02554682|Other|Teen Driving|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will review psychoeducational workbooks related to teen driving at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 6 months post baseline we will collect data to assess the effectiveness of the study materials.
9829993|NCT02554682|No Intervention|Teen Driving Control|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 6 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from the teen driving group.
9829994|NCT02554721|Experimental|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
9829995|NCT02554721|Experimental|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
9829996|NCT02554721|Experimental|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
9829997|NCT02554721|Experimental|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
9829998|NCT02554760|Experimental|All Study Participants|This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
9829999|NCT02554786|Experimental|QMF149 150/160 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered once daily (o.d) via Concept1 inhaler in the evening.
9830000|NCT02554786|Experimental|QMF149 150/320 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening.
9830001|NCT02554786|Active Comparator|MF 400 µg|Mometasone furoate (MF) 400 μg was delivered o.d via Twisthaler® in the evening
9830002|NCT02554786|Active Comparator|Salmeterol /fluticasone 50/500 μg|Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.
9830003|NCT02554786|Active Comparator|MF 800 μg|MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.
9830004|NCT02554799|Experimental|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
9830005|NCT02554799|Experimental|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
9984017|NCT04477291|Experimental|Dose Escalation and Expansion|Dose Escalation and Expansion; CG-806 will be given orally in ascending doses in patients with relapsed or refractory AML or higher-risk MDS (escalation cohort), until the maximum tolerated dose or candidate recommended Phase 2 dose is reached. Followed up by up to 50 patients enrolled in the expansion cohort at the recommended dose.
9984018|NCT04476745|Experimental|Experimental: VD3 group|Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,
9984019|NCT04476745|No Intervention|Control group|Control group No intervention was given
9984020|NCT04475991|Active Comparator|Currently used therapy (CT) only|"Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present."
9984021|NCT04475991|Experimental|Maraviroc+CT|"Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
9984022|NCT04475991|Experimental|Favipiravir+CT|"Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
10201880|NCT05194228|Experimental|Group 18|Payment by % EMAs 2 EMAs per day 15 questions per EMA Fixed schedule Likert first
10201881|NCT05194228|Experimental|Group 19|Payment by % EMAs 2 EMAs per day 15 questions per EMA Random schedule Slider first
10201882|NCT05194228|Experimental|Group 20|Payment by % EMAs 2 EMAs per day 15 questions per EMA Random schedule Likert first
10201883|NCT05194228|Experimental|Group 21|Payment by % EMAs 2 EMAs per day 25 questions per EMA Fixed schedule Slider first
10201884|NCT05194228|Experimental|Group 22|Payment by % EMAs 2 EMAs per day 25 questions per EMA Fixed schedule Likert first
10201885|NCT05194228|Experimental|Group 23|Payment by % EMAs 2 EMAs per day 25 questions per EMA Random schedule Slider first
9751372|NCT00474045|Active Comparator|Neutral Protamine Hagedorn (NPH) insulin|Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
9751373|NCT00474058|Experimental|Rotigotine|Rotigotine transdermal patch
9751374|NCT00474058|Placebo Comparator|Placebo|Placebo transdermal patch
9751375|NCT00474123|Active Comparator|Simvastatin 80 mg|Patients were treated with simvastatin 80 mg for 6 weeks
9751376|NCT00474123|Active Comparator|Ezetimibe 10 mg / Simvastatin 20 mg|Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
9751377|NCT00474175|Placebo Comparator|1|Placebo control
9751378|NCT00474175|Active Comparator|2|10% benzocaine gel formulation
9751379|NCT00474175|Active Comparator|3|20% benzocaine gel formulation
9751380|NCT00474201|Sham Comparator|Gemfibrozil PK without LPV/r|"Subjects received a single 600 mg dose of gemfibrozil without concurrent lopinavir-ritonavir 400mg/100mg; this is the control arm of a crossover study design."
9751381|NCT00474201|Experimental|Gemfibrozil PK after 2 weeks of LPV/r|Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
9751382|NCT00474240|Placebo Comparator|1|
9751383|NCT00474240|Active Comparator|2|
9751384|NCT00474240|Experimental|3|
9751385|NCT00474240|Experimental|4|
9751386|NCT00474240|Experimental|5|
9751387|NCT00474240|Experimental|6|
9751388|NCT00474253|Experimental|Rocuronium + Sugammadex|Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
9751389|NCT00474253|Active Comparator|Succinylcholine|Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
9751390|NCT00474266|Experimental|Nimenrix + Priorix-Tetra Group|Subjects received 1 dose of Nimenrix vaccine and 1 dose of Priorix-Tetra vaccine on Day 0 and a second dose of Priorix-Tetra vaccine on Day 84.
9751391|NCT00474266|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
9751392|NCT00474266|Active Comparator|Priorix-Tetra Group|Subjects received 1 dose of Priorix-Tetra vaccine on Day 0, 1 dose of Meningitec vaccine on Day 42 and a second dose of Priorix-Tetra vaccine on Day 84.
9751393|NCT00474266|Active Comparator|Meningitec Group|Subjects received 1 dose of Meningitec vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
9751394|NCT00474383|Experimental|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) tablet or capsule will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study, along with prednisone/prednisolone 5 mg tablet orally twice daily or dexamethasone 0.5 mg tablet orally once daily.
9751395|NCT00474487|Experimental|Novartis MenACWY Vaccine (19 to 55 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
9751396|NCT00474487|Active Comparator|Licensed polysaccharide vaccine|Licensed meningococcal ACWY polysaccharide vaccine
9751397|NCT00474487|Active Comparator|Licensed Conjugate Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
9751398|NCT00474487|Experimental|Novartis MenACWY Vaccine (56 to 65 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years
9751399|NCT00474526|Experimental|US1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751400|NCT00474526|Experimental|US1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751401|NCT00474526|Experimental|US2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751402|NCT00474526|Experimental|US3 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751403|NCT00474526|Experimental|US4A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751404|NCT00474526|Experimental|US4B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751405|NCT00474526|Experimental|US4C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9830006|NCT02554799|Experimental|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
9830007|NCT02554877|Placebo Comparator|Placebo|
9830008|NCT02554877|Experimental|PF-06291874, 30 mg|
9830009|NCT02554877|Experimental|PF-06291874, 60 mg|
9830010|NCT02554877|Experimental|PF-06291874, 100 mg|
9751406|NCT00474526|Experimental|LA1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months"
9751407|NCT00474526|Experimental|LA1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751408|NCT00474526|Experimental|LA2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751409|NCT00474526|Experimental|LA3A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 16 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751410|NCT00474526|Experimental|LA3B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 17 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751411|NCT00474526|Experimental|LA4 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 15 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751412|NCT00474526|Experimental|LA5 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751413|NCT00474526|Experimental|LA6A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12, and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751414|NCT00474526|Experimental|LA6B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751415|NCT00474526|Experimental|LA6C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
9751416|NCT00474539|Experimental|1|
9751417|NCT00474539|Active Comparator|2|
9751418|NCT00474617|Experimental|Participants 18 to 64 years old|Participants to receive an intravenous (IV) single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of second twitch (T2) with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
9751419|NCT00474617|Experimental|Participants 65 to 74 years old|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
9751420|NCT00474617|Experimental|Participants 75 years and older|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
9751421|NCT00474630|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy
9751422|NCT00474630|Placebo Comparator|Placebo|Placebo with ancillary therapy
9751423|NCT00474708|Experimental|1|1.Effexor XR Group
9751424|NCT00474708|Active Comparator|2|2.SSRI or Conventional Antidepressant Group
9751425|NCT00474760|Experimental|1|
9751426|NCT00474786|Experimental|1|
9751427|NCT00474786|Experimental|2|
9751428|NCT00474812|Experimental|Dasatinib Treatment|Patients receive oral dasatinib twice daily on days 1-28.
9751429|NCT00474851|Experimental|Norethindrone acetate + estrogens|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
9751430|NCT00474851|Placebo Comparator|norethindrone acetate + placebo|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.
9751431|NCT00474903|Active Comparator|Arm I (placebo, esomeprazole magnesium)|Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
9751432|NCT00474903|Experimental|Arm II (low-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
9751433|NCT00474903|Experimental|Arm III (higher-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
9751434|NCT00474929|Experimental|Multiple Myeloma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
9984023|NCT04475991|Experimental|Maraviroc+Favipiravir+CT|"Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients"
9751435|NCT00474929|Experimental|Lymphoma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
9751436|NCT00474955|Experimental|Peginterferon Alpha-2a|Eligible participants will be administered peginterferon alpha-2a [Pegasys] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of <15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
9751437|NCT00474968||Arm 1 - Experimental|e2 Cell Collector [SoftPAP(R)]
9751438|NCT00474968||Arm 2 - Control|Brush/spatula
9751439|NCT00474994|Experimental|Group A|Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
9751440|NCT00474994|Experimental|Group B|High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma [MFH]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
9751441|NCT00474994|Experimental|Group C|Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
9751442|NCT00475020|Experimental|Fludarabine + Busulfan + Thymoglobulin|Fludarabine 40 mg/m^2 by vein daily over 1 hour x 4 days. Busulfan test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days. Thymoglobulin 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor.
9751443|NCT00475033|Experimental|1|
9751444|NCT00475033|Active Comparator|2|
9751445|NCT00475085|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
9751446|NCT00475085|Experimental|Arm II|Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
9751447|NCT00475085|Active Comparator|Arm III|Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
9751448|NCT00475085|Experimental|Arm IV|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
9751449|NCT00475150|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
9751450|NCT00475176|Experimental|S-Adenosyl Methionine|
9751451|NCT00475215|Experimental|Rocuronium + Sugammadex 2.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 2.0 mg/kg.
9751452|NCT00475215|Experimental|Rocuronium + Sugammadex 4.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 4.0 mg/kg.
9751453|NCT00475228|Experimental|Arm I|Levonorgestrel IUD will be inserted immediately after completion of D&E
9751454|NCT00475228|Active Comparator|Arm 2|Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D&E procedure)
9751455|NCT00475241|Experimental|Prolonged Exposure Therapy|Prolonged exposure therapy for PTSD
9751456|NCT00475241|Active Comparator|Present Centered Therapy|Present centered therapy for PTSD
9751457|NCT00475306|Active Comparator|Metoclopramide 20+diphenhydramine|Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes
9751458|NCT00475306|Active Comparator|Metoclopramide 20+placebo|Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes
9751459|NCT00475306|Active Comparator|Metoclopramide 10 + placebo|Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes
9751460|NCT00475306|Active Comparator|Metoclopramide 10+diphenhydramine|Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes
9751461|NCT00475319|Placebo Comparator|Placebo|0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
9751462|NCT00475319|Experimental|1% OPC-12759 ophthalmic suspension|1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
9751463|NCT00475319|Experimental|2% OPC-12759 ophthalmic suspension|2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
9751464|NCT00475423|Experimental|1|
9751465|NCT00475501|Experimental|Arm 1|testosterone enanthate
9984024|NCT04475523|Experimental|CI-8993 dose escalation|Patients will be administered CI-8993 intravenously at a planned infusion rate over 2 hours at planned step-doses and subsequent full doses. The planned schedule of administration is every 2 weeks. The MTD of full doses of CI-8993 will be determined based on the occurrence of DLTs 28 days from the first full dose. Eligible patients may receive CI-8993 at the dose and schedule, according to their assigned cohorts, until disease progression or unacceptable toxicity.
9751466|NCT00475501|Experimental|Arm 2|finasteride
9751467|NCT00475501|Experimental|Arm 3|testosterone enanthate + finasteride
9751468|NCT00475501|Placebo Comparator|Arm 4|placebo
9782538|NCT01178281|Experimental|Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit (defined as a reduction from Baseline of ≥ 50% in RBC-transfusion frequency during the prior 84-day interval) could continue to receive pomalidomide until loss of RBC-transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
9751469|NCT00475644|Experimental|Enzastaurin|Enzastaurin: 1125 milligram (mg) loading dose then 500 mg, oral daily, up to 3 years
9751470|NCT00475670|Active Comparator|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.
9751471|NCT00475670|Experimental|Trastuzumab, Taxane|Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.
9751472|NCT00475709|Experimental|Trifecta Aortic Heart Valve|All subjects enrolled into the study are implanted with the Trifecta Aortic Heart Valve.
9751473|NCT00475722|Active Comparator|1 Healthy Eating|Healthy People 2010 Diet using an exchange list
9751474|NCT00475722|Experimental|2 Mediterranean|Mediterranean Diet using an exchange list
9751475|NCT00475735|Experimental|MK-0249|Total time in the study will be ~10 weeks.
9751476|NCT00475735|Active Comparator|Concerta|Total time in the study will be ~10 weeks.
9751477|NCT00475735|Placebo Comparator|Placebo|Total time in the study will be ~10 weeks.
9751478|NCT00475787|Experimental|Spinal Manipulative therapy|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
9751479|NCT00475787|Sham Comparator|Detuned Ultrasound|"Detuned Ultrasound involves utilizing an ultrasound machine that is set to 0 w/cm2 and US gel is applied to the spine for 11 minutes."
9751480|NCT00475852|Experimental|001|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
9751481|NCT00475852|Placebo Comparator|002|Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
9751482|NCT00475865|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate (GA) for 24 weeks
9751483|NCT00475865|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
9751484|NCT00475865|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
9751485|NCT00475878|Placebo Comparator|placebo|
9751486|NCT00475878|Active Comparator|escitalopram|
9751487|NCT00475904|Active Comparator|amitriptyline 4% ketamine 2% cream, placebo capsules|Np-1 cream and placebo gabapentin
9984025|NCT04474015|Active Comparator|Part A, Group 1|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 1 will receive forearm stimulation at 0.75 Hz with an oscillating direct current (DC) waveform while awake.
9984026|NCT04474015|Active Comparator|Part A, Group 2|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 2 will receive forearm stimulation at 0.75 Hz with a modified alternating current (AC) waveform while awake.
9751488|NCT00475904|Active Comparator|gabapentin capsules, placebo cream|gabapentin caps and placebo cream
9751489|NCT00475904|Placebo Comparator|placebo cream and capsules|placebo cream and capsules
9751490|NCT00475982|Experimental|Arm 1: Weight Loss|Weight Loss Group
9751491|NCT00475982|Active Comparator|Arm 2: No Weight Loss|No Weight Loss Group
9751492|NCT00476008|Placebo Comparator|Placebo|One tablet placebo morning and evening (BID) for 12 months
9751493|NCT00476008|Active Comparator|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
9751494|NCT00476021|Experimental|Postplacental IUD insertion|immediate postplacental levonorgestrel-releasing IUD (Mirena) insertion
9751495|NCT00476021|Active Comparator|Delayed IUD insertion|delayed levonorgestrel-releasing IUD (Mirena) insertion (6-8 weeks after delivery)
9751496|NCT00476047|Experimental|Treatment (monoclonal antibody therapy)|Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
9751497|NCT00476086|Experimental|Oxaliplatin/ Gemcitabine Then Radiation|Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed.
9751498|NCT00476151|Placebo Comparator|placebo cream|vehicle cream
9751499|NCT00476151|Active Comparator|amitriptyline 4% ketamine 2% cream|active topical cream
9751500|NCT00476229|Experimental|Radiation + Chemotherapy + BSCT|Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)
9751501|NCT00476242|Experimental|Memantine and Vivitrol|intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
9751502|NCT00476242|Placebo Comparator|Placebo and Vivitrol|intramuscular injection of Vivitrol 380 mg and Placebo
9751503|NCT00476476|Experimental|Erlotinib|Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
9751504|NCT00476593|Experimental|Diclofenac|Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
9751505|NCT00476593|Experimental|Dexamethasone|Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
9751506|NCT00476645|Experimental|Fulvestrant|
9751507|NCT00476788|Experimental|Omnipod Device|Patients will be placed on an Omnipod insulin pump
9751508|NCT00476957|Active Comparator|1|Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
9751509|NCT00476957|Active Comparator|2|Cordis Cypher® Sirolimus-eluting Coronary Stent
9751510|NCT00476996|Experimental|Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
9751511|NCT00476996|Experimental|Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
9751512|NCT00476996|Placebo Comparator|Placebo x 2 IV + Non-Biologic DMARD Therapy|Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
9751513|NCT00477087|Experimental|GM-CSF Plus Mitoxantrone|GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.
9751514|NCT00477152|Experimental|HYLENEX-augmented subcutaneous (SC ) rehydration|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
9751515|NCT00477165|Experimental|Citalopram|One 20mg capsule per day for 4 weeks, then 2 capsules per day (40mg) for 4 weeks
9751516|NCT00477165|Placebo Comparator|Placebo|Identical to citalopram 20mg capsule. One capsule per day for 4 weeks, then 2 capsules per day for 4 weeks
9751517|NCT00477191|Experimental|Etanercept|Etanercept
9751518|NCT00477204|Active Comparator|Simvastatin|Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin [simvastatin] + Zetia [ezetimibe].
9751519|NCT00477204|Active Comparator|Ezetimibe/Simvastatin|Vytorin(simvastatin [Zocor} + ezetimibe [Zetia])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin [simvastatin]).
9751520|NCT00477269|Experimental|STI571|STI571
9751521|NCT00477269|Placebo Comparator|Placebo|Placebo
9751522|NCT00477269|Experimental|All Patients|Open label extension
9751523|NCT00477295|Active Comparator|Zonisamide|
9751524|NCT00477295|Active Comparator|Carbamazepine|
9751525|NCT00477334|Experimental|1|Famciclovir 1000 mg; twice a day for one day.
9751526|NCT00477334|Placebo Comparator|2|Placebo; twice a day for one day.
9751527|NCT00477386|Experimental|Carboplatin combined with Decitabine|Decitabine at escalating dose levels will be given X 5 days followed by Carboplatin given on Day 8.
9751528|NCT00477451|Placebo Comparator|RCT Placebo|Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
9751529|NCT00477451|Experimental|RCT Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
9751530|NCT00477451|Experimental|Open Label Inhaled Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
9751531|NCT00477451|Experimental|Initial Inhaled Alprazolam 2 mg|Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
9751532|NCT00477464|Experimental|Lapatinib+capecitabine|Lapatinib 1250mg once daily +capecitabine 2000mg/m^2 twice daily (14 days out of 21 days)
9751533|NCT00477490|Placebo Comparator|Placebo|Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
9751534|NCT00477490|Experimental|desmopressin melt 10 μg|Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
9751535|NCT00477490|Experimental|desmopressin melt 25 μg|Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
9751536|NCT00477490|Experimental|desmopressin melt 50 μg|Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
9751537|NCT00477490|Experimental|desmopressin melt 100 μg|Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).
9751538|NCT00477594|Experimental|Mipomersen 200 mg per week|Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
9751539|NCT00477594|Experimental|Mipomersen 200 mg every other week|Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
9751540|NCT00477607|Experimental|Arm 1|Receiving alpha-lipoic acid during cisplatin treatment.
9751541|NCT00477607|Placebo Comparator|Arm 2|Receiving placebo during cisplatin treatment
9751542|NCT00477633|Experimental|Norethindrone/ethinyl estradiol|1 tablet per day
9751543|NCT00477659|Experimental|Donepezil hydrochloride|
9751544|NCT00477672|Experimental|2|Pimavanserin tartrate (ACP-103), 10 mg, tablet, once daily by mouth, 6 weeks
9751545|NCT00477672|Experimental|3|Pimavanserin tartrate (ACP-103), 40 mg, tablet, once daily by mouth, 6 weeks
9751546|NCT00477672|Placebo Comparator|1|Placebo tablet, once daily by mouth, 6 weeks
9751547|NCT00477685||OculusGen Collagen Matrix|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
9751548|NCT00477750|Experimental|Treatment (Lenalidomide, Melphalan, Prednisone)|"Intervention: Drug: lenalidomide Dose determined by Phase I treatment schedule. Taken orally days 1-21 every 28 days until progression~Intervention: Drug: melphalan Dose determined by Phase I treatment schedule. Taken orally days 1-4 every 28 days until progression~Intervention: Drug: prednisone 60mg/m^2, orally days 1-4 every 28 days until progression"
9751549|NCT00477971|Active Comparator|Arm A|"Patients receive low-dose melphalan IV over 15-30 minutes on day~1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses.~Study treatment beyond one year is not allowed."
9751550|NCT00477971|Experimental|Arm B|Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
9830011|NCT02554890|Experimental|sacubitril/valsartan (LCZ696)|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."
9830012|NCT02554890|Active Comparator|Enalapril|"Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"
9830013|NCT02554903|Experimental|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
9830014|NCT02554903|Placebo Comparator|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
9830015|NCT02554929|Experimental|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
9830016|NCT02554929|Active Comparator|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
9830017|NCT02554981|Experimental|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
9830018|NCT02555098|Experimental|Sapphire contact lenses|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
9830019|NCT02555098|Active Comparator|senofilcon A|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
9830020|NCT02555215|Experimental|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
9830021|NCT02555228|Experimental|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
9830022|NCT02555228|Placebo Comparator|Placebo|Just 5 mls of water
9830023|NCT02555306|Experimental|Low Dose DE-122|Single intravitreal injection of DE-122 Low Dose Injectable Solution
9830024|NCT02555306|Experimental|Medium-Low Dose DE-122|Single intravitreal injection of DE-122 Medium-Low Dose Injectable Solution
9984027|NCT04474015|Active Comparator|Part A, Group 3|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 3 will receive forearm stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform while awake.
9830025|NCT02555306|Experimental|Medium-High Dose DE-122|Single intravitreal injection of DE-122 Medium-High Dose Injectable Solution
9830026|NCT02555306|Experimental|High Dose DE-122|Single intravitreal injection of DE-122 High Dose Injectable Solution
9830027|NCT02555371|Experimental|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
9830028|NCT02555371|Placebo Comparator|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
9751551|NCT00478023|Active Comparator|Morphine|
9751552|NCT00478023|Experimental|Tapentadol 50 mg immediate release|
9751553|NCT00478023|Experimental|Tapentadol 75 mg immediate release|
9751554|NCT00478023|Experimental|Tapentadol 100 mg immediate release|
9751555|NCT00478023|Placebo Comparator|Matched placebo|
9751556|NCT00478036|Active Comparator|Acular LS|Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
9751557|NCT00478036|Active Comparator|Pred Forte|Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
9751558|NCT00478036|Placebo Comparator|Refresh Tears|Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
9751559|NCT00478140|Experimental|Trastuzumab|Participants receive trastuzumab loading dose 8 mg/kg intravenous (IV) over 30-90 minutes on day 1 and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9751560|NCT00478192|Experimental|Regimen 1 Conivaptan QD|20 mg conivaptan once a day
9751561|NCT00478192|Experimental|Regimen 2 Conivaptan BID|20 mg conivaptan two times a day
9751562|NCT00478192|Placebo Comparator|Regimen 3 Placebo|
9751563|NCT00478205|Experimental|1|
9751564|NCT00478205|Experimental|2|
9751565|NCT00478218|Experimental|Lenalidomide/Cyclophosphamide/Dexamethasone|
9751566|NCT00478231|Experimental|1|
9751567|NCT00478244|Experimental|Epidermolysis Bullosa (EB) Patients|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant.
9751568|NCT00478257|Active Comparator|1 Active Bright White Light Treatment|Intervention: Bright white light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
9751569|NCT00478257|Active Comparator|2 Comparator Red Light Treatment|Intervention: Dim red light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
9751570|NCT00478335|Experimental|Active Therapy|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, calcitonin, sildenafil
9751571|NCT00478335|Placebo Comparator|Placebo Control|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, placebo for calcitonin, placebo for sildenafil
9751572|NCT00478361|Experimental|Gemcitabine, Paclitaxel and Doxorubicin|Paclitaxel 135 mg/m^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m^2 IV over 90 min; Doxorubicin 40 mg/m^2 IV over 20 min; treatment may repeat every 2 weeks for up to nine courses. Injection of Pegfilgrastim on day 1.
9751573|NCT00478426|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9751574|NCT00478556|Active Comparator|1|Gastroview
9751575|NCT00478556|Experimental|2|Omnipaque
9751576|NCT00478569||Parathyroid Hormone (PTH) (1-84)|PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
9751577|NCT00478647|Experimental|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
9751578|NCT00478777|Experimental|lenalidomide plus dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
9751579|NCT00478881|Experimental|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
9751580|NCT00478881|Placebo Comparator|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
9751581|NCT00478933|Experimental|ICD Therapy, blood sampling|Blood sampling Defibrillator, Dual Chamber ; Implantable
9751582|NCT00479037|Active Comparator|PTH(1-84)|
9751583|NCT00479037|Active Comparator|Strontium Ranelate|
9751584|NCT00479089|Active Comparator|Weekly Docetaxel|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy.
9751585|NCT00479089|Active Comparator|Weekly Docetaxel + ZD1839|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy. ZD1839 250 mg by mouth daily, without break.
9751586|NCT00479115|Experimental|AMD3100|
9751587|NCT00479154|Experimental|Botulinum Toxin A|Injection of onabotulinumtoxinA
9751588|NCT00479154|Placebo Comparator|Placebo (saline)|Injection of saline placebo
9751589|NCT00479232|Experimental|Cohort 1: Vorinostat (sequential)|"Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
9751590|NCT00479232|Experimental|Cohort 2: Vorinostat (concurrent)|"Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
9751591|NCT00479336|Placebo Comparator|1|
9751592|NCT00479336|Experimental|2|
9751593|NCT00479336|Experimental|3|
9751594|NCT00479336|Experimental|4|
9751595|NCT00479388|Other|1|One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
9751596|NCT00479388|Active Comparator|2|Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
9751597|NCT00479401|Experimental|Pramipexole Extended Release (PPX ER)|
9751598|NCT00479401|Experimental|Pramipexole Immediate Release (PPX IR)|
9751599|NCT00479401|Placebo Comparator|Placebo|
9751600|NCT00479466|Experimental|MK0893 80 mg|MK0893 tablets totaling 80 mg once daily.
9751601|NCT00479466|Experimental|MK0893 60 mg|MK0893 tablets totaling 60 mg once daily.
9751602|NCT00479466|Experimental|MK0893 40 mg|MK0893 40 mg tablet once daily.
9751603|NCT00479466|Experimental|MK0893 20 mg|MK0893 20 mg tablet once daily.
9751604|NCT00479466|Active Comparator|Metformin|Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
9751605|NCT00479466|Placebo Comparator|Placebo|PLA tablets. 12 week treatment period.
9751606|NCT00479557|Active Comparator|1|arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
9751607|NCT00479557|Active Comparator|2|arm 2: ACC-001
9751608|NCT00479557|Placebo Comparator|3|arm 3: QS-21
9751609|NCT00479557|Placebo Comparator|4|Drug: Phosphate Buffered Saline (PBS)
9751610|NCT00479674|Experimental|Abraxane, Carboplatin, Bevacizumab|Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
9751611|NCT00479687|Active Comparator|Supartz|SUPARTZ® 3 injections over 2 weeks
9751612|NCT00479687|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline 3 injections over 2 weeks
9751613|NCT00479765|Experimental|1|OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
9751614|NCT00479856|Experimental|Lapatinib plus Chemotherapy|Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.
9751615|NCT00479882|Experimental|Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg|After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.
9751616|NCT00479882|Experimental|Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.
9751617|NCT00479882|Experimental|Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg|After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.
9751618|NCT00479882|Experimental|Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.
9751619|NCT00480025|Experimental|GSK1572932 Group|Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
9751620|NCT00480025|Placebo Comparator|Placebo Group|Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
9751621|NCT00480077|Experimental|Access Arm|HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report
9751622|NCT00480077|Active Comparator|Control arm|HF subjects managed with standard clinical assessment
9751623|NCT00480324|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
9751624|NCT00480324|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
9751625|NCT00480441|Active Comparator|1|Dronabinol+ BRENDA therapy
9751626|NCT00480441|Placebo Comparator|2|Placebo+BRENDA therapy
9751627|NCT00480493|Experimental|Parent mentor contact|Parent mentor provides face-to-face social support
9751628|NCT00480493|Active Comparator|Control Arm|Parent is given a phone contact
9751629|NCT00480532|Experimental|Doxycycline 100bid x5 days|
9751630|NCT00480532|Placebo Comparator|placebo bid x 5 days|
9751631|NCT00480532|Experimental|Subantimicrobial doxycycline daily|
9751632|NCT00480532|Placebo Comparator|placebo daily|
9751633|NCT00480636||One cohort of patients treated with dalteparin.|About 100 patients with deep-vein thrombosis and with or without pulmonary embolism will be included in the study.
9751634|NCT00480740|Experimental|Cardiac Transplant|diagnostic cardiac catheterization in children with a transplanted heart
9751635|NCT00480740|Experimental|Fontan procedure|diagnostic cardiac catheterization in children with a transplanted ventricle
9751636|NCT00480740|Other|Normal Physiology|diagnostic cardiac catheterization in children with normal cardiac physiology
9830029|NCT02555449|Experimental|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
9830030|NCT02555618|Experimental|TAK-850|A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.
9830031|NCT02555618|Active Comparator|Influenza HA Vaccine|A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.
9830032|NCT02555631|Experimental|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
9830033|NCT02555683|Experimental|QAW039 150 mg|QAW039 150 mg once daily
9830034|NCT02555683|Experimental|QAW039 450 mg|QAW039 450 mg once daily
9830035|NCT02555683|Placebo Comparator|Placebo|Placebo once daily
9830036|NCT02555722|Experimental|fanfilcon A (test)|Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
9830037|NCT02555722|Active Comparator|enfilcon A (control)|Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
9830038|NCT02555878|Experimental|Rivaroxaban|Participants will be administered rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.
9984713|NCT03807661|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
9830039|NCT02555878|Experimental|Placebo|Participants will be administered matching placebo tablet orally once daily for 180 days.
9830040|NCT02556112|Active Comparator|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
9830041|NCT02556112|Active Comparator|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
9830042|NCT02556112|Active Comparator|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
9830043|NCT02556138|Experimental|Orbera Intragastric Balloon|All subjects will be receiving the ORBERA Intragastric Balloon
9830044|NCT02556177|Active Comparator|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
9830045|NCT02556177|Active Comparator|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
9830046|NCT02556203|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.
9830047|NCT02556203|Active Comparator|Antiplatelet|Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.
9830048|NCT02556255|Experimental|B-Laser™ Atherectomy Catheter|Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
9830049|NCT02556307||Peginterferon alfa-2a + Ribavirin|
9830050|NCT02556333|Experimental|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
9830051|NCT02556554|No Intervention|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
9830052|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
9830053|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
9830054|NCT02556632|Experimental|Arm I (curcumin-based gel)|Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
9830055|NCT02556632|Experimental|Arm II (HPR Plus)|Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
9830056|NCT02556632|Placebo Comparator|Arm III (placebo gel)|Patients apply placebo gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
9830057|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
9830058|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
9830059|NCT02556788|Experimental|CD5789 (Trifarotene) 50µg/g Cream|CD5789 (trifarotene) 50µg/g Cream
9830060|NCT02556788|Placebo Comparator|Placebo Cream|Placebo Cream
9830061|NCT02556801|Placebo Comparator|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|42 subjects received placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
9830062|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|42 subjects received SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
9830063|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
9830064|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
9984028|NCT04474015|Active Comparator|Part B, Group 4|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). roup 4 will receive scalp stimulation at 0.75 Hz with an oscillating direct current (DC) waveform during sleep.
10201886|NCT05194228|Experimental|Group 24|Payment by % EMAs 2 EMAs per day 25 questions per EMA Random schedule Likert first
9830065|NCT02556918|Experimental|Sitagliptin|"Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
9830066|NCT02556918|Placebo Comparator|Placebo|"Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
9830067|NCT02557035|Experimental|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
9830068|NCT02557035|Active Comparator|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
9830069|NCT02557100|Experimental|Treatment A|Abatacept Single Blind Treatment Period
9830070|NCT02557100|Active Comparator|Treatment B|Adalimumab Single Blind Treatment Period
9830071|NCT02557100|Active Comparator|Treatment C|Abatacept Cumulative Treatment Period
9830072|NCT02557178|Experimental|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen. Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
9830073|NCT02557178|No Intervention|Control|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.
9830074|NCT02557399|Experimental|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
9830075|NCT02557399|Active Comparator|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
9830076|NCT02557516|Experimental|Phase 1 Level 1 - 1 mg/kg|In phase 1, Monalizumab given at the first dose level of 1 mg/kg.
9830077|NCT02557516|Experimental|Phase 1 Level 2 - 2 mg/kg|In phase 1, Monalizumab given at the second dose level of 2 mg/kg.
9830078|NCT02557516|Experimental|Phase 1 Level 3 - 4 mg/kg|In phase 1, Monalizumab given at the third dose level of 4 mg/kg.
9830079|NCT02557516|Experimental|Phase 2 RP2D - 2 mg/kg|In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.
9830080|NCT02557646||Pegasys + Copegus|Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.
9830081|NCT02557698|Experimental|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
9830082|NCT02557698|No Intervention|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
9830083|NCT02558231|Experimental|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
9830084|NCT02558231|Placebo Comparator|Dual oral combination treatment|Macitentan, tadalafil, and placebo
9830085|NCT02558296|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
9830086|NCT02558296|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
9830087|NCT02558374|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
9830088|NCT02558374|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
9751637|NCT00480779|Other|GLB Group|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
9751638|NCT00480779|Other|GLB DVD|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
9751639|NCT00480857|Experimental|Docetaxel|
9751640|NCT00480987|Experimental|Oxaliplatin + Cytarabine + Fludarabine|Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6
9751641|NCT00481065|Experimental|Concomitant alone|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
9751642|NCT00481065|Experimental|Concomitant +Mixed|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
9751643|NCT00481065|Experimental|Concomitant +MF59-eH5N1|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
9751644|NCT00481065|Experimental|Mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
9751645|NCT00481065|Experimental|Mixed and mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
9751646|NCT00481065|Experimental|Mixed+MF59-eH5N1|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
9751647|NCT00481065|Experimental|MF59-eH5N1+eTIV_a|1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
9751648|NCT00481065|Experimental|eTIV_a+MF59-eH5N1|1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
9751649|NCT00481078|Experimental|Arm I (vorinostat, paclitaxel, carboplatin)|Patients receive oral vorinostat (SAHA) at 400 mg once daily on days 1-14 and paclitaxel IV 200 mg/m2 over 3 hours and carboplatin IV dosed to achieve an area under the concentration versus time curve of 6 mg/mLXmin over 30 minutes on day 3.
9751650|NCT00481078|Active Comparator|Arm II (placebo, paclitaxel, carboplatin)|Patients receive an oral placebo once daily on days 1-14 and paclitaxel and carboplatin as in arm l.
9751651|NCT00481195|Active Comparator|Armodafinil|
9751652|NCT00481195|Placebo Comparator|Placebo|
9751653|NCT00481247|Experimental|Dasatinib|
9751654|NCT00481247|Active Comparator|Imatinib|
9751655|NCT00481351|Experimental|group1 ezetimibe|6 week wash out, followed by 06 week ezetimibe 10mg once a day e then 6 week ezetimibe 10mg plus sinvastatin 20mg for more 6 week.
9751656|NCT00481351|Active Comparator|group 2 simvastatin|6 week simvastatin 20mg once a day followed by 6 week simvastatin 80mg once a day.
9751657|NCT00481507|Placebo Comparator|Placebo|
9751658|NCT00481507|Experimental|Kefir|
9751659|NCT00481676|Experimental|Omalizumab 75-375 mg|Omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
9751660|NCT00481676|Placebo Comparator|Placebo to omalizumab|Placebo to omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
9751661|NCT00481767|Active Comparator|Cervarix Group|Healthy female subjects who received 3 doses of Cervarix at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
9751662|NCT00481767|Placebo Comparator|Placebo Group|Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
9751663|NCT00481832|Experimental|T & B Cell Mobilization Auto & Allo HCT|A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
9751664|NCT00481845|Experimental|Vandetanib + Anastrozole|Vandetanib and Anastrozole as neoadjuvant therapy
9751665|NCT00481845|Active Comparator|Anastrozole|Anastrozole as neoadjuvant therapy
9830089|NCT02558400|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
9830090|NCT02558400|Active Comparator|AR-13324 Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
9984029|NCT04474015|Active Comparator|Part B, Group 5|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 5 will receive scalp stimulation at 0.75 Hz with a modified alternating current (AC) waveform during sleep.
9751666|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Sequential Days|
9751667|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Same Day|
9751668|NCT00481988|Active Comparator|transcranial direct current stimulation|The active group of patients will receive active Iomed II Phoresor transcranial direct current stimulation for the first two weeks followed by another two weeks of active transcranial direct current stimulation.
9751669|NCT00481988|Sham Comparator|sham tDCS|The patients in the sham arm receive active Iomed II Phoresor transcranial direct current stimulation for the second two weeks of the clinical trial only. For the first two weeks the Iomed II Phoresor constant current generator is turned on for 10 seconds to produce the tingling sensation on the scalp experienced by the patients in the active arm but the generator is then turned off and the patients receive no stimulation for the remainder of the 20 minute session.
9751670|NCT00482001|Experimental|donepezil|donepezil, capsule, 5mg daily once daily for 14 days
9751671|NCT00482001|Placebo Comparator|placebo|placebo (cornstarch), capsule, once daily for 14 days
9751672|NCT00482014|Experimental|A: Pemetrexed + Carboplatin|Pemetrexed + Carboplatin
9751673|NCT00482014|Experimental|B: Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
9751674|NCT00482053|Experimental|Auto-HCT followed by Allo-HCT for Poor-risk DLBCL|"Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning [total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; & methylprednisolone."
9751675|NCT00482170|Experimental|1|Arm 1: Enbrel 50 mg Prefilled Syringe
9751676|NCT00482170|Active Comparator|2|Arm 2 Enbrel 50 mg Autoinjector
9751677|NCT00482391|Experimental|AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB|The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy, patients may receive trastuzumab on a q 3-weekly schedule, starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily, starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
9751678|NCT00482547|Experimental|Silver-coated catheter|Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System
9751679|NCT00482547|Placebo Comparator|Silicone-coated catheter|Bard silicone elastomer coated latex catheter system
9751680|NCT00482612|Experimental|Esmirtazapine 1.5 mg|Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
9751681|NCT00482612|Experimental|Esmirtazapine 3.0 mg|Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
9751682|NCT00482612|Experimental|Esmirtazapine 4.5 mg|Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
9751683|NCT00482612|Placebo Comparator|Placebo|Placebo to esmirtazapine
9751684|NCT00482625|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
9751685|NCT00482677|Active Comparator|Temozolomide|Temozolomide and short course radiation
9751686|NCT00482677|Active Comparator|Radiation|Short course radiation alone
9751687|NCT00482703|Experimental|A|
9751688|NCT00482703|Experimental|B|
9751689|NCT00482729|Experimental|1|Arm 1: drug
9751690|NCT00482729|Active Comparator|2|Arm 2: active comparator
9751691|NCT00482911|Experimental|Cohort 1-lenalidomide & cyclophosphamide|Participants first started on 2 Interventions (Dose A-QD) in Cycle 1, with 10 mg Lenalidomide (Len) once daily and 50 mg Cyclophosphamide (Cyc) once daily; 25 mg Sunitinib (Sun) was added once daily as a 3rd Intervention (Dose B-QD) from Cycle 2 onwards. Doses were adjusted in subsequent cycles depending on toxicity, including incremental step downs to 5/25/12.5 mg Len/Cyc/Sun once daily (Dose C-QD) or once every other day (Dose C-QOD).
9830091|NCT02558400|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
9830092|NCT02558790|Experimental|L-Threonic Acid Magnesium Salt (L-TAMS)|Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.
9751692|NCT00482911|Experimental|Cohort 2-sunitinib & cyclophosphamide|2 participants started Cycle 1 with Dose B as described above and had adjusted-dosing as described for Cohort 1. The remaining 7 participants began Cycle 1 with 10 mg Len, 25 mg Cyc and 12.5 mg Sun once daily (Dose D-QD). Doses were adjusted in subsequent cycles depending on toxicity, including step up to 10/50/12.5 mg Len/Cyc/Sun once daily (Dose E-QD) and step down to Dose D once every other day (Dose D-QOD).
9751693|NCT00483002||Healthy smokers|
9751694|NCT00483041|Experimental|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
9751695|NCT00483041|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
9751696|NCT00483184|Placebo Comparator|1|(placebo)0 IU IFNa
9751697|NCT00483184|Experimental|2|(Veldona)500 IU IFNα bid
9751698|NCT00483184|Experimental|3|(Veldona)1000 IU IFNα bid
9751699|NCT00483223|Experimental|Single Arm|Cisplatin or carboplatin (1 arm, 2 cohorts)
9751700|NCT00483262|Experimental|CCI779 and Bortezomib Phase I/II|In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.
9751701|NCT00483327|Experimental|Megestrol Acetate|80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
9751702|NCT00483379|Experimental|alglucosidase alfa 20 mg/kg every week|Participants were treated with alglucosidase alfa 20 mg/kg every week for 52 weeks. This was the 'frequent dose' arm.
9751703|NCT00483379|Experimental|alglucosidase alfa 40 mg/kg every other week|Participants were treated with alglucosidase alfa 40 mg/kg every other week for 52 weeks. This was the 'high dose' arm.
9751704|NCT00483405|Other|Single Arm Trial|Single Arm Trial
9751705|NCT00483496|Experimental|V0096CR actives and vehicle|"Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window).~Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator."
9751706|NCT00483509|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
9751707|NCT00483548|Experimental|Ziprasidone|Active treatment, double-blind, randomized treatment arm
9751708|NCT00483548|Placebo Comparator|Placebo|Inactive, placebo treatment, double-blind, randomized arm
9751709|NCT00483561|Experimental|Gefitinib plus Etoposide|"Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.~Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple)."
9751710|NCT00483574|Experimental|Group 1: Menactra® and Routine Pediatric Vaccines|Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate [PCV], and hepatitis A [HepA]) at age 12 months.
9751711|NCT00483574|Other|Group 2: Routine Pediatric Vaccines|Participants received routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate[PCV], and hepatitis A [HepA]) at age 12 months.
9751712|NCT00483652|Placebo Comparator|Placebo|Placebo control
9751713|NCT00483652|Active Comparator|Fampridine-SR|10 mg b.i.d.
9751714|NCT00483704|Experimental|Telcagepant 140 mg|Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
9751715|NCT00483704|Experimental|Telcagepant 280 mg|Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
9751716|NCT00483704|Placebo Comparator|Control Group 1|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
9751717|NCT00483704|Placebo Comparator|Control Group 2|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
9751718|NCT00483717|Placebo Comparator|Placebo|Intranasal Placebo
9751719|NCT00483717|Experimental|Ketorolac tromethamine|Intranasal ketorolac tromethamine
9751720|NCT00483756|Active Comparator|1|Treatment Arm 1 will also receive standard of care medications
9751721|NCT00483756|Experimental|2|Treatment Arm 2 will also receive standard of care medications
9751722|NCT00483756|Experimental|3|Treatment Arm 3 will also receive standard of care medications
9751723|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group A)|Participants with HCV RNA levels greater than (>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (>=) 15 IU/mL at Week 8, and either HCV RNA less than (<) 15 IU/mL or >=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
9751724|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group B)|Participants with HCV RNA levels >15 IU/mL at Week 4, HCV RNA >=15 IU/mL at Week 8, and either HCV RNA <15 IU/mL or >=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
9830093|NCT02558829|Experimental|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
9830094|NCT02558829|Experimental|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
9830095|NCT02558894|Experimental|MEDI4736 monotherapy|MEDI4736 via IV infusion.
9830096|NCT02558894|Experimental|tremelimumab+MEDI4736|MEDI4736+tremelimumab via IV infusion.
9830097|NCT02559115|Experimental|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass <= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
9830098|NCT02559206|Experimental|30 μg linaclotide DR1 and placebo|
9830099|NCT02559206|Experimental|100 μg linaclotide DR1 and placebo|
9830100|NCT02559206|Experimental|300 μg linaclotide DR1 and placebo|
9830101|NCT02559206|Experimental|30 μg linaclotide DR2 and placebo|
9830102|NCT02559206|Experimental|100 μg linaclotide DR2 and placebo|
9830103|NCT02559206|Experimental|300 μg linaclotide DR2 and placebo|
9830104|NCT02559206|Experimental|290 μg linaclotide IR and placebo|
9830105|NCT02559206|Placebo Comparator|Placebo|
9830106|NCT02559310|Experimental|Lefamulin|Intravenous lefamulin with potential step-down to oral lefamulin
9830107|NCT02559310|Active Comparator|Moxifloxacin +/- Linezolid|Intravenous moxifloxacin with potential step-down to oral moxifloxacin +/- linezolid
9830108|NCT02559414|No Intervention|Control|This arm of 10 subjects will be assigned randomly via a computer generated treatment sequence, and then be given no antiplatelet medication.
9830109|NCT02559414|Active Comparator|Aspirin|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given aspirin.
9830110|NCT02559414|Active Comparator|Clopidogrel|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given clopidogrel.
9830111|NCT02559505|Experimental|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
9830112|NCT02559505|Experimental|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
9830113|NCT02559505|Experimental|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
9830114|NCT02559505|Experimental|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
9830115|NCT02559505|Experimental|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
9830116|NCT02559505|Experimental|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
9830117|NCT02559505|Experimental|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
9830118|NCT02559505|Experimental|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
9830119|NCT02559570|Placebo Comparator|Placebo|Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.
9830120|NCT02559570|Experimental|LIN Dose A (9 ug or 18 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
9830121|NCT02559570|Experimental|LIN Dose B (18 ug or 36 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
9830122|NCT02559570|Experimental|LIN Dose C (36 ug or 72 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
9830123|NCT02559570|Experimental|LIN 145 µg|Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
9830124|NCT02559622|Experimental|300 mg secukinumab|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
9830125|NCT02559622|Experimental|150 mg secukinumab|150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
9830126|NCT02559622|Other|Placebo followed by 300 mg secukinumab|Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
9830127|NCT02559622|Other|Placebo followed by 150 mg secukinumab|Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
9751725|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group C)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
9751726|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group D)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
9751727|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group E)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
9751728|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group F)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
9751729|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group NR)|Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
9751730|NCT00484094||Rapamune|
9751731|NCT00484159|Experimental|1|Radiofrequency lumbar facet joint denervation only if positive response to 2 diagnostic facet blocks.
9751732|NCT00484159|Experimental|2|Radiofrequency lumbar facet joint denervation if positive response to single facet joint block.
9751733|NCT00484159|Experimental|3|Radiofrequency lumbar facet denervation without a diagnostic facet block.
9751734|NCT00484185||1|
9751735|NCT00484198|Placebo Comparator|1|
9751736|NCT00484198|Experimental|2|Rivoglitazone 1.0 mg
9751737|NCT00484198|Experimental|3|Rivoglitazone 1.5 mg
9751738|NCT00484198|Active Comparator|4|Pioglitazone 45 mg
9751739|NCT00484289|Experimental|Arm 1: Participants from Phase I study (IM101-034)|
9751740|NCT00484289|Experimental|Arm 2: Participants from Phase II study (IM101-071)|
9751741|NCT00484289|Experimental|Arm 3: New Participants with Methotrexate (MTX) Intolerance|
9751742|NCT00484315|Experimental|TAXUS Element|
9751743|NCT00484315|Active Comparator|TAXUS Express|
9751744|NCT00484354|Active Comparator|1|Bicarbonate administration
9751745|NCT00484354|Placebo Comparator|2|Normal saline administration
9751746|NCT00484393|Experimental|Tetracaine|Tetracaine 4% gel 1g applied to injection site
9751747|NCT00484393|Placebo Comparator|Placebo|Placebo cream (Aquatain) 1g applied to inejction site
9751748|NCT00484679|Experimental|1|Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
9751749|NCT00484874|Experimental|A Single Dose of I-131 Tositumomab|I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
9751750|NCT00484939|Experimental|Bevacizumab + capecitabine|Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
9751751|NCT00484939|Active Comparator|Capecitabine|Participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
9751752|NCT00485069|Experimental|Ropinirole Hydrochloride|
9751753|NCT00485134|Experimental|Stage 1: Group A, Dolphin 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of lipopolysaccharides (LPS). 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
9751754|NCT00485134|Experimental|Stage 1: Group B, Dolphin 480 µg|480 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
9751755|NCT00485134|Experimental|Stage 1: Group C, Dolphin 690 µg|690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
9751756|NCT00485134|Other|Stage 1: Group D, Pipette 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. These subjects received 200 μL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.
9830128|NCT02559687|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years)
9830129|NCT02559713|Experimental|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.
9830130|NCT02559817|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
9830131|NCT02559817|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
9830132|NCT02559817|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
9830133|NCT02559817|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
9830134|NCT02559817|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age~Placebo solid oral capsule in children 12-17 years of age"
9830135|NCT02559895|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
9830136|NCT02559895|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
9830137|NCT02559895|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
9830138|NCT02559895|Placebo Comparator|Placebo|Placebo (IV)
9830139|NCT02560012|Other|Personalized therapy|"Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules.~Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules."
9830140|NCT02560025|Experimental|Alisertib / MLN8237|"Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
9830141|NCT02560038|Experimental|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
9830142|NCT02560051|Active Comparator|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
9984030|NCT04474015|Active Comparator|Part B, Group 6|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 6 will receive scalp stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform during sleep.
9830143|NCT02560051|Active Comparator|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
9830144|NCT02560051|Active Comparator|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
9830145|NCT02560324|Experimental|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
9830146|NCT02560324|Placebo Comparator|Placebo|"5-day placebo-controlled medication period.~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
9830147|NCT02560389|Placebo Comparator|Placebo|Placebo administered in pill form once by mouth
9830148|NCT02560389|Active Comparator|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
9984031|NCT04474015|Active Comparator|Part C, Group 7|Pulsed Stimulation: Group 7 (Part C)will receive a series of brief stimulations of up to 500 millisecond duration and of up to 5 milliamperes of current, using either metal electrodes or sponge electrodes as stimulating electrodes.
9830149|NCT02560389|Active Comparator|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
9830150|NCT02560493|No Intervention|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
9830151|NCT02560493|Experimental|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
9830152|NCT02560558|Experimental|Belatacept 8-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
9830153|NCT02560558|Active Comparator|Belatacept 4-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.
9830154|NCT02560584|Experimental|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
9830155|NCT02560753|Experimental|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
9830156|NCT02560753|Experimental|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
9830157|NCT02560753|Experimental|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
9830158|NCT02560753|Experimental|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
9830159|NCT02560779|Experimental|Carotuximab (TRC105) and Sorafenib|Carotuximab (TRC105) in combination with standard dose Sorafenib.
9830160|NCT02560922|Experimental|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
9830161|NCT02560922|No Intervention|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
9830162|NCT02561000|Experimental|PZ-128 0.3 mg/kg|PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
9830163|NCT02561000|Experimental|PZ-128 0.5 mg/kg|PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
9830164|NCT02561000|Placebo Comparator|Placebo|Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
9830165|NCT02561078|Experimental|Human regular U-500 insulin administered by CSII|Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
9830166|NCT02561078|Active Comparator|Human regular U-500 insulin administered by MDI|Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
9830167|NCT02561130|Experimental|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
9830168|NCT02561130|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
9830169|NCT02561156|Experimental|Part 1 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9830170|NCT02561156|Experimental|Part 1 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9830171|NCT02561156|Experimental|Part 1 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9830172|NCT02561156|Experimental|Part 1 Cohort 4: TAK-653 5.0 mg|TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9830173|NCT02561156|Experimental|Part 1 Cohort 5: TAK-653 9.0 mg|TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
9830174|NCT02561156|Experimental|Part 1 Cohort 6: TAK- 653 18 mg|TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
9830175|NCT02561156|Experimental|Part 1 Additional Cohorts: TAK- 653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
9830176|NCT02561156|Experimental|Part 2 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
9830177|NCT02561156|Experimental|Part 2 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
9830178|NCT02561156|Experimental|Part 2 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
9984032|NCT04471545|Experimental|Interventional group|Intervention arm: PECS II block with ropivacaine
9830179|NCT02561156|Experimental|Part 2 Cohort 4: TAK-653 6 mg|TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
9830180|NCT02561156|Experimental|Part 2 Cohort 5: TAK-653 9 mg|TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
9830181|NCT02561156|Experimental|Part 2 Additional Cohorts: TAK-653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
9830182|NCT02561195|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
9830183|NCT02561195|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
9830184|NCT02561195|Placebo Comparator|Placebo (accelerated schedule)|
9830185|NCT02561195|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
9830186|NCT02561195|Experimental|High-Dose C. difficile Vaccine (non-accelerated schedule)|
9830187|NCT02561195|Placebo Comparator|Placebo (non-accelerated schedule)|
9830188|NCT02561221|Experimental|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm attended weekly (16 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention was delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm received a series of webinars on obesity science to help them manage and treat patients with obesity.
9830189|NCT02561221|No Intervention|Usual Care|Patients assigned to the usual care arm continued to interact with their Primary Care Practitioners according to their usual schedule, and received a series of newsletters on topics of interest, including importance of sleep for health, brain and memory health, goal setting, smoking cessation, etc. Primary Care Practitioners in the usual care arm received a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure was sent to the Primary Care Practitioners each year.
9830190|NCT02561247|Experimental|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 20 of the first 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
9830191|NCT02561273|Experimental|Treatment (combination chemotherapy, lenalidomide)|"Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows:~TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care.~MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9830192|NCT02561338|Experimental|HMS5552 dose 1|75mgQD oral administration
9830193|NCT02561338|Experimental|HMS5552 dose 2|100mgQD oral administration
9830194|NCT02561338|Experimental|HMS5552 dose 3|50mgBID oral administration
9830195|NCT02561338|Experimental|HMS5552 dose 4|75mgBID oral administration
9830196|NCT02561338|Placebo Comparator|Placebo|Placebo, BID/QD oral administration
9830197|NCT02561455|Experimental|Gilteritinib 40 mg|Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
9830198|NCT02561455|Experimental|Gilteritinib 80 mg|Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
9830199|NCT02561455|Experimental|Gilteritinib 120 mg|Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
9984033|NCT04471545|Placebo Comparator|Control group|Control arm: PECS II block with placebo (saline)
9984714|NCT03807414||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing treatment with oXiris will be prospectively observed.
9666861|NCT04174079|Experimental|Experimental group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
9666862|NCT04174079|No Intervention|control group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma were reviewed regularly after surgery.
9666863|NCT04173182||Inflammation on pCLE|Patients with inflammatory findings in the peridiverticular and colonic mucosa (crypt fusion and distortion, bright epithelium, and dilated-prominent branching vessels)
9666864|NCT04173182||No inflammation on pCLE|Patients with normal findings on pCLE evaluation of the peridiverticular and colonic mucosa (absence of inflammation)
9666865|NCT04171804|Active Comparator|Active|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
9666866|NCT04171804|Sham Comparator|Sham|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
9666867|NCT04166981|Active Comparator|Non-instrumented arm|Decompression with concomitant non-instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft.
9666868|NCT04166981|Experimental|Instrumented arm|Decompression with concomitant instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft and supplementary pedicle screw fixation.
9666869|NCT04166591|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
9666870|NCT04166591|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
9666871|NCT04165239|Experimental|Treatment A|Oral administration of 50 mg KH176 twice daily
9666872|NCT04165239|Experimental|Treatment B|Oral administration of 100 mg KH176 twice daily
9666873|NCT04165239|Placebo Comparator|Treatment C|Oral administration of matching placebo twice daily
9666874|NCT04163900|Experimental|A - NUC-1031 and cisplatin|725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
9666875|NCT04163900|Active Comparator|B - gemcitabine and cisplatin|1000 mg/m^2 gemcitabine administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
9666876|NCT04154826|Experimental|low dose|CYT107 10µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 10µg/kg/week for 4 weeks (wk9-12)
9666877|NCT04154826|Experimental|high dose|CYT107 20µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 20µg/kg/week for 4 weeks (wk9-12)
9666878|NCT04153435|Experimental|Calcium|The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
9666879|NCT04153435|Placebo Comparator|Placebo|"The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, normal saline) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline."
9666880|NCT04153188|Experimental|Pulsed Dye Laser & Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream for 4 weeks prior to 1st of 3 monthly Vbeam® Prima PDL treatments. Subjects will continue with once daily application of Oxymetazoline HCL 1% Cream during the 6-month post-baseline study with a 3-day washout of cream prior to each of the 3 PDL treatments.
9666881|NCT04153188|Active Comparator|Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream during the 6-month study.
9666882|NCT04149821|Experimental|Cohort A Post BTKi Therapy|Patients who progress after a BTKi containing regimen
9666883|NCT04149821|Experimental|Cohort B Post BCL-2 Therapy|"Patients who progress after BCL-2 containing regimens~Patients who progress on a regimen containing both a BTKi and a BCL-2 inhibitor"
9666884|NCT04147221|Experimental|Imipenem-Relebactam|Participants will receive a single dose of intravenous imipenem-relebactam (500mg-250mg) as a 30 minute infusion.
9666885|NCT04147130|Experimental|MultiPAP Plus intervention|Complex intervention with general practitioners and patients
9666886|NCT04147130|Active Comparator|Usual care|Patients will recieve the usual clinical care
9666887|NCT04144127|Experimental|Soccer Group|Participants in the soccer group will participate in soccer drills and other fitness routines (two 1-hour sessions per week). They will meet with the soccer coach after the soccer sessions to discuss the lifestyle education topics (Life's Simple 7 education topics). During the soccer sessions participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
9666888|NCT04143919|Experimental|Subjects with CV risk factors|Subjects with 2 or more CV risk factors will be identified. Cardiovascular risk factors include hypertension, dyslipidemia, obesity, vascular disease, diabetes mellitus, chronic kidney disease, arrhythmia requiring therapy, moderate to severe valvular disease, history of alcohol abuse, smoking, cancer chemotherapy, or thoracic radiotherapy, and abnormal findings in the most recent ECG or thoracic X-ray.
9666889|NCT04142788|No Intervention|Standard dose MRA|Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
9666890|NCT04142788|Experimental|Patiromer and high dose MRA|Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).
9666891|NCT04142307|Active Comparator|Group A (treatment)|Each session includes 20 minutes of training each with rest as needed. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. A fixation training target (FTT) will be selected by the trainer at a perceived better fixation point. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look in the direction of the FTT and listen simultaneously to the audio feedback. As performing this task, the participant will actively control the eye movements until the audio feedback becomes more frequent and then becomes a continuous sound pattern. This continuous sound will signalize to the patient that the FTT location was reached. Participants will be given take-home efficiency reading exercises.
9830200|NCT02561455|Experimental|Gilteritinib 200 mg|Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
9830201|NCT02561481|Active Comparator|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to ~ 15 µmol SF). The total dose per day will depend on participants' body weight:~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
9830202|NCT02561481|Placebo Comparator|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
9830203|NCT02561572|Experimental|Intervention|Acupuncture at the Yintang point for 30 minutes.
9830204|NCT02561572|No Intervention|Control|No intervention for 30 minutes.
9830205|NCT02561585|Experimental|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
9830206|NCT02561585|Placebo Comparator|Vehicle|LEO 124249 ointment vehicle twice daily
9830207|NCT02561702|Experimental|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
9830208|NCT02561702|Experimental|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
9830209|NCT02561806|Active Comparator|Ustekinumab|45 mg ustekinumab given as SC injection for participants ≤100 kilograms (kg) and 90 mg SC injection for participants >100 kg at Week 0, 4, 16, 28, and 40. Placebo for ixekizumab injections will be used for blinding.
9830210|NCT02561806|Experimental|Ixekizumab|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg ixekizumab given as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 52.Placebo for ustekinumab injections will be used for blinding.
9830211|NCT02561832|Experimental|Arm 1|Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery
9830212|NCT02561897|Experimental|Edoxaban|Edoxaban 30 or 60 mg
10201887|NCT05194228|Experimental|Group 25|Payment by % EMAs 4 EMAs per day 15 questions per EMA Fixed schedule Slider first
10201888|NCT05194228|Experimental|Group 26|Payment by % EMAs 4 EMAs per day 15 questions per EMA Fixed schedule Likert first
9830213|NCT02561897|Active Comparator|Warfarin|Warfarin 1 -1 0 mg
9830214|NCT02562066|Experimental|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
9984715|NCT03799588|Experimental|Biphasic Chest Cuirass Arm|This is the only arm in the study and all patients will receive negative pressure ventilation via the biphasic chest cuirass.
10201889|NCT05194228|Experimental|Group 27|Payment by % EMAs 4 EMAs per day 15 questions per EMA Random schedule Slider first
10201890|NCT05194228|Experimental|Group 28|Payment by % EMAs 4 EMAs per day 15 questions per EMA Random schedule Likert first
10201891|NCT05194228|Experimental|Group 29|Payment by % EMAs 4 EMAs per day 25 questions per EMA Fixed schedule Slider first
10201892|NCT05194228|Experimental|Group 30|Payment by % EMAs 4 EMAs per day 25 questions per EMA Fixed schedule Likert first
10201893|NCT05194228|Experimental|Group 31|Payment by % EMAs 4 EMAs per day 25 questions per EMA Random schedule Slider first
10201894|NCT05194228|Experimental|Group 32|Payment by % EMAs 4 EMAs per day 25 questions per EMA Random schedule Likert first
10201895|NCT05194202|Experimental|ED-HEART (Intervention Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive Emergency Department Healthcare Education Assessment and Response for Teen Relationships (ED HEART) by a trained health educator, complete an exit survey while in the ED, complete a 6-week check-in to confirm contact information and aid retention, and complete a 12-week follow up survey.
10201896|NCT05194202|No Intervention|Enhanced Standard Care (Control Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive enhanced standard care (i.e., standard care + teen resource list), complete a 6-week check in to confirm contact information and aid retention, and complete a 12-week follow up survey.
9830215|NCT02562066|Experimental|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
9830216|NCT02562482|Experimental|Group 1: VRC-CHKVLP059-00-VP 20 mcg|Group 1 subjects were randomized to receive two intramuscular (IM) injections of CHIKV VLP vaccine (VRC-CHKVLP059-00-VP) at Day 0 and Day 28 (+14 days) at a dose of 20 micrograms (mcg).
9830217|NCT02562482|Placebo Comparator|Group 2: Placebo (VRC-PBSPLA043-00-VP)|Group 2 subjects were randomized to receive two intramuscular (IM) injections of Phosphate Buffered Saline (VRC-PBSPLA043-00-VP) placebo at Day 0 and Day 28 (+14 days).
9830218|NCT02562521|Experimental|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy [NRT] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
9830219|NCT02562521|No Intervention|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
9830220|NCT02562755|Experimental|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
9830221|NCT02562755|Active Comparator|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
9830222|NCT02562898|Experimental|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
9830223|NCT02562898|Experimental|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
10201897|NCT05194176|No Intervention|Control|The control group will receive usual care. Patients will be instructed to perform respiratory exercises 8 times daily for 10 minutesand to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. Respiratory exercisesinclude using incentive spirometry and exercises for deep breathing, huffing and coughing. Patients receive a leaflet with theexercises described and the exercises will be performed once daily under supervision of a physiotherapist. The other sessions willbe unsupervised.
10201898|NCT05194176|Experimental|Virtual Reality|The intervention group will be instructed to perform the respiratory exercises using the VR-intervention 8 times daily for 10 minutesand to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. The respiratory exercisesin VR are comparable to the exercises in usual care but performed in a virtual environment and without incentive spirometry. Thephysical exercises consist of several games through which patients are challenged to reach out to objects while engaging their core.Patients are allowed to continue these exercises or play some relaxation games for up to 30 minutes per session in total. The exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
9830224|NCT02562924|Active Comparator|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
9830225|NCT02562924|Experimental|MEDIHONEY® rinse alone group|"Days 0-7: Same as 1a;~Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
9984034|NCT04469140||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
10201899|NCT05194150|Experimental|Rayone EMV|Patient will receive the non-diffractive monofocal IOL during cataract surgery
10201900|NCT05194150|Experimental|Acrysof IQ Vivity|Patient will receive the standard EDOF IOL during cataract surgery
10201901|NCT05194085|No Intervention|Female SOC/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and laboratory HIV testing at enrollment and every 6 months until 6 months postpartum
10201902|NCT05194085|Active Comparator|Female intervention/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and POC VL tests for women at enrollment, delivery, and 6 months post-partum
9751757|NCT00485134|Other|Stage 2: Immunized / Challenge|The selected dose was to be administered with the Dolphin™ using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
9751758|NCT00485134|Placebo Comparator|Stage 2: Controls|A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
9751759|NCT00485173|Experimental|INFUSE® Bone Graft|In this arm, patients will receive implant with INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate.
9751760|NCT00485264|Experimental|Cohort I|"Participants between the ages of 12 and 18 years; receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily."
9751761|NCT00485264|Experimental|Cohort IIA|"Participants between the ages of 6 and 11 years, receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet."
9751762|NCT00485264|Experimental|Cohort IIB|"Participants between the ages of 6 and 11 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
9751763|NCT00485264|Experimental|Cohort III|"Participants between the ages of 2 and 5 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
9751764|NCT00485264|Experimental|Cohort IV|"Participants between the ages of 6 and 23 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
9751765|NCT00485264|Experimental|Cohort V|"Participants between the ages of 4 weeks and 5 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
9751766|NCT00485303|Experimental|Abiraterone|Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
9751767|NCT00485433|Active Comparator|Bupivacaine HCl 105mg|Bupivacaine HCl given during hernia repair
9751768|NCT00485433|Experimental|SKY0402 low dose|SKY0402 low dose given during hernia repair
9751769|NCT00485433|Experimental|SKY0402 Middle dose|SKY0402 middle dose given during hernia repair
9751770|NCT00485433|Experimental|SKY0402 High dose|SKY0402 high dose given during hernia repair
9751771|NCT00485472|Experimental|Lacosamide|lacosamide (LCM)
9751772|NCT00485472|Placebo Comparator|Placebo|Placebo
9751773|NCT00485485|Experimental|Imatinib Mesylate + Docetaxel|Imatinib 400 mg orally daily; Docetaxel 60 mg/m^2 by vein over 1 hour every 3 weeks
9751774|NCT00485589|Placebo Comparator|Placebo|Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
9782539|NCT01178281|Placebo Comparator|Placebo|"Participants received placebo taken by mouth once daily for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit could continue to receive placebo until loss of RBC- transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
9830226|NCT02562924|Experimental|MEDIHONEY® and budesonide rinse group|"Days 0-7: Same as 1a.;~Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
9830227|NCT02562989|Experimental|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of ~185 megabecquerel (MBq) [18F]MK-6240 in Part 1 of the study
9830228|NCT02562989|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of ~160 MBq [18F]MK-6240, in Part 2 of the study
9830229|NCT02562989|Experimental|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of ~160 MBq [18F]MK-6240 in Part 2 of the study
9830230|NCT02563028|Experimental|SightSaver Visual Stimulator|A SightSaver Visual Stimulator mask will be applied during surgery. Baseline VEPs will be recorded prior to prone positioning. At the end of surgery, after supine positioning, the SightSaver Visual Stimulator mask will be removed and discarded.
9830231|NCT02563067|Experimental|QAW039 150 mg|QAW039 150 mg once daily
9830232|NCT02563067|Experimental|QAW039 450 mg|QAW039 450 mg once daily
9830233|NCT02563067|Placebo Comparator|Placebo|Placebo once daily
9830234|NCT02563093|Experimental|Study Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
9830235|NCT02563093|Experimental|Study Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
9830236|NCT02563093|Experimental|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
9830237|NCT02563093|Experimental|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
9830238|NCT02563106|Experimental|SYN-004|SYN-004 150 mg
9830239|NCT02563106|Placebo Comparator|Placebo|Matching placebo
9830240|NCT02563496|Experimental|Tafenoquine 50 mg|Subjects with weight band of >=5 to <=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
9830241|NCT02563496|Experimental|Tafenoquine 100 mg|Subjects with weight band of >10 to <=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
9830242|NCT02563496|Experimental|Tafenoquine 150 mg|Subjects with weight band of >10 to <=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
9830243|NCT02563496|Experimental|Tafenoquine 200 mg|Subjects with weight band of >20 to <=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
9830244|NCT02563496|Experimental|Tafenoquine 300 mg|Subjects with weight band of >35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
9830245|NCT02563548|Experimental|GAC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma (GAC) will receive PEGPH20 1.6 micrograms/kilogram (µg/kg) or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 milligrams/kilogram (mg/kg) every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory locally advanced or metastatic GAC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks).
9836151|NCT02771366|Placebo Comparator|Granulated Sugar, then Fermented Papaya Preparation|Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
9830246|NCT02563548|Experimental|NSCLC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory Stage IIIB or IV non-small cell lung cancer (NSCLC) will receive PEGPH20 1.6 µg/kg or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 mg/kg every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory Stage IIIB or IV NSCLC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 46 weeks).
9830247|NCT02563561|Experimental|1 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
9830248|NCT02563561|Experimental|2 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of 4 mg of apaziquone by intravesical administration via an indwelling catheter on Day 15 (±5 days).
9830249|NCT02563561|Placebo Comparator|Placebo|Participants were randomized to receive first dose of matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of matching placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
9830250|NCT02563808|Active Comparator|Standard Decision Aid|The brochure with standard information on surgery for early-stage breast cancer
9830251|NCT02563808|Experimental|Post-surgical Regret Decision Aid|The brochure that incorporates additional information on the rates of regret after surgical treatment of early-stage breast cancer.
9830252|NCT02563834|Experimental|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
9830253|NCT02563834|Experimental|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
9830254|NCT02563860|Experimental|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
9830255|NCT02563899|Experimental|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
9830256|NCT02563899|Placebo Comparator|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
9830257|NCT02563990|Experimental|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
9830258|NCT02563990|Active Comparator|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
9830259|NCT02564016|Active Comparator|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
9830260|NCT02564016|Experimental|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
9830261|NCT02564029|Experimental|PF-06372865 dose level 1|17.5 milligram (mg) single dose
9830262|NCT02564029|Experimental|PF-06372865 dose level 2|52.5 mg single dose
9830263|NCT02564029|Placebo Comparator|Placebo|Single dose
9830264|NCT02564029|Active Comparator|Lorazepam|2mg single dose
9830265|NCT02564042|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
9830266|NCT02564042|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
9830267|NCT02564042|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
9830268|NCT02564042|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
9830269|NCT02564042|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
9830270|NCT02564042|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
9830271|NCT02564055|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
9830272|NCT02564055|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
9830273|NCT02564055|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
10201903|NCT05194085|Active Comparator|Female SOC/Male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and laboratory-based HIV VL testing for women at enrollment, delivery, and 6 months post-partum
10201904|NCT05194085|Active Comparator|Female intervention/male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and POC viral load testing for women at enrollment, delivery, and 6 months post-partum
9751775|NCT00485589|Experimental|Ocrelizumab 200 mg|Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
9751776|NCT00485589|Experimental|Ocrelizumab 500 mg|Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
9751777|NCT00485693|Active Comparator|Bupivacaine HCl|Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
9751778|NCT00485693|Other|SKY0402|SKY0402 at various dosage levels. Single administration.
9751779|NCT00485732|Experimental|Cervarix Group|
9751780|NCT00485732|Placebo Comparator|Placebo Group|
9751781|NCT00485758|Other|1|Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
9751782|NCT00485758|Active Comparator|2|Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.
9751783|NCT00485836|Sham Comparator|Sham injection|
9751784|NCT00485836|Experimental|Ranibizumab injection 0.3 mg|
9751785|NCT00485836|Experimental|Ranibizumab injection 0.5 mg|
9751786|NCT00485953|Experimental|Active Medication Group|risedronate 35 mg weekly
9751787|NCT00485953|No Intervention|Placebo Group|Placebo
9751788|NCT00486018|Sham Comparator|Sham injection|
9751789|NCT00486018|Experimental|Ranibizumab injection 0.3 mg|
9751790|NCT00486018|Experimental|Ranibizumab injection 0.5 mg|
9751791|NCT00486031|Other|balsalazide disodium tablets,3.3 g BID,|
9751792|NCT00486044|Experimental|simvastatin|simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months
9751793|NCT00486044|Placebo Comparator|Placebo|Matching placebo tablet nightly for 9 months
9751794|NCT00486226||1 Endovascular|All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
9751795|NCT00486252||This is N/A due to the above description.|This is N/A due to the above description.
9751796|NCT00486278|Experimental|vatreptacog alfa 5 mcg/kg|
9751797|NCT00486278|Experimental|vatreptacog alfa 10 mcg/kg|
9751798|NCT00486278|Experimental|vatreptacog alfa 20 mcg/kg|
9751799|NCT00486278|Experimental|vatreptacog alfa 40 mcg/kg|
9751800|NCT00486278|Experimental|vatreptacog alfa 80 mcg/kg|
9751801|NCT00486278|Experimental|rFVIIa 90 mcg/kg|
9751802|NCT00486291|Experimental|1|Phentermine 15mg/topiramate 100mg
9751803|NCT00486291|Placebo Comparator|2|Matched placebo
9751804|NCT00486330|Other|Buprenorphine plus Tipranavir/Ritonavir|
9751805|NCT00486434|Active Comparator|1|SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months
9751806|NCT00486434|Placebo Comparator|2|SMC021 Placebo, orally twice daily during 24 months
9751807|NCT00486447|Experimental|Imaging|General imaging subjects receiving CT exams
9751808|NCT00486525|Experimental|Arm I: Yoga Therapy|Patients participate in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients are also encouraged to practice yoga at home using the appropriate DVD/video segments for the month.
9751809|NCT00486525|No Intervention|Arm II: Wait-List|Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.
9751810|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 200 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT. Starting dose of HCQ is 200mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
9751811|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 400 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 400 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
9751812|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 600 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 600 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
9830274|NCT02564055|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
9836152|NCT02771522|Other|Active post-othodontic lesions|Imaging with the Calcivis System
9830275|NCT02564055|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
9830276|NCT02564055|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
9830277|NCT02564198|Experimental|Ramucirumab|"(Part A-Non-CNS Solid Tumors) Escalating doses of 8 milligrams per kilogram (mg/kg) or 12 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle.~(Part B-CNS Tumors) Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle."
9830278|NCT02564211|Experimental|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
9830279|NCT02564354|Experimental|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
9830280|NCT02564354|Experimental|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
9830281|NCT02564432||POP 10 patient cohort|This is an observational study
9830282|NCT02564471|Experimental|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
9830283|NCT02564471|Experimental|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
9830284|NCT02564471|Experimental|Doxycycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
9830285|NCT02564471|Active Comparator|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
9830286|NCT02564497|Other|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
9830287|NCT02564497|Other|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
9830288|NCT02564718|Experimental|Arm 1|Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
10201905|NCT05194059|Experimental|Experimental Group|Participants will follow a personalized activity pacing program for 16 weeks with the support of a heath band and a mobile application for tablet
9830289|NCT02564887|Other|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
9830290|NCT02564887|Experimental|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
9830291|NCT02564926|Experimental|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
9830292|NCT02564926|Active Comparator|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
10201906|NCT05194059|No Intervention|Control Group|Participants will follow a personalized activity pacing program for 16 weeks without any other support
10201907|NCT05194046|Experimental|Sequence A|"T1→Washout period(D6~14)→ T3→Washout period(D20~28)→ T2~T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
10201908|NCT05194046|Experimental|Sequence B|"T1 →Washout period(D6~14)→ T2→Washout period(D20~28) → T3~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
10201909|NCT05194046|Experimental|Sequence C|"T2 →Washout period(D6~14)→ T3→Washout period(D20~28) → T1~T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
10201910|NCT05194046|Experimental|Sequence D|"T2 →Washout period(D6~14)→ T1→Washout period(D20~28) → T3~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
10201911|NCT05194046|Experimental|Sequence E|"T3 →Washout period(D6~14)→ T1→Washout period(D20~28) → T2~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
9830293|NCT02564952|Experimental|GWP42003-P|"Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P.~Clobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant."
9836153|NCT02771574|Experimental|Part A: Lyo avexitide 0.05 mg/kg|Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
9836154|NCT02771574|Experimental|Part A: Lyo avexitide 0.15 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
9836155|NCT02771574|Experimental|Part A: Lyo avexitide 0.35 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
9836156|NCT02771574|Experimental|Part A: Lyo avexitide 0.46 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
9830294|NCT02565108|Experimental|GWP42003-P 20 mg/kg/Day Dose|"Participants received GWP42003-P 20 milligrams [mg]/kilogram [kg]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study."
9830295|NCT02565108|Placebo Comparator|Placebo|"Participants received placebo (0 mg/milliliter [mL] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study."
9830296|NCT02565147|Experimental|PPCI with Bivalirudin|Bivalirudin was administered as a bolus (0.75 mg/kg) and an infusion (1.75 mg/kg/h) for the duration of the PPCI and continued for the first 4 h after completion of the procedure.
9830297|NCT02565147|Active Comparator|PPCI with Heparin|UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
9830298|NCT02565186|Experimental|Lasmiditan 100mg|Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
9830299|NCT02565186|Experimental|Lasmiditan 200mg|Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
9830300|NCT02565381|Active Comparator|Control (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling"
9830301|NCT02565381|Experimental|Financial rewards (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Contingent financial rewards for smoking abstinence"
9830302|NCT02565381|Experimental|Text messaging (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Text messages to support smoking abstinence"
9830303|NCT02565485|No Intervention|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
9830304|NCT02565485|Experimental|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
9830305|NCT02565511|Experimental|Cohort I (CAD106)|CAD106 (450 µg) + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
9830306|NCT02565511|Placebo Comparator|Cohort I (CAD106 Placebo)|Placebo to CAD106 + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
9830307|NCT02565511|Experimental|Cohort II (CNP520)|CNP520 (50 mg) capsules taken orally once daily
9830308|NCT02565511|Placebo Comparator|Cohort II (CNP520 Placebo)|Matching Placebo to CNP520 capsules taken orally once daily
9830309|NCT02565576|Active Comparator|CFZ533|CFZ533
9830310|NCT02565576|Placebo Comparator|Placebo|Placebo
9830311|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
9830312|NCT02565628|Experimental|PF-06669571|Once daily (QD) for 7 days
9830313|NCT02565628|Placebo Comparator|Placebo|QD for 7 days
9830314|NCT02565706|Active Comparator|WIC Fresh Start Program|Participants in this arm receive the Fresh Start program.
9830315|NCT02565706|Active Comparator|Existing Online Health Education|Participants in this arm receive existing online WIC health education.
9830316|NCT02565706|Experimental|WIC Fresh Start Program (FMNP)|Participants in this arm receive the Fresh Start program and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
9830317|NCT02565706|Active Comparator|Existing Online Health Education (FMNP)|Participants in this arm receive existing online WIC health education and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
9830318|NCT02565784|Experimental|Intradermal injection|Restylane and/or Perlane
9830319|NCT02565810|Experimental|SB5 40mg|
9836157|NCT02771574|Experimental|Part B: Liq avexitide 0.38 (±0.03) mg/kg|Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days
9836158|NCT02772302|Experimental|Patients|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
9751813|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 800 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 800 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
9751814|NCT00486603|Experimental|Phase 2: RT + TMZ + HCQ MTD|"Phse 2: daily hydroxychloroquine (HCQ) (MTD 600mg) on 1st day of RT and concomitant temozolomide for 6wks during RT. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~Other: pharmacological study (PK)~Pts will continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 2~Radiation (RT)"
9751815|NCT00486642|Experimental|Arm A (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-28.~."
9751816|NCT00486642|Experimental|Arm B (pazopanib hydrochloride, bicalutamide)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
9751817|NCT00486720|Experimental|1|vorinostat 400 mg
9751818|NCT00486720|Experimental|2|vorinostat 200 mg
9751819|NCT00486759|Experimental|Bevacizumab + rituximab + CHOP|Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
9751820|NCT00486759|Active Comparator|Placebo + rituximab + CHOP|Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
9751821|NCT00486811|Placebo Comparator|Matching Placebo (twice daily)|The starting dose of placebo was matched with the active treatment arms taken twice daily for the first 3 days. The dose was then increased to match the active treatments for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days as in the active treatment arms. Dose decreases were allowed without time restrictions.
9751822|NCT00486811|Experimental|Tapentadol ER (100 to 250 mg twice daily)|The starting dose was tapentadol ER 50 mg twice daily for 3 days. The dose was then increased to 100 mg tapentadol ER twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
9751823|NCT00486811|Active Comparator|Oxycodone CR (20 to 50 mg twice daily)|The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
9751824|NCT00486824|Active Comparator|Indomethacin|50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
9751825|NCT00486824|Active Comparator|Nifedipine|30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.
9751826|NCT00486837|Experimental|Group 1|Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
9751827|NCT00486837|Experimental|Group 2|Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
9751828|NCT00486863|Placebo Comparator|Control|Placebo at 12-16 weeks gestation.
9751829|NCT00486863|Experimental|Praziquantel|Praziquantel at 12-16 weeks gestation.
9751830|NCT00486902|Experimental|Ketamine|Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.
9751831|NCT00486902|Placebo Comparator|Placebo|Subjects receive IV Saline 20 mL 5 minutes after infant delivery
9751832|NCT00486954|Experimental|Paclitaxel plus Lapatinib|6 pills of lapatinib at 250 mg each once daily and infusion of paclitaxel at 80 mglm2 weekly
9751833|NCT00486954|Active Comparator|Paclitaxel alone|Infusion of paclitaxel at 80 mglm2 weekly
9751834|NCT00487084|Experimental|morphine - 2CP-saline (MCS)|morphine will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level; saline will be administered at skin incision
9751835|NCT00487084|Experimental|saline-2CP-morphine (SCM)|saline will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level;morphine will be administered at skin incision
9751836|NCT00487084|Active Comparator|saline-lidocaine-morphine (SLM)|Saline will be administered 30 min prior to epidural anesthesia; lidocaine will be used to achieve a T4 level; morphine will be administered at skin incision
9836159|NCT02772302|Experimental|Healthy Controls|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
9751837|NCT00487188|Experimental|ENF + HAART|Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
9751838|NCT00487188|Active Comparator|HAART|Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.
9751839|NCT00487240|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension twice daily
9751840|NCT00487240|Active Comparator|Detemir|Insulin Levemir (detemir) subcutaneous (SC) twice daily.
9751841|NCT00487279|Experimental|ICD Group|ICD (Implantable Cardioverter Defibrillator)
9751842|NCT00487279|Other|Control Group|Medial Therapy
9751843|NCT00487435|Experimental|001|Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks
9751844|NCT00487539|Placebo Comparator|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
9751845|NCT00487539|Experimental|Golimumab 100 mg -> 50 mg|Golimumab 100 milligram (mg) subcutaneous injection administered at Week 0 and dose is decreased to 50 mg at Week 2.
9751846|NCT00487539|Experimental|Golimumab 200 mg -> 100 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 and dose is decreased to 100 mg at Week 2.
9751847|NCT00487539|Experimental|Golimumab 400 mg -> 200 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 and dose is decreased to 200 mg at Week 2.
9751848|NCT00487552|Experimental|1|palliative treatment of gastric outlet obstruction
9751849|NCT00487565|Other|LCS Complete Posterior Stabilized knee implant|Total knee arthroplasty with a posterior stabilized implant
9751850|NCT00487669|Experimental|Paclitaxel Poliglumex with Pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued.
9751851|NCT00487695|Active Comparator|CLE followed by standard EGD|Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
9751852|NCT00487695|Active Comparator|standard EGD followed by CLE|Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.
9751853|NCT00487721|Experimental|Silibin-Phytosome|Subjects in this group will take Silibin-Phytosome 13 grams daily, in three divided doses for 2-10 weeks.
9751854|NCT00487721|No Intervention|Control|Patients in this arm will not take any intervention.
9751855|NCT00487747|Experimental|Peginterferon Alfa-2a|
9751856|NCT00487825|Experimental|Canakinumab + Methotrexate|Canakinumab, human anti-interleukin-1beta monoclonal antibody plus Methotrexate (MTX). Intravenous (IV) Infusion of 600mg canakinumab on Day 1, 15 continuing every 4 weeks up to week 26. MTX was given as variable dosing regimen of 7.5 mg-15 mg weekly.
9751857|NCT00487825|Active Comparator|Methotrexate + placebo|Methotrexate (MTX) was given as variable dosing regimen of 7.5 mg-15 mg weekly. Intravenous (IV) Placebo Solution, given in the same mode of administration as the canakinumab solution.
9751858|NCT00487942|Active Comparator|50 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 50 mg/day armodafinil treatment arm for the double-blind treatment period of the study took one 50 mg armodafinil tablet plus three placebo tablets each morning.
9751859|NCT00487942|Active Comparator|100 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 100 mg/day armodafinil treatment arm for the double-blind treatment period of the study took two 50 mg armodafinil tablets plus two placebo tablets each morning. Subjects began taking 50 mg/day and then titrated to 100 mg/day on Day 2 of the first week of the double-blind treatment period.
9751860|NCT00487942|Active Comparator|200 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 200 mg/day armodafinil treatment arm for the double-blind treatment period of the study took four 50 mg armodafinil tablet and no placebo tablets each morning. Subjects were titrated to this dose by starting treatment at 50 mg/day (1 tablet) and increasing by 50 mg increments on days 2, 4, and 6 until they were taking 200 mg/day.
9751861|NCT00487942|Placebo Comparator|Placebo|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
9751862|NCT00488033|No Intervention|1|Standard of Care
9751863|NCT00488033|Other|2|CT Angiography
9751864|NCT00488059|Experimental|Phase I|Phase 1: ENF 90mg SC BID): In the first phase or cohort phase of day I-1 through Week I-12 of the trial all patients received enfuvirtide (ENF) 90 mg subcutaneously (SC) twice daily (BID) + Isentress® [raltegravir] (RAL) 400-mg orally (PO) BID + optimized background (OB) with at least 1 fully active antiretroviral (ARV) agent excluding nucleoside reverse transcriptase inhibitor (NRTIs).
9836160|NCT02772432|Experimental|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
9830320|NCT02565901|Experimental|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
9830321|NCT02565901|Experimental|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
9830322|NCT02565914|Experimental|Part A: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
9830323|NCT02565914|Experimental|Part B: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
9830324|NCT02565914|Experimental|Part C: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
9830325|NCT02566005|Active Comparator|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
9830326|NCT02566005|Active Comparator|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
9830327|NCT02566031|Experimental|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
9830328|NCT02566031|Active Comparator|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
9830329|NCT02566044|Experimental|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
9830330|NCT02566044|Placebo Comparator|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
9830331|NCT02566083|Active Comparator|non-toric intraocular lens|non-toric approved intraocular lens
9830332|NCT02566083|Active Comparator|toric intraocular lens|approved toric intraocular lens
9830333|NCT02566109|Other|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
9830334|NCT02566135|Active Comparator|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
9830335|NCT02566135|Active Comparator|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
9830336|NCT02566239|Experimental|Shared Data|"Share activity data with care team.~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
9830337|NCT02566239|No Intervention|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
9835825|NCT02757092|Experimental|Home-based rehabilitation program|0-2 weeks,1. aerobic exercise intensity was targeted to reach 10-11 points of perceived exercise (RPE) scale 2. raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min 3.walked at a comfortable speed for 15 min twice per day.4. Triflo-II was performed 8-10 times per hour. inspiratory muscle training with the initial pressure set at 25%-30% of the maximum inspiratory pressure.3-6 weeks, aerobic exercise reach 12-15 points on the RPE scale. upper-limb resistance exercise (raising of a 250-cc water bottle) and lower-limb stepping for 20 min per day , walking exercise for a total of 30 min. Triflo-II was performed 8-10 times per hour, and train the inspiratory muscle with the pressure intensity adjusted to more than 5% of that in the first stage.
9836161|NCT02772432|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
9751865|NCT00488059|Experimental|Phase II|"In the randomized comparator Phase II of the trial- (Day II-1 through Week II-16): Virologic responders confirmed HIV-1 RNA ≤50 copies/mL from Phase I were randomized to 1 of 2 treatment arms of~(Phase II Arm A: Phase I then ENF 90mg SC BID): ENF 90 mg SC BID + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs or (Phase II Arm B: Phase I then ENF 180mg SC QD): ENF 180 mg SC once daily (QD) + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs."
9751866|NCT00488293|Experimental|Arm 1|Store and forward teledermatology consult process
9751867|NCT00488293|No Intervention|Arm 2|Conventional consult process
9751868|NCT00488319|Experimental|001|Paliperidone ER1.5 to 12 mg tablet once daily for 6 months
9751869|NCT00488345|Experimental|A|0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
9751870|NCT00488345|Experimental|B|1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
9751871|NCT00488345|Experimental|C|1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
9782540|NCT01178281|Experimental|China Extension: Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects, disease progression, or they received a RBC-transfusion.~Participants who experienced anemia response could continue treatment until the response was lost or other criteria for treatment discontinuation applied."
9782541|NCT01178294|Experimental|OBI-1|Initial dose: 200 U/kg - additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours)
9782542|NCT01178385|Experimental|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
9782543|NCT01178385|Active Comparator|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
9751872|NCT00488475||Patients with Rheumatoid Arthritis|
9751873|NCT00488488||A|
9751874|NCT00488514|Other|Active Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)
9751875|NCT00488592|Experimental|PR1/WT1 Vaccine Response in Participants With Low-Risk Myeloid Cancers|"Subjects were given 6 subcutaneous injects of PR1:169-177 in Montanide adjuvant and 6 subcutaneous injections of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
9751876|NCT00488618|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
9751877|NCT00488618|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
9751878|NCT00488631|Placebo Comparator|Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
9751879|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 50 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
9751880|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 100 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
9751881|NCT00488631|Placebo Comparator|Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance|Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
9751882|NCT00488631|Experimental|PBO-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
9751883|NCT00488631|Experimental|GLM-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
9751884|NCT00488644|Experimental|Levothyroxine + Liothyronine|Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks
9751885|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 1)|Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.
9751886|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 2)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months.~This group had an additional blood draw at the time of enrollment."
9751887|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 3)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months of age.~This group had an additional blood draw at 6-7 days after third dose of MenACWY-CRM."
9751888|NCT00488774|Placebo Comparator|Placebo|Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
9751889|NCT00488774|Experimental|Golimumab 1 milligram (mg) per kilogram (kg)|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
9751890|NCT00488774|Experimental|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
9751891|NCT00488774|Experimental|Golimumab 4 mg per kg|Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
9751892|NCT00488865|Other|Intravascular Filter Device|
9751893|NCT00488982|Experimental|Docetaxel + Observation|Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy
9751894|NCT00488982|Experimental|Docetaxel + GM-CSF|Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)
9751895|NCT00489086|Other|Tazarotene Cream|Open label
9751896|NCT00489216|Experimental|Efalizumab|All patients on study will receive a total of 8 injections of efalizumab
9751897|NCT00489255|Experimental|Trimethobenzamide (Tigan®)|
9751898|NCT00489255|Placebo Comparator|Inactive substance|
9751899|NCT00489268|Active Comparator|Phase I: 6 J/cm2|Subjects randomized to the energy density group of 6 J/cm2 through the HALO Ablation System.
9751900|NCT00489268|Active Comparator|Phase I: 8 J/cm2|Subjects randomized to the energy density group of 8 J/cm2 through the HALO Ablation System.
9751901|NCT00489268|Active Comparator|Phase I: 10 J/cm2|Subjects randomized to the energy density group of 10 J/cm2 through the HALO Ablation System.
9751902|NCT00489268|Active Comparator|Phase I: 12 J/cm2|Subjects randomized to the energy density group of 12 J/cm2 through the HALO Ablation System.
9751903|NCT00489268|Active Comparator|Phase II|All Halo 360 treatments performed at 10 J/cm2 through the HALO Ablation System. All Halo 90 treatments performed at 12 J/cm2 through the HALO Ablation System.
9751904|NCT00489281|Experimental|Transplant - 200 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 200. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
9751905|NCT00489281|Experimental|Transplant - 400 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 400. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
9751906|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 1|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
9751907|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 2|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
9751908|NCT00489411|Experimental|Arm I/Group A (Duloxetine then Placebo)|Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
9751909|NCT00489411|Experimental|Arm II/Group B (Placebo then Duloxetine)|Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
9751910|NCT00489424|Experimental|Acetaminophen|2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
9751911|NCT00489424|Experimental|Fluvastatin|2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
9751912|NCT00489424|Placebo Comparator|Placebo|2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
9751913|NCT00489476|Experimental|1.25 mg Staccato Loxapine|1.25 mg ADASUVE, single dose
9751914|NCT00489476|Experimental|2.5 mg Staccato Loxapine|2.5 mg ADASUVE, single dose
9751915|NCT00489476|Experimental|5 mg Staccato Loxapine|5 mg ADASUVE, single dose
9751916|NCT00489476|Experimental|Staccato Placebo|Staccato Placebo, 0 mg
9751917|NCT00489489|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
9751918|NCT00489489|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
9751919|NCT00489489|Placebo Comparator|Placebo + IFN-β|Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
9751920|NCT00489541|Experimental|TAXUS Element Stent System|
9751921|NCT00489554|Experimental|Synflorix Vaccine Group|Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
9751922|NCT00489736|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
9830338|NCT02566265|Experimental|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
9830339|NCT02566265|Active Comparator|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
10201912|NCT05194046|Experimental|Sequence F|"T3 →Washout period(D6~14)→ T2→Washout period(D20~28) → T1~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
10201913|NCT05194020|Experimental|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
10201914|NCT05193994|Experimental|Dolutegravir/Abacavir/Lamivudine|"Combination of Dolutegravir, Abacavir and Lamivudine in a single product/capsule.~4 capsules to be taken orally once daily (all 4 at the same time, each capsule is Dolutegravir 12.5mg, Abacavir 150mg and Lamivudine 75mg). Maximum duration is 24months"
10201915|NCT05193994|Placebo Comparator|Placebo|4 capsules to be taken orally once daily (all 4 at the same time). Maximum duration is 24months
10201916|NCT05193890||Epilepsy only|Epilepsy only patients who underwent our gene panel and the Clinical exome Solution
9830340|NCT02566317|Active Comparator|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
10201917|NCT05193890||Intelectual Disability only|Intelectual Disability only patients who underwent our gene panel and the Clinical exome Solution
10201918|NCT05193890||Epilepsy and Intelectual Disability|Intelectual Disability and Epilepsy patients who underwent our gene panel and the Clinical exome Solution
9830341|NCT02566317|Experimental|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
9830342|NCT02566369|Experimental|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
9830343|NCT02566369|Placebo Comparator|Placebo Cream|Placebo cream
9830344|NCT02566525|Experimental|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
9830345|NCT02566525|No Intervention|Control|Standard of care
9830346|NCT02566577|Active Comparator|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (<10 days old) followed by a transfusion of packed RBC units of storage-aged (>21 days old) blood.
9830347|NCT02566577|Active Comparator|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (<10 days old).
9830348|NCT02566590|Experimental|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
9830349|NCT02566590|Experimental|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
9830350|NCT02566759|Experimental|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
9830351|NCT02566759|Experimental|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
9830352|NCT02566759|Experimental|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
9830353|NCT02566759|Experimental|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
9830354|NCT02566759|Experimental|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
9830355|NCT02566759|Experimental|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
9830356|NCT02566759|Experimental|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
9830357|NCT02566759|Experimental|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
9830358|NCT02566759|Experimental|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
9830359|NCT02566759|Experimental|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
9830360|NCT02566759|Experimental|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
9830361|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
10201919|NCT05193864||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
10201920|NCT05193838||Allopurinol|we plan to follow up effect of Allopurinol on left ventricular function in children with dilated cardiomyopathy for 6 months
10201921|NCT05193786|Active Comparator|Low PEEP group|In low PEEP group, the PEEP was 5 cmH2O and inspiratory pressure was 10-20 cmH2O in noninvasive ventilation.
10201922|NCT05193786|Experimental|High PEEP group|In high PEEP group, the PEEP was 10-15 cmH2O and inspiratory pressure was 15-20 cmH2O in noninvasive ventilation.
10201923|NCT05193773|No Intervention|comparison group|The Control Group received no extra care.
9751923|NCT00489736|Active Comparator|Amiodarone 600mg/200mg od|over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
9751924|NCT00489827|Active Comparator|Intravenous glutamate|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
9751925|NCT00489827|Placebo Comparator|Saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
9751926|NCT00489853|Experimental|Symbicort then Formoterol then Placebo|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
9751927|NCT00489853|Experimental|Formoterol then Symbicort then Placebo|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
9751928|NCT00489853|Placebo Comparator|Placebo then Formoterol then Symbicort|Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily
9751929|NCT00489866|Experimental|Aripiprazole|
9751930|NCT00489866|Placebo Comparator|Placebo|
9751931|NCT00489918|Placebo Comparator|Macroflux® placebo|Macroflux® placebo patch
9751932|NCT00489918|Experimental|Macroflux® 20 mcg|Macroflux® 20 mcg patch
9751933|NCT00489918|Experimental|Macroflux® 30 mcg|Macroflux® 30 mcg patch
9751934|NCT00489918|Experimental|Macroflux® 40 mcg|Macroflux® 40 mcg patch
9751935|NCT00489918|Active Comparator|FORTEO®|FORTEO® 20 mcg injection
9751936|NCT00489970|Experimental|Boostrix Group|Subjects received in the primary study (NCT00346073) a single dose of Boostrix vaccine [Tdap](GSK776423) intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a second dose of Boostrix vaccine [Tdap](GSK776423).
9751937|NCT00489970|Active Comparator|Adacel Group|Subjects received in the primary study (NCT00346073) a single dose of Adacel vaccine intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a dose of Boostrix vaccine [Tdap](GSK776423).
9751938|NCT00489970|Active Comparator|Control group|Subjects received the first dose of Boostrix vaccine [Tdap](GSK776423) in this study at Year 9.
9751939|NCT00490009|Experimental|Bexxar + Total Body Irradiation (TBI)|Bexxar will be administered with pre-medications acetaminophen, diphenhydramine, and potassium iodide (KI).
9751940|NCT00490022|Active Comparator|1|DHT gel (70 mg/day) for one month
9751941|NCT00490022|Placebo Comparator|2|Placebo gel for one month
9751942|NCT00490035|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
9751943|NCT00490035|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
9751944|NCT00490035|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
9751945|NCT00490035|Experimental|Brivaracetam 100 mg/day|Brivaracetam 100 mg/day, 50 mg administered twice a day
9751946|NCT00490061|Experimental|Radiotherapy and Lapatinib with DCE-MRI|DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
9751947|NCT00490100|Experimental|Treatment|Treatment
9782544|NCT01178411|Experimental|Tivantinib (Monotherapy or Combination Therapy)|Tivantinib 360 mg will be administered twice daily, orally, with meals, as a monotherapy or in combination with other drug therapies.
9782545|NCT01178528|Experimental|Ivabradine|7.5 mg bd
9782546|NCT01178528|Active Comparator|Carvedilol|up to 25 mg bd
9782547|NCT01178528|Experimental|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
9782548|NCT01178671|Experimental|Sertraline and Mirtazapine|Flexible dose of both medications for up to 24 weeks
9830362|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
9830363|NCT02566759|Experimental|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
9830364|NCT02566785|Experimental|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
9830365|NCT02566785|Other|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
9830366|NCT02566889|Experimental|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses >6 mg/kg or with previous maintenance doses >6 mg/kg.
9830367|NCT02566889|Experimental|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
9830368|NCT02566902|Active Comparator|T-piece Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
9830369|NCT02566902|Experimental|Breath-Enhanced Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
9830370|NCT02566993|Experimental|Experimental Arm|Lurbinectedin (PM01183) / Doxorubicin
9830371|NCT02566993|Active Comparator|Control Arm 1|CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
9830372|NCT02566993|Active Comparator|Control Arm 2|Topotecan
9830373|NCT02567188||Cohort of CKD Participants|Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
9830374|NCT02567227|Experimental|Cognitive Remediation|An individualized computerized cognitive remediation program.
9830375|NCT02567227|Active Comparator|Active control|Individualized computer based exposure and interactive health education classes.
9830376|NCT02567266|Experimental|Unified Protocol for Adolescents (UP-A)|Participants will be treated with the Unified Protocol for the Treatment of Emotional Disorders in Adolescence. Their clinicians will also receive feedback using the Youth Outcomes Questionnaire feedback system.
9830377|NCT02567266|Experimental|Treatment as Usual Plus (TAU+)|Participants will be treated by clinicians who receive feedback using the Youth Outcomes Questionnaire, but who otherwise use Treatment as Usual
9830378|NCT02567266|Active Comparator|Treatment as Usual (TAU)|Participants will receive Treatment as Usual provided at the study clinics.
9830379|NCT02567552|Experimental|Prolutex|Subcutaneous progesterone
9830380|NCT02567552|Active Comparator|Prontogest|Intramuscular progesterone
10201924|NCT05193773|Experimental|Intervention Group|Intervention Group, Intervention with follow-up, will have a multifactorial interventions to reduce physical restraint.
10201925|NCT05193747||Paediatric patients scheduled for general anesthesia|Paediatric patients (between 1 year -19 years) undergoing elective general anaesthesia with presumed duration over 1 hour will be eligible for inclusion
9830381|NCT02567656|Experimental|Single arm|RP6530 administered orally twice a day.
9830382|NCT02567708|Experimental|GSK2269557 and Placebo|Each subject will complete two treatment periods: GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days (+/- 2 days) via the DISKUS DPI. The treatment periods will be separated by a washout of at least 4 weeks.
9830383|NCT02567968|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
9830384|NCT02567968|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
9830385|NCT02568046|Experimental|Sym004 12 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level 1
9830386|NCT02568046|Experimental|Sym004 9 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level -1
9830387|NCT02568046|Experimental|Sym004 (RP2D) + FOLFIRI|Phase 2a, Dose-Expansion: Sym004 in the RP2D in combination with FOLFIRI
9830388|NCT02568254|Active Comparator|Lens 1/ Lens 2/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
10201926|NCT05193734|Experimental|Group Pertagen|
9830389|NCT02568254|Active Comparator|Lens 1 / Lens 3 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
10201927|NCT05193734|Active Comparator|Group Control|
10201928|NCT05193656||Detecting bladder tumor|Patients with hematuria, or previous bladder tumor
10201929|NCT05193643|Experimental|Sonovein Treatment|
9830390|NCT02568254|Active Comparator|Lens 2/ Lens 3/ Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
9830391|NCT02568254|Active Comparator|Lens 2 / Lens 1/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
9830392|NCT02568254|Active Comparator|Lens 3 / Lens 1 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
9830393|NCT02568254|Active Comparator|Lens 3 / Lens 2 / Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
10201930|NCT05193617|Experimental|GP combine with peramprizumab and anlotinib neoadjuvant therapy+CCRT+peramprizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), peramprizumab (200mg, day1), and anlotinib (10mg days 1-14) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT) ,then followed by adjuvant therapy with peramprizumab (200mg) every three weeks for a maximum of nine cycles after radiotherapy.
10201931|NCT05193617|Active Comparator|GP combine with Peramprizumab neoadjuvant therapy+CCRT+Peramprizumab adjuvant therapy|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), peramprizumab (200mg, day1) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy (D1, D22, D43 of RT) ,then followed by adjuvant therapy with peramprizumab (200mg) every three weeks for a maximum of nine cycles after radiotherapy.
10201932|NCT05193604|Experimental|TQB2858 injection|"Cohort 1: TQB2858 injection administered intravenously on day 1 of each 21-day cycle.~Cohort 2: TQB2858 injection administered intravenously on day 1 of each 21-day cycle, gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle.~Cohort 3: TQB2858 injection administered intravenously on day 1 of each 21-day cycle，gemcitabine and albumin paclitaxel administered intravenously on day 1 and day 7 of each 21-day cycle，Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)."
9830394|NCT02568345|Experimental|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
9830395|NCT02568384|Experimental|Users of Onyx BG Meter / App System|"Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:~40 to 70% of subjects will have type 1 diabetes~Not more than 30% of subjects will use an insulin pump"
9830396|NCT02568397|Experimental|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
9830397|NCT02568397|Experimental|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
9830398|NCT02568475|Experimental|Decision aid|"Provision of Go to the Hospital or Stay Here?"
9830399|NCT02568475|No Intervention|No decision aid|Does not receive the decision aid.
9830400|NCT02568644|Experimental|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
9830401|NCT02568644|Placebo Comparator|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
9830402|NCT02568683|Experimental|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO+VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion.
9830403|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) may receive VCR+ENTO.
9830404|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DLBCL) may receive VCR+ENTO.
9830405|NCT02568852|Active Comparator|group 1|Laparoscopic cholecystectomy in general anaesthesia
9830406|NCT02568852|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
9830407|NCT02569112|Active Comparator|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
9830408|NCT02569112|Experimental|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
9830409|NCT02569398|Experimental|Group 1|Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
9830410|NCT02569398|Experimental|Group 2|Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
9830411|NCT02569398|Experimental|Group 3|Participants will receive one matching placebo tablet orally once daily up to 54 months.
9830412|NCT02569411|No Intervention|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
9830413|NCT02569411|Experimental|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
9830414|NCT02569437|Experimental|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
9830415|NCT02569437|Placebo Comparator|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
9830416|NCT02569541|Experimental|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:~6 months of treatment; or~24 months of treatment (if continued on chronic suppressive therapy)"
9830417|NCT02569632|Experimental|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
9830418|NCT02569658|Experimental|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
9830419|NCT02569658|Placebo Comparator|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
9830420|NCT02569710|Experimental|Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
9830421|NCT02569710|Experimental|Cohort 1b (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
9984035|NCT04469140||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
9830422|NCT02569710|Experimental|Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
9830423|NCT02569710|Experimental|Cohort 4 (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
9830424|NCT02569710|Experimental|Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
9830425|NCT02569710|Experimental|Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
9984036|NCT04469140||Cohort 3|Subjects with GA enrolled in another trial
9984037|NCT04468971|Placebo Comparator|Arm 1|Excipient
9830426|NCT02569710|Experimental|Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
9830427|NCT02569710|Experimental|Cohorts 12 to 15: AL-335+ODV With/without SMV|Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram [mg], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
9830428|NCT02569723|Experimental|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
9830429|NCT02569801|Active Comparator|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
9830430|NCT02569801|Experimental|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
9830431|NCT02569853|Experimental|DFN-11|DFN-11 active injection upon occurrence of migraine
9830432|NCT02569853|Placebo Comparator|Placebo|Placebo injection upon occurrence of migraine
9830433|NCT02569892|Experimental|Laser Arm|Participants receive treatment with sub-threshold macular laser photocoagulation
9830434|NCT02569892|Sham Comparator|Sham Laser Arm|Participants receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)
9830435|NCT02569996|Experimental|Rituximab|Participants will receive rituximab 375 milligrams per meter square (mg/m^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
9830436|NCT02570022|Experimental|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
9830437|NCT02570022|Active Comparator|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
9830438|NCT02570074|Experimental|Fosfomycin - 3 doses QoD/7 doses QD|Fosfomycin given as a 3 gm dose, every other day for 3 doses, followed by 3 gm dose, once a day for 7 doses.
9830439|NCT02570074|Experimental|Fosfomycin - 7 doses QD/3 doses QoD|Fosfomycin given as a 3 gm dose, once a day for 7 doses, followed by 3 gm dose, every other day for 3 doses.
9830440|NCT02570126|Experimental|VAR_HSA_F Group|2 doses of Varilrix HSA-free vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
9830441|NCT02570126|Active Comparator|VAR Group|2 doses of Varilrix™ vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
9830442|NCT02570139|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
9830443|NCT02570139|Active Comparator|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
9830444|NCT02570152|Experimental|AFI Group|Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
9830445|NCT02570165|Experimental|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
9984038|NCT04468971|Experimental|Arm 2|CK0802: 1x10^8 cells
9830446|NCT02570165|Experimental|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
9830447|NCT02570165|Experimental|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
9830448|NCT02570165|Experimental|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
9830449|NCT02570165|Experimental|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
9830450|NCT02570165|Experimental|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
9830451|NCT02570165|Experimental|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
9830452|NCT02570295|Experimental|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
9830453|NCT02570295|No Intervention|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
9830454|NCT02570425|Placebo Comparator|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
9830455|NCT02570425|Placebo Comparator|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
9830456|NCT02570711|Experimental|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
9984039|NCT04468971|Experimental|Arm 3|CK0802: 3x10^8 cells
9751948|NCT00490139|Active Comparator|Arm 1: Trastuzumab|"Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total)."
9751949|NCT00490139|Experimental|Arm 2: Lapatinib|"Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.~Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total)."
9751950|NCT00490139|Experimental|Arm 3: Trastuzumab followed by Lapatinib|"Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total)."
9751951|NCT00490139|Experimental|Arm 4: Lapatinib in combination with Trastuzumab|"Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total)."
9751952|NCT00490256|No Intervention|Control|Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.
9751953|NCT00490256|Active Comparator|Experimental|This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.
9751954|NCT00490269|Active Comparator|Dronabinol|
9751955|NCT00490269|Placebo Comparator|Placebo|
9751956|NCT00490282|Experimental|Image-Guided Adaptive Radiotherapy|Intensity Modulated Radiotherapy (IMRT) + Adaptive Radiotherapy (ART)
9751957|NCT00490451|Experimental|LY573636|
9751958|NCT00490477|No Intervention|CONVENTIONAL|
9751959|NCT00490477|Active Comparator|POLYMYXIN-B|an extracorporeal LPS removal
9751960|NCT00490490|Experimental|Tositumomab + XRT + KI|Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)
9751961|NCT00490529|Experimental|CpG-MCL Vaccine|An autologous anti-tumor vaccine.
9751962|NCT00490542|Placebo Comparator|Placebo arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.
9751963|NCT00490542|Active Comparator|Geodon arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received Geodon.
9751964|NCT00490555|Placebo Comparator|1|Placebo gel + Placebo pill + placebo injection
9751965|NCT00490555|Active Comparator|2|Testosterone 1% transdermal gel 10 g + placebo pill + placebo injection
9751966|NCT00490555|Active Comparator|3|Testosterone 1% transdermal gel 10 g + dutasteride 0.5 mg Orally + placebo injection
9751967|NCT00490555|Active Comparator|4|Testosterone 1% transdermal gel 10 g + placebo pill + DMPA 300 mg injection (IM)
9751968|NCT00490568|Experimental|Rosiglitazone XR|Investigational drug
9751969|NCT00490646|Experimental|Arm A|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
9751970|NCT00490646|Active Comparator|Arm B|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
9830457|NCT02570711|Experimental|Regimen 2|Nab-paclitaxel and gemcitabine
9751971|NCT00490698|Experimental|Zoledronate + Atorvastatin|Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily
9751972|NCT00490724|Experimental|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
9751973|NCT00490724|Experimental|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
9751974|NCT00490724|Experimental|Nesiritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
9751975|NCT00490802|Experimental|Intranasal Oxytocin|Subjects were given 24 IU intranasal oxytocin twice daily, in the morning and afternoon for 6 weeks.
9751976|NCT00490802|Placebo Comparator|Placebo|Subjects were given placebo twice daily, in the morning and afternoon for 6 weeks.
9751977|NCT00490815|Experimental|1|
9751978|NCT00490815|Experimental|2|
9751979|NCT00490841|Experimental|RX Herculink Elite|To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.
9751980|NCT00490919|Experimental|Double-blind BTDS 10 or 20|Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
9751981|NCT00490919|Placebo Comparator|Double-blind Placebo TDS|Placebo transdermal system to match BTDS patches, applied for 7 days
9751982|NCT00490971|Experimental|Paliperidone ER|
9751983|NCT00490971|Placebo Comparator|Placebo|
9751984|NCT00490971|Active Comparator|Olanzapine|
9751985|NCT00491075|Experimental|Pemetrexed + Gemcitabine|Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.
9751986|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 1|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks for HCV genotype 1
9751987|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 2|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks for HCV genotype 2
9751988|NCT00491244|Experimental|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
9751989|NCT00491244|Experimental|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
9751990|NCT00491322|Experimental|Ergocalciferol group|Ergocalciferol 50000 international units once a week for 12 weeks
9751991|NCT00491322|Placebo Comparator|Ergocalciferol Placebo group|Matching placebo once a week for 12 weeks
9751992|NCT00491374|Experimental|MFNS|
9751993|NCT00491374|Placebo Comparator|Placebo|
9751994|NCT00491491|Experimental|Z-BEAM|ibritumomab tiuxetan (zevalin) BEAM
9751995|NCT00491491|Active Comparator|standard BEAM|standard BEAM chemotherapy
9751996|NCT00491530|Experimental|ABT-335 + rosuvastatin calcium|
9751997|NCT00491530|Experimental|ABT-335 + simvastatin|
9751998|NCT00491530|Experimental|ABT-335 + atorvastatin calcium|
9751999|NCT00491556|Experimental|Experimental Arm|Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
9752000|NCT00491556|Other|Standard Care Arm|Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
9752001|NCT00491608|Experimental|1|rThrombin
9752002|NCT00491751|Experimental|Atorvastatin|Atorvastatin 40 or 80 mg/day
9752003|NCT00491751|Experimental|Ascorbic Acid|Ascorbic Acid 500 mg/day
9752004|NCT00491751|Placebo Comparator|Placebo|Placebo atorvastatin and Placebo ascorbic acid
9752005|NCT00491764|Experimental|Posaconazole 100 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
9752006|NCT00491764|Experimental|Posaconazole 200 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
9752007|NCT00491764|Experimental|Posaconazole 400 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
9752008|NCT00491764|Experimental|Posaconazole 400 mg QD for 12 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
9752009|NCT00491764|Active Comparator|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
9752010|NCT00491764|Placebo Comparator|Placebo|Placebo for 24 weeks.
9752011|NCT00491829|Experimental|flibanserin|50 mg qhs
9752012|NCT00491829|Experimental|flibanserin 100mg|100 mg qhs
9752013|NCT00491829|Placebo Comparator|placebo|placebo qhs
9752014|NCT00491894|Other|Patients with Chronic Drooling|Arm receiving study drug
9752015|NCT00492024|Experimental|Moxifloxacin 400 mg|Moxifloxacin 400mg once daily for 5 days
9752016|NCT00492024|Placebo Comparator|Placebo|Matching placebo for 5 days
9830458|NCT02570750||Group 1: smokers patients group|smokers (more than 10 cigarettes per day)
9830459|NCT02570750||Group 2 : non-smokers patients group|Smoking status will be classified as current and never/former. Former smokers will be defined as those who had stopped smoking at least 1 year before being interviewed for this study
9830460|NCT02571049|Experimental|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
9830461|NCT02571049|Experimental|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
9830462|NCT02571075|Experimental|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
9830463|NCT02571075|No Intervention|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
9830464|NCT02571153|Placebo Comparator|Saline group|Normal saline 0.9% (5 mL)
9830465|NCT02571153|Experimental|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
9830466|NCT02571153|Experimental|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
9830467|NCT02571218|Active Comparator|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
9830468|NCT02571218|Experimental|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
9830469|NCT02571244|Experimental|Motivational Interview plus text message|Inside the hospital: All participants have received the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended treatment: Participants in this arm have received a telephone counseling session using a motivational interviewing approach and fifteen or eight days of text messages. The timing, duration, and content of the counseling session were consistent with guideline-based recommendations.
9830470|NCT02571244|No Intervention|Control Arm|Inside the hospital: All participants have receive the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended care: None
9830471|NCT02571439|Experimental|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
9830472|NCT02571439|Active Comparator|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
9830473|NCT02571452|Experimental|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
9830474|NCT02571452|Active Comparator|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
9830475|NCT02571634|Other|Open label|Open label, no blinding, everyone receives Lazanda.
9830476|NCT02571777|Experimental|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
9830477|NCT02571777|Experimental|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
9830478|NCT02571777|Active Comparator|QMF149 150/320 µg o.d.|QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
9830479|NCT02571777|Active Comparator|QMF149 150/160 µg o.d.|QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
9830480|NCT02571777|Active Comparator|Salmeterol/fluticasone 50/500 μg b.i.d.|Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®
9752017|NCT00492063|Experimental|Cell culture-derived influenza vaccine (cTIV)|
9752018|NCT00492063|Active Comparator|Egg-derived influenza virus vaccine (TIV)|
9752019|NCT00492089|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9752020|NCT00492089|Placebo Comparator|Arm II|Patients receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9752021|NCT00492115|Active Comparator|"therapeutic CPAP Treatment (6 weeks)"|Intervention - The active comparator is an intervention of nightly therapeutic CPAP (continuous positive airway pressure) treatment for 6 weeks. Patients will use CPAP every night for the full duration of the study, i.e., 6 weeks
9752022|NCT00492115|Placebo Comparator|"Sham CPAP/therapetuic CPAP (6 weeks)"|"The placebo comparator is an intervention of placebo CPAP (continuous positive airway pressure) nightly for 3 weeks followed by therapeutic CPAP treatment nightly for 3 weeks.~Patients will use a sham CPAP (no real pressure) for 3 weeks and then will be switched to real CPAP for 3 weeks."
9752023|NCT00492206|Experimental|Cetuximab|"Cetuximab 400 mg/m2 IV week 0 only~External beam radiation weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly thereafter weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly weeks 8 - 26~Carboplatin AUC = 6 IV Paclitaxel 200 mg/m2 IV Every 3 weeks x 3 Cycles"
9752024|NCT00492232|Experimental|Ramelteon 8 mg QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
9752025|NCT00492232|Placebo Comparator|Placebo QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
9752026|NCT00492284|Experimental|1/4 Fluence Triple Therapy|Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
9752027|NCT00492284|Experimental|1/2 Fluence Triple Therapy|Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
9752028|NCT00492284|Experimental|1/2 Fluence Double Therapy|Reduced-fluence Visudyne followed by Lucentis double therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
9752029|NCT00492284|Experimental|Ranibizumab|Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
9752030|NCT00492297|Experimental|Sorafenib + Dacarbazine|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
9752031|NCT00492336|Active Comparator|Rasagiline|Treatment with Rasagiline
9752032|NCT00492336|Placebo Comparator|Inactive pill|Treatment with Placebo
9752033|NCT00492401|Experimental|Treatment (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9752034|NCT00492531|Experimental|Sildenafil|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo.
9752035|NCT00492531|Placebo Comparator|Placebo|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo
9752036|NCT00492544|Experimental|Cervarix|Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
9752037|NCT00492557|Experimental|13vPnC+TIV Followed by Placebo 1 month later|
9752038|NCT00492557|Active Comparator|Placebo+TIV Followed by 13vPnC 1 month later|
9752039|NCT00492583|Placebo Comparator|Placebo|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of placebo drink.
9752040|NCT00492583|Experimental|Bifidobacterium lactis (BB-12)|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of active drink.
9752041|NCT00492622|Experimental|Immediate-release omeprazole release first|subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
9752042|NCT00492622|Experimental|Delayed-release omeprazole first|subjects receive delayed release omeprazole for 7 days then immediate release for 7 days
9752043|NCT00492648|Experimental|GSK1437173A 18-30 Years Old Group|Subjects aged 18 to 30 years old receiving 2 doses GSK1437173A vaccine in the primary study.
9752044|NCT00492648|Experimental|GSK1437173A 50-70 Years Old Group|Subjects aged 50 to 70 years old receiving 2 doses GSK1437173A vaccine in the primary study.
9752045|NCT00492726|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
9752046|NCT00492726|Active Comparator|Ertapenem|Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
9752047|NCT00492752|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was administered orally at a dose of 400 mg (2 x 200 mg tablets) bid (twice daily); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily (od) and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment.
9752048|NCT00492752|Placebo Comparator|Placebo|Placebo tablets matching in appearance were orally administered bid (twice daily).
9984040|NCT04468841|Experimental|Prospective Group|Study participants with untreated, newly diagnosed follicular lymphoma will have blood collected for cfDNA testing before, during, and after their first-line treatment or observation period
9984716|NCT03796832|Experimental|Flat Flexible Shoes+Exercise Therapy|This arm will wear Flat Flexible Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
9782549|NCT01178671|Active Comparator|Sertraline and Sugar pill|Sertraline and Sugar pill for up to 24 weeks
9782550|NCT01178762|Experimental|Observation|
9782551|NCT01178827|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride), 60mg once daily for 10 days
9782552|NCT01178827|Active Comparator|Oxybutynin IR|Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days
9782553|NCT01178827|Placebo Comparator|Oxybutynin IR placebo|Oxybutynin IR placebo three times daily for 2 days
9782554|NCT01178853|Experimental|Pitavastatin/Rosuvastatin|
9782555|NCT01178853|Experimental|Rosuvastatin/Pitavastatin|
9782556|NCT01178944|Experimental|Treatment (pralatrexate, oxaliplatin)|Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
9782557|NCT01179048|Experimental|Liraglutide|
9782558|NCT01179048|Placebo Comparator|Placebo|
9782559|NCT01179113|Placebo Comparator|Placebo|Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively
9782560|NCT01179113|Active Comparator|Esmolol|Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively
9782561|NCT01179191|Experimental|morphine sulfate and naltrexone hydrochloride (EMBEDA)|
9782562|NCT01179217|Experimental|L-glutamine|Patients will be randomized to receive investigational product, L-Glutamine.
9782563|NCT01179217|Placebo Comparator|100% maltodextrin|Patients will be randomized to receive Placebo.
9782564|NCT01179334|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
9782565|NCT01179334|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
9782566|NCT01179347|Experimental|tiotropium|2 inhalations once daily delivered with Respimat® inhaler
9782567|NCT01179347|Placebo Comparator|placebo|2 inhalations once daily delivered with Respimat® inhaler
9782568|NCT01179490|Experimental|SyB L-0501 + prednisolone|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
9782569|NCT01179516|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
9782570|NCT01179516|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
9782571|NCT01179516|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
9782572|NCT01179568|Active Comparator|CGT with Citalopram|Targeted psychotherapy for complicated grief will be combined with SSRI medication.
9782573|NCT01179568|Active Comparator|Citalopram|Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
9782574|NCT01179568|Placebo Comparator|Placebo (Sugar pill)|Inactive medication. It will be combined with grief-focused clinical management.
9782575|NCT01179568|Active Comparator|CGT with Placebo|The targeted psychotherapy for complicated grief will be combined with inactive medication.
9782576|NCT01179672|Experimental|Duloxetine|
9782577|NCT01179672|Placebo Comparator|Placebo|
9782578|NCT01179919|Experimental|Oseltamivir Dosed Group|Oseltamivir 75 mg by mouth every 12 hours for 9 doses
9782579|NCT01179984|Experimental|PTA and study stent|Bard® LifeStent® Vascular Stent System
9782580|NCT01180036|Active Comparator|Rituximab Treatment Arm|Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of >25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of cluster of differentiation (CD) 19+ B cell count.
9782581|NCT01180036|Active Comparator|Cyclosporine Treatment Arm|Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a >25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.
9782582|NCT01180049|Active Comparator|temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly|
9782583|NCT01180049|Active Comparator|temsirolimus (Torisel) 75mg weekly|
9782584|NCT01180127|Active Comparator|exercise, dietary intervention|aerobic training and flavanol containing food product for 12 weeks
9752049|NCT00492856|Experimental|Post-consolidation therapy arm I|Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
9752050|NCT00492856|No Intervention|Post-consolidation therapy arm II|Patients receive no further chemotherapy. Patients are followed every 3 months for 1 year. (Randomization and observation arm closed as of 8/15/10)
9752051|NCT00492921|Experimental|Cyclophosphamide 50|Treatment with cyclophosphamide 50 mg/kg/d x 1 days.
9752052|NCT00492921|Experimental|Cyclophosphamide 100|Treatment with cyclophosphamide 50 mg/kg/d x 2 days.
9752053|NCT00492921|Experimental|Cyclophosphamide 150|Treatment with cyclophosphamide 50 mg/kg/d x 3 days.
9752054|NCT00492973|Active Comparator|Control|Patients in the active comparator group will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
9752055|NCT00492973|Experimental|Corticosteroid|Patients in the Corticosteroid group will have the same medications as the Control Group with the addition of a corticosteroid (methylprednisolone acetate)
9752056|NCT00493012|Experimental|vitamin D oil|oil containing vitamin D (Vigantol oil)
9752057|NCT00493012|Placebo Comparator|placebo oil|oil not containg vitamin D (Migliol oil)
9752058|NCT00493038|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
9752059|NCT00493038|Active Comparator|Amoxicillin/Clavulanate|Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
9752060|NCT00493064|Experimental|Prospective active treatment|Niacin 500mg TID PO for treatment of retinal vein occlusions.
9752061|NCT00493181|Experimental|Interleukin-11|Starting dose 10 mcg/kg subcutaneously 3 times a week
9752062|NCT00493220|Experimental|HYLENEX SC, Placebo SC, IV|subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
9752063|NCT00493220|Experimental|HYLENEX SC, IV, Placebo SC|subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
9752064|NCT00493220|Experimental|Placebo SC, HYLENEX SC, IV|subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
9752065|NCT00493220|Experimental|Placebo SC, IV, HYLENEX SC|subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
9752066|NCT00493220|Experimental|IV, HYLENEX SC, Placebo SC|IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
9752067|NCT00493220|Experimental|IV, Placebo SC, HYLENEX SC|IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
9752068|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)|Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
9752069|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 12.5 (mg/kg)|Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
9752070|NCT00493285|Active Comparator|1|MEDI-534 at 10^4 TCID50 at 0, 2, and 4 months (Nasal spray)
9752071|NCT00493285|Active Comparator|2|MEDI-534 at 10^5 TCID50 at 0, 2, and 4 months (Nasal Spray)
9752072|NCT00493285|Active Comparator|3|MEDI-534 at 10^6 TCID50 at 0, 2, and 4 months (Nasal Spray)
9752073|NCT00493311|Experimental|IV Acetaminophen|1 g of acetaminophen in 100 mL of intravenous solution
9752074|NCT00493311|Placebo Comparator|IV Placebo|100 mL of intravenous placebo solution
9752075|NCT00493454|Experimental|Ibritumomab tiuxetan + Rituximab|Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
9752076|NCT00493467|Experimental|Zevalin|Ibritumomab Tiuxetan (Zevalin) + Rituximab
9782585|NCT01180127|Active Comparator|no exercise, dietary intervention|wait list control plus flavanol containing food product for 12 weeks
9752077|NCT00493636|Active Comparator|A (Sorafenib + Gemcitabine or Capecitabine)|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
9752078|NCT00493636|Placebo Comparator|B (Placebo + Gemcitabine or Capecitabine)|Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
9782586|NCT01180127|Active Comparator|exercise, food product lacking flavanol|aerobic training plus food product without flavanol for 12 weeks
9782587|NCT01180127|Placebo Comparator|wait list control food additive without flavanol|wait list control plus food product without flavanol for 12 weeks
9782588|NCT01180244|Active Comparator|Active treatment|Subjects in this group will receive the noninvasive cortical stimulation signal from the treatment device
9782589|NCT01180244|Placebo Comparator|Placebo group|Subjects in this group will be provided the same experience as those in the active treatment arm, but will not receive the noninvasive cortical stimulation signal from the treatment device
9782590|NCT01180296|Experimental|Progesterone Group|Oral Micronized Progesterone
9782591|NCT01180296|Placebo Comparator|Placebo|Identical Placebo Tablet
9782592|NCT01180400|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
9782593|NCT01180400|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
9782594|NCT01180478|Other|Narrow Band Imaging|Narrow Band Imaging (NBI)
9782595|NCT01180478|Other|White Light Trans Urethral Resection|White Light Trans Urethral Resection
9782596|NCT01180647|Active Comparator|Extended-release naltrexone (XR-NTX)|A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
9782597|NCT01180647|Placebo Comparator|Motivational Enhancement Counseling Only|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
9782598|NCT01180660|Active Comparator|Lidocaine|Lidocaine infusion
9782599|NCT01180660|Placebo Comparator|Placebo|Placebo Normal Saline Infusion
9782600|NCT01180777|Other|etafilcon A (A)/etafilcon A (B)/etafilcon A (C)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
9782601|NCT01180777|Other|etafilcon A (A)/etafilcon A (C)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
9782602|NCT01180777|Other|etafilcon A (C)/etafilcon A (A)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
9782603|NCT01180777|Other|etafilcon A (B)/etafilcon A (C)/etafilcon A (A)|Printed etafilcon A Lens with PVP (B) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
9782604|NCT01180777|Other|etafilcon A (C)/etafilcon A (B)/etafilcon A (A)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
9782605|NCT01180777|Other|etafilcon A (B)/etafilcon A (A)/etafilcon A (C)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
9782606|NCT01180790|Experimental|Segment 1: 200 mg ACH-0141625|200 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a and ribavirin for 48 weeks
9782607|NCT01180790|Experimental|Segment 1: 400 mg ACH-0141625|400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
9782608|NCT01180790|Experimental|Segment 1: 800 mg ACH-0141625|800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
9782609|NCT01180790|Placebo Comparator|Segment 1: Placebo|Placebo for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
9782610|NCT01180790|Experimental|Segment 2: 200 mg ACH-0141625|200 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
9782611|NCT01180790|Experimental|Segment 2 : 400 mg ACH-0141625|400 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
9782612|NCT01180790|Experimental|Segment 2 : 800 mg ACH-0141625|800 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
9782613|NCT01180894|Active Comparator|Iron sucrose|100 mg IV TIW
9782614|NCT01180894|Placebo Comparator|Placebo|Pacebo - Normal Saline
9782615|NCT01180985|Other|galyfilcon A prototype/comfilcon A|The galyfilcon A prototype lenses are worn during first period and comfilcon A lenses worn during second period. Each period consists of daily lens wear for one week.
9782616|NCT01180985|Other|comfilcon A/galyfilcon A prototype|The comfilcon A lenses are worn during first period and galyfilcon A prototype lenses worn during second period. Each period consists of daily lens wear for one week.
9752079|NCT00493649|Experimental|TC+H|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.
9752080|NCT00493779|No Intervention|1|Effect of Clopidogrel withdrawal on biomarkers will be assessed via blood draws
9752081|NCT00493805|Experimental|Interventional Study arm (with insulin resistance)|"HOMA IR (homeostasis model assessment-estimated insulin resistance) of > 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment."
9752082|NCT00493805|Experimental|Non interventional study arm (without insulin resistance)|"HOMA IR <= 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to~European labeling)."
9752083|NCT00493974|Active Comparator|Zileuton|Zileuton (Zyflo, 600 mg 4 times a day)
9752084|NCT00493974|Placebo Comparator|Placebo|Placebo
9752085|NCT00494013|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
9752086|NCT00494013|Active Comparator|Detemir|Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
9752087|NCT00494026|Experimental|Pemetrexed + Carboplatin|
9752088|NCT00494091|Experimental|A.|
9752089|NCT00494091|Experimental|B.|
9752090|NCT00494143|Active Comparator|Conventional Prosthetic foot|A conventional prosthetic foot that has limited energy storage and return capabilities. It is standardized and used by all subjects in the study.
9752091|NCT00494143|Active Comparator|Prescribed Prosthetic foot|the Prosthetic foot that the subject had prescribed for them by their clinical providers and was worn prior to study initiation
9752092|NCT00494143|Experimental|CESR foot|the experimental CESR, controlled energy storage prosthetic foot
9752093|NCT00494221|Active Comparator|FOLFOX + Cediranib 20 mg|FOLFOX + Cediranib 20 mg
9752094|NCT00494221|Active Comparator|FOLFOX + Cediranib 30 mg|FOLFOX + Cediranib 30 mg
9752095|NCT00494221|Placebo Comparator|FOLFOX + Placebo Cediranib|FOLFOX + Placebo Cediranib
9752096|NCT00494299|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.
9752097|NCT00494299|Placebo Comparator|Placebo|Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).
9752098|NCT00494442|Experimental|KU-0059436 (AZD2281) 100 mg BID|
9752099|NCT00494442|Experimental|KU-0059436 (AZD2281) 400 mg BID|
9752100|NCT00494481|Placebo Comparator|1|Docetaxel + placebo vandetanib
9752101|NCT00494481|Experimental|2|Vandetanib + Docetaxel
9752102|NCT00494494|Active Comparator|Standard Treatment|topical antibiotic for 10 days and a topical corticosteroid for 1 month
9752103|NCT00494494|Experimental|Nepafenac|1 drop per study eye three times per day for 30 days in addition to standard care
9752104|NCT00494507|Active Comparator|HYP Dichlorphenamide|Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
9752105|NCT00494507|Placebo Comparator|HYP Placebo|Hyperkalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
9752106|NCT00494507|Active Comparator|HOP Dichlorphenamide|Hypokalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
9752107|NCT00494507|Placebo Comparator|HOP Placebo|Hypokalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
9752108|NCT00494585|Experimental|CEP-701|80 mg orally twice a day for 30 days
9752109|NCT00494676|Experimental|Real prism glasses first, then sham|Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
9752110|NCT00494676|Experimental|Sham prism glasses first, then real|Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period
9752111|NCT00494780|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
9752112|NCT00494780|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg
9752113|NCT00494806|Experimental|Rocking Group|Patients rocked in a rocking chair in 10-20 minute increments for at least one hour per day beginning on the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
9752114|NCT00494806|No Intervention|Standard Care|Standard care group got out of bed and sat in a non-rocking chair and ambulated beginning the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
9752115|NCT00494871|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
9752116|NCT00494871|Active Comparator|Warfarin|Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
9752117|NCT00494975|Experimental|NB-UVB|Narrow band-Ultraviolet B phototherapy
9752118|NCT00494975|Placebo Comparator|UVA|Ultraviolet A Phototherapy
9752119|NCT00495040|Experimental|Proton Radiotherapy|Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.
9517429|NCT03306459||2/CONTROL|The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
9752120|NCT00495079|Experimental|Marqibo|Eligible subjects received study drug at 2.25 mg/m^2 intravenously via peripheral or central venous access over 60 minutes (± 10 minutes).
9752121|NCT00495157|Experimental|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
9752122|NCT00495157|Experimental|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
9752123|NCT00495157|Experimental|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
9752124|NCT00495170|Experimental|Concurrent proton and Chemotherapy|Proton Radiotherapy + Carboplatin + Paclitaxel
9752125|NCT00495391|Active Comparator|1|Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
9752126|NCT00495391|Placebo Comparator|2|Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
9752127|NCT00495469|Experimental|GSK189075|Participants will receive GSK189075 for 12 weeks
9752128|NCT00495469|Placebo Comparator|Placebo|Participants will receive GSK189075 matching Placebo for 12 weeks
9752129|NCT00495495|Experimental|Ozone treatment|Ozone treatment of randomly selected study tooth for 60 seconds
9752130|NCT00495495|Placebo Comparator|Placebo, no ozone|Placebo treatment (no ozone) of randomly selected study tooth for 60 seconds.
9752131|NCT00495521|Experimental|Active|4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
9752132|NCT00495521|Placebo Comparator|Placebo|Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks
9752133|NCT00495586|Placebo Comparator|Placebo|Placebo pills t.i.d. for 8 days
9752134|NCT00495586|Active Comparator|Amoxycillin and clavulanic acid|Amoxycillin and clavulanate t.i.d. for 8 days
9752135|NCT00495612|Experimental|Omalizumab|Patients received omalizumab via subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. The dose administered and the dosing interval were determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
9752136|NCT00495612|Placebo Comparator|Placebo|Patients received placebo as a subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. Patients received injections at the same time intervals as the omalizumab group.
9752137|NCT00495625|Experimental|Sunitinib Malate (SUO11248) Treatment|
9752138|NCT00495677|Active Comparator|PF-00232798 40 mg|
9752139|NCT00495677|Active Comparator|PF-00232798 300 mg|
9752140|NCT00495677|Active Comparator|PF-00232798 400 mg|
9752141|NCT00495677|Active Comparator|PF-00232798 5 mg|
9752142|NCT00495677|Active Comparator|PF-00232798 20 mg|
9752143|NCT00495677|Active Comparator|PF-00232798 150 mg|
9752144|NCT00495755|Experimental|Campath (alemtuzumab)|
9752145|NCT00495794|Experimental|Pharmacist management|Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
9752146|NCT00495794|No Intervention|Usual care|Eligible patients receive usual care
9752147|NCT00495820|Experimental|Arm 1|Methylphenidate
9752148|NCT00495820|Placebo Comparator|Arm 2|Placebo
9752149|NCT00496015|Experimental|Synflorix I Group|Subjects were vaccinated with 3 primary vaccination doses of Synflorix™ vaccine with prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa along with prophylactic antipyretic treatment.
9752150|NCT00496015|Experimental|Synflorix II Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment
9752151|NCT00496015|Experimental|Synflorix PRE Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (before the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
9782617|NCT01180998|Other|Spherical contact lens users|Habitual spherical contact lens (non-toric lens) users tried one of two toric lenses in a daily wear modality.
9782618|NCT01180998|Other|Contact lens drop-outs|Habitual spectacle users (for vision correction) who have failed contact lens fit and wear, tried one of two toric lenses in a daily wear modality.
9830481|NCT02571972|Experimental|Dorzolamide-timolol|"On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.~Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.~Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits~At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients"
9830482|NCT02572076|Experimental|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
9830483|NCT02572167|Experimental|Brentuximab Vedotin + Nivolumab|Brentuximab vedotin plus nivolumab
9830484|NCT02572388|Active Comparator|Group 1|10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
9830485|NCT02572388|Active Comparator|Group 2|50µg of R21 on days 0, 28, and 56.
9830486|NCT02572388|Active Comparator|Group 3|50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
9830487|NCT02572388|Active Comparator|Group 4|2µg of R21 mixed with 50µg of Matrix-M
9830488|NCT02572401|Experimental|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
9830489|NCT02572401|No Intervention|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
9830490|NCT02572401|Experimental|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
9830491|NCT02572401|Experimental|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
9830492|NCT02572427|Experimental|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
9830493|NCT02572427|Active Comparator|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
9830494|NCT02572570|Experimental|Posterior Composite Resin Restoration|Participants will receive two commercially available tooth-colored restorative materials used for direct restoration as per manufacturer's instructions.
9830495|NCT02572609|Experimental|Mucosolvan ® adult syrup|
9830496|NCT02572609|Experimental|Ambroxol hydrochloride soft pastille|
9830497|NCT02572752|Experimental|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
9830498|NCT02572752|Experimental|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
9830499|NCT02572752|Experimental|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
9830500|NCT02572817|Experimental|High-titer anti-influenza plasma|Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
9830501|NCT02572817|Active Comparator|Low-titer anti-influenza plasma|Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
9830502|NCT02573012|Experimental|Tocilizumab+prednisone (constant dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
9830503|NCT02573012|Experimental|Tocilizumab+prednisone (tapering dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
9830504|NCT02573155|Experimental|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
9830505|NCT02573155|Experimental|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
9830506|NCT02573155|Experimental|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
9830507|NCT02573155|Experimental|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
9830508|NCT02573155|Experimental|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
9830509|NCT02573155|Experimental|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
9517430|NCT03306446|Experimental|Adalimumab in monotherapy|Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.
9752152|NCT00496015|Experimental|Synflorix POST Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (after the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
9752153|NCT00496015|Active Comparator|Mencevax + Infanrix Hexa Group|Age-matched pneumococcal vaccine unprimed group receiving a single dose of Mencevax™ vaccine co-administered with Infanrix™ hexa vaccine.
9752154|NCT00496054|Experimental|RotaTeq™ Vaccine (V260)|Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.
9752155|NCT00496080|Experimental|DUAO Device|Doppler-guided uterine artery occlusion device (Single-arm study)
9752156|NCT00496197|Experimental|1.|Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.
9752157|NCT00496262|Experimental|Human Fibrinogen Concentrate|
9752158|NCT00496340|Experimental|Conditioning Followed by HCT|"Pentostatin/Busulfan/Rituximab/Allogeneic Hematopoietic Cell Transplant (HCT).~Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.~Conditioning:~Patients will receive anti-seizure prophylaxis with lorazepam 0.5 mg every 6 hours beginning day -6.~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.~Patient will then receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.~Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.~Rituximab: Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
9752159|NCT00496366|Experimental|Capecitabine (Xeloda) + Lapatinib (Tykerb)|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Lapatinib will be taken daily continuously for 21 days (Days 1- 21)."
9752160|NCT00496379|Experimental|ZK219477|
9752161|NCT00496470|Active Comparator|Symbicort+TIO|Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
9752162|NCT00496470|Active Comparator|Spiriva® + Placebo Turbuhaler|Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily
9752163|NCT00496483|Active Comparator|LCP-Tacro (tacrolimus)|Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
9752164|NCT00496587|Experimental|Capecitabine + Gemcitabine + Bevacizumab|Capecitabine 800 mg/m^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.
9752165|NCT00496626|Experimental|1|V501 (Gardasil®)
9752166|NCT00496626|Placebo Comparator|2|Placebo
9752167|NCT00496769|Experimental|Apixaban|
9752168|NCT00496769|Active Comparator|Acetylasalicylic acid|
9752169|NCT00496808|Experimental|Herceptin|8 mg/kg intravenously (IV) Over 90 Minutes
9752170|NCT00496873|Experimental|Cytoxan + Rituxan + Nipent|Cytoxan 600 mg/m^2 on Day 1 of 21-day cycle. Rituxan 375 mg/m^2 on Day 1 of 21 Day Cycle. Nipent 4 mg/m^2 on Day 1 of 21 Day Cycle.
9752171|NCT00496964|Experimental|1|Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
9752172|NCT00496964|Placebo Comparator|2|Placebo injection + exercise
9752173|NCT00497055|Experimental|Aripiprazole|Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.
9752174|NCT00497055|Placebo Comparator|Placebo|Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
9752175|NCT00497081|Active Comparator|Mirtazapine|mirtazapine 30 mg daily
9752176|NCT00497081|Placebo Comparator|Placebo|placebo 30 mg daily
9752177|NCT00497146|Experimental|Paricalcitol|Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
9752178|NCT00497146|Placebo Comparator|Placebo|Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
9752179|NCT00497198|Experimental|MCI-196|
9752180|NCT00497198|Placebo Comparator|Placebo|
9752181|NCT00497289|Experimental|1|Lipidem 20 %
9752182|NCT00497289|Active Comparator|2|Lipofundin MCT/LCT 20%
9752183|NCT00497770||Caucasian|Caucasian patients receiving Alimta for 2nd line NSCLC
9752184|NCT00497770||African American|African American patients receiving Alimta for 2nd line NSCLC
9752185|NCT00497770||Asian American|Asian American patients receiving Alimta for 2nd line NSCLC
9752186|NCT00497770||Hispanic|Hispanic patients receiving Alimta for 2nd line NSCLC
9752187|NCT00497796|Experimental|1|
9752188|NCT00497796|Active Comparator|2|
9752189|NCT00497874|Experimental|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
9752190|NCT00497874|No Intervention|Usual care|Usual primary care treatment
9752191|NCT00498173|Experimental|Atomoxetine|Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
9830510|NCT02573155|Experimental|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
9752192|NCT00498173|Placebo Comparator|Placebo|Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
9752193|NCT00498186|Experimental|Rotigotine|Rotigotine trans-dermal patch
9752194|NCT00498355|Experimental|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
9752195|NCT00498368|Experimental|Rituximab Plus ACE/ARB|Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
9752196|NCT00498368|Active Comparator|ACE/ARB|ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
9752197|NCT00498433|Experimental|Aliskiren|"Part 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase (period 1) consisting of treatment with one tablet of placebo to aliskiren once daily (o.d.). This was followed by a 4 week treatment phase (period 2) consisting of treatment with 300 mg aliskiren o.d..~Part 2: Eligible randomized patients in this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks."
9752198|NCT00498433|Active Comparator|Amlodipine|"Part 1: After aliskiren treatment (period 2), each patient was entered into a second washout period (4 weeks) during which blood pressure was required to be ≤ 140/90 mmHg. If blood pressure exceeded 140/90 mmHg on two consecutive days (home monitoring) and was confirmed at the study center, the patient was entered into the amlodipine treatment period (period 3). In period 3, all patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.~Part 2: Eligible patients randomized to part 2 received amlodipine 5 mg o.d. and aliskiren placebo for 12 weeks"
9752199|NCT00498485|Placebo Comparator|Placebo|Patients were randomized and these received placebo
9752200|NCT00498485|Active Comparator|Sodium Oxybate|Patients were randomized and these received the active drug
9752201|NCT00498550|Experimental|Clozapine|Clozapine, Clozaril
9752202|NCT00498550|Active Comparator|Treatment as usual|Treatment as usual with any antipsychotic other than Clozapine.
9752203|NCT00498602|Experimental|1|ACC-001
9752204|NCT00498602|Other|2|QS-21
9752205|NCT00498602|Other|3|Diluent: Phosphate Buffered Saline
9752206|NCT00498602|Experimental|4|ACC-001
9752207|NCT00498615|Experimental|Fasudil 80 mg|Subject is given a single dose of 80 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
9752208|NCT00498615|Experimental|40 mg Fasudil|Subject is given a single dose of 40 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
9752209|NCT00498615|Placebo Comparator|placebo|Subject is given a single dose of placebo( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
9752210|NCT00498628|Experimental|1|Quetiapine fumarate plus medical management
9752211|NCT00498628|Placebo Comparator|2|Medical management plus placebo comparator
9752212|NCT00498706|Experimental|Telephone-administered CBT|Participants will receive telephone-administered cognitive behavioral therapy.
9752213|NCT00498706|Active Comparator|Face-to-face CBT|Participants will receive face-to-face cognitive behavioral therapy.
9752214|NCT00498927|Experimental|Temozolomide|Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
9752215|NCT00498940|Active Comparator|Biventricular Pacing|After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
9752216|NCT00498940|Active Comparator|Standard of Care|No continuous pacing occurred about surgery. Patients underwent optimization testing.
9752217|NCT00499031|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 120 minutes on day 1.
9752218|NCT00499083|Experimental|Vaccine|Patients with HER-2/neu negative tumors will receive IT DCs one week after the first three of four cycles of dose dense T therapy and then four cycles of dose dense AC therapy will be given (i.e. T-AC).
9752219|NCT00499096|Experimental|Chronic Care Model for Bipolar Disorder|An intervention group of patients with bipolar disorder and 1 or more risk factor for cardiovascular disease; group will receive self-management group sessions, followed by phone contacts by the Care Manager. This is the chronic care model for bipolar disorder
9752220|NCT00499096|No Intervention|Enhanced Usual Care|A group of patients with bipolar disorder and one or more risk factors for cardiovascular disease will be randomized to receive enhanced usual care. This group will receive usual care, plus mailings on wellness topics (attention control), and their providers will receive information on guideline concordant care.
9830511|NCT02573155|Experimental|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
9752221|NCT00499109|Experimental|E. Dual Agent Chemotherapy|"Experimental Arm E.~Patients received treatment according to gene expression strata with four doublet regimens.~Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.~Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.~High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.~High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group."
9752222|NCT00499109|Active Comparator|C. Standard of Care Control Arm|"Control Arm C: Gemcitabine and Carboplatin (GCb).~All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed."
9752223|NCT00499122|Experimental|NOV-002 and Chemotherapy|"NOV-002:~Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart~Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration~Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections~Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1~Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1~Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1"
9752224|NCT00499174|No Intervention|Active Surveillance|Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
9752225|NCT00499174|Active Comparator|Radical Intervention|Radical prostatectomy or radiotherapy based on patient and physician preference
9752226|NCT00499252|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9752227|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 2 Growth Factors|Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)
9752228|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 1 Growth Factor|Growth Factor = granulocyte-colony stimulating factor (G-CSF)
9752229|NCT00499369|Experimental|Arm I (chemotherapy, cetuximab)|Patients receive single-agent irinotecan hydrochloride IV or FOLFIRI IV. They also receive cetuximab IV over 1-2 hours on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
9752230|NCT00499369|Experimental|Arm II (chemotherapy, cetuximab, bevacizumab)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive bevacizumab IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
9752231|NCT00499369|Experimental|Arm III (closed to accrual as of 4/20/2009)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive a higher dose of bevacizumab (higher than in arm II) IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
9752232|NCT00499408|Experimental|Soy and Vitamin D|Patients will receive oral supplementation with both 2,000 IU per day of vitamin D (cholecalciferol) and soy (160 mg per day soy isoflavones). Serum PSA and plasma levels of vitamin D will be assessed monthly. Soy isoflavones levels will be assessed every three months.
9830512|NCT02573155|Experimental|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
9830513|NCT02573155|Experimental|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
9830514|NCT02573155|Experimental|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
9830515|NCT02573155|Experimental|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
9830516|NCT02573155|Experimental|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
9830517|NCT02573155|Experimental|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
9830518|NCT02573155|Experimental|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
9830519|NCT02573155|Experimental|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
9830520|NCT02573155|Experimental|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
9830521|NCT02573155|Experimental|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
9830522|NCT02573181|Experimental|V114|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
9830523|NCT02573181|Active Comparator|Prevnar 13™|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.
9830524|NCT02573246|Experimental|Cognitive Restructuring+rTMS (left)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the left side of the brain and will partake in short term and long term follow up testing.
9830525|NCT02573246|Sham Comparator|Cognitive Restructuring + sham rTMS|Participants in this arm will receive cognitive restructuring alone as an active intervention and will partake in short term and long term follow up testing.
9830526|NCT02573246|Experimental|Cognitive Restructuring+rTMS (right)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the right side of the brain and will partake in short term and long term follow up testing.
9830527|NCT02573311|Experimental|men|
9830528|NCT02573350|Experimental|Delamanid 100 mg BID + OBR|Participants received Delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) along with at least 4 additional anti-TB medications per optimized background regimen (OBR) from Week 0 to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment.
9830529|NCT02573350|Experimental|Delamanid 200 mg BID + OBR|Participants received Delamanid 200 mg (4x50 mg tablets), orally, BID along with at least 4 additional anti-TB medications per OBR up to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment. A participant might have been titrated to Delamanid 200 mg BID after an initial hospitalization of 2 weeks. Participants were grouped according to the longest duration of Delamanid dose administered during the study.
9830530|NCT02573402|Experimental|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
9830531|NCT02573402|Sham Comparator|Control|Sham stimulation.
9830532|NCT02573467|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
9830533|NCT02573467|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
9830534|NCT02573467|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
9830535|NCT02573467|Placebo Comparator|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
9835826|NCT02757092|Active Comparator|standard care|control group accept the pulmonary rehabilitation (breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day and without home based pulmonary rehabilitation.
9835827|NCT02757105|Experimental|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
9835828|NCT02757105|Placebo Comparator|Group B|Placebo, once daily for 8 weeks
9752233|NCT00499447|Experimental|Radiofrequency Ablation with External Beam Radiation|Radiofrequency Ablation (RFA)under computerized tomography guidance followed 3-4 weeks later with External Beam Radiation Therapy
9752234|NCT00499460|Other|Arm I|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
9752235|NCT00499460|Other|Arm II|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
9752236|NCT00499473|Experimental|Stratum 1 (kinase inhibitor therapy)|Non-EIAC patients receive oral sunitinib malate once daily for 4 consecutive weeks followed by 2 weeks of rest.
9752237|NCT00499473|Experimental|Stratum 2 (kinase inhibitor therapy)|EIAC & OSU patients receive oral sunitinib malate as in stratum 1. Patients receive escalating doses of oral sunitinib malate until the maximum tolerated dose (MTD) is determined.
9752238|NCT00499486|Experimental|Sirolimus|Sirolimus 5mg. po QD continously (28 days=cycle)
9752239|NCT00499603|Experimental|Paclitaxel + FEC|Paclitaxel 80 mg/m^2 intravenously (IV) on day 1(+/- 2 days) of each week, followed by four cycles of combination 5-Fluorouracil at 500 mg/m^2, Epirubicin at 100 mg/m^2 and Cyclophosphamide at 500 mg/m^2 (FEC) on day 1 every 3 weeks (+/- 7 days).
9752240|NCT00499603|Experimental|Paclitaxel + RAD001 + FEC|Paclitaxel + RAD001 Followed by FEC (5-Fluorouracil + Epirubicin + Cyclophosphamide)
9752241|NCT00499616|Experimental|Group 2 (chemotherapy, surgery)|2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
9752242|NCT00499616|Experimental|Group 3 (chemotherapy, surgery)|4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
9752243|NCT00499616|Experimental|Group 4 (chemotherapy, surgery, antineoplastic therapy)|8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients < 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
9752244|NCT00499616|Experimental|Non-intermediate risk enrolled on intermediate risk trial|The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
9752245|NCT00499655|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
9752246|NCT00499655|Experimental|Arm II|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
9752247|NCT00499681|Experimental|Arm I|Patients receive Lapatinib and Letrozole once daily for two weeks, following tumor measurement patients receive Lapatinib and Letrozole once daily for 14 weeks.
9752248|NCT00499681|Experimental|Arm II|Patients receive Letrozole and placebo once daily for 2 weeks, following tumor measurement patients receive Letrozole and Lapatinib once daily for 14 weeks.
9752249|NCT00499694|Experimental|Bevacizumab and Satraplatin|"Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)~Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days"
9752250|NCT00499746|Active Comparator|Tramadol|oral dose, once per day
9752251|NCT00499746|Placebo Comparator|Placebo|oral dose, once per day
9752252|NCT00499746|Active Comparator|hydromorphone|oral dose, once per day
9752253|NCT00499746|Active Comparator|methylphenidate|oral dose, once per day
9752254|NCT00499863|Experimental|Methylphenidate Transdermal System|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
9752255|NCT00499863|Placebo Comparator|2|Daily application of matching MTS Placebo Patch
9752256|NCT00499889|Experimental|Imatinib, Busulfan, Fludara + Antithymocyte Globulin|Oral Imatinib Mesylate 400 mg twice a day for 9 Days; Busulfan 130 mg/m^2 by vein (IV) daily for 2 Days; Fludara 40 mg/m^2 IV daily for 4 Days; Antithymocyte Globulin (ATG) 2.5 mg/kg IV daily for 3 Days; Tacrolimus levels maintained between 5-15 ng/dl, Day -2 to Day 180; Methotrexate 5 mg/m2 on days 1, 3, 6 and 11; and Donor bone marrow or blood stem cells infused on day 0 with possible donor lymphocyte infusion (DLI) for progressive disease.
9752257|NCT00499915|Experimental|Secondhand Smoke Reduction and Asthma Education|Parents of children in the experimental group will receive asthma education at NICU discharge as well as a secondhand smoke reduction program.
9752258|NCT00499915|Active Comparator|Asthma Education|Parents of children in the active comparator group will receive asthma education at NICU discharge.
9752259|NCT00500110|Experimental|Hormonal Ablation, Imatinib + Docetaxel|Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months
9752260|NCT00500149|Experimental|1|
9752261|NCT00500149|Placebo Comparator|2|
9752262|NCT00500240|No Intervention|Conventional Care|Control Group: Conventional care using blood sugar management with regular human insulin.
9752263|NCT00500240|Other|Intensive Insulin|Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine
9782619|NCT01180998|Other|Habitual Correction with Spectacles (Neophytes)|Habitual spectacle lens wearers (for vision correction) who have never used or been fitted with contact lenses tried one of two toric lenses in a daily wear modality.
9782620|NCT01181011|Experimental|amlodipine/telmisartan/combination|all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order
9782621|NCT01181050|Experimental|4.0 mg/kg|Subjects received a single dose of 4 mg/kg NNC0142-0002
9782622|NCT01181050|Placebo Comparator|Placebo|Subjects received a single dose of placebo
9782623|NCT01181076|Experimental|Individualized Nutrition|
9782624|NCT01181076|No Intervention|Control group|The patients in the control group will be nourished after established routine, first by the oral route, later by the PN route. Naso-jejunal tube will not be inserted and enteral nutrition will not be given.
9782625|NCT01181102|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
9782626|NCT01181102|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
9782627|NCT01181128|Experimental|Individualized (Tailored) Prophylaxis|"On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A >= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity."
9782628|NCT01181128|Experimental|Weekly Prophylaxis|65 IU/kg of rFVIIIFc via IV injection every 7 days
9782629|NCT01181128|Experimental|Episodic (On-Demand) Dosing|10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode
9782630|NCT01181141|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery
9782631|NCT01181141|Active Comparator|Enoxaparin sodium|Enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
9782632|NCT01181167|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
9782633|NCT01181167|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
9782634|NCT01181258|Experimental|Patients Receiving NK Cell Infusion|Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
9782635|NCT01181271|Experimental|Autologous then Allogeneic transplant|"All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.~Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.~Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD)."
9782636|NCT01181323|Experimental|Group 1: LAIV|0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN) and 0.5 ml of placebo given intramuscularly (IM) injection administered to 120 maternal subjects.
9782637|NCT01181323|Experimental|Group 2: TIV|0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM) and 0.2 ml of placebo given intranasally (IN) administered to 120 maternal subjects.
9782638|NCT01181349||P07535 study participants with a TOF ratio <0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio <0.9 at PACU arrival.
9782639|NCT01181349||P07535 study participants with a TOF ratio ≥0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio ≥0.9 at PACU arrival.
9782640|NCT01181479|Experimental|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel. Type of intervention is drug.
9782641|NCT01181479|Active Comparator|Lessina crossover to AG200-15|Lessina containing ethinyl estradiol and levonorgestrel for 6 cycles followed by AG200-15 for 6 cycles. Type of intervention is drug.
9782642|NCT01181492||*1/*1|Grouped by CYP3A4*1G polymorphism, wild-type homozygote
9782643|NCT01181492||*1/*1G|Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote
9782644|NCT01181492||*1G/*1G|Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote
9782645|NCT01181531|Active Comparator|Traditional Vitamin D Therapy|
9782646|NCT01181531|Experimental|Cinacalcet|
9752264|NCT00500266|Experimental|1|13-valent Pneumococcal Conjugate Vaccine
9752265|NCT00500292|Placebo Comparator|1|FOLFOX + Placebo vandetanib
9752266|NCT00500292|Experimental|2|FOLFOX + low dose vandetanib
9752267|NCT00500292|Experimental|3|FOLFOX + high dose vandetanib
9752268|NCT00500318|Experimental|Aclidinium|
9752269|NCT00500318|Placebo Comparator|Placebo|
9752270|NCT00500331|Experimental|Arm 1|GSK189075
9752271|NCT00500331|Placebo Comparator|Arm 2|Placebo
9752272|NCT00500331|Other|Arm 3|pioglitazone (active control)
9752273|NCT00500370|Experimental|Group A|
9752274|NCT00500370|Placebo Comparator|Group B|
9752275|NCT00500448|No Intervention|No Treatment|No treatment was delivered to this arm. Participants went about activities of daily living
9752276|NCT00500448|Experimental|Electrical Stimulation|Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
9752277|NCT00500578|Experimental|1: Standard Schedule - Ribavirin|Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
9752278|NCT00500578|Experimental|2: Modified Schedule - Ribavirin|Aerosolized Ribavirin 2 grams over 3 hours every 8 hours
9752279|NCT00500656|Experimental|Randomized controlled -Icatibant|"Subjects received S.C icatibant+ oral placebo~Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL)~Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart"
9752280|NCT00500656|Active Comparator|Randomized controlled-Tranexamic acid|"Subjects received oral Tranexamic acid+ S.C. placebo~Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart~Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region"
9752281|NCT00500656|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
9752282|NCT00500656|Experimental|Untreated patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
9752283|NCT00500682|Placebo Comparator|Placebo|
9752284|NCT00500682|Experimental|AST-120|
9752285|NCT00500760|Experimental|Panitumumab Plus Chemoradiation|Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
9752286|NCT00500760|Active Comparator|Chemoradiotherapy Alone|Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m^2 on Days 1, 22, and 43.
9752287|NCT00500903|Experimental|PIC Dose Escalation|Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).
9752288|NCT00500903|Experimental|ECT Dose Escalation|Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).
9752289|NCT00500903|Experimental|Relative Bioavailability|Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).
9752290|NCT00501007||Non-psychiatric smokers|Smokers not meeting criteria for Schizophrenia or Schizoaffective Disorder
9752291|NCT00501007||Smokers with Schizophrenia|Smokers meeting criteria for schizophrenia or schizoaffective disorder
9752292|NCT00501046|Placebo Comparator|Placebo|
9752293|NCT00501046|Experimental|AST-120|
9752294|NCT00501059|Experimental|Acetylsalicylic acid (Aspirin, BAYE4465)|Participants received 1 tablet of enteric-coated acetylsalicylic acid [100 milligram (mg)] orally once daily.
9752295|NCT00501059|Placebo Comparator|Placebo|Participants received 1 tablets of matching placebo orally once daily.
9752296|NCT00501085||LAP-BAND|Patients who receive the LAP-BAND AP Adjustable Gastric Banding System.
9752297|NCT00501293|Experimental|1|Methylphenidate Transdermal System
9752298|NCT00501540|Experimental|Lithium|Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
9752299|NCT00501592|Active Comparator|25 mg INT-747|
9752300|NCT00501592|Active Comparator|50 mg INT-747|
9752301|NCT00501592|Placebo Comparator|Placebo|
9752302|NCT00501631|Active Comparator|VIVITROL 380 mg|Administered via intramuscular (IM) injection once every 4 weeks.
9752303|NCT00501631|Placebo Comparator|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
9752304|NCT00501644|Experimental|Chemoimmunotherapy|GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days
9752305|NCT00501852|Experimental|NVA237 12.5 µg|12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
9752306|NCT00501852|Experimental|NVA237 25 µg|25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
9752307|NCT00501852|Experimental|NVA237 50 µg|50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
9752308|NCT00501852|Experimental|NVA237 100 µg|100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
9752309|NCT00501852|Placebo Comparator|Placebo|Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
9752310|NCT00501852|Active Comparator|Tiotropium 18 µg|18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
9752311|NCT00501891|Experimental|Bevacizumab and Metronomic Temozolomide|Patients will receive up to 12 cycles of bevacizumab (Avastin) and metronomic temozolomide (Temodar), and each cycle is 28 days. Bevacizumab will be administered at 10 mg/kg every other week beginning a minimum of 7 days after a biopsy or 28 days after a craniotomy. Temozolomide will be dosed at 50 mg/m2 daily in a 28-day cycle.
9752312|NCT00501943|Active Comparator|Riluzole|Riluzole + Avonex
9752313|NCT00501943|Placebo Comparator|Placebo|placebo + Avonex
9752314|NCT00501969|Experimental|Rotigotine|Rotigotine
9752315|NCT00501995|Experimental|IV Cyclophosphamide (50 mg/kg)|This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .
9752316|NCT00502203|Experimental|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m^2 intravenously (IV) over 3 hours and Carboplatin AUC 5 IV over 1 hour every 21 Days for 6 courses.
9752317|NCT00502216|Experimental|1|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
9752318|NCT00502216|Placebo Comparator|2|Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
9752319|NCT00502242|Active Comparator|A|Capsule - initial treatment is 5 mg (active)- oral - once per day
9752320|NCT00502242|Placebo Comparator|B|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
9752321|NCT00502307|Experimental|1|Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
9752322|NCT00502307|Placebo Comparator|2|solid oral capsule containing excipients dosed daily for three weeks per month
9752323|NCT00502320|Experimental|Ramelteon|8 mg
9752324|NCT00502320|Placebo Comparator|Placebo|
9752325|NCT00502593|Experimental|GSK1562902A-A Lot 1 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752326|NCT00502593|Active Comparator|Fluarix-A 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752327|NCT00502593|Experimental|GSK1562902A-A Lot 1 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752328|NCT00502593|Active Comparator|Fluarix-A 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752329|NCT00502593|Experimental|GSK1562902A-B Lot 2 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752330|NCT00502593|Active Comparator|Fluarix-B 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752331|NCT00502593|Experimental|GSK1562902A-B Lot 2 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752332|NCT00502593|Active Comparator|Fluarix-B 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752333|NCT00502593|Experimental|GSK1562902A-C Lot 3 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752334|NCT00502593|Active Comparator|Fluarix-C 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752335|NCT00502593|Experimental|GSK1562902A-C Lot 3 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9782647|NCT01181596||Arm 1: observational ultrasound|Collection of image data with the ultrasound probe.
9782648|NCT01181609|Experimental|1|
9782649|NCT01181674|Experimental|Group 1 (short)|
9782650|NCT01181674|Experimental|Group 2 (long)|
9752336|NCT00502593|Active Comparator|Fluarix-C 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
9752337|NCT00502671|Experimental|1|
9752338|NCT00502697|Experimental|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic visits. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
9752339|NCT00502697|Other|Conventional prenatal/postpartum care|Women assigned to the control arm of the study received conventional prenatal and postpartum clinic care.
9752340|NCT00502801|Experimental|Doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
9752341|NCT00502840|Experimental|1|
9752342|NCT00502853|Experimental|1|
9752343|NCT00502905|Experimental|Busulfan + Fludarabine|Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m^2 over 1 hour.
9752344|NCT00502944|Experimental|Counselor-based HIV screening|
9752345|NCT00502944|Active Comparator|Emergency staff member-based HIV screening|
9752346|NCT00502996|Experimental|Rituximab|Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
9752347|NCT00503113|Experimental|1|
9752348|NCT00503113|Experimental|2|
9752349|NCT00503113|Active Comparator|3|
9752350|NCT00503308|Experimental|Abbreviated Consenting|
9752351|NCT00503308|No Intervention|Standard Consenting|
9752352|NCT00503399|Experimental|Teriparatide|Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
9752353|NCT00503399|Active Comparator|Risedronate|Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)
9752354|NCT00503425|Experimental|1|
9752355|NCT00503685|Experimental|IMC-A12|Administered every 2 weeks
9752356|NCT00503685|Experimental|IMC-A12 + cetuximab|Administered every 2 weeks
9752357|NCT00503685|Experimental|IMC-A12 + cetuximab [Kirsten rat sarcoma (K-ras) wild-type]|Participants who have experienced confirmed partial response (PR) or stable disease (SD) ≥ 24 weeks on a prior anti-EGFR-containing therapy followed by disease progression are enrolled in this arm.
9752358|NCT00503698|Experimental|Somatropin|Somatropin once daily from week 0 to end of trial
9752359|NCT00503698|Placebo Comparator|Placebo|Placebo once daily to end of trial
9752360|NCT00503750|Active Comparator|Trastuzumab and Abraxane followed Trastuzumab and Vinorelbine|Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
9752361|NCT00503776|Active Comparator|Arm IA|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
9752362|NCT00503776|Active Comparator|Arm IB|Patients undergo SNT and low weight resistance training (LWRT).
9752363|NCT00503776|Experimental|Arm IIA|Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
9752364|NCT00503776|Experimental|Arm IIB|Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
9752365|NCT00503867|Experimental|SIR-Spheres microspheres|SIR-Spheres microspheres
9752366|NCT00503906|Experimental|Abraxane, Avastin and Gemcitabine|"Each treatment cycle is 28 days. Participants will be treated until disease progression:~Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
9782651|NCT01181674|Other|Standard care|
9782652|NCT01181726|Experimental|Investigational Test Product|Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
9830536|NCT02573493|Experimental|Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment~If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)~If <PR, move directly to CRT if not surgical candidates.~CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.~It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
9830537|NCT02573493|Experimental|Arm 2: nab-Paclitaxel (A) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment~If CR/PR, three more weeks of nab-paclitaxel followed by CRT~If <PR, move directly to CRT if not surgical candidates.~CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.~It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
9830538|NCT02573493|Experimental|Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT|"6 weeks of nab-paclitaxel and cisplatin (days 1 & 22) followed by primary tumor site assessment~If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab~If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab~CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy~Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study."
9830539|NCT02573857|Experimental|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
9830540|NCT02573857|Experimental|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
9830541|NCT02573857|Experimental|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
9830542|NCT02573870|Experimental|Batefenterol + Fluticasone Furoate|Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
9830543|NCT02573870|Placebo Comparator|Placebo|Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
9830544|NCT02573883|Experimental|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate
9830545|NCT02573883|Active Comparator|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate.
9830546|NCT02574078|Experimental|Group A Nivolumab|Opdivo specified dose on specified days
9830547|NCT02574078|Experimental|Group A Nivolumab + SOC maintenance therapy|"Opdivo/Bevacizumab specified dose on specified days~Opdivo/Pemetrexed specified dose on specified days"
9830548|NCT02574078|Active Comparator|Group A SOC maintenance therapy|"Bevacizumab specified dose on specified days~Pemetrexed specified dose on specified days"
9830549|NCT02574078|Experimental|Group B Nivolumab|Opdivo specified dose on specified days
9830550|NCT02574078|Other|Group B Best supportive care|Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
9830551|NCT02574078|Active Comparator|Group C Investigator's choice chemotherapy|"Carboplatin/nab-paclitaxel specified dose on specified days~Carboplatin/paclitaxel specified dose on specified days~Carboplatin/pemetrexed specified dose on specified days~Carboplatin/docetaxel specified dose on specified days~Carboplatin/gemcitabine specified dose on specified days~Paclitaxel specified dose on specified days~Docetaxel specified dose on specified days~Gemcitabine specified dose on specified days~Pemetrexed specified dose on specified days"
9830552|NCT02574078|Experimental|Group C Nivolumb|Opdivo specified dose on specified days
9830553|NCT02574078|Active Comparator|Group D Erlotinib|Erlotinib specified dose on specified days
9752367|NCT00503984|Experimental|Phase 1 - Aza + Doc|Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).
9752368|NCT00503984|Experimental|Phase 2 - Aza + Doc RPTD|Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel; and Prednisone; with optional growth factor support (pegfilgrastim/filgrastim).
9752369|NCT00503997|Experimental|drug therapy|
9752370|NCT00504023|Experimental|imiquimod|This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).
9752371|NCT00504075|Experimental|Gammaplex (intravenous immunoglobulin)|
9752372|NCT00504153|Experimental|Treatment (tyrosine Kinase Inhibitor)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9752373|NCT00504166|Active Comparator|alendronate sodium|alendronate sodium 70 mg tablet once a week for 24 months
9752374|NCT00504166|Placebo Comparator|placebo|placebo to match alendronate sodium
9752375|NCT00504231|Experimental|0.3 mL Influenza Vaccine ID|60% dose - 0.3 mL delivered intradermally with needle and syringe
9752376|NCT00504231|Experimental|0.15 mL twice Influenza Vaccine ID|60% dose - 0.15 mL delivered twice intradermally with needle and syringe
9752377|NCT00504231|Active Comparator|0.5 mL Influenza Vaccine by IM|100% dose - 0.5mL delivered intramuscularly with needle and syringe
9752378|NCT00504231|Experimental|0.3 mL Influenza Vaccine IM|60% dose - 0.3 mL delivered intramuscularly with needle and syringe
9752379|NCT00504257|Experimental|Avastin and Docetaxel|Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
9752380|NCT00504309|Experimental|4g P-OM3, then 1g P-OM3, then Placebo|4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
9752381|NCT00504309|Experimental|1g P-OM3, then 4g P-OM3, then Placebo|1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
9752382|NCT00504309|Experimental|Placebo, then 4g P-OM3, then 1g P-OM3|Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
9752383|NCT00504309|Experimental|4g P-OM3, then Placebo, then 1g P-OM3|4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
9752384|NCT00504309|Experimental|1g P-OM3, then Placebo, then 4g P-OM3|1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
9752385|NCT00504309|Experimental|Placebo, then 1g P-OM3, then 4g P-OM3|Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
9752386|NCT00504348|Experimental|Prospective investigation group|Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
9752387|NCT00504426|Placebo Comparator|1|
9752388|NCT00504426|Active Comparator|2|
9752389|NCT00504426|Active Comparator|3|
9752390|NCT00504426|Active Comparator|4|
9752391|NCT00504504|Experimental|Rituximab + ABVD Chemotherapy|Rituximab 375 mg/m^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m^2 IV, Bleomycin 10 U/m^2 IV, Vinblastine 6 mg/m^2 IV, DTIC 375 mg/m^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
9752392|NCT00504556|Experimental|1|DU-176b 30mg tablet once daily
9752393|NCT00504556|Experimental|2|DU-176b 60mg once daily
9752394|NCT00504556|Experimental|3|DU-176b 30mg b.i.d.
9752395|NCT00504556|Experimental|4|DU-176b 60mg tablets two times a day
9752396|NCT00504556|Active Comparator|5|warfarin tablets
9752399|NCT00504595|Experimental|ACZ885|"Healthy Volunteers: Single administration of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1, Day 15, and Day 43."
9752400|NCT00504595|Placebo Comparator|Placebo|"Healthy Volunteers: Single administration of 600 mg of Placebo Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of Placebo Intravenous (IV) on Day 1, Day 15, and Day 43."
9752401|NCT00504660|Active Comparator|1: Anaplastic Tumors|Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.
9752402|NCT00504660|Active Comparator|2: Anaplastic Tumors|"Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.~Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide."
9752403|NCT00504660|Active Comparator|3: Glioblastoma Multiforme|"Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.~Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide."
9752404|NCT00504725|Experimental|Ketamine|Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
9752405|NCT00504725|Placebo Comparator|Placebo|0.9 % saline bolus of equivalent volume
9752406|NCT00504751|Experimental|Study Treatment|This is a single arm study
9752407|NCT00504777|Experimental|1|
9752408|NCT00504829|Experimental|LCP-AtorFen|LCP-AtorFen 40/100mg fixed-dose combination tablet of 40mg atorvastatin and 145mg fenofibrate for treatment of mixed dyslipidemia
9752409|NCT00504829|Active Comparator|atorvastatin|atorvastatin 40mg tablet (Lipitor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
9752410|NCT00504829|Active Comparator|fenofibrate|fenofibrate 145mg tablet (Tricor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
9752411|NCT00504881|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
9752412|NCT00504881|Experimental|Brivaracetam|A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
9752413|NCT00504894|Placebo Comparator|Placebo|Placebo given in low dose to gauge subject's responses to visual stimuli.
9752414|NCT00504894|Active Comparator|Propofol|Propofol given at 0.90 μgml-1 to gauge subject's responses to visual stimuli.
9752415|NCT00504894|Active Comparator|Thiopental|Thiopental given at 3.0 μgml-1 to gauge subject's responses to visual stimuli.
9752416|NCT00505076|Experimental|MK-0777 8 mg|MK-0777 8 mg tablet by mouth twice daily for 4 weeks
9752417|NCT00505076|Experimental|MK-0777 3 mg|MK-0777 3 mg tablet by mouth twice daily for 4 weeks
9752418|NCT00505076|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 4 weeks
9752419|NCT00505284|Placebo Comparator|Placebo|
9752420|NCT00505284|Active Comparator|Perampanel 2mg|
9752421|NCT00505284|Active Comparator|Perampanel 4mg|
9752422|NCT00505284|Active Comparator|Perampanel 6mg|
9752423|NCT00505284|Active Comparator|Perampanel 8mg|
9752424|NCT00505362|Active Comparator|Rectus muscle closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
9752425|NCT00505362|No Intervention|Rectus muscle non-closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.
9752426|NCT00505375|Experimental|1|Intravenous infusions of CTLA-4 Ig
9752427|NCT00505375|Placebo Comparator|2|Intravenous infusions of placebo
9752428|NCT00505414|Placebo Comparator|Matching Placebo|Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
9752429|NCT00505414|Active Comparator|Morphine Controlled Release|Oral Morphine 45 mg to 90 mg twice daily.
9752430|NCT00505414|Experimental|Tapentadol Extended Release|Oral Tapentadol 100 mg to 250 mg twice daily.
9752431|NCT00505622|Experimental|E2007|E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).
9752432|NCT00505635|Experimental|Biochemotherapy with Temozolomide|Temozolomide 250 mg/m^2 every 4 hours Day 1; Biochemotherapy of Velban 1.5 mg/m^2 intravenous (IV) Days 1-4; Cisplatin 20 mg/m^2 IV Days 1-4; + Interleukin-2 9 MIU/m^2 IV over 24 Hours for 4 Doses Days 1-4; Intron-A 5 mu/m^2 subcutaneously daily Days 1-5; + Oral Thalidomide 400 mg daily.
9752433|NCT00505661|Experimental|Letrozole|2.5 mg by mouth (PO) daily
9752434|NCT00505687|Experimental|Rotigotine|Rotigotine
9752435|NCT00505752|Experimental|AS900672-Enriched 50 mcg|
9752436|NCT00505752|Experimental|AS900672-Enriched 100 mcg|
9752437|NCT00505752|Experimental|AS900672-Enriched 150 mcg|
9752438|NCT00505752|Active Comparator|Follitropin alfa 150 IU|
9752439|NCT00505765|Experimental|AL-108, 30 mg/day|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
9752440|NCT00505765|Experimental|AL-108, 5 mg/day|AL-108, 5 mg/day- one spray in each nostril once per day
9752441|NCT00505765|Placebo Comparator|Placebo, 3 sprays BID|Placebo- 3 sprays in each nostril, twice per day
9752442|NCT00505765|Placebo Comparator|Placebo, 1 Spray Daily|Placebo- one spray in each nostril, once per day
9752443|NCT00505778|Active Comparator|Mesalamine (Asacol) Once-Daily|an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
9752444|NCT00505778|Active Comparator|Mesalamine (Asacol) Twice-Daily|an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)
9752445|NCT00505895|Experimental|Fludarabine + Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).~Melphalan 140 mg/m^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 IV infused starting on day -5."
9752446|NCT00505895|Experimental|Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).~Lower-Dose Melphalan 100 mg/m^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 intravenous infused starting on day -5."
9752447|NCT00505921|Experimental|Campath-1H|"3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.~Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)~Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0."
9752448|NCT00505934|Experimental|Levetiracetam|
9752449|NCT00506025|Active Comparator|Cranberry 2xday|Cranberry juice (C) two times daily, a.m. and p.m.
9752450|NCT00506025|Active Comparator|Cranberry + Placebo|De-Activated Cranberry juice in the am, then placebo (P) in the pm
9752451|NCT00506025|Placebo Comparator|Placebo 2xday|Placebo in the form of juice two times daily in the a.m. and p.m.
9752452|NCT00506077|Experimental|MK0249|
9752453|NCT00506077|Placebo Comparator|Placebo|
9752454|NCT00506129|Experimental|Fludarabine + Melphalan with PBPC|Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 Days prior to Allogeneic Transplant, Melphalan 70 mg/m^2 IV daily for 2 Days prior to IV Allogeneic Transplant following Fludarabine & Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 & -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
9752455|NCT00506142|Experimental|Cohort 1|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
9752456|NCT00506142|Experimental|Cohort 2|Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
9752457|NCT00506155|Experimental|Neoadjuvant Chemotherapy with M-VAC + Avastin|Avastin 10 mg/kg by vein over 90 minutes. Cisplatin 70 mg/m^2 by vein over 4 hours. Doxorubicin 30 mg/m^2 by vein over 15 minutes. Methotrexate 30 mg/m^2 by vein over 30 minutes. Vinblastine Sulfate 3 mg/m^2 by vein over 30 minutes.
9752458|NCT00506285|Experimental|A|This arm was 4 weeks long. Subjects were treated using Methylphenidate Transdermal System. Patients were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone contact. MTS was initiated using a 12.5 cm patch. The dose was increased during the first 2 weeks based on treatment response and side effects to the largest tolerated dose/patch size. It was held steady the last 2 weeks.
9752459|NCT00506285|Placebo Comparator|B|This arm was 4 weeks long. Placebo patch was initiated using a 12.5 cm patch and then increased to the largest tolerated patch size during the first 2 weeks and held steady the last two weeks. Subjects were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone visit.
9752460|NCT00506350|Experimental|GSK1562902A non-AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
9752461|NCT00506350|Experimental|GSK1562902A non-AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
9752462|NCT00506350|Experimental|GSK1562902A non-AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
9752463|NCT00506350|Experimental|GSK1562902A non-AD F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
9752464|NCT00506350|Experimental|GSK1562902A AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
9752465|NCT00506350|Experimental|GSK1562902A AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
9752466|NCT00506350|Experimental|GSK1562902A AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
9752467|NCT00506350|Experimental|GSK1562902A AD Approved F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
9752468|NCT00506350|Experimental|Control Group|Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
9752469|NCT00506389|Experimental|Esmirtazapine 3.0 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 3.0 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
9752470|NCT00506389|Experimental|Esmirtazapine 4.5 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 4.5 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
9752471|NCT00506389|Placebo Comparator|Placebo|Participants took placebo tablets on Days -7 and -6, placebo tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
9752472|NCT00506415|Experimental|Open label: Rivastigmine (5 cm^2 / 10 cm^2)|Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
9752473|NCT00506415|Experimental|Double blind: Rivastigmine (10 cm^2)|Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.
9752474|NCT00506415|Experimental|Double blind: Rivastigmine (15 cm^2)|Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.
9752475|NCT00506415|Experimental|Extended open label Rivastigmine (10 cm^2)|Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
9782653|NCT01181726|Active Comparator|Reference Listed Drug|Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
9782654|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fed)|Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
9782655|NCT01181804|Experimental|Boceprevir Capsules then tablets (fed)|Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
9782656|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fasted)|Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
9782657|NCT01181804|Experimental|Boceprevir Capsules then Tablets (fasted)|Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
9782658|NCT01181895|Experimental|Vilanterol|Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
9782659|NCT01181895|Active Comparator|Salmeterol|Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
9782660|NCT01181895|Placebo Comparator|Placebo|Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
9782661|NCT01181947||patients undergoing TEVAR|Those with a thoracic aortic aneurysm/dissection
9782662|NCT01181986|Experimental|Exenatide SC (Sub-study 1)|Study groups will be individuals with recent onset (<3 years) or established (>5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.
9752476|NCT00506441|Experimental|1|
9752477|NCT00506441|Placebo Comparator|2|
9752478|NCT00506454|Active Comparator|Lipidose|Dosage of 1.5 mL/kg of Lipidose over a 2-hour period.
9752479|NCT00506454|Placebo Comparator|Placebo|Dosage of 1.5 mL/kg of Placebo over a 2-hour period.
9752480|NCT00506519|Experimental|AT-150|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 125-175%
9752481|NCT00506519|Experimental|AT-250|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 225-275%
9752482|NCT00506519|Active Comparator|Control|The best standard treatment for the underlying condition only
9752483|NCT00506597|Experimental|Erwinase|6 doses of 25,000 Units/m^2 Erwinase® intramuscular/subcutaneously every other day to replace each dose of Pegylated Asparaginase
9752484|NCT00506662|Experimental|Insulin detemir|Individually adjusted dose of insulin detemir once daily
9752485|NCT00506662|Active Comparator|Insulin NPH|Individually adjusted dose of insulin NPH once daily
9752486|NCT00506675|Active Comparator|Intensive|42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
9752487|NCT00506675|Active Comparator|Weaning|For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)
9752488|NCT00506714|Experimental|Adult subjects with hip osteoarthritis|Walk with and without a single point cane at baseline and after four weeks
9752489|NCT00506714|No Intervention|Healthy Subjects|Healthy adults walking without a cane at baseline
9752490|NCT00506753|Experimental|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
9752491|NCT00506753|Experimental|RT/TU|Relaxation Training followed by Treatment as Usual
9752492|NCT00506779|Experimental|Phase I: Paclitaxel + Imatinib Mesylate|Phase I MTD using oral dose Imatinib Mesylate escalation 400, 500, 600 mg daily; Paclitaxel 175 mg/m^2 every 21 days
9752493|NCT00506779|Experimental|Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate|"Intended randomization of Paclitaxel alone or Paclitaxel + Imatinib Mesylate; the study was terminated early due to poor enrollment and all patients are no longer being treated or followed. Single treatment arm MTD using oral dose Imatinib Mesylate escalation = 500 mg daily; Paclitaxel 175 mg/m^2 every 21 days~Phase II, (Arm 1) = Paclitaxel 175 mg/m^2 every 21 days Phase II, (Arm 2) Paclitaxel 175 mg/m^2 every 21 days+ Imatinib Mesylate MTD using oral dose Imatinib Mesylate escalation = 500 mg daily"
9752494|NCT00506831|Experimental|Imatinib mesylate|100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated
9752495|NCT00506857|Experimental|Busulfan + Fludarabine|Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.
9752496|NCT00506883|Experimental|High Dose Colchicine|After confirmation of a gout flare, patients were to begin standard dosing of colchicine 4.8mg (two capsules (1.8mg) initially followed by additional one capsule doses (0.6mg) every hour for an additional 6 doses).
9752497|NCT00506883|Experimental|Low Dose Colchicine|Within 12 hours of a confirmed gout flare, patients were to begin the low dose colchicine regimen consisting of a total dose of 1.8 mg - two colchicine capsules initially (1.2 mg)followed an hour later by a single additional capsule of active drug(0.6 mg)then by 5 additional hourly doses of an identical looking placebo capsules
9752498|NCT00506883|Placebo Comparator|Placebo|
9752499|NCT00506922|Experimental|No Pentostatin|Group 1: No Pentostatin
9752500|NCT00506922|Experimental|Pentostatin 0.5|Group 2: Pentostatin 0.5 mg/m^2
9752501|NCT00506922|Experimental|Pentostatin 1|Group 3: Pentostatin 1 mg/m^2
9752502|NCT00506922|Experimental|Pentostatin 1.5|Group 4: Pentostatin 1.5 mg/m^2
9752503|NCT00506922|Experimental|Pentostatin 2|Group 5: Pentostatin 2 mg/m^2
9752504|NCT00506948|Experimental|Thymoglobulin + Sirolimus + MMF|Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.
9752505|NCT00507026|Experimental|A|DIC075V (IV diclofenac)
9752506|NCT00507026|Active Comparator|B|IV Ketorolac
9752507|NCT00507026|Placebo Comparator|C|Placebo
9752508|NCT00507130|Experimental|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
9752509|NCT00507130|Experimental|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
9752510|NCT00507130|Experimental|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
9752511|NCT00507130|Placebo Comparator|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
9752512|NCT00507208|Experimental|Dynasplint|Participants randomized to this arm will be treated with the Dynasplint Trismus System
9830554|NCT02574078|Experimental|Group D Nivolumab + Erlotinib|Opdivo/Erlotnib specified dose on specified days
9752513|NCT00507208|Active Comparator|Control|Participants randomized to this arm will use tongue depressors for 3 months and if there is no improvement in their mouth opening at this timepoint, they will crossover to the Dynasplint Trismus System
9752514|NCT00507416|Experimental|Bortezomib and Dexamethasone (VD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
9752515|NCT00507416|Experimental|Bortezomib, Thalidomide, and Dexamethasone (VTD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
9752516|NCT00507416|Experimental|Bortezomib, Melphalan and Prednisone (VMP)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
9752517|NCT00507429|Experimental|Arm 1: CA4P + Carboplatin + paclitaxel|Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
9752518|NCT00507429|Active Comparator|Arm 2: Carboplatin + Paclitaxel|Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
9752519|NCT00507442|Experimental|VDR|VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
9752520|NCT00507442|Experimental|VDCR|VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
9752521|NCT00507442|Experimental|VDC|VELCADE (bortezomib), dexamethasone, cyclophosphamide
9752522|NCT00507442|Experimental|VDC-mod|Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
9752523|NCT00507455|Placebo Comparator|Placebo|Participants received once daily, oral doses of placebo matching solifenacin succinate and tamsulosin tablets for 12 weeks.
9752524|NCT00507455|Experimental|6 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 6 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
9752525|NCT00507455|Experimental|9 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 9 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
9752526|NCT00507507|Experimental|Tenofovir DF|Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
9752527|NCT00507507|Experimental|FTC+Tenofovir DF|Participants were randomized to receive FTC plus tenofovir DF once daily.
9752528|NCT00507546|Experimental|Ramelteon then placebo|8 mg nightly ramelteon for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of nightly placebo (cross-over)
9752529|NCT00507546|Experimental|Placebo then ramelteon|placebo nightly for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of 8 mg nightly ramelteon (cross-over)
9752530|NCT00507559|Experimental|AAA Repair System|
9752531|NCT00507689|Experimental|FTC/TDF+HBIg|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period.
9752532|NCT00507689|Experimental|FTC/TDF|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF in the randomized period.
9752533|NCT00507728|Experimental|Bupropion|Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).
9752534|NCT00507728|Experimental|Varenicline|Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).
9752535|NCT00507728|Placebo Comparator|Placebo|Placebo by mouth for 12 weeks.
9752536|NCT00507767|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9752537|NCT00507819|Active Comparator|Sildenafil, then Placebo|Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
9752538|NCT00507819|Active Comparator|Placebo, then Sildenafil|Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
9752539|NCT00508001|Placebo Comparator|1|Best Supportive Care + Placebo
9752540|NCT00508001|Experimental|2|Best Supportive Care + ZD6474 100 mg
9752541|NCT00508001|Experimental|3|Best Supportive Care + ZD6474 300 mg
9752542|NCT00508027|Other|Simvastatin, Dose Escalation|There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
9752543|NCT00508105|Active Comparator|subscapularis peel|
9752544|NCT00508105|Active Comparator|osteotomy|
9752545|NCT00508118|Experimental|1|Nicardipine
9752546|NCT00508118|Placebo Comparator|2|0.9% saline
9752547|NCT00508144|Experimental|Alimta|Alimta 500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks.
9752548|NCT00508157|Experimental|A|
9752549|NCT00508157|Active Comparator|B|
9752550|NCT00508183|Active Comparator|single row fixation|
9752551|NCT00508183|Active Comparator|double row fixation|
9752552|NCT00508261|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™
9752553|NCT00508261|Experimental|Group B|Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™
9752554|NCT00508261|Active Comparator|Group C|Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612
9752555|NCT00508261|Active Comparator|Group D|Meningitec™ vaccination
9752556|NCT00508274|Experimental|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
9752557|NCT00508300|Other|A|Epidural Analgesia (EDA) An epidural catheter was inserted at thoracic level (Th8-Th10) before induction of anesthesia. A bolus of 5 mL of bupivacaine 0.5% was started as soon as the epidural catheter was in place, and a continuous perfusion of bupivacaine 0.5% at 5 mL/hr was initiated until the end of surgical procedure.
9752558|NCT00508300|Other|B|Patient controlled analgesia (PCA) was assured by fentanyl (morphine-based) as needed.
9752559|NCT00508391|Experimental|Simultaneous 1st, Optimized 2nd|Lumax HF-T device programmed to simultaneous biventricular pacing first for 30 days, followed by optimized biventricular pacing for 30 days.
9752560|NCT00508391|Experimental|Optimized 1st, Simultaneous 2nd|Lumax HF-T device programmed to optimized biventricular pacing first for 30 days, followed by simultaneous biventricular pacing for 30 days.
9752561|NCT00508404|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.
9752562|NCT00508469|Experimental|Travalert with travoprost/timolol fixed combination|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
9752563|NCT00508469|Experimental|Travalert with travoprost and timolol|One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.
9752564|NCT00508482|Experimental|deep needling group|Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
9752565|NCT00508482|Active Comparator|lactulose group|Lactulose Oral Solution was taken orally at the dose of 20~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
9752566|NCT00508482|Active Comparator|shallow needling group|Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.
9752567|NCT00508521|Experimental|FES and Motor Learning Training|participants <6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
9752568|NCT00508521|Other|Control group|Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance
9752569|NCT00508651|Experimental|Cohort 1 MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM Luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
9752570|NCT00508651|Placebo Comparator|Cohort 1 Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM Luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
9752571|NCT00508716|No Intervention|A|Usual Care - Education about CHF by Primary Nurse on discharge. No teach-back is used in this arm.
9752572|NCT00508716|Experimental|B|"Tailored Intervention for patients with low health literacy and nurse-directed teachback: Educational leaflet which has been developed for low-health literacy patients. Adminstered by dedicated Nurse-educator. Nurse-educator asks Patient for teachback after Intervention. This means that the Patient repeats in his/her own words the Information received. Education ends once Patient has been able to repeat the Information back."
9752573|NCT00508742|Experimental|1|13 valent pneumococcal conjugate vaccine
9752574|NCT00508742|Active Comparator|2|7 valent pneumococcal conjugate vaccine
9752575|NCT00508755|Experimental|Arm 1|stroke
9752576|NCT00508820|Experimental|1|Romiplostim
9752577|NCT00508924|Experimental|ARG250|
9752578|NCT00508924|Experimental|ARG300|
9752579|NCT00508924|Experimental|ARG350|
9752580|NCT00508924|Placebo Comparator|Heparin|
9752581|NCT00509002|Experimental|Adenoid Cystic Salivary Gland Carcinoma Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
9752582|NCT00509002|Experimental|Other Carcinoma of Salivary Gland Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
9752583|NCT00509028|Experimental|BUD - Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
9752584|NCT00509028|Active Comparator|CONV - Conventional Asthma Therapy|Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
9752585|NCT00509041|Experimental|Dasatinib|Use of dasatinib in treatment of pts with previously treated malignant mesothelioma
9752586|NCT00509067|Experimental|A|Participants assigned to receive galantamine and CDP-choline
9752587|NCT00509067|Placebo Comparator|B|Participants assigned to receive placebo
9752588|NCT00509093|Experimental|Imatinib Mesylate|
9752589|NCT00509106|Experimental|Ceftaroline fosamil for injection|Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
9752590|NCT00509106|Active Comparator|IV Ceftriaxone|Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
9752591|NCT00509145|Experimental|Laquinimod|Laquinimod 0.6 mg, oral
9752592|NCT00509145|Placebo Comparator|Placebo|Matching placebo
9752593|NCT00509171|Active Comparator|1-Standard reamer|Standard reamer
9752594|NCT00509171|Active Comparator|2-Use of the Reamer-Irrigator Aspirator|Use of the Reamer-Irrigator Aspirator
9752595|NCT00509197|Active Comparator|Active treatment group (A)|Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
9752596|NCT00509197|Placebo Comparator|Control group treated with placebo (B)|treatment with placebo
9752597|NCT00509223|Experimental|Group 1|Lifestyle counseling with Positive Airway Pressure (PAP) therapy
9752598|NCT00509223|Active Comparator|Group 2|Lifestyle counseling without Positive Airway Pressure (PAP) therapy
9752599|NCT00509236|Experimental|Sitagliptin 25 mg|
9752600|NCT00509236|Active Comparator|Glipizide 2.5 mg - 20 mg|
9752601|NCT00509249|Experimental|Arm I|Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9752602|NCT00509262|Experimental|Sitagliptin|Sitagliptin + Placebo for Glipizide
9752603|NCT00509262|Active Comparator|Glipizide|Glipizide + Placebo for Sitagliptin
9752604|NCT00509288|Experimental|anti-MART-1 F5 TCR PBL + HD IL-2|Patients treated with peripheral blood lymphocytes (PBL)
9752605|NCT00509288|Experimental|anti-MART-1 F5 TCR TIL + HD IL-2|Patients treated with TIL (tumor infiltrating lymphocytes).
9752606|NCT00509366|Active Comparator|Cisplatin Sensitive (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Cisplatin day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Cisplatin day 1, Pemetrexed day 1~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin sensitive arm, based on histology (squamous/non-squamous)."
9752607|NCT00509366|Active Comparator|Cisplatin Resistant (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Docetaxel day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Pemetrexed day 1, Gemcitabine days 1 & 8~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin resistant arm, based on histology (squamous/non-squamous)."
9752608|NCT00509366|Active Comparator|Cisplatin Sensitive (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Cisplatin day 1, Gemcitabine days 1 & 8"
9752609|NCT00509366|Active Comparator|Cisplatin Resistant (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Pemetrexed day 1, Gemcitabine days 1 & 8"
9752610|NCT00509392|Active Comparator|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
9752611|NCT00509392|Active Comparator|Endovenous Laser|Treatment invention of venous disease with an Endovenous Laser.
9752612|NCT00509496|Experimental|anti-gp100:154-162 TCR PBL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
9752613|NCT00509496|Experimental|anti-gp100:154-162 TCR TIL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
9752614|NCT00509587|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9752615|NCT00509665|Experimental|Gemcitabine+doxorubicin|
9752616|NCT00509769|Experimental|Trastuzumab emtansine 3.6 mg/kg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
9752617|NCT00509795|Active Comparator|ranibizumab 0.5mg Q4|
9752618|NCT00509795|Experimental|aflibercept injection 2.0mg Q4|
9752619|NCT00509795|Experimental|aflibercept injection 0.5mg Q4|
9752620|NCT00509795|Experimental|aflibercept injection 2.0mg Q8|
9752621|NCT00509821|Experimental|Enzastaurin Once Daily (QD)|Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy.
9752622|NCT00509821|Experimental|Enzastaurin Twice Daily (BID)|Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO, with concomitant radiotherapy.
9752623|NCT00509873|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
9752624|NCT00509873|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
9752625|NCT00509899|Experimental|Ruxolitinib|All participants received oral ruxolitinib. Patients began treatment with either 10 mg twice a day (bid), 15 mg bid, 25 mg bid, 50 mg bid, 25 mg once a day (qd), 50 mg qd, 100 mg qd, or 200 mg qd, depending on the time period when they entered the study. The doses were titrated based on efficacy and safety to a maximum of 25 mg bid for patients who entered the study after sufficient dosing information had been obtained to define the maximum dose for patients in the study. Patients could continue receiving treatment indefinitely if receiving benefit at a dose that continues to maintain benefit but does not exceed a maximum dose of 25 mg BID.
9752626|NCT00509925|Experimental|Treatment period 1|Insulin detemir for 16 weeks (treatment period 1) followed by insulin NPH treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
9752627|NCT00509925|Experimental|Treatment period 2|Insulin NPH for 16 weeks (treatment period 1) followed by insulin detemir treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
9752628|NCT00510068|Experimental|Everolimus 10 mg/day|Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
9752629|NCT00510068|Placebo Comparator|Placebo|Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
9752630|NCT00510146|Experimental|Olanzapine|During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
9752631|NCT00510146|Placebo Comparator|Placebo|Matching placebo administered once daily, by mouth during double-blind treatment.
9752632|NCT00510146|Experimental|Olanzapine (open-label treatment period)|During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
9752633|NCT00510198|Active Comparator|Control Arm 1: SOC and CC with OptiVol|Standard of Care and Cardiac Compass with OptiVol as the Control. Intervention is standard of care, such as symptom assessment with the addition of viewing Cardiac Compass trends and the OptiVol diagnostic.
9752634|NCT00510198|Active Comparator|Control Arm 2: SOC|Intervention is Standard of Care alone, such as assessment of symptoms, only. Device trending information, but OptiVol is not allowed.
9752635|NCT00510224|Experimental|1|
9752636|NCT00510276|Experimental|Atomoxetine|
9752637|NCT00510276|Placebo Comparator|Placebo|
9752638|NCT00510289|Experimental|all patients|sorafenib
9752639|NCT00510458|Other|LFIT™Femoral Heads With X3® Insert|LFIT™ Femoral Heads With X3® Insert
9752640|NCT00510484|Experimental|A|
9752641|NCT00510484|Placebo Comparator|B|
9752642|NCT00510497|Experimental|Autologous HIV-1 ApB DC Vaccine|Subjects who will receive ApB Dendritic cell vaccine
9752643|NCT00510510|Experimental|NVA237 100 µg|
9752644|NCT00510510|Experimental|NVA237 200 µg|
9752645|NCT00510510|Placebo Comparator|Placebo|
9752646|NCT00510653|Experimental|Imatinib Mesylate|600 mg/day orally for 6 Weeks
9752647|NCT00510692|Experimental|2g/day Eicosapentanoic Acid (EPA)|"Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.~Endoscopy and biopsies taken as described under intervention."
9752648|NCT00510692|Placebo Comparator|Placebo|Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.
9752649|NCT00510718|Experimental|1|MDV3100
9752650|NCT00510744|Experimental|pancreatic enzyme supplementation|3 month supplementation in those gastric bypass patients shown to have a fat absorption less than 80%
9752651|NCT00510783|Active Comparator|Phenytoin/Fosphenytoin|Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
9752652|NCT00510783|Active Comparator|Levetiracetam|Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
9752653|NCT00510809|Active Comparator|1|Policosanol 20mg daily
9752654|NCT00510809|Placebo Comparator|2|
9752655|NCT00510809|Active Comparator|3|Policosanol 20mg daily Plus Statin Therapy Already In Use
9752656|NCT00510835|Experimental|1|Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
9752657|NCT00510835|Experimental|2|Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
9752658|NCT00510835|Active Comparator|3|Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
9752659|NCT00510874|Experimental|Pumarix Formulation 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
9752660|NCT00510874|Experimental|Pumarix Formulation 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
9752661|NCT00510874|Experimental|Pumarix Formulation 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
9752662|NCT00510874|Experimental|Pandemrix Formulation A Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
9752663|NCT00510874|Experimental|Pandemrix Formulation B Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
9752664|NCT00510874|Experimental|Pumarix Formulation 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
9752665|NCT00510874|Experimental|Pumarix Formulation 5 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
9752666|NCT00510887|Experimental|VR-FND|"Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum."
9752667|NCT00510952|Experimental|Lispro|Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
9752668|NCT00510952|Active Comparator|Glargine|Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
9752669|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole -STD|Standard therapy of DEC (300mg) and albendazole (400mg) yearly
9752670|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole- HD1|High dose of DEC (300mg) and albendazole (800mg) yearly
9752671|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole-HD2|High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
9752672|NCT00511095|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL
9752673|NCT00511108|Experimental|1|Arm 1: drug
9752674|NCT00511108|Active Comparator|2|Arm 2: active comparator
9752675|NCT00511108|Experimental|3|Arm 3: drug + active comparator
9752676|NCT00511108|Placebo Comparator|4|Arm 4: placebo comparator
9752677|NCT00511134|Experimental|Zyban + Lunesta|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
9752678|NCT00511134|Placebo Comparator|Zyban + Placebo|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)
9782663|NCT01181986|Experimental|Exenatide IV (Sub-study 2)|Study group will be individuals with recent onset (<1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).
9752679|NCT00511147|Experimental|IGIV3I Grifols 10% (All Subjects)|All subjects with Chronic ITP
9752680|NCT00511173|Experimental|Clinician dosing of warfarin|Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
9752681|NCT00511238|Experimental|carfilzomib (A0)|
9752682|NCT00511238|Experimental|carfilzomib (A1)|
9752683|NCT00511472|Experimental|MK-0941|
9752684|NCT00511472|Placebo Comparator|Placebo|
9752685|NCT00511667|Experimental|MK0941|
9752686|NCT00511667|Placebo Comparator|Placebo|
9752687|NCT00511706|Experimental|dexamethasone and ranibizumab|Intravitreal injection of dexamethasone 700 µg at Day 1; ranibizumab 500 µg at Day -30 and Day 7-14.
9752688|NCT00511706|Sham Comparator|sham and ranibizumab|Sham injection at Day 1; ranibizumab 500 µg at day -30 and Day 7-14.
9752689|NCT00511797|Experimental|DRSP 1 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
9752690|NCT00511797|Experimental|DRSP 2 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
9752691|NCT00511797|Experimental|DRSP 3 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
9752692|NCT00511797|Placebo Comparator|Placebo|1 tablet per day placebo for 28 days in each 28-day cycle
9752693|NCT00511810|Experimental|Low Dose Fish Oil|Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
9752694|NCT00511810|Experimental|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
9752695|NCT00511836|Experimental|VIVITROL 380 mg|
9752696|NCT00511836|Placebo Comparator|Placebo|
9752697|NCT00511862|Experimental|TheraSphere|Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer
9752698|NCT00511875|Experimental|Doxycycline Monohydrate|stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
9752699|NCT00511875|Placebo Comparator|Placebo|stratified equally to placebo taken once daily for 24 months
9752700|NCT00511901|Placebo Comparator|Placebo & Niferex|Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
9752701|NCT00511901|Active Comparator|epoetin alpha & Niferex|40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
9752702|NCT00511914|Experimental|cTIV (Adults)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
9752703|NCT00511914|Experimental|cTIV (Elderly)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
9752704|NCT00511992|Experimental|Avastin|
9752705|NCT00512096|Experimental|Cisplatin + Ifosfamide + Paclitaxel|Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1
9752706|NCT00512135|Experimental|IncobotulinumtoxinA (Xeomin) (20 units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
9752707|NCT00512148|Experimental|1|Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells
9752708|NCT00512252|Experimental|Phase I Dose Escalation|"AMD3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d"
9752709|NCT00512252|Experimental|Phase II Dose Treatment|"AMD 3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)"
9752710|NCT00512278|Experimental|Infliximab|Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
9752711|NCT00512278|Placebo Comparator|Placebo|Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
9752712|NCT00512707|Experimental|Active Testosterone Gel|Active Testosterone Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
9752713|NCT00512707|Placebo Comparator|Placebo Gel|Placebo Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
9752714|NCT00512798|Experimental|Phase I|
9752715|NCT00512798|Experimental|Phase II|
9752716|NCT00512902|Experimental|Group 1|SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.
9752717|NCT00513019|Active Comparator|1|Lamictal (lamotrigine)
9752718|NCT00513019|Placebo Comparator|2|Placebo
9752719|NCT00513071|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9752720|NCT00513240|Experimental|EPO group|Patients randomized to receive the 3 doses of erythropoetin.
9752721|NCT00513240|Placebo Comparator|Control group.|Patients randomized to receive 3 doses of normal saline control.
9782664|NCT01182103||Major depressive patients|
9782665|NCT01182103||Healthy subjects|
9782666|NCT01182181|Experimental|Investigational Test Product|Anastrozole Tablets, 1 mg
9782667|NCT01182181|Active Comparator|Reference Listed Drug|Arimidex® Tablets, 1 mg
9830555|NCT02574078|Experimental|Group E Nivolumab + Crizotinib|Opdivo/Crizotinib specified dose on specified days
9830556|NCT02574247|Experimental|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
9830557|NCT02574247|No Intervention|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
9830558|NCT02574247|No Intervention|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
9830559|NCT02574260|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
9830560|NCT02574312|Active Comparator|TKA with RUI|44 Subjects will receive TKA with RUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Reusable instruments (RUI).
9830561|NCT02574312|Experimental|TKA with SUI|44 Subjects will receive TKA with SUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Single Use Instruments (SUI).
9830562|NCT02574520|Placebo Comparator|Part 1|SABER-Bupivacaine and Saline Placebo
9830563|NCT02574520|Active Comparator|Part 2|SABER-Bupivacaine and Bupivacaine HCl
9830564|NCT02574598|Experimental|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
9830565|NCT02574598|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
9830566|NCT02574637|Placebo Comparator|Placebo|Placebo-matching brazikumab intravenous (IV) infusion and subcutaneous (SC) injection at Weeks 0 and 4 followed by placebo-matching brazikumab SC injection at Weeks 8 and 12 in the induction phase and at Weeks 16, 20 and 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection every 4 weeks up to Week 48 in the open-label period.
9830567|NCT02574637|Experimental|Brazikumab High Dose|Brazikumab 700 mg, IV infusion and placebo-matching brazikumab, SC injection at Weeks 0 and 4 followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
9830568|NCT02574637|Experimental|Brazikumab High-Medium Dose|Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
9830569|NCT02574637|Experimental|Brazikumab Low-Medium Dose|Brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 105 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 105 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 105 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
9830570|NCT02574637|Experimental|Brazikumab Low Dose|Brazikumab 70 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 35 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 35 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 35 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
9830571|NCT02574832|Experimental|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
9830572|NCT02574845|Experimental|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
9830573|NCT02574845|Experimental|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
9830574|NCT02574845|Experimental|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
9830575|NCT02574845|Experimental|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
9752722|NCT00513292|Active Comparator|FEC-75 then Paclitaxel/trastuzumab|Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
9752723|NCT00513292|Experimental|Paclitaxel/trastuzumab then trastuzumab/FEC-75|Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.
9752724|NCT00513305|Active Comparator|Low-dose cytarabine plus arsenic trioxide|Cycle 1 cytarabine 10 mg/m^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m^2 sc bid on days 1 through 7 of a 28-day cycle.
9752725|NCT00513305|Active Comparator|Low-dose cytarabine alone|Cytarabine was administered at a dose of 10 mg/m^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
9752726|NCT00513344|Experimental|dark chocolate containing polyphenols|dark chocolate
9752727|NCT00513344|Experimental|Milk chocolate containing polyphenols|Bespoke milk chocolate
9752728|NCT00513344|Active Comparator|Control chocolate with no polyphenols|cocoa-free chocolate
9752729|NCT00513357|Experimental|Melatonin|20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
9752730|NCT00513357|Placebo Comparator|Placebo|20 mg of Placebo before going to sleep at night for a period of 4 weeks.
9752731|NCT00513370|Experimental|1|
9752732|NCT00513409|Experimental|Synflorix Booster Group|Subjects previously primed with Synflorix™ and receiving in the current study Havrix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
9752733|NCT00513409|Experimental|Synflorix Catch-up Group|Subjects previously primed with Havrix™ co-administered with Infanrix™ hexa and receiving in the current study Synflorix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
9752734|NCT00513435|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
9752735|NCT00513461|Experimental|Arm I (SAMe)|Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
9752736|NCT00513461|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
9752737|NCT00513474|Experimental|Rasburicase Group|Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
9752738|NCT00513474|Other|Control Group|Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.
9752739|NCT00513500|Experimental|1|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
9752740|NCT00513500|Active Comparator|2|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility
9752741|NCT00513526|Experimental|Gardasil|Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
9752742|NCT00513604|Experimental|Cohort 1 - NMA, TIL, aldesleukin|"Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), & high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 1 = unselected TIL"
9752743|NCT00513604|Experimental|Cohort 2 - NMA, CD4+ TIL, aldesleukin|"Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 2 = CD4+ depleted (selected) TIL"
9752744|NCT00513604|Experimental|Cohort 3 - NMA, total body irradiation|"Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):~Nonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation"
9752745|NCT00513604|Experimental|Cohort 4 - NMA, young TIL, aldesleukin|"Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 4 = unselected TIL - it is the SAME as cohort 1"
9752746|NCT00513604|Experimental|Cohort 5 - NMA, CD4+TIL, HD aldesleukin|"Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2"
9752747|NCT00513682|Experimental|Ultrase® MT20|
9752748|NCT00513695|Experimental|Treatment (neoadjuvant chemotherapy before surgery)|Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
9752749|NCT00513708|No Intervention|Treatment As Usual (TAU)|"Treatment as Usual (TAU): Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during medically managed inpatient detoxification."
9782668|NCT01182194|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
9830576|NCT02574845|Experimental|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
9782669|NCT01182194|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
9782670|NCT01182207|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
9782671|NCT01182207|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
9782672|NCT01182285|Experimental|A - Phase I Radioiodine-Resistant|Drug: Valproic Acid Week 1 - 10 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
9782673|NCT01182285|Active Comparator|B1 - Phase 2 Schedule 1|Drug: Valproic Acid Week 11 - 17 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Drug: Cytomel (25 micrograms) Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Liothyronine Sodium (Cytomel) for 4 weeks (25 micrograms twice a day)
9782674|NCT01182285|Active Comparator|B2 - Phase 2 Schedule 2|Drug: Valproic Acid Week 11 - 52 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Weeks 17-52: Patients who show a response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have a decreased thyroglobulin level from Day 1 of the treatment (registered as a partial response to the treatment) will continue on valproic acid at their current dose for a total of 52 weeks.
9782675|NCT01182298||Hepatitis C|latino participants with Hepatitis C
9782676|NCT01182337|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
9782677|NCT01182337|Placebo Comparator|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
9782678|NCT01182350|Experimental|radiation + bevacizumab|"Cohort 1: MGMT-/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles"
9782679|NCT01182350|Experimental|radiation + bevacizumab + erlotinib|"Cohort 2: MGMT-/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
9782680|NCT01182350|Experimental|radiation + bevacizumab + temozolomide|"Cohort 3. MGMT+/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Temozolomide: Administered orally at 90 mg/m2/day continuously during radiation therapy, held through the interim period and then 200 mg/m2/day for 5 days for up to 10 maintenance cycles"
9752750|NCT00513708|Experimental|Motivational Enhancement Therapy (MET)|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Motivational Enhancement Therapy (MET) session delivered by a trained professional."
9752751|NCT00513708|Experimental|Peer-delivered Twelve Step Facilitation|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Peer-delivered Twelve Step Facilitation (P-TSF)session delivered by individuals from a common self-help program."
9752752|NCT00513747|Experimental|Arm I|Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
9752753|NCT00513747|Active Comparator|Arm II|Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
9752754|NCT00513799|Active Comparator|1: Hygiene Education|"Intensive education on prevention of skin infections through improvements in personal hygiene (also serves as control group)"
9752755|NCT00513799|Active Comparator|2: Hygiene education + mupirocin|Application of mupirocin in the nasal mucosa alone
9752756|NCT00513799|Active Comparator|Education + mupirocin + chlorhexidine|A combination of nasal application of mupirocin and chlorhexidine showers
9752757|NCT00513799|Active Comparator|4: Education + mupirocin + bleach baths|A combination of nasal application of mupirocin and bathing in dilute bleach water
9752758|NCT00514020|Experimental|Treatment|
9752759|NCT00514046|Experimental|Vandetanib|Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m^2/day.
9752760|NCT00514137|Experimental|Treatment (kinase inhibitor therapy)|Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9752761|NCT00514215|Experimental|Sargramostim, Flow Cytometry, Biopsy. Cryosurgery|Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32
9752762|NCT00514449|Experimental|Valacyclovir|1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
9752763|NCT00514449|Placebo Comparator|Sugar pill|2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.
9752764|NCT00514501|Experimental|Iodofiltic Acid I 123|
9752765|NCT00514514|Active Comparator|CNI standard regimen|Myfortic, Sandimmun Optoral and corticosteroids
9752766|NCT00514514|Experimental|CNI free regimen|"CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids"
9752767|NCT00514514|Active Comparator|CNI low regimen|"CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids"
9752768|NCT00514540|Experimental|First-Line/Second-Line Chemotherapy|"First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks.~Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks."
9752769|NCT00514592||All|All patients enter the same group
9752770|NCT00514683|Experimental|dose 1|low dose BIBF1120 once daily
9752771|NCT00514683|Experimental|dose 2|low dose BIBF 1120 twice daily
9752772|NCT00514683|Experimental|dose 3|intermediate dose BIBF 1120 twice daily
9752773|NCT00514683|Experimental|dose 4|high dose BIBF 1120 twice daily
9752774|NCT00514683|Placebo Comparator|placebo|placebo
9752775|NCT00514709|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
9752776|NCT00514709|Experimental|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
9752777|NCT00514735|Experimental|1|Ablation Management
9752778|NCT00514735|Active Comparator|2|Medical Management
9752779|NCT00514852|Experimental|1|Carboxymethylcellulose and Glycerin based artificial tear
9752780|NCT00514852|Active Comparator|2|Carboxymethylcellulose
9752781|NCT00514904|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9752782|NCT00514904|Active Comparator|Mencevax ACWY Group|Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.
9752783|NCT00514917|Experimental|Docetaxel+Leuprolide+Bicalutamide|Participants received docetaxel 75 milligram per square meter (mg/m^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
9752784|NCT00514917|Active Comparator|Leuprolide+Bicalutamide|Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
9752785|NCT00514943|Experimental|BIBW 2992|once daily taken orally
9752786|NCT00514943|Active Comparator|Cetuximab|once every week by intravenous injection
9752787|NCT00515008|Experimental|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi 18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
9752788|NCT00515008|Placebo Comparator|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
9752789|NCT00515021|Experimental|Daytime then nightime dosing|Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks.
9752790|NCT00515021|Experimental|Nighttime then daytime dosing|Eplerenone - 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks then patients cross over to 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks.
9752791|NCT00515034|Experimental|001|Doripenem 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
9752792|NCT00515034|Active Comparator|002|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
9752793|NCT00515034|Experimental|003|Doripenem 1 gram infused over 4 hours at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
9752794|NCT00515034|Active Comparator|004|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
9752795|NCT00515073|Experimental|Paclitaxel (Taxol) + Pelvic Radiation|"Paclitaxel (Taxol) 50 mg/m^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost."
9752796|NCT00515086|Experimental|No Surgery (Everolimus 10 mg)|Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
9752797|NCT00515086|Experimental|Everolimus 10 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
9752798|NCT00515086|Experimental|Everolimus 5 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
9752799|NCT00515086|Active Comparator|Everolimus 0 mg + Surgery|Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
9752800|NCT00515099|Experimental|Antithymocyte globulin|This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
9752801|NCT00515099|Placebo Comparator|Placebo|This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
9752802|NCT00515177|Experimental|MBSR|A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
9752803|NCT00515177|Active Comparator|PCT Sleeping Pills|A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.
9752804|NCT00515203|Placebo Comparator|II.|5 thrombocytopenic (as defined per protocol) subjects
9752805|NCT00515203|Experimental|I.|15 thrombocytopenic (as defined per protocol) subjects
9752806|NCT00515216|Experimental|Oxaliplatin/Leucovorin/5-FU|"Good risk patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks."
9752807|NCT00515294|Experimental|1Caffeinated Alcoholic Beer|Caffeinated Alcoholic beer
9752808|NCT00515294|Active Comparator|2Non-Caffeinated Alcoholic Beer|Non-Caffeinated Alcoholic beer
9752809|NCT00515294|Active Comparator|3Caffeinated Non-Alcoholic Beer|Caffeinated Non-Alcoholic Beer
9752810|NCT00515294|Placebo Comparator|4Non-Caffeinated, Non-Alcoholic Beer|Non-Caffeinated, Non-Alcoholic Beer
9752811|NCT00515411|Active Comparator|Arm A, - Modified DCF|"Drug Dose (mg/m2) Schedule~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments)."
9752812|NCT00515411|Active Comparator|ARM B - Parent DCF with G-CSF|"Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg"
9752813|NCT00515411|Active Comparator|Arm C - Modifid DCF + Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
9752814|NCT00515437|Experimental|1|1500U Myobloc
9752815|NCT00515437|Experimental|2|2500U Myobloc
9752816|NCT00515437|Experimental|3|3500U Myobloc
9752817|NCT00515437|Placebo Comparator|4|pooled placebo
9752818|NCT00515463|Experimental|Denosumab - Vial|Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
9752819|NCT00515463|Experimental|Denosumab - Prefilled syringe|Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
9752820|NCT00515502|Active Comparator|Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: umeclidinium bromide (UMEC) 250 micrograms (µg), UMEC 500 µg, Tiotropium 18 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
9752821|NCT00515502|Active Comparator|Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
9752822|NCT00515502|Active Comparator|Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752823|NCT00515502|Active Comparator|Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, placebo and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752824|NCT00515502|Active Comparator|Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752825|NCT00515502|Active Comparator|Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
9830577|NCT02574845|Experimental|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
9752826|NCT00515502|Active Comparator|Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, Tiotropium 18 µg, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752827|NCT00515502|Active Comparator|Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, placebo, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752828|NCT00515502|Active Comparator|Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
9752829|NCT00515502|Active Comparator|Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, placebo and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752830|NCT00515502|Active Comparator|Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752831|NCT00515502|Active Comparator|Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and Tiotropium 18 µg. Treatment periods were seperated by a washout period of at least 14 days.
9752832|NCT00515528|Experimental|Vaccine Alone|Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression.
9752833|NCT00515528|Experimental|Vaccine plus Ontak|Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration
9752834|NCT00515541|Active Comparator|A|Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
9752835|NCT00515541|Active Comparator|B|Patient is on regular dose of Aspirin ( < or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
9752836|NCT00515541|Active Comparator|C|Patient is taking regularly 75mg of clopidogrel daily and Aspirin (< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
9752837|NCT00515541|Active Comparator|D|Patient is regularly taking Warfarin daily and Aspirin (< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza
9752838|NCT00515619|Experimental|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing
9752839|NCT00515697|Experimental|Ramucirumab|Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.
9752840|NCT00515723|Active Comparator|Olanzapine|Participants in this group were randomized to flexibly-dosed treatment with olanzapine.
9752841|NCT00515723|Active Comparator|Risperidone|Participants in this group were randomized to flexibly-dosed treatment with risperidone.
9752842|NCT00515723|Active Comparator|Quetiapine|Participants in this group were randomized to flexibly-dosed treatment with quetiapine.
9752843|NCT00515723|Active Comparator|Ziprasidone|Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.
9752844|NCT00515827|Experimental|Raltegravir then Placebo (Arm A)|400 mg raltegravir (MK-0518) administered twice daily in addition to optimized background regimen (OBR) from entry to Week 12; halt raltegravir at Week 12 and add placebo twice daily for 12 weeks
9830578|NCT02574858|Experimental|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration).
9830579|NCT02575079|Experimental|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
9830580|NCT02575079|No Intervention|Historical Cohort|Pediatric patients receiving hematopoietic cell transplantation in the 16 months preceding the study intervention. Data were obtained retrospectively through medical records for the purpose of comparing CLABSI rates among recipients of parafilm to a control group.
9830581|NCT02575300|Experimental|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
9830582|NCT02575807|Experimental|Phase 1: CRS-207|"CRS-207 administered in 3-week cycles.~* CRS-207 (1 x 10e9 colony forming units [CFU]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle)."
9830583|NCT02575807|Experimental|Phase 1: CRS-207/IDO 100 mg|"CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (100 milligrams [mg]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle."
9830584|NCT02575807|Experimental|Phase 1: CRS-207/IDO 300 mg|"CRS-207 administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle."
9830585|NCT02575807|Experimental|Phase 2: CRS-207/Pembro/IDO|"CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.~IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle."
9830586|NCT02575807|Experimental|Phase 2: CRS-207/Pembro|"CRS-207 and pembro administered in 3-week cycles.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles."
9830587|NCT02575833|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
9830588|NCT02575833|Experimental|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
9830589|NCT02575911|Experimental|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
9830590|NCT02575950|Experimental|LEO43204 0,018%|Experimental drug
9830591|NCT02575950|Placebo Comparator|Vehicle|Placebo
9835829|NCT02757326|Experimental|Phase Ib/II|"For Phase Ib, the planned ABC294640 (Opaganib) doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
9835830|NCT02757352|Experimental|Q2W Ixekizumab|"Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period.~Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
9835831|NCT02757352|Experimental|Q4W Ixekizumab|"Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44."
9835832|NCT02757352|Placebo Comparator|Placebo|"Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
9835833|NCT02757625|Experimental|DA-9501|A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
9835834|NCT02757768|Experimental|Mirabegron|Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
9830592|NCT02576041|Experimental|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
9830593|NCT02576054|Experimental|V501|0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
9830594|NCT02576067|Experimental|Low dose methotrexate|average dose of 15-20 mg po/weekly
9830595|NCT02576067|Placebo Comparator|Placebo|matching placebo
9830596|NCT02576145|Experimental|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram [mg/kg]) with Day 1 vaccine administered immediately prior to the fifth dose.
9830597|NCT02576145|Active Comparator|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
9830598|NCT02576249|Active Comparator|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
9830599|NCT02576249|Experimental|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
9830600|NCT02576509|Experimental|Nivolumab|Nivolumab specified dose on specified days
9830601|NCT02576509|Active Comparator|Sorafenib|Sorafenib specified dose on specified days
9830602|NCT02576535|Experimental|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
9830603|NCT02576587|Other|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.~Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
9830604|NCT02576587|No Intervention|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
9830605|NCT02576639|Placebo Comparator|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
9830606|NCT02576639|Experimental|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
9830607|NCT02576639|Experimental|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
9830608|NCT02576639|Experimental|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
9830609|NCT02576639|Experimental|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
9830610|NCT02576652|Other|Osteoarthritis Participants|Participants previously treated with denosumab and planning to undergo total hip replacement (THR) received one cycle of tetracycline administered at either 250 mg four times a day or 500 mg twice a day for 3 days and one cycle of demeclocycline administered at either 150 mg four times a day or 300 mg twice a day for 3 days, ten days after last dose of tetracycline in cycle 1. THR surgery was performed 5 to 42 days after the last dose of demeclocycline.
9830611|NCT02576678|Experimental|Open label apremilast|"Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID).~A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects.~Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data."
9835835|NCT02757768|Placebo Comparator|Placebo|Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study.
9752845|NCT00515827|Experimental|Placebo then Raltegravir (Arm B)|Placebo administered twice daily in addition to OBR from entry until Week 12; halt placebo at Week 12 and add 400 mg raltegravir tablet twice daily for 12 weeks
9752846|NCT00515879|Experimental|CBT plus d-cycloserine|Participants will receive cognitive behavioral therapy plus D-cycloserine
9752847|NCT00515879|Placebo Comparator|CBT plus placebo|Participants will receive cognitive behavioral therapy plus pill placebo
9752848|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Negative|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
9752849|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Positive|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
9752850|NCT00516074|Experimental|Exenatide Arm|This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
9752851|NCT00516074|Placebo Comparator|Placebo Arm|This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
9752852|NCT00516139|Experimental|Lamotrigine|Open-label lamotrigine
9752853|NCT00516165|Experimental|RAD001|Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.
9752854|NCT00516217|Experimental|Galaximab|Induction: 500 mg/m^2 by IV over 60 minutes days 1, 8, 15 & 22 Extended Induction: 500 mg/m^2 by IV every 4 weeks until disease progression or unacceptable toxicity
9752855|NCT00516269|Experimental|Methylphenidate then Placebo|Methylphenidate 18 mg oral daily for 2 weeks then Placebo oral daily for 2 weeks
9752856|NCT00516269|Experimental|Placebo then Methylphenidate|Placebo oral daily for 2 weeks then Methylphenidate 18 mg oral daily for 2 weeks
9752857|NCT00516295|Experimental|Arm I (Feasibility assessment of VTCB)|Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 [course 5], 17, 18 [course 6], 26, 27 [course 9], 29, and 30 [course 10] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9752858|NCT00516295|Experimental|Arm II (VTCB)|Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in Arm I.
9752859|NCT00516295|Active Comparator|Arm III (CTC)|Patients receive vincristine, topotecan hydrochloride, and cyclophosphamide as in arm I.
9752860|NCT00516386|Experimental|Insulin like growth factor- 1 (IGF-1)|Adolescent girls with AN meeting inclusion criteria were administered recombinant human (rh) rhIGF-1 at a dose of 35-40 mcg/k twice daily by subcutaneous injections for a 7-10 day period.
9752861|NCT00516503|Experimental|Arm I|Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel> topically to each> area of pain,> numbness,> and/or tingling> on the> feet and/or hands twice daily> for> 4 weeks.
9752862|NCT00516503|Placebo Comparator|Arm II|Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks.
9752863|NCT00516893|Experimental|Natalizumab High Titer|natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
9752864|NCT00516906|Placebo Comparator|Transparent Adhesive Dressing|Standard of Care Non-Antimicrobial Transparent Adhesive Dressing
9752865|NCT00516906|Experimental|CHG antimicrobial transparent dressing|Chlorhexidine gluconate antimicrobial transparent adhesive dressing
9752866|NCT00516919|Experimental|1|Xenical + behavioral intervention
9752867|NCT00516919|Active Comparator|2|Placebo + behavioral intervention
9752868|NCT00517010|Experimental|proton beam with ranibizumab|Intervention is 24Gy proton radiation in 2 fractions given within 6 weeks of first dose of intravitreal ranibizumab (0.5mg) drug combined with four monthly doses of intravitreal lucentis and monthly prn lucentis thereafter.
9752869|NCT00517296|Experimental|Adalimumab with EUS guided therapy|Patients will be randomized to adalimumab treatment with EUS guided therapy decisions. Colorectal surgeon will have access to EUS data prior to EUA with possible seton placement.
9752870|NCT00517296|Active Comparator|Adalimumab|Patients will be randomized to adalimumab treatment. Colorectal surgeon will not have access to EUS data prior to EUA with possible seton placement.
9835836|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
10201933|NCT05193578|Active Comparator|Semaglutide|"Active Comparator: Semaglutide injection once-weekly~The participants start with Semaglutide given as 0.25 mg subcutaneously per week for 4 weeks. Then, the dose is uptitrated to 0.5 mg subcutaneously per week for 4 weeks, whereafter the highest dose is reached: 1 mg subcutaneously per week until the end of the study (week 30).~Subjects, who experience side effects that hinder a stepwise increase in study drug, will remain at the highest possible tolerated dose for the rest of the study."
10201934|NCT05193578|Placebo Comparator|Placebo|"Semaglutide-Placebo injections once weekly.~The Semaglutide-Placebo pens are produced by Novo Nordisk A/S and resemble the pens containing active drug.~Semaglutide-Placebo pens contain vehicle, i.e. no active drug. Semaglutide-Placebo is administered similarly to semaglutide. That is using the same uptitration regime and volume as the active comparator, Semaglutide.~Subjects, who experience side effects that hinder a stepwise increase in Semaglutide-Placebo, will remain at the highest possible tolerated dose for the rest of the study."
10201935|NCT05193513|Experimental|group (1)|tow perpendicular miniscrews supported hybrid expanders
10201936|NCT05193513|Experimental|group (2)|tow angulated miniscrews supported hybrid expanders
10201937|NCT05193461|Experimental|patients with radicular pain recieved pulsed mood radiofrequency|Investigation effect of neuroplasticity of patient on outcome of pulsed mood radiofrequency
10201938|NCT05193253||Solitary HCC <= 3 cm|Treatment-naive patients with HCC <= 3 cm
9830612|NCT02576899|Active Comparator|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program [FFS]. This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
9830613|NCT02576899|Placebo Comparator|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
9830614|NCT02576938|Experimental|Baricitinib|"Administered once daily in multiple oral dose cohorts for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
9830615|NCT02576938|Placebo Comparator|Placebo|"Administered orally once daily, for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
9830616|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part A|Galcanezumab solution formulation in a prefilled syringe given SC once.
9830617|NCT02576951|Placebo Comparator|Placebo-Part A|Placebo in a prefilled syringe given SC once.
9830618|NCT02576951|Experimental|Galcanezumab Lyophilized Formulation-Part B|Galcanezumab lyophilized (freeze dried) formulation given SC once.
9830619|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part B|Galcanezumab solution formulation in a prefilled syringe given SC once.
9830620|NCT02576977|Experimental|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
9830621|NCT02576977|Active Comparator|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
9830622|NCT02576990|Experimental|Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)|Participants with rrPMBCL receive pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years).
9830623|NCT02576990|Experimental|Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)|Participants with rrRS receive pembrolizumab 200 mg Q3W, IV for each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years). Effective with Protocol Amendment 04, enrollment into this cohort was closed.
9830624|NCT02577003|Experimental|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
9830625|NCT02577003|Active Comparator|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
9830626|NCT02577016|Experimental|Sitagliptin + Ipragliflozin|Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
9830627|NCT02577016|Active Comparator|Placebo + Ipragliflozin|Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
9830628|NCT02577029|Experimental|Cohort 1|"Treatment-naïve, hepatitis B e antigen (HBeAg)-positive participants with chronic hepatitis B (CHB) of any genotype administered ARC-520 (2 mg/kg intravenous [IV]) every 4 weeks for 48 weeks (13 doses)."
9830629|NCT02577029|Experimental|Cohort 2|Treatment-naïve, HBeAg-positive, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered peginterferon (PEG IFN) alpha 2a for 48 weeks starting Day 87.
9830630|NCT02577029|Experimental|Cohort 3|Treatment-naïve, HBeAg-negative, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
9830631|NCT02577029|Experimental|Cohort 4|Treatment-naïve, HBeAg-positive, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
9830632|NCT02577029|Experimental|Cohort 5|Treatment-naïve, HBeAg-negative, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
9830633|NCT02577029|Experimental|Cohort 6|Treatment-naïve, HBeAg-negative, Genotype D participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
9830634|NCT02577029|Experimental|Cohort 7|Treatment-naïve, HBeAg-negative or HBeAg-positive participants with hepatitis delta virus (HDV) administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 15.
9830635|NCT02577029|Experimental|Cohort 8|Treatment-naïve, HBeAg-positive participants with CHB of any genotype administered ARC-520 (4 mg/kg IV) every 4 weeks for 48 weeks (13 doses).
9830636|NCT02577042|Experimental|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
9830637|NCT02577042|Active Comparator|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
9830638|NCT02577107|Experimental|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
9830639|NCT02577107|Active Comparator|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
9752871|NCT00517413|Experimental|C.E.R.A|Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta [Mircera]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.
9752872|NCT00517530|Experimental|Phase I, NHL|Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
9752873|NCT00517530|Experimental|Phase I, CLL|Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
9752874|NCT00517530|Experimental|400/400 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
9752875|NCT00517530|Experimental|1600/800 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
9752876|NCT00517530|Experimental|400/400 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
9752877|NCT00517530|Experimental|1600/800 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
9752878|NCT00517530|Experimental|1000/1000 mg - Phase II, CLL|Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
9752879|NCT00517530|Experimental|Retreated Participants|Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
9752880|NCT00517556|Experimental|study group (CCOCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
9752881|NCT00517556|Active Comparator|control group (traditional OCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.
9752882|NCT00517634|Experimental|Sequence 1: FP, SFC, Placebo|Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
9752883|NCT00517634|Experimental|Sequence 2: Placebo, SFC, FP|Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
9752884|NCT00517634|Experimental|Sequence 3: SFC, FP, Placebo|Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
9752885|NCT00517634|Experimental|Sequence 4: SFC, Placebo, FP|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
9752886|NCT00517634|Experimental|Sequence 5: FP, Placebo, SFC|Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
9752887|NCT00517634|Experimental|Sequence 6: Placebo, FP, SFC|Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
9782681|NCT01182350|Experimental|radiation + bevacizumab + erlotinib + temozolomide|"Cohort 4. MGMT+/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
9782682|NCT01182376|Placebo Comparator|Placebo|Half of the patients will be assigned placebo.
9782683|NCT01182376|Experimental|Multaq® (dronedarone)|Half of the patients will be prescribed dronedarone.
9782684|NCT01182415|Experimental|High-dose chemotherapy with autologous stem cell transplant|
9782685|NCT01182428|Experimental|XIENCE V® / XIENCE PRIME™|
9517431|NCT03306407|No Intervention|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
9752888|NCT00517751|Experimental|X-STOP PEEK|In this arm, patients will undergo X-STOP PEEK surgery.
9752889|NCT00517829|Active Comparator|1- Docetaxel plus Oxaliplatin|Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
9752890|NCT00517829|Active Comparator|2- Docetaxel plus oxaliplatin plus cetuximab|Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
9752891|NCT00517881|Experimental|C.E.R.A.|
9752892|NCT00517933|Active Comparator|Sildenafil|20 mg of sildenafil 3 times a day (TID) for 12 weeks followed by 20 mg of sildenafil TID for an additional 12 weeks
9752893|NCT00517933|Placebo Comparator|Placebo / Sildanafil|20 mg of placebo TID for 12 weeks followed by 20 mg of sildenafil citrate TID for an additional 12 weeks
9752894|NCT00518011|Experimental|Erlotinib + Gemcitabine|Participants received Erlotinib 150 mg/day orally as a continuous schedule with Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
9752895|NCT00518011|Active Comparator|Gemcitabine|Participants received Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
9752896|NCT00518089|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
9752897|NCT00518089|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
9752898|NCT00518154|Experimental|A|Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
9752899|NCT00518180|Experimental|MenACWY + Tdap + HPV|Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
9752900|NCT00518180|Experimental|MenACWY →Tdap → HPV|Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
9752901|NCT00518180|Experimental|Tdap →MenACWY → HPV|Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8
9752902|NCT00518206|Experimental|Cohort 1|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
9752903|NCT00518206|Experimental|Cohort 2|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
9752904|NCT00518284|No Intervention|No Drug Treatment Control|Following revascularization, participants did not receive any study drug treatment.
9752905|NCT00518284|Experimental|Proximal to Lesion + IV|Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
9752906|NCT00518284|Experimental|During Flow Arrest|Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization.
9752907|NCT00518284|Experimental|During Flow Arrest + IV|Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
9752908|NCT00518323|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
9752909|NCT00518323|Experimental|002|Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
9752910|NCT00518323|Experimental|003|Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
9752911|NCT00518323|Placebo Comparator|004|Placebo Once daily for 6 weeks
9752912|NCT00518336|Experimental|Cervarix Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
9752913|NCT00518336|Placebo Comparator|Placebo Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
9752914|NCT00518349|Active Comparator|Prototype colonoscope|Colonoscopy using prototype colonoscope with passive bending function
9752915|NCT00518349|Placebo Comparator|Standard colonoscope|Colonoscopy using standard colonoscope with no passive bending function
9752916|NCT00518531|Other|Treatment Sequence B|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
9752917|NCT00518531|Other|Treatment Sequence A|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
9752918|NCT00518622|Experimental|1|25 mg b.i.d. MK7009
9752919|NCT00518622|Experimental|2|75 mg b.i.d. MK7009
9752920|NCT00518622|Experimental|3|250 mg b.i.d. MK7009
9752921|NCT00518622|Experimental|4|500 mg b.i.d. MK7009
9752922|NCT00518622|Experimental|5|700 mg b.i.d. MK7009
9752923|NCT00518622|Experimental|6|125 mg q.d. MK7009
9752924|NCT00518622|Experimental|7|600 mg q.d. MK7009
9752925|NCT00518622|Experimental|8|Placebo
9752926|NCT00518687|Experimental|V710 60 µg|
9752927|NCT00518687|Placebo Comparator|Placebo|
9752928|NCT00518713|Experimental|Clobazam Low Dose|
9752929|NCT00518713|Experimental|Clobazam Medium Dose|
9752930|NCT00518713|Experimental|Clobazam High Dose|
9752931|NCT00518713|Placebo Comparator|Placebo|
9752932|NCT00518882|Experimental|Liraglutide|Liraglutide 1.8 mg once daily + subject's own OAD treatment
9752933|NCT00518882|Active Comparator|Exenatide|Exenatide 10 mcg twice daily + subject's own OAD treatment
9752934|NCT00518973|Placebo Comparator|Placebo|The primary outcome was to determine the effect of quetiapine compared with placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorder Inventory-2 (EDI-2).
9752935|NCT00518973|Experimental|Quetiapine|Secondary outcomes were to determine if quetiapine is superior to placebo in reducing anxiety, depression and obsessionality assessed with the State Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM D) and Yale-Brown Obsessive Compulsive Scale, respectively. In addition, another secondary goal was to determine if quetiapine is superior to placebo in terms of weight gain. Adverse events were also determined.
9752936|NCT00518986|Active Comparator|1|armodafinil 200 mg/day
9752937|NCT00518986|Placebo Comparator|2|Placebo
9752938|NCT00519077|Experimental|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
9752939|NCT00519194|Experimental|Epicor Cardiac Ablation|
9752940|NCT00519285|Placebo Comparator|Placebo|Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
9752941|NCT00519285|Experimental|Aflibercept|Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
9752942|NCT00519376|Experimental|GW642444M 25mcg|
9752943|NCT00519376|Experimental|GW642444M 50mcg|
9752944|NCT00519376|Experimental|GW642444M 100mcg|
9752945|NCT00519376|Experimental|GW642444H 100mcg|
9752946|NCT00519376|Experimental|placebo|
9752947|NCT00519428|Experimental|escitalopram + bupropion|escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
9752948|NCT00519428|Active Comparator|escitalopram|escitalopram monotherapy
9752949|NCT00519428|Active Comparator|bupropion|bupropion extra long (XL) monotherapy
9752950|NCT00519532|Experimental|Rotigotine|Rotigotine Transdermal Patch
9752951|NCT00519584|Placebo Comparator|Ropivacaine/saline|Ropivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
9752952|NCT00519584|Active Comparator|Ropivacaine/dex|Ropivacaine and local steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic and 0.9% saline 2ml (systemic placebo) for intravenous injection with sedation for the block;
9752953|NCT00519584|Active Comparator|bupivacaine/dex|bupivacaine and systemic steroid: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block plus dexamethasone 8 mg (2 ml) administered intravenously with sedation administered for the block.
9752954|NCT00519584|Placebo Comparator|bupivacaine/Saline|bupivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
9752955|NCT00519623|Experimental|PassPort(R) Transdermal Insulin Delivery System|
9752956|NCT00519636|Active Comparator|FFNS, FPNS|fluticasone furoate nasal spray, fluticasone propionate nasal spray
9752957|NCT00519636|Active Comparator|FPNS, FFNS|fluticasone propionate nasal spray, fluticasone furoate nasal spray
9752958|NCT00519636|Placebo Comparator|placebo FFNS, placebo FPNS|placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
9752959|NCT00519636|Placebo Comparator|placebo FPNS, placebo FFNS|placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
9752960|NCT00519649|Experimental|Group Engerix|Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)
9752961|NCT00519779|Placebo Comparator|2|Placebo oral Omega-3 fish oil supplementation
9752962|NCT00519779|Experimental|1|oral Omega-3 fish oil supplementation
9752963|NCT00519831|Experimental|Vinflunine + Cetuximab|Patients may receive more than 4 cycles of therapy if they continue to demonstrate response to therapy, have limited toxicity, and if the treating physician determines that they are deriving clinical benefit from the treatment. The decision of continuing therapy beyond 4 cycles must be discussed with the principal investigator.
9752964|NCT00519896|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis therapy)|Patients receive sunitinib malate PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
9782686|NCT01182428|Active Comparator|CYPHER SELECT|
9782687|NCT01182441|Experimental|WATCHMAN|Subjects assigned to receive the WATCHMAN device.
9782688|NCT01182441|Active Comparator|Warfarin|Subjects assigned to warfarin therapy.
9752965|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year."
9752966|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
9752967|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation: None"
9752968|NCT00520039|Experimental|Standard Care Plus OMM|Subjects will receive active intervention with osteopathic manipulative medicine (OMM) using a prescribed standardized treatment protocol which is age appropriate. Subjects will also receive standard care for otitis media from their referring physician.
9752969|NCT00520039|No Intervention|Standard Care Only|Subjects will receive standard care only for otitis media from their regular referring physician
9752970|NCT00520130|Experimental|A - Tacrolimus, methotrexate, sirolimus (TMS) Arm|TMS Arm
9752971|NCT00520130|Experimental|B - Cyclosporine (AC) Arm|AC Arm
9752972|NCT00520234|Active Comparator|1 prophylaxis|Caspofungin 50 mg Intravenous (IV) daily up to 28 days of therapy
9752973|NCT00520234|Placebo Comparator|2 placebo|Normal Saline 100 cc IV daily
9752974|NCT00520286|Active Comparator|Modafinil|Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks
9752975|NCT00520286|Placebo Comparator|Placebo|Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks
9752976|NCT00520299|Experimental|Cohort 1|Subjects received ADI-PEG 20 at a dose of 40 IU/m^2
9752977|NCT00520299|Experimental|Cohort 2|Subjects received ADI-PEG 20 at a dose of 80 IU/m^2
9752978|NCT00520299|Experimental|Cohort 3|Subjects received ADI-PEG 20 at a dose of 160 IU/m^2
9752979|NCT00520351|Active Comparator|1|
9752980|NCT00520351|Active Comparator|2|
9752981|NCT00520403|Experimental|1|
9752982|NCT00520468|Experimental|Cytokine-Immunotherapy|Erythropoietin 40,000 units subcutaneously (SQ) weekly; G-CSF 300 mcg SQ twice a week; Prednisone 60 mg/Day for 7 days, taper over 1 month; Cyclosporin A 300 mg orally daily
9752983|NCT00520481|Experimental|IMC-A12|Thirty-one participants will receive IMC-A12 at 10 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). An additional 10 participants will receive IMC-A12 at a dose of 20 mg/kg every three weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Radiographic evaluation of response will be performed every 8 weeks for the participants treated with intravenous (i.v.) IMC-A12 at 10 mg/kg and every 9 weeks for the participants treated with i.v. IMC-A12 at 20 mg/kg.
9752984|NCT00520494|Experimental|Vivaglobin|Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
9752985|NCT00520533|Experimental|On Study|"Treatment (cycle 1):~cG250 10mg/m² IV weekly x 5 doses (1st & 5th doses trace-labelled with 124I)~Sunitinib 50 mg/day orally x 4 weeks commencing day 8~Followed by two-week break~Treatment (cycle 2 - investigator discretion):~cG250 10mg/m² IV weekly x4 doses~Sunitinib 50 mg/day orally x 4 weeks (commencing concurrently)~Followed by two-week break"
9752986|NCT00520546|Experimental|1|Patients with prostate carcinoma confirmed by needle biopsy, age >50 years, planned radical prostatectomy with lymph-node dissection, fasting for >12 hours before FEC-PET and an interval between biopsy and PET >3 weeks.
9752987|NCT00520572|Active Comparator|1|Etanercept 50mg, subcutaneous, once weekly
9752988|NCT00520572|Experimental|2|50mg oral, once daily
9752989|NCT00520572|Experimental|3|100 mg oral, once daily
9752990|NCT00520572|Experimental|4|200 mg oral, once daily
9752991|NCT00520572|Experimental|5|400mg once, daily
9752992|NCT00520572|Placebo Comparator|6|oral, once daily
9752993|NCT00520676|Experimental|pemetrexed plus carboplatin|"Drug: pemetrexed 500 milligrams per square meter (mg/m^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram*minute/milliLiter (mg*min/mL), IV, q 21 days x 6 cycles maximum"
9752994|NCT00520676|Active Comparator|docetaxel plus carboplatin|"Drug: docetaxel 75 mg/m^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum"
9752995|NCT00520741|Experimental|Lacosamide 400 mg/day|Lacosamide 400 mg/day
9752996|NCT00520741|Active Comparator|Lacosamide 300 mg/day|Lacosamide 300 mg/day
9782689|NCT01182493|Experimental|Insulin Pump Treatment|Patients will get an insulin pump
9830640|NCT02577146|Experimental|Study ultrasound|Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
9830641|NCT02577315|Experimental|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
9830642|NCT02577315|Experimental|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
9830643|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
9830644|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
9830645|NCT02577510|Experimental|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
9830646|NCT02577510|Experimental|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
9830647|NCT02577601|Active Comparator|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
9830648|NCT02577601|No Intervention|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
9830649|NCT02577601|Active Comparator|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
9830650|NCT02577640|Experimental|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
9830651|NCT02577640|Experimental|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
9830652|NCT02577718|Experimental|Nitroglycerin-Citrate-Ethanol (NiCE)|Antimicrobial Nitroglycerin-Citrate-Ethanol catheter lock solution was administered for 2 hours then flushed
9830653|NCT02577822|Other|Short Stem Group|Short femoral stem
9830654|NCT02577822|Other|Long Stem Group|standard-length stem
9830655|NCT02577900|Experimental|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
9830656|NCT02577900|Active Comparator|Honey gel sheet|Apply Honey gel sheet onto the ulcer
9830657|NCT02577900|Other|Jelonet|Apply Jelonet onto the ulcer
9830658|NCT02577978|Other|Medacta Sphere|Ball-and-socket
9830659|NCT02577978|Other|Medacta PS|Cam-and-post
9830660|NCT02577991|No Intervention|Control group|No steroid
9830661|NCT02577991|Experimental|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
9830662|NCT02577991|Experimental|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
9830663|NCT02578186|Experimental|Diphenhydramine Hydrochloride|Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
9830664|NCT02578186|Placebo Comparator|Placebo|Placebo elixir taken when subjects had trouble falling asleep
9830665|NCT02578199|Experimental|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
9830666|NCT02578238||Participants With Pediatric CD|Participants with pediatric CD who have been prescribed Humira® (adalimumab) by the treating physician.
9830667|NCT02578316|Experimental|Lenvatinib 24 mg|Participants with advanced solid tumors or lymphomas, who are unsuitable for, or had failed, existing therapies.
9830668|NCT02578706|Active Comparator|Aspirin and placebo|At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
9830669|NCT02578706|Active Comparator|Clopidogrel and placebo|At week 0, participants will be administered clopidogrel 75 mg (one tablet) and placebo for aspirin 81 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
9830670|NCT02578706|Placebo Comparator|Placebos only|At week 0, participants will be administered placebo for aspirin 81 mg (one tablet) and placebo for clopidogrel 75mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
9830671|NCT02578745|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
9830672|NCT02578745|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
9830673|NCT02578862|Experimental|Total Intravenous|Intravenous propofol for maintenance of anesthesia
9830674|NCT02578862|Active Comparator|Inhaled Anesthetic|Inhaled volatile anesthetic for maintenance of anesthesia
9830675|NCT02578901|Active Comparator|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
9830676|NCT02578901|Placebo Comparator|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
9830677|NCT02578940|Experimental|Single arm|Single intravenous administration of 18F-Fluciclovine for PET Scan
9830678|NCT02578992|Experimental|Head-lift Position|The patients' head was placed in the head-lift position(A 7 cm high pillow was set beneath the patients' head with head in neutral position) and then the patient was intubated with Trachway by single-handed chin lift technique
9830679|NCT02578992|No Intervention|Neutral Position|The patients' head was placed in the neutral position and then the patient was intubated with Trachway by single-handed chin lift technique
9830680|NCT02579057|Active Comparator|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
9830681|NCT02579057|Experimental|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
9830682|NCT02579135|Experimental|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
9830683|NCT02579135|Other|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
9830684|NCT02579343|Experimental|Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
9830685|NCT02579343|Sham Comparator|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
9830686|NCT02579382|Placebo Comparator|TDF + placebo|"Main Study Phase: Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily for up to 48 weeks + placebo administered orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
9830687|NCT02579382|Experimental|TDF + Vesatolimod 1 mg|"Main Study Phase:TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 1 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
9830688|NCT02579382|Experimental|TDF + Vesatolimod 2 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 2 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
9752997|NCT00520767|Experimental|Melphalan, Dexamethasone, Bortezomib,|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
9752998|NCT00520845|Experimental|Treatment Arm|Either docetaxel or pemetrexed given with celecoxib
9752999|NCT00520884|Placebo Comparator|Healthy 70+ Women Placebo Infusion|Healthy and Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
9753000|NCT00520884|Placebo Comparator|Frail 70+ Women Placebo Infusion|Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
9753001|NCT00520884|Active Comparator|Healthy 70+ Women Ghrelin Infusion|Healthy Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
9753002|NCT00520884|Active Comparator|Frail 70+ Women Ghrelin Infusion|Frail Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion at a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
9753003|NCT00520910|Experimental|Polypodium leucotomos extract|Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
9753004|NCT00520910|No Intervention|No intervention|Subject is not given any treatment.
9753005|NCT00520936|Experimental|Pemetrexed|
9753006|NCT00520975|Active Comparator|Arm A (chemotherapy and placebo)|"INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
9753007|NCT00520975|Experimental|Arm B (chemotherapy and bevacizumab)|"INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
9753008|NCT00521001|Experimental|everolimus + temozolomide|"Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.~After completion of study treatment, patients are followed every 8 weeks."
9753009|NCT00521014|Experimental|GM-CSF and Rituximab After Autologous Stem Cell Transplant|"GM-CSF: 250 mcg (flat dose) three times per week for 8 weeks, administered on alternate days. Thus, 24 doses of GM-CSF will be administered.~Rituximab: 375 mg/m2/week for 4 weeks, beginning within 3 days after the first dose of GM-CSF; rituximab. The second course of GM-CSF and rituximab will be administered approximately 22-26 weeks (day +154 to +182) after ASCT."
9753010|NCT00521053|Experimental|PV-10|
9753011|NCT00521079|Experimental|vBloc|Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
9753012|NCT00521079|Sham Comparator|Placebo|Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
9753013|NCT00521144|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive obatoclax mesylate IV over 3 hours on day 1 OR days 1 and 3 and topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
9753014|NCT00521339|Experimental|Apremilast 20 mg BID/ 30 mg BID|Apremilast 20 mg or 30 mg orally twice per day
9753015|NCT00521352|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
9753016|NCT00521352|Sham Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
9753017|NCT00521365|Experimental|Quetapine 600 mg|
9753018|NCT00521404|Experimental|CS-1008 + gemcitabine|CS-1008 + gemcitabine
9753019|NCT00521456|Experimental|1|
9753020|NCT00521456|Placebo Comparator|2|
9753021|NCT00521586|Other|1|arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
9753022|NCT00521586|Other|2|arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
9753023|NCT00521976||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
9753024|NCT00521989|Experimental|CRx-102 (2.7/90)|"2.7 mg prednisolone plus 90 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
9753025|NCT00521989|Experimental|CRx-102 (2.7/180)|"2.7 mg prednisolone plus 180 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
9753026|NCT00521989|Experimental|CRx-102 (2.7/360)|"2.7 mg prednisolone plus 360 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
9753027|NCT00521989|Active Comparator|Prednisolone|"2.7 mg prednisolone~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM."
9753028|NCT00521989|Placebo Comparator|Placebo|"Placebo~Subjects were dose twice daily through day 98."
9753029|NCT00522041|Experimental|Cellegesic (nitroglycerin 0.4%)|Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
9753030|NCT00522041|Placebo Comparator|Placebo 375 mg|Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
9753031|NCT00522171||Electro Surgery|Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.
9753032|NCT00522275|Experimental|Lacosamide|Up to 800 mg/day lacosamide (flexible dosing)
9753033|NCT00522379|Experimental|Rotigotine 2 mg/24 hr|
9753034|NCT00522379|Experimental|Rotigotine 4 mg/24 hr|
9753035|NCT00522379|Experimental|Rotigotine 6 mg/24 hr|
9753036|NCT00522379|Experimental|Rotigotine 8 mg/24 hr|
9753037|NCT00522379|Placebo Comparator|Placebo|
9753038|NCT00522392|Experimental|Arm A (VRD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
9753039|NCT00522392|Active Comparator|Arm B (VD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
9753040|NCT00522418|Experimental|VNS Therapy|VNS Therapy + Best Medical Practice
9753041|NCT00522418|Active Comparator|Best Medical Practice|Best Medical Practice
9753042|NCT00522431|Experimental|1|2% testosterone gel
9753043|NCT00522548|Active Comparator|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) at a target dose of 720 mg orally twice daily for 6 months after transplant.
9753044|NCT00522548|Active Comparator|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent manufactured by Sandoz, at a target dose of 1000 mg orally twice daily for 6 months after transplant.
9753045|NCT00522626||Observational|Opioid exposed pregnancies
9753046|NCT00522795|Experimental|PPX with cisplatin and radiation|PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
9753047|NCT00522873|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
9753048|NCT00522873|Active Comparator|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
9753049|NCT00522925|Placebo Comparator|1|Matching Placebo
9753050|NCT00522925|Experimental|2|
9753051|NCT00522925|Experimental|3|
9753052|NCT00522951|Experimental|Gadobutrol 0.1 mmol/kg bw|Participants received first injection (intravenous [i.v.]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
9753053|NCT00522951|Experimental|Gadobutrol 0.2 mmol/kg bw|Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
9753054|NCT00522951|Experimental|Gadoteridol (ProHance)|Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
9753055|NCT00523302|Active Comparator|Active TMS|Since cortical stimulation can be performed non-invasively by active Transcranial Magnetic Stimulation (TMS), Participants in the active TMS group, receive five 20 minute active TMS treatment sessions per week for two weeks.
9753056|NCT00523302|Sham Comparator|Sham TMS|To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
9753057|NCT00523341|Experimental|Denosumab|Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.
9753058|NCT00523367|No Intervention|esomeprazole|
9753059|NCT00523419|Experimental|Pemetrexed|Participants received pemetrexed 500 milligrams per square meter (mg/m^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
9753060|NCT00523549|Experimental|Standard treatment regimen|(Valsartan + Amlodipine to target SBP of < 140 mmHg)
9753061|NCT00523549|Experimental|Intensive treatment regimen|(Valsartan + Amlodipine to target SBP < 130 mm Hg)
9753062|NCT00523614||1: Cases|
9753063|NCT00523614||2: Controls|
9753064|NCT00523640|Experimental|I|"Combination of gemcitabine, capecitabine, and bevacizumab~gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle"
9753065|NCT00523705|Experimental|escitalopram|Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
9753066|NCT00523705|Placebo Comparator|placebo|Placebo tablets matched to drug.
9753067|NCT00523718|Experimental|riluzole|Patients randomized to this arm will receive riluzole augmentation, at a standard, fixed dose (50 mg bid), in addition to the medication regimen they are on at enrollment
9753068|NCT00523718|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from riluzole, in addition to the medication regimen they are on at study enrollment.
9753069|NCT00523744|Experimental|Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ|During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
9753070|NCT00523848|Experimental|Arm 1|Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
9753071|NCT00523978|Experimental|Experimental|Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
9753072|NCT00523978|Active Comparator|Control|Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.
9753073|NCT00523991|Placebo Comparator|placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
9753074|NCT00523991|Experimental|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
9753075|NCT00524017|Experimental|Arm I (treatment)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
9753076|NCT00524017|No Intervention|Arm II (control)|Patients receive regular follow-up care
9753077|NCT00524030|Experimental|1|
9753078|NCT00524030|Experimental|2|
9753079|NCT00524043|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
9753080|NCT00524043|Active Comparator|002|Paliperidone ER 6 mg tablet once daily for 6 weeks
9753081|NCT00524043|Placebo Comparator|003|Placebo Once daily for 6 weeks
9753082|NCT00524121|Experimental|Oral Erlotinib|Patients receive oral erlotinib hydrochloride once daily for 1 year
9782690|NCT01182493|No Intervention|Insulin treatment with MDI|patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day
9782691|NCT01182675|Experimental|T-cell Graft Permissive SCID|"Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only"
9782692|NCT01182675|Experimental|T-cell Graft Resistant SCID|Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
9782693|NCT01182805|Other|Single arm study.|
9782694|NCT01182844|No Intervention|Control|Usual care
9782695|NCT01182844|Experimental|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
9782696|NCT01183013|Active Comparator|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily
9782697|NCT01183013|Active Comparator|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily
9782698|NCT01183013|Active Comparator|Pioglitazone 45 mg|Pioglitazone Capsules 45 mg once daily
9782699|NCT01183013|Active Comparator|Linagliptin 5mg|Linagliptin 5mg Tablets once daily
9782700|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 15 mg|Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
9782701|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 30 mg|Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
9782702|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 45 mg|Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
9782703|NCT01183065|Experimental|pralatrexate and vitamin supplementation|This will be an open-label, single arm, Simon optimal two-stage design phase II study.
9782704|NCT01183104|Experimental|Sitagliptin|
9782705|NCT01183104|Active Comparator|Glimepiride|
9782706|NCT01183143|Experimental|GONAL-f®|
9782707|NCT01183169|Experimental|Treatment A: ALV 600 mg QD|Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks
9782708|NCT01183169|Experimental|Treatment B: ALV 800 mg QD|Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks
9782709|NCT01183169|Experimental|Treatment C1: ALV Placebo - 600 mg QD|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.
9782710|NCT01183169|Experimental|Treatment C2: ALV Placebo - 400 mg BID|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.
9782711|NCT01183169|Experimental|Treatment D: ALV 400 mg BID|Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks
9782712|NCT01183234|Experimental|SPD544 (Equasym XL)|
9782713|NCT01183234|Experimental|Methylphenidate hydrochloride (Metadate CD )|
9782714|NCT01183260|Experimental|Trabecular Metal Revision Cup|Patients randomized to this arm will receive a trabecular metal revision component which does not have a titanium inner surface and requires a cemented highly crosslinked polyethylene liner.
9782715|NCT01183260|Active Comparator|Trabecular Metal Modular Cup|Patients randomized to this arm will receive a trabecular metal modular component which has a titanium inner surface and requires a non-cemented highly crosslinked polyethylene liner.
9782716|NCT01183312|Experimental|Placebo, then Flumazenil|Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil
9782717|NCT01183312|Experimental|Flumazenil, then Placebo|Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo.
9782718|NCT01183390|Experimental|Investigational Test Product|Anastrozole 1 mg Tablets
9782719|NCT01183390|Active Comparator|Reference Listed Drug|Arimidex® 1 mg Tablets
9782720|NCT01183481|Experimental|Aprepitant and Granisetron|Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.
9782721|NCT01183533|Experimental|off label rt-PA used|off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.
9782722|NCT01183546||Wheelchair Users with Spinal Cord Injury|wheelchair users with spinal cord injury
9782723|NCT01183559|Other|Vandetanib|Vandetanib 100 mg (6 patients) or 200 mg (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.
9782724|NCT01183650|Experimental|Tadalafil|5 mg, administered orally, daily for 10 days
9782725|NCT01183689|No Intervention|Control Group|"Self-Guided Behavior Changes. This group will be used to determine average rate of weight gain over 3 years with little intervention. Participants randomized to this group will receive one face-to-face session that will provide general education of self-weighing and information about both the small and large changes approach. Participants will also be provided with quarterly newsletters describing study events and very limited information on health eating."
9753083|NCT00524173|Active Comparator|Tenofovir only|Tenofovir 300mg by mouth daily for 192 weeks
9753084|NCT00524173|Experimental|Tenofovir & emtricitabine|Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
9753085|NCT00524225|Experimental|Neumega (Interleukin 11, IL-11)|Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively
9753086|NCT00524264|Experimental|1|
9753087|NCT00524264|Placebo Comparator|2|
9753088|NCT00524303|Active Comparator|Arm 1|Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
9753089|NCT00524303|Experimental|Arm 2|Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
9753090|NCT00524303|Experimental|Arm 3|Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
9753091|NCT00524316|Experimental|Sunitinib|oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
9753092|NCT00524342|Experimental|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
9753093|NCT00524368|Experimental|DRV/rtv 800/100 mg once daily|Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
9753094|NCT00524368|Experimental|DRV/rtv 600/100 mg twice daily|One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
9753095|NCT00524420|Experimental|Active rTMS|Active rTMS involves administration of real rTMS to the patient.
9753096|NCT00524420|Sham Comparator|Sham rTMS|Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
9753097|NCT00524472|Experimental|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
9753098|NCT00524472|Other|Insulin at the standard of care levels|Group B will be administered insulin at the standard of care levels established by the participating institution.
9753099|NCT00524537||Adalimumab (Humira) Treatment|Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.
9753100|NCT00524576|Experimental|Engerix 2 Doses + Challenge Dose|Subjects received 2 doses of Engerix™-B (Month 0 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
9753101|NCT00524576|Experimental|Engerix 3 Doses + Challenge Dose|Subjects received 3 doses of Engerix™-B (Month 0, 1 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
9753102|NCT00524589|Experimental|Dexamethasone and Calcitriol|Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.
9753103|NCT00524680|Experimental|Arm I|Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
9753104|NCT00524680|Experimental|Arm II|Patients receive 6,000 IU of vitamin D3 once daily.
9753105|NCT00524680|Experimental|Arm III|Patients receive 8,000 IU of vitamin D3 once daily.
9753106|NCT00524680|Experimental|Arm IV|Patients receive 10,000 IU of vitamin D3 once daily.
9753107|NCT00524745|Active Comparator|0,2,6 month vaccination schedule|
9753108|NCT00524745|Active Comparator|0,3,9 month vaccination schedule|
9753109|NCT00524745|Active Comparator|0,6,12 month vaccination schedule|
9753110|NCT00524745|Active Comparator|0,12,24 month vaccination schedule|
9753111|NCT00524771||1|Users of NuvaRing
9753112|NCT00524771||2|Users of combined oral contraceptives
9753113|NCT00524940|Experimental|Study Group|
9753114|NCT00525031|Experimental|Temozolomide (TMZ)|Temozolomide = TMZ - 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
9753115|NCT00525031|Experimental|Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)|"Temozolomide = TMZ and PGI = Pegylated Interferon-alpha 2b~Temozolomide 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks. Pegylated Interferon-alpha 2b 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks."
9753116|NCT00525044|Placebo Comparator|Control|
9753117|NCT00525044|Experimental|Ambroxol|
9753118|NCT00525057|Experimental|Treatment (dalteparin)|Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
9753119|NCT00525135|Other|1|If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.
9753120|NCT00525135|Other|2|If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.
9753121|NCT00525148|Experimental|BIBW 2992|Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
9753122|NCT00525161|Experimental|Sorafenib & Endocrine Therapy|Sorafenib & Endocrine Therapy
9753123|NCT00525174|Active Comparator|Patching|2 hours daily patching of the sound eye plus one hour near activities while patching
9753124|NCT00525174|Active Comparator|Bangerter filters|Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
9753125|NCT00525265|Experimental|1|OPC-41061
9753126|NCT00525265|Placebo Comparator|2|placebo
9753127|NCT00525421|Experimental|Curcumin|Curcumin C3 Complex
9753128|NCT00525421|Placebo Comparator|Placebo|Placebo
9753129|NCT00525499|Placebo Comparator|1|Vehicle control cream applied topically to the face twice daily for 12 weeks
9753130|NCT00525499|Experimental|2|0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks
9753131|NCT00525499|Experimental|3|0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks
9753132|NCT00525499|Experimental|4|0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks
9753133|NCT00525512|Experimental|tiotropium 18mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
9753134|NCT00525512|Placebo Comparator|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
9753135|NCT00525525|Experimental|Efficacy Group|Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity
9753136|NCT00525525|Other|Safety Lead-in Group|"Fractionated radiotherapy in daily doses of 1.8-2.0 Gy delivered 5 days per week over ~6 weeks, to a total dose of 59.4 to 60 Gy.~Adjuvant temozolomide 200 mg/m^2/d x 5 d per 28-d cycle; Erlotinib 150-200 mg/d (or 500-600 mg/d for patients on enzyme-inducing antiepileptic drugs) on a continuous basis 7 days per week; Bevacizumab 10 mg/kg every 2 weeks"
9753137|NCT00525590|Experimental|1|
9753138|NCT00525603|Experimental|CFAR|CFAR = Cyclophosphamide 200 mg/m^2/day 3-5 intravenous (IV) 5-30 minutes, Fludarabine 20 mg/m^2/day 3-5 IV 5-30 minutes, Alemtuzumab 30 mg 1, 3,5 IV 2-4 hours, and Rituximab 375 mg/m^2/day 2 IV 4-6 hours
9753139|NCT00525629|Experimental|Walnut Diet|48 Grams of Walnuts Daily
9753140|NCT00525629|Placebo Comparator|Control Diet|Isocaloric Diet with No Walnuts
9753141|NCT00525733|Active Comparator|3-drug standard therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ +ritonavir 100 mg QD
9753142|NCT00525733|Experimental|5-drug experimental therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg + ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
9753143|NCT00525785|Experimental|5-Fluorouracil + Folinic Acid + Oxaliplatin|"PreOp Chemotherapy: 2 cycles (each cycle consisting of 4 weeks or 2 treatments) of chemotherapy with oxaliplatin, folinic acid and infusional 5-FU (FOLFOX-48). Oxaliplatin 100 mg/m^2 over 2 hours on day 1, folinic acid intravenous (IV) at 200 mg/m^2 over 30 minutes on day 1, and 5-FU 2,200 mg/m^2 over 48 hours as continuous infusion by outpatient pump starting on day 1. This therapy, FOLFOX-48 repeated every 2 weeks x 4 (8 weeks of induction chemotherapy).~PreOp Chemoradiotherapy begins 12 days after last dose of PreOp Chemo 5FU plus oxaliplatin; A total of 45 Gy (1.8 Gy fx/d) of radiotherapy concurrent to low-dose continuous infusion of 5-FU (300 mg/m^2/d Monday through Friday) & weekly oxaliplatin 45 mg/m^2 over 2 hours for 5 weeks (oxaliplatin administered on the first day of radiation week).~Surgical resection 4-6 weeks after completion of chemoradiotherapy"
9753144|NCT00525798|Active Comparator|1|SMC021 - Oral Calcitonin
9753145|NCT00525798|Placebo Comparator|SMC021- Placebo|SMC021 - placebo
9753146|NCT00525837|Other|varenicline|open label varenicline
9753147|NCT00525876|Experimental|Matched Sibling Transplant|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
9753148|NCT00525876|Experimental|Allo MUD & MM|Allo MUD & MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
9753149|NCT00525902|Experimental|Adalimumab|
9753150|NCT00525915|Experimental|Arm A: Chemo with Radiation Treatment|For 5 weeks, Chemo of 5-FU 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.
9753151|NCT00525915|Experimental|Arm B: Pre-Op Chemo + Chemo with Radiation Treatment|Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)
9753152|NCT00526058|Other|A (Secura then Futura)|The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
9753153|NCT00526058|Other|B (Futura then Secura)|The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
9753154|NCT00526071|Experimental|Migalastat|Migalastat was administered orally, 150 mg QOD, 250 mg QD for 3 days, 4 days off per week for 2 months, or 500 mg QD for 3 days, 4 days off per week for up to 10 months, depending on the approval date of the protocol amendments at each site. Participants received migalastat for up to 56 months.
9753155|NCT00526097|Experimental|Bisacodyl 5 mg x 2 once daily|patient to receive two enteric-coated tablets containing 5 mg bisacodyl
9753156|NCT00526097|Placebo Comparator|Placebo|patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl
9753157|NCT00526110|Experimental|5-Fluorouracil + Docetaxel + Oxaliplatin|5-Fluorouracil 2.2 Gm/m^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m^2 IV over 60 minutes. Oxaliplatin 85 mg/m^2 IV over 120 minutes on Day 1.
9753158|NCT00526123|Active Comparator|1|symmetric tip catheter
9753159|NCT00526123|Active Comparator|2|conventional split-tip catheter
9753160|NCT00526162|Experimental|Implantation of Consulta CRT-D|Patients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator
9753161|NCT00526188|Experimental|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
9753162|NCT00526292|Experimental|natural killer (NK) cells with salvage chemotherapy|This is a Phase II study, designed to determine the efficacy of natural killer (NK) cells isolated from HLA-haploidentical related donors when infused following a salvage chemotherapy regimen into patients who have relapsed or persistent leukemia following an allogeneic HLA-compatible HSCT and who are ineligible for a second HSCT.
9753163|NCT00526474|Placebo Comparator|Placebo|1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
9753164|NCT00526474|Experimental|Vorapaxar|one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
9753165|NCT00526591|Experimental|Low-dose Everolimus Cohort|5mg Everolimus daily continuously for 8 weeks and conventional surgery
9753166|NCT00526591|Active Comparator|High-dose Everolimus Cohort|10mg Everolimus daily continuously for 8 weeks and conventional surgery
9753167|NCT00526630|Active Comparator|1. MPD|Randomized to receive active Methylphenidate first. At cross-over, participants will receive placebo.
9753168|NCT00526630|Placebo Comparator|2. Placebo|Randomized to receive placebo first. At cross-over, participants will receive the active Methylphenidate.
9753169|NCT00526656|Experimental|sunitinib malate|Drug
9753170|NCT00526799|Experimental|Phase I|Topotecan 3.5 mg/m^2 + Sorafenib dose escalation:
9753171|NCT00526799|Experimental|Phase II|Topotecan 3.5 mg/m^2 + Sorafenib 400 mg po daily.
9753172|NCT00526890|Experimental|CPSR|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation
9753173|NCT00526994|Experimental|Screened|Screened w/4 questions on intimate partner violence; if positive, receives referral information
9753174|NCT00526994|Active Comparator|Universal education|all participants receive partner violence referral information
9753175|NCT00526994|No Intervention|Control|no screen and no referral
9753176|NCT00527072|Experimental|001|infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
9753177|NCT00527111|Experimental|Chemoradiotherapy plus Cetuximab|Pelvic irradiation plus 5-fluorouracil plus cetuximab
9753178|NCT00527111|Active Comparator|Chemoradiotherapy alone|Pelvic irradiation plus 5-fluorouracil
9753179|NCT00527124|Experimental|Arm I|Patients receive oral cediranib maleate once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21.
9753180|NCT00527124|Active Comparator|Arm II|Patients receive docetaxel and prednisone as in arm I.
9753181|NCT00527319|No Intervention|Group A, control group|Supportive care only
9753182|NCT00527319|Active Comparator|Group B, Low Dose VT-122|VT-122 (dose of etodolac: 400 mg/day) + supportive care
9753183|NCT00527319|Active Comparator|Group C, High Dose VT-122|VT-122 (dose of etodolac: 800 mg/day) + supportive care
9753184|NCT00527332|Active Comparator|A|Spinal anesthesia combined with intrathecal morphine. Spinal anesthesia applied in intervertebral space L3/L4 or L2/L3 with hyperbaric bupivacaine 20 mg and morphine 0.2 mg intrathecally. Sedation with propofol.
9753185|NCT00527332|Active Comparator|B|General anesthesia. General anesthesia induced with propofol, fentanyl and rocuronium, and maintained with propofol and oxygen in air. Rocuronium and fentanyl repeated when needed.
9753186|NCT00527397|Experimental|B|Type 2 Diabetes Mellitus (DM) who has not yet treated by Insulin
9753187|NCT00527397|Experimental|C|Type 2 DM who has already treated by Insulin
9753188|NCT00527397|Experimental|A|Type 1 DM
9753189|NCT00527423|Experimental|Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)|
9753190|NCT00527475|Active Comparator|Group I|Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
9753191|NCT00527475|Experimental|Group II|Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
9753192|NCT00527488|Experimental|Degarelix 16+16 mg|
9753193|NCT00527488|Experimental|Degarelix 32 mg|
9753194|NCT00527488|Experimental|Degarelix 32+32 mg|
9753195|NCT00527488|Experimental|Degarelix 64 mg|
9753196|NCT00527514|Experimental|1|
9753197|NCT00527566|Experimental|Mepolizumab|Subjects will receive open-label mepolizumab
9753198|NCT00527592|Experimental|Travoprost|Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
9753199|NCT00527592|Active Comparator|Latanoprost|Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
9753200|NCT00527605|Experimental|A|dutasteride 0.5mg once daily orally
9753201|NCT00527605|Placebo Comparator|B|Placebo matched once daily orally
9753202|NCT00527618|Active Comparator|Standard-dose acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
9753203|NCT00527618|Experimental|High-dose valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
9753204|NCT00527644|Other|Spring Clips|Subjects will undergo laparoscopic cholecystectomy with commercially available 5 mm spring clips utilized for the ligation of the cystic duct and artery.
9753205|NCT00527722|Experimental|Pleural Plug|Experimental lung plug after the lung biopsy.
9753206|NCT00527722|Active Comparator|No Pleural Plug|The standard lung biopsy without placement of the plug.
9753207|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)|
9753208|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)|
9753209|NCT00527735|Active Comparator|Ipilimumab placebo + paclitaxel + carboplatin|
9753210|NCT00527787|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
9753211|NCT00527787|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
9753212|NCT00527826|Active Comparator|arm 1|
9753213|NCT00527826|Active Comparator|arm 2|
9753214|NCT00527878|Experimental|Placebo/Ranitidine crossover|Patients took placebo for 12 months and then ranitidine for 12 months
9753215|NCT00527878|Experimental|Ranitidine/placebo crossover|Ranitidine for one year followed by placebo for one year
9753216|NCT00527904|Experimental|PN 400 (VIMOVO)|500 mg delayed release naproxen/20 mg immediate release esomeprazole
9753217|NCT00527943|Placebo Comparator|Placebo|Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
9753218|NCT00527943|Experimental|Vorapaxar|Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
9753219|NCT00528021|Active Comparator|1|
9753220|NCT00528021|Active Comparator|2|
9753221|NCT00528021|Active Comparator|3|
9753222|NCT00528021|Placebo Comparator|4|
9753223|NCT00528112|Experimental|LCS12|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro
9753224|NCT00528112|Experimental|LCS16|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro
9753225|NCT00528190|Experimental|Itraconazole|Itraconazole 5mg/kg/day for 24 weeks
9753226|NCT00528190|Placebo Comparator|Placebo|Placebo/day for 24 weeks
9753227|NCT00528268|Experimental|Cohort 1|Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies
9753228|NCT00528268|Experimental|Cohort 2|Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies
9753229|NCT00528372|Experimental|Group 1: Dapagliflozin, 2.5 mg AM|Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks.
9753230|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks.
9753231|NCT00528372|Experimental|Group 1: Dapagliflozin 2.5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks.
9753232|NCT00528372|Experimental|Group 1: Dapagliflozin, 5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks.
9753233|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks.
9753234|NCT00528372|Experimental|Group 2: Dapagliflozin, 5 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
9753235|NCT00528372|Experimental|Group 2: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
9753236|NCT00528372|Experimental|Group 1: Dapagliflozin placebo AM & PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks.
9753237|NCT00528372|Experimental|Group 1: Dapaglifozon, 5 mg AM|Participants with (HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
9753238|NCT00528398|Experimental|Treatment (idarubicin, cytarabine)|Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
9753239|NCT00528411|Active Comparator|1|Aspirin + Placebo
9753240|NCT00528411|Active Comparator|2|Aspirin + clopidogrel
9753241|NCT00528411|Experimental|3|Aspirin + Ticagrelor
9753242|NCT00528424|Experimental|AA4500 0.58 mg|
9753243|NCT00528450|Experimental|Tretinoin and Arsenic Trioxide With or Without Idarubicin|See Outline for details
9753244|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 750 milligram (mg) orally administered every 8 hours (hr) for 12 weeks, in combination with standard treatment composed of pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection at the dose of 180 microgram per week (mcg/week) and ribavirin (RBV) oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
9753245|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 750 mg orally administered every 8 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kilogram/week (mcg/kg/week) and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
9753246|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2a solution for subcutaneous injection at the dose of 180 mcg/week and RBV oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
9753247|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kg/week and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
9753248|NCT00528541|Active Comparator|BOTOX®|botulinum toxin type A (BOTOX®)
9753249|NCT00528541|Active Comparator|Dysport®|botulinum toxin type A (Dysport®)
9753250|NCT00528567|Experimental|Bevacizumab and Chemotherapy|Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.
9753251|NCT00528567|Active Comparator|Chemotherapy|Participants randomized to receive standard adjuvant chemotherapy as prescribed.
9753252|NCT00528580|Experimental|1|Simvastatin 80 mg once daily PO (or via NG or G-tube)
9753253|NCT00528580|Placebo Comparator|2|Identical-appearing placebo PO (or via NG or G-tube)
9753254|NCT00528606|Experimental|AA4500 0.58 mg|
9753255|NCT00528606|Placebo Comparator|Placebo|
9753256|NCT00528645|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies.
9753257|NCT00528788|Experimental|Pre and post doxicalciferol|ESRD: all patients with secondary hyperparathyroidism who are vitamin D naive will receive doxercalciferol 2 mcg or 4 mcg 3 times per week fopr 30 days (1 month). Blood work and vascular laboratory studies will be performed pre and post treatment.
9753258|NCT00528801||Cases (CLOSED)|These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).
9753259|NCT00528801||Controls (CLOSED)|These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level
9753260|NCT00528840|Experimental|AA4500 0.58 mg|
9753261|NCT00528866|Experimental|Androgen suppression + RT + docetaxel|LHRH agonist and oral antiandrogen (flutamide or bicalutamide), radiation therapy (RT), and docetaxel
9753262|NCT00528879|Placebo Comparator|Placebo + Metformin|Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
9753263|NCT00528879|Experimental|Dapagliflozin, 2.5 mg + Metformin|Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
9753264|NCT00528879|Experimental|Dapagliflozin, 5 mg + Metformin|Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
9753265|NCT00528879|Experimental|Dapagliflozin, 10 mg + Metformin|Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
9753266|NCT00528931|Experimental|AA4500 0.58 mg|
9753267|NCT00528957|Experimental|Tenofovir DF|
9753268|NCT00528957|Active Comparator|stavudine or zidovudine|
9753269|NCT00528970|Experimental|MOA-728 12 mg|Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
9753270|NCT00528970|Experimental|MOA-728 24 mg|Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
9753271|NCT00528970|Placebo Comparator|Placebo|Participants will receive placebo matching to MOA-728 as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
9753272|NCT00528996|Placebo Comparator|Placebo|Matching Placebo
9753273|NCT00528996|Experimental|BEA 2180 BR low dose|Low dose
9753274|NCT00528996|Experimental|BEA 2180 BR medium dose|Medium dose
9753275|NCT00528996|Experimental|BEA 2180 BR high dose|High dose
9753276|NCT00528996|Experimental|Tiotropium Bromide|Tiotropium Bromide
9753277|NCT00529035|Experimental|Interleukin-2|"Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)"
9753278|NCT00529087|Placebo Comparator|1|
9753279|NCT00529087|Experimental|2|
9753280|NCT00529087|Experimental|3|
9753281|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 1|Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m^2) IV through 500 mg/m^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
9753282|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 2|Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
9753283|NCT00529126|Experimental|SKY0402 high dose|SKY0402, single administration
9753284|NCT00529126|Experimental|SKY0402 middle dose|SKY0402, single administration
9753285|NCT00529126|Experimental|SKY0402 low dose|SKY0402, single administration
9753286|NCT00529126|Active Comparator|Bupivacaine HCl|Bupivacaine HCl
9753287|NCT00529191|Experimental|Atorvastatin|Two out of every three patients will receive atorvastatin.
9753288|NCT00529191|Placebo Comparator|Placebo|One out of three subjects will receive a placebo.
9753289|NCT00529204|Experimental|Exenatide|exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
9753290|NCT00529217|Experimental|Open-Label Active rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS)
9753291|NCT00529243|Experimental|MK-0518 (raltegravir)|Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
9753292|NCT00529308|Active Comparator|Active|
9753293|NCT00529308|Sham Comparator|Sham|
9753294|NCT00529373|Experimental|Odanacatib|Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
9753295|NCT00529373|Placebo Comparator|Placebo|Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
9753296|NCT00529386|Experimental|Botox|300 IU botox
9753297|NCT00529399|Experimental|1|3 injections of GAD-Alum vaccine
9753298|NCT00529399|Experimental|2|2 injections of GAD-Alum vaccine and one injection with Aluminum hydroxide alone
9753299|NCT00529399|Placebo Comparator|3|3 injections of Aluminum hydroxide alone
9753300|NCT00529451|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily
9753301|NCT00529451|Experimental|Aliskiren 150 mg|Aliskiren 150 mg once daily
9753302|NCT00529451|Experimental|Aliskiren 75 mg|Aliskiren 75 mg once daily
9753303|NCT00529451|Active Comparator|Ramipril 5 mg|Ramipril 5 mg once daily
9753304|NCT00529516|Experimental|FluAS25 Group|Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.
9753305|NCT00529516|Active Comparator|Fluarix ≥ 65 years age Group|Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
9753306|NCT00529516|Active Comparator|Fluarix 18-40 years age Group|Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
9753307|NCT00529529|Experimental|Indacaterol 300 μg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9753308|NCT00529529|Experimental|Indacaterol 600 μg|Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9753309|NCT00529529|Active Comparator|Salmeterol 50 μg|Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9753310|NCT00529542|Experimental|Atorvastatin|
9753311|NCT00529542|Placebo Comparator|Placebo|
9753312|NCT00529555|Sham Comparator|Scaling and root planing + SHAM TX|sham treatment
9753313|NCT00529555|Placebo Comparator|Scaling and root planing + Vehicle|Placebo
9753314|NCT00529555|Active Comparator|Scaling & root planing + Periocline Gel|Minocycline HCL 2.1%
9753315|NCT00529568|Experimental|eltrombopag|active treatment arm
9753316|NCT00529568|Placebo Comparator|placebo|placebo control arm
9753317|NCT00529633|Active Comparator|Thalidomide|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide."
9753318|NCT00529633|Placebo Comparator|No Drug|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive Placebo (Sugar pill) for a period of 24 weeks."
9753319|NCT00529659|Experimental|MK-0773|MK-0773
9753320|NCT00529659|Placebo Comparator|Placebo|Placebo
9753321|NCT00529789|Experimental|Duloxetine|
9753322|NCT00529802|Experimental|Everolimus (RAD001) 10mg daily|All patients were to receive 10mg everolimus (RAD001) daily.
9753323|NCT00529958|Active Comparator|Patellar Tendon (PT)|ACL reconstruction using a patellar tendon autograft
9753324|NCT00529958|Active Comparator|Hamstring (HT)|ACL reconstruction using a quadruple-strand semitendinosus/gracilis (hamstring) tendon single-bundle autograft
9753325|NCT00529958|Active Comparator|Double-Bundle (DB)|ACL reconstruction using a semitendinosus/gracilis (hamstring) tendon double-bundle autograft
9753326|NCT00530023|Active Comparator|1. 722|722 arm: MiniMed Paradigm REAL-Time System
9753327|NCT00530023|No Intervention|2. Multiple Daily Injections (MDI)|MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study.
9753328|NCT00530075|Experimental|1|Gusperimus
9753329|NCT00530088|Experimental|Porfimer Sodium|Patients receive porfimer sodium subcutaneously followed by photodynamic therapy (PDT) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber.
9753330|NCT00530218|Experimental|All Study Participants|Ganciclovir IV 5 mg/kg/bid x 7 days followed by Ganciclovir Oral 1000 mg tid 7 days per week x 5 weeks
9753331|NCT00530257|Placebo Comparator|Placebo|Placebo (sugar pill);Subjects will be equally randomized and will receive one week of treatment with placebo and compared to subjects who were randomized to receive one week of OROS-methylphenidate.
9753332|NCT00530257|Active Comparator|OROS-methylphenidate|Subjects will be equally randomized and will receive one week of treatment with the optimal dose of OROS methylphenidate compared with subjects randomized to receive one week of placebo.
9753333|NCT00530270|Active Comparator|Dexamethasone|
9753334|NCT00530270|Placebo Comparator|Placebo|
9753335|NCT00530335|Experimental|Atomoxetine|
9753336|NCT00530348|Experimental|Alemtuzumab|
9753337|NCT00530348|Active Comparator|Interferon Beta-1a|
9753338|NCT00530439|Experimental|Lifestyle intervention|physical activity, dietetic counselling
9753339|NCT00530439|No Intervention|Control|
9753340|NCT00530504|Experimental|Device|Device
9753341|NCT00530621|Experimental|Pemetrexed + Enzastaurin|
9753342|NCT00530621|Placebo Comparator|Pemetrexed + Placebo|
9753343|NCT00530634|Experimental|Gemcitabine + Cisplatin|Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.
9753344|NCT00530712|Experimental|PTA and Stenting with EverFlex device|Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System
9753345|NCT00530764|Experimental|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
9753346|NCT00530764|Experimental|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
9753347|NCT00530764|Experimental|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
9753348|NCT00530764|No Intervention|Placebo|Range of 1-16 sprays per day of placebo spray.
9753349|NCT00530777|Experimental|1|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
9753350|NCT00530777|Placebo Comparator|2|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
9753351|NCT00530790|Experimental|ropinirole CR-RLS|"Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use much improved as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day."
9753352|NCT00530803|Active Comparator|EMLA Cream|Participants will have a dose of EMLA Cream applied to the venipuncture site 1 hour before the procedure. Dosage based on age and weight: 4-6 years old and heavier than 10kg will receive 10g of EMLA; 7-12 years old and more than 20kg will receive 20g of EMLA.
9753353|NCT00530803|Active Comparator|Synera Patch|Participants will have a Synera Patch applied to the venipuncture site 20 minutes prior to the procedure.
9753354|NCT00530816|Experimental|Carfilzomib|"Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.~Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles."
9753355|NCT00530855|Experimental|Lacosamide|Lacosamide tablets for dosing 100 -800 mg/day
9753356|NCT00530894|Experimental|1|Cohort A: Sapien Valve
9753357|NCT00530894|Active Comparator|2|Cohort A: other surgical valve
9753358|NCT00530894|Experimental|3|Cohort B: Sapien Valve
9753359|NCT00530894|Active Comparator|4|Cohort B: Medical therapy
9753360|NCT00530946|Active Comparator|CI-1038 2.5mg/5mg|
9753361|NCT00530946|Active Comparator|CI-1038 2.5mg/10mg|
9753362|NCT00530946|Active Comparator|CI-1038 5mg/5mg|
9753363|NCT00530946|Active Comparator|CI-1038 5mg/10mg|
9753364|NCT00531011|Active Comparator|XIENCE V|Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)
9753365|NCT00531011|Active Comparator|TAXUS® Liberté™|Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
9753366|NCT00531050|Experimental|Part 1: Sequence A, Part 2: Sequence A|"Part 1: Sequence 'A' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus dry powder inhaler (DPI). Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'A' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
9753367|NCT00531050|Experimental|Part 1 : Sequence B, Part 2: Sequence B|"Part 1: Sequence 'B' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'B' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
9782726|NCT01183689|Experimental|Small behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate small changes (e.g., modify diet by approximately 100 kcal, decrease portion sizes or change types of food, increase activity by 2000 steps/day).
9753368|NCT00531050|Experimental|Part 1: Sequence C, Part 2: Sequence C|"Part 1: Sequence 'C' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus DPI. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'C' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device . In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
9753369|NCT00531050|Experimental|Part 1; Sequence D, Part 2: Sequence D|"Part 1: Sequence 'D' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'D' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
9753370|NCT00531050|Experimental|Part 1: Sequence E, Part 2: Sequence E|"Part 1: Sequence 'E' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'E' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
9753371|NCT00531050|Experimental|Part 1: Sequence F, Part 2: Sequence F|"Part 1: Sequence 'F' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'F' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
9753372|NCT00531206||All participants|
9753373|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753374|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753375|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753376|NCT00531284|Experimental|Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753377|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 36 mg/m²|Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9830689|NCT02579382|Experimental|TDF + Vesatolimod 4 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 4 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
9830690|NCT02579421|Active Comparator|Males - Progesterone|200 mg progesterone BID
9830691|NCT02579421|Placebo Comparator|Males - Placebo|placebo BID
9830692|NCT02579421|Active Comparator|Females - Progesterone|200 mg progesterone BID
9830693|NCT02579421|Placebo Comparator|Females - Placebo|placebo BID
9830694|NCT02579603|Experimental|Nintedanib|Nintedanib 150 mg bid
9830695|NCT02579603|Experimental|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
9830696|NCT02579616|Experimental|24 mg Lenvatinib|Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).
9830697|NCT02579629|Active Comparator|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
9830698|NCT02579629|Experimental|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
9830699|NCT02579629|Active Comparator|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
9830700|NCT02579759|Active Comparator|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
9830701|NCT02579759|Active Comparator|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
9830702|NCT02579759|Placebo Comparator|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
9830703|NCT02579772|Active Comparator|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC) pills
9830704|NCT02579772|Placebo Comparator|Placebo|Treatment with placebo pills
9830705|NCT02579811|Experimental|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
9830706|NCT02579863|Experimental|Pembrolizumab + Lenalidomide + Dexamethasone|Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
9830707|NCT02579863|Active Comparator|Lenalidomide + Dexamethasone|Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
9830708|NCT02579876|Active Comparator|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
9830709|NCT02579876|Placebo Comparator|Viaskin Placebo|Viaksin patch without any milk protein.
9830710|NCT02579915|Experimental|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
9830711|NCT02579915|Active Comparator|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
9830712|NCT02579928|Experimental|Ketamine|Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
9830713|NCT02579928|Experimental|Midazolam|Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),
9830714|NCT02580188|No Intervention|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
9753378|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 45 mg/m²|Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753379|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753380|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753381|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753382|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753383|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753384|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753385|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753386|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753387|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753388|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753389|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
9753390|NCT00531427|Experimental|1|Buprenorphine transdermal system 10 and 20 applied for 7-day wear
9753391|NCT00531427|Placebo Comparator|2|Placebo transdermal system to match BTDS patches, applied for 7-day wear
9753392|NCT00531453|Experimental|1|bortezomib, dexamethasone, and thalidomide
9753393|NCT00531453|Experimental|2|bortezomib, dexamethasone, thalidomide, and cyclophosphamide
9753394|NCT00531479|Active Comparator|Voriconazole|Voriconazole monotherapy
9753395|NCT00531479|Experimental|Voriconazole and Anidulafungin|Combination therapy with voriconazole and anidulafungin
9753396|NCT00531518|No Intervention|Control group|This is the control arm. Participants will be offered only case management. Participants may seek outside treatment, without guidance from study staff.
9753397|NCT00531518|Experimental|Family-aided Assertive Community Treatment|This is the experimental intervention arm for high-risk-for-psychosis participants. The intervention includes psychiatric drugs (aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine), psychoeducational multifamily group treatment and supported employment and education .
9753398|NCT00531661|Active Comparator|TREATMENT Group|Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
9753399|NCT00531661|Placebo Comparator|CONTROL Group|Standard of care HF management
9753400|NCT00531752|Experimental|Flexible Dose|
9753401|NCT00531752|Placebo Comparator|Placebo|
9753402|NCT00531752|Experimental|Fixed Dose|
9753403|NCT00531817|Experimental|Tocilizumab 8 mg/kg + DMARDs|
9753404|NCT00531817|Placebo Comparator|Placebo + DMARDs|
9753405|NCT00531843|Experimental|1A|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) >=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
9753406|NCT00531843|Active Comparator|1B|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS >=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
9753407|NCT00531843|Experimental|2A|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
9753408|NCT00531843|Active Comparator|2B|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).
9753409|NCT00531882|Experimental|1-pioglitazone|Pioglitazone
9753410|NCT00531882|Experimental|2-simvasatin|Simvastatin
9753411|NCT00531882|Active Comparator|3-Ibuprofen 1000-1600 mg/day|Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
9753412|NCT00531934|Experimental|1|
9753413|NCT00531934|Active Comparator|2|
9753414|NCT00531947|Experimental|EMSAM|Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
9753415|NCT00531947|Placebo Comparator|Placebo|Placebo Selegiline Transdermal System 6, 9 or 12
9753416|NCT00531960|Active Comparator|Bevacizumab, Chemotherapy|Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
9753417|NCT00531960|Experimental|Bevacizumab, Erlotinib|Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal.
9753418|NCT00532129|Experimental|Rituximab plus Chlorambucil|Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.
9753419|NCT00532155|Experimental|Placebo/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
9753420|NCT00532155|Placebo Comparator|Aflibercept/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
9753421|NCT00532259|Experimental|CT-011|The monoclonal antibody termed CT-011 (currently, pidilizumab).
9753422|NCT00532298|Experimental|GSK576389A- 2006/2007 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
9753423|NCT00532298|Experimental|GSK576389A - 2006/2007 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
9753424|NCT00532298|Active Comparator|Fluarix 2006/2007 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
9753425|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
9753426|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
9753427|NCT00532298|Active Comparator|Fluarix 2007/2008 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
9753428|NCT00532441|Experimental|Erlotinib and Docetaxel: Biliary|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
9753429|NCT00532441|Experimental|Erlotinib and Docetaxel: Hepatocellular|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
9753430|NCT00532480|Other|Duolxetine|Open-label duloxetine 30 - 60 mg oral administration
9753431|NCT00532493|Active Comparator|Prazosin Group|Subjects randomized to this arm will be on prazosin.
9753432|NCT00532493|Placebo Comparator|Placebo Group|Subjects randomized to this arm will be on placebo.
9753433|NCT00532779|Experimental|NB16|Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
9753434|NCT00532779|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
9753435|NCT00532779|Placebo Comparator|Placebo|Placebo with ancillary therapy
9753436|NCT00532844|Experimental|Sapropterin dihydrochloride|Sapropterin dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
9753437|NCT00532844|Experimental|Sapropterin dihydrochloride+Vitamin C|Sapropterin dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
9753438|NCT00532883|Placebo Comparator|Placebo Pills and Placebo Liquid|
9753439|NCT00532883|Active Comparator|Hydroxyurea Pills and Placebo Liquid|
9753440|NCT00532883|Active Comparator|Placebo Pills and Magnesium Pidolate Liquid|
9753441|NCT00532883|Active Comparator|Hydroxyurea Pills and Magnesium Pidolate Liquid|
9753442|NCT00532935|Experimental|1|Sitagliptin phosphate (+) metformin hydrochloride
9753443|NCT00532935|Active Comparator|2|pioglitazone
9753444|NCT00532948|Experimental|1|
9753445|NCT00533117|Experimental|Dialectical Behavior Therapy Fluoxetine|Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy (CBT) targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period,and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
9753446|NCT00533117|Placebo Comparator|Dialectical Behavior Therapy placebo|Dialectal behavior therapy and placebo Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period, and placebo for fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
9753447|NCT00533117|Experimental|Supportive therapy Fluoxetine|Supportive psychotherapy and fluoxetine Supportive therapy is a manualized psychotherapy aimed at strengthening coping skills and is delivered over a 12 month period, and fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
9753448|NCT00533117|Active Comparator|Supportive therapy placebo|Supportive psychotherapy and placebo See above for descriptions.
9753449|NCT00533273|Experimental|AA4500 0.58 mg|
9753450|NCT00533273|Placebo Comparator|Placebo|
9753451|NCT00533429|Experimental|A|Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin
9753452|NCT00533429|Placebo Comparator|B|Pemetrexed + Carboplatin + Bevacizumab + Placebo
9753453|NCT00533442|Active Comparator|Tacrolimus plus MMF plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
9753454|NCT00533442|Experimental|Tacrolimus plus Rapamycin plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
9753455|NCT00533507|Experimental|Synflorix group|Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
9753456|NCT00533546|Experimental|Tier One|Participants will receive APC by intravenous injection, receiving 50% of dose as a bolus and the remainder as an infusion over one ho.
9753457|NCT00533702|Experimental|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab)
9753458|NCT00533702|Active Comparator|IMC-1121B (ramucirumab) + dacarbazine|IMC-1121B (ramucirumab) + dacarbazine
9753459|NCT00533845|Experimental|On-Q pain pump|Bupivacaine
9753460|NCT00533845|Placebo Comparator|Placebo/control|Saline
9753461|NCT00533897|Experimental|Abatacept|
9753462|NCT00533897|Placebo Comparator|Placebo|
9753463|NCT00533910|Placebo Comparator|Placebo|Will be given placebo and follow the exact procedures as the experimental section
9753464|NCT00533910|Experimental|Drug|
9753465|NCT00533949|Active Comparator|60 Gy RT|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
9753466|NCT00533949|Experimental|74 Gy RT|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
9753467|NCT00533949|Experimental|60 Gy RT + Cetuximab|60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
9753468|NCT00533949|Experimental|74 Gy RT + Cetuximab|74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
9753469|NCT00534001|Experimental|Arm I (1-week run-in)|Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
9753470|NCT00534001|Experimental|Arm II (4-week run-in)|Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
9753471|NCT00534105||Gestational Diabetics|Patients with Gestational Diabetes
9753472|NCT00534105||2|Normal pregnant women without gestational diabetes
9753473|NCT00534118|Experimental|Infusion|Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
9753474|NCT00534209|Experimental|Arm I: Allogeneic B7.1/HLA-A1|"Patients will receive Allogeneic B7.1/HLA-A1 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.~Given intradermally."
9753475|NCT00534209|Placebo Comparator|Arm II: Placebo|Patients receive a placebo vaccine intradermally once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
9753476|NCT00534235|Active Comparator|Posterolateral Fusion w/Pedicle Screws|Control: Posterolateral fusion and implantation of pedicle screws after decompression
9753477|NCT00534235|Active Comparator|coflex Interlaminar Technolgy|Investigative: Implantation of coflex Interlaminar Technology after decompression
9753478|NCT00534248|Experimental|Zostavax™|Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
9753479|NCT00534248|Placebo Comparator|Placebo|Participants randomized to receive Placebo.
9753480|NCT00534313|Active Comparator|Abatacept (30/10)|Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg) thereafter.
9753481|NCT00534313|Active Comparator|Abatacept (10/10)|Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg).
9753482|NCT00534313|Active Comparator|Abatacept (3/3)|Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.
9753483|NCT00534313|Placebo Comparator|Placebo|Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.
9753484|NCT00534352|Experimental|001|TMC125; darunavir; ritonavirTMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
9753485|NCT00534365|Active Comparator|1|Tension-free vaginal tape procedure (TVT)
9753486|NCT00534365|Active Comparator|2|TVT-SECUR device
9753487|NCT00534404|Experimental|NRT Patch, Phone Counseling, Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
9753488|NCT00534404|Active Comparator|Nicotine Patches and Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
9753489|NCT00534404|Placebo Comparator|Internet|Research participants in this arm will have free access to internet-assisted tobacco treatment (iQuit Smoking website).
9753490|NCT00534417|Experimental|Capecitabine and fulvestrant|"Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 kg.~Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."
9753491|NCT00534495|Experimental|Group 1|Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
9753492|NCT00534495|Placebo Comparator|Group 2|Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
9782727|NCT01183689|Experimental|Large behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate large changes (e.g., modify diet to 1200-1500 or 1500-1800 kcal/day with < 30% fat, increase exercise to 250 minutes/week of moderate intensity activity).
9782728|NCT01183728|Experimental|MSV autologous transplantation|Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
9782729|NCT01183780|Experimental|FOLFIRI + Ramucirumab|
9782730|NCT01183780|Placebo Comparator|FOLFIRI + Placebo|
9782731|NCT01183858|Experimental|Erlotinib 150 mg|Erlotinib 150 mg single daily oral dose until disease progression.
9782732|NCT01183858|Experimental|Erlotinib 300 mg|Erlotinib 300 mg single daily oral dose until disease progression.
9782733|NCT01183923|Experimental|Broccoli Sprouts, then Alfalfa Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by alfalfa sprouts after washout.
9782734|NCT01183923|Experimental|Alfalfa Sprouts, then Broccoli Sprouts|Alfalfa Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by broccoli sprouts after washout.
9782735|NCT01183975||Patients treated with SAGB by solicited teams|Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
9782736|NCT01184014|Experimental|Experimental group|a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).
9782737|NCT01184014|Active Comparator|Control group|the standard recommended care (Methodist Hospital Complete Insulin Orders)
9782738|NCT01184053|Experimental|Trisenox treatment|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
9782739|NCT01184079|Experimental|12 months|Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
9782740|NCT01184079|Active Comparator|6 month|Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine
9830715|NCT02580188|Experimental|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
9830716|NCT02580201|Experimental|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
9830717|NCT02580240|Placebo Comparator|Placebo|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
9830718|NCT02580240|Experimental|hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
9830719|NCT02580318|Experimental|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
9830720|NCT02580357|Sham Comparator|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
9830721|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
9830722|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
9830723|NCT02580591|Experimental|Empagliflozin low dose|
9830724|NCT02580591|Experimental|Empagliflozin high dose|
9830725|NCT02580591|Experimental|Empagliflozin medium dose|
9830726|NCT02580591|Placebo Comparator|Placebo|
9830727|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
9830728|NCT02580877|Experimental|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
9753493|NCT00534599|Other|1|Adjunctive Placebo Seroquel XR to anxiety treatment
9753494|NCT00534599|Experimental|2|Adjunctive Seroquel XR to anxiety treatment
9753495|NCT00534638|Experimental|Cervarix/Engerix-B A Group|The A group includes subjects from communities where 70% of male and female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate study participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated subjects were randomized to Cervarix). Finally, subjects from A group were either vaccinated with Cervarix, Engerix-B (control vaccine), or not vaccinated (enrolled control without vaccination). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
9753496|NCT00534638|Experimental|Cervarix/Engerix-B B Group|The B group includes subjects from communities where 70% of female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate female participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated females were randomized to Cervarix). In this group, all male adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from B group were either vaccinated with Cervarix (females) or Engerix-B/not vaccinated (males and females). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
9753497|NCT00534638|Active Comparator|Engerix-B Group|In this control group, all adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from this group were either vaccinated with Engerix-B or not vaccinated. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
9753498|NCT00534703|Active Comparator|AAV1/SERCA2A|SERCA gene therapy
9753499|NCT00534703|Placebo Comparator|Placebo|Placebo (saline solution)
9753500|NCT00534794|Experimental|Elestat|
9753501|NCT00534794|Active Comparator|Pataday|
9753502|NCT00534833|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
9753503|NCT00534833|Active Comparator|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
9753504|NCT00534937|Active Comparator|Standard compression|Patients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
9753505|NCT00534937|Experimental|Flexitouch|Patients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).
9753506|NCT00535002|Other|Cocaine Females, Yohimbine then Placebo|Cocaine dependent females, received yohimbine day 1 and placebo day 2
9753507|NCT00535002|Other|Cocaine Females, Placebo the Yohimbine|Cocaine dependent females, received placebo day 1 and yohimbine day 2
9753508|NCT00535002|Other|Cocaine Males, Yohimbine then Placebo|Cocaine dependent males, received yohimbine day 1 and placebo day 2
9753509|NCT00535002|Other|Cocaine Males, Placebo thenYohimbine|Cocaine dependent males, received placebo day 1 and yohimbine day 2
9753510|NCT00535002|Other|Control Females, Yohimbine then Placebo|Non-dependent females, received yohimbine day 1 and placebo day 2
9753511|NCT00535002|Other|Control Females, Placebo then Yohimbine|Non-dependent females, received placebo day 1 and yohimbine day 2
9753512|NCT00535002|Other|Control Males, Yohimbine then Placebo|Non-dependent males, received yohimbine day 1 and placebo day 2
9753513|NCT00535002|Other|Control Males, Placebo then Yohimbine|Non-dependent males, received placebo day 1 and yohimbine day 2
9753514|NCT00535132|Experimental|002|Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
9753515|NCT00535132|Experimental|001|Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks
9753516|NCT00535145|Experimental|001|Treatment as usual (TAU), Paliperidone ERTreatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
9753517|NCT00535223|Experimental|Group Based Exposure Therapy|"Behavioral:~GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking."
9753518|NCT00535223|Experimental|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus. This lasted for 16 weeks."
9753519|NCT00535236|Experimental|Autologous HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753520|NCT00535236|Placebo Comparator|Autologous HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753521|NCT00535236|Experimental|Allogeneic HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753522|NCT00535236|Placebo Comparator|Allogeneic HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753523|NCT00535236|Experimental|STM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753524|NCT00535236|Placebo Comparator|STM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753525|NCT00535236|Experimental|HM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753526|NCT00535236|Placebo Comparator|HM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9830729|NCT02580877|Experimental|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
9753527|NCT00535236|Experimental|HIV-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753528|NCT00535236|Placebo Comparator|HIV-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9753529|NCT00535288|Placebo Comparator|Placebo|Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
9753530|NCT00535288|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
9753531|NCT00535288|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
9753532|NCT00535288|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
9753533|NCT00535288|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.
9753534|NCT00535301|Placebo Comparator|Anterior Colporrhaphy (sutured repair)|Anterior vaginal prolapse repair with anterior colporrhaphy (no graft) using sutures.
9753535|NCT00535301|Active Comparator|Perigee (grafted repair)|Anterior vaginal prolapse repair with graft
9753536|NCT00535392|Experimental|Levetiracetam|
9753537|NCT00535496|Experimental|1|sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
9753538|NCT00535496|Experimental|2|sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
9753539|NCT00535496|Experimental|3|sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
9753540|NCT00535496|Experimental|4|sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
9753541|NCT00535587|Experimental|1|
9753542|NCT00535587|Experimental|2|
9753543|NCT00535587|Experimental|3|
9753544|NCT00535587|Experimental|4|
9753545|NCT00535613|Experimental|1|propofol
9753546|NCT00535613|Sham Comparator|2|no propofol
9753547|NCT00535626|Other|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell used in revision total hip replacement
9753548|NCT00535652|Experimental|Ertapenem|Administration of 1 gram ertapenem I.V.
9753549|NCT00535730|Placebo Comparator|1|Placebo Comparator
9753550|NCT00535730|Experimental|2|vaccine
9753551|NCT00535743|Placebo Comparator|Arm A. Placebo; 3 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.
9753552|NCT00535743|Experimental|Arm B. 2 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753553|NCT00535743|Experimental|Arm C. 4 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753554|NCT00535743|Experimental|Arm D. 8 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753555|NCT00535743|Experimental|Arm E. 12 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753556|NCT00535743|Experimental|Arm F. 16 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753557|NCT00535743|Placebo Comparator|Arm G. Placebo; 15 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753558|NCT00535743|Experimental|Arm H. 2 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753559|NCT00535743|Experimental|Arm I. 4 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753560|NCT00535743|Experimental|Arm J. 8 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753561|NCT00535743|Experimental|Arm K. 12 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753562|NCT00535743|Experimental|Arm L. 16 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
9753563|NCT00535743|Placebo Comparator|Arm M. Placebo; 3 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753564|NCT00535743|Experimental|Arm N. 2 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753565|NCT00535743|Experimental|Arm O. 4 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753566|NCT00535743|Experimental|Arm P. 8 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753567|NCT00535743|Experimental|Arm Q. 12 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753568|NCT00535743|Experimental|Arm R. 16 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753569|NCT00535743|Placebo Comparator|Arm S. Placebo; 15 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9830730|NCT02581111|Experimental|Naloxone|Naloxone 8-mg IV given once after baseline ABG
9830731|NCT02581111|Sham Comparator|Placebo|Equivalent volume of saline given once
9753570|NCT00535743|Experimental|Arm T. 2 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753571|NCT00535743|Experimental|Arm U. 4 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753572|NCT00535743|Experimental|Arm V. 8 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753573|NCT00535743|Experimental|Arm W. 12 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753574|NCT00535743|Experimental|Arm X. 16 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
9753575|NCT00535769|Placebo Comparator|Electronic monitor + no text message|The control or placebo comparator group of subjects will receive the study sunscreen with the attached electronic monitor. They will be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If the subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
9753576|NCT00535769|Experimental|Electronic monitor + Text message|The text message experimental group of subjects will receive the study sunscreen with the attached electronic monitor. In addition, this group will receive daily text messages on their cellular phone to remind them to apply the sunscreen. The text message will also contain the daily weather information. This group will also be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
9753577|NCT00535782|Experimental|TCZ + MTX|Participants received 8 mg/kg tocilizumab (TCZ) by intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to Week 104, participants received open-label TCZ 8 mg/kg every 4 weeks plus 7.5-25 mg MTX weekly.
9753578|NCT00535782|Placebo Comparator|Placebo + MTX|Participants received placebo intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to 104, participants received open-label tocilizumab (TCZ) 8 mg/kg every 4 weeks plus 7.5-25 mg MTX.
9753579|NCT00535821|Experimental|MiCHO|A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
9753580|NCT00535821|Active Comparator|EGDT|A 6-hour resuscitation protocol utilizing CVP/ScvO2
9753581|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
9753582|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
9753583|NCT00535847|Experimental|Other|"Subjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects <75 kg and 1200 mg/day for subjects weighing >=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 [NCT00535847]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 [NCT00336479], VX05-950-104EU [NCT00372385] or VX06-950-106 [NCT00420784]) were included in Other reporting group."
9753584|NCT00535873|Experimental|Lenalidomide|Lenalidomide starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
9753585|NCT00535925|Active Comparator|Standard of Care (SoC) therapy|Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
9753586|NCT00535925|Experimental|Multifactorial Intensified therapy|"An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.~In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (<130/80 mmHg)."
9753587|NCT00535938||Naïve to Botox® treatment|Initiating treatment with BOTOX® upon entry to the project.
9753588|NCT00535938||Non-naïve to Botox® treatment|Receiving ongoing treatment with BOTOX® upon entry to the project.
9753589|NCT00536107|Active Comparator|Docetaxel|docetaxel
9753590|NCT00536107|Experimental|Gefitinib|Gefitinib (IRESSA)
9753591|NCT00536120|Experimental|Tysabri Plus Vaccinations|Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin [KLH] and tetanus diphtheria toxoid [Td], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
9753592|NCT00536120|Other|Vaccinations Only|Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH. They do not receive any treatment for their MS and remain in the study through Month 2.
9753593|NCT00536172|Experimental|Escitalopram|Participants will receive treatment with escitalopram
9753594|NCT00536172|Placebo Comparator|Placebo|Participants will receive treatment with placebo
9753595|NCT00536198|Experimental|Sertraline|Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
9753596|NCT00536198|Placebo Comparator|Placebo|Participants will take similar looking placebo during the symptomatic period.
9753597|NCT00536263|Active Comparator|PEG 1.0 mcg/kg weekly (QW) * 24 weeks|PegIntron 1.0 mcg/kg weekly (QW) * 24 weeks + 24 weeks follow-up
9753598|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 24 wks|PegIntron 1.5 mcg/kg QW * 24 wks + 24 wks follow-up
9753599|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 48 wks|PegIntron 1.5 mcg/kg QW * 48 wks + 24 wks follow-up
9753600|NCT00536341|Experimental|lenalidomide, fludarabine, rituximab|"Phase I Non-stratified, dose-escalation: >=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed.~Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation."
9753601|NCT00536471|Experimental|A|duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
9753602|NCT00536471|Placebo Comparator|B|placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months
9753603|NCT00536484|Experimental|Fesoterodine (Double-Blind)|
9753604|NCT00536484|Placebo Comparator|Placebo (Double-Blind)|
9753605|NCT00536510|Experimental|1|laropiprant/niacin (MK0524A)
9753606|NCT00536510|Placebo Comparator|2|placebo
9753607|NCT00536575|Experimental|Intervention|The trial was designed as a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. Phase I consisted of cohorts of 3 patients at each of three dose levels. Patients received bortezomib (Dose Level 1 - 1.3 mg/m2; Dose Level 2 - 1.6 mg/m2) by IV bolus on days 1, 8, 15, and 22 of each 5-week cycle with continuous oral dosing of sorafenib at 200 mg twice daily. Dose level 3 was planned as bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 with sorafenib 400 mg by mouth twice daily throughout each 5-week cycle.
9753608|NCT00536601|Experimental|Regimen CBV (patients with HL or NHL)|Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.
9753609|NCT00536601|Experimental|Regimen M200/M120 (patients with MM or amyloidosis)|Patients receive 200 or 120 mg/m^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.
9753610|NCT00536601|Experimental|Regimen BuC2iv (patients with ALL, AML, HL, or NHL)|Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.
9753611|NCT00536601|Experimental|Regimen CT6 (patients with ALL)|Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.
9753612|NCT00536601|Experimental|Regimen CTtCp (patients with other solid tumors)|Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
9753613|NCT00536601|Experimental|Regimen VCp (patients with testicular cancer)|Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.
9753614|NCT00536601|Experimental|Regimen TtC1500/ECpM (patients with NBL or SRBCT)|Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.
9753615|NCT00536731|Active Comparator|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
9753616|NCT00536731|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
9753617|NCT00536731|Active Comparator|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
9753618|NCT00536744|Active Comparator|Active PACE application - 4 applications|Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care
9753619|NCT00536744|Sham Comparator|Inactive, non-energy application|Non-energized (inactive - Sham)) application + standard of care
9753620|NCT00536809|Experimental|Phase I|Dose escalation of lapatinib along with capecitabine and oxaliplatin until the maximum tolerated dose is reached.
9753621|NCT00536809|Experimental|Phase II|Treatinng subjects at the maximum tolerated dose of lapatinib, capecitabine, and oxaliplatin
9753622|NCT00536874|Experimental|Gemcitabine And Oxaliplatin|A Phase II Study of Neoadjuvant Gemcitabine And Oxaliplatin In Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
9753623|NCT00536913|Experimental|With Spacer|Budesonide/formoterol pMDI 40/2.25ug + spacer
9753624|NCT00536913|Experimental|Without Spacer|Budesonide/formoterol pMDI 40/2.25 ug
9753625|NCT00536939|Experimental|Enzastaurin + Bevacizumab + Paclitaxel|"Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A)."
9753626|NCT00536939|Placebo Comparator|Bevacizumab + Paclitaxel + Placebo|Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.
9830732|NCT02581163||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
9830733|NCT02581189||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
9830734|NCT02581202||HIV-1 infected participants|HIV-1-infected participants on any triple highly active antiretroviral therapy (HAART) with plasma HIV-1 ribonucleic acid (RNA) level < 50 copies/mL for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically appropriate to lopinavir with ritonavir plus lamivudine (LPV/r+3TC) as decided by the physician in the routine clinical settings. Or HIV-1 infected participants who were switched on the dual therapy (LPV/r+3TC) no more than 60 days prior to enrollment.
9830735|NCT02581345|Experimental|M923|Participants assigned to receive M923
9830736|NCT02581345|Active Comparator|Humira|Participants assigned to receive Humira
9830737|NCT02581345|Other|M923 and Humira|Participants assigned to receive M923 and Humira
9830738|NCT02581384|Experimental|Cohort 1 Dose Level 1 [Phase I]|Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
9830739|NCT02581384|Experimental|Cohort 1 Dose Level 2 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
9830740|NCT02581384|Experimental|Cohort 1 Dose Level 3 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
9830741|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
9830742|NCT02581384|Experimental|Cohort 2 Dose Level 3 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
9830743|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase II]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
9830744|NCT02581410|Experimental|GSK1437173A Group|Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
9830745|NCT02581410|Active Comparator|Control Group|Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
9830746|NCT02581475|Active Comparator|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
9830747|NCT02581475|Experimental|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
9830748|NCT02581488|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks.
9830749|NCT02581488|Active Comparator|Product containing silver|Products containing silver will be applied per Investigator instructions and instructions for use/package insert for up to six weeks.
9830750|NCT02581839|Experimental|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
9830751|NCT02581865|Placebo Comparator|Placebo|Placebo administered once daily for 8 weeks
9830752|NCT02581865|Experimental|Dose Group 1|Fixed dose administered once daily for 8 weeks
9830753|NCT02581865|Experimental|Dose Group 2|Fixed dose administered once daily for 8 weeks
9830754|NCT02581891|Experimental|Early-start T&E / Arm 1|Early-start T&E arm: test group, early treatment individualization
9830755|NCT02581891|Active Comparator|Late-start T&E / Arm 2|Late-start T&E arm; per label, control group, treatment individualization after Year 1
9830756|NCT02581995|Experimental|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
9830757|NCT02582151|Sham Comparator|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
9830758|NCT02582151|Active Comparator|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
9830759|NCT02582216|Experimental|Open label|3D augmented reality
9830760|NCT02582242|Experimental|BIAsp 30 TID|
9830761|NCT02582242|Active Comparator|BIAsp 30 BID|
9830762|NCT02582255|Experimental|Sabin mOPV2 1 dose|IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
9830763|NCT02582255|Experimental|SABIN mOPV2 2 doses|IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)
9830764|NCT02582515|Experimental|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training.
9830765|NCT02582515|Placebo Comparator|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training.
9830766|NCT02582632|Experimental|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks
9830767|NCT02582658||Chronic infection of HCV GT1 or GT4|Participants with confirmed chronic hepatitis C genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) ± Ribavirin (RBV) according to standard of care and in line with the current local label
9830768|NCT02582671||Participants with HCV genotype 1|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
9830769|NCT02582684|Experimental|Arm 1: DTG 50 mg + 3TC 300 mg|Dolutegravir 50mg and Lamivudine 300mg, orally daily
9830770|NCT02582814|Experimental|dapagliflozin 5mg + insulin|dapagliflozin tablet 5mg + adjustable insulin
9830771|NCT02582814|Experimental|dapagliflozin 10mg + insulin|dapagliflozin tablet 10mg + adjustable insulin
9830772|NCT02582840|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
9830773|NCT02582840|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
9830774|NCT02582840|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
9830775|NCT02582866|Experimental|Lacosamide|"Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day.~Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks."
9830776|NCT02582970|Experimental|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
9830777|NCT02582983|Experimental|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
9830778|NCT02583230|Experimental|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
9830779|NCT02583256|Experimental|aQIV/aQIV|Subjects previously vaccinated with aQIV followed one year later by aQIV
9830780|NCT02583256|Experimental|aQIV/QIV|Subjects previously vaccinated with aQIV followed one year later by QIV
9830781|NCT02583256|Experimental|QIV/aQIV|Subjects previously vaccinated with QIV followed one year later by aQIV
9830782|NCT02583256|Experimental|QIV/QIV|Subjects previously vaccinated with QIV followed one year later by QIV
9830783|NCT02583360|Active Comparator|Study|Eligible subjects (study) will undergo diagnostic VFSS in combination with manometry, either concurrent or sequential. They will have parental choice of preferred feeding therapy.
9830784|NCT02583360|No Intervention|Control|Eligible subjects who had VFSS alone with provider recommendations from the same single center.
9830785|NCT02583399|Experimental|Ibuprofen|Ibuprofen, 10 mg/kg
9830786|NCT02583425|Experimental|DFN-11|DFN-11 Injection upon occurrence of migraine
9830787|NCT02583477|Experimental|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
9830788|NCT02583477|Experimental|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
9835837|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
9836162|NCT02772666|Experimental|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
9753627|NCT00536991|Experimental|Treatment (calcitriol, ketoconazole, hydrocortisone)|"PHASE I: Patients receive calcitriol PO QD on days 1-3, 8-10, 15-17, and 22-24. Patients also receive ketoconazole PO TID on days 1-24 and therapeutic hydrocortisone PO BID on days -1 to 24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive calcitriol and therapeutic hydrocortisone as in phase I. Patients also receive ketoconazole PO TID on days 4-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9753628|NCT00537017|Experimental|Preladenant 5 mg BID|Preladenant 5 mg twice daily (BID) given open-label for 36 weeks to participants with moderate to severe Parkinson's Disease who are on a long-term and stable L-dopa treatment regimen.
9753629|NCT00537030|Experimental|Treatment (chemotherapy)|Patients receive 6 doses of Erwinia asparaginase IM on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.
9753630|NCT00537056|Experimental|F-18 FDG PET/CT and DCE MRI|FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po
9753631|NCT00537082|Experimental|FTY720 0.5 mg|FTY720
9753632|NCT00537082|Experimental|FTY720 1.25 mg|FTY720
9753633|NCT00537082|Placebo Comparator|Placebo|
9753634|NCT00537095|Experimental|vandetanib (ZD6474)|vandetanib (ZD6474) 300 mg per os once daily
9753635|NCT00537095|Placebo Comparator|Placebo|Placebo
9753636|NCT00537238|Active Comparator|B|
9753637|NCT00537238|Active Comparator|A|
9753638|NCT00537277|Experimental|BIAsp 30|Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).
9753639|NCT00537290|Experimental|Rituximab|All patients will receive 1000 milligrams of rituximab by intravenous infusion on Days 1 and 15.
9753640|NCT00537303|Experimental|Advanced|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
9753641|NCT00537303|Active Comparator|Basic|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
9753642|NCT00537316|Experimental|Infliximab (IFX)|Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
9753643|NCT00537316|Active Comparator|Azathioprine (AZA)|AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).
9753644|NCT00537316|Experimental|IFX/AZA|IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
9753645|NCT00537316|Experimental|Maintenance IFX/AZA (during Part 2)|Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
9830789|NCT02584140|Other|AEGIS|All participants will be assigned to this arm of the study.
9753646|NCT00537316|Experimental|Maintenance IFX (during Part 2)|Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.
9753647|NCT00537316|Experimental|Intermittent IFX/AZA (during Part 2)|Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
9753648|NCT00537316|Experimental|Intermittent IFX (during Part 2)|Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
9753649|NCT00537329|Other|Open|This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.
9753650|NCT00537381|Active Comparator|Docetaxel + Prednisone + Placebo|Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
9753651|NCT00537381|Experimental|Docetaxel + Prednisone + Intetumumab|Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
9753652|NCT00537394|Experimental|A|Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
9753653|NCT00537394|Experimental|B|Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
9753654|NCT00537394|Other|C|Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
9753655|NCT00537407|Experimental|Treatment Arm A|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
9753656|NCT00537407|Experimental|Treatment Arm B|Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
9753657|NCT00537407|Experimental|Treatment Arm C|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
9753658|NCT00537407|Experimental|Treatment Arm D|Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
9753659|NCT00537407|Experimental|Treatment Arm E|Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
9753660|NCT00537485|Experimental|1|
9753661|NCT00537485|Placebo Comparator|2|
9753662|NCT00537511|Experimental|Dose-finding arm: Pomalidomide + Cisplatin + Etoposide|Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m^2 and IV etoposide 100 mg/m^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
9753663|NCT00537576|Experimental|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
9753664|NCT00537576|Experimental|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
9753665|NCT00537576|Experimental|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
9753666|NCT00537576|Placebo Comparator|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
9830790|NCT02584257|Placebo Comparator|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols and one actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
9830791|NCT02584257|Active Comparator|90 mcg ProAir HFA|90 mcg of ProAir HFA: 1 actuation each from ProAir HFA inhalation aerosol and the placebo ProAir HFA inhalation aerosol and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
9830792|NCT02584257|Active Comparator|180 mcg ProAir HFA|180 mcg of ProAir HFA: 1 actuation each from 2 different ProAir HFA inhalation aerosols and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
9830793|NCT02584257|Experimental|90 mcg Lupin albuterol HFA MDI|90 mcg of Lupin albuterol HFA MDI product: 1 actuation each from the Lupin albuterol HFA MDI inhalation aerosol and the placebo Lupin albuterol HFA MDI inhalation aerosol and 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols
9830794|NCT02584257|Experimental|180 mcg Lupin albuterol HFA MDI|180 mcg of Lupin albuterol HFA MDI: 1 actuation each from 2 different Lupin albuterol HFA MDI inhalation aerosols and 1 actuation each from 2 different placebo ProAir HFA product inhalation aerosols
9830795|NCT02584452|Active Comparator|Continuous Adductor Canal Nerve Catheter|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
9830796|NCT02584452|Active Comparator|Long Acting Single Bolus Adductor Canal Nerve Block|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
9830797|NCT02584504|Experimental|Alirocumab 150 mg Q4W|Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)
9830798|NCT02584504|Experimental|Alirocumab 150 mg Q2W|In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
9830799|NCT02584504|Placebo Comparator|Placebo Q2W|In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
9830800|NCT02584608|Experimental|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
9830801|NCT02584660|Experimental|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
9830802|NCT02584660|Experimental|local Standard-of-care|Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
9753667|NCT00537576|Placebo Comparator|Medium dose Placebo applicator|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
9753668|NCT00537576|Placebo Comparator|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
9753669|NCT00537680|Experimental|1|mid dose Idebenone
9753670|NCT00537680|Experimental|2|high dose Idebenone
9753671|NCT00537680|Placebo Comparator|3|
9753672|NCT00537745|Experimental|Vivitrol|Vivitrol 380 mg/monthly, plus individual compliance enhancement therapy (Medication Management Therapy).
9753673|NCT00537771|Experimental|1|Anastrozole (ARIMIDEX)
9753674|NCT00537771|Active Comparator|2|Tamoxifen
9753675|NCT00537810|Experimental|Sibutramine|Sibutramine 15 mg daily
9753676|NCT00537810|Placebo Comparator|Placebo|Placebo Daily
9753677|NCT00537810|Experimental|Placebo/CBTsh|Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
9753678|NCT00537810|Experimental|Sibutramine/CBTsh|Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
9753679|NCT00537823|Experimental|Arm 1 - Wildtype|"Neoadjuvant therapy~Week 1~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly~Weeks 3, 5, 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Week 1, 3, 5, 7, 9, 11, 13, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8, 10, 12, 16~*Cetuximab 250 mg/m^2 IV weekly"
9753680|NCT00537823|Experimental|Arm 2 K-Ras 12/13 codon mutation|"Neoadjuvant Therapy~Weeks 1, 3, 5~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Weeks 1, 3, 5, 9, 11, 13~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2"
9753681|NCT00537940|Active Comparator|A|
9753682|NCT00537940|Active Comparator|B|
9753683|NCT00537979|Active Comparator|Paricalcitol injection|ABT-358 Zemplar
9753684|NCT00537979|Active Comparator|Paricalcitol capsules|ABT-358 Zemplar
9753685|NCT00538213|Experimental|Adjuvanted influenza vaccine GSK576389A Group|Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A.
9753686|NCT00538213|Active Comparator|Fluarix young Group|Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
9830803|NCT02584673|Experimental|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
9753687|NCT00538213|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
9753688|NCT00538291|Experimental|Arm 1|Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.
9753689|NCT00538304|Experimental|1|bimatoprost eye drops
9753690|NCT00538304|Placebo Comparator|2|placebo
9753691|NCT00538434|Experimental|Reslizumab 1 mg/kg|reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
9753692|NCT00538434|Experimental|Reslizumab 2 mg/kg|reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
9753693|NCT00538434|Experimental|Reslizumab 3 mg/kg|reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
9753694|NCT00538434|Placebo Comparator|Placebo|saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
9753695|NCT00538473|Experimental|FluAS25 (GSK576389A) Group|Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
9753696|NCT00538473|Active Comparator|Fluarix Group|Subjects received 1 dose of Fluarix™.
9753697|NCT00538512|Active Comparator|TIV|the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
9753698|NCT00538512|Active Comparator|LAIV|live-attenuated influenza vaccine Flumist, manufactured by MedImmune
9753699|NCT00538512|Placebo Comparator|Placebo|Physiologic saline administered as a nasal spray or intramuscular injection
9753700|NCT00538590|Active Comparator|MITOMYCIN-C|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
9753701|NCT00538590|Experimental|ologen (Oculusgen)|20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
9753702|NCT00538616|Active Comparator|Precedex-Propofol|Patients received an infusion of precedex for six hours and then a washout and then a propofol infusion for six hours.
9753703|NCT00538616|Active Comparator|Propofol- Precedex|Patients received an infusion of propofol for six hours and then a washout and then a precedex infusion for six hours.
9753704|NCT00538629||Schizophrenia|Patients with schizophrenia
9753705|NCT00538629||Bipolar disorder|Patients with bipolar disorder
9753706|NCT00538642|No Intervention|Stay on current antipsychotic|Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated.
9753707|NCT00538642|Active Comparator|ziprasidone treatment|Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.
9753708|NCT00538681|Experimental|Enzastaurin + Pemetrexed + Cisplatin|
9753709|NCT00538681|Placebo Comparator|Placebo + Pemetrexed + Cisplatin|
9753710|NCT00538733|Experimental|T-BiRD Therapy|"All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).~After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.~Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.~Patients in CR/sCR or that achieve a plateau of disease for > 2 cycles on BiRD or T-BiRD therapy will receive maintenance."
9753711|NCT00538759|Experimental|EBRT|External beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
9753712|NCT00538759|Sham Comparator|Control|Sham external beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
9753713|NCT00538785|Experimental|Motavizumab|Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
9753714|NCT00538785|Active Comparator|Pailvizumab|Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
9753715|NCT00538824|Experimental|DexTR (all patients)|All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.
9753716|NCT00538850|Experimental|Fentanyl sublingual spray|Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.
9830804|NCT02584673|No Intervention|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
9753717|NCT00538863|Experimental|Fentanyl sublingual spray titration|Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.
9753718|NCT00538863|Experimental|Fentanyl sublingual spray maintenance|Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.
9753719|NCT00538902|Placebo Comparator|Placebo|Placebo administered subcutaneously every other week
9753720|NCT00538902|Experimental|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously every other week
9753721|NCT00538902|Experimental|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week
9753722|NCT00538915|Experimental|Nabi-IGIV Infused Every 3- or 4-Weeks|
9753723|NCT00539006|Active Comparator|FFNS, FPNS|active compound
9753724|NCT00539006|Active Comparator|FPNS, FFNS|active compound
9753725|NCT00539006|Placebo Comparator|placebo FFNS, placebo FPNS|placebo arm
9753726|NCT00539006|Placebo Comparator|placebo FPNS, placebo FFNS|placebo arm
9753727|NCT00539032|Experimental|Group 1: Menactra® Booster Group|Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
9753728|NCT00539032|Experimental|Group 2: Menactra® Primary Vaccine (Control) Group|Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.
9753729|NCT00539110|Experimental|zolpidem|zolpidem or ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
10201939|NCT05191108|Experimental|The Effect of mİNDFULNESS Stress Reduction Program on Premenstrual Symptoms|In order to prevent bias in the study groups, the Introductory Information Form and PMSS scale will be applied via online Google forms. Participants who meet the criteria will be randomly assigned to the mindfulness stress reduction group (Group 1) and control group (Group 2) in the number determined by power analysis and a simple random number generator program (www.random.org). These experimental and control groups will be recorded by the researchers as a list. Participants participating in the study will be informed about the mindfulness stress reduction application, but they will not be informed about what the mindfulness stress reduction application does (single-blind method). These participants will be asked to sign the consent form by expressing that they can withdraw from the study at any time.
9753730|NCT00539110|Active Comparator|ramelteon|ramelteon or zolpidem dosed at 2200 and 0200 per the feeding tube depending on randomization
9753731|NCT00539188|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment
9753732|NCT00539188|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
9753733|NCT00539240|Placebo Comparator|Rabeprazole morning/evening placebo bedtime|AciPhex 20 mg BID and once daily placebo
9753734|NCT00539240|Placebo Comparator|Rabeprazole breakfast, placebo dinner and bedtime|AcipHex 20 mg once daily and BID placebo
9753735|NCT00539240|Active Comparator|Rabeprazole breakfast, placebo dinner, nortriptyline bedtime|AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
9753736|NCT00539253|Other|Gadobenate Dimeglumine (Multi Hance)|If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
9753737|NCT00539279|Experimental|Prolonged Exposure Therapy (PE)|Prolonged Exposure Therapy (PE)
9753738|NCT00539279|Active Comparator|Relaxation Training (RT)|Relaxation Training (RT)
9753739|NCT00539305|Experimental|Study drug; testosterone transdermal gel|Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
9753740|NCT00539305|Placebo Comparator|2|
9753741|NCT00539500|Experimental|Transplantation CD133+ cells|Stem Cell Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan
9753742|NCT00539513|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
9753743|NCT00539513|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
9753744|NCT00539526|Experimental|1|bimatoprost 0.03%
9753745|NCT00539526|Active Comparator|2|travoprost 0.004%
9753746|NCT00539526|Active Comparator|3|latanoprost 0.005%
9830805|NCT02584686|Experimental|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
10201940|NCT05190783|Experimental|formocresol pulpotomy|gold standard arm which pulpotomy will be done with formocresol
10201941|NCT05190783|Active Comparator|formocresol partial pulpotomy|partial pulpotomy will be done with formocresol
10201942|NCT05190783|Active Comparator|MTA pulpotomy|in this group complete pulpotomy will be done with MTA
10201943|NCT05190783|Active Comparator|MTA partial pulpotomy|in this study group partial pulpotomy will be done with MTA
10201944|NCT05190783|Active Comparator|pulpotomy with Theracal LC|in this study group complete pulpotomy will be done with Theracal LC
10201945|NCT05190783|Active Comparator|partial pulpotomy with Theracal LC|in this study group partial pulpotomy technique will be done with Theracal LC
9830806|NCT02584686|Placebo Comparator|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
9830807|NCT02584725|Active Comparator|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
9830808|NCT02584725|Active Comparator|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
9830809|NCT02584725|Active Comparator|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
9830810|NCT02584790|Other|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
9830811|NCT02584855|Experimental|Ixekizumab Open Label|Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
9830812|NCT02584855|Experimental|Ixekizumab|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse)."
9830813|NCT02584855|Placebo Comparator|Placebo|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)"
9830814|NCT02584855|Experimental|IXE80Q2W Non-randomized|"Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period."
9830815|NCT02584868|Experimental|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
9830816|NCT02584868|Active Comparator|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
9830817|NCT02584959|Experimental|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
9830818|NCT02584959|Experimental|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
9830819|NCT02584959|Experimental|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
9830820|NCT02584998|No Intervention|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
9830821|NCT02584998|Active Comparator|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
9753747|NCT00539539|Active Comparator|Feedback On|Automated real-time feedback on CPR Process activated
9753748|NCT00539539|No Intervention|Feedback Off|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
9753749|NCT00539656|Experimental|Receive two cord blood units|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
9753750|NCT00539695|Experimental|IL2 Administration|"SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.~Time will be measured as 'week beginning with first IL-2 injection.'~T cell Induction via IL-2 to reduce GVHD"
9753751|NCT00539864|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~135μg total"
9753752|NCT00539864|Active Comparator|TIV (Fluzone)|"Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~45μg total~(Fluzone, sanofi pasteur)"
9753753|NCT00539942|Active Comparator|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
9753754|NCT00539942|Experimental|Arixtra (fondaparinux sodium)|Patients randomized to treatment arm will initiate Arixtra (fondaparinux sodium) treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
9753755|NCT00539994|Experimental|Treatment B|200mg BID retapamulin 5 days
9753756|NCT00539994|Placebo Comparator|Treatment C|200mg BID placebo 5 days
9753757|NCT00539994|Experimental|Treatment A|200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days
9753758|NCT00540007|Experimental|Cohort 1 - Lenalidomide daily on days 1-21|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-21 of a 28 day cycle."
9753759|NCT00540007|Experimental|Cohort 2 - Lenalidomide daily on days 1-28|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-28 of a 28 day cycle."
9753760|NCT00540046|Active Comparator|A/Immediate|The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure
9753761|NCT00540046|Active Comparator|B/Delayed|The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.
9753762|NCT00540124|Experimental|Tadalafil|
9753763|NCT00540124|Placebo Comparator|Placebo|
9753764|NCT00540124|Active Comparator|Tamsulosin|
9753765|NCT00540228|Experimental|GSK1247446A 1 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9753766|NCT00540228|Experimental|GSK1247446A 2 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9753767|NCT00540228|Experimental|GSK1247446A 3 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9753768|NCT00540228|Experimental|GSK1247446A 4 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9753769|NCT00540228|Active Comparator|Fluarix Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9753770|NCT00540293|Experimental|Treatment group|this patient group consists of dyslipidemia patients with various CVD risk factors
9753771|NCT00540423|Experimental|SB-497115-GR group|Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
9753772|NCT00540423|Placebo Comparator|placebo group|Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
9753773|NCT00540436|Experimental|GSK1325760A|Single arm safety and efficacy
9753774|NCT00540449|Active Comparator|Efavirenz|Efavirenz 600mg once daily for 96 weeks
9753775|NCT00540449|Experimental|TMC278|TMC278 25 mg tablet once daily for 96 weeks
9753776|NCT00540514|Experimental|Albumin-bound paclitaxel + Carboplatin|Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
9753777|NCT00540514|Active Comparator|Paclitaxel + Carboplatin|Participants received 200 mg/m^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
9753778|NCT00540579|Experimental|Intervention|All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
9753779|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 1 Group|Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
9753780|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 2 Group|Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
9753781|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 3 Group|Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
9753782|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 4 Group|Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
9753783|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 5 Group|Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
9753784|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 6 Group|Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
9753785|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 7 Group|Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
9753786|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 8 Group|Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
9753787|NCT00540592|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received one dose of Fluarix vaccine.
9753788|NCT00540592|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received one dose of Fluarix vaccine.
9753789|NCT00540644|Experimental|Revlimid, Cyclophosphamide, Prednisone|"Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Prednisone every other day orally."
9753790|NCT00540722|Experimental|Treatment (R-(-)-gossypol acetic acid)|"Patients receive oral R-(-)-gossypol once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Patients undergo tumor tissue and blood sample collection at baseline and periodically during study for biomarker correlative studies. Archived tumor tissue samples, if available, are analyzed for Bcl-2 family protein expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain for BH3 members only) and MGMT gene methylation status. Blood samples are analyzed for apoptotic protein levels (Bcl-2) by enzyme-linked immunosorbent assay."
9753791|NCT00540982|Experimental|Normal Liver Function|
9753792|NCT00540982|Experimental|Mild Liver Dysfunction|
9753793|NCT00540982|Experimental|Moderate Liver Dysfunction|
9753794|NCT00540982|Experimental|Severe Liver Dysfunction|
9753795|NCT00541034|Experimental|cyclophosphamide, pentostatin & rituximab|Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9753796|NCT00541099|Experimental|Avastin & Docetaxel|Avastin 10.0 mg/kg on days 1 and 15; Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel; Docetaxel 35 mg/m2 on day 1, 8, 15
9984717|NCT03796832|Active Comparator|Stable Supportive Shoes+Exercise Therapy|This arm will wear Stable Supportive Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
9984718|NCT03795883||Participants with atrial fibrillation|Patients with atrial fibrillation admitted for standard pulmonary vein ablation.
9753797|NCT00541190|Experimental|cystic fibrosis|Cystic fibrosis patients
9753798|NCT00541190|Experimental|healthy controls|Healthy control subjects
9753799|NCT00541229|Experimental|1|sitagliptin 100 mg
9753800|NCT00541229|Experimental|2|sitagliptin 200 mg
9753801|NCT00541229|Placebo Comparator|3|Placebo
9753802|NCT00541242|Active Comparator|1|bimatoprost 0.03% eye drops
9753803|NCT00541242|Active Comparator|2|latanoprost 0.005% eye drops
9753804|NCT00541307|Experimental|GORE VIABHAN Endoprothesis|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
9753805|NCT00541346|Experimental|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
9753806|NCT00541385|Experimental|PA group|"Oral pyronaridine/artesunate (PA, 60:20mg granules) once a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
9753807|NCT00541385|Active Comparator|AL group|"Oral artemether/lumefantrine (AL, 20:120mg crushed tablets) twice a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
9753808|NCT00541450|Experimental|Sita/Met FDC|"In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone."
9753809|NCT00541450|Active Comparator|Pioglitazone|"In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks)."
9753810|NCT00541593|Experimental|NOTES pancreatic pseudocystgastrostomy|Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.
9753811|NCT00541658|Active Comparator|5 mg Before Breakfast|5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
9753812|NCT00541658|Experimental|35 mg After Breakfast|35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
9753813|NCT00541658|Experimental|35 mg Before Breakfast|35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)
9753814|NCT00541671|Placebo Comparator|1|Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
9753815|NCT00541671|Active Comparator|2|Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
9753816|NCT00541775|Experimental|Sitagliptin|sitagliptin 100 mg
9753817|NCT00541775|Active Comparator|Rosiglitazone|rosiglitazone 8 mg
9753818|NCT00541775|Placebo Comparator|Placebo|placebo
9753819|NCT00541866|Experimental|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A:~Schedule B:~Expansion Phase~Schedule A:~Schedule B:"
9753820|NCT00541931|Other|Nonsmoker|Nonsmokers Intervention: Dietary Supplement: LifePak Nano
9753821|NCT00541931|Other|Smoker|Smoker arm Intervention: Dietary Supplement: LifePak Nano
9753822|NCT00541970|Experimental|Cervarix 1/Placebo Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
9753823|NCT00541970|Experimental|Cervarix 1/Placebo/Cervarix 1 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
9753824|NCT00541970|Experimental|Cervarix 2/Placebo/Cervarix 2 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
9753825|NCT00541970|Experimental|Cervarix 2 Group|Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
9753826|NCT00542178|Experimental|Intensive glycemia control|A strategy of intensive glycemia treatment to HbA1c less than 6%
9753827|NCT00542178|Active Comparator|Standard glycemia control|A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
9753828|NCT00542178|Experimental|Intensive BP control|A strategy of BP treatment for SBP less than 120 mm Hg
9753829|NCT00542178|Active Comparator|Standard BP control|A strategy of BP treatment for SBP less than 140 mm Hg
9753830|NCT00542178|Experimental|Fibrate|Blinded fenofibrate + simvastatin 20-40 mg/d
9753831|NCT00542178|Placebo Comparator|Fibrate Placebo|Blinded placebo + simvastatin 20-40 mg/d
9753832|NCT00542191|Experimental|Neoadjuvant metronomic AC followed by weekly TC|Neoadjuvant chemotherapy with metronomic AC followed by weekly TC then surgery
9753833|NCT00542269|Experimental|Aliskiren / ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
9753834|NCT00542269|Experimental|Aliskiren / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
9753835|NCT00542269|Active Comparator|Ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
9753836|NCT00542308|Experimental|Zalutumumab 4-16 mg/kg|Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
9753837|NCT00542321|Experimental|Kinetic Therapy Bed|Kinetic Therapy Bed: Continuous automated turning to 45 degrees with head of the bed elevated 30 degrees or more for up to 7 continuous days
9753838|NCT00542321|Active Comparator|Manual Turn|Manual Turn: lateral rotation every 2 hours from back to left to back to right to back, with >/= 45 degree lateral rotation angle and 30 degree head of bed elevation
9753839|NCT00542386|Experimental|1|
9753840|NCT00542386|Placebo Comparator|2|
9753841|NCT00542425|Placebo Comparator|Placebo|
9753842|NCT00542425|Experimental|BA058 20 µg|
9753843|NCT00542425|Experimental|BA058 40 µg|
9753844|NCT00542425|Experimental|BA058 80 µg|
9753845|NCT00542425|Active Comparator|teriparatide|
9753846|NCT00542490|Experimental|Vaginal Cuff Brachytherapy|
9753847|NCT00542620|Experimental|Mixed injection|
9753848|NCT00542620|Active Comparator|Separate injection|
9753849|NCT00542750|Experimental|N-Acetylcysteine|All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
9753850|NCT00542789|Placebo Comparator|1|Placebo
9753851|NCT00542789|Experimental|2|Esomeprazole 20 mg
9753852|NCT00542815|Experimental|1|
9753853|NCT00542815|Active Comparator|2|
9753854|NCT00542828|Experimental|Thymoglobulin|
9753855|NCT00542880|Experimental|Symbicort Turbuhaler First, then Seretide Diskus|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg
9753856|NCT00542880|Experimental|Seretide Diskus First, then Symbicort Turbuhaler|Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
9753857|NCT00542919|Experimental|T-Cell|T-Cell (TCL): Peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Participants received enzastaurin 1125 milligram (mg) loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
9753858|NCT00542919|Experimental|Indolent B-Cell|Indolent B-Cell (IBCL): Small lymphocytic lymphoma, follicular lymphoma (Grade 1 or 2) and marginal zone lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
9753859|NCT00542919|Experimental|Aggressive B-Cell|Aggressive B-Cell (ABCL): Primary central nervous system (CNS) lymphoma, follicular lymphoma (Grade 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
9753860|NCT00542971|Experimental|Sorafenib + Idarubicin + Ara-C|Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m^2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m^2 IV over 24 hours daily (days 1-4)
9753861|NCT00542997|Experimental|IgPro20|
9753862|NCT00543062|Other|Treatment Sequence ABCD|Treatment Sequence ABCD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
9753863|NCT00543062|Other|Treatment Sequence BDAC|Treatment Sequence BDAC where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
9753864|NCT00543062|Other|Treatment Sequence CABD|Treatment Sequence CABD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
9753865|NCT00543062|Other|Treatment Sequence DCBA|Treatment Sequence DCBA where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
9753866|NCT00543101|Active Comparator|Switch to DRV/r|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
9753867|NCT00543101|Active Comparator|Continue on Current Dual Boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and are followed for an additional 24 weeks
9753868|NCT00543127|Experimental|Fulvestrant + Anastrozole|Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
9753869|NCT00543127|Active Comparator|Anastrozole|Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.
9753870|NCT00543140|Other|REALIZE™ Swedish Adjustable Gastric Band|All subjects have the REALIZE™ Swedish Adjustable Gastric Band. Single arm - no comparator.
9753871|NCT00543296|Experimental|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
9753872|NCT00543309|Experimental|I- nesiritide|Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
9753873|NCT00543309|Active Comparator|II- Milrinone|Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
9753874|NCT00543309|Placebo Comparator|III- placebo|Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
9753875|NCT00543387|Experimental|MK-5108 200 mg BID (Panel 1)|Participants receive 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
9753876|NCT00543387|Experimental|MK-5108 400 mg BID (Panel 1)|Participants receive 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
9753877|NCT00543387|Experimental|MK-5108 800 mg BID (Panel 1)|Participants receive 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
9753878|NCT00543387|Experimental|MK-5108 1200 mg BID (Panel 1)|Participants receive 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
9753879|NCT00543387|Experimental|MK-5108 1500 mg BID (Panel 1)|Participants receive 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
9753880|NCT00543387|Experimental|MK-5108 1800 mg BID (Panel 1)|Participants receive 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
9753881|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
9753882|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
9753883|NCT00543387|Experimental|MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
9753884|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
9753885|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
9753886|NCT00543400|Active Comparator|70 U/kg of unfractionated heparin given IV|Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
9753887|NCT00543400|Experimental|50 IU/KG of M118|Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
9753888|NCT00543400|Experimental|75 IU/KG of M118|Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
9753889|NCT00543400|Experimental|100 IU/KG of M118|Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
9753890|NCT00543439|Experimental|1|On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
9753891|NCT00543439|Experimental|2|Routine Prophylaxis Crossover
9753892|NCT00543543|Experimental|Low-dose V503|V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
9753893|NCT00543543|Experimental|Mid-dose V503|V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
9753894|NCT00543543|Experimental|High-dose V503|V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
9753895|NCT00543543|Active Comparator|Gardasil|Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
9753896|NCT00543569|Active Comparator|Tacrolimus/MMF/Basiliximab|Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
9753897|NCT00543569|Experimental|Alefacept QW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
9753898|NCT00543569|Experimental|Alefacept QW/Tacrolimus|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
9753899|NCT00543569|Experimental|Alefacept QOW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
9753900|NCT00543725|Active Comparator|002|efavirenz 600 mg tablet once daily for 96 weeks
9753901|NCT00543725|Experimental|001|TMC278 25 mg tablet once daily for 96 weeks
9753902|NCT00543764||Pre pathway|Pre pathway
9753903|NCT00543764||Post pathway|Post pathway
9753904|NCT00543777|Experimental|MRE + 2PD MRI|MRE - Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue. 2PD MRI - Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
9753905|NCT00543855|Experimental|3 mg Donepezil hydrochloride|
9753906|NCT00543855|Experimental|5 mg Donepezil hydrochloride|
9753907|NCT00543855|Experimental|10 mg Donepezil hydrochloride|
9753908|NCT00543855|Placebo Comparator|Placebo|
9753909|NCT00543985|Experimental|Stress Echocardiography|Echocardiography was performed prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
9753910|NCT00544076|Experimental|Sildenafil Citrate/Mo+Aprostadil/day|Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
9753911|NCT00544076|Active Comparator|Sildenafil Citrate Monthly|Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
9753912|NCT00544076|Experimental|Daily Sildenafil Citrate|Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
9753913|NCT00544167|Experimental|Intervention|All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated.
9753914|NCT00544440|Experimental|Abiraterone acetate plus prednisone|Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
9753915|NCT00544544|Experimental|Riluzole|Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.
9753916|NCT00544557||Patients with Ankylosing Spondylitis|
9753917|NCT00544648|Experimental|Treatment|nab-paclitaxel+ carboplatin + radiation
9753918|NCT00544674|Experimental|PR104|PR104 will be administered once every 21 days by IV
9830822|NCT02584998|Active Comparator|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
9830823|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
9830824|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
9830825|NCT02585700|Experimental|Vaccine|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~X-181 reassortant of H1/A/California/7/2009~X-223A reassortant of H3/A/Texas/50/2012."
9830826|NCT02585700|Placebo Comparator|Placebo|0.5 mL of phosphate buffered saline
9830827|NCT02585713|Experimental|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
9830828|NCT02585713|Experimental|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
9830829|NCT02585778|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
9830830|NCT02585778|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.
9830831|NCT02585843|Experimental|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
9830832|NCT02585843|Active Comparator|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
9830833|NCT02585895|Experimental|Evolocumab|Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
9830834|NCT02585895|Active Comparator|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
9830835|NCT02585934|Experimental|RVT-101|RVT-101 adjunct to 5 mg or 10 mg donepezil
9830836|NCT02585934|Placebo Comparator|Placebo|Placebo adjunct to 5 mg or 10 mg donepezil
9830837|NCT02585960|Experimental|Pharmacokinetic (PK) evaluation of BAX 855|Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.
9830838|NCT02585960|Experimental|FVIII trough target 1-3%|Standard treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 1-3%
9830839|NCT02585960|Experimental|FVIII trough target 8-12%|Intensified treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 8-12%
9830840|NCT02585999|Other|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
9830841|NCT02586012|Experimental|TBW, LBM, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).
9984719|NCT03795883||Participants without atrial fibrillation|Patients without atrial fibrillation admitted for standard left sided supra ventricular tachycardia ablation or patients admitted to mitral clip procedure.
9753919|NCT00544713|Experimental|Carboxymethylcellulose and Glycerin based artificial tear|Carboxymethylcellulose and Glycerin based artificial tear
9753920|NCT00544713|Active Comparator|Carboxymethylcellulose based artificial tear|Carboxymethylcellulose based artificial tear
9753921|NCT00544778|Experimental|Arm 1|High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.
9753922|NCT00544817|Experimental|Combination Therapy|"In the combined modality portion of the study, patients were administered:~Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily~Patients took a four week break before beginning follow-up systemic therapy:~Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
9753923|NCT00544869|Experimental|1|
9753924|NCT00544882|Experimental|DR-1021|After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
9753925|NCT00544882|Active Comparator|Mircette|After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
9753926|NCT00544908|Experimental|Dasatinib|Dasatinib 70 mg po bid (1 cycle=28 days)
9753927|NCT00545025|Experimental|GSK1247446A Group|Subjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
9753928|NCT00545025|Active Comparator|Fluarix Group|Subjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
9753929|NCT00545051|Experimental|Ibandronate|Participants received monthly oral ibandronate (150 milligrams [mg]) for 12 months.
9753930|NCT00545051|Placebo Comparator|Placebo|Participants received monthly oral placebo for 12 months.
9753931|NCT00545077|Active Comparator|Arm A: Endocrine Therapy (ET)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
9753932|NCT00545077|Experimental|Arm B: ET with Bevacizumab (ET-B)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
9753933|NCT00545103|Experimental|SPD476 (1.2 g)|
9753934|NCT00545103|Experimental|SPD476 (2.4 g)|
9753935|NCT00545103|Experimental|SPD476 (4.8 g)|
9753936|NCT00545103|Placebo Comparator|Placebo|
9753937|NCT00545155||Geriatric EMS Patients|Cohort for reliability and concurrent validity testing.
9753938|NCT00545168|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
9753939|NCT00545168|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
9753940|NCT00545168|Active Comparator|C - NIX|Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
9753941|NCT00545181|Experimental|Metronidazole plus gel|Receive metronidazole plus vaginal gel
9753942|NCT00545181|Active Comparator|Control- metronidazole alone|Oral Metronidazole antibiotic therapy alone
9753943|NCT00545233|Experimental|PEG-INF alpha-2a + ribavirin+ pioglitazone|Participants received pioglitazone in a 16 week run-in period (30 mg per day orally for 8 weeks followed by 45 mg per day orally for 8 weeks). Participants then received piogliatzone 45 mg daily orally plus 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase. Participants received 45 mg of pioglitazone per day orally in the 24 week follow-up period.
9753944|NCT00545233|Active Comparator|PEG-INF alpha-2a + ribavirin|Participants received 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase followed by a treatment free 24 week follow-up period.
9984720|NCT03794726|Active Comparator|Orthodontic Molar Protraction|Molar protraction using orthodontic tooth movement alone
9753945|NCT00545272|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9753946|NCT00545272|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9753947|NCT00545272|Experimental|indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9753948|NCT00545272|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9753949|NCT00545272|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9753950|NCT00545272|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9753951|NCT00545298|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only
9753952|NCT00545298|Experimental|B Same treatment for 6 weeks|200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
9753953|NCT00545298|Experimental|C - modified treatment, 5 wks lower dose|200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
9753954|NCT00545363|Experimental|Bone Marker Feedback (BMF) Participants|"Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A BMF-form will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake."
9753955|NCT00545363|Active Comparator|No BMF Participants|Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants will be supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
9753956|NCT00545402|Experimental|MMF, Adjusted Dose; Tacrolimus; Corticosteroids|Participants received mycophenolate mofetil (MMF) 3 grams per day (g/d), orally (PO), twice per day (BID) with meals from Day 0 to Day 4; the dose was adjusted based on total exposure (AUC) using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12. Participants also received tacrolimus adjusted to a target trough level of 8 to (-) 12 nanograms per milliliter (ng/mL) from Day 0 to Month 1; the dose was adjusted to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 milligrams per kilogram (mg/kg), intravenously (IV), pre-operation on Day 0.
9753957|NCT00545402|Active Comparator|MMF, Standard Dose; Tacrolimus; Corticosteroids|Participants received MMF 2 g/d, PO, BID with meals from Day 0 to Month 12. Participants also received tacrolimus adjusted to a target trough level of 8-12 ng/mL from Day 0 to Month 1; the dose was reduced to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 mg/kg, IV, pre-operation on Day 0; followed by 20 mg/d, PO, 4 times per day (QDS) from Day 0 through Month 1; 15 mg/d, PO, 3 times per day (TID) from the end of Month 1 through Month 2; 10 mg/d, PO, BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
9753958|NCT00545441|Experimental|1|Surgisis® AFP
9753959|NCT00545441|Active Comparator|2|Flap
9753960|NCT00545532|Experimental|Conventional dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
9753961|NCT00545532|Experimental|Double dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
9984721|NCT03794726|Experimental|Orthodontic Molar Protraction and PAOO|Molar protraction using orthodontic tooth movement and adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO)
9753962|NCT00545571|Experimental|Mircera in Renal Anemia|Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
9782741|NCT01184118|No Intervention|FP Discontinued|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
9782742|NCT01184118|Active Comparator|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
9782743|NCT01184326|Experimental|Dose Level 0: Everolimus 5mg + Pazopanib 600 mg|Everolimus 5mg + Pazopanib 600 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
9782744|NCT01184326|Experimental|Dose Level -1: Everolimus 5mg + Pazopanib 400 mg|Everolimus 5mg + Pazopanib 400 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
9782745|NCT01184326|Experimental|All Phase I Dose Expansion Participants|All phase I dose expansion participants received Everolimus 5mg and Pazopanib at the maximum tolerated dose established in the dose finding part of the study.
9782746|NCT01184326|Experimental|All Phase I Participants|All phase I participants received Everolimus 5mg and Pazopanib according to the established dose escalation schedule or the maximum tolerated dose established in the dose finding part of the study.
9782747|NCT01184417|Active Comparator|Phenobarbital group|10 mg/kg IV phenobarbital in 100 ml saline
9782748|NCT01184417|Placebo Comparator|Placebo group|100 ml saline
9782749|NCT01184508|Experimental|LY2300559|
9782750|NCT01184508|Placebo Comparator|Placebo|
9782751|NCT01184755|Experimental|Resperate device used for 8 weeks|Participants to use Resperate device to guide breathing for 8 weeks. After the primary 8-week trial, this group is divided into two subgroups to examine 16-week data: one subgroup that stops using the device after 8 weeks, and one asked to continue to use the device for the full 16 weeks.
9782752|NCT01184755|Active Comparator|Relaxation control device|Participants use modified device to pace breathing in the 13/minute range for daily practice for 8 weeks and no device thereafter
9782753|NCT01184755|No Intervention|Usual Care|Participants continue their usual medication and other management for their hypertension. All participants (including UC) are given a home BP monitor and asked to take their BP in morning and evening 3 days/week.
9782754|NCT01184846|Experimental|IgPro10|10% liquid formulation of human immunoglobulin (IgPro10). IgPro10 will be administered by IV infusion as one induction dose of 2 g/kg body weight (bw), followed by seven 3-weekly maintenance doses of 1 g/kg bw.
9782755|NCT01184859|Experimental|Desmopressin 10µg|Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.
9782756|NCT01184859|Experimental|Desmopressin 25µg|Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.
9782757|NCT01184859|Experimental|Desmopressin 50µg|Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
9782758|NCT01184859|Experimental|Desmopressin 100µg|Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.
9782759|NCT01184859|Placebo Comparator|Placebo|Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.
9782760|NCT01184872|Experimental|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
9782761|NCT01184872|Active Comparator|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
9830842|NCT02586012|Experimental|LBM, IBW, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).
9830843|NCT02586012|Experimental|IBW, TBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
9830844|NCT02586012|Experimental|TBW, IBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
9830845|NCT02586012|Experimental|LBM, TBW, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).
9830846|NCT02586012|Experimental|IBW, LBM, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).
9830847|NCT02586064|Experimental|Interpersonal Psychotherapy for PTSD|Relationally-focused intervention addressing PTSD symptoms and relationship dysfunctions, 12 weekly sessions
9830848|NCT02586064|Active Comparator|Prolonged Exposure|Exposure based intervention including exposure to memories and avoided places and activities
9830849|NCT02586077|Experimental|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
9830850|NCT02586155|Experimental|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
9830851|NCT02586155|Active Comparator|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
9830852|NCT02586233|Experimental|DS-1040b|Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
9830853|NCT02586233|Placebo Comparator|Placebo|Participants who will be randomized to receive intravenous (IV) infusion of placebo.
9830854|NCT02586415|Active Comparator|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.~Devices approved for use in DEFUSE 3:~Trevo Retriever~Solitaire™ FR Revascularization Device~Penumbra thrombectomy system~Covidien MindFrame Capture Revascularization Device"
9830855|NCT02586415|No Intervention|Medical Management|standard medical therapy alone
9830856|NCT02586493|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
9830857|NCT02586506|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
9830858|NCT02586727|Active Comparator|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
9830859|NCT02586727|Active Comparator|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
9830860|NCT02586805|Experimental|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
9830861|NCT02586805|Experimental|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
9830862|NCT02586805|Experimental|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
9830863|NCT02586805|Placebo Comparator|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
9830864|NCT02586896|Experimental|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management-assessment, planning, linking, monitoring and advocacy-and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
9984722|NCT03794076|Active Comparator|Cromoglycate|Cromoglycate nasal spray
9984723|NCT03794076|Placebo Comparator|Placebo|Saline nasal spray
9782762|NCT01184885|Experimental|Hyper-CVAD and Sirolimus|Hyper-CVAD and Sirolimus
9782763|NCT01184898|Experimental|Sirolimus and MEC|Sirolimus and MEC (Mitoxantrone, Etoposide, and Cytarabine)
9782764|NCT01184989|Other|Dabigatran etexilate|open label, once daily dose approved by EMEA and Health Canada
9782765|NCT01185028|Experimental|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
9782766|NCT01185080|Experimental|1. AZD8848|20 μg AZD8848 three times weekly
9782767|NCT01185080|Placebo Comparator|2. Placebo|Placebo three times weekly
9782768|NCT01185080|Experimental|3. AZD8848 and placebo|60 μg AZD8848 once weekly and placebo twice weekly
9782769|NCT01185171|Experimental|ZD1839 500mg by mouth (po) daily|Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.
9782770|NCT01185249|Experimental|Body weight taken in a standing position|Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.
9782771|NCT01185288|Experimental|Adalimumab + Low Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
9782772|NCT01185288|Active Comparator|Adalimumab + High Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
9782773|NCT01185301|Active Comparator|ADA + 2.5 mg MTX|2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
9782774|NCT01185301|Active Comparator|ADA + 5 mg MTX|5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
9782775|NCT01185301|Active Comparator|ADA + 10 mg MTX|10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
9782776|NCT01185301|Active Comparator|ADA + 20 mg MTX|MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
9782777|NCT01185340|Experimental|LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.~For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
9782778|NCT01185340|Placebo Comparator|Placebo + SSRI|"Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
9782779|NCT01185353|Experimental|1 mg LY3009104 once daily|Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
9782780|NCT01185353|Experimental|2 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
9782781|NCT01185353|Experimental|4 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
9782782|NCT01185353|Experimental|8 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
9753963|NCT00545584|Experimental|Sitagliptin with Standard of Care|Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
9753964|NCT00545584|Experimental|Sitagliptin with Diet Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet which includes advice on diet with a leaflet and a diary"
9753965|NCT00545584|Experimental|Sitagliptin with Diet and Physical Activity Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."
9753966|NCT00545623|Active Comparator|ACU+RR|acupuncture + relaxation response CD
9753967|NCT00545623|Active Comparator|SHAM+RR|sham acupuncture + relaxation response CD
9753968|NCT00545623|Active Comparator|ACU+EDU|acupuncture+control CD
9753969|NCT00545623|Sham Comparator|SHAM+EDU|sham acupuncture+control CD
9753970|NCT00545662|Experimental|Placebo|Placebo tablets formulated to resemble the citicoline treatment.
9753971|NCT00545662|Experimental|Citicoline|Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
9753972|NCT00545688|Experimental|1|
9753973|NCT00545688|Experimental|2|
9753974|NCT00545688|Experimental|3|
9753975|NCT00545688|Experimental|4|
9753976|NCT00545714|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter [mg/m^2] as intravenous [IV] infusion on Day 0 of Cycle 1 and 500 mg/m^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m^2 on Days 1-3) and cyclophosphamide (250 mg/m^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
9753977|NCT00545740|Experimental|SPD476 (1.2 g)|
9984724|NCT03793881|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
10201946|NCT05190445|Experimental|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|Patients aged 18 years or older with HER2-positive gastric or GEJ adenocarcinoma who have progressed on prior treatment with a regimen containing a platinum and fluoropyrimidine and a HER2-directed therapy such as trastuzumab and now are candidates for treatment with ramucirumab and paclitaxel
9753978|NCT00545740|Experimental|SPD476 (2.4 g)|
9753979|NCT00545740|Experimental|SPD476 (4.8 g)|
9753980|NCT00545740|Placebo Comparator|Placebo|
9753981|NCT00545753|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
9753982|NCT00545753|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
10201947|NCT05190445|Experimental|Cinrebafusp alfa (PRS-343) in combination with tucatinib|Patients aged 18 years or older with HER2 low (IHC 1+ or IHC 2+ without HER2/neu amplification) gastric or GEJ adenocarcinoma who have received at least one prior treatment regimen
10201948|NCT05190172|Experimental|Radiation therapy with protons|Radiation therapy with protons at The Skandion Clinic, Uppsala, Sweden
10201949|NCT05190172|Active Comparator|Radiation therapy with photons|Radiation therapy with photons at an University Hospital nearby subject's home address
10201950|NCT05187611|Experimental|Conduction system pacing|"Pacing the His-Purkinje system.~Crossover to biventricular pacing was allowed in case of failed conduction system pacing: failed His bundle pacing and failed Left bundle branch pacing (high thresholds (>3.5V / 1ms); no left bundle branch pacing criteria; no left bundle branch correction).~Electrocardiographic optimization allowed in order to obtain the narrowest QRS."
10201951|NCT05187611|Active Comparator|Biventricular pacing|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.~Crossover from biventricular pacing to conduction system pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
10201952|NCT05186480|Active Comparator|test group|they receive the immune enhancing formula
10201953|NCT05186480|No Intervention|control group|they receive the conventional formula
10201954|NCT05186116|Experimental|LDLT recipients|Patients that undergo LDLT for CRLM in the study period
10201955|NCT05185466|Experimental|Experimental Group|Experimental Group
10201956|NCT05185466|No Intervention|Control Group|Control Group
10201957|NCT05183945|Experimental|Localization needle insertion|Patients undergo localization needle insertion on day 1.
9753983|NCT00545753|Active Comparator|C - NIX|NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
9753984|NCT00545779|Experimental|Ibandronate|Participants completed Candidate Identification Questionnaire (CIQ) in Part A and received Ibandronate 150 milligram (mg) tablet orally once-monthly up to 6 months in Part B of the study.
9753985|NCT00545792|Experimental|Avastin|Avastin
9753986|NCT00545818|Experimental|Group-1, Implant length 6 mm|Subjects treated with OsseoSpeed™ implant, length: 6 mm
9753987|NCT00545818|Other|Group-2, Implant length 11 mm|Subjects treated with OsseoSpeed™ implant, length: 11 mm
9753988|NCT00545948|Other|Arm A-Vinorelbine|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
9753989|NCT00545948|Other|Arm B-Pemetrexed|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
9984725|NCT03793881|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Cardiology.
10201958|NCT05183945|Active Comparator|Coil insertion|Patients undergo coil insertion on day 1.
9753990|NCT00545974|Experimental|1|Memantine 10mg BID
9753991|NCT00545974|Placebo Comparator|2|Placebo condition
9753992|NCT00546000|Experimental|1|Receive between 22 and 29 days of Cutivate lotion treatment
9753993|NCT00546078|Experimental|Cervarix™ 4-Dose Group|Subjects who had received 3 doses of Cervarix™ in study 580299/001 (NCT00689741), received a 4th dose of Cervarix™ on Day 0 in the current study.
9753994|NCT00546078|Experimental|Cervarix™ 3-Dose Group|Subjects who had received 3 doses of placebo in study 580299/001 (NCT00689741), received 3 doses of Cervarix™ (Day 0, Month 1 and Month 6) in the current study.
9753995|NCT00546104|Experimental|Dasatinib|50- 100 mg PO BID
9753996|NCT00546117|Experimental|Lansoprazole (Prevacid)|Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
9753997|NCT00546117|Placebo Comparator|Placebo|Placebo SoluTab once daily for 2 months
9753998|NCT00546156|Active Comparator|HR+, HER2-|Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
9753999|NCT00546156|Active Comparator|Triple Negative Breast Cancer Cohort|Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
9754000|NCT00546260|Placebo Comparator|1|Placebo for each Dose cohort: 10, 20, 40, and 60 mg
9754001|NCT00546260|Experimental|2|Experimental drug for each Dose cohort: 10, 20, 40, and 60 mg
9754002|NCT00546351|Experimental|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
9754003|NCT00546364|Experimental|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|
9754004|NCT00546364|Experimental|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|
9754005|NCT00546364|Active Comparator|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|
9754006|NCT00546377|Experimental|Mitoxantrone|
9754007|NCT00546390|Experimental|Ischemic Preconditioned Group (rIP)|A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
9754008|NCT00546390|No Intervention|No Cuff|No rIP
9754009|NCT00546429|Other|A|Monitoring of trochanteric fractures after treatment with the ATN system.
9754010|NCT00546481|Experimental|Correction Phase: CERA|
9754011|NCT00546481|Active Comparator|Correction Phase: Epoetin Beta|
9754012|NCT00546572|Experimental|1|Receives 13vPnC at year 0 and 13vPnC at year 1
9754013|NCT00546572|Active Comparator|2|Receives 23vPS at year 0 and 13vPnC at year 1
9754014|NCT00546637|Experimental|Fesoterodine 4mg or 8mg|
9754015|NCT00546637|Placebo Comparator|Placebo|
9754016|NCT00546715|Active Comparator|Dose Panel A|"Daclatasvir - 1 mg~Placebo - 0 mg"
9754017|NCT00546715|Active Comparator|Dose Panel B|"Daclatasvir - 10 mg~Placebo - 0 mg"
9754018|NCT00546715|Active Comparator|Dose Panel C|"Daclatasvir - 100 mg~Placebo - 0 mg"
9754019|NCT00546715|Active Comparator|Dose Panel D|"Daclatasvir - 0.5 - 200 mg (to be determined)~Placebo - 0 mg"
9754020|NCT00546728|Experimental|Exenatide|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
9754021|NCT00546728|Active Comparator|Metformin|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
9754022|NCT00546819|Experimental|ZOSTAVAX™|Participants administered ZOSTAVAX™ on Day 1.
9754023|NCT00546819|Placebo Comparator|Placebo|Participants administered Placebo on Day 1.
9754024|NCT00546884|Placebo Comparator|MI|The MI condition will expose participants to the provision of an advance directive and written instructions, roughly mimicking community standards and the requirements of the federal Patient Self Determination Act.
9754025|NCT00546884|Active Comparator|GI|Subjects randomized to the GI group will be invited to meet individually with a health care professional specializing in EOL care
9754026|NCT00546897|Experimental|Cohort 1|"Lenalidomide 50 mg/day oral for 14 days followed by 30 days of rest. Lenalidomide 50 mg/day oral for 21 days (this is Cycle 1 and Cycle 2).~If no progressive disease (PD) then lenalidomide 10 mg/day oral for 28 days for 12 cycles."
9754027|NCT00546897|Experimental|Cohort 2|"Cycle 1: Oral lenalidomide 50 mg/day x 28 days induction therapy. Treatment will then depend on the response to Cycle 1: if patients obtain a complete remission (CR) they will proceed to low dose lenalidomide therapy, if patients have a non-CR they will receive a second high dose cycle of lenalidomide 50 mg/day x 28 days (Cycle 2) Cycle 2 consists of lenalidomide 50mg/day x 28 days Further treatment will depend on the response to Cycle 2: if patients obtain a CR/partial remission (PR)/stable disease (SD) they will proceed to low dose lenalidomide therapy, if patients have PD they will be removed from the study.~Low Dose Cycles: low dose lenalidomide therapy consisting of 10 mg daily for a 28 day cycle.be 1) For patients that achieve a CR, 2 cycles of low dose lenalidomide will be administered, and then patients observed off therapy. For patients with PR/SD, low dose lenalidomide will continue for a total of 6 cycles and then patients will be observed off therapy."
9754028|NCT00546910|Experimental|Atomoxetine|0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
9754029|NCT00546910|Placebo Comparator|Placebo|Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine
10201959|NCT05183217|Active Comparator|Online continence promotion program without tailoring|Participants will be allocated to the online continence promotion program without tailoring.
10201960|NCT05183217|Experimental|Online continence promotion program with tailoring|Participants will be allocated to the online continence promotion program with tailoring.
9754030|NCT00547105|Experimental|erlotinib in combination with SBRT|Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib
9754031|NCT00547118|Experimental|1|Rimonabant
9754032|NCT00547118|Placebo Comparator|2|Placebo
9830865|NCT02586896|Active Comparator|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
9830866|NCT02586909|Experimental|RVT-101 35 mg tablets|once daily, oral tablets
9830867|NCT02586974|Experimental|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
9830868|NCT02586974|No Intervention|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
9830869|NCT02587065|Experimental|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
9830870|NCT02587117|Experimental|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
9830871|NCT02587117|Active Comparator|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
10201961|NCT05182749|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
9830872|NCT02587143|Active Comparator|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
9830873|NCT02587143|Experimental|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
9830874|NCT02587221|Experimental|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
9830875|NCT02587221|Placebo Comparator|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
9830876|NCT02587234|Experimental|Active|2 hours of active peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
9830877|NCT02587234|Sham Comparator|Sham PNS|2 hours of sham peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
9830878|NCT02587351|Active Comparator|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
9830879|NCT02587351|Placebo Comparator|Placebo|Matched placebo
9830880|NCT02587819|Experimental|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
9830881|NCT02587962|Experimental|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
9830882|NCT02588092|Experimental|Part 1: ADCT-301 (dose escalation)|"Weekly administration - Participants will receive an IV infusion of ADCT-301, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-301, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
9830883|NCT02588092|Experimental|Part 2: ADCT-301 (dose expansion)|Participants will be assigned to receive the recommended dose and/or schedule of ADCT-301 as determined by the Dose Escalation Steering Committee.
9830884|NCT05249621|Experimental|MZE001|MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease.
9830885|NCT05249621|Placebo Comparator|Placebo|Excipients containing no active ingredients.
9830886|NCT05249608|Other|Single arm|A single arm study, only investigational product-the Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity in patients with a BMI ≥ 30 kg/m2. to evaluate the safety and performance of the investigational device for the intended use.
9830887|NCT05249595|Experimental|Group A - Particiapnts without neurological disorders|Individuals without neurological disorders will be recruited (Group A).
9830888|NCT05249595|Experimental|Group S - Participants with iSCI or transverse myelitis|Individuals with neurological disorders, like iSCI or transverse myelitis, will be recruited (Group S). These individuals usually have weakened ankle joint functionalities but can walk independently.
9984726|NCT03793855|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
9830890|NCT05249556|Experimental|GNX|The suspension contains GNX (50 mg/mL), hydroxypropyl methylcellulose, polyvinyl alcohol, sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, and sodium citrate at pH 3.5 to 4.2, and is sweetened with sucralose and flavored with artificial cherry.
9830891|NCT05249556|Placebo Comparator|Placebo|The PBO suspension consists of titanium dioxide, Avicel® (microcrystalline cellulose and carboxymethylcellulose sodium), sodium lauryl sulfate, simethicone, methylparaben, propylparaben, citric acid, sodium citrate and is sweetened with sucralose and flavored with artificial cherry
9830892|NCT05249517|Experimental|Pain Neuroscience Education (PNE)|Telerehabilitation based pain neuroscience education
9830893|NCT05249517|Active Comparator|Neurodevelopmental Yoga + PNE|Telerehabilitation based Neurodevelopmental Yoga and PNE
9830894|NCT05249504|Experimental|1. Intervention group|"AMICOPE multicomponent intervention:~Physical activity (VIVIFRAIL program): 10 hours.~Nutrition: 6,5 hours.~Psychology: 6,5 hours.~Personal autonomy: 4,5 hours~Learn about community resources: 2, 5 hours"
9830895|NCT05249504|Active Comparator|2. Control group|Control group participants will receive usual advice on healthy lifestyle habits and a follow-up phone call from healthcare professionals.
9830896|NCT05249491||Group 1|Children with black tooth stain
9830897|NCT05249491||Group 2|Children without black tooth stain
9830898|NCT05249478|Active Comparator|epidural catheter inserted before spinal anesthesia.|"As for the epidural analgesia, it will be performed under complete aseptic precautions, by introducing a needle between the lumbar vertebrae at level of L3-L4 or L4-L5 and injecting anesthetic medication into the epidural space, via the epidural catheter inserted through the needle into the epidural space.~A small amount of air (1 to 2 mL) may be injected into the epidural space, avoid injecting larger amounts of air as this may contribute to patchy anesthesia."
9984727|NCT03793855|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
10201962|NCT05182749|Experimental|Bacteriophage|Dose is 1mL of bacteriophage preparation given orally three times a day for 7 days (Phase 1) or 6 days (Phase 2a)
10201963|NCT05182541|Experimental|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
9830899|NCT05249478|Active Comparator|ultrasound guided femoral nerve catheter inserted before spinal anesthesia.|"As for the femoral nerve block, it will be performed under complete aseptic precautions, using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed on the femoral crease to obtain the images of the femoral nerve & artery.~The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, Once the femoral nerve is visualized, the needle will be inserted in-plane in a lateral to medial orientation and advanced towards the nerve. Once the tip placed adjacent to the nerve, the catheter is introduced through it, then the needle is removed, the location of the catheter can be confirmed by visualization of the catheter and spread of local anesthetic (LA)."
9830900|NCT05249478|Active Comparator|ultrasound guided adductor canal block inserted before spinal anesthesia.|As for the adductor canal block,using a transportable Sonosite M-Turbo ultrasound system with linear transducer placed perpendicular to the thigh at the midpoint between the anterior superior iliac spine and the base of the patella,The needle used for the block will be an echogenic needle of 18 Gauge and 3.5 inches. Before proceeding, skin infiltration with local anesthesia will be done using a syringe containing 5ml of 1% lidocaine, the saphenous nerve is identified as it lies adjacent proximally lateral then distally superior to the femoral artery. Saphenous nerve is followed distally as it becomes more superficial, traveling with an arterial branch just deep to the sartorius muscle. Using an in-plane approach, after negative aspiration, the tip of the needle is placed deep to the sartorius muscle, at the lateral border of the artery, Once the needle is in position, the catheter is introduced through it, then the needle is removed.
9830901|NCT05249465|Experimental|Condition 1|Core Only
9830902|NCT05249465|Experimental|Condition 2|Core + Track Weight
9830903|NCT05249465|Experimental|Condition 3|Core + Track Steps
9830904|NCT05249465|Experimental|Condition 4|Core + Track Diet
9830905|NCT05249465|Experimental|Condition 5|Core + Track Weight + Track Steps
9830906|NCT05249465|Experimental|Condition 6|Core + Track Weight + Track Diet
9830907|NCT05249465|Experimental|Condition 7|Core + Track Steps + Track Diet
9830908|NCT05249465|Experimental|Condition 8|Core + Track Weight + Track Steps + Track Diet
9830909|NCT05249452||Adult transplant-eligible SCD patients with a MSD|Sickle cell disease patients aged 16 years and older with an available matched sibling donor.
9830910|NCT05249439|Experimental|I-SatPro|Patients in the I-SatPro group will attend I-SatPro patient group sessions and follow the I-SatPro weight loss programme
9830911|NCT05249439|Active Comparator|Control|Patients in the control group will attend NHS Tier 3 patient group sessions and follow the NHS Tier 3 weight loss programme
9830912|NCT05249413||Endophthalmitis after primary cataract surgery.|Cases diagnosed as acute post-operative endophthalmitis after primary cataract surgery.
9830913|NCT05249400|Experimental|Off-site assistance group|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom. The trainer was not allowed to enter the procedure room and touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
9830914|NCT05249400|No Intervention|On-site assistance group|The trainer supervised the trainee's cannulation operation in the procedure room. The trainer was allowed to provide unlimited verbal instructions to the trainee on-site. The trainer was not allowed to touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
9830915|NCT05249374|Experimental|Control group|10 g/ bottle (20%, 50 mL)
9830916|NCT05249374|Experimental|test group|10 g/bottle (20%, 50 mL)
9830917|NCT05249361||Duchenne Muscular Dystrophy|Children aged 5 to 18 years with Duchenne muscular dystrophy
9830918|NCT05249348|Experimental|Part 1 Sequence A|Period 1 will be fed, then washout, then Period 2 will be fasted.
9830919|NCT05249348|Experimental|Part 1 Sequence B|Period 1 will be fasted, then washout, then Period 2 will be fed.
9830920|NCT05249348|Experimental|Part 2 Sequence C|Period 1 will be fed, then washout, then Period 2 will be fasted. A different dose of PC14586 will be tested.
9830921|NCT05249348|Experimental|Part 2 Sequence D|Period 1 will be fasted, then washout, then Period 2 will be fed. A different dose of PC14586 will be tested.
9984728|NCT03788993|Experimental|Blue-depleted evening light condition|
10201964|NCT05182541|Experimental|Face to face PST course|Problem cognition and emotional response guidance
10201965|NCT05182541|Experimental|Professional psychological intervention|Give the pregnancy woman the professional psychological intervention
10201966|NCT05180110|Experimental|Symptoms of inflammation, Infection, tissue injury|Venous blood draw of up to 24mL and up to 6 capillary fingersticks
10201967|NCT05179928|Active Comparator|Group E (n=30)|Erector Spinae Plane Block
10201968|NCT05179928|Active Comparator|Group R (n=30)|Rectus Sheath Block
10201969|NCT05177835|Experimental|ABX464 -25mg|All subjects will receive ABX464 given at 25 mg QD.
10201970|NCT05176158|Experimental|Morning dosage|Dexketoprofen pill at morning; Placebo at night
10201971|NCT05176158|Experimental|Night dosage|Placebo pill at morning; Dexketoprofen at night
10201972|NCT05175846||Normal volunteers|Participants with negative COVID-19 test
10201973|NCT05175846||COVID-19|Participants with positive COVID-19 test and severe symptoms of disease
10201974|NCT05175196|Experimental|Pediatric Participants with GAS|"Children age 5-17 years old diagnosed via standard Rapid Antigen Detection Test with acute pharyngitis caused by Group A Streptococcus (GAS), along with their parent or legal guardian (aka caregiver)."
9830922|NCT05249348|Experimental|Part 2 Japanese Cohort|6 Japanese participants will be administered a single dose of PC14586.
9830923|NCT05249335|Experimental|OST|2 days split dosing regimen
9830924|NCT05249335|Active Comparator|2L-PEG/Asc|2 days split dosing regimen
9830925|NCT05249322|Experimental|Follow-up alternating between face-to-face consultation and teleconsultation every three months|Patients of this arm will be followed alternating between face-to-face consultation and teleconsultation respecting the recommended frequency (every three months) during 12 months (M+3:teleconsultation - M+6:in-hospital consultation - M+9:teleconsultation - M+12 : in-hospital consultation)
9830926|NCT05249309||Treatment|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
9830927|NCT05249309||Control|Will be checked weight, height and waist circumference and collected about 15 mL of peripheral blood.
9830928|NCT05249296|Experimental|Group 1: intervention/control group|"Phase 1: Two weeks of green space intervention~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
9830929|NCT05249296|Experimental|Group 2: control/intervention group|"Phase 1: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of green space intervention~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
9830930|NCT05249270||Safe and Sound Protocol Participants|Parents of children receiving the Safe and Sound Protocol (a clinical auditory therapy provided outside of the study) will complete questionnaires to assess sensory behaviors prior to therapy initiation (baseline), 1 week after therapy conclusion, and 4 weeks after therapy conclusion. The SSP typically consists of 1 hour of listening per day, for 5 consecutive days. If modifications of the typical dosage are implemented due to client needs, they will be documented by parents in the 1 week post therapy questionnaire.
9830931|NCT05249244||observation group|huachansu oral preparation (tablet, capsule) was used.
9830932|NCT05249244||control group|huachansu was not used.
9830933|NCT05249231|Active Comparator|Hall technique|group of carious primary molars to be treated by hall technique
9830934|NCT05249231|Experimental|silver diamine fluoride|group of carious primary molars to be treated by silver diamine fluoride
9830935|NCT05249218|Active Comparator|Group starting intervention with vegetable protein|Phase A followed by Phases B, C, D, E.
9830936|NCT05249218|Active Comparator|Group starting intervention with animal protein|Phase A followed by Phases D, E, B, C.
9830937|NCT05249192|Experimental|Immediate UC removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
9830938|NCT05249192|Active Comparator|Early UC removal|Urinary catheter removal on first postoperative day (6 a.m.) as per standard protocol
9830939|NCT05249179|Experimental|Group 1 (Oral stimulation)|The group that will receive oral stimulation with the Backman method once a day from the 29th week
9830940|NCT05249179|Experimental|Group 2 (Pacifier)|The group that will be given a pacifier three times a day from the 29th week
9830941|NCT05249179|Experimental|Group 3 (oral stimulation + pacifier)|Starting from the 29th week, the group will be given a pacifier three times a day and a Backman oral stimulation will be applied once a day.
9830942|NCT05249179|No Intervention|Group 4 (Enteral feeding by tube)|The group fed enterally by tube in routine practice, in which no intervention will be made.
9830943|NCT05249166|Placebo Comparator|Control group|Subjects assigned to this arm will follow the habitual recommendations to develop skills for a healthy diet. No specific foods or cooking methods will be applied
9984729|NCT03788993|Active Comparator|Normal light condition|
9754033|NCT00547157|Active Comparator|ARM 1 CRT|Cisplatin plus RT
9754034|NCT00547157|Experimental|ARM 2 PRT|Panitumumab plus RT
9754035|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.
9754036|NCT00547248|Active Comparator|Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.
9984730|NCT03788421|Active Comparator|Study group|Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.
9830944|NCT05249166|Experimental|ALINFA group|This group will receive, in addition to the usual recommendations, meals, and foods designed to increase the healthiness of the diet. Foods and meals have been designed to increase the fiber content, decrease sugars and saturated fats, and limit salt intake.
9830945|NCT05249153|No Intervention|Sufen|PCIA: continue with 0.05ug/kg/h sufentanil, 0.05ug/kg sufentainil bolus
9830946|NCT05249153|Experimental|Sufen with low DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.05ug/kg/h dexmedetomidine bolus
9830947|NCT05249153|Experimental|Sufen with high DEX|PCIA: continue with 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine, 0.05ug/kg/h sufentanil and 0.1ug/kg/h dexmedetomidine bolus
9830948|NCT05249114|Experimental|Cohort 1|Cabozantinib 20 mg daily with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 20 mg qd.
9830949|NCT05249114|Experimental|Cohort 2|Cabozantinib 40 mg qod alternating with 20 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
9830950|NCT05249114|Experimental|Cohort 3|Cabozantinib 40 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 40 mg qd.
9830951|NCT05249114|Experimental|Cohort 4|Cabozantinib 60 mg qod alternating with 40 mg qod with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd.
9830952|NCT05249114|Experimental|Cohort 5|Cabozantinib 60 mg qd with Lu-177 DOTATE administration IV. For cycles 5+, single-agent maintenance of cabozantinib is given at 60 mg qd until disease progression.
9830953|NCT05249101|Experimental|Ivaltinostat plus Capecitabine|Ivaltinostat plus Capecitabine
9830954|NCT05249101|Active Comparator|Capecitabine Monotherapy|Capecitabine Monotherapy
9830955|NCT05249062|Experimental|intervention|The intervention being piloted in this study is a novel system of supporting older individuals with multiple long-term conditions to self-manage their chronic conditions through the daily use of a digital health product that can also facilitate the remote monitoring of a person's health status.
9830956|NCT05249049|Experimental|e-OPRA Implant System for Transtibial Amputees|Implantation of e-OPRA Implant System in lower limb.
9830957|NCT05249023|Experimental|Irritable Bowel Syndrome (IBS) participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
9830958|NCT05249023|Experimental|Healthy participants|100 mM sodium butyrate solution containing indigo carmine as a dye agent will be administered to subjects in this arm.
9830959|NCT05248971||Children screened for trauma and/or posttraumatic stress|Children were screened for trauma exposure and posttraumatic stress at one of the first meetings at the child and adolescent mental health clinic. For participants receiving TF-CBT, posttraumatic stress was also assessed during and after therapy.
9830960|NCT05248945|Experimental|Evobrutinib plus Carbamazepine|
9830961|NCT05248932|Active Comparator|infusion|patients will receive an infusion of norepinephrine that will be started at 2.5μg/min immediately after intrathecal injection and then manually adjusted according to monitoring of blood pressure (bp), heart rate, fluid responsiveness (thoracic volume variations and stroke volume variations), cardiac index and systemic vascular resistance by using cardiometry, with the objective of maintaining values near baseline
9830962|NCT05248932|Active Comparator|bolus|patient with no prophylactic vasopressor and a bolus of 5 μg norepinephrine will be given whenever systolic BP decreases to <80% of the baseline value.
9830963|NCT05248919|Active Comparator|12 weeks treatment with sofosbuvir/velpatasvir|134 first-line treatment failure patients randomly allocated to receive 12 weeks treatment with sofosbuvir/velpatasvir
9830964|NCT05248919|Active Comparator|24 weeks treatment with sofosbuvir/velpatasvir|134 first-line treatment failure patients randomly allocated to receive 24 weeks treatment with sofosbuvir/velpatasvir
9830965|NCT05248919|Active Comparator|Observational|50 patients with decompensated cirrhosis who will receive 24 weeks of sofosbuvir/velpatasvir.
9830966|NCT05248815||Study group|Patients scheduled for total knee replacement.
9830967|NCT05248815||Control|Healthy age-matched controls.
9830968|NCT05248789|Experimental|OH2|OH2 dosage: 1x10e7 CCID50/mL Administration：intratumoral injection Frequency：once two weeks
9830969|NCT05248776|Experimental|CPL207280 60 mg|16 participants are to receive IMP at dose 60 mg.IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
9830970|NCT05248776|Experimental|CPL207280 120 mg|16 participants are to receive IMP at dose 120 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
9830971|NCT05248776|Experimental|CPL207280 240 mg|16 participants are to receive IMP at dose 240 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized.
9830972|NCT05248776|Experimental|CPL207280 480 mg|16 participants are to receive IMP at dose 480 mg. IMP will be administered for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
9830973|NCT05248776|Placebo Comparator|Placebo|16 participants are to receive masking placebo tablets once daily for 14 days, every morning, after a minimum 8-hours overnight fast. Participants are to be randomized
9830974|NCT05248737||Group 1 - DHA/EPA bioenhanced poultry (n=24)|Participants will be asked to consume two meals of chicken, one meal will contain chicken that has been fed omega-3 fatty acids so the chicken contains omega 3 (DHA/EPA) fatty acids and the other meal will consist of non enhanced chicken and a DHA supplement. Each participant will be asked to eat both of these forms of chicken in random order. Each study is expected to take 9-hours and the two visits will be separated by a period of two weeks. A total of 5 blood samples will be collected over a 9-h period.
9830975|NCT05248737||Group 2 - 25(OH)D bioenhanced poultry (n=36)|Participants will be asked to consume 1 serving of 25-hydroxyvitamin D (25(OH)D enhanced chicken or non-fortified chicken that does not contain additional 25(OH)D and a vitamin D supplement every day for 21 days. Your participation in the study is expected to last 3 weeks. On Monday-Friday you will be asked to eat lunch in the HMRU on the Cornell campus. On weekends you will be given packaged chicken to eat at home. At 4 timepoints over the 3-week study, a blood draw will be collected to measure vitamin D status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit should last about 30 minutes. The total time needed to complete study visits in the HMRU is 10 hours over the 21-day period.
9830976|NCT05248737||Group 3 - DHA/EPA and 25(OH)D bioenhanced poultry (n=24)|Participants will be asked to consume chicken that contains both omega3 (DHA/EPA) fatty acids and vitamin D (25(OH)D) for a 3week period. On the first day, you will be asked to spend around 9h in the HMRU, and will be fed a breakfast containing this chicken. A total of 5 blood samples will be collected over the 9h period. You will be asked to stay in the HMRU for this 9h study and will be fed breakfast, lunch and dinner. For the next 3w you will be asked to eat this chicken at lunch in the HMRU on the Cornell campus on weekdays (Monday-Friday). On weekends you will be given two packaged frozen chicken servings to eat at home (one serving per day). At 4 timepoints over the 3-week study, a blood draw will be collected to measure (25(OH)D) status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit to the HMRU should last about 30 minutes. The time needed to complete this study in the HMRU is 10 hours over the 3w period.
9830977|NCT05248698|Experimental|group 1|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
9830978|NCT05248698|Active Comparator|group 2|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
9830979|NCT05248685|Experimental|Dual CD33/CLL1 CAR T|All patients who receive Dual CD33/CLL1 CAR T Cell infusion
9830980|NCT05248672|Experimental|CT1812 150 mg QD|
9830981|NCT05248672|Experimental|CT1812 150 mg BID|
9830982|NCT05248672|Experimental|CT1812 300 mg QD|
9830983|NCT05248659|Experimental|Sibeprenlimab 400 mg s.c. q 4 weeks|
10201975|NCT05175157||General practitioner|Answer the Gut Fellings questionnaire
10201976|NCT05175157||Internal|Answer the Gut Fellings questionnaire
9830986|NCT05248581||All Participants|Potential subjects for this registry must have Stage IV colorectal cancer with liver metastases and be candidates for liver transplantation based on multidisciplinary discussion by the Liver transplantation team. Patients must demonstrate favorable tumor biology and no evidence of extra hepatic disease.
9830987|NCT05248555||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing.
9830988|NCT05248542|Experimental|Virtual Reality group|Each participant in the experimental group received a 30 minutes of individualized VR-based simulation education in a dedicated oral skills training room.
9830989|NCT05248542|No Intervention|Control group|The control group only received repeated questionnaires and did not receive any education about geriatric oral hygiene.
9835838|NCT02757963|Other|BPE/BPO screening and IPSS screening tool|Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS >=8 and/or BPE/BPO questionnaire >=3 with a PSA >=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
9835839|NCT02758119|Experimental|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
9835840|NCT02758119|Active Comparator|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
9835841|NCT02758171|Experimental|Empagliflozin+Linagliptin FDC|One tablet fix dose combination (FDC)
9835842|NCT02758171|Active Comparator|Empagliflozin+Linagliptin single tablets|
9835843|NCT02758210|Experimental|Participants with MICRA Device|Participants that received the MICRA device prior to study enrollment will have monitored use of Smart Phone and Tablet at one study visit. Electrogram printing will take place during use of each device to see if there is any pacing inhibition or asynchronous pacing.
10201977|NCT05174416|Experimental|Mavacamten|Mavacamten Capsules
9517432|NCT03306407|Active Comparator|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
9754037|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.
9754038|NCT00547248|Active Comparator|Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.
9754039|NCT00547365|Experimental|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
9754040|NCT00547378|Other|1|InterStim Therapy
9754041|NCT00547378|Active Comparator|2|Standard Medical Therapy
9754042|NCT00547521|Experimental|Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
9754043|NCT00547521|Experimental|SC Abatacept Monotherapy Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
9754044|NCT00547534|Experimental|Lymphoma Subjects receiving protocol therapy|Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
9754045|NCT00547586|Placebo Comparator|Placebo|
9754046|NCT00547586|Experimental|150 mg|
9754047|NCT00547586|Experimental|300 mg|
9754048|NCT00547586|Experimental|450 mg|
9754049|NCT00547586|Experimental|600 mg|
9754050|NCT00547638|Experimental|Dermabond Protape|DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
9754051|NCT00547638|Active Comparator|Dermabond HVD|DERMABOND HVD Topical Skin Adhesive
9754052|NCT00547703|Active Comparator|Nortriptyline|Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
9754053|NCT00547703|Placebo Comparator|Sugar pill|Patients in this group will receive an identical placebo capsule at night for 8 weeks.
9754054|NCT00547729|Experimental|HeartPOD™ System|Implantation of HeartPOD™ Heart Failure Management System with DynamicRx®
9754055|NCT00547898|Experimental|Placebo|
9754056|NCT00547898|Experimental|Crofelemer 125 mg|
9754057|NCT00547898|Experimental|Crofelemer 250 mg|
9754058|NCT00547898|Experimental|Crofelemer 500 mg|
9754059|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT|Each subject received 400 mg of droxidopa (LDOPS) with three separate interventions, i.e., LDOPS with 200 mg placebo, LDOPS with 200 mg carbidopa (CAR), and LDOPS with 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + CAR, followed by LDOPS + ENT.
9754060|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + ENT; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.
9754061|NCT00547911|Experimental|LDOPS + CAR; LDOPS + Placebo; LDOPS + ENT|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + Placebo, and lastly LDOPS + ENT.
9754062|NCT00547911|Experimental|LDOPS + CAR; LDOPS + ENT; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + ENT, and lastly LDOPS + Placebo.
9830990|NCT05248516|Other|Control|no nutritional treatment administered
9830991|NCT05248516|Experimental|Simplified treatment|children are provided with 1 sachet of RUTF until discharge
9984731|NCT03788421|Active Comparator|Control group|Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.
9830992|NCT05248516|Active Comparator|Standard treatment|"children are provided nutritional treatment according to their weight-for-height z-score (WHZ) and their weight:~children with a WHZ<-3 will receive 200kcal/kg/d of nutritional product until discharge~children with a WHZ between -3 and -2 are provided with 1 sachet of RUTF until discharge~children with a WHZ >= -2 will not be provided any nutritional treatment"
9830993|NCT05248503||Nurse|Pediatric nurses taking charge of the care of patients with epidermolysis bullosa at Necker Hospital
9830994|NCT05248477|No Intervention|usual practice|
9830995|NCT05248477|Experimental|Premex protocol|a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol, involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children
9830996|NCT05248451||Normal Renal Function|Patients undergoing inpatient non-cardiac surgery at St. Paul's Hospital with normal preoperative Estimated Glomerular Filtration Rate (eGFR) results. eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates.
9830997|NCT05248451||Renal Dysfunction, Chronic Kidney Disease (CKD)|Patients undergoing non-cardiac surgery with abnormal preoperative Estimated Glomerular Filtration Rate (eGFR). eGFR values considered will be from samples drawn within a one year period preceding surgery. Values from samples drawn within the 7 days immediately preceding surgery will be excluded, in order to avoid introducing bias from acute kidney injuries. All available eGFR values in the 7 to 365 days preceding an individual's surgery will be included, and the average of these values will be used as their preoperative eGFR. Investigators will include all people that have one or more measure. Depending on sample size, investigators may decide to limit inclusion to those that have two or more eGFR estimates. As eGFR is not accurate in the setting of dialysis, patients receiving dialysis for at least 90 days prior to their surgical procedure will also be included as a separate eGFR category.
9830998|NCT05248438||Multiple sclerosis patients|patients affected by multiple sclerosis based on McDonald Criteria 2017
9984732|NCT03786783|Experimental|Treatment(chemotherapy, dinutuximab, sargramostim, ASCT, EBRT)|See Detailed Description
9984733|NCT03782792|Experimental|Spesolimab|
9831001|NCT05248399|Experimental|COVID-19 Group Problem Solving|
9831002|NCT05248399|Active Comparator|Control Group-standard of care|
9831003|NCT05248386|Experimental|RTX-GRT7039|Participants will receive 2 intra-articular injections of RTX-GRT7039 during the 52-week double-blind treatment period.
9831004|NCT05248386|Placebo Comparator|Placebo|Participants will receive 2 intra-articular injections of placebo matching to RTX-GRT7039 during the 52-week double-blind treatment period.
9831005|NCT05248360|Experimental|Experimental group|Hydrogen-oxygen mixed gas(H2-O2, 66.6% hydrogen, 33.3% oxygen) inhalation, 900ml/min, 2h/d
9831006|NCT05248360|Placebo Comparator|Control group|Air inhalation, 900ml/min, 2h/d
9831007|NCT05248347|Active Comparator|Bronchoscopy training simulator|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan) was used to train the participants.
9831008|NCT05248347|Experimental|The BRONCH Mentor|Group B: The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA) was used.
9831009|NCT05248334|Experimental|Ranibizumab group|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
9831010|NCT05248334|Active Comparator|PPV group|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
9831011|NCT05248308|Experimental|Genicular artery embolization|Study participants will undergo genicular artery embolization (GAE) for treatment of chronic moderate to severe pain following knee arthroplasty or revision arthroplasty. Embolization will be performed using Embozene Microspheres.
9831012|NCT05248295|Experimental|Intervention|All participants will repeat sentences under four speech conditions, in a 2x2 design
9831013|NCT05248269|Experimental|Thermocoagulation of epileptogenic zone|
9831014|NCT05248256|Experimental|Treatment Arm|"Radiation therapy must be administered per standard of care, will be prescribed to between 6000cGy to 6600cGy, and can be delivered with either 3DCRT (conformal radiation therapy) or IMRT (Intensity modulated radiation therapy) although IMRT is preferred. Radiotherapy will be delivered 5 days per week.~Immunotherapy will be initiated after concurrent CRT with either durvalumab or an alternative immune checkpoint agent acceptable per NCCN (National Comprehensive Cancer Network) guidelines. Dosing and frequency of immunotherapy will be performed per standard of care. Immunotherapy should begin ideally within 14-21 days after concurrent CRT."
9831015|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 1|Single inhalational administration of 4D-710 Dose Level 1
9831016|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 2|Single inhalational administration of 4D-710 Dose Level 2
9984734|NCT03782792|Experimental|Placebo|
9984735|NCT03782558||Patients with CTS|Surgical transection of transverse ligament
9984736|NCT03781154|Experimental|Group-based exercise|Virtually-delivered supervised exercise sessions will take place twice per week for approximately one hour, and include aerobic, muscular strength and endurance, balance, and flexibility components.
9754063|NCT00547911|Experimental|LDOPS + ENT; LDOPS + Placebo; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + Placebo, and lastly LDOPS + CAR.
9754064|NCT00547911|Experimental|LDOPS + ENT; LDOPS + CAR; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + CAR, and lastly LDOPS + Placebo.
9754065|NCT00548041|Other|Rapid HIV Tested|Subjects have HIV testing by oral swab performed.
9754066|NCT00548132|No Intervention|1|Patients in this arm will continue to get routine care
9754067|NCT00548132|Experimental|Chlorhexidine-impregnated foam dressing|Patient's catheters were cleaned with chlorhexidine-alcohol solution at least weekly before application of the Biopatch. These were evaluated daily and if the dressing was bloody, soiled or damaged, the dressing and the Biopatch were replaced prior to the 7-day period.
9754068|NCT00548145|Experimental|1|
9754069|NCT00548145|Active Comparator|2|
9754070|NCT00548171|Experimental|Boostrix I Group|Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.
9754071|NCT00548171|Active Comparator|Boostrix II Group|Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.
9754072|NCT00548184|Experimental|Single Group Assignment|Lapatinib Trastuzumab Endocrine
9754073|NCT00548197|Experimental|Intervention group|Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
9754074|NCT00548197|No Intervention|Control group|no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy
9754075|NCT00548249|Placebo Comparator|0 µg iron/dL of dialysate|Placebo 0 micrograms (µg) of iron/ deciliter (dL) of dialysate
9754076|NCT00548249|Experimental|5 µg iron/dL of dialysate|5 micrograms (µg) of iron/ deciliter (dL) of dialysate
9754077|NCT00548249|Experimental|10 µg iron/dL of dialysate|10 micrograms (µg) of iron/ deciliter (dL) of dialysate
9754078|NCT00548249|Experimental|12 µg iron/dL of dialysate|12 micrograms (µg) of iron/ deciliter (dL) of dialysate
9754079|NCT00548249|Experimental|15 µg iron/dL of dialysate|15 micrograms (µg) of iron/ deciliter (dL) of dialysate
9754080|NCT00548262|Experimental|1|
9754081|NCT00548340|Experimental|VEC-162 20 mg|VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
9754082|NCT00548340|Experimental|VEC-162 50 mg|VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
9754083|NCT00548340|Placebo Comparator|Placebo|Placebo capsules PO daily five weeks
9831017|NCT05248230|Experimental|4D-710 Dose Expansion Cohort|Single inhalational administration of 4D-710 at the selected dose
9754084|NCT00548405|Experimental|Alemtuzumab 12 mg|Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
9754085|NCT00548405|Experimental|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
9754086|NCT00548405|Active Comparator|Interferon Beta-1a|Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
9754087|NCT00548418|Experimental|I|"Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle~Bevacizumab 15 mg/kg day 1 of a 21 day cycle"
9754088|NCT00548431|Experimental|6 mercaptopurine arm|All patients received basic daily 6MP (6-mercaptopurine) (25 mg/m^2) and in addition high-dose methotrexate(HDM) every 3rd week (3 times HDM in total) and PEG-asparaginase every 14th day. Patients increased the dose of 6MP 2 weeks after each HDM if if the myelotoxicity had been acceptable. This means 2 increments since the study stopped 2 weeks after the last HDM
9754089|NCT00548470|Experimental|varenicline|open label varenicline 2mg/day
9754090|NCT00548548|Experimental|Bevacizumab|Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
9754091|NCT00548548|Placebo Comparator|Placebo|Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
9754092|NCT00548652|No Intervention|1|standard nutrition counselling
9754093|NCT00548652|Experimental|2|MOVE -weight loss intervention
9754094|NCT00548652|Experimental|3|MOVE plus medical crisis counselling
9754095|NCT00548652|Experimental|4|MOVE plus methylphenidate
9754096|NCT00548652|Experimental|5|MOVE plus methyphenidate plus medical crisis counselling
9754097|NCT00548691|Experimental|Ferric Carboxymaltose (FCM)|Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
9754098|NCT00548691|Active Comparator|Standard Medical Care (SMC)|SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
9754099|NCT00548717|Experimental|Siro/MMF|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
9754100|NCT00548717|Experimental|Siro/MMF/Bort|Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) *added with study reopening in 2012
9754101|NCT00548808|Experimental|Insulin lispro low mixture|Insulin lispro low mixture (1, 2 or 3 daily injections)
9754102|NCT00548808|Active Comparator|Insulin glargine|Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)
9754103|NCT00548847|Experimental|GM-CSF, Interferon-α-2b|
9754104|NCT00548860|Experimental|Ferric Carboxymaltose (FCM)|Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
9754105|NCT00548860|Active Comparator|Standard Medical Care (SMC)|Varied as determined by the Investigator
9754106|NCT00549042|Experimental|OROS hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
9754107|NCT00549042|Placebo Comparator|placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
9754108|NCT00549055||1|Patients who obtained reimbursement of Macugen.
9754109|NCT00549172|Active Comparator|Operative (O)|Partial resection of degenerative tear of medial meniscus
9754110|NCT00549172|Sham Comparator|Conservative (K)|Arthroscopy (diagnostic)
9754111|NCT00549198|Experimental|ABC/3TC + EFV|
9754112|NCT00549198|Active Comparator|TDF/FTC + EFV|
9754113|NCT00549302|Active Comparator|20 mg tadalafil|20 milligram (mg) tadalafil taken once a day
9754114|NCT00549302|Active Comparator|40 mg tadalafil|40 mg tadalafil tablet taken once a day
9754115|NCT00549393|Experimental|1|Daily bathing with 2% chlorhexidine gluconate
9754116|NCT00549393|No Intervention|2|Standard bathing with soap and water basin or disposable cloth
9754117|NCT00549445||Azithromycin-treated|Participants in the COPD Network Macrolide Study who received azithromycin for 1 year.
9754118|NCT00549445||Placebo-treated|Participants in the COPD Network Macrolide Study who received placebo for 1 year.
9754119|NCT00549549|Active Comparator|1|
9754120|NCT00549549|Experimental|2|
9754121|NCT00549549|Experimental|3|
9754122|NCT00549549|Experimental|4|
9754123|NCT00549562|Other|Paliperidone ER|8-Week Open-Label
9754124|NCT00549601|Experimental|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|
9754125|NCT00549601|Experimental|Rivastigmine patch (9.5 mg/day)|
9754126|NCT00549601|Active Comparator|Rivastigmine capsules (6 mg to 12 mg/day)|
9754127|NCT00549640|Active Comparator|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
10201978|NCT05174416|Placebo Comparator|placebo|Matching Placebo Capsules
10201979|NCT05174364||Epidural Block|Epidural block for the control group will be done before induction of general anesthesia. Patients will be positioned in the sitting position, an 18-gauge Tuohy needle will be inserted into epidural space of Th 11-12 intervertebral space under aseptic condition. In the medial approach, the site of the insertion of the needle is between the spaces created by the vertebral spinous processes. Upon locating the desired spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle
9754128|NCT00549640|Placebo Comparator|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
9754129|NCT00549718|Experimental|Lurasidone 40mg|
9754130|NCT00549718|Experimental|Lurasidone 80mg|
9754131|NCT00549718|Experimental|Lurasidone 120mg|
9754132|NCT00549718|Placebo Comparator|Sugar Pill|
9754133|NCT00549757|Experimental|Aliskiren|"In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment"
9754134|NCT00549757|Placebo Comparator|Placebo|"In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment."
9754135|NCT00549770|Experimental|LCZ696 100 mg|Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
9754136|NCT00549770|Experimental|LCZ696 200 mg|Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
9754137|NCT00549770|Experimental|LCZ696 400 mg|Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
9754138|NCT00549770|Active Comparator|Valsartan 80 mg|Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
9754139|NCT00549770|Active Comparator|Valsartan 160 mg|Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
9754140|NCT00549770|Active Comparator|Valsartan 320 mg|Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
9754141|NCT00549770|Experimental|AHU377 200 mg|Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
9754142|NCT00549770|Placebo Comparator|Placebo|Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
9754143|NCT00549783|Active Comparator|Botulinum toxin type A 900kD|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
9754144|NCT00549783|Placebo Comparator|Placebo|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
9754145|NCT00549822|Experimental|Intermittent letrozole therapy|Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
9754146|NCT00549900|Experimental|Cervarix Group|Subjects received 3 doses of GSK580299 vaccine (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine) according to a 0, 1, 6-month schedule.
9754147|NCT00549939|Placebo Comparator|Placebo|Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day
9754148|NCT00549939|Experimental|Alfuzosin 0.1 mg/kg/day|
9754149|NCT00549939|Experimental|Alfuzosin 0.2 mg/kg/day|
9754150|NCT00550043|Experimental|Cohort 1: Treatment Group A|INCB018424 15 mg twice daily (BID) or matching placebo
9754151|NCT00550043|Experimental|Cohort 2: Treatment Group B|INCB018424 5 mg BID or matching placebo
9754152|NCT00550043|Experimental|Cohort 2: Treatment Group C|INCB018424 25 mg BID or matching placebo
9754153|NCT00550043|Experimental|Cohort 2: Treatment Group D|INCB018424 50 mg once daily (QD) or matching placebo
9754154|NCT00550043|Placebo Comparator|Placebo|Matching placebo, oral
9754155|NCT00550147|Experimental|1|Oros Methylphenidate and Quetiapine
9754156|NCT00550173|Experimental|Pemetrexed + Erlotinib|Pemetrexed 500 milligrams per meter squared (mg/m^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
9754157|NCT00550173|Active Comparator|Erlotinib|Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
9754158|NCT00550173|Active Comparator|Pemetrexed|Pemetrexed 500 mg/m^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.
9754159|NCT00550238|Experimental|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
9754160|NCT00550277|Other|Treatment|LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles. Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
9754161|NCT00550290|Active Comparator|Cefazolin Preoperatively|Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
9754162|NCT00550290|Experimental|Cefazolin Postoperatively|Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
9754163|NCT00550368|Experimental|Helicobacter pylori negative|Persons who tested negative for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
9754164|NCT00550368|Experimental|Helicobacter pylori positive|Persons who tested positive for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
9754165|NCT00550394|Active Comparator|Quetiapine and Placebo|Quetiapine and Placebo
9754166|NCT00550394|Experimental|Quetiapine and Topiramate|Quetiapine and Topiramate
9754167|NCT00550407|Placebo Comparator|Placebo|
9754168|NCT00550407|Active Comparator|BW430C(lamotrigine)|
9754169|NCT00550420|Experimental|Arm 1|Rosiglitazone XR
9754170|NCT00550446|Active Comparator|1|
9754171|NCT00550446|Experimental|2|
9754172|NCT00550446|Experimental|3|
9754173|NCT00550446|Experimental|4|
9754174|NCT00550446|Experimental|5|
9754175|NCT00550446|Experimental|6|
9754176|NCT00550446|Placebo Comparator|7|
9754177|NCT00550459|Placebo Comparator|1|Placebo tablet given once a day for 21 days
9754178|NCT00550459|Active Comparator|2|Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
9754179|NCT00550537|Experimental|Treatment|Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
9754180|NCT00550550|Placebo Comparator|Placebo|Matching Placebo
9754181|NCT00550550|Experimental|SCH 697243|Grass Sublingual Tablet (Phleum pratense extract)
9754182|NCT00550589|Experimental|Cidofovir|1.0% topical cidofovir cream
9782783|NCT01185353|Placebo Comparator|Placebo once daily|Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
9782784|NCT01185353|Experimental|2 mg LY3009104 twice daily|(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
9782785|NCT01185366|Experimental|Everolimus Group 1|Everolimus 10 mg by mouth once a day.
9782786|NCT01185366|Active Comparator|Sunitinib Group 2|Sunitinib 50 mg by mouth daily for 4 weeks on / 2 weeks off.
9782787|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Cohort A|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by fluorescence in situ hybridization (FISH) (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
9831018|NCT05248217|Other|healthcare workers|doctors, nurses, medical secretaries, security guards, and cleaning staff
9831019|NCT05248204|Experimental|Scotchbond Universal Plus Treatment|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using Scotchbond Universal Plus (SBU+) Adhesive (Treatment).
9831020|NCT05248204|Active Comparator|Scotchbond Universal Comparator|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using the predicate device, Scotchbond Universal (SBU) Adhesive (Control).
9754183|NCT00550615|Experimental|Dasatinib Dose Escalation|Phase 1 employed a standard 3+3 dose-escalation design to assess safety, MTD and dose-limiting toxicity (DLT). Maximum Tolerated Dose (MTD) was defined as the next lowest dose level below where ≥ 2/3 or ≥ 3/6 patients experience dose limiting toxicities in cycle 1.
9754184|NCT00550615|Experimental|Dasatinib Maximum Tolerated Dose|Once the maximum tolerated dose is determined, an additional patients will be enrolled into the Phase II portion of this trial.
9754185|NCT00550654|Experimental|Radiation Therapy in Metastatic Cancer|Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
9754186|NCT00550680|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).
9754187|NCT00550732|Experimental|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
9754188|NCT00550745|Experimental|1|Arm 1: vaccine
9754189|NCT00550745|Placebo Comparator|2|Arm 2: Placebo Comparator
9754190|NCT00550771|Active Comparator|Doxorubicin Based Regimen|
9754191|NCT00550771|Experimental|Pegylated Liposomal Doxorubicin (PLD) Based Regimen|
9754192|NCT00550836|Active Comparator|Arm A: GE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
9754193|NCT00550836|Experimental|Arm B: PGE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
9754194|NCT00550862|Experimental|INT-747 10 mg|INT-747 10 mg once daily in combination with URSO for 12 weeks.
9754195|NCT00550862|Experimental|INT-747 25 mg|INT-747 25 mg once daily in combination with URSO for 12 weeks.
9754196|NCT00550862|Experimental|INT-747 50 mg|INT-747 50 mg once daily in combination with URSO for 12 weeks.
9754197|NCT00550862|Placebo Comparator|Placebo|Placebo once daily in combination with URSO for 12 weeks.
9754198|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 1|Influenza Virus Vaccine Formulation 1
9754199|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 2|Influenza Virus Vaccine Formulation 2
9754200|NCT00551031|Active Comparator|Fluzone® Elderly Group|
9754201|NCT00551031|Active Comparator|Fluzone® High-dose Group|Participants enrolled at age ≥ 65 years
9754202|NCT00551031|Active Comparator|Fluzone® Adults Group|Participants enrolled at age 18-49 years.
9831021|NCT05248152|Placebo Comparator|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
9754203|NCT00551070|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9754204|NCT00551135|Experimental|3|
9754205|NCT00551135|Placebo Comparator|4|
9754206|NCT00551135|Experimental|2|
9754207|NCT00551135|Experimental|1|
9754208|NCT00551161|Experimental|single-arm|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 20 mg per day, in addition to their ongoing stable cholinesterase inhibitor treatment
9754209|NCT00551174|Experimental|1|
9754210|NCT00551174|Active Comparator|2|
9754211|NCT00551200|Active Comparator|BUPHENYL® to HPN-100 vs. HPN-100|Buphenyl treatment for one week was followed by dose escalation to HPN-100. Dose of Buphenyl was gradually decreased while HPN-100 dose was gradually increased until subject reached dosing of 100% HPN-100. HPN-100 at 100% of the dose was given for 1 week before subject was switched back to original Buphenyl treatment.
9754212|NCT00551213|Experimental|Robatumumab→Robatumumab|Participants receive 1 dose of robatumumab 0.3 mg/kg intravenously (IV) followed by 1 dose of robatumumab 10 mg/kg IV once every 2 weeks (Q2W) until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
9831022|NCT05248152|Experimental|Pregabalin|Patients will receive pregabalin 150 mg in the hour before surgery and two intravenous doses of saline before surgical incision.
9831023|NCT05248152|Experimental|Paracetamol and Ibuprofen|Patients will receive a placebo capsule in the hour before surgery and an intravenous dose of paracetamol 1 g and ibuprofen 400 mg before surgical incision.
9831024|NCT05248113|Experimental|Intraoperative electrical stimulation of cochlear nerve|Electrical stimulation of the cochlear nerve will be tested intraoperatively in patients undergoing vestibular schwannoma resection.
9831025|NCT05248100|Experimental|Conditional Cash Transfer|Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 Tanzanian Shillings (TSH) (~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
9831026|NCT05248100|No Intervention|Control|Eligible and consenting participants living in a control health facility catchment area will receive the standard of care HIV tracing and clinical services.
9831027|NCT05248087|Experimental|The rapid maxillary expansion|The rapid maxillary expansion will be applied using a McNamara-type (bonded) appliance.
9831028|NCT05248087|Active Comparator|The slow maxillary expansion|The slow maxillary expansion will be applied using a removable palatal expansion appliance.
9831029|NCT05248048|Experimental|NKG2D CAR-NK|CAR-T infusion
9831030|NCT05248022|Experimental|Combination Treatment Group|Drug-eluting Beads Bronchial Arterial Chemoembolization combined with Programmed Cell Death Protein 1 Inhibitor was used for treatment.
9831031|NCT05248022|Active Comparator|Single Treatment Group|Only receive drug-eluting beads bronchial arterial chemoembolization treatment.
9831032|NCT05248009|Experimental|Semi-Permanent Tattoo Ink|Semi-Permanent Tattoo Ink
9831033|NCT05247996|Experimental|"Transcatheter arterial chemoembolization Combined With Target Immune Therapy"|Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors and multi-target drugs was used for treatment.
9831034|NCT05247996|Active Comparator|Traditional Systemic Intravenous Chemotherapy Group|Traditional systemic intravenous chemotherapy with GEMOX regimen was used for comparison.
9831035|NCT05247983||experimental group|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
9831036|NCT05247983||control group|Tension-free repair of inguinal hernia with traditional method
9831037|NCT05247957|Experimental|NKG2DL-specific CAR-NK cells|Experimental: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7 After preconditioning with chemotherapy, NKG2DL-specific CAR-NK cells will be evaluated
9517433|NCT03306381|Experimental|Dietary intervention subject group|n=130. Participants on low FODMAP-similar diet during 4-week study period.
9831038|NCT05247944||F-BEVAR|Patients with complex abdominal aortic aneurysm who underwent fenestrated and branched endovascular aortic repair (F-BEVAR) at the Aortic Center of Lille (ACL; Lille, France).
9831039|NCT05247944||OPEN SURGERY REPAIR|Patients with complex abdominal aortic aneurysm who underwent open surgery repair the Unit of Vascular Surgery of Policlinic Gemelli (FPUG; Rome, Italy).
9831040|NCT05247931||CASE|patients experiencing a recurrent stroke while on ASA therapy
9831041|NCT05247931||CONTROL|ASA-naïve patients experiencing a first atherothrombotic stroke
9831044|NCT05247905|Experimental|Arm I (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9754213|NCT00551213|Active Comparator|Chemotherapy→Robatumumab|Participants receive 1 cycle of standard colorectal cancer chemotherapy currently approved and available on the market for use in colorectal cancer (to be selected by the Investigator based on participant's prior treatment) followed by 1 dose of robatumumab 10 mg/kg IV Q2W until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
9754214|NCT00551291|Experimental|Mycophenolate Mofetil + Prednisone + Erythropoietin Beta|Mycophenolate mofetil (MMF) 1 gm twice daily orally and prednisone 10 mg/day orally until the end of the study. Recombinant human erythropoietin beta 30,000 IU/week, subcutaneously for 6 weeks was added in case of no significant response at Week 12.
9754215|NCT00551369|Experimental|SBRT|Stereotactic body radiation therapy (SBRT)
9754216|NCT00551421|Experimental|Arm I|"Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I)."
9754217|NCT00551460|Experimental|Treatment|"Induction:~ATRA 45mg/m2 PO D1-CR Gemtuzumab Ozogamicin 9 mg/m2 IV D1 Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk D10-CR~Consolidation 1 and 2:~Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk x 5 weeks, repeat after 2 weeks rest~Consolidation 2 and 3:~ATRA 45 mg/m2 PO D1-7 Daunomycin 50 mg/m2/d IV D1-3~Consolidation 5 and 6:~GO 9mg/m2 IV D1~Maintenance:~ATRA 45 mg/m2/d PO D1-7 every 14 days 6-MP 60 mg/m2/d PO daily for 1 year Methotrexate 20 mg/m2 PO once/wk for 1 year"
9754218|NCT00551525|Experimental|Radiotherapy + Samarium 153|Samarium 153 infusion followed by radiotherapy 12 weeks later
9754219|NCT00551642|Active Comparator|Inhaled Nitric Oxide (INO)|INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days
9754220|NCT00551642|Placebo Comparator|Placebo|Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days.
9754221|NCT00551707|Experimental|CRx-102 (2.7/180)|CRx-102 dose 1 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM titration dose (days 0-13) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM
9754222|NCT00551707|Experimental|CRx-102 (2.7/360)|CRx-102 Dose 2 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 360 mg dipyridamole administered as 1.8 mg prednisolone plus 180 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM
9754223|NCT00551707|Active Comparator|Prednisolone|treatment dose ( days 0-98) total daily dose of 2.7 mg prednisolone administered as 1.8 mg prednisolone at 8 AM and 0.9 mg prednisolone at 1 PM
9754224|NCT00551707|Active Comparator|Dipyridamole|total daily dose during treatment period (days 14-98) 360 mg dipyridamole administered as 180 mg dipyridamole at 8 AM and and 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 90 mg dipyridamole administered 45 mg dipyridamole at 8 AM and 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 180 mg dipyridamole administered as 90 mg dipyridamole at 8 AM and 90 mg dipyridamole at 1 PM
9754225|NCT00551707|Placebo Comparator|Placebo|placebo administered twice per day at 8 AM and 1 PM
9754226|NCT00551746|Active Comparator|1|Grape Juice
9754227|NCT00551746|Placebo Comparator|2|Grape Juice Placebo
9754228|NCT00551759|Experimental|Neoadjuvant therapy, Surgery, adjuvant therapy|"Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
9754229|NCT00552058|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg for subcutaneous (sc) injection
9754230|NCT00552058|Placebo Comparator|Placebo|Placebo, saline solution for sc injection
9754231|NCT00552071|Experimental|Ultrasound-guided IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months.
9754232|NCT00552071|Active Comparator|Regular IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via regular IM gluteal injections every 28 days for 3 months
9754233|NCT00552084|Experimental|Fish Oil|4 grams fish oil daily for 24 weeks
9754234|NCT00552084|Placebo Comparator|Placebo|corn oil taken daily for 24 weeks
9754235|NCT00552110|Experimental|Combination1|Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily
9754236|NCT00552110|Experimental|Combination3|MFNS with OXY 3 sprays once daily
9517434|NCT03306381|No Intervention|Control group|n=20. Participants on traditional IBS diet during 4-week study period.
9754237|NCT00552110|Active Comparator|Mometasone|MFNS once daily
9754238|NCT00552110|Active Comparator|Oxymetazoline|OXY twice daily
9754239|NCT00552110|Placebo Comparator|Placebo|Placebo nasal spray
9754240|NCT00552175|Experimental|Duloxetine 60|duloxetine 60 milligram (mg) taken orally every day
9754241|NCT00552175|Experimental|Duloxetine 40|Duloxetine 40 mg taken orally every day
9754242|NCT00552175|Placebo Comparator|Placebo|placebo comparator taken orally every day
9754243|NCT00552188|Experimental|VIA-2291|VIA-2291 100mg
9754244|NCT00552188|Placebo Comparator|Placebo|Matching placebo
9754245|NCT00552240|Active Comparator|NVP 200mg bis indie (BID)|after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
9754246|NCT00552240|Active Comparator|Atazanavir 300 mg QD/ritonavir 100 mg QD|patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
9754247|NCT00552279|Experimental|Cervarix-12 Group|Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule
9754248|NCT00552279|Active Comparator|Cervarix-6 Group|Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.
9754249|NCT00552305|Experimental|Lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
9754250|NCT00552344|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.
9754251|NCT00552409|Experimental|Cholecalciferol|
9754252|NCT00552409|Placebo Comparator|Placebo|
9754253|NCT00552422|Experimental|Domperidone Arm|Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.
9754254|NCT00552448|Experimental|1|Use of the HFCC device in addition to standard therapy for status asthmaticus. The use of HFCC will not affect the therapy received
9754255|NCT00552448|No Intervention|2|This group will not use the VEST or HFCC. They will just have standard therapy for status asthmaticus. The standard therapy will not be affected if they are in this group.
9754256|NCT00552578|Active Comparator|Tapering doses of buprenorphine|Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
9754257|NCT00552578|Experimental|Steady doses of buprenrophine|Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.
9754258|NCT00552617|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
9754259|NCT00552617|Experimental|Rocuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
9754260|NCT00552617|Experimental|Rocuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
9754261|NCT00552617|Experimental|Rocuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
9754262|NCT00552617|Experimental|Rocuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
9754263|NCT00552617|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
9754264|NCT00552617|Experimental|Vecuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
9754265|NCT00552617|Experimental|Vecuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
9754266|NCT00552617|Experimental|Vecuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
9754267|NCT00552617|Experimental|Vecuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
9754268|NCT00552669|Experimental|A--Oral Rapamycin plus BMS|Oral sirolimus plus bare metal stent implantation
9754269|NCT00552669|Active Comparator|B -- Drug Eluting Stent|Drug Eluting Stents
9754270|NCT00552695|Active Comparator|1|Lidocaine 70 mg/tetracaine 70 mg skin patch
9754271|NCT00552695|Placebo Comparator|2|
9754272|NCT00552760|Experimental|Ramelteon|8 mg
9754273|NCT00552760|Placebo Comparator|Placebo|
9754274|NCT00552786|Experimental|Acetin|
9754275|NCT00552786|Placebo Comparator|Glucose|
9754276|NCT00552812|Experimental|Stent therapy of aortic coarctation|Stenting of aortic coarctation
9754277|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
9754278|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
9754279|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
9754280|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
9754281|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
9754282|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
9754283|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
9754284|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
9754285|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
9754286|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
9754287|NCT00553059|Experimental|Arm I: Palonosetron, Dexamethasone + Dronabinol|Palonosetron hydrochloride intravenous (IV) and dexamethasone IV 30 minutes before chemotherapy administration on day 1, and oral dronabinol 3 times a day for 5 days beginning 30 minutes before chemotherapy administration on day 1.
9754288|NCT00553059|Active Comparator|Arm II: Palonosetron + Dexamethasone|Palonosetron hydrochloride and dexamethasone as in arm I, and oral placebo 3 times a day for 5 days beginning 30 minutes before chemotherapy on day 1.
9754289|NCT00553098|Experimental|Treatment (chemotherapy, low dose radiation)|"CONDITIONING REGIMEN: *Patients with no life-threatening viral or fungal infections within 1 month before the planned HCT receive alemtuzumab IV over 6 hours on day -10 and fludarabine phosphate IV over 30 minutes on days -4 to -2. They also undergo low-dose TBI on day 0. Patients with HLH, IPEX syndrome, DiGeorge syndrome, or life-threatening viral or fungal infections within 1 month before the planned HCT receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo 2 low doses of TBI on day 0.~HEMATOPOIETIC CELL TRANSPLANTATION: Patients undergo HCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. They also receive mycophenolate mofetil IV or PO 3 times daily beginning on day 0 and continuing until day 40 followed by a taper until day 96."
9754290|NCT00553150|Experimental|Everolimus (RAD001), Radiation (RT), Temozolomide (TMZ)|"Patients receive oral everolimus and oral temozolomide and 3D-conformal radiotherapy or IMRT as in phase I. Patients will undergo a 4-6 week rest period in course 2 and then proceed to adjuvant therapy.~Adjuvant therapy with everolimus and temozolomide (courses 3-8): Patients receive oral everolimus and oral temozolomide as in phase I.~Adjuvant therapy with everolimus alone (courses 9 and all subsequent courses): Patients receive oral everolimus as in phase I.~All patients undergo fludeoxyglucose (FDG)- or fluorothymidine-labeled PET/CT scans at baseline and periodically during treatment."
9754291|NCT00553163|Active Comparator|Gut-focussed hypnotherapy (GFH).|Gut-focussed hypnotherapy (GFH).
9754292|NCT00553163|Sham Comparator|Educational sessions|Regular sessions to learn about UC from research nurse
9754293|NCT00553202|Experimental|Treatment (chemotherapy and allogeneic SCT)|"Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.~Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.~Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives"
9754294|NCT00553254|Experimental|1|
9754295|NCT00553280|Experimental|pregabalin|
9754296|NCT00553319|Placebo Comparator|Placebo|Placebo
9754297|NCT00553319|Experimental|Adderall-XR 60 mg|Adderall-XR 60 mg
9754298|NCT00553319|Experimental|Adderall-XR 80 mg|Adderall-XR 80 mg
9754299|NCT00553332|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9754300|NCT00553358|Experimental|Arm 1 Lapatinib|1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
9754301|NCT00553358|Active Comparator|Arm 2 Trastuzumab|4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
9754302|NCT00553358|Experimental|Arm 3 Lapatinib plus Trastuzumab|1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
9831045|NCT05247905|Experimental|Arm II (capecitabin, temozolomide)|Patients receive capecitabine PO BID days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9831046|NCT05247879|Active Comparator|Commercial reduced-osmolarity oral rehydration solution (ORS|
9831047|NCT05247879|Experimental|VS011, new children's ORS, a sugar-free blend of amino acids and electrolytes|
9831048|NCT05247853||Group 1|HPV-vaccinated women living with HIV
9831049|NCT05247853||Group 2|HPV-unvaccinated women living with HIV
9831050|NCT05247853||Group 3|HIV[-] women who are HPV-vaccinated
9831051|NCT05247840||diabetic children|Children aged 5-18 years (boys, girls) with type 1, type 2 and monogenic diabetes mellitus who are treated at the Endocrinology Department and Outpatient Clinic of Heim Pál National Pediatric Institute (HOGYI, Budapest, Hungary) will be enrolled. Definition of diabetes is based on the American Diabetes Association (ADA) criteria. All patients who meet the inclusion criteria will be informed of the possibility of taking part in the INTACT Trial.
9831052|NCT05247840||healthy children|Healthy children aged 5-18 years (boys, girls) without any acute or chronical disease will be will enrolled and the same tests will be performed on them as in diabetic children. Children with voided volume <20 mL, postvoid residual volume >15%, and signs of an overstretched bladder [voided volume more than: 30 x age (years) + 30 mL] will be excluded.
9831053|NCT05247827|No Intervention|Control Group|Participants will receive usual and customary post-amputation treatment
9831054|NCT05247827|Experimental|Exercise Group|Participants will be trained for 3 consecutive weeks to perform the targeted exercise of their phantom limb in addition to receiving usual and customary post-amputation treatment.
9831055|NCT05247814||Patients admitted to interdisciplinary polypharmacy consultation service|Patients admitted to the Interdisciplinary Polypharmacy Consultation Service of the Department of Geriatric's University Outpatient Clinic in cooperation with the Institute of Clinical Pharmacology
9831056|NCT05247801|Experimental|Experimental Group (Psychoeducational Intervention)|Two hundred and sixteen caregivers of multi-pathological and polypharmacy patients will receive psychoeducational intervention based on virtual reality and a dosing device for safer medication use at home. The intervention will be developed in a previous project phase using a mixed methodology (observational study and qualitative techniques). The intervention will be group-based and consist of motivational discussions and a review of audiovisual materials to promote self-efficacy and health literacy on the safe use of medication at home (most frequent errors, preventive strategies, etc.). Study period: 15 days intervention and follow-up 12 months.
9831057|NCT05247801|Active Comparator|Control Group (Dosing Device)|The 216 subjects assigned to the control group will use a medication dosing device and will receive information on how to use it for medication errors. Study period: 15 days intervention and follow-up 12 months.
9831058|NCT05247788|Experimental|Intoxicated risk awareness training session|Participants will complete an intoxicated risk awareness training session in which they receive a controlled alcohol dose with structured feedback and training to accurately appraise the impairing effects of alcohol and estimate their blood alcohol concentration (BAC).
9831059|NCT05247788|Active Comparator|Alcohol exposure only|Participants assigned to the alcohol-exposure-only condition undergo the same alcohol dose exposures over the session but receive a general body scan and do not receive feedback concerning BAC or performance.
9831060|NCT05247775|Experimental|Patients with prostate cancer|We performed urethral pressure profilometry prior to open retropubic radical prostatectomy (ORRP). Patients were interviewed about the urinary incontinence by the usage of pads and International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) prior to ORRP and at 2, 8, 16 and 24 weeks after ORRP.
9831061|NCT05247762|Sham Comparator|Sham acupuncture group|Use Wangbuliu Xingzi Paste on the skin, once a week, once for 20 minutes, for 24 weeks.
9831062|NCT05247762|Experimental|Acupuncture group|Use stainless steel needles on the skin, once a week, once for 20 minutes, for 24 consecutive weeks.
9831063|NCT05247749|Experimental|Convivo Imaging|The brain area that the operating surgeon plans to resect will be scanned using the CONVIVO device
9831064|NCT05247710||Patients diagnosed with non-superficial basal cell carcinoma|
9831065|NCT05247697|Experimental|Treatment|Mirtazapine 7.5 mg
9831066|NCT05247697|Placebo Comparator|Control|Matching placebo
9831067|NCT05247684|Experimental|arm 1(AK112)|Neoadjuvant therapy was 3-4 cycles of AK112(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
9984737|NCT03781154|No Intervention|Control Group|A physical activity education control group
9754303|NCT00553410|Active Comparator|Continuous letrozole|Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
9754304|NCT00553410|Experimental|Intermittent letrozole|Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
9754305|NCT00553436|Experimental|Enrolled Subjects treated with TAS device|All enrolled subjects treated with the Tissue Apposition System (TAS) device
9754306|NCT00553462|Experimental|paclitaxel + carboplatin + radiation + erlotinib|"Patients receive paclitaxel IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease progression outside of the chest after induction therapy are removed from study.~Patients with intrathoracic disease progression within the potential radiation field may continue protocol therapy at the discretion of the Study Chair. Patients with no disease progression outside the planned radiation field (either regional or distant) proceed to concurrent erlotinib hydrochloride and radiotherapy.~Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily. Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions) in the absence of rapid disease progression outside of the chest or unacceptable toxicity.~After completion of study therapy, patients are followed every 3 months for 1 year, and then every 6 months for up to 2 years"
9754307|NCT00553475|Placebo Comparator|Placebo|
9754308|NCT00553475|Experimental|Pregabalin 300 mg/day|
9754309|NCT00553475|Experimental|Pregabalin 600 mg/day|
9754310|NCT00553501|Experimental|Epratuzumab Plus Rituximab|"Induction Therapy (Month 1): Epratuzumab 360 mg/m^2 by IV days 1, 8, 15 & 22; Rituximab 375 mg/m^2 by IV day 3, 8, 15 & 22~Extended Induction (Weeks 12, 20, 28 & 36) Epratuzumab 360 mg/m^2 by IV weeks 12, 20, 28 & 36; Rituximab 375 mg/m^2 by IV weeks 12, 20, 28 & 36"
9754311|NCT00553514|Experimental|AS900672-Enriched 10 mcg|
9754312|NCT00553514|Experimental|AS900672-Enriched 20 mcg|
9754313|NCT00553514|Experimental|AS900672-Enriched 30 mcg|
9754314|NCT00553514|Experimental|AS900672-Enriched 40 mcg|
9754315|NCT00553514|Active Comparator|Follitropin alfa 75 IU|
9754316|NCT00553540|No Intervention|Control Group|Patients in this group will receive physical therapy and posture education for low back pain
9754317|NCT00553540|Active Comparator|Test Group|Patients in this group will receive spinal / back supports in addition to physical therapy and posture education for low back pain
9754318|NCT00553605|Active Comparator|I|Ketoprofen plus placebo parecoxib
9754319|NCT00553605|Active Comparator|II|Parecoxib plus placebo ketoprofen
9754320|NCT00553631|Experimental|GA-GCB|VPRIV™ ,velaglucerase alfa
9754321|NCT00553631|Active Comparator|imiglucerase|
9754322|NCT00553644|Experimental|Treatment (bortezomib, lenalidomide)|Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
9754323|NCT00553696|Experimental|A|
9754324|NCT00553735|Active Comparator|Cyclosporine A 0.05%|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
9754325|NCT00553735|Placebo Comparator|Artificial Tear|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
9754326|NCT00553787|Experimental|VI-0521 Top|high dose experimental treatment
9754327|NCT00553787|Experimental|VI-0521 Mid|mid dose experimental treatment
9754328|NCT00553787|Placebo Comparator|Placebo|Placebo
9754329|NCT00553839|Other|Ketamine|Then a 2 mg/kg IV bolus of Ketamine hydrochloride will be given as part of general anesthesia for procedure
9754330|NCT00553969|Experimental|1|Coreg CR + lisinopril
9754331|NCT00553969|Experimental|2|Coreg CR + placebo
9754332|NCT00553969|Experimental|3|lisinopril + placebo
9754333|NCT00553969|Placebo Comparator|4|placebo + placebo
9754334|NCT00554099|Placebo Comparator|Placebo|Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
9754335|NCT00554099|Active Comparator|Mesalamine|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
9754336|NCT00554099|Active Comparator|Mesalamine & Probiotic|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
9754337|NCT00554216|Experimental|VI-0521 Low|VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
9754338|NCT00554216|Experimental|VI-0521 Top|Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
9754339|NCT00554216|Placebo Comparator|Placebo|Placebo to match
9754340|NCT00554229|Experimental|ZD4054|ZD4054 10 mg oral tablet once daily
9754341|NCT00554229|Placebo Comparator|Placebo|Matching Placebo, oral tablets once daily
9754342|NCT00554372|Experimental|Low Dose|1e8 pfu (plaque forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
9754343|NCT00554372|Experimental|High Dose|1e9 pfu (plaque-forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
9754344|NCT00554463|Experimental|Combined Modality Therapy with Growth Factor Support|Concurrent radiation therapy, cisplatin, etoposide, and filgrastim followed by adjuvant cisplatin, etoposide, and pegfilgrastim.
9754345|NCT00554515|Experimental|HD IL2|Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.
9754346|NCT00554619|Experimental|GSK1325760A|
9754347|NCT00554671|Experimental|Pharmacist-led Group Visits|Algorithm driven medication titration, Behavioral: Monitoring, Behavioral: Group support, Behavioral: Self efficacy
9754348|NCT00554671|No Intervention|Usual Care|Patient continues on usual care for diabetes
9754349|NCT00554749|Other|1 Behavioral intervention|Behavioral intervention in all seven subjects Weekly sessions in the home and the kindergarten using defocused communication and stimulus fading interventions
9754350|NCT00554788|Experimental|Treatment (chemotherapy, radiotherapy, autologous SCI)|"INDUCTION: Patients receive vincristine IV; cisplatin IV; cyclophosphamide IV; and G-CSF SC beginning on day 3 and continuing until blood counts recover.~CONSOLIDATION (stage 4a or 4b disease only): Patients receive carboplatin IV; thiotepa IV; and etoposide IV.~AUTOLOGOUS STEM CELL INFUSION (stage 4a or 4b disease only): Patients undergo autologous stem cell infusion on day 0 and receive G-CSF SC beginning on day 1 and continuing until blood counts recover.~RADIOTHERAPY: Patients with stage 2 or 3 disease (orbital and/or regional involvement) undergo radiotherapy to sites that were initially involved beginning within 42 days after the start of course 4 of induction chemotherapy. Patients with stage 4a or 4b disease undergo radiotherapy to sites initially involved based on response beginning approximately 42 days after autologous stem cell infusion."
9754351|NCT00554801|Experimental|Blast|The study group includes soldiers who have recently been exposed to a high-explosive blast while stationed in Iraq or Afghanistan. They will be recruited at Walter Reed Army Medical Center, Washington, DC. They will undergo audiological testing.
9754352|NCT00554801|Active Comparator|Control|Control group are subjects matched to the experimental group by age, gender, and hearing loss, but who have not been exposed to a blast. They will undergo the same audiological testing as the experimental group
9754353|NCT00554853|Other|Pioglitazone then placebo|Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
9754354|NCT00554853|Other|placebo then study drug (pioglitazone)|Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
9754355|NCT00554970|Other|Treatment 1 then Treatment 2|Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
9754356|NCT00554970|Other|Treatment 2 then Treatment 1|Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
9754357|NCT00554970|Other|Treatment 3 then Treatment 4|Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
9754358|NCT00554970|Other|Treatment 4 then Treatment 3|Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
9754359|NCT00554996|Other|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
9754360|NCT00555048|Experimental|Alemtuzumab|Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.
9754361|NCT00555061|Experimental|Arm 1|Single Arm Retapamulin 1% Ointment
9517435|NCT03306368|No Intervention|Treatment as Usual (TAU)|Participants receiving treatment as usual post-residential detox. TAU clinic-based treatment receiving standard clinic-based XR-NTX.
9754362|NCT00555152|Experimental|Arm I (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
9754363|NCT00555152|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
9754364|NCT00555217|Experimental|Combination of ARB and ACEI|Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
9754365|NCT00555217|Active Comparator|Monotherapy ARB|Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)
9754366|NCT00555321|Experimental|Group 1: Basiliximab+Belatacept (MI) + MMF|
9754367|NCT00555321|Experimental|Group 2: Belatacept (MI) + MMF|
9754368|NCT00555321|Experimental|Group 3: Belatacept Less Intensive (LI) + MMF|
9754369|NCT00555321|Other|Group 4: Tacrolimus + MMF|Other
9754370|NCT00555321|Active Comparator|Group 5: Tacrolimus|
9754371|NCT00555360|Experimental|Arm 1|Veterans with heart failure that can identify an out-of-home informal caregiver
9754372|NCT00555360|Active Comparator|Arm 2|Veterans with heart failure that can identify an out-of-home informal caregiver
9754373|NCT00555425|Active Comparator|1|Buprenorphine/naloxone maintenance (Mtn) is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services.
9754374|NCT00555425|Experimental|2|Buprenorphine/naloxone detoxification (Dtx) is identical to Mtn for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Buprenorphine/naloxone.
9754375|NCT00555438|Experimental|1|patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery
9754376|NCT00555464|Experimental|1|Vincristine is a drug that has been used to treat cancers in children (including infants). It has been effective in treating a small number of infants with hemangiomas, most of whom failed previous therapies including steroids. Vincristine must be administered into a vein. Given the encouraging response data and documented safety record, Vincristine is a good choice for a clinical trial treating infants with complicated hemangiomas.
9754377|NCT00555464|Active Comparator|2|The standard treatment for hemangioma at most centers is oral steroids (Prednisolone). Prednisolone has been used to stop the growth of infantile hemangiomas that are life threatening, that could harm important functions, or are likely to result in severe disfigurement (scarring) without treatment.
9754378|NCT00555477|Experimental|anastrozole|
9754379|NCT00555568|Experimental|Peer-led Groups|Arm 1 is a 3-month recovery-focused mental health education and support group led by peer facilitators
9754380|NCT00555568|Experimental|Clinician-led Groups|Arm 2 is a 3-month recovery-focused mental health education and support group led by a mental health clinician
9754381|NCT00555568|No Intervention|Treatment as Usual|Arm 3 is treatment as usual (no intervention)
9754382|NCT00555581|Experimental|400 mg daily of Imatinib Mesylate|All patients were treated with imatinib mesylate at a target dose of 400 mg daily by mouth for 12 months. Dose modifications and interruptions were made for AE and were recorded. After 12 months of treatment, imatinib was stopped for 3 months. Patients were reassessed and offered entrance to an extension phase of the trial.
9754383|NCT00555620|Experimental|A|
9754384|NCT00555620|Experimental|B|
9782788|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Main Cohort|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
9782789|NCT01185522||Tocilizumab|Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months
9782790|NCT01185548|Experimental|Tasisulam and Tolbutamide|"Three study periods and continued access to tasisulam every 28 days (except Period 1 which was tolbutamide only and lasted 4 days) until disease progression:~Period 1: 500 milligram (mg) tolbutamide administered on Day 1.~Period 2: 500 mg of tolbutamide and individualized tasisulam dose [based on area under the curve albumin-corrected threshold (AUCalb)]. The AUCalb is a surrogate marker for unbound tasisulam, and this dosing approach represents the maximum level of unbound tasisulam which may be achieved clinically, administered on Day 1.~Period 3: Individualized tasisulam dose (based on AUCalb) administered on Day 1 and 500 mg tolbutamide administered on Day 4."
9782791|NCT01185561|No Intervention|Usual medical care|Participants assigned to this arm represent the control group and will receive usual medical care only.
9782792|NCT01185561|Experimental|Psychoeducational intervention|Participants assigned to this arm represent the experimental group and will receive group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes
9782793|NCT01185600|Active Comparator|Transfusion with washed RBC|Subject assigned to this arm will be transfused with washed RBC
9754385|NCT00555672|Experimental|A|
9754386|NCT00555750|Experimental|eszopiclone (3mg)|active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
9754387|NCT00555750|Placebo Comparator|placebo|identical placebo tablet by mouth nightly 30 min before bed
9754388|NCT00555880|Experimental|1|
9754389|NCT00555880|Placebo Comparator|2|
9754390|NCT00555893|Experimental|Active Drug|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
9754391|NCT00555893|Placebo Comparator|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
9754392|NCT00555906|Experimental|1|
9754393|NCT00555971|Placebo Comparator|Placebo Group|Subjects randomized to placebo
9754394|NCT00555971|Active Comparator|Omalizumab Group|Subjects randomized to omalizumab
9754395|NCT00555997|Active Comparator|1|Patients in group 1 will receive Ziprasidone for the full 12 weeks of the study.
9754396|NCT00555997|Active Comparator|2|Patients in Group 2 will receive placebo for the first 6 weeks of the study, then will receive Ziprasidone for the last 6 weeks.
9754397|NCT00555997|Placebo Comparator|3|Patients in Group 3 will receive placebo for the full 12 weeks of the study.
9754398|NCT00556049|Experimental|1|Sunitinib and gemcitabine
9754399|NCT00556140|Experimental|Major Depression with Psychotic Features|
9754400|NCT00556322|Experimental|1|
9754401|NCT00556322|Active Comparator|2|
9754402|NCT00556374|Experimental|Denosumab|Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
9754403|NCT00556374|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
9754404|NCT00556374|Experimental|SubStudy: Zoledronic Acid|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
9754405|NCT00556374|Other|Substudy: Standard of Care|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
9754406|NCT00556426|Experimental|Filter|All subjects enrolled to the study are in this arm. All subjects receive a filter.
9754407|NCT00556439|Experimental|A and C|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to abatacept at this point will be in Group A for giant cell arteritis and Group C for Takayasu arteritis.
9754408|NCT00556439|Placebo Comparator|B and D|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to placebo at this point will be in Group B for giant cell arteritis and Group D for Takayasu arteritis.
9754409|NCT00556452|Experimental|Clo/BU4|"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant."
9754410|NCT00556478|Active Comparator|Double-Blind Active|Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
9754411|NCT00556478|Placebo Comparator|Double-Blind Placebo|Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
9754412|NCT00556478|Active Comparator|Open Label Phase|Subjects will all receive PSD502 if they wish to continue in the trial.
9754413|NCT00556491|Active Comparator|minocycline|
9754414|NCT00556491|Placebo Comparator|placebo|
9754415|NCT00556504|Experimental|TCM-700C|an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
9754416|NCT00556504|Placebo Comparator|Placebo|placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
9754417|NCT00556543|Other|Treatment|
9754418|NCT00556673|Experimental|Indacaterol/mometasone - Placebo|In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
9754419|NCT00556673|Experimental|Placebo - indacaterol/mometasone|In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
9754420|NCT00556712|Experimental|Erlotinib|Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
9754421|NCT00556712|Placebo Comparator|Placebo|Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.
9754422|NCT00556842|Active Comparator|1|Participants will undergo total hip arthroplasty.
9754423|NCT00556842|Active Comparator|2|Participants will undergo hemi-arthroplasty.
9754424|NCT00556894|Experimental|CF101 0.1 mg|CF101 0.1 mg was given orally q12h
9754425|NCT00556894|Experimental|CF101 1 mg|CF101 1 mg was given orally q12h
9754426|NCT00556894|Placebo Comparator|Placebo|Matched placebo was given orally q12h
9754427|NCT00556933|Experimental|Group 1|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
9754428|NCT00556933|Experimental|Group 2|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
9754429|NCT00556933|Experimental|Group 3|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
9754430|NCT00556933|Experimental|Group 4|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
9754431|NCT00556946|Other|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains
9754432|NCT00556972|Experimental|Fecal Incontinence management system|Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.
9754433|NCT00556998|Experimental|1|
9754434|NCT00557076|Experimental|Familiar Auditory Sensory Training|FAST is a standardized passive auditory stimulation protocol. The patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. The FAST protocol is provided on compact discs (CDs), using portable players and noise cancelling headphones, while patients were awake (ie, eyes open). Speakers were used for one patient not tolerating his headphones. The CDs were identical according to track duration, labeling, and administration procedures.
9754435|NCT00557076|Sham Comparator|Sham Auditory Sensory Training|Placebo protocol is silence. Patients receive sham protocols for 10 minutes 4 times per day, with at least 2 hours in between, for 6 weeks.
9754436|NCT00557245|Active Comparator|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
9754437|NCT00557245|Active Comparator|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
9754438|NCT00557245|Placebo Comparator|Placebo|Placebo TDF + Placebo FTC/TDF orally, once daily.
9754439|NCT00557284|Experimental|1|Montelukast
9754440|NCT00557284|Placebo Comparator|2|
9754441|NCT00557310|Experimental|Teriparatide|20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
9754442|NCT00557323||1|Patients being treated for hyperphosphatemia with any marketed product
9754443|NCT00557349|Active Comparator|Omeprazole|40 mg Omeprazole daily
9754444|NCT00557349|Active Comparator|Famotidine|40 mg Famotidine daily
9754445|NCT00557362|Active Comparator|1|Topical voriconazole with corneal de-epithelialization
9754446|NCT00557362|Active Comparator|2|Topical voriconazole without corneal de-epithelialization
9754447|NCT00557362|Active Comparator|3|Topical natamycin with corneal de-epithelialization
9754448|NCT00557362|Active Comparator|4|Topical natamycin without corneal de-epithelialization
9754449|NCT00557440|Experimental|Ind/M - FP/Salm - Pbo|"In Treatment Period 1 (Days 1 & 2) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
9754450|NCT00557440|Experimental|FP/Salm - Pbo - Ind/M|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
9754451|NCT00557440|Experimental|Pbo - Ind/M - FP/Salm|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
9754452|NCT00557466|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9754453|NCT00557466|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9754454|NCT00557466|Experimental|Indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9754455|NCT00557466|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9754456|NCT00557466|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9754457|NCT00557466|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
9754458|NCT00557492|Experimental|Single Arm|"Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43~Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).~Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy"
9754459|NCT00557505|Experimental|PF-03732010|Single Arm study
9754460|NCT00557622|Experimental|paroxetine|Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved [i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
9754461|NCT00557622|Placebo Comparator|placebo|placebo
9754462|NCT00557830|Active Comparator|Group A: Escalated Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
9754463|NCT00557830|Active Comparator|Group B: Standard Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
9754464|NCT00557856|Experimental|1|
9754465|NCT00557882|Active Comparator|mesh|Vaginal reconstructive surgery with synthetic polypropylene mesh
9754466|NCT00557882|Active Comparator|no mesh|Vaginal reconstructive surgery without mesh
9754467|NCT00557947|Experimental|I|Dermabond Protape-Incision segments are randomized & patient is own control
9754468|NCT00557947|Active Comparator|II|Intradermal Suture - Incision segments are randomized & patient is own control. Investigator selected suture on the basis of standard local practice.
9754469|NCT00558012|Experimental|Active Medication Group|One-time dose: Intravenous Zoledronic Acid 5.0 mg; Vitamin D (800 IU/daily); Calcium 1200 mg/daily (supplement plus diet)
9754470|NCT00558012|Placebo Comparator|Placebo|One-time dose: intravenous saline; Vitamin D (800 IU/daily); 1200 mg calcium (supplement plus diet)
9754471|NCT00558025|Experimental|Pramipexole Extended Release (ER)|Pramipexole Extended Release (ER) once daily
9754472|NCT00558025|Experimental|Pramipexole Immediate Release (IR)|Pramipexole Immediate Release (IR) once daily
9754473|NCT00558103|Active Comparator|arm 1|Lapatinib
9754474|NCT00558103|Active Comparator|arm2|Pazopanib monotherapy (open label)
9754475|NCT00558103|Experimental|arm3|Lapatinib+ pazopanib
9754476|NCT00558246|Experimental|I|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
9754477|NCT00558246|Active Comparator|II|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
9754478|NCT00558259|Experimental|dabigatran etexilate 150 mg BID|Patient to receive dabigatran etexilatate capsules 150 mg twice daily
9754479|NCT00558259|Placebo Comparator|matching placebo twice daily (BID)|Patient to receive dabigatran extexilate matching placebo capsules twice daily
9754480|NCT00558272|Experimental|AZD0530 175 mg|AZD0530 (saracatinib) 175 mg once daily
9754481|NCT00558272|Experimental|Zoledronic Acid 4 mg|Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period
9754482|NCT00558285|Experimental|indacaterol/glycopyrrolate 600/100 μg|"Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
9754483|NCT00558285|Experimental|indacaterol/glycopyrrolate 300/100 μg|"One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
9754484|NCT00558285|Experimental|indacaterol/glycopyrrolate 150/100 μg|"One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
9754485|NCT00558285|Active Comparator|indacaterol 300 μg|"One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
9754486|NCT00558285|Placebo Comparator|placebo|"Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
9782794|NCT01185600|Active Comparator|Transfusion with unwashed RBC|Subjects assigned to this arm will be transfused with unwashed RBC
9831068|NCT05247684|Experimental|arm 2(AK112+Carboplatin/cisplatin + paclitaxel)|Neoadjuvant therapy was 3-4 cycles of AK112 plus Carboplatin/cisplatin + paclitaxel(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)
9831069|NCT05247671||Case|All eligible patients will be recruited to the study and will be assessed for SNPs in both ERCC1 and OCT2 and their association with cisplatin-induced nephrotoxicity through the measurement of cystatin C before taking cisplatin and after receiving the second cycle of cisplatin.
9831070|NCT05247619|Experimental|Intervention|Tislelizumab + Bevacizumab + Paclitaxel + Cisplatin/Carboplatin
9831071|NCT05247606|Experimental|Intervention group|Mobile application
9831072|NCT05247606|No Intervention|Control group|Usual care
9831073|NCT05247593||Dayingpian exposure group 1|The exposure of interest is Dayingpian. Patients in this group take Dayingpian combined with conventional mood stabilizers. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
9831074|NCT05247593||Non-exposure group|The non-exposure group is the patients who do not take Dayingpian. Patients in this group take conventional mood stabilizers. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
9831075|NCT05247593||Dayingpian exposure group 2|The exposure of interest is Dayingpian. Patients in this group take Dayingpian as monotherapy for bipolar disorder. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
9831076|NCT05247567|Other|First year students|Students in their first year of Hairdressing School
9831077|NCT05247567|Other|Third year students|Students in their third year of Hairdressing School
9831078|NCT05247554|Experimental|Hydroxychloroquine+low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
9831079|NCT05247554|Active Comparator|Medium-dose prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to M6).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
9831080|NCT05247541|Active Comparator|Healthy Participants|
9831081|NCT05247541|Experimental|Study participants|
9831082|NCT05247515|Experimental|Treated group: Nexpowder application on the scar after EMR with coagulation of visible vessels|To compare of the risk of bleeding after EMR application of nexpower (not a drug but a device with CE mark) on the resect area (scar) to cover the whole surface of mucosal resection.
9831083|NCT05247515|No Intervention|standard procedure : EMR with coagulation of visible vessels|After EMR with coagulation of visible vessels, if the patient is randomized in the comparative group, not nexpowder will be applied on the scar (common practice)
9831084|NCT05245682|Experimental|Treatment (tolinapant, radiation therapy)|Patients undergo standard of care radiation therapy for a total of 35 fractions over 7 weeks and receive tolinapant PO daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity.
9831085|NCT05243563|Experimental|Fractionated CO2 laser plus topical steroids|3 laser treatments at 6 week intervals for 6 months by a single trained operator
9831086|NCT05243563|Active Comparator|topical steroids alone|self-applied topical steroid therapy using clobetasol propionate 0.05%
9831087|NCT05231694|Other|sham EA + placebo group|sham EA + placebo group contain sham EA intervention and placebo injection
9831088|NCT05231694|Other|sham EA + NGF group|sham EA + NGF group contain sham EA intervention and NGF injection
9831089|NCT05231694|Other|EA + placebo group|EA + placebo group contain EA intervention and placebo injection
9831090|NCT05231694|Other|EA + NGF group|EA + NGF group contain EA intervention and NGF injection
9831091|NCT05227131|Experimental|Margetuximab + Tucatinib + Capecitabine|All eligible patients will receive the combination of margetuximab 15 mg/kg by intravenous infusion on Day 1 of each cycle (no loading dose is required), capecitabine at 1000 mg per square meter of body-surface area orally twice daily on days 1 to 14 of each 21-day cycle, and tucatinib 300 mg orally twice daily (every 12 hours) continuously in 21-day cycles.
9831092|NCT05224622|Experimental|Drive In|Drive In attendees will undergo one breath sampling.
9831093|NCT05224622|Experimental|Healthy|Healthy attendees will undergo two successive breath sampling.
9984738|NCT03778944|Active Comparator|M group|Mannitol infusion
9754487|NCT00558363|Experimental|Avodart|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
9754488|NCT00558363|Placebo Comparator|Placebo Arm|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
9754489|NCT00558467|Other|Pramipexole|
9754490|NCT00558467|Placebo Comparator|Placebo|
9754491|NCT00558519|Experimental|Treatment (chemotherapy, radiotherapy)|"Patients are given a series of leukemia treatments that are divided into several sequential courses and different chemotherapy combinations of treatment. Please see the Detailed Description section for more information."
9754492|NCT00558571|Placebo Comparator|Placebo|
9754493|NCT00558571|Experimental|BI 10773 low dose|
9754494|NCT00558571|Experimental|BI 10773 medium dose|
9754495|NCT00558571|Experimental|BI 10773 high dose|
9754496|NCT00558636|Experimental|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
9754497|NCT00558636|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
9754498|NCT00558701|Active Comparator|Microcurrent Stimulator + Silverlon|Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
9754499|NCT00558701|Sham Comparator|Silverlon alone|Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
9754500|NCT00558753|Placebo Comparator|1 Placebo|Half of the patients will receive PO placebo for 14 days
9754501|NCT00558753|Experimental|2 Pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
9754502|NCT00558792|Experimental|Isovue 370, 70 mL|iopamidol injection 370, 70 mL
9754503|NCT00558792|Experimental|Isovue 370, 80 mL|iopamidol injection 370, 80 mL
9754504|NCT00558792|Experimental|Isovue 370, 90 mL|iopamidol injection 370, 90 mL
9754505|NCT00558831|Active Comparator|Benzoyl Peroxide|Benzoyl Peroxide (BP) 2.5%
9754506|NCT00558831|Active Comparator|Benzoyl Peroxide plus moisturizing lotion|Benzyol Peroxide 2.5% plus moisturizing lotion
9754507|NCT00558844|Active Comparator|A|Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
9754508|NCT00558844|Placebo Comparator|B|Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
9754509|NCT00558844|Active Comparator|C|Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
9754510|NCT00558844|Active Comparator|D|Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
9754511|NCT00558844|Placebo Comparator|E|Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
9754512|NCT00558896|Experimental|Relapsed Myeloma (<4 Prior Regimens)|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
9754513|NCT00558896|Experimental|Lenalidomide Refractory Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
9754514|NCT00558896|Experimental|Bortezomib/Lenalidomide Refractory/Relapsed Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
9754515|NCT00558896|Experimental|Bortezomib/Lenalidomide Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
9754516|NCT00558896|Experimental|Relapsed Myeloma (< 4 Prior Regimens)|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
9754517|NCT00558896|Experimental|Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
9754518|NCT00558896|Experimental|Relapsed Amyloidosis|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
9754519|NCT00559013|Active Comparator|1|PSD Veritas Collagen Matrix Reinforcement Arm
9754520|NCT00559104|Active Comparator|Irradiation in conditioning|total-body irradiation, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematologic stem cell transplantation, peripheral blood stem cell transplantation
9754521|NCT00559104|Active Comparator|Carmustine in conditioning|Carmustine, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
9754522|NCT00559273|Experimental|Mircera|Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
9782795|NCT01185639|Experimental|SBRT for metastatic NSCLC|SBRT for lung lesions, liver lesions, adrenal lesions, spinal lesions
9754523|NCT00559273|Active Comparator|Darbepoetin Alfa|Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
9984739|NCT03778944|Active Comparator|D group|Dopamine infusion
9984740|NCT03778944|Active Comparator|C group|Adequate hydration
9754524|NCT00559364|Experimental|Viokase® 16|
9754525|NCT00559364|Placebo Comparator|Placebo|
9754526|NCT00559377|Experimental|Diagnostic FMISO AND FDG PET|Patients receive ^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.
9754527|NCT00559468|Experimental|Sugammadex + Sevoflurane|After receiving sevoflurane and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
9754528|NCT00559468|Experimental|Sugammadex + Propofol|After receiving propofol and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
9754529|NCT00559507|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9754530|NCT00559585|Active Comparator|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
9754531|NCT00559585|Active Comparator|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
9754532|NCT00559637|Experimental|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
9754533|NCT00559754|Experimental|1|
9754534|NCT00559845|Experimental|Bevacizumab|Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.
10201980|NCT05174364||Quadratus Lumborum Block|Bilateral QL block type 3 (anterior) for the intervention group will be performed on both sides of the patient after induction of general anesthesia. Patient will be positioned in semi-lateral decubitus and using low-frequency ultrasonography (USG) guidance attached to inferior lumbar region (Petit's triangle) that is consisted of inferior iliac crest and bordered by two muscles such as latissimus dorsi muscle in the posterior, abdominal external oblique muscle in the anterior. The USG will display the Shamrock sign, where the transverse process of vertebrae L4 role as the trunk, erector spinae muscle on the posterior side, psoas major (PM) on the anterior side, and QL muscle on the lateral side. After the visualization of QL and PM muscles, the Contiplex R needle will be directed parallel to the posterior side of the ultrasound probe until the tip of needle is confirmed in the border of QL and PM muscle
9754536|NCT00559949|Experimental|Arm I|Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
9754537|NCT00559962|Placebo Comparator|1|Placebo
9754538|NCT00559962|Active Comparator|2|2.5 mg AEGR-733
9754539|NCT00559962|Active Comparator|3|5 mg AEGR-733
9754540|NCT00559962|Active Comparator|4|7.5 mg AEGR-733
9754541|NCT00559962|Active Comparator|5|10 mg AEGR-733
9754542|NCT00559962|Active Comparator|6|5 mg AEGR-733 + 20 mg atorvastatin
9754543|NCT00559962|Active Comparator|7|5 mg AEGR-733 + 145 mg fenofibrate
9754544|NCT00559962|Active Comparator|8|5 mg AEGR-733 + 10 mg ezetimibe
9754545|NCT00559988|Experimental|Home Monitoring Guided OAC|Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
9754546|NCT00559988|Active Comparator|Physician-Directed OAC|"In Control (Group 2), Home Monitoring is active for Safety Net alerts, but the remote AF/AFL data is not revealed to the patient or treating physician. These patients receive physician-directed OAC consistent with current standards of care.~Safety Net data include:~ERI/EOS~Special Implant Status~Implant in Backup Mode (ROM)~VT/ VF Detection Inactive~Emergency Pacing~250 Ω > RV Pacing Impedance > 1500 Ω~Symptomatic VT/VF therapies including both ATP and shock~VT/VF storm~HM transmission failure >3 days"
9754547|NCT00560066|Experimental|cTIV|Subjects received one vaccination of cell culture-derived influenza vaccine
9754548|NCT00560066|Active Comparator|TIV|Subjects received one vaccination of egg-derived influenza vaccine
9754549|NCT00560105|Active Comparator|Acapella|The Active Comparator is the Acapella, a OPEP device
9754550|NCT00560105|Experimental|Lung Flute|The Active Comparator is the Lung Flute, a new indication of this device
9754551|NCT00560235|Experimental|1|
9754552|NCT00560313|Experimental|4CMenB|
9754553|NCT00560313|Experimental|MenACWY CRM|
9754554|NCT00560352|Experimental|Dasatinib + Bortezomib + Dexamethasone|Phase I dose escalation study
9754555|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 15 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
9754556|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
9754557|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
9754558|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 25 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
9754559|NCT00560391|Experimental|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, lenalidomide, and dexamethasone in varying doses in 28-day cycles.
9754560|NCT00560404|Experimental|1|
9754561|NCT00560404|Active Comparator|2|
9754562|NCT00560417|Active Comparator|ILPS|Insulin Lispro Protamine Suspension (ILPS)
9754563|NCT00560417|Active Comparator|Glargine|Insulin Glargine
9754564|NCT00560508|Experimental|Pramipexole Extended Release|patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
9754565|NCT00560508|Active Comparator|Pramipexole Immediate Release|patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
9754566|NCT00560560|Experimental|1|Single arm study
9754567|NCT00560573|Experimental|1|
9754568|NCT00560612|Active Comparator|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
9754569|NCT00560612|Placebo Comparator|Placebo|
9754570|NCT00560703|Active Comparator|COL-101 (doxycycline, USP) capsules|COL-101
9754571|NCT00560703|Placebo Comparator|Placebo|Sugar capsule
9754572|NCT00560755|Experimental|ProQuad®|Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.
9754573|NCT00560794|Experimental|Blinatumomab|Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m^2/day. A dose increase to 30 μg/m^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
9754574|NCT00560833|Placebo Comparator|Placebo|Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks
9754575|NCT00560833|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks
9754576|NCT00560833|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks
9754577|NCT00560833|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine 9 mg, encapsulated tablets, PO, QD for up to 12 weeks
9754578|NCT00560833|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine 18 mg, encapsulated tablets, PO, QD for up to 12 weeks
9754579|NCT00560859|Active Comparator|Early AT Surgery|There will be removal of tonsils and adenoids that will be performed within 4 weeks of the baseline visit.
9754580|NCT00560859|Other|Watchful Waiting|Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
9754581|NCT00560885|Experimental|AtriCure Bipolar System|The AtriCure Synergy Bipolar Ablation system is used to create lesions outlined in the Maze IV procedure during a concomitant open cardiac surgical procedure.
9754582|NCT00560937|Active Comparator|1|Pregnenolone
9754583|NCT00560937|Placebo Comparator|2|Placebo
9754584|NCT00560950|Experimental|1st Revaccination Group|
9754585|NCT00560950|Experimental|2nd Revaccination Group|
9754586|NCT00561002|Experimental|Influenza vaccine Naive/Inadequately Primed|Participants had no more than one previous lifetime dose of influenza vaccine and received two doses of Fluzone®, on Days 0 and 14.
9754587|NCT00561002|Experimental|Influenza Vaccine Primed|Participants had previously received 2 injections of Influenza vaccine in the same season and received a single dose of Fluzone® on Day 0.
9754588|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2|Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase). Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
9782796|NCT01185704|Experimental|Day 1 protocol|
9782797|NCT01185704|Experimental|Day 7 protocol|
9782798|NCT01185782|Experimental|SJ-0021 group|
9782799|NCT01185782|Active Comparator|Purified pituitary gonadotropin group|
9782800|NCT01185821|Experimental|BAF312 10 mg/2 mg|10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
9782801|NCT01185821|Experimental|BAF312 2 mg/2 mg|2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
9782802|NCT01185821|Experimental|BAF312 1.25 mg/2 mg|1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
9754589|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
9782803|NCT01185821|Experimental|BAF312 .5 mg/2 mg|.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
9782804|NCT01185821|Experimental|BAF312 .25 mg/2 mg|.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
9782805|NCT01185964|Experimental|Phase 1b: Olaratumab + doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
9782806|NCT01185964|Experimental|Phase 2: Olaratumab and doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
9782807|NCT01185964|Active Comparator|Phase 2: Doxorubicin: Optional Olaratumab After Progression|"All cycles are 21 days.~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression."
9782808|NCT01186250|Active Comparator|Pioglitazone|Pioglitazone
9782809|NCT01186250|Placebo Comparator|Placebo|Placebo
9782810|NCT01186328|Experimental|Single Arm|Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine).
9782811|NCT01186406|Experimental|Gliadel, Radiation Therapy, Avastin, Temodar|Single arm study where patients with newly diagnosed Grade IV malignant glioma will receive Gliadel at the time of resection, followed by radiation therapy (XRT), Avastin, and Temodar for approximately 6 1/2 weeks, followed by Avastin and Temodar post-radiation
9754590|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
9754591|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase). Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
9754592|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
9754593|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
9754594|NCT00561080|Experimental|Single Dose of Zostavax|Zostavax 0.65mL intramuscular injection administered on Day 0
9754595|NCT00561080|Experimental|Zostavax - Day 0 and Month 1|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
9754596|NCT00561080|Experimental|Zostavax - Day 0 and Month 3|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
9782812|NCT01186419|Experimental|SPD602 (16mg)|
9782813|NCT01186419|Experimental|SPD602 (32mg)|
9782814|NCT01186458|Experimental|Fludarabine, Velcade and Rituximab|Fludarabine, Velcade and Rituximab
9782815|NCT01186562|Active Comparator|Sitagliptin|
9782816|NCT01186562|Placebo Comparator|Placebo|
9782817|NCT01186692|Experimental|Melody TPV Implant|Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
9782818|NCT01186705|Experimental|MK-2206|This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.
9782819|NCT01186744|Experimental|Active Treatment (10 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
9782820|NCT01186744|Experimental|Active Treatment (10 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
9782821|NCT01186744|Experimental|Active Treatment (5 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
9782822|NCT01186744|Experimental|Active Treatment (5 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
9782823|NCT01186770|Experimental|MNTX 150 mg|Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).
9782824|NCT01186770|Experimental|MNTX 300 mg|Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
9782825|NCT01186770|Experimental|MNTX 450 mg|Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
9782826|NCT01186770|Placebo Comparator|Placebo|Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).
9782827|NCT01186796|Experimental|Fulvestrant|
9782828|NCT01186809|Experimental|Cytokine Induced Killer|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
9782829|NCT01186939|Experimental|Azacitidine|Azacitidine (study drug) plus best supportive care.
9831094|NCT05224622|Experimental|Corona Department|Healthy attendees will undergo five successive breath sampling.
9754597|NCT00561145|Experimental|Young men|Energy restriction period
9754598|NCT00561145|Experimental|Elderly men|Energy restriction period
9754599|NCT00561340|Experimental|1 Can of Pediasure Supplement Plus Nutritional Counseling|Pediasure and nutritional counseling
9754600|NCT00561340|Active Comparator|Counseling by the Provider on Ways to Encourage Caloric Intake|Behavioral intervention - Nutritional Counseling
9754601|NCT00561353|Experimental|TMC435 25 mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B).
9754602|NCT00561353|Experimental|TMC435 75mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily for 21 days with PegIFNα-2a (P) and ribavirin (R) OR TMC435 75 mg once daily coadministered with PR for 28 days (Panel B).
9754603|NCT00561353|Placebo Comparator|Placebo (Cohort 1/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 25/75 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR and Placebo once daily coadministered with PR for 28 days (Panel B).
9754604|NCT00561353|Experimental|TMC435 200 mg (Cohort 2, Panel A and B)|Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 200 mg once daily coadministered with PR for 28 days (Panel B).
9754605|NCT00561353|Placebo Comparator|Placebo (Cohort 2/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR placebo once daily coadministered with PR for 28 days (Panel B).
9754606|NCT00561353|Experimental|TMC435 75 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
9754607|NCT00561353|Experimental|TMC435 150 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
9754608|NCT00561353|Experimental|TMC435 200 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
9754609|NCT00561353|Placebo Comparator|Placebo (Cohort 4/Panel C)|Treatment-experienced non-responders received placebo once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
9754610|NCT00561353|Experimental|TMC435 200 mg (Cohort 5/Panel D)|Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
9754611|NCT00561392|Experimental|Rivastigmine 5 and 10 cm^2 patch|For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm^2 patch, with adjustments as necessary for safety and tolerability.
9754612|NCT00561418|Experimental|Vorinostat (SAHA)|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.
9754613|NCT00561431|Active Comparator|1|Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr
9754614|NCT00561431|Experimental|2|High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr
9754615|NCT00561457|Experimental|Iliac Stenting|Stent placement in the iliac artery
9754616|NCT00561470|Placebo Comparator|Placebo/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
9754617|NCT00561470|Experimental|Aflibercept/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
9754618|NCT00561574|Experimental|Esmirtazapine 1.5 mg|Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
9754619|NCT00561574|Experimental|Esmirtazapine 3.0 mg|Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
9754620|NCT00561600|Active Comparator|A|ASR™-XL Modular Acetabular Cup System stem
9754621|NCT00561600|Active Comparator|B|Pinnacle™ acetabular shell, with a 28mm or 36mm ULTAMET® metal liner, and a 28mm or 36mm Articul/eze M head.
9782830|NCT01186978|Other|Single arm|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve CR and have a negative post-chemotherapy PET scan following 4 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
9782831|NCT01187004||Acute Lung Injury (ALI)|patients who might develop acute lung injury (ALI) after cardiac surgery with cardiopulmonary by pass
10201981|NCT05174221|Experimental|Mezagitamab|Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period.
10201982|NCT05173597||Patients receiving treatment with Follitropin-delta|The included patients are adult women from the routine clinical care settings with indication for ovarian stimulation with follitropin delta in a GnRH-antagonist protocol who are making a first treatment attempt IVF or ICSI. This study is intended to be conducted in non-vulnerable population. No vulnerable subjects will be enrolled in the study.
10201983|NCT05173558|Experimental|Uninterrupted motionless standing|20minutes of uninterrupted motionless standing
10201984|NCT05173558|Experimental|Uninterrupted motionless sitting|20 minutes of uninterrupted motionless sitting
10201985|NCT05173558|Experimental|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
10201986|NCT05172999|Active Comparator|LNG-IUS|enrolled patients will receive LNG-IUS for 6 months or longer till complete response
9754622|NCT00561652|Active Comparator|Education + exercise|Education was provided in four, 1-hour sessions to improve patients' understanding of their back problem, reduce unwarranted concern about serious outcomes, & empower them to maintain normal activities & reduce risk of future back problems. Patients were taught that recovery depends on moving & restoring normal function & fitness. Patients were shown stretching & strengthening exercises to perform daily at home to enhance mobility & increase trunk endurance while minimizing spinal load. At follow-up, therapists reviewed exercise form & adherence. Participants allocated to no chiropractic care also were scheduled for 10 weekly 10-15 minute sessions to equalize provider attention vs. the group also receiving chiropractic care & not to provide education, exercise instruction, or therapy.
9754623|NCT00561652|Experimental|Education + exercise + chiropractic|In addition to education & exercise, all participants in this arm will be assigned chiropractic treatment. A minimum of 4 & up to 12 treatments will be provided over 6 weeks, based on patient response (i.e. treatments stopped if symptoms resolve). Each treatment visit will last 10-20 minutes. After 6 weeks, if the treating chiropractor determined that the patient's LBP was continuing to improve but hadn't reached therapy goals defined at baseline, the patient could receive up to 12 additional treatments over the next 6 weeks. Chiropractic treatment was delivered following standardized protocols. Treatment consisted of manual therapies, including SMT and mobilization techniques, with the assistance of light soft tissue techniques as indicated to facilitate the SMT.
9754624|NCT00561678|Experimental|Precedex|Precedex (Dexmedetomidine)
9754625|NCT00561678|Placebo Comparator|Placebo|Placebo - normal saline
9754626|NCT00561730||Pantoprazole|All patients enrolled
9754627|NCT00561821|Experimental|Esmirtazapine 0.5 mg|one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
9754628|NCT00561821|Experimental|Esmirtazapine 1.5 mg|one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
9754629|NCT00561821|Experimental|Esmirtazapine 3.0 mg|one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
9754630|NCT00561821|Placebo Comparator|Placebo|one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days
9754631|NCT00561834|Experimental|Ranibizumab|To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.
9754632|NCT00561925|Experimental|nevirapine XR|400 mg QD
9754633|NCT00561925|Active Comparator|nevirapine IR|200 mg BID
9754634|NCT00561951|Experimental|Fesoterodine fumarate 4 mg (Double-Blind)|
9754635|NCT00561951|Placebo Comparator|Placebo (Double-Blind)|
9754636|NCT00561951|Experimental|Fesoterodine fumarate 8 mg (Double-Blind)|
9754637|NCT00561977|Active Comparator|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
9754638|NCT00561977|Active Comparator|Low Saturated Fat|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal per day.
9754639|NCT00561977|Active Comparator|Combination Diet|Combination low saturated fat (≤7% of total calories);high fiber (>30g fiber per day) -500 kcal from RMR, not less than 1200 kcal/day.
9754640|NCT00562094||Pantoprazole|
9754641|NCT00562120|Placebo Comparator|Placebo|
9754642|NCT00562120|Active Comparator|Allegra|
9754643|NCT00562120|Active Comparator|Allegra-D|
9754644|NCT00562120|Experimental|PF-03654746|
9754645|NCT00562159|Placebo Comparator|Placebo|Matching Placebo
9754646|NCT00562159|Experimental|SCH 697243|
9754647|NCT00562302|Experimental|Bio-Seal Group|Bio-Seal Plug Implanted
9754648|NCT00562302|No Intervention|Control Group|Control group with no intervention
9754649|NCT00562315|Other|FACBC PET-CT and ProstaScint CT|Participants diagnosed with localized prostate carcinoma with subsequent definitive therapy or suspicion of recurrent cancer will undergo an FACBC PET-CT scan and the ProstaScinct CT.
9754650|NCT00562328|Experimental|Alemtuzumab + Rituximab + GM-CSF|Alemtuzumab + Rituximab + GM-CSF
9754651|NCT00562354|Experimental|1|Stratum 1: >= 65 years of age
9754652|NCT00562354|Experimental|2|Stratum 2: 50 to 64 years of age
9754653|NCT00562484|Experimental|1|
9754654|NCT00562484|Other|2|
9754655|NCT00562627|Experimental|LIA IV|Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine
9754656|NCT00562627|Experimental|LIA IA|Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine
9754657|NCT00562627|Active Comparator|EDA|standard continuous epidural analgesia
10201987|NCT05172999|Experimental|LOX+LNG-IUS|enrolled patients will receive LNG-IUS plus polyethylene glycol loxenatide for treatment.
10201988|NCT05172986|Experimental|RAAC (Program Arm)|Patient under RAAC Program
10201989|NCT05172986|No Intervention|Standard Arm|Standard patient procedure
10201990|NCT05172843|Active Comparator|Knee Arthroplasty|Surgical knee replacement using either total knee replacement (TKA) or unicompartmental knee replacement (UKA)
10201991|NCT05172843|Experimental|Supervised weight loss program|The supervised intensive dietary weight loss program with meal replacements
10201992|NCT05172154||15 subjects testing themselves|15 subjects 14 years of age and older
10201993|NCT05172154||15 subjects testing someone else|15 adult subjects testing individuals ages 2-13
10201994|NCT05170763|Experimental|PA9159 10 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 10 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
9754658|NCT00562718|Experimental|Surgery and Chemotherapy|Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.
9754659|NCT00562861|Active Comparator|citalopram + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to citalopram.
9754660|NCT00562861|Placebo Comparator|placebo + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to placebo
9754661|NCT00562965|Experimental|A|Subjects will receive rituximab intravenously at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered intravenously at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days.
9754662|NCT00562965|Active Comparator|B|Subjects will receive the investigator's choice from the following rituximab-containing regimens: R-CVP or R-FND. The investigator's choice of therapy will be administered every 21 days. Dosing for R-CVP will be intravenous rituximab at a dose of 375 mg/m2 on day 1, intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1, intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 intravenous on day 1, mitoxantrone 10 mg/m2 intravenous on day 2, fludarabine 25 mg/m2 intravenous on days 2 through 4 and oral dexamethasone 20 mg/day on days 1-5.
9754663|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
9754664|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
9754665|NCT00563186|Experimental|A|Admission to a novel hospital ward (e.g. abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
9754666|NCT00563186|No Intervention|B|Hospital admission to a ward with traditional design features (eg. lack of sinks, predominance of 4-bed rooms [80%], shared bathrooms, curtains present)
9754667|NCT00563290|Experimental|Arm I (dasatinib 100 mg PO BID)|Patients receive 100 mg dasatinib PO BID on days 1-28
9754668|NCT00563290|Experimental|Arm II (dasatinib 70 mg PO BID)|Patients receive 70 mg dasatinib PO BID on days 1-28
9754669|NCT00563316|Experimental|Panitumumab + Irinotecan|Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.
9754670|NCT00563368|Experimental|VI-0521 Top|VI-0521; high dose phentermine/topiramate
9754671|NCT00563368|Experimental|VI-0521 Mid|VI-0521; mid dose phentermine/topiramate
9754672|NCT00563368|Active Comparator|TPM 46|mid dose topiramate
9754673|NCT00563368|Active Comparator|TPM 92|high dose topiramate
9754674|NCT00563368|Active Comparator|PHEN 7.5|mid dose phentermine
9754675|NCT00563368|Active Comparator|PHEN 15|high dose phentermine
9754676|NCT00563368|Placebo Comparator|Placebo|
9754677|NCT00563381|Active Comparator|Tiotropium + Placebo|patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
9754678|NCT00563381|Active Comparator|Salmeterol + Placebo|patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
9754679|NCT00563706|Experimental|1|
9754680|NCT00563706|Active Comparator|2|4mg/day
9754681|NCT00563706|Placebo Comparator|3|matching placebo
9754682|NCT00563784|Experimental|Erlotinib + Paclitaxel + Carboplatin|Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles
9754683|NCT00563797|Experimental|Mecamylamine|Mecamylamine is a noncompetitive, high-affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Those receiving mecamylamine started at 2.5mg once daily (second dose was placebo). The dose was increased to 5.0 mg twice daily over 3 weeks.
9754684|NCT00563797|Placebo Comparator|Placebo|Placebo capsules were prepared by the pharmacy and were identical in size and color to the medication capsules.
10201995|NCT05170763|Experimental|PA9159 20 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 20 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
9754685|NCT00564018|Experimental|Detemir|24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
9754686|NCT00564018|Experimental|Glargine|24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
9754687|NCT00564018|Experimental|NPH|24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.
9754688|NCT00564070|Active Comparator|Enhanced treatment as usual|Enhanced treatment as usual plus single-session life-steps treatment
9754689|NCT00564070|Experimental|CBT-AD|Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)
9754690|NCT00564265||GIST|GIST from all gastrointestinal origins: esophagus, stomach, duodenum, jejunum, ileum, colon and rectum
9754691|NCT00564278|Active Comparator|Standard antidepressant therapy|Participants will receive standard antidepressant therapy, including selecting among 9 FDA-approved antidepressants from several classes.
9754692|NCT00564278|Experimental|Motivational antidepressant therapy|Participants will receive motivational antidepressant therapy, including selecting among the same list of 9 FDA-approved antidepressants from several classes as in the control arm.
9754693|NCT00564395|Experimental|Insulin Detemir+RAI, then Insulin Detemir and RAI separately|Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days.
9754694|NCT00564395|Active Comparator|Insulin Detemir and RAI separately, then Insulin Detemir+RAI|Participants first received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for 10 days. Then they received Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for the next 10 days.
9754695|NCT00564447|Experimental|Azithromycin-30 minutes Post dose|
9754696|NCT00564447|Experimental|Azithromycin-2 hours post dose|
9754697|NCT00564447|Experimental|Azithromycin-12 hours post dose|
9754698|NCT00564447|Experimental|Azithromycin-24 hours post dose|
9754699|NCT00564447|Experimental|Moxifloxacin-30 minutes post dose|
9754700|NCT00564447|Experimental|Moxifloxacin-2 hours post dose|
9754701|NCT00564447|Experimental|Moxifloxacin-12 hours post dose|
9754702|NCT00564447|Experimental|Moxafloxacin-24 hours post dose|
9754703|NCT00564486|Placebo Comparator|IV Placebo 100 ml|IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).
9754704|NCT00564486|Placebo Comparator|IV Placebo 65 ml|IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).
9754705|NCT00564486|Experimental|IV Acetaminophen 1 gm|IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).
9754706|NCT00564486|Experimental|IV Acetaminophen 650 mg|IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).
9754707|NCT00564629|Experimental|IV acetaminophen plus oral placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.
9754708|NCT00564629|Active Comparator|Oral acetaminophen plus IV placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.
9754709|NCT00564681|Active Comparator|botulinum toxin Type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
9754710|NCT00564681|Active Comparator|botulinum toxin Type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
10201996|NCT05170763|Experimental|PA9159 40 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 40 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
10201997|NCT05170763|Experimental|PA9159 80 μg single dose and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 80 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data.
10201998|NCT05170763|Experimental|PA9159 20 μg repeated doses and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 20 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
9754711|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
9754712|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A Formulation 2|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A Formulation 2 for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
9754713|NCT00564733|Experimental|Chemotherapy|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients undergo FDG PET/CT (fludeoxyglucose F 18 positron emission tomography/computed tomography) scan between days 18-21. The FDG PET/CT is an imaging biomarker analysis. Patients that are responding to treatment receive paclitaxel IV and carboplatin IV on day 1. Treatment repeats every 3 weeks for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.Patients that are not responding to chemotherapy per FDG PET then receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Non-responding patients undergo an additional FDG PET/CT scan between days 18-21 of course 2.
9754714|NCT00564850|Experimental|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|
9754715|NCT00564889|Experimental|CRD|"Lenalidomide 15mg daily (days 1-21)~Cyclophosphamide 300 mg/m^2 (days 1, 8, 15)~Dexamethasone 40 mg weekly"
9754716|NCT00564902|Placebo Comparator|Lutein|9 mg of Lutein for 12 months
9754717|NCT00564902|Active Comparator|Zeaxanthin and Lutein|3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
9754718|NCT00564902|Active Comparator|Zeaxanthin|3R 3'R Zeaxanthin 8 mg per day during 12 months
9754719|NCT00564954|Experimental|Dex-methylphenidate hydrochloride (Focalin XR)|20 mg capsule orally once a day for 7 days
9754720|NCT00564954|Placebo Comparator|Placebo|orally once a day for 7 days
9754721|NCT00565045|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Stimulation to finger and thumb extensors and flexors only in response to and with an intensity proportional to opening and closing of the contralateral unimpaired hand~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity~Therapy sessions are done with the subject being assisted by the CCFES system."
9754722|NCT00565045|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation.~Preprogrammed cycles of finger and thumb flexor and extensor stimulation repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Therapy sessions are done without the stimulation system"
9754723|NCT00565058|Experimental|Pilot|Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group, addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.
9754724|NCT00565058|Experimental|Phase II arm|Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group, GTI-2040 is given 24 hours prior to addition of HiDAC.
9754725|NCT00565084|Active Comparator|1|Ibuprofen
9754726|NCT00565084|Placebo Comparator|2|Placebo 1
9754727|NCT00565084|Placebo Comparator|3|Placebo 2
9754728|NCT00565110|No Intervention|Enhanced Usual Care|EUC patients receive medical center standard oncology care and supportive services routinely provided to all patients with cancer. In addition, EUC patients are given a patient focused and a family focused educational pamphlet on depression and cancer and a listing of financial and community resources (in Spanish for Spanish-speaking patients). With patient consent, as described in the informed written consent, the treating oncologist is informed via medical chart note if EUC patients screen positive for major depression. Treating oncology attending physicians, fellows and residents are invited to attend a didactic session led by the study psychiatrist on treating depression in cancer patients.
9754729|NCT00565110|Experimental|ADAPt-C intervention|Intervention patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
9754730|NCT00565136|Experimental|TOPAS|TOPAS AMS Pelvic Floor Repair System
9754731|NCT00565266|Experimental|"Tio + 1xICS || LABA + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
9782832|NCT01187017|Experimental|Fludarabine/Cyclophosphamide in Participants with Severe Aplastic Anemia|Participants with Severe Aplastic Anemia will receive Fludarabine at 125 mg/m squared plus Cyclophosphamide at 60 mg/kg (Flu/Cy).
9782833|NCT01187043|Experimental|ARM 1|1 mg Proellex
9782834|NCT01187043|Experimental|ARM 2|3 mg Proellex
9754732|NCT00565266|Experimental|"TIO + 1xICS || 2xICS || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
9754733|NCT00565266|Experimental|"LABA + 1xICS || Tio + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
9754734|NCT00565266|Experimental|"LABA + 1xICS || 2xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
9754735|NCT00565266|Experimental|"2xICS || Tio + 1xICS| || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
9754736|NCT00565266|Experimental|"2xICS || LABA + 1xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
9754737|NCT00565370|Experimental|A|XP+sorafenib
9754738|NCT00565370|Placebo Comparator|B|XP
9754739|NCT00565409|Active Comparator|1|
9754740|NCT00565409|Active Comparator|2|
9754741|NCT00565409|Placebo Comparator|3|
9754742|NCT00565448|Experimental|Docetaxel/Cisplatin/5-FU (TCF)|"Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks~Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
9754743|NCT00565448|Active Comparator|Cisplatin/5-FU (CF)|"Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy.~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
9754744|NCT00565604|Experimental|Short Catheter Delviery|Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
9754745|NCT00565643|Experimental|HA-CMC Group|Hyaluronic Acid-Carboxymethylcellulose placed as an adhesion barrier
9754746|NCT00565643|Placebo Comparator|Routine Closure Group|Routine Closure without placement of an adhesion barrier
9754747|NCT00565669|Experimental|Blink Tears|
9754748|NCT00565669|Experimental|Systane|
9754749|NCT00565721|Experimental|Fluciclatide Injection - (AH111585 (F18))|Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
9754750|NCT00565747|Experimental|Test culture|Culture with GM-CSF
9754751|NCT00565747|Placebo Comparator|Control culture|Culture without GM-CSF
9754752|NCT00565773|Experimental|Immunosuppressive medications|"Renal transplant recipients will be given an experimental combination of immunosuppressive drugs. Participants will receive a single dose of alemtuzumab on the day of transplantation and will receive belatacept and sirolimus for 1 year.~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes, followed within 1 hour by an IV infusion of 30 mg of alemtuzumab over 3 hours."
9754753|NCT00565812|Active Comparator|200 mg|High dose active comparator
9754754|NCT00565812|Active Comparator|50 mg|Low dose active comparator
9754755|NCT00565812|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
9754756|NCT00565864|Experimental|1 (Low-normal TSH target)|Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
9782835|NCT01187043|Experimental|ARM 3|6 mg Proellex
9782836|NCT01187043|Experimental|ARM 4|9 mg Proellex
9782837|NCT01187043|Experimental|ARM 5|12 mg proellex
9754757|NCT00565864|Experimental|2 (High-normal TSH target)|"Treatment arm 2 targeting a TSH of 2.5 - 5.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
9754758|NCT00565864|Experimental|3 (Mildly elevated TSH target)|"Treatment arm 3 is targeting a TSH level o f 5.1-12.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
9754759|NCT00565916|Experimental|estrogen plus progesterone|Hormone replacement therapy (HRT): estrogen plus progesterone
9754760|NCT00565916|Active Comparator|estrogen plus placebo|Hormone replacement therapy (HRT): estrogen plus placebo
9754761|NCT00566020|Experimental|Lamotrigine|study drug
9754762|NCT00566098|Experimental|ASCT+MILs|Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.
9754763|NCT00566111|Active Comparator|A|
9754764|NCT00566111|Placebo Comparator|P|
9754765|NCT00566150|Active Comparator|Levetiracetam|
9754766|NCT00566150|Placebo Comparator|Placebo|
9754767|NCT00566228|Experimental|Immunologic autograft engineering|Patients' stem cells are collected according to modified Amicus settings (i.e., MNC OFFSET = 0.0 and RBC = 7.0). Patients undergo ASCT IV on the day of apheresis (lymphocyte enriched autograft).
9754768|NCT00566228|Active Comparator|Standard autograft collection|Patients' stem cells are collected according to standard Amicus settings (i.e., MNC OFFSET = 1.5 and RBC OFFSET = 5.0). Patients undergo ASCT IV on the day of apheresis.
9754769|NCT00566254|Placebo Comparator|Placebo|Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
9754770|NCT00566254|Experimental|Zonisamide|Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
9754771|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).
9754772|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).
9754773|NCT00566527|Experimental|Arm 1: ProQuad® at 9 and 12 months|Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.
9754774|NCT00566527|Experimental|Arm 2: ProQuad® at 11 and 14 months|Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.
9754775|NCT00566527|Active Comparator|Arm 3: ProQuad at 12 and 15 months|Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.
9754776|NCT00566540|Experimental|Treatment (neoadjuvant, adjuvant chemotherapy and radiation)|"PREOPERATIVE:Patients receive cisplatin IV over 2 hours three times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.~SURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.~INTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.~POSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10."
9754777|NCT00566579|Experimental|A|Double-freezing cryotherapy was done within one month after the primary hpv testing was positive. Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
9754778|NCT00566579|No Intervention|B|Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
9754779|NCT00566631|Experimental|Paliperidone Extended Release (ER)|
9754780|NCT00566696|Experimental|High-Risk Hematologic Malignancies|"Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.~Grafts from suitable haploidentical donors are processed using the CliniMACS system."
9754781|NCT00566709|Experimental|RBCT based on rSO2 value|Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
9754782|NCT00566709|Active Comparator|RBCT based on hemoglobin level value|Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.
9754783|NCT00566722|Experimental|Open Label|
9754784|NCT00566735|Placebo Comparator|1|
9754785|NCT00566735|Active Comparator|2, Galantamine|
9782838|NCT01187095|Experimental|counselling|Does couples in IVF treatment benefit from emotional disclosure
9831095|NCT05221983||Patients with COVID-19 + with vitamin D levels|Patients with COVID-19 + and vitamin D levels were included in the study retrospectively. Vitamin D level was categorized into 3 groups as inadequacy, deficiency and normal from medical records. No intervention was made.
9831096|NCT05220813|Active Comparator|local anesthetic group (control group)|44 patients will receive local infiltration anesthesia.
9831097|NCT05220813|Active Comparator|ilioinguinal iliohypogastric group|44patients will receive ilioinguinal iliohypogastric nerve blocks
9831098|NCT05219994|Experimental|Oral Glucose Tolerance Test|Subjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.
9831099|NCT05217368|Experimental|experimental group/mandala painting|Mandala painting will be done in addition to routine antenatal education.
9831100|NCT05217368|No Intervention|antenatal education class|Only routine antenatal education will be done.
9831101|NCT05217277||patient with juvenile idiopathic arthritis and gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and gingivitis, have not used medication yet.
9782839|NCT01187095|Active Comparator|Control|Neutral writing exercise
9782840|NCT01187329|Experimental|hyperinsulinemic normoglycemic clamp (HNC)|Patients will be randomized to receive treatment with HNC during cardiac surgery.
9782841|NCT01187329|Placebo Comparator|standard glucose management|Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.
9782842|NCT01187355|Experimental|Alcon MPDS|MPDS used for 30 days as specified in protocol for contact lens care.
9782843|NCT01187355|Active Comparator|renu fresh MPS|MPS used for 30 days as indicated for contact lens care.
9782844|NCT01187381||Participants with Breast Cancer|Participants with early or metastatic HER2-positive breast cancer who were receiving treatment with trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines, will be observed. Dosing and treatment duration of the trastuzumab will be at the discretion of the treating physician.
9831102|NCT05217277||healthy patient group with gingivitis|It is a group of healthy patients with gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
9831103|NCT05217277||healthy patient group without gingivitis|It is a group of healthy patients without gingivitis between the ages of 5-16 who have not taken antibiotics in the last 3 months.
9831104|NCT05217277||patient with juvenile idiopathic arthritis and without gingivitis|It is a group of patients between the ages of 5 and 16 who have recently been diagnosed with juvenile idiopathic arthritis and without gingivitis, have not used medication yet.
9831105|NCT05216497|Experimental|Ingavirin®, 90 mg capsules|Ingavirin®, 90 mg capsules will be administered on top of standard therapy: days 1-3: 180 mg (2 capsules once a day); days 4-7: 90 mg (1 capsule 1 time per day).
9831106|NCT05216497|Placebo Comparator|Placebo|Placebo capsules will be administered on top of standard therapy: days 1-3: 2 capsules once a day; days 4-7: 1 capsule 1 time per day.
9831107|NCT05216224|Experimental|ATI-450|ATI-450 50mg oral tablet BID
9831108|NCT05216224|Experimental|Placebo|Placebo oral tablet BID
9831109|NCT05215509|Experimental|RA patients TNFi Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at >85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
9831110|NCT05215509|Active Comparator|RA patients TNFi Control|"This group will be allocated to control and therefore no supervised exercise regimen"
9831111|NCT05215509|Experimental|RA patients IL-6Rb Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at >85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 5 min cool-down of 50% Hrmax"
9831112|NCT05215509|Active Comparator|RA patients IL-6Rb Control|"This group will be allocated to control and therefore no supervised exercise regimen"
9831113|NCT05215236|Experimental|Opiate Sparing|Standard icing and elevation therapy Acetaminophen 1000 milligrams by mouth every 8 hours for five days then as needed every 8 hours for pain control Gabapentin 100 milligrams by mouth three times per day for 14 days Celecoxib 100 milligrams by mouth two times per day for 5 days Esomeprazole 20 milligrams by mouth once per day for 14 days Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone Oxycodone 5 milligrams by mouth every 6 hours as needed for pain control unresponsive to other medications
9831114|NCT05215236|Active Comparator|Opiate Based|Standard icing and elevation therapy Oxycodone 5-10 milligrams by mouth every 4 to 6 hours as needed for pain control Acetaminophen 1000 milligrams by mouth every 8 hours as needed for pain control Promethazine 12.5 milligrams by mouth every 8 hours as needed for nausea or vomiting Docusate 100 milligrams by mouth two times per day while taking oxycodone
9831115|NCT05212792||Case with COVID-19 vaccine adverse event|Patients with GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
9831116|NCT05212792||Control without COVID-19 vaccine adverse event|Participants without experiencing GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
9831117|NCT05212233||Patients with MM and/or CLL|This is a non-interventional study. All enrolled patients will complete a telephone interview. A subset of patients will complete the optional follow-up interview. The clinical practice sites through which patients are being recruited and enrolled on to the study will each complete the Site Survey. Physicians at these sites who treat patients with MM or CLL will be invited to complete the Physician Survey.
9831118|NCT05208437|Experimental|Complete oral feeding intervention group|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale. Feeding of premature infants using different interventions based on the results of the Feeding Preparation Scale.
9831119|NCT05208437|Active Comparator|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding. Routine nursing care is identical to the control group.
9831120|NCT05208320|Experimental|intervention ward|"Patients received interventions as follow:~The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~Home health education by Community Health Workers every month for 6 months"
9831121|NCT05208320|No Intervention|control ward|Patients received usual care, consisted of existing services in the community
9831122|NCT05204199||Group A|Patients without a urological or gastrointestinal malignancy undergoing non-oncological bladder surgery or transurethral resection of the prostate (TUR-P)
9831123|NCT05204199||Group B|Low Risk NMIBC (primary, solitary, Ta / low grad < 3cm, no carcinoma in situ (CIS))
9831124|NCT05204199||Group C|NMIBC patients, BCG candidates, assessed as intermediate (between the category of low- and high risk) or high risk (T1 or high grade or CIS or multiple, recurrent and large (> 3 cm) Ta/ low grade tumours).
9831125|NCT05202808|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
9831126|NCT05202808|Active Comparator|Control IOL|
9831127|NCT05201703|Experimental|Fycompa 4 mg daily|
9831128|NCT05201703|Active Comparator|Fycompa 4 mg daily with a boost of 8 mg|
9831129|NCT05201027|Experimental|trifocal intraocular lens|Implantation of new trifocal intraocular lens
9831130|NCT05192434|Experimental|Expressive Writing + Contingency Management|A total of 180 WWID will be randomly assigned to the EW+CM (expressive writing + contingency management) intervention arm. To begin each session, participants will complete a brief battery of psychological measures. Then, in a private setting, they will be asked to write for 20 minutes about a major trauma that occurred three or more months in the past. WWID who prefer not to write (e.g., have lower literacy) will be provided the opportunity to talk aloud about the traumatic experience while being audio recorded, which yields comparable effects to writing. Next, women will respond to a prompt that encourages cognitive processing of the trauma for ten additional minutes. To complete the session, participants will answer the same brief battery of psychological measures for the purposes of identifying acute distress. Those exhibiting clinically elevated distress symptoms will engage in a brief de-escalation and evaluation session with study staff who will be trained.
9835844|NCT02758301||Diagnostic|The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
9835845|NCT02758613|Experimental|2 milligram (mg) Baricitinib|2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
9835846|NCT02758613|Experimental|4mg Baricitinib|4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
9754786|NCT00566813|Active Comparator|Group 1 (Islet Cell Transplant)|1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.
9754787|NCT00566813|Active Comparator|Group 2 (Islet Cell Transplant plus)|1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily for I week, then up to 10-mcg twice daily for 6 months after the last islet transplant.
9754788|NCT00566852|Experimental|WBRT+Memantine|Whole brain radiation therapy (WBRT) and memantine
9754789|NCT00566852|Active Comparator|WBRT+Placebo|Whole brain radiation therapy (WBRT) and placebo
9754790|NCT00566930|No Intervention|1|
9754791|NCT00566930|Active Comparator|2|spinal manipulation
9754792|NCT00566930|Experimental|3|Spinal manipulation + exercises
9754793|NCT00566943|Active Comparator|Control|"Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple lines including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine). intestine or mesentery.~Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without buttress at the GJ anastomosis. Linear buttress at the stomach/pouch staple line is required."
9754794|NCT00566943|Experimental|PSD Veritas|"Linear Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas used as a staple line buttress at the stomach/pouch.~In addition to buttress of the stomach/pouch, patients may have PSD Veritas linear buttress at any of the following staple lines: intestine, mesentery, or anastomosis junction (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine).~Circular Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas circular buttress used as a staple line buttress at the GJ anastomosis. Linear buttress at the stomach/pouch is required."
9754795|NCT00566969|Placebo Comparator|Sugar Pill|To be compared to active drug
9754796|NCT00566969|Active Comparator|Carvedilol 25 mg|To be compared to placebo and Carvedilol 50 mg
9754797|NCT00566969|Active Comparator|Carvedilol 50 mg|To be compared to placebo and Carvedilol 25 mg
9754798|NCT00566982|Experimental|Ospemifene 60 mg/day|Ospemifene will be taken orally, once daily, in the morning, with food for 52 weeks.
9754799|NCT00566982|Placebo Comparator|Placebo|Placebo will be taken once daily, in the morning, with food for 52 weeks.
9754800|NCT00567008|Experimental|1|Varenicline (Chantix)
9754801|NCT00567008|Placebo Comparator|2|Placebo
9754802|NCT00567112|Experimental|DFC (fasted)|
9754803|NCT00567112|Experimental|OCT (fasted)|
9754804|NCT00567112|Experimental|OCT (after meal)|
9754805|NCT00567112|Active Comparator|OCT (before meal)|
9754806|NCT00567164|Experimental|Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
9754807|NCT00567164|Experimental|Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
9754808|NCT00567164|Active Comparator|Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.
9754809|NCT00567190|Experimental|Pertuzumab + Trastuzumab + Docetaxel|Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
9831131|NCT05192434|Placebo Comparator|Neutral Writing + Contingency Management|A total of 180 WWID will be randomly assigned to the attention-control arm which includes neutral writing + CM. Women in this group will complete the same pre/post psychological measures as the intervention group for the purposes of time matching. During the writing session, they will be asked to describe their schedule from the preceding day as if they were reporting facts, without discussing personal thoughts and feelings (e.g., describe what you did from the time you got up until the time you went to bed). Those with lower literacy can opt to talk aloud while being audio recorded. This is the same attention-control used our previous work which balances contact time and study incentives.
9831132|NCT05184894|Experimental|AKI in Care Transitions (ACT) Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will participate in the ACT program which provides standardized education and assists with coordination of follow up care after hospital stay.
9831133|NCT05184894|No Intervention|Usual Care Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will receive standard of care from their inpatient and outpatient care teams.
9831134|NCT05184738|Experimental|Oligomeric nutritional formula arm (Bi1 peptidic)|Individuals will receive a Oligomeric nutritional formula.
9831135|NCT05184738|Other|Standard arm|Individuals will receive a Standard nutritional formula.
9831136|NCT05184348|Active Comparator|Narrow band Ultraviolet B phototherapy group|Patients will be treated with Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose of 1400 mJ/cm2.
9831137|NCT05184348|Active Comparator|Acitretin group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally for 3 months
9831138|NCT05184348|Active Comparator|Acitretin plus Narrow band Ultraviolet B phototherapy group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally plus NB-UVB phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
9831139|NCT05184348|No Intervention|Control group|30 healthy individuals un related , age, sex , BMI matched with volunteers.
9831140|NCT05179655|Experimental|ERITA + TAU (Treatment as usual)|The Emotion Regulation Individual Therapy for Adolescents (ERITA) intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth
9831141|NCT05179655|Other|TAU (Treatment as usual)|Within mental health services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this study the control intervention (TAU) consists of clinical assessment and treatment for patient's current primary psychiatric condition (referral condition and A-diagnosis).
9831142|NCT05171062|Experimental|Cohort 1|Study patients will receive 0.1-1 mg/kg bexmarilimab (FP-1350) given in combination with Pembrolizumab 200mg IV once every three weeks. The first subject will be started on 0.1mg to establish toleration, for one dose, and then the dose will be escalated to 1mg. This subject will be included in Cohort 1 data.
9831143|NCT05171062|Experimental|Cohort 2|Study participants will receive 3mg/kg Bexmarilimab given in combination with Pembrolizumab 200mg IV once every three weeks. 3 participants will need to complete this level before the next cohort dosing begins.
9831144|NCT05171062|Experimental|Cohort 3|Study participants will receive 10 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks. 3 participants will need to complete this level before the next cohort dosing begins.
9831145|NCT05171062|Experimental|Cohort 4|Study participants will receive 30 mg/kg Bexmarilimab plus pembrolizumab 200mg IV once every 3 weeks.
9831146|NCT05170945|No Intervention|Retrospective Cohort|Colonoscopy was performed, either early bowel preparation, late bowel preparation or no bowel preparation patients.
9831147|NCT05170945|Experimental|Prospective Cohort|Early bowel preparation for colonoscopy patients
9831148|NCT05169151||Observational (physical activity tracking)|Patients utilize smartphone application to monitor physical activity and mobility up to 180 days during treatment or post-treatment.
9831149|NCT05166200|Experimental|Experimental Formula|One 237 ml serving of study product
9831150|NCT05166200|Active Comparator|Test Meal|48 g Instant oatmeal
9831151|NCT05165693|Experimental|Experimental Formula|One 296 mL serving of study product
9831152|NCT05165693|Active Comparator|Test Meal|48 g Instant oatmeal
9831153|NCT05164926|Experimental|Experimental group, whose perineum was massaged with St. John's Wort oil during labor|St. John's Wort oil will be applied to this group during perineal massage during labor.
9831154|NCT05160480|Experimental|Total-body PET scan|All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.
9831155|NCT05159193|Experimental|PLD + C + HP followed by THP|pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 followed by docetaxel (T) 90~100 mg/m^2, i.v., d1 + trastuzumab (H) 6 mg/kg, i.v., d1 + pertuzumab (P) 420 mg, i.v., d1 q3w, for 4 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
9831156|NCT05159193|Active Comparator|TCbHP|docetaxel (T) 75 mg/m^2, i.v., d1 + carboplatin (Cb) AUC 6, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 q3w, for 6 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
9831157|NCT05156437|Experimental|Group I (Experimental)|Two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of oral therapy with outpatient follow-up.
9754810|NCT00567190|Placebo Comparator|Placebo + Trastuzumab + Docetaxel|Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
9754811|NCT00567229|Experimental|Lenalidomide and Rituximab|This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.
9754812|NCT00567242|Experimental|Word-finding with intention component|Treats word-finding (picture naming, category member generation) with an intention manipulation (complex left-hand movement to initiate word-finding trials)
9754813|NCT00567242|Active Comparator|Word-finding with no intention component|Word-finding trials similar to intention mediated treatment, but without intention manipulation
9754814|NCT00567255|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
9754815|NCT00567255|Placebo Comparator|Placebo|Placebo with ancillary therapy
9782845|NCT01187407|Experimental|12 or 18 mg flexible dose LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to a 12 or 18 mg flexible dose of LY2216684.~During the AT Phase, participants first received 6 mg LY2216684 QD for 3 days, followed by 12 mg QD for the next 11 days. Then, based on efficacy and tolerability, dosage could be increased to 18 mg QD over the next 6 weeks. Participants on 18 mg QD could have had their dose decreased back to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
9782846|NCT01187407|Experimental|6 mg fixed dose LY2216684 + SSRI|"LY2216684: fixed dose of 6 mg, administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to 6 mg fixed dose of LY2216684.~During the AT Phase, participants received a 6 mg fixed dose of LY2216684 adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
9782847|NCT01187407|Placebo Comparator|Placebo + SSRI|"Placebo: administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to placebo.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
9782848|NCT01187446|Experimental|TSEBT & Vorinostat|"Total skin electron beam therapy (TSEBT) will be performed per institution guidelines.~Vorinostat will be administered at a dose of 400 mg/day, starting one day prior to the initiation of TSEBT. During TSEBT, vorinostat should be taken in the morning and preferably prior to TSEBT."
9782849|NCT01187446|Active Comparator|TSEBT only|"Total skin electron beam therapy (TSEBT) will be administered according to the Stanford 6-field technique or equivalent technique per institutional standards. Patients will receive a planned total skin dose of 12 grey (Gy) fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. Supplements will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions (1-2 Gy fractions to a total dose of 12 Gy). Discrete tumors may receive additional boost treatment not to exceed 12 Gy."
9782850|NCT01187498|Experimental|Behavioral Training|Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
9782851|NCT01187498|Active Comparator|Drug Therapy|Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg
9782852|NCT01187511|Active Comparator|GSK561679|GSK561679 was given orally, once a day in the evening, for 21 days, at a dose of 350mg, administered as four tablets consisting of 3 x 100mg tablets plus 1 x 50mg tablet.
9782853|NCT01187511|Placebo Comparator|Placebo|Placebo was given orally, once a day in the evening, for 21 days, in the form of four tablets that matched those of GSK561679
9782854|NCT01187771|Active Comparator|Laparoscopic Gastric Banding|
9782855|NCT01187771|Active Comparator|Continuous Positive Airway Pressure|
9782856|NCT01187901|Active Comparator|Erlotinib and Sulindac|Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
9754816|NCT00567268||Gabapentin|Patients taking Gabapentin
9754817|NCT00567307|Experimental|The Red Heart Pill 2b (Polypill) (A)|The Polypill is composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
9754818|NCT00567307|Active Comparator|Standard Practice Group (B)|Standard Practice
9754819|NCT00567320|Active Comparator|Varenicline|
9754820|NCT00567320|Active Comparator|Sugar Pill or Placebo|Placebo is compared to active drug varenicline
9754821|NCT00567359|Experimental|Erlotinib|
9754822|NCT00567398|Active Comparator|non glucose sparing|Dianeal only
9754823|NCT00567398|Experimental|Glucose sparing|Physioneal, Extraneal, Nutrineal
9754824|NCT00567476|Active Comparator|Omalizumab + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
9754825|NCT00567476|Active Comparator|Conventional Therapy|Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
9754826|NCT00567489|Active Comparator|Non glucose sparing|Dianeal only
9754827|NCT00567489|Experimental|glucose sparing|PEN solutions: Nutrineal, Extraneal, and Physioneal
9754828|NCT00567502||1|XAGRID® (anagrelide hydrochloride)
9754829|NCT00567502||2|Xagrid + Other cytoreductive
9754830|NCT00567502||3|Other cytoreductive
9754831|NCT00567541|Active Comparator|Active BBPM stimulation|Therapeutic Stimulation is applied via the Battery Powered Microneuromodulator (BBPM) which is programmed to deliver set stimulation parameters with approximate frequency of 30 Hz, current 5mA for 200 microseconds for the first 12 weeks of the study. The BBPM is implanted near the axillary nerve within the quadrilateral space.
9754832|NCT00567541|Placebo Comparator|Sham BBPM stimulation|The Battery Powered Microneuromodulator is implanted near the axillary nerve within the quadrilateral space. The BBPM is programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, the device will be reprogrammed to deliver therapeutic stimulation over a 12 week period.
9754833|NCT00567593|Other|Rosiglitazone|Rosiglitazone; 8mg tablet once a day for 14 days
9754834|NCT00567840|Experimental|1|PA-824 200 mg/qd
9754835|NCT00567840|Experimental|2|PA-824 600 mg/qd
9754836|NCT00567840|Experimental|3|PA-824 1000 mg/qd
9754837|NCT00567840|Experimental|4|PA-824 1200 mg/qd
9754838|NCT00567840|Active Comparator|5|Rifafour e-275 mg
9754839|NCT00567879|Experimental|Panobinostat with trastuzumab|Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.
9754840|NCT00567892|Experimental|1. rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
9754841|NCT00567892|Sham Comparator|2. Sham rTMS|Sham rTMS appears identical to and mimics sounds and sensations of active magnet.
9754842|NCT00567996|Experimental|Indacaterol 150 μg|"Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9754843|NCT00567996|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9754844|NCT00567996|Active Comparator|Salmeterol 50 μg|"Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9754845|NCT00568022|Experimental|Ixabepilone + Capecitabine|
9754846|NCT00568061|Experimental|Inhaled Nitric Oxide|Inhaled Nitric oxide administered at 80 parts per million (ppm)
9754847|NCT00568061|Placebo Comparator|Placebo|Inhaled nitrogen gas (Placebo) administered at 80 ppm
9754848|NCT00568087|Active Comparator|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
9754849|NCT00568087|Placebo Comparator|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
9754850|NCT00568126|Experimental|Maca Root|Subjects in this arm will be given 3g/day of maca root for 12 weeks
9754851|NCT00568126|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo for 12 weeks.
9754852|NCT00568321|Experimental|1|
9754853|NCT00568321|Active Comparator|2|
9754854|NCT00568321|Placebo Comparator|3|
9754855|NCT00568334|Experimental|VARILRIX HSA-FREE GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
9754856|NCT00568334|Experimental|VARILRIX GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
9754857|NCT00568386|Experimental|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop in each eye one time
9754858|NCT00568386|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each one time
9754859|NCT00568399|Experimental|Active Treatment|This is the only arm and involves active treatment with sodium thiosulfate in those subjects with high coronary artery calcium scores.
9754860|NCT00568451|Experimental|PC (previously treated)|Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
9754861|NCT00568451|Experimental|PC (chemo naive)|Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
9754862|NCT00568451|Experimental|TMZ (previously treated)|Previously chemotherapy treated cohorts: Temozolomide (TMZ)
9754863|NCT00568451|Experimental|TMZ (chemo naive)|Chemotherapy-naive cohorts: Temozolomide (TMZ)
9754864|NCT00568555|Experimental|Low Dose Naltrexone first|LDN first, then placebo.
9754865|NCT00568555|Placebo Comparator|Placebo - sugar pill first|Placebo first, then LDN.
9754866|NCT00568633|Experimental|Allo-HSCT + TLI + ATG|"Participants achieving complete remission after consolidation therapy & who have 5 of 6 HLA-match sibling donor to provide PBSC harvest for transplant. Pre-transplant subjects receive:~Total lymphoid radiation (TLI) Days -11 to -7, and Days -4 to -1 (2 fractions on day -1)~Anti-thymocyte globulin (ATG) Days -11 to -7~Methylprednisolone Days -11 to -7~Cyclosporine (CSP) Days -4 to +2~5+ of 6 HLA-matched CD34+ cells on Day 0~Mycophenolate mofetil (MMF), Day 0 to Day +28"
9754867|NCT00568633|Active Comparator|Best Standard Care|"Regular medical care for participants who achieve complete remission after standard consolidation therapy, but do not have a 5 of 6 HLA-match sibling donor. Treatment may consist of:~Additional consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~Autologous transplantation~Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~Umbilical cord blood transplantation~Haploidentical transplantation"
9754868|NCT00568685|Active Comparator|Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)|
10201999|NCT05170763|Experimental|PA9159 40 μg repeated doses and placebo|Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 40 μg PA9159 or placebo once a day for 7 days. There will be a one week follow-up period to review all available clinical and laboratory safety data.
10202000|NCT05170464|Experimental|Acute Exercise|20 minutes of moderate intensity acute exercise (treadmill speed to achieve ⅔ of maximum heart rate).
10202001|NCT05170464|Active Comparator|Caffeine Ingestion|1.2mg/kg of powdered caffeine (Caffeine powder, ReagentPlus® from Sigma-Aldrich) dissolved in 1 cup of water then sitting for 20 minutes.
9754869|NCT00568685|Active Comparator|Atomoxetine 0.5 mg/kg/day|
9754870|NCT00568685|Active Comparator|Atomoxetine 1.2 mg/kg/day|
9754871|NCT00568776|Placebo Comparator|1|
9754872|NCT00568776|Active Comparator|2|
9754873|NCT00568776|Active Comparator|3|
9754874|NCT00568776|Active Comparator|4|
9754875|NCT00568854|Active Comparator|Participants with diabetes|Persons with diagnosis of diabetes. Received biological intervention: BCG
9754876|NCT00568854|Active Comparator|Participants without diabetes|Persons with no diagnosis of diabetes and negative diabetes screening labs. Received biological intervention: BCG.
9754877|NCT00568958|Experimental|Naltrexone|Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling
9754878|NCT00568958|Placebo Comparator|Placebo Naltrexone|Placebo Naltrexone (targeted + daily) + BASICS Counseling
9754879|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 0|"Group 1 = Low-Dose Ara-C + Azacitidine-Level 0~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days"
9754880|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 1|"Group 2 = Low-Dose Ara-C + Azacitidine-Level 1~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
9754881|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 0|Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65years) AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days
9754882|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 1|"Group 4 = High-Dose Ara-C + Azacitidine-Level 1~High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65 years) AZA:Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
9754883|NCT00569166|Active Comparator|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
9754884|NCT00569166|Active Comparator|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
9754885|NCT00569166|Placebo Comparator|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
9754886|NCT00569192|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
9754887|NCT00569192|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
9754888|NCT00569192|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
9754889|NCT00569231|Experimental|Candida Antigen|
9754890|NCT00569270|Active Comparator|Tiotropium 18 µg capsule, bronchodilator|tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
9754891|NCT00569270|Placebo Comparator|2|placebo 18ug tiotropium for 1 month
9754892|NCT00569309|Experimental|Prevnar|The conjugate vaccine for Streptococcus pneumoniae will be administered during weeks 9, 17, and 25 after autologous HSCT - the study nurse will arrange for the vaccine to be administered at the specified time and the patient will be instructed to notify an investigator or study nurse of any side effects of vaccine administration. At the specified times, patients will fill out the quality-of-life assessment. All patients enrolled on this trial will have samples procured for all proposed laboratory correlative studies.
9754893|NCT00569530|Active Comparator|Treatment Surfactant (Infasurf) ONY, NY|Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
9754894|NCT00569530|Placebo Comparator|Sham (no treatment)|Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
9754895|NCT00569582|Experimental|1|
9754896|NCT00569660|Experimental|Azacitidine|75 mg/m^2 Subcutaneous Daily for 7 days every 4 weeks
9754897|NCT00569777|Experimental|K-lens|etafilcon A contact lens with ketotifen.
9754898|NCT00569777|Placebo Comparator|Placebo|etafilcon A contact lens without ketotifen
9754899|NCT00569803|Active Comparator|Belatacept 50 mg Subcutaneous Injection|Belatacept 50 mg subcutaneous (SC) injection
9754900|NCT00569803|Active Comparator|Belatacept 100 mg Subcutaneous Injection|Belatacept 100 mg SC injection
9754901|NCT00569803|Active Comparator|Belatacept 125 mg Subcutaneous Injection|Belatacept 125 mg SC injection
9754902|NCT00569803|Active Comparator|Belatacept 150 mg Subcutaneous Injections|2 SC injections of 75 mg Belatacept
9754903|NCT00569803|Active Comparator|Belatacept 200 mg Subcutaneous Injections|2 SC injections of 100 mg Belatacept
9754904|NCT00569803|Active Comparator|Belatacept 250 mg Subcutaneous Injections|2 SC injections of 125 mg Belatacept
9754905|NCT00569803|Active Comparator|Belatacept 125 mg Intravenous Infusion|125 mg Belatacept intravenous (IV) injection
9754906|NCT00569803|Placebo Comparator|Placebo|SC injection of placebo solution
9754907|NCT00569855|Experimental|1|Receive phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery
9754908|NCT00569946|Experimental|AG-013736|
9754909|NCT00570037|Active Comparator|Immunization Program|Intervention Hospital - Standing postpartum vaccine orders, influenza vaccine clinic on postpartum ward for household contacts, mailed vaccine reminders
9754910|NCT00570037|No Intervention|No Immunization Program|Comparison Hospital - Receipt of vaccine through routine clinical care
9754911|NCT00570063|Placebo Comparator|1|PF-02545920 15 mg tablets taken twice a day by mouth for 21 days
9754912|NCT00570063|Placebo Comparator|2|Matching placebo tablets taken twice a day by mouth for 21 days
9754913|NCT00570089|Experimental|Study Drug Ranexa, Then Placebo|"Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet)."
9754914|NCT00570089|Experimental|Placebo, Then Study Drug Ranexa(Ranolazine)|"Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval."
9754915|NCT00570128|Active Comparator|Donepezil HCl|
9754916|NCT00570128|Placebo Comparator|Placebo|
9754917|NCT00570141|Active Comparator|OASIS Wound Matrix (Oasis)|This is a single arm study with only the test article Oasis used on all subjects
9754918|NCT00570232|Other|Tarceva|All patients will be prescribed erlotinib 150mg daily
9754919|NCT00570310|Active Comparator|A|Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
9754920|NCT00570310|Placebo Comparator|B|Patients in Group B will be treated with placebo.
9754921|NCT00570323|Active Comparator|ARM A / Arimidex with Faslodex|Arimidex with Faslodex in postmenopausal women
9754922|NCT00570323|Active Comparator|ARM B Arimidex without Faslodex|Arimidex without Faslodex in postmenopausal women.
9754923|NCT00570349|Experimental|Low Dose Cohort|Subjects in the low dose cohort receive 20 part per million (ppm) of nitric oxide via nasal cannula over a 44 hour period.
9754924|NCT00570349|Experimental|High-Dose Cohort|Subjects in the high dose cohort receive 40 ppm of nitric oxide via nasal cannula over a 44 hour period.
9754925|NCT00570349|Placebo Comparator|Nitrogen|100% Nitrogen (placebo) will be administer at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
9754926|NCT00570401|Experimental|Dasatinib|"Beginning 1 week after completion of erlotinib hydrochloride or gefitinib therapy, patients receive oral dasatinib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.~Response is assessed by CT scan at 4 weeks, 8 weeks, and then every 8 weeks thereafter."
9754927|NCT00570492|Placebo Comparator|Placebo nasal spray|
9754928|NCT00570492|Experimental|Fluticasone furoate nasal spray|
9754929|NCT00570505|Experimental|LapBand|All subjects who receive the LAP-BAND System.
9754930|NCT00570661|Experimental|ITF2357|"ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength (dose strengths of 7.5, 10, 12.5, 15, 20 mg and 50 mg).~Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity"
9754931|NCT00570674|Experimental|Phase I Dose Level 1: ACE-RT|Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
9754932|NCT00570674|Experimental|Phase I Dose Level -1: AC-RT|Phase I Dose Level -1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
9754933|NCT00570674|Experimental|Phase I Dose Level 2: AC-RT|Phase I Dose Level 2 participants received Abraxane 30mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
9754934|NCT00570674|Experimental|Phase I Dose Level 3: AC-RT|Phase I Dose Level 3 participants received Abraxane 40mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
9754935|NCT00570674|Experimental|Phase I Dose Level 4: AC-RT|Phase I Dose Level 4 participants received Abraxane 50mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
9754936|NCT00570687|Experimental|1|Technosphere Insulin
9754937|NCT00570700|Experimental|Dasatinib|Patients receive oral dasatinib once daily in the absence of disease progression or unacceptable toxicity.
9782857|NCT01187901|Placebo Comparator|Placebo A and Placebo B|Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months
9782858|NCT01187914||Open Irrigation|Those individuals who had an ablation using open irrigation cooled-tip RF ablation.
9831158|NCT05156437|Active Comparator|Group II (Control Group)|Conventional two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of IV antibiotic therapy (inpatient or facility supervised if indwelling catheter utilized).
9831159|NCT05155423||group 1|patient using mask for immobilization
9831160|NCT05155423||group 2|patients using Elekta BodyFix
9831161|NCT05154045|Experimental|Experimental Formula|One 330 ml serving of study product
9831162|NCT05154045|Active Comparator|Test Meal|40 g Instant oatmeal
9831163|NCT05148546|Experimental|A: Neoadjuvant nivolumab|Neoadjuvant 2 cycles of nivolumab 360mg every 3 weeks
9831164|NCT05148546|Experimental|B: Neoadjuvant nivolumab + ipilimumab|Neoadjuvant 2 cycles of nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks
9831165|NCT05148546|Experimental|C: Neoadjuvant nivolumab + relatlimab|Neoadjuvant 2 cycles of nivolumab 360mg + relatlimab 360mg every 3 weeks
9831166|NCT05146986||Non-surgical group|Patients will receive analgesia and symptomatic management treatment
9831167|NCT05146986||Surgical group|Patients will receive surgical treatment using RibFix Blu Thoracic Fixation System
9835847|NCT02758613|Experimental|10mg Baricitinib|10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
9835848|NCT02758613|Placebo Comparator|Placebo|Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
9835849|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
9835850|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
9835851|NCT02759016|Experimental|BI 836826|BI 836826 administered in combination with Standard of Care Ibrutinib
9835852|NCT02759055|Experimental|Clinical Decision Support (CV Wizard)|In the Intervention arm, primary care providers will be provided with an EHR-linked, Web-based clinical decision support system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke, optimizing management and follow up of pre-diabetes patients with uncontrolled CV risk factors.
9835853|NCT02759055|No Intervention|Usual Care|In the No Intervention arm, patients receive usual care from their primary care clinic and care providers.
9835854|NCT02759120|Experimental|Antimicrobial therapy|Co-trimoxazole OR doxycycline
10202002|NCT05170438|Experimental|Lenvatinib 12 or 16 mg/day orally,D28; Paclitaxel 80 mg/m2 in 250-500 mL of NS, IV D 1, 8, 15;|one arm Lenvatinib 16 or 12 mg/day orally day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15;
10202003|NCT05168592|Experimental|Imaginal extinction|Conditioned fear will be diminished using imaginal extinction.
10202004|NCT05167552|Experimental|Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells|Group 1: Patients with allergic rhinitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
9835855|NCT02759120|Other|Standard of care|Standard of care for patients with IPF for comparison
9835856|NCT02759146|Experimental|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
9835857|NCT02759146|Experimental|Meditative Practice|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
10202005|NCT05167552|Experimental|Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells|Group 2: Patients with chronic polypous rhinosinusitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
9835858|NCT02759146|No Intervention|Control|Control - no intervention
9835859|NCT02759315|Experimental|GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
9835860|NCT02759315|Experimental|GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
9835861|NCT02759315|Experimental|GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
9835862|NCT02759315|Experimental|GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
9835863|NCT02759315|Experimental|GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
9835864|NCT02759315|Experimental|GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
9831168|NCT05146154|Experimental|Pharmacokinetic cohort|After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.
9831169|NCT05146154|Experimental|Safety cohort|After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm
9831170|NCT05143424|Active Comparator|CBD (350 mg)|CBD 350 mg twice per day for 3 days
10202006|NCT05167552|Active Comparator|Patients with allergic rhinitis receiving standard treatment|Group 3: Patients with allergic rhinitis receiving standard treatment
10202007|NCT05167552|Active Comparator|Patients with chronic polypous rhinosinusitis receiving standard treatment|Group 4: Patients with chronic polypous rhinosinusitis receiving standard treatment
10202008|NCT05167383|Active Comparator|Intervention VR group|. In the VRH group the patients received a 30-minute session of virtual reality hypnosis when in active labor and had access to standard care.
10202009|NCT05167383|Placebo Comparator|Standard treatment|Patients in the control group received only standard care.
9831171|NCT05143424|Active Comparator|CBD (700 mg)|CBD 700 mg twice per day for 3 days
9831172|NCT05143346|Other|Group A|Group A will include 168 patients and will be intubated by the use of video stylet.
9831173|NCT05143346|Other|Group B|Group B will include 168 patients and will intubated by the use of video laryngoscope
9831174|NCT05132166|Active Comparator|BAT|anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
9831175|NCT05132166|Experimental|DSC|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
9831176|NCT05131607|Experimental|Supine MRI|
9831177|NCT05131100||Participants receiving Somavert|
9831178|NCT05126485|Experimental|Randomizing Control and Biofeedback Phases|"The gait training and data collection procedure is split into two phases: a control phase and a biofeedback phase. The order of these phases is randomized across participants to reduce the probability of systematic error due participants warming-up or fatiguing between trials. Each phase consists of a pre-test, gait retraining session, and one or more post-tests."
9831179|NCT05123196|Experimental|MT-8554|MT-8554 will be started from a low dose, and gradually increase the dose in order.
9831180|NCT05123196|Placebo Comparator|Placebo|
9831181|NCT05115630|Experimental|Cyclophosphamide|On Days 3 and 4, you will receive cyclophosphamide by vein over about 3 hours to help lower the risk of graft-versus-host disease
9831182|NCT05115630|Experimental|Mesna|On Days 3 and 4, You will also receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses.
9831183|NCT05115630|Experimental|Filgrastim|Starting on Day 7, you will begin to receive filgrastim as an injection under the skin 1 time a day.
9831184|NCT05115630|Experimental|Melphalan|On Day -7, you will receive melphalan by vein over about 30 minutes.
9831185|NCT05115630|Experimental|Fludarabine phosphate|On Days -7, -6, -5, and -4, you will receive fludarabine by vein about 1 hour.
9831186|NCT05115630|Experimental|Tacrolimus|Starting on Day 5, you will begin receiving tacrolimus to help lower the risk of GVHD. You will begin by receiving it nonstop by vein until you are able to take it by mouth. You will then take tacrolimus by mouth 2 times a day for about 3 months.
9831187|NCT05115630|Experimental|Mycophenolate mofetil|by mouth 3 times a day for 90 days or longer.
9831188|NCT05115630|Experimental|Total Body Irradiation One Dose|on Day -2, you may receive 1 dose of total body irradiation (TBI).
9831189|NCT05114746|Experimental|177Lu-PSMA-617|PSMA positivity will be confirmed by PET/CT scan after administration of 68Ga-PSMA-11. All eligible participants will receive recommended dose of 177Lu-PSMA-617 via intravenous injection every 6 weeks (+/- 1 week) for a maximum of 6 cycles.
9831190|NCT05111392|Placebo Comparator|Placebo|Water
9831191|NCT05111392|Experimental|Oral rehydration solution 1|Beverage with 2.5% glucose with 45 mmol sodium/L.
9831192|NCT05111392|Experimental|Oral rehydration solution 2|Beverage with 1.7% glucose with 60 mmol sodium/L.
9831193|NCT05110794|Experimental|LY3502970 (Fed)|LY3502970 administered orally to participants who are in a fed state.
9831194|NCT05110794|Experimental|LY3502970 (Fasted)|LY3502970 administered orally to participants who are in a fasted state.
9831195|NCT05110677||Study group|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus gastrocnemius of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)~Physical assessment: Color-Coded Duplex Sonography/treadmill examination to determine actual walking distance/Ankle-Brachial-Index/defined walking distance of 150 meters under medical supervision"
9831196|NCT05107479|Experimental|Treatment|The participants in the treatment group will be invited to participate in a 5-module IVR training covering an overview of available COVID-19 vaccines and best practices for vaccine administration.
9831197|NCT05107479|Active Comparator|Control|Participants in the control group will receive the intervention following a one-month delay allowing for a comparison of outcomes with the treatment group.
10202010|NCT05167071|Experimental|HBM4003 and Toripalimab|HBM4003 combined with Toripalimab in patients with advanced NEN and other solid tumors
10202011|NCT05166954||LSG group|Laparoscopic sleeve gastrectomy (LSG) performed as a treatment for obesity
10202012|NCT05166954||RYGB group|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity
10202013|NCT05165355|Experimental|Experimental group|Furmonertinib (80 mg orally, once daily) for 3 years.
10202014|NCT05165251|Experimental|Amlodipine/atorvastatin|amlodipine/atorvastatin (5mg/10mg QD)
10202015|NCT05165251|Active Comparator|Amlodipine|amlodipine (5mg QD)
10202016|NCT05165251|Other|Lifestyle intervention|
10202017|NCT05164809||Tungsten/Teflon +|Dissection with novel electrodes (Tungsten needle electrode + Teflon coated Spatula electrode)
10202018|NCT05164809||Tungsten/Teflon -|Dissection without novel electrodes (Scalpel + Steel Spatula Electrode)
9754938|NCT00570713|Experimental|MORAb-009|MORAb-009 plus gemcitabine ('MORAb-009'): MORAb-009 was administered at 5 mg/kg on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
9754939|NCT00570713|Active Comparator|Placebo|Placebo plus gemcitabine ('Placebo') Placebo was administered on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
9754940|NCT00570739|Placebo Comparator|Diabetic Participants: Metformin HCl+Placebo for Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
9754941|NCT00570739|Experimental|Diabetic participants: Metformin HCl + Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
9754942|NCT00570739|Placebo Comparator|Pre-diabetic Participants: Colesevelam Placebo|Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
9754943|NCT00570739|Experimental|Pre-diabetes Participants: Colesevelam|Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
9754944|NCT00570765|Experimental|DB OCA 10 mg|OCA 10 mg for 3 months during the DB phase.
9754945|NCT00570765|Experimental|DB OCA 50 mg|OCA 50 mg for 3 months during the DB phase.
10202019|NCT05164276|Active Comparator|Sniffing group|Before intubation, the patient's shoulder is supported by a 5cm pillow to make neck flexion with extension of atlanto-occipital joint, confirming that the external auditory meatus and sternal notch plane are horizontal and aligned. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
9754946|NCT00570765|Placebo Comparator|DB OCA Placebo|Matching placebo for 3 months during the DB phase.
9754947|NCT00570765|Experimental|LTSE OCA Total|After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.
9754948|NCT00570778|Experimental|indacaterol/glycopyrrolate 300/50 μg|One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
9754949|NCT00570778|Active Comparator|indacaterol 600 μg|Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
9754950|NCT00570778|Active Comparator|indacaterol 300 μg|One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
9754951|NCT00570778|Placebo Comparator|placebo|Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
9754952|NCT00570908|Experimental|Study Group|capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib
9754953|NCT00570921|Experimental|Fulvestrant + Everolimus|"Fulvestrant + Everolimus~Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
9754954|NCT00570960|Experimental|1: Dextran 70|antibiotic therapy in addition to dextran 70, 1.0 g/kg on days one, two and three
9754955|NCT00570960|Active Comparator|2: Standard of Care Human Albumin|antibiotic therapy in addition to human albumin, 1.5 g/kg on day one and 1.0 g/kg on day three
9754956|NCT00571038|Experimental|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
9754957|NCT00571038|Active Comparator|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
9754958|NCT00571064|Experimental|1|
9754959|NCT00571103|Experimental|1 Open Label|Open Label. At visit 2, all participants were started on Acamprosate, 1,998 mg divided into 3 equal doses.
9754960|NCT00571259|Active Comparator|1|Catheter lock with heparin 1,000 units/mL
9754961|NCT00571259|Active Comparator|2|Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%
10202020|NCT05164276|Experimental|Neutral group|Before intubation, the patient's head is placed without a pillow on the bed. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
9754962|NCT00571324|Experimental|Exendin-(9-39) first, the Vehicle|Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
9782859|NCT01187953|Experimental|LCP-Tacro|The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
9831202|NCT05098431|Experimental|Experimental Arm|Receive Quadriceps MEPs during procedure
9754963|NCT00571324|Placebo Comparator|Vehicle first, then Exendin-(9-39)|Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.
9754964|NCT00571428|Experimental|15 mcg BID / 30 mcg QD|Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
9754965|NCT00571428|Experimental|30 mcg QD / 15 mcg BID|Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.
9754966|NCT00571493|Experimental|Bortezomib Dose Escalation|"The phase I section of the study will follow a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of bortezomib when added to a standard BEAM (BCNU (carmustine), etoposide, cytarabine, melphalan) conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT).~After the MTD is defined, additional patients will enroll in Phase II to obtain preliminary estimates of survival using the Phase I regimen."
9754967|NCT00571519|Experimental|1|rivoglitazone HCl 0.5mg
9754968|NCT00571519|Experimental|2|rivoglitazone HCl 1.0 mg
9754969|NCT00571519|Experimental|3|rivoglitazone HCl 1.5 mg
9754970|NCT00571519|Placebo Comparator|4|placebo matching rivoglitazone HCl tablets
9754971|NCT00571519|Active Comparator|5|pioglitazone HCl 15 mg
9754972|NCT00571519|Active Comparator|6|pioglitazone HCl 30 mg
9754973|NCT00571519|Active Comparator|7|pioglitazone HCl 45 mg
9754974|NCT00571519|Placebo Comparator|8|matching placebo for pioglitazone
9754975|NCT00571649|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
9754976|NCT00571649|Active Comparator|Enoxaparin|Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
9754977|NCT00571662|Experimental|Cohort I|Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day
9754978|NCT00571688|Experimental|Risperdal Consta|Risperdal Consta injection in conjunction with existing treatment
9754979|NCT00571688|Active Comparator|Treatment As Usual|Clinician and patient decide upon treatment, as in a non-research clinical setting. The only treatment exclusion is any form of risperidone.
9754980|NCT00571701|Active Comparator|celecoxib first, then placebo|Patients randomized to start celecoxib 6 months after enrollment. Then cross over to placebo after 1 year. Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients < 12kg
9754981|NCT00571701|Placebo Comparator|Placebo first, then celecoxib|Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
9754982|NCT00571948|Active Comparator|Babyfood with usual meat content and corn oil|Infants in the control group received vegetable-potato-meat-meals as part of complementary food containing common amounts of meat and corn oil marketed in Germany.
9754983|NCT00571948|Experimental|more meat and a vegetable oil rich in omega-3 fatty acids|Infants in the intervention group received vegetable-potato-meat-meals as part of complementary food containing higher amounts of meat than the control group and rapeseed oil instead of corn oil.
9754984|NCT00571961|Experimental|1|HIV negative subjects currently enrolled in a long-term buprenorphine maintenance therapy program for at least 3 months who have been on stable dose of buprenorphine for at least 3 weeks will be admitted to the General Clinical Research Center (GCRC) for pharmacokinetic (PK) blood draws at intervals over a 24-hour period. Subjects will then receive Kaletra and buprenorphine coadministered for 14 days. Subjects will be admitted to the GCRC for a second PK sampling day.
9831203|NCT05095441|Experimental|Part 1: Dose Escalation|C5252 single agent dose escalation in participants with glioblastoma
9754985|NCT00571974|Experimental|Phase 1 light dose escalation|"During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2."
9754986|NCT00571974|Experimental|Phase 2 - Treatment efficacy of PDT|"Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2."
9754987|NCT00571987|Other|1|This is a non-randomized one arm study, all subjects receive treatment (radiofrequency ablation).
9754988|NCT00572039|Experimental|PST|Problem Solving Treatment (PST)
9754989|NCT00572039|Placebo Comparator|ST|Supportive Therapy (ST)
9754990|NCT00572117|Placebo Comparator|Placebo (inert pill) Arm|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
9754991|NCT00572117|Experimental|Topiramate|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. The pills will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
9754992|NCT00572156|Active Comparator|1. rhGH Alone|
9754993|NCT00572156|Experimental|2. Combination Dose|
9754994|NCT00572156|Experimental|3. Combination Dose|
9754995|NCT00572156|Experimental|4. Combination Dose|
9754996|NCT00572195|Experimental|Evaluation Group (stimulation ON)|Group of subjects that have an RNS® System implanted, completed the RNS® System Pivotal or Feasibility study, and elected to continue to receive RNS® System responsive stimulation for the long term.
9754997|NCT00572234|Experimental|Receiving Bupropion SR|receiving bupropion SR 12 week course of bupropion SR 150 mg, BID (twice a day)
9754998|NCT00572234|No Intervention|Treatment as Usual|Not receiving bupropion
9754999|NCT00572455|Experimental|Stage 1: PF-04217329 - Lowest Dose|
9755000|NCT00572455|Experimental|Stage 1: PF-04217329 - Low Dose|
9755001|NCT00572455|Experimental|Stage 1: PF-04217329 - Middle Dose|
9755002|NCT00572455|Experimental|Stage 1: PF-04217329 - High Middle Dose|
9755003|NCT00572455|Experimental|Stage 1: PF-04217329 - High Dose|
9755004|NCT00572455|Experimental|Stage 1: PF-02417329 - Highest Dose|
9755005|NCT00572455|Experimental|Stage 1: PF-04217329 - Vehicle|
9755006|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle|
9755007|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle|
9755008|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle|
9755009|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005%|
9755010|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005%|
9755011|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost 0.005%|
9755012|NCT00572455|Experimental|Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005%|
9755013|NCT00572468|Active Comparator|Simvastatin|Twenty-two men will be on the Statin arm and take 40 mg of simvastatin.
9755014|NCT00572468|Placebo Comparator|Placebo|Twenty-two men will be on the placebo arm.
9755015|NCT00572533|Active Comparator|Control|ESA Dose Adjustment per standard Anemia Management Protocol
9755016|NCT00572533|Experimental|Treatment|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"
9755017|NCT00572572|Experimental|Arm A: Aprepitant, Then Placebo|Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
9755018|NCT00572572|Experimental|Arm B: Placebo, Then Aprepitant|Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
9755019|NCT00572624|Experimental|Diet|Participants who received counseling and instruction about weight loss through diet and exercise
9755020|NCT00572624|Experimental|Gastric bypass surgery|Participants who received gastric bypass surgery
9755021|NCT00572728|Experimental|Diagnostic (18F-FLT)|Patients undergo 18F-FLT PET /CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.
9755022|NCT00572832|Active Comparator|6 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
9755023|NCT00572832|Active Comparator|12 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.
9755024|NCT00572897|Experimental|Fludarabine, Melphalan +/- ATG|Fludarabine, Melphalan +/- ATG
9755025|NCT00572910|Experimental|V710 - Group 1|V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
9755026|NCT00572910|Experimental|V710 - Group 2|V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
9755027|NCT00572910|Experimental|V710 - Group 3|V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
9755028|NCT00572910|Experimental|V710 - Group 4|V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
9755029|NCT00572910|Experimental|V710 - Group 5|V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
9755030|NCT00572910|Placebo Comparator|Group 6|Placebo on Day 1, 28 and 180.
9755031|NCT00572936|Other|Latanoprost/Dorzolamide/Timolol|The participants received latanoprost at night and vehicle in the morning for two weeks, then 6 week washout, then Dorzolamide BID for two weeks, then 6 week washout, then Timolol BID for two weeks. The order in which the participants received the three different drugs was random.
9755032|NCT00573066|Experimental|Dosing level|A predetermined dose of Dexmedetomidine
9782860|NCT01187953|Experimental|Prograf (tacrolimus)|Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Doses will be adjusted according to whole blood tacrolimus trough levels. In the initial post-transplant period, plasma trough levels will be measured at 24 and 48 hours. Study drugs will be adjusted to maintain the whole blood pre-dose (trough) concentration of tacrolimus in the target range of 6 - 11 ng/mL for the first 30 days, then 4 - 11 ng/mL for the remainder of the study.
9782861|NCT01188109|Experimental|Gemcitabine / Cisplatin|Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.
9782862|NCT01188226|Experimental|Nano Hybrid Composite Denture teeth|Denture teeth are made of nano hybrid composite material
9782863|NCT01188343|Experimental|Group 1|Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42
9782864|NCT01188343|Experimental|Group 2|Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.
9782865|NCT01188343|Experimental|Group 3|Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0
9782866|NCT01188369|Experimental|levosimendan|infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation
9782867|NCT01188369|Placebo Comparator|Placebo|Identical placebo
9782868|NCT01188421|Active Comparator|buprenorphine|Sublingual buprenorphine/naloxone tablets (or placebo)
9782869|NCT01188421|Active Comparator|clonidine|Oral clonidine tablets (or placebo)
9782870|NCT01188421|Experimental|tramadol ER|Oral tramadol tablets (or placebo)
9782871|NCT01188447|Experimental|Eligible low-risk trauma patients|Paramedics will use the Canadian C-Spine Rule to evaluate low-risk trauma patients meeting the study inclusion criteria in order to determine the need for spinal immobilization for transport to the hospital.
9831204|NCT05095441|Experimental|Part 2: Dose Expansion|Recommended dose of C5252 as determined in Part 1 Dose Escalation in participants with glioblastoma
9755033|NCT00573131|Experimental|Group 1|OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
9755034|NCT00573131|Active Comparator|Group 2|Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
9755035|NCT00573144|Placebo Comparator|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator).
9755036|NCT00573144|Active Comparator|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
9755037|NCT00573170|Other|TPB|TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
9755038|NCT00573170|Other|TBP|TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
9755039|NCT00573170|Other|BTP|BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
9755040|NCT00573170|Other|BPT|BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
9755041|NCT00573170|Other|PTB|placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
9755042|NCT00573170|Other|PBT|placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)
9755043|NCT00573183|Experimental|STAGE-12|STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
9755044|NCT00573183|Active Comparator|Treatment as Usual|Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
9755045|NCT00573248|Experimental|4|
9755046|NCT00573261|Experimental|Pregabalin|Pregabalin medication
9755047|NCT00573261|Placebo Comparator|Placebo|Placebo
9755048|NCT00573287|Experimental|Clozapine|clozapine: clozapine--tablets, 12.5-100 mg, daily for 24 weeks
9755049|NCT00573287|Active Comparator|Risperidone|risperidone: risperidone--tablets, 0.5-5.0mg daily for 24 weeks
9755050|NCT00573313|Experimental|S-adenosylmethionine (SAMe)|Alcoholic liver disease patients receiving S-adenosylmethionine (SAMe)at 400 mg capsule three times daily for 24 weeks
9755051|NCT00573313|Placebo Comparator|Sugar pill|ALD subjects receiving Placebo three times daily for 24 weeks.
9755052|NCT00573430|Experimental|1|Candesartan Cilexetil
9755053|NCT00573430|Experimental|2|Candesartan Cilexetil
9755054|NCT00573430|Experimental|3|Candesartan Cilexetil
9755055|NCT00573443|Experimental|DM 30 mg/Q 10 mg|AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
9755056|NCT00573443|Experimental|DM 20 mg/ Q 10 mg|AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
9755057|NCT00573443|Placebo Comparator|Placebo|Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks
9755058|NCT00573469|Active Comparator|1|D9421-C 9 mg
9755059|NCT00573469|Active Comparator|2|D9421-C 15 mg
9755060|NCT00573469|Placebo Comparator|3|Placebo
9755061|NCT00573508|Active Comparator|Placebo|Matching placebo tablet taken once daily
9755062|NCT00573508|Experimental|Solifenacin Succinate|5mg or 10mg tablet taken once daily
9755063|NCT00573534|Experimental|Open Label Vyvanse|Open Label Vyvanse (lisdexamphetamine) in doses of 30-70 mgs over 8 weeks in younger siblings of substance abusing older siblings with a history of treatment for ADHD
9755064|NCT00573755|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9755065|NCT00573755|Active Comparator|Arm II|Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9755066|NCT00573768|Active Comparator|1|
9755067|NCT00573768|Placebo Comparator|2|
9755068|NCT00573768|Active Comparator|3|
9755069|NCT00573794|Experimental|Adalimumab 40 mg EOW/EW|Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
9755070|NCT00573833|Experimental|HDR Brachytherapy|9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
9755071|NCT00573859|Experimental|ADHD medication versus placebo|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication (e.g., Dextroamphetamine; Amphetamine mixed salts; Atomoxetine; O-Methylphenidate; Lisdexamfetamine). For the placebo condition, a placebo pill was administered.
9755072|NCT00573872|Experimental|Spinal Radiosurgery|Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
9755073|NCT00573989|Experimental|Erlotinib|Erlotinib
9755074|NCT00574067|Experimental|Buprenorphine+OTP|Buprenorphine and counseling in prison and continued at opioid treatment program (OTP) upon release.
9755075|NCT00574067|Experimental|Buprenorphine+CHC|Buprenorphine and counseling in prison and continued at a community health center (CHC) upon release.
9755076|NCT00574067|Active Comparator|Counseling + OTP|Counseling only in prison and Buprenorphine upon release at a opioid treatment program (OTP)
9755077|NCT00574067|Active Comparator|Counseling + CHC|Counseling only in prisons and Buprenorphine upon release at a community health center (CHC)
9755078|NCT00574119|Experimental|Results with spironolactone|patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.
9755079|NCT00574145|Experimental|Radiotherapy/Supportive Care (A)|Patients receive radiotherapy and healing touch therapy from a healing touch therapist once a week for the duration of their radiotherapy
9755080|NCT00574145|Sham Comparator|Control ARM (B)|Patients receive radiotherapy and sham healing touch therapy from a sham healing touch therapist once a week for the duration of their therapy
9755081|NCT00574171|Experimental|1|
9755082|NCT00574197|Other|Enteric-coated Mycophenolate Sodium (Myfortic)|1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months
9755083|NCT00574236|Experimental|A|
9755084|NCT00574249|Active Comparator|adalimumab + placebo|adalimumab + placebo (vehicle ointment)
9755085|NCT00574249|Active Comparator|adalimumab + calcipotriol/betamethasone|adalimumab + calcipotriol/betamethasone ointment
9755086|NCT00574275|Placebo Comparator|Placebo and Gemcitabine|Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m^2 Gemcitabine.
9755087|NCT00574275|Experimental|Aflibercept and Gemcitabine|Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m^2 Gemcitabine.
9755088|NCT00574288|Experimental|Dose Escalation: Daratumumab|
9755089|NCT00574288|Experimental|Dose Expansion: Daratumumab|
9755090|NCT00574340|Active Comparator|Control study then antecedent hypoglycemia study group|Day 1 euglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to antecedent hypoglycemia study Day 1 hypoglycemia, Day 2 hypoglycemia
9755091|NCT00574340|Active Comparator|Antecedent Hypoglycemic clamp study|Day 1 hypoglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to control study Day 1 euglycemia, Day 2 hypoglycemia
9755092|NCT00574405|Active Comparator|1|MDI = 3-4+ insulin injections/day, using split-mix NPH insulin + regular insulin or Lantus + Novolog® (or Humalog®).
9755093|NCT00574405|Experimental|2|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
9755094|NCT00574548|Experimental|Group 1.1|Group 1.1 = 13vPnC then 13vPnC
9755095|NCT00574548|Experimental|Group 1.2|Group 1.2 = 13vPnC then 23vPS
9755096|NCT00574548|Experimental|Group 2|Group 2 = 23vPS then 13vPnC
9755097|NCT00574587|Experimental|Vorinostat Plus Paclitaxel|Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks (and trastuzumab if HER2-positive), followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery
9755098|NCT00574704|Experimental|1|
9755099|NCT00574704|Placebo Comparator|2|
9755100|NCT00574704|Experimental|3|
9755101|NCT00574704|Placebo Comparator|4|
9755102|NCT00574834|Active Comparator|Ramipril|Patients randomized to 6 months treatment of Ramipril.
9755103|NCT00574834|Active Comparator|HCTZ|PAtients randomized to 6 months treatment of HCTZ.
9831205|NCT05092581|Experimental|casirivimab+imdevimab|
9755104|NCT00574834|Active Comparator|Ramipril+HCTZ|Patients randomized to 6 months treatment of Ramipril+HCTZ.
9755105|NCT00574847|Experimental|Escitalopram|Escitalopram treatment
9755106|NCT00574847|Placebo Comparator|Placebo|Placebo
9755107|NCT00574873|Experimental|1|Bosutinib
9755108|NCT00574873|Active Comparator|2|Imatinib
9755109|NCT00574912|Experimental|Placebo then Insulin Glargine|"Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)"
9755110|NCT00574951|Experimental|AMG 706|AMG 706 daily
9755111|NCT00574990||VA Physicians|VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
9755112|NCT00574990||VA Nurses|VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
9755113|NCT00574990||VA Pharmacists|VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
9755114|NCT00575016|Experimental|1|botulinum toxin Type A (50U); botulinum toxin Type A (200U)
9755115|NCT00575016|Experimental|2|botulinum toxin Type A (100U); botulinum toxin Type A (200U)
9755116|NCT00575016|Experimental|3|botulinum toxin Type A (200U)
9755117|NCT00575016|Other|4|placebo; botulinum toxin Type A (200U)
9755118|NCT00575029|Experimental|megace treatment|Study subjects will be given 600mg of MA for oral ingestion per day for duration of 8 weeks. They will be monitored every week clinically for the development of adrenal insufficiency by review of symptoms, physical exam, body weight, pulse, and blood pressure. Subjects also will undergo biochemical evaluation of adrenal status every two weeks by measurement of serum electrolytes, serum cortisol, serum adrenocorticotropic hormone(ACTH) levels, and the adrenal response to a low dose ACTH (1µgm) stimulation test(see methods).
9755119|NCT00575042|Experimental|Patients treated with Fenofibrate|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year
9755120|NCT00575146|Experimental|1|ketogenic diet
9755121|NCT00575159|Experimental|Arm a|GSK189075
9755122|NCT00575159|Placebo Comparator|Arm b|Placebo
9755123|NCT00575185|Active Comparator|Valomaciclovir|Valomaciclovir 2 grams orally twice daily for 21 days
9755124|NCT00575185|Placebo Comparator|placebo|placebo 2 tablets twice daily for 21 days
9755125|NCT00575328|Experimental|Maca Root|Subjects in this arm will be given 3g/day of Maca Root.
9755126|NCT00575328|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo.
9755127|NCT00575367|Active Comparator|AzaSite|
9755128|NCT00575367|Active Comparator|Vigamox|
9755129|NCT00575380|Active Comparator|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days
9755130|NCT00575380|Active Comparator|Vigamox Eye Drops|One drop three times a day for seven days
9755131|NCT00575510|Experimental|Intervention|Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
9755132|NCT00575510|Active Comparator|Active Control|nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
9755133|NCT00575510|No Intervention|Standard Care Only|Clinical standard of care at time of study
9755134|NCT00575588|Experimental|Saxagliptin|
9755135|NCT00575588|Experimental|Glipizide|
9755136|NCT00575666|Experimental|A|Intranasal Insulin Treatment
9755137|NCT00575666|Placebo Comparator|B|Drug: Placebo
9755138|NCT00575887|Experimental|1|
9755139|NCT00575965|Experimental|Simvastatin|Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.
9755140|NCT00576056|Experimental|Tace and Sorafenib|Patients with unresectable HCC will be treated with TACE in combination with oral sorafenib administration. TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin. Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment.
9755141|NCT00576147|Experimental|CT scan|The standard head CT done to head trauma patients
9755142|NCT00576199|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks and within 24-48 hours prior to each transarterial chemoembolization (TACE) until disease progression or unmanageable toxicity. TACE was conducted for 4 sessions at 8-10 week intervals.
9755143|NCT00576251|Experimental|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
9755144|NCT00576251|Active Comparator|TOBRADEX|TOBRADEX 1 drop 4 times daily in both eyes
9755145|NCT00576303|Experimental|RO0503821 (C.E.R.A.), 1x/4weeks|Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator [C.E.R.A]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks
9755146|NCT00576381|Experimental|A|Neonates will be administered a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours post cardiac surgery.
9755147|NCT00576420|Experimental|FS VH S/D 500 s-apr - 60-Seconds|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time
9755148|NCT00576420|Experimental|FS VH S/D 500 s-apr - 120-Seconds|FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time
9831206|NCT05090267|Experimental|Dietary Supplement (e.g., vitamins, minerals)|Visbiome probiotic supplement
9831207|NCT05090267|Active Comparator|Device (including sham)|Transcutaneous Vagal Nerve Stimulation (tVNS)
9831208|NCT05083364|Experimental|ARO-C3 (Healthy Volunteers)|1 dose of ARO-C3 by subcutaneous (sc) injection
9831209|NCT05083364|Placebo Comparator|Placebo (Healthy Volunteers)|placebo calculated volume to match active treatment by sc injection
9831210|NCT05083364|Experimental|ARO-C3 (Adult Patients with C3G or IgAN)|2 doses of ARO-C3 by sc injection
9831211|NCT05083364|Experimental|ARO-C3 (Adult Patients with PNH)|2 doses of ARO-C3 by sc injection
9831212|NCT05082155|Experimental|Right sided catheter bupivacaine 0.25% and left sided catheter normal saline|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Bupivacaine 0.25 will be administered through the right-sided catheter while normal saline will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
9831213|NCT05082155|Experimental|Right sided catheter normal saline and left sided catheter bupivacaine 0.25%|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Normal saline will be administered through the right-sided catheter while bupivacaine 0.25% will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
9831214|NCT05081388|Experimental|REGN14256 + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1 Phase 3: (Open label) (≥12 and <18 Years)
9831215|NCT05081388|Experimental|REGN14256|Phase 1, Phase 2: Randomized 1:1:1:1:1
9831216|NCT05081388|Experimental|Imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1
9831217|NCT05081388|Experimental|casirivimab + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
9831218|NCT05081388|Experimental|Placebo|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
9831219|NCT05078476|Active Comparator|Manchester Short Splint|Dorsal splint ending shortly behind the wrist. The splint will be worn for 6 weeks after surgery and the patient will perform active and passive exercises in the splint.
9831220|NCT05078476|Experimental|Relative Motion Flexion|In the relative motion splint the injured finger is positioned in relative flexion in the MCP joint to the adjacent fingers. Additionally to the relative motion flexion splint a wrist orthosis is adapted. Passive and active exercises will be performed out of the splint.
9831221|NCT05077787|Experimental|Experimental Group|Neonates recruited in experimental group will receive massage therapy and kinaesthetic stimulation for 15 minutes along with phototherapy for consecutive days . It will be given in three phases first massage therapy will be given for 5 minutes, followed by movement of limbs for 5 minutes and then again massage therapy will be repeated for 5 minutes.
9831222|NCT05077787|No Intervention|Control Group|Neonates recruited in control group will receive phototherapy alone along with regular care
9831223|NCT05074277|No Intervention|Control (8 hours nocturnal sleep)|Inpatient protocol involves 8-hour sleep opportunity during the biological night throughout.
9831224|NCT05074277|Experimental|Simulated Night Shift Work|Two inpatient stays, each involving a baseline night, followed by a 3-hour afternoon nap opportunity, and then three 12-hour night shifts, with 8-hour daytime sleep opportunity in between.
9831225|NCT05073068|Experimental|AM exercise|
9831226|NCT05073068|Experimental|PM exercise|
9831227|NCT05073068|Active Comparator|Control|
9831228|NCT05071131|Active Comparator|Inulin|30 grams inulin per day for 28 days
9831229|NCT05071131|Placebo Comparator|Placebo|30 grams maltodextrin per day for 28 days
9831230|NCT05055050|Experimental|UGN-201 Pre Radical Cystectomy|UGN-201 200 mg/50ml
9831231|NCT05038098|Experimental|Cohort I (preoperative injection)|Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally.
9831232|NCT05038098|Experimental|Cohort II (intraoperative)|Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.
9831233|NCT05035836|Experimental|Zanidatamab|zanidatamab by vein every 2 weeks (+/- 3 days) for up to 6 doses (3 study cycles
9755149|NCT00576420|Active Comparator|Control Group- Manual compression with surgical gauze pads|Treatment of the study-suture line will be manual compression with surgical gauze pads.
9755150|NCT00576472|Experimental|Treatment|
9755151|NCT00576576|Experimental|A|All patients in this arm are given atorvastatin therapy.
9755152|NCT00576628|Experimental|C.E.R.A|Participants received methoxy polyethylene glycol-epoetin beta (Continuous Erythropoietin Receptor Activator [C.E.R.A]) subcutaneously every four weeks for 44 weeks. The participants received initial dose of 1.2 microgram per kilogram (mcg/kg) of C.E.R.A. Once the Hemoglobin (Hb) concentration was attained within the target range of 11.0 and 13.0 gram per deciliter (g/dL), the dose was adjusted to maintain the Hb concentration within the target range.
9755153|NCT00576680|Experimental|Temozolomide with RAD001|
9755154|NCT00576693|Experimental|intensive medical management plus stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
9755155|NCT00576693|Experimental|intensive medical management alone|Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
9755156|NCT00576732|Experimental|001|Risperidone low dose Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
9755157|NCT00576732|Experimental|002|Risperidone high dose Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
9755158|NCT00576732|Placebo Comparator|003|Placebo Oral solution qd or bid for 6 weeks
9755159|NCT00576758|Experimental|Obinutuzumab|Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
9755160|NCT00576758|Active Comparator|Rituximab|Participants received 375 mg/m^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
9755161|NCT00576823|Experimental|Alfuzosin solution - 2-7 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children 2-7 years of age.
9755162|NCT00576823|Experimental|Alfuzosin solution - 8-16 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children and adolescents 8-16 years of age who were not able to swallow tablets or preferred to take the solution or had a body weight < 30 kg.
9755163|NCT00576823|Experimental|Alfuzosin tablet - 8-16 years|Alfuzosin tablet, daily dose divided in 2 doses given at breakfast and dinner to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30 kg.
9755164|NCT00576901|Experimental|1|
9755165|NCT00576927|Experimental|Group1|SHI followed by Active Drug Ramelteon
9755166|NCT00576927|Placebo Comparator|Group 2|SHI Followed by Placebo
9755167|NCT00577005|Experimental|1|Levetiracetam tablets
9755168|NCT00577005|Placebo Comparator|2|matching placebo
9755169|NCT00577031|Experimental|1|
9755170|NCT00577083|Experimental|Initial cap-fitted|Initial cap-fitted colonoscopy for the first insertion
9755171|NCT00577083|Active Comparator|Initial regular|Initial regular no cap on the end of the colonoscope for the first insertion
9755172|NCT00577096|Experimental|Exercise|Study participants were computer randomized to an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
9755173|NCT00577096|Active Comparator|usual care|Study participants were asked to remain as active as possible but not prescribed an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
9755174|NCT00577122|Experimental|Cohort I (MPA)|Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
9755175|NCT00577122|Experimental|Cohort II (MPA, low-dose chemotherapy)|"Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.~Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
9755176|NCT00577135|Experimental|Q12 hour bolus|Furosemide-Q12 hour bolus
9755177|NCT00577135|Experimental|Continuous Infusion|Furosemide-Continuous Infusion
9755178|NCT00577135|Experimental|Low Intensification|Furosemide-Low Intensification
9755179|NCT00577135|Experimental|High Intensification|Furosemide-High Intensification
9755180|NCT00577382|Experimental|Sunitinib|"Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
9755181|NCT00577408|Experimental|Depot Naltrexone|Depot Naltrexone. Vivitrol (380 mg)given monthly
9831234|NCT05028829|Experimental|Group A: Atorvastatin 20 mg|Atorvastatin 20mg will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
9755182|NCT00577408|Active Comparator|Oral Naltrexone|Oral Naltrexone. For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday).
9755183|NCT00577460|Active Comparator|Pramipexole|Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
9755184|NCT00577460|Placebo Comparator|Placebo|Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
9755185|NCT00577473|Active Comparator|1|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
9755186|NCT00577473|Experimental|2|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
9755187|NCT00577512|Experimental|HD DTPACE|DTPACE
9755188|NCT00577590|Placebo Comparator|Metformin Alone|Participants assigned to take Metformin alone.
9755189|NCT00577590|Experimental|Metformin and Rosiglitazone|Participants assigned to take Metformin and Rosiglitazone
9755190|NCT00577590|Experimental|Metformin and Lovaza|Participants assigned to take Metformin and Lovaza
9755191|NCT00577629|Experimental|Induction + Consolidation + Bexxar|Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
9755192|NCT00577642|Other|Single arm|Single arm biomarker study after a single dose of zoledronic acid
9755193|NCT00577655|Experimental|Albuterol|Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
9755194|NCT00577655|Placebo Comparator|Placebo|"A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)"
9755195|NCT00577707|Experimental|Patients With Stage IB-IIIA NSCLC With EGFR Mutations|This is a open label, single center, phase II trial for patients with clinical stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable tumors that harbor EGFR activating mutations. Patients will receive erlotinib x 3 weeks prior to initiation of concurrent erlotinib and chemotherapy.
9755196|NCT00577720|Active Comparator|35 mg IRBB|35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
9755197|NCT00577720|Experimental|35 mg DRFB|35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
9755198|NCT00577720|Experimental|50 mg DRFB|50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
9755199|NCT00577720|Experimental|50 mg DRBB|50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
10202021|NCT05164276|Experimental|Flexed group|Before intubation, the patient's neck is flexed with pads until the chin touches the chest. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Dublin, Ireland) using video-laryngoscope (AceScope, AceMedical, Seoul, Korea).
9755200|NCT00577824|Experimental|1|
9755201|NCT00577824|Experimental|2|
9755202|NCT00577824|Placebo Comparator|3|
9755203|NCT00577889|Experimental|Arm I (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
9755204|NCT00577889|Experimental|Arm II (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 2 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
9755205|NCT00577889|Experimental|Arm III (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on day 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 1 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
9755206|NCT00577993|Active Comparator|1: FND + Rituximab Followed by Interferon|Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon
9755207|NCT00577993|Active Comparator|2: FND Followed by Interferon & Rituximab|Fludarabine/Novantrone/Decadron Followed by Interferon & Rituximab
9755208|NCT00577993|Active Comparator|3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon|Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon
9755209|NCT00578071|Experimental|Treatment|panitumumab, oxaliplatin, capecitabine and EBRT
9755210|NCT00578136|Active Comparator|1|1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
9755211|NCT00578136|Active Comparator|2|2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
9755212|NCT00578175|Experimental|Group A|Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
10202022|NCT05160233|Active Comparator|Standard Implementation|All primary care clinics will implement reSET and reSET-O using standard implementation approach.
10202023|NCT05160233|Experimental|Standard Implementation Plus Health Coaching|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
10202024|NCT05160233|Experimental|Standard Implementation Plus Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and a practice facilitator will provide the clinic with support for implementation.
10202025|NCT05160233|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
9755213|NCT00578175|Experimental|Group B|Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
9755214|NCT00578175|Active Comparator|Group C|Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
9755215|NCT00578214|Active Comparator|Randomized Midazolam|Single-dose midazolam
9755216|NCT00578214|Placebo Comparator|Placebo|
9755217|NCT00578214|Experimental|Prospective Midazolam|
9755218|NCT00578227|Experimental|Cervarix™ & Twinrix™ Group|Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A & Hepatitis B (HAB) vaccine (Months 0, 1 & 6).
9755219|NCT00578227|Experimental|Cervarix™ Group|Subjects received 3 doses of HPV vaccine (Months 0, 1 & 6).
9755220|NCT00578227|Active Comparator|Twinrix™ Group|Subjects received 3 doses of HAB vaccine (Months 0, 1 & 6).
9782872|NCT01188460|Placebo Comparator|Control Group|Receive one weekly telephone follow-up call per week to monitor sleep progress, complete 7 weeks of sleep diaries only (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), complete questionnaires at three study timepoints
9782873|NCT01188460|Experimental|Experimental Group|Receive one weekly telephone call to monitor sleep progress, complete 7 weeks of sleep diaries (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), implement one chapter per week of self-help manual for insomnia over 7 weeks at home, complete questionnaires at three study timepoints
9782874|NCT01188499|Experimental|Carboplatin/Paclitaxel + Birinapant|Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
9782875|NCT01188499|Experimental|Irinotecan + Birinapant|Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
9782876|NCT01188499|Experimental|Docetaxel + Birinapant|Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
9782877|NCT01188499|Experimental|Gemcitabine + Birinapant|Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).
9782878|NCT01188499|Experimental|Liposomal Doxorubicin + Birinapant|Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).
9782879|NCT01188538|Experimental|Epiduo gel|"Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
9782880|NCT01188538|Active Comparator|BPO gel|"Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
9782881|NCT01188551|Experimental|dexmedetomidine w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of dexmedetomidine 1mcg/kg given intranasally in OR.
9782882|NCT01188551|Active Comparator|fentanyl w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of fentanyl 2mcg/kg given intranasally in OR.
9782883|NCT01188551|Experimental|dexmedetomidine w/o midazolam|1 dose of dexmedetomidine 1mcg/kg given intranasally in OR without any pre-medication.
9782884|NCT01188551|Active Comparator|fentanyl w/o midazolam|1 dose of fentanyl 2mcg/kg given intranasally in the OR without any pre-medication.
9782885|NCT01188564|Experimental|rhC1INH|
9782886|NCT01188564|Placebo Comparator|Placebo (Saline)|
9782887|NCT01188577|Experimental|Epinephrine Inhalation Aerosol, HFA|Experimental treatment of 10 inhalations of 125 mcg epinephrine base propelled by HFA 134a
9782888|NCT01188577|Active Comparator|Epinephrine Inhalation Aerosol, CFC|Epinephrine Inhalation Aerosol, CFC propelled, 220 mcg/inhalation , 10 inhalations
9782889|NCT01188603|Experimental|flibanserin|flibanserin 100 mg dose every evening
9755221|NCT00578279|Other|A|subject randomized to 10ml of dehydrated alcohol
9755222|NCT00578279|Experimental|B|subject randomized to 20ml of dehydrated alcohol
9755223|NCT00578292|Experimental|Bone Marrow or Stem Cell Infusion|"Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H~Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.~Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor."
9755224|NCT00578305|Experimental|Rituximab 500 mg|Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
9755225|NCT00578305|Experimental|Rituximab 1000 mg|Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
9755226|NCT00578305|Placebo Comparator|Placebo|Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
9755227|NCT00578318|Experimental|Motivational Interviewing Active|Patients received a stepped progression of talk based treatment utilizing Motivational Interviewing as the basis.
9755228|NCT00578318|Active Comparator|Delayed Control|Patients received Treatment as usual (TAU) (i.e. no specific intervention and supportive check-ins from the study staff)
9755229|NCT00578331|Experimental|Olopatadine 0.6% Nasal Spray|2 sprays each nostril twice daily
9755230|NCT00578331|Placebo Comparator|Placebo Nasal Spray|2 sprays each nostril twice daily
9755231|NCT00578344|Experimental|Allogeneic BMT/SCT Transplant|"Busulfan, Campath 1H, Cyclophosphamide and MESNA:~Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.~Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest."
9755232|NCT00578383|Sham Comparator|Sham (inactive) Treatment BPD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
9755233|NCT00578383|Active Comparator|Active LFMS treatment in BPD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
9755234|NCT00578383|Sham Comparator|Sham LFMS Comparator: in MD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
9755235|NCT00578383|Active Comparator|Experimental LFMS: in MD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
9755236|NCT00578448|Active Comparator|A|"10mg/kg~6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks"
9755237|NCT00578448|Active Comparator|B|"5mg/kg~33 doses (every 4 weeks) for 144 weeks"
9755238|NCT00578461|Experimental|Stem Cell Transplant|patient's will be recieving a stem cell transplant on study Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation
9782890|NCT01188655||Treatment Group Enbrel|
9782891|NCT01188668|Experimental|Aripiprazole + Desvenlafaxine SR|
9782892|NCT01188681|Experimental|Phase 1: 15 mg/kg TRU-016 + Bendamustine|TRU-016 (15 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
9755239|NCT00578539|Experimental|Stem Cell Transplant|All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.
9755240|NCT00578552|Placebo Comparator|Placebo|Non active placebo pill
9755241|NCT00578552|Active Comparator|Gabapentin - 1800 mg/day|Gabapentin - 1800 mg/day
9755242|NCT00578552|Active Comparator|Gabapentin - 2700 mg/day|Gabapentin - 2700 mg/day
9755243|NCT00578565|Experimental|1|open label, all subjects will receive rituximab
9755244|NCT00578617|Active Comparator|Pharmacologic Therapy|Pharmacologic Therapy Rate and/or Sinus Rhythm Control: Patients without other heart disease will receive beta or calcium channel blockers as first line rate control therapy. Patients with underlying coronary artery disease will receive beta-blockers, patients with limited ventricular hypertrophy not warranting exclusion would receive either beta- or calcium channel blockers, while patients with heart failure would be expected to receive carvedilol or metoprolol. Patients randomized to drug therapy may be started on a membrane active drug, in an approach consistent with the recommended Guidelines for Management of Subjects with AF. Each patient will be placed on an anti-arrhythmic drug for an appropriate period and the patient cardioverted to sinus rhythm if necessary. Patients will then be followed for a period of up to 3 months, during which dosage adjustment can be made or the drug replaced with a different anti-arrhythmic drug.
9755245|NCT00578617|Active Comparator|Ablation Therapy|Left Atrial Catheter Ablation: The specific choice of ablation catheters will be left to the investigator from the following list: Lifewire TC XLS, Therapy Dual/Thermocouple, NAVI-STAR/NAVI-STAR DS, Celsius Braided Tip, NAVI-STAR Thermo-Cool, Freezor/FreezorMax, Stinger, Blazer II RF/RPM/SteeroCath /XP, Chilli Cooled.
9755246|NCT00578643|Experimental|Allogeneic unrelated transplant|Conditioning from Day -9 to Day -1. Stem cells given on Day 0. Busulfan, alemtuzumab, cyclophosphamide, fludarabine, cyclosporine, stem cell infusion.
9755247|NCT00578669|Active Comparator|1|Sequential antidepressant pharmacotherapy with (20mg) fluoxetine, begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
9755248|NCT00578669|Placebo Comparator|2|Sequential placebo medication (dextrose), begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
9755249|NCT00578734|Experimental|Lucinactant|SURFAXIN® (lucinactant) for intratracheal instillation
9755250|NCT00578734|Sham Comparator|Sham Air|Sham air (placebo) instillation
9755251|NCT00578786|Experimental|Ambrisentan|2.5, 5 or 10 mg ambrisentan
9755252|NCT00578812|Experimental|PCM Cervical Disc - Investigational|PCM Cervical Disc replacement at one level from C3 to T1
9755253|NCT00578812|Active Comparator|ACDF - Control Group|Anterior cervical discectomy and fusion (ACDF) at one level from C3 to T1
9755254|NCT00578864|Experimental|Protracted Oral Etoposide|"Protracted oral etoposide for cycles 1, 2 and 4 of induction. Etoposide will be given in combination with IV cisplatin (a standard of care agent). If a subject does not respond after cycle 2, cycle 4 will be bolus etoposide in combination with IV cisplatin.~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
9755255|NCT00578864|Active Comparator|IV Bolus Etoposide|"IV bolus etoposide in combination with IV cisplatin will be given for cycles 1,2, and 4 of induction chemotherapy for patients who are not eligible for the experimental arm (e.g.require emergent treatment)~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
9755256|NCT00578877|Active Comparator|Arm 1|Gynol II (2% N-9 gel)
9755257|NCT00578877|Experimental|Arm 2|Buffer Gel
9755258|NCT00578903|Experimental|Patients|"Patients with a diagnosis of severe aplastic anemia who require an allogeneic stem cell transplant but lack an Human Leukocyte Antigen (HLA) identical family member.~Cytoxan, Campath, TBI-Total Body Irradiation, FK-506, Methotrexate, Stem Cell Infusion"
9755259|NCT00578929|Experimental|Olopatadine 0.6% 1 Spray|Olopatadine HCl 0.6% 1 spray per nostril twice daily
9755260|NCT00578929|Placebo Comparator|Vehicle 1 spray|Vehicle 1 spray per nostril twice daily
9755261|NCT00578929|Experimental|Olopatadine 0.6% 2 sprays|Olopatadine HCl 0.6% 2 sprays per nostril twice daily
9755262|NCT00578929|Placebo Comparator|Vehicle 2 sprays|Vehicle 2 sprays per nostril twice daily
9755263|NCT00578942|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
9755264|NCT00578968|Experimental|Tiotropium|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
9755265|NCT00578968|Placebo Comparator|Placebo|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
9755266|NCT00578968|No Intervention|Healthy Controls|Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.
9755267|NCT00579059|Other|1|Maxim® Pop-Top® Tibia
9755268|NCT00579059|Other|2|Maxim® Regular Tibia
9755269|NCT00579098|Active Comparator|Atorvastatin|Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
9831235|NCT05028829|Placebo Comparator|Group B: Placebo to Match (PTM)|PTM will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
9755270|NCT00579098|Placebo Comparator|Placebo|Placebo (dummy) tablet taken once daily by mouth for 90 days
9755271|NCT00579111|Experimental|HLA-identical sibling transplant|Recipients of HLA identical sibling stem cell transplants
9755272|NCT00579111|Experimental|Unrelated Matched or Single Antigen Mismatched transplant|Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
9755273|NCT00579137|Experimental|Participants With SCID or Primary Immunodeficiency Disorder|all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45
9755274|NCT00579280|Active Comparator|Quetiapine SR|Quetiapine SR (Quetiapine Sustained Release)
9755275|NCT00579280|Active Comparator|Divalproex Sodium ER|Divalproex Sodium ER (Divalproex Sodium Extended Release)
9755276|NCT00579280|Placebo Comparator|Placebo|placebo
9755277|NCT00579345|Experimental|cTIV|Cell culture derived seasonal trivalent influenza vaccine (cTIV)
9755278|NCT00579345|Active Comparator|eTIV_a|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
9755279|NCT00579345|Experimental|FLU (cTIV or eTIV_a)|Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
9755280|NCT00579345|Active Comparator|FLU (cTIV or eTIV_a) + PV|23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
9755281|NCT00579436|Active Comparator|Fish oil group|4g Lovaza (omega-3 fatty acid) daily.
9755282|NCT00579436|Placebo Comparator|Control group|placebo (4 non-active capsules daily)
9755283|NCT00579501|Experimental|Trabectedin|Trabectedin at a dose of 1.5 milligram per meter square (mg/m^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.
9755284|NCT00579553|Active Comparator|Intramuscular Progesterone|Intramuscular Progesterone
9755285|NCT00579553|Experimental|Vaginal Progesterone|Vaginal Progesterone
9755286|NCT00579813|No Intervention|1|Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.
9755287|NCT00579813|Active Comparator|2|Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
9755288|NCT00579878|Active Comparator|1 Leflunomide alone vs combination therapy|Group A: Leflunomide alone
9755289|NCT00579878|Active Comparator|Methotrexate-Sulfasalazine-Hydroxychloroquine|Methotrexate, Sulfasalazine, Hydroxychloroquine.
9755290|NCT00579878|Active Comparator|3|Leflunomide-Sulfasalazine-Hydroxychloroquine
9755291|NCT00579982|Experimental|Arm 1|Lamictal orally disintegrating tablet (ODT)
9755292|NCT00580034|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
9755293|NCT00580034|Other|Donor Apheresis|"Donor must be a sibling, half sibling, parent, child or first cousin familial relationship and 3-5/6 Human Leukocyte Antigen matched related to subject. They must not have any medical condition which would make apheresis and G-CSF administration more than a minimal risk, and should have the following:~Adequate cardiac function by history and physical examination~bilirubin and hepatic transaminases < 2.5 x upper limit of normal~normal hematologic parameters Females should have a negative serum pregnancy test."
9755294|NCT00580047|Active Comparator|1|Zoledronic Acid 4mg intravenously once a year for 2 years
9755295|NCT00580047|Active Comparator|2|Alendronate 70mg orally once a week for 2 years
9755296|NCT00580047|Placebo Comparator|3|Combination drug entity: calcium 1200 mg with vitamin D 800 International Units daily
9755297|NCT00580073|Experimental|1|FOLFOX4 + Cetuximab
9755298|NCT00580138||Stroke or Head & Neck Cancer|Any subject who has suffered a stroke or has some form of head & neck cancer (non-laryngectomee) may be enrolled.
9755299|NCT00580151|Experimental|1|
9755300|NCT00580151|Placebo Comparator|2|
9755301|NCT00580229|Experimental|prednisone|Prednisone 40mg by mouth 30-60 minutes prior to rituximab.
9755302|NCT00580294|Experimental|oxymorphone|participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed
9782893|NCT01188681|Experimental|Phase 1: 20 mg/kg TRU-016 + Bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
9782894|NCT01188681|Experimental|Phase 2: TRU-016 and bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 32 patients
9782895|NCT01188681|Active Comparator|Phase 2: Bendamustine|Bendamustine (70 mg/m2), n = 33 patients
9782896|NCT01188694|Experimental|Psychotherapy plus Methylene Blue, USP|
9782897|NCT01188694|Placebo Comparator|Psychotherapy Plus Placebo|
9782898|NCT01188694|Other|Delayed Psychotherapy|
9782899|NCT01188772|Experimental|Sofosbuvir 200 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
9782900|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
9782901|NCT01188772|Active Comparator|Placebo (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
9782902|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 2/3)|Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.
9782903|NCT01188811|Experimental|Arm 1: lipoic acid|28 subjects receive oral lipoic acid 1200mg daily
9782904|NCT01188811|Placebo Comparator|Arm 2: placebo|28 subjects receive placebo daily
9782905|NCT01188876|Experimental|Carboplatin/Pralatrexate|
9782906|NCT01188928|Experimental|LEO 80185|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
9782907|NCT01188928|Active Comparator|Betamethasone|Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
9782908|NCT01188928|Active Comparator|Calcipotriol|Calcipotriol 50 mcg/g in the topical suspension vehicle
9782909|NCT01188928|Placebo Comparator|Topical suspension vehicle|The topical suspension vehicle alone
9782910|NCT01188967|Experimental|GSK598809|Active medication
9782911|NCT01188967|Placebo Comparator|Placebo|Placebo
9782912|NCT01189032|Experimental|High concentration|
9782913|NCT01189032|Experimental|Low concentration|
9782914|NCT01189032|Placebo Comparator|Placebo|
9782915|NCT01189110|Active Comparator|Arm 1|Stimulation of auriculotherapy points on both ears with functioning Stim Flex 400A TENS unit once a week for 5 weeks.
9782916|NCT01189110|Placebo Comparator|Arm 2|Stimulation of auriculotherapy points on both ears with disabled Stim Flex 400A TENS unit once a week for 5 weeks.
9782917|NCT01189123|Active Comparator|Standard dose influenza vaccine|Fluzone (Sanofi Pasteur)
9782918|NCT01189123|Active Comparator|High Dose Vaccine|High Dose Fluzone by sanofi pasteur
9782919|NCT01189136|Sham Comparator|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
9782920|NCT01189136|Experimental|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
9782921|NCT01189201|Experimental|BI 10773/linagliptin FDC SID|medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
9782922|NCT01189201|Experimental|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
9782923|NCT01189201|Experimental|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
9782924|NCT01189201|Experimental|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
9782925|NCT01189240|Experimental|Phase I Dose Finding|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
9782926|NCT01189240|Experimental|Phase II Stage I|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
9782927|NCT01189240|Experimental|Phase II Stage II Arm 1|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
9782928|NCT01189240|Active Comparator|Phase II Stage II Arm 2|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
9755303|NCT00580333|Experimental|Cisplatin/Avastin|Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
9755304|NCT00580372|Experimental|Study Treatment|Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
9755305|NCT00580398|No Intervention|Control|Usual care included physician advice to quit smoking.
9755306|NCT00580398|Experimental|Intervention|Intervention participants were provided with a cognitive-behavioral 12-week program consisting of varenicline (1mg bid, with initial titration up over week 1) and smoking cessation counseling targeted to the issues of thoracic cancer patients. We offered 7 counseling sessions but were flexible in offering additional counseling when needed. Counseling was delivered by a certified Tobacco Treatment Counselor using Motivational Interviewing (MI) techniques.
9755307|NCT00580502|Experimental|LAGB for low BMI patients|the LAP-BAND® Adjustable Gastric Band (LAGB®) for patients with BMI between 30-40 kg/m2 with co-morbidities
9755308|NCT00580606|Experimental|Low Dose Peanut SLIT (Double Blind to Open Label)|Subjects ingest peanut protein (glycerinated peanut allergenic extract) daily starting with 0.000165 mcg, followed by a build-up phase (escalating peanut doses every 2 weeks, achieving maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and continue on an open label peanut protein maintenance dose of 1,386 mcg/day or may attempt escalation up to this dose. Subjects who at the Week 116 OFC are unable to consume >= 5,000 mg peanut powder or 10-fold the amount of peanut powder compared to the baseline OFC will discontinue study therapy. SLIT=Sublingual Immunotherapy.
9755309|NCT00580606|Placebo Comparator|Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL)|Subjects ingest placebo (glycerin) daily beginning with a dose of 0.000165 mcg, followed by a build-up phase (escalating placebo doses every 2 weeks, achieving a maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and subjects no longer receive placebo dosing but are crossed over and receive open label high dose peanut SLIT; the study procedures and schedule are the same as for the Low Dose Peanut SLIT group, the only difference is the maximum maintenance dose is almost 3-fold higher at 3,696 mcg/day. DB=Double Blind, SLIT=Sublingual Immunotherapy, OL=Open Label.
9755310|NCT00580645|Experimental|varenicline|varenicline 1mg/day or 2mg/day
9755311|NCT00580645|Placebo Comparator|Placebo|Placebo Controlled
9755312|NCT00580671|Experimental|MET/CBT+CM/BPT|Integrated psychosocial counseling. 14 weekly session. Twice weekly urine testing. Abstinence-based incentives based on urine test results. 14 weekly behavioral parenting sessions.
9755313|NCT00580671|Experimental|MET/CBT+CM|Integrated psychosocial counseling. 14 weekly sessions. Twice weekly urine testing. Abstinence-based incentives based on urine test results.
9755314|NCT00580671|Active Comparator|MET/CBT|Integrated psychosocial counseling. 14 weekly sessions.
9755315|NCT00580723|Experimental|PRK 124|Topical PRK 124 (Pyratine-6)(0.125%) moisturizing lotion applied twice daily to the face for 48 weeks. Subjects will wash their faces prior to application. The applications will occur in the mornings and one hour before bedtime.
9755316|NCT00580788|Experimental|PTHrP(1-36) 2 pmol/kg/hr|PTHrP(1-36) at 2 picomoles/kg/hr for one week.
9755317|NCT00580788|Experimental|PTHrP (1-36) 4 pmol/kg/hr|PTHrP(1-36) at 4 picomoles/kg/hr for one week.
9755318|NCT00580788|Experimental|PTHrP(1-36) 5 pmol/kg/hr|PTHrP(1-36) at 5 picomoles/kg/hr for one week.
9755319|NCT00580788|Experimental|PTHrP(1-36) 6 pmol/kg/hr|PTHrP(1-36) at 6 picomoles/kg/hr for one week.
9755320|NCT00580801|Experimental|Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 2 to 50.
9755321|NCT00580801|Experimental|Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
9755322|NCT00580801|Active Comparator|Placebo+Pegylated-interferon-alfa-2a+Ribavirin|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa 2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
9755323|NCT00580840|Active Comparator|Certolizumab pegol 400 mg and placebo|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
9755324|NCT00580840|Experimental|Certolizumab pegol 200 mg and placebo|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
9755325|NCT00580840|Placebo Comparator|Placebo|Placebo administered as two injections every 2 weeks
9755326|NCT00580853|Experimental|varenicline|varenicline 2mg/day
9755327|NCT00580853|Experimental|Bupropion|Bupropion 300mg/day
9755328|NCT00580853|Placebo Comparator|Placebo|Placebo Control
9755329|NCT00580866|Experimental|Joint Active Systems Brace (JAS Brace)|Elbow is placed in a brace to apply an extension force
9755330|NCT00580866|No Intervention|PT Only Group|No brace is used
9755331|NCT00580957|Experimental|Blocked|Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
9755332|NCT00580957|Placebo Comparator|Intact|Saline will be used instead of trimethaphan during insulin clamp
9755333|NCT00580970|Experimental|Lovastatin for 1 yr|Lovastatin (20-80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. Lovastatin once per day for 1 year. After the implant, they are asked to return for checkups (study visits 4-13) 4 weeks, 8 weeks, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after the procedure. At 8 weeks, 4 months, 6 months, 9 months and 12 months, will also have a blood test to check their liver.
9755334|NCT00580983|Experimental|Chemo-IMRT|"Chemotherapy:~Chemotherapy will consist of Paclitaxel 30mg/m² IV over 1 hour, followed by Carboplatin (AUC 1) IV over 30 minutes, or Carboplatin 100mg/m² per IV over 30 minutes or Cisplatin 100mg/m² per IV over 1 hour, or Cisplatin (80mg/m²) or Carboplatin (AUC 5) IV on day 1 and 5-Fluorouracil (1000mg/m²) as a 24-hour continuous infusion, daily x 4 days.~Intensity-modulated Radiation Therapy (IMRT):~Primary RT: 70 Gy to gross disease and 56-63 Gy to subclinical disease in 35 fractions.~Post-operative RT: 64 Gy to high-risk targets (postoperative tumor bed, first-echelon nodes) and 57.6 Gy to low-risk targets, in 32 fractions."
9755335|NCT00581048|Experimental|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
9755336|NCT00581061|Experimental|Vesicare Treatment|
9755337|NCT00581100|Active Comparator|1|etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
9755338|NCT00581100|Active Comparator|2|etanercept 50 mg SC once weekly for the complete 24 week treatment period
9755339|NCT00581230|Experimental|Laryngoscopy without RAMP|First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
9755340|NCT00581230|Experimental|Laryngoscopy with RAMP|Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.
9755341|NCT00581256|Experimental|1|Best Delivery-optimized radiotherapy technique (IMRT)
9755342|NCT00581256|Active Comparator|2|Best 3-dimensional standard PWTF technique
9755343|NCT00581308|Experimental|GORE® HELEX® Septal Occluder|Subjects who received a GORE® HELEX® Septal Occluder
9755344|NCT00581347|Other|Outreach|Receives outreach services
9755345|NCT00581347|No Intervention|Standard of Care|Receives standard medical care provided by primary care practice.
9755346|NCT00581360|Other|Bortezomib + Doxorubicin|Patients with incurable adenoid cystic carcinoma of the head and neck who receive doxorubicin and bortezomib
9755347|NCT00581386|Experimental|LTS-D|All the cases were divided into one of the group LTS-D, PLMA, and ETC
9755348|NCT00581386|Experimental|ProSeal Laryngeal Mask Airway|All patients were divided into either LTS-D, PLMA, or the ETC group.
9755349|NCT00581386|Experimental|Esophageal Tracheal Combitube (ETC)|All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
9755350|NCT00581399|Experimental|NO-NUMO Chest Tube|The NO-NUMO™ High Vacuum Body Cavity Drainage System consist of disposable NO-NUMO™ body cavity drainage tubes, disposable Vario™ fluid management canisters Vario™ portable vacuum pump
9755351|NCT00581399|Active Comparator|Standard Chest Tube|Classic PVC Chest Tube
9755352|NCT00581529|Experimental|Radiotherapy|IMRT (Intensity-modulated Radiation Therapy), 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
9755353|NCT00581542|Active Comparator|Moxifloxacin Opthalmic solution|
9755354|NCT00581542|Active Comparator|Polymyxin B-trimethoprim opthalmic solution|
9755355|NCT00581555|Experimental|etanercept|Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
9755356|NCT00581555|Placebo Comparator|placebo|Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.
9755357|NCT00581581||1|Randomized to cooling (original randomized clinical trial): All children, now 6-8 years old who were randomized to cooling in the original trial were included in this arm. Cooling was achieved via the CoolCap system (Olympic Medical/Natus Corporation) in these babies.
9755358|NCT00581581||2|Randomized to standard care (original randomized clinical trial): All children, now 6-8 years old, who were treated using the standard of care at the time (normal temperature) were included in this arm. Infants' temperatures were monitored per standard of care. Most infants were cared for on an open wamer that was servo-controlled to normal body temperature (37 C) or in a standard bassinette.
9755359|NCT00581776|Experimental|VCR-CVAD with rituximab maintenance|Induction chemotherapy with Bortezomib, cyclophosphamide, rituximab, vincristine, doxorubicin, and dexamethasone. Subjects will receive 6 cycles of induction chemotherapy, of 21 days each. After completing induction, subjects will receive rituximab consolidation (4 weeks), and then rituximab maintenance therapy for up to 5 years.
9755360|NCT00581828|Experimental|1|Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).
9755361|NCT00581867|Experimental|Intranasal Insulin Aspart|Participants were administered intranasal insulin aspart (40 IU) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
9755362|NCT00581867|Active Comparator|Intranasal Saline (placebo)|Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
9755363|NCT00581893|Experimental|1|Phenytoin administration
9755364|NCT00581893|Placebo Comparator|2|Placebo
9755365|NCT00581919|Experimental|Bort, Dex, and Dox with ALCAR|
9755366|NCT00581945|Experimental|Canakinumab|Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
9755367|NCT00581945|Placebo Comparator|Placebo|Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
9755368|NCT00581971|Experimental|Celecoxib+Carboplatin/Paclitaxel+Radiation Therapy|
9755369|NCT00582010|Experimental|1. Experimental|iNO administration
9755370|NCT00582010|Placebo Comparator|2. Placebo|Placebo (nitrogen)
9755371|NCT00582075|Experimental|Radiosurgery 15-24 Gy + Adjuvant Temozolomide|
9755372|NCT00582114|Active Comparator|1|Atenolol
9755373|NCT00582114|Experimental|2|Lisinopril
9755374|NCT00582166|Experimental|Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance|
9755375|NCT00582205|Experimental|Paclitaxel, Cisplatin IP|There is only one arm for this study and it represents the participants receiving the intraperitoneal chemotherapy
9755376|NCT00582309|Active Comparator|Glucommander|Glucommander-Guided Intravenous Insulin Infusion
9755377|NCT00582309|Active Comparator|Standard|Standard Intravenous Insulin Infusion Algorithm consists of four levels (Algorithm 1-3 and a doubling of the insulin rate). Most patients begin in algorithm 1, where the insulin rate varies from 0.2 units per hour for BG in the range 70-109 mg/dl up to 6 units/hr for BG > 360 mg/dl. If algorithm 1 fails to bring the patient's BG into target range in 2 hrs, then the patient is moved up to algorithm 2, where the insulin rate varies from 0.5 to 12 units/hr; and if that fails, the patient moved up to algorithm 3, where insulin rate varies from 1 to 16 units/hr depending on the latest BG. Algorithm failure is a blood glucose outside the target range for 2 hrs, and the blood glucose does not decrease by at least 60 mg/dl within 1 hr. If algorithm 3 fails, the insulin rate is doubled.
9755378|NCT00582309|Active Comparator|Simple|Simple Calculated Intravenous Insulin Infusion consists of an initial insulin infusion rate varying from 0.5 units per hour for BG in the target range 80-120 mg/dl up to 8 units/hour for BG > 400 mg/dl. After the initial insulin rate and if BG is still > 120 mg/dl, then the insulin rate is increased by 1-2 units every 1 hour until BG is in the target range. If BG is still >120 mg/dl in 2 hours, then the insulin rate is doubled.
9755379|NCT00582361|Active Comparator|1, A|Group A patients will have a standard dressing applied following initial treatment of their open fracture.
9755380|NCT00582361|Experimental|2, B|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture.
9755381|NCT00582400|Experimental|I|
9755382|NCT00582426|Experimental|Octreotide Long Acting Release|Prevention of Chemotherapy Induced Diarrhea (CID)
9755383|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
9755384|NCT00582491|Experimental|I|Modafinil 400mg orally everyday for 16 days
9755385|NCT00582491|Placebo Comparator|II|Placebo orally everyday for 16 days
9755386|NCT00582517|Active Comparator|Group A External Brace|Group A will have a non-invasive range of motion external brace placed following surgery
9755387|NCT00582517|Experimental|Group B Compass Knee Hinge|Group B will have a Compass Knee Hinge placed
9755388|NCT00582556|Active Comparator|1|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
9755389|NCT00582556|Active Comparator|2|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given at mo 6
9755390|NCT00582556|Active Comparator|3|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
9755391|NCT00582608|Experimental|131I-8H9 and 8H9|This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m^2 dose [intended specific activity of '20mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
9755392|NCT00582660|Active Comparator|study drug BID for 7 days before surgery|400 mg Celecoxib the study drug will be given for 7 days before surgery
9755393|NCT00582660|Placebo Comparator|Placebo for 7 days before surgery|Placebo in a one to one randomization prior to surgery
9755394|NCT00582738|Active Comparator|CsA-TAC|Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor [CNI] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)[MPA], with or without steroids) / no everolimus introduction.
9755395|NCT00582738|Experimental|everolimus|Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.
9755396|NCT00582790|Experimental|1|Interleukin-2 subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles in combination with Zoledronic acid IV on day 1 of every 4 week (28 days) cycle.
9755397|NCT00582816|Experimental|1|patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.
9755398|NCT00582894|Other|A|Preparative regimen of 1)Busulfex 3.2 mg/kg/day for 2 days, infused over 3 hours, on Day-6 and Day-5 2)Fludarabine 30 mg/m2/day for 5 days on Day-6 to D-2 and 3) Alemtuzumab 10 mg/day IV on days - 5 to -1
9782929|NCT01189240|Experimental|Phase I Dose Finding - Level 1 5mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
9782930|NCT01189240|Experimental|Phase I Dose Finding - Level 2 10mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
9782931|NCT01189240|Experimental|Phase I Dose Finding - Level 3 20mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
9782932|NCT01189266|Experimental|Arm 1 Phase I Vorinostat 180 mg/m^2|Patients in phase I received vorinostat at 180 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9782933|NCT01189266|Experimental|Arm 2 Phase 1 Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9782934|NCT01189266|Experimental|Arm 3 Phase II Evaluation Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/ day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9782935|NCT01189279|Experimental|Part 1: bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
9782936|NCT01189279|Experimental|Part 1: bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
9755399|NCT00582907|Experimental|1|Treatment Arm A: Rilonacept (IL-1 Trap) at a dose of 2.2 mg/kg/wk (max 160 mg)given by subcutaneous injection for 3 months plus colchicine at a stable dose for those subjects already taking colchicine, or without colchicine for those intolerant or non-compliant with colchicine. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention
9755400|NCT00582907|Placebo Comparator|2|Treatment Arm B: Placebo given by subcutaneous injection weekly with or without colchicine for 3 months. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention.
9755401|NCT00582933|Experimental|1|25 research participants with HLA Identical Related Donor using PBSC, 6 with BMT
9755402|NCT00582933|Experimental|2|70 research participants with HLA-Matched Unrelated Donor using PBSC, 17 with BMT
9755403|NCT00582933|Experimental|3|25 research participants with HLA-Mismatched Related Donor using PBSC, no BMT
9755404|NCT00582946|Experimental|Magnetic Contact Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
9755405|NCT00582972|Experimental|Experimental|Subjects will receive omeprazole 40 mg daily for 30 days
9755406|NCT00582998|Active Comparator|Standard Wound Dressing|Standard post-operative wound dressing
9755407|NCT00582998|Active Comparator|Vacuum Assisted Closure Device|Vacuum Assisted Closure (VAC) device
9755408|NCT00583011|Experimental|Local Anesthesia|Local anesthesia group. 2cc of 1% lidocaine with epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of 1% lidocaine to the depth of the peritoneum.
9755409|NCT00583011|Placebo Comparator|Placebo-Normal saline|Placebo normal saline group. 2cc of normal saline epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of normal saline to the depth of the peritoneum.
9755410|NCT00583050|Experimental|Endovascular Aneurysm Repair|Endovascular Aneurysm Repair of TAAA/AAA with Fenestrated/Branched Stent Grafts
9755411|NCT00583102|Experimental|Lovastatin followed by Cytarabine|The subject will receive high dose cytarabine as well as lovastatin. The subject will take doses of lovastatin twice a day, about 12 hours apart. On the third day, the subject will begin high-dose cytarabine IV over 3 hours, twice a day, starting 1 hour after the lovastatin dose for 5 days.
9755412|NCT00583219|Experimental|Botox/DMSO Solution|"Subjects received Botulinum-A toxin and Dimethyl sulfoxide solution. The first 3 subjects in Phase 1 underwent bladder instillation of 50 cc of the solution utilizing 200 units of botulinum-A toxin and 50cc DMSO. The next 6 subjects in the Phase 1 trial received 300 units of botulinum-A toxin and 50cc DMSO.~All subjects in the Phase 2 trial received 300 units of botulinum-A toxin and 50cc DMSO."
9755413|NCT00583362|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days.
9755414|NCT00583375|Active Comparator|Group 1|"Standard Rigid Fixation plus autograft~Standard of Care: Autologous Bone Graft"
9755415|NCT00583375|Experimental|Group 2|Standard Rigid Fixation plus Augment® Bone Graft
9755416|NCT00583414|Experimental|Endovascular Aneurysm Repair|Investigational stent-graft implant to exclude aneurysm
9755417|NCT00583453|Active Comparator|A|Celecoxib 200 mg tablets
9755418|NCT00583453|Placebo Comparator|B|Placebo with same dosing schedule as the active comparator arm
9755419|NCT00583492|Experimental|Ad5-yCD/mutTKSR39rep-ADP + IMRT|Gene Therapy + IMRT
9755420|NCT00583492|Active Comparator|IMRT Alone|IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
9755421|NCT00583557|Experimental|Belimumab|
9755422|NCT00583596|Experimental|implant to close PDA|
9755423|NCT00583622|Experimental|Bevacizumab + High-Dose Chemotherapy|Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
9755424|NCT00583661|Experimental|EXCOR Pediatric|Implantation of the EXCOR Pediatric Ventricular Assist Device
9755425|NCT00583700|No Intervention|1|Control for study - watchful waiting.
9755426|NCT00583700|Experimental|2|Combined treatment with Pentoxifylline and Vitamin E.
9755427|NCT00583713|Experimental|Renal Group|Patients with moderate renal impairment
9755428|NCT00583713|Active Comparator|Healthy volunteers|Healthy volunteers
9755429|NCT00583713|Experimental|Hepatic Group|Patients with mild/moderate hepatic impairment.
9782937|NCT01189279|Experimental|Part 2: bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
9755430|NCT00583791|Experimental|Main Cohort|Device closure with the AMPLATZER Muscular VSD Occluder for patients with muscular ventricular septal defects which are hemodynamically significant and are either isolated or present in conjunction with other congenital heart defects.
9755431|NCT00583908|Active Comparator|Group 1: lotrafilcon B/senofilcon A/balafilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. Period 1: lotrafilcon B /period 2: senofilcon A / period 3: balafilcon A / period 4: omafilcon A
9755432|NCT00583908|Active Comparator|Group 2 lotrafilcon B/omafilcon A/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: omafilcon A / period 3: senofilcon A / period 4: balafilcon A
9755433|NCT00583908|Active Comparator|Group 3 lotrafilcon B/balafilcon A/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: balafilcon A / period 3: senofilcon A / period 4: omafilcon A
9755434|NCT00583908|Active Comparator|Group 4 senofilcon A/lotrafilcon B/omafilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: balafilcon A
9755435|NCT00583908|Active Comparator|Group 5 senofilcon A/omafilcon A/balafilcon A/lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: omafilcon A / period 3: balafilcon A / period 4: lotrafilcon B
9755436|NCT00583908|Active Comparator|Group 6 senofilcon A/balafilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: balafilcon A / period 3: lotrafilcon B / period 4: omafilcon A
9755437|NCT00583908|Active Comparator|Group 7 omafilcon B/lotrafilcon B/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: omafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: balafilcon A
9755438|NCT00583908|Active Comparator|Group 8 balafilcon A/lotrafilcon B/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: omafilcon A
9755439|NCT00583908|Active Comparator|Group 9 balafilcon A/lotrafilcon B/omafilcon A/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: senofilcon A
9755440|NCT00583908|Active Comparator|Group 10 balafilcon A/senofilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: lotrafilcon B / period 4: omafilcon A
9755441|NCT00583908|Active Comparator|Group 11 balafilcon A/senofilcon A/omafilcon A//lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: omafilcon A / period 4: lotrafilcon B
9755442|NCT00583908|Active Comparator|Group 12 balafilcon A/omafilcon A/lotrafilcon B/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: omafilcon A / period 3: lotrafilcon B / period 4: senofilcon A
9755443|NCT00583947|Other|ARF/LEV|"Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
9755444|NCT00583947|Other|LEV/ARF|"Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
9755445|NCT00584077||Stable lung transplant recipients|All enrolled subjects receive the same procedures; bronchoscopy with administration of mechanical and chemical irritants to the airway mucosa
9755446|NCT00584194|Experimental|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
9782938|NCT01189292|Active Comparator|Dexamethasone injection|Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
9782939|NCT01189292|Placebo Comparator|Placebo (NaCl 0.9%)|
9755447|NCT00584220|Other|senofilcon A toric / alphafilcon A toric|senofilcon A toric contact lenses worn daily during the first period, then alphafilcon A toric contact lenses worn daily during the second period
9755448|NCT00584220|Other|alphafilcon A toric / senofilcon A toric|alphafilcon A toric contact lenses worn daily during the first period, then senofilcon A toric contact lenses worn daily during the second period
9755449|NCT00584285||Corneal Topographer Fluorescein Patterns|Use corneal topography to evaluate fluorescein pattern of rgp contact lens. Used corneal topography to develop theoretical fluorescein patters on a virtual eye. Theoretical lens developed by the topographer was ordered to compare to the actual fluorescein pattern on the actual eye.
9755450|NCT00584402|Experimental|Contrast sonography|Contrast-enhanced sonography perflutren lipid microspheres
9755451|NCT00584415|Active Comparator|GP + PVI ablation|This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
9755452|NCT00584454|Experimental|Q Fever Vaccine (NDBR 105)|Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
9755453|NCT00584480|Active Comparator|1|Active Hyperbaric Oxygen Treatment (HBOT)
9755454|NCT00584558||1|Patients undergoing catheter ablation.
9755455|NCT00584701|Experimental|Risperidone|Risperidone was started at 0.5mg at bedtime for 4 days. If that dosage was tolerated and there were continued behavioral symptoms, the dose was increased to 1mg at bedtime for an additional 4 days. If tolerated and indicated, 0.5mg was added in the morning for a daily total of 1.5 mg.
9755456|NCT00584727|Active Comparator|senofilcon A/alphafilcon A/etafilcon A|First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
9755457|NCT00584727|Active Comparator|alphafilcon A/etafilcon A/senofilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses
9755458|NCT00584727|Active Comparator|etafilcon A/senofilcon A/alphafilcon A|First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses
9755459|NCT00584727|Active Comparator|senofilcon A/etafilcon A/alphafilcon A|First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses
9755460|NCT00584727|Active Comparator|alphafilcon A/senofilcon A/etafilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
9755461|NCT00584727|Active Comparator|etafilcon A/alphafilcon A/senofilcon A|First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses
9755462|NCT00584740|Experimental|AIN457|AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
9755463|NCT00584740|Placebo Comparator|Placebo|Matching placebo to AIN457 was given as an infusion at day 1 and day 22.
9755464|NCT00584805|Experimental|Vaccination|Inactivated, Dried, TSI-GSD 104, EEE
9755465|NCT00584831|Active Comparator|Group 2 LSBO|contact lenses worn in this order: lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric
9755466|NCT00584831|Active Comparator|Group 3 LOSB|contact lenses worn in this order: lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric
9755467|NCT00584831|Active Comparator|Group 4 LBSO|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric
9755468|NCT00584831|Active Comparator|Group 5 LBOS|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A
9755469|NCT00584831|Active Comparator|Group 6 SLOB|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, omafilcon A toric, balafilcon A toric
9755470|NCT00584831|Active Comparator|Group 7 SLBO|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric
9755471|NCT00584831|Active Comparator|Group 8 SOLB|contact lenses worn in this order: senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric
9755472|NCT00584831|Active Comparator|Group 9 SBLO|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric
9755473|NCT00584831|Active Comparator|Group 10 SBOL|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric
9755474|NCT00584831|Active Comparator|Group 11 OSLB|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric
9755475|NCT00584831|Active Comparator|Group 12 OSBL|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric
9755476|NCT00584831|Active Comparator|Group 13 OBLS|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric
9755477|NCT00584831|Active Comparator|Group 14 OBSL|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric
9755478|NCT00584831|Active Comparator|Group 15 BLSO|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric
9755479|NCT00584831|Active Comparator|Group 16 BLOS|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric
9755480|NCT00584831|Active Comparator|Group 17 BSOL|contact lenses worn in this order: balafilcon A toric, senofilcon A toric, omafilcon A toric, lotrafilcon B toric
9755481|NCT00584831|Active Comparator|Group 18 BOLS|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric
9755482|NCT00584831|Active Comparator|Group 19 BOSL|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric
9755483|NCT00584831|Active Comparator|Group 1 LSOB|contact lenses worn in this order: lotrafilcon B toric/senofilcon A toric/omafilconA toric/balafilcon A toric
9755484|NCT00584844|Experimental|F tularensis Vaccine (0.0025 mL)|Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
9755485|NCT00584857|Experimental|Chemotherapy|Single
9755486|NCT00584870|Active Comparator|Naproxen|
9755487|NCT00584870|Placebo Comparator|Placebo|
9755488|NCT00584870|Experimental|RN624|
9755489|NCT00584909|Experimental|Open Label|
9755490|NCT00584922||AF ablation group|Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
9755491|NCT00584948|Experimental|Memantine|
9755492|NCT00584948|Placebo Comparator|Placebo|
9755493|NCT00584987|Placebo Comparator|Placebo FF + Placebo OXY|Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
9755494|NCT00584987|Active Comparator|FF + Placebo OXY|Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
9755495|NCT00584987|Active Comparator|Placebo FF + OXY|Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
9755496|NCT00584987|Active Comparator|FF + OXY|Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
9755497|NCT00585013|Experimental|Nitric Oxide Delivery Group|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
9755498|NCT00585013|No Intervention|Placebo|Placebo delivery of oxygen at standard dose.
9755499|NCT00585039|Experimental|A|levalbuterol nebulization
9755500|NCT00585052|Experimental|Paclitaxel and lovastatin|Paclitaxel given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly. Lovastatin self-administered at 80mg daily.
9755501|NCT00585078|Experimental|CAPOX|Participants self-administered capecitabine 1,000 mg/m2 orally twice daily (total daily dose 2,000 mg/m2), days 1-14 in 21-day cycles. Only 500 mg tablets were used, and doses were rounded to the nearest dose that could be administered with 500 mg tablets. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 every 21 (±2) days. Treatment continued until tumor progression or toxicity requiring discontinuation of therapy.
9755502|NCT00585104|Experimental|1|All randomized patients receive drug.
9755503|NCT00585169|Experimental|memantine|10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.
9755504|NCT00585182|Experimental|1|
9755505|NCT00585247|Experimental|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
9755506|NCT00585247|Placebo Comparator|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
9755507|NCT00585286|Experimental|Fractional carbon dioxide laser system|Thirty total healthy subjects from two research centers with skin type I-IV of moderate to severe acne scarring received treatment with the 10,600 nm fractional carbon dioxide laser system.
9755508|NCT00585312|Experimental|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
9755509|NCT00585312|Placebo Comparator|Placebo|Masked, placebo comparator
9755510|NCT00585325|Experimental|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
9755511|NCT00585325|Placebo Comparator|Instilled Placebo (0.9% Normal Saline)|receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
9755512|NCT00585351|Experimental|I|Advanced Notification + Ranitidine
9755513|NCT00585351|Active Comparator|II|Advanced Notification + Placebo
9755514|NCT00585351|Active Comparator|III|No advanced notification + Ranitidine
9755515|NCT00585351|Placebo Comparator|IV|No advanced notification + Placebo
9755516|NCT00585377|Other|1|
9755517|NCT00585468|Experimental|Myfortic - Fed State|Mycophenolate sodium taken with a meal.
9755518|NCT00585468|Experimental|Myfortic - Fasting State|Mycophenolate sodium taken separately from food by 2 hours.
9755519|NCT00585494||Preoperative orthopedic|Patients undergoing elective total hip, knee and spinal surgery at University of Wisconsin hospital, having their preoperative visit between December 1, 2007 and November 30, 2008.
9755520|NCT00585533|Other|A|
9755521|NCT00585546|Experimental|LVAD and Clenbuterol|
9755522|NCT00585637|Active Comparator|1|No Vitamin D
9755523|NCT00585637|Active Comparator|2|1000 IU of Vitamin D
9755524|NCT00585637|Active Comparator|3|2000 IU of Vitamin D
9755525|NCT00585637|Active Comparator|4|4000 IU of Vitamin D
9755526|NCT00585650|Experimental|Treatment Group|Etanercept (Enbrel) 50mg twice weekly injections for 12 weeks
9755527|NCT00585650|Placebo Comparator|Placebo Group|Placebo Injections twice weekly for 12 weeks
9755528|NCT00585689|Experimental|Neoadjuvant ABI-007, Carboplatin, and Gemcitabine|Neoadjuvant ABI-007 (260 mg/m^2) on day 1, Carboplatin (Target AUC [Area under the curve] =5) on day 1, and Gemcitabine (800 mg^m2) on days 1 and 8, every 21 days.
9755529|NCT00585715|Experimental|Candela DCD with cooling|Laser treatment with Candela DCD cooling which produces a cryogenic fluid that cools the epidermis prior to each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will receive a coolant during the laser procedure.
9755530|NCT00585715|Active Comparator|Candela DCD without Cooling|Laser treatment without cooling before each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will not receive a coolant during the laser procedure.
9755531|NCT00585780|Active Comparator|High Alcohol Withdrawal on Prazosin|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
9755532|NCT00585780|Placebo Comparator|High Alcohol Withdrawal on PLA|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
9755533|NCT00585780|Active Comparator|Low Alcohol Withdrawal on Prazosin|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. Low AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
9755534|NCT00585780|Placebo Comparator|Low Alcohol Withdrawal on PLA|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment.Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
9755535|NCT00585910|Experimental|1|Total treatment period is 7 weeks. Atomoxetine treatment will be initiated and maintained for 4 weeks. If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
9755536|NCT00585923|Active Comparator|Usage of Fixed hole C-Tek™ Plate|Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
9755537|NCT00585923|Active Comparator|Usage of Slotted hole C-Tek™ Plate|Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.
9755538|NCT00585975|Experimental|Bromfenac Ophthalmic Solution 0.18%|
9755539|NCT00585975|Experimental|Xibrom 0.09%|
9755540|NCT00586001|Experimental|1|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders The UP is a form of transdiagnostic cognitive-behavioral therapy (CBT) for individuals diagnosed with anxiety disorders, depression and related disorders.
9755541|NCT00586001|No Intervention|2|Wait-list control: Participants were asked to wait 16 weeks before receiving treatment.
9755542|NCT00586066|Placebo Comparator|Placebo|Placebo-matching memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to placebo-matching memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to placebo-matching memantine 5 mg in the morning and placebo-matching memantine 10 mg in the evening in Week 3; dose increase if tolerated to placebo-matching memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
9831236|NCT05024227|Experimental|Experimental: nursing education interventions|nursing education interventions (including e-health platform assistance)
9831237|NCT05024227|No Intervention|No Intervention: Routine care|Only the original form of nursing education leaflets are given
9755543|NCT00586066|Experimental|Memantine|Re-purposed Alzheimer's drug to treat cognitive dysfunction associated with bipolar disorder. Memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to memantine 5 mg in the morning and memantine 10 mg in the evening in Week 3; dose increase if tolerated to memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
9755544|NCT00586105|Experimental|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
9755545|NCT00586157|Active Comparator|Methylphenidate Transdermal System (MTS)|
9755546|NCT00586157|Placebo Comparator|Placebo|
9755547|NCT00586170|Experimental|EBI Bone Healing System + Surgery|Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
9755548|NCT00586170|Placebo Comparator|Placebo Device + Surgery|Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
9755549|NCT00586196|Active Comparator|1|
9755550|NCT00586196|Placebo Comparator|2|
9755551|NCT00586261|Placebo Comparator|Placebo|Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
9755552|NCT00586261|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
9755553|NCT00586313|Experimental|a1: Tru-Cut biopsy for liver|Tru-Cut Biospy.
9755554|NCT00586326|Experimental|Women with DCIS|Women with DCIS
9755555|NCT00586339|Experimental|HIV+/Cervarix Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm, according to a 0, 1, 6-month schedule.
9755556|NCT00586339|Active Comparator|HIV+/Aluminium Hydroxide Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of control Aluminium Hydroxide [Al(OH)3], administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
9755557|NCT00586339|Experimental|HIV-/Cervarix Group|Human immunodeficiency virus negative (HIV-) subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
9755558|NCT00586469|Experimental|Old Bulk|This group receives a full dose of Fluviral made from aged bulk material
9755559|NCT00586469|Active Comparator|New Bulk|This group receives a full dose of Fluviral made from new material
9755560|NCT00586482|Active Comparator|Nicotine lozenge|"Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
9755561|NCT00586482|Placebo Comparator|Placebo lozenge|"Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
9755562|NCT00586495|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
9755563|NCT00586508|Experimental|Enzastaurin + Bevacizumab|
9755564|NCT00586521|Experimental|rFVIII-FS (octocog-alfa), (Kogenate FS)|On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.
9755565|NCT00586573|Experimental|Namenda|
9755566|NCT00586612|Experimental|Preterm group|Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
9755567|NCT00586612|Active Comparator|Full-term group|Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
9755568|NCT00586625|Experimental|Bepreve|bepotastine besilate ophthalmic solution 1.5%
9755569|NCT00586625|Placebo Comparator|Placebo|vehicle
9755570|NCT00586664|Experimental|Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%|
9755571|NCT00586664|Experimental|Bepotastine Besilate Ophthalmic Solution 1.0%|
9755572|NCT00586664|Placebo Comparator|Placebo|
9755573|NCT00586690|Experimental|NK Cell Infusion|Natural Killer (NK) Cell infusion using CD56 monoclonal antibody
9755574|NCT00586690|Other|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
9755575|NCT00586703|Experimental|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors
9755576|NCT00586729|Experimental|Vashe|Vashe Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
9755577|NCT00586729|Active Comparator|5% Mafenide Acetate|5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
9755578|NCT00586820|Experimental|BQ-123|BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
9755579|NCT00586820|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
9755580|NCT00586846|Experimental|1|
9755581|NCT00586898|Experimental|1|
9755582|NCT00587041|Placebo Comparator|Placebo|Participants received placebo for 6 weeks: 1 placebo packet daily and 1 placebo capsule twice daily
9755583|NCT00587041|Active Comparator|Oxadrop|Participants received Oxadrop for 6 weeks: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis)
9755584|NCT00587041|Active Comparator|Agri-King Synbiotic|Participants received AKSB for 6 weeks: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
9755585|NCT00587054|Experimental|Transplant Patients|
9755586|NCT00587067|Experimental|1|
9755587|NCT00587132|Experimental|New Onset Diabetes|"Adults diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
9755588|NCT00587132|Experimental|Familial Pancreatic Cancer|"Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
9755589|NCT00587132|Experimental|Peutz-Jeghers Syndrome|"Adults age 35-99 with Peutz-Jeghers syndrome.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
9755590|NCT00587132|Experimental|Clinical Symptoms of Pancreatic Cancer, Normal CT|"Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
9755591|NCT00587158|Other|Immunosuppression without paricalcitol (control)|Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
9755592|NCT00587158|Active Comparator|Immunosuppression with paricalcitol|Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).
9755593|NCT00587171|Active Comparator|Active|2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
9755594|NCT00587171|Sham Comparator|Control|2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
9782940|NCT01189370|Experimental|Intra-Patient Dose Escalation: Sorafenib|All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
9782941|NCT01189409|Experimental|PEG then Senna|PEG in stepped bowel protocol
9755595|NCT00587288|Experimental|Reslizumab 3 mg/kg|Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
9755596|NCT00587288|Placebo Comparator|Placebo|Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
9755597|NCT00587431|Experimental|1|
9755598|NCT00587431|Active Comparator|2|
9755599|NCT00587457|Experimental|CAT-8015 5 microgram per kilogram (mcg/kg)|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
9755600|NCT00587457|Experimental|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
9755601|NCT00587457|Experimental|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
9755602|NCT00587483|Active Comparator|Lidocaine 1.5 mg /kg|Lidocaine is a class I (sodium channel block) antiarrhythmic drug.
9755603|NCT00587483|Active Comparator|Amiodarone 300 mg|Amiodarone is used to treat and prevent certain types of serious, life-threatening ventricular arrhythmias (a certain type of abnormal heart rhythm) when other medications did not help or could not be tolerated. Amiodarone is in a class of medications called antiarrhythmics. It works by relaxing overactive heart muscles.
9755604|NCT00587483|Placebo Comparator|placebo (saline)|
9755605|NCT00587587|Experimental|A|Apligraf (bilayered living cell therapy)
9755606|NCT00587587|Active Comparator|B|Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
9755607|NCT00587639|Experimental|rTMS Treatment|All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
9755608|NCT00587678|Experimental|Randomized|Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
9755609|NCT00587678|Experimental|Ezetemibe|Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.
9755610|NCT00587769|Experimental|Bupropion SR & Varenicline|All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.
9755611|NCT00587834|Experimental|1|Within-subject design: one side of the mouth receives Gintuit
9755612|NCT00587834|Active Comparator|2|Within-subject control: one side of mouth receives tissue harvested from the palate
9755613|NCT00587847|Other|Campath maintenance treatment|Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.
9755614|NCT05247476|Active Comparator|L-T4 therapy group|Patients with refractory hypothyroidism still receive L-T4 therapy as usual.
9755615|NCT05247476|Experimental|L-T4+T3 therapy group|Patients with refractory hypothyroidism receive L-T4+T3 therapy
9755616|NCT05247463||Women invited to Breast Cancer Screening in England|Women invited to Breast Cancer Screening in England up to 31st March 2018
9755617|NCT05247463||Women attending Breast Cancer Screening in England|Women attending mammography screening to examine the effect of screening test threshold on outcomes, up to 31st March 2018
9755618|NCT05247450|Experimental|FES-t along with conventional physiotherapy|Combined conventional physiotherapy and functional electrical stimulation therapy (FES-t) along with task-specific training
9755619|NCT05247450|Active Comparator|Conventional physiotherapy alone|Conventional physiotherapy alone (current standard of care)
9755620|NCT05247437|Experimental|FitD full version|
9755621|NCT05247437|Active Comparator|Digital Self-Help|
9755622|NCT05247424|Experimental|Early unfractionated heparin|Administration of UFH at a dose of 100 IU/kg body weight at first medical contact. Addition of UFH before coronary intervention according to ACT measurement after coronary angiography before coronary intervention.
9755623|NCT05247424|No Intervention|Control - Unfractionated heparin for coronary intervention only|Control arm with administration of UFH at a dose of 100 IU/kg body weight after coronary angiography before coronary intervention.
9755624|NCT05247411|Experimental|Educational intervention|a Skype-videoconference, which included a 30 min educational intervention, was held with each subject.
9755625|NCT05247398|Experimental|Dynamic Stability Exercise Program|Involves four 45-minute occupational therapy visits as well as a daily home program across a 6-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults. The intervention focuses on enhancing mobility and strength of the thumb for use during daily activities.
9755626|NCT05247385|Active Comparator|Prasugrel group|"Prasugrel (60mg loading dose, followed by 10 mg QD for 15 days)~+ Ticagrelor placebo (Placebo loading dose followed by two pills a day)"
9755627|NCT05247385|Active Comparator|Ticagrelor group|"Ticagrelor (180mg loading dose, followed by 90 mg BID)~+ Prasugrel placebo (Placebo loading dose followed by one pill a day)"
9755628|NCT05247346|Experimental|probe-based endoscopic Raman and scattering measurements of GI tissue|probe-based integrated Raman spectroscopy and scattering measurements of BE and colorectal tissue during GI endoscopy
9755629|NCT05247281|Active Comparator|Culture-based treatment|
9755630|NCT05247281|Active Comparator|Next Generation Sequencing (NGS) with Culture-based treatment|
9831238|NCT05013554|Experimental|SAR443216-Dose Escalation|Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive an IV infusion administration of SAR443216
9831239|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort A|Participants with metastatic breast cancers with HER2 high expression will receive an IV infusion administration of SAR443216
9831240|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort B|Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive an IV infusion administration of SAR443216
9831241|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort C|Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive an IV infusion administration of SAR443216
9831242|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort D|Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive an IV infusion administration of SAR443216
9831243|NCT05006963|Experimental|face-to-face group|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, totaling 24 face-to-face consultations lasting 40 minutes each. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms.Techniques of manual therapy and therapy by exercise. In general, extra-oral and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will be mouth opening exercise will be also performed with the tongue on the palate, proprioceptive exercises with hyperboloid. In addition to these, additional exercises may be performed, according to the patient's need. The conducts will be adapted according to the needs of each patient. The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene.
9831244|NCT05006963|Active Comparator|telerehabilitation|The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, by telerehabilitation lasting 40 minutes each.A physiotherapist through video call via WhatsApp application. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms. Patients will be instructed to perform extra-oral and intra-oral self-massage and in the cranio-cervical musculature, bone mobilization hyoid, which would replace the mobilization unspecific articulation performed in person.Exercise will also be carried out mouth opening with tongue on the palate, exercises proprioceptives with hyperboloid. The conducts will be adapted according to the needs of each patient.The conducts will be adapted according to the needs of each patient.The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene
9831245|NCT04990986|Other|Intervention|The complex intervention will be co-developed during first phase of the study.
9831246|NCT04990986|No Intervention|Control|Half of the group will be included as control and thus not exposed to the intervention.
9831247|NCT04990895|No Intervention|Control group|Participants in the control group will have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. Although they will not be asked to complete PROs in between clinic visits, they will be asked to respond to a series of HRQOL questionnaires at baseline, at 6 months (±2 weeks) from enrollment, and at completion of adjuvant systemic therapy if this date differs from the 6-month time point by more than 4 weeks. A satisfaction questionnaire will also be administered at the end of study.
9831248|NCT04990895|Experimental|Intervention|Participants in the intervention group will also have a planned clinic follow-up visit prior to each scheduled chemotherapy appointment. They will be asked to complete a series of HRQOL questionnaires at baseline, at 6 months, and at completion of adjuvant chemotherapy to evaluate their HRQOL and satisfaction levels with their care. In addition, however, they will also receive an email reminder at the mid-way point between scheduled clinic visits to prompt them to enter ePROs via the REDCap online system, including measures such as the ESASr, the EORTC-QLQ C30 and EORTC-BR23 or EORTC-CR29 and specific symptom questionnaires.
9831249|NCT04990128|Experimental|Bone marrow aspirate concentrate|Bone marrow that is aspirated then concentrated using a device.
9831250|NCT04990128|Active Comparator|Triamcinolone|Triamcinolone is a corticosteroid.
9831251|NCT04969224|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA fixed-dose combination (FDC) in the morning and IVA in the evening.
9831252|NCT04967742|Experimental|A group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 10 μg in V-122 study.
9831253|NCT04967742|Experimental|B group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 30 μg in V-122 study.
9831254|NCT04967742|Experimental|C group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 100 μg in V-122 study.
9831255|NCT04964544|Other|Open Label, Single Arm Technology-Assisted Cholesterol Trial|Open Label Single Arm study in All-comers population who self-report having concern about high cholesterol or heart health
9755633|NCT05247216|Experimental|Hemay007 800 mg QD group|Drug: 800mg QD of Hemay007; daily oral administrtion for 12 weeks
9755634|NCT05247216|Experimental|Hemay007 1200 mg QD group|Drug: 1200mg QD of Hemay007; daily oral administrtion for 12 weeks
9755635|NCT05247216|Experimental|Hemay007 600 mg QD group|Drug: 600mg QD of Hemay007; daily oral administrtion for 12 weeks
9755636|NCT05247216|Placebo Comparator|placebo group|Drug: placebo of Hemay007; daily oral administrtion for 12 weeks
9755637|NCT05247203|Experimental|Telitacicept Arm 1|Telitacicept 80mg, once a week for 24 weeks plus standard therapy
9755638|NCT05247203|Experimental|Telitacicept Arm 2|Telitacicept 160mg, once a week for 24 weeks plus standard therapy
9755639|NCT05247203|Experimental|Telitacicept Arm 3|Telitacicept 160mg, once a week for 12 weeks followed by once every two weeks for another 12 weeks plus standard therapy
9755640|NCT05247203|Experimental|Telitacicept Arm 4|Telitacicept 240mg, once a week for 24 weeks plus standard therapy
9755641|NCT05247203|Experimental|Telitacicept Arm 5|Telitacicept 240mg, once every two weeks for 24 weeks plus standard therapy
9755642|NCT05247190|Experimental|Treating self-criticism|8-session group intervention targeting self-criticism given 2-hrs/week with booster session after 3-months.
9755643|NCT05247177|Experimental|Multimodal general anesthesia|General anesthesia maintained by co-administration of sevoflurane, dexmedetomidine and ketamine by using a predefined EEG density spectrum array pattern
9755644|NCT05247177|Active Comparator|Conventional general anesthesia|General anesthesia maintained by administration of sevoflurane alone to keep a bispectral index between 40-60
9755645|NCT05247164|Experimental|PDAC Patients|Patients undergoing EUS for characterization of a PDAC lesion will receive EUS-guided portal blood sampling.
9755646|NCT05247151|Active Comparator|Oxytocin|The patients received either a spray of the synthetic oxytocin (24 I.U. Syntocinon®) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.
9755647|NCT05247151|Placebo Comparator|Placebo|The patients received either a spray of the synthetic placebo (24 I.U.) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.
9831256|NCT04960228|Experimental|Altruism Video Intervention|Participants will watch a 3-minute video about COVID-19 vaccination that elicits altruistic motives. The role of this arm is to test whether altruistic themes are an effective way to promote COVID-19 vaccination amongst young people and whether a video format is preferable for this group.
9831257|NCT04960228|Active Comparator|Informational Text Intervention|Participants will read a brief informational text including information drawn from the Public Health Agency of Canada website (https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html#self). The purpose of this arm is to provide an active comparator with information about COVID-19 preventative health behaviors that has been strongly recommended to the public since the beginning of the pandemic. By doing this, we will assess if the video intervention changes vaccination intentions more than a presentation of general, well-known COVID-19 related information.
9831258|NCT04956133|Experimental|Physical activity|Participants will be offered online, individualized physical activity sessions 2-3 times/week for 15-45 minutes/session for 8-12 weeks.
9831259|NCT04953884|Experimental|wilate treatment|PK: Single dose of 80 IU/kg body weight (BW). Prophylactic treatment: 30-50 IU/kg BW administered 2-3 times per week at the recommended dose of over 12 months. Minor haemorrhage: loading dose 30-50 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours to achieve von Willebrand factor activity (VWF:Ac) and FVIII:C trough levels of >30%. Major haemorrhage: loading dose 50-80 IU/kg BW followed by a maintenance dose of 30-50 IU/kg BW every 12-24 hours to achieve VWF:Ac and FVIII:C trough levels of >50%. Minor surgery: loading dose of 40-60 IU/kg BW followed by a maintenance dose of 20-30 IU/kg BW every 12- 24 hours for up to 3 days, to achieve VWF:Ac peak levels of 50% after loading dose and trough levels >30% during maintenance. Major surgery: loading dose of 60-80 IU/kg BW followed by a maintenance dose of 30-40 IU/kg BW every 12-24 hours for up to 6 days or longer, to achieve VWF:Ac peak levels of 100% after loading dose and trough levels >50% during maintenance
9831260|NCT04950881|Sham Comparator|Control group|Conventional monitor and treatment The surgery is performed after patient is under general anesthesia. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate.
9831261|NCT04950881|Experimental|Nerve block group|After the patient is under general anesthesia, an attending physicians perform the ultrasound-guided cervical vagus nerve block (using a 50mm Braun nerve stimulation needle, and the patients were injected with 10ml of lidocaine or ropivacaine ). Then the operation starts. If patient's heart rate significantly slows down or bradycardia/arrhythmia happens, the surgeon will be asked to suspend the operation. Meanwhile, atropine (0.01-0.02mg/kg) is given intravenously to increase the heart rate. If atropine fails to increase the heart rate, isoproterenol (1-2 μg/per time) will be given intravenously to increase the heart rate. After endotracheal tube is removed, the patient will be followed up for next 24 hours.
9831262|NCT04949139|Active Comparator|Rapid intermittent bolus group|"A : males < 65 ; B : females < 65 or males ≥ 65 ; C : females ≥ 65 yrs~<During the first 3 h>~Primary treatment over 1h A: 5DW 8 B: 5DW 7 C: 5DW 6 mL/kg~If undercorrected, Repeat the 5DW amount infused during primary treatment after 3 h~<At 3-24 h> Modify protocol based on sNa at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h~≥ 0.5: repeat the amount infused during primary treatment q 6 h~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion~<At 24-48 h> Modify protocol based on sNa at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~undercorrection < 0.5: repeat the amount infused during primary treatment q 3 h~≥ 0.5: repeat the amount infused during primary treatment q 6 h~target correction < 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion"
9831263|NCT04949139|Active Comparator|Slow continuous infusion group|"Participants will be divided into three groups same as above~<During the first 3 h>~Primary treatment A: 5DW 1.8 B: 5DW 1.57 C: 5DW 1.35 mL/kg/h~Modify protocol as described below based on sNa measurement at 3 h~undercorrection: maintain the infusion rate~target correction: stop the infusion~<At 3-24 h> Modify protocol based on sNa measurement at each time point (6/12/18/24 h)~Check U/S ratio at 0 h~• undercorrection~< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion~<At 24-48 h> Modify protocol based on sNa measurement at each time point (30/36/42/48 h)~Check U/S ratio at 24 h~• undercorrection~< 0.5: increase the infusion rate to twice that of the primary treatment~≥ 0.5: maintain the infusion rate~• target correction~< 0.5: maintain the infusion rate~≥ 0.5: stop the infusion"
9831264|NCT04945772|Experimental|vMCO-010- High Dose|Participants receive 1.2E11gc/eye of vMCO-010
9831265|NCT04945772|Experimental|vMCO-010- Medium Dose|Participants receive 0.9E11gc/eye of vMCO-010
9755648|NCT05247125|Experimental|Blue light exposure + Melatonin treatment|The participants will receive the combination of blue light exposure according to the protocol described by Killgore et al. (2020) and 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) for 14 days
9755649|NCT05247125|Experimental|Melatonin treatment|The participants will receive 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) and the morning placebo-light exposure according to the protocol described by Killgore et al. (2020) for 14 days
9755650|NCT05247125|Experimental|Blue light exposure|The participants will receive the morning blue light exposure according to the protocol described by Killgore et al. (2020) for 14 days and placebo pill 1 hour before going to sleep (approximately at 20:00)
9755651|NCT05247125|Placebo Comparator|Placebo group|The participants will receive placebo light exposure in the morning (lamp turned off) and placebo pill treatment in the evening for 14 days
9755652|NCT05247099||children with systemic diseases|Systemic diseases such as Nephritic syndrome, and other systemic diseases that can affect the eyes.
9755653|NCT05247099||healthy children|"The exclusion criteria for the subjects were eye diseases or other systemic diseases that can affect the quality or volume of tears or the secretion of tears. These included~eyelid diseases: eyelid entropion, eyelid ectropion, ptosis, and palpebral dyskinesia;~conjunctival diseases: pterygium and conjunctivitis;~history of ocular surface chemical injury;~history of eye surgery within 6 months or history of retinal laser photocoagulation;~systemic diseases: Sjogren syndrome, Parkinson's disease, rheumatoid arthritis, Grave's disease, systemic lupus erythematosus, and others."
9755654|NCT05247086|No Intervention|Convention closure|Conventional closure of the surgical wound after mesh removal surgery.
9755655|NCT05247086|Experimental|Negative pressure therapy|Negative pressure therapy of the surgical wound after mesh removal surgery.
9755656|NCT05247047|Experimental|Device|Clusters in this arm will start using the device and use it for 6 weeks.
9755657|NCT05247047|No Intervention|Control|Clusters in this arm will not receive the device it will continue with usual care with no changes.
9755658|NCT05247021|Experimental|erector spinae block group (E)|patients will receive bilateral ultrasound guided erector spinae block before the lumbar spine surgery starts.(20ml of bupivacaine 0.25%) after receiving general anesthesia
9755659|NCT05247021|No Intervention|control group (C)|patients will receive standard general anesthesia for lumbar spine surgery according to hospital protocol.
9755660|NCT05247008|Other|Thyme honey interventional arm in geriatric patients having end-stage renal disease.|Thyme honey used as mouth rinse in treatment of xerostomia in geriatric patients with end-stage renal disease.
9755661|NCT05246995|Experimental|IBI325 and Sintilimab combination does-escalation|
9755662|NCT05246982|Experimental|Arm A|HER2 negative and PD-L1 CPS≥5, as first-line therapy
9755663|NCT05246982|Experimental|Arm B|As third-line or above therapy
9755664|NCT05246956|Experimental|Intradialytic exercise in hemodialysis patients ( Experimental Group)|Intradialytic exercise group
9755665|NCT05246956|No Intervention|Control Group|No intervention
9755666|NCT05246943||UTMB's Colorectal Surgical Cohort|Subjects who meet the inclusion criteria that will have colorectal surgery at UTMB
9755667|NCT05246917|Experimental|Handsewn ileocolic anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
9755668|NCT05246917|No Intervention|Side to side stapled anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
9755669|NCT05246865|Experimental|Women with PCOS|Women with polycystic ovary syndrome
9755670|NCT05246865|Experimental|Age and BMI-matched healthy volunteers|Otherwise healthy women without PCOS but matching in age and body mass index to the above group
9755671|NCT05246826|Experimental|Clinical Pilates Exercises|Pilates exercises will be performed 3 days a week, for a total of 18 sessions for 6 weeks.
9755672|NCT05246826|Experimental|Clinical Pilates Exercises and Conventional Treatment|In addition to Pilates exercises, conventional treatment will be performed 3 days a week, for 6 weeks, a total of 18 sessions.
9755673|NCT05246813||Osteoporotic hip fracture patients|
9755674|NCT05246813||Hip osteoarthritis patients|
9755675|NCT05246800|Experimental|Experimental group|a structured 8-week mHealth mindfulness program.
9782942|NCT01189409|Experimental|Senna then PEG|Stepped bowel protocol with Senna then PEG
9755676|NCT05246800|No Intervention|Control group|The control group was suggested to read the information about stress and burnout on the website of the TV-programme.
9755677|NCT05246787|Experimental|Breastfeeding intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. If necessary, the researcher may verbally warn the mother in a calm tone to continue breastfeeding throughout the procedure. During the resting period (last 2 minutes) after the blood draw is completed, the baby stays on the mother's lap.
9755678|NCT05246787|Experimental|Shotblocker intervention|2 minutes before the procedure, the baby will be placed on the mother's lap. ShotBlocker is a small plastic tool that is blunt, short, has many points in contact with the skin, does not contain drugs, is in the shape of a horseshoe, invasive interventions can be applied through the space in the middle. It is positioned on the skin before the invasive procedure. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
9755679|NCT05246787|Experimental|Breastfeeding and Shotblocker intervention|The baby will be placed on the mother's lap 2 minutes before the procedure. 2 minutes before the heel lance, the mother starts to breastfeed her baby and continues to breastfeed throughout the procedure and until the last touch to baby. The investigator should make sure that the contact points touch the skin. Shotblocker is pressed firmly for 20 seconds before the intervention, it is pulled from the area and the heel is pierced with the lancet. After Shotblocker is applied to the skin, invasive intervention should be performed within 30 seconds and the protocol should be followed. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
9755680|NCT05246787|No Intervention|Control group/ Standard Care|The baby is placed on the mother's lap 2 minutes before the procedure and the mother is provided to hold the baby effectively and graspingly. Standard heel lance procedure is applied. No additional interventions are applied to the baby. During the resting period (last 2 minutes) after the heel lance is completed, the baby stays on the mother's lap.
9755681|NCT05246735|Other|MR-guided NIR|"Women with breast abnormalities will undergo an optical exam (NIR) in combination with MRI where the NIR light imaging system illuminates the breast from multiple positions covering the area of interest.~A total of 60 women will be evaluated: 20 with breast abnormalities receiving gadolinium (Gd) contrast enhancement, 20 with breast abnormalities receiving both Gd-contrast enhancement and indocyanine green (ICG) contrast enhancement, and 20 healthy volunteers not receiving any contrast agents."
9755682|NCT05246709|Active Comparator|Control Group|This group will be received the current standard of care (SOC) dressing method for PICC lines.
9755683|NCT05246709|Experimental|Cyanoacrylate Glue Group|This group will receive a few drops of cyanoacrylate glue on PICC line site prior to application of usual standard film dressing over the PICC line site.
9755684|NCT05246696||Patient group|
9755685|NCT05246683||cohort|Observational evaluation during the hospital stage on diagnosis, treatment and evolution of patients with cardiogenic shock.
9755686|NCT05246644|Experimental|Intravenous Acetaminophen|subjects will receive IV acetaminophen and a placebo oral acetaminophen starting immediately after surgery and for 8 doses
9755687|NCT05246644|Active Comparator|Oral acetaminophen|subjects will receive a placebo for IV acetaminophen and active oral acetaminophen starting immediately after surgery and for 8 doses
9755688|NCT05246631|Active Comparator|Dexamethasone|5 mg intravenous dexamethasone
9755689|NCT05246631|Active Comparator|Haloperidol|1 mg intravenous haloperidol
9755690|NCT05246592||Preponderant lymphatic reflux group|high ratio of axillary lymphatic reflux to axillary vein reflux
9755691|NCT05246592||Preponderant venous reflux group|low ratio of axillary lymphatic reflux to axillary vein reflux
9755692|NCT05246553|Experimental|Modified cochlear implant recipients|"Patients suffering from severe to profound hearing loss and severe bilateral vestibulopathy implanted with a modified cochlear implant providing 1 to 3 extracochlear electrodes implanted in proximity to the ampullary branches of the vestibular nerve (vestibular electrodes).~All experiments will be carried out while the vestibular electrodes are inactive, and while electrical stimulation is delivered to one or several vestibular electrodes, with and without concurrent cochlear stimulation."
9755693|NCT05246553|Active Comparator|Cochlear Implant Patients (CI)|Unilateral or bilateral cochlear implant recipients with normal vestibular function documented within the clinical follow up of their cochlear implant, and without previous history of vestibular symptoms or complaints.
9755694|NCT05246553|Active Comparator|Bilateral vestibulopathy Patients (BV)|Patients with documented diagnosis of bilateral vestibulopathy, according to the guidelines of the Barany society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
9755695|NCT05246553|Active Comparator|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
9755696|NCT05246553|No Intervention|Healthy Subjects (HS)|Normal auditory functiona and without previous auditory or vestibular symptoms or complaints. Normal vestibular function documented with the video-head impulse test.
9755697|NCT05246540||Patients|
9782943|NCT01189461|Experimental|pegaptanib sodium arm|all patients will receive pegaptanib sodium
9782944|NCT01189487|Experimental|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV
9782945|NCT01189500|Experimental|Tamoxifen and Desvenlafaxine SR|
9782946|NCT01189604|Placebo Comparator|Arm1 - Placebo|
9782947|NCT01189604|Active Comparator|Arm 2 - ICI35,868 (propofol)|
9782948|NCT01189604|Active Comparator|Arm 3 - ICI35,868 (propofol)|
9755698|NCT05246527|Experimental|Exercise|"30 min of cycling on a stationary ergometer, guided by a video of a professional cycling instructor.~Half of the patients (n=30) and their respective matched healthy controls (n=30) will perform moderate-intensity exercise: continuous cycling at 64-76% of the individual HRmax).~The other half will perform a high-intensity interval training (HIIT) protocol: 5 min warm-up phase, followed by bursts of high-intensity cycling interspersed with varied recovery times (21 min in total), 4 min cool-down. Excluding warm-up and cool-down, intensities will remain >77% of individual HRmax during the whole routine.~Heart rate will be continuously recorded using a chest strap heart rate monitor and monitored by the patients themselves and the experimenter."
9755699|NCT05246527|Active Comparator|Control condition|30 min of watching a documentary about the benefits of physical activity on health. Heart rate will be recorded also during the control condition.
9755700|NCT05246514|Experimental|T-DXd arm|Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.
9755701|NCT05246501|Experimental|Simulation|
9755702|NCT05246501|Active Comparator|control group|
9755703|NCT05246475|Experimental|PET-MRI|Simultaneous 18F-EF5 PET and DW-MRI
9755704|NCT05246462|Experimental|Experimental group|Gynecological cancer patients in a chemotherapy unit in Trabzon were recruited in the study. Inclusion criteria for the study were volunteering to take part in the study, being able to read and write in Turkish, being 18 years of age or older, having been diagnosed with gynecological cancer, knowing that s/he had been diagnosed with cancer, having received at least one chemotherapy treatment and having cancer stage 2 or 3. Exclusion criteria in the study were having a verbal communication disability, having been diagnosed with psychotic and neurological disorders, having received, or receiving psychotherapy, living outside the city center of Trabzon, and receiving treatment at intervals longer than 21 days. The experimental group received 7 sessions of logotherapy interviews.
9755705|NCT05246462|No Intervention|Control group|Gynecological cancer patients in a chemotherapy unit in Trabzon were recruited in the study. Inclusion criteria for the study were volunteering to take part in the study, being able to read and write in Turkish, being 18 years of age or older, having been diagnosed with gynecological cancer, knowing that s/he had been diagnosed with cancer, having received at least one chemotherapy treatment and having cancer stage 2 or 3. Exclusion criteria in the study were having a verbal communication disability, having been diagnosed with psychotic and neurological disorders, having received, or receiving psychotherapy, living outside the city center of Trabzon, and receiving treatment at intervals longer than 21 days. The control group received standard nursing care.
9755706|NCT05246436|Active Comparator|warm saline|Patients who used warm saline as a distention media in office hysteroscopy
9755707|NCT05246436|Sham Comparator|room temperature saline|Patients who used room temprature saline as a distention media in office hysteroscopy
9755708|NCT05246423||Observation group|Patients with paroxysmal atrial fibrillation, recruited at least two weeks after the last paroxysm
9755709|NCT05246397|Experimental|Cardiac surgery patients|Patients undergoing cardiac surgery
9755710|NCT05246371|Experimental|propofol and dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine
9755711|NCT05246371|Experimental|desflurane|Patients will receive maintenance of general anesthesia by desflurane.
9755712|NCT05246358|Experimental|ChroniSense Polso Respiratory Rate|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
9755713|NCT05246332|Experimental|Patient receive grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The grounding group use a grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
9755714|NCT05246332|Sham Comparator|Patient receive sham-grounding|The investigators use the grounding mat (EARTHING Conductive Earthing Uni-versal Mat with Earthing Cord) as the grounding method. The sham-grounding group use a sham grounding wire to sit on a chair barefoot in contact with the grounding mat for 30 minutes.
9755715|NCT05246319||Patients with small intestine neuroendocrine tumors|Evaluation of preoperative abdominal imaging in patients who underwent an a resection for neuroendocrine tumors
9782949|NCT01189604|Active Comparator|Arm 4 - ICI35,868 (propofol)|
9984041|NCT04468841|Experimental|Retrospective Group|Study participants who have received first-line treatment for follicular lymphoma and are in complete remission will have blood collected for cfDNA testing. In the retrospective cohort, MSKCC patients with CRs lasting ≥10 years after induction therapy will be studied. Initial tumor tissue (if available) will be collected to examine the status of ctDNA in patients with long-term remissions. Blood samples will be collected once, if the patient has interesting results (e.g. positive cfDNA sample despite CR on imaging, etc.) then additional blood samples may be taken during follow up visits.
9984042|NCT04468360|Experimental|IV Allopregnanolone (Allo) for Extinction Retention (Expt. 1)|Arm 1 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after completion of extinction training.
9984043|NCT04468360|Placebo Comparator|IV Placebo for Extinction Retention (Expt. 1)|Arm 2 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after completion of extinction training.
9755716|NCT05246306||Healthy group|Healthy adolescents aged 14-24 who have not been diagnosed with any chronic disease
9755717|NCT05246306||Patient with PCOS group|Adolescents between the ages of 14-24 diagnosed with Polycystic Ovary Syndrome according to the Rotherdam criteria.
9755718|NCT05246254||Prefrailty group|According to the frailty index(FI) and FI =0.12~0.25
9755719|NCT05246254||Frailty group|According to the frailty index(FI) and FI≥ 0.25
9755720|NCT05246254||Nonfrailty group|According to the frailty index(FI) and FI<0.12
9755721|NCT05246228||Patient with cSCC addressed to adjuvant radiotherapy as per clinical practice|The aim of the study is to evaluate patient's outcome according to the post-radiation lymphocytes count and to the changes induced in the immune cell population by a loco-regional treatment as radiotherapy. The way to objectivate these results is to collect some blood samples and analyze them.
9755722|NCT05246215||STEMI group.|60 participants of patients with STEMI treated with primary percutaneous coronary intervention (pPCI).
9755723|NCT05246215||healthy group.|15 participants of healthy people as a case control.
9755724|NCT05246215||Stable angina group.|15 participants of patients stable angina
9755725|NCT05246189||Patient with PXE working aged|Patient diagnosed with PXE on working age and followed up by the French Reference Center.
9755726|NCT05246176|Experimental|Cases|group of patient with inoperable malignant obstructive jaundice with failed internal drainage.
9755727|NCT05246111|Experimental|M6620, [14C]M6620 and Topotecan|
9755728|NCT05246072|Active Comparator|Ivermectin + colchicine + standard care|"In addition to the local standard of care for COVID 19 patients, the patient will receive:~Ivermectin + Colchicine"
9755729|NCT05246072|Active Comparator|Colchicine + standard care|"In addition to the local standard of care for COVID 19 patients, the patient will receive:~Colchicine"
9755730|NCT05246072|No Intervention|standard care|Patients will receive Standard care
9755731|NCT05246059|No Intervention|Control|12 weeks of observation, safety information provided
9755732|NCT05246059|Experimental|Treatment|12-weeks of daily olfactory training
9755733|NCT05246033|Experimental|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection
9755734|NCT05246033|Experimental|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
9755735|NCT05246033|Experimental|TransCon CNP >100 mcg|TransCon CNP >100 mcg CNP/kg delivered once weekly by subcutaneous injection (to be determined after completion of 100 mcg cohort)
9755736|NCT05246020|Experimental|NHIPEC|Treatment: Four tubes will be placed via the laparoscopic ports and HIPEC will be given within 24 hours after laparoscopic evaluation.
9755737|NCT05246020|Active Comparator|Intravenous NACT|Drug:Three cycles of intravenous NACT will be given in this group. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin area under curve(AUC) 5 for a 21-day cycle.
9755738|NCT05245994|Experimental|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|
9755739|NCT05245981|Experimental|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.
9755740|NCT05245968|Experimental|Dose Escalation Part|Pimitespib in combination with imatinib
9755741|NCT05245968|Experimental|Expansion Part-A|Pimitespib in combination with imatinib
9755742|NCT05245968|Experimental|Expansion Part-B|Pimitespib followed by imatinib
9755743|NCT05245968|Experimental|Expansion Part-C|Sunitinib
9755744|NCT05245955|Experimental|Robotic assessment of sensory hand function|This arm involves a group of persons with Parkinson's disease and an age-matched control group. Both groups undergo the assessments of kinaesthesia and haptic perception of the hand implemented on the ReHapticKnob.
9755745|NCT05245929|Active Comparator|Skeletally anchored Distal Jet appliance|
9755746|NCT05245929|Active Comparator|Skeletally anchored Hyrax screw distalizer|
9755747|NCT05245916|Experimental|IBI397 single-agent dose escalation|
9755748|NCT05245916|Experimental|IBI397+ Rituximab|
9755749|NCT05245916|Experimental|IBI397 + Sintilimab|
9755750|NCT05245903||Parent Study Participants|The single group in this study will consist of individuals enrolled in the parent study (ClinicalTrials.gov identifier NCT04430517). We aim to enroll approximately 40 individuals aged 18 -89 (inclusive) with either MCI or mild AD who will have the Emerald device deployed in their home for up to 12 weeks, spanning the time of approval of parent study screening and formal study enrollment.
9782950|NCT01189604|Active Comparator|Arm 5 - ICI35,868 (propofol)|
9831266|NCT04945772|Sham Comparator|Sham Injection|Participants receive sham injection
9831267|NCT04937582|Experimental|Confirmed cognitive disorder|"Patients with abnormal QPC score at screening visit and confirmed cognitive disorder on the neuropsychological assessment during Visit V1.~Intervention Completed by MRI (magnetic resonance imaging), EEG (Electroencephalogram) and possible psychiatric evaluation at Visit 1B.~Follow-up 2 years after initial hospitalisation (Visit 2 : neuropsychological assessment ; if needed MRI, EEG, lumbar puncture)"
9831268|NCT04937582|Experimental|Absence of cognitive disorder|Patients with abnormal QPC score at screening and absence of cognitive disorder on the neuropsychological assessment during Visit V1.
9831269|NCT04932915|Experimental|UNI91103 intranasal spray 1%|UNI91103 intranasal spray 1%, BID, 10 consecutive days
9831270|NCT04932915|Placebo Comparator|Placebo|Placebo intranasal spray, BID, 10 consecutive days
9831271|NCT04928872||Non-diabetic older adults|Non-diabetic older adults
9831272|NCT04926051|Experimental|Part A: SAD|SAD = Single Ascending Dose
9831273|NCT04926051|Experimental|Part B: MAD|MAD = Multiple Ascending Dose
9831274|NCT04926051|Experimental|Part C: JMAD|JMAD= Japanese Multiple Ascending Dose
9831275|NCT04926051|Experimental|Part D: FE/BA|FE/BA = Food Effect/Relative Bioavailability
9831276|NCT04922229|Active Comparator|Root canal treatment (RCT)|For cases with this diagnosis RCT is the standard of care and will be done according to clinically approved protocols
9831277|NCT04922229|Experimental|Vital Pulp Therapy (VPT)|VPT with tricalcium silicates has shown high clinical success in these cases. However, it is not known how this success compares to RCT under similar conditions and with an intent-to-treat study design, which will be employed here.
9831278|NCT04919642|Experimental|Cohort A1|FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor
9831279|NCT04919642|Experimental|Cohort A2|FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor and discontinued due to disease progression
9831280|NCT04919642|Experimental|Cohort B|Other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions
9831281|NCT04919642|Experimental|Cohort C|Negative for FGFR alterations (FGFR wild-type)
9831282|NCT04914767|Experimental|Nigella|"The patient will receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
9831283|NCT04914767|Placebo Comparator|Placebo Group|"The patient will also receive a study treatment containing 100 capsules:~One capsule every two hours for the first three days.~From the fourth day, the patient will take one capsule, three times a day for 12 days."
9831284|NCT04914117|Experimental|RC118 for injection|"Part A (Dose Escalation): RC118 will be administered through IV infusion at the various dose levels, including 0.25, 0.5, 1.0, 1.5, 2, 2.5, and 3 mg/kg, 1-12 subjects for each dose level.~Part B (Dose Confirmation): RC118 will be administered at up to two dose levels, which is equal or lower than MTD/MAD, through IV infusion. Each dose level contains 3-6 subjects."
9831285|NCT04905628||Dexcom CGM System|Dexcom CGM System
9831286|NCT04904822|Experimental|Study group|Vaginal bisection of uterus
9831287|NCT04904822|Experimental|Control group|Abdominal bisection
9831288|NCT04892277|Experimental|Treatment (cyclophosphamide, fludarabine, IC19/1563)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5, -4, -3 and IC19/1563 IV on day 0.
9831289|NCT04887779|Experimental|Intervention|Patient viewing ex-planted organ and microscopy with pathologist
9831290|NCT04874038|Experimental|Intervention|Intraoperative intravenous lidocaine/placebo infusion
9831291|NCT04874038|Placebo Comparator|Control|Intraoperative intravenous lidocaine/placebo infusion
9831292|NCT04871776|Experimental|"Why messaging"|In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. Messages will focus on reasons to get the COVID booster vaccine, including protecting self and loved ones or the idea of herd immunity.
9831293|NCT04871776|Experimental|"How messaging"|"In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. How messages will focus on the details of obtaining a vaccination at MGB, what to expect, and how to prepare for the visit."
9831294|NCT04871776|Active Comparator|Usual Care|In this arm, patients will not receive any additional message about their upcoming visit, beyond what they already receive by the health system.
9831295|NCT04867785|Experimental|LY3437943 Maintenance Dose 1|LY3437943 administered by subcutaneous (SC) injection
9831296|NCT04867785|Experimental|LY3437943 Maintenance Dose 2|LY3437943 administered by SC injection
9831297|NCT04867785|Experimental|LY3437943 Maintenance Dose 3|LY3437943 administered by SC injection
9831298|NCT04867785|Experimental|LY3437943 Dose 4|LY3437943 administered by SC injection
9831299|NCT04867785|Active Comparator|Dulaglutide|Dulaglutide will be given SC
9831300|NCT04867785|Placebo Comparator|Placebo|Placebo will be given SC
9831301|NCT04847167|Experimental|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|All ERCP was performed with the patient in the prone position using a SBE (SIF-H290S; Olympus Corp., Japan) under CO2 insufflation and conscious sedation. A soft transparent hood (D-201-11804; Olympus Corp., Japan) was used in all cases. The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
9831302|NCT04845828|Experimental|Sentinel lymph node mapping|The group composed of patients who undergo sentinel lymph node mapping
9831303|NCT04845828|Active Comparator|Routine lymph node dissection|The group composed of patients who undergo routine pelvic lymph node dissection
9831304|NCT04845490|Experimental|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with Mitomycin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
9831305|NCT04845490|Experimental|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
9831306|NCT04845490|No Intervention|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
9831307|NCT04844307|Active Comparator|Standard PT group|The standard PT group (control) will be receiving the standard 30 minute PT sessions 5 days a week. There will be no variations from standard inpatient PT treatment except that subjects may receive more days of PT than patients who are not participating in study.
9831308|NCT04844307|Experimental|Divided session PT group|The divided session PT group (experimental) will be receiving 15 minute sessions twice a day, five days a week. The total number of minutes of PT time per day/week will be identical to the standard PT group, but divided into shorter and more frequent sessions.
9831309|NCT04830397|Experimental|QLS-101 0.5%|
9831310|NCT04830397|Experimental|QLS-101 1%|
9831311|NCT04830397|Experimental|QLS-101 2%|
9831312|NCT04830397|Active Comparator|Timolol Maleate 0.5% preservative free ophthalmic solution|
9831313|NCT04819360|Active Comparator|Vesicare|Group 1: will be treated with an anticholinergic (Vesicare® 10 mg per day for 12 weeks)
9831314|NCT04819360|Active Comparator|Botox|Group 2: will receive an intra-detrusor injection of a low dose of botulinum toxin type A (100 U of BOTOX®).
9831315|NCT04808466|Experimental|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with paclitaxel): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
9831316|NCT04808466|Experimental|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
9831317|NCT04808466|No Intervention|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
9831318|NCT04796129||patients with hip osteoarthritis|the patients who aged 45 and older and have paint in the hips. and also without having any other comorbidities about inflammatory status.
9831319|NCT04796129||control|the participants who have any other comorbidities for impact on the inflammatory status and also no hip pain.
9831320|NCT04791384|Experimental|Abemaciclib/Elacestrant|Abemaciclib and Elacestrant combination
9831321|NCT04787354|Active Comparator|Control arm|"Standard adjuvant XELOX 8 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, total 8 cycles"
9984044|NCT04468360|Experimental|IV Allo for Reconsolidation Blockade (Expt. 2)|Arm 1 of Expt. 2 will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
9831322|NCT04787354|Experimental|Study arm|"Adjuvant XELOX 4 cycles followed by capecitabine monotherapy 4 cycles~Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles~followed by~Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles"
9831323|NCT04779177|Experimental|Lumateperone 42 mg once daily for 5 days|
9831324|NCT04779177|Experimental|Lumateperone 28 mg once daily for 5 days|
9831325|NCT04754191|Experimental|Treatment: all patients|Enfortumab will be administered in monotherapy on days 1, 8, and 15 as part of a 28-day cycle at 1.25 mg/kg up to 125 mg.
9831326|NCT04752449|Experimental|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
9831327|NCT04752449|No Intervention|Treatment as Usual|Participants continue with their regular standard of care without the addition of virtual Cognitive Behavioural Therapy for Psychosis.
9984045|NCT04468360|Placebo Comparator|IV Placebo for Reconsolidation Blockade (Expt. 2)|Arm 2 of Expt. 2 will include will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
9831329|NCT04746794|Experimental|Point of Care|In the point of care (POC) arm, patients will be approached at the time they come in to the clinic for a routine visit with their primary care provider. We will screen patients for familial cancer risk using electronic tablets in the waiting room or, in the case of a telehealth visit, through telephone contact before the visit. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers.
9831330|NCT04746794|Experimental|Direct Patient Engagement|"In the direct patient engagement (DPE) arm, patients will be identified by reviewing clinic records to create an active patient list (i.e., those who have had a visit in the past year). We will contact patients by postal mail and email to provide a link to the online risk screening tool. The patient outreach is not tied to a specific visit and the online screening can be completed at any time. Patients identified as high risk will be offered genetic testing for a panel of hereditary cancers."
9831331|NCT04746794|No Intervention|Stakeholder Interviews and Surveys|Samples of patients, providers, and clinic leaders will be assessed at several points throughout the study - baseline and multiple follow-ups. We will use a mixed methods approach, with both quantitative assessments (surveys) and qualitative assessments (interviews). Baseline assessments will provide initial data on the patient population and current clinic functioning and help in implementation planning. The midpoint and final assessments will provide estimates of change in patients, providers, and clinic leaders as a result of the implementation.
9831332|NCT04744389|Experimental|Hypothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
9831333|NCT04744389|Experimental|Normothermic Machine Perfusion|uDCD and cDCD after Normothermic Regional Perfusion matching the inclusion criteria, ECD matching the inclusion criteria, uDCD and cDCD exceeding the inclusion criteria.
9755751|NCT05245877|Experimental|Preoperative thromboprophylaxis|Preoperatively initiated tromboprophylaxis
9755752|NCT05245877|No Intervention|Postoperative thromboprophylaxis|Postoperatively initiated thromboprophylaxis
9755753|NCT05245838|Experimental|Z-1018 Dose Level 1|100 mcg gE + 3000 mcg CpG 1018
9755754|NCT05245838|Experimental|Z-1018 Dose Level 1a|100 mcg gE + 3000 mcg CpG 1018 + alum
9755755|NCT05245838|Experimental|Z-1018 Dose Level 2|100 mcg gE + 6000 mcg CpG 1018
9755756|NCT05245838|Experimental|Z-1018 Dose Level 2a|100 mcg gE + 6000 mcg CpG 1018 + alum
9755757|NCT05245838|Active Comparator|Shingrix|
9755758|NCT05245786|Experimental|Treatment (64Cu labeled M5A antibody and imaging)|Patients receive 64Cu labeled M5A antibody IV over 5 minutes on day 0 pre standard of care chemo/radiotherapy and on day 0 post chemo/radiotherapy. Patients also undergo 64Cu-M5A PET scan on day 1 pre chemo/radiotherapy and on day 1 post chemo/radiotherapy.
9755759|NCT05245734|Experimental|Main group|"Patients receive two prophylactic doses of the Human Anti-D (rh) immunoglobulin at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery. Patients receive the second dose only in the case of the birth of an Rh-positive child.~Before and after each injection of the drug, blood will be taken to control the level of anti-Rh0 (D) antibodies. after the last injection of the drug, blood samples are taken after 3 and 6 months to assess sensitization to the Rh antigen.~15 participants from the Main group are formed the Pharmacokinetics subgroup for additional blood samples taking, to determine the pharmacokinetic parameters"
9755760|NCT05245721|Active Comparator|Nalbuphine|
9755761|NCT05245721|Active Comparator|Bupivacaine|
9755762|NCT05245708|Experimental|oxytocin|a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
9755763|NCT05245708|Experimental|placebo|a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.
9755764|NCT05245643|Other|Patients with severe and resistant Anorexia Nervosa|12 consecutive patients fulfilling the inclusion criteria and consenting to participate in the research, recruted in the three inclusion centers.
9755765|NCT05245630||Robotic arm assisted PET/CT guided biopsy|"In this group, participants were recruited for robotic-assisted PET/CT guided biopsy from the FDG avid lung lesions.~biopsies were done using an automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) to guide the needle for biopsy. It is a robotic arm with a four-ax guide arm and a planning console. Pre-interventional fused PET/CT images from Biograph mCT 16 scanner were sent via LAN cable to the device (MAXIO-EX) console."
9755766|NCT05245630||PET fused CT-Fluoroscopy guided biopsy|"In this group, participants were recruited for PET fused CT-Fluoroscopy guided biopsy from the FDG avid lung lesions.~A biopsy needle was placed to the target lesion on PET/CT under CT fluoroscopy"
9755767|NCT05245604|Experimental|TJO-087|
9755768|NCT05245604|Active Comparator|Cyclosporine 0.05%|
9755769|NCT05245591|Experimental|Pentosan Polysulfate Sodium|U101 is available as a capsule containing 100 milligrams (mg) of pentosan polysulfate sodium. Subjects will be administered U101 at a dose of 300 milligrams (mg) three times daily (tid) for the initial 8 weeks and then 200 milligrams (mg) twice daily (bid) for another 8 weeks during the study.
9755770|NCT05245591|Placebo Comparator|Placebo Control|Placebo to match U101 is available as a capsule in 100 milligrams (mg). Subjects will be administered placebo at a dose of 300 milligrams (mg) three times daily (tid) for the initial 8 weeks and then 200 milligrams (mg) twice daily (bid) for another 8 weeks during the study.
9755771|NCT05245578|Experimental|KX01 ointment and Placebo ointment|
9782951|NCT01189604|Active Comparator|Arm 6 - ICI35,868 (propofol)|
9782952|NCT01189604|Active Comparator|Arm 7 - ICI35,868 (propofol)|
9782953|NCT01189617|Experimental|Formula PD-F-7619|At least twice per week for one week, massage about a dime-sized amount of the PD-F-7619 personal lubricant product to the application site as directed.
9782954|NCT01189747|Experimental|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1.
9782955|NCT01189747|Placebo Comparator|placebo (normal saline)|normal saline injected into bilateral Crow's Feet Line areas on Day 1.
9782956|NCT01189760|Experimental|onabotulinumtoxinA 44U|44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
9782957|NCT01189760|Other|onabotulinumtoxinA 24U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo (normal saline) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
9782958|NCT01189760|Placebo Comparator|placebo (normal saline)|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
9782959|NCT01189812|Placebo Comparator|sugar pill|
9782960|NCT01189812|Active Comparator|Lithium|
9782961|NCT01189890|Experimental|Sitagliptin|Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
9782962|NCT01189890|Active Comparator|Glimepiride|Glimepiride 1-6 mg QD
9782963|NCT01190007|Experimental|Caduet|
9782964|NCT01190020|Active Comparator|Lubiprostone|24mcg BID for 4 weeks, oral medication
9782965|NCT01190020|Placebo Comparator|Placebo|24mcg BID for 4 weeks (placebo), oral medication
9782966|NCT01190085|Active Comparator|Ghrelin (1 microg/kg)|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
9782967|NCT01190085|Active Comparator|Ghrelin (3 microg/kg)|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
9782968|NCT01190085|Placebo Comparator|Saline Solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
9782969|NCT01190098|Experimental|Lacosamide|
9984046|NCT04468256||Cardiomyopathy|Heart Hive registered participants with self-reported cardiomyopathy
10202026|NCT05157386||Participants in Braining, years 2017-2020|"Braining was primarily open for patients with a main or secondary diagnosis within affective disorder or anxiety syndromes, sleep disturbance or stress.~Participants in Braining (n≈600), who have participated in three or more training sessions 2017-2020 (n≈250), and who agree to contribute to this study, will be included."
10202027|NCT05154669|Active Comparator|Standard Smoking Cessation Coaching|Participants will receive 5 counseling sessions over approximately 8 weeks as per standard smoking cessation programs. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
10202028|NCT05154669|Experimental|Integrated Financial-Smoking Cessation Coaching|The integrated intervention will provide 5 counseling sessions over approximately 8 weeks that integrates financial coaching into the smoking cessation program. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
9782970|NCT01190098|Placebo Comparator|Sugar pill|
9782971|NCT01190124||CohortHIV|Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.
10202029|NCT05153655|Experimental|Ischemic post-conditioning group|The safety and tolerability of ischemic post-conditioning will be investigated using 3+3 dose-escalation trial design.
10202030|NCT05153564|Experimental|One-sequence cross-over arm|
10202031|NCT05151146|Experimental|ANJ900 in the fasted state|Single dose (1800 mg) of ANJ900
10202032|NCT05151146|Experimental|ANJ900 in the fed state|Single dose (1800 mg) of ANJ900
10202033|NCT05151146|Active Comparator|Metformin IR in the fasted state|Single dose (1000 mg) of metformin IR
10202034|NCT05150652|Experimental|Neoadjuvant Endocrine Therapy|Participants will begin treatment with Anastrozole. If not tolerated well, participants will discontinue and begin treatment using Letrozole. If not tolerated well, participants will discontinue and begin treatment using Exemestane. If not tolerated well, participants will discontinue and begin treatment on Tamoxifen.
10202035|NCT05147480|Active Comparator|yoga group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers intervention: 6-week, once a week internet-based mother and baby yoga
10202036|NCT05147480|No Intervention|control group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers the standardized follow-up without intervention
10202037|NCT05144048|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
10202038|NCT05144048|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women are observed 2 hours after they receive one dose of oral misoprostol before they leave the maternity unit.
10202039|NCT05143489|Active Comparator|Preservative Free Lidocaine Group|The patient will receive a 1mg/kg IV dose of preservative free lidocaine with a max dose of 40mg
10202040|NCT05143489|Active Comparator|Placebo Group|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
10202041|NCT05143073|No Intervention|No educational materials|No educational materials will be provided.
9782972|NCT01190150|Experimental|0.65 g / 1.3 g tranexamic acid|Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.
9782973|NCT01190150|Experimental|1.3 g / 0.65 g tranexamic acid|Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.
9782974|NCT01190176|Experimental|HPV-062 study subjects Group|HPV-015 (NCT00294047) study subjects who had normal cervical cytology, but tested positive for oncogenic HPV infection at their concluding HPV-015 (NCT00294047) study visit or were pregnant, so that no cervical sample could be collected at their concluding HPV-015 (NCT00294047) study visit.
9782975|NCT01190189|Experimental|Cervarix Group|Healthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.
9782976|NCT01190215|Experimental|Fluarix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
9782977|NCT01190215|Active Comparator|Havrix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
9782978|NCT01190410|Experimental|Certolizumab pegol: high-dose group|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
9782979|NCT01190410|Experimental|Certolizumab pegol: low-dose group (weight adjusted)|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
9782980|NCT01190436|Experimental|Bisoprolol|
9782981|NCT01190449|Experimental|Arm I|Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
9782982|NCT01190449|Experimental|Arm II|Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
9782983|NCT01190475|Experimental|BGS649 high dose|1 BGS649 1.0mg capsule with three 0.1 mg placebo capsules.
9782984|NCT01190475|Experimental|BGS649 low dose|1 BGS649 1.0 mg placebo capsule and 3 BGS649 0.1 mg capsules
9782985|NCT01190475|Placebo Comparator|Placebo to BGS649|1 matching placebo 1.0mg matching and three matching 0.1 mg placebo capsules
9782986|NCT01190514|Experimental|Bioequivalence and Food effect|
9782987|NCT01190527|Other|FDG-PET|All subjects will have the same course of treatment, the study treatment.
9782988|NCT01190813|Active Comparator|Levodopa/Carbidopa|Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
9782989|NCT01190813|Placebo Comparator|Placebo|Oral placebo tid
9782990|NCT01190839|Experimental|Infliximab|Infliximab Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
9782991|NCT01190839|Placebo Comparator|Placebo|Placebo Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
9755772|NCT05245565||PPS surgery|Patients who undergo modified PPS surgery in order to preserve anal sphincter function under the premise of radical resection of ultralow rectal cancer.
9755773|NCT05245565||Conventional|Patients who undergo conventional sphincter-preserving surgeries.
9755774|NCT05245552|Experimental|Safety group|PhaseⅠ,30 subjects will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
9755775|NCT05245552|Experimental|Experimental Group of quadrivalent influenza vaccine(0.25ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.25ml) on the immunization schedule of day 0,28.
9755776|NCT05245552|Experimental|Experimental Group of quadrivalent influenza vaccine(0.5ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
9755777|NCT05245552|Active Comparator|Control Group of trivalent influenza vaccine(BV)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BV) on the immunization schedule of day 0,28.
9755778|NCT05245552|Active Comparator|Control Group of trivalent influenza vaccine(BY)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BY) on the immunization schedule of day 0,28.
9755779|NCT05245513|Experimental|Recovery Community Center Linkage (RCCL)|The RCCL arm will involve a brief (~20 minutes) meeting with a recovery coach (i.e. linkage manager), in which the recovery coach will inform the participant of recovery community centers and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (i.e. peer facilitator).
9755780|NCT05245513|Active Comparator|Control Condition (CC)|The CC arm will involve a time-matched meeting with a recovery coach (i.e. linkage manager), in which the recovery coach will broadly inform the participant of recovery support services and provide them with a list of recovery support service resources.
9755781|NCT05245448|Experimental|tetrandrine|tetrandrine administered 40milligram (mg) orally thrice daily through Week 24.
9755782|NCT05245448|Placebo Comparator|placebo|Placebo administered orally thrice daily through Week 12. Starting at Week 12, participants were given tetrandrine 40 milligram (mg) orally thrice daily through Week 24.
9755783|NCT05245435|Other|planned to undergo cytoreductive prostatectomy|planned to undergo cytoreductive prostatectomy
9755784|NCT05245435|Other|newly diagnosed metastatic hormone-sensitive prostate cancer patients|planned to undergo androgen deprivation therapy, and/or treatment with abiraterone acetate, and/or enzalutamide and/or docetaxel
9755785|NCT05245435|Other|metastatic castration-resistant prostate cancer patients|who were not pre-treated with enzalutamide or abiraterone acetate and planned treatment with those drugs
9755786|NCT05245435|Other|primary oligometastatic hormone-sensitive prostate cancer patients|who refuse to undergo cytoreductive radical prostatectomy will serve as control group
9755787|NCT05243823||Danish cohort|Danish cohort starts on 1 January 2000 and ends on 31 December 2019. It consists of new users of low dose vaginal estrogens (LDVE) (split into Vagifem® and other LDVE products) in the study period, and a comparator group consisting of women using no hormone replacement therapy.
9755788|NCT05243823||US cohort|US cohort starts on 1 January 2007 and ends on 31 December 2019. It consists of new users of low dose vaginal estrogens (LDVE) (split into Vagifem® and other LDVE products) in the study period, and a comparator group consisting of women using no hormone replacement therapy.
9755789|NCT05243017|Experimental|Cohort 1 (Low Dose of AMT-130)|Low dose AMT-130 (6 × 10^12 gc/subject)
9755790|NCT05243017|Experimental|Cohort 2 (High Dose of AMT-130)|High dose AMT-130 (6 × 10^13 gc/subject)
9755791|NCT05233280||Group A|Early feeding group
9755792|NCT05233280||Group B|Delayed feeding group
9755793|NCT05223023||1/Assessment of the opinions of the physiotherapists|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
9755794|NCT05222360||female high school athletes|Athletes who identify as female at a local high school who are in an athletic program. There was no control group as the school wanted everyone to have the 3 educational sessions. The athletes underwent 3 educational sessions. No medication was used. Education was the intervention
9755795|NCT05221996|Experimental|Resistance exercise for 10 min|Resistance circuit training of 10 min
9755796|NCT05221996|Experimental|Resistance exercise for 20 min|Resistance circuit training of 20 min
9755797|NCT05221996|Experimental|Resistance exercise for 30 min|Resistance circuit training of 30 min
9782992|NCT01190865|Other|HP802-247|Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
9782993|NCT01190878|Experimental|ISV-303 BID|
9782994|NCT01190878|Experimental|ISV-303 QD|
9782995|NCT01190878|Active Comparator|Xibrom BID|
9755798|NCT05220930|Experimental|Foot bath for heel warming group|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap. Before piercing the heel, the heel will be wiped with a blanket and dried. After the intervention, blood collection from the heel will be performed by following the standard procedure steps that are routinely applied in the service.
9755799|NCT05220930|Other|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
9755800|NCT05220917||SGLT-2i (Comparison 1)|For SGLT-2i vs. DPP4i SGLT-2i - exposure group DPP4i - referent group
9755801|NCT05220917||DPP-4i (Comparison 1)|For SGLT-2i vs. DPP4i SGLT-2i - exposure group DPP-4i - referent group
9755802|NCT05220917||SGLT-2i (Comparison 2)|For SGLT-2i vs GLP-1 RA SGLT-2i - exposure group GLP-1 RA - referent group
9755803|NCT05220917||GLP-1 RA (Comparison 2)|For SGLT-2i vs GLP-1 RA SGLT-2i - exposure group GLP-1 RA - referent group
9755804|NCT05220917||GLP-1 RA (Comparison 3)|For GLP-1 RA vs DPP-4i GLP-1 RA - exposure group DPP-4i - referent group
9755805|NCT05220917||DPP-4i (Comparison 3)|For GLP-1 RA vs DPP-4i GLP-1 RA - exposure group DPP-4i - referent group
9755806|NCT05220917||SGLT-2i (Comparison 4)|For SGLT-2i vs SU SGLT-2i - exposure group SU - referent group
9755807|NCT05220917||SU (Comparison 4)|For SGLT-2i vs SU SGLT-2i - exposure group SU - referent group
9755808|NCT05220917||GLP-1 RA (Comparison 5)|For GLP-1 RA vs SU GLP-1 RA - exposure group SU - referent group
9755809|NCT05220917||SU (Comparison 5)|For GLP-1 RA vs SU GLP-1 RA - exposure group SU - referent group
9755810|NCT05220917||DPP-4i (Comparison 6)|For DPP-4i vs SU DPP-4i - exposure group SU - referent group
9755811|NCT05220917||SU (Comparison 6)|For DPP-4i vs SU DPP-4i - exposure group SU - referent group
9755812|NCT05220917||SGLT2i (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
9755813|NCT05220917||GLP-1 RA (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
9755814|NCT05220917||DPP-4i (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
9755815|NCT05220917||SU (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
9755816|NCT05220917||SGLT2i (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
9755817|NCT05220917||GLP-1 RA (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
9755818|NCT05220917||DPP-4i (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
9755819|NCT05220046|Experimental|Psilocybin Treatment Arm|Participant with pancreatobilliary cancer will receive 25mg of psilocybin in one 8-hour monitored session with supportive counseling before and after session.
9755820|NCT05220046|No Intervention|Family Observation Group|The study participant will select a family member who will provide parallel data regarding distress related to pancreatobiliary cancer.
9755821|NCT05219890|Experimental|OBESE PATIENTS|Obese patients will be recruited from the outpatient Clinic of Obesity at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
9755822|NCT05219890|Active Comparator|CONTROL GROUP|Healthy normal volunteers will be recruited from friends and family of the investigators, and staff at the INCMNSZ. They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
9755823|NCT05219877|Experimental|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
9755824|NCT05219877|Active Comparator|Post-urodynamic Levofloxacin|Levofloxacin 500 mg will be given for 3 days, once daily, post-urodynamic examination
9755825|NCT05219760|Active Comparator|LIVIA 1|LIVIA 1 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy.
9755826|NCT05219760|Experimental|LIVIA 2.0|LIVIA 2.0 is a 12-week intervention composed of 10 sessions, whereby we recommend completing one session per week. It includes psychoeducational content and exercises that are based on empirically validated intervention tools, mainly issued from Cognitive-Behavioral Therapy but also from positive psychology and cognitive psychopathology frame.
9755827|NCT05219695|Experimental|HMIgFUS|Each study participants' tumors will be imaged using Harmonic Motion Imaging (HMI), an ultrasound elastography method. A central portion of the tumor will then be ablated and monitored using Harmonic Motion Imaging guided Focus Ultrasound (HMIgFUS). Only one portion of the tumor will be ablated; the other portions of the tumor, including tumor margins, will not be ablated. Following ablation, the tumor will be imaged again using HMI.
9755828|NCT05219448|Experimental|Education and self-efficacy coaching|This arm will receive education, behavior change support in the form of self-efficacy coaching, and introduction of sugar-free water enhancers.
9782996|NCT01190878|Placebo Comparator|DuraSite Vehicle BID|
9831334|NCT04744155|Experimental|Multi-Level Intervention|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral.Those randomized to MLI will be offered immediate, ED-based contraception (i.e., oral pill, transdermal patch, vaginal ring, injection, subdermal implant) in addition to receive a warm referral (provider helping to schedule follow-up appointment) to follow-up on selected method (or to initiate in clinic, if preferred)
9831335|NCT04744155|Active Comparator|Enhanced Standard of Care|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral. eSOC participants may obtain contraception only at the referral.
9831336|NCT04743453|Experimental|Dapagliflozin|
9831337|NCT04743453|Placebo Comparator|Placebo|
9831338|NCT04740060|Experimental|Augmented Feedback without Virtual Reality(VR)|
9831339|NCT04740060|Experimental|Augmented Feedback with Non-Game based VR|
9831340|NCT04740060|Experimental|Augmented Feedback with Game based VR|
9831341|NCT04730206|Experimental|Camostat|4 x 200 milligram per day for 7 days
9831342|NCT04730206|Placebo Comparator|Placebo|4 x per day for 7 days
9831343|NCT04722042|Other|Default|The default frequency filters assigned by the clinical software
9831344|NCT04722042|Experimental|Place-based|Frequency filters adjusted to align with the cochlear place frequency
9831345|NCT04720378|Experimental|Cohort 1|0.1 ml/kg IV ST266 once a day for 5 days
9831346|NCT04720378|Experimental|Cohort 2|0.25 ml/kg IV ST266 once a day for 5 days
9831347|NCT04720378|Experimental|Cohort 3|0.5 ml/kg IV ST266 once a day for 5 days
9831348|NCT04720378|Experimental|Cohort 4|1.0 ml/kg IV ST266 once a day for 5 days
9831349|NCT04712383|Experimental|Fitbit Care intervention arm|The experimental arm will receive the full Fitbit Care product suite (Fitbit wrist-worn device, Fitbit connected weight scale, and Fitbit Premium + Health Coaching service). Participants in the experimental arm will also be offered support in improving health behaviors that are important to them, including activity, nutrition, sleep, stress management, and medication adherence.
9831350|NCT04712383|No Intervention|Fitbit study control arm|Participants in the control arm will have access to standard healthcare benefits available to all employees, but will not have access to any of the Fitbit Care interventions
9831351|NCT04710576|Active Comparator|Axatilimab (SNDX-6352) Dose Cohort 1 - 0.3 mg/kg IV Q2W|IV infusion; Axatilimab (SNDX-6352) 0.3 mg/kg Q2W
9831352|NCT04710576|Active Comparator|Axatilimab (SNDX-6352) Dose Cohort 2 - 1 mg/kg IV Q2W|IV infusion; Axatilimab (SNDX-6352) 1 mg/kg Q2W
9831353|NCT04710576|Active Comparator|Axatilimab (SNDX-6352) Dose Cohort 3 - 3 mg/kg IV Q4W|IV infusion; Axatilimab (SNDX-6352) 3 mg/kg Q4W
9831354|NCT04708847|Experimental|Pre-immobilization active drug group|Subjects will receive a single subcutaneous dose of GYM329 on Day 1 and a single subcutaneous dose of placebo on Day 15.
9984047|NCT04468256||Participants without Heart Disease|Heart Hive registered participants without cardiomyopathy or other heart disease.
9984048|NCT04463680|Experimental|Intervention|Will receive 2 week regimen of rifampin 600mg per day
9831355|NCT04708847|Experimental|Post-immobilization active drug group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of GYM329 on Day 15.
9831356|NCT04708847|Placebo Comparator|Placebo group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of placebo on Day 15.
9831357|NCT04690426|Placebo Comparator|Cohort 1, Low Dose, Placebo|Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals
9831358|NCT04690426|Experimental|Cohort 1, Low Dose, PRV-101|Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
9831359|NCT04690426|Placebo Comparator|Cohort 2, High Dose, Placebo|High dose of placebo by intramuscular injection, 3 doses at 4-week intervals
9831360|NCT04690426|Experimental|Cohort 2, High Dose, PRV-101|High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
9984049|NCT04462601||Patients with Sjögren Syndrome|
9984050|NCT04461210||Vulvodynia|Women with localized, provoked vulvodynia
9831361|NCT04678557|Experimental|Sentinel units (aka Cohort 1)|VC-01 Combination Product; Up to ten (10) VC-01 sentinels
9831362|NCT04678557|Experimental|Dose-finding units (aka Cohort 2)|VC-01 Combination Product; Up to twelve units implanted of which up to nine (9) are VC-01-DF (dose-finding) implants and the rest are VC-01 sentinels
9831363|NCT04670679|Experimental|Dose Escalation (Part A): ERAS-601 monotherapy|ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
9831364|NCT04670679|Experimental|Dose Escalation (Part B): ERAS-601 in combination with cetuximab|ERAS-601 will be administered in sequential ascending doses in combination with cetuximab to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
9831365|NCT04670679|Experimental|Dose Expansion (Part C): ERAS-601 monotherapy|ERAS-601 will be administered at the monotherapy recommended dose (as determined from Part A) to study participants with advanced or metastatic solid tumors that harbor specific molecular alterations.
9831366|NCT04670679|Experimental|Dose Expansion (Part D): ERAS-601 in combination with cetuximab|ERAS-601 will be administered with cetuximab at the combination therapy recommended dose (as determined from Part B) to study participants with advanced or metastatic head and neck squamous cell carcinomas (HNSCC) or colorectal cancer (CRC).
9831367|NCT04670640|Experimental|Breath Focus|Participants receiving the breath focus study intervention.
9831368|NCT04670640|Experimental|Vibration|Participants receiving the vibration study intervention.
9831369|NCT04670640|Experimental|Vibration With Breath Focus|Participants receiving the vibration with breath focus study intervention.
9831370|NCT04670640|Experimental|Screens Free|Participants receiving the screens free study intervention.
9831371|NCT04663945|Experimental|Intervention|"This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions.~Other: remote controlled exercise plus home exercise~Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise"
9831372|NCT04663945|No Intervention|Control|"This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training.~Other: basic education"
9831373|NCT04661072||Patients with Congenital Uterine Anomalies (CUA)|The rates of renal, breast, uterine, ovarian and vaginal cancers in women who have been diagnosed with a CUA will be studies
9831374|NCT04654130|Experimental|Neurofeedback (NFB)|Participants in the NFB condition will complete 19 weekly sessions of NFB from home with research staff supervision (via videoconferencing), and pre-, post- and 3-month follow-up assessments.
9831375|NCT04654130|No Intervention|Wait List|Participants in the Wait List condition will receive no NFB for approximately 31 weeks, and will be asked to complete pre-, post- and 3-month follow-up assessments. After study completion, they will be offered the same 19 weeks of NFB.
9835865|NCT02759354|Experimental|Group Vaxelis (3+1)|Participants previously vaccinated with a 3-dose primary series of Vaxelis® at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
9835866|NCT02759354|Active Comparator|Group Infanrix hexa (3+1)|Participants previously vaccinated with a 3-dose primary series of INFANRIX® hexa at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
9984051|NCT04461210||Health Controls|Women without vulvar pain or other vulvar disorders.
9755829|NCT05219448|No Intervention|Comparison|This arm will have the outcomes assessed but will not receive the intervention (education, behavior change support, and introduction of sugar-free water enhancers) until the end of the study.
9755830|NCT05219331|Other|Disorder of consciousness|Ventriculo peritoneal shunt
9755831|NCT05219240||Program participants|
9755832|NCT05216562|Experimental|Intervention group|Group participants who receive injection of EXOSOME-MSC as adjuvant
9755833|NCT05216562|Placebo Comparator|Control group|Group participants who receive injection of Placebo (NaCL) as adjuvant
9755834|NCT05216432|Experimental|RLY-2608 for patients with unresectable or metastatic solid tumors|Multiple doses of RLY-2608 for oral administration.
9755835|NCT05216432|Experimental|RLY-2608 + fulvestrant combination for HR+ HER2- locally advanced or metastatic breast cancer|Oral dose of RLY-2608 in addition to fulvestrant as determined during Part 1 Dose Escalation.
9755836|NCT05216159|Experimental|mHealth HAPA Intervention Group|This intervention group will receive a single one-on-one behavioural counselling session and weekly action and coping planning worksheets delivered through a downloaded smartphone application with the aim of increasing the breaking of consecutive work related sedentary behaviour. Counselling strategies will be grounded in the HAPA model, specifically focusing on the creation of action plans and the development of coping strategies to increase sedentary behaviour breaks. The weekly HAPA based worksheets will be sent out to participants at the beginning of their work week so that they can formulate their own personal action plans and coping strategies for the week to come. They will be prompted to refer back to the information conveyed in one-on-one counselling session where they should try to create action plans that are specific and meaningful to them. The intervention will last for a total of four weeks with the outcomes being measured through questionnaires.
9755837|NCT05216159|No Intervention|Control Group|The control group will receive no intervention or further instruction past the letter of information.
9755838|NCT05216094|Experimental|smart phone intervention group|smart phone intervention group stroke subjects completed smart phone App tasks with affected upper limb or bilateral arm movement for 12 weeks
9755839|NCT05216094|Active Comparator|conventional group|stroke subjects receive conventional rehabilitation home program for 12 weeks
9755840|NCT05215886||Surgery|Patients scheduled for or have already completed Weight Loss Surgery at UC Davis Medical Center
9755841|NCT05214625||Gastroenterology patients|"Patient receiving an endoscopic procedure because of regular care will be considered eligible for inclusion. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.~Patients will be asked to complete a questionnaire concerning AI. No intervention will be administered."
9755842|NCT05214625||Gastroenterology physicians|"GI physicians (both gastroenterologists and gastroenterology fellows), participating in a yearly gastroenterology and hepatology training day, will be asked for their participation in this study.~Physician will be asked to complete a questionnaire concerning AI. No intervention will be administered."
10202042|NCT05143073|Active Comparator|Alcohol use disorder and strategies to reduce risk|The information provided to participants will be related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies. The content is based on information from National Institute of Alcohol Abuse and Alcoholism websites, Mayo Clinic websites, and the National Survey on Drug Use and Health.
10202043|NCT05143073|Active Comparator|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk|The information provided to participants will explain polygenic risk scores by discussing genetic variation, risk variants, how polygenic scores are created, and how they can be interpreted. The participants will also receive the same information related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies.
10202044|NCT05139875|Experimental|Betamethasone (Diprospan)|Participant received single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate 1 ml
10202045|NCT05139875|Active Comparator|Triamcinolone acetonide|Participant received single intra-articular Triamcinolone acetonide 40 mg
10202046|NCT05137860|No Intervention|Standard Care Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
9755848|NCT05213845|Other|Patients with chronic low back pain|
9755849|NCT05213481|Experimental|Tepotinib then Carbamazepine|Participants will receive a single dose of tepotinib after standard breakfast on Day 1 and Day 26, along with carbamazepine twice daily at the same time each day in the morning and evening from Day 8 to Day 32.
9755850|NCT05213377|No Intervention|Group C|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will not receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
9755851|NCT05213377|Experimental|Group W|"Patients undergoing total hip replacement surgery by anterior approach, with general anesthesia and continuous core body temperature measurement via nasopharyngeal thermic probe.~Patients recruited for surgery who will receive the 30 minutes of preoperative warming through pulsed air thermal coverage."
10202047|NCT05137860|Experimental|Bortezomib Treatment Group|Each patient will receive their standard chemotherapy treatment for patients with relapsed Acute Lymphoblastic Leukemia based on the HyperCVAD scheme in combination with Bortezomib for a period of 12 weeks. Each chemotherapy cycle will be monitored by the health team corresponding to the Hematology service and the principal investigator.
10202048|NCT05136898|Experimental|UGN-102|Patients will receive 6 once-weekly intravesical instillations of UGN-102. Treatment Visit 1 will occur at the investigative site and instillation will be performed by a qualified physician. Treatment Visits 2 to 6 will occur at the patient's home and instillation will be performed by a properly trained and qualified home health professional.
10202049|NCT05135572|Active Comparator|control group|Fibromiyalgia patients with foot pain.
10202050|NCT05135572|Experimental|study group|Patients with foot pain
10202051|NCT05132855|Experimental|Booster group 1 (BNT162b2 30ug)|The participants in this group will receive BNT162b2 30ug as the booster dose.
9755852|NCT05210556||No Antibiotic Bowel Prep|Patients who did not receive a preoperative antibiotic bowel preparation
9755853|NCT05210556||Antibiotic Bowel Prep|Patients who did receive a preoperative antibiotic bowel preparation
9755854|NCT05208710|Experimental|PANHPVAX 10µg|PANHPVAX 10µg plus c-di AMP in escalating doses
9755855|NCT05208710|Experimental|PANHPVAX 40µg|PANHPVAX 40µg plus c-di AMP in escalating doses
9755856|NCT05208710|Experimental|PANHPVAX 100µg|PANHPVAX 100µg plus c-di AMP in escalating doses
9755857|NCT05208476|Experimental|Participants|All subjects will be observed for one menstrual cycle then given Osteopathic manipulative treatment during the second menstrual cycle. During the third menstrual cycle, participants will continue to be observed.
9755858|NCT05207020|Experimental|Blood sugar levels estimated by analysis of exhaled air|
9755859|NCT05204563|Experimental|Imipenem/Cilastatin/XNW4107|Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg, Q6h (0.5h Infusion)
9755860|NCT05204563|Active Comparator|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25g Q6h (0.5h Infusion)
9755861|NCT05204368|Experimental|Imipenem/Cilastatin/XNW4107|Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg ,q6h(0.5h infusion)
9755862|NCT05204368|Active Comparator|Meropenem|Meropenem 1g ,q8h (0.5h infusion)
9755863|NCT05204186||Group A|Patient with (Group A) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
9755864|NCT05204186||Group B|Patient without (Group B) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
9755865|NCT05194488|Experimental|Low level laser therapy|
9755866|NCT05194488|Experimental|Botulinum toxin type A|
9755867|NCT05194488|Active Comparator|Anterior repositioning appliance|
9755868|NCT05183984|Experimental|ARM A: carboplatin/paclitaxel + niraparib|carboplatin AUC 5-6 + paclitaxel 175 mg/m² q3w, 5 cycles, followed by niraparib 200* or 300 mg/d for 2 years.
9755869|NCT05183984|Experimental|ARM B: carboplatin/paclitaxel/bevaziumab + niraparib/bevacizumab|carboplatin AUC 5-6 + paclitaxel 175 mg/m² + bevacizumab 15 mg/kg q3w, 5 cycles, followed by bevacizumab 15 mg/kg q3w for 15 months + niraparib 200*or 300 mg/d for 2 years.
9755870|NCT05180123|Other|Patients after ACL reconstruction in adolescence|
9755871|NCT05179811||Cohort|Patients with functional dysphonia using the Voice Handicap Index score.
9755872|NCT05178459||Diabetic|Patient diagnosed with diabetes
9755873|NCT05178459||Neuropathic without diabetes|Patient diagnosed with neuropathy without diabetes
9755874|NCT05176405|Experimental|Elissa's EE Song|Participants will have to click on the watch button to start the YouTube video as it is without manipulation. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
9755875|NCT05176405|Active Comparator|Standard of Care|Participants will be assigned to read general infographic messages adopted from the Saudi Ministry of Health (MOH) in the breast cancer early screening context in Arabic/English. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
9755876|NCT05176405|No Intervention|Control Group|The third arm of this trial is the control group who will not be exposed to any preventative messages.
9755877|NCT05175768|Active Comparator|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
9755878|NCT05175768|Active Comparator|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
9755879|NCT05175768|Placebo Comparator|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
9755880|NCT05168748|Experimental|IMJ995 in ALL|Dose escalation and expansion of IMJ995 single agent in ALL
9755881|NCT05166616|Experimental|Treatment (minnelide, osimertinib)|Patients receive minnelide PO QD on days 1-21 and osimertinib PO QD on days 1-28. Cycles repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
9755882|NCT05163262|Experimental|experimental|Addition of a sexuality questionnaire during patient follow-up within 3 months after inclusion, 6 months after and at one year
9755883|NCT05162482|Active Comparator|Heterologous 1|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
9831376|NCT04647916|Experimental|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9831377|NCT04636619|Active Comparator|Incomplete polypectomy report|An online course will be offered that will explain the technique for excision of lesions with a cold loop and the importance of complete resection, techniques to determine the edges of the lesion and possible remains at the polypectomy base through images, video clips. and interaction with the speakers
9831378|NCT04636619|Active Comparator|On-line training course|Each participant will receive the global data, the results obtained by all the endoscopists (anonymously except for each interested party, the rest being identified by codes), as well as a detailed analysis of their results, comparing them with the joint data and the 3 tertiles.
9831379|NCT04631939|Experimental|study intervention|"The intervention consists of a puzzle adventure game, in which players have to explore the fantasy world Macu'ta. The puzzles are based on Metacognitive Training for Psychosis (MCT), an intervention using playful, entertaining exercises to increase awareness of reasoning biases in patients and 'sow the seeds of doubt' through corrective ('aha!') experiences. The tasks will address reasoning biases associated with the emergence and maintenance of delusions."
9831380|NCT04631939|Sham Comparator|control intervention|The control intervention consists of a puzzles focused exclusively on dexterity and accuracy.
9831381|NCT04631510|Experimental|Critically ill patients|Administer gabapentin 300 mg PO at 8 PM for sleep
9831382|NCT04603898|Experimental|Controlled Dietary Study|Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for six days. After two days of equilibration, subjects will provide a blood sample and ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on Day 3. The following day (Day 4), serial blood and urine collections will occur. On Days 5 through 7, subjects will complete a 24-hr urine collection and blood draw.
9831383|NCT04597554|Experimental|Cranberry|4 oz. cranberry beverage (breakfast) and 2 chewable cranberry gummies (lunch) per day for 8 weeks.
9831384|NCT04597554|Placebo Comparator|Placebo|4 oz. placebo beverage (breakfast) and 2 chewable placebo gummies (lunch) per day for 8 weeks.
9831385|NCT04590664|Experimental|Treatment (verteporfin)|Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9831386|NCT04586075||Undiagnosed Disease Group|Blood or other relevant biological samples obtained from consenting research subjects will be banked and extracted for DNA and RNA.
9831387|NCT04585464|Experimental|Healthy Volunteer: Single Ascending Dose|"Single oral ascending dose in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
10202052|NCT05132855|Experimental|Booster group 2 (mRNA-1273 50ug)|The participants in this group will receive mRNA-1273 50ug as the booster dose.
10202053|NCT05132855|Experimental|Booster group 3 (mRNA-1273 100ug)|The participants in this group will receive mRNA-1273 100ug as the booster dose.
9831388|NCT04585464|Experimental|Healthy Volunteer: Multiple Ascending Dose|"Multiple oral ascending doses in healthy volunteers~Interventions:~Drug: EDG-5506 Drug: Placebo"
9831389|NCT04585464|Experimental|Becker Muscular Dystrophy: Multiple Ascending Dose|"Multiple oral ascending doses in adults with Becker muscular dystrophy~Interventions:~Drug: EDG-5506 Drug: Placebo"
9831390|NCT04585204|Active Comparator|50 gr-100 gr OGTT|patients are tested firstly by 50 gr OGTT after that if necessary by 100 gr OGTT
9831391|NCT04585204|Active Comparator|75 gr OGTT|patients are tested by 75 gr OGTT
10202054|NCT05132855|Experimental|Booster group 4 (MVC-COV1901 15ug)|The participants in this group will receive MCV COVID-19 vaccine 15ug as the booster dose.
10202055|NCT05132478|Active Comparator|Standard Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITHOUT emotionally supportive statements
10202056|NCT05132478|Experimental|Emotionally Supportive Video|A video simulation of a patient-surgeon discussion about treatment options for low-risk thyroid cancer WITH emotionally supportive statements
10202057|NCT05131997|Experimental|AD-221|AD-221, Placebo of AD-221A, AD-221B and AD-221C
10202058|NCT05131997|Experimental|AD-221A|AD-221A, Placebo of AD-221, AD-221B and AD-221C
10202059|NCT05131997|Active Comparator|AD-221B|AD-221B, Placebo of AD-221, AD-221A and AD-221C
10202060|NCT05131997|Active Comparator|AD-221C|AD-221C, Placebo of AD-221, AD-221A and AD-221B
10202061|NCT05129644|Experimental|P1101 24 mcg|A total of 6 subjects received single dose of 24 mcg P1101
10202062|NCT05129644|Experimental|P1101 48 mcg|A total of 6 subjects received single dose of 48 mcg P1101
10202063|NCT05129644|Experimental|P1101 90 mcg|A total of 6 subjects received single dose of 90 mcg P1101
10202064|NCT05129644|Experimental|P1101 180 mcg|A total of 6 subjects received single dose of 180 mcg P1101
10202065|NCT05129644|Experimental|P1101 225 mcg|A total of 6 subjects received single dose of 225 mcg P1101
10202066|NCT05129644|Experimental|P1101 270 mcg|A total of 6 subjects received single dose of 270 mcg P1101
10202067|NCT05129644|Active Comparator|Pegasys 180 mcg|A total of 12 subjects received single dose of 180 mcg Pegasys
10202068|NCT05128487|Experimental|NDI-101150 (Monotherapy)|Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).
10202069|NCT05128487|Experimental|NDI-101150-Pembrolizumab (Combination therapy)|Patients in escalation and expansion phase, will receive NDI-101150 capsules orally once daily continuously in 3-week cycles (21 days), along with pembrolizumab via intravenous (IV) infusion at a dose of 200 mg every 3 weeks.
10202070|NCT05127109|Experimental|Nutrition Ecosystem pathway|"parenteral nutrition initiated within 72 hours of operative intervention~metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~expedited delivery of oral nutrition supplements and~a team-based approach on proper documentation of nutrition delivery and intake."
10202071|NCT05127109|Other|Comparator|300 historical matched control subjects not having received TPN in the first 7 hospital days will be enrolled from Duke Electronic Health Record between January 2018 and June 2020.
10202072|NCT05124210|Experimental|Cohort A: Participants receiving sotrovimab via Intravenous administration|
10202073|NCT05124210|Experimental|Cohort B: Participants receiving sotrovimab via Intramuscular administration|
9755884|NCT05162482|Active Comparator|Heterologous 2|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
10202074|NCT05123170|Active Comparator|Group I|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) alone diluted with normal saline 0.9% to make the final volume 30 ml
10202075|NCT05123170|Active Comparator|Group II|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.25 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml.
10202076|NCT05123170|Active Comparator|Group III|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.5 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml
10202077|NCT05123131|Experimental|Isa-RVD|"Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.~Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32. Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance [CrCl] ≥30 to <60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.~Dexamethasone (IV on the days of Isatuximab and PO on other days):~20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33.~If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32."
10202078|NCT05120180|Experimental|Branches Sparing|The patients in this arm will undergo axillary lymph node dissection with preserved axillary vein branches
10202079|NCT05120180|Active Comparator|None Branches Sparing|The patients in this arm will undergo axillary lymph node dissection without preserved axillary vein branches
10202080|NCT05117632|Experimental|ALTO-100|ALTO-100 PO tablet, daily dosing 8 weeks
10202081|NCT05116241|Experimental|BPZE1 intranasal and Placebo intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular placebo.
10202082|NCT05116241|Experimental|BPZE1 intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular Boostrix (acellular pertussis [aP] vaccine).
10202083|NCT05116241|Active Comparator|Placebo intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of placebo via the mucosal atomization device and a dose of intramuscular Boostrix (aP vaccine comparator).
10202084|NCT05114278|Experimental|Oral Iron + IV Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year.
10202085|NCT05114278|Active Comparator|Oral Iron only|Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
10202086|NCT05112835||brolucizumab|brolucizumab intravitreal injections in patients with nAMD treated in the UK
10202087|NCT05111509|Experimental|[203Pb]VMT-α-NET SPECT/CT|injection of [203Pb]VMT-α-NET with serialized imaging and dosimetry measurements
10202088|NCT05110690|Experimental|Patient Participants|"Behavioral activation (BA) will span across 3 months postoperatively & will begin pre-operatively, with sessions approximately weekly or biweekly, depending on patient preference & health condition.~Medications will be reviewed & optimized by a team of interventionists including a psychiatrist, pharmacologist, & pharmacists. While the participant is in-hospital, the interventionist's role will include coordinating with the hospital team to ensure that medication changes that were introduced preoperatively are maintained in-house & that no new inappropriate medications are initiated. After discharge, & up to approximately 3 months postoperatively, the interventionist will ensure that medication changes are reconciled during transitions of care. The interventionists will ensure the agreed-upon changes are implemented, or an alternative course of action is justified."
10202089|NCT05110690|No Intervention|Caregiver Participants|-Caregivers will be invited to participate in semi-structured interviews about the intervention bundle that can be conducted via Zoom/phone or in-person depending on participant choice.
10202090|NCT05110690|No Intervention|Clinician participants|-Clinicians will be invited to participate in semi-structured interviews about the intervention bundle that can be conducted via Zoom/phone or in-person depending on participant choice.
10202091|NCT05105750|Active Comparator|aspirin 100 mg/d therapy|
10202092|NCT05105750|Experimental|indobufen 200 mg bid therapy|
10202093|NCT05101083|Experimental|Hearing Aid 1|New Receiver-in-Canal device, successor of previous device generation
10202094|NCT05101083|Active Comparator|Hearing Aid 2|Legacy Receiver-in-Canal device that is currently available on the market
10202095|NCT05098834|Experimental|PICU and PCICU Patients|Patients younger than 17 years of age receiving mechanical ventilation for an acute respiratory illness will be approached to participate prior to initiation of an ERT for clinical purposes.
10202096|NCT05095168|Experimental|Single Ascending Dose (SAD)|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). Additional subjects may be added in any cohort if necessary.
10202097|NCT05095168|Placebo Comparator|placebo|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). In higher dose levels, subjects will be randomized to receive the treatment or placebo.
10202098|NCT05094245|Active Comparator|Stellate ganglion block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
10202099|NCT05094245|No Intervention|Conventional|Mecobalamin Tablets oral Mecobalamin Tablets tid-8
10202100|NCT05092997|No Intervention|Female SOC/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and laboratory HIV testing at enrollment and every 6 months until 6 months postpartum,
9755885|NCT05162482|Active Comparator|Heterologous 3|"CanSinoBIO (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
9755886|NCT05162482|Active Comparator|Heterologous 4|"CanSinoBIO (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
9755887|NCT05162482|Active Comparator|Heterologous 5|"AstraZeneca ChAdOx (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV(0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
9755888|NCT05162482|Active Comparator|Heterologous 6|"AstraZeneca ChAdOx (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
9755889|NCT05162482|Active Comparator|Homologous 7|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
9755890|NCT05162482|Active Comparator|Homologous 8|"CanSinoBIO (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
9755891|NCT05162482|Active Comparator|Homologous 9|"AstraZeneca ChAdOx (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
9755892|NCT05162157||at-home spirometry|This group performs spirometry at home with the Nuvoair spirometer
9755893|NCT05152459|Experimental|Treatment (tazemetostat, umbralisib, ublituximab)|Patients receive ublituximab IV on days 1, 8, and 15 of cycle 1, day 1 of cycle 2-6, and day 1 of every 3 cycles thereafter. Patients also receive tazemetostat PO BID umbralisib by PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
9755894|NCT05150691|Experimental|DB-1303 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 1 on Day 1 of each cycle Q3W
9755895|NCT05150691|Experimental|DB-1303 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 2 on Day 1 of each cycle Q3W
9755896|NCT05150691|Experimental|DB-1303 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 3 on Day 1 of each cycle Q3W
9755897|NCT05150691|Experimental|DB-1303 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 4 on Day 1 of each cycle Q3W
9755898|NCT05150691|Experimental|DB-1303 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 5 on Day 1 of each cycle Q3W
9755899|NCT05150691|Experimental|DB-1303 Dose Expansion 1|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
9755900|NCT05150691|Experimental|DB-1303 Dose Expansion 2|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
9755901|NCT05150691|Experimental|DB-1303 Dose Expansion 3|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
9755902|NCT05145010|Experimental|Arm 1: Rollover subjects|Children who have completed under QED-sponsored interventional study with infigratinib
9517436|NCT03306368|Experimental|Youth Opioid Recovery Support (YORS)|"Youth Opioid Recovery Support consists of the following component:~Home delivery of XR-NTX, family framework, assertive continuing care incorporates outreach, home delivery of evidence based psychosocial treatment and case management in a model that specifically targets engagement and motivation in youth, contingency management."
9755903|NCT05145010|Experimental|Arm 2: Treatment naïve subjects|Children naïve to infigratinib
9755904|NCT05143567|Experimental|patients with COVID-19 without thrombotic complications|Group I: 50 patients with confirmed coronavirus infection without thrombotic complications
9755905|NCT05143567|Experimental|patients with COVID-19 and VTE who received pharmacological prophylaxis of VTE|Group II: 50 patients with confirmed coronavirus infection with thrombotic complications confirmed by ultrasonography with pharmacological prophylaxis of VTE
9755906|NCT05143567|Experimental|patients with COVID-19 and VTE who received pharmacomechanical prophylaxis of VTE|Group III: 50 patients with confirmed coronavirus infection with ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities using pharmacomechanical prophylaxis of VTE.
9755907|NCT05139056|Experimental|Treatment (NSC-CRAd-S-pk7)|Patients undergo standard of care surgical resection. Patients then receive NSC-CRAd-S-pk7 intracerebrally over 10 minutes QW for up to 4 doses in the absence of disease progression or unacceptable toxicity.
9755908|NCT05139043|Active Comparator|Arm I (standard dose dexamethasone)|Patients receive standard dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive standard dose dexamethasone IV before and after the surgery. Patients receive standard dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
9755909|NCT05139043|Experimental|Arm II (lower dose dexamethasone)|Patients receive lower dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive lower dose dexamethasone IV before and after the surgery. Patients receive lower dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
9755910|NCT05139004|Experimental|Treatment (90Y-basiliximab, fludarabine, melphalan, TMLI)|Patients receive cold basiliximab IV, 111In-DOTA-anti-CD25 basiliximab IV, and 90Y-DOTA-anti-CD25 basiliximab IV on day -15. Patients also receive palifermin IV on days -11 to -9, fludarabine phosphate IV on days -4 to -2, melphalan IV on day -2, and undergo TMLI on days -8 to -5 in the absence of disease progression or unacceptable toxicity. Patients then undergo AHSCT on day 0.
9755911|NCT05138991|Experimental|Screening (echo, CMR, Vivio)|Patients undergo a one time assessment of cardiac function by echo, CMR, and the Vivio system in the clinic over 4-6 hours, and then undergo one at home assessment 1-5 days later using the Vivio system by themselves. Patients also complete questionnaires at baseline.
9755912|NCT05132153|Active Comparator|(Group A) will receive milrinone|Patients will receive milrinone 50 microgram/kg in 5ml volume, over 5 min by nebulization
9755913|NCT05132153|Placebo Comparator|(Group B) will receive normal saline|Patients will receive 5 ml saline by nebulization over 5 min
9755914|NCT05131737|Experimental|Constant work-rate at altitude 2500 m above sea level (high altitude)|Cycling at high altitude
9755915|NCT05131737|Active Comparator|Constant work-rate at altitude 470 m above sea level (low altitude)|Cycling at low altitude
9755916|NCT05123859||age groups|"A total of 30 participants in the 25- to 34-year age group~A total of 45 participants in the 35- to 44-year age group~A total of 50 participants in the 45- to 54-year age group~A total of 50 participants in the 55- to 64-year age group~A total of 45 participants in the 65- to 74-year age group~A total of 30 participants in the 75- to 85-year age group"
9755917|NCT05121350|Experimental|Arotinib hydrochloride capsule + Epirubicin|Arotinib hydrochloride capsule combined with epirubicin, 21 days as a treatment cycle
9755918|NCT05121350|Active Comparator|Placebo + Epirubicin|Placebo combined with epirubicin, 21 days as a treatment cycle
9755919|NCT05120466|Active Comparator|Usual Health Education Curriculum|Students will receive the school's usual health education curriculum.
9755920|NCT05120466|Experimental|Usual Health Education Curriculum plus Intervention|Students will receive the school's usual health education curriculum. Students will also receive the intervention. Delivery of the intervention (i.e., timing, frequency) will be determined by discussing the results of the Aim 1 focus groups with teachers and administrators.
9755921|NCT05117463||Healthy Younger Adults|Healthy younger adults without any neurological and orthopedic disorders.
9755922|NCT05117463||Healthy Older Adults|Healthy older adults without any neurological and orthopedic disorders.
9755923|NCT05117463||Older Adults with higher risk of falls|Older adults with a history of falls or poor balance based on the clinical balance and gait assessment.
9755924|NCT05112172|Experimental|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
9755925|NCT05111899|Experimental|Intervention|
9755926|NCT05111899|No Intervention|Control|
9755927|NCT05107700|Experimental|Start with: Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
9755928|NCT05107700|Placebo Comparator|Start with: Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m as comparator.
9755929|NCT05098457|Experimental|GP0112|Single injection and optional touch up injection with GP0112
9755930|NCT05098457|Active Comparator|Restylane Lyft Lidocaine|Single injection and optional touch up injection with Restylane Lyft Lidocaine
9755931|NCT05097846|Experimental|Group1: Vonoprazan Fumarate + amoxicillin + doxycycline|
9755932|NCT05097846|Experimental|Group2: Vonoprazan Fumarate + furazolidone + doxycycline|
9755933|NCT05097846|Experimental|Group3: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|
9755934|NCT05097846|Experimental|Group4: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|
9755935|NCT05096156|Active Comparator|Habitual Contact Lens|All subjects are re-fit into habitual Biofinity® brand contact lenses. Subjects are requested to wear the lenses for one week, for a minimum of at least 6 hours per day for 5 days.
9755936|NCT05096156|Active Comparator|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for two weeks, for a minimum of at least 6 hours per day for 10 days.
9755937|NCT05094986|Experimental|Intervention group: IMA Intervention|"General practitioners (GP) applied the IMA intervention to all patients receiving a new prescription for pharmacological treatments of cardiovascular disease or diabetes.~Following the IMA intervention, nurses and community pharmacists offered information support in line with the information provided by the GP. Professionals had the intervention support tools available (leaflets, website and dispensing alert in community pharmacies)."
9755938|NCT05094986|Active Comparator|Control group|Healthcare professionals from the control group prescribed medication and provided information as usual.
9755939|NCT05089487|Experimental|High altitude 2500 m above sea level|
9755940|NCT05089487|Active Comparator|Low altitude 470 m above sea level|
9755941|NCT05088291||The new protection device|A total of 100 patients underwent continuous coronary angiography (CAG) or percutaneous coronary intervention (PCI). The first surgeon does not need to wear a lead dress to stand inside the new protective device (NPD) to perform all operations.
9831392|NCT04584502|Experimental|Intervention as adjunct to Treatment as Usual|Participants will attend an 8-session group-based yoga-mindfulness intervention offered over the course of approximately 10 consecutive weeks. Participants will also be asked to use a mobile companion app once a week during the intervention period. All intervention participants also receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
9831393|NCT04584502|No Intervention|Treatment as Usual|Participants receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
9831394|NCT04582266||Arm 1|Pregnant women hospitalized and receiving RDV for treatment of COVID-19.
9831395|NCT04582266||Arm 2|Non-pregnant women of childbearing potential hospitalized and receiving RDV for treatment of COVID-19.
9831396|NCT04571619|Active Comparator|Pain Coping Skills Training|
9831397|NCT04571619|No Intervention|Usual Care|
9831398|NCT04571619|Active Comparator|Buprenorphine|
9831399|NCT04571619|No Intervention|No Buprenorphine|
9831400|NCT04568967|Experimental|intervention arm|"The intervention arm for this trial consists of HIV patients with TB testing performed regardless of presence of TB symptoms. Testing will be done on expectorated sputum, stool and concentrated urine with Ultra, and urine with AlereLAM.~To fulfil exploratory objectives, we will also collect and store 2x tongue swabs for molecular TB diagnostic assay (Xpert Ultra and/or LumiraDx) testing, blood for testing with CRP, and urine samples which will be stored for retrospective FujiLAM testing and analysis."
9831401|NCT04568967|No Intervention|control arm|"The control arm for this trial will consist of patients managed according to the current WHO recommended TB testing practices for HIV positive inpatients (as of Q1 2020).~TB testing will be done as follows:~Sputum Ultra performed whenever the patient has cough, fever, weight loss over night sweats and/or Ultra performed on any tissue (including lymph nodes) from patients with clinical suspicion of extrapulmonary TB.~and/or: Urine Alere TB-LAM performed if patients have signs and symptoms of TB (pulmonary and/or extrapulmonary), or with advanced HIV disease, or who are seriously ill, or else irrespective of signs and symptoms of TB, but combined with a CD4 cell count of less than 200 cells/mm ."
9831402|NCT04568954|Experimental|TB testing using the Truenat platform/TB assays|TB testing using the Truenat platform/TB assays placed at primary health care clinics combined with rapid communication of results and same day TB treatment initiation
9831403|NCT04568954|No Intervention|Standard of care Arm|Standard of care for TB testing using a combination of smear microscopy and laboratory (off-site) Xpert testing, may vary by clinic depending on availability of transport and stock of Xpert MTB/RIF or Xpert MTB/RIF Ultra cartridges (Xpert).
9831404|NCT04563923|Experimental|Drug|"Patients in this group will additionally receive 3 s.c. injections of avdoralimab every week during 12 weeks~They receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
9831405|NCT04563923|Other|Conventional therapy|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
9831406|NCT04555577|Experimental|Stage I (nedisertib, radiation therapy, temozolomide)|"CONCURRENT: Patients undergo standard of care radiation therapy daily (Monday-Friday) for 30 fractions. Patients also receive nedisertib PO on each day of radiation therapy and given 1-2 hours before each treatment fraction. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
9831407|NCT04555577|Experimental|Stage II (nedisertib, radiation, temozolomide, surgery)|"CONCURRENT: Patients receive nedisertib and undergo standard of care radiation therapy as in Stage I. Within 1-14 days after the completion of radiation therapy, patients undergo surgical resection.~ADJUVANT: Patients receive temozolomide as in Stage I."
9831408|NCT04545749|Experimental|Group A (Low dose)|20 subjects will be enrolled to receive low dose of UB-612 vaccine.
9831409|NCT04545749|Experimental|Group B (Medium dose)|20 subjects will be enrolled to receive medium dose of UB-612 vaccine.
9831410|NCT04545749|Experimental|Group C (High dose)|20 subjects will be enrolled to receive high dose of UB-612 vaccine.
9517437|NCT03306355|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
9831411|NCT04542434|Experimental|Niclosamide|
9831412|NCT04542434|Placebo Comparator|Placebo|
9831413|NCT04526795|Experimental|Treatment (pegcrisantaspase, fludarabine, cytarabine)|"INDUCTION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-11 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-10. Treatment repeats every 5 weeks for up 3 cycles in the absence of disease progression or unacceptable toxicity."
9831414|NCT04516057|Experimental|Nabilone Arm|Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.
9831415|NCT04516057|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive placebo capsules.
9831416|NCT04512144|Experimental|Intervention|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. She will be provided a three month gift subscription. Headspace will be downloaded to her smartphone and she will be instructed on use. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. The number of Headspace sessions will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
9831417|NCT04512144|No Intervention|Control|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. All patients in the control group may choose to practice calming or mindfulness exercises of their own accord but will not be specifically instructed to seek out such resources as is our standard practice. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
9831418|NCT04497272|Other|The metabolomic signature of COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
9831419|NCT04495439|Other|Treatment with ISS Sleeve|The biocompatible, resorbable ISS sleeve is used for augmentation to enhance screw anchorage. It is melted into the trabecular bone structure of the osteoporotic vertebra using ultrasound. A standard pedicle screw is inserted into the sleeve.
9831420|NCT04495439|Other|Treatment with PMMA|The bone cement Polymethylmethacrylat (PMMA) that is injected into the osteoporotic vertebra.PMMA augmentation of pedicle screws is done using standard cannulated and perforated pedicle screws. The cancellous bone surrounding the screw is enhanced with PMMA bone cement to increase screw anchorage.
9831421|NCT04488900|Experimental|CKD-508 Capsule in Single Dose|Single dose of CKD-508 capsules
9831422|NCT04488900|Placebo Comparator|Placebo Capsule in Single Dose|Single dose of Placebo capsules
9831423|NCT04488900|Experimental|CKD-508 Tablet in Single Dose|Single dose of CKD-508 tablets
9831424|NCT04488900|Placebo Comparator|Placebo Tablet in Single Dose|Single dose of Placebo tablets
9831425|NCT04488900|Experimental|CKD-508 Tablet in Multiple Dose|Multiple dose of CKD-508 tablets
9831426|NCT04488900|Placebo Comparator|Placebo Tablet in Multiple Dose|Multiple dose of placebo tablets
9831427|NCT04484285|Active Comparator|Younger Cohort|Healthy individuals aged 18 - 55
9831428|NCT04484285|Active Comparator|Older Cohort|Healthy individuals aged 56 - 85
9831429|NCT04479111|Experimental|LISRH group|Following the principle of complete mesocolic excision(CME), Ileocecus-Sparing Right colectomy refers to the resection of the most portion of the ascending colon, hepatic flexure and mid to distal transverse colon. The extent of lymph node dissection and length of distal resection margin are similar to conventional right hemicolectomy. The length of proximal resection margin varies.
9831430|NCT04477850|Experimental|Luspatercept Administration|
9831431|NCT04477733|Experimental|Butorphanol group|
9831432|NCT04477733|Placebo Comparator|control group|
9831433|NCT04452916|Active Comparator|Fasting|Starts immediately with 5 days of Buchinger fasting
9831434|NCT04452916|Placebo Comparator|Waiting list control|Starts with 5 days of Buchinger fasting after a waiting period of 12 weeks
9831435|NCT04443686|Experimental|ALA / Fractions of Radiotherapy|Subjects will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed.
9831436|NCT04443335|Sham Comparator|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
9831437|NCT04443335|Experimental|sequential feeding|This feeding mode utilizes a combination of continuous feeding in the beginning, time-restricted feeding in the second stage and oral feeding in the last stage
9835867|NCT02759354|Experimental|Group Vaxelis (2+1)|Participants previously vaccinated with a 2-dose primary series of Vaxelis® at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
9755942|NCT05088291||The traditional lead clothing|A total of 100 patients underwent continuous coronary angiography (CAG) or percutaneous coronary intervention (PCI). The first surgeon wears the traditional lead clothing (TLC) to perform all operations.
9755943|NCT05085496|Experimental|Treatment (SBRT, atezolizumab)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 of cycle 1. Beginning 1-2 days after SBRT, patients also receive atezolizumab IV on day 1. Treatment repeats every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
9755944|NCT05085210|Experimental|Visual Training with Noninvasive Brain Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of tRNS with visual training on the computer
9755945|NCT05085210|Experimental|Visual Training with Sham Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of sham stimulation with visual training on the computer
9755946|NCT05085210|Experimental|Noninvasive Brain Stimulation without visual training|10 daily (Monday-Friday) 20-30 minute sessions of tRNS alone
9755947|NCT05085210|Sham Comparator|Sham Stimulation without visual training|Placebo control. Simulation of tRNS without receiving any actual stimulation
9755948|NCT05084391|Experimental|Phase I:|Phase I there will be up to 15 patients treated with SABR and followed for 6 months post-treatment to ensure no significant acute grade 3 or 4 toxicity from SABR treatment.
9755949|NCT05084391|Experimental|Phase II|Phase II portion with 25 patients in each arm assigned to SABR or current practice (standard of care)
9755950|NCT05084222|Experimental|Buventol® Easyhaler® 200 µg/inhalation dmDPI|400 μg of salbutamol from Buventol Easyhaler is administered as two inhalations.
9755951|NCT05084222|Experimental|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.
9755952|NCT05084222|Active Comparator|Ventoline® Evohaler® 100 µg/inhalation pMDI|400 μg of salbutamol from Ventoline Evohaler is administered via Volumatic spacer as four inhalations.
9755953|NCT05081518|Experimental|Sequence 1: Lu AG06466-Placebo|Participants will receive Lu AG06466 capsules once daily (QD) at a low dose for 4 days (Days 1 to 4), medium dose for 4 days (Days 5 to 8), and high dose for 21 days (Days 9 to 29) in treatment period 1. Participants will receive matching placebo capsules from Day 1 to Day 29 in treatment period 2. Each treatment period will be separated by a washout period of 7 to 11 days.
9755954|NCT05081518|Experimental|Sequence 2: Placebo-Lu AG06466|Participants will receive matching placebo capsules QD from Day 1 to Day 29 in treatment period 1. Participants will receive Lu AG06466 capsules QD at a low dose for 4 days (Days 1 to 4), medium dose for 4 days (Days 5 to 8), and high dose for 21 days (Days 9 to 29) in treatment period 2. Each treatment period will be separated by a washout period of 7 to 11 days.
9755955|NCT05079750|Experimental|Group 1: Low Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10^9 vp
9755956|NCT05079750|Experimental|Group 2: Mid Dose|n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5x10^10 vp Note: may be increased to n=9 following interim safety reviews
9755957|NCT05079750|Experimental|Group 3: High Dose|n=14 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10^10 vp Note: will be decreased to n=11 if Group 2 is increased to n=9
9984052|NCT04458805|Experimental|NX-13 250mg|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
9755958|NCT05070013|Experimental|Adaptive DBS stimulation|Subjects experience adaptive stimulation during one week of at-home night sleep.
9755959|NCT05070013|Active Comparator|Open-loop DBS stimulation|Subjects experience open-loop stimulation (standard clinical stimulation therapy based on DBS programming for the treatment of motor symptoms) during one week of at-home night sleep.
9755960|NCT05070013|No Intervention|No DBS Stimulation|DBS stimulation is turned off (control) during one week of at-home night sleep.
9755961|NCT05069051|Experimental|Belimumab|Patients obtain belimumab in combination with rituximab/venetoclax
9755962|NCT05069051|Active Comparator|Standard of Care|Patients obtain the combination rituximab/venetoclax
9755963|NCT05059470|Experimental|Pembrolizumab|The infusions are given every 6 weeks
9755964|NCT05051618|Experimental|POWER-MS|The POWER-MS condition will deliver the Guidelines for Exercise in MS (GEMS) program with a remotely coached/guided, home-based setting using telerehabilitation. GEMS recommends 30 minutes of moderate intensity aerobic activity, 3x/week AND strength training exercises for major muscle groups, 3x/week.
9831438|NCT04438161|Active Comparator|Low Risk|"Low risk natural history study (n=250*)~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families."
9831439|NCT04438161|Experimental|High Risk|"High risk families in prospective longitudinal study of newborns (n=150*).~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families.~Participants in this arm will be randomized to:~PERCCS (see attached figure and table for details)~Care as Usual"
9831440|NCT04436731|Experimental|Hypoxia Exposure|A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
9831441|NCT04436458|Experimental|Niclosamide|Continued SOC therapy together with Niclosamide tablets for 14 days
9831442|NCT04436458|Placebo Comparator|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide
9831443|NCT04428385|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
9831444|NCT04428385|Experimental|Arm 2 (consumer-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
9831445|NCT04418206|Other|Samples With DNA|Nasopharyngal swab and blood samples
9831446|NCT04415528|Experimental|Intervention group|The intervention group will begin receiving the group intervention within one - two weeks of Time 1 assessment. This group will receive Time 2 assessments at the end of the group delivery. Time 3 assessments will be administered eight weeks after the completion of group delivery.
10202101|NCT05092997|Active Comparator|Female intervention/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and POC VL tests for women at enrollment, delivery, and 6 months post-partum;
10202102|NCT05092997|Active Comparator|Female SOC/Male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and laboratory-based HIV VL testing for women at enrollment, delivery, and 6 months post-partum;
9831447|NCT04415528|Active Comparator|Wait listed control group|The wait listed control group will be assessed at Time 1, eight weeks before receiving the intervention. This group will receive Time 2 assessments at the beginning of their group delivery. This group will complete Time 3 assessments eight weeks after the completion of group delivery.
9831448|NCT04413604|Experimental|YCM Group (1- <3) Years old|2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks
9831449|NCT04413604|No Intervention|Observation Group (1-<3) Years old|Habitual diet, consume the same regular foods and drinks as the children would normally
9831450|NCT04404088|Experimental|Treatment (acalabrutinib, lenalidomide, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21 and rituximab IV on days 1, 8, 15, and 22 of cycle 2 and day 1 of subsequent cycles. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
9831451|NCT04392453|Experimental|Robotic therapy|Upper limb robotic rehabilitation by means of the portable robot Icone.
9831452|NCT04358276|Experimental|Group I (PAE)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.
9831453|NCT04358276|Experimental|Group II (PAE, physician)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
9831454|NCT04358276|Experimental|Group III (PAE, physician, dermatoscope)|"Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and mimickers common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice."
9831455|NCT04355546||COPD patients|Trimbow 87/5/9 pMDI for COPD prescribed according to licensed indication
9831456|NCT04349644|Experimental|SENSE Theatre|A peer-mediated, theatre-based intervention designed to improve social cognition and behavior.
9831457|NCT04349644|No Intervention|Waitlist Control Group|This group will not receive the intervention during the testing phase of the intervention but will eventually receive the theatre intervention.
9831458|NCT04342429|Experimental|Prospective Study of Intensity-Modulated Proton Therapy (IMPT)|This is the first prospective study to investigate the safety and efficacy of IMPT for the treatment of SCLC. We will utilize adaptive planning throughout the radiation course. In addition, we will study the dosimetric parameters of IMPT and their correlation with treatment-related toxicities, particularly cardiac events.
10202103|NCT05092997|Active Comparator|Female intervention/male intervention arm|Women will be provided an invitation letter for male partners invitation letter for male partners for wellness visits and POC viral load testing for women at enrollment, delivery, and 6 months post-partum.
10202104|NCT05091073|Experimental|Fed group|Fed dosing conditions
9517438|NCT03306355|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
10202105|NCT05091073|Experimental|Fasting group|Fasting dosing conditions
10202106|NCT05091073|Active Comparator|Reference group|Reference dosing conditions
10202107|NCT05089955|Experimental|Intervention group|MRI examination with Ambient Experience with paediatric content
10202108|NCT05089955|No Intervention|Control group|MRI examination without Ambient Experience (standard of care)
10202109|NCT05087927||Focus Group|There will be 4 focus groups of up to 12 women in each focus group.
10202110|NCT05087927||Survey Group|There will be up to 200 women who complete the survey for this study.
9831459|NCT04339101|Experimental|Treatment (itacitinib adipate, tacrolimus, sirolimus)|"RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC HSCT: Patients undergo HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity."
9831460|NCT04336098|Experimental|Monotherapy Dose Escalation|The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of SRF617 as monotherapy in up to 36 patients with advanced solid tumors.
9831461|NCT04336098|Experimental|Monotherapy Tumor Biopsy Expansion|The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy in up to 20 patients at cleared and recommended phase 2 dose levels.
9831462|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel in patients with locally advanced or metastatic solid tumors.
9831463|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with pembrolizumab (Keytruda®) in patients with locally advanced or metastatic solid tumors.
9831464|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Expansion|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with advanced pancreatic ductal adenocarcinoma (PDAC) to further evaluate safety with SRF617 and gemcitabine + albumin-bound paclitaxel combination therapy.
9831465|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion GC/GEJ|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 28 additional patients with 2 anti-PD-(L) 1 naive HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma to further evaluate safety with SRF617 and pembrolizumab combination therapy.
9831466|NCT04336098|Experimental|SRF617 + Pembrolizumab + Gemcitabine + Albumin-bound Paclitaxel Quadruplet Dose Expansion|Enrollment at the recommended phase 2 combination dose established in the combination dose escalation arms (if recommended phase 2 combination doses differ, the lower of the starting 2 doses will be used) may be expanded to include up to approximately 30 additional patients with advanced 1L PDAC.
9831467|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion anti-PD-L1 GC/GEJ, PD-L1+ NSCLC|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 29 additional patients with anti-PD-(L) 1 relapsed/refractory PD-L1+ HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma or advanced PD-L1+ NSCLC to further evaluate safety with SRF617 and pembrolizumab combination therapy.
9831468|NCT04330989|Experimental|Group 1a: iNSC and Adherence supporter training|HIV-positive women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for ART.
9831469|NCT04330989|No Intervention|Group 1b: Standard of Care|HIV-positive participants randomly assigned to the control arm will antiretroviral educational material about HIV prevention and treatment (as appropriate to this arm).
9831470|NCT04330989|Experimental|Group 2a: iNSC and Adherence supporter training|HIV-negative women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for PrEP.
9831471|NCT04330989|No Intervention|Group 2b: Standard of Care|HIV-negative participants randomly assigned to the control arm will receive educational material about HIV prevention and treatment (as appropriate to this arm).
9831472|NCT04329728|Experimental|DLBCL and high-grade B-cell lymphoma|Diffuse Large Cell B-Lymphoma High-grade B-cell Lymphoma
9831473|NCT04329728|Experimental|MCL (Chronic Lymphoid Leukemia)|Chronic Lymphoid Leukemia
9517439|NCT03306329|Experimental|DNS-7801 (low-dose)|
9755965|NCT05051618|Active Comparator|FLEX-MS|The FLEX-MS condition will primarily focus on flexibility as the applicable exercise modality. As such, the program will emphasize that flexibility is an important component of fitness. The goal would be for each participant to enhance their flexibility by engaging in a titrated exercise prescription where the number of sets and time to hold per set will increase throughout the 16-week program.
9755966|NCT05043012|Experimental|Group 1|will have an mpMRI scan with a flexible AIR coil.
9755967|NCT05043012|Experimental|Group 2|will have an mpMRI scan with an endorectal coil
9755968|NCT05039996|Active Comparator|Intervention group|"Educational and training part. The educational part will be done once in the first visit in about 30 minutes Information and skills will be demonstrated and applied in the session through power point presentation, educational brochures, and video lessons and guided home-based practice.~Appropriate relaxation training Program~Relaxation training comprises deep breathing exercises and progressive muscle relaxation, to perform them daily and to keep a record of them.~Group meeting sessions for training will be held every week for the 1st 4 weeks~Video programs will be used as relaxation facilitators.~Patient will try these exercises for the first time in front of the researcher.~Patients will be advised to perform them daily for 8 weeks to achieve 60 sessions and to keep a record of them.~Follow up of the intervention group adherence to instructions will be done weekly by Telephone."
9755969|NCT05039996|Placebo Comparator|Control group|The control group will be advised to be adherent to the prescribed medications only and try not to change the treatment plan during the study period.
9755970|NCT05036408|Experimental|Supportive care (cancer pain rehabilitation program)|Patients participate in the cancer pain rehabilitation program for 6 weeks, including educational sessions over 2 hours once weekly, group psychological interventions, group physical therapy, and 1:1 physical and occupational therapy treatment per the patient's treatment plan. Patients may also undergo osteopathic manual treatments per physical and occupational therapy assessments.
9755971|NCT05032183|Experimental|Treatment (tagraxofusp, chemotherapy)|See Detailed Description
9755972|NCT05028751|Experimental|Part 1: Dose Escalation|Sequential cohorts of participants will receive escalating doses of lanraplenib (LANRA) once daily (QD) + gilteritinib QD in each 28 day cycle for determination of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of LANRA in combination with gilteritinib.
9755973|NCT05028751|Experimental|Part 2: Expansion Cohort|Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of lanraplenib (LANRA) in combination with gilteritinib in Part 1, an expansion cohort will enroll. The expansion cohort will receive LANRA in combination with gilteritinib at the MTD / RP2D once daily (QD) in each 28 day cycle.
9755974|NCT05023993|Active Comparator|Arm I (home exercise)|Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.
9755975|NCT05023993|Experimental|Arm II (home exercise, nicotinamide riboside)|Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside PO daily for 6 weeks.
9755976|NCT05019053|Experimental|Coping Crew Intervention|Interested participants who meet the screening criteria will be assigned to receive COPING CREW. First, following informed consent, eligible participants will complete a baseline assessment appointment in the week prior to the group beginning. During the baseline appointment, participants will provide informed consent, be instructed in the use of Microsoft Teams, complete a battery of self-report measures, be given a semi-structured diagnostic interview, and follow instructions to install a mobile app that will be used to track their mood and homework. Then, 4 groups of COPING CREW, with 6 participants per group, will be run. Participants will complete four weekly 60-minute virtual intervention sessions followed by a booster session two weeks later. Participants will complete daily surveys and homework assignments on their mobile devices. Links to follow-up surveys will be sent to participants at 1- and 3-month follow-ups.
9782997|NCT01190891|Active Comparator|Manual Physical Therapy|The orthopaedic manual physical therapy (OMPT) intervention approach used in this study will be based on an impairment model. The physical therapist providing the intervention will address the impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients will receive procedures tailored to their specific impairments. Procedures will include mobilizations and manipulations of the joint and soft-tissues.
9782998|NCT01190891|Active Comparator|Corticosteroid Injection (Subacromial)|Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL
9782999|NCT01190930|Experimental|Arm A (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
9783000|NCT01190930|Experimental|Arm B (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
9783001|NCT01190930|Experimental|Arm B-LLy (4-week cycle maintenance)|See Detailed Description.
9783002|NCT01190930|Experimental|Arm C (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
9831474|NCT04329728|Experimental|Primary Mediastinal Large B-cell lymphoma|Primary mediastinal large B-cell lymphoma
9517440|NCT03306329|Experimental|DNS-7801 (high-dose)|
10202111|NCT05082337|Experimental|Guidewire|The SAVVY guidewire will be used in all TAVR procedures of patients included in the study
10202112|NCT05081089|Active Comparator|Artemether-lumefantrine (AL)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days.
9755978|NCT05013541||Patients included|"Patients with lower urinary tract disorders assessed with multichannel cystometry and presence of rectal contractions.~Measure of amplitude and frequency of rectal contractions function of the bladder sensation and volume of bladder filling."
9755979|NCT05012371|Experimental|Arm A (lenvatinib, everolimus)|Patients receive lenvatinib PO QD and everolimus PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
9755980|NCT05012371|Active Comparator|Arm B (cabozantinib)|Patients receive cabozantinib PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
9755981|NCT04986176|Experimental|HC-1119 + Usual Care|4 (40mg) soft gel capsule, 160 mg total
9755982|NCT04986176|Placebo Comparator|Placebo + Usual Care|4 soft gel capsule
9755983|NCT04980833|Experimental|Alpelisib|All participants will receive alpelisib once a day
9755984|NCT04969575||day 3 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.~Media refreshment: Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3). Embryo grading will not be done day2-5. Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator. Embryo grading should be done prior to media refreshment. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
9755985|NCT04969575||day 5 refreshment|"All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.~Following ICSI, oocytes will be cultured in 2-4 culture dishes placed in 2 separate chambers.~Media refreshment and embryo grading timings: Zygote scoring on day 1 (18-20hpi). Embryo grading and culture media refreshment will be done 114-118 hours post insemination (Day5).~Culture media preparation and refreshment: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops. Dishes will be equilibrated overnight in a CO2 incubator.~Embryo grading and media refreshment is done prior to blastocyst biopsy. Time out of the incubator during media refreshment will be assessed on day 3 and day 5.~One operator should perform the ICSI. In case of multiple operators, each operator's injected oocytes will be split between the 2 groups."
9755986|NCT04964596|Active Comparator|a colonoscopy as surveillance exam|patients will undergo Colonoscopy, finding will be documented. Findings of colonoscopy will be documented and treated according to the institutional standards. Study participation for patients ends after the colonoscopy and follow-up of pathology results and complication assessment.
9755987|NCT04964596|Active Comparator|undergoing a FIT as surveillance exam|if the FIT test is positive: patients will have subsequent colonoscopy within 3 months. Findings of FIT testing and if positive the colonoscopy will be documented and participation in the study will end after that. Findings of the FIT test and colonoscopy will be treated according to the institutional standards. If FIT test is negative patient will leave the study and will have a follow up with a colonoscopy or FIT test in 1 to 2 years outside of this study.
9755988|NCT04964596|Active Comparator|undergoing CT colonography as surveillance exam|If CTC is positive: patients will have subsequent colonoscopy within 3 months. Findings will be documented and participation in the study will end there. Findings of the colonoscopy will be addressed according to our institution's guidelines. If CTC is negative for polypoid lesions patient will leave the study and will have a follow up 5 years after with either a CTC or colonoscopy.
9755989|NCT04961320|Experimental|Supportive care (OT, questionnaires)|Patients participate in OT sessions weekly for 3 weeks over 30 minutes each. Patients also complete questionnaires to assess anxiety, depression, fatigue and pain at baseline, 5 and 12 weeks.
9755990|NCT04959890||Subjects Previously Treated with Strimvelis Gene Therapy|It is expected that this study will include approximately 70 eligible samples from approximately 15 subjects previously treated with gamma retroviral gene therapy (gRV-GT).
9755991|NCT04955340|Experimental|[14C]-resminostat|single dose of 400 mg [14C]-resminostat
9755992|NCT04950686|Experimental|Intervention - Media Aware for Young Adults|This arm will receive Media Aware for Young Adults between the pretest and posttest questionnaire. Media Aware for Young Adults is a web-based sexual and relationship health promotion program that uses a media literacy education (MLE) approach. The program is self-paced and includes four modules.
9831475|NCT04329728|Experimental|Burkitt or Burkitt-like lymphoma/leukemia|Burkitt or Burkitt-like lymphoma/leukemia
9831476|NCT04329728|Experimental|CLL/SLL|Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
10202113|NCT05081089|Experimental|AL with 0.25mg/kg primaquine (PQ)|Subjects will receive artemether-lumefantrine (AL) twice daily for 3 days and a single dose of 0.25mg/kg primaquine (PQ) on the first day of AL treatment.
10202114|NCT05081089|Active Comparator|Sulphadoxine-pyrimethamine with amodiaquine (SPAQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days.
10202115|NCT05081089|Experimental|SPAQ with 1.66mg/kg tafenoquine (TQ)|Subjects will receive sulphadoxine-pyrimethamine with amodiaquine (SPAQ) once daily for 3 days and a single dose of 1.66mg/kg tafenoquine (TQ) on the first day of SPAQ treatment.
10202116|NCT05074758||non-COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) unrelated to COVID-19
10202117|NCT05074758||COVID-19 ARDS patients|20 patients with acute respiratory distress syndrome (ARDS) linked to COVID-19
10202118|NCT05072626|Active Comparator|high MCT formula with breast milk (or infant formula)|high MCT formula with breast milk（or infant formula）: Patients will be enrolled from 4 to 5 days after the Kasai operation. Daily dose: according to the amount of enteral nutrition, q2h, q3h, or tube feeding.
10202119|NCT05072626|Experimental|MCT powder with breast milk (or infant formula)|Patients will be enrolled from 4 to 5 days after the Kasai operation. Daily dose: according to the amount of enteral nutrition, q2h, q3h, or tube feeding.
9517441|NCT03306329|Placebo Comparator|Placebo|
9517442|NCT03306316|Experimental|Experimental|Experimental Arm
9755993|NCT04950686|Active Comparator|Active Control - Health Aware for Young Adults|This arm will receive Health Aware for Young Adults in between the pretest and posttest questionnaire. Health Aware for Young Adults is a web-based sexual and relationship health promotion program. The program contains the same health content as Media Aware for Young Adults but without the media literacy education components. The program is self-paced and includes four modules.
9755994|NCT04950686|No Intervention|Delayed Intervention Control|Participants in this condition will not receive a sexual or relationship health promotion program until after the 12-month follow-up survey. After that survey is complete, they will receive access to the Media Aware for Young Adults program.
9755995|NCT04941469|Experimental|Specifically optimized off-the-counter foot orthosis|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type."
9755996|NCT04941469|Active Comparator|Plain off-the-counter foot orthosis|The control device for this study would be the plain original Formthotics (Original Dual Hard).
9755997|NCT04941144||COVID-19 Vaccine Intramuscular Injection 0.5 mL|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
9755998|NCT04929392|Experimental|Treatment (chemoradiation, pembrolizumab, lenvatinib)|"CHEMORADIATION PHASE: Patients receive carboplatin IV and paclitaxel IV QW for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT over 6 weeks and receive pembrolizumab IV over 30 minutes on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity.~WINDOW PERIOD: Patients receive pembrolizumab IV over 30 minutes on day 1 of week 3 and lenvatinib mesylate PO QD at weeks 3-6 in the absence of disease progression or unacceptable toxicity.~SURGERY/SURVEILLANCE: Patients without complete response undergo standard of care surgical resection. Patients with complete response/pursue non-operative management undergo surveillance via periodic endoscopic biopsy."
9755999|NCT04906213|Active Comparator|Arm I: With Type II Diabetes|Kidney Transplant recipient with Type II diabetes, randomized to either dapagliflozin or a placebo.
9756000|NCT04906213|Active Comparator|Arm 2: Without Diabetes|Kidney Transplant recipient without Type II diabetes, randomized to either dapagliflozin or a placebo
9756001|NCT04904809|Experimental|All Registered Patients|All registered patients will have multiple access sites in a single vein closed utilizing the Perclose ProGlide Suture-Mediated Closure System and/or Perclose ProStyle Suture- Mediated Closure and Repair System.
9756002|NCT04901247||day 3|embryo grading and culture refreshment will be done 67-69 hours post insemination
9756003|NCT04901247||day 5|embryo grading and culture medium refreshment will be done 114-118 hours post insemination
9756004|NCT04897438|Experimental|Intervention|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. If absolute levels of dd-cfDNA are > 50 copies/ml, the patients receive a kidney allograft biopsy. Additionally, kidney allograft biopsies are performed according to standard of care as determined by the treating physicians.
9756005|NCT04897438|No Intervention|Control|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. These measurements are not used to guide kidney allograft biopsies. Those are performed according to standard of care as determined by the treating physicians.
9756006|NCT04892888||COVID-19 Vaccine Intramuscular Injection 0.5 mL|COVID-19 vaccine intramuscular injection, 2 doses of 0.5 mL per dose administered intramuscularly at an interval of 4 weeks.
9756007|NCT04890158|Experimental|Prone positioning for a total of 6 hours daily by study protocol|Patients will be positioned prone for 3 hours then placed supine for 3 hours then prone again for 3 additional hours. The change in position from prone t osupine and back is to more reliably document possible changes in ventilation, oxygenation, other vital signs and respiratory support required.
9756008|NCT04890158|No Intervention|usual positioning|"Patients in the newrbon intensive care unit are physically handled usually every 3-4 hours. Those study participants who are radomly assigned to usual position may rest in a variety of positions in any order based on nursing or perceived patient preference. Positions may include supine, right lateral, left lateral, and prone as well."
9984741|NCT03777709|Experimental|Intervention|The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
9756012|NCT04865367||DEG n1: euploid medium|culture media derived from euploid embryos
9756013|NCT04865367||DEG n2: aneuploid medium|culture media derived from aneuploid embryos
9756014|NCT04865367||DEG n3: medium arrested embryos|culture media derived from arrested embryos
9831477|NCT04329728|Experimental|B- or T-ALL|B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage, or natural killer (NK) cell lymphoblastic leukemia/lymphoma
9831478|NCT04328038||USA|Cohort from the USA
9831479|NCT04328038||Germany|Cohort from Germany
9831480|NCT04326179||Age 0 to 4 at day of visit|This study is entirely based on surveys and chart reviews. Data collected as part of this study will not directly inform the care of participating patients and families.
9831481|NCT04322448||Cubital Tunnel Syndrome Patients|Cubital Tunnel Syndrome patients. Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
9831482|NCT04322448||Peroneal Nerve Decompression Patients|Patients with compressive peroneal nerve neuropathy and will undergo a Peroneal Nerve Decompression (PND). Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
9831483|NCT04321954|Experimental|LENVATINIB|"Study procedures include screening for eligibility and study treatment, evaluations, and follow up visits~Lenvatinib will be administered orally daily at a predetermined dose for 2, 4, or 6 cycles, dependent on response. 1 cycle is 28 days.~Surgery per standard of care will follow lenvatinib treatment."
9831484|NCT04320901|Experimental|Harmonic|Endoscopic procedure will be done by Harmonic ACE7+
9831485|NCT04320901|Experimental|Ligasure|Endoscopic procedure will be done by Ligasure
9831486|NCT04317820|Experimental|DBR Condition|Involves 8 weekly sessions of DBR treatment.
9831487|NCT04317820|No Intervention|Wait-list Condition|No intervention for approximately 8 weeks.
9831488|NCT04283656|Other|Period I|Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone
9831489|NCT04283656|Other|Period II|Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo
9831490|NCT04283656|Other|Period III|Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone
9831491|NCT04272385||Focus Group|Qualitative research done with a group of patients with TN. Patients will describe their experience of living with the disease and what outcomes of treatment they consider to be important.
9831492|NCT04272385||Delphi survey|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment in a 3 round Delphi survey.
9831493|NCT04272385||Consensus meeting|Group of relevant stakeholders - patients, clinicians and researchers will rate the outcomes of treatment and finalise the COS for Trigeminal Neuralgia.
9831494|NCT04272060|Experimental|CT Angiography|Research CT angiography.
9831495|NCT04272060|Active Comparator|Conventional Angiography|Standard medical care which includes cardiac catheterization and invasive coronary angiography.
9831496|NCT04271878|Other|All participants|All participants will receive the same interventions
9831497|NCT04270617|No Intervention|Control arm|The control arm will involve usual care - 6 weeks of physical therapy, NSAIDs, and epidural steroid injections
9831498|NCT04270617|Experimental|Yoga Arm|The study arm will involve a yoga protocol devised by Eddie Stern - a renowned Ashtanga yoga practitioner, and can include NSAIDs.
9831499|NCT04250805|Active Comparator|Lidocaine|Patients will receive Lidocaine alone during percutaneous gastrostomy under radiological guidance
9831500|NCT04250805|Experimental|Lidocaine and Ropivacaine|Patients will receive Lidocaine and Ropivacaine during percutaneous gastrostomy under radiological guidance
9831501|NCT04247737|Experimental|gluten free diet|six week gluten free diet
9831502|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E7 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E7 Inf.U.
9831503|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E8 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E8 Inf.U.
9831504|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E9 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E9 Inf.U.
9831505|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E10 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E10 Inf.U.
9831506|NCT04246671|Experimental|Stage 2: Chordoma Cancer Cohort|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level defined in stage 1.
9831507|NCT04246671|Experimental|Stage 2: HER2-positive Breast Cancer Cohort (Trastuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of trastuzumab, every three weeks with three administrations in total at the dose defined in stage 1.
9831508|NCT04246671|Experimental|Stage 2: HER2-positive Breast Cancer Cohort (Trastuzumab + Pertuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of trastuzumab and pertuzumab. TAEK-VAC-HerBy will be administered every three weeks with three administrations in total at the dose defined in stage 1.
9517443|NCT03306316|Placebo Comparator|Control|Placebo Control Arm
9831509|NCT04246671|Experimental|Stage 2: HER2-positive Gastric/GEJ cancer cohort (Trastuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to HER2-positive gastric/GEJ cancer patients who are on stable dose of trastuzumab. TAEK-VAC-HerBy will be administered every three weeks with
9831510|NCT04244227|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower active treatment.
9831511|NCT04244227|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower sham treatment.
9831512|NCT04242173|Experimental|Cemiplimab-rwlc treatment|Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks
9831513|NCT04240665|Experimental|DMN Intervention|Subjects will attend 2-hour weekly sessions for 6- weeks. Participants will continue to use the DMN application for 4-weeks after the intervention is complete.
9831514|NCT04235309||Total Knee Replacement Cohort|Any patients who are scheduled to undergo a total knee replacement.
9831515|NCT04229771|Experimental|Participants with obstruction of the lacrimal system|Participants who have a blockage in their tear drainage system on probing and irrigation. Participants will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
9831516|NCT04229771|Experimental|Participants with no obstruction of the lacrimal system|Participants who do not have a blockage in their tear drainage system on probing and irrigation. Patients will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
9831517|NCT04218773|Experimental|Induced hypertension|The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.
9984742|NCT03777709|No Intervention|Delayed Intervention/Control|"The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases)."
9517444|NCT03306303||Quartile 1 of plasma melatonin|Quartile 1 of plasma melatonin
9517445|NCT03306303||Quartile 2 of plasma melatonin|Quartile 2 of plasma melatonin
9517446|NCT03306303||Quartile 3 of plasma melatonin|Quartile 3 of plasma melatonin
9831518|NCT04203160|Experimental|Phase 1 and Phase 2, Arm A (investigational)|On Day 1 and Day 8 of each 3-week cycle, patients will receive CPI-613 + gemcitabine and cisplatin. Patients may continue gemcitabine, cisplatin and CPI-613 for up to 2 years in absence of disease progression or unacceptable toxicity.
9831519|NCT04203160|Active Comparator|Phase 2, Arm B (standard of care)|On Day 1 and Day 8 of each 3-week cycle, patients will receive gemcitabine and cisplatin. Patients may continue gemcitabine and cisplatin for up to 2 years in absence of disease progression or unacceptable toxicity.
9831520|NCT04201262|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive open-label ravulizumab via intravenous (IV) infusion starting on Day 1. The end of the Primary Treatment Period will be triggered when the last enrolled participant completes between 26 and 50 weeks in the study (depending on the number of adjudicated On-Trial Relapse observed).~After completion of the Primary Treatment Period, all participants will have the opportunity to continue receiving ravulizumab in the Long-Term Extension Period of the study. For each participant, the Long-Term Extension Period continues for up to 2 years, or until ravulizumab is approved and/or available (in accordance with country-specific regulations), whichever occurs first."
9831521|NCT04186286|Active Comparator|1st drug Ivabradine|Patients will take Ivabradine first followed by Propranolol and Placebo
9831522|NCT04186286|Active Comparator|2nd drug Ivabradine|Patients will take either Propranolol or placebo first and then Ivabradine
9831523|NCT04186286|Active Comparator|3rd drug Ivabradine|Patients will take Propranolol and placebo first and then Ivabradine
9831524|NCT04180306|Other|Inpatient pediatric oncology patients|All patients admitted to the pediatric oncology ward will be in the cohort
9831525|NCT04178460|Experimental|Assigned Interventions|Niraparib combined with MGD013
9831526|NCT04169009|Active Comparator|ZVL >5 years previously|Participants have received Zostavax (ZVL) at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
9831527|NCT04169009|Active Comparator|ZVL 6-12 months previously|Participants who received ZVL 6-12 months previously will be administered an intradermal dose of vOka varicella zoster virus (ZVL) in non-dominant deltoid.
9831528|NCT04169009|Active Comparator|No previous ZVL|Participants who've never received a shingles vaccine will be given the 2 standard doses of RZV. Six months later they will be given the intradermal dose of vOka varicella zoster virus (ZVL) in the non-dominant deltoid.
9831529|NCT04169009|Active Comparator|SRX >5 years previously|Participants have received Shingrix at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
9831530|NCT04160429||Device feasibility (Macroduct Sweat Collection System)|Patients undergo collection of sweat samples via Macroduct Sweat Collection System 3710S and saliva and blood samples within 24 hours after medication administrations. Patients also complete questionnaires over 5-10 minutes and have medical charts reviewed.
9831531|NCT04158804|Experimental|Procalcitonin algorithm+stewardship team|antibiotic prescription guided by PCT values
9831532|NCT04158804|No Intervention|standard group|standard of care guided by current guidelines
9831533|NCT04156659|Experimental|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel will receive a single dose of tisagenlecleucel.~For subjects ≤ 50 kg, tisagenlecleucel will be administered as a single infusion of 0.2 to 5.0 x 10^6 CAR positive viable T cells per kg body weight.~For subjects > 50 kg, tisagenlecleucel will be administered as a single infusion of 0.1 to 2.5 x 10^8 CAR positive viable T cells."
9831534|NCT04154878||Pacemaker Optimization|Participants were referred for pacemaker optimization following implantation of a device. All had an intact atrial contraction either intrinsic or by device stimulation. A standard baseline echo was performed prior to programming changes with a final echo scan completed after all programming complete. Device programming consisted of adjusting atrial ventricular and right to left ventricular stimulation delays.
9831535|NCT04154878||Healthy|A brief cardiac history questionnaire and complete echocardiogram will be performed.
9831536|NCT04125251|Active Comparator|BISP,CT & LSB to Couples|In this arm 1, the LSB intervention will be offered to the BISP-CT beneficiary women and their spouses
9831537|NCT04125251|Active Comparator|BISP,CT & LSB to Women|In this arm, the LSB intervention will be offered to the BISP-CT beneficiary women only.
9831538|NCT04125251|No Intervention|BISP,CT & No LSB|This is the control group, where neither BISP-CT beneficiary women nor their spouses will be offered the LSB intervention
9831539|NCT04101487|No Intervention|Control|Participants in this arm will receive routine monthly visits along with survey administration and the regular package of health services provided at the facility level and at home by community health assistants
10202120|NCT05070689|Experimental|Single Group|A. Chohan Continuous squeezing Suture (ACCSS): An obstetrical procedure using half circle 40mm round body polyglactin 910 suture # 1 (Vicryl plus by Ethicon ®) for control of haemorrhage from the lower segment, in patients with Placenta Accreta for the prevention of hysterectomy at caesarean section
10205189|NCT03720366|Experimental|Arm 2: Administration of enasidenib and Arm 2 probes|Part 1: Subjects will receive prescribed doses of Arm 2 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 2 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
10205190|NCT03720366|Experimental|Arm 3: Administration of Enasidenib and Arm 3 probes|Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
10205191|NCT03710291|Experimental|TRC101|
10205192|NCT03710291|Placebo Comparator|Placebo|
10205193|NCT03698201||Cohort 1 / High grade Glioma|"Cohort 1:~Histologically confirmed high grade glioma (grade III) or glioblastoma (GBM, astrocytoma grade IV)~Planned treatment (RT alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
10205194|NCT03698201||Cohort 2 / Low grade Glioma|"Cohort 2:~Histologically confirmed low grade (grade II) glioma~Planned treatment either~expectant monitoring or~RT alone or~Chemotherapy alone or~a combination of RT/Chemotherapy"
9756015|NCT04865367||DEG n4: control culture medium|pure culture media without contact to embryos
9756016|NCT04856228|Other|diagnostic single group|Patients diagnosed with lateral epicondylitis with physical examinations will be evaluated with electrophysiology After electrophysiological evaluations, patients' effected extremity evaluated with ultrasonography for lateral epicondylitis and radial tunnel syndrome and compared with uneffected side 30 minutes after posterior interosseous nerve block with 1 cc 2% lidocaine with USG guide, full examination will be repeated for evaluation of NRS score changing to exact diagnose of radial tunnel syndrome 30 minutes after lateral epicondyle 1 cc 2% lidocaine injection with USG guide, full examination will be repeated for evaluation of NRS score changing to final diagnose of lateral epicondylitis
9756017|NCT04847427|Experimental|Core exercises training|Participants will perform 4 core exercises
9756018|NCT04847427|Experimental|Structural exercises training|Participants will perform 4 structural (Olympic lifting) exercises
9756019|NCT04847427|Experimental|Accentuated eccentric exercises training|Participants will perform 4 exercises with eccentric loading
9756020|NCT04847427|Experimental|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
9756021|NCT04842604|Experimental|Participants from B1371019 and B1371012|"Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed.~The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study.~Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study."
9756022|NCT04829747|Experimental|Atogepant|Participants will receive fixed dose of Atogepant once daily for 12 weeks.
9756023|NCT04827810|Experimental|Dose -1|Accelerated Phase: - Standard Phase: 5 mg
9756024|NCT04827810|Experimental|Dose 1|Accelerated Phase: 10 mg Standard Phase: 10 mg
9756025|NCT04827810|Experimental|Dose 2|Accelerated Phase: 20 mg Standard Phase: 20 mg
9756026|NCT04827810|Experimental|Dose 3|Accelerated Phase: 40 mg Standard Phase: 35 mg
9756027|NCT04827810|Experimental|Dose 4|Accelerated Phase: 80 mg Standard Phase: 50 mg
9756028|NCT04827810|Experimental|Dose 5|Accelerated Phase: 160 mg Standard Phase: 65 mg
9756029|NCT04827810|Experimental|Dose 6|Accelerated Phase: 320 mg Standard Phase: 85 mg
9756030|NCT04820023|Experimental|BBT-176|
9756031|NCT04820023|Experimental|BBT-176 in combination with Cetuximab|
9756032|NCT04819620|Experimental|Single Dose|Single dose administration
9756033|NCT04819620|Experimental|Multiple Dose|Multiple dose administration
9756034|NCT04819620|Experimental|Solid Dose Comparison|Solid dose administration
9756035|NCT04817098|Experimental|Journey of Life Intervention Group|Community members (caregivers, teachers, and community leaders) will participate in group workshops for a period of 6 weeks.
9756036|NCT04817098|Other|Waitlist Control Group|The waitlist control group will not receive the intervention during the first 6 months of implementation in order to assess the effects of the intervention compared to the control group. However, following intervention completion in the experimental group, the control group will receive 6 months of the intervention.
9756037|NCT04815330||Patient dyspnea under veno-arterial extracorporeal circulation|"Relief of dyspnea will be carried out by the clinician in charge of the patient. He will have complete control of his behaviour. He will carry out this test according to the practices in force in the department.~If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.~In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved."
9756038|NCT04813445|Experimental|Xingnaojing injection|"Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.~Interventions:~Drug: Xingnaojing injection Other: Standard care"
9756039|NCT04813445|No Intervention|Standard care|"Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care"
9756040|NCT04810702||patients with von Willebrand disease|
9756041|NCT04810702||case control|
9783003|NCT01190930|Experimental|Arm D (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
9783004|NCT01190930|Experimental|Arm LR-C (risk-adapted chemotherapy)|Patients receive consolidation, interim maintenance I, delayed intensification, interim maintenance II, and maintenance therapy. See detailed description.
9831540|NCT04101487|Experimental|Cash Transfers|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants and unconditional cash transfers every month
9831541|NCT04101487|Experimental|Cash Transfers and Nutrition Education|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants, unconditional cash transfers every month, and structured nutrition education provided at household level by community health assistants based on a structured nutrition education handbook.
9831542|NCT04094506|Experimental|Dose level A of ASP1948|Dose A of ASP1948 will be administered intravenously on Day 1 of every 2-week cycle.
9517447|NCT03306303||Quartile 4 of plasma melatonin|Quartile 4 of plasma melatonin
9831543|NCT04094506|Experimental|Dose level B of ASP1948|Dose B of ASP1948 will be administered intravenously on Day 1 of every 2-week cycle.
9831544|NCT04094506|Experimental|Dose level C of ASP1948|Dose C of ASP1948 will be administered intravenously on Day 1 of every 3-week cycle.
9831545|NCT04093349|Experimental|SPK-3006|All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.
9831546|NCT04092894|Active Comparator|Suvorexant|Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
9831547|NCT04092894|Placebo Comparator|Placebo|Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
9831548|NCT04055012|Experimental|High Dose Metformin|High Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1,000mg) for the first week then increase to 3 tabs per day (1,500mg) for the remaining 6 months.
9831549|NCT04055012|Experimental|Low Dose Metformin|Low Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 1 tab per day (1 metformin tab (500mg) for 6 months.
9831550|NCT04055012|Placebo Comparator|Placebo|Placebo Group (n=100). Subjects will receive placebo and will be instructed to take either 2 tabs per day for the first week then increase to 3 tabs per day for the remaining 6 months OR take 1 placebo tab for 6 months.
9831551|NCT04055012|Other|Wait-List Control|"Control Group (n=100). Subjects will be told that they are in the wait-list control group. They will have a 3 month waiting period before they will be randomized again to a treatment group. They will be randomized to one of the previous groups."
9831552|NCT04044560|Experimental|Blinatumomab Treatment|Eligible patients with detectable MRD will taper immunosuppressive medications, if applicable, and undergo treatment with blinatumomab. The duration of each cycle of blinatumomab treatment is 6 weeks. Adult and pediatric patients will be treated for 4 weeks followed by a 2-week treatment free period. Patients may receive up to 4 cycles total of blinatumomab therapy.
9831553|NCT04034797|Experimental|Photo|
9831554|NCT04034797|Active Comparator|No photo|
9831555|NCT04022343|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib orally once daily for 12 weeks in the absence of disease progression or unacceptable toxicity. The assigned starting dose for cabozantinib is 60 mg/day. Two dose reduction levels of cabozantinib are permitted
9831556|NCT04003740|Experimental|Active tDCS|The anode will be placed over the right dorsolateral prefrontal cortex (DLPFC) and the cathode over the left DLPFC. Stimulation will be performed for 30 minutes with a current intensity of 2 mA. A ramp-up time of 20 s for the current to go from zero to 2 mA and a ramp-down time that also takes 20 s for the current to go from 2 mA to zero will be used.
9831557|NCT04003740|Sham Comparator|Sham tDCS|The same montage will be used. Sham stimulation will have the same ramp-up and ramp-down time in three different moments (beginning, middle and at the end of the session).
9831558|NCT03992209|Other|Standard handwashing by anesthesia provider|Anesthesia provider will conduct patient care per their usual standard practice in the operating room.
9831559|NCT03992209|Active Comparator|Protocolized hand washing by anesthesia provider|Anesthesia provider will conduct patient care using a personal hand washing device to optimize hand washing and captures hand washing events in real time.
9831560|NCT03990896|Experimental|Talazoparib|-Talazoparib will be provided as capsules for oral administration daily
9831561|NCT03959566|Active Comparator|Arm 1 (U0)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily"
9831562|NCT03959566|Experimental|Arm 2 (U600)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~600 mg Sutezolid orally once daily"
9831563|NCT03959566|Experimental|Arm 3 (U1200)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~1200 mg Sutezolid orally once daily"
9831564|NCT03959566|Experimental|Arm 4 (U600BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~600 mg Sutezolid orally twice daily"
9831565|NCT03959566|Experimental|Arm 5 (U800BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.~200 mg Delamanid orally in two daily doses of 100 mg.~400 mg Moxifloxacin orally once daily~800 mg Sutezolid orally twice daily~2 mg Midazolam orally once per day on day-1 and day 14"
9831566|NCT03952130|Experimental|LY900014|LY900014 given subcutaneously (SC) with either insulin glargine given SC or insulin degludec given SC.
9831567|NCT03952130|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) given SC with either insulin glargine given SC or insulin degludec given SC.
9831568|NCT03944447|Experimental|Cannabis users|"Most patients will have used cannabis before their initial physician visit, and many current patients will be returning for an in-person follow-up. Patients will be given the survey shortly after the physician encounter to assess baseline parameters with current cannabis use. Any patient who is cannabis-naïve, defined as no use within the past year or longer, will be placed into a separate data analysis arm. The investigators will follow up with patients again at 3, 6, 9, and 12 months with the online survey. Patients returning for their annual physician encounter will continue on the 3-month survey schedule until the end of the study, or if lost to follow-up. There may be slight variations in the interval based on state law, for example in Florida the in-person follow-up with the physician is required every 210 days, and some states allow for 2 year in-person visits. Every attempt will be made to adhere to a 3-month interval survey distribution."
9831569|NCT03944447|Experimental|Cancer prevention|Non-cancer patient medical cannabis users with extensive or life-long cannabis use will be compared to the general population for incidence and prevalence of development of cancer. The hypothesis is that cannabis use acts as a cancer preventive substance.
9831570|NCT03944447|Experimental|Life-Threatening Conditions|"Opioids are a class of drugs naturally found in the opium poppy plant. Opioids are often used as medicines because they contain chemicals that relax the body and can relieve pain. Prescription opioids are used mostly to treat moderate to severe pain. Opioids can also make people feel very relaxed and high - which is why they are sometimes used for non-medical reasons. This can be dangerous because opioids can be highly addictive, and overdoses and death are common.~From 1999 to 2017, more than 700,000 people have died from a drug overdose. Around 68% of the more than 70,200 drug overdose deaths in 2017 involved an opioid.~In 2017, the number of overdose deaths involving opioids was 6 times higher than in 1999.~On average, 130 Americans die every day from an opioid overdose.~This study will focus on examining outcomes of patients that have been treated with cannabis as a replacement or alternative to life-threatening opioids or other prescription drugs."
9831571|NCT03944447|Experimental|COVID-19 / SARS-CoV-2|Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted through respiratory droplets, with potential for aerosol and contact spread. It uses receptor-mediated entry into the human host via angiotensin-converting enzyme II (ACE2) that is expressed in lung tissue, as well as oral and nasal mucosa. Modulation of ACE2 levels in these gateway tissues may prove a plausible strategy for decreasing disease susceptibility. Cannabis sativa, especially one high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been proposed to modulate gene expression and inflammation and possess anti-cancer and anti-inflammatory properties. Covid-19 infection rates in cannabis users will be compared to rates in the general population. Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population.
9831572|NCT03939234|Experimental|Vaccination|Untreated CLL patients with unmutated IgHV gene with a cut of at maximum of 2 % mutations. According to guidelines from the European Research Initiative on CLL (ERIC).
9831573|NCT03936335||Dupilumab cohort|"Exposed to dupilumab during the relevant exposure window:~First trimester~Pregnancy"
9831574|NCT03936335||Other systemic therapy or phototherapy cohort|"Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window:~First trimester~Pregnancy"
9756042|NCT04810546|Experimental|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
9756043|NCT04810546|No Intervention|Usual care|Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
9756044|NCT04798924|Experimental|Training in the blind field|Training in the blind field using specialized software
9756045|NCT04798924|Experimental|Training in the intact field|Training in the intact field using specialized software
9756046|NCT04794478|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
9756047|NCT04784052|Experimental|Depleted Stem Cell Transplant with JSP-191 Conditioning|Participants will receive an infusion of donor stem cells which have been depleted of αβ+T cells using the CliniMACS System device. Before the stem cell transplant, they will receive a reduced-intensity preparative regimen containing JSP191 in combination with rATG, cyclophosphamide, fludarabine and rituximab.
9756048|NCT04783220|Experimental|Intervention|The parents of babies in this group will receive an educational and intervention program
9756049|NCT04783220|No Intervention|Control|The parents of babies in this group will receive the standard parent education and follow-up.
9756050|NCT04778631|Experimental|Heat therapy|Local perineal heat therapy during active second stage of labor
9756051|NCT04778631|Experimental|Cryotherapy|Local perineal cryotherapy during the immediate postpartum period
9756052|NCT04778631|No Intervention|Active second stage usual car|Standard obstetrical care and perineal protection during active second stage of labor
9756053|NCT04778631|No Intervention|Postpartum usual care|Standard immediate (<2 hours) postpartum care
9756054|NCT04771871|Experimental|Epirubicin-Cyclophosphamide plus Paclitaxel- Carboplatin|Epirubicin 60mg/m2 with cyclophosphamide 600/m2 every three weeks for four courses followed by paclitaxel 120mg/m2 and carboplatin 6 AUC every three weeks for four courses
9756055|NCT04767854|Experimental|OA school + Virtual Training mobile health application|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The intervention group will receive an individually tailored exercise program through the Virtual Training mobile health application. After each exercise the patient score his/her execution of the exercise on a Likert-scale of 1 to 5, judging their effort from very poor to very good. After the session, patients rate their pain on a Numeric Rating Scale from 0 to 10. The patients in the intervention group will be instructed to exercise 3 times per week for 6 weeks. If the patients want to exercise more than 3 times per week, the exercise program will be available in the app once every day."
9756056|NCT04767854|Active Comparator|OA school + usual care|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The control group will receive individually tailored supervised exercise therapy by a physiotherapist individually or in a group setting, twice a week for 6 weeks. Additionally, the patients will be motivated to perform one session of home exercise a week, a total of 3 sessions per week"
9756057|NCT04766411|Experimental|Unresisted sprint training|Participants will perform an acute training bout of unresisted sprints.
9756058|NCT04766411|Experimental|Resisted sprint training with load equal to 10% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 10% of body weight.
9756059|NCT04766411|Experimental|Resisted sprint training with load equal to 20% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 20% of body weight.
9756060|NCT04766411|Experimental|Control trial|Participants will perform no training protocol. They will only perform all the measurements.
9756061|NCT04763499|Experimental|Freeze dried strawberry powder|"39g of freeze dried strawberry powder, which represents three daily servings of strawberries.~The powder will be mixed in one cup of water."
9756062|NCT04763499|Placebo Comparator|control powder|39 g of a powder that matches the sugar and caloric content of the experimental powder. The powder will be mixed in one cup of water.
9783005|NCT01190930|Experimental|Arm LR-M (risk-adapted chemotherapy)|Patients receive consolidation and maintenance therapy. See detailed description.
9783006|NCT01190930|Experimental|Arm SR DS (12-week cycle maintenance)|See Detailed Description
9831575|NCT03936335||Unexposed cohort|"Not exposed to systemic medications (including dupilumab) or phototherapy; and~Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window:~First trimester~Pregnancy"
9831576|NCT03922477|Experimental|Atezolizumab + Hu5F9-G4|An initial safety evaluation will be performed in participants with relapsed AML. If atezolizumab in combination with Hu5F9-G4 is initially safe and tolerable in participants an additional cohort with R/R AML will be evaluated to further test the safety and anti-tumor activity. If dose-limiting toxicities (DLT) are observed in >=33% of participants in this initial cohort, a dose de-escalation cohort will be enrolled. If less than 33% of enrolled and dosed participants in any given cohort experience a DLT, an expansion cohort of 15 participants will be enrolled at the highest tolerated dose for this combination. If a dose de-escalation cohort is needed, an expansion cohort will be enrolled at the lower tolerated dose for this combination.
9835868|NCT02759354|Active Comparator|Group Infanrix hexa (2+1)|Participants previously vaccinated with a 2-dose primary series of INFANRIX® hexa at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
9835869|NCT02759471|Experimental|comfilcon A asphere (test)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
9835870|NCT02759471|Active Comparator|comfilcon A sphere (control)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
9835871|NCT02759562|Experimental|Andecaliximab 600 mg (Part 1)|Andecaliximab 600 mg weekly for 8 weeks
9835872|NCT02759562|Placebo Comparator|Placebo (Part 1)|Placebo weekly for 8 weeks
9835873|NCT02759562|Experimental|Andecaliximab 300 mg (Part 2)|Andecaliximab 300 mg weekly for 8 weeks
9835874|NCT02759562|Experimental|Andecaliximab 150 mg (Part 2)|Andecaliximab 150 mg + placebo weekly for 8 weeks
9835875|NCT02759562|Placebo Comparator|Placebo (Part 2)|Placebo weekly for 8 weeks
10202121|NCT05068661|Active Comparator|Combined Spinal Epidural|10 mcg of preservative-free fentanyl and 2 mg of preservative-free isobaric 0.25% bupivacaine will be administered into the intrathecal space to initiate analgesia. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
10202122|NCT05068661|Active Comparator|Dural Puncture Epidural|A 25-G Whitacre needle will be used to puncture the dura. An initiation dose of 20 mL of ropivacaine 0.1% with fentanyl (2 mcg/mL) will be administered. Labor analgesia will be maintained by programmed intermittent bolus with patient-controlled epidural analgesia (PCEA) as per standard of care.
9835876|NCT02759562|Experimental|Open-Label Extension|(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
9835877|NCT02759575|Experimental|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
9835878|NCT02759692|Active Comparator|Group 1 (Test/Control/Test)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL / TEST wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
9835879|NCT02759692|Active Comparator|Group 2 (Control/Test/Control)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST / CONTROL wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
9835880|NCT02759939|Experimental|Arm 1|
9835881|NCT02759939|Experimental|Arm 2|
9835882|NCT02759939|Experimental|Arm 3|
9835883|NCT02759939|No Intervention|Arm 4|
9835884|NCT02760056|Active Comparator|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
9835885|NCT02760056|Placebo Comparator|Placebo|Subject will take matching placebo twice a day for one week
9835886|NCT02760069|Active Comparator|Inhaled ISO + oral ondansetron|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
9835887|NCT02760069|Experimental|Inhaled ISO + oral placebo|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
9835888|NCT02760069|Active Comparator|Inhaled placebo + oral ondansetron|Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
10202123|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Japanese subjects|
9835889|NCT02760264|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
9835890|NCT02760264|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
9835891|NCT02760264|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
9835892|NCT02760264|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
9835893|NCT02760277|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
9835894|NCT02760277|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
9835895|NCT02760277|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
10202124|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects|
10202125|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Caucasian subjects|
10202126|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects|
10202127|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Japanese subjects|
10202128|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects|
10202129|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Caucasian subjects|
10202130|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects|
10202131|NCT05064800|Active Comparator|Treatment A|Dabigatran only
9835896|NCT02760277|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
9783007|NCT01191008||Latan-timolol maleate fixed comb ophthalmic solution|
9783008|NCT01191086|Experimental|Open-label USL255|Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day
9783009|NCT01191190|Experimental|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.~Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity."
9783010|NCT01191255|Active Comparator|Active Control|PhosLo (calcium acetate) Renvela (sevelamer carbonate)
9783011|NCT01191255|Placebo Comparator|Placebo|Placebo
9783012|NCT01191255|Experimental|KRX-0502 (Ferric Citrate)|ferric citrate
9783013|NCT01191268|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
9783014|NCT01191268|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
9783015|NCT01191268|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
9783016|NCT01191320|Placebo Comparator|Placebo|Placebo
9783017|NCT01191320|Experimental|Androxal 12.5 mg|12.5 mg/day
9783018|NCT01191320|Experimental|Androxal 25 mg|25 mg/day
9783019|NCT01191333|Experimental|Active rTMS|Those receiving experimental treatment will receive 20 to 30 sessions of rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
9783020|NCT01191333|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 to 30 sessions of sham rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
9783021|NCT01191398|Placebo Comparator|Placebo and Ketamine|Normal Saline 0.9% will act as a placebo. Two ml of normal saline 0.9% will be administered intravenously 30 minutes prior to the administration of the ketamine.
9783022|NCT01191398|Active Comparator|Atropine and Ketamine|Atropine will be administered as a single dose of 0.01 mg/kg, with a minimum of dosage of 0.1 mg and a maximum dosage of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
9783023|NCT01191398|Active Comparator|Glycopyrrolate and Ketamine|Glycopyrrolate will be administered as a single dose of 0.01 mg/kg, with no minimum dosage and a maximum dose of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
9783024|NCT01191411|Active Comparator|Mailed invitations for FIT test kits|"Fecal Immunochemical Tests (FIT) kits from Polymedco Incorporated are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer using a Polymedco home FIT kit. Mailed invitation to complete a free one sample home FIT kit. Automated and live phone call reminders to promote screening completion, plus usual medical care.~Patients with abnormal FIT results are navigated to complete a diagnostic colonoscopy."
9783025|NCT01191411|Active Comparator|Mailed invitations for a colonoscopy|"Invitation to schedule a colonoscopy are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer with colonoscopy. Mailed invitation to complete one free colonoscopy. Automated and live phone reminders to promote screening completion, plus usual medical care.~Patients with abnormal polyps or adenomas will follow standard clinical protocol after their procedure."
9783026|NCT01191411|Active Comparator|Visit Based Care|"No invitation to complete colorectal cancer screening.~Intervention: Usual medical care. Patients will continue to see their regular physician, and follow their physician's regular standard of care."
9783027|NCT01191476|Active Comparator|Sevoflurane|Subjects received sevoflurane, a inhalational (volatile) anesthetic, which was administered for induction and maintenance of general anesthesia. Inhalational induction was induced via vital capacity induction at 8% and maintained at 0.8-1.5 minimum alveolar concentration (MAC).
9783028|NCT01191476|Active Comparator|Propofol|Subjects received propofol, an intravenous (IV) anesthetic, which was administered for induction and maintenance of general anesthesia.
9756063|NCT04760938|Experimental|Outdoor Behavioral Healthcare (OBH)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
9756064|NCT04760938|Experimental|Cognitive Behavioral Therapy (CBT)|Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
9756065|NCT04757649|Experimental|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
9756066|NCT04756232|Experimental|Anticholinergic Challenge|All participants will receive oral mecamylamine or IV scopolamine for 1 day
9756067|NCT04756232|Placebo Comparator|Placebo Challenge|All participants will receive oral placebo for 1 day
9756068|NCT04745312|Active Comparator|Ambient light|Fluorescent ambient lighting
9756069|NCT04745312|Experimental|Ambient light plus task lamp|Fluorescent ambient lighting plus task lamp
9756070|NCT04740905|Experimental|Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
9756071|NCT04740905|Active Comparator|Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)|In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
9756072|NCT04736940||Patients|Patients followed or currently treated for a solid or haematological neoplasia
9756073|NCT04736940||Doctors|Medical oncologist or haematologist
9756074|NCT04736940||Paramedical staff|Nurses or assistant nurses
9756075|NCT04736940||Oncopsychologist|Psychologist specialised in the care of patients with cancer
9756076|NCT04719832|Experimental|Participants receiving GSK3511294 (Depemokimab)|
9756077|NCT04719832|Placebo Comparator|Participants receiving placebo|
9756078|NCT04717453||Adult Patients with OTC Deficiency|Eligible subjects will be asked to participate in 5 clinic visits, each lasting up to 3 days. Each visit will assess rate of ureagenesis during the 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis. Patient interview, reported outcomes and cognitive assessments will take place over the 3 days.
9756079|NCT04693624||Hormonal levels|Blood samples are collected for analysis of progesterone, hCG, inhibin-A, and 17-OH-Progesterone levels.
9756080|NCT04692077|Experimental|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or may be offered the opportunity to join an open label CAB study instead, if such a study is being implemented in their area at the time.
9756081|NCT04691739|Active Comparator|In-person occupational therapy|occupational therapy delivered in-person
9756082|NCT04691739|Active Comparator|Teletherapy|Video-conferencing occupational therapy
9756083|NCT04689854||Cohere Cervical|
9756084|NCT04689854||Modulus Cervical|
9831577|NCT03922308|Placebo Comparator|Standard of Care (SoC) + Placebo Twice Daily|Participants will receive SoC daily plasma exchange (PEX) immediately followed by placebo (0.9% saline) and after 12 +/- 1 hours until remission is achieved.
9831578|NCT03922308|Experimental|SoC + SHP655 Once Daily + Placebo 12 Hours Later|Participants will receive SoC daily PEX and intravenous (i.v.) injection of 40 +/- 4 International units per kilogram (IU/kg) of SHP655 once daily immediately after PEX and placebo 12 +/- 1 hours after completion of PEX until remission is achieved.
9831579|NCT03922308|Experimental|SoC + SHP655 Twice Daily|Participants will receive SoC daily plasma exchange and i.v. injection of 40 +/- 4 IU/kg of SHP655 twice daily (BID) immediately after PEX and 12 +/- 1 hours after completion of PEX until remission is achieved.
9835897|NCT02760368|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
9835898|NCT02760368|Experimental|Arm 2: Olokizumab q2w|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
10205195|NCT03687060|Other|Organization Level|
9756085|NCT04689568|Active Comparator|Moodkit|MoodKit is a cognitive behavioral therapy (CBT)-based app designed to provide tools for managing depressed mood, anxiety and stress.
9756086|NCT04689568|Active Comparator|Moodgym|Moodgym is an online cognitive behavioral therapy (CBT)-based program designed to prevent or reduce symptoms of depression and anxiety by helping users identify and overcome problem emotions and to develop good coping skills.
9756087|NCT04689568|Active Comparator|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey. The Toolkit offers help to people who are experiencing problems with a mood disorder as well as with stress and anxiety.
9756088|NCT04688333|Experimental|Supportive care (iConquerFear program, questionnaires)|Patients complete 5 sessions of iConquerFear program online over 5 weeks. Patients also complete questionnaires at baseline, after the intervention, and 2 months later.
9756089|NCT04684147|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
9756090|NCT04673266|Experimental|romiplostim|Romiplostim will be administered from the beginning of the next chemotherapy cycle with a starting dose of 3 mcg/kg subcutaneously. Dose will be titrated based on nadir of the platelet counts during the prior cycle. The maximum dose of romiplostim will be 6 mcg/kg.
9756091|NCT04668391|Experimental|Quadratus lumborum block|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament.
9756092|NCT04668391|Active Comparator|Thoracic epidural analgesia|Thoracic epidural analgesia at the level of T7-10.
9756093|NCT04667260|Placebo Comparator|Bone substitue|Bone augmentation with bone substitute
9756094|NCT04667260|Experimental|Coagulum|Bone augmentation with coagulum
9756095|NCT04664881|No Intervention|Control (standard treatment) Group|Participants will receive routine cardiac treatment
9756096|NCT04664881|Experimental|SmartHeart Device Group|In addition to routine cardiac treatment, participants will wear the SmartHeart device
9756097|NCT04638283|Experimental|Interventioh group|"The intervention consists of~Eight group sessions of two hours duration, focusing on GMT and ADHD. The Group consists of six participants and is directed by one neuropsychologist and one psychologist.~Four individual sessions with the neuropsychologist/psychologist directing the Group where the participant is guided through the process of formulating GAS-goals.~Bi-weekly Telephone follow up focusing on GAS-goal attainment the thre first months following the Group session phase."
9756098|NCT04638283|No Intervention|Control Group|Participants in the Control Group receive TAU. Participation in the study does not influence decisions regarding pharmacological interventions in either of the groups.
9756099|NCT04633434|Experimental|The Talk Parenting Skill for Alexa|52 parents will be assessed at enrollment, then provided an Amazon Echo Dot and exposed to the prototype Bedtime Routine module of the Talk Parenting program for 6 weeks, and then re-assessed at 6 weeks (at treatment completion)
9756100|NCT04629937|Experimental|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
9756101|NCT04627545|Experimental|IVF: 2h exposure|Half of a patients' oocytes will be subjected to 2h exposure to sperm
9756102|NCT04627545|Active Comparator|IVF: overnight exposure|Half of a patients' oocytes will be subjected to overnight incubation with sperm (=usual practice).
9756103|NCT04621630|Experimental|Single Dose|Single dose administration
9756104|NCT04621630|Experimental|Multiple Dose|Multiple dose administration
9756105|NCT04621630|Experimental|Solid Dose Comparison|Solid dose administartion
9756106|NCT04616651|Active Comparator|Pre-Chatbot survey arm|Participants will take the self-appraisal survey prior to interacting with the O2O program via the online Chatbot.
9756107|NCT04616651|Experimental|Post-Chatbot survey arm|Participants will take the self-appraisal survey after interacting with the O2O program via the online Chatbot. (This arm will also answer additional questions regarding participants' satisfaction with the O2O Chatbot.)
9756108|NCT04608552|Active Comparator|Active Myofunctional Therapy|Active Myofunctional Therapy is comprised of five 30-minute weekly sessions for 4 weeks.
9756109|NCT04608552|Sham Comparator|Inactive Myofunctional Therapy|Sham MT will be comprised of recommendations for five 30-minute nasal breathing exercises each week, use of nasal lavage with application of 10ml of saline in each nostril two times per day.
9756110|NCT04603391|Experimental|Exposure A|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)
9756111|NCT04603391|Active Comparator|Exposure B|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.
9756112|NCT04599790|Experimental|TACE-Len-Sin|TACE combined with lenvatinib and sintilimab.
9756113|NCT04586478|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
9756114|NCT04583358|Active Comparator|AMT-101|AMT-101 Tablet
9756115|NCT04583358|Placebo Comparator|Placebo|Placebo Tablet
9756116|NCT04575857||Statin arm|To receive pill packet with atorvastatin (40mg/day) which will be taken nightly.
9756117|NCT04575857||Placebo arm|To receive pill packet with placebo which will be taken nightly
9756118|NCT04572022|Experimental|Intervention group rehabilitation teaching video instructions|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions module.
9756119|NCT04572022|No Intervention|Control group|Control group receive proximal humerus fracture standard care only.
9756120|NCT04565210|Experimental|Oriental music|Infants assigned to this group will be exposed to oriental music.
9756121|NCT04565210|Active Comparator|Western music|Infants assigned to this group will be exposed to western music.
9756122|NCT04565210|Placebo Comparator|Silence / control|Infants assigned to this group will be exposed to the same protocol but using a track of silence.
10205196|NCT03687060|Other|Provider Level|
10205197|NCT03687060|Other|Patient Level|
10205198|NCT03685539|Experimental|Diagnostic (DECT)|Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.
9835899|NCT02760368|Placebo Comparator|Arm 3: Placebo|Placebo Subcutaneous q2w + Methotrexate (oral)
9984743|NCT03777462|Active Comparator|Group A of neoadjuvant chemotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
10202132|NCT05064800|Experimental|Treatment B|PF-07321332/ritonavir + Dabigatran
10202133|NCT05064800|Active Comparator|Treatment C|Ritonavir + Dabigatran
10202134|NCT05062889|Experimental|Arm B FOLFOXIRI, part 1 (adjuvant)|FOLFOXIRI Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluoruracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. In the case of oxaliplatin and/or irinotecan interruption because of adverse events, patient's refusal or investigator's choice, the continuation of the other drugs until 12 cycles is recommended.
10202135|NCT05062889|Active Comparator|Arm A mFOLFOX6 or CAPOX (at investigator's choice), part 1 (adjuvant)|"mFOLFOX6 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. The continuation of 5FU/leucovorin until 12 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.~CAPOX Oxaliplatin 130 mg/sqm iv over 2 hours, day 1; Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14; to be repeated every 3 weeks until 8 cycles. The continuation of Capecitabine until 8 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.~Pending the results of ct-DNA analysis, up to 2 cycles of FOLFOX/CAPOX before randomization are allowed to start the adjuvant treatment within 8-10 weeks after surgery"
10202136|NCT05062889|Experimental|Arm B Trifluridine/Tipiracil, part 2 (post-adjuvant)|Trifluridine/Tipiracil: 35 mg/ m2/bid per os days 1-5 and 8-12 to be repeated every 4 weeks until 6 cycles.
10202137|NCT05062889|No Intervention|Arm A Observation, part 2 (post-adjuvant)|Follow-up
10202138|NCT05061238|Other|Vibrating Device|you will be asked to walk up and down a hallway 5 times with the vibrating device strapped to different parts of your leg.
10202139|NCT05057806|Experimental|Empagliflozin Group|Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months
10202140|NCT05057806|Placebo Comparator|Placebo group|Subjects will be randomized to receive the empagliflozin placebo for 3 months
10202141|NCT05053321|Experimental|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
10202142|NCT05048576|Experimental|Positive auditory cues|Participants will listen to the following auditory cues ~30 seconds apart Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job.
10202143|NCT05048576|Experimental|Negative auditory cues|Participants will listen to the following auditory cues ~30 seconds apart You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet.
10202144|NCT05048576|Experimental|Music|Participants will be allowed to select a streaming music station of their choice.
10202145|NCT05048576|Active Comparator|Silence|Participants will walk in silence while wearing noise cancelling headphones.
10202146|NCT05046054|Active Comparator|transcutaneous electrical nerve stimulation group|Transcutaneous electrical nerve stimulation was givent via two electrodes on the venous cannulation site 20 min before propofol injection
10202147|NCT05046054|Placebo Comparator|control group|No transcutaneous electrical nerve stimulation was not given via two electrodes on the venous cannulation site 20 min before propofol injection
10202148|NCT05045716|Experimental|Lecanemab 10 mg/kg|Participants will receive lecanemab 10 milligram per kilogram (mg/kg), as single dose IV infusion over approximately 1 hour on Day 1.
10202149|NCT05045716|Experimental|Lecanemab 700 mg|Participants will receive lecanemab 700 milligram (mg), as single fixed dose SC injection in the abdomen on Day 1.
10202150|NCT05044910||MAM children with TB disease|
10202151|NCT05044910||Wellnourished children with TB disease|
10202152|NCT05044910||MAM children with latent TB infection|
10202153|NCT05044910||Well-nourished children with latent TB infection|
10202154|NCT05042505|Active Comparator|Dapa Group|Patients with diabetes mellitus will receive dapagliflozin 10 mg once daily. Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
10202155|NCT05042505|Active Comparator|Sita Group|Patients with diabetes mellitus will receive sitagliptin 100 mg once daily.Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021
10202156|NCT05041673|Active Comparator|Group 1|metformin +/- insulin +/- sulfonylurea
10202157|NCT05041673|Experimental|Group 2|Metformin plus vildagliptin +/- insulin +/- sulfonylurea
10202158|NCT05041673|Experimental|Group 3|Metformin plus liraglutide +/- insulin+/- sulfonylurea
10202159|NCT05041673|Experimental|Group 4|Metformin plus empagliflozin +/- insulin +/- sulfonylurea
10202160|NCT05039775|Experimental|Study group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal and will use EROS-CTD Clitoral Therapy Device in addition to psychosexual support sessions and will be closely followed for three months.
10202161|NCT05039775|Other|Control group|Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal will receive psychosexual support sessions and will be closely followed after 3 months.
10202162|NCT05032950|Active Comparator|Treatment A|Midazolam orally
10202163|NCT05032950|Experimental|Treatment B|PF-07321332/ritonavir orally + Midazolam orally
9831580|NCT03921502|Experimental|ERCP with sphincterotomy + gall bladder drainage with LAMS|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist. After this, transmural drainage of the gallbladder will be performed by placing a LAMS Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL will be placed on it to generate the anastomosis between the aforementioned structures.
9831581|NCT03921502|Active Comparator|ERCP with sphincterotomy|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist.
9831582|NCT03915405|Experimental|KHK2455 in Combination with Avelumab|
9831583|NCT03907176|Experimental|Cohort 1|HTX-011; Ibuprofen and Acetaminophen (regimen 1)
9831584|NCT03907176|Experimental|Cohort 2|HTX-011; Ibuprofen and Acetaminophen (regimen 2)
9831585|NCT03897530|Experimental|Prevention|During the session, participants are presented with randomly ordered conditions: menthol cigarettes and five flavored e-cigarettes (menthol/mint, fruits, sweets, alcohol, snacks/meals), menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes, non-menthol cigarettes and five flavored e-cigarettes, and non-menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes. Participants' visual attention is evaluated by eye-tracking equipment.
9831586|NCT03892187|Experimental|Intervention Group|Participants are prescribed a walking prescription based on their baseline daily step count. During the interim between the day of consultation until the day of surgery, a study staff member will make weekly calls to each participant. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
9831587|NCT03892187|No Intervention|Control Group|Participants receive usual care prior to surgery. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
9831588|NCT03892187|No Intervention|Observation Group|Participants who are not frail will receive usual care prior to surgery and charts will be reviewed for outcomes following surgery.
9831589|NCT03879616|Experimental|An Enhanced Reminder|"Members randomized to this arm of the study will receive an enhanced reminder protocol, which will include multiple reminders, multiple modalities, and motivational messages. The timing of reminders will depend on the wait time between the date the appointment is made and the date of the appointment.~An email reminder will be sent to all members who have provided their personal email information.~Members will receive up to two text messages that roll over to an IVR automated phone call if the text cannot be delivered.~Members scheduled for colonoscopy will also receive a single IVR-T reminder to begin their bowel prep the morning of the calendar day prior to the procedure."
9831590|NCT03879616|Other|Control|"Members randomized to this arm of the study will receive a single text message that rolls over to an IVR automated phone call if the text cannot be delivered. This message will be delivered 7 business days prior to the appointment. This replicates the current protocol for GI procedures. Of note, members who schedule appointments within 7 days of the procedure currently receive no reminders."
9831591|NCT03876301||Observational Cohort|Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200
9831592|NCT03868787|Experimental|Active TENS|The active TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The program that will be used is a high frequency (80Hz) program that runs for an hour in duration. It will be initiated 5 minutes prior to speculum placement. Participants will be instructed to increase the amplitude of the current as needed to provide analgesia but avoiding discomfort from the TENS stimulation
10202164|NCT05032950|Active Comparator|Treatment C|Ritonavir orally + Midazolam orally
10202165|NCT05027568|Experimental|Drug: IOA-289 single dose|Single oral dose of IOA-289 liquid filled capsule formulation - ascending doses
10202166|NCT05027568|Placebo Comparator|Placebo single dose|Single oral dose of placebo liquid filled caspule formulation
10202167|NCT05026320|Experimental|Naproxen Topical Gel (BAYH006689)|UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
10202168|NCT05026320|Active Comparator|Diclofenac Diethylamine Gel|UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
10202169|NCT05026320|Placebo Comparator|Placebo Gel|UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
10202170|NCT05023031|Experimental|NVP-2102|NVP-2102
10202171|NCT05023031|Active Comparator|NVP-2102-R|NVP-2102-R
9756123|NCT04561206|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
9756124|NCT04559230|Experimental|Sacituzumab govitecan|Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle
9756125|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 600 mg three times daily
9756126|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine|N-Acetyl Cysteine 1,200 mg three times daily
9756127|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
9756128|NCT04545008|Experimental|High Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 1,800 mg three times daily
9756129|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
9756130|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
9756131|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
9756132|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
9756133|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
9756134|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
9756135|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
9517448|NCT03306290|Other|Bariatric surgery candidate|"Patients included in this study belong to this arm and put up with intervention Serum dosage of antibiotic prophylaxis CEFOXITIN"
9756136|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily
9756137|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 1|
9756138|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 2|
9756139|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 3|
9756140|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 4|
9756141|NCT04527770|Active Comparator|dexamethasone group|sonar guided median nerve hydrodissection by bupivacaine 0.5% and dexamethasone
9756142|NCT04527770|Active Comparator|midazolam group|sonar guided median nerve hydrodissection by bupivacaine 0.5% and midazolam
9756143|NCT04514211||Propofol|General anesthesia using propofol infusion
9756144|NCT04514211||Sevoflurane|General anesthesia using sevoflurane
9756145|NCT04507204|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily with or without food.
9756146|NCT04507204|Active Comparator|Concerta|Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.
9756147|NCT04506294|Experimental|eScreen Group|After randomization at baseline, use eScreen system (child screening component and parent information component) for 6 weeks.
9756148|NCT04506294|No Intervention|Usual Care Group|Treatment as usual from baseline. Optional access to the game only (no screening, no parent information component) after completion of T3 assessment (~12 weeks)
9756149|NCT04505566|Experimental|Adult Type II Diabetics - Moderate NPDR - Ketorolac|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy and HbA1c ≥ 8 randomized to Ketorolac treatment.
9756150|NCT04505566|Placebo Comparator|Adult Type II Diabetics - Moderate NPDR - Placebo|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy randomized to placebo treatment.
9756151|NCT04505566|Other|Adult Type II Diabetics - No Diabetic Retinopathy (DR)|23 Adult type II diabetic patients with no diabetic retinopathy as a control group.
9756152|NCT04505566|Other|Adult Type 2 Diabetics-Proliferative Diabetic Retinopathy(PDR)|23 Adult type II diabetic patients with proliferative diabetic retinopathy as a control group.
9756153|NCT04505566|Other|Age-matched Non-diabetics|We will also enroll 100 age-matched patients without diabetes who are undergoing unilateral vitrectomy surgery for non-inflammatory conditions such as epiretinal membrane or macular hole. Removed aqueous fluid that is typically discarded will instead be collected and stored at -80° C. Aqueous fluid will be tested for inflammatory markers as detailed below to provide a reference level for cross-comparison analysis.
9756154|NCT04504331|Experimental|Cohort 1: Infigratinib (100mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 100 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
9756155|NCT04504331|Experimental|Cohort 1: Infigratinib (125mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 125 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + + 20 mg/ day tamoxifen
9756156|NCT04504331|Experimental|Cohort 1: Infigratinib (75mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 75 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
9756157|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - Low dose|Volunteers will receive two administrations of the low dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28
9756158|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083/V-591) - High dose|Volunteers will receive two administrations of the high dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28.
9756159|NCT04497298|Experimental|One COVID-19 vaccine candidate (TMV-083/V-591) - High and placebo|Volunteers will receive one administration of the high dose COVID-19 vaccine candidate on day 0 by intramuscular (i.m.) injection and one administration of the placebo on day 28 by intramuscular (i.m.) injection.
9756160|NCT04497298|Placebo Comparator|Placebo|Volunteers will receive physiological saline solution (0.9% NaCl), administered by intra muscular (i.m.) injection
9756161|NCT04492436|Experimental|Low Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
9756162|NCT04492436|Experimental|High Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
9756163|NCT04492436|Placebo Comparator|Placebo|Reconstituted lyophilized placebo with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
9756164|NCT04488003|Experimental|Part A: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
9756165|NCT04488003|Experimental|Part B: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
9756166|NCT04488003|Experimental|Part B: Physician's choice of treatment|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice). If a patient progresses on physician's choice of treatment, crossover to the ulixertinib arm is permitted.
9756167|NCT04483102|Experimental|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. NMP of the donated declined liver utilizing the OrganOx® metra device. NMP involves (warm) machine perfusion with oxygenated blood at normal body temperature. During NMP, the device also allows for ongoing assessment of donor liver function and further viability assessment to help determine suitability of the organ for transplant.
9756168|NCT04483102|Active Comparator|Standard cold preservation of liver|This group will receive liver transplant using the standard method of preservation. There will be 3 comparison groups: one local comparison group and two comparison groups from the national UNOS data.
9756169|NCT04482244|Experimental|Cannabidiol|"After screening procedures confirm participation in the research study, participants will be randomized one of two groups:~Participants in the experimental arm will complete questionnaires and then receive a single dose of CBD prior to diagnostic CT scan or positron emission tomography (PET) .~Cannabidiol: Oral, per protocol dosage, single dose~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
9756170|NCT04482244|Placebo Comparator|Placebo|"After the screening procedures confirm participation in the research study, participants will be randomized one of two groups:~Participants in the placebo arm will complete questionnaire and then receive a single dose of placebo prior to diagnostic CT scan or positron emission tomography (PET) .~Placebo: Oral, per protocol dosage, single dose~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
9756171|NCT04473482|Experimental|MAIN-ART Behavior Tool|The Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Tool (MAIN-ART) behavioral intervention is an online web application with two modules: misconception correction and tailored, preference-sensitive alcohol use disorder (AUD) treatment matching.
9756172|NCT04473482|No Intervention|Routine care|Patients randomized to usual care will receive a pamphlet for alcohol treatment referral to the University of Michigan Addiction Treatment Services, but will receive no further education from the research team.
9756173|NCT04470180|Experimental|Virtual Teach-to-Goal (V-TTG)|They will be randomized to receive education via a virtual learning module.
9756174|NCT04470180|Active Comparator|standardized brief intervention|Intervention that mimics usual care to deliver inhaler technique education.
9756175|NCT04459715|Experimental|Debio 1143|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~Radiotherapy~Cisplatin~Debio 1143~Monotherapy period (Cycles 4-6):~• Debio 1143"
9756176|NCT04459715|Active Comparator|Placebo|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~Radiotherapy~Cisplatin~Matched placebo~Monotherapy period (Cycles 4-6):~• Matched placebo"
9783029|NCT01191476|Active Comparator|Propofol Induction and Sevoflurane Maintenance|Subjects received a bolus dose of propofol of 1.5 mg/kg administered for IV induction followed by sevoflurane at 0.8-1.5 MAC for maintenance anesthesia.
9783030|NCT01191541|Active Comparator|DNR+Ara-c(Ara-C group)|patients in this group were treated with DNR+Ara-C in consolidation
9783031|NCT01191541|Experimental|DNR(No Ara-C group)|patients in this group were treated with DNR alone in consolidation
10202172|NCT05022927|Experimental|Dose escalation part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to determine the MTD by evaluating DLTs of in patients with locally advanced or metastatic HCC.
10202173|NCT05022927|Experimental|Expansion part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent To evaluate the anti-tumor effect.
10202174|NCT05022927|Experimental|Concomitant use part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab and to determine the MTD.
10202175|NCT05022927|Experimental|Biomarker part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to evaluate the biomarkers.
10202176|NCT05016921|Experimental|Transcutaneous magnetic stimulation|Transcutaneous magnetic stimulation targeting the stellate ganglion
9756177|NCT04459117|Active Comparator|Acetaminophen|The active product is a 10 ml polyethylene ampoule of acetaminophen containing 100 mg of acetaminophen, solution for infusion, B BRAUN.
9756178|NCT04459117|Placebo Comparator|NaCL 0.9%|The placebo product is a polyethylene ampoule of 10ml of NaCL 0.9%, B BRAUN. Polyethylene ampoule of active and placebo products are with the same appearance, in accordance with Good Manufacturing Practices Drugs for Clinical Trials.
9756179|NCT04457557|Experimental|Low concentration|Interscalene block with 0.15% ropivacaine 15 ml
9756180|NCT04457557|Active Comparator|Usual concentration|Interscalene block with 0.5% ropivacaine 15 ml
9984053|NCT04458805|Placebo Comparator|Placebo|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
9756183|NCT04430335|Other|Telephone-Based Cognitive Behavioral Therapy|Participants with moderate or severe anxiety and/or depressive symptoms will participate in the telephone-based intervention that consists of the CBT workbook (15 minutes daily to complete exercises), plus psychotherapy delivered by telephone with a licensed bilingual mental health provider (45-50 minute sessions weekly).
9756184|NCT04427072|Experimental|Capmatinib|400mg of capmatinib tablets, administered orally twice daily
9756185|NCT04427072|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 solution administered by intravenous infusion on Day 1 of every 21-day cycle
9756186|NCT04425148|Experimental|tACS|40 Hz transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
9756187|NCT04425148|Sham Comparator|Sham tACS|Sham transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
9756188|NCT04418830||Base Interfixated System|
9756189|NCT04418830||Brigade Interfixated System|
9756190|NCT04418830||Coalesce Thoracolumbar Interbody|
9756191|NCT04418830||Cohere XLIF Interbody System|
9756192|NCT04418830||CoRoent Ti PLIF Interbody System|
9756193|NCT04418830||CoRoent Ti TLIF Interbody System|
9756194|NCT04418830||MLX - Medial Lateral Expandable Interbody System|
9756195|NCT04418830||Modulus TLIF Interbody System|
9756196|NCT04418830||Modulus XLIF Interbody System|
9517449|NCT03306264|Experimental|ASTX727|ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)
9517450|NCT03306264|Active Comparator|IV decitabine|Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)
9756197|NCT04418830||TLX Interbody System|
9756198|NCT04418830||XLX ACR Interbody System|
9756199|NCT04418830||CoRoent Ti XLIF Interbody System|
9756200|NCT04418830||Cohere TLIF|
9756201|NCT04418830||Modulus ALIF|
9756202|NCT04417569||stimulated cycles|Patients will have blood drawn on five separate occasions: before and following hCG trigger on the day of final oocyte maturation and day of egg collection
9756203|NCT04411680|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
9756204|NCT04411680|Active Comparator|Control Arm|Standard of care for COVID-19
9756205|NCT04409054||Patients undergoing the cough and Valsalva protocol|Patients over 18 years old, consulting in neuro urology departement, undergoing ano rectal manometry in order to explore ano rectal disorders
9756206|NCT04405908|Placebo Comparator|Adult Group 1|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg.
9756207|NCT04405908|Placebo Comparator|Adult Group 2|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
9756208|NCT04405908|Placebo Comparator|Adult Group 3|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
9756209|NCT04405908|Placebo Comparator|Adult Group 4|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg .
9756210|NCT04405908|Placebo Comparator|Adult Group 5|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
9756211|NCT04405908|Placebo Comparator|Adult Group 6|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
9756212|NCT04405908|Placebo Comparator|Adult Group 7|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg .
9756213|NCT04405908|Placebo Comparator|Adult Group 8|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
9756214|NCT04405908|Placebo Comparator|Adult Group 9|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
9756215|NCT04405908|Placebo Comparator|Elderly Group 10|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
9756216|NCT04405908|Placebo Comparator|Elderly Group 11|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
9517451|NCT03306238|Active Comparator|Open/Hasson|This group will undergo initial laparoscopic port insertion by the open or Hasson approach and then undergo the remaining laparoscopic surgery as usual
9756217|NCT04405908|Placebo Comparator|Elderly Group 12|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
9756218|NCT04405908|Placebo Comparator|Elderly Group 13|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
9756219|NCT04405908|Placebo Comparator|Elderly Group 14|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
9756220|NCT04405908|Placebo Comparator|Elderly Group 15|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
9756221|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 16|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg.
9756222|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 17|SARS-CoV-2 Seropositive subjects receive SCB-2019 9 µg with AS03 adjuvant.
9756223|NCT04405908|Placebo Comparator|SARS-CoV-2 Seropositive Group 18|SARS-CoV-2 Seropositive subjects receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
9756224|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Adult Group 19|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
9756225|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Adult Group 20|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
9756226|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Elderly Group 21|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
9756227|NCT04405908|Placebo Comparator|Adjuvant Dose Modification: Elderly Group 22|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
9756228|NCT04405908|Placebo Comparator|Alum Only Adjuvant Group 23|Subjects receive SCB-2019 9 µg with Alum adjuvant only.
9756229|NCT04405908|Placebo Comparator|Dose Expansion Phase: Adult Group 24|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
9756230|NCT04405908|Placebo Comparator|Dose Expansion Phase: Adult Group 25|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
9756231|NCT04405908|Placebo Comparator|Dose Expansion Phase: Elderly Group 26|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
9756232|NCT04405908|Placebo Comparator|Dose Expansion Phase: Elderly Group 27|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
9756233|NCT04398654|No Intervention|Control Group|Monitoring and therapy adjustment within the scope of the basic care described in the clinical trial plan.
9756234|NCT04398654|Active Comparator|Intervention Group|As in control group. In addition, in the intervention arm the CardioMEMSTM HF sensor implanted.
9756235|NCT04383327|Experimental|ParentCorps-Professional Development (PD)|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
9756236|NCT04383327|Experimental|ParentCorps-Professional Development (PD) + T-Wellness|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
9756237|NCT04383327|No Intervention|Control|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
9756238|NCT04377360|Experimental|Diffusing Alpha-emitter Radiation Therapy (DaRT)|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Tumor response to DaRT will be assessed periodically 3 months after removal.
9756239|NCT04368897||COVID-19 Male Patients|Males with laboratory confirmed SARS-CoV-2 infection
9756240|NCT04364984||ARB group|Hypertensive patients with COVID-19 who received ARBs
9756241|NCT04364984||ACEi group|Hypertensive patients with COVID-19 who received ACEis
9756242|NCT04364984||DRi group|Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)
9756243|NCT04363437|Active Comparator|Colchine|
9756244|NCT04363437|Active Comparator|Usual Care|
9756245|NCT04362839|Experimental|Treatment (regorafenib, nivolumab, ipilimumab)|Patients receive regorafenib PO QD on days 1-21, nivolumab IV over 30 minutes Q2W, and ipilimumab IV over 30 minutes Q6W. Cycles repeat every 28 day for up to 2 years in the absence of disease progression or unacceptable toxicity.
9756246|NCT04338646||Patients enrolled|Patient with multiple sclerosis and lower urinary tract symptoms, age >18 Expanded Disability Status Scale score between 1 and 6.5
9756247|NCT04333459|Active Comparator|Group 1 - Full Dose Hataan|"Group 1 will be vaccinated with the Full Dose of HTNV DNA vaccine, 2 mg of pWRG/HTN-M(co) with 0.5 mg/each deltoid."
9756248|NCT04333459|Active Comparator|Group 2 - Half Dose Hataan|"Group 2 will be vaccinated with the Half Dose of HTNV DNA vaccine, 1 mg of pWRG/HTN-M(co) with 1.0 mg/each deltoid."
9756249|NCT04333459|Active Comparator|Group 3 - Full Dose Puumala|"Group 3 will be vaccinated with the Full Dose of PUUV DNA vaccine, 2 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
9756250|NCT04333459|Active Comparator|Group 4 - Half Dose Puumala|"Group 4 will be vaccinated with the Half Dose of PUUV DNA vaccine, 1 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
9756251|NCT04333368|Experimental|MSC|
9756252|NCT04333368|Placebo Comparator|NaCl|
9756253|NCT04331496|Experimental|Hypertonic solution|Hypertonic solution 4 ml 3% , for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
9756254|NCT04331496|Active Comparator|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
9756255|NCT04304274|Experimental|PTPVB-ropivacaine|Programmed intermittent bolus infusion of a thoracic paravertebral block with ropivacaine and patient-controlled analgesia with morphine
9756256|NCT04304274|Placebo Comparator|PTPVB-saline|Programmed intermittent bolus infusion of a thoracic paravertebral block with saline and patient-controlled analgesia with morphine
9756257|NCT04298853|Active Comparator|Standard|Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.
9756258|NCT04298853|Experimental|Study|Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.
9756259|NCT04292080|Experimental|Group TECFIDERA™|30 patients will receive oral administration of Dimethyl Fumarate (Tecfidera™) 120 mg twice a day for the first week and then 240 mg of Tecfidera twice a day for 51 weeks following approved standard treatment scheme.
9756260|NCT04292080|Other|No comparator|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
9756261|NCT04285658||Ureteroscopy|
9756262|NCT04285658||Percutaneous Nephrolithotomy|
9756263|NCT04285658||Shock Wave Lithotripsy|
9756264|NCT04284488|Experimental|APG-1387 in combination with Toripalimab|
9756265|NCT04283994|Experimental|Survey-based Patient/Clinician Jumpstart|The Survey-based Patient/Clinician Jumpstart Guide will be developed with two types of data: 1) EHR data; and 2) Survey data. Using automated methods and NLP/ML algorithms, the presence/absence of POLST, advance directives and DPOA documentation will be identified from both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. The survey data will be completed by patients or their surrogate/family at enrollment and will provide assessments of the following: a) preferences for discussions about goals of care; b) most important barrier and facilitator for having such discussions; and c) current goals of care. These elements are contained within the Jumpstart guides and the information is tailored to each recipient (i.e., patient, surrogate/family, or clinician).
9756266|NCT04283994|Active Comparator|EHR-based Clinician Jumpstart|The EHR-based Clinician Jumpstart Guide will be developed by using automated methods and NLP/ML algorithms to both inpatient and outpatient EHR notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation. It will not include survey-based information.
9756267|NCT04283994|No Intervention|Usual care|Patients in this arm receive usual care; neither subjects nor providers will receive either version of the Jumpstart Guide.
9756268|NCT04262128||Type 2 Diabetes Mellitus|women age 60-75 years with uncomplicated type 2 diabetes mellitus
9756269|NCT04262128||Healthy Controls|healthy women age 60-75 years
9756270|NCT04257071|Active Comparator|Usual Care|Participants randomized to the usual care study arm will receive the usual care for their MS.
9756271|NCT04257071|Experimental|OOP Cost Communication and Optimization|Participants in this study arm in addition to usual care, will receive a personalized discussion of their OOP cost estimates for treatment obtained through an online price transparency tool, personalized analysis of expenses by financial counselor, and enrollment in any cost optimization opportunities for which they are eligible using a comprehensive financial navigation program.
9756272|NCT04253496||Prospective|
9756273|NCT04253496||Retrospective|
9756274|NCT04251806||Prenatal Repair|This group received prenatal myelomeningocele repair.
9756275|NCT04251806||Postnatal Repair|This group received postnatal myelomeningocele repair.
9756276|NCT04250545|Experimental|Treatment (CB-839 HCl, sapanisertib)|Patients receive glutaminase inhibitor CB-839 hydrochloride PO BID and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9756277|NCT04242602|Other|Study Subjects|
9756278|NCT04239989|Experimental|Treatment (itacitinib)|Patents receive itacitinib PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity.
9756279|NCT04233567|Experimental|Treatment (infigratinib)|Patients receive infigratinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9756280|NCT04228978|Experimental|Weight loss + exercise (WL+EX)|Weight loss + home based walking exercise (WL+EX)
9756281|NCT04228978|Active Comparator|Exercise alone (EX)|Home based walking exercise (EX)
9756282|NCT04224740|Experimental|Pembrolizumab plus standard of care chemotherapy|"-Pembrolizumab combined with standard of care therapy~Standard of care therapy: ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles"
9756283|NCT04220684|Experimental|Conditioning Regimen|Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2g/ m2/day (days -6 to day -2)
9756284|NCT04220684|Experimental|Induction|Six doses of third-party-donor mbIL-21 expanded (KDS-1001) cells given thrice weekly for two weeks. Days may vary and KDS-1001 can be given from days 0 to 21
9756285|NCT04188990|Active Comparator|Intervention arm|"The Intervention arm includes an intervention in the groups of patients who, after screening, are identified as having disease-related malnutrition (DRM) or at risk of DRM, and a follow-up of the rest of the patients"
9756286|NCT04188990|Placebo Comparator|By demand arm|"The By demand arm will include patients in whom the nutritional intervention, if given, is performed by demand by the medical staff responsible for each patient."
9756287|NCT04188990|Placebo Comparator|Usual care arm|"In the Usual care arm usual hospital practice is followed without any explicit nutritional intervention"
9756288|NCT04179929|Other|CHEMOTHERAPY|Pediatric-type of chemotherapy
9756289|NCT04179929|Other|allogeneic HSCT|allogeneic HSCT
9756290|NCT04168528|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|Phase I
9756291|NCT04168528|Experimental|Part II: tumor targeting potential and correlation to ICH|Phase II
9756292|NCT04164173|Experimental|EzPAP|The patient will have EzPAP postoperative respiratory therapy as 3 x 10 breaths at a 1:4 ratio four times daily
9756293|NCT04164173|Experimental|Metaneb|The patient will have Metaneb postoperative respiratory therapy as 10 minutes Continuous Positive End Expiratory Pressure (CPEP) four times daily
9756294|NCT04164173|Experimental|Intermittent Positive Pressure Breathing (IPPB)|The patient will have Intermittent positive pressure breathing (IPPB) postoperatively for 10 minutes four times daily
9756295|NCT04159974|Experimental|Durvalumab|Treatment arm A will receive durvalumab IV in a dosage of 1500mg every four weeks for 12 months as mono therapy.
9756296|NCT04159974|Experimental|Durvalumab + Tremelimumab|Treatment arm B receives durvalumab in a dosage of 1500mg every 4 weeks (-3/+7 days) for 12 months post-surgery. In addition these patients receive tremelimumab IV in a fixed dose of 75mg for the first four months on day 1; 29; 57; 85 (-3/+7).
9756297|NCT04157725|Experimental|Group A (mild stimulation protocol)|
9756298|NCT04157725|Active Comparator|Group B (conventional stimulation protocol)|
9756299|NCT04148144||Adolescents with low back pain|Adolescents aged 8-19 with low back pain.
9756300|NCT04148144||Parents of included adolescents|Parents recruited for the parallel cohort, are required to be a parent or a legal guardian of the included adolescent. Siblings, grandparents or a similar person are not eligible for inclusion in the parallel cohort.
9756301|NCT04142502|Active Comparator|Propofol group|Using propofol as a sedation drug Infusion rate control Effect site concentration 0.3~1.0 mg/ml using target concentration infusion Bispectral index 60~80
9756302|NCT04142502|Active Comparator|Dexmedetomidine group|Using dexmedetomidine as a sedation drug First 10 minutes 1.0 mcg/kg loading After 10 minutes 0.3-1.0 mcg/kg/hr maintenance Bispectral index 60~80
9756303|NCT04122053|Experimental|study group|group will receive dietary advice and genotype information
9756304|NCT04122053|Active Comparator|Control group|group will receive dietary advice
9756305|NCT04118166|Experimental|Ipilimumab/nivolumab+ cryotherapy|1 mg/kg with nivolumab 3 mg/kg every 3 weeks x 4 doses. (One cycle of treatment is 3 weeks). Cryotherapy (cryoablation) will be performed between investigational agent treatment Cycles 1 and 2
9756306|NCT04117581|Active Comparator|Vitamin D3 supplement|Participant will be asked to take one capsule of vitamin D3 supplement (5000 IU) (125 μg) daily for a total duration of 12 weeks.
9756307|NCT04117581|Placebo Comparator|Placebo|Participants will be asked to take one capsule of placebo (inert filler) daily for a total duration of 12 weeks.
9756308|NCT04117425|Other|Pregnant women|"40 Pregnant women and 10 Pregnant women that have a medical interruption of pregnancy who were already treated by levetiracetam.~Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption"
9756309|NCT04113616|Experimental|Part A - Arm 1|"KRT-232+LDAC:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle."
9756310|NCT04113616|Experimental|Part A - Arm 2|"KRT-232(7-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
9756311|NCT04113616|Experimental|Part A - Arm 3|"KRT-232(14-Day)+Decitabine:~KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle."
9756312|NCT04113616|Experimental|Part B - Arm 1|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle
9756313|NCT04113616|Experimental|Part B - Arm 2|KRT-232 administered at 360 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day treatment cycle in Cycle 1, followed by 240 mg orally, once daily (QD) on Days 1-7 with 21 days off on a 28-day cycle, in the subsequent cycles.
9756314|NCT04113616|Experimental|Part B - Arm 3|KRT-232 administered at 180 mg orally, once daily (QD) on Days 1-7 with 14 days off on a 21-day treatment cycle.
9756315|NCT04109027|Experimental|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
9756316|NCT04109027|Active Comparator|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
9756317|NCT04101955|Other|Incisionless Threaded Carpal Tunnel|
9756318|NCT04101955|Other|Standard Mini-Open Carpal Tunnel|
9756319|NCT04095871||Patients included|"Patients over 18 years old performed CISC for more than 1 month, exclusive or not, are included.~At home, patients have to complete one diary on the specific duration of a 24-hour CISC and the next day a second diary on the total duration of CISC.~The specific time of CISC described by the timed duration from the moment when the circumstances of care are combined to carry it out : isolated place, nearby equipment.~The total time of CISC described by the timed duration from the moment of the intention to self-catheter until the return to the initial activity."
9756320|NCT04095520|Active Comparator|Paste Type Traditional Composite-GC G Aenial Anterior|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with microhybrid composite
9756321|NCT04095520|Experimental|Injectable Composite- GC G Aenial Universal Injectable|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with injectable form composite
9756322|NCT04089579|Experimental|MSC|One dose of 6x10e6 cells/kg administered intravenously.
9756323|NCT04089579|Placebo Comparator|Placebo Infusion|Placebo infusion
9756324|NCT04072354|Experimental|SEP-363856 50mg|SEP-363856 50mg dosed once daily
9756325|NCT04072354|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
9756326|NCT04072354|Placebo Comparator|Placebo|Placebo dosed once daily
9756327|NCT04066725|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 60 days
9756328|NCT04066725|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 60 days.
9756329|NCT04066725|Placebo Comparator|Placebo|Participants will be given a placebo orally once daily for a total of 60 days.
9756330|NCT04066504||Sonidegib|Patients with laBCC undergoing sonidegib treatment in routine clinical practice
9756331|NCT04062032|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 7 days
9756332|NCT04062032|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 7 days.
9756333|NCT04058561|Experimental|6 weeks|6-week lengthening interval
9756334|NCT04058561|Active Comparator|16 weeks|16-week lengthening interval
9756335|NCT04055844|Experimental|Decitabine + Ruxolitinib + DLI|Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
9756336|NCT04052698|Experimental|All patients|Patients with type 3, type 2 (except 2N), or severe type 1 VWD aged ≥6 years at screening receiving Wilate for prophylactic treatment.
9756337|NCT04047693|Experimental|ddMVAC|4 cycles of neoadjuvant chemotherapy using dose dense MVAC with G-CSF
9756338|NCT04036396|Active Comparator|Standard of Care|A client-centered assessment of priorities and needs and customized prevention and testing referrals.
9756339|NCT04036396|Experimental|Mobile Enhanced Prevention Support|Standard of Care in addition to a client-centered assessment of priorities and needs and customized prevention and testing referrals, and the Mobile Enhanced Prevention Support Program
9756340|NCT04033991||Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic)
9756341|NCT04027361|Active Comparator|Amphetamine ER Tablets, 20 mg|Double-blind amphetamine extended-release tablets, 20 mg dose, single tablet, administered at baseline
9756342|NCT04027361|Placebo Comparator|Placebo|Matching double-blind placebo tablets, 20 mg dose, single tablet, administered at baseline
9756343|NCT04024267|Experimental|Eurythmy therapy (ERYT)|"Eurythmy therapy (ERYT) is a standardized movement therapy and for each medical condition standardized ERYT exercise (series) exist. In such, in the present study, the cancer series O-E-M-L-I-B-D that is specific and standardized for breast cancer patients will be applied. Patients can perform and maintain the postures without stress and tension. Patients are instructed by ERYT therapists in sessions with 1 to 4 patients."
9756344|NCT04024267|Active Comparator|CoordiFit|The CoordiFit program consists of standardized exercises that address physical coordination, stability, balance and dexterity. These exercises serve as a control intervention and are non-specific with respect of cancer-related fatigue and breast cancer. They mimic those of ERYT but have no mindfulness features. Patients are instructed by physical therapists in session with 1 to 4 patients.
9756345|NCT04024085||Participants|adult with a multiple sclerosis diagnosis, able to walk 50 meters without human help, Expanded Disability Status Scale (EDSS) < 7, consulting in a neuro-urology department
9756346|NCT04022187||Bulbocavernosus reflex assessment|Patients over 18 years old, consulting in neuro-urology department for urinary, anorectal or genito-sexual disorders.
9756347|NCT04008758|Experimental|sono group|Evaluate the participant's lung condition using ultrasound and do recruitment maneuver if it is necessary
9756348|NCT04008758|No Intervention|control group|If participants need recruitment maneuver (decreasing saturation, peak airway pressure > 35 mmHg) by clinical judgement, do recruitment maneuver not using lung ultrasound
9756349|NCT03991091|Experimental|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm
9756350|NCT03991091|Active Comparator|continuation of oxytocin administration|Standard care in France, i.e. when oxytocin is started during the latent phase of the 1st stage, administration of oxytocin is continued during the active 1st stage and during the 2nd stage if the fetal heart rate is reassuring.
9756351|NCT03983291|Experimental|FaReWell Depression|Physiotherapeutic exercises for the relaxation of facial muscles associated with the expression of negative emotions and for the activation and strengthening of facial muscles associated with the expression of positive emotions 15 minutes daily
9756352|NCT03983291|Placebo Comparator|Resting exercise|Resting 15 minutes daily
9756353|NCT03981380||MESA study participants|Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study
9984054|NCT04458753|Experimental|Lumbar focused + knee focused exercise group|Will receive strengthening of back , abdominal, and quadriceps muscles, and stretching if calf and Hamstring muscles
9831593|NCT03868787|Sham Comparator|Sham TENS|The sham TENS will be the same unit without the true TENS electrical connections. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes
9831594|NCT03866655|Experimental|Intervention|
9831595|NCT03866655|No Intervention|Control|
9831596|NCT03838146|No Intervention|Non-Exercise Control|This group will come in regularly for measurements, but will not have an exercise intervention. If necessary for retention of participants, then we will meet with controls 3 times a week to stress reduction techniques.
9831597|NCT03838146|Experimental|Resistance Type of Exercise|This group will participate in resistance exercise intervention 3 times per week from enrollment to delivery.The resistance training (RT) group will perform three sets of 12-15 repetitions of 10-12 resistance exercises in a circuit, with rest of 30-60 seconds between sets as needed. Participants will use a combination of Cybex machines (Cybex International, Medway, MA), resistance bands, and free weights. Routines will change every 3 weeks to add variety and improve compliance.
9831598|NCT03838146|Experimental|Combination Type of Exercise|This group will participate in combination (aerobic+resistance) exercise intervention 3 times per week from enrollment to delivery. The combination (CT) group will alternate between resistance and aerobic exercises. Participants will perform 4.5 minute bouts of aerobic exercise and perform four resistance exercises of 12-15 repetition that vary between aerobic bouts[17-19]. The aerobic exercise bouts will be performed on the aerobic machine of the participant's choosing as described above. The resistance routine will follow similar guidelines as the resistance group.
9831599|NCT03838146|Experimental|Aerobic Type of Exercise|This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
9831600|NCT03832439|Active Comparator|Probiotic|This arm will be receiving probiotic supplements.
9831601|NCT03832439|Placebo Comparator|Placebo|This arm will be receiving placebo containing microcrystalline cellulose.
9831602|NCT03830320|Active Comparator|Healthy Volunteers|Twenty (20) healthy adult subjects will be injected with [64Cu]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
9831603|NCT03830320|Experimental|Atrial Fibrillation Patients|Thirty-five (35) patients with LAA thrombus documented by TEE will be injected with [64Cu]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care. Thirty-five (35) patients with atrial fibrillation and negative TEE will be injected with [64Cu]FBP8 and imaged for LAA thrombus. Forty (40) patients with atrial fibrillation who are scheduled for TEE in the upcoming 14 days will be injected with [64Cu]FBP8 and imaged for LAA thrombus.
9756354|NCT03973229|Experimental|Cohort 1: PTSD Receiving Estradiol then Placebo|Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
9756355|NCT03973229|Experimental|Cohort 1: PTSD Receiving Placebo then Estradiol|Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
9756356|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Estradiol then Placebo|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
9756357|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Placebo then Estradiol|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
9756358|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
9756359|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
9756360|NCT03973229|Experimental|Cohort 2: PTSD Receiving Estradiol then Placebo|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
9756361|NCT03973229|Experimental|Cohort 2: PTSD Receiving Placebo then Estradiol|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
9756362|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Estradiol, then Placebo|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
9756363|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Placebo then Estradiol|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
9756364|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
9756365|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
9756366|NCT03956277||Observational PUG|Patients receive gastrostomy via percutaneous ultrasound gastrostomy.
9756367|NCT03947151|Other|one arm|one arm
9756368|NCT03934840|Experimental|Carboplatin, Cabazitaxel and Abiraterone|
10202177|NCT05011201|Experimental|Experimental Group|Participants will undergo a single testing session of gait retraining using two variants of the dual joint visual feedback system (DJVF). The DJVF system uses IMU sensors to measure knee and hip joint motions and calculates the users foot position, relative to their pelvis. The relative foot position is represented in real time on a screen in front of the user with feedback designed to elicit increases in anteriorly located foot positions.
9831604|NCT03830320|Experimental|COVID-19 Patients|Thirty (30) COVID-19 patients will be injected with [64Cu]FBP8 and imaged for thrombi in the body.
9831605|NCT03830320|Experimental|Cancer Patients|Thirty (30) cancer patients will be injected with [64Cu]FBP8 and imaged for thrombi in the body.
9831606|NCT03830320|Experimental|Other Thrombotic Condition Patients|Fifty (50) patients with other thrombotic conditions will be injected with [64Cu]FBP8 and imaged for thrombi in the body.
9831607|NCT03816995|Active Comparator|Alexis O Wound Protector|Participants will undergo standard surgical procedure using the Alexis O wound protector.
9831608|NCT03816995|Experimental|CleanCision Wound Protector|Participants will undergo standard surgical procedure using the CleanCision Wound Retraction and Protection System
9831609|NCT03808558|Experimental|TVB-2640|Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
9831610|NCT03808402||High dose surfactant|Infants who receive a first dose of surfactant between 170 and 200 mg/kg
9831611|NCT03808402||Low dose surfactant|Infants who receive a first dose of surfactant between 100 and 130 mg/kg
9831612|NCT03807440||Subjects with Diabetes Mellitus, Type 2|
9831613|NCT03801369|Experimental|Treatment (Olaparib and Durvalumab)|Patients with biopsy proven TNBC will undergo a pre-treatment biopsy, after which they will receive a 28 days induction treatment of olaparib (oral, twice a day). At the 2 week mark, patients will then undergo a repeat on-treatment biopsy. Beginning cycle 2, durvalumab will be administered (IV over 1 hr) every 4 weeks, in addition to olaparib. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, may continue on therapy beyond the planned 13 cycles.
9831614|NCT03791060|Experimental|Secukinumab Subcutaneous Injection|"300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks.~Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks."
9831615|NCT03787680|Experimental|Cohort 1 (DRPro)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
9831616|NCT03787680|Experimental|Cohort 2 (DRDef)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).
9831617|NCT03782506|Experimental|Interactive Music Therapy|Ten 45-minute individual interactive music therapy sessions.
9831618|NCT03782506|Active Comparator|Verbal-based Support|Ten 45-minute individual verbal support sessions.
9831619|NCT03778060|Experimental|Transcutaneous stimulation|Participants in the clinical study will consist of subjects with essential tremor who are scheduled more than 3 months in advance to undergo deep brain stimulation surgery for treatment of essential tremor at Mayo Clinic. Subjects will wear a Cala TWO stimulator to reduce hand tremors.
9831620|NCT03777436|Experimental|Arm A- Apremilast with Placebo|Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
9831621|NCT03777436|Experimental|Arm B - Apremilast 30 mg|All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study
9831622|NCT03776253|Experimental|Supportive care (CFS)|"Patients attend CFS psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. Patients also complete home practice assignments comprising attention training technique and mindfulness practice after each session.~Patients complete self-report questionnaires at baseline (T1), 8 weeks (T2) and 12 weeks (T3)."
9835900|NCT02760407|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg subcutaneous q4w +placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
9835901|NCT02760407|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
10202178|NCT05009628|Experimental|automated oxygenation with a sitting patient position in the ICU|
10202179|NCT05009628|No Intervention|controlled oxygenation with a lying patient position in the ICU|
10202180|NCT05009628|Experimental|automated oxygenation with the patient lying down in the ICU|
10202181|NCT05009628|Experimental|control oxygenation with the patient in a sitting position in the ICU|
10202182|NCT05008276||Youth with obesity and elevated HbA1c|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
10202183|NCT05008276||Healthy normal-weight controls|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
10202184|NCT05005312|Experimental|Cohort 1|Healthy Volunteer
10202185|NCT05005312|Experimental|Cohort 2|Hepatic Impairment
10202186|NCT05002062|Sham Comparator|G1 ( Conventional Physical Therapy Program group)|"Patients in G1 underwent conventional physical therapy program continued for 3 months, included (aerobic training 20 minutes, resistive training for 15 minutes and flexibility program for 15 minutes).~The whole treatment session lasted from 50 minutes to one hour, 3 times per week for 3 consecutive months."
9831623|NCT03761914|Experimental|Colorectal Cancer (CRC)|"N=20;~Metastatic CRC priorly Rxed with ≥2 lines of ChemoRx (3rd/4th line); must have documented disease progression post last administration of or intolerance to standard therapies, which must have included a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS wild-type, cetuximab or panitumumab. Prior regorafenib or trifluridine/tipiracil is allowed, but not mandated;~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
9831624|NCT03761914|Experimental|Ovarian Cancer (OvC)|"N=20;~Metastatic OvC priorly Rxed with ≥1 line of platinum-containing ChemoRx (2nd/3rd line) with either relapse or disease refractoriness; interval surgery permitted, as long as subjects have measurable disease by imaging and concomitant CA-125 increase, and/or biopsy showing OvC; must have either received (or been offered) bevacizumab therapy; those with BRCA germline mutations (gBRCA mut) must have been offered therapy with poly-ADP ribose polymerase (PARP) inhibitors.~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
9831625|NCT03761914|Experimental|Small Cell Lung Cancer (SCLC)|"N=20;~Advanced SCLC priorly Rxed with 1 line of ChemoRx (2nd line); must have measurable disease by imaging after they progressed or were resistant to 1 prior systemic therapy; asymptomatic or treated brain metastases are allowed;~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
9831626|NCT03761914|Experimental|Triple Negative Breast Cancer (TNBC)|"N=15;~TNBC priorly Rxed with 1 line of ChemoRx with residual or recurrent disease (2nd line); estrogen (ER) and progesterone receptor (PgR) negative, and HER2(-) by IHC AND HER2 non-amplified by fluorescence in situ hybridization; weak IHC positivity for ER or PgR (i.e., < 5%) eligible; must have undergone 2nd line therapy after 1st line Rx could include: neoadjuvant Rx if macroscopic disease still present after surgery OR adjuvant Rx but only if relapse occurred > 6 months from the start of pembrolizumab (P);~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
9835902|NCT02760407|Active Comparator|Arm 3: Adalimumab q2w|"Adalimumab 40mg q2w subcutaneous + Methotrexate~Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
9835903|NCT02760407|Placebo Comparator|Arm 4: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
9984055|NCT04458753|Active Comparator|Knee focused exercise group|Will receive strengthening of quadriceps and stretching of calf and Hamstring muscles
9831627|NCT03761914|Experimental|Acute Myelogenous Leukemia (AML)|"N=15;~Pts with AML who are not eligible for allogeneic stem cell transplant and have been able to achieve morphological partial remission (PR) as their best ever response at the time of completion of their 4th cycle of upfront Rx with HMA; prior initial upfront hydroxyurea or leukapheresis Rx or history of induction early failure after up to 2 cycles of ChemoRx (7+3 or similar regimen) with seamless immediate transitioning to HMA Rx eligible; must remain on HMA therapy throughout the trial.~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
9831628|NCT03759288|Experimental|(Stage 1) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
9831629|NCT03759288|Experimental|(Stage 1) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
9831630|NCT03759288|Placebo Comparator|(Stage 1) Placebo|Intravenous placebo on Days 1, 29, and 57, followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
9831631|NCT03759288|Experimental|(Stage 2) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
9831632|NCT03759288|Experimental|(Stage 2) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous on Day 85 and every 4 weeks through Week 48
9831633|NCT03759288|Active Comparator|(Stage 2) Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50
9831634|NCT03753919|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks up to 4 cycles followed by durvalumab 1500 mg every 4 weeks until disease progression, unacceptable toxicity or patients' decision.
9831635|NCT03740256|Experimental|Treatment Phase|"Seven dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.T cells 3 days later (Day 4), according to the following dose levels.~Dose Level 1 CAdVEC = 5.00E+9 HER2 specific CAR-T cells = 0~Dose Level 2 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 0~Dose Level 3 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 1.00E+06~Dose Level 4 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+06~Dose Level 5 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+07~Dose Level 6 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+07~Dose Level 7 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+08"
9831636|NCT03688074|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
9831637|NCT03688074|Placebo Comparator|Placebo|Placebo subcutaneous injection
9831638|NCT03686007|Experimental|Group I (MSM intervention)|Patients and FCGs receive the MSM intervention consisting of videos, a handbook, and research nurse coaching over 40-60 minutes, approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive research nurse support via telephone(separate sessions for FCGs and patients) over 20-30 minutes at 2 and 7 days, and 2 months post-discharge.
9517452|NCT03306238|Active Comparator|Closed/ Veress|This group will undergo initial laparoscopic port insertion by the closed or Veress approach and then undergo the remaining laparoscopic surgery as usual
9517453|NCT03306212|Experimental|Casting Group|Patients treated by botulinum toxin A and occupational therapy and intermittent serial casting
9517454|NCT03306212|Active Comparator|Control Group|Patients treated by botulinum toxin A and occupational therapy
9517455|NCT03306186|Experimental|HemoSpec|Diagnosis of sepsis using HemoSpec device
9756369|NCT03930849|Experimental|AIMS Intervention|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol.
9756370|NCT03930849|No Intervention|No Intervention|Participants randomized to the no intervention arm will not be enrolled in the Annie text messaging program.
9756371|NCT03930849|Experimental|AIMS Intervention Plus|Participants randomized to the AIMS Intervention Plus arm will be enrolled in VA's Annie text messaging program/study protocol and receive a weekly phone call.
9756372|NCT03930732|Experimental|Dupilumab|Dupilumab administered every 2 weeks
9756373|NCT03930732|Placebo Comparator|Placebo|Placebo dose administered every 2 weeks
9756374|NCT03896659|Experimental|Depressed: Hydrocortisone, then Placebo|"Participants in the depressed' arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
9756375|NCT03896659|Experimental|Depressed: Placebo, then Hydrocortisone|"Participants in the depressed' arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
9756376|NCT03896659|Experimental|Healthy Controls: Hydrocortisone, then Placebo|"Participants in the healthy control arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
9756377|NCT03896659|Experimental|Healthy Controls: Placebo, then Hydrocortisone|"Participants in the healthy control arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
9756378|NCT03891875|Experimental|Elamipretide|40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
9756379|NCT03891875|Placebo Comparator|Placebo|subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
9756380|NCT03879629|Experimental|Pre-Emptive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated one week before start of therapy and continued until end of therapy
9756381|NCT03879629|Experimental|Reactive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of subclinical cardiotoxicity, defined by an abnormal global longitudinal strain (GLS) or high-sensitive cardiac troponin (hsTnI) elevation and continued until end of therapy
9756382|NCT03879629|Active Comparator|Standard of Care|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of a drop in LVEF by >10% to a value less than 53% and continued until end of therapy
9984056|NCT04458441|Active Comparator|warm skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be heated sterile to 38 degrees with a ben-mari method and its temperature will be controlled by degrees. When it reaches the appropriate degree, the skin cleaning of the baby will be done sterile.
9756384|NCT03868423|Experimental|Treatment (brigatinib)|Patients receive brigatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9756385|NCT03860740||High intensity physical exercise|Supervised Exercise Group: Customized and supervised exercise high intensity training program during 2-3 weeks previous surgery.
9756386|NCT03860740||Control|Supervised Stretching Group: a stretching and body balance classes will be developed to control the possible confounders and to control the exercise level of participants.
9756387|NCT03843580|No Intervention|Standard Allocation|apnea without oxygenation like usual traitement
9756388|NCT03843580|Experimental|oxygenation optiflow|optiflow oxygenation during apnea
9756389|NCT03843125|Experimental|Baricitinib High Dose|Baricitinib administered orally.
9756390|NCT03843125|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
9756391|NCT03830151|Experimental|Diagnostic (carbon C 13 pyruvate, MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
9756392|NCT03820479||Apfel score 1|Female
9756393|NCT03820479||Apfel score 2|Female, non smoker
9756394|NCT03820479||Apfel score 3|Female, non smoker, under 40 years old
9756395|NCT03820479||Apfel score 4|Female, non smoker, under 40 years old, previous history of PONV
9756396|NCT03793439|Experimental|Open-label treatment|All subjects will receive tofacitinib 5mg twice daily from week 0 to week 16, and a corticosteroid taper starting at week 16. Participants also undergo spirometry, RNA sequence testing, and laboratory evaluations.
9756397|NCT03782402|Experimental|Cannabinoids of varied strength|Strengths of cannabinoids will vary across groups
9756398|NCT03782402|Active Comparator|Cannabinoids of various strengths|Strengths of cannabinoids will vary across groups
9783032|NCT01191723|Other|Treatment A, then Treatment B, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
9783033|NCT01191723|Other|Treatment A, then Treatment C, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
9783034|NCT01191723|Other|Treatment B, then Treatment A, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
9984057|NCT04458441|No Intervention|cold skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be used in the skin cleaning of the baby without any heating procedure.
9756399|NCT03755518|Experimental|Administration of Fedratinib 400mg/day|Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
9756400|NCT03755518|Experimental|Administration of Luspatercept 1.33 mg/kg|Administered as a subcutaneous injection concomitantly with Fedratinib at 3-week (21 day) cycles
9756401|NCT03745079||Group 1|"Participants' temperature measured at 3 places at the same time~Esophagus~Skin near to temporal artery~Skin near to carotid artery"
9756402|NCT03732118||Minimal hepatic encephalopathy|
9756403|NCT03732118||No hepatic encephalopathy (minimal or clinical)|
9756404|NCT03729401|Active Comparator|DAPT - Aspirin and Ticagrelor|As per results of the PEGASUS trial, patients will be treated with aspirin 81mg daily and ticagrelor 60mg twice daily
9756405|NCT03729401|Experimental|Ticagrelor Monotherapy|Patients will only receive ticagrelor 60mg twice daily.
9756406|NCT03729401|Experimental|Personalized Therapy Arm|Patients allocated to the personalized arm (PA) will have a DAPT score calculated. For those with a score of < 2, only aspirin at 81 mg daily will be prescribed. For those with a score of ≥ 2, P2Y12 inhibitor choice will be dependent on carrier status of CYP2C19 LOF alleles. Heterozygous or homozygous carriers will receive be prescribed ticagrelor 60mg twice daily and non-carriers with will be prescribed clopidogrel 75mg daily.
9756407|NCT03725436|Experimental|Treatment (paclitaxel, ALRN-6924)|Patients receive paclitaxel IV over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9756408|NCT03722966|Experimental|Varenicline/Counseling + Med Reminders|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and automated medication reminders via their smartphones.
9756409|NCT03722966|Experimental|Varenicline/Counseling|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and no automated medication reminders.
9756410|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and no automated medication reminders.
9756411|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT + Med Reminders|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and automated medication reminders via their smartphones.
9756412|NCT03719976|Experimental|Healthcare navigation workshops|All enrolled caregivers and parents will partake in the group-based educational intervention.
9756413|NCT03711266|Experimental|PE-PC|Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.
9756414|NCT03708354|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
9756415|NCT03708354|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
9756416|NCT03701334|Experimental|Ribociclib + Endocrine Therapy|"ribociclib 400 mg once daily on days 1-21 of a 28 day cycle followed by 7 days off and endocrine therapy (ET) once daily continuously"
9756417|NCT03701334|Active Comparator|Endocrine Therapy|endocrine therapy (ET) only once daily continuously
9756418|NCT03700190||Control|Healthy child
9756419|NCT03700190||Experimental|Patients with Autism Spectrum Disorder
9756420|NCT03696303||Cases|Suspected community-acquired bacterial pneumonia
9756421|NCT03696303||Controls|Healthy children, age-matched to enrolled cases
9756422|NCT03696303||Controls with URI|Children 5 years of age or younger with upper respiratory infection (URI) (controls with URI)
9756423|NCT03678493|Experimental|AML Patients undergoing Intensive Chemothera|
9756424|NCT03678493|Placebo Comparator|AML Patients undergoing Intensive Chemotherapy Control|
9756425|NCT03678493|Experimental|AML Patients undergoing Allo-HCT Patients|
9756426|NCT03678493|Placebo Comparator|AML Patients undergoing Allo-HCT Patients Control|
9756427|NCT03656536|Experimental|Pemigatinib|
9756428|NCT03656536|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
9756429|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
9756430|NCT03630393|Experimental|Pressure 6 mmHg|Pneumoperitoneum Pressure 6 mmHg
9756431|NCT03630393|Active Comparator|Pressure 15 mmHg|Pneumoperitoneum Pressure 15 mmHg
9756432|NCT03573466|Experimental|Amyotrophic Lateral Sclerosis|
9756433|NCT03571191|Experimental|1|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
9756434|NCT03559075||Group 1|Participants will be randomized into group 1 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756435|NCT03559075||Group 2|Participants will be randomized into group 2 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756436|NCT03559075||Group 3|Participants will be randomized into group 3 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756437|NCT03559075||Group 4|Participants will be randomized into group 4 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756438|NCT03559075||Group 5|Participants will be randomized into group 5 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756439|NCT03559075||Group 6|Participants will be randomized into group 6 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756440|NCT03559075||Group 7|Participants will be randomized into group 7 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756441|NCT03559075||Group 8|Participants will be randomized into group 8 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
9756442|NCT03531788|Experimental|Armon Ayura (Kinova)|Participants will trial the Armon Ayura dynamic arm support.
9756443|NCT03531788|Experimental|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
9756444|NCT03527472|Experimental|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
9756445|NCT03527472|Placebo Comparator|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
9756446|NCT03498066|Experimental|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
9756447|NCT03498066|Active Comparator|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
9756448|NCT03497975|Active Comparator|Active|162 mg nalbuphine ER tablets, BID
9756449|NCT03497975|Placebo Comparator|Placebo|Matching placebo tablets
9756450|NCT03480971|Active Comparator|Active 1000 mg Tempol Solution|Patients will take 1000 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
9756451|NCT03480971|Placebo Comparator|Placebo Solution|Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)
9756452|NCT03475251|Experimental|CS1003|
9756453|NCT03475251|Experimental|CS1003 + regorafenib|
9756454|NCT03445130|Active Comparator|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
9756455|NCT03445130|Active Comparator|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
9756456|NCT03445130|Active Comparator|Almond oil (AO)|2 Drops in Oxygen Mask
9756457|NCT03445130|Active Comparator|Water|2 Drops in Oxygen Mask
9756458|NCT03433833|Experimental|Intervention|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.5-0.9 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
9831639|NCT03686007|Active Comparator|Group II (Attention Control)|"Patients and FCGs receive attention control intervention consisting of videos (American Cancer Society video on Clinical Trials), American Cancer Society print materials, and assistance from a CRA approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive assistance from CRAs via telephone at 2 and 7 days, and 2 months post-discharge."
9831640|NCT03683992||cemented and cementless Triathlon group|cemented group are patients who get randomized to receive cemented knee implant and Patient randomized to receiving cement less knee implant.
9831641|NCT03675672|Active Comparator|Group 1|Misoprostol Oral tablet, 200mcg, QID
9831642|NCT03675672|Placebo Comparator|Group 2|Placebo Oral Tablet, 1 tab, QID
9831643|NCT03664830|Experimental|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
9831644|NCT03654898|Active Comparator|VITAL Start|VITAL Start: Video-based pre-ART counseling
9984058|NCT04454671|Experimental|ultrasound-guided percutaneous neuromodulation|Technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor point. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
9984059|NCT04454671|Placebo Comparator|Ultrasound-guided dry needling|Dry needling technique applied by ultrasound-guided but without electrical stimulation of a peripheral nerve.
9831645|NCT03654898|Placebo Comparator|Standard of Care|pre-ART education as conducted via routine facility methods
9831646|NCT03639948|Experimental|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve [AUC] 6 intravenously [IV]) and Docetaxel (75 milligrams per meter squared [mg/m2], IV) plus Pembrolizumab (200 milligrams [mg], IV) every 21 days for 6 cycles.~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
9831647|NCT03637816|Experimental|Arm I (anamorelin hydrochloride)|Patients receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
9831648|NCT03637816|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
9831649|NCT03626883|Experimental|1 hamstring|Patients will receive the intervention of 'single-bundle, single-hamstring ACL reconstruction'.
9831650|NCT03626883|Active Comparator|2 hamstrings|Patients will receive the intervention of 'single-bundle, double-hamstring ACL reconstruction'.
10202187|NCT05002062|Active Comparator|G2 ( Computer-based Cognitive Therapy group)|"Patients in G2 underwent Computer-based cognitive training continued for 3 months, included (attention/concentration, memory and reaction behavior training).~The whole treatment session timing lasted 50 minutes to one hour, 3 times per week for 3 consecutive months."
10202188|NCT04998318|Active Comparator|Standard of Care|"Visual Inspection with Acetic Acid (VIA): First, the cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied to the cervix using a spray bottle or fox swab. After approximately 1-minute, any changes to the cervix using the naked eye will be noted. Acetic acid may be reapplied if acetowhitening diminishes during visual inspection.~Visual Inspection with Lugol's Iodine (VILI): After imaging with Acetic acid, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Lesion location(s) will be noted on a clock-face diagram and used to direct biopsy if a lesion is present or random biopsies will be obtained from two quadrants in the absence of a visible lesion."
9831653|NCT03619707|Experimental|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
9831654|NCT03619707|Experimental|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
9831655|NCT03586999|Experimental|Nivolumab and EPOCH|Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.
9831656|NCT03580031|Experimental|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
9831657|NCT03580031|Placebo Comparator|Control group|Saline 2m Injection im 48 hours after the first triggering dose
9831658|NCT03572153|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
9984060|NCT04454203|Experimental|Mepivacaine Block Group|Infiltration of local anesthetic (mepivacaine) above and beside the femoral artery through a perineural catheter.
9984061|NCT04454203|Placebo Comparator|Saline Sham Group|Infiltration of salt water (saline) above and beside the femoral artery through a perineural catheter.
10202189|NCT04998318|Experimental|Pocket Colposcope|"Pocket-Assisted Visual Inspection with Acetic Acid (PA-VIA): The cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied using a spray bottle or fox swab. After approximately 1-minute, using the Pocket Colposcope any changes to the cervix will be noted. Using the Calla Health image acquisition software, both white and green images of the cervix will be captured at low-resolution. High-resolution green light images will be obtained at the provider's discretion. Acetic acid may be reapplied between white and green imaging at the provider's discretion if acetowhitening diminishes.~Pocket-Assisted Visual Inspection with Lugol's Iodine (PA-VILI): After imaging with AA, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Images will be acquired. A biopsy will be obtained using the pocket. Random biopsies will be obtained from 2 quadrants in the absence of a visible lesion."
10202190|NCT04995224||Study 1A|Prospective cohort study with 150 newly diagnosed patients with inflammatory bowel disease
10202191|NCT04995224||Study 1B|Prospective cohort study with 450 newly diagnosed patients with IBD
10202192|NCT04995224||Study 2|Cross-sectional study with 10,000 patients in IBD Boost study
9756459|NCT03390140|Experimental|Group|ReInventing Yourself after SCI structured group CBT and ReInventing Yourself after SCI study-specific workbook
9756460|NCT03390140|Active Comparator|Indiv|ReInventing Yourself after SCI study-specific workbook and ReInventing Yourself after SCI YouTube videos
9756461|NCT03390140|No Intervention|Control|No group sessions, no YouTube videos, no workbook
9756462|NCT03376646|Experimental|Cohort A: Dissolve™|
9756463|NCT03376646|Active Comparator|Cohort A: Resolute™ Integrity|
9756464|NCT03376646|Experimental|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
9756465|NCT03375307|Experimental|Cohort I (olaparib)|Patients that have cancer-associated DNA-repair gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9756466|NCT03375307|Experimental|Cohort II (biospecimen collection)|Patients that do not have cancer-associated DNA-repair gene mutations undergo blood sample collection at baseline.
9756467|NCT03373695|Experimental|Dissolve™|
9756468|NCT03373695|Active Comparator|SeQuent®Please|
9756469|NCT03366051|Active Comparator|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
9756470|NCT03366051|Experimental|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
9756471|NCT03359811|Experimental|Standard-of-Care Thoracic Epidural Analgesia (TEA)|An epidural catheter placed before induction of anesthesia by an anesthesiologist. A bolus or infusion of the local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
9756472|NCT03359811|Active Comparator|4Q-TAP Blocks|Participants have an ultrasound guided 4Q-TAP block. A maximum of 80 cc of a solution consisting of 30 mg of bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) and 65 mg of liposomal bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
9756473|NCT03350906|Experimental|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The DHA/EPA soft gels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. The duration of the intervention will be 6 months.
9756474|NCT03350906|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing soybean oil. Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The duration of the intervention will be 6 months.
9756475|NCT03348956|Experimental|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
9756476|NCT03344471|Other|women with PTSD after preterm deliver|
9756477|NCT03344471|Other|women without PTSD after preterm deliver|
9756478|NCT03330665|No Intervention|Control|No meditation
9756479|NCT03330665|Experimental|Intervention|Meditate using headspace app 3 times a week
9756480|NCT03262662|Experimental|Extended Run-In|"** 4 weeks of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
9831659|NCT03572153|Active Comparator|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
9831660|NCT03566017|Experimental|Experimental open label|pegunigalsidase alfa
9756481|NCT03262662|Active Comparator|Standard Run-In|"** 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
10202193|NCT04995224||Study 3|Cross-sectional study with 15,000 patients in IBD BioResource
10202194|NCT04995120|Experimental|Induction chemotherapy and Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If ORR of primary tumor is CR/PR, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
9756484|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
9756485|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
9756486|NCT03241589||Rural Veterans|Originally the aim was to include VA sites who received the direct to patient facing app from OCC. Due to a lack of enrollment, the first arm or group has been redefined as Veterans living in rural areas receiving a request to use the patient facing app.
9756487|NCT03241589||Nonrural Veterans|Originally the comparison group consisted of VA sites to eventually receive the direct to patient facing apps. Since our enrollment at the facility level was low, this arm now consists of Veterans receiving a request to use the patient facing app, living in nonrural areas.
9756488|NCT03211832|No Intervention|Control|The control group will conduct usual public health practice.
9756489|NCT03211832|Active Comparator|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
9756490|NCT03198234|Experimental|Cohort 1|Participants will receive 1 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
9756491|NCT03198234|Experimental|Cohort 2|Participants will receive 3 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
9756492|NCT03198234|Experimental|Cohort 3|Participants will receive 9 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
9756493|NCT03179163|No Intervention|Normotensive|Blood Pressure <120/80 mmHg
9756494|NCT03179163|Experimental|Hypertensive - ACEi +SH|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
9756495|NCT03179163|Experimental|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
9756496|NCT03179163|Active Comparator|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
9756497|NCT03177122|Experimental|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
9756498|NCT03177122|No Intervention|No intervention|Standard care: 400 ug of Folic acid
9756499|NCT03160859|Other|Control Method|One arm of the study will include unsedated colonoscopy with water exchange (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
9756500|NCT03160859|Other|Study Method|The other arm will include unsedated colonoscopy with water exchange (WE) and the addition of a simple commercially available accessory to the colonoscopy device: a cap (Disposable Distal Attachment, Olympus Medical Systems Corp., Tokyo, Japan) fitted to the colonoscope per manufacturer instruction. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
9756501|NCT03154801|Experimental|Paramedical care|paramedical early detection of sexual dysfunction and sexual health counseling
9756502|NCT03109210|No Intervention|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
9756503|NCT03109210|Experimental|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
9756504|NCT03109028|Active Comparator|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
9756505|NCT03109028|Experimental|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
9756506|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
9756507|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
10202195|NCT04992598|Experimental|Hypnosis group|
10202196|NCT04992598|Placebo Comparator|Control group|
10202197|NCT04989946|Active Comparator|Degarelix|Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57
10202198|NCT04989946|Experimental|Degarelix and pTVG-AR|Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57 pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71
9756508|NCT03037476|Experimental|Web-Based PFI|Participants randomized to the web-based PFI in Studies 2 and 3 will receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
9756509|NCT03037476|Experimental|In-person PFI|Participants randomized to the in-person PFI condition in Study 3 will be scheduled to meet with a trained intervention provider in a Student Counseling and Health Center setting for a 1.5 hour session to discuss the student's PSM misuse, alcohol and other drug use, and review personalized graphic feedback. The intervention provider will utilize a motivational interviewing approach in reviewing the students personalized feedback with them. They will use the student's past experiences with PSM as a starting point and will help the student to develop discrepancies, elicit change talk, provide students with opportunities to more thoroughly explore and question their beliefs, and offer alternatives by reviewing their personalized responses.
9756510|NCT03037476|No Intervention|Control|The control group will only receive assessments in Studies 2 and 3.
9756511|NCT03004443|Experimental|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
9756512|NCT03004443|Placebo Comparator|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
9756513|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
9756514|NCT02959775|Experimental|60 µg dose hepatitis B vaccine|Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
9756515|NCT02959775|Experimental|20 µg dose hepatitis B vaccine|Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
9756516|NCT02959775|No Intervention|Control|Receive no vaccination during the study period
9756517|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 60 mg + Bendamustine 90 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced progressive disease (PD) or unacceptable toxicities or up to 39 cycles.
9756518|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 80 mg + Bendamustine 90 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
9756519|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 100 mg + Bendamustine 90 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
9756520|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 60 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
9756521|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 80 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
9783035|NCT01191723|Other|Treatment B, then Treatment C, then Treatment A|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
9756522|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 100 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
9756523|NCT02954406|Experimental|Dose Escalation Phase Cohort C: TAK-659 60 mg + Gemcitabine 1000 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 2 cycles.
9756524|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 40 mg + Lenalidomide 25 mg|TAK-659 40 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 60 mg dose was de-escalated to 40 mg in case of dose limiting toxicity or if the starting dose was determined to be not tolerable. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
9756525|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 60 mg + Lenalidomide 25 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
9756526|NCT02954406|Experimental|Dose Escalation Phase Cohort E: TAK-659 60 mg + Ibrutinib 560 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 3 cycles.
9756527|NCT02954406|Experimental|Safety Expansion Phase Cohort B: TAK-659 + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 immediate-release tablet, at the MTD/maximally administered dose (MAD)/RP2D determined from Dose Escalation Phase, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles in participants (who were to be entered in Phase 2) with advanced FL or MZL. Treatment could then be continued until they experienced PD or unacceptable toxicities or up to 12 cycles in participants who were to be enrolled in the Safety Expansion Phase Cohort.
9984062|NCT04450914|Other|Health Systems - First Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the first step, health systems will be assigned to usual care (passive implementation of CV Prevention Choice).
9984063|NCT04450914|Other|Health Systems - Second Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the second step, health systems (in an order to be determined by randomization and staggered over time) will move into active implementation.
9831661|NCT03555279|Experimental|Probation Staff (PS) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm intervention is delivered by Probation Staff working at the intervention site. Dosage is 8 2-hour sessions delivered over two weeks.
9831662|NCT03555279|Experimental|Youth Representative (YR) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm intervention is delivered by young adults who were formally in the juvenile justice system. Dosage is 8 2-hour sessions delivered over two weeks.
9831663|NCT03539900|Experimental|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
9831664|NCT03539900|Placebo Comparator|Placebo|Placebo will be inactive and taken daily in pill form.
9831665|NCT03536572|Active Comparator|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
9831666|NCT03536572|Experimental|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
9831667|NCT03535675|Experimental|Muscadine Plus|Each treatment cycle consists of once daily oral dosing of 4000 mg Muscadine Plus, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of study drug and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
9831668|NCT03535675|Experimental|Placebo|Each treatment cycle consists of once daily oral dosing of 4000 mg placebos, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of placebo and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
9831669|NCT03517293|Experimental|Aerobic Exercise Intervention|Aerobic Exercise training 50 minutes of moderate intensity exercise, 3 times per week from ~16-40 weeks of pregnancy
9831670|NCT03517293|No Intervention|Control|usual daily activities - not exercise, not elevating heart rate
9831671|NCT03500380|Experimental|RC48-ADC|Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
9831672|NCT03500380|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.
9831673|NCT03498729||Persistent AF|
9831674|NCT03498729||Paroxysmal AF|
9831675|NCT03498729||Psoriasis|
9831676|NCT03498729||Healthy Controls|
9831677|NCT03494569|Experimental|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
9831678|NCT03468218|Experimental|Treatment (pembrolizumab, cabozantinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9831679|NCT03438747|Experimental|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
9831680|NCT03438747|Active Comparator|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
9831681|NCT03432247|Experimental|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
9831682|NCT03432247|Active Comparator|Verbal-based support|Six 45-minute individual verbal support sessions
9831683|NCT03416998|Active Comparator|Phototherapy Active|Phototherapy active group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
9831684|NCT03416998|Placebo Comparator|Placebo Phototherapy|"Phototherapy placebo group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.~For placebo treatment, the same procedures and treatment times will be employed, but the equipment will be set in placebo mode. Only the researcher in charge of programming the device will have knowledge regarding which treatment is being used. However, the programmer will not participate in the execution of the treatment, evaluations or data analysis"
9984064|NCT04450914|Other|Health Systems - Third Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions.In the third step, all health systems will move to maintenance implementation.
9984065|NCT04450888|Other|Model A|Total cardiovascular disease (CVD)-free life expectancy gain in one's remaining life.
9756531|NCT02927145|Active Comparator|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
9984066|NCT04450888|Other|Model B|Average CVD-free life expectancy gain per year.
9984067|NCT04450888|Other|Model C|Total CVD-free life expectancy loss that can be reclaimed in one's remaining life.
9756532|NCT02927145|Active Comparator|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
9756533|NCT02927145|Active Comparator|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
9756534|NCT02927145|Active Comparator|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
9756535|NCT02927145|Active Comparator|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
9756536|NCT02927145|No Intervention|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
9756537|NCT02927145|Active Comparator|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
9756538|NCT02927145|No Intervention|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
9756539|NCT02927145|No Intervention|Group 9 -Phase IIa|Group 9 are new infectivity controls
9756540|NCT02924714|Other|Discontinuation of imatinib|Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
9756541|NCT02923063|Experimental|Combined Aerobic and Resistance Exercise|Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Each session will start at 30 minutes in duration and include either high-intensity interval targeting a relative perceived exertion (RPE) of greater than 14 (on a scale of 6-20) or strength training (RPE 12-14) or power walking (RPE 12-14). Each 1 week of supervised sessions will alternate with 1 week of self-directed sessions with mid-week trainer check-in.
9756542|NCT02923063|No Intervention|Usual Care|"The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a Go4Life Workout to go sample exercise routing created by the national institutes on aging (NIA)."
9756543|NCT02910583|Experimental|Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax|Participants receive 420 mg of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment (ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule) for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
9756544|NCT02910583|Experimental|MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).~Participants with confirmed uMRD are randomized to receive ibrutinib 420 mg orally once daily on a continuous schedule until MRD-positive relapse, disease progression (PD), or unacceptable toxicity.~After MRD-positive relapse or disease progression (PD) by iwCLL criteria, participants can reintroduce 400 mg venetoclax with a 5-week ramp up. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
9756545|NCT02910583|Placebo Comparator|MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).~Participants with confirmed uMRD are randomized to receive placebo orally once daily on a continuous schedule until MRD-positive relapse, PD or unacceptable toxicity.~If MRD-positive relapse or PD is confirmed after restaging per iwCLL criteria, participants can first reintroduce oral daily ibrutinib with the option of subsequently reintroducing 400 mg venetoclax with a 5-week ramp up, if subsequent disease relapse per iwCLL criteria occurs after ibrutinib reintroduction. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
9756546|NCT02910583|Experimental|MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).~Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg orally once daily on a continuous schedule until PD or unacceptable toxicity.~In case of confirmed PD after restaging per iwCLL criteria, participants can continue ibrutinib and reintroduce venetoclax treatment. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity."
9984068|NCT04450888|Other|Model D|Average CVD-free life expectancy loss that can be reclaimed per year.
9984069|NCT04448951||sepsis/septic shock|target population
9984070|NCT04448951||non-septic critically ill|demographically-matched control group
9756547|NCT02910583|Experimental|MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)|"Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).~Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. Venetoclax was allowed for administration up to 2 years cumulatively from first dose started in the pre-randomization phase to last dose in the randomization phase."
9756548|NCT02899065|Experimental|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
9756549|NCT02899065|No Intervention|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
9756550|NCT02869945|Other|COMT HH|COMT HH gene
9756551|NCT02869945|Other|COMT HL|COMT HL gene
9756552|NCT02869945|Other|COMT LL|COMT LL gene
9756553|NCT02863029|Other|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
9756554|NCT02829268|Experimental|Pediatric|Pediatric patients treated with dantrolene sodium
9756555|NCT02829268|Experimental|Adult|Adult patients treated with dantrolene sodium
9756556|NCT02827513|Experimental|Arm 1|Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
9756557|NCT02827513|Experimental|Arm 2|Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
9756558|NCT02827513|Experimental|Arm 3|Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
9756559|NCT02827513|Experimental|Arm 4|Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
9756560|NCT02784535|Placebo Comparator|placebo|placebo capsules
9756561|NCT02784535|Active Comparator|atomoxetine|atomoxetine capsules 10 mg or 18 mg
9756562|NCT02776605|Experimental|Ponatinib|"Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)~Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.~Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT.~HSCT (performed ideally within 1 month from the end of consolidation).~Post HSCT therapy (MRD monitoring)"
9756563|NCT02721537|Active Comparator|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
9756564|NCT02721537|Placebo Comparator|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
9756565|NCT02699060|Experimental|NERD patients|Patients have typical reflux syndrome without esophageal injury.
9756566|NCT02699060|Experimental|EE patients|Patients have erosion(s) or ulcer(s) in esophagus.
9756567|NCT02699060|Experimental|BE patients|Patients have esophageal specialized intestinal metaplasia.
9756568|NCT02697227|Active Comparator|Group I (NRT, SC)|Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
9984071|NCT04448951||healthy control|control group
9756569|NCT02697227|Active Comparator|Group II (NRT, BATS)|Patients receive NRT patch daily for 8 weeks. Patients complete individual treatment sessions consisting of SC strategies and BA strategies over 45 minutes for 8 sessions.
9756570|NCT02673671||Subjects with unknown POI status consented pre-surgery|Up to 100 subjects may be consented prior to surgery who are planned to undergo gastrointestinal surgery or a planned surgery that does not involve the abdominal cavity. The investigator does not change the routine medical care of study participants.
9756571|NCT02673671||Subjects with known/unknown POI status consented post-surgery|Up to 50 subjects who have undergone gastrointestinal surgery or surgery not involving the abdominal cavity may be consented post- operatively during their hospital stay for this study.The investigator does not change the routine medical care of study participants.
9756572|NCT02664155|Experimental|DOA : Direct Oral Anticoagulants|"The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:~Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months~Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months."
9756573|NCT02664155|Active Comparator|SOC : Standard Of Care|The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
9756574|NCT02645487|Experimental|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
9756575|NCT02598388|Experimental|Part 1 (US Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
9756576|NCT02598388|Experimental|Part 2 Group 1 (African Participants)|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.
9756577|NCT02598388|Experimental|Part 2 Group 2 (African Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
9756578|NCT02592356|Experimental|Cabozantinib or Lenvatinib|Patients treated with cabozantinib s-malate or lenvatinib mesylate are observed for body weight, skeletal muscle and adipose tissue changes. Patients complete 3 to 4 questionnaires every 2 weeks for 6 months and then monthly up to 12 months. Patients also undergo physical assessments and body composition measurements by DXA and CT scans at baseline, months 3, 6, and 12.
9756579|NCT02579889|Experimental|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
9756580|NCT02579889|Active Comparator|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
9756581|NCT02549222||Control Cohort|During the Control cohort period patients will have study data collected following transfusion with only conventional PCs for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
9756582|NCT02549222||INTERCEPT Cohort|During the INTERCEPT phase, patients will receive only INTERCEPT PCs and will have study data collected following transfusion for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
9756583|NCT02506933|Experimental|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
9756584|NCT02506933|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
9756585|NCT02493751|Experimental|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
9756586|NCT02463773|Experimental|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
9756587|NCT02461537|Active Comparator|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
9756588|NCT02461537|Experimental|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
9756589|NCT02446964|Experimental|Treatment (TMLI, chemotherapy, transplant, GVHD prophylaxis)|"CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.~TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GHVD PROPHYLAXIS: Patients receive tacrolimus* IV QD or PO BID on days 5-180. Patients also receive mycophenolate mofetil PO TID or IV on days 5-35. Treatment with tacrolimus and mycophenolate mofetil may continue in the presence of active GVHD.~*NOTE: Patients intolerant of tacrolimus may receive cyclosporine."
9756590|NCT02394834|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
9756591|NCT02394834|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
9756592|NCT02394795|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
9756593|NCT02394795|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
9756594|NCT02328599||Surgical|Prior Bariatric surgery
9756595|NCT02328599||Non-surgical|Medical / Lifestyle management
9756596|NCT02285166||Ever User of Omega-3 fatty acid ethyl esters 2 g|The usual adult dosage for oral use was 2 g of omega-3 fatty acid ethyl esters administered once daily or twice daily immediately after meals for treatment of hyperlipidemia. Participants received both interventions and standard antihyperlipidemic therapy as part of routine medical care.
9756597|NCT02285166||Never User of Omega-3 fatty acid ethyl esters 2 g|Participants received standard antihyperlipidemic therapy without omega-3 fatty acid ethyl esters 2 g as part of routine medical care.
9756598|NCT02278120|Experimental|Ribociclib (LEE011) + NSAI/tamoxifen + goserelin|LEE011 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
9756599|NCT02278120|Placebo Comparator|LEE011 placebo+NSAI/tamoxifen+goserelin|LEE011 Placebo 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
9756600|NCT02230124|Experimental|MRE|
9756601|NCT02202772|Experimental|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
9756602|NCT02202772|Experimental|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
9756603|NCT02202772|Experimental|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
9756604|NCT02202772|Experimental|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
9756605|NCT02202772|Experimental|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
9756606|NCT02192359|Experimental|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9756607|NCT02174822|Experimental|Paroxetine + AVP-786|Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
9756608|NCT02174822|Experimental|AVP-786 + paroxetine|AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
9756609|NCT02174822|Experimental|Duloxetine + AVP-786|Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
9756610|NCT02174822|Experimental|AVP-786 + duloxetine|AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
9984072|NCT04446000|Experimental|CSL730 (dose 1 with premedication)|administered as a single dose by subcutaneous (SC) injection or by SC infusion
9756612|NCT02145351|Active Comparator|Pacing off|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
9756613|NCT02145351|Experimental|Pacing on|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
9984073|NCT04446000|Experimental|CSL730 (dose 2 with premedication)|administered as a single dose by SC injection or by SC infusion
9783036|NCT01191723|Other|Treatment C, then Treatment A, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
9783037|NCT01191723|Other|Treatment C, then Treatment B, then Treatment A|"There was 48 hour wash-out between treatment visits.~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
9783038|NCT01191736|Experimental|No training, assessed within 60 mins|Subjects receive no training
9783039|NCT01191736|Experimental|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
9783040|NCT01191736|Experimental|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
9783041|NCT01191736|Experimental|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
9783042|NCT01191736|Experimental|Ultra-brief video; assessed at 2 months|
9783043|NCT01191736|Experimental|Brief video; assessed 2 months later|
9783044|NCT01191736|Experimental|Brief video + hands-on; ass'd 2 ms later|
9783045|NCT01191749|Experimental|Alemtuzumab|Alemtuzumab 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
9984074|NCT04446000|Experimental|CSL730 (dose 3 with premedication)|administered as a single dose by SC injection or by SC infusion
9984075|NCT04446000|Experimental|CSL730 (dose 1 without premedication)|administered as a single dose by SC injection or by SC infusion
9984076|NCT04446000|Experimental|CSL730 (dose 2 without premedication)|administered as a single dose by SC injection or by SC infusion
9984077|NCT04446000|Experimental|CSL730 (dose 3 without premedication)|administered as a single dose by SC injection or by SC infusion
9756615|NCT02075593|Experimental|DTG/ABC/3TC|All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
9756616|NCT02041416||Group 1|REDCap and paper pencil
9756617|NCT02041416||Group 2|REDCap twice
9756618|NCT02041416||Group 3|Support Screen and paper pencil
9756619|NCT02041416||Group 4|Support Screen twice
9756620|NCT02011685|Active Comparator|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
9756621|NCT02011685|Experimental|HBPTM + Nurse Case Management (NCM)|Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
9756622|NCT01961063|Experimental|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
9756623|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
9756624|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
9756625|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
9756626|NCT01909245|Experimental|Single Arm Study|Allogenic Human Islet Cell Transplant with immunosuppression
9756627|NCT01894646|Experimental|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
9756628|NCT01894646|Experimental|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
9756629|NCT01894646|Other|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
9756630|NCT01885689|Experimental|Treatment (clofarabine, melphalan, transplant)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure."
9756631|NCT01872260|Experimental|LEE011 + letrozole Arm 1|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day
9756632|NCT01872260|Experimental|BYL719 + letrozole Arm 2|BYL719 - daily (dose escalating) letrozole - 2.5 mg/day
9756633|NCT01872260|Experimental|LEE011 + BYL719 + letrozole Arm 3|LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day
9756634|NCT01872260|Experimental|LEE011+ BYL719+letrozole Arm 4|LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day
9756635|NCT01824745|Experimental|Arm I (SCP-BCS template booklet and counseling)|Participants receive SCP-BCS template booklet and receive counseling sessions with a patient navigator for 40 minutes twice weekly for 4 sessions.
9756636|NCT01824745|Active Comparator|Arm II (SCP-BCS template booklet)|Participants receive SCP-BCS template booklet and receive standard follow-up care.
9783046|NCT01191762|Active Comparator|sevelamer carbonate|2400 mg (3 pills) with each meal
9831685|NCT03401853|Experimental|Arm I (pembrolizumab, rituximab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity."
9831686|NCT03401853|Experimental|Arm II (pembrolizumab, obinutuzumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycle 2.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better, who are experiencing clinical benefit in the judgment of the investigator, may receive obinutuzumab IV on day 1 of cycles 5, 9, 13, 17, 21, and 25."
9831687|NCT03391973|Experimental|Arm 1 - Pembrolizumab|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
9831688|NCT03389620|Active Comparator|Transforaminal Cervical Epidural Corticosteroid Injections|
9831689|NCT03389620|Experimental|Lateralized Interlaminar Epidural Corticosteroid Injections|
9831690|NCT03386721|Experimental|Cohort A (Part I)|Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
9831691|NCT03386721|Experimental|Cohort B (Part I)|CPI-Experienced Participants (NSCLC) who have received CPI therapy previously will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
9831692|NCT03386721|Experimental|Cohort C (Part I)|"This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants. Participants (NSCLC) will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
9831693|NCT03386721|Experimental|Cohort D Arm I (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
9831694|NCT03386721|Experimental|Cohort D Arm 2 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.~Participants will receive simlukafusp alfa intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
9831695|NCT03386721|Experimental|Cohort D Arm 3 (Part I)|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
9831696|NCT03386721|Experimental|Cohort E Arm I (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
9984078|NCT04446000|Experimental|CSL730 (dose 4 without premedication)|administered as a single dose by SC injection or by SC infusion
9984079|NCT04446000|Experimental|CSL730 (dose 5 without premedication)|administered as a single dose by SC injection or by SC infusion
9756637|NCT01815749|Experimental|Treatment (genetically modified T cell infusion)|Patients undergo mobilization for autologous stem cell collection with cytoreductive chemotherapy and filgrastim and/or plerixafor per current standard operating policies. Patients undergo myeloablative conditioning regimen per institutional standards beginning day -7 followed by hematopoietic stem cell transplantation on day 0. Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3 (may be delayed up to day 45 if the patient is not yet eligible). Patients who experience disease progression and have not experienced DLTs at greater than or equal to 100 days post HSCT will be allowed to receive an optional second T cell infusion.
9984080|NCT04446000|Experimental|CSL730 (dose 6 without premedication)|administered as a single dose by SC injection or by SC infusion
9756639|NCT01740648|Experimental|Treatment (trametinib, fluorouracil, radiation, surgery)|"Patients receive trametinib PO (by mouth) QD (daily) on days -14 through -10 and 1-38 and fluorouracil IV continuously 5 days a week from days 1-38. Patients also undergo radiation therapy 5 days a week on days 1-33. Patients then undergo surgery 6-10 weeks later.~Patients achieving negative surgical margins after complete resection of tumor receive postoperative chemotherapy comprising leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15 OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
9756640|NCT01728402||Blood Draw|
9756641|NCT01685424||Etoricoxib Prescription (Period 1)|First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
9756642|NCT01685424||Etoricoxib Prescription (Period 2)|First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
9756643|NCT01685424||Repeat Etoricoxib Prescription|One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
9756644|NCT01639924||Study Cohort|Patients with known or suspected gastrointestinal disease
9756645|NCT01592721|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
9756646|NCT01591356|Experimental|Treatment (EphA2-targeting DOPC-encapsulated siRNA)|Patients receive EphA2-targeting DOPC-encapsulated siRNA IV over 120 minutes on days 1 and 4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9756647|NCT01587235|Experimental|Vytorin|
9756648|NCT01587235|Active Comparator|Other Statin|
9756649|NCT01583322|Experimental|vargatef/Nintedanib|
9756650|NCT01583322|Placebo Comparator|placebo|
9756651|NCT01571128|Experimental|Male-Specific Intervention Package|Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
9756652|NCT01571128|Experimental|Female-Specific Intervention Package|Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
9756653|NCT01571128|No Intervention|HIV Positive Cohort (Males and Females)|Behavioral data on HIV positive youth. Longitudinal Arm.
9756654|NCT01571128|Experimental|Pre-Exposure Prophylaxis (Females)|PrEP adherence and feasibility. Longitudinal Arm.
9756655|NCT01571128|Experimental|Cash Transfer Cohort (Females)|School attendance, behavioral data, and feasibility. Longitudinal Arm
9756656|NCT01474148|Experimental|Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
9756657|NCT01429168|Experimental|Part 1: All Enrolled Participants|All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
9756658|NCT01429168|Experimental|Part 2: Etoricoxib|
9756659|NCT01429168|Placebo Comparator|Part 2: Placebo|
9756660|NCT01327638||Patients with SpA/AS and etoricoxib treatment|
9756661|NCT01327638||Patients with SpA/AS and other COX-2 inhibitor treatment|
9756662|NCT01327638||Patients with SpA/AS and nsNSAIDs treatment|
9756663|NCT01077843||Exposure|Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
9756664|NCT01077843||Non-exposure|Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
9756665|NCT00802789||1|Mild to moderate adult asthmatics (≥18years of age) insufficiently treated with ICS or ICS + LABA.
9756666|NCT00771160|Experimental|1|MK0476 5mg
9756667|NCT00771160|Experimental|2|MK0476 10mg
9756668|NCT00756418|Experimental|1|
9756669|NCT00756418|Active Comparator|2|
9756670|NCT00755794|Experimental|1|Montelukast
9984081|NCT04446000|Experimental|CSL730 (dose 7 without premedication)|administered as a single dose by SC injection or by SC infusion
9984082|NCT04446000|Placebo Comparator|Placebo|A solution matching the excipient profile of CSL730 without the active substance administered as a single dose by SC injection or by SC infusion
9984083|NCT04444323|Experimental|3D Telemedicine|Single arm. All patient seen face-to-face and then with 3D telemedicine.
9756671|NCT00700661|Experimental|1|Drug
9756672|NCT00700661|Placebo Comparator|2|Pbo
9756673|NCT00659711|Active Comparator|Januvia 100mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
9756674|NCT00659711|Placebo Comparator|placebo|will be placed on a placebo for 12 weeks.
9756675|NCT00653276|Active Comparator|Treatment A|Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
9756676|NCT00653276|Active Comparator|Treatment B|Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
9756677|NCT00652847|Experimental|group 1|group 1: ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by an observational phase of 6 months.
9756678|NCT00652847|Active Comparator|Group 2|Group 2: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase.
9756679|NCT00652717|Experimental|1|arm 1 - Ezetimibe 10 mg daily that was added on Statin Therapy (prescribed clinically suitable dose by the physician).
9756680|NCT00652717|Active Comparator|2|arm 2- simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
9756681|NCT00652444|Experimental|1|Coadministration arm: simvastatin 20mg and ezetimibe 10mg
9756682|NCT00652444|Experimental|2|Monotherapy arm: simvastatin 20mg and ezetimibe placebo
9756683|NCT00652301|Experimental|1|ezetimibe 10 mg tablet plus simvastatin 20 mg tablet
9756684|NCT00652301|Active Comparator|2|ezetimibe 10 mg tablet
9756685|NCT00652301|Active Comparator|3|simvastatin 20 mg tablet
9756686|NCT00652301|Placebo Comparator|4|matching placebo
9756688|NCT00587860|Placebo Comparator|Placebo|
9756689|NCT00587860|Active Comparator|St. John's Wort|
9756690|NCT00553891|Experimental|Nasonex Nasal Spray|
9756691|NCT00553891|Placebo Comparator|Placebo Nasal Spray|
9756692|NCT00295139|Experimental|1|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
9756693|NCT00295139|Experimental|2|Behavioral Treatment for Substance Abuse in SPMI (BTSAS) + Critical Time Intervention (CTI)
9756694|NCT00295139|Active Comparator|3|Supportive Treatment in Addiction Recovery (STAR)
9756695|NCT00199238|Placebo Comparator|Placebo|Once daily/ 28 days
9756696|NCT00199238|Experimental|rupatadine 5mg|Once daily/ 28 days
9756697|NCT00199238|Experimental|rupatadine 10 mg|Once daily/ 28 days
9756698|NCT00199238|Experimental|rupatadine 20 mg|Once daily/ 28 days
9756699|NCT00166530|Active Comparator|1|Arm 1: Active comparator
9756700|NCT00166530|Experimental|2|Arm 2: Drug
9756701|NCT00092833|Experimental|1|Ezetimibe
9756702|NCT00587964|Experimental|Treatment|
9756703|NCT00587990|Experimental|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
9756704|NCT00587990|Experimental|Higher dose MSC injection|Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
9756705|NCT00587990|Placebo Comparator|(3) Placebo|Participants will receive placebo injections
9756706|NCT00588094|Experimental|Treatment|R-ICEesc will be administered with the intent of administering 2 cycles, each 21 days apart admixed with 4 doses of rituximab. G-CSF will be administered at 960 ug or 10 ug/kg if patient is > 100 kg after cycles one and two for PBPC collection for the first 10 patients enrolled. G-CSF will be administered in standard dosing for cycle one and then at 960 ug or 10 ug/kg (if patient is > 100 kg) after cycle two for PBPC collection for the remaining 22 patients. All responding patients who make at least 2 x 106 CD34+ cells/kg will receive high dose therapy and ASCT on other protocols.
9756707|NCT00588159|Experimental|Gabapentin preoperatively|Preoperative gabapentin 600 mg orally within 2 hours prior to surgery.
9756708|NCT00588159|Placebo Comparator|Active placebo|Diphenhydramine 12.5 mg orally 2 hours preoperatively.
9756709|NCT00588237|Experimental|1|Paclitaxel, Cisplatin, Bevacizumab
9756710|NCT00588341|Experimental|Treatment|
9756711|NCT00588354|Experimental|Clonidine|Transforaminal epidural clonidine injection
9756712|NCT00588354|Active Comparator|Steroid|Transforaminal epidural steroid injection
9756713|NCT00588380|Experimental|GLP-1|All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour
9756714|NCT00588406|Experimental|B|Budesonide, 2mg, 4 doses, plus standard care
9756715|NCT00588406|Placebo Comparator|P|Placebo plus standard care
9756716|NCT00588445|Experimental|Treatment|
9756717|NCT00588536|Experimental|1|MTX, 6-TG, Leucovorin
9756718|NCT00588640|Experimental|Phase I, Group|This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.
9756719|NCT00588640|Experimental|Phase II, Group I|patients receiving around the clock opioid therapy-No patients were accrued to this group
9756720|NCT00588640|Experimental|Phase II, Group II|patients not receiving around the clock opioid therapy.No patients were accrued to this group
9783047|NCT01191762|Placebo Comparator|placebo control|3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
9756721|NCT00588666|Experimental|Bevacizumab, Carboplatin, Gemcitabine|Patients will initially receive bevacizumab 10 mg/kg followed by a 2 week treatment-free interval. Treatment will then begin with combination therapy. Gemcitabine 1000 mg/m2 will be administered intravenously on day 1 and 8 and carboplatin AUC 4.5 on day 1 with treatment recycled every 21 days. Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of each 21-day cycle. Restaging evaluations will be performed after every 3 cycles of treatment (approximately 9 weeks). Patients will receive a total of 6 cycles of chemotherapy unless disease progression or unacceptable toxicity occurs. Patients who achieve stable disease, a partial response, or a complete response after completion of 6 cycles, will be eligible to continue bevacizumab at the same dose and schedule until disease progression for a maximum of 18 additional doses.
9756722|NCT00588692|Active Comparator|SphygmoCor Unblinded|The use of the sphygmocor values will determine medication adjustments to optimize HF treatment.
9756723|NCT00588692|Placebo Comparator|SphygmoCor Blinded|Sphygmocor values will be blinded to the investigator.
9756724|NCT00588731|Experimental|Cannabidiol|
9756725|NCT00588731|Placebo Comparator|Placebo|
9756726|NCT00588809|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
9756727|NCT00588822|Experimental|Rituximab|"Subjects will receive rituximab administered at the standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months. If the neuropathy is stable or responding at 6 months, the subject will receive Cycle 2 of rituximab, followed by a re-evaluation at 12 months.~Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22)."
9756728|NCT00588848|Experimental|Autoadjusting CPAP (VPAP auto)|The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
9756729|NCT00588848|Active Comparator|CPAP arm (usual care)|The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.
9756730|NCT00588900|Experimental|irinotecan + cediranib|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.~After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry."
9756731|NCT00588952|Experimental|Family History Positive|Subjects with a positive family history of alcoholism
9756732|NCT00588952|Experimental|Family History Negative|Subjects with a negative family history of alcoholism
9756733|NCT00588965|Placebo Comparator|1|Subjects are assigned to placebo.
9756734|NCT00588965|Active Comparator|2|Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.
9756735|NCT00589056|Experimental|Single arm|Nelfinavir
9756736|NCT00589108|Active Comparator|Mobile-Bearing Knee|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
9756737|NCT00589108|Active Comparator|Modular-Metal-Backed Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
9756738|NCT00589108|Active Comparator|All-Polyethylene Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
9756739|NCT00589121|Experimental|Cohort A - Chemotherapy|Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
9756740|NCT00589121|Experimental|Cohort B - No Chemotherapy|Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
9756741|NCT00589277|Experimental|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
9756742|NCT00589277|Placebo Comparator|Standard care counseling + standard materials|Standard care counseling + standard care print information
9783048|NCT01191788|Experimental|Group CBT|Clients received up to 16 sessions of group CBT for depression
9831697|NCT03386721|Experimental|Cohort E Arm 2 (Part II)|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive simlukafusp alfa IV infusion in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
9831698|NCT03386721|Experimental|Cohort F (Part I)|"CPI-experienced, docetaxel naive participants (NSCLC) who experienced disease progression during or following treatment with a platinum - containing regimen. Participants will receive combination of simlukafusp alfa and atezolizumab in a Q3W schedule. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.~Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional."
9831699|NCT03386721|Experimental|Cohort G (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort G Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
9831700|NCT03386721|Experimental|Cohort H (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and heck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort H Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
9831701|NCT03386721|Experimental|Cohort I (Part III)|Previously treated, CPI-naïve squamous esophageal cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort I Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
9831702|NCT03386721|Experimental|Cohort J (Part III)|Previously treated, CPI-naïve squamous cervical cancer (20 response evaluable participants): mandatory biopsy. Participants in cohort J Part III will receive simlukafusp alfa Q3W in combination with atezolizumab Q3W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
9831703|NCT03386721|Experimental|Cohort K (Part III)|CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort K Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
9984084|NCT04444076|Experimental|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a bovine mesh that will be implanted following supraspinatus tendon repair.
9984085|NCT04444076|No Intervention|Standard of Care|Supraspinatus tendon repair.
9756743|NCT00589290|Experimental|Belinostat Treatment|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
9756744|NCT00589303|Active Comparator|Drug Therapy|FDA approved rate and rhythm control drugs
9756745|NCT00589303|Active Comparator|Atrioventricular Node (AVN) Ablation / Pacing|AV Node ablation and device implant
9756746|NCT00589329|Experimental|A|"roup A will be assigned to receive antibiotics:~Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days."
9756747|NCT00589329|Placebo Comparator|B|Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
9756748|NCT00589472|Experimental|Treatment (Antihormone therapy and enzyme inhibitor therapy)|Patients receive bicalutamide PO QD for 1 month and leuprolide acetate IM or goserelin acetate SC once a month until surgery. Patients also receive vorinostat PO QD beginning on the first day of androgen depletion therapy and continuing for up to 8 weeks or until the day of surgery. Patients then undergo an open or laparoscopic radical prostatectomy. Patients with positive surgical margins undergo immediate adjuvant external beam radiotherapy to the prostatic fossa, based on the judgment of the treating physician.
9756749|NCT00589563|Experimental|Fludarabine/Melphalan Conditioning|"Fludarabine/Melphalan Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
9756750|NCT00589563|Experimental|FTBI/Cytoxan Conditioning|FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
9756751|NCT00589563|Experimental|FTBI/Etoposide Conditioning|"FTBI/Etoposide Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
9756752|NCT00589602|Experimental|T-Cell Depletion Transplant|"Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.~Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'"
9756753|NCT00589628|Active Comparator|1|5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
9756754|NCT00589628|Active Comparator|2|10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.
9756755|NCT00589667|Experimental|Treatment|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
9756756|NCT00589693|Experimental|Doripenem|Doripenem from Days 1 to 7 and imipenem-cilastatin placebo from Days 1 to 10
9756757|NCT00589693|Active Comparator|Imipenem-Cilastatin|Imipenem-Cilastatin Days 1 to 10 and doripenem placebo from Days 1 to 7
9831704|NCT03386721|Experimental|Cohort L (Part III)|Previously treated, CPI-experienced squamous cell carcinoma head and neck cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort L Part III will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion.
9831705|NCT03386721|Experimental|Cohort M (Part III)|Esophageal SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
9831706|NCT03386721|Experimental|Cohort N (Part III)|Cervical SCC participants will receive simlukafusp alfa QW in combination with atezolizumab Q2W for 4 weeks followed by simlukafusp alfa in combination with atezolizumab Q2W. Simlukafusp alfa will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg. Tumor biopsies: one mandatory fresh tumor biopsy will be collected at baseline. Additional on-treatment biopsies will be optional.
9831707|NCT03378141|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
9831708|NCT03378141|No Intervention|A&T-non intensive|A&T-non intensive arm only receives standard MNCH services
10202199|NCT04989946|Experimental|Degarelix and pTVG-AR and Nivolumab|Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57 pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71 Nivolumab 240 mg IV administered at days 29, 43, 57 and 71
10202200|NCT04987879|Experimental|Exercise Arm 1|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min/wk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
10202201|NCT04987879|Experimental|Exercise Arm 2|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 1,000 MET-min/wk for 3-5 days per week, 30-60 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
9831709|NCT03345849|Experimental|Arm A: Upadacitinib|Participants will receive Upadacitinib dose A for 12 weeks. Non-responders will receive Upadacitinib dose B for 12 weeks
9831710|NCT03345849|Experimental|Arm B: Placebo and Upadacitinib|Participants will receive placebo for 12 weeks. Non-responders will receive Upadacitinib dose A for 12 weeks.
9831711|NCT03342001|Experimental|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
9831712|NCT03337100|Experimental|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
9831713|NCT03337100|No Intervention|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
9831714|NCT03331497|Experimental|Tonsillotomy|The patients diagnosed with PFAPA will have tonsillotomy performed in one month from randomisation.
9831715|NCT03331497|No Intervention|Follow up|The patients diagnosed with PFAPA will be monitored for 3 months time. If the symptoms still persist, tonsillectomy will be performed
9831716|NCT03319940|Experimental|Part A|AMG 757 Monotherapy
9831717|NCT03319940|Experimental|Part C|AMG 757 with Pembrolizumab
10202202|NCT04987879|No Intervention|Standard of Care|This group will receive best NASH clinical practices counseling at baseline and end-of-trial in accordance with NAFLD clinical practice guidelines and be reinforced by handouts from the American Liver Foundation.
10202203|NCT04976309|Experimental|Placebo + saline|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
10202204|NCT04976309|Experimental|Placebo + VIP and PACAP|Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
10202205|NCT04976309|Experimental|Lu AG09222 + VIP and PACAP|Lu AG09222, single dose intravenous infusion over 30 minutes
10202206|NCT04971980|Experimental|hUC-MSC infusion (BC-U001)|Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001
10202207|NCT04971837|Experimental|Two Visits Including A Test Meal|Separated by a minimum of 4 days.
10202208|NCT04971837|Experimental|Five Visits Not Involving A Test Meal|Separated by a minimum of 14 days.
10202209|NCT04969302|Experimental|Intervention Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 37°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the warm group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
10205199|NCT03684980|Experimental|Arm A - Rituximab + MTX + Glucarpidase|Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort A) will receive MTX 3 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
9783049|NCT01191788|Active Comparator|Comparison|Treatment as Usual comparison condition
9783050|NCT01191801|Experimental|Group A: vosaroxin + cytarabine|vosaroxin (short IV infusion within 10 minutes) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
9783051|NCT01191801|Placebo Comparator|Group B: placebo + cytarabine|placebo (short IV infusion within 10 minutes and volume matched to vosaroxin) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
9783052|NCT01191827||risperidone|
9783053|NCT01191827||clozapine|Patients with schizophrenia treated with clozapine
9783054|NCT01191840|Experimental|Algorithm-determined therapy|
9783055|NCT01191840|Active Comparator|Standard of Care|
9783056|NCT01191944|Experimental|pramipexole Extended release|subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement
9783057|NCT01191944|Active Comparator|pramipexole Immediate release|subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement
9783058|NCT01192022|Active Comparator|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
9783059|NCT01192022|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
9783060|NCT01192100|Experimental|Breakfast Skipping|Breakfast skipping serves as the baseline/control arm since the participants habitually skip breakfast (i.e., skip breakfast at least 5 times/week). Thus, during the week prior to and including the testing day, the participants will continue to skip breakfast each morning.
9783061|NCT01192100|Experimental|Normal Protein Breakfast Meals|For 7 days, the participants will consume normal protein breakfast meals each morning. These meals will consist of cereal-based foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 15% protein (13 g of dietary protein), 65% CHO, and 20% fat.
9783062|NCT01192100|Experimental|Protein-rich Breakfast Meals|For 7 days, the participants will consume protein-rich breakfast meals each morning. These meals will consist of home-cooked foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 40% protein (35 g of protein), 40% CHO, and 20% fat.
9783063|NCT01192126|Experimental|Bausch & Lomb new daily disposable|New daily disposable contact lenses
9783064|NCT01192126|Active Comparator|Johnson & Johnson Acuvue Moist|Contact lenses
9783065|NCT01192139|Experimental|5 mg saxagliptin + a single 500 mg metformin XR tablet|
9783066|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)|under fed state
9783067|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)|under fasted state
9783068|NCT01192152|Experimental|5 mg saxagliptin + 2 Glucophage XR 500 mg tablet|
9783069|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)|under fed state, single dose
9783070|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)|under fed state, 4 days
9783071|NCT01192178|Active Comparator|FLOVENT™ DISKUS™ 100 mcg|FLOVENT™ DISKUS™ 100 mcg is an inhaled corticosteroid indicated in the US for maintenance treatment of asthma as prophylactic therapy in patients 4 years and older.
9756758|NCT00589784|Experimental|Treatment|Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.
9756759|NCT00589797|Experimental|Investigational|Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
9756760|NCT00589797|Active Comparator|Control|Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
9756761|NCT00589836||Cardiac Pathologies|Patients with cardiomyopathy, ischemic heart disease, will have tissue Doppler echocardiograms performed
9756762|NCT00589849||1|
9756763|NCT00589888|Active Comparator|Intralipid 20%@ 20cc/hour|Intralipid 20% IV infusion at 20cc/hour
9756764|NCT00589888|Active Comparator|Intralipid 20% @ 40cc/hour|Intralipid 20% IV infusion at 40cc/hour
9756765|NCT00589888|Placebo Comparator|Normal Saline infusion @ 40cc/hour|Normal Saline continuous IV infusion at 40cc/hour for 8 hours
9756766|NCT00589888|Active Comparator|32-gram oral fat load|32-gram oral fat load once
9756767|NCT00589888|Active Comparator|64-gram oral fat load|64-gram oral fat load once
9783072|NCT01192178|Experimental|ADVAIR™ DISKUS™ 100/50 mcg|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a corticosteroid and a long acting beta2 adrenergic agonist indicated for; maintenance treatment of asthma in patients 4 years of age and older.
9785464|NCT01252667|Experimental|Part 2 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
9785465|NCT01252667|Experimental|Part 2 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
9785466|NCT01252732|Experimental|Single-Dose IV Oritavancin Diphosphate|
9785467|NCT01252732|Active Comparator|IV Vancomycin|
9785468|NCT01252745|Experimental|10.0 mg of TBS-1, 4.0% T.I.D.|TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 30 mg/day)
9785469|NCT01252745|Experimental|13.5 mg of TBS-1, 4.5% B.I.D|TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of Testosterone per nostril (intra-nasal) given b.i.d. at 2100 and 0700 hours. (total dose 27.0 mg/day)
9785470|NCT01252745|Experimental|11.25 mg of TBS-1, 4.5% T.I.D|TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 33.75 mg/day)
9785471|NCT01252810|Experimental|GE 145 320mg I/ml injection|
9785472|NCT01252810|Active Comparator|Iopamidol 370mg I/ml injection|
9785473|NCT01252940|Experimental|FTC/RPV/TDF|Participants will switch from their existing treatment regimen to the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) at the beginning of the study.
9785474|NCT01252940|Experimental|SBR/Delayed Switch|Participants will stay on baseline regimen (SBR; their existing treatment regimen of PI+RTV plus 2 NRTIs) at the beginning of the study through Week 24, and may switch to the FTC/RPV/TDF STR (Delayed Switch) at the Week 24 visit.
9785475|NCT01252966|Experimental|Cognitive Training|Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
9785476|NCT01252966|Placebo Comparator|Control Training|Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
9785477|NCT01253018|Experimental|Robot Therapy|12 weeks of robotic therapy
9785478|NCT01253018|Active Comparator|Transition to Task Training|12 weeks of task specific practice combined with robotic therapy
9785479|NCT01253044|Experimental|Acceptance and Commitment Therapy|12 weeks of individually delivered Acceptance and Commitment Therapy
9785480|NCT01253044|Active Comparator|Present Centered Therapy|12 weeks of individually delivered Present Centered Therapy
9785481|NCT01253135|Placebo Comparator|Control|White Petrolatum
9785482|NCT01253135|Other|Test article|Vehicle (fibrinogen)
9831718|NCT03319940|Experimental|Part D|AMG 757 with additional cytokine release syndrome (CRS) mitigation strategies
9831719|NCT03319940|Experimental|Part E|AMG 757 administration with 24-hour monitoring
9831720|NCT03319940|Experimental|Part F|"AMG 757 administered in outpatient infusion centers with 8-hour monitoring~Optional wearable digital device substudy (US sites only)"
9831721|NCT03319940|Experimental|Part G|"AMG 757 additional dosing schedule~Optional wearable digital device substudy (US sites only)"
9831722|NCT03317119|Experimental|Treatment (TAS-102, trametinib)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9831723|NCT03306992|Experimental|Personalized Exercise Program|
9831724|NCT03306992|No Intervention|Standard of Care - No Exercise|
9831725|NCT03297710|Experimental|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
9831726|NCT03267524|Experimental|Supportive Care (Walking for Recovery from Surgery)|Patients and caregivers receive Walking for Recovery from Surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge.
9831727|NCT03267238|Experimental|Fecal Microbial transplantation|Fecal Microbial Transplantation will be offered to patients eligible to be part of the study.
9831728|NCT03256916|Experimental|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.~Then Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 # will be given."
9831729|NCT03256916|Other|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).~In this patient will receive Pelvic EBRT (45-50 Gy/23-25 #/5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 #"
10202210|NCT04969302|No Intervention|Control Group|"Skin preparations will performe using Povidone 10% 1000 mL solution (Turkuaz Chemistry, İstanbul, Turkey) Povidone-iodine will heat to 20°C using a gel warmer (KGW-1 Keewell Medical Technology, Foshen, China) in the room heat group.~The day before the operation, the patient will be met and informed about the study and verbal and written consent will be obtained stating that they are willing to participate in the study.~The weight tracking of the patients will be determined using a digital weight meter provided by the researcher. Patient evaluation will be made with NRS-2002 in terms of malnutrition risk.~Antibiotic prophylaxis of 1000 mg available in the operating room will be administered 30-60 minutes before the operation.~Before the incision, a wound culture sample will be taken with sterile transport swap and sent to the laboratory for culture study."
9831731|NCT03241771|Experimental|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
9831732|NCT03241771|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
9831733|NCT03233854|Experimental|Treatment (CD19/CD22 CAR T cells, chemotherapy)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
9831734|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
9831735|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
9831736|NCT03220776|Experimental|N-Acetylcysteine|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
10202211|NCT04964960|Experimental|Pembrolizumab with standard of care chemotherapy treatment|Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).
10202212|NCT04961112|Experimental|Experimental - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
10202213|NCT04961112|Experimental|Experimental - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered cranial electrotherapy stimulation with a frequency of .5 Hz and a current of 100 microamps during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
9756768|NCT00589914|Active Comparator|RISPERDAL CONSTA|RISPERDAL CONSTA 25-50 mg eq every 2 weeks
9756769|NCT00589914|Experimental|R092670|Paliperidone Palmitate 50-150 mg eq every 4 wks
9756770|NCT00589979|Experimental|Lidoderm (Lidocaine 5% Patch)|Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
9756771|NCT00589979|Placebo Comparator|Placebo Patch|Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
9756772|NCT00590005||Children with severe asthma|This group consists of children with severe asthma as defined per ATS workshop criteria (published in 2000).
9756773|NCT00590005||Children with non-severe asthma|This group includes children with asthma who do not meet the ATS criteria for severe asthma as outlined in the 2000 workshop report.
9756774|NCT00590018|Experimental|1|Subjects in this arm will receive a 5 day tapering course of hydrocortisone.
9756775|NCT00590018|Placebo Comparator|2|Subjects in this arm will receive 5 days of placebo.
9756776|NCT00590031|Experimental|1|External Beam Radiation Therapy, Cisplatin, Irinotecan
9756777|NCT00590044|Experimental|Insulin glargine+glulisine|Daily insulin glargine + glulisine before meals
9756778|NCT00590044|Active Comparator|Split-mixed NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
9756779|NCT00590161|Experimental|1|Pentoxifylline (PTX) 400 mg by mouth (PO) three times daily (TID)
9756780|NCT00590161|Placebo Comparator|2|Placebo three times daily (TID)
9756781|NCT00590226|Experimental|detremir + aspart insulin|Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously
9756782|NCT00590226|Active Comparator|NPH + regular insulin|NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously
9756783|NCT00590317|Active Comparator|Prochlorperazine|Patients receiving Prochlorperazine 10mg IV
9756784|NCT00590317|Active Comparator|Ondansetron|Patient receiving Ondansetron 4mg IV
9756785|NCT00590369|Active Comparator|1|KCI VAC type negative pressure wound therapy device
9756786|NCT00590369|Experimental|2|Versatile One (EZCare) negative wound therapy device
9756787|NCT00590395|Experimental|FDG-PET/CT to determine Cholecystitis|19 patients with suspected acute cholecystitis and a positive HIDA will be included in the study. This is purposely a highly selective population which most likely will have surgical proof of the findings. Subjects will receive an FDG PET/CT exam to determine the presence of gallbladder inflammation/infection(cholecystitis). Please note that 18FDG is an FDA approved radiopharmaceutical.
9756788|NCT00590460|Experimental|Single Arm Study: Stem Cell Transplant|CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion
9756789|NCT00590564|Experimental|1|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal.
9756790|NCT00590577|Experimental|001|Paliperidone palmitate 25 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8 36 64
9756791|NCT00590577|Experimental|002|Paliperidone palmitate 100 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8 36 64
9756792|NCT00590577|Experimental|003|Paliperidone palmitate 150 mg eq. Paliperidone palmitate 150 mg eq. i.m. Days 1 8 36 64
9831737|NCT03220776|Experimental|Gabapentin|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
9831738|NCT03220776|Placebo Comparator|Placebo Oral Tablet|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
9831739|NCT03207009|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
9831740|NCT03178617|Active Comparator|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
9831741|NCT03178617|Experimental|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
9831742|NCT03173534|Active Comparator|TAVR + Medical Therapy|n=175 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
9831743|NCT03173534|Experimental|TAVR + WATCHMAN|n=175 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
9831744|NCT03169166|Experimental|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
9831745|NCT03169166|No Intervention|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
9831746|NCT03157687||Healthy controls|"Blood sampling for nutrition and inflammatory status~Stool sampling before preventive gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
9831747|NCT03157687||Inflammatory bowel disease (IBD)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
9831748|NCT03157687||Liver transplantation recipient (LTX)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
9831749|NCT03128359|Experimental|Regimen A (fludarabine, melphalan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
9831750|NCT03128359|Experimental|Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
10202214|NCT04961112|Sham Comparator|Sham - Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. Participants will be told they may receive additional shocks for poor performance during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
9831751|NCT03128359|Experimental|Regimen C (fludarabine, TBI, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
9831752|NCT03113487|Experimental|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
9831753|NCT03094884|Experimental|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
9831754|NCT03091192|Experimental|Savolitinib|See: intervention description
9831755|NCT03091192|Active Comparator|Sunitinib|See: intervention description
9984086|NCT04443751|Experimental|SHR-1702 monotherapy|SHR-1702 monotherapy, given intravenously (IV); dose escalation and dose expansion.
10202215|NCT04961112|Sham Comparator|Sham - No Induced Anxiety|"Participants will be administered a shock procedure in which they are exposed to safe electrical shock that will be gradually increase from (1) 30 milliseconds to (4) 80 milliseconds to an individual threshold that is uncomfortable but not painful. After this procedure, the shock belt will be turned off. Participants will be told they will not receive additional shocks during cognitive assessments.~Participants will be administered sham cranial electrotherapy stimulation with no current during 30 minutes of cognitive assessments of task switching, inhibition (stroop), working memory (n-back), and processing speed (simple reaction time)."
9756793|NCT00590577|Placebo Comparator|004|Placebo Placebo i.m. Days 1 8 36 64
9756794|NCT00590590|Placebo Comparator|3 (Placebo)|
9756795|NCT00590590|Experimental|1 (Lidocaine)|
9756796|NCT00590590|Experimental|2 (Lidocaine/Diphenhydramine)|
9756797|NCT00590681|Experimental|one|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
9756798|NCT00590707|Active Comparator|Deeper sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 0. This is the deeper sedation arm."
9756799|NCT00590707|Active Comparator|Moderate sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 4-5. This is the moderate sedation arm."
9756800|NCT00590720|Experimental|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
9756801|NCT00590720|Placebo Comparator|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
9756802|NCT00590759|Other|GORE TAG® Thoracic Endoprosthesis|
9756803|NCT00590772|Active Comparator|montelukast|montelukast 10 mg daily
9756804|NCT00590772|Placebo Comparator|Placebo|Placebo tablet
9756805|NCT00590824|Experimental|A|Hu14.18-IL2 -->Resection-->Hu14.18-IL2
9756806|NCT00590824|Experimental|B|Resection -->Hu14.18-IL2-->Hu14.18-IL2
9756807|NCT00590863|Active Comparator|SSRI + placebo|Participants will take escitalopram plus placebo.
9756808|NCT00590863|Active Comparator|Escitalopram + Bupropion SR|Participants will take escitalopram + bupropion-SR.
9756809|NCT00590863|Active Comparator|Venlafaxine XR + Mirtazapine|Participants will take venlafaxine-XR + mirtazapine.
9756810|NCT00590889|Other|St. Jude Medical (SJM) Conventional|St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff
9756811|NCT00590889|Other|St. Jude Medical (SJM) Silzone|St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating
9756812|NCT00590902|Experimental|1 - OSI-774|
9756813|NCT00590954|Experimental|Treatment|Following a diagnosis of tumor recurrence or progression, all patients will receive perifosine monotherapy until toxicity, progression, or death.
9756814|NCT00590967|Experimental|Treatment Group 1|"Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin 40 mg/m^2"
9756815|NCT00590967|Experimental|Treatment Group 2|"Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m^2)"
9756816|NCT00590980||Observation|Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.
9756817|NCT00591006|Experimental|Four Treatments Per Participant|This study has one arm due to a crossover design. All 17 subjects received 4 treatments: placebo then placebo, phenytoin then placebo, placebo then hydrocortisone, and phenytoin then hydrocortisone. Each treatment was randomly assigned and had a unique sequence out of 24 possible sequences.
9756818|NCT00591019|Active Comparator|modafinil|
9756819|NCT00591019|Placebo Comparator|Placebo|
9756820|NCT00591123|Experimental|FOLFOX, plus 5-FU and Erlotinib|single arm
9756821|NCT00591149|Experimental|1|"Patients will be treated with oxaliplatin 130 MG/M2 IV over 2 hours on day 1 and docetaxel 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle. Cycles of treatment will be repeated every 3 weeks for a total of 4 cycles or until disease progression or intolerable toxicity.~Patients who were treated with 4 cycles of oxaliplatin and docetaxel and had a response or stable disease will be treated with cetuximab at 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks, or until disease progression or intolerable toxicity."
9756822|NCT00591214|Experimental|MP-424|
9756823|NCT00591240||Multiplex pathogen identification.|Urine samples of patients at risk for urinary tract infections were collected. Biosensor based assays were used to detect the most common uropathogens in these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
9831756|NCT03063918|Experimental|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
9831757|NCT03063606|Experimental|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
9831758|NCT03063606|Active Comparator|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
9831759|NCT03047005|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
9831760|NCT03047005|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
9831761|NCT03009240|Experimental|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
9831762|NCT03006016|Experimental|Omega 3|The patient will take Omega 3 before intervention 4-week course of 1.500 Mg/ day without caloric restriction
9831763|NCT03006016|Placebo Comparator|Placebo|The patient will take placebo before intervention 4-week course of 1.500 Mg/ day without caloric restriction
9831764|NCT03002103|Experimental|ET+P+G|
9831765|NCT03002103|Active Comparator|Control|
9831766|NCT02997865|Experimental|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.
9831767|NCT02997865|No Intervention|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
9831768|NCT02996825|Experimental|Treatment (IMGN853, gemcitabine hydrochloride)|Patients receive mirvetuximab soravtansine IV on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
9831769|NCT02944617|Experimental|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF-TKI treatment.
9831770|NCT02944617|Active Comparator|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
9984087|NCT04436042|Experimental|MyHand Treatment|Participants will use the MyHand device during repetitive grasp and release tasks.
9984088|NCT04435756||Observational (blood collection)|Patients undergo collection of blood every 3-6 months for up to 3 years.
9831773|NCT02918734|Experimental|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
9831774|NCT02918734|Active Comparator|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
9831775|NCT02905370|Experimental|Progressive Multi-Component (PMC)|High intensity strength training protocol, daily protein supplementation, functionally enhanced transitions of care
9831776|NCT02905370|Active Comparator|Usual Care (UC)|Low intensity rehabilitation protocol, standard education for nutrition, standard transitions of care
9984089|NCT04433390|Experimental|Naloxegol group|naloxégol tablet by oral route
9984090|NCT04433390|Placebo Comparator|Placebo group|inert tablet by oral route
9984091|NCT04432610|Experimental|Bisoprolol first, Nebivolol Second|In this arm, patient will first receive bisoprolol, and after 1 week washout period, nebivolol
9984092|NCT04432610|Experimental|Nebivolol first, Bisoprolol second|In this arm, patient will first receive nebivolol, and after 1 week washout period, bisoprolol
10202216|NCT04958044|Experimental|Calcium electroporation|Calcium gluconate 0.23 mmol/ml Maxium dosage 20 ml Intra tumoral injection
10202217|NCT04957992|Active Comparator|Control Feeding Group|Milk based product
10202218|NCT04957992|Experimental|Experimental Feeding Group|Milk based product with oligosaccharides
10202219|NCT04954469|Experimental|CoVAC-1 Vaccine|Peptide vaccination should be started as soon as possible after the screening visit. Or in case of two vaccinations: Peptide vaccination should be started as soon as possible after the screening visit (V1) and on day 42 (V5)
10202220|NCT04954196|Experimental|Amlodipine arm|Single dose per os Amlodipine 5mg administration per day
10202221|NCT04954196|Placebo Comparator|Placebo arm|Single dose per os placebo (microcrystalline cellulose) administration per day
10202222|NCT04950296|Active Comparator|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
10202223|NCT04950296|Active Comparator|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
10202224|NCT04950296|Placebo Comparator|Microcrystalline Cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
10202225|NCT04945395|Experimental|FES and conventional training|The experimental group will wear the Functional electrical stimulation system L3100 Go for dorsiflexion of the ankle during conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
9756824|NCT00591240||Antimicrobial susceptibility testing.|Urine samples of patients at risk of urinary tract infections were collected. Biosensor based antimicrobial susceptibility test, in concert with pathogen identification assay was directly performed on these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
9756825|NCT00591253|Experimental|Azilsartan Medoxomil 40 mg QD|
9756826|NCT00591253|Experimental|Azilsartan Medoxomil 80 mg QD|
9756827|NCT00591253|Placebo Comparator|Placebo QD|
9756828|NCT00591266|Experimental|Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD|
9756829|NCT00591266|Experimental|Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD|
9756830|NCT00591266|Active Comparator|Amlodipine 5 mg QD|
9756831|NCT00591305|Experimental|PDL+DIM pill|once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
9756832|NCT00591305|Placebo Comparator|PDL+placebo pill|once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects
9756833|NCT00591344|Active Comparator|Progressive resistance training|Subjects will perform between 60 and 90 minutes of progressive resistance training two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
9756834|NCT00591344|Active Comparator|Modified Fitness Counts|Subjects will perform between 60 and 90 minutes of modified Fitness Counts two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
9756835|NCT00591370|Experimental|1 - Temozolomide (TMZ)|
9756836|NCT00591409|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
9756837|NCT00591409|Experimental|Rocuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
9756838|NCT00591409|Experimental|Rocuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
9756839|NCT00591409|Experimental|Rocuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
9756840|NCT00591409|Experimental|Rocuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
9756841|NCT00591409|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
9756842|NCT00591409|Experimental|Vecuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
9756843|NCT00591409|Experimental|Vecuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
9756844|NCT00591409|Experimental|Vecuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
9756845|NCT00591409|Experimental|Vecuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
9756846|NCT00591565|Experimental|1|acamprosate tablets
9756847|NCT00591578|Experimental|Azilsartan Medoxomil 40 mg QD|
9756848|NCT00591578|Experimental|Azilsartan Medoxomil 80 mg QD|
9756849|NCT00591578|Active Comparator|Valsartan 320 mg QD|
9756850|NCT00591591|Experimental|OSA|Persons with suspected obstructive sleep apnea (OSA) undergoning overnight sleep evaluation
9984093|NCT04432272|Experimental|Group A|Hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring >6 L of oxygen to maintain oxygen saturation >92%. Patient may not require intubation, and may be admitted for no longer than 14 days.
9831779|NCT02876380||Prospective cohort|These are women who are currently pregnant and who have a LQTS mutation. This also includes women whose partner/father of the baby has a LQTS mutation. If the father of the child has the LQTS mutation, the father will also be enrolled.
9831780|NCT02876380||Retrospective cohort|In this cohort the investigators will collect information about previous pregnancies affected by the LQTS mutation. Parents may enroll in both retrospective and prospective cohorts
9831781|NCT02871934|Experimental|PGx+|Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
9831782|NCT02871934|Experimental|PGx-|Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
9831783|NCT02865135|Experimental|DPX-E7 Vaccine|Subjects will 2 priming doses of DPX-E7 at a pre-determine dosage 3 weeks apart followed by a predetermine booster dose every 8 weeks until clinical progression.
9831784|NCT02859558|Experimental|Arm 1: Fiebig I/II|Participants enrolled during Fiebig stages I or II (non-reactive HIV-1 antibody).
9831785|NCT02859558|Experimental|Arm 2: Fiebig III/IV|Participants enrolled during Fiebig stages III or IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2).
9831786|NCT02859558|Experimental|Arm 3: Fiebig V|Participants enrolled during Fiebig stage V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band).
9831787|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
9756851|NCT00591591|No Intervention|Controls|Healthy controls
9756852|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
9756853|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant
9756854|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant + Rituximab|BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
9756855|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant|BEAM + Rituximab Followed by Stem Cell Transplant
9756856|NCT00591721|Experimental|Energy conservation education|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles
9756857|NCT00591721|Other|Wait list control|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles.
9756858|NCT00591734|Experimental|Intervention|All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
9756859|NCT00591760|Experimental|GH|Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy
9831788|NCT02828839|Experimental|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
9831789|NCT02822469|Experimental|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
9831790|NCT02822469|Placebo Comparator|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
9831791|NCT02818920|Experimental|Pembrolizumab prior to and after surgery|
9756860|NCT00591760|No Intervention|Placebo|PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment
9756861|NCT00591773|Experimental|Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD|
9756862|NCT00591773|Experimental|Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD|
9756863|NCT00591773|Active Comparator|Chlorthalidone 25 mg QD|
9756864|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
9756865|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
9831792|NCT02787668|Experimental|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat.
9831793|NCT02787668|Active Comparator|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
9831794|NCT02754557|Experimental|Breath-Focused Meditation|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation.
9756866|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
9756867|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
9756868|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.8 mg/kg sugammadex was administered IV.
9756869|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
9756870|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
9756871|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
9756872|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
9756873|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
9756874|NCT00591825|Placebo Comparator|Non-Phobic Control - Placebo|Participants without phobia will be given one placebo administration.
9756875|NCT00591825|Active Comparator|Non-Phobic Control - DCS|Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
9756876|NCT00591825|Placebo Comparator|Spider-phobic Placebo|Participants with phobia will be given one placebo administration.
9756877|NCT00591825|Experimental|Spider-phobic DCS|Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
9756878|NCT00591838|Experimental|Phase I Dose Level A: SBRT 9Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
9756879|NCT00591838|Experimental|Phase I Dose Level B: SBRT 10Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
9756880|NCT00591838|Experimental|Phase I Dose Level C: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
9756881|NCT00591838|Experimental|Phase I Dose Level D: SBRT 12Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
9756882|NCT00591838|Experimental|Phase II: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
9756883|NCT00591851|No Intervention|1|single arm study
9756884|NCT00591942|Active Comparator|VivaGlass dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross over design. One dental crown cemented with VivaGlass Cement/subject. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
9756885|NCT00591942|Active Comparator|MultiLink dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross Over design. One dental crown per subject was cemented with Multilink Dental Cement. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
9756886|NCT00592072|Experimental|Medium chain fatty acid (Octanoic and Decanoic acid)|
9756887|NCT00592072|Placebo Comparator|Splenda (Placebo Control)|
9756888|NCT00592124|Experimental|1|Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
9756889|NCT00592124|Experimental|2|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
9756890|NCT00592124|Experimental|3|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
9756891|NCT00592124|Experimental|4|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
9756892|NCT00592124|Experimental|5|Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
9756893|NCT00592124|Experimental|6|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
9756894|NCT00592176|Experimental|Bevacizumab|Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
9756895|NCT00592319|Experimental|PDL+Celebrex|endoscopic treatment with once-time PDL radiation at 6.0-8.0 J on laryngeal papilloma, followed by oral taking of 9-month Celebrex (100mg, BID), in 15 subjects
9756896|NCT00592319|Active Comparator|standard surgery|"once-time and routine surgery, with either of carbon dioxide (CO2) laser radiation at 10.0-20.0 W or cold surgery with microinstruments, in 15 subjects"
9756897|NCT00592358|Experimental|1|
9756898|NCT00592384|Placebo Comparator|placebo|identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
9756899|NCT00592384|Experimental|venlafaxine XR|venlafaxine XR 37.5 - 300 mg/day for 12 weeks
9756900|NCT00592475|Experimental|Regimen 1 Conivaptan 12.5 mg|Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours
9756901|NCT00592475|Experimental|Regimen 2 Conivaptan 25 mg|Conivaptan intravenous loading dose (20 mg) + 5 mg continuous infusion over 6.5 hours
9756902|NCT00592475|Placebo Comparator|Regimen 3 Placebo|Placebo continuous intravenous infusion over 6.5 hours
9756903|NCT00592488|Other|A|Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
9756904|NCT00592488|Other|B|Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
9756905|NCT00592501|Experimental|Proton/Photon Radiotherapy, Cisplatin, Fluorouracil|
9756906|NCT00592553|Experimental|High-Dose Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.
9756907|NCT00592553|Experimental|Low-Dose Ataluren|Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
9756908|NCT00592553|Placebo Comparator|Placebo|Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.
9756909|NCT00592631|Experimental|CPAP|Subjects will use CPAP of 8-12 during days 2 through 6 of the study.
9756910|NCT00592631|Sham Comparator|SHAM|Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.
9756911|NCT00592683|Active Comparator|Aripiprazole plus Fish Oil|Subjects administered aripiprazole and randomized to receive fish oil
9756912|NCT00592683|Placebo Comparator|Aripiprazole plus Placebo|Subjects administered aripiprazole and randomized to receive placebo
9756913|NCT00592761|Experimental|Within subjects treatment, no-treatment|Within subject, treatment and no-treatment periods. Each participant served as his/her own control in this AABB/BBAA alternating treatment conditions design. Results were also compared across groups (treatment v. no-treatment).
9756914|NCT00592774|Placebo Comparator|Placebo Cohort 1|
9756915|NCT00592774|Experimental|Perampanel Cohort 1, 3-week Titration|
9756916|NCT00592774|Experimental|Placebo Cohort 2|
9756917|NCT00592774|Experimental|Perampanel Cohort 2, 1-week Titration|
9756918|NCT00592774|Experimental|Perampanel Cohort 2, 2- Week Titration|
9756919|NCT00592839|Experimental|1|0.3 mg SCE-B Daily
9756920|NCT00592839|Experimental|2|0.625 mg SCE-B Daily
9756921|NCT00592839|Placebo Comparator|3|Placebo
9756922|NCT00592852|Experimental|Fluoxetine|
9756923|NCT00592904|Experimental|1|
9756924|NCT00592943|Active Comparator|Armodafinil (100mg)|
9756925|NCT00592943|Active Comparator|Armodafinil (250 mg)|
9756926|NCT00593112|Experimental|OROS Methylphenidate|
9756927|NCT00593112|Other|Control|Healthy Volunteer Control group
9756928|NCT00593333|Active Comparator|1, A|Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.
9756929|NCT00593333|Experimental|2, B|Trigen Trochanteric Femoral Nail (Smith & Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur
9756930|NCT00593346|Experimental|Accelerated partial breast brachytherapy|Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
9756931|NCT00593372|Experimental|I|Drug Plus Behavioral Therapy
9756932|NCT00593372|No Intervention|II|Drug Therapy Only
9756933|NCT00593385|Other|iCAST covered stent|This is a one arm trial. All subjects received the iCAST covered stent.
9756934|NCT00593450|Active Comparator|1|Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.
9756935|NCT00593450|Experimental|2|Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.
9756936|NCT00593450|Experimental|3|Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
9756937|NCT00593450|Experimental|4|Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
9756938|NCT00593489|Experimental|Basal Insulin Initiation Strategy|"Basal Insulin Initiation Strategy which includes:~support by community pharmacist~support by diabetes specialist"
9756939|NCT00593489|No Intervention|Usual Practice|The physicians randomized to this group proceeded with their usual practice
9756940|NCT00593554|Active Comparator|1|Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
9756941|NCT00593554|Experimental|2|Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG
9756942|NCT00593606|Experimental|Rotigotine|Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.
9756943|NCT00593645|Experimental|Arm 1: Non-myeloablative conditioning regimen|"Clofarabine 40mg/m2/day IV over two hours daily x 5 days on Days -6 thru -2~Cytarabine 1gm/m2/day IV over two hours daily x 5 days on Days -6 thru -2 after the START of Clofarabine.~Thymoglobulin 1.0mg/kg IV over 6 hours X 1 day on Day -4, then 2.5mg/kg/day x 2 days on Days -3 and -2.~Stem Cell Transplant - On day 0 a minimum of total CD34+ cell dose of 2 x10E6/kg (actual weight of recipient) will be infused."
9756944|NCT00593684|Experimental|Algidex patch|Infants in this group received the Algidex patch on top of the line insertion sites of any of the following lines: umbilical arterial line, umbilical venous line, peripheral arterial line, peripheral long line, and central venous line. This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2. Every 7 days, each insertion site was cleansed and then a new patch was placed and covered with a fresh occlusive dressing (Tegaderm, Opsite).
9756945|NCT00593684|No Intervention|Control group|Infants in this group served as the control group and received line-dressing changes every 7 days according to standard hospital protocol specific for the type of line inserted. Insertion sites were covered with only an occlusive dressing (Tegaderm, Opsite).
9756946|NCT00593736|Experimental|Ramelteon 1 mg QD|
9756947|NCT00593736|Experimental|Ramelteon 4 mg QD|
9756948|NCT00593736|Experimental|Ramelteon 8 mg QD|
9756949|NCT00593736|Placebo Comparator|Placebo QD|
9756950|NCT00593827|Active Comparator|Arm 1|ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest
9756951|NCT00593827|Active Comparator|Arm 2|ixabepilone 40 mg/m^2 every 3 weeks
9756952|NCT00593840|Experimental|Intensity modulated radiation therapy (IMRT)|-This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume.
9756953|NCT00593866|Experimental|Radiation Dose Escalation with Gemcitabine|"INTENSITY MODULATED RADIOTHERAPY~Radiation dose escalation:~Total dose Dose per fraction BED* Dose equivalent (1.8 Gy/fraction) Level 1 45.0 1.8 53.1 45.0 Level 2 50.0 2.0 60.0 50.4 Level 3 52.5 2.1 63.5 54.0 Level 4 55.0 2.2 67.1 57.0 Level 5 57.5 2.3 70.7 60.0 Level 6 60.0 2.4 74.4 63.0 Level 7 62.5 2.5 78.1 66.2 Level 8 65.0 2.6 81.9 69.4~BED=Biological Effective Dose; =10 Five fractions weekly, fraction size determined by dose level~Gemcitabine:~1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment"
9756954|NCT00593918||Toll-like Receptor 4 -2026/GG Genotype|Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
9756955|NCT00593918||Toll-like Receptor 4 -2026/AG and AA Genotypes|Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection
9756956|NCT00593957|Experimental|DM1( 0.25 mg/kg /day)|Dextromethorphan 0.25 mg/kg per day
9756957|NCT00593957|Experimental|DM2 (2.5 mg/kg/day)|Dextromethorphan 2.5 mg/kg/day
9756958|NCT00593957|Experimental|DM3 (5mg/kg/day)|Dextromethorphan 5mg/kg/day
9756959|NCT00594009|Experimental|Venovenous CO2 Removal (VVCO2R) in COPD|All patients enrolled in the trial will receive VVCO2R which consists of a circuit with a centrifugal pump, tubing, double lumen intravenous catheter and hollow fiber oxygenator
9756960|NCT00594022|Active Comparator|"Group 1- VirtuSom - Stim"|Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
9756961|NCT00594022|Placebo Comparator|"Group 2- VirtuSom- Sham"|Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
9756962|NCT00594035|Experimental|1|Spinal Sealant
9756963|NCT00594035|Active Comparator|2|Standard of care
9756964|NCT00594061|Experimental|A|There is no arm to this study--(each participant serves ashis or her own control). Blinding or masking procedures are not included in the design, as it is not possible to conceal the presence or absence of a cochlear implant from device recipients and/or clinical investigators.
9756965|NCT00594100|Experimental|GFRS Pivotal Subjects|All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).
9756966|NCT00594165|Experimental|Rotigotine|Rotigotine
10202226|NCT04945395|Active Comparator|AFO and Conventional training only|The control group will wear an ankle-foot-orthosis (AFO) to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
10202227|NCT04944199|No Intervention|Control Group|
10202228|NCT04944199|Active Comparator|Intervention Group|
10202229|NCT04944108|Experimental|Surfactant administration with less invasive surfactant administration (LISA) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter)
10202230|NCT04944108|Active Comparator|Surfactant administration with intubation (INSURE) approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
10202231|NCT04941183|Experimental|NTR-441|Single Ascending Dose; Multiple Ascending Dose.
10202232|NCT04941183|Placebo Comparator|Placebo|Single Ascending Dose; Multiple Ascending Dose.
10202233|NCT04931771|Experimental|vFFR guided revascularization|
10202234|NCT04931771|Active Comparator|FFR guided revascularization|
10202235|NCT04927715||Diseased|Females with peripartum cardiomyopathy
10202236|NCT04927715||Control|Healthy females
9756967|NCT00594178|Experimental|A|Exercise group
9756968|NCT00594204|Active Comparator|varenicline|
10202237|NCT04923464||ELX/TEZ/IVA|CF participants who are currently on a stable regimen of commercially available ELX/TEZ/IVA will be evaluated for the performance of wearable technology devices. Wearable devices include a wrist-worn actigraphy sensor and an ambulatory cough monitoring system.
10202238|NCT04921865||Patients treated with the DPS VA-LCP® Clavicle Plate 2.7 System or Hook Plate 2.7 System|Any patient undergoing surgical treatment for the fixation of clavicle bone fragments and acromioclavicular joint dislocations using the DPS VA-LCP® Clavicle Plate 2.7 System or DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 .
9756969|NCT00594204|Placebo Comparator|placebo|
9756970|NCT00594230|Experimental|Panobinostat 20 mg|Treatment with LBH589 (Panobinostat) 20 mg
9756971|NCT00594230|Experimental|Panobinostat 30 mg|Treatment with LBH589 (Panobinostat) 30 mg
9756972|NCT00594256|Experimental|Sodium oxybate|Active treatment
9783073|NCT01192191|Experimental|Fluticasone Furoate/GW642444 100/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
9783074|NCT01192191|Experimental|Fluticasone Furoate/GW642444 200/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
9783075|NCT01192204|Active Comparator|10% FBR containing bioadhesive gel|Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site
9783076|NCT01192204|Placebo Comparator|Placebo Gel|Color/consistency matched placebo (no black raspberry) gel
9783077|NCT01192282||Genital Warts|All female patients with Genital Warts presenting to Groote Schuur Hospital
9783078|NCT01192295|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride (HCl) controlled-release (CR)
9783079|NCT01192399|Experimental|Eculizumab|Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses
9783080|NCT01192412|Active Comparator|'Less tight' control.|The diastolic blood pressure (dBP) treatment goal is 100 mmHg.
9783081|NCT01192412|Active Comparator|'Tight' control.|The diastolic blood pressure (dBP) treatment goal is 85 mmHg.
9783082|NCT01192516|Experimental|Arm 1|Tailored activity pacing
9783083|NCT01192516|Experimental|Arm 2|General activity pacing and symptom management (Occupational therapy)
9783084|NCT01192516|No Intervention|Arm 3|Usual care group
9783085|NCT01192542|Other|galyfilcon A prototype lens/enfilcon A lens|galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.
9783086|NCT01192542|Other|enfilcon A lens/galyfilcon A prototype lens|enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.
9783087|NCT01192815|Experimental|Arm I|Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9783088|NCT01192828|Experimental|Taurine|Treatment with Taurine
9783089|NCT01193010|Active Comparator|Control|Surgery without computer-assisted planning.
9783090|NCT01193010|Experimental|Computer-Assisted Surgical Planning|
9783091|NCT01193049|Experimental|Prednisone, then Placebo|Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
9783092|NCT01193049|Experimental|Placebo, then Prednisone|Placebo in the first crossover treatment period and prednisone in the second crossover treatment period
9783093|NCT01193101|Experimental|LCZ696 100 mg|LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
9783094|NCT01193101|Experimental|LCZ696 200 mg|LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
9783095|NCT01193101|Experimental|LCZ696 400 mg|LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.
9783096|NCT01193101|Placebo Comparator|Placebo|Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.
9783097|NCT01193114|Experimental|Ecologically-Based Behavioral Treatment|Ecologically-Based Treatment was provided over a period of 6 months. The treatment integrated independent housing, case management services and substance abuse counseling. Specifically, the mothers were housed in an apartment of their choice and received three months of utility and rental assistance of up to $600 per month.
9783098|NCT01193114|Active Comparator|Treatment as Usual|The Mothers were offered services provided through the family shelter.
9783099|NCT01193127|Experimental|OMS302 Solution|OMS302 Solution
9783100|NCT01193127|Experimental|OMS302 Mydriatic Solution|OMS302 Mydriatic Solution
9783101|NCT01193127|Experimental|OMS302 Anti-inflammatory Solution|OMS302 Anti-inflammatory Solution
9756973|NCT00594386|Experimental|Rotigotine|
9756974|NCT00594399|Experimental|Arm 1 Physical Activity counseling|Physical activity (PA) counseling program with the following components: baseline in-person counseling session; telephone calls, one physician endorsement of PA in a primary care clinic visit, monthly automated telephone calls from the primary care provider encouraging PA; and quarterly mailed materials providing personalized feedback.
9756975|NCT00594399|No Intervention|Arm 2|Usual care from primary, womens or geriatric clinics
9756976|NCT00594425|Experimental|1|PDT using MAL concentration A
9756977|NCT00594425|Experimental|2|PDT using MAL concentration B
9756978|NCT00594425|Placebo Comparator|3|PDT using Placebo cream
9756979|NCT00594464|Experimental|1|Rotigotine
9756980|NCT00594516|Experimental|001|tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
9756981|NCT00594516|Experimental|002|tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
9756982|NCT00594568|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.
9756983|NCT00594568|Experimental|100 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
9756984|NCT00594568|Experimental|140 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
9756985|NCT00594646|Other|Group 1|TRUVADA + raltegravir
9756986|NCT00594659|Active Comparator|1|Therapist delivered cognitive behavioral treatment
9756987|NCT00594659|Experimental|2|Computerized Cognitive Behavioral treatment
9756988|NCT00594659|Active Comparator|3|Motivational enhancement therapy
9756989|NCT00594685||Isolated HIT|Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test
9756990|NCT00594815|Experimental|1|
9756991|NCT00594854|Experimental|PN400|PN 400 (esomeprazole/naproxen) dosed twice daily
9756992|NCT00594854|Active Comparator|Diclofenac/Misoprostol|diclofenac 75mg/misoprostol 200 mcg dosed twice daily
9756993|NCT00594880|Active Comparator|Pegasys 180 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
9756994|NCT00594880|Active Comparator|Pegasys 90 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
9756995|NCT00594906|Active Comparator|Injection|30 participants will receive teriparatide (Forteo) injection pens.
9756996|NCT00594906|Placebo Comparator|Placebo|30 participants will receive placebo injection pens.
9756997|NCT00594932|Active Comparator|Arm I:|Participants randomly assigned to Arm I will receive mycophenolate mofetil in ascending doses during Month 1, and 3 grams/day (or less if there are tolerance issues) for Months 2 through 6. During Month 1 these participants receive the same number of pills as every other month, but with ascending doses of mycophenolate mofetil and descending numbers of placebo pills. Week one for a total of 1.5 gm/day of mycophenolate mofetil, Week two 2.0 gm/day, Week three 2.5 gm/day and Week 4 3 gm/day. Dose can be held or decreased for tolerance issues at any time.
9756998|NCT00594932|Placebo Comparator|Arm 2|Patients Randomly Assigned to Arm 2 will receive a placebo comparator. The placebo treatment will be structured so that they will undergo the same type of dosing in Month 1 that the ascending dose patient from Arm 1 undergo, but will have placebo in both bottles of pills. At the end of three months, after assessment of primary outcome, these patients enter open label treatment for three more months. During the fourth month this group continues to receive the same number of pills as they received before, with ascending doses of mycophenolate mofetil given vs descending placebo pills so that their induction is the same as those in Arm 1 at the first month.
9756999|NCT00594945|Experimental|Intranasal Clonazepam 2 mg|
9757000|NCT00594945|Experimental|Intranasal Clonazepam 3 mg|
9757001|NCT00594945|Experimental|Intranasal Clonazepam both Dose Groups 2 mg & 3 mg|
9757002|NCT00594958|Active Comparator|IC51 Group A|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
9757003|NCT00594958|Active Comparator|IC51 Group B|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
9757004|NCT00594958|Active Comparator|IC51 Group C|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
9757005|NCT00594997|Experimental|Education|Students who receive an educational intervention which consists of a 45 minute interactive presentation as well as a 30 minute health education entertainment by a juggler.
9757006|NCT00594997|Active Comparator|Control|Students who fill out pre and post surveys and receive the intervention after the post-survey
9757007|NCT00595075|Experimental|1|Ramelteon 8 mg will be given once prior to a 2-hour nap
9757008|NCT00595075|Placebo Comparator|2|Placebo will be given once prior to a 2-hour nap
10202239|NCT04920799|Active Comparator|Nitrate rich beetroot juice|
9984094|NCT04432272|Experimental|Group B|Hospitalized COVID-19 patients ages ≥18 years requiring intubation.
9757009|NCT00595088|Experimental|20 mg of BC-819/PEI|Six intravesical instillations of 20 mg of plasmid DNA (BC-819) complexed with PEI into the bladder of patients with intermediate-risk superficial bladder cancer [recurrent stages Ta (low or high grade) and T1 (low grade) TCC] who have failed prior intravesical therapies including BCG and/or chemotherapy.
9757010|NCT00595101|Experimental|PF-03187207 High Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
9757011|NCT00595101|Experimental|Latanoprost 0.005% and PF-03187207 Vehicle|A single drop of each, once daily in study eye for 28 days
9757012|NCT00595101|Experimental|PF-03187207 Medium Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
9757013|NCT00595101|Experimental|PF-03187207 Low Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
9757014|NCT00595114||MIA 1|Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo
9757015|NCT00595114||MIA 2|Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin
9757016|NCT00595114||MIA 3|Participants from the MIA trial who are PCR positive and have received treatment with placebo
9757017|NCT00595114||MIA 4|Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin
9757018|NCT00595114||LEUKO 1|Participants from the LEUKO trial who have received treatment with placebo
9757019|NCT00595114||LEUKO 2|Participants from the LEUKO trial who have received treatment with zileuton
9757020|NCT00595127|Experimental|1|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m^2 of unlabeled 8H9.
9757021|NCT00595153|Active Comparator|B|Asthmatics not on inhaled corticosteroids who will be put on an inhaled steroid during the study
9757022|NCT00595153|No Intervention|A|Healthy, non-asthmatics who will not be put on any intervention
9757023|NCT00595153|Active Comparator|C|Asthmatics, who are already on inhaled corticosteroids who will be put on standardized dose of inhaled corticosteroids
9757024|NCT00595231|Experimental|SYN111|500 mg 1 week, followed by 1000 mg for 7 weeks
9757025|NCT00595231|Placebo Comparator|Placebo|0 mg tablets
9757026|NCT00595270|Other|IC51|In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.
9757027|NCT00595309|Active Comparator|A|
9831795|NCT02754557|Experimental|Breath-Focused Meditation + Physiological Feedback|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation and physiological feedback.
9831796|NCT02716246|Experimental|Cohort 1 Low Dose|Dose of 0.5 X 10^13 vg/kg
9831797|NCT02716246|Experimental|Cohort 2 Mid Dose|Dose of 1 X 10^13 vg/kg
9831798|NCT02716246|Experimental|Cohort 3 High Dose|Dose of 3 X 10^13 vg/kg
9831799|NCT02692950|Other|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
9831800|NCT02657551|Experimental|Regorafenib|Regorafenib tablets orally, once daily at predetermined dosage for 21 days per cycle
9831801|NCT02633943||Subjects with Transfusion-Dependent β-Thalassemia|Subjects treated with ex vivo gene therapy product in a bluebird bio-sponsored clinical trial who agree to participate in this study
9831802|NCT02632045|Experimental|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
9831803|NCT02632045|Placebo Comparator|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
9831804|NCT02572791|Experimental|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
9831805|NCT02572791|Experimental|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
9831806|NCT02572791|Experimental|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
9831807|NCT02517034|Experimental|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
9831808|NCT02517034|Active Comparator|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
9984095|NCT04429685|Experimental|Low Dose Ketamine|
9984096|NCT04429685|Placebo Comparator|Saline (placebo)|
10202240|NCT04920799|Placebo Comparator|Nitrate depleted beetroot juice|
10202241|NCT04915274|Experimental|Adult cancer patients|Patients will be provided with the QuestOnco application for monitoring
9984097|NCT04428398||No renal involvement|Patients with ANCA-vasculitis and no ANCA-associated renal involvement in disease history
10202242|NCT04909957||Absence of invaded lymph node after extensive lymph node dissection|Absence of invaded lymph node after extensive lymph node dissection
10202243|NCT04909957||Presence of invaded lymph node after extensive lymph node dissection|Presence of invaded lymph node after extensive lymph node dissection
10202244|NCT04904029|Experimental|1. Digital Assessment Routing Tool (DART) 2. Physiotherapy-led remote triage|Participants complete the Digital Assessment Routing Tool (DART), which is followed by physiotherapy-led remote triage with the usual care clinician.
10202245|NCT04904029|Experimental|1. Physiotherapy-led remote triage 2. Digital Assessment Routing Tool (DART)|Participants complete their physiotherapy-led remote triage with the usual care clinician, which is followed by the Digital Assessment Routing Tool.
10202246|NCT04903717|Experimental|Intervention - Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record which alerts to the presence of HFrEF and the fact that the patient is not currently prescribed an MRA. A link to an order set for MRAs (or to potassium binders should a patient be hyperkalemic) will provided, along with a link to current best practices surrounding the use of MRAs.
10202247|NCT04903717|No Intervention|Usual Care|Providers will not receive a best practice alert for eligible patients and will continue to care for patients as usual.
10202248|NCT04891809|Experimental|IRd followed by IR|Induction: 8 cycles isatuximab+lenalidomide+dexamethasone; Maintenance: up to 24 cylces isatuximab+lenalidomide
10202249|NCT04891809|Other|Rd followed by R|Induction: 8 cycles lenalidomide+dexamethasone; Maintenance: up to 24 cylces lenalidomide
10202250|NCT04890938|Experimental|Sputum-guided management and comprehensive care management|The intervention consists of 6-months of CCM and sputum biomarker-directed treatment of airway inflammation, including hospital and clinic visits. Clinic visits at 2, 6, and 16 weeks. The key elements of CCM will be provided, including case management, self-management education, and coordination of community/hospital resources (1). Clinic nurse will review inhaler technique with the patient. Sputum (spontaneous) biomarkers will be measured with results used to direct therapy at the time of AECOPD and during clinic visits after hospital discharge, at both sites.
10202251|NCT04890938|Active Comparator|Usual Care|This group will also receive clinic visits at 2, 6, and 16 weeks with a study physician, and also education material, inhaler technique assessment and education, and case management from the clinic personnel. The study physician will pursue further investigation and/or further intervention if they see fit.
10202252|NCT04890106|Experimental|Bimatoprost 0.01% Ophthalmic Solution|"Bimatoprost Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Mankind Pharma Limited, India.~Intervention Drug: Test - Bimatoprost 0.01% Ophthalmic Solution"
10202253|NCT04890106|Active Comparator|LUMIGAN® 0.01% Ophthalmic Solution|"LUMIGAN® ( Contains Bimatoprost) Pharmaceutical dosage form: Ophthalmic Solution Strength: 0.01% Manufactured by: Allergan, Inc.,~Intervention Drug: Reference - Bimatoprost 0.01% Ophthalmic Solution"
10202254|NCT04889755|Other|SibACCESS|This is a single-arm trial of a group-based, posttraumatic stress intervention for adolescent siblings of children with cancer. The intervention includes one parent session and seven bi-weekly sibling sessions.
10202255|NCT04886427||Quickscan for patients and their kin|Patients and/or kin who are treated in the hospitals will be invited to fill in the quickscan.
10202256|NCT04886427||Quickscan for healthcare professionals|Healthcare professionals working in the hospitals will be invited to fill in the quickscan.
10202257|NCT04886388|Experimental|BT-001 + Standard of Care|BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
9984098|NCT04428398||Renal remission|Patient with ANCA-vasculitis in renal remission
10202258|NCT04886388|Active Comparator|Standard of Care|Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician
10202259|NCT04885881|Active Comparator|Ozone therapy group|Patients with myofascial pain syndrome receiving ozone injection
10202260|NCT04885881|Active Comparator|Lidocaine injection group|Patients with myofascial pain syndrome receiving lidocaine injection
10202261|NCT04885257|Placebo Comparator|Placebo|Patient with both PTSD and recent history of stroke. Placebo control arm. The frequency will be up to twice a day, with oral dosing.
10202262|NCT04885257|Experimental|Methylphenidate|Patient with both PTSD and recent history of stroke. Methylphenidate active arm. The oral dosing maximum will be up to 20mg twice daily.
10202263|NCT04884789|Experimental|Post-Burn Face scar|Use of 3d printed TFO with silicone interface (COFIS 3D)
10202264|NCT04883099|Experimental|APIOC for Presbyopia and Presbyopia with Astigmatism|Presbyopic Spherical or Toric Contact Lens
10202265|NCT04881916||Sample Collection|"Participation In:~Initial data completion: Telephone collection of information on disease, treatment and testing~Medical record collection: Collection of medical records regarding cancer, testing, and treatment history~Archival tissue collection: Collection of tumor from prior standard of care procedure~Saliva collection: Saliva collection with at home kit~Follow up data completion: Telephone collection of medical condition every 3-6 months up to 2 years."
10202266|NCT04881500|Experimental|Motivational interview|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient was randomized to the intervention group, the patient will receive 2 individual sessions (motivational interview) by telephone within 1 month of inclusion. They will then be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
10202267|NCT04881500|Active Comparator|Routine Care|"Patients followed in the primary care network participating in the study and those followed in the addictology network of northern Finistère in the context of their pathology will be offered the opportunity to participate in the study.~If the patient has been randomized to the control group, the patient will be assessed at month 1, month 3 and month 6. These assessments will be done by telephone."
10202268|NCT04880330|Experimental|Experimental: Cryo-Auriculotherapy|Patients benefit from 1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
10202269|NCT04880330|Sham Comparator|Sham Comparator: Control group|Patients benefit from 1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points..
10202270|NCT04878055|Experimental|Reparixin|Reparixin oral tablets, 1200 mg three times daily (TID) (2 tablets 600 mg each, TID) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care
10202271|NCT04878055|Placebo Comparator|Placebo|placebo, 2 tablets TID (identical to Reparixin tablets) for up to 21 days or until decision of discharge from the hospital, on top of standard supportive care.
10202272|NCT04872595|Experimental|P-rATG with total body irradiation, thiotepa, cyclophosphamide|"P-rATG days (always starting on Day -12 to -10)~Hyper fractionated total body irradiation (1375 - 1500cGy*) Day -9 to -6~Thiotepa (5mg/kg/day x 2 day) Day -5 to -4~Cyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2~GCSF Day +7 *TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
10202273|NCT04872595|Experimental|P-rATG with busulfan, melphalan and fludarabine|"P-rATG days (Appendix A - always starting on Day -12 to -10)~Busulfan -Day -9 to -7~Initial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5~Fludarabine (25mg/m2/day x 5 days) Day -6 to -2~GCSF Day +7"
10202274|NCT04871971|Placebo Comparator|Glucose|Glucose 50 g available carbohydrate
10202275|NCT04871971|Experimental|10 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 10 g NUTRALYS®S85 Plus pea protein
10202276|NCT04871971|Experimental|20 g NUTRALYS®S85 Plus pea protein|50 g available carbohydrate Glucose + 20 g NUTRALYS®S85 Plus pea protein
10202277|NCT04871971|Experimental|10 g Whey protein concentrate|50 g available carbohydrate Glucose + 10 g Whey protein concentrate
10202278|NCT04871971|Experimental|20 g Whey protein concentrate|50 g available carbohydrate Glucose + 20 g Whey protein concentrate
10202279|NCT04871360|Experimental|Citrulline group|Group of adolescents supplemented orally with 6 g / day of pure L-citrulline in capsules. The dose will be met by taking four (3 g) capsules in the morning before the first meal and four capsules (3 g) in the evening after the last meal.
10202280|NCT04871360|Placebo Comparator|Placebo group|Group of adolescents supplemented with placebo (carboxymethyl cellulose). The indication for taking will be the same as in the experimental group, four capsules in the morning before the first meal and four capsules at night, after the last meal.
10202281|NCT04867434|Active Comparator|RZL-012 50mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses 270 mg for the high doses. Each injection point will be dosed with 7.5 mg for the high dose in a volume of 0.15 mL/injection site.
9757028|NCT00595335|Experimental|Rituximab|Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion.
9757029|NCT00595335|Placebo Comparator|Placebo|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
9757030|NCT00595361|Active Comparator|Arg/Arg|Arg/Arg subjects on 2 week salmeterol treatment
9757031|NCT00595361|Active Comparator|Gly/Gly|Gly/Gly subjects on 2 week salmeterol treatment
9757032|NCT00595413|Experimental|Atacicept 150 mg with loading dose|
9757033|NCT00595413|Experimental|Atacicept 150 mg without loading dose|
9757034|NCT00595413|Active Comparator|Adalimumab|
9757035|NCT00595413|Placebo Comparator|Placebo|
9757036|NCT00595465|Active Comparator|IC51 Batch A|
9757037|NCT00595465|Active Comparator|IC51 Batch B|
9757038|NCT00595465|Active Comparator|IC51 Batch C|
9757039|NCT00595478|Experimental|1|Motivational Enhancement Therapy (MET)/CBT+CM/BPT
9757040|NCT00595478|Active Comparator|2|Motivational Enhancement Therapy (MET)/CBT
9757041|NCT00595504|Experimental|1|Ramelteon 8mg/day
9757042|NCT00595504|Placebo Comparator|2|sugar pill
9757043|NCT00595517|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
9757044|NCT00595530|Experimental|Ketamine|This group will receive ketamine
9757045|NCT00595556|Experimental|A|Zonisamide
9757046|NCT00595556|Placebo Comparator|B|placebo
9757047|NCT00595621|Active Comparator|MGP-1 ON|Experimental Pacemaker on for 6 weeks
9757048|NCT00595621|Active Comparator|MGP-1 OFF|Experimental Pacemaker on or off for 4 weeks
9757049|NCT00595764|Active Comparator|1|Physician Management
9757050|NCT00595764|Experimental|2|Physician Management plus Cognitive Behavioral Therapy
9757051|NCT00595790|Active Comparator|IC51 2 x 6 mcg|2 x 6 mcg (microgram)
9757052|NCT00595790|Active Comparator|IC51 1 x 12 mcg|1 x 12 mcg (microgram)
9757053|NCT00595790|Active Comparator|IC51 1 x 6 mcg|1 x 6 mcg (microgram)
9757054|NCT00595868|Experimental|Varenicline|
9757055|NCT00595868|Placebo Comparator|Placebo|
9757056|NCT00595881||Ultrasound|One group of patients will undergo emergency bedside ultrasound in addition to the clinical examination.
9757057|NCT00595946|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
9757058|NCT00595946|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
9757059|NCT00595959|Experimental|Laser Treatment|CLiRpath Photoablation Atherectomy System
9757060|NCT00596011|Active Comparator|Polyphenon E Treatment|Polyphenon E, 200 mg epigallocatechin gallate (EGCG) twice a day (BID)
9757061|NCT00596011|Placebo Comparator|Placebo Administration|Matching placebo BID
9757062|NCT00596167|Experimental|Intravenous antibiotics|Intervention: administer intravenous vancomycin, gentamicin and levofloxacin. This study will determine the pharmacokinetics of intravenous vancomycin, gentamicin and levofloxacin in subjects receiving short-daily hemodialysis. There will not be a control arm for this study. The intervention for this arm will be to administer intravenous vancomycin, gentamicin and levofloxacin and draw blood samples at periodic intervals. The blood samples will be tested for these medications and pharmacokinetic analysis will be performed.
9757063|NCT00596271|Active Comparator|IC51 and Placebo|6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
9757064|NCT00596271|Active Comparator|HAVRIX and placebo|HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
9757065|NCT00596271|Active Comparator|IC51 and HAVRIX|IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)
9757066|NCT00596362|Experimental|1|AVASTIN
9757067|NCT00596427|Placebo Comparator|Placebo tablet 3 tablets 2x/day|Type-2 diabetes mellitus patients
9757068|NCT00596427|Experimental|Colesevelam HCL 625 mg: 3 tablets 2x/day|Type-2 diabetes mellitus patients
9757069|NCT00596440||1|Relatives of Cancer Patients
9757070|NCT00596440||2|Relatives of Orthopedic Patients
9757071|NCT00596453|Placebo Comparator|Placebo|
9757072|NCT00596453|Experimental|Ciprofloxacin hydrochloride|
9757073|NCT00596466|Experimental|1|
9757074|NCT00596622|Experimental|Bipolar Manic Subjects Treated|Bipolar mania picture response during fMRI before and after treatment with lithium
9757075|NCT00596622|Experimental|Bipolar Depressed Subjects Treated|Bipolar depression picture response during fMRI before and after treatment with lithium
9757076|NCT00596622|Experimental|Bipolar Euthymic Subjects Treated|Bipolar euthymia picture response before and after treatment with lithium
9757077|NCT00596635|No Intervention|Control Group|No cranberry capsules administered
9757078|NCT00596635|Active Comparator|One cranberry capsule|1 650mg cranberry capsule daily
9757079|NCT00596635|Active Comparator|Two cranberry capsules|1 650 mg cranberry capsule twice daily (bid)
9757080|NCT00596687|Experimental|1|Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG > 140
9757081|NCT00596687|Active Comparator|2|Sliding scale regular insulin four-times daily achs.
9757082|NCT00596752|Experimental|Alprostadil|Prostavasin® 40 μg will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
9757083|NCT00596752|Placebo Comparator|Placebo|Placebo will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
9757084|NCT00596817|Placebo Comparator|Placebo|
9757085|NCT00596817|Experimental|Vortioxetine: 5 or 10 mg|
9757086|NCT00596830|Experimental|A|Patients in Arm A will receive CP-751, 871 in combination with paclitaxel and carboplatin intravenously every 21 days for up to six cycles.'
9757087|NCT00596830|Active Comparator|B|Patient in Arm B will receive paclitaxel and carboplatin intravenously every 21 days for up to six cycles.
9757088|NCT00596934|Experimental|Metreleptin treatment group|Treatment group
9757089|NCT00596960|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy
9757090|NCT00596960|Active Comparator|Health Education|health education intervention
9757091|NCT00597012|Experimental|Surgical|Participants will undergo arthroscopic partial menisectomy (APM) surgery and offered postoperative rehabilitative physical therapy.
9757092|NCT00597012|Active Comparator|Nonoperative|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks.
9757093|NCT00597038|Experimental|Phase I Dose Escalation|Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established.
9757094|NCT00597038|Experimental|Phase II Dose Treatment|Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm^2.
9757095|NCT00597116|Active Comparator|1|Vinorelbine
9757096|NCT00597116|Experimental|2|Vandetanib
9757097|NCT00597207|Experimental|1|Mechanical CPR with AutoPulse
9757098|NCT00597207|Other|2|Manual CPR
9757099|NCT00597246|Experimental|1|
9757100|NCT00597272|Experimental|1|Vaccine- KLH conjugates with GD2L and GD3L
9757101|NCT00597376|Experimental|1|On Cerefolin NAC and open-label multivitamin supplement
9757102|NCT00597376|Placebo Comparator|2|On placebo and open label multivitamin supplement
9757103|NCT00597402|Experimental|Avastin, radiation, temozolomide, and irinotecan|
9757104|NCT00597428|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
9757105|NCT00597428|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
9757106|NCT00597493|Experimental|Sorafenib + Temozolomide|"Subjects receive 400mg of Sorafenib twice daily and 50mg/m^2 of Temozolomide once daily~Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure"
9757107|NCT00597506|Experimental|Bevacizumab and Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
9757108|NCT00597519|Experimental|Treatment|Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
9757109|NCT00597545|Active Comparator|Conventional Shunt|"Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt only if it is indicated by EEG, by conventional management."
9783102|NCT01193127|Placebo Comparator|Balanced Salt Solution (BSS) Solution|Balanced Salt Solution (BSS) Solution
9757110|NCT00597545|Experimental|Prophylactic Shunt|Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt even when by standard criteria they would not need to receive one.
9757111|NCT00597558|Experimental|Egg white protein|Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
9757112|NCT00597584|Experimental|Peginesatide|
9757113|NCT00597584|Active Comparator|Epoetin|
9757114|NCT00597675|Placebo Comparator|Placebo|Oat flour ingested daily as a placebo
9757115|NCT00597675|Active Comparator|Peanut OIT|Peanut flour ingested daily as oral mucosal immunotherapy
9757116|NCT00597701|Active Comparator|Baclofen|Standard benzodiazepine therapy plus baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
9757117|NCT00597701|Placebo Comparator|Placebo|Standard benzodiazepine therapy plus placebo every eight hous as inpatients for 72 hours or until discharge if less than 72 hours.
9757118|NCT00597714|Experimental|Cohort A - Lymphoid Disease|Group A: Patients with a high chance of progressive lymphoid or myelomatous disease undergo Non-myeloablative Stem Cell Transplantation.
9757119|NCT00597714|Experimental|Cohort B - Myeloid Disease|Group B: Patients with a high chance of progressive myeloid diseases, marrow failure syndromes or myeloproliferative disorders undergo Non-myeloablative Stem Cell Transplantation.
9757120|NCT00597714|No Intervention|Donor|Donor priming and apheresis will include filgrastim 8 mcg/kg subcutaneously twice daily for 4 days prior to stem cell collection and continuing until pheresis is completed. Alternative mobilization strategies may be employed at the investigator's discretion.
9757121|NCT00597727|Active Comparator|Blinded Peanut SLIT|Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
9757122|NCT00597727|Placebo Comparator|Blinded Placebo SLIT|Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
9757123|NCT00597727|Other|Ext. maint. open label peanut SLIT|After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
9757124|NCT00597727|Other|Early unblinded peanut SLIT|Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
9757125|NCT00597727|Other|Pilot peanut SLIT rollover cohort|Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.
9757126|NCT00597753|Experimental|Peginesatide|
9757127|NCT00597753|Active Comparator|Epoetin alfa|
9757128|NCT00597766|Active Comparator|Low Dose|"Drug: Lidocaine (Neer's Test)~Drug: 20 mg Triamcinolone + Lidocaine"
9757129|NCT00597766|Active Comparator|Standard Dose|"Drug: Lidocaine (Neer's Test)~Drug: 40 mg Triamcinolone + Lidocaine"
9757130|NCT00597766|Experimental|High Dose|"Drug: Lidocaine (Neer's Test)~Drug: 60 mg Triamcinolone + Lidocaine"
9757131|NCT00597818|Placebo Comparator|Placebo|Participants receive matching placebo capsules for 20 months
9757132|NCT00597818|Experimental|Cobiprostone QD|Participants receive 18 mcg cobiprostone once daily (QD) for 20 months
9757133|NCT00597818|Experimental|Cobiprostone BID|Participants receive 18 mcg cobiprostone twice daily (BID) for 20 months
9757134|NCT00597818|Experimental|Cobiprostone TID|Participants receive 18 mcg cobiprostone three times daily (TID) for 20 months
9757135|NCT00597896|Experimental|Active pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
9757136|NCT00597896|Placebo Comparator|Placebo pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
9757137|NCT00597935|Experimental|SSLF and PMT|Sacrospinous Ligament Fixation (SSLF) and Pelvic Muscle Training & Exercises (PMT)
9757138|NCT00597935|Experimental|ULS and PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) and Pelvic Muscle Training & Exercises (PMT)
9757139|NCT00597935|Experimental|SSLF without PMT|Sacrospinous Ligament Fixation (SSLF) without Pelvic Muscle Training & Exercises (PMT)
9757140|NCT00597935|Experimental|ULS without PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) without Pelvic Muscle Training & Exercises (PMT)
9757141|NCT00598078|Experimental|1|
9757142|NCT00598078|Experimental|2|
9757143|NCT00598078|Placebo Comparator|3|
9757144|NCT00598273|Experimental|Peginesatide 0.025 mg/kg|
9757145|NCT00598273|Experimental|Peginesatide 0.04 mg/kg|
9757146|NCT00598273|Active Comparator|Darbepoetin Alfa|
9757147|NCT00598442|Experimental|Peginesatide 0.025 mg/kg|
9757148|NCT00598442|Experimental|Peginesatide 0.04 mg/kg|
9757149|NCT00598442|Active Comparator|Darbepoetin alfa|
9757150|NCT00598481|Experimental|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
9757151|NCT00598507|Experimental|Chemotherapy - ZK-EPO|ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.
9757152|NCT00598559|Experimental|1 g IV Acetaminophen|1 g q6h IV Acetaminophen
9757153|NCT00598559|Experimental|650 mg IV Acetaminophen|650 mg q4h IV Acetaminophen
9757154|NCT00598559|Other|Standard of Care|The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
9757155|NCT00598585|Experimental|sidenafil|sidenafil
9757156|NCT00598585|Placebo Comparator|placebo|placebo
9757157|NCT00598650|Experimental|1|
9757158|NCT00598663|Experimental|Off/On|"6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]~4 month wash out period~6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]"
9757159|NCT00598663|Experimental|On/Off|"6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]~4 month wash out period~6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]"
9757160|NCT00598689|Experimental|Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive 0.3% hypromellose ophthalmic solution prior to surgery.
9757161|NCT00598689|No Intervention|No Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive no intervention of 0.3% hypromellose ophthalmic solution prior to surgery
9757162|NCT00598702|Experimental|IV Acetaminophen|40 to 75 mg/kg/day every 4 to 6 hours
9757163|NCT00598806|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
9757164|NCT00598806|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
9757165|NCT00598819|Experimental|Healthy Volunteers|Healthy subjects testing the device.
9757166|NCT00598832|Experimental|Adapalene lotion 0.1%|
9757167|NCT00598832|Placebo Comparator|Adapalene Lotion vehicle|
9757168|NCT00598871|Placebo Comparator|2|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
9757169|NCT00598871|Active Comparator|1|There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
9757170|NCT00598975|Active Comparator|NKTR-102 100 mg/m2 + Cetuximab|"NKTR-102 100 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
9757171|NCT00598975|Active Comparator|NKTR-102 125 mg/m2 + Cetuximab|"NKTR-102 125 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
9783103|NCT01193153|Experimental|001|paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
9783104|NCT01193153|Placebo Comparator|002|Placebo monthly by i.m. injection for 15 months
9783105|NCT01193218|Experimental|BI 10773 low dose QD|BI 10773 tablets low dose once a day
9783106|NCT01193218|Experimental|BI 10773 mid-low dose QD|BI 10773 tablets mid-low dose once a day
9783107|NCT01193218|Experimental|BI 10773 mid-high dose QD|BI 10773 tablets mid-high dose once a day
9783108|NCT01193218|Experimental|BI 10773 high dose QD|BI 10773 tablets high dose once a day
9783109|NCT01193218|Placebo Comparator|Placebo|Placebo tablets once a day
9783110|NCT01193244|Experimental|Orteronel + prednisone|
9783111|NCT01193244|Placebo Comparator|Placebo + prednisone|
9783112|NCT01193257|Experimental|Orteronel + prednisone|
9783113|NCT01193257|Placebo Comparator|Placebo + prednisone|
9785483|NCT01253148|Experimental|Arterial Injection of 90-Y Microspheres|Intrahepatic Arterial Injection of 90-Y Glass Microspheres as First-Line Treatment For Cholangiocarcinoma
9984099|NCT04426812||MTurk sample|Data collected from a sample of participants in an online convenience platform called MTurk who self-identify as having chronic pain.
9757172|NCT00599053|Experimental|1|Early treatment with azithromycin
9757173|NCT00599053|No Intervention|2|Expectant (usual) management
9757174|NCT00599196|Experimental|Rotigotine|Rotigotine
9757175|NCT00599248|Experimental|1|TissueGene-C single intraarticular injection of 3x10e6 cells/joint
9757176|NCT00599248|Experimental|2|TissueGene-C single intraarticular injection of 1x10e7 cells/joint
9757177|NCT00599248|Experimental|3|TissueGene-C single intraarticular injection of 3x10e7 cells/joint
9757178|NCT00599248|Placebo Comparator|4|Placebo control single intraarticular injection
9757179|NCT00599313|Experimental|Sunitinib Malate|Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
9757180|NCT00599326|Experimental|A|
9757181|NCT00599339||Neupro|Neupro at study onset
9757182|NCT00599339||Dopamine Agonist|Other Dopamine-Agonist at study onset
9757183|NCT00599339||L-Dopa|L-Dopa
9757184|NCT00599339||Neupro + L-Dopa|Neupro in combination with L-Dopa at study onset
9757185|NCT00599339||Dopamine Agonist + L-Dopa|Other Dopamine Agonist in combination with L-Dopa at study onset
9757186|NCT00599521|Experimental|Adapalene lotion 0.1%|
9757187|NCT00599521|Placebo Comparator|Adapalene Lotion vehicle|
9757188|NCT00599638|Active Comparator|1|
9984100|NCT04426812||KnowledgePanel|Data collected from a sample of panel members in an online representative panel called KnowledgePanel who self-identify as having chronic pain.
9984101|NCT04423458||Transplanted kidney|No intervention is required. Routine Doppler assessment + 3D scan + Shear wave elastography + MicrFlow Imaging will be immediately recorded afterwards
9757189|NCT00599638|Experimental|2|
9757190|NCT00599638|Placebo Comparator|3|
9757191|NCT00599755|Experimental|Gem/Cis or Gem/Carbo|
9757192|NCT00599872|Active Comparator|Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract administered via the sublingual oral route (27.6 to 77.3 Amb a 1 Units)
9757193|NCT00599872|Placebo Comparator|Placebo|Standardized Ragweed Allergenic Extract Placebo via the sublingual oral route
9757194|NCT00599924|Experimental|Single arm|"SU011248 [sunitinib] in combination with FOLFOX; FOLFOX is a chemotherapy regimen that combines oxaliplatin and leucovorin with bolus and infusion 5-FU. The modified FOLFOX 6 (mFOLFOX6) regimen is one of several different regimens of FOLFOX used in clinic, according to different dosages of the 4 drugs. mFOLFOX6 was administered every 2 weeks on Days 1 and 2 of each cycle.~25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in three different dosing regimens: schedule 2/2 (2 weeks on, 2 weeks off), schedule 4/2 (4 weeks on, 2 weeks off), and continuous daily dosing (every day); FOLFOX will be administered every 2 weeks, using the modified FOLFOX 6 (mFOLFOX6) regimen, consisting of: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 as a 2-hr IV infusion; 5-FU 400 mg/m2 IV bolus, followed by - 5-FU 2400 mg/m2 as a 46-hr IV infusion"
9757195|NCT00600028|Experimental|Experimental: Thalidomide, then placebo|Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
9757196|NCT00600028|Experimental|Experimental: Placebo, then Thalidomide|Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.
9757197|NCT00600067|Experimental|1|
9757198|NCT00600067|Placebo Comparator|2|
9757199|NCT00600080|Other|etafilcon A first nelfilcon A second|etafilcon A worn daily during week 1, nelfilcon A worn daily for week 2
9757200|NCT00600080|Other|nelfilcon A first, etafilcon A second|nelfilcon A worn daily during week 1, etafilcon A worn daily for week 2
9757201|NCT00600106|Active Comparator|Hormone replacement therapy|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
9757202|NCT00600106|Placebo Comparator|Placebo|1mg placebo
9757203|NCT00600119|Placebo Comparator|A|Placebo
9757204|NCT00600119|Experimental|B|NKTR-118
9757205|NCT00600171|Placebo Comparator|Placebo|Placebo Multi dose dry powder inhlaer
9757206|NCT00600171|Experimental|GW642444M|GW642444M
9757207|NCT00600340|Active Comparator|A Bev+Pac|Bevacizumab plus Paclitaxel
9757208|NCT00600340|Active Comparator|B Bev+Cap|Bevacizumab plus Capecitabine
9783114|NCT01193283|Experimental|SAA hematologic response|Treatment-naive severe aplastic anemia patients will receive a low dose of cyclophosphamide (120mg/kg) and low dose cyclosporine ( target therapeutic level of 100-200 micrograms per liter). Cyclophosphamide will be given once daily for 4 doses. Cyclosporine will be started after cyclophosphamide completion, cyclosporine will be given twice daily. The dosing will be modified to attain the therapeutic level.
9783115|NCT01193335|Active Comparator|Group 1: Preterm infants|Infant born at < 37 weeks of gestation.
9783116|NCT01193335|Active Comparator|Group 2: Term infants|Infants born at ≥ 37 weeks of gestation
9783117|NCT01193348|Experimental|Eculizumab|
9783118|NCT01193517|Experimental|Phase I|Dose Escalation of Azacitidine + CAPOX (Capecitabine, Oxaliplatin)
9783119|NCT01193517|Experimental|Phase II|MTD of Azacitidine + CAPOX
9783120|NCT01193582|Experimental|Group 1|
9783121|NCT01193582|Experimental|Group 2|
9783122|NCT01193582|Experimental|Group 3|
9783123|NCT01193582|Experimental|Group 4|
9783124|NCT01193608|Experimental|0.5 mg/kg AAB-003|
9783125|NCT01193608|Experimental|1 mg/kg AAB-003|
9783126|NCT01193608|Experimental|2 mg/kg AAB-003|
9783127|NCT01193608|Experimental|4 mg/kg AAB-003|
9783128|NCT01193608|Experimental|8 mg/kg AAB-003|
9783129|NCT01193608|Placebo Comparator|Placebo|
9783130|NCT01193660|Experimental|Umbilical Cord Blood & Erythropoietin & Rehabilitation|Allogenic umbilical cord blood infusion, erythropoietin injection & active rehabilitation
9783131|NCT01193660|Active Comparator|Erythropoietin & Rehabilitation|Erythropoietin injection, active rehabilitation
9783132|NCT01193660|Placebo Comparator|Only Rehabilitation|Active rehabilitation
9783133|NCT01193686|Experimental|Peer Visitation Training (Peer Mentor)|Veteran Peer Visitors participated in a 2-day training program and then provide at 1-5 visits to at least 2 recipients.
9783134|NCT01193686|Experimental|Peer Visitation|Veterans who received at least one visit from a Veteran Peer Visitor.
9783135|NCT01193868|Experimental|RO4929097|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for pharmacogenetic, pharmacodynamic, and biomarker studies by IHC, FISH, and TUNEL assay."
9783136|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 12.5 mcg|1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM
9783137|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 5 mcg|1 dose of 0.5 mL containing 5 mcg of Vi-CRM
9783138|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 1.25 mcg|1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM
9783139|NCT01193907|Active Comparator|Typherix|1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide
9783140|NCT01193920|Experimental|1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg|Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
9783141|NCT01193920|Placebo Comparator|2: Placebo - Sterile saline|Non-Pregnant Women who received two injection of saline solution.
9831809|NCT02486718|Experimental|Atezolizumab|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
9757209|NCT00600353|Experimental|Melphalan, dexamethasone, aprepitant, palonosetron|"Group A: Subjects with Multiple Myeloma~Conditioning regimen, over a 7 day period, includes:~Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion~Group B: Subjects with Lymphoma~Conditioning regimen, over a 7 day period, includes: (BEAC)~BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant"
9757210|NCT00600613|Experimental|1|Patients going for treatment of liver metastases with radiation therapy.
9831810|NCT02486718|Active Comparator|Best Supportive Care|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
9831811|NCT02483988|Experimental|NUsurface Meniscus Implant|All eligible patients will receive the NUsurface® Meniscus Implant.
9831812|NCT02481310|Experimental|Treatment (combination chemotherapy, rituximab, ixazomib)|"INDUCTION:~Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.~CNS PROPHYLAXIS:~Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.~MAINTENANCE:~Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity."
9831813|NCT02472665|Experimental|plasma-derived FVIII/VWF concentrate|Pharmacokinetic single dose study with Fanhdi (high-purity Von Willebrand containing FVIII concentrate)
9757211|NCT00600704|Active Comparator|RESTRICTED FLUIDS|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass
9757212|NCT00600704|Active Comparator|FREE FLUIDS|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
9757213|NCT00600743|Placebo Comparator|1 'Instructions to eat normally'|'Instructions to eat normally' Placebo 1 mg dose
9831814|NCT02463305|Experimental|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
9757214|NCT00600743|Active Comparator|2 'Instructions to eat normally'|'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
9757215|NCT00600743|Placebo Comparator|3 'Instructions to eat normally'|'Instructions to eat normally' 2 mg placebo
9757216|NCT00600743|Active Comparator|4 'Instructions to eat normally'|'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
9757217|NCT00600743|Placebo Comparator|5 'Instructions to eat normally'|'Instructions to eat normally' 4 mg placebo
9831815|NCT02463305|Placebo Comparator|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
10202282|NCT04867434|Active Comparator|RZL-012 34mg/ml|Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal doses of 183.6 mg for the low dose. Each injection point will be dosed with 5.1 mg RZL-012 for the low dose in a volume of 0.15 mL/injection site.
10202283|NCT04867434|Placebo Comparator|Placebo|Placebo (vehicle) subjects will be injected with a 0.15 mL vehicle per each injection site. The maximal injection volume for all groups will be up to 5.4 mL.
10202284|NCT04864925|Experimental|Colgate Total Clean Mint|Brush with toothpaste for a minimum of 2 minutes
10202285|NCT04864925|Active Comparator|Tom's Botanically Bright Peppermint|Brush with toothpaste for a minimum of 2 minutes
10202286|NCT04860804|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
9757218|NCT00600743|Active Comparator|6 'Instructions to eat normally'|'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
10202287|NCT04860804|Active Comparator|OK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine
10202288|NCT04856904|Placebo Comparator|Trifarotene Vehicle Cream|
10202289|NCT04856904|Experimental|Trifarotene (CD5789) 50 mcg/g Cream|
10202290|NCT04856488|Experimental|Iodine Potassium Iodide solution|Participants receive Iodine Potassium Iodide solution oral drops 3 times per day for 10 Days prior to thyroidectomy in addition to standard preoperative treatment
10202291|NCT04856488|No Intervention|No intervention|Participants continue with standard preoperative treatment
10202292|NCT04855474|Experimental|Low Protein|0.2 g/kg/day of protein provided as crystalline amino acid made after egg protein.
10202293|NCT04855474|Experimental|Moderate Protein|1.2g/kg/day of protein provided as crystalline amino acid made after egg protein.
10202294|NCT04855474|Experimental|High Protein|2.0 g/kg/day of protein provided as crystalline amino acid made after egg protein.
10202295|NCT04854642|Experimental|T - R (fed then fasting condition)|Subjects were assigned to the sequence of treatments TR to receive Ladarixin in fed conditions (T treatment) during period 1 and in fasting conditions (R treatment) in period 2.
9757219|NCT00600743|Placebo Comparator|7 Instructions to binge eat|Instructions to binge eat 4 mg placebo
9757220|NCT00600743|Active Comparator|8 Instructions to binge eat|Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'
9757221|NCT00600756|Experimental|Quetiapine XR|
9757222|NCT00600756|Active Comparator|Risperidone|
9757223|NCT00600821|Active Comparator|B|Bevacizumab will be administered in combination with carboplatin and paclitaxel.
9757224|NCT00600821|Experimental|A|AG-013736 will be administered in combination with carboplatin and paclitaxel.
9757225|NCT00600886|Experimental|Pasireotide LAR|Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
9757226|NCT00600886|Active Comparator|Octreotide LAR|Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
9757227|NCT00600925|Experimental|1|Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
9757228|NCT00600925|No Intervention|2|Standard of care, ie, no gentamicin-collagen sponge.
9757229|NCT00600938|Experimental|Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
10202296|NCT04854642|Experimental|R - T (fasting then fed condition)|Subjects were assigned to the sequence of treatments RT to receive Ladarixin ini fasting conditions (R treatment) in period 1 and in fed conditions (T treatment) during period 2.
10202297|NCT04854629|Experimental|Spinomed active orthosis|Wearing the orthosis for 16 weeks
9757230|NCT00600938|Active Comparator|Deferasirox Placebo|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
9757231|NCT00600938|Experimental|Extension: deferoxamine to deferasirox|"DFO to ICL (patients who switched from DFO to deferasirox in extension)"
9757232|NCT00600938|Experimental|Extension: deferasirox to deferoxamine|"ICL to DFO (patients who switched from deferasirox to DFO in extension)"
9757233|NCT00601107|Experimental|Doxercalciferol 2.5 mcg/day|Doxercalciferol 2.5 microgram (mcg) capsule orally once daily up to Week 24.
9757234|NCT00601107|Experimental|Doxercalciferol 5 mcg/day|Doxercalciferol 5 mcg capsules orally once daily up to Week 24.
9757235|NCT00601107|Experimental|Doxercalciferol 7.5 mcg/day|Doxercalciferol 7.5 mcg capsules orally once daily up to Week 24.
9757236|NCT00601107|Placebo Comparator|Placebo|Placebo matching to doxercalciferol capsules orally once daily up to Week 24.
9757237|NCT00601146|Experimental|Low-dose Chest CT screening|Annual low-dose Chest CT screening
9757238|NCT00601172|Placebo Comparator|Control|Placebo + standard antiemetics
9757239|NCT00601172|Experimental|Single Dose IV|Casopitant + standard antiemetics
9757240|NCT00601250|Experimental|Linagliptin|Patients receive linagliptin 5 mg tablets once daily
9757241|NCT00601250|Placebo Comparator|Placebo|Patients receive placebo tablets matching linagliptin 5 mg tablets once daily
9757242|NCT00601354|Experimental|Emotion Regulation Group therapy + alli|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program, plus 12 weekly sessions of guided self-help group psychotherapy
9757243|NCT00601354|Active Comparator|Orlistat/alli program meds only|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program alone
10202298|NCT04854629|No Intervention|Control group|No intervention: non spinomed active control
10202299|NCT04850820|Experimental|Novel essential amino acid supplementation (EAA+)|Arm will investigate the effect of a novel essential amino acid-based formula (essential amino acids enriched with active botanical compounds; EAA+) developed by Iovate Health Sciences International Inc. on post-exercise anabolism. The formulation was recently granted a Natural Product Number (NPN: 80087022) and approved by the Natural and Non-prescription Health Products Directorate of Health Canada.
10202300|NCT04850820|Active Comparator|Branched-chain amino acid supplementation (BCAA)|Arm will used a branched-chain amino acid supplement developed by Iovate Health Sciences International Inc. to compare with the experimental arm after exercise.
10202301|NCT04850820|Placebo Comparator|Isocaloric carbohydrate supplementation|Carbohydrate supplement that is isocaloric to the EAA+ supplement and designed to function as a placebo to the experimental arm after exercise.
10202302|NCT04850820|Other|Rested control|Carbohydrate supplement that is isocaloric to the EAA+ supplement but consumed at rest to serve as the baseline control
10202303|NCT04844983|Experimental|Part 1: Arm A|STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.
10202304|NCT04844983|Experimental|Part 1: Arm B|STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.
10202305|NCT04844983|Experimental|Part 1: Arm C|STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.
10202306|NCT04844983|Other|Part 1: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
10202307|NCT04844983|Experimental|Part 2: Arm A, B or C|STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.
10202308|NCT04844983|Experimental|Part 2: Arm A or B or C|STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.
10202309|NCT04844983|Other|Part 2: Arm D|Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
10202310|NCT04840901|Experimental|Lebrikizumab - Pre-Filled Syringe with Needle Safety Device|Lebrikizumab administered subcutaneously (SC) via pre-filled syringe with needle safety device (PFS-NSD).
9831816|NCT02463305|Experimental|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
9831817|NCT02456389|Active Comparator|Standard perioperative management|Standard postoperative care
9831818|NCT02456389|Experimental|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
9831819|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)|Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9831820|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)|Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9831821|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A)|Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9831822|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)|BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9831823|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)|Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9831824|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort B)|Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9984102|NCT04423211|Active Comparator|Arm A (EBRT, goserelin, leuprolide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline.~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT for 6 months. Patients also receive goserelin acetate SC or leuprolide acetate IM for 6 months starting up to 3 months prior to EBRT but no later than the first fraction of EBRT. All treatment continues for 6 months in the absence of disease progression or unacceptable toxicity."
9984103|NCT04423211|Experimental|Arm B (EBRT, goserelin, leuprolide, apalutamide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline.~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide PO QD for 6 months in the absence of disease progression or unacceptable toxicity."
9984104|NCT04423211|Experimental|Arm C (EBRT, goserelin, leuprolide, apalutamide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline. NOTE: Patients randomized to Arm C undergo a repeat fluciclovine F18 PET/CT at time of second PSA recurrence or 12 months after completion of enhanced systemic therapy.~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide PO QD as in Arm B."
9984105|NCT04423211|Experimental|Arm D (EBRT, goserelin, leuprolide, apalutamide, RT)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline. NOTE: Patients randomized to Arm D undergo a repeat fluciclovine F18 PET/CT at time of second PSA recurrence or 12 months after completion of enhanced systemic therapy.~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A and apalutamide PO QD as in Arm B. Patients also undergo SBRT or 3D CRT, IMRT (including VMAT), and IMPT over 3-5 fractions in the absence of disease progression or unacceptable toxicity."
9984106|NCT04418466|Experimental|DLP-114 alpha-4 (6-months)|2 360mg Risperidone Implants
9984107|NCT04418466|Experimental|DLP-114 alpha-7 (12-months)|2 435mg Risperidone Implants
9831825|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort C)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9831826|NCT02443324|Experimental|Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)|Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9984108|NCT04418297|Experimental|CT-G20|
9984109|NCT04418297|Placebo Comparator|Placebo|
9984110|NCT04416581|Experimental|P-CAB 50mg group|"tegoprazan 50 mg + rabeprazole 20mg placebo + tegoprazan 25 mg placebo, once daily.~Target enrollment: 1250"
9984111|NCT04416581|Active Comparator|PPI group|"rabeprazole 20mg + tegoprazan 50 mg placebo + tegoprazan 25 mg placebo, once daily.~Target enrollment: 1250"
9984112|NCT04416581|Other|P-CAB 25mg group|"tegoprazan 25 mg + rabeprazole 20mg placebo + tegoprazan 50 mg placebo, once daily.~Target enrollment: 500"
10202311|NCT04840901|Experimental|Lebrikizumab - Autoinjector|Lebrikizumab administered SC via autoinjector (AI).
10202312|NCT04827290|Experimental|Normal-protein and low-AGE through raw or rare proteins diet|Normal-protein (0,8g/kg/day) and low-AGE through raw or rare proteins diet during 24 months
10202313|NCT04827290|Active Comparator|Normal-protein and AGE-rich diet|Normal-protein (0,8g/kg/day) and high-AGE through overcooked proteins diet during 24 months
10202314|NCT04826809|Experimental|Health care workers|Health care workers will complete a fit test while wearing the Nordell Single E-100 layer + (cotton layer) mask, Nordell Double E-100 layer mask and an N95 mask
10202315|NCT04826315|Experimental|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
10202316|NCT04823702|Experimental|Child-Pugh A (Mild Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
10202317|NCT04823702|Experimental|Child-Pugh B (Moderate Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
10202318|NCT04823702|Experimental|Child-Pugh C (Severe Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
10205200|NCT03684980|Experimental|Arm B - Rituximab + MTX + Glucarpidase|Patients will receive up to 8 cycles of treatment consisting of rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort B) will receive MTX 8 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
9757244|NCT00601367|Experimental|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
9757245|NCT00601419||Somatropin|Patients administered Somatropin.
9757246|NCT00601458|Active Comparator|Arm 1: Pregabalin 300 mg|
9757247|NCT00601458|Active Comparator|Arm 2: naproxen sodium 550 mg|
9757248|NCT00601458|Placebo Comparator|Arm 3: Placebo|
9757249|NCT00601484|Experimental|1|
9757250|NCT00601484|Placebo Comparator|2|
9757251|NCT00601523|Active Comparator|Pramipexole|Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily
9757252|NCT00601523|Placebo Comparator|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
9757253|NCT00601627|Experimental|Panitumumab|"Chemotherapy concurrent with radiation: Radiation 5 days per week for 5½ weeks; Panitumumab on days 1, 15, and 29 of radiation therapy 5-fluorouracil (5FU) continuous infusion, starting on day 1 and through last day of radiation.~4-6 weeks after completion of radiation therapy: Gemcitabine on days 1, 8, and 15 of each cycle, for 3 cycles; Panitumumab on days 1 and 15 of each cycle, for 3 cycles. Maintenance therapy: Panitumumab on days 1 and 15 of each cycle, for 6 cycles."
9757254|NCT00601640|Experimental|Eflornithine HCL|Patients apply Eflornithine HCL ointment to their left forearm twice daily on days 1-90.
9757255|NCT00601640|Active Comparator|Diclofenac Na|Patients apply topical Diclofenac Na gel to their left forearm once daily on days 1-90.
9757256|NCT00601640|Experimental|Eflornithine HCL and Diclofenac Na|Eflornithine HCl ointment and Diclofenac Na gel applied twice and once daily, respectively on days 1-90.
9757257|NCT00601705|Experimental|Epirubicin, Oxaliplatin and Fluorouracil|
9984113|NCT04416451|Experimental|Rituximab and Venetoclax|Patients will be treated with an Induction phase of rituximab 375 mg/m2 weekly for 4 weeks. Patients will undergo restaging imaging after the last of 4 weekly rituximab doses and before beginning venetoclax. Based on post-rituximab restaging studies, patients will be risk-stratified for risk of Tumor Lysis Syndrome (TLS) and treated in the appropriate setting with TLS prophylaxis per institutional TLS guide lines starting at week 5. Oral venetoclax will follow a ramp-up dosing schedule and will be taken daily after 4 weeks of rituximab therapy. Following the 4-week ramped-up phase of venetoclax, patients will begin their target dose of venetoclax and continue for a maximum of 24 months. In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months. Venetoclax may be continued after this period if patient has not achieved a complete remission
9984114|NCT04414514|Experimental|Open-label|Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks
9984115|NCT04412616|Experimental|ZZ06 0.03 mg/kg dose group|ZZ06 0.03 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
9984116|NCT04412616|Experimental|ZZ06 0.06 mg/kg dose group|ZZ06 0.06 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
9757258|NCT00601718|Experimental|Treatment (enzyme inhibitor, monoclonal antibody, chemotherapy|Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
9757259|NCT00601731|Experimental|Adjuvanted MenACWY vaccine group|Blood test
9757260|NCT00601731|Active Comparator|Non-adjuvanted MenACWY vaccine group|Blood test
9757261|NCT00601796|Experimental|Combination Immunotherapy|Vaccine + Cytoxan + ATRA as outlined in Detailed Description
9757262|NCT00601835|Experimental|Canadian Td Vaccine Group|Participants received Canadian manufactured Td vaccine
9757263|NCT00601835|Active Comparator|United States Td Vaccine Group|Participants received US manufactured Td vaccine
9757264|NCT00601926|Experimental|Bevacizumab|15 mg/kg over 90 minutes
9757265|NCT00601952|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
9757266|NCT00601952|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
9757267|NCT00601965|Experimental|CBT/Escitalopram|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
9757268|NCT00601965|Active Comparator|No CBT/escitalopram|12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.
9757269|NCT00601965|Placebo Comparator|CBT/placebo|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
9757270|NCT00601965|Placebo Comparator|No CBT/placebo|"12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo~12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks."
9757271|NCT00602043|Experimental|Diagnostic (FES)|Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.
9757272|NCT00602225|Experimental|Arm I|See Detailed Description
9757273|NCT00602290|Active Comparator|1 - Citalopram and placebo|Participants will take a combination of citalopram and placebo for 16 weeks
9757274|NCT00602290|Active Comparator|2 - Methylphenidate and placebo|Participants will take a combination of methylphenidate and placebo for 16 weeks
9757275|NCT00602290|Active Comparator|3 - Methylphenidate and Citalopram|Participants will take a combination of methylphenidate and citalopram for 16 weeks
9757276|NCT00602355|Placebo Comparator|1 (Placebo)|Participants receiving placebo pill with clinical management plus mothercrafting
9757277|NCT00602355|Active Comparator|2 (Sertraline)|Participants receiving active medication sertraline with clinical management plus mothercrafting
9757278|NCT00602355|Active Comparator|3 (IPT)|Participants receiving interpersonal psychotherapy (IPT) alone
9757279|NCT00602420|Experimental|Naproxen|Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
9757280|NCT00602420|Placebo Comparator|Placebo|Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
9757281|NCT00602446|Experimental|Deferasirox Treated|Includes patients that were treated with deferasirox for 6 months.
9757282|NCT00602472|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
9757283|NCT00602472|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
9757284|NCT00602537|Experimental|I|Antidepressant therapy
9757285|NCT00602537|Active Comparator|II|Mood stabilizer therapy
9757286|NCT00602771|Experimental|Arm I|Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
9757287|NCT00602771|Experimental|Arm II (closed to accrual as of November 2008)|Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.
9757288|NCT00602797|Experimental|Treatment (vinorelbine tartrate, paclitaxel)|Patients receive vinorelbine tartrate IV over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks.
9757289|NCT00602836|Experimental|PCR-Lenalidomide|Pentostatin, Cyclophosphamide, Rituximab + Lenalidomide
9757290|NCT00602927|Placebo Comparator|Placebo|
9757291|NCT00602927|Active Comparator|Varenicline|
9757292|NCT00602953||Healthy volunteers|Normal weight and normal glucose tolerance.
9757293|NCT00602953||Pre-diabetes|Impaired fasting glucose of impaired glucose tolerance.
9757294|NCT00602953||Overweight|Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
9757295|NCT00602953||Type 2 diabetes|Patients with type 2 diabetes.
9757296|NCT00602953||Type 1 diabetes|Patients with type 1 diabetes.
9757297|NCT00602979|Other|Macintosh laryngoscope|Macintosh laryngoscope (control group/direct laryngoscopy) - current standard
9757298|NCT00602979|Other|Airtraq Optical Laryngoscope|Airtraq® Optical Laryngoscope (an experimental group/indirect laryngoscopy)
9757299|NCT00602979|Other|Storz DCI Video Laryngoscope|Storz DCI Video Laryngoscope® (an experimental group/indirect laryngoscopy)
9757300|NCT00602979|Other|GlideScope Video Laryngoscope|GlideScope® Video Laryngoscope (an experimental group/indirect laryngoscopy)
9757301|NCT00602979|Other|McGRATH Video Laryngoscope|McGRATH® Video Laryngoscope (an experimental group/indirect laryngoscopy)
9757302|NCT00603018|Experimental|Annorexia nervosa|Participants recovered from anorexia nervosa before and after administration of fluoxetine
9757303|NCT00603044|Active Comparator|Fluticasone furoate|55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
9757304|NCT00603044|No Intervention|No treatment|
9757305|NCT00603239|Experimental|Exenatide twice daily (BID)|
9757306|NCT00603239|Placebo Comparator|Placebo|
9757307|NCT00603265|Experimental|ADL5859|2 x 50 milligrams (mg) ADL5859 capsules administered orally once in the morning and once in the evening for 28 days
9757308|NCT00603265|Active Comparator|Duloxetine|2 x 30 mg duloxetine capsules administered orally once in the morning and 2 placebo capsules filled with lactose administered orally once in the evening for 28 days
9757309|NCT00603265|Placebo Comparator|Placebo|2 placebo capsules filled with lactose administered orally once in the morning and once in the evening for 28 days
9757310|NCT00603278|Placebo Comparator|Arm 1|
9757311|NCT00603278|Experimental|Arm 2|
9757312|NCT00603291|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
9757313|NCT00603291|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
9757314|NCT00603291|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
9757315|NCT00603304|Placebo Comparator|Placebo|Participants will take one 320 mg placebo gelcap daily for 24 weeks one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
9757316|NCT00603304|Active Comparator|Saw Palmetto|Extract of Serenoa Repens 320 mg once daily for 24 weeks (one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
9757317|NCT00603382|Placebo Comparator|Placebo|
9757318|NCT00603382|Experimental|GW685698X|
9757319|NCT00603408|Experimental|Cisplatin + Radiation + Recommended Surgery|"Cisplatin 75 mg/m^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection"
9757320|NCT00603447|Experimental|Carfilzomib + Lenalidomide + Dexamethasone|Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
9757321|NCT00603473|Experimental|gabapentin|
9757322|NCT00603512|Placebo Comparator|CP-690,550, 0mg|
9757323|NCT00603512|Experimental|CP-690,550, 10mg|
9757324|NCT00603512|Experimental|CP-690,550, 1mg|
9757325|NCT00603512|Experimental|CP-690,550, 3mg|
9757326|NCT00603512|Experimental|CP-690,550, 5mg|
9757327|NCT00603525|Experimental|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
9831827|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort E)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
9831828|NCT02408406|Experimental|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
9831829|NCT02408406|Active Comparator|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
9831830|NCT02396134|Experimental|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A*0201 peptide vaccine SC on days 28 and 56 after HCT.
9831831|NCT02396134|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
9831832|NCT02343952|Experimental|Experimental Arm|Pembrolizumab -200 mg IV 3 weeks
9831833|NCT02339779|Experimental|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
9831834|NCT02339779|Active Comparator|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
9831835|NCT02331134|Other|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
9831836|NCT02326155||Remsima™|Patients were not treated with infliximab before enrollment. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
9831837|NCT02326155||Switched to Remsima|Patients were treated with infliximab prior to enrollment of the study. Patients were administered CT-P13 5mg/kg by intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter.
9831838|NCT02304367|Experimental|Burosumab|Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
9831839|NCT02295059|Experimental|Omega 3 fatty acids - high dose|~5 g EPA+DHA in 5 capsules per day
9831840|NCT02295059|Experimental|Omega 3 fatty acids - low dose|~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
9831841|NCT02244463|Experimental|MLN0128|Treatment will be administered on an outpatient basis. MLN0128 at fixed dose will be administered orally, daily for treatment cycle. The participant will be requested to maintain a medication diary of medication. The medication diary will be returned to clinic staff at the end of each cycle. Treatment with MLN0128 will continue until progression or withdrawal of consent.
9831842|NCT02205762|Experimental|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
9831843|NCT02205762|Experimental|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
9831844|NCT02205762|Experimental|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
9831845|NCT02205762|Experimental|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
9831846|NCT02205762|Experimental|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
9831847|NCT02205762|Experimental|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.~Treatment Options- Management (mostly wait & see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.~Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.~Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
9831848|NCT02159495|Experimental|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
9831849|NCT02157051|Experimental|Arm 1 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 1 injection ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
9831850|NCT02157051|Experimental|Arm 2 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/M2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
9831851|NCT02157051|Experimental|Arm 3 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 3 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
9831852|NCT02157051|Experimental|Arm 4 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 1 additional STEMVAC vaccine at 3 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
9831853|NCT02136901|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
9831854|NCT02136901|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
9831855|NCT02134301|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
9831856|NCT02108496|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
9831857|NCT02108496|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
9984117|NCT04412616|Experimental|ZZ06 0.12 mg/kg dose group|ZZ06 0.12 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
9984118|NCT04412616|Experimental|ZZ06 0.22 mg/kg dose group|ZZ06 0.22 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
9984119|NCT04412616|Experimental|ZZ06 0.39 mg/kg dose group|ZZ06 0.39 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
9984120|NCT04412616|Experimental|ZZ06 0.70 mg/kg dose group|ZZ06 0.70 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
9757328|NCT00603525|Placebo Comparator|1000 ml Saline|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
9757329|NCT00603538|Experimental|CP-751,871|
9757330|NCT00603564|Active Comparator|1|CPAP delivered by a helmet
9757331|NCT00603564|No Intervention|2|O2 administration via a conventional Venturi mask
9757332|NCT00603590|Experimental|Polypill|Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg
9757333|NCT00603590|Placebo Comparator|Control|Identical placebo
9757334|NCT00603642|Placebo Comparator|AMG 531|Double blinded placebo-controlled study
9757335|NCT00603642|Placebo Comparator|Placebo|
9757336|NCT00603720|Active Comparator|L-Name in Young|20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
9757337|NCT00603720|Active Comparator|Phenylephrine|25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
9757338|NCT00603720|Active Comparator|L-arginine in Young|20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
9757339|NCT00603720|Active Comparator|L-arginine in Old|20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
9757340|NCT00603720|Experimental|L-NAME in Old|20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
9757341|NCT00603733|Experimental|Pentasa® modified extended release|5-ASA (5-Aminosalicylate)
9757342|NCT00603733|Active Comparator|Pentasa®|5-ASA (5-Aminosalicylate)
9757343|NCT00603746|Experimental|GW685698X|GW685698X
9757344|NCT00603798|Active Comparator|3.75% imiquimod cream|
9757345|NCT00603798|Active Comparator|2.5% imiquimod cream|
9757346|NCT00603798|Placebo Comparator|Placebo cream|
9757347|NCT00603837|Experimental|Blanket|This arm includes those Extremely low gestational age newborns (ELGANs) who are to be placed on a sodium acetate warming blanket after delivery.
9757348|NCT00603837|Experimental|Wrap|This arm includes those ELGANs randomized to be wrapped in polyethylene after delivery.
9757349|NCT00603889|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will have the same number of concentrations of the Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
9757350|NCT00603902|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
9757351|NCT00603902|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
9757352|NCT00603902|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
9757353|NCT00603915|Experimental|GC Plus Erlotinib|Eligible patients are treated with cisplatin/carboplatin and gemcitabine (GC) for 6 cycles of therapy followed by maintenance erlotinib. Those patients achieving SD or PR with chemotherapy will be started on maintenance erlotinib until disease progression. Those patients achieving CR with chemotherapy will be started on erlotinib for 6 cycles of treatment and those achieving CR on erlotinib will be treated with a maximum of 6 further cycles of erlotinib. Those patients with disease progression while on chemotherapy will be offered erlotinib 2 weeks following the last dose of chemotherapy until further disease progression.
9757354|NCT00603941|Experimental|Cohort 1; 0.15 mg CS-7017|Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 [Dose Level 1a] or 175 [Dose Level 1b] mg/m^2 intravenous (IV) paclitaxel once every 3 weeks.
9757355|NCT00603941|Experimental|Cohort 2; 0.30 mg CS-7017|Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
9757356|NCT00603941|Experimental|Cohort 3; 0.50 mg CS-7017|Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
9757357|NCT00603980|Other|Treatment sequence 1|Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757358|NCT00603980|Other|Treatment sequence 2|Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757359|NCT00603980|Other|Treatment sequence 3|Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757360|NCT00603980|Other|Treatment sequence 4|Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757361|NCT00603980|Other|Treatment sequence 5|Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757362|NCT00603980|Other|Treatment sequence 6|Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757363|NCT00603980|Other|Treatment sequence 7|Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757364|NCT00603980|Other|Treatment sequence 8|Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757365|NCT00603980|Other|Treatment sequence 9|Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757366|NCT00603980|Other|Treatment sequence 10|Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757367|NCT00603980|Other|Treatment sequence 11|Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757368|NCT00603980|Other|Treatment sequence 12|Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9831858|NCT02069730|Experimental|Unmatched Treatment (Selinexor)|"Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.~If patients have a druggable aberration but there is no access to the relevant agent, then patients will receive selinexor"
9984121|NCT04412616|Experimental|ZZ06 1.00 mg/kg dose group|ZZ06 1.00 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
9757369|NCT00603980|Other|Treatment sequence 13|Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757370|NCT00603980|Other|Treatment sequence 14|Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
9757371|NCT00603993|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT 00235872]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
9757372|NCT00604019|Active Comparator|Dopamine|Patients that get Dopamine as an infusion for hypotension
9757373|NCT00604019|Active Comparator|Norepinephrine|Patients that get norepinephrine as an infusion for hypotension
9757374|NCT00604045|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
9757375|NCT00604045|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
9757376|NCT00604162|Experimental|PillCam COLON and Colonoscopy|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases, had capsule endoscopy with PillCam COLON after bowel preparation and before standard colonoscopy.
9757377|NCT00604175|Experimental|Stratum A|Participants with screening CD4 count >350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
9757378|NCT00604175|Experimental|Stratum B|Participants with screening CD4 count >200 to <=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
9757379|NCT00604175|Experimental|Stratum C|Participants with screening CD4 count <=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
9517456|NCT03306147|Experimental|Chronic pain or long-acting opioid use|Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.
9517457|NCT03306134||BETA-BLOCKERS|Patients taking beta-blockers with or without dysphagia
9517458|NCT03306134||NO BETA-BLOCKERS|Patients not taking beta-blockers with or without dysphagia
9831859|NCT02069730|Experimental|Matched Therapy|"EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .~If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator."
9831860|NCT02057133|Experimental|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
9831861|NCT02057133|Experimental|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
9831862|NCT02057133|Experimental|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
9831863|NCT02057133|Experimental|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
9831864|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
9831865|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
9831866|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
9831867|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
9831868|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
9831869|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
9831870|NCT02057133|Experimental|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
9831871|NCT02057133|Experimental|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
9831872|NCT02057133|Experimental|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
9835904|NCT02760433|Experimental|Arm 1: Olokizumab q4w|"Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate~Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)"
9783142|NCT01193920|Experimental|3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg|Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
9783143|NCT01193920|Experimental|4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg|Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
9783144|NCT01193920|Experimental|5: GBS Trivalent Vaccine - 5/5/5 µg|Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
9783145|NCT01193920|Placebo Comparator|6: Placebo - Sterile saline|Pregnant Women who received one injection of saline solution.
9783146|NCT01194089|Active Comparator|Nasal Nicotine Spray|3 mg of nasal nicotine will be administered postoperatively.
9783147|NCT01194089|Placebo Comparator|Nasal Normal Saline Spray|1 ml of nasal normal saline spray will be administered postoperatively.
9783148|NCT01194154|Experimental|Mircera|
9783149|NCT01194154|Placebo Comparator|Placebo|
9783150|NCT01194245|Experimental|Lispro-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
9831873|NCT02056236|Experimental|Anti-epileptic drugs|"Step 1: Phenytoin (loading dose 15-20 mg/kg iv, maintenance doses 150 mg iv twice per day) PLUS one of the following benzodiazepines (bolus + continuous infusion): lorazepam or midazolam. Benzodiazepine dosing regimes should be based on national and local protocols for status epilepticus treatment~Step 2: Propofol infusion (with a maximum rate of 8 mg/kg/hour) PLUS a second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.~Step 3: Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages, treatment should be guided by the EEG pattern."
9831874|NCT02056236|Active Comparator|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
9831875|NCT02007044|Experimental|Arm I (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9831876|NCT02007044|Experimental|Arm II (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm I beginning on day 1 or 2. Patients also receive rituximab IV over 3-8 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9831877|NCT01962246|Active Comparator|postoperative chemotherapy,XELOX|
9831878|NCT01962246|Experimental|Preoperative Concurrent Chemoradiotherapy|
9831879|NCT01810705|Experimental|GRASPA|"patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm Control)"
9831880|NCT01810705|No Intervention|Control|patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months
10202319|NCT04821648|Experimental|Dosage group A|"Dosage group A will consist of 6 subjects, 1:1:1 (A1:A2:A3 below):~A1: 0.04 mg/injection; A2: 0.075 mg/injection; A3: 0.15 mg/injection Two subjects will be dosed in the area scheduled for resection with 5 injections of the lowest of the 3 RJV001 test article strengths (i.e., 0.04 mg/injection); the two subjects will also be dosed with a single injection of vehicle in the area scheduled for resection for a total of 6 injections. At the conclusion of a given test article dose group, if tolerated, enrollment will continue to the next higher dose after approval to advance based upon an interim safety review. This same process will be repeated for the 0.075 mg/injection dose with 2 additional subjects. Assuming the interim safety review for the mid dose (i.e., 0.075 mg/injection) is deemed acceptable, the 2 final subjects will be treated with the high dose (0.15 mg/injection)."
9831881|NCT01777035|Experimental|Early physical therapy(PT) occupational therapy (OT)|Early PT OT assessments begin on first day of study. Therapy delivered by a team consisting of physical and occupational therapists and coordinated with daily sedative interruption
9831882|NCT01777035|No Intervention|standard care|PT OT delivered as ordered by the primary ICU team
9831883|NCT01714349|Experimental|Nerve Transfer|Surgical - Nerve transfers for patients with stable cervical spinal cord injuries
9831884|NCT01712191|Experimental|NUsurface Meniscus Implant|
10202320|NCT04821648|Experimental|Dosage group B|"Dosage group B will consist of 3 subjects (if only 1 dose from Dosage group A is well tolerated) or 6 subjects (if 2 doses from Dosage group A are well tolerated), randomized 1:1 (B1:B2 below).~B1: RJV001 Solution for Injection, Dose 1 B2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Dosage group A, referred to as Dose 1 and Dose 2). Up to 13 injections (12 active and 1 vehicle) will be administered in an open label manner in the area scheduled for resection. If tolerated, enrollment will continue to Dosage group C after approval to advance based upon an interim safety review."
10202321|NCT04821648|Experimental|Dosage group C|"Dosage group C will consist of 3 subjects (if only 1 dose from dosage group B is well tolerated) or 6 subjects (if 2 doses from Dosage group B are well tolerated), randomized 1:1 (C1:C2 below).~C1: RJV001 Solution for Injection, Dose 1~C2: RJV001 Solution for Injection, Dose 2 Subjects will be dosed with 1 RJV001 test article (i.e., one of the 2 highest concentrations of RJV001 doses that were well tolerated in Cohort B, referred to as Dose 1 and Dose 2). Up to 31 injections (30 active and 1 vehicle) will be administered in an open-label manner in the area scheduled for resection."
10202322|NCT04815551|Experimental|AV-380 IV 4 mg/kg|IV infusion of AV-380 at dose level 4 mg/kg
10202323|NCT04815551|Experimental|AV-380 IV 8 mg/kg|IV infusion of AV-380 at dose level 8 mg/kg
10202324|NCT04815551|Experimental|AV-380 IV 13 mg/kg|IV infusion of AV-380 at dose level 13 mg/kg
10202325|NCT04815551|Experimental|AV-380 IV 20 mg/kg|IV infusion of AV-380 at dose level 20 mg/kg
10202326|NCT04815551|Experimental|AV-380 SC 4 mg/kg|Subcutaneous injection of AV-380 at dose level 4 mg/kg
10202327|NCT04815551|Experimental|AV-380 SC 2 mg/kg|Subcutaneous injection of AV-380 at dose level 2 mg/kg
10202328|NCT04815551|Experimental|AV-380 SC 1 mg/kg|Subcutaneous injection of AV-380 at dose level 1 mg/kg
10202329|NCT04815551|Placebo Comparator|Placebo|
10202330|NCT04815278|Experimental|Control Group|Participants will receive usual DSS employment services that include, but are not limited to, consultation with an employments specialist, resume writing guidance, educational classes and attendance at job fairs. Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
10202331|NCT04815278|Experimental|Employer Intervention Only|Participants will receive usual DSS employment services and an employer level workplace equity, job & health supports intervention. The employer intervention will include an implicit bias workshop and supervisor support training in addition to regular supervisor check-ins every other week.
9757380|NCT00604188|Experimental|Direct Suboxone Induction|Participants received 8 mg of Suboxone and placebo Subutex on Day 1, 16 mg of Suboxone and placebo Subutex on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
9757381|NCT00604188|Active Comparator|Subutex-to-Suboxone Induction|Participants received 8 mg Subutex and placebo Suboxone on Day 1, 16 mg Subutex and placebo Suboxone on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
9757382|NCT00604214|Experimental|Drotrecogin alfa (activated)|
9757383|NCT00604214|Placebo Comparator|Placebo|
9757384|NCT00604279|Experimental|Paliperidone palmitate|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
9757385|NCT00604279|Active Comparator|Risperidone long acting injection (LAI)|Risperidone LAI intramuscular at a dose of 25 milligram (mg) on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
9757386|NCT00604383|Experimental|Ruboxistaurin|
9757387|NCT00604383|Placebo Comparator|Placebo|
9757388|NCT00604461|Experimental|Dose Escalation Followed by Maintenance Therapy|"A: Tiered Dose Escalation/Phase II Dose -~Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~B: Maintenance Therapy -~Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first."
9757389|NCT00604552|Other|Lifeline Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by the Foundation of Society for the Vascular Surgery (SVS)
9757390|NCT00604552|Other|PS Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by Medtronic
9783151|NCT01194245|Experimental|Aspart-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
9785484|NCT01253174|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 film-coated SHT470FA tablet (Yasmin with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
9785485|NCT01253174|Experimental|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532A tablet (with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
9785486|NCT01253174|Active Comparator|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SHT04532C, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
9757391|NCT00604565|Experimental|SFP dialysate|dialysate with added soluble ferric pyrophosphate (SFP)
9757392|NCT00604565|Placebo Comparator|standard dialysate|standard dialysate without soluble ferric pyrophosphate (SFP)
9757393|NCT00604695|Active Comparator|1|Two (4mg) doses of tenecteplase
9757394|NCT00604695|Placebo Comparator|2|Two (4mL) doses of sterile saline
9757395|NCT00604708|Experimental|IC51|6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28
9984122|NCT04411420|Active Comparator|Integrated Care Pathway|The integrated care pathway provides both on-site physical therapy services and centrally-delivered services via telephone or video from study providers at the Durham VA.
9757396|NCT00604708|Active Comparator|JE-VAX|given s.c. on Day 0, 7 and 28
9757397|NCT00604721|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive a single dose of selumetinib on day 1 and undergo blood collection for PK sampling pre-dose (within 30 min of dosing), 15 and 30 minutes and 1, 2, 4, 8, 12, 24 and 48 hours post-dose. Beginning 48 hours after the initial dose and continuing until day 21, patients receive oral selumetinib twice daily. Patients also undergo blood collection for PK sampling on day 15 of course 1. In all subsequent courses, patients receive selumetinib on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9757398|NCT00604786|Experimental|Omalizumab subcutaneous|"This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks"
9757399|NCT00604786|Placebo Comparator|Placebo Subcutaneous|"This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks."
9757400|NCT00604825|Placebo Comparator|Placebo|Placebo
9757401|NCT00604825|Active Comparator|GSK232802|GSK232802
9757402|NCT00604825|Experimental|PREMARIN|PREMARIN
9757403|NCT00604890|Experimental|1|Active cream, 3% AM & PM
9757404|NCT00604890|Placebo Comparator|2|Placebo cream AM ; 3% active cream PM
9757405|NCT00604890|Placebo Comparator|3|Placebo cream AM; 1.5% active cream PM
9757406|NCT00604890|Placebo Comparator|4|Placebo AM and PM
9757407|NCT00604968|Experimental|Caelyx|
9757408|NCT00605033|Active Comparator|Suboxone|Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
9757409|NCT00605033|Active Comparator|Subutex|Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
9757410|NCT00605072|Experimental|Candesartan|Angiotensin Receptor Blocker
9757411|NCT00605072|Experimental|Lisinopril|Angiotensin-Converting Enzyme (ACE) Inhibitor
9757412|NCT00605072|Active Comparator|HCTZ|Hydrochlorothiazide (diuretic)
9757413|NCT00605085|Experimental|1|IC51
9757414|NCT00605085|Placebo Comparator|2|Placebo
9757415|NCT00605176|Active Comparator|3.75% imiquimod cream|
9757416|NCT00605176|Active Comparator|2.5% imiquimod cream|
9757417|NCT00605176|Placebo Comparator|Placebo cream|
9757418|NCT00605189|Active Comparator|VAC NPWT|
9757419|NCT00605189|Active Comparator|Gauze-Based NPWT|
9757420|NCT00605189|Active Comparator|Moist Wound Therapy|
9757421|NCT00605202|Active Comparator|Licorice|
9757422|NCT00605202|Active Comparator|Licorice and HCTZ|
9757423|NCT00605267|Active Comparator|1|Tamoxifen
9757424|NCT00605267|Experimental|2|Anastrazole (Arimidex)
9757425|NCT00605280|Sham Comparator|Sham Control|
9757426|NCT00605280|Experimental|Macugen|
9984123|NCT04411420|Active Comparator|Coordinated Care Management Pathway|The care management pathway involves a referral of patients from a physician to a pain navigator on site at the local VA who is knowledgeable in current recommended treatment guidelines for low back pain.
9984124|NCT04408222||Awake Proning|COVID-19 patients with hypoxemic respiratory failure with awake prone positioning, as tolerated, up to 24 hours daily.
9984125|NCT04407806|Active Comparator|Continuous Pulse Oximetry Monitoring of Oxygen Saturation|Continuous pulse oximetry to measure oxygen saturation
9757427|NCT00605293|Experimental|C.E.R.A|Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
9757428|NCT00605293|Active Comparator|Epoetin Alfa|Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.
9757429|NCT00605306|Experimental|indacaterol maleate/mometasone furoate|Participants received 2 inhalations of indacaterol maleate / mometasone furoate 250/400 μg once daily in the evening (full dose 500/800 μg) delivered via the Twisthaler device for 14 days.
9757430|NCT00605306|Placebo Comparator|Placebo|Participants received 2 inhalations of placebo to indacaterol maleate / mometasone furoate once daily in the evening delivered via the Twisthaler device for 14 days.
9757431|NCT00605319|Other|Toviaz (Fesoterodine)|Toviaz 4mg to 8mg
9757432|NCT00605345|Experimental|CERA Treatment Once Monthly|
9757433|NCT00605345|Active Comparator|Darbepoetin Alfa Once Biweekly|
9757434|NCT00605358|Active Comparator|Open Door Intervention|Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
9757435|NCT00605358|No Intervention|Services Referral|"Subjects who do not receive the Open Door intervention will receive:~an evaluation~referral to a local mental health provider~booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors."
9757436|NCT00605384|Experimental|1|
9757437|NCT00605384|Experimental|2|
9757438|NCT00605423|Active Comparator|1|Dose 0.2 ug/day Medidur implant
9757439|NCT00605423|Active Comparator|2|Dose 0.5 ug/day Medidur implant
9757440|NCT00605475|Experimental|Canakinumab|"Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
9757441|NCT00605475|Placebo Comparator|Placebo|"Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
9757442|NCT00605540||Study COPD population|Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
9757443|NCT00605566|Experimental|I|Patients will receive sorafenib and cyclophosphamide.
9757444|NCT00605644|Placebo Comparator|Placebo|Placebo
9757445|NCT00605644|Experimental|150 mg|MOA-728
9757446|NCT00605644|Experimental|300 mg|MOA-728
9757447|NCT00605644|Experimental|450 mg|MOA-728
9757448|NCT00605644|Experimental|600 mg|MOA-728
9757449|NCT00605657|Experimental|Valproic acid|Single arm study involving oral administration of valproic acid and monitoring of its efficacy by CT scans done before and after the intervention. Blood samples were also obtained to monitor safety labs and biomarkers.
9757450|NCT00605696|Experimental|1|Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
9757451|NCT00605696|Active Comparator|2|Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
9757452|NCT00605722|Experimental|bevacizumab + erlotinib|Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.
9757453|NCT00605813||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
9757454|NCT00605826|Experimental|Blinded injection of NASHA/Dx gel at randomization.|Blinded injection of NASHA/Dx (Solesta) Gel. For each treatment, a series of 4 equally spaced injections with 1 mL of Solesta into the anal canal. Subjects will be followed for 6 months during the blinded phase. During a subsequent open phase, these subjects will be followed to Month 36 (ie, for an additional 30 months).
9757455|NCT00605826|Sham Comparator|Blinded sham inject. at randomization|"Blinded sham injection (needle stick with empty syringes). For each treatment, a series of 4 equally spaced Sham injections (needle sticks) into the anal canal. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
9757456|NCT00605826|Other|Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.|"Blinded sham injection at randomization. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
9757457|NCT00605839|Experimental|Glucopak Care|Glucopak cell phone and intensive monitoring. This group will be given the experimental device, and placed in close communication with the clinic.
9757458|NCT00605839|Active Comparator|Cell Phone Care|Cell phone only, without the Glucopak. Participants will be given cell phones and encouraged to communicate more closely with the clinic, but will not use the Glucopak.
9757459|NCT00605839|Placebo Comparator|Usual Care|Usual care, without cell phone or glucopak
9757460|NCT00605865||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
9757461|NCT00605904|Experimental|Acamprosate|Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.
9757462|NCT00605904|Placebo Comparator|Placebo|Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.
9757463|NCT00605917||Sertraline hydrochloride.|The patients of Panic disorder taking Sertraline hydrochloride.
9757464|NCT00606008|Experimental|Sutent Treatment|Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
9757465|NCT00606021|Experimental|A: Pemetrexed + Best Supportive Care|"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."
9984126|NCT04407806|Active Comparator|Intermittent Pulse Oximetry Monitoring of Oxygen Saturation|Intermittent pulse oximetry to measure oxygen saturation, measured every 4 hours
9757466|NCT00606021|Active Comparator|B: Best Supportive Care|Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
9757467|NCT00606034|Experimental|All subjects active|All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
9757468|NCT00606047||Asymptomatic patients|Asymptomatic, healthy patients (without hip pain or prior hip disease) will be recruited. Patients will undergo a magnetic resonance imaging (MRI) of the hip joints to evaluate for the prevalence of femoroacetabular impingement (FAI).
9757469|NCT00606086|Experimental|1|GI-5005 monotherapy continuing on to triple therapy
9757470|NCT00606086|Active Comparator|2|Standard of care alone
9757471|NCT00606138|Experimental|Anti-VEGF injection|Intravitreal injection of 0.5-mg dose of ranibizumab
9757472|NCT00606138|Active Comparator|PRP Laser|Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
9757473|NCT00606177|Experimental|1|
9757474|NCT00606177|Placebo Comparator|2|
9757475|NCT00606229|Experimental|1|
9757476|NCT00606281|Experimental|1|
9757477|NCT00606281|Placebo Comparator|2|
9757478|NCT00606294|Experimental|Cohort 1 (closed to accrual)|Cohort 1 (closed to accrual) Cohort 1 (closed to accrual) There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy. This is currently one accepted standard of care. In a subcohort of patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/ CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.
9757479|NCT00606294|Experimental|Cohort 2 (closed to accrual)|Experimental: Cohort 2 (closed to accrual) Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-4 month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.
9757480|NCT00606307|Experimental|ITF2357|Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity.
9757481|NCT00606320|Experimental|Aripiprazole|
9984127|NCT04399746|Experimental|Combination|Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days).
9757482|NCT00606489|Placebo Comparator|1|
9757483|NCT00606489|Experimental|2|
9757484|NCT00606502|Experimental|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
9757485|NCT00606502|Active Comparator|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
9757486|NCT00606554|Experimental|Computer-assisted weaning|Group assigned to the computer-assisted weaning program
9757487|NCT00606554|Active Comparator|Standard of care weaning|Group assigned to receive current, evidence-based, standard of care for discontinuation of mechanical ventilation.
9757488|NCT00606580|Experimental|WR 279,396 Topical Treament|WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
9757489|NCT00606580|Experimental|Paromomycin Alone Topical treatment|Paromomycin Alone topical cream (15% paromomycin topical cream)
9757490|NCT00606580|Placebo Comparator|Vehicle Placebo Cream|The cream base without the addition of paromomycin or gentamicin
9757491|NCT00606593|Experimental|ABECD|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757492|NCT00606593|Experimental|BCADE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9984128|NCT04399746|No Intervention|Control|No intervention
9984129|NCT04397484|Active Comparator|Levobupivacaine|0.5% levobupivacaine (0.5% Chirocaine) 30ml (150mg) will be injected once for regional anaesthesia before surgery
9984130|NCT04397484|Active Comparator|Xylocaine + adrenaline|2% Xylocaine with adrenaline 1:200,000 30ml (450mg) will be injected once for regional anaesthesia before surgery
9757493|NCT00606593|Experimental|CDBEA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757494|NCT00606593|Experimental|DECAB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757495|NCT00606593|Experimental|EADBC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757496|NCT00606593|Experimental|DCEBA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757497|NCT00606593|Experimental|EDACB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757498|NCT00606593|Experimental|AEBDC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757499|NCT00606593|Experimental|BACED|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757500|NCT00606593|Experimental|CBDAE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
9757501|NCT00606632|Other|124-Iodine-cG250 (124I-cG250)|Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.
9757502|NCT00606684|Active Comparator|GW642444|GW642444
9757503|NCT00606684|Placebo Comparator|placebo|
9757504|NCT00606801|Active Comparator|Galantamine 8 mg/day|Galantamine 8 mg/day
9757505|NCT00606801|Placebo Comparator|Placebo|placebo
9757506|NCT00606892|Experimental|Placebo First, varenicline, + IV Nic|Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
9757507|NCT00606892|Experimental|Varenicline first, placebo, + IV Nic|Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).
10202332|NCT04815278|Experimental|CDPP Only|Participants will receive the individual level CDPP intervention and no employer intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions. Content for the program will include healthy lifestyle habits, managing stress and staying motivated.
9757508|NCT00606905|Active Comparator|1|IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution
9757509|NCT00606905|Placebo Comparator|2|normal saline
9757510|NCT00606931|Experimental|one arm|
10202333|NCT04815278|Experimental|CDPP and Employer Intervention|Participants will receive the individual level CDPP intervention and employer level workplace equity, job & health supports intervention. The CDPP is a 24-week online curriculum that consists of 8 learning modules and 7 lifestyle coach sessions and check-ins. Content for the program will include healthy lifestyle habits, managing stress and staying motivated. The employer intervention will include an implicit bias workshop and supervisor support training, in addition to regular supervisor check-ins every other week..
10202334|NCT04814654|Experimental|CHALO! 2.0|MSM randomized to this arm will receive twice weekly digital media messages for 12 weeks about HIV, HIV-testing, prevention, and treatment and a a link to a study-specific webpage listing MSM specific testing, prevention, and care resources. Participants will also be able to interact with online outreach workers.
9757511|NCT00606944|Experimental|ERP group|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
9757512|NCT00606944|No Intervention|control group|traditional, conventional care group
9757513|NCT00607022|Active Comparator|immediate load|immediate load of dental implant based on the bone quality determined by the insertion torque value
9757514|NCT00607022|Active Comparator|Loading at 6 weeks|delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
9757515|NCT00607022|Active Comparator|Loading at 12 weeks|traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
9757516|NCT00607048|Other|Schedule A|Schedule A (CP-870,893 administration schedule)
9757517|NCT00607048|Other|Schedule B|Schedule B (CP-870,893 administration schedule)
9757518|NCT00607087|Experimental|sequence 1|sequence 1: insulin glulisine / insulin aspart / insulin lispro.
9757519|NCT00607087|Experimental|Sequence 2|Sequence 2: insulin aspart / insulin lispro / insulin glulisine
9757520|NCT00607087|Experimental|Sequence 3|Sequence 3: insulin lispro / insulin glulisine / insulin aspart
9757521|NCT00607113|Experimental|Avastin|Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV)
9757522|NCT00607113|Experimental|Avastin + RAD001|Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks
9757523|NCT00607113|Experimental|RAD001|Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days
9757524|NCT00607126|Experimental|1|locomotor training using body weight support on a treadmill, using robotic device to provide locomotor training. Locomotor training will be done using the Lokomat device. the patient is suspended over a treadmill while their legs are in the Lokomat, which moves the legs on the treadmill.
9757525|NCT00607126|Active Comparator|2|resistive training using weights and therabands
9757526|NCT00607243|Experimental|Conventional dose group|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
9757527|NCT00607243|Experimental|Low dose group|Diluted CJ-50300 2.5 x 10000pfu/dose vaccination
9757528|NCT00607269|No Intervention|Control|Control condition receiving minimal incentives for service program attendance and participation.
9785487|NCT01253187|Experimental|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|single oral administration of 1 film-coated SHT00186D tablet (YAZ), containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)
9831885|NCT01568918|Experimental|Tamsulosin|Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
9831886|NCT01568918|Placebo Comparator|Placebo|Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.
9831887|NCT01517243|Experimental|Alternating Sunitinib and Temsirolimus|"A cycle is defined as:~Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest"
9831888|NCT01448915||Persons with HIV and HCV coinfection|Persons with HIV and HCV coinfection who receive medical care for HIV infection at Johns Hopkins Hospital
9831889|NCT01354002||Protocol Participants|All participants enrolled on protocols
9831890|NCT01269190|Experimental|Diagnostic (widefield multispectral imaging and HRME)|Patients undergo evaluation of oral cavity using a widefield multispectral imaging device and a high-resolution optical system (HRME) at baseline, after induction of general anesthesia, and prior to surgery.
9831891|NCT00641381|Experimental|Treatment (high-dose chemotherapy, anti-HIV therapy)|Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
9831892|NCT00596401||1|HP eradication group
9831893|NCT00596401||2|No eradication group
9831894|NCT00596401||3|No Hp group
9831895|NCT00544414|Experimental|Treatment|"Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.~Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.~Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy."
9831896|NCT00534469|Active Comparator|HD ARA-C with Idarubicin|HD ARA-C with Idarubicin Consolidation, Busulfan/FTBI/VP16/PSC/BMT
9831897|NCT00534469|Active Comparator|HD ARA-C without Idarubicin|HD ARA-C Consolidation, Busulfan/FTBI/VP16/PSC/BMT
9831898|NCT00534430|Experimental|Busulfan, FTBI and VP16|IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
9831899|NCT00097292||Annual Re-Testing/Annual Metabolic Monitoring|Participants will be monitored annually for risk of type 1 diabetes.
10202335|NCT04814654|Active Comparator|Attention-matched control (AMC)|MSM randomized to the AMC arm will receive twice weekly digital media messages for 12 weeks about general health and a link to a study-specific webpage listing testing resources and MSM-specific services. Participants will also be able to interact with online outreach workers.
10202336|NCT04814654|Active Comparator|Digital coupon only control (DCO)|MSM randomized to the DCO arm will receive, at study entry, a digital coupon for free HIV testing and a study specific webpage link listing testing and MSM specific services.
9831900|NCT00097292||Semi-Annual Metabolic Monitoring|Participants will be monitored every six months for risk of type 1 diabetes
9831901|NCT00003927|Experimental|High Dose chemotherapy followed by cell rescue|Doxorubicin, cyclophosphamide, Taxol, amifostine
9831902|NCT02588261|Experimental|ASP8273|Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
9831903|NCT02588261|Active Comparator|erlotinib or gefitinib|Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
9831904|NCT02588339|Experimental|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
9831905|NCT02588573|Active Comparator|Etafilcon A (control)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
10202337|NCT04813900|Experimental|Patient suspected to suffer from interstitial syndrome needing an arterial blood gas analysis|
10202338|NCT04812171||smoker participants|"Current cigarette smokers older than 18 years, without previously reported systemic disease, not taking medications influencing imunological system or bone metabolism.~Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment."
10202339|NCT04812171||non-smoker participants|Healthy non-smokers paired with smoker group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
10202340|NCT04812171||diabetic participants|Participants reporting diabetes melitus type II, having gycated hemoglobin test, not taking medications influencing imunological system or bone metabolism, non-smokers Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
10202341|NCT04812171||non-diabetic participants|Healthy non-smokers paired with diabetic group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
9757529|NCT00607269|Experimental|Contingency Management|Contingency management (Voucher-Based Reinforcement Therapy) intervention providing positive reinforcement for service program participation and attendance, enactment of prosocial/health behavior, and/or clean urine samples (i.e., no illicit drug use) and clean breathalyzer tests (i.e., BA < 0.05).
9757530|NCT00607321|Experimental|1|Medtronic Bifurcation Stent System
9757531|NCT00607373|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
9757532|NCT00607373|Placebo Comparator|Placebo|Participants received placebo as a subcutaneous injection once a week for 26 weeks.
9757533|NCT00607386|Other|Idursulfase|Open-label treatment with idursulfase
9757534|NCT00607594|Experimental|Treatment (kinase inhibitor therapy)|Patients receive saracatinib PO, at a dose of 175 mg QD in the absence of disease progression or unacceptable toxicity.
9757535|NCT00607620|Experimental|Intervention|Providers receive training in alcohol screening and brief interventions from study staff in compliance with American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
9757536|NCT00607620|No Intervention|Usual Care|Usual care for alcohol use problems after American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
9757537|NCT00607672|Placebo Comparator|1|Patients are randomized to placebo prior to surgery
9757538|NCT00607672|Active Comparator|2|Patients are randomized to Ramipril prior to surgery
9831906|NCT02588573|Active Comparator|Somofilcon A (test)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
9831907|NCT02588586|Experimental|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
9757539|NCT00607672|Active Comparator|3|Patients are randomized to Candesartan (ARB) prior to surgery
9757540|NCT00607724|Experimental|Stage 1: GDC-0449 (150 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
9757541|NCT00607724|Experimental|Stage 1: GDC-0449 (270 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
9757542|NCT00607724|Experimental|Stage 1: GDC-0449 (540 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
9757543|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (150 mg)]|Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
9757544|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (270 mg)]|Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
9757545|NCT00607724|Experimental|Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)]|Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
9757546|NCT00607724|Experimental|Stage 2: New Formulation [GDC-0449 (150 mg )]|Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
9757547|NCT00607789|Experimental|Duloxetine Group|Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.
9757548|NCT00607789|Placebo Comparator|Placebo Group|Sugar pill with matching dosage as Duloxetine
9757549|NCT00607815|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy
9757550|NCT00607815|Active Comparator|Present Centered Therapy|Present Centered Therapy
9757551|NCT00607867|Active Comparator|Arm 1|A LoBAG30, weight maintenance diet will be given to subjects on metformin. All food will be provided for 5 weeks.
9757552|NCT00607867|Placebo Comparator|Arm 2|A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin. All food will be provided for 5 weeks.
9757553|NCT00607880|Active Comparator|Standard Port|Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.
9757554|NCT00607880|Experimental|Vortex Implantable Access Port|Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.
9757555|NCT00607893|Sham Comparator|Sham CPAP|Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
9757556|NCT00607893|Active Comparator|Treatment CPAP|Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
9757557|NCT00607919|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
9757558|NCT00607919|Placebo Comparator|Placebo|Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.
9757559|NCT00607997|Experimental|All Study Patients|"Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~Schedule C: 72 mg/m2 on Days 1 and 4, or~Schedule C: 90 mg/m2 on Days 1 and 4"
9757560|NCT00608062|Experimental|Pre1|Premenopausal - GnRHant plus estradiol
9757561|NCT00608062|Placebo Comparator|Pre2|Premenopausal - GnRHant plus placebo
9757562|NCT00608062|Experimental|Peri1|Perimenopausal (early) - GnRHant plus estradiol
9757563|NCT00608062|Placebo Comparator|Peri2|Perimenopausal (early) - GnRHant plus placebo
9757564|NCT00608062|Experimental|Peri3|Perimenopausal (late) - GnRHant plus estradiol
9757565|NCT00608062|Placebo Comparator|Peri4|Perimenopausal (late) - GnRHant plus placebo
9757566|NCT00608062|Experimental|Post1|Postmenopausal - GnRHant plus estradiol
9757567|NCT00608062|Placebo Comparator|Post2|Postmenopausal - GnRHant plus placebo
9757568|NCT00608140|Experimental|1|Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
9757569|NCT00608140|Active Comparator|2|Participants will receive optimal medical therapy alone
9757570|NCT00608140|Experimental|3|Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement
9757571|NCT00608205|Active Comparator|Arm A: Radiation with concurrent Cisplatin|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
9757572|NCT00608205|Experimental|Arm B: Radiation with concurrent 5-FU and Cisplatin|Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
10202342|NCT04809350|Active Comparator|Adjustable Human Milk Fortification|Human milk fortification based on blood urea levels
10202343|NCT04809350|Experimental|Targeted Human Milk Fortification|Human milk fortification based on milk analysis
10202344|NCT04806802|Experimental|APIOC Sphere or Astigmatism|Single Vision Spherical or Toric Contact Lens
10202345|NCT04804774|Experimental|WW program modified for people with Type 2 diabetes|Includes weekly Virtual Workshops and use of the WW App.
10202346|NCT04800536|Experimental|Cardiovascular effects of rapidly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with a rapidly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
9984131|NCT04394130|Experimental|CI group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~Then a continuous infusion of ropivacaine 0.2% at a flow rate of 6 ml.h-1 will be running for 48h after the bolus administration.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
9757573|NCT00608244|Experimental|LCP-Tacro|"Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.~LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
9757574|NCT00608322|Experimental|1|Subjects receive inhaled nitric oxide (40 parts per million) for six hours.
9757575|NCT00608322|Sham Comparator|2|Subjects receive sham inhaled nitric oxide for six hours.
9757576|NCT00608426|No Intervention|Usual Care|Group who can elect to receive reactive (usual) care for smoking cessation.
9757577|NCT00608426|Experimental|Proactive Care|Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).
9757578|NCT00608491|Active Comparator|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
9757579|NCT00608491|Experimental|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
9757580|NCT00608517|Experimental|Pediatric Myeloablative conditioning|Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
9757581|NCT00608517|Experimental|Adult Myeloablative conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
9757582|NCT00608517|Experimental|Reduced-intensity conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
9757583|NCT00608530|Experimental|Cognitive Behavioral Therapy-Psychologist-Delivered|10 hours of Cognitive Behavioral Training delivered by a psychologist over 8 weeks by telephone and face-to-face contact
9757584|NCT00608530|Active Comparator|Supportive Psychotherapy-Psychologist-Delivered|10 hours of Rogerian Psychotherapy delivered by a psychologist over 8 weeks by telephone and face-to-face contact
9757585|NCT00608530|Experimental|Cognitive Behavioral Therapy-Nurse-Delivered|10 hours of Cognitive Behavioral Training delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
9757586|NCT00608530|Active Comparator|Supportive Psychotherapy-Nurse-Delivered|10 hours of Rogerian Psychotherapy delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
9757587|NCT00608543|Other|Aripiprazole augmentation|This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment.
9757588|NCT00608569|Experimental|mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.
9757589|NCT00608569|Active Comparator|non-mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.
9757590|NCT00608582|Experimental|Real rTMS|These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
9757591|NCT00608582|Sham Comparator|Sham rTMS|Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.
9757592|NCT00608634|Placebo Comparator|Placebo|Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
9757593|NCT00608634|Experimental|Low Dose POH 0.30%|Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
9757594|NCT00608634|Experimental|High Dose POH 0.76%|Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
9757595|NCT00608829|Experimental|GORE TAG® Thoracic Endoprosthesis|Gore 45mm TAG Thoracic Endograft Implantation
9757596|NCT00608842|Experimental|Deoxycholic Acid 1%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
9757597|NCT00608842|Experimental|Deoxycholic Acid 2%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
9757598|NCT00608842|Experimental|Deoxycholic Acid 4%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
9757599|NCT00608842|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
9757600|NCT00608881|Active Comparator|A - coenzyme Q10 2400 mg/day|Randomized to active treatment (coenzyme Q10 2400 mg/day)
9757601|NCT00608881|Placebo Comparator|B - Placebo|Randomized to placebo
9757602|NCT00608894|Experimental|LCP-Tacro|LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
9757603|NCT00608894|Active Comparator|Azathioprine|Azathioprine tablets(50mg)+ prednisone tablets(5mg)
9783152|NCT01194258|Experimental|Lispro-PH20/Insulin lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next, participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (combined: Lispro-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
9783153|NCT01194258|Experimental|Aspart-PH20/Insulin Lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 U/mL insulin glulisine, injected SC, pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 µg/mL rHuPH20 (combined: Aspart-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
9783154|NCT01194271|Experimental|Neoadjuvant Ipilimumab|Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
9783155|NCT01194297|Experimental|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
9783156|NCT01194297|Active Comparator|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
9783157|NCT01194414|Experimental|Tocilizumab SC|"Participants received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab intravenous (IV) infusion every 4 weeks for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
9783158|NCT01194414|Experimental|Tocilizumab IV|"Participants received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
9783159|NCT01194414|Experimental|Tocilizumab SC Then Tocilizumab IV|"Participants who received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab IV infusion every 4 weeks for 24 weeks in double blind treatment period switched to tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
9783160|NCT01194414|Experimental|Tocilizumab IV Then Tocilizumab SC|"Participants who received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly in double blind treatment period switched to tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose will be continued throughout the study."
9757604|NCT00608907|Experimental|VELCADE|Control arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
9757605|NCT00608907|Experimental|VELCADE + rifampicin|Treatment Arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
9757606|NCT00608907|Experimental|VELCADE + dexamethasone|Treatment arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
9757607|NCT00608959|Experimental|omiganan 1% gel|Omiganan has a rapid bactericidal and fungicidal effect which is under development for the prevention of infections arising from short-term central venous catheters, as well as for the prevention of surgical wound infections in contaminated wounds.
9757608|NCT00608959|Active Comparator|chlorhexidine 2%|
9757609|NCT00608985|Experimental|1|almorexant 200 mg
9757610|NCT00608985|Experimental|2|almorexant 100 mg
9757611|NCT00608985|Placebo Comparator|3|Placebo
9757612|NCT00608985|Active Comparator|4|zolpidem 10 mg
9757613|NCT00609128|Experimental|Olopatadine|one drop in one eye only two times per day at an interval of 6 to 8 hours for 1 week
9757614|NCT00609245|Experimental|Placebo then Valproic Acid (VPA)|all patients will have placebo on day 1 and VPA infusion on day 2
9757615|NCT00609271|Experimental|1|low carbohydrate diet
9757616|NCT00609271|Active Comparator|2|low fat diet
9757617|NCT00609336|Experimental|Treatment (chemotherapy, radiation, pancreaticoduodenectomy)|See Detailed Description
9757618|NCT00609362|Active Comparator|Rosiglitazone|25 women age 60 to 75 years receiving rosiglitazone 8 mg/day
9757619|NCT00609362|Placebo Comparator|Placebo|25 women 60 to 75 years of age receiving placebo once a day for 14 weeks
9757620|NCT00609466|Experimental|1|CG5503 IR 75mg 4 to 6 hourly for 72 hours
9757621|NCT00609466|Active Comparator|2|Morphine IR 30 mg 4 to 6 hourly for 72 hours
9757622|NCT00609466|Placebo Comparator|3|Matching placebo 4 to 6 hourly for 72 hours
9757623|NCT00609492|Experimental|Preterm I Group|Children born after a gestation period of 27-30 weeks
9757624|NCT00609492|Experimental|Preterm II Group|Children born after a gestation period of 31-36 weeks
9757625|NCT00609492|Active Comparator|Full term Group|Children born after a gestation period of more than 36 weeks
9757626|NCT00609518|Active Comparator|Standard Vitamin and Steroid Schedule + Pemetrexed|Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
9757627|NCT00609518|Experimental|Simplified Vitamin and Steroid Schedule + Pemetrexed|Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
9757628|NCT00609609|Experimental|Corticosteroids|Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
9757629|NCT00609609|Experimental|ECP + Corticosteroids|Extracorporeal Photopheresis (ECP) 8-9 treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60 + Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
9757630|NCT00609622|Experimental|A|Treatment arm A - sunitinib plus mFOLFOX6
9757631|NCT00609622|Active Comparator|B|Treatment arm B - bevacizumab plus mFOLFOX6
9757632|NCT00609674|Experimental|fluticasone furoate nasal spray|
9757633|NCT00609674|Placebo Comparator|Placebo|
9757634|NCT00609739|Experimental|Cytarabine + Mitoxantrone|This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.
9757635|NCT00609804|Experimental|Sorafenib+Erlotinib|Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth
9757636|NCT00609804|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily by mouth.
9757637|NCT00609869|Experimental|Lenalidomide and Rituximab|"28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.~Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.~Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15."
9757638|NCT00609947|Experimental|Endeavor Zotarolimus-Eluting Coronary Stent|Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
9757639|NCT00609973|Active Comparator|A|Ciprofloxacin 500 mg bid
9757640|NCT00609973|Placebo Comparator|B|Placebo bid
9757641|NCT00609986|Experimental|Intensive|The experimental group will receive the intravenous regular insulin infusion protocol for the maintenance of blood sugar levels 70-110 mg/dL while hospitalized up to 7 am post operative day #3 and after hospitalization will receive subcutaneous insulin to maintain blood sugar levels 70-140 mg/dL.
9757642|NCT00609986|Active Comparator|Control|The control group will receive subcutaneous insulin injections (NPH or glargine and aspartame) to maintain a blood sugar level between 70-180 mg/dL while hospitalized and after hospitalization subcutaneous insulin to maintain blood sugar levels 90-180 mg/dL.
9757643|NCT00610116|Other|LV lead electronically repositioning|Single arm study
9757644|NCT00610129|Experimental|1|MK-0646
9757645|NCT00610155|Placebo Comparator|1|
9757646|NCT00610155|Experimental|2|
9757647|NCT00610155|Experimental|3|
9757648|NCT00610168|Experimental|BOOSTRIX I GROUP|Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
9757649|NCT00610168|Experimental|BOOSTRIX II GROUP|Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
9757650|NCT00610207|Experimental|AFP|Anal fistula plug placement performed during surgical procedure
9757651|NCT00610311|Experimental|ALVAC plus anti-gp100:154-162 TCR PBL + HD IL-2|"ALVAC plus anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin-2 (IL-2): ALVAC vaccine two hours prior to cell infusion patients will receive 0.5 ml containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6.4 to 107.9/mL of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL. This will be repeated on day 14.~Aldesleukin (IL2, Proleukin, Recombinant human interleukin 2)- 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)"
9757652|NCT00610363|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
9757653|NCT00610363|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.
9757654|NCT00610428|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
9757655|NCT00610428|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
9757656|NCT00610428|Placebo Comparator|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
9757657|NCT00610441|Experimental|MK-8777 FD→PBO|Participants receive a fixed dose (FD) of MK-8777 100 mg twice each day (BID) for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of placebo (PBO) BID for 3 weeks (Treatment Period 2).
9757658|NCT00610441|Experimental|PBO→MK-8777 FD|Participants receive a fixed dose of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of MK-8777 100 mg BID for 3 weeks (Treatment Period 2).
9757659|NCT00610441|Experimental|MK-8777 RD→PBO|Participants receive rising doses (RD) of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of placebo BID for 3 weeks (Treatment Period 2).
9757660|NCT00610441|Placebo Comparator|PBO→MK-8777 RD|Participants receive rising doses of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 2).
9757661|NCT00610480|Active Comparator|Optive, then Systane Artificial Tears|Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.
9757662|NCT00610480|Active Comparator|Systane, then Optive Artificial Tears|Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Optive, 40 microliters) will be administered using the same procedure protocol.
9757663|NCT00610649|Experimental|Part 1: Block A MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days.
9757664|NCT00610649|Placebo Comparator|Part 1: Block A Placebo|Participants receive placebo BID for a total of 16 days.
9757665|NCT00610649|Experimental|Part 1: Block B MK-8777|Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 13 days.
9757666|NCT00610649|Placebo Comparator|Part 1: Block B Placebo|Participants receive placebo BID for a total of 13 days.
9757667|NCT00610649|Experimental|Part 1: Block C MK-8777|Participants receive MK-8777 initiated at 300 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 10 days.
9757668|NCT00610649|Placebo Comparator|Part 1: Block C Placebo|Participants receive placebo BID for a total of 10 days.
9757669|NCT00610649|Experimental|Part 1: Block D MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum dose determined by the results of Block A. Participants receive MK-8777 for a total of 13 days.
9757670|NCT00610649|Placebo Comparator|Part 1: Block D Placebo|Participants receive placebo BID for a total of 13 days.
9757671|NCT00610649|Experimental|Part 2: MK-8777 200 mg|Participants receive MK-8777 100 mg BID for 27 days followed by one day of 100 mg QD. Participants receive MK-8777 for a total of 28 days.
9757672|NCT00610649|Experimental|Part 2: MK-8777 800 mg|Participants receive MK-8777 200 mg BID for 3 days followed by 400 mg BID for 24 days followed by one day of 400 mg QD. Participants receive MK-8777 for a total of 28 days.
9757673|NCT00610649|Placebo Comparator|Part 2: Placebo|Participants receive placebo BID for 27 days followed by one day of placebo QD. Participants receive placebo for 28 days.
9757674|NCT00610675|Experimental|Esmirtazapine|One tablet of Esmirtazapine, 4.5 mg orally, daily for up to 52 weeks
9757675|NCT00610688|Placebo Comparator|Prenatal Vitamin D3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a placebo tablet containing 0IU of Vitamin D
9757676|NCT00610688|Experimental|2|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)
9757677|NCT00610688|Experimental|3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3) along with a tablet containing 3600IU of Cholecalciferol (Vitamin D3).
9757678|NCT00610701|Experimental|Anterior pin placement|Anterior pin placement
9757679|NCT00610701|Experimental|Lateral pin placement|Lateral pin placement
9757680|NCT00610714|Active Comparator|Active Comparator|carboplatin plus paclitaxel
9757681|NCT00610714|Experimental|2|AZD0530 in combination with carboplatin plus paclitaxel
9757682|NCT00610727|Experimental|Inhaled prochlorperazine 0.625 mg vs IV|Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
9757683|NCT00610727|Experimental|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato prochlorperazine 1.25 mg
9757684|NCT00610727|Experimental|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato prochlorperazine 2.5 mg
9757685|NCT00610727|Experimental|Inhaled prochlorperazine 5 mg|Inhaled Staccato prochlorperazine 5 mg
9757686|NCT00610727|Experimental|Inhaled prochlorperazine 10 mg|Inhaled Staccato prochlorperazine 10 mg
9757687|NCT00610727|Placebo Comparator|inhaled Placebo|inhaled Staccato Placebo (0 mg)
9757688|NCT00610740|Experimental|Patients Treated with CerviPrep™|CerviPrep™, a novel drug delivery device, was developed specifically for applying pharmaceuticals directly on the cervix. It consists of a syringe-like tube attached to a plastic cap that covers the cervix. Drug can be delivered through the tube, directly to the cervix without spillage onto vaginal or vulvar tissues.
9757689|NCT00610857|Experimental|Anti-CTLA4 monoclonal antibody and HDI|Specific Aim #1: Test the hypothesis that the combination of IFNa-2b and anti-CTLA-4 monoclonal antibody will improve the response rate in patients with recurrent inoperable AJCC stage III and stage IV melanoma. Our therapeutic target is achieving, with acceptable toxicity, a 20% or better rate of objective response, CR or PR by RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study. Study size is planned in terms of our primary efficacy endpoint, objective response.
9757690|NCT00610883|Experimental|1 - LSA4|
9757691|NCT00610935|Placebo Comparator|Placebo|Placebo intramuscular injection
9757692|NCT00610935|Experimental|Peramivir|Single intramuscular injection of 300mg peramivir
9757693|NCT00610987|Active Comparator|Cefazolin|Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours after surgical repair of the closed limb fracture.
9757694|NCT00610987|Placebo Comparator|Placebo|Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo, after the intraoperative dose(s) of cefazolin
9757695|NCT00611026|Active Comparator|1|
9757696|NCT00611026|Placebo Comparator|2|
9757697|NCT00611026|Experimental|3|
9757698|NCT00611130|Experimental|1|3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks
9757699|NCT00611130|Placebo Comparator|2|3 Placebo Tablets, bid, for 9 weeks
9757700|NCT00611247|Experimental|Methylated AGAT Promoter (Group 1)|Induction: 200 mg/m2/day oral Temozolomide x 7 days
9757701|NCT00611247|Experimental|Un-Methylated AGAT Promoter (Group 2)|Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days
9757702|NCT00611325|Experimental|EIAED|Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
9757703|NCT00611325|Experimental|Non-EIAED|Patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 1.7 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
9757704|NCT00611351|Experimental|Unrelated Donor Allogeneic|Matched unrelated donor allogeneic stem cell transplantation with a conditioning regimen of targeted busulfan, cyclophosphamide and thymoglobulin.
9757705|NCT00611403|Active Comparator|RESTASIS®|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
9757706|NCT00611403|Active Comparator|REFRESH ENDURA®|Artificial Tears (REFRESH ENDURA®)
9757707|NCT00611442|Active Comparator|1|split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment
9757708|NCT00611442|Placebo Comparator|2|split-dose PEG solution without dietary restrictions plus placebo pretreatment
9757709|NCT00611455|Experimental|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
9757710|NCT00611455|Placebo Comparator|1000 ml Saline|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
9757711|NCT00611468|Experimental|Intravenous Topotecan and Oral Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
9757712|NCT00611533|Active Comparator|Atomoxetine|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
9757713|NCT00611533|Placebo Comparator|Placebo|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
9757714|NCT00611559|Experimental|Infanrix hexa Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
9757715|NCT00611559|Active Comparator|Infanrix hexa Preservative-Containing Formulation Group|Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
9757716|NCT00611559|Active Comparator|Infanrix penta Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
9757717|NCT00611624|Experimental|Five Days of Mammosite Therapy|Five Days of Mammosite Therapy (Radiotherapy)
9757718|NCT00611715|Experimental|First line/hormone-therapy naive|
9757719|NCT00611715|Experimental|Second-line/prev hormone-therapy tx|
9757720|NCT00611767|Active Comparator|Family History Negative for Alcoholism|Family History Negative for Alcoholism subjects will receive 2 interventions
9757721|NCT00611767|Placebo Comparator|Family History Positive for Alcoholism|Family History Positive for Alcoholism subjects will receive 2 interventions
9757722|NCT00611806|Active Comparator|Folate with B12|Participants will take folic acid plus B12 for 18 weeks.
9757723|NCT00611806|Placebo Comparator|Placebo|Participants will take placebo for 18 weeks.
9757724|NCT00611858|Experimental|Cetuximab, 5-FU and Radiation|"Cetuximab: Participants first receive cetuximab at the initial dose of 400 mg/m2 intravenously (IV) administered over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Cetuximab is given as single agent during the first 3 weeks on study and then in combination with 5-FU and radiation.~Radiation: Radiation therapy given as standard of care is initiated after the 3rd dose of cetuximab with a total dose of 50.4 Gray (Gy) in 28 fractions over approximately 5.5 weeks.~5-FU: Participants receive 5-Fluorouracil (5-FU) continuous infusion through central venous access at 225 mg/m2/day given 7 days a week starting day 1 of radiation (no later than 3 days) and lasting the duration of radiation therapy.~Duration of neoadjuvant therapy is estimated to be 9 weeks. Surgery follows at week 13-17. Sigmoidoscopy is performed for biopsy prior to the 1st dose and after 3rd dose of cetuximab before the initiation of radiation and/or 5-FU."
9757725|NCT00611884|Experimental|SIBA (D)|
9757726|NCT00611884|Experimental|SIBA (E)|
9757727|NCT00611884|Experimental|SIBA (D) M, W, F|
9757728|NCT00611884|Active Comparator|IGlar|
9757729|NCT00611897|Active Comparator|Arm I|The NAC capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after NAC administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
9757730|NCT00611897|Placebo Comparator|Arm II|The placebo capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after placebo administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
9757731|NCT00611923|Placebo Comparator|B|Participants will take placebo flutamide
9757732|NCT00611923|Experimental|A|Participants will take flutamide
9757733|NCT00611975|Experimental|A|Participants will receive treatment with fluoxetine for 2 months
9757734|NCT00611975|Experimental|B|Participants will receive treatment with bupropion for 2 months
9757735|NCT00612040|Experimental|SIBA (D)|
9757736|NCT00612040|Experimental|SIBA (E)|
9757737|NCT00612040|Experimental|IGlar|
9757738|NCT00612066|Experimental|Rosiglitazone|
9757739|NCT00612105|Experimental|1|Retigabine
9757740|NCT00612105|Placebo Comparator|2|Placebo
9757741|NCT00612222|Experimental|ALVAC plus anti-MART-1 F5 TCR PBL + HD IL-2|"ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.~Aldesleukin - 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days."
9757742|NCT00612235||Lamotrigine Monotherapy|Lamotrigine Monotherapy
9757743|NCT00612235||Levetiracetam Monotherapy|Levetiracetam Monotherapy
9757744|NCT00612235||Carbamazepine Monotherapy|Carbamazepine Monotherapy
9757745|NCT00612235||Normal control (no epilepsy)|Normal control (no epilepsy)
9757746|NCT00612313|Active Comparator|Continued medication alone|Participants will receive antidepressant treatment with fluoxetine for 30 weeks
9757747|NCT00612313|Experimental|Continued medication plus CBT|Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment
9757748|NCT00612339|Experimental|Avastin and Temozolomide|Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.
9757749|NCT00612352|Active Comparator|Family HIstory Positive|Subjects with a positive family history of alcoholism.
9757750|NCT00612352|Active Comparator|Family History Negative|Subjects with a negative family history of alcoholism.
9517459|NCT03306121|Experimental|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
9757751|NCT00612430|Experimental|Bevacizumab + Etoposide|Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.
9757752|NCT00612456|Experimental|Arm 1|Pazopanib eye drops formulation 5 mg/mL daily for 28 days
9757753|NCT00612456|Experimental|Arm 2|Pazopanib eye drop formulation 5mg/mL TID for 28 days
9757754|NCT00612456|Experimental|Arm 3|Pazopanib eye drop formulation 2mg/mL TID for 28 days
9757755|NCT00612508|Active Comparator|Desogen|"Drug: ethinyl estradiol and desogestrel~1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.~Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles"
9757756|NCT00612508|Active Comparator|NuvaRing|"Intravaginal Contraception~ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring~Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles"
9757757|NCT00612534|Experimental|1|
9757758|NCT00612534|Experimental|2|
9757759|NCT00612534|Experimental|3|
9757760|NCT00612534|Placebo Comparator|4|
9757761|NCT00612560|Experimental|2|Flaxseed 25 mg per day and 1 placebo pill per day
9757762|NCT00612560|Experimental|3|25 mg flaxseed per day and 1 mg anastrozole pill per day
9757763|NCT00612560|Placebo Comparator|4|Placebo pill 1 per day
9757764|NCT00612560|Experimental|1|Anastrozole 1 mg pill per day
9757765|NCT00612573|Experimental|Doxycyline 0.6 mg/kg/day|Doxycycline dosed at 40 mg/day to subjects of appropriate weights
9757766|NCT00612573|Experimental|Doxycycline 1.2 mg/kg/day|Doxycycline dosed at 80 mg/day to subjects of appropriate weights
9757767|NCT00612573|Experimental|Doxycycline 2.4 mg/kg/day|Doxycycline dosed at 160 mg/day to subjects of appropriate weights
9757768|NCT00612573|Placebo Comparator|Placebo|
9757769|NCT00612586|Experimental|Enzastaurin + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with enzastaurin
9757770|NCT00612586|Placebo Comparator|Placebo + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with placebo
9757771|NCT00612690|Experimental|Links to Learning|Participants received the community mental health consultation model program.
9757772|NCT00612690|Active Comparator|Services as Usual|Participants received treatment as usual and referrals.
9517460|NCT03306121|Active Comparator|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
9517461|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
9757773|NCT00612716|Experimental|Allogeneic Transplantation|Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.
9757774|NCT00612768|Experimental|T.R.U.E. Test allergens Fragrance Mix and Thimerosol|"Concordance (agreement) between positive patch reactions to~fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)~thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)~fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)~thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)~will be measured"
9757775|NCT00612807|Active Comparator|Control|Medication management with a study doctor every other week.
9757776|NCT00612807|Experimental|Combination|Medication management with a study doctor every other week plus weekly marital therapy.
9757777|NCT00612924|Experimental|Anaconda|
9757778|NCT00613015|Experimental|Modafinil/Stress|Participants received placebo for 2 days. modafinil on the third day and participated in the TRIER social stress task on the third day.
9757779|NCT00613015|Experimental|Modafinil/no stress|Participants received placebo for 2 days. modafinil on the third day and did not participate in the TRIER social stress task on the third day.
9757780|NCT00613015|Experimental|Guanfacine/stress|Participants received guanfacine for 3 days and participated in the TRIER social stress task on the third day.
9757781|NCT00613015|Experimental|Guanfacine/no stress|Participants received guanfacine for 3 days and did not participate in the TRIER social stress task on the third day.
9757782|NCT00613015|Placebo Comparator|Placebo/Stress|Participants received placebo for 3 days and participated in the TRIER social stress task on the third day.
9757783|NCT00613015|Placebo Comparator|Placebo/no stress|Participants received placebo for 3 days and did not participate in the TRIER social stress task on the third day.
9757784|NCT00613028|Experimental|Temo + Avastin|Patients treated with bevacizumab + temozolomide
9757785|NCT00613028|Experimental|VP-16 + Avastin|Patients treated with bevacizumab and VP-16 (etoposide)
9757786|NCT00613080|Other|IMRT + Chemotherapy , Resection, Postoperative Chemotherapy|Radiation therapy (intensity modulated radiation therapy [IMRT] + three dimensional conformal radiation therapy [3D-CRT]) + neoadjuvant chemotherapy (capecitabine and oxaliplatin) followed by resection and postoperative chemotherapy (FOLFOX)
9757787|NCT00613106|Experimental|HZT-501|HZT-501: ibuprofen 800mg/famotidine 26.6mg
9757788|NCT00613106|Active Comparator|Ibuprofen|Ibuprofen 800mg
9757789|NCT00613171|Experimental|ST1571|Participants received ST1571 100 mg tablets, orally, once daily. Initiated at an oral dose of 200 mg/day for 4 weeks then titrated up to 400 mg/day for 2 weeks followed by 600 mg/day until Week 24, if well tolerated.
9757790|NCT00613327|Experimental|Oxybutynin Chloride OROS|
9757791|NCT00613366|Experimental|Misoprostol|Cervical preparation with misoprostol prior to intrauterine device insertion
9757792|NCT00613366|Placebo Comparator|Placebo|Cervical preparation with placebo prior to intrauterine device insertion
9757793|NCT00613379|Experimental|Arm 1|10 mg/kg PRO 140, one IV dose (N=10)
9757794|NCT00613379|Experimental|Arm 2|5 mg/kg PRO 140, one IV dose (N=10)
9757795|NCT00613379|Placebo Comparator|Arm 3|Placebo, one IV dose (N=10)
9757796|NCT00613405|Experimental|Stress + cue exposure|Individuals were exposed to the Trier Social Stress Test (TSST) as well as neutral cues and marijana cues.
9757797|NCT00613405|Experimental|No stress + cue exposure|Individuals were not exposed to a stress test, but were exposed to neutral cues and marijuana cues.
9757798|NCT00613509|Experimental|Study Group 1: ALVAC melanoma vaccine|Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
9757799|NCT00613509|Active Comparator|Study Group 2: Interferon alpha-2b|Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.
9757800|NCT00613626|Placebo Comparator|Arm A: ZD6474 Matched Placebo|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
9757801|NCT00613626|Active Comparator|Arm B: ZD6474|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
9757802|NCT00613626|Experimental|Safety Lead-In|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator. The safety lead-in will be conducted to determine the safety of the combination of ZD6474 and cisplation + etopiside. If this combination is found to be unsafe, no patients will be randomized in the Phase II portion of the trial. If the combination is deemed safe according to the protocol, participants from the safety lead-in cohort will not be included in the efficacy analysis.
9757803|NCT00613821|Experimental|Lidocaine infusion|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
9757804|NCT00613821|Active Comparator|Paracervical block only|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
9757805|NCT00613834|Experimental|Lidocaine group|Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization
9757806|NCT00613834|Placebo Comparator|Control group|Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization
9757807|NCT00613925|Active Comparator|Pipelle Group|Women were randomized to have an endometrial biopsy collected using Pipelle de Cornier instrument.
9757808|NCT00613925|Active Comparator|Explora group|Women were randomized to have an endometrial biopsy collected using Explora curette instrument.
9757809|NCT00613938|Placebo Comparator|004|placebo 1 capsule q4-6 hrs for 3 days
9517462|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e > 4 hours after the EVL procedure
9517463|NCT03306069|Experimental|Control|Nutritional therapy / no exercise
9517464|NCT03306069|Experimental|HIIT|High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy
9517465|NCT03306069|Experimental|MIIT-HR|Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy
9757810|NCT00613938|Active Comparator|003|oxycodone 10mg capsule q4-6 hrs for 3 days
9831908|NCT02588599|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
9831909|NCT02588612|Experimental|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
9831910|NCT02588664|No Intervention|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
9831911|NCT02588664|Active Comparator|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
9831912|NCT02588833|Experimental|Cohort 1|180 mg pegcetacoplan/day
9831913|NCT02588833|Experimental|Cohort 2|270 mg pegcetacoplan/day
9831914|NCT02588872|Active Comparator|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
9831915|NCT02588872|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
9831916|NCT02588976|Other|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
9831917|NCT02589067|Experimental|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
9757811|NCT00613938|Experimental|001|Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
9757812|NCT00613938|Experimental|002|Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days
9831918|NCT02589067|Placebo Comparator|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
9831919|NCT02589171|Experimental|Neo Close Abdominal Closure|
9831920|NCT02589171|Active Comparator|Carter Thomason Device|
9831921|NCT02589405|Experimental|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
9831922|NCT02589626|Experimental|empagliflozin 10 mg|empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
9831923|NCT02589626|Experimental|empagliflozin 25 mg|empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
9831924|NCT02589639|Experimental|empagliflozin 10 mg|
9831925|NCT02589639|Experimental|empagliflozin 25 mg|
9831926|NCT02589639|Placebo Comparator|placebo|
9831927|NCT02589665|Experimental|50 mg Mirikizumab IV Q4W (Induction)|50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
9831928|NCT02589665|Experimental|200 mg Mirikizumab IV Q4W (induction)|"200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
9831929|NCT02589665|Experimental|600 mg Mirikizumab IV Q4W (Induction)|"600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
9831930|NCT02589665|Placebo Comparator|Placebo IV Q4W (Induction)|Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
9831931|NCT02589665|Experimental|200 mg Mirikizumab SC Q4W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
9831932|NCT02589665|Experimental|200 mg Mirikizumab SC Q12W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
9831933|NCT02589665|Placebo Comparator|Placebo SC Q4W (Maintenance)|Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
9831934|NCT02589665|Experimental|600mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
9831935|NCT02589665|Experimental|1000mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
9831936|NCT02589665|Experimental|200mg Mirikizumab SC Q4W Extension Open-Label|Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
9831937|NCT02589808|Experimental|Full TTE|Full echocardiogram.
9831938|NCT02589808|Experimental|VScan|Handheld echocardiogram.
9831939|NCT02589847|Experimental|RBX2660 Open-label|RBX2660 (microbiota suspension)
10202347|NCT04800536|Experimental|Cardiovascular effects of slowly declining plasma glucose|A combined hyperglycaemic and euglycaemic clamp with slowly declining plasma glucose (<0.085 mmol/l/min). A combined hyperglycaemic and euglycaemic clamp with a slowly declining plasma glucose (>0.15 mmol/l/min). Plasma glucose will be measured every 5 minute and cardiovascular effects of the plasma glucose decline rate will be assessed using Holter-ECG, echocardiography, thrombelastography and blood sampling.
10202348|NCT04796948|Experimental|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|"irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion.~oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial.~5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.~LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution."
10202349|NCT04792567|Experimental|Siponimod - continuous|Continuous treatment with siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) during SARS-CoV-2 mRNA vaccination
9831940|NCT02589847|Other|Historical control antibiotics|Retrospective Historical Control with standard of care
9831941|NCT02589977|Other|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
9831942|NCT02589977|Other|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
9831943|NCT02589977|Other|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
10202350|NCT04792567|Experimental|Siponimod- interrupted|Siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) with treatment interruption (for approx. 2-3 months) for the purpose of a SARS-CoV-2 mRNA vaccination
10202351|NCT04792567|Active Comparator|Comparator|Baseline DMTs or no treatment during SARS-CoV-2 mRNA vaccination
10202352|NCT04789200|Experimental|NX9 oral contrast agent|Subjects will be given a 9% w/w HBGM concentration of NX9 provided as 1.2L of liquid.
10202353|NCT04788563|Experimental|Heat-sensitive moxibustion group A|In this group, patients are compulsively randomized to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
10202354|NCT04788563|Active Comparator|Control group A|In this group, patients are compulsively randomized to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
10202355|NCT04788563|Experimental|Heat-sensitive moxibustion group B|Patients who voluntarily choose to receive randomization and are randomly assigned to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
10202356|NCT04788563|Active Comparator|Control group B|Patients who voluntarily choose to receive randomization and are randomly assigned to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
10202357|NCT04788563|Experimental|Heat-sensitive moxibustion group C|Patients who voluntarily choose to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
10202358|NCT04788563|Active Comparator|Control group C|Patients who voluntarily choose to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
10202359|NCT04781465|Experimental|Immersive Virtual Reality|"The patients are divided into groups of 3. Each group of patients will attend 2 days of care per week (for 4 weeks) Group N ° 1: Monday and Thursday. Group N ° 2: Tuesday and Friday.~At each visit, the patient will participate in:~[a Kinesitherapy treatment and a Virtual Immersion treatment] + [a Balneotherapy treatment or an Adapted Physical Activity treatment). Each treatment lasts 1 hour 10 minutes.~Each patient will therefore come to the center 8 times over 1 month, or 4 hours 40 minutes a week, not counting virtual reality.~If the groups are not full or according to the advice of the healthcare team, only one group will be selected (always 3 patients) and will attend 3 days per week."
10202360|NCT04781127|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
10202361|NCT04779229|Experimental|Parent Activation|This group of JPOs will deliver Parent Activation as a service to the juveniles and families on their caseloads.
10202362|NCT04779229|Active Comparator|Usual Services|This group of JPOs will deliver services as usual to the juveniles and families on their caseloads.
10202363|NCT04778592|Experimental|ETX-018810|Drug: ETX-018810 bid
10202364|NCT04778592|Placebo Comparator|Placebo|Matching Placebo bid
10202365|NCT04778111||Patients with exclusion|
10202366|NCT04778111||Control|
9757813|NCT00613951|Experimental|SIAC 30 (B)|
9757814|NCT00613951|Experimental|SIAC 45 (B)|
9757815|NCT00613951|Active Comparator|BIAsp 30|
9757816|NCT00614055|Active Comparator|Insulin glargine|
9757817|NCT00614055|Experimental|SIAC 30 (B)|
9757818|NCT00614055|Experimental|SIAC 45 (B)|
9757819|NCT00614120|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg + metformin + glimepiride placebo
9757820|NCT00614120|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg + metformin + glimepiride placebo
9757821|NCT00614120|Experimental|Lira 1.8 + Met|Liraglutide + metformin + glimepiride placebo
9757822|NCT00614120|Experimental|Glim + Met|Glimepiride 4.0 mg + metformin + liraglutide placebo
9757823|NCT00614198|Experimental|Gluten- and casein-free diet|Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
9757824|NCT00614198|No Intervention|No dietary intervention|Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).
9757825|NCT00614315|Experimental|FLAIR Endovascular Stent Graft and Delivery System|
9757826|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (DB)|In double-blind (DB) Week 1, participants receive cetuximab 400 mg/m^2 intravenously (IV) loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV one time each week (Q1W) maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
9757827|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)|In the open-label (OL) portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
9757828|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (OL)|In the OL portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
9757829|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
9757830|NCT00614393|Active Comparator|Placebo + Cetuximab + Irinotecan (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB normal saline (placebo) IV Q1W for up to 32 months of treatment.
9757831|NCT00614406|Experimental|1|
9757832|NCT00614406|Placebo Comparator|2|
9757833|NCT00614432||1|Women who are anticoagulated.
9757834|NCT00614432||2|Matched case controls.
9757835|NCT00614445|Experimental|Diclectin®|Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
9757836|NCT00614445|Placebo Comparator|Placebo|Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)
9757837|NCT00614458|Experimental|Raltegravir and VPA to ART|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
9757838|NCT00614484|Experimental|Proton therapy with chemotherapy|"Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.~Proton therapy - 76 Gy in 5 weeks to lung tumor."
9757839|NCT00614523|Experimental|Romiplostim|Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
9757840|NCT00614523|Placebo Comparator|Placebo|Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
9831944|NCT02590003|Experimental|Platinum-based doublet chemotherapy|"Carboplatin AUC 5 30 minute infusion IV on day 1~Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
9831945|NCT02590003|Active Comparator|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
9831946|NCT02590354|Experimental|Treatment interruption|The ART treatment in patients with a very low viral reservoir will be interrupted.
9831947|NCT02590406|Active Comparator|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
9831948|NCT02590406|Experimental|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
9831949|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Open Label)|LINZESS® (linaclotide) 145 μg capsules, orally, once daily for up to 52 weeks for participants with CIC. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
9831950|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Open Label)|LINZESS® 290 μg capsules, orally, once daily for up to 52 weeks for participants with IBS-C. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
9831951|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 290 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
9831952|NCT02590432|Experimental|LINZESS® 145 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
9831953|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
9831954|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was reduced to 72 μg, if applicable.
9831955|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
9831956|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with CIC.
9757841|NCT00614575||BI-Sifrol® Tablets (Pramipexole)|BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy
9757842|NCT00614614|Experimental|Menhibrix 1 Group|Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].
9757843|NCT00614614|Active Comparator|ActHIB- Infanrix Group|Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.
9757844|NCT00614744|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
9757845|NCT00614744|Active Comparator|Normothermia|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
9757846|NCT00614822|Other|one arm for study|Carboplatin, Pemetrexed and Bevacizumab are given day 1 every 3 weeks for 6 cycles and will be continued if patient tolerates treatments and has stable disease. The Bevacizumab will be continued every 3 weeks for 1 year if the patient tolerates treatment and has stable disease.
9757847|NCT00614874|Experimental|1|Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks
9757848|NCT00614926|Experimental|Modafinil|Eligible patients will be treated at baseline through Week 4. Those who choose to continue will have additional in-person visits at Weeks 8 and 12 visits (and Week 16 for those starting modafinil at Week 4).
9757849|NCT00614926|Placebo Comparator|Placebo|Sugar pill equivalent to the active comparator. Dosing schedule will be the same as the dosing schedule for Modafinil.
9757850|NCT00614939|Experimental|Saxa|Saxagliptin
9757851|NCT00614939|No Intervention|Placebo|Placebo to match
9757852|NCT00614991|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID Period 3-Fosamprenavir 1400mg BID + Raltegravir 400mg BID
9757853|NCT00614991|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg BID
9757854|NCT00614991|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
9757855|NCT00614991|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Raltegravir 100mg BID
9757856|NCT00614991|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
9757857|NCT00614991|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
9757858|NCT00615017|Experimental|AZD9773 cohort 1 (50 units/kg)|AZD9773: single infusion of 50 units/kg
9757859|NCT00615017|Experimental|AZD9773 cohort 2 (250 units/kg)|AZD9773: single infusion of 250 units/kg
9757860|NCT00615017|Experimental|AZD9773 cohort 3 (250/50 units/kg)|AZD9773: loading infusion of 250 units/kg then 9 maintenance doses of 50 units/kg q12hrs
9757861|NCT00615017|Experimental|AZD9773 cohort 4 (500/100 units/kg)|AZD9773: loading infusion of 500 units/kg then 9 maintenance doses of 100 units/kg q12hrs
9757862|NCT00615017|Experimental|AZD9773 cohort 5 (750/250 units/kg)|AZD9773: loading infusion of 750 units/kg then 9 maintenance doses of 250 units/kg q12hrs
9757863|NCT00615017|Placebo Comparator|Placebo|Placebo
9757864|NCT00615030|Experimental|Indacaterol Morning,Indacaterol Evening, Salmeterol|In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757865|NCT00615030|Experimental|Indacaterol Evening,Indacaterol Morning, Placebo|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
10202367|NCT04778046|Experimental|PAH:|Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease or other causes of non-Group 1 PH.
10202368|NCT04778046|Experimental|COPD-noPH|Clinical diagnosis of COPD in the absence of precapillary PH.
10202369|NCT04778046|Experimental|COPD-PH|Clinical diagnosis of COPD with precapillary PH
10202370|NCT04778046|Experimental|IPF-noPH|Clinical diagnosis of IPF in the absence of precapillary PH
10202371|NCT04778046|Experimental|IPF-PH|Clinical diagnosis of IPF with precapillary PH
10202372|NCT04777435|Experimental|Patients with Thrombotic micro-angiopathy|
10202373|NCT04774107|Experimental|P1101 + Ribavirin|P1101 400 µg SC Ribavirin 800-1400 mg PO
9831957|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with IBS-C.
9831958|NCT02590562||RA patients treated with routine clinical practice|Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)
9831959|NCT02590588|Experimental|Idelalisib|Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
9831960|NCT02590939|Experimental|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
9831961|NCT02590939|Sham Comparator|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
9831962|NCT02591056|Experimental|Erchonia Verju Laser + Green PRESS 8|All subjects receive 12 combination treatments over 6 weeks (two per week) with the Erchonia® Verju™ Laser and the Green PRESS 8 devices simultaneously.
9831963|NCT02591238|Placebo Comparator|non-smoker + placebo|non-smoker oral placebo
9831964|NCT02591238|Active Comparator|non-smoker + melatonin|non-smoker oral melatonin
9831965|NCT02591238|Placebo Comparator|smoker + placebo|smoker oral placebo
9831966|NCT02591238|Active Comparator|smoker + melatonin|smoker oral melatonin
9831967|NCT02591290|Experimental|Menactra® Vaccine|Participants received 2-dose series of the study vaccine with 8-week interval.
9831968|NCT02591511|Experimental|health-education app|Smart phone and pad is a stroke-related health education app intervention group
9831969|NCT02591511|Active Comparator|health education manuals|stroke-related health education manual control group
9831970|NCT02591537|Experimental|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
9831971|NCT02591537|No Intervention|Standard Tegaderm Dressing|Tegaderm will be applied.
9831972|NCT02592018|Experimental|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
9831973|NCT02592421|Active Comparator|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
9831974|NCT02592421|Placebo Comparator|Placebo|10 subjects will receive placebo
9831975|NCT02592434|Experimental|CP-690,550|Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
9831976|NCT02592434|Placebo Comparator|Placebo|Control arm: matching placebo tablets or solution for tofacitinib
9831977|NCT02592447|Experimental|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
9831978|NCT02592447|Other|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
9831979|NCT02592486|Active Comparator|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
9831980|NCT02592486|Active Comparator|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
9831981|NCT02592629|Active Comparator|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
9831982|NCT02592629|Active Comparator|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
10202374|NCT04772261|Experimental|Lot-to-Lot Variability|Participants will be administered up to six different 13C-Spirulina test meal lots
10202375|NCT04772261|Experimental|Biological Variability|Participants will be administered the same 13C-Spirulina test meal lot on two different occasions
10202376|NCT04770480|Active Comparator|Standard Care (SC)|Standard Post-Surgical Care utilizing opioids.
10202377|NCT04770480|Active Comparator|Enriched Surgical Management Pathway (EMP)|Enriched Surgical Management Pathway utilizing Physical Therapy and Mindfulness in addition to Standard Protocol.
10202378|NCT04769856|Experimental|Non-fasting group|
10202379|NCT04769856|Experimental|Fasting group|
10202380|NCT04768114|Experimental|Genetically-Informed RiskProfile|
10202381|NCT04768114|Active Comparator|Brief Cessation Advice|
10202382|NCT04764864|Active Comparator|Angioembolization|
10202383|NCT04764864|Active Comparator|Preperitoneal Pelvic Packing|
10202384|NCT04762238|Experimental|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
10202385|NCT04762238|Sham Comparator|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
10202386|NCT04754893|Experimental|Group A|Healthdot directly after surgery and leave the hospital on the same day (evening) (group A)
10202387|NCT04754893|No Intervention|Group b|Standard of care by staying one night in the hospital before returning home (group B)
10202388|NCT04752293||Hypertension Cohort|Participants with newly diagnosed primary hypertension
10202389|NCT04752293||Control Cohort|Healthy participants with normal blood pressure
10202390|NCT04750824||Afatinib cohort|Afatinib cohort
10202391|NCT04750824||other systemic therapy cohort|other systemic therapy cohort
9831983|NCT02592629|Active Comparator|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
9831984|NCT02592655|Active Comparator|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
9831985|NCT02592655|Active Comparator|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
9831986|NCT02592655|Experimental|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
9831987|NCT02592655|Experimental|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
9835905|NCT02760433|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
9835906|NCT02760433|Placebo Comparator|Arm 3: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)~Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group."
9835907|NCT02760654|Experimental|Online Self Management|Participants will interact with an online self management program based on cognitive behavioral principles for 8 weeks as much as they want.
9835908|NCT02760654|No Intervention|Control|Treatment as usual
9835909|NCT02760810|Experimental|narafilcon A|Subjects who are new contact lens wearers (neophytes) between the ages of 18-45 will be dispensed the Test Lens and evaluated over a period of 2 weeks.
9835910|NCT02760862|Active Comparator|Group (I) (N=25)|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours (Hydrocortisone as sodium succinate, vial, equivalent to hydrocortisone 100mg, Egyptian INT, Pharmaceutical Industries CO. ARE,EIPICO.EGYPT).
9835911|NCT02760862|Active Comparator|Group (II) (N=25)|group (II), received mannitol 20% intravenous fluid (100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis for 48 hours) (Manufactured by Allmed Middle East, Egypt).
9835912|NCT02760927|Experimental|Endotracheal Tube Fastener|The intervention administered is a revised commercially available endotracheal tube holder with a tract to accommodate a subglottic suction lumen of an oral endotracheal tube.
10202392|NCT04745676||Experimental|The SICG program consists of the Serious Illness Conversation Guide as well as training and system-level support for physicians to conduct ACP conversations.
10202393|NCT04744025|Experimental|Microfluidics|Half of participants eggs will be injected with sperm processed using a microfluidics chamber.
10202394|NCT04744025|Active Comparator|Density gradient centrifugation|Half of participants eggs will be injected with sperm processed using a density gradient centrifugation (the standard method).
10202395|NCT04731233|Experimental|PRGF Arm|The PRGF experimental group will have two cc of PRGF infused into the upper joint space after the TMJ arthrocentesis procedure.
10202396|NCT04731233|Active Comparator|Steroid Arm|Two cc containing 40 mg of triamcinolone acetonide with 5 mg bupivacaine will be infused into the upper joint space after the TMJ arthrocentesis procedure.
10202397|NCT04726475|Experimental|CBD-WR|"300 mg CBD-rich hemp extract oil administered within the reconsolidation window.~The timing of CBD-rich oil administration is based on preclinical studies demonstrating that CBD's disruptive effects on reconsolidation procedurally depend on timing pharmacological administration to be within the memory reconsolidation window (< 6 hrs. post-retrieval).~Thus, immediately after the 35% CO2 interoceptive memory reactivation procedure and associated measures (see measures), participants will be asked to take a single 300mg CBD-rich oral dose of a hemp-derived oil formulation."
10202398|NCT04726475|Placebo Comparator|PBO-WR|"Placebo administered within the reconsolidation window.~Immediately after the 35% CO2 interoceptive memory reactivation procedure and associated measures (see measures), participants will be asked to take a single dose of an MCT coconut oil placebo solution."
10202399|NCT04726475|Active Comparator|CBD-OR|"CBD-rich hemp extract oil administered outside of the reconsolidation window.~Participants will be asked to take a single 300mg oral dose of CBD-rich oil approximately 24 hrs after the initial 35% CO2 interoceptive memory reactivation challenge.~Thus, CBD will be administered well beyond the critical period for memory reconsolidation. The inclusion of this third arm provides a more robust test of the specific reconsolidation theory-based study hypotheses and aids in controlling for any nonspecific possible anxiolytic effects of CBD."
10202400|NCT04721613||Hypoactive ICU delirium|
10202401|NCT04721613||Hyperactive or mixed ICU delirium|
10202402|NCT04721613||Critically ill patients not suffering form ICU delirium|
10202403|NCT04720976|Experimental|JAB-3312+Pembrolizumab dose escalation|Dose escalation part 1
10202404|NCT04720976|Experimental|JAB-3312+ Binimetinib dose escalation|Dose escalation part2
10202405|NCT04720976|Experimental|JAB-3312+Pembrolizumab dose expansion|Dose expansion part1
10202406|NCT04720976|Experimental|JAB-3312+Binimetinib dose expansion|Dose expansion part2
10202407|NCT04720976|Experimental|JAB-3312+Sotorasib dose escalation|Dose escalation part3
9757866|NCT00615030|Experimental|Salmeterol, Placebo, Indacaterol Morning|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757867|NCT00615030|Experimental|Placebo, Salmeterol, Indacaterol Evening|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757868|NCT00615030|Experimental|Indacaterol Morning, Placebo, Indacaterol Evening|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757869|NCT00615030|Experimental|Indacaterol Evening,Salmeterol, Indacaterol Morning|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9783161|NCT01194440|Experimental|Arm I - IV Zoledronic Acid Prophylaxis|Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
9783162|NCT01194453|Experimental|Group A|
9783163|NCT01194453|Active Comparator|Group B|
9517466|NCT03306069|Experimental|MIIT-LT|Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding ~70-75% HRmax) combined with Nutritional therapy
9757870|NCT00615030|Experimental|Salmeterol, Indacaterol Evening, Placebo|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757871|NCT00615030|Experimental|Placebo, Indacaterol Morning, Salmeterol|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757872|NCT00615030|Experimental|Indacaterol Morning, Salmeterol, Placebo|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757873|NCT00615030|Experimental|Indacaterol Evening, Placebo, Salmeterol|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757874|NCT00615030|Experimental|Salmeterol, Indacaterol Morning, Indacaterol Evening|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757875|NCT00615030|Experimental|Placebo, Indacaterol Evening, Indacaterol Morning|In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757876|NCT00615056|Active Comparator|B|Bevacizumab (avastin)
9757877|NCT00615056|Experimental|C|AG-013736 (axitinib)
9757878|NCT00615056|Experimental|A|AG-013736 (axitinib)
9757879|NCT00615056|Active Comparator|D|bevacizumab (avastin)
9757880|NCT00615069|Experimental|31 mm GORE EXCLUDER® Test Subjects|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
9757881|NCT00615199|Experimental|1mg BD|
9757882|NCT00615199|Experimental|5mg BD|
9757883|NCT00615199|Experimental|15mg BD|
9757884|NCT00615199|Placebo Comparator|Placebo BID|
9757885|NCT00615264|Experimental|DiaPep277|DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
9757886|NCT00615264|Placebo Comparator|Placebo|Mannitol 40 mg in 0.5 mL lipid emulsion.
9757887|NCT00615420|Experimental|Manuka Honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
9757888|NCT00615420|Placebo Comparator|Placebo|Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
9757889|NCT00615433|Experimental|Lurasdione 40mg tablets|
9757890|NCT00615433|Experimental|120mg|
9757891|NCT00615433|Active Comparator|15mg Olz|
9757892|NCT00615433|Placebo Comparator|Sugar pill|
9757893|NCT00615459|Experimental|Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg|In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry powder inhaler (SDDPI). In period III, indacaterol 150 μg once daily delivered via SDDPI and placebo to tiotropium was delivered once daily via the tiotropium inhalation device. Daily inhaled corticosteroid (ICS) monotherapy (where applicable) was provided to remain stable throughout study. The Short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
9757894|NCT00615459|Experimental|Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium|In period I,indacaterol 300 μg once daily delivered via single dose dry powder inhaler (SDDPI)and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
9757895|NCT00615459|Experimental|Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo|In period I, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
9783164|NCT01194466|Active Comparator|Active TENS|Active high frequency TENS will be use for Active TENS.
9783165|NCT01194466|Experimental|Placebo (low intensity) TENS|Placebo TENS will be applied for one arm of the study
9783166|NCT01194466|Sham Comparator|No Treatment|TENS unit in place but not turned on
9783167|NCT01194479|Active Comparator|Type 1 Diabetics|The active group were participants with type 1 diabetes.
10202408|NCT04720976|Experimental|JAB-3312+ Osimertinib dose escalation|Dose escalation part4
10202409|NCT04720976|Experimental|JAB-3312+ Sotorasib dose expansion|Dose expansion part3
9517467|NCT03306056|Experimental|Control|Nutritional therapy / no exercise
10202410|NCT04720976|Experimental|JAB-3312+ Osimertinib dose expansion|Dose expansion part4
10202411|NCT04720274|Experimental|Participants with Hip Pain or Injuries|
10202412|NCT04720274|Active Comparator|Healthy Participants|
10202413|NCT04717934|Experimental|GAL1906|
10202414|NCT04717934|No Intervention|Control|
10202415|NCT04717362|Experimental|Standard Reboot with Natesto|Standard Reboot Protocol + Natesto
10202416|NCT04715581|Experimental|Multicomponent prehabilitation group|Patients in the intervention group will receive nutritional optimization and exercise training before the surgery.
10202417|NCT04715581|No Intervention|Control group|Patients in the control group will maintain normal diet and normal activity before surgery.
9517468|NCT03306056|Experimental|Standard Strength Training|Nutritional therapy combined with a Standard Strength Training program
9757896|NCT00615459|Experimental|Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg|In period I, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. In period II, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period III, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
9757897|NCT00615472|Experimental|Group 1|Inhaled Anesthesia - isoflurane
9757898|NCT00615472|Experimental|Group 2|Intravenous Anesthesia - propofol, remifentanil
9757899|NCT00615550|Placebo Comparator|Placebo|placebo vaginal gel
9757900|NCT00615550|Active Comparator|Prochieve|Progesterone 8% Vaginal Gel
9757901|NCT00615589|Experimental|Flu-Bu4|Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.
9757902|NCT00615719||ED patients undergoing coronary CTA|Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.
9757903|NCT00615784|Experimental|A|
9757904|NCT00615836|Experimental|Desmopressin Melt 10 μg|Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
9757905|NCT00615836|Experimental|Desmopressin Melt 25 μg|Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
9757906|NCT00615836|Experimental|Desmopressin Melt 50 μg|Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
9757907|NCT00615836|Experimental|Desmopressin Melt 100 μg|Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
9757908|NCT00615901|Experimental|1|This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.
9757909|NCT00615927|Experimental|Astrocytoma|Grade II Astrocytoma
9757910|NCT00615927|Experimental|Oligodendroglioma|Grade II Oligodendroglioma or oligoastrocytomas
9757911|NCT00616018|Experimental|A|all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
9757912|NCT00616109|Experimental|Maintenance Sunitinib|"Main interventional arm of study. Subjects who received maintenance sunitinib experimentally on this study were from a population of (consenting) patients with histologically or cytologically documented Extensive-State Small Cell Lung Cancer (ES-SCLC) who did not progress (were classified as Complete Response or CR, Partial Response or PR, or Stable Disease or SD) after an induction chemotherapy (Cisplatin and etoposide)"
9757913|NCT00616122|Experimental|Sunitinib, Cyclophosphamide, and Methotrexate|
9757914|NCT00616200|Experimental|A|
9757915|NCT00616239|Active Comparator|A|Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
9757916|NCT00616239|Active Comparator|B|Subjects randomized to have the left side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
9757917|NCT00616421|Experimental|MenACWY-CRM (1 dose)|1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
9757918|NCT00616421|Active Comparator|Licensed polysaccharide vaccine|1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
9757919|NCT00616421|Experimental|MenACWY-CRM (2 doses)|2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.
9757920|NCT00616434|Experimental|Interferon beta-1a|Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
9757921|NCT00616434|Placebo Comparator|Placebo|Placebo IM injection twice weekly for 12 weeks
9757922|NCT00616655|Active Comparator|1|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
9757923|NCT00616655|Active Comparator|2|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
9757924|NCT00616655|Placebo Comparator|3|Placebo total daily dose 0.9 mg
9757925|NCT00616772|Experimental|ABT-335 + Atorvastatin|ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.
9757926|NCT00616772|Placebo Comparator|Placebo + Atorvastatin|Placebo and atorvastatin (up to 40 mg) once daily for 2 years.
9757927|NCT00616902|Active Comparator|Paricalcitol Injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL given intravenously 3 times per week during dialysis
9757928|NCT00616902|Placebo Comparator|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
9757929|NCT00616928|Experimental|Influenza A (H5N1) 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757930|NCT00616928|Placebo Comparator|Placebo 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757931|NCT00616928|Experimental|Influenza A (H5N1) >64Y Group|Subjects aged > 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9517469|NCT03306056|Experimental|Low-volume Strength Training|Nutritional therapy combined with a low-volume Strength Training program
9757932|NCT00616928|Placebo Comparator|Placebo >64Y Group|Subjects aged > 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757933|NCT00616928|Experimental|Influenza A (H5N1) Group|Pooled group of subjects aged >18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757934|NCT00616928|Placebo Comparator|Placebo Group|Pooled group of subjects aged >18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757935|NCT00616928|Experimental|Influenza A (H5N1) 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757936|NCT00616928|Placebo Comparator|Placebo 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757937|NCT00616928|Experimental|Influenza A (H5N1) >60Y Group|Subjects aged >60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757938|NCT00616928|Placebo Comparator|Placebo >60Y Group|Subjects aged > 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
9757939|NCT00616941|Experimental|Cohort 1|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) once every 3 weeks for a total of 5 vaccinations.
9757940|NCT00616941|Experimental|Cohort 2|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 vegetable grade (VG) once every 3 weeks for a total of 5 vaccinations.
9757941|NCT00616941|Experimental|Cohort 3|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 VG and poly-ICLC once every 3 weeks for a total of 5 vaccinations.
9757942|NCT00617058|Experimental|1|metformin, 250mg-2000 mg/day, in BID to TID doses for 26 weeks. Open, flexibly adjusted.
9757943|NCT00617058|Experimental|2|Healthy lifestyle intervention. Additional meeting at each psychiatric visit to review weight changes, level of physical activity and healthy eating behaviors
9757944|NCT00617058|No Intervention|3|Self-selected patients will be followed at major timepoints to assess weight and related measures.
9757945|NCT00617084|Active Comparator|1. Resolute|Medtronic Endeavor Resolute
9757946|NCT00617084|Active Comparator|2. XIENCE V|Abbott Xience V
9757947|NCT00617097|Active Comparator|paracervical block with lidocaine|Subjects who receive pain control using paracervical block with lidocaine during first trimester surgical abortion
9757948|NCT00617097|Experimental|paracervical block with ketorolac and lidocaine|Subjects who receive pain control using paracervical block with ketorolac and lidocaine during first trimester surgical abortion
9757949|NCT00617123|Experimental|Vorapaxar|Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year
9757950|NCT00617123|Placebo Comparator|Placebo|Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year
9757951|NCT00617175|Experimental|Long NID|Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
9757952|NCT00617175|Active Comparator|Short NID|Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia
9757953|NCT00617188|Experimental|Fulvestrant|Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
9757954|NCT00617201|Experimental|1|Atomoxetine
9757955|NCT00617201|Placebo Comparator|2|Matched Placebo
9757956|NCT00617240|Experimental|1|metformin in doses from 250mg to 2000mg/day for 26 weeks
9757957|NCT00617240|Placebo Comparator|2|Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day
9757958|NCT00617279|Active Comparator|GORE PROPATEN Vascular Graft:|
9757959|NCT00617279|Active Comparator|Disadvantaged Autologous Vein Graft|
9757960|NCT00617305|Experimental|Ambrisentan|Patients were assigned ambrisentan at open-label enrollment or randomization, and received at least one dose of ambrisentan plus an approved phosphodiesterase type-5 (PDE-5) inhibitor (PDE-5i; sildenafil or tadalafil).
9517470|NCT03306056|Experimental|Whole-body Electromyostimulation|Nutritional therapy combined with Whole-Body Electromyostimulation
9757961|NCT00617305|Active Comparator|Placebo|Patients were assigned placebo at randomization and received at least one dose of placebo plus an approved PDE-5i (sildenafil or tadalafil).
9757962|NCT00617344|Experimental|CYD Dengue Vaccine 5555 Formulation|Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
9757963|NCT00617344|Experimental|CYD Dengue Vaccine 5553 Formulation|Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
9517471|NCT03306030|Active Comparator|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
9757964|NCT00617344|Experimental|CYD Dengue Vaccine 4444 Formulation|Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
9757965|NCT00617357|Experimental|1|Strattice Reconstructive Tissue Matrix
9757966|NCT00617396|Experimental|Quetiapine treatment group|All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
9757967|NCT00617409|Active Comparator|Standard of Care|Arm A - Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy
9757968|NCT00617409|Experimental|Ad.p53-DC Vaccines|Arm B - Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy
9757969|NCT00617409|Experimental|Ad.p53-DC Vaccines + ATRA|Arm C - Experimental: Ad.p53-DC vaccines + All -trans Retinoic Acid (ATRA) + Second Line Chemotherapy
9757970|NCT00617461|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, 4 weeks treatment in either the first or second treatment period
9757971|NCT00617461|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, 4 weeks treatment in either the first or second treatment period
9757972|NCT00617539|Experimental|irinotecan and temozolomide|
9757973|NCT00617591|Experimental|Induction and Maintenance Therapy|"Induction Phase Followed by Maintenance Therapy.~Patients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.~At the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.~Dd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description."
9757974|NCT00617604|Placebo Comparator|Placebo|Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
9757975|NCT00617604|Experimental|Alefacept|Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
9757976|NCT00617669|Active Comparator|Placebo + Docetaxel|placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
9757977|NCT00617669|Experimental|ZD4054 + Docetaxel|ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
9757978|NCT00617734|Experimental|IMC-A12 (cixutumumab)|
9757979|NCT00617734|Experimental|IMC-A12 (cixutumumab) + cetuximab|
9757980|NCT00617773|Experimental|hu3S193|
9757981|NCT00617851|Experimental|Influenza virus vaccine (lot A)|Lot A of the investigational influenza virus vaccine
9757982|NCT00617851|Experimental|Influenza virus vaccine (lot B)|Lot B of the investigational influenza virus vaccine
9757983|NCT00617851|Experimental|Influenza virus vaccine (lot C)|Lot C of the investigational influenza virus vaccine
9757984|NCT00617851|Experimental|Influenza virus vaccine (pooled)|Pooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine
9517472|NCT03306030|Experimental|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
9757985|NCT00617851|Active Comparator|Comparator influenza vaccine|A US licensed influenza virus vaccine
9757986|NCT00617890|Experimental|Group 1: 0.3 mg/kg|Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
9831988|NCT02592798|Experimental|Abatacept|"Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
9831989|NCT02592798|Placebo Comparator|Placebo|"Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
9831990|NCT02592876|Experimental|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
9831991|NCT02592876|Active Comparator|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
9831992|NCT02593032|Experimental|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
9831993|NCT02593032|No Intervention|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
9831994|NCT02593097|Experimental|Metformin first, then matching placebo|Subjects will be randomized into the Metformin group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with matching placebo for 12 weeks.
9831995|NCT02593097|Experimental|Matching placebo first, then Metformin|Subjects will be randomized into the matching placebo group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with Metformin for 12 weeks.
9831996|NCT02593149|Experimental|Treatment|ClearGuard HD End Cap
9831997|NCT02593149|No Intervention|Control|Tego® connector with the CurosTM for Tego disinfecting port protector
9831998|NCT02593305|Experimental|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
9831999|NCT02593305|Experimental|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
9832000|NCT02593305|No Intervention|Young Comparison|Young control group, used for age-related comparisons. This group did not go through any intervention.
9832001|NCT02593318|Experimental|Part 1 - Oxaloacetate (OAA) 1 gram/day|Participants take 1 gram of OAA per day for period of 4 weeks
9832002|NCT02593318|Experimental|Part 2 - Oxaloacetate (OAA)2 gram/day|Participants take 2 grams of OAA per day for period of 4 weeks
9832003|NCT02593396|Placebo Comparator|placebo|Placebo BD
9832004|NCT02593396|Experimental|Active|Bupropion hydrochloride sustained-release 150mg BD
9832005|NCT02593539|Experimental|Participants recieving nemiralisib|
10202418|NCT04715386||Group 1- StrataXRT|
10202419|NCT04712669|Experimental|Rodatristat Ethyl 300 mg BID|Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks
10202420|NCT04712669|Experimental|Rodatristat Ethyl 600 mg BID|Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks
10202421|NCT04712669|Placebo Comparator|Placebo|Matching placebo tablet + standard of care medication(s) taken for 24 weeks
10202422|NCT04709874|Experimental|Paravertebral block|Patients will receive paravertebral block guided by a nerve stimulator.
10202423|NCT04709874|Active Comparator|Suprascapular block|Patients will receive suprascapular block
10202424|NCT04707326||DTG/3TC|HIVRNA suppressed HIV patients who switched to DTG/3TC
10202425|NCT04707326||Triple drug cART|Matched HIVRNA suppressed patients who remained on triple drug cART
10202426|NCT04704869|Experimental|Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Cryoprecipitate will be given in addition to the standard of care massive transfusion protocol products, which include red blood cells, plasma, platelets and whole blood. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
10202427|NCT04704869|Active Comparator|Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Only standard of care massive transfusion protocol products will be given, including red blood cells, plasma, platelets, and whole blood.
10202428|NCT04703101|Experimental|Treatment (IMRT, mFOLFOX6, CapeOX, TME)|Patients undergo SCRT in the form of IMRT over 5 fractions daily for 5 consecutive days. Beginning 11-18 days after the last day of radiation therapy, patients receive either oxaliplatin IV and leucovorin IV on day 1 and fluorouracil IV on days 1-3 (mFOLFOX6) or oxaliplatin IV on day 1 and capecitabine PO BID on days 1-14 (CapeOX). Treatment with mFOLFOX6 repeats every 2 weeks for up to 8 cycles, and treatment with CapeOX repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. At 8-12 weeks after completion of all therapy, patients with residual tumor undergo TME. Patients with cCR undergo NOM.
10202429|NCT04702451|Experimental|Tailored|Tailored ablation strategy
10202430|NCT04702451|Active Comparator|Anatomical|Anatomical ablation strategy
10202431|NCT04699435|Experimental|Control|Patients with a BMI <25 kg / m² requiring general anesthesia with a pre-oxygenation for 3 minutes
10202432|NCT04699435|Experimental|PreOx_3min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 3 minutes
10202433|NCT04699435|Experimental|PreOx_6min|Patients with a BMI between 30 kg / m² and 40 kg / m² requiring general anesthesia randomized to the pre-oxygenation group for 6 minutes
10202434|NCT04698161||NSCLC|Patients with non-small-cell lung cancer (NSCLC)
10202435|NCT04698161||metastatic melanoma|patients with metastatic melanoma
10202436|NCT04698148||CDI patients|Patients with Clostridium Difficile Infection
10202437|NCT04698148||MDRO patients|Patients with Multi Drug Resistant Organisms infection
10202438|NCT04698148||IBD patients|Patients with Chronic Inflammatory Bowel Disease
10202439|NCT04698148||IBS patients|Patients with Irritable Bowel Syndrome
10202440|NCT04698148||Hepatic Encephalopathy patients|Patients with Hepatic Encephalopathy
10202441|NCT04698148||healthy volunteers|healthy volunteers
10202442|NCT04698135||morbid obesity|Patients with morbid obesity
10202443|NCT04698135||Metabolically healthy obesity|Patients with metabolically healthy obesity
10202444|NCT04698135||Healthy volunteers|Healthy volunteers
9757987|NCT00617890|Experimental|Group 1: 10 mg/kg|Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
9757988|NCT00617890|Experimental|Group 2: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
9757989|NCT00617890|Experimental|Group 3: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
9757990|NCT00617903|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
9757991|NCT00617903|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
9757992|NCT00617929|Experimental|Conditioning for Graft Failure|Primary or secondary graft failure after hematopoietic stem cell transplantation defined as a > 50% loss of previously best donor chimerism or less than 25% donor chimerism beyond day +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of donor, hematopoietic cell graft or conditioning regimen should be considered for this study. Patients receive anti-thymocyte globulin, rituximab, and clofarabine.
9757993|NCT00617942|Experimental|Neo-adjuvant cohort 1|
9757994|NCT00617942|Experimental|Neo-adjuvant cohort 2|
9757995|NCT00617942|Experimental|Adjuvant cohort 1|
9757996|NCT00617942|Experimental|Adjuvant cohort 2|
9757997|NCT00617981|Experimental|1|ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
9757998|NCT00617981|Sham Comparator|2|Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
9757999|NCT00618072|Placebo Comparator|A: Study diet|EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
9758000|NCT00618072|Active Comparator|B: Study diet plus Metformin|"Metformin and Rosiglitazone Placebo~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
9758001|NCT00618072|Active Comparator|C: Study diet plus metformin and avandia|"Metformin and Rosiglitazone~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
9758002|NCT00618332|Active Comparator|1|2 weeks of treatment
9758003|NCT00618332|Placebo Comparator|2|2 weeks of treatment
9758004|NCT00618371|Experimental|Raltegravir intensification|Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy
9758005|NCT00618410|Active Comparator|Carbon dioxide|nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
9758006|NCT00618410|Placebo Comparator|Placebo|nasal placebo administered 30 minutes prior to nasal challenge
9758007|NCT00618436|Active Comparator|Levetiracetam|Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
9758008|NCT00618436|Active Comparator|Phenytoin|Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.
9758009|NCT00618449|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with 1 gm oral dose of Azithromycin; receive a second 1 gm oral dose of Azithromycin at Day 30; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
9758010|NCT00618449|Active Comparator|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); be treated at Day 30 with the WHO standard of care for trachoma - 1 gm oral dose of Azithromycin; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
9758011|NCT00618514|Active Comparator|1|Bright Tip Laser Fiber - FDA-cleared study device
9758012|NCT00618514|Active Comparator|2|Standard bare tip Laser Fiber - Any commercially available laser device (the control)
9783168|NCT01194479|Other|Healthy Volunteers|The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
10202445|NCT04698109||recurrent cervicovaginitis|patients with recurrent cervicovaginitis
10202446|NCT04698109||endometriosis|patients with endometriosis
10202447|NCT04698109||repeated implantation failures|patients with repeated implantation failures
10202448|NCT04698109||healthy volunteers|healthy volunteers
10202449|NCT04694794|Experimental|Interventional|Single arm, interventional. All participants will be administered Educational Brochure to educate them regarding management of side effects experienced during chemotherapy treatment
10202450|NCT04692961|Experimental|Patients after free flap harvested|Patients receiving peroneal artery-based free flap harvest
9758013|NCT00618540|Experimental|Alemtuzumab|Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
9758014|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/0.7 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758015|NCT00618618|Placebo Comparator|Placebo 0.2 mL/0.7 cm|Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758016|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/1.0 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758017|NCT00618618|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants received placebo administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758018|NCT00618618|Experimental|Deoxycholic Acid Injection 0.4 mL/1.0 cm|Participants received deoxycholic acid administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758019|NCT00618618|Placebo Comparator|Placebo 0.4 mL/1.0 cm|Participants received placebo administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758020|NCT00618722|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received 0.5% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (1 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758021|NCT00618722|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received 1.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (2 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758022|NCT00618722|Experimental|Deoxycholic acid Injection 4 mg/cm²|Participants received 2.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (4 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758023|NCT00618722|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9758024|NCT00618748|Experimental|Pre-Olanzapine|Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
9758025|NCT00618748|Experimental|Pre-Placebo|Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
9758026|NCT00618748|Experimental|New Olanzapine|Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
9758027|NCT00618787|Active Comparator|Arm 1|
9758028|NCT00618787|Active Comparator|Arm 2|
9758029|NCT00618813|Experimental|Treatment (combination chemotherapy)|See Detailed Description
9758030|NCT00618826|Experimental|Treatment Period|Treatment will be administered once every 2 weeks. One cycle of therapy will consist of 14 days. Paclitaxel is administered first after appropriate premedications. Gemcitabine is administered second and Avastin is administered after chemotherapy, all given on day 1 of each cycle.
9758031|NCT00618839|Experimental|StrataGraft : cadaver allograft|All patients enrolled received StrataGraft skin tissue and an intrapatient control area treated with cadaver allograft in a split-wound design
9758032|NCT00618917|Experimental|Radiation + MnSOD PL + Paclitaxel + Carboplatin|MnSOD PL (0.3, 3, or 30 mg) + (Paclitaxel + Carboplatin (45mg/m^2)) + Radiation 1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
9783169|NCT01194531|No Intervention|CONTROL arm|Subjects assigned to this arm of the study will receive no PGS testing.
9783170|NCT01194531|Other|TEST arm|Subjects assigned to this arm of the study will receive PGS testing.
9783171|NCT01194674|Experimental|Microplasmin|
9783172|NCT01194804|Experimental|Eculizumab|Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
9783173|NCT01194830|Active Comparator|Linagliptin|1 Tablet PO QD
9783174|NCT01194830|Placebo Comparator|Placebo|1 Tablet PO QD
9783175|NCT01194869|Experimental|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
9783176|NCT01194973|Experimental|Eculizumab|
10202451|NCT04690023|Active Comparator|PENG block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block. Patients in PENG group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
10202452|NCT04690023|Active Comparator|SFICB block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block. Patients in SFICB group receive multimodal postoperative analgesia techniques coupled with morphine PCA pump.
10202453|NCT04687059|Experimental|PQ Grass Standard Dosing Regimen|Cumulative dose 27600 SU
9783177|NCT01194999|Experimental|Pubovaginal sling procedure|Patients undergoing pubovaginal slings for stress urinary incontinence.
9783178|NCT01195025|Other|A.acetatedRingers, B.colloid & C.colloid+acetatedRingers|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by 150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
9758033|NCT00618956|Experimental|1|
9758034|NCT00618956|Placebo Comparator|2|
9758035|NCT00618982|Experimental|Sorafenib (Nexavar, BAY43-9006)|Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
9758036|NCT00618995|Experimental|A|Arm A: ER niacin/laropiprant + Placebo to laropiprant
9758037|NCT00618995|Experimental|B|Arm B: ER niacin + Placebo to laropiprant
9758038|NCT00618995|Experimental|C|Arm C: laropiprant + Placebo to ER Niacin/laropiprant
9758039|NCT00618995|Placebo Comparator|D|Arm D: Placebo
9758040|NCT00619060|Experimental|Myristyl (right), Placebo (Left)|Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
9758041|NCT00619060|Experimental|Myristyl (Left), Placebo (Right)|Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
9758042|NCT00619073|Active Comparator|Clopidogrel + aspirin|The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.
9758043|NCT00619073|Placebo Comparator|Placebo + aspirin|The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.
9758044|NCT00619099|Experimental|1|
9758045|NCT00619099|Experimental|2|
9758046|NCT00619112|Experimental|Temozolomide|single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14
9758047|NCT00619190|Experimental|open aripipraprazole|Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
9758048|NCT00619190|No Intervention|no medication control|group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
9758049|NCT00619229|Experimental|Alprostadil|Alprostadil
9758050|NCT00619229|Placebo Comparator|Placebo|Placebo
9758051|NCT00619255|Experimental|Intervention|Adolescent Trauma Support Program
9758052|NCT00619255|No Intervention|Control|Usual Care Control Condition
9758053|NCT00619307|Active Comparator|Transition with prophylactic ibuprofen|
9758054|NCT00619307|Active Comparator|Transition with PRN ibuprofen|
9758055|NCT00619359|Experimental|1|Arm 1: study medication
9758056|NCT00619359|Active Comparator|2|Arm 2: Active comparator
9758057|NCT00619385|Experimental|Proellex 100 mg|Proellex 100 mg daily for 7 days
9758058|NCT00619385|Experimental|Proellex 150 mg|Proellex 150 mg daily for 7 days
9758059|NCT00619385|Experimental|Proellex 200 mg|Proellex 200 mg daily for 7 days
9758060|NCT00619476|Placebo Comparator|Placebo|placebo
9758061|NCT00619476|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
9758062|NCT00619476|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
9758063|NCT00619476|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
9758064|NCT00619489|Experimental|Vedolizumab 2 mg/kg|Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
9758065|NCT00619489|Experimental|Vedolizumab 6 mg/kg|Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
9758066|NCT00619502|Experimental|DTaP-IPV-Hep B-PRP~T Vaccine Group|Participants received a primary series of 3 vaccinations with DTaP-IPV-Hep B-PRP~T, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-HepB-PRP~T at 15 to 18 months of age in the present study
9758067|NCT00619502|Active Comparator|Pentaxim™ + Engerix B™ Vaccines Group|Participants received a primary series of 3 vaccinations with Pentaxim™ and Engerix B™ vaccines, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-Hep B-PRP~T at 15 to 18 months of age in the present study.
9758068|NCT00619619|Experimental|A|
9758069|NCT00619645|Other|RIST for Heme malignancies|Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy
9758070|NCT00619684|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.
9785488|NCT01253187|Experimental|EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532B tablet, containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
10202454|NCT04687059|Experimental|PQ Grass Alternative Dosing Regimen|Cumulative dose 27600 SU
10202455|NCT04687059|Placebo Comparator|Placebo Option 1|Suspension for injection
10202456|NCT04687059|Placebo Comparator|Placebo option 2|Solution for injection
10202457|NCT04682145||Haemophilia A patients|All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS
10202458|NCT04679870|Experimental|GB2064|GB2064 will be administered orally as 4 x 250 mg tablets twice a day.
10202459|NCT04678895|Experimental|Group A, Low-Dose Naltrexone, Then Placebo|Group A will receive active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the first 8 weeks. Capsules of different dosages will be indistinguishable. Then followed by 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily).
9785489|NCT01253187|Experimental|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated SHT04532C tablet, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
9785490|NCT01253200|Experimental|Blazer® Open-Irrigated Ablation Catheter|Patients treated with the Blazer® Open-Irrigated Ablation Catheter
9785491|NCT01253200|Active Comparator|Control Catheter|Patients treated with an open-irrigated radiofrequency ablation catheter that has received FDA market approval for the treatment of type 1 atrial flutter( Biosense Webster ThermoCool® ablation catheters (NaviStar™, EZ Steer, or SF) or St. Jude Medical ablation catheters (Therapy™ Cool Path™ or Safire BLU™),
9785492|NCT01253226|Experimental|30 milligrams (mg) Tabalumab|30 mg tabalumab every 4 weeks (Q4W) for 20 weeks (6 doses of study drug)
9785493|NCT01253226|Experimental|60 mg Tabalumab|60 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
10202460|NCT04678895|Experimental|Group B, Placebo, Then Low-Dose Naltrexone|Group B will receive 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily). Then followed by active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the last 8 weeks. Capsules of different dosages will be indistinguishable.
9785494|NCT01253226|Experimental|120 mg Tabalumab|120 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
9785495|NCT01253226|Placebo Comparator|Placebo Q4W|Q4W for 20 weeks
9785496|NCT01253226|Experimental|120 mg once every 2 weeks (Q2W) Tabalumab|Initial loading dose of 240 mg tabalumab followed by 120 mg Q2W for 20 weeks (10 doses of study drug)
9785497|NCT01253226|Placebo Comparator|Placebo Q2W|Q2W for 20 weeks
9785498|NCT01253265|Experimental|30 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
10202461|NCT04675489|Other|Vivity Toric IOL|Patients with cataract that had phacoemulsification and Vivity Toric IOL implantation.
10202462|NCT04674852|Other|Marking cN+ nodes|These patients have already undergone neoadjuvant chemotherapy for locally advanced breast cancer with metastasis to the axillary lymph nodes. During standard of care needle-directed I-125 seed localization, the research marker will also be deployed through the same needle. Ultrasound detection of the marker will be compared to conventional biopsy markers and the I-25 seed.
10202463|NCT04674436|Experimental|6 minute walking break|Participants will walk casually for 6 minutes following one hour of game play, then continue play for one more hour.
10202464|NCT04674436|Experimental|6 minute rest break|Participants will rest supine for 6 minutes following one hour of game play, then continue play for one more hour.
10202465|NCT04674436|No Intervention|Continuous play|Participants will play continuous for 2 hours.
10202466|NCT04673994||Chronic Stroke|Individuals 40-80 years old who have had a stroke 6 months to 5 years ago.
10202467|NCT04673994||CON|Control group (CON) comprised of age- and sex-matched healthy adults.
10202468|NCT04673994||CONyoung|Healthy, young adult control group (CONyoung) who are age 18-30 years old.
9785499|NCT01253265|Experimental|80 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
9785500|NCT01253265|Experimental|180 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
9785501|NCT01253265|Placebo Comparator|Placebo|Placebo is administered subcutaneously in the same manner as active drug in each dose group
9785502|NCT01253265|Experimental|120 mg LY2439821|Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week
9785503|NCT01253291|Experimental|30mg/120 mg LY2127399|Participants in the 30 milligrams (mg) every 4 weeks arm of the lead-in study will receive 30 mg every 4 weeks until the safety of the 120 mg every 4 weeks dose is confirmed in the lead-in study.
9785504|NCT01253291|Experimental|120 mg LY2127399|Participants in the 60 mg every 4 weeks, 120 mg every 4 weeks and 120 mg every 2 weeks arms of the lead-in study will receive 120 mg every 4 weeks as these participants will enroll in this study after the safety of the 120 mg every 4 weeks dose in the lead-in study is confirmed.
9785505|NCT01253304|Experimental|Normal hepatic function|LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function
9785506|NCT01253304|Experimental|Mild hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A)
9785507|NCT01253304|Experimental|Moderate hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with moderate hepatic impairment (Child-Pugh B)
9785508|NCT01253304|Experimental|Severe hepatic impairment|LY2189265: A single, SC-1.5 mg injection on Day 1 in participants with severe hepatic impairment (Child-Pugh C)
10202469|NCT04669808|Experimental|Cohort A: STP705 30 μg dose|Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks
10202470|NCT04669808|Experimental|Cohort B: STP705 60 μg dose|Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks
9785509|NCT01253317|Experimental|rhIGF-1|Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.
10202471|NCT04669808|Experimental|Cohort C: STP705 90 μg dose|Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks
9758071|NCT00619723|Active Comparator|Citicoline|Participants will receive active medication throughout the study. Citicoline will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
9758072|NCT00619723|Placebo Comparator|Placebo|Participants will receive placebo identical in appearance to Citicoline throughout the study. Placebo will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
9758073|NCT00619801|Placebo Comparator|Placebo|
9758074|NCT00619801|Experimental|Levocetirizine|
9758075|NCT00619827|Experimental|300 IR|300 IR grass pollen allergen extract tablet
9758076|NCT00619827|Placebo Comparator|Placebo|Placebo tablet
9758077|NCT00619866|Placebo Comparator|Placebo|Participants received placebo tablets once a day for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) QD for 12 weeks.
9758078|NCT00619866|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg QD for an additional 12 weeks.
9758079|NCT00619866|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
9758080|NCT00619892|Active Comparator|Quetiapine XR|Our target daily dose for quetiapine XR was 200 mg/day. The detailed quetiapine XR dosing guidelines were as follows: 50 mg 1 tab po at HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 2 tabs at HS × 4 days; at the beginning of week 2, if the last dose was tolerated increase to 50 mg 3 tabs at HS × 3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; at the beginning of week 3, if no efficacy & the 200 mg dose was well tolerated, increase to one 300 mg tab at HS-otherwise remain at 200 mg one tab at HS; at week 4 if still no improvement, & 300 mg was tolerable, increase to 200 mg tablet 2 at HS. From the beginning of week 5 to the end of the trial, quetiapine XR doses were held. We used quetiapine XR tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
9758081|NCT00619892|Placebo Comparator|Placebo|Subjects received identical-appearing placebo tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
9758082|NCT00619918|Experimental|1|3% saline
9758083|NCT00619918|Placebo Comparator|2|Normal saline
9758084|NCT00619957|Placebo Comparator|1|Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
9758085|NCT00619957|Experimental|Risedronate|35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years
9758086|NCT00619970|Active Comparator|Healthy Control|Healthy controls
9758087|NCT00619970|Active Comparator|Children receiving Rifaximin|2/3 Patients with CAP
9758088|NCT00619970|Placebo Comparator|Children receiving Placebo|1/3 patients with CAP
9758089|NCT00619983|Active Comparator|Donepezil|Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
9758090|NCT00619983|Active Comparator|Duloxetine|Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
9758091|NCT00619983|Active Comparator|Donepezil + Duloxetine|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
9758092|NCT00619983|Placebo Comparator|Placebo|Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.
9758093|NCT00620022|Experimental|Indacaterol 300 μg followed by placebo|Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9832006|NCT02593630|Experimental|Unicirc circumcision|Unicirc circumcision under topical anaesthetic, wound sealing with cyanoacrylate tissue adhesive
9832007|NCT02593773|Experimental|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
9832008|NCT02593825|Experimental|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
9832009|NCT02593825|Active Comparator|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
9832010|NCT02593864|Experimental|Variable-Stiffness Shoe|Subjects will wear a load-modifying variable-stiffness shoe for 6 months
9832011|NCT02593903|Experimental|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
9832012|NCT02593903|No Intervention|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
9832013|NCT02594098|Experimental|Secukinumab|Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes
9832014|NCT02594098|Placebo Comparator|Placebo|Placebo via subcutaneous injection using 2 prefilled syringes
9832015|NCT02594111|Active Comparator|Colchicine|Colchicine 1.8 mg PO over 1 hour
9832016|NCT02594111|Placebo Comparator|Placebo|Matching placebo
9832017|NCT02594163|Experimental|Brentuximab Vedotin|Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
9832018|NCT02594163|Active Comparator|Rituximab,Bendamustine control|Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
9832019|NCT02594644|Experimental|10-minute Incubation with Microneedle Roller & Sham|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
9832020|NCT02594644|Experimental|20-minute Incubation with Microneedle Roller & Sham|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
9832021|NCT02594826|Experimental|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
9832022|NCT02594826|Active Comparator|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
10202472|NCT04669301|Active Comparator|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
10202473|NCT04669301|Experimental|MAAT-G intervention|The MAAT-G intervention will be delivered by a trained psychology fellow at the University of Rochester Medical Center. The intervention will be delivered through televideoconferencing and participants will be provided a tablet equipped with a HIPPA compliant televideoconferencing application to use for the MAAT-G workshop sessions. We will use the University of Rochester Zoom application which is HIPPA compliant. A tablet instruction manual will be given to patients to help guide them through how to use a tablet and how to navigate the Zoom application. A unique meeting ID number will be given to each patient to log in to the Zoom application. If participants do not have access to wireless internet, the tablet will be equipped with a data package for participant use for the purposes of this study
9785510|NCT01253343||inpatient high aggression|
9785511|NCT01253343||inpatient low aggression|
9785512|NCT01253369|Experimental|Pazopanib|Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
9785513|NCT01253408|Experimental|Dronabinol 2.5 mg bid|Dronabinol 2.5 mg will be taken orally with water twice per day for two days.
9785514|NCT01253408|Experimental|Dronabinol 5 mg bid|Dronabinol 5 mg will be taken orally with water twice per day for two days.
9785515|NCT01253408|Placebo Comparator|Placebo|Placebo will be taken orally with water twice per day for two days.
9785516|NCT01253421|Active Comparator|MDD-amisulpride|Subjects experiencing a current episode of major depression who are randomized to receive amisulpride
9785517|NCT01253421|Placebo Comparator|MDD-placebo|Subjects experiencing a current episode of major depression who are randomized to receive placebo
9785518|NCT01253421|Active Comparator|HC-amisulpride|Subjects having no history of mental disorder (healthy controls, HC) who are randomized to receive amisulpride
9785519|NCT01253421|Placebo Comparator|HC-placebo|Subjects having no history of mental disorder who are randomized to receive placebo
9785520|NCT01253447|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 200 mg orally once a week for each 28 day treatment cycle
9785521|NCT01253460|Experimental|Cyclophosphamide, Rituximab + Sapacitabine|After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.
9785522|NCT01253525|Experimental|Ramucirumab (IMC-1121B ) and Pacitaxel|Each treatment cycle is 4 weeks (28 days)
9785523|NCT01253564|Experimental|Single Arm|
9785524|NCT01253577|Active Comparator|Drug Coated|Sinus stent coated with steroid
9785525|NCT01253577|Placebo Comparator|Non coated|Sinus stent without drug coating
9785526|NCT01253642|Experimental|Treatment (antiangiogenesis, chemosensitizer, chemotherapy)|Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
9785527|NCT01253811|Experimental|rFXIII 35 IU/kg|
9785528|NCT01253824|Experimental|NPC-01|1mg norethisterone and 0.02mg ethinyl estradiol
9785529|NCT01253824|Active Comparator|IKH-01|1mg norethisterone and 0.35mg ethinyl estradiol
9785530|NCT01253902|Active Comparator|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
9785531|NCT01253902|Active Comparator|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
9785532|NCT01253902|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
9785533|NCT01253980|Active Comparator|Amoxicillin|Amoxicillin
9785534|NCT01253980|Placebo Comparator|Placebo suspension|Placebo
9785535|NCT01254019|Experimental|GSK2402968|6mg/kg
9785536|NCT01254019|Experimental|Placebo|dose-matched
9785537|NCT01254045|Experimental|placebo, oxytocin 24IU, oxytocin 48IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
9785538|NCT01254045|Experimental|oxytocin 24IU, placebo, oxytocin 48IU|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
9785539|NCT01254045|Experimental|oxytocin 48IU, oxytocin 24IU, placebo|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
9832023|NCT02595008|Experimental|DSXS topical product|treatment with DSXS twice daily for 28 days
9832024|NCT02595073|Experimental|DSXS topical product|DSXS Active treatment
9832025|NCT02595073|Placebo Comparator|Placebo topical product|Placebo treatment
9832026|NCT02595398|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
9832027|NCT02595398|Sham Comparator|Sham Procedure|Matching suprachoroidal syringe with sham procedure
9832028|NCT02595437|Experimental|Triferic via IV and Hemodialysate|On study Day 1, patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment. On study Day 3, Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
9832029|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
9832030|NCT02595502|Active Comparator|Sequence 1: Test Control Test|Test/control/test using the Johnson & Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
9832031|NCT02595502|Active Comparator|Sequence 2: Control Test Control|Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
9832032|NCT02595528|Experimental|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
9835913|NCT02761252|Experimental|Bilastine+montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
9835914|NCT02761252|Active Comparator|Bilastine+placebo montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
9835915|NCT02761252|Active Comparator|Montelukast+placebo bilastine|Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
9832033|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
9832034|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
9832035|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
9832036|NCT02595567|Other|ITPC|
9832037|NCT02595684|Experimental|Tadalafil|Tadalafil capsules
9832038|NCT02595684|Placebo Comparator|Placebo|Calcined magnesia capsules
9832039|NCT02595723|Experimental|Phenytoin, Then Megestrol|Participants first received pretreatment with Phenytoin 200 mg capsule twice/day for one day. Participants then received both Phenytoin (200 mg capsule twice/day) and liquid Megestrol (800 mg/day) for three consecutive days.
9832040|NCT02595723|Experimental|Placebo, Then Megestrol|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Megestrol (800 mg/day) for three consecutive days.
9832041|NCT02595723|Experimental|Placebo, Then Placebo|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Placebo (matching liquid Megestrol 800 mg/day) for three consecutive days.
9832042|NCT02595749|Experimental|Placebo then Intranasal Oxytocin (40 IU)|Participants received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
9832043|NCT02595749|Experimental|Intranasal Oxytocin (40 IU) then Placebo|Participants received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
9832044|NCT02595970|Experimental|Secukinumab|Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
9832045|NCT02595983|Experimental|All Patients|All patients who received at least 1 dose of revusiran (ALN-TTRSC)
10202474|NCT04666181|Experimental|Dual-task training|Dual-task training will consist of balancing on the dynamic stability platform and responding to auditory stimuli. Participants will perform 18 trials total in 3 blocks of 6 trials. Each trial will be 30 seconds (s) in duration followed by 30 s of rest (i.e. quiet standing on the platform while holding onto the rails.) Between each training block, the participant will step off the platform and rest for 2 minutes. Dual-task training will occur on consecutive visits 2-6.
10202475|NCT04661995|Experimental|Amplification + Notched Noise Therapy|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. This treatment group will include a Notched Noise Therapy, a 1-10 kHz noise notched within a 1-octave range centered around the psychoacoustic tinnitus pitch match measured. Randomized participants will wear their hearing aids with this loaded software for 8 weeks. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
10202476|NCT04661995|Active Comparator|Amplification + Broadband Noise|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. A popular and commonly used sound therapy treatment, this treatment group will listen to a broadband noise, or white noise, that is housed on the manufacturer's hearing aid tinnitus program. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
10202477|NCT04661995|Placebo Comparator|Amplification Only|Following the baseline assessment, participants will be randomly assigned to one of the study groups. Hearing aids are ear-level, self-contained, FDA-approved hearing device. Hearing aids help individuals with hearing loss and provide safe amplification/gain to frequencies that have loss.
10202478|NCT04655313|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
10202479|NCT04653818|Active Comparator|DAAs group|Those with complete HCC ablation who will start sofosbuvir / velpatasvir aiming to eradicate HCV.
9832046|NCT02596009|Experimental|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
9832047|NCT02596009|Other|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
9832048|NCT02596009|Other|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
9832049|NCT02596022|Experimental|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
9832050|NCT02596022|Active Comparator|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
9832051|NCT02596035|Experimental|Nivolumab|Nivolumab dose as specified
9832052|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
9832053|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
9832054|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
9832055|NCT02596321|Experimental|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
9832056|NCT02596321|Placebo Comparator|Placebo tablet|Placebo tablet
9832057|NCT02596451|Experimental|Diclofenac Sodium gel, 1%|apply gel to the target knee
9832058|NCT02596451|Active Comparator|Voltaren® Gel|apply gel to the target knee
9832059|NCT02596451|Placebo Comparator|Placebo|apply gel to the target knee
9832060|NCT02596620|Experimental|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
9832061|NCT02596620|Active Comparator|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
9832062|NCT02596711|Experimental|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
9832063|NCT02596711|Experimental|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
9832064|NCT02596711|Experimental|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
9832065|NCT02596750|Active Comparator|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
9832066|NCT02596750|Sham Comparator|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
10202480|NCT04653818|Active Comparator|Postponed DAAs group|Those who will not start DAAs within the 12 months follow up from HCC ablation procedure. Patients of this group will receive DAAs provided that there is no HCC recurrence after the end of 1 year.
10202481|NCT04650490|Experimental|Immediate SRS followed by IO|Participants will receive SRS followed by physician's choice of standard of care immunotherapy, given at the FDA-approved dose within 14 days of SRS.
10202482|NCT04650490|Experimental|Immediate IO followed by SRS|Participants will receive physician's choice of immunotherapy, given at the FDA-approved dose followed by SRS, if deemed appropriate, at the time of intracranial progression.
9832067|NCT02596854|Experimental|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
10202483|NCT04648085|Experimental|Pre and Post Treatment with Trigeminal Nerve Stimulation (TNS)|Individuals will receive treatment with trigeminal nerve stimulation for 20 minutes at a frequency of 100 Hertz (Hz). Ocular pain intensity will be recorded prior and after the use of therapy.
10202484|NCT04646590|Experimental|Investigational Vaccine|Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 25 μg NCP-RBD protein. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
10202485|NCT04646590|Placebo Comparator|Placebo comparator|Placebo for Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 0.25mg Aluminum hydroxide adjuvant. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
10202486|NCT04645667||Adult patients of allogeneic hematopoietic HCT|Patients who receive their first allogeneic HCT transplant and who receive tacrolimus for aGVHD prophylaxis per standard of care.
10202487|NCT04638309|Experimental|Cohort 1|Dose level 1
10202488|NCT04638309|Experimental|Cohort 2|Dose level 2
10202489|NCT04638309|Experimental|Cohort 3|Dose level 3
10202490|NCT04635904|Experimental|Imaginal exposure|A behavioral intervention in imagery
9758094|NCT00620022|Experimental|Placebo followed by indacaterol 300 μg|Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758095|NCT00620061|Experimental|All Participants|Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks
9758096|NCT00620074|Experimental|combination 2|anidulafungin plus voriconazole
9758097|NCT00620074|Experimental|combination 1|anidulafungin plus voriconazole
9758098|NCT00620113|Placebo Comparator|Placebo|After an observation period of ~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
9758099|NCT00620113|Experimental|Odanacatib 10 mg|After an observation period of ~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
9758100|NCT00620113|Experimental|Odanacatib 25 mg|After an observation period of ~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
9758101|NCT00620113|Placebo Comparator|Odanacatib 50 mg|After an observation period of ~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
9758102|NCT00620126|Experimental|Intervention|UC Home Automated Telemanagement
9758103|NCT00620126|Active Comparator|Control|Best Available Care
9758104|NCT00620191|Placebo Comparator|Matching Placebo|Placebo identical to metformin
9758105|NCT00620191|Experimental|Metformin|Metformin 1000 mg twice a day
9758106|NCT00620282|Experimental|Lira 1.8|Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
9758107|NCT00620282|Placebo Comparator|Placebo|Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
9758108|NCT00620282|Active Comparator|Glimepiride|Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
9758109|NCT00620321|Experimental|LY2181308 sodium, idarubicin, cytarabine|
9758110|NCT00620373|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.
9758111|NCT00620503|Experimental|Formulation A Fed|Single dose of Proellex 25 mg formulation A, fed
9758112|NCT00620503|Experimental|Formulation B Fed|Single dose of Proellex 25 mg formulation B, fed
9758113|NCT00620503|Experimental|Formulation B Fasted|Single dose of Proellex 25 mg formulation B, fasted
9758114|NCT00620542|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg distributed in 2-week run-in period
9758115|NCT00620542|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg distributed in 2-week run-in period
9758116|NCT00620542|Experimental|Rosuvastatin 40 mg|Rosuvastatin 40 mg distributed in core 2-year study
9758117|NCT00620542|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg distributed in core 2-year study
9758118|NCT00620555|Experimental|gabapentin|
9758119|NCT00620659|Experimental|1|Arm 1: Treatment period 1: MK0249; Treatment period 2: Placebo; Treatment period 3: modafinil
9758120|NCT00620659|Experimental|2|Arm 2: Treatment period 1: Placebo; Treatment period 2: modafinil; Treatment period 3: MK0249
9758121|NCT00620659|Experimental|3|Arm 3: Treatment period 1: modafinil; Treatment period 2: MK0249; Treatment period 3: Placebo
9758122|NCT00620659|Experimental|4|Arm 4: Treatment period 1: MK0249; Treatment period 2: modafinil; Treatment period 3: Placebo
9758123|NCT00620659|Experimental|5|Arm 5: Treatment period 1: Placebo; Treatment period 2: MK0249; Treatment period 3: modafinil
9758124|NCT00620659|Experimental|6|Arm 6: Treatment period 1: modafinil; Treatment period 2: Placebo; Treatment period 3: MK0249
10202491|NCT04635904|Experimental|Imagery rescripting|A different behavioral intervention in imagery
10202492|NCT04635800|Experimental|Cohort 1|Cohort 1; open-label, non-randomized, single administration
9758125|NCT00620698||ALS patients|Patients with clinically established amyotrophic lateral sclerosis
9758126|NCT00620711|Experimental|1|Babies that meet criteria will be offered participation in feasibility trial, there are no other arms.
9758127|NCT00620750|Experimental|Extended release injectable naltrexone|
9758128|NCT00620763|Experimental|A|Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
9758129|NCT00620763|Experimental|B|Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet
9758130|NCT00620776|Experimental|Combined Treatment|Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
9758131|NCT00620776|Active Comparator|Venlafaxine XR 75-225 mg alone|These patients receive only medication treatment for GAD. Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period. Medication continued for the full 6 months.
9758132|NCT00620815|Experimental|T/P-A|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22
9758133|NCT00620815|Experimental|A/P-T|One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.
9758134|NCT00620815|Active Comparator|A/S-A|One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22.
9758135|NCT00620815|Experimental|T/P-A (V2 blood draw)|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by a blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
9758136|NCT00620815|Experimental|A/P-T (V2 blood draw)|One dose of the Aflunov(A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by additional blood draw at visit 2 (V2) prior to the Tetravalent influenza vaccination (T) on day 22.
9758137|NCT00620815|Active Comparator|A/S-A (V2 blood draw)|One dose of Aflunov (A)and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed by an additional blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
9758138|NCT00620828|Placebo Comparator|Block Negative|Subjects receive intra-op saline injection per protocol
9758139|NCT00620828|Experimental|Block Positive|Subjects receive intra-op Ropivicaine 0.5% injection per protocol
9758140|NCT00620854|Experimental|rsCTA|Oral Tablet
9758141|NCT00620854|Experimental|rsCTB|Oral Tablet
9758142|NCT00620854|Active Comparator|Fortical|Nasal Spray
9758143|NCT00620945|Experimental|1|Treatment Group
9758144|NCT00621023|Experimental|1|Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
9758145|NCT00621049|Experimental|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|
9758146|NCT00621049|Active Comparator|Docetaxel and Carboplatin|
9758147|NCT00621140|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
9758148|NCT00621140|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
9758149|NCT00621153|Active Comparator|1|Candesartan cilexetil 16mg monotherapy
9758150|NCT00621153|Experimental|2|Candesartan cilexetil 16mg/HCT combination therapy
9758151|NCT00621153|Active Comparator|3|candesartan cilexetil 32mg monotherapy
9758152|NCT00621153|Experimental|4|Candesartan Cilexetil 32 mg/HCT combination therapy
9758153|NCT00621179|Active Comparator|Group 1|Positive endometrial alpha v, beta 3 vitronectin expression. Standard controlled ovarian stimulation protocol followed by in vitro fertilization Intervention: No intervention
9758154|NCT00621179|Experimental|Group 2|Intervention: Positive endometrial alpha v beta 3 vitronectin expression, 3 months of leuprolide acetate in depot suspension administration prior to initiation of controlled ovarian stimulation followed by in vitro fertilization
9758155|NCT00621179|Experimental|Group 3|Negative endometrial alpha v, beta 3 vitronectin and administration of leuprolide acetate in depot suspension for 3 months prior to initiation of controlled ovarian stimulation
9758156|NCT00621179|Active Comparator|Group 4|Negative endometrial alpha v, beta 3 vitronectin expression and standard controlled ovarian stimulation protocol followed by in vitro fertilization. Intervention: No intervention
9758157|NCT00621192|Experimental|Meropenem|"These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA <2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and <91 days; Group 3: GA at birth 32 weeks or older - PNA <2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and <91 days."
9758158|NCT00621244|Experimental|Arm 1, Group X|
9758159|NCT00621244|Experimental|Arm 1, Group Y|
9758160|NCT00621244|Experimental|Arm 2, Group X|
9758161|NCT00621244|Experimental|Arm 2, Group Y|Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.
9758162|NCT00621257|Active Comparator|Treatment A|2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)
9758163|NCT00621257|Experimental|Treatment B|2,000 IU/day of cholecalciferol orally for 6 weeks
9758164|NCT00621257|Experimental|Treatment C|50,000 IU of ergocalciferol once a week orally for 6 weeks
9758165|NCT00621257|Active Comparator|Maintenance A|400 IU/day of ergocalciferol orally over 2 years (control arm)
9758166|NCT00621257|Experimental|Maintenance B|2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years
9758167|NCT00621296|Experimental|MP-424|
9758168|NCT00621309|Active Comparator|1|Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
9758169|NCT00621309|Active Comparator|2|Sulforaphane (SFN), a natural product derived from broccoli sprouts, is utilized as a putative inhibitor of ligand (Rifampin) activation of the Pregnane X-receptor. In this arm, both SFN (putative inhibitor of ligand binding to PXR) and Rifampin (strong activating ligand of PXR) are given together.
9832068|NCT02596867|Experimental|open label single arm, drug propanolol|all subjects will receive the experimental drug
10202493|NCT04635800|Experimental|Cohort 2|Cohort 2; open-label, non-randomized, single administration
10202494|NCT04635800|Experimental|Cohort 3|Cohort 3, open-label; non-randomized, single administration
10202495|NCT04635800|Experimental|Cohort 4|Cohort 4, open-label, non-randomized, single administration
10202496|NCT04635254|Active Comparator|Halophites-based cream 24 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
10202497|NCT04635254|Active Comparator|Halophites-based cream 48 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
10202498|NCT04634435|Experimental|Newly diagnosed multiple myeloma patients|Newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT)
10202499|NCT04627441|Experimental|TESS-EES|Transcutaneous Electrical Spinal Stimulation (TESS), used during the first month of training sessions, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
10202500|NCT04625946|Experimental|Metformin|Standard of care ablation with recommendations for lifestyle modification and metformin.
10202501|NCT04625946|Other|Standard of care|Standard of care ablation with recommendations for lifestyle modification.
9758170|NCT00621309|Active Comparator|3|This arm involves the administration of Sulforaphane (SFN) alone, in the absence of the PXR ligand, rifampicin. The hypothesis is that SFN will have no effect on the expression of PXR-regulated genes. Alternatively, it is possible that SFN could inhibit as yet unidentified endogenous ligands to the PXR receptor, thereby causing down-regulations of genes regulated wholely or in part by PXR. SFN is administered as a broccoli sprout extract at a dose rate of 75 mg (~420 umoles) per day for 7 days.
9758171|NCT00621322|Placebo Comparator|Control Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the control GSK Biologicals' AS01B adjuvanted system, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
9758172|NCT00621322|Active Comparator|GSK692342_F1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the non-adjuvanted GSK692342 vaccine formulation 1 (F1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
9758173|NCT00621322|Experimental|GSK692342_F2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 2 (F2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
9758174|NCT00621322|Experimental|GSK692342_F3 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 3, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
9758175|NCT00621322|Experimental|GSK692342_F4D1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 1 (F4D1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
9758176|NCT00621322|Experimental|GSK692342_F4D2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 2 (F4D2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
9758177|NCT00621348|Active Comparator|Isotonic fluid group|Normal saline in 5% dextrose at standard maintenance rate
9758178|NCT00621348|Active Comparator|Fluid restriction group|Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
9758179|NCT00621348|Active Comparator|Hypotonic fluid group|N/5 saline in 5% dextrose at standard maintenance rate
9758180|NCT00621504|Experimental|Ceftaroline fosamil for Injection|"Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
9758181|NCT00621504|Active Comparator|IV Ceftriaxone|"Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
9758182|NCT00621517|Experimental|1|Participants will receive 150MG Bupropion nightly.
9758183|NCT00621517|Placebo Comparator|2|Participants will receive matching placebo capsule nightly.
9758184|NCT00621530|Experimental|Ketorolac|ketorolac 2 mg ketorolac tromethamine opthalmic solution
9758185|NCT00621530|Placebo Comparator|Placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
9758186|NCT00621543|Experimental|Observation- All subjects|Women choosing intra-uterine contraception after medical abortion.
9758187|NCT00621621|Experimental|Freezor Catheter for AVNRT|Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
9758188|NCT00621621|Other|External Data Supporting the Study|This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.
9758189|NCT00621686|Experimental|Sorafenib + Bevacizumab/Group A|"Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
9832069|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
9517473|NCT03306017|Experimental|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
9517474|NCT03306004||Health Care Providers|Providers answer questionaires
9758190|NCT00621686|Experimental|Sorafenib + Bevacizumab /Group B|"Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
9758191|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 1)|Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
9758192|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 2)|Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
9758193|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 3)|Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
9758194|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 4)|Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
9758195|NCT00621777|Active Comparator|Randomized Phase: Varenicline|Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
9758196|NCT00621777|Placebo Comparator|Randomized Phase: Placebo|
9758197|NCT00621842|Experimental|Open-Label Lamotrigine Treatment|
9758198|NCT00621855|Experimental|Dabigatran etexilate 50mg|twice daily dosing,
9758199|NCT00621855|Experimental|Dabigatran etexilate 75mg|twice daily dosing, patients with moderate renal impairment allocated 50mg bid
9758200|NCT00621855|Experimental|Dabigatran etexilate 110mg|twice daily dosing, patients with moderate renal impairment allocated 75mg bid
9758201|NCT00621855|Experimental|dabigatran etexilate 150mg|twice daily dosing, patients with moderate renal impairment allocated 110mg bid
9758202|NCT00621855|Placebo Comparator|placebo|matched placebo
9758203|NCT00621933||All Patients Receiving Cataract Surgery|All Patients Receiving Cataract Surgery
9758204|NCT00621946|Placebo Comparator|Placebo|Placebo Matching Escitalopram given orally daily (for a 12-week duration).
9517475|NCT03306004||Mothers|Mothers answer questionaires
9517476|NCT03305978|Experimental|Ultra low dose chest CT|
9517477|NCT03305978|Active Comparator|Low dose chest CT|
9758205|NCT00621946|Active Comparator|Escitalopram|Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.
9758206|NCT00621959|Placebo Comparator|Placebo|Matched placebo tablets once daily
9758207|NCT00621959|Experimental|LCTZ|5 mg levocetirizine dihydrochloride tablet
9758208|NCT00621985|Experimental|Experimental|Experimental therapy with nocturnal dexamethasone.
9758209|NCT00622180|Active Comparator|Daavlin Right vs. Excilite Left|Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.
10202502|NCT04624997||Patient suspected COVID-19|"Follow-up of patients as usual in care for infection. No specific puncture. Blood sample collect at admission and every 72h during hospitalisation for hemostasis evaluation, DNA extraction, Circulating endothelial cells measuring.~Sampling can be delayed for 24h to match a planned blood collection for care or other research."
10202503|NCT04622527|Active Comparator|A = Virtual Reality paradigm A|Paradigm A with virtual reality headgear
9832070|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
10202504|NCT04622527|Active Comparator|B = Virtual Reality paradigm B|Paradigm B with virtual reality headgear
10202505|NCT04622527|Sham Comparator|C = Non-Virtual Reality paradigm A|Paradigm A without virtual reality headgear
10202506|NCT04622527|Sham Comparator|D = Non-Virtual Reality paradigm B|Paradigm B without virtual reality headgear
10202507|NCT04618406|Experimental|PICO VAC|PICO14 device from Smith and Nephew. It is a Single-Use Negative Pressure Wound Therapy Device that provides an effective negative pressure of -80 mmHg for 14 days. It is an easily applied all-in-one system that ensures uniform application each time it is applied. The dressing consists of 4 distinct layers that reduce the risk of skin trauma, applies equal negative pressure to the skin and manages fluid transport away from the wound through a combination of absorption and evaporation through an airlock layer. The device is approved for the treatment of open wounds, closed surgical incisions and skin grafts. Both PICO-VAC and soft dressing are applied immediately postoperatively and removed after 12 days.
10202508|NCT04618406|Active Comparator|Standard care|Standard care (sterile surgical silicone foam dressing and soft dressing)
10202509|NCT04610918||Cases - Pediatric Intestinal Failure Patients|DXA BIA Skin fold measurements Strength tests Physical activity monitoring
10202510|NCT04610918||Controls|BIA Skin fold measurements Strength tests Physical activity monitoring
10202511|NCT04608344|Experimental|Sequence AB|Participants will receive atorvastatin (ATV) 40 mg tablet on Day 1, followed by a washout period of 1 day, and then pravastatin (PRA) 40 mg + rosuvastatin (ROS) 10 mg tablets on Day 3 in Treatment A, Period 1. In Treatment B, Period 2 participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 12 and PRA 40 mg + ROS 10 mg tablets on Day 14. Period 1 and Period 2 will be separated by a washout period of 3 days.
10202512|NCT04608344|Experimental|Sequence BA|Participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 6 and PRA 40 mg + ROS 10 mg tablets on Day 8 in Treatment B, Period 1. In Treatment A, Period 2 participants will receive ATV 40 mg tablet on Day 18, followed by a washout period of 1 day and PRA 40 mg + ROS 10 mg tablets on Day 20. Period 1 and Period 2 will be separated by a washout period of 6 days.
9517478|NCT03305965|Experimental|Patient navigation|
9517479|NCT03305965|No Intervention|Care as usual|
9758210|NCT00622180|Active Comparator|Excilite Right vs. Daavlin Left|Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
9758211|NCT00622284|Experimental|BI 1356 5mg, once daily|patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
9758212|NCT00622284|Active Comparator|Glimepiride|patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
9758213|NCT00622336|Experimental|Lenalidomide 25mg (CC-5013)|Oral 25mg daily on Days 1-21 every 28 days
9758214|NCT00622388|Experimental|Ofatumumab|8 weekly intra-venous (I.V.) infusions, 1 x 300mg and 7 x 1000mg
9758215|NCT00622401|Experimental|Group 1|Dendritic Cell/Tumor Fusion Vaccine Only
9758216|NCT00622401|Experimental|Group 2|Dendritic Cell/tumor fusion vaccine and low dose IL-12
9758217|NCT00622401|Experimental|Group 3|Dendritic Cell/tumor fusion vaccine and higher dose IL-12
9758218|NCT00622427|Experimental|Ramelteon then placebo|8 mg tablets every night for 2 weeks, then a 2 week washout,then crossover to placebo tablets for 2 weeks.
9758219|NCT00622427|Experimental|Placebo then Ramelteon|placebo tablets for every night for 2 weeks, then a 2 week washout, followed by 8 mg tablets every night for 2 weeks.
9758220|NCT00622440|Active Comparator|1|
9758221|NCT00622440|Placebo Comparator|2|
9758222|NCT00622466|Experimental|Sorfenib + Paclitaxel|Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
10202513|NCT04604496|Experimental|PF-06882961 participants without Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
10202514|NCT04604496|Experimental|PF-06882961 participants with mild Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
10202515|NCT04604496|Experimental|PF-06882961 participants with moderate Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
10202516|NCT04604496|Experimental|PF-06882961 participants with severe Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
10202517|NCT04597359|Experimental|Arm A (green tea catechins)|Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity.
10202518|NCT04597359|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO BID for up to 6 months.
10202519|NCT04595188|Experimental|Sulphur amino acids in Adults > 60|"Total sulphur amino acid, as methionine only: all subjects will receive up to 7 methionine test levels, without dietary cysteine, assigned in random order.~Minimum methionine, with excess dietary cysteine: all subjects will receive up to 7 methionine test levels, in the presence of excess and constant dietary cysteine, assigned in random order."
10202520|NCT04592861|Experimental|Carbon ion radiotherapy|Carbon ion radiotherapy will be administered 5 days each week (Monday-Friday). The prescription dose will be 60 GyE in 20 fractions, to be delivered over four weeks.
10202521|NCT04592861|Active Comparator|Routine standard of care|Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.
10202522|NCT04591002|Active Comparator|Osemertinib|
10202523|NCT04591002|No Intervention|Observation|
9665389|NCT05070247|Experimental|Dose Expansion: TAK-500 (dosed Q3W and/or Q2W) + Pembrolizumab (dosed Q3W)|TAK-500, infusion, intravenously, once on Days 1 and 22 (Q3W), and/or once on Days 1, 15, and 29, once every 2 weeks (Q2W), in a 42-days treatment cycle with pembrolizumab 200 mg infusion, intravenously, once on Days 1 and 22 (Q3W), in a 42-days treatment cycle for up to 1 year. The dose of TAK-500 for the Dose Expansion arm will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
9665390|NCT05069961|Active Comparator|ESPB Group|20ml Ropivacaine is injected near the nerves in the back and then continued using an infusion pump.
9665391|NCT05069961|Active Comparator|TEA Group|5ml Bupivacaine is injected into the space around the spinal cord and then continued using an infusion pump.
9665392|NCT05069207||Monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
9665393|NCT05069207||Non-monosymptomatic Enuresis|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
9665394|NCT05069207||Daytime Urinary Incontinence|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
9665395|NCT05069207||Control Group Healthy Individuals|Quality of Life Scale in Children with Urinary Incontinence (PIN-Q) Voiding Disorders Symptom Score (IBSS) Dynamic Neuromuscular Stabilization (DNS) Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
9665396|NCT05068674|Active Comparator|Cohort 1|Low dose (50M cells)
9665397|NCT05068674|Active Comparator|Cohort 2|Medium dose (150M cells)
9665398|NCT05068674|Active Comparator|Cohort 3|High dose (300M cells)
9665399|NCT05068024|Experimental|Treatment of NSCLC patients with EGFR genetic alterations|
9665400|NCT05066308|Experimental|Cannabidiol (CBD)|The recommended starting dosage is 2.5mg/kg taken twice daily. The titration schedule recommended in the EPIDIOLEX label will be followed, with 2.5 mg/kg twice daily in week 1, 5 mg/kg twice daily in week 2, 7.5 mg/kg twice daily in week 3, and 10 mg/kg twice daily in week 4 with the second PET scan conducted after one week at the maximum labeled dose. Any participant not tolerating a given dose can either go back down to the next lowest dose or delay uptitration at any week in the protocol. Participants will be instructed to take Epidiolex with a meal rather than in a fasted state. Participants will be treated for 4 weeks in total.
9665401|NCT05066308|Placebo Comparator|Placebo|The placebo will be taken at identical doses to the active drug condition.
9665402|NCT05066087|Experimental|DAHLIA treatment|6 weeks of online behavioural treatment; mainly self-guided and weekly contact with their therapist
9665403|NCT05066087|Other|Treatment as usual|receive usual treatment at their rehabilitation centre; detailed information will be collected to define what treatment as usual means in clinical settings.
9665404|NCT05065957|Experimental|Phase IIa:Dose-Finding Stage|"Level -4: 20 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).~Level -3: 40 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).~Level -2: 60 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).~Level -1: 80 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).~Level 1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m^2 Xeloda (or 20/30/40 mg/m^2 TS-1).~Level 2: 100 mg D07001-softgel capsules plus 800 mg/m^2 Xeloda (or 30/40/50 mg/m^2 TS-1).~Level 3: 100 mg D07001-softgel capsules plus 1000 mg/m^2 Xeloda (or 40/50/60 mg/m^2 TS-1)."
9665405|NCT05065957|Active Comparator|Phase IIb/III: Dose Expansion Stage|"ASC+ D07001-softgel capsules plus Xeloda (or TS-1)~ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)"
9665406|NCT05065242|Experimental|Cognitive Behavioural Therapy|Cognitive Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles and to a lesser extent some cognitive exercises. focused on handling sleep disturbing thought activities.
9665407|NCT05065242|No Intervention|Waitlist|The waitlist serves as a passive control which will receive the same measures as the cognitive behaviour therapy group.
9665408|NCT05064865|Experimental|Freeze-dried table grape powder|The intervention group will consume 46 g/day of a freeze-dried table grape powder.
9665409|NCT05064865|Placebo Comparator|Placebo grape powder|The control group will consume the same amount of a placebo with a similar taste to the table grape powder.
9665410|NCT05064540|Experimental|Alto Abdominal Stent Graft System|Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
9665411|NCT05064540|Active Comparator|Comparators|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
9665412|NCT05064358|Experimental|Cohort 1: Participants receiving belantamab mafodotin at dose level (DL) 1|
9665413|NCT05064358|Experimental|Cohort 2: Participants receiving belantamab mafodotin at DL 2|
9665414|NCT05064358|Experimental|Cohort 3: Participants receiving belantamab mafodotin at DL 3|
9665415|NCT05064358|Experimental|Cohort 4: Participants receiving belantamab mafodotin at DL 4|
9665416|NCT05064358|Experimental|Cohort 5: Participants receiving belantamab mafodotin at DL4 with alternative dose modification|
9665417|NCT05064293|Other|Control Arm|"Data will be collected at baseline and 6-month follow-up from the standardized instruments and automated sources for all eligible subjects randomized to the control arm.~Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider.~Study clinicians will document clinically relevant information from their assessment in a telephone encounter and route these to the child's KP primary care provider in Epic as well as the site navigator.~Control arm participants do not receive navigation."
9665418|NCT05064293|Experimental|Navigation Arm|"6-months of telephonic support from a mental health (MH) navigator to promote early access, engagement, coordination, and personalization of mental health treatment and services as soon as early symptoms of mental health problems are detected in children.~The navigator model and implementation to be tested include:~Automated identification of early symptoms for children~Virtual collection of self-reported, standardized assessment scores~Psychologists interpreting assessment scores and providing feedback to families and PCPs~Trained clinicians serving as MH navigators to conduct family outreach, engage them in MH care, and coordinate with and between clinicians for up to 6-months~Up to 4 video-based behavioral health sessions with the MH navigator, as needed, while barriers to initiation of ongoing mental health services can be explored and addressed over the 6-month period."
9665419|NCT05062460|Other|1-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 1 hour after eating.
9665420|NCT05062460|Other|2-hour post-prandial blood glucose monitoring Arm|Arm in which participants are randomized to blood glucose monitoring at 2 hours after eating.
9665421|NCT05062057||Palpitations|n=20 peri- and postmenopausal women with self-reported palpitations within 2 weeks prior to enrollment
9665422|NCT05062057||No palpitations|n=20 peri- and postmenopausal women with no self-reported palpitations within 6 months prior to enrollment
9665423|NCT05061485|Experimental|Sucrose|The participants will be served a test drink with 75g sucrose dissolved in water
9665424|NCT05061485|Experimental|Sucrose + protein|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal protein (whey protein)
9665425|NCT05061485|Experimental|Sucrose + fat|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal fat (cream)
9665426|NCT05060601|Experimental|Gracey micro-curettes|Subgingival mechanical debridement will be performed using an ultrasonic scaler with specific thin tips and Gracey micro-curette.
9665427|NCT05060601|Active Comparator|Standard Gracey curettes|Subgingival mechanical debridement will be performed using a conventional ultrasonic scaler and standard Gracey curettes.
9665428|NCT05060432|Experimental|Part 1A - EOS-448 + anti-PD1|Participants will receive EOS-448 and anti-PD1 at every cycle
9665429|NCT05060432|Experimental|Part 1B - EOS-448 + inupadenant|Participants will receive EOS-448 at every cycle and inupadenant on a ongoing basis
9665430|NCT05058326||TEST GROUP|Women with fecal incontinence referred to outpatients clinic.
9665431|NCT05055271||Delphi panel|The Delphi panel will include 10 international experts in sleep and respiratory medicine. Two panelists will serve as co-chairs and eight panelists will serve as section leads for the major topic areas throughout the process. A series of planning sessions will be conducted with the co-chairs and section leads prior to implementation of the survey.
9665432|NCT05054790|Experimental|"Autologous Neo-Bladder Construct"|All subjects enrolled will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
9665433|NCT05052697|Experimental|SSA: mIRV A (dose level 1) + QIV|
9665434|NCT05052697|Experimental|SSA: mIRV A (dose level 2) + QIV|
9665435|NCT05052697|Experimental|SSA: mIRV A (dose level 3) + QIV|
9665436|NCT05052697|Experimental|SSA: mIRV A (dose level 4) + QIV|
9665437|NCT05052697|Experimental|SSA: mIRV B (dose level 1) + QIV|
9665438|NCT05052697|Experimental|SSA: mIRV B (dose level 2) + QIV|
9665439|NCT05052697|Experimental|SSA: mIRV B (dose level 3) + QIV|
9665440|NCT05052697|Experimental|SSA: mIRV B (dose level 4) + QIV|
9665441|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 1) + QIV|
9665442|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 2) + QIV|
9665443|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 3) + QIV|
9665444|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 4) + QIV|
9665445|NCT05052697|Experimental|SSA: QIV + mIRV A strain (dose level 4)|
9665446|NCT05052697|Experimental|SSA: qIRV (dose level 1) + QIV|
9665447|NCT05052697|Experimental|SSA: QIV + mIRV B strain (dose level 4)|
9665448|NCT05052697|Experimental|SSB: 2 doses of qIRV (dose level 1), 2-visit schedule|
9665449|NCT05052697|Experimental|SSB: 2 doses of QIV, 2-visit schedule|
9665450|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 1), 2-visit schedule|
9665451|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 2), 2-visit schedule|
9665452|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 1), 1-visit schedule|
9665453|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 2), 1-visit schedule|
9665454|NCT05052697|Experimental|SSB: qIRV (dose level 2, dose combination 1), 1-visit schedule|NOTE: Arm Description has not been entered.
9665455|NCT05052697|Experimental|SSB: qIRV (dose level 2, dose combination 2), 1-visit schedule|NOTE: Arm Description has not been entered
9665456|NCT05052697|Experimental|SSB: qIRV (dose level 3), 1-visit schedule|NOTE: Arm Description has not been entered
9665457|NCT05052697|Experimental|SSB: bIRV AA + bIRV BB (both dose level combination 1), 1-visit schedule|NOTE: Arm Description has not been entered
9832071|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
9832072|NCT02596893|Placebo Comparator|Placebo|Placebo once daily (QD) until the Week 52 Visit
9832073|NCT02596906|Experimental|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
9832074|NCT02596906|Sham Comparator|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
9832075|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
9832076|NCT02596958||Bevacizumab|Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).
9832077|NCT02596971|Experimental|Atezo-G-Benda (Safety Run-In and Expansion Phases)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month [q2m]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
9832078|NCT02596971|Experimental|Atezo-G-CHOP (Safety Run-In Phase)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, obinutuzumab, and CHOP during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months, during maintenance treatment.
9832079|NCT02596971|Experimental|Atezo-R-CHOP (Expansion Phase)|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, rituximab, and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles, as determined by the investigator), during induction treatment, followed by atezolizumab from Cycles 9-25 during consolidation treatment.
9832080|NCT02597049|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.
9832081|NCT02597049|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide given SC once a week for 24 weeks.
9832082|NCT02597049|Placebo Comparator|Placebo|Placebo given SC once a week for 24 weeks.
9832083|NCT02597101|Placebo Comparator|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
9832084|NCT02597101|Experimental|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
9832085|NCT02597127|Experimental|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
9832086|NCT02597127|Experimental|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
9832087|NCT02597127|Experimental|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
9832088|NCT02597127|Placebo Comparator|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
9832089|NCT02597127|Experimental|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
9832090|NCT02597127|Experimental|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
9832091|NCT02597127|Experimental|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
9832092|NCT02597127|Placebo Comparator|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
9832093|NCT02597452|Other|intelligent Breast Exam, iBE|Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.
10202524|NCT04589351|Active Comparator|Ezetimibe|One treatment period of 16 weeks with1 capsule of ezetimibe 10mg per day, as add-on to standard care.
10202525|NCT04589351|Placebo Comparator|Placebo|One treatment period of 16 weeks with 1 capsule of matching placebo per day, as add-on to standard care.
9665458|NCT05052697|Experimental|SSB: 1 dose of QIV, 1-visit schedule|NOTE: Arm Description has not been entered
9665459|NCT05050903||Asthma|
9665460|NCT05050903||Healthy controls|
9758223|NCT00622505|Experimental|Zoledronic acid|Participants received 4 milligrams (mg) or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes, every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine N-telopeptide of type 1 collagen (NTx) measurement (greater than or equal to [≥] 50 nanomoles per millimoles [nmol/mmol] creatinine or <50 nmol/mmol creatinine, respectively).
9758224|NCT00622518|Active Comparator|1|homeopathic ear drops in addition to standard care for otitis media
9758225|NCT00622518|No Intervention|2|No ear drops, standard care for otitis
9758226|NCT00622635|Experimental|Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758227|NCT00622635|Experimental|Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758228|NCT00622635|Experimental|Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758229|NCT00622635|Experimental|Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758230|NCT00622635|Experimental|Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758231|NCT00622635|Experimental|Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758232|NCT00622700|Placebo Comparator|Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg|"Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally."
9758233|NCT00622700|Experimental|Teriflunomide 7 mg/7 mg|"Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally."
9758234|NCT00622700|Experimental|Teriflunomide 14 mg/14 mg|"Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally."
9758235|NCT00622726|Experimental|Bevacizumab for ROP|Intravitreal Bevacizumab Therapy is the Experimental Arm of this Study
9758236|NCT00622726|Active Comparator|Conventional Laser for ROP|Conventional Laser to the Peripheral Retina is the Control Arm of this Study
9758237|NCT00622739|Active Comparator|ziprasidone rapid dose|Rapid Dose Titration Group
9758238|NCT00622739|Active Comparator|ziprasidone slow dose|Slow Dose Titration Group
9758239|NCT00622869|Experimental|Everolimus + reduced tacrolimus|Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
9758240|NCT00622869|Experimental|Tacrolimus elimination|Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
9758241|NCT00622869|Active Comparator|Tacrolimus control|Control dose tacrolimus + corticosteroids.
9758242|NCT00622895|Experimental|Treatment: allogeneic UCB after reduced intensity conditioning|Patients receive fludarabine phosphate IV on days -4, -3 and -2, cyclophosphamide IV over 1-2 hours on days -6, -5, 3, and 4, and undergo low-dose TBI on day -1. Patients receive hematopoietic cell transplantation on day 0.
9758243|NCT00622908|Experimental|ISV-403|ISV-403 0.6%
9758244|NCT00622908|Placebo Comparator|Vehicle|Vehicle of ISV-403
9758245|NCT00623012|Experimental|1|
9783179|NCT01195025|Other|A.colloid, B.colloid+acetatedRinger & C.acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
9783180|NCT01195025|Other|A.acetatedRingers, B.acetatedRingers+colloid & C.colloid|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B.Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples."
9783181|NCT01195025|Other|A.colloid, B.acetatedRingers & C.colloid+acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
9783182|NCT01195025|Other|A.colloid+acetatedRingers, B.colloid & C.acetated Ringers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
9783183|NCT01195090|Active Comparator|sitagliptin|add sitagliptin100mg/d to pre-study OADs
9783184|NCT01195090|Active Comparator|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
9783185|NCT01195103|Experimental|10 mg/kg Lusedra|10 mg/kg Lusedra initial bolus.
9783186|NCT01195103|Active Comparator|6.5 mg/kg Lusedra|6.5 mg/kg Lusedra initial bolus.
9783187|NCT01195103|Active Comparator|Placebo + Midazolam|Placebo initial bolus with dose of midazolam based on patient's weight
9783188|NCT01195116|Active Comparator|Dexmedetomidine|Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.
9783189|NCT01195116|Placebo Comparator|Normal Saline|
9783190|NCT01195272|Experimental|Single Arm|
9783191|NCT01195363|Active Comparator|quetiapine SR|quetiapine SR, 200-600mg, po, qd
9783192|NCT01195363|Placebo Comparator|quetiapine sr Placebo|quetiapine SR placebo, 200-600mg, po qd
9783193|NCT01195415|Experimental|Treatment (vismodegib, gemcitabine hydrochloride)|Patients receive vismodegib PO QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 (beginning in course 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9783194|NCT01195467|Experimental|All Subjects Truvada/Raltegravir|All Subjects will receive the same intervention, Truvada/Raltegravir
9783195|NCT01195545|Experimental|Veritas Mesh in Hernia Repair|Subjects undergoing laparoscopic paraesophageal hiatal hernia repair using a bovine pericardium mesh (BP) (Veritas® Collagen Matrix, Synovis ®, St. Paul MN) as a reinforcing material during repair.
9783196|NCT01195584||BMI < 25|Body Mass Index (WHO) established by WHO. BMI < 25 has been defined as 'normal weight'.
9783197|NCT01195584||25 >= BMI < 30|Body Mass Index (WHO) established by WHO. BMI >= 25 and < 30 has been defined as 'overweight'.
9783198|NCT01195584||BMI >= 30|Body Mass Index (WHO) established by WHO. BMI > 30 has been defined as 'obese'.
9783199|NCT01195597|Experimental|E-Cigarette 7.2 mg nicotine|Well characterized group of 40 regular smokers not intending to quit experimenting the E-Cigarette with 7.2 mg nicotine cartridges.
9783200|NCT01195623|Active Comparator|varicose vein surgery with preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination and has then the extra information available from a preoperative duplex examination to plan surgery more in detail
9783201|NCT01195623|No Intervention|varicose vein surgery no preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination only
9783202|NCT01195636|Experimental|XPF-002|
9758246|NCT00623103|Experimental|Rivastigmine capsule|Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
9758247|NCT00623103|Experimental|Rivastigmine patch|Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm^2 patch or the highest well tolerated dose was maintained until week 76.
9758248|NCT00623181|Experimental|Fluzone Intradermal First, Then Fluzone Intramuscular|
9758249|NCT00623181|Experimental|Fluzone Intramuscular First, Then Fluzone Intradermal|
9758250|NCT00623194|Experimental|insulin detemir|Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
9758251|NCT00623233|Experimental|Gemcitabine + Bevacizumab|"Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.~Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
9758252|NCT00623363|Active Comparator|piclozotan|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of piclozotan administered at a plasma level of 30 ng/mL over 2 inpatient days.
9758253|NCT00623363|Placebo Comparator|0.9 % sodium chloride (normal saline)|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of 0.9 % sodium chloride (normal saline) administered at a plasma level of 30 ng/mL over 2 inpatient days.
9758254|NCT00623428|Experimental|PEG-IFN alfa-2a + Ribavirin for 24 weeks|After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
9758255|NCT00623428|Active Comparator|PEG-IFN alfa-2a + Ribavirin for 48 weeks|After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
9758256|NCT00623467|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.
9758257|NCT00623480|Experimental|Recombinant Factor VIII prophylaxis treatment|Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
9758258|NCT00623480|Experimental|Recombinant Factor VIII on-demand treatment|Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
9758259|NCT00623506|Active Comparator|1|Pregnenolone
9758260|NCT00623506|Placebo Comparator|2|Placebo
9758261|NCT00623545|Experimental|Exenatide|Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.
9758262|NCT00623597|Experimental|1|
9758263|NCT00623623|Experimental|Tenecteplase|Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
9758264|NCT00623623|Other|primary PCI|Standard primary PCI
9783203|NCT01195636|Placebo Comparator|Placebo|
9783204|NCT01195662|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablets
9832094|NCT02597478|Experimental|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
9832095|NCT02597478|Experimental|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
9832096|NCT02597543|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
9832097|NCT02597543|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
9832098|NCT02597582|Active Comparator|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
9832099|NCT02597582|Other|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
9832100|NCT02597673|Active Comparator|Standard rehabilitation protocol|Home Exercise Program (HEP). All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
9832101|NCT02597673|Experimental|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
9832102|NCT02597673|Experimental|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
9832103|NCT02597673|Experimental|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
9832104|NCT02597712|Experimental|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
9832105|NCT02597712|Placebo Comparator|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
9832106|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
9832107|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
9832108|NCT02597907|Experimental|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
9832109|NCT02597907|Active Comparator|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
9832110|NCT02597920||Switch patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
9832111|NCT02597920||New AF patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
9832112|NCT02597933|Experimental|Nintedanib|patient receives capsules containing nintedanib twice a day
9832113|NCT02597933|Placebo Comparator|Placebo|patient receives capsules identical to those containing active drug
9832114|NCT02597946|Experimental|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
9832115|NCT02598076|Active Comparator|control|Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
9832116|NCT02598076|Experimental|MI|"Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms)."
9832117|NCT02598089|Experimental|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~NYMC X-179A reassortant of A/California/7/2009 (H1N1)~NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
9832118|NCT02598089|Placebo Comparator|Placebo|This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline
9832119|NCT02598128|Experimental|RELiZORB|Treatment (RELiZORB)
9832120|NCT02598128|Placebo Comparator|Control|Placebo control
9984132|NCT04394130|No Intervention|SS group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.~After the injection, the catheter will be removed.~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
9984133|NCT04393974||Cancer patients with COVID-19|All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
9832121|NCT02598193|Experimental|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
9832122|NCT02598297|Active Comparator|Ruxolitinib|Two tablets of ruxolitinib 5 mg were administered orally twice per day.
9832123|NCT02598297|Placebo Comparator|Ruxolitinib Placebo|Two tablets of 5mg placebo were administered orally twice per day.
9984134|NCT04391608|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25 mg/day
9984135|NCT04391608|No Intervention|TDF dose reduction|TDF dose reduction
9832124|NCT02598583|Experimental|Cohort 1|"Intravenous infusion of ALXN1210 as follows:~Induction phase: a) 400 milligrams (mg) on Day 1 and Day 8, 600 mg on Day 15; or b) 600 mg on Day 1, 600 mg on Day 15~Maintenance phase: the first 5 doses of 900 mg on Day 29 and every 4 weeks thereafter~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:~≥40 to <60 kilograms (kg): 3000 mg every 8 weeks~≥60 to <100 kg: 3300 mg every 8 weeks~≥100 kg: 3600 mg every 8 weeks"
9832125|NCT02598583|Experimental|Cohort 2|"Intravenous infusion of ALXN1210 as follows:~Induction phase: 600 mg on Day 1, 900 mg on Day 15~Maintenance phase: the first of 5 doses of 1800 mg on Day 29 and every 4 weeks thereafter~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:~≥40 to <60 kg: 3000 mg every 8 weeks~≥60 to <100 kg: 3300 mg every 8 weeks~≥100 kg: 3600 mg every 8 weeks"
9832126|NCT02598934|Experimental|Ibandronate Group 1|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
9832127|NCT02598934|Experimental|Ibandronate Group 2|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not receive a physician consultation.
9984136|NCT04389177|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin|Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks
9832128|NCT02599129|Experimental|Secukinumab|300 mg subcutaneous injections
9832129|NCT02599129|Placebo Comparator|Placebo|matching placebo subcutaneous injections
9832130|NCT02599194|Experimental|18F-FSPG and 18F-FDG Intragroup Comparision|Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
9758265|NCT00623636|Experimental|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks.
9758266|NCT00623636|Other|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks.
9758267|NCT00623714|Experimental|Arm 1|study medication + Pbo
9758268|NCT00623714|Experimental|Arm 2|Pbo + study medication
9758269|NCT00623727|Experimental|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))
9758270|NCT00623727|Active Comparator|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)
9758271|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients|Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
9758272|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients|Participants who were dependent on corticosteroid therapy received ipilimumab, 10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
9758273|NCT00623805|Active Comparator|Bevacizumab+capecitabine+oxaliplatin|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
9758274|NCT00623805|Experimental|Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
9758275|NCT00623831|Experimental|Cohort 1|Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
9758276|NCT00623831|Experimental|Cohort 2|Subjects received MBV twice weekly at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.
9758277|NCT00623935|Experimental|Fludarabine plus Busulfan (CR)|Patients in CR will receive a reduced intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu2).
9758278|NCT00623935|Experimental|Fludarabine plus Busulfan (PR)|Patients in PR will receive a full intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu4).
9758279|NCT00624013|Placebo Comparator|Placebo|Placebo 50 mg up to 100 mg daily for 6 months
9758280|NCT00624013|Active Comparator|Sertraline (Zoloft)|Sertraline (Zoloft) 50 mg up to 100 mg daily for 6 months
9758281|NCT00624065|Experimental|carvedilol CR + lisinopril|
9758282|NCT00624065|Active Comparator|lisinopril + placebo|
9758283|NCT00624195|Experimental|CNS-targeted|"CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).~Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
9758284|NCT00624195|Active Comparator|non-CNS-targeted|"Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen (see list of FDA approved antiretrovirals listed below) designed to suppress plasma Viral Load, but not expected to have targeted CNS penetration.~Combinations of FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
9758285|NCT00624221|Active Comparator|1|An Eye bank pre-cut the donor grafts used for the corneal transplant procedures.
9758286|NCT00624221|Active Comparator|2|The surgeon dissected the donor grafts used for the transplant procedures.
9758287|NCT00624234|Experimental|NF-Tutoring Program 1|Tutoring Program I
9758288|NCT00624234|Experimental|NF-Tutoring Program 2|Tutoring Program II
9758289|NCT00624234|No Intervention|Typically Developing Readers|Control group
9758290|NCT00624234|Experimental|IRD-Tutoring Program 1|Tutoring Program I
9758291|NCT00624234|Experimental|IRD-Tutoring Program 2|Tutoring Program II
9758292|NCT00624234|No Intervention|Waitlist Control|Intervention Control Group (RD)
9758293|NCT00624286|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9783205|NCT01195662|Placebo Comparator|Placebo matching Dapagliflozin|Placebo tablets matching dapagliflozin tablets
9758294|NCT00624286|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9758295|NCT00624338|Experimental|Atacicept 75 mg|
9758296|NCT00624338|Experimental|Atacicept 150 mg|
9758297|NCT00624338|Placebo Comparator|Placebo|
9758298|NCT00624377||COPD patients|
9758299|NCT00624416|Other|Prednisolone and Isoproteronol Together|Beta-adrenergic agonists and corticosteroid
9758300|NCT00624442|Experimental|Cohort 1|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
9758301|NCT00624442|Experimental|Cohort 2|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
9758302|NCT00624442|Experimental|Cohort 3|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
9758303|NCT00624442|Experimental|Cohort 4|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
9758304|NCT00624442|Experimental|Cohort 5|2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
9758305|NCT00624468|Experimental|Atacicept|
9758306|NCT00624468|Placebo Comparator|Placebo|
9758307|NCT00624520|Active Comparator|Cognitive Behavioral Stress Management|10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
9758308|NCT00624520|Active Comparator|Patient Education|10 week program of once weekly Patient Education group sessions
9758309|NCT00624559|Experimental|Celebrex; Low sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
9758310|NCT00624559|Experimental|Celebrex, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
9758311|NCT00624559|Placebo Comparator|Placebo, Low Sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
9758312|NCT00624559|Placebo Comparator|Placebo, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
9758313|NCT00624585|Experimental|Dasatinib Dose Escalation|Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.
9758314|NCT00624780|Experimental|1|
9758315|NCT00624780|Active Comparator|2|
9758316|NCT00624780|Experimental|3|
9758317|NCT00624780|Placebo Comparator|4|
9758318|NCT00624806|Experimental|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers
9758319|NCT00624806|Active Comparator|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
9758320|NCT00624819|Experimental|Synflorix + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).
9758321|NCT00624819|Active Comparator|Prevenar + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
9758322|NCT00624819|Experimental|Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix|This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
9758323|NCT00624819|Experimental|Unprimed Group|"This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2).~The Unprimed Group was added only in Year 4 of the study."
9758324|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
9758325|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
9758326|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
9758327|NCT00624832|Placebo Comparator|Placebo|By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
9758328|NCT00624910|Experimental|1|A total of three 5 × 5-cm bupivacaine sponges implanted at specified layers in the wound prior to wound closure
9758329|NCT00624910|Placebo Comparator|2|A total of three 5 × 5-cm collagen sponges implanted at specified layers in the wound prior to wound closure
9758330|NCT00624910|No Intervention|3|The patient will recieve the standard of care, but no implant during surgery
9758331|NCT00624923|Experimental|1- Active Pharmacologic|Salsalate
9758332|NCT00624923|Placebo Comparator|2- Placebo|Placebo
9758333|NCT00625131|Active Comparator|Active Nicotine Patch Group|Transdermal nicotine patch
9758334|NCT00625131|Placebo Comparator|Placebo Patch Group|Transdermal placebo patch
9758335|NCT00625183|Experimental|Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy|Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends
9758336|NCT00625365|Other|DEFINITY® (Perflutren Lipid Microsphere)|Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
9758337|NCT00625391|Placebo Comparator|Placebo pill|24 weeks of placebo.
9758338|NCT00625391|Active Comparator|Green Tea Polyphenols (GTP)|24 weeks of green tea polyphenols
9758339|NCT00625391|Active Comparator|Placebo+Tai Chi (TC)|24 weeks of placebo plus Tai Chi exercise.
9758340|NCT00625391|Active Comparator|GTP+TC|24 weeks of green tea polyphenols plus Tai Chi exercise.
9758341|NCT00625404|Experimental|Truvada Arm|Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
9832131|NCT02599402|Experimental|Combination therapy: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab specified dose on specified days
9832132|NCT02599402|Experimental|Monotherapy: Nivolumab|Nivolumab specified dose on specified days
9832133|NCT02599441||Ankle fracture cases|
9832134|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
9832135|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
9832136|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
9832137|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
9832138|NCT02599766|Experimental|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
9832139|NCT02599766|Active Comparator|standard therapy|"Standard therapy without the presence of an animal."
9832140|NCT02599961|Experimental|UX007|UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.
9832141|NCT02600325|Experimental|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
9832142|NCT02600351|Experimental|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
9832143|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
9832144|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
9832145|NCT02600351|Experimental|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
9832146|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
9832147|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
9832148|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
9832149|NCT02600559|Experimental|0.1 mL OTO-201|Ciprofloxacin
9832150|NCT02600611|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
9832151|NCT02600611|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
9832152|NCT02600637|Experimental|MBSR|Mindfulness-based Stress Reduction program
9832153|NCT02600637|Active Comparator|Education|Educational group program
9832154|NCT02600715|Experimental|Active B&O suppository of belladonna|Receive the B&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
9832155|NCT02600715|Placebo Comparator|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
9832156|NCT02600767|Other|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
9832157|NCT02600819|Experimental|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
9832158|NCT02600819|Experimental|Open-Label Rollover Extension B/F/TAF|At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
9984137|NCT04384939|Experimental|Double-J ureteral stent|Pediatric patient with an uropathy or kidney graft need the insertion of Double-J ureteral stent in a routine care
9984138|NCT04383756|Experimental|Donor Blood|Between 2-4 units of donor leukoreduced whole blood (each unit will contain up to 350mL) transfused as needed in Liver transplantation participants
10202526|NCT04589273|Experimental|Alginate capsule|The participants of this arm will be give the alginate capsules
10202527|NCT04589273|Placebo Comparator|Placebo|The participants of this arm will be give the placebo capsules
10202528|NCT04585451||Chronic Pain Patients|
10202529|NCT04585451||Healthy Controls|
10202530|NCT04583592|Experimental|Camostat Mesilate|Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.
10202531|NCT04583592|Placebo Comparator|Placebo|Participants will receive placebo for 14 days in addition to standard of care treatment.
10202532|NCT04580615|Experimental|Inpatients subjects|Inpatients subjects diagnosed with a Respiratory disease/impairment or subjects with no known Respiratory disease/impairment
10202533|NCT04579146||HIV-1 patients and treated effectively for more than 12 months|X-ray examination with contrast by a 64-slice CT coronary angiography.
10202534|NCT04576442|Experimental|Asthma-PASS Intervention|Collaboration with PCPs to optimize management. Community Health Worker (CHW) to ensure PCP plan is followed. Two asthma education sessions with children/caregivers focusing on self-efficacy and physical activity promotion. Promotion of asthma awareness in school. School personnel training in asthma
10202535|NCT04576442|Active Comparator|Asthma Management Comparison Group|Includes two sessions of basic asthma education and PCP notification of child's asthma severity level.
10202536|NCT04575259|Experimental|ANAVEX2-73 Active|Oral capsules
10202537|NCT04572399|Experimental|Endotracheal UV Light|Mechanically ventilated patients who will receive UV Light therapy
10202538|NCT04570904||Early HCWs|Health Care Workers vaccinated early prior to the influenza season
10202539|NCT04570904||Late HCWs|Health Care Workers vaccinated just prior to the influenza season
10202540|NCT04570904||Inpatients|Inpatients recruited for evaluation of new approaches to influenza diagnosis
10202541|NCT04565756|Experimental|Dose Escalation Cohort 1|Each subject will receive a low-dose 0.5 mg/mL (0.05%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
10202542|NCT04565756|Experimental|Dose Escalation Cohort 2|Each subject will receive a mid-dose 1 mg/mL (0.1%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
10202543|NCT04565756|Experimental|Dose Escalation Cohort 3|Each subject will receive a high-dose 1.5 mg/mL (0.15%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
10202544|NCT04565756|Experimental|Dose Expansion Cohort|The highest well-tolerated dose of EXN407 will be evaluated where subjects will receive EXN407 at the selected dose or placebo twice a day for up to 84 days resulting in a total of 168 doses
10202545|NCT04564092|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ ioflupane (123I) injection into an arm vein, followed by planar whole-body imaging at prespecified time points over a period of 48 hours after administration. Brain SPECT imaging will be acquired at 3 and 6 hours after administration.
10205201|NCT03684980|Experimental|Arm C - HD-MTX (Arm Outpatient MTX Therapy in times of COVID-19)|MTX ≤ 3.5 g/m2 will be administered on Day 1, along with pre- and post- hydration. Patients will return on Day 2 for continued hydration and glucarpidase 2000 units. Glucarpidase rapidly and sustainably reduces serum MTX levels >95% without crossing the blood brain barrier, effectively resulting in systemic MTX clearance. Patients will return for bloodwork on Day 3 to document MTX clearance. Arm Outpatient MTX Therapy in times of COVID-19 will only be a single-institution arm, only open at Memorial Sloan Kettering Cancer Center.
10202546|NCT04561232|Other|Locomotor Learning|"This study has three phases. The first phase of the study will be the observation of early spontaneous leg movements which will be measured monthly from 1-4 months of age.~The prone locomotor intervention phase using the Self-Initiated Prone Progression Crawler (SIPPC) will occur from 5-9 months of post-term age, or end earlier if the child achieves the ability to crawl six feet. Treatment will occur at an intensity of 3 times per week for 15-30 minutes. Infants will use the SIPPC for the duration of each therapy session~The upright locomotor intervention phase using DWS will occur from 9-18 months of age, or begin earlier if the child achieves the ability to crawl six feet before 9 months of age, and end earlier if the child achieves independent walking before 18 months of age. Treatment will occur at an intensity of 3 times per week for 30 minutes. Infants will receive dynamic weight support (DWS) for the duration of the 30-minute therapy session."
10202547|NCT04555330|Experimental|Visual Feedback|Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level and motivation to move. This information will be visible to the health personnel, the patients and visitors.
9832159|NCT02600845|Experimental|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
9832160|NCT02600871|Experimental|Provodine|"Provodine patients will have standard care including incision and drainage. The contents of 1 packet of Provodine applied with a Q-tip to the walls and floor of the abscess cavity. The contents of a 2nd packet will be applied to the surrounding skin within 5 cm around the incision.~Provodine patients will return within 48-72 hours for a follow-up visit, have the packing removed and the contents of the packet reapplied to the abscess cavity and surrounding skin.~Provodine patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will wash their hands with soap and water, pat dry, and apply the contents of 1 packet of Provodine to dorsum and palmar aspects of hands and fingers and rub together for 1 minute. They will apply the contents of a 2nd packet to the abscess cavity, and a 3rd packet to the surrounding skin. They will be then rinse their hands with water, pat dry, and cover the wound with 4x4 gauze."
9832161|NCT02600871|Active Comparator|Standard Care|"Standard care patients will have standard care including incision and drainage.~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
9832162|NCT02601001|Placebo Comparator|Placebo|Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).
10202548|NCT04555330|Other|Control Group|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.No feedback on physical activity is provided.
10202549|NCT04548570||approximation of both recti group|
10202550|NCT04548570||non approximation of both recti group|
10202551|NCT04547699|Placebo Comparator|HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein,
10202552|NCT04547699|Experimental|CYK+ high HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma),and 5ng/mL LIF (SRP9001 Sigma).
10202553|NCT04547699|Active Comparator|CYK+low HSA|A single step culture medium (SSCM; Global, Life Global) +2mg/ml (5% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma), and 5ng/mL LIF (SRP9001 Sigma).
10202554|NCT04533815|Experimental|LOCK sleep intervention|Nursing home staff receive the LOCK sleep intervention training and thus provide to nursing home residents with dementia the LOCK sleep intervention
10202555|NCT04529850|Experimental|Open Label Active Arm|90mg GC4419 by IV
10202556|NCT04529291|Other|Group with walking disorder|This Group with walking disorder corresponds to patient reporting walking disorders due to his illness.
10202557|NCT04529291|Other|Group without walking disorder|This Group without walking disorder corresponds to patients not reporting walking disorders due to his illness.
10202558|NCT04527302|Active Comparator|active tDCS+exposure based CBT|the exposure and response prevention (ERP) treatment combined with an anode transcranial direct current stimulation over the mPFC will be applied twice a week for the fist two weeks. For the next four weeks, the active tDCS+ERP will be applied once a week. 8 times in total
10202559|NCT04527302|Sham Comparator|sham tDCS +exposure based CBT|the exposure and response prevention (ERP) treatment combined with an sham transcranial direct current stimulation over the mPFC will be applied twice a week for the fist two weeks. For the next four weeks, the sham tDCS+ERP will be applied once a week. 8 times in total
10202560|NCT04523961|Active Comparator|2.5 g of lidocaine 23% / tetracaine 7% ointment|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion for 60 minutes.
10202561|NCT04523961|Active Comparator|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion for 60 minutes.
10202562|NCT04522778|Experimental|Device|Those in the device arm will be given two wearable central line securement devices and the investigators will encourage continuous wear throughout the duration of the study.
10202563|NCT04522778|Active Comparator|Traditional Securement Dressing|Those is the non-device arm will continue to wear a traditional central line securement dressing as is the standard of care.
10202564|NCT04522518||DD group|160 pairs of children with disabilities 6-12 years of age and their caregivers (n=320)
9758342|NCT00625404|Placebo Comparator|Placebo Arm|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
9758343|NCT00625443|Experimental|Placebo (double-blind)|
9758344|NCT00625443|Experimental|Avatrombopag tablets (open-label)|
9758345|NCT00625443|Experimental|Avatrombopag tablets (double-blind)|
9758346|NCT00625729|Experimental|Treated Patients|Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.
9758347|NCT00625807|Active Comparator|Program A - Relaxation Response (RR)|One of the 2 stress reduction courses
9758348|NCT00625807|Active Comparator|Program B - Mindfullness-based stress reduction (MBSR)|One of the 2 stress reduction courses
9758349|NCT00625820|Experimental|6R BH4|Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure .
9758350|NCT00625846|Experimental|Cohort 1 (DTC)|Patients with differentiated thyroid cancer (DTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9758351|NCT00625846|Experimental|Cohort 2 (MTC)|Patients with medullary thyroid cancer (MTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9758352|NCT00625846|Experimental|Cohort 3 (ATC)|Patients with anaplastic thyroid cancer (ATC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9758353|NCT00625846|Experimental|Expansion Cohort (DTC)|Patients with confirmed, differentiated thyroid cancer (DTC) who are thyroglobulin antibody negative receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9758354|NCT00625872|Active Comparator|Treatment Group|Somatropin for 12 months
9758355|NCT00625872|Other|Control Group|In the first 6 months no intervention, afterwards Somatropin for 12 months
9758356|NCT00625989|Placebo Comparator|Diluent|Inhalation challenge preformed with diluent.
9758357|NCT00625989|Active Comparator|Allergen|Inhalation challenge preformed with allergen.
9758358|NCT00626028|Experimental|Nitric Oxide First, Oxygen Last|10 minute dose of Nitric Oxide (NO) at 80 ppm, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of 100% Oxygen on Day 1.
9758359|NCT00626028|Experimental|Oxygen First, Nitric Oxide Last|10 minute dose of 100% Oxygen, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of NO at 80 ppm on Day 1.
9758360|NCT00626093|Other|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.
9758361|NCT00626197|Experimental|OCR 400 mg + SOC|Participants received Ocrelizumab 400 mg i.v. infusion on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
9758362|NCT00626197|Experimental|OCR 1000 mg + SOC|Participants received Ocrelizumab 1000 mg i.v. infusion on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
9758363|NCT00626197|Placebo Comparator|Placebo + SOC|Participants received placebo i.v. infusion on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks plus SOC regimen.
9758364|NCT00626210|Experimental|Modafinil|
9758365|NCT00626275|Experimental|ADL5859 -- 200 mg (Part A)|ADL5859: 200 milligrams (mg), capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
9758366|NCT00626275|Active Comparator|Naproxen -- 500 mg (Part A)|Naproxen: 500 mg, capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
9758367|NCT00626275|Placebo Comparator|Placebo (Part A)|Matching placebo, capsules, administered orally, as a single dose during 1 of 3 Treatment Periods in Part A of the study
9758368|NCT00626275|Experimental|ADL5859 - 100 mg (Part B)|ADL5859: 100 mg, capsules, administered orally, twice daily (BID) for 2 weeks during Part B of the study
9758369|NCT00626275|Placebo Comparator|Placebo (Part B)|Matching placebo, capsules, administered orally, BID for 2 weeks during Part B of the study
9758370|NCT00626327|Experimental|MenACWY-CRM+ MMRV|
9758371|NCT00626327|Active Comparator|MMRV|
9758372|NCT00626327|Experimental|MenACWY-CRM|
9758373|NCT00626340|Active Comparator|MDD diagnosis and Estrogen treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen alone.
9758374|NCT00626340|Active Comparator|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
9783206|NCT01195675|Experimental|BI 10773|single oral (high and low) dose per subject
9758375|NCT00626340|Active Comparator|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
9758376|NCT00626340|Active Comparator|No depression and estrogen treatment|Non-depressed menopausal women between the ages of 40-70 receiving treatment with estrogen alone.
9758377|NCT00626366|Experimental|Nasal spray|This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
9758378|NCT00626366|Experimental|Nasal drop|This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
9758379|NCT00626392|Experimental|NER 500; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
9758380|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
9758381|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
9758382|NCT00626392|Experimental|NER 1000; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
9758383|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
9758384|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
9758385|NCT00626405|Experimental|Arm I|Patients receive oral temozolomide on days 1-5 and bevacizumab IV over 30-90 minutes on days 1 and 15.
9758386|NCT00626405|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1.
9758387|NCT00626431|Experimental|Leuprolide acetate - Formulation A|Leuprolide acetate 45 mg, 6-month depot
9758388|NCT00626431|Experimental|Leuprolide acetate - Formulation B|Leuprolide acetate, 45 mg, 6-month depot
9758389|NCT00626522|Experimental|1|
9758390|NCT00626522|Experimental|2|
9758391|NCT00626522|Experimental|3|
9758392|NCT00626522|Placebo Comparator|4|
9758393|NCT00626522|Placebo Comparator|5|
9758394|NCT00626522|Placebo Comparator|6|
9758395|NCT00626548|Placebo Comparator|Placebo|Matching Placebo
9758396|NCT00626548|Experimental|ZD4054|ZD4054 (Zibotentan)
9758397|NCT00626574|Active Comparator|A|Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
9758398|NCT00626574|Placebo Comparator|B|Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
9758399|NCT00626626|Experimental|"Clofar, Cyclophos, Alemtuzumab"|"Phase 1: 1-3 patients will be treated in order to establish Cyclophosphamide and Clofarabine dose and to confirm reasonable safety and engraftment efficacy.~Drug - Clofarabine,Cyclophosphamide & Alemtuzumab - Clofar (30mg/m2) D -8 to -4; Cyclo (500mg/m2) D -8 & -7 & Alem (20mg over 2hrs)"
9758400|NCT00626626|Experimental|"Clofar, Cyclophos,Alemtuzumab(Ph II)"|"Phase II patients 4-9 will treat at the selected dose level of Clofarabine and Cyclophosphamide.~Drug - Clofarabine, Cyclophosphamide & Alemtuzumab Clofar (30mg/m2) D -8 to -4; Cyclo (1000mg/m2) D -8 & -7 & Alem (20mg)-pts."
9758401|NCT00626639|Placebo Comparator|Placebo|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of matching placebo. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of matching placebo after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
9758402|NCT00626639|Experimental|Palifermin|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
9758403|NCT00626743|Experimental|SK3530|Active Drug
9758404|NCT00626743|Placebo Comparator|Placebo|Tablet which has the same appearance and taste but doesn't contain active ingredient
9783207|NCT01195675|Placebo Comparator|Placebo|2 single oral doses per subject
9758405|NCT00626782|Experimental|A: Ranibizumab 0.5mg (0.05mL) injection|Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriorly to the limbus as an antifibrotic agent.
9758406|NCT00626782|Active Comparator|B: Mitomycin C 0.4 mg/ml sponge|Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
9758407|NCT00626795|Experimental|1|
9758408|NCT00626795|Experimental|2|
9758409|NCT00626795|Active Comparator|3|
9758410|NCT00626808||1|Children less than 24 months of age
9758411|NCT00626808||2|Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
9758412|NCT00626808||3|Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
9758413|NCT00626808||4|Children 24-59 months of age with immunosuppression
9758414|NCT00626821|Experimental|1|
9758415|NCT00626886|Experimental|1|Two, 5x5cm bupivacaine collagen sponges implanted during surgery
9758416|NCT00626886|Placebo Comparator|2|Placebo collagen sponge implanted during surgery
9758417|NCT00626912|Active Comparator|1|platinum coils
9758418|NCT00626912|Active Comparator|2|hydrogel coils
9758419|NCT00626925|Active Comparator|Total Topiramate Group|topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
9758420|NCT00626925|Placebo Comparator|Total Placebo Group|inactive placebo matched in appearance with topiramate capsules
9758421|NCT00627016|Experimental|Dexlansoprazole 30 mg QD|
9758422|NCT00627016|Placebo Comparator|Placebo|
9758423|NCT00627042|Experimental|Ramucirumab (IMC-1121B)|
9758424|NCT00627094|Experimental|Biatain Ibu|Biatain Ibu
9758425|NCT00627094|Active Comparator|Biatain|Biatain
9758426|NCT00627367|Experimental|Protocolized|"1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer yes to the question, Do you want more pain medication?"
9758427|NCT00627367|Active Comparator|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clincian
9758428|NCT00627393|Experimental|1|Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy
9758429|NCT00627393|Active Comparator|2|Participants will receive standard antimicrobial therapy alone
9758430|NCT00627393|Other|3|Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
9758431|NCT00627406|Experimental|A|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl)
9758432|NCT00627406|Active Comparator|B|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with hCG (Pregnyl) 5.000 IU (s.c.)
9758433|NCT00627406|Experimental|C|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl) (s.c.) at 35 hours and 1500 IU hCG (Pregnyl) (s.c.) 7 days after triggering of ovulation (OPU + 5)
9758434|NCT00627406|Active Comparator|D|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 5000 IU hCG (Pregnyl) (s.c.)
9758435|NCT00627445|Experimental|BIAsp 50-50-30|Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
9758436|NCT00627445|Active Comparator|BIAsp 30-30|Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
9758437|NCT00627458|Experimental|INFANRIX HEXA PF GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
9758438|NCT00627458|Experimental|INFANRIX HEXA PC GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
9758439|NCT00627458|Active Comparator|CONTROL GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
9758440|NCT00627497|Experimental|DIAM Group1|
9758441|NCT00627497|Active Comparator|Single-Level Posterior Decompression|
9758442|NCT00627497|Experimental|DIAM Group2|
9758443|NCT00627497|Active Comparator|Posterolateral Interbody Fusion|
9758444|NCT00627523|Experimental|Active|The active treatment arm
9758445|NCT00627523|Experimental|Control|Control
9758446|NCT00627679|Experimental|Treatment sequence: A, B, D, C|Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5
9758447|NCT00627679|Experimental|Treatment sequence: B, C, A, D|Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5
9783208|NCT01195675|Active Comparator|Moxifloxacin|single oral dose per subject
9783209|NCT01195701||Anorgasmia (cases)|Women with difficulty or inability to reach sexual climax will be the cases in this study.
9783210|NCT01195701||Normal orgasmic function|Women who report that they usually or always achieve sexual climax will be the controls in this study.
9758448|NCT00627679|Experimental|Treatment sequence: C, D, B, A|Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5
9758449|NCT00627679|Experimental|Treatment sequence: D, A, C, B|Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5
9758450|NCT00627705|Active Comparator|N-Acetyl Cysteine|active compound N-Acetyl Cysteine
9758451|NCT00627705|Placebo Comparator|Sugar pill|Placebo or sugar pill
9758452|NCT00627861|Experimental|Aliskiren and metoprolol succinate|
9758453|NCT00627926|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
9758454|NCT00627926|Experimental|Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
9758455|NCT00627926|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
9758456|NCT00627978|Experimental|Ixabepilone|Participants are treated with Ixabepilone.
9758457|NCT00627978|No Intervention|Control|
9758458|NCT00628030|Experimental|NOURISH|The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
9758459|NCT00628030|Placebo Comparator|Wellness Group|The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.
9758460|NCT00628108|Placebo Comparator|Placebo|
9758461|NCT00628108|Experimental|Levocetirizine|
9758462|NCT00628134|Experimental|1|Subjects inhaled calfactant then isotonic saline
9758463|NCT00628134|Experimental|2|Subjects inhaled isotonic saline then calfactant
9758464|NCT00628147|Experimental|Narrow band imaging colonoscope|narrow band imaging colonoscope
9758465|NCT00628147|No Intervention|White Light|Conventional White Light Examination
9758466|NCT00628212|Experimental|Teneligliptin 10 mg|Teneligliptin 10 mg, orally, once daily
9758467|NCT00628212|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
9758468|NCT00628212|Experimental|Teneligliptin 40 mg|Teneligliptin 40 mg, orally, once daily
10202565|NCT04522518||TD group|160 pairs of typically developing children 6-12 years of age and their caregivers (n=320)
10202566|NCT04505605||Patient hospitalized without being transferred in the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 (day of the enrollment = the day of hospitalization in the healthcare institution). The total volume of blood collected as part of the research is therefore 5 ml.
9758469|NCT00628212|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
9758470|NCT00628251|Experimental|1|AZD2281 Oral 200 mg BID
9758471|NCT00628251|Active Comparator|2|Liposomal Doxorubicin
9758472|NCT00628251|Experimental|3|AZD2281 Oral 400 mg BID
10202567|NCT04505605||Patient directly hospitalized in the ICU|A blood sample on a dry tube with a 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 and D3 of the admission to intensive care. The total volume of blood collected for research is therefore 10 ml.
10202568|NCT04505605||Patient transferred from an other hospital service to the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test that will be taken at D1 and D3 of the patient's admission to the intensive care unit, even if it has already been included in the study during the patient's admission to the unit (D1 hospitalization). The total volume of blood collected for the research is therefore 15 ml.
10202569|NCT04504708|Experimental|ZX-101A Dose Level 1|Starting dose (SD) of ZX-101A administered orally once daily in a 28-day cycle
10202570|NCT04504708|Experimental|ZX-101A Dose Level 2|2-times the SD of ZX-101A administered orally once daily in a 28-day cycle
10202571|NCT04504708|Experimental|ZX-101A Dose Level 3|3-times the SD of ZX-101A administered orally once daily in a 28-day cycle
9984139|NCT04383756|Active Comparator|Banked Blood|Standard of Care - Up to 350mL Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets) transfused as needed in Liver transplantation participants
9758473|NCT00628355|Experimental|lidocaine injection|"Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks"
9783211|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
9783212|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
9783213|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
9783214|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
9783215|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
9783216|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
9783217|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
9783218|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
9783219|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
9783220|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
9783221|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
9783222|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
9783223|NCT01195779|Experimental|GSK2321138A vaccine Group|Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
9783224|NCT01195779|Active Comparator|Fluarix Group|Subjects received 2 doses of Fluarix Vaccine.
9783225|NCT01195831|Experimental|Xamiol® gel|Calcipotriol (as hydrate) 50mcg/g plus betamethasone 0.5mg/g (dipropionate)
9783226|NCT01195831|Active Comparator|Calcipotriol scalp solution|Calcipotriol (as hydrate) 50 mcg/ml
9758474|NCT00628355|Experimental|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
9783227|NCT01195844||Brazilian Children With Rotavirus Gastroenteritis|Brazilian children under 5 years of age who have diarrhea attributed to rotavirus located in 4 hospitals from 4 different Brazilian regions
9783228|NCT01195883|Active Comparator|Crystalloid|Lactated Ringers solution will be used for fluid replacement.
9783229|NCT01195883|Active Comparator|Colloid|Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
9783230|NCT01195922|Experimental|Sirolimus|Subjects will be treated with sirolimus 21 days
9783231|NCT01195948|Experimental|B27PD 1 mg|Participants randomly assigned to the B27PD 1 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
9783232|NCT01195948|Experimental|B27PD 4 mg|Participants randomly assigned to the B27PD 4 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
9783233|NCT01195948|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
9783234|NCT01196026|Experimental|Fluarix 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
9783235|NCT01196026|Experimental|Fluarix 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
9783236|NCT01196026|Experimental|Fluarix 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
9783237|NCT01196026|Active Comparator|Havrix Junior 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
9783238|NCT01196026|Active Comparator|Havrix Junior 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
9783239|NCT01196026|Active Comparator|Havrix Junior 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
9783240|NCT01196052|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.
9783241|NCT01196078|Experimental|1|
9783242|NCT01196078|Active Comparator|2|
9783243|NCT01196091|Experimental|LY2127399 every 2 weeks|Administered SC
9783244|NCT01196091|Experimental|LY2127399 every 4 wks|During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
9783245|NCT01196091|Placebo Comparator|Placebo|Administered SC
9783246|NCT01196104|Experimental|Technosphere® Insulin Inhalation Powder (TI)|Insulin Glargine and Technosphere® Insulin Inhalation Powder
9783247|NCT01196104|Active Comparator|Comparator|Insulin Glargine and Insulin Aspart
9783248|NCT01196117|Placebo Comparator|14 days of Placebo therapy, then CPAP|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
9783249|NCT01196117|Active Comparator|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
9783250|NCT01196377|Active Comparator|Nebulized albuterol 10mg/hr continuous|Active control arm, 10mg/hr continuous.
9783251|NCT01196377|Experimental|10mg/hr pulsed|Experimental 10mg/hr pulsed albuterol regimen.
9783252|NCT01196377|Experimental|25mg/hr continuous|Experimental 25mg/hr continuous albuterol.
9783253|NCT01196377|Experimental|25mg/hr pulsed|Experimental 25mg/hr pulsed albuterol
9783254|NCT01196416|Experimental|Treatment (RO4929097, cisplatin, vinblastine, temozolomide)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21, cisplatin IV over 30 minutes and vinblastine IV over 30 minutes on days 1-3, and temozolomide PO QD on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without progressive disease continue to receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temozolomide as above in the absence of disease progression or unacceptable toxicity.
9783255|NCT01196429|Experimental|Treatment (paclitaxel, carboplatin, temsirolimus, docetaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV on days 1 and 8. Treatment repeats every 3 weeks for 6 courses. Patients then receive consolidation therapy comprising temsirolimus IV on days 1, 8, and 15. Treatment repeats every 3 weeks for 11 courses in the absence of disease progression or unacceptable toxicity.~NOTE: * For circumstances in which docetaxel should be substituted for paclitaxel, docetaxel is given IV over 1 hour."
9783256|NCT01196442|Experimental|Arm I electric stimulation pain therapy|Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
9783257|NCT01196533|Experimental|Non Invasive Monitoring|Intervention: Device: Non invasive peripheral blood monitoring
9783258|NCT01196741|Active Comparator|Saracatinib plus weekly paclitaxel|
9758475|NCT00628394|Other|Atomox/CR|Patients are given the drug Atomoxetine and Cognitive Remediation training.
9758476|NCT00628394|Other|Atomox/Control|Patients are given the drug Atomoxetine and Remediation Control training.
9758477|NCT00628394|Other|Placebo/CR|Patients are given a Placebo and Cognitive Remediation training.
9758478|NCT00628394|Other|Placebo/Control|Patients are given Placebo and Remediation Control training.
9758479|NCT00628498|Experimental|Defibrotide|Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
9758480|NCT00628589|Experimental|Inhaled Loxapine 5 mg|Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours
9758481|NCT00628589|Experimental|Inhaled Loxapine 10 mg|Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours
9758482|NCT00628589|Placebo Comparator|Inhaled placebo|Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours
9758483|NCT00628628|Experimental|Group A|As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
9758484|NCT00628628|Experimental|Group B|Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily
9758485|NCT00628758|Experimental|Symbicort|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
9758486|NCT00628758|Experimental|Conventional BP|Conventional Best Practice for Treatment of Asthma
9758487|NCT00628862|Experimental|F 4.5 bid|Formoterol 4.5 ug twice daily (bid)
9758488|NCT00628862|Experimental|F 9.0 bid|Formoterol 9.0 ug bid
9758489|NCT00628862|Placebo Comparator|PBO|Placebo
9758490|NCT00628901|Experimental|Arm 1|
9758491|NCT00628901|Active Comparator|Arm 2|
9758492|NCT00628927||METH and/or cocaine dependent group|The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment. This group will be analyzed based on whether or not they completed treatment as defined by the study.
9758493|NCT00628927||Non METH and/or cocaine dependent group|The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
9758494|NCT00629018|Experimental|SC Group|"SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':~In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect"
9758495|NCT00629018|No Intervention|Controls|Patients receiving no cell therapy.
9758496|NCT00629083|Experimental|1|Bulkamid Hydrogel injection
9758497|NCT00629083|Active Comparator|2|Contigen injection
9758498|NCT00629122|Experimental|A: Tacrolimus and Nystatin Suspension|"Administer sublingual tacrolimus 2 mg every 12 hours (subject weight < 90 kg) or 3 mg every 12 hours (subject weight > 90kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Nystatin suspension 5 mL every 12 hours (study days 1 - 3 and 6 - 8)."
9758499|NCT00629122|Experimental|B: Tacrolimus and Clotrimazole Troche|"Administer sublingual tacrolimus 1 mg every 12 hours (subject weight < 90 kg) or 2 mg every 12 hours (subject weight > 90 kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Clotrimazole troche 10 mg every 12 hours (study day 1 - 3 and 6 - 8)."
9758500|NCT00629239|Experimental|1|AZD4818
9758501|NCT00629239|Placebo Comparator|2|Placebo
9758502|NCT00629265|Active Comparator|Active NMES + Swallowing Exercise|Active Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
9758503|NCT00629265|Sham Comparator|Sham NMES + Swallowing Exercise|Sham (inactive) Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
9758504|NCT00629499|Experimental|Intervention|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks [84 days]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks.
9758505|NCT00629525|Experimental|RAD001|RAD001 at a dose of 10 mg PO daily
9758506|NCT00629707|Active Comparator|1|Slower infusion rate: Patients in this arm will receive an initial intravenous fluid bolus of 10cc/Kg followed by rehydration calculated to replace a deficit of 7.5% of body weight over 48 hours.
9783259|NCT01196741|Placebo Comparator|Placebo plus weekly paclitaxel|
9783260|NCT01196793||febrile children, age 3 m to 5 y|
9758507|NCT00629707|Active Comparator|2|More rapid infusion: Patients in this arm will receive an initial bolus of 20 cc/Kg of intravenous fluids followed by replacement of an estimated deficit of 10% of body weight over 36 hours plus replacement of 1/2 of urine output volume.
9758508|NCT00629772|Placebo Comparator|Placebo then infliximab|Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
9758509|NCT00629772|Active Comparator|Infliximab|Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
9758510|NCT00630032|Active Comparator|Docetaxel|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
9758511|NCT00630032|Experimental|Ixabepilone|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
9758512|NCT00630058|Experimental|Group A (MP-424 High)|
9758513|NCT00630058|Experimental|Group B (MP-424 Low)|
9758514|NCT00630253|Experimental|Marrow Isolex|bone marrow processed using Isolex 300i (for patients enrolled through April 2010)
9758515|NCT00630253|Experimental|UCB|No processing Notes: sibling donor UCB is used as the stem cell source and co-enroll for unlicensed UCB registry
9758516|NCT00630253|Experimental|Marrow Clinimax|bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)
9758517|NCT00630305|Other|Session A|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session A only contains senofilcon A toric and alphafilcon A toric lenses.
9758518|NCT00630305|Other|Session B|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session B only contains senofilcon A toric and alphafilcon A toric lenses.
9758519|NCT00630305|Other|Session C|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
9758520|NCT00630305|Other|Session D|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
9758521|NCT00630331|Experimental|CCI|Subjects received one dose of cell culture-derived influenza vaccine.
9758522|NCT00630331|Experimental|IVV|Subjects received one dose of the trivalent egg-derived influenza vaccine.
9758523|NCT00630331|Placebo Comparator|Placebo|Subjects received one dose of phosphate buffered solution (PBS).
9758524|NCT00630344|Experimental|RAD001 + Bicalutamide|"RAD001: once daily dose of 10 mg (5 mg tablets)~Bicalutamide: once daily dose of 50 mg (50 mg tablets)~1 cycle=28 days~Both agents are administered continuously until progression of disease or unacceptable toxicity."
9758525|NCT00630409|Experimental|Treatment|Patients will receive 3 cycles of therapy as an outpatient. Each 21-day cycle of therapy will comprise: Gemcitabine: IV on days 1 and 8. Doxil: on day 1. Patients with either responding or stable disease will continue to receive additional 3 cycles of therapy with gemcitabine and Doxil until there is radiological evidence of disease progression or they are unable or unwilling to continue treatment.
9758526|NCT00630539|Placebo Comparator|Subjects on placebo|Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks
9758527|NCT00630539|Experimental|Subjects on ospemifene 5 mg/day|Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks
9758528|NCT00630539|Experimental|Subjects on ospemifene 15 mg/day|Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks
9758529|NCT00630539|Experimental|Subjects on ospemifene 30 mg/day|Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks
9758530|NCT00630734|Experimental|SLCO1B1 Group 1|Participants with the SLCO1B1 *1A/*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
9758531|NCT00630734|Experimental|SLCO1B1 Group 2|Participants with the SLCO1B1 *1A/*1B or *1B/*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
10202572|NCT04504708|Experimental|ZX-101A Dose Level 4|4-times the SD of ZX-101A administered orally once daily in a 28-day cycle
9758532|NCT00630734|Experimental|SLCO1B1 Group 3|Participants who carry at least one SLCO1B1 *5, *15, or *17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
9758533|NCT00630747|Experimental|Idursulfase|
9758534|NCT00630786|Experimental|Panitumumab plus conatumumab|Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
9758535|NCT00630812|Experimental|A|active treatment
9758536|NCT00630812|Placebo Comparator|B|
9758537|NCT00630825|Experimental|1.0/2.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
9758538|NCT00630825|Experimental|1.0/1.0 milligram (mg) LY2189265|LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
9758539|NCT00630825|Experimental|0.5/1.0 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
9758540|NCT00630825|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
9758541|NCT00630838|Experimental|1|VSL#3 probiotic
9783261|NCT01196819|Active Comparator|Xience V|Implantation of Xience V drug eluting stent
9783262|NCT01196819|Experimental|Firehawk|Implantation of Firehawk drug eluting stent
10202573|NCT04504708|Experimental|ZX-101A Dose Level 5|5-times the SD of ZX-101A administered orally once daily in a 28-day cycle
9758542|NCT00630838|Placebo Comparator|2|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
9758543|NCT00630864|Experimental|1|Fx-1006A 20mg soft gelatin capsules once daily for 12 months
9758544|NCT00630877|Experimental|NER/ASA|
9758545|NCT00630877|Experimental|NER/ASA Placebo|
9758546|NCT00630877|Experimental|NER Placebo/ASA Placebo|
9758547|NCT00630916|No Intervention|A|
9758548|NCT00630955|Experimental|1|20 mg memantine
9758549|NCT00630955|Experimental|2|40 mg memantine
9758550|NCT00630955|Placebo Comparator|3|
9758551|NCT00631007|Experimental|INT131 besylate 0.5 mg|INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
9758552|NCT00631007|Experimental|INT131 besylate 1 mg|INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
9758553|NCT00631007|Experimental|INT131 besylate 2 mg|INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
9758554|NCT00631007|Experimental|INT131 besylate 3 mg|INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
9758555|NCT00631007|Active Comparator|pioglitazone HCl 45 mg|pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
9758556|NCT00631007|Placebo Comparator|placebo|placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
9758557|NCT00631020|Experimental|CBME +/- NRT|6 weeks CBME with optional 4 weeks NRT
9758558|NCT00631163|Experimental|Deferasirox|Participants received initial dose of 20 milligrams per kilogram (mg/kg) Deferasirox tablets was administered orally once daily (OD) based on the Participants body weight. The dose of Deferasirox was adjusted to either 10 mg/kg or 30 mg/kg based on the volumes of blood transfusions being administered.
9758559|NCT00631189|Active Comparator|1|Rosuvastatin and Pravastatin
9758560|NCT00631189|Active Comparator|2|Rosuvastatin and Atorvastatin
9758561|NCT00631319|Experimental|OROS Hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
9758562|NCT00631319|Placebo Comparator|Placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
9758563|NCT00631358|Experimental|Maxidex|Maxidex
9758564|NCT00631358|Sham Comparator|No treatment|Healthy normal control group receiving no treatment
9758565|NCT00631371|Experimental|1|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly
9758566|NCT00631371|Active Comparator|2|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW
9758567|NCT00631410|Experimental|A|
9758568|NCT00631410|Experimental|B|
9758569|NCT00631449|Active Comparator|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
9758570|NCT00631449|Placebo Comparator|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
9758571|NCT00631475|Experimental|1|"For patients who were administered bosentan during BUILD 3 (NCT00391443):~Same dose will continue~For patients who were administered placebo during BUILD 3 (NCT00391443):~Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg"
9758572|NCT00631488|Experimental|MK-0893 + Sitagliptin|
9758573|NCT00631488|Experimental|MK-0893 + Metformin|
9758574|NCT00631488|Active Comparator|Sitagliptin + Metformin|
9758575|NCT00631540|Experimental|1|renal artery stenting
9758576|NCT00631566|Experimental|1|
9758577|NCT00631566|Placebo Comparator|2|
9758578|NCT00631566|No Intervention|No MRSA colonization|
9758579|NCT00631657|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
9758580|NCT00631657|Placebo Comparator|Placebo|Participants receive placebo tablets, administered once a day for 6 months
9758581|NCT00631670|Experimental|Single Treatment Group|15 Gy dose in one stereotactic body radiation treatment
9758582|NCT00631670|Experimental|25 Treatments Group|25 treatments, given once a day, Monday through Friday for about five weeks; Dose: 70 Gy at 2.8 Gy/treatment
9758583|NCT00631696|Experimental|1|
9758584|NCT00631696|Placebo Comparator|2|
9758585|NCT00631748|Experimental|Study Drug|Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as tolerated. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
9783263|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg)|
9783264|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg)|
9783265|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg)|
9783266|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg)|
9783267|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg)|
9758586|NCT00631748|Placebo Comparator|Placebo|Subjects randomized to the placebo arm of the study will follow the same titration and dosing procedure as the experimental arm but will receive matched placebo tablets. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
9758587|NCT00631852|Experimental|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
9758588|NCT00631917|Experimental|Aliskiren|For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
9758589|NCT00631917|Active Comparator|Ramipril|For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
9758590|NCT00631969|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
9758591|NCT00631969|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
9758592|NCT00632021|No Intervention|1|Patients will receive usual care at hospital discharge, which generally includes physician reconciliation of medications and a nurse-provided explanation of how to take medications at the time of discharge.
9758593|NCT00632021|Experimental|2|Participants will receive pharmacist-led medication reconciliation, pharmacist counseling prior to discharge, a follow-up telephone call 1-4 days after discharge, and additional telephone support as needed.
9758594|NCT00632099|Placebo Comparator|Placebo|matched placebo
9758595|NCT00632099|Experimental|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day)
9758596|NCT00632125|Experimental|HX575 epoetin alfa i.v.|This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.
9758597|NCT00632203|Experimental|Temozolomide treatment|Subjects will receive temozolomide at a dose of 75 mg/m^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
9758598|NCT00632203|No Intervention|Observation|Observation
9758599|NCT00632229|Experimental|Paliperidone|Recieves study medication called paliperidone
9758600|NCT00632229|Placebo Comparator|Pill placebo|Placebo comparator
9758601|NCT00632359|Experimental|Lenalidomide|Lenalidomide 10 mg daily given for 12 months.
9758602|NCT00632411|Experimental|Proactive group|Research study staff will contact participant to initiate the program. Half of participants will be randomized to the proactive condition and the other half to the reactive conditions.
9758603|NCT00632411|Experimental|Reactive group|Participant will contact the research study staff to initiate the program.
9758604|NCT00632424|Experimental|1|
9758605|NCT00632463|Experimental|1|Dose regimen 1
9758606|NCT00632463|Experimental|2|Dose regimen 2
9758607|NCT00632463|Placebo Comparator|3|Placebo
9758608|NCT00632489|Experimental|LBH589 with Capecitabine|MTD, LBH589 with Capecitabine
9758609|NCT00632489|Experimental|LBH589 and Lapatinib|LBH589 and Lapatinib
9758610|NCT00632489|Experimental|LBH589, Capecitabine and Lapatinib|LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)
9758611|NCT00632502|Experimental|Navarixin|Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks
9758612|NCT00632502|Placebo Comparator|Placebo|Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks
9758613|NCT00632541|Experimental|Single Arm A|Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle
9758614|NCT00632619|Active Comparator|1|Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
9758615|NCT00632619|Experimental|2|Participants will receive stimulant medication therapy and group-based behavior therapy.
9758616|NCT00632632|Experimental|D-Cycloserine (DCS)|
9758617|NCT00632632|Placebo Comparator|Placebo|
9758618|NCT00632736|Active Comparator|Ropinirole XL (formerly CR)|Ropinirole XL (formerly CR)
9758619|NCT00632749|Experimental|Schedule A|BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
9758620|NCT00632749|Experimental|Schedule B|BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
9758621|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg qw|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week [qw] (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
9758622|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), biw (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week [biw] (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
9758623|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), tiw (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week [tiw] (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for participants in this group
9783268|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg)|
9783269|NCT01196923|Experimental|HeartLight Ablation|
9783270|NCT01196975|Experimental|GSK2282512A 1 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9783271|NCT01196975|Experimental|GSK2282512A 2 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9783272|NCT01196975|Experimental|GSK2282512A 3 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9783273|NCT01196975|Active Comparator|Victoria Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9783274|NCT01196975|Active Comparator|Yamagata Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9783275|NCT01196988|Experimental|GSK2321138A 1 Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
9783276|NCT01196988|Active Comparator|Fluarix Group|Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
9783277|NCT01196988|Active Comparator|GSK2604409A Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
9783278|NCT01196988|Experimental|GSK2321138A 2 Group|Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
9783279|NCT01197300|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
9783280|NCT01197326||Group 1|Patients who triggered MET/RRT calls prior to the use of the MP5 EWS patient monitor.
9783281|NCT01197326||Group 2|Patients who triggered MET/RRT calls after the use of the MP5 EWS patient monitor.
9783282|NCT01197378|Experimental|Cysteamine Bitartrate|Cysteamine bitartrate delayed-release capsules were administered twice daily for up to 96 months.
9783283|NCT01197417|Experimental|Magnesium group|Intravenous Magnesium Sulfate
9783284|NCT01197417|Placebo Comparator|Placebo group|Normal Saline placebo
9783285|NCT01197456||Exposed/chemotherapy|Breast cancer patients who will undergo chemotherapy
9783286|NCT01197456||Unexposed|Breast cancer patients who will not undergo chemotherapy
9783287|NCT01197495|Experimental|Treatment|Juvederm(R) Ultra XC Injectable Gel
9832163|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 37.5 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
9832164|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 50 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
9832165|NCT02601027|Experimental|0.125% Bupivacaine|0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter
9832166|NCT02601027|Placebo Comparator|Placebo|Saline infusion (sham) via transversus abdominis plane (TAP) catheter.
9832167|NCT02601105|Placebo Comparator|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
9783288|NCT01197495|Experimental|Control|No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.
9783289|NCT01197508|Experimental|0.1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.1 mg BID
9783290|NCT01197508|Experimental|1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1 mg BID
9783291|NCT01197508|Experimental|4 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
9783292|NCT01197508|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
9783293|NCT01197521|Experimental|Dosing Regimen A|Oral Treatment
9783294|NCT01197521|Experimental|Dosing Regimen B|Oral Treatment
9783295|NCT01197521|Placebo Comparator|Dosing Regimen C|Oral Treatment
9783296|NCT01197534|Experimental|Dosing Regimen A|Oral Treatment
9783297|NCT01197534|Experimental|Dosing Regimen B|Oral Treatment
9783298|NCT01197534|Placebo Comparator|Dosing Regimen C|Oral Treatment
9783299|NCT01197547|Other|Genesys HTA|Genesys HTA Endometrial Ablation
9783300|NCT01197560|Experimental|Lenalidomide|Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
9783301|NCT01197560|Active Comparator|Investigators Choice|"One of the following:~Gemcitabine, Oxaliplatin, Rituximab, or Etoposide"
9832168|NCT02601105|Experimental|Centella Asiatica Cream|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
9832169|NCT02601170|Experimental|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
9832170|NCT02601170|Active Comparator|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
9832171|NCT02601300|Experimental|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
9832172|NCT02601313|Experimental|Axicabtagene ciloleucel/brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma (MCL) will receive conditioning chemotherapy (CTE) consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg on Day 0 or brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 CAR T cells/kg, with a maximum dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 1 or brexucabtagene autoleucel at a targeted dose of 0.5 x 10^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 2.
9832173|NCT02601469|Experimental|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
9832174|NCT02601560|Experimental|MEDI6012 24 mg IV|Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
9832175|NCT02601560|Experimental|MEDI6012 80 mg IV|Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
9832176|NCT02601560|Experimental|MEDI6012 240 mg IV|Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
9832177|NCT02601560|Experimental|MEDI6012 800 mg IV|Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
9832178|NCT02601560|Experimental|MEDI6012 80 mg SC|Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
9832179|NCT02601560|Placebo Comparator|Placebo Intravenous (IV)|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
9832180|NCT02601560|Experimental|MEDI6012 600 mg SC|Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
9832181|NCT02601560|Placebo Comparator|Placebo Subcutaneous (SC)|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
9832182|NCT02601573|Experimental|Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks|TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.
9832183|NCT02601573|Experimental|Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks|TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
9832184|NCT02601573|Experimental|Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
9832185|NCT02601573|Experimental|Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.
9758624|NCT00632827|Experimental|Treatment Plan|(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5
9758625|NCT00632931|Experimental|A|Arm A: Drug/Placebo
9758626|NCT00632931|Experimental|B|Arm B: Placebo/Drug
9758627|NCT00632970|Experimental|Raltegravir plus Truvada|Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
9758628|NCT00632970|Active Comparator|Lopinavir/Ritonavir plus Truvada|Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
9758629|NCT00633009|Active Comparator|LtSTA 15 ug|Naive volunteers tested with 15 ug injection of LtSTA. Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin tests were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
9758630|NCT00633009|Active Comparator|LtSTA 30 ug|Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
9758631|NCT00633009|Active Comparator|LtSTA 50 ug|Naive volunteers tested with 50 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
9758632|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG TWICE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod orally twice daily, each morning and evening for a period of 12 weeks
9758633|NCT00633022|Placebo Comparator|Placebo|Participants received 1 tablet of placebo matching Losmapimod orally twice daily, each morning and evening for a period of 12 weeks.
9758634|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG ONCE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod each morning once daily and placebo tablet each evening once daily orally for a period of 12 weeks.
9758635|NCT00633074|Experimental|Thiomersal-free FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal-free FluAS25 adjuvanted vaccine
9758636|NCT00633074|Experimental|Thiomersal reduced FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal reduced FluAS25 adjuvanted vaccine
9758637|NCT00633126|Experimental|A|ceftaroline
9758638|NCT00633139|Experimental|Cohort 1|Cohort 1: 50 U/kg Recombinant human Arylsulfatase A (rhASA)
9758639|NCT00633139|Experimental|Cohort 2|Cohort 2: 100 U/kg Recombinant human Arylsulfatase A (rhASA)
9758640|NCT00633139|Experimental|Cohort 3|Cohort 3: 200 U/kg Recombinant human Arylsulfatase A (rhASA)
9758641|NCT00633152|Experimental|Ceftaroline|Intramuscular every 12 hours
9758642|NCT00633152|Active Comparator|linezolid plus optional aztreonam|Intravenous every 12 hours
9758643|NCT00633217|Active Comparator|arm 1|
9758644|NCT00633217|Experimental|arm 2|
9758645|NCT00633243|Experimental|Modified Directly Observed Therapy (mDOT)|Hepatitis C Virus (HCV) Treatment in Modified Directly Observed Therapy (mDOT) in Methadone Maintenance Treatment (MMT)
9758646|NCT00633243|Active Comparator|Self-Administered Therapy at Liver Specialty Clinic (SAT)|Hepatitis C virus (HCV) at a liver specialty clinic as self-administered therapy
9758647|NCT00633256|Experimental|Cycloserine|50 mg cycloserine
9758648|NCT00633256|Sham Comparator|Placebo|Matched placebo
9758649|NCT00633360|Experimental|Drospirenone and ethinyl estradiol|
9758650|NCT00633360|Placebo Comparator|Placebo|
9758651|NCT00633399|Experimental|1|Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.
9758652|NCT00633399|Placebo Comparator|2|Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.
9758653|NCT00633464|Experimental|Arm A (ixabepilone 40 mg^2)|ixabepilone 40 mg/m^2 every 3 weeks
9758654|NCT00633464|Experimental|Arm B (cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2)|cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks
9758655|NCT00633477|Experimental|Resatorvid 2.4 mg/kg/day|
9758656|NCT00633477|Placebo Comparator|Placebo|
9758657|NCT00633594|Experimental|rituximab/bortezomib/lenalidomide|"Patients in Phase I & II to receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles up to 6 cycles.~Phase I: Cohorts of 3 patients will be enrolled at escalating dose levels to determine the maximum tolerated dose (MTD). Doses may be de-escalated if necessary.~Phase II: patients will be treated with the MTD determined in Phase I."
9758658|NCT00633750|Experimental|Tarceva|
9758659|NCT00633867|Active Comparator|Intubation c McGrath videolaryngoscope|Tracheal Intubation using McGrath video-laryngoscope
9758660|NCT00633867|Active Comparator|Intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
9758661|NCT00633880|Experimental|Droxidopa|Double-blind
9758662|NCT00633880|Placebo Comparator|Placebo|Double-blind
9758663|NCT00633893|Experimental|1|2.5 mg
9758664|NCT00633893|Experimental|2|5.0 mg
9758665|NCT00633893|Active Comparator|3|0 mg
9758666|NCT00633919|Active Comparator|Active|SLITone Dermatophagoides Mix
9758667|NCT00633919|Placebo Comparator|Placebo|SLITone Placebo
9758668|NCT00633932|Experimental|1|Esomeprazole 20mg
9758669|NCT00633932|Experimental|2|Esomeprazole 40mg
9758670|NCT00633932|Active Comparator|3|Omeprazole 20mg
9758671|NCT00633945|Experimental|Lenalidomide|Open label lenalidomide received.
9758672|NCT00633945|Experimental|Lenalidomide 2|Open label lenalidomide received.
9783302|NCT01197573|Active Comparator|Standard DCD liver transplant|Standard method of liver transplant utilizing a DCD organ
9783303|NCT01197573|Active Comparator|rTPA Treatment Liver Transplant|Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA
9783304|NCT01197573|Active Comparator|Standard DCD kidney transplant|Standard method of kidney transplant utilizing a DCD organ
9783305|NCT01197573|Active Comparator|rTPA Treatment Kidney Transplant|Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA
9783306|NCT01197612|Other|Single Arm; nostrils as experimental and comparator|each subject serves as their own control with one nostril being treated with pulmicort and one not
9783307|NCT01197755|Experimental|Dosing Regimen A|Oral Treatment
9783308|NCT01197755|Experimental|Dosing Regimen B|Oral Treatment
9783309|NCT01197755|Placebo Comparator|Dosing Regimen C|Oral Treatment
9783310|NCT01197794|Experimental|AZD1981 10 mg|AZD1981 10 mg
9783311|NCT01197794|Experimental|AZD1981 40 mg|AZD1981 40 mg
9783312|NCT01197794|Experimental|AZD1981 100 mg|AZD1981 100 mg
9783313|NCT01197794|Experimental|AZD1981 400 mg|AZD1981 400 mg
9783314|NCT01197794|Experimental|AZD1981 80 mg|AZD1981 80 mg
9783315|NCT01197794|Experimental|AZD1981 200 mg|AZD1981 200 mg
9783316|NCT01197794|Placebo Comparator|Placebo|
9783317|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable microfoam 0.125%|Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
9783318|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable micrfoam, 1.0%|Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
9783319|NCT01197833|Active Comparator|endovenous ablation+vehicle (placebo)|endovenous ablation followed by injection of vehicle (placebo) to target vein
9783320|NCT01197898|Experimental|Collagenase Santyl|Ointment applied once daily
9783321|NCT01197898|Placebo Comparator|Vehicle Base|Applied once daily
9783322|NCT01197911|Experimental|Mild impairment|
9783323|NCT01197911|Experimental|Moderate impairment|
9783324|NCT01197911|Experimental|Normal HF|
9783325|NCT01198002|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 100 weeks. Participants receive a 240 mg loading dose when initiating treatment. During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Weeks 16 and 52, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
9783326|NCT01198002|Experimental|90 mg LY2127399|"Given Q2W for 100 weeks. Participants receive a 180 mg loading dose when initiating treatment.~At Weeks 16 and 52, responders will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
9783327|NCT01198002|Placebo Comparator|Placebo|"Given Q2W for 52 weeks. At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 52 weeks.~At Week 52, responders are randomized to receive 1 of the 2 doses of LY2127399, with loading dose of 240 mg or 180 mg of LY2127399, followed by 120 mg of LY2127399 Q4W or 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.~At Week 16, NR will receive a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
9783328|NCT01198028|Experimental|Treatment (erlotinib)|Participants receive erlotinib PO QD in the absence of disease progression or unacceptable toxicity.
9783329|NCT01198132|Experimental|Cholecalciferol|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 3 times a week.
9783330|NCT01198132|Placebo Comparator|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks along with subcutaneous injection of Rebif 3 times weekly.
9783331|NCT01198145|Experimental|Arm I: Sulfasalazine|Patients receive oral sulfasalazine twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
9758673|NCT00633984|Active Comparator|Cognitive Behavioral Group Therapy + D-Cycloserine|Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
9758674|NCT00633984|Placebo Comparator|Cognitive Behavioral Group Therapy + Placebo|Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
9758675|NCT00634036|Active Comparator|1|
9758676|NCT00634036|Placebo Comparator|2|
9758677|NCT00634049|Experimental|Isavuconazole|Administration of isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days followed by daily administration of isavuconazole (IV) or oral
9758678|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Dose Level 1
9758679|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Dose Level 2
9758680|NCT00634088|Experimental|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Dose Level 3
9758681|NCT00634088|Experimental|Ixabepilone + Lapatinib + Capecitabine|Triplet Combination
9758682|NCT00634101|Active Comparator|nefilcon A|Subjects randomized to this arm received the nelfilcon A lens throughout the entire duration of the study.
9758683|NCT00634101|Experimental|narafilcon A|Subjects randomized to this arm received the narafilcon A lens throughout the entire duration of the study.
9758684|NCT00634114|Experimental|1|Esomeprazole and Omeprazole
9758685|NCT00634114|Experimental|2|Esomeprazole
9758686|NCT00634166|Other|Historical Control|Treated within the last 5 years (if possible) with topical prophylactic therapies that did not include mafenide acetate or mafenide salt forms.
9758687|NCT00634166|Experimental|Prospective Patients/Active Drug|Prospective subjects with thermal injuries of 20-60% TBSA on the chest, abdomen, or proximal upper and lower extremities requiring meshed autografts on these areas will receive SS5% as the initial topical moist dressing over the meshed autograft(s) placed at the initial graft procedure (Day 1).
9758688|NCT00634179|Experimental|Treatment (VR-CHOP regimen)|"INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.~MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity."
9758689|NCT00634244|Experimental|Arm A (carboplatin and topotecan hydrochloride)|Patients receive carboplatin and topotecan hydrochloride IV continuously over 24 hours on days 1-5.
9758690|NCT00634244|Experimental|Arm B (alvocidib, mitoxantrone, cytarabine)|Patients receive alvocidib IV over 4.5 hours QD on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9.
9758691|NCT00634244|Experimental|Arm C (sirolimus, mitoxantrone, etoposide, cytarabine)|Patients receive sirolimus PO QD on days 2-9, mitoxantrone hydrochloride IV over 15 minutes QD, etoposide IV over 1 hour QD, and cytarabine IV over 3 hours QD on days 4-8 or 5-9. (Closed to accrual)
9758692|NCT00634270|Experimental|Sirolimus|"Design~Sirolimus oral solution will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment course) with pharmacokinetically-guided dosing.~Disease status will be evaluated using volumetric MRI analysis at regular intervals.~The plasma pharmacokinetics and pharmacodynamics of sirolimus will be evaluated, as will pharmacogenetic polymorphisms and their influence on the metabolism of sirolimus in this patient population.~Pain reduction and quality of life outcomes will also be assessed.~Toxicity of chronic sirolimus administered will be evaluated using physical and laboratory evaluations."
9758693|NCT00634283|Experimental|antidepressant-experienced|Subjects who had previously been exposed to active antidepressant medication (venlafaxine)
9758694|NCT00634283|Placebo Comparator|antidepressant-naive|Subjects who had previously been exposed to placebo only (and never to active antidepressant medication)
9758695|NCT00634504|Experimental|A|High-dose methotrexate, leucovorin, and Voraxaze
9758696|NCT00634504|Active Comparator|B|High-dose methotrexate and leucovorin without Voraxaze (glucarpidase)
9758697|NCT00634543|Experimental|Tramadol hydrochloride (HCl)/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3, 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
9758698|NCT00634543|Active Comparator|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
9758699|NCT00634569|Experimental|Flebogamma 5% DIF|
9758700|NCT00634647|Experimental|Satraplatin|satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days
9758701|NCT00634751|Experimental|Phase I: 200mg Sorafenib+2DOC|"Cohort 1: 200mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
9758702|NCT00634751|Experimental|Phase I: 400mg Sorafenib BID+2DOC|"Cohort 2: 400mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
9758703|NCT00634751|Experimental|Phase II: Pancreatic Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
9758704|NCT00634751|Experimental|Phase II: Biliary Tract Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
9758705|NCT00634803|Experimental|CBT for POD|Integrated cognitive behavioral therapy for chronic pain and opioid dependence
9758706|NCT00634803|Active Comparator|Educational Counseling for POD|Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
9758707|NCT00634803|Active Comparator|Physician Management|PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
9758708|NCT00634842|Experimental|FPG 70-90 mg/dL|Aggressive FPG (fasting plasma glucose) titration target range group
9758709|NCT00634842|Experimental|FPG 80-110 mg/dL|Conventional FPG (fasting plasma glucose) titration target range group
9758710|NCT00634907|Experimental|Pharmacogenetic-based warfarin dosing|"Pharmacogenetic-based warfarin dosing: Warfarin dosing based on formula that incorporates genetic testing results.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
9783332|NCT01198145|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
9783333|NCT01198158|Active Comparator|Arm I (everolimus)|Patients receive everolimus PO QD on days 1-28.
9783334|NCT01198158|Experimental|Arm II (everolimus with bevacizumab)|Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15.
9783335|NCT01198275|Active Comparator|n-3 PUFAs|
9783336|NCT01198275|Placebo Comparator|placebo|
9783337|NCT01198327|Experimental|Ranibizumab as needed|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.
9758711|NCT00634907|Active Comparator|Standard of care (control)|"Control or usual care warfarin dosing~NOTE: Standard of care (usual care) for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
9758712|NCT00634920|Experimental|Everolimus (CNI-free)|Patients in this group were converted to everolimus immunosuppressive therapy. The patients in the everolimus group were treated with everolimus, off-label (CNI-free) use, and EC-MPS and corticosteroids in accordance with local practice and approved label. Conversion to everolimus was as follows: Day 1: begin everolimus 3 mg in the evening. Usual morning dose of CsA and 50% reduced evening dose of CsA Day 2: everolimus 2 mg in the morning and 2 mg in the evening, complete discontinuation of CsA Day 3 or 4, and onwards: everolimus according to trough level 6-10 ng/mL.The given total daily dose of the immunosuppressive drugs (everolimus) was divided into two (equal) doses, applied 12 hours apart.
9758713|NCT00634920|Active Comparator|Control (CsA)|Patients in the control group continued on an immunosuppressive regimen. The patients in this Control group were treated with CsA, EC-MPS and corticosteroids in accordance with local practice and approved label. The given total daily dose of the immunosuppressive drugs (CsA and EC-MPS) was divided into two (equal) doses, applied 12 hours apart.
9758714|NCT00634933|Experimental|Arm 1|Consists of Arms 1a and 1b
9758715|NCT00634933|Experimental|Arm 2|Consists of Arms 2a and 2b
9758716|NCT00634933|Placebo Comparator|Arm 3|Consists of Arms 3a and 3b.
9758717|NCT00635024|Experimental|Anti-thymocyte Globulin/Melphalan|Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)
9758718|NCT00635050|Experimental|Doxil, Paclitaxel, Cyclophosphamide + Avastin|Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, in patients with locally advanced invasive breast cancer.
9758719|NCT00635089|Other|Open-Label Reslizumab|Open-label reslizumab intravenous (IV) infusion at an initial dose of 1 mg/kg monthly
9758720|NCT00635102|Active Comparator|Alcohol dependent|Alcohol dependent patients will receive 4 interventions
9758721|NCT00635102|Active Comparator|Healthy subjects|Healthy subjects will receive 4 interventions
9758722|NCT00635128|Experimental|BOOSTRIX-POLIO GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
9758723|NCT00635128|Experimental|BOOSTRIX + IPV MÉRIEUX GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
9758724|NCT00635154|Experimental|Anakinra with/without Dexamethasone|"Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra."
9758725|NCT00635219|Placebo Comparator|Placebo|
9758726|NCT00635219|Experimental|Vortioxetine: 2.5 mg|
9758727|NCT00635219|Experimental|Vortioxetine: 5 mg|
9758728|NCT00635219|Experimental|Vortioxetine: 10 mg|
9758729|NCT00635219|Other|Duloxetine: 60 mg|Active reference
9758730|NCT00635232|Active Comparator|Irbesartan 300mg|Irbesartan 300 mg once daily
9758731|NCT00635232|Placebo Comparator|Placebo|Blinded Placebo Treatment
9758732|NCT00635232|Experimental|PS433540 200mg|PS433540 200mg once daily
9758733|NCT00635232|Experimental|PS433540 400mg|PS433540 400mg once daily
9758734|NCT00635232|Experimental|PS433540 800mg|PS433540 800mg once daily
9758735|NCT00635349|Active Comparator|Non-steroidal Anti-inflammatory Drug (NSAIDs)|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.
9758736|NCT00635349|Experimental|Tramadol Hydrochloride Plus Acetaminophen|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
9758737|NCT00635362|Experimental|postplacental insertion after cesarean|"Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
9758738|NCT00635362|Active Comparator|delayed insertion group|"Insertion of the LNG-IUS 4-8 weeks after cesarean delivery~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
9758739|NCT00635427|Experimental|VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039)|"This arm is the Overall velaglucerase alfa (VPRIV) 60 U/kg and includes patients from the following groups:~VPRIV 45 U/kg or 60 U/kg, IV, EOW for 51 weeks in parent study TKT032 (NCT00430625) and switched to 60 U/kg in HGT-GCB-044 to maintain blindness or 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)"
9758740|NCT00635427|Experimental|VPRIV 60 U/kg (Parent study-imiglucerase(60 U/kg) HGT-GCB-039)|imiglucerase 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)and switched 60 U/kg VPRIV in HGT-GCB-044
9758741|NCT00635427|Experimental|VPRIV 15-60 U/kg (Parent study VPRIV (15-60 U/kg) TKT034)|VPRIV 15- 60 U/kg, IV, EOW for 51 weeks in parent study TKT034 (NCT00478647) and continued in HGT-GCB-044 at the same dose as prescribed in TKT034
9758742|NCT00635453|Experimental|I, Intervention|"Physicians, nurses and administrative staff of all intervention health centers participated in a training of Dietary Advice in January 2008 based on the Ten Steps for Healthy Feeding for Brazilian Children from Birth to Two Years of Age guideline.13 An experienced nutritionist conducted a standardized session for the health care team to outline the Ten Steps recommendations and strategies and to provide suggestions how best to incorporate these into the consultations. Printed materials were provided to the Health Care Centers for use by these professionals and for access to the Brazilian Ministry of Healthy Nutrition Department´s website. Health staff members received a pocket guide for use during the appointments and waiting room sessions."
9832186|NCT02601573|Experimental|Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.
9832187|NCT02601625|Experimental|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
9832188|NCT02601625|Experimental|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
9832189|NCT02601625|Experimental|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
9832190|NCT02601625|Placebo Comparator|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
9832191|NCT02601625|Placebo Comparator|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
9832192|NCT02601625|Placebo Comparator|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
10202574|NCT04504682|Experimental|Ambulation|Participants in this arm will be encouraged to ambulate with epidural in place.
9835916|NCT02761330|Active Comparator|Etomidate + ECT|General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
9835917|NCT02761330|Experimental|Ketamine + ECT|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
9835918|NCT02761330|Sham Comparator|Ketamine alone|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
9835919|NCT02761629|Experimental|Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
9835920|NCT02761629|Active Comparator|Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
9835921|NCT02761642|Experimental|Epoetin Beta|Anemic breast cancer participants will receive epoetin beta treatment for 12 weeks.
9835922|NCT02761733|Experimental|mPOWR System|Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
9835923|NCT02761733|No Intervention|Control|Treatment as usual
9835924|NCT02761915|Other|Dose Level 1|Patients in Dose Level 1 will receive 1x10^7 1RG-CART/m^2 intravenously (IV) on Day 0.
9835925|NCT02761915|Other|Dose Level 2|Patients in Dose Level 2 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
9835926|NCT02761915|Other|Dose Level 3|Patients in Dose Level 3 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
9835927|NCT02761915|Other|Dose Level 4|Patients in Dose Level 4 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 IV on Day 0.
9835928|NCT02761915|Other|Dose Level 5|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 IV which could be be split over two days (Day 0 and Day 1).
9835929|NCT02761915|Other|Patients who underwent leukapheresis but did not proceed to receive any IMP|Patients who were enrolled and underwent leukapheresis but who did not receive any IMP.
9835930|NCT02761967|Experimental|Physical activity|"The women in the EG (Exercise Group) performed moderate physical exercise in water, following the SWEP method (Study of Water-based Exercise during Pregnancy). It consists of performing moderate physical exercise in an aquatic environment from weeks 20 to 37 of gestation. The sessions take place three times weekly, with a duration of 60 minutes each (45 minutes of activity followed by 15 minutes of relaxation). The sessions are composed of three phases: a) warm-up; b) the main phase, divided into aerobic exercise and strength-endurance exercises, designed specifically for pregnant women; c) stretching and relaxation.~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
9835931|NCT02761967|No Intervention|No exercise|"The CG (Control Group) received the standard recommendations during pregnancy, including guidelines from the midwife on the positive effects of physical exercise. These participants received the usual visits from healthcare providers (midwives, obstetricians and family doctor) during pregnancy, as did those in the EG.~After the postpartum period, the women in the control group did not perform regulated physical activity."
9835932|NCT02761980|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
9835933|NCT02761980|Active Comparator|Ibuprofen 250 mg|Single dose of 2 caplets of IBU 125 mg by mouth
10202575|NCT04500509|Experimental|Group A|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure
10202576|NCT04500509|Placebo Comparator|Group B|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure
10202577|NCT04500470|Experimental|Group A|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
10202578|NCT04500470|Placebo Comparator|Group B|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table vaginal placebo by the patient 12 hours before the procedure
10202579|NCT04495816|Active Comparator|Omega-3|1,000 mg of omega-3 fatty acid (2 softgels per day for 6 weeks)
10202580|NCT04495816|Sham Comparator|Placebo/Control|2 softgels per day for 6 weeks
10202581|NCT04493658||Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and a diagnosis of Sjogren's syndrome made according to the 2016 revised criteria
9758743|NCT00635453|No Intervention|II, Control|Healthcare centers randomized to the non-intervention group continued their routine medical assistance without any involvement of the research team. No materials were provided to these clinics.
9758744|NCT00635479|Experimental|VAC Device placement|will have the VAC device used for post-operative management of acetabular fractures and pelvic fractures.
9758745|NCT00635479|Active Comparator|Gauze dressing|will receive current traditional surgical wound management with daily dressing changes in post operative management of acetabular fractures and pelvic fractures.
9758746|NCT00635492||1|exenatide
9758747|NCT00635492||2|insulin
9758748|NCT00635570|Active Comparator|Contraceptive vaginal ring|Contraceptive vaginal ring (NuvaRing)
9758749|NCT00635570|Active Comparator|Oral contraceptive pill|Oral contraceptive pill (Ortho Tri-cyclen Lo)
9758750|NCT00635609|Experimental|Doxycycline hyclate (Doryx)|
9758751|NCT00635609|Active Comparator|Doxycycline hyclate|
9758752|NCT00635648|Experimental|Caspofungin 50 mg Intravenous (IV)|
9758753|NCT00635700|Experimental|1|
9758754|NCT00635700|Placebo Comparator|2|
9758755|NCT00635739|Active Comparator|A, 1|
9758756|NCT00635739|Placebo Comparator|A, 2|
9758757|NCT00635778|Experimental|dalotuzumab 2.5/2.5 mg/kg|Participants received a loading dose of dalotuzumab 2.5 mg/kg administered by intravenous (IV) infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 2.5 mg/kg administered by IV infusion every two weeks for up to 18 months.
9758758|NCT00635778|Experimental|dalotuzumab 5.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 5.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
9758759|NCT00635778|Experimental|dalotuzumab 10.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 10.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
9758760|NCT00635778|Experimental|dalotuzumab 15.0/5.0mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
9758761|NCT00635778|Experimental|dalotuzumab 20.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 20.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
9758762|NCT00635778|Experimental|dalotuzumab 15.0/10.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 10.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
9758763|NCT00635778|Experimental|dalotuzumab 15.0/15.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 15.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
9758764|NCT00635804|Experimental|Pt 1: MK-3281 100 mg BID (Panel A)|Healthy male participants in this Part I serial panel receive 100 mg MK-3281 orally twice daily (BID) for 10 consecutive days for a total daily dose administered of 200 mg. The evening (PM) dose of MK-3281 was not administered on Day 10.
9758765|NCT00635804|Experimental|Pt 1: MK-3281 200 mg BID (Panel B)|Healthy male participants in this Part I serial panel receive 200 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 400 mg. The PM dose of MK-3281 was not administered on Day 10.
9758766|NCT00635804|Experimental|Pt 1: MK-3281 400 mg BID (Panel C)|Healthy male participants in this Part I serial panel receive 400 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 800 mg. The PM dose of MK-3281 was not administered on Day 10.
9758767|NCT00635804|Experimental|Pt 1: MK-3281 800 mg BID (Panel D)|Healthy male participants in this Part I serial panel receive 800 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 10.
9758768|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel E)|Genotype (GT)1 HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
9758769|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel F)|GT1a/GT1-nontypeable/GT3/GT1b HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
9758770|NCT00635804|Experimental|Pt 2: MK-3281 1200 mg BID (Panel G)|GT1a (and/or GT1 nontypeable) and GT1b HCV-infected male participants in this Part II serial panel receive 1200 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 2400 mg. The PM dose of MK-3281 was not administered on Day 7.
9783338|NCT01198366|Placebo Comparator|Dose Finding Gr 1 placebo x 2|Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.
9832193|NCT02601833|Experimental|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
9832194|NCT02601833|Active Comparator|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
9832195|NCT02601976|Experimental|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
9832196|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
9832197|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
9832198|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
9832199|NCT02602223|Experimental|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
9832200|NCT02602223|Active Comparator|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
9832201|NCT02602496|Experimental|Control|3 servings of refined grains per day.
9832202|NCT02602496|Experimental|Fruits and Vegetables|5 servings of fruits and vegetable per day.
9832203|NCT02602496|Experimental|Whole Grain|3 servings of whole grains per day.
9832204|NCT02603107|Experimental|B/F/TAF|"Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks, without regard to food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
9832205|NCT02603107|Experimental|Stay on Baseline Regimen (SBR)|"Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) for at least 48 weeks with food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
9832206|NCT02603120|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
9832207|NCT02603120|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
9832208|NCT02603120|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
9832209|NCT02603172|Experimental|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
9832210|NCT02603172|Experimental|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
9758771|NCT00635804|Placebo Comparator|Placebo|Participants receive dose-matched placebo to MK-3281 orally BID for 7 or 10 consecutive days depending on randomization. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
9758772|NCT00635817|Experimental|Leuprolide acetate 11.25 mg|There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
9758773|NCT00635817|Experimental|Leuprolide acetate 30 mg|There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
9758774|NCT00635830|Experimental|1|Open Label
9758775|NCT00635999|Experimental|Purely Behavioral therapy|Participants will receive treatment with progressive and applied relaxation and self-control desensitization.
9758776|NCT00635999|Experimental|Cognitive-Behavioral Therapy|Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization
9758777|NCT00635999|Experimental|Cognitive Therapy (CT)|Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.
9758778|NCT00636077|Other|HD-C4 Big|3 consecutive treatments with the HD-C4 Big dialyzer.
9758779|NCT00636077|Other|HD-C4 Small|3 consecutive treatments with the HD-C4 Small dialyzer.
9758780|NCT00636077|Other|F160NR|3 consecutive treatments with the F160NR dialyzer.
9758781|NCT00636077|Other|F200NR|3 consecutive treatments with the F200NR dialyzer.
9758782|NCT00636155|Experimental|all patients|EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)
9758783|NCT00636168|Active Comparator|A|
9758784|NCT00636168|Placebo Comparator|B|
9758785|NCT00636181|Active Comparator|Auto Aflex|auto adjusting positive pressure therapy with AFLEX
9758786|NCT00636181|Active Comparator|Auto CPAP|auto adjusting positive pressure therapy
9758787|NCT00636181|Active Comparator|CPAP|continuous positive airway pressure
9758788|NCT00636194|Experimental|B&L Multipurpose solution|Bausch & Lomb Multipurpose Contact Lens Solution
9758789|NCT00636194|Active Comparator|Alcon Multipurpose Solution|Alcon OptiFree Replenish Multipurpose Contact Lens Solution
9758790|NCT00636207|Experimental|Montelukast 0.1 mg|"Participants receive Montelukast inhalation powder, 0.1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
9758791|NCT00636207|Experimental|Montelukast 0.3 mg|"Participants receive Montelukast inhalation powder, 0.3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
9758792|NCT00636207|Experimental|Montelukast 1 mg|"Participants receive Montelukast inhalation powder, 1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period."
9758793|NCT00636207|Experimental|Montelukast 3 mg|"Participants receive Montelukast inhalation powder, 3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
9758794|NCT00636207|Experimental|Montelukast 10 mg|"Participants receive Montelukast inhalation powder, 10 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
9758795|NCT00636207|Placebo Comparator|Placebo|"Participants receive Placebo to Montelukast inhalation powder.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
9758796|NCT00636220||A, Observational|
9758797|NCT00636363|Experimental|Multipurpose Solution - Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
9758798|NCT00636363|Experimental|Multipurpose Solution - No Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
9758799|NCT00636363|Active Comparator|Ciba Vision Aquify Multipurpose Solution|Ciba Vision Aquify Multipurpose Solution for use with contact lens care
9758800|NCT00636389|Other|HD-C4 First, then 210H|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
9783339|NCT01198366|Experimental|Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2|Subjects received two doses (x2) of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.
9758801|NCT00636389|Other|210H First, then HD-C4|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux 210H dialyzer. Following the third treatment, the subjects will be switched to the Polyflux HD-C4 dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
9758802|NCT00636441|Active Comparator|Guided Arm|"Genomically-guided treatment allocation.~This arm has the following cohorts:~AC sensitive patients [>60% probability of response to AC]~TC sensitive patients [>60% probability of response to TC]~Patients sensitive to neither AC nor TC; randomized to AC or TC"
9758803|NCT00636441|Active Comparator|Non-Guided Arm|"Non-genomically-guided treatment allocation.~This arm has the following cohorts:~In patients randomly assigned to AC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC~In patients randomly assigned to TC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC"
9758804|NCT00636506|Experimental|AMS 700 IPP 2005 Implant Group|Male subjects 21 years of age and older who are implanted with an AMS 700 IPP with MS (Momentary Squeeze) pump for erectile dysfunction.
9758805|NCT00636610|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily starting on Day 3 of each 2-week treatment cycle. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
9758806|NCT00636610|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily starting on Day 3 of each 2-week treatment. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
9758807|NCT00636636|Experimental|G-ER|Gabapentin - Extended Release
9758808|NCT00636636|Placebo Comparator|Placebo|Sugar pill
9758809|NCT00636649|Experimental|A|Escitalopram
9758810|NCT00636649|Placebo Comparator|B|Placebo
9758811|NCT00636675|Experimental|Fall QI|Falls QI includes quality improvement training about falls to be implement by indigenous nursing home staff with support of study personnel.
9758812|NCT00636675|Experimental|Connect & Falls QI|Connect is delivered, followed by Falls. Behavioral intervention to improve staff interaction for better care planning and execution. Connect will be delivered, followed by the Falls quality improvement intervention.
9758813|NCT00636701|Experimental|Primed rTMS|Receive 10 min. of 6-Hz rTMS Repetitive Transcranial Magnetic Stimulation at 90% RMT (3,600 pulses). Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
9758814|NCT00636701|Placebo Comparator|Unprimed rTMS)|Receive 10 min. of sham rTMS Repetitive Transcranial Magnetic Stimulation. Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
9758815|NCT00636792|Experimental|1|This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
9758816|NCT00636805|Experimental|1|Patient receives IV Aloxi
9758817|NCT00636818|Experimental|Atomoxetine|
9758818|NCT00636961|Experimental|Sequence 1: Indacaterol 300μg followed by Placebo|In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
9758819|NCT00636961|Experimental|Sequence 2 : Placebo followed by Indacaterol 300μg|In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
9758820|NCT00636987|Other|Implanted with Biocor or Biocor Supra Valves|
9758821|NCT00637000|Experimental|Buprenorphine soluble film|"Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours."
9758822|NCT00637000|Experimental|Buprenorphine/naloxone soluble film|"Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours."
9758823|NCT00637156|Experimental|PRESTIGE LP Device|
9758824|NCT00637156|Other|ATLANTIS Cervical Plate System|
9832211|NCT02603172|Experimental|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
9832212|NCT02603172|Experimental|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
9832213|NCT02603172|Experimental|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
9832214|NCT02603211||Women with Breast Tumors|Women with breast tumors.
9832215|NCT02603393|Experimental|QVA149|
9832216|NCT02603393|Active Comparator|Tiotropium + salmeterol/fluticasone|
9832217|NCT02603419|Experimental|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
9832218|NCT02603419|Experimental|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
9832219|NCT02603419|Experimental|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
9832220|NCT02603419|Experimental|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
9832221|NCT02603419|Experimental|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
9832222|NCT02603419|Experimental|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
9832223|NCT02603666|Other|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
9832224|NCT02603809|Placebo Comparator|Placebo|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
9832225|NCT02603809|Experimental|Aprocitentan 5 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
9832226|NCT02603809|Experimental|Aprocitentan 10 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
9832227|NCT02603809|Experimental|Aprocitentan 25 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
9758825|NCT00637195|Experimental|Cervarix™ & Engerix™ Group|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) (Months 0, 1 & 6) and 4 doses of Hepatitis B (Engerix™) vaccine (Months 0, 1, 2 & 12).
9758826|NCT00637195|Active Comparator|Engerix™ Group|Subjects received 4 doses of Hepatitis B (HBV) vaccine (Months 0, 1, 2 & 12).
9758827|NCT00637247|Experimental|imexon + gemcitabine|imexon + gemcitabine
9758828|NCT00637247|Active Comparator|Placebo + gemcitabine|Placebo in combination with gemcitabine
9758829|NCT00637273|Experimental|1|
9758830|NCT00637273|Active Comparator|2|
9758831|NCT00637273|Active Comparator|3|
9758832|NCT00637299|Active Comparator|Active osteopathic treatment (OMT+PR)|The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
9758833|NCT00637299|Sham Comparator|SOT + PR|Sham osteopathic treatment (manipulation)
9758834|NCT00637377|Active Comparator|Ranibizumab 0.5mg Q4|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
9758835|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
9758836|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
9758837|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
9758838|NCT00637494|Active Comparator|1|Mifepristone followed by an antidepressant
9758839|NCT00637494|Placebo Comparator|2|Placebo followed by an antidepressant
9758840|NCT00637572|Experimental|Megestrol acetate oral suspension nanocrystal dispersion|Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
9758841|NCT00637572|Active Comparator|Megestrol acetate oral suspension micronized formulation|Megestrol acetate oral suspension micronized formulation 60 mg/mL
9758842|NCT00637780|Experimental|1|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
9758843|NCT00637923|Experimental|1|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
9758844|NCT00637923|Placebo Comparator|2|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
9758845|NCT00638014|Active Comparator|1|Conventional wires only
9758846|NCT00638014|Experimental|2|Rapid Sternal Closure System supplemented with wires
9758847|NCT00638027|Experimental|1|Memantine 10 mg bid
9758848|NCT00638027|Placebo Comparator|2|Placebo
9758849|NCT00638157|Active Comparator|Daptomycin Alone|daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
9758850|NCT00638157|Experimental|Daptomycin plus gentamicin|daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
9758851|NCT00638235||Phase I (IntePro, US only)|AMS Apogee™ with IntePro(Began May 2006 - Closed)
9758852|NCT00638235||Phase I (InteXen LP, US only)|AMS Apogee™ with InteXen LP (Began May 2006 - Closed)
9758853|NCT00638235||Phase II (France only)|AMS Perigee™ with IntePro (Began February 2007 - Closed)
9758854|NCT00638235||Phase III/IV (Perigee IntePro Lite, US only)|AMS Perigee™ with IntePro Lite (Began April 2007 - Closed)
9758855|NCT00638235||Phase III/IV (Apogee IntePro Lite, US only)|AMS Apogee™ with IntePro Lite (Began April 2007 - Closed)
9758856|NCT00638235||Phase V (Elevate Posterior IntePro Lite, US & EU)|AMS Elevate™ Apical & Posteiror with IntePro Lite (Began April 2008 - Closed)
9758857|NCT00638235||Phase V (Elevate Posterior InteXen, US only)|AMS Elevate™ Apical & Posteiror with IntXen LP (Began April 2008 - Closed)
9758858|NCT00638235||Phase VI (Elevate Anterior Gen 1, For Study Use Only, EU only)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 1, For Study Use Only, Began October 2008 - Closed)
9758859|NCT00638235||Phase VII (Elevate Anterior Gen 2, US & EU)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 2, Began April 2009 - Closed)
9758860|NCT00638274|Active Comparator|Air|Air 3 ml used to identify epidural space
9758861|NCT00638274|Active Comparator|Saline|Saline 3 ml used to identify epidural space
9758862|NCT00638365|Experimental|1|KB001, a monoclonal antibody
9758863|NCT00638365|Placebo Comparator|2|Placebo
9783340|NCT01198366|Experimental|Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2|Subjects received two doses (x2) of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.
9758864|NCT00638378|Experimental|Ruxolitinib|Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
9758865|NCT00638404||1|Elective Cesarean Sections-this portion completed
9758866|NCT00638404||3|Any in-patient gynecologic procedure- this portion completed
9758867|NCT00638443|Other|Pregabalin then Diphenhydramine|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days; no drug for 7 days; diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
9758868|NCT00638443|Other|Diphenhydramine then Pregabalin|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days; no drug for 7 days; pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
9758869|NCT00638456|Active Comparator|1|oral viscous budesonide plus Prevacid
9758870|NCT00638456|Placebo Comparator|2|placebo plus Prevacid
9758871|NCT00638508|Active Comparator|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
9758872|NCT00638508|Experimental|Ketorolac with Ropivacaine|Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site
9758873|NCT00638651|Active Comparator|1|The tattoo will be treated with laser and imiquimod 5% cream
9758874|NCT00638651|Placebo Comparator|2|The tattoo will be treated with laser and placebo topical cream
9758875|NCT00638690|Experimental|Abiraterone acetate plus prednisone/prednisolone|
9758876|NCT00638690|Placebo Comparator|Placebo plus prednisone/prednisolone|
9758877|NCT00638716|Experimental|1|12 weekly doses of 1.5 mg CJC-1134-PC
9758878|NCT00638716|Experimental|2|4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
9758879|NCT00638716|Placebo Comparator|3|12 weekly doses of placebo
9758880|NCT00638820|Experimental|Intent-To-Treat|Patients enrolled and received study treatment.
9758881|NCT00638846|Experimental|senofilcon A toric|senofilcon A, daily wear, toric contact lens worn for two weeks
9758882|NCT00638846|Active Comparator|balafilcon A toric|balafilcon A, daily wear, toric contact lens worn for two weeks
9758883|NCT00638885||Group 1|
9758884|NCT00638924||Exercise Capacity|Individuals from the female gender; age range of 20 to 30 years old; considered healthy (i.e. with no diagnosed health condition; considered sedentary (i.e. performing less than 150 minutes of moderate intensity physical activity per week); will be asked to volunteer in the research and perform a exercise capacity test.
9758885|NCT00638937|Experimental|Treatment (saracatinib)|Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
9758886|NCT00638963|Experimental|Temozolomide|
9758887|NCT00638963|No Intervention|Observational|
9783341|NCT01198366|Experimental|Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2|Subjects received two doses (x2) of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.
9783342|NCT01198366|Experimental|Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3|Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.
9783343|NCT01198366|Placebo Comparator|Expanded Safety Phase Gr 5 Placebo x3|Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.
9783344|NCT01198470|Experimental|TRIUMPH® Artificial Disc|Treatment of degenerative disc disease with the TRIUMPH Lumbar Artificial Disc. This is a non-randomized pilot study with only one arm (no control).
9783345|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - doxycycline|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
9783346|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - vancomycin|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
9783347|NCT01198509|No Intervention|RA, PsA, healthy|"Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.~Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.~Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients."
9783348|NCT01198574|Experimental|Iron group|
9783349|NCT01198574|Experimental|Vitamin A group|Vitamin A group
9783350|NCT01198574|Experimental|Iron and Vitamin A group|Iron and Vitamin A group
9783351|NCT01198574|Experimental|Placebo group|Placebo group with folic acid
9783352|NCT01198587|Experimental|Outpatient Zinc Sulfate|Zinc Sulfate
9783353|NCT01198587|Experimental|Inpatient Zinc Sulfate|Zinc Sulfate
9783354|NCT01198587|Placebo Comparator|Outpatient Placebo|Placebo oral capsule
9783355|NCT01198587|Placebo Comparator|Inpatient Placebo|Placebo oral capsule
9783356|NCT01198600|Other|Phase 1: Habitual no Replacement, then Habitual Replacement|Contact lenses per participant's habitual prescription worn for 30 days with no replacement, followed by contact lenses per habitual prescription worn for 30 days with a replacement pair dispensed at Day 28.
9783357|NCT01198600|Other|Phase 1: Habitual Replacement, then Habitual no Replacement|Contact lenses per participant's habitual prescription worn for 30 days with replacement pair dispensed at Day 28, followed by contact lenses per habitual prescription worn for 30 days with no replacement.
9758888|NCT00638989|Experimental|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
9758889|NCT00638989|Experimental|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
9758890|NCT00638989|Experimental|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
9758891|NCT00639002|Experimental|Ruxolitinib then Ruxolitinib + Dexamethasone|Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
9758892|NCT00639093|Experimental|1|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
9758893|NCT00639093|Active Comparator|2|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
9758894|NCT00639158|Active Comparator|ABT-335 + atorvastatin + ezetimibe|
9758895|NCT00639158|Placebo Comparator|Placebo + atorvastatin + ezetimibe|
9758896|NCT00639223|Active Comparator|Pravastatin|
9758897|NCT00639223|Experimental|Red yeast Rice|
9758898|NCT00639379|Experimental|senofilcon A|senofilcon A toric daily wear contact lenses
9758899|NCT00639379|Active Comparator|alphafilcon A|alphafilcon A toric daily wear contact lenses
9758900|NCT00639418||Participants 6 to 23 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 6 to 23 months of age
9758901|NCT00639418||Participants 24 to 59 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 24 to 59 months of age
9758902|NCT00639418||Participants 5 to 8 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 5 to 8 years of age
9758903|NCT00639418||Participants 9 to 17 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 9 to 17 years of age
9758904|NCT00639457|Experimental|Pioglitazone|Pioglitazone (Actos; 30mg/day) for 16 weeks.
9758905|NCT00639457|Active Comparator|Pioglitazone + Exercise training|Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.
9758906|NCT00639509|Experimental|Treatment (monoclonal antibody therapy)|Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
9758907|NCT00639678|Experimental|1|
9758908|NCT00639678|Experimental|2|
9758909|NCT00639678|Placebo Comparator|3|
9758910|NCT00639678|Placebo Comparator|4|
9758911|NCT00639717|Experimental|Etanercept and ECP|"Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention:~Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant.~GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant."
9758912|NCT00639769|Experimental|Therapeutic Intervention|
9758913|NCT00639860|Experimental|Placing OSSIX-Plus in Extraction Site|Placement of OSSIX-Plus, a resorbable collagen membrane, and the promotion of bone healing following exodontia.
9758914|NCT00640016|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
9758915|NCT00640016|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
9758916|NCT00640016|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
9758917|NCT00640016|Experimental|CAT-354 10 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56
9758918|NCT00640042|Experimental|1|
9758919|NCT00640133|Active Comparator|Active DBS|Participants will receive deep brain stimulation.
9758920|NCT00640133|Sham Comparator|Sham DBS|Participants will receive sham deep brain stimulation for several months and then active deep brain stimulation thereafter.
9758921|NCT00640146|Experimental|MNTX|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
9758922|NCT00640146|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
9758923|NCT00640224|Active Comparator|Rosiglitazone|Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
9758924|NCT00640224|Active Comparator|Drospirenone/ethinyl estradiol|Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
9758925|NCT00640224|No Intervention|Overweight/Obese without PCOS|Overweight adolescent females without PCOS to use as comparison of normal developmental changes. *No participants were enrolled in this Arm.
9758926|NCT00640224|No Intervention|Lean without PCOS|Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. *No participants were enrolled in this Arm.
9758927|NCT00640250|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
9758928|NCT00640289|Experimental|A|Treatment
9758929|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 1.0 mg|Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.
9758930|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 2.5 mg|Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.
9758931|NCT00640328|Experimental|Cohort 1.1|100mg ofatumumab then placebo
9758932|NCT00640328|Experimental|Cohort 1.2|placebo then 100mg ofatumumab
9758933|NCT00640328|Experimental|Cohort 2.1|300mg ofatumumab then placebo
9758934|NCT00640328|Experimental|Cohort 2.2|placebo then 300mg ofatumumab
9758935|NCT00640328|Experimental|Cohort 3.1|700mg ofatumumab then placebo
9758936|NCT00640328|Experimental|Cohort 3.2|placebo then 700mg ofatumumab
9758937|NCT00640341|Experimental|PureVision|PureVision Contact Lens
9758938|NCT00640341|Active Comparator|Acuvue Oasys|Acuvue Oasys Contact Lens
9758939|NCT00640341|Active Comparator|O2Optix|O2Optix Contact Lens
9758940|NCT00640393|Active Comparator|Part 1 - Etanercept|All participants received etanercept 50 mg twice a week for 12 weeks.
9758941|NCT00640393|Active Comparator|Part 2 - Etanercept and nbUVB|Participants who did not reach a 90 percent reduction in psoriasis area and severity index (PASI-90) after 12 weeks and were randomized to the narrow band ultra violet B (nbUVB) group. They received nbUVB treatments three times a week and 50 mg Etanercept once per week.
9758942|NCT00640393|Active Comparator|Part 2 - Etanercept|Participants who did not reach PASI-90 after 12 weeks and were randomized to the Etanercept group. They received 50 mg Etanercept once per a week.
9758943|NCT00640510|Experimental|IM olanzapine 10mg|Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
9758944|NCT00640510|Placebo Comparator|IM placebo|Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
9758945|NCT00640562|Experimental|Quetiapine Extended Release|
9758946|NCT00640562|Active Comparator|Risperidone|
9758947|NCT00640614|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to any of the seven allergens. Subjects must otherwise be healthy and fulfill entry criteria.
9758948|NCT00640614|Experimental|Consecutives|Subjects who are being seen for standard allergy patch testing, that are asked to participate in the study.
9758949|NCT00640653|Experimental|Abstinence-only|Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
9758950|NCT00640653|Experimental|Safer-sex only|Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
9758951|NCT00640653|Experimental|Comprehensive-long|Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
9758952|NCT00640653|Experimental|Comprehensive-short|Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
9758953|NCT00640653|Active Comparator|Health-promotion control|Participants will receive the health promotion control intervention.
9758954|NCT00640822|Experimental|Calcipotriol plus Hydrocortisone ointment|Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
9758955|NCT00640822|Active Comparator|Tacalcitol|Tacalcitol once daily for up to 8 weeks
9758956|NCT00640822|Placebo Comparator|Calcipotriol plus Hydrocortisone ointment vehicle|Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
9758957|NCT00640835|Experimental|Sublingual administration|Buprenorphine/naloxone film strip administered sublingually
9758958|NCT00640835|Experimental|Buccal administration|Buprenorphine/naloxone film strip administered buccally
9758959|NCT00640926|Experimental|1|Radezolid 300 mg
9758960|NCT00640926|Experimental|2|Radezolid 450 mg
9758961|NCT00640926|Experimental|3|Radezolid 450 mg BID
9758962|NCT00640978|Experimental|Erlotinib + RAD001|Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
9758963|NCT00641043|Experimental|BI 1356 (5 mg)|BI 1356 5mg in initial combination therapy with pioglitazone 30 mg
9758964|NCT00641043|Placebo Comparator|Placebo matching BI 1356 5 mg|Placebo in initial combination therapy with pioglitazone 30 mg
9758965|NCT00641056|Experimental|1|
9758966|NCT00641056|Active Comparator|2|
9758967|NCT00641147|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 12 months. Laboratory Biomarker Analysis
9758968|NCT00641147|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 months. Laboratory Biomarker Analysis
9758969|NCT00641563|Active Comparator|Dex/Remi followed by Mida/Remi|Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week
9758970|NCT00641563|Active Comparator|Mida/Remi followed by Dexa/Remi|Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week
9758971|NCT00641641|Experimental|antiretroviral therapy|tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.
9758972|NCT00641667|Experimental|Fentanyl|
9758973|NCT00641706|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9758974|NCT00641706|Experimental|Stratum 2 (undergoing surgery)|Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
9758975|NCT00641719|Experimental|Duloxetine 40 mg|Duloxetine 40 milligrams (mg) once daily (QD), orally (PO), 1 year
9758976|NCT00641719|Experimental|Duloxetine 60 mg|Duloxetine 60 mg QD, PO, 1 year
9758977|NCT00641745|Experimental|1|Lurasidone
9758978|NCT00641745|Active Comparator|2|Risperidone
9758979|NCT00641797|Active Comparator|Arm 1, Conventional Therapy|Patients will receive standard conventional medication therapy (i.e., meclizine, diphenhydramine, lorazepam, ondansetron).
9758980|NCT00641797|Experimental|Arm 2, Epley Maneuver|Patients will receive vestibular rehabilitation (the Epley Maneuver).
9758981|NCT00641862|Active Comparator|Vitamin B12|Vitamin B12
9758982|NCT00641862|Placebo Comparator|Placebo|Placebo
9758983|NCT00642018|Active Comparator|A: Docetaxel|Standard of care (SOC) docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel therapy
9758984|NCT00642018|Experimental|B: LY2181308 + Docetaxel|LY2181308 administered with docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel
9758985|NCT00642174|Experimental|Prasugrel|Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
9758986|NCT00642174|Active Comparator|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.
9758987|NCT00642278|Experimental|Canagliflozin 50 mg daily|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
9758988|NCT00642278|Experimental|Canagliflozin 100 mg daily|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
9758989|NCT00642278|Experimental|Canagliflozin 200 mg daily|Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
9758990|NCT00642278|Experimental|Canagliflozin 300 mg daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
9758991|NCT00642278|Experimental|Canagliflozin 300 mg twice daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
9758992|NCT00642278|Active Comparator|Sitagliptin 100 mg daily|Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
9758993|NCT00642278|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 12 weeks.
9758994|NCT00642304|Experimental|methoxy polyethylene glycol-epoetin beta|
9758995|NCT00642356|Experimental|Carbidopa/levodopa/entacapone|
9758996|NCT00642356|Active Comparator|Immediate release carbidopa/levodopa|
9758997|NCT00642369|Experimental|quetiapine fumarate|quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.
9758998|NCT00642369|Active Comparator|haloperidol|haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.
9758999|NCT00642460|Experimental|1|
9759000|NCT00642460|Placebo Comparator|2|
9759001|NCT00642473|Experimental|Prevention (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
9759002|NCT00642473|Experimental|Treatment (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
9759003|NCT00642616|Experimental|Technosphere® Insulin (Asthma)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
9759004|NCT00642616|Active Comparator|Usual Care (Asthma)|Usual anti diabetic care in Diabetic participants with Asthma
9759005|NCT00642616|Experimental|Technosphere® Insulin (COPD)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
9759006|NCT00642616|Active Comparator|Usual Care (COPD)|Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
9759007|NCT00642642|Experimental|Double blinded active|Subject will receive autologous fibroblast treatment on either their left or right side of their face
9759008|NCT00642642|Placebo Comparator|Double blinded placebo|Subject will receive placebo treatment on the opposite side of the face from active treatment
9759009|NCT00642668|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
9759010|NCT00642694|Experimental|1|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)
9759011|NCT00642694|Placebo Comparator|2|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)
9759012|NCT00642707|Active Comparator|Arm 1|PRO 140 for three single SC doses: Days 1, 8, and 15
9759013|NCT00642707|Active Comparator|Arm 2|PRO 140 for three single SC doses: Days 1, 8 and 15
9759014|NCT00642707|Active Comparator|Arm 3|PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
9759015|NCT00642707|Placebo Comparator|Arm 4|PBO for three single SC doses: Days 1, 8 and 15
9759016|NCT00642746|Experimental|FOLFOX with Erlotinib|Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
9759017|NCT00642746|Experimental|FOLFIRI with Erlotinib|Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
9759018|NCT00642759|Experimental|Chemotherapy|Carboplatin, nab-paclitaxel, and bevacizumab
9759019|NCT00642772|Experimental|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
9759020|NCT00642811|Experimental|1|Aspirin + Ticagrelor
9759021|NCT00642811|Active Comparator|2|Aspirin + Clopidogrel
9759022|NCT00642850|Experimental|1|
9759023|NCT00642902|Experimental|Atacicept 25 mg|
9759024|NCT00642902|Experimental|Atacicept 75 mg|
9759025|NCT00642902|Experimental|Atacicept 150 mg|
9759026|NCT00642902|Placebo Comparator|Placebo|
9759027|NCT00642941|Experimental|Cohort 1: Ewings Sarcoma Primary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
9759028|NCT00642941|Experimental|Cohort 2: Ewings Sarcoma Secondary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
9759029|NCT00642941|Experimental|Cohort 3: Ewings Sarcoma Expanded Cohort|Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
9759030|NCT00642941|Experimental|Cohort 4: Osteosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
9759031|NCT00642941|Experimental|Cohort 5: Synovial Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
9759032|NCT00642941|Experimental|Cohort 6: Rhabdomyosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
9759033|NCT00642941|Experimental|Cohort 7a: Alveolar Soft Part Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
9759034|NCT00642941|Experimental|Cohort 7b: Desmoplastic Small Round Cell Tumors.|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
9759035|NCT00642941|Experimental|Cohort 7c: Extraskeletal Myxoid Chondrosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
9759036|NCT00642941|Experimental|Cohort 7d: Clear Cell Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
9759037|NCT00642941|Experimental|Cohort 7e: Myxoid Liposarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
9759038|NCT00642941|Experimental|Cohort 8: Diagnosis Not Specified|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
9759039|NCT00642954|Experimental|Level 1: Vorinostat 300 mg + lenalidomide 10 mg|Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
9759040|NCT00642954|Experimental|Level 2: Vorinostat 400 mg + lenalidomide 10 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
9759041|NCT00642954|Experimental|Level 3: Vorinostat 400 mg + lenalidomide 15 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
9759042|NCT00642954|Experimental|Level 4: Vorinostat 400 mg + lenalidomide 20 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
9783358|NCT01198600|Other|Phase 2: Lotrafilcon B Replacement|Contact lenses worn for 56 days with replacement pair dispensed at Day 28.
9759043|NCT00642954|Experimental|Level 5: Vorinostat 400 mg + lenalidomide 25 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
9759044|NCT00642993|Experimental|SCH 497079|SCH 497079, administered orally, once daily
9759045|NCT00642993|Placebo Comparator|Placebo|Placebo capsules, administered orally, once daily
9759046|NCT00643006|Experimental|A. High intensive exercise|High intensive exercise
9759047|NCT00643006|Active Comparator|B. Low-intensive exercise|Low-to-moderate intensive supervised walks
9759048|NCT00643097|Experimental|Arm I (ACTIVATE)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, every 2 weeks starting 4 weeks after the completion of radiation. Subsequent vaccinations were given once a month until clinical or radiographic evidence of progression or death.
9759049|NCT00643097|Experimental|Arm II (ACT II STD)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 200 mg/m2 for the first 5 days of a 28 day cycle.
9759050|NCT00643097|Experimental|Arm III (ACT II DI)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 100 mg/m2 for the first 21 days of a 28 day cycle.
9759051|NCT00643123|Experimental|Allopurinol|Subjects will be randomized to allopurinol at a fixed dose of 300 mg/day for the first week and then 600mg/day while continuing their current medications during the 7-week study. A battery of assessments will be administered at baseline and weeks 1, 2, 4, 6 after baseline. At each assessment, subjects will also be asked about side effects including potential side effects of allopurinol. Side effects will be assessed by the Treatment Emergent Side Effects Scale. Serum levels of lithium, valproic acid, carbamazepine, atypical antipsychotics or atypical antipsychotic metabolite, uric acid blood levels will be drawn at screen and at week 6 after baseline. Subjects taking only lithium, valproic acid, and/or carbamazepine will also have their serum levels drawn at week 2.
9759052|NCT00643123|Placebo Comparator|Placebo|Subjects will be randomized to placebo and will follow the same protocol as the allopurinol group.
9759053|NCT00643162|Experimental|Swedish Massage|Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
9759054|NCT00643162|Sham Comparator|Light-Touch|Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
9759055|NCT00643201|Active Comparator|Apixaban|apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
9759056|NCT00643201|Experimental|Enoxaparin + Warfarin|Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
9759057|NCT00643279|Experimental|CHRONICLE|Subjects randomized to the CHRONICLE group were managed using data from an implantable hemodynamic monitoring (IHM) device, including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The Chronicle IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
9759058|NCT00643279|Placebo Comparator|CONTROL|Subjects randomized to the CONTROL group implanted with the Chronicle implantable hemodynamic monitoring (IHM) device, but the intracardiac diagnostic information was blinded to both the patient and the physician during the randomized period of the study. Subjects were managed conventionally with standard of care. Physicians and patients have access to the intracardiac data after the randomized period of the study is over, at 6 months.
9759059|NCT00643448|Experimental|AZD1305 loading dose 250 mg + 125 mg|Tablets
9759060|NCT00643448|Experimental|AZD1305 loading dose 500 mg + placebo|Tablets
9759061|NCT00643448|Placebo Comparator|Placebo corresponding to AZD1305 loading dose|Tablets
9759062|NCT00643487||1|observation of the behavior of the infrapatellar plica
9783359|NCT01198600|Other|Phase 3: Lotrafilcon B Replacement Replacement|Contact lenses worn for 43 days with replacement pair dispensed at Day 1 and Day 28.
9783360|NCT01198691|Placebo Comparator|Control Group|This group will receive the standard metallic staples to close their incision.
9783361|NCT01198691|Experimental|Case Group|This group will receive the Insorb absorbable staples to close their incision.
9783362|NCT01198756|Experimental|GSK2282512A 1 Group|Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9759063|NCT00643565|Experimental|Bevacizumab + Chemotherapy|Participants received continuous IV infusion of bevacizumab (7.5 mg/kg every 3 weeks) on Day 1 of 3-week cycles followed by induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy) as per institutional practice for a total of 9 cycles during induction treatment phase. As per the investigator decision, local therapy (radiotherapy and /or surgery) was expected to start after 4 weeks of the last bevacizumab administration in the induction phase and resumed to bevacizumab in the maintenance phase at least 4 weeks after the last dose of local therapy. During maintenance treatment phase, participants received IV infusion of bevacizumab (5 mg/kg every 2 weeks) followed by vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Days 1 and 15 of 4-week cycles for a total of 12 cycles.
9759064|NCT00643565|Active Comparator|Chemotherapy|Participants received 9 cycles of induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy administered every 3 weeks as per institutional practice. As per the investigator evaluation, participants had option to undergo local therapy (radiotherapy and /or surgery) during last 3 cycles of IVA (i.e. from Cycle 6 to Cycle 9). During maintenance treatment phase, participants received vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Day 1 and 15 of 4-week cycles for a total of 12 cycles.
9759065|NCT00643578|Active Comparator|2|a single dose of 24 mcg of formoterol
9759066|NCT00643578|Active Comparator|1|a single dose of 12 mcg of formoterol
9759067|NCT00643604|Experimental|treprostinil sodium|all subjects had switched from IV epoprostenol to IV treprostinil sodium
9759068|NCT00643682|Experimental|A|Patients in this arm will be given an educational card in addition to the standard pre-endoscopy instructions.
9759069|NCT00643682|No Intervention|B|Patients in this arm will be given the standard pre-endoscopy instructions.
9759070|NCT00643760|Placebo Comparator|Placebo|Placebo
9759071|NCT00643760|Other|Pregabalin|Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks
9759072|NCT00643760|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
9759073|NCT00643760|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
9759074|NCT00643760|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks
9759075|NCT00643851|Experimental|Arm 1|Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
9759076|NCT00643851|Experimental|Arm 2|Dapagliflozin (5 mg)
9759077|NCT00643851|Active Comparator|Arm 3|Metformin XR (500 mg up to 2000 mg)
9759078|NCT00643916|Experimental|Vaccinated at Age 9 and 12 Months|Participants received Menactra® vaccine at 9 and 12 Months of age
9759079|NCT00643916|Experimental|Vaccinated at Age 9 and 15 Months|Participants received Menactra® vaccine at 9 and 15 Months of age
9759080|NCT00643916|Experimental|Vaccinated at Age 12 and 15 Months|Participants received Menactra® vaccine at Age 12 and 12 Months of age
9759081|NCT00643916|Experimental|Vaccinated at Age 15 Months|Participants received Menactra® vaccine at 15 Months of age
9759082|NCT00643916|Experimental|Vaccinated at Age 18 Months|Participants received Menactra® vaccine at 18 Months of age
9759083|NCT00643916|Active Comparator|Vaccinated at Age 3 Years to <6 Years|Participants received Menomune® vaccine at Age 3 years to <6 years of age
9759084|NCT00644059|Experimental|TIV-adj|Adjuvanted trivalent inactivated subunit influenza vaccine
9759085|NCT00644059|Active Comparator|Flu-control|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
9759086|NCT00644059|Sham Comparator|Non-flu Control|Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
9759087|NCT00644189|Other|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
9759088|NCT00644280|Active Comparator|Ranibizumab|Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
9759089|NCT00644280|No Intervention|Usual care|Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab
9759090|NCT00644358|Experimental|Vilazodone|Vilazodone titrated up to 40 mg/day for 1 year.
9759091|NCT00644423|Active Comparator|1|Omega-3 Fatty Acid
9759092|NCT00644423|Placebo Comparator|2|Placebo
9759093|NCT00644592|Active Comparator|1-Fenofibrate then Placebo|4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
9759094|NCT00644592|Active Comparator|2 Placebo then Fenofibrate|4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.
9759095|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
9759096|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
9759097|NCT00644787|Active Comparator|Fentanyl 3-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
9759098|NCT00644878|Experimental|Nilotinib|
9759099|NCT00644917|Experimental|A|Drug
9759100|NCT00644917|Placebo Comparator|B|Placebo comparator
9759101|NCT00644917|No Intervention|C|Subjects serve as own controls.
9759102|NCT00644969|Placebo Comparator|Placebo Arm|Randomization 2:1 treatment to placebo
9759103|NCT00644969|Active Comparator|Treatment Arm|
9759104|NCT00644995|Active Comparator|Usual Care Control|Participants will receive usual care which includes advice to stop smoking and referral to standard care treatment available through participants' health insurance and health plan.
9759105|NCT00644995|Experimental|Step Up Intervention|Participants will receive the Step Up Wellness Program. The intervention is detailed below.
9759106|NCT00645047|Experimental|Telemedicine CBT|Cognitive behaviour therapy (CBT) delivered using videoconference telemedicine.
9759107|NCT00645047|Active Comparator|In-Person CBT|Cognitive behaviour therapy (CBT) delivered using in-person consultation.
9759108|NCT00645099|Experimental|001|paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
9759109|NCT00645099|Active Comparator|002|olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
9759110|NCT00645164|Experimental|Xenaderm|Subject serves as own control
9759111|NCT00645333|Experimental|MK-0752, Docetaxel, Pegfilgrastim|MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752
9984140|NCT04380831|Experimental|Treatment (TBI using IMRT, cyclophosphamide, HSCT)|Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.
9759112|NCT00645411|Experimental|Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV|All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
9759113|NCT00645411|Active Comparator|Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV|All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.
9759114|NCT00645411|Experimental|Cohort 3 (3-8 Yrs) cTIV|All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
9759115|NCT00645411|Active Comparator|Cohort 3 (3-8 Yrs) eTIV|All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
9759116|NCT00645450|Experimental|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
9759117|NCT00645450|Placebo Comparator|Placebo|Weekly doses of placebo following recollection of traumatic memory
9783363|NCT01198756|Active Comparator|Victoria strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9783364|NCT01198756|Active Comparator|Yamagata strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9783365|NCT01198756|Experimental|GSK2282512A 2 Group|Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants <12 months of age.
9783366|NCT01198769|Experimental|Rotarix Group|subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
9783367|NCT01198795|Experimental|1|Flexible-dose 10mg-20mg once-daily oral (10mg tablets) dose of escitalopram
9783368|NCT01198873|Experimental|Dronedarone|Dronedarone 400 mg twice a day
9783369|NCT01198873|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day
9783370|NCT01198977|Active Comparator|Brief telephone-based counseling|Telephone based counseling and instructional video
9783371|NCT01198977|Placebo Comparator|Education Counseling|Mailed Physical Activity information and instructional video only
9783372|NCT01199016||1|
9783373|NCT01199042|Other|BiPAP autoSV Advanced Device|Positive airway pressure device
9783374|NCT01199055|Experimental|CS-7017+Carboplatin/Paclitaxel|"Drug: CS-7017 from 0.25 mg twice a day (BID) to 0.50 mg BID for up to 4~6 cycles (1 cycle: 3 weeks)~Drug: Carboplatin IV, Area under the curve (AUC) of 6 mg/mL*min, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)~Drug: Paclitaxel IV, 200mg/m^2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)"
9783375|NCT01199068|Experimental|CS-7017+Erlotinib|Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily
9783376|NCT01199146|Experimental|Abiraterone acetate|
9783377|NCT01199198|Experimental|Tolvaptan Group|Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.
9783378|NCT01199198|Placebo Comparator|Placebo Group|Placebo Group: Placebo by mouth once a day for 14 days.
9783379|NCT01199237|Active Comparator|Sevoflurane|Patients receive sevoflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
9783380|NCT01199237|Active Comparator|Desflurane|Patients receive Desflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
9783381|NCT01199263|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
9984141|NCT04368299|Experimental|Telemedicine|Telemedicine group will receive scheduled follow-ups via videoconferencing.
9832228|NCT02603809|Experimental|Aprocitentan 50 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
9832229|NCT02603809|Active Comparator|Lisinopril 20 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
9984142|NCT04368299|Active Comparator|Standard care|Standard care group patients will continue conventional standard in-person outpatient care.
9832230|NCT02603926|Experimental|Allopregnanolone|Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
9832231|NCT02603952|Placebo Comparator|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
9832232|NCT02603952|Experimental|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
9984143|NCT04368091||All-comers, real-world registry|Subjects requiring infrainguinal revascularization with the Xtreme Touch - Neo (Magic Touch PTA)
9984144|NCT04367883||CST Hospital Incomes|"Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.~No intervention is performed."
9759118|NCT00645528|Experimental|Insulin Education Class Participants|Participation in an insulin educational class at week 0 and again at week 2
9759119|NCT00645593|Active Comparator|Arm 1, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin, as described in the intervention
9759120|NCT00645593|Experimental|Arm 2, Cetuximab, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin with Cetuximab, as described in the intervention
9759121|NCT00645671|Experimental|Loteprednol Etabonate|Loteprednol etabonate 0.5% ophthalmic ointment
9759122|NCT00645671|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ointment
9759123|NCT00645710|Experimental|Arm I|"Patients receive floxuridine as a continuous hepatic arterial infusion on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 9 and 11. Patients also receive yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV over 25 minutes on day 9. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive an additional course of floxuridine in combination with systemic therapy at the discretion of the treating physician."
9759124|NCT00645762|Active Comparator|Balloon Dilation|Balloon dilation with FinESS device
9759125|NCT00645788|Experimental|32.50 mg Ciprofloxacin DPI (BAYQ3939)|32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
9759126|NCT00645788|Experimental|48.75 mg Ciprofloxacin DPI (BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
9759127|NCT00645788|Placebo Comparator|Matching Placebo for 32.50 mg|Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days
9759128|NCT00645788|Placebo Comparator|Matching Placebo for 48.75 mg|Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days
9759129|NCT00645827|Experimental|Insulin infusion conversion equation|Insulin infusion conversion equation is used to determine subcutaneous insulin dosing for first 24 hours after cessation of an IV insulin infusion.
9759130|NCT00645827|Active Comparator|Control|Judgment of patient's healthcare provider is used to determine subcutaneous insulin dosing for first 24 hours after cessation of IV insulin infusion.
9759131|NCT00645840|Experimental|Anakinra|After study enrollment, all subjects started anakinra (Kineret™; Amgen, Thousand Oaks, CA, USA) as a subcutaneous daily injection. Subjects weighing >25 kg at the time of enrollment received 100 mg daily, whereas those weighing <25 kg received 50 mg daily. Anakinra was continued for 28 d with no dose adjustment.
9759132|NCT00645853|Experimental|1|
9759133|NCT00645853|Active Comparator|2|
9759134|NCT00645944|Experimental|Eszopiclone Group|Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
9759135|NCT00645944|Placebo Comparator|Placebo Group|"Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study."
9759136|NCT00645970||Group 1|
9759137|NCT00646048|Experimental|Arm 1|This arm is for patient that receive the TriVascular Stent-Graft System.
9759138|NCT00646113|Experimental|OsseoSpeed™ TX 3.0S (Dental implant)|OsseoSpeed™ TX 3.0S, Dental implants, 3.0 mm diameter, in lengths of 11, 13 and 15 mm
9759139|NCT00646399|Placebo Comparator|Placebo|Phosphate Buffered Saline
9759140|NCT00646399|Experimental|Pagibaximab 50 mg/mL|Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.
9759141|NCT00646451|Active Comparator|Pregabalin (Lyrica)|Pregabalin (Lyrica) 75 mg bid to a maximum dose of 300 mg bid
9759142|NCT00646451|Placebo Comparator|Placebo|Placebo to 4 capsules bid
9759143|NCT00646581|Placebo Comparator|Placebo (1)|Subjects are given a one-time, single dose of placebo intranasal spray
9759144|NCT00646581|Experimental|Single-Dose Intranasal Insulin|Subjects are given a one-time, single dose of intranasal insulin
9759145|NCT00646646|Active Comparator|propofol|active drug
9759146|NCT00646646|Active Comparator|dexmedetomidine|sedative
9759147|NCT00646646|Active Comparator|midazolam|Sedative
9759148|NCT00646646|Placebo Comparator|placebo|placebo control
9759149|NCT00646763|Active Comparator|Abdomen|These subjects will have their cytokine injections administered only to their abdomen.
9759150|NCT00646763|Active Comparator|Extremities|The extremity arm will have their injections administered to their upper and/or lower extremities.
9759151|NCT00646776|Active Comparator|A|
9759152|NCT00646776|Active Comparator|B|
9759153|NCT00646906|Experimental|Phase 1a: Acetaminophen 1000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
9759154|NCT00646906|Experimental|Phase 1a: Acetaminophen 2000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover Period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
9759155|NCT00646906|Experimental|Phase 1b: Acetaminophen 1000 mg alone|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM (see Acetaminophen 1000 mg/d intervention). Study assessments will be performed on day 1 and on day 6. This is not a crossover design. Just one treatment period."
9759156|NCT00646906|Experimental|Phase 2: Acetaminophen vs. Ibuprofen|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. In one period of this crossover study acetaminophen (1000 mg p.o.) will be administered orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Acetaminophen 4000 mg/d intervention). The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Ibuprofen 800 mg/d intervention). The last dose will be administered on day four at 8 AM Study assessments will be performed on day 1 and day 4 of each crossover period. The occurrence of the two crossover periods will be randomized by order."
9759157|NCT00646958|Experimental|1|Radezolid 450 mg PO QD
9759158|NCT00646958|Experimental|2|Radezolid 450 mg PO BID
9759159|NCT00646958|Active Comparator|3|Linezolid 600 mg PO BID
9759160|NCT00647270|Placebo Comparator|Placebo|Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
9759161|NCT00647270|Active Comparator|40 mg|40 mg every other week
9759162|NCT00647270|Active Comparator|80 mg|80 mg monthly
9759163|NCT00647296|Placebo Comparator|Part 1: Placebo or Dexpramipexole|During Part 1, subjects received twice daily doses of dexpramipexole (50 mg/day, 150 mg/day, or 300 mg/day) or matching placebo for approximately 12 weeks.
9759164|NCT00647296|Experimental|Part 2: Placebo washout|At the beginning of Part 2, subjects received twice daily doses of placebo for approximately 4 weeks.
9759165|NCT00647296|Experimental|Part 2: Dexpramipexole|Following the Part 2 placebo washout, subjects received dexpramipexole (50 mg/day or 300 mg/day), subjects received twice daily doses of placebo for up to 18 months.
9759166|NCT00647348|Active Comparator|1|Simvastatin 80mg OD
9759167|NCT00647348|Placebo Comparator|2|Placebo
9759168|NCT00647400|Experimental|Adalimumab 40 mg every other week|
9759169|NCT00647400|Experimental|Adalimumab 80 mg every other week|
9759170|NCT00647556|Active Comparator|adapalene|adapalene
9759171|NCT00647556|Active Comparator|tretinoin|Tretinoin
9759172|NCT00647699|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
9759173|NCT00647699|Sham Comparator|Control Group|riboflavin ophthalmic solution without UVA irradiation.
9759174|NCT00647998|Experimental|Darbepoetin|Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
9759175|NCT00647998|Placebo Comparator|Standard care|No Darbepoetin
9783382|NCT01199263|Experimental|Arm II (paclitaxel and wild-type reovirus)|Patients receive paclitaxel as in arm I and wild-type reovirus IV over 1 hour on days 1-5.
9759176|NCT00648037|Experimental|Rituximab|Patients following a T cell depleted HLA-mis-matched related or unrelated hematopoietic stem cell transplant (HSCT) will be treated with monthly Rituximab.
9759177|NCT00648115|Other|Basic Vocational Services|Veteran receives basic vocational services
9759178|NCT00648115|Active Comparator|Self-Study|Veteran participates in self-study vocational program
9759179|NCT00648115|Active Comparator|Group program|Group based vocational program
9759180|NCT00648167|Experimental|KRX-0502 (ferric citrate)|All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
9759181|NCT00648375|Experimental|Propranolol|Participants will take propranolol for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
9759182|NCT00648375|Placebo Comparator|Placebo|Participants will take placebo for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
9759183|NCT00648648|Experimental|MK-1775 325 mg Single Dose|Participants received MK-1775 325 mg, orally, on Day 1.
9759184|NCT00648648|Experimental|MK-1775 650 mg Single Dose|Participants received MK-1775 650 mg, orally, on Day 1.
9759185|NCT00648648|Experimental|MK-1775 1300 mg Single Dose|Participants received MK-1775 1300 mg, orally, on Day 1.
9759186|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an intravenous (IV) infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 100 mg single dose, orally, on Day 2 of each cycle.
9759187|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 200 mg single dose, orally, on Day 2 of each cycle.
9759188|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
9759189|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
9759190|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5) as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
9759191|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
9759192|NCT00648648|Experimental|MK-1775 325 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg single dose orally, on Day 2 of each cycle.
9759193|NCT00648648|Experimental|MK-1775 25 mg BID x2.5 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4-week cycle plus MK-1775 25 mg orally twice daily (BID) for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each cycle.
9759194|NCT00648648|Experimental|MK-1775 50/25 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
9759195|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given once weekly for 3 consecutive weeks of a 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 50 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
9759196|NCT00648648|Experimental|MK-1775 100 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 100 mg orally once daily (QD) on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
9759197|NCT00648648|Experimental|MK-1775 125 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 125 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
9759198|NCT00648648|Experimental|MK-1775 150 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 150 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
9759199|NCT00648648|Experimental|MK-1775 175 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
9759200|NCT00648648|Experimental|MK-1775 200 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 200 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
9835934|NCT02761980|Active Comparator|Acetaminophen 500 mg|Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
9832233|NCT02603952|Experimental|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
9832234|NCT02603952|Experimental|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
9518048|NCT03300375|Active Comparator|Home-Based Resistance Exercise Intervention Group|Participants in the HBRX group will be coached through six phases of the intervention with two weeks per phase. Exercise will use body weight and resistance exercise bands. A set of commercial elastic resistive bands and a stability pad (TheraBand, Inc.) will be provided to each participant to keep for personal use after their participation in the study. The use of elastic bands for resistance training can induce similar results in neuromuscular adaptations as well as strength to those achieved by weight machines and free-weights.
9832235|NCT02604017|Experimental|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
9832236|NCT02604017|Experimental|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
9783383|NCT01199289|Placebo Comparator|Placebo|Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
9783384|NCT01199289|Experimental|AMG 827 140 mg|Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
9783385|NCT01199289|Experimental|AMG 827 210 mg|Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
9783386|NCT01199289|Experimental|AMG 827 280 mg|Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
9783387|NCT01199380|Active Comparator|Standard Treatment (ST)|Participants will receive a standard, group smoking cessation treatment equated for contact time, based on the most recent clinical practice guideline for treating tobacco. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will complete between group exercises and will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events. Participants will also receive 8 weeks of the transdermal nicotine patch.
10202582|NCT04493658||Non-Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and no diagnosis of Sjogren's syndrome based on 2016 revised criteria.
10202583|NCT04493658||Control|Normal individuals with no previous diagnosis of dry eye or Sjogren's syndrome
10202584|NCT04487782||High SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be African-American/Black.
10202585|NCT04487782||High SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be Caucasian/White.
10202586|NCT04487782||Low SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be African-American/Black.
9759201|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759202|NCT00648648|Experimental|MK-1775 100 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759203|NCT00648648|Experimental|MK-1775 125 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 125 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759204|NCT00648648|Experimental|MK-1775 150 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759205|NCT00648648|Experimental|MK-1775 200 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759206|NCT00648648|Experimental|MK-1775 250 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 250 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759207|NCT00648648|Experimental|MK-1775 75 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 75 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759208|NCT00648648|Experimental|MK-1775 150 mg BID x 2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759209|NCT00648648|Experimental|MK-1775 225 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 225 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759210|NCT00648648|Experimental|MK-1775 325 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
9759211|NCT00648739|Experimental|Samalizumab|All doses of samalizumab were individualized based on the participant's body surface area in mg/m^2 based on screening height and weight. Participants were assigned to a dose cohort, ranging from 50 to 600 mg/m^2, and received a single IV dose of samalizumab. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose. If no participants enrolled into a cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. If any 1 of the initial 3 participants in the cohort experienced a DLT, the cohort was expanded to at least 6 participants. Then, if less than one third of participants within the cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. Dose cohorts were enrolled sequentially.
9759212|NCT00649220|Experimental|Memantine|
9759213|NCT00649389|Experimental|OM40/AML10|olmesartan medoxomil 40mg and amlodipine 10mg
9759214|NCT00649389|Active Comparator|OM40/HCTZ25|olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
9759215|NCT00649389|Active Comparator|AML10/HCTZ25|amlodipine 10mg and hydrochlorothiazide 25mg
9759216|NCT00649389|Active Comparator|OM40/AML10/HCTZ25|olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg
9759217|NCT00649428|Experimental|Active|
9759218|NCT00649428|Placebo Comparator|Control|
9759219|NCT00649961|Experimental|Melatonin Open Label Single Arm|Infants born less than 31 weeks gestation who are less than 7 days old
9759220|NCT00650078|Experimental|NP01|Modified Release (MR) prednisone 5 mg
9759221|NCT00650078|Placebo Comparator|Placebo|
9759222|NCT00650091|Active Comparator|1|Participants will receive N-acetylcysteine (NAC) for 60 weeks.
9759223|NCT00650091|Placebo Comparator|2|Participants will receive placebo for 60 weeks.
9759224|NCT00650104|Active Comparator|Active|Open label medication - Ropinirole CR
9759225|NCT00650260|Experimental|vH2 System Group|The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
9759226|NCT00650260|Active Comparator|Control Group|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
9759227|NCT00650546|Experimental|A pre treatment NAS score|liver biopsy score pre treatment with exenatide 5 micrograms SQ (sub-cutaneous) twice a day titrated to 10 mcg SQ twice a day as tolerated
9759228|NCT00650585|No Intervention|Control group|Did not receive Project ALERT
9759229|NCT00650585|Experimental|Treatment group|Received Project ALERT
9759230|NCT00650767|Experimental|ARRY-438162 (Schedule 1)|
9759231|NCT00650767|Experimental|ARRY-438162 (Schedule 2)|
9759232|NCT00650767|Experimental|ARRY-438162 (Schedule 3)|
9759233|NCT00650767|Placebo Comparator|Placebo|
9759234|NCT00650806|Experimental|Canagliflozin 50 mg|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
9759235|NCT00650806|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
9832237|NCT02604160|Experimental|LY3113593|Escalating doses of LY3113593 administered by intravenous (IV) infusion once every 4 weeks (Q4W) on (Day 1 and 29) in part A.
9832238|NCT02604160|Placebo Comparator|Placebo|0.9% saline, administered by intravenous (IV) infusion once Q4W (Day 1 and 29) in part A.
9832239|NCT02604173|Experimental|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
9665806|NCT04892446|Experimental|Dose Expansion Cohort (Magrolimab+Carfilzomib+Dexamethasone)|Participants with relapsed/refractory multiple myeloma who have had 3 or more prior therapies including an IMiD and a PI will receive magrolimab at the RP2D determined in the Safety Run-in Cohort and carfilzomib 4 mg on Days 1 to 21 (daily) of Cycle 1, Days 1 to 21 (daily) of Cycle 2 and onward and dexamethasone 40 mg on Days 1, 8, 15, 22, 29 of Cycle 1, Days 1, 8, 15, 22 of Cycle 2 and onward. (Cycle 1=35 days, All other Cycles=28 days).
9832240|NCT02604173|Active Comparator|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
9832241|NCT02604173|Sham Comparator|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
9832242|NCT02604199|Placebo Comparator|PBO Low Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
9832243|NCT02604199|Placebo Comparator|PBO High Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
9832244|NCT02604199|Experimental|ARC-520 Injection 1 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
9832245|NCT02604199|Experimental|ARC-520 Injection 2 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
9832246|NCT02604212|Placebo Comparator|Placebo Low Dose Comparator|Placebo (low dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
9832247|NCT02604212|Placebo Comparator|Placebo High Dose Comparator|Placebo (high dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
9832248|NCT02604212|Experimental|ARC-520 1.0 mg/kg|Low dose (1.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
10202587|NCT04487782||Low SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be Caucasian/White.
10202588|NCT04485286|Experimental|Lung Cancer or Pancreatic Cancer Subjects Undergoing Radiation Therapy|Lung cancer or pancreatic cancer patients will receive [68Ga]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy
10202589|NCT04480658|Experimental|Bryophyllum pinnatum|Bryophyllum pinnatum (BP) muscle relaxing substance
10202590|NCT04476953|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
10202591|NCT04476953|Placebo Comparator|Placebo Group|Subjects will receive placebo
10202592|NCT04476108|Experimental|LY3016859|LY3016859 administered intravenously (IV).
10202593|NCT04476108|Placebo Comparator|Placebo|Placebo administered IV.
10202594|NCT04461015|Other|0.4mU Insulin|During the euglycemic clamp insulin will be infused at 0.4mU/Kg/Min
10202595|NCT04461015|Other|0.8mU Insulin|During the euglycemic clamp insulin will be infused at 0.8mU/Kg/Min
10202596|NCT04457297|Experimental|trifluridine and tipiracil|
10202597|NCT04457297|Placebo Comparator|Placebo|
10202598|NCT04454255|Experimental|Primo-FunSpeech|Participants will begin the study by a period using FunSpeech (45 days) followed by a control period without the game (45 days). This sequence will be repeated once.
10202599|NCT04454255|Experimental|Primo-control|Participants will begin the study by a control period without the game (45 days) followed by a period using FunSpeech (45 days). This sequence will be repeated once.
10202600|NCT04442945|Experimental|ANAVEX3-71 Oral|Up to four single ascending doses of ANAVEX3-71 administered orally
10202601|NCT04442945|Placebo Comparator|Placebo arm Oral|Placebo administered orally
10202602|NCT04441073|Experimental|Lignocaine|preoperative nebulization of lignocaine
10202603|NCT04441073|Placebo Comparator|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
10202604|NCT04439734|Experimental|Whole-Body Electromyostimulation|WB-EMS once per week for for 16 week (85 Hz, 350 µs, bipolar, duty cycle 4s-4s)
10202605|NCT04439734|No Intervention|Non WB-EMS control|No WB intervention, but maintained physical activity and habitual exercise habits
10202606|NCT04437732|Other|Apioc Lens|All subjects will wear either the Apioc-P or Apioc-PT contact lens design
10202607|NCT04436289|No Intervention|Care-as-usual (CAU) study arm|Participants will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
10202608|NCT04436289|Experimental|Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take <30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
10202609|NCT04424212|Experimental|Experimental: Intervention group CoronaCope|ICBT, were participants receive 8 out of 15 possible modules depending on their current problems and needs, 7 week long internet intervention for reducing mental health issues related to the coronavirus pandemic.
10202610|NCT04424212|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
10202611|NCT04421950|Active Comparator|Wild Blueberry Supplement|30 grams of wild blueberry powder per day in foods items provided to them
9759236|NCT00650806|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
9759237|NCT00650806|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 12 weeks.
9759238|NCT00650845|Experimental|Dotarem®-enhanced MRI|Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes
9759239|NCT00650845|Other|Non-enhanced MRI|Patients undergoing non-enhanced MRI for diagnostic purposes
9759240|NCT00650858|Active Comparator|0.3 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
9759241|NCT00650858|Active Comparator|1.0 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
9759242|NCT00650858|Experimental|1.0 mg Rt-PA q8h|In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
9759243|NCT00650936|Other|AMPLATZER Septal Occluder|Subjects were enrolled if the implant of the AMPLATZER Septal Occluder device was completed or was attempted (delivery system entered the subject's body).
9759244|NCT00651040|Active Comparator|Prednison|"Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.~ARM 1 has only Prednisone"
9759245|NCT00651040|Active Comparator|Prednison + methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
9759246|NCT00651118|Active Comparator|fluticasone propionate|
9759247|NCT00651118|Experimental|azelastineHcl/fluticasone propionate|
9759248|NCT00651118|Placebo Comparator|Placebo|
9759249|NCT00651118|Active Comparator|azelastine Hcl|
9759250|NCT00651157|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus (Reolysin®) IV administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9759251|NCT00651261|Experimental|Induction and consolidation chemotherapy plus midostaurin|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
9759252|NCT00651261|Active Comparator|Induction and consolidation chemotherapy plus placebo|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
9759253|NCT00651313|Active Comparator|Active|Lidocaine 10% (150mg) vaginal gel
9759254|NCT00651313|Placebo Comparator|Placebo|Placebo vaginal gel
9759255|NCT00651482|Experimental|Bevacizumab + RAD001 (everolimus)|"Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles~Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)~Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)"
9665834|NCT04871113|Experimental|Part 2: Participants receiving GSK3810109A (Cohort 5)|Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1.
9665835|NCT04869319||MyChart message|MyChart message subjects with high A1C blood tests to help manage their diabetes and prevent some of the complications caused by high sugars. The message recommends that they schedule a visit with their doctor who can recheck the blood test and help get their diabetes under control.
9665836|NCT04869319||No MyChart message|No message
9665837|NCT04868006|Experimental|End-range mobilization + proprioception training|End-range Maitland mobilization performed in end-range internal rotation of the shoulder accompanied with 8--week long proprioception training
9665838|NCT04868006|Active Comparator|Non end-range mobilization+ proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
9665839|NCT04868006|Sham Comparator|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
9832249|NCT02604212|Experimental|ARC-520 2.0 mg/kg|High dose (2.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
9832250|NCT02604264|Active Comparator|ClearGuard HD end cap|Treatment
9759256|NCT00651573|Active Comparator|Blood transfusion triggers of 24% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 24%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 24%, no further transfusions will be administered.
9759257|NCT00651573|Active Comparator|Blood transfusion triggers of 28% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 28%, no further transfusions will be administered.
9759258|NCT00651625|Experimental|1|The intervention is the use of the reciprocating procedure device (RPD) (AVANCA Re No. 1091001) (intervention) (Arm 1) with and without ultrasound guidance (intervention) in a syringe and needle procedure in comparison to a conventional syringe (BD Ref 309604) (control, Arm 2).
9759259|NCT00651625|Active Comparator|2|The conventional syringe (BD Ref 309604) is used to performed the syringe and needle procedure and outcome (effect of procedure (pain scores at 2 weeks and 6 months compared to preprocedural pain scores), and procedural pain (pain scores during procedure) are determined) and compared to Arm 1.
9759260|NCT00651664|Experimental|Alisertib 5 mg QD 7D|Alisertib 5 mg, capsules, orally, once daily (QD) for 7 days (D) followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles).
9759261|NCT00651664|Experimental|Alisertib 80 mg QD 7D|Alisertib 80 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 4 cycles).
9759262|NCT00651664|Experimental|Alisertib 150 mg QD 7D|Alisertib 150 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
9759263|NCT00651664|Experimental|Alisertib 50 mg BID 7D|Alisertib 50 mg, capsules, orally, twice daily (BID) for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 29 cycles).
9759264|NCT00651664|Experimental|Alisertib 60 mg BID 7D|Alisertib 60 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
9759265|NCT00651664|Experimental|Alisertib 75 mg BID 7D|Alisertib 75 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 8 cycles).
9759266|NCT00651664|Experimental|Alisertib 100 mg BID 7D|Alisertib 100 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 21 cycles).
9759267|NCT00651664|Experimental|Alisertib 50 mg QD 14D|Alisertib 50 mg, capsules, orally, QD for 14 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 25 cycles).
9759268|NCT00651664|Experimental|Alisertib 50 mg QD 21D|Alisertib 50 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 10 cycles).
9759269|NCT00651664|Experimental|Alisertib 70 mg QD 21D|Alisertib 70 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
9759270|NCT00651755|Experimental|Aprepitant + CHOP/R-CHOP|Aprepitant 125 mg oral (PO) Day 1 of Cycle 1 followed by 80 mg PO Daily Days 2-3 with CHOP (steroid in CHOP) or R-CHOP plus Rituximab 375 mg/m^2 intravenous Day 1. CHOP or R-CHOP chemotherapy: (1) bolus or 48-hour infusion CHOP [cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given bolus or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days]; or (2) Bolus or 48-hour infusion R-CHOP [Rituximab 375 mg/m^2 on Day 1 + CHOP as above]. [For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician]
9759271|NCT00651755|Experimental|Standard of Care (Control) + CHOP/R-CHOP|Anti-emetics, Ondansetron 8 mg daily for 2 days, plus steroids in CHOP or R-CHOP regimen.
9759272|NCT00651794|Active Comparator|Control (NRP Curriculum with LFT and no team training)|Standard Neonatal Resuscitation Program (NRP) curriculum with no team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
9759273|NCT00651794|Experimental|NRP with LFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
9759274|NCT00651794|Experimental|NRP with HFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitations using high-fidelity simulators for high-fidelity training (HFT)
9759275|NCT00651820|Experimental|Collagenase Santyl Rate of Wound Closure|Dermatome-induced skin wounds treated with drug active (collagenase).
9759276|NCT00651820|Placebo Comparator|Vehicle Rate of Wound Closure|Dermatome-induced skin wounds treated with Vehicle alone.
9759277|NCT00651924|No Intervention|Phase 1|Review the materials and provide feedback regarding how understandable, engaging, and informative the materials are
9759278|NCT00651924|Experimental|Phase 2|Piloting the 'IVR-based Cognitive-behavior therapy' using the new materials
9759279|NCT00651937|Active Comparator|Standard Dose|Melphalan + Stem Cell Infusion (Standard Dose): Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 cluster of differentiation 34 (CD34)/kg on Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
9832251|NCT02604264|No Intervention|Standard hemodialysis end cap|Control
9832252|NCT02604342|Experimental|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
9759280|NCT00651937|Active Comparator|High Dose|Melphalan + Stem Cell Infusion (High Dose): High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
9759281|NCT00652028|Other|Group 1|Dose level 1
9759282|NCT00652028|Other|Group 2|Dose level 2
9759283|NCT00652028|Other|Group 3|Dose level 3
9759284|NCT00652028|Other|Group 4|Dose level 4
9759285|NCT00652080|Experimental|1|Active Cream 3%; AM & PM
9759286|NCT00652093|Experimental|Opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
9759287|NCT00652093|Experimental|Opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
9759288|NCT00652093|Experimental|Placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
9759289|NCT00652093|Experimental|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
9759290|NCT00652093|Experimental|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
9759291|NCT00652093|Experimental|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
9759292|NCT00652145|Experimental|Increase mesalamine dose by 2.4g/day|Increase dose of mesalamine by 2.4 gm per day
9759293|NCT00652145|No Intervention|Maintain mesalmine dose|Maintain current mesalamine dose at 2.4 g/day
9759294|NCT00652314|Experimental|1 - Thrombi-gel treatment|Thrombi-gel treatment
9759295|NCT00652314|Active Comparator|2 - Gelatin Sponge (Gelfoam)|Gelatin Sponge (Gelfoam) plus thrombin
9759296|NCT00652340|Experimental|A|
9759297|NCT00652340|Placebo Comparator|B|
9759298|NCT00652366|Active Comparator|Gemcitabine, Erlotinib Standard Dose|Participants received erlotinib, 100 milligrams (mg), orally (PO), once daily until disease progression or unacceptable toxicity. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
9759299|NCT00652366|Experimental|Gemcitabine, Erlotinib Escalating Dose|Participants received erlotinib, beginning at 150 mg/day, PO, once daily, and increasing in increments of 50 mg every 2 weeks up to a maximum of 250 mg/day, until development of a grade 2 rash, or occurrence of other, non-rash, dose-limiting toxicity; treatment was continued until disease progression, unacceptable toxicity, death or withdrawal. Participants also received gemcitabine, 1000 mg/m^2, IV, on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
9759300|NCT00652626|Experimental|Azacitidine 25 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
9759301|NCT00652626|Experimental|Azacitidine 50 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
9759302|NCT00652626|Experimental|Azacitidine 75 mg/m^2|Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
9759303|NCT00652626|Experimental|Azacitidine 100 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
9835935|NCT02761980|Placebo Comparator|Placebo|Single dose of 2 caplets of Placebo by mouth
9832253|NCT02604342|Active Comparator|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
9832254|NCT02604407|Experimental|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
9832255|NCT02604407|Experimental|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
9832256|NCT02604407|Placebo Comparator|Placebo|Subjects will receive matching placebo
10202612|NCT04421950|Placebo Comparator|Placebo supplement|Food items will be provided to them without the wild blueberry power.
10202613|NCT04421131|Experimental|mIVAA|Screened for cervical cancer with mIVAA in mobile units
10202614|NCT04421131|No Intervention|Historical controls|Screened for cervical cancer in mobile units using standard of care; Data from medical records of women screened in the year(s) prior to mIVAA implementation
10202615|NCT04415021|Experimental|Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
10202616|NCT04415021|Sham Comparator|Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
10202617|NCT04409665|Experimental|Ketamine sedated group|30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA
10202618|NCT04409665|Active Comparator|Glucose sedated group|30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA
10202619|NCT04407481||Adults with autosomal dominant polycystic kidney disease|All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
10202620|NCT04407481||Healthy Controls|Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).
10202621|NCT04403139|Other|Cohort 1: 30-40 year of age|
10202622|NCT04403139|Other|Cohort 2: 70 years of age or older|
9832257|NCT02604550|Active Comparator|Femoral Nerve Block|Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
10202623|NCT04401410|Experimental|Dose Finding Phase|"This phase is designed to evaluate the maximum tolerated dose (MTD) of partially HLA-matched SARS-CoVSTs administered to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.~The dose finding phase is a standard 3+3 safety study design. The 3 dose levels are:~DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose)"
10202624|NCT04401410|Experimental|Randomized Pilot - SARS-CoVSTs|Partially HLA-matched Virus Specific T cells (VSTs) will be given by intravenous injection.
10202625|NCT04401410|Active Comparator|Randomized Pilot - Routine Care|Hospitalized patients with COVID-19 will be treated per current institutional guidelines.
10202626|NCT04394923|Experimental|"Intervention group or PRINT group"|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print, which is the zone where the atrioesophageal distance is shorter. The maximal distance and the area between the original line and the modified line will be noted. In cases when ablation through the red layer is unavoidable, the delivered energy can be lowered to an ablation index (AI) of 300 regardless of the local wall thickness. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
10202627|NCT04394923|Other|Control group|The ablation line will not be modified from the original one drawn before randomization and RF applications will follow the regular path. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
10202628|NCT04392336|Experimental|Trust/Respect feedback|Clinicians with consumers in this arm receive feedback on trust/respect in addition to symptom feedback.
10202629|NCT04392336|No Intervention|No Trust/Respect feedback|Clinicians with consumers in this arm do not receive feedback on trust/respect and only receive symptom feedback.
10202630|NCT04391894|Experimental|ECF843 0.45 mg/mL TID or vehicle (Part 1)|ECF843 0.45 mg/mL TID or vehicle (Part 1)
10202631|NCT04391894|Experimental|ECF843 0.15 mg/mL TID or vehicle (Part 1)|ECF843 0.15 mg/mL TID or vehicle (Part 1)
10202632|NCT04391894|Placebo Comparator|ECF843 vehicle TID (Part 1)|ECF843 vehicle TID (Part 1)
10202633|NCT04391894|Experimental|ECF843 0.15 mg/mL BID or vehicle (Part 1)|ECF843 0.15 mg/mL BID or vehicle (Part 1)
10202634|NCT04391894|Placebo Comparator|ECF843 vehicle BID (Part 1)|ECF843 vehicle BID (Part 1)
10202635|NCT04391894|Experimental|ECF843 -Part 2 (concentration/frequency TBD from Part 1)|ECF843 -Part 2 (concentration/frequency TBD from Part 1)
10202636|NCT04391894|Placebo Comparator|ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)|ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)
10202637|NCT04389827||Incident & Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
10202638|NCT04388787|Experimental|stochastic resonance (SR) vibration|SR applied sub threshold at 90% of participant's detection threshold
10202639|NCT04388787|Sham Comparator|Sham treatment|SR devices worn but not turned on (0% of participant's detection threshold).
10202640|NCT04388787|Experimental|Unblinded treatment|SR is applied above participant's detection threshold at a participant selected intensity.
9759304|NCT00652626|Experimental|Severe RI: azacitidine 75 mg/m^2|Participants with severe renal impairment (RI; defined as creatinine clearance < 30 mL/min/1.73 m^2) received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
9759305|NCT00652743|Experimental|GSK1562902A M6 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
9759306|NCT00652743|Experimental|GSK1562902A M12 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
10202641|NCT04384822|Experimental|Tai Chi Group|Subjects will participate in a tai chi program conducted in small groups (10 subjects per group) delivered by qualified instructors, who have experience in teaching tai chi to older adults. The tai chi intervention will be prescribed as a 3-month program with two 1-hour sessions weekly. Tai chi forms will be taught for 2 months followed by 1 month of consolidation. The 24-form simplified Yang-style tai chi will be adopted, as it is the most popular form of tai chi and older adults can manage to learn this simplified form of tai chi within 2-3 months. The instructors will introduce the safety issues, proper training principles, and skills to the subjects in their first class to minimize any avoidable adverse events due to improper skill/practice. The appropriate intensity will be individually determined for each subject by the attending instructors to achieve the training principle of progressive adaptation regarding the exercise intensity.
9759307|NCT00652743|Experimental|GSK1562902A M36 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
9759308|NCT00652834|Other|kidney recipients with GI symptoms|This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) on the equimola basis.
9759309|NCT00652899|Experimental|Total Body Irradiation|"This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
10202642|NCT04384822|Active Comparator|CBT-I Group|Subjects will participate in a conventional CBT-I program conducted in small groups (10 subjects per group) delivered by trained personnel. The CBT-I will be prescribed as a 3-month program with two 1-hour sessions weekly. The CBT-I components will be delivered for 2 months, which is consistent with the duration of the majority of CBT-I treatments, followed by 1 month of consolidation.
10202643|NCT04382937|Experimental|P1101 + Ribavirin|P1101 400 µg SC Q2W
9759310|NCT00652899|Experimental|No Total Body Irradiation|"This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
9759311|NCT00652938|Active Comparator|Cervarix & Engerix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) co-administered with Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
9759312|NCT00652938|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) according to a 0, 1, 6-month schedule.
10202644|NCT04382937|Active Comparator|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W
10202645|NCT04380337|Experimental|Radiation/FOLFOXIRI|Treatment will comprise 6 daily fractions of radiotherapy at 5 Gy per fraction followed by 4 months of FOLFOXIRI. Patients who have performance status or conditions that may preclude use of FOLFOXIRI may be treated with FOLFOX or XELOX. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard of care total mesorectal excision (TME).
10202646|NCT04380090|Active Comparator|Drug: Docusate Sodium|Docusate sodium one pill to be taken twice a day by mouth for 28 days
10202647|NCT04380090|Experimental|Drug: Propylene Glycol|One standard dose (17 grams) of propylene glycol by mouth on postoperative day one
10202648|NCT04377620|Placebo Comparator|Placebo + Standard of Care (SoC)|Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
10202649|NCT04377620|Experimental|Ruxolitinib 5mg + Standard of Care (SoC)|Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
10202650|NCT04377620|Experimental|Ruxolitininb 15mg + Standard of Care (SoC)|Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
10202651|NCT04369040|Other|High-flow nasal oxygen therapy|Ventilation with High-flow nasal oxygen therapy
10202652|NCT04369040|Experimental|Flow Controlled Ventilation|Ventilation with laryngeal tri-tube with Flow Controlled Ventilation technique
10202653|NCT04362644|Experimental|PET/CT using PET ligands [18F]FDG and [18F]DPA-714|
9759313|NCT00652938|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
9759314|NCT00652951|Active Comparator|Synflorix + Infanrix hexa Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with Infanrix hexaTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (Infanrix hexaTM) thigh or deltoid.
9835936|NCT02761993|Active Comparator|Group 1|Group 1 received ST266 treatment daily on Days 1 through 5, 8 through 12, 22, and 30, and then monthly for 7 months (Days 60, 90, 120, 150, 180, 210, and 240).
9759315|NCT00652951|Experimental|Synflorix + Pediacel Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with PediacelTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (PediacelTM) thigh or deltoid.thigh or deltoid.
9832258|NCT02604550|Active Comparator|Adductor Canal Block|Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
9665840|NCT04866680|Experimental|Personalized Circulating DNA follow-up|FFPE tissue sample + blood sample (20ml)
9832259|NCT02604589|Placebo Comparator|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
9984145|NCT04365920|No Intervention|Re-Entry as Usual|The type and level of services provided to individuals at re-entry will vary across jails and will be carefully documented. For the most part, individuals released to the community will receive a referral to an opioid treatment provider (OTP) for treatment with MOUD, and a subset may potentially be mandated to participate in community based treatment and/or recovery programs such as recovery coaching, and/or sentenced to varying levels of probation.
10202654|NCT04361396|Other|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy).
10202655|NCT04355169|Experimental|Naldemedine 1.25 mg|Participants will receive 1.25 milligrams (mg) naldemedine twice daily (BID) beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
10202656|NCT04355169|Experimental|Naldemedine 2.5 mg|Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
10202657|NCT04355169|Experimental|Naldemedine 5 mg|Participants will receive 5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
10202658|NCT04355169|Placebo Comparator|Placebo|Participants will receive matching placebo BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.
9665841|NCT04865653|Experimental|Oral drinking solution of LSD base|Oral drinking solution of 0.1 mg LSD base in 96% ethanol
9665842|NCT04865653|Experimental|Solid orodispersible film containing LSD base|Solid orodispersible film containing 0.1 mg LSD base
9665843|NCT04865653|Experimental|Oral drinking solution of LSD tartrate|Oral drinking solution of 0.146 mg LSD tartrate in water
9665844|NCT04865653|Experimental|Intravenous administration of LSD tartrate|Intravenous administration of 0.146 mg LSD tartrate in water
9665845|NCT04865653|Placebo Comparator|Placebo|Placebo for all formulations
9665846|NCT04863469|Experimental|B-POC high load Intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
9665847|NCT04863469|Sham Comparator|B-POC low load intervention|aerobic exercise [heartrate range (HRR) 70-75% of max HR, on treadmill] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
9665848|NCT04862286|Experimental|Risankizumab|Participants will receive risankizumab subcutaneous (SC) injection every 12 weeks for 204 weeks.
9665849|NCT04859868|Experimental|Galvanic Vestibular Stimulation during the entire session|Subjects will be given galvanic vestibular stimulation (GVS), which applies low electrical currents to the vestibular system, during the entire session.
9665850|NCT04859868|No Intervention|Placebo Group|Subjects will be not be given galvanic vestibular stimulation (GVS) during the entire session.
9665851|NCT04859868|Experimental|Galvanic Vestibular Stimulation starting from mid-session|Subjects will be given galvanic vestibular stimulation (GVS), which applies low electrical currents to the vestibular system, starting from mid-session.
9665854|NCT04858256|Experimental|Cohort 1: PTCL, NOS|Patients will receive single agent pacritinib.
9665855|NCT04858256|Experimental|Cohort 2: AITL/TFH PTCL|Patients will receive single agent pacritinib.
9665856|NCT04858256|Experimental|Cohort 3: CTCL (MF/SS)|Patients will receive single agent pacritinib.
9665857|NCT04858256|Experimental|Cohort 4: Less common PTCL subtypes|Patients will receive single agent pacritinib.
9665858|NCT04857619||Retrospective: Cohort 1|All patients recruited outside China and Brazil, including Australia, Singapore, Taiwan, Korea, and Hong Kong special administrative region (SAR) and who are diagnosed with HER2-positive unresectable or mBC since either the date of T-DM1 (Kadcyla) availability through reimbursement or patient access programme that makes it a valid local treatment option for patients or 01 January 2017 and have received at least 1 LOT in the advanced setting will be included.
9665859|NCT04857619||Retrospective: Cohort 2|Patients from all countries, including China and Brazil who are diagnosed with HER2-positive unresectable or mBC, since either the date of T-DM1 (Kadcyla) availability through reimbursement or patient access programme that makes it a valid local treatment option for patients or 01 January 2017 and have received at least 1 LOT in the advanced setting will be included.
9665860|NCT04857255|Active Comparator|Technology Assisted Language Intervention (TALI)|Augmentative and alternative communication software incorporated into active speech-language therapy
9665861|NCT04857255|Active Comparator|Treatment as Usual|Speech language therapy child is typically receiving (no change to current care)
9665862|NCT04854083|Experimental|Semaglutide|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to semaglutide 1.34mg/ml treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
9665863|NCT04854083|Placebo Comparator|Placebo|The intervention study for the patients with T2DM begins with a low-calorie diet (LCD) phase run-in for 13 weeks. During re-introduction of food, the participants will be assigned to placebo treatment for 44 weeks (dose escalation in total 8 weeks, maintenance period for 36 weeks).
9665864|NCT04853121|Active Comparator|tapered implant|
9665865|NCT04853121|Placebo Comparator|straight implant|
9665866|NCT04852887|Active Comparator|Arm 1: Breast Radiation Therapy + Endocrine Therapy|Radiation therapy to the breast and hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
9759316|NCT00652951|Active Comparator|Prevenar + Pediacel Group|Subjects received 3 doses of PrevenarTM co-administered with PediacelTM vaccine at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (PrevenarTM) or left (PediacelTM) thigh or deltoid.
9759317|NCT00653133|Active Comparator|USPNB|Ultrasound imaging guided peripheral nerve block
9759318|NCT00653133|Active Comparator|NSPNB|Peripheral nerve stimulator guided peripheral nerve block catheter placement for continuous infusion of local anesthetic
9759319|NCT00653159|Active Comparator|Mirena IUD [LNG-IUS]|Participants in this arm had a Levonorgestrel-releasing intrauterine device (LNG-IUS), also known as the Mirena IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
9759320|NCT00653159|Active Comparator|Paragard IUD [Copper T380A]|Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
9759321|NCT00653224|Placebo Comparator|Placebo|Matched placebo tablets
9759322|NCT00653224|Experimental|LCTZ|5 mg tablet
9759323|NCT00653263||Methamphetamine dependent|Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
9759324|NCT00653328|Experimental|Therapeutic Intervention|
9759325|NCT00653432|Experimental|Monovisc®|Injectable Hyaluronic Acid Gel
9759326|NCT00653432|Placebo Comparator|Saline|0.9% Sterile Saline
9759327|NCT00653861|Experimental|Juvederm with Lidocaine|Subjects receive Juvederm with Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in one nasolabial fold.
9759328|NCT00653861|Active Comparator|Juvederm|Subjects receive Juvederm without Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in the other nasolabial fold.
9759329|NCT00653939|Active Comparator|Arm 1: Chemotherapy+Bevacizumab|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
9759330|NCT00653939|Experimental|Arm 2: Active Comparator+Fosbretabulin|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
9759331|NCT00653991|Experimental|SOLVE-IT|Participants will receive the intervention SOLVE-IT. The SOLVE-IT intervention is a videogame designed to optimize self-regulation, reduce shame, and reduce risky choices for young men who have sex with men (YMSM).
9759332|NCT00653991|Active Comparator|Waitlist Control|Participants will receive the intervention, SOLVE-IT, a video game designed to optimize self-regulation reduce shame, and reduce risky sexual choices for YMSM, after a 6-month waitlist period.
9759333|NCT00654004||Subjects|Subjects are patients with a long-chain fatty acid oxidation disorder including CPT2, VLCAD, TFP or LCHAD deficiency.
9759334|NCT00654004||Controls|Subjects do not have a fatty acid oxidation disorder.
9759335|NCT00654030|Experimental|1650-G Vaccine|Patients receive 2 injections of 1650-G Vaccine given 4 weeks apart, for a total of 52 weeks on study.
9759336|NCT00654069|Placebo Comparator|Placebo|Tablet
9759337|NCT00654069|Active Comparator|Acurox 5/30mg|Oxycodone HCl 5mg/Niacin 30mg tablet
9759338|NCT00654069|Placebo Comparator|Acurox 7.5/30|Oxycodone HCl 7.5mg/Niacin 30mg tablet
9759339|NCT00654147|Active Comparator|Raltegravir & Lopinavir/ritonavir|Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks
9759340|NCT00654147|Active Comparator|Raltegravir & emtricitabine/tenofovir|Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks
9759341|NCT00654186|Experimental|1|
9759342|NCT00654238|Experimental|1|This is a single arm study.
9759343|NCT00654329|Experimental|Dexmedetomidine 1microgram/kilogram|Dexmedetomidine 1microgram/kilogram intranasal
9759344|NCT00654329|Experimental|Dexmedetomidine 2 micrograms/kilogram|Dexmedetomidine 2 micrograms/kilogram intranasal
9759345|NCT00654329|Active Comparator|Fentanyl 2 micrograms/kilogram|Fentanyl 2 micrograms/kilogram intranasal
9759346|NCT00654329|Placebo Comparator|Normal saline placebo|Normal saline placebo intranasal
9759347|NCT00654355|Experimental|Active Drug|tacrolimus ointment
9759348|NCT00654368|Active Comparator|Etanercept + Methotrexate|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to continue both etanercept plus methotrexate for an additional 18 months.
9759349|NCT00654368|Experimental|Etanercept Only|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to discontinue methotrexate (tapered over 6 weeks) and continue etanercept alone for an additional 18 months.
9759350|NCT00654381|Active Comparator|voglibose 0.2 mg three times a day (TID)|patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
9759351|NCT00654381|Experimental|BI 1356 low dose|patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
9759352|NCT00654381|Experimental|BI 1356 high dose|patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
9759353|NCT00654381|Placebo Comparator|placebo|patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose
9759354|NCT00654420|Experimental|Ph I: Dalotuzumab 5 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
9759355|NCT00654420|Experimental|Ph I: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
9759356|NCT00654420|Experimental|Ph II: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase II part of the study, participants are randomized to receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
9759357|NCT00654420|Active Comparator|Ph II: Erlotinib|During the Phase II part of the study, participants are randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
9759358|NCT00654498|Other|Pramipexole|4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
9759359|NCT00654498|Other|Placebo|4 weeks of individual dose titration as for the investigational product, once daily
9783388|NCT01199380|Experimental|Behavioral Activation for Smoking|Behavioral Activation Treatment for Smoking (BATS) includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Participants will also receive 8 weeks of the transdermal nicotine patch.
9783389|NCT01199471||Chinese Patients Requiring Surgery with Anesthesia|Chinese patients 18 to 70 years of age, meeting the American Society of Anesthesiologists (ASA) Physical Status Class 1 (normal healthy), Class 2 (mild systemic disease), or Class 3 (severe systemic disease), who underwent surgery requiring general anesthesia (sevoflurane) administered per local Prescribing Information and endotracheal intubation or laryngeal mask airway (LMA).
9783390|NCT01199575|Experimental|Revlimid + Rituximab|"A: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.~Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity."
9783391|NCT01199601|Experimental|Concentrated postpartum counseling|Women randomized to receiving concentrated postpartum counseling from the retrained provider.
9783392|NCT01199601|No Intervention|Routine postpartum counseling|Women receiving intra-partum testing and post-partum counseling from existing cadres of hospital providers at standard of care.
9783393|NCT01199705|Experimental|IgPro20|
9783394|NCT01199731|Experimental|GSK2248761 100mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
9783395|NCT01199731|Experimental|GSK2248761 200mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
9783396|NCT01199731|Active Comparator|Etravirine|In combination with darunavir/ritonavir BID and raltegravir BID
9783397|NCT01199744||Influenza virus infection patients exposed to zanamivir|Safety of Influenza virus infection patients exposed to zanamivir
9783398|NCT01199822|Experimental|Olaratumab|
9783399|NCT01199848|Placebo Comparator|Placebo|Pbo
9783400|NCT01199848|Experimental|10G STRB powder|Dose 1
9783401|NCT01199848|Experimental|20G STRB powder|Dose 2
9783402|NCT01199848|Experimental|40G STRB powder|Dose 3
9783403|NCT01199848|Placebo Comparator|PlacebonoFiber|Placebo without fiber
9783404|NCT01199861|Experimental|Fingolimod|Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
9835937|NCT02761993|Active Comparator|Group 2|Group 2 received ST266 treatment 2x/week (with at least 1 day between treatments) for the first 3 months, and then monthly for 5 months (Days 120, 150, 180, 210, and 240).
9832260|NCT02604589|Experimental|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
9832261|NCT02604589|Experimental|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
9832262|NCT02604810|Active Comparator|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
9832263|NCT02604810|Experimental|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
9832264|NCT02605122|Experimental|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
9832265|NCT02605122|Active Comparator|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
9832266|NCT02605174|Experimental|Lasmiditan 50 milligram (mg)|Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
9832267|NCT02605174|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
9832268|NCT02605174|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
9665867|NCT04852887|Active Comparator|Arm 2: No Breast Radiation Therapy + Endocrine Therapy|No radiation therapy, only hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
10202659|NCT04354259|Experimental|Ambulatory Cohort - Treatment|to receive a single dose of peginterferon lambda 180µg SC at baseline (day 0).
10202660|NCT04354259|Placebo Comparator|Ambulatory Cohort - placebo|Patients in the arm will be given a single injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
10202661|NCT04354259|Experimental|Hospitalized Cohort - Treatment|To receive a dose of peginterferon lambda 180µg SC at baseline and a second dose on day 5.
9759360|NCT00654511|Active Comparator|Fentanyl 1|Fentanyl 1 micrograms (mcg)/kilogram (kg)
9759361|NCT00654511|Active Comparator|Fentanyl 2|Fentanyl 2 micrograms (mcg)/kilogram (kg)
9759362|NCT00654511|Experimental|Dex 3|Dexmedetomidine 2 micrograms (mcg)/kilogram (kg)
9759363|NCT00654511|Experimental|Dex 4|Dexmedetomidine 4 micrograms (mcg)/kilogram (kg)
9759364|NCT00654615|Active Comparator|1|"Intramedullary Radius Fixation (Micronail) - Group 1~A new device was developed to provide intramedullary distal radius fracture fixation. This new device allows the placement of the orthopaedic hardware inside the medullary canal of the radius."
9759365|NCT00654615|Active Comparator|2|"Volar Plate Fixation - Group 2~Volar locking plates provide rigid external fixation and are placed on the outside of the radius. Volar plates are placed directly on the distal radius using a metal plate contoured to the shape of the distal radius."
9759366|NCT00654641|Experimental|Negative pressure wound closure|Negative Pressure wound closure
9759367|NCT00654641|Active Comparator|Standard wound closure|Standard Wound Closure
9759368|NCT00654654|Experimental|Active|
9759369|NCT00654732|Experimental|Arm A (rituximab, combination chemotherapy)|Participants receive rituximab intravenously IV over 7 hours on days 1, 8, 15, and 22 of course 1 and on days 1 and 8 of course 2. Participants also receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine IV over 1 hour on days 1 and 15. Treatment with ABVD repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9759370|NCT00654732|Active Comparator|Arm B (combination chemotherapy)|Participants receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine as in Arm A.
9759371|NCT00654745|Experimental|aml + olm + hctz|amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.
9759372|NCT00654784|Experimental|1|
9759373|NCT00654784|Placebo Comparator|2|
9759374|NCT00654836|Experimental|Carboplatin, ABI-007 and Bevacizumab|Participants will receive combination carboplatin, nanoparticle albumin-bound paclitaxel (ABI-007-Abraxane), and bevacizumab (Avastin)
9759375|NCT00654875|Experimental|Aliskiren 300 mg (Once a Day)|Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
9759376|NCT00654875|Experimental|Aliskiren 150 mg (Twice a Day)|Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
9759377|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 1|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651); and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
9759378|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 2|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
9759379|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 3|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
9759380|NCT00654901|Active Comparator|Infanrix Hexa™|Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), (Infanrix Hexa™) plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 (NCT00404651) and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
9759381|NCT00654940|Active Comparator|A|
9759382|NCT00654940|Placebo Comparator|B|
9759383|NCT00654953|Placebo Comparator|1|Placebo capsules
9759384|NCT00654953|Experimental|2|sertraline (200 mg/day)
9759385|NCT00654953|Experimental|3|sertraline (200 mg/day) plus gabapentin (1,200 mg/day)
9759386|NCT00655083|Experimental|1|Nepadutant 0.1 mg/kg
9759387|NCT00655083|Experimental|2|Nepadutant 0.5 mg/kg
9759388|NCT00655356|Experimental|Active|
9759389|NCT00655356|Placebo Comparator|Placebo|
9759390|NCT00655473|Experimental|Dalcetrapib (RO4607381)|
9759391|NCT00655473|Placebo Comparator|Placebo|
9759392|NCT00655486|Experimental|Lacosamide|Lacosamide 100 to 800 mg/day, flexible dosing, administered twice daily throughout the duration of the study (up to 2 years)
9759393|NCT00655499|Experimental|Panitumumab + CPT11 (irinotecan hydrochloride)|1 cycle every 14 days (J1= J15)
9759394|NCT00655538|Experimental|Dalcetrapib|
9759395|NCT00655538|Placebo Comparator|Placebo|
9759396|NCT00655551|Experimental|Lacosamide 200 mg cohort|Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
9759397|NCT00655551|Experimental|Lacosamide 300 mg combined cohorts|Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
9759398|NCT00655551|Experimental|Lacosamide 400 mg cohort|Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily
9759399|NCT00655564|Experimental|Alefacept|Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
9759400|NCT00655629|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
9759401|NCT00655629|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
9759402|NCT00655642|Active Comparator|Ondansetron|Ondansetron 4 mg intravenous administration
9759403|NCT00655642|Active Comparator|Metoclopramide|Metoclopramide 10 mg intravenous administration
9759404|NCT00655642|Active Comparator|Promethazine|Promethazine 10 mg intravenous administration
9759405|NCT00655642|Placebo Comparator|Saline Placebo|Volume-matched saline placebo
9759406|NCT00655668|Experimental|Lenalidomide|Open-label, oral lenalidomide monotherapy
9759407|NCT00655707|Experimental|Autologous CD34+ cells|Autologous Cluster Designation 34+(CD34+) cells
9759408|NCT00655733|Experimental|HMPL-004|Subjects who fulfilled all entry criteria and randomized HMPL-004 arm will receive HMPL-004 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
9759409|NCT00655733|Placebo Comparator|Placebo|Subjects who fulfilled all entry criteria and randomized Placebo arm will receive matching placebo 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
9759410|NCT00655746|Experimental|1|
9759411|NCT00655811|Active Comparator|Capsaicin|Capsaicin 0.1% cream application to the volar side of forearm.
9759412|NCT00655811|Placebo Comparator|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.) to the opposite forearm.
9759413|NCT00655850|Experimental|Paclitaxel and Gemcitabine + Avastin|Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
9759414|NCT00655863|Placebo Comparator|Placebo QD|
9759415|NCT00655863|Experimental|Alogliptin 25 mg QD|
9759416|NCT00655863|Experimental|Alogliptin 25 mg QD + Pioglitazone 30 mg QD|
9759417|NCT00655876|Experimental|Chemoradiation + Cetuximab|External beam radiation therapy (RT) with concurrent weekly paclitaxel, cisplatin, and cetuximab
9759418|NCT00655876|Active Comparator|Chemoradiation|External beam radiation therapy with concurrent weekly paclitaxel, and cisplatin
9759419|NCT00655889|Experimental|Active|
9759420|NCT00655928|Experimental|N-acetylcysteine|Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
10202662|NCT04354259|Placebo Comparator|Hospitalized Cohort - placebo|Patients in the arm will be given an injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse. Patients will be administered a second dose of placebo on day 5.
10202663|NCT04351698|Active Comparator|Investigation|Montelukast
10202664|NCT04351698|Placebo Comparator|Match Placebo|Matched Placebo
10202665|NCT04351009|Experimental|Indocyanine green sentinel lymph node mapping|Indocyanine green dye is injected in the submucosa or subserosa around the tumor to identify sentinel lymph nodes intra-operatively with near infrared fluorescence imaging.
10202666|NCT04346459|Active Comparator|Group A- Fastrach (control group)|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using intubating laryngeal mask airway Fastrach following blind intubating method through Fastrach"
9759421|NCT00655928|Placebo Comparator|Placebo|Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively
9759422|NCT00655980|Experimental|Treatment|Vitamin B12 and folic acid
9759423|NCT00655980|Placebo Comparator|Comparator|Nitrous oxide and placebo
9759424|NCT00655980|Other|Standard of care|standard of care
9759425|NCT00656019|No Intervention|Normal Vitamin D Levels|No additional Vitamin D administered
9759426|NCT00656019|Experimental|Low-normal Vitamin D Levels|2000 IU dose of Vitamin D per day administered orally
9759427|NCT00656019|Experimental|Low Vitamin D Levels|4000 IU dose of Vitamin D per day administered orally
9759428|NCT00656019|Experimental|Very-low Vitamin D Levels|6000 IU dose of Vitamin D per day administered orally
9759429|NCT00656058|Experimental|Montelukast to Treat Bronchiolitis Obliterans|Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
9783405|NCT01199861|Placebo Comparator|Placebo|Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
9984146|NCT04365920|Experimental|Recovery Management Checkups (RMC)|In the RMC condition, participants will have access to services provided as a part of re-entry as usual. In addition, checkups will be provided on a fixed schedule that includes face-to-face monthly checkups for the initial 3 months, and quarterly for the rest of the two years. Participants will have access to referrals and services provided by the jail and linkage to an OTP as part of their usual re-entry procedures. Individuals will meet with a Linkage Manager (LM) upon study enrollment and during each quarterly checkup, during which they will complete a Brief Treatment Needs Assessment, receive motivational interviewing, linkage assistance, or a check-in on continuing care and recovery support. The priority is to engage the individual into treatment with MOUD as soon as possible at the time of release, however, if individuals express a preference for another form of SUD treatment, the LM will work with that individual to link, engage, and retain them in that form of treatment.
9665870|NCT04850846|Experimental|Metformin|"Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last an additional 6 months.~Metformin Extension:~Participants will have the option of unblinding at the end of their 6months treatment and those who were randomly assigned to the metformin experimental arm can continue taking metformin if they opt in. The extended intervention duration will last an additional 6 months. (1500mg Metformin XR or highest tolerated dose )"
9835938|NCT02761993|Placebo Comparator|Group 3|Group 3 received commercially available sterile saline (0.9% sodium chloride) according to the same schedule as Group 1.
10202667|NCT04346459|Active Comparator|Group B- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using I-gel supraglottic airway device as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
10202668|NCT04346459|Active Comparator|Group C- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using the Protector laryngeal mask airway as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
10202669|NCT04343417||Biorepository|Participants who contributed biospecimen samples (kidney tissue, blood, urine, DNA).
10202670|NCT04338971|Experimental|IpsiHand Device|All participants will receive treatment with the IpsiHand Device.
9665871|NCT04850846|Experimental|Placebo|Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months.
9665872|NCT04849273|Experimental|TPX-0131|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.~The Phase 2 part of the study will determine the safety, tolerability, PK and preliminary efficacy of TPX-0131 in specific cohorts."
9665873|NCT04849260|Experimental|Pexa-Vec combined with ZKAB001|"The combined treatment group is divided into two dose groups. The principle of 3+3 is adopted to determine RP2D, and RP2D will be used in subsequent patients in this cohort."
9665874|NCT04849260|Active Comparator|ZKAB001 monotherapy|ZKAB001 monotherapy.
9665875|NCT04848779||Cohort 1|
9665876|NCT04845178|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
9665877|NCT04845178|Experimental|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles.
9665878|NCT04845178|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur) intramuscular injections into specified muscles.
9665884|NCT04843683|Experimental|Stereotactic ablative radiotherapy (SBRT)|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
9665885|NCT04841889|Other|Associated factors with decannulation|Collection of demographic, biological, ventilatory, respiratory and extra-respiratory parameters at the admission and the end of stay in the respiratory weaning center. Lung and diaphragm ultrasound, swallowing and muscles assessment will be performed.
9665886|NCT04839718||Control|Patients receiving referral to specialty mental healthcare
9665887|NCT04839718||ADAPT|ADAPT
9665888|NCT04835506|Experimental|proactive infliximab optimization|proactive infliximab optimization using a pharmacokinetic dashboard
9665889|NCT04835506|Experimental|standard of care infliximab dosing|standard of care infliximab dosing
9665890|NCT04832295|Experimental|Intervention|Photo-supported conversations about well-being, in addition to care as usual
9665891|NCT04832295|Active Comparator|Control|Care as usual
9665892|NCT04831385|Experimental|CBT-i|
9665893|NCT04831385|No Intervention|Control (Usual Care)|Control
9665895|NCT04829448|Experimental|Protein Intervention Group|Patients who receive the protein nutritional supplement as part of their prescribed exercise-based rehabilitation program.
9665896|NCT04829448|No Intervention|Control Group|Patients who receive the prescribed exercise-based rehabilitation program, without protein supplement.
9665897|NCT04827459|Experimental|MI Sleep Coach Mobile Application|The Sleep Coach app includes evidence-based CBT-I strategies, interactive activities and a computerized dialogue agent to engage users in the adoption of and adherence to CBT-I strategies.
9665898|NCT04825067|Experimental|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
9665899|NCT04824521|Experimental|Mindfulness-Oriented Recovery Enhancement via tele-health|Participants will be assigned to 8 weeks of Mindfulness-Oriented Recovery Enhancement delivered via tele-health.
9759430|NCT00656084|Experimental|Experimental arm|Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
9759431|NCT00656136|Placebo Comparator|Placebo|Patients receive placebo once daily
9759432|NCT00656136|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
9759433|NCT00656175|Active Comparator|Immediate|Immediate switch of PI or NNRTI to Raltegravir
9759434|NCT00656175|Active Comparator|Delayed|Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir
9759435|NCT00656201|Active Comparator|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
9759436|NCT00656201|Active Comparator|Intramuscular Progesterone|"Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.~."
9759437|NCT00656292|Placebo Comparator|Simvastatin|Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
9759438|NCT00656292|Experimental|Placebo|Subjects randomized to this arm will receive placebo two days before surgery -- allowing three doses of placebo before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of placebo), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
9759439|NCT00656305|Experimental|ExAblate Treatment Arm|
9759440|NCT00656305|Sham Comparator|ExAblate Sham Arm|
9759441|NCT00656370|Experimental|NS Infusion Group|Normal Saline (NS) and Hylenex
9759442|NCT00656370|Experimental|LR Infusion Group|Lactated Ringer's (LR) and Hylenex
9759443|NCT00656448|Experimental|Procrit Arm|Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
9759444|NCT00656448|No Intervention|No Procrit: Standard Arm|Participants do not receive Procrit before receiving blood transfusions.
9759445|NCT00656474|Experimental|1|GLYC-101 Active Retro-auricular Site (1 per participant)
9759446|NCT00656474|Placebo Comparator|2 Comparator|"Placebo Retro-auricular Site (1 per participant)~This arm undergoes laser ablation with subsequent Placebo gel administration"
9759447|NCT00656487|Experimental|Cannabis-dependent rimonabant|Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
9759448|NCT00656487|Placebo Comparator|Cannabis-dependent placebo|Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
9759449|NCT00656487|No Intervention|Non-cannabis using control|Non-cannabis using demographically similar young adults followed for 28 days.
9759450|NCT00656513|Active Comparator|Pilocarpine: Phase III|
9759451|NCT00656513|Experimental|ALTENS: Phase III|
9759452|NCT00656513|Experimental|ALTENS: Phase II|
9759453|NCT00656617|Experimental|Idarubicin + Ara-C + Vorinostat|Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
9759454|NCT00656630|Active Comparator|1|Acamprosate
9759455|NCT00656630|Active Comparator|2|Naltrexone
9759456|NCT00656630|Placebo Comparator|3|
9759457|NCT00656656|Other|Immunoadsorption/Dexamethasone/Rituximab|
9759458|NCT00656669|Experimental|1|The study will be conducted in 3 sequential treatment segments.
9759459|NCT00656799|Experimental|Sugammadex|IV single bolus dose of 4.0 mg/kg sugammadex
9759460|NCT00656851|Active Comparator|Pioglitazone|Pioglitazone (Actos, 30mg/day for 16 weeks)
9759461|NCT00656851|Active Comparator|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
9759462|NCT00656968|Active Comparator|10-day concomitant therapy|esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
9759463|NCT00656968|Experimental|10-day sequential therapy|esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
9759464|NCT00657020|Experimental|Nicotine lozenge|Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
9759465|NCT00657020|Placebo Comparator|Placebo lozenge|Placebo lozenge to be placed in mouth and suck to dissolution.
9759466|NCT00657046|Active Comparator|1|Droxidopa at 400 mg (2 capsules each containing 200 mg droxidopa plus one capsule with Placebo)
9759467|NCT00657046|Active Comparator|2|Droxidopa at 600 mg (3 capsules each containing 200 mg droxidopa)
9759468|NCT00657046|Placebo Comparator|3|Placebo (3 capsules with mannitol substituted for droxidopa)
9759469|NCT00657150|Experimental|Dabigatran etexilate|220 mg once daily
9759470|NCT00657150|Active Comparator|Enoxaparin|40 mg once daily
9759471|NCT00657267|Experimental|Single-Arm Study|
9759472|NCT00657280|Experimental|All subjects recieve Sitagliptin|All subjects are aware of what they are taking. Nobody is blinded in this study. study
9759473|NCT00657358|Experimental|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
9759474|NCT00657371|Experimental|Third Eye Retroscope|Colonoscopy exam using the Third Eye Retroscope device
9759475|NCT00657540|Experimental|Analatro|Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
9759476|NCT00657540|Placebo Comparator|Normal Saline Placebo|Normal Saline
9759477|NCT00657605|Experimental|Recombinant methionyl human leptin|Participants with congenital leptin deficiency will receive the Recombinant methionyl human leptin intervention subcutaneously, once a day with a dose of 0.02 to 0.04 mg/kg (adjusted according to weight loss).
9759478|NCT00657618|Experimental|Treatment only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Sodium Stibogluconate (SSG).
9759479|NCT00657657|Experimental|Group 1|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12, 60 (5 doses)
9759480|NCT00657657|Experimental|Group 2|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
9759481|NCT00657657|Experimental|Group 4|Neonates from mother HBsAg (+) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
9759482|NCT00657657|Experimental|Group 6|Neonates from mother HBsAg (-) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
9759483|NCT00657709|Experimental|rMenB Lot1|Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
9759484|NCT00657709|Experimental|rMenB Lot2|Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
9759485|NCT00657709|Experimental|rMenB Lot3|Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
9759486|NCT00657709|Active Comparator|Routine|Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
9759487|NCT00657709|Active Comparator|MenC + Routine|Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.
9759488|NCT00657917|Experimental|Paromomycin +Gentamicin topical cream|WR279,396 topically twice a day for 20 days
9759489|NCT00658021|Placebo Comparator|Placebo|Subcutaneous injection, twice a day
9759490|NCT00658021|Experimental|Exenatide 5 µg|Subcutaneous injection, twice a day
9759491|NCT00658021|Experimental|Exenatide 10 µg|Subcutaneous injection, twice a day
9759492|NCT00658112|Experimental|Benzoyl Peroxide 5%|Subjects will be given standard instructions in the use of topical benzoyl peroxide gel and will be provided with a supply of medication fitted with a Medication Event Monitoring System (MEMS) cap. This cap records dates and times the assembly is opened which can be downloaded at the final visit and tabulated with associated software. When the tubes are weighed, data from the MEMS Caps will be collected. Study coordinators will record adherence, while assessors are blinded to adherence rates. All subjects will be assigned to treatment with topical benzoyl peroxide to the entire face.
9759493|NCT00658138|Experimental|Adhesive A|
9759494|NCT00658138|Active Comparator|Adhesive B|
9759495|NCT00658320|Experimental|Everolimus + Reduced dose of cyclosporine|An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) was administered 24-36 hours from reperfusion after transplantation and dose adjustments based on everolimus trough level (target trough level 3-8 ng/mL). Reduced dose of cyclosporine was initiated either pre-transplantation or within 24 hours after transplantation following the local regimen. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study. Everolimus was available after 24 months for compassionate use.
9759496|NCT00658320|Active Comparator|Mycophenolate mofetil (MMF) + Standard dose of cyclosporine|Patients were treated with 1 gram twice a day (2 grams/day) of Mycophenolate mofetil (MMF) and standard dose of cyclosporine for 12 months post renal transplant. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study.
9759497|NCT00658333|Experimental|Enteric-coated Mycophenolate Acid|Equimolar dose of enteric-coated mycophenolate acid with mycophenolate mofetil placebo. 1000 mg mycophenolate mofetil = 720 mg enteric-coated mycophenolate acid (MPA equivalent dose). The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
9759498|NCT00658333|Active Comparator|Mycophenolate Mofetil|Mycophenolate mofetil therapy with placebo enteric-coated mycophenolate acid. The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
9759499|NCT00658359|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications
9759500|NCT00658359|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive standard of care medications
9759501|NCT00658359|Experimental|Treatment Arm 3|Treatment Arm 3 will also receive standard of care medications
9759502|NCT00658385|Experimental|1|GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)
9759503|NCT00658411|Experimental|All patients|Deferoxamine for >=2 weeks prior to stem cells
9759504|NCT00658515|Experimental|Dalcetrapib (RO4607381)|
9759505|NCT00658515|Placebo Comparator|Placebo|
9759506|NCT00658528|Experimental|1|
9759507|NCT00658528|Active Comparator|2|
9759508|NCT00658541|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
9759509|NCT00658541|Active Comparator|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
9759510|NCT00658567|Experimental|2|pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks
9759511|NCT00658567|Placebo Comparator|Placebo|Placebo tablet, once daily by mouth, 6 weeks
9759512|NCT00658567|Experimental|1|pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks
9759513|NCT00658606|Active Comparator|Alefacept alone|15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
9759514|NCT00658606|Experimental|Alefacept + nbUVB|15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks
9759515|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
9759516|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
9759517|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
9759518|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
9759519|NCT00658619|Sham Comparator|Sham (no implant) Stage 2|Stage 2: sham in both eyes on Day 1 and Month 6.
9759520|NCT00658632|Experimental|1|
9759521|NCT00658632|Active Comparator|2|
9759522|NCT00658658|Experimental|Panitumumab|Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
9759523|NCT00658684|Experimental|Fesoterodine fumarate|
9759524|NCT00658697|Experimental|Docetaxel, Bevacizumab, and ADT|"Docetaxel:~Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles~Bevacizumab:~Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles~ADT or Luteinizing hormone-releasing hormone agonist (LHRH):~Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)~Bicalutamide:~Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)"
9759525|NCT00658723|Experimental|1|
9759526|NCT00658723|Active Comparator|2|SURGICEL™ Absorbable Hemostat
9759527|NCT00658736|Experimental|1|EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
9759528|NCT00658736|Placebo Comparator|2|EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
9759529|NCT00658775|Experimental|1|
9759530|NCT00658775|Active Comparator|2|
9759531|NCT00658788|Active Comparator|Study Treatment|"clobetasol propionate spray 0.05%~Other Names:~Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily~calcitriol ointment~Other Names:~Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily"
9759532|NCT00658879||Somavert (Pegvisomant)|Patients taking Somavert (Pegvisomant).
9759533|NCT00658996|Experimental|SofLens DD Toric|Bausch & Lomb SofLens Daily Disposable Toric Contact Lens
9759534|NCT00658996|Active Comparator|Ciba Vision Toric Lens|Ciba Vision Focus Dailies Toric Contact Lens
9759535|NCT00659165|Experimental|Insulin Detemir|Insulin Detemir
9759536|NCT00659165|Experimental|Insulin Glargine|Insulin Glargine
9759537|NCT00659230|Placebo Comparator|Placebo|Arm 1
9759538|NCT00659230|Active Comparator|Nepicastat|Arm 2
9759539|NCT00659269|Active Comparator|Multivitamin (MV)|1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)
9759540|NCT00659269|Experimental|Multivitamin + Vitamin B12 + Vitamin B6|"1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts).~The patient will also take the following, starting on the first day of chemotherapy:~pyridoxine 50 mg three times per day, orally and continue for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)~Vitamin B12 one mg injected intramuscularly, every 3 or 4 weeks, depending on the timing of the chemotherapy for 4 doses."
9759541|NCT00659295||Type 1 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
9759542|NCT00659295||Type 2 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
9759543|NCT00659334|Active Comparator|1|Adults with brain tumor to receive Combidex infusion only
9759544|NCT00659334|Active Comparator|2|Adults with brain tumors to receive Combidex infusion and neurosurgery
9759545|NCT00659334|Other|3|Adults with brain tumors to receive neurosurgery only (NO Combidex)
9759546|NCT00659334|Active Comparator|4|Children with brain tumors to receive Combidex only
9759547|NCT00659334|Active Comparator|5|Children with brain tumors to receive Combidex and neurosurgery
9759548|NCT00659334|Other|6|Children with brain tumors to receive neurosurgery only, NO Combidex
9759549|NCT00659334|Active Comparator|7|Adults with Inflammatory lesions (stroke or MS) to receive Combidex only
9759550|NCT00659360|Experimental|Arm I|Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.
9759551|NCT00659373|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
9759552|NCT00659373|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
9759553|NCT00659373|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
9759554|NCT00659425|Experimental|5 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759555|NCT00659425|Experimental|10 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759556|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759557|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759558|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759559|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759560|NCT00659425|Experimental|40 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759561|NCT00659425|Experimental|32 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
9759562|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
9759563|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
9759564|NCT00659438|Experimental|1|Bicalutamide 150mg + ZD6474 300mg
9759565|NCT00659438|Placebo Comparator|2|Bicalutamide 150mg + placebo
9783406|NCT01199926|Experimental|Vitamin D|Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
9783407|NCT01199926|Placebo Comparator|Placebo|Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.
9783408|NCT01199939|Experimental|ETR + DRV/rtv|Darunavir 800mg once daily orally for 48 weeks,Etravirine 400mg once daily orally for 48 weeks,Ritonavir 100mg once daily orally for 48 weeks
9783409|NCT01199952|No Intervention|Control|The control group will not receive a counseling phone call one month after enrollment.
9783410|NCT01199952|Experimental|Intervention|Intervention arm receives a counseling phone call 3 to 4 weeks after enrollment. The call is from a health educator intended to assist with contraception.
9783411|NCT01199965|Other|IV DHE then MAP0004|Smokers and non-smokers received Intravenous Dihydroergotamine Mesylate (IV DHE) at Visit 2 followed by MAP0004 7-11 days later at Visit 3.
9783412|NCT01199965|Other|MAP0004 then IV DHE|Smokers and non-smokers received MAP0004 at Visit 2 followed by Intravenous Dihydroergotamine Mesylate (IV DHE) 7-11 days later at Visit 3.
9783413|NCT01200030|Experimental|electrical stimulation with exercises|The TENS + TRTT group received TENS simultaneously with the TRTT at home under the instruction of a physical therapist.
9759566|NCT00659490|Experimental|AZD1940|AZD1940 800ug given predose
9759567|NCT00659490|Active Comparator|Naproxen|Naproxen 500mg given pre-surgery
9759568|NCT00659490|Placebo Comparator|Placebo|Placebo given pre-surgery
9759569|NCT00659529|Experimental|1|All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
9759570|NCT00659581||Patients with hypertension|
9759571|NCT00659633|Experimental|Lidocaine|Intravenous lidocaine for neuropathic pain
9759572|NCT00659737|Placebo Comparator|Aprepitant|"Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.~Emend (Aprepitant) + Placebo"
9759573|NCT00659737|Active Comparator|Scopolamine|Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.
9759574|NCT00659789|Experimental|Vacc-4x|Vacc-4x reconstituted in sterile water (0.1 mL) at a dose of 1.2mg per intradermal administration. Participants are given a total of 6 immunizations over 18 weeks (weeks 1, 2, 3, 4, 16, 18). Recombinant human granulocyte macrophage colony stimulating factor (rhuGM-CSF) Leukine (0.06mg in 0.1 mL) administered intradermally is used as a local adjuvant.
9759575|NCT00659789|Placebo Comparator|Placebo|Placebo injections consisting of sterile water (0.1 mL) in place of Vacc-4x. Placebo injections consisting of sterile water (0.1 mL) in place of Leukine.
9759576|NCT00659802|Placebo Comparator|placebo|Matching dose of placebo will be given orally in capsules three times per day for 56 days.
9759577|NCT00659802|Experimental|HMPL-004 low dose|A total of 1200 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
9759578|NCT00659802|Experimental|HMPL-004 high dose|A total of 1800 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
9759579|NCT00659815|Active Comparator|ReNu in Currently Marketed Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
9759580|NCT00659815|Experimental|ReNu in Clear Resin Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
9759581|NCT00659828|Experimental|Recombinant Methionyl Human Leptin|Recombinant methionyl human leptin: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss).
9759582|NCT00659945|Active Comparator|1|Pre-op Aprepitant plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
9759583|NCT00659945|Placebo Comparator|2|Pre-op Placebo plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
9783414|NCT01200030|Placebo Comparator|placebo stimulation with exercises|The TENS + TRTT group received placebo-simultaneously with the TRTT at home under the instruction of a physical therapist.
9984147|NCT04365920|Experimental|RMC-Adaptive|In the RMC-Adaptive condition, checkups will be provided based on the participant's current need for treatment and will be adapted in three ways. First, the interval between RMC-A check-ups will vary (in 1-month increments) depending upon the individual's assessed need for treatment at the prior check-up. Second, in cases where participants have 3 consecutive checkups in which they need treatment, the LM and treatment provider will discuss how to better meet the participant's needs, e.g., a different treatment provider, different type of MOUD or other types of treatment, and/or additional services. Third, if RMC-A participants are re-incarcerated at the time of their checkup, the LM will meet with the individual while incarcerated to discuss a recovery plan, which may include initiation of treatment with MOUD while incarcerated and re-linkage to an OTP upon release.
9984148|NCT04364087||Infertile PCOS women|All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.
9783415|NCT01200030|No Intervention|Control|Subjects in this group did not receive any active training. Home safety advice and health education including diet control and blood pressure monitoring were given to the subjects during the home-visit and telephone follow-up.
9783416|NCT01200069|Placebo Comparator|Sugar water|500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
9783417|NCT01200069|Active Comparator|Ibuprofen|300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
9783418|NCT01200160||Lipid abnormalities|Niacin
9783419|NCT01200238|Experimental|STA-9090: Cohort A|"Cohort A participants received STA-9090 200 mg/m2 given intravenously (IV) over 1 hour once weekly (d1, 8, 15 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
9783420|NCT01200238|Experimental|STA-9090: Cohort B|"Cohort B participants received STA-9090 150 mg/m2 given intravenously over 1 hour (IV) twice weekly (d1, 4, 8, 11, 15, 18 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
9783421|NCT01200290|Experimental|LY2127399|
9783422|NCT01200329|Experimental|Gemcitabine + Busulfan + Melphalan|Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.
9783423|NCT01200342|Experimental|Genasense + Paclitaxel + Carboplatin|Genasense 900 mg intravenous (IV) on a fixed-dose as a 1-hour infusion on Days 1, 3, and 5 of a 21 day cycle; Paclitaxel 175 mg/m^2 IV over 3 hours Day 3 after Genasense; Carboplatin dose in mg (target area under the concentration [AUC)]=6) administered over 30 minutes IV Piggyback (IVPB) on Day 3 after Paclitaxel.
9832269|NCT02605174|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
9832270|NCT02605187|Active Comparator|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
9832271|NCT02605187|Experimental|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
9832272|NCT02605187|Experimental|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
9832273|NCT02605187|Experimental|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
9832274|NCT02605304|Experimental|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
9832275|NCT02605304|Experimental|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
9832276|NCT02605395|Experimental|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
9832277|NCT02605395|Experimental|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
9832278|NCT02605447|Experimental|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
9832279|NCT02605642||CT-P13|biosimilar infliximab
9832280|NCT02605837|Experimental|Oral Budesonide Suspension (OBS)|Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
9832281|NCT02605837|Placebo Comparator|Placebo|Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
9832282|NCT02605863|Experimental|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
9832283|NCT02605863|Experimental|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
9832284|NCT02605876|Experimental|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
9984149|NCT04362436|Experimental|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Radiation therapy
9832285|NCT02605876|Experimental|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
9832286|NCT02605876|No Intervention|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
9832287|NCT02605928|Experimental|BIP Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It measures bioimpedance and detects synovial fluid during inta-articular injection.
9832288|NCT02605954|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
9832289|NCT02605954|Active Comparator|ABC/3TC+3rd Agent|"Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC.~Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed."
9832290|NCT02606253|Active Comparator|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
9832291|NCT02606253|Experimental|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
9832292|NCT02606253|Experimental|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
9759584|NCT00659984|Experimental|Ultratrace™ Iobenguane I 131|"Eligible patients received a diagnostic imaging dose of Ultratrace™ Iobenguane I 131 (1-5 mCi) within 7 days of study enrollment, followed by three dosimetry scans over 3-6 days. If the imaging dose demonstrated normal biodistribution and tumor uptake, then the patient received a therapeutic dose within 7-28 days of the diagnostic imaging dose, followed by a single imaging scan on Day 7 post therapy. As per protocol, therapeutic dosing was to begin at 12.0 mCi/kg and escalate to 15.0, 18.0, and 21.0 mCi/kg until the MTD was established or the 21.0 mCi/kg dose level was reached. Actual doses administered ranged from 8.8 to 18.6 mCi/kg. Based on actual doses administered, patients were grouped into 3 mean dose groups: 11.2, 15.5, and 18.2 mCi/kg.~The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30 to 60 minutes."
9759585|NCT00660010|Experimental|1|
9759586|NCT00660023|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.
9759587|NCT00660049|Experimental|SNaP application|"This is an open label pilot study of SNaP Advanced Wound Care System"
9759588|NCT00660075|Experimental|1|Sitagliptin 100 mg/d for 6 weeks
10202671|NCT04331587|Experimental|Bronchoscopy|"Following airway inspection, the radial endobronchial ultrasound probe will be inserted through the working channel of the 4mm bronchoscope and will be advanced into the targeted bronchial segment towards the targeted lesion. Bronchoscopy will be performed using monoplanar fluoroscopic guidance until the peripheral lesion is located and confirmed using radial probe EBUS.~a. If a concentric view is obtained, biopsy will proceed using conventional instruments (TBNA) through the 4mm bronchoscope.~b. If an eccentric view is obtained, the 4mm bronchoscope will be withdrawn and the 3mm bronchoscope with the radial ultrasound probe will be advanced to the target lesion. Attempts will be made using the 3mm bronchoscope to obtain concentric views and ability to do so will be recorded. Biopsies will be obtained using conventional instruments (TBNA)through the 3mm bronchoscope regardless of the final ultrasound image (concentric or eccentric)."
10202672|NCT04331158|Experimental|Dry cupping group|The dry cupping will be applied with a force of two suctions generating a negative pressure on the skin during the time of 15 minutes.
10202673|NCT04331158|Placebo Comparator|Dry cupping sham group|The dry cupping sham group will receive the same procedures as the dry cup group, with the difference that the negative pressure imposed after application will be released in a few seconds.
9759589|NCT00660075|Placebo Comparator|2|Placebo for 6 weeks
9759590|NCT00660179|Experimental|1|Macitentan (ACT-064992) tablet, 3 mg, once daily
10202674|NCT04330716|Active Comparator|Group A: Standard genetic counseling|Will receive standard genetic counseling prior to genetic testing.
9759591|NCT00660179|Experimental|2|Macitentan (ACT-064992) tablet, 10 mg, once daily
9759592|NCT00660179|Placebo Comparator|3|Matching placebo, once daily
10202675|NCT04330716|Experimental|Group B: Educational video|Will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing.
10202676|NCT04319627|Experimental|Rosuvastatin|Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.
9759593|NCT00660192|Placebo Comparator|Placebo|Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
9759594|NCT00660192|Active Comparator|Botox|Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
10202677|NCT04319627|Placebo Comparator|Placebo|Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.
10202678|NCT04310566|Experimental|Test/Control|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
9759595|NCT00660309|Experimental|Aliskiren|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received aliskiren 300 mg tablets orally once a day for 14 days.
9759596|NCT00660309|Active Comparator|Irbesartan|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received irbesartan 300 mg tablets orally once a day for 14 days.
10202679|NCT04310566|Experimental|Control/Test|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
10202680|NCT04308603|Experimental|pregnant patient whose fetuses have an antenatal NIH|All pregnant patients whose fetuses have an antenatal revelation of NIH from the first trimester ultrasound scan will be included in this study.
10202681|NCT04305951|No Intervention|Routine care group|Subjects assigned to this group will continue their routine care without receiving any acupuncture and acupressure treatment during the study period. The routine care may include physiotherapy and intellectual activities. Post-trial treatment of either CAT, CAE, or CAT+CAE will be offered to serve as a compensation for their participation.
10202682|NCT04305951|Active Comparator|CAT group|Subjects assigned to comprehensive acupuncture therapy (CAT) group will receive CAT treatment in addition to routine care.
10202683|NCT04305951|Active Comparator|CAE group|Subjects assigned to 'Comfy Acupressure for the Elderly (CAE)' group will receive CAE in addition to routine care.
10202684|NCT04305951|Active Comparator|CAT + CAE group|Subjects assigned to CAT+CAE group will receive CAT+CAE in addition to routine care.
9759597|NCT00660387|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
9759598|NCT00660387|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
9759599|NCT00660400|Experimental|Combined Therapy|5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
9759600|NCT00660504|Experimental|1|Amrubicin Hydrochloride-Cisplatin combined chemotherapy
9759601|NCT00660504|Active Comparator|2|Etoposide-Cisplatin combined chemotherapy
9759602|NCT00660517|Experimental|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray
9759603|NCT00660517|Active Comparator|azelastine Hcl 548 mcg|azelastine Hcl 548 mcg nasal spray
9759604|NCT00660517|Active Comparator|fluticasone propionate 200 mcg|fluticasone propionate 200 mcg nasal spray
9759605|NCT00660517|Placebo Comparator|placebo|placebo nasal spray
9759606|NCT00660530|Active Comparator|1|One week before the administration of crushed or chewed lanthanum, the subjects were instructed to discontinue their P-binding agents, if prescribed previously. At the end of the 1-week washout period, subjects whose serum P exceeded 5.5 mg/dL were randomized to receive, in a crossover fashion, lanthanum 1000 mg (Fosrenol, Shire US Inc., Wayne, PA, USA) 3 times daily to be chewed with meals (chewed LAN) or lanthanum 1000 mg crushed into a ﬁne powder and taken with meals 3 times daily (crushed LAN), for 4 weeks each. The lanthanum tablets were crushed into a ﬁne powder using a mortar and pestle by the investigators, individually wrapped in powder packets and dispensed to the subjects on a weekly basis. The subjects were instructed to empty the powder into a small plastic cup provided, mix with 2 tablespoonfuls of applesauce and take it with meals. After each treatment (chewed or crushed LAN), there was a 1-week washout period.
9759607|NCT00660530|Experimental|2|After the one-week washout period, the subject received the other lanthanum treatment (chewed or crushed) that they did not receive in the initial treatment period.
9759608|NCT00660543|Experimental|Ferumoxytol|Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
9759609|NCT00660543|Active Comparator|Gadoteridol|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
9759610|NCT00660543|Active Comparator|Gadoteridol Leakage Corrected|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
9759611|NCT00660660|Experimental|Nexium 20mg|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
9759612|NCT00660660|Placebo Comparator|Placebo|
9759613|NCT00660699|Experimental|Arm 1 (gemcitabine, docetaxel, 5FU, radiation)|"Gemcitabine 1000 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~Docetaxel 35 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~5FU CIVI 225 mg/m2 per day throughout radiation (starts 3 weeks after start of cycle 2)~Radiation 5040 cGy or 5400 cGy for positive margins (starts 3 weeks after start of cycle 2). Daily dose of 1.8 Gy five days per week.~Gemcitabine 1000 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)~Docetaxel 35 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)"
9759614|NCT00660790||Patients with Type 2 Diabetes|diabetic subjects, above targets
9759615|NCT00660816|Active Comparator|Arm I|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
9759616|NCT00660816|Experimental|Arm II|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride PO once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
9759617|NCT00660829|Placebo Comparator|1|Placebo
9759618|NCT00660829|Active Comparator|2|0.15% Azelastine Hydrochloride
9759619|NCT00660907|Experimental|1|dapagliflozin plus metformin
9759620|NCT00660907|Active Comparator|2|glipizide plus metformin
9759621|NCT00660985|Experimental|Differin® Gel, 0.3%|Gel, 0.3%, 2g, once daily for 30 days
9759622|NCT00660985|Active Comparator|Differin® Gel, 0.1%|Gel, 0.1%, 2g, once daily for 30 days
9759623|NCT00661037||1|Patients having VF induction with shock termination at implant
9759624|NCT00661037||2|Patients not having VF induction at implant or during follow-up
9759625|NCT00661089|Experimental|Intramuscular OnabotulinumtoxinA|Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
9759626|NCT00661089|Active Comparator|Intramuscular Placebo (Saline)|Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
9759627|NCT00661141|Experimental|Cohort 1: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
9832293|NCT02606500|Experimental|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
9759628|NCT00661141|Experimental|Cohort 2: Antizol 3.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
9759629|NCT00661141|Experimental|Cohort 3: Antizol 5.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
9759630|NCT00661141|Experimental|Cohort 4: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
9759631|NCT00661193|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9759632|NCT00661193|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9759633|NCT00661258|Experimental|Intervention|The intervention group patients were given their electronic drug monitoring feedback data at each monthly visit. The study coordinator would quickly calculate whether the patient's adherence was below 95% in the previous month. If so, that patient was flagged for enhanced counseling with a clinic doctor and this counseling was based on a printout containing the electronic drug monitoring data.
9759634|NCT00661258|No Intervention|Comparison|"The comparison group patients were not given the data from the electronic data monitoring feedback data. Instead, they filled out a self report form that all patients fill out. If they indicated in this report that their adherence in the previous was less than 95%, then they were flagged for enhanced counseling with a doctor. This counseling was based on the patient's self report. Thus both groups received enhanced counseling if they indicated poor adherence, but only the intervention group were given their electronic data output."
9759635|NCT00661271|Experimental|Mindfulness-Based Stress Reduction|8-week mindfulness-based stress reduction program with one retreat session
9759636|NCT00661271|Active Comparator|Healthy Topics|8-week health education program with one retreat session - based on a health curriculum developed by McGraw/Hill
9759637|NCT00661362|Experimental|1|Metformin + Saxagliptin
9759638|NCT00661362|Placebo Comparator|2|Metformin + Placebo
9759639|NCT00661388|Experimental|Continuous erythropoietin receptor activator (C.E.R.A.)|Eligible participants will be administered C.E.R.A subcutaneously, every 4 weeks for 44 weeks. The initial dose of C.E.R.A. will be 1.2 micrograms/kilogram. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin within the target range of 10.0 and 12.0 grams/deciliter.
9759640|NCT00661427|Active Comparator|Cetuximab 500 mg/m^2|Cetuximab 500 mg/m^2 IV over 2 hours every other week
9759641|NCT00661427|Active Comparator|Cetuximab 750 mg/m^2|Cetuximab 750 mg/m^2 IV over 3 hours every other week
9759642|NCT00661453|Experimental|1|All patients will receive VPA and carnitine.
9759643|NCT00661479|Experimental|400 µg Brimonidine Tartrate Implant Group B|400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
9759644|NCT00661479|Experimental|200 µg Brimonidine Tartrate Implant Group B|200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
9759645|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group B|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
9759646|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group A|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
9759647|NCT00661492|Experimental|Arm 1|Erbitux (cetuximab) and Novantrone (mitoxantrone)
9759648|NCT00661492|Experimental|Arm 2|Novantrone (mitoxantrone)
9759649|NCT00661505|Experimental|C.E.R.A. 120, 200, or 360 mcg|Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA). The ESA therapy was administered from enrollment to the 4 weeks stability verification period (SVP), weekly, either as epoetin (<8000 IU, 8000-16000 IU, or >16000 IU) or darbepoetin alpha (<40 mcg, 40-80 mcg, or >80 mcg). A telephone follow-up visit took place 4 weeks after the end of C.E.R.A. treatment (Week 28).
9759650|NCT00661531|Experimental|Estrace & Anastrozole|Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered
9759651|NCT00661544|Experimental|Arsenic Trioxide + Vitamin C + Melphalan|Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
9759652|NCT00661557|Experimental|Mencevax Primed Group|Subjects who were previously vaccinated with meningococcal vaccine Mencevax ACWY in study NCT00227422 received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
9832294|NCT02606500|Active Comparator|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
9832295|NCT02606604|Experimental|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
9832296|NCT02606604|Active Comparator|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
9832297|NCT02606643|Active Comparator|Group 1 Catheter to slight traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
9832298|NCT02606643|Active Comparator|Group 2 Catheter to no traction|"Foley catheter to no traction placed as SOC No traction applied"
10202685|NCT04298632|Experimental|Youth-only|Only the youth receives the education program
9832299|NCT02606708|Experimental|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
10202686|NCT04298632|Experimental|Family enhanced|A parent and the youth both receive the education program
9832300|NCT02606734|Other|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
9832301|NCT02606838|Experimental|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
9832302|NCT02606877|Experimental|Treatment naïve|Treatment naïve to pirfenidone
9832303|NCT02606877|Experimental|Pirfenidone-treated|Treatment before with pirfenidone
9832304|NCT02606903|Experimental|BI 695501 prefilled syringe|
9832305|NCT02606903|Experimental|BI 695501 autoinjector|
10202687|NCT04298632|No Intervention|Control|neither parent, nor youth receives the education program
10202688|NCT04294095|Experimental|Intervention|During the first four weeks of the MBMM+ program, participants will receive electronic informational handouts covering topics on weight management as well as the benefits and safety concerns related to prenatal physical activity. Starting week 5 of the 12-week intervention, participants will attend two in-person, group physical activity sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics. Sessions will be held on weekday evenings and weekend mornings as these times were preferred by pregnant women. Each session will include both didactic and experiential components to increase knowledge and skill building.
10202689|NCT04294095|Active Comparator|Control|Electronic materials related to various prenatal topics including preparation for birth, birthing options, and responsive parenting will be distributed twice a week for the first 4-weeks of the program. Starting week 5 of the 12-week intervention, participants will attend two in-person, group sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics.
10202690|NCT04286451|Experimental|Sleep Restriction|Women will undergo 4 nights of sleep restriction treatment.
10202691|NCT04286451|Experimental|Habitual Sleep|Women will undergo 4 nights of habitual sleep treatment.
10202692|NCT04273490||Hereditary hypophosphatemia|Adult persons with genetically or biochemically verified hereditary hypophosphatemia.
10202693|NCT04273490||Control|Adult control persons without disturbances in calcium, vitamin D or phosphate homeostasis matched on age, gender and menopausal status.
10202694|NCT04263597|Experimental|2'-fucosyllactose|"Patients will be randomized 1:1 to either receive 2FL at dose level 0 (starting dose) or placebo (2g oral glucose).~Starting Dose for ages 0-5 years: 2.5 g/day; Ages 5.1-10 years: 5 g/day; Ages >10 years: 10 g/day~After 20 patients are enrolled at the first dose level for an arm, enrollment of that arm will be paused. Randomization for the 20 patients will be unblinded and the safety and tolerability of 2FL doses will be compared to placebo for that arm. If 6/10 patients can take 80% of their planned doses, that dose level will be determined as tolerable and a dose escalation will be performed. If 5/10 patients are unable to take at least 80% of planned doses the dose will be determined to not be well tolerated and a dose de-escalation will be done.~Dose escalation for ages 0-5 years: 5 g/day; Ages 5.1-10 years: 7.5 g/day; Ages >10 years: 15 g/day~Dose de-escalation for ages 0-5 years: 1.25 g/day; Ages 5.1-10 years: 2.5 g/day; Ages >10 years: 5 g/day"
10202695|NCT04263597|Placebo Comparator|Placebo (2g oral glucose)|Patients will be randomized 1:1 to either receive 2FL at dose level 0 (starting dose) or placebo (2 g oral glucose).
10202696|NCT04263597|Experimental|Initial enrollment to establish safety|The investigators will enroll 5 patients of ages ≥10 years undergoing allogeneic HSCT. 2'-FL will be administered to these patients from day-7 until day+30 after HSCT at the starting dose. Once safety is determined the investigators will then enroll an additional 5 patients of ages 5-10 years and administer 2'FL to these patients at the proposed dose for this age group from day-7 to day+30 after HSCT. Once safety is determined, the investigators will enroll 5 patients of ages 0-5 years and administer 2'FL at starting doses to children from day-7 to day+30 after HSCT. Once safety is established in these patients we will proceed with the randomized portion of the study.
10202697|NCT04262726|Experimental|REMOTION + TAU|Participants in the REMOTION group receive REMOTION in addition to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
10202698|NCT04262726|Active Comparator|TAU|Participants in TAU receive psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
10202699|NCT04261413|Experimental|RS-0139|There will be only RS-0139 arm in the study.
9759653|NCT00661557|Active Comparator|Mencevax Naive Group|Subjects who did not receive (or had not received in the preceding 10 years) any meningococcal vaccination received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
9759654|NCT00661570|Experimental|Early feasability arm|
9759655|NCT00661583|Experimental|Ranibizumab alone|Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
9759656|NCT00661583|Experimental|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
9759657|NCT00661583|Active Comparator|MMC alone|MMC therapy alone (n=10)
9759658|NCT00661609|Experimental|AZD4877|Single agent AZD4877
9759659|NCT00661622|Experimental|Immunoembolization|Liver embolization treatment with injection of GM-CSF.
9759660|NCT00661622|Active Comparator|Plain embolization|Liver embolization with normal saline injected in place of GM-CSF
9759661|NCT00661661|Experimental|CP-690,550|
9759662|NCT00661674|Experimental|Sequence 1: Placebo, Combo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Palonosetron"
9759663|NCT00661674|Experimental|Sequence 2: Palonosetron, Combo, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Placebo"
9783424|NCT01200355|Experimental|micafungin|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
9783425|NCT01200355|Experimental|posaconazole|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
9783426|NCT01200368|Experimental|1|Experimental
9783427|NCT01200368|Active Comparator|2|Active comparator
9783428|NCT01200368|Active Comparator|3|Active comparator
9783429|NCT01200394|Experimental|PF-00489791|
9783430|NCT01200394|Placebo Comparator|Placebo|
9783431|NCT01200407||Filipino Hypertensive patients|Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
9783432|NCT01200433|Active Comparator|propofol|Subjects will be sedated with propofol.
9783433|NCT01200433|Active Comparator|dexmedetomidine|Subjects will be sedated with dexmedetomidine.
9759664|NCT00661674|Experimental|Sequence 3: Combo, Placebo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Placebo~Week 3: Palonosetron"
9759665|NCT00661674|Experimental|Sequence 4: Placebo, Palonosetron, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron only~Week 3: Palonosetron + Hydroxyzine Combo"
9759666|NCT00661674|Experimental|Sequence 5: Combo, Palonosetron, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Palonosetron only~Week 3: Placebo"
9759667|NCT00661674|Experimental|Sequence 6: Palonosetron, Placebo, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron only~Week 2: Placebo~Week 3:Palonosetron + Hydroxyzine Combo"
9759668|NCT00661687|Active Comparator|Purevision Contact Lens #1|PureVision Soft Contact Lens Design (currently marketed)
9759669|NCT00661687|Experimental|PureVision Contact Lens #2|Redesign of the currently marketed PureVision soft contact lens.
9759670|NCT00661713|Experimental|rMenB06|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
9759671|NCT00661713|Experimental|rMenB0|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
9759672|NCT00661713|Experimental|rMenB016|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
9759673|NCT00661713|Experimental|rMenB01|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
9759674|NCT00661713|Experimental|rMenB026|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
9759675|NCT00661713|Experimental|rMenB02|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
9759676|NCT00661713|Experimental|rMenB012|Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
9759677|NCT00661713|Experimental|rMenB6|Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
9759678|NCT00661726|Experimental|1|Participants will receive injected decitabine for 12 weeks.
9759679|NCT00661778|Experimental|Bevacizumab + cisplatin + docetaxel|Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
9759680|NCT00661830|Experimental|1|Gemcitabine + Sorafenib
9759681|NCT00661830|Placebo Comparator|2|Gemcitabine + Placebo
9759682|NCT00661895|Experimental|Intervention|Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).
9759683|NCT00661895|Active Comparator|Control|No intervention
9759684|NCT00661960|No Intervention|1|HIV Negative volunteers
9759685|NCT00661960|Active Comparator|2|HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
9759686|NCT00661960|Active Comparator|3|HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other nucleoside reverse transcriptase inhibitor (NRTI) medications
9759687|NCT00661999|Experimental|Arm I|Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
9759688|NCT00661999|Experimental|Arm II|Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
9759689|NCT00661999|Experimental|Arm III|Patients receive darbepoetin alfa as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
9759690|NCT00662012|Experimental|Sodium Stibogluconate (SSG) 20 mg/kg|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
9759691|NCT00662025|Experimental|1|
9759692|NCT00662038|Experimental|Treatment|pirfenidone
9759693|NCT00662129|Experimental|paclitaxel + gemcitabine + bevacizumab|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after every other course, and then after completion of treatment.~After completion of study treatment, patients are followed periodically for 5 years."
9759694|NCT00662155|Experimental|Continuous 1 (QHS-10)|continued nightly use with 10mg zolpidem
9759695|NCT00662155|Experimental|Partial Reinforcement (PRS-10)|partial reinforcement with 10mg zolpidem (PRS-10 [nightly pill use with 50% active meds and 50% placebos])
9759696|NCT00662155|Experimental|Intermittent (IDS-10)|intermittent dosing with 10mg zolpidem
9759697|NCT00662155|Experimental|Continuous 2 (QHS-5)|continued nightly use with 5mg zolpidem
9759698|NCT00662207|Experimental|Arm 1|Use a vibrator on the patient's bottom to determine if it will induce a bladder contraction; Use an anal dilator to determine if urethral relaxation will occur
9759699|NCT00662259|Experimental|alprazolam|Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.
9759700|NCT00662259|Placebo Comparator|placebo|A placebo comparator will be administered to 12 patients with generalized anxiety disorder
9759701|NCT00662298|Experimental|Severe Asthma|
9759702|NCT00662311|Experimental|Treatment (vorinostat with paclitaxel and radiotherapy)|Patients receive vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.
9759703|NCT00662363|Experimental|Lubiprostone and placebo Senna|Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon
9759704|NCT00662363|Active Comparator|Senna active plus Lubiprostone Placebo|Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID
9759705|NCT00662532|Experimental|Minocycline HCl|1 mg microspheres of minocycline hydrochloride
9759706|NCT00662532|No Intervention|No Intervention|Control group receiving no drug intervention
9759707|NCT00662545|Experimental|A|Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine
9759708|NCT00662545|Active Comparator|B|continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine
9759709|NCT00662558|Experimental|celecoxib|
9759710|NCT00662558|Active Comparator|tramadol|
9759711|NCT00662649|Experimental|Fingolimod 1.25 mg|Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
9759712|NCT00662649|Experimental|Fingolimod 0.5 mg|Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
9759713|NCT00662649|Experimental|Placebo-fingolimod|Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
9759714|NCT00662649|Experimental|Placebo-fingolimod 1.25 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
9759715|NCT00662649|Experimental|Placebo-fingolimod 0.5 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
9759716|NCT00662675|Experimental|001|Pancrease MT 10.5 or MT 21 Pancrease MT capsules for maximum dose of 10 000 lipase units / Kg / day
9759717|NCT00662675|Experimental|002|Placebo for Pancrease MT 10.5 or MT 21 Capsules with Pancrease MT excipients without the active enzymes
9759718|NCT00662818|Experimental|Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg|Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
9759719|NCT00662818|Experimental|Placebo and APAP 1000 mg→Telcagepant 300 mg|Participants receive 1 dose of placebo to APAP and placebo to telcagepant for the first migraine attack and then up to 11 doses of APAP and placebo to telcagepant for up to 11 migraine attacks in Period 1 (6 weeks). Participants receive up to 12 doses of telcagepant and placebo to APAP for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
9759720|NCT00662831|Experimental|Active|Active study treatment
9759721|NCT00662831|Placebo Comparator|Placebo|Placebo
9759722|NCT00662857|Experimental|1: TI Inhalation Powder A|Technosphere® Insulin Inhalation Powder, two 15 U cartridges
9759723|NCT00662857|Experimental|2: TI Inhalation Powder B|Technosphere® Insulin Inhalation Powder, one 30 U cartridge
9759724|NCT00662857|Experimental|3: RAA Population|Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro
9759725|NCT00662909|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
9759726|NCT00662909|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
9759727|NCT00662909|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 m tablets, orally once a day for 12 weeks
9759728|NCT00663026|Experimental|A|5 mg/week
9759729|NCT00663026|Experimental|B|10 mg/week
9759730|NCT00663026|Experimental|C|Placebo
9759731|NCT00663039|Experimental|Oxytocin, then Placebo|Participants first received 24IU of Oxytocin administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received placebo.
9759732|NCT00663039|Experimental|Placebo, then Oxytocin|Participants first received a placebo (saline nasal spray) administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received Oxytocin.
9759733|NCT00663117|Placebo Comparator|Placebo, Sugar pill|placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
9759734|NCT00663117|Active Comparator|Naltrexone-HCl|Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.
9759735|NCT00663169|Experimental|Canakinumab|Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.
9759736|NCT00663169|Active Comparator|Dexamethasone|Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.
9759737|NCT00663208|Active Comparator|Group 1|"Daclatasvir (1 mg), once daily~or~Matching Placebo, once daily"
9759738|NCT00663208|Active Comparator|Group 2|"Daclatasvir (10 mg), once daily~or~Matching Placebo, once daily"
9759739|NCT00663208|Active Comparator|Group 3|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
9759740|NCT00663208|Active Comparator|Group 4|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
9759741|NCT00663208|Active Comparator|Group 5|"Group 5: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
9759742|NCT00663208|Active Comparator|Group 6|"Group 6: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
9759743|NCT00663234|Experimental|Age 10 to 14|Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
9759744|NCT00663234|Experimental|Age 15 to 23|Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
9759745|NCT00663260|Active Comparator|Dapagliflozin (10 mg)|
9759746|NCT00663260|Active Comparator|Dapagliflozin (5 mg)|
9759747|NCT00663260|Placebo Comparator|Placebo|
9759748|NCT00663702|Experimental|1|
9759749|NCT00663793|Experimental|Oral testosterone|"(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
9759750|NCT00663793|Experimental|Finasteride plus Oral Testosterone|"(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
9759751|NCT00663819|Active Comparator|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
9759752|NCT00663819|Other|Procedure/Surgery|Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
9759753|NCT00663858|Experimental|Cetrorelix 78+78|
9759754|NCT00663858|Experimental|Cetrorelix 78 + Placebo|
9759755|NCT00663858|Placebo Comparator|Placebo|
9759756|NCT00663871|Active Comparator|Fish Oil|Participants will take fish oil supplements daily for 4 months.
9759757|NCT00663871|Placebo Comparator|Placebo|Participants will take soybean oil (placebo) supplements daily for 4 months.
9759758|NCT00663923|Experimental|cross-cylinder|In this technique the laser is programmed with the axis and amount of cylinder,so that the steepest meridian is flattened with central cylindrical ablation and the flattest meridian steepens with paracentral ablation
9759759|NCT00663923|Active Comparator|single|In this technique ,cylinder is treated only on one meridian by performing an elliptical ablation to to flatten the steeper meridian to match the flatter meridian.
9759760|NCT00663962|Experimental|Perioperative pregabalin|Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).
9759761|NCT00663962|Placebo Comparator|Placebo control|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)
9759762|NCT00664105|Experimental|Therapeutic Intervention|
9759763|NCT00664209|Other|Active-placebo|These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
9759764|NCT00664209|Other|Placebo-active|These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
9783434|NCT01200485|Experimental|Rasburicase Alone|Rasburicase by vein on Day 1 (0.15 mg/kg or a flat dose of 3 mg) as a single dose, plus as needed dosing (until day 5), during cycle 1 (21 day cycle).
9783435|NCT01200485|Experimental|Arm A (Rasburicase)|Participants randomized to Rasburicase (0.15 mg/kg) by vein on day 1 plus as needed dosing (until day 5) during Cycle 2.
9783436|NCT01200485|Experimental|Arm B (Allopurinol)|Participants randomized to Allopurinol (300 mg/day) by vein each day on Days 1-5 of Cycle 2.
9783437|NCT01200498|Experimental|SB939|SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
9783438|NCT01200511|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
9783439|NCT01200524|Experimental|AZD2423, 20mg|
9783440|NCT01200524|Experimental|AZD2423, 150 mg|
9783441|NCT01200524|Placebo Comparator|Placebo|Tablet to match the 20 mg and 50 mg AZD2423 active tablet
9783442|NCT01200589|Experimental|Arm A: Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
9783443|NCT01200589|Active Comparator|Arm B: Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
9783444|NCT01200758|Active Comparator|Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
9783445|NCT01200758|Experimental|Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
9783446|NCT01200797|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9759765|NCT00664326|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle
9759766|NCT00664430|Other|Calcitriol challenge followed by paricalcitol|Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.
9759767|NCT00664521|Experimental|Rituximab Plus Atacicept|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
9759768|NCT00664521|Placebo Comparator|Rituximab Plus Placebo|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
9759769|NCT00664534|Active Comparator|Glargine|Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)
9759770|NCT00664534|Experimental|Premixed Insulin Lispro|Premixed Insulin Lispro (mid-mixture or low-mixture) 1,2 or 3 injections plus OAMs
9759771|NCT00664560|Experimental|ARM 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole
9759772|NCT00664560|Active Comparator|Arm 2 (celebrex)|Celecoxib 200 mg
9759773|NCT00664560|Placebo Comparator|Arm 3 (placebo)|sugar pill
9759774|NCT00664742|Experimental|Fluvastatin XL® Treatment|80 mg once daily, at bedtime.
9759775|NCT00664755|Experimental|Varenicline|Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
9759776|NCT00664755|Active Comparator|Transdermal Nicotine Patch|Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
9759777|NCT00664859|Experimental|Single|Open-label LCP-AtorFen
9759778|NCT00665002|Experimental|WT-1 Analog Peptide Vaccine|Participants received 6 bi-weekly vaccinations over 10 weeks. WT-1 vaccine was given with Montanide. Participants also received an injection of Sargramostim (GM-CSF) two days before each vaccination and again on the day of the WT-1 injection at the same spot.
9759779|NCT00665132|Experimental|StimRouter (SR) for CTS|Percutaneous implantation of StimRouter System
9759780|NCT00665353|Experimental|PIO (step 1) then PIO+PEG-INF+RBV (step 2)|All participants in this study will receive pioglitazone therapy for 24 to 28 weeks. Participants will continue pioglitazone and add peginterferon and ribavirin to their treatment regimen for up to 48 additional weeks.
9759781|NCT00665366|Placebo Comparator|Placebo + valproate or lithium|Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
9759782|NCT00665366|Active Comparator|Aripiprazole + valproate or lithium|Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
9759783|NCT00665392|Experimental|cetuximab|Cetuximab by intravenous (IV) infusion over 1-2 h on day
9759784|NCT00665431|Experimental|Arm 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole bid
9759785|NCT00665431|Active Comparator|Arm 2 (Celebrex)|Celecoxib 200 mg
9759786|NCT00665431|Placebo Comparator|Arm 3 (Placebo)|sugar pill
9759787|NCT00665457|Experimental|Celecoxib|"•Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team."
9759788|NCT00665470|Experimental|Cohort I - high dose Aldesleukin|Patients receive high-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
9759789|NCT00665470|Experimental|Cohort II - low dose Aldesleukin|Beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion, patients receive low-dose aldesleukin subcutaneous (SC) once daily 5 days a week for up to 6 weeks.
9759790|NCT00665561||Maraviroc exposed|
9759791|NCT00665561||Maraviroc unexposed|
9759792|NCT00665626|Experimental|Arm 1|Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day
9759793|NCT00665626|Placebo Comparator|Arm 2|Placebo, orally, twice-a-day
9759794|NCT00665652|Experimental|Lenalidomide|
9759795|NCT00665704|Experimental|Tobacco Tactics Website|Nine veteran smokers who will pilot test the Tobacco Tactics website
9759796|NCT00665847|Experimental|Etravirine (TMC125)|
9759797|NCT00665925|Experimental|1|R788, 100 mg tablet, orally, twice-a-day
9759798|NCT00665925|Experimental|2|R788, 150 mg tablet, orally, once a day
9759799|NCT00665925|Placebo Comparator|3|Placebo, orally, either once a day, or twice a day
9759800|NCT00666029|Active Comparator|Atorvastatin|Active arm atorvastatin 40 mg. o.d.
9759801|NCT00666029|Placebo Comparator|Placebo|Placebo arm dummy pill
9759802|NCT00666198||SILDENAFIL|Patients taking SILDENAFIL.
9759803|NCT00666211|Active Comparator|Standard of Care|Standard pain control drugs.
9759804|NCT00666211|Experimental|Opioid Titration|Pain will be Monitored and Medication Titrated
9759805|NCT00666224|Experimental|Glatiramer acetate|Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
9759806|NCT00666224|Placebo Comparator|Placebo (DB) to GA (OL)|Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).
9759807|NCT00666263|Experimental|IGIV, 10% Then Placebo|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle)."
9759808|NCT00666263|Experimental|Placebo Then IGIV, 10%|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)"
9759809|NCT00666276||linezolid (Zyvox)|Patients taking Linezolid.
9759810|NCT00666328|Experimental|clevidipine|This will be a single-arm study with no reference therapy.
9759811|NCT00666406|Experimental|1|Advate rAHF-PFM
9759812|NCT00666406|Active Comparator|2|Recombinate rAHF
9759813|NCT00666458|Experimental|1|saxagliptin add-on to metformin
9759814|NCT00666458|Active Comparator|2|sitagliptin add-on to metformin
9759815|NCT00666536|Active Comparator|Aggressive treatment regimen (5/320 mg to 10/320 mg)|Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
9759816|NCT00666536|Active Comparator|Moderate treatment regimen (5/160 mg)|Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
9759817|NCT00666562|Placebo Comparator|Arm I (placebo)|Patients receive six oral placebo capsules once daily for 14-28 days.
9759818|NCT00666562|Experimental|Arm II (polyphenon E, placebo)|Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
9759819|NCT00666562|Experimental|Arm III (polyphenon E, trans-urethral resection or cystectomy)|Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
9759820|NCT00666588|Experimental|Bortezomib 1.3mg/m2-assess efficacy-low anthracycline exposure|Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age < 3 years old.
9759821|NCT00666588|Experimental|Bortezomib 1.0mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.0 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.0 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9759822|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.3 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (dose-finding phase closed as of 10/10).
9759823|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess efficacy high anthracycline exp|Bortezomib 1.3 mg/m2 to assess efficacy in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity
9832306|NCT02607124|Experimental|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
9832307|NCT02607124|Experimental|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
9759824|NCT00666666|Experimental|AT101 (R-(-)-gossypol acetic acid)|Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.
9759825|NCT00666679|Active Comparator|1|mometasone
9759826|NCT00666679|Placebo Comparator|2|montelukast followed by placebo; or placebo followed by montelukast.
9759827|NCT00666705|Experimental|Maraviroc alone|
9759828|NCT00666705|Experimental|Maraviroc + Raltegravir|
9759829|NCT00666705|Experimental|Raltegravir alone|
9759830|NCT00666718|Active Comparator|Glargine|Glargine plus Insulin Lispro (2-3 injections)
9759831|NCT00666718|Experimental|ILPS|Insulin Lispro Protamine Suspension (ILPS) plus Insulin Lispro (2-3 injections)
9759832|NCT00666757|Experimental|duloxetine|study drug
9759833|NCT00666757|Active Comparator|citalopram|
9759834|NCT00666757|Active Comparator|fluoxetine|
9759835|NCT00666757|Active Comparator|paroxetine|
9759836|NCT00666757|Active Comparator|sertraline|
9759837|NCT00666835|Experimental|HX575 epoetin alfa Hexal AG|Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
9759838|NCT00666835|Active Comparator|ERYPO®, Janssen-Cilag|Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
9759839|NCT00666848|Placebo Comparator|2 (enalapril 5mg)|Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .
9759840|NCT00666848|Placebo Comparator|1 (placebo)|Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.
9759841|NCT00666848|Placebo Comparator|3 (enalapril 10mg)|Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.
9759842|NCT00666926|Experimental|1|
9759843|NCT00666926|Experimental|2|
9759844|NCT00666926|Experimental|3|
9759845|NCT00666926|Experimental|4|
9759846|NCT00666965|Placebo Comparator|1|inactive placebo
9759847|NCT00666965|Experimental|2|2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
9759848|NCT00666965|Experimental|3|4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
9759849|NCT00666965|Experimental|4|6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
9759850|NCT00666978|Experimental|Bupropion Arm|Subjects undergo smoking cessation intervention and take bupropion.
9759851|NCT00666978|Placebo Comparator|Health Education Arm|Subjects receive counseling intervention and take placebo.
9759852|NCT00667004|Experimental|1|ecabet ophthalmic solution
9759853|NCT00667004|Placebo Comparator|2|Placebo comparator
9759854|NCT00667095|Experimental|Botox and DMSO instillation|Botulinum-A Toxin (Botox) 300 units in 50 cubic centimeters of Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution
9832308|NCT02607228|Experimental|Alobresib Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of alobresib up to 9 mg to determine the MTD.
9759855|NCT00667095|Placebo Comparator|DMSO instillation|Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters
9759856|NCT00667186|Active Comparator|Targeted Screening|"Targeted Screening~Participants approached at ED for voluntary HIV counseling and testing based on risk for HIV"
9759857|NCT00667186|Active Comparator|Routine Screening|"Routine Screening~Participants approached at ED for voluntary HIV counseling and testing regardless of established risk according to age criteria"
9759858|NCT00667225|Placebo Comparator|I|Subjects in this group will have topical application of cantharidin's vehicle at each visit.
9759859|NCT00667225|Experimental|II|Subjects in this group will have topical application of cantharidin at each visit.
9759860|NCT00667277|Experimental|bevacizumab (Avastin)|Use of bevacizumab (Avastin) in the treatment of myelofibrosis.
9759861|NCT00667342|Experimental|Localized Resectable Disease (Stratum A)|Participants with localized resectable disease receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin, and doxorubicin, or methotrexate. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, or methotrexate.
9759862|NCT00667342|Experimental|Metastatic Disease (Stratum B)|Participants with metastatic disease (Stratum B) receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
9759863|NCT00667342|Experimental|Unresectable Disease (Stratum C)|Participants with unresectable disease (Stratum C) receive treatment identical to Stratum B: Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
9759864|NCT00667355|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
9759865|NCT00667368|No Intervention|Control|Bi-monthly testing for BV without treatment.
9759866|NCT00667368|Experimental|Intervention|Metronidazole 500mg twice daily for 7 days for Bacterial Vaginosis (BV) detection
9759867|NCT00667381|No Intervention|Control|The combination of anatomic landmarks and fluoroscopic localization of the femoral head will be used to guide femoral arterial access.
9759868|NCT00667381|Experimental|Ultrasound|Patients randomized to Ultrasound will have anatomic landmarks checked and real-time ultrasound guidance to aid femoral arterial access.
9759869|NCT00667394|Experimental|Tandutinib & Bevacizumab in GBM Patients|GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
9759870|NCT00667394|Experimental|Tandutinib & Bevacizumab in AG Patients|AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
9759871|NCT00667420|Experimental|EOXP chemotherapy|open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle
9759872|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 11.25 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
9759873|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 30 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
9759874|NCT00667459|Experimental|Investigational|PRESTIGE® LP Cervical Disc
9759875|NCT00667459|Active Comparator|Control|Control patients who received a ACDF fusion treatment from a previous IDE trial (NCT00642876)
9759876|NCT00667511|Active Comparator|Home Short Daily Hemodialysis|Intervention: Patients perform short daily hemodialysis (2 to 4 hour treatments) in the home setting using the NxStage System One.
9759877|NCT00667511|Experimental|Home Nocturnal Hemodialysis|Intervention: Patients perform nocturnal hemodialysis (6 to 10 hour treatments) in the home setting using the NxStage System One.
9759878|NCT00667563|Experimental|Gardasil Vaccination|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
9759879|NCT00667576|Experimental|Paricalcitol 2 µg ± 1 µg|Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg
9759880|NCT00667576|Experimental|Paricalcitol 2 µg ± 2 µg|Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg
9759881|NCT00667576|Experimental|Paricalcitol 4 µg ± 1 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg
9759882|NCT00667576|Experimental|Paricalcitol 4 µg ± 2 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg
9759883|NCT00667576|Other|Maxacalcitol 5 or 10 µg ± 2.5 µg|Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg
9759884|NCT00667589|Experimental|urea 40% cream|
9759885|NCT00667589|Experimental|fluocinonide 0.05% cream|
9759886|NCT00667589|Experimental|tazarotene 0.1% cream|
9759887|NCT00667589|Experimental|bland emollient cream|
9832309|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive less than or equal to MTD of alobresib in combination with enzalutamide 160 mg once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of alobresib may be increased.
9832310|NCT02607228|Experimental|Alobresib Dose Expansion (Group 1)|Participants will receive a dose less than or equal to MTD of alobresib (based on safety, pharmacodynamics (PD), and tolerability).
9832311|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 2)|Participants will receive a dose less than or equal to MTD of alobresib plus enzalutamide (based on safety, PD, and tolerability).
9832312|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 3)|Participants will receive alobresib plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
9832313|NCT02607254|Experimental|Pregabalin Treatment phase|All patients will be initially treated with pregabalin in a single blind fashion
9832314|NCT02607254|Experimental|Withdrawal phase|After finishing the treatment phase, some patients will be randomized to the placebo or continue on pregabalin for the 4 weeks of withdrawal phase.
9832315|NCT02607280|Experimental|DS-5565 group|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
9832316|NCT02607306|Experimental|Insulin degludec/liraglutide OD|
9832317|NCT02607306|Active Comparator|Insulin degludec OD|
9832318|NCT02607306|Active Comparator|Liraglutide OD|
9832319|NCT02607618|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
9832320|NCT02607618|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
9832321|NCT02607735|Experimental|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
9832322|NCT02607735|Experimental|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
9832323|NCT02607735|Experimental|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
9832324|NCT02607800|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
9832325|NCT02607800|Active Comparator|SOF/VEL 12 weeks|SOF/VEL tablet for 12 weeks
9832326|NCT02607865|Experimental|Semaglutide 3 mg|
9832327|NCT02607865|Experimental|Semaglutide 7 mg|
9832328|NCT02607865|Experimental|Semaglutide 14 mg|
9832329|NCT02607865|Active Comparator|Sitagliptin 100 mg|
9759888|NCT00667602|Experimental|MenACWY-CRM197 (2 doses) + Concomitant Vaccines|Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
9759889|NCT00667602|Experimental|MenACWY-CRM197 (1 dose) + Concomitant Vaccines|Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
9759890|NCT00667602|Active Comparator|MenC (1 dose) + Concomitant Vaccines|Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
9759891|NCT00667615|Experimental|1|vorinostat in combination with cyclophosphamide, etoposide,prednisone and rituximab,peg-filgrastim or filgrastim
9759892|NCT00667693|Active Comparator|Macintosh laryngoscope|Intubation with a Macintosh laryngoscope
9759893|NCT00667693|Active Comparator|Pentax AWS|Intubation with a Pentax AWS
9759894|NCT00667719|Experimental|Aliskiren/Amlodipine/Hydrochlorothiazide|Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 12.5 mg for one week, at Week 2. Following Week 2, participants were force titrated up to aliskiren 300 mg plus amlodipine 10 mg plus hydrochlorothiazide 25 mg for 26 to 52 weeks (Weeks 28 to 54). All study medications were taken orally with water, once daily in the morning.
9759895|NCT00667732|Active Comparator|1|Participants will receive exenatide as part of their diabetes treatment
9759896|NCT00667732|Placebo Comparator|2|Participants will receive placebo rather than exenatide as part of their diabetes treatment
9759897|NCT00667745|Experimental|1|Participants received lithium plus optimized medication treatment, as needed.
9759898|NCT00667745|Active Comparator|2|Participants only received optimized medication treatment, as needed; lithium was not be used.
9759899|NCT00667810|Experimental|Bapineuzumab 0.5 mg/kg|
9759900|NCT00667810|Experimental|Bapineuzumab 1.0 mg/kg|
9759901|NCT00667810|Placebo Comparator|Placebo|
9759902|NCT00667849|Active Comparator|Exogen 4000+|Single arm, Exogen 4000+
9759903|NCT00667849|Sham Comparator|Sham|Single arm, sham (identical device with the exception of administration of ultrasound).
9759904|NCT00667862|Experimental|Panobinostat|Participants with metastatic hormone refractory prostate cancer received 20 milligrams per meter square (mg/m^2) of panobinostat intravenously (i.v.) on Days 1 and 8 of a 21-day cycle. Treatment continued until disease progression as per investigator, intolerable toxicity, start of new cancer therapy, death, or withdrawal of consent.
9759905|NCT00667875|Placebo Comparator|1|
9759906|NCT00667875|Active Comparator|2|Naltrexone
9759907|NCT00667875|Active Comparator|3|Naltrexone + Aripiprazole
9759908|NCT00667888|Active Comparator|Intensity Modulated Radiotherapy (IMRT)|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
9759909|NCT00667888|Experimental|Hypofractionated Intensity Modulated Radiotherapy (HIMRT)|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
9759910|NCT00667992|Active Comparator|Budesonide Hydrofluoroalkane (HFA) 100|Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks
9759911|NCT00667992|Active Comparator|Budesonide HFA 400|Budesonide HFA 400 mcg twice daily for 2 weeks
9759912|NCT00667992|Active Comparator|Budesonide Chlorofluorocarbon (CFC) 100|Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks
9759913|NCT00667992|Active Comparator|Budesonide CFC 400|Budesonide CFC 400 mcg twice daily for 2 weeks
9759914|NCT00668148|Experimental|IMC-A12 (cixutumumab)|
9832330|NCT02608099|Active Comparator|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
9832331|NCT02608099|Experimental|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
9832332|NCT02608177|Experimental|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
9832333|NCT02608177|Experimental|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
9832334|NCT02608229|Experimental|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals).~BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.~Nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.~Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.~Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
9832335|NCT02608229|Experimental|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~First 2 patients enrolled: BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Remaining 6 patients enrolled: BVD-523 450 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 800 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
9832336|NCT02608450|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
9832337|NCT02608450|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
9832338|NCT02608463|Other|Part A - Neuropathic Pain|Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.
9832339|NCT02608463|Other|Part A - Non-Neuropathic Pain|Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.
9832340|NCT02608463|Other|Part A - Control|Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.
9832341|NCT02608463|Experimental|Part B - rTMS|Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).
9832342|NCT02608476|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
9832343|NCT02608476|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
9832344|NCT02608489|Active Comparator|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
9832345|NCT02608489|Placebo Comparator|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
9832346|NCT02608879|Experimental|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
9832347|NCT02608879|Other|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
9832348|NCT02608892|Experimental|Intervention|BSweet2Babies video
9832349|NCT02608892|No Intervention|Control|Usual care
9832350|NCT02609100|Active Comparator|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
9832351|NCT02609100|Active Comparator|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
9832352|NCT02609113|Active Comparator|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
9832353|NCT02609113|Placebo Comparator|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
9832354|NCT02609178|Experimental|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
9832355|NCT02609178|No Intervention|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
9832356|NCT02609204|Experimental|Healthy Controls|Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
9832357|NCT02609308|Active Comparator|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
9832358|NCT02609308|Experimental|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
9832359|NCT02609399|Experimental|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
9832360|NCT02609399|Experimental|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
9832361|NCT02609607|Placebo Comparator|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
9832362|NCT02609607|Experimental|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
9832363|NCT02609633|Active Comparator|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
9832364|NCT02609633|Experimental|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
9832365|NCT02609659|Experimental|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) plus RBV (ribavirin [600 mg once daily]) for 12 weeks.
9832366|NCT02609672|Experimental|Exercise|The participants in this arm were asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Four class times were offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
9832367|NCT02609672|Other|No Exercise|The participants in this arm were asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group were offered a free exercise pass following completion of the study. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
9832368|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
9832369|NCT02609984|Experimental|CMB305 (sequentially administered LV305 and G305)+Atezolizumab|Participants received CMB305 treatment in combination with 1200 mg/day atezolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 2 years. CMB305 treatment consisted of 2 doses of LV305 administered intradermally (ID) on Days 0 and 14 followed every 2 weeks with alternating doses of G305 administered intramuscularly (IM) and LV305. LV305 was administered at a dose of 1×10^10 vector genomes and G305 at a dose of 5 mcg glucopyranosyl lipid A stable emulsion mixed with 250 mcg of NY ESO-1 protein.
9832370|NCT02609984|Active Comparator|Atezolizumab|Participants received 1200 mg/day atezolizumab by IV infusion Q3W for up to approximately 2 years.
9832371|NCT02610140|Experimental|BAY94-9343|Drug Anetumab ravtansine given Intravenously (IV)
9832372|NCT02610140|Active Comparator|Vinorelbine|Drug Vinorelbine given Intravenously
9832373|NCT02610231|Experimental|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
9832374|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
9832375|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
9832376|NCT02610725|Other|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
9832377|NCT02610777|Active Comparator|Azacitidine|Azacitidine 75 milligram per square meter (mg/m^2), intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles.
9832378|NCT02610777|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 mg/m^2, intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+ or - 10) infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles.
9759915|NCT00668200|Other|zoledronic acid|5 mg of Reclast (ZOL446, zoledronic acid) injection in 100 mL ready to infuse solution administered intravenously via a vented line. The infusion time was to be not less than 15 minutes given over a constant infusion rate.
9759916|NCT00668317|Other|omeprazole and ranitidine|20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte
9759917|NCT00668382|Experimental|Alpha-Gal Glycosphingolipid injection|Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)
9759918|NCT00668395|Other|CYP2B6*1/*1 genotype|Efavirenz clearance in this genotype was compared with the other genotypes
9759919|NCT00668395|Other|CYP2B6*1/*6|Efavirenz clearance in this genotype was compared with the other genotypes
9759920|NCT00668395|Other|CYP2B6*6/*6|Efavirenz clearance in this genotype was compared with the other genotypes
9759921|NCT00668434|Experimental|Prednisone|Participants will receive a 15-day tapering course of prednisone capsules.
9759922|NCT00668434|Placebo Comparator|Placebo|Participants will receive a 15-day course of placebo capsules.
9759923|NCT00668525|Active Comparator|2|Escitalopram low dose
9759924|NCT00668525|Experimental|3|Escitalopram high dose
9759925|NCT00668525|Placebo Comparator|1|Placebo
9759926|NCT00668564|Experimental|Intent-to-Treat|All patients treated with study regimen.
9759927|NCT00668707|Experimental|Melatonin|To receive 20 mg of melatonin nightly for 1 year post-surgery
9832379|NCT02610816|Active Comparator|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
9759928|NCT00668707|Placebo Comparator|Placebo|To receive 20 mg placebo nightly for 1 year post-surgery
9759929|NCT00668746|Experimental|Minocycline HCl microspheres|Minocycline HCl microspheres
9759930|NCT00668746|No Intervention|No drug intervention|No drug intervention
9759931|NCT00668811|Experimental|Treatment Arm - Sutent|Sutent 37.5 mg/day will be given orally.
9759932|NCT00668863|Experimental|1|
9759933|NCT00668902|Experimental|EM of CYP2C19|CYP2C19 enzyme activity in extensive metabolizers of CYP2C19 (CYP2C19*1/*1 genotype, or wild type) was measured by 13C)Pantoprazole breath test.
9759934|NCT00668902|Experimental|IM of CYP2C19|CYP2C19 activity in heterozygous for deficient CYP2C19 alleles (*2 and *3, IM of CYP2C19) was measured by (13C)Pantoprazole breath test.
9759935|NCT00668902|Experimental|PM of CYP2C19|Homozygous for CYP2C19 null alleles (*2/*2, *2/*3 or *3/*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.
9759936|NCT00669019|Experimental|Saracatinib|Patients receive saracatinib 175 mg oral once daily in the absence of disease progression or unacceptable toxicity.
9759937|NCT00669032|Experimental|hyaluronic acid|Cycles of 5 injections of hyaluronic acid at specified intervals
9759938|NCT00669032|Placebo Comparator|Placebo|Cycles of 5 injections of saline at specified intervals
9759939|NCT00669071|Active Comparator|IPL / Tri-Luma® Cream|
9759940|NCT00669071|Active Comparator|IPL/Cetaphil® Moisturizing Cream as Inactive Control|
9759941|NCT00669110|Experimental|A|
9759942|NCT00669162|Experimental|RT, Docetaxel, Hormonal Therapy|Radiation Therapy (RT) to 66 Gy in 33 treatment fractions at 2.0 Gy/fx Concurrent Docetaxel (with RT) at 20 mg/m2 weekly x 7 Casodex (50 mg po daily)x 6 months Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)
9759943|NCT00669214|Experimental|Efalizumab|
9759944|NCT00669214|Placebo Comparator|Placebo|
9759945|NCT00669240||1. Non-interventional|Patients prescribed varenicline in a non interventional manner.
9759946|NCT00669279|Experimental|Carvedilol CR|
9759947|NCT00669279|Experimental|Atenolol|
9759948|NCT00669318|Experimental|Treatment (Pentostatin, Alemtuzumab, Rituximab)|"Course 1: Patients receive:~2 mg/m^2 pentostatin IV on days 8 and 22;~3 mg alemtuzumab subcutaneously (SC) on day 3;~10 mg alemtuzumab SC on day 4;~30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.~Courses 2 and 3: Patients receive:~2 mg/m^2 pentostatin IV on days 1 and 15;~30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3)."
9759949|NCT00669331|Experimental|Mannitol|Inhaled mannitol 400mg
9759950|NCT00669331|Placebo Comparator|Control|Matched control - inhaled mannitol 50mg
9759951|NCT00669383|Active Comparator|A|Betamethasone (Celestone) 12 mg intramuscular q 24 hours x 2 doses
9759952|NCT00669383|Placebo Comparator|B|Placebo dose intramuscular q 24 hours x 2 doses
9759953|NCT00669396|Experimental|1|IUD
9759954|NCT00669396|Active Comparator|2|Oral levonorgestrel
9759955|NCT00669409|Experimental|10 mcg/kg|
9759956|NCT00669409|Experimental|100 mcg/kg|
9759957|NCT00669409|Experimental|200 mcg/kg|
9759958|NCT00669409|Experimental|25 mcg/kg|
9759959|NCT00669409|Experimental|50 mcg/kg|
9759960|NCT00669409|Placebo Comparator|Placebo|
9783447|NCT01200810|Placebo Comparator|Arm I|"Patients receive oral placebo once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
9783448|NCT01200810|Experimental|Arm II|"Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
9783449|NCT01200992|Experimental|EN3348|8 mg mixed with sterile water for injection for a total volume of 50mL
9783450|NCT01200992|Active Comparator|Mitomycin C|40 mg powder will be reconstituted with sterile water for injection to a total volume of 40 mL
9783451|NCT01201057|Experimental|0.5% SPL7013 Gel|
9783452|NCT01201057|Experimental|1.0% SPL7013 Gel|
9783453|NCT01201057|Experimental|3.0% SPL7013 Gel|
9783454|NCT01201057|Placebo Comparator|Placebo Gel|
9783455|NCT01201265|Experimental|Overall Participants|Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.
9783456|NCT01201317|Experimental|AZD2423, 150 mg|Tablets, 150 mg once daily in the morning.
9783457|NCT01201317|Experimental|AZD2423, 20 mg|Tablets, 20 mg once daily in the morning.
9783458|NCT01201317|Placebo Comparator|Placebo|Tablets, placebo, once daily in the morning.
9783459|NCT01201356|Experimental|Fingolimod 0.5 mg/day|Open-label fingolimod 0.5 mg, taken orally once daily
9783460|NCT01201486||Pregnant women|Pregnant females in the 2nd trimester.
9783461|NCT01201629|Sham Comparator|t DC stimulation|Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
9759961|NCT00669539||Combined-Mechanism Amblyopia|
9759962|NCT00669539||Strabismus-Only Amblyopia|
9759963|NCT00669552||Medtronic defibrillator|Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal.
9759964|NCT00669578|Experimental|CC-4047|
9759965|NCT00669617|Experimental|Ind 150μg, Salm/flut, Ind 300μg, Placebo, Salbut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Placebo, Salbutamol 200 μg (Salbut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9759966|NCT00669617|Experimental|Ind 300μg, Ind 150μg, Salbut, Salm/flut, Placebo|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo. At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9759967|NCT00669617|Experimental|Salm/flut, Placebo, Ind 150μg, Salbut, Ind 300μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo, Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9759968|NCT00669617|Experimental|Salbut, Ind 300μg, Placebo, Ind 150μg, Salm/flut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg), Placebo, Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9759969|NCT00669617|Experimental|Placebo, Salbut, Salm/flut , Ind 300μg, Ind 150μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Placebo, Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9759970|NCT00669682||Group A|The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance.
9759971|NCT00669864|Experimental|BIAsp 30-30|Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily
9759972|NCT00669877|Experimental|Hyper-CVAD|Hyper-CVAD (odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses. Rituximab 375 mg/m2 days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses. Cyclophosphamide 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3. Doxorubicin 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses). Vincristine 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses). Dexamethasone 40 mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses). G-CSF 10 mg/kg/day (rounded) until neutrophil recovery 1 x 10^9/L or higher can be substituted or can be added to pegfilgrastim if neutrophils have not recovered to 1 x 10^9/L by day 21.
9759973|NCT00669903|Experimental|1|AZD0328 low dose
9759974|NCT00669903|Experimental|2|AZD0328 Optimal dose
9759975|NCT00669903|Experimental|3|AZD0328 High dose
9759976|NCT00669903|Placebo Comparator|4|Placebo Comparator
9759977|NCT00669916|Experimental|AIN457|AIN457A 3mg/kg was administered intravenously as a single dose.
9759978|NCT00669916|Placebo Comparator|Placebo|Placebo was administered intravenously as a single dose.
9759979|NCT00669942|Experimental|Part 1 - AIN457A 0.3 mg/kg|AIN457A 0.3 mg/kg was administered intravenously as a single dose.
9759980|NCT00669942|Experimental|Part 1 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as a single dose.
9759981|NCT00669942|Experimental|Part 1 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
9759982|NCT00669942|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
9759983|NCT00669942|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
9759984|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
9783462|NCT01201629|Experimental|tDC stimulation|Actual DC stimulation
9759985|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
9984150|NCT04362007|Experimental|Phase 1 dose-escalation part|Subjects with r/r PTCL and r/r CTCL will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RD is determined.
9984151|NCT04362007|Experimental|Phase 1 ATLL expansion part|Subjects with r/r ATLL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
9759986|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
9759987|NCT00669942|Placebo Comparator|Parts 2 and 3 - Placebo|Placebo to AIN457A was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
9759988|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 3 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
9759989|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 10 mg/kg|AIN457A 10 mg/kg was administered intravenously as a single dose.
9759990|NCT00669942|Placebo Comparator|Part 1 - Healthy Volunteers - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
9759991|NCT00669955|Active Comparator|OAC 7 days|Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
9759992|NCT00669955|Experimental|OBMT 10 days|OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.
9759993|NCT00670007|Experimental|Zemaira®|
9759994|NCT00670046|Other|Arm I (standard of care)|Patients undergo observation according to the standard of care. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
9759995|NCT00670046|Experimental|Arm II (valproic acid)|Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
9759996|NCT00670111|Experimental|RAP On then Off at 1 month visit|"Rate Adaptive Pacing (RAP) On for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) Off for second cardiopulmonary exercise test (CPX) at one month."
9759997|NCT00670111|Experimental|RAP Off then On at 1 month visit|"Rate Adaptive Pacing (RAP) Off for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) On for second cardiopulmonary exercise test (CPX) at one month."
9759998|NCT00670202|Experimental|Drug: Fasudil hydrochloride|Fasudil hydrochloride 40 mg three times a day X 14 days
9759999|NCT00670202|Placebo Comparator|Drug: Placebo oral tablet|Placebo 1 tablet three times daily x 14 days
9760000|NCT00670228|Active Comparator|Intensive Insulin Therapy (IIT)|In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
9760001|NCT00670228|Active Comparator|Standard Glycemic Care (SGC)|"In SGC arm subjects assigned to standard of care received subcutaneous regular insulin per sliding scale."
9760002|NCT00670241|Active Comparator|1|
9760003|NCT00670241|Active Comparator|2|
9760004|NCT00670241|Placebo Comparator|3|
9760005|NCT00670267|Experimental|Open Label treatment with oral Nadolol|Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.
9760006|NCT00670306|Experimental|Cetrorelix 78 mg|Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.
9760007|NCT00670449|Experimental|Fingolimod 0.5 mg|Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
9760008|NCT00670449|Experimental|Fingolimod 1.25 mg|Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
9760009|NCT00670449|Experimental|Placebo-fingolimod|Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
9760010|NCT00670462|Active Comparator|Standard Behavioral Treatment (SBT)|"Standard Behavioral Treatment (SBT) for weight loss intervention introduces a core set of instructions on diet and exercise at the beginning of the intervention and then embellishes these instructions with suggested refinements of behavioral choices over time (e.g., different menus and amounts or types of physical activity)."
9783463|NCT01201759|Experimental|Placebo to Salsalate 2gr BID|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
9783464|NCT01201759|Experimental|Salsalate 2gr BID to placebo|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days.
9760011|NCT00670462|Experimental|Maintenance-Tailored Treatment (MTT)|"Maintenance-Tailored Treatment (MTT) for weight loss intervention treats diet and exercise strategy embellishments as separate interventions with discrete and independent status. MTT differs from SBT in its emphasis on skills for long-term weight control, namely, the strategy of initiating varied weight-control strategies as a response to the demands of changing environmental challenges and to sustain effective cues and reinforcements needed to motivate weight-loss behaviors."
9760012|NCT00670488|Experimental|MK-2206 30 mg QOD|Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
9760013|NCT00670488|Experimental|MK-2206 60 mg QOD|Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
9760014|NCT00670488|Experimental|MK-2206 75 mg QOD|Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
9760015|NCT00670488|Experimental|MK-2206 90 mg QOD|Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
9760016|NCT00670488|Experimental|MK-2206 90 mg QW|Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
9760017|NCT00670488|Experimental|MK-2206 135 mg QW|Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.
9760018|NCT00670488|Experimental|MK-2206 200 mg QW|Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.
9760019|NCT00670488|Experimental|MK-2206 300 mg QW|Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
9760020|NCT00670488|Experimental|MK-2206 250 mg QW|Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.
9760021|NCT00670488|Experimental|MK-2206 150 mg QW|Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.
9760022|NCT00670540||1|patients with suspected Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
9760023|NCT00670709||1|Subjects with mild or moderate Huntington's Disease
9760024|NCT00670709||2|Normal Controls
9760025|NCT00670748|Experimental|#1 Anti-NY-ESO-1 TCR PBL+HD IL-2 Mel/RCC|Patients with melanoma or renal cell cancer (RCC) will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin.
9760026|NCT00670748|Experimental|#2 Anti-NY-ESO-1 TCR PBL+HD IL-2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 TCR PBL and high dose (HD) aldesleukin
9760027|NCT00670748|Experimental|#3ESO1 TCR PBL+ALVAC ESO1+HD IL2 Mel/RCC|Patients with melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by replication-defective recombinant canarypox virus (ALVAC) NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
9760028|NCT00670748|Experimental|#4ESO1 TCR PBL+ALVAC ESO1+HD IL2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by ALVAC NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
9760029|NCT00670774|Experimental|Eculizumab|Patients received eculizumab intravenously according to details provided in the intervention description.
9760030|NCT00670800|No Intervention|Normal Controls|Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
9760031|NCT00670800|Experimental|PCOS Affected Women-Metformin Treatment|Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast & lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch & dinner.
9760032|NCT00670930|Active Comparator|omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single use, 5 ml vial that was designed to deliver 150 mg of omalizumab for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The dose administered was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and the number of injections and injection volume was determined using protocol-specified dosing tables. Omalizumab 75 to 375 mg was administered SQ every 2 or 4 weeks depending on the dose for the 78 weeks duration of double-blinded treatment.
9760033|NCT00670930|Placebo Comparator|Placebo|Omalizumab matching placebo was supplied as lyophilized, sterile powder in a single-use, 5 ml vial that was designed to deliver omalizumab matching placebo for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The number of injections and injection volume was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and was determined using protocol-specified dosing tables. Placebo was administered SQ every 2 or 4 weeks for the 78 weeks duration of double-blinded treatment.
9760034|NCT00670956|Active Comparator|Active Study Group|STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
9760035|NCT00670956|Placebo Comparator|Placebo Group|PLACEBO: IM x 2 doses 24 hours apart
9783465|NCT01201772|Active Comparator|Prasugrel 60mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
9760036|NCT00670982|Experimental|First line treatment|Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week
9760037|NCT00670982|Experimental|Second line treatment|Patients with 1 prior line for metastatic breast cancer will receive bevacizumab intravenously every two weeks, vinorelbine intravenously once per week, and trastuzumab intravenously once per week.
9760038|NCT00671034|Experimental|Arm I (combination chemotherapy)|Patients receive calaspargase pegol together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 4 years.
9760039|NCT00671034|Active Comparator|Arm II (combination chemotherapy)|Patients receive pegaspargase together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo RT to the head. Treatment may continue for up to 4 years.
9783466|NCT01201772|Active Comparator|Prasugrel 30mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
9783467|NCT01201772|No Intervention|Prasugrel 10mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
9783468|NCT01201785|Experimental|Aspirin dose range|
9760040|NCT00671060|Active Comparator|2|Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
9783469|NCT01201798|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
9760041|NCT00671060|Placebo Comparator|1|Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
9760042|NCT00671177|Experimental|Water Immersion Colonoscopy|Water Immersion Colonoscopy
9760043|NCT00671177|Active Comparator|Standard Air Colonoscopy|Standard Air Colonoscopy
9760044|NCT00671437|Experimental|Arm 1|"Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)~Cetuximab 400 mg/m2 intravenously (IV) over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.~Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)~Cetuximab 250 mg/m2 IV over 1 hour on Day 57~Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease"
9760045|NCT00671502|Experimental|Carisoprodol 700mg|tablet sustained release (SR)
9760046|NCT00671502|Experimental|Carisoprodol 500mg|sustained release(SR) tablet
9760047|NCT00671502|Placebo Comparator|Placebo|tablet
9760048|NCT00671515|Experimental|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
9760049|NCT00671554|Experimental|Melaxin and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration
9760050|NCT00671658|Experimental|HYPER-CVAD|Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.
9760051|NCT00671671|Experimental|Cohort B|
9760052|NCT00671671|Experimental|Cohort A|Dose study drug in subjects who have previously failed to respond to interferon based therapies
9760053|NCT00671723|Placebo Comparator|Normal saline|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
9760054|NCT00671723|Active Comparator|Hypertonic saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
9760055|NCT00671723|Active Comparator|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
9760056|NCT00671749|Experimental|Study Treatment|"adapalene gel, 0.3%~Other Names:~Differin® Gel, 0.3% Applied once daily at bedtime~clindamycin/benzoyl peroxide gel~Other Names:~Duac® Gel Applied once daily in the morning"
9760057|NCT00671788|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9760058|NCT00671853|Experimental|1|Quetiapine XR
9760059|NCT00671853|Placebo Comparator|2|Placebo for quetiapine XR
9760060|NCT00671879|Experimental|Carisprodol SR 700 mg|Carisoprodol 700 mg twice daily
9760061|NCT00671879|Experimental|Carisoprodol SR 500mg|Carisoprodol SR 500 mg twice daily
9760062|NCT00671879|Placebo Comparator|Placebo|Placebo
9760063|NCT00671918|Experimental|Lymphoseek, Lymphatic mapping, Injection|
9760064|NCT00671931|Active Comparator|I|Dexmedetomidine low infusion, Propofol low infusion
9760065|NCT00671931|Active Comparator|II|Dexmedetomidine high infusion, Propofol low infusion
9760066|NCT00671931|Active Comparator|IV|Dexmedetomidine high infusion, Propofol high infusion
9760067|NCT00671931|Active Comparator|V|Dexmedetomidine intermediate infusion, Propofol intermediate infusion
9760068|NCT00671931|Active Comparator|III|Dexmedetomidine low infusion, Propofol high infusion
9760069|NCT00671970|Experimental|Bevacizumab + Erlotinib|Bevacizumab + Erlotinib
9760070|NCT00672100|Active Comparator|A|Initial Bolus 5 ml Ropivacaine
9760071|NCT00672100|Active Comparator|B|Initial Bolus 10 ml Ropivacaine
9760072|NCT00672100|Active Comparator|C|Initial Bolus 20 ml Ropivacaine
9760073|NCT00672139|Experimental|Methylnaltrexone bromide|"Methylnaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study.~Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information."
9760074|NCT00672204|Experimental|1|Allogeneic islets of Langerhans
9760075|NCT00672243|Experimental|Erlotinib + Sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
9760076|NCT00672256|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
9760077|NCT00672438|Placebo Comparator|Saline placebo infusion|Subjects will receive an intravenous infusion of normal saline.
9760078|NCT00672438|Experimental|Alfentanil infusion|Subjects will receive an intravenous infusion of alfentanil.
9760079|NCT00672451|Experimental|rhubarb extract|will receive rhubarb extract
9760080|NCT00672451|Placebo Comparator|placebo|receive placebo
9760081|NCT00672477|Experimental|Methylnaltrexone|Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
9760082|NCT00672477|Placebo Comparator|Placebo|Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and < 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.
9760083|NCT00672490|Experimental|1|Quetiapine Fumarate - tablets
9760084|NCT00672490|Experimental|2|Quetiapine Fumarate - tablets and Lithium
9760085|NCT00672555|Experimental|Pilonidal Sinus T. With Limberg F.|All patients treated by excision and covering of the defect by a Limberg-flap, who gave their informed consent to participate in the study, as there is only one study group.
9760086|NCT00672594|Experimental|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
9760087|NCT00672620|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
9760088|NCT00672620|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
9760089|NCT00672620|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
9760090|NCT00672620|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
9760091|NCT00672633|Experimental|A , Experimental|Lovaza, 4 grams/day orally for 6 months
9760092|NCT00672633|Placebo Comparator|Corn Oil Pill|Corn Oil Pill, 4 pills/day orally for 6 months
9760093|NCT00672646|Experimental|AZD1386|
9760094|NCT00672646|Active Comparator|Naproxen|
9760095|NCT00672646|Placebo Comparator|Placebo|Placebo matching AZD1386
9832380|NCT02610816|Active Comparator|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
9832381|NCT02610816|Other|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
9832382|NCT02610816|Other|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
9832383|NCT02610842|Experimental|Handbook group|"Patients will receive a home based program named Hands on - a hand care guide in Systemic Sclerosis which includes a handbook with instructions about the disease and hand exercises. Patients will be asked to follow the program instructions and carry out the exercises daily during the following 12 weeks."
9832384|NCT02610868|Experimental|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
9832385|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
9832386|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
9832387|NCT02611154|Experimental|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
9832388|NCT02611362|Experimental|Intervention|"Subjects in the intervention group will each receive a smartphone with a data service plan as the active arm. The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
9832389|NCT02611362|No Intervention|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
9832390|NCT02611752|Experimental|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
9832391|NCT02611752|Experimental|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
9832392|NCT02611765|Experimental|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
9832393|NCT02611765|Active Comparator|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
9832394|NCT02611778|Experimental|FYB201|FYB201 is provided as single use vials and will be administered by intra-vitreal injection.
9832395|NCT02611778|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.
9832396|NCT02611817|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
9832397|NCT02611817|Placebo Comparator|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
9984152|NCT04362007|Experimental|Phase 2|Subjects with r/r PTCL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
9760096|NCT00672737||Males at risk for OSA|"Males at risk for obstructive sleep apnea were invited to have a sleep study either at home or at Stanford Sleep Center.~A week after their sleep study (Polysomnography), all volunteers underwent quantitative sensory testing in the laboratory, during which their pain thresholds and tolerances to heat (Heat pain threshold and tolerance) and cold (Cold pain threshold and tolerance) stimuli were assessed, under two different concentrations (1 and 2 mcg/mL, in randomized order) of remifentanil, a short-acting opioid, given as a computer-controlled infusion."
9760097|NCT00672841|Active Comparator|2|Standard care/empiric therapy group
9760098|NCT00672841|Experimental|1|Active surveillance/ preemptive therapy group
9760099|NCT00672854|Active Comparator|Intralipid 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving Intralipid 20% (soybean-based)
9760100|NCT00672854|Experimental|ClinOleic 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving ClinOleic 20% (olive oil based)
9760101|NCT00672932|Experimental|raltegravir group|The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
9760102|NCT00672932|No Intervention|No augmented treatment|Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.
9760103|NCT00672958|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.
9760104|NCT00672958|Experimental|Vortioxetine|Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.
9760105|NCT00672984|Experimental|Immediate-release Guanfacine HCl|
9760106|NCT00672984|Active Comparator|Moxifloxacin HCl|
9760107|NCT00672984|Placebo Comparator|Placebo|
9760108|NCT00673049|Experimental|Arm A|"The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.~CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter."
9760109|NCT00673049|Active Comparator|Arm B|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)
9760110|NCT00673075|Active Comparator|1|Encapsulated Nebivolol
9760111|NCT00673075|Active Comparator|2|Encapsulated Carvedilol
9760112|NCT00673114|Other|Transplant Recipients|
9760113|NCT00673127|Experimental|KHAD|Ketoconazole, Hydrocortisone and Dutasteride Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Dutasteride: 0.5 mg once a day
9760114|NCT00673153|Experimental|Arm I|"REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .~CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.~MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses."
9760115|NCT00673231|Experimental|1|2.5mg
9760116|NCT00673231|Experimental|2|5mg
9760117|NCT00673231|Experimental|3|10mg
9760118|NCT00673231|Placebo Comparator|4|
9760119|NCT00673244|Experimental|1|
9783470|NCT01201798|Active Comparator|Pred Forte|Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period
9783471|NCT01201811|Experimental|Single-Arm|Azacitidine 75 mg/m^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
9783472|NCT01201850|Experimental|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses.
9760120|NCT00673257|Experimental|Pharmacokinetics of Daunorubicin chemotherapy patients|Patients receiving a chemotherapy regimen including daunorubicin hydrochloride administered as an infusion of any duration < 24 hours on a 1 or a 2 day schedule. Pre-study evaluations no greater than 14 days prior to daunomycin administration. If patients have had significant intercurrent illness or treatment that might affect organ function, laboratory work should be performed at an appropriately closer interval to daunomycin administration. A complete history and physical examination including height, weight and body surface area. Patients should be weighed with only light clothing; shoes must be removed before weight is measured. Patients height should be measured using a stadiometer after removing shoes. Laboratory evaluation: a) CBC with differential and platelet count. b) ALT, AST, bilirubin, creatinine, total protein, albumin, alkaline phosphatase, GGT.
9760121|NCT00673387|Placebo Comparator|Placebo-P + Placebo-M|Placebo matched to pramlintide BID plus placebo matched to metreleptin BID
9760122|NCT00673387|Experimental|Pramlintide 360 mcg + Placebo-M|360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID
9760123|NCT00673387|Experimental|Placebo-P + Metreleptin 5.0 mg|Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID
9760124|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 2.5 mg|Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID
9760125|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 5.0 mg|Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID
9760126|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 1.25 mg|Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID
9760127|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 2.5 mg|Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID
9760128|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 5.0 mg|Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID
9760129|NCT00673400|Other|Stapled transanal rectum resection|patients operated with stapled transanal rectum resection
9760130|NCT00673439|Experimental|Fondaparinux|daily subcutaneous injection of fondaparinux (7.5-10 mg)
9760131|NCT00673452|Experimental|Duloxetine|60-120 mg, oral, every day, 12 weeks
9760132|NCT00673452|Placebo Comparator|Placebo|oral, daily, 12 weeks
9760133|NCT00673465|Experimental|Treatment sequence 1: SCH 497079 → Placebo → Metformin|Participants received SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks followed by metformin daily for 4 weeks.
9760134|NCT00673465|Experimental|Treatment sequence 2: Placebo → Metformin → SCH 497079|Participants received placebo daily for 4 weeks followed by metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
9760135|NCT00673465|Experimental|Treatment sequence 3: Metformin → SCH 497079 → Placebo|Participants received metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks.
9760136|NCT00673465|Experimental|Treatment sequence 4: SCH 497079 → Metformin → Placebo|Participants received SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks followed by placebo daily for 4 weeks.
9760137|NCT00673465|Experimental|Treatment sequence 5: Placebo → SCH 49709 → Metformin|Participants received placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks.
9760138|NCT00673465|Experimental|Treatment sequence 6: Metformin → Placebo → SCH 497079|Participants received metformin daily for 4 weeks followed by placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
9760139|NCT00673660||Statins|Patients with dyslipidemia who are taking or planning to take a statin treatment (Atorvastatin, Fluvastatin, Prevastatin, Rosuvastatin, Simvastatin or generics).
9760140|NCT00673673|Experimental|1|FOLFOX in combination with bevacizumab
9760141|NCT00673712|Experimental|Continuous Sternal Block|Continuous Sternal block with infusion of local anesthetic via ON-Q Painbuster Silver Soaker system
9760142|NCT00673712|Active Comparator|Opioid based analgesia|Opioid based analgesia including Patient controlled analgesia plus IM, Oral narcotics and other analgesics
9760143|NCT00673738|Experimental|Cetuximab Plus Radiotherapy|Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.
9760144|NCT00673764|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
9760145|NCT00673764|Active Comparator|Optive|Optive Lubricant Eye Drops
9760146|NCT00673790|Active Comparator|Nebivolol|Nebivolol with concomitant losartan or lisinopril
9760147|NCT00673790|Active Comparator|Hydrochlorothiazide (HCTZ)|HCTZ with concomitant losartan or lisinopril
9760148|NCT00673790|Placebo Comparator|Placebo|Placebo with concomitant losartan or lisinopril
9760149|NCT00673816|Experimental|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
9760150|NCT00673855|Experimental|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye one time
9760151|NCT00673855|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye 1 time
9760152|NCT00673881|Experimental|Abt-335|ABT-335 (choline fenofibrate)
9760153|NCT00673894|Experimental|Glutamine+Sitagliptin|Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin
9760154|NCT00673894|Placebo Comparator|Glutamine+Placebo|Glutamine 30 g/d (15 g with breakfast and dinner) + placebo
10202700|NCT04261257|Experimental|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a serum pregnancy test for women of childbearing age, a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of your care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks (CT scan of the cerebral arteries), a transcranial Doppler, a biological assessment, a 24-hour holter or long-term holter.~Within 24 hours after admission: The cerebral artery scan, (usual care), is carried out and is supplemented by the additional examination of this research corresponding to a cardiac scanner (not requiring additional injection of contrast medium).~The following examinations of usual care are carried out within 3 days of inclusion: a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care."
10202701|NCT04249674||Patient under a CYP2D6 inhibitor and under Tramadol|
10202702|NCT04249674||Patient not under a CYP2D6 inhibitor but under Tramadol|
10202703|NCT04234295|Active Comparator|Lean, Healthy Controls|Subjects with a body mass index (BMI) of 25 or less will have a fat tissue biopsy collected
10202704|NCT04234295|Experimental|Obese, Non-Diabetic|Subject with a BMI between 30 and 50 kg/m2 will have fat tissue biopsy collected
10202705|NCT04233879|Experimental|Group 1: DOR/ISL|Treatment-naïve participants with HIV-1 receive DOR/ISL and placebo to BIC/FTC/TAF once daily (QD) for 96 weeks.
10202706|NCT04233879|Active Comparator|Group 2: BIC/FTC/TAF|Treatment-naïve participants with HIV-1 receive BIC/FTC/TAF and placebo to DOR/ISL QD for 96 weeks.
10205202|NCT03684980|Experimental|Arm D -Rituximab + MTX + Glucarpidase|Up to 12 patients will be included in Arm D of this study. Cycles will be 14 days long. All patients will receive MTX 3.5 g/m2 administered Day 1 of each cycle (+/- 7 days, a minimum of 14 days required between doses). Glucarpidase will be administered 24 hours (+/- 2 hr) after start of MTX infusion except in cycles 1-2 of Cohort B. Dose of glucarpidase will be 2000 units in Cohort A (first 4 patients) and 1000 units in Cohort B (remaining 8 patients). Patients in Arm D will receive 8 cycles of treatment. Cycles 1 and 2 will be administered in patient while Cycles 3-8 may be in the outpatient setting. Concurrent chemotherapy such as vincristine, procarbazine, and/or ibrutinib may be administered at the investigator's discretion and in accordance with standard of care. In Cohort B, all cycles will be administered with rituximab 500 mg/m2. Rituximab should be administered prior to glucarpidase (window -4 days).
10205203|NCT03678181|Active Comparator|Information-Only Arm|The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
10205204|NCT03678181|Experimental|HMP 2.0 Arm|Participants in this experimental arm will receive access to HMP 2.0, an interactive site that includes a Knowledge Center focused on HIV prevention content, interactive forums, and a provider question & answer platform.
10205205|NCT03678181|Experimental|Peer-referred HMP network arm|Participants randomized to Intervention Arm 2 (peer-created network) will be enrolled into a parallel (but separate) version of HMP 2.0. The only difference between the two intervention arms is that the peer-referred HMP network arm will allow participants to refer and enroll 2 peers of their choosing into the study.
10205206|NCT03649672|Experimental|Awake calibration|The dominant arm of the patient
10205207|NCT03649672|Active Comparator|Asleep calibration|The non dominant arm of the patient
10205208|NCT03644017|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
10205209|NCT03634241|Active Comparator|Arm A (standard of care)|Participants receive standard of care.
10205210|NCT03634241|Experimental|Arm B (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10205211|NCT03602677|Experimental|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
10205212|NCT03602677|No Intervention|Standard procedure|Standard colorectal surgery and anastomosis.
10205213|NCT03596905|Experimental|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
10205214|NCT03596905|Experimental|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
10205215|NCT03596905|Experimental|2.0 mg plecanatide|Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
10205216|NCT03596905|Experimental|3.0 mg plecanatide|Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
10205217|NCT03596905|Placebo Comparator|Matching placebo|Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
10205218|NCT03592186|Experimental|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
10205219|NCT03592186|Active Comparator|Treatment as Usual|"The active comparator is defined as residential treatment services as usual.~At short-term facility, average length of stay was 6-10 days. At long-term facility, average length of stay was 30-45 days."
10205220|NCT03567551||Women w/ Preeclampsia w/o Visual Disturbances or Headache|Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
10205221|NCT03567551||Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
10205222|NCT03567551||Women w/o Preeclampsia|Normal Pregnancy Blood Pressure: <140/90
10205223|NCT03560531|Experimental|ZN-c5 monotherapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.
9760155|NCT00673920|Placebo Comparator|Placebo|"Participants received matching placebo:~on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)~on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)"
9760156|NCT00673920|Experimental|Ocrelizumab 400mg|Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.
9760157|NCT00673920|Experimental|Ocrelizumab 200mg|Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.
9760158|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 200mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
9760159|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 400mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
9760160|NCT00673920|Experimental|Ocrelizumab 400mg/ Ocrelizumab 400mg|Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
9760161|NCT00673920|Experimental|Placebo/ Ocrelizumab 200mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
9760162|NCT00673920|Experimental|Placebo/ Ocrelizumab 400mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
9760163|NCT00673933|Experimental|1|PDT using MAL crem
9760164|NCT00673933|Placebo Comparator|2|PDT using Placebo cream
9760165|NCT00673959|Experimental|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
9760166|NCT00673959|Active Comparator|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
9760167|NCT00674115|Experimental|Single Dose Zegerid for 1 or 7 days|Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension
9760168|NCT00674115|Active Comparator|Single Dose Prilosec 1 or 7 days|Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet
9760169|NCT00674115|Active Comparator|Sodium Bicarbonate|Sodium Bicarbonate 1680 mg Oral Suspension
9760170|NCT00674128|Experimental|Adhesive|Cyanoacrylate tissue adhesive.
9760171|NCT00674128|Active Comparator|Suture|Polyglactin 910 suture.
9760172|NCT00674154|Experimental|Vitamin D group|Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
9760173|NCT00674154|Placebo Comparator|Placebo group|Placebo, two tablets daily in 52 weeks.
10202707|NCT04233632|Active Comparator|FC2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit.
9760174|NCT00674206|Experimental|Gemcitabine and Oxaliplatin|All patients enrolled on clinical trial will receive Gemcitabine 1000mg/m^2 on Day 1 and Oxaliplatin 100 mg/m^2 intravenously over 2 hours on Day 2.
9760175|NCT00674219|Active Comparator|OCD group|OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
9760176|NCT00674219|Active Comparator|GAD group|GAD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
9760177|NCT00674297|Experimental|Fluvastatin|All patients will take Fluvastatin 40 mg daily for 3 months.
9760178|NCT00674323|Experimental|Verteporfin and Ranibizumab|Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
9835939|NCT02762071|Active Comparator|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
10202708|NCT04233632|Active Comparator|Cupid Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
10202709|NCT04233632|Active Comparator|Cupid 2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
10202710|NCT04230941|Experimental|MAAT-G Intervention|MAAT-G Workshops & participant workbook use (8 workshops)
10202711|NCT04229472|Experimental|Normal subject control group|High density mapping of left atrial voltages in patients with supraventricular tachycardia
10202712|NCT04229472|Experimental|Atrial fibrillation group|High density mapping of left atrial voltages
10202713|NCT04229472|Experimental|AcQMap atrial fibrillation group|High density mapping of left atrial voltages and AcQMap propagation patterns alongside cardiac MRI
10202714|NCT04226833|Experimental|Mild|Participants with mild hepatic impairment will receive 1x100 milligram (mg) F06 (entrectinib) capsule administered orally with approximately 240 milliliter (mL) water within 30 minutes after consumption of a standardized meal.
10202715|NCT04226833|Experimental|Moderate|Participants with moderate hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
10202716|NCT04226833|Experimental|Severe|Participants with severe hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
10202717|NCT04226833|Experimental|Normal|Participants with normal hepatic function will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
10202718|NCT04215952|Experimental|SFA Experimental Intervention|A modified version of Semantic Feature Analysis will be administered.
9760179|NCT00674323|Active Comparator|Verteporfin monotherapy|Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
9760180|NCT00674323|Active Comparator|Ranibizumab monotherapy|Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
9783473|NCT01201863|Experimental|Low T Intervention - Androgel Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Androgel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
9783474|NCT01201863|Placebo Comparator|Low T Intervention - Placebo Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Placebo gel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
9783475|NCT01201863|No Intervention|Normal T|A subset of men with TBI meeting study criteria with normal T at screening were assessed at all data collection time points to provide a control group. Thirty-eight men obtained normal T levels at screening of which 24 were followed.
9783476|NCT01201915|Experimental|Cohort 1: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
9783477|NCT01201915|Experimental|Cohort 2: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
9783478|NCT01201915|Experimental|Cohort 3: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 8 weeks, followed by 4 weeks with no treatment, followed by a second 8-week vismodegib treatment period.
9783479|NCT01201967|Experimental|Collaborative care|Study care manager provides education and coordinates treatment between study psychiatrist, patient, and primary medical physician. This occurs in the hospital and by phone after discharge. Care manager may also provide phone-based therapy.
9783480|NCT01201967|Placebo Comparator|Usual care|Patient's physicians are informed of diagnosis of depression/anxiety disorder
9783481|NCT01202071|Experimental|Rabeprazole sodium Tablets, 5 mg|
9783482|NCT01202071|Experimental|Rabeprazole sodium Tablets, 10 mg|
9783483|NCT01202071|Experimental|Rabeprazole sodium Tablets, 20 mg|
9783484|NCT01202071|Experimental|Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets)|
9783485|NCT01202162|Active Comparator|Desflurane|Administration of Desflurane
9783486|NCT01202162|Active Comparator|Sevoflurane|Administration of Sevoflurane
9783487|NCT01202175|Experimental|Nebivolol|
9783488|NCT01202175|Placebo Comparator|Sugar pill|
9783489|NCT01202188|Experimental|indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
9783490|NCT01202188|Active Comparator|glycopyrronium (NVA237)|NVA237 50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
9783491|NCT01202188|Active Comparator|indacaterol (QAB149)|QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
9783492|NCT01202188|Active Comparator|tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
9783493|NCT01202188|Placebo Comparator|Placebo|Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
9783494|NCT01202227|Experimental|Pregabalin|Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
9783495|NCT01202253||Anidulafungin|
9783496|NCT01202279|Active Comparator|Mucinex D|Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
9783497|NCT01202279|Placebo Comparator|Placebo|Placebo given bid with a full glass of water for 7 days
9783498|NCT01202409|Experimental|Panitumumab|Starting Dose of Panitumumab: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
9783499|NCT01202565||Adalimumab|Participants with moderate to severe plaque psoriasis received adalimumab (Humira®) therapy according to the local product label and prescription/reimbursement guidelines.
9783500|NCT01202578|Experimental|tympanostomy tube|performance and safety of tympanostomy tube delivery system
9783501|NCT01202591|Experimental|AZD4547 + exemestane|Safety run-in: AZD4547 plus exemestane
9783502|NCT01202591|Experimental|AZD4547 + fulvestrant|A Randomised phase IIa: AZD4547 plus fulvestrant
9783503|NCT01202591|Placebo Comparator|Placebo + fulvestrant|Randomised phase IIa: Matching placebo plus fulvestrant
9783504|NCT01202643|Experimental|G-CSF|G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
9783505|NCT01202643|Placebo Comparator|Saline|Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
9760181|NCT00674362|Experimental|Certolizumab pegol 200 mg (CDP870)|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
9760182|NCT00674362|Placebo Comparator|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
9760183|NCT00674466|Experimental|1|Twice-a-week dose of 1.5 mg CJC-1134-PC
9760184|NCT00674466|Experimental|2|Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo
9760185|NCT00674466|Placebo Comparator|3|Twice-a-week placebo for CJC-1134-PC
9760186|NCT00674479|Experimental|INCB018424|The starting dose of INCB018424 will be 25 mg by mouth twice daily.
9760187|NCT00674492||Hepatitis C patients|patients who initiated antiviral treatment for hepatitis C
9760188|NCT00674570|Experimental|Arm 1: Hydrocortisone|Hydrocortisone
9760189|NCT00674570|Experimental|Arm 2: D-Cycloserine|D-Cycloserine
9760190|NCT00674570|Placebo Comparator|Arm 3: Placebo|Placebo
9760191|NCT00674583|Experimental|Nimenrix Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Nimenrix™ vaccine into the non-dominant deltoid region, at Day 0.
9760192|NCT00674583|Active Comparator|Menjugate Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Menjugate® vaccine into the non-dominant thigh region, at Day 0.
9760193|NCT00674609|Placebo Comparator|Placebo|Placebo control
9760194|NCT00674609|Experimental|Sativex|Active treatment
9760195|NCT00674609|Experimental|THC Alone|Active treatment
9760196|NCT00674622|Experimental|Group 1-Prolotherapy|Deep injection with 15% dextrose in lidocaine
9760197|NCT00674622|Placebo Comparator|Group 2-Deep Saline/Lidocaine|Deep injection with saline/lidocaine
9760198|NCT00674622|Placebo Comparator|Group 3-Superficial Saline/lidocaine|Superficial injection with saline/lidocaine
9760199|NCT00674661|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
9760200|NCT00674661|Sham Comparator|Control Group|riboflavin opthalmic solution without UVA irradiation
9760201|NCT00674700|Active Comparator|300 IR|300 IR house dust mites allergen extract tablet
9760202|NCT00674700|Active Comparator|500 IR|500 IR house dust mites allergen extract tablet
9760203|NCT00674700|Placebo Comparator|Placebo|Placebo tablet
9760204|NCT00674739|Experimental|imiquimod cream|2.5% imiquimod cream applied daily to wart area for up to 8 weeks
9760205|NCT00674739|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
9760206|NCT00674739|Placebo Comparator|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
9760207|NCT00674765|Experimental|1|Seroquel
9760208|NCT00674765|Placebo Comparator|2|Placebo
9760209|NCT00674817|Experimental|400 microgrammes GSK961081 and salbutamol|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
9760210|NCT00674817|Experimental|1200 microgrammes GSK961081 and salbutamol|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
9760211|NCT00674817|Experimental|400 microgrammes GSK961081 and ipratropium bromide|400 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
9760212|NCT00674817|Experimental|1200 microgrammes of GSK961081 and ipratropium bromide|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
9760213|NCT00674817|Placebo Comparator|400 microgrammes of GSK961081 and placebo|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
9760214|NCT00674817|Placebo Comparator|1200 microgrammes of GSK961081 and placebo|1200 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
9760215|NCT00674973|Experimental|Erlotinib|Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
9760216|NCT00674973|Placebo Comparator|Placebo|Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
9760217|NCT00674986|Other|Active Control Group (ACG)|Participants in the Active Control Group received enhanced standard of care (more frequent clinic visits, free blood glucose meters and strips and point-of-care Hemoglobin A1c (HbA1c) test) for management of their Type 2 diabetes.
9760218|NCT00674986|Experimental|Structured Testing Group (STG)|Participants in the Structured Testing Group in addition to enhanced standard of care for the treatment of their Type 2 diabetes used the ACCU-CHEK® 360° View blood glucose analysis system (Tool) to monitor glucose levels at least quarterly.
9783506|NCT01202656|Experimental|G-CSF then Saline|G-CSF (Granulocyte colony stimulating factor)
9783507|NCT01202656|Placebo Comparator|Saline then G-CSF|Normal Saline
9835940|NCT02762071|Experimental|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
9835941|NCT02762084|Experimental|Patidegib gel 2%|Patidegib gel 2%, applied topically, twice daily for 26 weeks
9760219|NCT00675025|Experimental|Prior Donepezil-DB|All participants started with a dose of 2.5 mg/day (2.5 mL/day). Dose escalations occurred in 2.5 mg/day increments every 2 weeks (steady state levels assumed to have been reached) to a maximum dose of 10 mg/day, according to the participant's weight schedule and the Investigator's judgment of safety and tolerability. Re-titration was done to maintain the blinding of the double-blind study (E2020-A001-219). Doses could be decreased due to tolerability and could be increased or decreased to maintain a maximum dose of 0.1 to 0.2 mg/kg/day based on the participant's weight at clinic visits during the study duration.
9760220|NCT00675103|Experimental|pegloticase|
9760221|NCT00675259|Experimental|Neoadjuvant, Surgery, Adjuvant|Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel and carboplatin on days 1, 8, and 15. Definitive surgery with either lumpectomy or mastectomy along with axillary lymph node dissection for all pre neo adjuvant chemotherapy node-positive patients approximately 4-5 weeks after the completion of NCT. Use of additional adjuvant chemotherapy and/or radiation therapy depends upon the treating physicians' judgment. Radiation therapy should begin no sooner than 6 weeks after breast cancer surgery. All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
9760222|NCT00675415|Active Comparator|Capnography|"Capnography: Subjects randomized to capnography-titration arm: The endoscopy team would be made aware of the capnographic abnormalities as they arise.~In this arm, the endoscopy team will have the graphic representation of respiratory activity (capnography) as well as end-epxiratory levels of carbon dioxide in addition to the normal physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography.~This observation phase would take place for a baseline prior to sedation, during the administration of sedation as well as throughout the procedure. Monitoring for the study would stop upon completion of the endoscopic procedure."
9760223|NCT00675415|No Intervention|Standard Monitoring|Subjects randomized to capnography-blinded arm: In this arm, the endoscopy team will not have the graphic representation of respiratory activity (capnography) as well as end-expiratory levels of carbon dioxide available. Only a standard of care physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography at the disposal of the endoscopy team to titrate the sedative medications.
9760224|NCT00675428|Experimental|Natalizumab 300 mg|Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
9760225|NCT00675428|Experimental|Natalizumab 450 mg|Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
9760226|NCT00675441|Experimental|Lenalidomide|Lenalidomide 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
9760227|NCT00675506|Experimental|1|Participants will receive treatment with growth hormone releasing hormone 1-44 (TH9507).
9760228|NCT00675506|Placebo Comparator|2|Participants will receive treatment with placebo medication.
9760229|NCT00675558||Non-Obese (NO)|Patients with a BMI < 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.
9760230|NCT00675558||Morbidly Obese (MO)|Patients with a BMI > 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.
9760231|NCT00675558||Super-morbidly Obese (SMO)|"Patients with a BMI > 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.~10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study."
9760232|NCT00675584|Active Comparator|Placebo Budesonide|Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
9760233|NCT00675584|Experimental|Budesonide|Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study.
9760234|NCT00675597|Experimental|1|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients with Resected Stage I-III Non-small Cell Lung Cancer
9760235|NCT00675766||Group 1|HIV-positive adults 50 and older/ HIV-positive adults 18-40 years old
9760236|NCT00675766||Group 2|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
9760237|NCT00675766||Group 3|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
9760238|NCT00675766||Group 4|HIV-negative controls 18-40 years old
9760239|NCT00675792|Experimental|Sugammadex|4 mg/kg sugammadex
9760240|NCT00675792|Active Comparator|Neostigmine|50 µg/kg neostigmine
9760241|NCT00675909|Active Comparator|Oral Midazolam|Oral midazolam 0.5mg/kg
9760242|NCT00675909|Experimental|Aerosolized intranasal midazolam|Intranasal midazolam 0.3mg/kg
9760243|NCT00675909|Experimental|Aerosolized buccal midazolam|Buccal midazolam 0.3mg/kg
9783508|NCT01202721|Experimental|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg.
9835942|NCT02762084|Experimental|Patidegib gel 4%|Patidegib gel 4%, applied topically, twice daily for 26 weeks
9835943|NCT02762084|Placebo Comparator|Vehicle gel|Vehicle gel, applied topically, twice daily for 26 weeks
10202719|NCT04215952|Active Comparator|SFA Active Comparator Intervention|A standard version of Semantic Feature Analysis will be administered.
9783509|NCT01202721|Experimental|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg
9783510|NCT01202747|Experimental|LipiFlow Treatment|Treatment with LipiFlow device
9783511|NCT01202760|Experimental|120 mg LY2127399|"LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.~During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.~After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
9783512|NCT01202760|Experimental|90 mg LY2127399|"LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.~After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
10202720|NCT04215185|Experimental|Blood pressure monitor|The CS6BP device will be placed on non-anesthetized subjects in the ICU (Intensive Care Unit) with arterial line placement in the radial artery. The first measurement will be for up to 24h; subsequent measures will be up to 5h.
10202721|NCT04214860|Experimental|APR-246|APR-246 4.5 g/day
10202722|NCT04208724|Experimental|Training program|Community-based organizations participate in the support program, consisting of 2 half-day training workshops over 2 weeks, and 30-minute bi-weekly consultations in order to adapt and implement the cancer screening intervention for community members.
10202723|NCT04206020|Placebo Comparator|Placebo Comparator: SkQ1 Vehicle|Vehicle for SkQ1 Ophthalmic Solution
9783513|NCT01202760|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.~After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
9783514|NCT01202773|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.~During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
9783515|NCT01202773|Experimental|90 mg LY2127399|"Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.~At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
9783516|NCT01202773|Placebo Comparator|Placebo|"Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.~At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.~At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
10202724|NCT04206020|Active Comparator|SkQ1|SkQ1 Ophthalmic Solution
10202725|NCT04205994|Experimental|Tolcapone|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in a single 200mg dosage once in randomized, double-blind, counterbalanced fashion with a placebo.
10202726|NCT04205994|Placebo Comparator|Placebo|Placebo will be administered in a single pill once in randomized, double-blind, counterbalanced fashion with a placebo.
10202727|NCT04200313|Experimental|Bionic Pancreas (BP)|Adults (RCT and Extension) and peds (RCT) will use the Bionic Pancreas (BP) with lispro or aspart for 13 weeks
10202728|NCT04200313|Experimental|Bionic Pancreas with Fiasp (BPFiasp)|Adults will use the Bionic Pancreas (BP) with Fiasp for 13 weeks during RCT Peds will use the Bionic Pancreas (BP) with Fiasp for 13 weeks during Extension
10202729|NCT04200313|No Intervention|Usual Care (UC)|Adults and peds will use their own diabetes regimen
10202730|NCT04197310|Experimental|Nivolumab and Cabozantinib|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Cabozantinib will be administered at a dose of 40mg orally, once daily~Nivolumab will be given at a dose of 240mg every 14 days, intravenously~Retreat Phase (Optional)~Participants may elect to stop nivolumab and cabozantinib with confirmed CR after at least 24 weeks of treatment.~Participants who elect to stop and then the condition progresses after stopping study treatment may be eligible to resume nivolumab and cabozantinib therapy.~This resumption will be termed as a retreatment second course phase and is available only while the study remains open and the subject meets specified criteria."
10202731|NCT04189536|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
10202732|NCT04187495|Experimental|MAX-40279-01|
10202733|NCT04185428|Experimental|Standard of care with integrative therapy|For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.
9832398|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 108 mg SC|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
9832399|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 300 mg IV|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
9832400|NCT02611830|Experimental|Maintenance Phase: Induction IV + Placebo|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
9984153|NCT04361266|Experimental|Rotium patch recipient|Subjects with Rotium nano scaffold patch included in rotator cuff repair construct
9665900|NCT04823273|Experimental|General improvement|"Using the expertise of the study personnel, electronic-health record system architects working for UCHealth, and incorporating feedback from the users who participated in the user-centered design sessions we made changes to the blood transfusion order-set as well as the prepare and transfuse orders. The intention of the changes to the interface are to be more intuitive for ordering clinicians."
9832401|NCT02611882|Experimental|High-risk prostate cancer pre-prostatectomy (preRP) population|"Patients with high-risk prostate cancer pre-prostatectomy.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
9832402|NCT02611882|Experimental|Biochemical Recurrence (BCR)|"Patients with prostate cancer with biochemical recurrence~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
9832403|NCT02611882|Experimental|Castrate Resistant Prostate cancer (CRCP) population|"Patients with castrate resistant prostate cancer.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
9835944|NCT02762331|Experimental|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
9665901|NCT04823273|Experimental|In-line help text|In addition to general improvement changes, subjects exposed to the in-line help text arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. This text appears within the transfusion order but is non-interruptive as it does not require users to acknowledge the text nor does is require any additional keystrokes or clicks.
9760244|NCT00675922|Experimental|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.
9760245|NCT00675948|Experimental|Sativex|Active treatment
9760246|NCT00675948|Experimental|GW-2000-02|Active treatment
9760247|NCT00675987|Active Comparator|Losartan|Losartan 100 mg 1 tab po QD
9760248|NCT00675987|Placebo Comparator|Placebo|Placebo 1 tab po QD
9760249|NCT00676013|Experimental|Alloderm, Integra, Homograft, Autograft|Burn debridement and grafting using interventions of 1) AlloDerm, 2) Integra, 3) Homograft and 4) Autograft on four separate sites on each patient
9760250|NCT00676052|Experimental|Arm 1|GSK233705 12.5mcg
9760251|NCT00676052|Experimental|Arm 2|GSK233705 25mcg
9760252|NCT00676052|Experimental|Arm 3|GSK233705 50mcg
9760253|NCT00676052|Experimental|Arm 4|GSK233705 100mcg
9760254|NCT00676052|Experimental|Arm 5|GSK233705 200mcg
9760255|NCT00676052|Placebo Comparator|Arm 6|Placebo
9760256|NCT00676065||1|Women who take oral contraceptives containing drospirenone
9760257|NCT00676065||2|Women who take oral contraceptives containing levonorgestrel
9760258|NCT00676065||3|Women who take oral contraceptives containing other progestogens
9760259|NCT00676091|Experimental|13vPnC|13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
9760260|NCT00676091|Active Comparator|7vPnC|7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
9760261|NCT00676130|Active Comparator|Standard therapy|cephalexin plus placebo
9760262|NCT00676130|Experimental|Standard plus anti-CA-MRSA|cephalexin plus trimethoprim-sulfamethoxazole
9760263|NCT00676143|Experimental|Bapineuzumab 0.5 mg/kg|
9760264|NCT00676143|Placebo Comparator|Placebo|
9760265|NCT00676182||Arm 1: Telerehabilitation|telerehabilitation
9760266|NCT00676195|Experimental|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
9760267|NCT00676208|Experimental|Shared Medical Appointments|Medical students participated in shared medical appointments for patients with diabetes for one month.
9760268|NCT00676208|No Intervention|No shared medical appointments|Medical students in this arm did not participate in shared medical appointments.
9760269|NCT00676338|Experimental|Exenatide Once Weekly|
9760270|NCT00676338|Active Comparator|Metformin|
9760271|NCT00676338|Active Comparator|Sitagliptin|
9760272|NCT00676338|Active Comparator|Pioglitazone|
9760273|NCT00676364|Active Comparator|4% lidocaine topical anesthetic cream|This group received topical 4% lidocaine anesthetic cream under occlusive dressing for 15 minutes prior to needle stick.
9760274|NCT00676364|Placebo Comparator|Placebo|This group received matching placebo cream under occlusive dressing for 15 minutes prior to needle stick.
9760275|NCT00676403|Placebo Comparator|1|Placebo
9760276|NCT00676403|Experimental|2|investigational treatment
9760277|NCT00676403|Experimental|3|investigational treatment
9760278|NCT00676403|Experimental|4|investigational treatment
9760279|NCT00676403|Experimental|5|investigational treatment
9760280|NCT00676403|Experimental|6|investigational treatment
9760281|NCT00676520||1|Single-arm study
9760282|NCT00676572||Severe asthma|
9760283|NCT00676572||Non-severe asthma|
9760284|NCT00676585|Placebo Comparator|2|Normal Saline
9760285|NCT00676585|Experimental|1|Hydrocortisone 100mg every 8 hours.
9760286|NCT00676650|Experimental|A|Treatment Arm A - sunitinib + prednisone
9760287|NCT00676650|Placebo Comparator|B|Treatment Arm B - placebo + prednisone
9666137|NCT04690465|Experimental|Resistance training|In the 16 week resistance training, there will be 3 sessions per week, the duration of each session will be 60 minutes, which include 10min of warm-up, 40min of main exercise, and 10min of cool-down. The intensity will be light to somewhat hard (Rating of Perceived Exertion (RPE) 11 to 13; using the Cantonese version of RPE). In resistance training, the weights (resistance) will be from participants' own bodies, dumbbells, and adjustable ankle weights.
9666138|NCT04690465|Active Comparator|Eight-form Yang-style Tai Chi program|In Tai Chi, the 16-week program will be divided into cognitive, associated, and automatic stages. The coach will apply a group teaching with individual instruction on specific movements based on participant's needs in skills learning and acquisition. The same training principles of individuality and progression as well as training log-book used in resistance training will also be applied to Tai Chi training program.
9760288|NCT00676663|Experimental|Exemestane 25 mg + Entinostat 5 mg|Exemestane (Aromasin®) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
9760289|NCT00676663|Placebo Comparator|Exemestane 25 mg + Placebo|Exemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
9760290|NCT00676676|Active Comparator|Testosterone|Testosterone patch delivering 300mcg daily for 8-weeks.
9760291|NCT00676689|Experimental|SAPIEN THV|
9760292|NCT00676780|Experimental|ECGC Extract|Single arm for a phase II study
9760293|NCT00676793|Experimental|Polyphenon E|This is a single arm study comparing changes within patients before and after receiving the experimental drug Polyphenon E for the duration of the study, between recruitment and surgery for breast cancer.
9760294|NCT00676806|Experimental|Myeloablative conditioning|Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
9760295|NCT00676806|Experimental|Reduced intensity conditioning|Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
9760296|NCT00676897|Experimental|1|Simvastatin 40 mg PO or NGT
9760297|NCT00676897|Placebo Comparator|2|Placebo
9760298|NCT00677014|Active Comparator|Echo optimized AV delay|Echo optimized AV delay
9760299|NCT00677014|Active Comparator|Algorithm optimized AV delay|Algorithm optimized AV delay
9760300|NCT00677014|Active Comparator|Fixed AV Delay|Fixed AV Delay
9760301|NCT00677092|Experimental|Imatinib Mesylate (IM) Treatment|Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.
9760302|NCT00677235|Experimental|FLAIR|FLAIR Endovascular Stent Graft
9760303|NCT00677235|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
9760304|NCT00677352|Experimental|1|
9760305|NCT00677352|Active Comparator|2|
9760306|NCT00677365|Placebo Comparator|Placebo|Placebo inhaled either once or twice daily via the PARI eFlow nebulizer for 28 days
9760307|NCT00677365|Experimental|MP-376 120 mg QD|MP-376 120 mg inhaled Once Daily (QD) via the PARI eFlow nebulizer for 28 days
9760308|NCT00677365|Experimental|MP-376 240 mg QD|MP-376 240 mg inhaled QD bia the PARI eFlow nebulizer for 28 days
9760309|NCT00677365|Experimental|MP-376 240 mg BID|MP-376 240 mg inhaled twice daily (BID) via the PARI eFlow nebulizer for 28 days
9760310|NCT00677534|Experimental|1|Cholecalciferol (Vitamin D)
9760311|NCT00677690|Active Comparator|NM+PR|Patients undergone to combination of neuromuscular stimulation and pulmonary rehabilitation (NM+PR)
9760312|NCT00677690|Placebo Comparator|SS+PR|Patients undergone to pulmonary rehabilitation
9760313|NCT00677807|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9760314|NCT00677807|Experimental|Indacaterol 300 µg|"Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9760315|NCT00677807|Placebo Comparator|Placebo|"Placebo once-daily (o.d.) via SDDPI.~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
9760316|NCT00677820|Experimental|Trivalent influenza virus vaccine|Frozen trivalent vaccine containing new strains
9760317|NCT00677820|Placebo Comparator|Placebo|treatment with placebo
9760318|NCT00677833|Experimental|1|
9760319|NCT00677833|Experimental|2|
9760320|NCT00677898|Experimental|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
9760321|NCT00677898|Active Comparator|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
9760322|NCT00677924|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with Irinotecan
9760323|NCT00677924|Experimental|Zalutumumab 16 mg/kg|Zalutumumab in combination with Irinotecan
9760324|NCT00678015|Experimental|1|
9760325|NCT00678080|Experimental|Metformin|Metformin therapy as prescribed by their health care provider
9760326|NCT00678080|Active Comparator|Insulin|Insulin as prescribed by their health care provider
9760327|NCT00678210|Experimental|1|
9760328|NCT00678210|Experimental|2|
9760329|NCT00678210|Experimental|3|
9760330|NCT00678210|Placebo Comparator|4|
9760331|NCT00678249|Experimental|FLAIR|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
9760332|NCT00678249|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
9760333|NCT00678249|Experimental|FLAIR Roll-in Participants|Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
9760334|NCT00678301|Experimental|SYNFLORIX™ + ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Synflorix™ vaccine, according to a 3-dose schedule at 6-10-14 weeks of age co-administered with 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to the same schedule. The Synflorix™ and Zilbrix™ Hib vaccines were administered by intramuscular injection, in the right and left thigh respectively. The Polio Sabin™ vaccine was administered orally.
9760335|NCT00678301|Experimental|ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to a 3-dose schedule at 6-10-14 weeks of age. The Zilbrix™ Hib vaccine was administered by intramuscular injection, in the left thigh. The Polio Sabin™ vaccine was administered orally.
9760336|NCT00678379|Placebo Comparator|Normal Saline|1.5 ml injection of Normal Saline into each tonsillar fossa pre-tonsillectomy
9760337|NCT00678379|Active Comparator|Lidocaine (1%) + Bupivacaine 0.5%|Submucosal injection of 1.5 mL Lidocaine (1%) + Bupivacaine 0.5% into the tonsillar fossa, pre-tonsillectomy
9760338|NCT00678379|Experimental|Lidocaine + Bupivacaine + Clondine|Submucosal injection of 1.5 mL Lidocaine 1% + Bupivacaine 0.5% + Clondine 25mcg into the tonsillar fossa, pre-tonsillectomy
9760339|NCT00678392|Experimental|Axitinib|
9760340|NCT00678392|Active Comparator|Sorafenib|
9760341|NCT00678418|Experimental|VIVITROL® 380 mg|
9760342|NCT00678418|Placebo Comparator|Placebo|
9760343|NCT00678444|No Intervention|Arm 1: Non-educational video self-cath|Randomized to not watching educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
9760344|NCT00678444|Experimental|Arm 2: Educational Video Self-cath|Randomized to watch educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
9760345|NCT00678470|Experimental|Single Arm|Investigational intervention without random assignment
9760346|NCT00678496|Experimental|1|CBT software delivered at home or in a primary care facility (n=12)
9760347|NCT00678496|Other|2|Treatment as usual (n=12)
9760348|NCT00678535|Experimental|Cetuximab plus Capecitabine plus Cisplatin|
9835945|NCT02762331|Placebo Comparator|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
9760349|NCT00678535|Active Comparator|Capecitabine plus Cisplatin|
9760350|NCT00678561|Experimental|2% CP-690,550 QD|
9760351|NCT00678561|Experimental|0.2% CP-690,550 QD|
9760352|NCT00678561|Experimental|0.02% CP-690,550 QD|
9760353|NCT00678561|Experimental|2% CP-690,550 BID|
9760354|NCT00678561|Experimental|0.2% CP-690,550 BID|
9760355|NCT00678561|Experimental|0.02% CP-690,550 BID|
9760356|NCT00678561|Placebo Comparator|Placebo Vehicle QD|
9760357|NCT00678561|Placebo Comparator|Placebo Vehicle BID|
9760358|NCT00678587|Placebo Comparator|Placebo|placebo, once daily, oral
9760359|NCT00678587|Active Comparator|Active|75 mg, once daily, oral
9760360|NCT00678639|Experimental|Emergency Department (ED) Observation unit|Emergency Department observation unit- Cardiac Magnetic Resonance Imaging (MRI) Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
9760361|NCT00678639|No Intervention|Usual care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
9760362|NCT00678652|Experimental|10 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 10 μg with Adjuvant
9760363|NCT00678652|Experimental|25 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 25 μg with Adjuvant
9760364|NCT00678652|Experimental|50 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 50 μg with Adjuvant
9760365|NCT00678652|Experimental|75 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 75 μg with Adjuvant
9760366|NCT00678691|Experimental|A,1|armodafinil
10202734|NCT04185428|No Intervention|Standard of care only|For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.
10202735|NCT04183764|Experimental|MAX-40279-01|capsule, 5mg and 25mg
10202736|NCT04178798|Experimental|Arm A_Acalabrutinib|Patients assigned to arm A, will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos schedule until disease progression, unacceptable toxicity or early withdrawal.
10202737|NCT04178798|No Intervention|Arm B_Standard of care|"Patients assigned to arm B, will receive standard of care for the management of early Binet stage A patients clinical observation (watch & wait) until disease progression or early withdrawal."
10202738|NCT04176848|Experimental|CFI-400945 + Durvalumab|
10202739|NCT04175730|Other|MRI and Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI positive for suspected prostate cancer followed by MRI/ultrasound fusion directed prostate needle biopsies
10202740|NCT04175730|Other|Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI negative for suspected prostate cancer followed by standard ultrasound guided prostate needle biospies
10202741|NCT04168112|Experimental|Group A|Intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days).
10202742|NCT04168112|Active Comparator|Group B|Patients are placed on standard postoperative regimen of postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: QID x1 week, TID x 1 week, BID x 1 week, and Qday x 1 week.
10202743|NCT04166227|Active Comparator|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
10202744|NCT04166227|Active Comparator|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
10202745|NCT04165863|Experimental|A|treatment of the surgical wound healing process with Platelet-rich-fibrin in patients undergoing total knee replacement surgery
10202746|NCT04165863|Active Comparator|B|Gold standard treatment of the surgical wound healing process without Platelet-rich-fibrin in patients undergoing total knee replacement surgery
10202747|NCT04165408|Experimental|Device Use|Only one arm
10202748|NCT04165122|Experimental|HDIT101 + Valaciclovir placebo|"Group A:~Patients treated with a single i.v. infusion of 2 g HDIT101 for 60 min at the randomization visit and with an episodic Valaciclovir placebo bid for 3 days."
10202749|NCT04165122|Active Comparator|HDIT101 placebo + Valaciclovir|"Group B:~Patients treated with a single i.v. infusion of HDIT101 placebo for 60 min at the randomization visit and with episodic Valaciclovir 500 mg twice daily for 3 days."
10202750|NCT04159753|Other|Spinal Cord Stimulator|Burst neurostimulation
10202751|NCT04159571|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
10202752|NCT04159571|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
10202753|NCT04159571|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
10202754|NCT04159571|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
10202755|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Feasibility|Feasibility Phase.
10202756|NCT04159350|Experimental|Rectal Expulsion Device (RED) - Validation|Validation Phase.
10202757|NCT04145466|Experimental|Fat responders (1)|receiving high-fat diet
10202758|NCT04145466|Experimental|Carbohydrate responders (1)|receiving high-fat diet
10202759|NCT04145466|Experimental|Fat responders (2)|receiving high-carbohydrate diet
10202760|NCT04145466|Experimental|Carbohydrate responders (2)|receiving high-carbohydrate diet
10202761|NCT04140227|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
9760367|NCT00678691|Placebo Comparator|A,2|placebo
9835946|NCT02762370|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
10202762|NCT04139902|Experimental|Dostarlimab (TSR-042) (singly)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
10205224|NCT03560531|Experimental|ZN-c5 + palbociclib combination therapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 in combination with palbociclib as well as a Phase 2 cohort.
10205225|NCT03548467|Experimental|VB10.NEO intervention|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing to patients within the selected tumor types.
10205226|NCT03548467|Experimental|VB10.NEO in combination with bempegaldesleukin (NKTR-214)|Bempegaldesleukin (NKTR-214) will be given in combination with VB10.NEO in up to 10 patients with SCCHN. Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. Bempegaldesleukin (NKTR-214) will be given after at least 4 doses of VB10.NEO.
10205227|NCT03533985|Experimental|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
10205228|NCT03533985|Experimental|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
10205229|NCT03533985|Experimental|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
10205230|NCT03533985|Experimental|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
10205231|NCT03533985|Experimental|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
10205232|NCT03533985|Experimental|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
10205233|NCT03529942|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
10205234|NCT03517956|Experimental|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.~Dose expansion (urothelial cancer):~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
10205235|NCT03503370|Experimental|chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
10205236|NCT03503370|Placebo Comparator|placebo|Participants randomized to the placebo will wash their feet using bath CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
10205237|NCT03495011||Cohort A|Patient with recently identified calcifications on mammography requiring biopsy. Patients will undergo a quantitative, multiparametric breast MRI as part of their clinical care. MRI will not change need for biopsy, but could identify additional suspicious sites. Only patients diagnosed with pure DCIS at biopsy and eventual surgical excision will receive Oncotype DX DCIS score testing.
10205238|NCT03495011||Cohort B|Patient with recent diagnosis of biopsy-proven DCIS would complete a research quantitative, multiparametric breast MRI as part of their clinical care. Only patients diagnosed with pure DCIS at surgical resection will receive Oncotype DX DCIS score testing.
10205239|NCT03471663|Experimental|D-0502|D-0502
10205240|NCT03471663|Experimental|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
10205241|NCT03463330|Experimental|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
10205242|NCT03463330|Sham Comparator|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
10205243|NCT03460704|Experimental|Drug: Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45% Other Name: Promixin
10205244|NCT03460704|Placebo Comparator|Drug: Saline Solution|1 ml saline solution 0.45%
10205245|NCT03451162|Experimental|Dose Escalation Cohort: DHES0815A|Participants will receive DHES0815A in escalating doses in the dose-escalation cohort of the study. Participants will receive additional infusions of DHES0815A on Day 1 of subsequent cycles provided that they meet the protocol specified criteria for acceptable toxicity and ongoing clinical benefit.
10205246|NCT03451162|Experimental|Dose Expansion Cohort: DHES0815A|Participants will be treated at or below the Maximum Tolerated Dose (MTD) of DHES0815A (based on the review of the totality of the data) to obtain additional safety, tolerability, PK, and anti-tumor activity data.
10205247|NCT03424824|Experimental|BP1.3656 low dose|administration of BP1.3656 at 30 µg
10205248|NCT03424824|Experimental|BP1.3656 intermediate dose|administration of BP1.3656 at 60 µg
10205249|NCT03424824|Placebo Comparator|Placebo|administration of placebo
10205250|NCT03424824|Experimental|BP1.3656 high dose|administration of BP1.3656 at 90 µg
9760368|NCT00678795|Experimental|Sativex|Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
9760369|NCT00678795|Placebo Comparator|Placebo|Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
9760370|NCT00678834|Active Comparator|Arm 1|To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
9760371|NCT00678834|Active Comparator|Arm 2|To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
9760372|NCT00678834|Active Comparator|Arm 3|Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).
9760373|NCT00678886|Experimental|otelixizumab|otelixizumab
9760374|NCT00678886|Placebo Comparator|placebo|Placebo
9760375|NCT00678899|Experimental|Surgery|Implantation with the Nucleus Hybrid L24 Cochlear Implant
9760376|NCT00679029|Experimental|Chemotherapy with Bevacizumab|"AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.~TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.~Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7."
9760377|NCT00679042|Experimental|Treatment|All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.
9760378|NCT00679055|Experimental|MK-0736|Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
9760379|NCT00679055|Placebo Comparator|Placebo|Participants will be orally administered placebo once daily for 12 weeks.
9760380|NCT00679081|Experimental|CelTx|CelTx
9760381|NCT00679081|Active Comparator|Autologous CTG|Autologous sub-epithelial connective tissue graft
9760382|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 1|Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
9760383|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 2|Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
9760384|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 3|Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
9760385|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 4|Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
9760386|NCT00679211|Experimental|Trastuzumab emtansine|Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.
9760387|NCT00679263|Experimental|MN-221|
9760388|NCT00679263|Placebo Comparator|PLACEBO|Placebo intravenous infusion with dosing volume equivalent to active treatment.
9760389|NCT00679289|Experimental|Cohort 1|"KW2871: 5 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
9760390|NCT00679289|Experimental|Cohort 2|"KW2871: 10 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
9760391|NCT00679289|Experimental|Cohort 3|"KW2871: 20 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
9760392|NCT00679302|Placebo Comparator|placebo group|Maalox and bitter mixture
9760393|NCT00679302|Active Comparator|antibiotic group|Trimethoprim-sulfamethoxazole suspension
9760394|NCT00679341|Experimental|Trastuzumab emtansine|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
9760395|NCT00679341|Active Comparator|Trastuzumab + docetaxel|Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of all subsequent 21-day cycles.
9760396|NCT00679354|Experimental|Treatment (cilengitide)|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9760397|NCT00679367|Experimental|Melphalan Revlimid and Dexamethasone|Melphalan Lenalidomide Dexamethasone
9760398|NCT00679380|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
9760399|NCT00679380|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
9760400|NCT00679380|Active Comparator|3: Entocort EC® 3 mg|Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.
9984154|NCT04361266|Active Comparator|Control|Subjects undergoing non-patch augmented rotator cuff repair
9760401|NCT00679380|Placebo Comparator|4: Placebo|Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.
9760402|NCT00679432|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
9760403|NCT00679432|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
9760404|NCT00679432|Placebo Comparator|3: Placebo|Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
9760405|NCT00679432|Active Comparator|4: Asacol® 400 mg|Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
9760406|NCT00679549|Experimental|DEVICE|Provided CPAP as an inpatient
9760407|NCT00679549|No Intervention|Control|No device provided
9760408|NCT00679627|Experimental|Galantamine|Galantamine 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
9760409|NCT00679627|Placebo Comparator|Placebo|Matching placeco
9760410|NCT00679913|Active Comparator|1|standard pancreatoduodenectomy
9760411|NCT00679913|Active Comparator|2|extended pancreatoduodenectomy
9760412|NCT00679939|Active Comparator|Arm 1 Treatment A|rosiglitazone up to 8mg/day
9760413|NCT00679939|Active Comparator|Arm 2 Treatment B|metformin up to 2000mg/day
9760414|NCT00679952|Active Comparator|1|closed suction drainage group (CD group)
9760415|NCT00679952|Active Comparator|2|natural drainage group (ND group)
9760416|NCT00680017|Experimental|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
9760417|NCT00680017|Active Comparator|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
9760418|NCT00680043|Experimental|Peginesatide 0.04 mg/kg|
9760419|NCT00680043|Experimental|Peginesatide 0.08 mg/kg|
9760420|NCT00680043|Active Comparator|Epoetin Alfa|
9760421|NCT00680056|Active Comparator|1|Formoterol plus Placebo (Tiotropium)
9760422|NCT00680056|Experimental|2|Formoterol plus Tiotropium
9760423|NCT00680121|Placebo Comparator|Control Group|Placebo
9760424|NCT00680121|Experimental|Benfotiamine|Benfotiamine 600 mg
9760425|NCT00680186|Experimental|Dabigatran etexilate (150mg bid)|Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
9760426|NCT00680186|Active Comparator|Warfarin (INR 2.0-3.0)|Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
9760427|NCT00680225|Experimental|Lucentis Injection|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
9760428|NCT00680368||Residents and Attending Physicians|This group contains the residents and the attending physicians who consented to participate in the study. They participated in a survey administered by a research assistant. Both physician resident and attending physicians were administered the survey twice within 24-hours and their test-retest responses were compared for reliability. Responses to attending and resident physicians covering the care for the patient and clinical care encounter were compared for accuracy.
9760429|NCT00680407|Experimental|silymarin 420 mg|420 mg Legalon (silymarin) three times daily
9760430|NCT00680407|Experimental|silymarin 700 mg|700 mg of Legalon (silymarin) three times daily
9760431|NCT00680407|Placebo Comparator|Placebo|Placebo (lactose pill)
9760432|NCT00680459|Experimental|1|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
9760433|NCT00680459|Placebo Comparator|2|heparin flush 10 units/ml lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. heparin flush solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
9760434|NCT00680524|Experimental|Phone Based Outreach Intervention Group|Open pilot trial
9760435|NCT00680628|Placebo Comparator|2|Saline + Enoxaparin
9760436|NCT00680628|Experimental|1|Tenecteplase + Enoxaparin
9760437|NCT00680706|Experimental|Thiamine|Receives thiamine
9760438|NCT00680706|Placebo Comparator|Control|
9760439|NCT00680745|Experimental|1|dapagliflozin 2.5mg + Glimepiride
9760440|NCT00680745|Experimental|2|dapagliflozin 5mg + Glimepiride
9760441|NCT00680745|Experimental|3|dapagliflozin 10mg + Glimepiride
9760442|NCT00680745|Placebo Comparator|4|Placebo + Glimepiride
9760443|NCT00680771||1|Primary Insomnia
9760444|NCT00680771||2|Good Sleepers
9760445|NCT00680797|Experimental|+T +E|+Testosterone, +Estrogen
9760446|NCT00680797|Experimental|+T -E|+Testosterone, -Estrogen
9984155|NCT04360252|Experimental|Gracie Diet|Patients will have a nutritional consultation and will follow the Gracie diet for a month.
9984156|NCT04353115||Training with Serious Game|Trained group, 5 weeks training with the serious game; patients have a vestibular impairment.
9666139|NCT04690465|No Intervention|Non-treatment Concurrent Control|Participants in this group will not participate in any specific intervention during the whole study (the 16-week intervention and 12-week follow-up periods), but they will be asked to keep a daily log on their physical activity, medicine used, illness, diet, sleep quality and other health and physical activity related information (e.g., attending healthy eating workshops).
9666140|NCT04689997|Experimental|computerized Substance Brief Intervention cSBI|Enhanced care PCPs will address the serious morbidity of teen substance use during routine check-up visits using cSBI and follow up care using a new Module of CHADIS that facilitates guideline-based care. The CHADIS c-SBI Module will include pre-visit screening tools and embedded education that cover substance use and strengths and goals. It will also include reminders to the patient about their goals and commitments for change and teleprompted interview hints for the PCP. These hints will be aimed at enhancing a patient focused discussion of individual strengths and barriers related to the teens' goals in a motivational interviewing style.
9666141|NCT04689997|No Intervention|Standard care|Standard care PCPs will screen using a standard SU tool and carry out their usual health supervision visits without additional decision support.
9666142|NCT04686799|Experimental|SD-doxycycline group|12 weeks SD-doxycycline: doxycycline hyclate 20 mg tablet by mouth twice daily
9666143|NCT04685070|Experimental|HS-10296 (Almonertinib)|
9666144|NCT04684589|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.
9666145|NCT04684589|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.
9666146|NCT04682743|Sham Comparator|saline group|
9666147|NCT04682743|Active Comparator|ondansetron group|
9666148|NCT04682743|Active Comparator|paracetamol group|
9666149|NCT04681677|Experimental|Experimental: Intra-operative Radiation Therapy - IORT|Radiation: Intra-operative Radiation Therapy - IORT
9666150|NCT04678232|Experimental|receive PATH therapy|PATH includes six 60-90 min, weekly sessions, with two booster sessions for partial responders. Session 1 provides the PATH rationale and a review of life events (PATH of life: negative and positive). A rationale for an explicit focus on positive events/emotions will be provided. Sessions 2-4 focus on a verbal narrative of the destabilizing life event, reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. Sessions 5 focuses on constructive processing and provides opportunity for integration and consolidation of learning. Session 6 focuses on future negative and positive events to promote application of new learning and resilience. Booster sessions focus on positive and negative life events since the last session and adaptive processes (constructive processing, approach, and reward). All sessions will include cultivation and elaboration of positive emotions to promote engagement and to build on the benefits of positive emotions.
9666151|NCT04677257|Experimental|STEMI acute myocardial infarction treated with effective primary PCI|STEMI patients treated with effective primary PCI to assess the ability of coronary physiology parameters (CFR and IMR) measured soon after recanalization to predict myocardial tissue characterization assessed with cardiac magnetic resonance (CMR) within a week of the acute event.
9666152|NCT04676646|Experimental|Open-label run-in phase|"Cohort 1 (4 weeks duration): Patients who are hyperkalemic at study entry will begin SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily).~Cohort 2 (up to 6 weeks duration): Patients who develop hyperkalemia during the uptitration of spironolactone will receive SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
9666153|NCT04676646|Experimental|Randomized withdrawal phase (8 months)|"SZC arm and Placebo arm: Patients will continue on the SZC dose they were receiving at the end of the run-in phase.~The SZC / Placebo dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
9666154|NCT04674761|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 24 weeks.
9666155|NCT04674761|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks.
9760447|NCT00680797|Experimental|-T +E|-Testosterone, +Estrogen
9760448|NCT00680797|No Intervention|-T -E|-Testosterone, -Estrogen
9760449|NCT00680823|Experimental|Ropivacaine Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
9760450|NCT00680823|Placebo Comparator|Normal Saline Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
9760451|NCT00680823|No Intervention|Observation|Observation for 30 minutes.
9760452|NCT00680836|Active Comparator|Treatment Group|These patients have IBS and are receiving the rifaximin.
9760453|NCT00680836|Placebo Comparator|Placebo group|These patients have IBS and are receiving the placebo.
9760454|NCT00680862||Group 1|VA employees
9760455|NCT00680914|Experimental|Synflorix Group|Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
9760456|NCT00680914|Active Comparator|Prevenar Group|Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
9760457|NCT00680953|Experimental|1|Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
9760458|NCT00680953|Placebo Comparator|2|Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
9760459|NCT00680953|Active Comparator|3|Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
9760460|NCT00680992|Experimental|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
9835947|NCT02762370|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release Formulation
9760461|NCT00681031|Experimental|All Enrolled|Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)
9760462|NCT00681083|Experimental|1|Heated breathing tube
9760463|NCT00681083|Active Comparator|2|Non heated breathing tube
9760464|NCT00681109|Active Comparator|Treatment Arm 1|2.5% IL-1Ra
9760465|NCT00681109|Placebo Comparator|Placebo|Artificial Tear
9760466|NCT00681109|Active Comparator|Treatment Arm 2|5% IL-1Ra
9760467|NCT00681265|Experimental|glycerin|One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
9760468|NCT00681265|Active Comparator|polyethylene glycol 400/propylene glycol|The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
9760469|NCT00681291|Active Comparator|1|lightweight polypropylene mesh
9760470|NCT00681291|Active Comparator|2|Strattice
9760471|NCT00681473|Experimental|Proton Radiation Therapy|Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.
9832404|NCT02612064|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
9984157|NCT04350125|Experimental|Platelet Rich Plasma Treatment|Male subjects diagnosed with Erectile Dysfunction (ED) will receive platelet rich plasma injections.
9984158|NCT04349891|Experimental|TEA at ST36 and PC6 first and then sham TEA|Patients in this group will be treated with TEA at ST36 and PC6 for 4 weeks, followed with a 2-week washout period and another 4-week period with sham TEA.
9984159|NCT04349891|Experimental|Sham-TEA and then TEA ST36 and PC6|Patients in this group will be treated with sham-TEA for 4 weeks, followed with a 2-week washout period and another 4-week period with TEA at ST36 and PC6.
9666159|NCT04668872||Participants with colorectal cancer liver metastases|The study population is represented by patients with colorectal cancer liver metastases that have been deemed clinically appropriate/eligible to receive Y90 TARE for the management of their liver metastases.
9666160|NCT04665336|Experimental|Intervention Group Lifestyle counseling|"Obese individuals with evening chronotype will be trained on sleep hygiene in order to create behavioral changes in line with circadian rhythms and an intervention program called Circadian Timing Program which was created by the researcher in line with the relevant literature will be implemented for 12 weeks. This program includes sleep hygiene recommendations and regulation of daylight exposure, sleep, meal, caffeine intake and exercise times. To determine participants' sleep times they will be asked to keep a sleep diary and sleep records will be taken with the smart bracelet. Participants will be given a password to access the research website. The website of the study will be used for the training, control, motivation and communication of the Participants."
9666161|NCT04665336|No Intervention|Control group|Participants will be asked to follow their normal daily lifestyle, maintain normal sleep and eating habits and no further instructions or suggestions will be provided during the study.
9666162|NCT04662879|Experimental|Intervention Arm|"Two interventions are performed:~Have Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated, and if Score is >0,~Have abdominal imaging performed."
9666163|NCT04662879|No Intervention|Observation Arm|Passive follow-up by electronic medical record for study endpoints of pancreatic cancer diagnosis.
9666164|NCT04662320|Experimental|Brief Electrical Stimulation|Single, 10 minute dose of electrical stimulation delivered to the ulnar nerve during surgical intervention for cubital tunnel decompression.
9666165|NCT04662320|No Intervention|Standard of Care|Surgical intervention for cubital tunnel decompression.
9666166|NCT04662008|Active Comparator|High resource tailored intervention|Tele-coaching arm
9666167|NCT04662008|Active Comparator|Low-resource web-only intervention|Website arm
9666168|NCT04660968|Experimental|Dyadic Health Behaviour Change Intervention|The dyadic health behaviour change intervention is a 10 sessions program provided over 16 weeks. It includes nutritional, physical activity and sedentary related information, as well as couples-based adaptation of motivational interviewing, self-monitoring, goals setting, stimulus control, problem-solving, and relapse prevention as well as specific strategies to support their partner's autonomy and intrinsic motivation.
9666169|NCT04660968|Active Comparator|Dyadic nutrition counselling intervention|The couples-based nutrition counselling intervention is a 10 sessions program provided over 16 weeks. Topics are based on Dietitians of Canada's Practice-based Evidence in Nutrition discussions. Participants are also encouraged to meet the current physical activity recommendations. Both members of the couples are seen at the same, but no intervention target specifically the behaviour change process or the romantic relationship.
9666170|NCT04657822|Experimental|Crizanlizumab|All participants will receive crizanlizumab (SEG101) at the same dose/schedule as in the parent study.
9666171|NCT04657120|Experimental|YEARS algorithm|Patients randomized to this arm will be evaluated according to the YEARS algorithm.
9666172|NCT04657120|Active Comparator|CTPA as single test|Patients randomized to this arm will undergo a contrast enhanced CTPA.
9666173|NCT04656470|Experimental|Dexmedetomidine|During the study visit, patients will be delivered dexmedetomidine anesthesia. 0.5mcg/kg of dexmedetomidine solution will be infused over 10 minutes, and then up to 0.5mcg/kg/hr will be maintained for an additional 20-30 minutes.
9832405|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
9984160|NCT04346745|Experimental|Treatment group|The treatment group will receive intervention of a peer mentoring program plus usual services they could receive from community agencies.
9832406|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
9835948|NCT02762500|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 8 weeks
9984161|NCT04346745|No Intervention|Control group|The control group will receive usual services they could receive from community agencies.
9832407|NCT02612155|Experimental|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
9984162|NCT04341350|Active Comparator|Usual sedation|Sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug.
9984163|NCT04341350|Experimental|Inhaled sedation|Sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of an analgesic drug.
9984164|NCT04337931|Experimental|Cohort 1|APX005M every 3 weeks
9984165|NCT04337931|Experimental|Cohort 2|APX005M every 2 weeks
9984166|NCT04337931|Experimental|Cohort 3|APX005M every 2 weeks plus radiation therapy
9984167|NCT04336826|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 24 weeks.
9984168|NCT04331379|Experimental|Nasal Elevator|
9984169|NCT04331379|Active Comparator|Taping Alone|
9984170|NCT04329715|Experimental|Expedited instructions|
9984171|NCT04329715|Active Comparator|Restricted instructions|
9666174|NCT04652570|Experimental|VB119 dose escalation|Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.
9666175|NCT04649593|No Intervention|according to clinical guidlines|Dystocic progress and an observed low AFL value (< 12.0 mmol/l).
9666176|NCT04649593|Experimental|intevention|"At dystocic labor and an observed high AFL value, the woman is randomized to one of the intended two study groups.~Group 1) Delivery according to the clinic's guidelines in case labor dystocia, i.e., oxytocin stimulation Group 2) Two bags of Samarin mixed in a glass of water. After an hour, In case of lack of progress, oxytocin stimulation is started."
9666177|NCT04648202|Experimental|FS120 Q4W|The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design.
9666185|NCT04647526|Experimental|[Lu-177]-PNT2002 (Arm A)|[Lu-177]-PNT2002 (6.8 GBq (±10%) every 8 weeks for 4 cycles)
9666186|NCT04647526|Active Comparator|Control Arm (Arm B)|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone) or enzalutamide (160 mg orally qd).
9666187|NCT04647500|Other|22q11DS naive|22q11DS participants naive to methylphenidate
9666188|NCT04647500|Other|22q11DS consumer|22q11DS participants with a prolonged treatment of methylphenidate
9666189|NCT04645329|Experimental|group I (no immobilization)|patients will be allowed to freely use their arm without any immobilization after surgery
9666190|NCT04645329|Active Comparator|group II (3-week immobilization)|patients will be kept in an immobilization device for three weeks after surgery
9666191|NCT04644575|Experimental|Arm A: Previously treated in BIVV001 study|This arm includes all participants who have completed the previous phase 3 studies on BIVV001, as well as participants who have completed Arm B or Arm C of this study rolling over in Arm A, and participants who will have completed any future BIVV001 study who will be proposed to continue BIVV001 treatment. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once-weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
9666192|NCT04644575|Experimental|Arm B: Newly initiated (China Only) in BIVV001|This arm includes Chinese participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) for 52 weeks. After 52 weeks of treatment in this arm B, participants will be able to roll into arm A.
9666193|NCT04644575|Experimental|Arm C: Newly initiated in BIVV001 with planned major surgery|This arm includes participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) and will undergo planned major surgery after at least 6 initial EDs with BIVV001, and within 26 weeks from Day 1. After 52 weeks of treatment in arm C, participants will be able to roll into arm A.
9760472|NCT00681538|Experimental|Sativex|"Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours"
9760473|NCT00681538|Placebo Comparator|Placebo|Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours.
9760474|NCT00681564|Experimental|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
9760475|NCT00681564|Active Comparator|Periodontal care|Basic oral hygiene instructions Supragingival plaque removal
9760476|NCT00681590|Active Comparator|1|vitamin D (cholecalciferol) 400 IU daily orally - low dose
9760477|NCT00681590|Active Comparator|2|vitamin D (cholecalciferol) 2000 IU daily orally - high dose
9760478|NCT00681668|Experimental|Quetiapine Fumarate 150 - 800mg|Quetiapine 150-800mg
9760479|NCT00681811|Experimental|HGT-1111 100 U/kg|
9760480|NCT00681811|Experimental|HGT-1111 200 U/kg|
9760481|NCT00681824|Experimental|FS VH S/D 500 s-apr|Application of FS VH S/D 500 s-apr on top of suture
9760482|NCT00681824|Active Comparator|Standard of Care (Control group)|The treatment of the control group consisted of Standard of Care (SoC) which was defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen based dura substitute.
9760483|NCT00681863|Active Comparator|pramipexole 0.0625 mg BID (twice daily)|all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
9760484|NCT00681863|Active Comparator|pramipexole 0.0625 mg QD (once daily)|patients to receive one tablet of pramipexole 0.0625 mg QD
9760485|NCT00681863|Active Comparator|pramipexole 0.125 mg BID|patients to receive one tablet of pramipexole 0.125 mg BID
9760486|NCT00681863|Active Comparator|pramipexole 0.125 mg TID (three times daily)|patients to receive one tablet of pramipexole 0.125 mg TID
9760487|NCT00681863|Active Comparator|pramipexole 0.25 mg BID|patients to receive one tablet of pramipexole 0.25 mg BID
9760488|NCT00681889|Experimental|Treatment Arm|10 Patients will receive treatment (Ranibizumab)
9760489|NCT00682357|Experimental|1|Methylprednisone 80 mg and Lidocaine 20 mg
9760490|NCT00682357|Experimental|2|Methylprednisolone 16 mg and Lidocaine 20 mg
9760491|NCT00682357|Placebo Comparator|3|Placebo and Lidocaine 20 mg
9760492|NCT00682435|Experimental|Hydromorphone|1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
9760493|NCT00682448|Active Comparator|1|Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.
9760494|NCT00682448|Placebo Comparator|2|Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.
9760495|NCT00682461|Active Comparator|Marketed formulation|Marketed nicotine replacement therapy product
9760496|NCT00682461|Experimental|prototype|Nicotine prototype
9760497|NCT00682539|Active Comparator|Avastin|15 patients with clinical significant macular edema receive an injection of 2,5 mg Avastin every month. After three initial injections of Avastin re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
9760498|NCT00682539|Active Comparator|Triamciolone|30 patients with a clinical significant diabetic macular edema receive an intraocular injection of 8mg triamcinolone at baseline under sterile conditions. 1 and 2 month after the baseline injection, patients receive a sham injection. After three month re-injection of 8mg Triamcinolone is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns patients will receive a sham injection. In between two injection of 8mg Triamcinolone must be an temporal interval of at least 3 months.
9760499|NCT00682539|Active Comparator|Lucentis|15 patients with clinical significant macular edema receive an injection of 0,5 mg Lucentis every month. After three initial injections of Lucentis re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
9760500|NCT00682565|Experimental|Mid Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
9835949|NCT02762500|Placebo Comparator|Placebo PO QD|Matching placebo by mouth once daily for 8 weeks
9760501|NCT00682565|Experimental|High Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
9760502|NCT00682617|Experimental|Waitlist Control|Delayed intervention. 3 months on waitlist, crossover to intervention (3 additional months)
9760503|NCT00682617|Experimental|3 Month Exercise Program|3 month exercise program
9760504|NCT00682643|Placebo Comparator|vehicle placebo nasal spray|
9760505|NCT00682643|Active Comparator|fluticasone furoate nasal spray|
9760506|NCT00682734|Active Comparator|1|Metoclopramide 10 mg+ diphenhydramine 25 mg. This medication was administered as an intravenous drip over 20 minutes
9760507|NCT00682734|Experimental|2|metoclopramide 20 mg + diphenhydramine 25 mg. Administered as an intravenous drip over 20 minutes.
9760508|NCT00682734|Experimental|3|metoclopramide 40 mg + diphenhdyramine 25mg. Administered as an intravenous drip over 20 minutes.
9760509|NCT00682786|Experimental|Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
9760510|NCT00682786|Experimental|Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Irinotecan 50 mg/m2 IV weekly for 5 doses.~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
9760511|NCT00682838|Experimental|Self-Management (SM)|Active Intervention - Self-management: Self-management Educational component focused on sleep apnea and CPAP from a self-management perspective
9760512|NCT00682838|Active Comparator|Telemonitored Care (TC)|Active Comparator - Telemonitored care: Telemonitored care Consists of CPAP therapist actively monitoring care at a distance, and acting on that data per a set protocol
9760513|NCT00682838|Experimental|SM + TC|Self-management and Telemonitored care: Combination of both SM + TC intervention
9760514|NCT00682838|No Intervention|Usual care (UC)|Control Group
9760515|NCT00682890|Placebo Comparator|1|Placebo tablet and birth control pill daily
9760516|NCT00682890|Active Comparator|2|metformin 2000 mg and birth control pill daily
9760517|NCT00682929|Active Comparator|1) Inhaled Cannabis|Inhaled cannabis is compared to oral placebo.
9760518|NCT00682929|Active Comparator|2) Oral THC|Inhaled placebo is compared to oral THC.
9760519|NCT00682929|Placebo Comparator|3) Placebo|Inhaled placebo is compared to oral placebo.
9760520|NCT00683020|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support.
9760521|NCT00683020|No Intervention|WAIT LIST Control|WAIT LIST Control: six month Wait List.
9760522|NCT00683046|Experimental|Drug Intervention|
9760523|NCT00683085|Experimental|Peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.
9760524|NCT00683163|Active Comparator|A: 6 months both + 18 months oral only|Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
9760525|NCT00683163|Active Comparator|B: (3 months injection + 9 months oral) x 2 years|Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.
9760526|NCT00683293|Active Comparator|1|Randomized group of patients receiving conventional laparoscopic hysterectomy
9760527|NCT00683293|Active Comparator|2|Randomized group of patients receiving robot-assisted laparoscopic hysterectomy
9760528|NCT00683332||A|
9760529|NCT00683384||1|
9760530|NCT00683410||1|
9760531|NCT00683449|Experimental|IV infusion of MN-221|MN-221 total dose of 240 mcg
9760532|NCT00683449|Placebo Comparator|MN-221 PLACEBO|i.v. infusion of MN-221 Placebo for 15 min
9760533|NCT00683475|Experimental|IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone|
9760534|NCT00683475|Experimental|IMC-A12 + Mitoxantrone + Prednisone|
9760535|NCT00683592|Experimental|1|vilazodone
9760536|NCT00683592|Placebo Comparator|2|
9760537|NCT00683618|Experimental|1|Rosuvastatin 5mg qd
9760538|NCT00683618|Experimental|2|Rosuvastatin 10mg qd
9760539|NCT00683618|Active Comparator|3|Atorvastatin 10mg qd
9760540|NCT00683644|Experimental|1 - zinc placebo|Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months. Washout 1 month. Placebo oral capsule taken once a day for 4 months.
9760541|NCT00683644|Experimental|2 - placebo zinc|Placebo oral capsule taken once a day for 4 months. Washout 1 month. Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months.
9760542|NCT00683657|Experimental|Saxagliptin 5 mg + Metformin|
9760543|NCT00683657|Placebo Comparator|Placebo + Metformin|
9760544|NCT00683696|Experimental|CRT=ON|Cardiac Resynchronization Therapy activated.
9760545|NCT00683696|Active Comparator|CRT=OFF|Cardiac Resynchronization Therapy deactivated.
9760546|NCT00683774|Experimental|PCOS subjects|PCOS subjects given diazoxide
9760547|NCT00683774|Active Comparator|Normal subjects|Normal subjects given diazoxide
9760548|NCT00683800|Experimental|1|desvenlafaxine succinate (DVS) SR
9760549|NCT00683800|Placebo Comparator|2|Placebo
9760550|NCT00683826|Experimental|L-Leucine 4grams|This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
9760551|NCT00683826|Experimental|L-Leucine 8 grams|Arm number two of the study will be a dose of Leucine of 8g.
9760552|NCT00683826|Placebo Comparator|L-Leucine 0 grams|The third arm of the study will be composed of a control drink with no leucine in it.
9760553|NCT00683852|Active Comparator|Drug 2mg/Drug 5mg|patients randomly assigned to the drug/drug sequence, the dose of aripiprazole will be 2 mg/day during the first phase of the study, and 5 mg/day in the second phase.
9760554|NCT00683852|Active Comparator|Placebo/Drug 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study.
9760555|NCT00683852|Placebo Comparator|Placebo/Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study.
9760556|NCT00683878|Experimental|Arm 1|
9760557|NCT00683878|Experimental|Arm 2|
9760558|NCT00683878|Placebo Comparator|Arm 3|
9760559|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|
9760560|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|
9760561|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
9760562|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
9760563|NCT00683930|Placebo Comparator|Placebo|
9760564|NCT00684021|Active Comparator|1|Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
9760565|NCT00684021|Active Comparator|2|Participants will receive active adult stem cell infusion 7 days after PCI.
9760566|NCT00684021|Placebo Comparator|3|Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
9760567|NCT00684021|Placebo Comparator|4|Participants will receive placebo infusion (5% HSA) 7 days after PCI.
9760568|NCT00684047|Experimental|FS Grifols Preliminary Part (I)|Open label administration of FS Grifols to all subjects
9760569|NCT00684047|Experimental|FS Grifols Primary Part (II)|Single-blind, randomized (2:1)
9760570|NCT00684047|Active Comparator|Manual Compression Primary Part (II)|Single-blind, randomized (2:1)
9760571|NCT00684060|Experimental|1|Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
9760572|NCT00684060|Placebo Comparator|2|Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
9760573|NCT00684073|Experimental|Subutex®/Suboxone®|Subutex® for first two days of study followed by Suboxone® for last 3 days of study
9760574|NCT00684138|Experimental|ReSTOR Aspheric +3.0D|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
9760575|NCT00684138|Active Comparator|ReSTOR Aspheric +4.0D|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
9760576|NCT00684177|Experimental|Retapamulin Ointment, 1%|
9760577|NCT00684177|Placebo Comparator|Placebo Ointment|
9760578|NCT00684203|Experimental|Vorapaxar 20 mg/1 mg|Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
9760579|NCT00684203|Experimental|Vorapaxar 20 mg/2.5 mg|Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
9760580|NCT00684203|Experimental|Vorapaxar 40 mg/1 mg|Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
9760581|NCT00684203|Experimental|Vorapaxar 40 mg/2.5 mg|Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
9760582|NCT00684203|Placebo Comparator|Placebo|Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)
9760583|NCT00684242|Experimental|Lenalidomide|10 mg by mouth daily
9760584|NCT00684307|Experimental|1|AZD0837 450 mg
9760585|NCT00684307|Experimental|2|AZD0837 200 mg
9760586|NCT00684307|Experimental|3|AZD0837 300 mg
9760587|NCT00684307|Experimental|4|AZD0837 150 mg
9760588|NCT00684307|Active Comparator|5|Vitamin-K antagonist at INR 2-3
9760589|NCT00684320|Active Comparator|2 Placebo Condition (PC)|The placebo, group will complete the PC procedure, which is identical to the ADT procedure except that during the presentation of the trials where a disgust or angry face is present, the probe will appear with equal frequency in the position of disgust or angry and neutral face. Thus, disgust, angry nor neutral face will have signal value regarding the position of the probe.
9760590|NCT00684320|Experimental|1 Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
9760591|NCT00684411|Experimental|Imatinib mesylate|The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
9760592|NCT00684424||Outpatients with epilepsy|
9760593|NCT00684515|Experimental|Vorapaxar 2.5 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
9760594|NCT00684515|Experimental|Vorapaxar 1 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
9760595|NCT00684515|Placebo Comparator|Placebo + Aspirin|Placebo oral tablets; once daily for 60 days + Aspirin
9760596|NCT00684541|Experimental|Interpretation Modification Program|The IMP procedure was identical to the word-sentence association paradigm (WSAP; Beard & Amir, 2009) except participants received feedback about their responses. Participants received positive feedback when they endorsed benign interpretations or rejected threat interpretations of the ambiguous sentences on 100% of trials and negative feedback when they endorsed threat interpretations or rejected benign interpretations on 100% of trials. This feedback manipulation was intended to reinforce a benign interpretation bias and extinguish the threat interpretation bias. Participants completed two blocks of 110 training trials in each session. Participants who completed Set A during the WSAP assessment saw Set B during the IMP and vice versa. Each IMP session lasted approximately 20 min.
9760597|NCT00684541|Placebo Comparator|Interpretation Control Condition|The ICC was identical to the IMP, except that participants received positive feedback when they endorsed threat interpretations on half (50%) of the trials and negative feedback when they endorsed threat interpretations for the remaining half (50%) of trials. This frequency was the same for benign interpretations. Thus, the control group was reinforced equally for making threat and benign interpretations. The ICC was not intended to change interpretation significantly in either direction.
9760598|NCT00684554|Active Comparator|Unobserved-at home|Buprenorphine Unobserved at home induction
9760599|NCT00684554|Active Comparator|Observed|Buprenorphine Observed in office induction
9760600|NCT00684567|Experimental|Single arm|It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.
9760601|NCT00684593|Experimental|Navarixin|Navarixin 30 mg administered orally once daily for 28 days.
9760602|NCT00684593|Placebo Comparator|Placebo|Matching placebo to Navarixin administered orally once daily for 28 days.
9760603|NCT00684645||Patients treated with SUTENT®|Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
9760604|NCT00684671|Experimental|Twinrix Group|Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
9760605|NCT00684671|Active Comparator|Engerix + Havrix Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
9760606|NCT00684671|Active Comparator|HB VAX PRO + Vaqta Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).
9760607|NCT00684723|Experimental|Lovastatin 40 mg Tablet|A single dose of Lovastatin 40 mg administered under fed conditions.
9760608|NCT00684723|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered under fed conditions.
9783517|NCT01202877|Experimental|5-azacytidine + PKC412|5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
9783518|NCT01202903|Experimental|Omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 mL vial that was designed to deliver 150 mg of omalizumab for subcutaneous administration upon reconstitution with 1.4 mL sterile water for injection. The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
9783519|NCT01202903|Placebo Comparator|Placebo|The placebo was the same mixture of inactive excipients, in quality and quantity, as those used for the drug product. The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
9783520|NCT01202955|Active Comparator|Tolcapone|Tolcapone
9783521|NCT01202955|Placebo Comparator|Placebo|Placebo
9783522|NCT01202994|Experimental|Flute|Flutemetamol PET scan.
9783523|NCT01203046|Active Comparator|GROUP A: 7 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery.
9783524|NCT01203046|Experimental|GROUP B - 3 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.
9783525|NCT01203072|Experimental|DU-176b 5 mg|
9783526|NCT01203072|Experimental|DU-176b 15 mg|
9783527|NCT01203072|Experimental|DU-176b 30 mg|
9783528|NCT01203072|Experimental|DU-176b 60 mg|
9783529|NCT01203072|Placebo Comparator|Placebo|
9783530|NCT01203098|Experimental|DU-176b 30mg once daily|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
9783531|NCT01203098|Active Comparator|Enoxaparin sodium twice daily|Enoxaparin sodium 20mg (=2000IU) / 0.2mL twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
9783532|NCT01203098|Experimental|DU-176b 15mg once daily|DU-176b 15mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
9783533|NCT01203189|Active Comparator|Shampoo Group|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
9783534|NCT01203189|Active Comparator|Foam group|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
9783535|NCT01203189|Active Comparator|Cross Over Group|apply ketoconazole 2% foam to scalp twice daily for four weeks. Subjects in the Shampoo group will be able to cross over into the Foam group if the TDSS score does not improve by 60% at the end of the four week treatment period using shampoo.
9783536|NCT01203319|Experimental|60mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
9783537|NCT01203319|Experimental|30mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
9783538|NCT01203319|Placebo Comparator|10mcg/1.0ml recombinant hepatitis B vaccine|300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
9783539|NCT01203644|Active Comparator|Bupivacaine HCl|(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
9783540|NCT01203644|Active Comparator|SKY0402|Low dose, low-mid dose, mid-dose, and high dose
9783541|NCT01203774|Active Comparator|Pen-administered vs syringe-admnistered Glargine|SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin
9783542|NCT01203774|Active Comparator|Syringe-administered vs pen-administered Glargine|Syringe-administered Glargine insulin and then pen-administered Glargine insulin
9783543|NCT01203787|Active Comparator|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24
9783544|NCT01203787|Experimental|Sorafenib Ramp-Up Regimen|200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
9783545|NCT01203826|Experimental|asfotase alfa|asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection
9783546|NCT01203852|Experimental|Metoprolol + Chlorthalidone|Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) > 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.
9783547|NCT01203878|Experimental|Imiquimod & photodynamic therapy|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
9783548|NCT01203878|Active Comparator|Imiquimod|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation
9783549|NCT01203917|Other|1|gefitinib 250mg tablet
9783550|NCT01203930|Experimental|Idelalisib|This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.
9984172|NCT04328779|Experimental|multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks.
9984173|NCT04328779|Active Comparator|multi-task treadmill walking|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill.
9760609|NCT00684762|Experimental|Cilostazol|A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
9984174|NCT04328779|Active Comparator|traditional rehabilitation|Traditional rehabilitation group will train strength, balance, and gait.
9984175|NCT04328090|Experimental|CDSS-Antimicrobial stewardship|Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm.
9984176|NCT04328090|No Intervention|Standard of care|Teams in the control arm will continue with usual standard clinical care.
9760610|NCT00684762|Experimental|Pletal® (cilostazol)|A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
9760611|NCT00684775|No Intervention|Work Plus Naltrexone Prescription|Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.
9760612|NCT00684775|Experimental|Work Plus Naltrexone Contingency|Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.
9760613|NCT00684788|No Intervention|No Intervention|Participants were offered depot naltrexone injections and were not required to take scheduled injections to work.
9760614|NCT00684788|Experimental|Employment-based reinforcement|Participants were offered depot naltrexone injections and were required to take scheduled injections to work.
9760615|NCT00684814|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered after an overnight fast of at least 10 hours.
9760616|NCT00684814|Experimental|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered after an overnight fast of at least 10 hours.
9760617|NCT00684983|Active Comparator|Arm A (lapatinib ditosylate, capecitabine)|Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9760618|NCT00684983|Experimental|Arm B (cixutumumab, lapatinib ditosylate, capecitabine)|Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also receive cixutumumab IV over 1 hour on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9760619|NCT00684996|Active Comparator|Phase II Arm I|Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
9760620|NCT00684996|Active Comparator|Phase II Arm II|Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
9760621|NCT00685035|Active Comparator|HFCWC with higher pressure/variable frequency settings|Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
9760622|NCT00685035|Active Comparator|HFCWC with lower pressure/mid-frequency settings|lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency
9760623|NCT00685139|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered after an overnight fast.
9760624|NCT00685139|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered after an overnight fast.
9760625|NCT00685165|Experimental|Primidone 50 mg Tablets|A single dose of primidone 50 mg administered after an overnight fast of at least 10 hours.
9760626|NCT00685165|Experimental|Primidone (Mysoline®) 50 mg Tablets|A single dose of Mysoline® 50 mg administered after an overnight fast of at least 10 hours.
9760627|NCT00685178|Experimental|1 topiramate + CR|topiramate and contingency reinforcement for urine sample confirming cocaine abstinence
9760628|NCT00685178|Experimental|2 topiramate + NonCR|Topiramate and random reinforcement irrespective of cocaine use
9760629|NCT00685178|Placebo Comparator|4 Placebo + NonCR|
9760630|NCT00685178|Active Comparator|3 Placebo + CR|Placebo and contingency reinforcement for urine sample confirming cocaine abstinence
9760631|NCT00685295|Experimental|Arm 1 / Fentora|"Intervention Group:~Subject receives:~placebo oral/swallowed pill~Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet"
9760632|NCT00685295|Active Comparator|Arm 2 / Percocet/Prevacid|"Active Comparator Group:~Subject receives:~Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill~Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet"
9760633|NCT00685334|Experimental|1|Participants will take olanzapine
9760634|NCT00685334|Active Comparator|2|Participants will take aripiprazole
9760635|NCT00685373|Experimental|Canakinumab (ACZ885)|Subcutaneous injection every 8 weeks based on participant's body weight. Body weight >40 kilogram (kg): 150 milligrams (mg) per injection and body weight <= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.
9760636|NCT00685399|Experimental|Cohort 1|Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.
9760637|NCT00685399|Experimental|Cohort 2|Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
9760638|NCT00685399|Experimental|Cohort 3|Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.
9783551|NCT01203956|Experimental|SmartFlex|Use Continuous Airway Pressure device with SmartFlex engaged
9760639|NCT00685399|Experimental|Cohort 4|Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.
9783552|NCT01203956|Active Comparator|Standard|Use Continuous Airway Pressure device without SmartFlex engaged
9760640|NCT00685399|Experimental|Cohort 5|Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
9760641|NCT00685399|Experimental|Cohort 6 Arm 1|Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).
9760642|NCT00685399|Experimental|Cohort 6 Arm 2|Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).
9760643|NCT00685399|Experimental|Cohort 6 Arm 3|Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.
9760644|NCT00685477|Active Comparator|Experimental Sequence ABC|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
9760645|NCT00685477|Active Comparator|Experimental Sequence ACB|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
9760646|NCT00685477|Active Comparator|Experimental Sequence BAC|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
9832408|NCT02612155|Placebo Comparator|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
9832409|NCT02612428|Experimental|ELAD System|This group will receive treatment with ELAD plus standard of care therapy.
9832410|NCT02612428|Other|Standard of Care (Control)|This group will receive standard of care therapy as defined in the protocol.
9835950|NCT02762513|Experimental|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
9835951|NCT02762565|Experimental|breast scanner|
9984177|NCT04327635|Experimental|PEP in Acute Myocardial Infarction|Patients with an acute myocardial infarction who undergo cardiac catheterization at least four hours after onset of symptoms will receive a one-time intracoronary infusion of PEP within 20 minutes after stent placement or post-dilation.
9760647|NCT00685477|Active Comparator|Experimental Sequence BCA|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
9760648|NCT00685477|Active Comparator|Experimental Sequence CAB|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
9835952|NCT02762578|Experimental|IDegAsp BID|
9835953|NCT02762578|Active Comparator|BIAsp 30 BID|
9832411|NCT02612610|Placebo Comparator|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
9832412|NCT02612610|Experimental|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
9832413|NCT02612610|Experimental|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
9832414|NCT02612610|Experimental|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
9832415|NCT02612623|Experimental|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
10202763|NCT04139902|Experimental|Dostarlimab (TSR-042) and TSR-022 (combination)|"Pre-Operative Phase:~Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Post-Operative Phase:~Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered."
10202764|NCT04130893|Experimental|A stimulation of G13 then G15|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G13 auricular stimulation At the Third session: Cold water hand immersion + G15 auricular stimulation
10202765|NCT04130893|Experimental|B: stimulation of G15 then G13|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G15 auricular stimulation At the Third session: Cold water hand immersion + G13 auricular stimulation
10202766|NCT04122339|Experimental|MAX-10181|tablet
10202767|NCT04109820|Experimental|Sickle cell patients|Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)
10202768|NCT04109820|Active Comparator|Non Sickle cell Control subjects|Normal control subjects administered oral MitoQ (20mg once a day for 14 days)
10202769|NCT04106973||Pleural mesothelioma|Participants with all types of histologically identified pleural mesothelioma prior to, subsequent to,or concurrent with treatment.
10202770|NCT04106973||Asbestos exposed without pleural mesothelioma|Participants with asbestos exposure radiographically confirmed by the presence of bilateral pleural plaques or bilateral pleural thickening and without presence of pleural mesothelioma.
10202771|NCT04103554|Experimental|sacubitril/valsartan|
10202772|NCT04103554|Active Comparator|Standard of care|Standard of care for treating blood pressure per center protocols
10202773|NCT04097301|Experimental|MLM-CAR44.1 T-cells infusion|"PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design.~PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD).~Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3"
10202774|NCT04097158||Upper Motor Neuron predominant ALS|
10202775|NCT04097158||Lower Motor Neuron predominant ALS|
10202776|NCT04097158||Bulbar predominant ALS|
10202777|NCT04097158||Generalized ALS|
10202778|NCT04088890|Experimental|R/R ALL|"Relapsed/refractory ALL~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22 CAR T cells will be administered intravenously at Dose1: 3 x 10^5cells/kg (± 20%) 10"
10202779|NCT04088890|Experimental|R/R aggressive B-cell NHL|"Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3~Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) to determine MTD/RP2D.~Dose1: 1 x 10^6 cells/kg (± 20%) Dose2: 3 x 10^6 cells/kg (± 20%) Dose3: 1 x 10^7 cells/kg (± 20%)"
10202780|NCT04087512|Experimental|Instrumented perturbation-based balance training|
10202781|NCT04087512|Experimental|Conventional perturbation-based balance training|
10202782|NCT04087512|No Intervention|Control|
10202783|NCT04086550|Experimental|Investigational arm|Application of LIQOSEAL after closure of dura mater
10202784|NCT04086550|Active Comparator|Control arm|Application of Adherus or DurSeal after closure of dura mater
10202785|NCT04080843|Experimental|Group A|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1).~If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression."
10202786|NCT04073147|Experimental|Dosing group 1|Venetoclax 600mg + Obinutuzumab 1000mg
10202787|NCT04073147|Experimental|Dosing group 2|Venetoclax 800mg + Obinutuzumab 1000mg
10202788|NCT04073147|Experimental|Dosing group 3|Venetoclax 1000mg + Obinutuzumab 1000mg
10202789|NCT04071379|Experimental|HepB + Penta batch 1|Recombinant Hepatitis B + DTP-HB-Hib batch 1
10202790|NCT04071379|Active Comparator|Hep B + Pentabio (registered)|Recombinant Hepatitis B + Pentabio (registered)
10202791|NCT04069923|Experimental|Treatment (OsteoCrete)|Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation.
10202792|NCT04062292||Obstructive lung diseases group|"Having been diagnosed with obstructive pulmonary disease,~No acute exacerbation or infection in the past 1 week, Being between the ages of 18 and 65,"
10202793|NCT04062292||Healthy group|Age and sex matched healthy subjects without orthopedic and chronic diseases
10202794|NCT04054375|Experimental|Weekly Steroid|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
10202795|NCT04052139|Active Comparator|Low-dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
9984178|NCT04324021|Active Comparator|Emapalumab|Emapalumab i.v. infusion every 3rd day for a total 5 infusions. Day 1: 6mg/kg. Days 4, 7, 10 and 13: 3 mg/kg
9760649|NCT00685477|Active Comparator|Experimental Sequence CBA|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
9760650|NCT00685516|Active Comparator|Arm I - Green Tea|Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
9760651|NCT00685516|Placebo Comparator|Arm II - Water|Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
9760652|NCT00685516|Active Comparator|Arm III - Decaffeinated black tea|Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
9760653|NCT00685659|Active Comparator|TAU only|Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
9760654|NCT00685659|Experimental|TMAC only|Adaptive telephone-based counseling
9760655|NCT00685659|Experimental|TMAC plus|Adaptive telephone-based counseling, plus incentives
9760656|NCT00685685|Experimental|Lovastatin 40 mg tablet|A single dose of Lovastatin 40 mg administered after an overnight fast of at least 10 hours.
9760657|NCT00685685|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered after an overnight fast of at least 10 hours.
9760658|NCT00685698|Other|Nemonoxacin|Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
9760659|NCT00685750|Other|ME1|Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment
9760660|NCT00685750|Other|ME2|Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only
9760661|NCT00685750|Other|ME3|Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment
9760662|NCT00685750|Other|ME4|Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions
9760663|NCT00685750|Other|ME5|Patients with cutaneous metastatic melanoma receiving local imiquimod
9760664|NCT00685750|Other|NSC|Non-small cell lung cancer patients
9760665|NCT00685750|Other|ME6|Patients with cutaneous metastatic melanoma receiving ipilimumab
9760666|NCT00685763|Experimental|Proton radiation and chemotherapy|"Chemotherapy and Radiation Combination~Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks.~Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only.~Consolidation Chemotherapy starting 4 weeks after the completion of radiation~Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses."
9760667|NCT00685802|Experimental|Cilostazol 50 mg Tablets|A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
9760668|NCT00685802|Experimental|Cilostazol (Pletal® ) 50 mg Tablets|A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
9760669|NCT00685932|No Intervention|Control|This arm will be randomly assigned to have conventional retractions (ie Rich retractors and similar) used in the usual fashion during the cesarean procedure.
9760670|NCT00685932|Experimental|Mobius|This arm will be randomized to have the providers who are performing the cesarean section use the Mobius retractor during the cesarean section procedure after the peritoneal cavity is opened.
9760671|NCT00685945|Experimental|Control (bradykinin infusion)|Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
9760672|NCT00685945|Experimental|L-NMMA + bradykinin|N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
9760673|NCT00685945|Experimental|Isosorbide + L-NMMA + bradykinin|Isosorbide (NO donor)
9760674|NCT00685945|Experimental|Sildenafil + L-NMMA + bradykinin|Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor
9760675|NCT00686075|Experimental|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
9832416|NCT02612623|Experimental|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
9984179|NCT04324021|Active Comparator|Anakinra|Anakinra i.v. infusion four times daily for 15 days. 400 mg/day in total, divided into 4 doses given every 6 hours
9760676|NCT00686075|Placebo Comparator|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
9760677|NCT00686075|Experimental|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
9760678|NCT00686075|Placebo Comparator|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
9760679|NCT00686075|Experimental|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
9760680|NCT00686075|Placebo Comparator|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
9760681|NCT00686075|Experimental|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
9760682|NCT00686075|Placebo Comparator|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
9760683|NCT00686075|Experimental|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
9760684|NCT00686075|Placebo Comparator|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
9760685|NCT00686127|Active Comparator|Lidocaine Patch|Drug: lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1 patch was applied topically to the affected site(s) for 12 hours each day.
9760686|NCT00686127|Placebo Comparator|Placebo Patch|Drug: placebo patch, 1 patch was applied topically to the affected site(s) for 12 hours each day.
9832417|NCT02612623|Experimental|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
9832418|NCT02612623|Experimental|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
10202796|NCT04052139|Active Comparator|Gabapentin|Participants randomized to the gabapentin arm begin on a dose of 300 mg daily (300 mg qd). In week 2, participants will take 300 mg of gabapentin three times daily. In week 3 the dose will be titrated up to 1800 mg daily (300 mg+300 mg tid) will remain on the dose until week 8, when they will be tapered back down to 900 mg daily (300 mg tid). In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
10202797|NCT04052139|Placebo Comparator|Placebo|Participants will receive a placebo to be taken three times daily for 8 weeks.
9832419|NCT02612688|Experimental|ACP Video Program|Facility asked to implement ACP Video Program
9832420|NCT02612688|No Intervention|Usual ACP procedures|Facility follows usual ACP procedures
9832421|NCT02612727|Experimental|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
9832422|NCT02612727|Active Comparator|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
10202798|NCT04034719|Experimental|Experimental group|"Newborn hospitalized in the neonatal department with their parent will be included.~They will have a portage scarf to help them to keep their child skin-to-skin"
10202799|NCT04034719|Active Comparator|Control group|"Newborn hospitalized in the neonatal department with their parent will be included.~They wont have a portage scarf."
10202800|NCT04032301|Experimental|Intravenous ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
10202801|NCT04032301|Placebo Comparator|Intravenous saline infusions|Six infusions of normal saline solution over 3 weeks.
10202802|NCT04027101|Experimental|Experimental group|Oral baricitinib 4mg/day for 12 weeks. Then, at week 12, if PMR-AS≤10, patients will receive baricitinib 2 mg for 12 weeks. If PMR-AS ≤10, the patients will not receive any treatment until W24 At W24, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1 mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) according to investigator's opinion.
10202803|NCT04027101|Placebo Comparator|Control group|Oral placebo every day during 3 months (W12). Then, at week 12, if PMR-AS ≤10, placebo for 12 weeks. If PMR-AS ≤10, the patients do not receive any treatment until a flare. If PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) and according to investigator's opinion.
10202804|NCT04024904|No Intervention|control group|In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD (Virtual Reality Hypnosis Distraction).
10202805|NCT04024904|Experimental|VRHD1|In the study group VRHD (Virtual Reality Hypnosis Distraction) 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
10202806|NCT04024904|Experimental|VRHD2|In the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
10202807|NCT04015167||T2 Alpha Tibia|Subjects in the clinical investigation will undergo placement of the Tibial Nail of the T2 Alpha Tibia Nailing System, according to the approved Instructions for Use and Operative Technique Manual.
10202808|NCT04015154||T2 Alpha Femoral Nail PF|Subjects in the clinical investigation will undergo placement of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the piriformis fossa, according to the Instructions for Use and Operative Technique Manual
10202809|NCT04015128||T2 Alpha Femoral Nail GT|Subjects in the clinical investigation will undergo placement of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the tip of the greater trochanter, according to the approved Instructions for Use and Operative Technique Manual.
10202810|NCT04011787|Active Comparator|Intervention|bolus NGT feeding
10202811|NCT04011787|Other|Control|Continuous NGT feeding (standard care)
10202812|NCT04009733|Experimental|Osteogenesis imperfecta type 1|Patients with OI type 1
10202813|NCT04009733|Experimental|Osteogenesis imperfecta type 3|Patients with OI type 3
10202814|NCT04009733|Active Comparator|Control population|The control population corresponds to a pre-existing serum collection of osteoarthritis cohorts (OFELY and MODAM for women, STRAMBO for men).
10202815|NCT04009213|Experimental|LiquiBand FIX8®|LiquiBand FIX8® is an n-butyl-2-cyanoacrylate adhesive monomer and D&C Violet #2 dye
10202816|NCT04009213|Active Comparator|AbsorbaTack™|AbsorbaTack™ is an absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D&C Violet No. 2
10202817|NCT03998319|Experimental|Tenecteplase (1/3 systemic weight based dose)|Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/3 of the weight based dose, and administered by intracoronary infusion over 3 minutes.
10202818|NCT03998319|Placebo Comparator|Sterile Water for injection (WFI)|Water for injection will be prepared to 20mL over an equivalent time period to the reconstitution time of the experimental arm, in order to maintain the blind, and administered by intracoronary infusion over 3 minutes.
10202819|NCT03998319|Experimental|Tenecteplase (1/6 systemic weight based dose)|Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/6 of the weight based dose, and administered by intracoronary infusion over 3 minutes.
10202820|NCT03997240|Other|Wait-list control|Six-week wait list control
9760687|NCT00686166|Experimental|Chemo + Chemo and radiation + Surgery|"Chemotherapy Cycle 1 (1 cycle is 35 days):~Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Cetuximab, 400 mg/m^2, IV, Day 1~Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2:~Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78~Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78~Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)~Radiation therapy: Planning target value 1: 4500 cGy (centigray) in 25 fractions; Planning target value 2 (stage T3 patients): Boost of 540 cGy in 3 fractions; Planning target value 2 (stage T4 patients): Boost of 900 cGy in 5 fractions.~Therapeutic Surgical procedure: Resection"
9760688|NCT00686205|Experimental|ABBOTT PRISM HIV O Plus assay for Specificity|All subjects will have their blood tested by the investigational HIV test.
9760689|NCT00686205|No Intervention|ABBOTT PRISM HIV O Plus Assay for Sensitivity|Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.
9760690|NCT00686231|Experimental|Dose Test 15mg NTG|Nitroglycerin 15mg (NTG) applied topically to one wrist and placebo to the other wrist at Visit 1
9760691|NCT00686231|Experimental|Dose Test 30mg NTG|Nitroglycerin 30mg applied topically to one wrist and placebo to the other wrist at Visit 1
9760692|NCT00686231|Experimental|Combination Test 20mg Lidocaine|Lidocaine 20mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 20mg + placebo applied to the other wrist, at Visit 2
9760693|NCT00686231|Experimental|Combination Test 40mg Lidocaine|Lidocaine 40mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 40mg + placebo applied to the other wrist, at Visit 2
9760694|NCT00686257|Experimental|1|Patients receiving NPPV by the 'Total Face Mask'
9760695|NCT00686257|Active Comparator|2|Patients receiving NPPV by 'standard oronasal mask'
9760696|NCT00686335|Experimental|Lodotra|After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
9760697|NCT00686335|Active Comparator|Cortancyl|During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.
9760698|NCT00686517|Experimental|PEG-IFN 24|pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
9760699|NCT00686517|Experimental|PEG-IFN 12|pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
9760700|NCT00686517|Experimental|PEG-IFN + RVB 12|pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
9760701|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15|POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.
9760702|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.
9760703|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.
9760704|NCT00686582|Experimental|Initially Vaccinia Naive, 2 dose primed, 1 booster dose|"Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
9760705|NCT00686582|Experimental|Initially Vaccinia Naive, 1 dose primed, 1 booster dose|"Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
9760706|NCT00686582|Other|Vaccinia Experienced, boosted, blood draw only|"Group 4 Vaccinia Experienced~1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)"
9760707|NCT00686595|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg intravenous (IV) infusion administered at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
9760708|NCT00686634|Experimental|1|Sitagliptin 100 mg once daily
9760709|NCT00686686|Experimental|Infliximab 5 mg/kg|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
9760710|NCT00686699|Experimental|Preladenant 25 mg BID→Placebo BID|Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
9760711|NCT00686699|Placebo Comparator|Placebo BID→Preladenant 25 mg BID|Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
9760712|NCT00686712|Experimental|1 - Insulin glargine QHS|Insulin glargine injected subcutaneously once daily at bedtime
9760713|NCT00686712|Experimental|2 - Insulin glargine QAM|Insulin glargine injected subcutaneously once daily in the morning
9760714|NCT00686712|Active Comparator|3 - NPH Insulin QHS|NPH insulin injected subcutaneously once daily at bedtime
9832423|NCT02612779|Experimental|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
9832424|NCT02612779|Experimental|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
9832425|NCT02612857|Placebo Comparator|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
9832426|NCT02612857|Experimental|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
9832427|NCT02612857|Experimental|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
9832428|NCT02612909|Placebo Comparator|Phase 2: Placebo|Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
9832429|NCT02612909|Active Comparator|Phase 2: Vaccine (15 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
9832430|NCT02612909|Active Comparator|Phase 2: Vaccine (30 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
9760715|NCT00686725|Active Comparator|Temozolomide + Radiation|"Standard therapy regimen:~Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m^2/day, and may be increased to 200 mg/m^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used.~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
9760716|NCT00686725|Experimental|Temozolomide alone, then Temozolomide + Radiation|"Early postsurgery temozolomide chemotherapy plus standard regimen:~Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen).~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
9760717|NCT00686777|Experimental|PEG-IFN + Ribavirin|Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.
9760718|NCT00686790|Experimental|PegIntron|All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.
9760719|NCT00686803|Experimental|PL3994 Dose A|PL3994 Dose A
9760720|NCT00686803|Experimental|PL3994 Dose B|PL3994 Dose B
9760721|NCT00686803|Experimental|PL3994 Dose C|PL3994 Dose C
9760722|NCT00686803|Experimental|PL3994 Dose D|PL3994 Dose D
9760723|NCT00686803|Experimental|PL3994 Dose E|PL3994 Dose E
9760724|NCT00686803|Placebo Comparator|Placebo|Placebo
9760725|NCT00686829|Experimental|VCV 30 mg|Participants take VCV 30 mg once daily.
9760726|NCT00686842|Experimental|VEGF Inhibitor PTC299|Single arm study - all subjects received PTC299
9760727|NCT00686855|Experimental|Tacrolimus|Tacrolimus Arm Closed to Accrual as of January 2012
9760728|NCT00686855|Experimental|Dexamethasone|
9760729|NCT00686881|Experimental|PegIFN-2b|Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
9760730|NCT00686881|Active Comparator|SNMC|Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.
9760731|NCT00686894|Experimental|Infliximab 5 mg/kg|Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6.
9760732|NCT00686920|Experimental|Rifaximin|Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.
9760733|NCT00686959|Experimental|Arm A: Pemetrexed + Cisplatin and TRT|"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (Concurrent Phase) for three 21-day cycles, followed by a 3-5 week Recovery Period, then treated with consolidation chemotherapy with pemetrexed (Consolidation Phase) for up to four 21-day cycles~Concurrent Phase:~Pemetrexed: 500 milligrams per meter squared (mg/m^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.~Cisplatin: 75 mg/m^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray [Gy] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.~Consolidation Phase:~Pemetrexed: 500 mg/m^2, IV on Day 1 of each 21-day cycle up to 4 cycles"
9760734|NCT00686959|Active Comparator|Arm B: Etoposide + Cisplatin and TRT|"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (Concurrent Phase) for two 28-day cycles, followed by a 3-5 week Recovery Period, then received consolidation treatment with cytotoxic chemotherapy of choice (Consolidation Phase) for up to 2 cycles~Concurrent Phase:~Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m^2, IV on Days1, 8, 29, and 36~Consolidation Phase options:~Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"
9760735|NCT00686998|Experimental|AZD2624|AZD2624 40 mg
9760736|NCT00686998|Other|Olanzapine|Olanzapine 15 mg
9760737|NCT00686998|Placebo Comparator|Placebo|Matching Placebo
9760738|NCT00687076|Experimental|1|Participants will receive standard of medical care and treatment with intensive lipid modification using a statin plus Ezetimibe and Niaspan.
9760739|NCT00687076|Active Comparator|2|Participants will receive standard of medical care and treatment with standard lipid modifying medications plus placebo Ezetimibe and placebo Niaspan.
9760740|NCT00687102|Experimental|Star participants assigned to Tamoxifen|Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
9760741|NCT00687102|Experimental|Star participants assigned to Raloxifene|Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
9760742|NCT00687167|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
9760743|NCT00687167|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
9760744|NCT00687193|Placebo Comparator|Placebo|
9760745|NCT00687193|Experimental|CP-690,550, 10mg|
9760746|NCT00687193|Experimental|CP-690,550, 15mg|
9760747|NCT00687193|Experimental|CP-690,550, 1mg|
9760748|NCT00687193|Experimental|CP-690,550, 3mg|
9760749|NCT00687193|Experimental|CP-690,550, 5mg|
9760750|NCT00687219|Experimental|Peginterferon alfa-2b + Ribavirin|
9760751|NCT00687271|Experimental|MK-6213 160 mg + Atorvastatin 20 mg|1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks
9760752|NCT00687271|Active Comparator|Atorvastatin 20 mg|1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks
9760753|NCT00687271|Experimental|MK-6213 160 mg|1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks
9760754|NCT00687271|Placebo Comparator|Placebo|1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks
9760755|NCT00687297|Active Comparator|Vandetanib Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, vandetanib maintenance daily until progression.
9760756|NCT00687297|Placebo Comparator|Placebo Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, placebo maintenance daily until progression.
9760757|NCT00687323|Experimental|Temozolomide|Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), then 200 mg/m^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m^2/day for 21 days of each 28-day cycle (12 cycle maximum).
9760758|NCT00687362|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
9760759|NCT00687401|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6, and 14.
9760760|NCT00687440|Experimental|Caelyx, Docetaxel, Trastuzumab|"Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.~Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab."
9760761|NCT00687453|Experimental|1|Insulin glargine at bedtime
9760762|NCT00687453|Active Comparator|2|NPH twice-daily
9760763|NCT00687544|Experimental|PEG-IFN + RBV|PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
9760764|NCT00687609|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
9760765|NCT00687674|Experimental|Sorafenib + Lenalidomide + Dexamethasone|
9760766|NCT00687713|Active Comparator|Bupropion|Subjects will receive bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
9760767|NCT00687713|Placebo Comparator|Placebo|Subjects will receive a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
9760768|NCT00687739|Placebo Comparator|1|GnRH agonist + placebo
9760769|NCT00687739|Active Comparator|2|GnRH agonist + placebo + exercise
9760770|NCT00687739|Experimental|3|GnRH agonist + Estradiol
9760771|NCT00687739|Experimental|4|GnRH agonist + Estradiol + exercise
9760772|NCT00687804|Experimental|Ranibizumab 0.5 mg|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
9760773|NCT00687804|Experimental|Ranibizumab 0.5 mg + laser|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
9783553|NCT01204203|Experimental|Zometa|Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.
9984180|NCT04324021|No Intervention|Standard of care|Standard of care according to local practice
9760774|NCT00687804|Active Comparator|Laser|"Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
9760775|NCT00687830|Active Comparator|Polythylene Glycol (PEG) in the evening|"Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.~'Polyethylene Glycol afternoon'"
9760776|NCT00687830|Experimental|Polythylene Glycol (PEG) in the Morning|"Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.~'Polyethylene Glycol morning'"
9760777|NCT00687856||LVAD Recipients|Participants who have had or are about to have a left ventricular assist device (LVAD) implanted
9760778|NCT00687908|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel once daily
9760779|NCT00687908|Placebo Comparator|2|Vehicle Gel once daily
9760780|NCT00687973|Experimental|Valsartan/amlodipine 160/10 mg|Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
9760781|NCT00687973|Active Comparator|Atenolol/amlodipine 100/10 mg|Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
9760782|NCT00688064|Experimental|1|Adapalene-BPO + Doxycyline
9760783|NCT00688064|Active Comparator|2|Vehicle + Doxycycline
9760784|NCT00688103|Active Comparator|ETN Alone|etanercept (25mg, twice/week, s.c.)
9760785|NCT00688103|Active Comparator|ETN+MTX|etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)
9760786|NCT00688155|Experimental|Physical Activity Training|The Physical Activity Training ((PAT) intervention consisted of center-based and home-based sessions comprised of aerobic, strength, flexibility, and balance training with a targeted duration of 150 mins/wk.
9760787|NCT00688155|Experimental|Cognitive Training|The Cognitive Training (CT) intervention was developed to improve consciously-controlled memory processing or recollection of episodic memory information.
9832431|NCT02612909|Placebo Comparator|Phase 3: Placebo|Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
9832432|NCT02612909|Experimental|Phase 3: Vaccine|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
9832433|NCT02613117|Other|potassium oxalate gel|potassium oxalate gel self applied
9832434|NCT02613117|Other|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
9984181|NCT04320810||mNGS diagnosis|Using mNGS to diagnosis infectious disease of this group
9832435|NCT02613169|Experimental|Isoniazid|Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
9832436|NCT02613169|No Intervention|No Isoniazid|No INH will be administered to this arm.
9832437|NCT02613182|Experimental|Open Label|Open Label Study Drug NEOD001
9832438|NCT02613208||Participants With Metastatic Breast Cancer|Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
9832439|NCT02613221|Experimental|panitumumab + TAS-102 combination therapy|Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).
9832440|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
9984182|NCT04320797||Active lupus nephritis|Patients with proliferative lupus nephritis (Class III and IV)
9984183|NCT04320797||Control|Patients with systemic lupus erythematodes without lupus nephritis or lupus nephritis I, II or VI
9984184|NCT04320667||Active ANCA glomerulonephritis|Patients with ANCA related disease (Microscopic Polyangiitis, Granulomatosis with Polyangiitis or Churg-Strauss Syndrome) and active renal involvement
9984185|NCT04320667||Control|Patients with ANCA related disease (MPA, GPA, CSS) without renal involvement or complete remission
9760788|NCT00688155|Experimental|Combined Intervention|"The Combined Intervention (PACT) was designed so that participants received both cognitive and physical activity training on the same day.~."
9760789|NCT00688155|Active Comparator|Healthy Aging Education|The Healthy Aging Education control intervention consisted of weekly lectures based on health education.
9760790|NCT00688181||Subjects treated with the Prefyx PPS System|All patients presenting to the institution for treatment of female Stress Urinary Incontinence (SUI), excluding those patients meeting any of the contraindications as noted in the Directions For Use.
9760791|NCT00688259|Experimental|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
9760792|NCT00688259|Active Comparator|Supportive Therapy (ST)|approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns
9760793|NCT00688324|Experimental|Single Arm|All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
9760794|NCT00688467|Experimental|Navarixin → Placebo|Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2
9760795|NCT00688467|Experimental|Placebo → Navarixin|Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2
9760796|NCT00688519|Experimental|U0267 Foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
9760797|NCT00688519|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
9760798|NCT00688545||Celecoxib|Patients treated with celecoxib as per treating physician's judgement
9760799|NCT00688545||nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)|Patients treated with nsNSAIDs as per treating physician's judgement
9760800|NCT00688597|Experimental|Cohort 1|Regimen 1: Low-dose duvoglustat (2.5 grams [g]) once a day (QD) for 3 days, followed by no drug for 4 days, for 11 weeks.
9760801|NCT00688597|Experimental|Cohort 2|Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks.
9760802|NCT00688597|Experimental|Cohort 3|Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks.
9760803|NCT00688623|Experimental|Everolimus|Everolimus
9760804|NCT00688636|Active Comparator|1|
9760805|NCT00688636|Placebo Comparator|2|
9760806|NCT00688662|Active Comparator|1.ERCP with sphincterotomy|ERCP with sphincterotomy: cutting the biliary sphincter muscle (sphincterotomy)
9760807|NCT00688662|Placebo Comparator|2.ERCP without sphincterotomy|ERCP without cutting the biliary sphincter muscle (sphincterotomy)
9760808|NCT00688688|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
9760809|NCT00688688|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
9760810|NCT00688688|Active Comparator|Tolterodine ER 4 mg|Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.
9760811|NCT00688701|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
9760812|NCT00688701|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
9760813|NCT00688701|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
9760814|NCT00688701|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
9760815|NCT00688740|Experimental|TAC (Docetaxel)|docetaxel (75 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
9760816|NCT00688740|Active Comparator|FAC (5-fluorouracil)|5-fluorouracil (500 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
9760817|NCT00688753|Experimental|RAD001|two 5 mg tablets of everolimus orally, once daily
9760818|NCT00688844||PKU subjects - baseline|Male and female subjects with PKU at baseline starting KuvanTM therapy.
9760819|NCT00688870|Experimental|1|13vPnC
9760820|NCT00688870|Active Comparator|2|7vPnC
9760821|NCT00688909|Experimental|Letrozole|Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.
9760822|NCT00689026|Experimental|Experimental|The lubiprostone group will receive an additional two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
9760823|NCT00689026|Active Comparator|Control|All patients in the study will receive a standard oral dosing of 4L Polyethylene glycol with electrolytes colonoscopy preparation the day prior to their scheduled colonoscopy.
9760824|NCT00689078|Active Comparator|Pred acetate 1%|Prednisolone acetate 1.0% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
9760825|NCT00689078|Active Comparator|Pred acetate .12%|Prednisolone acetate 0.12% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
9760826|NCT00689078|Active Comparator|Lot Etab 0.2%|Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
9832441|NCT02613364|Experimental|Arm I (behavioral intervention-yoga)|Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
9832442|NCT02613364|Experimental|Arm II (cognitive intervention-CBT-I)|Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
9832443|NCT02613364|Active Comparator|Arm III (educational intervention)|"Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families."
9832444|NCT02613403|Experimental|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
9832445|NCT02613403|Experimental|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
9832446|NCT02613403|Experimental|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
9760827|NCT00689078|Placebo Comparator|Placebo|Tears Naturale (Artificial Tears) in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
9760828|NCT00689091|Experimental|BIS group|This group will have BIS values visible and will receive alerts when the value is >60.
9760829|NCT00689091|Active Comparator|MAC Alert|This group will receive an alert if total MAC (including intravenous infusions) is <0.5 age-adjusted.
9760830|NCT00689104|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets and matching tolterodine slow release (SR) placebo capsules orally once a day for 12 weeks.
9760831|NCT00689104|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
9760832|NCT00689104|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
9760833|NCT00689104|Active Comparator|Tolterodine SR 4 mg|Participants received tolterodine SR 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 weeks.
9760834|NCT00689117|Experimental|1|CT Gel
9760835|NCT00689117|Active Comparator|2|Clindamycin Gel (clindamycin)
9760836|NCT00689117|Active Comparator|3|Tretinoin Gel (tretinoin)
9760837|NCT00689117|Placebo Comparator|4|Vehicle Gel
9760838|NCT00689221|Experimental|Cilengitide + Temozolomide + Radiotherapy|
9760839|NCT00689221|Active Comparator|Temozolomide + Radiotherapy|
9783554|NCT01204255|Experimental|Arm I|Patients apply lorazepam, diphenhydramine hydrochloride, and haloperidol gel topically over 2 minutes.
9783555|NCT01204294|Experimental|Bigu+Lina|biguanide plus linagliptin
9783556|NCT01204294|Experimental|Glin+Lina|glinide plus linagliptin
9783557|NCT01204294|Experimental|Glit+Lina|glitazone plus linagliptin
9783558|NCT01204294|Experimental|SU+Lina|sulfonylurea plus linagliptin
9783559|NCT01204294|Experimental|A-GI+Lina|alpha-glucosidase inhibitor plus linagliptin
9783560|NCT01204294|Active Comparator|SU+Met|sulfonylurea plus metformin
9783561|NCT01204294|Active Comparator|A-GI+Met|alpha-glucosidase inhibitor plus metformin
9783562|NCT01204398|Experimental|eligible hypertension patient|Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
9783563|NCT01204658|Experimental|10PP-LD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses (LD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD) co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
9785540|NCT01254045|Experimental|oxytocin 24IU, oxytocin 48IU, placebo|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
10202821|NCT03997240|Experimental|Immediate intervention|Immediate treatment group
10202822|NCT03991624|Other|Alzheimer's patients (lack of executive functions)|
10202823|NCT03991624|Other|control (lack of executive functions)|
10202824|NCT03991624|Other|Alzheimer's patients (lack of working memory)|
10202825|NCT03991624|Other|control (lack of working memory)|
10202826|NCT03991624|Other|Alzheimer's patients (lack of episodic memory)|
10202827|NCT03991624|Other|control (lack of episodic memory)|
10202828|NCT03988998|Experimental|Radiofrequency ablation with radiotherapy|Patients in this arm will receive liver radiotherapy around the primary tumor margin within one month after radiofrequency ablation for hepatocellular carcinoma.
10202829|NCT03988998|Active Comparator|Radiofrequency ablation alone|Patients in this arm will only receive radiofrequency ablation for hepatocellular carcinoma.
10202830|NCT03984214|Active Comparator|Dronabinol|BX-1 contains 25 mg dronabinol/ml (2.5% delta-9-trans-tetrahydrocannabinol = THC), oral solution; three applications per day from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets)
10202831|NCT03984214|Placebo Comparator|Placebo|Placebo: oral solution with cannabis flavor without active substance and otherwise identical to active comparator, three applications per day from 3 x 1 droplet up to 3 x 12 droplets
10202832|NCT03983733|Experimental|Dietary Intervention|Dietary intervention using standardised test meals, on up to 8 days within the study period.
10202833|NCT03981497||Small Renal Tumors|Subjects with small renal tumors (SRT) ad described by current ESMO (European Society for Medical Oncology) guidelines who are candidates for MWA
10202834|NCT03981497||Primary and Secondary Liver cancer|Primary liver tumors: subjects who are candidates for MWA with nodules ≤ 3 cm Liver metastases: subjects who are candidates for MWA with nodules less than ≤ 3 cm
10202835|NCT03980899||Patients with PPI|
10202836|NCT03976323|Experimental|Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4).~If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.~For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21-day cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until progressive disease, physician decision or intolerable toxicity."
9760840|NCT00689260|Active Comparator|1 - Log Aware|Dose Log Aware (patient is aware that the device records their injection information) Half the subjects in the log aware arm will complete a diary. The other half in the log aware arm will not complete the diary.
9760841|NCT00689260|Active Comparator|2 - Log Unaware|Dose Log Unaware (patient is not aware that the device records their injection information) Half the subjects in the log unaware arm will complete a diary. The other half in the log unaware arm will not complete the diary.
9760842|NCT00689273|Experimental|PF-04136309|
9760843|NCT00689273|Placebo Comparator|Placebo|
9760844|NCT00689299|Placebo Comparator|Dose Group C|Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo
9760845|NCT00689299|Active Comparator|Dose Group A|Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units
9760846|NCT00689299|Active Comparator|Dose Group B|Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units
9760847|NCT00689338|Experimental|Treatment Group|Option to treat with oral azole therapy following treatment with anidulafungin
9760848|NCT00689351|Experimental|1|13vPnC
9760849|NCT00689351|Active Comparator|2|7vPnC
9760850|NCT00689390|Other|Participants from Boceprevir Studies|Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
9760851|NCT00689390|Other|Participants from Narlaprevir Studies|Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
9760852|NCT00689481|Experimental|U0267 foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
9760853|NCT00689481|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
9760854|NCT00689572|Experimental|Ondansetron|Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
9760855|NCT00689572|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
9760856|NCT00689611|Placebo Comparator|P|Half of patients will receive placebo for 9 weeks.
9760857|NCT00689611|Active Comparator|A|Half of patients will receive bupropion for 9 weeks.
9760858|NCT00689728|Experimental|30 milligram (mg) LY2127399|"Double-blind Treatment: 30 mg LY2127399 administered as a single intravenous (IV) infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
9760859|NCT00689728|Experimental|80 mg LY2127399|"Double-blind Treatment: 80 mg LY2127399 administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
9760860|NCT00689728|Placebo Comparator|Placebo|"Double-blind Treatment: Placebo comparator administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on same initial randomized treatment up to Week 24.~Follow-Up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
9760861|NCT00689793|Active Comparator|1|
9760862|NCT00689793|Placebo Comparator|2|
9760863|NCT00689819|Active Comparator|BP < 140/90 mmHg|This arm will target a blood pressure of < 140/90 mmHg (or < 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
9760864|NCT00689819|Experimental|BP < 120/80 mmHg|This arm will target a more aggressive blood pressure target of < 120/80 mmHg.
9760865|NCT00689871|Experimental|1|Primary augmentation
9760866|NCT00689871|Experimental|2|Primary reconstruction
9760867|NCT00689871|Experimental|3|Revision-augmentation
9760868|NCT00689871|Experimental|4|Revision-reconstruction
9760869|NCT00689936|Experimental|Lenalidomide / Dexamethasone until disease progression|Lenalidomide plus low-dose dexamethasone given until disease progression
9760870|NCT00689936|Experimental|Lenalidomide / Dexamethasone for 18 cycles|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
9760871|NCT00689936|Active Comparator|Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles|Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
9760872|NCT00690040|Active Comparator|1|Ripening of the unfavorable cervix is done with Single balloon catheter (Foley catheter)
9760873|NCT00690040|Active Comparator|2|Ripening of the unfavorable cervix is done with double balloon catheter (Atad catheter)
9760874|NCT00690235|Other|Placebo|Patients will be given the Placebo for injection twice daily
9760875|NCT00690235|Other|Pramlintide|volunteers are given 180mg of pramlintide, twice daily
9760876|NCT00690274|Placebo Comparator|Placebo|Volunteers are given Placebo, up to 20mg per day
9760877|NCT00690274|Active Comparator|BF2.649|Volunteers are given BF2.649, up to 20mg per day
9760878|NCT00690339|Experimental|1|Augmentation
9760879|NCT00690339|Experimental|2|Reconstruction
9760880|NCT00690339|Experimental|3|Revision-augmentation
9760881|NCT00690339|Experimental|4|Revision-reconstruction
9760882|NCT00690378|Experimental|1|NXL/104 ceftazidime
9760883|NCT00690378|Active Comparator|2|comparator 4 x daily
9760884|NCT00690430|Active Comparator|Pasireotide LAR|Patients assigned to pasireotide LAR will receive a 60 mg dose of pasireotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 40 mg is permitted if tolerability issues arise. In addition, after 24 hours of the first LAR injections the patients were permitted to use pasireotide s.c. formulation for breakthrough symptoms as needed.
9760885|NCT00690430|Active Comparator|Octreotide LAR|Patients assigned to octreotide LAR will receive a 40mg dose of octreotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 30 mg is permitted if tolerability issues arise. Patients requiring a dose reduction are to return to the higher dose once the tolerability issue is resolved, if required for efficacy In addition, after 24 hours of the first LAR injections the patients were permitted to use octreotide s.c. formulation for breakthrough symptoms as needed.
9760886|NCT00690443|Active Comparator|2|2.5 mg AEGR 733 plus atorvastatin 20 mg weeks 1-4 followed by 5 mg AEGR 733 plus atorvastatin 20 mg weeks 5-8
9760887|NCT00690443|Active Comparator|1|Following 35-day washout + diet run-in, subjects receive atorvastatin 20 mg for 8 wks.
9760888|NCT00690482|Experimental|AZD1981|AZD1981 Oral tablet, twice daily
9760889|NCT00690482|Placebo Comparator|Placebo|Placebo Oral tablet, twice daily
9760890|NCT00690495|Experimental|1|Modified propofol (Propofol 0.5%)
9760891|NCT00690495|Active Comparator|2|Propofol 1%
9760892|NCT00690573|Experimental|Adalimumab|
9760893|NCT00690612|Experimental|1|investigator determines efficacious dose based on child's BP response.
9760894|NCT00690755||Group 1|type 2 diabetic individuals
9760895|NCT00690755||Group 2|type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
9760896|NCT00690755||Group 3|non-diabetic individuals who are not considered to be overweight
9760897|NCT00690755||Group 4|non-diabetic individuals who are considered to be overweight
9760898|NCT00690755||Group 5|non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
9760899|NCT00690755||Group 6|individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
9760900|NCT00690755||Group 7|healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures
9760901|NCT00690794|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
9760902|NCT00690794|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
9760903|NCT00690820|Experimental|A|
9760904|NCT00690820|Placebo Comparator|B|
9760905|NCT00690833|Experimental|topical desonide hydrogel 0.05%|Approximately 40 male and female subjects (about 20 age 3 months to <13 years and 20 age 13 and up) with mild to moderate atopic dermatitis will apply desonate gel twice daily to ATD
9760906|NCT00690898|Experimental|Lanreotide autogel 120 mg|
9760907|NCT00690924|Experimental|Calcitriol|
9760908|NCT00691002|Experimental|LEO 80190|Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)
9760909|NCT00691002|Placebo Comparator|LEO 80190 vehicle|Ointment Vehicle
9760910|NCT00691002|Active Comparator|Calcipotriol|Calcipotriol 25 mcg/g in the ointment vehicle
9760911|NCT00691002|Active Comparator|Hydrocortisone|Hydrocortisone 10 mg/g in the ointment vehicle
9760912|NCT00691015|Experimental|Chemotherapy or chemotherapy + total body irradiation|"Standard of care (SOC) chemotherapy or ( SOC) chemotherapy + total body irradiation (TBI) of one of the following regimens:~Regimen I: Patients receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV;anti-thymocyte globulin IV.~Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV; anti-thymocyte globulin IV.~Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV; anti-thymocyte globulin IV.~Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI; anti-thymocyte globulin IV."
9760913|NCT00691028|Experimental|TA-650 3 mg/kg|
9760914|NCT00691028|Experimental|TA-650 6 mg/kg|
9760915|NCT00691028|Experimental|TA-650 10 mg/kg|
9760916|NCT00691054|Experimental|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4.
9760917|NCT00691093||fesoterodine|
9760918|NCT00691132|Experimental|PEITC - Placebo (short-term trial)|Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
9760919|NCT00691132|Experimental|Placebo - PEITC (short-term trial)|Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
9760920|NCT00691197|Experimental|Carboxymethylcellulose sodium and Glycerin|Carboxymethylcellulose sodium and Glycerin based rewetting drop
9760921|NCT00691197|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium based rewetting drop
9760922|NCT00691210|Experimental|V/N: Level 1|Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg
9760923|NCT00691210|Experimental|V/N: Level 2|Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg
9760924|NCT00691210|Experimental|V/N: Level 3|Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg
9760925|NCT00691210|Experimental|V/N: Level 4|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg
9760926|NCT00691210|Experimental|V/N: Level 5|Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg
9760927|NCT00691210|Experimental|V/N/E: Level 1|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2
9760928|NCT00691210|Experimental|V/N/E: Level 2|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2
9760929|NCT00691210|Experimental|V/N/E: Level 3|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2
9760930|NCT00691301|Experimental|Pemetrexed and cisplatin|Pemtrexed plus cisplatin on day 1 every 21 days
9760931|NCT00691327|Experimental|1|Primary reconstruction
9760932|NCT00691327|Experimental|2|Revision-reconstruction
9760933|NCT00691327|Experimental|3|Revision-augmentation
9760934|NCT00691483|Placebo Comparator|placebo|
9760935|NCT00691483|Experimental|varenicline|
9760936|NCT00691600|Active Comparator|oral trimethoprim/sulfamethoxazole|subjects with abscesses less than 5cm will be randomized to either study med or placebo
9760937|NCT00691600|Placebo Comparator|placebo|Placebo after incision and drainage of abscess less than 5 cm.
9760938|NCT00691665|Experimental|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
9760939|NCT00691665|Active Comparator|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
9760940|NCT00691704|Experimental|High-risk Multiple Myeloma|Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy
9760941|NCT00691808|Experimental|High Dose|
9760942|NCT00691808|Experimental|Low Dose|
9760943|NCT00691808|Placebo Comparator|Placebo|
9760944|NCT00691938|Experimental|Level 1|"LBH589 10 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
9760945|NCT00691938|Experimental|Level 2|"LBH589 15 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
9760946|NCT00691938|Experimental|Level 3|"LBH589 20 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
9760947|NCT00691938|Experimental|Level 4|"LBH589 30 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
9760948|NCT00691938|Experimental|Level 5|"LBH589 40 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
9760949|NCT00691938|Experimental|Level 5B|"LBH589 40 mg/day three times a week on nonconsecutive days for the first 2 weeks in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
9760950|NCT00691938|Experimental|Phase II|"LBH589 will be given in the dose and in the schedule that was found to work in the Phase I portion which was Level 5B.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
9760951|NCT00692185|Experimental|1|Participants will take olanzapine.
9760952|NCT00692185|Placebo Comparator|2|Participants will take matched placebo.
9760953|NCT00692198|Experimental|Supplemental oxygen therapy|Participants will receive treatment with supplemental oxygen therapy.
9760954|NCT00692198|No Intervention|No supplemental oxygen therapy|Participants will receive no supplemental oxygen therapy, unless the participant becomes severely hypoxemic at rest (e.g., meets conventional Medicare criteria for 24-hour supplemental oxygen due to severe hypoxemia at rest).
9760955|NCT00692211|Experimental|Arm 1: Fecal Immunochemical Tests|Mailed fecal immunochemical tests
9760956|NCT00692211|Experimental|Arm 2: Fecal Occult Blood Tests|Mailed fecal occult blood tests
9760957|NCT00692237|Active Comparator|1|Sildenafil 100 mg
9760958|NCT00692237|Placebo Comparator|2|Placebo 100 mg
9760959|NCT00692276|Experimental|1|Interspinous Process Spacer Device
9760960|NCT00692276|Active Comparator|2|Interspinous Process Spacer Device
9760961|NCT00692341|Experimental|Hepatic Function - Mild Impairment|Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)
9760962|NCT00692341|Experimental|Hepatic Function - Moderate Impairment|Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)
9760963|NCT00692341|Experimental|Hepatic Function - Normal|"Group 1~1) subjects with normal hepatic function"
9760964|NCT00692406|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
9760965|NCT00692419|Experimental|Symptom management nurse intervention|This arm of the study will have a symptom management nurse facilitate the management of pain, sexual dysfunction and depression. The nurse will work with the patient's renal provider to implement appropriate symptom alleviating treatment. The intervention is patient specific and entirely dependent on the treatment recommendation made by the symptom management nurse.
9760966|NCT00692419|Active Comparator|Feedback intervention|This arm of the study will have pain, sexual dysfunction and depression assessed monthly with feedback given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider. The intervention on symptoms is at the discretion of the renal provider. The interventions implemented were patient specific and consisted of therapies the patient's renal provider decided to implement.
9760967|NCT00692692|Experimental|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
9760968|NCT00692692|Active Comparator|Standard of care|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
9760969|NCT00692770|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
9760970|NCT00692770|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
9760971|NCT00692978|Experimental|Asthma|Asthma patients
9760972|NCT00692978|Active Comparator|Healthy volunters|Healthy participants
9760973|NCT00693160|Experimental|Intrathecal Ketorolac|In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
9760974|NCT00693160|Placebo Comparator|Placebo intrathecal injection|In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
9760975|NCT00693225|Active Comparator|Omeprazole/sodium bicarbonate AM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken in the morning
9760976|NCT00693225|Experimental|Omeprazole/sodium bicarbonate PM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken at bedtime
9760977|NCT00693303|Experimental|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
9760978|NCT00693420|Experimental|1|Bimatoprost 0.03% solution
9760979|NCT00693420|Placebo Comparator|2|Vehicle solution
9760980|NCT00693472|Experimental|Part 1: Preladenant|Preladenant 25 mg every 12 hours for 13 days
9760981|NCT00693472|Placebo Comparator|Part 1: Placebo|Placebo every 12 hours for 13 days
9760982|NCT00693472|Experimental|Part 2: Preladenant|Preladenant 25 mg every 12 hours for 13 days
9760983|NCT00693472|Active Comparator|Part 2: Standard of Care|Anticholinergic agents or Propranolol as standard-of-care dosing regimen (supplied by the study site)
9760984|NCT00693485|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
9760985|NCT00693485|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
9760986|NCT00693485|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
9760987|NCT00693498|Active Comparator|1|Standard leukoreduced irradiated blood cell transfusion group
9760988|NCT00693498|Experimental|2|Washed leukoreduced irradiated blood cell transfusion group
9760989|NCT00693654|Experimental|Sarna Lotion|1% pramoxine Sarna lotion
9760990|NCT00693654|Placebo Comparator|Placebo Cetaphil lotion|Placebo Cetaphil lotion
9760991|NCT00693693|Active Comparator|Cream-|topical hydrocortisone 17-butyrate 0.1% Cream preparation applied twice daily to all lesions of atopic dermatitis
9760992|NCT00693693|Active Comparator|Ointment|topical hydrocortisone 17-butyrate 0.1% Ointment preparation applied twice daily to all lesions of atopic dermatitis
9760993|NCT00693693|Active Comparator|Lipocream|topical hydrocortisone 17-butyrate 0.1% Lipocream preparation applied twice daily to all lesions of atopic dermatitis
9760994|NCT00693706|Experimental|GSK 1388442A Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of GSK 1388442A vaccine at Day 0. The GSK 1388442A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9760995|NCT00693706|Active Comparator|Fluarix Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of Fluarix® vaccine at Day 0. The Fluarix® vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9760996|NCT00693719|Experimental|Etoposide and Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15. Etoposide 50 mg PO x14 days followed by 2 weeks off.
9760997|NCT00693784|Experimental|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
9760998|NCT00693992|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9760999|NCT00693992|Placebo Comparator|Arm II (placebo)|Patients receive placebo 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9761000|NCT00694018|Active Comparator|Education and Standard Care|Received standard care and participated in an educational program for individuals with chronic back pain. Also received an uploading pedometer but no feedback or goals about their walking activity.
9761001|NCT00694018|Experimental|Internet Mediated Enhanced Pedometer|In addition to standard care and participating in an educational program, participants received an enhanced pedometer for uploading step information, e-mail messages with weekly step goals and access to a website that provided step goals and feedback, tailored motivational messages and on on-line community for communication asynchronously with staff and other participants.
9761002|NCT00694070||health care professionals and lay users|h= 8 health care professionals p= 43 lay users
9761003|NCT00694096|Experimental|1|
9761004|NCT00694109|Experimental|Mipomersen|Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.
9761005|NCT00694122|Active Comparator|Glargine (Lantus) insulin|"Long acting insulin, glargine, that subject currently used as an outpatient. SC injections. Dose given at 22:00 is based on past week blood glucose data during evening overnight hours and AM glucose. 20.2 +/- 11.7 units glargine (mean +/- SD).~Glargine (Lantus): Sanolfi Aventis~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the NPH insulin arm."
9832447|NCT02613403|Experimental|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
9832448|NCT02613403|Experimental|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 16 weeks.
9832449|NCT02613481|Other|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
9761006|NCT00694122|Active Comparator|NPH insulin|"Long acting insulin, NPH, that participant was currently while an outpatient. SC injections. Dose (units) given at 22:00 is based on past week blood glucose during evening overnight period and AM glucose. 20.7 +/- 10.0 units NPH (mean +/- SD).~NPH: Eli Lilly~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the glargine (Lantus) insulin arm."
9761007|NCT00694161|Experimental|Fx-1006A|
9761008|NCT00694304|Experimental|Vortioxetine|
9761009|NCT00694356|Experimental|Dalotuzumab 5 mg/kg|Participants receive dalotuzumab 5 mg/kg by intravenous (IV) infusion once each week for up to 1 year or until participant withdraws consent, experiences an adverse event (AE), progressive disease or major protocol violation, has moved or is lost to follow up.
9761010|NCT00694356|Experimental|Dalotuzumab 10 mg/kg|Participants receive dalotuzumab 10 mg/kg by IV infusion once each week for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
9761011|NCT00694356|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg|Participants receive an initial dose of dalotuzumab 15 mg/kg by IV infusion followed by a maintenance dose of dalotuzumab 7.5 mg/kg by IV infusion once every 2 weeks for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
9761012|NCT00694473|Experimental|Freestyle Navigator|Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
9761013|NCT00694551|Experimental|A. Level 100 mcg Peptide Vaccine|Peptide vaccine dose level 100 mcg + Poly IC-LC
9761014|NCT00694551|Experimental|B. Level 300 mcg Peptide Vaccine|Peptide vaccine dose level 300 mcg + Poly IC-LC
9761015|NCT00694551|Experimental|C. Level 1 mg Peptide Vaccine|Peptide vaccine dose level 1 mg + Poly IC-LC
9761016|NCT00694564|Experimental|Treatment|This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
9761017|NCT00694603|Experimental|Cetuximab|400mg/m2 IV x 1 and then 250mg/m2 IV weekly
9761018|NCT00694707|Placebo Comparator|Placebo|Participants received placebo orally once a day for 6 weeks.
9761019|NCT00694707|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
9761020|NCT00694707|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
9761021|NCT00694707|Experimental|Cariprazine 4.5 mg|Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
9761022|NCT00694707|Active Comparator|Risperidone 4.0 mg|Participants received risperidone 4.0 mg orally once a day for 6 weeks.
9761023|NCT00695019|Experimental|500 IU qd|500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day
9761024|NCT00695019|Experimental|500 IU tid|500 IU interferon-alpha lozenge taken 3 times per day
9761025|NCT00695019|Placebo Comparator|placebo|placebo lozenges taken 3 times per day
9761026|NCT00695097|Active Comparator|1|Rituximab Group: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15) and followed up monthly for 1 year. Biopsy was done Baseline and Month 3 and other labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing). Physical exam and vital signs were done.
9761027|NCT00695097|Active Comparator|2|No Rituximab: received standard immunosuppression and was followed up monthly for 1 year. Labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing) vital signs, and physical exam was done.
9761028|NCT00695110|Experimental|All study participants|"Treatment Period 1: Three capsules each containing 100 mg testosterone (T) as testosterone undecanoate (TU), twice daily (BID) for 7 days.~Treatment Period 2: Two capsules each containing 200 mg T as TU and testosterone enanthate (TE), BID for 7 days.~Treatment Period 3: Two capsules each containing 100 mg T as TU, BID for 8 days.~Treatment Period 4: Two capsules each containing 150 mg T as TU and TE, BID for 7 days."
9761029|NCT00695136|Experimental|Open label single arm|Single group study of Donepezil
9761030|NCT00695188|Other|Standard dose|Escalating dose
9761031|NCT00695188|Active Comparator|High dose|25 mg
9761032|NCT00695253|Other|Talent Endoluminal Spring Graft System|Single Arm study of the endoluminal treatment of Abdominal Aortic Aneurysms using the Talent Endoluminal Spring Graft System
9785541|NCT01254045|Experimental|oxytocin 48IU, placebo, oxytocin 24IU|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
9761033|NCT00695292|Experimental|Intervention|"Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study."
9761034|NCT00695318|Experimental|A, 2, I 0.2 µg/Day + Sham|0.2 µg/Day
9761035|NCT00695318|Experimental|A, 2, II 0.5 µg/Day + Sham|0.5 µg/Day
9761036|NCT00695396|Experimental|001|Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
9761037|NCT00695396|Experimental|002|Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
9761038|NCT00695396|Placebo Comparator|003|Placebo Matching volume 1 mL for 48 weeks
9761039|NCT00695396|Placebo Comparator|004|Placebo Matching volume 2 mLfor 48 weeks
9761040|NCT00695409|Experimental|Treatment (RIT, ZBEAM, ASCT)|RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8*. NOTE: * Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.
9761041|NCT00695435|Experimental|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
9761042|NCT00695435|Active Comparator|TOBREX® Ophthalmic Solution|TOBREX® Ophthalmic Solution
9761043|NCT00695435|Active Comparator|TOBRADEX® Ophthalmic Suspension|TOBRADEX® Ophthalmic Suspension
9761044|NCT00695500|Experimental|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
9761045|NCT00695500|Placebo Comparator|Placebo|Placebo tablets, 0 mg per day for 3 weeks
9761046|NCT00695565|Placebo Comparator|Placebo Gel|Placebo Gel is vehicle without clonidine
9761047|NCT00695565|Active Comparator|Clonidine Topical Gel (ARC-4558)|Clonidine Topical Gel contains 0.1% clonidine hydrochloride
9761048|NCT00695578|Experimental|Biafin on left arm|Subjects were randomized to apply Biafine® to wounds on the left forearm and polysporin (standard of care) to wounds on the right forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
9761049|NCT00695578|Experimental|Biafin on right arm|Subjects were randomized to apply Biafine to wounds on the right forearm and Polysporin to wounds on the left forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
9761050|NCT00695669|Experimental|Influenza A (H5N1) 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
9761051|NCT00695669|Experimental|Influenza A (H5N1) 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 14. The vaccine was administered intramuscularly in the deltoid region of the arm.
9761052|NCT00695669|Experimental|Influenza A (H5N1) 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 7. The vaccine was administered intramuscularly in the deltoid region of the arm.
9761053|NCT00695669|Experimental|Influenza A (H5N1) 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0. The vaccine was administered intramuscularly in the deltoid region of the arm.
9761054|NCT00695786|Experimental|Schedule A (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 1-21 and rituximab IV over 4-8 hours on day 1 of courses 1-12. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
9761055|NCT00695786|Experimental|Schedule B (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 2-22 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9783564|NCT01204658|Experimental|10PP-HD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with high doses (HD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD), co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
9785542|NCT01254045|Experimental|placebo, oxytocin 48IU, oxytocin 24IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
9785543|NCT01254188|Experimental|Nilotinib|300 mg BID
9832450|NCT02613507|Experimental|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
9832451|NCT02613507|Active Comparator|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
9832452|NCT02613572|Experimental|alpha lipoic acid (ALA) 600mg once daily x 5 days|All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.
10202837|NCT03976323|Active Comparator|Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed|"For the Induction Phase, participants receive 4 cycles:~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy. For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21 day-cycle for up to 31 cycles PLUS maintenance pemetrexed IV 500 mg/m^2 on Day 1 of each 21-day cycle. In the Maintenance Phase, the participant continues to receive maintenance pemetrexed until progressive disease, physician decision or intolerable toxicity."
10202838|NCT03975387|Experimental|ASTX295|
10202839|NCT03971994|Active Comparator|Young adults|Participants aged between 18 and 40 years old.
10202840|NCT03971994|Active Comparator|Healthy old adults|Participants aged between 65 and 95 years old.
10202841|NCT03971994|Experimental|Patients with Alzheimer's Disease|Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.
10202842|NCT03965390|No Intervention|Classical care pathway|"Patients are following classical care pathway. Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the control group, patients will be evaluated at 6 and 12months after surgery, during classical follow up visits."
10202843|NCT03965390|Experimental|Oral education|"Patients are following classical care pathway but combined at each visit with an oral education Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the experimental group, patients will be evaluated at 6 and 12 months after surgery, during classical follow up visits. At each timepoint an oral education will be realized in parallel."
10202844|NCT03965130|Experimental|Glucagon|Participants will receive glucagon or saline during the PINTA study
10202845|NCT03964246|Experimental|Compassion Meditation (CM) intervention group|"Thee CBCT-Vet includes 10 90-minute sessions that will be led by certified CBCT therapist with significant experience in administering CBCT-Vet. Sessions 1 - 4 assist participants in basic mindfulness breathing practices; sessions 4 - 8 focus on personal analysis of factors underlying difficulties with compassion for self or others; the final two sessions (9 and 10) review content and assist with relapse prevention. Session by session topics are: (1) Introduction and learning breathing meditation, (2) Focused attention, (3) Creating space, (4) Mindful awareness, (5) Re-engaging with heroic spirit, (6) Seeing ourselves in others, (7) Appreciation and gratitude, (8) Empathy and engaged compassion, (9) Putting it all together, and (10) Putting it all together 2."
10202846|NCT03964246|Active Comparator|Psychoeducational healthy aging group|The investigators will develop and test a 10-week psychoeducational group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent VA Merit-supported randomized controlled trial. This will include multiple resources for community education regarding healthy aging, including a library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity. These resources will be incorporated into 90-minute sessions wherein the key information from talks is shown to participants, with a follow-up discussion and review period led by the group facilitator. In the context of the present feasibility study, the investigators anticipate modifying and refining the content and format of the group in response to participant feedback.
10202847|NCT03958383|Experimental|Experimental Groups|"PHASE IA: As described above. Participants receive hu14.18-IL2 fusion protein intratumorally (IT).~PHASE IB: As described above. Participants undergo palliative RT and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE IC: As described above. Participants undergo palliative RT, receive nivolumab, and hu14.18-IL2 fusion protein IT as in phase IA.~PHASE ID: As described above. Participants undergo palliative RT, receive nivolumab in combination with ipilimumab, and hu14.18-IL2 fusion protein IT as in phase IA."
10202848|NCT03956030|Experimental|Intervention|Intervention group will receive educational handout on contraception.
10202849|NCT03956030|Experimental|Control|Control group will receive educational handout on nutrition.
10202850|NCT03953079|Experimental|GB-102 1 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 1 mg in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
10202851|NCT03953079|Experimental|GB-102 2 mg/1 mg|Participants will receive intravitreal (IVT) GB-102 2 mg in the study eye at Baseline, intravitreal (IVT) GB-102 1 mg at Month 6 and sham at Months 2, 4, 8 and 10.
10202852|NCT03953079|Active Comparator|Aflibercept 2 mg|Participants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.
10202853|NCT03952377|Placebo Comparator|0.9% Sodium Chloride for Injection|
10202854|NCT03952377|Experimental|12.5 mg SX600|Low Dose
10202855|NCT03952377|Experimental|25.0 mg SX600|High Dose
10202856|NCT03944876|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
10202857|NCT03944876|Placebo Comparator|Controls|placebo injections
10202858|NCT03944577|Experimental|Treatment Arm|Patients who will receive the study drug.
10202859|NCT03938116|Experimental|Healing Hearts Together|
10202860|NCT03938116|No Intervention|Usual Care|
10202861|NCT03934268||infants with seizure with KCNQ2 gene mutation.|Infants who met the inclusion criteria were enrolled in this study. The infants will get their own DNA sequencing results by WES technology. The researchers found that some of them carried mutations in the KCNQ2 gene. so they wanted to compare whether there were differences with or without KCNQ2 gene mutations in the efficacy of anticonvulsants or long-term neurodevelopment in different exposure groups.
10202862|NCT03931291|Experimental|Experimental arm: APR-246 + azacitidine|APR-246 and azacitidine maintenance therapy will continue for a maximum of 12 cycles
10202863|NCT03924219||Pediatric Solid Organ Transplant (SOT) Recipients|Pediatric patients (<18 years of age) undergoing or anticipated to undergo solid organ transplantation (heart, kidney, or liver) will be prospectively enrolled with serial blood collection for CMV T cell Immunity Assay performance.
10202864|NCT03922971|Other|National comparison|Ability to view center's rate compared with all others
9761056|NCT00695864|Placebo Comparator|Placebo - sugar pill|Placebo - sugar pill
9761057|NCT00695864|Experimental|Ondansetron|Ondansetron
9761058|NCT00695903|Experimental|daptomycin 10 mg/kg|Daptomycin 10 mg/kg IV every 24 hours
9761059|NCT00695903|Experimental|vancomycin high-dose|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
10202865|NCT03922971|Other|National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1
10202866|NCT03922750|Experimental|Insulin 287 (with 100% loading dose)|Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
10202867|NCT03922750|Experimental|Insulin 287 (without loading dose)|Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
10202868|NCT03922750|Active Comparator|Insulin glargine U100|Participants will receive insulin glargine U100 once daily (OD).
10202869|NCT03917745|Experimental|eHealth mindfulness intervention group|8 weeks of internet mindfulness training
10202870|NCT03917745|No Intervention|Control group|Care as usual
10202871|NCT03910673|Experimental|2-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 2 hours after start of third infusion dose. n = 6
10202872|NCT03910673|Experimental|30-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 30 minutes after start of third infusion dose. n = 6
10202873|NCT03910673|Experimental|5-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 5 hours after start of third infusion dose. n = 6
10202874|NCT03910673|Experimental|75-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 75 minutes after start of third infusion dose. n = 6
10202875|NCT03910673|Experimental|8-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 8 hours after start of third infusion dose. n = 6
10202876|NCT03909282|Active Comparator|Surgical Excision|Surgical excision of ductal carcinoma
10202877|NCT03909282|Experimental|Neoadjuvant partial breast irradiation|Partial breast irradiation will be delivered once a day for 5 days before surgery. The planned daily dose is 6 Gy.
10202878|NCT03906695|Experimental|10-Day Schedule|"10-Day Schedule~Investigational Medicinal Products (IMP) will be administered for 10 days in total per 4 weeks, i.e. a 28-day cycle."
10202879|NCT03906695|Experimental|5-Day Schedule A|"5-Day Schedule A~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
10202880|NCT03906695|Experimental|5-Day Schedule B|"5-Day Schedule B~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
10202881|NCT03906695|Experimental|5-Day Schedule C|"5-Day Schedule C~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
10202882|NCT03906695|Experimental|7-Day Schedule|"7-Day Schedule~IMP will be administered for 7 days in total per 4 weeks, i.e. a 28-day cycle."
10202883|NCT03905226||Heart Failure|Patients whom initiated a hospital pathway for heart failure management within the Paris Saint Joseph Hospital Group (GHPSJ) between January 1, 2015 and December 31, 2018.
10202884|NCT03900845|Experimental|Environmental Chamber|All participants will wear all three study prostheses in an environmental chamber set at 35 degrees Celsius and 50% relative humidity.
10202885|NCT03900845|Experimental|Field Measurements|All participants will wear all three study prostheses in their home, work, and community environments for two weeks.
10202886|NCT03896828|Experimental|Sedentary|Sedentary (SED): Participants will remain seated in the lab all-day (7.5 hr).
10202887|NCT03896828|Experimental|Walking Breaks|Walking breaks (WALK): Participants will perform 2-minute walking breaks at 3.1 mph on a treadmill every 30 minutes (7.5 hr).
10202888|NCT03896828|Experimental|Resistance-exercise breaks|"Resistance exercise breaks (RE): Participants will perform 15 squats (1-minute) every 30 minutes. To reduce the risk of injury, standardize squat-depth, and recruit similar muscle groups as walking, the squats performed will be a chair-stand with calf-raise (7.5 hr)."
10202889|NCT03894956||Participants with Hidradenitis Suppurativa (HS)|Participants who along with their treating physician have elected for treatment with Humira as per routine clinical practice for the treatment of HS
10202890|NCT03890913||Observation|All childcare centers enrolled to Aim 1 will be observed. The physical activity environment will be examined before and after the implementation of playground stencils.
10205251|NCT03423277|Experimental|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 8 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
10205252|NCT03422679|Experimental|CB-103|CB-103 capsules will be administered orally in treatment cycles of 28-days each.
10205253|NCT03373760|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10205254|NCT03367702|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy (IMRT) once daily 5 fractions per week for 28 fractions over less than 32 business days.
10205255|NCT03367702|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.
10205256|NCT03358979||Severe eye dryness|
10205257|NCT03358979||absence of eye dryness|
9761060|NCT00695955|Experimental|Azilsartan Medoxomil|
9761061|NCT00696020|Experimental|BI 1744 CL low dose/tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
9761062|NCT00696020|Experimental|BI1744CL medium dose/tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
9761063|NCT00696020|Experimental|BI 1744 CL high dose/tiotropium bromide|BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
9761064|NCT00696020|Experimental|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
9761065|NCT00696072|Active Comparator|A1|
9761066|NCT00696072|Active Comparator|A2|
9761067|NCT00696137|Experimental|BEMA Fentanyl|BEMA Fentanyl
9761068|NCT00696241|Experimental|Azilsartan Medoxomil 20 mg QD|
9761069|NCT00696241|Experimental|Azilsartan Medoxomil 40 mg QD|
9984186|NCT04320407|Experimental|Osia 2 System|Osia 2 Active Osseointegrated Implant System for Bone Conduction
9984187|NCT04318821|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), PC6 (Neiguan, B3), ST25 (Tianshu, B3), ST36 (Zusanli, B2), CV4 (Guanyuan), CV12 (Zhongwan, B3).
9761070|NCT00696241|Experimental|Azilsartan Medoxomil 80 mg QD|
9761071|NCT00696241|Active Comparator|Olmesartan 40 mg QD|
9761072|NCT00696241|Placebo Comparator|Placebo QD|
9761073|NCT00696293|Experimental|1|"Duloxetine + clinical management~NOTE -- THIS WORK WAS CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. THE CLINICALTRIALS.GOV DESCRIPTION OF THE STUDY WAS UPDATED 1/5/16 TO UPDATE THE OPEN LABEL NATURE OF THIS WORK. THIS IS WHAT IS REPORTED HERE AND HAS BEEN PEER REVIEWED AND PUBLISHED."
9761074|NCT00696384|Experimental|Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)|
9761075|NCT00696384|Experimental|Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)|
9761076|NCT00696384|Placebo Comparator|Placebo QD - Double-Blind Phase (Week 26- 32)|
9761077|NCT00696410|Experimental|CHF patients Given Zinc Acetate|Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
9761078|NCT00696410|No Intervention|Healthy controls|Health controls; no zinc acetate administered.
9761079|NCT00696423|Experimental|Infanrix/Hib Single Injection Group|Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
9761080|NCT00696423|Active Comparator|Infanrix + Hiberix Separate Injection Group|Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
9761081|NCT00696436|Experimental|Azilsartan Medoxomil 40 mg QD|
9761082|NCT00696436|Experimental|Azilsartan Medoxomil 80 mg QD|
9761083|NCT00696436|Active Comparator|Valsartan 320 mg QD|
9761084|NCT00696436|Active Comparator|Olmesartan 40 mg QD|
9761085|NCT00696436|Placebo Comparator|Placebo QD|
9761086|NCT00696449|Experimental|Frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
9761087|NCT00696449|Experimental|Electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
9761088|NCT00696449|Experimental|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
9761089|NCT00696449|Experimental|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
9984188|NCT04318821|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
9984189|NCT04318808|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), LI11 (Quchi, B2), PC6 (Neiguan, B3), ST36 (Zusanli, B2), ST37 (Shangjuxu, B2), ST39 (Xiajuxu, B2), SP4 (Gongsun, B3) , SP9 (Yinlingquan, B2).
9761090|NCT00696488|Experimental|Fluorouracil 0.5%|each subject will receive the study medication: Carac® 0.5% Fluorouracil, a standard treatment for actinic keratoses. Carac® will be dispensed to the subjects in the original tube with MEMS electronic monitoring caps attached. Subjects will be asked to apply the medication daily to AK lesions
9761091|NCT00696618|Experimental|A|Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home(Stage 2), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
9761092|NCT00696618|Experimental|B|Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
9761093|NCT00696618|Experimental|C|Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Normosol-R enema(iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
9761094|NCT00696657|Experimental|A|
9761095|NCT00696657|Experimental|B|
9761096|NCT00696657|Experimental|C|
9761097|NCT00696657|Experimental|D|
9761098|NCT00696657|Experimental|E|
9761099|NCT00696657|Experimental|F|
9761100|NCT00696657|Placebo Comparator|G1|
9761101|NCT00696657|Placebo Comparator|G2|
9761102|NCT00696657|Placebo Comparator|G3|
9761103|NCT00696657|Placebo Comparator|G4|
9761104|NCT00696657|Placebo Comparator|G5|
9761105|NCT00696657|Placebo Comparator|G6|
9761106|NCT00696657|Experimental|H|
9761107|NCT00696657|Experimental|I|
9761108|NCT00696696|Experimental|Combination GES|Combination of Gemcitabine, Erlotinib, and Sorafenib
9761109|NCT00696709|Experimental|Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine|Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered ~30 days apart.
9761110|NCT00696709|Experimental|Part 1: Gamma- Irradiated VZV Vaccine A|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered ~30 days apart.
9761111|NCT00696709|Placebo Comparator|Part 1: Placebo|Participants received a 4-dose placebo regimen administered ~30 days apart.
9761112|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine B|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered ~30 days apart.
9761113|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine C|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered ~30 days apart.
9761114|NCT00696761|Active Comparator|group1|Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
9761115|NCT00696761|Active Comparator|group2|BOOI≥ 20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
9761116|NCT00696761|Active Comparator|group 3|BOOI<20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
9761117|NCT00696761|Active Comparator|group 4|BOOI<20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
9761118|NCT00696774|Experimental|Duloxetine|Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.
9761119|NCT00696787|Placebo Comparator|Placebo|In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.
9761120|NCT00696787|Experimental|DVS SR|In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
9761121|NCT00696787|Active Comparator|Pregabalin|In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.
9761122|NCT00697073|Experimental|1|high dose Idebenone
9761123|NCT00697112||A|
9761124|NCT00697190|Active Comparator|senofilcon A/galyfilcon A|senofilcon A silicone hydrogel toric contact lenses will be worn first. galyfilcon A silicone hydrogel toric contact lenses will be worn second.
9761125|NCT00697190|Active Comparator|galyfilcon A/senofilcon A|galyfilcon A silicone hydrogel toric contact lenses worn first. senofilcon A silicone hydrogel toric contact lenses worn second.
9761126|NCT00697203|Experimental|Dalcetrapib 300mg|
9761127|NCT00697203|Experimental|Dalcetrapib 600mg|
9761128|NCT00697203|Experimental|Dalcetrapib 900mg|
9761129|NCT00697203|Placebo Comparator|Placebo|
9761130|NCT00697346|Experimental|Part 1: PIC Dose Escalation|Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
9761131|NCT00697346|Experimental|Part 1: ECT Dose Escalation|Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
9761132|NCT00697346|Experimental|Part 2: PTCL|Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
9761133|NCT00697463|Experimental|Women with Idiopathic osteoporosis (IOP)|Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months
9761134|NCT00697515|Active Comparator|Lisdexamfetamine Dimesylate (LDX, SPD489)|
9761135|NCT00697515|Placebo Comparator|Placebo|
9761136|NCT00697541|Experimental|A|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours
9761137|NCT00697541|Active Comparator|B|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
9761138|NCT00697593|Experimental|Efalizumab|
9761139|NCT00697619|Experimental|Test Group|Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
9761140|NCT00697619|No Intervention|Contorl Group|Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.
9761141|NCT00697697|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
9761142|NCT00697697|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
9761143|NCT00697788|Experimental|Ascending dose study|Ascending doses of dexmedetomidine (as per protocol)
9761144|NCT00697801|Experimental|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
9761145|NCT00697801|Experimental|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
9761146|NCT00697801|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
9761147|NCT00697827|Experimental|1|In-Space
9761148|NCT00697827|Active Comparator|2|X STOP
9761149|NCT00698035|Active Comparator|Testosterone Cream|Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
9761150|NCT00698035|Active Comparator|Estring|Estring 2mg ring inserted vaginally once every 12 weeks
9761151|NCT00698139|Active Comparator|Intervention first, then control|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, they will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. The rest of the protocol will be as described for the first encounter."
9761152|NCT00698139|Active Comparator|Control first, then intervention|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, the control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The rest of the protocol will be as described for the first encounter."
9832453|NCT02613572|Experimental|alpha lipoic acid 800mg|once daily with meal x 5 days
10202891|NCT03887988||Orbital Fracture|Patients with dislocated fracture of the inferior and/or medial orbital wall
10202892|NCT03887910|Experimental|Enhanced Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and referrals and developmental toys.
10202893|NCT03887910|Experimental|Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and developmental screening and parent guides only.
10202894|NCT03887910|No Intervention|Control|Usual care with developmental toys.
10202895|NCT03885999|Experimental|Fecobionics studies|
10202896|NCT03885518|Active Comparator|Intervention|Participants attending the childcare centers randomized to this arm will receive the stencil activities after baseline assessments have been completed. We will follow-up with assessments after 6-8 weeks
10202897|NCT03885518|Placebo Comparator|Wait-List|Participants attending the childcare centers randomized to this arm will receive the stencil activities approximately 8 weeks after enrolling, after baseline and follow-up assessments have been completed.
10202898|NCT03882970|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
10202899|NCT03882970|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
10202900|NCT03882970|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
10202901|NCT03882970|Active Comparator|Insulin Degludec|Insulin degludec administered SC once a day.
10202902|NCT03880955||ReUnion RSA System|"Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following:~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis~Failed previous shoulder joint replacement"
10202903|NCT03879525|Experimental|EMR Group|Participants assigned to this arm will complete the questionnaires in the EMR using the EMR-based-interventional method.
10202904|NCT03879525|Active Comparator|Phone Group|Participants assigned to this arm will complete the questionnaires via the Phone using the Telephone-based-standard method.
10202905|NCT03867734|Experimental|2g Aztreonam|Subjects to receive 2g Aztreonam IM for the treatment of gonorrhea
10202906|NCT03861689|Active Comparator|Tight control arm|Patients in the tight control arm will have additional FiLAC treatment within 24 months if the anatomy of the fistula is favourable. MRI pelvis will be performed at baseline and every 6 months. Biologic dosage will be adjusted according to MRI pelvis findings.
9761153|NCT00698139|Active Comparator|Intervention Only|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour."
9761154|NCT00698204|Experimental|I- Celecoxib|
9761155|NCT00698204|Placebo Comparator|II|
9761156|NCT00698451|Experimental|001|doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
9761157|NCT00698516|Experimental|Open label, Single arm|Oral topotecan + IV Bevacizumab
9761158|NCT00698581|Experimental|Brivaracetam 50 mg|50 mg/day
9761159|NCT00698581|Experimental|Brivaracetam 100 mg|100 mg/day
9761160|NCT00698646|Active Comparator|Valsartan|(patients initiated on valsartan)
9761161|NCT00698646|Active Comparator|HCTZ|(patients initiated on HCTZ)
9761162|NCT00698646|Experimental|Valsartan + HCTZ|(patients initiated on Valsartan+HCTZ)
9761163|NCT00698685|Experimental|Preparative Regimen|"Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)~Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)~Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper."
9761164|NCT00698841|Experimental|Cetuximab|
9761165|NCT00698867||Discovery™ Elbow|Discovery™ Elbow minimally constrained
9761166|NCT00698932|Experimental|Saxagliptin 5mg|
9761167|NCT00698932|Placebo Comparator|Placebo|
9761168|NCT00698997|Experimental|1 Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
9761169|NCT00698997|Other|2 Standard Care available in the Community|Any intervention that were available and that families accessed in their communities
9761170|NCT00699010|Active Comparator|Acurox 5/30mg taken first|oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
9761171|NCT00699010|Active Comparator|Oxycodone 5mg taken first|oxycodone HCl 5mg tablets; 8 tablets per dose
9761172|NCT00699140|Experimental|1 treatment group with IGIV3I Grifols|"Open label, non-randomized treatment group with IGIV3I Grifols~Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses."
9761173|NCT00699153|Experimental|Loteprednol Etabonate|Loteprednol Etabonate 0.5%
9761174|NCT00699153|Placebo Comparator|Vehicle|Vehicle of Ophthalmic Loteprednol Etabonate
9761175|NCT00699192|Experimental|Amlodipine/Valsartan 5/80 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
9761176|NCT00699192|Active Comparator|Amlodipine/Valsartan 5/40 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
9761177|NCT00699192|Active Comparator|Amlodipine 5 mg|1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
9761178|NCT00699218|Experimental|rTMS treatment|Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
9761179|NCT00699283|Experimental|Brivaracetam (BRV) 1|50 mg daily
9761180|NCT00699283|Experimental|Brivaracetam (BRV) 2|100 mg daily
9761181|NCT00699348|Experimental|C.E.R.A.|
9761182|NCT00699374|Experimental|Arm A|sunitinib arm
9761183|NCT00699374|Active Comparator|Arm B|sorafenib arm
9761184|NCT00699491|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 (cixutumumab is given on days 8, 15, and 22 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9761185|NCT00699556|Experimental|patch+spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + nicotine nasal spray.
9832454|NCT02613572|Experimental|alpha lipoic acid 1200mg|once daily x 5 days
9761186|NCT00699556|Placebo Comparator|patch+placebo spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + placebo nicotine nasal spray.
9761187|NCT00699582|Experimental|1|
9761188|NCT00699582|Experimental|2|
9761189|NCT00699582|Placebo Comparator|3|
9761190|NCT00699608|Experimental|Crossover|All subjects received all three treatments in a randomised order
9761191|NCT00699660|Experimental|CAPS/WHODAS|PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
9761192|NCT00699660|Active Comparator|Nonstructured Interview|Usual clinical interview to assess PTSD, without CAPS or WHODAS
9761193|NCT00699751|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
9761194|NCT00699751|Placebo Comparator|Placebo|Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
9761195|NCT00699803|Active Comparator|T-Pred|Tobramycin prednisolone acetate combination
9761196|NCT00699803|Active Comparator|Pred Forte|Prednisolone acetate
9761197|NCT00699816|Experimental|Immunotherapy Group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
9761198|NCT00699816|No Intervention|Control Group|Patients who had undergone curative treatment(surgical resection, radiofrequency ablation[RFA], or percutaneous ethanol injection[PEI]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
9761199|NCT00699907|Active Comparator|Treatment Arm|Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
9761200|NCT00699907|No Intervention|High Risk Arm|High risk patients underwent risk-reducing salpingo-oophorectomy.
9761201|NCT00699907|No Intervention|Low Risk Arm|Low risk patients underwent salpingo-oophorectomy for a medical indication.
9761202|NCT00699972|Experimental|1|
9761203|NCT00699972|Experimental|2|
9761204|NCT00699972|Placebo Comparator|3|
9761205|NCT00699998|Experimental|Prasugrel|Prasugrel and Low-dose Commercially-available Aspirin
9761206|NCT00699998|Active Comparator|Clopidogrel|Clopidogrel and Low-Dose Commercially-available Aspirin
9761207|NCT00700011|Active Comparator|10 mg/m2 group|Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
9761208|NCT00700011|Active Comparator|5 mg/m2 group|Patients were treated with Clofarabine 5 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
9761209|NCT00700063|Experimental|1|
9761210|NCT00700063|Experimental|2|
9761211|NCT00700063|Experimental|3|
9761212|NCT00700063|Placebo Comparator|4|
9761213|NCT00700063|Experimental|5|
9761214|NCT00700063|Experimental|6|
9761215|NCT00700063|Experimental|7|
9761216|NCT00700063|Placebo Comparator|8|
9761217|NCT00700102|Active Comparator|Chemotherapy|Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
9761218|NCT00700102|Experimental|Chemotherapy + Bevacizumab|Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
9761219|NCT00700115|Experimental|Kaletra + Isentress|Kaletra + Isentress
9761220|NCT00700115|Active Comparator|Standard HAART|Pre-study Antiretroviral regimen
9761221|NCT00700180|Experimental|1|
9761222|NCT00700180|Experimental|2|
9761223|NCT00700271|Experimental|Morning Intake|After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
9761224|NCT00700271|Experimental|Evening Intake|After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
9761225|NCT00700310|Active Comparator|1|
9761226|NCT00700310|Active Comparator|2|
9761227|NCT00700310|Active Comparator|3|
9761228|NCT00700310|Placebo Comparator|4|
9761229|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501: Phase 2|pemetrexed, cisplatin and CBP501
9761230|NCT00700336|Active Comparator|Pemetrexed and Cisplatin: Phase 2|pemetrexed and cisplatin
9761231|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501:Phase 1|MTD, which was equal to recommended dose for the Phase II part, was determined by 6 patients (3+3)
9761232|NCT00700375|Experimental|Sodium bicarbonate|
9761233|NCT00700375|Experimental|Sodium chloride|
9761234|NCT00700401||Peginterferon Alfa-2a + Ribavirin|
9761235|NCT00700427|Experimental|Atomoxetine|Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
9761236|NCT00700427|Placebo Comparator|Placebo|Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.
9761237|NCT00700440|Experimental|Cetuximab|400mg/m^2 intravenous infusion one week before radiotherapy, then 250mg/m^2 intravenous infusion weekly during radiotherapy
9761238|NCT00700570|Experimental|1|
9761239|NCT00700622|Experimental|TI + Insulin glargine|Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)
9761240|NCT00700622|Experimental|Insulin lispro + Insulin glargine|Humalog (insulin lispro) in combination with Lantus (insulin glargine)
9761241|NCT00700635|Experimental|Menactra® Group 1|Participants aged 2 to < 4 years
9761242|NCT00700635|Experimental|Menactra® Group 2|Participants aged 4 to < 6 years
9761243|NCT00700635|Active Comparator|Menactra® Group 3|Participants aged 6 to < 11 years
9761244|NCT00700713|Experimental|One-Dose Menactra Group|Participants received one dose of Menactra® in Study MTA26
9761245|NCT00700713|Experimental|Two-Dose Menactra Group|Participants received two doses of Menactra® in Study MTA26
9761246|NCT00700713|Active Comparator|Menactra vaccine-naïve Group|Participants had never received Menactra® vaccine.
9761247|NCT00700739|Other|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
9761248|NCT00700739|Active Comparator|Cervical Total Disc Replacement|DISCOVER™ Artificial Cervical Disc
9761249|NCT00700752|Active Comparator|senofilcon A/balafilcon A|senofilcon A silicone hydrogel contact lens worn during first 4-week period, balafilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
9984190|NCT04318808|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
9761250|NCT00700752|Active Comparator|balafilcon A/senofilcon A|balafilcon A silicone hydrogel contact lens worn worn during first 4-week period, senofilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
9761251|NCT00700804|Experimental|High Calcium Diet|
9761252|NCT00700804|Experimental|Low Calcium Diet|
9761253|NCT00700817|Experimental|Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg|Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
9761254|NCT00700817|Experimental|Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg|Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
9761255|NCT00700817|Active Comparator|Sita -> Sita|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).
9761256|NCT00700817|Experimental|Sita -> Sita -> Lira 1.2 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.
9761257|NCT00700817|Experimental|Sita -> Sita -> Lira 1.8 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.
9761258|NCT00700882|Experimental|Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9761259|NCT00700973|Active Comparator|Arm 1|Substance use disorder usual care
9761260|NCT00700973|Experimental|Arm 2|Interpersonal violence prevention intervention
9761261|NCT00700999|Other|Arm 1|Intervention-Paroxetine
9761262|NCT00700999|No Intervention|Arm 2|No Intervention
9761263|NCT00701038|Experimental|Device|Provided with an auto adjusting bi-level positive airway pressure device
9984191|NCT04317534|Experimental|Arm A- Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks x 9 cycles
9984192|NCT04317534|No Intervention|Arm B - Observation|Observation only
10202907|NCT03861689|No Intervention|Control arm|Patients in the control arm will have management according to physician own decision.
10202908|NCT03858517||ReUnion TSA System|"Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System:~Aseptic necrosis of the humeral head~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis~Failed previous total shoulder replacement, resurfacing or other procedure"
9761264|NCT00701038|No Intervention|Control|No device
9761265|NCT00701051|Active Comparator|Arm 1|Older adults, normal glucose tolerance
9761266|NCT00701051|Experimental|Arm 2|Older adults, impaired glucose tolerance
9761267|NCT00701064|Experimental|Bright Light Exposure|Bright Light (30 min/day)
9761268|NCT00701064|Placebo Comparator|Negative Ion Generator|Negative Ion Generator (30 min/day)
9761269|NCT00701090|Experimental|1|sitagliptin
9761270|NCT00701090|Active Comparator|2|glimepiride
9761271|NCT00701103|Experimental|Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
9761272|NCT00701103|Experimental|Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
9761273|NCT00701103|Experimental|Dalotuzumab 5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
9761274|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
9761275|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
10202909|NCT03857256|Experimental|Active Treatment|CP105F (Oat beta-glucan), 0.5g TID (3, 6 or 12 tablets per day for a dose of either 1.5g, 3g or 6gr) for 12 weeks.
10202910|NCT03857256|Placebo Comparator|Placebo|matching placebo 3, 6 or 12 tablets per day for 12 weeks.
10202911|NCT03854903|Experimental|Dose Level A1|"Palbociclib: 75mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
9761276|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
9761277|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
9761278|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
9761279|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
9761280|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q2W (20 mg/mL)|Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
9761281|NCT00701103|Experimental|Dalotuzumab 30 mg/kg Q3W (20 mg/mL)|Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).
9761282|NCT00701129|Experimental|Alglucosidase Alfa|Alglucosidase alfa (Myozyme®) 20 milligrams per kilogram (mg/kg) intravenous (IV) infusion every other week (qow) (or optionally 20 mg/kg IV infusion every week [qw]) beginning from Day 0 to a minimum of 18 months or if the patient was less than (<) 6 months of age at the time of enrollment, until the patient was 2 years of age, along with methotrexate 0.4 mg/kg subcutaneously for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab 375 milligrams per square meter (mg/m^2) (or 12.5 mg/kg for patients with body surface area less than or equal to 0.5 m^2) IV infusion qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.
9761283|NCT00701311|Experimental|Study Drug CC-10004|Study drug CC-10004 20mg taken orally twice a day.
9783565|NCT01204658|Active Comparator|Synflorix/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Synflorix™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Synflorix™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Synflorix™ and on the right side for Infanrix hexa™.
9783566|NCT01204658|Active Comparator|Prevnar 13/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Prevnar 13™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Prevnar 13™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Prevnar 13™ and on the right side for Infanrix hexa™.
9783567|NCT01204671|Experimental|GSK2321138A Lot 1 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
9783568|NCT01204671|Experimental|GSK2321138A Lot 2 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
9783569|NCT01204671|Experimental|GSK2321138A Lot 3 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
9783570|NCT01204671|Active Comparator|Fluarix Group|Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
9783571|NCT01204671|Active Comparator|GSK2604409A Group|Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
9783572|NCT01204697|Experimental|A|
9783573|NCT01204697|Experimental|B|
9783574|NCT01204710|Experimental|Olaratumab + Mitoxantrone|1 cycle = 3 weeks (21 days)
9783575|NCT01204710|Active Comparator|Mitoxantrone: Optional Olaratumab Monotherapy|"1 cycle = 3 weeks (21 days)~Participants who experience progressive disease (PD) have the option to receive olaratumab monotherapy treatment."
9783576|NCT01204736||Group 1|Subjects with posterior deltoid-to-triceps tendon transfers
9783577|NCT01204736||Group 2|Subjects with biceps-to-triceps tendon transfers
9783578|NCT01204736||Group 3|Subjects with cervical SCI who have not had tendon transfers
9783579|NCT01204736||Group 4|Unimpaired control subjects
9783580|NCT01204775|Experimental|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
9783581|NCT01204775|Placebo Comparator|Placebo|Placebo matching saxagliptin tablet
9783582|NCT01204853|Experimental|Sitaxentan treatment|
9783583|NCT01204905|Experimental|Open Label ART|Patients received raltegravir 400 mg PO BID and maraviroc 300 mg PO BID in combination for 48 weeks.
9783584|NCT01204918|Experimental|Riluzole addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 8 weeks
9783585|NCT01204918|Placebo Comparator|Placebo addition to standard SSRI antidepressant|Placebo will be added to ongoing SSRI or SNRI antidepressant treatment for 8 weeks
9783586|NCT01204918|Experimental|Riluzole/Placebo addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 4 weeks and placebo will added to ongoing SSRI or SNRI antidepressant treatment for 4 weeks
9761284|NCT00701363|Experimental|Lanreotide Autogel 120 mg|
9761285|NCT00701376|Other|liver function|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
9761286|NCT00701389|Experimental|Sequence 1: A→C→D→B|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A); Period 2: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 3: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D); Period 4: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B). Each dosing period is separated by a 5-day washout.
9761287|NCT00701389|Experimental|Sequence 2: B→D→C→A|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 2: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D): Period 3: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 4:single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A). Each dosing period is separated by a 5-day washout.
9761288|NCT00701389|Experimental|Sequence 3: C→B→A→D|Participants receive the following: Period 1 :single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C), Period 2: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 3: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A): Period 4: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D). Each dosing period is separated by a 5-day washout.
9761289|NCT00701389|Experimental|Sequence 4: D→A→B→C|Participants receive the following: Period 1: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D), Period 2: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treament A); Period 3: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 4: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C). Each dosing period is separated by a 5-day washout.
9761290|NCT00701415|Experimental|Fabrazyme 0.5 mg/kg|Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
9761291|NCT00701415|Experimental|Fabrazyme 1.0 mg/kg|Fabrazyme 1.0 mg/kg was administered every 4 weeks (up to 66 infusion) up to 260 weeks, the total infusion time was not less than 90 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
9761292|NCT00701441||Control group: healthy individuals without OSA|healthy individuals without OSA who are matched in weight and age to the participating OSA patients
9761293|NCT00701441||OSA group|Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.
9761294|NCT00701558|Experimental|Erlotinib + Gemcitabine|Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.
9761295|NCT00701636|Experimental|Cases|The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
9761296|NCT00701636|No Intervention|Controls|15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.
9761297|NCT00701662|Experimental|Vivaglobin|Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).
9761298|NCT00701675|Experimental|Sertraline 50mg|sertraline 50 mg daily
9761299|NCT00701675|Experimental|Sertraline 100mg|sertraline 100mg daily
9761300|NCT00701675|Placebo Comparator|Placebo|placebo 50 or 100mg
9761301|NCT00701701|Experimental|Regimen A: Alglucosidase alfa and Cyclophosphamide|Participants exhibiting clinical decline since starting alglucosidase alfa (Myozyme®) therapy and having inhibitory antibodies and/or a sustained high recombinant human acid alpha-glucosidase (rhGAA) antibody titer (defined as at least 2 titers greater than or equal to [>=] 25,600 obtained at least 1 month apart), regardless of their CRIM status, were assigned to Regimen A. In Regimen A, participants received alglucosidase alfa (Myozyme®) Intravenous (IV) infusion of 20 milligram per kilogram (mg/kg) every other week (qow) for a minimum of 18 months or, until the participant reached the age of 2 years (if the participant was less than [<6] months of age at the time of enrollment). In addition, cyclophosphamide 250 milligram per square meter (mg/m^2) IV infusion was administered every 4 weeks (q4w) after Myozyme® infusion for 6 months.
9761302|NCT00701701|Experimental|Regimen B: Alglucosidase alfa, Rituximab and Methotrexate|CRIM-negative participants were assigned to Regimen B if they either(1)exhibited clinical decline since starting alglucosidase alfa (Myozyme®)therapy and did not have inhibitory antibodies and/or a sustained rhGAA antibody titer(defined as at least 2 titers >=25,600 obtained at least 1 month apart),or(2) did not exhibit clinical decline since starting alglucosidase alfa(Myozyme®) therapy, regardless of their anti-rhGAA or inhibitory antibody status. Regimen B participants with CRIM-negative status received alglucosidase alfa(Myozyme®) IV infusion of 20 mg/kg qow for a minimum of 18 months or,until participant reached the age of 2 years (if participant was <6 months of age at time of enrollment). In addition,rituximab 375 mg/m^2 IV was administered weekly beginning the day after Myozyme® infusion for 4 weeks(an optional 2nd cycle could be administered at the discretion of the investigator) and biweekly methotrexate 15 mg/m^2 subcutaneous on the day after Myozyme® infusion for 6 months.
9761303|NCT00701714|Experimental|1|HX575, EPO HEXAL
9761304|NCT00701714|Active Comparator|2|ERYPO
9761305|NCT00701727|Experimental|1|ezetimibe (10mg/day)for 7 weeks
9761306|NCT00701727|Placebo Comparator|2|Placebo control
9761307|NCT00701779|Experimental|Dutasteride|"Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.~Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks."
9761308|NCT00701805|Experimental|Paricalcitol 2 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
9761309|NCT00701805|Experimental|Paricalcitol 2 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
9761310|NCT00701805|Experimental|Paricalcitol 4 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
9761311|NCT00701805|Experimental|Paricalcitol 4 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
9761312|NCT00701896|Other|Healthy Control - Non-smoking|Healthy Control arm with 51 subjects who are HIV negative and do not smoke
9761313|NCT00701896|Other|Healthy Control - Smoker|Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
9761314|NCT00701896|Active Comparator|HIV Smoking Cessation Arm|Includes up to 365 subjects who are HIV positive and initiate smoking cessation
9761315|NCT00701896|Experimental|Motivational Intervention|Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
9761316|NCT00701935|Placebo Comparator|1|
9761317|NCT00701935|Experimental|2|
9761318|NCT00702052|Experimental|Everolimus|Participants received everolimus tablets, 10 mg, orally, once daily during each 28 day cycle until determination of objective tumor progression or unacceptable toxicity, or death, or consent withdrawal, or discontinuation from the study for any other reason.
9761319|NCT00702143|Experimental|AD subjects|
9761320|NCT00702143|Experimental|MCI Subjects|MCI (mild cognitive impairment)
9761321|NCT00702143|Experimental|Healthy controls|
9761322|NCT00702208|Other|Single arm study|Paired laboratory results for clinician-collected and Screener collected specimens for cytology (and high-risk human papillomavirus testing for sub-sample)
9761323|NCT00702221|Experimental|ATV with CoVaccine HT™|Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
9761324|NCT00702221|Placebo Comparator|CoVaccine HT™ adjuvant alone|CoVaccine HT™ adjuvant alone
9761325|NCT00702299|Experimental|Receiving Treatment|Dose escalation of day 1 i.p. pemetrexed disodium accrued three patients to each of five dose levels (60-1,000 mg/m2), along with day 2 i.p. cisplatin (75 mg/m2) and day 8 i.p. paclitaxel (60 mg/m2) with a biologic sample preservation procedure
9761326|NCT00702325|Experimental|1|
9761327|NCT00702325|Active Comparator|2|
9761328|NCT00702364|Experimental|Atomoxetine|40mg atomoxetine twice a day for 2 weeks
9761329|NCT00702364|Placebo Comparator|placebo|Placebo twice a day for two weeks
9761330|NCT00702377|Experimental|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops
9761331|NCT00702377|Active Comparator|OPTIVE|OPTIVE Lubricant Eye Drops
9783587|NCT01205035|No Intervention|Observation|Observation; No treatment given
9783588|NCT01205035|Experimental|Intravitreal ranibizumab 2.0mg|Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
9761332|NCT00702403|Experimental|Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)|"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.~Treatment continues in the absence of disease progression or unacceptable toxicity."
9761333|NCT00702468|Experimental|Sativex|Sativex
9761334|NCT00702468|Placebo Comparator|Placebo|Placebo
9761335|NCT00702507|Active Comparator|Miconazole Nitrate|
9761336|NCT00702650|Experimental|Testosterone MD-Lotion|"Participants received Testosterone Metered Dose (MD)-Lotion for 120 days. Participants started by receiving 3.0 mL (60 mg) of 2% Testosterone MD-Lotion, and based upon restoration to eugonadal levels, may have had their dose of testosterone adjusted upwards or downwards on Days 45 and 90.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 1 dose to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).~6.0 mL (120 mg) of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
9761337|NCT00702689|Experimental|Imatinib mesylate in patients with cGVHD|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
9761338|NCT00702715|Experimental|Participants with severe renal impairment|Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance <30mL/min.
9761339|NCT00702715|Active Comparator|Participants with normal renal function|Participants with normal renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Normal renal function was defined as creatinine clearance >=80mL/min.
9761340|NCT00702780|Experimental|Escitalopram|Escitalopram 20mg tablet by mouth once a day
9761341|NCT00702780|Placebo Comparator|Placebo|Placebo 20mg tablet by mouth once a day
9761342|NCT00702884|Experimental|Sunitinib|Sunitinib 37.5 mg daily for a 4 week cycle
9761343|NCT00702923|Experimental|1|Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
9761344|NCT00702949|Experimental|Pregabalin75|Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
9761345|NCT00702949|Experimental|Pregabalin150|Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
9761346|NCT00702949|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 6 weeks.
9761347|NCT00703053|Experimental|Group 1|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.
9761348|NCT00703053|Experimental|Group 9|100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.
9761349|NCT00703053|Experimental|Group 8|100 subjects: Day 0, A/Vietnam/04 90 mcg.
9761350|NCT00703053|Experimental|Group 7|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.
9761351|NCT00703053|Experimental|Group 6|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.
9761352|NCT00703053|Experimental|Group 5|50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.
9761353|NCT00703053|Experimental|Group 4|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.
9761354|NCT00703053|Experimental|Group 3|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.
9761355|NCT00703053|Experimental|Group 2|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.
9761356|NCT00703118|Experimental|Group A: T12/PR48|Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
9761357|NCT00703118|Experimental|Group B: T12(DS)/PR48|Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
9761358|NCT00703118|Experimental|Group C: Pbo/PR48|Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.
9761359|NCT00703157|Active Comparator|1|Arm 1: Catheter Ablation
9761360|NCT00703157|Active Comparator|2|Arm 2: Surgical Ablation.
9761361|NCT00703261|Active Comparator|10 mg Atorvastatin|10 mg atorvastatin + placebo
9761362|NCT00703261|Active Comparator|80 mg Atorvastatin|80 mg atorvastatin + placebo
10202912|NCT03854903|Experimental|Dose Level A2|"Palbociclib: 75mg daily for the first 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle"
9761363|NCT00703391|Experimental|1|Active Treatment
9761364|NCT00703391|Placebo Comparator|2|Placebo Treatment
9761365|NCT00703508|Experimental|Metformin|Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
9761366|NCT00703664|Experimental|Treatment (vorinostat, bortezomib)|"Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.~Treatment arm consists of 3 cohorts, all receiving the same treatment:~A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib."
9832455|NCT02613572|Placebo Comparator|Placebo 600mg|All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the
9832456|NCT02613572|Experimental|ALA 600 mg|once daily with a meal for 2 weeks
9832457|NCT02613572|Placebo Comparator|Placebo 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
9832458|NCT02613572|Experimental|ALA 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
9832459|NCT02613871|Experimental|LDV/SOF|LDV/SOF FDC for 12 weeks
9832460|NCT02613884|Experimental|Treatment|All patients with a 25OHD level <30 ng/dL will be given 250,000 IU D3 (cholecalciferol) orally at one point in time and during CF clinic.
9832461|NCT02613897|Active Comparator|DAPA/SAXA (dapagliflozin plus saxagliptin)|Dapagliflozin 10mg + Saxagliptin 5mg (plus standard of care treatment of metformin or metformin plus sulfonylurea).
9832462|NCT02613897|Active Comparator|DAPA (Dapagliflozin plus placebo)|Dapagliflozin 10mg + Placebo (plus standard of care treatment of metformin or metformin plus sulfonylurea).
9832463|NCT02613897|Placebo Comparator|PCB (Placebo plus placebo)|Placebo (for dapagliflozin) + placebo (for saxagliptin) (plus standard of care treatment of metformin or metformin plus sulfonylurea).
9832464|NCT02613910|Experimental|Ofatumumab|t the Baseline (Bln) and wk 4 visits, Subjects will receive 40mg ofatumumab sc (Oft) (as two 20mg sc inj) and as 1 Oft 20mg sc inj every 4 wks from wk 8 through wk 56. Subjects will return to clinic 4 wks after the last dose for a follow-up (f/u) visit (wk 60). Antihistamine 10 mg and Acetaminophen/paracetamol (A/P) 1 grams(g) will be given 1-2 hours(h) before and 4 h after each dose of Oft. A/P 1 g will be supplied for self administration if needed. Prednisone/Prednisolone dose will continue to be tapered during core study period (CSP) by 1 dose level every 2 wks to <= 10 mg/day from Bln through wk 60. Upon completion of the CSP, subjects will enter Individualized f/u Period, where subjects will monitored every 12 wks for a minimum of 1 yr and for up to 2 yr, until CD19+ B-LC or IgG recover to lower limit of normal (LLN) or to the subject's Bln value from Study OPV116910 (if <LLN) or if study withdrawal criteria are met or for a maximum of 2 yr after the last dose of Oft.
9832465|NCT02614079|Experimental|DSSEP|DSSEP testing after SCS trial lead placement
9832466|NCT02614131|Experimental|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
9832467|NCT02614131|Placebo Comparator|Placebo (Part A)|Placebo matching LY2599666 given SC once.
9832468|NCT02614131|Experimental|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
9832469|NCT02614131|Placebo Comparator|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
9832470|NCT02614131|Experimental|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
9832471|NCT02614131|Placebo Comparator|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
9832472|NCT02614183|Experimental|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
9832473|NCT02614183|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
9832474|NCT02614183|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
9832475|NCT02614196|Experimental|Galcanezumab 120mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
9832476|NCT02614196|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
9832477|NCT02614196|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
9832478|NCT02614196|Experimental|Galcanezumab 120mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
9832479|NCT02614196|Experimental|Galcanezumab 240mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given by SC injection once a month for 6 months.
9832480|NCT02614196|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo given by SC injection once a month for 6 months.
9832481|NCT02614222|Experimental|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
9832482|NCT02614222|No Intervention|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
9832483|NCT02614261|Experimental|Galcanezumab 120 mg|"Galcanezumab 240 mg given as loading dose at first dosing visit followed by 120 mg once a month for 2 months by subcutaneous (SC) injection.~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
9832484|NCT02614261|Experimental|Galcanezumab 240 mg|"Galcanezumab 240 mg given by SC injection once a month for 3 months.~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
9832485|NCT02614261|Placebo Comparator|Placebo|"Placebo given by SC injection once a month for 3 months.~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
9832486|NCT02614274|Experimental|Nutraceutical joint health formulation|A Proprietary Blend
9832487|NCT02614287|Experimental|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
9832488|NCT02614287|Experimental|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
9832489|NCT02614469|Experimental|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
9832490|NCT02614469|Experimental|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
9832491|NCT02614560|Experimental|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
9832492|NCT02614560|Experimental|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
9832493|NCT02614703|Experimental|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
9832494|NCT02614703|Active Comparator|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
9832495|NCT02614729|Experimental|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
9832496|NCT02614729|Experimental|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
9832497|NCT02614794|Experimental|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib + capecitabine + trastuzumab
9832498|NCT02614794|Active Comparator|Placebo in combination with capecitabine & trastuzumab|Placebo + capecitabine + trastuzumab
9832499|NCT02614924|Other|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
9832500|NCT02614924|Other|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
9832501|NCT02615145||Genotype 1a (G1a) Participants|"Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
9832502|NCT02615145||Genotype 1b (G1b) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 [G4]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
9832503|NCT02615145||Genotype 4 (G4) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
9761367|NCT00703677|Other|1|All participants will receive lithium. The dosage will be titrated over a 5-week period. Participants will then be followed prospectively for 6 months. Participants will be evaluated at the screening visit, baseline visit, and weeks 2 and 5 during the titration phase. Clinic study visits will then occur on alternate months through week 28. Telephone visits will occur between clinic study visits.
9761368|NCT00703729|Experimental|Cold Compression (CC)|The Game Ready device provides both active, continuous cold and intermittent, pneumatic compression to the post-op shoulder. The first group will use the Game Ready™ Device (CC) for one week following surgery and will use standard ice bags wrapped to the shoulder (IW) for the remainder of the study period.
9761369|NCT00703729|Active Comparator|Ice Wrap (IW)|The ice bag (IW)is secured to the shoulder using an elastic wrap. The second group will use standard ice bags wrapped to the shoulder (IW) for one week following surgery and will use the Game Ready™ Device (CC) for the remainder of the study period
9761370|NCT00703781|Experimental|Bromfenac|Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
9761371|NCT00703781|Placebo Comparator|Placebo|Placebo, Dosed 1 Drop Daily
9761372|NCT00703820|Active Comparator|ADE|"Cytarabine + Daunorubicin + Etoposide~NK cells for infusion are prepared using the CliniMACS System."
9761373|NCT00703820|Active Comparator|Clo/AraC|"Clofarabine + Cytarabine~NK cells for infusion are prepared using the CliniMACS System."
9761374|NCT00703846|Other|KETOCONAZOLE|
9761375|NCT00703911||activated recombinant human factor VII|Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
9761376|NCT00703924|Experimental|WR 279,396|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
9761377|NCT00703924|Placebo Comparator|Placebo|Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.
9761378|NCT00703937|Experimental|Ferric Carboxymaltose (FCM)|750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg).
9761379|NCT00703937|Active Comparator|Standard Medical Care (SMC) for the treatment of IDA|SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
9761380|NCT00703963|Active Comparator|Usual Care|Subjects will be having their INR tested by their Primary Care Provider as often as their Care Provider dictates. This study phase is twelve weeks long beginning at the day of discharge from our hospital.
9761381|NCT00703963|Active Comparator|Patient Self Testing|Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
9761382|NCT00703976|Active Comparator|Cetuximab, Pemetrexed and Radiation therapy|"Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks"
9761383|NCT00703976|Experimental|Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab|"Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy."
9761384|NCT00704028|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
9832504|NCT02615158|Experimental|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
9832505|NCT02615158|Experimental|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
9832506|NCT02615158|Experimental|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
9832507|NCT02615171|Active Comparator|Comprehensive Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
9832508|NCT02615171|Active Comparator|Simple Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
9832509|NCT02615249|Experimental|Metal Allergen Epicutaneous Patch|8 allergens were tested. Not all subjects tested each allergen. Section reports number of subjects with positive responses to each allergen.
9832510|NCT02615470|Experimental|Enhanced immunization delivery model|Pharmacist-technician pairs employed by community pharmacies that are assigned to this arm will receive a) immunization update training, b) training by immunization experts to enhance immunization delivery model and foster practice change at the beginning of 6-month and c) regular feedback and clinical support for the period of 6 months.
9832511|NCT02615470|Active Comparator|Immunization update|Pharmacist-technician pairs employed by community pharmacies that are assigned to the control arm will receive an immunization update training. They will not receive a training by immunization experts nor regular feedback and clinical support.
9832512|NCT02615509|Other|Imaging on experimental tomo device|"Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.~After collecting the cases together with ground truth a readers study will be performed."
9832513|NCT02615535|Experimental|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
9832514|NCT02615535|Active Comparator|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
9832515|NCT02615717|Experimental|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
9832516|NCT02615717|Active Comparator|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
9832517|NCT02615743|Experimental|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
9832518|NCT02615743|Other|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
9832519|NCT02616029|Experimental|Part 1: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG)."
9832520|NCT02616029|Experimental|Part 2: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG."
9832521|NCT02616250|Experimental|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
9761385|NCT00704028|Active Comparator|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
9761386|NCT00704132|Experimental|sitagliptin|Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
9761387|NCT00704132|Placebo Comparator|Placebo|Participants randomized to this arm will be administered matching placebo, daily for six weeks.
9761388|NCT00704171|Experimental|PleuraSeal|PleuraSeal Lung Sealant System
9761389|NCT00704171|Active Comparator|Standard of Care|Standard tissue closure techniques (control) - sutures or staples only
9761390|NCT00704184|Placebo Comparator|Placebo + Peg-IFN/Ribavirin|Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
9761391|NCT00704184|Experimental|Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
9761392|NCT00704184|Experimental|Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
9761393|NCT00704184|Experimental|Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
9761394|NCT00704184|Experimental|Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
9761395|NCT00704262|Experimental|Calcipotriol plus hydrocortisone (LEO 80190)|
9761396|NCT00704340|Experimental|1|"DuraSeal Dural Sealant System - FDA Approved Device:~The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel."
9761397|NCT00704340|Active Comparator|2|"Standard of Care (control):~Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator."
9761398|NCT00704353|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
9761399|NCT00704353|Active Comparator|Standard Medical Care|Per product label
9761400|NCT00704379|Placebo Comparator|Placebo|Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.
9761401|NCT00704379|Experimental|Sertraline|Sertraline will be given in a double blind fashion via tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention.
9761402|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
9761403|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
9761404|NCT00704405|Experimental|48-wk Vaniprevir 300 mg + Peg-IFN/RBV|Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
9761405|NCT00704405|Experimental|48-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
9761406|NCT00704405|Placebo Comparator|48-wk PBO + Peg-IFN/RBV|PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
9761407|NCT00704418|Experimental|Bromfenac|Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
9761408|NCT00704418|Placebo Comparator|Placebo|Placebo, dosed 1 drop daily
9761409|NCT00704522||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C at sites in Austria.
9761410|NCT00704717||All Treated Patients|All patients participating in the study.
9761411|NCT00704730|Experimental|1|
9761412|NCT00704730|Placebo Comparator|2|
9761413|NCT00704808||Patients|Patients with newly diagnosed and operated glioblastoma multiforme.
9761414|NCT00704847|Active Comparator|1|SMC021 Oral Calcitonin
9761415|NCT00704847|Placebo Comparator|2|SMC021 Placebo
9761416|NCT00704912|Active Comparator|Lifestyle intervention|Orlistat/Meal Replacement/Lifestyle Modification
9761417|NCT00704912|Active Comparator|Oral Contraceptives (OCP)|Loestrin 1/20
9761418|NCT00704912|Active Comparator|Lifestyle/OCP Combined|Combination of treatments
9761419|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC|Patients with melanoma and renal cell cancer will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
9761420|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Other histology|Patients with other histologies, such as breast cancer, will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
9761421|NCT00704964||All participants|Each site will be evaluated by a site questionnaire and assigned as either a high or low participant management site. Participants are not randomized to a group. However, treatment completion rates will be evaluated based on the high vs low participant management sites.
9761422|NCT00705003|Experimental|Active Drug Combination|BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
9761423|NCT00705003|Active Comparator|BCI-024 (Buspirone)|BCI-024: over-encapsulated Buspirone 15 mg QD
9761424|NCT00705003|Placebo Comparator|Matching placebo|Placebo: 1 capsule QD
9761425|NCT00705016|Experimental|Cilengitide 2000 mg once weekly+Cetuximab+5-FU+Cisplatin|
9761426|NCT00705016|Experimental|Cilengitide 2000 mg twice weekly+Cetuximab+5-FU+Cisplatin|
9761427|NCT00705016|Active Comparator|Cetuximab+5-FU+Cisplatin|
9761428|NCT00705107||All Treated Patients|All patients participating in the study
9761429|NCT00705133|Experimental|Treprostinil-treated|Patients with pulmonary fibrosis with an advanced pulmonary hypertension phenotype will be treated with parenteral treprostinil in an open-label fashion
9761430|NCT00705146|Active Comparator|Comfort Cool Splint|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks.
9761431|NCT00705146|Active Comparator|Hybrid Custom-made splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks.
9761432|NCT00705159|Experimental|Loteprednol etabonate and tobramycin|Drug: Zylet (loteprednol etabonate and tobramycin)
9761433|NCT00705159|Active Comparator|Loteprednol etabonate|Drug: Lotemax (loteprednol etabonate)
9761434|NCT00705159|Active Comparator|Tobramycin|Drug: Tobramycin
9761435|NCT00705159|Placebo Comparator|Vehicle|Vehicle of Zylet
9761436|NCT00705224||Patients with chronic hepatitis C|Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
9761437|NCT00705250|Experimental|1|bendamustine hcl 120mg/m^2
9761438|NCT00705263||Patients with chronic hepatitis C|Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
9761439|NCT00705289||RA Subjects/ Infliximab 3 mg/kg|Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics [SPC] of Remicade®).
9761440|NCT00705341|Active Comparator|Low dose fluticasone for phase 2|For people with asthma, fluticasone at 250 mcg per day; phase 2 of study
9761441|NCT00705341|Active Comparator|High dose fluticasone for phase 2|For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study
9761442|NCT00705341|No Intervention|Nonasthmatic controls for phase 1|People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
9761443|NCT00705341|No Intervention|Asthmatic controls for phase 1|People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
9761444|NCT00705367|Placebo Comparator|Placebo|
9761445|NCT00705367|Active Comparator|Abatacept, 30 mg/kg|
9761446|NCT00705367|Other|Abatacept, 10 mg/kg|Open-label long-term extension phase
9761447|NCT00705406|Experimental|Peramivir 600 mg|600 mg peramivir administered as bilateral 2-mL intramuscular injection.
9761448|NCT00705406|Placebo Comparator|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
9761449|NCT00705432|Placebo Comparator|1. Placebo + PEG + RBV|PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
9761450|NCT00705432|Experimental|2. Boceprevir + PEG + RBV - 24 Weeks (RGT)|"PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.~At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.~At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up."
9761451|NCT00705432|Experimental|3. Boceprevir + PEG + RBV - 44 Weeks|PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
9761452|NCT00705484||Remicade Group|Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
9761453|NCT00705484||Standard Therapy Group|Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
9761454|NCT00705523|Active Comparator|1|
9761455|NCT00705523|Placebo Comparator|2|
9761456|NCT00705536|Active Comparator|Humalog first, then Humalog + rHuPH20|"Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days"
9761457|NCT00705536|Active Comparator|Humalog + rHuPH20 first, then Humalog|"Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog~A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days"
9783589|NCT01205126|Experimental|OROS Hydromorphone hydrochloride (HCl)|OROS Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
9832522|NCT02616250|Placebo Comparator|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
9832523|NCT02616380||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
9832524|NCT02616523|Active Comparator|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
9832525|NCT02616523|Active Comparator|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
9832526|NCT02616523|Placebo Comparator|placebo|The placebo group will receive intravenous infusion of normal saline only.
9832527|NCT02616601|Experimental|Generic Fluorouracil Cream|Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
9832528|NCT02616601|Active Comparator|Carac® (Fluorouracil) Cream|Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
9832529|NCT02616601|Placebo Comparator|Vehicle Cream|Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
9832530|NCT02616614|Active Comparator|Onexton gel|Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
9832531|NCT02616614|Experimental|Clindamycin/benzoyl peroxide gel|Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
9832532|NCT02616614|Placebo Comparator|Placebo|A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
9832533|NCT02616783|Experimental|E/C/F/TAF|Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
9832534|NCT02616783|Active Comparator|Remain current regimen|Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
9832535|NCT02616900|Experimental|eSight Eyewear|Main arm
9832536|NCT02617628|Active Comparator|Before Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
9832537|NCT02617628|Active Comparator|After Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
9832538|NCT02617667|Experimental|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
9832539|NCT02617667|Experimental|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
9832540|NCT02617667|Placebo Comparator|Placebo Ophthalmic Solution|Vehicle only
9832541|NCT02617667|Active Comparator|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
9832542|NCT02617784|Experimental|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
9832543|NCT02617784|Experimental|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
9832544|NCT02617888|Active Comparator|CCTA Breast Shields|Within female subset, randomization to wearing bismuth breast shield.
9761458|NCT00705536|Active Comparator|Humulin-R first, then Humulin-R + rHuPH20|"Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days"
9761459|NCT00705536|Active Comparator|Humulin-R + rHuPH20 first, then Humulin-R|"Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R~A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days"
9761460|NCT00705575|Experimental|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|
9761461|NCT00705575|Active Comparator|Aliskiren (300 mg)|
9761462|NCT00705614||Remicade Group|Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
9761463|NCT00705614||Standard Therapy Group|Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
9761464|NCT00705614||Switched to Remicade Group|Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
9761465|NCT00705653|Experimental|PG-11047|
9761466|NCT00705666||PegIntron as monotherapy or in combination with Ribavirin.|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.
9761467|NCT00705679|Experimental|1|TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
9761468|NCT00705679|Experimental|2|TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
9761469|NCT00705679|Experimental|3|TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
9761470|NCT00705679|Experimental|4|Application of tenofovir 1% vaginal gel once daily
9761471|NCT00705679|Experimental|5|Application of tenofovir placebo gel once daily
9761472|NCT00705718|Experimental|Endurant Bifurcated arm|The Bifurcated arm includes subjects who have received a bifurcated device. The Endurant Stent Graft System Bifurcated device is administered to treat patients with an Abdominal Aortic Aneurysm.
9761473|NCT00705718|Experimental|Endurant AUI arm|The AUI arm includes subjects who have received an AUI device. The Endurant Stent Graft System AUI device is administered to treat patients with an Abdominal Aortic Aneurysm.
9761474|NCT00705757|Active Comparator|Lumigan|Patients assigned to Lumigan/bimatoprost one drop before bedtime (qhs) to affected eye(s)
9761475|NCT00705757|Active Comparator|Xalatan|Patients assigned to Xalatan/latanoprost one drop before bedtime (qhs) to affected eye(s)
9761476|NCT00705757|Active Comparator|Travatan|Patients assigned to Travatan/travoprost one drop before bedtime (qhs) to affected eye(s)
9761477|NCT00705783|Experimental|Aripiprazole depot|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.
9761478|NCT00705783|Placebo Comparator|Placebo depot|Patients received placebo intramuscularly every 28 days for 52 weeks.
9761479|NCT00705874|Experimental|1|CGC-11047 in combination with Gemcitabine
9761480|NCT00705874|Experimental|2|CGC-11047 in combination with Docetaxel
9761481|NCT00705874|Experimental|3|CGC-11047 in combination with Bevacizumab
9761482|NCT00705874|Experimental|4|CGC-11047 in combination with Erlotinib
9761483|NCT00705874|Experimental|5|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
9761484|NCT00705874|Experimental|6|CGC-11047 in combination with 5-Flurouracil / Leucovorin
9761485|NCT00705874|Experimental|7|CGC-11047 in combination with Sunitinib
9761486|NCT00705939|Experimental|Naive 30 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
9761487|NCT00705939|Experimental|Naive 60 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
9761488|NCT00705939|Experimental|Switchover|Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)
9761489|NCT00706030|Experimental|neratinib 160 mg + vinorelbine|neratinib 160 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
9761490|NCT00706030|Experimental|neratinib 240 mg + vinorelbine|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
9761491|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, No Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
9761492|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
9761493|NCT00706095|Experimental|E7389 1.4 mg/m^2|
9761494|NCT00706095|Experimental|E7389 1.1 mg/m^2|
9761495|NCT00706095|Experimental|E7839 0.7 mg/m^2|
9783590|NCT01205126|Active Comparator|Oxycodone HCl Controlled release (CR)|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
9783591|NCT01205152|Experimental|asfotase alfa|An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week
9783592|NCT01205165|Experimental|Adefovir Dipivoxil 10mg|All enrolled subject were enrolled to adefovir dipivoxil 10mg arm.
9783593|NCT01205230|Experimental|Pazonib+ketoconazole|Administration of oral pazopanib 400mg (2 200-mg tablets) once-daily each morning for at least 7 consecutive doses during Period 1. Then administration of oral ketoconazole 400 mg (2 - 200 mg tablets) followed immediately by pazopanib 400 mg (2 -200 mg tablets) once-daily each morning for a total of 5 consecutive doses during Period 2.
9783594|NCT01205230|Experimental|Pazonib+esomeprazole|Subjects will receive orally administered pazopanib 800mg (4 - 200mg tablets) once-daily each morning for at least 7 consecutive doses in Period 1. In the evening on the last day of Period 1, subjects will take their initial dose of esomeprazole 40 mg (1 - 40 mg capsule) approximately 3 hours after the evening meal. Subjects will continue to receive pazopanib (each morning) and esomeprazole each evening once-daily for a total of 5 consecutive doses.
9783595|NCT01205269|Experimental|First 50 mcg, then 200 mcg, then placebo|period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo
9783596|NCT01205269|Experimental|First 50 mcg, then placebo, then 200 mcg|period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg
9783597|NCT01205269|Experimental|First 200 mcg, then placebo, then 50 mcg|period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg
9783598|NCT01205269|Experimental|First 200 mcg, then 50 mcg, then placebo|period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo
9783599|NCT01205269|Experimental|First placebo, then 200 mcg, then 50 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg
9783600|NCT01205269|Experimental|First placebo, then 50 mcg, then 200 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg
9783601|NCT01205399||AlloMax Surgical Graft Group|
9783602|NCT01205438|Experimental|LY2127399 every 2 weeks|
9783603|NCT01205438|Experimental|LY2127399 every 4 weeks|During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
9783604|NCT01205438|Placebo Comparator|Placebo|
9783605|NCT01205451|Experimental|BTX-A|Botulinum toxin type A
9783606|NCT01205503|Other|Cycle 1 Saline; Cycle 2 Mesna|Saline infused over 15 minutes administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
9783607|NCT01205503|Other|Cycle 1 Mesna; Cycle 2 Saline|Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Saline administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
9783608|NCT01205529|Other|AF with ST changes on ECG|Those patients with ST segment or J Point elevation on electrocardiogram. Can be on initial screening electrocardiogram or on electrocardiograms during procainamide infusion. These subjects will harbor cardiac sodium channel gene variants.
9783609|NCT01205568|Experimental|Patients with Resistant Pulmonary Artery Stenosis|Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
9761496|NCT00706121|Experimental|Vitamin E + selenium placebo|Vitamin E and selenium placebo daily for 7 - 12 years
9761497|NCT00706121|Experimental|Selenium + vitamin E placebo|Selenium and vitamin E placebo daily for 7 - 12 years
9761498|NCT00706121|Experimental|Vitamin E + selenium|Vitamin E and selenium daily for 7 - 12 years
9761499|NCT00706121|Placebo Comparator|Vitamin E placebo + selenium placebo|Vitamin E placebo and selenium placebo daily for 7 - 12 years
9761500|NCT00706134|Placebo Comparator|Placebo|
9761501|NCT00706134|Experimental|Aliskiren 75 mg|
9761502|NCT00706134|Experimental|Aliskiren 150 mg|
9761503|NCT00706134|Experimental|Aliskiren 300 mg|
9761504|NCT00706238|Experimental|GSK1203486A Group|"Patients received 4 cycles of MAGE-A3 product as follows:~Cycle 1: 6 doses, each given at a 2-week interval,~Cycle 2: 6 doses, each given at a 3-week interval~Cycle 3: 4 doses, each given at a 6-week interval~Cycle 4: 4 doses, each given at a 3-month interval followed by 4 doses, each given at a 6-month interval.~The MAGE-A3 product was administered intramuscularly in the deltoid or lateral regions of the thighs, alternately on the right and left sides."
9761505|NCT00706264|No Intervention|1|Expectant management
9761506|NCT00706264|Experimental|2|Placement of arabin pessary since 23 weeks until 37 weeks
9761507|NCT00706342|Experimental|1|
9761508|NCT00706355|Experimental|1|
9761509|NCT00706381|Experimental|1: Carb meal, fat meal, sincalide, placebo, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, and IV placebo + PO Ursodiol 15mg/kg day 5
9761510|NCT00706381|Experimental|2: Fat meal, carb meal, sincalide, placebo, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
9761511|NCT00706381|Experimental|3: Carb meal, fat meal, placebo, sincalide, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
9761512|NCT00706381|Experimental|4: Fat meal, carb meal, placebo, sincalide, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, the IV placebo + PO Ursodiol 15mg/kg day 5
9761513|NCT00706394|Experimental|A|Powerlink 34mm cuff stent graft
9761514|NCT00706407|Experimental|Fully integrated Uro-NIRS:UDS|
9761515|NCT00706433|Active Comparator|ALA 1000 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
9761516|NCT00706433|Active Comparator|ALA 500 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes and 20 seconds)
9761517|NCT00706433|Placebo Comparator|Vehicle 1000 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
9761518|NCT00706433|Placebo Comparator|Vehicle 500 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes 20 seconds)
9761519|NCT00706446|Experimental|1 - Tio/ICS in the Arg/Arg genotype|Tiotropium bromide 18 mcg qd plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
9761520|NCT00706446|Experimental|2 - Tio/ICS in the Arg/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
9761521|NCT00706446|Experimental|3 - Tio/ICS in the Gly/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly/Gly genotype
9761522|NCT00706446|Active Comparator|4 - LABA/ICS in the Arg/Arg genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
9761523|NCT00706446|Active Comparator|5 - LABA/ICS in the Arg/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
9761524|NCT00706446|Active Comparator|6 - LABA/ICS in the Gly/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly-Gly genotype
9761525|NCT00706485|Experimental|Dural brachytherapy plaque|Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.
9761526|NCT00706511|Experimental|Group with OSA|Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
9761527|NCT00706511|No Intervention|Group without OSA|Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol
9761528|NCT00706550|Other|Immediate|"Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
9761529|NCT00706550|Other|Delayed|"Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
9761530|NCT00706563|Experimental|Fluarix Adult Group|Subjects who are 18-40 years of age received one dose of Fluarix™.
9761531|NCT00706563|Experimental|Fluarix Elderly Group|Subjects who are ≥ 60 years of age received one dose of Fluarix™.
9761532|NCT00706589|Experimental|1|Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
9761533|NCT00706589|Placebo Comparator|2|Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
9761534|NCT00706641|Experimental|Experimental: Neoadjuvant Dasatinib + Radical Cystectomy|Dasatinib 100 mg PO qd x 4 weeks followed by radical cystectomy 8-24 hours post last administered dasatinib dose
9761535|NCT00706654|Experimental|Aripiprazole depot 300 or 400 mg|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
9761536|NCT00706654|Active Comparator|Aripiprazole 10-30 mg orally|Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
9761537|NCT00706654|Experimental|Aripiprazole depot 25 or 50 mg|Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
9761538|NCT00706706|Experimental|sunitinib|single agent sunitinib, single arm
9761539|NCT00706719|Experimental|25 mg Androxal no wash out|1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
9761540|NCT00706719|Active Comparator|Testim 1% (topical testosterone)|Testim 1% Gel applied topically for 6 months
9761541|NCT00706719|Experimental|25 mg Androxal wash out|1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
9761542|NCT00706784|Experimental|A|
9761543|NCT00706810|Experimental|All participants|
9761544|NCT00706823|Experimental|i-gel-SGA|Patients who received i-gel supraglottic device (i-gel airway) for intubation
9761545|NCT00706823|Active Comparator|LMA-Unique|Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation
9761546|NCT00706836|Active Comparator|Pregabalin 50 mg|Pregabalin oral tablets (50 mg)
9761547|NCT00706836|Active Comparator|Pregabalin 200 mg|Pregabalin oral tablets (200 mg)
9761548|NCT00706836|Placebo Comparator|Placebo|Placebo
9761549|NCT00706849|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
9761550|NCT00706849|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection once a week for 26 weeks.
9761551|NCT00706901|Experimental|Arm 1 GMI|Patients randomized to GMI received four structured 75-minute sessions consistent with the central principles and style of motivational interviewing (Miller & Rollnick, 2012). The goal of MI is to develop a sense of discrepancy between personal goals and current behavior and enhance change talk among participants, particularly for taking responsibility of one's substance use and being proactive for remaining in treatment.
9761552|NCT00706901|Experimental|Arm 2 IHMD|Participants randomized to In-Home-Messaging Devices (IHMD) received a 27-day Care Coordination Home Telehealth (CCHT) program targeting their acute recovery from alcohol and other substance use disorder. Participants received their IHMD device through the Charleston VAMC CCHT program, including device accessories and a phone number to reach their CCHT provider. They were provided with specific instructions on how to set up their IHMD in their residence after discharge. The research associate followed-up with the patient one day after receiving the device to ensure that the device was successfully set up and to provide assistance as necessary. Participants received standard VA CCHT services.
9761553|NCT00706901|Active Comparator|Arm 3 TCC|Participants randomized to the Treatment Control Condition (TCC) received a psycho-educational group (e.g., addiction as a chronic disease, relapse prevention, developing a plan to prevent relapse) that was delivered with the aid of sequential standardized PowerPoint presentations. Group members were encouraged to ask questions and make comments. Therapists were encouraged to conduct the sessions using an instructional quality that minimized the use of GMI strategies. TCC consisted of four sessions, lasting 75 minutes, and was conducted on four consecutive days within the course of one week.
9761554|NCT00706914|Experimental|Once-daily aclidinium/formoterol|Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
9761555|NCT00706914|Experimental|Morning aclidinium/formoterol plus evening formoterol|Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
9761556|NCT00706914|Active Comparator|Formoterol BID|Formoterol fumarate 12 µg twice-daily (BID)
9761557|NCT00706966|Experimental|Dutasteride|Dutasteride was administered at a dose of 3.5 mg as an oral soft gelatin capsule once daily for 6 months
9761558|NCT00706979|Experimental|1|Practice Quit Attempt plus Nicotine Replacement Therapy
9761559|NCT00706979|Active Comparator|2|Practice Quit Attempt only
9761560|NCT00706992|Experimental|Arm I - Adj-4 A2 F5 cells|Patients receive anti-MART-1 F5 TCR-transduced peripheral blood lymphocytes (PBLs) intravenously (IV) over 20-30 minutes on day 0. 1 x 10e9 to 5 x 10e10 IV.
9761561|NCT00706992|Experimental|Arm II-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously.
9761562|NCT00706992|Experimental|Arm III-Adj-4 A2 F5 cells + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
9761563|NCT00706992|Experimental|Arm IV-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide+SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
9761564|NCT00706992|Experimental|Arm V-Adj-4 A2 F5 cells + ALVAC MART-1:26-35(27L) Vaccine|Patients receive anti-MART-1 F5 TCR-transduced PBLs IV over 20-30 minutes on day 0, and ALVAC-MART-1 vaccine SC on days 0 and 14. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
9761565|NCT00706992|Experimental|Arm VI-Adj-4 A2 F5 cells + ALVAC MART-1 VAccine + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs and ALVAC-MART-1 vaccine as in arm V, and low-dose aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL)+ 125,000 IU/kg/day subcutaneously.
9761566|NCT00706992|Experimental|Arm VII-Adj-4 A2 ALVAC MART-1:26-35(27L) Vaccine|Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
9761567|NCT00707031|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9761568|NCT00707031|Active Comparator|Exenatide|1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.
9761569|NCT00707057|Experimental|Ibuprofen 600 mg ER group|One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
9761570|NCT00707057|Placebo Comparator|Placebo group|Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
9761571|NCT00707174|Active Comparator|1|"Topical imiquimod group:~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site."
9761572|NCT00707174|Experimental|2|"Topical imiquimod and topical tazarotene 0.1% cream group:~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week."
9761573|NCT00707239|Experimental|A|
9761574|NCT00707239|Experimental|B|
9984193|NCT04314284|Other|Historical Control Survey|-The investigators will conduct a historic control survey of 80-100 recently diagnosed gynecologic, colorectal, and lung cancer patients. They can complete the survey in-person, over the phone, or online. The survey will take approximately 15 minutes to complete. It will ask about their knowledge of health insurance and confidence communicating about care costs.
10202913|NCT03854903|Experimental|Dose Level B1|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
9761575|NCT00707239|Active Comparator|C|
9761576|NCT00707343|Experimental|All patients|All participants enrolled.
9761577|NCT00707447|Placebo Comparator|1/Control|Control group received written information about diabetes risks with instructions about healthy eating and increasing physical exercise
9761578|NCT00707447|Experimental|2/PREDIAS|Intervention consists of a group programme (PREDIAS) aiming at modification of lifestyle
9761579|NCT00707486|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
9761580|NCT00707486|Active Comparator|Gauze with pressure and/or Gelfoam|Post operative care for oral surgery subjects consists of the subject biting on sterile cotton gauze to provide pressure to the extraction site. A common alternative practice involves the placement of Gelfoam (with or without antibiotic/steroid medication) into the extraction socket prior to application of the sterile gauze pressure dressing. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard of care for oral surgery subjects, including the use of cotton gauze and/or Gelfoam to control post operative bleeding.
9761581|NCT00707577|Experimental|Internet-based maintenance program|9-month Internet based self-monitoring maintenance program to track weight, exercise, and food logs
9761582|NCT00707577|No Intervention|Control|No maintenance program provided
9761583|NCT00707655|Experimental|Zalutumumab 4 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
9761584|NCT00707655|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
9761585|NCT00707746|Placebo Comparator|Placebo|1 mL placebo saline, weekly subcutaneous injections for 26 weeks
9761586|NCT00707746|Experimental|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
9761587|NCT00707759|Experimental|A: withdrawal steroids|"Arms A: TAC + MMF + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
9761588|NCT00707759|Active Comparator|B|"Arms B: TAC + MMF + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
9761589|NCT00707863|Other|Depressed Subjects Age: 18 - 25 yrs|Subjects receiving Escitalopram (trade name: Lexapro) that are in the age range of 18-25
9761590|NCT00707863|Other|Depressed Subjects Age: 16 - 50 yrs|Subjects receiving Escitalopram (trade name: Lexapro) in the age range of 26-50
9761591|NCT00707915|Experimental|Dose reduction|The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.
9761592|NCT00707954|Experimental|TA-7284|
9761593|NCT00707954|Placebo Comparator|Placebo of TA-7284|
9761594|NCT00707967|Experimental|Group A|Subjects receiving the candidate vaccine
9761595|NCT00707967|Placebo Comparator|Group B|Subjects receiving the adjuvant
9761596|NCT00707967|Placebo Comparator|Group C|Subjects receiving physiological saline
9761597|NCT00707980|Experimental|Vortioxetine|Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
9761598|NCT00707993|Experimental|Alogliptin 25 mg QD|
9761599|NCT00707993|Active Comparator|Glipizide 5 mg QD|
9761600|NCT00708019|Experimental|Low dose|Low dose of the psychoeducational intervention (i.e., 8.0 hours with the intervention nurse over 10 weeks)
9761601|NCT00708019|Experimental|High dose|High dose of the psychoeducational intervention (i.e., 12.3 hours with the intervention nurse over 10 weeks)
9761602|NCT00708032|Other|spectacles|habitual spectacles worn daily for 12 months
9761603|NCT00708032|Experimental|narafilcon A soft contact lenses|narafilcon A soft contact lenses worn as daily disposable for 12 months
9761604|NCT00708071|Experimental|1|One side of the face is treated with FS VH S/D 4; the other side of the face is treated using standard of care.
9761605|NCT00708097|Experimental|NaF toothpaste(1450 ppmF)|Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
9761606|NCT00708097|Active Comparator|NaF toothpaste (1400 ppmF)|Study toothpaste containing 1400 ppm F as NaF
9761607|NCT00708097|Active Comparator|NaMFP/NaF toothpaste (1450 ppmF)|Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
9761608|NCT00708097|Active Comparator|NaF toothpaste (675 ppmF)|Study toothpaste containing 675 ppm F as NaF
9832545|NCT02617888|No Intervention|CCTA No Breast Shields|Within female subset, randomization to wearing no bismuth breast shield (standard of care).
9832546|NCT02617888|No Intervention|Observational Arm|Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
9832547|NCT02617901|Experimental|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).~Bone age will be assessed according to the Greulich & Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
9832548|NCT02618031|Other|Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
9832549|NCT02618031|Experimental|Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
9832550|NCT02618187|Experimental|Weekly SER-287, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
9832551|NCT02618187|Placebo Comparator|Daily placebo, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once daily placebo for 8 weeks
9832552|NCT02618187|Experimental|Daily SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
9832553|NCT02618187|Experimental|Weekly SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
9832554|NCT02618343|Experimental|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
9832555|NCT02618343|Active Comparator|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
9832556|NCT02618382|Experimental|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
9832557|NCT02618512|Experimental|SBC-103|Patients were administered 1 mg/kg by IV infusion once every other week (qow) for at least 12 weeks. After evaluation of 12-week safety, tolerability, and pharmacodynamic data in individual patients, the dose was increased to 3 mg/kg qow. Infusions were to be at least 10 days apart and were administered every 14 days ±5 days.
9832558|NCT02618616|Experimental|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.
9666199|NCT04642053|Experimental|Immediate Treatment|Participants in the Immediate Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin between 1-3 weeks following the diagnostic evaluation.
9832559|NCT02618616|Placebo Comparator|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
10202914|NCT03854903|Experimental|Dose Level B2|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
10202915|NCT03852784||Bone and joint infection with Streptococcus peumoniae|Patients having had an osteoarticular infection with Streptococcus peumoniae
10202916|NCT03843346||Cohort 1: Postoperative group|"Consists of 75 patients who have completed definite surgery for their primary breast cancer as determined by a Consultant Surgeon and have been referred to a Medical Oncologist for consideration of adjuvant chemotherapy.~Tumours of any size will be eligible~Between 1 and 3 lymph nodes involved by tumour as assessed by Consultant Pathologist~Micro metastases (<=0.2mm) will be eligibile~Isolated tumour cells only (node negative i+/i-) are excluded"
10202917|NCT03843346||Cohort 2: Preoperative group|"Consists of 75 patients who have been referred by a Consultant Surgeon to a Medical Oncologist for consideration of neoadjuvant (preoperative) chemotherapy.~Min tumour size 2.1mm (T2)~Histological proof of involvement of at 1 lymph node, including micrometastases (<=0.2mm)"
10202918|NCT03836846|Placebo Comparator|Treatment As Usual|Standard of care as usual with follow-up at 1-, 3-, and 6-months
10202919|NCT03836846|Active Comparator|Intervention with CBT Mobile App|Treatment as usual with additional treatment using cognitive behavioral therapy (CBT) mobile apps (ie What's Up?)
10202920|NCT03830840||Adult Individuals with Type 2 diabetes|Individuals ≥18 years of Hispanic/Latino heritage with an established diagnosis of type 2 diabetes
10202921|NCT03830840||Adult Family member|Adult family members, ≥18 years, of the individual with type 2 diabetes
10202922|NCT03830840||Child family member with diabetes|Child, ≥7 years but <18 years, family member with diabetes
10202923|NCT03830840||Child family member without diabetes|Child, ≥7 years but <18 years, family member without diabetes
10202924|NCT03829891|Experimental|Beinaglutide|"Beinaglutide for 8 weeks,~Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
10202925|NCT03829891|Active Comparator|glargine|"Glargine for 8 weeks,~Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
10202926|NCT03829410|Experimental|Onvansertib + FOLFIRI + Bevacizumab|"Phase 1b: Onvansertib escalating starting dose of 12 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab. This Phase 1b portion of the study has been completed.~Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) of 15 mg/m^2 orally Day 1 through Day 5 and Day 15 through Day 19 of every 28-day cycle in combination with FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle."
10205258|NCT03349775|Active Comparator|Metformin|Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
9761609|NCT00708097|Placebo Comparator|Placebo toothpaste (0 ppmF)|Fluoride free placebo toothpaste (0 ppm F)
9761610|NCT00708110|Experimental|Treatment A|GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
9761611|NCT00708110|Experimental|Treatment B|GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
9761612|NCT00708110|Experimental|Treatment C|GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
9761613|NCT00708123|Active Comparator|Sodium Fluoride (NaF) toothpaste[1350 parts per million(ppm)F]|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (1350 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
9761614|NCT00708123|Experimental|NaF/Carbopol toothpaste (1400 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF and 0.5% carbopol toothpaste (1450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
9761615|NCT00708123|Active Comparator|NaMFP/NaF toothpaste (1450 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaMFPand NaF toothpaste (1450 ppm F - 1000 ppm F as NaMFP and 450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
9761616|NCT00708123|Active Comparator|NaF toothpaste (250 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (250 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
9761617|NCT00708123|Placebo Comparator|Placebo toothpaste (0 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of fluoride free toothpaste (0 ppm F) for one timed minute, after removing their partial denture from their mouth.
9761618|NCT00708162|Experimental|Elvitegravir|"EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg."
9761619|NCT00708162|Active Comparator|Raltegravir|"RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg."
9761620|NCT00708175|Experimental|Pioglitazone|
9761621|NCT00708175|Placebo Comparator|Placebo|
9761622|NCT00708201|Experimental|Alvimopan|"12 milligrams (mg)~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment"
9761623|NCT00708201|Placebo Comparator|Placebo|"300 mg polyethylene glycol in a capsule~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery."
9761624|NCT00708214|Experimental|BIBW 2992|To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer
9761625|NCT00708214|Other|Letrozole|Hormonotherapy for metastatic breast cancer
9984194|NCT04314284|Other|Oncology Providers|-The investigators will train 15 gynecologic, colorectal, and lung cancer care providers in using I Can PIC and discussing costs with patients in a brief 15 minute presentation that can be delivered in-person or virtually. Providers will complete a survey before and after their brief training at the start of the study. These surveys will take approximately 5-10 mins to complete in total. During the study, at 3- and 6- months, the investigators will give real-time feedback to providers on the percent of time that they screened for financial distress and referred patients to I Can PIC. At the end of the study, the investigators will examine adoption, implementation, and maintenance measures.
9761626|NCT00708227||Whites ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
9761627|NCT00708227||Whites ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
9761628|NCT00708227||African American ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
9761629|NCT00708227||African American ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
9761630|NCT00708305|Experimental|NaF toothpaste (1450 parts per million [ppm] fluoride [F])|Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
9761631|NCT00708305|Active Comparator|NaF toothpaste (1400ppmF)|Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
9761632|NCT00708305|Active Comparator|Sodium monofluorophosphate (NaMFP)/ NaF toothpaste (1450ppmF))|Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
9761633|NCT00708305|Placebo Comparator|Placebo toothpaste (0ppmF)|Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
9761634|NCT00708422|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
9761635|NCT00708422|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
9761636|NCT00708435|Experimental|Beriplex® P/N|
9761637|NCT00708435|Active Comparator|Fresh frozen plasma|
9761638|NCT00708461|Experimental|Worksite Environmental Intervention|Changes to healthy food availability, physical activity opportunities and promotion, body weight scale access, and media enhancements to target weight gain prevention
9761639|NCT00708461|No Intervention|No-contact control|No-treatment control condition. Worksites were offered program materials upon completion of programs at intervention sites.
9761640|NCT00708500|Placebo Comparator|Placebo+PEG2b+RBV, x 44 weeks|Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
9761641|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, Response Guided Therapy|"Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.~PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:~36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.~48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion."
9761642|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, x 44 weeks|Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
9761643|NCT00708526|Experimental|Phase 1 Recovery|Quick Emergence Device is in place for phase 1 anesthesia recovery
9761644|NCT00708526|Other|Standard of care|Tidal volume and respiratory rate are not changed during phase 1 recovery from anesthesia
9761645|NCT00708552|Experimental|SB-742457 - 15mg|SB-742457 - 15mg
9761646|NCT00708552|Placebo Comparator|Placebo|
9761647|NCT00708552|Experimental|SB-742457 - 35mg|SB-742457 - 35mg
9761648|NCT00708552|Active Comparator|Donepezil|
9761649|NCT00708643|Active Comparator|Habitual silicone hydrogel|Habitual contact lens wear.
9761650|NCT00708643|Experimental|narafilcon A|Silicone hydrogel daily disposable contact lens
9761651|NCT00708682|Experimental|A|
9761652|NCT00708708||A|Patients with moderate to severe plaque psoriasis
9761653|NCT00708721|Experimental|All patients|All participants enrolled.
9761654|NCT00708851|Active Comparator|NB-UVB Light Device (311-315 nm)|the subject will receive full body NB-UVB light therapy
9761655|NCT00708851|Experimental|LCD Solution with NB-UVB Phototherapy|on half of the body will receive LCD while the full body receives NB-UVB therapy
9761656|NCT00708877|Experimental|All participants|
9761657|NCT00708942|Active Comparator|1|HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
9761658|NCT00708942|Placebo Comparator|2|Placebo suppository (single administration), laser illumination (50J/cm2)
9761659|NCT00708942|No Intervention|3|
9761660|NCT00708942|Active Comparator|4|HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
9761661|NCT00708942|Placebo Comparator|5|Placebo ointment (single administration), no illumination
9761662|NCT00709059||PegIntron Plus Rebetol|Previously untreated patients infected with HCV genotype 1, 4, 5, or 6.
9761663|NCT00709098|Active Comparator|iloprost power 6|iloprost power 15
9761664|NCT00709098|Experimental|iloprost power 15|iloprost power 15
9761665|NCT00709111|Experimental|Maraviroc|Maraviroc (MVC) was taken for 24 weeks, in addition to the subject's current antiretroviral therapy (ART) drug regimen. At week 24, subjects discontinued MVC and were followed for an additional 24 weeks off MVC, but still on current ART drug regimen.
9761666|NCT00709124|Experimental|NMES|60 minute daily NMES sessions every day for the duration of subject's ICU stay.
9761667|NCT00709124|Sham Comparator|Sham|60 minute sham sessions every day for the duration of subjects ICU stay. No voltage will be applied to those receiving sham sessions.
9761668|NCT00709202|Active Comparator|1|Subjects assigned to this arm will receive Betahistine.
9761669|NCT00709202|Placebo Comparator|2|Subjects in this group will received placebo.
9761670|NCT00709228||PegIntron plus Rebetol|Those with chronic Hepatitis C infected with HCV LVL G1
9761671|NCT00709306|Placebo Comparator|Education|Participants were given a packet of standard skin cancer prevention educational brochures and handouts from major professional organizations to review independently for 10-15 minutes.
9761672|NCT00709306|Active Comparator|Motivational Interviewing|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
9761673|NCT00709306|Active Comparator|UV-detect photos|"Participants were shown a regular black and white photo and a black and white UV-filtered photo of their face. Participants were told that Any dark, spotted, freckled, wrinkled, uneven, or pitted areas indicate existing underlying skin damage that is difficult to reverse. However, protecting the skin from UV radiation can prevent future damage. Participants were asked what they noticed about the photos, what their reactions were, and how this might affect their behavior. These sessions took 12 minutes on average."
9761674|NCT00709306|Experimental|UV-detect photos & MI|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. In addition to baseline feedback, participants were also interviewed about the black & white and UV-filtered photos of their faces. These sessions took about 25 minutes.
9761675|NCT00709319||Primary|Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness >300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
9761676|NCT00709592|Experimental|ATG 1.7 mg/kg, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 5.1 mg/kg in three divided doses (1.7 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive lower dose anti-thymocyte globulin IV on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
9761677|NCT00709592|Experimental|ATG 2.5 mg/kg/d, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 7.5 mg/kg in three divided doses (2.5 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive higher dose anti-thymocyte globulin intravenously (IV) on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
9761678|NCT00709696|Placebo Comparator|1|Placebo Varenicline
9761679|NCT00709696|Active Comparator|2|Varenicline
9761680|NCT00709722|Experimental|1|NKT-01
9761681|NCT00709735|Experimental|Reactivation Propranolol (RP)|"0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
10202927|NCT03827291|Experimental|Quadratus lumborum block|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
10202928|NCT03827291|Other|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia.
10202929|NCT03818802|Active Comparator|Nicotinamide Riboside|NR is a single chemical moiety containing nicotinamide and ribose. The investigational product is a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels.
10202930|NCT03818802|Placebo Comparator|Placebo|Correspondent placebo, a pill not containing the active component.
9761682|NCT00709735|Active Comparator|Non-Reactivation Propranolol (NRP)|"0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
9761683|NCT00709761|Experimental|Single Arm|Single arm combination therapy of Lap and NabPaclitaxel combination
9761684|NCT00709826|Experimental|apricoxib + gemcitabine + erlotinib|400mg apricoxib + 1000mg/m2 gemcitabine + 100mg erlotinib
9761685|NCT00709826|Placebo Comparator|placebo + gemcitabine + erlotinib|placebo + 1000mg/m2 gemcitabine + 100mg erlotinib
9761686|NCT00709852|Experimental|Gadobutrol then Gadoteridol|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) in Period 1 and a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 2.
9761687|NCT00709852|Experimental|Gadoteridol then Gadobutrol|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 1 and a single dose of gadobutrol 0.1 mmol/kg bw via i.v. in Period 2.
9761688|NCT00709878||L|Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash.
9761689|NCT00709878||C|Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash.
9761690|NCT00709878||P|Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash.
9761691|NCT00709878||E|Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash.
9761692|NCT00709891|Experimental|cobas® 4800 HPV Test|The cobas 4800 human papillomavirus (HPV) Test combines in a single assay the identification of pooled high-risk oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), as well as genotypes 16 and 18 individually.
9761693|NCT00709956|Experimental|Active / placebo|Single dose of iloprost (5 µg) on study day 2 followed by single dose of placebo on study day 3
9761694|NCT00709956|Placebo Comparator|Placebo / active|Single dose of placebo on study day 2 followed by single dose of iloprost (5 µg) on study day 3
9761695|NCT00709995|Experimental|Part 1 Arm A: Enzastaurin + Sunitinib|"(Cohort 1): On cycle 1, day 1 a loading dose 125 milligram (mg) of Enzastaurin was administered by mouth orally, (BID) twice a day, followed by Enzastaurin 125 mg administered, twice a day, Days 2 through 42 of a 6-week cycle.~(Cohort 2): Cycle 1, Day 1 loading dose 375 mg of Enzastaurin administered po three times a day (TID), followed by 250 mg, po, BID continuously until disease progression, unacceptable toxicity, death, or discontinuation from the study for any other reason.~Sunitinib 50 mg was administered orally, once daily, Days 1-28, then rest (no drug given) days 29-42.~Phase 2 (Part 2): Randomized Double-Blind: Dosing was determined by Part 1. Part 2 was not activated per recommendation of safety review committee.~Enzastaurin: Cycle 1, Day 1 loading dose 375 mg administered orally, (TID) three times a day, followed by Part 1 dose twice a day on Days 2-42 of 6 week cycle.~Sunitinib: 50 mg administered orally, once daily, on Days 1-28, then rest Days 29-42."
9761696|NCT00709995|Placebo Comparator|Part 2 Arm B: Sunitinib + Placebo|"Part 2 was not activated per recommendation of safety review committee.~Sunitinib: 50 mg administered orally, once daily, Day 1-28, then rest Days 29-42.~Placebo: Cycle 1 Day 1 loading dose 3 tablets on Day 1, then 2 tablets daily, days 2-42."
9761697|NCT00710021|Experimental|vitamin D3 2000 IU|Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks.
9761698|NCT00710021|Experimental|vitamin D3 4000 IU|Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks.
9761699|NCT00710021|Placebo Comparator|vitamin D3 placebo|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks.
9761700|NCT00710034|Active Comparator|Nicotine Gum|Nicotine replacement therapy (4 mg nicotine gum) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute nicotine gum for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
9761701|NCT00710034|Experimental|Snus|Oral tobacco (Camel Snus) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute snus for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
9761702|NCT00710203|Active Comparator|Pulsed dye laser|Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
9761703|NCT00710203|Active Comparator|Curettage|Four lesions are selected on each subject for study. A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
9761704|NCT00710203|Active Comparator|Electrodesiccation|Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
9761705|NCT00710203|Active Comparator|No treatment|Four lesions are selected on each subject for study. A fourth lesion will not be treated and will serve as a control.
9761706|NCT00710385|Active Comparator|Heroin|Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
9761707|NCT00710385|Active Comparator|Naloxone|Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
9832560|NCT02618642|Active Comparator|Piler light + red filter|Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
9832561|NCT02618642|Active Comparator|Piler light + blue filter|Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
9832562|NCT02618642|Active Comparator|Piler light without a filter|Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
9832563|NCT02618642|Placebo Comparator|placebo|Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle
9832564|NCT02618759|Experimental|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
9832565|NCT02618759|Placebo Comparator|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
9832566|NCT02618772|Placebo Comparator|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
9832567|NCT02618772|Active Comparator|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
9832568|NCT02618915|Experimental|DTX101, Cohort 1|a single peripheral intravenous (IV) infusion of 1.6 x 10^12 genome copies (GC)/kg DTX101
9832569|NCT02618915|Experimental|DTX101, Cohort 2|a single peripheral IV infusion of 5.0 x 10^12 GC/kg DTX101
9832570|NCT02618928||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
9832571|NCT02618967|Experimental|AMG 570 - 7 mg|Participants will receive a single dose 7 mg dose of AMG 570 administered subcutaneously.
9832572|NCT02618967|Experimental|AMG 570 - 21 mg|Participants will receive a single 21 mg dose of AMG 570 administered subcutaneously.
9832573|NCT02618967|Experimental|AMG 570 - 70 mg|Participants will receive a single 70 mg dose of AMG 570 administered subcutaneously.
9832574|NCT02618967|Experimental|AMG 570 - 140 mg|Participants will receive a single 140 mg dose of AMG 570 administered subcutaneously.
9832575|NCT02618967|Experimental|AMG 570 - 210 mg|Participants will receive a single 210 mg dose of AMG 570 administered subcutaneously.
9832576|NCT02618967|Experimental|AMG 570 - 420 mg|Participants will receive a single 420 mg dose of AMG 570 administered subcutaneously.
9832577|NCT02618967|Experimental|AMG 570 - 700 mg|Participants will receive a single 700 mg dose of AMG 570 administered subcutaneously.
9832578|NCT02618967|Placebo Comparator|Placebo|Participants will receive a single dose of the matching AMG 570 placebo administered subcutaneously.
9832579|NCT02619175|Experimental|Perturbation-based balance training|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
9832580|NCT02619175|Active Comparator|Weight shifting and gait training|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
9832581|NCT02619396|Active Comparator|"Group 20 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
9832582|NCT02619396|Active Comparator|"Group 40 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
9832583|NCT02619396|Active Comparator|"Group 20 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
9832584|NCT02619396|Active Comparator|"Group 40 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
9832585|NCT02619409|Placebo Comparator|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
9761708|NCT00710385|Experimental|Low Bup Dose|Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
9761709|NCT00710385|Experimental|Low Bup/Nal Dose|Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
9761710|NCT00710385|Experimental|High Bup Dose|Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
9761711|NCT00710385|Experimental|High Bup/Nal Dose|Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
9761712|NCT00710385|Placebo Comparator|Placebo|Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
9761713|NCT00710424|Experimental|Sativex|
9761714|NCT00710424|Placebo Comparator|Placebo|
9761715|NCT00710554|Experimental|Sativex|
9761716|NCT00710554|Placebo Comparator|Placebo|
9761717|NCT00710593|Active Comparator|A: HAART naive or no HAART in past 6 months|Participants who are ART naïve or, if ART-exposed, have not received highly active antiretroviral therapy (HAART) for at least the six months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
9761718|NCT00710593|Active Comparator|B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months|Participants who have been receiving highly active antiretroviral therapy (HAART) for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads < 400 copies/ml on two previous clinical visits within the 6 months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
9783610|NCT01205581|Active Comparator|Leukemia-HD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
9783611|NCT01205581|Active Comparator|Leukemia-SD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
9783612|NCT01205581|Active Comparator|Solid Tumor-HD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
9783613|NCT01205581|Active Comparator|Solid Tumor-SD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
9783614|NCT01205581|Active Comparator|HIV-HD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
9783615|NCT01205581|Active Comparator|HIV-SD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
9783616|NCT01205646|Experimental|Zometa & PET Scans|Zoledronate therapy & PET scan ;2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.
9783617|NCT01205685|Experimental|OSI-906 + Erlotinib + Letrozole + Goserelin|"OSI-906 in a pill form, by mouth, twice a day (12 hours a part)~Erlotinib in a pill form, by mouth, once a day~Letrozole in a pill form, by mouth, once a day~Goserelin, by injection once per month for women who are pre-menopausal"
9783618|NCT01205776|Active Comparator|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
9783619|NCT01205776|Active Comparator|Coronary Artery Bypass Graft|Those patients receiving CABG
9783620|NCT01205828|Experimental|Temozolomide and ABT-888 in HCC patients|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
9785544|NCT01254214|Experimental|tMBSR|telephone-adapted Mindfulness Based Stress Reduction (tMBSR) is an 8-week program of training in mindfulness meditation consisting of two in-person group meetings and 6 conference calls, led by a trained meditation teacher.
9832586|NCT02619409|Active Comparator|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
9832587|NCT02619409|Active Comparator|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
9832588|NCT02619409|Active Comparator|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
9832589|NCT02619409|Active Comparator|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
9832590|NCT02619591|Active Comparator|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
9832591|NCT02619591|Experimental|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
9832592|NCT02619617|Experimental|SOM230 0.9mg|cohort 2
9832593|NCT02619617|Experimental|SOM230 1.5 mg|cohort 1
9832594|NCT02619799|Active Comparator|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
9832595|NCT02619799|Active Comparator|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
9832596|NCT02620020|Experimental|Fasinumab 6 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
9832597|NCT02620020|Experimental|Fasinumab 9 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
9832598|NCT02620020|Experimental|Fasinumab 9 mg IV Q8W and Placebo SC Q4W|Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
9832599|NCT02620020|Experimental|Placebo SC Q4W and Placebo IV Q8W|Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.
9832600|NCT02620384|Placebo Comparator|Experimental: Placebo|This group will receive all standard heart failure therapy and placebo pill.
9832601|NCT02620384|Active Comparator|Experimental: Metolazone|This group will receive all standard heart failure therapy with addition of metolazone.
9832602|NCT02620683|Active Comparator|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
9832603|NCT02620683|Active Comparator|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
9832604|NCT02620774|Experimental|Diabetic Wound Infection|Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
9832605|NCT02620774|Active Comparator|Healthy Volunteer|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
9832606|NCT02620787|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
9835954|NCT02762799|Experimental|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
9785545|NCT01254214|Active Comparator|Support Group|The Support Group is a group intervention led by a trained facilitator and designed to match the intervention for time, attention and social support
9785546|NCT01254227|Experimental|Deferasirox|Deferoxamine combination followed by Deferasirox monotherapy
9785547|NCT01254292|Experimental|LCS12 (Skyla, BAY86-5028)|Participants received LCS12 (low dose levonorgestrel [LNG] intrauterine delivery system [IUS]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
9785548|NCT01254292|Active Comparator|EE30/DRSP (Yasmin, BAY86-5131)|Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
9785549|NCT01254305|Experimental|1|40 -120 mg/day Levomilnacipran ER capsules, oral administration
9785550|NCT01254305|Active Comparator|2|Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
9785551|NCT01254305|Placebo Comparator|3|Matching placebo capsules, oral administration
9785552|NCT01254318||Participants at high risk for IFI|Participants will be considered high risk if they are undergoing high dose chemotherapy for leukemia. This includes, but is not limited to participants with acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Participants are also considered to be at high risk for IFI if they have undergone allogeneic hematopoietic stem-cell transplantation.
9785553|NCT01254331|Experimental|Single arm|
9785554|NCT01254344|Experimental|Ertapenem sodium 1 g|Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
9785555|NCT01254344|Active Comparator|Ceftriaxone sodium 2 g|Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose
9785556|NCT01254396|Active Comparator|Sildenafil ODT tablet 50 mg, Fasted|Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
9785557|NCT01254396|Experimental|Sildenafil ODT tablet 50 mg, Fed|Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
9785558|NCT01254552|Experimental|Dotarem and Xenetix 350|
9785559|NCT01254565|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
9785560|NCT01254565|Placebo Comparator|Placebo|Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).
9785561|NCT01254604|Experimental|Tafluprost|One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
9785562|NCT01254604|Active Comparator|Timolol|One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
9785563|NCT01254630|Experimental|V212-STM|Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
9785564|NCT01254630|Experimental|V212-HM|Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
9785565|NCT01254630|Placebo Comparator|Placebo-STM|Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
9785566|NCT01254630|Placebo Comparator|Placebo-HM|Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
9785567|NCT01254643|Experimental|All Enrolled|9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
9785568|NCT01254656|Experimental|LRV 500mg|
9785569|NCT01254656|Experimental|LRV 750mg +TVD|
9785570|NCT01254656|Active Comparator|EFV|
9785571|NCT01254656|Experimental|LRV 750mg+ DRV/r + OBT|
9785572|NCT01254656|Experimental|LRV 1000mg +DRV/r + OBT|
9785573|NCT01254656|Active Comparator|ETR|
9761719|NCT00710606|Experimental|1- Obese Women /Nuvaring|Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
9761720|NCT00710606|Active Comparator|2- Normal Weight / Nuvaring|Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
9761721|NCT00710684|Experimental|DONEPEZIL + SB-742457 15 MG|SB-742457 - 15mg added to existing donepezil treatment
9761722|NCT00710684|Placebo Comparator|DONEPEZIL + PLACEBO|Placebo added to existing donepezil
9761723|NCT00710684|Experimental|DONEPEZIL + SB-742457 35 MG|SB-742457 - 35mg added to existing donepezil
9761724|NCT00710749|Experimental|Disposable device first, then Digital device|
9761725|NCT00710749|Experimental|Digital device first, then Disposable device|
9761726|NCT00710762|Experimental|BIBF1120|
9761727|NCT00710762|Placebo Comparator|Placebo|
9761728|NCT00710814|Experimental|Leptin - Placebo|Leptin self-administered subcutaneously twice each day for 16 weeks, then Placebo for 16 weeks.
9761729|NCT00710814|Placebo Comparator|Placebo - Leptin|Placebo self-administered subcutaneously twice each day for 16 weeks, then Leptin for 16 weeks.
9761730|NCT00710840|Experimental|1|
9761731|NCT00710840|Active Comparator|2|
9761732|NCT00710866|Experimental|1|2 doses 0.5mL VAXIGRIP® at months 0, 1
9761733|NCT00710866|Active Comparator|2|2 doses 0.25mL VAXIGRIP® at months 0, 1
9761734|NCT00710879|Experimental|Multipurpose Solution|Multi-purpose solution administered to adapted FDA group I soft contact lens wearers and FDA group IV soft contact lens wearers.
9761735|NCT00710905|Experimental|ReSTOR|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
9761736|NCT00710931|Experimental|ReSTOR +3 Multifocal Lens|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL)
9761737|NCT00710944|Experimental|Extraction Sockets|Immediate loading in extraction sockets.
9761738|NCT00710944|Experimental|Healed Ridges|Immediate loading in healed ridges.
9761739|NCT00710944|Experimental|Grafted Sites|Immediate loading of implants placed in grafted sites (four months healing after grafting).
9761740|NCT00710996||AcrySof Natural Intraocular Lens|"AcrySof Natural Intraocular Lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SN"
9761741|NCT00710996||AcrySof clear intraocular lens|"AcrySof clear intraocular lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SA"
9761742|NCT00710996||Phakic patients|Phakic patients - Age matched patients who have not had cataract surgery
9761743|NCT00711009|Active Comparator|LPV/r + FTC/TDF|lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily
9761744|NCT00711009|Experimental|LPV/r + RAL|lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily
9761745|NCT00711022|Experimental|OsseoSpeed|
9761746|NCT00711100|Experimental|Camel Snus|Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
9761747|NCT00711100|Experimental|Marlboro Snus|Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.
9761748|NCT00711100|Experimental|Stonewall|Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
9761749|NCT00711100|Experimental|Ariva|Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.
9761750|NCT00711100|Experimental|General Snus|General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.
9761751|NCT00711113|Experimental|A|
9761752|NCT00711191|Experimental|single arm|
9761753|NCT00711243|Experimental|Cohort 1a|Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
9761754|NCT00711243|Experimental|Cohort 2a|Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
9761755|NCT00711243|Experimental|Cohort 3a|Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
9761756|NCT00711243|Experimental|Cohort 4a|Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
9761757|NCT00711243|Experimental|Cohort 5a|Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
9761758|NCT00711347|Active Comparator|DisCoVisc|Alcon's DisCoVisc Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
9761759|NCT00711347|Active Comparator|Healon5|Abbott Medical Optic's (AMO) Healon5 Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
9761760|NCT00711412|Experimental|Induction, Combination and surgery|"Weeks 1-6:~Capecitabine 1000mg/m2 twice daily Oxaliplatin 70mg/m2 on days 1 and 8~Weeks 7-12:~Capecitabine 825 mg/m2 twice daily Oxaliplatin 50mg/m2 weekly Radiation 1.8 Gy Monday-Friday~Evaluation for response and resection surgery"
9761761|NCT00711425|Experimental|A|
9761762|NCT00711464|Experimental|100 mg|modafinil 100 milligrams oral dose
9761763|NCT00711464|Experimental|200 mg|modafinil 200 mg oral dose
9761764|NCT00711464|Experimental|400 mg|modafinil 400 mg oral dose
9761765|NCT00711464|Placebo Comparator|Placebo|Single oral placebo capsule
9761766|NCT00711477|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day
9761767|NCT00711477|Placebo Comparator|Placebo|Placebo tablets
9761768|NCT00711490|Experimental|Sirolimus|The study eye was treated with sirolimus.
9761769|NCT00711516|Experimental|1|Armodafinil treatment (200 mg/day) - Study drug was supplied as 50 mg tablets and the dose was titrated from a starting dose of 50 mg taken once daily in the morning (before 0800), increasing to 100 mg/day on Day 2, 150 mg/day on day 5, and then 200 mg/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
9761770|NCT00711516|Placebo Comparator|2|Placebo comparator - Placebo tablets matching the armodafinil 50 mg tablets drug were supplied and the dose was titrated from a starting dose of one tablet taken once daily in the morning (before 0800), increasing to two tablets/day on Day 2, three tablets/day on day 5, and then four tablets/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
9761771|NCT00711529|Experimental|Hypnotherapy|"Patients randomized to the experimental arm were scheduled for three one-hour inductions by a single hypnotherapist, each one week apart. Standardized outlines were used for each induction. The second and third sessions also began with a standardized induction, followed by the establishment of an anchor, or physical reference point (forefinger to thumb), used to invoke images of coolness, which were individualized according to patient preference.~Patients were also instructed by the same hypnotherapist in self-hypnosis and guided imagery techniques to be used at home with the assistance of standardized audio compact disks. Participation lasted eight weeks."
9761772|NCT00711529|Active Comparator|Gabapentin|Patients randomized to the gabapentin arm were prescribed 900mg of the drug daily (300 mg by mouth three times daily).
9761773|NCT00711594|Experimental|BIBW 2992 MA2|Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally. Escalating doses of BIBW 2992 starting at 20mg daily.
9761774|NCT00711594|Experimental|BIBW 2992 QD|Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
9761775|NCT00711646|Experimental|Sativex|
9761776|NCT00711646|Placebo Comparator|Placebo|
9761777|NCT00711711|Experimental|Manual lymphatic drainage|this arm will receive 5 manual lymphatic drainage treatments from day 2 to day 7 post surgery
9761778|NCT00711711|Placebo Comparator|Relaxation|This arm will receive 5 relaxation treatments from day 2 to day 7 post surgery
9761779|NCT00711802|Experimental|Daptomycin|"Administered intravenously (IV) every 24 hours for up to 14 days at the following age-dependent dosages.~Participants ages 7 to 17 years: daptomycin was dissolved in a volume of 50 milliliters (mL) 0.9% sodium chloride for injection over 30 minutes (min) with an infusion rate of 1.67 mL/min.~Participants 1 to 6 years-old: daptomycin was dissolved in a volume of 25 mL 0.9% sodium chloride for injection over 60 min with an infusion rate was 0.42 mL/min.~Age Group 1 (for ages 12 to 17 years): 5 milligrams/kilogram (mg/kg)~Age Group 2 (for ages 7 to 11 years): 7 mg/kg~Age Group 3 (for ages 2 to 6 years): 9 mg/kg~Age Group 4 (for ages 1 to <2 years): 10 mg/kg"
9761780|NCT00711802|Active Comparator|Standard of Care (SOC)|The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.
9761781|NCT00711828|Experimental|Treatment (R-CYBOR-D)|Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9761782|NCT00711867|Experimental|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
9761783|NCT00711867|Active Comparator|Bair Hugger|Arizant Bair Hugger temperature management system.
9761784|NCT00711880|Experimental|Sativex|
9761785|NCT00711880|Placebo Comparator|Placebo|
9761786|NCT00711958|Experimental|HX575 epoetin alfa Hexal AG|HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
9761787|NCT00711958|Active Comparator|ERYPO® Janssen-Cilag|ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
9761788|NCT00711971|Active Comparator|EPA-rich fish oil supplement|EPA-rich fish oil supplement
9761789|NCT00711971|Active Comparator|DHA-rich fish oil supplement|DHA-rich fish oil supplement
9761790|NCT00711971|Placebo Comparator|Soy Oil placebo|Soy oil
9761791|NCT00711997|Experimental|BC-819|Intratumoral administration of BC-819
9761792|NCT00712010|Experimental|Whey protein native|Whey protein native versus the 6 other arms
9761793|NCT00712010|Experimental|Whey protein microgels|Whey protein microgels versus the 6 other arms
9761794|NCT00712010|Experimental|Hydrolyzed whey protein|Hydrolyzed whey protein versus the 6 other arms
9761795|NCT00712010|Experimental|Casein native|Casein native versus the 6 other arms
9761796|NCT00712010|Experimental|Hydrolyzed casein|Hydrolyzed casein versus the 6 other arms
9761797|NCT00712010|Experimental|Total milk protein native|Total milk protein native versus the 6 other arms
9761798|NCT00712010|Experimental|Hydrolyzed milk protein|Hydrolyzed milk protein versus the 6 other arms
10205259|NCT03349775|Placebo Comparator|Placebo|Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
10205260|NCT03337724|Experimental|Ipatasertib + Paclitaxel|
10205261|NCT03337724|Experimental|Placebo + Paclitaxel|
10205262|NCT03329963|Experimental|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
10205263|NCT03329963|Active Comparator|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
9761799|NCT00712075|Experimental|CBSST+PDA|PDA-Assisted Cognitive-Behavioral Social Skills Training (CBSST+PDA): The CBSST rehabilitation intervention will be combined with the use of a PDA to facilitate homework completion and progress towards recovery goal attainment in consumers.
9761800|NCT00712075|Active Comparator|CBSST|Cognitive Behavioral Social Skills Training (CBSST): CBSST is a psychosocial rehabilitation intervention that combines skills from cognitive behavioral therapy and social skills training to assist consumers in improving functioning and recovery goal attainment.
9761801|NCT00712075|Active Comparator|PDA-Only|PDA-only: To control of device contact, the PDA-only arm will not receive CBSST and will only carry a PDA with access to the basic features of the device.
9761802|NCT00712166|Placebo Comparator|Placebo three times daily (TID)|
9761803|NCT00712166|Experimental|AZLI 75 mg three times daily (TID)|
9761804|NCT00712179||Stroke Survivors|Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.
9761805|NCT00712244|Active Comparator|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.
9761806|NCT00712244|Active Comparator|DuoVisc|Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.
9761807|NCT00712244|Active Comparator|Healon5|Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.
9761808|NCT00712244|Active Comparator|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.
9761809|NCT00712270|No Intervention|Standard of Care|Screening and Baseline Procedures followed by Referral to Community Care. Baseline Procedures may be repeated at a later time if appropriate.
9761810|NCT00712270|Active Comparator|Drug: Aripiprazole|Screening and Baseline Procedures followed by 16 weeks of treatment with aripiprazole, followed by repeat of baseline procedures and referral to community care.
9761811|NCT00712270|Active Comparator|Risperidone|Screening and Baseline Procedures followed by 16 weeks of treatment with Risperidone,followed by repeat of baseline procedures and referral to community care.
9761812|NCT00712296|Experimental|ASHMI 4|ASHMI 4 capsules twice a day
9761813|NCT00712296|Experimental|ASHMI 12|ASHMI 12 capsules twice a day
9761814|NCT00712296|Placebo Comparator|Placebo|Placebo 6 capsules twice a day
9761815|NCT00712335|Experimental|1|"Asthmatic smokers treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
9761816|NCT00712335|Experimental|2|"Asthmatic smoker treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
9761817|NCT00712335|Active Comparator|3|"Non-smoking asthmatics treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
9761818|NCT00712335|Active Comparator|4|"Non-smoking asthmatic treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
9761819|NCT00712335|No Intervention|5|Normal controls
9761820|NCT00712348|Experimental|Taliglucerase alfa|Open label taliglucerase alfa treatment
9761821|NCT00712530|Experimental|1|"Single low-dose DermaVir immunization~0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir~Administered topically with DermaPrep under two skin patches (0.4 mL/patch)"
9761822|NCT00712530|Experimental|2|"Single medium-dose DermaVir immunization~0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir~Administered topically with DermaPrep under four skin patches (0.8 mL/patch)"
9761823|NCT00712530|Experimental|3|"Single high-dose DermaVir immunization~0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir~Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)"
9761824|NCT00712543|Experimental|1|Kristalose®, as prescribed, for 7 days.
9761825|NCT00712543|Experimental|2|Liquid lactulose, as prescribed, for 7 days.
9761826|NCT00712673|Experimental|Lixisenatide (Morning Injection)|2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
9761827|NCT00712673|Experimental|Lixisenatide (Evening Injection)|2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
9761828|NCT00712673|Placebo Comparator|Placebo (Morning Injection)|2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
9761829|NCT00712673|Placebo Comparator|Placebo (Evening Injection)|2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
9761830|NCT00712712|Experimental|Patient who has undergone radiofrequency ablation of bone metastases|Patient who has undergone radiofrequency ablation of bone metastases, localized, causing pain refractory to radiotherapy or not accessible to new irradiation, biphosphonates and well-conducted morphine analgesic treatment.
9761831|NCT00712725|Experimental|1|MK3207- 2.5 mg
9761832|NCT00712725|Experimental|2|MK3207- 5 mg
9761833|NCT00712725|Experimental|3|MK3207- 10 mg
9761834|NCT00712725|Experimental|4|MK3207- 20 mg
9761835|NCT00712725|Experimental|5|MK3207- 50 mg
9761836|NCT00712725|Experimental|6|MK3207- 100 mg
9761837|NCT00712725|Placebo Comparator|7|Placebo
9761838|NCT00712920|Placebo Comparator|1|Placebo
9761839|NCT00712920|Experimental|2|0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
9761840|NCT00712920|Experimental|3|0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks
9761841|NCT00712959|Experimental|Group 1: Previous Tdap or Tdap-IPV Recipients|Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
9832607|NCT02620787|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
9832608|NCT02620878|Experimental|AP|"Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.~Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence"
9832609|NCT02620878|Active Comparator|SAP|"Active Comparator: Sensor Augmented Pump (SAP teraphy : CGM + insulin pump) will be used for 72 hours during day and night (3 days).~Patients will be randomly assigned to receive either 3 days of SAP (Control) followed by 3 days of automated closed-loop insulin delivery (intervention), or the inverted sequence"
9832610|NCT02620904|Active Comparator|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
9832611|NCT02620904|Placebo Comparator|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
9832612|NCT02621034|Experimental|Control|K-file hand instrumentation
9832613|NCT02621034|Experimental|Reciproc|rotary reciprocating protocol
9832614|NCT02621034|Experimental|One shape|one shape continuous rotation protocol
9832615|NCT02621047|Experimental|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
9832616|NCT02621047|Experimental|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
9832617|NCT02621047|Experimental|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
9832618|NCT02621060|Placebo Comparator|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
9832619|NCT02621060|Experimental|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
9832620|NCT02621073|Active Comparator|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
9832621|NCT02621073|Active Comparator|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
9832622|NCT02621463|Experimental|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
9832623|NCT02621606|Experimental|Part 1, Healthy Participants|Healthy participants receive a single intravenous (IV) dose of ~370 megabecquerel (MBq) [11C]MK-6884 in Part 1 of the study.
10202931|NCT03810313|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
10202932|NCT03810313|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
10202933|NCT03808051|Experimental|Physiological-based cord clamping|Stabilisation of the infant is performed while the cord is intact and the cord will be clamped after the infant is cardiopulmonary stable. Stable is defined as the establishment of heart rate greater than 100 bpm and oxygen saturation above 85% while using supplemental oxygen lower than 40%. The maximum cord clamping time is 10 minutes and prior to cord clamping a trial of weaning from PPV to CPAP is performed. With the exception that the infant is stabilised close to the mother and the cord is clamped later, the infant will receive standard resuscitation interventions.
10202934|NCT03808051|Active Comparator|Time-based cord clamping|Infants are clamped first and then moved to the standard resuscitation table for further treatment and intervention needed for cardiopulmonary stabilisation. Clamping is time based and performed immediately or delayed at 30-60 seconds, depending on the clinical condition of the infant. Uterotonic drugs are administered immediately after cord clamping.
9832624|NCT02621606|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants receive two separate IV doses of ~370 MBq [11C]MK-6884 in Part 2 of the study. Administration of the two doses is separated by at least 3 hours.
9832625|NCT02621606|Experimental|Part 3, Participants with AD|Participants with AD receive a single IV dose of ~370 MBq [11C]MK-6884 in Part 3 of the study.
9832626|NCT02621619|Experimental|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
9832627|NCT02621619|Placebo Comparator|Normal saline + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
9832628|NCT02621892|Experimental|50mg BID|Tenapanor
9832629|NCT02621892|Placebo Comparator|Placebo|Placebo
9832630|NCT02621931|Placebo Comparator|Placebo|Matching Placebo
9835955|NCT02762799|Experimental|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
10202935|NCT03807973|Experimental|Fibromyalgia|
9761842|NCT00712959|Active Comparator|Group 2: Tdap vaccine-naïve|Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
9761843|NCT00712959|No Intervention|Group 3|Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study
9761844|NCT00712985|Experimental|Zometa (Zoledronic Acid) X 1 dose|Zometa (Zoledronic Acid) 5 mg IV X 1 dose
9761845|NCT00713219|Experimental|1|CHEMORADIATION
9761846|NCT00713284|Other|Study|All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus. There is no comparotor arm
9761847|NCT00713310|Experimental|Low-Dose|1.2 - 2.4 g/day Asacol dependent on body weight
9761848|NCT00713310|Experimental|High-Dose|2.0 - 4.8 g/day Asacol dependent on body weight
9761849|NCT00713323|Experimental|Sativex|Active treatment
9761850|NCT00713349|Other|1|Xenaderm Vehicle
9761851|NCT00713349|Placebo Comparator|2|Placebo Comparator
9761852|NCT00713427|Other|WallFlex Stent|All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted.
9761853|NCT00713479|Placebo Comparator|Sugar pill|Sugar pill (placebo) drug dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
9761854|NCT00713479|Active Comparator|Varenicline|Varenicline dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
9761855|NCT00713544|Active Comparator|1|
9761856|NCT00713544|Experimental|2|20mg
9761857|NCT00713544|Experimental|3|50mg
9761858|NCT00713544|Experimental|4|100mg
9761859|NCT00713544|Experimental|5|150mg
9761860|NCT00713544|Placebo Comparator|6|
9761861|NCT00713583|Experimental|Levodopa pharmacotherapy|Levodopa pharmacotherapy (800mg levodopa and 200mg carbidopa per day), cognitive behavioral therapy (CBT), and contingency management (CM).
9761862|NCT00713583|Placebo Comparator|Placebo|Placebo, cognitive behavioral therapy (CBT), and contingency management (CM).
9761863|NCT00713609|Experimental|1|Benzoyl peroxide/clindamycin gel + tazarotene cream
9761864|NCT00713609|Active Comparator|2|Benzoyl peroxide/clindamycin gel + vehicle cream
9761865|NCT00713609|Active Comparator|3|Benzoyl peroxide gel + tazarotene cream
9761866|NCT00713609|Active Comparator|4|Clindamycin gel + tazarotene cream
9761867|NCT00713609|Active Comparator|5|Vehicle gel+ tazarotene cream
9761868|NCT00713609|Placebo Comparator|6|Vehicle gel + vehicle cream
9761869|NCT00713648|Experimental|rFXIII|
9761870|NCT00713661|Experimental|TachoSil®|
9761871|NCT00713700|Experimental|Device|
9761872|NCT00713817|Experimental|Sativex|
9761873|NCT00713817|Placebo Comparator|Placebo|
9761874|NCT00713830|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9761875|NCT00713830|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9761876|NCT00714051|Experimental|Fall Prevention Training|The falls prevention training group participated in four weekly training sessions on a custom-built treadmill that produced trip-simulating perturbations (movements). While harnessed overhead to prevent actual falls, the treadmill stopped or moved suddenly. The goal for the participant was to try and prevent a fall. Each week, the level of difficulty of the task was increased.
9761877|NCT00714051|Active Comparator|Attention Control|The attention control group participated in four weekly treadmill walking sessions at a self-selected speed.
9761878|NCT00714168|Active Comparator|1|Participants will take part in a standard behavioral weight loss program.
9761879|NCT00714168|Experimental|2|Participants will take part in a stepped-care weight loss program.
9761880|NCT00714233|Experimental|1|Metformin
9761881|NCT00714233|Experimental|2|Oral Contraceptive Pills
9761882|NCT00714233|Active Comparator|3|lifestyle modification program
9761883|NCT00714233|Placebo Comparator|4|placebo to active metformin arm
9761884|NCT00714259|Other|Non Myeloablative Treatment|"Non-myeloablative Transplant Conditioning Chemotherapy :~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight."
9761885|NCT00714272|Experimental|A|Granulocytapheresis treatment
9761886|NCT00714272|Placebo Comparator|B|Sham device treatment
9761887|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
9761888|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
9761889|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
9785574|NCT01254669|No Intervention|control, standard of care|Mothers assigned to the Control Group received the low-literacy, standard-practice, HPV-vaccine information sheet
9761890|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
9761891|NCT00714311|Active Comparator|TFP|Transference-Focused Psychotherapy
9761892|NCT00714311|Active Comparator|ECP|treatment by experienced community psychotherapists
9761893|NCT00714415||A|Patients with Hemophilia B
9761894|NCT00714493|Other|001|Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
9761895|NCT00714571|Active Comparator|MST healthy older adults Stage 1|Mnemonic strategy training
9761896|NCT00714571|Active Comparator|MST MCI Stage 1|Exposure training
9761897|NCT00714571|Active Comparator|XP healthy older adults Stage 1|XP healthy older adults Stage 1
9761898|NCT00714571|Active Comparator|XP MCI Stage 1|XP MCI Stage 1
9761899|NCT00714571|Active Comparator|MST healthy older adults Stage 2|MST healthy older adults Stage 2
9761900|NCT00714571|Active Comparator|SCT healthy older adults Stage 2|SCT healthy older adults Stage 2
9761901|NCT00714688|Experimental|001|prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
9761902|NCT00714688|Experimental|002|prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
9761903|NCT00714688|Placebo Comparator|003|Placebo 2xplacebo once daily for 13 weeks
9761904|NCT00714714|Experimental|Tretinoin and Adapalene gels|Adapalene facial gel and tretinoin facial gel applied daily for two weeks on opposite sides of the face (in a split-face model)
9761905|NCT00714753|Experimental|Intervention Group|Protocol treatment consists of either two high dose-rate (HDR) brachytherapy implantation sessions or one HDR brachytherapy session followed by external beam radiotherapy (EBRT). Each HDR session consists of two 9.5Gy fractions. After the first HDR session of two fractions, patients express a preference for: (1) a second HDR brachytherapy implantation session, or (2) EBRT. The second HDR session or EBRT will begin 2-4 weeks after the first HDR brachytherapy session.
9761906|NCT00714792||1|Subjects with urge incontinence due to overactive bladder
9761907|NCT00714792||2|women with no urge symptoms
9761908|NCT00714870|Other|1|intervention: this group will attend the nutrition and exercise program control group: this group will not attend the nutrition and exercise program
9761909|NCT00715026|Other|Trilogy AB Acetabular Hip Implant System|Post Approval Study of Device.
9761910|NCT00715078|Active Comparator|Cohort A|Sipuleucel-T with the concentration of 10 μg/mL PA2024 in a cell suspension of 1 x 10^7 peripheral blood mononuclear cells (PBMCs) per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
9761911|NCT00715078|Active Comparator|Cohort B|Sipuleucel-T with the concentration of 5 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
9761912|NCT00715078|Active Comparator|Cohort C|Sipuleucel-T with the concentration of 2 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
9761913|NCT00715104|Experimental|Sipuleucel-T with Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
9761914|NCT00715104|Experimental|Sipuleucel-T without Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.
9761915|NCT00715117|Placebo Comparator|Sugar pill|Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
9761916|NCT00715117|Experimental|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.
9761917|NCT00715208|Experimental|VELCADE R-CAP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
9761918|NCT00715208|Experimental|VELCADE R-CP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
9761919|NCT00715299|Other|Locomotor Training Group|persons who have sustained a stroke within greater than 6 months ago and less than 5 years.
9761920|NCT00715390||1-Children receiving anesthesia|The sample of patients screened will be the entire electronic anesthesia record database from 1998 until 2004 looking for subjects that have dysrhythmias.
9761921|NCT00715429|Experimental|vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks|Vitamin D arm
9761922|NCT00715429|Placebo Comparator|placebo x 10d, + placebo weekly 7 wks|placebo
10202936|NCT03807973|Experimental|Chronic Fatigue Syndrome|
10202937|NCT03807973|Experimental|Multiple Sclerosis|
10202938|NCT03807973|Experimental|Healthy Controls|
10202939|NCT03806335|Experimental|Infiltration|Patients will receive pre-incision infiltration of 2.5 ml local anesthesia mixture in each tonsil.
10202940|NCT03806335|Placebo Comparator|Placebo|Patients will receive pre-incision infiltration of 2.5 ml saline in each tonsil.
10202941|NCT03802630|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
10202942|NCT03802630|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
10202943|NCT03796156|Experimental|Aspirin|75mg of non enteric coated or dispersible aspirin once daily added to usual medications
10202944|NCT03796156|No Intervention|Usual care|Usual medications only
9832631|NCT02621931|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to the fremanezumab 675 mg/placebo/placebo treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
9832632|NCT02621931|Experimental|Fremanezumab 675/225/225 mg|Participants randomized to the fremanezumab 675/225/225 mg treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0 and 225 mg of fremanezumab as 1 active injection (225 mg/1.5 mL) on Days 28 and 56.
9832633|NCT02621983|Active Comparator|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
9832634|NCT02621983|Active Comparator|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
9832635|NCT02622074|Experimental|Cohort A: KNp / KAC|Participants receive pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via intravenous (IV) infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
9832636|NCT02622074|Experimental|Cohort B: KNpCb (Regimen 1) / KAC|Participants first receive KNpCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
9832637|NCT02622074|Experimental|Cohort C: KNpCb (Regimen 2) / KAC|Participants first receive KNpCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
9832638|NCT02622074|Experimental|Cohort D: KNpCb (Regimen 3) / KAC|Participants first receive KNpCb Regimen 3 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
9832639|NCT02622074|Experimental|Cohort E: KTCb (Regimen 1) / KAC|Participants first receive KTCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
9832640|NCT02622074|Experimental|Cohort F: KTCb (Regimen 2) / KAC|Participants first receive KTCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
9832641|NCT02622113|Experimental|Canagliflozin (TA-7284) ＋insulin|
9761923|NCT00715520|Experimental|Aim 1|Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.
9761924|NCT00715520|Experimental|Aim 2|Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.
9761925|NCT00715520|Experimental|Aim 3|Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.
9761926|NCT00715559|Experimental|cysteamine bitartrate|Participants received cysteamine bitartrate by mouth up to 300 mg three times daily.
9761927|NCT00715624|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9761928|NCT00715624|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9761929|NCT00715650|Experimental|Arm 1|This counseling consists of four sessions each approximately 60 minutes each. The four sessions are organized as follows: a) Orientation to Benefits Counseling: Your Benefits and Your Goals b) Work and Claims c) Financial Review: Implications of Your Work Plan and d) Your Plans After the Benefits Notice. The first session focuses on the disability application process as a non-confrontational way to explore attitudes towards work. The second session more directly addresses the claimant's attitudes about work and beliefs about whether work will prevent receipt of disability benefits. The third session addresses the same issue as the second, ambivalence about work and disability, from a financial perspective. The fourth session occurs after the disability determination has been made, and it is possible the veteran may feel differently about a benefit that has been awarded.
9761930|NCT00715650|Active Comparator|Arm 2|This will consist of four-session orientation with the sessions organized as follows: a) overview of VHA services, b) Primary Care c) Pharmacy and laboratory services and d) specialty services. After the description of each service, participants will be invited to discuss which services they plan to utilize. The counselor will provide telephone numbers and directions to the sites at which these services are provided.
9761931|NCT00715676|Placebo Comparator|Group 1|
9761932|NCT00715676|Experimental|Group 2|220 ng
9761933|NCT00715676|Experimental|Group 3|440 ng
9761934|NCT00715728||1: Bair Hugger|Intraoperative warming with Bair Hugger forced air system
9761935|NCT00715728||2: Hot Dog|Intraoperative warming with Hot Dog resistive heating system
9761936|NCT00715741|Active Comparator|1|Group 1 will receive 30% oxygen plus PEEP + 3 to 5 cm Water duration of anesthesia and surgery
9761937|NCT00715741|Active Comparator|2|Group 2 will receive 30% oxygen without PEEP for the duration of anesthesia and surgery
9761938|NCT00715741|Active Comparator|3|Group 3 will receive > 90% oxygen plus PEEP + 3 to 5 cm of water for the duration of anesthesia and surgery
9761939|NCT00715741|Active Comparator|4|Group 4 will receive > 90% oxygen and no PEEP for the duration of anesthesia and surgery
9783621|NCT01206062|Experimental|Intensive Control of SBP|"Participants randomized into the Intensive BP arm will have a goal of SBP <120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP <120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal."
9783622|NCT01206062|Active Comparator|Standard Control of SBP|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP <130 mm Hg @ 1 visit; <135 mm Hg @ 2 consecutive visits
9783623|NCT01206140|Experimental|Arm I (selumetinib and temsirolimus)|Patients receive selumetinib PO twice daily on days 1-28 and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22.
9783624|NCT01206140|Experimental|Arm II (selumetinib)|Patients receive selumetinib as in arm I. Patients who experience disease progression may cross over to arm I.
10202945|NCT03794427|Experimental|unilateral lumbosacral nerve block|Sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
10202946|NCT03794427|Active Comparator|Spinal anesthesia|spinal anesthesia will be performed
10202947|NCT03793842|Experimental|Usual care then PEEP titration by EIT|Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan ARDS protocol high-PEEP arm
10202948|NCT03793842|Experimental|PEEP titration by EIT then usual care|Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.
10202949|NCT03785665|Experimental|Participants|All study participants will be examined by the MD1 capsules, 2-5 capsules per person, one capsule at a time. Efforts will be made to maintain balanced numbers between men and women and even distribution of ages
10202950|NCT03782467|Experimental|ATOR-1015|ATOR-1015 administered by intravenous infusions every 2 weeks until confirmed progressive disease, unacceptable toxicity or withdrawal of consent.
10202951|NCT03781778|Experimental|Group I (resistant starch foods)|Patients eat a diet consisting of resistant starch foods daily for 8 weeks.
10202952|NCT03781778|Active Comparator|Group II (foods with regular corn starch)|Patients eat a diet consisting of regular corn starch foods daily for 8 weeks.
10202953|NCT03779126|Experimental|Active comparator|Low frequency electrical stimulation for 60 minutes, three times a week during 60 days.
10202954|NCT03779126|Experimental|Other|High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
10202955|NCT03779126|Experimental|Experimental group|Low and High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
10202956|NCT03779126|Placebo Comparator|Placebo|Placebo electrical stimulation for 60 minutes, three times a week during 60 days. In the intervention groups will be used highest intensity tolerated by the individual, and in the sham will be maintained the minimum intensity after beginning of the perception of the electric current
9832642|NCT02622178|Experimental|Healthy Subjects|42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
9832643|NCT02622178|Experimental|Glaucoma Suspects|45 Glaucoma suspects with glaucomatous appearance optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
9832644|NCT02622178|Experimental|Glaucoma Patients|49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
9832645|NCT02622191|Experimental|Open-angle glaucoma|Participants with primary open-angle glaucoma and an abnormal visual field defect in one eye. Spectral domain Optical Coherence Tomography will be obtained from the effected eye and fellow eye of each glaucoma patient.
9832646|NCT02622191|Experimental|Healthy Controls|Participants without glaucoma and no other eye diseases. Spectral domain Optical Coherence Tomography will be obtained from eyes of each healthy control.
9832647|NCT02622321|Experimental|Arm A: 1.5 mg/kg Emicizumab QW|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
9832648|NCT02622321|Active Comparator|Arm B (Control): No Prophylaxis, Then Emicizumab|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
9832649|NCT02622321|Experimental|Arm C: 1.5 mg/kg Emicizumab QW|Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
9832650|NCT02622321|Experimental|Arm D: 1.5 mg/kg Emicizumab QW|Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
10202957|NCT03770676|Experimental|Flavour 1|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 1. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
10202958|NCT03770676|Experimental|Flavour 2|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 2. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits biscuit for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
10202959|NCT03770676|Experimental|Flavour 3|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 3. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
10202960|NCT03770455|Experimental|Avelumab + 2nd generation ADT|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
10202961|NCT03764735|Placebo Comparator|SkQ1 Vehicle|SkQ1 (Vehicle)
10202962|NCT03764735|Active Comparator|Low Dose - SkQ1|Low-dose ophthalmic solution
10202963|NCT03764735|Active Comparator|High Dose - SkQ1|High-dose ophthalmic solution
9761940|NCT00715793|Experimental|Single Arm|
9761941|NCT00715884|Experimental|1|CYPHER® ELITE™ Sirolimus-Eluting Stent System.
9761942|NCT00715884|Active Comparator|2|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
9761943|NCT00715910|Experimental|Nimenrix 1 Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
9761944|NCT00715910|Active Comparator|Menactra Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
10202964|NCT03764514||Spinal Cord Stimulator - Permanent Implantation|
10202965|NCT03763240|Active Comparator|BSE|Sulforaphane-containing broccoli sprout extract (BSE). The study product is BSE with standardized amounts of sulforaphane. BSE contains a mixture of maltodextrin as a bulking agent and copper chlorophyllin (E 141) as a food additive. BSE is a dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane.
10202966|NCT03763240|Placebo Comparator|Placebo|A mixture of maltodextrin and copper chlorophyllin will be used as placebo. The active compound and the placebo are the same except BSE. The placebo will look similar to the BSE-containing mixture.
10202967|NCT03762447|Experimental|INCB086550|
9761945|NCT00715910|Experimental|Nimenrix 2 Group|Subjects 10<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
9761946|NCT00715910|Experimental|Nimenrix Naive Group|Subjects 15 to <31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
9832651|NCT02622568|Active Comparator|Cryotherapy and Veregen|Cryotherapy will be performed on the day of first clinic visit according to current standard of care in Children's Medical Center pediatric outpatient dermatology clinic, which consists of two freeze/thaw cycles for maximum of 10 seconds each. Sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Sinecathecins 15% ointment will be applied to verrucous lesions twice daily. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
9832652|NCT02622568|Experimental|Veregen only|Veregen ™or sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Veregen ™ or sinecathecins 15% ointment will be applied to verrucous lesions twice daily per current Children's Medical Center protocol. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
9835956|NCT02762799|Experimental|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
9835957|NCT02762799|Experimental|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
9835958|NCT02762877||A|Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib)
9835959|NCT02762877||B|Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
9835960|NCT02762994|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
9835961|NCT02762994|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
9835962|NCT02762994|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
9835963|NCT02762994|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
9835964|NCT02763046|Experimental|Secukinumab - delayed NSAID tapering|"Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (delayed tapering)."
9835965|NCT02763046|Experimental|Secukinumab - early NSAID tapering|"Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (early tapering)."
9835966|NCT02763046|Placebo Comparator|Placebo|"Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20).~NSAID tapering allowed from Week 4."
9835967|NCT02763124|Experimental|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions.
9835968|NCT02763215||Total|
9835969|NCT02763254|Experimental|baltaleucel-T|Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
9835970|NCT02763566|Experimental|Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)|Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
9835971|NCT02763566|Experimental|Placebo + NSAI|Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
9835972|NCT02763566|Experimental|Abemaciclib + Fulvestrant|Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
9835973|NCT02763566|Experimental|Placebo + Fulvestrant|Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
10202968|NCT03760458|Experimental|Weight Band #1 (6 to less than 10 kg)|Children weighing 6 to less than 10 kg will receive 3 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
10202969|NCT03760458|Experimental|Weight Band #2 (10 to less than 14 kg)|Children weighing 10 to less than 14 kg will receive 4 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
10202970|NCT03760458|Experimental|Weight Band #3 (14 to less than 20 kg)|Children weighing 14 to less than 20 kg will receive 5 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
10202971|NCT03760458|Experimental|Weight Band #4 (20 to less than 25 kg)|Children weighing 20 to less than 25 kg will receive 6 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
10202972|NCT03760458|Experimental|Weight Band #5 (25 kg or greater)|Children weighing 25 kg or greater will receive 1 immediate release tablet of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
10202973|NCT03752866|Experimental|Portico™ Valve, Delivery System(s) and Loading Systems(s)|Implantation of the Portico ™ Valve using the Portico Delivery and Loading Systems
10202974|NCT03752866|Experimental|Portico™ Valve, FlexNav Delivery and Loading System(s)|Implantation of the Portico ™ Valve using the FlexNav Delivery and Loading Systems
10202975|NCT03743064|Experimental|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
10202976|NCT03743064|Placebo Comparator|Placebo|Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
10202977|NCT03743051|Experimental|100mg Anamorelin HCl|
10202978|NCT03743051|Placebo Comparator|placebo|
9761947|NCT00715910|Experimental|Nimenrix Pooled Group|Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
9761948|NCT00715910|Active Comparator|Menactra Booster Group|Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.
9761949|NCT00715949||Mild Traumatic Brain Injury (MTBI) admits|admitted pediatric patients with mild traumatic brain injury (concussion)
9761950|NCT00715962|Active Comparator|Mobility Group|The Walking Intervention includes assistance to walk twice daily with or without a rolling walker. In addition, a behavioral intervention that included goal setting and discussion of how to overcome mobility barriers was used to encourage the mobility group to be more active throughout hospital stay. Participants will keep a diary of out of bed activity and will be encouraged to set goals for additional out of bed activity daily.
9761951|NCT00715962|Placebo Comparator|Control Group|The control group will receive twice daily friendly visits to counter the attention being paid to the intervention group. They will complete a diary but of visitors to their room.
9761952|NCT00716079|Other|Intensive BP lowering|Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
9761953|NCT00716079|Other|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the American Heart Association (AHA) in 2007 and 2010. The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
9761954|NCT00716092|Placebo Comparator|Placebo|Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
9761955|NCT00716092|Experimental|Linagliptin|Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
9761956|NCT00716092|Active Comparator|Sitagliptin|Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
9761957|NCT00716144|Active Comparator|A|Talarozole 0.5 mg
9761958|NCT00716144|Active Comparator|B|Talarozole 1.0 mg
9761959|NCT00716144|Active Comparator|C|Talarozole 2.0 mg
9761960|NCT00716144|Placebo Comparator|D|Talarozole matching Placebo
9761961|NCT00716274|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
9761962|NCT00716274|Placebo Comparator|Placebo|Placebo will be packaged in the same way as active comparator to enforce double-blind study design
9761963|NCT00716417|Experimental|A. BIBW 2992-cisplatin-paclitaxel|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
9761964|NCT00716417|Experimental|B. BIBW 2992-cisplatin-5FU|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
9761965|NCT00716443|Active Comparator|Pliaglis® Cream|tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
9761966|NCT00716443|Active Comparator|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
9761967|NCT00716456|Experimental|1|In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
9761968|NCT00716586|Experimental|Trusopt (2% dorzolamide)|Intent to treat population. All participants assigned to Trusopt (2% dorzolamide)
9761969|NCT00716625||sunitinib malate|Patients taking sunitinib malate
9761970|NCT00716742||1|bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
9761971|NCT00716820||SUNITINIB MALATE|Patients taking Sutent.
9761972|NCT00716859|Active Comparator|Timolol|
9761973|NCT00716859|Experimental|latanoprost|
9761974|NCT00716963|Active Comparator|1|Fluticasone propionate (Flovent Diskus) 250 mcg
9761975|NCT00716963|Active Comparator|2|budesonide 400mcg
9761976|NCT00716963|Placebo Comparator|3|placebo
9761977|NCT00716976|Experimental|STS Arm (sodium thiosulfate treatment)|Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.
9761978|NCT00716976|Experimental|Observation Arm (No sodium thiosulfate treatment)|Patients do not receive sodium thiosulfate.
9761979|NCT00717041||Presenting to the ED|Patients who present to the ED
9832653|NCT02622724|Experimental|FP-1201-lyo 10 μg|"FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
9832654|NCT02622724|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection."
9832655|NCT02623218|Experimental|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
9832656|NCT02623218|Sham Comparator|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
9832657|NCT02623218|Active Comparator|C-ACUP|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
9832658|NCT02623218|Sham Comparator|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
9832659|NCT02623218|Active Comparator|C-EX|This group of participants without TBI will receive one acupuncture treatment following 30-60 minutes of aerobic exercise, and serve as a healthy control group.
9832660|NCT02623322|Experimental|MHAA4549A 3600 milligrams (mg)|Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.
9832661|NCT02623322|Experimental|MHAA4549A 8400 mg|Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.
9832662|NCT02623322|Placebo Comparator|Placebo|Participants will receive single-dose placebo by IV administration.
9832663|NCT02623335|Experimental|QPL (question prompt list) brochure|Patients were mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
9832664|NCT02623335|No Intervention|Usual care|The investigators observed that usual care included informed consent and a surgeon-directed deliberative phase in which surgeons presented their own evaluation of the trade-offs and goals of the proposed intervention.
9832665|NCT02623348|Experimental|pedometer|Patients will be given pedometers and instructions to increase physical activity based on pedometer output
9832666|NCT02623348|No Intervention|usual care|No intervention
9832667|NCT02623361|Placebo Comparator|Sham|
9832668|NCT02623361|Active Comparator|Fascia Iliaca Compartment Block|
9832669|NCT02623803|Active Comparator|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
9832670|NCT02623803|Placebo Comparator|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
9832671|NCT02623829|Experimental|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
9832672|NCT02623829|Sham Comparator|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
9832673|NCT02623855|Active Comparator|Park prescription|Park prescription, pedometry.
9832674|NCT02623855|Experimental|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
9832675|NCT02624050|Active Comparator|Methohexital|Methohexital will be administered intravenously as a general anesthetic at a dosage of 1.5mg per kg of patient body weight.
9832676|NCT02624050|Active Comparator|Propofol|Propofol will be administered intravenously as a general anesthetic at a dosage of 2.5mg per kg of patient body weight.
9832677|NCT02624180|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth
9832678|NCT02624180|Placebo Comparator|Placebo|Placebo for colchicine 1 tablet by mouth daily
9761980|NCT00717054|Active Comparator|Aprepitant and Scopolamine group|Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a difference in incidence of events.
9761981|NCT00717054|Placebo Comparator|Aprepitant and Scopolamine Placebo Group|Patients receiving aprepitant and placebo scopolamine for prevention of postoperative nausea and vomiting then followed through the post operative period looking for signs of nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine looking for a difference in incidence of events.
9761982|NCT00717067|Experimental|Healthy Subjects|Subjects with Normal Renal Function (Creatinine Clearance > 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir
9761983|NCT00717067|Experimental|Mild Renal Impairment|Subjects with Mild Renal Impairment (Creatinine Clearance >50 and ≤80 mL/min)
9761984|NCT00717067|Experimental|Moderate Renal Impairment|Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)
9761985|NCT00717067|Experimental|Severe Renal Impairment|Subjects with Severe Renal Impairment (Creatinine Clearance <30 mL/min)
9761986|NCT00717067|Experimental|ESRD on Hemodialysis|Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance <30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis
9761987|NCT00717093|Experimental|Active|
9761988|NCT00717093|Placebo Comparator|Placebo|
9761989|NCT00717197|Experimental|Capecitabine|Capecitabine (1,000-1,250 mg/m2) taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
9761990|NCT00717236|Experimental|Certolizumab pegol (CZP)|
9761991|NCT00717236|Placebo Comparator|Placebo|
9761992|NCT00717249|Experimental|Test Lens|galyfilcon A contact lens with a silver additive
9761993|NCT00717249|Active Comparator|Control Lens|galyfilcon A control contact lens
9761994|NCT00717288|Active Comparator|1|Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily
9761995|NCT00717288|Active Comparator|2|Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily
9761996|NCT00717288|Active Comparator|3|Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily
9761997|NCT00717314|Experimental|MMF, 50% CNI Reduction|Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52.
9761998|NCT00717314|Experimental|MMF, ≥75% CNI Reduction|Participants received MMF, 1.5 to 2.0 g daily, PO, BID from BL to Week 52. Participants also received a 75% reduced dose of CNI from BL to Week 52.
9761999|NCT00717366|Experimental|MIRCERA Group 1: Intermediate-Conversion-Factor Group|Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 * previous weekly epoetin dose [international units {IU}]/250 or 4 * previous weekly darbepoetin alfa dose [micrograms {mcg}]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
10202979|NCT03739996|Experimental|CAB LA + VRC07-523LS|"Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.~Step 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.~VRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.~Step 3: SOC oral ART regimen for approximately 48 weeks."
10202980|NCT03730480|Experimental|Subjects with and without Diabetes test Contour Next and Contour TV3|All subjects test CONTOUR NEXT BGMS and CONTOUR TV3 BGMS
9783625|NCT01206166|Experimental|Enteral Nutrition + Parenteral Nutrition|Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
9783626|NCT01206166|No Intervention|Enteral Nutrition Only|Enteral nutrition only - no intervention
10202981|NCT03729648|Experimental|Intervention|This arm of participants will be receiving Expressive Arts Therapy as intervention
10202982|NCT03729648|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a wait-list control group
10202983|NCT03726476|Experimental|Patient Centered pre-op education|Patient centered pre-operative education and patient centered post-operative care.
10202984|NCT03726476|Active Comparator|Routine Pre-op education|Participants will receive routine pre-operative education and post-op will receive a standardized number of narcotics
10202985|NCT03726359|Experimental|Fractionated Stereotactic Radiation Therapy|This study is unique in that it employs a continuous reassessment methodology (CRM) to determine the Maximum Tolerated Dose. Information for the proper dose level for each subsequent patient enrolled will be determined based on DLTs from previous patients enrolled in the trial.
10202986|NCT03716726|Experimental|Intervention-WE CARE|"The WE CARE SDoH Screening Survey will be given at all visits by the front desk staff to all parents of Sickle Cell Anemia patients who present to the pediatric hematology clinic. They will also be provided the Family Resource Book.~Clinical team members (i.e. medical assistants and providers) will be trained to review the WE CARE Social Determinants of Health survey at visits and to provide community resource information sheets to parents with needs. The completed surveys will be scanned into the electronic health record."
10202987|NCT03716726|Experimental|Control-Standard of Care|Standard of care for pediatric patients with sickle cell anemia will be delivered.
10202988|NCT03713073|Experimental|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
10202989|NCT03713073|Active Comparator|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
10205264|NCT03329131|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
10205265|NCT03292471|Experimental|Inhibitory only|Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).
10205266|NCT03292471|Experimental|Excitatory primed|The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).
10205267|NCT03263078|Experimental|TIVA with Propofol in free flap surgery|Total intravenous anesthesia(TIVA) with Propofol
10205268|NCT03263078|Active Comparator|Sevoflurane in free flap surgery|Inhalation anesthesia with Sevoflurane
9783627|NCT01206322|Experimental|Insulin vs. placebo|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
9783628|NCT01206322|Other|Healthy vs. Diabetic|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
9783629|NCT01206387|Experimental|active product|Desoximetasone Spray 0.25%
9783630|NCT01206387|Placebo Comparator|placebo comparator|vehicle
9783631|NCT01206452|Experimental|Ablation plus prednisone|Participants undergo ablation procedure and receive predinisone at protocol determined times.
9783632|NCT01206452|Placebo Comparator|Ablation plus placebo|Participants undergo ablation procedure and receive placebo at protocol determined times.
9783633|NCT01206465|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9783634|NCT01206478|Experimental|Amitriptyline plus Megestrol|Amitriptyline once daily at bedtime plus megestrol starting at visit 2
9783635|NCT01206478|Active Comparator|Placebo plus Megestrol|Matching placebo once daily at bedtime plus megestrol starting at visit 2
9783636|NCT01206582|Active Comparator|Hemin|Panhematin®, Ovation Pharmaceuticals, Deerfield, Illinois (IL). Hemin was diluted in 25% albumin to obtain a concentration of 2.4 mg/mL and administered at a dose of 1.25 mL/Kg and at a rate of 60 mL/hour. 10 iv infusions for 8 weeks
9783637|NCT01206582|Placebo Comparator|Albumin|10 iv infusions for 8 weeks
9783638|NCT01206595|Active Comparator|SKY0402|Low-dose (175 mg), low-mid dose( 225 mg), and mid-dose (350 mg)
9783639|NCT01206595|Active Comparator|Bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
9783640|NCT01206608|Active Comparator|Low-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
9783641|NCT01206608|Active Comparator|Mid-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
9783642|NCT01206660|Experimental|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
9783643|NCT01206660|Placebo Comparator|placebo|Placebo administered to affected area twice a day for 28 days
9783644|NCT01206738|Experimental|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
9783645|NCT01206738|Experimental|Alternative intervention|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
9783646|NCT01206738|Active Comparator|General information|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
9783647|NCT01206764|Experimental|RAD001|
9783648|NCT01206777|Experimental|Rituximab|
9783649|NCT01206816|Experimental|two experimental arms|patients receive increasing doses of BI 6727 in combination with increasing doses of BIBW 2992
9783650|NCT01207219|Experimental|Yoga therapy|Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
9783651|NCT01207219|Experimental|Aerobic exercise|Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
9783652|NCT01207219|No Intervention|Waitlist group|Patients in waiting list will be treated as usual and acted as control group.
9783653|NCT01207388|Experimental|Blinatumomab|Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
9783654|NCT01207401|Experimental|Paracervical Block|
9783655|NCT01207401|No Intervention|No Paracervical Block|
9783656|NCT01207414|Experimental|iloperidone gradual switch|"Participants taking risperidone, olanzapine or aripiprazole gradually decreased the dose they were taking: 50% of original dose on Day 1, 25% of original dose after the first week and the total discontinuation of the drug after the second week.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
9783657|NCT01207414|Experimental|iloperidone immediate switch|"Participants taking risperidone, olanzapine or aripiprazole discontinued the drug immediately.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
9762000|NCT00717366|Experimental|MIRCERA Group 2: High-Conversion-Factor Group|Participants will receive MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 * previous weekly epoetin dose [IU]/125 or 4 * previous weekly darbepoetin alfa dose [mcg]/0.55) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with Hb within ± 1 g/dL of their baseline Hb and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
9762001|NCT00717405|Experimental|1|
9762002|NCT00717418||1|"cyclosporine ophthalmic emulsion 0.05%~artificial tears"
9762003|NCT00717522|Experimental|Pomalidomide|7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
9762004|NCT00717574|Active Comparator|Sevoflurane group|Sevoflurane based general anesthesia
9762005|NCT00717574|Active Comparator|Propofol group|Propofol based general anesthesia
9762006|NCT00717626|Experimental|Daily administration of low dose FVIII|Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)
9762007|NCT00717756|Experimental|Lenalidomide|
9762008|NCT00717769|Experimental|SUN13834|
9762009|NCT00717769|Placebo Comparator|Placebo|
9762010|NCT00717860|Experimental|Caspofungin|caspofungin acetate (MK0991)
9762011|NCT00717860|Active Comparator|Micafungin|Micafungin sodium
9762012|NCT00717873|Experimental|HFCWO Arm|Airway clearance provided by the Vest Airway Clearance System
9762013|NCT00717873|No Intervention|CPT Arm|Airway clearance provided by manual CPT
9762014|NCT00717886|Experimental|1|Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity approximately 3 hours before surgery.
9762015|NCT00717912|Experimental|Arm 1|Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup
9762016|NCT00717912|Experimental|Arm 2|Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup
9762017|NCT00717912|Experimental|Arm 3|Experimental sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup / Experimental sweetener syrup
9762018|NCT00717912|Experimental|Arm 4|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup
9762019|NCT00717912|Experimental|Arm 5|Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup
9762020|NCT00717912|Experimental|Arm 6|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup
9762021|NCT00718042|Experimental|1|All subjects will have their blood tested by the investigational Chagas screening assay.
9762022|NCT00718042|Experimental|2|Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.
9762023|NCT00718081|Experimental|1|Oral Sufentanil
9762024|NCT00718081|Experimental|2|Oral sufentanil
9762025|NCT00718081|Placebo Comparator|3|Oral dosage of placebo
9762026|NCT00718094|Experimental|Polyphenon E treatment|Polyphenon E® therapy was given for 56 days.
9762027|NCT00718094|Placebo Comparator|Placebo|Oral Placebo
9762028|NCT00718120|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years received a single dose of Fluviral® vaccine.
9762029|NCT00718120|Experimental|Fluviral Elderly Group|Subjects aged more than 60 years received a single dose of Fluviral® vaccine.
9762030|NCT00718159|Experimental|LY573636|
9762031|NCT00718237|Experimental|1|RotaTeq™
9762032|NCT00718237|Placebo Comparator|2|Placebo
9762033|NCT00718302|Experimental|Randomized treatment; antiglide plate|Randomized treatment; antiglide plate
9762034|NCT00718302|Experimental|Randomized treatment; lateral plate|Randomized treatment; lateral plate
9762035|NCT00718315|Experimental|1|
9762036|NCT00718315|Experimental|2|
9762037|NCT00718315|Experimental|3|
9762038|NCT00718328|Experimental|I|Simvastatin Group
9762039|NCT00718328|Placebo Comparator|II|Placebo Group
9762040|NCT00718419|Experimental|A: Enzastaurin|
9762041|NCT00718510|Active Comparator|L-arginine first/placebo second|Patients with diagnosis of schizophrenia will be randomised to receive L-arginine first/placebo second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
9832679|NCT02624284|Sham Comparator|Sham dose|Participants in this arm will receive the sham transcranial direct current stimulation (tDCS) procedure. During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
9832680|NCT02624284|Experimental|1mA dose|Participants in this arm will receive the 1mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
9832681|NCT02624284|Experimental|2 mA dose|Participants in this arm will receive the 2 mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
9832682|NCT02624375|Experimental|10 persons over 70 years of age that received Zostavax|10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
9832683|NCT02624492|Experimental|BI 836826-GemOx|
9832684|NCT02624492|Active Comparator|R-GemOx|
9832685|NCT02624687|Active Comparator|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
9832686|NCT02624687|Placebo Comparator|Control|These subjects will receive no intervention.
9832687|NCT02624700|Experimental|A: Pemetrexed + Sorafenib|Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle
9832688|NCT02624700|Experimental|B: Pemetrexed + Sorafenib|Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.
9832689|NCT02624713|Other|Retrospective Random Controlled Research|"In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the Maccabi Active program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch."
9832690|NCT02624713|Other|The Prospective study|The Prospective study had only an intervention group (obesity treatment). Forty-two families took part in this study, with 78 children: 48 overweight children and 30 siblings . The parameters were measured in three different times. Before the program (time 1), at the end of the program (after 6 months - time 2) and 8 months after completing the program (time 3).
9832691|NCT02624791|Experimental|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
9832692|NCT02624791|Experimental|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
9832693|NCT02624791|Experimental|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
9832694|NCT02624791|Experimental|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
9832695|NCT02624791|Experimental|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
9832696|NCT02624791|Experimental|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
9832697|NCT02624843|Experimental|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
9832698|NCT02624843|Active Comparator|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
9762042|NCT00718510|Placebo Comparator|Placebo first/L-arginine second|Patients with diagnosis of schizophrenia will be randomised to receive placebo first/L-arginine second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
9762043|NCT00718523|Placebo Comparator|A|Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
9762044|NCT00718523|Experimental|B|AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
9762045|NCT00718549|Experimental|Induction: Rituximab, Cladribine, Cyclophosphamide|Participants will receive rituximab at a dose of 375 milligrams per meter squared (mg/m^2) as intravenous (IV) infusion on Day 1, cladribine at a dose of 0.12 milligrams per kilogram per day (mg/kg/day) as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 in Cycle 1. Then, rituximab at a dose of 500 mg/m^2 as IV infusion on Day 1, cladribine at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 will be administered in Cycles 2-6. Each cycle will be of 28 days in duration.
9762046|NCT00718549|Experimental|Maintenance Arm: Rituximab|Participants with PR or CR after induction phase who will be randomized to maintenance arm will receive rituximab treatment for 8 cycles. Twelve weeks after the last induction cycle, participants will receive rituximab at a dose of 375 mg/m^2 as IV infusion on Day 1 of each 12-week cycle until disease progression (up to approximately 96 weeks).
9762047|NCT00718549|No Intervention|Observation Arm: No Intervention|Participants with PR or CR after induction phase who will be randomized to observation arm will not receive any intervention. Participants will be assessed every 4-weeks for the first 12 weeks and every 12-weeks afterwards up to 96 weeks.
9762048|NCT00718666|Experimental|Group A|Subjects who were previously vaccinated with one dose of GSK134612 at 12 months of age.
9762049|NCT00718666|Experimental|Group B|Subjects who were previously vaccinated with two doses of GSK134612, one each at 9 and 12 months of age.
9762050|NCT00718666|Experimental|Group C|Subjects aged 5-6 years not previously administered meningococcal vaccine.
9762051|NCT00718718|Experimental|Part A, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
9762052|NCT00718718|Experimental|Part A, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
9762053|NCT00718718|Experimental|Part B, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
9762054|NCT00718718|Experimental|Part B, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
9762055|NCT00718718|Experimental|Part B, Group 3|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
9762056|NCT00718718|Experimental|Part B, Group 4|Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
9762057|NCT00718718|Experimental|Part B, Group 5|Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
9762058|NCT00718770|Experimental|Bexarotene|Open label - all patients receive intervention
9762059|NCT00718809|Experimental|Arm I|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9762060|NCT00718861|Placebo Comparator|Placebo|Matching placebo administered intravenously.
9762061|NCT00718861|Experimental|Zoledronic acid|
9762062|NCT00718887|Experimental|Entecavir, 0.5 mg QD|
9762063|NCT00718887|Other|Adefovir, 10 mg QD/Entecavir, 0.5 mg QD|Control
9762064|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F1-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 1 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
9762065|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F2-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
9783658|NCT01207427|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally twice daily (BID) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
9762066|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F3-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 3 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 3 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
9762067|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F1-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) vaccine formulation 1 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
9762068|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F4-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 4 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 4 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
9762069|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F2-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
9762070|NCT00719043|Placebo Comparator|Naïve Placebo-A/turkey Influenza (H5N1)-F3-Group|Healthy subjects aged 18 years of age or older at the time of vaccination received one dose of placebo (phosphate buffered saline, PBS) at Day 0 followed by two doses of A/turkey H5N1 vaccine formulation 3, one dose administered at Day 182 and the other at Day 549. Placebo vaccine and one dose of A/turkey H5N1 vaccine (Day 549) was administered intramuscularly in the deltoid region of the non-dominant arm while the other dose of A/turkey H5N1 vaccine (Day 182) was administered intramuscularly in the deltoid region of the dominant arm.
9762071|NCT00719134|Experimental|1|Maxalt administration at onset of migraine
9762072|NCT00719134|Placebo Comparator|2|
9762073|NCT00719134|Experimental|3|
9762074|NCT00719134|Placebo Comparator|4|
9762075|NCT00719134|Experimental|5|
9762076|NCT00719134|Experimental|6|
9762077|NCT00719160|Placebo Comparator|Esomeprazole|
9762078|NCT00719160|Active Comparator|Placebo|
9762079|NCT00719186|Active Comparator|A|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
9762080|NCT00719186|Active Comparator|B|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
9762081|NCT00719212|Experimental|AMG 479|AMG 479 administered on day 1 of each 21-day cycle up to disease progression, unacceptable toxicity, withdrawal of consent or sponsor decision to stop the study.
9762082|NCT00719264|Experimental|bevacizumab, RAD001 (everolimus)|Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks
9762083|NCT00719264|Active Comparator|bevacizumab, interferon alfa-2a (IFN)|Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks
9762084|NCT00719329|Experimental|A|Chlorhexidine cleansing of the cord for seven days
9762085|NCT00719329|Experimental|B|Chlorhexidine cleansing of the cord for 1 day
9762086|NCT00719329|Placebo Comparator|C|Dry cord care, as recommended by WHO
9762087|NCT00719355|Experimental|Walking with Poles|Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
9762088|NCT00719355|Active Comparator|Traditional walking program|Patients were assigned to a 24 week traditional walking program.
9762089|NCT00719472|Experimental|Rituximab 375 mg/m^2|Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
9762090|NCT00719537|Placebo Comparator|Aspirin plus Placebo Oral Tablet|Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
9762091|NCT00719537|Active Comparator|Aspirin plus Progesterone|Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day
9762092|NCT00719563|Experimental|Arm I|Patients receive oral American ginseng twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
9762093|NCT00719563|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
9762094|NCT00719576|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
9762095|NCT00719576|Active Comparator|Microfracture|Microfracture
9762096|NCT00719615||Thyroid Cancer in Remission Group|Thyroid Cancer-Remission Group & use of Vitamin D
9762097|NCT00719615||Thyroid Cancer with Active Disease Group|Thyroid Cancer-Active Group & use of Vitamin D
9762098|NCT00719615||Thyroid nodule group (no cancer) & Vit D|Thyroid nodule group without cancer and use of Vitamin D
9762099|NCT00719680|Experimental|IgPro20|The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)
9762100|NCT00719706|Active Comparator|1|1000-3000mg/day of acetyl-l-carnitine PLUS 600-1800mg/day of alpha-lipoic acid
9762101|NCT00719706|Placebo Comparator|2|
9762102|NCT00719732|Experimental|ReSTOR Aspheric +3|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
9762103|NCT00719810|Experimental|1|
9762104|NCT00719810|Experimental|2|
9762105|NCT00719810|Active Comparator|3|
9762106|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI|"Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy."
9762107|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI/ATG|Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
9762108|NCT00719862|Placebo Comparator|Placebo Nasal Spray|0mg Placebo Nasal Spray
9762109|NCT00719862|Active Comparator|0.15% azelastine hydrochloride nasal spray|0.15% azelastine hydrochloride
9762110|NCT00719901|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9762111|NCT00720057|Experimental|Naproxen sodium ER (BAYH6689)|single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
9762112|NCT00720057|Placebo Comparator|Placebo|Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
9762113|NCT00720096|Experimental|Liposomal Doxorubicin|Liposomal Doxorubicin - Chemotherapy single agent systemic.
9762114|NCT00720096|Experimental|Topotecan|Topotecan - Chemotherapy single agent systemic.
9762115|NCT00720109|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|See Detailed Description
9762116|NCT00720122|Experimental|Anorexia Nervosa Females|
9762117|NCT00720213|Active Comparator|Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3|Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
9762118|NCT00720213|Experimental|Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2|Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.
9762119|NCT00720226|Experimental|Losartan|Losartan 100 mg daily
9762120|NCT00720226|Placebo Comparator|Placebo|Placebo 1 pill daily
9762121|NCT00720278|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray
9762122|NCT00720278|Experimental|Astepro 0.1%|0.1% azelastine hydrochloride nasal spray
9762123|NCT00720278|Experimental|Astepro 0.15%|0.15% azelastine hydrochloride nasal spray
9832699|NCT02624843|Placebo Comparator|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
9832700|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
9832701|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
9832702|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
9832703|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).
9832704|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).
9832705|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
9832706|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
9832707|NCT02624986|Experimental|FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
9832708|NCT02625181|Experimental|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
9832709|NCT02625207|Experimental|Cohort 1|African-Americans with No CYP3A5*1 alleles (poor metabolizer)
9832710|NCT02625207|Experimental|Cohort 2|African-Americans with One CYP3A5*1 allele (intermediate metabolizer)
9832711|NCT02625207|Experimental|Cohort 3|African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)
9832712|NCT02625207|Experimental|Cohort 4|Caucasians with No CYP3A5*1 alleles (poor metabolizer)
9832713|NCT02625220|Experimental|Prototype toric lens senofilcon A|Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.
9832714|NCT02625233|Experimental|senofilcon C|Vistakon Investigational Contact Lens (Test)
9832715|NCT02625233|Active Comparator|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
9832716|NCT02625259|Experimental|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
9832717|NCT02625259|Experimental|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
9832718|NCT02625259|Experimental|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
9762124|NCT00720330|Active Comparator|Ropivacaine|Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
9762125|NCT00720330|Active Comparator|Lidocaine/ketamine|Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
9762126|NCT00720330|Placebo Comparator|Placebo|General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery
9762127|NCT00720356|Experimental|Treatment|erlotinib and bevacizumab
9762128|NCT00720369|Experimental|CoEnzyme Q10|Open Label Study
9762129|NCT00720369|No Intervention|Healthy Controls|Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.
9762130|NCT00720382|Experimental|1|0.15% azelastine hydrochloride 1644 mcg
9762131|NCT00720382|Experimental|2|Mometasone furoate 200 mcg
9762132|NCT00720434|Experimental|A|500 mg BID
9762133|NCT00720434|Experimental|B|300 mg BID
9762134|NCT00720434|Experimental|C|200 mg BID
9762135|NCT00720434|Placebo Comparator|D|Placebo
9762136|NCT00720473|Other|A: Other|Open Label Study
9762137|NCT00720473|No Intervention|B: Healthy Controls|
9762138|NCT00720499|Experimental|BI 1744 CL low dose+tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
9762139|NCT00720499|Experimental|BI 1744 CL medium dose+tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
9762140|NCT00720629|Experimental|First Study Stage: Study Treatment|Visilizumab, Tacrolimus and Methotrexate.
9762141|NCT00720629|Active Comparator|Second Study Stage: Standard Treatment|Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
9762142|NCT00720759|Experimental|Arm 1|D-cycloserine + distributed treatment
9762143|NCT00720759|Sham Comparator|Arm 2|D-cycloserine + condensed treatment
9762144|NCT00720759|Placebo Comparator|Arm 3|Placebo + distributed treatment
9762145|NCT00720759|Placebo Comparator|Arm 4|Placebo + condensed treatment
9762146|NCT00720798|Experimental|Tocilizumab|Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
9783659|NCT01207427|Experimental|ADL5945 0.1 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.1-milligrams (mg) ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
9783660|NCT01207427|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-mg ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
9783661|NCT01207440|Experimental|Cohort A: CP-CML R-I|CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
9783662|NCT01207440|Experimental|Cohort B: CP-CML with T315I Mutation|CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
9783663|NCT01207440|Experimental|Cohort C: Accelerated Phase (AP)-CML R-I|AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
9783664|NCT01207440|Experimental|Cohort D: AP-CML with T315I Mutation|AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
9783665|NCT01207440|Experimental|Cohort E: Blast Phase (BP)-CML/Ph+ ALL R-I|BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
9783666|NCT01207440|Experimental|Cohort F: BP-CML or Ph+ ALL with T315I Mutation|BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
9762147|NCT00720876|Experimental|Vorinostat and Rituximab|Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
9762148|NCT00720941|Active Comparator|Sunitinib|Control arm
9762149|NCT00720941|Experimental|Pazopanib|Experimental arm
9762150|NCT00721110|Active Comparator|Lidocaine|Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
9762151|NCT00721110|Placebo Comparator|Placebo|A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
9762152|NCT00721110|Active Comparator|Ketamine|Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
9762153|NCT00721110|Active Comparator|ketamine + Lidocaine|both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.
9762154|NCT00721123|Experimental|Tocilizumab 8 mg/kg|All participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.
9762155|NCT00721136|Experimental|1|Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
9762156|NCT00721136|Active Comparator|2|Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
9762157|NCT00721136|Experimental|3|High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
9762158|NCT00721136|Active Comparator|4|"High risk patients randomized to holding coumadin for 4-5 days and using bridging anticoagulation with heparin while the coumadin is held."
9762159|NCT00721149|Experimental|NaviStar ThermoCool|
9762160|NCT00721162|Experimental|Ramucirumab|
9762161|NCT00721175|Experimental|SEMS|self-expandable metal stent group
9762162|NCT00721175|Active Comparator|PS|plastic stent group
9762163|NCT00721188|Experimental|Pharmacokinetic Population|All subjects who received study drug and completed Pharmacokinetic testing through 24 hours post-dose.
9762164|NCT00721214|Experimental|Arm A: 5-azacytidine|5-azacytidine as pre-transplant cytoreduction prior to allogeneic stem cell transplantation for High Risk Myelodysplatic Syndromes.
9762165|NCT00721227|Active Comparator|Anterior Curve|Reduction Gastroplasty by Gastric Plication on Anterior Curve
9762166|NCT00721227|Active Comparator|Greater Curve|Reduction Gastroplasty by Gastric Plication on Greater Curve
9762167|NCT00721253|Active Comparator|ReSTOR Aspheric +4|ACRYSOF ReSTOR Aspheric +4 Model SN6AD3
9762168|NCT00721253|Active Comparator|Tecnis MF|Abbott Medical Optics Tecnis Multifocal Intraocular Lens (IOL) Model ZM900
9762169|NCT00721253|Active Comparator|Acri.LISA|Meditec Acri.LISA Intraocular Lens (IOL) Model 366D
9762170|NCT00721357||Stroke|Stroke subjects
9762171|NCT00721357||Control|neurologically healthy subjects
9762172|NCT00721396|Experimental|B+R246|Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
9762173|NCT00721396|Experimental|B246_R357|Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
9762174|NCT00721396|Experimental|B+R234|Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
9762175|NCT00721396|Active Comparator|R234|Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.
9762176|NCT00721409|Experimental|Arm A|letrozole + PD 0332991
9762177|NCT00721409|Active Comparator|Arm B|letrozole
9762178|NCT00721500|Experimental|narafilcon A / etafilcon A - etafilcon A - narafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.
9762179|NCT00721500|Experimental|narafilcon A / etafilcon A - narafilcon A - etafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.
9762180|NCT00721500|Experimental|narafilcon A - etafilcon A - narafilcon A / etafilcon A|First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
9762181|NCT00721500|Experimental|etafilcon A - narafilcon A - narafilcon A / etafilcon A|First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
9762182|NCT00721513|Experimental|TPFChemotherapy + Concomitant Cetuximab & RT|Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab & Radiation Therapy
9762183|NCT00721539|Other|Transoral Robotic Surgery|Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
9762184|NCT00721578||1|
9762185|NCT00721617|Active Comparator|Obese subjects|Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
9762186|NCT00721617|Active Comparator|Lean subjects|Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
9762187|NCT00721630|Experimental|1|The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.
9517990|NCT03301064|Active Comparator|Control Condition: Alcohol education brochure|Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
9762188|NCT00721734|Experimental|Carfilzomib|"Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.~If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles."
9762189|NCT00721799|Experimental|FLT PET scan|"Subjects receive 2 18F-Fluorothymidine PET scans~Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)~Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)"
9762190|NCT00721955|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, may repeat after 2 hours x 2
9762191|NCT00721955|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
9762192|NCT00721955|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
9762193|NCT00721968|Active Comparator|1|Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
9762194|NCT00721968|Placebo Comparator|2|Control Group (Group 2): Cataract surgery only
9762195|NCT00722007|Experimental|Cormet Hip Resurfacing Post-PMA Group|hip resurfacing
9762196|NCT00722020|Experimental|Vest Arm|HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
9762197|NCT00722020|No Intervention|Control|Historical control for PICU asthma patients
9762198|NCT00722072|Experimental|Fulvestrant/ Sorafenib|"Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:~500 mg IM on Day 1~250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.~Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs."
9762199|NCT00722111|Experimental|Arm 1|lingual press (high-intensity, oral, non-swallowing)
9762200|NCT00722111|Experimental|Arm 2|effortful swallowing (high-intensity swallowing)
9762201|NCT00722111|Experimental|Arm 3|natural swallowing (high frequency, low intensity swallowing)
9762202|NCT00722111|Sham Comparator|Arm 4|non-oral sham (control) exercise
9762203|NCT00722124|Active Comparator|SAMe 800|Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
9762204|NCT00722124|Active Comparator|SAMe 1600|Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
9762205|NCT00722124|Placebo Comparator|Placebo|Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
9762206|NCT00722137|Active Comparator|R-CHOP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, Vincristine 1.4 mg/m^2, and Prednisone 100 mg/m^2
9762207|NCT00722137|Experimental|VcR-CAP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, and Prednisone 100 mg/m^2
9762208|NCT00722371|Experimental|Sitagliptin 100 mg|
9762209|NCT00722371|Experimental|Pioglitazone 15 mg|
9762210|NCT00722371|Experimental|Pioglitazone 30 mg|
9762211|NCT00722371|Experimental|Pioglitazone 45 mg|
9762212|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 15 mg|
9762213|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 30 mg|
9762214|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 45 mg|
9762215|NCT00722423|Experimental|Integrated Care Model|Integrated Care
9762216|NCT00722423|Experimental|Usual Care Model|Usual Care
9762217|NCT00722436|Experimental|Tranexamic acid|Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous
9762218|NCT00722436|Placebo Comparator|Placebo|Saline was administered intravenously
9762219|NCT00722553|Other|Dietary Supplement Vitamin B12 & Folic Acid (Vitamin B9)|"Vitamin B12 : 1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.~Folic Acid: 1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
9762220|NCT00722566|Experimental|1|VELCADE administered by subcutaneous injection
9762221|NCT00722566|Active Comparator|2|VELCADE administered by intravenous infusion
9762222|NCT00722722|Active Comparator|4 dose group|4 doses of bortezomib (1.3mg/m^2 of body surface area)
9762223|NCT00722722|Active Comparator|16 dose group|16 doses of bortezomib (1.3mg/m^2 of body surface area)
9517991|NCT03301025|Active Comparator|Pregabalin group|(n=53):
9762224|NCT00722722|Active Comparator|32 dose group|32 doses of bortezomib (1.3mg/m^2 of body surface area)
9762225|NCT00722761|Active Comparator|Drosperinone and Ethinyl estradiol|Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day
9762226|NCT00722761|Placebo Comparator|Placebo tablet|Placebo tablet once a day
9762227|NCT00722800|Experimental|A|drospirenone and ethinyl estradiol
9762228|NCT00722800|Placebo Comparator|B|Placebo
9762229|NCT00722865|Other|Avastin (Bevacizumab)|single-arm, open-label
9762230|NCT00723008|Experimental|A|Upon randomization, a double blinded Alpha Stim 100 device preset to the lowest effective setting (1/6) will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
9762231|NCT00723008|Experimental|B|Upon randomization, a double blinded Alpha Stim 100 device preset to no stimulation (0/6)will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
9762232|NCT00723021|Experimental|PF-04191834 30mg|
9762233|NCT00723021|Experimental|PF-04191834 100mg|
9762234|NCT00723021|Experimental|PF-04191834 2000mg|
9762235|NCT00723021|Active Comparator|zileuton|
9762236|NCT00723021|Placebo Comparator|placebo|
9762237|NCT00723073||Caspofungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an Absolute Neutrophil Count (ANC) < 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.
9762238|NCT00723073||Micafungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an Absolute Neutrophil Count (ANC) < 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent
9762239|NCT00723099|Experimental|Treatment (chemotherapy, transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.~IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96."
9762240|NCT00723125|Experimental|Cohort 1|"Avastin 10 mg/kg IV over 90 minutes day -14~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10~Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
9762241|NCT00723125|Experimental|Cohort 2|"Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks"
9762242|NCT00723177|Placebo Comparator|Placebo|This group will receive placebo drug
9762243|NCT00723177|Experimental|Low-dose AV411|This group will receive a low dose of AV411
9762244|NCT00723177|Experimental|High-dose AV411|This group will receive a high dose of AV411
9762245|NCT00723190|Experimental|Arm A|CLONICEL (Clonidine HCl sustained release)
9517992|NCT03301025|Placebo Comparator|placebo group|(n=53):
9762246|NCT00723203|Experimental|Treatment (panobinostat)|"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle"
9762247|NCT00723229|Active Comparator|1|
9762248|NCT00723229|No Intervention|2|
9762249|NCT00723255|Experimental|Treatment (bevacizumab, temsirolimus)|Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
9762250|NCT00723294|Experimental|Treatment (cryoablation)|A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
9762251|NCT00723398|No Intervention|Group 1: Control|Control, no intervention
9762252|NCT00723398|Experimental|Group 2: Raloxifene 60 Mg Oral Tablet|Raloxifene 60 mg Orally Daily
9762253|NCT00723398|Experimental|Group 3: Raloxifene 30 Mg Oral Tablet|Raloxifene 30 mg Orally Daily
9762254|NCT00723398|Experimental|Group 4: Lovaza 4 gm oral|Lovaza 4 gm/day Orally with Meals
9762255|NCT00723398|Experimental|Group 5: Lovaza 4gm & Raloxifene 30mg|Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily
9762256|NCT00723450|Placebo Comparator|placebo|Placebo Controlled
9762257|NCT00723450|Experimental|lamictal|Flexible Dosing
9762258|NCT00723489|Experimental|YFV-17D (Right Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
9984195|NCT04314284|Experimental|I Can PIC|-Approximately 80-100 participants will use I Can PIC. This will take approximately 10-15 minutes. After their next appointment with their provider, they will complete a brief survey about their knowledge of health insurance and confidence communicating about care costs. This will take about 10 mins. Patient participants who choose to complete the study in person may view I Can PIC on a tablet provided in the clinic or at the office. Then after their appointment, they can complete the survey on a tablet provided in the clinic or at the office. If they choose to complete it over the phone, the investigators will email them the link to I Can PIC and then call them when it is time to complete the survey. If they wish to complete it online, the investigators will email them the link to I Can PIC, and then the survey after their appointment. After 3-6 months, participants will receive a 5-10 minute follow-up survey which they can complete in-person, online, or over the phone.
9762259|NCT00723489|Experimental|YFV-17D (Left Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccination. In this arm, participants will receive YFV-17D vaccination (1x10^3 Plaque Forming Units) by transcutaneous administration (then covered with a semi-occlusive dressing to optimize YFV-17D absorption) in the left deltoid and placebo by subcutaneous administration in the right deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administered treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
9762260|NCT00723528|Placebo Comparator|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
9762261|NCT00723528|Active Comparator|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
9762262|NCT00723528|Active Comparator|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
9762263|NCT00723528|Placebo Comparator|Placebo A (After CP)|After the controlled period (that is [i.e.], during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
9762264|NCT00723528|Placebo Comparator|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
9762265|NCT00723528|Active Comparator|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
9762266|NCT00723528|Active Comparator|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
9762267|NCT00723554|Experimental|Iloprost|"The study enrolled patients who were already using iloprost with PD-6 without any safety or tolerability concerns, thereby facilitating a direct comparison of the PD-15 to the PD-6.~The single-arm design allowed each patient to serve as his/her own control"
9762268|NCT00723580|Experimental|Sleep and Activity by Treatment Condition|Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.
9762269|NCT00723606|Experimental|Intramuscular ziprasidone|
9762270|NCT00723606|Active Comparator|Intramuscular haloperidol|
9762271|NCT00723632||Peginterferon alfa-2b and ribavirin|All participants included in the study
9762272|NCT00723645||PEG IFN alfa-2b + RBV|Adult participants with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response prior to the study. Participants received no treatment during this study.
9762273|NCT00723697||Patients|Patients addicted to opiates and requiring replacement treatment. Patients in this non-interventional study were prescribed treatment as per usual clinical practice.
9832719|NCT02625259|Experimental|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
9832720|NCT02625259|Experimental|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
10202990|NCT03713034|Experimental|Active Game|"PlayTest! is an interactive world in which the player, using an avatar they have created, travels through life in high school. They face challenges that bring different risks and benefits, requiring them to practice decision-making skills. The player learns skills that aim to empower them to make safe choices in situations that may otherwise increase their risk for HIV/STI infection. The game also provides opportunities for the player to practice advocating for their health by modeling a conversation with a medical professional. PlayTest! incorporates evidence-based tools for behavior change including social learning theory and self-efficacy. message framing, motivational interviewing to identify the variables that must be targeted to increase HTC among adolescents."
9832721|NCT02625298|Experimental|ProRoot MTA|Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
9832722|NCT02625298|Experimental|MTA+ Cercamed|Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment
9832723|NCT02625324|Experimental|Endovascular repair|Valiant Evo Thoracic Stent Graft System
9832724|NCT02625402|Experimental|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
9832725|NCT02625402|Experimental|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
9832726|NCT02625428|Experimental|For Cause|For cause biopsies to evaluate a recent rise in serum creatinine.
9832727|NCT02625428|Experimental|Surveillance|Surveillance biopsies done after transplant mostly looking for subclinical rejection.
9832728|NCT02625545|Experimental|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
9832729|NCT02625571|Experimental|Intervention|
9832730|NCT02625610|Experimental|Chemotherapy + Best Supportive Care (BSC)|In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.
9984196|NCT04311437|Experimental|Self-acupressure group|The subjects in experimental group will undergo additional self-acupressure therapy in addition to Valsalva and Toynbee maneuvers before the first HBOT. The acupoints used are TE17 (Yifeng, 翳風), TE21 (Ermen, 耳門), SI19 (Tinggong, 聽宮), GB2 (Tinghui, 聽會).
9984197|NCT04311437|Placebo Comparator|Control group|The subjects in control group will receive Valsalva and Toynbee maneuvers alone.
10202991|NCT03713034|Active Comparator|Control Game|Some examples of control games that participants could play are: The Sims, Harry Potter, Subway Surfer, Tetris. The control games contained not relevant content related to HIV Testing and Counseling.
9984198|NCT04310956|Experimental|Y-Knot group|Patients use Y-Knot all-suture anchor
10202992|NCT03696446|Experimental|Virtual Cardiac Rehabilitation Program|This group will receive access to the NWC (NexJ Connected Wellness TM (NCW) and will be provided with a fitness tracker (Garmin Vivofit 3) to monitor their exercise, sedentary behaviours, and sleep patterns. The NWC platform includes components for education (health library, workbooks etc), collaboration (personal care plan, appointment scheduler, secure messaging system etc), and motivation (motivational messages on their homepage etc). With the Health Coach, participants will engage in: reviews of their risk factor profile and health priorities; goal setting and action planning; problem solving and skill building; and discussions of relapse prevention. Participants will receive a total of seven hours of health coaching delivered across nine sessions over a 26-week period
10202993|NCT03696446|Other|Case Managed Home Program|The Case Managed Home Program (CMHP) is delivered primarily via telephone. Following their CR intake, patients are linked with their CMHP Health Coach and attends their visit (in person or over the phone) which includes a comprehensive review of their health history, current symptoms, medications, activity, and individual concerns. Following this visit, participants will receive a total of 10 individualized telephone calls over a 26 week period. The program action plan is individually formulated based on the participant's goals and learning needs. Participants are provided with educational kits (exercise, nutrition, stress management or prevention) that are based on the principle of single point learning and incorporate behavioural change techniques.
10202994|NCT03689712|Experimental|GC4419|
10202995|NCT03689712|Placebo Comparator|Placebo|
10202996|NCT03688672|Other|Apioc Lens|All subjects will wear the same, Apioc Contact Lens design.
10202997|NCT03654404|Experimental|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
10202998|NCT03653143|Experimental|Treatment Group|Assessment #1 Baseline Visit >> 3 month JASPER intervention (weekly) >> Assessment #2 Research Visit >> 3 month treatment as usual >> Assessment #3 Research Visit
10202999|NCT03653143|Experimental|Control/Wait-list Group|Assessment #1 Baseline Visit >> 3 month treatment as usual >> Assessment #2 Research Visit >> 3 month JASPER intervention >> Assessment #3 Research Visit
9984199|NCT04310956|Active Comparator|Biocomposite suture anchor|Patients use Biocomposite suture anchor
9984200|NCT04310592|Experimental|Dose escalation/MTD or MPD determination in MRD positive AML patients|Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
9984201|NCT04310592|Experimental|Dose escalation/MTD or MPD determination in Relapsed/Refractory AML patients|Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
9984202|NCT04309513|Active Comparator|Step Counter to motivate physical activity|Participants will be encouraged to work up to achieving at least 10,000 steps a day, higher if possible and reasonable, as measured by a wearable device.
10203000|NCT03642808|Experimental|rehabilitation program|"Duration of 8 weeks for a cycle of rehabilitation at the rate of two half-days per week~Two interventions per half-day: 30 minutes of education and 1h30 of rehabilitation: physiotherapist, psychomotricity, adapted physical activity"
10203001|NCT03642782|Experimental|early age of glaucoma or with important risk factors|All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
10203002|NCT03636581|Experimental|Intervention|This group will receive a smart watch to track activity and diet. This group will also receive education on nutrition and exercise.
10203003|NCT03636581|No Intervention|Control|This group will receive a smart watch to track activity only with no intervention.
10203004|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
10203005|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center [NCT01748994] will serve as a comparator (control) group.
10203006|NCT03631446||Patients administered Picoprep® for bowel cleansing|Patients administered Sodium Picosulfate, Magnesium Oxide and Citric Acid for bowel cleansing
10203007|NCT03630640|Experimental|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
10203008|NCT03629119|Experimental|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet.
10203009|NCT03627351||Healthy Women and Men|Group of healthy women and men
10203010|NCT03625388|Other|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
10203011|NCT03625388|Other|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
10203012|NCT03621397|Experimental|Cognitive Intervention Group|Research participants in the cognitive intervention group will undergo a baseline neuropsychological evaluation. One week later, they will receive the online training program (brainHQ by Posit Science) three times a week for 45 minutes for a total of 12 weeks. This group will return one week after completing the online intervention program for their follow-up neuropsychological evaluation. They will then return again one year later for another follow-up neuropsychological evaluation.
10203013|NCT03621397|No Intervention|Control Group|Research participants in the control group will undergo a baseline neuropsychological evaluation. They will then return 13 weeks after their baseline neuropsychological evaluation for a follow-up neuropsychological evaluation and again one year later.
9762274|NCT00723710||Intron A|Patients with malignant melanoma who are free of disease post-surgery but at high risk for systemic recurrence.
9762275|NCT00723749||Suboxone|Patients for whom a drug dependence therapy with SUBOXONE® is planned and indicated, and who have already been pre-treated with SUBUTEX®, or another maintenance drug for at least 6 months.
9762276|NCT00723788|Experimental|Only one arm|All patients enrolled will receive an MRI of the abdomen with detailed views of the appendix
9762277|NCT00723801|Active Comparator|Subjects Randomized to Losartan|Losartan: 100 mg PO QD
9762278|NCT00723801|Active Comparator|Subjects Randomized to Atenolol|Atenolol: 50 mg PO QD
9762279|NCT00723827||All Participants|Participants with newly diagnosed glioblastoma multiforme (treat with temozolomide & radiotherapy) or participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy (treat with temozolomide).
9762280|NCT00723840||Crohn's Disease Participants|"Participants with Crohn's Disease for at least 6 months, who have a Crohn's Disease Activity Index (CDAI) score >= 150. The CDAI score evaluates Crohn's disease symptoms - a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.~These participants have active disease despite drug therapy."
9762281|NCT00723892||PegIntron/Rebetol and psychotherapy support program|Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
9762282|NCT00723892||PegIntron/Rebetol alone (no psychotherapy)|Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
9762283|NCT00723931||Participants with Chronic Hepatitis C|Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with Chronic Hepatitis C are generally treated.
9762284|NCT00723957|Experimental|Ixabepilone, 32 mg/m^2 + Carboplatin (AUC 6)|
9762285|NCT00723957|Active Comparator|Paclitaxel, 200 mg/m^2 + Carboplatin (AUC 6)|
9762286|NCT00724009|Experimental|Clofarabine|Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days
9762287|NCT00724061|Experimental|PEG-IFN-α-2b + UV therapy|Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).
9762288|NCT00724126|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
9762289|NCT00724126|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
9783667|NCT01207440|Experimental|Unassigned to Cohorts A-F|Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not R-I to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
10203014|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
10203015|NCT03592771|No Intervention|Usual Care|Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication.
9832731|NCT02625610|Experimental|Avelumab|In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.
9832732|NCT02625623|Experimental|Physician choice chemotherapy+Best Supportive Care (BSC)|Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
9832733|NCT02625623|Active Comparator|Avelumab+BSC|Participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with BSC. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
9832734|NCT02625844||Monopegylated Epoetin Beta|Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.
9832735|NCT02625844||Other Erythropoiesis Stimulating Agents (ESAs)|Health care personnel performing anemia management tasks for patients using other ESAs.
9832736|NCT02625909|Experimental|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
9832737|NCT02625909|Experimental|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
9832738|NCT02625922|Experimental|Serelaxin followed by Placebo|On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
9832739|NCT02625922|Experimental|Placebo followed by Serelaxin|On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
9832740|NCT02625974|Experimental|Nifurtimox 60 days / Arm 1|Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
9832741|NCT02625974|Other|Nifurtimox 30 days / Arm 2|Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
9984203|NCT04309513|Experimental|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device.
9984204|NCT04309396|Experimental|Breath analyzer|Candidates who, after the screening period are eligible to receive the AIRE device.
10203016|NCT03592771|Active Comparator|App|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
10203017|NCT03592771|Active Comparator|App+Feedback|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.~In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase.~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
10203018|NCT03582462|Experimental|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
10203019|NCT03582462|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
10203020|NCT03577704|Experimental|HLX07+Gemcitabine+Cisplatin arm|"HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
10203021|NCT03577704|Experimental|HLX07+Paclitaxel+Carboplatin arm|"HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
10203022|NCT03577704|Experimental|HLX07+mFOLFOX6 arm|"HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
9832742|NCT02626000|Experimental|Talimogene Laherparepvec + Pembrolizumab|Talimogene laherparepvec is administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 3 weeks after the initial dose and every 3 weeks (Q3W) thereafter. Pembrolizumab is administered by intravenous infusion at a dose of 200 mg Q3W after the initial dose. Participants are treated until complete response, no injectable lesions, confirmed disease progression, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first.
9832743|NCT02626026|Experimental|Cohort 1, Part A: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
9832744|NCT02626026|Placebo Comparator|Cohort 1, Part A: Placebo|Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
10203023|NCT03567057|Experimental|ADS-5102, 274 mg|274 mg ADS-5102, administered once daily at bedtime for up to 52 weeks
10203024|NCT03566511|Experimental|Healthy (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
9832745|NCT02626026|Experimental|Cohort 2, Part A: Tirabrutinib 10 mg BID|Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
9832746|NCT02626026|Placebo Comparator|Cohort 2, Part A: Placebo|Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
9832747|NCT02626026|Experimental|Part B: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally QD for 4 weeks.
9832748|NCT02626026|Placebo Comparator|Part B: Placebo|Placebo to match tirabrutinib capsules orally QD for 4 weeks.
10203025|NCT03566511|Placebo Comparator|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
10203026|NCT03566511|Experimental|T2D (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
10203027|NCT03566511|Placebo Comparator|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
10203028|NCT03565237|Experimental|All Study Participants|Study participants with Hemophilia B in India receiving Rixubis
10203029|NCT03559270|Experimental|Baricitinib|Baricitinib administered orally.
10203030|NCT03553563|Experimental|Group1|Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
10203031|NCT03553563|Experimental|Group2|Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
10203032|NCT03553563|Experimental|Group3|D961H 10 mg once-daily (32 or 52 weeks)
10203033|NCT03553563|Experimental|Group4|D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)
10203034|NCT03552068|Placebo Comparator|Patients under placebo|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
10203035|NCT03552068|Active Comparator|Patient under clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
10203036|NCT03551509|No Intervention|Control Group|Patients randomly assigned into the control group will undergo open or arthroscopic rotator cuff repair using the surgeon's standard practice. No ECM graft will be used.
10203037|NCT03551509|Active Comparator|Treatment Group|Patients randomly assigned into the treatment group will undergo open or arthroscopic rotator cuff repair and the surgeon will use the ArthroFLEX® ECM graft to augment the repair. ECM scaffold grafts are indicated for the reinforcement of soft tissues repaired by sutures or suture anchors during tendon repair surgery, including rotator cuff.
10203038|NCT03551509|Other|Crossover Group|Patients initially randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
10203039|NCT03548987|Experimental|Semaglutide|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
10203040|NCT03548987|Placebo Comparator|Placebo|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
10203041|NCT03548064|Experimental|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
10203042|NCT03548064|Experimental|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
10203043|NCT03548064|Experimental|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
10203044|NCT03548064|Experimental|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
10203045|NCT03548064|Experimental|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
10203046|NCT03548064|Experimental|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
9832749|NCT02626156|Experimental|Cooling gel pack|A cooling pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
9832750|NCT02626156|Active Comparator|Cooling cotton pack|A cooling cotton pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
9832751|NCT02626182|Experimental|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
9832752|NCT02626182|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
9832753|NCT02626611|Placebo Comparator|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
9832754|NCT02626611|Active Comparator|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
9832755|NCT02626611|Active Comparator|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
9832756|NCT02626780|Experimental|SVF Injection|Liposuction of a small amount of adipose tissue will be taken from each subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
9832757|NCT02626819|Experimental|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
9832758|NCT02626819|Active Comparator|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
9832759|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
9832760|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
9832761|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
9832762|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
9832763|NCT02627001|Experimental|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
9832764|NCT02627001|Active Comparator|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
9832765|NCT02627118|Experimental|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
9832766|NCT02627144||Advanced and/or Metastatic RCC participants|Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.
9832767|NCT02627495|Experimental|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
9832768|NCT02627677|Experimental|Cohort A: Ponatinib 30 mg|Ponatinib 30 mg, tablets, orally, once daily (QD) until achievement of major molecular response (MMR) up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 42 months.
10203047|NCT03548064|Experimental|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
9518024|NCT03300648|Experimental|Hypertonic saline|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days
9832769|NCT02627677|Experimental|Cohort B: Ponatinib 15 mg|Ponatinib 15 mg, tablets, orally, QD until achievement of MMR up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 45 months.
9832770|NCT02627677|Active Comparator|Cohort C: Nilotinib 400 mg|Nilotinib 400 mg, tablets, orally, twice daily up to approximately 42 months.
9518025|NCT03300635|Other|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
9518026|NCT03300635|Other|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
10203048|NCT03548064|Experimental|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
10203049|NCT03548064|Experimental|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
10203050|NCT03534635|Experimental|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
10203051|NCT03527316|Experimental|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
10203052|NCT03527316|Experimental|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
10203053|NCT03526679|Experimental|Experimental arm|The combination of lenvatinib and eribulin
10203054|NCT03521232|Experimental|150 mg/60 ml|Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks
10203055|NCT03521232|Experimental|450 mg/60 ml|Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks
10203056|NCT03511963|Experimental|HLX04|
10203057|NCT03511963|Active Comparator|Bevacizumab|
10203058|NCT03508557|Experimental|Advance care planning tools|Advance care planning education and structured conversation using tools
10203059|NCT03502785|Experimental|Cohort A|Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 therapy. Cohort A participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
10203060|NCT03502785|Experimental|Cohort B|Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy. Cohort B participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
10203061|NCT03502668|Experimental|Phase 1 Stage A|3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD
10203062|NCT03502668|Experimental|Phase 1 Stage B|3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD
10203063|NCT03502668|Experimental|Phase 2|80 additional subjects randomized in a 1:1 ratio studying two different doses
10203064|NCT03500172|Active Comparator|DTP, Continue DTP if Responsive|
10203065|NCT03500172|Active Comparator|DTP, Standard of Care (SoC) if Responsive|
10203066|NCT03500172|Active Comparator|DTP, Continue DTP if Non-Responsive|
10203067|NCT03500172|Active Comparator|DTP, DTP+ICM if Non-Responsive|
10203068|NCT03500172|Active Comparator|ICM, Continue ICM if Responsive|
10203069|NCT03500172|Active Comparator|ICM, SoC if Responsive|
10203070|NCT03500172|Active Comparator|ICM, Continue ICM if Non-Responsive|
10203071|NCT03500172|Active Comparator|ICM, ICM+DTP if Non-Responsive|
10203072|NCT03496610|Active Comparator|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
10203073|NCT03496610|Active Comparator|Surgical wound infiltration|Patients will receive 166 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
10203074|NCT03487367||Early stage subjects|This cohort is defined by individuals with a total SARA score of less than or equal to 9.5
10203075|NCT03487367||Premanifest mutation carriers|This cohort is defined by the presence of positive genetic diagnosis but no signs of ataxia and total SARA score of less than or equal to 2.5
10203076|NCT03487367||50%-at-risk subjects|This cohort is defined by individuals who are at risk for SCA1 or SCA3 because they have a family member who tested positive for SCA1 or SCA3. Total SARA score is less than or equal to 2.5
10203077|NCT03487367||Previously diagnosed early stage|This cohort is defined by individuals who were included in prior CRC-SCA, EUROSCA, ESMI or SPATAX studies who had a total SARA score of less than or equal to 10 in 2009-2012
10203078|NCT03478566|Experimental|Transcutaneous CO2 monitoring|
10203079|NCT03475264||Healthy|Healthy Participants
10203080|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
10203081|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
10203082|NCT03461406|Experimental|Fibrin Sealant Grifols|human fibrinogen (component 1: 80 mg/mL solution) and human thrombin (component 2: 500 IU/mL solution)
10203083|NCT03461406|Active Comparator|EVICEL|human fibrinogen (55-85 mg/mL) and human thrombin (800-1200 IU/mL)
10203084|NCT03459365|Experimental|Euflexxa|Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
10203085|NCT03446456|Placebo Comparator|Saline|"Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.~Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril."
10203086|NCT03446456|Experimental|Arginine vasopressin|Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).
9762290|NCT00724152|Experimental|Arm 1/Cognitive Behavioral Therapy|Participants randomly assigned to this experimental group received six weeks of tinnitus education plus cognitive behavioral therapy. Cognitive behavioral therapy for tinnitus participants addressed cognitive and behavioral skills targeting the management of tinnitus and the negative impacts of tinnitus. Long-term self-efficacy and self-sufficiency were emphasized. The major components of CBT for tinnitus included identification of individual responses and beliefs about tinnitus and hearing loss, re-conceptualization of the tinnitus experience as one in which the patient has personal control, presentation of skills to modify cognitions and change behaviors, and reinforcement of skills via goals setting, homework and activities. Skills related to attention control, sleep hygiene, relaxation training are provided. Tinnitus education also included causes, treatments, current research, etc.
9762291|NCT00724152|Active Comparator|Arm 2/Tinnitus Education|Participants randomly assigned to this group received six weeks of tinnitus education. Tinnitus education and skills related to attention control, sleep hygiene and relaxation training such as imagery techniques were provided. Tinnitus education included causes, treatments, current research, epidemiological information, basic anatomy of the ear and brain, and support resources.
9762292|NCT00724152|No Intervention|Arm 3/Standard Care|Participants randomly assigned to this control group received only standard care. Standard care involves audiological measurement and brief education during the standard care appointment.
9762293|NCT00724243||Rheumatoid Arthritis Patients in Slovakia|Rheumatoid arthritis patients in Slovakia who are starting treatment with infliximab for the first time, in accordance with normal clinical practice.
9762294|NCT00724308|Experimental|Arm 1|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
9762295|NCT00724308|Experimental|Arm 2|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state smoking cessation Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
9762296|NCT00724347|Experimental|Arm 1|Hearing impaired listeners with hearing aids underwent two months of consonant identification training in their homes.
9762297|NCT00724373||Participants with genotype 1 Hepatitis C Virus infection.|Participants with genotype 1 Hepatitis C Virus (HCV) infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months
9762298|NCT00724451||Participants with Chronic Hepatitis C (CHC)|Peginterferon-naïve participants with CHC seen in general clinical practice in Italy and treated with either pegylated interferon alfa-2a or alfa-2b + ribavirin.
9762299|NCT00724464||Participants with Chronic Hepatitis C|Treatment-naïve participants with chronic hepatitis C, undergoing treatment with a standard treatment regimen of PegIntron and Rebetol in clinical practice at approximately 28 sites in Greece
9762300|NCT00724503|Experimental|mFOLFOX6 + SIRT|A single injection of SIR-Spheres microspheres into the liver plus systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX)
9762301|NCT00724503|Active Comparator|mFOLFOX6|Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).
9762302|NCT00724568|Experimental|Combination Drug Therapy|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.
9762303|NCT00724594|Experimental|N-acetylcysteine|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
9762304|NCT00724594|Active Comparator|Control|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
9762305|NCT00724711|Experimental|FTC/TDF (Truvada [TVD]) + PI/r|Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.
9762306|NCT00724711|Active Comparator|ABC/3TC + PI/r|Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.
9762307|NCT00724750|Experimental|G-SUC|Gauze suction (G-SUC) Negative Pressure Wound Therapy, continuous wall suction at 75 to 80 mm Hg was applied and dressings were changed daily.
9762308|NCT00724750|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Closure Device (VAC) Negative Pressure Wound Therapy, continuous suction at 75 to 125 mm Hg and the dressing was changed every 48 hours.
9762309|NCT00724815|Experimental|Sumatriptan|NP101 - sumatriptan iontophoretic transdermal patch
9762310|NCT00724815|Placebo Comparator|Placebo|Placebo iontophoretic transdermal patch
9762311|NCT00724854||Mono-infected with HCV|Participants infected with Hepatitis C Virus (HCV).
9762312|NCT00724854||Co-infected with HCV and HIV|Participants co-infected with HCV and Human Immunodeficiency Virus (HIV).
9762313|NCT00724867|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV every 28 days
9762314|NCT00724867|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV every 28 days
9762315|NCT00724893||Stage 1 Participants|Participants with CHC receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
9762316|NCT00724893||Stage 2 Participants|Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
9762317|NCT00724932|Experimental|Sugammadex|4.0 mg.kg-1 sugammadex at 1-2 PTC
9762318|NCT00724932|Experimental|Neostigmine|50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2
9762319|NCT00724945|Active Comparator|senofilcon A / balafilcon A|senofilcon A multifocal lenses worn first, balafilcon A multifocal lenses worn second
9762320|NCT00724945|Active Comparator|balafilcon A/senofilcon A|balafilcon A multifocal lenses worn first, senofilcon A multifocal lenses worn second
9762321|NCT00724958||Remicade|Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.
9762322|NCT00724971|Experimental|Inotuzumab Ozogamicin + Rituximab|
9762323|NCT00724984|Experimental|1|
9762324|NCT00725010||Patients|Participants with newly diagnosed Glioblastoma multiforme who were prescribed temozolomide and radiotherapy as standard care.
9762325|NCT00725075|Experimental|MK-8435 (Org 25935) 8-16 mg per day|Participants will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and receive 4-8 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
9762326|NCT00725075|Experimental|MK-8435 (Org 25935) 24-32 mg per day|Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
9762327|NCT00725075|Placebo Comparator|Placebo|Participants will be maintained on a stable dose of SGA and receive matching placebo for MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days.
9762328|NCT00725101||Fibromyalgia (FM) Participants|FM participants starting any new pharmacologic FM agent.
9762329|NCT00725153|Other|PureVision/Acuvue 2|PureVision contact lenses worn first, with Acuvue 2 contact lenses worn second. Both products worn for 10 hours each.
9762330|NCT00725153|Other|Acuvue 2/PureVision|Acuvue 2 contact lenses worn first, with PureVision contact lenses worn second. Both products worn for 10 hours each.
9762331|NCT00725205||Chronic hepatitis C participants|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection pen) and Ribavirin combination therapy as their usual medical treatment according to the approved dosage/regimen were selected for this study.
9783668|NCT01207453|Other|Milnacipran then placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
9783669|NCT01207453|Other|Placebo then milnacipran|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to milnacipran for 6 weeks."
9783670|NCT01207466|Other|Nelfilcon A invest'l / nelfilconA comm'l|Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
9783671|NCT01207466|Other|Nelfilcon A comm'l / nelfilconA invest'l|Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
9783672|NCT01207570|Experimental|Endermotherapy|The subjects in the experimental group will receive a single session (5 minutes) of endermotherapy) applied to the gastrocnemius/soleus muscle group in the more affected side. The treatment will b e carried out by a qualified physiotherapist.
9783673|NCT01207570|Active Comparator|Passive stretching|The subjects in this group will receive a single session of passive stretching of the gastrocnemius/soleus muscle for 5 minutes.
9783674|NCT01207583||healthy children after vaccination|healthy children after vaccination
9783675|NCT01207596|Active Comparator|Hydromorphone|
9783676|NCT01207648||Retrospective Cohort|Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
9783677|NCT01207687|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
9783678|NCT01207752|Experimental|Systane Balance|Artificial tear emulsion
9783679|NCT01207752|Active Comparator|Optive Lubricant Eye Drops|Artificial tear
9785575|NCT01254669|Experimental|BNI-brief Negotiated Interview|The BNI intervention addressed mothers' beliefs, values, and concerns about HPV prevention and takes their priorities for health and well-being into account.
10203087|NCT03434392|Active Comparator|Healthy Controls|"Subjects with no pancreatic disease and no abdominal pain.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
10203088|NCT03434392|Active Comparator|Suspected CP|"Suspected Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
10203089|NCT03434392|Active Comparator|Definite CP|"Definite Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires.~A subset of these patients who undergo endotherapy as per clinical recommendation from clinical provider independent of this study will be followed for 6 months after their clinical intervention for repeat Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3 and questionnaires."
10203090|NCT03434392|Active Comparator|Sphincter of Oddi Dysfunction or Functional Dyspepsia|"Patients with Sphincter of Oddi Dysfunction Type 1 or Type 2, or who have a prior diagnosis of Functional Dyspepsia.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
10203091|NCT03412292|Experimental|MAX-40279|"MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).~After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts."
10203092|NCT03396692|Active Comparator|Control Arm|Pain management use intravenous morphine patient-controlled analgesia (PCA)
9762332|NCT00725270|Placebo Comparator|Placebo|Patients will be randomized to placebo
9762333|NCT00725270|Experimental|Mifepristone|Patients will be randomized to mifepristone
9762334|NCT00725283|Experimental|GSK2130579A Group|Patients with cytologically proven AML, as defined by the World Health Organization classification, who were administered a standard dose of GSK2130579A treatment. Patients received 24 doses of the study treatment over a period of approximately 4 years.
9762335|NCT00725296||Remicade (Infliximab)|Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.
9762336|NCT00725322|Experimental|Placebo then Botox|
9762337|NCT00725322|Experimental|Botox then Placebo|
9762338|NCT00725361|Experimental|Active|Ambrisentan
9762339|NCT00725452||Infliximab|Subjects with plaque psoriasis will receive Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
9762340|NCT00725504|Experimental|Lidocaine infusion|Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.
9762341|NCT00725530|Active Comparator|balafilcon A / etafilcon A|Balafilcon A worn first, with etafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
9762342|NCT00725530|Active Comparator|etafilcon A / balafilcon A|Etafilcon A worn first, with balafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
9762343|NCT00725543||Remicade|Subjects with AS with severe axial symptoms and elevated serological markers of inflammatory activity will receive Remicade induction therapy consisting of 3 Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians. Whole observation period cannot exceed 102 weeks per subject if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) is taken into consideration.
9762344|NCT00725608||Patients|Opioid dependent patients currently in maintenance treatment with another medication who are switched to Suboxone (buprenorphine plus naloxone)
9762345|NCT00725621||Remicade|Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.
9762346|NCT00725712|Experimental|5-days on/9-days off|Dosing for first 5 days in every 14-day period.
9762347|NCT00725712|Experimental|daily dosing|dosed every day
9762348|NCT00725725|Experimental|4 mg Org 25935|Participants took a total of 3 doses of 4 mg Org 25935 prior to therapy sessions over a 2-week period.
9762349|NCT00725725|Experimental|12 mg Org 25935|Participants took a total of 3 doses of 12 mg Org 25935 prior to therapy sessions over a 2-week period.
9762350|NCT00725725|Placebo Comparator|Placebo|Participants took a total of 3 doses of placebo matched to Org 25935 prior to therapy sessions over a 2-week period.
9762351|NCT00725751||PegIFN-2b/ribavirin with substitution therapy|Participants in this cohort received antiviral treatment and substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
9762352|NCT00725751||PegIFN-2b/ribavirin without substitution therapy|Participants in this cohort received antiviral treatment but did not receive substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
9762353|NCT00725764|Experimental|Single Arm|Participants who qualified for study entry received 240 mg of GSK1363089 (foretinib) on a 5-day on 9-day off schedule every 2 weeks.
9785576|NCT01254721|Experimental|1|Seroquel XR tablet
9785577|NCT01254721|Active Comparator|2|Seroquel XR + lithium
9762354|NCT00725842||Peg-IFN alfa-2b + ribavirin|Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).
9762355|NCT00725920|Experimental|Topiramate|patients receiving the active drug: topiramate
9762356|NCT00725920|Placebo Comparator|Placebo Control group|patients received pills content placebo, that were identical to the pills content active drug
9762357|NCT00725959|Experimental|Facebook Arm|Participants in this arm will have exposure to innovative, dynamic and regularly updated HIV Prevention messages on Facebook
9762358|NCT00725959|Active Comparator|Control arm|Participants in this arm will have exposure to static information on HIV prevention currently available online
9762359|NCT00726232|Experimental|Ruxolitinib 10 mg BID|Participants received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
9762360|NCT00726232|Experimental|Ruxolitinib 25 mg BID|Participants received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
9762361|NCT00726232|Experimental|Ruxolitinib 50 mg QD|Participants received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
9762362|NCT00726323|Experimental|5/9 dosing|240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
9762363|NCT00726323|Experimental|daily dosing|80 mg foretinib on a daily dosing regimen
9762364|NCT00726375|Experimental|Etanercept|a maximum of 8 SQ doses of 'Etanercept (Enbrel) at 0.4mg/kg per dose up to a maximum of 25 mg per dose
9762365|NCT00726388|Experimental|A|IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days
9762366|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
9762367|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
9762368|NCT00726453|Experimental|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
9762369|NCT00726557||PegIntron + Rebetol|There will be a distinction between the patients depending on the type of substitution drug used (secondary parameters).
9762370|NCT00726609||Posaconazole (assigned by physician in normal practice)|"Treatment of invasive fungal infection.~Prophylaxis of invasive fungal infection."
9762371|NCT00726622|Active Comparator|Arm 1: Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection. The standard form of surgery is open laparotomy rectal resection. During open laparotomy, the surgeon makes a large incision or cut in the abdomen, and goes in through that cut to remove the tumor and lymph nodes from the rectum.
9762372|NCT00726622|Experimental|Arm 2: Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection. Laparoscopic-assisted rectal resection is performed using small instruments on long handles introduced into the abdomen through small ports called trocars in 3 - 6 positions on the abdomen through incisions measuring 5 -10 mm, under the guidance of a video camera. The abdominal wall is held up with carbon dioxide under pressure. The piece of bowel or intestine is removed through another incision (about 8 centimeters), and the ends of the intestine are reconnected to provide normal bowel function.
9762373|NCT00726661||Chemotherapy Cohort|Eligible participants with HER2-negative disease who received their first cytotoxic chemotherapy and/or targeted therapy were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
9762374|NCT00726661||Hormonal Therapy Cohort|Eligible participants with hormone receptor positive disease who received their first hormonal therapy for advanced disease were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
9762375|NCT00726713|Experimental|1|Metanx
9762376|NCT00726713|Placebo Comparator|2|Placebo
9762377|NCT00726739|Experimental|Arm I - LMI + aldesleukin|Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
9762378|NCT00726739|Active Comparator|Arm II (control) - aldesleukin|Patients receive aldesleukin SC on days 1 and 2. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over and receive treatment on arm I.
9783680|NCT01207765|Experimental|Zevalin|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging on study day +1. 90Y Zevalin will be administered seven to nine days after 111In Zevalin administration. The dose of 90Y Zevalin will be 0.4 mCi/kg, capped at a maximum dose of 32 mCi.
9783681|NCT01207908|Experimental|IGF-1|IGF-1 plus standard steroid treatment
9832771|NCT02627794|Experimental|Silastic Silicone & Restora™ Steroid eluting spacer|"Silastic Silicone spacers are actively being used as the standard of care.~Restora™ Steroid eluting spacer (experimental).~Each nostril will receive one each of above spacers."
9832772|NCT02627924||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
9832773|NCT02628028|Experimental|Part A 5 mg LY3337641|Given once a day for 4 weeks.
9832774|NCT02628028|Experimental|Part A 10 mg LY3337641|Given once a day for 4 weeks.
9832775|NCT02628028|Experimental|Part A 30 mg LY3337641|Given once a day for 4 weeks.
9832776|NCT02628028|Placebo Comparator|Part A Placebo|Given once a day for 4 weeks.
9832777|NCT02628028|Experimental|Part B 5 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
9832778|NCT02628028|Experimental|Part B 10 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
9832779|NCT02628028|Experimental|Part B 30 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
9832780|NCT02628028|Placebo Comparator|Part B Placebo|Given once a day for 12 weeks.
9832781|NCT02628093|Other|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
9518027|NCT03300609|Experimental|Arm I (panitumumab, leucovorin calcium, fluorouracil)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive panitumumab IV over 30 minutes, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
9832782|NCT02628093|Other|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
9832783|NCT02628106|Experimental|Lipo-prostaglandin E1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days.
9832784|NCT02628223|Active Comparator|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
9832785|NCT02628223|Active Comparator|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
9832786|NCT02628236|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
9832787|NCT02628418|Experimental|Gloreha Group|"The patients in the Gloreha Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation by Gloreha device"
9832788|NCT02628418|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation performed by physiotherapist"
9832789|NCT02628600|Experimental|Prior LAI + Multidrug Regimen|Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR.
9832790|NCT02628600|Experimental|Prior Multidrug Regimen Alone|Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR.
9832791|NCT02628743|Experimental|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
9832792|NCT02628769|Experimental|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
9832793|NCT02628769|Placebo Comparator|Placebo|28 day treatment with placebo taken once per day.
9832794|NCT02628873|Experimental|Arm 1 (HyCoSy followed by HSG)|HyCoSy procedure followed by HSG procedure
9832795|NCT02628873|Experimental|Arm 2 (HSG followed by HyCoSy)|HSG procedure followed by HyCoSy procedure
9832796|NCT02628938|Experimental|Miswak extract mouth wash|50% mouthwash aqueous solution 5ml twice a day for 7 days
9832797|NCT02628938|Experimental|Miswak sticks|Sticks twice a day for 7 days
9832798|NCT02628938|Active Comparator|Chlorohexidine gluconate mouth wash|0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days
9832799|NCT02628964|Active Comparator|4.5% e-cig|e-cigarettes with nicotine cartridges
9832800|NCT02628964|Placebo Comparator|0 mg e-cig|e-cigarettes with placebo cartridges (0mg).
9832801|NCT02629094|Experimental|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
9832802|NCT02629133|Experimental|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
10203093|NCT03396692|Experimental|Posterior exo-thoracic fascia block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine
10203094|NCT03396692|Experimental|Paravertebral block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine
10203095|NCT03395639|Experimental|Edoxaban|Two out of three participants will be randomized for treatment with edoxaban solution or tablets
10203096|NCT03395639|Active Comparator|Standard of Care (SOC)|One out of three participants will be randomized for treatment with the institution's SOC regimen
10203097|NCT03394079|Experimental|OCT-guided|
10203098|NCT03394079|Active Comparator|IVUS-guided|
10203099|NCT03393598|Experimental|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
9832803|NCT02629133|No Intervention|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
9832804|NCT02629354|Experimental|Ibuprofen and Caffeine|
9832805|NCT02629354|Active Comparator|Ibuprofen|
9832806|NCT02629822|Experimental|DOR/3TC/TDF|Treatment-naïve HIV-1 infected participants with NNRTI transmitted resistance-associated mutations were treated with open-label MK-1439A (DOR/3TC/TDF 100mg/300mg/300mg) as a FDC tablet taken once daily by mouth for 96 weeks in the Base Study. In addition, eligible participants continued to receive the same MK-1439A regimen from Week 96 to Week 192 during the Extension Study.
9832807|NCT02629861|Placebo Comparator|Placebo|Matching Placebo
9832808|NCT02629861|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
9832809|NCT02629861|Experimental|Fremanezumab 225/225/225 mg|Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.
9832810|NCT02629965|Experimental|tiotropium + olodaterol|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
9832811|NCT02629965|Active Comparator|tiotropium|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
9832812|NCT02629991|Experimental|Intranasal Oxytocin|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
9832813|NCT02629991|Placebo Comparator|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
9832814|NCT02630017|Experimental|ADHD group|Adults with ADHD
9832815|NCT02630017|Experimental|non-ADHD group|Adults without ADHD
10203100|NCT03393598|Experimental|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
10203101|NCT03393598|Experimental|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
9832816|NCT02630030|Experimental|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
9832817|NCT02630186|Experimental|Single Arm Rociletinib and MPDL3280A|Specific doses of rociletinib, taken continuously BID, will be administered in combination with a fixed dose of MPDL3280A, given intravenously on Day 1 of each 21-day cycle.
9832818|NCT02630251|Experimental|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a >=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
9832819|NCT02630316|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer four times daily
9832820|NCT02630316|Active Comparator|Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily
9984205|NCT04306939||Case/Chronic complex disorders|Chronic complex disorders are composed of multiple population sub classifications - many of which have not been fully defined. Thus, all eligible patients should be included to maximize study power. Sufficient numbers of controls, those individuals in the general population, who may or may not have complex disorders are needed to match future comparison studies for a subset of questions, and so should also be included.
10203102|NCT03393598|No Intervention|Control|No preconditioning methods will be applied.
10203103|NCT03388190|Active Comparator|Control Arm|The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
10203104|NCT03388190|Experimental|Experimental Arm|The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
10203105|NCT03382834|Experimental|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
10203106|NCT03382834|Active Comparator|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
10203107|NCT03380273|No Intervention|pre-intervention|The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
10203108|NCT03380273|Other|post-intervention|Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.
10203109|NCT03374657|Experimental|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
10203110|NCT03374657|Experimental|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
10203111|NCT03374657|Experimental|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
10203112|NCT03374657|Experimental|CPK Dose 4 (next to highest dose)|CPK850, one subretinal injection to the study eye
10203113|NCT03374657|Experimental|CPK Dose 5 (highest dose)|CPK850, one subretinal injection to the study eye
10203114|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
10203115|NCT03371823|Other|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
9984206|NCT04306939||Control|The number of controls that are anticipated for this study is less than patient numbers since they will not be needed for calculating the minor allele frequency of the majority of genetic polymorphism of interest in genetic association studies. This data is already available in public and research databases. Controls will be useful for evaluating case report form questions, providing assessment of the local genetic pool, and for possibly participating in future studies as provided by the consent.
9984207|NCT04305834|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9984208|NCT04305366||Head and Neck Cancers|This study will target patients with a diagnosis squamous cell carcinoma in the head and neck. In addition, this study will also target patients undergoing tonsillectomy or sleep surgery as the control group. This study will aim to enroll an equal number of patients into both the study group and control group. However, this will be dependent on patient encounters within the adult ENT clinic.
9984209|NCT04304729||Diabetics|Girls and boys aged 14-18 years old, living with Type 1 Diabetes.
9832828|NCT02630563|Experimental|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
9832829|NCT02630693|Active Comparator|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
9832830|NCT02630693|Active Comparator|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
9832831|NCT02630706|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
9832832|NCT02630706|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
9832833|NCT02630706|Placebo Comparator|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
9832834|NCT02630719|Active Comparator|Timolol eye drops|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
9832835|NCT02630719|Placebo Comparator|Artificial tears|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
9832836|NCT02630953|Active Comparator|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
9984210|NCT04304729||Control|Age and sex matched adolescents without any type of diabetes
9832837|NCT02630953|Experimental|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
9832838|NCT02630966|Experimental|Group 1: Vedolizumab IV 300 mg + Placebo|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.
9832839|NCT02630966|Experimental|Group 2: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
9832840|NCT02630992|Experimental|amoxicillin-clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)
9832841|NCT02631057||Non-Valvular Atrial Fibrillation|
9832842|NCT02631057||acute ischemic stroke|
9832843|NCT02631525|Active Comparator|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
9984211|NCT04302168|Active Comparator|Choline Supplement Group|Choline Supplement 470 mg twice daily for total of 8 weeks.
9984212|NCT04302168|Placebo Comparator|Placebo Group|Placebo pill twice daily for total of 8 weeks.
9984213|NCT04301271|Experimental|Simvastatin|Simvastatin and Escitalopram
9984214|NCT04301271|Placebo Comparator|Placebo|Placebo and Escitalopram
9762379|NCT00726739|Experimental|Arm III - Crossover Patients|"Patients who have progressive disease on Arm II were be offered crossover to Arm I provided they continued to meet all study criteria.~Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity"
9762380|NCT00726752|Experimental|Axitinib|
9762381|NCT00726882|Other|HCV-infected Participants|"Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT-333.~Participants received no treatment in this follow-up study."
9762382|NCT00726895|Experimental|Quinine Sulfate Capsules 1 x 324 mg Dose|Quinine Sulfate 1 x 324 mg capsule dose.
9762383|NCT00726895|Experimental|Quinine Sulfate Capsules 2 x 324 mg Dose|Quinine Sulfate 2 x 324 mg capsules dose.
9762384|NCT00726986|Experimental|Sorafenib, Cisplatin, and Etoposide|
9762385|NCT00726999|Active Comparator|1|Gabapentin
9762386|NCT00726999|Placebo Comparator|2|Placebo Comparator -- pill matched in appearance to gabapentin
9762387|NCT00727064|Active Comparator|DVS/VEN|
9762388|NCT00727064|Active Comparator|VEN/DVS|
9762389|NCT00727194|Experimental|1|eculizumab
9762390|NCT00727194|Placebo Comparator|2|Placebo
9762391|NCT00727220||Insulin Pump Therapy|Children starting insulin pump therapy
9762392|NCT00727220||Insulin Injections|Children remaining on insulin injections.
9762393|NCT00727246|Experimental|CDP-Choline|Treatment with CDP-Choline
9762394|NCT00727246|Placebo Comparator|Placebo|Treatment with Placebo
9762395|NCT00727259||Patients with chronic hepatitis C|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
9762396|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fasting|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
9762397|NCT00727272|Experimental|Quinine Sulphate Tabs 300 mg - Fasting|A single dose of quinine sulphate 300 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
9762398|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fed|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water thirty minutes after the initiation of a standardized, high-fat breakfast.
9762399|NCT00727298||Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
9762400|NCT00727311||PegIntron + Rebetol|Participants with chronic hepatitis C, who are either treatment-naïve or previously relapsed after receiving interferon monotherapy
9762401|NCT00727337|Experimental|LACE-DVD|Participants will complete the LACE training, however, not in an interactive computer mode but through a static DVD mode
9762402|NCT00727337|Experimental|LACE-COMPUTER|Participants will complete a computer-based auditory training program (i.e., LACE)
9762403|NCT00727337|Active Comparator|PLACEBO-DIRECTED LISTENING|Participants will complete a directed listening to books on CD treatment
9762404|NCT00727337|Active Comparator|CONTROL|Participants will be provided with hearing aids
9762405|NCT00727402||Observational|healthy patients fit into lotrafilcon A contact lenses for continuous wear
9762406|NCT00727441|Experimental|Arm A|Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.
9762407|NCT00727441|Experimental|Arm B|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..
9762408|NCT00727441|Experimental|Arm C|Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.
9762409|NCT00727506|Experimental|BIBW 2992|BIBW 2992 once daily
9762410|NCT00727506|Active Comparator|TMZ|TMZ 21/28 days
9762411|NCT00727506|Experimental|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
9762412|NCT00727532|Experimental|Sorafenib|Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.
9762413|NCT00727558|Active Comparator|narafilcon A|spherical soft contact lens worn as a daily disposable modality for one week
9762414|NCT00727558|Active Comparator|nelfilcon A|spherical soft contact lens worn as a daily disposable modality for one week
9762415|NCT00727571||No CKD or Anemia|Chronic kidney disease (CKD) is based on estimated Glomerular Filtration Rate (GFR), calculated by the Modification of Diet in Renal Disease (MDRD) method, of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per World Health Organization (WHO) criteria. Participants completed the study after Week 1; data contributed to prevalence estimates.
9762416|NCT00727571||No CKD, but Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants completed the study at Week 2 and completed an anemia work-up; data contributed to prevalence estimates.
9762417|NCT00727571||CKD with Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.
9762418|NCT00727571||CKD with no Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed mobility and physical performance assessments.
9762419|NCT00727597|Experimental|Arm A : Boosted Lexiva plus Epzicom|Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).
9762420|NCT00727597|Experimental|Arm B: Efavirenz plus Epzicom|QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
9762421|NCT00727636|Experimental|Gardasil vaccine - Prospective Study|Prospective study participants received the Gardasil vaccine during the study
9762422|NCT00727636|No Intervention|Retrospective Study|Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider
9762423|NCT00727649|Active Comparator|Arm 1|Fiber (psyllium) powder
9762424|NCT00727649|Active Comparator|Arm 2|Loperamide
9762425|NCT00727740|Experimental|1|Indomethacin liquid suspension 100 mg (25 mg/5ml) which is 20 cc of suspension instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
9762426|NCT00727740|Placebo Comparator|2|Placebo suspension in the same volume (20 cc) which is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. The placebo suspension is also flushed with 5 cc of normal saline.
9762427|NCT00727844|Experimental|Delayed Start Linezolid|Subjects continued their existing regimen for 2 months after which LZD (600 mg once daily) was added. After 2 consecutive AFB negative sputum smears (not to exceed 4 months of LZD therapy), subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
9762428|NCT00727844|Experimental|Immediate Start Linezolid|Upon completion of entry criteria, subjects had LZD (600 mg once daily) added to their regimen. After 2 consecutive AFB negative sputum smears (or at 4 months) subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
9762429|NCT00727857|Experimental|Pioglitazone 15 mg /Metformin 850 mg BID|
9762430|NCT00727857|Active Comparator|Pioglitazone 15 mg BID|
9762431|NCT00727857|Active Comparator|Metformin 850 mg BID|
9762432|NCT00727909|Experimental|Hearing Aid Treatments|"Hearing aid treatments:~TC (Traditional Custom), RITA (Receiver-in-the Aid), and RITE (Receiver-in the-Ear)"
9762433|NCT00727961|Experimental|Arm 1|Caelyx Intravenous, 50 mg/m^2, given for 6 cycles
9762434|NCT00728130|Experimental|A|A neck dissection of at least the ipsilateral sub-level 1B will be performed in all patients
9762435|NCT00728182|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
9762436|NCT00728182|Placebo Comparator|Placebo|
9762437|NCT00728260||Menactra Vaccine Recipients|"Children 2 years through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period. They served as their own controls for evaluation of acute (Days 0-30) events. Rates of events occurring during Days 0-30 following vaccination were compared to rates of events occurring during Days 31-60 following vaccination.~Six-month surveillance: For each individual receiving Menactra vaccine, the rate of an event in the 30-day follow-up period was compared with the rate of the same event in the 31-180-day follow-up period using age, sex, and seasonality as covariates in Cox regression analyses.~Menactra vaccine was administered according to routine clinical practice."
9762438|NCT00728468|Experimental|Treatment arm|
9762439|NCT00728481|Active Comparator|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study (GERD)
9762440|NCT00728481|Active Comparator|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
9762441|NCT00728494||Treatment and Patient Assistance Program|Patient assistance program was provided to the participants treated with PegIntron/Rebetol. The support program consisted of training by physicians or specialized nurses on the significance of treatment compliance, methods for managing adverse events, and correct drug administration, as well as informational materials and assistance in the management of adverse events.
9762442|NCT00728494||Treatment Alone|PegIntron/Rebetol treatment only.
9762443|NCT00728507|Experimental|1|Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
9762444|NCT00728507|Active Comparator|2|Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
9762445|NCT00728689|Active Comparator|Group ST-246 Form I (followed by Form V)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
9762446|NCT00728689|Active Comparator|Group ST-246 Form V (followed by Form I)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
9762447|NCT00728728|Active Comparator|Arm 1: Pregnenolone|Pregnenolone
9762448|NCT00728728|Placebo Comparator|Arm 2: Placebo|Placebo
9762449|NCT00728819|Active Comparator|1|Tapered PICC
9762450|NCT00728819|Active Comparator|2|Non-tapered PICC
9762451|NCT00728910|Active Comparator|Atorvastatin|atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
9762452|NCT00728910|Active Comparator|ABT335|ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
9762453|NCT00728910|Active Comparator|ER niacin|ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks
9762454|NCT00728923|Experimental|1|Minocycline (NPL-2003)
9762455|NCT00728936|Experimental|IMO-2125 0.04 mg/kg q week|IMO-2125 given weekly at 0.04 mg/kg
9762456|NCT00728936|Experimental|IMO-2125 0.08 mg/kg q week|IMO-2125 given weekly at 0.08 mg/kg
9762457|NCT00728936|Experimental|IMO-2125 0.16 mg/kg q week|IMO-2125 given weekly at 0.16 mg/kg
9762458|NCT00728936|Experimental|IMO-2125 0.32 mg/kg q week|IMO-2125 given weekly at 0.32 mg/kg
9762459|NCT00728936|Experimental|IMO-2125 0.48 mg/kg q week|IMO-2125 given weekly at 0.48 mg/kg
9762460|NCT00728936|Placebo Comparator|Placebo|Weekly saline placebo
9762461|NCT00728936|Experimental|IMO-2125 0.16 mg/kg twice a week|IMO-2125 given twice a week at 0.16 mg/kg
9762462|NCT00728949|Active Comparator|IMC-A12 (cixutumumab) + antiestrogen therapy|Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory.
9762463|NCT00728949|Experimental|IMC-A12 (cixutumumab)|Participants will receive only IMC-A12 (10 mg/kg over 1 hour every 2 weeks).
9762464|NCT00728988|Experimental|Atorvastatin Group|
9762465|NCT00728988|Other|Usual Care Group|
9762466|NCT00729053|Active Comparator|Previous treatment, 0.16mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
9762467|NCT00729053|Active Comparator|Previous treatment, 0.64mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
9762468|NCT00729053|Active Comparator|Treatment Naive, 0.16mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
9762469|NCT00729053|Active Comparator|Treatment Naive, 0.64mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
9762470|NCT00729157|Experimental|Treatment (ziv-aflibercept and fludeoxyglucose F 18)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo FDG-PET scans at baseline and after 8 weeks of study therapy to evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and periodically during study for laboratory correlative studies. Samples are examined for pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.
9762471|NCT00729183|Experimental|Odanacatib 50 mg|Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
9762472|NCT00729183|Placebo Comparator|Placebo|Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
9762473|NCT00729326|Experimental|Sequence A|
9762474|NCT00729326|Experimental|Sequence B|
9762475|NCT00729378|Experimental|Exercise Intervention|Implementation of intervention program designed to provide skeletal loading through high impact activities. All activities performed by subjects in exercise intervention arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
9783682|NCT01207908|No Intervention|Standard steroid treatment alone|Standard daily steroid treatment for DMD
9783683|NCT01207934|Placebo Comparator|placebo|saline placebo for fourteen days
9832844|NCT02631525|Active Comparator|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
9832845|NCT02631538|Placebo Comparator|Placebo|Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
9832846|NCT02631538|Experimental|Belimumab monotherapy|Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
9832847|NCT02631538|Experimental|Belimumab and Rituximab co-administration therapy|Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
9832848|NCT02631538|Active Comparator|Rituximab monotherapy|Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
9832849|NCT02631551|Experimental|GSP 301 NS|
9832850|NCT02631551|Active Comparator|Olopatadine HCl NS|
9832851|NCT02631551|Active Comparator|Mometasone furoate NS|
9832852|NCT02631551|Placebo Comparator|GSP 301 Placebo NS|
9832853|NCT02631590|Experimental|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m^2 ) + Gemcitabine (1000 mg/m^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
9832854|NCT02631746|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity.
9832855|NCT02631772|Experimental|Late Cohort, Arm 1|Ledispasvir (LDV) and Sofosbuvir (SOF) monotherapy x 12 weeks
9832856|NCT02631772|Active Comparator|Late Cohort, Arm 2|Ledispasvir (LDV) and Sofosbuvir (SOF) +ribavirin x 12 weeks
9832857|NCT02631850|Active Comparator|Traditional CI Therapy|"Participants will receive a 35-hour dose of CI therapy. Treatment will consist of 35 therapist/client contact hours in the clinic, 10 weekdays, over 3 weeks. To promote carry-over of motor gains to daily activities, participants will complete: (1) a treatment contract, (2) daily self-report of arm use, and (3) problem-solving to overcome barriers to use of the more affected upper extremity. In addition, the client will agree to wear a padded restraint mitt on the less affected hand for the majority of waking hours to encourage use of the weaker hand for daily activities. Finally, the participant will agree to 30 minutes per day of individualized task-practice outside the clinic (in addition to training in the clinic) focused on functional activities catered towards accomplishing the person's therapeutic goals."
9832858|NCT02631850|Active Comparator|Gaming CI Therapy|15 hours of progressive massed motor practice will occur through in-home video game play over 15 consecutive weekdays. Participants will play the game during times of their choosing. The participant will wear an activity monitor biofeedback device for the majority of waking hours. As with traditional CI therapy, the client will agree to an additional 30 minutes per day of individualized task-practice. Five therapist/client contact hours will occur in the clinic on approximate treatment days 1, 3, 6, and 11 and will focus on treatment elements that cannot be readily addressed through the game, such as problem-solving to help the participant carry over motor gains to daily life.
9762476|NCT00729378|No Intervention|Control|Participants in this arm will not take part in exercise intervention. All activities performed by subjects in control arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
9762477|NCT00729430|Experimental|Omega-3 Fatty Acids|Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
9762478|NCT00729430|Placebo Comparator|Placebo|Participants will receive placebo for 6 months.
9762479|NCT00729469|Experimental|Ospemifene 60 mg/day and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
9762480|NCT00729469|Placebo Comparator|Placebo and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
9762481|NCT00729482|Experimental|1|Treatment Arm (RAD001)
9762482|NCT00729521|No Intervention|Control|a control group receiving no special resources or guidance related to fall injury prevention or the community health improvement process;
9762483|NCT00729521|Active Comparator|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
9762484|NCT00729521|Experimental|Facilitative System|"a Facilitative System group receiving facilitative system support in addition to the resources provided the Standard Program group"
9762485|NCT00729586|Experimental|Arm I (temsirolimus)|Patients receive temsirolimus IV over 30 minutes once weekly for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9762486|NCT00729586|Experimental|Arm II (temsirolimus, megestrol acetate, tamoxifen citrate)|Patients receive temsirolimus as in Arm I and megestrol acetate PO BID for 3 weeks alternating with tamoxifen citrate PO BID for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9762487|NCT00729612|Experimental|Treatment (nab-paclitaxel, carboplatin)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9762488|NCT00729690|Experimental|1 Multi-Dose Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
9762489|NCT00729690|Experimental|2 single-dose pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
9762490|NCT00729690|Placebo Comparator|3 Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
9762491|NCT00729781|Experimental|Polyester Implants|There is one arm for this study. All subjects in this study will receive the investigational nasal implants. See the detailed description for procedure information.
9762492|NCT00729807|Experimental|Pentamidine|
9762493|NCT00729833|Experimental|CP-751,871 + Sunitinib|Escalating cohorts of CP-751,871 + Sunitinib
9762494|NCT00729846|Experimental|A|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence [300mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
9762495|NCT00729846|Experimental|B|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
9762496|NCT00729859|Experimental|Group 1|Acyline 300 µg/kg injections every two weeks (2 doses) + placebo (no active ingredients) gel daily for 28 days + oral placebo pill daily for 28 days
9762497|NCT00729859|Experimental|Group 2|Acyline 300 µg/kg injections every two weeks (2 doses) + Testosterone gel 100 mg daily for 28 days + oral placebo pill daily for 28 days
9762498|NCT00729859|Experimental|Group 3|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
9762499|NCT00729924|Experimental|Open label oral raltegravir|Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
9762500|NCT00729937|Experimental|TMP/SMX vs. Placebo|Subjects with an acute uncomplicated cutaneous abscess will be randomized to receive either Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or 4 placebo pills (twice per day).
9762501|NCT00729937|Experimental|TMP/SMX vs. Clindamycin|Subjects with an acute uncomplicated wound infection will be randomized to receive Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day, with alternating 1 identical placebo pill, twice per day) or clindamycin (300 mg, four times per day, with 3 placebo pills on alternating doses).
9762502|NCT00729937|Experimental|Cephalexin and TMP/SMX vs. Cephalexin|Subjects with acute uncomplicated cellulitis will be randomized to receive cephalexin (500 mg, four times per day) and Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or cephalexin (500 mg, four times per day) and placebo (4 pills, twice per day).
9762503|NCT00730015|Experimental|145 μg linaclotide|
9762504|NCT00730015|Experimental|290 μg linaclotide|
9762505|NCT00730015|Placebo Comparator|Matching Placebo|
9762506|NCT00730028|Experimental|Limited Abscess|Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
9783684|NCT01207934|Experimental|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
9783685|NCT01207934|Experimental|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
9783686|NCT01208038|Experimental|Testosterone|Testosterone transdermal patch 300micrograms, twice weekly for 12 weeks
9783687|NCT01208051|Experimental|Arm A (cediranib maleate)|Patients receive cediranib maleate 30 mg PO QD on days 1-28. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9783688|NCT01208051|Experimental|Arm B (cediranib maleate plus lenalidomide thru April 10, 2015)|Patients receive cediranib maleate 30 mg PO and lenalidomide 15 mg PO on days 1-21. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. NOTE: As of April 10, 2015, patients assigned to this arm are discontinued lenalidomide and continued on cediranib alone.
9783689|NCT01208103|Experimental|Treatment (oxaliplatin, bevacizumab, capecitabine)|Participants receive oxaliplatin via CVC over 2 hours and bevacizumab IV over 30-90 minutes on day 1. Participants also receive capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9783690|NCT01208220|Active Comparator|Negative pressure wound therapy|NPWT changed TIW
9783691|NCT01208220|Experimental|NPWT plus Collagenase Ointment|Collagenase applied TIW with NPWT
9783692|NCT01208233|Experimental|1 mg PF-03049423|
9783693|NCT01208233|Experimental|3 mg of PF-03049423|
9783694|NCT01208233|Experimental|6 mg of PF-03049423|
9783695|NCT01208233|Placebo Comparator|Placebo|
9783696|NCT01208324|Active Comparator|Estrogen patch|Vivelle Dot® 0.10 - 0.15 mg/day for 8 weeks
9783697|NCT01208324|Active Comparator|Amino Acids|L-Isoleucine (4.2 g), L-Leucine (6.6 g), L-Lysine (4.8 g), L-Methionine (1.5 g), L-Phenylalanine (6.6 g), L-Threonine (3.0 g), L-Valine (4.8 g)
9783698|NCT01208324|Placebo Comparator|Placebo Patch|Placebo
9783699|NCT01208324|Placebo Comparator|Placebo pills|31.5 g of lactose or microcellulose
9783700|NCT01208337|Other|Alemtuzumab induction|Intestine transplant recipients who receive induction with alemtuzumab prior to transplantation.
9783701|NCT01208402|Active Comparator|oral long acting beta blocker|oral administration of long acting beta blocker as standard of care on the day of surgery
9984215|NCT04301011|Experimental|Arm A: TBio-6517 alone|Dose escalation of TBio-6517 alone administered by direct injection into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months.
9762507|NCT00730028|Experimental|Cellulitis or Larger Abscess|Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.
9762508|NCT00730041|Active Comparator|Palatal Implants|Pillar(R) Palatal Implants in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
9762509|NCT00730041|Sham Comparator|Sham procedure|Sham (procedure but no implants inserted) in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
9783702|NCT01208402|Experimental|Esmolol infusion|given 30 minutes prior to induction up to 12 hours post-op
9783703|NCT01208415|Experimental|Device Implant|
9783704|NCT01208870|Experimental|Variety Group|Traditional family based weight control treatment program with components to reduce variety of high energy dense foods incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
9783705|NCT01208870|Experimental|Nutrition Education Control|Traditional family based weight control treatment program, without components from habituation theory incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
9783706|NCT01208922|Experimental|Group A|Rifamycin SV-MMX® 200 mg tablets
9783707|NCT01208922|Active Comparator|Group B|Ciprofloxacin 500 mg capsules
9783708|NCT01208961|Active Comparator|Epanova-Lovaza-Epanova-Lovaza|
9783709|NCT01208961|Active Comparator|Lovaza-Epanova-Lovaza-Epanova|
9783710|NCT01209078|Experimental|Regimen 1|GSK1322322 1500mg and Placebo Linezolid given twice a day (BID) for 10 days
9783711|NCT01209078|Active Comparator|Regimen 2|Linezolid 600mg and placebo GSK1322322 given BID for 10 days
9783712|NCT01209143|Experimental|Vismodegib + rosiglitazone|Participants received rosiglitazone 4 mg orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
9783713|NCT01209143|Experimental|Vismodegib + oral contraceptive|Participants received the oral contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
9783714|NCT01209195|Experimental|MM-121 + Paclitaxel|Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW
9785578|NCT01254747|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
9785579|NCT01254747|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
9785580|NCT01254747|Active Comparator|Nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
9785581|NCT01254747|Active Comparator|Narafilcon A|Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
9785582|NCT01254760|Other|Investigational multifocal / Commercial multifocal|Investigational multifocal contact lenses worn first, with commercial multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
9785583|NCT01254760|Other|Commercial multifocal / Investigational multifocal|Commercial multifocal contact lenses worn first, with investigational multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
9785770|NCT01259492|Experimental|Ritalin LA 60 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14.In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
9785771|NCT01259492|Experimental|Ritalin LA 80 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3 and to 80 mg at week 4. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
9832859|NCT02631850|Active Comparator|Gaming CI Therapy with Additional Contact via Video Conference|This group will receive treatment that is identical to Group 2, but will receive an additional 2.6 hours video conference consultation throughout the treatment period.
9762510|NCT00730158|Experimental|Arm A|irinotecan+ KD018
9762511|NCT00730158|Experimental|Arm B|irinotecan + placebo
9762512|NCT00730171|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator.
9762513|NCT00730236|Experimental|AEGR-733|
9762514|NCT00730275|Experimental|Sitagliptin 50 mg|Participants were randomized to sitagliptin 50 mg
9762515|NCT00730275|Experimental|Sitagliptin 100 mg|Participants were randomized to sitagliptin 100 mg
9762516|NCT00730275|Experimental|Sitagliptin 200 mg|Participants were randomized to a single dose of sitagliptin 200 mg
9762517|NCT00730275|Placebo Comparator|Placebo to sitagliptin|Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
9762518|NCT00730327|Experimental|BIB®|Receives BioEnterics® Intragastric Balloon Intervention as well as diet and exercise counseling with the Behavioral Modification Intervention.
9762519|NCT00730327|Other|Control|Control arm receives the Behavioral modification intervention only.
9762520|NCT00730353|Experimental|1|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.~Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.~Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion."
9762521|NCT00730405|Active Comparator|Albaconazole 100mg|Albaconazole for 36 weeks
9762522|NCT00730405|Active Comparator|Albaconazole 200mg|Albaconazole for 36 weeks
9762523|NCT00730405|Active Comparator|Albaconazole 400mg|Albaconazole for 36 weeks
9762524|NCT00730405|Active Comparator|Albaconazole 400mg 24 weeks, Placebo 12 weeks|Albaconazole for 24 weeks, Placebo for 12 weeks
9762525|NCT00730405|Placebo Comparator|Placebo 400 mg|Placebo for 36 weeks
9762526|NCT00730483|Experimental|DEB-TACE|PVA microporous hydrospheres loaded with doxorubicin hydrochloride used for the treatment of unresectable liver metastases from neuroendocrine tumors.
9762527|NCT00730522|Active Comparator|1|CPP-109 vigabatrin tablets
9762528|NCT00730522|Placebo Comparator|2|Matching Placebo Tablets
9762529|NCT00730691|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
9762530|NCT00730691|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
9762531|NCT00730691|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
9762532|NCT00730691|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
9762533|NCT00730691|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
9762534|NCT00730730|Experimental|Complete SE Iliac Stent|Complete SE Iliac Stent
9762535|NCT00730756|Active Comparator|Arm A|Fluticasone Furoate Nasal Spray 110mcg intranasally once daily
9762536|NCT00730756|Placebo Comparator|Arm B|Matching placebo nasal spray intranasally once daily
9762537|NCT00730847|Experimental|Cervarix Group|Healthy female subjects who received three doses of the Cervarix vaccine, administered intramuscularly in the deltoid region according to a 0, 1 and 6-month schedule.
9762538|NCT00730912|Experimental|Pediatrics 3 to 6 years|Pediatrics 3 to 6 years
9762539|NCT00730912|Experimental|Pediatrics 7 to 15 years|Pediatrics 7 to 15 years
9762540|NCT00730912|Experimental|Adults 16 to 64 years|Adults 16 to 64 years
9762541|NCT00730925|Experimental|BIBW 2992|patient to receive tablets of BIBW 2992 once a day, starting at high dose until progression of the disease
9762542|NCT00730925|Experimental|BIBW 2992 + paclitaxel|patient whose disease progressed on treatment with BIBW 2992 monotherapy to receive tablet of BIBW 2992 once a day in combination with i.v. paclitaxel 3 weekly
9762543|NCT00730964|Other|Phase 4|Open Label
9762544|NCT00731042|Experimental|Avagard|3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers
9762545|NCT00731042|Active Comparator|Purell|Purell Surgical Scrub with Moisturizers
9762546|NCT00731055|Experimental|Intervention 1|"Each participant participates in 4 consecutive interventions in random order.~Placebo, 1 capsule before the session~0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session~4. 2 mg varenicline, 1 capsule before the session"
9762547|NCT00731055|Experimental|Intervention 2|Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session
9762548|NCT00731055|Experimental|Intervention 3|Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session
9984216|NCT04301011|Experimental|Arm B: TBio-6517 and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. TBio-6517 will be directly injected into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.
9762549|NCT00731055|Experimental|Intervention 4|Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session
9762550|NCT00731094|Experimental|Physical Activity Intervention|Expert system-based physical activity counseling: Individualized baseline counseling and guided goal setting to increase physical activity gradually to at least 150 minutes/week of moderate intensity, with a 12-month follow-up via postal mail of 14 additional counseling contacts generated by responses to a physical activity questionnaire and individually tailored computer-generated expert system feedback messages for physical activity based on stages of the motivational readiness for change model
9783715|NCT01209234|Active Comparator|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
9783716|NCT01209234|Active Comparator|Education Arm|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.
9783717|NCT01209260|Experimental|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
9783718|NCT01209260|Active Comparator|Mechanical needle|Mechanical (Brockenbrough) needle for transseptal access
9783719|NCT01209286|Experimental|Blinatumomab 15 μg|Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
9783720|NCT01209286|Experimental|Blinatumomab 5/15 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
9783721|NCT01209286|Experimental|Blinatumomab 5/15/30 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
9783722|NCT01209325|Experimental|Vaccination|Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
9783723|NCT01209442|Experimental|RT with Temozolomide and Bevacizumab|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
9783724|NCT01209598|Experimental|Palbociclib 200mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
9783725|NCT01209598|Experimental|Palbociclib 125mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
9783726|NCT01209689|Experimental|Tocilizumab 4 mg/kg|Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
9783727|NCT01209689|Experimental|Tocilizumab 8 mg/kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
9783728|NCT01209689|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.
9783729|NCT01209702|Placebo Comparator|Part 1: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
9783730|NCT01209702|Experimental|Part 1: Tocilizumab|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
9783731|NCT01209702|Placebo Comparator|Part 2: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 24. Participants who did not attain an ASsessment in Ankylosing Spondylitis-20 (ASAS20) response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
9762551|NCT00731094|No Intervention|Attention Control|Generalized baseline healthy lifestyle education and suggestion to increase physical activity, with a 12-month follow-up via postal mail of 14 wellness newsletters focused on health issues other than physical activity
9762552|NCT00731120|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
9762553|NCT00731120|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
9762554|NCT00731120|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
9762555|NCT00731133|Other|Disulfiram|Disulfiram at 250 mg daily
9762556|NCT00731198|Experimental|1|Drotaverine hydrochloride
9762557|NCT00731198|Active Comparator|2|Hyoscine-N-butylbromide
9762558|NCT00731211|Experimental|Pazopanib|800 mg of pazopanib orally each day continuously
9762559|NCT00731341|Experimental|Hysteroscopic cryoablation|Women undergoing hysteroscopic ultrasound guided cryoablation for the treatment of uterine fibroids.
9762560|NCT00731484||Volunteer Patients/Subjects|These subjects should present the general population.
9762561|NCT00731549|Experimental|1|Active Treatment of aripiprazole IM depot (300mg or 400mg)
9762562|NCT00731588|Experimental|PPG1A - Adults|Phase I completed: Healthy male and post-menopausal female volunteers between the ages of 18 and 65. Volunteers must not have donated blood in the previous 8 weeks.
9762563|NCT00731588|Experimental|PPG1B - Infants|Phase II in progress: Newborns >= 24 weeks gestation who are patients in the Neonatal Intensive Care Unit at the University of Iowa Hospitals and Clinics that are being treated with the expectation of survival.
9762564|NCT00731614|Experimental|Arm 1|Cognitive Behavior Therapy + mirror retraining
9762565|NCT00731614|Active Comparator|Arm 2|Supportive psychotherapy
9762566|NCT00731640|Active Comparator|Monofocal|Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye
9762567|NCT00731640|Active Comparator|Phakic|Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending
9762568|NCT00731653|Experimental|1|BCI-024 and BCI-049
9762569|NCT00731666|Other|Titan® IPP|Subjects implanted with Titan® IPP
9762570|NCT00731679|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
9762571|NCT00731679|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
9762572|NCT00731692|Experimental|FTY720D 0.5 mg|Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment
9762573|NCT00731692|Placebo Comparator|Placebo|Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization
9762574|NCT00731692|Experimental|FTY720D 1.25 mg switch to 0.5 mg|Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009
9762575|NCT00731783|Active Comparator|Index patient only|Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
9762576|NCT00731783|Active Comparator|Household|All members of the household (over the age of 6 months) will be asked to follow the study protocol.
9762577|NCT00731874|Active Comparator|Arm 1 (6 to 8 ng/mL)|Target tacrolimus trough concentration of 6 to 8 ng/mL
9762578|NCT00731874|Active Comparator|Arm 2 (3 to 5 ng.mL)|Target tacrolimus trough concentration of 3 to 5 ng/mL
9762579|NCT00731939|Other|Titan® OTR IPP|Subjects implanted with Titan® One Touch Release (OTR) Inflatable Penile Prosthesis (IPP)
9762580|NCT00732030|Experimental|AcrySof Toric T3|Each enrolled eye receives AcrySof Toric Model SN60T3 Intraocular Lens (IOL)
9762581|NCT00732069|Active Comparator|Placebo, then ramipril, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
9762582|NCT00732069|Active Comparator|Placebo, then valsartan, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
9762583|NCT00732069|Active Comparator|Ramipril, then placebo, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
9762584|NCT00732069|Active Comparator|Valsartan, then placebo, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
9762585|NCT00732069|Active Comparator|Ramipril, then valsartan, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
9762586|NCT00732069|Active Comparator|Valsartan, then ramipril, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
9762587|NCT00732160|Experimental|HS-V/A; LS-V/A|High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion
9762588|NCT00732160|Experimental|HS-A/V; LS-A/V|High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion
9762589|NCT00732160|Experimental|LS-V/A; HS-V/A|Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion
9762590|NCT00732160|Experimental|LS-A/V; HS-A/V|Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion
9762591|NCT00732199|Other|Arm 1|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Young adults.
9762592|NCT00732199|Experimental|Arm 2|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Older adults.
9762593|NCT00732212|Experimental|Doppler endoscopic probe hemostasis|In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
9762594|NCT00732212|Active Comparator|Standard Endoscopic Hemostasis|Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
9762595|NCT00732225|Active Comparator|DisCoVisc|Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
9762596|NCT00732225|Active Comparator|DuoVisc|Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
9762597|NCT00732225|Active Comparator|BioVisc|Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
9762598|NCT00732225|Active Comparator|Healon5|AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
9762599|NCT00732225|Active Comparator|Amvisc Plus|Bausch & Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
9762600|NCT00732238|Experimental|Arm 1|Removal of Bladder Catheter. Urine Culture Post Catheter Removal. Shorter Duration of Antibiotic Therapy.
9762601|NCT00732238|Active Comparator|Arm 2|Urinary Catheter Is Not Exchanged. Antibiotic Therapy Is Based On Culture Obtained From Existing Catheter. Longer Duration of Antibiotic Therapy.
9762602|NCT00732251|Experimental|Allopurinol|Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.
9762603|NCT00732303|Experimental|1|"Pemetrexed (Alimta) 500mg/m^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles~Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
9762604|NCT00732472|Experimental|7 day repeat dose|7 day repeat dose
9762605|NCT00732498|Experimental|ESHAP followed by Zevalin and Rituximab|Etoposide, Methylprednisolone, Cytarabine, Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.
9762606|NCT00732615|Placebo Comparator|Placebo|Sterile water for injection
9762607|NCT00732615|Experimental|50, 75, 100 mcg NPSP558|Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
9762608|NCT00732641|Experimental|Peginterferon α-2b|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
9762609|NCT00732641|No Intervention|No Treatment|Participants will be observed and will receive no treatment.
9762610|NCT00732654|Experimental|Sublingual Immunotherapy (SLIT)|"These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.~Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years."
9762611|NCT00732654|Experimental|SLIT/ Oral Immunotherpay (OIT) B|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years."
9785584|NCT01254851|Active Comparator|goal-augmented post-operative care.|Patients in this group will be given a goal number of steps to take on each post-operative day.
9785585|NCT01254851|No Intervention|Usual care|routine post-operative ambulation
9785586|NCT01254877|Placebo Comparator|Placebo Ondansetron - sugar pill|Placebo is an oral preparation made to appear and taste like the active drug preparation.
9762612|NCT00732654|Experimental|SLIT/ OIT A|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.~Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks."
9762613|NCT00732758|Experimental|Vitamin D3|Vitamin D3 1000 IU Tablet
9762614|NCT00732758|Placebo Comparator|Placebo|Placebo Tablet
9762615|NCT00732875|Experimental|Open Label Infliximab + Methotrexate|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
9762616|NCT00732901|Experimental|A (escitalopram)|Escitalopram
9762617|NCT00732901|Experimental|B (placebo)|Placebo
9762618|NCT00732940|Experimental|Belimumab Q2WKS|Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
9762619|NCT00732940|Experimental|Belimumab 3X/WK|Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
9762620|NCT00732992|Experimental|CDD|
9762621|NCT00732992|Experimental|2/1|
9762622|NCT00733096|Experimental|1|Epidural etanercept 4 mg, two doses 2 weeks apart
9762623|NCT00733096|Active Comparator|2|Epidural methylprednisolone 60 mg, two doses 2 weeks apart
9762624|NCT00733096|Placebo Comparator|3|Epidural saline, two doses 2 weeks apart
9762625|NCT00733135|Other|Atherectomy with embolic protection|All subjects were treated with atherectomy (with SilverHawk or TurboHawk device) in conjunction with embolic protection (SpiderFX device).
9762626|NCT00733226|Active Comparator|1 Broncho-Vaxom|The children received one capsule per oral, OM-85 BV (3.5 mg) per day for the first 10 consecutive days of each month for 3 consecutive months.
9762627|NCT00733226|Placebo Comparator|2 (Placebo OM-85 BV)|The children received one capsule per oral, placebo per day for the first 10 consecutive days of each month for 3 consecutive months.
9762628|NCT00733278|Experimental|Copper IUD|Copper IUD
9762629|NCT00733291|Active Comparator|Nelfilcon A soak / Nelfilcon A no-soak|Nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by nelfilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
9762630|NCT00733291|Active Comparator|Nelfilcon A no soak / nelfilcon A soak|Nelfilcon A contact lenses inserted directly from the blister package, followed by nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
9762631|NCT00733291|Active Comparator|Etafilcon A soak / etafilcon A no soak|Etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by etafilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
9762632|NCT00733291|Active Comparator|Etafilcon A no soak / etafilcon A soak|Etafilcon A contact lenses inserted directly from the blister package, followed by etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
9762633|NCT00733304|Experimental|5 mg/ml TID|eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)
9762634|NCT00733304|Experimental|2 mg/ml TID|eligible participants received 2 mg/ml Pazopanib eye drops three times daily
9762635|NCT00733304|Experimental|5 mg/ml QD|eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)
9762636|NCT00733330|Other|Conventional TKR arm|Patients to receive treatment with either a P.F.C. Sigma or L.C.S. knee using the conventional manual surgical technique
9762637|NCT00733330|Active Comparator|MiTKR CAS arm|Patients to receive treatment with either a P.F.C. or L.C.S. knees in chronological order into the CAS group which will use minimally invasive surgery and computer navigation
9762638|NCT00733343|Active Comparator|Treatment Group|treatment with Adaptive Servoventilation (Europe: AutoSet CS (USA: VPAP (Variable Positive Airway Pressure) Adapt SV)) + standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
9762639|NCT00733343|No Intervention|Control Group|standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
9762640|NCT00733356|Experimental|Vyvanse Treatment|All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
9762641|NCT00733369|Other|PFC Sigma RP-F|125 patients to be allocated to this arm according to blinding envelopes
9762642|NCT00733369|Active Comparator|PFC Sigma RP|125 patients to be allocated to this arm according to blinding envelopes
9762643|NCT00733408|Experimental|Tx (chemo, MoAb, and enzyme inhibitor)|"INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity."
9762644|NCT00733421|Experimental|1|"Active study drug:~Etoricoxib 90 mg once daily"
9762645|NCT00733421|Active Comparator|2|Tramadol 100 mg slow release twice daily
9762646|NCT00733499|Other|LCS Complete Duofix|102 patients
9762647|NCT00733499|Active Comparator|LCS Complete Porocoat|104 patients
9762648|NCT00733512||ReSTOR|AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL)
9762649|NCT00733746|Experimental|Neoadjuvant therapy + Surgery + Adjuvant therapy|As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
9762650|NCT00733824|Experimental|Cohort 1|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
9762651|NCT00733824|Experimental|Cohort 2|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
9762652|NCT00733824|Experimental|Cohort 3|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
9762653|NCT00733824|Experimental|Cohort 4|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
9762654|NCT00733824|Experimental|Phase II|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
9762655|NCT00733902|Experimental|Tanezumab 10 mg|
9762656|NCT00733902|Experimental|Tanezumab 5 mg|
9762657|NCT00733902|Experimental|Tanezumab 2.5 mg|
9762658|NCT00733902|Placebo Comparator|Placebo|
9762659|NCT00733954|Active Comparator|clobetasol propionate spray|clobetasol propionate spray 0.05%
9762660|NCT00733954|Active Comparator|clobetasol propionate ointment|clobetasol propionate ointment 0.05%
9762661|NCT00733980|Experimental|GSK561679 arm|Double blind GSK561679
9762662|NCT00733980|Placebo Comparator|placebo arm|Double blind placebo
9762663|NCT00733993|Experimental|1 Caffeine 150 mg|Caffeine 150 mg
9762664|NCT00733993|Placebo Comparator|2 Placebo|Placebo
9762665|NCT00733993|Experimental|3 Amphetamine|Amphetamine
9762666|NCT00733993|Experimental|4 Caffeine 300 mg|Caffeine 300 mg
9762667|NCT00734032|Placebo Comparator|Placebo Group|Matched Placebo
9762668|NCT00734032|Experimental|SB480848 40mg Group|SB480848 40mg/day
9762669|NCT00734032|Experimental|SB480848 80mg Group|SB480848 80mg/day
9762670|NCT00734032|Experimental|SB480848 160mg Group|SB480848 160mg/day
9762671|NCT00734071|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
9762672|NCT00734071|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
9762673|NCT00734097|Experimental|Nexium 40 mgs|
9762674|NCT00734149|Experimental|Bortezomib+Melphalan+Prednisone|Bortezomib 1.3 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle. Six cycles are planned. On days when both melphalan and bortezomib are given, melphalan is given at least one hour prior to bortezomib. Melphalan 6 mg/m2 is administered orally on an empty stomach daily on days 1-7 of each cycle. Prednisone 60 mg/m2 is administered orally daily on days 1-7 of each cycle.
9762675|NCT00734162|Experimental|Tenofovir disoproxil fumarate (TDF)|
9762676|NCT00734162|Placebo Comparator|Placebo|
9762677|NCT00734214|Experimental|0.9% NaCl|
9762678|NCT00734214|Active Comparator|0.45% NaCl|
9762679|NCT00734305|Experimental|Dose Escalation|Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D
9762680|NCT00734344|Active Comparator|Arm 1|Raltegravir plus Truvada
9762681|NCT00734344|Active Comparator|Arm 2|Efavirenz plus Truvada
9762682|NCT00734409|Experimental|RASS plus (BIS)|Participants in this arm will receive sedation assessment with the RASS scale augmented with Bispectral Index (BIS) Monitor
9762683|NCT00734409|No Intervention|RASS only|Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution
9762684|NCT00734474|Experimental|3.0 mg LY2189265|"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
9762685|NCT00734474|Experimental|2.0 mg LY2189265|"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
9762686|NCT00734474|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
9762687|NCT00734474|Experimental|1.0 mg LY2189265|"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
9785587|NCT01254877|Experimental|low dose ondansetron (0.2 mg bid)|
9785588|NCT01254877|Experimental|moderate dose ondansetron (0.8 mg bid)|
9762688|NCT00734474|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
9762689|NCT00734474|Experimental|0.5 mg LY2189265|"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
9762690|NCT00734474|Experimental|0.25 mg LY2189265|"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
9762691|NCT00734474|Active Comparator|Sitagliptin|"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
9762692|NCT00734474|Placebo Comparator|Placebo/Sitagliptin (Baseline Through 104 Weeks)|"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Placebo: tablet, administered orally, once daily for 26 weeks~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
9762693|NCT00734500|Experimental|Treatment|Treatment
9762694|NCT00734539|Experimental|1|fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
9762695|NCT00734539|Placebo Comparator|2|Placebo IV or PO twice weekly for 6 weeks
9762696|NCT00734578|Experimental|SPD503-AM|SPD503 (Guanfacine Extended Release)
9762697|NCT00734578|Experimental|SPD503-PM|SPD503 (Guanfacine Extended Release)
9762698|NCT00734578|Placebo Comparator|Placebo|
9762699|NCT00734591||Previously treated with Exubera|
9762700|NCT00734591||Previously treated with comparator|Subjects who had been treated with a comparator (other diabetes treatment such as injected insulin) in a prior Exubera controlled trial.
9762701|NCT00734604|Experimental|T(OaD)/S(PRN)/T(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
9762702|NCT00734604|Experimental|T(OaD)/T(PRN)/S(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
9762703|NCT00734604|Experimental|S(PRN)/T(OaD)/T(PRN)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
9762704|NCT00734604|Experimental|S(PRN)/T(PRN)/T(OaD)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
9762705|NCT00734604|Experimental|T(PRN)/T(OaD)/S(PRN)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
9762706|NCT00734604|Experimental|T(PRN)/S(PRN)/T(OaD)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
9762707|NCT00734617|Experimental|Less Dependent Smokers|
9762708|NCT00734617|Experimental|More Dependent Smokers|
9762709|NCT00734630|Active Comparator|Nebivolol|Nebivolol 5 mg, 5 mg nontrade tablets, oral administration Nebivolol 10 mg, 10 mg nontrade tablets, oral administration Nebivolol 20 mg, 20 mg nontrade tablets, oral administration Nebivolol 40 mg (two 20 mg nontrade tablets), oral administration
9762710|NCT00734630|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
9762711|NCT00734656|Placebo Comparator|Placebo medication + placebo alcohol|
9762712|NCT00734656|Experimental|Placebo Medication + 0.8 gr/kg Ethanol|
9762713|NCT00734656|Experimental|4 mg Dutasteride + Placebo Alcohol|
9762714|NCT00734656|Experimental|4 mg Dutasteride + 0.8 gr/kg Ethanol|
9762715|NCT00734734|Experimental|1|
9762716|NCT00734747|Experimental|Medigus SRS Endoscopic Stapling System|Endoluminal fundoplication for the treatment of GERD
9762717|NCT00734799|No Intervention|2|Usual Care/Wait-List Control
9762718|NCT00734799|Experimental|1|Sleep Intervention for PTSD (SIP)
9762719|NCT00734851|Experimental|Multimodality|4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks
9762720|NCT00734903|Experimental|A Woman's Path to Recovery (WPR)|A gender-focused approach to addiction recovery
9762721|NCT00734903|Active Comparator|12-Step Facilitation (TSF)|An evidence-based, non-gender-focused approach to addiction recovery
9762722|NCT00734929|Experimental|1|Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
9762723|NCT00734929|Active Comparator|2|Ondansetron 4 mg within 30 min of the end of surgery + Dexamethasone 10 mg after induction of anesthesia
9783732|NCT01209702|Experimental|Part 2: Tocilizumab 4 mg/kg|Participants received intravenous infusions of 4 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
9783733|NCT01209702|Experimental|Part 2: Tocilizumab 8 mg/kg|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
9783734|NCT01209780|Experimental|TIV (3-8 years)|Non-Naive subjects received one dose and naive subjects received two doses, administered 4 weeks apart, of investigational trivalent influenza vaccine (TIV)
9783735|NCT01209780|Active Comparator|Control TIV (3-8 years)|Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to <4 years and subjects aged 4 to 8 years received different control TIV.
9783736|NCT01209780|Experimental|TIV ( 9-17 years)|All subjects received one dose of investigational TIV. The subjects in this cohort were included only for safety analysis.
9783737|NCT01209780|Active Comparator|Control TIV ( (9-17 years)|All subjects received one dose of the control vaccine. The subjects from this cohort were included only for safety analysis.
9783738|NCT01209832|Experimental|Drug Interaction arm|
9783739|NCT01209949|Other|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|
9783740|NCT01210001|Experimental|BI 10773 low dose|BI 10773 tablets once daily
9783741|NCT01210001|Experimental|BI 10773 high dose|BI 10773 tablets once daily
9783742|NCT01210001|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
9783743|NCT01210079|Experimental|Gabapentin|
9783744|NCT01210079|Placebo Comparator|Placebo|
9783745|NCT01210118|Experimental|High intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
9783746|NCT01210118|Other|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
9783747|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Long Agonist Protocol|
9783748|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Multi-dose Antagonist Protocol|
9783749|NCT01210170|Experimental|mometasone 400 mcg - 30 min|randomly assigned intervention
9783750|NCT01210170|Experimental|mometasone 400 mcg simultaneous|randomly assigned intervention
9783751|NCT01210170|Placebo Comparator|placebo- 30 min|randomly assigned intervention
9783752|NCT01210170|Placebo Comparator|placebo simultaneous|randomly assigned intervention
9783753|NCT01210170|Experimental|mometasone 400 mcg - 60 min|randomly assigned intervention
9783754|NCT01210170|Placebo Comparator|placebo- 60 min|randomly assigned intervention
9783755|NCT01210170|Experimental|mometasone 200 mcg - 30 min|randomly assigned intervention
9783756|NCT01210170|Experimental|mometasone 200 mcg - 60 min|randomly assigned intervention
9783757|NCT01210170|Experimental|mometasone 200 mcg simultaneous|randomly assigned intervention
9783758|NCT01210222|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9783759|NCT01210352|Experimental|CII Drug|Open Label
9783760|NCT01210443|Experimental|Sitaxentan treatment|
9762724|NCT00734968|Experimental|Treatment|Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
9762725|NCT00734968|Placebo Comparator|Placebo|Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)
9762726|NCT00734994|Experimental|Hyperthermia system, Mitomycin C|Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.
9762727|NCT00735007|Experimental|1|
9762728|NCT00735072|Experimental|Maraviroc|Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
9762729|NCT00735072|Placebo Comparator|Placebo|Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
9762730|NCT00735306|Experimental|1|Avastin, Tarceva and Radiation Therapy
9762731|NCT00735371|Active Comparator|Lisdexamfetamine Dimesylate (LDX) 30 mg|
9762732|NCT00735371|Active Comparator|LDX 50 mg|
9762733|NCT00735371|Active Comparator|LDX 70 mg|
9762734|NCT00735371|Placebo Comparator|Placebo|
9762735|NCT00735397|Experimental|Perampanel|Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.
9762736|NCT00735436|Other|Gliadel/Avastin/CPT-11|Gliadel/Avastin/CPT-11
9762737|NCT00735449|Active Comparator|Combigan ®|Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)
9762738|NCT00735449|Active Comparator|Timolol Maleate 0.5%|Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)
9762739|NCT00735462|Experimental|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks
9762740|NCT00735462|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
9762741|NCT00735462|Placebo Comparator|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks.
9762742|NCT00735475|Experimental|Afluria®|
9762743|NCT00735475|Active Comparator|Fluzone®|
9762744|NCT00735618|Experimental|Guided Relaxation|Heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation program
9762745|NCT00735644|Experimental|JE-CV GPO MBP (Lot 1)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
9762746|NCT00735644|Experimental|JE-CV GPO MBP (Lot 2)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
9762747|NCT00735644|Experimental|JE-CV GPO MBP (Lot 3)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
9762748|NCT00735644|Active Comparator|JE-CV WRAIR (Group 4)|Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
9762749|NCT00735644|Sham Comparator|Hepatitis A (Group 5)|Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine
9762750|NCT00735670|Experimental|Venlafaxine|Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder. The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week. While this was the standard protocol, study drug tapering was individualized based on side effects and the clinical judgment of the prescriber.
9762751|NCT00735670|Placebo Comparator|Placebo|Placebo capsules were compounded by filling a matching gelatin capsule with lactose. Titration up and down followed the same schedule as the treatment group.
9762752|NCT00735696|Experimental|ramucirumab + paclitaxel + carboplatin|"Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle).~In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks."
9762753|NCT00735709|Experimental|Vortioxetine 1 mg|Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.
9762754|NCT00735709|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.
9762755|NCT00735709|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.
9762756|NCT00735709|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
9762757|NCT00735787|Placebo Comparator|Placebo/Adalimumab|"Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15.~In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27."
9762758|NCT00735787|Active Comparator|Adalimumab|80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.
9762759|NCT00735826|Experimental|Vorinostat 400 mg|Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.
9762760|NCT00735839|Experimental|V710|V710 vaccination (60 mcg) single dose on Day 1
9762761|NCT00735839|Placebo Comparator|Placebo|Placebo single dose on Day 1
9762762|NCT00735878|Experimental|ABT-751 100 mg and Carboplatin|100 mg BID ABT-751 orally for 7 days. Carboplatin AUC 4.5 once every 21 days.
9762763|NCT00735878|Experimental|ABT-751 125 mg and Carboplatin|125 mg BID ABT-751orally for 7 days. Carboplatin AUC 4.5 or 6 once every 21 days.
9762764|NCT00735878|Experimental|ABT-751 150 mg and Carboplatin|150 mg BID ABT-751orally for 7 days. Carboplatin AUC 6 once every 21 days.
9762765|NCT00735904|Experimental|AG-013736/Cisplatin/Gemcitabine|
9762766|NCT00735917|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9762767|NCT00736073|Active Comparator|1|aprepitant
9762768|NCT00736073|Placebo Comparator|2|Placebo
9762769|NCT00736099|Experimental|linagliptin 5 mg|open label
9762770|NCT00736099|Experimental|linagliptin 5 mg and pioglitazone 30 mg|open label
9762771|NCT00736125|Active Comparator|1|
9762772|NCT00736125|Active Comparator|2|
9762773|NCT00736190|Experimental|TDF|300-mg tablet (marketed formulation) taken orally once daily
9762774|NCT00736229|Experimental|Exenatide|0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
9762775|NCT00736242||PEG-IFN alfa-2b + RBV|Participants received a combination of PEG-IFN alfa-2b plus RBV according to routine clinical practice and locally-approved product recommendations for a minimum of 12 weeks. No investigational medicinal product was provided by the sponsor.
9762776|NCT00736255|Experimental|Vyvanse and transdermal nicotine patch|The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date.
9762777|NCT00736255|Placebo Comparator|Placebo and transdermal nicotine patch|The second group will receive matching placebo and NRT after the quit date.
9762778|NCT00736333||Pegylated Liposomal Doxorubicin|Subjects with metastatic breast cancer
9762779|NCT00736450|Experimental|Arm I|See Detailed Description
9762780|NCT00736476|Experimental|1|
9762781|NCT00736476|Placebo Comparator|2|
9762782|NCT00736489|Experimental|crossover dose 1|AZD3199 120 microgram
9762783|NCT00736489|Experimental|crossover dose 2|AZD3199 480 microgram
9762784|NCT00736489|Experimental|crossover dose 3|AZD3199 1920 microgram
9762785|NCT00736489|Placebo Comparator|crossover dose 4|Placebo
9762786|NCT00736489|Active Comparator|crossover dose 5|Formoterol 9 microgram
9762787|NCT00736489|Active Comparator|crossover dose 6|Formoterol 36 microgram
9762788|NCT00736502||Patients HIV-1 positive|
9762789|NCT00736580|Active Comparator|Blunt Needles|Cesarean Delivery Performed with Blunt-tipped surgical Needles
9762790|NCT00736580|Placebo Comparator|Sharp Needles|Cesarean delivery performed with sharp surgical needles.
9762791|NCT00736632|Placebo Comparator|Placebo|Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.
9762792|NCT00736632|Active Comparator|Vitamin D|Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.
9762793|NCT00736645|Experimental|Arm I|Patients receive oral selenomethionine and oral finasteride once daily for 4-5 weeks.
9762794|NCT00736645|Experimental|Arm II|Patients receive oral placebo and oral finasteride once daily for 4-5 weeks.
9762795|NCT00736645|Experimental|Arm III|Patients receive oral selenomethionine and oral placebo once daily for 4-5 weeks.
9762796|NCT00736645|Placebo Comparator|Arm IV|Patients receive two oral placebos once daily for 4-5 weeks.
9762797|NCT00736723||Patients non-septic shock|Postoperative/posttraumatic critically ill patients with non-septic shock
9762798|NCT00736723||Patients septic shock|Postoperative/posttraumatic critically ill patients with septic shock
9762799|NCT00736840|Other|CLD (chronic liver disease)|Chronic liver disease subjects with recent biopsy will be tested with a breath tests using a 13C enriched substrate metabolized by their liver
9762800|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|
9762801|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Double Blind)|
9762802|NCT00736853|Placebo Comparator|Placebo (Double-Blind)|
9762803|NCT00736879|Experimental|Dapagliflozin 1 mg|Dapagliflozin: 1 mg
9762804|NCT00736879|Experimental|Dapagliflozin 2.5 mg|Dapagliflozin: 2.5 mg
9762805|NCT00736879|Experimental|Dapagliflozin 5 mg|Dapagliflozin: 5 mg
9762806|NCT00736879|Placebo Comparator|Placebo|Placebo: 0 mg
9762807|NCT00736944|Experimental|1|"Induction chemotherapy followed by Radiation therapy plus Cisplatin~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42."
9762808|NCT00736944|Experimental|2|"Induction chemotherapy followed by Radiation therapy plus Cetuximab~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB"
9762809|NCT00736957|Experimental|Tramadol HCL plus Acetaminophen|
9762810|NCT00736996|Experimental|Pioglitazone|"Pioglitazone~30 - 45mg tablet daily for 6 months"
9762811|NCT00736996|Active Comparator|Endurance Exercise Training|Endurance Exercise Training (EET) Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
9762812|NCT00736996|Placebo Comparator|Placebo|Placebo matching tablet sugar pill daily for 6 months
9762813|NCT00737048|Experimental|Tramadol plus Acetaminophen and Placebo|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
9762814|NCT00737048|Experimental|Tramadol and Placebo|Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
9762815|NCT00737048|Experimental|Acetaminophen and Placebo|Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
9762816|NCT00737061|Experimental|Adiana Transcervical Sterilization System|Single arm treatment
9762817|NCT00737100|Experimental|Tiotropium Respimat 2.5 mcg|patient to receive low dose tiotropium once daily
9762818|NCT00737100|Experimental|Tiotropium Respimat 5 mcg|patient to receive high dose tiotropium once daily
9762819|NCT00737100|Placebo Comparator|Placebo Respimat|patient to receive placebo once daily
9762820|NCT00737178|Active Comparator|Immediate IUD insertion|Insertion of CuT380A at the routine medication abortion follow-up visit one week after initiation of a medication abortion
9762821|NCT00737178|Active Comparator|Delayed IUD insertion|Insertion of CuT380A four to six weeks after initiation of a medication abortion
9762822|NCT00737204|Experimental|Armodafinil|Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
9762823|NCT00737204|Placebo Comparator|Placebo|Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.
9762824|NCT00737243|Experimental|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
9762825|NCT00737243|Other|Treatment determined by physician|Other treatment determined by physician based on molecular profiling assay
9762826|NCT00737360|Experimental|1|
9783761|NCT01210495|Experimental|A|Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
9785589|NCT01254890|Experimental|Azacitidine + Sorafenib|Azacitidine (AZA) 75 mg/m^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days; Sorafenib 200 mg orally twice a day.
9832860|NCT02631850|Active Comparator|Traditional Occupational Therapy/Physical Therapy|Five therapist/client contact hours will occur on approximate treatment days 1, 3, 6, and 11 (same schedule as gaming CI therapy). 1 hour progressive resistance exercise to establish and progress an upper extremity home exercise program, 2 hours of neuromuscular reeducation, and 2 hours functional practice on activities of daily living (ADLs) with verbal encouragement to use the more affected upper extremity to the largest extent possible. Home practice consists of strengthening exercises, designed to increase range of motion, prescribed twice daily. After completing their participation in the standard OT condition (6 months), participants will be crossed-over to a CI therapy gaming only condition. This condition will be identical to that described above, excluding therapist contact throughout the intervention. Rather, participants will receive a DVD explaining the intervention and guiding them through use of the system.
9832861|NCT02631876|Experimental|Mirvetuximab Soravtansine|Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee [BIRC]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
9832862|NCT02631876|Experimental|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
9832863|NCT02631954|Experimental|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
9832864|NCT02631954|Experimental|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
9832865|NCT02632110|Experimental|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
9832866|NCT02632110|Experimental|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
9832867|NCT02632110|Experimental|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
9832868|NCT02632110|Experimental|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
9832869|NCT02632110|Experimental|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
9832870|NCT02632110|Experimental|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
10205269|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Triple Negative Breast Cancer (TNBC)|Participants with TNBC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 plaque-forming units/milliliter (PFU/mL) on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
9832871|NCT02632110|Experimental|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
9832872|NCT02632110|Experimental|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
9832873|NCT02632110|Placebo Comparator|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
9832874|NCT02632110|Placebo Comparator|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
9832875|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
9832876|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
9832877|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
9832878|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
9832879|NCT02632526|Experimental|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
9832880|NCT02632526|Experimental|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
9832881|NCT02632526|Experimental|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
9832882|NCT02632526|Experimental|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
9832883|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
9832884|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
9832885|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
9762827|NCT00737438|Experimental|1|"Initial chemo for ALL pts (ECX + BEV): Epirubicin 50 mg/m2 d1 every 21 days Cisplatin 60 mg/m2 d1 every 21 days, Capecitabine 625 mg/m2 po bid days 2-21 (held for 48 hours prior to FDG-PET/CT in week 3) Bev 15 mg/kg d1 every 21 days (cycle 1 & cycle 2 only) Salvage chemotherapy for metabolic non-responders (DI + BEV): Docetaxel 30 mg/m2 d1, d8 every 21 days, CPT-11 50 mg/m2 d1, d8 every 21 days, Bev 15 mg/kg d1, cycle 2 only 2 cycles are planned prior to resection.~Pts who aren't Cisplatin candidates (i.e. Creatinine clearance 40-60/cc, older age, marginal PS,etc.) may get oxaliplatin instead of cisplatin after discus with the PI. Oxaliplatin will be admin at 130 mg/m2 on day 1 every 21 days. Pts who aren't able to get Capecitabine (i.e. insurance restriction, unable to swallow, etc.) may get infusional fluorouracil instead of capecitabine after discus with the PI. Fluorouracil will be admin at 200 mg/m2/d x 21 days (held for 48 hours prior to FDGPET/ CT scan in week 3 of cycle 1)."
9762828|NCT00737464|Experimental|Mircera|Participant with chronic renal anemia will receive methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.
9762829|NCT00737477|Experimental|Mircera in Renal Anemia|Participants will receive SC methoxy polyethylene glycol-epoetin beta (Mircera) every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
9762830|NCT00737529|Experimental|Lenalidomide|"Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but < 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal."
9762831|NCT00737568|Experimental|Tenofovir DF|TDF plus placebo to match FTC/TDF
9762832|NCT00737568|Experimental|FTC/TDF|FTC/TDF plus placebo to match TDF
9762833|NCT00737633|Experimental|16-Week population|Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
9762834|NCT00737633|Experimental|72-Week population|Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
9762835|NCT00737672|Experimental|VIABAHN Treatment Group|Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
9762836|NCT00737672|Active Comparator|PTA Treatment Group|Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm
9762837|NCT00737698|Experimental|Exercise|Exercise
9762838|NCT00737698|Experimental|Repetitive magnetic stimulation|Repetitive magnetic stimulation of femoral nerve
9762839|NCT00737698|No Intervention|Control|No active treatment
9762840|NCT00737711|Experimental|Mircera|
9762841|NCT00737737|Experimental|Opioid|Participants will receive MS Contin over a 4 week period starting at 15 mg bid. Doses will titrated upwards as tolerated by increments of 15-30 mg to a highest attained dose or a maximum dose of 90 mg
9762842|NCT00737737|Experimental|Placebo|Participants will receive a similar number of placebo tablets which match the study drug with regards to appearance over a period of 4 weeks
9762843|NCT00737893|Experimental|Erythropoietin (EPO)|20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.
9762844|NCT00737893|Placebo Comparator|Placebo|Placebo doses given the day before surgery, the day of surgery, and the day after surgery.
9762845|NCT00738023|Active Comparator|Diabetics|Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
9762846|NCT00738023|Active Comparator|Non-Diabetic|Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours
9762847|NCT00738049|Active Comparator|Group 1|Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
9762848|NCT00738049|Active Comparator|Group 2|Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
9762849|NCT00738062|Active Comparator|Droxidopa|Study medication
9762850|NCT00738062|Placebo Comparator|Placebo|Placebo
9762851|NCT00738101|Experimental|Fish Oil Emulsion Arm|"In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours."
9762852|NCT00738361|Experimental|nab-paclitaxel|Administered via intravenous bolus at a dose of 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
9762853|NCT00738374|Experimental|1|
9762854|NCT00738400|Experimental|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
9762855|NCT00738400|Placebo Comparator|Placebo|Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks
9762856|NCT00738426|Active Comparator|Erchonia ML Scanner (MLS)|Red diode low level laser light energy
9762857|NCT00738426|Sham Comparator|Sham device|non-therapeutic sham light output
9785590|NCT01255137|Experimental|Adrenal Cortex Neoplasms|Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
9785591|NCT01255163|Experimental|Exendin-4|Exenatide 5 mcg or 10 mcg SC twice daily
9785592|NCT01255163|Placebo Comparator|Placebo|Placebo SC twice daily
9832886|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
9785593|NCT01255306||NO IOP|Patients without raised IOP
9785594|NCT01255306||RAISED IOP|Patients with raised IOP
9785595|NCT01255423|Experimental|Diclofenac sodium topical gel 1%|
9785596|NCT01255423|Placebo Comparator|Placebo|
9785597|NCT01255436|Experimental|SMS text reminders|Participants in this arm will receive SMS text messages on top of the usual care they receive from their physicians.
9785598|NCT01255436|Other|Usual Care|Participants in this arm will receive the usual care they receive from their physicians.
9785599|NCT01255449|Experimental|albuterol|Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
9785600|NCT01255592|Experimental|1|Treatment arm AZD5069
9785601|NCT01255592|Placebo Comparator|2|Placebo dose.
9785602|NCT01255631|Sham Comparator|Sham PEMF device|
9785603|NCT01255631|Active Comparator|PEMF Device|
9785604|NCT01255670|Active Comparator|penicillin and metronidazole|After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess
9785605|NCT01255670|Placebo Comparator|penicillin and placebo|After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess
9785606|NCT01255722|Experimental|Iobitridol|Patients were IV injected with a single dose of iobitridol before a coronary CT angiography
9785607|NCT01255722|Active Comparator|Iopromide|Patients were IV injected with a single dose of iopromide before a coronary CT angiography
9785608|NCT01255722|Active Comparator|Iomeprol|Patients were IV injected with a single dose of iomeprol before a coronary CT angiography
9785609|NCT01255761|Other|RAPID3 to assess response to Cimzia|"RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points"
9785610|NCT01255761|Other|CDAI to assess response to Cimzia|"CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)"
9785611|NCT01255787|Experimental|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.
9785612|NCT01255787|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
9785613|NCT01255787|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
9785614|NCT01255787|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.
9785615|NCT01255865||A1 - up to 1 month|Age group 0 up to 1 month
9785616|NCT01255865||A2 - 1 to 3 months|Age group from 1 month to 3 months
9785617|NCT01255865||A3 - 3 months to 1 year|Age group from 3 months to 1 year
9785618|NCT01255865||B - 1 year to 5 years|Age group from older than 1y and younger than 5 years
9785619|NCT01255865||C - 5 years to 12 years|Age group from older than 5y and younger than 12 years
9785620|NCT01255865||D - 12 years to 21 years|Age group from older than 12 years and younger than 21 years
9785621|NCT01255865||E - 21 years and older|Age group older than 21 years
9785622|NCT01255904|Experimental|Arm 1|Oral Chloral and intranasal placebo
9785623|NCT01255904|Experimental|Arm 2|oral placebo and intranasal dexmedetomidine
9785624|NCT01256008|Placebo Comparator|stage 1 Clinical Management|The group will receive clinical management treatment only each session.
9785625|NCT01256008|Experimental|stage1 CBT|The experimental group will receive CBT
9785626|NCT01256008|No Intervention|stage1 Control group|Participants with breast cancer in the control group received standard medical care, but don't receive any other interventions.
9785627|NCT01256034|Active Comparator|Group A|preoperative immunonutrition
9785628|NCT01256034|No Intervention|Group B|ordinary diet
9785629|NCT01256060|Experimental|Intanasal Oxytocin|A modified dose finding method will be used to determine safety among four dose levels for Intranasal Oxytocin. Half the dose (0.2 IU/kg /dose) is the minimum dose and two intermediate doses will also be evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations will be done in groups of three patients.Three patients will be studied at the first dose level. If none of these patients experience dose limiting toxicity, the dose will be escalated. If one experiences dose limiting toxicity, up to three more will be accrued at the same level. If none of these experience dose limiting toxicity, the dose will be escalated. If one or more of these experience dose-limiting toxicity, entry at that dose level will be stopped. Up to three more patients will be treated at the next lower dose. If zero out of these experience dose limiting toxicity, an additional three patients will be treated at that dose.
9785630|NCT01256164|Experimental|Fibrocaps + Gelfoam|After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
9762858|NCT00738530|Experimental|Bevacizumab + IFN-Alfa-2A|Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
9762859|NCT00738530|Placebo Comparator|Placebo + IFN-Alfa-2A|Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
9762860|NCT00738543|Experimental|Whole group of 48 volunteers|The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
9762861|NCT00738673|Experimental|Degarelix|"Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0.~Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections."
9762862|NCT00738699|Active Comparator|1|MORAb-003 (Farletuzumab) Plus Paclitaxel
9762863|NCT00738699|Placebo Comparator|2|Placebo Plus Paclitaxel
9762864|NCT00738881|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9762865|NCT00738881|Experimental|Arm II (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9762866|NCT00738894|Active Comparator|Medical Management|Antiplatelet medical therapy alone
9762867|NCT00738894|Experimental|Device Closure|PFO closure with study septal occluder device plus antiplatelet medical therapy
9762868|NCT00739102|Experimental|1|S.M.A.R.T.® Nitinol Self-Expandable Stent System
9762869|NCT00739297|Placebo Comparator|1|montelukast Placebo
9762870|NCT00739297|Experimental|2|montelukast
9762871|NCT00739297|Experimental|3|montelukast
9762872|NCT00739297|Experimental|4|montelukast
9762873|NCT00739310|Experimental|Vest Treatment (HFCWO)|Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
9762874|NCT00739336|Experimental|A, 1|Intervention: Immediate 3 month program
9762875|NCT00739336|No Intervention|A, 2|Wait-List Control
9762876|NCT00739583|Active Comparator|1|Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)
9762877|NCT00739583|Active Comparator|2|Skin preparation for hip replacement with an Iodine based skin preparation solution, Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA.
9762878|NCT00739596|Experimental|Aliskiren Hydrochlorothiazide (HCTZ)|
9762879|NCT00739596|Active Comparator|Amlodipine|
9762880|NCT00739648|Placebo Comparator|Placebo|Placebo inhaled twice daily via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
9762881|NCT00739648|Experimental|MP-376 240 mg Twice Daily (BID)|MP-376 240 mg BID inhaled via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
9762882|NCT00739661|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
9762883|NCT00739661|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
9762884|NCT00739752|Experimental|Non-Framed-Offered|Non-Framed, Information Only Condition. Vaccine Offered.
9762885|NCT00739752|Experimental|Non-Framed-Recommended|Non-Framed, Information Only Condition. Vaccine Recommended.
9762886|NCT00739752|Experimental|Gain-Framed-Offered|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
9762887|NCT00739752|Experimental|Gain-Framed-Recommended|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
9762888|NCT00739752|Experimental|Loss-Framed-Offered|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
9762889|NCT00739752|Experimental|Loss-Framed-Recommended|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.
9762890|NCT00739765|Experimental|1 Interpersonal Psychotherapy (IPT)|Participants will receive interpersonal psychotherapy.
9762891|NCT00739765|Active Comparator|2 Prolonged Exposure (PE)|Participants will receive prolonged exposure therapy.
9762892|NCT00739765|Active Comparator|3 Relaxation therapy|Participants will receive relaxation therapy.
9762893|NCT00739908|Experimental|CX157 (TriRima)|
9762894|NCT00739908|Placebo Comparator|Placebo|
9762895|NCT00739934|Experimental|Children aged 2 to <12 years|Immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.
9762896|NCT00739960|Other|Abatacept|
9762897|NCT00739973|Placebo Comparator|Placebo|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
9762898|NCT00739973|Experimental|Aliskiren 150 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
9762899|NCT00739973|Experimental|Aliskiren 300 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
9762900|NCT00739973|Experimental|Amlodipine 5 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
9762901|NCT00739973|Experimental|Amlodipine 10 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
9762902|NCT00739973|Experimental|Aliskiren/amlodipine 150/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
9762903|NCT00739973|Experimental|Aliskiren/amlodipine 150/10 mg tablet|150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
9762904|NCT00739973|Experimental|Aliskiren/amlodipine 300/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
9762905|NCT00739973|Experimental|Aliskiren/amlodipine 300/10 mg tablet|300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
9762906|NCT00739999|Other|1|6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.
9762907|NCT00739999|Other|2|10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.
9762908|NCT00740051|Experimental|Linagliptin|52 week treatment
9762909|NCT00740051|Placebo Comparator|Placebo|First 18 weeks of treatment
9762910|NCT00740051|Active Comparator|Glimepiride|Placebo patients switch to glimepiride week19-52
9762911|NCT00740129|Experimental|Zoledronic Acid 5 mg|Participants received single re-treatment dose of zoledronic acid 5 mg intravenous (IV) infusion.
9762912|NCT00740207|Active Comparator|Isovue 250|
9762913|NCT00740207|Active Comparator|VISIPAQUE 270|
9762914|NCT00740220||A|Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
9762915|NCT00740376|Experimental|Uniglide Mobile Bearing|Uniglide Mobile Bearing Unicondylar Knee System (MBK)
9762916|NCT00740376|Active Comparator|Uniglide Fixed Bearing|Uniglide Fixed Bearing Unicondylar Knee System (FBK)
9762917|NCT00740584|Experimental|Open Label, only arm|3%w/w SPL7013 vaginal gel (VivaGel)
9762918|NCT00740636|Experimental|75 mg/m2/day Temozolomide|75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
9762919|NCT00740636|Experimental|200 mg/m2/day Temozolomide|200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
9762920|NCT00740714|Experimental|A|Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)
9762921|NCT00740714|Experimental|B|Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)
9762922|NCT00740714|Placebo Comparator|C|Placebo (with vitamin E 1200 IU/day)
9762923|NCT00740779|Experimental|Silodosin 4 mg|4 mg daily
9762924|NCT00740779|Experimental|Silodosin 8 mg|Silodosin 8 mg daily
9762925|NCT00740779|Placebo Comparator|Placebo|1 placebo capsule daily
9762926|NCT00740792|Experimental|azelastine HCl/fluticasone propionate|nasal spray
9762927|NCT00740792|Active Comparator|azelastine HCL|nasal spray
9762928|NCT00740792|Active Comparator|fluticasone propionate|nasal spray
9762929|NCT00740792|Placebo Comparator|placebo|nasal spray
9762930|NCT00740831|Experimental|A (PGL4001 5 mg)|Drug: PGL4001 5mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
9762931|NCT00740831|Experimental|B (PGL4001 10mg)|Drug: PGL4001 10 mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
9762932|NCT00740831|Active Comparator|C (GnRH-agonist)|PGL4001 matching placebo (oral tablets) and leuprorelin 3.75 mg (intramuscular injection)
9762933|NCT00740857|Placebo Comparator|1|
9762934|NCT00740857|Active Comparator|2|
9762935|NCT00740857|Active Comparator|3|
9762936|NCT00740870|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
9762937|NCT00741013|Placebo Comparator|Placebo pill and placebo IV|
9762938|NCT00741013|Experimental|Lovastatin pill and placebo IV|
9762939|NCT00741013|Experimental|Placebo pill and rhAPC IV|
9762940|NCT00741026|Placebo Comparator|Placebo|Placebo
9762941|NCT00741026|Experimental|Olanzapine|Olanzapine 10mg po daily x 3 days
9762942|NCT00741039|Experimental|1,|Patients > or = to 65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23 valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly).
9762943|NCT00741039|Experimental|2|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly).
9762944|NCT00741091|Experimental|Registry|Registry to gather data on early clinical outcomes for the Carotid WALLSTENT Endoprosthesis and FilterWire EZ System in routine clinical practice.
9762945|NCT00741104||RA patients|Patients on maintenance therapy for RA with infliximab for >= the past 12 months.
9762946|NCT00741156|Experimental|Enalaprilat|enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose
9762947|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Level 1)|Neratinib 160 mg and Capecitabine 1500 mg/m^2
9762948|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 2)|Neratinib 240 mg and Capecitabine 1500 mg/m^2
9762949|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 3)|Neratinib 240 mg and Capecitabine 2000 mg/m^2
9762950|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 4)|Neratinib 200 mg and Capecitabine 2000 mg/m^2
9762951|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 5)|Neratinib 160 mg and Capecitabine 2000 mg/m^2
9762952|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 6)|Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
9762953|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 7)|Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib
9762954|NCT00741273|Experimental|Proellex 25 mg healthy|Proellex 25 mg in healthy females
9762955|NCT00741273|Experimental|Proellex 25 mg Impaired|Proellex 50 mg in hepatically impaired females
9762956|NCT00741286|Placebo Comparator|Asprin (100mg) plus placebo|Asprin (100mg) plus placebo
9762957|NCT00741286|Active Comparator|Asprin (100mg) plus cilostazol (200mg)|Asprin (100mg) plus cilostazol (200mg)
9762958|NCT00741338|Experimental|Cohort 1|Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.
9762959|NCT00741338|Experimental|Cohort 2|TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.
9762960|NCT00741390|Other|Arm A|In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
9762961|NCT00741390|Other|Arm B|In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
9762962|NCT00741390|Other|Arm C|In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
9762963|NCT00741390|Other|Arm D|In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.
9762964|NCT00741455|Experimental|Study Treatment|Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate
9762965|NCT00741468|Experimental|All subjects|Proellex 50 mg CYP1A2 probe CYP2C9 probe CYP2C19 probe CYP2D6 probe CYP3A4 probe
9762966|NCT00741598|Experimental|Galantamine-ER|Participants will receive treatment with extended release galantamine
9762967|NCT00741598|Placebo Comparator|Galantamine placebo|Participants will receive treatment with placebo.
9762968|NCT00741611|Experimental|Mesh|Ablation with HD Mesh Ablation System
9762969|NCT00741611|Active Comparator|Drug|Treatment with anti-arrhythmic drugs
9762970|NCT00741819|Experimental|Inhaled treprostinil|Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.
9762971|NCT00741858|Experimental|DuraGen (sutureless)|Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.
9762972|NCT00741858|Active Comparator|DuraGuard (suturable)|Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.
9762973|NCT00741936|Experimental|MaZiRenWan (MZRW)|MZRW granule, 7.5g/sachet
9762974|NCT00741936|Placebo Comparator|Placebo|Placebo granule, 7.5g/sachet
9762975|NCT00742001|Experimental|Mirasol Illumination Dose #1|Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)
9762976|NCT00742001|Experimental|Mirasol Illumination Dose #2|Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs
9762977|NCT00742001|Experimental|Mirasol Illumination Dose #3|Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs
9762978|NCT00742027|Experimental|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, thrice every week (i.e. days 1, 3 and 5), in each cycle of 21 days until unacceptable toxicity, disease progression, start of new anti-cancer therapy or withdrawal of consent (up to approximately 48 months).
9762979|NCT00742053|Experimental|1|Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.
9762980|NCT00742079|Experimental|1 D-cycloserine, placebo|Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
9762981|NCT00742079|Experimental|2 Placebo, D-cycloserine|Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
9762982|NCT00742170|Active Comparator|Active electroacupuncture|In the active electroacupuncture condition, the current is set at 2 times threshold (approximately 6-10 mA), which typically produces muscle twitching.
9762983|NCT00742170|Sham Comparator|Sham electroacupuncture|In the sham electroacupuncture condition, the current is set at 1 mA, the lowest intensity possible before the HANS device shuts off; this is undetectable stimulation.
9762984|NCT00742183|Experimental|Mepilex® Ag|"Mepilex® Ag consists of a Safetac® soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film. Mepilex® Ag is an antimicrobial soft silicone foam dressing that absorbs exudate and maintains a moist wound environment.~Mepilex® Ag contains silver sulphate that releases silver ions to inactivate a wide range of wound related pathogens (bacteria and fungi), shown in vitro. By reducing the number of microorganisms, Mepilex® Ag may also reduce odour."
9762985|NCT00742183|Active Comparator|Silvadene® Cream 1%|Silvadene® Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second-and third-degree burns.
9762986|NCT00742209|Placebo Comparator|Placebo|PBO
9762987|NCT00742209|Active Comparator|GSK 1838262 1200 mg/day|600 or 1200 mg/day
9762988|NCT00742209|Active Comparator|GSK 1838262 1800 mg/day|600 or 1200 or 1800 mg/day
9762989|NCT00742209|Active Comparator|GSK 1838262 2400 mg/day|600 or 1200 or 1800 or 2400 mg/day
9762990|NCT00742209|Active Comparator|GSK 1838262 3000 mg/day|600 or 1200 or 1800 or 2400 or 3000 mg/day
9762991|NCT00742235|Experimental|1|Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
9762992|NCT00742235|No Intervention|Vitamin D sufficient|Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml
9762993|NCT00742274|Experimental|1|TAG+BMT
9762994|NCT00742274|Active Comparator|2|BMT alone
9832887|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
9832888|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
9832889|NCT02632526|Experimental|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
9832890|NCT02632526|Experimental|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
9832891|NCT02632526|Experimental|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
9832892|NCT02632552|Experimental|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
9832893|NCT02632552|Active Comparator|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
9832894|NCT02632747|Experimental|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
9832895|NCT02632747|Experimental|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
9832896|NCT02632786|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
9832897|NCT02632786|Placebo Comparator|Placebo|Placebo
9832898|NCT02632812|Experimental|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
9832899|NCT02632812|Placebo Comparator|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
9518028|NCT03300609|Active Comparator|Arm II (capecitabine)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive capecitabine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
9762995|NCT00742313|Experimental|Arm A|Arm A has FloSeal Matrix applied to EVH wound bed.
9762996|NCT00742313|No Intervention|Arm B|Arm B does not have FloSeal Matrix applied to EVH wound bed.
9762997|NCT00742326|Experimental|Pioglitazone|pioglitazone 45 mg daily for 48 weeks
9762998|NCT00742326|Placebo Comparator|Placebo|one capsule daily for 48 weeks
9762999|NCT00742391|Active Comparator|1|PEP005 (ingenol mebutate) Gel
9763000|NCT00742391|Placebo Comparator|2|Vehicle gel
9763001|NCT00742417|Experimental|Albutein 5%|Patients allocated to this arm underwent plasma exchange with Albutein 5%.
9763002|NCT00742417|Sham Comparator|Control|
9763003|NCT00742469|Active Comparator|1|Rifaximin
9763004|NCT00742469|Placebo Comparator|2|Placebo
9763005|NCT00742508|Experimental|SK&F-105517-D group|SK&F-105517-D 10-80 mg/day
9763006|NCT00742508|Other|Carvedilol-IR group|Carvedilol-IR 5-20 mg/day
9763007|NCT00742560|Experimental|Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
9763008|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
9763009|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
9517924|NCT03301610|Experimental|Mobile Education Delivery|The participants in the study arm will receive comprehensive pain management education delivered using mobile iPads at the point of care. The mobile based education modules will be inclusive of the use of the pain rating scale and assessment of pain; communication with healthcare providers; daily expectations for pain and pain management; pharmacologic and non-pharmacologic treatment options; medication side effects and safety; and discharge instructions including safe handling of opioids, disposal, tapering, and when to call the provider. It will also include an interactive pain and discomfort menu, knowledge based questions, and medication tracking log.
9763010|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
9763011|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
9763012|NCT00742573|Active Comparator|1 Texas Medication Algorithm|Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
9763013|NCT00742573|Experimental|2 Patient Choice|Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
9763014|NCT00742625|Experimental|Treatment (daunorubicin hydrochloride and bortezomib)|See Detailed Description
9763015|NCT00742781|Experimental|Dietary supplement|Dietary supplement of vitamin D
9763016|NCT00742859|Experimental|Arm 1: Betrixaban|Betrixaban, 40 mg, orally, once daily for at least 3 months.
9763017|NCT00742859|Experimental|Arm 2: Betrixaban|Betrixaban, 60 mg, orally, once daily for at least 3 months
9763018|NCT00742859|Experimental|Arm 3: Betrixaban|Betrixaban, 80 mg, orally, once daily for at least 3 months
9763019|NCT00742859|Active Comparator|Arm 4: Warfarin|Warfarin will be prescribed by investigators according to the standard of care.
9763020|NCT00742872|Experimental|1|Mosapride
9763021|NCT00742872|Placebo Comparator|2|Placebo
9763022|NCT00742885|Experimental|Influenza A (H5N1) 20-40 Years Group|Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
9763023|NCT00742885|Experimental|Influenza A (H5N1) 41-64 Years Group|Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
9763024|NCT00742924|Experimental|Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery .~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
9763025|NCT00742924|Experimental|Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
9783762|NCT01210495|Placebo Comparator|B|Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
9783763|NCT01210560|Experimental|20 mg MR|
9783764|NCT01210560|Experimental|40 mg MR|
9783765|NCT01210560|Experimental|60 mg MR|
9783766|NCT01210560|Experimental|120 mg MR|
9832900|NCT02632838|Experimental|the mHealth Group|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor on a daily basis at HOME and also will be asked to visit community health center once a week to receive the regular hypertension care for the 6-month period as usual.
9832901|NCT02632838|No Intervention|the Standard Follow-up Group|The standard follow-up group will receive regular hypertension care as usual which consists: nursing assessment, medication management, patient education, follow up and continuing care in the community health center
9832902|NCT02633020|Experimental|AMG 714|Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
9832903|NCT02633020|Placebo Comparator|Placebo|Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
9832904|NCT02633046|Other|Acthar Gel|Acthar Gel, 1 mL (80 U) by subcutaneous injection (SC) 3x/week will be administered to all participants from Week 0 to 50. Tapering of dose to 1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 2x/week it must remain at this level. Participants unable to tolerate 1 mL SC 2x/week will be discontinued. All participants will have an End of Study/Early Termination Visit 4 weeks after discontinuing Investigational Medicinal Product (IMP).
9832905|NCT02633215|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
9832906|NCT02633215|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
9832907|NCT02633306|Experimental|Transcranial Magnetic Stimulation|transcranial magnetic stimulation
9832908|NCT02633358|Experimental|Therapeutic hypothermia group|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
9832909|NCT02633358|No Intervention|Control group|No therapeutic hypothermia for controlled data.
9832910|NCT02633371|Experimental|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
9832911|NCT02633488|Placebo Comparator|Placebo|12 weeks of Placebo tablet 3 x daily
9832912|NCT02633488|Experimental|Metformin|12 weeks of Metformin tablet 850 mg 3 x daily
9832913|NCT02633501|Experimental|Subset 1 Arm 1|One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
9832914|NCT02633501|Experimental|Subset 1 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
9832915|NCT02633501|Experimental|Subset 2 Arm 1|One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
9832916|NCT02633501|Experimental|Subset 2 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
9832917|NCT02633527|Placebo Comparator|Placebo|Placebo, qd, oral capsule
9832918|NCT02633527|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
9832919|NCT02633527|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
9832920|NCT02633527|Experimental|300mg SPN-812|300mg SPN-812, qd, oral capsule
9832921|NCT02633527|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
9832922|NCT02633735|Experimental|Appy CDS|The Appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The intervention is administered to providers in this arm.
9763026|NCT00742924|Experimental|Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
9763027|NCT00742924|Experimental|Chemotherapy and 2.3 mg/m2 Zoledronic Acid after MTD|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
9763028|NCT00742963|Experimental|1|75 mg/m2 of Doxorubicin administered by bolus injection starting on Day 1 of a 21-day cycle.
9763029|NCT00743093|Experimental|acetaminophen|acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
9763030|NCT00743093|Placebo Comparator|placebo|placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)
9763031|NCT00743106|Placebo Comparator|Placebo Comparator|Placebo (0.9% Nacl)infusion beginning during surgery and lasting for up to 24 hours
9763032|NCT00743106|Active Comparator|Fenoldopam Comparator|Fenoldopam (0.1 ~g/kg/min)infusion will commence after placing the patient in a lateral/flex position during the operation. The infusion will continue for a total of 24 hours.
9763033|NCT00743119|Placebo Comparator|Placebo + inactive marijuana (0% THC)|Participants received placebo capsules and smoked inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
9763034|NCT00743119|Experimental|Dronabinol 10 mg + Marijuana (0% THC)|Participants received low dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
9763035|NCT00743119|Experimental|Dronabinol 20 mg + Marijuana (0% THC)|Participants received High dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
9763036|NCT00743119|Experimental|Placebo + Marijuana (1.98% THC)|Participants received placebo + low THC marijuana (1.98% THC) on 1 of 5 outpatient sessions in randomized order.
9763037|NCT00743119|Experimental|Placebo + Marijuana (3.56% THC)|Participants received placebo + smoked high THC marijuana (3.56 % THC) on 1 of 5 outpatient sessions in randomized order.
9763038|NCT00743145|Placebo Comparator|Placebo naltrexone + Inactive marijuana|Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
9763039|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (5.5% THC)|Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
9763040|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (6.2% THC)|Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
9763041|NCT00743145|Experimental|Naltrexone + Active marijuana (5.5% THC)|Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
9763042|NCT00743145|Experimental|Naltrexone + Active marijuana (6.2% THC)|Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
9763043|NCT00743145|Placebo Comparator|Naltrexone + Inactive marijuana|Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
9763044|NCT00743249|Experimental|Canalicular stent, 10 mm|MINI MONOKA canalicular stent (tube), 10 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
9783767|NCT01210560|Experimental|120 mg IR|
9832923|NCT02633735|No Intervention|Usual Care|
9518029|NCT03300596|Experimental|brief intervention to prevent suicide attempt|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
9763045|NCT00743249|Experimental|Canalicular stent, 20 mm|MINI MONOKA canalicular stent (tube), 20 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
9763046|NCT00743275|Experimental|Study Group|Participants received one dose of Fluzone® vaccine on Day 0.
9763047|NCT00743288|Experimental|Melphalan and Panobinostat|"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.~Toxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.~Schedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1."
9763048|NCT00743340|Experimental|Emtricitabine|Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
9763049|NCT00743366|Experimental|Quetiapine (200mg/day), Marijuana (6.2%, 0.0%)|"Quetiapine (200mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (200 mg) were administered 2 times per day ((1100 and 2300 hours).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
9763050|NCT00743366|Placebo Comparator|Placebo, Marijuana (6.2%, 0.0%)|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
9763051|NCT00743431||1|Women with advanced ovarian cancer
9763052|NCT00743444|Experimental|1|AZD3355
9763053|NCT00743444|Placebo Comparator|2|
9763054|NCT00743483|Experimental|rhBSSL|170 mg rhBSSL three times daily for 5 to 6 consecutive days
9763055|NCT00743509|Experimental|Oral Cyclophosphamide and Sirolimus (OCR)|Sarcoma patients were given oral Cyclophosphamide and Sirolimus (OCR) in 28 day cycles.
9763056|NCT00743574|Experimental|Vitamin D plus Calcium (Ca) supplementation|
9763057|NCT00743652|Experimental|Group1|Subjects 6 weeks to <10 months of age with 0 prior dose of Prevnar.
9763058|NCT00743652|Experimental|Group 2|Subjects <12 months of age with 1 prior dose of Prevnar.
9763059|NCT00743652|Experimental|Group 3|Subjects <12 months of age with 2 prior doses of Prevnar.
9763060|NCT00743652|Experimental|Group 4|Subjects ≥12 months to <2 years of age.
9763061|NCT00743652|Experimental|Group 5|Subjects ≥2 years to <5 years of age
9763062|NCT00743717|Experimental|1|
9763063|NCT00743717|Active Comparator|2|
9763064|NCT00743730|Active Comparator|I|Parent and Nurse Controlled Analgesics with basal
9763065|NCT00743730|Active Comparator|II|Parent and Nurse Controlled Analgesics without basal
9763066|NCT00743730|Active Comparator|III|"Intermittent opioid administered IV on an as needed basis"
9763067|NCT00744042|Other|asfotase alfa|asfotase alfa
9763068|NCT00744055|Experimental|Prazosin|prazosin (16mg/day)
9763069|NCT00744055|Placebo Comparator|Placebo|Placebo in identical looking capsule blister packs
9763070|NCT00744211|Placebo Comparator|Vehicle|Vehicle Group
9763071|NCT00744211|Experimental|ET-ARA 1mg/kg|ET-ARA 1 mg/kg
9763072|NCT00744211|Experimental|ET-ARA 2mg/kg|ET-ARA 2 mg/kg
9763073|NCT00744237|Experimental|1|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration~Open-label amlodipine may be given"
9763074|NCT00744237|Active Comparator|2|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration~Open-label amlodipine may be given"
9763075|NCT00744237|Active Comparator|3|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration~Open-label amlodipine may be given"
9763076|NCT00744263|Placebo Comparator|Placebo|
9763077|NCT00744263|Experimental|13-valent pneumococcal conjugate vaccine|
9763078|NCT00744328|Experimental|Transdermal Estradiol|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains transdermal estradiol ranging in dose from 50 to 200 mcg/day
9763079|NCT00744328|Active Comparator|Sertraline|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The skin patch contains no active ingredients, though packaging is designed to match active patches. The capsules contain sertraline ranging in dose from 25 to 200mg/day
9763080|NCT00744328|Placebo Comparator|Placebo|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains no active ingredients, though packaging is designed to match active patches.
9763081|NCT00744380|Active Comparator|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4) as other sedatives are down titrated. Daily awakenings are used.
9763082|NCT00744380|Experimental|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)as other sedatives are down titrated. Daily awakenings are used.
9763083|NCT00744471|Experimental|Tanezumab 10 mg|Tanezumab 10 mg IV every 8 weeks
9763084|NCT00744471|Experimental|Tanezumab 5 mg|Tanezumab 5mg IV every 8 weeks
9763085|NCT00744471|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg IV every 8 weeks.
9763086|NCT00744471|Experimental|Placebo|Placebo
9763087|NCT00744497|Placebo Comparator|Placebo|Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
9763088|NCT00744497|Active Comparator|Dasatinib|Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
9763089|NCT00744523|Experimental|Mo.ma cerebral protection device|Mo.Ma cerebral protection device
9763090|NCT00744627|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
9763091|NCT00744627|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
9763092|NCT00744653|Other|1|Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
9763093|NCT00744692|Experimental|RIC Cord Blood Transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
9763094|NCT00744757|Experimental|Decitabine|Decitabine 20 milligram per square meter (mg per m^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
9763095|NCT00744796||DSAEK: Outcomes in patients with corneal edema|Best spectacle corrected visual acuity and anterior segment optical coherence tomography (OCT) at minimum will be performed in patients who have undergone DSAEK for corneal edema secondary to corneal endothelial dysfunction.
9763096|NCT00744848|Active Comparator|Bupivacaine HCl|"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
9763097|NCT00744848|Other|SKY0402|"300 mg SKY0402 in a 40-mL injection volume.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
9763098|NCT00744861|Active Comparator|Exogen 4000+|Low intensity pulsed ultrasound (LIPUS) delivered via Exogen 4000+ (single transducer) device for a treatment duration of 20 minutes per fusion site per day.
9763099|NCT00744861|Sham Comparator|Exogen 4000+ sham|Non-active sham device identical to Exogen 4000+ (single transducer); treatment duration of 20 minutes per fusion site per day
9763100|NCT00744861|Active Comparator|Exospine|Low intensity pulsed ultrasound delivered via Exospine device (dual transducers); treatment duration of 20 minutes per day
9763101|NCT00744861|Sham Comparator|Exospine sham|Non-active sham device identical to Exospine (dual transducers); treatment duration of 20 minutes per day
9763102|NCT00744874|Experimental|Ablated Patients|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
9763103|NCT00744939||Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Participants received Magnevist in accordance with its labeling
9763104|NCT00744965|Active Comparator|Glyburide|Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
9763105|NCT00744965|Placebo Comparator|Placebo|Women with mild gestational diabetes will be started ADA diet and placebo.
9763106|NCT00744978|Experimental|Varenicline|
9763107|NCT00744978|Placebo Comparator|Placebo|
9763108|NCT00744991|Experimental|Enzastaurin|Open Label
9763109|NCT00745095|No Intervention|SCI MoviPrep® (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI, GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (without neostigmine plus glycopyrrolate [NG])
9763110|NCT00745095|No Intervention|SCI PIEE (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation [PIEE] (without neostigmine plus glycopyrrolate [NG])
9763111|NCT00745095|No Intervention|Control MoviPrep® only|(Control, glomerular filtration rate (GFR)>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep®) only (no NG)
9763112|NCT00745095|No Intervention|Control PIEE only|(Control, glomerular filtration rate (GFR)>=50ml/min), pulsed irrigation enhanced evacuation (PIEE) only (no NG)
9763113|NCT00745095|Experimental|SCI MoviPrep® (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (with neostigmine plus glycopyrrolate [NG])
9763114|NCT00745095|Experimental|SCI PIEE (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate [NG])
9763115|NCT00745121|Experimental|Group-A, Osteoporosis/osteopenia|Patients with osteoporosis/osteopenia.
9763116|NCT00745121|Experimental|Group-B, Control|Control (non-osteoporotic/-osteopenic patients).
9763117|NCT00745251|Experimental|VI-0521|15 mg Phentermine and 92 mg Topiramate
9763118|NCT00745251|Placebo Comparator|Placebo|
9763119|NCT00745290|Active Comparator|Bupivacaine HCl|Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration
9763120|NCT00745290|Other|SKY0402|Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
9763121|NCT00745368|Experimental|Raltegravir|Raltegravir 400 mg tablets twice daily
9763122|NCT00745420|Experimental|Hematopoietic Stem Cell Transplantation|Bone Marrow Transplant with GVHD Prophylaxis Regimen
9763123|NCT00745498|Experimental|Preop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy
9763124|NCT00745498|Experimental|Intraop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
9763125|NCT00745498|No Intervention|No IVB|Patients will not receive bevacizumab before nor during vitrectomy
9763126|NCT00745615|Experimental|Double-Blind: Laquinimod 0.3 mg|Participants who will be receiving laquinimod 0.3 milligram (mg) tablet once daily orally in double-blind core study, will continue to receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
9763127|NCT00745615|Experimental|Double-Blind: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally in double-blind core study, will continue to receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
9763128|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.3 mg|Participants who will be receiving placebo matching to laquinimod 0.3 mg tablet once daily orally in double-blind core study, will receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
9763129|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.6 mg|Participants who will be receiving placebo matching to laquinimod 0.6 mg (2 tablets of placebo) once daily orally in double-blind core study, will receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
9763130|NCT00745615|Experimental|Open-Label: Laquinimod 0.3 mg/Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.3 mg tablet once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
9763131|NCT00745615|Experimental|Open Label: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
9763132|NCT00745823|Active Comparator|Raltegravir 400 mg b.i.d.|
9517925|NCT03301610|Placebo Comparator|Standard verbal and written education|The control group will receive the current standard of care which consists of verbal instruction and pain management educational pamphlets. At a minimum, the patients will receive two educational pamphlets titled Your Pain and Discomfort Management Menu and Communicating About Your Pain. Verbal instruction is nurse dependent. At a minimum the nurse will provide the two pamphlets to the patient and follow-up with the patient to address any questions.
9763133|NCT00745823|Experimental|Raltegravir 800 mg q.d.|
9763134|NCT00745849|Experimental|1|esomeprazole 40mg po bid
9763135|NCT00745849|Placebo Comparator|2|
9783768|NCT01210651|Experimental|Hatha Yoga Practice Group|Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
9783769|NCT01210651|Active Comparator|Attention Control Education Group|Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.
9783770|NCT01210664|Experimental|Polyclonal Regulatory T Cells|Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion
9783771|NCT01210690||Patients, 1 - 11 months old, prescribed Keppra® oral solution|Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
9783772|NCT01210716|Experimental|AMICUS Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
9783773|NCT01210716|Active Comparator|Spectra Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
9783774|NCT01210807|Experimental|Multifocal Intraocular Lens|ZMB00 multifocal intraocular lens
9783775|NCT01210807|Active Comparator|Monofocal Intraocular Lens|ZCB00 monofocal intraocular lens
9783776|NCT01210820|Experimental|Natural Astigmatism|Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
9783777|NCT01210820|Experimental|Post cataract with residual astigmatism|Subjects who have had cataract removal surgery but have residual astigmatism.
9783778|NCT01211106|Experimental|Arm 1: Integrated Conditions|Motivational enhancement therapy for addiction is combined with Prolonged exposure therapy for PTSD from the beginning of treatment. Both are delivered by the same provider throughout treatment.
9783779|NCT01211106|Experimental|Arm 2 Sequential therapy|Motivational enhancement therapy for addiction is delivered in the first 4 weeks and only after the addiction is addressed is the Prolonged exposure therapy for PTSD started.
9783780|NCT01211145|Placebo Comparator|1|Placebo
9783781|NCT01211145|Experimental|2|ZOMIG 0.5 mg
9783782|NCT01211145|Experimental|3|ZOMIG 2.5 mg
9783783|NCT01211145|Experimental|4|ZOMIG 5.0 mg
9783784|NCT01211184|Placebo Comparator|Fasting|patients undergo surgery in the fasting state
9783785|NCT01211184|Active Comparator|Water administration|Patients undergo hip surgery after receiving 800 ml water by mouth the morning 2 hours before surgery
9783786|NCT01211184|Active Comparator|carbohydrate drink|Patients undergo hip surgery after receiving 800 ml carbohydrate drink by mouth
9783787|NCT01211197|Experimental|A|3 treatments will be investigated in randomized order
9783788|NCT01211197|Experimental|B|3 treatments will be investigated in randomized order
9783789|NCT01211197|Experimental|C|3 treatments will be investigated in randomized order
9783790|NCT01211262|Experimental|IMCgp100 weekly dosing regimen|Weekly intravenous (IV) infusions of IMCgp100 over treatment cycles of 8 weeks each.
9783791|NCT01211262|Experimental|IMCgp100 daily dosing regimen|Daily IV infusions of IMCgp100 administered on days 1 to 4 and days 22 to 25 of a six-week treatment cycle.
9783792|NCT01211288|Active Comparator|HIV negative group|This group contains participants consented to receive implants and identified as negative for HIV
9783793|NCT01211288|Experimental|HIV positive group|This group contains participants consented to receive implants and identified as positive for HIV
9783794|NCT01211340|No Intervention|Usual Care|Usual hospice care- there is no intervention in this arm
9783795|NCT01211340|Experimental|ACTIVE|Behavioral intervention using web conferencing
9783796|NCT01211483|Experimental|Part A: U3-1287 (high dose) + Erlotinib|U3-1287 (high dose) intravenously (IV) every three weeks (Q3W) + Erlotinib 150 mg/day orally (PO) until cancer gets worse, side effects become unacceptable or participant withdraws consent
9763136|NCT00745875|Experimental|1|ZD4054 + Pemetrexed
9763137|NCT00745875|Placebo Comparator|2|ZD4054 matched placebo + pemetrexed
9763138|NCT00745940|Experimental|MBCT Intervention Group|The curriculum of our mindfulness intervention draws upon elements from the mindfulness-based stress reduction program, and Segal and colleagues manual for mindfulness-based cognitive therapy. It was modified by one of the investigators to address issues associated with traumatic brain injury (e.g., problems with attention, concentration, memory, fatigue). The intervention was increased to ten weeks with one and a half hour weekly sessions, along with a 20-30 minute daily meditation home practice. Further adaptations included simplified language, the use of repetition to reinforce concepts, and visual aids. More attention was paid to fostering learning conditions to encourage an environment of trust and non-judgement. Connections between learning activities was also made more explicit.
9763139|NCT00745940|No Intervention|MBCT Control Group|Control group waited.
9763140|NCT00746096|Experimental|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
9763141|NCT00746096|Placebo Comparator|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
9763142|NCT00746122|Other|Open repair|Immediate Open Surgery
9763143|NCT00746122|Experimental|Endovascular strategy|Endovascular strategy involves immediate computed tomography (CT) and emergency Endovascular aneurysm repair (EVAR), with open repair for patients anatomically unsuitable for EVAR
9763144|NCT00746187|Experimental|ASTRA TECH Implant System; Fixture ST|Ø 4.5 cm in lengths 9-13 mm
9763145|NCT00746187|Experimental|Biomet 3i; Osseotite® Implants|Ø 4.0 cm in lengths 8.5-13 mm
9763146|NCT00746252|Experimental|1|risperidone
9763147|NCT00746252|Experimental|2|aripiprazole
9763148|NCT00746330|Experimental|F12M - PL - F12D - MFF|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
9763149|NCT00746330|Experimental|F12D - F12M - MFF - PL|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
9763150|NCT00746330|Experimental|MFF - F12D - PL - F12M|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
9763151|NCT00746330|Experimental|PL - MFF - F12M - F12D|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
9763152|NCT00746356|Experimental|Promote RF CRT-D|Patients with CRT-D device will have the autocapture features of the device tested.
9763153|NCT00746356|Experimental|Current RF ICD|Patients with ICD device will have the autocapture features of the device tested.
9517926|NCT03301597|Other|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
9763154|NCT00746395|Active Comparator|lubiprostone 24mcg single dose|lubiprostone 24mcg single dose po prior to capsule endoscopy
9763155|NCT00746395|Placebo Comparator|Sugar pill|Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
9763156|NCT00746421|Experimental|1|Quetiapine XR 200-400 mg/day
9517927|NCT03301597|Experimental|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
9517928|NCT03301597|Experimental|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
9763157|NCT00746421|Placebo Comparator|2|Placebo one pill per day matching 200, 300, or 400 mg
9984217|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in MSS-CRC|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with microsatellite stable colorectal carcinoma (MSS-CRC). Booster injections of TBio-6517 are permitted for up to 24 months.
9763158|NCT00746512|Experimental|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days
9763159|NCT00746512|Placebo Comparator|Placebo 15 mg|Prednisone 15 mg placebo tablets once daily for 15 days
9763160|NCT00746512|Experimental|Prednisone 7.5 mg|"Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
9763161|NCT00746512|Placebo Comparator|Placebo 7.5 mg|"Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
9763162|NCT00746551|Active Comparator|Ferrous fumarate, Ferri-6®, Oral tablet|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
9763163|NCT00746551|Experimental|iron sucrose, Venofer®, intravenous drug|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
9763164|NCT00746564|Experimental|Open Label|SJM Confirm Device
9763165|NCT00746668|Experimental|Control Group|Subjects randomly assigned to this group had their training delayed for 18 weeks. These subjects underwent four assessments: baseline and at three 6-week intervals' but, they were not given any training during this time. After this data collection period, these control subjects were given training on the three modules. However, their performance after each period of training was not assessed.
9763166|NCT00746668|Experimental|Group 1|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 3 (Reading Practice with RSVP)"
9763167|NCT00746668|Experimental|Group 2|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
9763168|NCT00746668|Experimental|Group 3|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 2 (Control of Reading Eye Movements)"
9517929|NCT03301597|Experimental|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
9763169|NCT00746668|Experimental|Group 4|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 2 (Control of Reading Eye Movements)"
9763170|NCT00746668|Experimental|Group 5|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 3 (Reading Practice with RSVP)"
9763171|NCT00746668|Experimental|Group 6|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
9763172|NCT00746694||Caelyx|Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.
9763173|NCT00746733|Experimental|Vyvanse (LDX)|
9763174|NCT00746733|Experimental|Adderall XR (AXR)|
9763175|NCT00746785|Experimental|2.5 mg Olanzapine|"2.5 mg Olanzapine~1x per day for 12 weeks."
9763176|NCT00746785|Active Comparator|5mg Olanzapine|"5 mg Olanzapine~1x per day for 12 weeks."
9763177|NCT00746785|Placebo Comparator|Placebo|"Placebo~1x per day for 12 weeks."
9763178|NCT00746798|Experimental|ChimeriVax WN02 vaccine, low dose|Participants randomized to receive ChimeriVax WN02 vaccine, low dose
9763179|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, medium dose|Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
9763180|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, high dose|Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
9763181|NCT00746798|Placebo Comparator|Placebo|Participants randomized to receive Placebo (Saline)
9763182|NCT00746863|Experimental|1|Patients randomized to this arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
9763183|NCT00746863|No Intervention|2|Patients assigned to this arm will have the mid-urethral sling placed via the suprapubic approach in the standard fashion with no injection of Marcaine into the retropubic space.
9763184|NCT00746889|Active Comparator|Corticosteroid Injection|40 mg of intraarticular triamcinolone acetonide
9763185|NCT00746889|Placebo Comparator|Placebo Injection|Intraarticular injection of 0.9% saline
9763186|NCT00746941|No Intervention|Local standard of care|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants in this treatment arm had the option of adding 250 mg mefloquine by mouth at Week 4 (Day 28) or Week 8 (Day 56) daily for 3 days, and then weekly through Week 24."
9763187|NCT00746941|Experimental|Local standard of care plus mefloquine 250 mg|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants received 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24."
9763188|NCT00746954|Other|Arm 1 BUS to PLA to ACET|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
9763189|NCT00746954|Other|ARM 2 ACET to BUS to PLA|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
9763190|NCT00746954|Other|ARM 3 PLA to ACET to BUS|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=2
9763191|NCT00747006|Experimental|TI Inhalation Powder (original protocol)|Under the original protocol, subjects with Type 1 and Type 2 diabetes will have TI Inhalation Powder administered prandially during dose optimization visits and meal challenge visits (with meals of varying carbohydrate contents). Subjects with Type 2 diabetes will also use TI Inhalation Powder daily at each meal between visits.
9763192|NCT00747006|Other|TI Inhalation Powder and Humalog (Amendment 1)|Under Amendment 1, TI Inhalation Powder will be administered prandially to a new subset of subjects with Type 2 diabetes during TI dose optimization visits and TI meal challenge visits (with meals of varying carbohydrate contents). Subjects will be crossed over to administration of Humalog 15 minutes before meals during Humalog dose optimization visits and Humalog meal challenge visits (with meals of varying carbohydrate contents). Subjects will also use TI Inhalation Powder daily at each meal between visits.
9763193|NCT00747149|Experimental|Rosuvastatin 1|titrated
9763194|NCT00747149|Experimental|Rosuvastatin 2|Non-titrated
9763195|NCT00747214|Experimental|CRx-102 plus DMARD therapy|
9763196|NCT00747214|Placebo Comparator|Placebo plus DMARD therapy|
9763197|NCT00747227|Experimental|ZV9003|modified light transmission intraocular lens
9763198|NCT00747227|Active Comparator|ZA9003|monofocal acrylic intraocular lens
9763199|NCT00747344|Placebo Comparator|Placebo - Controlled Period (CP)|
9763200|NCT00747344|Experimental|Ustekinumab 45 mg - CP|
9763201|NCT00747344|Experimental|Placebo to ustekinumab 45 mg - after CP|
9763202|NCT00747344|Experimental|Ustekinumab 45 mg - after CP|
9763203|NCT00747435|Experimental|Original Audiological Criteria|"Inclusion Criteria:~Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition."
9763204|NCT00747435|Experimental|Expanded Audiological Criteria|"Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition.~Study Arm 2 candidates are those who meet the inclusion criteria listed above with the exception that:~In the ear to be implanted, the pure-tone air conduction threshold(s) at 250, 500, and/or 750 Hz will be greater than or equal to 0 dB HL and less than 10 dB HL, and/or In the ear to be implanted, the pure-tone air conduction threshold(s) at 1000 and/or 1500 Hz will be greater than or equal to 0 dB HL and less than 60 dB HL and/or In their best-aided condition, they score 51-60% on monosyllabic word scores."
9763205|NCT00747474|Experimental|Lipotecan|Intravenous Lipotecan (TLC388 HCl for Injection)
9763206|NCT00747565|Experimental|Tecnis Multifocal IOL group|Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
9763207|NCT00747565|Active Comparator|CeeOn 911A monofocal control IOL group|Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
9763208|NCT00747617|Active Comparator|PCOS group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
9763209|NCT00747617|Active Comparator|Control group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
9763210|NCT00747643|Active Comparator|Varenicline|For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15.
9763211|NCT00747643|Placebo Comparator|Placebo|Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
9763212|NCT00747747|No Intervention|Control|No coadiuvant treatment. The subject is treated with the antibiotic only and forbidden to take any coadiuvant medicine as a remedy for the symptoms during the period of the study.
9763213|NCT00747747|Active Comparator|Saline solution|Saline solution sprayed according to the product indication. Only one brand/specific product has been selected.
9763214|NCT00747747|Experimental|Sinuclean treatment|Sinuclean DM Spray.
9763215|NCT00747812|Experimental|1|Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
9832924|NCT02633787|Experimental|Study Group|Participants received a booster dose of Menactra vaccine approximately four years earlier
9832925|NCT02633800|Experimental|Patritumab|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
9832926|NCT02633800|Placebo Comparator|Placebo|All participants receive placebo with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
9832927|NCT02633956|Experimental|5 mg Obeticholic Acid|5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
9832928|NCT02633956|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
9832929|NCT02633956|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
9832930|NCT02633956|Placebo Comparator|Placebo|One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
9832931|NCT02634073|Experimental|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
9832932|NCT02634073|Experimental|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
9832933|NCT02634073|Experimental|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
9832934|NCT02634073|Experimental|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
9832935|NCT02634151|Placebo Comparator|Placebo|Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
9832936|NCT02634151|Experimental|Gemcabene 600 mg|Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
9832937|NCT02634177|Active Comparator|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
9832938|NCT02634177|Placebo Comparator|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
9832939|NCT02634320|Other|Aripiprazole Lauroxil|Intramuscular (IM) injection
9832940|NCT02634333|Sham Comparator|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
9832941|NCT02634333|Experimental|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
9832942|NCT02634346|Experimental|ALKS 3831|Administered as a coated bilayer tablet
9832943|NCT02634346|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
9832944|NCT02634346|Placebo Comparator|Placebo|Administered as a coated bilayer tablet
9832945|NCT02634580|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
9832946|NCT02634580|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
9832947|NCT02634580|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
9832948|NCT02634580|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
9832949|NCT02634684|Active Comparator|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
9984218|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in cutaneous melanoma|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with malignant melanoma of the skin. Booster injections of TBio-6517 are permitted for up to 24 months.
9763216|NCT00747812|Sham Comparator|2|Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
9763217|NCT00748033|Experimental|LoFric POBE Hydro-Kit II, 5 seconds and then LoFric POBE Hydro-Kit II, 24 hours|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 5 seconds.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 24 hours."
9763218|NCT00748033|Experimental|LoFric POBE Hydro-Kit II, 24 hours and then LoFric POBE Hydro-Kit II, 5 seconds|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 24 hours.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 5 seconds."
9763219|NCT00748072|Placebo Comparator|Saline solution|patients treated with 1 ml of s.c. saline solution
9763220|NCT00748072|Experimental|DDAVP|treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy
9763221|NCT00748098|Other|GSK1838262:placebo|GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
9763222|NCT00748098|Other|Placebo:GSK1838262|Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2
9763223|NCT00748189|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
9763224|NCT00748189|Active Comparator|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
9763225|NCT00748215|Experimental|Arm I: CASAD|Oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may receive CASAD for an additional 6 weeks.
9763226|NCT00748215|Placebo Comparator|Arm II: Placebo|Oral placebo 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may then receive CASAD for 6 weeks.
9763227|NCT00748241|Experimental|Astra Tech Fixture ST|
9763228|NCT00748410|Experimental|7 Days Repeat Dose|
9763229|NCT00748540|Experimental|Implanted|Implanted with Vibrant Soundbridge
9763230|NCT00748553|Experimental|All patients|All participants enrolled.
9763231|NCT00748566|Experimental|Active treatment (switch to oral Ziprasidone)|
9763232|NCT00748657|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9763233|NCT00748709|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
9763234|NCT00748826||Infliximab -Rheumatoid Arthritis Participants|
9763235|NCT00748865|Experimental|Systane Ultra|Systane Ultra 1 drop each eye one time
9763236|NCT00748865|Active Comparator|Systane|Systane 1 drop each eye one time
9763237|NCT00748956|Experimental|Low dose NPY|Low dose, Receive 50 nmol dose of NPY
9763238|NCT00748956|Experimental|High dose NPY|High Dose, Receive 100 nmol dose of NPY
9763239|NCT00748956|Placebo Comparator|Placebo|Placebo comparator
9763240|NCT00748969|Experimental|Growth hormone treatmen|Growth hormone treatment arm. Somatropin (DNA origin)
9763241|NCT00748969|No Intervention|No growth hormone treatment in year 1|No growth hormone treatment in year 1; option for treatment in year 2 open-label period.
9763242|NCT00748982|Experimental|1|
9763243|NCT00748982|Placebo Comparator|2|
9763244|NCT00749073|Other|Percutaneous Lumbar Decompression procedure|mild percutaneous lumbar decompression procedure
9763245|NCT00749125|Experimental|1 Lexapro|The depressed participants in this arm will be given Lexapro.
9763246|NCT00749125|No Intervention|2 Control|The nondepressed participants in this arm will not be given any intervention for depression.
9763247|NCT00749203|Experimental|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
9763248|NCT00749203|Active Comparator|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
9763249|NCT00749268|Active Comparator|A|
9763250|NCT00749268|Active Comparator|B|
9763251|NCT00749398||Infliximab|Subjects with moderate-to-severe psoriasis who are treated with infliximab in daily clinics according to local country regulations and reimbursements.
9763252|NCT00749411|Experimental|Arm 1|
9763253|NCT00749411|Placebo Comparator|Arm 2|
9763254|NCT00749463|Experimental|Gum 2|Nicotine Gum 2 mg for subjects smoking less than 20 cigarettes per day; 2 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
9763255|NCT00749463|Experimental|Gum 4|Nicotine Gum 4 mg for subjects smoking 20 or more cigarettes per day; 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
9763256|NCT00749463|Experimental|Patch|Nicotine Patch; Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
9763257|NCT00749515|Experimental|Single Arm|All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring and HIDA scan. Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well).
9832950|NCT02634684|Placebo Comparator|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
9832951|NCT02634788|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
9832952|NCT02634788|Experimental|Buprenorphine 0.25 mg TID|Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
9832953|NCT02634788|Experimental|Buprenorphine 0.125 mg TID|Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
9832954|NCT02634788|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray TID for two days.
9517938|NCT03301480||No contraception/18-19 years old|
9517939|NCT03301480||Use of ENG-I/18 - 19 years old|
9832955|NCT02634801|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
9832956|NCT02634801|Active Comparator|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
9832957|NCT02634801|Active Comparator|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
9832958|NCT02634814|Experimental|TENS and Therapeutic Exercise|Patients assigned to the TENS+Therapeutic Exercise (TE) group will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN), and 8 hours of TENS per day (150 pulses per second, 150 msec phase duration at a patient-perceived strong sensory intensity). Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
9832959|NCT02634814|Sham Comparator|Sham TENS and Therapeutic Exercise|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program."
9832960|NCT02634814|Active Comparator|Therapeutic Exercise Only|The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
9832961|NCT02634983|Experimental|QVA149 110/50 mcg then Matching placebo|Single daily dose of 110/50 μg QVA149 for 8-10 days.
9832962|NCT02634983|Placebo Comparator|Matching placebo then QVA149 110/50 mcg|Single daily dose of matching placebo for 8-10 days.
9832963|NCT02635035|Experimental|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
9832964|NCT02635035|Experimental|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
9832965|NCT02635204|Experimental|DFD-06 Cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
9832966|NCT02635204|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
9832967|NCT02635347|Experimental|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
9832968|NCT02635386|Experimental|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
9832969|NCT02635386|Experimental|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
9832970|NCT02635386|Experimental|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
9832971|NCT02635386|Experimental|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
9517940|NCT03301480||LNG-IUS/18-19 years old|
9517941|NCT03301480||No Contraception/ 25 - 45 years old|
9517942|NCT03301480||Use of ENG-I/25 - 45 years old|
9517943|NCT03301480||LNG-IUS/25-45 years old|
9517944|NCT03301454|Experimental|Arm A|Pursuit of chemotherapy.
9517945|NCT03301454|No Intervention|Arm B|Interruption of chemotherapy, best supportive care
9517946|NCT03301428|Experimental|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
9763258|NCT00749580|Experimental|1: Boosted PI+RAL|Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
9763259|NCT00749580|No Intervention|2: Boosted PI+NRTIs|Group 2 Continue the same regimen without change
9763260|NCT00749606|Experimental|Individual Telephone Intervention|Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
9763261|NCT00749606|Active Comparator|Group Telephone Intervention|Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.
9763262|NCT00749671|Active Comparator|ICD testing BIS|Bispectral Index Monitoring will be used to assess adequacy of moderate sedation during DFT.
9763263|NCT00749671|Active Comparator|ICD testing Ramsey|Ramsey Sedation Scale will be used to assess adequacy of moderate sedation during DFT
9763264|NCT00749684||Adults with malignant melanoma at high risk of relapse|"Adults with malignant melanoma of the following stages:~II and III (>/= 1.5 mm Breslow thickness without distant metastases~melanoma with lymph node metastases"
9763265|NCT00749749|Experimental|Bupivacaine collagen sponge|Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.
9763266|NCT00749749|Active Comparator|ON-ON-Q PainBuster Post-op Pain relief SystemQ system|Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.
9763267|NCT00749775||Eplerenone|Subjects who are treated with Eplerenone tablet for hypertension disease
9763268|NCT00749879|Experimental|25 mg AMCC fed|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fed State"
9763269|NCT00749879|Experimental|25 mg AMCC fasting|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fasting State"
9763270|NCT00749879|Experimental|50 mg AMCC fed|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fed State"
9763271|NCT00749879|Experimental|50 mg AMCC fasting|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fasting State"
9763272|NCT00749879|Experimental|50 mg SMCC fasting|"2, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose~Fasting State"
9763273|NCT00749892|Experimental|Treatment (erlotinib hydrochloride)|Participants receive erlotinib hydrochloride PO QD for 3-5 weeks in the absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose, participants undergo cystectomy.
9763274|NCT00749931|Active Comparator|SOC|Standard of Care arm - standard of care lumpectomy procedure
9763275|NCT00749931|Experimental|Device + SOC|Use of the device in addition to the standard of care lumpectomy procedure.
9763276|NCT00749944|Experimental|varenicline|
9763277|NCT00749944|Placebo Comparator|placebo|
9763278|NCT00749957|Experimental|1|Subjects at least 6 y/o treated with a lower dose of the vector by subretinal injection
9763279|NCT00749957|Experimental|2|Subjects at least 6 y/o treated with a higher dose of the vector by subretinal injection
9763280|NCT00749996|Experimental|Investigational group|Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
9763281|NCT00749996|Active Comparator|Control group|Single level herniectomy
9763282|NCT00750061|Placebo Comparator|Placebo|Placebo tablet
9763283|NCT00750061|Experimental|Lithium carbonate|Lithium Carbonate tablet, 250mg
9763284|NCT00750139|Experimental|1|Naftin 2% cream applied daily for 2 weeks
9763285|NCT00750139|Placebo Comparator|2|Placebo cream applied daily for two weeks
9763286|NCT00750139|Active Comparator|3|Active comparator applied daily for 4 weeks
9763287|NCT00750139|Placebo Comparator|4|placebo cream applied daily for 4 weeks
9763288|NCT00750152|Placebo Comparator|2|placebo
9763289|NCT00750152|Experimental|1|NAFT-500
9763290|NCT00750165|Experimental|Titration Night|Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device
9763291|NCT00750191|Active Comparator|Intradiscal Biacuplasty|"On the day of the procedure, patients were given midazolam for relaxation and, if needed, fentanyl IV during the procedure. For treatment subjects, two TransDiscal probes were positioned under fluoroscopic guidance in the posterior annulus of the intervertebral disc. The probes were attached to the Radiofrequency generator and Radiofrequency energy was delivered. Placement of the probes within the disc annulus was confirmed using oblique, lateral, and anterior-posterior fluoroscopic images.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure."
9763292|NCT00750191|Placebo Comparator|Sham|"Sham procedures mimicked active treatment procedures, except that the probes were positioned just outside of the disc and no radiofrequency energy was delivered through the electrodes. Thus, sham patients were provided similar tactile, auditory and visual experiences as treatment patients, without receiving the active RF treatment.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.~The study will be unblinded at 6 months. If the patients in the IDB group show significant improvement compared to placebo they will be offered IDB."
9763293|NCT00750269|Experimental|Level 1: 8.0 Gy/FX|SBRT 40.0 Gy
9763294|NCT00750269|Experimental|Level 2: 8.5 Gy/FX|SBRT 42.5 Gy
9763295|NCT00750269|Experimental|Level 3: 9.0 Gy/FX|SBRT 45.0 Gy
9763296|NCT00750269|Experimental|Level 4: 9.5 Gy/FX|SBRT 47.5 Gy
9763297|NCT00750269|Experimental|Level 5: 10.0 Gy/FX|SBRT 50.0 Gy
9763298|NCT00750269|Experimental|Level 6: 10.5 Gy/FX|SBRT 52.5 Gy
9763299|NCT00750269|Experimental|Level 7: 11.0 Gy/FX|SBRT 55.0 Gy
9763300|NCT00750269|Experimental|Level 8: 11.5 Gy/FX|SBRT 57.5 Gy
10203116|NCT03371823|Experimental|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
10203117|NCT03363919|Active Comparator|1 Hz left prefrontal rTMS|36 sessions of 1 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 continuous pulses.
10203118|NCT03363919|Active Comparator|10 Hz left prefrontal rTMS|36 sessions of 10 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 pulses with 4 seconds on and 36 seconds off.
9517947|NCT03301428|Experimental|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
9517948|NCT03301428|No Intervention|Control|Participants in this group will receive the 2 educational tools at the end of the study
9517949|NCT03301402|Active Comparator|Filter|
9517950|NCT03301402|No Intervention|No filter|
9517951|NCT03301389||Control group|
9517952|NCT03301389||Pretreatment group|Patients in pretreatment state
9763301|NCT00750269|Experimental|Level 9: 12.0 Gy/FX|SBRT 60.0 Gy
9763302|NCT00750282|Experimental|Florbetaben (BAY94-9172)|
9763303|NCT00750308|Active Comparator|tadalafil, ramapril, combo, placebo|placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks
9763304|NCT00750308|Active Comparator|ramipril, tadalafil, placebo, combo|placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks
9763305|NCT00750308|Active Comparator|combo, placebo, tadalafil, ramipril|ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks
9763306|NCT00750308|Active Comparator|placebo, combo, ramipril, tadalafil|placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks
9763307|NCT00750308|Active Comparator|tadalafil, placebo, ramipril, combo|placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks
9763308|NCT00750308|Active Comparator|ramipril, combo, tadalfil, placebo|placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks
9763309|NCT00750308|Active Comparator|combo, ramipril, placebo, tadalafil|ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks
9763310|NCT00750308|Active Comparator|placebo, tadalafil, combo, ramipril|placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks
9763311|NCT00750308|Active Comparator|tadalafil, combo, placebo, ramipril|placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks
9763312|NCT00750308|Active Comparator|ramipril, placebo, combo, tadalafil|placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks
9763313|NCT00750308|Active Comparator|combo, tadalafil, ramipril, placebo|ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks
9763314|NCT00750308|Active Comparator|placebo, ramipril, tadalafil, combo|placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks
9763315|NCT00750360|Experimental|Unprimed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who were previously not vaccinated against influenza (unprimed).
9763316|NCT00750360|Experimental|Unprimed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who were previously not vaccinated against influenza (unprimed).
9763317|NCT00750360|Experimental|Primed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who previously received a vaccination against influenza (primed).
9763318|NCT00750360|Experimental|Primed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who previously received a vaccination against influenza (primed).
9763319|NCT00750360|Experimental|Primed, ≥ 108 to < 216 Months|Subjects aged ≥ 108 months to < 216 months who previously received a vaccination against influenza (primed).
9763320|NCT00750360|Experimental|Primed, ≥ 216 Months|Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).
9763321|NCT00750373|No Intervention|Conventional|Conventional Treatment based on current guidelines
9763322|NCT00750373|Active Comparator|Surgery|Early surgery within 48 hours of randomization
9763323|NCT00750438|Experimental|Propionate ester|
9763324|NCT00750438|Placebo Comparator|Fermentable control|
9763325|NCT00750438|Placebo Comparator|Non fermentable control|
9763326|NCT00750737|Experimental|Posaconazole|Posaconazole 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
9763327|NCT00750737|Experimental|Amphotericin B Lipid Complex (ABLC)|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
9783797|NCT01211483|Experimental|Part B: U3-1287 (low dose) + Erlotinib|U3-1287 (low dose) IV Q3W + Erlotinib 150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
9783798|NCT01211483|Placebo Comparator|Part B: Placebo + Erlotinib|Placebo matching U3-1287 IV Q3W + Erlotinib150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
9783799|NCT01211522|Experimental|Haloperidol|Haloperidol
9783800|NCT01211522|Experimental|Ziprasidone|Ziprasidone
9763328|NCT00750815|Experimental|A. Phase I - Dose Escalation|"Dose of Cyclophosphamide to depend on how many patients we treated:~Dose Level 1: Cyclophosphamide 250 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 2: Cyclophosphamide 500 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 3: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 4: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.3 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12"
9763329|NCT00750815|Experimental|B. Phase II - Maximum Planned Dose (MPD)|Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
9763330|NCT00750867|Experimental|1|Interventions included monthly infusions of intravenous immunoglobulin.
9763331|NCT00750880|Experimental|1|
9763332|NCT00750893||Rotarix Group|Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
9763333|NCT00750919|Experimental|Esmirtazapine|Participants receive esmirtazapine 4.5 mg tablet, orally, once daily (QD) for up to 6 months.
9763334|NCT00751023|Experimental|1|Modafinil 400 mg daily
9763335|NCT00751023|Placebo Comparator|2|Placebo
9763336|NCT00751036|Experimental|Nilotinib|Patients who were assigned to this treatment group received 400 mg. nilotinib bid.
9763337|NCT00751036|Active Comparator|Imatinib|Patients who were assigned to this treatment group received 400 mg. imatinib bid.
9763338|NCT00751101|Experimental|Arm A: Prior to initiation of capecitabine|Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
9763339|NCT00751101|Experimental|Arm B: After hand-foot syndrome symptoms appear|Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
9763340|NCT00751114|Experimental|Insulin Glargine|Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL<FPG≤100mg/dL (3.9mmol/L<FPG≤5.5mmol/L).
9763341|NCT00751114|Active Comparator|Sitagliptin|Dose of 100 mg once a day administered with or without food.
9763342|NCT00751140|Experimental|Lymph Node Dissection at Time of Nephroureterectomy|A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
9763343|NCT00751179|Active Comparator|Rocuronium - Sugammadex|Rocuronium - Sugammadex 4.0 mg/kg
9763344|NCT00751179|Active Comparator|Succinylcholine|Succinylcholine 1.0 mg/kg
9763345|NCT00751296|Experimental|Lenalidiomide|Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.
9763346|NCT00751348|Experimental|PRIORIX-TETRA GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra® vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.
9763347|NCT00751348|Active Comparator|PRIORIX + VARILRIX GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.
9763348|NCT00751400|Experimental|Naproxen Sodium ER (BAYH6689)|subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
9783801|NCT01211522|Placebo Comparator|Placebo|Placebo
9783802|NCT01211535|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days
9783803|NCT01211535|Active Comparator|ReNu Biotrue|ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days
9783804|NCT01211600|Active Comparator|Staples|Interrupted Ethicon Staples
9517953|NCT03301389||Anthracycline-based chemotherapy (3 months)|Patients who received anthracycline-based chemotherapy 3 months ago
9517954|NCT03301389||Anthracycline-based chemotherapy (6 months)|Patients who received anthracycline-based chemotherapy 6 months ago
9517955|NCT03301389||Anthracycline-based chemotherapy (more than 1 year ago)|Patients who received anthracycline-based chemotherapy more than 1 year ago
9763349|NCT00751530||Protease Inhibitor Group|Subjects who required a protease inhibitor in their new ART regimen
9763350|NCT00751530||Non-protease Inhibitor|Subjects who did not take a protease inhibitor in their regimen
9763351|NCT00751621|Experimental|IgPro20|Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).
9763352|NCT00751634|Experimental|A|Application of the Gaymar Rapr-Round device per approved use
9763353|NCT00751777|Experimental|Group 1: 37.5 µg LT patch|80 subjects will receive a two vaccination regimen with a LT patch.
9763354|NCT00751777|Placebo Comparator|Group 2: 0 µg LT patch (placebo)|40 subjects will receive a two vaccination regimen with a placebo patch.
9763355|NCT00751790|Experimental|Triptorelin|
9763356|NCT00751881|Experimental|Teriflunomide 7 mg / 14 mg|Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
9763357|NCT00751881|Experimental|Teriflunomide 14 mg / 14 mg|Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
9763358|NCT00751881|Placebo Comparator|Placebo / Teriflunomide 14 mg|Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.
9763359|NCT00751972|Experimental|HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
9763360|NCT00751998||Arm 1|Test of SpyGlass device
9763361|NCT00752089|Experimental|Sodium fluoride/potassium nitrate/Isopentane dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice containing active ingredients: 1450 ppm F as sodium fluoride (NaF) and 5% potassium nitrate (KNO3) and isopentane as an excipient ingredient.
9763362|NCT00752089|Experimental|NaF/KNO3 Dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice, containing as active ingredients: 1450 ppm NaF and 5% KNO3 but no isopentane.
9763363|NCT00752089|Active Comparator|NaF Dentifrice|Participants to brush their teeth for one timed minute twice daily with a dentifrice containing 1450 ppm F as NaF.
9763364|NCT00752089|Placebo Comparator|Placebo Dentifrice|Participants to brush their teeth for one timed minute twice daily with a fluoride free dentifrice (0 ppm F).
9763365|NCT00752102|Active Comparator|Calcitriol|"Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Calcitriol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/ml of calcitriol. All dosage forms contain butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) as antioxidants.~Subjects taking calcitriol started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels."
9763366|NCT00752102|Active Comparator|Paricalcitol|"Paricalcitol, USP, the active ingredient in Zemplar® Capsules, is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Zemplar is available as soft gelatin capsules for oral administration containing 1 mcg, 2 mcg or 4 mcg of paricalcitol. Each capsule also contains medium chain triglycerides, alcohol, and butylated hydroxytoluene.~Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels."
9763367|NCT00752206|Active Comparator|Saracatinib|Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be 13 cycles.
9763368|NCT00752206|Placebo Comparator|Placebo|Placebo will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with placebo will be 13 cycles.
9763369|NCT00752219|Experimental|NXL104/CAZ/MTZ|NXL104/ceftazidime + metronidazole
9763370|NCT00752219|Active Comparator|Meropenem|
9763371|NCT00752232|Experimental|ACC-001+QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
9763372|NCT00752232|Experimental|ACC-001|Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
9763373|NCT00752232|Placebo Comparator|QS-21|Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
9763374|NCT00752232|Placebo Comparator|PBS|Placebo, IM injection, Day 1, month 3, 6, 9, 12
9763375|NCT00752557|Experimental|1|rhBMP-2/CPM , 1.0 mg/mL
9763376|NCT00752557|Experimental|2|rhBMP-2/CPM , 2.0 mg/mL
9763377|NCT00752557|Active Comparator|3|Oral bisphosphonate therapy (standard of care)
9763378|NCT00752609|Experimental|Peginesatide|
9763379|NCT00752622|Experimental|Shortened interval|Infliximab 5 mg/kg, then Infliximab 5 mg/kg every 6 weeks
9763380|NCT00752622|Experimental|Increased dose|Infliximab 5 mg/kg, then Infliximab 7 mg/kg every 8 weeks
9763381|NCT00752726|Active Comparator|Orlistat|Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day
9763382|NCT00752726|Placebo Comparator|Placebo|Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
9763383|NCT00752791|Experimental|Peginesatide|
9763384|NCT00752856|Experimental|1 - Kaletra + Isentress taken twice daily|Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
9763385|NCT00752856|Active Comparator|2 - Atripla taken once daily|Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
9763386|NCT00752895|Experimental|Arm I - Ginseng|Patients receive oral American ginseng extract twice daily.
9763387|NCT00752895|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily.
9763388|NCT00752908||Obese patients|Obese patients
9763389|NCT00752908||Normal weight patients and volunteers|Normal weight patients and volunteers
9763390|NCT00752973|Experimental|Treatment arm|MALG treatment
9763391|NCT00753012|Experimental|Lisdexamfetamine|"Adults who meet DSM-IV-TR criteria for ADHD.~Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of <135/85."
10203119|NCT03363061||Antithrombotics|The patients should be on antithrombotics on the day of colonoscopy arrangement
9763392|NCT00753142|Active Comparator|Participants with ketosis-prone diabetes|Obese African Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA) receiving Intralipid 20% and a glucose infusion.
9763393|NCT00753142|Active Comparator|Participants with ketosis-resistant diabetes|Obese African American with type 2 diabetes with hyperglycemia without ketosis receiving Intralipid 20% and a glucose infusion.
9763394|NCT00753142|Active Comparator|Non-diabetic control group|Obese African Americans without diabetes receiving a glucose infusion.
9763395|NCT00753220|Experimental|VDC2008|Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10^7, 7.5 x 10^7, or 1.0 x 10^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
9763396|NCT00753272|Experimental|FluNG Group|subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
9763397|NCT00753272|Active Comparator|Fluarix Group|subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
9763398|NCT00753298|Experimental|LoFric Primo (POBE) single-use urinary catheter|
9763399|NCT00753298|Active Comparator|LoFric Primo (PVC) single-use urinary catheter|
9763400|NCT00753337|Experimental|Assurant Cobalt Iliac Stent|Assurant® Cobalt Iliac Stent System
9763401|NCT00753363|Experimental|Arm 1|6 months of aerobic exercise training
9763402|NCT00753363|Experimental|Arm 2|6 months of weight loss
9763403|NCT00753415|Experimental|Part A: V935 LD|Two intramuscular (IM) injections of V935 low dose (LD), 1 given every other week over a 3-week period.
9763404|NCT00753415|Experimental|Part A: V934 LD(3)+V935 LD|Three electroporation (EP) injections of V934 (LD) , 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (LD) will be administered, 1 given every other week over a 3-week period.
9763405|NCT00753415|Experimental|Part A: V935 HD|Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.
9763406|NCT00753415|Experimental|Part A: V934 HD(3)+V935 HD|Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
9763407|NCT00753415|Experimental|Part A: V934 HD(5)+V935 HD|Five EP injections of V934 (HD), 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
9763408|NCT00753415|Experimental|Part B: V935 LD/V934 Booster|Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.
9763409|NCT00753415|Experimental|Part B: V934 LD(3)+V935 LD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
9763410|NCT00753415|Experimental|Part B: V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
9763411|NCT00753415|Experimental|Part B: V934 HD(3)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
9763412|NCT00753415|Experimental|Part B: V934 HD(5)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
9763413|NCT00753454|Experimental|CDP870|Patients having completed the week 34 assessment in C87077 (NCT00580840) or patients having been randomized at Week 18 and having met the pre-defined criteria for flare, will be given the option to enroll in C87084 and receive: 400 mg CZP at Entry, Week 2, and Week 4 followed by 200 mg every two weeks in combination with MTX until the drug is commercially available for the indication of RA in the patient's country or region (or until further notice from UCB).
9763414|NCT00753506|Active Comparator|Artemisinin|100 mg artemisinin capsule
9763415|NCT00753506|Placebo Comparator|Placebo|Identical looking placebo capsule
9763416|NCT00753519|Experimental|Real iTBS|iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes that standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals. The 2 sec trains were repeated 20 times every 10 sec. iTBS was applied to the primary motor and the dorsolateral prefrontal cortex bilaterally.
9763417|NCT00753519|Sham Comparator|Sham iTBS|The sham coil was placed in the same areas, and made a similar sound as the rTMS but was without a magnetic pulse.
9763418|NCT00753623|Active Comparator|Ramelteon first, placebo second|"In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
9763419|NCT00753623|Placebo Comparator|Placebo first, ramelteon second|"In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
9763420|NCT00753636|Experimental|Dynacirc CR (Isradipine)|Dynacirc CR (Isradipine) will start at 5mg dose and increased in increments of 5mg every 2 weeks
9763421|NCT00753649|Experimental|Aboriginal infants group|
9832972|NCT02635386|Active Comparator|Phentermine /Topiramate (PHEN/ TPM) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
9763422|NCT00753649|Active Comparator|Other Non-Aboriginal infants|
9763423|NCT00753675|Experimental|A|Vandetanib 300 mg as a once daily oral dose, from Day 1
9763424|NCT00753675|Experimental|B|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)
9783805|NCT01211600|Active Comparator|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
9783806|NCT01211613|Experimental|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
9783807|NCT01211613|Experimental|Mechanical Manipulation|Doctor of chiropractic will apply a mechanically-assisted thrust to the lumbar spine of research participants using the Activator IV Instrument.
9783808|NCT01211613|Active Comparator|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
9783809|NCT01211665|Experimental|Pulsed IVMP|Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles). If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
9783810|NCT01211665|Experimental|IVMP with oral prednisolone taper|Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg). If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
9783811|NCT01211730|Active Comparator|140 Group|Insulin treatment to target blood glucose at 140 mg/dl
9783812|NCT01211730|Active Comparator|180 Group|Insulin treatment to target blood glucose at 180 mg/dl
9783813|NCT01211769|Experimental|PUFAs|Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;
9783814|NCT01211769|Active Comparator|Naltrexone|Naltrexone chlorhydrate 50 mg
9783815|NCT01211769|Placebo Comparator|Placebo|"Naltrexone Placebo: pill with 50mg of talcum powder, identical to the pill of naltrexone;~Polyunsaturated fatty acids Placebo (PUFAs Placebo): yellow liquid paraffin identical to the pills of borage seed and fish oil."
9783816|NCT01211769|Other|Naltrexone + PUFAs|"Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;~Naltrexone chlorhydrate 50 mg"
9783817|NCT01211873|Experimental|Dotarem (gadoterate meglumine )|Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
9783818|NCT01211873|Active Comparator|Magnevist (gadopentetate dimeglumine)|Dotarem and Magnevist were randomised as 2:1 ratio
9783819|NCT01211873|Experimental|Dotarem 2 (gadoterate meglumine )|Pediatric patients were assigned to Dotarem group only.
9783820|NCT01212094|Experimental|Rituximab|Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
9783821|NCT01212094|Placebo Comparator|Placebo|Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
9783822|NCT01212094|No Intervention|Baseline|Patients in their first year baseline prior to study drug phase
9783823|NCT01212107|Experimental|Part A: 2 mg FGF Receptor QD|"Part A: Dose escalation~2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783824|NCT01212107|Experimental|Part A: 4 mg FGF Receptor QD|"Part A: Dose escalation~4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783825|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD|"Part A: Dose escalation~10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
9783826|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD + Phosphate Binders|"Part A: Dose escalation~10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783827|NCT01212107|Experimental|Part A: 8 mg FGF Receptor BID|"Part A: Dose escalation~8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783828|NCT01212107|Experimental|Part A: 10 mg FGF Receptor BID|"Part A: Dose escalation~10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783829|NCT01212107|Experimental|Part A: 14 mg FGF Receptor BID|"Part A: Dose escalation~14 FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783830|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID|"Part A: Dose escalation~18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783831|NCT01212107|Experimental|Part A: 24 mg FGF Receptor BID|"Part A: Dose escalation~24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
9517956|NCT03301389||Other therapy group|Patients who have been treated with other therapies (other chemo-therapies, combined radiation therapy, target agent therapy, hormone therapy)
9763425|NCT00753675|Placebo Comparator|C|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).
9763426|NCT00753688|Placebo Comparator|PLACEBO|matching placebo 800 mg once daily orally
9763427|NCT00753688|Experimental|PAZOPANIB|800 mg once daily orally
9763428|NCT00753714|Experimental|A|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
9763429|NCT00753714|Placebo Comparator|B|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
9763430|NCT00753766|Experimental|Multifactorial Intervention|Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
9763431|NCT00753766|No Intervention|Usual care|Control group
9763432|NCT00753896|Experimental|1|
9763433|NCT00753922|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
9763434|NCT00753922|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
9763435|NCT00753922|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
9763436|NCT00753922|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
9763437|NCT00753935|Experimental|Enteric-coated aspirin|patients received enteric-coated aspirin 81 mg qd for 2 weeks
9763438|NCT00753935|Active Comparator|Chewable aspirin|Patients received chewable aspirin 81 mg qd for 2 weeks
9763439|NCT00753948|Experimental|Chronic Tetraplegia|Individuals with chronic tetraplegia
9763440|NCT00753948|Active Comparator|Mild Asthma|Individuals with diagnosed mild asthma
9763441|NCT00753948|Placebo Comparator|Healthy Control|Neurologically intact, otherwise healthy, age-matched control
9763442|NCT00754065|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 26 days, followed by one capsule placebo for 2 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
9763443|NCT00754065|Active Comparator|Ortho Tri-Cyclen Lo|Daily oral administration of one capsule Ortho Tri-Cyclen Lo [Ethinylestradiol (EE)/ Norgestimate (NGM)] for 21 days, followed by one capsule placebo for 7 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
9763444|NCT00754130|Experimental|Placebo/MK-0941 20mg|Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
9763445|NCT00754130|Experimental|MK-0941 5mg/Placebo|Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
9763446|NCT00754130|Experimental|MK-0941 5mg/MK-0941 20mg|Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
9763447|NCT00754130|Experimental|Placebo/MK-0941 40mg|Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
9763448|NCT00754130|Experimental|MK-0941 10mg/Placebo|Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
9763449|NCT00754130|Experimental|MK-0941 10mg/MK-0941 40mg|Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
9763450|NCT00754156|Active Comparator|1 ABRA plus KCI ABThera or KCI VAC|ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
9763451|NCT00754156|Active Comparator|KCI V.A.C. Therapy or ABThera Alone|KCI V.A.C. Therapy ABThera Alone
9518030|NCT03300596|Other|standard of care|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
9763452|NCT00754208|Other|methylpehnidate|open-label treatment with methylphenidate
9763453|NCT00754234|Experimental|MyPyramid Menu Days 1-7|Iron absorption measured from one of the 7 different USDA MyPyramid menus for 1 day each, in randomized order for each subject, separated by 2 weeks
9763454|NCT00754247|Experimental|Regimen A|0.5% hydrocortisone, silicone, vitamin E lotion
9763455|NCT00754247|Experimental|Regimen B|Onion extract gel
9763456|NCT00754247|Placebo Comparator|Regimen C|Cetearyl alcohol lotion
9763457|NCT00754325|Active Comparator|Arm 1 (Dasatinib +Fulvestrant)|
9763458|NCT00754325|Active Comparator|Arm 2 (Fulvestrant)|
9763459|NCT00754338|Active Comparator|Phase1 - Arm 1|
9763460|NCT00754338|Active Comparator|Phase1 - Arm 2|
9763461|NCT00754338|Active Comparator|Phase 2 - Arm 1|
9763462|NCT00754338|Active Comparator|Phase 2 - Arm 2|
9763463|NCT00754377||PBLI Curriculum group|To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
9763464|NCT00754377||Comparison group|Received a different curriculum.
9763465|NCT00754390|Experimental|Overall Study|Participants consumed 4 experimental diets for 4 weeks each in randomized order
9763466|NCT00754442|Active Comparator|teriparatide control|control subject
9763467|NCT00754442|Experimental|Teriparatide Patient|Patient with secondary hyperparathyroidism
9763468|NCT00754468|Experimental|Group 1: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 4 cycles x 10 seconds
9763469|NCT00754468|Experimental|Group 2: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 2 cycles x20 seconds
9763470|NCT00754494|Experimental|Erlotinib Hydrochloride (25 mg)|Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
9763471|NCT00754494|Experimental|Erlotinib Hydrochloride (50 mg)|Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
9763472|NCT00754494|Experimental|Erlotinib Hydrochloride (100 mg)|Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
9763473|NCT00754546|Active Comparator|Arformoterol tartrate|Bronchodilator therapy with arformoterol solution 15 mcg
9763474|NCT00754546|Placebo Comparator|Normal saline|Placebo using normal saline
9763475|NCT00754559|Experimental|Tocilizumab|
9763476|NCT00754572|Experimental|1|
9763477|NCT00754624|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
9763478|NCT00754650|Experimental|Bevacizumab 15 mg/kg|Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.
9763479|NCT00754741|No Intervention|Usual care|All Physicians are given limited training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software when they see patients assigned to this arm
9763480|NCT00754741|Active Comparator|Adherence|
9763481|NCT00754741|Active Comparator|Adherence Plus|
9763482|NCT00754832|Experimental|1|Period 1 with Ginseng therapy intervention; Washout Period with no drug; Period 2 with placebo
9763483|NCT00754832|Experimental|2|Period 1 with placebo; Washout period with no drug; Period 2 with ginseng therapy intervention
9763484|NCT00754845|Experimental|Letrozole|Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
9763485|NCT00754845|Placebo Comparator|Placebo|Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
9763486|NCT00754923|Experimental|Treatment: Sorafenib|Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
9763487|NCT00754936|Experimental|Escitalopram|12 week open label with 2 week placebo period (14 weeks total)
9763488|NCT00755040|Experimental|Ocular Cyclosporine (Restasis)|Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.
9763489|NCT00755040|Placebo Comparator|Placebo|Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.
9763490|NCT00755079|Placebo Comparator|Arm 1|group of persons with spinal cord injury will receive blinded placebo capsule
9763491|NCT00755079|Experimental|Arm 2|group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
9763492|NCT00755131|Experimental|Training Group|Postinfarction patients undergo 6-month exercise-based Cardiac Rehabilitation Program
9763493|NCT00755131|No Intervention|Control Group|Postinfarction patients NOT undergoing 6-months exercise-based Cardiac Rehabilitation program
9763494|NCT00755183|Experimental|testosterone ophthalmic solution|testosterone ophthalmic solution 0.03%
9763495|NCT00755183|Placebo Comparator|vehicle|vehicle of testosterone ophthalmic solution
9763496|NCT00755196|Active Comparator|1|AN2728 Ointment, 5%
9763497|NCT00755196|Placebo Comparator|2|AN2728 Ointment vehicle
9763498|NCT00755222|Experimental|AA4500|Clostridial collagenase for injection
9763499|NCT00755222|Placebo Comparator|Placebo|
9763500|NCT00755235|Experimental|1|Participants will receive depression care management by secure messaging.
9763501|NCT00755235|No Intervention|2|Participants will receive their usual care, with no additional education or care management services.
9763502|NCT00755274|Experimental|Group 1: Primed|Have received 2 or more lifetime Flu Vaccinations Prior to Visit 1
9763503|NCT00755274|Experimental|Group 2: Naive/Inadequately Primed|Never Received or Received Only 1 Lifetime Flu Vaccination Prior to Visit 1
9763504|NCT00755326|Active Comparator|Huo-Luo-Xiao-Ling|Active herb Huo-Luo-Xiao-Ling (HLXL) The subjects in the HLXL group received the medium dose of HLXL (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/day) for the subsequent 6 weeks.
9763505|NCT00755326|Placebo Comparator|Placebo|Placebo Huo-Luo-Xiao-Ling (HLXL): Subjects in the placebo group received an equal number of placebo capsule.
9832973|NCT02635425|Experimental|7 eggs collection|Aspiration of 7 eggs only
9832974|NCT02635425|Active Comparator|Full eggs collection|Aspiration of all eggs
9763506|NCT00755417|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
9763507|NCT00755417|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
9763508|NCT00755417|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
9763509|NCT00755716|Placebo Comparator|Placebo (sugar pill)|Person receives an inactive placebo
9763510|NCT00755716|Active Comparator|Topiramate|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day for a total time of 10 weeks.
9763511|NCT00755716|Active Comparator|Topiramate and Nicotine patch|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day and one week taper for a total time of 10 weeks. On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
9763512|NCT00755755|Experimental|A (PGL4001 5mg)|PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
9763513|NCT00755755|Experimental|B (PGL4001 10mg)|PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
9763514|NCT00755755|Placebo Comparator|C (placebo)|PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
9763515|NCT00755807|Placebo Comparator|Placebo|
9763516|NCT00755807|Experimental|Duloxetine|
9763517|NCT00755846|Experimental|Alogliptin 6.25 mg QD|
9763518|NCT00755846|Experimental|Alogliptin 12.5 mg QD|
9763519|NCT00755846|Experimental|Alogliptin 25 mg QD|
9763520|NCT00755846|Experimental|Alogliptin 50 mg QD|
9763521|NCT00755846|Experimental|Alogliptin 100 mg QD|
9763522|NCT00755846|Placebo Comparator|Placebo QD|
9763523|NCT00755911|Experimental|Tissue Repair Cells (TRC)|Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier
9763524|NCT00755911|Sham Comparator|Control|Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy.
9763525|NCT00755937||Subjects receiving Remicade|Crohn's disease subjects receiving Remicade® per Product Monograph.
9763526|NCT00756002|Experimental|Ramelteon 4 mg QD|
9763527|NCT00756002|Placebo Comparator|Placebo QD|
9763528|NCT00756093|Experimental|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each one time
9763529|NCT00756093|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
9763530|NCT00756093|Active Comparator|Blink Tears|Blink Tears 1 drop each eye one time
9763531|NCT00756093|Active Comparator|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops 1 drop each eye one time
9763532|NCT00756106|Experimental|Temozolomide and Radiation Therapy|
9763533|NCT00756236|Experimental|M-Group|Patients were randomly assigned to Metoprolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 1mg/ml Metoprolol. Investigators and patients were blinded to the group assignment.
9763534|NCT00756236|Experimental|E-Group|Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.
9763535|NCT00756236|Placebo Comparator|P-Group|Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml & 5ml syringes.
9763536|NCT00756275|Active Comparator|Nicotine Replacement + PLA pill|Nicotine replacement treatment patch plus matched placebo pill
9763537|NCT00756275|Active Comparator|Varenicline + PLA patch|Varenicline plus matched placebo patches containing no nicotine
9763538|NCT00756314|Experimental|Personalized contraceptive counseling|All 123 allocated women for the intervention group received personalized counseling (face-to-face) and the contraceptive method chosen for free by a specialized trained doctor in family planning.
9763539|NCT00756314|No Intervention|Control|All 123 women allocated to control group received a standard care available at IMIP.Standard care is comprised of educational group counseling by specialized nursing staff in family planning discussing about contraceptive methods and side effects
9763540|NCT00756444|Active Comparator|Panitumumab plus Chemotherapy|Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
9763541|NCT00756444|Active Comparator|Chemotherapy Alone|Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
9763542|NCT00756457|Active Comparator|Active Treatment Group|Participants in Group A will undergo bracing and perform stretching exercises.
9763543|NCT00756457|Experimental|Passive Treatment Group|Participants in Group B will undergo bracing and perform stretching and strengthening exercises.
9832975|NCT02635542|Active Comparator|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
9832976|NCT02635542|Experimental|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
9832977|NCT02635646|Experimental|Family and interdisciplinary approach|Family and interdisciplinary approach: Patients in this group will receive a Family and interdisciplinary approach that includes nutritional, physical activity and psychological counseling + metformin 850mg twice at day for 12 months
9832978|NCT02635646|Active Comparator|individual approach|individual approach: Patients in this group will receive individual approach that includes nutritional and physical activity counseling + metformin 850mg twice at day for 12 months
9518031|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
9832979|NCT02635724|Experimental|Peramivir|Single dose 600 mg IV injection
9832980|NCT02635737|Experimental|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
9832981|NCT02635828|Experimental|Triple therapy PONV prophylaxis|At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
9832982|NCT02635880|Experimental|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
9832983|NCT02635984|Placebo Comparator|Triplet Therapy Plus Placebo|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
9832984|NCT02635984|Active Comparator|Triplet Therapy Plus Olanzapine|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
9832985|NCT02636049|Experimental|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
10203120|NCT03356470||FLT/PET + biopsy|F-FDG and FLT PET/CT imaging will be obtained prior to anti-cancer treatment and 10-12 weeks after starting treatment with anti-PD-1 antibody.
10203121|NCT03353350|Experimental|Efpeglenatide 2mg|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
10203122|NCT03353350|Experimental|Efpeglenatide 4 mg|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
10203123|NCT03353350|Experimental|Efpeglenatide 6 mg|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
10203124|NCT03353350|Placebo Comparator|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
9832986|NCT02636049|Experimental|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
9832987|NCT02636361|Experimental|LY900014 Test B|Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
9832988|NCT02636361|Experimental|LY900014 Test A|Test formulation B: Single dose of LY900014 formulation administered SC in one of five periods
9832989|NCT02636361|Experimental|LY900014 Test C|Test formulation C: Single dose of LY900014 formulation administered SC in one of five periods
9832990|NCT02636361|Experimental|LY900014 Test D|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
9832991|NCT02636361|Active Comparator|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
10203125|NCT03350503|Experimental|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
10203126|NCT03330067|Sham Comparator|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
10203127|NCT03330067|Experimental|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
10203128|NCT03329313|Active Comparator|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
10203129|NCT03329313|Sham Comparator|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
10203130|NCT03328091|Active Comparator|Traditional pre-test genetic counseling|"In-person consultation with licensed genetic counselor at the Center for Cancer Genetics and Prevention before genetic testing~Participant is given a pamphlet introducing prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is given the Genetic Testing Information for Decision Making packet. After the genetic counseling session, patient is asked if they would like to proceed with genetic testing."
9518032|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
9763544|NCT00756470|Experimental|Neoadjuvant Lapatinib plus Chemotherapy|"Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.~Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.~Week 3 Paclitaxel 80 mg/m^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.~Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m^2, Epirubicin 75 mg/m^2, and Cyclophosphamide 500 mg/m^2 every 3 weeks for 4 cycles)."
9763545|NCT00756496|Experimental|1|
9763546|NCT00756548|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
9763547|NCT00756548|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
9763548|NCT00756600|Active Comparator|1|Regional Anesthesia
9763549|NCT00756600|Active Comparator|2|General Anesthesia
9763550|NCT00756613||465 VADT participants|The participants had previously participated in the VADT CSP #465 study
9763551|NCT00756652||MemoryGel Breast Implant Participants|MemoryGel Breast Implant Participants received Mentor Silicone Gel-Filled Breast Implants (MemoryGel) during their Breast Augmentation, Breast Reconstruction, or Revision surgery
9763552|NCT00756652||Saline Breast Implant Control Participants|Saline Breast Implant Control Participants received Saline Filled Breast Implants during their Breast Augmentation, Breast Reconstruction, or Revision surgery
9783832|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID Extension|"Part A: Dose escalation~18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783833|NCT01212107|Experimental|Part A: 16 mg FGF Receptor BID|"Part A: Dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783834|NCT01212107|Experimental|Part B: 16 mg FGF Receptor BID|"Part B: Dose determined by part a dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
9783835|NCT01212159|No Intervention|No self monitoring device|Standard or usual care of high LDL including lab lipid profiles after treatment with statin therapy. No device or telemedicine education will be provided
9783836|NCT01212159|Experimental|Self Monitoring Lipid Analyzer|Self measured blood lipids using a home lipidometer, and telephone reporting of data to the clinical center.
9783837|NCT01212172|Active Comparator|Soprano/SHR|Alma Soprano/SHR 810 nm Diode Laser
9783838|NCT01212172|Active Comparator|LightSheer|LightSheer Duet 810 nm diode laser
9783839|NCT01212185|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin.
9783840|NCT01212185|Experimental|intranasal oxytocin spray|Twice daily intranasal oxytocin spray
10203131|NCT03328091|Experimental|Pre-test video education|"Participant is given a pamphlet that describes the basics of prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is approached in clinic by research staff at a pre-planned time~The patient is given the Genetic Testing Information for Decision Making packet~The pre-test video education is a short video. Information will be provided about the basics of genetics and mutations, the potential benefits, risks, and limitations of genetic testing, and the possible results the participant may receive"
10203132|NCT03326193|Experimental|Participants receiving niraparib+ bevacizumab|Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle. On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
9783841|NCT01212302|Experimental|aspirin, clopidogrel|If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)
9783842|NCT01212445|Experimental|PEG + E, 13.125 g|Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time
9783843|NCT01212445|Experimental|PEG + E, 26.25 g|Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time
9783844|NCT01212445|Experimental|PEG + E, 39.375 g|Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time
9783845|NCT01212471|Experimental|Bromfenac Ophthalmic Solution A|Bromfenac ophthalmic solution A
9783846|NCT01212471|Experimental|Bromfenac Ophthalmic Solution B|Bromfenac ophthalmic solution B
9783847|NCT01212471|Placebo Comparator|Placebo Comparator|Placebo Comparator
10203133|NCT03320317||Colorectal cancer|
9783848|NCT01212484|Experimental|Placebo (first), Carbidopa (second)|Crossover design Placebo first followed by carbidopa
9783849|NCT01212484|Experimental|Carbidopa (first), Placebo (second)|Crossover design carbidopa first followed by placebo
9783850|NCT01212588|Experimental|Mifepristone|Mifepristone 600mg once daily x 7 days
9783851|NCT01212588|Placebo Comparator|Placebo|Matching placebo tablets one daily
9783852|NCT01212627|Experimental|Ridaforolimus|Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
9783853|NCT01212744|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses
9783854|NCT01212757|Experimental|Apremilast 20mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
9783855|NCT01212757|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
10203134|NCT03310905|Experimental|Isolated Abdominal Wall Transplant|
9518033|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
9763553|NCT00756678|Active Comparator|1|Carboxymethylcellulose and Glycerin
9763554|NCT00756678|Active Comparator|2|Polyethylene glycol 400
9763555|NCT00756717|Experimental|MK-0752|Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days
9763556|NCT00756730|Other|Switch to DRV/r (800mg/100mg) QD|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
9763557|NCT00756730|Other|Switch to ATV/r (300mg/100mg QD)|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study
9763558|NCT00756886|Active Comparator|Atorvastatin|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
9763559|NCT00756886|Placebo Comparator|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
9763560|NCT00756964|Active Comparator|Rasburicase|patients receiving rasburicase to lower serum uric acid
9763561|NCT00756964|Placebo Comparator|Placebo|patients will receive a placebo
9763562|NCT00756977|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
9763563|NCT00756977|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
9763564|NCT00757003|Experimental|Treatment Arm - Placement of TAG device|A TAG device will be used to repair the pathology in the thoracic aorta
9763565|NCT00757172|Other|Docetaxel + Cisplatin + Panitumumab + RT|Patients received docetaxel (40 mg/m^2), cisplatin (40 mg/m^2) and panitumumab (6 mg/kg) on weeks 1, 3, 5, 7, and 9 with radiotherapy (RT) (5040 cGy, 180 cGy/day x 28 days) beginning week 5. Resection was planned after completing chemotherapy (CRT).
9763566|NCT00757237|Experimental|AZLI 75 mg 3 times a day (TID)|
9763567|NCT00757237|Active Comparator|TIS 300 mg 2 times a day (BID)|
9763568|NCT00757588|Experimental|Saxagliptin, 5 mg + insulin|Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
9763569|NCT00757588|Placebo Comparator|Placebo + insulin|Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
9763570|NCT00757601|Experimental|15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)|Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.
9763571|NCT00757601|Experimental|Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)|Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
9763572|NCT00757601|Experimental|15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
9763573|NCT00757601|Experimental|15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
9832992|NCT02636595|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
10203135|NCT03310905|Experimental|Abdominal Wall with Solid Organ Transplant|
10203136|NCT03310879|Experimental|Participants with CCND1, CCND2, or CCND3|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
10203137|NCT03310879|Experimental|Participants with CDK4 or CDK6|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
10203138|NCT03310190||Participants receiving venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
10203139|NCT03302286|Active Comparator|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
10203140|NCT03302286|Active Comparator|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
10203141|NCT03297554|Experimental|m-health approach|See intervention description
10203142|NCT03297541|Experimental|m-health approach|All dyads will receive the m-health approach.
10203143|NCT03287687|Active Comparator|Air for insufflation|In this arm of patients, air which is currently used as standard of care will be used for insufflation
10203144|NCT03287687|Experimental|Carbon dioxide gas for insufflation|in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy
10203145|NCT03285269||Shock Group|Patients presenting with signs and symptoms of shock will undergo the E-RUSH ultrasound protocol and bioreactance before and after a passive leg raise maneuver.
10203146|NCT03282565|Experimental|Functional Resistance Training with a Brace|Participants will receive functional resistance training via a knee brace while walking on a treadmill 2-3 times a week for about 8 weeks.
10203147|NCT03282565|Experimental|Functional Resistance Training with Elastic Band|Participants will receive functional resistance training via an elastic band attached at the ankle while walking on a treadmill 2-3 times a week for about 8 weeks.
10203148|NCT03282565|Sham Comparator|Control|Participants will while on a treadmill without an applied resistance 2-3 times a week for about 8 weeks.
9518034|NCT03300531|Experimental|P-PRP|Blood will be drawn and pure platelet-rich plasma will be injected into the tendon.
9763574|NCT00757601|Experimental|60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo|Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
9763575|NCT00757601|Experimental|Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5
9763576|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
9763577|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
9763578|NCT00757601|Experimental|140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo|Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
9763579|NCT00757601|Experimental|Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
9763580|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5
9763581|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
9763582|NCT00757666|Active Comparator|Accelerometer|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
9763583|NCT00757666|Active Comparator|Minute Ventilation|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.
9763584|NCT00757705|Experimental|Paliperidone Extended-Release (ER)|
9763585|NCT00757783|Experimental|darunavir|darunavir 800 mg tablet once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
9763586|NCT00757783|Experimental|atazanavir|atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
9763587|NCT00757822|Experimental|Arm 1|dronabinol
9763588|NCT00757822|Active Comparator|Arm 2|ondansetron
9763589|NCT00757848|Experimental|AZD9668|
9763590|NCT00757848|Placebo Comparator|Placebo|
9763591|NCT00758043|Experimental|T12PR24 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
9763592|NCT00758043|Experimental|T12PR48 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
9763593|NCT00758043|Experimental|T12PR48 (eRVR-)|Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
9763594|NCT00758043|Experimental|Other|Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.
9763595|NCT00758069|Placebo Comparator|1|Placebo
9763596|NCT00758069|Experimental|2|Sitagliptin 100 mg
9763597|NCT00758069|Experimental|3|Sitagliptin 50 mg
9763598|NCT00758160|Experimental|OROS methylphenidate|Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
9763599|NCT00758264|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
9763600|NCT00758264|Active Comparator|Group B|Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
9763601|NCT00758264|Active Comparator|Group C|Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
9763602|NCT00758342|Experimental|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
9763603|NCT00758342|Active Comparator|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
9763604|NCT00758394|Placebo Comparator|Fluoride - A|Fluoride only toothpaste
9763605|NCT00758394|Active Comparator|Total + Whitening toothpaste - B|Triclosan/fluoride toothpaste
9763606|NCT00758394|Experimental|Triclosan/fluoride/Amino Acid - C|toothpaste containing amino acid #1
9763607|NCT00758394|Experimental|Triclosan/fluoride/Cavistat -D|toothpaste containing amino acid/bicarbonate
9763608|NCT00758420|Active Comparator|1|Varisolve (polidocanol endovenous mircofoam)
9763609|NCT00758420|Placebo Comparator|2|Agitated saline
9763610|NCT00758459|Experimental|1|
9763611|NCT00758459|Placebo Comparator|2|
9763612|NCT00758485|Experimental|sugammadex|Participants receiving 4.0 mg.kg-1 Sugammadex at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
10203149|NCT03281824|Experimental|ALT-P7|"8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,~Administration: Day 1 of each 3-week cycle"
9763613|NCT00758485|Placebo Comparator|Placebo|Participants receiving Placebo (0.9% NaCl) at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
9763614|NCT00758498|Experimental|1|armodafinil - dosage of 50 mg/day
9763615|NCT00758498|Experimental|2|armodafinil - dosage of 150 mg/day
10203150|NCT03276936|Experimental|Minocycline Foam 1.5%|FMX-103
10203151|NCT03271021|Experimental|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
10203152|NCT03271021|Placebo Comparator|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
10203153|NCT03266536|No Intervention|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
10203154|NCT03266536|Experimental|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
10203155|NCT03264352|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
10203156|NCT03264352|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
10203157|NCT03262623|Experimental|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
10203158|NCT03262623|Placebo Comparator|Placebo|Patients will receive placebo through radial nerve block
10203159|NCT03255083|Experimental|DS-1205c with osimertinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1200 mg) in combination with daily 80 mg oral dose of osimertinib
9763616|NCT00758498|Placebo Comparator|3|matching placebo
9763617|NCT00758524|Experimental|Core Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.
9763618|NCT00758524|Experimental|Core Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.
9763619|NCT00758524|Experimental|Core Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.
9763620|NCT00758524|Experimental|Core Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
9763621|NCT00758524|Active Comparator|Core Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.
9763622|NCT00758524|Placebo Comparator|Core Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.
9763623|NCT00758524|Experimental|Withdrawal Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
9763624|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.25 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
9763625|NCT00758524|Experimental|Withdrawal Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
9763626|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.5 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
9763627|NCT00758524|Experimental|Withdrawal Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
9763628|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 1.0 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
9763629|NCT00758524|Experimental|Withdrawal Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
9763630|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.5 mg BID Placebo|Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
9763631|NCT00758524|Active Comparator|Withdrawal Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
9763632|NCT00758524|Placebo Comparator|Withdrawal Period: Eplerenone 50 mg BID Placebo|Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
9763633|NCT00758524|Placebo Comparator|Withdrawal Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).
9763634|NCT00758550|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
9763635|NCT00758550|Active Comparator|AcrySof Natural IOL|AcrySof Natural Intraocular Lens (IOL)
9763636|NCT00758576|Experimental|SN6AD1|AcrySof ReSTOR Model SN6AD1 Intraocular Lens
9763637|NCT00758589|Experimental|AZD1981 50 mg|AZD1981 50 mg Twice Daily (Bid)
9763638|NCT00758589|Placebo Comparator|Placebo|Placebo
9763639|NCT00758589|Experimental|AZD1981 400 mg|AZD1981 400 mg Twice Daily (Bid)
9763640|NCT00758589|Experimental|AZD1981 1000 mg|AZD1981 1000 mg Twice Daily (Bid)
9763641|NCT00758602|Active Comparator|MMF, Standard Dose Tacrolimus|Participants received mycophenolate mofetil (MMF) 0.75 to (-) 1 gram (g), orally (PO), twice daily (BID) from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 milligrams per kilogram (mg/kg), PO, BID to reach a target trough dose of 8-10 nanograms per milliliter (ng/mL) from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
9763642|NCT00758602|Experimental|MMF, Low Dose Tacrolimus|Participants received MMF 0.75-1 g, PO, BID from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 mg/kg, PO, BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to 0.05-0.08 mg/kg, PO, BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
9763643|NCT00758667|No Intervention|Standard treatment|Standard treatment
9763644|NCT00758667|Experimental|Use of Mesna|Standard surgical procedure with Mesna
9763645|NCT00758680|Experimental|MK-1006 20 mg Once Daily (Panel A)|After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU).
9763646|NCT00758680|Experimental|MK-1006 40 mg Once Daily (Panel B)|After a 2-week run-in/wash-off period, participants received single daily doses of 40 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
9763647|NCT00758680|Experimental|MK-1006 80 mg Once Daily (Panel C)|After a 2-week run-in/wash-off period, participants received single daily doses of 80 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
9763648|NCT00758680|Experimental|MK-1006 120 mg Once Daily (Panel D)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
9763649|NCT00758680|Experimental|MK-1006 20 mg Twice Daily (Panel E)|After a 2-week run-in/wash-off period, participants received twice-daily doses (b.i.d.) of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
9763650|NCT00758680|Experimental|MK-1006 30 mg Twice Daily (Panel F)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 30 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
9763651|NCT00758680|Experimental|MK-1006 50 mg Twice Daily (Panel G)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
9763652|NCT00758680|Experimental|MK-1006 120 mg Once Daily Outpatient (Panel H)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
9763653|NCT00758680|Experimental|MK-1006 50 mg Twice Daily Outpatient (Panel I)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
9763654|NCT00758680|Placebo Comparator|Placebo|After a 2-week run-in/wash-off period, participants received dose-matched placebo to MK-1006 over a multiple-dosing period while remaining domiciled in the CRU.
9763655|NCT00758706|Experimental|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
9763656|NCT00758706|Placebo Comparator|Placebo|Dosing to match AZD1236
9763657|NCT00758745|Active Comparator|Model SN60WF|Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
9763658|NCT00758745|Active Comparator|Model MA60AC|Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
9763659|NCT00758758|Experimental|Experimental Arm 1|Hedrocel 1 level - No plate
9763660|NCT00758758|Experimental|Experimental Arm 2|Hedrocel 1 level with plate
9763661|NCT00758758|Experimental|Experimental Arm 3|Hedrocel 2 levels with plate
9763662|NCT00758758|Active Comparator|Control Arm 1|Autograft alone - Illiac crest
9763663|NCT00758758|Active Comparator|Control Arm 2|Autograft 1 level with plate
9763664|NCT00758758|Active Comparator|Control Arm 3|Allograft 1 level with plate
9763665|NCT00758758|Active Comparator|Control Arm 4|Autograft 2 levels with plate
9763666|NCT00758758|Active Comparator|Control Arm 5|Allograft 2 levels with plate
9763667|NCT00758771||Cystic Fibrosis|People who have been diagnosed with cystic fibrosis
9763668|NCT00758771||Healthy|People who do not have cystic fibrosis and who do not have any other lung conditions
9763669|NCT00758784|Experimental|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
9763670|NCT00758836|Placebo Comparator|Placebo|Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
9763671|NCT00758836|Experimental|Telcagepant 280 mg +Ibuprofen 400 mg|Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
9763672|NCT00758836|Experimental|Telcagepant 280 mg +APAP 1000 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
9763673|NCT00758836|Placebo Comparator|Telcagepant 280 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine
9763674|NCT00758862|Experimental|1|
9763675|NCT00759031|Placebo Comparator|A - Marketed fluoride toothpaste|
9763676|NCT00759031|Active Comparator|B -Triclosan/NaF/CoPolymer toothpaste|
9763677|NCT00759096|Experimental|Acrysof ReSTOR IOL|AcrySof ReSTOR Intraocular lens (IOL) implanted
9763678|NCT00759109|Experimental|Arm A - PegIntron|Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.
9763679|NCT00759109|Other|Arm B - Control|Participants randomized to Arm B were under observation and received no treatment.
9763680|NCT00759148|Experimental|Moxifloxacin AF|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
9763681|NCT00759148|Placebo Comparator|Vehicle|Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days
9763682|NCT00759161|Active Comparator|1|AN2728 Ointment, 5%
9763683|NCT00759161|Placebo Comparator|2|AN2728 Ointment Vehicle
9763684|NCT00759174||Case Group|
9763685|NCT00759187|Placebo Comparator|A|
9763686|NCT00759187|Active Comparator|B|
9763687|NCT00759187|Active Comparator|C|
9763688|NCT00759330|Placebo Comparator|Placebo Tape (Arm 1)|Placebo tape remained on for 12 hours of continuous treatment per day.
9763689|NCT00759330|Experimental|Flurbiprofen Tape (Arm 2)|Flurbiprofen tape remained on for 12 hours of continuous treatment per day.
9763690|NCT00759330|Placebo Comparator|Placebo Tape (Arm 3)|Placebo tape remained on for 24 hours of continuous treatment per day.
9763691|NCT00759330|Experimental|Flurbiprofen Tape (Arm 4)|Flurbiprofen tape remained on for 24 hours of continuous treatment per day.
9763692|NCT00759356|Other|1|Treatment A (test product) followed by Treatment B (reference product)
9763693|NCT00759356|Other|2|Treatment B (reference product) followed by Treatment A (test product)
9763694|NCT00759395|Experimental|AZD2327|AZD2327 3mg BID
9763695|NCT00759395|Placebo Comparator|Placebo|Placebo BID
9763696|NCT00759408|Experimental|1|BQ-123
9763697|NCT00759473|Placebo Comparator|Placebo/Placebo/Placebo/Placebo|Participants were assigned to receive placebo for each of 3 cue exposure sessions and at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
9763698|NCT00759473|Experimental|DCS/DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 3 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
9763699|NCT00759473|Other|DCS/Placebo/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) at the first and third cue exposure sessions and a placebo at the second cue exposure and the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
9763700|NCT00759473|Experimental|DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
9785631|NCT01256164|Active Comparator|Gelfoam|Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
9785632|NCT01256177|Experimental|1|
9785633|NCT01256177|Placebo Comparator|2|
9763701|NCT00759473|Active Comparator|Placebo/Placebo/Placebo|Participants were assigned to placebo for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
9763702|NCT00759525|Active Comparator|1|Glycyrrhetic Acid
9763703|NCT00759525|Placebo Comparator|2|Placebo
9763704|NCT00759564|Experimental|IV CP-70,429 and cross over to PF-03709270|
9763705|NCT00759603|Experimental|Lenalidomide + Rituximab|Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
9763706|NCT00759642|Experimental|Lapatinib|lapatinib
9763707|NCT00759655|Other|open label|
9763708|NCT00759668|Experimental|SN60D3|AcrySof Natural ReSTOR Intraocular Lens (IOL) Model SN60D3
9763709|NCT00759668|Active Comparator|SN60AT|AcrySof Natural Monofocal Intraocular Lens (IOL) Model SN60AT
9763710|NCT00759681|Active Comparator|Control|Gelfoam and Thrombin
9763711|NCT00759681|Experimental|Investigational Device|ArterX Surgical Sealant
9763712|NCT00759707|Experimental|1|ultrasound imaging of saphenous vein bypass graft following an ischemic stimulus, administration of sublingual nitroglycerin and intravenous administration of L-NMMA.
9763713|NCT00759759|Other|1|Treatment A (test product) followed by Treatment B (reference product)
9763714|NCT00759759|Other|2|Treatment B (reference product) followed by Treatment A (test product)
9763715|NCT00759772|Active Comparator|Teriparatide|
9763716|NCT00759772|Placebo Comparator|Placebo|
9763717|NCT00759785|Experimental|ER-positive Luminal B|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
9763718|NCT00759785|Experimental|Triple Negative|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
9763719|NCT00759798|Experimental|Fludarabine, Cyclophosphamide, Rituximab|"Fludarabine 25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
9763720|NCT00759811|Experimental|Methotrexate|Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
9763721|NCT00759811|Placebo Comparator|Placebo|Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
9763722|NCT00759863|Experimental|Lifezig|Subjects watch personalized reminiscence video channels developed by program staff with the help of family members/caregivers (using the LifeZig system)
9763723|NCT00759863|No Intervention|Usual Care|Subjects follow routine activities applied by nurses or caregivers, such as traditional reminiscence, crafts, singing, recreational activities, and other activities.
9763724|NCT00759876|Experimental|Ataluren|Participants will receive ataluren 3 times per day with meals at doses of 20 milligrams per kilogram (mg/kg) (breakfast), 20 mg/kg (lunch), and 40 mg/kg (dinner) for up to 89 weeks.
9763725|NCT00759902|Other|1|Treatment A (test product) followed by Treatment B (reference product)
9763726|NCT00759902|Other|2|Treatment B (reference product) followed by Treatment A (test product)
9763727|NCT00759915|Other|1|Treatment A (test product) followed by Treatment B (reference product)
9763728|NCT00759915|Other|2|Treatment B (reference product) followed by Treatment A (test product)
9763729|NCT00759941|Experimental|Xalatan + Azopt|Xalatan dosed once a day at 10 pm, with Azopt dosed three times a day at 8 AM, 2 PM, and 10:05 PM as an adjunctive therapy for 3 months.
9763730|NCT00759941|Active Comparator|Xalatan + Placebo|Xalatan dosed once a day at 10 pm, with placebo dosed three times a day at 8 AM, 2 PM, and 10:05 PM concomitantly for 3 months.
9763731|NCT00759954|Other|1|Treatment A (test product) followed by Treatment B (reference product)
9763732|NCT00759954|Other|2|Treatment B (reference product) followed by Treatment A (test product)
9785634|NCT01256190|Experimental|Fibrocaps + Gelatin sponge|Topical Fibrocaps powder followed by application of gelatin sponge
9763733|NCT00759967|Active Comparator|Short daily hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of short daily hemodialysis(2 hours/day,6 days/week)B/P will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 month period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
9763734|NCT00759967|Active Comparator|Conventional hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of conventional hemodialysis 3 days/week 3.5-4 hours/ treatment. BP will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 moth period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
9763735|NCT00760006|Active Comparator|Unasyn Antibiotic Arm|Unasyn® is a parenteral antibiotic that combines ampicillin with sulbactam, a beta-lactamase inhibitor. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. The study aims to assess the efficacy of the prophylactic antibiotic in cleft surgery to: decrease the incidence of surgical site infections, speed the progression of postoperative healing, improve the final quality of wound healing achieved, and decrease the rate of palatal fistula formation.
9763736|NCT00760006|Placebo Comparator|Saline Placebo Arm|Saline Placebo. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. This will act as the placebo control.
9763737|NCT00760019|Active Comparator|Salsalate first, then Placebo|In this crossover study, this group was randomly allocated therapy with salsalate first, a 4 week washout, then 4 weeks of placebo therapy in a double-blinded fashion.
9763738|NCT00760019|Placebo Comparator|Placebo first, then Salsalate|In this crossover study, this group was randomly allocated therapy with placebo first, a 4 week washout, then 4 weeks of salsalate therapy in a double-blinded fashion.
9763739|NCT00760084|Experimental|A|Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
9763740|NCT00760214|Experimental|Azilsartan Medoxomil 40 mg QD|
9763741|NCT00760214|Experimental|Azilsartan Medoxomil 80 mg QD|
9763742|NCT00760214|Active Comparator|Ramipril 10 mg QD|
9763743|NCT00760266|Experimental|Aliskiren/HCTZ 300/25 mg|
9763744|NCT00760266|Active Comparator|HCTZ 25 mg|
9763745|NCT00760383|Experimental|EAA+PT|20 g EAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
9763746|NCT00760383|Placebo Comparator|ALA+PT|20 g NEAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
9763747|NCT00760435|Experimental|1|Infliximab plus Intravenous immunoglobulin (IVIG)
9763748|NCT00760435|Placebo Comparator|2|Placebo plus IVIG
9763749|NCT00760474|Experimental|Pregabalin, then placebo|
9763750|NCT00760474|Experimental|Placebo, then pregabalin|
9763751|NCT00760487|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
9763752|NCT00760513|Active Comparator|Omega 3 fatty acid (fish oil)|OMACOR (alternative name: Lovaza) 4 grammes daily, oral capsule
9763753|NCT00760513|Placebo Comparator|dummy pill|4 grammes daily, oral capsule (olive oil)
9763754|NCT00760526|Active Comparator|1|continuous glucose monitoring
9763755|NCT00760526|Active Comparator|2|Standard glucose monitoring with a home glucose meter
9832993|NCT02636608||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
9832994|NCT02636699|Experimental|Viaskin Peanut 250mcg|
9832995|NCT02636699|Placebo Comparator|Placebo|
9832996|NCT02636712||ImageReady™ MR Conditional Pacing System|"Subject must have the ImageReady™ System as their initial (de novo) pacing system implant~Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
9832997|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Group|Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
9832998|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Expansion Cohort|Expansion cohort for up to 10 additional patients with alveolar soft part sarcoma. Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
9832999|NCT02636868|Experimental|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
9833000|NCT02636868|Experimental|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
9833001|NCT02636868|Active Comparator|nasal CPAP|nCPAP alone
9984219|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in cutaneous squamous cell carcinoma of the skin|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with cSCC. Booster injections of TBio-6517 are permitted for up to 24 months.
10203160|NCT03253172|Placebo Comparator|Placebo|Placebo
10203161|NCT03253172|Experimental|Potassium Chloride|Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
9833002|NCT02636907|Experimental|BI 695501|
9833003|NCT02637037|Experimental|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
9833004|NCT02637037|Active Comparator|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
9833005|NCT02637037|Experimental|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
9833006|NCT02637037|Active Comparator|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
9833007|NCT02637037|Experimental|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
9833008|NCT02637037|Active Comparator|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
9833009|NCT02637037|Experimental|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
9833010|NCT02637037|Active Comparator|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
9833011|NCT02637063|Experimental|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
10203162|NCT03253172|Experimental|Potassium Citrate|Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
10203163|NCT03245593||Shared Decision making for care|
9833012|NCT02637063|Experimental|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
9833013|NCT02637063|Other|Usual care|No intervention beyond the participants' personal medical care.
9833014|NCT02637076|Experimental|narcolepsy with cataplexy|patients given single dose of Xyrem
9833015|NCT02637076|Experimental|healthy controls|healthy controls given a single dose of Xyrem
10203164|NCT03245593||Standard decision making for care|
10203165|NCT03243656|No Intervention|historical group|Immunosuppressive therapy (cyclosporine alone ),
10203166|NCT03243656|Active Comparator|case arm|cyclosporine plus an oral dose of Eltrombopag
10203167|NCT03240419|Experimental|Probiotics|Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
10203168|NCT03240419|Placebo Comparator|Placebo|Participants in this group will take one capsule containing microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate (all ingredients listed in the probiotic capsules except the culture) . Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
10203169|NCT03227471|Placebo Comparator|Part A: Pooled Placebo (Except Cohort A7)|Participants without CF who received single dose of placebo matched to VX-445 in Cohort A1 to A5.
10203170|NCT03227471|Experimental|Part A: VX-445 (Except Cohort A7)|Participants without CF who received single ascending dose of VX-445 tablet starting from 20 milligrams (mg) to 360 mg in Cohort A1 to A5.
9833016|NCT02637141|Experimental|AMG 714 150 mg|Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
9833017|NCT02637141|Experimental|AMG 714 300 mg|Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
9833018|NCT02637141|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
9833019|NCT02637232||Mirvaso® / Onreltea TM|
9833020|NCT02637323|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
9833021|NCT02637323|Active Comparator|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
10203171|NCT03227471|Experimental|Part A: VX-445 (Cohort A7)|Participants without CF who received single dose of VX-445 100 mg tablet on Day 1 in fasted state and on Day 7 in fed state, followed by VX-445 20 mg intravenous (IV) injection on Day 13 in fed state in Cohort A7.
10203172|NCT03227471|Placebo Comparator|Part B: Pooled Placebo (Cohort B1 to B4)|Participants without CF who received multiple doses of placebo matched to VX-445 once daily (qd) for 10 days in Cohort B1 to B4.
9833022|NCT02637427|Experimental|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
9833023|NCT02637427|No Intervention|No transfusion|No transfusions prior to the procedure
9833024|NCT02637557|Placebo Comparator|Control|Matching placebo twice daily
9833025|NCT02637557|Experimental|500 mg IW-3718|500 mg IW-3718 twice daily
9833026|NCT02637557|Experimental|1000 mg IW-3718|1000 mg IW-3718 twice daily
9833027|NCT02637557|Experimental|1500 mg IW-3718|1500 mg IW-3718 twice daily
9833028|NCT02637804|Active Comparator|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
9833029|NCT02637804|Active Comparator|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
10203173|NCT03227471|Experimental|Part B: VX-445 (Cohort B1 to B4)|Participants without CF who received VX-445 tablet qd for 10 days in Cohort B1 (60 mg), B2 (120 mg), B3 (240 mg) and B4 (340 mg).
9833030|NCT02637856|Experimental|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
9833031|NCT02637856|Experimental|Ocrelizumab (substudy)|Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
9833032|NCT02637895|Placebo Comparator|Placebo|Placebo pill once daily for 12 weeks of active treatment.
9833033|NCT02637895|Active Comparator|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
9833034|NCT02637999|Experimental|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
9833035|NCT02637999|Experimental|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
9833036|NCT02637999|Active Comparator|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
9833037|NCT02638012|Experimental|HHT - Floseal|"Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity.~If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care)."
9833038|NCT02638051|Experimental|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
9833039|NCT02638051|Active Comparator|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
9836163|NCT02772666|Active Comparator|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
10203174|NCT03227471|Placebo Comparator|Part C: Pooled Placebo (Cohort C1 to C3)|Participants without CF who received placebo matched to VX-445/TEZ/IVA triple combination (TC) qd in the morning and placebo matched to IVA in the evening for 14 days.
10203175|NCT03227471|Experimental|Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3)|Participants without CF who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C1; VX-445 280 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C2 and VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C3 for 14 days.
10203176|NCT03227471|Placebo Comparator|Part D: Placebo|Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/IVA TC qd in the morning and placebo matched to IVA qd in the evening for 4 weeks in the TC treatment period.
10203177|NCT03227471|Experimental|Part D: VX-445/TEZ/IVA TC - Low Dose|Participants with CF, F/MF genotype who received VX-445 50 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
10203178|NCT03227471|Experimental|Part D: VX-445/TEZ/IVA TC - Medium Dose|Participants with CF, F/MF genotype who received VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
10203179|NCT03227471|Experimental|Part D: VX-445/TEZ/IVA TC - High Dose|Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
10203180|NCT03227471|Active Comparator|Part E: TEZ/IVA|Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received TEZ 100 mg qd/IVA 150 mg q12h and placebo matched to VX-445 for 4 weeks in the TC treatment period.
10203181|NCT03227471|Experimental|Part E: VX-445/TEZ/IVA TC|Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received VX-445 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h for 4 weeks in the TC treatment period.
10203182|NCT03227471|Placebo Comparator|Part F: Placebo|Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/VX-561 for 4 weeks in the TC treatment period.
10203183|NCT03227471|Experimental|Part F: VX-445/TEZ/VX-561 TC|Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/VX-561 150 mg qd for 4 weeks in the TC treatment period.
9763756|NCT00760552|Active Comparator|Arm 1|VA patients with uncontrolled HTN.
10203184|NCT03221842|Experimental|C1-INH|C1-esterase inhibitor
10203185|NCT03221842|Placebo Comparator|Placebo|Excipients of C1-INH plus albumin
10203186|NCT03208049|Experimental|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs and adherence to treatment, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves having difficulty staying awake during the day, they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
9763757|NCT00760552|Active Comparator|Arm 2|VA patients with uncontrolled HTN.
9763758|NCT00760578|Placebo Comparator|Placebo|Microcrystaline cellulose once daily
9763759|NCT00760578|Active Comparator|Pioglitazone|Pioglitazone 45 mg once daily
9763760|NCT00760578|Experimental|MSDC-0160 90 mg|MSDC-0160 90 mg once daily
9763761|NCT00760578|Experimental|MSDC-0160 220 mg|MSDC-0160 220 mg once daily
9763762|NCT00760617|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
9763763|NCT00760617|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received 1 dose of Fluarix vaccine
9763764|NCT00760617|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received 1 dose of Fluarix vaccine
9763765|NCT00760669||Participants Receiving Infiximab|Participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA) receiving infliximab injection will be observed.
9763766|NCT00760747|Experimental|Slow Switching Group|Slow Switching Group (switch from full stimulant dose to atomoxetine, 1.2 mg/kg/day, orally (PO), during 10 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
9763767|NCT00760747|Experimental|Fast Switching Group|Fast Switching Group (switch from full stimulant dose to atomoxetine 1.2 mg/kg/day, PO, during 2 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
9763768|NCT00760838|Experimental|Azithromycin|"Azithromycin 250 mg~1x/day during 5 days 3x/week afterwards"
9763769|NCT00760838|Placebo Comparator|placebo|"Placebo~1x/day during 5 days 3x/week afterwards"
9763770|NCT00760877|Experimental|Nilotinib|Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
9763771|NCT00760877|Active Comparator|Imatinib|Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
9763772|NCT00760929|Placebo Comparator|Placebo for R1507 (16mg/kg iv)|
9763773|NCT00760929|Placebo Comparator|Placebo for R1507 (9mg/kg iv)|
9763774|NCT00760929|Experimental|R1507 (16mg/kg iv)|
9763775|NCT00760929|Experimental|R1507 (9mg/kg iv)|
9763776|NCT00760994|Experimental|1 - Experiential Accepatance|Experiential acceptance
9763777|NCT00760994|Active Comparator|2 - Cognitive Restructuring|Cognitive restructuring
9763778|NCT00760994|Placebo Comparator|3 - Control|No-intervention control: Nutrition information
9763779|NCT00761007|Experimental|Ibodutant 10 mg|
9763780|NCT00761007|Experimental|Ibodutant 30 mg|
9763781|NCT00761007|Experimental|Ibodutant 60 mg|
9763782|NCT00761007|Placebo Comparator|Placebo|
9763783|NCT00761085|Active Comparator|Methadone-Children|Methadone comparison to standard of care for pain management
9763784|NCT00761085|Active Comparator|Morphine-Children|Morphine standard of Care pain management
9763785|NCT00761085|Active Comparator|Methadone-Adults|Methadone comparison to standard of care for pain management
9763786|NCT00761085|Active Comparator|Morphine-Adults|Morphine standard of Care pain management
9763787|NCT00761137|Experimental|Tropicamide placebo|subject received (blinded) each of the 4 drug doses at different visits - 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
9763788|NCT00761137|Experimental|Tropicamide 0.3 mg|subject received (blinded) each of the 4 drug doses at different visits - 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide
9763789|NCT00761137|Experimental|Tropicamide 1 mg|subject received (blinded) each of the 4 drug doses at different visits - 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide
9785635|NCT01256190|Active Comparator|Gelatin Sponge|approved device for surgical bleeding
9518035|NCT03300531|Experimental|PRP|Blood will be drawn and platelet-rich plasma will be injected into the tendon.
9763790|NCT00761137|Experimental|Tropicamide 3 mg|subject received (blinded) each of the 4 drug doses at different visits - 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide
9763791|NCT00761150|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
9763792|NCT00761150|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
9763793|NCT00761150|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
9763794|NCT00761189|Experimental|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
9763795|NCT00761202|Active Comparator|1|Optive Eyedrops
9763796|NCT00761202|Active Comparator|2|Hylocomod Eyedrops
9763797|NCT00761215|Experimental|TR-701 200 mg|
9763798|NCT00761215|Experimental|TR-701 300 mg|
9763799|NCT00761215|Experimental|TR-701 400 mg|
9783856|NCT01212757|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
9783857|NCT01212757|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
9783858|NCT01212770|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
9783859|NCT01212770|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
9783860|NCT01212770|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
9783861|NCT01212770|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
9783862|NCT01212874|Active Comparator|Nitroglycerin|nitroglycerin titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
9783863|NCT01212874|Active Comparator|Esmolol|esmolol titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
9783864|NCT01212900|Experimental|Imaging|Lipid targets assigned according to the severity of atherosclerotic plaque measured as wall volume in the common and internal carotid arteries by MRI
9783865|NCT01212900|Active Comparator|Standard|Standardized statin therapy based on NCEP ATP IIIR guidelines, including clinical risk factors and blood lipid levels.
9836164|NCT02772757|Active Comparator|Standard of Care group|Standard of Care group will receive the standard, face-to-face hearing aid fitting and verification approach
10203187|NCT03208049|Experimental|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identify dysfunctional sleep cognitions, 2) challenge their validity, and 3) replace them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are provided with information about relevant elements of the science of sleep and healthy sleep practices.
10203188|NCT03197675|Sham Comparator|Control group|Participants who are randomized to the control group will not receive any acupuncture. Participants will however be assessed weekly to obtain the same data on their pain scale and other outcome measures as the treatment group. Participants will be evaluated in person during their standard of care clinical follow up appointments at the three month and six month points for in person interviews and data collection .
9517980|NCT03301103|Placebo Comparator|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
9763800|NCT00761267|Experimental|Anidulafungin IV|All subjects meeting screening criteria will receive IV anidulafungin.
9763801|NCT00761280|Experimental|trabedersen 10 µM|10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
9763802|NCT00761280|Active Comparator|Chemotherapy|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
9763803|NCT00761306|Experimental|Vortioxetine|
9763804|NCT00761319|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
9763805|NCT00761319|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
9763806|NCT00761345|Experimental|radiotherapy and chemotherapy|gemcitabine will be administered at 1000mg/m2 IV on days 1 and 8 of each 21 day cycle. erlotinib at either 100mg (cohort 1-3) or 150mg (cohort 4) PO daily. Low dose fractionated radiotherapy (LDRT) will be given BID on days 1 and 2 and 8 and 9 of each 21 day cycle
9763807|NCT00761462|Experimental|Ciprofloxacin|Subjects receiving Ciprofloxacin (group followed-up for 5 years)
9763808|NCT00761462|Active Comparator|Non-quinolone antibiotic|Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
9763809|NCT00761514|Experimental|1|All subjects will receive Adalimumab
9763810|NCT00761579|Experimental|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
9763811|NCT00761592|Active Comparator|1|
9763812|NCT00761592|Active Comparator|2|
9763813|NCT00761605|Experimental|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
9763814|NCT00761631|Experimental|Single|Open label
9763815|NCT00761657|Experimental|Roxadustat 0.7 mg/kg BIW|Participants will receive roxadustat 0.7 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
9763816|NCT00761657|Experimental|Roxadustat 0.7 mg/kg TIW|Participants will receive roxadustat 0.7 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
9763817|NCT00761657|Experimental|Roxadustat 1.0 mg/kg BIW|Participants will receive roxadustat 1.0 mg/kg BIW orally with doses administered at least 72 hours apart for 29 days.
9763818|NCT00761657|Experimental|Roxadustat 1.0 mg/kg TIW|Participants will receive roxadustat 1.0 mg/kg TIW orally with doses administered at least 48 hours apart for 26 days.
9763819|NCT00761657|Experimental|Roxadustat 1.5 mg/kg BIW|Participants will receive roxadustat 1.5 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
9763820|NCT00761657|Experimental|Roxadustat 1.5 mg/kg TIW|Participants will receive roxadustat 1.5 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
9763821|NCT00761657|Experimental|Roxadustat 2.0 mg/kg BIW|Participants will receive roxadustat 2.0 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
9763822|NCT00761657|Experimental|Roxadustat 2.0 mg/kg TIW|Participants will receive roxadustat 2.0 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
9763823|NCT00761657|Placebo Comparator|Placebo|Participants will receive placebo orally, matching to the roxadustat dose, number of days per week, and duration.
9763824|NCT00761735|Other|PEG-IFN + RBV: LTFU|Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
9763825|NCT00761748|Experimental|SenSura|SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
9763826|NCT00761748|Active Comparator|Convatec|Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
9763827|NCT00761761|Experimental|1- Sensoril (Ashwagandha)|Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
9763828|NCT00761761|Placebo Comparator|2 - Placebo|Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
9763829|NCT00761774|Experimental|Brivaracetam|Brivaracetam at flexible dosing up to 200mg /day
9763830|NCT00761813|Experimental|Single Sliding Hip Screw|
9763831|NCT00761813|Experimental|Multiple Cancellous Screws|
9763832|NCT00761865|Active Comparator|Air Cast Stirrup Brace|50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
9763833|NCT00761865|Active Comparator|High Tide Fracture Boot|50 patients will be randomly assigned to the High Tide Fracture Boot.
9763834|NCT00761891|Experimental|Chewable aspirin|81 mg daily for 2 weeks
9763835|NCT00761930|Placebo Comparator|A|commercially available Fluoride toothpaste
9763836|NCT00761930|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
9763837|NCT00761930|Experimental|C|fluoride/herbal toothpaste
9763838|NCT00761956|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen CR-Flex Fixed Bearing Knee.
9763839|NCT00761956|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen CR Knee.
9763840|NCT00761969||PAB|Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =< 0.90.
9763841|NCT00761969||Control|Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
9763842|NCT00762021|Experimental|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT
9763843|NCT00762021|Active Comparator|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF
9763844|NCT00762034|Experimental|Pem/Carbo/Bev|Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab
9763845|NCT00762034|Active Comparator|Pac/Carbo/Bev|Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab
9763846|NCT00762073|Placebo Comparator|1|
9763847|NCT00762073|Experimental|2|Low Dose Group
9763848|NCT00762073|Experimental|3|Medium Dose Group
9763849|NCT00762073|Experimental|4|High Dose Group
9763850|NCT00762086|Active Comparator|Treatment Group|AngioPress Intermittent pneumatic compression (IPC) Device
9763851|NCT00762086|Other|Control Group|Aspirin/Clopidegrol and Standard walking exercises
9763852|NCT00762164|Active Comparator|1Vytorin 10/80 divided into 4|Vytorin 10/80 divided into 4
9763853|NCT00762164|Active Comparator|Simvastatin|Simvastatin 20 milligrams
9763854|NCT00762177|Placebo Comparator|A -Control|fluoride toothpaste
9763855|NCT00762177|Experimental|B Experimental toothpaste|Stannous fluoride toothpaste
10203189|NCT03197675|Active Comparator|treatment group|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
10203190|NCT03195478|Experimental|Nivo/Ipi Combination Therapy A|Specified Dose of Nivolumab and Ipilimumab on specified days
10203191|NCT03195478|Experimental|Nivo/Ipi Combination Therapy B|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
10203192|NCT03195478|Experimental|Nivo/Ipi Combination Therapy C|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
10203193|NCT03195478|Experimental|Nivo/Ipi Combination Arm D|Specified dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
10203194|NCT03194321|Experimental|Tacrolimus Extended-Release Arm|All patients will receive tacrolimus extended-release adjusted to target trough levels, mycophenolate mofetil or mycophenolate sodium, and prednisone per CSMC practice.
9763856|NCT00762177|Active Comparator|C- positive control|fluoride/triclosan/copolymer toothpaste
9763857|NCT00762216|Other|Toric|Implantation with the AcrySof® Toric intraocular lens
9763858|NCT00762229|Active Comparator|Ezetimibe 10 mg|A whole ezetimibe 10 mg tablet
9763859|NCT00762229|Experimental|Ezetimibe 5 mg|"Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half"
9763860|NCT00762268|Experimental|SAMe|"SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
9763861|NCT00762268|Placebo Comparator|placebo|"Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day rest-period, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period."
9763862|NCT00762307|Experimental|Treatment Group 1|Cooling Intensity Factor = 33 Duration = 60 minutes
9763863|NCT00762307|Experimental|Treatment Group 2|Cooling Intensity Factor = 37 Duration = 30 minutes
9763864|NCT00762307|Experimental|Treatment Group 3|Cooling Intensity Factor = 37 Duration = 45 minutes
9763865|NCT00762307|Experimental|Treatment Group 4|Cooling Intensity Factor = 42 Cooling Duration = 30 minutes
9763866|NCT00762320|Experimental|Low dose Kaletra tablets|Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)
9763867|NCT00762359|Experimental|Lansoprazole 15 mg QD|
9763868|NCT00762359|Active Comparator|Gefarnate 50 mg BID|
9763869|NCT00762372|Experimental|desflurane|
9763870|NCT00762372|Experimental|desflurane/N2O|
9763871|NCT00762372|Active Comparator|sevoflurane/N2O|
9763872|NCT00762385|Active Comparator|galyfilcon A/comfilcon A|galyfilcon A first, comfilcon A second
9763873|NCT00762385|Active Comparator|comfilcon A/galyfilcon A|comfilcon A first, galyfilcon A second
9763874|NCT00762411|Experimental|LY450139|Participants received 60 milligrams (mg) LY450139 orally once daily for 2 weeks followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
9763875|NCT00762411|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, participants in the placebo arm received LY450139 titrated up to 140 mg orally once daily until Week 88.
9763876|NCT00762424|Active Comparator|Tamsulosin|
9763877|NCT00762424|Placebo Comparator|Placebo|
9763878|NCT00762450|Active Comparator|A- Positive Control|fluoride/triclosan/copolymer toothpaste
9763879|NCT00762450|Placebo Comparator|B - Silica control|fluoride only toothpaste
9763880|NCT00762450|Experimental|C- Experimental product|fluoride/triclosan/amino acid toothpaste
9763881|NCT00762463|Experimental|Celecoxib 200 mg QD|
9763882|NCT00762463|Active Comparator|Diclofenac SR 75 mg QD|
9763883|NCT00762476|Placebo Comparator|Placebo|
9763884|NCT00762476|Experimental|3804-250A|
9763885|NCT00762502|Active Comparator|senofilcon A toric bilaterally|senofilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
9763886|NCT00762502|Active Comparator|balafilcon A toric bilaterally|balafilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
9763887|NCT00762502|Active Comparator|senofilcon A/balafilcon A contralaterally|senofilcon A lens worn in one eye and balafilcon A lens worn in the other eye (contralaterally), daily for 3 months, replaced weekly.
9763888|NCT00762515|Placebo Comparator|A|commercially available Fluoride only toothpaste
9763889|NCT00762515|Active Comparator|B|Commercially available triclosan/copolymer/fluoride toothpaste
9763890|NCT00762528|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
9763891|NCT00762528|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
9763892|NCT00762606|Active Comparator|Phaco|Cataract extraction surgery utilizing Phacoemulsification
9763893|NCT00762606|Active Comparator|SICS|Small incision cataract surgery (SICS)
9763894|NCT00762619|Placebo Comparator|A -|fluoride toothpaste (Ultrabrite)
9763895|NCT00762619|Active Comparator|B - Postive control|fluoride/triclosan/copolymer toothpaste
9763896|NCT00762645|Experimental|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
9763897|NCT00762645|Active Comparator|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
9763898|NCT00762710|Experimental|1 - Prazosin Medication|Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
9763899|NCT00762710|Placebo Comparator|2 - Placebo Medication|Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
9763900|NCT00762762|Active Comparator|A|
9763901|NCT00762762|Placebo Comparator|B|
9763902|NCT00762788|Active Comparator|senofilcon A contact lens|ACUVUE OASYS
9763903|NCT00762788|Active Comparator|lotrafilcon A contact lens|NIGHT&DAY
9763904|NCT00762788|Active Comparator|lotrafilcon B contact lens|O2Optix
9763905|NCT00762788|Active Comparator|balafilcon A contact lens|PureVision
9763906|NCT00762788|Active Comparator|comfilcon A contact lens|Biofinity
9763907|NCT00762788|Active Comparator|etafilcon A contact lens|ACUVUE 2
9763908|NCT00762853|Placebo Comparator|A|fluoride toothpaste from Thailand
9763909|NCT00762853|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
9763910|NCT00762892|Active Comparator|Raltegravir|Raltegravir in combination with truvada (tenofovir and emtricitabine)
9763911|NCT00762892|Active Comparator|Atazanavir|Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
9763912|NCT00762931|Experimental|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation, all subjects will receive active treatment
10203195|NCT03189693|Experimental|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
10203196|NCT03189693|Placebo Comparator|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
10203197|NCT03188081||Cohort A|Adult RA patients followed up according to local clinical practice only at the hospital wards
10203198|NCT03188081||Cohort B|Adult RA patients followed up according to local clinical practice at the Hospital wards and additionally at their home through a support program
10203199|NCT03180268|Other|Arm I (Clinical Observation)|Patients undergo observation after gross total resection.
10203200|NCT03180268|Experimental|Arm II (Radiation Therapy)|Patients undergo radiation therapy 5 days a week over 6.5-7 weeks for a total of 33 fractions after gross total resection.
10203201|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 1|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
9518036|NCT03300531|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) )
9763913|NCT00762970|Experimental|Test Lens 1|Investigational soft contact lenses worn daily.
9763914|NCT00762970|Experimental|Test Lens 2|Investigational soft contact lenses worn daily.
9763915|NCT00762970|Active Comparator|Control lens|Spectacle lenses worn daily.
9763916|NCT00762996|Active Comparator|etafilcon A/etafilcon A|Period 1: etafilcon A, Period 2: etafilcon A
9763917|NCT00762996|Active Comparator|etafilcon A/omafilcon A|Period 1: etafilcon A, Period 2: omafilcon A
9763918|NCT00762996|Active Comparator|omafilcon A/etafilcon A|Period 1: omafilcon A, Period 2: etafilcon A
9763919|NCT00762996|Active Comparator|omafilcon A/omafilcon A|Period 1: omafilcon A, Period 2: omafilcon A
9763920|NCT00763035|Active Comparator|A|Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
9763921|NCT00763035|Active Comparator|B|Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
9763922|NCT00763048|Placebo Comparator|A -Control|Fluoride toothpaste (Colgate Great Regular Flavor) is the control for this study. All study toothpastes contain fluoride. The study is evaluating the additional ingredients in the other toothpastes.
9763923|NCT00763048|Active Comparator|B|fluoride/triclosan/copolymer toothpaste (Colgate Total Toothpaste)
9763924|NCT00763061|Experimental|Travoprost 0.004%|Travoprost 0.004%
9763925|NCT00763061|Active Comparator|Timolol 0.5%|Timolol 0.5%
9763926|NCT00763139|Experimental|Placebo First|Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
9763927|NCT00763139|Experimental|Pioglitazone First|Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.
9763928|NCT00763243|Experimental|Cogmed Working Memory Training|Cogmed Working Memory Training Program
9763929|NCT00763256|Active Comparator|A|
9763930|NCT00763256|Placebo Comparator|B|
9763931|NCT00763269|Experimental|A|sensitive toothpaste
9763932|NCT00763269|Active Comparator|B|Triclosan control toothpaste
9763933|NCT00763282|Experimental|SM+MI|Self Management (SM) + Motivational Interviewing (MI). Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. Motivational Interviewing (MI) is an evidence-based form of counseling to help individuals to engage in behavior change. Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
9763934|NCT00763282|Active Comparator|ED|Education (ED). An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures. The ED intervention will differ only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
9763935|NCT00763321|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
9763936|NCT00763321|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
9763937|NCT00763321|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
9763938|NCT00763360|Experimental|DisCoVisc®|DisCoVisc® Ophthalmic Viscosurgical Device
9763939|NCT00763360|Active Comparator|Healon|Healon
9763940|NCT00763360|Active Comparator|Amvisc Plus|Amvisc Plus
9763941|NCT00763386|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
9763942|NCT00763386|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
9763943|NCT00763412|Placebo Comparator|1 Placebo|1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.
9763944|NCT00763412|Experimental|2. repaglinide|repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.
9763945|NCT00763451|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9763946|NCT00763451|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
9763947|NCT00763451|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9763948|NCT00763451|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
9763949|NCT00763490|Experimental|Double cord blood transplant|'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
9763950|NCT00763698|Experimental|QuickFlex micro 1258T left heart lead|
9763951|NCT00763750|Experimental|PPX +TMZ+XRT|XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
9763952|NCT00763815|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9763953|NCT00763815|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
9763954|NCT00763867|Placebo Comparator|Placebo|Placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
9763955|NCT00763867|Experimental|Sildenafil|Sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
9763956|NCT00763919|Experimental|Customized Adherence Enhancement (CAE)|"Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles.~Treatment Modules:~Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module"
9763957|NCT00763958|Experimental|Buprenorphine|Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months
9763958|NCT00763958|Placebo Comparator|Placebo|Placebo sublingual medication provided to individuals randomized to control up to 3 months
9763959|NCT00763971|Experimental|Lisdexamfetamine Dimesylate (LDX)|Overencapsulated LDX 30, 50, or 70mg
9763960|NCT00763971|Active Comparator|Methylphenidate Hydrochloride|Overencapsulated Concerta 18, 36, or 54mg
9763961|NCT00763971|Placebo Comparator|Placebo|Overencapsulated Placebo
9763962|NCT00764309|Experimental|A1|
9763963|NCT00764322|Experimental|Tamoxifen 20|One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg.
9763964|NCT00764322|Active Comparator|Tamoxifen 40|This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.
9763965|NCT00764361|Experimental|NanoDOX™ Hydrogel|1.0% doxycycline gel
9763966|NCT00764361|Placebo Comparator|Placebo|placebo gel
9763967|NCT00764465|Active Comparator|Group A|Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID
9763968|NCT00764465|Active Comparator|Group B|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID
9763969|NCT00764465|Active Comparator|Group C|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID
9763970|NCT00764465|Active Comparator|Group D|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
9763971|NCT00764465|Active Comparator|Group E|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID
9763972|NCT00764465|Active Comparator|Group F|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
9763973|NCT00764491|Experimental|Optimesh 1500S|OptiMesh 1500S, filled with a mixture of demineralized bone matrix (DBM) and cortico-cancellous bone, placed into the interbody space from the posterior approach and supplemental pedicle screws.
9763974|NCT00764491|Active Comparator|Structural Allograft Spacer|Structural Allograft Spacer with pedicle screws.
9763975|NCT00764504|Experimental|Primary|Primary shoulder
9763976|NCT00764504|Experimental|Revision|Revision shoulder
9763977|NCT00764504|Experimental|Continued Access|Primary shoulder subjects enrolled at a later date in order to collect more data.
9833040|NCT02638103|Experimental|TEV-48125 225 mg Monthly: New/Placebo Rollover Participants|Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
9833041|NCT02638103|Experimental|TEV-48125 225 mg Monthly: Active Rollover Participants|Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
9833042|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants|Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
9833043|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: Active Rollover Participants|Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
9833044|NCT02638168|Active Comparator|Immediate Release Methylphenidate|With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
9833045|NCT02638168|Placebo Comparator|Placebo|inert placebo ingredient
9833046|NCT02638207|Experimental|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
9833047|NCT02638207|Experimental|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
9833048|NCT02638207|Experimental|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
9833049|NCT02638259|Experimental|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
9833050|NCT02638259|Active Comparator|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
9833051|NCT02638337|Experimental|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
9833052|NCT02638337|Placebo Comparator|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
9833053|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
9833054|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
9833055|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
9833056|NCT02638597|Experimental|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
9833057|NCT02638597|Other|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
9833058|NCT02638623|Active Comparator|Drug Lactated Ringer|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
9833059|NCT02638623|Placebo Comparator|Placebo|Covered empty bag with no hydration supplement
9833060|NCT02638948|Placebo Comparator|Placebo|Placebo + Methotrexate dose as specified
9833061|NCT02638948|Experimental|Dose Level 1|BMS-986142 at dose level 1+ Methotrexate as specified
9833062|NCT02638948|Experimental|Dose Level 2|BMS-986142 at dose level 2 + Methotrexate as specified
9833063|NCT02638974|Experimental|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
9833064|NCT02638974|No Intervention|Wait List Control|This arm will receive medical skin camouflage at the end of the study
9763978|NCT00764517|Experimental|Previously untreated|"Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) [Group I].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
9763979|NCT00764517|Experimental|Relapsed|"Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) [Group II].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
9763980|NCT00764660|Experimental|SCH 900435|Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
9763981|NCT00764660|Placebo Comparator|Placebo|Participants received matching placebo tablets by mouth twice daily for 12 weeks.
9763982|NCT00764673|Other|Primary|Post market study
9763983|NCT00764738|Active Comparator|Monthly|Ranibizumab injections every month for 12 months.
9763984|NCT00764738|Active Comparator|As Needed|Ranibizumab injections monthly for 4 months then as needed thereafter.
9763985|NCT00764751|Experimental|1|
9763986|NCT00764751|Active Comparator|2|
9763987|NCT00764751|Placebo Comparator|3|
9763988|NCT00764790|Experimental|Fluarix Dose A Group|"Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
9763989|NCT00764790|Experimental|Fluarix Dose B Group|"Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
9763990|NCT00764790|Active Comparator|Fluzone Group|"Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
9763991|NCT00764868|Experimental|LDX|Lisdexamfetamine Dimesylate (LDX)
9763992|NCT00764881|Experimental|EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.
9763993|NCT00764881|Active Comparator|EE/LNG (Microgynon) + Placebo|Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.
9763994|NCT00764946|Experimental|1|raltegravir
9763995|NCT00765037||Encore RSP|Subjects who need treatment for rotator cuff deficiency or glenohumeral arthritis, received the Encore Reverse Shoulder Prosthesis and are willing to participate in the study.
9763996|NCT00765063|Experimental|Active|Active study treatment
9833065|NCT02639052|Experimental|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
9833066|NCT02639052|Placebo Comparator|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
9833067|NCT02639182|Experimental|AGS-16C3F|Participants received 1.8 milligram per kilogram (mg/kg) of AGS-16C3F once every three weeks by single intravenous (IV) infusion.
9833068|NCT02639182|Active Comparator|Axitinib|Participants received 2 to 10 milligram (mg) of axitinib twice daily by oral administration as defined in the product label and per local institutional guidelines.
9833069|NCT02639247|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
9833070|NCT02639247|Experimental|SOF/VEL|SOF/VEL for 12 weeks
9833071|NCT02639286|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC)
9833072|NCT02639286|Experimental|ISIS 304801|300 mg of study drug administered via SC
9833073|NCT02639338|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
9833074|NCT02639338|Experimental|SOF/VEL|SOF/VEL tablet for 12 weeks
9833075|NCT02639351|Experimental|LHD153R Formulation 1 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.
9833076|NCT02639351|Experimental|LHD153R Formulation 2 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.
9833077|NCT02639351|Experimental|LHD153R Formulation 3 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.
9833078|NCT02639351|Experimental|LHD153R Formulation 4 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.
9833079|NCT02639351|Active Comparator|MenC Group|Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.
9833080|NCT02639429|Experimental|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
9833081|NCT02639429|Active Comparator|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score > 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
9833082|NCT02639494|Experimental|Self-Centering Guide Catheter|Subjects who provided written informed consent and an attempt is made to insert the Self-Centering Guide Catheter into the subject's femoral artery.
9833083|NCT02639637|Other|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
9833084|NCT02639637|Other|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
9833085|NCT02639637|Placebo Comparator|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
9833086|NCT02639637|Placebo Comparator|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
9833087|NCT02639884|Experimental|Evaluation Group|All subjects will be enrolled into the evaluation group and will receive SedLine EEG and RRa monitoring
9833088|NCT02640053|Experimental|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
9833089|NCT02640053|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
9833090|NCT02640157|Experimental|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
9833091|NCT02640157|Active Comparator|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
9833092|NCT02640157|Experimental|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
9518037|NCT03300492|Experimental|NK-DLI|"Preemptive immunotherapy with ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses following haplo-HSCT."
9833093|NCT02640235|Experimental|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
10203202|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 2|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
10203203|NCT03170206|Experimental|Binimetinib Phase 2|"Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
10203204|NCT03170206|Experimental|Palbociclib Phase 2|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle"
10203205|NCT03150173|Experimental|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
10203206|NCT03150173|Active Comparator|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
10203207|NCT03093922|Experimental|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator. This cohort is NO LONGER ACCRUING patients since 5/22/2018.
9763997|NCT00765076|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0
9763998|NCT00765076|Active Comparator|Fluarix elderly Group|Subjects aged >= 65 years receiving 1 dose of Fluarix vaccine at Day 0
9763999|NCT00765076|Active Comparator|Fluarix young Group|Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0
9764000|NCT00765102|Experimental|Romidepsin + Bortezomib|"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
9764001|NCT00765128|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
9764002|NCT00765128|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
9764003|NCT00765193|Other|Skin cancer screening|
9764004|NCT00765206|Experimental|Zegerid|Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule
9764005|NCT00765206|Active Comparator|Prilosec|Omeprazole magnesium 20 mg OTC tablet
9764006|NCT00765232|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
9764007|NCT00765232|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
9764008|NCT00765245|Experimental|Arm I: Lenalidomide|
9764009|NCT00765245|Experimental|Arm II: Lenalidomide and Rituximab IV|Patients receive lenalidomide as in arm I and rituximab IV on day 8 of courses 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
9783866|NCT01212952|Experimental|Arm I|Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9783867|NCT01212991|Experimental|Enzalutamide|
9783868|NCT01212991|Placebo Comparator|Placebo|
9783869|NCT01213043|Active Comparator|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
9783870|NCT01213043|Experimental|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
9783871|NCT01213082|Experimental|24GyE + anti-VEGF|
9783872|NCT01213082|Experimental|16GyE + anti-VEGF|
9783873|NCT01213082|Sham Comparator|Sham Irradiation + anti-VEGF|
9783874|NCT01213173|Active Comparator|1|
9783875|NCT01213173|Experimental|2|
9783876|NCT01213199|Experimental|Differin 0.3%|"Differin® 0.3% Gel~Adapalene 0.3%~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks."
9783877|NCT01213251|Experimental|Single Site Pacing|
9783878|NCT01213251|Experimental|Dual Site Pacing|
9783879|NCT01213251|No Intervention|Control|
9783880|NCT01213264||Spontaneous NMB reversal|Participants whose reversal from NMB is spontaneous (no reversal agent used)
9783881|NCT01213264||NMB reversal with sugammadex|Participants who are administered sugammadex for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
9783882|NCT01213264||NMB reversal with other agents|Participants who are administered any other agent (other than sugammadex) for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
9783883|NCT01213316||Overall Participants|HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
9764010|NCT00765336|Active Comparator|Minocycline Extended-Release Tablets|
9764011|NCT00765336|Placebo Comparator|Placebo|
9764012|NCT00765362|Experimental|1|Subjects who are candidates for a total knee replacement and meet the inclusion/exclusion criteria of the study.
9764013|NCT00765375|Experimental|Botox and Placebo on each side of face|Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)
9764014|NCT00765388|Experimental|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
9764015|NCT00765388|Active Comparator|hollister Uro|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive
9764016|NCT00765570|Active Comparator|Treatment Group 1|Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
9764017|NCT00765570|Active Comparator|Treatment Group-2|Treatment Group 2-15 treatments with standard radiation
9764018|NCT00765648|Active Comparator|1|nicardipine intravenous
9764019|NCT00765648|Active Comparator|2|Labetalol
9764020|NCT00765661|Experimental|LCP-Tacro|The initial dose starting at 0.14 mg/kg (the starting daily dose for African-American patients was 0.17 mg/kg), will be administered orally in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
9764021|NCT00765661|Active Comparator|Prograf (tacrolimus)|"Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
9764022|NCT00765674|Experimental|Aliskiren / amlodipine|Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
9764023|NCT00765674|Experimental|Aliskiren / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
9764024|NCT00765674|Experimental|Amlodipine / hydrochlorothiazide|Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
9764025|NCT00765674|Experimental|Aliskiren / amlodipine / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
9764026|NCT00765726|Other|Moroctocog alfa(AF-CC)|
9764027|NCT00765817|Placebo Comparator|1|
9764028|NCT00765817|Experimental|2|
9764029|NCT00765843|Active Comparator|custom foot orthoses|Subjects will receive custom fabricated orthoses created from casts of the feet and according to individualized prescriptions. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
9833094|NCT02640235|Active Comparator|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
9833095|NCT02640404|Experimental|Menactra® Vaccine (9 to 23 Months)|Participants (infants and toddlers) received 2-dose series of study vaccine with 3-month interval (first dose at Day 0 and second dose 3 months after dose 1).
9833096|NCT02640404|Experimental|Menactra® Vaccine (2 to 55 Years)|Participants (children, adolescents and adults) received 1 dose of study vaccine at Day 0.
9833097|NCT02640482|Experimental|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind [DB] treatment period)
9833098|NCT02640482|Experimental|Arm B DB Placebo|Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
9833099|NCT02640482|Experimental|Arm B OL Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label [OL] treatment period)
9833100|NCT02640547||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
9833101|NCT02640612|Experimental|BI 695501|
9833102|NCT02640716|Active Comparator|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
9833103|NCT02640716|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
9833104|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
9833105|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
9833106|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
9833107|NCT02640807|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
9833108|NCT02640807|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
9833109|NCT02640807|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
9833110|NCT02641067|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
9833111|NCT02641067|Experimental|Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
9833112|NCT02641080|Active Comparator|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
9833113|NCT02641080|Active Comparator|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
9833114|NCT02641249|No Intervention|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
9833115|NCT02641249|Experimental|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
9833116|NCT02641353|Experimental|Treatment A: Apremilast 30 mg Tablet - Fasted|A single oral dose of 30 mg apremilast tablet after an overnight fast.
9833117|NCT02641353|Experimental|Treatment B: Apremilast 30 mg Oral Suspension - Fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.
9833118|NCT02641353|Experimental|Treatment C - Apremilast 30 mg Oral Suspension - Fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.
9833119|NCT02641379|Experimental|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram [mcg]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (<75 kilogram (kg); >75 kg) for 24 weeks.
9833120|NCT02641379|Experimental|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 72
9833121|NCT02641379|Experimental|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) for 48 weeks.
9833122|NCT02641379|Experimental|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (<75 kg; > 75 kg) for 72 weeks.
9833123|NCT02641392|Experimental|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
10203208|NCT03093922|Experimental|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
10203209|NCT03093922|Experimental|Atezolizumab alone for 1 cycle prior to gemcitabine, cisplatin|"Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigators discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course."
10203210|NCT03088111|Other|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
10203211|NCT03087955|Experimental|Acoziborole (SCYX-7158)|Acoziborole (SCYX-7158), in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
10203212|NCT03085095|Experimental|Relugolix|Relugolix for 48 weeks
9764030|NCT00765843|Active Comparator|pre-fabricated orthoses|Subjects will be provided pre-fabricated (non-customized) orthoses. These orthoses are to be used in the standardized shoes provided to all subjects in the study. for use in their shoes.
9764031|NCT00765843|Sham Comparator|sham insoles|Subjects will receive sham orthoses that are soft and pliable, but not designed to relieve pain. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
9764032|NCT00765856|Experimental|Oxymorphone ER|
9764033|NCT00765882|Experimental|1|Linaclotide 290 micrograms
9764034|NCT00765882|Experimental|2|Linaclotide 145 micrograms
9764035|NCT00765882|Placebo Comparator|3|Matching placebo
9764036|NCT00765895|Active Comparator|Nortriptyline|Nortriptyline Hydrochloride dose escalation from 10 mg to 75 mg
9764037|NCT00765895|Placebo Comparator|Placebo (for nortriptyline)|No treatment
9764038|NCT00765947|Experimental|Aliskiren-based regimen|All pts starting on aliskiren 150 mg (uptitrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (uptitrated to 25 mg) and amlodipine 5 mg (uptitrated to 10 mg), as necessary to achieve the Blood Pressure goal.
9764039|NCT00765999|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks in participants with either CC or IBS-C. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator if a participant experienced AEs intolerable enough to prompt consideration of study withdrawal. After a temporary suspension of dosing, participants may have received either 145 μg/day or 290 μg/day of linaclotide, at the discretion of the Investigator. Subsequent dose adjustments (increases or decreases between 290 μg/day and 145 μg/day) were permitted also at the Investigator's discretion.
9764040|NCT00766038|Experimental|1|The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
9764041|NCT00766038|Placebo Comparator|2|Doses for participants receiving placebo will also be adjusted monthly to maintain the blinding.
9764042|NCT00766051|Experimental|Intervention Group|The infants in the intervention group were problem eaters with various diagnosis
9764043|NCT00766051|No Intervention|Matched Historical Comparison Group|The matched historical comparison group were also problem eaters and these infants did not receive the neurophysiologically based occupational therapy Intervention.
9764044|NCT00766090|Experimental|GW685698X|
9764045|NCT00766116|Experimental|Phase 1 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza 2 days then GO at 3 mg/m^2"
9764046|NCT00766116|Experimental|Phase 1 Dose Level 2|"5-Azacitidine, Gemtuzumab ozogamicin~75mg/m^2 5-Aza for 4 days then GO at 6 mg/m^2"
9764047|NCT00766116|Experimental|Phase I Dose Level 3|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
9764048|NCT00766116|Experimental|Phase 2 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
9764049|NCT00766142|Experimental|Chemotherapy + Cetuximab|Surgery + Chemotherapy + Cetuximab
9764050|NCT00766363|Experimental|EVP-6124 (0.1 mg/day)|
9764051|NCT00766363|Experimental|EVP-6124 (0.3 mg/day)|
9764052|NCT00766363|Experimental|EVP-6124 (1.0 mg/day)|
9764053|NCT00766363|Placebo Comparator|Placebo|
9764054|NCT00766415|Experimental|AZD1981|
9764055|NCT00766415|Placebo Comparator|Placebo|
9764056|NCT00766467|Experimental|Group 1|Armodafinil
9764057|NCT00766467|Placebo Comparator|Group 2|Placebo
9764058|NCT00766493|Experimental|GORE® Embolic Filter|Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
9764059|NCT00766506|Experimental|Fentanyl IONSYS|Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
9764060|NCT00766506|Active Comparator|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
9764061|NCT00766532|Experimental|aromatase inhibitor therapy|aromatase inhibitor therapy for six weeks
9764062|NCT00766597|Experimental|Vicriviroc in tablet form (20/30 mg) or liquid form (1 mg/ml)|HIV-1 Infected Antiretroviral Therapy Experienced Participants with CCR5-tropic Virus
9764063|NCT00766649|Experimental|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
9764064|NCT00766675|Experimental|Tramadol hydrochloride/acetaminophen|Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
9764065|NCT00766727|Experimental|GLYDe Dressing|Investigational Dressing
9764066|NCT00766727|No Intervention|Standard of Care|Standard of care comparator
9764067|NCT00766753|Experimental|Single|All consenting, eligible subjects receive the intervention
9764068|NCT00766831|Experimental|Hydromorphone OROS|Participants will receive hydromorphone OROS (8 milligram [mg] up to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
9764069|NCT00767000|Experimental|MK-0941 10 mg|
9764070|NCT00767000|Experimental|MK-0941 20 mg|
9764071|NCT00767000|Experimental|MK-0941 30 mg|
9764072|NCT00767000|Experimental|MK-0941 40 mg|
9764073|NCT00767000|Placebo Comparator|Placebo|
9764074|NCT00767039|Active Comparator|1|Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
9764075|NCT00767039|Experimental|2|Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
9764076|NCT00767104|Experimental|Silk-Like Pillowcase|Silk- Like pillowcase-One-half of subjects will be assigned to sleep on the study product, which is a standard size pillowcase made of a silk-like fabric every night for 12 weeks. The study pillowcases are fabricated from a light-weight plain-weave fabric woven of 100 percent synthetic yarns. The fabric is comprised of approximately 50% polyester and 50% nylon. The yarns in the fabric are formed from continuous-filament fibers, with no fibers projecting beyond the planar surface of the fabric. The antimicrobial technology used in the fabric is incorporated into the fibers during the finishing process and does not migrate out of the fabric or cause adverse reactions with skin contact.
9764077|NCT00767104|Placebo Comparator|Cotton Pillowcase|Placebo Comparator-One-half of subjects will be assigned to sleep on the placebo pillow case every night for 12 weeks. Placebo pillowcase is made of 100% cotton
9764078|NCT00767325|Experimental|Abatacept, 10 mg/kg|
9764079|NCT00767338|Active Comparator|No surgery + IUI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
9764080|NCT00767338|Active Comparator|No Surgery + TI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
9764081|NCT00767338|Active Comparator|Surgery + IUI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
9764082|NCT00767338|Active Comparator|Surgery + TI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
9764083|NCT00767364|Experimental|Infants with bowel resection|Infants with bowel resection who will receive the oral rotavirus vaccine, RotaTeq(R).
9764084|NCT00767364|Active Comparator|Healthy Infants|Healthy infants that are gest. age and age-matched controls within 14 days will be given the oral rotavirus vaccine, RotaTeq(R).
9764085|NCT00767455|Sham Comparator|Positive, Negative Controls|
9764086|NCT00767507|Experimental|Cangrelor|Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
9764087|NCT00767507|Placebo Comparator|Placebo|A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.
9764088|NCT00767520|Active Comparator|A|
9764089|NCT00767520|Placebo Comparator|B|
9764090|NCT00767572|Experimental|atorvastatin|Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
9764091|NCT00767572|Placebo Comparator|sugar pill|See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.
9764092|NCT00767624|Other|antidepressant + desensitization|Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
9764093|NCT00767624|Other|antidepressant + cognitive behavioral|Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
9764094|NCT00767676|Other|1|
9764095|NCT00767767|Placebo Comparator|Placebos|Saline Infusion
9764096|NCT00767767|Active Comparator|Propofol 0.45mcg/mL|Anesthetic Drug Infusion
9764097|NCT00767767|Active Comparator|Propofol 0.90mcg/mL|Anesthetic Drug Infusion
9764098|NCT00767767|Active Comparator|Thiopental 1.5mcg/mL|Anesthetic Drug Infusion
9764099|NCT00767767|Active Comparator|Thiopental 3mcg/mL|Anesthetic Drug Infusion
9764100|NCT00767806|Experimental|Duloxetine|Participants received duloxetine 60 milligram by mouth once daily for 12 weeks of double-blind treatment
9764101|NCT00767806|Placebo Comparator|Placebo|Patients received placebo by mouth once daily for 12 weeks of double-blind treatment
9764102|NCT00767819|Experimental|Arm 1|Progressive or metastatic bone or soft tissue sarcomas
9764103|NCT00767819|Experimental|Arm 2|Progressive gastrointestinal stromal tumors (GIST) after failure of prior imatinib and sunitinib 1st and 2nd line
9833124|NCT02641392|Experimental|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
9833125|NCT02641392|Experimental|Intermittent placebo and GED-0301 40 mg|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
9833126|NCT02641392|Experimental|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
9833127|NCT02641392|Experimental|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
9833128|NCT02641522|Experimental|Post-Infusion|Single infusion of siltuximab (11 mg/kg)
9833129|NCT02641561|Placebo Comparator|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
9833130|NCT02641561|Active Comparator|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
9833131|NCT02641561|Active Comparator|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
9833132|NCT02641561|Experimental|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
9833133|NCT02641587|Experimental|CHTP 1.2|Ad libitum use of the CHTP 1.2
9833134|NCT02641587|Active Comparator|CC|Ad libitum use of subject's own preferred non-menthol brand of CC
9835974|NCT02763579|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
9835975|NCT02763579|Active Comparator|Placebo + Carboplatin + Etoposide|Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
9835976|NCT02763644|Experimental|LFG316 plus SoC|LFG316 plus SoC (excluding plasmapheresis and prohibited treatment)
9835977|NCT02763644|Experimental|All SoC first|Standard of Care then LFG316 plus SoC
9835978|NCT02763826|Experimental|Determine the Optimal tDCS current|We will invesitigate the optimal curent in range of 1 mA to 4 mA. We hypothesize that 4 mA is tolerable, safe and can induce the highest level of cortical excitability in the lesional motor cortex.
9835979|NCT02763826|Experimental|Determine the optimal tDCS electrode montage|We hypothesize that the bi-hemispheric stimulation with anodal stimulation on the lesional hemisphere and simultaneous cathodal stimulation on the non-lesional hemisphere induces more cortical excitability in the lesional hemisphere than either anodal stimulation on the affected hemisphere or cathodal stimulation on non-lesional hemisphere alone.
9835980|NCT02763865|Experimental|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
9835981|NCT02763865|Sham Comparator|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
9835982|NCT02764151|Experimental|PF-06840003|Daily Oral PF-06840003
9835983|NCT02764164|Experimental|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
9835984|NCT02764190|Experimental|I-ACT with Check Yourself|Adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Check Yourself includes the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive I-ACT and the Check Yourself summary report of health risk behaviors before an adolescent patient's appointment. I-ACT will provide training in adolescent-preferred communication methods and use of Check Yourself as a framework for the provider to use motivational interviewing to consider the patients' change readiness and their personal health goals. I-ACT includes online interactive, case-based learning, with booster sessions and feedback reports to reinforce new skills.
9836165|NCT02772757|Experimental|Average RECD group|This group will have their hearing aid fitting via the coupler using average RECD values during the fitting
9833135|NCT02641691|Experimental|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.~An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.~Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.~Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.~5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles~Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
9833136|NCT02641730|Experimental|Group 1|Participants will receive guselkumab 200 milligram (mg) at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, and two syringes of placebo at Week 16 to maintain the blind.
9833137|NCT02641730|Experimental|Group 2|Participants will receive a syringe of guselkumab 100 mg and a syringe of placebo for guselkumab at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, two syringes of placebo at Week 16 to maintain the blind.
9833138|NCT02641730|Experimental|Group 3|Participants will receive two syringes of placebo at Week 0, 4 and 12. At Week 16, placebo participants will be randomized in a 1:1 ratio to guselkumab mg arm (Group 3a) or 100 mg arm (Group 3b). Group 3a participants will receive guselkumab 200 mg at Week 16, 20 and every 8 weeks thereafter through Week 60. Group 3b participants will receive guselkumab 100 mg and a syringe of placebo at Week 16, 20 and every 8 weeks thereafter through Week 60.
9833139|NCT02641834|Experimental|Veg Group|Group that starts with the Vegetarian diet
10203213|NCT03085095|Active Comparator|Leuprolide Acetate|Leuprolide acetate for 48 weeks
10203214|NCT03078348|Active Comparator|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:~Baseline~6 month follow-up"
10203215|NCT03078348|Active Comparator|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:~Baseline~Post 6 month follow-up"
9833140|NCT02641834|Active Comparator|Med group|Group that starts with the Mediterranean diet
9833141|NCT02641912|Experimental|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
9833142|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
9833143|NCT02642159|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels >=100 mg/dL (2.59 mmol/L) at Week 8.
9833144|NCT02642159|Active Comparator|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
9833145|NCT02642237|Experimental|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
9833146|NCT02642237|Placebo Comparator|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
9833147|NCT02642393|Experimental|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
9833148|NCT02642393|Placebo Comparator|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
10203216|NCT03065062|Experimental|Combination Of Palbociclib and Gedatolisib|"Palbociclib will be administered orally once daily on Days 1-21 for each of the 4-week cycles at a pre-determined dose.~Gedatolisib will be administered intravenously once weekly on the first day for each of the four weeks during the 4-week cycles at a pre-determined dose."
10203217|NCT03057431|Placebo Comparator|Placebo|Once daily for 3 years
10203218|NCT03057431|Experimental|12.5 mg hydrochlorothiazide|Once daily for 3 years
10203219|NCT03057431|Experimental|25.0 mg hydrochlorothiazide|Once daily for 3 years
10203220|NCT03057431|Experimental|50.0 mg hydrochlorothiazide|Once daily for 3 years
10203221|NCT03048422|Experimental|Arm 1: Maternal DTG+FTC/TAF|Mothers randomized to receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
10203222|NCT03048422|Experimental|Arm 2: Maternal DTG+FTC/TDF|Mothers randomized to receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
10203223|NCT03048422|Active Comparator|Arm 3: Maternal EFV/FTC/TDF|Mothers randomized to receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
10203224|NCT03048422|No Intervention|Arm 1 Infants|Infants born to women in Arm 1. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
10203225|NCT03048422|No Intervention|Arm 2 Infants|Infants born to women in Arm 2. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
10203226|NCT03048422|No Intervention|Arm 3 Infants|Infants born to women in Arm 3. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
10203227|NCT03039296||One side endoscopic rhizotomy|Endoscopic rhizotomy will be provided only on one back side according pain
10203228|NCT03039296||Both sides endoscopic rhizotomy|Endoscopic rhizotomy will be provided on both back sides according pain
10203229|NCT03032068|Experimental|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
10203230|NCT03031626|Experimental|Arm A: Medical air followed by oxygen|
10203231|NCT03031626|Experimental|Arm B: Oxygen followed by medical air|
10203232|NCT03029507|Experimental|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
10203233|NCT03029507|Active Comparator|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
10203234|NCT03022279|Active Comparator|TAP blocks|TAP block group will receive three injections performed by an Anesthesiologist trained in the procedure, prior to initiation of the surgical procedure. Bilateral posterior transversalis fascial plane blocks and a right sided subcostal transverse abdominal plane block will be placed under ultrasound guidance. Normal saline will be used to confirm proper muscle layer placement before instillation of the local anesthesia. All patients will receive 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL (divided equally amongst the injection sites).
10205270|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Colorectal Cancer (CRC)|Participants with CRC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 PFU/mL on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
9764104|NCT00767819|Experimental|Arm 3|Progressive or metastatic alveolar soft part sarcoma (ASPS)
9764105|NCT00768053|Experimental|1|
9764106|NCT00768066|Experimental|1|Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).
9764107|NCT00768066|Experimental|2|Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).
9764108|NCT00768066|Placebo Comparator|3|Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS).
9764109|NCT00768079|Placebo Comparator|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
9764110|NCT00768079|Experimental|Benralizumab 0.3 mg/kg|A single dose of benralizumab (MEDI-563) 0.3 milligram per kilogram (mg/kg) of body weight intravenous infusion over at least 30 minutes on Day 0.
9764111|NCT00768079|Experimental|Benralizumab 1.0 mg/kg|A single dose of benralizumab (MEDI-563) 1.0 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
9764112|NCT00768118|Experimental|Curcumin, Green Tea extract, Polygonum Cuspidatum & Soybean|Total number of visits: 2, pre-intervention blood draw and urine sample collection, post-intervention blood draw and urine sample collection and interview Length of each visit: 15-30 minutes Total expected duration of participants' involvement: 15 days During the two-week intervention, volunteers will take two 1/2g capsules of the combination capsule, twice daily immediately after morning and evening meals.
9764113|NCT00768144|Experimental|Sunitinib|Patients received oral Sunitinib at the daily dose of 37.5 mg continuously over a 28- day treatment cycle. Treatment continued until clinical or radiological evidence of progressive disease or excessive toxicity.
9764114|NCT00768222|Active Comparator|Chinese Silk Suture|Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
9764115|NCT00768222|Experimental|VICRYL* Plus Suture|Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
9764116|NCT00768261|No Intervention|Very Mild to Mild DAT Untreated|Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine
9764117|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/ Donepezil|Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with Donepezil (Aricept®).
9764118|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/Combination|Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of Donepezil (Aricept®) and Memantine (Namenda®)
9764119|NCT00768261|No Intervention|Nondemented Comparison Subjects|Group 4) nondemented comparison subjects.
9764120|NCT00768287|Experimental|IB1001|
9764121|NCT00768287|Active Comparator|nonacog alfa|
9764122|NCT00768300|Experimental|Ambrisentan|
9764123|NCT00768300|Placebo Comparator|Placebo|
9764124|NCT00768430|Experimental|1|Ketamine
9764125|NCT00768430|Active Comparator|2|Midazolam
9764126|NCT00768469|Experimental|Nera 160 + Pac|Neratinib 160 mg + Paclitaxel 80 mg/m^2
9764127|NCT00768469|Experimental|Nera 240 + Pac|Neratinib 240 mg + Paclitaxel 80 mg/m^2
9764128|NCT00768521|Experimental|1|Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
9764129|NCT00768521|Experimental|2|Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
9764130|NCT00768521|Experimental|3|Part II, Sequence 1: study drug crossing over to placebo
9764131|NCT00768521|Experimental|4|Part II, Sequence 2: placebo crossing over to study drug
9764132|NCT00768560|Active Comparator|Nifedipine (Adalat CR, BAYA1040) 40 mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
9764133|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 40 mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
9764134|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 80 mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
9764135|NCT00768599|Active Comparator|1|Econazole Nitrate Cream 1%
9764136|NCT00768599|Experimental|2|Econazole Nitrate Foam 1%
9764137|NCT00768599|Placebo Comparator|3|Vehicle Foam
9833149|NCT02642432|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
9833150|NCT02642536|Active Comparator|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
9833151|NCT02642536|Active Comparator|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
9833152|NCT02642614|Experimental|BI 1026706 low dose|
9833153|NCT02642614|Experimental|BI 1026706 medium|
9833154|NCT02642614|Experimental|BI 1026706 high dose|
9833155|NCT02642614|Placebo Comparator|Placebo|
9833156|NCT02642627|Experimental|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
9833157|NCT02642653|Active Comparator|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
9833158|NCT02642653|Placebo Comparator|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
9833159|NCT02642679|Experimental|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
9833160|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
9833161|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
9833162|NCT02642991|Experimental|Phenacite Test lens then comfilcon A control lens|Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.
9833163|NCT02642991|Active Comparator|Comfilcon A control lens then Phenacite test Lens|Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.
9833164|NCT02643004|Active Comparator|Senofilcon A|Participants were randomized to wear senofilcon A lens pair for one week during the crossover study.
9833165|NCT02643004|Active Comparator|Stenfilcon A|Participants were randomized to wear stenfilcon A lens pair for one week during the crossover study.
9833166|NCT02643082|Experimental|GFF MDI, 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
9833167|NCT02643082|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI)
9833168|NCT02643095|Experimental|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
9833169|NCT02643225||pregnant women with gestational diabetes|case group
9833170|NCT02643225||non diabetic pregnant women|control group
10203235|NCT03022279|Active Comparator|Local Wound Infiltration|Local wound infiltration (LWI) will be performed by the operative surgeon using 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL divided amongst the four port sites. 40% of the total dose will be given at the umbilicus, and 20% will be given at each of the other 3 ports. The majority of the anesthetic will be administered at the peritoneal level. Laparoscopic/robotic cholecystectomy will be performed with a port at the umbilicus and three smaller ports in a standard fashion in the subxiphoid and right upper quadrant regions. If conversion to open cholecystectomy occurs, the study data will still be collected, but the patient's data will be excluded from analysis.
9833171|NCT02643251|Experimental|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
9833172|NCT02643251|Placebo Comparator|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
9833173|NCT02643355|Experimental|Standard of Care - Olanzapine|Drug of interest in the study - Olanzapine
9833174|NCT02643355|Active Comparator|Standard of Care - Clonidine|Standard of care - clonidine
9833175|NCT02643394|Active Comparator|Oral Acetaminophen|Oral Acetaminophen 1-hour before surgery
9833176|NCT02643394|Active Comparator|Intravenous Acetaminophen|Intravenous Acetaminophen within 1-hour prior to anesthetic emergence
10203236|NCT03019029|Experimental|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
10203237|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
9833177|NCT02643459|No Intervention|Conventional|no suPAR measurement. Standard care.
9833178|NCT02643459|Experimental|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
9836166|NCT02772757|Experimental|Measured RECD group|This group will have their hearing aid fitting via the coupler using measured RECD values during the fitting
10203238|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
10203239|NCT02992990|Other|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
10205271|NCT03216187|Experimental|Pregabalin|Pregabalin 150 mg twice daily, starting from the evening before surgery, continuing with two times 150mg per day for 12 days, and ending with one 150mg capsule every evening for the final 3 days.
9833179|NCT02643472|Other|Care Notebook|Parents of infants who were discharged from the Children's National NICU will be randomized to receive enhanced usual care by provision of a NICU care resource notebook. Parents will be notified about group assignment prior to discharge. Stratification will occur according to birth weight.
9833180|NCT02643472|Experimental|Care Notebook + Parent Navigator|Parents of infants who were discharged from the Children's National NICU will be randomized to receive a care notebook + Parent Navigation. Parents will be notified about group assignment prior to discharge. Stratification will occur according to the birth weight.
9984220|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in HPV positive head and neck cancer|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with HPV associated oropharyngeal cancer. Booster injections of TBio-6517 are permitted for up to 24 months.
9518038|NCT03300453|Experimental|rAAV2/5-hNAGLU|Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).
9833181|NCT02643615|Experimental|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
9833182|NCT02643615|Experimental|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
9833183|NCT02643628|Experimental|Microneedling Only|All eligible scars within the treatment areas on each side of the face will receive microneedling treatment. The device will be rolled in a horizontal direction with medium pressure. After every roll, the device will be lifted and positioned a few millimeters inferior to the previous starting point. Rolling will be repeated until the entire skin area has been treated. The device will then be reoriented vertically and rolling will be repeated in a vertical direction.
9833184|NCT02643628|Experimental|Microneedling followed by Bellafill treatment|Subjects undergo microneedling as described for the Microneedling Only group. Then at Week 12, all eligible scars within the treatment areas on each side of the face will be treated with Bellafill (injected using a standard tunneling technique). A touch-up treatment is allowed at Month 1 after initial treatment, if additional treatment is required to achieve optimal correction.
9833185|NCT02643693|Experimental|P3L Product use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
9833186|NCT02643693|Experimental|VUSE Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
9833187|NCT02643693|Experimental|CC Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
9518039|NCT03300440|Experimental|Intervention group|Probiotics and vitamin B7
9833188|NCT02643849|Experimental|Spanner|
9833189|NCT02643862|Active Comparator|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
9833190|NCT02643862|Placebo Comparator|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
9833191|NCT02643875|Sham Comparator|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
9833192|NCT02643875|Active Comparator|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
9833193|NCT02643979|Experimental|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
9833194|NCT02643979|Active Comparator|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
9833195|NCT02644096|No Intervention|conventional treatment|After surgery, patients with total hip replacement are only seen once 3 months after surgery, and they have no further contact with the hospital.
9833196|NCT02644096|Other|Intervention|counselling and support after discharge from hospital
9833197|NCT02644109|Experimental|Phytosterols|"Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
9833198|NCT02644109|Placebo Comparator|Placebo|"Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
9764138|NCT00768651|Experimental|One arm: Sitagliptin + Pantoprazole|"Intervention Details:~Sitagliptin 100 mg daily and Pantoprazole 40 mg bid for 6 months, followed by a three-month washout."
9764139|NCT00768664|Experimental|A|
9764140|NCT00768716|Experimental|White subjects|2 x 500 mg acetaminophen by mouth once
9764141|NCT00768716|Experimental|Black subjects|2 x 500 mg acetaminophen by mouth once
9764142|NCT00768755|Experimental|I|Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
9764143|NCT00768755|Experimental|II|Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
9764144|NCT00768755|Active Comparator|III|pemetrexed and cisplatin
9764145|NCT00768755|Experimental|IV|Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
9764146|NCT00768755|Active Comparator|V|pemetrexed and cisplatin
9764147|NCT00768898||2.5 microliters lissamine green|
9764148|NCT00768898||5.0 microliters lissamine green|
9764149|NCT00768898||10.0 microliters lissamine green|
9764150|NCT00768989|Experimental|Atazanavir + Raltegravir|Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
9764151|NCT00768989|Active Comparator|Atazanavir + Ritonavir + Tenofovir /Emtricitabine|Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily
9764152|NCT00769015|Experimental|BA-LVR|In BA-LVR, a low vision occupational therapist (OT) will deliver Behavior Activation (BA), a psychological treatment to prevent depression. This will be administered in the context of the standard of low vision care for OTs as defined by the American Occupational Therapy Association (AOTA). The OTs will collaborate with low vision optometrists, who will deliver the standard of low vision care as defined by the American Optometric Association. The optometrists will evaluate remaining vision and magnification needs, prescribe optical devices, and provide the OTs with initial care plans. The OTs will subsequently meet with subjects in their homes 6 times over 12 weeks to enhance device use, home modifications, and compensatory strategies.
9764153|NCT00769015|Placebo Comparator|ST-LVR|Subjects randomized to ST-LVR will receive clinic-based low vision optometry, in addition to 6 in-home Supportive Therapy (ST) sessions. ST is a placebo condition that controls for the attention that subjects in the active treatment arm will receive.
9764154|NCT00769067|Active Comparator|A|
9518040|NCT03300440|Placebo Comparator|Control group|Placebo and vitamin B7
9764155|NCT00769067|Experimental|B|
9764156|NCT00769119|Experimental|AZD9668 active treatment|
9764157|NCT00769119|Placebo Comparator|AZD9668 placebo treatment|
9764158|NCT00769132|Experimental|A|ER niacin/laropiprant + Placebo to laropiprant
9764159|NCT00769132|Active Comparator|B|ER niacin + Placebo to laropiprant
9764160|NCT00769132|Experimental|C|laropiprant + Placebo to ER niacin/laropiprant
9764161|NCT00769132|Placebo Comparator|D|Placebo
9764162|NCT00769184|Experimental|Corticosteroid + LCD|corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
9764163|NCT00769184|Placebo Comparator|Corticosteroid + Placebo|corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)
9764164|NCT00769314|Experimental|1|Acyclovir Lauriad 50mg
9764165|NCT00769314|Placebo Comparator|2|
9764166|NCT00769392|Other|All Participants|All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
9764167|NCT00769483|Experimental|Phase I, Arm A|MK-0646 + Gemcitabine
9764168|NCT00769483|Experimental|Phase I, Arm B|MK-0646 + Gemcitabine + Erlotinib
9764169|NCT00769483|Experimental|Phase II, Arm A|Gemcitabine + Erlotinib
9764170|NCT00769483|Experimental|Phase II, Arm B|MK-0646 + Gemcitabine + Erlotinib
9764171|NCT00769483|Experimental|Phase II, Arm C|Gemcitabine + Erlotinib
9833199|NCT02644122|Experimental|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
9833200|NCT02644278|Experimental|VX-984 120 mg + PLD 40 mg/m^2|
9833201|NCT02644278|Experimental|VX-984 240 mg + PLD 40 mg/m^2|
9833202|NCT02644278|Experimental|VX-984 480 mg + PLD 40 mg/m^2|
9833203|NCT02644278|Experimental|VX-984 720 mg + PLD 40 mg/m^2|
9833204|NCT02644343|Experimental|Remote Programming Group|"Subjects will undergo remote programming of Nucleus cochlear implants via Custom Sound software using an online interactive meeting platform.~The intervention is the programming of the cochlear implant, the experimental aspect is the remote delivery method."
9833205|NCT02644356|Experimental|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
9833206|NCT02644668|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.
10203240|NCT02990715|Active Comparator|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
10203241|NCT02990715|Experimental|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
9833207|NCT02644668|Experimental|Reldesemtiv 150 mg twice daily|Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.
9833208|NCT02644668|Experimental|Reldesemtiv 450 mg twice daily|Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.
10203242|NCT02984800|Experimental|Group I|Patients will receive one PVB injection at L1-L2 .
9833209|NCT02645019||Cuffed ETT|Airway secured using a cuffed endotracheal tube.
10203243|NCT02984800|Experimental|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
10203244|NCT02971046|Experimental|Protein intake|Varying protein intakes.
9833210|NCT02645019||LMA 2|Airway secured using a size 2 laryngeal mask airway.
9833211|NCT02645019||LMA 2.5|Airway secured using a size 2.5 laryngeal mask airway.
9833212|NCT02645019||LMA 3|Airway secured using a size 3 laryngeal mask airway.
10203245|NCT02965729|Active Comparator|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
9833213|NCT02645019||LMA 4|Airway secured using a size 4 laryngeal mask airway.
9833214|NCT02645123|Experimental|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
9833215|NCT02645123|Sham Comparator|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
9833216|NCT02645123|Active Comparator|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
9833217|NCT02645253|Experimental|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
9833218|NCT02645253|Experimental|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
9833219|NCT02645253|Experimental|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
9833220|NCT02645253|Experimental|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
9833221|NCT02645409|Experimental|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
9833222|NCT02645409|Experimental|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
9833223|NCT02645617|Experimental|Varnish|Dental varnish containing povidone iodine and sodium fluoride
9833224|NCT02645760|Active Comparator|Core stabilization exercise|7-weeks of core stabilization exercise
9833225|NCT02645760|Active Comparator|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
9833226|NCT02646124|Experimental|Diazepam|Naproxen +Diazepam
9833227|NCT02646124|Active Comparator|Placebo|Naproxen + Placebo
9833228|NCT02646332|Experimental|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
10203246|NCT02965729|Active Comparator|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
10203247|NCT02965729|Active Comparator|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
9833229|NCT02646332|Active Comparator|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
9833230|NCT02646371|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
9833231|NCT02646371|Placebo Comparator|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
9833232|NCT02646423|Experimental|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
9833233|NCT02646423|No Intervention|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
10203248|NCT02964884|Active Comparator|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.~And one week of intensive, one-on-one reading tutoring intervention"
9833234|NCT02646449|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
9833235|NCT02646449|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
9833236|NCT02646566|Experimental|APD421 standard|Single (standard) dose IV APD421
9833237|NCT02646566|Experimental|APD421 high|Single (high) dose IV APD421
9833238|NCT02646566|Placebo Comparator|Placebo|Single IV placebo
9833239|NCT02646618|Active Comparator|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
9833240|NCT02646618|Active Comparator|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
9833241|NCT02646761|Experimental|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
9833242|NCT02646761|Other|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
9833243|NCT02646826|Placebo Comparator|Placebo|Subjects are treated with placebo tablets.
9833244|NCT02646826|Experimental|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
9833245|NCT02646826|Experimental|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
9833246|NCT02646826|Experimental|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
9833247|NCT02646891|Placebo Comparator|Adults: Placebo|Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
9833248|NCT02646891|Experimental|Adults: 30 µg P2-VP8|Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
9833249|NCT02646891|Experimental|Adults: 90 µg P2-VP8|Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
9833250|NCT02646891|Placebo Comparator|Toddlers: Placebo|Toddlers received one intramuscular injection of placebo on Day 0.
9833251|NCT02646891|Experimental|Toddlers: 30 µg P2-VP8|Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
9833252|NCT02646891|Experimental|Toddlers: 90 µg P2-VP8|Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
9833253|NCT02646891|Placebo Comparator|Infants: Placebo|Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
9833254|NCT02646891|Experimental|Infants: 15 µg P2-VP8|Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
9833255|NCT02646891|Experimental|Infants: 30 µg P2-VP8|Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
9833256|NCT02646891|Experimental|Infants: 90 µg P2-VP8|Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
9833257|NCT02646917|Active Comparator|SkinPen II|Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.
10203249|NCT02964884|Placebo Comparator|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
10203250|NCT02964884|Placebo Comparator|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
9833258|NCT02646917|Active Comparator|SkinPen Precision|Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.
9833259|NCT02647203|Experimental|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
9833260|NCT02647203|Active Comparator|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
9833261|NCT02647281|Experimental|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
9833262|NCT02647281|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
9833263|NCT02647281|Experimental|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
9833264|NCT02647281|Experimental|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
9833265|NCT02647281|Experimental|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
9833266|NCT02647281|Experimental|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
9833267|NCT02647281|Placebo Comparator|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
9833268|NCT02647281|Experimental|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
9833269|NCT02647281|Experimental|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
9833270|NCT02647320|Experimental|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
9833271|NCT02647320|Experimental|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
9833272|NCT02647320|Experimental|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
9833273|NCT02647320|Placebo Comparator|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
9833274|NCT02647320|Active Comparator|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
9833275|NCT02647346|Experimental|Participant cohort|Participants with diabetes that each have a history of healed Diabetic Foot Ulcer (DFU) prior to enrollment.
9833276|NCT02647645|Active Comparator|Cognitive Training|Cognitive training Sham tDCS
9833277|NCT02647645|Experimental|Cognitive Training with tDCS|Cognitive training Active tDCS
9833278|NCT02647658|Experimental|GBC+PIPT|Guideline Based Care plus Psychologically Informed Physical Therapy (GBC+PIPT)
9833279|NCT02647658|Active Comparator|GBC|Guideline Based Care (GBC)
9833280|NCT02647788|Active Comparator|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
9833281|NCT02647788|Active Comparator|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
9833282|NCT02647866|Experimental|KHK4083 Cohort 1|Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
9833283|NCT02647866|Experimental|KHK4083 Cohort 2|Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
9833284|NCT02647866|Experimental|KHK4083 Cohort 3|Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
9833285|NCT02647866|Experimental|KHK4083 Cohort 4|Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
9984221|NCT04301011|Experimental|Arm C: TBio-6517 intravenous|Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months.
9764172|NCT00769561|Experimental|BFB-CBT|"Biofeedback-based cognitive-behavioral treatment:~The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits."
9764173|NCT00769561|Active Comparator|Occlusal Splint (OS)|"Dental treatment with occlusal splints:~Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment."
9764174|NCT00769600|Active Comparator|Itraconazole with Pemetrexed|Pemetrexed IV every 21 days with oral Itraconazole 200mg daily.
9764175|NCT00769600|Active Comparator|Single agent pemetrexed|Pemetrexed IV on day 1 of 21-day cycle.
9764176|NCT00769704|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.
9764177|NCT00769704|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.
9764178|NCT00769808|Experimental|Technolas 217z Excimer Laser|Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
9764179|NCT00769860|Active Comparator|1|Arimoclomol
9764180|NCT00769860|Placebo Comparator|2|
9764181|NCT00769886|Experimental|KetoNaph|KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution
9764182|NCT00769886|Active Comparator|Naphazoline|Naphazoline HCl 0.05% ophthalmic solution
9764183|NCT00769886|Active Comparator|Ketotifen|Ketotifen fumarate 0.025% ophthalmic solution
9764184|NCT00769886|Placebo Comparator|Vehicle|Vehicle of KetoNaph ophthalmic solution
9764185|NCT00770029|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
9764186|NCT00770029|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
9764187|NCT00770120|Experimental|Everolimus|Daily oral Everolimus 10 mg/day
9764188|NCT00770133|Experimental|Ketotifen/naphazoline|Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
9764189|NCT00770133|Placebo Comparator|Vehicle|Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
9764190|NCT00770133|Active Comparator|Naphazoline|Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
9764191|NCT00770133|Active Comparator|Ketotifen|Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
9764192|NCT00770146|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a week for 26 weeks.
9764193|NCT00770146|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
9764194|NCT00770211|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
9833286|NCT02647866|Placebo Comparator|Placebo|Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
9833287|NCT02647905|Experimental|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
9833288|NCT02647944|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
9833289|NCT02647944|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
9833290|NCT02648022|Experimental|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
9833291|NCT02648022|No Intervention|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
9833292|NCT02648178|Active Comparator|HALO G6|HALO cigalike model
9833293|NCT02648178|Active Comparator|HALO Triton|HALO tank model
9833294|NCT02648204|Experimental|Semaglutide 0.5 mg/Week|
9984222|NCT04301011|Experimental|Arm D: TBio-6517 intravenous and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.
9833295|NCT02648204|Experimental|Semaglutide 1.0 mg/Week|
9833296|NCT02648204|Active Comparator|Dulaglutide 0.75 mg/Week|
9833297|NCT02648204|Active Comparator|Dulaglutide 1.5 mg/Week|
9833298|NCT02648217|Experimental|IDegAsp U100 BID|
10203251|NCT02964884|Sham Comparator|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
9833299|NCT02648217|Active Comparator|BIAsp U100 BID|
9833300|NCT02648230|Experimental|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
9833301|NCT02648438|Experimental|Treatment sequence 1|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
9833302|NCT02648438|Experimental|Treatment sequence 2|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
9833303|NCT02648646|Experimental|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
9833304|NCT02648880|Experimental|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
9833305|NCT02648880|Active Comparator|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
10203252|NCT02950987|Experimental|Whole Body MRI|"Magnetic resonance imaging will be performed on participants~Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
9833306|NCT02648919|Experimental|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules with breakfast, 4 capsules with lunch and 4 capsules with dinner)
9833307|NCT02648932|Other|Haplo-Cord Search|If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
9833308|NCT02648932|Other|Matched Unrelated Donor Search (MUD)|If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
9833309|NCT02648971|Active Comparator|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
10203253|NCT02950506|Active Comparator|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
9833310|NCT02648971|Active Comparator|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
9833311|NCT02649192|Active Comparator|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
9833312|NCT02649192|Placebo Comparator|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
9833313|NCT02649218|Experimental|Ligelizumab|QGE031 240 mg s.c. q4w x 13 treatments
9833314|NCT02649231|Experimental|Ketamine+Psychological Therapy|Ketamine with psychological therapy
9833315|NCT02649231|Active Comparator|Ketamine+Education|ketamine with alcohol education
9833316|NCT02649231|Active Comparator|Placebo+Psychological Therapy|placebo with psychological therapy
9833317|NCT02649231|Placebo Comparator|Placebo+Education|placebo with simple alcohol education
9833318|NCT02649322|Experimental|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
9833319|NCT02649322|Active Comparator|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
9833320|NCT02649439|Experimental|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
9833321|NCT02649439|Experimental|B/ Delayed PROSTVAC treatment|Surveillance for 6 months followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
9833322|NCT02649556|Experimental|THS 2.2|Ad libitum use of THS 2.2
9833323|NCT02649556|Active Comparator|CC|Ad libitum use of CC
9833324|NCT02649608|Experimental|0.04 mg Lu AE04621|Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.
9833325|NCT02649608|Experimental|0.08 mg Lu AE04621|Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.
9833326|NCT02649608|Experimental|0.2 mg Lu AE04621|Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.
9833327|NCT02649608|Experimental|0.4 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
9833328|NCT02649608|Experimental|0.6 mg Lu AE04621|Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.
9833329|NCT02649608|Experimental|0.8 mg Lu AE04621|Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.
9833330|NCT02649608|Experimental|1.0 mg Lu AE04621|Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.
9833331|NCT02649608|Experimental|1.2 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
9833332|NCT02649634|Experimental|Motivational Interviewing|Two 45-60 minute motivational interviewing sessions focusing on exploring and resolving ambivalence towards change.
9833333|NCT02649634|Active Comparator|Attention Control|Two 45-60 minute semi-structured interviews, acting as a pseudo-intervention, ascertaining information relevant to health history, weight history, diet history, as well as dietary and physical activity habits.
9833334|NCT02649842|Experimental|Extended Cylinder IOL|Approved toric intraocular lenses, Model ZCT450, ZCT525 or ZCT600
9833335|NCT02649894|Experimental|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
9833336|NCT02649894|Active Comparator|Approved Uncoated PleurX Indwelling Pleural Catheter|Approved Uncoated PleurX Indwelling Pleural Catheter
9833337|NCT02650128|Experimental|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
9833338|NCT02650193|Experimental|HSP-130|"Cycle 0:~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)~Cycles 1-4:~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
9833339|NCT02650219||gaucher disease type 1|"Inclusion criteria:~Adult patients >= 18 years old~Gaucher disease type 1, proved by low betaglucosidase, with or without treatment~Patients must have read, understood and signed informed consent. intervention : genetic analyses"
9833340|NCT02650219||Control|healthy subjects intervention: genetic analyses
9833341|NCT02650284|Other|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
9833342|NCT02650284|Other|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using Stryker's robotic-arm assisted surgery system Mako
9833343|NCT02650440|Experimental|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
9764195|NCT00770211|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
9764196|NCT00770224|Experimental|R-CHOP, tositumomab and rituximab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration."
9764197|NCT00770289||Single group|
9764198|NCT00770315|Experimental|SCH 39641 1.5 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
9764199|NCT00770315|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
9764200|NCT00770315|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
9764201|NCT00770315|Placebo Comparator|Placebo|Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
9764202|NCT00770328|Experimental|Pentoxifylline|Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
10203254|NCT02950506|Sham Comparator|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
10203255|NCT02950428|Experimental|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
9764203|NCT00770328|Placebo Comparator|Placebo|Patients take a placebo TID for 8 weeks.
9764204|NCT00770341|Experimental|MK-3009 (daptomycin) 4 mg/kg|
9764205|NCT00770341|Active Comparator|Vancomycin|
9764206|NCT00770341|Experimental|MK-3009 (daptomycin) 6 mg/kg|
9764207|NCT00770367|Experimental|Pioglitazone then Placebo|18 volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take Pioglitazone for the first 12 week period of the study and then take the placebo for the final 12 weeks of the study.
9764208|NCT00770367|Experimental|Placebo then Pioglitazone|18 (other half of participants) volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take the placebo for the first 12 week period of the study and then take the Pioglitazone for the final 12 weeks of the study.
9984223|NCT04300738|Other|Patients undergoing CT scann for CCS determination|
9984224|NCT04300127|Experimental|Pioglitazone|Candidates who after the screening period are eligible to receive Pioglitazone
10203256|NCT02928172|Other|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
10203257|NCT02925650|Experimental|Low Dose|The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
10203258|NCT02925650|Experimental|Medium Dose|The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
10203259|NCT02925650|Experimental|High Dose|The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
10203260|NCT02925650|Placebo Comparator|Placebo|The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
10203261|NCT02925221||ADPKD patients on tolvaptan|ADPKD patients who are newly prescribed with tolvaptan or already treated with tolvaptan will be eligible.
10203262|NCT02911675||Standard of Care Group|Study Group 1: Standard EVD/IVC management with therapeutic CSF drainage as appropriate and hourly EVD/IVC ICP measurements per standard of care with simultaneous IPM/Camino ICP measurements collected.
10203263|NCT02911675||Experimental Group|Study Group 2: Therapeutic CSF drainage as appropriate, with EVD/IVC closure and ICP assessment approximately every 12 hours with simultaneous IPM/Camino ICP measurements collected.
10203264|NCT02910843|Experimental|Regorafenib & Capecitabine|"Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.~Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.~External beam Radiotherapy~Surgery"
10203265|NCT02891811|Experimental|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
10203266|NCT02891811|Active Comparator|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
10203267|NCT02881268||Patient with sepsis|Patient hospitalized in intensive care unit
10203268|NCT02881268||Patient without sepsis|Patient hospitalized in intensive care unit
10203269|NCT02876510|Experimental|IMA101 product only (Cohort 1)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~Infusion of the IMA101 T-cell product(s)~Post-infusion administration of low-dose recombinant human interleukin-2"
10203270|NCT02876510|Experimental|IMA101 product + atezolizumab (Cohort 2)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~Infusion of the IMA101 T-cell product(s)~Post-infusion administration of low-dose recombinant human interleukin-2~Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year"
9764209|NCT00770432|Active Comparator|Polyethylene glycol 3350 powder for solution|MiraLAX® (polyethylene glycol 3350 powder for solution)
9764210|NCT00770432|Placebo Comparator|Placebo|MALTRIN 500® M500 (maltodextrin 500)
9764211|NCT00770484|Experimental|Propranolol then placebo|Active treatment
9764212|NCT00770484|Placebo Comparator|Placebo then propranolol|Placebo Treatment
9764213|NCT00770510|Experimental|Eszopiclone 1 mg|
9764214|NCT00770510|Experimental|Eszopiclone 2 mg|
9764215|NCT00770510|Experimental|Eszopiclone 3 mg|
9764216|NCT00770510|Placebo Comparator|Placebo|
9764217|NCT00770510|Active Comparator|Zolpidem Tartrate 10 mg|
9764218|NCT00770562|Active Comparator|Dexamethasone|Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
9764219|NCT00770562|Experimental|Dexamethasone plus Rituximab|Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (<) 20 x10^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
9764220|NCT00770588|Experimental|gefitinib|Gefitinib (Iressa® 250 mg) 1 tablet daily
9764221|NCT00770588|Placebo Comparator|placebo|placebo 1 tablet daily
9764222|NCT00770601|Experimental|Canakinumab|Participants received body-weight stratified dosage of canakinumab treatment at 300 milligrams (mg) (for participants weighing more than 40 kilograms (kg)) and at 2 mg/kg (for participants weight less than or equal to 40 kg) subcutaneously every 4-8 weeks as per investigator discretion for a treatment period of 6 months. The first 3 Neonatal-Onset Multisystem Inflammatory Disease (NOMID) participants enrolled received a dose of 150 mg (>40 kg) and 2 mg/kg for children <40 kg. Since this dose was insufficient to fully control the symptoms of the disease the 300 mg / 4mg/kg dose was introduced by Protocol Amendment 2.
9783884|NCT01213316||Aging Participants|"HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort)."
9783885|NCT01213472|Experimental|NY-ESO 1 Group|Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.
9783886|NCT01213524|Active Comparator|Active nicotine replacement (NRT) + denicotinized cigarettes|42 mg nicotine replacement plus sensorimotor replacement
9783887|NCT01213524|Active Comparator|Placebo NRT + denicotinized cigarettes|inactive transdermal patches plus sensorimotor replacement
9783888|NCT01213524|Active Comparator|Active NRT + no cigarettes|42 mg nicotine replacement with no sensorimotor replacement
9783889|NCT01213524|Placebo Comparator|Placebo NRT + No cigarettes|Double placebo: No nicotine or sensorimotor replacement
9783890|NCT01213524|Active Comparator|usual brand smoking|positive control: usual brand smoking
9783891|NCT01213576|Active Comparator|albendazole 400mg and ivermectin 200mcg/kg|Annual treatment
9783892|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg/kg|Annual treatment
9783893|NCT01213576|Active Comparator|Albendazole 400mg and ivermectin 200mcg/kg|albendazole 400mg and ivermectin 200mcg/kg given twice a year
9783894|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg /kg bi-annually|Albendazole 800mg and ivermectin 400mcg/kg given twice a year
9783895|NCT01213589||Descending thoracic aortic dissection|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
9783896|NCT01213706|Experimental|Whole Body Periodic Acceleration (WBPA)|All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.
9783897|NCT01213706|Experimental|Sham WBPA|"Sham WBPA :~All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge."
9833344|NCT02650440|Experimental|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
9984225|NCT04298437|Experimental|Parent Group Treatment|Families who meet inclusion criteria will participate in the Parent Group Treatment (ADAPT Program).
9764223|NCT00770653|Experimental|Pioglitazone 15 mg and Metformin 850 mg BID|
9764224|NCT00770653|Active Comparator|Glimepiride 2 mg and Metformin 850 mg BID|
9764225|NCT00770679|Experimental|High-Dose Statin|80 mg atorvastatin daily for 3 weeks
9764226|NCT00770692|Experimental|Eszopiclone 1 mg- Elderly|
9764227|NCT00770692|Experimental|Eszopiclone 2 mg- Elderly|
9764228|NCT00770692|Experimental|Eszopiclone 2 mg- Non-elderly|
9764229|NCT00770692|Experimental|Eszopiclone 3 mg- Non-elderly|
9764230|NCT00770757|Experimental|CC-4047 Arm|CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).
9764231|NCT00770770|Experimental|Fluocinolone Acetonide 0.2 µg/day|0.2 µg/day
9764232|NCT00770770|Experimental|Fluocinolone Acetonide 0.5 µg/day|0.5 µg/day
9764233|NCT00770861|Active Comparator|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
9764234|NCT00770861|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
9764235|NCT00770874|Experimental|1|S-1 + Cisplatin (arm A)
9764236|NCT00770874|Active Comparator|2|Cisplatin (arm B)
9764237|NCT00770913|Active Comparator|1|
9764238|NCT00770913|Experimental|2|
9764239|NCT00770913|Experimental|3|
9764240|NCT00770991|Experimental|Black Raspberry (BRB) Slurry plus BRB suppositories|20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS
9764241|NCT00770991|Experimental|Black Raspberry (BRB) Placebo Slurry plus BRB suppositories|20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS
9764242|NCT00771030|Placebo Comparator|Placebo SC (Cohorts 1-3)|Participants received placebo to brodalumab by subcutaneous (SC) injection once every 2 weeks for a total of six doses.
9764243|NCT00771030|Placebo Comparator|Placebo IV (Cohorts 5-6)|Participants received placebo to brodalumab by intravenous (IV) infusion every 4 weeks for a total of two doses.
9764244|NCT00771030|Experimental|Brodalumab 50 mg SC (Cohort 1)|Participants received 50 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
9764245|NCT00771030|Experimental|Brodalumab 140 mg SC (Cohort 2)|Participants received 140 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
9764246|NCT00771030|Experimental|Brodalumab 210 mg SC (Cohort 3)|Participants received 210 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
9764247|NCT00771030|Experimental|Brodalumab 420 mg IV (Cohort 5)|Participants received 420 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
9764248|NCT00771030|Experimental|Brodalumab 700 mg IV (Cohort 6)|Participants received 700 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
9764249|NCT00771056|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg po daily for up to one year.
9764250|NCT00771173|Active Comparator|Study Medication Group|Participants that are randomized to the phenazopyridine HCl group will receive the study medication (200 mg of phenzopyridine HCl orally) after leaving the operating room. We anticipate the first dose to be given after the patient has left the recovery area. We will continue use of study medication until it has been given up to 24 hours after the first VAS collection or catheter removal, whichever occurs first
9764251|NCT00771173|Placebo Comparator|Placebo tablet Group|For participants randomized to the placebo group will follow the same dosing schedule for the study medication, although they will receive an inert placebo tablet.
9764252|NCT00771238|Experimental|P500 Mattress|The new P500 Low Air Loss mattress will be used to replace the standard mattress for this study arm.
9764253|NCT00771238|No Intervention|Standard of Care Mattress|Cardiovascular ICU patients that receive standard of care mattress (Total Care Treatment Mattress) and standard pressure ulcer prevention care. All patients had daily skin assessments, as per normal care.
9764254|NCT00771264|Active Comparator|Urgent PC|
9764255|NCT00771264|No Intervention|Sham / Placebo|
9764256|NCT00771277|Experimental|Arm 1|Use of volunteer support teams to provide services
9764257|NCT00771407|Active Comparator|Strattice fascial inlay|Strattice will be placed as a fascial inlay to support the ostomy site
9764258|NCT00771407|Other|Standard ostomy construction|Ostomy will be created in the standard fashion
9764259|NCT00771472|Experimental|Vorinostat|
9764260|NCT00771537|No Intervention|Arm 1. Control PLUS Control|
9764261|NCT00771537|Experimental|Arm 2. Control PLUS 1-Sided|No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764262|NCT00771537|Experimental|Arm 3. Control PLUS 2-Sided Trivial|No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
9764263|NCT00771537|Experimental|Arm 4. Control PLUS 2-Sided Major|No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
9764264|NCT00771537|Experimental|Arm 5. 1-Sided PLUS Control|1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
9764265|NCT00771537|Experimental|Arm 6. 1-Sided PLUS 1-Sided|1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764266|NCT00771537|Experimental|Arm 7. 1-Sided PLUS 2-Sided Trivial|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764267|NCT00771537|Experimental|Aim 8. 1-Sided PLUS 2-Sided Major|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764268|NCT00771537|Experimental|Arm 9. 2-Sided Trivial PLUS Control|2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
9764269|NCT00771537|Experimental|Arm 10. 2-Sided Trivial PLUS 1-Sided|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764270|NCT00771537|Experimental|Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764271|NCT00771537|Experimental|Arm 12. 2-Sided Trivial PLUS 2-Sided Major|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764272|NCT00771537|Experimental|Arm 13. 2-Sided Major PLUS Control|2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
9764273|NCT00771537|Experimental|Arm 14. 2-Sided Major PLUS 1-Sided|2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764274|NCT00771537|Experimental|Arm 15. 2-Sided Major PLUS 2-Sided Trivial|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764275|NCT00771537|Experimental|Arm 16. 2-Sided Major PLUS 2-Sided Major|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
9764276|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation A Group|Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764277|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764278|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764279|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764280|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764281|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764282|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764283|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9833345|NCT02650466|Experimental|Nanopulse treatment|The study will be a single center, open label, non-randomized clinical trial that will provide efficacy data for the treatment of common warts by the Nanopulse system in terms of efficacy and cosmetic outcome with 1 - 4 application (treatment) sessions. All subjects will receive a minimum number of applications per discrete skin wart lesion. Up to 4 warts per subject will be treated with the Nanopulse device. The wart will be debulked to the point of pinpoint bleeding prior to the initial application. The subject will return after 1 week for an evaluation visit and at 4 weeks for a second treatment and 2 additional monthly treatments if warranted. If the subject is declared clinically clear at any of the application visits, they will be placed into follow up. The minimum number of treatments per wart is one and the maximum is 4. They will return at the 12 week point post last visit for final assessment and evaluation.
9833346|NCT02650856|Experimental|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10ml X-GEN pharmaceuticals inc.) diluted in 80ml of physiologic solution and will be divided in two applications.~First application: 40ml of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.~Second application: The rest of 40ml of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
9833347|NCT02650856|Active Comparator|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.~First application: 8 ml of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.~Second application: The rest of the 8 ml are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
9833348|NCT02650895|Experimental|CD24Fc|Single dose of CD24Fc is administrated as intravenous infusion in one hour. There are 5 dose cohorts, 10mg, 30mg, 60mg, 120mg, 240mg. Each cohort has 6 subjects in CD24Fc and 2 subject in placebo.
9833349|NCT02650895|Placebo Comparator|Saline|Single dose of 100 ml normal saline is administrated as intravenous infusion in one hour.
9833350|NCT02650921|Experimental|Restylane Lyft with Lidocaine|
9833351|NCT02650921|No Intervention|No Intervention|
9833352|NCT02650999|Experimental|Pembrolizumab|Single arm, pembrolizumab 200mg IV every 3 weeks until progression/toxicity
9833353|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
9835985|NCT02764190|No Intervention|Usual care|In the usual care group, adolescents are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive I-ACT or the Check Yourself summary report of the adolescent's health risk behaviors.
9835986|NCT02764229|Experimental|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
9835987|NCT02764320|Active Comparator|Discontinuation|Migraine prophylactic therapy will be initiated or optimized with the immediate discontinuation of the overused medication(s)
9835988|NCT02764320|Active Comparator|Preventive Therapy Only|Migraine prophylactic therapy will be initiated or optimized without the early discontinuation of the overused medication(s)
9835989|NCT02764333|Experimental|vaccine|Patients will receive an intradermal (ID) injection of TPIV200 (500 μg per peptide) and GM-CSF (125 μg per peptide) on Day 1 of cycles 1-6. They will also receive intravenous (IV) injections of durvalumab (750mg) on Days 1 and 15 of cycles 1-12. Radiologic tumor assessment will be repeated every 12 weeks (or 3 cycles) during and after treatment, until time of progression. Treatment will continue until progression, intolerance, withdrawal, study completion, or study termination.
9835990|NCT02764385|Other|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
9835991|NCT02764385|Other|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
9835992|NCT02764697|Other|H.P. Acthar Subcutaneous Gel Injection|For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
9835993|NCT02764762|Experimental|Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)|In Triple Combination Therapy Phase: Vedolizumab 300 mg, intravenous infusion, once at Weeks 0, 2, 6, 14 and 22, with adalimumab 160 mg subcutaneously, once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34.
9835994|NCT02764775|Experimental|Headed utilization|Use of Headpod for 6 months duration; 3 x per day for a minimum of 15 minutes each time;
9835995|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
9835996|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
9835997|NCT02765035|Experimental|C-Leg 3, then C-Leg 4|Participants are first fitted with a C-Leg 3, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 4, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
9835998|NCT02765035|Experimental|C-Leg 4, then C-Leg 3|Participants are first fitted with a C-Leg 4, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 3, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
9835999|NCT02765100|Experimental|Low CRP|Subjects have CRP > 3
9836000|NCT02765100|Experimental|High CRP|Subjects have CRP =/> 3
9833354|NCT02651116|Experimental|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
9833355|NCT02651116|Placebo Comparator|Placebo|10 mL of Placebo
9833356|NCT02651155|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
9833357|NCT02651155|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
9833358|NCT02651194|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
9833359|NCT02651220|Experimental|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
9833360|NCT02651220|Active Comparator|Epiduo® Forte Gel 0.3%/2.5% w/w|
9833361|NCT02651220|Placebo Comparator|Placebo (vehicle) Topical Gel|
9833362|NCT02651259|Experimental|Cohort 1 (pregnant women enrolled in the second trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
9833363|NCT02651259|Experimental|Cohort 2 (pregnant women enrolled in the third trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
9833364|NCT02651272|Experimental|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
9833365|NCT02651337|Experimental|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
9833366|NCT02651415|Experimental|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
9833367|NCT02651428|Experimental|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
9833368|NCT02651428|Active Comparator|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
9833369|NCT02651467|Experimental|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
9833370|NCT02651467|Experimental|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
9833371|NCT02651467|Placebo Comparator|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
9833372|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
9833373|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
9833374|NCT02651584|Experimental|SL BPN/NX tabs + placebo SC injections|"SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w)."
9833375|NCT02651584|Experimental|CAM2038 SC injections + SL placebo tabs|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily"
9833376|NCT02651688|Experimental|Enclomiphene 12.5 mg|Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
9833377|NCT02651688|Experimental|Enclomiphene 25 mg|Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
9833378|NCT02651688|Placebo Comparator|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
9833379|NCT02651987|Experimental|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
9836001|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1a|USL311, intravenous, once per week, starting at 60 mg/m˄2
9984226|NCT04298437|No Intervention|No Treatment|Families who do not meet inclusion criteria will not be invited to participate in the ADAPT Program.
9764284|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
9764285|NCT00771667|Placebo Comparator|Placebo (IP)|
9764286|NCT00771667|Experimental|Ustekinumab 1mg/kg (IP)|
9764287|NCT00771667|Experimental|Ustekinumab 3 mg/kg (IP)|
9764288|NCT00771667|Experimental|Ustekinumab 6 mg/kg (IP)|
9764289|NCT00771667|Placebo Comparator|Placebo IV - Responder - Placebo SC (MP)|
9764290|NCT00771667|Placebo Comparator|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC|
9764291|NCT00771667|Placebo Comparator|Ustekinumab IV - Responder - Placebo SC (MP)|
9764292|NCT00771667|Experimental|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|
9764293|NCT00771667|Placebo Comparator|Ustekinumab IV - Nonresponder - Placebo SC (MP)|
9764294|NCT00771667|Experimental|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|
9764295|NCT00771745|Active Comparator|rATG 4 doses|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
9764296|NCT00771745|Active Comparator|rATG 3 doses|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
9764297|NCT00771758|Experimental|001|tapentadol IR 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 450 mg
9764298|NCT00771758|Experimental|002|oxycodone IR 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 60 mg
9764299|NCT00771758|Placebo Comparator|003|placebo 1 capsule every 4 - 6 hr as needed for up to 10 days
9764300|NCT00771810|Placebo Comparator|Placebo|Combination gemcitabine and platinum-based chemotherapy with concurrent placebo
9764301|NCT00771810|Experimental|TXA127 100 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
9764302|NCT00771810|Experimental|TXA127 300 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
9764303|NCT00771849|Experimental|Menactra® Vaccine Group|Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
9764304|NCT00771849|Active Comparator|Hiberix® Vaccine Group|Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
9764305|NCT00771875|Active Comparator|Rabbit Antithymocyte Globulin (RATG)|Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
9764306|NCT00771875|Experimental|RATG/Rituximab|Rabbit Antithymocyte Globulin (RATG) + Rituximab Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
9764307|NCT00771875|Experimental|RATG/Bortezomib|Rabbit Antithymocyte Globulin (RATG) + Bortezomib -Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3). Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Bortezomib will be given at a dose of 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Methylprednisolone will be administered prior to each bortezomib dose. On days 2 and 5, administer methylprednisolone 100 mg intravenous push (IVP). On days 9 and 12, administer methylprednisolone 50 mg intravenous push (IVP). If thymoglobulin is administered the same day as bortezomib, the order of administration is- methylprednisolone, then bortezomib, then thymoglobulin.
9764308|NCT00771901|Placebo Comparator|Placebo|Subjects will be given a placebo rather than tauroursodeoxycholic acid.
9764309|NCT00771901|Experimental|tauroursodeoxycholic acid|Subjects will receive tauroursodeoxycholic acid for four weeks.
9764310|NCT00771901|Experimental|PBA|Subjects will receive sodium phenylbutyrate for four weeks.
9764311|NCT00771914|Experimental|Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza|First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
9764312|NCT00771914|Experimental|Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo|First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
9764313|NCT00771914|Experimental|Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin|First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
9764314|NCT00771914|Experimental|Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin|First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin
9764315|NCT00771927||Lacosamide|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with add-on Vimpat
9764316|NCT00771927||Other AED|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with other approved AED as add-on therapy
9764317|NCT00771953|Experimental|Apricoxib|Apricoxib 400mg once a day
9764318|NCT00771953|Placebo Comparator|Placebo|Placebo once a day
9764319|NCT00772005|Active Comparator|150 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
9764320|NCT00772005|Active Comparator|200 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
9764321|NCT00772005|Active Comparator|250 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
9764322|NCT00772005|Placebo Comparator|Matching Placebo|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
9764323|NCT00772031|Active Comparator|1|Participants will receive propranolol and topiramate.
9764324|NCT00772031|Placebo Comparator|2|Participants will receive a placebo and topiramate.
9764325|NCT00772070|Experimental|Previously received TetraMenD|Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
9764326|NCT00772070|Experimental|Meningococcal vaccine-naїve|Participants have never received a Meningococcal vaccine in the past.
9764327|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 1|Participants will receive a dose of Influenza intradermal vaccine Lot 1
9764328|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 2|Participants will receive a dose of Influenza intradermal vaccine Lot 2
9764329|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 3|Participants will receive a dose of Influenza intradermal vaccine Lot 3
9764330|NCT00772109|Active Comparator|Fluzone Intramuscular Vaccine|Participants will receive a dose of influenza intramuscular vaccine
9764331|NCT00772148|Experimental|LCP-Tacro|LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
9764332|NCT00772148|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
9764333|NCT00772304|Experimental|1|Olopatadine 0.6% / Azelastine 137 mcg
9764334|NCT00772330|Experimental|MIDI Arrow|Ab externo glaucoma drainage device with no reservoir
9764335|NCT00772382|Experimental|MCI-196|
9764336|NCT00772447|Experimental|AZ drug|Daptomycin
9764337|NCT00772447|Active Comparator|Comparator|Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin
9764338|NCT00772538|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
9764339|NCT00772538|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
9764340|NCT00772577|Experimental|1|Aliskiren Hydrochlorothiazide(HCTZ)
9764341|NCT00772577|Active Comparator|2|Ramipril
9764342|NCT00772590|Experimental|Raltegravir, bovine colostrum|Raltegravir and hyper-immune bovine colostrum
9764343|NCT00772590|Experimental|Hyper-immune bovine colostrum|Hyper-immune bovine colostrum and Raltegravir placebo
9764344|NCT00772590|Experimental|Raltegravir|Raltegravir and Hyper-immune Bovine Colostrum Placebo
9764345|NCT00772590|Placebo Comparator|Placebo|Raltegravir placebo and hyper-immune bovine colostrum placebo
9764346|NCT00772603|Placebo Comparator|Placebo|Placebo - four identical tablets taken orally once daily
9764347|NCT00772603|Active Comparator|2400 mg SPN-804|2400mg OXC XR taken orally once daily as four identical tablets
9764348|NCT00772603|Active Comparator|1200mg SPN-804|1200mg OXC XR taken orally once daily as four identical tablets
9764349|NCT00772629|Experimental|Group 1|Subjects naïve to any meningococcal vaccination
9764350|NCT00772629|Experimental|Group 2|Subjects who previously received unconjugated polysaccharide vaccine (either bivalent A and C or tetravalent A, C, Y, and W 135)
9764351|NCT00772668|Experimental|RCVELP|"Rituximab, Cyclophosphamide, Bortezomib, Prednisone (RCVELP):~Rituximab~Induction: 375 mg/m2 IV infusion on Day 1 of every 21 days cycle for 8 cycles~Maintenance: 375/m2 Days 1, 8, 15, 22 every 6 months for up to 4 cycles~Cyclophosphamide: 750 mg/m2 intravenous piggyback (IVPB) on Day 1 of every 21 day cycle for 8 cycles~Bortezomib: 1.6 mg/m2 IV push on Days 1 and 8 of every 21 days cycle for 8 cycles~Prednisone: 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles"
9764352|NCT00772707|Experimental|Opti-Free Replenish|Multi-purpose contact lens solution for cleaning and disinfecting study contact lenses used on a daily basis for 30 days.
9764353|NCT00772772|Experimental|Vitamin D3|Vitamin D3 30,000 international units orally per week for 8 weeks
9764354|NCT00772889|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
9764355|NCT00772889|Active Comparator|Fluarix elderly Group|Subjects aged ≥66 years received one dose of Fluarix vaccine.
9764356|NCT00772889|Active Comparator|Fluarix young Group|Subjects aged 19-43 years received one dose of Fluarix vaccine.
9764357|NCT00772915|Experimental|Lenalidomide with On-Demand Dexamethasone|"Lenalidmoide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Dexamethasone: 10-40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression."
9764358|NCT00772928|Experimental|Pentacel™ concurrently with Prevnar®|Participants had Pentacel™ concurrently administered with Prevnar®
9764359|NCT00772928|Experimental|Pentacel™ staggered schedule with Prevnar®|Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule).
9764360|NCT00772941||Varenicline|Patients taking Varenicline.
9764361|NCT00772954|Placebo Comparator|Placebo vaccine group|Participants scheduled to receive a dose of placebo vaccine on Day 0, Day 28, and Day 56, respectively.
9764362|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 1|Participants scheduled to receive a dose of 50 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
9764363|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 2|Participants scheduled to receive a dose of 100 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
9764364|NCT00772967|Experimental|Placebo, Naproxen, Ultracet|Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
9764365|NCT00772967|Experimental|Naproxen, Ultracet, Placebo|Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
9764366|NCT00772967|Experimental|Ultracet, Placebo, Naproxen|Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
9764367|NCT00772967|Experimental|Placebo, Ultracet, Naproxen|Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
9764368|NCT00772967|Experimental|Naproxen, Placebo, Ultracet|Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
9764369|NCT00772967|Experimental|Ultracet, Naproxen, Placebo|Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
9764370|NCT00773097|Experimental|MUC1 Poly-ICLC|
9764371|NCT00773136|Active Comparator|Bimatoprost Suspension|Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline. They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left). The intervention was the one eye with the Bimatoprost.
9764372|NCT00773175|Active Comparator|Subcutaneous|Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)
9764373|NCT00773175|Active Comparator|Intravenous|Isotonic fluid rehydration by IV
9764374|NCT00773253|Active Comparator|standard EMG-guided Botox injection|All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.
9764375|NCT00773253|Experimental|Multi-channel EMG-guided Botox injection|Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.
9764376|NCT00773279|Experimental|PDS290 --> FlexPen®|Subjects will receive trial drug with PDS290 for 12 weeks (treatment sequence 1) followed by FlexPen® for 12 weeks (treatment sequence 2)
9764377|NCT00773279|Experimental|FlexPen® --> PDS290|Subjects will receive trial drug with FlexPen® for 12 weeks (treatment sequence 1) followed by PDS290 for 12 weeks (treatment sequence 2)
9764378|NCT00773292|Experimental|ciclosporin|48 weeks treatment with ciclosporin
9764379|NCT00773370|Experimental|APA-Stroke|The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
9764380|NCT00773370|Active Comparator|Sittercise|Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.
9764381|NCT00773383|Experimental|1|
9764382|NCT00773422|Experimental|naltrexone + varenicline|naltrexone (25mg) + varenicline (2mg)
9764383|NCT00773422|Experimental|varenicline|varenicline 2mg
9764384|NCT00773422|Placebo Comparator|placebo|placebo control
9764385|NCT00773461|Experimental|1|
9764386|NCT00773461|Placebo Comparator|2|
9764387|NCT00773474|Experimental|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
9764388|NCT00773513|Active Comparator|Erythropoiesis Stimulating Agents|Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
9764389|NCT00773513|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.
9764390|NCT00773604|Other|Treatment|Deep Brain Stimulation
9764391|NCT00773734|Experimental|Apremilast 10mg|Apremilast 10 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 10 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
9764392|NCT00773734|Experimental|Apremilast 20mg|Apremilast 20 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 20 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
9764393|NCT00773734|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
9764394|NCT00773734|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 16 weeks during the placebo-controlled phase.
9764395|NCT00773734|Experimental|Placebo/Apremilast 20 mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 20 mg apremilast BID during the 8 week active treatment phase
9764396|NCT00773734|Experimental|Placebo/Apremilast 30mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 30 mg apremilast BID during the 8 week active treatment phase
9764397|NCT00773747|Experimental|Vorinostat + Bortezomib|Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
9764398|NCT00773747|Placebo Comparator|Placebo + Bortezomib|Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
9764399|NCT00773786|Experimental|Arformoterol|Arformoterol twice daily for 1 week via nebulizer
9764400|NCT00773786|Placebo Comparator|Placebo|Placebo twice daily for 1 week
9764401|NCT00773838|Experimental|Vorinostat + Bortezomib|Participants receive vorinostat 400 mg, orally, once daily (QD) on Days 1-14 of each 21-day treatment cycle and bortezomib 1.3mg/m^2 intravenous (IV) injection QD on Days 1, 4, 8 and 11 of each 21-day treatment cycle for up to 26 cycles. Participants with progressive disease (PD) after 2 cycles of treatment or no change (NC) after 4 cycles of treatment receive additional treatment of Dexamethasone, 20 mg of total daily dose, orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle for up to 26 cycles. Eligible participants could receive additional treatment on an extension.
9764402|NCT00773955|Experimental|Treatment (R-(-)-gossypol)|Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9764403|NCT00773968|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants will receive methoxy polyethylene glycol-epoetin beta once monthly by subcutaneous (SC) injection for 28 weeks.
9764404|NCT00774046|Experimental|Induction chemotherapy followed by stem cell transplant|Ara-C Mitoxantrone Etoposide Stem cell mobilization Autologous transplant
9764405|NCT00774163|Experimental|1|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
9764406|NCT00774163|Placebo Comparator|2|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
9764407|NCT00774202|Active Comparator|Rituximab, Cyclophosphamide, Vincristine, Prednisone|"'Standard Dose of Rituximab administered with C, V, P (CVP)'~Interventions: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses at standard rates and use of premedication. The schedule will be to give the first rituximab infusion 5 days (± 3 days) prior to first administration of CVP, and the following 3 infusions will be given on the same day as the 3 cycles of C, V, P. On those days, the IV Cyclophosphamide and Vincristine will be given first so that the administration of fluids with the rituximab can be used as post-cyclophosphamide hydration, Cyclophosphamide dosing will be 750mg/m2 (maximum 2000mg), vincristine 1.4 mg/m2 (up to 1.6 mg), prednisone 100mg po daily for 5 days."
9833380|NCT02652156|Active Comparator|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
9764408|NCT00774202|Active Comparator|Higher Dose of Rituximab|In this arm, Rituximab will be administered at a dose of 750 mg/m2 once a week x 4 consecutive weeks (4 infusions in total). We will perform EKG monitor tracings before, during and after Rituxan infusions. This will be a single-lead tracing that will allow us to look at the Q-T interval.
9764409|NCT00774267||1|
9764410|NCT00774267||2|
9764411|NCT00774267||3|
9764412|NCT00774267||4|
9764413|NCT00774397|Experimental|240 mg QD TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
9764414|NCT00774397|Experimental|240 mg QD / LI-TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
9764415|NCT00774397|Placebo Comparator|Placebo|Placebo once daily combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
9764416|NCT00774397|Experimental|120 mg QD / LI-TN|120 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in (LI) phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), followed by an additional 24 weeks of PegIFN/RBV in treatment naive (TN) patients
9764417|NCT00774397|Experimental|240 mg QD TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment experienced (TE) patients
9764418|NCT00774397|Experimental|240 mg QD / LI-TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-experienced (TE) patients
9764419|NCT00774397|Experimental|240 mg BID / LI-TE|240mg BI 201335 NA (Faldaprevir) twice daily combined with PegIFN/RBV for 24 or 48 weeks, with 3-day lead-in phase of PegIFN/RBV, in treatment-experienced patients
9764420|NCT00774566|Active Comparator|1|segmental PVI using an irrigated tip catheter
9764421|NCT00774566|Active Comparator|2|PVI using the Cryo-Balloon
9764422|NCT00774579||1|Patients with growth hormone (GH) deficiency starting GH replacement.
9764423|NCT00774579||2|Patients with growth hormone (GH) deficiency not starting GH replacement.
9764424|NCT00774748|Experimental|I|All participants in the study will use the subcutaneous catheter twice for a period of one week each to inject the enoxaparin. For the remainder of the study the participants will inject subcutaneously.
9764425|NCT00774787|Experimental|Imiquimod, treatment, topical cream|Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp
9764426|NCT00774787|No Intervention|Control, Untreated|No treatment of treatment area on the other half of the face and/or balding scalp
9833381|NCT02652156|Active Comparator|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
9833382|NCT02652156|Active Comparator|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
9833383|NCT02652208|Active Comparator|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
9833384|NCT02652208|Active Comparator|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
9833385|NCT02652221|Experimental|Study cohort|Acoustic Radiation Force Imaging
9833386|NCT02652260|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded doravirine, tenofovir, lamivudine orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 312 weeks.
9833387|NCT02652260|Experimental|Deferred Switch to Doravirine, Tenofovir, Lamivudine|Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 324 weeks.
9833388|NCT02652390|Experimental|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
9833389|NCT02652390|Experimental|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
9833390|NCT02652390|Placebo Comparator|Placebo|Local injection of saline into the carpal tunnel
9833391|NCT02652416|Experimental|SRD part (low dose)|Chinese, Japanese both
9833392|NCT02652416|Experimental|SRD part (medium dose)|Chinese, Japanese both
9833393|NCT02652416|Experimental|SRD part (high dose)|Chinese, Japanese both
9833394|NCT02652416|Experimental|MD part (high dose)|Chinese, Japanese both
9833395|NCT02652416|Experimental|Placebo (SRD part)|placebo
9833396|NCT02652416|Placebo Comparator|Placebo (MD part)|placebo
9833397|NCT02652442|Experimental|Centrifugation Parameters|Three experiments were performed to identify optimal centrifugation parameters: (1) distance off-axis (3.5 vs 7 cm); (2) duration (1 min vs 3 mins); (3) schedule (daily vs biweekly). The comparisons were all within subjects; i.e., each subject was tested systematically for each centrifugation parameter under both conditions. The change in the outcome measure SVV (from pre- to post-off-axis rotation) for each condition (e.g., 3.5 vs 7 cm) within a parameter was compared.
9833398|NCT02652481|Other|ImageReady MR Conditional Defibrillation System Group|"Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).~De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit"
9833399|NCT02652624|Experimental|B/F/TAF|Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
9833400|NCT02652624|Active Comparator|Baseline Regimen|Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
9833401|NCT02652624|Experimental|Extension Phase|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
9833402|NCT02652767|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
9833403|NCT02652767|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
9833404|NCT02652780|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
9764427|NCT00774800|Experimental|First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R|"Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified.~Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal.~Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified.~Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal.~Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL.~All dose finding visits and interventions were separated by 3-10 days."
9764428|NCT00774852|Experimental|Treatment|Abatacept plus Euro-lupus regimen
9764429|NCT00774852|Placebo Comparator|Control|Abatacept placebo plus Euro-lupus regimen
9764430|NCT00774930|Experimental|Lanreotide Autogel (Somatuline Depot) 120 mg|"Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for early roll over [ERO]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
9764431|NCT00774930|Placebo Comparator|Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE|"Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
9764432|NCT00774995|Experimental|Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
9764433|NCT00774995|Experimental|Engerix(3-dose)+HBIg|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
9764434|NCT00774995|Experimental|Engerix(4-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
9764435|NCT00774995|Experimental|Engerix(3-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
9764436|NCT00775021|Active Comparator|etafilcon A/nelfilcon A|etafilcon A contact lens worn first and nelfilcon A contact lens worn second
9764437|NCT00775021|Active Comparator|nelfilcon A/etafilcon A|nelfilcon A contact lens worn first and etafilcon A contact lens second.
9764438|NCT00775138|Experimental|Cohort 1 - 280 mg Arikayce™|Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™
9764439|NCT00775138|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of the cohort 1 will receive matching placebo.
9764440|NCT00775138|Experimental|Cohort 2 - 560 mg Arikayce™|Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™
9764441|NCT00775138|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of the cohort 2 will receive matching placebo
9764442|NCT00775203|Experimental|Trazodone Contramid Once A Day (OAD)|
9764443|NCT00775203|Placebo Comparator|Placebo|
9764444|NCT00775229|Active Comparator|1|Naltrexone
9764445|NCT00775229|Placebo Comparator|2|Placebo
9764446|NCT00775268|Experimental|Group A - Participants Scanned at Baseline & After Chemotherapy|Patients undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fluorodeoxyglucose F 18 (FDG) PET/CT scans at baseline, after 2 courses of chemotherapy, and after completion of chemotherapy. Patients with residual FDG-positive mass after completion of therapy may be enrolled in group B.
9764447|NCT00775268|Experimental|Group B - Participants Scanned in the Evaluation of Residual Masses After Therapy|Patients who have completed treatment in whom FDG-PET shows a remaining tumor mass undergo an FLT PET/CT scan . Patients also undergo a biopsy or fine-needle aspiration, if clinically indicated.
9764448|NCT00775346||Polysomnography (PSG) Subjects|Subjects who have been prescribed with needing a polysomnography (PSG) will be enrolled into the study.
9764449|NCT00775411|Experimental|700 µg dexamethasone and ranibizumab|700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
9764450|NCT00775437|Experimental|Adalimumab|Adalimumab 24 mg/m^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
9764451|NCT00775450|Experimental|Group 1a: Fluzone ID After Fluzone ID|
9764452|NCT00775450|Experimental|Group 1b: Fluzone IM After Fluzone ID|
9764453|NCT00775450|Active Comparator|Group 2a: Fluzone IM After Fluzone IM|
9764454|NCT00775450|Experimental|Group 2b: Fluzone ID After Fluzone IM|
9764455|NCT00775450|Active Comparator|Group 3: Fluzone HD After Fluzone HD|
9764456|NCT00775463|Experimental|treprostinil diethanolamine|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
9836002|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1b|USL311, oral, daily, starting at 40 mg
9833405|NCT02652780|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
9833406|NCT02653144|Experimental|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
9833407|NCT02653144|Experimental|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
9833408|NCT02653144|Active Comparator|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
9833409|NCT02653170|No Intervention|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
9833410|NCT02653170|Experimental|SCM|"One intervention is provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
9833411|NCT02653170|Experimental|SCM and VSSP|"Two interventions are provided:~SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:~VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
9833412|NCT02653183|Active Comparator|Device Aquacel Surgical|"Aquacel Surgical is a sterile, one piece post-operative dressing from Convatec.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
9833413|NCT02653183|Experimental|Device Mepilex Border Post-Op|"Post-operative all-in-one self-adherent soft silicone coated foam dressing.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
9833414|NCT02653300|Experimental|Oral Insulin|treatment
9833415|NCT02653326|Experimental|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
9833416|NCT02653326|Active Comparator|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
9833417|NCT02653391|Experimental|Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
9833418|NCT02653391|Experimental|Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
9833419|NCT02653391|Placebo Comparator|Placebo A|Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
9833420|NCT02653391|Placebo Comparator|Part B Placebo|Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
9833421|NCT02653417|Experimental|Regimen 1|RAD1901 5 mg/day
9833422|NCT02653417|Experimental|Regimen 2|RAD1901 10 mg/day
9833423|NCT02653417|Experimental|Regimen 3|RAD1901 20 mg/day
9833424|NCT02653417|Placebo Comparator|Regimen 4|Placebo
9764457|NCT00775463|Placebo Comparator|placebo (sugar pill)|Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
9764458|NCT00775528|Experimental|A|
9764459|NCT00775606|Active Comparator|ARM A/Lopinar/ritonavir|Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
9764460|NCT00775606|Active Comparator|ARM B/Efavirenz|Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD
9764461|NCT00775645|Experimental|Arm I|Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
9764462|NCT00775645|Placebo Comparator|Arm II|Patients receive oral placebo 3 times daily for 24 weeks.
9764463|NCT00775658|Active Comparator|olopatadine then placebo|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
9764464|NCT00775658|Active Comparator|placebo then olopatadine|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
9783898|NCT01213823||Cases|Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
9783899|NCT01213823||Controls|Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)
9783900|NCT01213836|Active Comparator|First Seroquel XR then Seroquel IR|Patients randomised to Seroquel XR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel IR for 10-16 days
9783901|NCT01213836|Active Comparator|First Seroquel IR then Seroquel XR|Patients randomised to Seroquel IR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel XR for 10-16 days
9783902|NCT01213940|Other|baratric surgery|surgery vs.weight loss program 6 months prior to bariatric surgery
9783903|NCT01213940|Other|pre-bariatric weight loss program|weight loss program prior to bariatric surgery
9783904|NCT01213966|Experimental|800 mg OZ439 po single dose|800 mg OZ439 po single dose
9783905|NCT01213966|Experimental|400 mg OZ439 p.o. single dose|400 mg OZ439 p.o. single dose
9783906|NCT01213966|Experimental|200mg OZ439 p.o. single dose|200mg OZ439 p.o. single dose
9783907|NCT01213966|Experimental|1200 mg OZ439 po single dose|1200 mg OZ439 po single dose
9783908|NCT01214044|Experimental|Study Drug|Subjects will have a total of 12 visits to Oregon Clinical & Translational Research Institute at Oregon Health & Science University over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.
9783909|NCT01214057|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
9833425|NCT02653456|Experimental|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
9833426|NCT02653560|Experimental|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
9833427|NCT02653560|Experimental|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
9833428|NCT02653560|Experimental|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
9833429|NCT02653560|Placebo Comparator|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
9833430|NCT02653625|Experimental|Cenicriviroc 150 mg|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
9833431|NCT02653664|Experimental|Condition #1: PsychoEducation (ED)|Condition #1 will include 8 90-minute group sessions that will educate the subject about chronic pain, discuss the impact of pain, and inform the subject of different ways to manage it in hopes of decreasing pain and its impact on the subject's life. Participants in this condition will be given pre-recorded audio recordings of the content of the sessions to listen to.
9833432|NCT02653664|Experimental|Condition #2:Self-Hypnosis Training (HYP)|In condition #2, the facilitator will perform a standard hypnotic short induction followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the clinician read a standardized hypnotic script that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
9833433|NCT02653664|Experimental|Condition #3: Mindfulness Meditation (MM)|In condition #3, the facilitator will teach participants Vipassana meditation, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Time will also be devoted to problem solving around any difficulties with MM practice.
9833434|NCT02653768|Experimental|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
9833435|NCT02653768|Active Comparator|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
9833436|NCT02653872|Experimental|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
9833437|NCT02653872|Active Comparator|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
9833438|NCT02653872|Active Comparator|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
9833439|NCT02653872|Active Comparator|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
9833440|NCT02654002|Experimental|Cohort 1: Cilofexor 10 mg|Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
10203271|NCT02850406|Experimental|Voxelotor|"Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:~Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)~Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)~Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)~Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg equivalent dose)"
10203272|NCT02845479|Experimental|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
10203273|NCT02839915|Experimental|Folinic Acid|Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - < 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.
9833441|NCT02654002|Experimental|Cohort 2: Cilofexor 30 mg|Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.
10205272|NCT03216187|Placebo Comparator|Placebo|Identical placebo capsules twice daily, starting from the evening before surgery, continuing with two capsules per day for 12 days, and ending with one capsule every evening for the final 3 days.
9764465|NCT00775671|Active Comparator|Nebivolol|Nebivolol 5mg by mouth daily for 12 weeks.
9764466|NCT00775671|Active Comparator|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
9764467|NCT00775684|Experimental|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
9764468|NCT00775684|Experimental|Sitagliptin|Sitagliptin (Januvia®)-100 mg by mouth every morning
9764469|NCT00775684|Active Comparator|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
9764470|NCT00775931|Active Comparator|marrow graft transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan, Fludarabine monophosphate, and total lymphoid irradiation followed by unrelated or matched related donor marrow graft transplantation (both peripheral blood and marrow) and a second CD34 cell infusion on Day 42.
9764471|NCT00775931|Active Comparator|cord blood transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan and Cyclophosphamide followed by unrelated umbilical cord blood transplantation and a second smaller portion cord blood graft infusion on Day 42.
9764472|NCT00775944|Active Comparator|Standard support|Standard 'Together Programme' telephone support for smoking cessation & advice to obtain nicotine addiction treatment
9764473|NCT00775944|Active Comparator|Proactive telephone support|Proactive support & advice to obtain nicotine addiction treatment
9764474|NCT00775944|Active Comparator|Standard support & offer NRT|Reactive telephone support (i.e. Together Programme) and offer of voucher for cost free Nicotine Replacement Therapy
9764475|NCT00775944|Active Comparator|Proactive support & offer NRT|Proactive telephone support and offer of voucher for cost free NRT
9764476|NCT00775983|Active Comparator|laminaria|laminaria placed for cervical dilation; usual standard of care in study clinic
9764477|NCT00775983|Experimental|Dilapan-S|experimental treatment
9764478|NCT00776009|Experimental|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
9764479|NCT00776009|Active Comparator|Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
9764480|NCT00776009|Placebo Comparator|Placebo|Two Capsules taken orally once a day for 7 days
9764481|NCT00776230|Active Comparator|IC51 (~12 months post filling)|6 mcg (~12 months post filling)
9764482|NCT00776230|Active Comparator|IC51 (~18 months post filling)|6 mcg (~18 months post filling)
9764483|NCT00776230|Active Comparator|IC51 (~24 months post filling)|6 mcg (~24 months post filling)
9764484|NCT00776295|Experimental|adeno virus vectored p53|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
9764485|NCT00776594|Experimental|Group 1|Androgen Deprivation Therapy Plus Bevacizumab
9764486|NCT00776594|Experimental|Group 2|Androgen Deprivation Therapy Alone
9764487|NCT00776659||Observational|
9764488|NCT00776789|Experimental|skin to skin contact|Infants randomized to this group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. Mothers in both the groups received support for initiating breastfeeding, if required. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
9764489|NCT00776789|Experimental|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
9764490|NCT00776919|Experimental|1|clindamycin / benzoyl peroxide gel
9764491|NCT00776919|Active Comparator|2|Clindamycin gel
9764492|NCT00776919|Active Comparator|3|BPO gel
9764493|NCT00776919|Placebo Comparator|4|vehicle gel
9764494|NCT00776984|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
9764495|NCT00776984|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
9764496|NCT00776997|Other|Magnetic Sphincter Augmentation|Single-arm study: all subjects were treated with magnetic sphincter augmentation. A subject's baseline measurements prior to sphincter augmentation were compared to post-sphincter augmentation measurements. Subjects served as their own control.
9764497|NCT00777023|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
9764498|NCT00777023|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
9764499|NCT00777023|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
9764500|NCT00777049|Experimental|ER+ and/or PgR+ (Arm I)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
9764501|NCT00777049|Experimental|ER- and PgR- (Arm II)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
9764502|NCT00777062|Experimental|1|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6
9764503|NCT00777062|Placebo Comparator|2|Placebo injection, 380 mg injection at the start of weeks 2 and 6.
9764504|NCT00777088|Experimental|Pipeline|Placement of Pipeline Embolization Device in the parent artery at the aneurysm location
9764505|NCT00777101|Experimental|Neratinib|
9764506|NCT00777101|Active Comparator|Lapatinib plus Capecitabine|
9764507|NCT00777153|Experimental|Cediranib 30mg|Cediranib 30mg
9764508|NCT00777153|Other|Cediranib 20mg + lomustine|Cediranib 20mg + lomustine
9764509|NCT00777153|Active Comparator|Lomustine and Placebo Cediranib|Lomustine and Placebo Cediranib
9764510|NCT00777179|Experimental|Vandetanib|
9764511|NCT00777179|Placebo Comparator|Placebo|
9764512|NCT00777205|Active Comparator|Enhanced Usual Care|Patients in the enhanced usual care arm received their usual mental health care, a copy of the Depression Helpbook, and bi-weekly study mailings with depression management tips.
9764513|NCT00777205|Experimental|Telephone-based peer support|Participants in the intervention arm received usual mental health care and biweekly study mailings. In addition, they had access to a telephone platform over which they could make free calls to their peer partner for mutual peer support over a 6-month period of time.
9764514|NCT00777257|Experimental|Study Group A|Tdap vaccine + placebo concomitantly on Day 0; Menactra® vaccine 28 days later
9764515|NCT00777257|Experimental|Study Group B|Tdap vaccine + Menactra® vaccine concomitantly on Day 0; placebo 28 days later
9764516|NCT00777257|Experimental|Study Group C|Menactra® vaccine + placebo concomitantly on Day 0; Tdap vaccine 28 days later
9764517|NCT00777296|Experimental|Cohort 1 - 280 mg ARIKACE™|Subjects in this cohort will receive 280 mg of ARIKACE™
9764518|NCT00777296|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of cohort 1 will receive matching placebo
9764519|NCT00777296|Experimental|Cohort 2 - 560 mg ARIKACE™|Subjects in this cohort will receive 560 mg of ARIKACE™
9764520|NCT00777296|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of cohort 2 will receive matching placebo
9764521|NCT00777335|Experimental|Panobinostat i.v.|
9764522|NCT00777335|Experimental|Panobinostat oral|
9764523|NCT00777491|Experimental|5-FU and Cisplatin + BID Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction 5-fluorouracil, induction cisplatin, induction BID radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation 5-fluorouracil, consolidation cisplatin, consolidation BID radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine, adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
9764524|NCT00777491|Experimental|Gemcitabine + QD Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction gemcitabine and induction QD radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation gemcitabine and consolidation QD radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine and adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
9764525|NCT00777556|Experimental|DR-104|One tablet for emergency contraception
9764526|NCT00777608|Experimental|Donepezil 5-10 mg|There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
9764527|NCT00777608|Placebo Comparator|Placebo|There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
9764528|NCT00777634||Binge eating disorder (BED)|Individuals who meet criteria for binge eating disorder.
9764529|NCT00777634||Without BED|Individuals who do not meet criteria for binge eating disorder.
9764530|NCT00777764|Experimental|Healthy Volunteers|Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
9764531|NCT00777764|Experimental|Allergic Asthma Participants|Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
9764532|NCT00777790|Experimental|Menactra® Group|Received Menactra® vaccine in Study MTA02
9764533|NCT00777790|Experimental|Menomune® Group|Received Menomune® vaccine in Study MTA02
9764534|NCT00777790|Experimental|Control Group|Meningococcal vaccine-naïve Control Group.
9764535|NCT00777803|Experimental|IncobotulinumtoxinA (Xeomin®/Bocouture®)|IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
9764536|NCT00777803|Active Comparator|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.
9764537|NCT00777829|Experimental|zolpidem first, then placebo|Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap.
9764538|NCT00777829|Placebo Comparator|Placebo first, then zolpidem|Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap.
9764539|NCT00777855|Experimental|warfarin then warfarin plus rifampin|
9764540|NCT00777920|Experimental|Ambrisentan|Participants will receive ambrisentan 2.5 mg, 5 mg or 10 mg tablet orally once daily until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
9764541|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 5 mg|Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
9833442|NCT02654002|Experimental|Cohort 3: Cilofexor 100 mg|Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.
9833443|NCT02654002|Experimental|Cohort 4: Cilofexor 300 mg|Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.
9833444|NCT02654002|Experimental|Cohort 5: Cilofexor 100 mg|Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.
9833445|NCT02654002|Experimental|Cohort 6: Cilofexor 50 mg|Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.
9833446|NCT02654002|Experimental|Cohort 7: Cilofexor 15 mg|Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.
9833447|NCT02654002|Experimental|Cohort 8: Cilofexor 10 mg|Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
9833448|NCT02654002|Experimental|Cohort 9: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
9833449|NCT02654002|Experimental|Cohort 10: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
9833450|NCT02654054|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
9833451|NCT02654054|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
9833452|NCT02654054|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
9833453|NCT02654145|Experimental|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
9833454|NCT02654483|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
9833455|NCT02654483|Placebo Comparator|Placebo|Placebo tablets to be taken daily by mouth for 56 days
9833456|NCT02654652|Experimental|Symbiotic|Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
9833457|NCT02654652|Placebo Comparator|Maltodextrin|Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
9833458|NCT02654717|Experimental|DFD-07 cream|DFD-07 cream applied twice daily
9833459|NCT02654717|Placebo Comparator|Placebo cream|Placebo cream applied twice daily
9833460|NCT02654769|Active Comparator|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
9833461|NCT02654769|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% [Test]
9833462|NCT02654769|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
9833463|NCT02654808|Active Comparator|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
9833464|NCT02654808|Active Comparator|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
9833465|NCT02654808|Active Comparator|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
9833466|NCT02654808|Active Comparator|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
9833467|NCT02654860|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
9833468|NCT02654860|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
9833469|NCT02654860|Experimental|120 mg Paracetamol 3% (4mL)|120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
9833470|NCT02654860|Placebo Comparator|Phase II Only: Saline solution 0.9%|Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
9833471|NCT02654977|Experimental|Metreleptin|Metreleptin open-label
9833472|NCT02655224|Experimental|Relugolix 40 mg|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix 40 mg, tablet, orally once daily before breakfast for 12 weeks.
9833473|NCT02655224|Placebo Comparator|Placebo|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix placebo-matching tablet, orally once daily before breakfast for 12 weeks.
9833474|NCT02655237|Experimental|Relugolix 40 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by relugolix 40 mg, tablets, orally, once daily and leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 24 weeks in treatment period.
9783910|NCT01214057|Active Comparator|Inhaled Anesthesia|Inhaled anesthesia with sevoflurane and remifentanyl.
9783911|NCT01214083|Experimental|Arm 1|N-acetylcysteine + high-dose naltrexone (150 mg)
9783912|NCT01214083|Experimental|Arm 2|High-dose naltrexone (150 mg) alone
9783913|NCT01214083|Active Comparator|Arm 3|Low-dose naltrexone (50 mg) alone
9783914|NCT01214109|Experimental|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
9783915|NCT01214109|Active Comparator|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
9783916|NCT01214161|Experimental|lidocaine gel|This group will be those randomized to receiving the intervention with 2% lidocaine gel.
9783917|NCT01214161|Placebo Comparator|placebo gel (surgilube)|This group will be randomized to having the intervention with the placebo surgilube gel.
9783918|NCT01214174|Experimental|Dose 1|513ug
9783919|NCT01214174|Experimental|Dose 2|776ug
9783920|NCT01214174|Experimental|Dose 3|1046ug
9783921|NCT01214187|Experimental|carbon monoxide inhalation|The primary intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
9783922|NCT01214187|Placebo Comparator|Oxygen 21%|
9783923|NCT01214200|Experimental|High Intensity Non Invasive Pos.Pressure|The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV) for 90 days. Participants will receive HINPPV via bilevel positive airway pressure (BiPAP Synchrony) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O (centimeters of water); or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
9783924|NCT01214239|Experimental|Linagliptin|once a day
9783925|NCT01214239|Placebo Comparator|Placebo|once a day
9783926|NCT01214252||Permacol Patients|Patients who have undergone surgical repair of their abdominal wall defect with Permacol Surgical Implants with at least 12 months follow up.
9783927|NCT01214317|Active Comparator|mitoxantrone and plasmapheresis|Monthly Plasmapheresis (plasma exchange machine: Haemonetics, model TCS2, USA) 25 ml/kg for 5 cycles, with replacement of 0.9% saline and 5% human serum albumin followed by monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) at the end of each Plasmapheresis course for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
9783928|NCT01214317|No Intervention|mitoxantrone|Monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
9783929|NCT01214330|Experimental|Patient-Collected Cervical Pap Smear|women will receive a self Papanicolaou Smear test (SoloPap) in addition to their physician-collected Papanicolaou Smear
9783930|NCT01214356|Placebo Comparator|Lower Dose Vitamin D|Vitamin D3 supplementation of 400 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
9783931|NCT01214356|Active Comparator|Higher Dose Vitamin D|Vitamin D3 supplementation of 4000 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
9783932|NCT01214421|Experimental|Tolvaptan|Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning [AM]/15 mg in the evening [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.
9783933|NCT01214434|Experimental|Promiseb Topical Cream|
9783934|NCT01214434|Sham Comparator|Bland emollient|
9783935|NCT01214603|Experimental|LY2090314|"Cohort 1: 40 milligrams (mg) LY2090314 administered on Days 1, 8, and 15 of a 28-day cycle for at least two (2) 28-day cycles. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.~Due to a protocol amendment on September 2010, the study added 2 additional treatment schedules/cohorts. Cohort 2: 40 mg dose given on Days 1, 5, and 9 of a 21-day cycle. Cohort 3: 40 mg dose given on Days 1, 5, 9, and 12 of a 21-day cycle. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met."
9783936|NCT01214616|Experimental|afatinib and vinorelbine IV|patient to receive 20mg or 40mg of po daily afatinib in combination with vinorelbine IV
9783937|NCT01214629|Experimental|LY2523355|
9783938|NCT01214629|Experimental|LY2523355 + pegfilgrastim|
9783939|NCT01214642|Experimental|LY2523355 Days 1, 5, 9|LY2523355 administered intravenously on Days 1, 5 and 9, starting dose is 2 milligrams per meter squared (mg/m^2) for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
9783940|NCT01214642|Experimental|LY2523355 Days 1, 8|LY2523355 administered intravenously on Days 1 and 8, starting dose is 8 mg/m^2 for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
9764542|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 10 mg|Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
9764543|NCT00777946|Active Comparator|Aliskiren 300 mg|Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
9764544|NCT00778102|Experimental|1|
9764545|NCT00778102|Active Comparator|2|
9764546|NCT00778167|Experimental|Arm I (Enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
9764547|NCT00778167|Experimental|Arm II (Enzyme inhibitor and monoclonal antibody therapy)|Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.
9764548|NCT00778258|Experimental|Milk-allergic; Non-consumption|Subjects in this arm reacted to the lowest baseline dose of baked milk (muffin) and will continue strict milk avoidance, returning for re-evaluation with laboratory tests at 12 and 24 months and baked milk challenge at 36 months. Individual participants may be challenged at 12 and or 24 months.
9764549|NCT00778258|Experimental|Tolerated Muffin, Reacted to Pizza|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin but react to ingesting the amount of baked milk in a standardized portion of pizza. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
9764550|NCT00778258|Experimental|Reacted to Rice Pudding|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin and a standardized portion of pizza but react to a standardized dose of baked milk in rice pudding. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
9764551|NCT00778258|Experimental|Reacted to Non-baked Milk|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin, pizza and rice pudding but react to a standardized dose of non-baked milk. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
9764552|NCT00778258|Experimental|Tolerant to Baked and Non-baked Milk|"Biological/Vaccine: Baked Milk At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.~Biological/Vaccine: Non-baked Milk Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk."
9764553|NCT00778258|No Intervention|Non-Interventional Comparison|Thirty subjects who fulfill inclusion criteria but are unwilling to participate in the full protocol will be enrolled as a comparison group to the active arms.
9764554|NCT00778310|Experimental|Concerta|The subject will be administered their usual dose of Concerta the morning of the FMRI scan in a double blind fashion
9764555|NCT00778310|Placebo Comparator|Placebo|The subject will be administered a placebo the morning of the FMRI scan in a double blind fashion
9764556|NCT00778336||Limb Ischemia|Patients presenting with limb ischemia for treatment
9764557|NCT00778336||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
9764558|NCT00778336||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
9764559|NCT00778336||Other Thrombotic Conditions|Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.
9764560|NCT00778375|Experimental|Clofarabine + Cytarabine + Decitabine|Clofarabine 20 mg/m^2 by vein (IV) as a 1- to 2-hour intravenous infusion daily for 5 days. Cytarabine 20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions. Decitabine 20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
9764561|NCT00778622|Experimental|A1|Normal Weight by Body Weight Index
9764562|NCT00778622|Experimental|A2|Overweight by Body Weight Index
9764563|NCT00778622|Experimental|A3|Obese by Body Weight Index
9764564|NCT00778648|Experimental|Juice Plus|
9764565|NCT00778648|Placebo Comparator|Placebo|
9764566|NCT00778817|Experimental|Arm II (Mitotane + IMC-A12)|Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
9764567|NCT00778830|Experimental|Cetuximab plus FOLFIRI|
9764568|NCT00778830|Experimental|Cetuximab plus FOLFOX|
9764569|NCT00778869|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
9764570|NCT00778895|Experimental|Fluviral F1 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 1 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
9833475|NCT02655237|Active Comparator|Leuprorelin 1.88 mg or 3.75 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by leuprorelin acetate 1.88 mg or 3.75 mg, injection, SC, once in 4 weeks and relugolix placebo matching tablets, orally, once daily for 24 weeks in treatment period.
9833476|NCT02655354|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
9833477|NCT02655354|No Intervention|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
9833478|NCT02655419|Experimental|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
9833479|NCT02655510|Experimental|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
9833480|NCT02655653|Experimental|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
10203274|NCT02839915|Placebo Comparator|Placebo Control|Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
10203275|NCT02839720|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional cycles.
9833481|NCT02655653|Experimental|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
9833482|NCT02655666||Medtronic MiniMed Paradigm® REAL-Time System|Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor
9833483|NCT02655679|Experimental|VTP-38543 0.05%|VTP-38543 0.05% administered topically every 12 hours for 28 days.
9833484|NCT02655679|Experimental|VTP-38543 0.15%|VTP-38543 0.15% administered topically every 12 hours for 28 days.
9833485|NCT02655679|Placebo Comparator|Vehicle without Transcutol®P|Vehicle without Transcutol®P administered topically every 12 hours for 28 days.
9833486|NCT02655679|Experimental|VTP-38543 1%|VTP-38543 1% administered topically every 12 hours for 28 days.
9833487|NCT02655679|Placebo Comparator|Vehicle with Transcutol®P|Vehicle with Transcutol®P administered topically every 12 hours for 28 days.
9833488|NCT02655887|Experimental|VENOVO™ Venous Stent.|Implant of the VENOVO™ Venous Stent
9833489|NCT02656069|Other|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
9833490|NCT02656069|Other|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
9833491|NCT02656160|Placebo Comparator|Placebo|
9833492|NCT02656160|Active Comparator|Dalfampridine|
9833493|NCT02656173|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day along with tamsulosin 0.2 mg for 12 weeks
9833494|NCT02656173|Experimental|Placebo|Participants who received matching placebo once a day along with tamsulosin 0.2 mg for 12 weeks.
9836003|NCT02765165|Experimental|Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2|USL311, oral, daily, starting at dose as determined in Part 1b, in combination with lomustine 90 mg/m˄2, oral, once every 6 weeks
9984227|NCT04294043|Experimental|Infusion of IV Gallium|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
9984228|NCT04293679|Experimental|Cohort A: STP705 10 μg dose|Cohort A: STP705 10 μg dose, intradermal injection, given once a week for up to 6 weeks
9984229|NCT04293679|Experimental|Cohort B: STP705 20 μg dose|Cohort B: STP705 20 μg dose, intradermal injection, given once a week for up to 6 weeks
9984230|NCT04293679|Experimental|Cohort C: STP705 30 μg dose|Cohort C: STP705 30 μg dose, intradermal injection, given once a week for up to 6 weeks
10203276|NCT02838316|Experimental|150 x 106 dosage|10 subjects will be receiving a dosage of 150 x 106 AMDC-GIR
10203277|NCT02838316|Experimental|300 x 106 dosage|10 subjects will be receiving a dosage of 300 x 106 AMDC-GIR
10203278|NCT02835690|Experimental|Pembrolizumab 2 mg/kg|Participants receive pembrolizumab 2 mg/kg administered intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
10203279|NCT02835690|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
10203280|NCT02835690|Experimental|Pembrolizumab 200 mg Fixed Dose|Participants receive pembrolizumab 200 mg fixed dose administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
9833495|NCT02656329|Experimental|AdreView™|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) <1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M >= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
10203281|NCT02828982|Experimental|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
9833496|NCT02656329|Experimental|Standard of Care|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
9833497|NCT02656420|Placebo Comparator|Placebos|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
9833498|NCT02656420|Experimental|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
9833499|NCT02656420|Experimental|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
9833500|NCT02656420|Experimental|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
9833501|NCT02656485|Experimental|Dose I|B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
9833502|NCT02656485|Experimental|Dose II|B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
9833503|NCT02656485|Experimental|Dose III|B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
9833504|NCT02656485|Placebo Comparator|Placebo|Placebo to Match B244
9833505|NCT02656680|Experimental|FB+Friends|FB+Friends is a Facebook-delivered weight loss intervention. For this group, the study team continued to enroll participants through week 8.
9833506|NCT02656680|Active Comparator|FB Only|FB Only Facebook-delivered weight loss intervention including only study participants.
9833507|NCT02656693|Experimental|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
9833508|NCT02656693|Experimental|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
9833509|NCT02656693|No Intervention|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
9833510|NCT02656745|Experimental|Mobile Smoking Cessation Solution|Subjects download & use the mobile application.
9833511|NCT02656875|Experimental|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
9833512|NCT02657031|Active Comparator|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
9833513|NCT02657031|Experimental|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
9833514|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
9833515|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
9833516|NCT02657252|Active Comparator|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
9833517|NCT02657252|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
9833518|NCT02657369|Experimental|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
9833519|NCT02657408|Experimental|BI 1026706|
9833520|NCT02657408|Experimental|Placebo|
9833521|NCT02657538|Active Comparator|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
9833522|NCT02657538|Active Comparator|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
9833523|NCT02657564|Other|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
9833524|NCT02657629|Active Comparator|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
9833525|NCT02657629|Active Comparator|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
9833526|NCT02657889|Experimental|niraparib plus pembrolizumab|"Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle~Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle"
9836004|NCT02765165|Experimental|Dose-Expansion, USL311, GBM, Part 3|USL311, oral, daily, starting at dose determined in Part 1b
9764571|NCT00778895|Experimental|Fluviral F2 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 2 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
9764572|NCT00778895|Active Comparator|Vaxigrip Group|Subjects 6 months to 3 years of age received if primed, 1 dose of Vaxigrip vaccine at Day 0 and if unprimed, 2 doses of Vaxigrip vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
9764573|NCT00778921|Experimental|Amlodipine 10 mg|Amlodipine 10 mg
9764574|NCT00778921|Experimental|Aliskiren/Amlodipine 150/10 mg|Aliskiren/Amlodipine 150/10 mg
9764575|NCT00778921|Experimental|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg
9764576|NCT00779025|Active Comparator|MINE Alone|Female Personal Lubricant (PD-F-5254)
9764577|NCT00779025|Experimental|YOURS and MINE|Male Personal Lubricant (10855-096) used in conjunction with Female Personal Lubricant (PD-F-5254)
9764578|NCT00779103|Experimental|Histrelin Subcutaneous Implant (50 mg)|Subcutaneous implant designed to deliver histrelin continously for 12 months.
9764579|NCT00779142|Other|Methotrexate 25mg/ml|Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.
9764580|NCT00779155|Placebo Comparator|Inactive Resonator Therapy|Inactive magnetic resonance therapy
9764581|NCT00779155|Active Comparator|Active Resonator Therapy|active magnetic resonance therapy
9764582|NCT00779246|Active Comparator|1|Active surveillance cultures (ASC) (via nasal swabs) will be performed for all patients admitted to the medical intensive care unit (ICU) during the designated study period. All patients will be placed in contact isolation until nasal swabs return negative; otherwise will remain in isolation.
9764583|NCT00779246|Active Comparator|2|Chlorhexidine gluconate (CHG) cloths will be used to bathe patients daily instead of standard soap and water. Active surveillance cultures (ASC) will also be used in this arm, but results will be blinded and not used to determine whether patients should be in contact isolation.
9764584|NCT00779259|Active Comparator|Theophylline alone|baseline theophylline pharmacokinetics
9764585|NCT00779259|Active Comparator|Quinine alone|baseline quinine pharmacokinetics at steady state
9764586|NCT00779259|Experimental|Theophylline with steady state quinine|Theophylline pharmacokinetics in the presence of steady state quinine and quinine pharmacokinetics in the presence of theophylline.
9764587|NCT00779285|Experimental|Single-arm|Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
9764588|NCT00779311|Experimental|Experimenal|All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle. Sorafenib will be administered daily throughout treatment beginning on day 1
9764589|NCT00779324|Experimental|Amantadine|Amantadine 100 mg every morning and Noon
9764590|NCT00779324|Placebo Comparator|Placebo|Placebo tablets
9764591|NCT00779402|Experimental|Sipuleucel-T|Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
9764592|NCT00779402|Placebo Comparator|Control|Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions.
9764593|NCT00779467|Experimental|Bupivacaine with Neostimgine 8 mcg/ml|STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
9764594|NCT00779467|Experimental|Bupivacaine and Neostigmine 4 mcg/ml|STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
9764595|NCT00779467|Experimental|Bupivacaine with Neostigmine 2 mcg/ml|STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
9764596|NCT00779467|Active Comparator|BUPIVACAINE WITH FENTANYL 2 MCG/ML|Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
10203282|NCT02828982|Sham Comparator|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
10203283|NCT02828761|Experimental|Coronary Calcium Scoring|Coronary calcium scoring by multidetector row computed tomography (MDCT).
10203284|NCT02828761|Active Comparator|Standard Care|Standard evaluation of chest pain patient which often includes immediate non-invasive imaging.
9764597|NCT00779506|Experimental|Quetiapine Fumarate XR|Seroquel XR 400-800mg
9764598|NCT00779558|Active Comparator|Study drug|Heparin sulfate infusion at 10 units/kg/hour
9764599|NCT00779558|Placebo Comparator|Placebo|Placebo - normal saline infusion
9764600|NCT00779584|Experimental|MK-8776 10mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 10 mg/m^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
10203285|NCT02823457|Other|VBMI intervention group|All patients will receive a 12 week VBMI intervention to promote treatment completion
10205273|NCT03207815|Experimental|Filgotinib|Participants will receive filgotinib 200 milligrams (mg) once daily for up to 52 weeks along with a standardized prednisone burst of 60 milligrams per day (mg/day) at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
10205274|NCT03207815|Placebo Comparator|Placebo|Participants will receive placebo to match filgotinib once daily for up to 52 weeks along with a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
10205275|NCT03163368|Experimental|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
10205276|NCT03159936|Experimental|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
9764601|NCT00779584|Experimental|MK-8776 20mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 20 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764602|NCT00779584|Experimental|MK-8776 40mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 40 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764603|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764604|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764605|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764606|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764607|NCT00779584|Experimental|MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 150 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764608|NCT00779584|Experimental|MK-8776 200mg+Gemcitabine 1000mg/m^2|Participants received MK-8776 200 mg given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
9764609|NCT00779675||Infliximab 5 mg/kg|
9764610|NCT00779701|Other|A|All subjects placed on insulin infusion.
9764611|NCT00779766|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
9764612|NCT00779766|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo. Placebo was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
9764613|NCT00779779||Rotarix Group|Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.
9764614|NCT00779857|Experimental|AtriCure LAA Exclusion System|AtriCure LAA Exclusion System
9764615|NCT00779870||1|healthy volunteers
9764616|NCT00779870||2|mild asthmatics
9764617|NCT00779870||3|moderately-severe asthmatics
9764618|NCT00779870||4|severe asthmatics
9764619|NCT00779909|Placebo Comparator|1- Placebo|placebo capsule once per day
9764620|NCT00779909|Experimental|2- Vitamin D3, 500 IU|vitamin D3, 500 IU capsule once per day
9764621|NCT00779909|Experimental|3- Vitamin D3, 2500 IU|vitamin D3, 2500 IU capsule once per day
9764622|NCT00779909|Experimental|4- Vitamin D3, 5000 IU|vitamin D3, 5000 IU capsule once per day
9764623|NCT00780026|Experimental|Strict Glycemic Control|strict glycemic control (80 to 110 mg/dl)
9764624|NCT00780026|No Intervention|Standard of Care Control|standard of care insulin dosing
9764625|NCT00780143|Experimental|Arm 1|Plitidepsin in combination with Cytarabine
9764626|NCT00780208|Other|Daytrana (methylphenidate patch)|Methylphenidate patch
9764627|NCT00780234|Experimental|Arm 1: pioglitazone|Current or former smokers receive 6 months of treatment with pioglitazone
9764628|NCT00780234|Placebo Comparator|Arm 2: placebo|Current or former smokers receive 6 months of treatment with placebo
9764629|NCT00780273|Experimental|Ankylos dental implants.|"3 Ankylos dental implants placed in platform switch configuration on one side of the mandible in support of a fixed restoration.~A total number of 19 subjects participated in this randomized, split mouth, masked, prospective, open, comparison, monocenter study. Participants were subjects with an edentulous mandible who recieved 3 implants on each side which were splinted for the delivery of a fixed prosthesis."
9764630|NCT00780273|Active Comparator|3i Prevail dental implants.|"Three 3i Prevail dental implants placed on the opposite side of the mandible from the Ankylos implants in support of fixed dental restoration.~After a baseline phase of 1 month the mandible sides of subjects were randomly assigned to one of the 2 parallel treatment groups: one side received ANKYLOS plus implants. The contralateral sde recieved Certain PREVAIL Implants. Abutments were installed and loaded immediately by a fixed temporary bridge. After 3 months the final prosthesis was incorporated."
9764631|NCT00780338|Experimental|1|Cohort 1: receives the Assets Getting To Outcomes intervention first. The AGTO intervention includes three types of assistance which are adapted to fit the needs and priorities of the individuals involved, as well as the inner and outer setting: (1) a manual of text and tools; (2) face-to-face training, and (3) onsite technical assistance (TA). These three types of assistance aim to improve the implementation process for each program. Two full-time, Maine-based staff, one with a master's and one with a bachelor's degree, provided AGTO tools, training, and TA to the intervention coalitions and programs during the two year intervention period. The tools are in the Search Institute-published manual, Getting To Outcomes with Developmental Assets: Ten steps to measuring success in youth programs and communities, which all intervention participants received.
9764632|NCT00780338|Active Comparator|2|Cohort 2: receives the Assets Getting To Outcomes intervention second, after Cohort 1 is done receiving the intervention.
9764633|NCT00780416|Experimental|TRV/PEG/RBV|
9764634|NCT00780416|Active Comparator|PEG/RBV|
9764635|NCT00780442|Experimental|DCS|D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
9764636|NCT00780442|Placebo Comparator|Placebo|Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
9833527|NCT02657915|Placebo Comparator|Placebo|This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.
9833528|NCT02657915|Experimental|BIIB033 100mg/Kg|This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.
9833529|NCT02657928|Experimental|Treatment (ribociclib and letrozole)|Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9833530|NCT02658019|Experimental|Pembrolizumab in Advanced HCC|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.
9833531|NCT02658084|Experimental|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
9833532|NCT02658084|Experimental|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
9833533|NCT02658149|Experimental|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
9833534|NCT02658149|Active Comparator|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
9833535|NCT02658175|Experimental|Treatment-naïve Group|Treatment naïve group included combined group of ISIS 304801-CS7 (CS7-New) study participant and participant on placebo in index studies (ISIS 304801-CS6 [NCT02211209] and ISIS 304801-CS16 [NCT02300233]), were to receive 300 mg of volanesorsen as single SC once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following Week 52 visit, participants had option of participating in expanded access program or continuing treatment with 300 mg of volanesorsen as single SC once-weekly for up to additional 52 weeks (Weeks 53-104) and in France participants, up to additional 104 weeks for total of 156 weeks (Weeks 105 to Week 156) until expanded access program was approved and available in their country. Participants who were not participating in expanded access program were to enter 13-week post-treatment (PT) evaluation period and in France, participants not continuing treatment were to enter 26-week PT follow-up period.
9833536|NCT02658175|Experimental|CS6-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS6 (NCT02211209) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
9833537|NCT02658175|Experimental|CS16-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS16 (NCT02300233) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
9833538|NCT02658240|Active Comparator|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
9833539|NCT02658240|Active Comparator|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
9833540|NCT02658448|Experimental|GTx-024 3 mg|GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
9833541|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
9833542|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
9833543|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
9764637|NCT00780494|Experimental|bevacizumab+ carboplatin +capecitabine|Participants receive bevacizumab 15 mg/kg intravenously followed by carboplatin AUC 6 intravenously on Day 1 of a 21-day cycle, concurrently with capecitabine 850 mg/m2 twice-daily by mouth on Cycle Days 1-to-14, followed by a 1-week break.
9764638|NCT00780559|Other|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
9764639|NCT00780559|Other|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
9764640|NCT00780572|Experimental|Arm 1: ADE Alerts|Arm 1 is a random intervention group in which half of the patients admitted to the VASLCHCS during study time period will be randomly selected. Providers will see ADE alerts for all patient in the randomly selected experimental group
9764641|NCT00780572|No Intervention|Arm 2: Control/No Alerts|The second arm is the control. Alerts will not be displayed for these patients.
9764642|NCT00780676|Experimental|Dasatinib sensitivity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
9764643|NCT00780676|Experimental|SRC pathway activity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
9764644|NCT00780676|Experimental|Dasatinib target index|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
9764645|NCT00780676|Experimental|Selumetinib pathway predictor|Participants predicted to respond to selumetinib/AZD6244 by predictive gene signature (either MEK pathway activity predictor positive or MEK pathway predictor negative) receive selumetinib 75 mg by mouth twice daily (BID).
9764646|NCT00780715|Active Comparator|Gliclazide MR|
9764647|NCT00780715|Active Comparator|Sitagliptin|
9764648|NCT00780715|Active Comparator|Pioglitazone|
9764649|NCT00780715|Experimental|Metformin|
9764650|NCT00780741|Active Comparator|Immediate Office Probing|Probing to be performed in the office setting using topical anesthesia and infant restraint. Probing to be performed either the same day as randomization or within two weeks.
9764651|NCT00780741|Active Comparator|Deferred Facility Probing|Probing to be performed in a surgical facility under general anesthesia within four weeks after completion of the 26-week visit if any of the clinical signs persist.
9764652|NCT00780910|Experimental|MP-424|
9764653|NCT00780962|Experimental|N-Acetylcysteine group|Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
9764654|NCT00780962|Placebo Comparator|0.9% Sodium-chloride group|Subjects in this group will receive 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 67 cc per hour of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
9764655|NCT00780975|Experimental|Arm 1|Aplidin (Plitidepsin)
9764656|NCT00781079|Experimental|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
9764657|NCT00781079|No Intervention|Care as Usual|Care as usual
9517981|NCT03301103|Experimental|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
9517982|NCT03301090|Experimental|Cohort A|REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
9764658|NCT00781274|Experimental|MP-424|
9764659|NCT00781326|Other|Open Label Antidepressant|In Phase 1, all participants will be placed on antidepressant medication. In Phase 2, participants will continue with their antidepressant medication and also receive receive either nimodipine or placebo.
9764660|NCT00781365|No Intervention|Control|Patients in the control group will receive usual care from their primary care physicians at HealthPartners Medical Group clinics.
9764661|NCT00781365|Experimental|Telemonitors and pharmacy management|The telemonitoring intervention (TI) patients will receive a home blood pressure telemonitor and will work with a clinical pharmacist case manager to control elevated blood pressure. Patients will use their home telemonitors to read and send their blood pressures to their Pharmacist case manager, who will use phone meetings with the patient to make medication adjustments.
9764662|NCT00781391|Active Comparator|Warfarin/placebo edoxaban|Warfarin tablets plus placebo Edoxaban tablets
9764663|NCT00781391|Experimental|high dose edoxaban/placebo warfarin|Edoxaban tablets (60mg) plus warfarin placebo tablets
9764664|NCT00781391|Experimental|low dose edoxaban/placebo warfarin|Edoxaban tablets (30mg) plus warfarin placebo tablets
9764665|NCT00781456|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
9764666|NCT00781456|Placebo Comparator|Placebo|Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
9764667|NCT00781508|Experimental|sildenafil|Effect of oral administration of a single dose of sildenafil 50 mg on left ventricular filling pressures as evaluated 1 hr after sildenafil administration in patients with heart failure
9764668|NCT00781508|Placebo Comparator|placebo|Inactive placebo prepared to mimic the appearance of sildenafil.
9764669|NCT00781599|Active Comparator|1|Chantix for 3 months and Standard Counseling
9764670|NCT00781599|Experimental|2|Chantix for 3 months and Adherence Counseling
9764671|NCT00781768|Placebo Comparator|Standard PO (Zofran + Dexamethasone)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
9764672|NCT00781768|Active Comparator|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
9764673|NCT00781859|Experimental|125µg Ocriplasmin|125µg intravitreal injection of ocriplasmin
9764674|NCT00781859|Placebo Comparator|Placebo|placebo intravitreal injection
9764675|NCT00781898|Active Comparator|Depot Naltrexone|
9764676|NCT00781898|Placebo Comparator|Placebo|
9764677|NCT00781911|Experimental|Carcinoid tumor|Participants with carcinoid tumor will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
9764678|NCT00781911|Experimental|Islet cell carcinoma|Participants with islet cell carcinoma will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
9984231|NCT04293679|Experimental|Cohort D: STP705 60 μg dose|Cohort D: STP705 60 μg dose, intradermal injection, given once a week for up to 6 weeks
9783941|NCT01214642|Experimental|LY2523355 Days 1, 5 + pegfilgrastim|LY2523355 administered intravenously on Days 1 and 5, starting dose is 8 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 6 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
9783942|NCT01214642|Experimental|LY2523355 Days 1, 4 + pegfilgrastim|LY2523355 administered on Days 1 and 4, starting dose is 12 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 5 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
9783943|NCT01214655|Experimental|LY2523355 on Days 1, 2, and 3|Starting dose was 2 milligrams per meter squared (mg/m^2) administered by a 1-hour intravenous (IV) infusion on Days 1, 2, and 3 of every 21-day Cycle.
9783944|NCT01214655|Experimental|LY2523355 on Days 1, 5, and 9|Starting dose was 8 milligrams per meter squared (mg/m^2) administered by a 1-hour IV infusion over 1 hour on Days 1, 5, and 9 of every 21-day Cycle.
9783945|NCT01214668|Experimental|LY573636 + Liposomal Doxorubicin|
9785636|NCT01256294|Experimental|Sequence 1 - Branded Tacrolimus / Generic Tacrolimus|In Period 1 (Days 1-14) participants received branded tacrolimus (Prograf) orally twice a day and in Period 2 (Days 15 - 28) participants received generic tacrolimus (Sandoz) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
9785637|NCT01256294|Active Comparator|Sequence 2 - Generic Tacrolimus / Branded Tacrolimus|In Period 1 (Days 1 - 14) participants received generic tacrolimus (Sandoz) orally twice a day and in Period 2 (Days 15 - 28) participants received branded tacrolimus (Prograf) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
9984232|NCT04293679|Experimental|Cohort E: STP705 120 μg dose|Cohort E: STP705 120 μg dose, intradermal injection, given once a week for up to 6 weeks
9517983|NCT03301090|Experimental|Cohort B|REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
9764679|NCT00781937|Experimental|Lira 3.0 mg|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
9764680|NCT00781937|Placebo Comparator|Placebo|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period
9764681|NCT00781950|Placebo Comparator|Placebo|Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.
9764682|NCT00781950|Experimental|Flaxseed|Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
9764683|NCT00781963|Experimental|CBT-I|Manual-based cognitive behavioral therapy for insomnia (CBT-I) provided in 5 individual or group sessions by a non-clinician sleep coach.
9764684|NCT00781963|Active Comparator|Control|Non-directive sleep education provided in 5 group sessions by a health educator.
9764685|NCT00782067|Experimental|Midostaurin (PKC412)|Midostaurin was administered at a dose of 100 mg twice daily (bid) in continuous cycles of 28 days until disease progression, intolerable toxicity or withdrawal due to any cause, whichever occurred first.
9764686|NCT00782171|Active Comparator|Immediate Loading|SLActive dental implant(s) will be restored with a temporary restoration on the day of surgery.
9764687|NCT00782171|Active Comparator|Early Loading|Healing caps will be placed on the SLActive dental implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
9764688|NCT00782210|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
9764689|NCT00782210|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
9764690|NCT00782210|Placebo Comparator|Placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
9764691|NCT00782275|Experimental|bevacizumab and temsirolimus|"bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)~temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22~1 cycle=28-days~There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression."
9764692|NCT00782340|Active Comparator|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
9764693|NCT00782340|Placebo Comparator|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
9764694|NCT00782379|Experimental|Myeloablative Haploidentical Transplant|All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.
9764695|NCT00782418|Active Comparator|1|exenatide 5mcg
9764696|NCT00782418|Active Comparator|2|exenatide 1.5mcg
9764697|NCT00782418|Placebo Comparator|3|Placebo
9764698|NCT00782496|Experimental|Level1 Basic Meter Features|Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood. The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
9764699|NCT00782496|Experimental|Level 2 Advanced Meter Features|Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing. The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
9764700|NCT00782509|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
9764701|NCT00782509|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
9764702|NCT00782509|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
9764703|NCT00782626|Experimental|everolimus|Patients rcvd oral everolimus 5.0 mg/m2/day for a 28-day treatment course up to a total of 12 courses (48 weeks) if a patient had stable disease except if toxicity was unacceptable. Two dose reductions were permitted (3.0 5.0 mg/m2/day and 2.0 mg/m2/day).
9517984|NCT03301090|Experimental|Cohort C|REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
9517985|NCT03301090|Experimental|Cohort D|REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
9764704|NCT00782639|Active Comparator|Iopamiro-370|
9764705|NCT00782639|Active Comparator|Visipaque 320|
9764706|NCT00782717|Experimental|NEVANAC|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
9764707|NCT00782717|Placebo Comparator|Nepafenac Vehicle|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
9764708|NCT00782756|Experimental|RT, with temozolomide and bevacizumab|This treatment regimen is novel in that it delivers the initial course of RT over 2 weeks instead of 6 weeks; also, the addition of bevacizumab during and after RT is a new approach.
9764709|NCT00782795|Active Comparator|Pioglitazone|30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
9833544|NCT02658487|Experimental|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
9833545|NCT02658630|Experimental|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
9984233|NCT04293562|Experimental|Arm A High Risk Group|Arm A High Risk Group: See Detailed Description.
10203286|NCT02815280|Experimental|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
9833546|NCT02658734|Experimental|Trastuzumab emtansine|
9833547|NCT02658851|Experimental|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
9833548|NCT02658994|Experimental|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
9833549|NCT02658994|Active Comparator|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
9833550|NCT02659020|Experimental|Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 15 milligrams per kilogram (mg/kg) on days 1, 8 plus gemcitabine 900 milligrams per meter square (mg/m^2) on days 1, 8 plus docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met.
9833551|NCT02659020|Experimental|Phase 1b: Cohort 2 overall - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 20 mg/kg on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met (cohort 2). Following a protocol amendment, additional participants were enrolled into this group to confirm the safety of the 20 mg/kg dose level prior to opening the Phase 2 (cohort 2 expansion).
9833552|NCT02659020|Experimental|Phase 2: Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
10203287|NCT02815280|Placebo Comparator|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
9833553|NCT02659020|Placebo Comparator|Phase 2: Placebo + Gemcitabine + Docetaxel|Participants received intravenous infusions of placebo on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
9833554|NCT02659098|Experimental|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
9833555|NCT02659150|Other|Open-Label tocilizumab|tocilizumab will be given to rheumatoid arthritis patients at a dose of 162 mg subcutaneously a week
9984234|NCT04293562|Experimental|Arm A Low Risk Group 1|Arm A Low Risk Group 1: See Detailed Description.
9984235|NCT04293562|Experimental|Arm A Low Risk Group 2|Arm A Low Risk Group 2: See Detailed Description.
9984236|NCT04293562|Experimental|Arm AC High Risk Group|Arm AC High Risk Group: See Detailed Description.
10203288|NCT02815267|Experimental|FMX-101, 4% minocycline foam|Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
10203289|NCT02815267|Placebo Comparator|Vehicle foam|Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed
10203290|NCT02811783|Active Comparator|Naloxone Hydrochloride Lotion, 0.5%|Naloxone Hydrochloride Lotion 0.5%
10203291|NCT02811783|Placebo Comparator|Placebo Lotion|Placebo Lotion
10203292|NCT02802228|Experimental|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
10203293|NCT02802228|Placebo Comparator|Placebo|90 day course of placebo following intravenous dose of 5% dextrose in water (D5W)
10203294|NCT02801448|Placebo Comparator|Placebo|Placebo containing maltodextrine but no active sulforaphane
10203295|NCT02801448|Active Comparator|BSE|Broccoli sprout extract once daily for 12 weeks
10203296|NCT02746029||Children with cardiac murmur|
10203297|NCT02737462|Experimental|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
10203298|NCT02719691|Experimental|Dose-Escalation of Alisertib and MLN0128|This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.
10205277|NCT03156816|Experimental|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
10205278|NCT03156816|Placebo Comparator|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
10205279|NCT03155022|Experimental|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
10205280|NCT03155022|Other|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
9517986|NCT03301090|Experimental|Cohort E|REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
9517987|NCT03301090|Experimental|Cohort F|REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
9517988|NCT03301077||General population|recruited from schools and other institutions like job-centers or child and adolescent psychiatries
9783946|NCT01214720|Experimental|1|
9783947|NCT01214759|Other|Truvada and Raltegravir|Single arm
9783948|NCT01214811|Other|Mepilex Border Ag|Non comparative study with one active arm - Mepilex Border Ag
9783949|NCT01214837|Experimental|MenACWY3|Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
9783950|NCT01214837|Experimental|MenACWY4|All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
9783951|NCT01214837|Placebo Comparator|Routine Vaccines|Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.
9783952|NCT01214850|Experimental|rMenB+OMV|Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart
9783953|NCT01214850|Experimental|MenACWY|Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart
9783954|NCT01214850|Active Comparator|Control|Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart
9783955|NCT01214915|Experimental|Anagrelide Hydrochloride|
9783956|NCT01214980|Experimental|MIST Therapy in conjunction with SOC|Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
9783957|NCT01214980|Active Comparator|Control arm|Standard of care treatment
9783958|NCT01215032|Experimental|Metformin|This is the only arm of this phase 2 open label study
9783959|NCT01215097|Experimental|Linagliptin|once a day
9783960|NCT01215097|Placebo Comparator|placebo|once a day
9783961|NCT01215110|Experimental|TMC207 700/500/400|TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14
9783962|NCT01215110|Experimental|TMC207 500/400/300|TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.
9783963|NCT01215110|Experimental|TMC207 400/300/200|TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14
9783964|NCT01215110|Experimental|TMC207 200/100|TMC207- 200 mg Day 1 and 100 mg Days 2-14
9783965|NCT01215110|Active Comparator|Rifafour e-275 mg|Rifafour e-275 mg
9783966|NCT01215123||Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
9783967|NCT01215175|Active Comparator|Prevnar™ - Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
9783968|NCT01215175|Experimental|V114 Adjuvanted -Toddler Cohort|Healthy toddler (12-15 months of age) participants who had completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
9783969|NCT01215175|Experimental|V114 Nonadjuvanted-Toddler Cohort|Healthy toddlers (12-15 months of age) participants who completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of non-adjuvanted V114 on Day 1.
9783970|NCT01215175|Active Comparator|Prevnar™- Toddler Cohort|Healthy toddlers (12-15 months of age) participants who had previously completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
9783971|NCT01215175|Experimental|V114 Adjuvanted -Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
9783972|NCT01215188|Experimental|V114 Aluminum-adjuvanted|Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
9783973|NCT01215188|Experimental|V114 Non-adjuvanted|Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
9783974|NCT01215188|Active Comparator|Prevnar 13®|Four IM doses at 0.5 mL of Prevnar 13® at 2, 4, 6, and 12 to 15 months of age.
9783975|NCT01215227|Experimental|Preladenant 2 mg|Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 2 mg in this extension study. Participants will receive preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
9783976|NCT01215227|Experimental|Preladenant 5 mg|Participants who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
9783977|NCT01215227|Experimental|Preladenant 5 mg (on placebo in parent study)|Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 will receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
9783978|NCT01215227|Experimental|Preladenant 10 mg|Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 10 mg in this extension study. Participants will receive preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
9783979|NCT01215227|Active Comparator|Rasagiline 1 mg|Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 will continue to receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
9783980|NCT01215227|Active Comparator|Rasagiline 1 mg (on placebo in parent study)|Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 will receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
9764710|NCT00782795|Placebo Comparator|sugar pill (placebo)|1 sugar pill (placebo) taken once daily for 48 weeks.
9764711|NCT00782821|Active Comparator|Rabbit Antithymocyte Globulin (rATG)|Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.
9764712|NCT00782821|Experimental|RATG/Rituxan|Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.
9764713|NCT00782821|Experimental|RATG/Velcade|Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.
9764714|NCT00782821|Experimental|RATG/Rituxan/Velcade|"Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade.~rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1."
9764715|NCT00783094|Experimental|Tadalafil 2.5 milligrams (mg)|2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
9764716|NCT00783094|Experimental|Tadalafil 5 mg|5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
9764717|NCT00783094|Placebo Comparator|Placebo|"Placebo tablet taken by mouth once a day for 12 weeks.~Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks."
9764718|NCT00783198|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
9764719|NCT00783198|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
9764720|NCT00783198|Placebo Comparator|Placebo|Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
9764721|NCT00783289|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
9764722|NCT00783289|Experimental|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
9764723|NCT00783289|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
9764724|NCT00783289|Experimental|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
9764725|NCT00783367|Experimental|Lenalidomide plus rituximab with dexamethasone|Lenalidomide-low dose dexamethasone plus rituximab
9764726|NCT00783432|Experimental|1|Astepro Nasal Spray (0.1% azelastine hydrochloride)
9764727|NCT00783432|Active Comparator|2|Astelin Nasal Spray (0.1% azelastine hydrochloride)
9764728|NCT00783614|Active Comparator|1|Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily
9764729|NCT00783614|Placebo Comparator|2|Start antiretroviral therapy (ART) immediately and initiate placebo pill daily
9764730|NCT00783614|Active Comparator|3|Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily
9764731|NCT00783614|Placebo Comparator|4|Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily
9764732|NCT00783692|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
9764733|NCT00783692|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
9764734|NCT00783705|Experimental|Arm I (inositol)|Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
9764735|NCT00783705|Experimental|Arm II (placebo)|Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
9783981|NCT01215240|Experimental|Prophylactic peritoneal dialysis|Prophylactic peritoneal dialysis
9783982|NCT01215240|No Intervention|Standard care without PDC|
9785638|NCT01256385|Experimental|Arm A (cetuximab and temsirolimus)|Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9764736|NCT00783718|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
9764737|NCT00783718|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
9764738|NCT00783796|Experimental|2.25mm XIENCE V®|Patients receiving the 2.25 mm XIENCE V® stent
9764739|NCT00783835|Experimental|Methylphenidate|
9764740|NCT00783952|Other|1|Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes
9764741|NCT00783965|Experimental|Arm I|Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.
9764742|NCT00783965|Experimental|Arm II|Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.
9764743|NCT00784030|Other|Polycystic Kidney Disease Patients|Patients who present with polycystic kidney disease (PKD)
9764744|NCT00784030|Other|Healthy Patients|
9764745|NCT00784095|Experimental|Preparation and Completion|"Subjects in the first group (treatment) met with the facilitator three times for a period of forty-five minutes to one hour to discuss issues of life completion and preparation. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects discussed issues of heritage and legacy."
9764746|NCT00784095|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
9764747|NCT00784095|No Intervention|True Control|"Subjects in the third group (true control) were exposed to no intervention or attention control."
9764748|NCT00784134|Experimental|Alteplase|administration of alteplase via the intraventricular catheter
9764749|NCT00784134|Placebo Comparator|Saline Placebo|1 ml of normal saline administered via the intraventricular catheter
9764750|NCT00784147|Active Comparator|Ibalizumab 800 mg|every 2 weeks, combined with an Optimized Background Regimen
9764751|NCT00784147|Active Comparator|Ibalizumab 2000 mg|every 4 weeks, combined with an Optimized Background Regimen
9764752|NCT00784225|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
9764753|NCT00784225|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
9764754|NCT00784225|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
9764755|NCT00784225|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamin E placebo and selenium placebo daily for 7-12 years
9764756|NCT00784238|Experimental|Paliperidone|Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
9764757|NCT00784277|Experimental|001|Tapentadol IR (CG5503) 50mg for 14 days
9764758|NCT00784277|Experimental|002|Tapentadol IR (CG5503) 75mg for 14 days
9764759|NCT00784277|Active Comparator|003|oxycodone IR 10mg for 14 days
9764760|NCT00784277|Placebo Comparator|004|placebo 1 capsule for 14 days
9764761|NCT00784277|Experimental|005|Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
9764762|NCT00784277|Active Comparator|006|oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
9764763|NCT00784277|Placebo Comparator|007|placebo Tablets and capsules 2 x a day for 28 days
9764764|NCT00784303|Experimental|DTC cohort|This arm will enroll participants with radioiodine (131 I)-refractory/resistant differentiated thyroid cancer.
9764765|NCT00784303|Experimental|MTC cohort|This arm will enroll participants with medullary thyroid cancer.
9764766|NCT00784368|Experimental|SFI (ITCZ Oral Solution Monotherapy)|Participants with deep-seated mycosis (Systemic Fungal Infection [SFI]) received itraconazole (ITCZ) oral solution in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks as per Investigator's discretion.
9764767|NCT00784368|Experimental|SFI (Switched Treatment)|Participants with SFI received 200 milligram (mg) twice daily itraconazole intravenous (into the vein) infusion (ITCZ-IV) for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
9764768|NCT00784368|Experimental|FN (Switched treatment)|Participants with febrile neutropenia (FN) with suspected fungal infection received 200 mg twice daily ITCZ-IV for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
9764769|NCT00784459|Experimental|Treatment with Abatacept|Administration of Abatacept intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
9764770|NCT00784459|Placebo Comparator|Placebo|Administration of placebo (normal saline) intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
9764771|NCT00784524|Experimental|LMI Vaccination + IL-2|Patients receiving allogeneic large multivalent immunogen breast cancer vaccine and aldesleukin.
9984237|NCT04293562|Experimental|Arm AC Low Risk Group 2|Arm AC Low Risk Group 2: See Detailed Description.
9764772|NCT00784550|Experimental|ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler|Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
9764773|NCT00784550|Active Comparator|SPIRIVA® HANDIHALER® inhaler|Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID
9764774|NCT00784563|Active Comparator|Continuous training|Aerobic walking using continuous heart rate training.
9764775|NCT00784563|Active Comparator|Interval training|Aerobic walking using interval heart rate training
9764776|NCT00784641|Experimental|Novel Bausch & Lomb Contact Lens|Novel Bausch & Lomb daily disposable contact lenses
9764777|NCT00784641|Active Comparator|SofLens|Bausch & Lomb SofLens daily disposable contact lenses
9764778|NCT00784641|Active Comparator|Acuvue|Johnson and Johnson 1-Day Acuvue Moist contact lenses
9764779|NCT00784654|Experimental|Lisdexamfetamine dimesylate (LDX)|Open-label 30, 50, or 70mg
9764780|NCT00784654|Placebo Comparator|Placebo|
9764781|NCT00784693|Experimental|Tanezumab|
9764782|NCT00784693|Placebo Comparator|Placebo|
9764783|NCT00784719|Experimental|Treatment 1|
9764784|NCT00784719|Experimental|Treatment 2|
9764785|NCT00784719|Experimental|Treatment 3|
9764786|NCT00784719|Experimental|Treatment 4|
9764787|NCT00784719|Active Comparator|Active comparator|
9764788|NCT00784719|Placebo Comparator|Placebo|
9764789|NCT00784758|Experimental|Fenzian Device|Subjects randomized to this arm will receive treatment with the Fenzian Device
9764790|NCT00784758|Sham Comparator|Sham Device|Subjects randomized to this arm will receive treatment with the sham device.
9764791|NCT00784784|Experimental|Influenza vaccine|Influenza vaccine, using Fluviral trivalent split virus vaccine
9764792|NCT00784784|Experimental|Antiviral prophylaxis|Zanamivir antiviral prophylaxis
9764793|NCT00784810|Experimental|Oxycodone/Naloxone Tablets|Oxycodone/Naloxone combination
9764794|NCT00784810|Active Comparator|Codeine/Paracetamol Tablets|Codeine/Paracetamol combination
9764795|NCT00784836|Experimental|Avonex|Avonex 30 mcg given subcutaneously, once weekly, for 18 months.
9764796|NCT00784849|Experimental|1|One arm diagnostic
9764797|NCT00784875|Experimental|Period A|2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.
9764798|NCT00784875|Experimental|Period B|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.
9764799|NCT00784875|Experimental|Period C|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.
9764800|NCT00784875|Experimental|Period D|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.
9764801|NCT00784927|Experimental|Treatment|"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:~375 mg/m^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22."
9764802|NCT00784979|No Intervention|CMVIG followed by PP|MMF or rapamycin was given with CMVIG for 4 weeks followed by plasmapheresis
9764803|NCT00785044||Group|No participants received any drug administration. No intervention conducted.
9764804|NCT00785213|Active Comparator|Rosiglitazone Alone|Baseline rosiglitazone pharmacokinetics.
9764805|NCT00785213|Experimental|Rosiglitazone with Steady State Quinine Sulfate|Rosiglitazone pharmacokinetics in the presence of steady state quinine sulfate.
9785639|NCT01256385|Experimental|Arm B (temsirolimus)|Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.
9764806|NCT00785486|Other|Midazolam alone|Baseline midazolam and 1-hydroxy-midazolam pharmacokinetics. One day 1 after a fast of at least 10 hours patients received a single oral dose of midazolam 2 mg. Blood was drawn at times sufficient to characterize the pharmacokinetics of midazolam and its main metabolite.
9764807|NCT00785486|Other|Qualaquin (quinine) alone steady state|On the morning of day 9 after taking Qualaquin (quinine) capsules 324 mg orally every 8 hours for the prior 5 days, and following a fast of at least 10 hours all study participants received their usual morning dose of Qualaquin (quinine) 324 mg. Blood was drawn at times sufficient to determine the steady state Cmax and AUC 0-tau for Qualaquin (quinine).
9764808|NCT00785486|Experimental|Midazolam with Qualaquin (quinine)|On day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen, all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg. Blood was drawn sufficient to characterize the steady state kinetics of quinine and the kinetics of midazolam and 1-hydroxy-midazolam in the presence of each other.
9764809|NCT00785512|Active Comparator|1|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
9764810|NCT00785512|Placebo Comparator|2|Matching placebo tablets, oral administration
9764811|NCT00785538|Experimental|IMC-A12|All participants will receive intravenous (I.V.) infusions of IMC-A12, with the dose depending on which cohort they are enrolled into. A minimum of three participants will be enrolled in each cohort. When all participants complete a cohort, dose escalation to the next cohort will occur.
9764812|NCT00785577|Placebo Comparator|Placebo|LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks
9764813|NCT00785577|Active Comparator|Pregabalin|"Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
9764814|NCT00785577|Experimental|LY545694 21 mg|"LY545694 21 milligrams (mg) BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
9764815|NCT00785577|Experimental|LY545694 49 mg|"LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
9764816|NCT00785577|Experimental|LY545694 105 mg|"LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
9764817|NCT00785629|Active Comparator|Calcium Acetate|667 mg with meals
9764818|NCT00785629|Active Comparator|Lanthanum Carbonate|500 mg with meals
9764819|NCT00785629|Active Comparator|Sevelamer Carbonate|800 mg with meals
9764820|NCT00785629|Placebo Comparator|Placebo|with meals
9764821|NCT00785707||cochlear implant|children less than 24 months at time of cochlear implantation
9764822|NCT00785772|Experimental|1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min|
9764823|NCT00785772|Experimental|2: Patients with CLcr 15-29 mL/min|
9764824|NCT00785772|Experimental|3: Patients with CLcr 30-59 mL/min|
9764825|NCT00785785|Experimental|Nilotinib|nilotinib 400 mg twice a day
9764826|NCT00785785|Active Comparator|Imatinib|imatinib 400 mg once daily
9764827|NCT00785928|Experimental|Placebo|
9764828|NCT00785928|Experimental|1 mg LY2127399|
9764829|NCT00785928|Experimental|3 mg LY2127399|
9764830|NCT00785928|Experimental|10 mg LY2127399|
9764831|NCT00785928|Experimental|30 mg LY2127399|
9764832|NCT00785928|Experimental|60 mg LY2127399|
9764833|NCT00785928|Experimental|120 mg LY2127399|
9764834|NCT00785980|Active Comparator|Quinine Sulfate|Baseline quinine sulfate pharmacokinetics
9764835|NCT00785980|Experimental|Quinine Sulfate with Ciprofloxacin|Quinine sulfate pharmacokinetics in the presence of steady state ciprofloxacin
9764836|NCT00786019|Experimental|Ascorbic acid|All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
9764837|NCT00786032||BCI Device|All participants will use the BCI System as a means of communication.
9764838|NCT00786188|Experimental|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
9764839|NCT00786188|Placebo Comparator|Placebo - Sugar Pill|Eligible subjects will be randomized to receive a sugar pill.
9764840|NCT00786409|Other|Gardasil|30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.
9764841|NCT00786422|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|
9764842|NCT00786474|Placebo Comparator|Placebo|
9764843|NCT00786474|Experimental|Dalteparin|
9764844|NCT00786487|Experimental|lipid trained|20% lipid infusion in trained subjects
9764845|NCT00786487|Active Comparator|glycerol trained|glycerol infusion into trained subjects
9764846|NCT00786487|Experimental|lipid untrained|lipid infusion into untrained subjects
9764847|NCT00786487|Active Comparator|glycerol untrained|glycerol infusion into untrained subjects
9764848|NCT00786565|Experimental|Advanced Akreos Adapt|Advanced Akreos Adapt Aspheric Intraocular Lens (IOL).
9764849|NCT00786565|Experimental|Akreos Adapt|Akreos Adapt Spherical Intraocular Lens (IOL).
9764850|NCT00786643|Experimental|Stratum 1|Patients in stratum 1 have not received prior chemotherapy in the metastatic setting.
9764851|NCT00786643|Experimental|Stratum 2|Patients in stratum 2 have received 1-2 prior chemotherapy regimens in the metastatic setting.
9764852|NCT00786799|Active Comparator|Omega-3 Fatty Acids|
9764853|NCT00786799|Placebo Comparator|Placebo|
9764854|NCT00786825|Experimental|somatostatin|Type 1 diabetes and Hypoglycemia unawareness
9764855|NCT00786825|No Intervention|2|Healthy control subjects
9764856|NCT00786838|Experimental|Trabectedin|3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).
9764857|NCT00786864|Experimental|1. Experimental Group|Exercise Intervention Group
9764858|NCT00786864|No Intervention|2. Control Group|Control group - no intervention
9764859|NCT00786916|Placebo Comparator|Group A|Saline
9764860|NCT00786916|Active Comparator|Group B|Lidocaine 0.25 mg/kg
9764861|NCT00786916|Active Comparator|Group C|Lidocaine 0.5 mg/kg
9764862|NCT00786994|Experimental|1|Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
9764863|NCT00786994|Experimental|2|Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
9764864|NCT00786994|Placebo Comparator|3|Placebo (petroleum jelly) for three months once a day (27 patients)
9764865|NCT00786994|Placebo Comparator|4|Placebo (petroleum jelly) for three months twice a day (27 patients)
9764866|NCT00787020||Ventriculostomy Open|Subjects are treated with near continuous cerebrospinal fluid (CSF) diversion by positioning the stopcock in the open position and the intracranial pressure (ICP) is monitored once each hour: CSF drains into an external ventricular drainage bag.
9764867|NCT00787020||Ventriculostomy Monitored|Subjects are treated with intermittent cerebrospinal fluid (CSF) diversion. Intracranial pressure (ICP) is monitored and CSF is drained only when the ICP exceeds a threshold dictated by the attending physician.
9764868|NCT00787137|Experimental|PG102 0.3 mg/kg|Lowest dose PG102
9764869|NCT00787137|Experimental|PG102 1 mg/kg|Second dose PG102
9764870|NCT00787137|Placebo Comparator|Placebo (phosphate-buffered saline)|Control
9764871|NCT00787150|Experimental|Apixaban 5mg BID|
9764872|NCT00787150|Experimental|Apixaban 2.5mg BID|
9764873|NCT00787150|Active Comparator|Warfarin|
9764874|NCT00787189|Active Comparator|The Hearing Laser|Active low level laser light therapy of 635 nanometers (nm)
9764875|NCT00787189|Placebo Comparator|Placebo Laser|inactive low level laser light therapy with no therapeutic output
9764876|NCT00787202|Experimental|15 mg BID|
9764877|NCT00787202|Experimental|10 mg BID|
9764878|NCT00787202|Experimental|3 mg BID|
9764879|NCT00787202|Experimental|0.5 mg BID|
9764880|NCT00787202|Placebo Comparator|Placebo|
9764881|NCT00787241||Mild preeclampsia|Preeclampsia without eclampsia or HELLP syndrome
9764882|NCT00787241||Severe preeclampsia|Severe preeclampsia with eclampsia and/or HELLP syndrome
9764883|NCT00787241||Mild preeclampsia superimposed on chronic hypertension|Mild preeclampsia in association with chronic hypertension
9764884|NCT00787254|Experimental|Lansoprazole 15 mg QD|
9764885|NCT00787254|Active Comparator|Gefarnate 50 mg BID|
9764886|NCT00787267|Experimental|Dasatinib|"After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal.~For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined."
9764887|NCT00787319||AMD|
9764888|NCT00787332|Experimental|Desirudin|Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
9764889|NCT00787332|Active Comparator|Argatroban®|Patients randomized to IV Argatroban®
9764890|NCT00787527|Experimental|Zolinza + CHOP|Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
9764891|NCT00787566|Experimental|0.5 mg of TRG (intranasal granisetron)|0.5 mg dose, intranasal powder, single spray, administered once
9764892|NCT00787566|Experimental|1.0 mg of TRG (intranasal granisetron)|1.0 mg dose, intranasal powder, songle spray, administered once
9764893|NCT00787566|Experimental|2.0 mg of TRG (intranasal granisetron)|2.0 mg dose, intranasal powder, single spray, administered once
9764894|NCT00787605|Active Comparator|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
9764895|NCT00787605|Experimental|Aliskiren / HCTZ|Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
9764896|NCT00787644|Active Comparator|1|
9764897|NCT00787644|Placebo Comparator|2|
9785640|NCT01256411|Experimental|LCZ696|
9764898|NCT00787722|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
9783983|NCT01215253|Active Comparator|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
9783984|NCT01215253|Placebo Comparator|Placebo|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
9783985|NCT01215279|Experimental|AZD2423|AZD2423 Oral Treatment for 28 days
9783986|NCT01215279|Placebo Comparator|Placebo|Oral treatment for 28 days
9783987|NCT01215292|Placebo Comparator|Acyline & T Gel & Placebo Ketoconazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10
9783988|NCT01215292|Experimental|Acyline & T Gel & Ketoconazole 400|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10
9783989|NCT01215292|Experimental|Acyline & T gel & Ketoconazole 800|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10
9783990|NCT01215292|Experimental|Acyline & T gel & Dutasteride|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10
9783991|NCT01215292|Experimental|Group 5: anastrazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10
9783992|NCT01215318|Experimental|Modified vaginal tampons|Patients using modified vaginal tampons during FDG PET/CT
9783993|NCT01215318|Placebo Comparator|Unmodified vaginal tampons|Patients using unmodified vaginal tampons during FDG PET/CT
9783994|NCT01215344|Experimental|VRD|VELCADE, Lenalidomide, Dexamethasone
9783995|NCT01215344|Experimental|VDD|VELCADE, liposomal doxorubicin, dexamethasone
9783996|NCT01215357|Experimental|Ecopipam|Ecopipam is a selective antagonist of one the classes of dopamine receptor.
9783997|NCT01215422||children intubated with Glidescope|children intubated with Glidescope
9783998|NCT01215422||children intubated with DCI|children intubated with DCI
9783999|NCT01215435|Experimental|Pre-breakfast BIAsp 30|
10203299|NCT02719691|Experimental|Dose-Expansion of Alisertib and MLN0128|"Group 1:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Group 2:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Pancreatic Cancer Cohort:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
10203300|NCT02719184||Healthy volunteers|
10203301|NCT02719184||COPD GOLD I|Chronic obstructive pulmonary disease
9764899|NCT00787761|Experimental|ATG, Cytoxan, Bu/Flu based Allogeneic Transplant|All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
9764900|NCT00787787|Experimental|Treatment (sunitinib malate and capecitabine)|Patients receive sunitinib malate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence or disease progression or unacceptable toxicity.
10203302|NCT02719184||COPD GOLD II|Chronic obstructive pulmonary disease
10203303|NCT02719184||COPD GOLD III|Chronic obstructive pulmonary disease
10203304|NCT02719184||A1AT Deficiency|Alpha one anti-trypsin deficiency
10203305|NCT02675790|Active Comparator|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
9764901|NCT00787800|Active Comparator|Dual Chamber ICD|Dual chamber Implantable Cardioverter-Defibrillator (ICD): Atrial therapies and minimized ventricular pacing will be programmed on along with Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation.
9764902|NCT00787800|Active Comparator|Single Chamber ICD|Single chamber Implantable Cardioverter-Defibrillator: Optimally programmed Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies will be programmed on including use of detection enhancements.
9764903|NCT00787839||Group 1|Atlanta VA Medical Center patients who meet criteria for screening for prediabetes and early diabetes based on standard guidelines of the VA, the American Diabetes Association, and the National Institutes of Health
9764904|NCT00787852|Experimental|Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
9764905|NCT00787852|Experimental|Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
9764906|NCT00787891|Experimental|Rabeprazole 0.5 mg/kg|rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
9764907|NCT00787891|Experimental|Rabeprazole 1.0 mg/kg|rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
9764908|NCT00787904||Surgical Menopause|Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
9764909|NCT00787904||Surgical Control|Pre-menopausal women undergoing abdominal surgery but without ovary removal
9764910|NCT00787904||Healthy|Healthy matched pre-menopausal controls
9764911|NCT00787930||Manic Subject with DWM Hyperintensities >2|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid) who had a BOYKO DWM Hyperintensity rating >2 and a YMRS <15 at week 3.
9764912|NCT00787930||Manic Subjects with DWM Hyperintensities <3|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid)who had a BOYKO DWM Hyperintensity rating <3 and a YMRS <15 at week 3.
9764913|NCT00787943|Experimental|Left side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to left side of the face.
9764914|NCT00787943|Experimental|Right side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to right side of the face.
9764915|NCT00788008|Active Comparator|1|Inhalational anesthesia with isoflurane
9764916|NCT00788008|Active Comparator|2|total intravenous anesthesia with propofol
9764917|NCT00788073|Active Comparator|STX209|STX209 variable dose from 1mg bid to 10mg tid, capsule, oral, 4 weeks
9764918|NCT00788073|Placebo Comparator|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
9764919|NCT00788255||All participants|"For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows:~Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL~After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation."
9784000|NCT01215435|Experimental|Pre-dinner BIAsp 30|
9784001|NCT01215513|Experimental|Degarelix|
9785641|NCT01256424|Experimental|HAL 5% with illumination|HAL PDT 5%
9984238|NCT04293562|Experimental|Arm AD High Risk Group|Arm AD High Risk Group: See Detailed Description.
9764920|NCT00788372|Experimental|Fentanyl|Fentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
9764921|NCT00788593|Placebo Comparator|Placebo|
9764922|NCT00788593|Experimental|EUR-1008 (APT-1008) High Dose|
9764923|NCT00788593|Experimental|EUR-1008 (APT-1008) Low Dose|
9764924|NCT00788697|Other|Patients who received SonoVue|"Patients with at least 1 target lesion requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US): procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard"
9764925|NCT00788775|Experimental|Nilotinib|Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.
9764926|NCT00788827|Experimental|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
9764927|NCT00788892|Experimental|Arm A: CPX-351|First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3
9764928|NCT00788892|Active Comparator|Arm B: Cytarabine + Daunorubicin|First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice
9764929|NCT00788957|Experimental|Part 1: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
9764930|NCT00788957|Active Comparator|Part 2: Panitumumab Alone|Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
9764931|NCT00788957|Experimental|Part 2: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
9764932|NCT00788957|Experimental|Part 2: Panitumumab + Ganitumab|Participants received panitumumab 6 mg/kg and ganitumab 12 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
9764933|NCT00789074|Experimental|Varenicline pre-treatmemt|Participants will use varenicline (1mg BD) 4-weeks prior to quitting
9764934|NCT00789074|Placebo Comparator|Placebo|Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
9764935|NCT00789113|Experimental|Extended Release Lamotrigine|Extended Release Lamotrigine
9764936|NCT00789191|Experimental|Comb|Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
9764937|NCT00789191|Active Comparator|Sita|Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment
9764938|NCT00789256|Experimental|Study treatment|All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
9764939|NCT00789321|Experimental|1|amlodipine
9764940|NCT00789321|Placebo Comparator|2|Placebo to amlodipine
9764941|NCT00789360|Experimental|Inhaled Placebo crossed over to Inhaled Loxapine|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart; washout of at least 4 days; Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart
9764942|NCT00789360|Experimental|Inhaled Loxapine crossed over to Inhaled Placebo|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart; washout of at least 4 days; Inhaled Staccato Placebo, 2 inhalations, 8 hours apart;
9764943|NCT00789373|Experimental|pemetrexed + cisplatin followed by pemetrexed|pemetrexed plus cisplatin followed by pemetrexed plus best supportive care
9764944|NCT00789373|Placebo Comparator|pemetrexed + cisplatin followed by placebo|pemetrexed plus cisplatin followed by placebo plus best supportive care
9764945|NCT00789438||General Anesthesia|Patients undergoing short-term surgery (30-90 min) under general anesthesia
9764946|NCT00789438||Spinal|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia
9764947|NCT00789438||Spinal + Sedation|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia with sedation
9764948|NCT00789477|Experimental|Intravitreal Aflibercept Injection .5Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks
9764949|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks
9764950|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q8|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks
9764951|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2PRN|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria
9764952|NCT00789477|Active Comparator|Laser Photocoagulation|Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.
9764953|NCT00789529|Active Comparator|1|Opti-Free® RepleniSH® MPDS
9764954|NCT00789529|Active Comparator|2|Renu MultiPlus®
9764955|NCT00789555|Experimental|PATANASE|Olopatadine hydrochloride 0.6% nasal spray (PATANASE), two sprays in each nostril twice a day (morning and evening) for up to 12 months
9764956|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 3.7|Olopatadine nasal spray vehicle, pH 3.7, two sprays in each nostril twice a day (morning and evening) for up to 12 months
9764957|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 7.0|Olopatadine nasal spray vehicle, pH 7.0, two sprays in each nostril twice a day (morning and evening) for up to 12 months
9764958|NCT00789581|Experimental|Doxorubicin/cyclophosphamide, ixabepilone|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
9764959|NCT00789581|Active Comparator|Doxorubicin/cyclophosphamide, paclitaxel|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
9764960|NCT00789672|Active Comparator|Lower Dose (3-1) levodopa/carbidopa|Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
9764961|NCT00789672|Active Comparator|Higher Dose (4.5-1) levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
9764962|NCT00789685|Experimental|Interferon Beta|Interferon Beta
9764963|NCT00789698|Experimental|Lurasidone HC1|
9764964|NCT00789698|Active Comparator|Quetiapine|
9764965|NCT00789724|Experimental|Anakinra|Anakinra 100 mg given daily by subcutaneous injection for 14 days
9764966|NCT00789724|Placebo Comparator|Placebo|0.67 ml of NaCl 0.9% solution
9764967|NCT00789737|Experimental|Welchol|Welchol 625mg tablets
9764968|NCT00789737|Placebo Comparator|placebo|placebo
9764969|NCT00789750|Experimental|Colesevelam|Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
9764970|NCT00789750|Placebo Comparator|Placebo|Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
9764971|NCT00789776|Experimental|Treatment (non-myeloablative transplant)|"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.~DONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.~POST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 to 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 to 84, followed by a taper until day 180 in the absence of GVHD.~NK CELL INFUSION: Patients undergo donor lymphocyte infusion of NK cells on day 7."
9764972|NCT00789802|Experimental|transdermal estradiol|participants will be randomized to transdermal estradiol
9764973|NCT00789802|Experimental|oral naproxen|participants will be randomized to oral naproxen
9764974|NCT00789802|Placebo Comparator|oral placebo|participants will be randomized to oral placebo
9764975|NCT00789815|Active Comparator|BIS-guided propofol infusion|In the study group, induction was started using alfentanil 4~5μg/kg bolus following repeated propofol boluses (0.5~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
9764976|NCT00789815|Active Comparator|Clinical-judged midazolam administration|In the control group, induction was started using alfentanil 4~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved
9764977|NCT00789828|Experimental|Everolimus|Everolimus was administered orally at a starting dose of 4.5mg/m^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
9764978|NCT00789828|Placebo Comparator|Placebo|Matching Placebo administered orally.
9764979|NCT00789854|Active Comparator|Add-on Quetiapine XR+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline."
9764980|NCT00789854|Active Comparator|Add-on Lithium+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline."
9764981|NCT00789854|Active Comparator|Monotherapy Quetiapine XR|Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
9764982|NCT00789867|Experimental|20ml pGM169/GL67A|Received a nebulized dose 20ml via an breath-actuated nebulizer
9764983|NCT00789867|Experimental|10ml pGM169/GL67A|Received a nebulized dose 10ml via an breath-actuated nebulizer
9764984|NCT00789867|Experimental|5ml pGM169/GL67A|Received a nebulized dose 5ml via an breath-actuated nebulizer
9764985|NCT00789880|Experimental|Vitamin D3|Subjects received a 21-day course of oral vitamin D3 (cholecalciferol, 4,000 international units [IU]
9764986|NCT00789880|Placebo Comparator|Placebo|Subjects received a 21-day course of oral vitamin D3-placebo
9764987|NCT00789958|Experimental|Adjuvant Chemo+ Chemoradiotherapy|"Adjuvant Chemotherapy~Capecitabine, 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Gemcitabine hydrochloride, 1000 mg/m^2, IV, Days 1 & 8 of each cycle~Chemoradiotherapy~-Capecitabine, 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT~Radiation (RT):~3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.~intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions."
9764988|NCT00789997|Experimental|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later prednisone placebo po daily for 10 days Levofloxacin 750 mg po daily for 10 days.
9764989|NCT00789997|Active Comparator|Prednisone|prednisone 40 mg daily for 10 days etanercept placebo subcutaneous given on the day of randomization and one week later Levofloxacin 750 mg daily for 10 days.
9764990|NCT00790023|Experimental|80 mcg Ciclesonide|80 mcg Ciclesonide once daily
9764991|NCT00790023|Experimental|160 mcg Ciclesonide|160 mcg Ciclesonide once daily
9764992|NCT00790023|Placebo Comparator|Placebo|Placebo once daily
9764993|NCT00790036|Experimental|Everolimus|Participants who received Everolimus 10 mg (two 5 mg tablets), daily for 12 months
9764994|NCT00790036|Placebo Comparator|Placebo|Participants who received Everolimus placebo 10 mg (two 5 mg tablets), daily for 12 months
9764995|NCT00790062|Active Comparator|Oxytocin 10 units/500cc|1 dose only for prophylaxis given over 1 hour
9764996|NCT00790062|Experimental|Oxytocin 40 units/500cc|One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
9764997|NCT00790062|Experimental|Oxytocin 80U/500cc|1 dose only given over 1 hour
9764998|NCT00790192|Experimental|Lurasidone 80mg|
9764999|NCT00790192|Experimental|Lurasidone 160mg|
9765000|NCT00790192|Active Comparator|Quetiapine XR|
9765001|NCT00790192|Placebo Comparator|Placebo|
9765002|NCT00790205|Experimental|Sitagliptin|Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
9765003|NCT00790205|Placebo Comparator|Placebo|Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
9765004|NCT00790218|Experimental|CF102|An open-label trial (1, 5, and 25 mg BID) in 28-day cycles.
9765005|NCT00790270|Active Comparator|Cyclobenzaprine|
9765006|NCT00790270|Active Comparator|Ibuprofen|
9765007|NCT00790270|Experimental|Ibuprophen plus Cyclobenzaprine|
9765008|NCT00790296|Experimental|Thyrotropin releasing hormone (TRH)|TRH
9765009|NCT00790296|Placebo Comparator|Saline|Placebo
9765010|NCT00790335|Experimental|A-Intervention|PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
9765011|NCT00790335|No Intervention|B-Control|Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
9765012|NCT00790400|Experimental|Everolimus|Study drug was given by continuous oral daily dosing of two 5 mg tablets.
9765013|NCT00790400|Placebo Comparator|Placebo|Placebo was given by continuous oral daily dosing of two 5 mg tablets.
9765014|NCT00790556|Experimental|1|MK8245
9765015|NCT00790556|Placebo Comparator|2|Placebo Comparator
9765016|NCT00790569|Experimental|Arm I|Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
9765017|NCT00790569|Placebo Comparator|Arm II|Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
9784002|NCT01215643|Experimental|ALV 1000 mg|Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
9785642|NCT01256424|Experimental|HAL 1% with illumination|HAL PDT 1%
9765018|NCT00790569|Active Comparator|Arm III|Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
9765019|NCT00790582|Experimental|lithium carbonate|
9765020|NCT00790647|Experimental|Stem Cell Transplant with Bortezomib and Melphalan|Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
9765021|NCT00790673|Experimental|1|CF102 1 mg qd
9765022|NCT00790673|Experimental|2|CF102 1 mg bid
9765023|NCT00790673|Experimental|3|CF102 1 mg bid; 16 weeks
9765024|NCT00790673|Placebo Comparator|5|
9765025|NCT00790699|Active Comparator|I-PORT|Treatment group
9765026|NCT00790699|Active Comparator|standard injections|control group
9765027|NCT00790738|Experimental|1|liothyronine (T3)
9765028|NCT00790738|Placebo Comparator|2|placebo
9765029|NCT00790751|Placebo Comparator|placebo|
9765030|NCT00790751|Experimental|avanafil 50 mg|
9765031|NCT00790751|Experimental|avanafil 100 mg|
9765032|NCT00790751|Experimental|avanafil 200 mg|
9765033|NCT00790790|Placebo Comparator|Placebo|Participants randomized to LY545694 placebo were given LY545694 placebo twice daily (BID) oral (po) for 5 weeks.
9765034|NCT00790790|Experimental|LY545694 49 mg|Participants randomized to LY545694 49 milligrams (mg) BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. Participants who were intolerant of this dose were titrated back down to 21 mg BID po for the remainder of study treatment.
9765035|NCT00790790|Experimental|LY545694 105 mg|Participants randomized to LY545694 105 mg BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. At Visit 5, participants were titrated to the final dose of LY545694 105 mg BID po. Participants who were intolerant of this dose were titrated back down to LY545694 49 mg BID po for the remainder of study treatment.
9765036|NCT00790842|Experimental|Group A - CrCl 30-60 mL/min|Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
9765037|NCT00790842|Experimental|Group B, CrCl < 30 mL/min|Creatinine clearance < 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
9765038|NCT00790842|Experimental|Group C, CrCl < 30 mL/min, on dialysis|Creatinine clearance < 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
9765039|NCT00790855|Experimental|Bendamustine|Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.
9765040|NCT00790868|Experimental|D-cycloserine|DCS-augmented CBT
9765041|NCT00790868|Placebo Comparator|Placebo|placebo-augmented CBT
9765042|NCT00790907|Experimental|Open label fondaparinux background and standard dose UFH|Subjects indicated for PCI and randomized to receive standard dose UFH
9765043|NCT00790907|Experimental|Open label fondaparinux background and low dose UFH|Subjects indicated for PCI and randomized to receive low dose UFH
9765044|NCT00790907|Other|Open label fondapaparinux|Subjects not indicated for PCI and not randomized
9765045|NCT00790933|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, 30-minute intravenous (IV) infusion every 4 weeks, starting at Week 0 for approximately up to 510 weeks.
10203306|NCT02675790|Active Comparator|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
10203307|NCT02675491|Experimental|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
10203308|NCT02674516|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
10203309|NCT02674516|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
9765046|NCT00791037|Experimental|Treatment (vaccine therapy)|"Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.~Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals."
9765047|NCT00791089|Experimental|Fish Oil, Ablation, Sinus Rhythm|Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
9765048|NCT00791089|Placebo Comparator|placebo, Ablation, sinus rhythm|Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
9765049|NCT00791102|Active Comparator|1|Topical ASP-1001
9765050|NCT00791102|Placebo Comparator|2|Placebo for Topical ASP-1001
9765051|NCT00791128|Experimental|EndoBarrier GI Liner|22 patients were implanted with the GI Liner for a 52-week duration. Assessments were performed during the 6 months post-explant period.
9765052|NCT00791219|Experimental|Test|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
9785643|NCT01256424|Experimental|HAL 0.2% with illumination|HAL PDT 0.2%
10203310|NCT02671435|Experimental|Part 1 -Dose escalation with 5 dose escalation cohorts|Durvalumab and monalizumab
9765053|NCT00791219|Active Comparator|Reference|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
9765054|NCT00791219|Placebo Comparator|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
9765055|NCT00791258|Experimental|1|Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks
9765056|NCT00791323|Active Comparator|1|Ketorolac 0.4%
9765057|NCT00791323|Active Comparator|2|Mineral Oil Emollient
9765058|NCT00791388|Placebo Comparator|placebo|placebo capsule
9765059|NCT00791388|Experimental|50 mg PG 760564|50 mg PG 760564 active
9765060|NCT00791388|Experimental|100 mg PG 760564|100 mg PG 760564 active
9765061|NCT00791388|Experimental|200 mg PG 760564|200 mg PG 760564 active
9765062|NCT00791388|Experimental|400 mg PG 760564|400 mg PG 760564 active
9765063|NCT00791479|Experimental|0.1 milligram (mg) LY2189265|LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
9765064|NCT00791479|Experimental|0.5 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
9765065|NCT00791479|Experimental|1.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
9765066|NCT00791479|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
9765067|NCT00791479|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) once weekly (QW)
9765068|NCT00791492|Experimental|Fx-1006A|
9765069|NCT00791518||No group|No group
9765070|NCT00791557|Experimental|Infliximab|Single arm open label IV Infliximab given at weeks 1,2,14,22
9765071|NCT00791648|Experimental|statin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
9765072|NCT00791648|Placebo Comparator|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
9765073|NCT00791661|Experimental|Panel A: MK-1006 15/30/45|Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
9765074|NCT00791661|Experimental|Panel B: MK-1006 60/80/60 fed|Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
9765075|NCT00791661|Experimental|Panel C: MK-1006 100/140/170|Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
9765076|NCT00791700|Experimental|Maraviroc|"Subjects will be stratified by age and formulation into one of the following cohorts:~Cohort 1: ≥2-<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-<18 years of age, maraviroc tablet formulation."
9765077|NCT00791765|Experimental|Placebo BIW/Etanercept 50 mg BIW|Participants received placebo subcutaneous injections twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg BIW.
9765078|NCT00791765|Experimental|Etanercept 50 mg BIW/Etanercept 50 mg QW|Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
9765079|NCT00791778|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)
9765080|NCT00791778|Placebo Comparator|Placebo|Participants received 2 matching placebo tablets per oral twice daily
9765081|NCT00791817|Experimental|200 mg PG 760564, Subjects Fasted|200 mg PG 760564, Subjects Fasted, single dose
9765082|NCT00791817|Experimental|200 mg PG 760564, Subjects Fed|200 mg PG 760564, Subjects Fed high fat meal
9765083|NCT00791908|Experimental|electrodessication (ED)|Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
9765084|NCT00791908|Experimental|pulsed dye laser (PDL)|Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
9765085|NCT00791908|Experimental|potassium titanyl phosphate (KTP) laser|Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
9765086|NCT00791921|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
9765087|NCT00791921|Placebo Comparator|Placebo|Placebo of CDP870
9765088|NCT00791934|Experimental|Stratus Microflow Ethmoid Spacer|Temporary implantation of Ethmoid spacer with Triamcinolone Acetonide for 28 days.
9765089|NCT00791973|Active Comparator|Veramyst, then Placebo|fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
9765090|NCT00791973|Active Comparator|Placebo, then Veramyst|placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
9765091|NCT00791999|Experimental|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks
9765092|NCT00791999|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks
9765093|NCT00791999|Experimental|CDP870 400mg|400mg CDP870 given every 2 weeks
9765094|NCT00791999|Placebo Comparator|Placebo|Placebo given every 2 weeks
9765095|NCT00792077|Experimental|Sleep time|"Assessment of patients with chronic lymphocytic leukemia (CLL) experience severe cancer related fatigue (CRF):~Lenalidomide + Actigraph + Questionnaire + Sleep Test"
9765096|NCT00792103|Experimental|NP101|sumatriptan iontophoretic transdermal patch
9765097|NCT00792142|Experimental|Treatment (stem cell transplant, maintenance treatment)|Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
9765098|NCT00792298|Experimental|Suvorexant 10 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 10 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
9765099|NCT00792298|Experimental|Placebo → Suvorexant 10 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 10 mg suvorexant daily prior to bedtime during Treatment Period 2.
9765100|NCT00792298|Experimental|Suvorexant 20 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 20 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
9765101|NCT00792298|Experimental|Placebo → Suvorexant 20 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 20 mg suvorexant daily prior to bedtime during Treatment Period 2.
9765102|NCT00792298|Experimental|Suvorexant 40 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 40 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
9765103|NCT00792298|Experimental|Placebo → Suvorexant 40 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 40 mg suvorexant daily prior to bedtime during Treatment Period 2.
9765104|NCT00792298|Experimental|Suvorexant 80 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 80 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
9765105|NCT00792298|Experimental|Placebo → Suvorexant 80 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 80 mg suvorexant daily prior to bedtime during Treatment Period 2.
9765106|NCT00792428|Active Comparator|Real-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with real transcranial direct current stimulation (tDCS) over the motor region for up to 30 min.
9765107|NCT00792428|Sham Comparator|Sham-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with sham (pretend) tDCS for up to 30 min. over the motor region.
9784003|NCT01215643|Experimental|ALV 600 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
9784004|NCT01215643|Experimental|ALV 800 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
9784005|NCT01215643|Experimental|ALV 600 mg+PEG|Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
9784006|NCT01215643|Active Comparator|PEG+RBV|Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.
9784007|NCT01215695|Active Comparator|Control|Patients will be randomly assigned to having their ETT placed with use of a pre-formed stylet provided by the manufacturer of the GVL (control group)
9833556|NCT02659501|Active Comparator|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
9833557|NCT02659501|Experimental|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
9833558|NCT02659540|Experimental|Cohort A (Conventional RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a conventional total palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
9833559|NCT02659540|Experimental|Cohort B (Hypofractionated RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a hypofractionated high-dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
9833560|NCT02659631|Experimental|PF-06671008|
9833561|NCT02659709||Glaucoma Patients and Caregivers|Glaucoma patients and caregivers will complete a 20 item questionnaire providing demographic information, glaucoma eye drop compliance, interest in medication reminders, availability to smartphone, tablet and social media technology and interest in using a glaucoma application on social media.
9984239|NCT04293562|Experimental|Arm AD Low Risk Group 2|Arm AD Low Risk Group 2: See Detailed Description.
9784008|NCT01215695|Experimental|Intervention|Patients will be randomly assigned to either having their ETT placed with use of flexible, disposable tracheoscope (aScope, Ambu, Denmark) (intervention group).
9784009|NCT01215721|Experimental|Vesicare|Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
9784010|NCT01215734|Active Comparator|High-Dose Trivalent Inactivated Influenza Vaccine|Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine
9784011|NCT01215734|Active Comparator|Standard dose Trivalent Inactivated Flu Vaccine|Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.
9784012|NCT01215786|Other|AGN-207281 ophthalmic solution|AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
9784013|NCT01215786|Active Comparator|Timolol ophthalmic solution 0.5%|timolol ophthalmic solution 0.5%
9784014|NCT01215786|Placebo Comparator|Placebo|AGN-207281 vehicle ophthalmic solution (Placebo)
9784015|NCT01215851|Experimental|TMC207|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide placebo administered once daily
9784016|NCT01215851|Experimental|TMC207 and pyrazinamide|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day
9784017|NCT01215851|Experimental|PA-824 and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin placebo (matched to moxifloxacin tablets) administered once daily
9784018|NCT01215851|Experimental|PA-824 and moxifloxacin and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin administered once daily as 400mg tablets
9784019|NCT01215851|Active Comparator|Rifafour e-275 mg|Rifafour e-275 administered once daily with each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol and dose by weight as follows: 30kg-37kg received 2 tablets/day; 38kg-54kg received 3 tablets/days; 55kg-70kg received 4 tablets/day; > or = 71kg received 5 tablets/day
9765108|NCT00792467|Experimental|ITF2357|"Patients received the following therapy cycle~ITF2357, 50 mg every 6 hours, per os, days 1 - 3;~Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy was administered every 21 days as long as there was no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles.~The mean number of complete treatment cycles received by patients was 5.25, with a minimum of 1 cycle and a maximum of 12 cycles."
9765109|NCT00792571|Experimental|B.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, b.i.d (twice a day dosing)
9765110|NCT00792571|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, q.i.d (four times a day dosing)
9765111|NCT00792610|Experimental|Hepatitis B booster|They receive 3 doses of hepatitis B vaccine (Engerix-B Injection, recombinant HBsAg, 20mcg/ml/vial, GSK) at 0, 1st, 6th month during follow-up. Their anti-HBs status were checked at baseline, one week, one month, sixth month, and seven months later after the first dose of hepatitis B vaccine.
9765112|NCT00792623|Experimental|Varilrix Group|Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation.
9765113|NCT00792636|Experimental|sumatriptan and naproxen sodium combination|
9765114|NCT00792636|Active Comparator|sumatriptan|
9765115|NCT00792636|Active Comparator|naproxen sodium|
9765116|NCT00792688|Experimental|1|GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
9765117|NCT00792688|Experimental|2|GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
9765118|NCT00792688|Experimental|3|GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
9765119|NCT00792701|Experimental|Arm II|Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9765120|NCT00792805|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9765121|NCT00792805|Experimental|Indacaterol 300 μg|Patients inhaled indacaterol 300 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9765122|NCT00792805|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9765123|NCT00792909|Experimental|Synflorix™ Group 1|Subjects previously vaccinated with the Synflorix™ vaccine according to a 2+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
9765124|NCT00792909|Experimental|Synflorix™ Group 2|Subjects previously vaccinated with the Synflorix™ vaccine according to a 3+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
9765125|NCT00792909|Active Comparator|Unprimed Group|Age-matched subjects not previously vaccinated with any pneumococcal vaccine receiving two doses of Synflorix™ at 36-46 and 38-48 months of age. Age-matching was ensured by the enrolment of subjects 36-46 months of age.
9765126|NCT00792922|Active Comparator|≥90% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
9765127|NCT00792922|Active Comparator|80%-89% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
9765128|NCT00792922|Active Comparator|≥90% coverage with azithromycin , treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
9784020|NCT01215851|Experimental|TMC207 and PA-824|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus PA-824 administered once daily as 200mg tablets
9765129|NCT00792922|Active Comparator|80%-89% coverage with azithromycin : treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
9765130|NCT00792935|Experimental|MK-0941|
9765131|NCT00792935|Active Comparator|Glimepiride|
9765132|NCT00793104|Other|CR Plug|Placement of allograft CR Plug in primary injury site
9765133|NCT00793182|Active Comparator|1|Ioversol 320 mgI/mL
9765134|NCT00793182|Active Comparator|2|Iodixanol 320 mgI/mL
9765135|NCT00793325||Somatropin|Patients administered Somatropin.
9765136|NCT00793403||1|As per routine clinical care
9765137|NCT00793455|Experimental|Intervention Group|Received Educational Outreach
9765138|NCT00793455|No Intervention|Usual Care Control Group|Participants in this arm will receive normal care until outcome assessment is performed at 6 months following the placement of the order for the preventive service. They will be sent a letter reminding them to obtain the ordered preventive service test.
9765139|NCT00793546|Experimental|1|combination of bosutinib and exemestane
9765140|NCT00793546|Active Comparator|2|exemestane
9765141|NCT00793572|Experimental|Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy|See Detailed Description
9765142|NCT00793585|Experimental|Allopurinol|Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
9765143|NCT00793585|Other|Control group|Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
9765144|NCT00793598|Experimental|Brincidofovir|"Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows:~20 mg BCV once weekly (QW) on Days 0, 7, and 14; or~10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28."
9765145|NCT00793598|Placebo Comparator|Placebo|"Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28."
9765146|NCT00793611|Active Comparator|Behavioral therapy|"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)"
9765147|NCT00793611|Experimental|hypnotherapy|patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder
9765148|NCT00793624|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
9765149|NCT00793624|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
9765150|NCT00793624|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
9765151|NCT00793624|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
9765152|NCT00793650|Active Comparator|Bortezomib before Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours before melphalan.
9765153|NCT00793650|Active Comparator|Bortezomib after Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours after melphalan.
9765154|NCT00793780|Active Comparator|Naltrexone 25mg|
9765155|NCT00793780|Placebo Comparator|Placebo|
9765156|NCT00793793|Experimental|20mg|patient to receive 20mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
9765157|NCT00793793|Experimental|48mg|patient to receive 48mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
9765158|NCT00793793|Experimental|120mg|patient to receive 120mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
9765159|NCT00793793|Experimental|240mg|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
9765160|NCT00793793|Placebo Comparator|Placebo|
9765161|NCT00793819|Experimental|1 Silodosin|
9765162|NCT00793819|Placebo Comparator|2 Placebo|
9765163|NCT00793871|Experimental|sunitinib|single agent sunitinib, single arm
9765164|NCT00793910|Active Comparator|Gabapentin|oral medication
9765165|NCT00793910|Placebo Comparator|placebo|
9765166|NCT00794040|Active Comparator|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
9765167|NCT00794040|Placebo Comparator|Add-on placebo after optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
9765168|NCT00794118||1.0|As per routinary clinical practice
9765169|NCT00794144|Experimental|1|Olopatadine Hydrochloride Nasal Spray 0.6%
9765170|NCT00794144|Placebo Comparator|2|Olopatadine Hydrochloride Nasal Spray Vehicle
9765171|NCT00794157|Experimental|Indacaterol 150 µg|Patients received indacaterol 150 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9765172|NCT00794157|Experimental|Indacaterol 300 µg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9765173|NCT00794157|Placebo Comparator|Placebo|Patients received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9765174|NCT00794170|Experimental|Telephone and print based intervention|The I-SIGHT intervention consists of twelve interactive voice recognition (IVR) phone calls over a nine-month period and accompanying printed materials that are mailed to participants following each call. The phone call messages and print materials are tailored to individuals' circumstances using data from the screening and baseline interviews. The intervention is based on theoretical constructs from Social Cognitive Theory and the Health Belief Model, and emphasizes self-efficacy, medication taking skills, outcome expectancies, facilitators and barriers to compliance, and social support. The treatment group receives the tailored telephone intervention and mailed, printed materials.
9765175|NCT00794170|No Intervention|Usual care|The control group received usual care at each clinical site and interacted with study personnel only for data collection.
9765176|NCT00794196|No Intervention|Usual Care|The control group will be receiving usual medical and pharmaceutical care.
9765177|NCT00794196|Experimental|Intervention Group|Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
9765178|NCT00794313|Experimental|Amantadine|
9765179|NCT00794313|Experimental|Amantadine plus Topiramate|
9765180|NCT00794313|Placebo Comparator|Sugar Pill|
9765181|NCT00794339|Experimental|Copper ATSM|pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT
9765182|NCT00794365||Open-label|
9765183|NCT00794417|Experimental|Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
9784021|NCT01215916|Experimental|Experimental: Pemetrexed followed by LY573636|Pemetrexed on Day 1 followed by LY573636 on Day 4
9784022|NCT01215916|Experimental|Experimental: LY573636 followed by Pemetrexed|LY573636 on Day 1, pemetrexed on Day 4
9765184|NCT00794417|Experimental|Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m^2) and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
9765185|NCT00794417|Experimental|Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
9765186|NCT00794417|Experimental|Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.
9765187|NCT00794469||Water|obese children (body mass index > 95th percentile for age and sex) that will drink cold water
9765188|NCT00794508|Experimental|Retroviral-mediated ADA gene transfer|Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.
9765189|NCT00794547|Experimental|1|In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.
9765190|NCT00794547|Experimental|2|In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.
9765191|NCT00794560|Experimental|clinical setting: intervention|"Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital.~Intervention: patient education"
9765192|NCT00794560|No Intervention|clinical setting: standard care|Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
9765193|NCT00794560|Experimental|daily life setting: intervention|"Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists.~Intervention: patient education"
9765194|NCT00794560|No Intervention|daily life setting: standard care|Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
9765195|NCT00794573|Experimental|Varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
9765196|NCT00794573|Placebo Comparator|Sugar pill|placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
9765197|NCT00794664|Placebo Comparator|Placebo|Weekly subcutaneous injections for 26 weeks
9765198|NCT00794664|Experimental|Mipomersen|200 mg weekly subcutaneous injections for 26 weeks
9765199|NCT00794820|Experimental|FCR-Multiple Dose Rituximab|Fludarabine phosphate + Cyclophosphamide + Rituximab
9765200|NCT00794950|Experimental|Sunitinib treatment|Intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma.
9765201|NCT00794963|Experimental|Integrated care|Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
9765202|NCT00794963|Other|Usual Care|Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community
9765203|NCT00795002|Experimental|Arm I|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
9765204|NCT00795002|Experimental|Arm II|Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.
9765205|NCT00795132|Active Comparator|Related BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
9765206|NCT00795132|Active Comparator|Unrelated BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
9765207|NCT00795132|Active Comparator|Unrelated Blood Cord|Blood Cord donated from a donor unrelated to the participant/recipient
9765208|NCT00795145|Placebo Comparator|Cohort 1: Placebo|
9765209|NCT00795145|Experimental|Cohort 1: 900 mg linezolid|
9765210|NCT00795145|Experimental|Cohort 1: 1200 mg linezolid|
9765211|NCT00795145|Placebo Comparator|Cohort 2: Placebo|
9765212|NCT00795145|Experimental|Cohort 2: 600 mg linezolid|
9765213|NCT00795145|Experimental|Cohort 2: 1200 mg linezolid|
9765214|NCT00795145|Active Comparator|Cohort 2: 400 mg Moxifloxacin|
9765215|NCT00795184|Other|Imaging Procedures HDWLE first NBI second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
9765216|NCT00795184|Other|Imaging Procedures NBI first HDWLE second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
9765217|NCT00795210|Experimental|GH 6mcg/kg/d|Recombinant human growth hormone 6mcg/kg SC once daily
9765218|NCT00795210|Experimental|GH 2mg daily|Recombinant human growth hormone 2mg SC once daily
9765219|NCT00795210|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
9765220|NCT00795275|Experimental|Impaired Fasting Glucose|Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)
9765221|NCT00795275|Experimental|Normal glucose tolerance|Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)
9765222|NCT00795288|Experimental|Simvastatin, 80 mg/day|Simvastatin, 80 mg/day for 21 days
9765223|NCT00795288|Placebo Comparator|Placebo|Placebo
9765224|NCT00795340|Experimental|Arm I Cediranib|Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
9765225|NCT00795340|Placebo Comparator|Arm II Placebo|Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
9765226|NCT00795366|Active Comparator|AVP, arginine vasopressin|Vasopressin
9765227|NCT00795366|Active Comparator|Standard Catecholamine|levophed, dopamine, phenylephrine)
9765228|NCT00795509||Tolterodine tartrate.|Patients taking Tolterodine tartrate.
9765229|NCT00795600|Experimental|insulin detemir|Insulin detemir injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
9765230|NCT00795600|Active Comparator|insulin NPH|Insulin isophane (Neutral Protamine Hagedorn, NPH) injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
9765231|NCT00795639|Experimental|Sitaxsentan|Monotherapy
9765232|NCT00795639|Placebo Comparator|Sitaxsentan Placebo|Monotherapy
9765233|NCT00795704|Placebo Comparator|Placebo|Control Group
9765234|NCT00795704|Active Comparator|Mulberry Leaf Extract|
9765235|NCT00795717|Active Comparator|Lovaza|Lovaza, dietary counseling
9765236|NCT00795717|Placebo Comparator|Placebo|Placebo, dietary counseling
9765237|NCT00795769|Experimental|Ondansetron therapy|Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
9765238|NCT00795821|Experimental|LY2216684|"10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.~1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
9765239|NCT00795821|Placebo Comparator|Placebo|"10-week Acute Treatment Phase: 3 tablets QD for 10 weeks~1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
9765240|NCT00795886|Experimental|All participants|
9765241|NCT00795951|Experimental|TRUE Test panels 1.1, 2.1, 3.1|All subjects were patched with 3 T.R.U.E. Test panels containing 28 allergens and 1 negative control.
9765242|NCT00796003|Experimental|Phase I: JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
9765243|NCT00796003|Experimental|Phase I: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
9765244|NCT00796003|Experimental|Phase II: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles
9765245|NCT00796120|Experimental|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
9784023|NCT01215916|Experimental|Experimental: LY573636 and Pemetrexed on Day 1|LY573636 and Pemetrexed on Day 1
9765246|NCT00796120|Active Comparator|Doxorubicin plus Ifosfamide|Doxorubicin (as a monotherapy) 75 mg per m^2 will be given intravenously every 3 weeks or Doxorubicin 60 mg per m^2 will be given intravenously every 3 weeks followed by ifosfamide 6 to 9 gram (g)/m^2 every 3 weeks until disease progression.
9765247|NCT00796224|Active Comparator|1.|60 mg/kg azithromycin ER (Extended Release)arm
9765248|NCT00796224|Active Comparator|2.|30 mg/kg azithromycin IR (Immediate Release) arm
9765249|NCT00796302|Experimental|1|Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
9765250|NCT00796302|Active Comparator|2|Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.
9765251|NCT00796315|Experimental|Doxylamine Succinate (USP)|Doxylamine Succinate United States Pharmacopeia (USP)
9765252|NCT00796328|Experimental|1|
9765253|NCT00796367|Placebo Comparator|Placebo|Placebo
9765254|NCT00796367|Experimental|VI-0521 Mid|7.5 mg phentermine and 46 mg topiramate
9765255|NCT00796367|Experimental|VI-0521 Top|15 mg phentermine and 92 mg topiramate
9765256|NCT00796419|Experimental|1|Intravenous 5% human albumin
9765257|NCT00796419|Experimental|2|Intravenous 6% hetastarch
9765258|NCT00796445|Experimental|MAGE-A3 Group|Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of ASCI product at 3-week intervals, followed by 8 doses of ASCI product at 12-week intervals.
9765259|NCT00796445|Placebo Comparator|Placebo Group|Patients who received up to 13 doses of placebo. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of placebo at 3-week intervals, followed by 8 doses of placebo at 12-week intervals.
9765260|NCT00796549|Experimental|BIBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
9765261|NCT00796562|Experimental|Myeloablative haploidentical BMT|"All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.~Participants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days."
9765262|NCT00796614|Placebo Comparator|Placebo|Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks
9765263|NCT00796614|Experimental|Low dose|Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
9765264|NCT00796614|Experimental|Medium dose|Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
9765265|NCT00796614|Experimental|High dose|Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
9765266|NCT00796627|Sham Comparator|Healthy volunteers|"Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating bone marrow stem cells will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study."
9765267|NCT00796627|Active Comparator|Burn volunteer|To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP > 100 mm Hg systolic; heart rate < 100 beats/minute; urine output > 30 ml/hour; area of burn < 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin > 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension > 1 year; smoking > 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men < 55 and women < 65 years of age).Six 12 ml tubes will be taken at 5 time points
9765268|NCT00796653|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
9765269|NCT00796653|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
9765270|NCT00796653|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
9765271|NCT00796653|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
9765272|NCT00796666|Experimental|Sitaxsentan and Placebo|Monotherapy arm
9765273|NCT00796666|Experimental|Sitaxsentan and Sildenafil|Combination treatment
9765274|NCT00796705|Experimental|Adalimumab / Adalimumab Placebo|1 sub-cutaneous (SQ) injection of adalimumab or 1 SQ injection of placebo will be given in a blinded and alternating fashion for a total of 12 weeks
9765275|NCT00796705|Experimental|Etanercept|Participants will receive 1 SQ injection of etanercept each week for 12 weeks
9765276|NCT00796718|Experimental|Capecitabine|Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.
9765277|NCT00796744|Placebo Comparator|Placebo Vehicle Control|control placebo vehicle gel
9765278|NCT00796744|Active Comparator|0.03% DSC127|0.03 % DSC127 in Vehicle Control
9765279|NCT00796744|Active Comparator|0.01% DSC127|0.01% DSC127 in Vehicle Control
10203311|NCT02671435|Experimental|Part 2 - Dose expansion with 4 dose expansion cohorts|Durvalumab with monalizumab
10203312|NCT02671435|Experimental|Part 3 -Dose Exploration with 10 dose exploration cohorts.|Durvalumab and monalizumab and standard of standard of care systemic therapy with or without a biologic agent and monalizumab in combination with biologic agent in CRC.
10203313|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
10203314|NCT02661022|Experimental|SL-401/Pomalidomide/ Dexamethasone|SL-401 in combination with Pomalidomide and Dexamethasone
10203315|NCT02655016|Experimental|Participants receiving Niraparib|
10203316|NCT02655016|Placebo Comparator|Participants receiving Placebo|
10203317|NCT02654028|Experimental|Autotransfusion group|These group of patients will receive autotransfusion before liver resection.
10203318|NCT02654028|Active Comparator|Control group|These group of patients will not receive autotransfusion before or after liver resection.
10203319|NCT02652195|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
10203320|NCT02652195|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
10203321|NCT02650271|Experimental|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
10203322|NCT02650271|Active Comparator|Tenofovir|Patients will be received tenofovir (1#/d) after 3 days of liver resection.
10203323|NCT02649855|Experimental|A/Sequential docetaxel followed by PROSTVAC|Standard ADT followed by sequential docetaxel + prostvac
10203324|NCT02649855|Experimental|B/ Combined docetaxel with PROSTVAC|Standard ADT followed by combined docetaxel + prostvac
10203325|NCT02649855|Experimental|C/ PROSTVAC prior to docetaxel|Standard ADT followed by prostvac, then docetaxel
9765280|NCT00796757|Experimental|1|
9765281|NCT00796822|Experimental|1|Participants will receive pentoxifylline.
9765282|NCT00796822|Placebo Comparator|2|Participants will receive placebo.
9765283|NCT00796926|Experimental|Systane Ultra|Used four times a day topically to each eye
9765284|NCT00796926|Active Comparator|Refresh|Used four times a day topically to each eye
9765285|NCT00796978|Experimental|trastuzumab|
9765286|NCT00796991|Active Comparator|Arm A|
9765287|NCT00796991|Active Comparator|Arm B|
9765288|NCT00796991|Active Comparator|Arm C|
9765289|NCT00797108|Experimental|1|Loading dose of IV sulopenem with switch to oral PF-03709270
9765290|NCT00797108|Experimental|2|IV sulopenem with switch to oral PF-03709270
9765291|NCT00797108|Active Comparator|3|IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator
9765292|NCT00797212|Other|Subjects with diabetes|Subjects with diabetes use a new Apollo Blood Glucose Monitoring System with blood obtained from the palm and forearm
9765293|NCT00797225|Placebo Comparator|Placebo|Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
9765294|NCT00797225|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
9765295|NCT00797225|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
9765296|NCT00797225|Other|Leuprorelin|Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
9765297|NCT00797277|Experimental|IM olanzapine|Patients of this arm received 10 mg IM olanzapine after randomization
9765298|NCT00797277|Active Comparator|IM haloperidol plus lorazepam|Patients of this arm received 5 mg IM haloperidol plus 2 mg IM lorazepam after randomization
9765299|NCT00797316|Experimental|Aliskiren plus Hydrochlorothiazide|Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
9765300|NCT00797316|Active Comparator|Aliskiren|Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
9765301|NCT00797459|Experimental|Restylane and Restylane with Lidocaine|This is a split-face design injecting both Restylane and Restylane-L injectable gels, administered once. Each subject received Restylane on one side of the face, and Restylane-L on the other. Subjects were blinded to which side of their face received Restylane or Restylane-L. The study was randomized and treatments successive.
9765302|NCT00797511|Experimental|Study Group|Participants will receive one dose of Tetanus, diphtheria (reduced antigen content), pertussis (acellular components) vaccine (TdcP-IPV, ADACEL Polio) on Day 0
9765303|NCT00797563|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system (BGMS) Apollo Blood Glucose Monitoring System with capillary blood; healthcare professionals use the new BGMS with subject capillary and venous blood.
9765304|NCT00797667|Experimental|Telcagepant 140 mg|Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
9765305|NCT00797667|Experimental|Telcagepant 280 mg|Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks
9765306|NCT00797667|Placebo Comparator|Placebo|Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
9784024|NCT01215929|Active Comparator|Dextroamphetamine|
9984240|NCT04293562|Experimental|Arm B High Risk Group|Arm B High Risk Group: See Detailed Description.
9984241|NCT04293562|Experimental|Arm B Low Risk Group 1|Arm B Low Risk Group 1: See Detailed Description.
9984242|NCT04293562|Experimental|Arm B Low Risk Group 2|Arm B Low Risk Group 2: See Detailed Description.
9984243|NCT04293562|Experimental|Arm BC High Risk Group|Arm BC High Risk Group: See Detailed Description.
9984244|NCT04293562|Experimental|Arm BC Low Risk Group 2|Arm BC Low Risk Group 2: See Detailed Description.
9984245|NCT04293562|Experimental|Arm BD High Risk Group|Arm BD High Risk Group: See Detailed Description.
9984246|NCT04293562|Experimental|Arm BD Low Risk Group 2|Arm BD Low Risk Group 2: See Detailed Description.
10203326|NCT02628899|Other|Prospective TAVR Arm|200 patients prospectively undergoing transfemoral TAVR
10203327|NCT02628899|Other|Historical SAVR Controls|Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
9765307|NCT00797732|Active Comparator|Active Acupuncture|The active intervention used a three-phase step-up protocol to gradually increase the body areas treated and needling intensity. Acupuncture needles (0.20x25mm) were inserted with a depth of 5-10 mm into predefined points based on a systematic literature review following the STRICTA guideline. Needles were stimulated to obtain the de qi sensation. An electroacupuncture (EA) device was connected at two acupoints. All needles remained in place for 30 minutes. The active acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; MacPherson H, Altman DG et al. PLoS Med 2010;7:e1000261]
9784025|NCT01215929|Placebo Comparator|Placebo|
9784026|NCT01215942|Experimental|120 milligrams (mg) of LY2127399|"Given every 4 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 240 mg loading dose when initiating treatment.~Or~Given every 4 weeks for 168 weeks for those participants from Study BCDM."
9784027|NCT01215942|Experimental|90 mg LY2127399|"Given every 2 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 180 mg loading dose when initiating treatment.~Or~Given every 2 weeks for 168 weeks for those participants from Study BCDM."
9784028|NCT01215955|Experimental|3 Day Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the past three days.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
9784029|NCT01215955|Experimental|Daily Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the previous day.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
10203328|NCT02628899|Other|Low-Risk TAVR with Bicuspid Aortic Valve|The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
9784030|NCT01215968|Placebo Comparator|Placebo|"Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.~Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
9784031|NCT01215968|Experimental|LY2189265|"Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.~1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
9784032|NCT01215981|Active Comparator|Participants Receiving 1 Dose of Vaccine|"Control group participants (healthy volunteers):~Age 18 to 50 years~No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~No flu vaccine in previous 4 months~and/or HSCT recipients who are greater than 60 days post transplant."
9784033|NCT01215981|Active Comparator|Participants Receiving 2 Doses of Vaccine|Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.
9784034|NCT01216072|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
9784035|NCT01216072|Active Comparator|Multiple Sclerosis Disease Modifying Treatments (MS DMTs)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
9784036|NCT01216163|Experimental|Treatment A|
9784037|NCT01216163|Active Comparator|Treatment B|
9784038|NCT01216163|Placebo Comparator|Treatment C|
9784039|NCT01216176|Experimental|Phase 1 - Cohort A|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer
9784040|NCT01216176|Active Comparator|Phase 2 - Cohort B [Anastrozole + AZD0530]|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression or 4-6 months of treatment completed.
9784041|NCT01216176|Placebo Comparator|Phase 2 - Cohort B [Anastrozole + Placebo]|Dual treatment with 1 mg anastrozole orally once daily together with Placebo orally once daily, or as specified per protocol, until disease progression or4-6 months of treatment completed.
9784042|NCT01216189||Preoperative radiotherapy|Women with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
9784043|NCT01216189||No preoperative radiotherapy|Women with rectal cancer treated with surgery alone (no RT).
9784044|NCT01216202||Preoperative RT|Men with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
9784045|NCT01216202||No preoperative RT|Men with rectal cancer or prostate cancer treated with surgery alone (no RT).
9784046|NCT01216241|Active Comparator|Daptomycin|Daptomycin intravenous 8mg/kg once per day 5-10 days.
9765308|NCT00797732|Sham Comparator|Sham Acupuncture|The sham intervention was designed to be maximally inert and minimally invasive, while simulating most aspects of the active protocol. Sham needles (0.12x30mm) were inserted at 14 locations paralleling the same body regions needled in the active group; however, all sham point locations were off the pathways of traditional Chinese medicine acupuncture meridians and points. An identical but deactivated EA device was used following sham protocols previously used. The sham acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; Wayne PA, Krebs DE et al. Arch Phys Med Rehabil 2005;86:2248-2255]
9765309|NCT00797797|Experimental|Milnacipran Added|
9765310|NCT00797797|Experimental|No Treatment Added|
9784047|NCT01216241|Placebo Comparator|Saline Placebo|Saline solution
9784048|NCT01216319|Experimental|Nipple Reconstruction Cylinder|
9784049|NCT01216332|Experimental|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
9784050|NCT01216332|Active Comparator|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
9784051|NCT01216397|Experimental|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
9784052|NCT01216397|Experimental|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
9784053|NCT01216410|Active Comparator|Metoclopramide|Prophylaxis with metoclopramide and phenylephrine infusion.
9784054|NCT01216410|Placebo Comparator|Phenylephrine infusion|Prophylactic phenylephrine infusion and placebo antiemetics
9784055|NCT01216410|Active Comparator|Combination Group|Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion
9784056|NCT01216735|Active Comparator|smokers, Fluticasone first, then Placebo|The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.
9784057|NCT01216735|Placebo Comparator|smokers Placebo first, then Fluticasone|The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
9784058|NCT01216735|No Intervention|health non-smokers|The healthy non-smokers will have only visit 1 and no intervention.
9784059|NCT01216748|Experimental|health life-time non smokers|health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation
9784060|NCT01216761|Active Comparator|CHG then PI then IT|"Skin antisepsis prior to any peripheral blood culture collection on Floor A was performed with CHG for 3 months, followed by PI for 3 months, followed by IT for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT"
9784061|NCT01216761|Active Comparator|IT then CHG then PI|"Skin antisepsis prior to any peripheral blood culture collection on Floor B was performed with iodine tincture for 3 months, followed by Chlorhexidine gluconate for 3 months, followed by povidone iodine for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI"
9784062|NCT01216761|Active Comparator|PI then IT then CHG|"Skin antisepsis prior to any peripheral blood culture collection on Floor C was performed with povidone iodine for 3 months, followed by iodine tincture for 3 months, followed by chlorhexidine gluconate for 3 months. Each 3 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG"
9784063|NCT01216943|Experimental|Triple Combination Therapy|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
9784064|NCT01217073|Experimental|Omarigliptin 0.25 mg (Base)|Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
9784065|NCT01217073|Experimental|Omarigliptin 1 mg (Base)|Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
9784066|NCT01217073|Experimental|Omarigliptin 3 mg (Base)|Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
9784067|NCT01217073|Experimental|Omarigliptin 10 mg (Base)|Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
9784068|NCT01217073|Experimental|Omarigliptin 25 mg (Base)|Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
9784069|NCT01217073|Placebo Comparator|Placebo (Base)|Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
9984247|NCT04291859|Experimental|Lu AF28996|Participants will receive ascending oral doses of Lu AF28996 once daily for 14 days (Day 1 to Day 14) in all cohorts. On Day 15, the participant will initiate down-titration of Lu AF28996 as per Investigator's judgement.
9784070|NCT01217073|Experimental|Pooled omarigliptin (Extension)|Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
9785644|NCT01256424|Placebo Comparator|Placebo ointment without illumination|Placebo without illumination
10205281|NCT03146754|Experimental|Stable ADHF patients|Lung ultrasound to access b lines
9765311|NCT00797823|Placebo Comparator|Insulin + Placebo|Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.
9765312|NCT00797823|Active Comparator|Insulin + Glucagon|Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.
9765313|NCT00797823|Experimental|Pilot Study|Pilot studies designed to assess safety of the system. Includes 6 participants undergoing 7 studies.
9765314|NCT00797862|Experimental|Aliskiren + Amlodipine|Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
9765315|NCT00797862|Experimental|Aliskiren Start - Amlodipine Add-On|Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
9765316|NCT00797862|Experimental|Amlodipine Start- Aliskiren Add-On|Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
9765317|NCT00797966|Experimental|1|OPC-34712 + ADT
9765318|NCT00797966|Placebo Comparator|2|Placebo + ADT
9765319|NCT00798018|Placebo Comparator|Air|air was used to inflate the cuff.
9765320|NCT00798018|Placebo Comparator|Normal Saline|Normal saline was used to inflate the cuff.
9765321|NCT00798018|Active Comparator|lidocaine|2% lidocaine was used to inflate the cuff.
9765322|NCT00798018|Experimental|tetracaine|1% tetracaine was used to inflate the cuff.
9765323|NCT00798096|Experimental|1|
9765324|NCT00798135|Experimental|itraconazole|Patients will receive oral itraconazole 200mg a day until disease progression.
9765325|NCT00798161|Experimental|BI 1356 + metformin|BI 1356 low dose + metformin 500 mg, twice daily
9765326|NCT00798161|Placebo Comparator|matching placebo|matching placebo
9765327|NCT00798161|Experimental|BI 1356+ Metformin|BI 1356 low dose + metformin 1000 mg, twice daily
9765328|NCT00798161|Active Comparator|Metformin|Metformin 500 mg, twice daily
9765329|NCT00798161|Active Comparator|metformin|Metformin 1000 mg, twice daily
9765330|NCT00798161|Experimental|BI 1356|BI 1356 high dose, once daily
9765331|NCT00798174|Experimental|Standard configuration vs. azygos coil|"The DFT with the standard Superior Vena Cava (SVC) coil vs. DFT with the azygos coil.~In this crossover study, each patient serves and own control, with defibrillation testing performed with and with the azygos coil"
9765332|NCT00798304|Experimental|1|Dose level 1 of meningococcal B rLP2086 vaccine and routine childhood vaccines
9765333|NCT00798304|Experimental|2|Dose level 2 of meningococcal B rLP2086 vaccine and routine childhood vaccines
9765334|NCT00798304|Experimental|3|Control group
9765335|NCT00798317|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
9765336|NCT00798317|Placebo Comparator|Placebo|Intravitreal injection of placebo
9765337|NCT00798369|Experimental|Canakinumab 10 mg|Canakinumab 10 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
9765338|NCT00798369|Experimental|Canakinumab 25 mg|Canakinumab 25 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
9765339|NCT00798369|Experimental|Canakinumab 50 mg|Canakinumab 50 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
9765340|NCT00798369|Experimental|Canakinumab 90 mg|Canakinumab 90 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
9765341|NCT00798369|Experimental|Canakinumab 150 mg|Canakinumab 150 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
9765342|NCT00798369|Active Comparator|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg intramuscularly (i.m) once. The i.m. injection was recommended to be administered deeply into the gluteal muscle. Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
9785645|NCT01256450|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
10205282|NCT03146754|Active Comparator|Control Patients|Patients without any cardiopulmonary disease will be control patients for the active subjects, age-matched accordingly.
10205283|NCT03141983|Active Comparator|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
9765343|NCT00798434|Active Comparator|Placebo|Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
9765344|NCT00798434|Active Comparator|Fesoterodine|Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
9765345|NCT00798486|Other|Subjects with and without Diabetes|Subjects participating in this study included 93 who had diabetes and 17 who did not have diabetes.
9765346|NCT00798577|Experimental|Vigamox|Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)
10205284|NCT03141983|Placebo Comparator|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
10205285|NCT03077737|Experimental|Population health management|Population health management for smoking cessation in low-income smokers: the Choose to Change intervention
10205286|NCT03077737|Active Comparator|Enhanced usual care|Usual clinic-based care enhanced by an EHR system that can deliver an electronic referral for quitline treatment
10205287|NCT03062449|Active Comparator|L-Serine Gummy Arm|L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
10205288|NCT03062449|Placebo Comparator|Placebo Gummy Arm|Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.
10205289|NCT03049033|Experimental|Neurologic Music Therapy (NMT)|Neurologic Music Therapy is a 5-week intervention using different musical instruments and auditory cues to specifically improve fine motor movements.
10205290|NCT03049033|Active Comparator|Occupational Therapy (OT)|Standard of care occupational therapy uses traditional motor training.
10205291|NCT03049033|No Intervention|Waitlist Control|Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT, MST or OT sessions.
10205292|NCT03049033|Active Comparator|Music Supported Therapy (MST)|Music Supported Therapy uses musical instruments to train fine motor movements.
10205293|NCT03019640|Experimental|Treatment (chemotherapy, NK infusion, stem cell transplant)|See Detailed Description.
10205294|NCT03008291||Heart Failure Group|Patients who have left bundle branch block (LBBB), right bundle branch block (RBBB) or interventricular conduction delay (IVCD) with a QRS duration of greater than 120 ms and left ventricular ejection fraction (LVEF) ≤ 35% will be enrolled in this arm. The primary care physician will have recommended either CRT-D Implantation or CRT-P Implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
10205295|NCT03008291||Atrioventricular Block Group|Patients who have developed second or third degree atrioventricular block (AV block). The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
10205296|NCT02991937|Active Comparator|Medical Therapy|Subjects in the medical therapy arm will be treated with piperacillin/tazobactam for at least 24 hours. Ciprofloxacin/metronidazole will be used in penicillin-allergic patients. Subjects will be maintained on nothing by mouth with intravenous fluids for at least 12 hours. Subjects will be transitioned to oral antibiotics when their WBC is normal, they have a decrease in CRP by ≥ 15%, and they have been afebrile for 24 hours on IV antibiotics.
10205297|NCT02991937|Active Comparator|Surgical Intervention|Subjects in the surgical treatment arm will receive intravenous antibiotics until the time of operation, and will be maintained on intravenous fluids and no oral intake until they undergo appendectomy as per standard of care. Appendectomy will occur within 24 hours of enrollment. Subjects in the surgical treatment arm will receive post-operative antibiotics as per standard of care.
10205298|NCT02989025|Experimental|Experimental|To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
10205299|NCT02968563|Experimental|Tirabrutinib + Idelalisib|Tirabrutinib 80 mg (4 x 20 mg tablets/2 x 40 mg tablets/1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks.
10205300|NCT02968563|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab|Tirabrutinib 80 mg (4 x 20 mg tablets/ 2 x 40 mg tablets/ 1 x 80 mg tablet) once daily + idelalisib 100 mg (1 x 100 mg tablet) once daily for up to 104 weeks + obinutuzumab 100 mg on Day 1, 900 mg on Day 1 or 2, and 1000 mg subsequently for up to 8 doses on Day 1 of Weeks 2, 3, 5, and then every 4 weeks through Week 21.
10205301|NCT02931890|Active Comparator|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
10205302|NCT02931890|Active Comparator|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
10205303|NCT02931890|Active Comparator|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
10205304|NCT02929810|Experimental|sleep extension|
10205305|NCT02929810|Active Comparator|sleep maintenance|
9765347|NCT00798577|Placebo Comparator|BSS Placebo|Balanced Salt Solution
9765348|NCT00798603|Experimental|pemetrexed + carboplatin + bevacizumab|Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease or partial or complete response after 6 courses may continue to receive pemetrexed disodium and bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
9765349|NCT00798655|Experimental|Panitumumab, Cisplatin plus radiation|Standard radiation 60-66 Gy with 200 cGy daily fractions in 6-7 weeks Cisplatin* 30 mg/m2 IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements) Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements)
9765350|NCT00798694|Other|New to Meds|Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
9765351|NCT00798694|Other|Currently on Xalatan|Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
9765352|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 25 mg|
9765353|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
9765354|NCT00798707|Placebo Comparator|Placebo|
9765355|NCT00798720|Experimental|Vorinostat + Bortezomib|Vorinostat 400 mg + Bortezomib 1.3 mg/m2
9765356|NCT00798759|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
9765357|NCT00798759|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
9765358|NCT00798889|Experimental|Sunitinib|
9765359|NCT00798967|Experimental|Teduglutide|0.05 mg/kg/day sc dose of teduglutide
9765360|NCT00798967|Placebo Comparator|Placebo|Matching subcutaneous dose of placebo to teduglutide
9765361|NCT00799227|Experimental|700 µg Dexamethasone Implant|700 µg dexamethasone implant in the study eye at Day 1
9765362|NCT00799383|Experimental|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
9765363|NCT00799383|Placebo Comparator|Placebo|Placebo
9765364|NCT00799409|Experimental|1|CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
9765365|NCT00799409|Experimental|2|Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
9765366|NCT00799422|Active Comparator|ReNu MultiPlus|ReNu MultiPlus used as specified in the protocol for contact lens care. In this crossover study, ReNu MultiPlus was dispensed in randomized order with Complete Easy Rub and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
9765367|NCT00799422|Active Comparator|Complete Easy Rub|Complete Easy Rub used as specified in the protocol for contact lens care. In this crossover study, Complete Easy Rub was dispensed in randomized order with ReNu MultiPlus and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
9765368|NCT00799422|Active Comparator|Clear Care|Clear Care used as specified in the protocol for contact lens care. In this crossover study, Clear Care was dispensed in randomized order with Complete Easy Rub and ReNu MultiPlus. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
9765369|NCT00799435|No Intervention|1|Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
9765370|NCT00799435|Experimental|2|Participants will receive exenatide for 12 weeks.
9765371|NCT00799487|Experimental|1|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
9765372|NCT00799487|Experimental|2|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
9765373|NCT00799578|Experimental|Cystagon-EC|
9765374|NCT00799591||1|Intensive Care
9765375|NCT00799604|Experimental|clevidipine|"Patients were sequentially assigned to one of following three planned dose cohorts for Bolus 1 within the clevidipine arm:~Cohort 1: clevidipine 250 µg (0.5 mL)~Cohort 2: clevidipine 500 µg (1 mL)~Cohort 3: clevidipine 125 µg (0.25 mL or 0.5 mL of a 1:1 solution)"
9765376|NCT00799617|Active Comparator|AndroGel® (testosterone gel)|The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
9765377|NCT00799617|Placebo Comparator|Placebo gel|Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
9765378|NCT00799643|Active Comparator|1|Salsalate, 3.5 g/d orally, divided dosing
9765379|NCT00799643|Placebo Comparator|2|Salsalate Placebo, orally, divided dosing
9765380|NCT00799708|Placebo Comparator|1|Placebo
9765381|NCT00799708|Active Comparator|2|Estrace 0.5 mg
9765382|NCT00799708|Active Comparator|3|Estrace 2 mg
9765383|NCT00799812|Experimental|CHG Swabstick (3 @ once)|Chlorhexidine gluconate (CHG) 2% w/v CHG/isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied @ same time
9765384|NCT00799812|Experimental|CHG Swabstick sequential|Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially
9765385|NCT00799812|Active Comparator|Hibiclens|Chlorhexidine gluconate (CHG) 4% w/v in an aqueous base
9765386|NCT00799812|Placebo Comparator|Sterile water swab (3 @ once)|Sterile swabstick wetted with sterile deionized water - 3 swabsticks applied at the same time.
9765387|NCT00799812|Placebo Comparator|Sterile water swabstick (sequential)|Sterile swabstick wetted with sterile water--3 swabsticks applied sequentially.
9765388|NCT00799825|Experimental|Cervarix group|Female subjects who previously received the active control i.e. Hepatitis A vaccine in the primary study (NCT00122681) and who received the Cervarix vaccine in the current study. The Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1 and 6 months schedule.
9765389|NCT00799903|Experimental|Darapladib|Single daily oral tablet
9765390|NCT00799903|Placebo Comparator|Placebo|Single daily oral tablet
9765391|NCT00799981|Experimental|AABB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 7 cm then 10 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
9765392|NCT00799981|Experimental|ABAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
9765393|NCT00799981|Experimental|ABBA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
9765394|NCT00799981|Experimental|BAAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 7 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
9765395|NCT00799981|Experimental|BABA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then then 7 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
9765396|NCT00799981|Experimental|BBAA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 10 cm then 7 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
9765397|NCT00800176|Placebo Comparator|Placebo|"During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast.~During the 12-week double-blind treatment period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test."
9765398|NCT00800176|Experimental|RO4998452 10mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 10 mg of RO4998452.
9765399|NCT00800176|Experimental|RO4998452 2.5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 2.5 mg of RO4998452.
9765400|NCT00800176|Experimental|RO4998452 20mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 20 mg of RO4998452.
9765401|NCT00800176|Experimental|RO4998452 40mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 40 mg of RO4998452.
9765402|NCT00800176|Experimental|RO4998452 5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 5 mg of RO4998452.
9765403|NCT00800202|Experimental|1|
9765404|NCT00800202|Experimental|2|
9765405|NCT00800254|Experimental|Neuromuscular Electrical Stimulation (NMES)|
9765406|NCT00800254|Active Comparator|Standard Rehabilitation Protocol|
9765407|NCT00800345|Experimental|Experimenal|Metronomic oral topotecan and oral pazopanib will be administered by mouth beginning on Cycle 1 Day 1. Patients will be enrolled and observed for dose limiting toxicity (DLT) for 1 cycle of treatment. Dose modification of the combination will depend on the number of patients experiencing DLT(s) at each dose level.
9765408|NCT00800384|Experimental|1|ICD implant without defibrillation testing
10203329|NCT02611076|Experimental|Stop Smoking for Good Intervention in Spanish|Study II: Stop Smoking for Good Intervention in Spanish (SS-SP) will comprise a series of 10 booklets distributed over 18 months, plus additional monthly contacts via 9 supportive pamphlets developed in Study I. Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP) Assessments will occur at six-month intervals, through 24 months.
10203330|NCT02611076|Active Comparator|Usual Care|Study II: Usual Care (UC) will comprise a single, Spanish-language, smoking cessation booklet developed by the National Cancer Institute (NCI). Behavioral: Usual care (UC) Assessments will occur at six-month intervals, through 24 months.
9833562|NCT02659787|Active Comparator|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
9833563|NCT02659787|Placebo Comparator|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
9833564|NCT02659943|Experimental|LEVEL 1 - Participants Who Received 0.66x10^6 CAR T Cells Only|LEVEL 1 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells only
9833565|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 2-Participants Who Received - 0.66x10^6 CAR T Cells Foll/by 2x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 2 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 2x10^6 CAR T cells
10203331|NCT02608346|Other|Blood sampling|
10203332|NCT02607046|Experimental|Exercise|Exercise Training
9833566|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 3 - Participants Who Received 0.66x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 3 - participant who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
9833567|NCT02659943|Experimental|LEVEL 2 - Participants Who Received 2x10^6 CAR T Cells Only|LEVEL 2 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells only
9833568|NCT02659943|Experimental|LEVEL 2 Followed by LEVEL 3-Participants Who Received 2x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 2 followed by LEVEL 3 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
9833569|NCT02659943|Experimental|LEVEL 3 - Participants Who Received 6x10^6 CAR T Cells Only|LEVEL 3 - participants who received - 6x10^6 Chimeric Antigen Receptor (CAR) T cells only
9833570|NCT02660112|Experimental|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
9833571|NCT02660138|Experimental|600 U Dysport® Group|
9833572|NCT02660138|Placebo Comparator|600 U Dysport® Placebo Group|
9833573|NCT02660138|Experimental|800 U Dysport® Group|
9833574|NCT02660138|Placebo Comparator|800 U Dysport® Placebo Group|
9833575|NCT02660229|Experimental|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
9833576|NCT02660229|Active Comparator|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
9833577|NCT02660242|No Intervention|Control|No basal insulin adjustment, no carbohydrate intake (until glucose drops <70 mg/dL).
9833578|NCT02660242|Active Comparator|Basal insulin reduction|Basal insulin reduction to 50% five minutes before the start of exercise.
9833579|NCT02660242|Active Comparator|Glucose Tabs|Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
9833580|NCT02660242|Experimental|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
9833581|NCT02660359|Experimental|600 U Dysport® Group|
9833582|NCT02660359|Placebo Comparator|600 U Dysport® Placebo Group|
9833583|NCT02660359|Experimental|800 U Dysport® Group|
10203333|NCT02607046|Experimental|NMES|Neuromuscular Electrical Stimulation
10203334|NCT02571673||Survivors of head and neck cancer|Data collection will take place in two parts. Aim 1: Part 1 will enroll 10 patients at MSK to participate in component pilot testing and usability testing of HN-STAR and the associated surveys. We will also elicit feedback from the NP. After incorporating any changes to HN-STAR or the surveys based on findings from Aim 1: Part 1, Aim 1: Part 2 will enroll 30 additional patients from MSK and 15 from HH to provide feedback on usability. We will also survey each patient's PCP in Aim 1: Part 2.
9833584|NCT02660359|Placebo Comparator|800 U Dysport® Placebo Group|
9833585|NCT02660489|Experimental|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
9833586|NCT02660489|Placebo Comparator|Placebo|Placebo tablet once daily for 5 weeks
9833587|NCT02660580|Experimental|MSB11022 (Core Treatment Period)|Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
10203335|NCT02570984|Active Comparator|Active|omalizumab 0.016 mg/kg/IU total IgE
10203336|NCT02570984|Placebo Comparator|Placebo|looks like active drug
10203337|NCT02547311|Experimental|Team Clinic Intervention|Middle School and High School Team Clinic Intervention
10203338|NCT02547311|No Intervention|Standard Clinical Care - Control|Standard Clinical Care - Control
10203339|NCT02539693|Experimental|Clonidine 75|Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).
10203340|NCT02539693|Experimental|Clonidine 150|Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).
10203341|NCT02537678|Experimental|Stepped Care TF-CBT|Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
10203342|NCT02537678|Active Comparator|Standard TF-CBT|Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.
10203343|NCT02534012|Experimental|PVB group|Patients will receive nerve stimulator guided paravertebral block
10203344|NCT02534012|Experimental|GA group|Patients will receive general anesthesia
10203345|NCT02505425|Experimental|Active Intervention|"Behavioral: behavioral support~Usual HF Care + ENABLE CHF-PC"
10203346|NCT02505425|Active Comparator|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
10203347|NCT02505204|Experimental|Clonidine|Will receive bilateral PVB with clonidine.
9765409|NCT00800384|Active Comparator|2|ICD implant with defibrillation testing
9765410|NCT00800436|Experimental|Part 1: Cohort 1|Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
9765411|NCT00800436|Experimental|Part 1: Cohort 2|Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
9765412|NCT00800436|Experimental|Part 1: Cohort 3|Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
9765413|NCT00800436|Experimental|Part 1: Cohort 4|Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
9765414|NCT00800436|Experimental|Part 1: Cohort 5|Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
9765415|NCT00800436|Experimental|Part 2: Cohort A|Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
9765416|NCT00800436|Experimental|Part 2: Cohort B|Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.
9765417|NCT00800540|Other|AZARGA/COMBIGAN|AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
9765418|NCT00800540|Other|COMBIGAN/AZARGA|COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
9765419|NCT00800683|Experimental|BI 1356|patient to receive a tablet containing BI 1356 once daily
9765420|NCT00800683|Placebo Comparator|placebo|patient to receive a tablet identical to BI 1356 once daily
9765421|NCT00800735|Experimental|Pegylated-interferon alfa-2a plus ribavirin|Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing < 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
9765422|NCT00800839|Experimental|Busulfan + Fludarabine + Cyclophosphamide|Busulfan starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
9765423|NCT00800865|Other|Biomarker Evaluation Group I|Biomarker evaluation before and after dosing with cytotoxic agent(s)
9765424|NCT00800865|Other|Biomarker Evaluation Group II|Biomarker evaluation before and after dosing with cytotoxic agent(s)
9765425|NCT00800982|Active Comparator|1 (Etanercept only)|Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months. No UVB will be given. Sham UVB will not be used because the subjects are not blinded because they often know they are receiving sham UVB due to differences in light intensity and heat.
9765426|NCT00800982|Experimental|2 (Etanercept + nb-UVB)|"Subjects will receive etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.~In addition, for months 3-6, subjects will receive Narrow Band Ultraviolet B phototherapy three times a week for 12 weeks in addition to the etanercept maintenance dose. The safety and efficacy of the combination therapy will be evaluated by the registered phototherapy nurses at each phototherapy visit and by the study investigator at monthly visits. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff."
9765427|NCT00801099|Experimental|Abx|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
9765428|NCT00801138|Placebo Comparator|Group 1|Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
9765429|NCT00801138|Placebo Comparator|Group 2|Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
9765430|NCT00801138|Active Comparator|Group 3|Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
9765431|NCT00801138|Active Comparator|Group 4|Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).
9765432|NCT00801229|Active Comparator|Vyvanse|Patients may be randomized to the active comparator arm. Participants randomized to this arm will receive 30, 50, or 70mg Vyvanse daily.
9765433|NCT00801229|Placebo Comparator|Placebo|Patients may be randomized to the placebo comparator arm. Those randomized to this arm will receive 30, 50, or 70mg placebo daily.
9765434|NCT00801242|Experimental|Degarelix 240 mg / 80 mg|
9765435|NCT00801398|Experimental|Oxymorphone IR|Open-Label, 2 part ascending-dose multicenter study
9765436|NCT00801632|Experimental|Kidney and Marrow Recipients|Combined kidney and bone marrow transplant
9765437|NCT00801684|Placebo Comparator|Placebo|Represents Dose A in the Dosing Sequence assignments.
9765438|NCT00801684|Experimental|TrIP-2D (100mcg)|Represents Dose B
9765439|NCT00801684|Experimental|TrIP-2SS (100mcg)|Represents Dose C
9765440|NCT00801684|Experimental|TrIP-2D (400mcg)|Represents Dose D
9765441|NCT00801684|Experimental|TrIP-2SS (100mcg) + Foradil (12mcg)|Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.
9765442|NCT00801723|Experimental|1: Budesonide MMX® 6 mg|One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
9765443|NCT00801723|Placebo Comparator|2: Placebo|One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
9785646|NCT01256450|Placebo Comparator|BEMA Placebo|placebo buccal soluble film
9785647|NCT01256476|Experimental|pitavastatin 4 mg once daily (QD)|
9785648|NCT01256476|Active Comparator|pravastatin 40 mg once daily (QD)|
9785649|NCT01256502|Other|Implanted Participants|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
9785650|NCT01256567|Experimental|ramucirumab and docetaxel combination|
9765444|NCT00801801|Experimental|Metronomic Docetaxel + Sorafenib|"Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.~Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle."
9765445|NCT00801827|Experimental|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET) scans of their brains using F-18 (fallypride), a dopamine type 2/3 (DA D2/3) receptor radioligand whose binding is sensitive to competition with endogenous dopamine, before and after the operation.
9765446|NCT00801892|Active Comparator|1 subjects treated with CPAP|Continuous Positive Airway Pressure treatment (CPAP)
9765447|NCT00801892|Sham Comparator|2 subjects treated with sham-CPAP|Sham Continuous Positive Airway Pressure treatment (sham-CPAP)
9984248|NCT04288726|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~Dose Level 1: 4 × 107 CD30.CAR-EBVST cells~Dose Level 2: 1 × 108 CD30.CAR-EBVST cells~Dose Level 3: 4 × 108 CD30.CAR-EBVST cells"
10203348|NCT02505204|Placebo Comparator|Placebo|Will receive bilateral PVB with placebo.
9765448|NCT00801983|Experimental|A|Subject receives typical keyboard first for 6 months and alternative keyboard second for 6 months
9765449|NCT00801983|Experimental|B|Subject receives alternative keyboard first for 6 months and typical keyboard second for 6 months
9765450|NCT00802074|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Raltegravir 400mg BID
9765451|NCT00802074|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3 Fosamprenavir 1400mg BID
9765452|NCT00802074|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period2- Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
9765453|NCT00802074|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
9765454|NCT00802074|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
9765455|NCT00802074|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
9765456|NCT00802100|Experimental|Olanzapine|Participants will receive treatment with olanzapine and metformin, with the possible addition of simvastatin or benztropine, depending on side effects.
9765457|NCT00802100|Experimental|Perphenazine|Participants will receive treatment with perphenazine and benztropine, with the possible addition of simvastatin or metformin, depending on side effects.
9765458|NCT00802100|Experimental|Aripiprazole|Participants will receive treatment with aripiprazole, with the possible addition of simvastatin, metformin, or benztropine, depending on side effects.
9765459|NCT00802113|Experimental|Arm A - Family Donor|Fludarabine and Busulfan: Patients who have a matched family (allogeneic) donor will go on to receive non-ablative therapy, followed by an infusion of donor stem cells; this is called an allogeneic peripheral blood stem cell transplant. The non-ablative therapy will be busulfan and ﬂudarabine, Usually large (myeloablative) doses of these drugs are used for an allogeneic transplant. However, in this study lower doses (non-ablative) of chemotherapy will be given. In patients who still have evidence of disease after allogeneic transplant, additional donor immune cells (donor lymphocyte infusion) (DLI) will be given twice to further treat the lymphoma.
9765460|NCT00802113|Experimental|Arm B - Unrelated Cord Blood or Adult|Fludarabine, Busulfan and ATG: For patients who don't have a matched family donor, a cord blood search and unrelated adult search will be done at all of the cord blood banks and adult donor registries in the world. If a closely matched cord blood donor or unrelated adult donor is found, non-ablative chemotherapy with busulfan, ﬂudarabine and antithymocyte globulin (ATG) followed by the infusion of matched unrelated cord blood cells or adult donor stem cells or bone marrow to restore the bone marrow will be given.
9765461|NCT00802204|Active Comparator|Lean controls|Lean complete baseline outcome measures only
9765462|NCT00802204|Experimental|Obese|Obese completing baseline and post-VLCD outcome measures
9765463|NCT00802360|Experimental|Menopur/Endometrin|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9765464|NCT00802360|Experimental|Menopur/Progesterone in Oil|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9765465|NCT00802360|Active Comparator|Follistim/Endometrin|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9765466|NCT00802360|Active Comparator|Follistim/Progesterone in Oil|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9785651|NCT01256593||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
9765467|NCT00802412|Other|Topiramate|The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
9765468|NCT00802412|Placebo Comparator|Placebo|90 participants, will receive matching placebo
9765469|NCT00802438|Experimental|Mepolizumab|up to 3 monthly doses of 750mg i.v. mepolizumab
9765470|NCT00802464|Experimental|GSK1437173A formulation 1 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
9765471|NCT00802464|Experimental|GSK1437173A formulation 2 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
9765472|NCT00802464|Experimental|GSK1437173A formulation 3 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
9765473|NCT00802464|Placebo Comparator|Control Group|Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
9765474|NCT00802503|Experimental|SPN group|"experimental arm: Supplemental Parenteral Nutrition (SPN) is added to enteral nutrition (EN) to reach 100% of their predicted energy needs from ICU day 4.~In the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line. Nutritional products as currently used in our institution. SPN is composed of EN and PN, both techniques being currently used in our institution."
9765475|NCT00802503|No Intervention|Control gr|EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
9765476|NCT00802529|Experimental|Steroid (Methylprednisolone)|Steroid (Methylprednisolone)
9765477|NCT00802529|Active Comparator|Gentamicin|Gentamicin
9765478|NCT00802633|Active Comparator|Stapling device|Efficacy of stapling device during radical cystectomy
9765479|NCT00802633|Active Comparator|Ligasure Device|Efficacy of ligasure tissue sealing device during radical cystectomy
9765480|NCT00802672|Experimental|Test Product|Ciclopirox Olamine Cream 0.77%
9765481|NCT00802672|Active Comparator|Reference Product|Loprox Cream 0.77%
9765482|NCT00802672|Placebo Comparator|Vehicle Product|placebo of test product
9765483|NCT00802685|Experimental|early ibuprofen|"Drug: Early ibuprofen~IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to early treatment will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
9765484|NCT00802685|Other|Late Ibuprofen expectant group (placebo)|"Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to late expectant group will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, late ibuprofen or expectant)."
9765485|NCT00802737|Experimental|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
9765486|NCT00802841|Experimental|Nilotinib|Participants received 400 mg nilotinib twice daily (BID).
9765487|NCT00802841|Active Comparator|Imatinib|Participants received 600 mg imatinib once daily (QD).
9765488|NCT00802867|Experimental|1|Subjects in Study 494-01 and Study 494-03 who had received 4 doses of Pentacel™ vaccine.
9765489|NCT00802880|Experimental|Dacarbazine|Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.
9765490|NCT00802919|Experimental|Varenicline|Varenciline 1-2 mg/day
9765491|NCT00802919|Placebo Comparator|Matched Placebo|placebo for varenicline
9765492|NCT00802945|Experimental|NKTR-102 q14d|NKTR-102
9765493|NCT00802945|Experimental|NKTR-102 q21d|NKTR-102
9765494|NCT00802997|Active Comparator|1|Treatment with Sinergy system
9765495|NCT00802997|Placebo Comparator|2|placebo controlled
9765496|NCT00803010|Active Comparator|Tacrolimus / Rapamycin (TAC/RAPA)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year."
9765497|NCT00803010|Active Comparator|Tacrolimus / Methotrexate (TAC/MTX)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant."
9765498|NCT00803023|Experimental|1|Sodium Oxybate Oral Solution (4.5 grams)
9765499|NCT00803023|Experimental|2|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams)
9765500|NCT00803023|Experimental|3|Sodium Oxybate Oral Solution (6 grams)
9765501|NCT00803023|Experimental|4|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)
9765502|NCT00803049|Experimental|Placebo/Teriflunomide 7 mg|Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.
9765503|NCT00803049|Experimental|Teriflunomide 7 mg/7 mg|Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
9765504|NCT00803049|Experimental|Placebo/Teriflunomide 14 mg|Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
9765505|NCT00803049|Experimental|Teriflunomide 14 mg/14 mg|Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
9765506|NCT00803062|Active Comparator|Arm I (paclitaxel and cisplatin)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
9765507|NCT00803062|Experimental|Arm II (paclitaxel, cisplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
9765508|NCT00803062|Experimental|Arm III (topotecan hydrochloride and paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
9765509|NCT00803062|Experimental|Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
9765510|NCT00803101|Experimental|Beriplex® P/N|
9765511|NCT00803101|Active Comparator|Fresh frozen plasma|
9765512|NCT00803205|Experimental|Ataluren|Participants will receive ataluren 3 times per day (TID): 10 milligrams (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
9765513|NCT00803205|Placebo Comparator|Placebo|Participants will receive placebo TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
9765514|NCT00803244|Experimental|300 IR|300 IR grass pollen allergen extract tablet
9765515|NCT00803244|Placebo Comparator|Placebo|Placebo tablet
9765516|NCT00803270|Active Comparator|Surgical Treatment|Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
9765517|NCT00803270|Active Comparator|Non Surgical Treatment|"The non-surgical treatment will include two components:~Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~Behavioral therapy."
9765518|NCT00803361|Experimental|Duloxetine|
9765519|NCT00803361|Placebo Comparator|Placebo|
9765520|NCT00803400|Active Comparator|Alprazolam|Patients assigned to the pharmacological plan
9765521|NCT00803400|Active Comparator|Alprazolam + Aerobic exercise|Patients assigned to mix plan
9765522|NCT00803452|Active Comparator|Doxycycline|Oral doxycycline
9765523|NCT00803452|Active Comparator|azithromycin|Topical azithromycin daily to the conjunctival culdesac
9765524|NCT00803543|Active Comparator|Valacyclovir|This is the arm taking Valacyclovir
9765525|NCT00803543|Placebo Comparator|Placebo|This is the arm taking the placebo
9765526|NCT00803569|Experimental|ALVAC(2)-NY-ESO-1(M)/TRICOM + GM-CSF|Patients received SC injections with ALVAC(2)-NY-ESO-1(M)/TRICOM (0.5 mL) on Day 1 and the GM-CSF sargramostim (100 μg) on Days 1 through 4 in continuous 28-day cycles for up to 6 cycles.
9765527|NCT00803595|Experimental|CS-8958 Low Dose|CS-8958 powder to be inhaled - low-dose arm
9765528|NCT00803595|Experimental|CS-8958 High Dose|CS-8958 powder to be inhaled - high-dose arm
9765529|NCT00803595|Active Comparator|Oseltamivir phosphate|oseltamivir phosphate oral capsules
9765530|NCT00803634|Experimental|Clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was administered intravenously via a single dedicated line to all patients randomized to the clevidipine arm. Clevidipine was infused at an initial rate of 2 mg/h for the first 3 minutes. If blood pressure was not in the target range at 3 minutes, clevidipine was titrated to effect thereafter by doubling the dose every 3 min, per physician discretion and as tolerated by the patient until the desired effect until the SBP target range was attained. Once target range was achieved, the infusion rate could be increased or decreased as needed to maintain blood pressure for minimum of 30 minutes and a maximum duration of 96 hours. The minimum infusion rate was 1 mg/h and maximum infusion rate was 32 mg/h.
9765531|NCT00803634|Active Comparator|Standard of Care IV antihypertensive|For patients randomized to standard of care (SOC) IV antihypertensive treatment, a continuous infusion of an intravenous antihypertensive agent represented standard of care. The selection of treatment was at the discretion of the investigator. The infusion was to be administered according to the institution's treatment practice.
9784071|NCT01217073|Active Comparator|Placebo/Metformin|Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.
9784072|NCT01217112|Active Comparator|GWP42004 and placebo|Contains GWP42004 5 mg and placebo (excipients only)
9784073|NCT01217112|Active Comparator|1:1 GWP42003 : GWP42004|Contains 5 mg each of GWP42003 and GWP42004
9784074|NCT01217112|Active Comparator|20:1 GWP42003 : GWP42004|Contains 100 mg GWP42003 and 5 mg GWP42004
9765532|NCT00803647|Experimental|treatment|mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab
9765533|NCT00803686|Experimental|Part 1 Double Blind Oral rsCT Tablet|Intervention: Oral rsCT tablet given once 4 hours after evening meal.
9765534|NCT00803686|Placebo Comparator|Part 1, Double-blind Oral Placebo Tablet|Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
9765535|NCT00803686|Experimental|Part 2 Open label, Oral rsCT tablet|Intervention: Oral rsCT tablet given once 2 hours after evening meal.
9765536|NCT00803686|Active Comparator|Part 2, Open Label Fortical Nasal Spray|Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
9765537|NCT00803712|Experimental|Cinacalcet Group|Cinacalcet plus low dose active Vitamin D (if prescribed)
9765538|NCT00803712|Active Comparator|Control Group|Flexible active vitamin D dosing
9765539|NCT00803738|Experimental|Test Product|Terconazole Vaginal Suppository
9765540|NCT00803738|Active Comparator|Reference Product|Terazol Vaginal Suppository
9765541|NCT00803751|Experimental|Truview intubation|Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
9765542|NCT00803751|Active Comparator|Macintosh intubation|Macintosh blade will be used first followed by laryngoscopy and intubation with the truview
9765543|NCT00803777|Experimental|Intended Users of the Monitoring System|Subjects with type 1 diabetes and healthcare professionals (HCP) used a new blood glucose monitoring system (BGMS) with subject capillary blood. Any subject under age 18 was accompanied by a parent or guardian, who assisted subject if applicable.
9765544|NCT00803959|Active Comparator|No UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation only.
9765545|NCT00803959|Active Comparator|UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation with preoperative urodynamic studies prior to surgery.
9765546|NCT00804141|Experimental|MOA-728 12 mg QD|Participants will receive MOA-728 12 milligrams (mg) SC once daily (QD) for 48 weeks. Dosing could be adjusted to an as needed (PRN) basis with a minimum 1 dose per week and maximum 1 dose per day.
9765547|NCT00804193|Experimental|Test Product|Ciclopirox Olamine Topical Suspension
9765548|NCT00804193|Active Comparator|Reference Product|Loprox® Topical Suspension 0.77%
9765549|NCT00804193|Placebo Comparator|Vehicle Product|placebo of test product
9765550|NCT00804570|Experimental|LY2196044|
9765551|NCT00804570|Placebo Comparator|Placebo|
9765552|NCT00804596|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system with subject capillary blood.
9765553|NCT00804609|Active Comparator|DepoDur following epidural lidocaine|Epidural DepoDur was administered 60 minutes after an epidural Lidocaine top-up for surgical anesthetic in cesarean section patients.
9765554|NCT00804609|Active Comparator|DepoDur following spinal anesthetic|Epidural DepoDur was administered 60 minutes after a standard spinal anesthetic. No prior epidural local anesthetic was used prior to DepoDur in this group assignment.
9765555|NCT00804648|Active Comparator|hemihydrate/maleate/maleate gel|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
9765556|NCT00804648|Active Comparator|maleate/maleate gel/hemihydrate|Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
9765557|NCT00804648|Active Comparator|maleate gel/hemihydrate/maleate|Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
9765558|NCT00804648|Active Comparator|hemihydrate/maleate gel/maleate|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
9765559|NCT00804648|Active Comparator|maleate/hemihydrate/maleate gel|Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
9765560|NCT00804648|Active Comparator|maleate gel, maleate, hemihydrate|Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
9784075|NCT01217112|Placebo Comparator|Placebo|Contains excipients only
9765561|NCT00804687|Experimental|JNJ-39220675 then Pseudoephedrine then Placebo|Single-dose of JNJ-39220675 will be administered as 1 milliliter (ml) of 10 milligram/milliliter (mg/ml) solution orally along with placebo tablet in first treatment period; after that in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 milligram (mg) pseudoephedrine tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
9765562|NCT00804687|Experimental|JNJ-39220675 then Placebo then Pseudoephedrine|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
9765563|NCT00804687|Experimental|Placebo then JNJ-39220675 then Pseudoephedrine|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
9765564|NCT00804687|Experimental|Placebo then Pseudoephedrine then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
9765565|NCT00804687|Experimental|Pseudoephedrine then JNJ-39220675 then Placebo|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
9784076|NCT01217112|Active Comparator|GWP42003 and placebo|Contains 100 mg GWP42003 and placebo (excipients only)
9784077|NCT01217190|Experimental|Ondansetron ODFS then Zofran ODT|Single dose of Ondansetron Orally Dissolving Film Strip 8 mg followed by single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg with 7 days washout between the 2 periods
9784078|NCT01217190|Experimental|Zofran ODT then Ondansetron ODFS|Single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg followed by single dose of Ondansetron Orally Dissolving Film Strip 8 mg with 7 days washout between the 2 periods
9784079|NCT01217229|Experimental|PLX3397|
9784080|NCT01217307|Experimental|Metformin|metformin 500mg twice daily during 4 months
9784081|NCT01217307|Placebo Comparator|Placebo|Placebo twice daily during 4 months
9784082|NCT01217385|Experimental|DOSI Pre-Surgery|Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.
9784083|NCT01217411|Active Comparator|Arm I (WBRT or SRS)|Patients with >= 4 brain lesions undergo WBRT as in phase I and patients with =< 3 brain lesions undergo SRS as in phase I.
9784084|NCT01217411|Experimental|Arm II (WBRT or SRS and RO4929097)|Patients with >= 4 brain lesions receive RO4929097 and undergo WBRT as in phase I and patients with =< 3 brain lesions receive RO4929097 and undergo SRS as in phase I.
9784085|NCT01217437|Experimental|Arm I (temozolomide, irinotecan hydrochloride)|Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.
9784086|NCT01217437|Experimental|Arm II (temozolomide, irinotecan hydrochloride, bevacizumab)|Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
9784087|NCT01217463|Active Comparator|Trafermin 0.01% spray|
9784088|NCT01217463|Placebo Comparator|Matching placebo spray|
9784089|NCT01217476|Active Comparator|Trafermin 0.01% spray|
9784090|NCT01217476|Placebo Comparator|Matching placebo spray|
9784091|NCT01217515|Experimental|Diltiazem hydrochloride 4% cream|2.5 cm Diltiazem hydrochloride 4% cream applied peri-anally three times daily for eight weeks.
9784092|NCT01217515|Experimental|Diltiazem hydrochloride 2% cream|2.5 cm of Diltiazem hydrochloride 2% cream applied peri-anally three times daily for eight weeks.
9784093|NCT01217515|Placebo Comparator|Placebo cream|2.5 cm placebo cream applied peri-anally three times daily for eight weeks.
9784094|NCT01217606|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
9984249|NCT04288479|Experimental|Doing a single HIT session in gestational week 22-36|
9765566|NCT00804687|Experimental|Pseudoephedrine then Placebo then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
9765567|NCT00804843|Experimental|Statin 80 mg + Niacin extended-release (ER)|Participants in Russia and Brasil will receive 80 mg Simvastatin + niacin. All other participants will receive 80 mg Atorvastatin + niacin.
9765568|NCT00804843|Active Comparator|Statin 10 mg|Participants in Russia and Brasil will receive 10 mg Simvastatin. All other participants will receive 10 mg Atorvastatin.
9765569|NCT00804908|Placebo Comparator|Placebo for ABT-888 BID + TMZ QD|Placebo for ABT-888 twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
9765570|NCT00804908|Active Comparator|ABT-888 20 mg BID + TMZ QD|ABT-888 20 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
9765571|NCT00804908|Active Comparator|ABT-888 40 mg BID + TMZ QD|ABT-888 40 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
9765572|NCT00804973|Experimental|1|
9765573|NCT00804973|Placebo Comparator|2|
9765574|NCT00804973|Active Comparator|3|
9765575|NCT00804986|Experimental|0.5 mg LY2428757|Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
9765576|NCT00804986|Experimental|2.0 mg LY2428757|Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
9765577|NCT00804986|Experimental|6.2 mg LY2428757|Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
9765578|NCT00804986|Experimental|12.0 mg LY2428757|Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
9765579|NCT00804986|Experimental|17.6 mg LY2428757|Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
9765580|NCT00804986|Placebo Comparator|Placebo|Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
9765581|NCT00804999|Placebo Comparator|Placebo 1|Subjects that have never worn contacts with no ocular problems were selected. A baseline HRT was performed. Trial contact lenses were soaked in clear care solution for 10 hours. After 10 hours of the lenses soaking in clear care the subject returned. The contacts lenses that were soaked in clear care were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contact lenses were removed. An HRT was performed immediately after removing the contact lenses. The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
9785652|NCT01256658|Experimental|Intervention|Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.
9984250|NCT04288115|Active Comparator|"Levothyroxine group (sham discontinuation)"|Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).
9984251|NCT04288115|Placebo Comparator|"Placebo group (real discontinuation)"|Stop the current dose of levothyroxine and take study placebo
9984252|NCT04287049|Experimental|14 Day Azithromycin Monotherapy|For the first 14 days of therapy, participants will receive Azithromycin 250mg PO daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.
9765582|NCT00804999|Active Comparator|Renu|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in ReNu contact solution for 10 hours. After 10 hours of the lenses soaking in ReNu the subject returned. The contacts were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contacts lenses were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
9765583|NCT00804999|Active Comparator|Optifree|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
9765584|NCT00805025|Experimental|AZLI|Participants were evaluated beginning 14 days prior to starting a 28-day course of AZLI (Day 0 to Day 28), followed by post-treatment assessments every 14 days through Day 56, for a total of 70 days of participation in the study.
9765585|NCT00805038|Placebo Comparator|Control|Usual care
9765586|NCT00805038|Experimental|Intervention|Navigator will assist patients in completing steps in transplant process
9765587|NCT00805142|Experimental|Opioid-Naive Participants (Tapentadol PR)|Opioid-naive participants are defined as those who had moderate to severe cancer pain that is not controlled sufficiently with non-opioid medications. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in the maintenance period. Treatment will be initiated with tapentadol prolonged release (JNS024PR, PR) 25 milligram (mg) oral tablet twice daily. Dose will be increased or decreased as per Investigator's discretion up to Day 14. Maximum dose limit will be 500 mg per day. Participants will then be assigned to the treatment in the maintenance period (15-19 days). The maintenance period is duration between the first dose and the final assessment in the maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at the same dose used on last day of titration period.
9765588|NCT00805142|Experimental|Opioid-Switch Participants (Tapentadol PR)|Opioid-switching participants are defined as those who had moderate to severe cancer pain that is controlled sufficiently with opioid therapy. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in maintenance period. Initial dose of tapentadol PR is selected according to daily dose of opioid (morphine sustained release [SR] preparation, oxycodone hydrochloride [HCl] SR tablet or fentanyl patch). Equivalent dose of tapentadol PR oral tablet twice daily is given depending on daily dose of opioid at completion of Screening period. Maximum dose limit is 500 mg per day. Participants will then be assigned to treatment in maintenance period (15-19 days). Maintenance period is defined as duration between first dose and final assessment in maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at same dose used on last day of titration period.
9765589|NCT00805194|Experimental|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
9765590|NCT00805194|Placebo Comparator|Placebo plus docetaxel|Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
9765591|NCT00805207|Experimental|Progesterone - PCOS|Women with obesity and polycystic ovary syndrome
9765592|NCT00805207|Experimental|Testosterone - premenopausal women|Healthy premenopausal women.
9765593|NCT00805207|Experimental|Continuous positive airway pressure|Women and men with obesity and obstructive sleep apnea
9765594|NCT00805207|Experimental|Glucocorticoid|Lean and obese healthy women, and obese men
9765595|NCT00805207|Experimental|Estrogen|Postmenopausal women
9765596|NCT00805207|Other|control|Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits
9765597|NCT00805207|No Intervention|control - baseline testing only|Healthy men and women
9765598|NCT00805207|Experimental|Progesterone - Postmenopausal women|Postmenopausal women
9765599|NCT00805207|Experimental|Testosterone - Postmenopausal women|Postmenopausal women
9765600|NCT00805285|Experimental|Combination Oral Budesonide and Rectal Hydrocortisone|See intervention
9765601|NCT00805389|Experimental|GSK223192A 1 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
9784095|NCT01217606|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
9784096|NCT01217749|Experimental|Group 1|In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
9784097|NCT01217749|Experimental|Group 2|In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
9784098|NCT01217749|Experimental|Group 3|In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily
9784099|NCT01217801|Experimental|Ondansetron (ODFS)|single dose of Ondansetron Orally Dissolving Filmstrip 8 mg
9784100|NCT01217801|Active Comparator|Zofran (ODT)|Single dose of Zofran (Ondansetron) ODT Orally Disintegrating Tablets 8 mg
9784101|NCT01217814|Placebo Comparator|Placebo|Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
9784102|NCT01217814|Active Comparator|Golimumab 50 mg|Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
9784103|NCT01217814|Experimental|Sarilumab 150 mg|Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.
9784104|NCT01217827|Experimental|Clinical Reminder|Reminder of potential candidacy for an implantable cardioverter defibrillator. The reminder is placed in the medical record with copy to the primary provider and any cardiologist managing the patient.
9784105|NCT01217827|No Intervention|Control|This group does not receive an intervention.
9784106|NCT01217840|Experimental|vitamin D|"Subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop (Sanofi-Aventis)), given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments.~Intervention: Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks"
9784107|NCT01217840|Placebo Comparator|Placebo|Subjects were assigned to receive two observed doses of placebo, given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks
9784108|NCT01217892|Experimental|1|Dapagliflozin 2.5 mg twice-daily plus open-label metformin
9784109|NCT01217892|Experimental|2|Dapagliflozin 5.0 mg twice-daily plus open-label metformin
9784110|NCT01217892|Experimental|3|Dapagliflozin 10 mg once-daily plus open-label metformin
9784111|NCT01217892|Placebo Comparator|4|Placebo plus open-label metformin
9784112|NCT01217944|Experimental|Ranibizumab driven by disease activity|Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
9784113|NCT01217944|Experimental|Ranibizumab driven by stabilization criteria|Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
9784114|NCT01217944|Active Comparator|Verteporfin PDT|Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.
9785653|NCT01256658|Experimental|Control|Participants received COA566 treatment for symptomatic malaria episodes only.
9785654|NCT01256671|Experimental|DHEA|0.5% DHEA (intravaginal)
9785655|NCT01256684|Placebo Comparator|Placebo|
9785656|NCT01256684|Experimental|0.25% DHEA|
9785657|NCT01256684|Experimental|0.5% DHEA|
9833588|NCT02660580|Active Comparator|EU-Humira|Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
9833589|NCT02660580|Experimental|MSB11022 (Extended Treatment Period)|Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
9833590|NCT02660580|Active Comparator|EU-Humira/EU-Humira|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
9833591|NCT02660580|Experimental|EU-Humira/MSB11022|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
9833592|NCT02660788|Active Comparator|Control Arm|Mail
9833593|NCT02660788|Experimental|Family Physician Reminder Letter Arm|Mail
9833594|NCT02660801|Experimental|Spinal manipulation|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
9833595|NCT02660801|Experimental|Spinal mobilization|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
9833596|NCT02660853|Other|Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
9833597|NCT02660918|Experimental|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
9833598|NCT02660918|Placebo Comparator|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
9833599|NCT02660944|Experimental|RSLV-132|10 mg/kg RSLV-132
9833600|NCT02660944|Placebo Comparator|Placebo|Saline placebo
9833601|NCT02660983|Placebo Comparator|Double Blind Phase: Placebo|Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
9833602|NCT02660983|Experimental|Double Blind Phase: Donepezil|Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
9833603|NCT02660983|Experimental|Open-Label Extension Phase: Donepezil|All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
9833604|NCT02661061|Experimental|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
9833605|NCT02661061|Active Comparator|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
9833606|NCT02661126|Experimental|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m^2 to <60 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
9833607|NCT02661126|Experimental|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m^2 to <30 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
9833608|NCT02661126|Experimental|Healthy Participants|Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
9833609|NCT02661178|Experimental|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
9833610|NCT02661178|Placebo Comparator|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
9833611|NCT02661217|Other|Pre-discharge treatment initiation|Patients received first dose at any point after Randomization but no later than 12 h before discharge.
9833612|NCT02661217|Other|Post-discharge treatment initiation|Patients received first dose after discharge and up to 14 days thereafter.
9833613|NCT02661256|Active Comparator|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
9765602|NCT00805389|Experimental|GSK223192A 2 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
9765603|NCT00805389|Experimental|GSK223192A 3 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
9765604|NCT00805389|Experimental|Fendrix Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
9765605|NCT00805389|Active Comparator|Engerix-B Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
9765606|NCT00805441|Placebo Comparator|Placebo|
9765607|NCT00805441|Experimental|LY686017|
9765608|NCT00805467|Experimental|1|R935788 50 mg tablet, orally, twice-a-day
9765609|NCT00805467|Experimental|2|R935788 100 mg tablet, orally, twice-a-day
9765610|NCT00805467|Experimental|3|R935788 100 mg tablet, orally, once-a-day
9765611|NCT00805467|Experimental|4|R935788 150 mg tablet, orally, once-a-day
9765612|NCT00805480|Experimental|AIN457 3 mg/kg|Participants randomized to this arm received AIN457 3 mg/kg on day 1, and then matching placebo on days 15 and 29.
9765613|NCT00805480|Experimental|AIN457 10 mg/kg|Participants randomized to this arm received AIN457 10 mg/kg on day 1, and then matching placebo on days 15 and 29.
9765614|NCT00805480|Experimental|AIN457 10 mg/kg x3|Participants randomized to this arm received AIN457 3 mg/kg on days 1, 15 and 29.
9765615|NCT00805480|Placebo Comparator|Placebo|Participants randomized to this arm received matching placebo to AIN457 on days 1, 15 and 29
9765616|NCT00805493|No Intervention|Medication Taper|All participants begin with gradual tapering to the point of discontinuing medication
9765617|NCT00805493|No Intervention|Random assignment to placebo|Once they are medication-free, 50% of participants are randomized to placebo
9765618|NCT00805493|Active Comparator|Random assignment to riluzole|One they are medication-free, 50% of participants are randomized to riluzole
9765619|NCT00805532|Experimental|Behavioral Activation|Behavioral Activation (BA), modified to be delivered in 6-8, 60 minute sessions to address PTSD-related problems.
9765620|NCT00805532|Active Comparator|Treatment as Usual|Treatment As Usual for PTSD (TAU) within VA PTSD specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system.
9765621|NCT00805545|Experimental|A|Group of patients that will receive antibiotics 30-60 minutes prior to incision
9765622|NCT00805545|Active Comparator|B|Group of patients that will receive antibiotics immediately after clamping the umbilical cord
9785658|NCT01256788|Experimental|Viscosupplementation|Hyaluronic acid injection
9785659|NCT01256788|Placebo Comparator|Saline injection|
9785660|NCT01256840||Calorie Restricting Group|
9785661|NCT01256840||Normal-eating controls|
9785662|NCT01256840||Obese comparison group|
9833614|NCT02661256|Active Comparator|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
9833615|NCT02661490|Experimental|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.
9833616|NCT02661490|Experimental|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.
9833617|NCT02661490|Experimental|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.
9833618|NCT02661490|Experimental|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.
9833619|NCT02661490|Experimental|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.
9833620|NCT02661594|Experimental|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
9833621|NCT02661594|Experimental|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
9833622|NCT02661594|Experimental|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
9833623|NCT02661594|Active Comparator|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
9833624|NCT02661737||YVOIRE volume s|Treatment with YVOIRE volume s
9833625|NCT02661815|Experimental|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
9833626|NCT02661815|Experimental|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
9833627|NCT02661815|Experimental|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
9833628|NCT02661815|Experimental|Phase 1 Escalation Cohort|Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).
9833629|NCT02661828|Active Comparator|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
9833630|NCT02661828|Active Comparator|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
9833631|NCT02662023|Experimental|RIGHT side BOLUS and left side basal|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours
9984253|NCT04278560|Experimental|Behavioral intervention plus tDCS|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of transcranial direct current stimulation (tDCS) designed to increase the excitability of the left dorsolateral prefrontal cortex.
9833632|NCT02662023|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours. For the left catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later
9833633|NCT02662036|Active Comparator|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
9833634|NCT02662036|Experimental|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
9833635|NCT02662244|Experimental|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
9833636|NCT02662387|Active Comparator|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
9833637|NCT02662387|Experimental|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
9833638|NCT02662556|Experimental|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg
9833639|NCT02662569|Active Comparator|Atorvastatin (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
9833640|NCT02662569|Active Comparator|Atorvastatin (QM)|Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
9984254|NCT04278560|Active Comparator|Behavioral intervention plus sham stimulation|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of sham stimulation.
9833641|NCT02662569|Experimental|Evolocumab Q2W + Atorvastatin|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
9833642|NCT02662569|Experimental|Evolocumab QM + Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.
9833643|NCT02662582|Experimental|CK-2127107 1000 mg, then placebo|Participants received CK-2127107 500 milligram (mg), orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
9833644|NCT02662582|Experimental|Placebo, then CK-212710 1000 mg|Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
9833645|NCT02662608|Experimental|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
9833646|NCT02662764|Experimental|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
9833647|NCT02663128|Experimental|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
9833648|NCT02663128|Experimental|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
9833649|NCT02663128|Experimental|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
9833650|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
9833651|NCT02663453|Experimental|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
9833652|NCT02663453|Active Comparator|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
9833653|NCT02663674|Placebo Comparator|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
9833654|NCT02663674|Experimental|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
9833655|NCT02663687|Experimental|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
9833656|NCT02663687|Placebo Comparator|Placebo|3 Subjects will receive placebo for each cohort
9833657|NCT02663817|Experimental|IMRT|Study participants being treated according to the standard of care with intensity modulated radiotherapy (IMRT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (between fraction 10 and 20), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
9833658|NCT02663882|Experimental|smoking-related self control task|self control practice - smoking related task
9833659|NCT02663882|Active Comparator|Non-smoking-related self control task|self control practice - non-smoking related task
9833660|NCT02663895|Experimental|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months
9833661|NCT02664220|Experimental|Povidone-iodine irrigation|
9833662|NCT02664220|Active Comparator|No irrigation|
9833663|NCT02664311|Placebo Comparator|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
9833664|NCT02664311|Active Comparator|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
9833665|NCT02664363|Experimental|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10^6/kg, #2: 1.5 x 10^7/kg, #3: 4.5 x 10^7/kg, and #4: 1.5 x 10^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
9833666|NCT02664415|Experimental|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
9833667|NCT02664415|Placebo Comparator|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
9836005|NCT02765165|Experimental|Dose-Expansion, USL311 with Lomustine, GBM, Part 4|USL311, oral, daily, in combination with lomustine, oral, once every 6 weeks, at dose(s) as determined in part 2
10203349|NCT02487979|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
10203350|NCT02466685|Experimental|JNJ-18038683|Subjects will be randomized to receive JNJ-18038683 or placebo after the completion of the baseline assessments. Subjects randomized to JNJ-18038683 will receive 10 mg for one week, then titrate to 20 mg for the duration of the trial, with the provision for a single, downward dose adjustment for intolerance, based upon investigator judgment.
10203351|NCT02466685|Placebo Comparator|Placebo|Placebo treatment for 8 weeks.
10203352|NCT02463448|Experimental|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
10203353|NCT02452008|Experimental|Arm 1: Enzalutamide with LY2157299|
9833668|NCT02664532|Experimental|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
9833669|NCT02664532|Other|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
9833670|NCT02664610|No Intervention|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
9833671|NCT02664610|Experimental|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
9833672|NCT02664909|Experimental|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
9833673|NCT02664909|Placebo Comparator|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
9833674|NCT02664922|Experimental|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
9833675|NCT02664922|Experimental|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
9833676|NCT02664922|Experimental|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
9833677|NCT02664922|Experimental|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
9833678|NCT02664961|Experimental|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
9833679|NCT02664987||Patients receiving cancer pain treatment|
9833680|NCT02665052|Experimental|Home-Based BATRAC|Home-based BATRAC training will consist of 45 minutes of high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
9833681|NCT02665052|Experimental|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and rest periods followed by 15 minutes of therapist guided transition to task training (TTT).
9833682|NCT02665052|Placebo Comparator|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
9833683|NCT02665260|Active Comparator|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
9833684|NCT02665260|Experimental|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
9833685|NCT02665260|Placebo Comparator|Placebo with occlusion|Placebo topical with occlusion
9833686|NCT02665260|Placebo Comparator|Placebo without occlusion|Placebo topical without occlusion
9833687|NCT02665273|Experimental|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
9833688|NCT02665273|Sham Comparator|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
9833689|NCT02665286|Placebo Comparator|Placebo|Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
9833690|NCT02665286|Active Comparator|Orphenadrine|Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
9785663|NCT01256879|Experimental|CimTest-A|200mg cimetidine (as 2 capsules)
9785664|NCT01256879|Experimental|CimTest-B|200mg cimetidine (as 2 capsules)
9785665|NCT01256879|Active Comparator|Sorbitol-free cimetidine solution|200mg cimetidine (as oral liquid)
9785666|NCT01256879|Experimental|Commercial cimetidine solution|200mg cimetidine (as oral liquid)
9785667|NCT01256944||Control|The normal reproductive-aged women
9785668|NCT01256944||PCOS|"Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:~Oligo- or anovulation~Clinical and/or biochemical signs of hyperandrogenism~Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)"
9785669|NCT01256983|Experimental|Bright Light Therapy|Bright Light Therapy with 10000 lux beginning at day 21 until day 42
9785670|NCT01256983|Other|Wait-list intervention|Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
9785671|NCT01257087|Experimental|Intensive glycaemic control|Intensive glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
9785672|NCT01257087|Active Comparator|Conservative glycaemic control|Conservative glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
9785673|NCT01257204|Active Comparator|Control|Placebo + Pegylated interferon alfa-2a + Ribavirin
9785674|NCT01257204|Experimental|12 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
9785675|NCT01257204|Experimental|16 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
9785676|NCT01257217|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1 or AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT, lens assignment and model determined by preoperative keratometric astigmatism, bilateral implantation
9785677|NCT01257217|Active Comparator|Acri.LISA|Acri.LISA® 366D IOL or Acri.LISA® 466TD Toric IOL, lens assignment determined by preoperative keratometric astigmatism, bilateral implantation
9785678|NCT01257230|Placebo Comparator|placebo|once daily, delivered with Respimat inhaler
9785679|NCT01257230|Experimental|tiotropium low dose|once daily, delivered with Respimat inhaler
9785680|NCT01257230|Experimental|tiotropium high dose|once daily, delivered with Respimat inhaler
9785681|NCT01257347|Other|Concealment (control)|Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
9785682|NCT01257347|Experimental|Disclosure (intervention)|"Disclosure of adherence report to clinician:~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox)."
9785683|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.|
9785684|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.|
9785685|NCT01257438|Experimental|Fluency Plus Endovascular Stent Graft|Fluency Plus Endovascular Stent Graft
9785686|NCT01257438|Active Comparator|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty only
9785687|NCT01257503|Experimental|Homeopathic cold remedy|5 ml of homeopathic cold remedy given by mouth up to 6 times per day as needed for cold symptoms
9785688|NCT01257503|Placebo Comparator|placebo|5 ml of placebo given by mouth up to 6 times per day as needed for cold symptoms
9785689|NCT01257542|Experimental|Active|
9785690|NCT01257542|Placebo Comparator|Placebo|
9785691|NCT01257581|Experimental|Creatine 30gm|"Creatine will be taken as a powder mixed into food or liquid twice a day. Volunteers in this arm will take a total of 30gm of creatine per day for 38 weeks. Volunteers will also take placebo capsules twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Creatine is a nutritional supplement and is not approved by the U.S. Food and Drug Administration (FDA) for treating ALS."
9785692|NCT01257581|Experimental|Tamoxifen 40mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 40mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
9765623|NCT00805675|Experimental|Telbivudine 600 mg monotherapy|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
9765624|NCT00805675|Active Comparator|Tenofovir disproxil fumarate 300 mg monotherapy|All patients in this arm were randomized to receive Tenofovir disoproxil fumarate 300 mg(equivalent to tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
9765625|NCT00805675|Active Comparator|Telbivudine 600 mg and Tenofovir 300 mg|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD and Tenofovir (TDF) 300 mg (equivalent to Tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
9765626|NCT00805740|Experimental|Anidulafungin arm|
9765627|NCT00805740|Experimental|Caspofungin arm|
9765628|NCT00805766|Experimental|TA-650|
9765629|NCT00805792|Experimental|Donepezil|Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.
9765630|NCT00805870|Experimental|Fish Oil|Lovaza, 3 grams/day for 65 days
9765631|NCT00805870|Placebo Comparator|Control|Wheat Germ Oil, 3 grams/day for 65 days
9765632|NCT00805935|Experimental|Menotropin/Progesterone vaginal insert|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 100 mg starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9765633|NCT00805935|Experimental|Menotropin/Progesterone in oil|"Menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9765634|NCT00805935|Active Comparator|Follitropin beta/Progesterone vaginal insert|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9765635|NCT00805935|Active Comparator|Follitropin beta/Progesterone in oil|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
9765636|NCT00805948|Experimental|DeNovo|Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
9765637|NCT00805948|No Intervention|Valor|Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study
9765638|NCT00806026|Experimental|PBO/PGB 300 mg|
9765639|NCT00806026|Active Comparator|PBO/PPX 0.25 mg|
9765640|NCT00806026|Active Comparator|PBO/PPX 0.5 mg|
9765641|NCT00806026|Experimental|PGB 300 mg|
9765642|NCT00806026|Active Comparator|PPX 0.25 mg|
9765643|NCT00806026|Active Comparator|PPX 0.5 mg|
9765644|NCT00806078|Experimental|1|Single dose intact capsules 2 x 324 mg
10203354|NCT02452008|Experimental|Arm 2: Enzalutamide alone|
10203355|NCT02431871||Treated for DDH in childhood|Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
10203356|NCT02431871||Control|Age an sex matched controls of DDH patients
10203357|NCT02364843|Experimental|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
10203358|NCT02310867|Experimental|Hand transplant with Belatacept|
10203359|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
10203360|NCT02303431|Experimental|Cohort 1a|12 to < 18 years of age: edoxaban low dose group
10203361|NCT02303431|Experimental|Cohort 1b|12 to < 18 years of age: edoxaban high dose group
10203362|NCT02303431|Experimental|Cohort 2a|6 to < 12 years of age: edoxaban low dose group
10203363|NCT02303431|Experimental|Cohort 2b|6 to < 12 years of age: edoxaban high dose group
10203364|NCT02303431|Experimental|Cohort 3a|2 to < 6 years of age: edoxaban low dose group
10203365|NCT02303431|Experimental|Cohort 3b|2 to < 6 years of age: edoxaban high dose group
10203366|NCT02303431|Experimental|Cohort 4a|6 months to <2 years of age: edoxaban low dose group
10203367|NCT02303431|Experimental|Cohort 4b|6 months to <2 years of age: edoxaban high dose group
10203368|NCT02303431|Experimental|Cohort 5a|0 to 6 months of age: edoxaban low dose group
10203369|NCT02303431|Experimental|Cohort 5b|0 to 6 months: edoxaban high dose group
10203370|NCT02300961|Experimental|Cognitive rehabilitation arm|Cognitive rehabilitation program
10203371|NCT02288897|Experimental|PV-10|Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
9984255|NCT04275869|Experimental|Experimental Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
9765645|NCT00806078|Experimental|2|Single dose contents of two capsules (2 x 324 mg) opened and mixed in 120 mL of chocolate pudding
9765646|NCT00806156|Experimental|NKTR-102 q14d|NKTR-102 was administered as an intravenous (IV) infusion over 90 ± 10 minutes, on Day 1 of each 2-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 4 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
9765647|NCT00806156|Experimental|NKTR-102 q21d|NKTR-102 was administered as an IV infusion over 90 ± 10 minutes, on Day 1 of each 3-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 6 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
9765648|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Non-Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - infants who only provided SAEs (Serious Adverse Events) and medically attended AEs (Adverse Events)."
9765649|NCT00806195|Active Comparator|Routine Vaccines (Non-Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - subjects who only provided SAEs and medically attended AEs."
9765650|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
9765651|NCT00806195|Active Comparator|Routine Vaccines (Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
9765652|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (All)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
9765653|NCT00806195|Active Comparator|Routine Vaccines (All)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
9765654|NCT00806221|Experimental|Emollient|Skin barrier protection from birth
9765655|NCT00806234|Active Comparator|1|Participants will continue on current antipsychotic medication.
9765656|NCT00806234|Experimental|2|Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.
9765657|NCT00806234|Experimental|3|Participants will add metformin to current antipsychotic medication treatment.
9765658|NCT00806260|Experimental|Treatment 1|Dosed first with alcohol, then active VI-0521, and last, VI-0521 placebo
9765659|NCT00806260|Experimental|Treatment 2|First dosed with alcohol placebo (fruit juice), then active VI-0521, and last, placebo VI-0521
9765660|NCT00806260|Experimental|Treatment 3|First dosed with alcohol, then VI-0521 placebo, and last, active VI-0521
9765661|NCT00806260|Experimental|Treatment 4|First dosed with alcohol placebo, then VI-0521 placebo, and last, active VI-0521
9765662|NCT00806286|Experimental|CS-7017 with Paclitaxel and Carboplatin|
9765663|NCT00806286|Placebo Comparator|Paclitaxel and Carboplatin|
9765664|NCT00806351|Experimental|Anidulafungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
9765665|NCT00806351|Experimental|Caspofungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
9765666|NCT00806442|Experimental|1: Borage Seed Oil and Echium Seed Oil|Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
9765667|NCT00806442|Placebo Comparator|2: Placebo Comparator|Placebo comparator: 9 g/day corn oil
9765668|NCT00806494|Experimental|Treatment Arm|Fesoterodine 4mg, escalating to 8mg as required
9765669|NCT00806546|Experimental|NP101|sumatriptan iontophoretic transdermal patch
9765670|NCT00806585|Experimental|MK-0736 0.5 mg|One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
9765671|NCT00806585|Experimental|MK-0736 2.0 mg|One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
9765672|NCT00806585|Experimental|MK-0736 8.0 mg|One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
9765673|NCT00806585|Active Comparator|HCTZ 12.5 mg → MK-0736 8.0 mg|one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks. Participant then switched to MK-0736 8.0 mg for 12 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
9765674|NCT00806585|Placebo Comparator|Placebo|One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)
9765675|NCT00806598|Experimental|Thymoglobulin + Cyclosporin|Combination of Thymoglobulin 3.5 or 2.5 mg/kg/day intravenous (IV) for 5 days + Methylprednisone 1 mg/kg/day IV for 5 days, before each dose Thymoglobulin + Cyclosporin 5 mg/kg orally for 6 months following Thymoglobulin + Granulocyte - Colony Stimulating Factor (G-CSF) 5 microgram/kg subcutaneously daily up to 3 months
9765676|NCT00806624|Experimental|2|DU-176b tablets: high-dose
9765677|NCT00806624|Active Comparator|3|Warfarin tablets
9765678|NCT00806624|Experimental|1|DU-176b tablets: low-dose
9765679|NCT00806676|Other|1. Chronic Kidney Disease, NKF Stage 1-4|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
9765680|NCT00806676|Other|2. ESRD (dialysis)|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
9765681|NCT00806676|Other|3. Kidney Transplant Recipient|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
9765682|NCT00806819|Experimental|nintedanib (BIBF1120) plus pemetrexed|nintedanib (BIBF1120) along with standard therapy of pemetrexed
9765683|NCT00806819|Placebo Comparator|Placebo plus pemetrexed|Pemetrexed standard therapy
9765684|NCT00806819|Experimental|nintedanib (BIBF1120) monotherapy|nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
9765685|NCT00806819|Active Comparator|pemetrexed monotherapy|pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
9765686|NCT00806819|Placebo Comparator|placebo monotherapy|placebo monotherapy only for patients who discontinue pemetrexed
9765687|NCT00806988|Active Comparator|Mitral Valve Repair|Participants will undergo CABG and a mitral valve repair procedure.
9765688|NCT00806988|Active Comparator|CABG|Participants will undergo CABG.
9765689|NCT00807001|Experimental|Cohort A|Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
9765690|NCT00807001|Experimental|Cohort B|Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
9833691|NCT02665286|Active Comparator|Methocarbamol|Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
9833692|NCT02665364|Experimental|IFNα-Kinoid|IFNα-Kinoid (IFN-K) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at W0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
9833693|NCT02665364|Placebo Comparator|Placebo|Placebo normal saline (0.9% Sodium Chloride) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at week (W)0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
9833694|NCT02665455|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
9833695|NCT02665468|Other|Arm 1: Supported Adoption Intervention (SAI)|Supported adoption intervention
9833696|NCT02665468|Active Comparator|Arm 2: General wellness information|General wellness information
9833697|NCT02665689|Active Comparator|Regular Glycemic Control|Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
9833698|NCT02665689|Experimental|Intensified Glycemic Control|"Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level < 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake."
9833699|NCT02665728|Experimental|BLI400|BLI400 Laxative
9833700|NCT02665741|Other|Control|Standard colonoscopy - no distal colonoscope attachment will be used in this arm
9833701|NCT02665741|Experimental|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
9833702|NCT02665741|Experimental|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
9833703|NCT02665975|Experimental|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
9833704|NCT02665975|Active Comparator|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
9833705|NCT02666352|Experimental|Moderate HI Participants|On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
9833706|NCT02666352|Experimental|Severe HI Participants|On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
9833707|NCT02666352|Experimental|Healthy Participants|On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
9833708|NCT02666508|Active Comparator|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
9833709|NCT02666508|Active Comparator|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
9833710|NCT02666560|Active Comparator|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
9833711|NCT02666560|Experimental|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
9833712|NCT02666664|Experimental|ETC-1002|ETC-1002 180 mg/day
9833713|NCT02666664|Placebo Comparator|Placebo|Placebo control
9833714|NCT02666742|Experimental|DOAC (Direct Oral Anticoagulant)|Participants will be asked to take standard dose approved for stroke prophylaxis
9833715|NCT02666742|Active Comparator|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
9833716|NCT02666846|Experimental|Cohort 1: TIB200 gel 10%|All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
9833717|NCT02666846|Active Comparator|Cohort 1: Nurofen gel 10%|All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
9833718|NCT02666846|Active Comparator|Cohort 1: Nurofen tablets|All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
9833719|NCT02666846|Placebo Comparator|Cohort 1: TIB200 Placebo gel|All Cohort 1 Participants: TIB200 matching placebo gel
9833720|NCT02666846|Active Comparator|Cohort 2: DCF100 gel 2%|All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
9765691|NCT00807001|Experimental|Cohort C|Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
9765692|NCT00807001|Experimental|Cohort D|Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
9765693|NCT00807014|Experimental|Duac Gel|Duac Gel
9765694|NCT00807014|Active Comparator|Differin gel|Differin gel
9765695|NCT00807040|Active Comparator|Mitral Valve Repair with Annuloplasty|Participants will undergo mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
9765696|NCT00807040|Active Comparator|Mitral Valve Replacement|Participants will undergo mitral valve replacement and complete preservation of the sub-valvular apparatus.
9833721|NCT02666846|Experimental|Cohort 2: DCF100 gel 4%|All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
9833722|NCT02666846|Active Comparator|Cohort 2: Voltaren gel 2%|All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
9765697|NCT00807092|Experimental|BIAsp 30|BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BIAsp 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
9765698|NCT00807092|Experimental|BHI 30|BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BHI 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
9765699|NCT00807144|Experimental|Prolonged-Release Tacrolimus|Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy
9765700|NCT00807144|Active Comparator|Standard-Release tacrolimus|Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy
9765701|NCT00807209|Experimental|High Dose SKY0402|
9765702|NCT00807209|Active Comparator|Standard of Care|
9765703|NCT00807209|Experimental|Low Dose SKY0402|
9765704|NCT00807235|Experimental|Regimen 1|
9765705|NCT00807235|Experimental|Regimen 2|
9765706|NCT00807248|Placebo Comparator|Escitalopram placebo and gaboxadol placebo|
9765707|NCT00807248|Active Comparator|Escitalopram 20 mg and gaboxadol placebo|
9765708|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 5 mg|
9765709|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 10 mg|
9765710|NCT00807456|Experimental|ASTRA TECH Implant System, OsseoSpeed™|
9765711|NCT00807495|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
9765712|NCT00807560|Experimental|FBT-PO|Family Based Therapy for Pediatric Overweight.
9765713|NCT00807560|Active Comparator|NEC-control|Nutritional Educational Control Condition (NEC).
9765714|NCT00807573|Experimental|Paclitaxel, Bevacizumab & Pemetrexed|During each 28-day cycle, paclitaxel, pemetrexed and bevacizumab will be given intravenously on days 1 and 15. Paclitaxel will be administered at 90mg/m^2 over 60 minutes on days 1 and 15. Pemetrexed 500mg/m^2 will be administered over 10 minutes on days 1 and 15. Bevacizumab will be given at 10mg/kg over 20 minutes on days 1 and 15
9765715|NCT00807586|Experimental|Steroid|
9765716|NCT00807586|Placebo Comparator|Placebo|
9765717|NCT00807599|Experimental|Stem cell transplant x 1 or x 2|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone, saving stem cell transplant for a later time."
9765718|NCT00807599|Experimental|Continue lenalidomide and dexamethasone|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone~saving stem cell transplant for a later time."
9765719|NCT00807664|Experimental|1|Biatain Ag dressing
9765720|NCT00807664|Active Comparator|2|Biatain dressing
9765721|NCT00807742|Experimental|Contingency Management (CM)|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
9765722|NCT00807742|Active Comparator|Noncontingent Reinforcement (NR)|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
9765723|NCT00807768|Active Comparator|Arm I (pelvic radiation therapy)|Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
9765724|NCT00807768|Experimental|Arm II (brachytherapy, paclitaxel, carboplatin)|Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9765725|NCT00807846|Experimental|Celecoxib|
9765726|NCT00807846|Experimental|Naproxen|
9765727|NCT00807885|Experimental|Tegaderm-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm
9765728|NCT00807885|Experimental|Tape-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron
9765729|NCT00807885|Experimental|Tegaderm-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm
9765730|NCT00807885|Experimental|Tape-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron
9833723|NCT02666846|Active Comparator|Cohort 2: Voltarol oral tablet|All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
9833724|NCT02666846|Placebo Comparator|Cohort 2: DCF100 Placebo gel|All Cohort 2 Participants: DCF100 matching placebo gel
9765731|NCT00807885|Experimental|Tegaderm-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm
9765732|NCT00807885|Experimental|Tape-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron
9765733|NCT00807885|Experimental|Tegaderm-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm
9765734|NCT00807885|Experimental|Tape-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron
9765735|NCT00807885|Experimental|SC button with 27 ga X 9 mm needle|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)
9765736|NCT00807937|Experimental|A|AZD7325 5mg twice daily
9765737|NCT00807937|Experimental|B|AZD7325 15mg twice daily
9765738|NCT00807937|Active Comparator|C|Lorazepam 2mg twice daily
9765739|NCT00807937|Placebo Comparator|D|Placebo
9765740|NCT00807989|Active Comparator|Carbamazepine|Carbamazepine
9765741|NCT00807989|Experimental|Lamotrigine/Valproate|Lamotrigine and Valproate combination therapy
9765742|NCT00808015||Patients in routine practice|Patients prescribed Champix by treating physician and then entered into trial
9765743|NCT00808028|Experimental|1|dose level 1 rLP2086 vaccine
9765744|NCT00808028|Experimental|2|dose level 2 rLP2086 vaccine
9765745|NCT00808028|Experimental|3|dose level 3 rLP2086 vaccine
9765746|NCT00808028|Placebo Comparator|4|normal saline (placebo)
9765747|NCT00808067|Experimental|dabigatran dose 1|dabigatran high dose twice daily
9765748|NCT00808067|Experimental|dabigatran dose 2|dabigatran low dose twice daily
9765749|NCT00808132|Experimental|1|bazedoxifene 20 mg/conjugated estrogens 0.45 mg
9765750|NCT00808132|Experimental|2|bazedoxifene 20 mg/conjugated estrogens 0.625 mg
9765751|NCT00808132|Experimental|3|bazedoxifene 20 mg
9765752|NCT00808132|Active Comparator|4|Prempro
9765753|NCT00808132|Placebo Comparator|5|Placebo
9765754|NCT00808210|Experimental|Ocrelizumab 200mg|Participants received two intravenous (IV) infusions of 200 mg ocrelizumab administered on Day 1 and Day 15 and placebo IV infliximab infusions administered on Day 1, Day 15, Week 6, and Week 14. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
9833725|NCT02666846|Active Comparator|Cohort 3: SPR300 gel (15%:7%)|All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
9833726|NCT02666846|Placebo Comparator|Cohort 3: SPR300 Placebo gel|All Cohort 3 Participants: SPR300 matching placebo gel
9833727|NCT02666950|Experimental|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
9765755|NCT00808210|Active Comparator|Infliximab 5mg/kg|Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
9765756|NCT00808236|Experimental|RhinoChill|Intra-arrest cooling with the RhinoChill during advanced cardiac life support
9765757|NCT00808236|Other|Control|Advanced cardiac life support, only
9765758|NCT00808249|Experimental|A-AZD7325 2mg|AZD7325 2mg BID
9765759|NCT00808249|Experimental|B-AZD7325 5mg|AZD7325 5mg BID
9765760|NCT00808249|Experimental|C-AZD7325 10mg|AZD7325 10mg QD
9765761|NCT00808249|Experimental|D-Placebo|Placebo
9765762|NCT00808340|Active Comparator|senofilA test/senofilA prod/balafilconA|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, senofilcon A production worn second, and balafilcon A worn third.
9765763|NCT00808340|Active Comparator|senofilcon A test/balafilcon A/senofilcon A prod|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, balafilcon A worn second, and senofilcon A production worn third.
9765764|NCT00808340|Active Comparator|senofilcon A prod/senofilcon A test/balafilcon A|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, senofilcon A test worn second, and balafilcon A worn third.
9765765|NCT00808340|Active Comparator|senofilcon A prod/ balifilcon A/ senofilcon A test|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, balafilcon A worn second, and senofilcon A test worn third.
9765766|NCT00808340|Active Comparator|balafilcon A/senofilcon A test/senofilcon A prod|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A test worn second, and senofilcon A production worn third.
9765767|NCT00808340|Active Comparator|balafilcon A/senofilcon A prod/senofilcon A test|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A production worn second, senofilcon A test worn third.
9765768|NCT00808405|Active Comparator|acyclovir|
9765769|NCT00808405|Placebo Comparator|placebo|
9765770|NCT00808444|Experimental|Synflorix Clinical Lot & Infanrix Group|Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
9765771|NCT00808444|Experimental|Synflorix Commercial Lot Infanrix Group|Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
9765772|NCT00808470|Experimental|Nutrients|Subjects in University of Florida music player study who are assigned to nutrient condition(beta-carotene, vitamins C and E, magnesium). Nutrient tablets are consumed for 4 days.
9765773|NCT00808470|Placebo Comparator|Placebo for nutrients|Subjects in University of Florida music player study who are assigned to control (placebo) condition. Placebo tablets are consumed for 4 days.
9765774|NCT00808483|Experimental|Walking skill training group|Participation in the supervised walking skill training program.
9765775|NCT00808483|No Intervention|Control group|No participation in the supervised walking skill training program
9765776|NCT00808509|Active Comparator|Adalimumab + MTX|Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
9765777|NCT00808509|Experimental|Methotrexate|Participants discontinued adalimumab and continued to receive methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. Participants with a significant increase in RA disease activity were re-instituted to adalimumab 40 mg every other week (rescue arm). After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
9765778|NCT00808639|Experimental|Dose Dense MVAC|Chemo therapy with methotrexate, vinblastine, Adriamycin, Cisplatin
9765779|NCT00808665|Experimental|Dexmedetomidine|At the beginning of spinal surgery, patients will receive 1 hour dexmedetomidine intravenous bolus of 0.7 mcg/kg, followed by infusion of dexmedetomidine at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of dexmedetomidine at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
9765780|NCT00808665|Placebo Comparator|Saline|Since this is a blinded study, at the beginning of spinal surgery, patients will receive a 1 hour 0.9% saline intravenous bolus at a rate and volume commensurate with a 0.7 mcg/kg/hour bolus of dexmedetomidine. Similarly, this will be followed with a saline infusion at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of saline at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
9765781|NCT00808808||Arm A (Control)|A control arm of usual care offering TIV with baseline advertisement
9765782|NCT00808808||Arm B (Choice)|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
9765783|NCT00808808||Arm C (Choice Plus)|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
9765784|NCT00808834|Other|Senofilcon A / Lotrafilcon A|Senofilcon A, followed by Lotrafilcon A
9765785|NCT00808834|Other|Lotrafilcon A / Senofilcon A|Lotrafilcon A, followed by Senofilcon A
9765786|NCT00809055|Experimental|High dose caffeine|Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.
9765787|NCT00809055|Active Comparator|Standard dose caffeine|Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.
9765788|NCT00809094|Placebo Comparator|Placebo|Placebo was administered oral tablet TID for 24 weeks.
9765789|NCT00809094|Active Comparator|N-Acetylcysteine|Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.
9765790|NCT00809133|Experimental|Part A|BIBW2992 + Paclitaxel
9765791|NCT00809133|Experimental|Part B|BIBW2992 + Paclitaxel + Bevacizumab
9765792|NCT00809133|Experimental|Part C|BIBW2992 + Carboplatin
9765793|NCT00809133|Experimental|Part D|BIBW2992 +Paclitaxel + Carboplatin
9765794|NCT00809146|Active Comparator|Intramuscular (IM) anticonvulsant|This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
9765795|NCT00809146|Active Comparator|Intravenous (IV) anticonvulsant|This group gets active treatment with an anticonvulsant by the intravenous route of administration.
9765796|NCT00809159|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
9765797|NCT00809159|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose
9765798|NCT00809159|Experimental|Parts 1 and 2 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
9765799|NCT00809159|Experimental|Part 1 and 2 - AIN457 0.1 mg/kg|AIN457A 0.1 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
9765800|NCT00809159|Experimental|Part 1 and 2 - AIN457 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
9784115|NCT01217957|Experimental|Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 1.68 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
9784116|NCT01217957|Experimental|Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.23 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
9784117|NCT01217957|Experimental|Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.97 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
9784118|NCT01217957|Experimental|Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 3.95 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
9833728|NCT02666950|Experimental|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
9765801|NCT00809185|Experimental|RAD001 (everolimus)|RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis
9765802|NCT00809328|Experimental|Azithromycin|Azithromycin switch therapy (switch from intravenous to oral)
9765803|NCT00809354|Active Comparator|IV Placebo + NSAID|Oral NSAID
9765804|NCT00809354|Experimental|Tanezumab 5 mg|IV tanezumab 5 mg every 8 weeks (through Week 48)
9765805|NCT00809354|Experimental|Tanezumab 10 mg|IV tanezumab 10 mg every 8 weeks (through Week 48)
9765806|NCT00809354|Experimental|Tanezumab 5 mg + NSAID|IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
9765807|NCT00809354|Experimental|Tanezumab 10 mg + NSAID|IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
9765808|NCT00809445|Experimental|HIV rapid test & counseling|Participants will be offered an oral fluid HIV rapid test (via oral swab) and brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach (Project RESPECT-2 counseling). Prior to receiving testing, study participants must first provide consent for HIV testing. Consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test.
9765809|NCT00809445|Experimental|HIV rapid test and info|Participants will be offered an oral fluid HIV rapid test (via oral swab). Prior to receiving testing, study participants must first provide consent for HIV testing. Again, consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test. Participants will receive rapid HIV testing and test results after signing the consent to be tested. In both Groups 1 and 2, participants who test reactive (preliminary positive) will be counseled on the sexual risk behaviors associated with transmission of HIV and the acquisition of STDs, as is current clinical practice with those testing HIV positive. Confirmed positives will be linked to HIV primary care.
9765810|NCT00809445|Active Comparator|HIV testing referral|Participants randomized to group 3 will receive a referral list for HIV community-testing agencies. Each CTP site will have previously prepared an extensive referral list of testing sites in the surrounding geographic area. By virtue of their status as patients in the CTPs, they will receive whatever HIV testing and HIV education referrals the CTPs normally provide to their patients. This is the standard of care at CTPs that do not provide on-site testing.
9765811|NCT00809471|Placebo Comparator|placebo|
9765812|NCT00809471|Experimental|avanafil 100 mg|
9765813|NCT00809471|Experimental|avanafil 200 mg|
9765814|NCT00809523|Experimental|Inactivated negative ion generator|Equivalent exposure to inactivated Negative Ion Generator
9765815|NCT00809523|Experimental|LED light treatment device|Light-emitting photodiode light treatment device, used for 30 min before 8 am
9765816|NCT00809614|Experimental|AIN457 (2x 10mg/kg)|Each patient received 10 mg/kg AIN457 intravenously, on Day 1 and Day 22.
9765817|NCT00809614|Placebo Comparator|Placebo|Each patient received 10 mg/kg of matching placebo intravenously, on Day 1 and Day 22.
9765818|NCT00809757|Experimental|1|90 ug Levalbuterol (2 actuations)
9765819|NCT00809757|Active Comparator|2|0.31 ug Levalbuterol UDV TID
9765820|NCT00809757|Placebo Comparator|3|Placebo
9765821|NCT00809783|Experimental|Tanezumab 10 mg|Tanezumab 10 mg
9765822|NCT00809783|Experimental|Tanezumab 5 mg|Tanezumab 5 mg
9765823|NCT00809783|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg
9765824|NCT00809809|Active Comparator|Zinc gluconate|Oral swabs containing homeopathic Zinc gluconate
9765825|NCT00809809|Placebo Comparator|Placebo|placebo
9765826|NCT00809835|No Intervention|Standard Treatment As Usual (TAU)|Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
9765827|NCT00809835|Experimental|TAU Plus Galantamine|Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
9765828|NCT00809835|Experimental|TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)|TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
9765829|NCT00809835|Experimental|TAU plus CBT plus galantamine|Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
9765830|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
9765831|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
9765832|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
9765833|NCT00809848|Active Comparator|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
9765834|NCT00809848|Placebo Comparator|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
9833729|NCT02667236|Active Comparator|A-101 Solution|A-101 Solution 40% administered once
9833730|NCT02667236|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
9833731|NCT02667275|Experimental|A-101 Solution|A-101 Solution 40% administered once
9833732|NCT02667275|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
9833733|NCT02667288|Experimental|A-101 Solution|A-101 Solution 40% administered once
9833734|NCT02667301|Experimental|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:~The patient is subjected to tympanometry test on the specific ear,~The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,~The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
9833735|NCT02667392|Experimental|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
10203372|NCT02288897|Active Comparator|Chemotherapy or Oncolytic Viral Therapy|Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
10203373|NCT02276547|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
9833736|NCT02667392|Active Comparator|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
9833737|NCT02667457|Experimental|CAD Participants|Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an intraveneous (IV) catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
9833738|NCT02667457|Experimental|Healthy Participants|Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
9833739|NCT02667626|Experimental|SCPR Intervention|"Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.~Healthcare providers of young breast cancer participants randomized to the intervention arm will receive their patient's SCPR and access to the same additional web-based educational reproductive health information as their patient, including resource lists of helpful websites."
9833740|NCT02667626|Active Comparator|Control|"Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.~Healthcare providers of young breast cancer participants randomized to the waitlist control arm will receive access to the same web-based resources as their patient."
9833741|NCT02667704|Experimental|Nintedanib|
9833742|NCT02667704|Experimental|Bosentan|
9833743|NCT02667821|Experimental|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
9833744|NCT02667912|Experimental|Distal renal denervation|Endovascular denervation of segmental branches of renal artery
9833745|NCT02667912|Active Comparator|Conventional renal denervation|Endovascular denervation of main trunk of renal artery
9833746|NCT02667951|No Intervention|Control group|Caregivers received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
9833747|NCT02667951|Experimental|Intervention group|Caregivers received solutions for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
9833748|NCT02668003|Experimental|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
9833749|NCT02668003|No Intervention|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
10203374|NCT02270463|Experimental|SL-401|
10203375|NCT02263885|Experimental|ExAblate Transcranial System|Transcranial ExAblate MRgFUS
10203376|NCT02213926|Experimental|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
10203377|NCT02207075||Subjects with SPMS|"Secondary progressive MS Subjects either untreated or on consistent treatment for six months prior to enrollment.~SPMS subjects will have two baseline [11C]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months."
10203378|NCT02207075||Normal Control Subjects|Healthy Controls will have 2 baseline [C11]PK-1195 PET scans and 1 MRI.
10203379|NCT02193295|Experimental|Lifestyle Intervention|Caloric Restriction.
9765835|NCT00809926|Experimental|Valsartan/aliskiren|
9765836|NCT00809926|Active Comparator|Valsartan|
9765837|NCT00809965|Experimental|Rivaroxaban 2.5 mg bid|One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
9765838|NCT00809965|Experimental|Rivaroxaban 5 mg bid|One 5 mg rivaroxaban tablet twice daily for up to 6 months
9765839|NCT00809965|Placebo Comparator|Placebo|One placebo tablet twice daily for up to 6 months
9765840|NCT00810043|Active Comparator|Curette-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, curettage was performed prior to use of inflatable bone tamps.
9765841|NCT00810043|Active Comparator|IBT-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, inflatable bone tamps were used prior to curettage, then followed by a second inflation of the bone tamps.
9765842|NCT00810069|Experimental|Early Intervention|Escitalopram 10 milligrams per day for 4 weeks (one 10 milligram [mg]-capsule) followed by Duloxetine flexible dose (60 or 120 mg daily) for 12 weeks.
9765843|NCT00810069|Experimental|Delayed Intervention|Escitalopram 10 mg per day for 4 weeks (one 10 mg-capsule) followed by Escitalopram 10 to 20 mg per day for 4 weeks (one or two 10 mg capsule[s]). Then, non-responders switched to Duloxetine 60 or 120 mg per day for 8 weeks , and responders continued on Escitalopram 10 to 20 mg per day for 8 weeks.
9765844|NCT00810082|Active Comparator|Group A|Standard physical therapy for fall prevention
9765845|NCT00810082|Experimental|Group B|Physical therapy for fall prevention that includes ActiveStep
9765846|NCT00810095|Experimental|Treatment Arm|
9765847|NCT00810108|Experimental|Whole Then Crushed Tablets|These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.
9765848|NCT00810108|Experimental|Crushed Then Whole Tablets|These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.
9765849|NCT00810199|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
9765850|NCT00810199|Placebo Comparator|Tocilizumab + Placebo|Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
9765851|NCT00810264||Data Collection Group|
9765852|NCT00810277|Experimental|1|
9765853|NCT00810303|Experimental|whole study group|A study with a duration of 34 days with 4 periods (= 4 pharmakokinetics) on 12 healthy subjects.
9765854|NCT00810342|Experimental|1- physical activity tailored|Tailored telephone counseling about how to become more physically active and goal setting. Email feedback on physical activity progress. Website listing resources new mothers can use to become more active.
9765855|NCT00810342|Active Comparator|2 - physical activity standard|Standard Website resources / information on physical activity
9765856|NCT00810355|Active Comparator|Arm 1|Support group
9765857|NCT00810355|Experimental|Arm 2|Cognitive Behavior Therapy
9765858|NCT00810355|Experimental|Arm 3|Cognitive Behavior Therapy and Cognitive Remediation
9765859|NCT00810368|Active Comparator|Carnosine treatment group|Carnosine treatment group
9765860|NCT00810368|Placebo Comparator|Placebo control group|Placebo control group
9765861|NCT00810394|Experimental|Sorafenib|Dose Re-Escalation Following a Dose Reduction
9765862|NCT00810407||rifabutin|Patients administered Rifabutin.
9765863|NCT00810459|Experimental|Trilogy ventilator|Trilogy ventilator
9765864|NCT00810459|Active Comparator|Standard of Care|Participants currently prescribed ventilator
9765865|NCT00810498|Experimental|Trilogy|Trilogy Device
9765866|NCT00810498|Active Comparator|Standard of Care|Participants prescribed ventilator
9765867|NCT00810511|Experimental|Lotrafilcon A|Investigational, spherical, silicone hydrogel contact lenses
9765868|NCT00810511|Active Comparator|Comfilcon A|Commercially marketed, spherical, silicone hydrogel contact lenses
10203380|NCT02193295|Experimental|NAFLD|Placebo or ACC inhibitor treatment for 12 weeks.
9765869|NCT00810576|Experimental|Vorinostat + Bortezomib|Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m^2 intravenous (IV) on Days 1, 4, 8, 11.
9765870|NCT00810602|Experimental|Vorinostat prophylaxis|Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
10203381|NCT02193295|Experimental|NAFLD Extension|A 48-week open-label extension arm with following either completion of either both arms or one arm of the 12-week double-blind crossover study.
10203382|NCT02192671|Experimental|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
9833750|NCT02668185|Experimental|Active drug first|Baseline period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Washout period - 2 weeks Matched placebo orally bd - 2 weeks Monitoring period - 2 weeks
9833751|NCT02668185|Placebo Comparator|Placebo|Baseline period - 2 weeks Matched placebo orally bd - 2 weeks Washout period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Monitoring period - 2 weeks
9833752|NCT02668198|Experimental|Endoscopic scar assessment|Using endoscope with high definition white light, high definition white light with near focus, narrow band imagining, and narrow band imaging with near focus.
9833753|NCT02668302|Experimental|Treatment|Bilateral in-office placement of a steroid-eluting sinus implant following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids
9833754|NCT02668302|Active Comparator|Control|Post-op standard of care, including debridement, irrigation, and topical steroids
9833755|NCT02668393|Other|Level 0|Nintedanib low dose with docetaxel
9833756|NCT02668393|Other|Level 1|Nintedanib medium dose with docetaxel
9833757|NCT02668393|Other|Level 2|Nintedanib high dose with docetaxel
9833758|NCT02668393|Other|Level 3|Nintedanib continuous high dose with docetaxel
9833759|NCT02668432|Experimental|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive <4g IV or < 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
9833760|NCT02668432|Active Comparator|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
9833761|NCT02668640||Participants with RA receiving adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks
9833762|NCT02668692|Experimental|LEO 80185 gel|
9833763|NCT02668692|Active Comparator|Dovobet ® ointment|
9833764|NCT02668952|Active Comparator|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
9833765|NCT02668952|Experimental|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
10203383|NCT02192671|Active Comparator|Radiofrequency ablation|RFA is performed in less than one week after clinical diagnosis.
10203384|NCT02160691|Experimental|Anxiety Meter|The Anxiety Meter (experimental) group will receive a real-time display of physiological arousal on the Anxiety Meter during the intervention period in visit #4.
10203385|NCT02160691|No Intervention|No Anxiety Meter|The control group will have the Anxiety Meter during the intervention period, but the marker will not move.
10203386|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
10203387|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
10203388|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
10203389|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
10203390|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
10203391|NCT02022982|Experimental|Palbociclib and PD-0325901|"Palbociclib by mouth once a day, every day for 3 weeks every 4 in each cycle.~PD-0325901 by mouth twice a day, every day for 3 weeks every 4 in each cycle. ."
10203392|NCT02008396|Placebo Comparator|Inactive Placebo with Psychotherapy|Subjects will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
10203393|NCT02008396|Experimental|75 mg to 125 mg MDMA with Psychotherapy|Participants will receive 75 to 125 mg during two psychotherapy sessions lasting approximately 7 hours; first session dose lower than second session dose.
10203394|NCT01995175|Other|Prospective Cohort|Newborn subjects followed up for LRTI symptoms from birth until they are 2 years of age and for incidence of wheeze and asthma up to 6 years of age.
10203395|NCT01917903|Experimental|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
10203396|NCT01917903|Experimental|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
10203397|NCT01898312|Experimental|Mifepristone|treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
10203398|NCT01898312|Placebo Comparator|TrioBe|treatment with a quarter of a tablet of TrioBe every second day for 12 weeks
10203399|NCT01883804|Experimental|Study group|All participants selected to continue with Methyldopa administration.
10203400|NCT01881048|No Intervention|Arm I|Patients undergo observation.
10203401|NCT01881048|Experimental|Arm II (fish oil)|Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
9765871|NCT00810615|Sham Comparator|Sham treatment|Subject will breathe air at less than 1.3 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at less that 1.3 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
9765872|NCT00810615|Experimental|Hyperbaric oxygen 2.4 ATA|Subject will breathe 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
9765873|NCT00810641|Active Comparator|Gufoni maneuver|Gufoni maneuver for apogeotropic HC-BPPV
9765874|NCT00810641|Active Comparator|Headshaking maneuver|headshaking maneuver for apogeotropic HC BPPV
9765875|NCT00810641|Sham Comparator|sham maneuver|sham maneuver for apogeotropic HC BPPV
9765876|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
9765877|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
9765878|NCT00810693|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks
9765879|NCT00810719|Experimental|Gemcitabine and Erlotinib|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.Erlotinib will be dosed at 150mg orally (tablets) on days 2-5, 9-12, and 16-26 of a 28 day cycle.
9765880|NCT00810771|Experimental|Preference-tailored (PT) intervention|"Intervention:~Behavioral: Standard Information Behavioral: Preference-tailored Information"
9765881|NCT00810771|Active Comparator|Standard information (SI) intervention|Behavioral: Standard Information
9765882|NCT00810771|No Intervention|Usual Care|Due to budget and time constraints this group was not powered as a true study arm but was used to assess the impact of our baseline physician information letter and to control for any other interventions of system-wide initiatives that may occur during the study timeframe and impact rated of CRC screening. Data was not collected on every participant in this arm.
9765883|NCT00810797|Experimental|Treatment (exemestane)|Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9765884|NCT00810810|Active Comparator|1|Blood components with no additional treatment
9765885|NCT00810810|Experimental|2|Blood components leukoreduced
9765886|NCT00810810|Experimental|3|Blood components leukoreduced and irradiated
9765887|NCT00810888|Active Comparator|Group 1-Recombinant activated factor VII|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL)."
9765888|NCT00810888|Placebo Comparator|Group 2 - Placebo|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive placebo."
9765889|NCT00810888|No Intervention|Group 3 - Observation Only Arm|"Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA spot sign negative) enrolled into a prospective observational group."
9765890|NCT00810901|Experimental|Organ Donor|Intervention used a DVD, text messaging, emails, a website, US Mail, and telephone calls to educate teens about their choice to become a designated organ donor on their first driver's license application.
9765891|NCT00810901|Active Comparator|Alcohol Prevention|Intervention used a DVD and text messages, to educate teens about the laws that prohibit underage minors purchasing and consuming alcohol
9765892|NCT00811018|Experimental|Sitaxsentan|Sitaxsentan
9765893|NCT00811057|Active Comparator|1 Magnesium Sulfate|
9765894|NCT00811057|Active Comparator|2 Nifedipine|Participants randomized to this group will receive the medication nifedipine orally.
9765895|NCT00811057|Active Comparator|3 Indomethacin|Participants randomized to this arm will receive the medication indomethacin per rectum and orally.
9765896|NCT00811070|Experimental|1|
9765897|NCT00811135|Experimental|1|
9765898|NCT00811174|Experimental|Octagam 10%|
9765899|NCT00811187|Experimental|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
9765900|NCT00811187|Placebo Comparator|Saline placebo injection|5cc Normal Saline injection in each paracervical region
9765901|NCT00811252|Placebo Comparator|Placebo|
9765902|NCT00811252|Experimental|Vortioxetine 5 mg|
9765903|NCT00811252|Other|Duloxetine 60 mg|Active reference
9833766|NCT02669017|Experimental|Part 1: ADCT-402 dose escalation|In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.
9833767|NCT02669017|Experimental|Part 2: ADCT-402 dose expansion|"In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.~Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W)."
9833768|NCT02669043|Experimental|Ketamine|All participants receive open-label ketamine
9833769|NCT02669082|Experimental|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
9833770|NCT02669095|Experimental|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
9833771|NCT02669095|Active Comparator|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
9833772|NCT02669121|Placebo Comparator|Placebo|NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.
9833773|NCT02669121|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.
9833774|NCT02669264|Experimental|Part 1: ADCT-402 dose escalation|"Weekly administration - Participants will receive an intravenous (IV) infusion of ADCT-402, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-402, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
9833775|NCT02669264|Experimental|Part 2: ADCT-402 expansion|All participants will be assigned to the recommended dose and/or schedule of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee
9833776|NCT02669329|Experimental|Upper arm treatment with vacuum applicator|Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
9833777|NCT02669407|Experimental|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
9836006|NCT02765256|Experimental|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
9836007|NCT02765256|Placebo Comparator|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
9836167|NCT02772783|Experimental|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
9836168|NCT02772783|Experimental|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
9836169|NCT02772783|Active Comparator|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
9836170|NCT02772809|Other|Stroke survivors with low and moderate motor deficits|Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
9836171|NCT02772978|Active Comparator|tolcapone arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
9836172|NCT02772978|Placebo Comparator|placebo arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
9836173|NCT02773368|Experimental|IDegLira|
9836174|NCT02773368|Active Comparator|IGlar|
9836175|NCT02773446|Experimental|Cohort 1 group A|Volunteers will receive 8 logs of E. coli strain B7A after overnight fast
9836176|NCT02773446|Experimental|Cohort 1 group B|Volunteers will receive 9 logs of E. coli strain B7A after 90 minute fast
9836177|NCT02773446|Experimental|Cohort 1 group C|Volunteers will receive 9 logs of E. coli strain B7A after overnight fast
9836178|NCT02773446|Experimental|Cohort 1 group D|Volunteers will receive 10 logs of E. coli strain B7A after 90 minute fast
9836179|NCT02773446|Experimental|Cohort 2 group A|subjects from Cohort 1 who met primary endpoint will receive optimal regimen as determined by analysis after Cohort 1.
9833778|NCT02669433|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
9833779|NCT02669433|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
9833780|NCT02669433|Placebo Comparator|Placebo|Placebo
9833781|NCT02669615|Experimental|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
9833782|NCT02669667|Experimental|Cohort 1|single dose of MEDI9314 or placebo
9833783|NCT02669667|Experimental|Cohort 2|single dose of MEDI9314 or placebo
9833784|NCT02669667|Experimental|Cohort 3|single dose of MEDI9314 or placebo
9833785|NCT02669667|Experimental|Cohort 4|single dose of MEDI9314 or placebo
9833786|NCT02669667|Experimental|Japanese Cohort|single dose of MEDI9314 or placebo
9833787|NCT02669667|Experimental|Cohort 5|single dose of MEDI9314 or placebo
9833788|NCT02669758|Experimental|ALKS 3831|Olanzapine + samidorphan; administered as a coated bilayer tablet.
10203402|NCT01881048|Experimental|Arm III (celecoxib)|Patients receive celecoxib by mouth twice a day until the morning of surgery.
10203403|NCT01840293||Primary Breast Cancer|
9833789|NCT02669784|Active Comparator|Low Dose Contrast (40mL)|CTA of the chest: 40 mL of intravenous contrast at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
9833790|NCT02669784|Active Comparator|Low Dose Contrast (50mL)|CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
9833791|NCT02669849|Placebo Comparator|Placebo|
9833792|NCT02669849|Experimental|VX-210|
9833793|NCT02669862|Experimental|A-101 Solution 40|A-101 Solution 40% administered once per week
9833794|NCT02669862|Experimental|A-101 Solution 45|A-101 Solution 45% administered once per week
9833795|NCT02669862|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once per week
9833796|NCT02669914|Experimental|Cohort A: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
9765904|NCT00811317|Experimental|Closed-loop|Type 1 diabetic subjects under closed-loop blood glucose control
9765905|NCT00811382|Experimental|1: Access to HMSC (Home Monitoring Service Center)|Full functionality of the Home Monitoring System for an early optimization of CRT and management of AF with a full access for the treating physician to the HMSC
9833797|NCT02669914|Experimental|Cohort B: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
9833798|NCT02669914|Experimental|Cohort C: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
10203404|NCT01840293||Recurrent/Metastatic Breast Cancer|
10203405|NCT01804296|Experimental|Part 2 Active|Open-label, active repetitive transcranial magnetic stimulation
9765906|NCT00811382|Active Comparator|2: No access to HMSC|Limited access of the treating physician to the HMSC where only events regarding implant and lead status will be generated and sent to the physician.
10203406|NCT01804270|Active Comparator|Part 1 Active|Blinded, active repetitive transcranial magnetic stimulation
9765907|NCT00811395|Placebo Comparator|Placebo + IFN-β|Placebo (for teriflunomide) once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
9765908|NCT00811395|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
9765909|NCT00811395|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
9765910|NCT00811395|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
10203407|NCT01804270|Sham Comparator|Part 1 Sham|Blinded, sham repetitive transcranial magnetic stimulation
10203408|NCT01781390|Placebo Comparator|Placebo|Participants received matching-placebo solution 2 milliliters per minute (mL/min) infused intravenously for 60 min including line flush [0 Mesenchymal Precursor Cells (MPCs)/min] on Day 0.
10203409|NCT01781390|Experimental|Mesenchymal Precursor Cells (MPC) 12.5 M|Participants received MPC 12.5 solution 2 mL/min infused intravenously for 60 min including line flush (2.5x10^5 MPCs/min) on Day 0.
10203410|NCT01781390|Experimental|Mesenchymal Precursor Cells (MPC) 25 M|Participants received MPC 12.5 solution 2 mL/min infused intravenously for 60 min including line flush (5.0x10^5 MPCs/min) on Day 0.
10203411|NCT01720147|Experimental|Quercetin - Dietary Supplement|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required) for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
9984256|NCT04275869|No Intervention|Control Group|Control group will receive the standard treatment which consists of regular gynaecological visits; the Reproduction Service gynaecologists will recommend healthy lifestyle habits and give the patients a document detailing a specific diet they should follow for weight loss.
9765911|NCT00811395|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
9765912|NCT00811395|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
9765913|NCT00811434|Active Comparator|Lactulose|3 months of Lactulose therapy based on pt. weight
9765914|NCT00811434|Placebo Comparator|placebo|1.5 ml/kg day po of sugar water placebo for three months
9765915|NCT00811473|Experimental|Quetiapine XR|
9765916|NCT00811473|Placebo Comparator|Placebo|
9765917|NCT00811564|Active Comparator|1|Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
9765918|NCT00811564|Active Comparator|2|Latanoprost 0.005% ophthalmic solution
9765919|NCT00811577|Experimental|AZX100-placebo|Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
9765920|NCT00811577|Placebo Comparator|Placebo-only|Three trocar sites on each patient received one dose of placebo (saline).
9765921|NCT00811642|Experimental|Posaconazole|Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
9765922|NCT00811655|Experimental|Pre-Operative SRS|SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.
9765923|NCT00811720|Placebo Comparator|Placebo|
9765924|NCT00811720|Experimental|Nalmefene|
9765925|NCT00811733|Experimental|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
9765926|NCT00811798|Experimental|Cervarix Group|
9765927|NCT00811850|Active Comparator|Combigan®|Combigan® (fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
9765928|NCT00811850|Active Comparator|Cosopt®|Cosopt® (fixed combination of dorzolamide hydrochloride - timolol maleate ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
9765929|NCT00811928|Active Comparator|Posaconazole|Posaconazole oral suspension 200 mg three times a day (TID)
9765930|NCT00811928|Active Comparator|Fluconazole|Fluconazole 400 mg once daily (QD)
9765931|NCT00811941|Placebo Comparator|Placebo|
9765932|NCT00811941|Experimental|Nalmefene|
9765933|NCT00811954|Experimental|Arm A: ATV/RTV + FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
9765934|NCT00811954|Experimental|Arm B: RAL + FTC/TDF|FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
9765935|NCT00811954|Experimental|Arm C: DRV/RTV + FTC/TDF|FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
9765936|NCT00812097|Other|Primary Augmentation|The Primary Augmentation cohort will include patients who wish general breast enlargement receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
9765937|NCT00812097|Other|Primary Reconstruction|The Primary Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
9765938|NCT00812097|Other|Revision Augmentation|The Revision Augmentation cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast augmentation surgery.
9765939|NCT00812097|Other|Revision Reconstruction|The Revision Reconstruction cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast reconstruction surgery.
9765940|NCT00812253|Experimental|Intravenous Insulin|
9765941|NCT00812253|Active Comparator|Subcutaneous Insulin|Basal bolus insulin (4 injections per day)
9765942|NCT00812331|Experimental|Genotype 2|Participants with chronic genotype 2 hepatitis C virus (HCV) infection
9765943|NCT00812331|Experimental|Genotype 3|Participants with chronic genotype 3 HCV infection
9984257|NCT04275700|Experimental|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma.
9765944|NCT00812331|Experimental|Genotype 4|Participants with chronic genotype 4 HCV infection
9765945|NCT00812331|Experimental|Genotype 5|Participants with chronic genotype 5 HCV infection
9765946|NCT00812331|Experimental|Genotype 6|Participants with chronic genotype 6 HCV infection
9765947|NCT00812461|Placebo Comparator|Placebo|
9765948|NCT00812461|Experimental|Nalmefene|
9765949|NCT00812487|Experimental|Intravenous insulin|
9765950|NCT00812487|Active Comparator|Subcutaneous Insulin|4 injections of insulin/day
9765951|NCT00812565|Placebo Comparator|Placebo every 2 weeks|Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).
9765952|NCT00812565|Experimental|0.1 g/kg octagam 10% every 2 weeks|Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).
9765953|NCT00812565|Experimental|0.25 g/kg octagam 10% every 2 weeks|Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
9765954|NCT00812565|Experimental|0.4 g/kg octagam 10% every 2 weeks|Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
9836180|NCT02773446|Experimental|Cohort 2 group B|Naive subjects who will receive optimal regimen as determined by analysis after Cohort 1
9765955|NCT00812565|Placebo Comparator|Placebo every 4 weeks|Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).
9765956|NCT00812565|Experimental|0.2 g/kg octagam 10% every 4 weeks|Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).
9765957|NCT00812565|Experimental|0.5 g/kg octagam 10% every 4 weeks|Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
9765958|NCT00812565|Experimental|0.8 g/kg octagam 10% every 4 weeks|Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
9765959|NCT00812604|Experimental|Ping On Ointment|Ping On Ointment
9765960|NCT00812604|Placebo Comparator|Vaseline|Vaseline with minor trace of Ping On ointment to give medicinal smell
9765961|NCT00812812|Experimental|paroxetine group|paroxetine 10-40mg/day
9765962|NCT00812812|Placebo Comparator|placebo group|matched placebo to paroxetine
9765963|NCT00812838|Experimental|100 units of Botulinum Toxin Type A|Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
9765964|NCT00812838|Placebo Comparator|Normal saline|"Injection solution will consist of 10 cc preservative free normal saline~Subjects had the choice of crossing over to ARM 1 at the end of 16 weeks.~Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16."
9765965|NCT00812877|Active Comparator|Mineral Trioxide Aggregate|Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
9765966|NCT00812877|Active Comparator|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide used as a direct pulp cap
9765967|NCT00812916||RF ablation|RF Ablation using specialized CFAE software
9765968|NCT00812929|Placebo Comparator|Placebo|
9765969|NCT00812929|Experimental|GSK2190915 10 mg|
9765970|NCT00812929|Experimental|GSK2190915 50 mg|
9765971|NCT00812929|Experimental|GSK2190915 100 mg|
9765972|NCT00812929|Experimental|GSK2190915 200 mg|
9765973|NCT00812955|Experimental|A - ABT-143 capsules 5/135 mg|ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
9765974|NCT00812955|Experimental|B - ABT-143 capsules 10/135 mg|ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
9765975|NCT00812955|Experimental|C - ABT-143 capsules 20/135 mg|ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
9765976|NCT00812955|Active Comparator|D - Simvastatin capsules 40 mg|Simvastatin capsules 40 mg daily for 8 weeks
9765977|NCT00812968|Experimental|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
9765978|NCT00812981|Experimental|1562902A NP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
9765979|NCT00812981|Experimental|1562902A CP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
9765980|NCT00813098|Experimental|High dose|A high dose of LX1031; daily oral intake for 28 days
9765981|NCT00813098|Experimental|Low Dose|A low dose of LX1031; daily oral intake for 28 days
9765982|NCT00813098|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake
9765983|NCT00813111|Experimental|SKY0402|A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
9765984|NCT00813111|Active Comparator|Bupivacaine HCl|A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
9765985|NCT00813124|Experimental|Azacytidine Maintenance after allotx|Busulfan + Fludarabine + ATG + Azacytidine after allogeneic stem cell transplantation (allotx)
9765986|NCT00813150|Experimental|Vd (bortezomib + dexamethasone)|"Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days~1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle."
9765987|NCT00813150|Active Comparator|Vcd (bortezomib + low-dose dexamethasone + cyclophosphamide)|Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.
9765988|NCT00813176|Active Comparator|Double Lumen Endotracheal Tube|We used a device called a double lumen tube ( DLT Broncho-Cath®). It is a bifurcated endotracheal tube designed to independently collapse the operated lung.
9765989|NCT00813176|Active Comparator|Arndt Bronchial Blocker|We used a device called a bronchial blocker (9 Fr Arndt® blocker) along with a standard single-lumen tracheal tube (8.0-9.0 mm ID). The Arndt bronchial blocker is a single device, with a distal balloon that is passed thru the single lumen endotracheal once the patient is intubated. The Arndt bronchial blocker is designed to collapse the operated lung.
9765990|NCT00813293|Experimental|Sorafenib|Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
9765991|NCT00813293|Placebo Comparator|Placebo|Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
9833799|NCT02669940||Participants With Chronic Hepatitis C Genotype 1|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.
9833800|NCT02670083|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
9833801|NCT02670083|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
9833802|NCT02670122||Patients with non resectable HCC|DEB-TACE with doxorubicin eluting 100 µ microspheres
9833803|NCT02670330|Experimental|Experimental: SD-101-6.0 cream|All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
9833804|NCT02670343|Experimental|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
9833805|NCT02670382|Experimental|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
9833806|NCT02670382|Experimental|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
9833807|NCT02670382|Placebo Comparator|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals during 4 week long lead-in phase.
9833808|NCT02670473|No Intervention|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
9833809|NCT02670473|Experimental|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
9833810|NCT02670538|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
9833811|NCT02670538|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
9833812|NCT02670538|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
9833813|NCT02670551|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
9833814|NCT02670551|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
9833815|NCT02670551|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
9833816|NCT02670629|Active Comparator|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
9833817|NCT02670629|Experimental|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
9833818|NCT02670811|Experimental|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
9833819|NCT02670811|Placebo Comparator|Placebo|Daily consumption of 150 mL of artificially acidified milk
9833820|NCT02670915|Experimental|Meal-time faster-acting insulin aspart and insulin degludec|
9833821|NCT02670915|Active Comparator|Meal-time NovoRapid® (insulin aspart) and insulin degludec|
9833822|NCT02670915|Experimental|Post-meal faster-acting insulin aspart and insulin degludec|
9833823|NCT02670928|Active Comparator|Active group of patients|Active group of patients underwent program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
9833824|NCT02670928|Experimental|Control group of patients|Control group pf patients were being monitored for the same criteria as active group but did not take part in the lifestyle change management program.
9833825|NCT02671032|Experimental|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
9833826|NCT02671266|Experimental|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
9833827|NCT02671266|Experimental|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
9833828|NCT02671500|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
9833829|NCT02671760|Experimental|Treatment|SM-1
9833830|NCT02671760|Active Comparator|Comparator|2-drug combination
9833831|NCT02671760|Placebo Comparator|Placebo|Placebo
9833832|NCT02672111|Experimental|CAM2038 q1w or q4w exposure to SL BPN/NX|"CAM2038 (buprenorphine FluidCrystal®)~Subjects previously exposed to SL BPN/NX who received CAM2038 q1w or q4w"
9833833|NCT02672111|Experimental|CAM2038 q1w or q4w new to BPN treatment|CAM2038 (buprenorphine FluidCrystal®) New to BPN Treatment who received CAM2038r q1w or q4w
9833834|NCT02672176|Sham Comparator|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
9833835|NCT02672176|Active Comparator|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
9833836|NCT02672423|Experimental|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
9833837|NCT02672423|Experimental|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
9833838|NCT02672423|Experimental|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
9833839|NCT02672514|Active Comparator|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
9833840|NCT02672514|Active Comparator|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
9833841|NCT02672553|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
9833842|NCT02672553|Active Comparator|Stented Aortic Bioprostheses|Stented Aortic Bioprostheses
9833843|NCT02672852|Experimental|Risankizumab|Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).
9833844|NCT02672852|Placebo Comparator|Placebo|Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).
9833845|NCT02673138|Active Comparator|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
9833846|NCT02673138|Experimental|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
9833847|NCT02673203|Active Comparator|Lean Healthy Control|(BMI <25 kg/m2)
9833848|NCT02673203|Active Comparator|Obese non-diabetic subject|BMI > 30 kg/m2
9833849|NCT02673372|Active Comparator|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
9833850|NCT02673372|Experimental|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
9833851|NCT02673489|Experimental|Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)|Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
9833852|NCT02673515|Active Comparator|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
9833853|NCT02673515|No Intervention|control group|control group
9833854|NCT02673541|Active Comparator|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
9833855|NCT02673541|Active Comparator|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
9833856|NCT02673619|Experimental|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter [µL]/centimeter [cm]^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
9833857|NCT02673619|Placebo Comparator|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
9833858|NCT02673918|Experimental|Part 1: Rehabilitation after surgery for breast cancer|Home-based upper-body rehabilitation with online support
9833859|NCT02673918|Experimental|Part 2: Rehabilitation after radiation for breast cancer|Home-based upper-body rehabilitation with online support
9833860|NCT02673944|Experimental|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
9833861|NCT02674334|Active Comparator|NIRS Monitored Not Treated|Anesthesiologist blinded to Near Infrared Spectroscopy (NIRS)
9833862|NCT02674334|Active Comparator|NIRS Monitored and Treated|Anesthesiologist treats based on Near Infrared Spectroscopy (NIRS)
9833863|NCT02674386|Other|Cohort 1|long-term observational study of subjects from tanezumab parent study
9833864|NCT02674399|Experimental|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
9833865|NCT02674399|Active Comparator|Synvisc-One|hyaluronic acid
9833866|NCT02674412|Experimental|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
9833867|NCT02674412|Experimental|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
9833868|NCT02674477|Experimental|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using participant's specific login information. Participants can use it as much or as little as participants like. Participants will continue with treatment as usual during and after hospitalization, as well.
9833869|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
9833870|NCT02674568|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine administered intravenously on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for 2 cycles. An additional 2 cycles of rovalpituzumab tesirine (retreatment) was permitted for eligible participants.
9833871|NCT02674633|Active Comparator|AKL-T01 (EVO Multi)|AKL-T01, or EVO Multi, is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
9833872|NCT02674633|Active Comparator|AKL-T09 (EVO Words)|AKL-T09, or EVO Words, is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
9833873|NCT02674659|Experimental|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
9833874|NCT02674659|Experimental|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
9833875|NCT02674854|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
9833876|NCT02674854|Active Comparator|Netarsudil (AR-13324) ophthalmic solution 0.02%|Netarsudil 0.02% ophthalmic solution
9833877|NCT02674854|Active Comparator|Latanoprost ophthalmic solution 0.005%|Latanoprost 0.005 % ophthalmic solution
9833878|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
9833879|NCT02675517||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD)guidelines
9984258|NCT04274335|Experimental|Intravenous tranexamic acid|
9833880|NCT02675543|Experimental|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
9833881|NCT02675543|Experimental|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
9833882|NCT02675634|Experimental|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
9833883|NCT02675634|Experimental|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
9833884|NCT02675634|Experimental|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
9833885|NCT02675634|Experimental|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
9833886|NCT02675634|Experimental|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
9833887|NCT02675634|Experimental|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
9833888|NCT02675764|Experimental|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
9833889|NCT02675764|Active Comparator|Placebo|"The control group will wear the vibration device with no vibration.~Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
9833890|NCT02675907|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
9833891|NCT02675907|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
9833892|NCT02675998|Experimental|3mg BID|Tenapanor, 3mg BID (6mg total)
9833893|NCT02675998|Experimental|10mg BID|Tenapanor, 10mg BID (20mg total)
9833894|NCT02675998|Experimental|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
9833895|NCT02675998|Placebo Comparator|Placebo|Placebo
9833896|NCT02676375|Other|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
9833897|NCT02676375|Experimental|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
9833898|NCT02676375|Experimental|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
9833899|NCT02676466|Experimental|Fish oil Active|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
9833900|NCT02676466|Placebo Comparator|Fish oil Placebo|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
9836008|NCT02765269|Experimental|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
9984259|NCT04274335|Experimental|Intramuscular tranexamic acid|
9833901|NCT02676466|Active Comparator|Losartan Active|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
9833902|NCT02676466|Placebo Comparator|Losartan Placebo|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
9833903|NCT02676466|Active Comparator|Fish oil Active + Losartan Active|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
9833904|NCT02676466|Other|Fish oil Active + Losartan Placebo|"This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.~In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan."
9833905|NCT02676466|Other|Fish oil Placebo + Losartan Active|"This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.~In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months."
9833906|NCT02676466|Other|Fish oil Placebo + Losartan Placebo|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
9833907|NCT02676778|Experimental|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
9833908|NCT02676843|Experimental|18F-AV-1451|Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
9833909|NCT02676882|Other|EnBrace HR for Prevention of Depressive Relapse (Group 1)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score </= 10.
9833910|NCT02676882|Other|EnBrace HR for Acute Treatment of Major Depression (Group 2)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score >/= 15.
9833911|NCT02676895|Experimental|1790GAHB 25 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 25 μg of S. sonnei.
9833912|NCT02676895|Experimental|1790GAHB 100 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 100 μg of S. sonnei.
9833913|NCT02676895|Active Comparator|Control Group|Subjects who received one dose of Menveo vaccine and a second dose of Boostrix vaccine.
9833914|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9833915|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9836181|NCT02773537|Active Comparator|Randomization Group 1|Femoral nerve catheter and sciatic nerve block
9984260|NCT04274335|Experimental|Oral liquid tranexamic acid|
9765992|NCT00813319|Experimental|1 - Girls OnGuard/HPV awareness|Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses.
9765993|NCT00813319|No Intervention|2 - General health promotion|Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.
9765994|NCT00813358|Experimental|Endovascular repair|treatment
9765995|NCT00813488|Experimental|Fentanyl buccal tablet first then immediate release oxycodone|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
9765996|NCT00813488|Experimental|Immediate Release Oxycodone first then FBT|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
9765997|NCT00813592|Experimental|All participants|
9765998|NCT00813709|Active Comparator|RNF 44 mcg thrice weekly|
9765999|NCT00813709|Active Comparator|RNF 44 mcg once weekly and placebo|
9766000|NCT00813709|Active Comparator|Placebo/RNF 44 mcg thrice weekly|
9766001|NCT00813761|Other|02Optix CL and ReNu MPS with SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
9766002|NCT00813761|Other|Proclear CL and ReNu MPS with SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
9766003|NCT00813761|Other|02Optix CL and Clear Care LCS with SICS|O2Optix contact lens and Clear Care lens care solution subject
9766004|NCT00813761|Other|Proclear CL and Clear Care LCS with SICS|Proclear contact lens and Clear Care lens care solution
9766005|NCT00813761|Other|02Optix CL and ReNu MPS without SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
9766006|NCT00813761|Other|Proclear CL and ReNu MPS without SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
9766007|NCT00813761|Other|02Optix CL and Clear Care LCS without SICS|O2Optix contact lens and Clear Care lens care solution
9766008|NCT00813761|Other|Proclear CL and Clear Care LCS without SICS|Proclear contact lens and Clear Care lens care solution
9766009|NCT00813800|Experimental|Varenicline|Open-label; subjects will receive a behavioral intervention in addition to Varenicline.
9766010|NCT00813813|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
9766011|NCT00813865|Experimental|Afegostat Tartrate Treatment Regimen 1|Afegostat tartrate was administered orally at a dose of 225 mg QD for 3 or 7 consecutive days followed by no study medication for 4 or 7 consecutive days (consecutive 3-days-on/4-days-off or 7-days-on/7-days-off, respectively). Amendment 2 added a MWF 3-days-on/4-days-off regimen. After Amendment 2 was implemented, all participants were assigned to one of the two 3-days-on/4-days-off regimens. Amendment 4 removed the consecutive 3-days-on/4-days-off regimen, and all participants were assigned to the MWF 3-days-on/4-days-off regimen. Participants were to receive afegostat tartrate for 30 months and be followed for 6 months after EOT.
9766012|NCT00813904|Experimental|rThrombin, 1000 IU/mL|
9766013|NCT00813917|Active Comparator|varenicline|
9766014|NCT00813917|Placebo Comparator|Placebo|
9833916|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9984261|NCT04274335|No Intervention|No tranexamic acid|
9766015|NCT00813943|Experimental|Cilengitide (2-times weekly) + Temozolomide + Radiotherapy|
9766016|NCT00813943|Experimental|Cilengitide (5-times weekly) + Temozolomide + Radiotherapy|
9766017|NCT00813943|Active Comparator|Temozolomide + Radiotherapy|
9766018|NCT00813982|Experimental|Experimental Lotrafilcon A Contact Lens|Lotrafilcon A experimental contact lens randomly assigned to one eye
9766019|NCT00813982|Active Comparator|Commercial Lotrafilcon A Contact Lens|Lotrafilcon A commercial contact lens randomly assigned to one eye
9766020|NCT00813995|Experimental|Sitagliptin|
9766021|NCT00813995|Placebo Comparator|Placebo|
9766022|NCT00814138|Active Comparator|1|Methotrexate
9766023|NCT00814138|Placebo Comparator|2|Placebo
9766024|NCT00814164|Experimental|Clorafarbine with daunorubicin|Patients receive clofarabine IV over 1 hour on days 1-5 and daunorubicin hydrochloride IV over 5 minutes on days 1, 3, and 5.
9766025|NCT00814177|Experimental|No change|Intervention Drug warfarin no change in the dose is performed
9766026|NCT00814177|Active Comparator|Change|Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level
9766027|NCT00814255|Experimental|2|Conservative medical therapy plus adalimumab
9766028|NCT00814255|Active Comparator|1|Conservative medical therapy (lisinopril, losartan, atorvastatin)
9766029|NCT00814255|Experimental|conservative medical therapy plus galactose|drug: galactose 0.2 g /kg/dose (maximum dose 15g) po BID
9766030|NCT00814307|Experimental|Active 5mg|
9766031|NCT00814307|Experimental|Active 10 mg|
9766032|NCT00814307|Placebo Comparator|Placebo Sequence 1|
9766033|NCT00814307|Placebo Comparator|Placebo Sequence 2|
9766034|NCT00814320|Experimental|1|Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
9766035|NCT00814320|Experimental|2|Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
9766036|NCT00814346|Active Comparator|EGb 120 mg|
9766037|NCT00814346|Placebo Comparator|Placebo|
9766038|NCT00814463|Active Comparator|Post-operative SRS|All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
9766039|NCT00814489|Experimental|GSK2254233A Group|Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9766040|NCT00814489|Experimental|GSK2254232A Group|Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9766041|NCT00814489|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9766042|NCT00814502|Active Comparator|Zolpidem CR|Subjects randomized to Zolpidem CR
9766043|NCT00814502|Placebo Comparator|Placebo|Subjects randomized to Placebo
9766044|NCT00814580|Experimental|001|Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
9766045|NCT00814580|Active Comparator|002|Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
9766046|NCT00814632|Experimental|Study Drug CC 10004|Study drug CC-10004 20mg taken orally twice a day.
9766047|NCT00814658|Experimental|Galantamine + Nimodipine|
9766048|NCT00814658|Experimental|Galantamine + Placebo|
9766049|NCT00814671|Experimental|RPT450|Rifapentine 450mg daily
9766050|NCT00814671|Active Comparator|RIF 600|Rifampin 600mg daily
9766051|NCT00814671|Experimental|RPT 600|Rifapentine 600mg daily
9766052|NCT00814697|Experimental|Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Coil Stimulation (rTMS) treatment in Alzheimer's disease. The Magstim Rapid2 stimulator with a peak magnetic field of 0.5-3.5 Tesla at 100% output was used over the right and left dorsolateral prefrontal cortex. Patients received 4 sessions of rTMS over 2 weeks, lasting approximately 30 minutes, 2 consecutive days a week for 2 weeks.
9766053|NCT00814710|Experimental|Synflorix & Tritanrix-HebB/Hib Group|Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
9766054|NCT00814710|Active Comparator|Hiberix group & Tritanrix-HebB Group|Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
9766055|NCT00814775|Active Comparator|Group 1|Fastrach Laryngeal Mask Airway intubation
9766056|NCT00814775|Active Comparator|Group 2|Intubation of difficult airway using CTrach Laryngeal Mask
9766057|NCT00814788|Experimental|Bicalutamide + Everolimus|Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9766058|NCT00814801|Placebo Comparator|Placebo|
9766059|NCT00814801|Experimental|Galantamine 16 mg/day|
9766060|NCT00814801|Experimental|Galantamine 24 mg/day|
9766061|NCT00814879|Active Comparator|a.|N(t)RTI(s) based backbone & PI/r
9766062|NCT00814879|Experimental|b.|Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
9766063|NCT00814970|Experimental|Complete SE Vascular Stent System|COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.
9766064|NCT00815035|Active Comparator|Peanut OIT|Subjects randomized to receive active treatment with peanut protein flour.
9766065|NCT00815035|Placebo Comparator|Placebo|Subjects randomized to receive placebo in the form of oat flour.
9766066|NCT00815087|Experimental|Functional Electrical Stimulation (FES)|Functional electrical stimulation: Experimental
9766067|NCT00815087|Active Comparator|Home Rehabilitation Program (HRP)|Exercise home program
9766068|NCT00815191|Active Comparator|Vital Heat|Vital HEAT (vH2) Temperature Management System
9766069|NCT00815191|Active Comparator|Forced air|Forced-air warming
9766070|NCT00815295|Experimental|Cetuximab + sorafenib|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib will be given at 200mg/m2 twice daily.
9766071|NCT00815308|Experimental|cetuximab, concurrent chemo-radiotherapy|Cetuximab, injection, loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction daily, Days 1-5 every week for Weeks 2-7, and Days 1-3 for Week 8
9766072|NCT00815347|Other|1 Crossover|
9766073|NCT00815360|Experimental|Treatment group|"single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)~peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography"
9766074|NCT00815360|Active Comparator|Control Group|"single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)~macular laser per treatment criteria"
9766075|NCT00815490|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
9766076|NCT00815516|Experimental|Micafungin|Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
9766077|NCT00815516|Active Comparator|Amphotericin B deoxycholate|Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
9766078|NCT00815659|Experimental|Rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
9766079|NCT00815685|Experimental|Eicosapentaenoic Acid|
9766080|NCT00815698|Active Comparator|no suture|self-adhesive mesh, i.e. no suture for mesh fixation
9766081|NCT00815698|Experimental|Suture|Suture for mesh fixation
9766082|NCT00815776|Experimental|1|Treatment group receiving the CID
9766083|NCT00815776|Active Comparator|2|Group assigned a mouth splint
9833917|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9833918|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9833919|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9833920|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9833921|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9833922|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
9833923|NCT02677220|Experimental|Surgical|Subjects to be implanted with the CI532 cochlear implant in one ear
9833924|NCT02677324|Experimental|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
9833925|NCT02677428|Experimental|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
9833926|NCT02677428|Active Comparator|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
10203412|NCT01694004|Experimental|Benzocaine Infusion into Duodenum|The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.
10203413|NCT01571895|Experimental|DF 2156A 150 mg|150 mg capsule twice a day (every 12 h) for a maximum of 14 days
10203414|NCT01566695|Experimental|Oral Azacitidine|Arm 1: Oral azacitidine tablets 300 mg daily (QD) + best supportive care (BSC) on days 1 through 21 of each 28-day treatment cycle.
10203415|NCT01566695|Placebo Comparator|Placebo|Arm 2: Identically matching placebo tablets plus best supportive care on days 1 to 21 of each 28-day treatment cycle.
10203416|NCT01561157||Acute Intermittent Porphyria (AIP)|Patients with a documented diagnosis of AIP
10203417|NCT01561157||Hereditary Coproporphyria (HCP)|Patients with a documented diagnosis of HCP
10203418|NCT01561157||Variegate Porphyria (VP)|Patients with a documented diagnosis of VP
10203419|NCT01561157||Congenital Erythropoietic Porphyria (CEP)|Patients with a documented diagnosis of CEP
10203420|NCT01561157||Hepatoerythropoietic Porphyria (HEP)|Patients with a documented diagnosis of HEP
10203421|NCT01561157||Porphyria Cutanea Tarda (PCT)|Patients with a documented diagnosis of PCT
10203422|NCT01561157||Erythropoietic Protoporphyria (EPP)|Patients with a documented diagnosis of EPP
10203423|NCT01561157||X-Linked Protoporphyria (XLP)|Patients with a documented diagnosis of XLP
10203424|NCT01561157||Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)|Patients with a documented diagnosis of ALAD, ADP
10203425|NCT01561157||Homozygous Dominant Acute Hepatic Porphyria|Patients with a documented diagnosis of Homozygous Dominant AHP
10203426|NCT01429727||SCAD Registry|Individuals who have experienced at least one episode of spontaneous coronary artery dissection.
10203427|NCT01366898|Experimental|Chemotherapy|
10203428|NCT01338636|Other|Exercise-induced PAH|Open-label ambrisentan
10203429|NCT01308034|Experimental|association sunitinib radiotherapy|
9833927|NCT02677493|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
9833928|NCT02677493|Active Comparator|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
9833929|NCT02677493|Active Comparator|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
9833930|NCT02677623|Experimental|A- Pyridium|"Method of administration: oral~Dose: 200 mg PO with small sip of water~Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, < 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps~Contraindications: to be used in caution in patients with renal impairment Cr Cl < 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
9833931|NCT02677623|Experimental|B- Sodium Fluorescein|"Method of administration: intravenous~Dose: 25 mg~Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,~Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
9833932|NCT02677623|Experimental|C- Mannitol|"Method of administration: irrigant during cystoscopy~Dose: 300cc during cystoscopy to visualize the ureters~Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection~Contraindications when used as a genitourinary irrigation solution: anuria"
9833933|NCT02677623|Experimental|Control- Normal saline|"Method of administration: irrigant during cystoscopy~Dose: 300cc~Known adverse events: no known significant adverse events~Contraindications: none"
9833934|NCT02677701|Active Comparator|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
9833935|NCT02677701|Placebo Comparator|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
9833936|NCT02677714|Experimental|Patients with breast cancer receiving chemotherapy|After reconstitution and radiolabeling, 99mTc-rhAnnexin V-128 was administered as a single intravenous bolus of 350 MBq +/- 10% at baseline, after the 2nd cycle, after the 4th cycle and 12 weeks after AC chemotherapy.
9833937|NCT02677740|Experimental|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
9833938|NCT02677740|Experimental|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
9833939|NCT02677753|Active Comparator|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
9833940|NCT02677753|No Intervention|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
9833941|NCT02677766|Experimental|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
9833942|NCT02677766|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
9833943|NCT02677779|Experimental|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
9833944|NCT02677779|Active Comparator|Traditional surgery|Ulcer debridement with traditional surgery
9833945|NCT02677844|Experimental|Abemaciclib|200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
9833946|NCT02677844|Placebo Comparator|Placebo|Single oral dose of placebo on Day 1 of 1 study period.
9833947|NCT02677844|Active Comparator|Loperamide|Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
9833948|NCT02677844|Experimental|Loperamide + Abemaciclib|Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
9833949|NCT02677844|Active Comparator|Loperamide + Placebo|Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
9833950|NCT02678000|Experimental|LHW090|"For Part 1, patients will receive 3 doses of LHW090 once daily with escalating doses every 4 days for a total 12 days of treatment.~For Part 2, patients will receive LHW090 once daily for 4 weeks."
9833951|NCT02678000|Placebo Comparator|Placebo|For Part 1, patients will receive matching placebo once daily for 12 days. For Part 2, patients will receive matching placebo once daily for 4 weeks.
9833952|NCT02678039|Experimental|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
9984262|NCT04273802|Experimental|Cohort A - First line treatment|Untreated patients
9836182|NCT02773537|Active Comparator|Randomization Group 2|Adductor canal catheter and selective tibial block
9766084|NCT00815776|Active Comparator|Exercise Control Group|Group who received no device but were instead assigned a study-specified jaw exercise program
9766085|NCT00815919|Experimental|Velcade (bortezomib)|
9766086|NCT00815997|Sham Comparator|6-Fr TRI (transradial coronary intervention)|TRI will be performed using a 6-Fr guiding catheter.
9766087|NCT00815997|Active Comparator|4-Fr TRI|TRI will be performed using a 4-Fr guiding catheter.
9766088|NCT00816023|Experimental|Ecallantide Low Dose|target steady state concentration of 0.15 mg/L
9766089|NCT00816023|Experimental|Ecallantide Medium Dose|target steady state concentration of 0.75 mg/L
9766090|NCT00816023|Experimental|Ecallantide High Dose|target steady state concentration of 2.25 mg/L
9766091|NCT00816023|Placebo Comparator|Placebo|placebo
9766092|NCT00816036|No Intervention|Arm 1|Baseline Period
9766093|NCT00816036|Experimental|Arm 2|Intervention Period
9766094|NCT00816062|Experimental|Treatment|Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.
9766095|NCT00816101|Experimental|PROCELLERA™Antimicrobial Dressing|Dressing changes every 3 days, more frequently if needed
9766096|NCT00816101|Active Comparator|Mepilex® Border Lite|Dressing changes every 2-3 days, more frequently if needed
9766097|NCT00816101|Active Comparator|Band-Aid® Adhesive Bandage|Dressing changes every 2-3 days, more frequently if needed.
9766098|NCT00816166|Experimental|Stent Group|"Medical therapy + PHAROS Vitesse neurovascular stent (Stent Group)"
9766099|NCT00816166|Active Comparator|Medical Therapy Group|"Medical therapy alone (Medical Therapy Group)"
9766100|NCT00816348|Other|Omegaven|All subjects will receive Omegaven
9766101|NCT00816361|Experimental|MEDI-573 0.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 0.5 milligram per kilogram (mg/kg) as a 60-minute intravenous (IV) infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766102|NCT00816361|Experimental|MEDI-573 1.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 1.5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766103|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766104|NCT00816361|Experimental|MEDI-573 10 mg/Kg QWk Dose Escalation|Participants received MEDI-573 10 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766105|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Escalation|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766106|NCT00816361|Experimental|MEDI-573 30 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 30 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766107|NCT00816361|Experimental|MEDI-573 45 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 45 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766108|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Expansion|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766109|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Expansion|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
9766110|NCT00816400|Experimental|MEDI-575, 3.0 mg/kg QWk Escalation Phase (Cohort 1)|Single lead-in dose of MEDI-575 at 0.5 mg/kg as a 60-minute intravenous (IV) infusion administered 7 days prior to first dose at 3.0 mg/kg; MEDI-575 administered at 3.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (once every 7 days [QWk]) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9766111|NCT00816400|Experimental|MEDI-575, 6.0 mg/kg QWk Escalation Phase (Cohort 2)|MEDI-575 administered at 6.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9766112|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Escalation Phase (Cohort 3)|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9766113|NCT00816400|Experimental|MEDI-575, 12 mg/kg QWk Escalation Phase (Cohort 4)|MEDI-575 administered at 12.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9833953|NCT02678039|Active Comparator|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
9833954|NCT02678247|Active Comparator|NU-FlexSIV Socket|The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
9833955|NCT02678247|Active Comparator|IC Socket|The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.
9833956|NCT02678286|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
9833957|NCT02678286|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
9833958|NCT02678390|Experimental|Healthy women|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~A control day with no MCT and no aerobic exercise.~A 5 day consecutive MCT intake of 30 g/day.~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
9766114|NCT00816400|Experimental|MEDI-575, 15 mg/kg QWk Escalation Phase (Cohort 5)|MEDI-575 administered at 15.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9833959|NCT02678390|Experimental|Women with prediabetes|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~A control day with no MCT and no aerobic exercise.~A 5 day consecutive MCT intake of 30 g/day.~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
9833960|NCT02678416|Experimental|IV Acetaminophen|All participants receive IV acetaminophen as one of 4 interventions in random sequence
9833961|NCT02678416|Experimental|Oral Acetaminophen|All participants receive oral acetaminophen as one of 4 interventions in random sequence
9833962|NCT02678416|Experimental|Placebo|All participants receive placebo as one of 4 interventions in random sequence
9833963|NCT02678416|Experimental|Morphine|All participants receive morphine as one of 4 interventions in random sequence
9833964|NCT02678442|Active Comparator|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
9833965|NCT02678442|Active Comparator|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
9833966|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
9833967|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
9833968|NCT02678923|Experimental|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
9833969|NCT02678923|Placebo Comparator|Placebo|360 mL of placebo (0.9% sodium chloride [NaCl] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
9833970|NCT02679079|Placebo Comparator|Placebo|Administered once daily for 6 weeks
9833971|NCT02679079|Experimental|Dose Group 1|Administered once daily for 6 weeks
9766115|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Escalation Phase (Cohort 6)|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (once every 21 days [Q3Wk]) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9833972|NCT02679079|Experimental|Dose Group 2|Administered once daily for 6 weeks
9833973|NCT02679222|Experimental|Supplementation|Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT [tricaprylin/tricaprin]; coconut oil + MCT [50:50]; Coconut oil + tricaprylin [50:50]) taken twice, once at breakfast and once at mid-day.
9833974|NCT02679235|Experimental|Triheptanoin|Participant will undergo POST Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night) after a control PRE supplementation imaging protocol.
9833975|NCT02679274|Placebo Comparator|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
9833976|NCT02679274|Experimental|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
9836183|NCT02773537|Active Comparator|Randomization Group 3|Adductor canal catheter only
9833977|NCT02679287|Experimental|Group A|"Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
9833978|NCT02679287|Experimental|Group B|"Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
9833979|NCT02679469|Experimental|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
9833980|NCT02679573|Experimental|Delafloxacin|IV delafloxacin with potential to switch to oral delafloxacin
9833981|NCT02679573|Active Comparator|Moxifloxacin/Linezolid|IV moxifloxacin with potential to switch to oral moxifloxacin, and potential to switch moxifloxacin to IV linezolid for confirmed MRSA
9833982|NCT02679690|Experimental|Standard dietary sodium education|Standard dietary sodium education provided to patients with heart failure using voice over powerpoint presentation.
9833983|NCT02679690|Experimental|color-coded cue cards|The use of a color-coded cue cards to educate patients with heart failure on dietary sodium. The education regarding the use of the color-coded cue card was provided using a voice over powerpoint presentation.
9833984|NCT02679729|Experimental|Part A, Dose Level 1|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
9833985|NCT02679729|Experimental|Part A, Dose Level 2|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
9833986|NCT02679729|Experimental|Part A, Dose Level 3|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
9833987|NCT02679729|Experimental|Part A, Dose Level 4|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
9833988|NCT02679729|Experimental|Part A, Dose Level 5|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
9833989|NCT02679729|Experimental|Part A, Dose Level 6|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
9833990|NCT02679729|Experimental|Part A, Dose Level 7|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
9833991|NCT02679729|Experimental|Part B, Dose Level 1|Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
9833992|NCT02679755|Experimental|Experimental arm|Palbociclib plus Letrozole
9833993|NCT02679807|Active Comparator|Bifidobacterium lactis Bl-04|2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
9833994|NCT02679807|Placebo Comparator|Placebo|sucrose
9833995|NCT02679911|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
9833996|NCT02679911|Active Comparator|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
9833997|NCT02679976|Experimental|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
9833998|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
9833999|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
9834000|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
9834001|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
9834002|NCT02680002|Experimental|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
9834003|NCT02680002|Experimental|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
9836009|NCT02765269|No Intervention|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
9836010|NCT02765490|Experimental|Group A|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
9836011|NCT02765490|Experimental|Group B|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.
9836012|NCT02766023|Experimental|LACTIN-V|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive LACTIN-V 2x10^9 cfu/dose applied vaginally for 5 days then twice weekly for 10 weeks. N=152
9834004|NCT02680041|Experimental|18F-fluciclovine PET CT|Single intravenous administration of 18F-fluciclovine PET CT.
9834005|NCT02680054|Active Comparator|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
9834006|NCT02680054|Active Comparator|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
9834007|NCT02680054|Active Comparator|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
9834008|NCT02680145|Experimental|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
9834009|NCT02680158|Experimental|Sequence 1-Intranasal: Extranasal: Sham|Oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device, intranasal (control) application, for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
9834010|NCT02680158|Experimental|Sequence 2-Intranasal: Sham: Extranasal|Oculeve device, intranasal (test) application for approximately 3 minutes followed by sham device, intranasal (control) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
9834011|NCT02680158|Experimental|Sequence 3-Extranasal: Intranasal: Sham|Oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes, followed by sham device (control), intranasal application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
9834012|NCT02680158|Experimental|Sequence 4-Extranasal: Sham: Intranasal|Oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
9834013|NCT02680158|Experimental|Sequence 5-Sham: Intranasal: Extranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
9834014|NCT02680158|Experimental|Sequence 6-Sham: Extranasal: Intranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
9834015|NCT02680301|Other|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
9834016|NCT02680301|Other|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
9834017|NCT02680314|Active Comparator|Single Dose|single dose of misoprostol
9834018|NCT02680314|Active Comparator|Multiple Dose|multiple doses of misoprostol
9834019|NCT02680457|Active Comparator|Insulin Degludec - Insulin Glargine|Insulin Degludec 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Glargine 10 IU SC every 24 hours for 6 days
9834020|NCT02680457|Active Comparator|Insulin Glargine - Insulin Degludec|Insulin Glargine 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Degludec 10 IU SC every 24 hours for 6 days
9834021|NCT02680639|Active Comparator|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
9834022|NCT02680639|Experimental|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
9834023|NCT02680639|Experimental|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
9834024|NCT02680639|Experimental|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4 cmH2O and IPAP will be set at 10 cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
9834025|NCT02680756|Experimental|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
9834026|NCT02680756|Active Comparator|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
10203430|NCT01208974|Experimental|Phase 1 MTD NAC RT|"Participants will undergo a Nipple-Areolar Complex (NAC)-sparing mastectomy with immediate reconstruction and axillary surgery, if indicated, on Week 1. Anytime between Weeks 5-8, participants will undergo a dose-escalation/de-escalation of prophylactic NAC radiation treatment (RT) twice daily (minimum of 4 hours apart) for 5 days. Dose escalation/de-escalation design are as follows:~Dose Level I - 10 fractions of 2.0 Gy for a total of 20 Gy~Dose Level II - 10 fractions of 2.5 Gy for a total of 25 Gy~Dose Level III - 10 fractions of 3.0 Gy for a total of 30 Gy~Dose Level IV - 10 fractions of 3.5 Gy for a total of 35 Gy~Participants will be treated between cohorts of 2-6 patients per dose level starting at dose level II. Dose escalation stops when 2 out of 2-6 participants encounter Dose Limiting Toxicities (DLT).~Standard of care chemotherapy, at treating physician's discretion, can be initiated 2 weeks after RT."
10203431|NCT01194817|Other|Cemented fixation|Nexgen High-Flexion Knee Replacement System using Cemented Fixation
9834027|NCT02680834|Experimental|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
9834028|NCT02680834|Active Comparator|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
9834029|NCT02680847|Experimental|ALO-02|One arm, open label, active
9834030|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
9834031|NCT02681094|Active Comparator|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
9834032|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
9834033|NCT02681172|Experimental|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%."
9834034|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
9834035|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
9834036|NCT02681510|Experimental|Three drug intervention|varenicline, nicotine patch and nicotine lozenge for 12 weeks
9834037|NCT02681523|Experimental|Single arm study|3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.
9834038|NCT02681614|Experimental|Uronav|"Participants will undergo a Uronav guided biopsy with Magnetic Resonance Imaging confirmation.~All biopsies will be completed in the outpatient setting in the ambulatory OR prior to routine prostate brachytherapy under general anesthesia."
9834039|NCT02681757|Active Comparator|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
9834040|NCT02681757|Experimental|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
9834041|NCT02681809|Experimental|Ocriplasmin 0.0625mg|
9834042|NCT02681809|Experimental|Ocriplasmin 0.125mg|
9834043|NCT02681809|Sham Comparator|Sham injection|
9834044|NCT02682030|Active Comparator|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
9834045|NCT02682030|Active Comparator|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
9834046|NCT02682056|Other|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
9834047|NCT02682069|Experimental|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
9834048|NCT02682264|Experimental|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
9834049|NCT02682381|Experimental|0.025 mg/kg/day Teduglutide|0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
9834050|NCT02682381|Experimental|0.05 mg/kg/day Teduglutide|0.05 mg/kg/day of teduglutide for 24 weeks.
9834051|NCT02682381|Active Comparator|Standard of care|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
9834052|NCT02682420|Other|endoAVF|
9834053|NCT02682498|Active Comparator|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
9834054|NCT02682498|Active Comparator|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
9834055|NCT02682563|Experimental|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
9834056|NCT02682563|Active Comparator|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
9834057|NCT02682602||Diseased Hip|Subjects will have a diseased hip which requires replacement, which will be implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA.
9834058|NCT02682602||Normal Hip|Subjects will have a normal hip.
9834059|NCT02682602||Implanted Group|All subjects from the Diseased Hip group were implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA
9834060|NCT02682784|Experimental|Oxytocin/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to oxytocin.
9834061|NCT02682784|Active Comparator|Placebo/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to placebo.
9834062|NCT02682784|Experimental|Oxytocin/Control|Healthy controls who are randomized to oxytocin.
9834063|NCT02682784|Active Comparator|Placebo/Control|Healthy controls who are randomized to placebo.
9834064|NCT02682823|Experimental|Caregivers|CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
9834065|NCT02682823|Experimental|Healthcare Professionals|HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
9834066|NCT02682823|Experimental|RA Group 1 (Self-Administration)|Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
9834067|NCT02682823|Other|RA Group 2 (Administration by CG)|CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
9834068|NCT02682823|Other|RA Group 3 (Administration by HCP)|HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
9834069|NCT02683083|Experimental|[131I]-SGMIB Anti-HER2 VHH1|
9834070|NCT02683109|Experimental|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
9834071|NCT02683109|Active Comparator|Free combination tiotropium + olodaterol|
9834072|NCT02683161|Other|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
9834073|NCT02683174|Experimental|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
9834074|NCT02683187|Active Comparator|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
9834075|NCT02683187|Placebo Comparator|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
9834076|NCT02683421|Other|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
9834077|NCT02683421|Other|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
9834078|NCT02683421|Experimental|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
9834079|NCT02683421|Experimental|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
9766116|NCT00816400|Experimental|MEDI-575, 35 mg/kg Q3Wk Escalation Phase (Cohort 7)|MEDI-575 administered at 35.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9766117|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Expansion Phase|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9766118|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Expansion Phase|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
9766119|NCT00816556|Active Comparator|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
9766120|NCT00816556|Active Comparator|Estradiol|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
9766121|NCT00816556|Placebo Comparator|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
9766122|NCT00816595|Experimental|Arm A: Pentostatin, Cyclophosphamide, Rituximab, and Avastin|Patients receive 15 mg/kg bevacizumab IV over 30-90 minutes on day 1 of courses 1-5 and on days 1, 22, and 43 of course 6; 375 mg/m^2 rituximab IV over 2-4 hours on days 2 and 3 of course 1 and on day 1 of courses 2-6; and 2 mg/m^3 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 2 of course 1 and on day 1 of courses 2-6. Patients also receive 6 mg pegfilgrastim subcutaneously (SC) on day 3 of course 1 and on day 2 of courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9766123|NCT00816595|Experimental|Arm B: Pentostatin, Cyclophosphamide, and Rituximab|Patients receive 100 mg rituximab IV over 2-4 hours on day 1 and 375 mg/m^2 on day 2 of course 1 and 375 mg/m^2 on day 1 of courses 2-6. They receive 2 mg/m^2 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1. Patients also receive 6 mg pegfilgrastim SC on day 2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9766124|NCT00816751|Active Comparator|1|
9766125|NCT00816751|Experimental|2|
9766126|NCT00816829|Placebo Comparator|1|Fenofibrate-matching placebo tablet
9766127|NCT00816829|Experimental|2|145 mg NanoCrystal fenofibrate tablet
9766128|NCT00816907|Experimental|Metformin|Encapsulated metformin 1000-2000 mg/day
9766129|NCT00816907|Placebo Comparator|Placebo|Matching placebo capsules 2-4 daily
9766130|NCT00817063|Experimental|Alitretinoin|Patients will receive alitretinoin 30mg capsule for up to 24 weeks
9766131|NCT00817063|Experimental|Placebo|Patients will receive placebo 30mg capsule for up to 24 weeks
9766132|NCT00817089|Placebo Comparator|Group 1 Asn40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
9766133|NCT00817089|Active Comparator|Group 2 Asn40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
9766134|NCT00817089|Placebo Comparator|Group 3 Asp40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
9766135|NCT00817089|Active Comparator|Group 4 Asp40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
9766136|NCT00817206|Experimental|LCP-Tacro|LCP-Tacro tablets™, once daily (LifeCycle Pharma A/S, Hoersholm DK)
9766137|NCT00817206|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
9766138|NCT00817219|Experimental|TACLONEX ointment|
9766139|NCT00817336|Experimental|D-serine|60 mg/kg/day
9766140|NCT00817336|Placebo Comparator|Placebo|
9766141|NCT00817414|Experimental|Cohort A: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.
9766142|NCT00817414|Experimental|Cohort A: LCI699 1.0 mg QD|Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
9766143|NCT00817414|Experimental|Cohort B1: LCI699 1.0 mg BID|Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.
9766144|NCT00817414|Experimental|Cohort B1: LCI699 2.0 mg QD|Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
9834080|NCT02683525|Experimental|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
9834081|NCT02683577|Experimental|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
9834082|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
9834083|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
9834084|NCT02683668|Experimental|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
9834085|NCT02683707|Experimental|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
9834086|NCT02683707|Active Comparator|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
9834087|NCT02683746|Experimental|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
9834088|NCT02683746|Experimental|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
9834089|NCT02683772|Experimental|iVAPS with AutoEPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
9834090|NCT02683772|Active Comparator|iVAPS with manual EPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
9834091|NCT02683785|Experimental|GSK3196165|Subjects will receive a total of 8 doses of GSK3196165 over a 12-week treatment period.
9834092|NCT02683785|Placebo Comparator|Placebo|Subjects will receive a total of 8 doses of placebo over a 12-week treatment period.
9834093|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
9834094|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
9834095|NCT02683928|Experimental|GBR 830|Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
9834096|NCT02683928|Placebo Comparator|Placebo|Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.
9834097|NCT02683941|Experimental|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
9834098|NCT02683941|Placebo Comparator|Placebo|120mg every 28 days until disease progression, death, or unacceptable toxicity during the double-blind phase. The patient may enter open-label phase for treatment with Lanreotide.
9834099|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
9834100|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
9834101|NCT02684097|Active Comparator|Tralokinumab|Tralokinumab subcutaneous injection every two weeks for 24 weeks
9834102|NCT02684097|Placebo Comparator|Placebo|Saline subcutaneous injection every two weeks for 24 weeks.
9766145|NCT00817414|Placebo Comparator|Placebo|Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.
9766146|NCT00817479|Active Comparator|Dexamethasone|20 mg of dexamethasone
9766147|NCT00817479|Placebo Comparator|Placebo [Saline]|Saline
9766148|NCT00817531|Experimental|All subjects take open label Dasatinib|Dasatinib / Sprycel 100 mg
9766149|NCT00817635|Experimental|LCI699 0.25 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.25 mg, capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
9766150|NCT00817635|Experimental|LCI699 1 mg QD|Following a 2-week placebo run-in period, participants received LCI699 1 mg, capsules, orally, once daily (QD), with or without food for up to 8 weeks.
9766151|NCT00817635|Experimental|LCI699 0.5 mg followed by LCI699 1 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.5 mg, capsules, orally, BID, with or without food for up to 4 weeks, followed by LCI699 1 mg, capsules, orally, BID with or without food for up to 4 weeks.
9766152|NCT00817635|Active Comparator|Eplerenone 50 mg BID|Following a 2-week placebo run-in period, participants received eplerenone 50 mg, capsules, orally, BID, with or without food for up to 8 weeks.
9766153|NCT00817635|Placebo Comparator|Placebo|For a 2-week placebo run-in period, followed by 8 weeks of the treatment period, participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food.
9766154|NCT00817778|Experimental|AZD1656|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
9766155|NCT00817778|Placebo Comparator|Placebo|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
9766156|NCT00817804|Experimental|V60 then Conventional|Study device first
9766157|NCT00817804|Experimental|Conventional then V60|Conventional device first
9766158|NCT00817843|Experimental|First Simva 80mg then Simvai/Eze10/10mg|First 6 weeks of Simvastatin 80mg, then 6 weeks of Simvastatin/Ezetimibe 10/10mg after 6 weeks of placebo washout
9766159|NCT00817843|Experimental|First Simva/Eze 10/10mg then Simva 80mg|First 6 weeks of Simvastatin/Ezetimibe 10/10mg, then 6 weeks of Simvastatin 80mg after 6 weeks of placebo washout
9766160|NCT00817999|Experimental|Loading Dose|Participants received a 300 mg dose of clopidogrel with or without GFJ.
9766161|NCT00817999|Experimental|Maintenance Dose|Participants received clopidogrel 75 mg/day for 7 days with or without GFJ
9766162|NCT00818116|Experimental|ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
9766163|NCT00818168||Infliximab|Subjects with ankylosing spondylitis who were treated with infliximab. The dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)
9766164|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
9766165|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.
9766166|NCT00818246|Sham Comparator|Sham light|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with a Sham light on the experimental periorbital area
9766167|NCT00818246|Experimental|LED-treated|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with 660 nm Light emitting diode (LED) on the experimental periorbital area
9766168|NCT00818259|Experimental|Part IA-fosaprepitant 115 mg/aprepitant|Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
9766169|NCT00818259|Experimental|Part IB-fosaprepitant 150 mg|Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
9766170|NCT00818259|Experimental|Part IIA-aprepitant 80 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to <12 years of age - 47 mg/m^2; 4 months to <6 months of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
9766171|NCT00818259|Experimental|Part IIB-aprepitant 125 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to <12 years of age - 74 mg/m^2; 6 months to <2 years of age - 1.3 mg/kg; 4 months to <6 months of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; birth to <1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
9766172|NCT00818259|Active Comparator|Part III-ondansetron|Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to <12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.
9834103|NCT02684136|Experimental|suvorexant|9 nights of 20 mg suvorexant
9834104|NCT02684136|Placebo Comparator|placebo|9 nights placebo
9834105|NCT02684188|No Intervention|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
9766173|NCT00818259|Experimental|Part IV-aprepitant regimen|Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; Birth to <1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; Birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.
9766174|NCT00818259|Experimental|Part V-fosaprepitant regimen|Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to <12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
9766175|NCT00818272||Remicade (infliximab)|Participants with confirmed diagnosis of active Crohn's disease.
9766176|NCT00818324|Experimental|OPC-12759 Ophthalmic suspension|Instillation, 4times/day
9766177|NCT00818337|Active Comparator|Aspirin 81mg|Resistant
9766178|NCT00818363|Experimental|Group 1: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
9766179|NCT00818363|Placebo Comparator|Group 2: SABER-Placebo|5.0 mL SABER-Placebo/Once
9766180|NCT00818389|Active Comparator|1|Participants randomized to lithium/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
9766181|NCT00818389|Placebo Comparator|2|Participants randomized to placebo/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
9766182|NCT00818441|Experimental|Cohort A|Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
9766183|NCT00818441|Experimental|Cohort B|Dacomitinib in patients with HER2 mutated or amplified NSCLC
9766184|NCT00818519|Experimental|EE20/Drospirenone (YAZ, BAY86-5300)|In the active treatment group, participants received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP (Drospirenone) and 20µg EE (Ethinyl estradiol).
9766185|NCT00818519|Placebo Comparator|Placebo|The participants of the placebo group received inert but identical-appearing, color-matched tablets.
9766186|NCT00818623|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
9766187|NCT00818623|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
9766188|NCT00818623|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
9766189|NCT00818623|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
9766190|NCT00818623|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
9766191|NCT00818623|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
9766192|NCT00818623|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
9766193|NCT00818623|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
9766194|NCT00818649|Experimental|Velcade + Vorinostat|This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
9766195|NCT00818662|Experimental|IGIV, 10% 400mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
9766196|NCT00818662|Experimental|IGIV, 10% 200mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
9766197|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 4 mL/kg|0.25% human albumin solution infused at 4 mL/kg/2weeks
9766198|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 2 mL/kg|0.25% human albumin solution infused at 2 mL/kg/2weeks
9766199|NCT00818753|Experimental|Dabigatran 110 mg|experimental drug therapy in this indication
9766200|NCT00818753|Experimental|Dabigatran 150 mg|experimental drug therapy in this indication
9766201|NCT00818753|Active Comparator|Unfractionated Heparin|standard therapy in this indication as comparator
9766202|NCT00818766|Active Comparator|Antibiotic|Participants received intravenous (IV) cefazolin or vancomycin (for participants allergic to cephalosporin) immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
9766203|NCT00818766|Placebo Comparator|Placebo|Participants received IV placebo-matching antibiotics immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
9766204|NCT00818779|Experimental|Aliskiren|Aliskiren 150-300 mg once daily
9766205|NCT00818779|Active Comparator|Amlodipine|5-10 mg amlodipine once daily
9766206|NCT00818805|Experimental|Olopatadine 0.1% one eye|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
9766207|NCT00818805|Experimental|Tranilast 0.5% one eye|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
9766208|NCT00818805|Placebo Comparator|Placebo (Olopatadine)|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
9766209|NCT00818805|Placebo Comparator|Placebo (Tranilast)|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
9766210|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD|
9766211|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD|
9766212|NCT00818961|Other|Hematopoietic Stem Cell Transplantation|All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type
9766213|NCT00819013|Experimental|Study Group 1|ACAM-FLU-A low dose + Adjuvant 1
9766214|NCT00819013|Experimental|Study Group 2|ACAM-FLU-A low dose + Adjuvant 2
9766215|NCT00819013|Experimental|Study Group 3|ACAM-FLU-A low dose
9766216|NCT00819013|Placebo Comparator|Study Group 4|Saline placebo
9834106|NCT02684188|Experimental|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
9834107|NCT02684279|Experimental|Dasotraline|4, 6, 8 mg flexibly dosed
9834108|NCT02684344|Experimental|Tamsulosin Group|"Subjects will receive:~0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery~education about signs and symptoms of urinary retention"
9834109|NCT02684344|Active Comparator|Education Group|"Subjects will receive:~1) education about signs and symptoms of urinary retention"
9834110|NCT02684357|Placebo Comparator|Placebo (Part A)|Participants were randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9834111|NCT02684357|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9834112|NCT02684357|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9834113|NCT02684370|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9834114|NCT02684370|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9834115|NCT02684370|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9834116|NCT02684396|Experimental|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
9834117|NCT02684396|Experimental|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
9834118|NCT02684396|Experimental|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
9834119|NCT02684396|Experimental|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
9834120|NCT02684396|Experimental|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
9834121|NCT02684396|Placebo Comparator|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
9834122|NCT02684435|Experimental|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
9834123|NCT02684591|Experimental|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.~Intervention: Aramchol"
9834124|NCT02684591|Placebo Comparator|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
9834125|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
9834126|NCT02684604||Fertile women|44 fertile women
9834127|NCT02684617|Experimental|rrCLL Cohort|Participants with refractory chronic lymphocytic leukemia (rrCLL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
9834128|NCT02684617|Experimental|rrMM Cohort|Participants with relapsed or refractory multiple myeloma (rrMM) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
9834129|NCT02684617|Experimental|rrDLBCL Cohort|Participants with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
9834130|NCT02684630|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
9834131|NCT02684630|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
9834132|NCT02684942|Active Comparator|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
9836013|NCT02766023|Placebo Comparator|Placebo|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive placebo applied vaginally for 5 days then twice weekly for 10 weeks. N=76
9984263|NCT04273802|Experimental|Cohort B - Hypomethylating failure|Patients in absence of response after hypomethylating agents treatment
9834133|NCT02684942|Active Comparator|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
9834134|NCT02684942|Active Comparator|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
9834135|NCT02684942|Active Comparator|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
9834136|NCT02684942|Active Comparator|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
9834137|NCT02684942|Active Comparator|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
9834138|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
9834139|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
9834140|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
9834141|NCT02685033|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was < 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.
9834142|NCT02685033|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
9834143|NCT02685072|Experimental|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
9834144|NCT02685072|Placebo Comparator|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
9834145|NCT02685267|Active Comparator|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
9834146|NCT02685267|Active Comparator|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
9834147|NCT02685293|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
9834148|NCT02685293|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
9834149|NCT02685436|Other|omeprazole and domperidone|wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day).
9834150|NCT02685488|Active Comparator|Transcranial Ultrasound Power|Transcranial Ultrasound Power
9834151|NCT02685488|Sham Comparator|Transcranial Ultrasound Sham|Transcranial Ultrasound Sham. Unknown to both participants and experimenters, the ultrasound will not stimulate.
9834152|NCT02685566|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
9834153|NCT02685566|Active Comparator|Full-Field Digital Mammography|Breast Images with FFDM alone
9834154|NCT02685826|Experimental|Cohort A: High risk, TNE|"High risk, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle"
9834155|NCT02685826|Experimental|Cohort B: >=65 years old, TNE|">= 65 years old, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles"
9834156|NCT02685826|Experimental|Cohort C: High risk, Post-transplant|"High risk, post-transplant NDMM participants were administered the following as maintenance therapy:~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
9834157|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
9984264|NCT04272281|Experimental|Share making tool decision|Patient recruited from general practitioner in this group will use a share making tool decision to adapt antibiotherapy
9834158|NCT02685995|Active Comparator|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
9834159|NCT02685995|Active Comparator|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
9834160|NCT02686034|Active Comparator|gammaCore-S|Treatment of up to 5 migraine attacks with the Active gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
9834161|NCT02686034|Sham Comparator|gammaCore-S Sham|Treatment of up to 5 migraine attacks with the Sham gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
9834162|NCT02686138|Experimental|50mg BID|Tenapanor, 50mg BID (100mg total)
9834163|NCT02686138|Placebo Comparator|Placebo|Placebo
9834164|NCT02686164|Experimental|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
9834165|NCT02686437|Experimental|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
9834166|NCT02686437|Sham Comparator|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
9834167|NCT02687035|Experimental|TAVR|Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)
9834168|NCT02687126|Other|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
9834169|NCT02687139|Experimental|18F-DCFPyL PET/CT|
9834170|NCT02687191|Experimental|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
9834171|NCT02687191|Experimental|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
9834172|NCT02687191|Experimental|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
9834173|NCT02687191|Experimental|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
9834174|NCT02687191|Experimental|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
9834175|NCT02687191|Experimental|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
9834176|NCT02687191|Experimental|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
9834177|NCT02687191|Experimental|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
9834178|NCT02687191|Experimental|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
9834179|NCT02687191|Experimental|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
9834180|NCT02687191|Experimental|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
9834181|NCT02687191|Experimental|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
9834182|NCT02687191|Experimental|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
9834183|NCT02687191|Experimental|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
9834184|NCT02687191|Experimental|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
9834185|NCT02687217|No Intervention|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
9834186|NCT02687217|Experimental|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
9834187|NCT02687412|Experimental|Fast-track Surgery|Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
9984265|NCT04272281|Active Comparator|Standard recommandation|Patients recruited from general practitioner will receive the standard medical care
10203432|NCT01194817|Other|Cementless fixation|Nexgen High-Flexion Knee Replacement System using Cementless Fixation
10203433|NCT01149083|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID on days 1-21.
10203434|NCT01149083|Experimental|Arm II (veliparib, carboplatin)|Patients receive carboplatin IV over 30 minutes on day 1 and veliparib as in Arm I.
10203435|NCT01131117||Pregnant women|
10203436|NCT01016613||Chronic Kidney Disease Cohort|chronic kidney disease patients with any type of kidney disease
10203437|NCT01016613||Matched Control Group|Healthy controls
10203438|NCT01016613||Trios|First degree relatives of pediatric chronic kidney disease cohort members
9834188|NCT02687412|Other|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
9834189|NCT02687451|Experimental|Oxymorphone HCl Open-Label Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; open-label, single-dose, dose selection phase.
9834190|NCT02687451|Experimental|Oxymorphone HCl Multiple-Dose Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; placebo controlled, randomized, double-blinded multiple-dose phase.
9834191|NCT02687451|Placebo Comparator|Placebo|Sodium Chloride 0.9% solution; comparator for multiple-dose phase.
9834192|NCT02687529||Low Risk|Tested with CST001
9834193|NCT02687529||Known Risk|Tested with CST001
9834194|NCT02687542|Placebo Comparator|Placebo|Placebo
9834195|NCT02687542|Experimental|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
9834196|NCT02687542|Experimental|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
9834197|NCT02687542|Experimental|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
9834198|NCT02687542|Experimental|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
9834199|NCT02687815|Experimental|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
9834200|NCT02687815|Placebo Comparator|placebo|placebo formulations will be in gel cap form and identical to the active drug
9834201|NCT02687919|Experimental|Modified Paleo Diet Intervention (MPDI)|Consumed a modified Paleo diet, described as nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
9834202|NCT02687919|No Intervention|Usual Care|Typical physician recommendations for MS.
9834203|NCT02688153|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
9834204|NCT02688153|Active Comparator|Stented aortic bioprostheses|Stented aortic bioprostheses
9834205|NCT02688192|Active Comparator|Arm I (Intervention)|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~Participate in a fitness program which includes:~8 group meetings of 90 minutes weekly~Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
9834206|NCT02688192|Active Comparator|Arm II (Waitlist Control [WLC])|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~After waiting 6 months they will begin the fitness program as described in Arm I"
9834207|NCT02688218|Experimental|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
9834208|NCT02688218|Experimental|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
9834209|NCT02688387|Experimental|Part 1|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
9834210|NCT02688387|Experimental|Part 2|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
9834211|NCT02688387|Experimental|Part 3|Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
9834212|NCT02688556|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
9834213|NCT02688556|Placebo Comparator|Vehicle|vehicle of OTX-101
9834214|NCT02688621|Active Comparator|Internet only|Participants will be required to attend a weekly Internet chat session with your group members and one of the behavioral weight control therapists. Participants will learn the principles of managing eating and exercise behaviors in weekly, hour-long chat sessions and by completing weekly lessons. Participants are asked to self-monitor foods and exercise through the use of a smartphone ap. Participants will wear a tracking device that monitors steps. All participants will be contacted via e-mail individually, by their group leader who will monitor their progress and offer advice and encouragement. Meetings are weekly for 24 weeks and monthly for 12 months.
10203439|NCT00938912|Experimental|Lacosamide|Subjects and their caregivers may chose to receive Lacosamide oral solution (syrup) or Lacosamide tablets. The maximum duration of LCM administration will be approximately 2 years.
10203440|NCT00925652|Experimental|Lifestyle: Diet|The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
10203441|NCT00925652|Experimental|Lifestyle: Diet+Exericise|The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. The exercise intervention is comprised of a target physical activity goal of 180 minutes of moderate-intensity activity each week. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
9834215|NCT02688621|Experimental|Internet + Incentives|Participants are given the same intervention as described for the internet only group, with the exception that they will have the opportunity to earn financial incentives. Financial incentives will be based on participants weight loss, and compliance with certain weight loss behaviors including meeting exercise goals, self-monitoring foods consumed, and daily weighing and reporting.
9834216|NCT02688764|Experimental|PA21 (Velphoro®)|"PA21 (Velphoro®), chewable tablets 500 mg iron~PA21 (Velphoro®), chewable tablets 250 mg iron~PA21 (Velphoro®), powder for oral suspension 500 mg iron~PA21 (Velphoro®), powder for oral suspension 250 mg iron~PA21 (Velphoro®), powder for oral suspension 125 mg iron"
9834217|NCT02688764|Active Comparator|Calcium Acetate (Phoslyra®)|Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.
9834218|NCT02688829|Experimental|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
9834219|NCT02688842|Experimental|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
9834220|NCT02688868|Experimental|new specifications (Diameter 2.25mm)of Firehawk stent|Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
9836014|NCT02766088|Experimental|Total Group|Subjects aged between 6 months and 50 years at the time of enrolment living in geographically-defined communities in Latin America and Southeast Asia. The study population comprised household members and should include between 30% and 50% of adults (aged 18 years or above) per site.The appropriate recruitment strategy was selected by each participating site. Two approaches might be considered: a school-based approach and a community-based approach without school involvement The expected period for recruiting the target sample size was approximately three months.
9836015|NCT02766244|Experimental|ICG/SPY|Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.
9836016|NCT02766283||Iodinated contrast agents|children age 0-3 years (inclusive), who underwent a iodine contrast enhanced radiological examination.
9836017|NCT02766374|Experimental|Heart Rate Variability Biofeedback|"During the first training session, we will measure heart rate variability (HRV) amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal heart rate variability biofeedback (HRV-BF), and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
9836018|NCT02766374|Placebo Comparator|Placebo Biofeedback|"A credible Placebo Biofeedback (PBO-BF) consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
9836019|NCT02766400|Experimental|Guided Training|"Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence."
9836184|NCT02773758|Experimental|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
9836185|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
9834221|NCT02689063|Experimental|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
9834222|NCT02689063|Active Comparator|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
9834223|NCT02689063|Active Comparator|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
9834224|NCT02689063|Placebo Comparator|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
9834225|NCT02689076|Experimental|HIE Notification plus Care Coordination|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) plus post-hospital geriatric care transitions intervention
9834226|NCT02689076|Active Comparator|HIE Notification alone|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) followed by usual post-hospital care
9834227|NCT02689076|No Intervention|Usual Care (No HIE Notification and No Care Coordination)|Absence of VA provider notification of non-VA hospitalization via HIE plus Absence of post-hospital geriatric care transitions intervention [Usual Care]
9834228|NCT02689154|Experimental|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
9834229|NCT02689206|Experimental|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
9834230|NCT02689206|Experimental|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
9834231|NCT02689206|Experimental|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
9834232|NCT02689206|Experimental|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
9834233|NCT02689206|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
9834234|NCT02689219|Experimental|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
9834235|NCT02689219|Experimental|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
9834236|NCT02689804|Other|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
9834237|NCT02689804|Other|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
9834238|NCT02689973|Experimental|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
9834239|NCT02689973|Experimental|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
9834240|NCT02689973|Experimental|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
9834241|NCT02689973|Active Comparator|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
9834242|NCT02690168||Healthy Men|
9834243|NCT02690181|Experimental|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
9834244|NCT02690181|Experimental|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
9834245|NCT02690181|Experimental|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
9836186|NCT02773836||Greek cohort|Participants recruited from Greece will receive a questionnaire at pre- and post- intervention
9766217|NCT00819039|Experimental|Part 1: Oral Aprepitant|In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
9766218|NCT00819039|Experimental|Part 2: Oral Aprepitant|In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
9766219|NCT00819039|Active Comparator|Part 2: Intravenous Ondansetron|In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
9766220|NCT00819052|Active Comparator|NVP IR|200 mg orally twice a day (po BID)
9766221|NCT00819052|Experimental|NVP XR|400 mg orally once a day (po QD)
9766222|NCT00819091|Active Comparator|BI 1356|5 mg orally (po) once daily
9766223|NCT00819091|Placebo Comparator|Placebo|one tablet once daily
9766224|NCT00819156|Experimental|Degarelix 200/80|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
9766225|NCT00819156|Experimental|Degarelix 200/120|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
9766226|NCT00819156|Experimental|Degarelix 200/160|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
9766227|NCT00819156|Experimental|Degarelix 240/80|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
9766228|NCT00819156|Experimental|Degarelix 240/120|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
9766229|NCT00819156|Experimental|Degarelix 240/160|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
9766230|NCT00819182|Experimental|Paced respiration|The paced respiration intervention group received a compact disc with paper booklet. The booklet reinforced instructions on the first audio track for how to accomplish a target breath rate of 6-8 breaths per minute, practice twice per day for 15 minutes, and apply the breathing at the onset of each hot flash. Women were instructed to do slow, deep, abdominal breathing in through the nose and out through the mouth as per international recommendations (4). They were also instructed to practice twice per day for 15 minutes as per the small, laboratory-based studies (5, 6). The second and third tracks contained specially composed, digitally recorded music to help entrain the breath rate and structure the length of practice.
9766231|NCT00819182|Sham Comparator|Sham comparator: Fast, shallow breathing|The sham comparator group received a digital videodisc with paper booklet. The booklet reinforced voice-over and video demonstration to practice twice per day and apply the fast shallow breathing at the onset of each flash. A previously published report provides additional details and data indicating this program was a suitable attention control.
9766232|NCT00819182|No Intervention|Control: Usual Care|The usual care group received an investigator-signed letter explaining they were not selected to receive any study materials during the 16-week follow-up. These participants received paced respiration materials by mail after study completion.
9766233|NCT00819234|Placebo Comparator|1|
9766234|NCT00819234|Experimental|2|Pramlintide and 1.25mg Metreleptin
9766235|NCT00819234|Experimental|3|Pramlintide and 2.5mg Metreleptin
9766236|NCT00819234|Experimental|4|Pramlintide and 5.0mg Metreleptin
9766237|NCT00819247|Experimental|Degarelix 80/80 + 40|Loading doses of Degarelix 80 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
9766238|NCT00819247|Experimental|Degarelix 40/40 + 40|Loading doses of Degarelix 40 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
9766239|NCT00819247|Experimental|Degarelix 80 + 20|Loading dose of Degarelix 80 mg (20 mg/mL) on Day 0. Maintenance doses of 20 mg (10 mg/mL) given on days 28, 56, 84, 112 and 140.
9766240|NCT00819260|Experimental|Harmonic Reduced Breast|harmonic scalpel used to reduce breast on that side
9766241|NCT00819260|Active Comparator|Electrocautery Reduced Breast|Electrocautery (current practice = control) used to reduce breast on that side
9766242|NCT00819286|Active Comparator|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
9766243|NCT00819286|Experimental|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates.
9766244|NCT00819390|Experimental|A: Chloroquine then Placebo for Off-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
9766245|NCT00819390|Experimental|B: Placebo then Chloroquine for Off-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
9766246|NCT00819390|Experimental|C: Chloroquine then Placebo for On-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
9766247|NCT00819390|Experimental|D: Placebo then Chloroquine for On-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
9766248|NCT00819403|Active Comparator|simvastatin|Simvastatin 40 mg daily
9836187|NCT02773836||German cohort|Participants recruited from Germany will receive a questionnaire at pre- and post- intervention
9766249|NCT00819403|Active Comparator|simvastatin/ezetimibe|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
9784119|NCT01217957|Experimental|Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone|In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
9834246|NCT02690181|Experimental|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
9834247|NCT02690181|Experimental|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
9834248|NCT02690181|Experimental|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
9834249|NCT02690194|Placebo Comparator|Placebo Group|"Pre-Placebo therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PLACEBO THERAPY SESSION~Post-Placebo therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
9834250|NCT02690194|Experimental|Experimental (Buddhify) Group|"Pre-Buddhify therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~BUDDHIFY THERAPY SESSION~Post-Buddhify therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
9834251|NCT02690194|No Intervention|Control Group|"Pre-Procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
9834252|NCT02690207|Experimental|HZ/su Group|Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm
9834253|NCT02690558|Experimental|pembrolizumab, gemcitabine and cisplatin|There is one arm in this study. Subjects will receive Pembrolizumab 200mg IV on day 1 in combination with cisplatin 35mg/m2 and gemcitabine 1000mg/m2 on day 1 and day 8 every 3 weeks for 4 cycles over 12 weeks.
9834254|NCT02690649|Experimental|Health Messaging (Non-Procedural)|"PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use."
9834255|NCT02690649|No Intervention|No Health Messaging|"No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Standard care, training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use"
9834256|NCT02690701|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
9834257|NCT02690701|Placebo Comparator|Placebo then Secukinumab|"Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8.~Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive."
9834258|NCT02690714|Experimental|6.6 mg/kg Plasminogen (Human) Intravenous|6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion
9834259|NCT02690727|Experimental|RP6530 in fast condition|A single dose of RP6530 following fast condition
9834260|NCT02690727|Experimental|RP6530 in fed condition|A single dose of RP6530 following fed condition
9834261|NCT02690935|Experimental|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH~Impregnated on lactose saccharose globules (380 mg/capsule)"
9834262|NCT02690935|Placebo Comparator|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
9834263|NCT02690948|Experimental|Pembrolizumab Monotherapy|Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
9834264|NCT02690948|Experimental|Pembrolizumab plus Vismodegib Combination Therapy|Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
9834265|NCT02690974|Other|LCZ696 (sacubitril / valsartan)|All patients were initiated on either LCZ696 at 24 mg sacubitril / 26 mg valsartan or LCZ696 at 49 mg sacubitril / 51 mg valsartan bid for 2-4 weeks and were up-titrated to the next higher dose for another 2 - 4 weeks as applicable.
9834266|NCT02691143|Experimental|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
9834267|NCT02691143|No Intervention|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
9834268|NCT02691247|Experimental|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
9834269|NCT02691247|Experimental|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
9834270|NCT02691247|Placebo Comparator|Placebo|A single infusion of placebo, consisting of the infusion solution only
9834271|NCT02691260|No Intervention|no incentives|Participants do not receive financial incentives.
9834272|NCT02691260|Active Comparator|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
9834273|NCT02691260|Active Comparator|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
9834274|NCT02691260|Experimental|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
9834275|NCT02691416|Experimental|propofol postconditioning|1.2mg/L propofol
9834276|NCT02691416|Experimental|sevoflurane|0.5%-2% sevoflurane
9834277|NCT02691455|Active Comparator|Second Aqueous Shunt|"Second Aqueous Shunt~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
9834278|NCT02691455|Active Comparator|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
9834279|NCT02691468|Active Comparator|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
9834280|NCT02691468|Active Comparator|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
9834281|NCT02691494|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)
9834282|NCT02691494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
9834283|NCT02691494|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
9834284|NCT02691507|Active Comparator|Positive Control|Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
9834285|NCT02691507|Experimental|Experimental|Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.
9834286|NCT02691572|Active Comparator|Wound Infiltration|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
9834287|NCT02691572|Experimental|Transversus abdominis plane block|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
9834288|NCT02691702|Experimental|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
9834289|NCT02691702|Experimental|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
9834290|NCT02691702|Experimental|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
9834291|NCT02691741|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
9834292|NCT02691741|Active Comparator|839MP|AT LISA® tri IOL, bilateral implantation
9834293|NCT02691936|Experimental|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
9834294|NCT02691936|Active Comparator|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
9834295|NCT02691962|Experimental|Xen Matrix AB|Subjects treated with Xen Matrix AB
9834296|NCT02692040|Experimental|12-24 mg (B1) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 24 mg."
9834297|NCT02692040|Experimental|6-10 mg (B2) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 10 mg."
9834298|NCT02692040|Experimental|5-16 mg (B3) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 16 mg."
9834299|NCT02692040|Experimental|3.2mg (C) infusion pump dose of G3215|G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo [saline]).
9834300|NCT02692040|Placebo Comparator|Placebo (B) - saline|5 subcutaneous injections of 0.9% saline, over a 4 week treatment period
9834301|NCT02692040|Placebo Comparator|Placebo (A) - saline|Single subcutaneous injection of 0.9% saline
9834302|NCT02692040|Experimental|0.1 mg dose G3215 (A1)|0.1 mg G3215 single dose, subcutaneous injection
9834303|NCT02692040|Experimental|0.5 mg dose G3215 (A1)|0.5 mg G3215 single dose, subcutaneous injection
9834304|NCT02692040|Experimental|1.5 mg dose G3215 (A1)|1.5 mg G3215 single dose, subcutaneous injection
9834305|NCT02692040|Experimental|4 mg dose G3215 (A2) with varied formulation|4 mg G3215 single dose, subcutaneous injection
9834306|NCT02692040|Experimental|4 mg dose G3215 (A3) with varied formulation|4 mg G3215 single dose, subcutaneous injection
9834307|NCT02692040|Experimental|4 mg dose G3215 (A4) with varied formulation|4 mg G3215 single dose, subcutaneous injection
9834308|NCT02692040|Experimental|4 mg dose G3215 (A5) with varied formulation|4 mg G3215 single dose, subcutaneous injection
9834309|NCT02692040|Experimental|8 mg dose G3215 (A7)|8 mg G3215 single dose, subcutaneous injection
9834310|NCT02692040|Experimental|10 mg dose G3215 (A6)|10 mg G3215 single dose, subcutaneous injection
9834311|NCT02692040|Experimental|12 mg dose G3215 (A8)|12 mg G3215 single dose, subcutaneous injection
9834312|NCT02692040|Experimental|16 mg dose G3215 (A9)|16 mg G3215 single dose, subcutaneous injection
9834313|NCT02692040|Experimental|32 mg dose G3215 (A10)|32 mg G3215 single dose, subcutaneous injection
9834314|NCT02692040|Experimental|48 mg dose G3215 (A11)|48 mg G3215 single dose, subcutaneous injection
9834315|NCT02692209||FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
9834316|NCT02692209||Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
9834317|NCT02692235|Experimental|carnitine|24 weeks l-carnitine-l-tartrate supplementation
9834318|NCT02692235|Placebo Comparator|placebo|24 weeks isonitrogenous supplementation
9834319|NCT02692391|Placebo Comparator|Placebo|6 doses, Q8hrs for a total period of 48 hours
9834320|NCT02692391|Active Comparator|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
9834321|NCT02692417|Experimental|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
9834322|NCT02692417|Experimental|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
9834323|NCT02692482|Experimental|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
9766250|NCT00819507|Experimental|Vanos Cream|glucocorticoid cream
9766251|NCT00819585|Experimental|Core study: Canakinumab 25 mg|Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
9766252|NCT00819585|Experimental|Core study: Canakinumab 50 mg|Canakinumab 50 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
9834324|NCT02692482|Active Comparator|standard care|
9834325|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
9834326|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
9834327|NCT02692560|Experimental|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
9834328|NCT02692560|Active Comparator|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
9834329|NCT02692586|Experimental|FlowTriever System|
9834330|NCT02692703|Experimental|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
9834331|NCT02692716|Experimental|Oral semaglutide|
9834332|NCT02692716|Placebo Comparator|Placebo|
9834333|NCT02692755|Experimental|Palbociclib + Letrozole or Fulvestrant|
9834334|NCT02692859|Experimental|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
9834335|NCT02692859|Active Comparator|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
9834336|NCT02693106|Experimental|Ketogenic potential|"Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling.~Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT"
9834337|NCT02693119|Experimental|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
9834338|NCT02693119|Experimental|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
9834339|NCT02693119|Experimental|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
9834340|NCT02693119|Experimental|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
9834341|NCT02693132|Experimental|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
9834342|NCT02693132|Experimental|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
9834343|NCT02693132|Experimental|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
9834344|NCT02693262|Experimental|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
9834345|NCT02693262|Active Comparator|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
9834346|NCT02693418|Experimental|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
9834347|NCT02693418|Experimental|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
9834348|NCT02693418|Experimental|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
9834349|NCT02693418|Placebo Comparator|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
9834350|NCT02693418|No Intervention|No intervention, Group E|No vaginal product administered
9834351|NCT02693704|Experimental|Normal hearing|People showing no hearing loss (< 20 dB HL). Introduction of speech signal via the DAI of two hearing aids Phonak Naida IX SP.
9834352|NCT02693704|Experimental|Moderate hearing impaired|"Patients showing moderate hearing loss (40-60 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
9834353|NCT02693704|Experimental|Severe hearing impaired|"Patients showing severe hearing loss (60-80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
9834354|NCT02693704|Experimental|Profound hearing impaired|"Patients showing profound hearing loss (> 80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
9834355|NCT02693834|Experimental|PLS AFO first then DA AFO|Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
9834356|NCT02693834|Experimental|DA AFO first then PLS AFO|Participants will be assigned to practice with Double adjustable AFO for a week, then they will be assigned to practice with Posterior Leaf spring AFO for another week
9834357|NCT02694029|Active Comparator|ABC (Active Breathing Coordinator ), Then VRT|Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
9834358|NCT02694029|Active Comparator|VisionRT (VRT), Then ABC|VisionRT-based deep inspiration breath-hold to assist radiation therapy. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH
9834359|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
9834360|NCT02694328|Experimental|ALKS 3831|Administered as a coated bilayer tablet
9834361|NCT02694328|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
9834362|NCT02694523|Active Comparator|Adalimumab (Part A)|Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).
9834363|NCT02694523|Experimental|Risankizumab (Part A)|Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).
9834364|NCT02694536|Experimental|Erlotinib + Gemcitabine|Participants will receive erlotinib in combination with standard of care chemotherapy (gemcitabine) until disease progression, unacceptable toxicity, or withdrawal for any reason.
9834365|NCT02694549|Experimental|CaveoVasc|
9834366|NCT02694562|Experimental|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
9834367|NCT02694601|Experimental|Ketonemia following caffeine intake|"Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.~Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)"
9834368|NCT02694718|Experimental|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m^2) on Days 1-14, and 825 mg/m^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m^2/once a day (d) on Day 1 and 50 mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
9834369|NCT02694744|Experimental|Group 1 - Dosing Without Food|Patiromer dosing without food
9834370|NCT02694744|Active Comparator|Group 2 - Dosing With Food|Patiromer dosing with food
9834371|NCT02694835|Experimental|DT1 UV|Delefilcon A contact lenses with Ultraviolet (UV) Absorber worn bilaterally (in both eyes) for 9 hours
9834372|NCT02694835|Active Comparator|DT1|Delefilcon A contact lenses worn bilaterally for 9 hours
9834373|NCT02694978|Experimental|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter [mL]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
9834374|NCT02694978|Active Comparator|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
9834375|NCT02695290|Experimental|Afatinib|
9834376|NCT02695329|Active Comparator|Vanguard with KneeAlign 2|Having total knee arthroplasty surgery with the use of a navigation system KneeAlign 2.
9834377|NCT02695329|No Intervention|Vanguard without KneeAlign 2|Having total knee arthroplasty surgery with the use of conventional surgical instruments, and without a navigation system KneeAlign 2.
9834378|NCT02695420|Placebo Comparator|Placebo BID|Participants will receive placebo BID.
9834379|NCT02695420|Experimental|25 mg Omecamtiv Mecarbil BID|Participants will receive 25 mg omecamtiv mecarbil BID.
9834380|NCT02695420|Experimental|37.5 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
9834381|NCT02695420|Experimental|50 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
9834382|NCT02695446|Other|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
9834383|NCT02695524|Active Comparator|Scapula-focused exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
9834384|NCT02695524|Experimental|Motor control exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
9834385|NCT02695537|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
9834386|NCT02695628|Experimental|Diagnostic (18F-fluoromisonidazole, PET/CT, embolization)|Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.
9834387|NCT02695719|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
9834388|NCT02695719|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
9836188|NCT02773836||Romanian Cohort|Participants recruited from Romania will receive a questionnaire at pre- and post- intervention
9766253|NCT00819585|Experimental|Core study: Canakinumab 100 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
9766254|NCT00819585|Experimental|Core study: Canakinumab 200 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
9766255|NCT00819585|Experimental|Core study: Canakinumab 300 mg|Canakinumab 300 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
9766256|NCT00819585|Experimental|Core study: Canakinumab q4wk|Canakinumab 50 mg sc at Days 1, and 29 followed by canakinumab 25 mg sc on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
9766257|NCT00819585|Active Comparator|Core study: Colchicine 0.5 mg|Colchicine 0.5 mg capsule orally once daily throughout the whole treatment phase of 16 weeks plus placebo matching canakinumab s.c. at Days 1, 29, 57, and 85. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
9766258|NCT00819585|Experimental|Extension study: Group A|Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.
9766259|NCT00819585|Experimental|Extension study: Group B|Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.
9766260|NCT00819585|Experimental|Extension study: Group C|Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.
9766261|NCT00819585|Experimental|Extension study: Group D|Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.
9766262|NCT00819637|Experimental|Arformoterol 3 doses|
9766263|NCT00819637|Experimental|Arformoterol 1 dose, placebo 2 doses|
9766264|NCT00819637|Active Comparator|Levalbuterol 3 doses|
9766265|NCT00819741|Experimental|Repaglinide + metformin|Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
9766266|NCT00819741|Active Comparator|Repaglinide|Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.
9766267|NCT00819767|Experimental|Aliskiren|For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
9766268|NCT00819767|Active Comparator|Valsartan|For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
9766269|NCT00819780|Experimental|Panitumumab Plus mFOLFOX6|Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2) and 5-fluorouracil (5-FU) (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
9766270|NCT00819780|Active Comparator|Bevacizumab Plus mFOLFOX6|Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2), followed by 5-FU (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
9766271|NCT00819793|Experimental|CentriMag Ventricular Assist System|All patients meeting the patient selection criteria will be treated with the CentriMag Ventricular Assist System.
9766272|NCT00819910|Active Comparator|Rosiglitazone + Placebo|Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
9766273|NCT00819910|Active Comparator|Fenofibrate + Placebo|Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks
9766274|NCT00819910|Experimental|Rosiglitazone +Fenofibrate|Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks
9766275|NCT00819910|Placebo Comparator|Placebo Therapy Daily|Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
9766276|NCT00820040|Experimental|Permacol|
10203442|NCT00925652|Experimental|Lifestyle: Diet and Bevicizumab+CM|"The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.~Bevicizumab: 15 mg/kg administered intravenously day 1 of a 3-week cycle for 6 months and day 1 of a 6 week cycle up to 2 years Cyclophosphamide: 50 mg orally each day of a 3-week cycle for 6 months Methotrexate: 2.5 mg orally twice daily of a 3-week cycle for 6 months"
10203443|NCT00925652|Experimental|Lifestyle: Diet+Exericise and Bevicizumab+CM|"The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. The exercise intervention is comprised of a target physical activity goal of 180 minutes of moderate-intensity activity each week. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.~Bevicizumab: 15 mg/kg administered intravenously day 1 of a 3-week cycle for 6 months and day 1 of a 6 week cycle up to 2 years Cyclophosphamide: 50 mg orally each day of a 3-week cycle for 6 months Methotrexate: 2.5 mg orally twice daily of a 3-week cycle for 6 months"
10203444|NCT00766584||PROOF cohort|This cohort is the same than the PROOF study (NCT00759304). Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and were eligible if aged 65 at the inclusion date in the PROOF study
10203445|NCT00732797|No Intervention|Routine Care|Participants will receive routine care.
10203446|NCT00732797|Active Comparator|Booklet|Participants will receive self-treatment booklets, but no expert telephone support.
10203447|NCT00732797|Active Comparator|Booklet &Therapist Support|Participants will receive self-treatment booklets, and up to an hour's expert telephone support.
10203448|NCT00700258||1|Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
10203449|NCT00700258||2|Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
9766277|NCT00820170|Experimental|dasatinib and paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.~The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel."
9766278|NCT00820222|Experimental|Lapatinib plus capecitabine|Lapatinib 1250 mg once daily and capecitabine 2000mg/m2/day, days 1-14, every 21 days
9766279|NCT00820222|Active Comparator|Trastuzumab plus capecitabine|trastuzumab loading dose of 8mg/kg followed by 6mg/kg q3weekly infusions, and capecitabine 2500mg/m2/day, days 1-14, every 21 days
9766280|NCT00820235|Experimental|A|
9766281|NCT00820235|Active Comparator|B|
9766282|NCT00820235|Active Comparator|C|
9766283|NCT00820248|Active Comparator|Arm I|Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
9766284|NCT00820248|Experimental|Arm II|Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.
9766285|NCT00820443|Experimental|Ceramic on metal prosthesis|Ceramic on metal prosthesis
9766286|NCT00820534|Experimental|Penciclovir|Penciclovir
9766287|NCT00820534|Placebo Comparator|Placebo|Placebo
9766288|NCT00820573|Placebo Comparator|Placebo|Placebo to be provided for 6 weeks
9766289|NCT00820573|Experimental|Sitagliptin|Sitagliptin to be provided for 6 weeks
9766290|NCT00820573|Experimental|Metformin|Metformin to be provided for 6 weeks
9766291|NCT00820573|Experimental|Sitagliptin+Metfromin|Sitagliptin + Metformin combined will be provided for 6 weeks
9766292|NCT00820599|Experimental|TAVR|Transaortic Valve Replacement
9766293|NCT00820612|Active Comparator|1|Indomethacin suppository
9766294|NCT00820612|Placebo Comparator|2|Placebo suppository
9766295|NCT00820664|Active Comparator|17β-estradiol 2.0 milligrams|Estrace 2.0 mg tablet
9766296|NCT00820664|Active Comparator|17β-estradiol 0.5 milligrams|Estrace 0.5 mg tablet
9766297|NCT00820664|Placebo Comparator|3|Placebo
9766298|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy|
9766299|NCT00820755|Active Comparator|Cetuximab 500 mg/m^2 every 2 weeks|
9766300|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 weekly|
9784120|NCT01218009|Experimental|Albuterol Spiromax|Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
9836189|NCT02773836||Spanish Cohort|Participants recruited from Spain will receive a questionnaire at pre- and post- intervention
10203450|NCT00700258||3|Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
10203451|NCT00700258||4|Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
10203452|NCT00700258||5|Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)
10203453|NCT00676715|Placebo Comparator|Placebo|Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
10203454|NCT00676715|Experimental|Ocrelizumab 600 mg|Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
10203455|NCT00676715|Experimental|Ocrelizumab 1000 mg|Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
10203456|NCT00676715|Active Comparator|Avonex|Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
10203457|NCT00592267||1|
10203458|NCT00592254||A|
10203459|NCT00579826|Experimental|Letrozole|Letrozole, 2.5 mg daily for 6 months
9834395|NCT02696070|Other|Sham of Provant|Sham of Provant
9834396|NCT02696070|Other|Active Treatment|Active Provant Treatment
9834397|NCT02696083|Experimental|Active Treatment|
9834398|NCT02696200|Experimental|Subjects Wearing the Q Collar|Subjects wearing the Q collar throughout the football season
9834399|NCT02696200|No Intervention|Subjects Not Wearing the Q Collar|Control group of subjects not wearing the q collar
9834400|NCT02696291|Experimental|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
9834401|NCT02696291|Experimental|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
9834402|NCT02696291|Experimental|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
9834403|NCT02696291|Experimental|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
9834404|NCT02696291|Experimental|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
9834405|NCT02696317|Other|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
9834406|NCT02696317|Other|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
9834407|NCT02696434|Active Comparator|PBO NTX + BUP|Placebo naltrexone + buprenorphine
9834408|NCT02696434|Experimental|NTX + BUP|Naltrexone + buprenorphine
9834409|NCT02696785|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
9834410|NCT02696785|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
9834411|NCT02696785|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
9834412|NCT02696785|Active Comparator|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
9834413|NCT02696798|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
10203460|NCT00579826|Placebo Comparator|Placebo|Placebo, daily for 6 months
10203461|NCT00541294||B|M.tb unexposed HIV-infected and uninfected children <15 years of age
10203462|NCT00541294||A|M.tb exposed HIV-infected and uninfected children <15 years of age
10205306|NCT02915783|Experimental|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
10205307|NCT02913482|Experimental|Part 1 (Dose Finding): Risdiplam (RO7034067)|Participants will receive multiple ascending doses of risdiplam (RO7034067), administered orally once daily for a minimum of 4 weeks to select the dose for Part 2. During the first year of treatment, most participants will switch to the Part 2 dose. During the second year of treatment, all Part 1 participants will be receiving the Part 2 dose. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
10205308|NCT02913482|Experimental|Part 2 (Confirmatory): Risdiplam (RO7034067)|Participants will receive risdiplam (RO7034067), administered orally once daily at the dose defined in Part 1 of the study, for a duration of 24 months. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
10205309|NCT02875301|Experimental|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
10205310|NCT02875301|Experimental|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
10205311|NCT02875301|Active Comparator|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
10205312|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.~Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.~Complete 9 follow-up phone calls to assess for relapse."
10205313|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline and 2 month time points.~Complete MRI brain imaging data collection at the baseline and 2 month time points."
10205314|NCT02817659|Experimental|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
10205315|NCT02811510|Active Comparator|THC|10 mg Dronabinol will be administered orally.
10205316|NCT02811510|Placebo Comparator|Placebo|Placebo pill (no active cannabinoids).
10205317|NCT02800915|Experimental|Intervention, telemedicine and multidisciplinary cooperation|The intervention group will be offered regular multidisciplinary outpatient follow-up via telemedicine.
9834414|NCT02696798|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
9834415|NCT02696798|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
9834416|NCT02696850|Experimental|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
9834417|NCT02696850|Placebo Comparator|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
9834418|NCT02696902|Experimental|MEDI3902 500 mg|Participants will receive a single intravenous (IV) dose of 500 mg MEDI3902.
9834419|NCT02696902|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
9834420|NCT02696902|Experimental|MEDI3902 1500 mg|Participants will receive a single IV dose of 1500 mg MEDI3902.
9834421|NCT02696967|Experimental|CLR325|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of CLR325 (i.v.) in double blind manner.
9834422|NCT02696967|Placebo Comparator|Placebo|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of placebo (i.v.) in double blind manner.
9834423|NCT02697071|Placebo Comparator|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
9834424|NCT02697071|Experimental|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
9834425|NCT02697188|Experimental|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
9834426|NCT02697188|Active Comparator|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
9834427|NCT02697214|Active Comparator|Apple Watch|Apple Watch heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device .
9834428|NCT02697214|Active Comparator|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
9834429|NCT02697214|Active Comparator|Mio Fuse|Mio Fuse heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
9834430|NCT02697214|Active Comparator|Basis Peak|Basis Peak heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
9834431|NCT02697240|Experimental|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
9834432|NCT02697292|Placebo Comparator|Placebo/Normal Saline Group|Subjects will receive placebo for 4 infusions. After completion of the blinded phase, subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
9834433|NCT02697292|Active Comparator|Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group|Subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
9834434|NCT02697435|Experimental|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain.
9834435|NCT02697435|Placebo Comparator|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
9834436|NCT02697591|Experimental|Phase 1: 20.0 Milligram Per Kilograms (mg/kg) Every 2 Weeks (Q2W)|Participants received IV infusion of study drug at a dose of 20.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834437|NCT02697591|Experimental|Phase 1: 0.03 mg/kg Q2W|Participants received intravenous (IV) infusion of study drug at a dose of 0.03 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834438|NCT02697591|Experimental|Phase 1: 0.1 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.1 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834439|NCT02697591|Experimental|Phase 1: 0.3 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.3 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834440|NCT02697591|Experimental|Phase 1: 1.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 1.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9784121|NCT01218009|Placebo Comparator|Placebo Spiromax|Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
9784122|NCT01218048|Experimental|Neo-Adjuvant Cetuximab|"Neo-Adjuvant Cetuximab + Surgery + Post-Surgical Radiation + Cisplatin (or Carboplatin)~NOTE: Based the results of surgery if the treating physician feels patient is not a candidate for chemotherapy, radiation can be given alone or with cetuximab."
9784123|NCT01218087|Experimental|Cranial cup device and Moldable positioner device|The cranial cup for 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours
9784124|NCT01218087|Active Comparator|Moldable positioner device|Moldable positioner device was used for positioning infants for 24/24 hours
9784125|NCT01218100|Experimental|1|Combination group - starting dose level nebivolol 5mg and lisinopril 10mg
9784126|NCT01218100|Active Comparator|2|Nebivolol monotherapy group - starting dose level nebivolol 5mg
9784127|NCT01218100|Active Comparator|3|Lisinopril monotherapy group - starting dose level lisinopril 10mg
9784128|NCT01218100|Placebo Comparator|4|Placebo group - starting dose is placebo
9784129|NCT01218113|Experimental|3D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
9784130|NCT01218113|Experimental|2D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm.
9784131|NCT01218113|Placebo Comparator|Control Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
9784132|NCT01218126|Experimental|losmapimod 2.5 mg|losmapimod 2.5 mg
9784133|NCT01218126|Placebo Comparator|placebo|
9784134|NCT01218126|Experimental|losmapimod 7.5 mg|losmapimod 7.5 mg
9784135|NCT01218126|Experimental|losmapimod 15 mg|losmapimod 15 mg
9784136|NCT01218204|Other|Part A Run-in|Subjects on stable 40mg atorvastatin > 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
9784137|NCT01218204|Experimental|Part A Co-Dosing 800mg GSK1292263|Dosing for 14 days
9784138|NCT01218204|Other|Part B Washout|Washout for 4 weeks
9784139|NCT01218204|Active Comparator|Part B Run-in 10mg atorvastatin|Dosing for 4 weeks
9784140|NCT01218204|Active Comparator|Part B Run-in 80mg atorvastatin|Dosing for 4 weeks
9784141|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263|Dosing for 14 days
9784142|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263|Dosing for 14 days
9784143|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
9784144|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe|Dosing for 14 days
9784145|NCT01218204|Experimental|Part B Dosing 100mg GSK1292263|Dosing for 14 days
9784146|NCT01218204|Experimental|Part B Dosing 300mg GSK1292263|Dosing for 14 days
9784147|NCT01218204|Experimental|Part B Dosing 800mg GSK1292263|Dosing for 14 days
9784148|NCT01218204|Experimental|Part B Dosing Placebo GSK1292263|Dosing for 14 days
9784149|NCT01218204|Experimental|Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
9784150|NCT01218204|Experimental|Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
9784151|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
9784152|NCT01218243|Experimental|acupoint|Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
9784153|NCT01218243|Sham Comparator|non-acupoint|Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
9784154|NCT01218308|Experimental|FluLaval® Quadrivalent Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of FluLaval® Quadrivalent vaccine at Day 0 and, if unprimed, 2 doses of FluLaval® Quadrivalent vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
9766301|NCT00820872|Experimental|docetaxel + carboplatin + trastuzumab + lapatinib|"Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years."
9766302|NCT00820898|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9766303|NCT00821015|Experimental|Experimental|All study subjects will undergo cryoablation. This is a non-randomized trial.
9766304|NCT00821041|No Intervention|Waiting list control|
9766305|NCT00821041|Experimental|CBT|A 6 weeks online course. Each week participants log on to view videos and read information that focus on a variety of intervention techniques. These include relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training. Participants also monitor their sleep using an online sleep diary and respond to questions regarding their adherence to the program.
9766306|NCT00821093|Experimental|Indacaterol 150 µg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Patients also inhaled placebo to salmeterol twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9766307|NCT00821093|Active Comparator|Salmeterol 50 µg|Patients inhaled salmeterol 50 μg twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Patients also inhaled placebo to indacaterol once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9766308|NCT00821119|Active Comparator|NCPAP|preterm infants with nasal positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome will be compared to preterm infants with nasal intermittent positive pressure ventilation
9766309|NCT00821119|Experimental|NIPPV|preterm with nasal intermittent positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome
9766310|NCT00821184|Active Comparator|Vesicare|Vesicare alone
9766311|NCT00821184|Active Comparator|Vesicare/behavioral modification|Vesicare plus behavioral modification
9766312|NCT05237154|Experimental|Intermittent fasting (IF)|Alternate-day intermittent fasting. Consumption of 25% of daily energy requirements on scheduled fasting days involving energy restriction for 2 non-consecutive days of the week and ad libitum feeding on the other 5 days of the week. Period: 8 weeks.
9766313|NCT05237154|Experimental|Exercise: High-Intensity Interval Training (HIIT)|High intensity circuit training. Progressive training protocol 3x/week, for 8 weeks, with at least 1 day of rest between sessions and duration of 25 minutes each session - 4 minutes of initial warm-up, 18 minutes of the main part and 3 minutes of relaxation. First and second week: 30 second run and recovery time. Third and fourth week: 35-second runtime and 25-second recovery time. Fifth and Sixth Week: 40-second runtime and 20-second recovery time. Seventh and eighth weeks: 45-second runtime and 15-second recovery time.
9766314|NCT05237115|Experimental|Clostridium butyricum group|given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
9766315|NCT05237115|Experimental|Bacillus clotting group|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
9766316|NCT05237115|Active Comparator|bismuth quadruple therapy|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
9766317|NCT05237089|Active Comparator|EA group：Electroacupuncture+health education|Acupuncture is the most popular adjuvant and alternative therapy in China, and it has been used to treat various diseases for thousands of years. Electroacupuncture is an innovation of traditional Chinese acupuncture, which improves the clinical effect by transmitting electrical pulses to the needles and then enhances the stimulation at the acupoints to receive better effects. Studies show that EA has been used as an alternative therapy for obesity in clinical practice.
9766318|NCT05237089|Sham Comparator|Sham acupuncture group：shallow acupuncture+health education|Sham acupuncture method in this study is set as the superficial acupuncture manipulated at the same main acupoints with the thinner and shorter needles. The aim of the sham acupuncture is to eliminate the possible placebo effect of EA treatment.
9766319|NCT05237076|Experimental|Diabetes Type 2|Patients with DM Type 2 using Oral Diabetes Medications only.
9766320|NCT05237076|Active Comparator|Healthy controls|Healthy controls without comorbidities.
9834441|NCT02697591|Experimental|Phase 1: 3.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 3.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834442|NCT02697591|Experimental|Phase 1: 5.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 5.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834443|NCT02697591|Experimental|Phase 1: 10.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 10.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834444|NCT02697591|Experimental|Phase 1: 400 mg/kg Every 4 Weeks (Q4W)|Participants received IV infusion of study drug at a dose of 400 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834445|NCT02697591|Experimental|Phase 2: 300 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 300 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
9834446|NCT02697617|Placebo Comparator|Placebo Arm|Subject will be on placebo
9834447|NCT02697617|Active Comparator|Pioglitazone Arm|Subject will be on pioglitazone
9834448|NCT02697734|Experimental|osilodrostat Group|Participants in this arm were randomized to receive the study drug, osilodrostat followed after Week 12 by open-label osilodrostat at the starting dose (with a second dose titration)
9834449|NCT02697734|Placebo Comparator|osilodrostat Placebo Group|Participants in this arm were randomized to receive osilodrostat placebo followed after Week 12 by open-label osilodrostat at the starting dose (with a dose titration)
9834450|NCT02697773|Placebo Comparator|Placebo|placebo administered subcutaneously at day 0 and week 8
9834451|NCT02697773|Experimental|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
9834452|NCT02697773|Experimental|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
9834453|NCT02697890|Active Comparator|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:~Procedure: Ridge preservation procedure"
9834454|NCT02697890|Experimental|FDBA (MinerOss®) + Mucograft® seal|"Interventions:~Device: Mucograft® seal Procedure: Ridge preservation procedure"
9834455|NCT02697916|Active Comparator|ASA 81mg|aspirin 81mg
9834456|NCT02697916|Active Comparator|ASA 325mg|aspirin 325mg
9834457|NCT02698033||Low dose challenge passed|Individuals who tolerated without dose limiting symptoms the screening food challenge for a parent interventional trial
9836020|NCT02766400|Active Comparator|Directed Training|Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.
9836021|NCT02766517|Experimental|Capsaicin|Single topical dose of capsaicin
9836022|NCT02766608|Experimental|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
9836023|NCT02766608|Experimental|BFF MDI 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
9836024|NCT02766608|Experimental|FF MDI 9.6 μg|Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
9836025|NCT02766608|Experimental|BD MDI 320 μg|Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
9836026|NCT02766608|Other|Symbicort® TBH 400/12 μg|Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
9836027|NCT02766673|Active Comparator|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
9836028|NCT02766673|Active Comparator|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
9836029|NCT02766673|Placebo Comparator|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
9836030|NCT02766777|Experimental|Lubiprostone|Participants received lubiprostone twice daily (BID). Participants received either lubiprostone 12 mcg BID, lubiprostone 24 mcg BID (dose based on participant's weight) up to 24 weeks.
9836031|NCT02766907|Active Comparator|Study|prospective arm receiving cryopreserved amniotic membrane
9836032|NCT02766907|No Intervention|Control|Retrospective review of debridement without cryopreserved amniotic membrane
9836033|NCT02767011|Experimental|THEM|Patients receive telehealth electronic health care monitoring.
9836034|NCT02767011|No Intervention|Standard of Care (SOC)|Patients receive normal standard of follow-up care
9836035|NCT02767128|Experimental|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
9836036|NCT02767128|Experimental|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
9836037|NCT02767128|Experimental|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
9836038|NCT02767128|Experimental|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
9836190|NCT02773836||Hungarian Cohort|Participants recruited from Hungary will receive a questionnaire at pre- and post- intervention
9834458|NCT02698176|Experimental|Birabresib 20 mg CRPC Cohort-Part A|Participants in the CRPC cohort in Part A of the study received birabresib 20 mg orally (PO), twice a day (BID), in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
9834459|NCT02698176|Experimental|Birabresib 20 mg NMC Cohort-Part A|Participants in the NMC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
9834460|NCT02698176|Experimental|Birabresib 20 mg TNBC Cohort-Part A|Participants in the TNBC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
9834461|NCT02698176|Experimental|NMC Cohort-Part B|Participants (up to 30) in Part B will receive birabresib at one dose level below the dose currently being administered in Part A of the study. Once the recommended Phase 2 dose (RP2D) from Part A is established, participants in Part B will receive birabresib at the RP2D. Participants will continue receiving birabresib at an assigned/adjusted dose level for continuous cycles up to 24 months.
9834462|NCT02698189|Experimental|Birabresib 20 mg AML Cohort|Participants in the AML cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
9834463|NCT02698189|Experimental|Birabresib 20 mg DLBCL Cohort|Participants in the DLBCL cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
9834464|NCT02698215|Experimental|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
9834465|NCT02698215|Placebo Comparator|Varenicline|VAR (1 mg twice daily)
9834466|NCT02698241|Other|Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
9834467|NCT02698371|Active Comparator|FBDC-SE (G1; Control)|Futurabond DC (single dose blister) will be applied as thickness to the enamel/dentine and rub into the tooth surface for 20s; FBDC drying layer for at least 5s with an air syringe; This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20s.
9834468|NCT02698371|Active Comparator|FBDC-SE-EE (G2; Control )|Etch with 36% phosphoric acid, during 30s in enamel structures. Remove the 36% phosphoric acid with water during 1 minute. The remove of water excess will be done with weak air spray, not to dry the dentine completely. The dentine surface must slightly remain wet. Application of Futurabond DC (FBDC) as self-etch mode simultaneously in dentin and enamel, and the light-cured (LED light; 1000mW/cm2), during 20s.
9834469|NCT02698371|Other|FBU-ER (G3)|FuturabondU® (FBU) apply in enamel and dentin as etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15s in dentin and 30s in enamel) and then rinse with water for 1 min. Dry off excess moisture with a gentle stream of air. Activating FBU SingleDose. FBU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 20s.
9834470|NCT02698371|Other|FBU-SE (G4)|FuturabondU® (FBU) apply in enamel and dentin as SE mode. Activating FBU SingleDose. FBU adhesive will be homogeneously apply to all cavity surfaces and rub in for 20 s using the Single Tim; Dry off the adhesive layer with dry, oil-free air for at least 5 s in order to remove any solvents. This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20 seconds.
9834471|NCT02698371|Other|ADU-ER (G5)|Adhese®Universal (ADU) apply by etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15 seconds in dentin and 30 seconds in enamel); Etch agent rinse with water for 1 minute. Dry off excess moisture with a gentle stream of air. Keep dentin dry, do not over dry; Adhesive ADU will be scrubbed into the tooth surface (enamel and dentin) for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2 for 20s.
9834472|NCT02698371|Other|ADU-SE (G6)|Adhese®Universal (ADU)apply by self-etch (SE) mode. Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with ADU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 20 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2.
9834473|NCT02698410|Experimental|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
9834474|NCT02698423|Experimental|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
9834475|NCT02698423|Active Comparator|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
9834476|NCT02698436|Experimental|Acne Mask|"The light therapy acne device is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.~Other Names: Cleanser is marketed while the device is not marketed"
9834477|NCT02698436|Active Comparator|2.5% Benzoyl Peroxide Treatment|"Cleanser and 2.5% Benzoyl Peroxide Treatment Both the cleanser and the 2.5% Benzoyl Peroxide Treatment are applied twice daily, once in the morning and once in the evening.~Other names: Both products are marketed"
9836191|NCT02773836||Polish cohort|Participants recruited from Poland will receive a questionnaire at pre- and post- intervention
9834478|NCT02698475|Experimental|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg; participants weighing >100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
9834479|NCT02698566|Experimental|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
9834480|NCT02698735|Experimental|Gentamicin|Gentamicin antibiotic
9834481|NCT02698735|Placebo Comparator|Placebo|Vehicle control
9834482|NCT02698787|Experimental|Group 1|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 1 will be receiving the FAST (experimental) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 1 will be switched to the commercially available ACE (control) sound coding strategy.
9834483|NCT02698787|Experimental|Group 2|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 2 will be the commercially available ACE (control) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 2 will be switched to the receiving intervention of the FAST (experimental) sound coding strategy. The experimental sound coding strategy will be used from 3-6 months post activation.
9834484|NCT02698800|Experimental|Blue blocking (BB)|Wearing of BB lenses.
9834485|NCT02698800|Placebo Comparator|Clear|Wearing of clear lenses
9834486|NCT02699099|Experimental|Coad group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
9834487|NCT02699099|Experimental|RTS,S group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
9834488|NCT02699099|Experimental|Control group|Children randomized received Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. These children received SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
9834489|NCT02699125|Experimental|Placebo, Guanfacine, Hydrochlorothyazide|Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
9834490|NCT02699125|Experimental|Placebo, Hydrochlorothyazide, Guanfacine|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.
9834491|NCT02699450|Active Comparator|Arm A: 0.3 mg Ranibizumab|Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
9834492|NCT02699450|Experimental|Arm B: 1.5 mg Faricimab|Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
9834493|NCT02699450|Experimental|Arm C: 6 mg Faricimab|Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
9834494|NCT02699463|Active Comparator|Continous Positive Airway Pressure|Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
9834495|NCT02699463|Placebo Comparator|Control Group|Participants will receive standard care (Sleep hygiene counseling) during the study.
10203463|NCT00365157|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10203464|NCT00322218|Experimental|Zevalin|"Patients received Zevalin.~Zevalin Therapeutic Regimen:~Day 1: Initial administration of 250 mg/m^2 rituximab, followed immediately by administration of 185 MBq of [111In]-ibritumomab tiuxetan ,in centers where centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.~- Day 7-9: Rituximab 250 mg/m^2, followed immediately by [90Y]-ibritumomab tiuxetan 14.8 MBq/kg given as a slow intravenous push over 10 minutes.~Two treatment days one week apart were followed by a 12-week safety period."
9766321|NCT05237024||Physiology Monitoring|The study's objective is to test the hypothesis that immune system activation and subsequent systemic inflammation can be detected through continuously tracking multiple bio signals including physiologic variables (ECG, skin temperature and their derivatives) and behavioral variables (activity and sleep from accelerometers) collected during routine activities of daily living using wearable biosensors.
9766322|NCT05237024||Physiology & Immune Monitoring|A limited sub-study including 30 individuals enrolled in the primary study (not retrospective group) will incorporate serial blood draws relative to the vaccine doses. The purpose of the serologies and immunoassays is to explore the correlation an individual's development of a vaccine-induced immune response with changes in the continuous physiologic data surrounding the immunization process.
9766323|NCT05236998|Experimental|Sequence A|Period 1: Dapagliflozin and Sitagliptin / Period 2: SID1903 (FDC)
9766324|NCT05236998|Experimental|Sequence B|Period 1: SID1903 (FDC) / Period 2: Dapagliflozin and Sitagliptin
9766325|NCT05236972|Experimental|Sintilimab|Sintilimab 200mg iv drip Q3W for 8 courses
9766326|NCT05236972|Experimental|XELOX|Patients receive chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 or 8 courses
9766327|NCT05236959|Experimental|Mindfulness-Based Cognitive Therapy|A group-based treatment combining intensive training in mindfulness mediation and elements of cognitive therapy (see further above).
9766328|NCT05236959|Other|Treatment as Usual|Participants in this group continue with their usual care and follow the regimes suggested by their GP or mental health professionals (see further above).
9766329|NCT05236946|Active Comparator|Upfront Cranial Radiotherapy|Stereotactic radiosurgery or Whole brain radiotherapy upfront in asymptomatic brain metastases
9766330|NCT05236946|Experimental|Observation (Delayed Cranial Radiotherapy)|Observation (Delayed Cranial radiotherapy) of Asymptomatic brain metastases
9766331|NCT05236920|No Intervention|Standard Care|Participants randomized to this arm will receive standard care for cardiac arrest, which consists of advanced cardiovascular life support (ACLS)
9766332|NCT05236920|Experimental|Standard Care Plus Intervention|Participants randomized to this arm will receive standard care for cardiac arrest, which consists of advanced cardiovascular life support (ACLS) plus the study intervention
9766333|NCT05236907|Placebo Comparator|Control Group|Patients in this group received nothing for sedation.
9766334|NCT05236907|Active Comparator|Midazolam group|7.5 mg of Midazolam were given orally the night before operation. Another dose 90 min. preoperatively.
9766335|NCT05236907|Experimental|Melatonin group|5 mg of Melatonin were given orally the night before operation. Another dose 90 min. preoperatively
9766336|NCT05236855||Intervention|Women seen at the colposcopy clinic at Nova Scotia Health in Gynaecology-Oncology because of an abnormal cervical screen lab report
9766337|NCT05236855||Control|Women seen at the General Gynaecology Clinic and the Izaak Walton Killam (IWK) Health Centre with a normal cervical screen lab report
9766338|NCT05236842|Active Comparator|Sulthiame 100 mg|Sulthiame film-coated tablets 100 mg once daily 15 weeks
9766339|NCT05236842|Active Comparator|Sulthiame 200 mg|Sulthiame film-coated tablets 200 mg once daily 15 weeks
9766340|NCT05236842|Active Comparator|Sulthiame 300 mg|Sulthiame film-coated tablets 300 mg once daily 15 weeks
9766341|NCT05236842|Placebo Comparator|Placebo|Placebo film-coated tablets once daily 15 weeks
9766342|NCT05236777||Natalizumab Cohort|The cohort will include participants with MS who are newly treated with natalizumab (administered as a standard of care/routine clinical practice) from 1st January 2019 including those participants who terminate or discontinue the treatment during the observational period.
9766343|NCT05236764|Experimental|Alpha beta+ T cell depleted CD34+ stem cells|The patient will be receiving a donor stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The investigators will be specially treating the donor's blood cells used for the stem cell transplant.
9766344|NCT05236751||Elective intracranial intervention patients|Adult patients (18-89 years at the time of surgery) scheduled for elective intracranial (open surgical or endoscopic) intervention and require general anesthesia and a hospital stay of at least one day post-procedure.
9766348|NCT05236712|Experimental|Mobile health|Participants will receive access to a mobile app installed on their device and will be asked to use the app at least once a week
9766349|NCT05236712|No Intervention|Usual care|Participants will receive information on public online resources
9766350|NCT05236699|Experimental|DEB-TACE combined with Surufatinib and Camrelizumab|
9766351|NCT05236686|Experimental|Hepato-celiac lymphadenectomy|This single-arm, single-center, phase II trial is to evaluate the safety and effectiveness of hepato-celiac lymphadenectomy in the treatment of ovarian cancer with hepato-celiac lymph nodes metastases, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
9766352|NCT05236660|Experimental|Multimodal care|Multimodal personalised treatment
9766353|NCT05236660|No Intervention|Usual care|Usual care as offered to high-risk patients as offered in the Netherlands
9766354|NCT05236634|Active Comparator|Group A|Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks.
9766355|NCT05236634|Active Comparator|Group B|Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks.
9766356|NCT05236634|Active Comparator|Group C|Forty patients with LUTS due to BPH will be given combined therapy(tamsulosin 0.4 mg and tadalafil 5 mg) for 12 weeks.
9766357|NCT05236621|Experimental|Permadomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
9836039|NCT02767128|Experimental|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
9834496|NCT02699593|Experimental|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
9834497|NCT02699593|Active Comparator|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
9834498|NCT02699684|Other|AOHG, then AOA|Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
9834499|NCT02699684|Other|AOA, then AOHG|Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
9834500|NCT02699749|Experimental|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.~If the PK from the early cohorts support BID dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
9834501|NCT02699866|Experimental|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
9834502|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
9834503|NCT02699970||Selected features|"No intervention is administered to the selected features. They only need to be observed by the pathologist.~The features are part of tissue that is present on a slide. This slide is fully scanned and the digital image is than viewed by the pathologist who indicates if he can see the feature. By repeating the scan three times and having the pathologist view three times, the consistency of the feedback can be monitored. The consistency is a measure on how repeatable and reproducible the scanner is. To be very clear: the scanner does not do anything to the tissue. It only takes a digital 'photo' of the tissue. It is no treatment or intervention. It just takes a picture."
9834504|NCT02699983|Experimental|Group I (SparkPeople program)|"Participants receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and they may request additional training if needed.~Participants are instructed to self-monitor their diet at least weekly using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.~Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.~All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3, and 6 months."
9834505|NCT02699983|Active Comparator|Group II (wait list)|Participants receive the weight loss handout and a Fitbit activity monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I. All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3 and 6 months.
9834506|NCT02699996|Experimental|self-management + peer mentoring|Participants complete the self-management + peer mentoring intervention comprising 5 online educational modules and 6 videoconference or phone calls with the peer mentor.
9834507|NCT02700165|Experimental|CoolSculpting with CoolMini|The treatments are designed to see if fat in the submandibular/submental area (chin), can be reduced using cryolipolysis.
9834508|NCT02700334|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
9834509|NCT02700334|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
9836040|NCT02767128|Experimental|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
9836041|NCT02767128|No Intervention|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
9984266|NCT04271956|Experimental|Tislelizumab + Zanubrutinib|"Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib~Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib~Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation"
9984267|NCT04269161|Experimental|Automatic Oxygen Control|In this arm, an automatic oxygen control device will be used to make adjustments to the blend of oxygen and air supplied to the subject.
9834510|NCT02700412|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
9834511|NCT02700425|Active Comparator|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
9834512|NCT02700425|Active Comparator|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
9834513|NCT02700815|Experimental|Diclofenac and capsaicin|Fixed dose combination
9834514|NCT02700815|Active Comparator|Diclofenac|
9834515|NCT02700815|Active Comparator|Capsaicin|
9834516|NCT02700815|Placebo Comparator|Placebo|
9834517|NCT02700919|Experimental|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
9834518|NCT02700919|Experimental|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
9834519|NCT02700919|Placebo Comparator|Regimen 3|Placebo Day 1 to Day 5
9834520|NCT02700984|Experimental|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
9834521|NCT02700984|Active Comparator|Cataract Surgery Only|Cataract Surgery (COMPASS trial) with no CyPass Micro-Stent implantation
9834522|NCT02700997|Experimental|Vascular clip|Application of a clip to dissolvable sutures.
9834523|NCT02701049|Other|SO/GI Collection|Methods to collect SO/GI information in the ED
9834524|NCT02701062|Other|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
9834525|NCT02701062|Active Comparator|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
9834526|NCT02701101|Other|Daily Skin Assessments (SoC and SEM Scanner Readings)|"The SEM Scanner 200 measures sub-epidermal moisture (SEM), which has been studied as an indicator of localized edema characteristic of pressure-induced tissue damage. Daily assessments were performed at the sacrum and both heels unless the anatomical location(s) were not assessable. Daily assessments included:~Risk Assessment (standard of care; Braden, Waterlow, or Norton)~Skin Assessment (standard of care visual skin assessments utilizing tactile and visual cues)~SEM Scanner readings (test variable in this study). Standard of care evaluations were conducted by individuals meeting the definition of Specialist specified in the study protocol whereas separate individuals meeting the definition of Generalist performed SEM Scanner 200 measurements. Specialists were blinded to the assessment by the Generalists, and vice versa."
9834527|NCT02701257|Active Comparator|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
9834528|NCT02701257|Experimental|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
9834529|NCT02701257|Experimental|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
9834530|NCT02701257|Experimental|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
9834531|NCT02701257|Active Comparator|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
9834532|NCT02701270|Experimental|Experimental Dietary Fibre 1|
9834533|NCT02701270|Experimental|Experimental Dietary Fibre 2|
9834534|NCT02701270|Active Comparator|Polydextrose|
9834535|NCT02701270|Active Comparator|Dextrose control|
9834536|NCT02701296|Experimental|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
9834537|NCT02701296|Active Comparator|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
9834538|NCT02701361|Active Comparator|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
9834539|NCT02701361|Experimental|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
9834540|NCT02701361|Experimental|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
9834541|NCT02701387|Experimental|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
9834542|NCT02701387|Active Comparator|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
9984268|NCT04269161|No Intervention|Manual Oxygen Control|In this arm, a nurse will manually make adjustments to the blend of oxygen and air supplied to the subject as in the standard of care.
9834543|NCT02701400|Experimental|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
9834544|NCT02701400|Active Comparator|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
9834545|NCT02701413|Experimental|ApexM Device|The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
9834546|NCT02701413|Sham Comparator|Sham Device|The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.
9834547|NCT02701582|Experimental|Goal Directed Therapy|Flotrack monitor is connected and based on what anesthesiologist sees and following study algorithm, anesthesiologist chooses: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
9834548|NCT02701582|Active Comparator|Control Group|FloTrac monitor is connected, but he anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be given a study algorithm to follow for the duration of the surgery, and based on it will choose: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
9834549|NCT02701634|Experimental|ENTO|ENTO 400 mg or 200 mg tablet twice daily for 48 weeks
9834550|NCT02701634|Placebo Comparator|Placebo|Placebo to match tablet twice daily for 48 weeks
9834551|NCT02701647|Experimental|25Hz-TT|Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
9834552|NCT02701647|Experimental|1Hz-TT|Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.
9834553|NCT02701647|Sham Comparator|Sham-TT|Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.
9834554|NCT02701764|Experimental|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
9834555|NCT02701764|Placebo Comparator|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
9834556|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the Pennington Biomedical Demonstration Kitchen over the course of approximately 3 months.
9834557|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
9834558|NCT02701985|Placebo Comparator|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
9834559|NCT02701985|Experimental|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
9834560|NCT02702011|Experimental|empagliflozin low dose|
9834561|NCT02702011|Experimental|empagliflozin medium dose|
9834562|NCT02702011|Experimental|empagliflozin high dose|
9834563|NCT02702011|Placebo Comparator|placebo|
9834564|NCT02702193|Experimental|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers.
9834565|NCT02702193|No Intervention|TAU|Treatment as usual - the usual outpatient substance abuse or mental health services received by the mothers with no additional services provided by the study team.
9834566|NCT02702388|Experimental|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
9834567|NCT02702388|Experimental|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
9766358|NCT05236595||Rare genetic disease individualized drug development screening candidate|Patients with targetable disease-causing genetic alterations will be evaluated on a case by case basis. The research study will utilize biospecimens to determine if an individualized therapeutic may be developed as a possible treatment option. If an individualized therapeutic drug can be developed, a future IND FDA application (n=1) will be filed.
9766359|NCT05236582|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take Herombopag at the indicated dose.
9766360|NCT05236569|Experimental|Tranexamic acid|The intervention was 1 ml of 10 mg/ml of tranexamic acid solution which was given intradermally.
9766361|NCT05236569|Placebo Comparator|Placebo|The placebo was 1 ml of 0.9% normal saline which was given intradermally.
9766362|NCT05236556|Experimental|Intervention|Receive best practice advisory (BPA)
9766363|NCT05236556|No Intervention|Control|Does not receive best practice advisory (BPA)
9766364|NCT05236504|Experimental|Supplement|Melatonin and magnesium-containing pod
9766365|NCT05236504|Placebo Comparator|Placebo|Placebo pod
9766366|NCT05236452|Experimental|Integrating of the traditional TB care with modern care through screening, and referral linkage|Integrating traditional care with modern care is a collaboration of two systems through referral linkage. A referral linkage model will be used to detect TB cases in both traditional and modern care services. Health care providers, traditional care providers will participate in the integration process.
9766367|NCT05236452|Active Comparator|Patients proceed with the usual care/ control group|The control group will be followed the existing passive case-findings system (self-referral patients to nearby health facilities that use the same national guidelines to treat TB). The usual care will be carried out using nationally standardized guidelines. The findings obtained from the control groups will be compared with the intervention groups. Finally, changes among the two groups will be assessed and concluded.
9766368|NCT05236439|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
9766369|NCT05236413|Experimental|High Intensity Interval Exercise|Enrolled patients will perform supervised exercise on 3 nonconsecutive days of the week for 4 weeks.
9766370|NCT05236413|Experimental|Dietary Approaches to Stop Hypertension (DASH) Diet|Enrolled patients will have all of their food prepared for them by a registered dietician for the duration of the study period. The diet will consist of a high fiber content DASH diet.
9766371|NCT05236413|Experimental|Exercise + DASH Diet|Enrolled subjects will undergo both the exercise training visits and be provided with the DASH diet.
9766372|NCT05236374|Experimental|Beef Protein|A beef stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);
9766373|NCT05236374|Active Comparator|Animal Protein|A control plant protein stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);
9766374|NCT05236348|Experimental|Patients with Aktiia.product-us|All study participants will wear the Aktiia.product-us during eight visits that will be held over the span of seven days.
9766375|NCT05236335|Experimental|Ketone ester|
9766376|NCT05236335|Placebo Comparator|Placebo|
9766377|NCT05236322||study group|Removal by soft tissue laser of the tumor
9766378|NCT05236322||control group|Removal by ordinary surgical scalpel
9766379|NCT05236283||Bern ICU|
9766380|NCT05236283||Lausanne ICU|
9766381|NCT05236218||Pilot study (n = 10)|10 participants will be recruited to complete the questionnaire (version 1). A research assistant will be present to help support them /answer any questions around the format. Readability and comprehension will be noted. Any changes (if needed) can be implemented to its format before the main data collection.
9766382|NCT05236218||Discrete Choice Experiment Questionnaire (n = 50)|Discrete Choice Experiment (DCE) Patients
9766383|NCT05236192|Experimental|Take Root Home Visitation (TRHV)|TRHV is an evidence-informed, manualized home-visiting curriculum.
9766384|NCT05236192|Active Comparator|Services as Usual (SAU)|SAU involves the current standard of care implemented at the participating Navy and Marine Corps installations.
9766385|NCT05236166|Other|Rapid withdrawal|Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).
9766386|NCT05236166|Other|Slow withdrawal|Reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).
9766387|NCT05236140|Experimental|Perineal electrical stimulation (Stimulation group)|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
9766388|NCT05236140|No Intervention|Control group|Subjects in the control group will go through baseline assessment and will not receive treatment or instructions to perform pelvic floor exercises at home. After 8 weeks they will be submitted to the final assessment. After the final evaluation, they will be invited to start treatment in the urogynecological rehabilitation unit.
9766389|NCT05236127|Experimental|Fasted|Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for the entire 8-day period of the study.
9518041|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
9766390|NCT05236127|Experimental|Pre-heading fasted|Pre-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a 4 hour eating window for a 5-day period prior to the soccer heading.
9766391|NCT05236127|Experimental|Post-heading fasted|Post-Heading Fasted Group: Individuals randomly assigned to undergo a 20 hour fast with a four hour eating window for a 3-day period following the soccer heading.
9766392|NCT05236127|Experimental|Control|Control Group: Individuals randomly assigned to eat per usual over the course of the entire 8-day study period.
9766393|NCT05236127|Active Comparator|Subconcussive Head Impact|"All four groups undergo the same soccer heading model as described below.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by 30 second intervals."
9766394|NCT05236101|Experimental|CD:H Scale|Pictures drawn using the CD:H Scale were evaluated.
9766395|NCT05236088|Experimental|NMES group|Neuromuscular electrical stimulation (NMES) will be applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device for 30 minutes 3 days a week during 4 weeks
9766396|NCT05236088|Sham Comparator|Sham group|Sham group will be applied from the same device (INNOVO brand (Atlantic Therapeutics, Galway, Ireland)), for 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
9766398|NCT05236062|Experimental|Exercise Group|"Home-based, virtually supervised via Zoom, 3x weekly for 12-weeks aerobic and resistance exercise program~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
9766399|NCT05236062|Experimental|Attention control Group|"Home-based, 12-week stretching program only with participants asked not to change their activity behavior.~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
9766400|NCT05236049|Experimental|SclerFIX|Strip of umbilical cord lining membrane allograft wrapped around the bioceramic enucleation implant. The assembly is placed inside the void orbital cavity and the muscles are sutured to the SclerFIX strips.
9766401|NCT05236010|Active Comparator|Active rTMS with Attention Process Training|Subjects in this arm will receive active rTMS and then complete the assigned Attention Process Training battery immediately following active rTMS.
9766402|NCT05236010|Sham Comparator|Sham rTMS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training immediately following sham rTMS.
9766403|NCT05236010|Active Comparator|Active HD-tDCS with Attention Process Training|Subjects in this arm will receive active HD-tDCS and complete the assigned Attention Process Training battery during active HD-tDCS.
9766404|NCT05236010|Sham Comparator|Sham HD-tDCS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training during sham HD-tDCS.
9766405|NCT05235997|Experimental|Hydrolized Collagen Peptide|This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
9766406|NCT05235997|Placebo Comparator|Placebo|This arm will be allocated randomly and receive placebo throughout the study.
9766407|NCT05235945|Experimental|Online exercise intervention|A four-week preoperative physical activity intervention, involving a combination of supervised and unsupervised (live or pre-recorded), online exercise sessions. These sessions will be designed to meet the National physical activity guidelines (2020) of at least 150 minutes of low-moderate or 75 minutes of vigorous physical activity per week (or a combination of the two). The intervention will involve moderate intensity activities that aim to increase or maintain muscle strength (resistance training) as well as short bouts of vigorous aerobic exercise, using major muscle groups in the lower and upper body.
9766408|NCT05235945|No Intervention|Control|Usual care
9766409|NCT05235932|Experimental|Robotic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received robotic radical total gastrectomy with D2 lymphadenectomy
9766410|NCT05235932|Active Comparator|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received laparoscopic radical total gastrectomy with D2 lymphadenectomy
9766411|NCT05235919|Experimental|repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 rTMS sessions for 3 weeks.
9766412|NCT05235919|Sham Comparator|Sham|Participants will receive 15 sessions of sham stimulation for 3 weeks.
9766413|NCT05235906|Experimental|Surufatinib + Sintilimab|
9766414|NCT05235867||dumpers|"male and female patients~age 13-24 years~diagnosis of restrictive-type anorexia nervosa~hospitalization for nutritional support~>4 cc/kg/day of urine output (a.k.a. fluid dumpers; n=5)"
9766415|NCT05235867||non-dumpers|"male and female patients~age 13-24 years~diagnosis of restrictive-type anorexia nervosa~hospitalization for nutritional support~<2 cc/kg/d of urine output (a.k.a. non-dumpers; n=5)"
9766416|NCT05235854|Active Comparator|Meniscal wall infiltration group|Administration of Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe under ultrasound control.
9766417|NCT05235854|Active Comparator|Intra-articular infiltration group|"The procedure is identical in all respects to the experimental group, except that the ultrasound procedure is mimicked and the infiltration of dexamethasone 2 mg (Diprostene®) is performed intra-articularly.~Administration Diprostene: 1 ml syringe of Betamethasone 2 mg; injectable suspension in pre-filled syringe."
9766418|NCT05235841|Experimental|AG|The group that met the criteria of the study and applied acupressure protocol before Coronary Angiography
9766419|NCT05235841|No Intervention|CG|BEFORE CORONARY ANGIOGRAPHY, THE GROUP WITHOUT ANY INTERVENTION, CONTROL GROUP
9834568|NCT02702401|Experimental|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
9834569|NCT02702401|Placebo Comparator|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
9834570|NCT02702518|Active Comparator|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
9834571|NCT02702518|Placebo Comparator|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
10203465|NCT00322218|No Intervention|Observational|Patients in this arm did not receive any reference therapy; they remained free of any anti-lymphoma therapy and were observed for relapse. This was non-interventional Stage consisting of a longterm follow-up period (until completion of a median observation period of 5 years).
10203466|NCT00186888|Other|Stratum A|Patients with early bilateral or unilateral, or patients with bilateral that have already had the advanced eye enucleated. Treatment included vincristine and carboplatin for 8 courses, given at 3-4 week intervals. Focal therapies any time after second course can include cryotherapy, laser photocoagulation, thermotherapy, and plaque radiotherapy
9834572|NCT02702609|Experimental|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
9834573|NCT02702609|Active Comparator|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
9834574|NCT02702921|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
9834575|NCT02702921|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
9834576|NCT02702999|Active Comparator|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
9834577|NCT02702999|Experimental|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
9834578|NCT02703259|Active Comparator|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
9834579|NCT02703259|Placebo Comparator|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
9834580|NCT02703311|Other|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
9834581|NCT02703324|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
9834582|NCT02703324|Active Comparator|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
9834583|NCT02703337|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
9834584|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
9518042|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
9834585|NCT02703337|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
9834586|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
9834587|NCT02703350|Experimental|LY900014 - Test (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
9834588|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
9834589|NCT02703350|Experimental|LY900014 - Test (Part B)|Individualized doses of LY900014 administered by injection under the skin immediately before each meal for 14 days
9834590|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin immediately before each meal for 14 days
10203467|NCT00186888|Other|Stratum B|"Patients with bilateral disease (at least one advanced stage eye), candidate for conservative management.~Treatment included window treatment with vincristine and topotecan, Followed by 3 more courses of vincristine-topotecan if they had a response to the window+ 6 courses of vincristine and carboplatin. If they do not respond to the window, they receive 6 courses of vincristine, carboplatin, and etoposide. Periocular carboplatin is also given three times, depending on whether they respond to window. External Beam Radiation 44-46 Gy administered using standard practices."
10205318|NCT02800915|Active Comparator|Control, multidisciplinary guidance on request.|The control group will receive guidance based on existing routines (on-site consultations at the wound clinic and telephone consultations), and based on initiative taken by the local healthcare service/ patient/ next of kin.
10205319|NCT02796261|Experimental|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
9766420|NCT05235828|Experimental|Active intervention (ACT) group|8-12 participants will meet for 3-hour sessions for the first 5 days of the intervention. This is followed by five weeks of 1-hour sessions twice per week. In total, the intervention will be 15 sessions that run for a total of 25 hours over 6-weeks. Experienced and licensed SKY instructors from the International Association for Human Values (IAHV) and Art of Living Foundation (AOLF) will provide the intervention through video calls. Instructors will guide participants through the v-SKY intervention through visual demonstrations and verbal guidance. All sessions will be delivered virtually using Zoom. Sessions will not be recorded.
9766421|NCT05235828|No Intervention|Waitlist control (WLC) group|8-12 participants will not receive the intervention for 6-weeks. The 6-weeks will line up with the v-SKY intervention that the ACT group receives. After the waitlist period, the WLC group will receive the same v-SKY intervention as the ACT group. According to our earlier estimates, a high number of veterans with PTSD may not be actively receiving treatment for their illness. For these reasons, a waitlist control design may better reflect the current treatment environment for veterans with PTSD.
9766422|NCT05235802||Patients with traumatic brain injury about 10 years ago|Patients that had suffered a TBI and being managed at the Neurosurgical Department at the Karolinska University Hospital between 2007 and 2015.
9766423|NCT05235789|Experimental|Intervention group|The social workers in each center of primary care held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
9766424|NCT05235789|Active Comparator|Control group|The control group (GC) in each center of primary care will take the usual medical care for depression, according with up-dated national and international guidelines.
9766425|NCT05235685|Active Comparator|Patients with COPD|Patients with COPD will only exercise under medical air (for between-group comparison: COPD vs COPD-HF)
9766426|NCT05235685|Experimental|Patients with COPD-HF overlap|Patients with COPD-HF overlap will first exercise under medical air (for between-group comparison: COPD vs COPD-HF); Patients with COPD-HF overlap will then exercise under interventions (randomized order: non-invasive ventilation + medical air; non-invasive ventilation + hyperoxia, for within-group comparison: medical air vs intervention trials)
9766427|NCT05235659|Experimental|Condition 1|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
9766428|NCT05235659|Experimental|Condition 2|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
9766429|NCT05235659|Experimental|Condition 3|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
9766430|NCT05235659|Experimental|Condition 4|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
9766431|NCT05235659|Experimental|Condition 5|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
9766432|NCT05235659|Experimental|Condition 6|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
9766433|NCT05235659|Experimental|Condition 7|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
9766434|NCT05235659|Experimental|Condition 8|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
9766435|NCT05235659|Experimental|Condition 9|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
9766436|NCT05235659|Experimental|Condition 10|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
9766437|NCT05235659|Experimental|Condition 11|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
9766438|NCT05235659|Experimental|Condition 12|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
9766439|NCT05235659|Experimental|Condition 13|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
9766440|NCT05235659|Experimental|Condition 14|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
9766441|NCT05235659|Experimental|Condition 15|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
9834591|NCT02703454|Experimental|FIRM-only|Subjects in this arm will be treated with FIRM-guided RF ablation without pulmonary vein isolation (PVI).
9766442|NCT05235659|Experimental|Condition 16|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
9766443|NCT05235620||Pharmacy staff|Pharmacy staff working at pharmacies which have chosen to implement PatientToc software for this implementation science project and evaluation. Pharmacy staff will be observed and participate in interviews pertaining to their experiences using PatientToc.
9766444|NCT05235620||Pharmacy patients|Patients engaged in completing medication adherence-related questionnaires in the PatientToc software at their pharmacies. Patient-level medication, health history, and self-reported adherence information will be collected from patients meeting eligibility criteria. Patients will also be observed and interviewed about their experiences using PatientToc.
9766445|NCT05235607|Experimental|Tumor antigen-sensitized vaccine and their sensitized T cells|"Tumor antigen-sensitized vaccine is administrated, 1- week interval, totally 2 times.~Then, Neo-antigen DC vaccine and their sensitized T cells are administrated, 2-week interval, totally 5 times."
9766446|NCT05235594|Experimental|Experimental: Smart shirt|The research intervention is, for all twenty patients, to wear a smart t-shirt connected to a smart phone throughout the day (preferably 8 hours pr day) for 2 weeks.
9766447|NCT05235581|Experimental|BCAD's arm|The 4 interventions are in the BCAD's order.
9766448|NCT05235581|Experimental|BACD's arm|The 4 interventions are in the BACD's order.
9766449|NCT05235581|Experimental|CABD's arm|The 4 interventions are in the CABD's order.
9766450|NCT05235581|Experimental|ACBD's arm|The 4 interventions are in the ACBD's order.
9766451|NCT05235568|Other|Valvosoft|Treatment with VALVOSOFT device
9766452|NCT05235555||Patients with symptomatic severe AS undergoing TAVI.|
9784155|NCT01218308|Active Comparator|Havrix Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of Havrix™ vaccine at Day 0 and, if unprimed, 2 doses of Havrix™ vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
9784156|NCT01218399|Active Comparator|Budesonide|"Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm."
9784157|NCT01218399|Placebo Comparator|Placebo Comparator: Budesonide|"Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm."
9784158|NCT01218438|Experimental|Study Epochs 1-4|"Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.~Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.~Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.~Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion."
9784159|NCT01218477|Experimental|Dasatinib, 100/140 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
9784160|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
9784161|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD|Participants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
9784162|NCT01218477|Experimental|Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD|Participants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
9784163|NCT01218516|Active Comparator|Farletuzumab plus Chemotherapy|During Combination Therapy, farletuzumab will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive farletuzumab as monotherapy until disease progression.
9784164|NCT01218516|Placebo Comparator|Placebo plus Chemotherapy|During Combination Therapy, placebo will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6 cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive placebo as monotherapy until disease progression.
9784165|NCT01218542|Experimental|Volumetric modulated arc therapy|Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.
9784166|NCT01218594|Experimental|Endostatin combine CCRT|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
9784167|NCT01218646|Experimental|Group 1: Investigational Quadrivalent Influenza Vaccine|Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
9784168|NCT01218646|Experimental|Group 2: Investigational Trivalent Influenza Vaccine|Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
9784169|NCT01218646|Active Comparator|Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
9834592|NCT02703454|Active Comparator|Conventional|Subjects in this arm will undergo conventional radio frequency (RF) ablation with confirmation of PVI.
9834593|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
9834594|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
9834595|NCT02703532|Experimental|Stroke Survivors with CARE-CITE Carepartners|Stroke survivors with a carepartner randomized to the CARE-CITE intervention. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
9834596|NCT02703532|Experimental|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
9834597|NCT02703532|Active Comparator|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
9834598|NCT02703532|Active Comparator|Stroke Survivors with Traditional Education Carepartners|Stroke survivors with a carepartner randomized to receive traditional education. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
9834599|NCT02703636|Other|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
9834600|NCT02703779|Active Comparator|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
9834601|NCT02703779|Experimental|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
9834602|NCT02703909|Experimental|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
9834603|NCT02703909|Active Comparator|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
9834604|NCT02703909|Experimental|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
9834605|NCT02703909|Experimental|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
9834606|NCT02703948|Other|Restylane Silk with Lidocaine|
9834607|NCT02703987|Experimental|Group I|Fermented infant milk formula
9834608|NCT02703987|Active Comparator|Group II|Non-fermented infant milk formula
9834609|NCT02704091|Active Comparator|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
9834610|NCT02704091|Placebo Comparator|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
9834611|NCT02704104|Experimental|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
9834612|NCT02704104|Placebo Comparator|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
9834613|NCT02704143|Experimental|Combination of Cyberknife with S-1|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
9834614|NCT02704156|Experimental|SBRT plus Pembrolizumab and Trametinib|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
9834615|NCT02704156|Active Comparator|SBRT plus Gemcitabine|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
9834616|NCT02704689|Experimental|AccuLIF|
9834617|NCT02704702|Other|Sequence 1 (ABC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)~There will be a washout of at least 7 days between the each period."
9834618|NCT02704702|Other|Sequence 2 (ACB)|"Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
9834619|NCT02704702|Other|Sequence 3 (BAC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)~There will be a washout of at least 7 days between the each period."
9834620|NCT02704702|Other|Sequence 4 (BCA)|"Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
9834621|NCT02704702|Other|Sequence 5 (CAB)|"Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
10205320|NCT02796261|Active Comparator|Lomustine|Lomustine dosed every 6 weeks
9766453|NCT05235542|Experimental|Phase Ib#Dosage regimen 1#|Subjects receive AK104 plus AK117 every 3- week cycle (Q3W) until progression
9766454|NCT05235542|Experimental|Phase Ib#Dosage regimen 2#|Subjects receive AK104 plus AK117 every 6- week cycle (Q6W) until progression
9766455|NCT05235542|Experimental|Phase II#Cohort 1#|Gastric Cancer or Gastroesophageal Junction Cancer: AK104 + XELOX (Oxaliplatin + Capecitabine)+AK117 every 3- week cycle (Q3W) until progression
9766456|NCT05235542|Experimental|Phase II#Cohort 2#|Esophageal squamous cell cancer: AK104 + 5-FU/Paclitaxel+Cisplatin± AK117 every 3- week cycle (Q3W) until progression
9766457|NCT05235542|Experimental|Phase II#Cohort 3#|Gastric Cancer or Gastroesophageal Junction Cancer or Esophageal squamous cell cancer: AK117 +Paclitaxel/Docetaxel/Irinotecan every 3- or 4- week cycle (Q3W or Q4W) until progression
9766458|NCT05235529||Aortic valve replacement with surgery (SVAo)|This group of patients with severe aortic stenosis will be treated with aortic valve replacement with surgery.
9766459|NCT05235529||Transcatheter aortic valve implant (TAVI)|This group of patients with severe aortic stenosis will be treated with transcatheter aortic valve implant (TAVI).
9766460|NCT05235516|Experimental|treatment arm|
9766461|NCT05235516|Placebo Comparator|placebo arm|
9766462|NCT05235503|Experimental|20mg Oxycodon (capsule) + 100 mg Bedrocan (vaporized)|As stated above
9766463|NCT05235503|Placebo Comparator|Placebo oxycodon (capsule) + 100 mg Bedrocan (vaporized)|As stated above
9766464|NCT05235477|Experimental|Tube technique.|"The excavator is used to do the same on the palatal aspect. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect. To harvest the graft, the incision is made parallel to and 2 mm away from the gingival margin. A thin flap containing the keratinized tissue is separated, then the second incision is made parallel to the gingival margin, but perpendicular to the alveolar bone. With a sharp periosteal elevator, the graft is raised with the periosteum and released at its anterior and posterior ends, and then from its base ."
9766465|NCT05235477|Active Comparator|Hyaluronic acid.|The product used in this trial is Restylane Lidocaine (Restylane-Lidocaine cross-linked Hyaluronic Acid Filler, Galderma S.A, Sweden). Restylane was the first FDA-approved HA filler in 2003. Restylane is a non-animal stabilised cross-linked HA filler with an HA concentration of 20 mg/ml. It is a minimally invasive non-surgical injection of hyaluronic acid that observed to overcome the major limiting factor in most surgical techniques regarding the limited blood supply and the small working space. Supported by a recent study conducted by Jinng etal. 2019, who reported significant increase in the height of the gingival papilla and reduction of the area of the black triangle between baseline and 3 or 6 months in a group with thick gingival biotype after injection with hyaluronic acid, that was adding possible maximum effect with minimal postoperative hazards.
9766466|NCT05235464|Active Comparator|Standard meal|
9766467|NCT05235464|Experimental|High animal protein meal|
9766468|NCT05235464|Experimental|High plant protein meal|
9766469|NCT05235464|Experimental|High plant protein meal with additional leucine|
9766470|NCT05235438|Experimental|IMM27M|IMM27M 0.1, 0.3, 1.0, 2.0, 3.0 mg/kg
9766471|NCT05235373||group A: (mild cases): with no progression of the respiratory symptoms.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
9766472|NCT05235373||group B: (moderate cases): who have worsened disease but not requiring ICU admission.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
9766473|NCT05235373||Group C: (sever cases): patient who needed ICU admission.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
9766474|NCT05235373||Group D: (fatality cases): cases who died with or without ICU admission).|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
9766475|NCT05235334|Experimental|Device user|Participant will engage in treatment with the MySOLIUS device, twice per week for 16 weeks
9766476|NCT05235321|Active Comparator|Standard GAT|This is the standard method for IOP measurement in clinical practice
9766477|NCT05235321|Experimental|Fixed-force GAT|From the patient perspective, this method will feel identical to the standard GAT. The eye is given topical fluorescein/anesthetic. The GAT dial is set at 1.8 or 2.0, a C-MOS camera is connected to one of the oculars of the slit lamp machine and under blue light illumination, the GAT prism contacts the eye while the CMOS camera makes a video of the mire appearance through the ocular. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
9766478|NCT05235321|Experimental|Upright applanating prototype|With this prototype, an applanating prism (custom manufactured with medical grade acrylic in an ISO-13485 certified facility) is attached to a fixed-force spring that creates a force equivalent to 1.8 or 2.0 on the GAT dial. Blue LED lights on the prototype are used to create the blue illumination similar to the blue light used in clinical practice on the slit lamp or Perkins tonometer. A C-MOS camera is aligned with the GAT prism to image the applanation mires. The eye is given topical fluorescein/anesthetic. Like fixed-force GAT, the GAT prism contacts the eye while the CMOS camera makes a video of the mire appearance. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
9518043|NCT03300401|Experimental|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
9518044|NCT03300388|Placebo Comparator|Control|Dietary advice for a healthy diet supplemented with placebo (olive oil).
9518045|NCT03300388|Experimental|Omega-3|Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA).
9518046|NCT03300388|Experimental|Resistance Training|Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program.
9766479|NCT05235321|Experimental|Supine Applanating Prototype|With this method, a 5 gram clear acrylic cylinder (custom manufactured with medical grade acrylic in an ISO-13485 certified facility) is aligned with the lens of the CMOS camera and the distal tip of the cylinder is illuminated with blue light using an LED similar to the blue light used in clinical practice on the slit lamp or Perkins tonometer. The eye is given topical fluorescein/anesthetic. While the CMOS camera is recording, the 5 gram weight will rest upon the eye and circular applanation mires are recorded. The diameters of the recorded mire images are measured and the IOP is calculated based on the mire diameter
9766480|NCT05235269|Other|Single arm|I-124 AT-01
9766481|NCT05235256|Active Comparator|SPGB Group|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
9766482|NCT05235256|Active Comparator|GONB Group|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
9766483|NCT05235243|Experimental|The Full Intervention (FI) group|The full intervention (FI) group received a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules, and self-monitoring modules.
9766484|NCT05235243|Active Comparator|The partial intervention (PI) group|The partial intervention (PI) group received an intervention identical to the FI group (a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules) with the exclusion of the self-monitoring modules.
9766485|NCT05235243|No Intervention|Waiting List (WL) group|Waiting List (WL) group did not undergo any intervention during the study period. However, WL participants were told that the program will commence in three months. During their waiting time participants were instructed to reduce their daydreaming activity to the best of their ability. Since all participants were recruited for this study from an online support forum (that is not part of this research design), the investigators labeled WL as the Internet Support as Usual (ISAU) group.
9766486|NCT05235230|Experimental|Test product (T) 25 mg Film Coated Tablets|Single oral dose of 25 mg tablet
9766487|NCT05235230|Active Comparator|Reference product (R) 25 mg Film Coated Tablets (first dose)|Single oral dose of 25 mg tablet
9766488|NCT05235230|Active Comparator|Reference product (R) 25 mg Film Coated Tablets (second dose)|Single oral dose of 25 mg tablet
9766489|NCT05235217|Experimental|Test product (T) 40 mg Hard Gelatin Capsules|Single oral dose of 40 mg capsule
9766490|NCT05235217|Active Comparator|Reference product (R) 40 mg Hard Gelatin Capsules (first dose)|Single oral dose of 40 mg capsule
9766491|NCT05235217|Active Comparator|Reference product (R) 40 mg Hard Gelatin Capsules (second dose)|Single oral dose of 40 mg capsule
9766492|NCT05235204|Experimental|Foley catheter removal day 2 or 3 post-operative procedure|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
9766493|NCT05235191|Experimental|methadone|In this arm patients will take methadone 5mg
9766494|NCT05235191|Placebo Comparator|placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
9766495|NCT05235178||Study group|Due to catastrophic bleeding events in patients who are anticoagulated with FXa inhibitors undergoing emergency surgery on the proximal aorta and lack of antidote (not available in Norway and most likely not compatible with heparin), the department has decided to use hemadsorber in these cases.
9766496|NCT05232474|Other|Control group: no access to KomPas+|Therapists in the control group will not have access to KomPas+ and will continue to deliver usual care by using the KNGF guideline. They will also maintain access to KomPas. As with KomPas+, therapists are free to choose whether to use KomPas or not. The use of KomPas will also be encouraged.
9784170|NCT01218646|Active Comparator|Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
9766497|NCT05232474|Experimental|Experimental group: access to KomPas+|KomPas+ will be implemented within the experimental group. The use of KomPas+ in the physiotherapeutic treatment of patients with intermittent claudication will not be mandatory but will be encouraged through an implementation strategy. Therapists are free to choose whether to use it or not.
9766498|NCT05231954|No Intervention|Annual Well Visit or any other visit to Primary Care Doctor|Annual Well Visit or any other visit to Primary Care Doctor: This is the usual care arm. Electronic Health Record Data for patients from the clinics randomized to usual care will be collected for comparison with the other 2 arms. Patients from these primary care clinics must have had a visit to their doctor either as an annual well visit (AWV) or any other type of visit. These clinics will not have to do anything for the study but run their business as usual without altering anything.
9766499|NCT05231954|Experimental|Passive Digital Marker (PDM)|Passive Digital Marker (PDM): Electronic Health Record Data from those clinics randomized to PDM will be run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset.
9766500|NCT05231954|Active Comparator|Passive Digital Marker (PDM) + Quick Dementia Rating Scale (QDRS)|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
9766501|NCT05227339|Experimental|Interventional (RAE + Usual Care)|Subjects will receive usual care through an outpatient substance use disorder treatment facility, will be provided with a wearable sensor and the RAE mobile application. Participants will be instructed to use the RAE app for a minimum of 30 days.
9766502|NCT05227339|No Intervention|Control (Usual care)|Subjects will receive usual care through an outpatient substance use disorder treatment facility and will be provided with a wearable sensor (fitness tracker). They will not be given access to the RAE mobile app.
9766503|NCT05216926|Experimental|Hypoglycemia predicition and preventive treatment|
9766504|NCT05216926|Other|Corrective hypoglycemia treament (at hypogylcemia)|
9766505|NCT05215860|Active Comparator|Habit cessation counselling with management for OPMD|n=100; Habit cessation counselling with general and medical management for OPMD
9766506|NCT05215860|Experimental|Habit cessation counselling, management for OPMD and intraoral photographs|n=100; Habit cessation counselling with standard management for OPMD and visual exposure to personal intraoral photographs of oral lesions at baseline and review
9766507|NCT05215158|Active Comparator|Peribulbar dexmedetomidine|Peribulbar block will done using mixture of Lidocaine 2%, bupivacaine 0.5% plus 0.5 μg / kg dexmedetomidine perineurally (30 patients).
9766508|NCT05215158|Active Comparator|Intravenous dexmedetomidine|The peribulbar block will be done using a mixture of Lidocaine 2%, bupivacaine 0.5% plus 0.5 μg / kg dexmedetomidine in 50 mL of normal saline administered as an infusion over 10 min and is given 10 min before the start of the peribulbar block(30 patients).
9766509|NCT05214196|Experimental|Hypochlorous acid group|The effect of 0.02% Hypochlorous acid solution on viral load was investigated by using 25 COVID-19 patients as an oral antiseptic for 30 seconds.
9766510|NCT05214196|Active Comparator|Povidone-iodine group|The effect on viral load was investigated by using 0.5% Povidone-iodine solution as an oral antiseptic for 30 seconds in 25 COVID-19 patients.
9766511|NCT05214196|Placebo Comparator|Saline group|The effect on viral load was investigated by using 0.9% isotonic saline solution as a placebo for 30 seconds in 25 COVID-19 patients.
10203468|NCT00186888|Other|Stratum C|"Patients with advanced unilateral advanced intraocular disease. First intervention is enucleation.~If enucleated eye does not have disease outside the retina (low risk), no additional treatment is given.~For patients whose enucleated eye shows tumor outside the retina (intermediate risk), they will receive 4 courses of vincristine, cyclophosphamide, and doxorubicin followed by G-CSF.~For patients with high risk disease (involvement of the sclera, optic nerve at the level of the cut-end), treatment after enucleation is 6 courses of alternating chemotherapy with vincristine, carboplatin, etoposide (VCE) to alternate with vincristine, cyclophosphamide, and doxorubicin (VCD). High risk patients also receive external-beam radiation therapy."
10203469|NCT00001563|Experimental|1|EPOCH-R every 3 weeks for up to 6 cycle
10203470|NCT05200585|Experimental|Healthy Liver/Hígado Sano program|
10203471|NCT05200585|Active Comparator|Control Group|
10203472|NCT05200572|Experimental|Cancer Patients|Dyadic Life Review will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes.
10203473|NCT05200533|Experimental|Task-sharing and shifting|In the task-sharing and shifting group, family physicians shifted acute low back pain consultations to physiotherapists. Patients with acute low back pain are seen by the physiotherapist instead of family physician. Physiotherapist diagnose acute low back pain, identify red and yellow flags, prescribe sick leave and medications and can refer the patient to additional physical therapy treatment.
10203474|NCT05200533|Active Comparator|Usual care|In the usual care group, patients with acute low back pain are seen by their family physician.
10203475|NCT05200520|Experimental|Appetite Self-Regulation|Participants will attend 12-weekly classes, delivered through virtual small group sessions (via zoom), self-monitor the participant's episodes of hunger and satiety with digital eating behavior website, weigh daily with a wireless Wi-Fi enabled scale, and use a FitBit to track physical activity. Participants will also receive weekly tailored feedback on eating, physical activity, and weight trends. Assessments will be conducted at 0, 3, and 6 months.
10203476|NCT05200507||High frequency precussive ventilation|After positioning a silicon belt for Electrical Impedance Tomography (EIT) and a baseline record, patients will receive the treatment of High Frequency Percussive Ventilation. Further recordings will be acquired soon after the end of the treatment, 1 and 3 hours later.
10203477|NCT05200494|No Intervention|Flexible Bronchoscopy without Recruiting Maneuver|At the end of the bronchoscopy, no further interventions or ventilator maneuvers will be done.
10205321|NCT02787044|Experimental|High Dose Influenza Vaccine|High Dose Influenza Vaccine
10205322|NCT02787044|Active Comparator|Standard Dose Influenza Vaccine|Standard Dose Influenza Vaccine
10203478|NCT05200494|Experimental|Flexible Bronchoscopy with Recruiting Maneuver|At the end of the bronchoscopy, a recruiting maneuver will be applied to the patients. Recruiting Maneuver consists in the application of an airway pressure of 30 cmH2O for a period of 30 seconds.
10203479|NCT05200481|Other|Brigatinib monotherapy Arm A|Brigatinib 180mg QD (1 x 180mg tablet) until progression
10203480|NCT05200481|Experimental|Brigatinib Carboplatin-Pemetrexed combination therapy Arm B|Brigatinib 180mg QD (1 x 180mg tablet) until progression + Carboplatin AUC of 5 mg/mL/min IV infusion every 3 weeks for 4 infusions + pemetrexed 500 mg/m² IV infusion every 3 weeks for 4 infusions
10203481|NCT05200455|Experimental|Microelectrodes|Patients who qualify for this study will be implanted with standard electrodes as well as microelectrodes for their intracranial seizure monitoring.
10205323|NCT02781519|Active Comparator|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
9766512|NCT05213026||Apexification|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~Having no systemic or periodontal problems,~Asymptomatic or diagnosed with apical periodontitis with fistula tract,~Not having external/internal resorption, fracture, more than one root/canal,~Root canal filling is sufficient for the MTA,~Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
9766513|NCT05213026||Regenerative|"Apexification treatment was applied by a single operator (GK) in Istanbul University Faculty of Dentistry, Department of Pedodontics,~Having no systemic or periodontal problems,~Asymptomatic or diagnosed with apical periodontitis with fistula tract,~Not having external/internal resorption, fracture, more than one root/canal,~Root canal filling and coronal restorations were completed in Istanbul University Faculty of Dentistry Department of Pedodontics,~Cases with periapical radiographs taken before the procedure and at least one year after the procedure was included."
9766514|NCT05212948|Experimental|S-268019-b, Then Placebo|Participants will first receive a dose of S-268019-b via intramuscular (IM) injection on Day 1 and Day 29 during the initial vaccination period. After the initial vaccination period, participants will then receive a placebo IM injection (matching S-268019-b) on Day 225 and Day 253.
9766515|NCT05212948|Experimental|Placebo, Then S-268019-b|Participants will first receive a dose of placebo IM injection (matching S-268019-b) on Day 1 and Day 29 during the initial vaccination period. After the initial vaccination period, participants will then receive S-268019-b IM injection on Day 225 and Day 253.
9766516|NCT05210673|Experimental|group A|non ERAS pathway
9766517|NCT05210673|Active Comparator|group B|ERAS pathway
9766518|NCT05210621|Other|Patients with MS who have completed the CONSONANCE study|
9766519|NCT05209620|Experimental|Orelabrutinib Combined with Pemetrexed|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration, Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
9766520|NCT05209399|Active Comparator|Hip injection with prior local anesthesia|
9766521|NCT05209399|Active Comparator|Hip injection without prior local anesthesia|
9766522|NCT05209308|Experimental|Cohort A|"Ven low dose + Rituximab + Zandelisib"
9766523|NCT05209308|Experimental|Cohort B|"Ven standard dose + Rituximab + Zandelisib"
9766524|NCT05207891|Experimental|Intervention mattress|"At every shift during the seven days project period, the nurses will check for pressure wounds, and mark identified pressure wounds and their category on a pressure injury body map. At every shift the nurses will use a custom made form to register resources needed in each position changing of the patient, the number of times the position is changed, as well as the level of physical strain in the nurses. All participants will start with seven days use of the newly developed intervention mattress. At the end of the testing period, the participants will register their feeling of quality of life, bedrest comfort, sleep-wellness, pain and satisfaction in the study period.~A custom made semi-structured interview guide has been conducted asking in more details of experienced quality in use and in managing the mattress. One participant and one nurse will be asked to participate in in-depth interviews after testing both mattresses."
9766525|NCT05207891|No Intervention|Regulare care mattress|"At every shift during the seven days project period, the nurses will check for pressure wounds, and mark identified pressure wounds and their category on a pressure injury body map. At every shift the nurses will use a custom made form to register resources needed in each position changing of the patient, the number of times the position is changed, as well as physical strain in the nurses. At the end of the testing period, the participants will register their feeling of quality of life, bedrest comfort, sleep-wellness, pain and satisfaction in the test period.~A custom made semi-structured interview guide has been conducted asking in more details of experienced quality in use and in managing the mattress. One participant and one nurse will be asked to participate in in-depth interviews after testing both mattresses."
9766526|NCT05206812|Experimental|durvalumab|The operable non-small cell lung carcinoma patients (resectable stage IIA~IIIB)
9766527|NCT05205044||Recurrent pregnancy loss|
9766528|NCT05205044||Healthy|
9766529|NCT05204875||Functional lung imaging|Assess the applicability of XV ventilation distribution and heterogeneity for BLVR candidate screening compared to conventional tools of quantitative HRCT and ventilation perfusion scanning.
9766530|NCT05201144|Active Comparator|Sildenafil citrate|Sildenafil citrate 1mg/kg every 8 hours (PO or NG) for up to 14 days
9766531|NCT05201144|Placebo Comparator|Placebo|Equivalent volume of Ora-sweet©/Ora-plus© every 8 hours (PO or NG) for up to 14 days
9766532|NCT05199155|Experimental|NerVFIX|Biological regeneration nerve conduit of allogeneic artery or vein from umbilical cord used as a conduit for gap < 2 cm or as a wrap after peripheral nerve suture
9766533|NCT05198232|No Intervention|Control Group|This group will complete normal daily activities. The participants will complete pre-test, 10 weeks of normal daily activities, and post-test. No changes to their daily schedule will be made by the researcher, the control group will participate in normal activities as part of their community day program.
9784171|NCT01218659|Experimental|Migalastat|Participants received 150 mg migalastat orally QOD during the 18-month randomized treatment period and the optional 12-month OLE period. Participants received an inactive reminder capsule on alternate days during both treatment periods.
9766534|NCT05198232|Experimental|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
9766535|NCT05198232|Experimental|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
9766536|NCT05198167|Experimental|Hyperoxygenated Fatty Acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
9766537|NCT05198167|Experimental|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
9766538|NCT05195164||Older transgender women|This cohort will consist of healthy transgender women aged 45 and above who have not undergone but desire orchiectomy, who have been on estrogen (history of oral, transdermal or injectable) and spironolactone for at least one year.
9766539|NCT05195164||Younger transgender women|This cohort will consist of healthy transgender women aged 18-44 who have not undergone but desire orchiectomy, who have been on estrogen (history of oral, transdermal or injectable) and spironolactone for at least one year.
9766540|NCT05191901|Experimental|stress ball group|
9766541|NCT05191901|No Intervention|control group|
9766542|NCT05188677|Experimental|Group 1a (primary series: Comirnaty)|participants will receive one dose of SCB-2019 vaccine on Day 1 and one dose of placebo on Day 15
9766543|NCT05188677|Experimental|Group 1b (primary series: Comirnaty)|participants will receive one dose of placebo on Day 1 and one dose of SCB-2019 vaccine on Day 15
9766544|NCT05188677|Experimental|Group 2a (primary series: COVID-19 Vaccine Janssen)|participants will receive one dose of SCB-2019 vaccine on Day 1 and one dose of placebo on Day 15
9766545|NCT05188677|Experimental|Group 2b (primary series: COVID-19 Vaccine Janssen)|participants will receive one dose of placebo on Day 1 and one dose of SCB-2019 vaccine on Day 15
9766546|NCT05188677|Experimental|Group 3a (primary series: CoronaVac)|participants will receive one dose of SCB-2019 vaccine on Day 1 and one dose of placebo on Day 15
9766547|NCT05188677|Experimental|Group 3b (primary series: CoronaVac)|participants will receive one dose of placebo on Day 1 and one dose of SCB-2019 vaccine on Day 15
9766548|NCT05188677|Experimental|Group 4a (primary series: SCB-2019 Vaccine)|participants will receive one dose of SCB-2019 vaccine on Day 1 and one dose of placebo on Day 15
9766549|NCT05188677|Experimental|Group 4b (primary series: SCB-2019 Vaccine)|participants will receive one dose of placebo on Day 1 and one dose of SCB-2019 vaccine on Day 15
9766550|NCT05186285|Experimental|CM338 30mg, IV|30mg, single dose, IV
9766551|NCT05186285|Experimental|CM338 60mg, IV|60mg, single dose, IV
9766552|NCT05186285|Experimental|CM338 120mg, IV|120mg, single dose, IV
9766553|NCT05186285|Experimental|CM338 240mg, IV|240mg, single dose, IV
9766554|NCT05186285|Experimental|CM338 240mg, SC|240mg, single dose, SC
9766555|NCT05186285|Experimental|CM338 480mg, IV|480mg, single dose, IV
9766556|NCT05186285|Experimental|CM338 600mg, IV|600mg, single dose, IV
9766557|NCT05186285|Experimental|CM338 600mg, SC|600mg, single dose, SC
9766558|NCT05186285|Placebo Comparator|Placebo|Placebo, single dose, IV or SC
9766559|NCT05184075|Other|PCI - endo-CABG|Patients will receive a PCI within two weeks after the diagnostic coronarography. Furthermore, they will undergo the endo-CABG within two weeks after the PCI.
9766560|NCT05184075|Other|endo-CABG - PCI|Patients will undergo the endo-CABG within two weeks after the diagnostic coronarography. Furthermore, they will receive a PCI within two weeks after the endo-CABG.
9766561|NCT05180058|Experimental|Wrapping + Breastmilk Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of breast milk will be given by the researcher with a sterile syringe 2 minutes before the OGT insertion to the same newborn. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
9785693|NCT01257581|Experimental|Tamoxifen 80mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 80mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
9834622|NCT02704702|Other|Sequence 6 (CBA)|"Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
9518047|NCT03300388|Experimental|Omega-3 + Resistance Training|Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program.
9785694|NCT01257698|Active Comparator|Dorzolamide-timolol topical drops|
9785695|NCT01257698|No Intervention|Standard of care|
9785696|NCT01257737|Experimental|HPN-100|Participants continued HPN-100 treatment after completion of HPN-100-005SE, HPN-100-007, or HPN-100-012SE.
9785697|NCT01257750|Experimental|Pazopanib|This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.
9785698|NCT01257802|Active Comparator|LUPRON|Monthly depot leuprolide acetate 3.75 mg injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
9785699|NCT01257802|Placebo Comparator|Placebo|Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
9785700|NCT01257880||Control (absence of PFO)|Persons who have migraine aura and no evidence of PFO, based on transcranial Doppler evaluation.
9785701|NCT01257880||Large PFO|Persons who have migraine aura and large PFO, as assessed by transcranial Doppler evaluation.
9785702|NCT01258049|Experimental|ArTiMist|
9785703|NCT01258049|Active Comparator|Quinine|
9785704|NCT01258075|Experimental|Colesevelam|High-dose colesevelam suspended in a drink for oral administration once daily with dinner
9785705|NCT01258075|Experimental|Placebo proxy|Low-dose colesevelam suspended in a drink for oral administration once daily with dinner
9785706|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (24 Weeks)|Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).
9785707|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (24 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.
9785708|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.
9785709|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.
9785710|NCT01258153|Experimental|Nepadutant Low Dose|
9785711|NCT01258153|Experimental|Nepadutant High Dose|
9785712|NCT01258153|Placebo Comparator|Placebo|
9785713|NCT01258348|Experimental|LY573636 +sunitinib|
9785714|NCT01258374||Single arm with dual therapy|Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD
9785715|NCT01258387|Placebo Comparator|GGF2|Seven dosing cohorts: 2 patients randomized to receive 1 GGF2, 1 placebo; if no drug-related dose-limiting toxicities in GGF2-treated patient, other 4 patients in cohort will be randomized (3:1) and dosed
9785716|NCT01258504||CYP2C9 wild type|"CYP2C9 wild type =extensive metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
9785717|NCT01258504||CYP2C9 mutant|"CYP2C9 *2/*2 or 2*/*3 or *3/*3 = poor metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
9785718|NCT01258582|Experimental|Oral HIV testing|
9785719|NCT01258582|Active Comparator|Fingerstick HIV testing|
9785720|NCT01258595|Experimental|High-Dose Trivalent Inactivated Influenza Vaccine|
9785721|NCT01258595|Active Comparator|Trivalent Inactivated Influenza Vaccine|
9785722|NCT01258608|Experimental|Sorafenib plus mapatumumab|Mapatumumab 30 milligrams (mg)/kilogram (kg) intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
9785723|NCT01258608|Placebo Comparator|Sorafenib plus Placebo|Placebo intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
9785724|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
9785725|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
9834623|NCT02705105|Experimental|Dose-Finding Cohort|"Cycle 1 Days 1, 8, 15, and 22: Dose Level 1 of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Dose Level 1 of Mogamulizumab + Nivolumab~If >1 patient has a DLT at first dose level, then the following cohort will be enrolled:~Cycle 1 Days 1, 8, 15, and 22: Optional Dose Level of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Optional Dose Level of Mogamulizumab + Nivolumab"
9834624|NCT02705105|Experimental|Expansion Cohort|"Cycle 1 Days 1, 8, 15, and 22: Maximum Tolerated Dose of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Maximum Tolerated Dose of Mogamulizumab + Nivolumab~Subjects will be separated further into cohorts by tumor type"
9834625|NCT02705352|Experimental|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
9834626|NCT02705352|Placebo Comparator|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
9834627|NCT02705365|Experimental|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
9834628|NCT02705365|Active Comparator|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
9834629|NCT02705586|Experimental|only one arm - open label study|2 hour video based mindfulness-based stress reduction class once a week for 10 weeks.
9834630|NCT02705625|Experimental|MIV-711:1|MIV-711 for a total of 26 w
9834631|NCT02705625|Experimental|MIV-711:2|MIV-711 for a total of 26 w
9834632|NCT02705625|Placebo Comparator|Placebo|Placebo for a total of 26 w
9834633|NCT02705716|Experimental|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
9834634|NCT02705716|Placebo Comparator|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
9834635|NCT02705807|Experimental|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
9834636|NCT02706041|Active Comparator|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
9834637|NCT02706041|Other|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
9834638|NCT02706249|Active Comparator|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
9834639|NCT02706249|Active Comparator|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.~On study Enoxaparin will be administered for up 14 days during hospitalization."
9834640|NCT02706327|Experimental|CAD/CAM|8-week follow-up with CAD/CAM insole and home based exercise program
9834641|NCT02706327|Experimental|Semi-custom|8-week follow-up with semi-custom insole and home based exercise program
9834642|NCT02706327|Placebo Comparator|Control|8-week follow-up with placebo insole and home based exercise program
9834643|NCT02706483|Experimental|Plecanatide|Plecanatide 6.0 mg tablets
9834644|NCT02706717|Active Comparator|Visbiome Extra Strength|
9834645|NCT02706717|Placebo Comparator|Placebo for Visbiome Extra Strength|
9834646|NCT02706834|Experimental|Cohort 1, Sequence I|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
9834647|NCT02706834|Experimental|Cohort 1, Sequence II|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
9836042|NCT02767271|Experimental|Tinea Pedis|Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
10205324|NCT02781519|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
10205325|NCT02773732|Experimental|Ciprofloxacin and Etoposide|
9766562|NCT05180058|Experimental|Wrapping + Oral Sucrose Group|Preterm newborns will be wrapped by the researcher 10 minutes before OGT insertion. Then, 2 ml of 20% oral sucrose will be given to the same newborn by the researcher with a sterile syringe 2 minutes before OGT insertion. Oral sucrose will be slowly introduced into the mouth of the preterm newborn on the upper part of the tongue through an injector. Preterm newborns will be recorded with a video camera for 10 minutes before the procedure and for 5 minutes during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at 1 minute before the procedure, during and after the procedure at 1 minute and 2 minutes (4 measurements).
9766563|NCT05180058|Experimental|Fetal Position + Breastmilk Group|The fetal position will be given to the preterm newborn immediately after 2 ml of breast milk is given by the researcher 3 minutes before OGT insertion. Breast milk will be given slowly into the mouth of the preterm newborn, on the upper part of the tongue, through an injector. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure. Newborns will be recorded with a video camera before, during and after the procedure. Then, using video recordings, the pain and comfort of newborns will be evaluated at the 1st minute before the procedure, at the 1st minute and 2nd minute (4 measurements) during and after the procedure.
9766564|NCT05180058|Experimental|Fetal Position + Oral Sucrose Group|The fetal position will be given to the preterm newborn immediately after 2 ml of oral sucrose is given by the researcher 3 minutes before OGT insertion. Oral sucrose will be slowly injected into the mouth of the preterm newborn on the upper part of the tongue by means of an injector. At the end of the 3rd minute, the clinic nurse will insert the OGT as part of the treatment. The preterm newborn will remain in the fetal position for 5 minutes during and after the procedure.
9766565|NCT05177198|Experimental|Test group (M-MIST + Clindamycin augmented PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
9766566|NCT05177198|Experimental|Control group (M-MIST + PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with platelet-rich fibrin alone .
9766567|NCT05174988|Experimental|Angle stitch|"If the allocation corresponds to Angle stitch, surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) apexes. Knot tying technique (intra-corporeal vs extracorporeal) will be up to surgeon preference. After this is completed, barbed suture will be used to re-approximate the remainder of the vaginal cuff from right to left, backtracking once at the end for reinforcement."
9766568|NCT05174988|No Intervention|control|"If the subject's group corresponds to Control group, the surgeon will re-approximate the cuff in a standard fashion, using a running-barbed suture (2-0 V-LOC 90 with tapered needle), starting at the right apex, moving towards the left, and then back-tracking once to further reinforce the closure."
10203482|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 (Starting Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Group 1/ Dose Level 1:~Participants in group 0 will receive the starting dose of study drugs (below):~VS-6766 (2.4mg) orally twice a week~cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
10203483|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 2- Dose Level 2 (Second Highest Dose)|"This study will use two dose levels (a starting dose at level 1 and a second dose highest dose at level 2) of the VS-6766 and cetuximab regimen. If participants in group 1 don't experience severe negative side effects to the starting dose of the regimen, then more participants will be assigned to group 2 at a higher dose until the safest/ most tolerable dose is found. If participants show toxic side effects to the first pre-determined dose, the dose will be decreased to the next lower dose level.~Participants in group 2 will receive the second highest dose of study drugs (below):~VS-6766 (3.4mg) orally twice a week~cetuximab (500mg) via intravenous (IV) needle in vein every 2 weeks~During phase 1, VS-6766 and cetuximab will be given in 28-day cycles (a period of time when participants receive study drugs). Participants in this portion of the study will receive 12 cycles of VS-6766 and cetuximab."
10203484|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 3 - Lower Dose Level 1|"Participants in this group will received a lower dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~VS-6766 (2.4mg) orally twice a week~cetuximab (400mg) via intravenous (IV) needle in vein every 2 weeks"
10203485|NCT05200442|Experimental|Phase 1(Dose-Finding Arm): Group 4 - Lower Dose Level 2|"Participants in this group will received the second lowest dose of the VS6766 and cetuximab regimen. Inclusion in this group is optional and based on whether the participant reports serious side effects in response to a higher dose of the regimen.~If participants are included in this group, they will receive:~VS-6766 (2.4mg) orally twice a week~cetuximab (300mg) via intravenous (IV) needle in vein every 2 weeks"
9834648|NCT02706834|Experimental|Cohort 1, Sequence III|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
9834649|NCT02706834|Experimental|Cohort 1, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
9834650|NCT02706834|Experimental|Cohort 2, Sequence I|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
9834651|NCT02706834|Experimental|Cohort 2, Sequence II|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
9834652|NCT02706834|Experimental|Cohort 2, Sequence III|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
9834653|NCT02706834|Experimental|Cohort 2, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. There was a 7-day washout period between each period. Each period lasted 4 days with a 7-day washout period between periods.
9834654|NCT02706834|Experimental|Cohort 3, Sequence I|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
9834655|NCT02706834|Experimental|Cohort 3, Sequence II|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
9834656|NCT02706834|Experimental|Cohort 3, Sequence III|Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
9834657|NCT02706873|Active Comparator|Methotrexate|"Period 1: Participants will receive placebo to upadacitinib once daily and methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on placebo to upadacitinib once daily and methotrexate once weekly until the study is unblinded, after which participants will receive open-label methotrexate up to Week 260."
9834658|NCT02706873|Experimental|Upadacitinib 7.5 mg (Japan-only)|"Period 1: Participants will receive upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 7.5 mg up to Week 260."
9834659|NCT02706873|Experimental|Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 15 mg up to Week 260."
9834660|NCT02706873|Experimental|Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 30 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 30 mg once daily. After implementation of Protocol Amendment 6 participants will receive upadacitinib 15 mg once daily up to Week 260."
9834661|NCT02706886|Placebo Comparator|Part A: SAD: Placebo|A single dose of matching placebo will be administered subcutaneously (SC).
9834662|NCT02706886|Experimental|Part A: SAD: Lumasiran 0.3 mg/kg|A single dose of 0.3 mg/kg lumasiran will be administered SC.
9834663|NCT02706886|Experimental|Part A: SAD: Lumasiran 1.0 mg/kg|A single dose of 1.0 mg/kg lumasiran will be administered SC.
9834664|NCT02706886|Experimental|Part A: SAD: Lumasiran 3.0 mg/kg|A single dose of 3.0 mg/kg lumasiran will be administered SC.
9834665|NCT02706886|Experimental|Part A: SAD: Lumasiran 6.0 mg/kg|A single dose of 6.0 mg/kg lumasiran will be administered SC.
9834666|NCT02706886|Placebo Comparator|Part B: MAD: Placebo|Participants with primary hyperoxaluria type 1 (PH1) will be treated with placebo matching one of the lumasiran dosages in the lumasiran arms (one placebo participant for each lumasiran arm). At Day 85 these placebo treated participants will cross over to their respective Part B lumasiran arms in the Part B: MAD Study Day 85-End of Study Period and will then be treated with lumasiran. The estimated total time on study was up to 546 days.
9834667|NCT02706886|Experimental|Part B: MAD: Lumasiran 1.0 mg/kg qM|Participants with PH1 will be treated with 1.0 mg/kg lumasiran SC once monthly (qM) on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
9834668|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg qM|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC qM on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
9834669|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg q3M|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC once every three months (q3M) on Days 1 and 85. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
9834670|NCT02706899|Experimental|33A + azacitidine|Vadastuximab talirine plus azacitidine
9834671|NCT02706899|Active Comparator|Placebo + azacitidine|placebo plus azacitidine
9834672|NCT02706925|Experimental|BI 443651|
9834673|NCT02706925|Placebo Comparator|Placebo|
9766569|NCT05174663|Experimental|Almond-enriched diet dose 1|Participants will be instructed to ingest 1.5 oz of almonds daily for 16 weeks. The 1.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
9766570|NCT05174663|Experimental|Almond-enriched diet dose 2|Participants will be instructed to ingest 2.5 oz of almonds daily for 16 weeks. The 2.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
9766571|NCT05174663|Other|Nut-free diet|Participants will be instructed to ingest the control snack (Iso-caloric [to 1.5 oz of almonds] control snack of chocolate chip cookies or Oreo cookies) daily for 16 weeks. The control snack can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of snack daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
9766572|NCT05172648|Active Comparator|control group|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength
9766573|NCT05172648|Other|contrast group|Moisten the mouth with sterile distilled water with an oral cotton swab.
9766574|NCT05171114|Experimental|moderate Scleroderma|Patients with Cochin hand score less than or equal to 16
9766575|NCT05171114|Experimental|severe Scleroderma|Patients with Cochin hand score greater than 16
9766576|NCT05170841|Active Comparator|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase film coated tablets (administered as one tablet)
9766577|NCT05170841|Active Comparator|Tramadol Hydrochloride 100 mg treatment|Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5) In this arm patients will receive during each phase (administered as 2 capsules of Tramadol 50 mg)
9766578|NCT05170841|Placebo Comparator|Placebo and Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg treatment|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo film-coated tablets matching Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg MULTIPLE DOSE PHASE: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg film coated tablets (administered as one tablet)"
9766579|NCT05170841|Placebo Comparator|Placebo and Tramadol Hydrochloride 100 mg|"Two phase intervention. Single dose phase (time 0 - time 8h) and Multiple dose phase (time 8h - Day 5).~SINGLE DOSE PHASE: Placebo capsules matching active comparator (administered as 2 capsules of Tramadol 50 mg) MULTIPLE DOSE PHASE: Tramadol Hydrochloride 100 mg (administered as 2 capsules of Tramadol 50 mg)"
9766580|NCT05157685|Experimental|Azithromycin oral tablet|Azithromycin 250 mg once daily morning or evening (with or without meals)
9766581|NCT05157685|Placebo Comparator|Placebo|Placebo once daily morning or evening (with or without meals)
9766582|NCT05153941||Main Study (tier 1)|Observational Study -The main study (tier 1) comprises 3,510 subjects matched by age and gender at a group level and aged over 50 years with a study partner available to actively contribute to the study will be recruited from memory clinics and/or ongoing observational studies in 3 sites across Greece
9766583|NCT05153941||Tier 2|Observational Study- Sub-study at the baseline visit (Tier 2) Amyloid Positron Emission Tomography (PET): groups (1), (2), (3), (4) as described below fluorodeoxyglucose (FDG) PET : groups (1), (2), (3), (4) as described below More than 400 subjects comprised of (1) >100 of cognitively unimpaired with (A-, T-, (N)-) group, (2) >100 of cognitively unimpaired with (A+, T+, (N)- or A+, T+, (N)+) groups, (3) >100 of mild cognitive impairment with (A+, T+, (N)- or A+, T+, (N)+) groups and (4) >100 of mild cognitive impairment with (A-, T-, (N)-) group will take Amyloid PET and FDG PET as sub-study.
10205326|NCT02764489|Experimental|Part 1 Regular then reduced volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA reconstituted in regular volume then FEIBA reconstituted in 50% reduced volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
10203486|NCT05200442|Experimental|Phase 2 (Efficacy Arm/ Expansion Cohort)|"Participants in this arm will help test the efficacy of the VS-6766 and cetuximab dose established in phase 1 of the study. Participants will take the same two drugs ( VS-6766 and cetuximab) at the best tolerated dose that was found during the first phase of the study.~Participants in this group will also keep a pill diary. This helps you keep track of when you take your pills. The study team at your doctor's office will show you how to use this diary. Each time you visit the clinic, you must bring the pill diary, any remaining pills, and the pill bottle."
10203487|NCT05200429||Pre-Therapy Participants|All CF people with CF who do not have any known contraindications to CFTR modulator therapy and will be initiated on CFTR modulator therapy by their treating physician as part of clinical care are eligible and will be asked to participate in this study.
9766588|NCT05152108|Experimental|Stroke patients|Experimental group of stroke survivors for testing the feasibility of a BCI system
9766589|NCT05151991|Active Comparator|Groups MET|Patients from this group will undergo orthodontic fixed treatment with stainless steel brackets.
9766590|NCT05151991|Active Comparator|Group CER|Patients from this group will undergo orthodontic fixed treatment with ceramic brackets.
9766591|NCT05148806||Solid organ transplant patients|Patients who have received a solid organ transplant and who have received 3 doses of Covid-19 vaccine
9766592|NCT05148806||Rare autoimmune diseases|Patients with a rare autoimmune disease who have received 3 doses of Covid-19 vaccine
9766593|NCT05148806||Blood cancer|Patients with acute myeloid and lymphoid blood cancers who have received 3 doses of Covid-19 vaccine.
9766594|NCT05142345|Experimental|CONTINUUM Intervention Post-Hospital Discharge|Participants will receive CONTINUUM intervention visit with a nurse practitioner within three business days of hospital discharge and complete questionnaires about their cancer and care.
9766595|NCT05142345|Active Comparator|Usual Care Post-Hospital Discharge|Participants will receive standard oncology care following hospital discharge with follow-up appointments scheduled per primary team and participant preferences. Participants will complete questionnaires about their cancer and care.
9766596|NCT05131152|Experimental|cyclosporine group|"Mild DE patients: topical usage of 0.05% cyclosporine Eye Drops BID + 0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks.~Moderate DE patients: topical usage of 0.05% cyclosporine Eye Drops BID +0.1% Sodium Hyaluronate Eye Drops QID, both use for 16 weeks, and 0.02% Fluoromethalone Eye Drops BID for 4 weeks."
9766597|NCT05131152|Experimental|control group|Mild DE patients: 0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks Moderate DE patients: 0.02% Fluoromethalone Eye Drops BID for 4 weeks +0.1% Sodium Hyaluronate Eye Drops QID for 16 weeks.
9766598|NCT05130632|Experimental|The community working group|Female participants over the age of 15 randomized to the intervention group will participate in working group sessions over 12 weeks' time that addresses plastic waste and introduce strategies to reduce use, recycle, and repurpose plastic. Community members of participants in the intervention group will also be invited to participate in the working groups.
9766599|NCT05130632|No Intervention|Control Group.|No specific activities
9766600|NCT05129345||Aim 1|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit including being consented electronically and complete a demographic survey, a photography training visit and an interview visit.
9766601|NCT05129345||Aim 2|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit and be electronically consented to study and complete an electronic survey.
9766602|NCT05129345||Aim 3|Group composed of 10 willing participants recruited from the participating clinics and community based organizations and may include, HIV providers, nurses, pharmacists, people living with HIV who have cardiometabolic disorders, and representatives of the community advisory boards, and any other key stakeholders. There will be 3 one hour meetings over 3 months.
9766603|NCT05126784|Experimental|AVT03 Arm|AVT03 is the proposed biosimilar for Prolia. Subjects in this arm will receive a single 60mg dose of Alvotech's AVT03
9766604|NCT05126784|Active Comparator|Prolia Arm|Subjects in this arm will get 60mg of Commercially available Prolia
9766605|NCT05125029|No Intervention|Placebo|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
9785726|NCT01258738|Active Comparator|etanercept|In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
10203488|NCT05200416|Experimental|Test Product - Heylo|The Test product will be used together with the subjects own ostomy products. Subjects will change the products as usual, according to their normal change routine
10203489|NCT05200416|Active Comparator|Standard of Care|"In the Standard of Care arm, the subjects will only use their own ostomy products.~Subjects will change the products as usual, according to their normal change routine"
10203490|NCT05200390|Experimental|Continuous Glucose Monitor|Adult patients with Type 2 Diabetes on any anti-diabetic regimen utilizing continuous glucose monitors for 3 months
10203491|NCT05200377||Cerebral small vessel disease group|Patients with clinically and radiologically evidenced cerebral small vessel disease. Patients are grouped by severity of cerebral small vessel disease assessed by comprehensive MRI findings.
9834674|NCT02706938|Other|Head of bed elevation - Control|Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
9834675|NCT02706938|Other|Control - Head of bed elevation|Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
9834676|NCT02706951|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
9834677|NCT02706951|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
9834678|NCT02706951|Experimental|Methotrexate / Upadacitinib 30 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
9834679|NCT02706951|Experimental|Methotrexate / Upadacitinib 15 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
9834680|NCT02707146|Experimental|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
9834681|NCT02707146|Active Comparator|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
9834682|NCT02707172|Experimental|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
9834683|NCT02707172|Placebo Comparator|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
9834684|NCT02707432|Experimental|Time 1 (T1) Intervention Group|"This group will be the first to receive the adapted intervention, Heart Matters (adapted from the PREMIER intervention). The intervention will be 12 months long."
9834685|NCT02707432|Experimental|Time 2 (T2) Intervention Group|"This delayed intervention group will receive the adapted intervention, Heart Matters, six months after the T1 Intervention group. The intervention will be 12 months long."
9834686|NCT02707523|Placebo Comparator|Control|Placebo controlled (normal saline) daily for 3 days
9834687|NCT02707523|Active Comparator|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
9834688|NCT02707523|Active Comparator|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
9836043|NCT02767271|Experimental|Tinea Cruris|Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the groin, thighs, and abdomen.
9836044|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC (Aim1a)|excitatory rTMS applied over the DLPFC (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
9836045|NCT02767323|Experimental|Active or Sham rTMS over the Parietal cortex (Aim1b)|excitatory rTMS applied over the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
9836046|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC and the Parietal cortex (Aim1c)|excitatory rTMS applied over the DLPFC and the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
9836047|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
9836048|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
9836049|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
9984269|NCT04268277|Experimental|Rituximab & Pembrolizumab|"Cycle 1 (21 days cycle):~Rituximab: 375 mg/m2 day 1, 8, 15 Pembrolizumab: 200 mg IV fixed dose day 2~Cycle 2-18 (21 days cycle) or until progression or non-tolerable toxicity:~Rituximab: 375 mg/m2 day 1 every second cycle Pembrolizumab: 200 mg IV fixed dose day 1"
9834689|NCT02707601|Experimental|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
9834690|NCT02707601|Experimental|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.~Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
9834691|NCT02707640|Placebo Comparator|Matching Placebo|
9834692|NCT02707640|Experimental|N-Acetylcysteine|
9834693|NCT02707640|Other|Pirfenidone|Background therapy
9834694|NCT02707757|Active Comparator|Iron sucrose|Iron sucrose 200mg for 5 doses
9834695|NCT02707757|Active Comparator|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
9834696|NCT02707770|Experimental|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
9834697|NCT02707770|Placebo Comparator|Room air|Patient will breath on room air during pulmonary rehabilitation programme
9834698|NCT02707861|Experimental|Cohort 1|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~OR~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~Administered for 48 weeks, or until ibalizumab becomes commercially available"
9834699|NCT02707861|Experimental|Cohort 2|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for qualifying patients who have never received ibalizumab~Administered for 48 weeks, or until ibalizumab becomes commercially available"
9834700|NCT02707952|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) for 8 weeks in HCV genotype(GT)1 -infected, DAA treatment-naïve participants without cirrhosis.
9834701|NCT02707952|Active Comparator|Arm B|Ombitasvir (25 mg)/paritaprevir (150 mg)/ritonavir (100mg) (OBV/PTV/r) QD for 12 weeks in HCV GT1 infected, DAA treatment-naïve participants without cirrhosis.
9834702|NCT02707952|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120mg) QD for 12 weeks in HCV GT1- or GT2-infected participants with compensated cirrhosis, HCV GT3-, 4-, 5- and 6-infected participants (with compensated cirrhosis or without cirrhosis), HCV GT1- and GT2-infected participants who had failed prior DAA treatments (with compensated cirrhosis or without cirrhosis), and HCV GT1- or GT2-infected participants with severe renal impairment and compensated cirrhosis.
9834703|NCT02707952|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in GT1- or GT2-infected participants with severe renal impairment and without cirrhosis.
9834704|NCT02707965|Active Comparator|Sequence 1|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
9834705|NCT02707965|Active Comparator|Sequence 2|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
9834706|NCT02707991|No Intervention|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
9834707|NCT02707991|Experimental|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
9834708|NCT02708095|Experimental|2 mg Baricitinib|Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
9834709|NCT02708095|Experimental|4 mg Baricitinib|Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
9834710|NCT02708095|Placebo Comparator|Placebo|Participants received Placebo orally once daily (QD) for 24 weeks.
9834711|NCT02708121|Experimental|Intervention arm|Participant receives intervention to motivate weight loss treatment initiation and access to weight loss treatment.
9984270|NCT04267393|Experimental|Dose A BMS-986263|
9834712|NCT02708121|Active Comparator|Comparator Arm|Participant receives access to weight loss treatment alone.
9834713|NCT02708186|Experimental|Nelotanserin|Nelotanserin 80 mg
9834714|NCT02708186|Placebo Comparator|Placebo|Placebo
9834715|NCT02708212|Active Comparator|EGD-colonoscopy group|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to EGD and colonoscopy examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
9834716|NCT02708212|Active Comparator|Colonoscopy-EGD group|In this study group, patients receive a colonoscopy followed by an EGD during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to colonoscopy and EGD examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
9834717|NCT02708238|Experimental|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
9834718|NCT02708238|Active Comparator|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
9834719|NCT02708238|Active Comparator|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
9834720|NCT02708277|Experimental|Group A|At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
9834721|NCT02708277|Experimental|Group B|At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.
9834722|NCT02708290||Test arm|The test group included participants who completed more than one thousand exercises and made no more than one error per exercise.
9834723|NCT02708290||Control arm|The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation.
9834724|NCT02708355|Experimental|Esomeprazole 20 mg once daily|Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
9766606|NCT05125029|Active Comparator|10 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
9766607|NCT05125029|Active Comparator|20 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
9766608|NCT05124704|Experimental|Combined epidural with general anesthesia|Patients in this group received 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction.Followed by a continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction during surgery.
9766609|NCT05124704|Sham Comparator|General anesthesia|In this group, same dose of normal saline was administered before induction and during surgery.
9766610|NCT05120505|Experimental|Metformin group|The patients will be obtain Metformin starting from 50mg everyday to 1-2g per day for 6 months.
9766611|NCT05120505|Placebo Comparator|Placebo group|The patients will be obtain starch tablets starting from 50mg everyday to 1-2g per day for 6 months.
9766612|NCT05117086|Experimental|Dietary Intervention Arm|Subjects will receive the active intervention of nutrition education and medical nutrition therapy counseling for dietary and behavioral lifestyle changes. The focus will be on DASH diet implementation and adherence for management of heart failure. The subjects will have 4 study visits with a Registered Dietitian over 6 months (visits at 1, 2, 3, and 6 months). Outcome measures will be assessed at baseline, 3 and 6 months.
9766613|NCT05116475|Experimental|Arm A|Arm A: ADT + Intensity-Modulated Image-Guided Radiation Therapy + Darolutamide ADT will be associated with LHRH agonists or antagonists for 24 months4. Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
9766614|NCT05116475|Placebo Comparator|Arm B|"Arm B: ADT + Intensity-Modulated Image-Guided Radiation Therapy + Placebo of Darolutamide~ADT will be associated with LHRH agonists or antagonists for 24 months4. Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months."
9766615|NCT05114967||Patients undergoing surgery|Patients undergoing surgery during the 4th wave of the pandemic for 1 month duration in the University Hospital of Larissa
9766616|NCT05110872|Experimental|Menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 menthol cigarettes per day will be recruited.
9766617|NCT05110872|Experimental|Non-menthol cigarette smokers|Adults (21 y.o. and older) who smoke ate least 10 non-menthol cigarettes per day will be recruited.
9766618|NCT05109715|Active Comparator|Control group|"Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure.~Blood will be drawn:~At baseline: before general anaesthesia~After start of heart-lung machine~After clamping the aorta~Before unclamping the aorta~After the operation~5 h after clamping the aorta~12 hours after clamping the aorta~24 hours after aortic clamping~48h after clamping the aorta~72 hours after clamping the aorta"
9766619|NCT05109715|Experimental|Ventilation group|"Ventilation is continued from going on CPB until clamping of the ascending aorta.~Blood will be drawn:~At baseline: before general anaesthesia~After start of heart-lung machine~After clamping the aorta~Before unclamping the aorta~After the operation~5 h after clamping the aorta~12 hours after clamping the aorta~24 hours after aortic clamping~48h after clamping the aorta~72 hours after clamping the aorta"
9766620|NCT05106036|Experimental|Intervention Arm|Home BP data will be averaged each month via OmronConnect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health.Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the CDS (Clinical Decision Support) tool to assist their physicians with their blood pressure management. Study Team will not be involved in treatment decision making, it will be determined by subject's treating physician. .
9984271|NCT04267393|Experimental|Dose B BMS-986263|
9984272|NCT04267393|Placebo Comparator|Placebo|
9766621|NCT05106036|No Intervention|Usual Care Arm|Physicians will continue to make decisions about the participant's blood hypertension management as usual without the CDS tool.
9766622|NCT05102318|Experimental|Direct Pulp Capping with Biodentine|Direct Pulp Capping with Biodentine
9766623|NCT05102318|Experimental|Partial Pulpotomy with Biodentine|Partial Pulpotomy with Biodentine
9766624|NCT05102318|Experimental|Pulpotomy with Biodentine|Pulpotomy with Biodentine
9766625|NCT05102318|Experimental|Direct Pulp Capping with MTA|Direct Pulp Capping with MTA
9766626|NCT05102318|Experimental|Partial Pulpotomy with MTA|Partial Pulpotomy with MTA
9766627|NCT05102318|Experimental|Pulpotomy with MTA|Pulpotomy with MTA
9766628|NCT05101213|Experimental|Treatment for viral infections (virus-specific CTLs)|Patients receive virus-specific CTLs intravenously (IV) over 30 minutes. Patients with partial response, stable disease, or progressive disease may receive up to 8 additional infusions of virus-specific CTL at least 2 weeks between each infusion.
9766629|NCT05101070|Experimental|Part A-1: S-531011 Monotherapy|Participants will receive escalating doses of S-531011 by intravenous infusion for up to approximately 12 months.
9766630|NCT05101070|Experimental|Part A-2: S-531011 + Pembrolizumab|Participants will receive escalating doses of S-531011 in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
9766631|NCT05101070|Experimental|Part B: S-531011 Monotherapy|Participants will receive S-531011 at the the RP2D by intravenous infusion for up to approximately 12 months.
9766632|NCT05101070|Experimental|Part C: S-531011 + Pembrolizumab|Participants will receive S-531011 at the RP2D in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
9766633|NCT05092022|Experimental|Requested self-sampled HPV test|This group will receive the self-sampled HPV test. Included with the test are the test instructions, a lab requisition form, and a pre-paid mailer so that it can be sent back to the lab for testing. Results of the test will be shared with the participant.
9766634|NCT05091645||Hip fracture_GFI|Greek patients with hip fracture assessed for frailty syndrome with the adapted for the greek population GFI questionnaire
9766635|NCT05089682|Experimental|Deep Brain Stimulation (DBS) system|Subjects with existing DBS systems implanted for neurological disease (e.g., Parkinson's, pain, epilepsy) will have targeted stimulation patterns during specific stages of sleep using their existing DBS device.
9766636|NCT05086354|Experimental|One group that all receive the intervention of jumping rope.|All participants will be in one group. Every participant receives the same intervention.
9766637|NCT05085795||All participants|
9766638|NCT05085730|Experimental|Treatment|All subjects will receive 4 separate treatments with the InMode Morpheus8 System.
9766639|NCT05083611|No Intervention|Control group|The control group will receive an information session on phantom limb pain (1 hour) and will continue with the usual treatment received.
9766640|NCT05083611|Experimental|Experimental group|The experimental group will receive an educational session on phantom limb pain and the previously designed GraMI protocol through a systematic review and validation through a study with Delphi methodology. This protocol contains the three techniques with their defined intensity, frequency, duration and progression.
9766641|NCT05081297|Experimental|Qigong practitioner group|This arm is the experimental group where qigong intervention is going to be applied to practitioners with experience
9766642|NCT05081297|No Intervention|No practice|This group has no intervention and acts as control
9766643|NCT05081297|Experimental|Beginner Qigong practitioner group|This arm is the experimental group where qigong intervention is going to be applied to practitioners with no experience.
9766644|NCT05077293||Best Practice Alert group|Providers will receive a BPA at the time of visit for patients with HFrEF who are not on MRA (and who do not have contraindication to MRA). This alert will be visible on the first screen displayed in the electronic health record and will display the patient's current HFrEF therapies, EF, blood pressure, potassium, and glomerular filtration rate. The alert will give access to an outpatient heart failure order set, and also provide links to the most recent guidelines.
9766645|NCT05077293||In-Basket Message group|Providers will receive a biweekly in-basket messages linking to a list of patients who have been seen in the past year with HFrEF who are not on MRA (and who do not have contraindication to MRA). This list will display each patient's current hFrEF therapies, EF, blood pressure, potassium, glomerular filtration rate, and date of last visit. From the list, providers can access the patient's chart, order medications, and document communication with the patient.
9766646|NCT05077293||Control group|Patients who will receive the current standard practice of care (no alerts)
9766647|NCT05076110|Active Comparator|Standard of Care Group|Subjects will receive standard of care pain medication Oxycodone for pain control following hip arthroscopy procedure
9766648|NCT05076110|Experimental|Non-Opiate Pain Control Group|Subjects will receive a non-opiate pain control regime using Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol for pain control following hip arthroscopy procedure.
9766649|NCT05075798||group patients|Patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR neuropathy with proven mutation, having benefited from a brain MRI.
9766650|NCT05071079|Experimental|Challenge with whole dose blood-stage inoculum (neat)|Whole dose: one whole vial, containing approximately 0.5 mL of red blood cells, will be reconstituted in 0.9% saline, to a total volume of 5 mL
9766651|NCT05071079|Experimental|Challenge with 1:5 dilution blood-stage inoculum|1:5 dilution: one fifth of a vial (containing approximately 0.1 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
9766652|NCT05071079|Experimental|Challenge with 1:10 dilution blood-stage inoculum|1:10 dilution: one tenth of a vial (containing approximately 0.05 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
9766653|NCT05071079|Experimental|Challenge with 1:20 dilution blood-stage inoculum|1:20 dilution: one twenties of a vial (containing approximately 0.025 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
9766654|NCT05063201|Experimental|Cariprazine|
9766655|NCT05063201|Placebo Comparator|Placebo|
9766656|NCT05059678|Experimental|Group I (education material, videoconference session)|Participants receive education materials (brochure and a video) and attend 2 weekly videoconference intervention sessions over 45 minutes each. Caregivers attend 2 additional weekly intervention sessions over 45 minutes each.
9766657|NCT05059678|Active Comparator|Group II (waitlist control)|Participants receive standard of care.
9766658|NCT05057858|Experimental|Perfect Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC once daily (7 doses per week).
9766659|NCT05057858|Experimental|Moderate Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet 4 times per week (Monday, Tuesday, Thursday, Friday)
9766660|NCT05057858|Experimental|Poor Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet twice per week(Monday and Tuesday)
9766661|NCT05056714||patients with Nasosinus Polyposis|patients with Nasosinus Polyposis included in the study
9766662|NCT05046574|Experimental|Therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have a therapy dog present during their stroke rehabilitative therapy sessions.
9766663|NCT05046574|No Intervention|No therapy dog during stroke rehabilitative therapy sessions|Participants randomized to this arm will have stroke rehabilitative therapy sessions per standard of care with no therapy dog present.
9766664|NCT05044949|Active Comparator|Low dose L reuteri capsules|Subjects will be asked to consume 2 capsules with high dose L reuteri per day in 28 days.
9766665|NCT05044949|Active Comparator|High dose L reuteri capsules|Subjects will be asked to consume 2 capsules with a low dose L reuteri per day in 28 days.
9766666|NCT05044949|Placebo Comparator|Placebo capsules|Subjects will be asked to consume 2 capsules with placebo powder per day in 28 days.
9784172|NCT01218659|Active Comparator|ERT|Participants received ERT (either agalsidase alfa or agalsidase beta) as prescribed by the participant's treating physician and administered in accordance with the approved prescribing information during the 18-month randomized treatment period. Participants were required to be given >80% of the currently labeled dose and regimen during the 18-month randomized treatment period. During the optional 12-month OLE period, participants received 150 mg migalastat orally QOD. Participants received an inactive reminder capsule on alternate days during the OLE.
9784173|NCT01218672|Experimental|GreenLight XPS|Photoselective vaporization of the prostate using GreenLight XPS laser system.
9784174|NCT01218672|Active Comparator|Transurethral Resection of the Prostate|Monopolar and bipolar Transuretheral resection of the prostate (TURP)
9784175|NCT01218802|Active Comparator|Rosuvastatin|Participants will take Rosuvastatin 10 mg. daily for 96 weeks
9766667|NCT05039736|Experimental|cabozantinib|cabozantinib by mouth every day for 6 weeks
9766668|NCT05039736|Experimental|nivolumab|nivolumab by vein every 4 weeks for up to 2 years
9766669|NCT05038839|Experimental|Treatment (cabozantinib, pamiparib)|Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9766670|NCT05037149|Experimental|Part 1: Arm A|Cohort 1: STP707 3 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
9766671|NCT05037149|Experimental|Part 1: Arm B|Cohort 2: STP707 6 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
9766672|NCT05037149|Experimental|Part 1: Arm C|Cohort 3: STP707 12 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
9766673|NCT05037149|Experimental|Part 1: Arm D|Cohort 4: STP707 24 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
9766674|NCT05037149|Experimental|Part 1: Arm E|Cohort 5: STP707 48 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
9766675|NCT05028075|No Intervention|Usual Care|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity, hours of direct patient care, percent of time providing care for patients with COVID-19) at enrollment; 0 months, 6 months, and 9 months.
9766676|NCT05028075|Experimental|Intervention|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months and 9 months. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
9766677|NCT05016791|Active Comparator|Active|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider. In addition, participants in this arm shall be loaned an Apple Watch device and undergo an education session to familiarise themselves with the study recording schedule and how to perform recordings.
9766678|NCT05016791|No Intervention|Control|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider.
9766679|NCT05015504|Experimental|Time restricted feeding|The study will consist of three phases. In phase I all study subjects will be in the ad libitum feeding phase for one week followed by Phase II. In Phase II the subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week. For phase III (final week), patients will be returned to an ad libitum feeding. The first and third phases will serve as control phases, and the second phase will be the experimental phase
9766680|NCT05006443|Other|Moderate or severe tricuspid regurgitation|40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.
9766681|NCT05003089|Experimental|BAY1834845 arm|BAY1834845 will be administered twice daily for 7 consecutive days (Days 1 - 7).
9766682|NCT05003089|Experimental|BAY1830839 arm|BAY1830839 will be administered twice daily for 7 consecutive days (Days 1 - 7).
9766683|NCT05003089|Active Comparator|Prednisolone arm|Prednisolone will be administered twice daily for 7 consecutive days (Days 1 - 7).
9766684|NCT05003089|Placebo Comparator|Placebo arm|Placebo will be administered twice daily for 7 consecutive days (Days 1 - 7).
9766685|NCT05002608|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
9766686|NCT05002608|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
9766687|NCT05000450|Experimental|ALLO-605, ALLO-647|
9834725|NCT02708355|Experimental|Esomeprazole 20 mg twice daily|Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
9834726|NCT02708355|Placebo Comparator|Placebo|Placebo administered orally in the morning and placebo administered orally in the evening
9834727|NCT02708433|Active Comparator|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~In week two the alternate anesthetic would be administered.~Mandibular molar and canine tested for pulpal anesthesia"
9834728|NCT02708433|Active Comparator|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~Mandibular molar and canine tested for pulpal anesthesia"
9834729|NCT02708485|No Intervention|Control group|No intervention
9834730|NCT02708485|Experimental|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
9834731|NCT02708498|Experimental|Kronoberg Educational Intervention|The educational intervention is provided to ten nursing homes.
9834732|NCT02708498|No Intervention|Skåne Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
9834733|NCT02708498|Experimental|Skåne Educational Intervention|The educational intervention is provided to ten nursing homes.
9834734|NCT02708498|No Intervention|Kronoberg Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
9834735|NCT02708524|Experimental|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
9834736|NCT02708524|Active Comparator|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
9834737|NCT02708524|Active Comparator|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
9834738|NCT02708524|Active Comparator|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
9834739|NCT02708641|Experimental|AML patients|pembrolizumab 200 mg given IV once every three weeks
9834740|NCT02708745|Placebo Comparator|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
9834741|NCT02708745|Experimental|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
9834742|NCT02708862|Experimental|Preoxygenation|All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 15 L/min for 3 min 3) Non-rebreather at 60 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
9834743|NCT02708966|Experimental|Gymnema Sylvestre|Patients with IGT
9834744|NCT02708966|Placebo Comparator|Placebo|Patients with IGT
9834745|NCT02709005|Experimental|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
9834746|NCT02709005|Placebo Comparator|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
9834747|NCT02709018|Experimental|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
9834748|NCT02709018|Placebo Comparator|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
9834749|NCT02709096|Experimental|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
9834750|NCT02709096|Placebo Comparator|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
9834751|NCT02709109|Experimental|Sequence 1: VX-371 + Hypertonic Saline (HS), then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 milligram (mg)/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their cystic fibrosis (CF) standard of care.
9834752|NCT02709109|Experimental|Sequence 2: HS, then VX-371 + HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
10203492|NCT05200338|Other|Cohort 1a|SCD patients that are vaccinated against hepatitis B virus before matched sibling donor allogeneic SCT.
10203493|NCT05200338|Other|Cohort 1b|SCD patients that are vaccinated against hepatitis B virus before haploidentical donor allogeneic SCT.
10203494|NCT05200338|Other|Cohort 2|SCD patients that are vaccinated against hepatitis B virus without undergoing allogeneic SCT (control group).
10203495|NCT05200338|Other|Cohort 3a|SCD patients undergoing matched sibling donor allogeneic SCT whose donor is vaccinated against hepatitis B virus before stem cell collection.
10203496|NCT05200338|Other|Cohort 3b|SCD patients undergoing haploidentical donor allogeneic SCT whose donor is vaccinated against hepatitis B virus before stem cell collection.
10203497|NCT05200299|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 12 cycles as adjuvant chemotherapy. They can change the regimen to mFOLFOX6 or CapeOx after accepting not less than two complete chemotherapy regimen, if can not tolerate the adverse reaction of mFOLFOXIRI. Total 24 weeks.
10203498|NCT05200299|Active Comparator|mFOLFOX6 or CapeOx adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 12 cycles as adjuvant chemotherapy or CapeOx once every three weeks for 8 cycles as adjuvant chemotherapy. Total 24 weeks.
9834753|NCT02709109|Experimental|Sequence 3: VX-371 + Placebo, then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
9834754|NCT02709109|Experimental|Sequence 4: Placebo, then VX-371 + Placebo|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
9834755|NCT02709330|Experimental|Lunasin regimen|"The Lunasin regimen consists of:~LunaRich X Capsules (12 capsules per day)~Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)~Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
9834756|NCT02709330|Active Comparator|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
9834757|NCT02709369|Experimental|Active HIRREM|This is a single site, single-arm, open-label, developmental study. Participants are recruited to receive eight to twenty sessions of High-resolution, relational, resonance-based electroencephalic mirroring (HIRREM), in addition to their usual care.
9834758|NCT02709486|Experimental|Low dose|Investigational product
9834759|NCT02709486|Experimental|High dose|Investigational product
9834760|NCT02709486|Placebo Comparator|Placebo|Investigational product
9834761|NCT02709538|Experimental|GSP 301 NS|
9834762|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 3.7|
9834763|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 7.0|
9834764|NCT02709577|Experimental|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
9834765|NCT02709577|Experimental|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
9834766|NCT02709746|Experimental|Vortioxetine 10 mg/day|
9834767|NCT02709746|Experimental|Vortioxetine 20 mg/day|
9834768|NCT02709746|Active Comparator|Fluoxetine 20 mg/day,|
9834769|NCT02709746|Placebo Comparator|Placebo|
9834770|NCT02709785|Experimental|Group 1 SmartMouth|24 subjects with plaque and gingival inflammation
9834771|NCT02709785|Experimental|Group 2 Chlorhexidine|28 subjects with plaque and gingival inflammation
9834772|NCT02709785|Placebo Comparator|Group 3 Placebo|28 subjects with plaque and gingival inflammation
9834773|NCT02709889|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
9834774|NCT02710045|Active Comparator|MV at 9 months|"Measles Vaccine at 9 months of age. Measles Vaccine at 18 months of age. All vaccines given as per normal Gambia schedule until 9 months of age, including third dose of diphtheria-tetanus-whole cell pertussis (DTP3), hepatitis B vaccine (HBV) and oral polio vaccine (OPV) at four months of age.~At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age."
9834775|NCT02710045|Active Comparator|DTP + MV at 9 months|Measles Vaccine at 9 months of age. DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid, and i.m. DTP (Serum Institute of India Ltd.) in the thigh. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age.
9834776|NCT02710045|Active Comparator|DTP at 9 months|DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given i.m. DTP (Serum Institute of India Ltd.) in the thigh. MV, OPV and YF administered at 11 months of age. Given a standard MV challenge at 18 months of age.
9834777|NCT02710071|Experimental|Placebo, Nebivolol, Hydrochlorothyazide|Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
9834778|NCT02710071|Experimental|Placebo, Hydrochlorothyazide, Nebivolol|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.
9984273|NCT04265365|Experimental|rTMS+rPMS_iTBS_R|In this group, they received intermittent theta burst stimulation(iTBS) on affected hemisphere after following iTBS at radial nerve on affected hand.
10203499|NCT05200273|Experimental|Intervention/treatment|Experimental
10203500|NCT05200260|Experimental|Upfront cytoreductive surgery with maintenance therapy|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
9834779|NCT02710136|Experimental|Glycerinated CR Allergenic Extract|"Complete Arm Title: Glycerinated German Cockroach Allergenic Extract.~Cockroach sensitive subjects are exposed to cockroach nasal allergen (NAC) intranasally at at increasing doses per protocol. The NAC aim is pursuit of optimal dose range as determined by tolerability and eliciting a threshold of nasal symptoms."
9834780|NCT02710214|Experimental|Duavee|1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
9834781|NCT02710214|Placebo Comparator|Placebo|Placebo pill daily for 8 weeks.
9834782|NCT02710240|Experimental|ICG Arm|Subjects undergo indocyanine green injection within 72 hours prior to surgery. Permitting infusion time within 72 hours of operation is believed to be adequate for tissue glow/surgical visualization. Alternately, patients may receive 25 mg of indocyanine green during induction. Dose and time of administration will be determined by the neurosurgeon during surgical planning. This 25 mg dose of indocyanine green is similar to dosing for other intraoperative vascular visualization.
9834783|NCT02710292|Other|DT1, then TE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
9834784|NCT02710292|Other|TE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
9834785|NCT02710422|Experimental|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
9834786|NCT02710422|Other|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
9834787|NCT02710526|Experimental|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
9834788|NCT02710526|Experimental|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
9834789|NCT02710526|Experimental|160 mg CAM2038 monthly injection|Group 3: 24mg sublingual BPN for the first 7 days, and then 160 mg of CAM2038 subcutaneous monthly injection in the buttocks starting on Day 8.
9834790|NCT02710591|Experimental|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
9834791|NCT02710630|Active Comparator|Dabigatran etexilate capsule|
9834792|NCT02710630|Experimental|Dabigatran etexilate tablet A1|
9834793|NCT02710630|Experimental|Dabigatran etexilate tablet B1|
9834794|NCT02710630|Experimental|Dabigatran etexilate tablet C1|
9834795|NCT02710630|Experimental|Dabigatran etexilate tablet D1|
9834796|NCT02710630|Experimental|Dabigatran etexilate tablet E1|
9834797|NCT02710669|Experimental|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
9834798|NCT02710669|Active Comparator|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
9834799|NCT02710669|Placebo Comparator|Placebo|Placebo (normal saline) is infused over 10 minutes
9834800|NCT02710890|Experimental|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are >=8 to <17 years. For Cohort 2 every attempt will be made to enroll 20 subjects >= 4 to < 8 years of age, 12 subjects >= 2 to < 4 years of age and 12 subjects >= 1 month to < 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
9834801|NCT02710981|Active Comparator|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (<8mm) in at least 3 cycles.
9766688|NCT04999267|Experimental|INVEST Intervention|
9766689|NCT04999267|No Intervention|Control|The control arm will not receive the INVEST Intervention and will receive the usual vaccine information materials by the schools.
9766690|NCT04994431|Experimental|Perioperative Tamsulosin Hydrochloride|Participants undergoing thoracic surgery will receive 0.4mgTamsulosin Hydrochloride orally nightly for the two nights immediately prior to surgery and the morning of surgery.
9766691|NCT04994431|No Intervention|Historical Comparator|Participants who underwent thoracic surgery (historical). Information about occurrence of Peri-Operative Urinary Retention in thoracic surgery patients will be obtained via retrospective chart review.
9766692|NCT04987229|Experimental|All subjects|All subjects will receive OLZ/SAM at a dose determined by the Investigator and based on the olanzapine dosing received in the antecedent study (ALKS 3831-A311 or ALKS 3831-A312 ENLIGHTEN-Youth)
9766693|NCT04984356|Experimental|WU-CART-007|"A CD7-directed chimeric antigen receptor (CAR) T-cell product.~A single IV infusion of WU-CART-007 Cells on Day 1 after Lymphodepletion(LD) Therapy. Cyclophosphamide 500 mg/m2/day x 3 (days -5 to -3) Fludarabine 30 mg/m2/day x 3 (days -5 to -3)"
9766694|NCT04982718|Experimental|Oral fluid-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the first 250 participants in the intervention group will receive an oral fluid-based HCV ST.
9766695|NCT04982718|Experimental|Blood-based HCV ST|In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. The kit will include the test, instructions for use, and information about additional supporting materials, such as access to live chat and a call center for questions about testing. In order to evaluate two sampling methods for HCV self-testing, the next 250 participants will receive a blood-based fingerstick HCV ST.
9766696|NCT04982718|No Intervention|Control standard of care|In the control group, participants will receive information about standard of care HCV antibody testing available at local testing sites in their community and information about additional supporting materials, such as access to live chat and a call center for questions about testing.
9766697|NCT04982289|Experimental|ALXN1830 Dosing Arm 1|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
9766698|NCT04982289|Experimental|ALXN1830 Dosing Arm 2|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
9766699|NCT04982289|Experimental|ALXN1830 Dosing Arm 3|Participants will receive placebo for 8 weeks, then ALXN1830 for 8 weeks, followed by an Observation Period (no treatment) for 8 weeks.
9766700|NCT04981301|Active Comparator|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.
9766701|NCT04981301|No Intervention|Group C = Control group|"Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group."
9766702|NCT04977947|Experimental|Healthy Eating for My Infant Intervention|Participants and their parents will participate in a 6 session intervention targeting healthy introduction of complementary foods, and responsive feeding and mealtime behaviors. Intervention sessions will occur when the infant is 3, 4, 5, 6, 7, and 8 months of age.
9766703|NCT04977947|No Intervention|Control|Participants and their parents will complete baseline and post-treatment study visits to assess study outcomes. They will receive no intervention.
9766704|NCT04977310|No Intervention|Control|After LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.
9766705|NCT04977310|Experimental|Intervention|After LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.
9766706|NCT04974775||Critically Ill|Critically ill patients and patients in need of post-operative intensive care.
9766707|NCT04974775||Cardiac Arrest|Cardiac Arrest according to the ICD-10 I469 diagnosis.
9766708|NCT04974775||Sepsis|Sepsis according to the sepsis-3 criteria.
9766709|NCT04974775||Covid-19|Critically ill patients with a positive Covid-19 test.
9766710|NCT04974775||Influenza|Critically ill patients with a positive influenza test.
9766711|NCT04974775||Trauma|Critically ill patients after a severe traumatic event.
9766712|NCT04974775||Healthy controls|Healthy at the time of blood sampling
9766713|NCT04974359|Experimental|Lu AG06466|Participants will receive an oral titrated dose of Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
9766714|NCT04974359|Placebo Comparator|Placebo|Participants will receive an oral dose of placebo matching to Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
9766715|NCT04970966|Experimental|PuraSinus|Placement of PuraSinus in ethmoid cavity following ESS
9766716|NCT04970966|Active Comparator|Bioresorbable Nasal Dressing|Placement of bioresorbable nasal dressing (PosiSep X) in ethmoid cavity following ESS
9766717|NCT04970771|Experimental|Solving Wellness Platform Group|Participants will receive a 1-year membership to the Solving Wellness virtual platform containing interactive wellness resources.
9834802|NCT02710981|Experimental|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
9834803|NCT02711306|Experimental|GMN Diet|In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.
9834804|NCT02711306|Placebo Comparator|PN Diet|In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.
9834805|NCT02711345|Experimental|Escalation|
9834806|NCT02711345|Experimental|Expansion Group 1|
9834807|NCT02711345|Experimental|Expansion Group 2|
9834808|NCT02711345|Experimental|Expansion Group 3|
9834809|NCT02711345|Experimental|Expansion Group 4|
9834810|NCT02711553|Experimental|8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).
9834811|NCT02711553|Placebo Comparator|Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable and equivalent volume to ramucirumab) plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
9834812|NCT02711553|Experimental|80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 80 mg merestinib orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for merestinib therapy).
9834813|NCT02711553|Placebo Comparator|Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable to merestinib) orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days. Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
9834814|NCT02711800|Experimental|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
9834815|NCT02711839|Placebo Comparator|Control Group|Commercial diabetic formula
9834816|NCT02711839|Experimental|Treatment Group|White sweet potato formula
9834817|NCT02711956|Experimental|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.~Two patient populations will be enrolled in DE and DC. Cohort A: Patients with prior progression on enzalutamide or apalutamide by PCWG2 criteria who were receiving a stable dose of enzalutamide at the time of study entry. Cohort B: Patients who were enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria."
9984274|NCT04265365|Experimental|rTMS+rPMS_cTBS_R|In this group, they received intermittent theta burst stimulation on affected hemisphere after following continuous theta burst stimulation(cTBS) at radial nerve on affected hand.
10203501|NCT05200260|Active Comparator|Neoadjuvant chemotherapy with maintenance therapy|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy.
10203502|NCT05200234|Experimental|Intervention group|Nattokinase + standard medical treatment
10203503|NCT05200234|Placebo Comparator|Control group|Placebo + Standard medical treatment
9834818|NCT02711995|Experimental|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
9834819|NCT02711995|Active Comparator|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
9834820|NCT02712008|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
9834821|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.
9834822|NCT02712008|Active Comparator|Aflibercept 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.
9834823|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.
9834824|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.
9834825|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
9834826|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
9834827|NCT02712008|Experimental|Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.
9834828|NCT02712047|Experimental|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
9834829|NCT02712047|Placebo Comparator|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
9834830|NCT02712320|Experimental|LMIS 50 mg|50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)
9834831|NCT02712333|Experimental|Air purifiers|Participants in this group received an intervention of true air purifiers placed in the center of the room.
9834832|NCT02712333|Sham Comparator|Control|Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.
10203504|NCT05200195||International Cohort Training Set|The Training Set of the International Cohort (N=3,326) was composed of the 70% (n=2328) HCC patients transplanted from 2000 to 2018 across 17 centers in North America, Europe, and Asia.
10203505|NCT05200195||International Cohort Test Set|The Test Set of the International Cohort (N=3,326) was composed of the 30% (n=998) HCC patients transplanted from 2000 to 2018 across 17 centers in North America, Europe, and Asia.
10203506|NCT05200195||Validation Cohort|The external Validation Cohort was composed of 470 HCC patients transplanted at Bologna University during the period 2000-2018.
10203507|NCT05200156|Experimental|Choline supplement group|Phosphatidyl choline tablets at a dose of 1200 mg twice per day plus conventional management for 12 weeks
10203508|NCT05200156|No Intervention|Control group|conventional management only for 12 weeks
10203509|NCT05200130|Active Comparator|Home exercise group|The home exercise program will be explained to the patients in the control group by the physiotherapist and the relevant brochures will be delivered to the patients. Home exercise program will take 30-45 min. İt will be applied 5 days a week for 8 weeks. Patients will receive a reminder message from the physiotherapist once a week.
10203510|NCT05200130|Active Comparator|Manual Therapy Group|Patients in the Manual Therapy Group will receive one-to-one physiotherapy sessions in the hospital 2 days a week for 8 weeks. In these sessions, soft tissue and joint mobilizations and exercises will be applied by physiotherapist.
10203511|NCT05200130|Experimental|Telerehabilitation Supported Group|Telerehabilitation program will be applied 2 days a week for 8 weeks to patients in the telerehabilitation group. İt will take 30-45 min. A physiotherapist will meet with patients via videoconferencing over the internet and guide the program.
10203512|NCT05200091|Experimental|Combined explosive strength and specific balance training group|This group will be formed with participants with incomplete spinal cord injury. This group will perform 4 weeks of combined explosive strength and specific balance training.
10203513|NCT05200091|No Intervention|Spinal cord injury control group|This group will be formed with participants with incomplete spinal cord injury. They will perform all the evaluation before and after a 4-week period of rest (no training).
9834833|NCT02712359|Other|Havrix 1 dose_Year 8 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
9834834|NCT02712359|Other|Havrix 2 doses_Year 8 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the last vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
9834835|NCT02712359|Other|Havrix 1 dose_Year 10 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
9834836|NCT02712359|Other|Havrix 2 doses_Year 10 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
9834837|NCT02712398|Experimental|Phasix™ ST|Subjects treated with Phasix™ ST mesh
9834838|NCT02712424|Active Comparator|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
9834839|NCT02712424|Placebo Comparator|Placebo|0.1 mL intradermal injection of sterile saline for human use
9834840|NCT02712554|Experimental|Treatment A:CL-108 22.5mg/975mg/37.5mg|CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
9834841|NCT02712554|Experimental|Treatment B:CL-108 37.5mg/1625mg/62.5mg|CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
9834842|NCT02712554|Active Comparator|Treatment C:M366 22.5mg/975mg|M366 22.5 mg/975 mg tablet by mouth
9834843|NCT02712554|Active Comparator|Treatment D: M366 37.5mg/1625mg|M366 37.5 mg/1625 mg tablet by mouth
9834844|NCT02712554|Placebo Comparator|Treatment E: Placebo|Placebo 0 mg tablet by mouth
9834845|NCT02712788|Active Comparator|Milrinone|Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
9834846|NCT02712788|Placebo Comparator|Placebo|Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
9834847|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)
9834848|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP/PBO|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
9834849|NCT02712983|Placebo Comparator|Cohort A (3 capsules o.d.): PBO|Cohort A (3 capsules o.d.): Inhaled placebo (PBO)
9834850|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)
9834851|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP/PBO|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
9834852|NCT02712983|Placebo Comparator|Cohort B (5 capsules o.d.): PBO|Cohort B (5 capsules o.d.): inhaled placebo (PBO)
9834853|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)
9834854|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP/PBO|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
9834855|NCT02712983|Placebo Comparator|Cohort C (4 capsules b.i.d.): PBO|Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)
9834856|NCT02712996|Active Comparator|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
9834857|NCT02712996|Placebo Comparator|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
9834858|NCT02713178|Active Comparator|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
9834859|NCT02713178|Active Comparator|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
9834860|NCT02713178|Placebo Comparator|Placebo|Normal saline (20 mL).
9834861|NCT02713204|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram [mg]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
9834862|NCT02713204|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
9984275|NCT04265365|Sham Comparator|rTMS +sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at radial nerve on affected hand.
9784176|NCT01218802|Placebo Comparator|Sugar Pill placebo|Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.
9784177|NCT01218867|Experimental|Cohort 1 (1x10(6) cells (high dose IL-2)|Patients will receive (1x10(6) cells plus high dose aldesleukin
9784178|NCT01218867|Experimental|Cohort 2 (3x10(6) cells (high dose IL-2)|Patients will receive (3x10(6) cells plus high dose aldesleukin
9784179|NCT01218867|Experimental|Cohort 3 (1x10(7) cells (high dose IL-2)|Patients will receive (1x10(7) cells plus high dose aldesleukin
9784180|NCT01218867|Experimental|Cohort 4 (3x10(7) cells (high dose IL-2)|Patients will receive (3x10(7) cells plus high dose aldesleukin
9784181|NCT01218867|Experimental|Cohort 5 (1x10(8) cells (high dose IL-2)|Patients will receive (1x10(8) cells plus high dose aldesleukin
9784182|NCT01218867|Experimental|Cohort 6 (3x10(8) cells (high dose IL-2)|Patients will receive (3x10(8) cells plus high dose aldesleukin
9784183|NCT01218867|Experimental|Cohort 7 (1x10(9) cells (high dose IL-2)|Patients will receive (1x10(9) cells plus high dose aldesleukin
9784184|NCT01218867|Experimental|Cohort 8 (1x10(9) cells (low dose IL-2)|Patients will receive (1x10(9) cells plus low dose aldesleukin
9784185|NCT01218867|Experimental|Cohort 9 (3x10(9) cells (low dose IL-2)|Patients will receive (3x10(9) cells plus low dose aldesleukin
9784186|NCT01218867|Experimental|Cohort10(1x10(10) cells (low dose IL-2)|Patients will receive (1x10(10) cells plus low dose aldesleukin
9784187|NCT01218867|Experimental|Cohort11(3x10(10) cells (low dose IL-2)|Patients will receive (3x10(10) cells plus low dose aldesleukin
9784188|NCT01218958|Experimental|Medisorb naltrexone 190 mg|
9784189|NCT01218958|Experimental|Medisorb naltrexone 380 mg|
9784190|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 190 mg|
9784191|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 380 mg|
9784192|NCT01218971|Experimental|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.
9784193|NCT01218971|Experimental|Medisorb naltrexone 190 mg|IM injection administered once every 4 weeks for up to 48 weeks.
9784194|NCT01218984|Experimental|Medisorb naltrexone 75 mg|
9784195|NCT01218984|Experimental|Medisorb naltrexone 150 mg|
9784196|NCT01218984|Experimental|Medisorb naltrexone 300 mg|
9784197|NCT01218997|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
9784198|NCT01218997|Active Comparator|Oral naltrexone 50 mg|
9784199|NCT01219738|Experimental|budesonide 360ug|asthmatic subject received different doses of inhaled budesonide in random other
9784200|NCT01219738|Experimental|budesonide 720ug|asthmatic subject received different doses of inhaled budesonide in random other
9784201|NCT01219738|Experimental|budesonide 1440ug|asthmatic subject received different doses of inhaled budesonide in random other
9784202|NCT01219738|Placebo Comparator|placebo|asthmatic subject received inhaled placebo
9784203|NCT01219738|Experimental|Budesonide720ug 4 times|asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.
9784204|NCT01219777|Experimental|Carboplatin|AUC 5.0 or 6.0
9784205|NCT01219777|Experimental|Bevacizumab|15 mg/kg
9784206|NCT01219777|Experimental|Paclitaxel|60-80 mg/m2
9784207|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 60µg|
9784208|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 90µg|
9784209|NCT01219855|Placebo Comparator|Cohort 1: Sugar Capsule|
9784210|NCT01219855|Experimental|Cohort 2: CTAP101 Capsules 30µg|
9784211|NCT01219855|Placebo Comparator|Cohort 2: Sugar Capsule|
9784212|NCT01219881|Active Comparator|Desflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.
9784213|NCT01219881|Active Comparator|Sevoflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.
9784214|NCT01219933|Experimental|1|
9766718|NCT04969978|Active Comparator|Arm I (Quitline eReferral)|Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
9766719|NCT04969978|Experimental|ARM II (Quitline eReferral plus enhanced AD)|Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions, written training materials for all providers and staff, including new hires, and monthly performance audit and feedback.
9766720|NCT04964947|Experimental|Tobramycin Treatment Group|Participants in this group receive a local aqueous tobramycin injection (2mg/mL) plus standard of care treatment.
9766721|NCT04964947|No Intervention|Standard of Care Treatment Group|Participants in this group receive standard of care treatment.
9766722|NCT04964440||PURE EP Guided Procedures|Redo AF procedures guided by Pure EP System during an AF Ablation
9766723|NCT04964440||Standard Recording System Guided Procedures|Redo AF procedures guided by the Standard Recording System during an AF Ablation
9766724|NCT04963517|Experimental|Exercise therapy|"8 weeks personalized, multi-modal exercise with focus on lower extremity~Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations~2x per week multi-modal group-based and supervised exercise (endurance, strength, mobility, coordination)~week 1 and 2 supervised, week 3 and 4 partially supervised, week 5 and 6 only one supervised session, week 7 and 8 last two sessions supervised"
9766725|NCT04963517|Active Comparator|Information group|"Initial consultation with recommendations for general physical activity~Brochure with exercise recommendations."
9766726|NCT04956276|Experimental|Cohort 1: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
9766727|NCT04956276|Experimental|Cohort 2: ALXN1830/Placebo|Participants will be randomized 3:1 to receive ALXN1830 or placebo. Treatment will be received for 8 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
9766728|NCT04956276|Experimental|Cohort 3: ALXN1830|If initiated, participants will receive ALXN1830. Treatment will be received for 12 weeks followed by a follow-up period (no treatment) for 8 weeks. Once complete, participants may continue participation in the study at the participant's and investigator's discretion during the OLE period for up to 2 years inclusive of primary treatment period.
9766729|NCT04946994|Experimental|High intensity interval training|
9766730|NCT04946994|Active Comparator|Continuous moderate intensity exercise|
9766731|NCT04942405|Experimental|TURKOVAC SARS-COV-2 Vaccine|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
9766732|NCT04942405|Active Comparator|CoronaVac|600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 28 days apart.
9766734|NCT04937725||Patients without neurological pathologies|Patients with no history of neurological diseases
9766735|NCT04937725||Patients with neurological pathologies|
9784215|NCT01219959|Active Comparator|Non-glucose Sparing|Dianeal only
9784216|NCT01219959|Experimental|Glucose Sparing|Dianeal, Extraneal, Nutrineal
9784217|NCT01219985|Experimental|Investigation arm|"standard and respiratory-gated PET acquisitions  for patients included in the trial."
9784218|NCT01220024|Experimental|2, 5x5cm bupivacaine collagen sponges|collagen sponges
9784219|NCT01220024|Placebo Comparator|2, Placebo collagen sponges|Placebo collagen sponges
9784220|NCT01220128|Experimental|Cohort A-GSK2302024A Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of GSK2302024A according to the treatment schedule.
9784221|NCT01220128|Placebo Comparator|Cohort A-Placebo Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.
9784222|NCT01220128|Experimental|Cohort B-GSK2302024A Group|This group included breast cancer patients who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
9784223|NCT01220128|Placebo Comparator|Cohort B-Placebo Group|This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
9784224|NCT01220128|Experimental|Cohort C-GSK2302024A Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of GSK2302024A, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
9784225|NCT01220128|Placebo Comparator|Cohort C-Placebo Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
9784226|NCT01220128|Experimental|Cohort D-GSK2302024A-D14 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
9784227|NCT01220167|Experimental|Sequence ABC|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
9784228|NCT01220167|Experimental|Sequence BCA|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
9784229|NCT01220167|Experimental|Sequence CAB|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
9784230|NCT01220180||Epilepsy|
9784231|NCT01220180||Neuropathic Pain|
9784232|NCT01220180||Fibromyalgia|
9784233|NCT01220297|Experimental|Carmustine Etoposide Cyclophosphamide|Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
9784234|NCT01220297|Experimental|FTBI + Cyclophosphamide|FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
9784235|NCT01220401|Experimental|ERRT-M|Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
9784236|NCT01220414|Active Comparator|Men|
9784237|NCT01220414|Active Comparator|Women|
9784238|NCT01220466|Experimental|Refractive Error|
9784239|NCT01220557|Experimental|PRIMAS group|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
9784240|NCT01220557|Active Comparator|Control group|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
9784241|NCT01220609|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9784242|NCT01220687|Placebo Comparator|Placebo 20ppm|Nitrogen at 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
9784243|NCT01220687|Experimental|Inhaled Nitric Oxide (iNO) 20 ppm|Inhaled Nitric Oxide 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
9784244|NCT01220726|Active Comparator|Botox|200U onabotulinumtoxinA (botox)
9784245|NCT01220726|Placebo Comparator|Placebo|200U Saline
9784246|NCT01220739|Sham Comparator|IV tPA + Sham Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
9834863|NCT02713204|Experimental|Aflibercept (IAI) 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.
9834864|NCT02713230|Active Comparator|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
9834865|NCT02713230|Active Comparator|EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
9834866|NCT02713230|Placebo Comparator|Placebo|20 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
9834867|NCT02713243|Experimental|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
9834868|NCT02713243|Experimental|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
9834869|NCT02713256|Experimental|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
9834870|NCT02713425|Experimental|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game. Parents will observe and provide their own feedback about the game.
9834871|NCT02713490|Active Comparator|EXPAREL|Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
9834872|NCT02713490|Active Comparator|Bupivacaine|Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
9834873|NCT02713529|Experimental|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
9834874|NCT02713542|Experimental|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
9834875|NCT02713542|Placebo Comparator|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
9834876|NCT02713594|Placebo Comparator|Control|Counseling from WTQL
9834877|NCT02713594|Experimental|Incentive|Counseling from WTQL; Financial incentive to participate
9834878|NCT02713659|Experimental|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
9834879|NCT02713659|Active Comparator|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
9834880|NCT02713698||Group 1 (≥18 years, BMI<35kg/m2)|Patients with 18 or more years presenting for inpatient nose and ear surgery.
9834881|NCT02713698||Group 2 (≥18 years, ≥35kg/m2)|Patients with 18 or more years presenting for inpatient bariatric surgery.
9834882|NCT02713698||Group 3 (≥65 years)|Patients with 65 or more years presenting for orthopaedic surgery.
9834883|NCT02713711|No Intervention|control group|The control group plaques did not receive any treatment.
9834884|NCT02713711|Experimental|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
9834885|NCT02713711|Experimental|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
9834886|NCT02713711|Experimental|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
9834887|NCT02713789|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
9834888|NCT02713789|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
9834889|NCT02713828|Experimental|Phase I: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Dose-Limiting Toxicity (DLT) evaluation period for determination of the appropriateness of dose-escalation will be through the end of the second treatment cycle.
9834890|NCT02713828|Experimental|Phase II: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Maximum Tolerated Dose (MTD) determined in Phase I will be used in Phase II.
9834891|NCT02714153|Experimental|Bridge Occlusion Balloon|Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
9834892|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
9834893|NCT02714400|Active Comparator|Venlafaxine|50mg of Venlafaxine before sleep
9834894|NCT02714400|Placebo Comparator|Placebo|One piece of placebo before sleep
9834895|NCT02714426|Active Comparator|Brain Health|In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop), Positive and Negative Affect Scale (PANAS), Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS), Five Facet Mindfulness Questionnaire (FFMQ), Emotion Regulation Questionnaire (ERQ), State-Trait Anxiety Inventory (STAI), and Starkstein Apathy Scale (AS). In weeks 4-11, participants receive the Brain Health control instruction.
9834896|NCT02714426|Experimental|Mindfulness-inspired Treatment/Testing|"Participants receive all of the same measures as the active comparator Brain Health condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment"
9834897|NCT02714504|No Intervention|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
9834898|NCT02714504|Experimental|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
9834899|NCT02714569|Experimental|Part A: LY3202328 (LY)|Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.
9834900|NCT02714569|Placebo Comparator|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
9834901|NCT02714569|Experimental|Part B: LY3202328 (LY)|A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
9834902|NCT02714569|Placebo Comparator|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
9834903|NCT02714595|Experimental|Cefiderocol|Participants will receive cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
9834904|NCT02714595|Active Comparator|Best Available Therapy (BAT)|Best available therapy (BAT) will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
9834905|NCT02714868|Experimental|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
9834906|NCT02714868|Active Comparator|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
9834907|NCT02715076|Experimental|Ambient Temp 19°C & Passive Insulation|Ambient Temperature 19°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
9834908|NCT02715076|Experimental|Ambient Temp 19°C & Forced-air Warming|Ambient Temperature 19°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
9834909|NCT02715076|Experimental|Ambient Temp 21°C & Passive Insulation|Ambient Temperature 21°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
9834910|NCT02715076|Experimental|Ambient Temp 21°C & Forced-air Warming|Ambient Temperature 21°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
9834911|NCT02715076|Experimental|Ambient Temp 23°C & Passive Insulation|Ambient Temperature 23°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
9834912|NCT02715076|Experimental|Ambient Temp 23°C & Forced-air Warming|Ambient Temperature 23°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
9834913|NCT02715258|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will self-administer bexagliflozin tablets once daily for 24 weeks.
9834914|NCT02715258|Placebo Comparator|Placebo tablets|Each subject will self-administer placebo (inactive tablet) once daily for 24 weeks.
9834915|NCT02715700|Experimental|Maintenance Methadone and MK-1439|Participants maintained on a stable methadone regimen (20 to 200 mg once daily) for ≥14 days prior to Day 1 will continue to receive methadone maintenance once per day on Days 1 to 7. From Day 2 to 6, participants will also receive doravirine 100 mg once daily.
9984276|NCT04265365|Experimental|rTMS+rPMS_iTBS_M/U|In this group, they received iTBS on affected hemisphere after following iTBS at median/ulnar nerve on affected hand.
9834916|NCT02715726|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
9834917|NCT02715726|Experimental|Alirocumab 75 mg Q2W/up to 150 mg Q2W|Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was >=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter [mmol/L]) at Week 8.
9834918|NCT02715804|Experimental|PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m^2) nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
9834919|NCT02715804|Placebo Comparator|AG: Placebo + nab-Paclitaxel + Gemcitabine|Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m^2 nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
9834920|NCT02716194|Experimental|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
9834921|NCT02716194|Experimental|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
9834922|NCT02716194|Experimental|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
9834923|NCT02716298|Active Comparator|fanfilcon A|Study participants are randomized to wear fanfilcon A lens during the crossover study
9834924|NCT02716298|Active Comparator|lotrafilcon B|Study participants are randomized to wear lotrafilcon B lens during the crossover study.
9834925|NCT02716324|Active Comparator|ADHD Portal|In this arm, the ADHD Portal was used alone as an electronic communication tool.The ADHD portal is considered standard of care at our institution for communicating information between clinicians, teachers, and parents.
9834926|NCT02716324|Experimental|ADHD Portal plus Care Manager (CM)|In this arm, the ADHD Portal was combined with the CM. Clinicians, teachers, and parents used the ADHD Portal as standard of care. In addition, clinicians, teachers, parents, and any external mental health providers interacted with a CM, who had access to information contained in the ADHD Portal.
9836050|NCT02767427|Active Comparator|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
9836051|NCT02767427|Experimental|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
10203514|NCT05200091|No Intervention|Healthy control group|Healthy participants will be recruited based on the age and sex of the participants with incomplete spinal cord injury to realize clinical and neurophysiological cortical evaluations.
10203515|NCT05200078||Radiotherapy at free-breathing|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at free-breathing
10203516|NCT05200078||Radiotherapy at deep inspiration breath-hold|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at deep inspiration breath-hold
10203517|NCT05200065|Experimental|Thulium Laser Enucleation|Patients in this arm will undergo thulium laser enucleation of the prostate.
10203518|NCT05200065|Experimental|Bipolar Enucleation|Patients in this arm will undergo bipolar enucleation of the prostate.
10203519|NCT05200039||Study group|Older men who were treated for localized or locally advanced prostate cancer with curative intent at the age of 70 years or more
10203520|NCT05200039||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019, matched on age and education
10203521|NCT05200013|Experimental|Cohort 1|Dose 0.3mg/kg
10203522|NCT05200013|Experimental|Cohort 2|Dose 1mg/kg
10203523|NCT05200013|Experimental|Cohort 3|Dose: 3 mg/kg
10203524|NCT05200013|Experimental|Cohort 4|Dose: 10 mg/kg
10203525|NCT05200013|Experimental|Cohort 5|Dose: 20 mg/kg
10203526|NCT05200013|Experimental|Cohort 6|Dose: 40 mg/kg
10203527|NCT05200000|Experimental|SygeLIX-Coll-T|Extract of umbilical cord lining constituted of Wharton's jelly put in suspension in microvials. Instillation by the patient in the sick eye of 1 drop 5 times a days (morning, noon, afternoon, evening and bedtime) for 40 days.
10203528|NCT05199922|Active Comparator|Group M = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
9834927|NCT02716506||Symptomatic POP|POP surgery in year 2015
9834928|NCT02716584|Experimental|Physical exercise|Participants participate in brisk walking exercises.
9834929|NCT02716584|Active Comparator|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
9834930|NCT02716714|Active Comparator|ingenol mebutate gel 0.015%|Applied on face and scalp for three days.
9834931|NCT02716714|Active Comparator|ingenol mebutate gel 0.05%|Applied on trunk and extremities for two days.
9834932|NCT02716727|Active Comparator|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
9834933|NCT02716727|Active Comparator|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
9834934|NCT02716779|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
9834935|NCT02716779|Placebo Comparator|Placebo|Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
9834936|NCT02716779|Experimental|Ribavirin|Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
9834937|NCT02716805|Experimental|Cohort 1|"Subjects received Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
9834938|NCT02716805|Experimental|Cohort 2|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
9834939|NCT02716805|Experimental|Cohort 3|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
9834940|NCT02716805|Experimental|Cohort 4|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
9834941|NCT02716818|Experimental|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
9834942|NCT02716818|Active Comparator|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
9834943|NCT02716896|Active Comparator|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, Glomerular Filtration rate (GFR), participant's preference, and availability of chemotherapeutic regimen.
9834944|NCT02716896|Active Comparator|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
9834945|NCT02716987|Experimental|Set A: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally, once on Day 1 and up to 100 megabecquerel (MBq) of Positron Emission Tomography (PET) ligand PGM028299 labeled with [18F] ([18F]PGM299) with a maximal mass up to 12.5 microgram (mcg), injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
9834946|NCT02716987|Experimental|Set A: TAK-831 200 mg|TAK-831 200 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
9834947|NCT02716987|Experimental|Set A: TAK-831 250 mg|TAK-831 250 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
9834948|NCT02716987|Experimental|Set A: TAK-831 500 mg|TAK-831 500 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
9834949|NCT02716987|Experimental|Set B: [18F]PGM299|[18F]PGM299 up to 100 MBq (with a maximal mass up to 12.5 mcg), injection, intravenously, prior to PET imaging on Days 1 and 10.
9834950|NCT02717195|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
9834951|NCT02717195|Experimental|Double-blind Treatment (DBT) Period, Lu AF35700 10 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
9834952|NCT02717195|Experimental|DBT Period, Lu AF35700 20 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
9834953|NCT02717195|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
9834954|NCT02717273|Active Comparator|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
9834955|NCT02717273|Experimental|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
9834956|NCT02717494|Experimental|Arm 1A (PPV-23)|In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
9834957|NCT02717494|Experimental|Arm 1B (PCV-10)|In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
9834958|NCT02717494|Placebo Comparator|Arm 1C (placebo)|In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
9834959|NCT02717494|Experimental|Arm 2A (PPV-23)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
9834960|NCT02717494|Experimental|Arm 2B (PCV-10)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
9834961|NCT02717494|Experimental|Step 3 (PCV-10)|In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy were administered a 0.5 mL dose of PCV-10 intramuscularly once.
9834962|NCT02717546||Group One|Distal Tibia Fracture repaired with Zimmer MotionLoc Screw
9834963|NCT02717754|Experimental|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
9834964|NCT02717754|Experimental|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
9834965|NCT02717754|Placebo Comparator|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
9834966|NCT02718040|Experimental|Emervel Treatment Group|Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
9834967|NCT02718118|Experimental|1.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
9834968|NCT02718118|Experimental|2.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
9834969|NCT02718131|Active Comparator|INFUSE Bone Graft (BMP-2)|Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.
9834970|NCT02718131|Placebo Comparator|Control Group|Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
9834971|NCT02718157|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
9834972|NCT02718248|Experimental|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
9834973|NCT02718326|Experimental|Dosing regimen 1|Participants will receive IVT aflibercept dosing regimen 1
9834974|NCT02718326|Experimental|Dosing regimen 2|Participants will receive IVT aflibercept dosing regimen 2
9834975|NCT02718326|Sham Comparator|Dosing regimen 3|Participants will receive matching sham injections
9834976|NCT02718417|Active Comparator|Arm A|Chemotherapy followed by observation
9834977|NCT02718417|Experimental|Arm B|Chemotherapy followed by avelumab in maintenance
9834978|NCT02718417|Experimental|Arm C|Chemotherapy in combination with avelumab followed by avelumab in maintenance
9834979|NCT02718625|Experimental|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
9834980|NCT02718625|Active Comparator|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
9834981|NCT02718898|Experimental|Ixekizumab|"Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40."
9834982|NCT02718898|Placebo Comparator|Placebo|"Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40."
9834983|NCT02718963|Experimental|Control group|"control group(N=10): who does not have dysphagia symptom~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
9834984|NCT02718963|Experimental|Experimental group|"experimental group(N=10): who have dysphagia symptoms~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
9834985|NCT02719028|Placebo Comparator|Placebo|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
9834986|NCT02719028|Experimental|Antroquinonol 50 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
9834987|NCT02719028|Experimental|Antroquinonol 100 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
10203529|NCT05199922|No Intervention|Group C = Control group|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia."
9834988|NCT02719028|Experimental|Antroquinonol 150 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
10203530|NCT05199909|Experimental|Intervention ( zanubrutinib)|10 enrolled patients are picked up to take zanubrutinib at the indicated dose.
9834989|NCT02719158|Experimental|6 mg OTO-201|6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
9834990|NCT02719158|Experimental|12 mg OTO-201|12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
9834991|NCT02719158|Sham Comparator|Sham (empty syringe)|Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)
9834992|NCT02719171|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
9834993|NCT02719171|Experimental|Risankizumab 150 mg Every 4 Weeks|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
9834994|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0, 4, and 16|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
9834995|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0 and 12|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
9834996|NCT02719171|Experimental|Risankizumab 75 mg Week 0|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
9834997|NCT02719353|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
9834998|NCT02719353|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
9834999|NCT02719366|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
9835000|NCT02719366|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
9835001|NCT02719535|Experimental|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
9836052|NCT02767492|Experimental|BioDRestore™|BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.
10203531|NCT05199896|Experimental|All protocols (behavioral and EEG and fMRI)|If participants accepts (non-sighted participants and Healthy volunteers), they will carry out the behavioral protocol and the EEG protocol and fMRI protocol.
9835002|NCT02719743|Active Comparator|H5N1 Formulation 1 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.
9835003|NCT02719743|Experimental|H5N1 Formulation 2 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
9835004|NCT02719743|Experimental|H5N1 Formulation 3 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
9835005|NCT02719743|Experimental|H5N1 Formulation 4 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
9835006|NCT02719743|Experimental|H5N1 Formulation 5 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
9835007|NCT02719938|Experimental|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
9835008|NCT02719938|No Intervention|Control|Usual care.
9835009|NCT02720042|Experimental|Phasix™ Mesh|Patients treated with Phasix™ Mesh for hernia repair
9835010|NCT02720081|Experimental|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
9835011|NCT02720081|Placebo Comparator|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
9835012|NCT02720107|Experimental|fingolimod|Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).
9835013|NCT02720198|Active Comparator|Levomilnacipran|Levomilnacipran ER is switched from SSRI.
9835014|NCT02720198|Active Comparator|Quetiapine|Quetiapine XR is added in addition to current SSRI.
9835015|NCT02720224|Experimental|Estetrol|A single oral dose of 15 mg carbon 14 labelled estetrol ([14C]-estetrol), containing approximately 2.8 MBq (76 µCi) 14C
9835016|NCT02720484|Experimental|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
9835017|NCT02720523|Experimental|Placebo / Upadacitinib 7.5 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks."
9835018|NCT02720523|Experimental|Placebo / Upadacitinib 15 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
9835019|NCT02720523|Experimental|Placebo / Upadacitinib 30 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
9835020|NCT02720523|Experimental|Upadacitinib 7.5 mg / Upadacitinib 7.5 mg|"Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks."
9835021|NCT02720523|Experimental|Upadacitinib 15 mg / Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
9835022|NCT02720523|Experimental|Upadacitinib 30 mg / Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
9835023|NCT02720536|Experimental|Deferasirox|Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.
9835024|NCT02720627|Experimental|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
9835025|NCT02720757||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
9835026|NCT02720952|Experimental|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
9835027|NCT02721017|Experimental|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
10203532|NCT05199896|Experimental|Behavioral protocol and EEG protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
9835028|NCT02721017|Active Comparator|Thoracic Epidural|Thoracic epidural (ropivicaine, fentanyl).
9835029|NCT02721147|Experimental|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
9835030|NCT02721147|Active Comparator|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
9835031|NCT02721251|Experimental|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
9835032|NCT02721251|Experimental|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
9835033|NCT02721251|Experimental|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
9835034|NCT02721355|Experimental|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
9835035|NCT02721355|No Intervention|Control|The subjects undergo the routine treatment regime without taking food supplement
9835036|NCT02721641|Experimental|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
9835037|NCT02721875|Experimental|Volasertib monotherapy|
9835038|NCT02721875|Experimental|Volasertib + azacitidine combination|
9835039|NCT02721966|Experimental|AIN457 150mg|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
9835040|NCT02721966|Experimental|AIN457 300mg|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
9835041|NCT02721966|Placebo Comparator|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
9835042|NCT02722044|Experimental|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
9835043|NCT02722148|Experimental|Enrolled Patients|All enrolled subjects will receive a novel allergen-specific immune signature directed approach to dietary elimination therapy
9835044|NCT02722239|Experimental|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
9835045|NCT02722239|Experimental|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
9835046|NCT02722278|Experimental|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
9835047|NCT02722278|Active Comparator|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
9835048|NCT02722304|Experimental|ARALAST NP 60 mg/kg|60 mg/kg body weight/week
9835049|NCT02722304|Experimental|ARALAST NP 120 mg/kg|120 mg/kg body weight/week
9835050|NCT02722304|Experimental|GLASSIA 60 mg/kg|60 mg/kg body weight/week
9835051|NCT02722304|Experimental|GLASSIA 120 mg/kg|120 mg/kg body weight/week
9835052|NCT02722304|Placebo Comparator|Placebo|Human Albumin 2%
9835053|NCT02722330|Experimental|Baha 5 SuperPower on Baha Attract System|"The device involves the following parts:~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling."
9835054|NCT02722408|Experimental|Gemcabene|Participants with homozygous familial hypercholesterolemia (HoFH) on stable lipid lowering therapy received 300 milligram (mg) of Gemcabene, orally once daily from day 1 to 28 followed by 600 mg of Gemcabene, orally once daily from day 29 to 56 followed by 900 mg of Gemcabene, orally once daily from day 57 to 84. Participants were followed until Day 112.
9835055|NCT02722499|Experimental|High Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the high frequency incentive structure
9835056|NCT02722499|Experimental|Moderate Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the moderate frequency incentive structure
9835057|NCT02722499|Experimental|Low Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the low frequency incentive structure
9835058|NCT02722564|Experimental|all study participants|subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.
9835059|NCT02722837|Experimental|SOF/VEL|SOF/VEL for 12 weeks
9835060|NCT02722928|No Intervention|Conventional 1:1 oxygen/air gas mixture|80 patients will receive ventilation during the surgery with a 1:1 oxygen / air gas mixture
9835061|NCT02722928|Experimental|Pure oxygen ventilation|Patients will receive controlled ventilation with a conventional 1:1 oxygen / air gas mixture (60% oxygen concentration) during the approach and tumor removal phases. Once tumor resection is completed and hemostasis started, this group of patients will be switched to ventilation with 100% (pure) oxygen concentration
9835062|NCT02722967|Experimental|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
9835063|NCT02723006|Experimental|TAK-580 + nivolumab|TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
9835064|NCT02723006|Experimental|TAK-202 (plozalizumab) + nivolumab|TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
9835065|NCT02723006|Experimental|vedolizumab + nivolumab + ipilimumab|Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
9835066|NCT02723084|Experimental|Arm A|Co-formulated ABT-493/ABT-530 (300 mg/120 mg) administered once daily (QD) for 8 weeks in HCV genotype (GT) 2 -infected, DAA treatment-naïve participants without cirrhosis.
9835067|NCT02723084|Active Comparator|Arm B|sofosbuvir (400 mg) QD co-administered with weight based ribavirin (RBV) 600-1000 mg divided twice daily (BID) for 12 weeks in HCV GT2 -infected, DAA treatment-naïve participants without cirrhosis.
9835068|NCT02723175|Experimental|Sham tDCS Stimulation|"30 minutes of the sham transcranial Direct Current Stimulation~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
9835069|NCT02723175|Experimental|Anodal tDCS Stimulation of DLPFC|"30 minutes of the active transcranial Direct Current Stimulation (tDCS)~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
9835070|NCT02723188|Sham Comparator|Sham|Sham electrical stimulation
9835071|NCT02723188|Experimental|DC: Direct current|Direct current electrical stimulation
9835072|NCT02723188|Experimental|AC: Alternating current|Alternating current electrical stimulation
9835073|NCT02723201|Experimental|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
9835074|NCT02723201|Experimental|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
9835075|NCT02723201|Experimental|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
9835076|NCT02723201|Experimental|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
9835077|NCT02723201|Experimental|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
9835078|NCT02723201|Experimental|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
9835079|NCT02723201|Experimental|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
9835080|NCT02723344|Experimental|L. reuteri|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
9835081|NCT02723344|Placebo Comparator|Sunflower and medium chain triglyceride oils|Sunflower and medium chain triglyceride oils
9836053|NCT02767492|Active Comparator|Corticosteroid|Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.
9836054|NCT02767609|Experimental|Magentic Resonance Imaging|magnetic Resonance Imaging.
9766736|NCT04935762|Experimental|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
9766737|NCT04935762|Experimental|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 and matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
9766738|NCT04932824|No Intervention|Subjects Without Treatment Cross-over|these subjects will not receive any vaccination during this study.
9766739|NCT04932824|Experimental|Subjects With Treatment Cross-over (From 1st Dose of Active Study Vaccine Onwards)|Once the treatment assignments of study CLO-SCB-2019-001 are unblinded, those subjects who have received placebo and provided there is active study vaccine available, will be given the option to receive 2 doses of active study vaccine 21 days apart (ie, treatment cross-over)
9766740|NCT04932824|Experimental|Subjects who will receive Booster Vaccine|For subjects out of those who received SCB-2019 CpG/Alum-adjuvanted vaccine in study CLO-SCB-2019-001: the subjects will receive a booster dose.
9766741|NCT04929678|Experimental|Braive™ Growth Modulation System (Braive™ GMS)|
9766742|NCT04929496|No Intervention|Angiographical guidance only|Standard of care
9766743|NCT04929496|Experimental|Post-PCI FFR guidance|Post-PCI Fractional Flow Reserve and non-hyperemic pressure ratios measurement
9766744|NCT04926324|Experimental|Cohort 1 (starting)|niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
9766745|NCT04926324|Experimental|Cohort 2|niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
9766746|NCT04925388|Experimental|multiplex PCR|peritoneal samples will be analysed using Unyvero IAI test and using conventional method
9766747|NCT04925388|Other|conventional method|peritoneal samples will be analysed using only conventional method
9766748|NCT04920370|Experimental|ALXN1720 Single Dose SC|Participants will receive a single dose of ALXN1720 SC.
9766749|NCT04920370|Experimental|ALXN1720 Multiple Dose SC|Participants will receive multiple doses of ALXN1720 SC.
9766750|NCT04920370|Experimental|ALXN1720 Single Dose SC + rHuPH20|Participants will receive a single dose of ALXN1720 SC in combination with rHuPH20.
9766751|NCT04920370|Experimental|ALXN1720 Single Dose IV|Participants will receive a single dose of ALXN1720 IV.
9766752|NCT04920370|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
9766753|NCT04918407|Experimental|Empagliflozin|Adding 25mg Empagliflozin on Insulin
9766754|NCT04918407|Active Comparator|Insulin alone|Just contriling the blood glucose with Insulin
9766755|NCT04916769|Experimental|Bosutinib capsule contents mixed with applesauce|Bosutinib capsule contents mixed with applesauce to healthy participants
9766756|NCT04916769|Experimental|Bosutinib capsule contents mixed with yogurt|Bosutinib capsule contents mixed with yogurt to healthy participants
9766757|NCT04916769|Active Comparator|Bosutinib intact capsules|Bosutinib intact capsules to healthy participants
9766758|NCT04905342|Experimental|NVP-1805|NVP-1805 (80/10/20.8mg)
9766759|NCT04905342|Active Comparator|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
9766760|NCT04902482|Experimental|iCycle training|Participants will attend 3 training sessions per week at the RNOH. During these sessions, participants will tether their wheelchair (from under the seat) to the front of the iCycle, and their feet will be attached to the iCycle pedals. For training, participants will complete virtual reality cycle races displayed on a large screen in front of the iCycle: the more voluntary effort the participant contributes the greater the speed of the avatar. During cycling, a motor will control cycling speed, and muscle stimulation (FES) will be applied to the leg muscles (right and left gluteus, quadriceps and hamstrings) on alternative revolutions of the pedals. A dashboard screen will display controls for the stimulation, speed, brake, game switch and an emergency stop. Sessions will increase from 20 mins or the maximum achievable at the start (whichever is lower) up to at least 1 hour.
9766761|NCT04900207||Observed Group|Participants will be enrolled in the study at the time of their first-trimester screen (10w3d-13w6d weeks of gestation) to the time of their delivery. Collection of first-trimester 3D-volume ultrasound imaging to measure the placental volume, blood flow, and vascularity and maternal serum markers will occur over a 6-12 months period. Collection of descriptive and pregnancy outcome information will be obtained from the electronic medical records will continue through their pregnancy episode (typical 9 months).
9766762|NCT04900116|Active Comparator|Group 1|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
9766763|NCT04900116|Active Comparator|Group 2|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
9766764|NCT04900116|Active Comparator|Group 3|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
9766765|NCT04900116|Placebo Comparator|Group 4|In this group, US guided PENG block will be performed with 20 ml saline solution (%0.9 NaCl) using a 22 gauge 10 mm block needle.
9766766|NCT04895215|Experimental|AB-2004 High dose|
9766767|NCT04895215|Active Comparator|AB-2004 Low Dose|
9766768|NCT04895215|Placebo Comparator|Placebo|
9766769|NCT04894123|Experimental|trifluridine/tipiracil +/- oxaliplatin|"Trifluridine/tipiracil 35 mg/m² orally twice a day from day 1 to day 5 plus oxaliplatin 85 mg/m² intravenous at day 1 every 14 days.~If oxaliplatin is stopped for neurotoxicity, allergic reaction or other reason, or it is not indicated, patients will continue trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
9766770|NCT04871048|Experimental|active tDCS stimulation|Transcranial direct current stimulation tDCS-Stimulation will be performed using a Neurocan DC-Stimulator Plus
9766771|NCT04871048|Sham Comparator|sham tDCS stimulation|Transcranial direct current stimulation tDCS-The control group will receive the sham stimulation following the same regimen, using the sham procedure .
9766772|NCT04869059|Experimental|Transcranial direct current stimulation|20 minutes of 1 milliamp transcranial direct current stimulation to presupplementary motor area for 15 sessions
9766773|NCT04869059|Sham Comparator|Sham transcranial direct current stimulation|20 minutes of sham transcranial direct current stimulation to presupplementary motor area for 15 sessions
9766774|NCT04867278|Experimental|External Beam Radiation (XRT) with Debridement|Patients will receive gluteus minimus debridement in the OR, which is the standard of care at Shock Trauma. If randomized to the treatment group, patients that undergo surgical fixation of an acetabular fracture via a posterior or combined anterior and posterior approach will undergo a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery. This treatment is currently the standard procedure performed for all patients who undergo a posterior or combined approach at our institution.
9766775|NCT04867278|Active Comparator|Debridement Alone (Control)|The control treatment arm will only include gluteus minimus debridement in the OR and will not receive XRT.
9766777|NCT04857684|Experimental|Stereotactic beam radiation therapy (SBRT) +Atezolizumab + Bevacizumab|"Participants will:~undergo a pre-treatment biopsy with fiducial marker placement~receive Stereotactic beam radiation therapy (SBRT) on three treatment days which will be arranged on an every-other-day basis~receive two 3-week (21 days) cycles of atezolizumab plus bevacizumab~receive Atezolizumab on day 1 for 2 study cycles.~receive Bevacizumab 1x weekly for 2 study cycles~Surgery after SBRT and the two cycles of atezolizumab and bevacizumab, unless participants are otherwise informed by their doctor. The planned surgery will take place 6-8 weeks after the last infusions of atezolizumab and bevacizumab."
9766778|NCT04856657||Session 1: tACS at IAPF + 2 Hz|Participants in this arm will undergo tACS at a frequency 2 Hz above their IAPF during stimulation session 1. They will undergo tACS at a frequency 2 Hz below their IAPF during stimulation session 2.
9766779|NCT04856657||Session 1: tACS at IAPF - 2 Hz|Participants in this arm will undergo tACS at a frequency 2 Hz below their IAPF during stimulation session 1. They will undergo tACS at a frequency 2 Hz above their IAPF during stimulation session 2.
9766780|NCT04852731|Experimental|Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording and exercise ECG,~And specifically for research purposes : injected cardiac MRI and a blood collection."
9766781|NCT04852731|Experimental|Group A (b) : patients without mitral regurgitation with ventricular extrasystole (>10/hour)|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
9766782|NCT04852731|Experimental|Group B : patients with Mitral valve prolapse with trivial mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
9766783|NCT04852731|Experimental|Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation|"These patients will undergo at the inclusion and 36 months after the inclusion :~According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,~And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection."
9766784|NCT04849000|Experimental|SHR-1209|
9766785|NCT04849000|Placebo Comparator|SHR-1209 Placebo|
9766786|NCT04846140|Experimental|tDCS group|This group is defined as the participants who will receive tDCS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
9766787|NCT04846140|Experimental|tACS group|This group is defined as the participants who will receive tACS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
9766788|NCT04846140|Experimental|tRNS group|This group is defined as the participants who will receive tRNS at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
9766789|NCT04846140|Experimental|sham group|This group is defined as the participants who will receive sham stimulation at the first session. Participants in this group will receive 4 stimulation types (active a-tDCS, tACS, tRNS, and sham) in random order with at least a 48-hour separation between visits.
9766790|NCT04825275|Experimental|Posaconazole|Participants will be taking 300 mg of the study drug (three 100 mg tablets) by mouth twice a day the first day and then 300 mg once a day until the day of biopsy or surgery. On the day of biopsy or surgery, participants will take their medication the morning of their biopsy or surgery (before the operation). Participants will then take the last dose of the medication in the morning of the day after their biopsy or surgery. Participants will be given 12 days' worth of the study drug (pills) and verbally instructed how and when to take them.
9766791|NCT04825275|No Intervention|Control|Participants will not undergo any intervention.
9766792|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - telemedicine before face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have undergone telemedicine consultation before face-to-face evaluation
9836055|NCT02767765|Experimental|r-HuEPO|Anemic cancer participants will receive r-HuEPO for 4 weeks.
9835082|NCT02723591|Active Comparator|Tacrolimus, Extended Release (Astagraf XL®) Once Daily|Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
9835083|NCT02723591|Active Comparator|Tacrolimus, Immediate Release Twice Daily (BID)|Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
9835084|NCT02723630|Experimental|Sequence A:|Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
9835085|NCT02723630|Experimental|Sequence B|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
9835086|NCT02723630|Experimental|Sequence C|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
9835087|NCT02723630|Experimental|Sequence D|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
9835088|NCT02723630|Experimental|Sequence E|Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
9835089|NCT02723630|Experimental|Sequence F|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
9835090|NCT02723786|Experimental|GSK1070806 3 mg/kg IV|Subjects received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Subjects also received a combination immunosuppression comprized of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.
9835091|NCT02723916|Experimental|Intervention: ezParent Program|
9835092|NCT02723916|Active Comparator|Control: Health-e Kids App|
9835093|NCT02723929|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
9835094|NCT02723929|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
9835095|NCT02724020|Active Comparator|Arm A: Single-agent Everolimus 10 mg QD|Everolimus 10 mg capsules, orally, once daily in a 28-day treatment cycle until disease progression, consent withdrawal, death, or transfer to the Post-trial Access (PTA) program (Median duration of treatment was 15.43 weeks up to end of study).
9835096|NCT02724020|Experimental|Arm B: Single-agent MLN0128 30 mg QW|MLN0128 30 mg capsules, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.64 weeks up to end of study).
9835097|NCT02724020|Experimental|Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD|MLN0128 4 mg and MLN1117 200 mg capsules, orally, both once daily for 3 days per week (QD X 3) on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.43 weeks up to end of study).
9835098|NCT02724033|Active Comparator|Group A|Group A - regional nerve block
9835099|NCT02724033|Active Comparator|Group B|Group B - antiemetic
9835100|NCT02724033|Active Comparator|Group C|Group C - block and antiemetic
9835101|NCT02724111|Experimental|deep neuromuscular blockade|This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade [NMB] (train-of-four [TOF] count 0, post-tetanic count [PTC] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
9835102|NCT02724111|Active Comparator|restricted neuromuscular blockade|This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade [NMB] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change [a prone position]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.
9835103|NCT02724423|Experimental|NRL-1 Ictal|During the ictal or peri-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
9835104|NCT02724423|Experimental|NRL-1 Inter-Ictal|During the inter-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
9835105|NCT02724449|Experimental|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
9835106|NCT02724462|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
9835107|NCT02724462|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
9835108|NCT02724592|Experimental|intervention|intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
9835109|NCT02724592|Active Comparator|control|control group, only Fluoride varnish (Duraphat®)
9835110|NCT02724644|Experimental|EN3835 Active|EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
9835111|NCT02724644|Placebo Comparator|EN3835 Placebo|Placebo
9835112|NCT02724787|Other|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
9835113|NCT02724800|Active Comparator|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
9835114|NCT02724800|Active Comparator|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
9835115|NCT02724839|Experimental|Biweekly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place biweekly.
9835116|NCT02724839|Experimental|Monthly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place monthly.
9835117|NCT02724839|Experimental|Weekly|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place weekly.
9835118|NCT02724956|Experimental|Ambu AuraGain|"SGAD placement using Ambu AuraGain~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
9835119|NCT02724956|Experimental|Teleflex LMA Protector|"SGAD placement using the Teleflex LMA Protector~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
9835120|NCT02725008|Active Comparator|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
9835121|NCT02725008|Experimental|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
9835122|NCT02725268|Experimental|Paclitaxel 80 mg/m^2|Paclitaxel 80 milligrams per square meter (mg/m^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).
9835123|NCT02725268|Experimental|Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg|Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).
9835124|NCT02725268|Experimental|Sapanisertib 30 mg|Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).
9835125|NCT02725268|Experimental|Sapanisertib 4 mg + MLN1117 200 mg|Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).
9835126|NCT02725411|Active Comparator|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
9835127|NCT02725411|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
9835128|NCT02725411|Experimental|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
9835129|NCT02725476|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
9835130|NCT02725515|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 16 infusions
9835131|NCT02725515|Placebo Comparator|Placebo|Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
9835132|NCT02725645|Experimental|Healthy school children|elementary school children will be presented with different backpack loading conditions
9835133|NCT02725710|Active Comparator|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
9835134|NCT02725710|Active Comparator|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
9835135|NCT02725788|Experimental|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
9835136|NCT02725788|Other|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
9835137|NCT02725801|Active Comparator|one-port|intervention is placement of one-port tissue expander at time of reconstruction
9766793|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - only face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have only face-to-face evaluation
9766794|NCT04802057|Experimental|BIVV020|Repeat dose of BIVV020
9766795|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 1 and test drug 2|
9766796|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 3 and test drug 4|
9766797|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 5 and test drug 6|
9766798|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 7|
9766799|NCT04792684||Arm A.|Subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC still not resected and scheduled for surgery
9766800|NCT04792684||Arm B|Subjects at average-risk for CRC and scheduled for CRC screening colonoscopy
9766801|NCT04791891||Low Back Pain (LBP)|"Adult women and men with self-reported LBP.~Inclusion Criteria for potential LBP participants~At least 18 years old;~Internet access;~Fluent in English or French;~Self-reported LBP.~Exclusion Criteria: No exclusion criteria will be adopted in this study.~No exclusion criteria will be adopted in this study"
9766802|NCT04787744|Active Comparator|Standard Systemic Therapy (SST)|All Veterans will receive SST
9766803|NCT04787744|Experimental|SST + PET-directed local therapy|"In addition to SST, all Veterans will receive PET-directed local therapy to all metastases using surgery or radiation. The selection of surgery or radiation to each metastasis will be determined using shared decision-making between the physician and Veteran.~For Veterans with a local recurrence, this will be treated with salvage local therapy."
9766804|NCT04785144|Experimental|Arm 1A|50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
9766805|NCT04785144|Experimental|Arm 1B|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
9766806|NCT04785144|Experimental|Arm 2A|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
9766807|NCT04785144|Experimental|Arm 2B|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
9766808|NCT04785144|Experimental|Arm 2C|100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
9766809|NCT04785144|Experimental|Arm 2D|50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
9766810|NCT04785144|Experimental|Arm 2E|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
9766811|NCT04785144|Experimental|Arm 2F|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
9766812|NCT04785144|Experimental|Arm 2G|50 mcg of mRNA-1273 and 50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
9766813|NCT04785144|Experimental|Arm 2H|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
9766814|NCT04782895|Experimental|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group|Subjects would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
9766815|NCT04782895|Active Comparator|Gardasil®9 group|Subjects would receive 3 doses of 270μg/0.5ml Gardasil®9 .
9766816|NCT04775719|Other|Outcome Prediction Group|Patient-Specific Prediction of Functional Outcome and Standard Pre-Operative Total Knee Arthroplasty Information
9766817|NCT04775719|Other|Standard Care Group|Standard Pre-Operative Total Knee Arthroplasty Information
9766818|NCT04767984|Experimental|Arm I (atorvastatin, biospecimen collection)|Patients receive atorvastatin PO QD for 12 months.
9766819|NCT04767984|Placebo Comparator|Arm II (placebo, biospecimen collection)|Patients receive placebo PO QD for 12 months.
9766820|NCT04760275|Active Comparator|Medication - Fluoxetine|"Approved medication by the U.S. Food and Drug Administration (FDA) for treating anxiety disorders in children.~The study's starting dose, and minimum permitted, will be 10 mg/day; should that not be tolerated, the patient will be withdrawn from active treatment (but not from study follow-up). After 1 week at 10 mg/day, the dose will increase to 20 mg/day. After completion of week 4, 10 mg/day dose increases will be permitted every other week as tolerated, up to a maximum daily dose of 80 mg/day. If patients are on doses >20mg/day, the total daily dose can be prescribed either once daily or split into twice daily administrations."
9766821|NCT04760275|Active Comparator|Cognitive Behavioral Therapy (CBT)|"Type of talk therapy that aims to identify and replace negative thoughts, using positive behavioral skills to create and maintain positive moods and healthy relationships.~The Coping Cat (CC) program will be used as the behavioral intervention for this study.CC is an established evidence-based CBT treatment for pediatric anxiety. It is delivered in individual therapy sessions with anxious children."
9766822|NCT04756869||Health Care Workers at Risk for COVID-19|Health care workers at risk for COVID-19 will be monitored using wearing sensors and smartphone technology.
9766823|NCT04751786|Experimental|PRECIOUS-01|Eligible subjects will receive three i.v. infusions of PRECIOUS-01 at a 3-weekly interval in three dose-finding cohorts (low: 0.4 mg/kg, intermediate: 0.8 mg/kg, and high: 1.6 mg/kg fixed doses). Subjects will be monitored for safety and the occurrence of Dose-Limiting Toxicities (DLTs). A 3+3 design is used for the dose escalation steps. Three subjects will be enrolled sequentially per cohort. If the maximum tolerated dose (MTD) is not reached in the planned dose escalation cohorts, the RP2D will be based on the observed safety and immune modulatory activity as pharmacodynamic parameter supporting the RP2D. The sample size is based on the determination of the MTD/RP2D. In order to collect sufficient information regarding changes in immune related parameters as readout for pharmacodynamics of the particles, it is planned to extend the two highest dosing cohorts to a total of six subjects or to extend the highest dosing cohort to a total of nine subjects, depending on observed toxicity
9766824|NCT04747613|Experimental|Iptacopan|Participants will be receiving open label oral iptacopan 200 mg b.i.d monotherapy
9766825|NCT04745169|Other|Intervention|Participants will be asked to complete an 8-week home-based exercise intervention
9766826|NCT04742283|Experimental|DE-126 Opthalmic Solution 0.002% QD and Vehicle QD|DE-126 Ophthalmic Solution 0.002% is administered once daily (QD)
9766827|NCT04742283|Active Comparator|Timolol Maleate Opthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution 0.5% is administered twice daily (BID)
9766828|NCT04740164|Experimental|Arm I (ERCP with LMA Gastro)|Patients undergo ERCP with LMA Gastro.
9766829|NCT04740164|Active Comparator|Arm II (ERCP with standard nasal cannula)|Patients undergo ERCP with standard nasal cannula.
9766830|NCT04736303|No Intervention|POD without BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery, with CAM and Nu-DESC tools.
9766831|NCT04736303|Active Comparator|POD with BIS|Assessing the incidence of POD in patients under general anethesia for elective non cardiac surgery with the implementation of BIS monitoring, with CAM and Nu-DESC tools.
9766832|NCT04729725|Experimental|Treatment (SAR439459, cemiplimab)|Patients receive SAR439459 IV over 30 minutes on day 1 and cemiplimab IV over 30 minutes on day 1 starting cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9766833|NCT04720911|Experimental|In-person TASCS|This intervention is designed to assess the TASCS app administered via an in-person clinician in the ED, with follow-up telephone calls by a clinician
9766834|NCT04720911|Active Comparator|Telehealth TASCS|This comparison condition is designed to assess the telehealth modality of TASCS in the ED (in contrast to in-person clinician modality), with follow-up telephone calls by a clinician
9766835|NCT04720911|Active Comparator|Self-administered TASCS|This comparison condition is designed to assess the self-administered modality of TASCS (in contrast to clinician modality), with follow-up telephone calls by a clinician
9766836|NCT04719143|Active Comparator|CBT-I|
9766837|NCT04719143|No Intervention|Waitlist Control|
9766838|NCT04718909|Experimental|Regorafenib + sintilimab|Regorafenib combined with sintilimab.
9766839|NCT04718909|Active Comparator|Regorafenib|Regorafenib alone.
9766840|NCT04703335|Experimental|Non-inferiority and Persistence|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution).
9766841|NCT04699890||preserved ejection fraction|Patients with a preserved ejection fraction (HF / FEp)
9766842|NCT04699890||reduced ejection fraction|Patients with a reduced ejection fraction (HF / FEr)
9766843|NCT04699890||without heart failure|Patient without heart failure
9766844|NCT04699266|Experimental|Experimental: POD F GF IOL Implantation|Experimental: POD F GF IOL Implantation experimental Multi-center, single-arm, non-masked study Mono- or bilateral implantation of trifocal intraocular lenses POD F GF
9766845|NCT04695301|Experimental|digital platform rehabilitation|Rehabilitation program through a digital platform for 3 months
9766846|NCT04695301|Experimental|control group|Patients without access to technology will do the exercises using booklets and will compose the control group
9766847|NCT04694976||Sickle cell disease children from Lyon, France|Sickle cell disease children, followed in IHOPe (Institut d'Hématologie et d'Oncologie Pédiatrique) center, consulting their referring haematologist doctor or in emergency ward, with prescribed blood sample.
9766848|NCT04691635||Group 1|Patients with Progressive Supranuclear Palsy
10203533|NCT05199896|Experimental|Behavioral protocol and fMRI protocol|"Participants who agree to participate in only one of the experiments (EEG or MRI) will be randomly (by a randomization list) assigned to either the EEG or fMRI type of study in each subgroup.~All participants (non-sighted participants and Healthy volunteers) will do the behavioral session and at least one EEG or MRI session depending on randomization."
10203534|NCT05199870||Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head|Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head to repair hip malfunction/disease/injury.
10203535|NCT05199831||Participants living with HIV|Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity
10203536|NCT05199831||Controls not infected with HIV|Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity
10203537|NCT05199805|Experimental|Mindfulness-based pain management|The program consists of sessions of 150 minutes once a week over the course of 8 weeks. Treatment as usual is allowed.
10203538|NCT05199805|No Intervention|Waiting-List|The control group will receive no active intervention in addition to treatment as usual during the study period.
10203539|NCT05199792||2x dose of Dotarem|qualifying MRA
10203540|NCT05199766|Experimental|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks, in case of discontinuation due to patient's wishes and/or adverse event above grade 2 : 1000mg during 14 days then complete discontinuation if no resolution. In case of sudden discontinuation a therapeutic phlebotomy will be authorized.
10203541|NCT05199740||mtDNA mutation carriers|Carriers of a pathogenic mtDNA mutation
10203542|NCT05199727|Experimental|Shockwave group|This group will receive 6 sessions (2 per week) with average 6,000 shocks per session with the PiezoWave2 unit
9766849|NCT04691635||Group 2|Patients with Parkinson's disease
9766850|NCT04691635||Group 3|Healthy controls
9766851|NCT04690530||patients admitted in medical intensive care unit who require mechanical ventilation and sedation|The main goals of the study are to characterize cerebral hemodynamics and oxygenation as well as to study the effects of therapeutics on it in critically-ill patients. For this purpose, we plan to include all consecutive patients admitted in our medical intensive care unit who require mechanical ventilation and sedation and in whom the attending physician decides to perform one of the studied therapeutics (fluids, vasopressors or inotropes administration, blood transfusion, prone positioning, passive leg raising test, end-expiratory occlusion test) within the first 72h of ventilation onset. Cerebral hemodynamics (cerebral blood flow and cerebral autoregulation) as well as cerebral oxygenation will be non-invasively studied before and after therapeutics.
9766852|NCT04661280|No Intervention|Cognitive remediation|Non-drug treatment, cognitive remediation, cognitive stimulation
9766853|NCT04661280|Experimental|Cognitive remediation + Donepezil|Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
9766854|NCT04659421|Experimental|Low-grade gliomas|Treated with Recombinant human endostatin, Carboplatin, and Vincristine
9766855|NCT04655924|Experimental|Active Intervention|Intervention delivered to patients by digital health platform.
9766856|NCT04655924|Active Comparator|Active Control|Intervention delivered to patients by digital health platform.
9766857|NCT04645550|Experimental|Apixaban with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Apixaban 2.5mg bid for six months.
9766858|NCT04645550|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for six months irrespective of the occurrence of portal vein thrombus.
9766859|NCT04645550|Experimental|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for six months.
9766860|NCT04643015||Study Participants|Patients of any age, including males and females, who are being treated in the Department of Pediatrics and are already scheduled to undergo MRI
9766861|NCT04641260|Experimental|Fezolinetant: Fed State then Fasted State|Participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 2.
9766862|NCT04641260|Experimental|Fezolinetant: Fasted State then Fed State|Participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 2.
9766863|NCT04640974|Experimental|Cingal|
9766864|NCT04640961|Experimental|Cingal|
9766865|NCT04640298|Experimental|Cingal|
9766866|NCT04639622|Other|asymptomatic at-risk individual|First-degree relative of a family member affected with the frontotemporal dementia.
9766867|NCT04639622|Other|symptomatic individual|Patient who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum
9784247|NCT01220739|Active Comparator|IV tPA +Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
9784248|NCT01220856|Experimental|Reparixin|"Reparixin + Immunosuppression~Reparixin was administered at a dose of 2.772 mg/kg body weight/hour for 7 days (168 hours) at each transplant. It was administered as a continuous IV infusion into a (high-flow) central vein. Investigational Product infusion was to begin approximately 12 hours (range between 6 to 16 hours) before each pancreatic islet infusion was started. The Investigator identified the time to start study drug administration.~Reparixin was given to all patients of this arm using the same dosing solution (reparixin 11.00 mg/mL), but the pump rate was adjusted to provide an infusion rate of approximately 0.25 mL/kg/hour.~For immunosoppression regimen see the other arm description."
9784249|NCT01220856|No Intervention|No experimental intervention|Immunosuppression only. Induction: First islet infusion: anti-thymocyte globulin (ATG), administered IV (central vein) at the dose of 1.5 mg/kg on Day -1, 0, 1, and 2 of islet infusion. The first ATG injection was preceded by a bolus IV injection of 500 mg methylprednisolone. Induction for the second islet infusion was to be administered per center practice. Maintenance: Mycophenolate mofetil (MMF), administered orally at the dose of 1 g twice a day, starting on Day -1 of the first islet infusion; Tacrolimus, administered orally starting on Day -1 of the first islet infusion at a dose of 0.087 mg/kg twice a day. Thereafter, dosing was to be targeted to blood trough levels of 8 to 10 ng/mL. Administration continued up to Month 3 after the first transplant. Rapamycin was to replace tacrolimus from Month 3 after the first transplant. It was to be administered orally at the starting dose of 0.1 mg/kg once a day, then targeted to a blood trough level of 10 to 12 ng/mL.
9784250|NCT01220869|Experimental|Degarelix|
9784251|NCT01220973|Experimental|Atorvastatin and Celecoxib|
9784252|NCT01220999|Experimental|Cohort 1|Subjects received an initial loading dose of 111^In-CS-1008 (0.2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
9784253|NCT01220999|Experimental|Cohort 2|Subjects received an initial loading dose of 111^In-CS-1008 (1 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
9766868|NCT04638062|Experimental|Post Isometric Relaxation|"This study ARM will receive following therapies~Post isometric relaxation (Upper Trapezius and Levator Scapulae muscles)~Isometric neck strengthening exercises~Cryotherapy"
9766869|NCT04638062|Experimental|Myofascial Release Therapy|"This study ARM will receive following therapies~Myofascial release therapy (Upper Trapezius and Levator Scapulae muscles~Isometric neck strengthening exercises~Cryotherapy"
9766870|NCT04634227|Experimental|Gemcitabine + High-Dose Ascorbate|Ascorabte is administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator. Treatment will be terminated with progression of disease. Disease will be assessed by CT of the chest, abdomen and pelvis or MRI of the lesion every 2 cycles for progression.
9766871|NCT04634071|Experimental|Group 1: Varenicline, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766872|NCT04634071|Experimental|Group : Varenicline, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766873|NCT04634071|Experimental|Group 3: Varenicline, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766874|NCT04634071|Experimental|Group 4: Varenicline, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766875|NCT04634071|Experimental|Group 5: Buproprion, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766876|NCT04634071|Experimental|Group 6: Buproprion, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766877|NCT04634071|Experimental|Group 7: Buproprion, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766878|NCT04634071|Experimental|Group 8: Buproprion, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766879|NCT04634071|Experimental|Group 9: Nicotine, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766880|NCT04634071|Experimental|Group 10: Nicotine, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766881|NCT04634071|Experimental|Group 11: Nicotine, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766882|NCT04634071|Experimental|Group 12: Nicotine, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
9766883|NCT04630483||Group I: INHA|Inhalational anesthesia (INHA)
9766884|NCT04630483||Group II: TIVA|Total intravenous anesthesia (TIVA)
9766885|NCT04623801|Experimental|Participants with papillary microcarcinoma (PTMC)|Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.
9766886|NCT04622150|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the experimental intervention, Customized Adherence Enhancement (CAE).
9766887|NCT04622150|Active Comparator|Enhanced Treatment as Usual (eTAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (eTAU).
9766888|NCT04617548|Experimental|tDCS and CO-OP Group|One-hour session three times per week for 4 weeks. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. Following each tDCS session, the participants will complete a sensations questionnaire.The basis for each session will be task-based practice of client-chosen goals and the use of cognitive strategies using CO-OP.
9835138|NCT02725801|Active Comparator|two-port|intervention is placement of two-port tissue expander at time of reconstruction
9835139|NCT02725866||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
9835140|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
9835141|NCT02726074|Experimental|Perampanel 12 mg|During the Titration Period, participants will receive perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.
9836056|NCT02767843|Experimental|treatment|continuous negative external pressure (cNEP) at various negative pressures
9836057|NCT02767869|Experimental|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
9836058|NCT02767869|Placebo Comparator|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
9836059|NCT02767934|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
9836060|NCT02767947|Experimental|Luliconazole Cream 1%|Luliconazole cream 1% will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
9836061|NCT02767947|Placebo Comparator|Vehicle Cream|Vehicle cream (containing no active ingredient) will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
9836062|NCT02768103|Experimental|SCI transfer + training|Individuals with tetraplegia and brachioradialis to flexor pollicis longus transfer will participate in 10 week home training program to improve surgical outcome (pinch strength)
10203543|NCT05199727|Active Comparator|Medical Treatment Group|This group will receive self-administered Tadalafil on-demand
9836063|NCT02768129|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
9836064|NCT02768129|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
9836065|NCT02768194|Experimental|Test Product (0.454% stannous fluoride)|Participants will use dentifrice containing 0.454% stannous fluoride. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
9836066|NCT02768194|Active Comparator|Reference Product (0.76% sodium monofluorophosphate)|Participants will use dentifrice containing 0.76% sodium monofluorophosphate. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
9836067|NCT02768194|Other|Negative Control (Mineral water)|Participants will use commercially available mineral water. Appliances brushed ex situ in mineral water twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in mineral water. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
9836068|NCT02768298|Experimental|LCZ696|LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.
9836069|NCT02768298|Active Comparator|Enalapril|"Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
9836070|NCT02768558|Experimental|Nivolumab|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
9836071|NCT02768558|Placebo Comparator|Placebo|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
9836072|NCT02768753|Experimental|The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
9836073|NCT02768753|Experimental|The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
10203544|NCT05199675|Experimental|Digital Peer Support Training Program|The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments. The pre-post with control evaluation design will be utilized to evaluate program outcomes. Fidelity will be the primary outcome assessed to demonstrate the effectiveness of the digital peer support training program. It will be measured by the extent to which adolescents' responses to real-cases of peer disclosure indicate Mattering, selfhood, compassion and mindfulness. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes. Cost-effectiveness analysis will inform the development of a scalability and sustainability plan.
9766889|NCT04617275|Experimental|Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
9766890|NCT04617275|Experimental|Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
9766891|NCT04617275|Experimental|Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
9766892|NCT04617275|Experimental|Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
9766893|NCT04617275|Placebo Comparator|Arm 5 - Placebo in subjects with T2DM and Obesity|Matching Placebo tablets taken twice a day (BID)
9766894|NCT04617275|Experimental|Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
9766895|NCT04617275|Experimental|Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
9766896|NCT04611568|Experimental|Prevention (health educational campaign)|"MEDIA CAMPAIGN: Participants view digital media strategies.~PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.~MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.~HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture."
9766897|NCT04609514|Experimental|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
9766898|NCT04609514|Active Comparator|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
9766899|NCT04608201|Experimental|NICOTINE transdermal patch|NICOTINE 7 mg / 24h, transdermal patch
9766900|NCT04608201|Placebo Comparator|Placebo of NICOTINE transdermal patch|Placebo of nicotine patch
9766901|NCT04604093||SMBG, self-monitoring of blood glucose|Subjects will be randomized to continue use traditional SMBG, self-monitoring of blood glucose, to manage their diabetes.
9766902|NCT04604093||FreeStyle Libre 2|Subjects will be randomized to use the FreeStyle Libre 2 Flash Glucose Monitoring System to manage their diabetes.
9766903|NCT04603248|Experimental|Single Arm|
9766904|NCT04597944||Participants with Hereditary or Acquired Angioedema|Participants older than 18 years that are diagnosed with Hereditary or Acquired Angioedema and treated by lanadelumab.
9766905|NCT04594902|Experimental|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
9784254|NCT01220999|Experimental|Cohort 3|Subjects received an initial loading dose of 111^In-CS-1008 (2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
9835142|NCT02726113|Active Comparator|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
9835143|NCT02726113|Placebo Comparator|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
9835144|NCT02726178|Experimental|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
9835145|NCT02726178|Placebo Comparator|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
9835146|NCT02726451|Placebo Comparator|Basic Skin Care|Subjects use a basic skin care regimen.
9835147|NCT02726451|Active Comparator|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products in additional to a basic skin care regiment.
9835148|NCT02726542|Experimental|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
9835149|NCT02726542|No Intervention|No treatment|(no study treatment - observation only)
9835150|NCT02726620|Experimental|Hypotension decision support|"The intervention period. Several decision support elements are implemented to notify anesthesia providers: attending anesthesiologists and in-room anesthesia providers of intraoperative hypotension (threshold of a mean arterial pressure below 60 mmHg). Two types of decision support will be implemented: near real-time decision support and feedback emails.~Near real-time decision support elements will notify the anesthesia providers of a blood pressure drop below the threshold and display the associated increased risk of acute kidney injury. The notification is presented through the pager system for attending anesthesiologists and through the anesthesia information management system for the in-room anesthesia provider.~All providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension that is associated with an increased risk of organ injury due to organ ischemia."
9835151|NCT02726620|Active Comparator|Usual care group|The 'before' period - or historic control group - during which no decision support for intraoperative hypotension was being used, also known as 'usual care'. This is the three year period prior to the intervention period (the 'Intraoperative hypotension decision support' arm).
9835152|NCT02726789|Experimental|Experimental|Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.
9835153|NCT02726945|Experimental|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
9835154|NCT02726945|Experimental|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
9835155|NCT02726945|Placebo Comparator|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
9835156|NCT02726971|Experimental|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
9835157|NCT02726971|Active Comparator|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
9835158|NCT02727192|Active Comparator|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
9835159|NCT02727192|No Intervention|Control group|No sleep apnea treatment
9835160|NCT02727322|Active Comparator|Nitrofurantoin|Receives once daily nitrofurantoin 100mg
9835161|NCT02727322|Placebo Comparator|Placebo|Receives matching placebo
9835162|NCT02727660|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
9835163|NCT02727660|Experimental|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
9835164|NCT02727660|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
9835165|NCT02727699|Experimental|Xanamem™|Oral Xanamem™ capsules 10mg, to be administered once daily
9835166|NCT02727699|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily
9835167|NCT02727751|Experimental|50mg BID|Tenapanor, 50 mg BID (100 mg total)
9835168|NCT02727777|Experimental|Aggressive Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Aggressive NHL: Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Transformed Large Cell Lymphoma, and Follicular Lymphoma (FL) grade 3b Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
9835169|NCT02727777|Experimental|Indolent Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Indolent NHL: Follicular Lymphoma (FL) grade 1-3a, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
9835170|NCT02727777|Experimental|Hodgkin Lymphoma - TAK228|"Phase II - Hodgkin Lymphoma Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
9835171|NCT02727816|Experimental|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
9835172|NCT02727816|Experimental|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
9835173|NCT02727816|Experimental|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
9835174|NCT02727816|Experimental|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
9835175|NCT02727842|Experimental|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
9835176|NCT02727894||Screening Group|CRC diagnosed by screening was defined as cancer diagnosed by primary screening colonoscopy, or colonoscopy after a positive immunochemical based faecal occult blood test i(FOBT) in patients without symptoms invited to examination according to the national screening programme policy
9835177|NCT02727894||Non-screening Group|Symptomatic CRC was defined as cancer diagnosed in symptomatic patients.
9835178|NCT02728089|Experimental|MK-7625A|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion every 8 hours for 7 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
9835179|NCT02728102|Experimental|Lenalidomide, vaccine, and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.
9835180|NCT02728102|Active Comparator|Lenalidomide and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.
9835181|NCT02728102|Active Comparator|Maintenance Lenalidomide|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.
9835182|NCT02728206|Experimental|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
9835183|NCT02728830|Experimental|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
9835184|NCT02728895|Experimental|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
9835185|NCT02728895|Experimental|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
9835186|NCT02728895|Experimental|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
9835187|NCT02729025|Placebo Comparator|Placebo|Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
9835188|NCT02729025|Experimental|Evolocumab 420 mg QM|Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
9835189|NCT02729038|Experimental|Part 1: Subjects with normal renal function (Group A)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
9835190|NCT02729038|Experimental|Part 1: subjects with moderate renal impairment (Group B)|Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
9835191|NCT02729038|Experimental|Part 1: subjects with severe renal impairment (Group C)|Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
9835192|NCT02729038|Experimental|Part 2: subjects with normal renal function (Group D)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
9835193|NCT02729038|Experimental|Part 2: subjects with mild renal impairment (Group E)|Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
9835194|NCT02729038|Experimental|Part 2: subjects with ESRD on hemodialysis (Group F)|Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
9835195|NCT02729051|Experimental|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9835196|NCT02729051|Active Comparator|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9836192|NCT02774226|Experimental|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
10205327|NCT02764489|Experimental|Part 1 Reduced then regular volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA Reconstituted in 50% Reduced Volume then FEIBA Reconstituted in Regular Volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
9835197|NCT02729194|Experimental|Pazopanib|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.
9835198|NCT02729545|Experimental|Tung's acupuncture|The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
9835199|NCT02729545|Active Comparator|CPA/EE|Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
9835200|NCT02729740|Other|Penumbra Smart System|
9835201|NCT02729831|Experimental|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
9835202|NCT02729831|Experimental|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
9835203|NCT02729831|Experimental|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
9835204|NCT02729831|Experimental|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
9835205|NCT02729896|Experimental|Dose-Escalation Phase|During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months, during maintenance treatment for FL participants.
9835206|NCT02729896|Experimental|Expansion Phase|For FL during the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola at identified RP2D (decided from dose-escalation phase) on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1 and Pola at RP2D on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months (during maintenance treatment for FL participants).
9835207|NCT02729896|Experimental|Safety Run-In Phase|For DLBCL, during the induction treatment Cycles 1-6 (21-day cycles): participants will receive rituximab on Day 1 and Pola on Day 1.
9835208|NCT02729909|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
9835209|NCT02729909|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
9835210|NCT02730169|Experimental|BGS649 0.1 mg|BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
9835211|NCT02730169|Experimental|BGS649 0.3 mg|BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
9835212|NCT02730169|Experimental|BGS649 1.0 mg|BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
9835213|NCT02730169|Placebo Comparator|Placebo|Placebo weekly (3 indistinguishable placebo capsules)
9835214|NCT02730195|Experimental|Pioglitazone & TKI therapy|Patients receive pioglitazone PO QD on days 1-28. Patients also start or continue the same tyrosine kinase inhibitor (TKI) therapy at the pre-discontinuation doses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
9835215|NCT02730208|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.
9835216|NCT02730208|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.
9835217|NCT02730234|Experimental|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
9835218|NCT02730247|Experimental|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
9835219|NCT02730260|Active Comparator|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
9835220|NCT02730260|Experimental|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
9835221|NCT02730351|Experimental|FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®|Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.
9835222|NCT02730351|Experimental|FP 250 mcg + Placebo ELLIPTA®|Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.
9835223|NCT02730377|Experimental|Liraglutide 1.8 mg|Add-on to metformin
9766906|NCT04594902|Active Comparator|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
9766907|NCT04591925|Experimental|"Investigative Device - SteadiSet™ device with coil-reinforced soft polymer indwelling cannula"|Participants are randomized into the investigational device (SteadiSet™) insulin infusion set group and then switched to a Commercially available infusion set (using a soft Teflon indwelling cannula) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the investigational infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Control device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
9766908|NCT04591925|Active Comparator|Commercially available Insulin Infusion device using a soft Teflon indwelling cannula|Participants are randomized into the Commercially available insulin infusion set (using a soft Teflon indwelling cannula) group and then switched to Investigative Device infusion set (SteadiSet™) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the Control infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Investigational Device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
9766909|NCT04581629|Experimental|CLTX-305|CLTX-305 (encaleret) dose finding study to determine safety, tolerability and dose response during three (3) periods and a long term extension of this study with dose levels at QD and BID; up to 41 months of active treatment per participant
9766910|NCT04581460||Patients|Patients entered in the register of the reference Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris, and having reported at least one pregnancy or attempted pregnancy
9766911|NCT04572256|Experimental|Montelukast|Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
9766912|NCT04572256|Placebo Comparator|Placebo|Patients will receive an oral placebo daily for 6 months after surgery.
9766913|NCT04565730|Active Comparator|Grup I= General anesthesia group|After applying standard ASA monitoring; 2-2,5 mg/kg propofol, and 0,6 mg/kg rocuronium IV will be performed for general anesthesia induction, and then orotracheal intubation will be performed. The patients will be placed in the supine position. General anesthesia will be maintained with sevoflurane in the mixture of oxygen-fresh air. Controlled mechanical ventilation will be initiated with a tidal volume of 8-10 ml/kg at 12 breaths per minute (I:E ratio 1:2), a fresh gas flow rate of 2 L per min, end tidal CO2 value at 30-35 mmHg, and peak airway pressure of maximally 30 cm H2O. All patients will undergo cesarean delivery surgery with the same technique by the same surgical team.
9766914|NCT04565730|Active Comparator|Grup II= Spinal anesthesia group|A standardized spinal anesthesia will administrated to the patients. After skin disinfection, 25G needle will used for puncture at the level of L2-L3 or L3-L4. After observing the cerebrospinal fluid, 15 mg bupivacaine (marcain spinal heavy) will be administered into the subarachnoid space. The level of anesthesia below T6 will be controlled.
9766915|NCT04562467|Experimental|Icosapent Ethyl + Standard of Care|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] 2 x 1g capsules BID (4g total) as per REDUCE-IT
9766916|NCT04562467|No Intervention|Standard of Care|Standard of care therapy (including statin therapy as per inclusion criteria)
9766917|NCT04550481|Experimental|Prevention (lisinopril)|Patients receive lisinopril PO QD for 24 weeks in absence of unacceptable toxicity.
9766918|NCT04539275|Experimental|Convalescent Plasma|The study intervention consists of intravenous administration of 200-500mL of convalescent plasma administered in two equally divided doses, less than 12 hours apart.
9766919|NCT04539275|Placebo Comparator|Masked Saline Placebo|The study intervention consists of intravenous administration of 200-500mL of 0.9% saline administered in two equally divided doses, less than 12 hours apart.
9766920|NCT04537156|Experimental|HPV vaccine (6,11,16,18,31,33,45,52,58 Types)|Participants in this arm would receive 270μg/0.5ml HPV vaccines (6,11,16,18,31,33,45,52,58 Types).
9766921|NCT04537156|Active Comparator|HPV vaccine (16,18 Types)|Participants in this arm would receive 60μg/0.5ml HPV vaccines (16,18 Types).
9766922|NCT04528719|Experimental|Cohort 1: Dose A in Younger Adults|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
9766923|NCT04528719|Experimental|Cohort 2: Dose B in Younger Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
9766924|NCT04528719|Experimental|Cohort 3: Dose B in Younger Adults|Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
9766925|NCT04528719|Experimental|Cohort 4: Dose C in Younger Adults|Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.
9766926|NCT04528719|Experimental|Cohort 5: Dose D in Children|Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
9766927|NCT04528719|Experimental|Cohort 6: Dose G in Children|Three total injections, 1 injection of either Dose G of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
9766928|NCT04528719|Experimental|Cohort 7: Dose A in Older Adults|Two total injections, 1 injection of either Dose A of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
9766929|NCT04528719|Experimental|Cohort 8: Dose B in Older Adults|Two total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
9766930|NCT04528719|Experimental|Cohort 9: Dose C in Older Adults|Two total injections, 1 injection of either Dose C of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
9766931|NCT04528719|Experimental|Cohort 10: Dose E in Older Adults|Two total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
9766932|NCT04528719|Experimental|Cohort 11: Dose F in Older Adults|Two total injections, 1 injection of either Dose F of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.
9766933|NCT04528719|Experimental|Cohort 12: Dose E in Women of Child-Bearing Potential|Single injection of Dose E of mRNA-1345 or matching-placebo on Day 1.
9766934|NCT04528719|Experimental|Cohort 13: Dose F in Women of Child-Bearing Potential|Single injection of Dose F of mRNA-1345 or matching-placebo on Day 1.
9766935|NCT04528719|Experimental|Cohort 14: Dose A in Women of Child-Bearing Potential|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
9766936|NCT04528719|Experimental|Cohort 15: Dose B in Japanese Older Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
9766937|NCT04526691|Experimental|Datopotamab deruxtecan (Dato-DXd)|Dose Escalation and Dose Expansion: Datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic NSCLC
9766938|NCT04524689|Experimental|Tusamitamab ravtasine + Pembrolizumab|Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
9766939|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + carboplatin|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
9766940|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + cisplatin|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
9766941|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + carboplatin + pemetrexed|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
9766942|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + cisplatin + pemetrexed|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
9766943|NCT04501718|Experimental|Test group|
9766944|NCT04501705|Experimental|test group|
9766945|NCT04494945|Other|Screening (genetic testing)|Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
9766946|NCT04490018|Experimental|Group 1 (investigational group - sequential administration)|MenACYW conjugate vaccine on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
9766947|NCT04490018|Active Comparator|Group 2 (control group - sequential administration)|Nimenrix® on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
9766948|NCT04490018|Experimental|Group 3 (investigational group - concomitant administration)|MenACYW conjugate vaccine + 9vHPV* + Tdap-IPV vaccines on Day 01: n=116
9766949|NCT04481490||Home-based|Cardiac rehabilitation (including exercise training) delivered in a home-based setting, facilitated remotely by Mayo Clinic staff.
9766950|NCT04481490||Center-based|Cardiac rehabilitation (including exercise training) delivered in a center-based setting, facilitated in person by Mayo Clinic staff.
9766951|NCT04468672|Active Comparator|Day worker|Men and women who work only day shift for at least 3 consecutive days of the week
9766952|NCT04468672|Active Comparator|Night worker|Men and women who work only night shift for at least 3 consecutive days of the week
9766953|NCT04458532|Experimental|(A) breast cancer after completion of chemo|300 min/wk for 16 weeks, followed by 16 weeks of usual care.
9766954|NCT04458532|Experimental|(B) breast cancer after completion of chemo|150 min/wk for 32 weeks.
9766955|NCT04458532|Experimental|(C) breast cancer after completion of chemo|300 min/wk for 32 weeks.
9766956|NCT04458532|Active Comparator|(D) breast cancer after completion of chemo|150 min/wk for 16 weeks, followed by 16 weeks of usual care.
9766957|NCT04425629|Experimental|casirivimab+imdevimab low dose|Low dose or body-weight equivalent for those under 18 years of age.
9984277|NCT04265365|Experimental|rTMS+rPMS_cTBS_M/U|In this group, they received iTBS on affected hemisphere after following cTBS at median/ulnar nerve on affected hand.
9766960|NCT04410406|Active Comparator|IA (Ivermectin + Albendazole)|Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
9766961|NCT04410406|Active Comparator|MoxA (Moxidectin + Albendazole)|Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
9766962|NCT04410406|Active Comparator|IDA (Ivermectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
9766963|NCT04410406|Active Comparator|MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.
9766964|NCT04402281||suPAR algoritm control|Control arm (Meilahti hospital): Samples are collected and suPAR measured but no algorithm is implemented.
9766965|NCT04402281||suPAR algoritm intervention|"Intervention arm (Jorvi Hospital).~According the algorithm when admitting a patient with suPAR below 3 ng/ml, physician should answer the following question~Are you sure it is the right decision to admit this patient? Please discuss this with a senior physician.~If discharging a patient with suPAR above 6 ng/ml, physician should answer the following question~Are you sure it is the right decision to discharge this patient? Please discuss this with a senior physician."
9766966|NCT04401891|No Intervention|Routine Pre-Operative Education in MD office prior to surgery|
9766967|NCT04401891|Experimental|Formal Pre-operative education/therapy prior to surgery|
9766968|NCT04392765|Other|Therapy arm|Six week use of eXciteOSA device. Once daily for 20 minutes.
9766969|NCT04388748|Experimental|SMART-D Intervention Group|Subjects will participate in Stress Management and Resiliency Training for Depression (SMART-D) therapy as well as treatment as usual which consists of any ongoing medication or psychotherapy based treatments that are currently in place.
9766970|NCT04388748|No Intervention|Standard of Care Group|Treatment as usual will consist of any ongoing medication or psychotherapy based treatments that are currently in place.
9766971|NCT04387162|Experimental|Immediate|Participants will enter treatment after one week baseline
9766972|NCT04387162|Experimental|Delayed|Participants will enter treatment after two week baseline
9766973|NCT04381468|Experimental|pepinemab 40mg/kg|The study drug, pepinemab, will be administered via monthly intravenous infusions.
9766974|NCT04381468|Placebo Comparator|Placebo|.A placebo control will be administered via monthly intravenous infusions.
9766975|NCT04373148||COVID-19|Participants diagnosed with COVID-19
9766976|NCT04373148||Controls|Participants not diagnosed with COVID-19
9766977|NCT04366401|Active Comparator|Conventional Dietary Advice|"The control group will consist of participants diagnosed on the schizophrenic spectrum who will receive conventional dietary counseling (n=25) on an individual basis.~In the control group, data will be collected on the psychopathological state (PANSS and PSP scales), and blood analysis (hemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
9766978|NCT04366401|Experimental|Prebiotic/Probiotic Dietary Modulation|"In the intervention group (n=25), individual dietary counseling will be established through intensive nutritional counseling to provide a high prebiotic and probiotic food pattern.~In the experimental group, data will be collected on psychopathological status (Positive and Negative Syndrome Scale -PANSS- and Personal and Social Functioning Scale -PSP-), and blood tests (haemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
9766979|NCT04358874|Experimental|Active follow-up|Participants randomized to the active follow-up arm will have follow-up visits in the AKI follow-up clinic every 4 weeks after discharge for a total of 90 days after discharge
9766980|NCT04358874|Active Comparator|Usual follow-up|Participants randomized to the usual follow-up arm will be called at home 4 weeks after the baseline visit to collect information on primary and secondary outcomes.
9766981|NCT04342975|Active Comparator|Basis|The investigational product, Basis™, contains a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels. Also contains Pterostilbene (Ptero) that is a stilbenoid compound, characterized by two aromatic rings connected by a methylene bridge backbone, and it has two methoxy groups and one hydroxyl group extending from the aromatic rings.
9766982|NCT04342975|Placebo Comparator|Placebo|Correspondent placebo, a capsule not containing the active component.
9766983|NCT04340700|Experimental|THC|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
9766984|NCT04340700|Placebo Comparator|Placebo|Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
9766985|NCT04332601|Experimental|ENERGY intervention|"ENERGY Intervention:~14 sessions of 1h CBT intervention (standardized fatigue treatment comprising six modules over 14 individual therapy sessions)~1 session per week~With a psychologist (different to the psychologist who will perform the assessments)~Individual sessions~and Treatment as usual"
9766986|NCT04332601|Other|Treatment as usual (TAU)|"Comparison group~TAU defined by antipsychotic medication coupled with day hospital care"
9766987|NCT04329494|Experimental|Arm I (PIPAC, doxorubicin, cisplatin)|Patients with ovarian, uterine, or gastric cancer, undergo PIPAC with doxorubicin IP, followed by cisplatin IP. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9766988|NCT04329494|Experimental|Arm II (PIPAC, oxaliplatin, leucovorin, fluorouracil)|Patients with colorectal or appendiceal cancer undergo PIPAC with oxaliplatin IP. For cycles 2 and 3, patients receive leucovorin IV over 10 minutes and fluorouracil IV over 15 minutes 1-24 hours before undergoing PIPAC. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9766989|NCT04329494|Experimental|Arm III (PIPAC, mitomycin, FOLFIRI)|Patients with colorectal or appendiceal cancer who have undergo at least 4 months (or 8 cycles) of first-line standard of care chemotherapy but have not progressed on second line chemotherapy undergo PIPAC with mitomycin IP. Patients also receive standard of care irinotecan IV over 90 on day 1, leucovorin IV over 30 minutes on day 1, and fluorouracil IV on days 1-2 during weeks 2, 4, 8, 10, 14 and 16. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9766990|NCT04315142|Experimental|Transcutaneous tibial nerve stimulation (TTNS)|
9766991|NCT04315142|Sham Comparator|TTNS sham stimulation|
9766992|NCT04311307|Experimental|Patients|GSDIa patients
9766993|NCT04311307|Active Comparator|Controls|Healthy volunteers
9766994|NCT04302051||Study Group|The hepatic fat estimation will be performed on the same subjects with the use of the thermo-acoustic device and by MRI-PDFF. The data obtained from the two estimations will be compared.
9766996|NCT04294069|Active Comparator|Azithromycin 500mg|500mg azithromycin PO daily for seven days
9766997|NCT04294069|Active Comparator|Azithromycin 1000mg|1000mg azithromycin PO once at admission
9766998|NCT04290689||Botulinum Toxin-A injection treatment|Toe walking Cerebral Palsy subject who are subject to Botulinum toxin-A injection treatment. The dosage will be determined by the Orthopaedic Consultant
9766999|NCT04290689||Serial casting stretching treatment|Toe walking Cerebral Palsy subject who are subject to serial casting stretching treatment.
9767000|NCT04283461|Experimental|Arm 1|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel)
9767001|NCT04283461|Experimental|Arm 10|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
9767002|NCT04283461|Experimental|Arm 11|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
9767003|NCT04283461|Experimental|Arm 12|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
9767004|NCT04283461|Experimental|Arm 13|10 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
9767005|NCT04283461|Experimental|Arm 14|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle after Day 209 in participants from Arm 1,4,7,10, 11, and 12 from 18 years of age or older. N=70.
9767006|NCT04283461|Experimental|Arm 15|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle no later than Day 394 in participants from Arm 2,3,5 and 8 from 18 years of age or older. N=50.
9767007|NCT04283461|Experimental|Arm 2|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
9767008|NCT04283461|Experimental|Arm 3|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
9767009|NCT04283461|Experimental|Arm 4|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
9767010|NCT04283461|Experimental|Arm 5|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
9767011|NCT04283461|Experimental|Arm 6|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
9767012|NCT04283461|Experimental|Arm 7|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
9767013|NCT04283461|Experimental|Arm 8|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
9767014|NCT04283461|Experimental|Arm 9|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
9767015|NCT04278534|Experimental|Arm I (VERT)|Patients complete a radiation therapist-led education module using virtual reality over 30 minutes at the first treatment appointment, prior to radiation therapy treatment.
9767016|NCT04278534|Active Comparator|Arm II Control Group I (usual education materials)|Patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
9767017|NCT04278534|Active Comparator|Arm II Control Group II (face-to-face education module)|Patients complete a radiation therapist-led face-to-face education module at the first treatment appointment, prior to radiation therapy treatment.
9767018|NCT04278534|Active Comparator|Observational Cohort (usual education materials)|Observational patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
9767019|NCT04277962|Experimental|Patients having vaginal delivery|EBL will be estimated visually vs quantitatively at time of vaginal delivery.
9767020|NCT04271904|Experimental|Anti-inflammatory Diet|Those on the anti-inflammatory diet will be given a meal plan and recipes to be followed at home after consultation with the study dietitian. In brief, this meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, refined sugars and wheat, etc.). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, etc.). Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes.
9767021|NCT04271904|Placebo Comparator|Placebo Diet|Participants on the placebo diet will be given a meal plan and recipes by the study dietitian. The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). There are many counter-intuitive restrictions in the anti-inflammatory diet that we will be using (banned foods include white beans, soy, eggplant, oats, raspberries, strawberries, prunes, walnuts, cashews, soy milk. Allowed foods include maple syrup, honey, lean beef, lamb, brown rice, feta cheese, butter). Therefore, even fairly astute and educated participants may have trouble discerning which diet they are consuming (anti-inflammatory or placebo).
9767022|NCT04271904|No Intervention|Non-dieting Control|Those in the non-dieting control condition will not be asked to alter their diet in any way.
9767023|NCT04270747|Experimental|ABP 938-Treatment Group A|Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.
9767024|NCT04270747|Active Comparator|Aflibercept-Treatment Group B|Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8).
9767025|NCT04270747|Active Comparator|Aflibercept-Treatment Group B1|Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48
9767026|NCT04270747|Experimental|ABP 938-Treatment group B2|Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48
9984278|NCT04265365|Sham Comparator|sham-rTMS+sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median/ulnar nerve on affected hand.
9984279|NCT04265365|Experimental|rTMS + optimal-rPMS|In this group, patient received iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation(rPMS) on affected hand.
9767029|NCT04268004|No Intervention|Standard of Care (Control)|Participants will receive a standard of care fertility consult.
9767030|NCT04268004|Experimental|FP Decision Tool and Discussion (Treatment)|Participants will receive a standard of care fertility consult and will participate in a family-centered psychoeducational intervention consisting of completing a FP Decision Tool and participating in a guided discussion about responses and discrepancies identified in the FP Decision Tool.
9767031|NCT04267978|Experimental|glioblastoma|
9767032|NCT04267978|Experimental|lower-grade glioma|
9767033|NCT04267198|Active Comparator|Massed Intention Treatment (massed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 3 weeks.
9767034|NCT04267198|Active Comparator|Distributed Intention Treatment (distributed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 12 weeks.
9767035|NCT04261075|Experimental|IPH5201 monotherapy dose escalation|IPH5201 monotherapy
9767036|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab|IPH5201 plus durvalumab
9767037|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab + oleclumab|IPH5201 plus durvalumab and oleclumab
9767038|NCT04260022|Experimental|Cohort A|
9767039|NCT04260022|Experimental|Cohort B|
9767040|NCT04260022|Experimental|Cohort C|
9767041|NCT04260022|Experimental|Cohort D|
9767042|NCT04250415||Operative Arm|
9767043|NCT04250415||Non-operative Arm|
9984280|NCT04265365|Experimental|rTMS+ sham-rPMS|In this group, patient received iTBS on affected hemisphere after following sham repetitive peripheral magnetic stimulation on affected hand.
9984281|NCT04265365|Sham Comparator|sham-rTMS+optimal-rPMS|In this group, patient received sham iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation on affected hand.
9767046|NCT04240080|No Intervention|Control Goup|Subjects will undergo clinically indicated facial injection procedures per standard of care without venous mapping
9767047|NCT04240080|Experimental|Intervention Group|Subjects will undergo clinically indicated facial injection procedure with pre-procedural facial venous mapping by Accuvein® Veinfinder
9767048|NCT04238455|Sham Comparator|Control Group|Sham serratus anterior plane block plus usual car
9767049|NCT04238455|Active Comparator|Treatment Group|Serratus anterior plane block plus usual care
9767050|NCT04234568|Experimental|Treatment (lutetium Lu 177 dotatate, triapine)|Patients receive lutetium Lu 177 dotatate IV over 30-40 minutes on day 1 and triapine PO QD on days 1-14. Treatment repeats every 8 weeks (56 days) for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9767051|NCT04233606|Placebo Comparator|Control|Participants will be infused with normal (0.9% NaCL) saline for a 120 minute period.
9767052|NCT04233606|Experimental|Hypertonic Saline|Participants will be infused with hypertonic (3% NaCL) saline for a 120 minute period.
9767053|NCT04219189|Experimental|Vaping to Control Group|Participants in this arm will undergo the vaping condition during the first visit and the control condition during the second visit.
9767054|NCT04219189|Experimental|Control to Vaping Group|Participants in this arm will undergo the control condition during the first visit and the vaping condition during the second visit.
9767055|NCT04213248|Experimental|UMSC-exo treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo intervention for 2 weeks.
9767056|NCT04208217|Experimental|Modeling to Learn (MTL)|12 clinics randomly assigned to MTL
9767057|NCT04208217|Experimental|Usual quality improvement (QI)|12 clinics randomly assigned to usual QI
9767058|NCT04203901|Experimental|Combination Arm|CMN-001 dosing (1x10^7 DC/dose) is initiated at Visit 2 during 1st line therapy and through 2nd line therapy. CMN-001 is administered as 1 dose every 3 weeks for 3 doses (Induction phase), followed by maintenance doses, 1 every 4 weeks for 7 doses (Maintenance phase), followed by booster doses, 1 dose every 12 weeks (Booster phase). 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression, 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
9767059|NCT04203901|Active Comparator|Standard Treatment|1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
9767060|NCT04199351|Experimental|Part A|AMG 171 or placebo, 2 SAD cohorts
9767061|NCT04199351|Experimental|Part B|AMG 171 or placebo, 1 MAD cohort
9767062|NCT04199351|Experimental|Part C|AMG 171 or placebo, 3 titration cohorts
9767063|NCT04196101|Experimental|EDP-938|Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days
9767064|NCT04196101|Placebo Comparator|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days
9767065|NCT04189640|Active Comparator|Group 20 = 20 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20ml will be injected here.
9767066|NCT04189640|Active Comparator|Group 30 = 30 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30ml will be injected here.
9767067|NCT04189640|Active Comparator|Group 40 = 40 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 40ml will be injected here.
9767068|NCT04189341|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
9767069|NCT04189341|Active Comparator|Group T = mTLIP group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
9767070|NCT04189341|No Intervention|Group C = Control group|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
9767071|NCT04188301|Active Comparator|IVM + ALB|Single dose of oral IVM (150 µg/kg) plus ALB (400 mg)
9767072|NCT04188301|Experimental|IDA x 1 dose|Single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
9767073|NCT04188301|Experimental|IDA x 3 doses|Once daily for 3 days oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
9767074|NCT04187989|Experimental|Social Media Intervention|Facebook page that will deliver health information focused on increasing well-being and reducing risky behaviors.
9767075|NCT04187989|No Intervention|Control|An Attention-Control E-News (control) condition
9767076|NCT04178005|Other|Cladribine|"All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI.~Each treatment course is divided into 2 treatment cycles:~Administration of first treatment course (year 1 treatment):~First cycle: Starts on Day 1 of the study~Second cycle: Administered 23 to 27 days after the last dose of first cycle.~Administration of second treatment course (year 2 treatment):~First cycle: Administered at least 43 weeks after the last dose of year 1 treatment~Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment.~The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days."
9767077|NCT04173494|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match danazol
9767078|NCT04173494|Active Comparator|Danazol|Participants will receive danazol plus placebo to match momelotinib
9767079|NCT04166851|Experimental|Open contest messages|Participants will view the top PrEP-promotion messages developed via an open contest.
9767080|NCT04166851|Active Comparator|Social marketing messages|Participants will view the PrEP-promotion messages developed via social marketing.
9767081|NCT04155164|Experimental|Metformin|Participants will receive Metformin for 12 months.
9767082|NCT04155164|Placebo Comparator|Placebo|Participants will receive placebo for 12 months.
9767083|NCT04149301||Typically developing children|Children who do not have a problem with their walking ie children who do not have cerebral palsy
9767084|NCT04149301||Children with cerebral palsy without foot deformity|
9767085|NCT04149301||Children with cerebral palsy with mild foot deformity|
9767086|NCT04149301||Children with cerebral palsy with severe foot deformity|
9767087|NCT04138316||Migraine patients|
9767088|NCT04134663|Experimental|vasoconstrictor + intranasal oxytocin group|subjects receive the vasoconstrictor followed by oxytocin
9767089|NCT04134663|Active Comparator|vasoconstrictor's placebo + intranasal oxytocin group|subjects receive the vasoconstrictor's placebo followed by oxytocin
9767090|NCT04134663|Placebo Comparator|vasoconstrictor + intranasal oxytocin placebo group|subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo
9767091|NCT04133701|Experimental|Time-Restricted Feeding|"Control (Baseline): Blood pressure and neurovascular control will be measured.~Post-Intervention: Blood pressure and neurovascular control will be measured."
9767092|NCT04131504||Phase I - Cross-sectional Study (CD and Suspected IBD)|150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.
9767093|NCT04131504||Phase I - Cross-sectional Study (healthy volunteers)|20 healthy controls will be enrolled at Cincinnati Children's Hospital only. Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.
9767094|NCT04131504||Phase II - Longitudinal Study of Participants with CD|70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.
9767095|NCT04126031|Experimental|Part A, Cohorts 1-3|Single dose pharmacokinetics. This arm will include three age cohorts.
9767096|NCT04126031|Experimental|Part B, Cohorts 1-3|Multi-dose pharmacokinetics. This arm will include three age cohorts.
9835224|NCT02730377|Active Comparator|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
9835225|NCT02730403||Opioid Use Disorder Patients|
9835226|NCT02730455|Experimental|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
9835227|NCT02730455|Experimental|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
9835228|NCT02730455|Experimental|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
9835229|NCT02730598|Experimental|Hybrid Training System (HTS)|HTS stimulation while walking at a comfortable pace for 30 minutes.
9835230|NCT02730598|Active Comparator|Transcutaneous Electrical Nerve Stimulation (TENS)|Sensory TENS while walking at a comfortable pace for 30 minutes.
9835231|NCT02730663|Experimental|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
9835232|NCT02730728|Active Comparator|Single shot adductor canal block|adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
9835233|NCT02730728|Active Comparator|24 hour continuous adductor canal block|adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
9835234|NCT02730728|Active Comparator|48 hour continuous adductor canal block|adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
9835235|NCT02730819|Experimental|Illuminate Cream|Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.
9835236|NCT02730871|Experimental|Simbrinza + Duotrav|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
9835237|NCT02730871|Placebo Comparator|Vehicle + Duotrav|Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
9835238|NCT02730884|Experimental|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
9835239|NCT02730962|Experimental|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
9835240|NCT02730962|Placebo Comparator|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
9835241|NCT02730988|Experimental|Weight Loss Lifestyle Counseling|The high protein weight loss group follows the Medifast 4 & 2 & 1 Plan™, a 1200 calorie, high protein diet targeting ~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
9835242|NCT02730988|Active Comparator|Weight Stable Lifestyle Counseling|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
9835243|NCT02731131|Experimental|Group A: Monotherapy with Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
9835244|NCT02731131|Experimental|Group B: Combination with Peginterferon alfa-2a + Ribavirin|Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
9835245|NCT02731157|Experimental|Transfusion with rejuvenated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
9835246|NCT02731157|Active Comparator|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
9835247|NCT02731300|Active Comparator|Active tDCS|2 mA of cathodal tDCS placed over M1 for 20 mins
9835248|NCT02731300|Sham Comparator|Sham tDCS|0 mA of sham tDCS placed over M1 for 20 mins
9835249|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
9835250|NCT02731469|Experimental|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
9835251|NCT02731469|Experimental|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
9767097|NCT04116853|Experimental|ADAPTIVE Extended-Care Group|"Participants randomized to the ADAPTIVE extended-care program will receive extended-care intervention phone delivered only if either 1) an algorithm developed by our study team detects that a participant is at high risk for weight regain or 2) the participant self-initiates a request for a session."
9767098|NCT04116853|Active Comparator|STATIC Extended-Care Group|Participants randomized to the STATIC extended-care program will receive the extended-care intervention phone calls on a fixed, once-per-month schedule (the schedule currently used in gold-standard weight maintenance programs).
9767099|NCT04114344|Active Comparator|TAPP (Trans Abdominal PrePeritoneal)|Trans Abdominal PrePeritoneal approach to inguinal hernia repair
9767100|NCT04114344|Experimental|TEP (Totally Extra Peritoneal)|Totally Extra Peritoneal approach to inguinal hernia repair
9767101|NCT04112433||PURE EP 2 Group|Enrolled and consented patients who are indicated for and receive an elective cardiac ablation procedure using the PURE EP 2 system for monitoring and collection of intracardiac electrogram signals.
9767102|NCT04112355||6 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provided a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
9767103|NCT04112355||12 months of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
9767104|NCT04112355||5 years of age|"Visit 1~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :~Draw a blood sample based on age groups below~Provide a temperature diary to fill out for the next week Visit 2~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :~Draw a blood sample based on age groups below~Collect temperature diary if not already mailed in"
9767105|NCT04109118|Other|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|"This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.~Of note, this is a pilot trial for feasibility and acceptability. There is no randomization and we are not comparing arms."
9767106|NCT04096859||PremiCron®|Assessment of PremiCron suture for cardiac valve reconstruction and replacement
9767107|NCT04095221|Experimental|Prexasertib and Irinotecan|Patients will have extent of disease scans following every 2 cycles (every 6 weeks on dose levels 0-3, and every 8 weeks on dose level -1 (if required). Patients will be allowed to continue therapy as long as they do not experience dose-limiting toxicities or progression of disease.
9767108|NCT04086446|Active Comparator|active tDCS|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
9767109|NCT04086446|Sham Comparator|sham tDCS|The sham transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
9767110|NCT04072952|Experimental|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
9767111|NCT04072952|Experimental|ARV-471 and palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days.
9767112|NCT04072380|Experimental|SUVN-G3031 2mg|Orally taken once daily for 14 days
9767113|NCT04072380|Experimental|SUVN-G3031 4mg|Orally taken once daily for 14 days
9767114|NCT04072380|Placebo Comparator|Placebo|Orally taken once daily for 14 days
9767115|NCT04070040|Experimental|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
9767116|NCT04045132|Active Comparator|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
9767117|NCT04045132|Experimental|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
9767118|NCT04037683||MOLI participants pre IOL|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) after recruitment to MOLI RCT but prior to the start of the induction of labour (IOL) process
9835252|NCT02731469|Experimental|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
9767119|NCT04037683||MOLI participants post IOL (misoprostol/misoprostol)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/misoprostol Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
9767120|NCT04037683||MOLI participants post IOL (misoprostol/oxytocin)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
9767121|NCT04037683||Staff focus group pre and during MOLI recruitment|"A focus group in each of the 2 recruitment sites before the start of the MOLI trial (n=2) A focus group in each of the 2 recruitment sites and with each cadre of staff during the MOLI trial (n=8)~Research assistants~Residents~Consultants~Midwives"
9767122|NCT04033224||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.
9767123|NCT04016818|Experimental|18-F FDG Study using Breast-Dedicated PET Camera|Breast-Dedicated PET Camera will be used with standard PET 18-F FDG tracer dose
9767124|NCT04007380|Other|CPAP-therapy arm|This single-arm clinical trial will examine the effects of 4-month period CPAP therapy in individuals living with SCI. The CPAP will be adjusted according to the results of the auto-titrating CPAP testing for each participant.
9767125|NCT03997422|Experimental|Vertical Sleeve Gastrectomy (VSG)|Bariatric surgical procedure
9767126|NCT03991156|Experimental|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|
9767127|NCT03969004|Experimental|Cemiplimab|
9767128|NCT03969004|Placebo Comparator|Placebo|
9767129|NCT03958474|Experimental|Active treatment followed by placebo treatment|Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
9767130|NCT03958474|Experimental|Placebo treatment followed by active treatment|Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
9767131|NCT03946618|Experimental|Epilepsy|Patients with dominant temporal lobe epilepsy and bilateral temporal lobe epilepsy
9767132|NCT03940261|Experimental|High Intensity Interval Training|
9767133|NCT03940261|Active Comparator|Continuous Moderate Intensity Training|
9767134|NCT03939819|Experimental|ViSiGi® 3D suction calibration device|"The ViSiGi® 3D is the first calibration system specifically intended for use during sleeve gastrectomy.ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.~Advantages of ViSiGi® 3D device include simplification of sleeve calibration in addition to suctioning the stomach and performing leak tests all with one device making operative steps simpler for both the anesthesiology team and surgeons. Since it is single patient use it does not require reprocessing."
9767135|NCT03939819|Active Comparator|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope, similar to The ViSiGi device, have suction, calibration, and leak testing capabilities.
9767136|NCT03936270|Experimental|Palbociclib 125mg + Letrozole 2.5mg|Palbociclib 125mg per day, administered orally in 4-week cycles (3 weeks of treatment followed by 1 week off) PLUS Letrozole 2.5mg per day administered orally (continuous treatment).
9767137|NCT03934905|Active Comparator|sulforaphane|Processed SFN-rich extract will be purchased in form of caplets from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts from Nutramax Labs will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Size of the caplet will be about 2 cm in length. Dosing will be based on weight and will be dosed daily for 12 weeks.
9767138|NCT03934905|Placebo Comparator|Placebo|Placebo caplets will comprise of microcrystalline cellulose from Nutramax Labs and will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Placebo pills will be identical in appearance to the sulforaphane pills and will be dosed in a similar manner (identical number of pills based on weight, daily dosing and for 12 weeks)
9767139|NCT03929393|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
9767140|NCT03929393|Active Comparator|Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
9767141|NCT03922126|Experimental|Listos peer intervention|Listos intervention (peer counseling, PrEP information, and HIV/STI testing kits)
9767142|NCT03922126|Active Comparator|Peer only group|Peer only group (peer counseling, PrEP information)
9767143|NCT03918850|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
9767144|NCT03918850|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
9767145|NCT03911739|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
9835253|NCT02731469|Experimental|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
9767146|NCT03911739|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
9767147|NCT03911466|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
9767148|NCT03911466|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
9767149|NCT03891654|Experimental|Dynamic Contrast Enhanced Computed Tomography|DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.
9767150|NCT03885167||Affected Individuals with Known SCA3|In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
9767151|NCT03885167||Healthy Individual Control Subjects|In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
9767152|NCT03878394|Experimental|Group 1|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.
9767153|NCT03878394|Experimental|Group 2|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
9767154|NCT03872180|Experimental|Venetoclax, bendamustine, obinutuzumab|Patients receive venetoclax PO on days 1-28 of course 1 and days 1-10 of subsequent courses, bendamustine IV on days 1 and 2, and obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unaccepted toxicity.
9767155|NCT03867305|Experimental|MOBIDERM group|
9767156|NCT03867305|No Intervention|Control group|
9767157|NCT03857321|Experimental|Insulin first, then placebo|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive placebo at visit 3 during second intervention period.
9767158|NCT03857321|Experimental|Placebo first, then insulin|Participants will be randomly assigned to receive placebo administered with an intranasal nebulizer-like device. At visit 3 during second intervention period, participants in this arm will receive insulin.
9767159|NCT03846219|Experimental|IMU-838 (30 mg/day)|"IMU-838 tablet containing 15 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 30 mg consists of 2 tablets IMU-838.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 9.5 years for the main trial)."
9767160|NCT03846219|Experimental|IMU-838 (45 mg/day)|"Tablet containing 22.5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 45 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838."
9767161|NCT03846219|Placebo Comparator|Placebo|"Tablet containing no active ingredient. The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Once-daily oral dose consists of 2 active compound-free tablets.~Duration: until the end of the main treatment period (24 weeks). The placebo is not applicable in the optional extended treatment period, in which participants who were receiving placebo in the main treatment period were re-randomized to IMU-838 for the extended treatment period."
9767162|NCT03846219|Experimental|IMU-838 (10 mg/day) - Cohort 2|"Cohort 2 sub-trial: additional sub-trial with a small double-blind, placebo-controlled, randomized, parallel-group assessment of a low IMU-838 dose (i.e. 10 mg/day) to provide additional data for pharmacodynamic modelling.~Tablet containing 5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 10 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 8.5 years for the cohort 2 sub-trial)."
9767163|NCT03845491||SR Classic|SR (Trevo®]) + BGC (FlowGate2] or Merci)
9767164|NCT03845491||SR Combination|"SR (Trevo) + Asp Cath (AXS Catalyst DAC, Vecta) ± Pump~+ LS (AXS Infinity LS, AXS Infinity LS Plus)~or~SR (Trevo) + Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2 or Merci)"
9767165|NCT03845491||Direct Aspiration|"Asp Cath (AXS Catalyst DAC, Vecta) ± Pump + LS (AXS Infinity LS, AXS Infinity LS Plus)~or~Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2, Merci)"
9767166|NCT03839446|Experimental|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6
9767167|NCT03834701|Experimental|EUS guided radiofrequency ablation|Radiofrequency ablation will be performed using a system that consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure.
9767168|NCT03812614|Experimental|FAM ACT|"Patient and Support Person (dyad) will be included together as much as possible. The dyad will:~Take part in a one-hour introductory session and review of the patient's Diabetes Complications Risk Assessment profile.~Be invited to 4-6 Support Person-focused, group diabetes self-management education (DSME) sessions lasting 1-2 ½ hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
9767169|NCT03812614|Active Comparator|I-DSME + CM|"This arm will focus on the patient only. The Support Person assigned to this arm will not be invited to the introduction sessions, care management contacts, or diabetes self-management education sessions. Patients assigned to this arm will:~Take part in a one-hour introductory session and review of patient's diabetes management risk assessment.~Be invited to 4-6 group diabetes self-management education (DSME) sessions lasting 45 min to 2 hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
9767170|NCT03781986|Experimental|APG-115 monotherapy|APG-115 will be administered in an open label fashion until progression, intolerance, or patient preference.
9767171|NCT03781986|Experimental|APG-115 + Carboplatin [terminated]|APG-115 and Carboplatin will be administered in an open label fashion until progression, intolerance, or patient preference. [Phase 1 was terminated early and this arm was discontinued. An MTD was not established during Phase 1.]
9767172|NCT03781934|Experimental|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|Phase 2a expansion cohort HCC
9767173|NCT03781934|Experimental|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|Phase 2a expansion cohort HCC
9767174|NCT03763656|Experimental|Open Label|Novel oral solution formulation of hydroxyurea
9767175|NCT03758404|Experimental|Low dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single low dose AAV CNGA3
9767176|NCT03758404|Experimental|Intermediate dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single intermediate dose AAV CNGA3
9767177|NCT03758404|Experimental|High dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single high dose AAV CNGA3
9767178|NCT03756766||RSV positive ARTI|"RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).~Group 1 participants are categorised into 4 groups as follows:~Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.~Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively."
9767179|NCT03756766||Healthy controls|"This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.~This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only."
9767180|NCT03753646|Experimental|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
9767181|NCT03753646|No Intervention|Only lactating allowance|Mothers will receive only lactating allowance
9767182|NCT03746509|Experimental|Low-High Treatment|Participants in the low-high treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
9767183|NCT03746509|Experimental|High-Low Treatment|Participants in the high-low treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency once a week for a duration of 4 weeks (low intensity).
9767184|NCT03746509|Active Comparator|Low-High Comparator|Participants in the low-high comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
9767185|NCT03746509|Active Comparator|High-Low Comparator|Participants in the high-low comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency once a week for a duration of 4 weeks (low intensity).
9767186|NCT03735745|Experimental|Caucasian, HPV positive, Non Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
9767187|NCT03735745|Experimental|Caucasian, HPV positive, Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
9767188|NCT03735745|Experimental|Newly diagnosed, African American/Black, HPV negative, Smoking|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
9767189|NCT03735745|Experimental|Young (<40 years old), Oral Cavity (Tongue) patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
9767190|NCT03735745|Experimental|Neoadjuvant PD-1 Blockade patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
9767191|NCT03735680|Experimental|Patients receiving ONM-100|All patients in this arm will receive ONM-100 for injection and undergo intraoperative imaging.
9767192|NCT03717974|Experimental|telemedecine's follow-up|Telemedecine follow-up after an intervention at home of the mobile team
9767193|NCT03717974|Active Comparator|mobile team's follow-up|Mobile team follow-up after an intervention at home of the mobile team
9767194|NCT03713645|Experimental|Tacrolimus extended-release 0.13mg/kg/day|Tacrolimus extended-release is initiated within post-operative day 3 of kidney transplant
9767195|NCT03706677|Active Comparator|CRYO group|"Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.~Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)"
9767196|NCT03706677|Active Comparator|RF group|"Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.~Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)"
9767197|NCT03698708|Experimental|CARES Intervention- 12 sessions|Participants in the intervention will participate in 12 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
9767198|NCT03698708|Experimental|CARES Intervention- 8 sessions|Participants in the intervention will participate in 8 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
9767199|NCT03690869|Experimental|Phase 1|Patients in both the Solid Tumor Cohort and the CNS Cohort will receive cemiplimab monotherapy. Each Cohort will have 2 subgroups by age (0 to <12 years, 12 to <18 years).
9767200|NCT03690869|Experimental|Efficacy with Newly Diagnosed DIPG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
9767201|NCT03690869|Experimental|Efficacy with Newly Diagnosed HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
9767202|NCT03690869|Experimental|Efficacy with Recurrent HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
9767203|NCT03663530|Experimental|Circadian misalignment|Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
9767204|NCT03663530|Active Comparator|Circadian alignment|Meals in this condition will be aligned to the sleep episode. Food intake during this period will be from 9 AM to 7 PM.
9767205|NCT03654573|Experimental|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
9767206|NCT03641001|Experimental|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
9767207|NCT03641001|No Intervention|Control|Control will receive usual health messages from government and NGO
9767208|NCT03638167|Experimental|ARM A (Tumor Cavity Infusion)|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
9767209|NCT03638167|Experimental|ARM B (Ventricular System Infusion)|Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
9767210|NCT03627507|Experimental|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
9767211|NCT03627507|Active Comparator|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
9767212|NCT03620981|Experimental|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
9767213|NCT03620981|Experimental|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
9767214|NCT03620981|Placebo Comparator|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
9767215|NCT03620773|Other|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
9767216|NCT03608696|Experimental|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose < Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
9767217|NCT03606668|Experimental|People with Multiple Sclerosis (PwMS) and Chronic Pain|"Participants with MS will only be able to receive eight treatment sessions in this study group and will complete their treatment over four weeks. Two treatments sessions must be completed each week (of the four weeks) and separated by at least one day.~Participants will attend a baseline visit with assessment and training procedures and receive their first treatment immediately after all baseline assessments. Participants will then complete the remaining seven treatment sessions over four weeks. At the final treatment session, participants will repeat assessments. One week following the final treatment session, participants will be asked to return to clinic to complete assessments once more to test cumulative benefits one week following treatment end."
9767218|NCT03587636|Experimental|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
9767219|NCT03587636|Active Comparator|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
9767220|NCT03584217|Other|Clinical Investigation|All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
9767221|NCT03582163||STN|Patients with Parkinson's disease who have undergone subthalamic nucleus (STN) DBS.
9767222|NCT03582163||GPi|Patients with Parkinson's disease who have undergone GPi (GPi) DBS.
9835254|NCT02731469|Experimental|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
9835255|NCT02731469|Experimental|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
9835256|NCT02731469|Experimental|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
9835257|NCT02731469|Active Comparator|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
9835258|NCT02731469|Active Comparator|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
9835259|NCT02731469|Experimental|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
9835260|NCT02731469|Experimental|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
9835261|NCT02731638|Experimental|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
9835262|NCT02731638|Active Comparator|Natamycin alone|Standard of care topical treatment for fungal keratitis
9835263|NCT02731690|Experimental|Open Label UX001, 6g/day|
9835264|NCT02731729|Experimental|ipilimumab and nivolumab|For patients in the combination arm, nivolumab will first be administered intravenously at a dose of 1 mg/kg of body weight over a period of 60 minutes, once every 3 weeks for four doses. Thirty minutes after the completion of each nivolumab infusion, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes.
9835265|NCT02731729|Experimental|ipilimumab|In the ipilimumab monotherapy group, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes once every 3 weeks for four doses.
9835266|NCT02731742|Experimental|Dose A MK-1966 + Dose A SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
9835267|NCT02731742|Experimental|Dose A MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
9835268|NCT02731742|Experimental|Dose B MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
9835269|NCT02731742|Experimental|Dose C MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
9835270|NCT02731742|Experimental|Part B Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
9835271|NCT02731742|Experimental|Part C Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
9835272|NCT02731755|Active Comparator|Oat intervention|67.7g oatflake and 22.5g oatbran concentrate - single intake (mixed with water)
9835273|NCT02731755|Placebo Comparator|Control|39.4g cream of rice, 6.1g sunflower oil, 29.5g skimmed milk, 5.6g pectin powder, 6.5g cellulose and mixed with water
9835274|NCT02731820|Experimental|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
9835275|NCT02731820|Placebo Comparator|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
9835276|NCT02731833|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
9835277|NCT02731833|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
9835278|NCT02732015|Experimental|Arm I (rolapitant hydrochloride)|"Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
9835279|NCT02732015|Active Comparator|Arm II (fosaprepitant dimeglumine)|"Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
9835280|NCT02732119|Experimental|Cohort A|Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
9835281|NCT02732119|Experimental|Cohort B|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
9835282|NCT02732119|Experimental|Cohort C|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
9835283|NCT02732119|Experimental|Group 1|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
9835284|NCT02732119|Experimental|Group 2|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
9835285|NCT02732145|Placebo Comparator|Normal vulva|"The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
9835286|NCT02732145|Placebo Comparator|Impaired vulvar skin|"The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
9835287|NCT02732145|Placebo Comparator|Vulvodynia|"The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
9835288|NCT02732145|Active Comparator|Vulvar dermatosis|"The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
9835289|NCT02732366|Experimental|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
9835290|NCT02732366|Active Comparator|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
9835291|NCT02732561|Sham Comparator|Sham Device|Sham device
9835292|NCT02732561|Active Comparator|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
9835293|NCT02732587|Experimental|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
9835294|NCT02732600|No Intervention|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
9835295|NCT02732600|Experimental|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
9835296|NCT02732639|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
9835297|NCT02732847|Other|Post-Dated Prescription|a delayed prescription dated 2 days after clinical office visit
9835298|NCT02732847|Other|Usual|usual date
9835299|NCT02732899|Experimental|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
9835300|NCT02732899|Active Comparator|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
9835301|NCT02732912|Active Comparator|Control|Patients in this arm will continue current standard management for sleep, which is largely reactive; if a patient requests night sedation or complains that they cannot sleep and that they want help, then zopiclone is prescribed, starting at 3.75 mg.
9835302|NCT02732912|Experimental|Eye mask and ear plugs|General management will be as for the control group. In addition, patients in this group will be given ear plugs and eye shades (masks) to use when trying to sleep. The patient will generally be responsible for using or not using the equipment, though ward nurses may remind patients if they notice that the patient has the equipment.
9835303|NCT02732938|Experimental|PF-04136309 + Nab-p + Gem|"PF-04136309 oral dosing~Nab-paclitaxel IV dosing Gemcitabine IV dosing"
9835304|NCT02732951|Experimental|BI 1026706|
9835305|NCT02732951|Active Comparator|Placebo|
9835306|NCT02733367|Experimental|Infacort|Infacort® granules
9835307|NCT02733588|Experimental|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
9835308|NCT02733627|Experimental|BI 1467335 10 mg (low dose)|
9835309|NCT02733627|Experimental|BI 1467335 15 mg (medium dose)|
9835310|NCT02733627|Experimental|BI 1467335 20 mg (high dose)|
9835311|NCT02733627|Placebo Comparator|Placebo|
9835312|NCT02733653|Experimental|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
9835313|NCT02733757|No Intervention|Sub-Tenon's group control|2% Lidocaine without epinephrine
9835314|NCT02733757|Experimental|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
9835315|NCT02733757|No Intervention|Peribulbar group control|2% Lidocaine without epinephrine
10205328|NCT02761603|Active Comparator|Healthy Aging Practice-centered Instruction (HAPI)|24 hours of group instruction in which experts present on a variety of health-related topics followed by class discussion, goal-setting, and goal review. Themes will include: sleep, nutrition, mental health, social support, bone-health, diabetes prevention, cognitive wellness, and resilience.
9767223|NCT03576365|Experimental|VOICE Intervention Arm|Participants participate in the online VOICE program to learn about perceived control and stress reduction to improve voice outcomes.
9767224|NCT03576365|Sham Comparator|Information-Only Arm|Participants participate in the information only program to learn about voice problems, anatomy and physiology.
9767225|NCT03575897|Experimental|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
9767226|NCT03575897|Active Comparator|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
9767227|NCT03541486|Experimental|Investigational Therapy (ASC)|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
9767228|NCT03541486|Active Comparator|Standard Therapy (ChemoRT)|600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
9767229|NCT03535623|Experimental|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
9767230|NCT03535623|Sham Comparator|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
9767231|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
9767232|NCT03506594|Active Comparator|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41° C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
9767233|NCT03506594|Placebo Comparator|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
9767234|NCT03500731|Experimental|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
9767235|NCT03493178|Active Comparator|MCI-active|30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. ll subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks.
9767236|NCT03493178|Placebo Comparator|MCI-placebo|30 subjects will received alanine for 12-weeks. All subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks
9767237|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When one antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
9767238|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSI-L).
9767239|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
9767240|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
9767241|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
9767242|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
9767243|NCT03435315|Active Comparator|Treadmill exercise|
9767244|NCT03435315|Experimental|Treadmill exercise with behavioral techniques|
9767245|NCT03419676|No Intervention|Control|No reinforcement.
9767246|NCT03419676|Experimental|Hemopatch|Reinforcement with Hemopatch.
9767247|NCT03417193|Active Comparator|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
9767248|NCT03417193|Active Comparator|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
9767249|NCT03414112|Placebo Comparator|Intranasal Oxytocin Placebo|Intranasal placebo
9767250|NCT03414112|Experimental|Intranasal Oxytocin|Intranasal oxytocin
9767251|NCT03410030|Experimental|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
9767252|NCT03402035||Whole Blood|Subjects at enrolling centers that utilize whole blood for hemorrhagic shock
9767253|NCT03402035||Component Therapy|Subjects at enrolling centers that utilize component therapy for hemorrhagic shock
9767254|NCT03386240|Experimental|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
9767255|NCT03386240|Placebo Comparator|Vicryl, monocryl, PDS (not coated with triclosan)|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
9767256|NCT03384108|Experimental|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
9767257|NCT03384108|Placebo Comparator|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
9767258|NCT03372317||Non-demented elders|Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
9767259|NCT03367845|Experimental|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
9767260|NCT03367845|Experimental|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity; with COVID-19, we now conduct remote visits using Zoom
9767261|NCT03367845|Experimental|Couples Intervention|Home visits to enhance constructive couples' communication; with COVID-19, we now conduct remote visits using Zoom
9767262|NCT03367845|Experimental|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions; with COVID-19, we now conduct remote visits using Zoom
9767263|NCT03356431|Experimental|Supervised group exercise|The supervised exercise group will receive a lower extremity exercise treatment, under physiotherapist supervision for 60 min, two times a week (12 sessions).
9767264|NCT03356431|Experimental|Home-based exercise|"For the home-based exercise group, exercises will be demonstrated to the patient with the supervision and guidance of a physiotherapist in an exercise session. These patients will perform the same exercise protocol at home at least twice a week.~In addition to the initial session, subjects will perform further two supervised sessions (at one week and four weeks after the initial session).~The exercise program are the same as the supervised group exercise."
9767265|NCT03343626|Placebo Comparator|Flavivirus-naïve Cohort: Placebo|Placebo injection, intramuscular (IM), once on Day 1 (first dose) and Day 29 (second dose).
9767266|NCT03343626|Experimental|Flavivirus-naïve Cohort: PIZV 2 mcg (Low Dose)|PIZV 0.5 mL, 2 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
9767267|NCT03343626|Experimental|Flavivirus-naïve Cohort: PIZV 5 mcg (Medium Dose)|PIZV 0.5 mL, 5 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
9767268|NCT03343626|Experimental|Flavivirus-naïve Cohort: PIZV 10 mcg (High Dose)|PIZV 0.5 mL, 10 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
9767269|NCT03343626|Placebo Comparator|Flavivirus-primed Cohort: Placebo|Placebo injection, IM, once on Day 1 (first dose) and Day 29 (second dose).
9767270|NCT03343626|Experimental|Flavivirus-primed Cohort: PIZV 2 mcg (Low Dose)|PIZV 0.5 mL, 2 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
9767271|NCT03343626|Experimental|Flavivirus-primed Cohort: PIZV 5 mcg (Medium Dose)|PIZV 0.5 mL, 5 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
9767272|NCT03343626|Experimental|Flavivirus-primed Cohort: PIZV 10 mcg (High dose)|PIZV 0.5 mL, 10 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
9767273|NCT03343197|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
9767274|NCT03343197|Experimental|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
9835316|NCT02733757|Experimental|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
9767275|NCT03343197|No Intervention|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
10203545|NCT05199675|Active Comparator|Waitlist control for Digital Peer Support Training Program|Students in the wait-list control arm will receive the training program after the conclusion of the trial with the intervention arm. The pre-post with control evaluation design will be utilized to evaluate program outcomes. The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments.The same set of primary and secondary outcomes assessed in the experimenter arm will be included. Specifically, fidelity will be the primary outcome assessed. Reach, acceptability, cost-effectiveness, and adolescent self-reported psychological well-being will be assessed as secondary outcomes.
9767276|NCT03341052|Active Comparator|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
9767277|NCT03341052|Active Comparator|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
9767278|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
9767279|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
9767280|NCT03334305|Experimental|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
9767281|NCT03334305|Experimental|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
9767282|NCT03328468|Experimental|Breathing Exercise|
10203546|NCT05199649|Experimental|Arm Sintilimab|Sintilimab Combined With Chemotherapy
9767283|NCT03326141|Active Comparator|Otago+PAM+Health / Wellness topics|"Condition 1:~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
9767284|NCT03326141|Experimental|Otago + PAM + Interpersonal strategies|"Condition 2:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
9767285|NCT03326141|Experimental|Otago, PAM, Intrapersonal strategies|"Condition 3:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
9767286|NCT03326141|Experimental|Otago,PAM, Inter+Intra strategies|"Condition 4:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
9767287|NCT03323580|Experimental|SVV-based GDFT group|The patients will receive fluid therapy under SVV-directed goal.
9767288|NCT03323580|Sham Comparator|non-SVV-based GDFT group|The patients will receive fluid therapy without SVV-directed goal.
9767289|NCT03300232|Experimental|Computer-based VC-CBT|Computer-based VC-CBT: Six, one-hour computerized therapy sessions delivered on an interactive computerized platform with two-session therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
9767290|NCT03300232|No Intervention|Treatment as Usual|Participants randomized to the treatment as usual control condition will not undergo the CBT therapy.
9784255|NCT01220999|Experimental|Cohort 4|Subjects received an initial loading dose of 111^In-CS-1008 (4 mg/kg) on Day 1, CS-1008 (4 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
9784256|NCT01220999|Experimental|Cohort 5|Subjects received an initial loading dose of 111^In-CS-1008 (6 mg/kg) on Day 1, CS-1008 (2 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
9784257|NCT01221090|Experimental|Personal Digital Assistant|Individuals in this arm were taught to use a diabetes self-care software, Diabetes Pilot™ (Digital Altitudes, Arlington Heights, IL), developed for PalmOS® (Palm, Sunnyvale, CA) which was loaded on to compatible PDAs, the Tungsten™ E2 handheld device. The Diabetes Pilot allowed participants to monitor their blood glucose, blood pressure, medication usage, physical activity, and dietary intake by tracking these measures in an electronic diary.
9784258|NCT01221090|Active Comparator|CDSMP|6-week, classroom-based program for diabetes self-management. The CDSMP, developed by Stanford University, equipped participants with the education and skill sets needed to take a more proactive approach in managing their chronic condition(s) and related symptoms.
9784259|NCT01221090|Active Comparator|PDA/CDSMP|Combined intervention
9784260|NCT01221090|No Intervention|Control|Usual Care
10203547|NCT05199623|Experimental|CHM(Chinese herbal medicine) group|Treatment with steroid, zinc, and olfactory training for one month. And then, take CHM(Chinese herbal medicine) (tailored Guizhi decoction) and perform OT(olfactory training) for 6 months
10203548|NCT05199623|Active Comparator|OT(olfactory training) group|Treatment with steroid, zinc, and olfactory training for one month. And then, perform OT(olfactory training) only for 6 months.
10203549|NCT05199597|Experimental|All participants|All participants will receive all four drops in randomized order
10203550|NCT05199571|Experimental|Ofatumumab|Ofatumumab 20 mg subcutaneous injections at Week 0, 1, 2 and monthly thereafter starting at Week 4
10203551|NCT05199519|Other|IBI345|Single arm
9835317|NCT02733991|Experimental|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
9835318|NCT02733991|Active Comparator|Control|MiniMed™640G alone
9835319|NCT02734056|Experimental|Music|The intervention to be administered is music
9835320|NCT02734056|Experimental|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
9835321|NCT02734147|Active Comparator|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
9835322|NCT02734147|Placebo Comparator|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
9835323|NCT02734212|Experimental|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
9835324|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
9835325|NCT02734238|Placebo Comparator|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
9835326|NCT02734238|Experimental|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
9835327|NCT02734355|Active Comparator|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
9835328|NCT02734355|Placebo Comparator|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
9835329|NCT02734498|Active Comparator|Right unilateral (RUL) ECT|Right Unilateral placement of treatment electrodes in electroconvulsive treatment.
9835330|NCT02734498|Active Comparator|Bilateral (BL) ECT|Bilateral placement of treatment electrodes in electroconvulsive treatment.
9835331|NCT02734498|No Intervention|Control group|No ECT treatment for control group.
9835332|NCT02734576|Experimental|Venous Sinus Stenting|Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation
9835333|NCT02734693|Experimental|Dasotraline 4mg|Dasotraline capsule 4mg/day
9835334|NCT02734693|Placebo Comparator|Placebo|Placebo capsule
9835335|NCT02734810|Experimental|Part A|Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age
9835336|NCT02734810|Experimental|Part B|Liprotamase Powder for Oral Solution in Subjects aged 28 days to <7 years
9835337|NCT02734849|Experimental|25 mg AK001|25 mg AK001 will be administered as multiple doses
9835338|NCT02734849|Experimental|250 mg AK001|250 mg AK001 will be administered as multiple doses
9835339|NCT02734849|Placebo Comparator|Placebo|A placebo comparator consisting of inactive excipients will be administered as multiple doses
9835340|NCT02734862|Experimental|Group 1|"Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
9836193|NCT02774226|Experimental|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
9835341|NCT02734862|Active Comparator|Group 3|"Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
9835342|NCT02734862|Experimental|Group 2|"Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
9835343|NCT02734953|Experimental|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
9835344|NCT02734979|Experimental|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
9835345|NCT02735096|Experimental|Vestibular Patients for EquiCue Testing|Subjects with vestibular deficiency will try the intraoral electronic balance aid to see whether there is improvement in balance.
9835346|NCT02735174|Experimental|Single arm asthma self-management|"Interventions include:~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
9835347|NCT02735187|Active Comparator|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
9835348|NCT02735187|Active Comparator|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
9835349|NCT02735200|Experimental|Topical Vitamin D3 application|Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
9835350|NCT02735200|Active Comparator|Aloe vera gel Application|Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days
9835351|NCT02735382|Experimental|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline EHR referral"
9835352|NCT02735382|Active Comparator|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline Fax referral"
9835353|NCT02735382|Experimental|EHR-based Clinic Staff|Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
9835354|NCT02735382|Active Comparator|Fax-based referral to quit line Clinic Staff|Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
9835355|NCT02735421|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening on half of the face (determined by randomization)
9835356|NCT02735421|Placebo Comparator|Vehicle gel|Vehicle gel, once daily in the evening on half of the face (determined by randomization)
9836074|NCT02768792|Other|open-label, multicenter, single-arm|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (i.e., beginning on day 1 of maintenance). Patients who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
9836075|NCT02769065|Placebo Comparator|SRD: Placebo Cohorts 1-6, 18 and 19|TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.
9836076|NCT02769065|Experimental|SRD: Cohort 1: TAK-071 1 mg|TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.
9767291|NCT03298802|Active Comparator|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
9767292|NCT03298802|Placebo Comparator|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
9767293|NCT03286387|Experimental|Memory for naturalistic episodes|Encoding of episode in real life situations (using Smartphones) or in a virtual environment, followed by memory retrieval (either behavior only or with fMRI, in successive studies)
9767294|NCT03272737|Active Comparator|Traditional strength exercise|"This group will be carried out to knee extension exercise without blood flow restriction.~Interventions:~Plethysmography;~Protocols of isometric exercise;~Pulse wave Velocity (PWV);~Flow-mediated dilatation (FMD);~Arterial pressure and blood pressure;~Quality of life (Euro Qol);~1RM test~Speed gait test~Anthropometric Assessment"
9767295|NCT03272737|Active Comparator|Strength exercise with KAATSU|"This group will be carried out to knee extension exercise with partial blood flow restriction.~Interventions:~Plethysmography;~Protocols of isometric exercise;~Pulse wave Velocity (PWV);~Flow-mediated dilatation (FMD);~Arterial pressure and blood pressure;~Quality of life (Euro Qol);~1RM test~Speed gait test~Anthropometric Assessment"
9767296|NCT03240861|Experimental|Treatment (Genetically engineered PBMC and PBSC)|"G-CSF AND PLERIXAFOR MOBILIZED LEUKAPHERESIS: Between 6 months and 3 weeks before infusion of cells, patients undergo G-CSF and plerixafor mobilization of CD34+ peripheral blood stem cells. Patients receive G-CSF SC on mobilization days 1-8 and plerixafor SC on mobilization days 4-7. Patients also undergo an unmobilized leukapheresis on day -5 before infusion of cells.~CHEMOTHERAPY CONDITIONING REGIMEN: Patients receive busulfan IV on days -4 to -2 and fludarabine IV over 30 minutes on days -3 to -2.~Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0, and after approximately 24 hours, patients receive RV-NYESO TCR PBMC IV on day 1. Beginning on day 2, patients receive aldesleukin SC BID for up to 7 days. Patients undergo blood collection for safety and immune monitoring on days 0, 1, 3, 5, 7, 14, 30, 60, 90, and 120. Patients receive 18F-FHBG IV, and after 1 hour, undergo PET/CT on days 25 and 120."
9767297|NCT03218891|Experimental|Clinical treatment physical training|"Patients with optimized clinical treatment group that will do physical training for 12 weeks. They will do the tests in moment 1 and after 3 mounths.~The intervention is the Cardiac Rehabilitation."
9767298|NCT03218891|No Intervention|Optimized clinical treatment|Patients with optimized clinical treatment group that will not do physical training.They will do the tests in moment 1 and after 3 mounths.
9767299|NCT03218891|No Intervention|Coronary insufficiency without angina|Group with coronary insufficiency without angina and will not do physical training. They will do the tests only one moment.
9767300|NCT03218891|No Intervention|Normal healthy subjects|Group normal healthy subjects, without coronary injuries, diabetes, hypertension and another chronic disease. These group have be sedentary and will not do physical training. They will do the tests only one moment.
9767301|NCT03204357|Experimental|Fresh Autologous whole blood transfusion|The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
9767302|NCT03204357|Active Comparator|Standard of Care Expectant Management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
9767303|NCT03201757|Experimental|ALKS 3831|Coated bilayer tablet
9767304|NCT03194971||TTField at Recurrence|
9767305|NCT03194971||TTField at New Diagnosis|
9767306|NCT03189004|Active Comparator|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
9767307|NCT03189004|Active Comparator|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
9767308|NCT03189004|Active Comparator|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
9785727|NCT01258738|Placebo Comparator|PLACEBO|In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
9767309|NCT03189004|Active Comparator|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
9767310|NCT03189004|Active Comparator|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
9767311|NCT03189004|Active Comparator|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
9767312|NCT03180580|Experimental|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
9767313|NCT03170258|Experimental|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
9767314|NCT03170258|Sham Comparator|Noise Control|Participants in this group will receive sham neurofeedback. Both groups will be debriefed at the end of the study.
9767315|NCT03166722|Experimental|Study group: Invos 5100|"Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy (INVOS 5100 ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine."
9767316|NCT03166722|Active Comparator|Control group: Routine care|Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
9767317|NCT03155347|Experimental|Tocilizumab + MTX|Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR <= 3.2).
9767318|NCT03155347|Experimental|Tocilizumab + Placebo Matched to MTX|Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
9767319|NCT03155347|Active Comparator|Placebo Matched to Tocilizumab + MTX|Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
9767320|NCT03151057|Experimental|Idelalisib 100mg|"Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant"
9767321|NCT03151057|Placebo Comparator|Placebo oral tablet|Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
9767322|NCT03149770|Experimental|1|Naloxone, intranasal 4mg
9767323|NCT03149770|Placebo Comparator|2|Placebo
9767324|NCT03143621|Experimental|Coffee|100 cc's of coffee administered three times per day until return to bowel function has been established.
9767325|NCT03143621|Placebo Comparator|Water|100 cc's of warm water administered three times per day until return to bowel function has been established.
9785728|NCT01258790|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, in the form of Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using a Sham TMS coil.
9835357|NCT02735551|Active Comparator|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
9835358|NCT02735551|Active Comparator|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
9835359|NCT02735551|Active Comparator|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
9835360|NCT02735577|Experimental|Disulfiram|Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.
9835361|NCT02735642|Experimental|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
9835362|NCT02735642|Experimental|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
9835363|NCT02735642|Experimental|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
9835364|NCT02735642|Experimental|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
9835365|NCT02735642|Other|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
9835366|NCT02735642|Other|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
9835367|NCT02735915|Experimental|GSK1437173A vaccine Group|Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
9835368|NCT02735980|Experimental|Prexasertib (Platinum Sensitive Disease)|105 mg/m^2 Intravenous (IV) prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had platinum-sensitive disease (has prior platinum based therapy with subsequent progression greater or less than 90 days after last dose of platinum based therapy).
9835369|NCT02735980|Experimental|Prexasertib (Platinum Resistant Disease)|105 mg/m^2 IV prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had resistant/refractory disease (did not have an objective response to platinum-based therapy or had progression greater than 90 days after the last dose of platinum).
9835370|NCT02735980|Experimental|Prexasertib Exploratory Addendum (Platinum Sensitive Disease)|40 mg/m^2 IV prexasertib Day 1, 2, and Day 3 of a 14 day cycle in participants with ED-SCLC platinum sensitive disease.
9835371|NCT02736175|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
9835372|NCT02736175|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
9835373|NCT02736188|Experimental|Drug: Aceneuramic Acid Extended-Release Tablets|Participants will take 4 tablets (500 mg Ace-ER each for 2 g per dose) orally 3 times per day (TID).
9835374|NCT02736409|Experimental|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
9835375|NCT02736409|Placebo Comparator|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
9835376|NCT02736409|Experimental|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
9835377|NCT02736409|Experimental|Arm D Placebo Completers|Arm D Placebo Completers
9835378|NCT02736474|Experimental|Naltrexone and Bupropion|Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.
9835379|NCT02736474|Placebo Comparator|Placebo Naltrexone and Bupropion|Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.
9835380|NCT02736578|Experimental|Cetuximab IRDye800, 50 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 50 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
9835381|NCT02736578|Experimental|Cetuximab IRDye800, 100 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 100 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
9835382|NCT02736721|Experimental|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
9835383|NCT02736825|Active Comparator|Group A, Ulthera System with standard transducers|"Subjects randomized to Group A will receive an Ultherapy® treatment to the lower face and neck with a total minimum pulse count of 672 pulses (+5%) at the 4.5mm and 3.0mm depths using standard transducers. Energy levels for each transducer will be set to EL2:~Deep-See (DS) 4-4.5 at 0.9 Joules (J) with pitch of 1.5mm and 17 Thermal Coagulation Points (TCP)s per line~DS 7-3.0 at 0.30J with pitch of 1.1mm and 23 TCPs per line"
9835384|NCT02736825|Experimental|Group B, Ulthera System with prototype 2 simulines transducers|"Subjects randomized to Group B will receive a Ultherapy® treatment with a total minimum pulse count of 336 pulses (+5%) using the prototype 2 simulines transducers at the 4.5mm and 3.0mm depths. Energy levels for each transducer will be set to EL2:~Deep-See 4-4.5 Simulines (DS 4-4.5S) at 1.23J with pitch of 1.5mm and 17 TCPs per line~DS 4-3.0S at 0.88J with pitch of 1.3mm and 20 TCPs per line"
9835385|NCT02736890|Active Comparator|Botulinum Toxin A|Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
9835386|NCT02736890|Placebo Comparator|Placebo|Placebo consists of 0.9% normal saline. Each injection will be 0.2mL, administered with a 25 gauge needle subcutaneously into the affected area. The marked area will have subcutaneous injections (maximum of 80) each separated from the surrounding ones by a radius of 1 cm.
9835387|NCT02736955|Experimental|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
9835388|NCT02737072|Experimental|20 mg LY2510924 + 1500 mg Durvalumab|20 milligrams (mg) LY2510924 given subcutaneously (SQ) once daily in combination with 1500 mg durvalumab given intravenously (IV) on Day 1 of each cycle (28 days).
9835389|NCT02737072|Experimental|30 mg LY2510924 + 1500 mg Durvalumab|30 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
9835390|NCT02737072|Experimental|40 mg LY2510924 + 1500 mg Durvalumab|40 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
9835391|NCT02737332|Active Comparator|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
9835392|NCT02737332|Experimental|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
9835393|NCT02737358|Placebo Comparator|Placebo|Matched placebo will be given to half of the study participants.
9835394|NCT02737358|Active Comparator|N-Acetylcysteine (NAC)|NAC will be given to half of the study participants. The dose of NAC will be 2400 mg per day (1200 mg taken twice per day as two 600 mg capsules)
9835395|NCT02737397|Experimental|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
9835396|NCT02737397|Active Comparator|pain medicine|SJP-304 and placebo
9835397|NCT02737397|Active Comparator|antihistamine|SJP-223 and placebo
9835398|NCT02737397|Placebo Comparator|placebo|placebo and placebo
9835399|NCT02737501|Experimental|Randomized Phase: Brigatinib 90 mg QD/180 QD|Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
9835400|NCT02737501|Active Comparator|Randomized Phase: Crizotinib 250 mg BID|Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
9835401|NCT02737501|Experimental|Crossover Phase: Brigatinib 90 mg QD/180 mg QD|Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).
9835402|NCT02737592|Experimental|Healthy subject|"Healthy subject exposed to Trojan Simply Pleasures Personal Lubricant at least four times weekly for two weeks"
9835403|NCT02737618|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon Personal Lubricant applied by occlusive patch"
9835404|NCT02737631|Experimental|Healthy subject|"Healthy subjects exposed to Chameleon personal lubricant via occlusive patch"
9835405|NCT02737722|Experimental|Bisphosphocin Nu-3|Dosage Form: Topical Antimicrobial, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
9835406|NCT02737722|Placebo Comparator|Placebo|Dosage Form: Diluent, Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
9835407|NCT02737826|Experimental|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
9836077|NCT02769065|Experimental|SRD: Cohort 2: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
9836078|NCT02769065|Experimental|SRD: Cohort 3: TAK-071 9 mg|TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
9767326|NCT03119883|Other|MGUS group|MGUS patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
9767327|NCT03119883|Other|Multiple Myeloma group|Multiple Myeloma patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
9767328|NCT03113305||Gastric bypass patients|Patients planned to undergo Gastric bypass procedure. Patients will be assessed -1 month, 3-, 24-, 48- and 60 months post surgery.
9767329|NCT03113305||Healthy controls|Healthy controls with no planned weight loss/gain. Control participant assessments will be time-matched with patients.
9767330|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
9767331|NCT03104257||Healthy Controls|Subjects with no current cannabis use
9767332|NCT03094832|Experimental|Part A: Miransertib PROS/PS|Participants with either PROS or PS receive miransertib orally at 15 mg/m^2 once daily (QD) for at least three 28-day cycles with an option to dose increase to 25 mg/m^2.
9767333|NCT03094832|Experimental|Part B: Miransertib PROS (Cohort 1)|Participants with PROS who have a measurable lesion by volumetric MRI receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
9767334|NCT03094832|Experimental|Part B: Miransertib PS (Cohort 2)|Participants with PS who have a measurable lesion by standardized digital photography receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
9767335|NCT03094832|Experimental|Part B: Miransertib PROS/PS (Cohort 3)|Participants with PROS or PS who do not meet all the eligibility criteria for Cohorts 1 or 2 receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
9767336|NCT03094832|Experimental|Part B: Miransertib Compassionate Use/Expanded Access (Cohort 4)|Participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access. Participants receive miransertib orally at 15 mg/m^2 QD for at least three 28-day cycles with an option to dose increase to 25 mg/m^2. Participants receiving miransertib at the time of enrollment under Compassionate Use/Expanded Access will continue with their current dose (not to exceed 25 mg/m^2). Treatment will continue for up to 48 cycles or until disease progression, unacceptable toxicity, or discontinuation.
9767337|NCT03088930|Experimental|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
9767338|NCT03084731|Experimental|Goup 1:Children with moderate stunting and wasting|Test 3 prototype MDCFs and the current rice-lentil RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week 2x /day intervention, with a 2 week post-intervention phase to assess durability of MDCF-induced changes in the microbiota.
9767339|NCT03084731|Experimental|Goup 2:Children with moderate stunting and wasting|Select most efficacious MDCF from study 1 and compare with 2 additional MDCF prototypes using the same design used in study 1.
9767340|NCT03084731|Experimental|Goup3:Children with moderate stunting and wasting|Select lead MDCF from studies 1, 2 and conduct final 'bake-off' vs current RUSF and also examine the impact of 1x vs 2x per day administration with a 4 week post-intervention period to provide additional information on the durability of MDCF-sponsored changes in the microbiota.
9767341|NCT03084731|No Intervention|Healthy controls|In order to construct a library of gut microbiota of healthy growing children of the same community, one spot fecal sample (1-2 gm) and spot blood sample (2 mL) will be collected from 30 children each who would be aged 12-18 months of either sex, having WLZ and LAZ : >-1
9767342|NCT03053440|Experimental|Arm A (Experimental Arm-BGB-3111)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive BGB-3111 in treatment [Arm A]
9767343|NCT03053440|Active Comparator|Arm B (Active Comparator-Ibrutinib)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive Ibrutinib in treatment [Arm B]
9767344|NCT03053440|Experimental|Arm C (Experimental Arm-BGB-3111)|Approximately 22 participants found to have MYD88 wild type will be enrolled in Cohort 2 and receive BGB-3111 in treatment [Arm C]
9767345|NCT03035188|Experimental|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
9767346|NCT03032276|Experimental|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
9767347|NCT03032276|No Intervention|Comparison|Another 15 union will be selected where no intervention will be implemented
9767348|NCT03032172|Experimental|Risdiplam|Participants will receive multiple doses of risdiplam orally once daily for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label extension (OLE) phase.
9767349|NCT02963415|Experimental|Virtual Reality Cognitive Training|Exergame to stimulate cognition
9767350|NCT02960204|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.
9767351|NCT02960204|Active Comparator|Emricasan (25 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.
9767352|NCT02960204|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.
9767353|NCT02960204|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.
9767354|NCT02959645||Cervical Dystonia|patients will have Cervical Dystonia
9767355|NCT02959645||Healthy control|Healthy Volunteers
9767356|NCT02955511|Active Comparator|Blade MAC size 3|"Patient will be intubated using a:~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
9767357|NCT02955511|Active Comparator|Blade MAC size 3.5|"Patient will be intubated using a:~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
9767358|NCT02955511|Experimental|Inscope Blade size 3.5|"Patient will be intubated using a:~Inscope DL-blade size 3.5"
9767359|NCT02944747|Experimental|Education & paper based calendar|"The participants will be counseled on importance of remembering LMP. In addition, a free calendar will be provided to the participant who will be asked to record menstrual bleeding and spotting dates in each month. The women will be asked to record no bleeding if she did not bleed for any particular month. Likewise, if anybody forgets to record, she will ask to keep a record of it in the subsequent month. Female counselors from the study team will conduct the group or individual education sessions."
9767360|NCT02944747|Experimental|Education & SMS system|Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
9767361|NCT02944747|Experimental|Education & smart-phone application|Smart phones with an application and an inbuilt reminder system will be provided free of cost to participants who will be asked for recording menstruation dates. Experienced programmer from icddr,b will be involved in developing the application. Again, participants will be asked to record bleeding dates each month and will upload the data in the central server via internet. If participants fail to record the dates and upload the data, an automatic reminder will be sent.
9767362|NCT02944747|No Intervention|Comparison|The participants will not receive any of the interventions that are focused in this study.
9984282|NCT04264143|Experimental|MTX110 and CED|All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
9984744|NCT03777462|Experimental|Group B of neoadjuvant chemoradiotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
10203552|NCT05199467|Experimental|Health Coaching|Receipt of up to 12 sessions of health coaching, plus printed materials providing information on VA benefits
9767366|NCT02923882|Experimental|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
9767367|NCT02923882|No Intervention|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
9767368|NCT02907099|Experimental|Treatment (CXCR4 antagonist BL-8040, pembrolizumab)|Patients receive CXCR4 antagonist BL-8040 SC on days 1-5 and 8-12 of cycle 1 and days 1, 4, 8, and 11 of subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over about 30 minutes on day 1. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9767369|NCT02901626|Experimental|Pessary|Arabin pessary. Participants where local standard of care includes vaginal progesterone will also receive progesterone.
9767370|NCT02901626|No Intervention|No Pessary|Participants that do not receive a pessary will receive the usual standard of care, including vaginal progesterone if that is the local standard.
10203553|NCT05199467|Active Comparator|VA Benefits Information|Receipt of printed materials providing information on VA benefits
10203554|NCT05199376|Experimental|Percutaneous cryotherapy|Cryoablation of the tumor
10203555|NCT05199363|Active Comparator|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
10203556|NCT05199363|Active Comparator|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
10203557|NCT05199363|Active Comparator|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers."
10203558|NCT05199363|No Intervention|Control|Study participant will obtain standard information about magnetic resonance imaging before examination.
10203559|NCT05199337|Experimental|Treatment Arm|Subjects will receive ZN-d5 orally (PO), once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10205329|NCT02761603|Experimental|Tai Chi (CHI)|24 hours of group instruction in 8 meditative Tai Chi movements.
9767371|NCT02897427||Screening (specimen collection, HPV testing)|"STAGE I: Participants fill out a survey and undergo collection of blood and oral rinse samples.~STAGE II: Participants complete a head and neck exam by using brushing of the oropharyngeal mucosa, a thorough oropharyngeal exam including narrow band imaging, collection of oral rinse sample, transcervical ultrasonography of the neck lymph nodes and oropharynx, anoscopy, penile exam, and complete Papanicolaou/HPV testing. Participants undergo repeat oropharyngeal screening, oral HPV DNA test, oral HPV integration testing, ultrasound, and blood sample collection once every year for 5 years. Select participants will provide oral rinse sample by mail every six months."
9767372|NCT02884401|Other|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
9767373|NCT02873715|Active Comparator|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
9767374|NCT02873715|Experimental|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two yeart study
9767375|NCT02856269|Active Comparator|45 mg daily|Participants in this arm will take a daily 45 mg dose of zinc gluconate.
9767376|NCT02856269|Active Comparator|90 mg daily|Participants in this arm will take a daily 90 mg dose of zinc gluconate.
9767377|NCT02845596|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
9767378|NCT02845596|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
9767379|NCT02839148|Experimental|Dietary supplementation|In case of dietary supplementation, we will provide milk and egg 6 days a week for 3 months to stunted children.
9767380|NCT02839148|Experimental|psychosocial stimulation|In case of psychosocial stimulation, we well provide PS weekly for first month, fortnightly for 2nd and 3rd months and then monthly for next 3 months. The total number of visits will be 11 over a period of 6 months.
9767381|NCT02833207|Experimental|EDD Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
9767382|NCT02833207|Experimental|EDD Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
9767383|NCT02833207|Experimental|ROV Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
9767384|NCT02833207|Experimental|ROV Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
9767385|NCT02829593|Experimental|type 1 diabetes|type 1 diabetes >5 years duration
9767386|NCT02829593|Placebo Comparator|healthy controls|
9767387|NCT02815995|Experimental|Adipocytic Tumors Group|"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
9767388|NCT02815995|Experimental|Vascular Tumors Group|"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
9836194|NCT02774278|Experimental|Erlotinib|Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
9767389|NCT02815995|Experimental|Undifferentiated Pleomorphic Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
9767390|NCT02815995|Experimental|Synovial Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
9767391|NCT02815995|Experimental|Osteosarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
9767392|NCT02815995|Experimental|Other Sarcomas Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
9767393|NCT02812615|Experimental|Malnourished participants|After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
9767394|NCT02807883|Experimental|Blinatumomab|Blinatumomab as continuous intravenous infusion at dose of 28 µg/24 hours over 4 weeks followed by 2 week treatment-free period for 6-week treatment cycle; 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
9767395|NCT02807363|Experimental|Treatment A: Leuprolide Oral Tablet, 4 mg QD|Leuprolide Oral Tablet QD: 4 mg for 28 consecutive days.
9767396|NCT02807363|Experimental|Treatment B: Leuprolide Oral Tablet, 4 mg BID|Leuprolide Oral Tablet BID: 4 mg, 12 hours apart for 28 consecutive days.
9767397|NCT02807363|Active Comparator|Treatment C: Leuprolide 1 month depot|Leuprolide Depot : intramuscular (IM) 3.75 mg depot injection administered for one month of therapy
9767398|NCT02807363|Experimental|Treatment D: Leuprolide Oral Tablet, 10 mg BID|Leuprolide Oral Tablet BID: 10 mg, 12 hours apart for 28 consecutive days
9767399|NCT02784496|Experimental|Treatment (ruxolitinib, follow-up)|Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
9767400|NCT02772731|Experimental|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
9767401|NCT02772731|Active Comparator|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
9767402|NCT02756403|Active Comparator|Azithromycin|500 mg of Azithromycin
9767403|NCT02756403|Active Comparator|Doxycycline|200 mg of Doxycycline
9767404|NCT02756403|Active Comparator|Metronidazole|500 mg of Metronidazole
9767405|NCT02756403|Placebo Comparator|Placebo|Inactive Ingredient
9767406|NCT02751502|Experimental|Bimanual-to-unimanual device home training program|
9767407|NCT02751502|No Intervention|Conventional non-device home training program|Subjects receive 6 weeks of ongoing usual and customary care schedule of home physical and occupational therapy as usual and customary care independent of the study.
9767408|NCT02739035|No Intervention|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
9767409|NCT02739035|Experimental|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
9767410|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
9767411|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
9767412|NCT02710851|Experimental|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
9767413|NCT02710851|Experimental|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
9767414|NCT02710851|Experimental|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
9767415|NCT02710851|Placebo Comparator|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
9767416|NCT02704858|Experimental|NEO100 Phase 1|Intranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose.
9767417|NCT02704858|Experimental|NEO100 Phase 2A|Intranasal delivery of NEO100 (perillyl alcohol) four times a day. Treatment of total of 25 patients at maximum tolerated dose.
9767418|NCT02682888|Experimental|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
9767419|NCT02682888|Experimental|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
9767420|NCT02682888|Experimental|oxytocin group|experiment 2: intranasal administration of oxytocin
9767421|NCT02682888|Placebo Comparator|placebo control group|experiment 2: intranasal administration of placebo
9767422|NCT02675452|Experimental|AMG 176 - Part 1a|Part 1a - Participants with muliple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion for two-consecutive days (QD2) followed by a 5 days break.
9767423|NCT02675452|Experimental|AMG 176 - Part 1b|Part 1b - Participants with multiple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
9767424|NCT02675452|Experimental|AMG 176 - Part 3a|Part 3a - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion once a day, for two-consecutive days (QD2) followed by a 5 day break.
9767425|NCT02675452|Experimental|AMG 176 - Part 3b|Part 3b - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
9767426|NCT02675452|Experimental|AMG 176 - Part 3c|Part 3c - Participants in Japan only with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
9767427|NCT02675452|Experimental|AMG 176 - Part 3d|Part 3d - Participants in the United States with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW), for 3 weeks, in combination with itraconazole.
9767428|NCT02675452|Experimental|AMG 176 - Part 4|Part 4 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
9767429|NCT02675452|Experimental|AMG 176 - Part 5|Part 5 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion at the maximum tolerated combination dose from Part 4, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
9767430|NCT02669186|Experimental|'Bupivacaine + Fentanyl' (Opioid Group)|Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
9767431|NCT02669186|Active Comparator|Bupivacaine (Local Anesthetic Group)|Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
9767432|NCT02667873|Experimental|SL-801|The starting dose regimen of SL-801 (i.e., the dose regimen in Cohort 1) is 5 mg/day on Days 1-4 and 8-11 every 21 days. In the 2nd portion of the dose escalation stage, patients receive SL-801 PO once daily on days 1-2, 8-9, 15-16 and 22-23 of a 28-day cycle. The starting dose will be 70 mg/day (the next planned dose level).The SL-801 dose regimen for a particular patient is dependent on the cohort in which the patient is enrolled
9767433|NCT02665117|Active Comparator|KMgCit + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.
9767434|NCT02665117|Active Comparator|KCl + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.
9767435|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
9767436|NCT02659202|Experimental|Precision Spinal Cord Stimulator System|Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
9767437|NCT02646839|Experimental|KIR Favorable Transplant|To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
9767438|NCT02641236|Active Comparator|Gut Decontamination with vancopoly|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
9767439|NCT02641236|No Intervention|No Gut Decontamination|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
9767440|NCT02513251||Case group|Chronic pain patient
9767441|NCT02487797|Experimental|High dose oxytocin regimen|The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
9767442|NCT02487797|Active Comparator|Low dose oxytocin regimen|The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
9767443|NCT02481154|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
9767444|NCT02476786|Experimental|Endocrine therapy alone|"Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen~Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment~After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy~Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire~Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
9767445|NCT02405520|Experimental|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
9767446|NCT02405520|Experimental|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
9767447|NCT02405520|Experimental|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
9767448|NCT02405520|Placebo Comparator|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
9767449|NCT02402088|Active Comparator|Normal Weight|BMI18.5-24.9 (normal range)
9767450|NCT02402088|Experimental|Overweight|body mass index between 25.0 - 29.9 (overweight range)
9767451|NCT02402088|Experimental|Obese|body mass index between 30 and 35 (obese range)
9767452|NCT02375802|Experimental|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
9767453|NCT02348762|Experimental|Glycine and N-acetylcysteine|Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months
9767454|NCT02348359|Experimental|50 mg of X-82 plus ivt anti-VEGF prn|Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
9767455|NCT02348359|Experimental|100 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
9767456|NCT02348359|Experimental|200 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
9767457|NCT02348359|Placebo Comparator|Placebo plus ivt anti-VEGF prn|Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
9767458|NCT02296450||Quality of Life (QoL) Assessment|Patients involved in this study will have a wide range of dermatologic conditions for which they will be assessed and managed by the treating physician. An appropriate QoL instrument will be administered at the initial visit, and if applicable, at subsequent follow-up visit(s). Treatment of the dermatologic condition will be at physician's discretion based on the patient's presenting symptoms and is not an intervention itself within this study.
9767459|NCT02285062|Experimental|R2-CHOP|Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
9767460|NCT02285062|Active Comparator|R-CHOP|Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
9767461|NCT02264977|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
9767462|NCT02252432|Active Comparator|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
9767463|NCT02252432|Active Comparator|Methadone|Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
9767464|NCT02252432|Experimental|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
9767465|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
9767466|NCT02224872|Experimental|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
9767467|NCT02206945|Experimental|neurofeedback|Two imaging sessions of neurofeedback.
9767468|NCT02206945|Placebo Comparator|control feedback|Two imaging sessions of feedback
9767469|NCT02187224|Experimental|Progesterone|For the three days prior to each test day every participant in this arm will receive progesterone.
9767470|NCT02187224|Placebo Comparator|Placebo|For the three days prior to each test day every participant in this arm will receive placebo.
9767471|NCT02093455|Active Comparator|Chardonnay Seed Flour (CSF)|Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
9767472|NCT02093455|Placebo Comparator|Placebo|Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.
9767473|NCT02079584||Warfarin|A study group taken from existing anticoagulant clinics treated with warfarin.
9767474|NCT02079584||Rivaroxaban|A group seen in the rivaroxaban clinic under study.
9767475|NCT02059499|Experimental|Arm A (imiquimod)|Patients apply imiquimod intra-anally QD for 16 weeks.
9767476|NCT02059499|Experimental|Arm B (fluorouracil)|Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
9767477|NCT02059499|No Intervention|Arm C (observation)|Patients receive no treatment. Patients who still have HSIL at week 20 and who agree to randomization may cross-over to Arm A or B.
9767478|NCT02054689|Other|Fractionated Stereotactic Radiosurgery|24 to 36 Gy in 3 fractions (8-12 Gy/fx).
9767479|NCT02009176|Experimental|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
9767480|NCT02009176|Active Comparator|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
9767481|NCT01995669|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive lenalidomide PO QD on days on days 2-22 and obinutuzumab IV over 4-5 hours on days 1, 2, 8, 15, and 22 of cycle 1 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients not experiencing progression and who in the opinion of treating physician are deriving benefit from combination treatment may continue lenalidomide for an additional 6 cycles (up to cycle 12) and obinutuzumab on day 1 every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
9767482|NCT01983410||BRCAmut carrier relatives of a BRCAmut PDAC patient|Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
9767483|NCT01983410||BRCAmut carrier relatives of a BRCA mutation PDAC|Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
9767484|NCT01983410||BRCAmut carriers|who are not related to a BRCAmut PDAC patient
9767485|NCT01983410||AJ PDAC patients|who are proven non-BRCAmut carriers.
9767486|NCT01983410||AJ first or second degree relatives of an AJ PDAC patient from a multiplex family|A family with at least two first or second degree relatives w ho have had PDAC.
9767487|NCT01981096|Experimental|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
9767488|NCT01981096|Active Comparator|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
9767489|NCT01968109|Experimental|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
9767490|NCT01968109|Experimental|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
9767491|NCT01968109|Experimental|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
9767492|NCT01962415|Experimental|UCBT:transfusion dependent anemias or increased rejection risk|Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
9767493|NCT01962415|Experimental|BMT, PBSCT and not transfusion dependent UCBT|Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
9767494|NCT01954550|Experimental|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
9767495|NCT01954550|Sham Comparator|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
9767496|NCT01950351|Experimental|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy in 15 fractions over 5-6 weeks.
9767497|NCT01935336|Experimental|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9767498|NCT01927731|Experimental|Arm I (cord blood transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.
9767499|NCT01927731|Experimental|Arm II (haploidentical donor stem cell transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.
9767500|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
9767501|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
9767502|NCT01889329|Experimental|RUTF-1|Made from local food ingredients
9767503|NCT01889329|Experimental|RUTF-2|Made from local food ingredients
9767504|NCT01889329|Active Comparator|Plumpynut|Made from peanut
9767505|NCT01885702|Experimental|MSI-positive CRC patients|I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)
9767506|NCT01885702|Experimental|Carriers of germline MMR-gene mutation|II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC
9785729|NCT01258790|Experimental|Active Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using an Active Magstim Figure-8 TMS coil.
9767507|NCT01853020|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
9767508|NCT01853020|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
9784261|NCT01221181|Experimental|Eculizumab|Patients will receive Eculizumab and be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitides vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
9784262|NCT01221194|Active Comparator|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
9784263|NCT01221194|Active Comparator|PFC Stockings|The stocking therapy group will be given PFC shear reducing stockings to wear.
9784264|NCT01221207|Active Comparator|Device - Total Contact Cast (TCC)|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
9784265|NCT01221207|Active Comparator|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
9784266|NCT01221207|Active Comparator|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
9784267|NCT01221233|Experimental|NMES AND Stabilization Exercises|Neuromuscular Electrical Stimulation and Lumbar Stabilization Exercises
9784268|NCT01221233|Active Comparator|Moist Heat AND Stabilization Exercises|Moist Heat and Lumbar Stabilization Exercises
9784269|NCT01221272|Experimental|Ranolazine/Placebo|Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
9784270|NCT01221272|Experimental|Placebo/Ranolazine|Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
9784271|NCT01221285|Experimental|German cockroach allergenic extract|Participants will receive weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
9784272|NCT01221298|Experimental|ABT-450/r and ABT-072, plus ribavirin (RBV)|ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.
9835408|NCT02737826|Active Comparator|Phase II - Gabapentin + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg oral gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
9835409|NCT02737826|Placebo Comparator|Phase II - Placebo + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
9835410|NCT02737826|Experimental|Phase II - Buprenorphine taper|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
9835411|NCT02737852|Experimental|Healthy subject|"Healthy subject exposed to Trojan Chameleon Personal Lubricant at least four times weekly for two weeks"
9835412|NCT02737891|Experimental|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
9835413|NCT02737891|Placebo Comparator|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
9835414|NCT02737917|Experimental|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
9835415|NCT02737917|Other|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
9835416|NCT02737930|Experimental|Fluoxetine|20 mg fluoxetine capsule by mouth once daily for 90 days
9835417|NCT02737930|Placebo Comparator|Placebo|Matching placebo
9835418|NCT02738008|Experimental|ARC-520 Injection|Multiple administrations of ARC-520 starting at a dose level of 2 mg/kg, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
9835419|NCT02738086|Experimental|Early PABC Intervention|GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
9835420|NCT02738086|Experimental|Wait-List Control Intervention|GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.
9835421|NCT02738138|Experimental|ABT-493/ABT-530 for 8 weeks|HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
9835422|NCT02738138|Experimental|ABT-493/ABT-530 for 12 weeks|HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks
9835423|NCT02738151|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
9835424|NCT02738151|Active Comparator|Tresiba|Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
9835425|NCT02738203|Experimental|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
9835426|NCT02738203|Placebo Comparator|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
9835427|NCT02738333|Experimental|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
9835428|NCT02738333|Experimental|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
9835429|NCT02738333|Experimental|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
9835430|NCT02738450|Active Comparator|ACI-24 low dose|Vaccine formulation will be administrated s.c. 7 times.
9835431|NCT02738450|Active Comparator|ACI-24 high dose|Vaccine formulation will be administrated s.c. 7 times.
9835432|NCT02738450|Placebo Comparator|Placebo|The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
9835433|NCT02738580|Active Comparator|rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
9835434|NCT02738580|Active Comparator|HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
9767509|NCT01797523|Experimental|Letrozole + Metformin + RAD001|"Patients have a 7-10 day lead in period where they take Metformin alone. The starting dose of Metformin 500 mg by mouth daily for 4 days and then increased to 500 mg by mouth twice a day. Everolimus and Letrozole added and considered the start of Cycle #1.~Everolimus administered by mouth as once daily dose of 10 mg. Letrozole 2.5 mg tablet by mouth once daily. The oral dose of Everolimus should be taken together with the daily dose of Letrozole 2.5mg."
9767510|NCT01733693|Experimental|Buprenorphine|Oral sublingual tablet, 8-32 mg per day, administered daily for duration of 4 months
9767511|NCT01733693|Active Comparator|Methadone|Oral sublingual tablet, 60-100 mg per day, administered daily for duration of 4 months
9767512|NCT01727284|Other|MR-guided cryoablation (freezing of tissue and/or tumors)|
9767513|NCT01712490|Experimental|A + AVD|A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
9767514|NCT01712490|Active Comparator|ABVD|ABVD consists of doxorubicin 25 mg/m^2, bleomycin 10 units per square meter (units/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
9767515|NCT01702805|Active Comparator|Low Threshold Transfusion|Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group
10203560|NCT05199324|Experimental|Early step-down to oral antibiotic therapy|The oral antibiotic options are fluoroquinolones (most commonly, ciprofloxacin) or trimethoprim-sulfamethoxazole. The recommended doses for patients with normal renal function would be ciprofloxacin 750 mg twice daily (if body weight ≥70 kg) or ciprofloxacin 500 mg twice daily (if body weight <70 kg) or trimethoprim-sulfamethoxazole 5 mg/kg (for trimethoprim component) every 12 hourly or trimethoprim-sulfamethoxazole (160 mg / 800 mg; double strength) two tablets twice daily. Doses may be adjusted in the setting of renal dysfunction. The minimum treatment duration should be 7 days of active antibiotics (including empiric therapy), although treatment regimen may be longer than 7 days due to regimen extension or requirement for prolonged regimen as clinically indicated.
10203561|NCT05199324|Active Comparator|Continuing intravenous antibiotic therapy|The intravenous antibiotic(s) to be administered will be determined by the treating doctor according to what would be considered standard of care in the hospital site. Commonly used intravenous antibiotics (and doses) for treatment of Gram-negative bacteraemia include ceftriaxone 2 g daily or cefazolin 2 g three times daily. The minimum treatment duration should be 7 days of active antibiotics (including empiric therapy), although treatment regimen may be longer than 7 days due to regimen extension or requirement for prolonged regimen as clinically indicated.
9767516|NCT01702805|Active Comparator|High Threshold Transfusion|Transfusions will be administered using a higher threshold hemoglobin value.
9767517|NCT01621152|Other|Conventional management arm|Patients with AKI receive standard of care in the conventional manner by the primary clinicians
9767518|NCT01621152|Active Comparator|AKI sniffer instigated AKI management|primary clinicians for the AKI patients in this arm receive a verbal alert and reminder of KDIGO guidelines.
9767519|NCT01603316|Active Comparator|Food Voucher Program (Voucher)|Food Voucher arm, each participant will receive a debit card specifically created for this program. Each month for the duration of study participation (6 months), the debit card will be credited with $128 & given to the patient in person or via mail. Patients will be instructed to use these cards only for food purchases. If patients are not able to use the debit card at their local grocery stores, patients will be provided with a money order of the same dollar value instead of the debit card. They will be counseled on using their vouchers only for healthful foods, in a way that stretches their food dollars. Purchases will be tracked by having patients bring their receipts in for review each month when they come in to pick-up their next monthly vouche, or by providing electronic copies of receipts. Patients will be provided with a receipt holder to assist in storing receipts for review. For voucher cards sent via mail, patients will receive a mailing letter accompanying each card.
9767520|NCT01603316|Experimental|Home Grocery Delivery (Delivery)|"In the Home Grocery Delivery arm, each participant will receive home grocery delivery from PeaPod grocery delivery service or from FreshDirect (depending on the participants zip code), worth $128 per month, for the duration of study participation (6 months). Patients in the Delivery arm will review a list of food categories and a subset of items in each category with a COA."
9767521|NCT01603316|Experimental|Medically-Tailored Hospital-Based Food Pantry (Pantry)|Patients in this arm will have access to the pantry for the duration of their study participation (6 months). Those accessing the medically-tailored food pantry will pick-up a pantry bag weekly or bi-weekly (per patient preference) at the hospital, either during one of their medical appointments or at another preferred time. Each patient's food prefereces will be assessed once during baseline and they will be given food bags, tailored when possible and when available to these preferences and to their medical needs and cultural preferences.
9767522|NCT01499160|Experimental|HER2-positive or negative|Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.
9767523|NCT01333436|Experimental|Diabetic participants|Diabetic participants with normal to moderately high LDL-C
9767524|NCT01333436|Experimental|Nondiabetic participants|Non-diabetic participants with normal to moderately high LDL-C
9767525|NCT01307631|Experimental|Treatment (Akt inhibitor MK2206|Patients receive Akt inhibitor MK2206 PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9767526|NCT01256086|Experimental|24 µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
9767527|NCT01256086|Experimental|12µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
9767528|NCT01256086|Active Comparator|24 µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
9767529|NCT01256086|Active Comparator|12µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
9767530|NCT01149850|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
9835435|NCT02738775|Experimental|Cohort 1|Participant received intravenous (IV) infusion of ublituximab 150 milligrams (mg)/4 hour (hr) on Day 1, 450 mg/3 hr on Day 15 and 450 mg/1.5 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /3 hr on Day 15 before receiving ublituximab.
9835436|NCT02738775|Experimental|Cohort 2|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1.5 hr on Day 15 and 450 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1.5 hr on Day 15 before receiving ublituximab.
9835437|NCT02738775|Experimental|Cohort 3|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
10203562|NCT05199259||HCC positive Group|Multi-analyte blood test screen in participants with a recent confirmed untreated diagnosis of HCC by CT scan, MRI or biopsy.
10203563|NCT05199259||HCC negative Group: Sub-Group 1|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by CT or MRI (No lesion, LR-1 or LR-2)
9835438|NCT02738775|Experimental|Cohort 4|Participant received IV infusion of ublituximab 150 mg/3 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /3 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
9835439|NCT02738775|Experimental|Cohort 5|Participant received IV infusion of ublituximab 150 mg/2 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /2 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
9835440|NCT02738775|Experimental|Cohort 6|Participant received IV infusion of ublituximab 150 mg/1 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /1 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
9835441|NCT02738801|Experimental|GLPG1690 600 mg once daily (QD)|
9835442|NCT02738801|Placebo Comparator|Placebo QD|
9835443|NCT02738840|Experimental|Prodigy MRI or Proclaim Elite MR|"The Prodigy MRI system is only MR conditional for scans of the head and extremities (upper except shoulder, lower except hip).~The Proclaim Elite system is MR conditional for scans of the head, extremities or any other body part."
9835444|NCT02738879|Experimental|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
9835445|NCT02738879|Placebo Comparator|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
9835446|NCT02739100|Experimental|Triferic via Hemodialysate|"Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.~Intervention Drug: Triferic"
9835447|NCT02739100|Experimental|Triferic via IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via the unused heparin infusion line (pre-dialyzer).~Intervention: Drug: Triferic"
9835448|NCT02739100|Experimental|Triferic IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via an infusion port (post-dialyzer).~Intervention: Drug: Triferic"
9835449|NCT02739269|Active Comparator|AMH group|Serum AMH measurement
9835450|NCT02739269|Sham Comparator|AFC group|AFC measurement
9835451|NCT02739321|Experimental|Mattress Technology On then Off|"Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention."
9835452|NCT02739321|Experimental|Mattress Technology Turned Off then On|"No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration."
9835453|NCT02739360|Experimental|Idelalisib|Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
9835454|NCT02739594|Experimental|Ibandronate|Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
9835455|NCT02739594|Active Comparator|Zoledronate|Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
9835456|NCT02739698|Experimental|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
9835457|NCT02739698|Experimental|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
10203564|NCT05199259||HCC negative Group: Sub-Group 2|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by ultrasound. Participants will be scheduled for a 6 month visit (at least 5 months but no more 9 months form enrollment) for a confirmatory ultrasound.
10203565|NCT05199220||Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
10203566|NCT05199207|Experimental|Sarcopenic patient|Patient with sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
10203567|NCT05199207|Active Comparator|Non sarcopenic patient|Patient without sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
10203568|NCT05199181|Experimental|Full pulpotomy|All patients were treated in one visit (with Full Pulpotomy); the previously trained General Practice Dentist performed all the clinical procedures
10203569|NCT05199168|No Intervention|Thoracoscopic esophagectomy without IONM|
9767531|NCT01090089|Experimental|Lenalidomid, PBSCT|A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
9767532|NCT01090089|Active Comparator|Lenalidomid|A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
9767533|NCT01061151|Active Comparator|Antepartum Arm A|Mothers received ZDV + sdNVP + TRV Tail
9767534|NCT01061151|Experimental|Antepartum Arm B|Mothers received Triple ARV (3TC-ZDV + LPV-RTV)
9767535|NCT01061151|Experimental|Antepartum Arm C|Mothers received Triple ARV (TRV + LPV-RTV)
9767536|NCT01061151|Other|Late Presenters|Registration to facilitate a structure to screen women and infants for randomization in the Postpartum Component.
9767537|NCT01061151|Experimental|Postpartum Arm A (Maternal Prophylaxis)|Mothers received prophylaxis [preferred regimen: TRV + LPV-RTV]. Infants received short-course NVP.
9767538|NCT01061151|Experimental|Postpartum Arm B (Infant Prophylaxis)|Infants received extended NVP.
9767539|NCT01061151|Experimental|Maternal Health Arm A (Continue triple ARVs)|Mothers continued receiving triple ARV regimen [preferred regimen: TRV + LPV-RTV].
9767540|NCT01061151|Active Comparator|Maternal Health Arm B (Discontinue triple ARVs)|Mothers discontinued triple ARV regimen.
9767541|NCT00981058|Experimental|Necitumumab + Gemcitabine + Cisplatin|
9767542|NCT00981058|Active Comparator|Gemcitabine + Cisplatin|
9767543|NCT00885495|Active Comparator|B|Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days
9767544|NCT00885495|Active Comparator|A|Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days
9767545|NCT00869817||1|Mutation Positive
9767546|NCT00869817||2|Mutation Negative
9767547|NCT00692939|Experimental|1|High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
9767548|NCT00625638|Experimental|Standard Care Only|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
9767549|NCT00625638|Experimental|Standard Care + IVR System|Standard Care + Interactive Voice Response (IVR) System Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes. Phone calls made once daily, each taking about 3-5 minutes to complete.
9767550|NCT00362284|Experimental|NYUCI-AC group|Adult children in this arm received the NYUCI-AC intervention, which consisted of 6 individual and family counseling sessions, the offering of an adult child specific support group, and the provision of ad hoc, or ongoing, consultation throughout the duration of participation.
9767551|NCT00362284|No Intervention|Usual care control|Adult children randomly assigned to the usual care control did not receive the NYUCI-AC intervention. If they were in crisis or required support, the NYUCI-AC counselors provided information and referral on an as-needed basis.
9767552|NCT00183482|Experimental|Family Group Cognitive Behavioral|The intervention is a family group cognitive behavioral program for families of parents with a history of depression to teach parenting skills to parents and coping skills to children.
9767553|NCT00183482|Active Comparator|Written Information|The comparison arm involves providing written information about depression and stress to parents with a history of depression and their children.
9767554|NCT00084799|Experimental|hu3S193 10 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 10 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
9767555|NCT00084799|Experimental|hu3S193 20 mg/m2|Patients with small cell lung cancer tumors confirmed to have Lewis Y expression were enrolled to receive 4 weekly injections of hu3S193 at a dose of 20 mg/m2. The dose of hu3S193 given on Weeks 1 and 4 was trace-labeled with 6-8 millicurie (mCi) of indium-111 (111In).
9767556|NCT00005398||1; no experimental groups in this study|Observational cohort study
9767557|NCT00821236|Active Comparator|Wavelight|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
9767558|NCT00821236|Active Comparator|AMO/VISX CustomVue|AMO/VISX CustomVue™
9767559|NCT00821236|Active Comparator|LADARVision 4000 excimer laser|LADARVision 4000 excimer laser
9767560|NCT00821327|Experimental|Study Arm|Gemcitabine, Cisplatin, Sunitinib
9767561|NCT00821431|Experimental|Compression device|The electrical compression device is operated from battery or a main adaptor. It is based upon the use of inflatable pneumatic cuffs that apply controlled compression to the foot, ankle and calf.
9767562|NCT00821431|Active Comparator|Profore, 4-layer bandage|A high compression 4-layer bandage (Profore, Trademark of Smith and Nephew). This is a four-layer system that can be purchased either separately or as a package: a wound contact layer (Knitted viscose), a sub-compression wadding bandage, two layers of elastane bandage plus a top cohesive layer.
9767563|NCT00821509|Active Comparator|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent hand washing in office and at home
9767564|NCT00821509|Active Comparator|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
9767565|NCT00821509|No Intervention|Control|No change in hygiene behaviour
9835458|NCT02739789|Sham Comparator|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
9835459|NCT02739789|Active Comparator|Active tDCS|tDCS stimulation will be administered over the brain area of interest
9835460|NCT02739828||Patients with Hidradenitis Suppurativa|Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.
9835461|NCT02739984|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
9835462|NCT02739984|Experimental|Evolocumab|Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
9835463|NCT02739997|Experimental|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
9835464|NCT02740049|Experimental|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
9835465|NCT02740114|Active Comparator|Bupivacaine Group|"Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
9835466|NCT02740114|Experimental|Liposomal Bupivacaine + Bupivacaine Group|"Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
9835467|NCT02740153||Urea Cycle Disorder with Liver Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~History of liver transplant"
9835468|NCT02740153||Urea Cycle Disorder without Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~No history of liver transplant, managed medically"
9835469|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
9835470|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
9835471|NCT02740478||Volunteers|20 volunteer subjects, no selection criteria
9835472|NCT02740504||Subjects|All 20 subjects. Selected to have a range of ages (18 to less than 75) and BMI from 18.5 to 45
9835473|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
9835474|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
9835475|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
9835476|NCT02740543|Active Comparator|Allergic Asthma (AA)|
9835477|NCT02740543|No Intervention|Control|
9835478|NCT02740582|Experimental|Tolcapone First, then Placebo|Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID
9835479|NCT02740582|Placebo Comparator|Placebo First, then Tolcapone|Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID
9835480|NCT02740660|Experimental|Caffeine 100mg / Albuterol 4mg|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
9835481|NCT02740660|Placebo Comparator|Placebo|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
9767566|NCT00821626|Active Comparator|Rapid test|Returning travelers with fever will have a rapid flu test
9767567|NCT00821626|Sham Comparator|Comparator|Returning travelers with fever will benefit of the usual medical care, without rapid flu test
9767568|NCT00821678|Experimental|Arm 1 Telemedicine Outreach for PTSD|Telemedicine-Based Collaborative Care
9767569|NCT00821678|No Intervention|Arm 2 Treatment as usual|Usual Care
9767570|NCT00821795|Active Comparator|NPH/Regular 70/30 mix|transition insulin therapy with NPH/Regular 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
9767571|NCT00821795|Active Comparator|Aspart insulin analog biphasic mix|transition insulin therapy with Aspart insulin analog 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
9767572|NCT00821821|Experimental|MCI-186|
9767573|NCT00821821|Placebo Comparator|Placebo Group|
9767574|NCT00821873|Experimental|CR Plug BackFill|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site
9767575|NCT00821886|Experimental|Ixabepilone/Trastuzumab/Carboplatin|Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
9767576|NCT00821951|Experimental|Vorinostat and Radiotherapy|
9767577|NCT00821964|Experimental|Treatment (biological therapy, chemo)|Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9767578|NCT00822094|Experimental|CPX-351 (Arm A)|First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
9767579|NCT00822094|Active Comparator|Salvage Therapy (Arm B)|First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
9767580|NCT00822107|Experimental|Thiazide Response|Hydrochlorothiazide 50 mg will be administered by mouth once.
9767581|NCT00822172|Active Comparator|Cilostazol + L-Carnitine|1 tablet cilostazol 100 mg PO BID and 3 capsules L-carnitine 334 mg PO BID
9767582|NCT00822172|Placebo Comparator|Cilostazol + Placebo|1 tablet cilostazol 100 mg PO BID and 3 capsules placebo PO BID
9767583|NCT00822185|Experimental|vatreptacog alfa, 5 mcg/kg|
9767584|NCT00822185|Experimental|vatreptacog alfa, 10 mcg/kg|
9767585|NCT00822185|Experimental|vatreptacog alfa, 20 mcg/kg|
9767586|NCT00822185|Experimental|vatreptacog alfa, 30 mcg/kg|
9767587|NCT00822237|Experimental|VARIVAX 2007 process + M-M-R II|
9767588|NCT00822237|Active Comparator|VARIVAX 1999 process + M-M-R II|
9767589|NCT00822328|Experimental|1|Fermented milk with Lactobacillus casei strain Shirota 100ml per day
9767590|NCT00822328|Placebo Comparator|2|Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
9767591|NCT00822354|Experimental|1|Subjects will receive tadalafil 20mg every other day for the first month, and then placebo for the second month.
9767592|NCT00822354|Experimental|2|Subjects will receive placebo for the first month, and tadalafil 20mg orally every other day for the second month.
9767593|NCT00822510|Experimental|Telephone Interpersonal Counseling|Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
9767594|NCT00822510|Active Comparator|Telephone delivered education only|Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.
9767595|NCT00822523|Experimental|Botulinum toxin type A, 20 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 20 units
9767596|NCT00822523|Experimental|Botulinum toxin, type A, 2 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 2 units
9767597|NCT00822523|Placebo Comparator|Placebo|Saline, Single dose, Intramuscular injection into right EDB
9767598|NCT00822588|Experimental|1|
9767599|NCT00822588|No Intervention|2|
9767600|NCT00822692|Active Comparator|Bactrim DS|Trim/sulfa (800/160) two tablets orally (PO) twice a day (BID) x 7 days
9767601|NCT00822692|Placebo Comparator|matched placebo|matched placebo 2 pills orally (PO) twice a day (BID) x 7 days
9767602|NCT00822757|Experimental|1|V710
9767603|NCT00822757|Placebo Comparator|2|Placebo
9767604|NCT00822770|Experimental|Phase I|ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
9767605|NCT00822770|Experimental|Phase II|ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
9767606|NCT00822900|Experimental|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone will be combined with a 20% Intralipid mixture for infusion.
9767607|NCT00822900|Placebo Comparator|Placebo|"Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion."
9767608|NCT00822926|Experimental|Placebo then Botox|Injection 1: Saline- Subcutaneous injection of saline into scar tissue Injection 2: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
9767609|NCT00822926|Experimental|Botox then Placebo|Injection 1: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue Injection 2: Saline- Subcutaneous injection of saline into scar tissue
9767610|NCT00823043||Timolol hemihydrate|Subjects currently prescribed timolol hemihydrate 0.5% solution.
9767611|NCT00823043||Timolol maleate|Subjects currently prescribed timolol maleate in sorbate.
9767612|NCT00823069|Other|Perlane and Perlane-L|This is a split-face design injecting both Perlane and Perlane-L injectable gels, administered once. Each subject received Perlane-L on one side of the face, and Perlane on the other. Subjects were blinded to which side of their face receive Perlane or Perlane-L. The study was randomized and treatments successive.
9767613|NCT00823082|Experimental|Antithrombin III treatment group|Preoperative ATIII supplementation administered immediately after anesthesia induction
9767614|NCT00823082|No Intervention|Control group|No preoperative ATIII supplementation administered
9767615|NCT00823134|Other|AL + polysomnography|Participant wears an Apnea Link sleep apnoea screening device during the polysomnography to detect apnoeas (obstructive, central).
9767616|NCT00823199|Experimental|Allopurinal treatment|Allopurinal 300mg once daily by mouth for four weeks
9767617|NCT00823212|Active Comparator|PROMUS|Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent
9767618|NCT00823212|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
9767619|NCT00823264|Experimental|Multiple Doses of Activated Charcoal|Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc
9767620|NCT00823264|No Intervention|Control|Will not receive activated charcoal. Serum levels will be followed.
9767621|NCT00823303|Experimental|Paricalcitol|titrated to achieve 40-60% PTH suppression
9767622|NCT00823303|Active Comparator|Calcitriol|titrated to achieve 40-60% PTH suppression
9767623|NCT00823459|Experimental|Single-Arm Everolimus|Single-arm study with patients receiving Everolimus orally once daily dosing of 10 mg continuously from Day 1 of study until progression of disease or unacceptable toxicity. In addition archival tissue will be analysed for markers of P13K/mTOR pathway activation.
9767624|NCT00823472|Experimental|Start rFSH cycle day 2|
9767625|NCT00823472|Experimental|Start rFSH on cycle day 5|
9767626|NCT00823615|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
9767627|NCT00823615|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
9767628|NCT00823719|Experimental|ofatumumab + DHAP or ICE chemotherapy regimen|This study is a single arm study, but the Investigators are required to prospectively choose to treat all of their subjects with either ICE or DHAP chemotherapy regimens in combination with ofatumumab. Regardless of whether the subject receives ICE or DHAP chemotherapy, all subjects will receive the same ofatumumab regimen and dose.
9767629|NCT00823797|Experimental|Treatment (bendamustine hydrochloride)|Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
9767630|NCT00823823|Active Comparator|Bivalved cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a bivalved cast
9835482|NCT02740920|Experimental|Pembrolizumab|200mg IV Day 1 every 3 weeks.
9767631|NCT00823823|Active Comparator|Circumferential cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a circumferential cast
9767632|NCT00823836|Experimental|ropinirolePR-PR group|
9767633|NCT00823836|Active Comparator|ropiniroleIR-PR group|
9767634|NCT00823901|Experimental|Clindamycin/Tretinoin Gel|Participants applied Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel on entire face (forehead, nose, chin, cheeks) once daily at night for 12 weeks
9767635|NCT00823901|Placebo Comparator|Placebo gel|Participants applied Placebo gel with no active medication on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks.
9767636|NCT00823966||Delavirdine Mesilate|Patients administered.
9767637|NCT00823979|Experimental|UK- 453,061 Dose One|
9767638|NCT00823979|Experimental|UK- 453,061 Dose Two|
9767639|NCT00823979|Active Comparator|Comparator|
9767640|NCT00824005|Placebo Comparator|Placebo Injections|Participants will receive placebo injections.
9767641|NCT00824005|Experimental|Active Stem Cell Injections|Participants will receive active stem cell injections.
9767642|NCT00824044|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.
9767643|NCT00824044|Active Comparator|Escitalopram|Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression
9767644|NCT00824070|Experimental|Besifloxacin|Besifloxacin ophthalmic suspension
9767645|NCT00824070|Active Comparator|Moxifloxacin|Vigamox (moxifloxacin ophthalmic solution, 0.5%)
9767646|NCT00824070|Active Comparator|Gatifloxacin|Zymar (gatifloxacin ophthalmic solution, 0.3%)
9767647|NCT00824161|Experimental|1|TAS-109
9767648|NCT00824265|Experimental|Ofatumumab, Fludarabine, Cyclophosphamide|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
9767649|NCT00824265|Active Comparator|Fludarabine, Cyclophosphamide|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
9767650|NCT00824291|Placebo Comparator|1|
9767651|NCT00824291|Experimental|2|
9767652|NCT00824369|No Intervention|Anti-retroviral therapy|Anti-retroviral therapy
9767653|NCT00824382|Experimental|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation
9767654|NCT00824382|Experimental|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation
9767655|NCT00824382|Placebo Comparator|Placebo|2 puffs
9767656|NCT00824382|Experimental|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation
9767657|NCT00824408|Experimental|BI 6727 +pemetrexed|BI 6727 plus 500 mg/^m2 pemetrexed i.v. on day 1 of 21 day cycle
9767658|NCT00824408|Active Comparator|pemetrexed|500 mg/m^2 i.v. on day 1 of a 21 day cycle
9767659|NCT00824421|Experimental|UK- 453,061 Dose One|UK 453,061 Dose One plus Truvada
9767660|NCT00824421|Experimental|UK-453,061 Dose Two|UK 453,061 Dose Two plus Truvada
9767661|NCT00824421|Active Comparator|Efavirenz + Truvada|Efavirenz + Truvada
9767662|NCT00824434|Experimental|Experimental Stent|
9767663|NCT00824460|Experimental|1.25 g PA21|
9767664|NCT00824460|Experimental|5.0 g PA21|
9767665|NCT00824460|Experimental|7.5 g PA21|
9767666|NCT00824460|Experimental|10.0 g PA21|
9767667|NCT00824460|Experimental|12.5 g PA21|
9767668|NCT00824460|Experimental|Sevelamer hydrochloride - active control|
9767669|NCT00824473|Placebo Comparator|1|Placebo
9767670|NCT00824473|Active Comparator|2|0.15% azelastine hydrochloride
9767671|NCT00824512|Experimental|EGb 761® 120 mg|
9767672|NCT00824512|Placebo Comparator|Placebo|
9767673|NCT00824538|Experimental|sunitinib|Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer
9767674|NCT00824564|Experimental|A|Tranexamic Acid plus standard of care
9767675|NCT00824564|Other|B|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss.
9767676|NCT00824616|Placebo Comparator|Placebo|Participants receiving placebo tablets three times daily plus insulin injection once daily
9767677|NCT00824616|Experimental|MK-0941|Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
9767678|NCT00824655|Experimental|Group 1|
9767679|NCT00824655|Experimental|Group 2|
9767680|NCT00824720|Experimental|High Dose Device|device worn continuously for 14 days
9767681|NCT00824720|Experimental|Low Dose Device|device worn continuously for 14 days
9767682|NCT00824720|Placebo Comparator|Placebo Device|device worn continuously for 14 days
9767683|NCT00824733|Experimental|Arm I: Treatment (PF03512676 in combination with Trastuzumab)|12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
9767684|NCT00824746|Experimental|Gefitinib retreatment group|Gefitinib retreatment
9767685|NCT00824824|Experimental|Brimonidine 0.2%-timolol 0.5% arm|Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
9767686|NCT00824824|Active Comparator|Dorzolamide 2%-timolol 0.5% arm|Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
9767687|NCT00824850|Experimental|1|Subjects received Prevnar in study D118-P8
9767688|NCT00824850|Experimental|2|Subjects received MnCC in study D118-P8
9767689|NCT00824993|Experimental|Ibandronate + Calcium + Vitamin D|Ibandronate infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant. Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
9767690|NCT00824993|Experimental|Calcium + Viatmin D|Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
9767691|NCT00825162|Experimental|Cohort A|Participants aged 6 months to less than 3 years
9767692|NCT00825162|Experimental|Cohort B|Participants aged 3 years to less than 9 years
9767693|NCT00825162|Experimental|Cohort C|Participants aged 9 years to less than 18 years
9767694|NCT00825175|Active Comparator|1|Treadmill Training in infants with Down syndrome only
9767695|NCT00825175|Experimental|2|Treadmill Training and supramalleolar orthoses use for infants with Down syndrome
9767696|NCT00825266|Active Comparator|bosentan|Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
9767697|NCT00825266|Active Comparator|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
9767698|NCT00825305|Experimental|Zagreb (2-1-1)|Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
9767699|NCT00825305|Active Comparator|Essen (1-1-1-1-1)|Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
9767700|NCT00825318|Experimental|Daily ultrafiltration|During the treatment phase of the study, the subject will undergo ultrafiltration 6 times a week and hemodialysis 2 times a week.
9767701|NCT00825344|Experimental|1|Etanercept 50 mg preoperatively
9767702|NCT00825344|Placebo Comparator|2|Subcutaneous saline preoperatively
9767703|NCT00825370|Experimental|Protocolized|"1 mg IV hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
9767704|NCT00825370|Active Comparator|Discretionary Care|Patients receive an IV opioid the type and dose of which is determined by the treating physician
9767705|NCT00825500|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo (0 mg)
9767706|NCT00825500|Active Comparator|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
9767707|NCT00825500|Experimental|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 2.5 mg, single dose
9767708|NCT00825565|Experimental|Alwextin cream|8 subjects enrolled in this single study arm. All 8 subjects completed the study.
9767709|NCT00825630|Active Comparator|Lansoprazole (Lanton)|Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning
9767710|NCT00825630|Active Comparator|Omeprazole (Losec)|Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning
9767711|NCT00825630|Active Comparator|Pantoprazole (Controloc)|Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning
9767712|NCT00825630|Active Comparator|Esomeprazole(Nexium)|Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning
9767713|NCT00825682|Experimental|1|20 breast cancer patients scheduled for adjunctive radiation treatment will be recruited for this study to receive reflexology treatment initiated at the beginning of radiation therapy, once a week, for 10 weeks.
9767714|NCT00825682|No Intervention|2|20 breast cancer patients, scheduled for adjunctive radiation treatment, matched by age to the intervention group will receive treatment as usual, and will be evaluated by the same measures as the intervention group.
9767715|NCT00825734|Experimental|Dose Level 1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)
9767716|NCT00825734|Experimental|Dose Level -1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)
9767717|NCT00825734|Experimental|Dose Level 1a|Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)
9767718|NCT00825786|Active Comparator|Group 1|combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence;
9767719|NCT00825786|Active Comparator|Group 2|sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1.
9767720|NCT00825812|Experimental|Sugammadex in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
9767721|NCT00825812|Active Comparator|Neostigmine in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
9767722|NCT00825812|Experimental|Sugammadex in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
9835483|NCT02741076|Experimental|Structured discontinuation opioid therapy Suboptimal Responder|
9835484|NCT02741076|Experimental|Structured discontinuation opioid therapy Optimal responders|
9835485|NCT02741076|Experimental|Continuation of opioid therapy Suboptimal responders|
9835486|NCT02741076|Experimental|Structured Continuation of opioid therapy Optimal responders|
9835487|NCT02741284|Experimental|No Oxygen|Room air
9835488|NCT02741284|Active Comparator|Oxygen|10L oxygen by nonrebreather mask
9835489|NCT02741297|Experimental|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
9835490|NCT02741310|Placebo Comparator|Placebo|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
9835491|NCT02741310|Experimental|Erenumab|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
9835492|NCT02741518|Active Comparator|Treatment Arm|The treatment arm will receive an induction dose of FMT via capsules (30) followed by monthly maintenance oral capsules(12) at week 4 and week 8. Donor Stool from healthy lean donors and placebo material will be obtained from OpenBiome. OpenBiome, is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use
9835493|NCT02741518|Placebo Comparator|Placebo Arm|The placebo group will receive a placebo FMT capsules at the time of their screening colonoscopy followed by monthly intake of oral placebo capsules at week 4 and week 8
9835494|NCT02741596|Experimental|Rollover Participants|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
9835495|NCT02741596|Experimental|Non-rollover Participants|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
9835496|NCT02741635|Experimental|New Nasal Pillows Mask|Participants to use nasal pillows mask one night in lab overnight polysomnography.
9835497|NCT02741687|Experimental|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
9835498|NCT02741687|Placebo Comparator|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
9835499|NCT02741713|Sham Comparator|Interscalene Block plus Sham Block|"Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block."
9767723|NCT00825812|Active Comparator|Neostigmine in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
9767724|NCT00825825|Active Comparator|Escitalopram|One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
9767725|NCT00825825|Active Comparator|Citalopram|One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
9767726|NCT00825825|Placebo Comparator|Placebo|Two weeks of placebo in healthy volunteers.
9767727|NCT00825916|Experimental|High Dose|
9767728|NCT00825916|Placebo Comparator|Placebo|
9984283|NCT04261153|Other|cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
9767729|NCT00825916|Experimental|Low Dose|
9767730|NCT00825994|Experimental|Omega-3|omega-3 fatty acids, 2grams qd [every day] (2 x 1 gram tablets), PO [by mouth]
9767731|NCT00826020|Experimental|Omegaven™|This study will be a prospective, non-randomized, open-label study of Omegaven™ for provision of parenteral lipid calories. The study cohort, receiving the parenteral nutrition (PN) lipid at 1g/kg/day, will be compared to historical controls at University of Nebraska Medical Center (UNMC) where parenteral lipid calories were provided exclusively through soybean-based formulations. The study is planned to enroll 100 patients. The Intestinal Rehabilitation Program at UNMC sees between 20 and 30 new pediatric patients per year, with almost all being PN-dependent and over 75% presenting with a bilirubin ≥ 2mg/dL. Based on these calculations, we estimate 4-5 years to enroll 100 patients.
9767732|NCT00826111|Active Comparator|Eszopiclone|Lexapro for 10 weeks together with eszopiclone.
9767733|NCT00826111|Placebo Comparator|Placebo|Lexapro for 10 weeks together with placebo.
9767734|NCT00826150|Experimental|BC-819|BC-819 60, 120 and 240 mg IP administration
9767735|NCT00826176|Experimental|Sugammadex in Caucasian Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Caucasian subjects living in Europe.
9767736|NCT00826176|Experimental|Sugammadex in Chinese Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Chinese subjects living in China.
9767737|NCT00826202|Experimental|D serine|60 mg/kg/day
9767738|NCT00826202|Placebo Comparator|Placebo|
9767739|NCT00826228|Experimental|PTH/Weight-Bearing|
9767740|NCT00826241|Experimental|Temozolomide + Lapatinib|Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
9767741|NCT00826267|Experimental|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
9767742|NCT00826267|Active Comparator|Lapatinib|Lapatinib tablets 1500 mg daily.
9767743|NCT00826267|Active Comparator|Trastuzumab|Trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly.
9767744|NCT00826280|Placebo Comparator|Placebo plus Regadenoson|Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
9767745|NCT00826280|Experimental|Caffeine 200 mg plus Regadenoson|One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
9767746|NCT00826280|Experimental|Caffeine 400 mg plus Regadenoson|Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
9767747|NCT00826449|Experimental|Phase I|Dasatinib + Erlotinib
9767748|NCT00826514|Experimental|Tanezumab|
9767749|NCT00826514|Placebo Comparator|Placebo|
9767750|NCT00826540|Experimental|Treatment (sorafenib tosylate and bevacizumab)|Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies
9767751|NCT00826618|Experimental|Ranibizumab|
9767752|NCT00826748|Experimental|Treated Smokers|The treatment with inhaled beclomethasone will be administered to this cohort from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days.
9767753|NCT00826748|No Intervention|Non-Treated Smokers|This cohort will act as control and include healthy smokers who receive no treatment.
9767754|NCT00826748|No Intervention|Non-Smokers|This cohort will act as control and include healthy non-smokers who receive no treatment.
9767755|NCT00826800|Experimental|Neoadjuvant FOLFOX Plus Bevacizumab|FOLFOX and bevacizumab will be given to colon cancer patients for 4 cycles over 8 weeks; an additional 2 cycles of FOLFOX without bevacizumab will be given for a total of 12 weeks of pre-operative chemotherapy.Restaging will be performed within 3 weeks of the 6th chemotherapy cycle. Colon surgery will be performed between weeks 3 and 6 subsequent to the 6th cycle of FOLFOX. Patients receiving preoperative chemotherapy without radiation will wait a minimum of 3 weeks from their last dose of chemotherapy, and 6 weeks from their last dose of bevacizumab, before proceeding to surgery. Specifically, it is intended that patients will undergo surgery between 3-6 weeks from completion of their neoadjuvant therapy as deemed clinically appropriate by their surgeon and medical oncologist. This permits a 7-10 week interval between the 4th bevacizumab administration and colon surgery.
9984284|NCT04260945|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
9984285|NCT04260932|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
9984286|NCT04260126|Experimental|Pembrolizumab and PDS0101|Pembrolizumab will be administered via IV Infusion followed by subcutaneous injections of PDS0101 five times throughout the course of the study. Pembrolizumab monotherapy will be administered every cycle there is not a combination treatment until disease progression or up to Cycle 35.
9767756|NCT00826943|Active Comparator|Levocetirzine|5 mg daily x 7 days (note = cross over = all participants receive active comparators and placebo)
9767757|NCT00826943|Active Comparator|cetirizine|10 mg daily x 7 days. Note = crossover study, so all participants recieve all active comparators and placebo.
9767758|NCT00826943|Placebo Comparator|placebo|one tablet daily x 7 days; note that this is a crossover study so all participants receive all active comparators and placebo
9767759|NCT00827073|Active Comparator|Tetracaine 0.5% drop|Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered
9767760|NCT00827073|Active Comparator|Lidocaine 2% Jelly|Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered
9767761|NCT00827112|Experimental|Arm A|maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.
9767762|NCT00827112|Experimental|Arm B|"emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD~Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study."
9767763|NCT00827242|Experimental|Tadalafil|
9767764|NCT00827242|Placebo Comparator|Placebo|
9767765|NCT00827255||Patients who received Restasis®|Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
9767766|NCT00827359|Experimental|Treatment|This is a single-arm study. All patients will receive everolimus.
9767767|NCT00827372|Experimental|Pazopanib Treatment|Pazopanib 800 mg orally once each day (maximum total duration of treatment = 24 weeks)
9767768|NCT00827541||1|Patients hospitalized because of cIAI or cSSTI
9767769|NCT00827606|Experimental|Atorvastatin|All subjects will be treated with atorvastatin
9767770|NCT00827632|Active Comparator|Normal Weight group|Participants with a BMI of 19-24.9 kg/m^2
9767771|NCT00827632|Active Comparator|Obese group|Participants with a BMI of 30-39.9 kg/m^2
9767772|NCT00827775|No Intervention|Control|Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions
9767773|NCT00827775|Active Comparator|Intervention|Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions
9767774|NCT00827827|Experimental|Arm 1|Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
9767775|NCT00827827|Active Comparator|Arm 2|Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
9767776|NCT00827918|Experimental|MK-8998|MK-8998, 6 mg twice a day (BID) for Days 1 to 7, and 8 mg BID thereafter for a 4-week total treatment period
9767777|NCT00827918|Active Comparator|Olanzapine|Olanzapine, 5 mg BID for Day 1 to 7, and 15 mg (5 mg in the morning and 10 mg in the evening) thereafter for a 4-week total treatment period
9767778|NCT00827918|Placebo Comparator|Placebo|Placebo Comparator to MK-8998 or olanzapine
9767779|NCT00827931|Experimental|A|end of the operation and on the mornings of the first, second, fourth and seventh postoperative days.
9767780|NCT00827931|Other|B|Standard of Care
9767781|NCT00827944|Active Comparator|1|Parietex ProGrip
9767782|NCT00827944|Active Comparator|2|Low weight polypropylene mesh
9767783|NCT00827983|Experimental|Progesterone SC|
9984287|NCT04256512|Experimental|Prevention (Elasto Gel Therapy Mittens and Foot Wraps)|Patients wear Elasto Gel Therapy Mittens and Foot Wraps on both hands and feet 15 minutes prior to each infusion, during the entire infusion, and for 15 minutes after the completion of each infusion during their three months of treatment.
10203570|NCT05199168|Experimental|Thoracoscopic esophagectomy with IONM|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
10203571|NCT05199129|Experimental|HCP1904-3|
9835500|NCT02741713|Active Comparator|Interscalene plus PECS Blocks|"Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al."
9835501|NCT02742077|Other|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
9835502|NCT02742103|Experimental|CSL_112|CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
9835503|NCT02742103|Placebo Comparator|Placebo|Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
9835504|NCT02742129|Experimental|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
9835505|NCT02742129|Placebo Comparator|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
9835506|NCT02742441|Experimental|122-0551 Foam|"122-0511 Foam, topically applied twice daily~Intervention: Drug: 122-0551 Foam"
9835507|NCT02742441|Placebo Comparator|Vehicle Foam|"Vehicle Foam, topically applied twice daily~Intervention: Drug: Vehicle Foam"
9835508|NCT02742519|Experimental|Part 1-Sequence 1|ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
9835509|NCT02742519|Experimental|Part 1 - Sequence 2|placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
9835510|NCT02742519|Experimental|Part 2: ivacaftor|open label period
9835511|NCT02742532|Experimental|Oxytocin|Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)
9835512|NCT02742532|Placebo Comparator|Placebo|Intra-nasal saline placebo (5 puffs in each nostril)
9835513|NCT02742649|Experimental|Fixed Combination (FC) Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one segment of timolol maleate combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
9835514|NCT02742649|Experimental|Bimatoprost Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
9835515|NCT02742649|Experimental|Timolol Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of timolol and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
9835516|NCT02742766|Experimental|Part 1 - GSK3008356 single dose and multiple doses|Healthy subjects will receive GSK3008356 in morning as single dose or multiple doses of 5 milligrams (mg), 10 mg, 30 mg,45 mg, 75 mg, 90 mg, 125, 180 mg, 200 mg, 250 mg total daily dose or matching placebo in eleven sequential cohorts while receiving a standard fat meal. The initial dosing for the first cohort will be staggered so that 2 subjects will be dosed as sentinel subjects. Provided there are no safety concerns, the remainder of the subjects scheduled for the cohort may be dosed. Eight subjects will be enrolled in each cohort.
9835517|NCT02742766|Experimental|Part 2 - GSK3008356 14 day repeat dose|Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
9835518|NCT02742766|Experimental|Part 3 - GSK3008356 28 day repeat dose|Obese subjects will receive GSK3008356 or matching placebo, as 28 daily doses in the three parallel cohorts. Cohort 1 will evaluate 1 dose strength of GSK3008356 (or matching placebo) administered as morning doses. Cohorts 2 and 3 will evaluate 2 dose strengths (1 per cohort) of GSK3008356 (or matching placebo) administered in the evening. Ten subjects will be enrolled in each cohort.
9835519|NCT02742818|Other|Upper body blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
10203572|NCT05199129|Active Comparator|RLD2001-1|
10203573|NCT05199103|Experimental|Rabbit antithymocyte globulin (rATG)|
10203574|NCT05199038|Experimental|2 Days of octreotide infusion|
10203575|NCT05199038|Active Comparator|5 Days of octreotide infusion|
10203576|NCT05198999|Experimental|Aqua-PLYO group|Participants in this group received the Aqua-PLYO training program
10203577|NCT05198999|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program
10203578|NCT05198986||ECMO Prone Position|After baseline assessment in supine position, patients will be positioned in prone position to assess modification of lung mechanics, aeration and hemodynamics
9835520|NCT02742818|Other|Underbody blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
9835521|NCT02742987|Experimental|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
9835522|NCT02742987|Experimental|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
9835523|NCT02743078|Experimental|Bevacizumab and TTFields Therapy|Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.
9835524|NCT02743117|Experimental|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
9835525|NCT02743117|Placebo Comparator|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
9835526|NCT02743221|Experimental|Trifluridine/tipiracil + bevacizumab|"Trifluridine/tipiracil (S95005): film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride.~Bevacizumab: concentrate for solution for IV infusion containing 25mg/ml of bevacizumab.~Trifluridine/tipiracil was administered at 35 mg/m2/dose orally within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period, with bevacizumab administered intravenously at the dose of 5 mg/kg every 2 weeks at Day 1 and Day 15.This treatment cycle was repeated every 4 weeks."
9835527|NCT02743221|Active Comparator|Capecitabine + bevacizumab|Capecitabine was administered at 1250 mg/m² orally BID (bis in die)on Days 1-14 of each cycle, with bevacizumab (7.5 mg/kg, IV) administered on Day 1 of each cycle. This treatment cycle was repeated every 3 weeks
9835528|NCT02743312|Experimental|Torso Weights then Sham Weights|"No weights worn for 4 weeks. Garment with torso weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with sham weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
9835529|NCT02743312|Experimental|Sham Weights then Torso Weights|"No weights worn for 4 weeks. Garment with sham weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with torso weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
9835530|NCT02743377|Experimental|Subjects with McCune-Albright syndrome (MAS)|Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans
9835531|NCT02743377|Experimental|Healthy control|Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans
9835532|NCT02743442|Experimental|Transoral surgery|
9835533|NCT02743520|Experimental|Cardiac event monitor|Participants will under go evaluation with a two week cardiac event monitor.
9835534|NCT02743702|Experimental|GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY|Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
9835535|NCT02743702|Experimental|GROUP RECEIVING THEIR USUAL THERAPIES|This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.
9835536|NCT02743780|Experimental|MGV354|Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days
9835537|NCT02743780|Placebo Comparator|Placebo|Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days
9835538|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:~An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;~No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and~Normal and stable allograft function at screening visit defined as-~For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)~For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) > 45 ml/min/1.73 m^2."
9835539|NCT02743936|Experimental|NIPPV with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula in place
9835540|NCT02743936|Active Comparator|NIPPV without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula
9835541|NCT02743949|Active Comparator|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
9835542|NCT02743949|Experimental|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
9835543|NCT02743949|Experimental|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
9836079|NCT02769065|Experimental|SRD: Cohort 4: TAK-071 20 mg|TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.
9835544|NCT02743962|Active Comparator|Usual physiotherapy treatment group|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome: dietary advice regarding fluid and fibre intake, advice regarding bladder retraining and 15 minutes manual intra-vaginal pelvic floor muscle myofascial release and gentle stretching each week for 6 weeks. They will be instructed to briefly contract and then fully relax their pelvic floor muscles independently (clothed, in a seated or lying position) for 5 minutes daily.
9835545|NCT02743962|Experimental|Therapeutic Wand group|This group will receive the standard specialist physiotherapy intervention for bladder pain syndrome for 6 weeks, but will also be provided with an intra-vaginal therapeutic wand and taught how to use it. They will then be asked to use the therapeutic wand at home twice a week to release and relax their pelvic floor muscles for 5 minutes.
9835546|NCT02744066|Other|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
9835547|NCT02744391|Experimental|L-DOPA|Patients will receive titration of L-DOPA from 150 mg to 450 mg.
9835548|NCT02744534|Experimental|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
9835549|NCT02744534|Active Comparator|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
9835550|NCT02744755|Experimental|GP2017|Group 1 will receive treatment with 40mg GP2017 (Adalimumab - GP2017) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response continue treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
9835551|NCT02744755|Active Comparator|US Licensed Humira|Group 2 will receive treatment with 40mg Humira® (Adalimumab - US licensed Humira®) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response will be switched to treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
9835552|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:~1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
9835553|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:~1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
9835554|NCT02744898|Experimental|Carboplatin AUC and Abraxane 100mg/m2|
9836080|NCT02769065|Experimental|SRD: Cohort 5: TAK-071 40 mg|TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.
9836081|NCT02769065|Experimental|SRD: Cohort 6: TAK-071 80 mg|TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5
9836082|NCT02769065|Placebo Comparator|MRD: Placebo Cohorts 7-9|TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.
9836083|NCT02769065|Experimental|MRD: Cohort 7: TAK-071 3 mg|TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
9836084|NCT02769065|Experimental|MRD: Cohort 8: TAK-071 9 mg|TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
9836085|NCT02769065|Experimental|MRD: Cohort 9: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
9836086|NCT02769065|Placebo Comparator|MRD: TAK-071 Placebo Cohorts 10-12+Donepezil|TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
9836087|NCT02769065|Experimental|MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg|TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
9836088|NCT02769065|Experimental|MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg|TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
9836089|NCT02769065|Experimental|MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg|TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
9767784|NCT00827983|Active Comparator|Progesterone Vaginal gel|
9784273|NCT01221311|Experimental|Fully Covered Metallic Stent|Among patients randomized to the covered, self-expandable metallic stent (cSEMS) group, the endoscopist will deploy a cSEMS of sufficient length to traverse the papilla. Dilation will not be performed unless the cSEMS deployment catheter cannot be advanced over a guidewire beyond the stricture. A biliary sphincterotomy may be performed at the discretion of the treating endoscopist.
9767785|NCT00828009|Experimental|Tecemotide/bevacizumab after chemoradiation|"Concomitant Chemoradiotherapy: Patients (pts) receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 15-30 minutes weekly for 6 weeks. Pts also receive radiotherapy 5 days a week for 6½ weeks. Pts with CR, PR, or SD proceed to consolidation chemotherapy.~Consolidation chemotherapy: Pts receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression (PD) or unacceptable toxicity. Pts with CR, PR, or SD proceed to maintenance therapy.~Maintenance therapy: Pts receive a single dose of cyclophosphamide IV over 15-30 minutes 3 days before the first dose of bevacizumab and tecemotide. Pts then receive bevacizumab IV over 30-90 minutes on day 1 and tecemotide subcutaneously on days 1, 8, and 15 of courses 1 and 2 and on day 1 of every other course beginning in course 4. Treatment repeats every 21 days for up to 34 courses in the absence of PD or unacceptable toxicity."
9767786|NCT00828061|Placebo Comparator|A|placebo
9767787|NCT00828061|Active Comparator|B|10 mg prednisone
9767788|NCT00828061|Active Comparator|C|25 mg prednisone
9767789|NCT00828074|Experimental|Treatment (vinorelbine tartrate and sorafenib tosylate)|Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9767790|NCT00828113|Experimental|Extended treatment|52-week varenicline therapy + individual smoking cessation counseling
9767791|NCT00828113|Active Comparator|Standard treatment|13 weeks of varenicline therapy + individual smoking cessation counseling
9767792|NCT00828139|Experimental|Arm I (ziv-aflibercept, topotecan hydrochloride)|Patients receive ziv-aflibercept IV over 1 hour on day 1 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive ziv-aflibercept IV on day 1 and topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9767793|NCT00828139|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9767794|NCT00828178|Active Comparator|Omega-3|3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery
9767795|NCT00828178|Placebo Comparator|corn starch|corn starch; flow-mediated dilation of the brachial artery
9767796|NCT00828191|Experimental|Progesterone SC|
9767797|NCT00828191|Active Comparator|Progesterone Tablets|
9767798|NCT00828204|Experimental|Avonex Single-Use Autoinjector|"Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes.~In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks."
9767799|NCT00828295|Experimental|1 mcg/kg arm|Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
9767800|NCT00828295|Experimental|3 mcg/kg arm|Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
9767801|NCT00828347|Other|1.0 μg/day Alfacalcidol|Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
9767802|NCT00828347|Other|0.25 μg/day Alfacalcidol|Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months
9767803|NCT00828412|Active Comparator|1|EpiCeram Skin Barrier Emulsion
9767804|NCT00828412|Active Comparator|2|Desonide Cream 0.05%
9767805|NCT00828451|Experimental|Preterm Infants for EGF Profiles|Premature infants born at < 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of [5,5,5-2H3]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
9767806|NCT00828464|Experimental|clobetasol propionate foam|All subjects receive clobetasol propionate
9767807|NCT00828516|Experimental|Usual treatment plus acupuncture|Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment
9767808|NCT00828542|Experimental|etonogestrel implant|Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
9767809|NCT00828542|Active Comparator|depot medroxyprogesterone acetate|At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).
9767810|NCT00828568|Experimental|Imiquimod 5% Taro|Imiquimod 5% manufactured by Taro applied for 16 weeks
9767811|NCT00828568|Active Comparator|Aldara - Imiquimod 5%|Aldara, Imiquimod 5% applied for 16 weeks
9767812|NCT00828568|Placebo Comparator|Vehicle|Imiquimod vehicle applied for 16 weeks
9767813|NCT00828672|Active Comparator|AXE (ARM 1)|Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
9835555|NCT02745080|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
9835556|NCT02745080|Active Comparator|Adalimumab 40 mg s.c.|Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.
9835557|NCT02745119|Experimental|Lampalizumab Every 4 Weeks|Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.
9835558|NCT02745119|Experimental|Lampalizumab Every 6 Weeks|Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.
9835559|NCT02745145|Experimental|Abituzumab 1500 milligram (mg)|
9835560|NCT02745145|Experimental|Abituzumab 500 mg|
9835561|NCT02745145|Placebo Comparator|Placebo|
9835562|NCT02745353|Active Comparator|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
9835563|NCT02745353|Active Comparator|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
9835564|NCT02745392|Experimental|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
9835565|NCT02745392|Experimental|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
9835566|NCT02745392|Experimental|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
9835567|NCT02745392|Placebo Comparator|Placebo|Placebo (either single or double patch) single administration
9835568|NCT02745626|Experimental|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
9835569|NCT02745626|Experimental|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
9835570|NCT02745626|Experimental|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
9835571|NCT02746107|Experimental|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
9835572|NCT02746107|Active Comparator|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
9835573|NCT02746107|Active Comparator|1year risk estimate|risk of stroke presented over a timeframe of 1 year
9835574|NCT02746107|Experimental|5year risk estimate|risk of stroke presented over a timeframe of 5 years
9835575|NCT02746107|Other|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
9835576|NCT02746107|Other|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
9835577|NCT02746107|Other|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
9835578|NCT02746107|Other|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
9835579|NCT02746107|Other|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
9835580|NCT02746107|Active Comparator|prescription to virtual patient|prescription is done for a virtual patient
9835581|NCT02746107|Experimental|prescription to physician himself|prescription is done to physician himself
9835582|NCT02746406|Experimental|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
9835583|NCT02746575|Experimental|treatment|Postsurgical: 5mg metoprolol, IV, prior to extubation, every 5 minutes to achieve target heart rate of 65/min, up to 15mg; then 25mg metoprolol, oral, every 8 hours for 72 hours.
9835584|NCT02746627|Active Comparator|Education|Participants receive educational materials in the mail every 2 weeks for 8 weeks.
10203579|NCT05198973|Experimental|Bumblebee Breath group|Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face. this group will be 28 patients to receive half an hour daily for ( 1 month)
10203580|NCT05198973|No Intervention|control group|this group (28 patients) will receive no training
9835585|NCT02746627|Experimental|Positive Affect - Text|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations, and gift cards) by SMS. Participants also receive educational materials in the mail every 2 weeks for 8 weeks.
9836090|NCT02769065|Experimental|MRD: Placebo Cohorts 13-15|TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.
10203581|NCT05198960|Experimental|Experimental group|Patients randomized to receive Direct Oral Anticoagulants, at the choice of the investigator Apixaban 2.5 mg both in day or Rivaroxaban 10 mg one per day, at the choice of the investigator
10203582|NCT05198960|Active Comparator|Control group|Patients randomized to receive Low-Dose Aspirin Aspirin 100 mg one per day
10203583|NCT05198947|Active Comparator|Group 1 Permethrin only|Standard regimen of permethrin 5% topical application to be repeated after 1 week.
10203584|NCT05198947|Active Comparator|Group 2 Permethrin and Ivermectin|A combination regimen of permethrin 5% topical application with oral ivermectin 200 mcg/kg given on the single day only
10203585|NCT05198921|Experimental|rTMS + neurorehabilitation|
10203586|NCT05198921|Active Comparator|neurorehabilitation|
10203587|NCT05198921|Sham Comparator|sham rTMS + neurorehabilitation|
10203588|NCT05198908|Experimental|VR group|VR (virtual reality glasse) group
10203589|NCT05198908|Experimental|skin to skin group|skin to contact group
9984288|NCT04253899|Active Comparator|Standard pediatric group:|patients ≤17 yo with acute perforated appendicitis and interval appendectomy (n=25)
9767814|NCT00828672|Active Comparator|AX (ARM 2)|Bevacizumab and Capecitabine concurrently with radiotherapy
9767815|NCT00828711|Experimental|MVI 100|MVI 100 mcg vaginal insert
9767816|NCT00828711|Experimental|MVI 150|MVI 150 mcg vaginal insert
9767817|NCT00828711|Experimental|MVI 200|MVI 200 mcg vaginal insert
9767818|NCT00828750|Experimental|Treatment|Eltrombopag oral tablets once daily
9767819|NCT00828841|Active Comparator|Paclitaxel, Carboplatin, Cetuximab (Arm A)|Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
9767820|NCT00828841|Active Comparator|Platinum, Gemcitabine, Cetuximab (Arm B)|Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
9767821|NCT00828841|Active Comparator|Platinum, Pemetrexed, Cetuximab (Arm C)|Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
9767822|NCT00828945||Hyperlipidemic Patients|
9767823|NCT00828984|Experimental|Arm A (high-dose PEG 3350)|Patients receive high-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
9767824|NCT00828984|Experimental|Arm B (low-dose polyethylene glycol)|Patients receive low-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
9767825|NCT00828984|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
9767826|NCT00829010|Experimental|HIV+/+ Group|Infants born from a HIV positive mother and confirmed as HIV infected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered intramuscularly in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
9767827|NCT00829010|Experimental|HIV+/- Group|Infants born from a HIV positive mother and confirmed as HIV exposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
9767828|NCT00829010|Experimental|HIV- (3+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
9836091|NCT02769065|Experimental|MRD: Cohort 13: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
9984289|NCT04253899|Experimental|Experimental pediatric group:|patients ≤17 yo with acute perforated appendicitis abscess and observation (n=25)
9984290|NCT04253899|Active Comparator|Standard adult group:|patients ≥18 yo with acute perforated appendicitis and interval appendectomy (n=25)
9767829|NCT00829010|Experimental|HIV- (EPI) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 3 primary doses of Synflorix™ vaccine (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
9767830|NCT00829010|Experimental|HIV- (2+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 2 primary doses (at 6 & 14 weeks of age at study Months 0 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
9767831|NCT00829036|Experimental|Wayfinding Prototype|A Wayfinding Prototype is evaluated in terms of the time it takes subjects to use this device to walk to specific indoor locations versus baseline walking time.
9767832|NCT00829049|Active Comparator|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
9767833|NCT00829049|Active Comparator|Adapalene Gel 0.3%|1 pea-size amount, QD x 16 weeks
9767834|NCT00829166|Experimental|Trastuzumab emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
9767835|NCT00829166|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
9767836|NCT00829244|Experimental|CONSORT Dosing|GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
9767837|NCT00829244|Active Comparator|Standard Dosing|GONAL-f® at a standard dose of 150 IU per day
9767838|NCT00829283|Active Comparator|1|Standard Care
9767839|NCT00829283|Experimental|2|Stepped-care
10203590|NCT05198908|No Intervention|Control group-none|Women in this group will not be subjected to any treatment other than the routine hospital protocol. Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary.
10203591|NCT05198895|Experimental|Open-label, single arm with identical assessment of both biomarkers for all participants|All participants will have their glycated nail keratin assessed by infrared and blood HbA1c levels measured via an assay (based on finger prick blood drop sample)
9767840|NCT00829296|Experimental|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
9767841|NCT00829296|Active Comparator|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
9767842|NCT00829387|Experimental|Behavioral|Cognitive behavioral therapy - Ten sessions of individual treatment delivered by a doctoral level psychologist.
9767843|NCT00829387|Active Comparator|Educational|Diabetes Education - Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator
9767844|NCT00829413|Other|Patients who received SonoVue|"Patients with at least one target lesions requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US):procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard~2.4 mL of sulfur hexafluoride microbubbles (SonoVue®) will be administered as a bolus injection in a peripheral vein."
9767845|NCT00829439|Experimental|Levodopa/Carbidopa|"Other Names:~Sinemet L-dopa~Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
10203592|NCT05198882|Experimental|LITT technology|Laser-induced thermocoagulation of intracerebral lesions responsible for drug-resistant epilepsy.
10203593|NCT05198869|Other|Spectral scan (All participants)|"Fitzpatrick skin assessment.~Fingertip scanned using the SpotLight-19 device. The scan is approximately 10-20 seconds. Participants will not feel any sensation from the device, i.e., no heat, no pain, no cold, no vibration or pressure.~Information collected from the medical record regarding participant age, COVID-19 vaccination status, presence of COVID-19 symptoms, and PCR test result."
9835586|NCT02746627|Experimental|Positive Affect - Phone|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
9835587|NCT02746679|Experimental|MBSR Group|The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
9835588|NCT02746679|No Intervention|wait-list control group|The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.
9835589|NCT02746705|Active Comparator|Transcranial Direct Current Stimulation (tDCS)|
9984291|NCT04253899|Experimental|Experimental adult group:|Patients ≥18 yo with acute perforated appendicitis and observation (n=25)
9835590|NCT02746705|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|
9835591|NCT02746874|Active Comparator|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
9835592|NCT02746874|Sham Comparator|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
9835593|NCT02746991|Sham Comparator|Sham Injection|Sham Injection
9835594|NCT02746991|Experimental|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
9835595|NCT02747004|Experimental|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
9835596|NCT02747004|Experimental|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
9835597|NCT02747004|Experimental|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
9835598|NCT02747043|Experimental|ABP 798|ABP 798 was administered at a dose of 375 mg/m^2 as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
9835599|NCT02747043|Active Comparator|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
9835600|NCT02747108|Experimental|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
9835601|NCT02747108|Active Comparator|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
9835602|NCT02747186|Active Comparator|Buffered 1% lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
9835603|NCT02747186|Active Comparator|Non-Buffered lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
9835604|NCT02747238|Active Comparator|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
9835605|NCT02747238|Active Comparator|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
9835606|NCT02747420|Experimental|Post Tibial Nerve Stimulation Group (PTNS)|
9835607|NCT02747420|Sham Comparator|Sham Group|
9835608|NCT02747433|Active Comparator|ALPS + Robot-Assisted Therapy (RT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 1 hr sessions 3x week for 6 weeks plus ALPS training
9835609|NCT02747433|Active Comparator|ALPS + Robot + Task-Oriented Training (RT-TOT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 30 mins, 3x week for 6 weeks plus ALPS training. Task oriented training will be provided for remaining 30 min of each treatment session
9835610|NCT02747615|Other|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
9835611|NCT02747615|Active Comparator|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
9835612|NCT02747628|Placebo Comparator|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
9835613|NCT02747628|Active Comparator|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
9984292|NCT04253080|No Intervention|patients with primary thin melanoma < 1mm|patients with primary thin melanoma (Breslow thickness less than 1 mm)
9984293|NCT04253080|No Intervention|patients with primary thick melanoma > 3 mm|patients with primary thick melanoma (Breslow greater than 3 mm)
9767846|NCT00829621|Active Comparator|75 mmHg suction|IVAC suction 75 mmHg
9767847|NCT00829621|Experimental|125 mmHg suction|IVAC suction 125 mmHg
9767848|NCT00829738||Group 1|All patients enrolled
9767849|NCT00829829|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
9767850|NCT00829829|Active Comparator|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
9767851|NCT00829829|Active Comparator|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
9767852|NCT00829933|Experimental|1|DU-176b low dose
9767853|NCT00829933|Experimental|2|DU-176b intermediate dose
9767854|NCT00829933|Experimental|3|DU-176b high dose
9767855|NCT00829933|Active Comparator|4|Warfarin
9767856|NCT00829985|Experimental|Glycerinated German Cockroach Allergenic Extract|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume [w/v]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
9767857|NCT00829985|Placebo Comparator|Placebo|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered daily doses of placebo placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The placebo was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 weight per volume [w/v]) was achieved.
9767858|NCT00830037|Experimental|IV Iron|
9767859|NCT00830037|Active Comparator|Oral Iron|
9767860|NCT00830063|Experimental|1|
9767861|NCT00830063|Experimental|2|
9767862|NCT00830063|Active Comparator|3|
9767863|NCT00830063|Placebo Comparator|4|
9767864|NCT00830076|Experimental|Sitagliptin + placebo metformin|
9767865|NCT00830076|Experimental|Metformin + placebo sitagliptin|
9767866|NCT00830076|Experimental|Sitagliptin + metformin|Co-administration of sitagliptin and metformin
9767867|NCT00830076|Placebo Comparator|Placebo sitagliptin + placebo metformin|Co-administration of placebo to sitagliptin and placebo to metformin
9767868|NCT00830115||Pantoprazole|All patients enrolled
9767869|NCT00830128|Experimental|pregabalin (Lyrica)|
9767870|NCT00830167|Placebo Comparator|Placebo|
9767871|NCT00830167|Experimental|Pregabalin|
9767872|NCT00830180|Experimental|Anti-NGF AB|
9767873|NCT00830232|Active Comparator|Closed-cell stent (Xact stent)|For patients randomized to the closed-cell stent group, the Xact closed-cell stents were used. The Xact stent is a FDA approved device.
9767874|NCT00830232|Active Comparator|Open-cell stent (Acculink carotid)|For patients randomized to the open-cell stent group, the Acculink carotid stent was used. The Acculink stent is a FDA approved device.
9767875|NCT00830284|Experimental|Recruitment|Patients with hypoxic respiratory failure
9767876|NCT00830310|Experimental|Customized Adherence Enhancement (CAE)|"Participants will be assigned to receive one or more of the study interventions based upon the participant's responses on the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) and reasons for non-adherence on the Rating of Medication Influences (ROMI).~Individuals will participate in a series of 4 60-minute sessions over a 4-week period, with the study therapist who will implement the module-based intervention. The number of modules may differ depending on the baseline adherence profile of the participant.~An intervention manual developed by the investigators will provide explicit guidelines regarding how modules may be co-administered in single or multiple sessions to minimize redundancy as well as time and effort burden on study participants. The manual for each module will specifically address how any module could be combined with the other modules."
9784274|NCT01221311|Active Comparator|Plastic Stent|Patients randomized to the plastic stent (PS) group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and multiple (as many as technically feasible) PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing endoscopic retrograde cholangiopancreatography (ERCP), until the stricture has been obliterated using clinical and fluoroscopic criteria (details below).
9784275|NCT01221350|Experimental|Lipoic acid|Lipoic acid 600 mg oral dose (two 300 mg capsules) once daily in the morning during 60 days
9767877|NCT00830362|Active Comparator|Propranolol 40mg|
9767878|NCT00830362|Placebo Comparator|Placebo|
10203594|NCT05198856|Experimental|Thalidomide|"The study is divided into two phases:~The first phase is a combination phase (chemotherapy +T) : Oxaliplatin (130mg/m2 iv d1) and capecitabine (1000mg/m2 d1-14 po bid) repeated every 21 days for a total of 4-6 cycles. Thalidomide tablet: 100 mg/d, qn, orally.~The second stage is maintenance stage: Patients who have obtained CR, PR or SD in the first stage enter the maintenance stage and receive maintenance treatment with thalidomide tablets: 100mg/d, qn, orally. Maintained until disease progression or adverse reactions are intolerable."
10203595|NCT05198778|Experimental|Test group 1: Renal impairment patient|Administer URC102, single-dose
10203596|NCT05198778|Experimental|Test group 2: Renal impairment patient|Administer URC102, single-dose
10203597|NCT05198778|Experimental|Control group: Healthy adult people|Administer URC102, 2 doses
10203598|NCT05198713|Experimental|Speech intelligibility in quiet|Monosyllabic words presented without competing noise in the sound field. Participants will be instructed to repeat the words, and a percentage correct performance will be calculated per participant per word list.
10203599|NCT05198713|Experimental|Speech intelligibility in noise|English Matrix Test material will be presented in noise with a fixed noise level and an adaptive speech level. Participants will be instructed to repeat sentences, and the level of the sentence will adapt to identify the level at which the participant is able to correctly repeat approximately 50% of the words. This level (SRT) will be recorded for each participant.
10203600|NCT05198661|Other|Paraneoplastic neurological syndrome patients and autoimmune encephalitis patient|patients with diagnosis of paraneoplastic neurological syndrome or autoimmune encephalitis
10203601|NCT05198609|Experimental|Camrelizumab, Apatinib Plus FOLFOX-HAIC|
10203602|NCT05198609|Active Comparator|Camrelizumab and Apatinib|
10203603|NCT05198583|Experimental|Intervention|The intervention group will have a play-based intervention, including online games, analogue card games as well as a weekly coaching session to enhance executive functions.
9767879|NCT00830375|Experimental|Memantine|10-30mg, memantine
9767880|NCT00830388|Experimental|Ketoconazole 2% Foam|Open-label study
9767881|NCT00830440|Experimental|EndoBarrier Device|EndoBarrier Device and Diet & Lifestyle Counseling
9767882|NCT00830440|Active Comparator|Control|Diet & Lifestyle Counseling
10203604|NCT05198583|No Intervention|Control|The control group does not receive any intervention.
10203605|NCT05198570||Intravenous Aciclovir|Patients receiving intravenous aciclovir for prophylaxis or treatment of herpes virus infections
10203606|NCT05198570||Oral Aciclovir|Patients receiving oral aciclovir/valaciclovir for prophylaxis or treatment of herpes virus infections
10203607|NCT05198518|Experimental|Active study device|A handheld micro-current TENS emitter device, which applies a small current of electricity to the forehead and maxillary region
9767883|NCT00830518|Experimental|Alisertib|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
9767884|NCT00830596|Active Comparator|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
9767885|NCT00830596|Active Comparator|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
9767886|NCT00830596|Placebo Comparator|Sham Intervention|Light effleurage and a sham mechanically-assisted chiropractic treatment for 2 weeks followed by full spine manipulation for 4 weeks
9767887|NCT00830765|Placebo Comparator|1 Placebo|The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
9767888|NCT00830765|Active Comparator|Progesterone|The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
9767889|NCT00830791|Experimental|MK-0941 20 mg Mild Renal Insufficiency|MK-0941 20 mg administered to participants with mild renal insufficiency and type 2 diabetes.
9767890|NCT00830791|Experimental|MK-0941 20 mg Moderate Renal Insufficiency|MK-0941 20 mg administered to participants with moderate renal insufficiency and type 2 diabetes.
9767891|NCT00830791|Experimental|MK-0941 5 mg Severe Renal Insufficiency|MK-0941 5 mg administered to participants with severe renal insufficiency and type 2 diabetes.
9767892|NCT00830791|Experimental|MK-0941 20 mg Matched Controls|MK-0941 20 mg administered to age-, gender-, race-, body mass index (BMI)-, and hemoglobin A1C (HbAIc)-matched control subjects with normal renal function and type 2 diabetes.
9767893|NCT00830791|Experimental|MK-0941 5 mg Matched Controls|MK-0941 5 mg administered to age-, gender-, race-, body mass index (BMI)-, and HbAIc-matched control subjects with normal renal function and type 2 diabetes.
9767894|NCT00830804|Experimental|RAL + DRV/RTV|Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks
9767895|NCT00830869|Experimental|Part 1: Ixazomib 0.125 milligram per square meter (mg/m^2)|Ixazomib (MLN9708) 0.125 mg/m^2, injection, intravenously (IV), once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
9767896|NCT00830869|Experimental|Part 1: Ixazomib 0.25 mg/m^2|Ixazomib (MLN9708) 0.25 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
9767897|NCT00830869|Experimental|Part 1: Ixazomib 0.5 mg/m^2|Ixazomib (MLN9708) 0.5 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
9767898|NCT00830869|Experimental|Part 1: Ixazomib 1 mg/m^2|Ixazomib (MLN9708) 1 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
10203608|NCT05198518|Sham Comparator|Sham device|The sham device appears identical to the active device while emitting no therapeutic microcurrent.
9784276|NCT01221350|Placebo Comparator|Placebo|Placebo (two placebo capsules) orally once daily in the morning during 60 days
9784277|NCT01221363|Active Comparator|Lifestyle counselling|Theory based individually tailored lifestyle counselling aimed at reduction of sitting time during leisure time and at work. Four individual sessions over a six months period.
9784278|NCT01221363|No Intervention|Control group|No intervention control group
9784279|NCT01221441|Experimental|TissueGene-C|TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
9784280|NCT01221441|Placebo Comparator|Placebo Control|Normal Saline injection
9784281|NCT01221597|Experimental|AA4500|collagenase clostridium histolyticum
9784282|NCT01221597|Placebo Comparator|Placebo|placebo
9784283|NCT01221623|Experimental|AA4500|collagenase clostridium histolyticum
9784284|NCT01221623|Placebo Comparator|Placebo|Placebo
9784285|NCT01221727|Other|Midazolam|All 27 subjects will receive midazolam.
9784286|NCT01221727|Active Comparator|Denosumab|Eighteen (18) subjects will receive denosumab.
9784287|NCT01221753|Experimental|TPF Induction Chemotherapy followed by Chemoradiotherapy|Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.
9784288|NCT01221857|Experimental|NiCord|
9784289|NCT01221948|Experimental|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
9784290|NCT01222078|Experimental|otelixizumab|otelixizumab
9784291|NCT01222091|Active Comparator|Propranolol, Then Placebo|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
9784292|NCT01222091|Placebo Comparator|Placebo, Then Propranolol|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
9784293|NCT01222104||Angio-Seal|Angio-Seal attempted and/or deployed
9784294|NCT01222104||Not deployed|Other method of closure
9784295|NCT01222117|Experimental|Plasmin Open-label Treatment Group A|Open-label 150 mg Plasmin administered without initial proximal pulse; 5-hour infusion using 10 mL/hour infusion rate.
9784296|NCT01222117|Experimental|Plasmin Open-label Treatment Group B|Open-label 150 mg Plasmin administered with initial proximal pulse; 5-hour infusion using 15 mL/hour infusion rate
9784297|NCT01222117|Experimental|Plasmin Open-label Treatment Group C|Open-label 150 mg Plasmin administered with proximal pulse; 5 hour infusion using 30 mL/hour infusion rate.
9784298|NCT01222117|Experimental|Plasmin Open-label Treatment Group D|Open-label 150 mg Plasmin administered with proximal pulse; 2-hour infusion using 35 mL/hour infusion rate
9784299|NCT01222117|Active Comparator|Plasminogen Activator Blinded Group E|PA administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice
9784300|NCT01222117|Placebo Comparator|PA Placebo Blinded Treatment Arm F|PA placebo (normal saline for injection) administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice for PA administration
9784301|NCT01222117|Experimental|Plasmin Open-label Treatment Group G|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 60 mL/hour infusion rate
9784302|NCT01222117|Experimental|Plasmin Open-label Treatment Group H|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 75 mL/hour infusion rate
9784303|NCT01222117|Experimental|Plasmin Open-label Treatment Group I|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
9784304|NCT01222117|Experimental|Plasmin Open-label Treatment Group J|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 35 mL/hour infusion rate with balloon occlusion catheter
9784305|NCT01222117|Experimental|Plasmin Open-label Treatment Group M|Open-label 250 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
9784306|NCT01222195|Experimental|Lenalidomide + Darbepoetin alfa|Lenalidomide 10 mg/day orally days 1-21 and Darbepoetin alfa 200 mcg subcutaneously every 2 weeks of 28 day cycle
9784307|NCT01222234|Experimental|Group 1: Cholecalciferol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
9784308|NCT01222234|Experimental|Group 2: Calcitriol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.
9784309|NCT01222234|Experimental|Group 3: Cholecalciferol - non-CKD|Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
9784310|NCT01222260|Experimental|Treatment Arm|Subjects with AL will receive Bendamustine and Dexamethasone
9784311|NCT01222273|Other|Open label|open label Vitamin D
9784312|NCT01222286|Experimental|IPH2101 0.2 mg/kg|0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
9784313|NCT01222286|Experimental|IPH2101 2 mg/kg|2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
9784314|NCT01222299|Experimental|Arm 1 - Low Dose|bepotastine besilate nasal product - low dose
9784315|NCT01222299|Experimental|Arm 2 - Medium Dose|bepotastine besilate nasal product - medium dose
9784316|NCT01222299|Experimental|Arm 3 - High Dose|bepotastine besilate nasal product - high dose
9784317|NCT01222299|Placebo Comparator|Arm 4 - Placebo|placebo comparator nasal product
9784318|NCT01222390|Experimental|Contour Profile Tissue Exander|Patients undergoing breast reconstruction using a Contour Profile Tissue Expander (CPX3).
9767899|NCT00830869|Experimental|Part 1: Ixazomib 1.33 mg/m^2|Ixazomib (MLN9708) 1.33 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
9767900|NCT00830869|Experimental|Part 1: Ixazomib 1.76 mg/m^2|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
9767901|NCT00830869|Experimental|Part 1: Ixazomib 2.34 mg/m^2|Ixazomib (MLN9708) 2.34 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study. Once the MTD will be established, participants with NSCLC, Head and Neck Cancer (H&N), Soft Tissue Sarcoma (STC) or Prostate Cancer (PC) will be included in MTD disease expanded cohort. An additional tumor pharmacodynamics expansion cohort (TPEC) will enroll participants with any type of solid tumor that can be biopsied for tissue analysis before and after treatment with ixazomib.
9767902|NCT00830869|Experimental|Part 2:Ixazomib 1.76 mg/m^2-NSCLC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with NSCLC during Part 2 of the study.
9767903|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-H&N|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with H&N during Part 2 of the study.
9784319|NCT01222403|Experimental|Fluad|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
9984294|NCT04253080|Other|patient with melanoma who received first line treatment|patient with melanoma (stages III or IV inoperable) and who received first line treatment with immunotherapy and / or targeted therapies
9767904|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-STC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with STC during Part 2 of the study.
9767905|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-PC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with PC during Part 2 of the study.
9767906|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-TPEC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with various types of solid tumors suitable for biopsy in tumor pharmacodynamic expansion cohort (TPEC) during Part 2 of the study.
9767907|NCT00830947|Experimental|OrthoAccel Device|Device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
9767908|NCT00830947|Sham Comparator|Sham Device (inactive device)|Sham device will look identical to active devices but will not deliver vibration to the patient.
9767909|NCT00830960|Experimental|Prasugrel 60/10 Primary|Loading dose 60 mg followed by maintenance dose 10 mg/day
9767910|NCT00830960|Experimental|Prasugrel 30/7.5 Primary|Loading dose 30 mg followed by maintenance dose 7.5 mg/day
9767911|NCT00830960|Experimental|Prasugrel 30/5 Primary|Loading dose 30 mg followed by maintenance dose 5 mg/day
9767912|NCT00830960|Active Comparator|Clopidogrel 300/75 Primary|Loading dose 300 mg followed by maintenance dose 75 mg/day
9767913|NCT00830960|Experimental|Prasugrel 30/5 Low Weight/Elderly|Loading dose 30 mg followed by maintenance dose 5 mg/day
9767914|NCT00830960|Active Comparator|Clopidogrel 300/75 Low Weight/Elderly|Loading dose 300 mg followed by maintenance dose 75 mg/day
9767915|NCT00831129|Active Comparator|Simvastatin + Placebo Rosiglitazone|Subjects will receive 40 mg Simvastatin + 1 tab Placebo Rosiglitazone daily
9767916|NCT00831129|Active Comparator|Simvastatin + rosiglitazone|Subjects will receive 40 mg Simvastatin + 4 mg Rosiglitazone once daily
9767917|NCT00831181|Experimental|Preoperative Chemoradiation|Preoperative Chemoradiation with oxaliplatin/5-FU followed by mesorectal excision and 5-FU / leucovorin (FOLFOX 6)
9767918|NCT00831233|Experimental|Degarelix 240 mg/80 mg|Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
9767919|NCT00831233|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|Goserelin (3.6 mg) + bicalutamide (50 mg)
9767920|NCT00831272|Experimental|Naltrexone|50mg/day of naltrexone
9767921|NCT00831272|Placebo Comparator|Placebo|Placebo
9767922|NCT00831311|Experimental|1|DTaP IPV HB-PRP~T vaccine group
9767923|NCT00831311|Active Comparator|2|PENTAXIM™ and ENGERIX B® vaccines group
9767924|NCT00831389|Experimental|Closed Loop (CL) Phase|Closed Loop (CL) Phase
9767925|NCT00831389|No Intervention|Standard of Care (OL) Phase|Standard of Care (OL) Phase or Open Loop Phase
9767926|NCT00831415|Experimental|1|DVS SR
9767927|NCT00831428||Scottish swimming team|
9767928|NCT00831441|Active Comparator|Apixaban|
9767929|NCT00831441|Placebo Comparator|Placebo|
9767930|NCT00831480|Experimental|1|All subjects will take everolimus
9767931|NCT00831493|Experimental|Vorinostat + Radiation Therapy|Vorinostat starting dose 200 mg orally once daily, Monday to Friday, Weeks 1 to 6; Radiation Therapy Dose of 50.4 Gray (Gy) in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
9767932|NCT00831675|Experimental|Infants <12 Months|Participants aged ≥ 6 to < 12 months at enrollment and received 2 doses of Fluzone® Vaccine
9767933|NCT00831675|Experimental|Toddlers ≥12 Months|Participants aged ≥ 12 to < 36 months at enrollment and received 2 doses of Fluzone® vaccine
9767934|NCT00831701|Active Comparator|Tamsulosin|Tamsulosin treatment
9767935|NCT00831701|Placebo Comparator|Placebo|Placebo treatment
9767936|NCT00831753|Experimental|Group 1|DTaP-IPV-Hep B-PRP~T vaccine group
9767937|NCT00831753|Active Comparator|Group 2|Infanrix® Hexa vaccine group
9767938|NCT00831766|Experimental|Phase I: Dose Escalation|"Induction: A dose escalation plan for induction therapy using a standard 3x3 design with dose escalation of Lenalidomide only, to determine maximum tolerated dose (MTD). Idarubicin and cytarabine doses will be fixed.~Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: According to dose escalation levels. Level 1: 5 mg/d; Level 2: 10 mg/d; Level 3: 15 mg/d; Level 4: 20 mg/d; Level 5: 25 mg/d."
9767939|NCT00831766|Experimental|Phase II: Treatment at MTD|"Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: Maximum Tolerated Dose (MTD)."
9767940|NCT00831779|Experimental|Dapagliflozin|
9767941|NCT00831779|Placebo Comparator|Placebo|
9784320|NCT01222403|Experimental|Vantaflu_aTIV|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
9767942|NCT00831792|Experimental|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day). Following an initial 4-week cycle at a starting dose of 400 mg 5 days- on and 2 days off, TKI258 may be escalated to 500 mg/day 5 days-on/2 days off if no significant Grade3/4 AEs or laboratory abnormalities are observed.
9767943|NCT00831844|Experimental|Group 1 - Recurrent or Refractory Hepatoblastoma|Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767944|NCT00831844|Experimental|Group 2 - Recurrent or Refractory Synovial Sarcoma|Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767945|NCT00831844|Experimental|Group 3 - Recurrent or Refractory Rhabdomyosarcoma|Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767946|NCT00831844|Experimental|Grp 4-Recurrent or Refractory Adrenocortical Carcinoma|Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767947|NCT00831844|Experimental|Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767948|NCT00831844|Experimental|Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease|Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767949|NCT00831844|Experimental|Grp 7-Neuroblastoma with measurable disease|Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767950|NCT00831844|Experimental|Group 8 - Recurrent Osteosarcoma|Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767951|NCT00831844|Experimental|Group 9 - Recurrent or Refractory Wilms Tumor|Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767952|NCT00831844|Experimental|Group 10 - Recurrent or Refractory Retinoblastoma|Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9767953|NCT00831987|Experimental|Fluzone® Vaccine Group - Age 18-59 Years|Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
9767954|NCT00831987|Experimental|Fluzone® Vaccine Group - Age ≥ 60 Years|Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
9767955|NCT00832000|Experimental|1|Participants will receive mexiletine for 4 weeks, then no intervention for 1 week, and finally placebo for 4 weeks.
9767956|NCT00832000|Experimental|2|Participants will receive placebo for 4 weeks, then no intervention for 1 week, and finally mexiletine for 4 weeks.
9767957|NCT00832078|Other|Group A|SCCM (SpeediCath Compact Male catheter) then SC (SpeediCath cathter) on test day 1. SC then SCCM on test day 2
10203609|NCT05198505|Experimental|TQB2868 Injection|The drug was administered once every 3 weeks (administration time window: ± 3 days), the dose of each administration was 1.5-600 mg, and 3 weeks was a treatment cycle until the disease progressed or the investigator judged that it was not suitable to continue the drug use.
9767958|NCT00832078|Other|Group B|SC (SpeediCath cathter)then SCCM (SpeediCath Compact Male catheter) on test day 1. SCCM then SC on test day 2
10203610|NCT05198479|Experimental|Arm 177 Lu-DOTA0-Tyr3-Octreotate|Treatment with 177Lu-DOTATATE consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
10203611|NCT05198440|Experimental|Neuromodulation of vection|
10203612|NCT05198414||Healthcare workers|Healthcare workers at the first line and healthcare directives.
10203613|NCT05198401||1|(previous covid-19 positive) n. =88
10203614|NCT05198401||2|(covid-19 negative) n.=91
10203615|NCT05198336|Experimental|Experimental Group of children aged 3-5 years old|200 subjects aged 3-5 years old who have received two doses of inactivated COVID-19 vaccine(CoronaVac) manufactured by Sinovac Research & Development Co., Ltd and is currently 28-42 days after the second dose
10203616|NCT05198336|Experimental|Experimental Group of children aged 6-11 years old|200 subjects aged 6-11 years old who have received two doses of inactivated COVID-19 vaccine(CoronaVac) manufactured by Sinovac Research & Development Co., Ltd and is currently 28-42 days after the second dose
10203617|NCT05198323|Experimental|LT3001 Drug Product|Administered by intravenous infusion
10203618|NCT05198323|Placebo Comparator|Placebo|Administered by intravenous infusion
10203619|NCT05198271|Experimental|Management of risk factors|"-6 month program for reduction /correction of risk factors in patient with active RA :~Smoking cessation~weightloss~Increased physical activity~Periodontal treatment~Decreased anxiety"
10203620|NCT05198206||The First Affiliated Hospital of Chongqing Medical University|
10203621|NCT05198206||West China Hospital|
10203622|NCT05198206||the First Affiliated Hospital of Xi'an Jiaotong University|
10203623|NCT05198206||Guangdong Provincial People's Hospital|
10203624|NCT05198206||Xiangya Hospital of Central South University|
9767959|NCT00832091|Active Comparator|1|There are 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were 3 concentrations used for topical administration to the active drug groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
9767960|NCT00832091|Placebo Comparator|2|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
9767961|NCT00832117|Experimental|Escalation and Expansion|
9767962|NCT00832130|Experimental|Manual Mini System|Treatment with experimental Manual Mini System
9767963|NCT00832130|Active Comparator|Warm Compress Therapy|Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase
9767964|NCT00832338|Experimental|Docetaxel with Cytoxan|Patients will be treated with docetaxel at 75 mg/m² concomitantly with cytoxan 600 mg/m² (TC) IV D1 every 3 weeks for 6 cycles. Due to known toxicity of docetaxel, all patients require dexamethasone 4 mg twice daily (BID) PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel to minimize hypersensitivity reactions and fluid retention.
9767965|NCT00832377|Experimental|Timolol/Dorzolamide|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
9767966|NCT00832390|Experimental|1|sitagliptin
9767967|NCT00832416|Experimental|1 Tramadol Once A Day 100mg|
9767968|NCT00832416|Experimental|2: Tramadol Once A Day 200mg|
9767969|NCT00832416|Experimental|3: Tramadol Once A Day 300mg|
9767970|NCT00832416|Experimental|4: Placebo|
9767971|NCT00832585|Experimental|Alefacept|"Amevive® has been shown to be a safe and effective agent in the treatment of psoriasis but may prove useful in treating atopic dermatitis at a dose of 15mg IM every week for 12 weeks. Unlike other biologics for the treatment of skin diseases, the use of alefacept is not associated with increased infection, congestive heart failure, demyelinating disorders or lupus- like syndromes."
9767972|NCT00832637|Experimental|Gemcitabine, Cisplatin, Erlotinib|A combination of Cisplatin at 40 mg/m2 + Gemcitabine at 1000 mg/m2, every 28 days + Erlotinib 100 mg daily, orally. Cycles will be repeated every four weeks.
9767973|NCT00832650|Experimental|Fesoterodine|Tablets
9767974|NCT00832650|Placebo Comparator|Placebo|Tablets
9767975|NCT00832650|Active Comparator|Solifenacin|Tablets
9767976|NCT00832767|Active Comparator|SILS Port|SILS™ Port Laparoscopic Cholecystectomy
9767977|NCT00832767|Active Comparator|Four Port|Four Port Laparoscopic Cholecystectomy
9767978|NCT00832780|Experimental|Stereotactic Body Radiation (SBRT)|60 Gy using 12 Gy per fraction over 5 fractions, to be given within 10 calendar days
9767979|NCT00832819|Experimental|E7080 (Dose Escalation Cohort)|This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
9767980|NCT00832819|Experimental|E7080 (Expansion Cohort)|Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.
9767981|NCT00832871|Experimental|Mifepristone|200 mg RU-486 (Mifepristone) daily
9767982|NCT00833027|Experimental|1|Sitagliptin
9767983|NCT00833040|Experimental|Titration of sufentanil, the DBL sufentanil & PBO|"During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain.~During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of which included seven active doses of sublingual sufentanil (dosage determined in Titration Phase) and three placebo doses taken in random order. One NanoTab™ was taken as needed for breakthrough pain."
9767984|NCT00833053|Experimental|IFX q 6 weeks|
9767985|NCT00833053|Experimental|IFX + MTX|
9767986|NCT00833092|Placebo Comparator|Sugar pill|Sugar Pill
9767987|NCT00833092|Active Comparator|magnesium|300 milligrams of magnesium daily
9767988|NCT00833105|Experimental|AMES treatment|The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.
9767989|NCT00833248|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
9767990|NCT00833248|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively."
9767991|NCT00833261|Experimental|Single Arm: Chemotherapy with Concurrent Radiation therapy|Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy
9767992|NCT00833365|Active Comparator|Early treatment|Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old
10203625|NCT05198206||The Second Affiliated Hospital of Harbin Medical University|
10203626|NCT05198206||Yan'an Hospital of Kunming City|
10203627|NCT05198206||Zhongshan Hospital|
10203628|NCT05198206||Gansu Provincial People's Hospital|
10203629|NCT05198206||Qilu Hospital of Shandong University|
10203630|NCT05198206||Shanxi Provincial Cardiovascular Hospital|
10203631|NCT05198206||West China Second Hospital|
10203632|NCT05198206||The First Affiliated Hospital of Jilin University|
10203633|NCT05198206||Xinqiao Hospital, Army Medical University|
10203634|NCT05198206||The First Affiliated Hospital of Guangzhou Medical University|
10203635|NCT05198206||the Second Xiangya Hospital of Central South University|
9767993|NCT00833365|Active Comparator|Late treatment|Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old.
9767994|NCT00833417|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
9767995|NCT00833443|Active Comparator|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.
9767996|NCT00833443|Placebo Comparator|Sugar Pill|
9767997|NCT00833469|Experimental|Escitalopram|Flexible dose escitalopram 10mg
9767998|NCT00833482|Active Comparator|Voriconazole, 200 mg BID (EM)|
9767999|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100 QD (EM & PM)|
9768000|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)|
9768001|NCT00833482|Active Comparator|Voriconazole, 50 mg BID (PM)|
9768002|NCT00833482|Active Comparator|Atazanavir/ritonavir, 300/100mgQD+voriconazole, 50mgBID (PM)|
9768003|NCT00833547|Experimental|Eszopiclone|3mg of eszopiclone on two consecutive nights
9768004|NCT00833547|Placebo Comparator|placebo|placebo capsule that looks identical to eszopiclone capsule on two consecutive nights
9768005|NCT00833560|Experimental|Cyclophosphamide + Bortezomib + Dexamethasone|Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
9768006|NCT00833638|Experimental|Tadalafil 2.5 mg|No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.
9768007|NCT00833638|Experimental|Tadalafil 5 mg|No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.
9768008|NCT00833638|Placebo Comparator|Placebo|No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.
9768009|NCT00833690|Placebo Comparator|[A:]|Placebo to produce no urate elevation
9768010|NCT00833690|Experimental|[B:]|"Inosine to produce a mild urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL"
9768011|NCT00833690|Experimental|[C.]|"Inosine to produce a moderate urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL"
9768012|NCT00833703|Placebo Comparator|Placebo|0.2 mL/kg/day matching placebo solution once daily.
9768013|NCT00833703|Experimental|Clopidogrel 0.2 mg/kg/day|0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.
9768014|NCT00833755|Active Comparator|Opioid - Ketamine|This group consists of 16 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
9768015|NCT00833755|Active Comparator|Non-opioid - Ketamine|This group consists of 22 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
9768016|NCT00833755|Placebo Comparator|Opioid - Placebos|This group consists of 18 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
9768017|NCT00833755|Placebo Comparator|Non-opioid - Placebos|This group consists of 23 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
9768018|NCT00833781|Active Comparator|mRNA-transfected dendritic cells|Participants in this arm/group received mRNA-transfected autologous dendritic cells
9768019|NCT00833781|Placebo Comparator|Dendritic cells without mRNA|Participants in this arm/group received autologous dendritic cells with no mRNA transfection
9768020|NCT00833794|Experimental|1 Tramadol Once A Day|
9768021|NCT00833794|Placebo Comparator|2 Placebo|
9768022|NCT00833833|Experimental|Phase 1: 2 mg pomalidomide|Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
9768023|NCT00833833|Experimental|Phase 1: 3 mg pomalidomide|Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
10203636|NCT05198206||Shengjing Hospital of China Medical University|
10203637|NCT05198206||The Second Affiliated Hospital of Nanchang University|
10203638|NCT05198206||Henan Provincial People's Hospital|
10203639|NCT05198206||Southwest Medical University Hospital|
10203640|NCT05198206||The First Affiliated Hospital of Gannan Medical University|
10203641|NCT05198206||University-town Hospital of Chongqing Medical University|
10203642|NCT05198206||Chongqing Health Center for Women and Children|
10203643|NCT05198206||Kunhua Hospital|
10203644|NCT05198206||Changdu People's Hospital of Tibet|
10203645|NCT05198206||The Sixth People's Hospital of Chengdu|
10203646|NCT05198206||Chongqing Bishan District People's Hospital|
9768024|NCT00833833|Experimental|Phase 1: 4 mg pomalidomide|Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
9768025|NCT00833833|Experimental|Phase 1: 5 mg pomalidomide|Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
9768026|NCT00833833|Experimental|Phase 2: pomalidomide + dexamethasone|Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (determined by age) on days 1, 8, 15, and 22 of each 28-day cycle. The starting dose of dexamethasone was 40 mg for participants who were ≤ 75 years of age and 20 mg for participants who were > 75 years of age. Dose reduction steps for dexamethasone were provided for drug-related toxicities.
9768027|NCT00833833|Experimental|Phase 2: pomalidomide|4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone on days 1, 8, 15, and 22 of each 28-day cycle at the starting dose of 20 or 40 mg depending on age in addition to their current dose of pomalidomide, or to discontinue treatment.
9768028|NCT00833898|No Intervention|Caregiver Control|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
9768029|NCT00833898|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), which included one-on-one psychoeducation, stress management intervention, with paced respiration.
9768030|NCT00833911|Experimental|Tramadol Contramid® OAD|
9768031|NCT00833924|Other|1|Treatment with Endovascular Graft
9768032|NCT00833976|Experimental|open-label Lovaza (omega-3 fatty acids)|4g per day (4g once a day or 2g two times a day) for 16 weeks
9768033|NCT00833989|Placebo Comparator|PLACEBO|
9768034|NCT00833989|Experimental|ACTIVE|
9768035|NCT00834041|Experimental|Aliskiren 2 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
9768036|NCT00834041|Experimental|Aliskiren 6 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning
9768037|NCT00834080|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
9768038|NCT00834106|Experimental|qHPV|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
9768039|NCT00834106|Placebo Comparator|Placebo|Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6
9768040|NCT00834171||1|Loteprednol etabonate ophthalmic suspension 0.5%
9768041|NCT00834171||2|Loteprednol etabonate (0.5%) and tobramycin (0.3%)
9768042|NCT00834210|Active Comparator|1|Dapsone Gel 5% and Tazarotene Cream 0.1%
9768043|NCT00834210|Active Comparator|2|Tazarotene Cream 0.1%
9768044|NCT00834236|Experimental|gastric cancer|gastric cancer patients
9768045|NCT00834236|Active Comparator|normal subject|healthy subject
9768046|NCT00834288|Experimental|1: 1x200 mg Tramadol HCl OAD tablet daily|
9768047|NCT00834288|Active Comparator|2: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly|
9768048|NCT00834366|Experimental|Tramadol HCl 200 mg Film-coated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
9768049|NCT00834366|Experimental|Tramadol HCl 200 mg Uncoated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
9768050|NCT00834483|Experimental|1|Knotless suture for wound closure
9768051|NCT00834483|Active Comparator|2|Layered traditional wound closure (monocryl)
9768052|NCT00834626|Other|Surgery group|Interventional study of the effects of a novel metabolic procedure of Ileal Interposition with Sleeve Gastrectomy
9768053|NCT00834652|Experimental|1|Participants will receive sertraline and metformin.
9768054|NCT00834652|Placebo Comparator|2|Participants will receive sertraline and placebo.
9768055|NCT00834678|Experimental|Bendamustine and Erlotinib|Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.
9768056|NCT00834808|Experimental|1: Tramadol HCl 100mg|
9768057|NCT00834808|Experimental|2: Tramadol HCl 200mg|
9768058|NCT00834808|Experimental|3: Tramadol HCl 300mg|
9768059|NCT00834834|Active Comparator|Fluoxetine|Participants will receive fluoxetine with clinical management, which may involve switching medication to citalopram, another SSRI.
9768060|NCT00834834|Active Comparator|Dialectical behavior therapy|Participants will receive dialectical behavioral therapy (DBT).
9768061|NCT00834886|Active Comparator|Combination|Bright light 10.000 lux + melatonin 3 mg
9768062|NCT00834886|Active Comparator|Melatonin|Melatonin 3 mg + placebo red light 400 lux
9768063|NCT00834886|Active Comparator|Bright light|Bright light 10.000 lux + placebo capsule 3 mg rice flour
9768064|NCT00834886|Placebo Comparator|Placebo|Placebo Red light 400 lux + placebo capsule 3 mg rice flour
9768065|NCT00834899|Experimental|1|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
9768066|NCT00834899|Placebo Comparator|2|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
9768067|NCT00834912|Experimental|1: Tramadol HCl (Confab Laboratories) fasting|
9768068|NCT00834912|Experimental|2: Tramadol HCl (Confab Laboratories) fed|
9768069|NCT00834912|Experimental|3: Tramadol HCl (Trillium Healthcare) fasting|
9768070|NCT00835003|Active Comparator|1|Elective caesarean section at 38 weeks and 3 days of gestation
10203647|NCT05198206||Sichuan Guangyuan People's Hospital|
9768071|NCT00835003|Active Comparator|2|Elective caesarean section at 39 weeks and 3 days of gestation
9768072|NCT00835068||BeneFIX|
9768073|NCT00835120|Experimental|Pioglitazone|Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes
9768074|NCT00835159|Experimental|Rivastigmine Patch|Group receiving Rivastigmine Patch
9768075|NCT00835159|Placebo Comparator|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
9768076|NCT00835185|Experimental|IMC-11F8 (necitumumab) /mFOLFOX-6 regimen|Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
9768077|NCT00835198|Active Comparator|1|Dapsone gel 5% and Tretinoin gel 0.025%
9768078|NCT00835198|Active Comparator|2|Tretinoin gel 0.025%
9768079|NCT00835224|Experimental|Midodrine|A drug to treat low blood pressure.
9768080|NCT00835224|Experimental|L-Name|L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
9768081|NCT00835224|Placebo Comparator|Placebo|Placebo: A pill with an inactive substance that looks like the study drug.
9768082|NCT00835237|Experimental|Boostrix Group|Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)
9768083|NCT00835237|Active Comparator|Decavac Group|Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)
9784321|NCT01222416|Experimental|fluorodeoxyglucose PET/CT (FDG-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
9784322|NCT01222416|Experimental|fluorodeoxythymidine PET/CT (FLT-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
9784323|NCT01222494|Placebo Comparator|Antipsychotic Treated Educational Cntrl|Antipsychotic treated participants randomized to this arm will receive diet and exercise education at monthly intervals with a study clinician or coordinator.
9784324|NCT01222494|Experimental|Antipsychotic Treated Weekly BWL|Antipsychotic treated participants randomized to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
9784325|NCT01222494|Active Comparator|Non-antipsychotic Treated Weekly BWL|Participants assigned to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
9784326|NCT01222507||Brain Speed Test|60 subjects who complete 60 Second Brain Game and Brain Speed Test
9784327|NCT01222520|Experimental|Telmisartan and amlodipine FDC|once a daily
9784328|NCT01222520|Active Comparator|Telmisartan monotherapy|once a daily
9784329|NCT01222533|Experimental|Tiotropium low|Tiotropium inhalation solution low dose
9784330|NCT01222533|Experimental|Tiotropium medium|Tiotropium inhalation solution medium dose
9784331|NCT01222533|Experimental|Tiotropium high|Tiotropium inhalation solution high dose
9784332|NCT01222533|Active Comparator|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
9784333|NCT01222533|Placebo Comparator|Tiotropium placebo|Placebo inhalation solution
9784334|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 1)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 54 Gy; Stereotactic Boost to Primary: 10 Gy; Total Dose to Primary: 64 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
9784335|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 2)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 50 Gy; Stereotactic Boost to Primary: 15 Gy; Total Dose to Primary: 65 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
9784336|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 3)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 46 Gy; Stereotactic Boost to Primary: 20 Gy; Total Dose to Primary: 66 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
9784337|NCT01222585|Experimental|Treatment|Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours
9784338|NCT01222689|Experimental|Treatment (erlotinib hydrochloride, selumetinib)|Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10203648|NCT05198206||Xinjiang Military Region General Hospital|
10203649|NCT05198206||Xinjiang Uygur Autonomous Region People's Hospital|
9768084|NCT00835341||p16-methylated|patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.
9768085|NCT00835341||p16-unmethylated|patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.
9768086|NCT00835380|Experimental|1|VAQTA™
9768087|NCT00835510|Experimental|Butenafine cream 1% (Taro)|Butenafine cream manufactured by Taro applied for 7 days
9768088|NCT00835510|Active Comparator|Lotrimin Ultra (butenafine) 1%|Lotrimin Ultra (butenafine) applied for 7 days
9768089|NCT00835510|Placebo Comparator|Vehicle|Butenafine vehicle applied for 7 days
9768090|NCT00835731|Experimental|1|400mcg buccal misoprostol
9768091|NCT00835731|Experimental|2|Dilapan-S, control: vitamin B-12 administered sublingually
9768092|NCT00835770|Experimental|BG00012 plus placebo|In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
9768093|NCT00835770|Experimental|BG00012|In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
9768094|NCT00835861|Experimental|Metformin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
9768095|NCT00835861|Active Comparator|Insulin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
9768096|NCT00835900|Experimental|varenicline|drug plus counseling.
9768097|NCT00835900|Active Comparator|placebo|placebo plus counseling
9768098|NCT00835926|Experimental|Fluzone® Vaccine Group 1|Participants aged 18 to 59 years at enrollment - Fluzone® Group
9768099|NCT00835926|Experimental|Fluzone® Vaccine Group 2|Participants aged 60 years and older at enrollment - Fluzone® Group
9768100|NCT00835978|Other|A|Randomized arm
9768101|NCT00835978|Other|B|Randomized arm
9768102|NCT00835978|Other|C|Non-randomized arm
9768103|NCT00836017||BOTOX®|Patients received BOTOX® (onabotulinumtoxinA) treatment as standard of care in clinical practice as prescribed by the physician. No intervention was administered as part of the study.
9768104|NCT00836095|Other|Supreme LMA|"Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
9768105|NCT00836095|Active Comparator|Proseal LMA|"Proseal is a multiple use, variant of the laryngeal mask airway.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
9768106|NCT00836186|Other|Radiation therapy|Women with non-metastatic breast cancer status post lumpectomy to negative margins and who are receiving whole breast irradiation as per standard treatment plan.
9768107|NCT00836277|Experimental|Irinotecan plus panitumumab|"Irinotecan 100 mg/m2 IV Day 1 and Day 8~+ Panitumumab 9mg/kg IV Day 1 Cycle = 21 days"
9768108|NCT00836342||Previous history of SCC|Participants had previous history of SCC
9768109|NCT00836342||Previous history of BCC|Participants had previous history of BCC
9768110|NCT00836342||Control|Participants had no previous history of squamous cell carcinoma or basal cell carcinoma
9768111|NCT00836407|Experimental|Arm 1: Ipilimumab Alone|Ipilimumab alone
9768112|NCT00836407|Experimental|Arm 2: Ipilimumab + Pancreatic Cancer Vaccine|Ipilimumab + Pancreatic Cancer Vaccine
9768113|NCT00836433|Active Comparator|FALLS only|Traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
9768114|NCT00836433|Experimental|CONNECT and FALLS|CONNECT educational intervention is designed to improve relationship-building and communication. The intervention includes 2 in-class session, group mapping exercise, individual relationship mapping exercises, Self-monitoring of interactions, individual staff coaching sessions. FALLS is a traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
9768115|NCT00836498|Experimental|Part I, RotaTeq|3 doses of RotaTeq
9768116|NCT00836498|Placebo Comparator|Part I, placebo|3 doses of placebo
9768117|NCT00836498|Experimental|Part II, RotaTeq|3 doses of RotaTeq
9768118|NCT00836498|Experimental|Part II, RotaTeq and placebo|1 dose of RotaTeq and 2 doses of placebo
9768119|NCT00836498|Placebo Comparator|Part II, placebo|3 doses of placebo
9768120|NCT00836589||Data Collection Group|
9768121|NCT00836641|Active Comparator|pneumococcal immunization (2 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 2 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
9768122|NCT00836641|Active Comparator|pneumococcal immunization (10 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 10 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
9768123|NCT00836693|Experimental|Tadalafil|
9768124|NCT00836693|Placebo Comparator|Placebo|
9768125|NCT00836719|Experimental|Polyphenon E|Standarized green tea extract containing 50% EGCG
9768126|NCT00836745||1|Non Interventional
9835614|NCT02747628|Active Comparator|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
9835615|NCT02747875|Active Comparator|Control - Fentanyl|Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
9835616|NCT02747875|Active Comparator|Treatment - Methadone|Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
9835617|NCT02747927|Placebo Comparator|Placebo|Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0).
9835618|NCT02747927|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received TDV, SC injection, based on the randomization on Day 1 (Month 0).
9835619|NCT02748070|Experimental|Prednisone|Provided oral steroid and topical steroid
9835620|NCT02748070|Placebo Comparator|Placebo|Provided oral placebo and topical steroid
9835621|NCT02748096|Experimental|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
9835622|NCT02748096|Active Comparator|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
9835623|NCT02748213|Experimental|Herceptin + Taxotere|Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.
9835624|NCT02748213|Experimental|Herceptin + Taxotere + Xeloda|Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.
9835625|NCT02748317|Experimental|Adults with Spinal Cord Injury|Lactobacillus rhamnosus GG
9835626|NCT02748356|Experimental|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
9835627|NCT02748512|Experimental|FAI Insert administered using the Mk II inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
9835628|NCT02748512|Active Comparator|FAI Insert administered using the Mk I inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
9835629|NCT02748525|Experimental|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
9835630|NCT02748694|Placebo Comparator|Part 1 (SRD): Placebo Cohorts 1-5|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
9768127|NCT00836758|Experimental|CPAP Device|Breathing event detection (AED) by the CPAP device will be compared to breathing event detection by a simultaneous PSG (manual PSG scoring).
9768128|NCT00836810|Experimental|Timed Release Tablet Prednisone|12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
9768129|NCT00836810|Active Comparator|Standard Prednisolone|12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
9768130|NCT00836875|Experimental|1|Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
9768131|NCT00836888|Experimental|Cohort|
9768132|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-5|Ridaforolimus 10 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus intravenous (IV) infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
9768133|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-6|Ridaforolimus 10 mg administered orally once daily on Days 1-6 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
9768134|NCT00836927|Experimental|Ridaforolimus 20 mg Days 1-5|Ridaforolimus 20 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
9768135|NCT00836927|Experimental|Ridaforolimus 30 mg Days 1-5|Ridaforolimus 30 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
9768136|NCT00836927|Experimental|Ridaforolimus 40 mg Days 1-5|Ridaforolimus 40 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
9768137|NCT00836953|Experimental|Study Group|Participants received 2 doses of Fluzone® vaccine
9768138|NCT00837031|Experimental|Intervention|"The study began with a lead-in portion to confirm the tolerability of lenalidomide (25mg PO days 1-21) in combination with gemcitabine (1000mg/m2 IV days 1, 8, and 15).~After completion of the lead-in phase, all subsequent patients received lenalidomide 25mg PO on days 1-21 and gemcitabine 1000mg/m2 IV days 1, 8, and 15 of 28-day treatment cycles. Patients were instructed to take lenalidomide at approximately the same time each morning. Patients were permitted to continue treatment until disease progression or intolerable toxicity occurred."
9768139|NCT00837096|Experimental|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distrubtes negative pressre across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
9768140|NCT00837096|Active Comparator|Moist Wound Therapy (MWT)|t wound therapy (MWT) is a widely used treatment modality that demonstrates benefit through the facilitation of a moist wound environment, which is known to promote faster relative wound healing compared to wounds exposed to air.
9768141|NCT00837148|Experimental|Sorafenib and Dacarbazine|This study is an open label, single arm, Simon two stage, phase 2 trial of continuous, daily oral sorafenib, with intravenous dacarbazine administered every three weeks for patients with synovial sarcoma, leiomyosarcoma and malignant peripheral nerve sheath tumor.
9768142|NCT00837161|Experimental|Philips MR guided HIFU system|Patient receiving HIFU treatment
9768143|NCT00837200|Experimental|Oncaspar, Doxil, Decadron Regimen|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
9768144|NCT00837213|Active Comparator|BPO with clindamycin foam|Benzoyl peroxide (BPO) wash with clindamycin foam
9768145|NCT00837213|Active Comparator|BPO + clindamycin foam + doxycycline|Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules
9768146|NCT00837252|Experimental|Finasteride|
9768147|NCT00837330|Experimental|Ranibizumab 0.5 mg/ 0.05 cc|Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
9768148|NCT00837330|Experimental|Ranibizumab 0.3 mg/ 0.05 cc|Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab
9768149|NCT00837434|Experimental|Etanercept|Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
9768150|NCT00837434|Experimental|Adalimumab|Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
9768151|NCT00837447|Active Comparator|NexGen CR knee prosthesis|side of knee operated with total knee replacement with Nexgen CR prosthesis
9768152|NCT00837447|Active Comparator|NexGen CR-Flex knee prosthesis|side of knee operated with total knee arthroplasty using Nexgen CR-flex prosthesis
9768153|NCT00837473|Other|Plexur-P Bone Void Filler|Single arm. Open Label.
9768154|NCT00837486|Active Comparator|Active Group - Active Stimulation|Receive active stimulation with Reclaim™ DBS System
9768155|NCT00837486|Sham Comparator|Control Group - Sham Stimulation|Receive sham stimulation with Reclaim™ DBS System
9768156|NCT00837512|Experimental|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
9768157|NCT00837512|Active Comparator|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
9768158|NCT00837577|Experimental|Sitagliptin/Sitagliptin|
9768159|NCT00837577|Experimental|Placebo/Sitagliptin|
9768160|NCT00837590|Experimental|Acute Salsalate|Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
9768161|NCT00837590|Experimental|Chronic Salsalate - Obese|Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
10203650|NCT05198206||The First Affiliated Hospital of Anhui Medical University|
10203651|NCT05198206||Yantai Yuhuangding Hospital|
10203652|NCT05198180|Active Comparator|Potassium hydroxide group|Patients with plantar warts will apply topical 30% potassium hydroxide solutions on warts
10203653|NCT05198180|Active Comparator|Hydrogen peroxide group|Patients with plantar warts will use topical 45% hydrogen peroxide solution on warts
10203654|NCT05198141|Active Comparator|Control group I (GI)|Patients who were undergoing surgical treatment
9768162|NCT00837590|Experimental|Chronic Salsalate - Lean|Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.
9768163|NCT00837616|Active Comparator|Group A|Group A will receive the oral estradiol for 12 months
9768164|NCT00837616|Active Comparator|Group B|Group B will receive the transdermal estradiol for 12 months
9768165|NCT00837694||1|Non-obese/0 kcal
9768166|NCT00837694||2|Non-obese/100 kcal
9768167|NCT00837694||3|Non-obese/300 kcal
9768168|NCT00837694||4|Obese/0 kcal
9768169|NCT00837694||5|Obese/100 kcal
9768170|NCT00837694||6|Obese/300 kcal
9768171|NCT00837759|Other|T1D group|This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.
9768172|NCT00837811|Experimental|LY2127399|
9768173|NCT00837824|Experimental|Fabrazyme 1mg/kg every 2 weeks|Fabrazyme 1.0 mg/kg every 2 weeks
9768174|NCT00837824|Experimental|Fabrazyme 3mg/kg every 2 weeks|Fabrazyme 3.0 mg/kg every 2 weeks
9768175|NCT00837876|Experimental|Treatment|Sorafenib + Erlotinib
9768176|NCT00837902|Experimental|Atenolol|"There is only 1 arm to this study. Intervention: All participants received atenolol. Genotyping for GRK5 was performed to identify if participants were GLN/GLN, GLN/LEU, or LEU/LEU.~Heart rates were measured at rest, and as participants performed graded incremental exercise on a supine bicycle ergometer (at 25, 50, and 75 W for 2 minutes each) twice, once before and once 2.5 hours after taking 25 mg of atenolol."
9768177|NCT00837967|Experimental|First Symbicort, then Terbutaline|Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
9768178|NCT00837967|Experimental|First Turbuhaler, then Symbicort|Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,
9768179|NCT00838006|Experimental|Biofeedback training|Heart rate variability biofeedback training and iPod with Breath Pacer app
9768180|NCT00838006|Experimental|Cognitive bias modification training|Cognitive bias modification training and iPod with cognitive bias training app
9768181|NCT00838006|Sham Comparator|Control Group|No additional resilience training and iPod with no resilience training apps
9768182|NCT00838097||Darbepoetin alfa|Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.
9768183|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 1)|
9768184|NCT00838110|Placebo Comparator|Placebo TID (Cohort 1)|
9768185|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 2)|
9768186|NCT00838110|Placebo Comparator|Placebo TID (Cohort 2)|
9768187|NCT00838162|Experimental|TMC310911/rtv 75/100 mg twice daily|TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14
9768188|NCT00838162|Experimental|TMC310911/rtv 150/100 mg twice daily|TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14
9768189|NCT00838162|Experimental|TMC310911/rtv 300/100 mg twice daily|TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14
9768190|NCT00838162|Experimental|TMC310911/rtv 300/100 mg once daily|TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14
9768191|NCT00838201|Experimental|Arm 1|
9768192|NCT00838331|Experimental|Fresh blood, then aged blood|
9768193|NCT00838435|Experimental|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
9768194|NCT00838513|Experimental|eculizumab|
9768195|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 1)|Neratinib 120 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9835631|NCT02748694|Experimental|Part 1 (SRD): Cohort 1: TAK-041 5/20 mg|TAK-041 5 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 20 mg, suspension, orally, once on Day 8 in the SRD period.
9768196|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 2)|Neratinib 120 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768197|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 3)|Neratinib 120 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768198|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 4)|Neratinib 120 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768199|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 5)|Neratinib 160 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768200|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 6)|Neratinib 160 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768201|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 7)|Neratinib 160 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768202|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 8)|Neratinib 160 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768203|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 9)|Neratinib 200 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768204|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 10)|Neratinib 200 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768205|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 11)|Neratinib 200 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768206|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 12)|Neratinib 240 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
9768207|NCT00838565|Placebo Comparator|Placebo|
9768208|NCT00838565|Experimental|PF-04236921|
9768209|NCT00838578|Experimental|KRN330 + Irinotecan|open label, single arm
9768210|NCT00838682|Experimental|rabeprazole sodium|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
9768211|NCT00838682|Active Comparator|Omeprazole|Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
9768212|NCT00838695|Experimental|African Americans|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
9768213|NCT00838695|Experimental|Caucasians|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
9768214|NCT00838903|Experimental|albiglutide + metformin|Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
9768215|NCT00838903|Active Comparator|sitagliptin + metformin|Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
9768216|NCT00838903|Active Comparator|glimepiride + metformin|Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
9768217|NCT00838903|Active Comparator|metformin + placebo|Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride
9768218|NCT00838916|Experimental|albiglutide weekly injection|albiglutide weekly subcutaneous injection
9768219|NCT00838916|Active Comparator|insulin glargine|insulin glargine daily injection
9768220|NCT00838929|Experimental|Vorinostat (200 mg) and radiation|Cohort 1: Patients receive 200 mg of Vorinostat and radiation
9768221|NCT00838929|Experimental|Vorinostat (300 mg) and radiation|Cohort 2: Patients receive 300 mg of vorinostat and radiation
9768222|NCT00838929|Experimental|Vorinostat (400 mg) and radiation|Cohort 3: Patients receive 400 mg of vorinostat and radiation
9768223|NCT00839072|Experimental|Trazodone Contramid OAD|
9768224|NCT00839072|Active Comparator|Desyrel|
9768225|NCT00839098|No Intervention|Control Group|Control Group
9768226|NCT00839098|Experimental|Instruction Group|Instruction Group
9768227|NCT00839098|Experimental|Instruction and Virtual Coach Group|Instruction and Virtual Coach Group
9768228|NCT00839241|Experimental|Autologous Blood Transfusion|
9768229|NCT00839241|Active Comparator|Allogenic Blood Transfusion|
9768230|NCT00839254|Experimental|10Pn3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
9768231|NCT00839254|Experimental|10Pn2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
9768232|NCT00839254|Active Comparator|Ctrl3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
9768233|NCT00839254|Active Comparator|Ctrl2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
9768234|NCT00839254|Experimental|10Pn7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9768235|NCT00839254|Active Comparator|Ctrl7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9768236|NCT00839254|Active Comparator|10Pn12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9768237|NCT00839254|Experimental|Ctrl12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9768238|NCT00839306|Experimental|1|
9768239|NCT00839306|Active Comparator|2|
9768240|NCT00839319|Experimental|Acyline plus Placebo|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
9768241|NCT00839319|Experimental|Acyline plus 15 IU hCG|Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
9768242|NCT00839319|Experimental|Acyline plus 60 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
9768243|NCT00839319|Experimental|Acyline plus 125 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
9768244|NCT00839319|Experimental|Acyline plus Testosterone gel|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days
9835632|NCT02748694|Experimental|Part 1 (SRD): Cohort 2: TAK-041 10/40 mg|TAK-041 10 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 40 mg, suspension, orally, once on Day 8 in the SRD period.
9768245|NCT00839332|Experimental|LY2603618 + Gemcitabine|"Participants participated in Phase 1 or 2.~LY2603618 (Phase 1): 70 to 250 milligrams/meter squared (mg/m^2) LY2603618 as a 1-hour continuous intravenous (IV) infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression (DP). Participants received LY2603618 as part of the dose escalation cohort (dose of 70, 105, 150, 200, or 250 mg/m^2) or the expansion cohort (flat dose of 200 mg or 230 mg).~LY2603618 (Phase 2): 230 mg LY2603618 as a 1-hour continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP.~Gemcitabine (Phase 1 and 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP. Participants received gemcitabine 24 hours prior to LY2603618 administration."
9768246|NCT00839332|Active Comparator|Gemcitabine|"Participants participated in Phase 2 only.~Gemcitabine (Phase 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression."
9768247|NCT00839423|Placebo Comparator|Placebo|
9768248|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 5 mg|
9768249|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 10 mg|
9768250|NCT00839423|Other|Venlafaxine XL 225 mg|Active Reference
9768251|NCT00839436|Experimental|3 microgram/kg CYT107|3 microgram/kg CYT107
9768252|NCT00839436|Experimental|10 microgram/kg CYT107|10 microgram/kg CYT107
9768253|NCT00839436|Experimental|20 microgram/kg CYT107|20 microgram/kg CYT107
9768254|NCT00839527|Active Comparator|metformin + glimepiride + pioglitazone + albiglutide placebo|Metformin + glimepiride + pioglitazone + matching albiglutide placebo
9768255|NCT00839527|Experimental|metformin + glimepiride + pioglitazone placebo + albiglutide|Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
9768256|NCT00839527|Active Comparator|met + glimepiride + pioglitazone placebo + albiglutide placebo|metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo
9768257|NCT00839540|Active Comparator|micafungin 100|Patients receive Micafungin 100 mg qd
9768258|NCT00839540|Active Comparator|micafungin 200|Patients receive 200 mg Micafungin qd
9768259|NCT00839540|Active Comparator|Caspofungin|Patients receive caspofungin 70 mg LD followed by 50 mg qd
9768260|NCT00839800|Experimental|1|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
9768261|NCT00839800|Active Comparator|2|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
9768262|NCT00839852|Experimental|Cariprazine 1.5mg|Participants received cariprazine 1.5 mg capsule once, twice or three times a day depending on their response and tolerability
9768263|NCT00839917|Experimental|ProQuad™|
9768264|NCT00839917|Active Comparator|M-M-R™ II and Varivax™|
9768265|NCT00839956|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
9768266|NCT00839982|Experimental|Treatment (chemotherapy)|Patients receive clofarabine PO QD on days 1-5 and low-dose cytarabine SC BID on days 1-10 or SC QD on days 1-14. Treatment repeats every 21-28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9768267|NCT00840034|Experimental|LY2216684|
9768268|NCT00840034|Placebo Comparator|Placebo|
10203655|NCT05198141|Experimental|low dose letrozole group II (GII)|patients who were medically treated with 5 mg of letrozole
10203656|NCT05198141|Experimental|High dose letrozole group (GIII)|patients who were medically treated with 10 mg of letrozole using
10203657|NCT05198076|No Intervention|G1 ( Conventional Physical Therapy Program group)|Patients in (G1) will be treated by a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration was 40min to 1 hour.
10203658|NCT05198076|Experimental|G2 ( High Frequency rTMS group)|Patients in (G2) will be treated by high frequency repetitive transcranial magnetic stimulation (HF-rTMS) in addition to the same physiotherapy program as in G1. The treatment will be conducted three sessions per week, day after day for successive four weeks. The session duration for rTMS will be 20-30 minutes, the physiotherapy session will be 40-45 min.
10203659|NCT05198050|Active Comparator|single dose letrozole tablets|starting from the first of January, patients will receive a single dose of letrozole (20 mg) two days, before starting misoprostol administration. Placebo tables with a similar appearance to letrozole will be administered the day before misoprostol administration and on the day of misoprostol administration.
10203660|NCT05198050|Active Comparator|multiple dose letrozole tablets|starting from the first of January, patients will receive 10 mg letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
9768269|NCT00840060|Experimental|AMALS|Addressing multiple aspects of language simultaneously
9768270|NCT00840060|Experimental|DTA|Discrete Trial Approach
9768271|NCT00840086|Experimental|rFVIII|
9768272|NCT00840294|No Intervention|Observation|Observation only for 2 weeks
9768273|NCT00840294|Active Comparator|Antibiotic|Ciprofloxacin 500 mg twice daily for 2 weeks
9768274|NCT00840450|Experimental|Paclitaxel + Imatinib Mesylate (Gleevec)|
9768275|NCT00840463|Active Comparator|1|
9768276|NCT00840463|Placebo Comparator|2|
9768277|NCT00840658|Placebo Comparator|Group A|Didactic safer injection & sexual activity education: In each city, 75 women will participate in a 60 minute lecture-format presentation and printed materials on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). In this component, there will be no theory-driven active skill building elements oriented towards safer sex or safer injection.
9768278|NCT00840658|Active Comparator|Group B|"Interactive injection risk intervention and didactic safer sex education: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] counseling session. This one-on-one intervention incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared. In addition, participants will be provided a lecture-format presentation on safer sex. However, in this component, there will be no theory-driven active skill building elements oriented towards safer sex."
9768279|NCT00840658|Active Comparator|Group C|"Interactive sexual risk intervention and didactic safer injection education: In each city, 75 women will participate in the 60 minute Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one on one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe sex and condom use with clients. In addition, participants will be provided a lecture format presentation on safer injection sharing. However, in this component, there will be no theory-driven active skill building elements oriented towards safer injection behavior."
9768280|NCT00840658|Experimental|Group D|"Interactive injection and sexual risk intervention: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] and Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one-on-one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy)."
9768281|NCT00840749|Experimental|CyberKnife Stereotactic Radiotherapy|
9768282|NCT00840749|Active Comparator|Surgery|
9768283|NCT00840970|Active Comparator|Efficacy Unilateral Control|Non-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator following FESS (control arm)
9768284|NCT00840970|Experimental|Efficacy Unilateral Treatment|Drug-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the intervention following FESS (treatment arm)
9768285|NCT00840970|Experimental|Safety/PK Bilateral Treatment|Drug-coated splints placed bilaterally in both ethmoid sinus openings following FESS
9768286|NCT00840996|Placebo Comparator|Placebo|Perioperative placebo IV infusion besides the standard anesthesia care, including general anesthesia and postoperative patient controlled analgesia.
9768287|NCT00840996|Active Comparator|Lidocaine|Perioperative intravenous lidocaine infusion besides the standard anesthesia care, including general anesthesia plus and post operative patient controlled analgesia.
9768288|NCT00841087|Experimental|SIBA|
9768289|NCT00841087|Active Comparator|Insulin Detemir|
9768290|NCT00841100|Experimental|Acute 24 Hour Component|Participants will receive one dose of Kuvan 20 mg/kg on Day 1 and assessed for Acute 24 hour Kuvan response.
9768291|NCT00841100|Experimental|Phase 1 Group|After completion of acute 24 hour component, participants can enroll in Phase 1 and will receive Kuvan 20 mg/kg by mouth once daily for 28 consecutive days
9768292|NCT00841100|Experimental|Phase 2 Group|Participants in Phase 1 that was not responsive will continue on to the Phase 2 of the study. Positive response is defined as a decrease of blood phenylalanine of 30% or greater from baseline taken from morning blood serum. The Phase 2 component of the study will be a 2 week period of dietary restriction.
9768293|NCT00841100|Experimental|Phase 3 Group|Participants in Phase 2 that achieves a fasting blood phenylalanine of less than 600 umol/l after 2 week dietary restriction will be retreated with Kuvan 20 mg/kg by mouth once daily for a period of 28 consecutive days.
9768294|NCT00841204|Experimental|Arm I|Participants receive oral sulindac twice daily for 8 weeks
9768295|NCT00841204|Placebo Comparator|Arm II|Participants receive oral placebo twice daily for 8 weeks
9768296|NCT00841269|Experimental|Uridine|Uridine 500 mg by mouth twice daily for 6 weeks
9768297|NCT00841269|No Intervention|Healthy Comparison|Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
9768298|NCT00841321|Active Comparator|Arm 1|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to take the intervention or placebo.
9768299|NCT00841321|Placebo Comparator|Arm 2|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to receive the placebo.
9768300|NCT00841412|Experimental|Immediate Intervention Group|Immediate Intervention: Long term care units assigned to the Immediate Intervention group were first to receive the staff training and management intervention to improve nutritional care processes.
9768301|NCT00841412|Active Comparator|Delayed Intervention Group|Delayed Intervention: Long term care units assigned to the Delayed Intervention group were monitored under usual care conditions to serve as a control for the Immediate Intervention group. Then, these units received the staff training and management intervention at a later date.
9784339|NCT01222715|Experimental|Arm I (vinorelbine tartrate, cyclophosphamide, bevacizumab)|Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
9784340|NCT01222715|Experimental|Arm II (vinorelbine tartrate, cyclophosphamide, temsirolimus)|Patients receive vinorelbine tartrate and cyclophosphamide as in arm I. Patients also receive temsirolimus IV over 30-60 minutes on days 1, 8, and 15.
9784341|NCT01222767|Experimental|Arm 1|
9784342|NCT01222832|Experimental|Bacitracin|Nasopore sponge soaked in Bacitracin, no oral antibiotics
9784343|NCT01222832|No Intervention|Saline|Nasopore sponge soaked in saline, routine oral antibiotics
9784344|NCT01222884|Active Comparator|Iron isomaltoside 1000|Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
9784345|NCT01222884|Active Comparator|Iron sucrose|Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
9768302|NCT00841555|Experimental|Hypofractionation Radiotherapy+Temozolomide|Patients will receive temozolomide PO daily for 5 weeks. Beginning week 1 after initiation of temozolomide therapy, patients undergo HIMRT times a week for a total of 15 fractions.
9768303|NCT00841568|Experimental|1|
9768304|NCT00841672|Experimental|Aliskiren/amlodipine 300/10 mg tablet|Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
9768305|NCT00841672|Active Comparator|Amlodipine 10 mg capsule|Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
9768306|NCT00841763|Experimental|TIV + aH5N1|First dose of the non-adjuvanted trivalent influenza virus vaccine (TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1).
9768307|NCT00841763|Active Comparator|PL + aTIV|First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV).
9768308|NCT00841776|Active Comparator|Duac gel|Clindamycin and benzoyl peroxide gel
9768309|NCT00841776|Active Comparator|Ziana gel|Clindamycin and tretinoin gel
9768310|NCT00841828|Experimental|Experimental|Epirubicin + Cyclophosphamide -> Docetaxel + Lapatinib
9768311|NCT00841828|Active Comparator|Control|Epirubicin + Cyclophosphamide -> Docetaxel + Trastuzumab
9768312|NCT00841906|Other|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
9768313|NCT00841906|Other|Alice PDx with written and verbal instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
9768314|NCT00841971|Experimental|anidulafungin|anti-fungal agent
9768315|NCT00841971|Active Comparator|Fluconazole|anti-fungal agent
9768316|NCT00842023|Experimental|Nesiritide Infusion|Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.
9768317|NCT00842023|Active Comparator|Nitroglycerin Infusion|Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.
9768318|NCT00842075|Experimental|1 Symlin|Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
9768319|NCT00842075|No Intervention|2 Usual Regimen|Usual bolus insulin dose at each meal
9768320|NCT00842153|Experimental|Clobetasol Propionate Foam|Topical foam formulation that includes clobetasol propionate (Steroid)
9768321|NCT00842153|Placebo Comparator|Vehicle Foam|Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.
9768322|NCT00842231||Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
9768323|NCT00842244|Experimental|A|
9768324|NCT00842257|Experimental|Panitumumab|Panitumumab administered by a central line infusion on days 1 and 15 of each 4 week cycle.
9768325|NCT00842296|Experimental|Seg. RF Ablation with CLF catheter|Single Arm with CLF Catheter
9768326|NCT00842309|Active Comparator|D-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
9768327|NCT00842309|Placebo Comparator|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
9768328|NCT00842335|Experimental|JI-101|
9768329|NCT00842348|Experimental|Lanreotide (Autogel formulation)|Patients from the preceding DB study (Study 726) were treated with open label lanreotide Autogel 120 mg by deep subcutaneous injections every 28 days. Patients were included if they had been treated with lanreotide (Autogel formulation) or placebo in DB Study 726 and had stable disease at the end of the 96-week treatment period, or if they had received placebo and had disease progression at any time during Study 726. Safety data were based on the safety population patients who received lanreotide in Study 729). The main efficacy analysis was based on the ITT population (patients randomised in Study 726 regardless of whether they continued into Study 729).
9768330|NCT00842361|Active Comparator|Mix30|
9768331|NCT00842361|Experimental|SIAC|
9768332|NCT00842543|Experimental|Overweight|Overweight Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
9768333|NCT00842543|Experimental|Lean|Lean Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
9768334|NCT00842608|Experimental|Haloperidol Eligible Intervention|0.5-1mg Haloperidol Q8h for 7 days, reduced exposure to anticholinergics, reduced exposure to benzodiazepines
9768335|NCT00842608|Active Comparator|Haloperidol Eligible Usual Care|Usual care
9768336|NCT00842608|Experimental|Haldol-Ineligible Arm|"Haldol-Ineligible arm for patients with contraindications for Haldol, unresolvable prolonged QTc, history of torsades de pointes, or history of seizures.~Patients are randomized and will still receive:~reduced exposure to anticholinergics, reduced exposure to benzodiazepines"
9768337|NCT00842608|Active Comparator|Haldol Ineligible Usual Care|Usual Care
9768338|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Gem|
9768339|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Vin|
9768340|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Gem|
9768341|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Vin|
9768342|NCT00842712|Experimental|Randomized part: Cil (Once Weekly) + Cetuximab + Chemotherapy|
9768343|NCT00842712|Experimental|Randomized part: Cil (Twice Weekly) + Cetuximab + Chemotherapy|
9768344|NCT00842712|Active Comparator|Randomized part: Cetuximab + Chemotherapy|
9768345|NCT00842751|Placebo Comparator|Testosterone Undecanoate + placebo finasteride|Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
9768346|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 0.5mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
9768347|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 1mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
9768348|NCT00842764|Experimental|Holmium: YAG laser|Subjects will go under minimally invasive Holmium: YAG laser blepharoplasty
9768349|NCT00842829|Experimental|FBT 100 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 100 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
9768350|NCT00842829|Active Comparator|FBT 200 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 200 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
9768351|NCT00842946|Experimental|Exposure w/ Acceptance-Based Rationale|Behavioral exposure within the context of psychological acceptance.
9768352|NCT00842946|Active Comparator|Exposure w/ Habituation-Based Rationale|Behavioral exposure within the context of habituation.
9768353|NCT00842985|Other|drug condition|Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.
9768354|NCT00843024|Experimental|Sumatriptan and Naproxen 1|Sumatriptan succinate and naproxen sodium combination 10mg/60mg
9768355|NCT00843024|Experimental|Sumatriptan and Naproxen 2|Sumatriptan succinate and naproxen sodium combination 30mg/180mg
9768356|NCT00843024|Experimental|Sumatriptan and Naproxen 3|Sumatriptan succinate and naproxen sodium combination 85mg/500mg
9768357|NCT00843024|Placebo Comparator|Placebo|Placebo to match
9768358|NCT00843115||Observational|This study was non-interventional and simply followed for 3 months patients initiating a treatment with donepezil
9768359|NCT00843167|Experimental|Sulforaphane Supplement|Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
9768360|NCT00843167|Placebo Comparator|Placebo|Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
9768361|NCT00843180|Experimental|massage|
9768362|NCT00843180|No Intervention|control|usual care only as control arm
9768363|NCT00843193|Experimental|GSK679586|Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
9768364|NCT00843193|Placebo Comparator|PLACEBO|Subjects will receive three, once monthly intravenous administration of saline, according to randomization
9768365|NCT00843284||Patients with neuropathic pain|
9768366|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC|dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
9768367|NCT00843349|Active Comparator|Ad Libitum Diet-LC|no dietary intervention + phosphorus binder (Lanthanum Carbonate)
9768368|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC Placebo|dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
9768369|NCT00843349|Placebo Comparator|Ad Libitum Diet-LC Placebo|no dietary intervention + placebo
9768370|NCT00843466|Active Comparator|Mild moisturizing Hand Cleanser|The test group will be provided with a mild moisturizing hand cleanser for all hand cleansing needs during the duration of the study.
9768371|NCT00843466|No Intervention|Current Hand Cleanser|The control group will continue to use their current cleanser for all hand washing.
9768372|NCT00843479||Elderly NGT|Normoglycemic subjects 65-80 years old
9768373|NCT00843479||Middle-age NGT|Middle-age normoglycemic subjects 35 to 50 years old.
9768374|NCT00843492|Active Comparator|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
9768375|NCT00843492|Experimental|Fondaparinux|After randomization (Day 1), subjects will receive subcutaneously, once daily, fondaparinux 2.5 mg (1.5 mg in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
9768376|NCT00843518|Experimental|LY451395|3 milligram (mg) LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
9768377|NCT00843518|Placebo Comparator|Placebo|Placebo orally twice daily for 12 weeks
9768378|NCT00843531|Experimental|RAD001 and erlotinib|"Each 28 day cycle:~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)"
9768379|NCT00843622|Experimental|1|Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants
9768380|NCT00843622|Placebo Comparator|2|Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants
9768381|NCT00843635|Experimental|Arm A - Tadalafil 10mg|Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
9768382|NCT00843635|Experimental|Arm B - Tadalafil 20mg|Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
9768383|NCT00843635|Placebo Comparator|Arm C - Placebo|Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
9768384|NCT00843713|Placebo Comparator|Placebo|For subjects assigned to the placebo group, patients will take a matching placebo pill of 400 mg by mouth twice daily for 24 weeks in addition to taking their current HIV medication
9768385|NCT00843713|Active Comparator|Raltegravir|For subjects assigned to the active comparator group, they will receive raltegravir at 400 mg by mouth twice daily for 24 weeks in addition to continuing to take their current HIV medication
9768386|NCT00843726|Experimental|Arm I|Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
9768387|NCT00843726|Experimental|Arm II|Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
9768388|NCT00843778|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg every two weeks at the hospital by a nurse. Certolizumab Pegol 200 mg every two weeks at the patient's home done by patient (self-injection).
9768389|NCT00843843|Active Comparator|9 hour sleep, then 3 hour nap and 6 hour sleep|
9768390|NCT00843843|Active Comparator|3 hour nap and 6 hour sleep, then 9 hour sleep|
9768391|NCT00843856|Active Comparator|tacrolimus|Intervention type -drug tacrolimus therapy 2mg bd adjust to obtain levels of 5-12ng/L
9768392|NCT00843856|Active Comparator|tacrolimus and mycophenolate mofetil|tacrolimus 2mgs bd (adjusted to obtain levels 5-12mg/L and mycophenolate mofetil 500mg bd adjusted to obtain levels 1.5-3mg/L
9768393|NCT00844051|No Intervention|No Intervention|No school-based influenza vaccination program
9768394|NCT00844051|Active Comparator|Intervention|School-based Influenza Vaccination Program
9768395|NCT00844090|Placebo Comparator|Arm 1|placebo tablets
9768396|NCT00844090|Experimental|Arm 2|methylphenidate tablets
9768397|NCT00844194|Other|DPNP with depression (1)|Patients that have diabetic polyneuropathy and depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
9768398|NCT00844194|Other|DPNP with depression (2)|Patients that have diabetic polyneuropathy and depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
9768399|NCT00844194|Other|DPNP without depression (1)|Patients that have diabetic polyneuropathy and no depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
9768400|NCT00844194|Other|DPNP without depression (2)|Patients that have diabetic polyneuropathy and no depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
9768401|NCT00844298|Experimental|Nilotinib+mVPD|Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
9768402|NCT00844376|Other|Test|Extemporaneous preparation suspension Atorvastatin prototype formulation
9768403|NCT00844376|Other|Reference|Commercial atorvastatin tablet (Lipitor®)
9768404|NCT00844415|Experimental|dabigatran etexilate|open label; patient to receive dabigatran etexilate BID for three days
9768405|NCT00844428|Experimental|Eculizumab|
9768406|NCT00844519|Active Comparator|Maraviroc|For subjects assigned to the maraviroc group, subjects will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medication. For subjects on ritonavir, the dose of maraviroc will be 150mg by mouth twice daily.
9768407|NCT00844519|Placebo Comparator|Placebo|
9768408|NCT00844532|Experimental|Absolute Pro™ Peripheral Self-Expanding Stent System|Arm includes both Absolute Pro™ and Absolute Pro™ Long Lesion (LL) Peripheral Self-Expanding Stent Systems
9768409|NCT00844545|Experimental|Eculizumab|
9984295|NCT04251078||Myelodysplastic Syndromes - Progression cohort|According to the literature (Greenberg et al, Blood. 2012), around 5-15% are expected to progress to high/very high-risk MDS subtype or to acute myeloid leukemia (AML). According to the total cohort of patients, it is expected that 20 of them would comprise this group and will be studied by targeted deep sequencing.
9768410|NCT00844558|Experimental|Gait Training|Gait Training Intervention Group Participants
9768411|NCT00844558|Placebo Comparator|Control|Gait Training Control Group Participants
9768412|NCT00844597|Experimental|Cohort 1 - 0.5 mg/kg/wk|Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
9768413|NCT00844597|Experimental|Cohort 2 - 1.0 mg/kg/wk|Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
9768414|NCT00844597|Experimental|Cohort 3 - 2.0 mg/kg/wk|Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
9768415|NCT00844597|Experimental|Cohort 4 - 4.0 mg/kg/wk|Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
9768416|NCT00844597|Experimental|Cohort 5 - 10.0 mg/kg/wk|Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
9768417|NCT00844597|Experimental|Cohort 6 - 20.0 mg/kg/wk|Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
9768418|NCT00844649|Experimental|Albumin-bound paclitaxel (ABI-007)/Gemcitabine|ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
9768419|NCT00844649|Active Comparator|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
9768420|NCT00844714|Experimental|Rituxan|
9768421|NCT00844753|Active Comparator|1|Atomoxetine + Parent Management Training
9768422|NCT00844753|Active Comparator|2|Atomoxetine without Parent Management Training
9768423|NCT00844753|Placebo Comparator|3|Placebo + Parent Management Training
9768424|NCT00844753|Placebo Comparator|4|Placebo without Parent Management Training
9768425|NCT00844805|Experimental|Infliximab + Naproxen|Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
9768426|NCT00844805|Placebo Comparator|Placebo + Naproxen|Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
9768427|NCT00844805|Experimental|Naproxen Only (Follow-Up)|For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
9768428|NCT00844805|No Intervention|No Treatment (Follow-Up)|For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
9768429|NCT00844831|Experimental|Treatment with lubiprostone|Subjects receive lubiprostone and bacteria is measured before and after
9768430|NCT00844844|Experimental|Eculizumab|
9768431|NCT00844857|Experimental|Olanzapine/Fluoxetine Combination|
9768432|NCT00844857|Placebo Comparator|Placebo|
9768433|NCT00844883|Experimental|sorafenib and drug eluting beads|single arm
9768434|NCT00844896|Active Comparator|DEF-only|Distress Emotional Support and Family Assessment Treatment
9768435|NCT00844896|Experimental|DEF + COPE|Distress Emotional Support and Family Assessment Treatment and Creating Opportunities for Parent Empowerment Treatment
9768436|NCT00845000|Experimental|SCH 420814 10 mg→SCH 420814 100 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
9768437|NCT00845000|Experimental|SCH 420814 100 mg→Placebo→ SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
9768438|NCT00845000|Experimental|Placebo→SCH 420814 10 mg→SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
9768439|NCT00845000|Experimental|SCH 420814 10 mg→ Placebo→ SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
9784346|NCT01223027|Experimental|Dovitinib + best supportive care (BSC)|Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.
9768440|NCT00845000|Experimental|SCH 420814 100 mg→ SCH 420814 10 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
9768441|NCT00845000|Experimental|Placebo→ SCH 420814 100 mg→SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
9768442|NCT00845039|Active Comparator|Cetuximab + Irinotecan|Participants in Treatment Group 1 will receive intravenous infusions of Cetuximab 500 milligrams per square meter (mg/m²) and Irinotecan 180 mg/m².
9768443|NCT00845039|Experimental|Cetuximab + IMC-A12 + Irinotecan|Participants in Treatment Group 2 will receive intravenous infusions of Cetuximab 500 mg/m², IMC-A12 10 milligrams/kilogram (mg/kg) and Irinotecan 180 mg/m².
9768444|NCT00845065|Placebo Comparator|Arm 1 (Control Arm)|Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by placebo (800 mg three times a day [TID] PO, using placebo matching SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks with 24 weeks post-treatment follow-up.
9768445|NCT00845065|Experimental|Arm 2 (Boceprevir Arm)|"Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by boceprevir (800 mg three times a day [TID] PO, using SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks~with 24 weeks post-treatment follow-up."
9768446|NCT00845130|Experimental|Diabetic Type II Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
9768447|NCT00845130|Experimental|Healthy Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
9768448|NCT00845182|Active Comparator|Pioglitazone|Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm
9768449|NCT00845182|Experimental|Exenatide|Exenatide: 15 subjects will be randomized to receive Exenatide
9768450|NCT00845182|Experimental|Drug Pioglitazone and Drug Exentatide|Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide
9768451|NCT00845195|Experimental|Olopatadine HCl Nasal Spray, 0.6%|
9768452|NCT00845195|Active Comparator|Azelastine HCl Nasal Spray, 0.1%|
9768453|NCT00845429|Experimental|Group 1: Standard-dose Cell-based Influenza Vaccine|Participants will receive a single dose of standard-dose cell-based influenza virus vaccine.
9768454|NCT00845429|Experimental|Group 2: High-dose Cell-based Influenza Vaccine|Participants will receive a single dose of high-dose cell-based influenza virus vaccine.
9768455|NCT00845429|Active Comparator|Group 3: Licensed Fluzone® Influenza Vaccine|Participants will receive a single dose of licensed Fluzone® influenza vaccine.
9768456|NCT00845481|Experimental|all patients apply all products|
9768457|NCT00845507|Experimental|Exenatide Group|Exenatide dstarted at 5 mcg subcutaneously twice daily within one hour before the morning and evening meals, and increased (as tolerated) to 10 mcg.
9768458|NCT00845507|Placebo Comparator|Placebo Group|Placebo: Sterile solution in equivalent doses as Exenatide
9768459|NCT00845520|Experimental|Lens implantation +1.00 diopter (D) postop target|Lens implant power calculated for postoperative MRSE target of +1.00 D
9768460|NCT00845520|Experimental|Lens implantation -1.00 D postop target|Lens implant power calculated for postoperative MRSE target of -1.00 D
9768461|NCT00845520|Experimental|Lens implantation 0.00 D postop target|Lens implant power calculated for postoperative MRSE target of 0.00 D
9768462|NCT00845650|Experimental|AIGIV 3.5 mg/kg (Cohort A)|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
9768463|NCT00845650|Other|Gamunex 90 mg/kg (Cohort A)|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
9768464|NCT00845650|Experimental|AIGIV 7.0 mg/kg (Cohort B)|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
9768465|NCT00845650|Other|Gamunex 180 mg/kg (Cohort B)|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
9768466|NCT00845650|Experimental|AIGIV 14.0 mg/kg (Cohort C)|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
9768467|NCT00845650|Other|Gamunex 360 mg/kg (Cohort C)|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
9768468|NCT00845663|Active Comparator|Pre-filled Syringe|pre-filled syringe (reference)
9768469|NCT00845663|Experimental|Auto-injection Device|Auto-injection device (test)
9768470|NCT00845676|Experimental|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a + Ribavirin
9768471|NCT00845728|Experimental|Indacaterol|Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
9768472|NCT00845728|Active Comparator|Tiotropium|Tiotropium 18 µg o.d. delivered via the handihaler®
9768473|NCT00845832|Experimental|1|
9768474|NCT00845832|Active Comparator|2|
9768475|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 10 mg|
9768476|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 14 mg|
9768477|NCT00845858|Placebo Comparator|Placebo Nasal Spray|
9768478|NCT00845871|Experimental|Deferasirox|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
9768479|NCT00845897|Placebo Comparator|1|Placebo (saline) injections into 6 sites in the calf muscle
9768480|NCT00845897|Active Comparator|2|Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles.
9768481|NCT00845897|Active Comparator|3|300 units of botulinum toxin injected into 6 sites in the calf muscle
9768482|NCT00845975|Active Comparator|Erchonia Hearing Lasers #1 & #2|"Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light."
9768483|NCT00845975|Placebo Comparator|Placebo Lasers|Inactive lasers that do not emit any therapeutic light.
9768484|NCT00846027|Experimental|Bevacizumab + paclitaxel + gemcitabine|Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
9768485|NCT00846040|Experimental|Obese RF then RC|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive an 85% reduction of baseline dietary fat (RF) for 2 weeks. After a washout period of 2 weeks, they then received a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks
9768486|NCT00846040|Experimental|Obese RC then RF|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks. After a washout period of 2 weeks, they then received an 85% reduction of baseline dietary fat (RF) for 2 weeks.
9768487|NCT00846040|Active Comparator|Lean Control|Lean adult volunteers (BMI below 30kg/m2) placed on a weight-maintenance diet using a standard diet composition of 50% carbohydrate, 35% fat, and 15% protein on an out-patient basis
9768488|NCT00846053|Other|Stable lung function|* Group S (n = 14) will consist of CF patients, aged 12-21 years old, who underwent FDG-PET with stable lung function during the past 4 years, defined as less than 2% decline per year. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
9768489|NCT00846053|Other|Rapidly deteriorating lung function|* Group R (n = 14) will contain CF patients, aged 12-21 years old, who underwent FDG-PET with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
9768490|NCT00846066|Experimental|Hands on Training|Hands on Training by a pediatric dentist
9768491|NCT00846066|Active Comparator|Web Based Training|Web Based Training for all residents before randomization
9768492|NCT00846287|Active Comparator|Drug Subjects|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. BROVANA (arformoterol tartrate) Inhalation Solution is supplied as 2 mL of arformoterol tartrate solution packaged in 2.1 mL unit-dose, low-density polyethylene (LDPE) unit-dose vials. Each unit-dose vial contains 15 mcg of arformoterol (equivalent to 22 mcg of arformoterol tartrate) in a sterile, isotonic saline solution, pH-adjusted to 5.0 with citric acid and sodium citrate. After administration of the drug, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
9768493|NCT00846287|Placebo Comparator|Saline|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the placebo (nebulized saline solution) will be administered (2.1 mL). After administration of the placebo, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
9768494|NCT00846365|Experimental|Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
9768495|NCT00846365|Experimental|Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
9768496|NCT00846365|Active Comparator|Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD|(dependant on blood pressure)
9768497|NCT00846391|Experimental|MK8245 5 mg b.i.d.|MK8245
9768498|NCT00846391|Experimental|MK8245 50 mg b.i.d.|MK8245
9768499|NCT00846391|Placebo Comparator|Placebo|Placebo
9768500|NCT00846482|Experimental|Resected or metastatic CRC|All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin
9768501|NCT00846495|Active Comparator|topiramate|Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.
9768502|NCT00846495|Active Comparator|frovatriptan|Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).
9768503|NCT00846521|Experimental|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
9768504|NCT00846547|Experimental|Arbaclofen|
9768505|NCT00846573|Experimental|Asthmatic Participants|This population is made up of only confirmed asthmatics. Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
9768506|NCT00846573|Experimental|Healthy|"This population is made up of subjects who are considered clinically healthy. This means that there are no records of any chronic disorders or pulmonary history.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
9768507|NCT00846573|Experimental|COPD Patients|"This population is made up of only confirmed COPD patients. Diagnosis must be confirmed through their doctor prior to enrollment.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
9768508|NCT00846573|Experimental|Cystic Fibrosis Patients|"This population is made up entirely of confirmed cystic fibrosis patients. Diagnosis must be confirmed through their physician.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
9768509|NCT00846586|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9768510|NCT00846586|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9768511|NCT00846651|Experimental|colloid, then phenylephrine infusion|colloid administration; with 0.5 L Hydroxyethylstarch solution at a rate of 17 ml/min and completed over 30 min. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
9768512|NCT00846651|Active Comparator|crystalloid, then phenylephrine infusion|crystalloid administration; The patients received 1.5 L Ringer's lactate infusion at a rate of 50 ml/min and completed over 30 min prior to spinal anesthesia for cesarean section. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
9784347|NCT01223027|Active Comparator|Sorafenib + BSC|Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.
9784348|NCT01223183|Active Comparator|isotonic saline then hypertonic saline|Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.
9784349|NCT01223183|Active Comparator|hypertonic saline then isotonic saline|Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.
9784350|NCT01223196|Placebo Comparator|Placebo|One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
9784351|NCT01223196|Active Comparator|Pioglitazone|One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months
9784352|NCT01223235|Experimental|bevacizumab & polyvalent vaccine-KLH conjugate + OPT-821|This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
9784353|NCT01223352|Experimental|Bosentan 2 mg/Kg t.i.d.|2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
9784354|NCT01223352|Experimental|Bosentan 2 mg/Kg b.i.d.|2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
9835633|NCT02748694|Experimental|Part 1 (SRD): Cohort 3: TAK-041 80 mg|TAK-041 80 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
9768513|NCT00846742|Experimental|Treatment|Participants receive Stanford V Chemotherapy with or without radiation therapy. Patients receive doxorubicin hydrochloride IV and vinblastine IV on day 1 of weeks 1, 3, 5, and 7; mechlorethamine hydrochloride IV on day 1 of weeks 1 and 5; vincristine sulfate IV and bleomycin IV on day 1 of weeks 2, 4, 6, and 8; etoposide IV on day 1 of weeks 3 and 7; and prednisone orally (PO) three times daily every other day of weeks 1-8. Beginning 2-3 weeks after completion of chemotherapy, patients not achieving complete response undergo radiation therapy to individual nodal sites (tailored fields)
9768514|NCT00846807||Patients 75 years or younger|
9768515|NCT00846846|Experimental|Endeavor® Zotarolimus Eluting Coronary Stent|Endeavor® Zotarolimus Eluting Coronary Stent System
9768516|NCT00847015|Experimental|Gemcitabine, Cisplatin, and Sunitinib|This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
9768517|NCT00847132|Experimental|Collaborative Care|Collaborative Care Treatment: A study care manager provides depression education, consults with study psychiatrist to develop individualized treatment recommendations, and collaborates with patient and medical team to implement those recommendations
9768518|NCT00847132|Active Comparator|Usual Care|Usual Care Treatment: Primary medical providers are informed that the patient has depression and that treatment is recommended.
9768519|NCT00847145|Experimental|12B12M (1a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
9768520|NCT00847145|Experimental|12B13M (1b)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
9768521|NCT00847145|Experimental|12M13B15B (2a)|Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
9768522|NCT00847145|Experimental|12M12B14B (2b)|Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
9768523|NCT00847145|Experimental|12B12M (3a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
9768524|NCT00847145|Experimental|12B13M (3b)|Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
9768525|NCT00847145|Experimental|12B12M_C (4a)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
10203661|NCT05198050|Active Comparator|misoprostol tablets|starting from the first of January, patients will receive placebo tablets with a similar appearance to letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
10203662|NCT05198037|Experimental|Active transcranial direct current stimulation (tDCS)|Weak direct currents with 2 mA are delivered 20 minutes per session (including 30s ramp-up and 30s ramp-down) during tailored upper extremity task practice. Total sessions are 20 over 10 days.
9768526|NCT00847145|Experimental|12B13M_C (4b)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
9768527|NCT00847171|Experimental|Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine|Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine
9768528|NCT00847197|Experimental|1|MK1903
9768529|NCT00847197|Placebo Comparator|2|Placebo to MK1903
9768530|NCT00847210|Experimental|Dexlansoprazole MR 30 mg QD|
9768531|NCT00847210|Experimental|Dexlansoprazole MR 60 mg QD|
9768532|NCT00847288|Experimental|Monthly Review Arm|Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
9768533|NCT00847288|Active Comparator|Quarterly Review Arm|Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months
9768534|NCT00847301||Renal Impairment|
9768535|NCT00847379|Experimental|Overall Participants: High-Dose Ataluren|All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.
9768536|NCT00847522|Experimental|All patients|All participants enrolled.
9768537|NCT00847535|Other|1|Transurethral dose escalation
9768538|NCT00847535|Other|2|Periurethral dose escalation
9768539|NCT00847561|Experimental|Family-based CBT|Family-based CBT. Participants will receive family-based cognitive behavioral therapy. Families in this group will learn about how to identify the signs and symptoms of anxiety, ways to cope with anxiety, relaxation techniques, and problem-solving skills. They will participate in 8, one-hour sessions, once/week with trained clinicians and 3 monthly booster sessions to reinforce what they learned.
9768540|NCT00847561|Placebo Comparator|Information Monitoring|Information Monitoring. Participants will receive a packet of information about anxiety. Participants in this group will be called monthly to monitor symptoms of anxiety.
9768541|NCT00847587|Experimental|1|Early postpartum insertion
9768542|NCT00847587|Active Comparator|2|Standard postpartum insertion
9768543|NCT00847613|Experimental|Sequence 1|
9768544|NCT00847613|Experimental|Sequence 2|
9768545|NCT00847613|Placebo Comparator|Sequence 3|
9768546|NCT00847613|Placebo Comparator|Sequence 4|
9768547|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD|
9768548|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD|
9768549|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD|
9768550|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD|
9768551|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD|
9768552|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD|
9768553|NCT00847626|Active Comparator|Chlorthalidone 12.5 mg QD|
9768554|NCT00847626|Active Comparator|Chlorthalidone 25 mg QD|
9768555|NCT00847626|Experimental|Azilsartan medoxomil 20 mg QD|
9768556|NCT00847626|Experimental|Azilsartan medoxomil 40 mg QD|
9768557|NCT00847626|Experimental|Azilsartan medoxomil 80 mg QD|
9768558|NCT00847665|Active Comparator|Turning every 4 hours|The four-hours repositioning group patients were turned every four hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
9768559|NCT00847665|Experimental|Turning every 2 hours|The two-hours repositioning group patients, were turned every two hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
9768560|NCT00847704|Experimental|Test treatment group|Device: Assisted movement and enhanced sensation
9768561|NCT00847730|Experimental|VAC GranuFoam Bridge Dressing|This is a medical device foam dressing allowing placement away from wound site. It is designed to simplify the bridging application. It is used in combination with the V.A.C. Negative Pressure Wound Therapy System. For each subject, the dressing was applied in compliance with the IFU for 48-72 hours.
9768562|NCT00847808|Experimental|1|
9768563|NCT00847886|Experimental|LX3305|Daily oral intake of LX3305 for 14 days.
9768564|NCT00847886|Placebo Comparator|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
9768565|NCT00847912|Experimental|Arm 1: 5-fluorouracil|Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
9768566|NCT00847912|Placebo Comparator|Arm 2: Placebo|Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
9768567|NCT00847938|Active Comparator|1|neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
9768568|NCT00847938|Active Comparator|2|neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
9768569|NCT00847938|Active Comparator|3|neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
9768570|NCT00847938|No Intervention|4|no injection of neostigmine
9768571|NCT00848016|Experimental|Treatment (R-(-)-gossypol acetic acid)|Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9768572|NCT00848042|Active Comparator|AuroShell-3.5|Group treated with the lowest treatment level with 4.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 3.5 watts. Device: AuroLase Therapy
9768573|NCT00848042|Active Comparator|AuroShell-4.5|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 4.5 watts. Device: AuroLase Therapy
9768574|NCT00848042|Active Comparator|AuroShell-5.0|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 5.0 watts. Device: AuroLase Therapy
9768575|NCT00848081|Placebo Comparator|Placebo|
9768576|NCT00848081|Experimental|Tadalafil|
9768577|NCT00848107|Experimental|Treprostinil|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
9768578|NCT00848120|Experimental|1|
9768579|NCT00848172|Active Comparator|Octanoic Acid|
9768580|NCT00848172|Placebo Comparator|Placebo|
9768581|NCT00848185||Antagonist-hCG for triggering|Protocol with antagonist and hCG to trigger oocyte maturation
9768582|NCT00848185||Antagonist-aGnRH for triggering|Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
9768583|NCT00848185||Long protocol-hCG for triggering|Long Protocol and hCG to trigger oocyte maturation
9768584|NCT00848198||Normal|Subjects with no objective signs of Dry Eye Disease
9768585|NCT00848198||Dry Eye Disease|Subjects with objective signs of Dry Eye Disease
9768586|NCT00848211|Placebo Comparator|Placebo|
9768587|NCT00848211|Experimental|TUTI-16 0.03 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
9768588|NCT00848211|Experimental|TUTI-16 0.1 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
9768589|NCT00848211|Experimental|TUTI-16 0.6 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
9768590|NCT00848237|Experimental|Treatment|All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
9768591|NCT00848250|Experimental|ACE inhibitor|Patients already on an ACE inhibitor will continue it until the day of surgery
9768592|NCT00848250|Experimental|No ACE inhibitor|Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery
9768593|NCT00848354|Experimental|Phase 1 Etanercept + methotrexate|Phase 1: Etanercept + methotrexate
9768594|NCT00848354|Active Comparator|Phase 1 Conventional DMARD (SSZ or HCQ) + MTX|Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate
9768595|NCT00848367|Experimental|High attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
9768596|NCT00848367|Experimental|Low attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
9768597|NCT00848393|Active Comparator|Fentanyl (High Dose)|This arm will receive a total of 25 mcg/kg of Fentanyl (High Dose) in two divided doses. First half-dose given at induction and second half-dose given before incision.
9768598|NCT00848393|Active Comparator|Fentanyl (Low Dose)|This arm will receive a total of 10 mcg/kg of Fentanyl (Low Dose). First half-dose will be given at induction and second half -dose given before incision.
9768599|NCT00848393|Active Comparator|Fentanyl (Low Dose) + Dexmedetomidine|This arm will receive10 mcg/kg of Fentanyl (Low Dose) -2 divided doses. Dexmedetomidine (Dex) loading dose-1 mcg/kg over 10 min, then Dex infusion at 0.5mcg/kg/hr.
9768600|NCT00848484|Experimental|1|MK5757
9768601|NCT00848484|Placebo Comparator|2|Placebo
9768602|NCT00848497|Active Comparator|Testim® + Viagra®|Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night
9768603|NCT00848497|Placebo Comparator|Placebo Testim® + Viagra®|Placebo Testim® gel once daily + Viagra® 25 mg tablet every night
9768604|NCT00848510|Experimental|EMD 525797|
9768605|NCT00848536|Experimental|TRAVATAN APS|One drop once daily in the evening for 3 months
9768606|NCT00848536|Active Comparator|TRAVATAN|One drop once daily in the evening for 3 months
9768607|NCT00848549|Active Comparator|ZNS|
9768608|NCT00848549|Active Comparator|CBZ|
9768609|NCT00848718|Experimental|MK-2206 + carboplatin + paclitaxel|MK-2206 combined with carboplatin and paclitaxel
9768610|NCT00848718|Experimental|MK-2206 + docetaxel|MK-2206 combined with docetaxel plus pretreatment with a corticosteroid
9768611|NCT00848718|Experimental|MK-2206 + erlotinib|MK-2206 combined with erlotinib
9768612|NCT00848744|Experimental|topical salicylic acid 1.0% cream|
9768613|NCT00848783|Experimental|A-with IP Floxuridine|"Induction treatment:~Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.~Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.~Randomization~Surgery.~Postoperative IP treatment:~Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once~Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral"
9768614|NCT00848783|Experimental|B-Without IP Floxuridine|Same as Arm A except no postoperative IP treatment.
9768615|NCT00848926|Experimental|Brentuximab vedotin|
9768616|NCT00848965|Placebo Comparator|Placebo|
9768617|NCT00848965|Experimental|Fluticasone propionate 25ug|
9768618|NCT00848965|Experimental|Fluticason propionate 50ug|
9768619|NCT00848965|Experimental|Fluticasone propionate 100ug|
9768620|NCT00848965|Experimental|Flutciasone propionate 200ug|
9768621|NCT00849017|Experimental|albiglutide|albiglutide weekly injection
9768622|NCT00849017|Placebo Comparator|placebo|albiglutide matching placebo
9768623|NCT00849017|Experimental|albiglutide up-titration|albiglutide weekly injection uptitration at week 12
9768624|NCT00849056|Placebo Comparator|placebo + pioglitazone (with or without metformin)|Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
9768625|NCT00849056|Experimental|albiglutide + pioglitazone (with or without metformin)|albiglutide weekly injection + pioglitazone (with or without meformin)
9768626|NCT00849108|Experimental|Cohort 1: dose range and dose interval|Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period.
9768627|NCT00849108|Experimental|Cohort 2: Pharm&exercise stress Efficacy|"Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress~For the Pharmacologic (Adenosine) Stress:~Doses at rest to range between 2.9 and 3.4 mCi.~Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~Doses at rest were to range between 1.7 and 2.0 mCi.~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
9768628|NCT00849121|Experimental|1|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then every 12 weeks until disease progression.
9768629|NCT00849121|Experimental|2|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then given every 2-week, 4-week, or 3-month intervals as dictated by cellular immune response measurement.
9768630|NCT00849147|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
9768631|NCT00849186|Experimental|Arm 1|
9768632|NCT00849212|Experimental|1|
9768633|NCT00849251|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9768634|NCT00849290|Experimental|APC8015F|
9768635|NCT00849381|Experimental|Cervarix Compliance Issue Centre Group|Subjects from one centre where compliance issues were discovered, who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study
9768636|NCT00849381|Experimental|Cervarix All Centres Group|Subjects from all study centres who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study.
9768637|NCT00849472|Experimental|Treatment Arm|"Preoperative~Cycles 1-4 Doxorubicin 60 mg/m2 IV over 15 minutes + Cyclophosphamide 600 mg/m2 IV over 30 minutes of Day 1 every 21 days~followed by:~Cycles 5-8 Paclitaxel 80 mg/m2 IV over 60 minutes (Days 1, 8, and 15) every 28 days in combination with pazopanib (800 mg) PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning on Day 1 of the first paclitaxel cycle Until 7 days before surgery~Followed by Surgery~Postoperative Pazopanib 800 mg PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning 4-6 weeks after surgery 6 months from first postoperative dose"
9768638|NCT00849680|Placebo Comparator|Placebo|Participants receiving 1.0 ml of placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine or the placebo to the MRKAd5 HIV-1 gag vaccine injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26 or a 2-dose regimen at Day 1 and Week 26 or Day 1 and Week 4.
9768639|NCT00849680|Experimental|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Participants receiving 1.0 ml of the Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
9768640|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
9768641|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
9768642|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
9768643|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
9768644|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26, or in a 2-dose regimen at Day 1 and Week 4 (with no vaccine administered at Week 26) or Day 1 and Week 26 (with placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine administered at Week 4)
9768645|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
9768646|NCT00849693|Placebo Comparator|Placebo|
9768647|NCT00849693|Active Comparator|Fluoxetine|
9768648|NCT00849693|Experimental|Duloxetine 60 mg|
9768649|NCT00849693|Experimental|Duloxetine 30 mg|
9768650|NCT00849810|Experimental|Metoprolol to nebivolol|metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
9768651|NCT00849875|Experimental|Group A|All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment
9768652|NCT00849901|Placebo Comparator|Placebo|
9768653|NCT00849901|Active Comparator|Fluoxetine|
9768654|NCT00849901|Experimental|Duloxetine|
9768655|NCT00849940|Experimental|CAS NIRS FORE-SIGHT oximeter|Pediatric patients presenting for cardiac catheterization.
9768656|NCT00850031|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
9768657|NCT00850070|Experimental|sapropterin, 100 mg capsules|Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
9768658|NCT00850070|Placebo Comparator|Placebo, matching active drug|The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
9768659|NCT00850096|Placebo Comparator|Placebo for Nasulin|Placebo for Nasulin Spray
9768660|NCT00850096|Active Comparator|Nasulin|Nasulin (intranasal insulin spray 1%)
9768661|NCT00850135|Other|Continuous Glucose Monitor in pregnancy|The Seven Continuous Glucose Monitoring System: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
9768662|NCT00850200|Experimental|Proton Radiation Plan|
9768663|NCT00850200|Active Comparator|Conventional Photon Radiation Plan|
9768664|NCT00850200|Active Comparator|Intensity Modulated Radiation Plan|
9768665|NCT00850343|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
9768666|NCT00850343|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
9768667|NCT00850395||1|Non-Interventional
9768668|NCT00850460|Placebo Comparator|Placebo|Lactose placebo pill
9768669|NCT00850460|Active Comparator|Statins|Statin medications
9768670|NCT00850473|Experimental|Positron Emitting Image|Patient will have a PET/CT imaging study to determine cardiac stenosis, F-18 FDG and heparin/intralipid infusion and Contrast Dye.will be administered.
9768671|NCT00850499|Experimental|VELCADE and fludarabine (Group A)|VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
9768672|NCT00850499|Active Comparator|fludarabine and rituximab (Group B)|fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
9768673|NCT00850564|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily
9768674|NCT00850603|Active Comparator|Group 1|0.5 mL Subcutaneous arm (Menomune® )
9768675|NCT00850603|Experimental|Group 2|0.1 mL Subcutaneous arm (Menomune®)
9768676|NCT00850603|Experimental|Group 3|0.05 mL Intradermal arm (Menomune®)
9768677|NCT00850603|Experimental|Group 4|0.1 mL Intradermal arm (Menomune®)
9768678|NCT00850603|Experimental|Group 5|0.15 mL Intradermal arm (Menomune®)
9768679|NCT00850642|Placebo Comparator|Placebo|12 day repeat dosing with placebo
9768680|NCT00850642|Experimental|GSK2190915 100mg|12 day repeat dosing treatment phase with 100mg GSK2190915.
9768681|NCT00850759|Experimental|virtual reality|street-crossing training in a virtual pedestrian environment
9768682|NCT00850759|Active Comparator|computer and video|exposure to training in pedestrian safety via computer software, internet games, and television videos
9835634|NCT02748694|Experimental|Part 1 (SRD): Cohort 4: TAK-041 120 mg|TAK-041 120 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
9835635|NCT02748694|Experimental|Part 1 (SRD): Cohort 5: TAK-041 160 mg|TAK-041 160 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
9835636|NCT02748694|Placebo Comparator|Part 2 (MRD): Placebo Cohorts 1-4|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the multiple-rising dose (MRD) period.
9835637|NCT02748694|Experimental|Part 2 (MRD): Cohort 1: TAK-041 40/20 mg|TAK-041 40 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 20 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
9835638|NCT02748694|Experimental|Part 2 (MRD): Cohort 2: TAK-041 80/40 mg|TAK-041 80 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 40 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
9835639|NCT02748694|Experimental|Part 2 (MRD): Cohort 3: TAK-041 120/60 mg|TAK-041 120 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 60 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
9835640|NCT02748694|Experimental|Part 2 (MRD): Cohort 4: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
9835641|NCT02748694|Experimental|Part 3: Relative Bioavailability (RBA)/Food Effect: Regimen A|TAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1.
9835642|NCT02748694|Experimental|Part 3: RBA/Food Effect: Regimen B|TAK-041 40 mg, tablet, orally, once on Day 1 in fed state (Regimen B) in Cohort 2.
9835643|NCT02748694|Placebo Comparator|Part 4: MRD: Placebo|TAK-041 placebo-matching, suspension, orally, on Days 1, 8, 15 and 22 in participants with schizophrenia
9835644|NCT02748694|Experimental|Part 4: MRD: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in participants with schizophrenia.
9835645|NCT02748785|Experimental|Group 1 (No MTX Hold before Vaccination)|Group 1 will continue MTX
9835646|NCT02748785|Experimental|Group 2 (MTX hold 4 Weeks before vaccination)|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
9835647|NCT02748785|Experimental|Group 3 (MTX hold 2 Weeks before Vaccination)|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
9835648|NCT02748785|Experimental|Group 4 (MTX hold on Day of Vaccination)|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
9835649|NCT02748863|Placebo Comparator|Placebo|Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
9835650|NCT02748863|Experimental|Secukinumab 2 mL form|Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
9835651|NCT02748863|Active Comparator|Secukinumab 1 mL form|Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
9835652|NCT02748889|Active Comparator|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
10203663|NCT05198037|Sham Comparator|Sham tDCS|The device is automatically shut down after 2-minute stimulation. Treatment sessions and frequency are the same as the Experimental arm.
9835653|NCT02748889|Experimental|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
9835654|NCT02748928|Experimental|UltraShape Power treatment to abdomen|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape Power device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
9835655|NCT02749201|Experimental|Analysis|Light Intensity and gastric wall thickness analysis
9835656|NCT02749370|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
9835657|NCT02749721|Other|Other - vortioxetine|Open-label vortioxetine
9835658|NCT02749799|Experimental|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
10205330|NCT02756845|Experimental|Talimogene Laherparepvec (TVEC)|The first dose of talimogene laherparepvec will be administered at a dose of up to 4.0 mL of 10ᶺ6 PFU/mL followed by a dose of up to 4.0 mL of 10ᶺ8 PFU/mL 21 days (+3 days) later. Subsequent doses of up to 4.0 mL of 10ᶺ8 PFU/mL will be administered every 14 days (± 3 days) thereafter. Cohorts will be assigned as follows: Cohort A1 (age 12 to ≤ 21 years). Cohort B1 (age 2 to < 12 years). The DLRT will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If dose de-escalation is needed and if permissible based on the incidence of DLTs, additional DLT-evaluable subjects will be enrolled and treated at a lower dose level of talimogene laherparepvec. Dose de-escalation cohorts will be assigned as follows and the same DLT rules will be applied: Cohort A2 (age 12 to ≤ 21 years), Cohort B2 (age 2 to < 12 years).
10205331|NCT02745847|Experimental|Re-irradiation with SBRT|Patients with relapsed pancreatic cancer meeting all inclusion criteria will receive re-irradiation with SBRT.
10205332|NCT02723409|Active Comparator|Round Procedure|umbilicoplasty technique
10205333|NCT02723409|Active Comparator|"Scarless round procedure"|umbilicoplasty technique
10205334|NCT02723409|Active Comparator|"Inverted U procedure"|umbilicoplasty technique
10205335|NCT02723409|Active Comparator|"Inverted V procedure"|umbilicoplasty technique
10205336|NCT02723409|Active Comparator|"Y deepithelialized procedure"|umbilicoplasty technique
9768683|NCT00850759|Active Comparator|streetside training|one-on-one training in street-crossing skills by an adult, at a streetside location
9768684|NCT00850759|No Intervention|no-contact control|no-contact control group.
9768685|NCT00850889|Active Comparator|1|Juvederm Ultra Injectable Gel with Lidocaine
9768686|NCT00850889|Active Comparator|2|Restylane Injectable Gel
9768687|NCT00850993|Experimental|Cohort 1: Stannsoporfin 1.5 mg/kg|Participants receive a single dose of 1.5 mg/kg by intramuscular (IM) injection, along with PhotoTherapy (PT) if and when needed.
9768688|NCT00850993|Experimental|Cohort 2: Stannsoporfin 3.0 mg/kg|Participants receive a single dose of 3.0 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
9768689|NCT00850993|Experimental|Cohort 3: Stannsoporfin 4.5 mg/kg|Participants receive a single dose of 4.5 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
9768690|NCT00850993|Placebo Comparator|Cohort 4: Placebo|Participants receive a single dose of placebo (sterile saline solution) by IM injection, along with PT if and when needed.
9768691|NCT00851006|Experimental|Open-Label Creatine|Creatine Monohydrate 4 grams daily by mouth
9768692|NCT00851084|Active Comparator|mFOLFOX6 only|modified FOLFOX6 chemotherapy regimen
9768693|NCT00851084|Experimental|mFOLFOX6 + aflibercept|modified FOLFOX6 chemotherapy regimen in combination with aflibercept
9768694|NCT00851253|Experimental|Group 1 (CK SRS boost therapy)|Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.
9768695|NCT00851253|Experimental|Group 2 (CK SRS salvage therapy)|Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.
9768696|NCT00851279|Experimental|Magnetic irrigated ablation catheter|Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
9768697|NCT00851318|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
9768698|NCT00851318|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
9768699|NCT00851357|Experimental|Active patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of nicotine patches
9768700|NCT00851357|Placebo Comparator|Placebo patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of placebo patches
9768701|NCT00851357|Active Comparator|Telephone counseling|Proactive Telephone Counseling
9768702|NCT00851357|Active Comparator|Active patches and materials|8-weeks of nicotine patches and materials
9768703|NCT00851357|Active Comparator|Placebo patches and materials|8-weeks placebo patches and materials
9768704|NCT00851357|Active Comparator|Materials|Self-help materials
9768705|NCT00851409|Other|Recombinant Human C1 Inhibitor|Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
9768706|NCT00851630|Experimental|Early|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 2 weeks after commencing antituberculous therapy
9768707|NCT00851630|Experimental|Delayed|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 8 weeks after commencing antituberculous therapy
9768708|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase A Control|Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.
9768709|NCT00851643|Experimental|Octavalent HPV with 15 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg AAHS and 15 mcg IMX.
9768710|NCT00851643|Experimental|Octavalent HPV with 30 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX.
9768711|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase B Control|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 60 mcg IMX / AAHS and Octavalent HPV with 120 mcg IMX / AAHS during Phase B.
9768712|NCT00851643|Experimental|Octavalent HPV with 60 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX.
9768713|NCT00851643|Experimental|Octavalent HPV with 120 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX.
9768714|NCT00851721|Experimental|Prophylaxis arm|
9768715|NCT00851721|Active Comparator|On-demand arm|
9836092|NCT02769065|Experimental|MRD: Cohort 14: TAK-071 9 mg|TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
9768716|NCT00851786|Experimental|1|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of ZOSTAVAX (Zoster Vaccine Live) at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted.
9768717|NCT00851786|Placebo Comparator|2|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of placebo at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted
9768718|NCT00851799||Cohort A|"ATV/RTV + FTC/TDF~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily."
9768719|NCT00851799||Cohort B|"RAL + FTC/TDF~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily."
9768720|NCT00851799||Cohort C|"DRV/RTV + FTC/TDF~FTC/TDF, darunavir (DRV), and RTV, orally, once daily."
9768721|NCT00851877|Experimental|arm one|Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
9768722|NCT00851890|Experimental|ABT-333 (300 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 300 mg ABT-333 BID for 2 days followed by 300 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9768723|NCT00851890|Experimental|ABT-333 (600 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 600 mg ABT-333 BID for 2 days followed by 600 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9768724|NCT00851890|Experimental|ABT-333 (1200 mg) once daily (QD) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 1200 mg ABT-333 QD for 2 days followed by 1200 mg ABT-333 QD with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9768725|NCT00851890|Placebo Comparator|Placebo + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naïve participants received matching placebo once daily (QD) or twice daily (BID) for 2 days followed by placebo QD or BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9768726|NCT00851903|Experimental|Combination insulin glargine and sitagliptin|"Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 < Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 <FPG ≤ 5.5 mmol/L).~Sitagliptin: stable dose of 100 mg once a day administered with or without food."
9768727|NCT00852137|Experimental|PEP005 (ingenol mebutate) Gel, 0.05%|
9768728|NCT00852137|Placebo Comparator|Vehicle Gel|
9784355|NCT01223365|Experimental|Hydrocodone ER|Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
9784356|NCT01223378|Experimental|BOL-303259-X|ophthalmic solution
9784357|NCT01223378|Active Comparator|Latanoprost|ophthalmic solution
9784358|NCT01223404|Experimental|Placebo, Nicotine, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
9784359|NCT01223404|Experimental|Nicotine, Placebo, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
9784360|NCT01223404|Experimental|Placebo, Mecamylamine, Nicotine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
9768729|NCT00852202|Experimental|1|0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
9768730|NCT00852202|Experimental|2|1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
9768731|NCT00852202|Placebo Comparator|3|Matching placebo capsules, oral administration, once daily dosing.
9768732|NCT00852397|Experimental|Apixaban 2.5 mg|
9768733|NCT00852397|Experimental|Apixaban 5.0 mg|
9768734|NCT00852397|Placebo Comparator|Placebo|
9768735|NCT00852475|Placebo Comparator|MUFA|Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program
9768736|NCT00852475|Active Comparator|PUFA|Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program
9768737|NCT00852527||Subjects with mild TBI|Presence of mild TBI defined by positive reference test
9768738|NCT00852527||Subjects without mild TBI|Absence of mild TBI defined by negative reference test
9768739|NCT00852540|Experimental|Retapamulin|
9768740|NCT00852540|Active Comparator|Linezolid|
9768741|NCT00852592|Active Comparator|Active Comparator|7000lux broad-spectrum light
9768742|NCT00852592|Placebo Comparator|Inactive Comparator|50lux dim red light
9768743|NCT00852644|Experimental|56 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
9768744|NCT00852644|Experimental|62 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
9768745|NCT00852644|Experimental|68 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
9768746|NCT00852644|Experimental|56 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
9768747|NCT00852644|Experimental|62 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
9768748|NCT00852644|Experimental|68 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
9768749|NCT00852761|Experimental|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam
9768750|NCT00852761|Active Comparator|Clobex lotion|Clobex (clobetasol propionate 0.05%) lotion.
9768751|NCT00852917|Experimental|1: Tramadol Once A Day 100mg|
9768752|NCT00852917|Experimental|2: Tramadol Once A Day 200mg|
9768753|NCT00852917|Experimental|3: Tramadol Once A Day 300mg|
9768754|NCT00852917|Placebo Comparator|4: Placebo|
9768755|NCT00852930|Experimental|laser alone|The intervention was therapist administered low level laser therapy using low level laser, number of sessions based upon patient response
9768756|NCT00852930|Active Comparator|mld alone|The intervention was therapist administered manual lymphatic drainage (mld) using standard massage techniques,number of sessions based upon patient response
9768757|NCT00852930|Experimental|laser and mld combined|The intervention was therapist administered low level laser and mld using low level laser and standard massage techniques, number of sessions based upon patient response
9768758|NCT00852969|Active Comparator|Niacin|
9768759|NCT00852969|Placebo Comparator|Placebo|
9768760|NCT00852995|Experimental|A - Low Q7D|Low dose HP802-247, applied at each visit
9768761|NCT00852995|Experimental|B - Low Q14D|Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
9768762|NCT00852995|Experimental|C - High Q7D|High dose HP802-247, applied at each visit
9768763|NCT00852995|Experimental|D - High Q14D|High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
9768764|NCT00852995|Placebo Comparator|E - Vehicle|Placebo (Vehicle), applied at each visit
9768765|NCT00853021|Experimental|Bevacizumab and Aldesleukin|
9768766|NCT00853047|Experimental|Telotristat Etiprate 150 mg Core Phase|Telotristat etiprate capsules,150 mg orally 3 times daily for 28 days in the double-blind treatment period (core phase) in combination with stable-dose octreotide long-acting release (LAR) depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
9768767|NCT00853047|Experimental|Telotristat Etiprate 250 mg Core Phase|Telotristat etiprate capsules, 250 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
9768768|NCT00853047|Experimental|Telotristat Etiprate 350 mg Core Phase|Telotristat etiprate capsules, 350 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
9768769|NCT00853047|Experimental|Telotristat Etiprate 500 mg Core Phase|Telotristat etiprate capsules, 500 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with a stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
9768770|NCT00853047|Experimental|Placebo Core Phase|Placebo-matching telotristat etiprate capsules, orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to receive telotristat etiprate in the optional open-label extension period.
9768771|NCT00853047|Experimental|Telotristat Etiprate Open-Label Extension Phase|Telotristat etiprate at assigned dose level for 8 weeks in combination with stable-dose octreotide LAR depot therapy given once per month in the open-label extension period. Upon completion of the 8-week period, participants could enter an additional extension period of 172 weeks, receiving telotristat etiprate at the assigned dose or maximum tolerated dose (500 mg 3 times daily).
9768772|NCT00853073|Active Comparator|Bevacizumab|subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
9768773|NCT00853073|Placebo Comparator|balanced salt solution|patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
9768774|NCT00853099|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
9768775|NCT00853099|Experimental|Adalimumab 80 mg/40 mg|Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
9768776|NCT00853099|Experimental|Adalimumab 160 mg/80 mg|Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
9768777|NCT00853112|Experimental|PF-00489791 1 mg|
9768778|NCT00853112|Experimental|PF-00489791 2 mg|
9768779|NCT00853112|Experimental|PF-00489791 4 mg|
9768780|NCT00853112|Experimental|PF-00489791 10 mg|
9768781|NCT00853112|Experimental|PF-00489791 20 mg|
9768782|NCT00853112|Placebo Comparator|Placebo|
9768783|NCT00853112|Active Comparator|Sildenafil|Observational comparator arm
9768784|NCT00853125|Experimental|Sunitinib plus Irradiated Allogeneic Lymphocytes|
9768785|NCT00853151|Experimental|LY2428757 plus TT223 3 milligrams (mg)|Weekly LY2428757 plus 3 milligrams (mg) daily TT223
9768786|NCT00853151|Experimental|LY2428757 plus TT223 2mg|Weekly LY2428757 plus 2 mg daily TT223
9768787|NCT00853151|Experimental|LY2428757 plus placebo|Weekly LY2428757 plus daily TT223 placebo
9768788|NCT00853151|Placebo Comparator|Placebo plus Placebo|Weekly LY2428757 placebo plus daily TT223 placebo
9768789|NCT00853242|Placebo Comparator|Placebo|Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
9768790|NCT00853242|Experimental|Genz-644470 2.4 Grams Per Day (g/day)|Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
9768791|NCT00853242|Experimental|Genz-644470 4.8 g/day|Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
9768792|NCT00853242|Experimental|Genz-644470 7.2 g/day|Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
9768793|NCT00853242|Active Comparator|Sevelamer Carbonate 2.4 g/day|Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
9768794|NCT00853242|Active Comparator|Sevelamer Carbonate 4.8 g/day|Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
9768795|NCT00853242|Active Comparator|Sevelamer Carbonate 7.2 g/day|Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
9768796|NCT00853333|Active Comparator|Propofol|Administration via an IV
9768797|NCT00853333|Active Comparator|Midazolam|Administration via an IV
9768798|NCT00853333|Active Comparator|Dexmedetomidine|Administration via an IV
9768799|NCT00853372|Experimental|Trebananib 10 mg/kg + Sunitinib|Trebananib 10 mg/kg intravenously (IV) once weekly (QW) plus sunitinib 50 mg orally (PO) once daily (QD) 4 weeks on/2 weeks off
9768800|NCT00853372|Experimental|Trebananib 15 mg/kg + Sunitinib|Trebananib 15 mg/kg IV QW plus sunitinib 50 mg PO QD 4 weeks on/2 weeks off
9768801|NCT00853385|Experimental|5mg|
9768802|NCT00853385|Experimental|10 mg|
9768803|NCT00853385|Placebo Comparator|Placebo Sequence 1|
9768804|NCT00853385|Placebo Comparator|Placebo Sequence 2|
9768805|NCT00853385|Active Comparator|adalimumab|
9768806|NCT00853489|Experimental|recombinant bone morphogenetic protein 2|The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
9768807|NCT00853489|Active Comparator|Autogenous iliac crest bone graft|Bone will be harvested from the iliac crest and placed in the bone defect.
9768808|NCT00853580|Placebo Comparator|2|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
9768809|NCT00853580|Experimental|1|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
9768810|NCT00853593|Experimental|Model 4396 LV Lead|Non-randomized study.
9768811|NCT00853606|Experimental|avanafil|
9768812|NCT00853645|Experimental|Subcutaneous implantable cardioverter defibrillator (S-ICD) System|Single-arm with 6 patients implanted with an S-ICD System
9768813|NCT00853658|Experimental|Combination Aliskiren / Enalapril|Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
9768814|NCT00853658|Experimental|Aliskiren|Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
9768815|NCT00853658|Active Comparator|Enalapril|Enalapril monotherapy -10 mg film-coated tablet and administered orally.
9768816|NCT00853671|Experimental|Adenosine Stress Dual-source CTP|A multiphase adenosine Stress Dual-source stress perfusion computed tomography imaging test, as described above, will be performed in all patients.
9768817|NCT00853723|Experimental|PTHrP 400 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
9768818|NCT00853723|Experimental|PTHrP 600 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
9768819|NCT00853723|Active Comparator|PTH 20 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.
9768820|NCT00853749|Other|Single|All subjects will receive a single dose of 13vPnC
9768821|NCT00853762|Experimental|Atacicept 25 mg (With Loading)|
9768822|NCT00853762|Experimental|Atacicept 75 mg (With Loading)|
9768823|NCT00853762|Experimental|Atacicept 150 mg (With Loading)|
9768824|NCT00853762|Experimental|Atacicept 150 mg (Without Loading)|
9768825|NCT00853827|Placebo Comparator|1|
9768826|NCT00853827|Experimental|2|Aliskiren 300 mg
9768827|NCT00853840|Experimental|1.|Maraviroc + Vardenafil
9768828|NCT00853840|Placebo Comparator|2.|Maraviroc + Placebo
9768829|NCT00853905|Experimental|Treatment 1(Triesence)|glaucoma surgery with 0.2cc Triesence adjunct.
9768830|NCT00853905|Active Comparator|Treatment 2 (balanced salt solution BSS)|glaucoma surgery with balanced salt solution, the standard technique.
9768831|NCT00853957|Experimental|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
9768832|NCT00853957|Active Comparator|Amlodipine|Amlodipine 5mg titrated to 10 mg
9768833|NCT00853970|Experimental|Bromfenac ophthalmic solution 0.09%|dosed 1 drop daily in study eye for 2 weeks
9768834|NCT00853970|Placebo Comparator|Placebo|dosed 1 drop daily in study eye for 2 weeks
9768835|NCT00853996|Experimental|Prevention (acolbifene hydrochloride)|Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
9768836|NCT00854061|Experimental|T-Pred|Tobramycin prednisolone acetate combination
9768837|NCT00854061|Active Comparator|Pred Forte|Prednisolone acetate
9768838|NCT00854087|Active Comparator|Fuzheng Huayu|Pill with Fuzheng Huayu
9768839|NCT00854087|Placebo Comparator|Placebo|Pill without Fuzheng Huayu (sugar pill)
9768840|NCT00854100|Placebo Comparator|Placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo
9768841|NCT00854100|Experimental|Cariprazine 0.1 - 0.3 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose
9768842|NCT00854100|Experimental|Cariprazine 1.0 - 2.0 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose
9768843|NCT00854113|Experimental|EGT0001474|Ascending doses of EGT0001474
9768844|NCT00854113|Placebo Comparator|Placebo|Placebo
9768845|NCT00854308|Experimental|MetMAb + Erlotinib|MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
9835659|NCT02749903|Other|Enzalutamide|Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
9835660|NCT02750267|Experimental|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
9835661|NCT02750267|Experimental|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
9835662|NCT02750306|Experimental|Suvorexant|Participants will receive 1 suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' suvorexant dose may be increased to 20 mg if their Clinical Global Impression of Insomnia Severity (CGI-S) is ≥3 and investigators feel they can tolerate the increased dose.
9835663|NCT02750306|Placebo Comparator|Placebo|Participants receive 1 placebo-matching suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' placebo-matching dose can be increased to 20 mg if their CGI-S is ≥3 and investigators feel they can tolerate the increased dose.
9835664|NCT02750332|Experimental|Treatment Sequence A (Fed) - B (Fasted)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835665|NCT02750332|Experimental|Treatment Sequence B (Fasted) - A (Fed)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835666|NCT02750345|Experimental|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835667|NCT02750345|Experimental|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835668|NCT02750345|Experimental|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
10203664|NCT05198024|Placebo Comparator|Usual care|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group took part in the 'Biggest loser' program in which the patients attended weekly sessions outside of their usual exercise class times. Each session follows a specific theme based on British Heart Foundation healthy eating guidelines.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
10203665|NCT05198024|Experimental|Usual care plus biggest loser|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group took part in the 'Biggest loser' program in which the patients attended weekly sessions outside of their usual exercise class times. Each session follows a specific theme based on British Heart Foundation healthy eating guidelines.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
9835669|NCT02750345|Experimental|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835670|NCT02750345|Experimental|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9836093|NCT02769065|Experimental|MRD: Cohort 15: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
10203666|NCT05198024|Experimental|Usual care plus new education programme|"Where patients access to two exercise classes per week and all facilities as part of their cardiac rehabilitation. In addition to this, patients in this group too part in a new education programme (anecdotally referred to as Healthy Heart Happy You) in which the same weekly topics as the biggest loser are covered yet with bespoke information regarding portion sizes and recipes provided each week and patients given a challenge each week in relation to the topic being covered e.g. include more vegetables.~Participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks."
10203667|NCT05198011|Experimental|3D mandibular ridge augmentation|
10203668|NCT05198011|Active Comparator|Conventional mandibular ridge augmentation|
9768846|NCT00854308|Placebo Comparator|Placebo + Erlotinib|Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.
9768847|NCT00854360|Experimental|BDP HFA 80 µg/day|During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.
9768848|NCT00854360|Experimental|BDP HFA 160 µg/day|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.
9768849|NCT00854360|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
9768850|NCT00854360|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
9768851|NCT00854373|Experimental|1|Bravelle
9768852|NCT00854373|Placebo Comparator|2|Saline
9768853|NCT00854581|Experimental|Induction (Up to Day 21)|"For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patients who achieve a PR will receive 7 more days of induction therapy and then go on to Part 1 Maintenance Therapy.:~Zidovudine:~Days 1-2: 1.5 grams intravenously (IV) twice daily~Days 3-21: 1.5 grams IV twice daily~Interferon alfa-2b (IFN):~5 10 million units (mu) intravenously twice daily"
9768854|NCT00854581|Experimental|Part 1 Maintenance (Up to Day 60)|"From Treatment Day 14 or 21 to start of Month 3 (Day 60). Study participants move on to Part 1 Maintenance Therapy only if they achieve complete response (CR) or partial response (PR) after induction therapy. Restaging and molecular evaluation of disease at start of Month 3:~Zidovudine: 600 mg orally twice daily in all phases of Maintenance Therapy~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly~Participants then proceed to Part 2 maintenance."
9768855|NCT00854581|Experimental|Part 2A Maintenance (Up to 12 Months)|"Participants achieving a CR with undetectable clonal disease. Participants will receive therapy for as long as response is maintained:~Zidovudine: 600 mg orally twice daily~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly"
9768856|NCT00854581|Experimental|Part 2B Maintenance (Up to 12 Months)|"Participants achieving a CR with minimal residual disease (by multiplex PCR) or PR in Part 1:~Zidovudine: 600 mg or 300 mg orally twice daily, per protocol~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly, per protocol~Valproic acid, 250 mg orally twice daily, per protocol"
9768857|NCT00854594|No Intervention|Control|Control sites will receive the baseline measures pre and post. These sites will receive traditional diabetes education, which includes teleconsultation.
9768858|NCT00854594|Experimental|ReSPECT Intervention|Intervention sites will receive baseline measures pre and post, but also in-depth Shared Medical Appointments (SMA)(The Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT) intervention) and at 15 months SMA video conferences. At the end of the 18 months the randomly selected patients and providers will be asked to take part in a qualitative interview.
9768859|NCT00854607||Invasive Aspergillosis|Observational
9768860|NCT00854620|Experimental|Sorafenib|"Cycle 1: 400 mg BID sorafenib~Cycle 2: 600 mg BID sorafenib~Cycle 3+: 800 mg BID sorafenib"
9768861|NCT00854724|Active Comparator|Puerarin|
9768862|NCT00854724|Placebo Comparator|Placebo|Sugar beet filler in capsule
9768863|NCT00854828|Active Comparator|Surgical Intervention|
9768864|NCT00854828|Active Comparator|Non-Operative Intervention|
9768865|NCT00854906||Keratometric Tear Breakup Time|These are the study participants whose tear break up times were measured with a keratometer.
9768866|NCT00854906||Fluorescein Break Up Time|These are the study participants whose tear break up times were measured with with fluorescein dye.
9768867|NCT00855010|Experimental|pioglitazone|pioglitazone tablet 45 mg once daily
9768868|NCT00855010|Placebo Comparator|placebo pill|placebo pill once daily (look-alike pill which contains no active ingredients)
9768869|NCT00855062|Active Comparator|Minocycline|Minocycline 100 mg orally every 12 hours
9768870|NCT00855062|Placebo Comparator|Placebo|Placebo minocycline capsules every 12 hours
10203669|NCT05197998|Experimental|Color Brave Program|The experimental group will be asked to download and complete a 6-week multi-module mobile app program designed to enhance and encourage critical conversations about race and racism among parents and their young children.
10203670|NCT05197998|Other|Wait-list Control|The wait-list control group will be placed on the wait-list for the first 6-weeks, the period in which the experimental group will complete the intervention program. Following the 6-week wait-list period they will receive the color brave program.
10203671|NCT05197985|Experimental|Integrated Early Childhood Development Intervention|Integrated Early Childhood Development Intervention is one intervention package. Inclusion criteria are adults (age 18+) who are primary caregiver of one or more children under the age of 5 years; and pregnant women (age 18+).
10203672|NCT05197985|No Intervention|Control Arm|This is the control arm that receives no intervention. Inclusion criteria are adults (age 18+) who are primary caregiver of one or more children under the age of 5 years; and pregnant women (age 18+).
10203673|NCT05197946||Subjects with CP survey|Subjects in this group are age 8 and older with a diagnosis of cerebral palsy. Participants are either able to affirmatively consent or assent with LAR consent. This sample will have a CFCS score ranging between 1 and 3 and should be able to unambiguously respond to a 65 item multiple choice survey.
10203674|NCT05197946||Control Subjects survey|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are either able to affirmatively consent or assent with LAR consent.
9768871|NCT00855166|Experimental|A|Dapagliflozin 10 mg plus Metformin
9768872|NCT00855166|Placebo Comparator|B|Placebo plus Metformin
9784361|NCT01223404|Experimental|Nicotine, Mecamylamine, Placebo|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
9768873|NCT00855218|Experimental|Sorafenib (Nexavar, BAY43-9006) + TACE|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Patients were then also treated with Transarterial Chemoembolization (TACE) performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of sorafenib, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
9768874|NCT00855218|Placebo Comparator|Placebo + TACE|Placebo was to be orally administered as 2 tablets bid (twice daily). Patients were then also treated with TACE performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of placebo, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
9768875|NCT00855309|Experimental|Arm I|Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
9768876|NCT00855309|Experimental|Arm II|Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.
9768877|NCT00855335|Experimental|Group 1: Darunavir 600 /Ritonavir 100|TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
9768878|NCT00855335|Experimental|Group 2: Darunavir 800/Ritonavir 100|TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
9768879|NCT00855335|Experimental|Group 3: Etravirine|TMC125 (etravirine) 200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
9768880|NCT00855335|Experimental|Group 4: Rilpivirine|TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
9768881|NCT00855335|Experimental|Group 5: Darunavir 800/Cobicistat 150|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
9768882|NCT00855413|Other|Darunavir/Ritonavir and Etravirine|"Darunavir/Ritonavir 800 mg/100 mg orally once daily.~ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen."
9768883|NCT00855439|Experimental|Exenatide|Subjects will take exenatide by subcutaneous injection twice daily for 18 months
9768884|NCT00855439|Active Comparator|glargine|Subjects will take 1 daily injection of insulin glargine for 18 months.
9768885|NCT00855465|Experimental|Riociguat (Adempas, BAY63-2521)_individual dose titration|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
9768886|NCT00855465|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks
9768887|NCT00855582|Experimental|Tadalafil 2.5 mg|
9768888|NCT00855582|Experimental|Tadalafil 5 mg|
9768889|NCT00855582|Placebo Comparator|Placebo|
9768890|NCT00855595|Experimental|Azelaic acid (Finacea, BAY39-6251) plus Doxycycline (Oracea)|Participants received topical azelaic acid gel 15% twice daily and doxycycline 40 mg once daily for 12 weeks
9768891|NCT00855595|Active Comparator|Metronidazole (Metrogel) plus Doxycycline (Oracea)|Participants received topical metronidazole 1% gel once daily and doxycycline 40 mg once daily for 12 weeks
9768892|NCT00855738|Other|1.0|
9768893|NCT00855816|Experimental|Breathing training|relaxation training
9768894|NCT00855816|No Intervention|Treatment as usual|treatment as usual
9768895|NCT00855842|Experimental|osmotic dilator|osmotic dilator
9768896|NCT00855894|Experimental|Pertuzumab + erlotinib|Patients received pertuzumab 840 mg intravenously (IV) 1 time (loading dose) followed by 420 mg IV (maintenance dose) every 3 weeks (q3w) plus erlotinib 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
9768897|NCT00855920|Active Comparator|Placebo (for Rilonacept) and Indomethacin|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 with Indomethacin orally thrice a day (TID) for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
9768898|NCT00855920|Active Comparator|Rilonacept and Indomethacin|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
9768899|NCT00855920|Active Comparator|Rilonacept and Placebo (for Indomethacin)|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Placebo (for Indomethacin) orally TID for 12 days.
9768900|NCT00855933|No Intervention|Control - no flossing|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily.
9836094|NCT02769065|Experimental|Cohort 16|
9835671|NCT02750345|Experimental|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835672|NCT02750410|Experimental|Dulaglutide|Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
9835673|NCT02750410|Placebo Comparator|Placebo|Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.
9835674|NCT02750501|Other|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
9835675|NCT02750514|Active Comparator|Nivolumab|Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
9835676|NCT02750514|Experimental|Nivolumab & Dasatinib|Nivolumab in combination with Dasatinib
9835677|NCT02750514|Experimental|Nivolumab & Relatlimab|Nivolumab in combination with Relatlimab
9835678|NCT02750514|Experimental|Nivolumab & Ipilimumab|Nivolumab in combination with Ipilimumab
9835679|NCT02750514|Experimental|Nivolumab & BMS-986205|Nivolumab in combination with BMS- 986205
9835680|NCT02750592|Experimental|secukinumab 150mg|A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.
9835681|NCT02750618|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
9835682|NCT02750709|Experimental|Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835683|NCT02750709|Experimental|Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835684|NCT02750709|Experimental|Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835685|NCT02750709|Experimental|Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835686|NCT02750709|Experimental|Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835687|NCT02750709|Experimental|Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
9835688|NCT02750761|Experimental|Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 5 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
9984296|NCT04251078||Myelodysplastic Syndromes - Non Progression cohort|20 patients without progression will be analyzed by targeted deep sequencing in order to find out if there are any differences in the mutational spectrum compared with those disease progression cases.
9768901|NCT00855933|Experimental|Experimental Floss|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily. Subjects flossed once daily with the experimental floss.
9768902|NCT00855959|Experimental|1|Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily
9768903|NCT00855959|Experimental|2|Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)
9768904|NCT00856024||Group 1: Naïve patients|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
9768905|NCT00856024||Group 2: Re-treatment|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
9768906|NCT00856024||Group 3: HIV/HCV co-infected patients|Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
9768907|NCT00856050|Experimental|letrozole|single arm trial - all patients received letrozole 2.5mg by mouth per day
9768908|NCT00856180|Experimental|Bevacizumab then Cyclophosphamide with Bevacizumab|Patients were given a regimen of sequential antiangiogenic blockade and disease assessed serologically and radiologically every 2 cycles/6 weeks. Patients started with bevacizumab 15 mg/kg IV every 3 weeks until they experienced progressive disease (PD) [RECIST 1.0 or Rustin criteria] or significant toxicity. If clinically stable as assessed by their treating physician, patients then received cyclophosphamide 50 mg orally (PO) daily continuously with bevacizumab treatment. If second PD occurred, patients discontinued the combination treatment.
9768909|NCT00856193|Placebo Comparator|Placebo then NVA237 50μg|Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.
9768910|NCT00856193|Experimental|NVA237 50μg then placebo|NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.
9768911|NCT00856206|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
9768912|NCT00856206|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
9768913|NCT00856232|No Intervention|Standard therapy|Standard emergency department evaluation and treatment for headache
9768914|NCT00856232|Placebo Comparator|Medical Air|Air inhalation at 15L / min x 15 minutes followed by standard emergency department evaluation and treatment for headache
9768915|NCT00856232|Experimental|Oxygen|Oxygen inhalation at 15 L/min for 15 minutes followed by standard emergency department evaluation and treatment for headache
9768916|NCT00856245|Other|Rituximab|Patients will be treated IV with rituximab at the rate of 50 milligrams per hour (mg/hour) for 1 hour. If patient tolerates the infusion, the rate is increased by increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. If patient has a severe reaction, the infusion is stopped temporarily and the infusion rate is decreased by 50%. Subsequent infusions are started at the rate of 100 mg/hour, increased by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour if tolerated. Vital signs are monitored every 15 minutes for 2 hours and every 30 minutes thereafter.
9768917|NCT00856284|Experimental|Metformin + Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
9768918|NCT00856284|Experimental|Metformin + Alogliptin 25 mg|Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
9768919|NCT00856284|Active Comparator|Metformin + Glipizide|Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.
9768920|NCT00856297|Experimental|MenACWY-CRM|Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
9768921|NCT00856297|Active Comparator|Licensed comparator|Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
9768922|NCT00856297|Other|Naive|Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
9768923|NCT00856297|Experimental|MenACWY-CRM/MenACWY-CRM|Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
9768924|NCT00856297|Experimental|Licensed comparator/MenACWY-CRM|Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
9768925|NCT00856323|Experimental|PEP/CM|Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.
9768926|NCT00856349||Analysis cohort|Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.
9768927|NCT00856375|Experimental|NKTR-102|NKTR-102 IV every 3 weeks
9768928|NCT00856375|Active Comparator|irinotecan|irinotecan IV every 3 weeks
9768929|NCT00856388|Experimental|Treatment (Reduced intensity allogeneic stem cell transplant)|"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.~Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan."
9768930|NCT00856414|Experimental|1|botulinum toxin Type A 20U
9768931|NCT00856492|Experimental|Arm 1|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
9768932|NCT00856492|Active Comparator|Arm 2|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12, and then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
9768933|NCT00856492|Active Comparator|Arm 3|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1, 3, 5, 7, 9, and 11, and then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.
9768934|NCT00856518|Active Comparator|Arm 1: EMST|The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
9768935|NCT00856518|Sham Comparator|Arm 2: Sham group|The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
9768936|NCT00856544|Experimental|Active 5 mg|
9768937|NCT00856544|Experimental|Active 10 mg|
9768938|NCT00856544|Placebo Comparator|Placebo Sequence 1|Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
9768939|NCT00856544|Placebo Comparator|Placebo Sequence 2|Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
9768940|NCT00856557|Experimental|Seminar and Practicum|Seminar and practicum that occurs over 4 week period for internal medicine residents, designed to provide a systematic approach to identifying and addressing contextual factors essential to planning patient care.
9768941|NCT00856557|No Intervention|No intervention|No educational intervention.
9768942|NCT00856583|Experimental|Sertindole|Normally in the range of 4 to 20 mg/day
9768943|NCT00856583|Active Comparator|Risperidone|Normally in the range of 2 to 8 mg/day
9768944|NCT00856609|Active Comparator|Exenatide|10 micrograms subcutaneously twice
9768945|NCT00856609|Placebo Comparator|Placebo|Twice daily
9768946|NCT00856635|Experimental|Glatiramer acetate|Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.
9768947|NCT00856635|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a day for up to 6 months.
9768948|NCT00856661|Experimental|Desmoteplase|
9768949|NCT00856661|Placebo Comparator|Placebo|
9768950|NCT00856726|Experimental|PTH infusion|(1-34) PTH infusion at a rate of 0.055 ug/kg/hour for six hours
9768951|NCT00856739||Group 1|
9768952|NCT00856778|Other|Virtue® Male Sling|Subjects implanted with Virtue® Male Sling
9768953|NCT00856791|Experimental|ON 01910.Na|3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle
9768954|NCT00856830|Experimental|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin.~This study has only one arm but it incorporates two phases. Phase I utilizes a combination of bendamustine and irinotecan for Regimen A followed by etoposide and carboplatin for Regimen B."
9784362|NCT01223404|Experimental|Mecamylamine, Placebo, Nicotine|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
9784363|NCT01223404|Experimental|Mecamylamine, Nicotine, Placebo|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
9784364|NCT01223469|Experimental|Atrial Fibrillation|
9768955|NCT00856843|Active Comparator|Polyethylene glycol 3350 based bowel preparation|Polyethylene glycol 3350 based bowel preparation
9768956|NCT00856843|Experimental|BLI800|BLI800
9768957|NCT00856856|Experimental|Absorb stent|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
9768958|NCT00856908|Experimental|1|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
9768959|NCT00856908|Placebo Comparator|2|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
9768960|NCT00856973|Experimental|Low dose eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
9768961|NCT00856973|Experimental|High dose eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
9768962|NCT00856973|Placebo Comparator|Placebo|Placebo 6-17 years
9768963|NCT00856986|Experimental|Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
9768964|NCT00856986|Experimental|Insulin detemir + Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
9768965|NCT00856986|Experimental|Non-Randomised Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%
9768966|NCT00856986|Other|Early Withdrawals Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial
9768967|NCT00856986|Other|Intensified group|Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c ≥ 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.
9768968|NCT00856999|Experimental|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
9768969|NCT00857207|Experimental|Arm 1: Treatment Goal Management Training|Treatment Goal Management Training
9768970|NCT00857207|No Intervention|Arm 2: Control-Brain Health Workshop|Control-Brain Health Workshop
9768971|NCT00857220|Experimental|2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)|
9768972|NCT00857233|Experimental|Memantine|
9768973|NCT00857246|Experimental|Induction/ surgery/ chemoRT|"Induction treatment (3 weeks/cycle x 4 cycles): Cisplatin and Irinotecan on days 1 and 8; Cetuximab on days 1, 8, and 15.~Surgery (starts 3-4 weeks after induction treatment).~Chemoradiation treatment (starts 4-6 weeks after surgery):~weeks 1-19: Cetuximab on day 1 of every week; week 1: 5-FU and Leucovorin (LV) x 5 days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU+ LV on days 1-4; week 9: 5-FU+ LV on days 1-3; weeks 14 and 19: 5-FU+LV x 5days"
9768974|NCT00857259|Experimental|Everolimus 5 mg|5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28
9768975|NCT00857259|Active Comparator|Ranibizumab 0.5 mg|Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline)
9768976|NCT00857259|Active Comparator|Oral Everolimus (5mg) and Ranibizumab (0.5mg)|Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)
9768977|NCT00857272|Active Comparator|HalfLytely with 10mg bisacodyl|Active control
9768978|NCT00857272|Experimental|HalfLytely with 5mg bisacodyl|Investigational dose
9768979|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^9 vp/dose|Participants administered MRKAd5 HIV-1 gag vaccine 1x10^9 viral particles (vp)/dose (V520), on Day 1, Week 4, and Week 26.
9768980|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^10 vp/dose|"Participants were to be administered MRKAd5 HIV-1 gag 1x10^10 vp/dose (V520) on Day 1, Week 4, and Week 26.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in the group MRKAd5 HIV-1 gag 1x10^10 vp/dose."
9768981|NCT00857311|Experimental|Placebo|Participants administered placebo to MRKAd5 HIV-1 gag vaccine (V520) on Day 1, Week 4, and Week 26.
9768982|NCT00857311|Sham Comparator|Open Label Tetanus and Diptheria Toxoids Adsorbed|"Participants were to be administered open label tetanus and diptheria toxoids adsorbed (Td) at Day 1 only.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in this group."
9768983|NCT00857389|Experimental|Thio-Clo-Bu with Allo SCT|"Pre-transplant conditioning regimen:~Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF~Post haploidentical stem cell transplant participants:~Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses."
9784365|NCT01223469|Experimental|Right-sided Supraventricular Tachycardia|
9768984|NCT00857415|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy.
9768985|NCT00857415|Experimental|Specificity Cohort|Younger healthy controls presumed to be devoid of beta-amyloid plaques.
9768986|NCT00857454|Experimental|Testosterone MD-lotion|"In this open-label extension of the MTE08 trial, participants received Testosterone Metered Dose (MD)-Lotion for 60 days (dosing from Day 121 of the MTE08 trial to Day 180 of the MTE09 trial). Participants in MTE08 initially received 3.0 milliliters (mL) (60 micrograms [mg]) of 2% Testosterone MD-Lotion, and may have had their dose of testosterone adjusted upwards or downwards.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg)of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg)of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 2 x 1.5 mL to the other axilla).~6.0 (120 mg)of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
9768987|NCT00857493|Experimental|Group 1|
9768988|NCT00857493|Experimental|Group 2|
9768989|NCT00857532|Experimental|Normal cognitive performance|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
9768990|NCT00857532|Experimental|Mild cognitive deficits|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
9768991|NCT00857532|Experimental|Severe cognitive impairment|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
9768992|NCT00857545|Experimental|Arm I (vaccine therapy and adjuvant)|Patients receive polyvalent antigen-KLH conjugate vaccine and immunological adjuvant OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 11, 23, 35, 47, 59, 71, and 83 in the absence of disease progression or unacceptable toxicity.
9768993|NCT00857545|Experimental|Arm II (adjuvant)|Patients receive immunological adjuvant OPT-821 SC as in arm I.
9768994|NCT00857584|Experimental|Quetiapine Extended Release|Lithium or valproate at stable doses within seric therapeutic levels
9768995|NCT00857584|Active Comparator|Sertraline|Lithium or valproate at stable doses within seric therapeutic levels
9768996|NCT00857623|Experimental|1|
9768997|NCT00857623|Placebo Comparator|2|
9768998|NCT00857649|Experimental|Memantine|
9768999|NCT00857649|Placebo Comparator|Placebo|
9769000|NCT00857727|Experimental|Drug|Dexmedetomidine
9769001|NCT00857727|Placebo Comparator|Control|Normal Saline IV solution
9769002|NCT00857766|Active Comparator|ADVAIR DISKUS|Subjects receive blinded Fluticasone Propionate/Salmeterol. At 4 months subjects will receive open label SPIRIVA HANDIHALER
9769003|NCT00857766|Placebo Comparator|Placebo|Subjects will receive placebo ADVAIR DISKUS. At 4 months subjects will receive open label SPIRIVA HANDIHALER
9769004|NCT00857792|Other|Open Label|
9769005|NCT00857818|Experimental|Aripiprazole|
9769006|NCT00857818|Active Comparator|Control group (Oanzapine, risperidone, or quetiapine)|
9769007|NCT00857857|Experimental|13 day repeat dose|
9769008|NCT00857896|Experimental|Fesoterodine once daily|
9769009|NCT00857948|Experimental|0.15% ivermectin|Participant on 0.15% ivermectin treatment conditioner
9769010|NCT00857948|Experimental|0.25% ivermectin|Participants on 0.25% ivermectin treatment conditioner
9769011|NCT00857948|Experimental|0.50% ivermectin|Participants on 0.50% ivermectin treatment conditioner
9769012|NCT00857948|Placebo Comparator|Placebo|participants on Placebo (Vehicle control)
9769013|NCT00857961|Experimental|3 mL (30 mg) of 1% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
9769014|NCT00857961|Experimental|1.5 mL (30 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.
9769015|NCT00857961|Experimental|3 mL (60 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
9769016|NCT00857961|Experimental|4.5 mL (90 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.
9769017|NCT00858013|Active Comparator|Nateglinide|Nateglinide 90~120mg three times a day
9769018|NCT00858013|Active Comparator|Glimepiride|Glimepiride 1~2mg once a day
9769019|NCT00858117|Experimental|Alemtuzumab and Rituximab|Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.
9769020|NCT00858130|Experimental|Veinoplus|Every subject enrolled in study will be in this experimental arm. VeinoPlus device will be used by all enrolled subjects.
9769021|NCT00858143||1|
9769022|NCT00858208||Patients with neovascular Age-Related Macula Degeneration|
9769023|NCT00858234|Experimental|Vorinostat + Bortezomib|Participants undergo up to 3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg once daily [QD] on Days 1 through 14) + bortezomib (1.3 mg/m^2 intravenous [IV] on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m^2 IV on Days 1, 4, 8, and 11).
9769024|NCT00858247|Experimental|Vitamin D3-low dose|Vitamin D3 400 IU capsule, one capsule daily for 12 weeks.
9769025|NCT00858247|Experimental|Vitamin D3-high dose|Vitamin D3 2000 IU capsule, one capsule daily for 12 weeks.
9769026|NCT00858364|Placebo Comparator|Placebo|Participants received placebo once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
9769027|NCT00858364|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
9769028|NCT00858390|No Intervention|1 standard care|organ donors receiving standard care
9769029|NCT00858390|Experimental|2 Enteral Feeding|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
9769030|NCT00858403|Experimental|Treatment with Dasatinib|Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing. This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
9769031|NCT00858442|Experimental|With PRP|Each patient received a single dose of 5cc PRP before the graft.
9769032|NCT00858442|No Intervention|Without PRP|Control patients did not receive any intervention before the graft.
9769033|NCT00858468|Experimental|Group 1|Participants aged 6 to 12 Weeks at enrollment
9769034|NCT00858468|Experimental|Group 2|Participants aged 24 to 36 Weeks at enrollment
9769035|NCT00858494|Experimental|homeopathic cold remedy|
9769036|NCT00858507|Experimental|Personal Health Assessment/RN Brief Intervention|RN-based medical outreach, administration of a personal health assessment and brief intervention
9769037|NCT00858507|Placebo Comparator|Social Work-Administered Outreach|Social work based outreach (usual care)
9769038|NCT00858637|Experimental|1 MCI-196|
9769039|NCT00858637|Placebo Comparator|2 Placebo of MCI-196|
9769040|NCT00858637|Active Comparator|3 Simvastatin|
9769041|NCT00858637|Placebo Comparator|4 Placebo of Simvastatin|
9769042|NCT00858689|Experimental|minocyline 50 mg or 100 mg PO BID|open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks
9769043|NCT00858780|Active Comparator|1|50mg once weekly + methotrexate
9769044|NCT00858780|Active Comparator|2|25mg once weekly + methotrexate
9769045|NCT00858780|Placebo Comparator|3|once weekly + methotrexate
9769046|NCT00858832|Experimental|Methergine|Methergine group received Methergine 0.2mg po every 6 hours for two days, plus routine postpartum care.
9769047|NCT00858832|No Intervention|No treatment|No treatment group received only routine postpartum care.
9769048|NCT00858845|Experimental|Clonidine patch|Participants assigned to wear a clonidine patch.
9769049|NCT00858845|Placebo Comparator|Placebo|Participants assigned to wear a matching placebo patch.
9769050|NCT00858858|Experimental|Arm 1|All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.
9769051|NCT00858962|Experimental|Bup/Ral|Buprenorphine and Raltegravir co-administration
9769052|NCT00858988|Experimental|Rifaximin|
9769053|NCT00858988|Placebo Comparator|Placebo|
9769054|NCT00859014|Experimental|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.
9769055|NCT00859027|Experimental|Risedronate|35 mg by mouth every week as directed
9769056|NCT00859027|Placebo Comparator|risedronate placebo tablet|Calcium and vitamin D
9769057|NCT00859040|Experimental|SOM230C|Monthly SOM230C (pasireotide LAR) - 60 mg intramuscularly (Single-Arm Trial)
9769058|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh A|
9769059|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh B|
9769060|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh C|
9769061|NCT00859053|Active Comparator|BMS-790052 in Healthy Subjects|
9769062|NCT00859131|Active Comparator|Thymoglobulin|Subjects receiving Thymoglobulin as induction agent in renal transplantation
9784366|NCT01223703|Active Comparator|n-3 PUFAs|
9769063|NCT00859131|Active Comparator|Zenapax|subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
9769064|NCT00859222|Experimental|Phase I Cohort 1: Bevacizumab +LBH589 20 mg every week|Phase I Cohort 1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting LBH589 dose of 20 mg/day orally, 3x per week, every week (days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26). Participants were treated until disease progression or unacceptable toxicity.
9769065|NCT00859222|Experimental|Phase I Cohort 2: Bevacizumab + LBH589 20 mg every other week|Phase I Cohort 2 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the amended starting LBH589 dose of 20 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
9769066|NCT00859222|Experimental|Phase I Cohort 3: Bevacizumab + LBH589 30 mg every other week|Phase I Cohort 3 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
9769067|NCT00859222|Experimental|All Phase I Participants|All phase I participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
9769068|NCT00859222|Experimental|Phase II GBM: Bevacizumab + LBH589 30 mg every other week|Phase II glioblastoma (GBM) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
9769069|NCT00859222|Experimental|Phase II AG: Bevacizumab + LBH589 30 mg every other week|Phase II Anaplastic Glioma (AG) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
9769070|NCT00859222|Experimental|All Phase II Participants|All phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
9769071|NCT00859313|Experimental|Sufentanil NanoTab PCA System/15 mcg|
9769072|NCT00859339|Experimental|Experimental Treatment|Neoadjuvant cisplatin, gemcitabine and sunitinib malate followed by radical cystectomy
9769073|NCT00859456|Experimental|Sunitinib|Patients with unresectable or metastatic angiosarcoma, epithelioid sarcoma-like hemangioendothelioma and Kaposi's sarcoma, either receiving Sunitinib as first-line therapy or failure after no more than 2 prior chemotherapy regimens.
9769074|NCT00859469|Experimental|Oxaliplatin and Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin 100 mg/m² IV infusion over 2 hours repeated for 14 days up to 6 cycles
9769075|NCT00859495|Experimental|Multimodal lung sparing regimen|"Intrapleural chemotherapy plus systemic chemotherapy:~Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy."
9769076|NCT00859508|Experimental|SyntheCel|
9769077|NCT00859508|Active Comparator|other FDA cleared dura replacements|
9769078|NCT00859547|Experimental|Recombinant thrombin (rThrombin), 1000 IU/mL|
9769079|NCT00859573|Active Comparator|1. Modafinil|
9769080|NCT00859573|Placebo Comparator|2: Placebo|Placebo
9769081|NCT00859586|Experimental|Miltenyi Magnetic cell sorter for CD3|"Miltenyi Magnetic cell sorter device will be used for CD3 selection of granulocyte colony stimulating factor mobilized allogeneic PBSCT. In stage 1, subjects will receive 1 x 10 to the eight power CD3 cells/kg. In stage II, the dose of CD3+ cells will be increased to 2 x 10 to the eight power cells/kg.~This phase II clinical trial is designed to evaluate a novel non-myeloablative but highly immunosuppressive disease specific conditioning regimen and infusion of unmanipulated lymphocytes from a haplo-identical familial donor in subjects with relapsed disease following matched sibling stem cell transplantation who are not candidates for alternative treatment options. The clinical trial will evaluate recipient survival at six months post-relapse of disease."
9769082|NCT00859638|Experimental|Intervention Group|Rehabilitation self-management group, on-line self monitoring of physical function, and organizational capacity building.
9769083|NCT00859638|No Intervention|Case matched controls|Usual care in primary health care.
9784367|NCT01223703|Placebo Comparator|Placebo|
9769084|NCT00859651|Active Comparator|20,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.~Cholecalciferol 20,000 IU (2 active capsules + 1 matching placebo capsule)"
9769085|NCT00859651|Active Comparator|30,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.~Cholecalciferol 30,000 IU (3 active capsules)"
9769086|NCT00859833|Experimental|myocardial perfusion reserve|Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequentially (30 minutes apart) in the same sequence in every patient. The shorter acting drug (adenosine) is given first so it has time to wear off before giving the second drug. It is ideal to measure MPR with each drug during the same imaging session so that there are no other clinical variables that change between the administration of the 2 agents. See below.
9769087|NCT00859898|Experimental|Dapagliflozin + Metformin XR|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"
9769088|NCT00859898|Experimental|Dapagliflozin + Placebo|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."
9769089|NCT00859898|Active Comparator|Metformin XR + Placebo|"Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"
9769090|NCT00859937|Experimental|Arm I|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9769091|NCT00859950|Active Comparator|Sleep Apnea|Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
9769092|NCT00859950|No Intervention|Normal Control|Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.
9769093|NCT00859976|Active Comparator|Plasma-sprayed shell|Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
9769094|NCT00859976|Experimental|BoneMaster coated shell|Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
9769095|NCT00860015|Experimental|Alimta/Gemcitabine|IV administration of drugs for 14 days for up to 4 cycles
9769096|NCT00860028|Experimental|Extended Varenicline Pretreatment|Arm 1 (Experimental) = 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
9769097|NCT00860028|Experimental|Short-term Varenicline Pretreatment|Arm 2 (Experimental) = 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
9769098|NCT00860067|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson (BD) Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
9769099|NCT00860067|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])a B strain of the Yamagata lineage.
9769100|NCT00860067|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria(trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004])a B strain of the Victoria lineage.
9784368|NCT01223937|Experimental|Desmopressin 25 μg|Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
9835689|NCT02750761|Experimental|Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
9835690|NCT02750761|Experimental|Group 2 Cohort 1: Tedizolid IV 6 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 6 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
9835691|NCT02750761|Experimental|Group 2 Cohort 2: Tedizolid IV 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
9835692|NCT02750761|Experimental|Group 3: Tedizolid oral 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single dose of tedizolid phosphate oral suspension dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
9835693|NCT02750761|Experimental|Group 4: Tedizolid oral 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single dose of tedizolid phosphate oral suspension dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
9835694|NCT02750800||Adalimumab and AbbVie Care 2.0|Adalimumab administered via subcutaneous (SC) injection for 12 months according to the approved EMA label and Hungarian financial protocols and supportive services via the AbbVie Care 2.0 patient support program
9835695|NCT02750813|Other|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
9835696|NCT02750813|Other|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
9835697|NCT02750930|Experimental|Albiglutide arm|Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
9835698|NCT02750943|Experimental|Stannous Fluoride|Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
9835699|NCT02750943|Active Comparator|Sodium Monofluorophosphate|Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
9835700|NCT02751320|Experimental|Experimental Dentifrice1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
9835701|NCT02751320|Experimental|Experimental Dentifrice 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
9835702|NCT02751320|Experimental|Experimental Dentifrice 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
9835703|NCT02751320|Placebo Comparator|Reference Product 1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
9835704|NCT02751320|Active Comparator|Reference Product 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
9835705|NCT02751320|Active Comparator|Reference Product 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
9835706|NCT02751359|Active Comparator|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
9835707|NCT02751359|Placebo Comparator|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
9835708|NCT02751385|Experimental|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
9835709|NCT02751424|Experimental|GSK3342830 single dose in Part 1|Enrolled subject will receive single escalation dose of GSK3342830. The escalating doses will be evaluated in six cohorts as A- 250 mg, B-500 mg, C-1000 mg, D-2000 mg, E-4000 mg, and F-=<6000 mg. In each cohort 6 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 36 subjects will receive GSK3342830. Dose escalation will be based on evaluation of the preceding dose levels in the study.
9835710|NCT02751424|Placebo Comparator|Placebo single dose in Part 1|Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
9836095|NCT02769065|Experimental|Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC|A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
9769101|NCT00860171|Experimental|Treatment (iodine I 131 monoclonal antibody B, autologous HCT)|Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
9769102|NCT00860262|Experimental|telmisartan and amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
9769103|NCT00860262|Active Comparator|amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
9769104|NCT00860262|Active Comparator|telmisartan|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
9769105|NCT00860314|Active Comparator|AP Position|Cardioversion with antero-posterior electrode position
9769106|NCT00860314|Active Comparator|AL Position|Cardioversion with antero-lateral electrode position
9769107|NCT00860379|Placebo Comparator|Placebo|Placebo
9769108|NCT00860379|Experimental|Selenium1|Subject will receive 2 ug/kg of IV selenium per day
9769109|NCT00860379|Experimental|Selenium2|Subject will receive 4 ug/kg of IV selenium per day
9769110|NCT00860405|Experimental|1|Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
9769111|NCT00860405|Active Comparator|2|Control drug: Human serum albumin (HSA 50g/L)
9769112|NCT00860457|Experimental|Chemotherapy|Fludarabine/Rituximab followed by Lenalidomide
9769113|NCT00860470|Active Comparator|1|Iron (27 mg) and folic acid (600 ug)
9769114|NCT00860470|Experimental|2|Multiple micronutrient
9769115|NCT00860535|Experimental|Ph+ CML or Ph+ ALL|GFS biomarker evaluation
9769116|NCT00860574|Experimental|Treatment (allogeneic transplantation)|CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
9769117|NCT00860743|No Intervention|Arm 1|"We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep."
9769118|NCT00860743|Experimental|ANTIOXIDANT COCKTAIL|We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
9769119|NCT00860795|Active Comparator|Echinacea|
9769120|NCT00860795|Placebo Comparator|placebo|
9769121|NCT00860847|Active Comparator|Aged Garlic Extract and Coenzyme Q10|"AGE (1200 mg) and CoQ10 (120 mg)~This is a combination of aged garlic extract and co-enzyme Q10"
9769122|NCT00860847|No Intervention|Placebo|placebo pills will be given
9769123|NCT00860938|Active Comparator|Budesonide|
9769124|NCT00860938|Placebo Comparator|Placebo|
9769125|NCT00860951|Other|Brain Computer Interface Keyboard|What effect does the environment (BCI, AT device, Computer) have on the accuracy of typing using a BCI keyboard?
9769126|NCT00861146|Experimental|1 concurrent smoking cessation|smoking cessation delivered concurrent with intensive alcohol treatment
9769127|NCT00861146|Active Comparator|2 deferred smoking cessation|smoking cessation delivered 12 weeks after intensive alcohol treatment
9769128|NCT00861198||ERCP|Patients who have a medical indication for ERCP with cholangioscopy and/or pancreatoscopy and are referred for the procedure as part of their standard medical care will be considered for the study.
9769129|NCT00861263|Other|spiral overtube|Any subject that has been referred for spiral enteroscopy will be asked to participate in this study. The purpose is to gather data about the technical aspects of the procedure,diagnostic capability and treatment as well as long term follow up.
9769130|NCT00861341|Experimental|Pioglitazone with or without Aspirin|Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.
9769131|NCT00861380|Experimental|10Pn3+1-6W- 6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
9769132|NCT00861380|Experimental|10Pn2+1-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
9769133|NCT00861380|Active Comparator|Ctrl-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
9769134|NCT00861380|Experimental|10Pn7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9769135|NCT00861380|Active Comparator|Ctrl7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9769136|NCT00861380|Experimental|10Pn12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9769137|NCT00861380|Active Comparator|Ctrl12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
9769138|NCT00861471|Experimental|Docetaxel +Gleevec|
9769139|NCT00861601|Experimental|low dose|eltrombopag 12.5 mg/day
9769140|NCT00861601|Experimental|middle dose|eltrombopag 25 mg/day
9769141|NCT00861601|Experimental|high dose|eltrombopag 37.5 mg/day
9784369|NCT01223937|Placebo Comparator|Placebo|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
9784370|NCT01223963||Macrolane|Women that have had breast enhancement with Macrolane Volume Restoration Factor.
9784371|NCT01224015|Other|onabotulinumtoxinA 24U|24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
9784372|NCT01224015|Placebo Comparator|placebo (normal saline)|Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
9784373|NCT01224015|Experimental|onabotulinumtoxinA 44U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
9784374|NCT01224145|Experimental|Drug: Bupivacaine Collagen Sponge|bupivacaine collagen sponges
9784375|NCT01224158|Experimental|PR-009577 Toothbrush|Experimental Power Toothbrush
9784376|NCT01224158|Active Comparator|PR-000172 Toothbrush|Flat trimmed Manual Toothbrush
9784377|NCT01224171|Placebo Comparator|Placebo|Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
9784378|NCT01224171|Experimental|Vedolizumab|Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
9784379|NCT01224210|Other|Ambrisentan (24 Weeks), Extension (4 Weeks)|Open Label Ambrisentan
9784380|NCT01224236|Experimental|iron supplementation|2 mg/kg/day of elemental iron as a multivitamin with iron solution
9784381|NCT01224236|Sham Comparator|control|multivitamin solution without iron
9784382|NCT01224431|Experimental|Buffered lidocaine J-tip|Needleless injection of buffered lidocaine prior to lumbar puncture versus placebo (Normal saline)
9769142|NCT00861614|Active Comparator|Ipilimumab|
9769143|NCT00861614|Placebo Comparator|Placebo|
9769144|NCT00861692|Experimental|Argatroban|
9769145|NCT00861744|Experimental|Priorix 1 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
9769146|NCT00861744|Experimental|Priorix 2 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 2) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
9769147|NCT00861744|Experimental|Priorix 3 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 3) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
9769148|NCT00861744|Active Comparator|MMR-II Group|Subjects between 12 and 15 months of age at the time of study vaccination who randomly received one dose of one of three different commercially-available lot of M-M-R II (Merck and Co.) vaccine subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
9769149|NCT00861757|Placebo Comparator|Placebo|
9769150|NCT00861757|Experimental|2.5 mg Tadalafil|
9769151|NCT00861757|Experimental|5.0 mg Tadalafil|
9769152|NCT00861757|Active Comparator|0.2 mg Tamsulosin|
9769153|NCT00861913|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9769154|NCT00862082|Experimental|PR104 + Sorafenib|PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily
9769155|NCT00862121|Experimental|Mesalazine|Mesalazine (Mesalamine) 2 g sachet; 6 g daily
9769156|NCT00862121|Placebo Comparator|Placebo|Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily
9769157|NCT00862134|Active Comparator|Docetaxel 75 mg/m^2|Subjects randomized to the docetaxel arm will be administered 75 mg/m^2, IV, every 21 days (an approved dose and schedule)
9769158|NCT00862134|Experimental|PR104 + 60 mg/m^2 docetaxel|Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m^2 docetaxel, IV, every 21 days plus 770 mg/m^2 PR104, IV, every 21 days and prophylactic G-CSF.
9769159|NCT00862186|Other|Self-Management Arm|Behavioral: 'Fatigue Facts & Fixes'
9769160|NCT00862277||Group 1: Menactra® from Previous Studies|Subjects previously received only one dose of meningococcal vaccine, Menactra® in Study MTA04, MTA12, MTA19, or MTA21.
9769161|NCT00862277||Group 2: Menomune® from Previous Study|Subjects previously received only one dose of meningococcal vaccine, Menomune® in Study MTA04
9769162|NCT00862277||Group 3: Control|Meningococcal vaccine-naive age matched subjects
9769163|NCT00862446|Experimental|Treatment|All infants will receive Omegaven
9769164|NCT00862459|Experimental|Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg body weight (BW) of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
9769165|NCT00862459|Experimental|Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
9769166|NCT00862459|Experimental|Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
9769167|NCT00862537||Active Resonator magnetic field therapy|Administration of active magnetic fields with the Resonator Device
9769168|NCT00862563|Experimental|Zonisamide|Encapsulated zonisamide with a target maintenance doses of 400 mg/day administered as 4 capsules per day.
9769169|NCT00862563|Experimental|Levetiracetam|Encapsulated levetiracetam with a target maintenance doses of 2000 mg/day administered as 4 capsules per day .
9769170|NCT00862563|Active Comparator|Topiramate|Encapsulated topiramate with a target maintenance doses of 300 mg/day administered as 4 capsules per day .
9769171|NCT00862563|Placebo Comparator|Sugar Pill|Encapsulated sugar pill with a target maintenance dose administered as 4 capsules per day.
9769172|NCT00862641|Placebo Comparator|Placebo - Asthma|Matching intravenous (IV) bolus injection, subjects with Asthma
9769173|NCT00862641|Experimental|Regadenoson - Asthma|0.4mg / 5mL intravenous bolus injection, subjects with Asthma
9769174|NCT00862641|Placebo Comparator|Placebo - COPD|Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
9769175|NCT00862641|Experimental|Regadenoson - COPD|0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
9769176|NCT00862654|Experimental|C propionate 4/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
9769177|NCT00862654|Experimental|C propionate 2/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
9769178|NCT00862654|Experimental|C propionate 2/week|Clobetasol propionate shampoo 0.05% (2/week)
9769179|NCT00862654|Active Comparator|Ketoconazole 2/week|Ketoconazole shampoo 2% (2/week)
9769180|NCT00862719|Experimental|Sitagliptin once per day|600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
9769181|NCT00862719|Experimental|Sitagliptin twice per day|600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
9769182|NCT00862719|Experimental|Sitagliptin three times per day|600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses
9769183|NCT00862745|Experimental|Active|fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.
9769184|NCT00862745|Placebo Comparator|Control|placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.
9769185|NCT00862784|Experimental|IMC-1121B (ramucirumab) + mFOLFOX-6|This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
9769186|NCT00862810|Other|Received HPV vaccine first|
9769187|NCT00862810|Other|Received concomitant vaccines first|
9769188|NCT00862823|Active Comparator|Atripla Tablet|Drug exposure after administration of Atripla Tablet
9769189|NCT00862823|Experimental|Atripla Liquid|Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla
9769190|NCT00862836|Experimental|1|Vandetanib added to standard therapy (pegliposomal doxorubicin)
9769191|NCT00862849|Experimental|Insulin Lispro, Regular Human Insulin, rHuPH20|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C).~Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20)~Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20~Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone~There was a washout period of 3 to 14 days between interventions.~The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections."
9769192|NCT00862940|Experimental|Memantine|
10203675|NCT05197946||Subjects with CP MRI|Subjects are 8 years or older with a diagnosis of cerebral palsy and clinical imaging demonstrating isolated periventricular white matter injury. Clinical assessment states that neurologic symptoms are attributed to this isolated injury. Subjects in this group must be able to lie still in a scanner for 1.5 hours in at most 2 sessions and be able to have an MRI. Participants must be able to affirmatively consent or assent with LAR consent.
10203676|NCT05197946||Control Subjects MRI|Subjects in this group are age 8 and older with no clinically significant neurologic or developmental diagnosis. Participants are able to affirmatively consent and are able to have an MRI. Subjects also should be able to lie still in a scanner for 1.5 hours.
10203677|NCT05197933|Experimental|Laparoscopic resection|laparoscopic resection for GIST at unfavorable anatomic sites of stomach
9769193|NCT00862940|Placebo Comparator|Placebo|
9769194|NCT00862979|Active Comparator|CNI-regimen|CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
9769195|NCT00862979|Experimental|CNI-free-regimen|CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids
9769196|NCT00862992|Experimental|1|
9769197|NCT00862992|Experimental|2|
9769198|NCT00862992|Experimental|3|
9769199|NCT00863057|Experimental|1|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone, (Period 3, Weeks 11 to 14) duloxetine and methadone, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone placebo
9769200|NCT00863057|Experimental|2|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine and methadone
10203678|NCT05197907|Experimental|Diaphragm fascial release group.|Ten minutes lasting fascial release techinques performed on diaphragm.
10203679|NCT05197907|Placebo Comparator|Classic massage group|Ten minutes lasting classic massage performed on abdomen.
10205337|NCT02698163|Active Comparator|Gutta Percha|For all the patients in the control arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The root canals will be filled with standard root canal filler material: gutta percha at the apical third up to and including the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
9769201|NCT00863057|Experimental|3|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone, (Period 2, Weeks 6 to 9) duloxetine and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone
9769202|NCT00863057|Experimental|4|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine and methadone, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone, (Period 4, Weeks 16 to 19) duloxetine and methadone placebo
9769203|NCT00863109||PEG + RBV (Standard Clinical Practice)|Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.
9769204|NCT00863122|Experimental|lapatinib|Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
9769205|NCT00863122|No Intervention|control|Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
9769206|NCT00863265|Experimental|Crossover order ABC|The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
9769207|NCT00863265|Experimental|Crossover order BCA|The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
9769208|NCT00863265|Experimental|Crossover order BAC|The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
9769209|NCT00863265|Experimental|Crossover order ACB|The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
9769210|NCT00863265|Experimental|Crossover order CAB|The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
9769211|NCT00863265|Experimental|Crossover order CBA|The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).
9769212|NCT00863304|Experimental|1|
9769213|NCT00863304|Experimental|2|
9769214|NCT00863304|Active Comparator|3|
9769215|NCT00863304|Placebo Comparator|4|
9769216|NCT00863317|Experimental|montelukast sodium|4mg granules PO QD for 14 days
9769217|NCT00863317|Placebo Comparator|Placebo|Sucrose granules PO QD for 14 days
9769218|NCT00863343||All|Anyone presenting with influenza-like-illness
9769219|NCT00863356|Experimental|Epistaxis Group|"Subjects presenting with epistaxis that have not been controlled by traditional nasal packing, or that recurred immediately upon removal of the nasal packing will be included in this study. Subject will be evaluated during the packing period to determine the effect of hemostasis. Chitosan coated packing will be removed after 48 hours. Subjects' nasal cavities will be examined endoscopically to evaluate bleeding control, morphological changes induced by the chitosan coated packing.~One week after the removal of the packing, the patients will be endoscopically examined to assess the healing of the packed area, to monitor control of bleeding, and observe any potential delayed reaction to the packing material."
9769220|NCT00863434|Experimental|Treatment (colony stimulating factor and chemotherapy)|Patients receive G-CSF SC QD on days 1-5 and clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month later, patients may receive one additional course of treatment in the absence of disease progression or unacceptable toxicity.
9769221|NCT00863551|Experimental|Trospium Chloride Extended Release, 60 mg|Trospium Chloride Extended Release, 60 mg
9769222|NCT00863655|Experimental|Everolimus + Exemestane|Everolimus 10 mg daily in combination with exemestane 25 mg daily
10203680|NCT05197894|Active Comparator|VR travel experience|Participants will be given instructions by a research assistant (approximately 10 minutes) on how to use the Google Earth VR ® application using Oculus Quest 2 ©. They will be given time for any questions they may have before starting their VR experience. Participants will be given a prompt that they may wish to visit a memorable place or an entirely new location for exploration. There is no limitation on where or how many places they visit during their allotted time, however, given time constraints it is suggested participants choose one starting location to begin exploration and move to others only if time permits. They will then have an approximately 30-minute session using Google Earth VR.
9769223|NCT00863655|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
9769224|NCT00863681|Experimental|Arm 1|
9769225|NCT00863707|Placebo Comparator|Placebo|Matching intravenous (IV) bolus injection
9769226|NCT00863707|Experimental|Regadenoson|0.4 mg/5 mL intravenous bolus injection
9769227|NCT00863746|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
9769228|NCT00863746|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
9769229|NCT00863772|Experimental|Tanezumab 5 mg|
9769230|NCT00863772|Experimental|Tanezumab 10 mg|
9769231|NCT00863772|Placebo Comparator|Placebo|
9769232|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 10 mg|
9769233|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 50 mg|
9769234|NCT00863798|Placebo Comparator|Placebo|
9769235|NCT00863928|No Intervention|Control Arm|No suppository given
9769236|NCT00863928|Experimental|B & O suppository|B & O suppository, belladonna 16.2 mg and opium 60 mg suppository (Paddock Laboratories, Minneapolis, MN)
9769237|NCT00864032|Experimental|Phase I|
9769238|NCT00864084|Experimental|Pulmonary rehabilitation|People with respiratory disease
9769239|NCT00864097|Experimental|Tanezumab 10 mg + diclofenac|IV tanezumab 10 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
9769240|NCT00864097|Experimental|Tanezumab 5 mg + diclofenac|IV tanezumab 5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
9769241|NCT00864097|Experimental|Tanezumab 2.5 mg + diclofenac|IV tanezumab 2.5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
9769242|NCT00864097|Placebo Comparator|IV placebo + diclofenac|IV placebo to match tanezumab every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
9769243|NCT00864123|Active Comparator|Cognitive-behavioral therapy + placebo|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of placebo. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
9769244|NCT00864123|Experimental|Cognitive-behavioral therapy + D-cycloserine|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
9769245|NCT00864253|Experimental|ABI-007|Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
9769246|NCT00864253|Active Comparator|Dacarbazine|Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
9769247|NCT00864383|Placebo Comparator|Regimen 1 - 2EHRZ/4HR (control regimen)|"Eight weeks of chemotherapy with Ethambutol, Isoniazid, Rifampicin and Pyrazinamide plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin only."
9769248|NCT00864383|Experimental|Regimen 2 - 2MHRZ/2MHR|"Eight weeks of chemotherapy with Moxifloxacin, Isoniazid, Rifampicin and Pyrazinamide plus the Ethambutol placebo, followed by~Nine weeks of Moxifloxacin, Isoniazid and Rifampicin, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo."
9769249|NCT00864383|Experimental|Regimen 3 - 2EMRZ/2MR|"Eight weeks of chemotherapy with Ethambutol, Moxifloxacin, Rifampicin and Pyrazinamide plus the Isoniazid placebo, followed by~Nine weeks of Moxifloxacin and Rifampicin plus the Isoniazid placebo, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo"
9769250|NCT00864513|Experimental|chemotherapy|pemetrexed
9769251|NCT00864539|Experimental|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 mL
9769252|NCT00864539|Active Comparator|plain milk|daily intake of 200 mL plain milk
9769253|NCT00864539|Experimental|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium
9769254|NCT00864539|Active Comparator|plane juice|subjects receiving plain orange juice
9769255|NCT00864539|Experimental|vitamin D-Ca supplement|Subjects receiving daily supplement containing 500 mg + 200 IU vitamin D
9769256|NCT00864539|Placebo Comparator|Placebo|Subjects receiving daily placebo containing 1g starch
9769257|NCT00864682|Placebo Comparator|Placebo|Saline pretreatment, saline admixture
9769258|NCT00864682|Active Comparator|Lidocaine pretreatment|Lidocaine pretreatment / saline-propofol admixture
9769259|NCT00864682|Active Comparator|Lidocaine-Propofol admixture|saline pretreatment / Lidocaine-propofol admixture
9769260|NCT00864708|Experimental|Arm 1|radio frequency-controlled (RF) Microstimulator (RFM) Gait System
9769261|NCT00864721|Experimental|Sunitinib Malate|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
9769262|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, every other week|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
9769263|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
9769264|NCT00864851|Active Comparator|Replagal 0.4 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.
9769265|NCT00864916|Experimental|1|Participants will receive pentoxifylline and combination antiretroviral therapy (cART).
9769266|NCT00864916|Active Comparator|2|Participants will receive placebo and cART.
9769267|NCT00865020|Experimental|Aliskiren 300 mg|Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
9769268|NCT00865020|Active Comparator|Telmisartan 80 mg|Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
9769269|NCT00865046|Experimental|PST + PST boosters|PST once a week for 10 weeks, then tapering over 6 months
9769270|NCT00865046|Active Comparator|PST + control-PST boosters|PST once a week for 10 weeks, then control-PST tapering over 6 months
9769271|NCT00865046|Placebo Comparator|Control-PST|control-PST for 10 weeks
9769272|NCT00865098|Experimental|Cetuximab With Radiotherapy|
9769273|NCT00865124|Experimental|Spironolactone (mineralocorticoid receptor [MR] blockade)|
9769274|NCT00865124|Active Comparator|Hydrochlorothiazide + potassium|
9769275|NCT00865124|Placebo Comparator|Placebo capsule|
9769276|NCT00865189|Experimental|Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)|In this arm, participants will undergo 3 phases of treatment. During the Phase 1, participants will receive induction chemotherapy with 6 two-week cycles of bevacizumab + Folfox-4 (5-FU + oxaliplatin + folinic acid) for 12 weeks followed by a treatment-free interval of 3 to 4 weeks. The Phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (intravenous [IV] infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The Phase 3 will be surgery involving a radical rectal excision using the total mesorectal excision (TME) technique.
9784383|NCT01224431|Placebo Comparator|Normal saline J-tip|Needleless injection of normal saline (placebo) prior to lumbar puncture versus use of buffered lidocaine
9769277|NCT00865189|Experimental|Arm B (Bevacizumab, Chemoradiotherapy)|In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.
9769278|NCT00865202|Experimental|L-Tryptophan|L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
9769279|NCT00865202|Placebo Comparator|Placebo|Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
9769280|NCT00865280|Experimental|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet, 300 mg (2 x 150 mg tablets)
9769281|NCT00865280|Active Comparator|Linezolid|Gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; Gram negative treatment: moxifloxacin 400 mg tablet and moxifloxacin 400 mg IV infusion solution
9769282|NCT00865306|Experimental|Active CBT|"Seven parent-only and 8-13 child-only sessions focusing on CBT for anxiety disorders using the Being Brave protocol."
9769283|NCT00865306|No Intervention|No intervention (wait-list controls)|Control children received no intervention.
9769284|NCT00865566|Experimental|1|Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
9769285|NCT00865566|Placebo Comparator|2|Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
9769286|NCT00865709|Experimental|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
9769287|NCT00865709|Placebo Comparator|Matching placebo + mFOLFOX6|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
9769288|NCT00865904|Placebo Comparator|Placebo|Placebo matched to VX-809 capsule orally once daily for 28 days.
9769289|NCT00865904|Experimental|VX-809, 25 mg|VX-809, 25 milligram (mg) capsule orally once daily for 28 days.
9769290|NCT00865904|Experimental|VX-809, 50 mg|VX-809, 50 mg capsule orally once daily for 28 days.
9769291|NCT00865904|Experimental|VX-809, 100 mg|VX-809, 100 mg capsule orally once daily for 28 days.
9769292|NCT00865904|Experimental|VX-809, 200 mg|VX-809, 200 mg capsule orally once daily for 28 days.
9769293|NCT00865969|Experimental|Belinostat|Belinostat 1000 mg/m^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.
9769294|NCT00866034|Experimental|CD2|Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
9769295|NCT00866034|Experimental|CD6|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
9769296|NCT00866047|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
9769297|NCT00866177|Experimental|Arm I|Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9769298|NCT00866281|Experimental|30 mg/m^2 bid|Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m^2 bid cohort was 60 mg/m^2.
9769299|NCT00866281|Experimental|60 mg/m^2 bid|Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m^2 bid through oral route. The total daily dose in 60 mg/m^2 bid cohort was 120 mg/m^2.
9769300|NCT00866294|Experimental|paroxetine CR group|controlled-release (CR) of paroxetine 12.5 to 50mg/day
9769301|NCT00866294|Other|paroxetine IR group|Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm
9769302|NCT00866294|Placebo Comparator|placebo group|matched placebo to both paroxetine CR and paroxetine IR
9769303|NCT00866307|Experimental|Arm I (HR-average)|See Detailed Description.
9769304|NCT00866307|Experimental|Arm II (HR-high)|See Detailed Description.
9769305|NCT00866320|Experimental|Sorafenib|Chemotherapy single agent systemic. Sorafenib given up to 600mg orally every 12 hours for up to 10 months (40 weeks).
9769306|NCT00866333|Experimental|Entinostat|"Regimen determined by protocol version.~Regimen 1: entinostat 10 mg (two 5 mg tablets) orally, once every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 2: entinostat 10 mg (two 5 mg tablets) orally on Day 1, increased to 15 mg (three 5 mg tablets) beginning on Day 15 of Cycle 1 for participants who had not experienced treatment-related adverse events with severity grade ≥2 (moderate), then continue 15 mg every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 3: entinostat 15 mg (three 5 mg tablets), orally, once weekly for 3 weeks followed by a 1-week break in a 4-week (28-day) cycle until disease progression or unacceptable toxicity."
9769307|NCT00866359|Active Comparator|A. Apremilast|
9769308|NCT00866359|Placebo Comparator|B. Placebo Comparator|
9769309|NCT00866606|Experimental|Benefix|Subjects received on-demand treatments with BeneFIX over a 6-month (calendar day) period.
9769310|NCT00866619|Experimental|GSK257049 [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
9769311|NCT00866619|Experimental|GSK257049 [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
9769312|NCT00866619|Active Comparator|VeroRab Comparator [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
9769313|NCT00866619|Experimental|Menjugate Comparator [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
9769314|NCT00866658|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
9769315|NCT00866658|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
9769316|NCT00866697|Placebo Comparator|Placebo|matched placebo tablet administered orally once daily for up to 24 months
9769317|NCT00866697|Experimental|Pazopanib|Pazopanib tablet administered orally at 800 mg once daily for up to 24 months
9769318|NCT00866723|Experimental|bevacizumab|Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. Treatment continued until disease progression or unacceptable toxicity.
9769319|NCT00866749|Experimental|Augmented BFM Therapy|Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
9769320|NCT00866775|Experimental|Eslicarbazepine 1600 mg QD|"Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD (Day 0) to 1200 mg QD (Week 1) to 1600 mg QD (Weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
9769321|NCT00866775|Experimental|Eslicarbazepine 1200 mg QD|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day 0) to 800 mg QD (week 1) to 1200 mg QD (weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
9769322|NCT00866788|Experimental|Omalizumab 75 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
9769323|NCT00866788|Experimental|Omalizumab 300 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
9784384|NCT01224444||All adenomatous polyps|Standard polypectomy snare of adenomatous polyps (included serrated adenomas) from ≤5mm to ≤20mm.
9769324|NCT00866788|Experimental|Omalizumab 600 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
9769325|NCT00866788|Placebo Comparator|Placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
9769326|NCT00866814||Ventrio Group|Patients diagnosed with a ventral hernia requiring an open surgery for repair.
9769327|NCT00866879|Active Comparator|Control|Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.
9769328|NCT00866879|Experimental|Transition to Sirolimus Group|Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus
9769329|NCT00866879|Other|Donors|Data and blood samples from the donors are collected in this study to contribute to the general knowledge to be used in assessing the two donor recipient groups, which are the target of this study.
9769330|NCT00866905|Experimental|Ixabepilone/Cyclophosphamide|Systemic Therapy followed by surgery and possible radiation therapy
9769331|NCT00867009|Experimental|Induction/maintenance Therapy|pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
9769332|NCT00867035|Active Comparator|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions from investigator: twice a day a tongue scraper was used with 4 or more strokes, followed by 20ml of 0.12% chlorhexidine gluconate mouthwash used for 30 sec, for one week.
9769333|NCT00867035|Experimental|Chlorine dioxide and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.1% stabilized chlor8ine dioxide rinse for 30sec, for one week.
9769334|NCT00867087|Experimental|Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2|Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
9769335|NCT00867100|Placebo Comparator|Placebo|Placebo treatment
9769336|NCT00867100|Experimental|140 mg SC|140 mg SC PsO
9769337|NCT00867100|Active Comparator|350 mg SC|350 mg SC PsO
9769338|NCT00867100|Experimental|700 mg IV|700 mg IV PsO
9769339|NCT00867113|Experimental|Imatinib|All subjects received in tablet form imatinib (STI571) 400 mg once daily.
9769340|NCT00867139|Experimental|TCAD-Randomized Arm|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
9769341|NCT00867139|Active Comparator|Neuraminidase Monotherapy Arm|Zanamivir or Oseltamivir
9769342|NCT00867139|Other|TCAD Open Label Arm|TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir
9769343|NCT00867217|Experimental|High Dose Vitamin D|High Dose Vitamin D3 capsule (3 x 10,000 IU capsules weekly). All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
9769344|NCT00867217|Placebo Comparator|Placebo|Placebo matched for High Dose Vitamin D3 capsules. All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
9769345|NCT00867308|Experimental|Lenalidomide 15 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 15 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
9769346|NCT00867308|Experimental|Lenalidomide 50 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 50 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
9769347|NCT00867334|Experimental|Imatinib mesylate and panitumumab|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 1. Each participant assigned to Arm 1 will receive imatinib mesylate for 28 days, followed by a combination of imatinib mesylate and panitumumab.
9769348|NCT00867334|Active Comparator|Panitumumab (standard-of-care)|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 2. Participants in Arm 2 will receive standard-of-care treatment with panitumumab.
9769349|NCT00867360|Experimental|Mifepristone|Receive mifepristone for 8 days
9769350|NCT00867360|Placebo Comparator|Placebo|Receive placebo rather than mifepristone
9769351|NCT00867451|Experimental|Immediate Treatment|Children will receive behavioral sleep interventions and, if needed, melatonin, to improve sleep functions.
9769352|NCT00867451|Experimental|Delayed Treatment|Children will only receive sleep behavior interventions for the first four weeks of the trial. Treatment with study drug will be delayed to the 5th week.
9784385|NCT01224626||Zyvox (linezolid)|Patients who have been treated with Zyvox (linezolid).
9784386|NCT01224639|Experimental|Group 1: Low Dose; SC|TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
9784387|NCT01224639|Experimental|Group 2: Low Dose; ID|TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
9784388|NCT01224639|Experimental|Group 3: High Dose; SC|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
9784389|NCT01224639|Experimental|Group 4: High Dose; ID|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
9784390|NCT01224639|Placebo Comparator|Placebo (SC)|Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.
9784391|NCT01224639|Placebo Comparator|Placebo (ID)|Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.
9784392|NCT01224678|Placebo Comparator|Placebo|Patients receive oral placebo once daily for 12 months.
9784393|NCT01224678|Experimental|Vitamin D|Patients receive oral vitamin D (2000 IU) once daily for 12 months.
9784394|NCT01224782||Chronic Kidney Disease, Secondary Hyperparathyroidism|All eligible participants with chronic kidney disease stage 3 and 4 and secondary hyperparathyroidism treated with Zemplar (paricalcitol) capsules according to the local marketing authorization
9784395|NCT01224821|Experimental|Tositumomab and Iodine I-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
9784396|NCT01224925|Active Comparator|Capping over carious exposure with Dycal|Total caries removal. In case of pulp exposure Direct Pulp capping with (Dycal®, Dentsply DeTrey GmbH, Konstanz, Germany)
9784397|NCT01224925|Experimental|Capping over carious exposure with WMTA|Total caries removal. In case of pulp exposure Direct Pulp capping with Mineral Trioxide Aggregate White ProRoot® (WMTA) (DENTSPLY, Tulsa Dental, Tulsa, OK, USA)
9784398|NCT01225029|No Intervention|Standard Fluids|Term neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
9784399|NCT01225029|Experimental|Restricted Fluids|Term neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
9784400|NCT01225055|Experimental|Teriparatide|Teriparatide alone with sham vibration
9769353|NCT00867490|Experimental|Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine|
9769354|NCT00867503|Experimental|bendamustine|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
9769355|NCT00867529|Experimental|Treatment (rituximab pre- and post-transplant)|Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
9769356|NCT00867659|Experimental|Cetrotide acetate|oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.
9769357|NCT00867789|Experimental|Trimethoprim-sulfamethaxazole|Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
9769358|NCT00867789|Placebo Comparator|Sugar pill|Incision and drainage of the abscess and treatment with oral placebo (100 patients)
9769359|NCT00867815|Other|Arm 1|
9769360|NCT00867932|Experimental|Eculizumab|Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.
9769361|NCT00868101|Experimental|Preconditioning|Children who received the preconditioning stimulus
9769362|NCT00868101|No Intervention|Control|Children who did not receive the preconditioning stimulus
9769363|NCT00868140|Experimental|1/Pioglitazone|Pioglitazone in pill form at 45mg twice per day for 6 months
9769364|NCT00868140|Placebo Comparator|2/Placebo|Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
9769365|NCT00868166|Experimental|Olesoxime|2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid
9769366|NCT00868166|Placebo Comparator|Placebo Comparator|2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
9769367|NCT00868192|Experimental|Pemetrexed and bevacizumab|"Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle~Bevacizumab 15 mg/kg IV on Day 1 of each 21 day cycle"
9769368|NCT00868218|Active Comparator|1|30µg HA vaccine Intramuscularly administered
9769369|NCT00868218|Active Comparator|2|1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
9769370|NCT00868218|Active Comparator|3|7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
9769371|NCT00868218|Active Comparator|4|30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
9769372|NCT00868231|Experimental|Aclidinium 400 μg bid|Aclidinium bromide 400 μg twice-daily by inhalation
9769373|NCT00868231|Active Comparator|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily by inhalation
9769374|NCT00868231|Placebo Comparator|Placebo|Placebo
9769375|NCT00868296|Active Comparator|Low dose|
9769376|NCT00868296|Active Comparator|High dose|
9769377|NCT00868309|Experimental|Anavip|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 30 minutes for Anavip
9769378|NCT00868309|Active Comparator|CroFab|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 60 minutes for CroFab, or as permitted by IV access.
9769379|NCT00868348|Placebo Comparator|Saline|
9769380|NCT00868348|Active Comparator|Ketorolac|
9769381|NCT00868374|Experimental|1|Quetiapine XR
9769382|NCT00868374|Placebo Comparator|2|
9769383|NCT00868439|Active Comparator|patiromer|
9769384|NCT00868439|Placebo Comparator|placebo|
9769385|NCT00868452|Experimental|Lurasidone|
9769386|NCT00868452|Placebo Comparator|Placebo|
9784401|NCT01225055|Experimental|Vibration|Vibration alone with placebo-teriparatide
9769387|NCT00868517|Experimental|True Group Auricular Acupuncture|Received true group auricular acupuncture twice weekly for a period of two months.
9769388|NCT00868517|Sham Comparator|Sham Group Auricular Acupuncture|Received sham group auricular acupuncture twice weekly for a period of two months.
9769389|NCT00868517|Other|Wait-List Control Group|Served as wait list control. Did not receive any acupuncture during the study period.
9769390|NCT00868530|Experimental|Xyntha|This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.
9769391|NCT00868608|Experimental|inotuzumab ozogamicin|inotuzumab ozogamicin
9769392|NCT00868699|Experimental|lurasidone low arm|
9769393|NCT00868699|Placebo Comparator|Placebo|
9769394|NCT00868699|Experimental|lurasidone high arm|
9769395|NCT00868712||1|Warfarin use < 6 months
9769396|NCT00868712||2|Warfarin use 6-24 months
9769397|NCT00868712||3|Warfarin use >24 months
9769398|NCT00868751|Experimental|Tocilizumab|Single arm study - treatment only
9769399|NCT00868790|Experimental|PLA→MK-3577 QD AM→MK-3577 QD PM→MK-3577 BID (Arm 1)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
9769400|NCT00868790|Experimental|MK-3577 QD AM→PLA→MK-3577 BID→MK-3577 QD PM (Arm 2)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
9769401|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 BID→PLA→MK-3577 QD AM (Arm 3)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed MK- 3577 25 mg BID for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
9769402|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD PM→MK-3577 QD AM→PLA (Arm 4)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
9769403|NCT00868790|Experimental|PLA→MK-3577 BID→MK-3577 QD AM→MK-3577 QD PM (Arm 5)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
9769404|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 QD PM→PLA→MK-3577 BID (Arm 6)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4.
9769405|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 QD AM→MK-3577 BID→PLA (Arm 7)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
9769406|NCT00868790|Experimental|MK-3577 BID→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 8)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
9784402|NCT01225055|Experimental|Teriparatide and vibration|Teriparatide with vibration applied in conjuction
9769407|NCT00868790|Experimental|PLA→MK-3577 QD PM→MK-3577 BID→MK-3577 QD AM (Arm 9)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
9769408|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 BID→MK-3577 QD PM→PLA (Arm 10)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
9769409|NCT00868790|Experimental|MK-3577 QD PM→PLA→MK-3577 QD AM→MK-3577 BID (Arm 11)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
9769410|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD AM→PLA→MK-3577 QD PM (Arm 12)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
9769411|NCT00868790|Experimental|PLA→METF→MK-3577 QD AM→MK-3577 QD PM (Arm 13)|Domiciled participants were to receive oral treatment with dose-matched placebo to metformin (METF) for 4 weeks during Period 1, followed by metformin 1000 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Participants in this arm were administered metformin placebo during Period 1 and active metformin during Period 2.
9769412|NCT00868790|Experimental|METF→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 14)|Domiciled participants were to receive oral treatment with metformin 1000 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to metformin for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4. Participants in this arm were administered active metformin during Period 1 and metformin placebo during Period 2.
9769413|NCT00868959|Experimental|lurasidone|
9769414|NCT00869024|Experimental|Stem Cell therapy|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
9769415|NCT00869024|Placebo Comparator|Placebo|Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
9769416|NCT00869050|Experimental|Capecitabine and Temozolomide|Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg and Temozolomide 150-200 mg/m2/day (PO divided BID).
9769417|NCT00869089|Experimental|CC-10004|"CC-10004 treament:~30mg,oral medication, BID, for 24 weeks (60mg total DAILY)"
9769418|NCT00869141|Experimental|Research arm (postop IOP>10)|Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
9769419|NCT00869141|Active Comparator|Standard of care arm (postop IOP>17)|Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
9769420|NCT00869167|Experimental|1: Ramelteon|
9769421|NCT00869167|Placebo Comparator|2: Placebo|
9769422|NCT00869206|Experimental|Arm I (zoledronic acid every 4 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9769423|NCT00869206|Experimental|Arm II (zoledronic acid every 12 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9769424|NCT00869323|Experimental|Treated Patients|This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).
9769425|NCT00869349|Experimental|IFS Intervention Group|
9769426|NCT00869349|Active Comparator|Education Group|
9769427|NCT00869362|Experimental|Diabetes Management Team|Evaluation and management by diabetes management team
9769428|NCT00869362|No Intervention|Control|Patients receive usual care for diabetes
9769429|NCT00869375|Active Comparator|CLEARWAY GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon
9769430|NCT00869375|Active Comparator|ANGIOJET GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System
9769431|NCT00869401|Experimental|Group 1 (Phase II) dasatinib + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 until progressive disease, unacceptable adverse events or refusal.
9769432|NCT00869401|Active Comparator|Group 2 (Phase II) placebo + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only placebo post cycle 8 until progressive disease, unacceptable adverse events or refusal.
9769433|NCT00869440|Experimental|1: Remimazolam (CNS 7056) 0.10 mg/kg|Remimazolam (CNS 7056) 0.10 mg/kg iv
9769434|NCT00869440|Experimental|2: Remimazolam (CNS 7056) 0.15 mg/kg|Remimazolam (CNS 7056) 0.15 mg/kg iv
9769435|NCT00869440|Experimental|3: Remimazolam (CNS 7056) 0.20 mg/kg|Remimazolam (CNS 7056) 0.20 mg/kg iv
9769436|NCT00869440|Experimental|4: Midazolam 0.075 mg/kg|Midazolam 0.075 mg/kg iv
9769437|NCT00869518|Active Comparator|Rifabutin|Subjects will be assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
9769438|NCT00869518|Placebo Comparator|Placebo|Subjects will be assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
9769439|NCT00869557|Experimental|Stribild|
9769440|NCT00869557|Active Comparator|Atripla|
9784403|NCT01225068|Experimental|Milnacipran|milnacipran 50 mg bid; can be increased to 100 mg bid
9784404|NCT01225068|Placebo Comparator|Placebo|Placebo
9769441|NCT00869609|Active Comparator|GLB Traditional Maintenance (TM)|Group Lifestyle Balance (GLB) program Traditional Maintenance: After completion of the GLB 12 core sessions, participants who are randomly assigned to GLB program Traditional Maintenance (TM) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions.
9769442|NCT00869609|Active Comparator|GLB-Carb-focused Maintenance (CF)|Group Lifestyle Balance (GLB) program Carb-focused Maintenance: After completion of the GLB 12 core sessions, participants randomly assigned to GLB Carb-focused Maintenance (CF) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information regarding healthy carbohydrate intake and hunger management.
9769443|NCT00869622|Active Comparator|Risedronate|Active drug
9769444|NCT00869622|Placebo Comparator|Placebo + Calcium and Vitamin D|All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
9769445|NCT00869778|Experimental|εPA-44 900μg|Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
9769446|NCT00869778|Experimental|εPA-44 600μg+Placebo 300μg|Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
9769447|NCT00869778|Placebo Comparator|Placebo 900μg|Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
9769448|NCT00869791|Other|Sequence 1|"Treatment Period 1:~IPX066 - 7 days; Washout Period - 7 days;~Treatment Period 2:~IR CD-LD- 7 days"
9769449|NCT00869791|Other|Sequence 2|"Treatment Period 1:~IR CD-LD - 7 days; Washout period - 7 days;~Treatment Period 2:~IPX066- 7 days"
9769450|NCT00869947|Experimental|Prosthesis|Powered ankle-foot prosthesis and passive-elastic prosthesis
10203681|NCT05197894|Experimental|VR non-travel experience|Participants will be given a choice from a list of predetermined applications as outlined in protocol, including but not excluded to: Anne Frank House VR ®, Titans of Space Plus ®, Ocean Rift ®, National Geographic Explore VR ®, Nature Treks VR ®. They will then be given instructions by a research assistant (approximately 10 minutes) on how to use the selected application using Oculus Quest 2 ©. Time is allotted for any questions they may have before starting their VR experience. Participants will be given a prompt that they may wish to visit a memorable place or an entirely new location for exploration. They will then have an approximately 30-minute session using Google Earth VR.
10203682|NCT05197855|Experimental|Technological innovations and CPAP|Patients will be equipped with 4 devices: a Dreem 3 Headband, a pulse oximeter, a continuous glucose sensor, and a pedometer. In parallel they will be equipped by the CPAP at home by Icadom.
10203683|NCT05197829|Experimental|Continuous Glucose Monitoring|
9769451|NCT00869947|Experimental|Non-amputee|Non-amputee
9769452|NCT00869960|Experimental|Antiretroviral therapy|Healthy volunteers received two doses of Tenofovir, Emtricitabine, Atazanavir and Ritonavir administered twice (on day 6 - 10 and day 20 - 25 after day of Follicular phase); with pharmacokinetic measurements at 6 - 10 days after menses and then again at day 20 - 25 after menses.
10203684|NCT05197829|Active Comparator|Care Coordination|
10203685|NCT05197816|Experimental|Deep brain stimulation|All patients will undergo adaptive deep brain stimulation with results compared before and after stimulation
10203686|NCT05197803|Experimental|Hearing aid model|Unaided, Unitron RIC and Unitron BTE hearing aid styles during one-time visit.
10203687|NCT05197517|Experimental|Rosuvastatin 10 mg film coated tablets|Single oral dose of 1 tablet (10 mg)
10203688|NCT05197517|Active Comparator|Crestor® 10 mg film coated tablets|Single oral dose of 1 tablet (10 mg)
10203689|NCT05195502||Screening colonoscopy patients|Patients referred for out-patient colonoscopy in the Danish Colorectal Screening program
10203690|NCT05189912|Experimental|Specimen retrieving bag group|Resected polyps were retrieved by specimen retrieving bag. This group was set as a experimental group.
9769453|NCT00870103|Experimental|Vigadexa eye drops|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
9769454|NCT00870194|Experimental|1|
9769455|NCT00870194|Placebo Comparator|2|
9769456|NCT00870233||GYN pts undergoing surgery|This study will assess patient use of WEBCORE, an online system designed for cancer patients to self-record toxicity-related symptoms based on NCI Common Terminology Criteria for Adverse Events and global quality of life (QoL) by European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).
10203691|NCT05189912|Active Comparator|Suction group|"Resected polyps were retrieved by removing the colonoscope suction valve and connecting a polyp trap to suction onto the instrument channel port.~This group was set as a control group."
10203692|NCT05188898|Experimental|Hyaluronic acid Group|Hyaluronic acid gel will be applied in intraosseous periodontal defects, after Minimally Invasive Non Surgical Debridement (MINSD)
9769457|NCT00870363|Active Comparator|1|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
9769458|NCT00870363|Active Comparator|2|maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
9769459|NCT00870363|Active Comparator|3|efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
9769460|NCT00870363|No Intervention|4|HIV-negative
9769461|NCT00870467|Placebo Comparator|DB Placebo|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
9769462|NCT00870467|Experimental|DB adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
9769463|NCT00870467|Experimental|DB Adalimumab/OL Adalimumab|Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
9769464|NCT00870467|Experimental|DB Placebo/OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
9769465|NCT00870467|Experimental|DB Adalimumab/RE OL Adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
9769466|NCT00870467|Experimental|DB Placebo/RE OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
9769467|NCT00870545|Experimental|Telephone support|12 telephone support group sessions based on the letters of the word BATTLEMIND
9769468|NCT00870584|Experimental|Omalizumab|The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.
9769469|NCT00870584|Placebo Comparator|Placebo|Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.
9769470|NCT00870727|Experimental|Arm 1. Aripiprazole oral product|Participants will receive Aripiprazole oral product with a minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
9769471|NCT00870727|Placebo Comparator|Arm 2. Placebo oral capsule|Participants will receive matching (identical in size and appearance to study drug) placebo oral capsules over 8-weeks of treatment.
9769472|NCT00870740|Experimental|Group 1: DAC HYP 150 mg|Participants who received placebo in 205MS201 receive DAC HYP 150 mg subcutaneous (SC) injection every 4 weeks for a total of 13 doses.
9769473|NCT00870740|Experimental|Group 1: DAC HYP 300 mg|Participants who received placebo in 205MS201 receive DAC HYP 300 mg SC injection every 4 weeks for a total of 13 doses.
9769474|NCT00870740|Experimental|Group 2: Washout then DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 150 mg SC every 4 weeks for a total of 8 doses.
9769475|NCT00870740|Experimental|Group 2: DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 receive DAC HYP 150 mg SC every 4 weeks for a total of 13 doses.
9769476|NCT00870740|Experimental|Group 3: Washout then DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 300 mg SC every 4 weeks for a total of 8 doses.
9769477|NCT00870740|Experimental|Group 3: DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 receive DAC HYP 300 mg SC every 4 weeks for a total of 13 doses.
9769478|NCT00870870|Experimental|GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)|"Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
9769479|NCT00870870|Active Comparator|GCiC (Gemcitabine/Cisplatin/Cetuximab)|"Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
9769480|NCT00870896|Experimental|Tiotropium|Cough reflex measured by capsaicin Inhalation Challenge will follow Dicpinigaitis performed at 1 and 3 months. Solutions prepared to make a stock solution of 0.01 Mol diluted with physiologic saline to yield 11 doubling concentrations from 0.98 to 1,000 uMol/L. Final diluted capsaicin concentrations are: 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1000 uMol/L. Then, place 1 ml of the first concentration into nebulizer. Subjects inhale single breath of capsaicin aerosol. Single breaths are delivered in ascending order, with normal saline randomly interspersed to increase blindness, until two or more coughs (C2) and five or more coughs (C5) are reached. The different concentrations are delivered at 2 minute intervals.
9769481|NCT00871000|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Boostrix Polio™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Boostrix Polio™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
9769482|NCT00871000|Active Comparator|TETRAVAC GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Tetravac™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Tetravac™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
9769483|NCT00871117|Experimental|Kinrix + M-M-R II + Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
9784405|NCT01225146|Active Comparator|Treatment Experienced (Cohort 1|"Previously treated with 6 or more intravitreal ranibizumab with persistent edema followed in RAVE 1 (FVF3348s).~Cohort 1 patients will receive 1 dose of ranibizumab 2.0 mg, followed by PRN based on pre-defined retreatment criteria"
9769484|NCT00871117|Active Comparator|Kinrix + M-M-R II -> Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.
9769485|NCT00871143|Experimental|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
9769486|NCT00871143|Active Comparator|Non Specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
9769487|NCT00871169|Experimental|Irinotecan, oxaliplatin, and cetuximab|The goal is to administer at least 4 cycles to each patient, but treatment may stop earlier if the treating physician deems stopping to be in the best interest of the patient. Repeated treatment may be given to patients who benefit (either complete or partial response or stabilization of disease)
9769488|NCT00871260|Other|Open Label|Approximately 25 healthy volunteers will be recruited as controls. Scan will be done with regadenoson contrast.
9769489|NCT00871286|Experimental|CT scan (sinus) pre-tx|Sinus CT scan performed at initial otolaryngology (ear, nose, and throat)visit
9769490|NCT00871286|Other|CT scan (sinus) post-tx|Sinus CT scan performed after 3-4 weeks of antibiotic treatment and any other indicated medical treatment(s), per insurance company guidelines
9769491|NCT00871338|Experimental|GSK2197870A Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2197870A vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2 and a booster dose of Menitorix™ vaccine at Month 10. All vaccines were administered intramuscularly. GSK2197870A and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh.
9769492|NCT00871338|Active Comparator|Pediacel Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of Pediacel™ vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2, 2 doses of Menjugate™ vaccine at Months 1 and 2 and a booster dose of Menitorix™ at Month 10. All vaccines were administered intramuscularly. Pediacel™ and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh and Menjugate™ vaccine in the left lower anterolateral thigh.
9769493|NCT00871377|Placebo Comparator|Placebo|Corn Oil Placebo (n-6 fatty acids)
9769494|NCT00871377|Experimental|High Dose Fish Oil|2160 mg of EPA + DHA
9769495|NCT00871377|Experimental|Low Dose Fish Oil|1060 mg of EPA + DHA
9769496|NCT00871403|Experimental|Arm 1|Investigational treatment (pazopanib and pemetrexed)
9769497|NCT00871403|Active Comparator|Arm 2|Standard treatment (pemetrexed and cisplatin)
9769498|NCT00871494|Experimental|Azithromycin switch therapy (switch from intravenous to oral).|
9769499|NCT00871572|Placebo Comparator|Placebo|
9769500|NCT00871572|Experimental|LY2409021 10 milligrams (mg)|
9769501|NCT00871572|Experimental|LY2409021 30 mg|
9769502|NCT00871572|Experimental|LY2409021 60 mg|
9769503|NCT00871624|Active Comparator|Dexmedetomidine|Subjects received active dexmedetomidine 0.2 -0.7 mcg/kg/hr
9769504|NCT00871624|Placebo Comparator|Placebo|Subjects received placebo saline solution 0.2-0.7 mcg/kg/hr
9769505|NCT00871689|Experimental|UCBT With Post-Transplant IL-2|Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
9769506|NCT00871715|Experimental|ASAP|A focused, intense, evidence-based, upper extremity rehabilitation program, administered during the early post-acute outpatient interval. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence.
9769507|NCT00871715|Active Comparator|DEUCC|Dose-equivalent usual and customary arm therapy administered early post-acutely in the outpatient setting. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
9769508|NCT00871715|Other|UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group with treatment dose administered in accordance with usual and customary practices.
9769509|NCT00871728|Experimental|Itraconazole|
9769510|NCT00871741|Experimental|GSK2202083A GROUP|Subjects in this group were to receive three doses of GSK2202083A vaccine at 3, 5 and 11 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
9769511|NCT00871741|Active Comparator|INFANRIX + MENJUGATE GROUP|Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
9769512|NCT00871780|Experimental|Natalizumab|natalizumab 300 mg IV every 4 weeks for 48 weeks
9769513|NCT00871819|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
9769514|NCT00871845|No Intervention|LEAN (non obese, naive)|Patients naive to hepatitis C therapy with body mass index (BMI) <25
9769515|NCT00871845|Other|OVERWEIGHT (obese, naive, control)|Patients naive to hepatitis C therapy with BMI ≥ 25, received Dietary and Lifestyle modification educational sessions (one-time 15 minute weight loss instruction and pamphlet and enrolled into weight management program with 5 weekly one-hour nutrition and physical exercise education sessions after initial evaluation followed by monthly follow up.)
9769516|NCT00871858|Active Comparator|Arm A (ANA)|Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.
9769517|NCT00871858|Experimental|Arm B (FULV)|Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.
9769518|NCT00871871|Experimental|Part I, Placebo-HCTZ|Placebo in Period 1 followed by HCTZ in Period 2
9769519|NCT00871871|Experimental|Part I, HCTZ-Placebo|HCTZ in Period 1, followed by placebo in Period 2
9769520|NCT00871871|Experimental|Part II, Placebo-ISMN|Placebo in Period 1, followed by ISMN in Period 2
9769521|NCT00871871|Experimental|Part II, ISMN-Placebo|ISMN in Period 1, followed by placebo in Period 2
9769522|NCT00871923|Experimental|Tarceva + RT|Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
9769523|NCT00871975|Experimental|Urodynamics + Tetra|All patients were recruited to the same arm and receive Urodynamics testing as part of the routine diagnostic work-up, plus the Tetra-NIRS intervention.
9769524|NCT00872001|Active Comparator|Acadesine|Acadesine intravenous (IV) infusion, plus cardioplegia solution with acadesine, and priming solution with acadesine in the heart lung machine during cardiopulmonary bypass (CPB)
9769525|NCT00872001|Placebo Comparator|Placebo|Normal saline, IV infusion, plus cardioplegia solution with added normal saline, and priming solution with added normal saline in the heart lung machine during CPB
9769526|NCT00872027|Experimental|1|Participants will receive 8 weeks of escitalopram treatment.
9769527|NCT00872027|Placebo Comparator|2|Participants will receive 8 weeks of placebo pills.
9769528|NCT00872079|Active Comparator|Genomics|"Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.~Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial."
9769529|NCT00872170|Active Comparator|Intervention|Participants with thalassemia who have pulmonary hypertension will receive sildenafil for 12 weeks.
9769530|NCT00872170|No Intervention|Control|Participants with thalassemia who do not have pulmonary hypertension will be part of a control group and will only be undergoing screening/baseline assessments.
9769531|NCT00872339||transfusion-dependant|People with transfusion-dependant thalassemia who received at least 8 transfusions in the past year.
9769532|NCT00872339||non-transfusion-dependant|People with non-transfusion-dependant thalassemia who received no transfusions in the past year.
9769533|NCT00872339||intermittently transfused|Intermittently transfused patients- individuals who received at least one but fewer than eight transfusions in the last year
9769534|NCT00872521|Experimental|bortezomib; doxorubicin; dexamethasone|PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 & 11) Doxorubicin 20 mg/m2 i.v. (D1 & 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 & 12)
9769535|NCT00872534|Experimental|PL-2200|PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
9769536|NCT00872534|Active Comparator|Aspirin|Immediate release 325mg aspirin
9769537|NCT00872599|Placebo Comparator|Placebo, then fenofibrate|Randomized study of fenofibrate versus placebo during high salt diet
9769538|NCT00872599|Placebo Comparator|Fenofibrate, then placebo|Randomized study of fenofibrate versus placebo during high salt intake.
9769539|NCT00872729|Active Comparator|Cystagon®|Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
9769540|NCT00872729|Experimental|RP103|Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
9769541|NCT00872833||age 18-29|People age groups 18-29 with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
9769542|NCT00872833||age 30+|People age groups 30+ years with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
9769543|NCT00872898|Experimental|1|Once daily oral administration of memantine for 12 weeks.
9769544|NCT00872898|Placebo Comparator|2|Once daily oral administration of placebo for 12 weeks.
9769545|NCT00872989|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.
9769546|NCT00872989|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9769547|NCT00873015|Experimental|Nitrite|Continuous intravenous infusion of Sodium Nitrite
9769548|NCT00873015|Placebo Comparator|Vehicle control|Continuous intravenous infusion of saline
9769549|NCT00873041|Experimental|5 mg/kg/day deferasirox|Participants received a starting dose of 5 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
9784406|NCT01225146|Active Comparator|Treatment Naive (Cohort 2)|Treatment naïve. Cohort 2 patients will receive 6 doses of ranibizumab 2.0 mg, followed by PRN based on pre-defined re-treatment criteria.
10203693|NCT05188898|Active Comparator|No-hyaluronic acid Group|Only Minimally Invasive Non Surgical Debridement (MINSD) will be performed
9769550|NCT00873041|Experimental|10 mg/kg/day deferasirox|Participants received a starting dose of 10 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
9769551|NCT00873041|Placebo Comparator|5 mg/kg/day placebo|Placebo tablet matching 5 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
9769552|NCT00873041|Placebo Comparator|10 mg/kg/day placebo|Placebo tablet matching 10 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
9769553|NCT00873093|Experimental|Pre-B ALL Relapse<18 mths from diagnosis (chemo) age<=21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
9769554|NCT00873093|Experimental|Pre-B ALL Relapse 18-36 mths from diagnosis (chemo) age<=21 yr|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
9769555|NCT00873093|Experimental|Pre-B ALL Relapse<36 mths from diagnosis (chemo) age>21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
9769556|NCT00873093|Experimental|T-cell ALL (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
9769557|NCT00873093|Experimental|T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
9769558|NCT00873119|Experimental|Arm A - BelCaP|Group A: belinostat 1000 mg/m² administered as a 30 minute IV infusion once daily on days 1, 2 and 3, with at least 18 hours between infusions, followed by belinostat 2000 mg administered orally once daily on days 4 and 5, every 3-weeks, in combination with paclitaxel 175 mg/m² administered as an IV infusion following the infusion of belinostat on cycle day 3, and carboplatin (AUC 6) administered as a 30-60 minute IV infusion directly after the paclitaxel administration on cycle day 3.
9769559|NCT00873119|Active Comparator|Arm B - CaP|Group B: paclitaxel 175 mg/m² administered as an IV infusion directly followed by carboplatin (AUC 6) administered as a 30-60 minute IV infusion on cycle day 1 of a 3-weekly cycle.
9784407|NCT01225159|Experimental|Tight glycaemic control (TGC)|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
9784408|NCT01225159|Placebo Comparator|Conventional glycaemic control (Control)|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
9784409|NCT01225172|Experimental|BMS-754807|
9784410|NCT01225172|Experimental|BMS-754807 + letrozole|
9784411|NCT01225211|Placebo Comparator|Cohort 1: Placebo|Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
9784412|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
9784413|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
9784414|NCT01225211|Placebo Comparator|Cohort 2 and 3: Placebo (HO and HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
9784415|NCT01225211|Experimental|Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
9784416|NCT01225211|Experimental|Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
9784417|NCT01225211|Experimental|Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
9784418|NCT01225211|Experimental|Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
9784419|NCT01225211|Placebo Comparator|Cohort 4: Placebo|Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
9784420|NCT01225211|Experimental|Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h|Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
9784421|NCT01225250|Experimental|Polydioxanone (PDS) plates|15 subjects will be randomized to receive a caudal septal extension graft using a PDS plated cartilagenous graft
9769560|NCT00873327|Active Comparator|1|Open label -- 6 interval doses
9769561|NCT00873457|Experimental|Perifosine|Perifosine 50 mg twice a day for a total of six 28-day cycles.
9769562|NCT00873730|Experimental|1|
9769563|NCT00873730|Active Comparator|2|
9769564|NCT00873782|Experimental|1|Participants will undergo retrograde high pressure transvenous limb perfusion with normal saline.
9769565|NCT00873821|Experimental|1|MK-0941
9769566|NCT00873821|Placebo Comparator|2|Placebo Comparator
9769567|NCT00873860|Placebo Comparator|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
9769568|NCT00873860|Experimental|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
9769569|NCT00873860|Experimental|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
9769570|NCT00873860|Experimental|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
9769571|NCT00873873||Persistent obstruction|(pattern of asthma progression)
9769572|NCT00873873||Late obstruction|(pattern of asthma progression)
9769573|NCT00873873||Late normal|(pattern of asthma progression)
9769574|NCT00873873||Persistent normal|(pattern of asthma progression)
9769575|NCT00873912|Experimental|Monovalent influenza virus vaccine|Frozen monovalent vaccine containing new strain
9769576|NCT00873912|Placebo Comparator|Placebo|Placebo
9769577|NCT00874029|Experimental|Halt Procedure|In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
9769578|NCT00874094|Active Comparator|platelet rich fibrin matrix|Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold
9769579|NCT00874120|Experimental|Phenylephrine HCl Extended-Release tablets 30 mg|Phenylephrine HCl Extended Release tablets 30 mg
9769580|NCT00874120|Placebo Comparator|Placebo|Placebo
9769581|NCT00874237|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
9769582|NCT00874237|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
9769583|NCT00874237|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
9769584|NCT00874237|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
9769585|NCT00874237|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
9769586|NCT00874237|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
9769587|NCT00874250|Experimental|GORE CTAG Device|The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.
9769588|NCT00874276|Experimental|No EGT Allele, slow metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
9769589|NCT00874276|Experimental|1+ EGT Allele, fast metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
9769590|NCT00874432|Active Comparator|Chronic Kidney Disease-ACE-I|ace inhibitor
9769591|NCT00874432|Placebo Comparator|Chronic Kidney Disease|
9769592|NCT00874432|Active Comparator|Age matched control-ACE-I|ace-inhibitor
9769593|NCT00874432|Placebo Comparator|Age matched control|Placebo
9769594|NCT00874497|Experimental|1 Tetomilast|
9769595|NCT00874497|Placebo Comparator|2 Placebo|
9769596|NCT00874510|No Intervention|Standard Schedule|interns work standard schedule, being on duty for 30 continuous hours
9769597|NCT00874510|Experimental|Mandatory Naps|interns on overnight extended duty shifts have mandatory sign out of cell phones and cross-coverage responsibilities for 5 hours roughly between 12 and 5 am. For Year 2, this will be two 3 hour shifts, the first between 12am-3am and the 2nd between 3am-6am.
9769598|NCT00874549|Active Comparator|Group 1: Menomune Day 0|Participants received a single dose of Menomune® vaccine on Day 0.
9769599|NCT00874549|Experimental|Group 2: Menactra® Day 0 x 2|Participants received two single-dose injections of Menactra® vaccine on Day 0
9769600|NCT00874549|Experimental|Group 3: Menactra® Day 0 and 14|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14
9769601|NCT00874549|Experimental|Group 4: Menactra® Day 0 and 28|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.
9769602|NCT00874614|Experimental|Ultratrace® Iobenguane I 131 Treatment|
9769603|NCT00874731|Experimental|Pt 1. Placebo/Ridaforolimus 100 mg; Pt 2. Ridaforolimus 40 mg|[Pt 1, Day 1]: Participants received a single dose of placebo (10 oral tablets) on Day 1 of Part 1. [Pt 1, Day 2]: Following completion of Part 1 / Day 1, participants received a single dose of ridaforolimus 100 mg (10 x 10 mg oral tablets) on Day 2 of Part 1. Following completion of Part 1 / Day 2, participants entered a washout period of ≥5 days before the first dose Part 2. [Pt 2]: Following completion of Part 1, participants received ridaforolimus 40 mg (4 x 10 mg oral tablets) given once daily (QD) for 5 consecutive days followed by 2 days off-drug.
9769604|NCT00874770|Experimental|Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)|Active Comparator
9769605|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (B)|Active Comparator
9769606|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (C)|Active Comparator
9769607|NCT00874770|Active Comparator|Placebo, Peginterferon alpha-2a, ribavirin (D)|
9769608|NCT00874822||Berlin|Patients diagnosed with obstructive sleep apnea by polysomnography after being screened with the Berlin questionnaire.
9769609|NCT00874848|Experimental|Imprime PGG|Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin
9769610|NCT00874848|Active Comparator|Control|Cetuximab + Paclitaxel/Carboplatin
9769611|NCT00874887|Active Comparator|Vigamox®|moxifloxacin 0.5% (m mg/mL), boric acid, sodium chloride, and purified water
9769612|NCT00874887|Active Comparator|Zymar®|gatifloxacin 0.3% (3 mg/mL), benzalkonium chloride 0.005%, edetate disodium; purified water and sodium chloride
9769613|NCT00875017|Experimental|Meal + Lanthanum|
9769614|NCT00875017|Active Comparator|Meal + Sevelamer|
9769615|NCT00875017|No Intervention|Meal Only|
9769616|NCT00875017|No Intervention|Fasting|
9769617|NCT00875056|Experimental|Follicular Lymphoma (FL)|Participants with relapsed/refractory FL received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
9769618|NCT00875056|Experimental|Indolent non-FL B-NHL or MCL|Participants with indolent non-follicular lymphoma (FL) B-cell non-Hodgkin's lymphoma (B-NHL), or with mantle cell Lymphoma (MCL) received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
9769619|NCT00875056|Experimental|Other Disease|Participants with disease other than relapsed/refractory follicular lymphoma (FL), non-FL B-cell non-Hodgkin's lymphoma (B-NHL), or mantle cell Lymphoma (MCL), as assessed by the Independent Central Pathological Committee, received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol. This group was created to include participants who enrolled, but whose later diagnoses by the Independent Central Pathological Committee excluded them from analysis in the FL and non-FL B-NHL/MCL groups because they had different disease than those prespecified in the protocol.
9769620|NCT00875212|Experimental|dentifrice intervention|4 types of dentifrices were used in 4 different periods in a crossover study design.
9769621|NCT00875277|Experimental|LEO 29102 cream|LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks
9769622|NCT00875277|Placebo Comparator|LEO 29102 Cream Vehicle|LEO 29102 cream vehicle applied topically twice daily for 4 weeks.
9769623|NCT00875277|Experimental|Betamethasone Dipropionate Cream|Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
9769624|NCT00875277|Experimental|LEO 29102 Plus Calcipotriol Cream|LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.
9769625|NCT00875277|Experimental|LEO 29102 Plus Betamethasone Dipropionate|LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
9769626|NCT00875277|Active Comparator|Daivobet® Ointment|Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.
9769627|NCT00875329||Group 1|A convenience sample of 97VHA patients who served during the OEF or OIF era, who are targeted in CPRS as requiring the TBI Clinical reminder will be included. This includes all ages, both sexes, and all races and ethnicities.
9769628|NCT00875342|Experimental|D-cycloserine|100 mg on days of therapy session
9769629|NCT00875342|Placebo Comparator|Placebo|Sugar pill
9769630|NCT00875420|Experimental|RAD1901 10 mg|Oral once a day for 28 days
9769631|NCT00875420|Experimental|RAD1901 25 mg|Oral once a day for 28 days
9769632|NCT00875420|Experimental|RAD1901 50 mg|Oral once a day for 28 days
9769633|NCT00875420|Experimental|RAD1901 100 mg|Oral once a day for 28 days
9769634|NCT00875420|Placebo Comparator|Placebo|Oral once a day for 28 days
9769635|NCT00875433|Experimental|Monotherapy|BIBW 2992 high dose, once daily, continuous, monotherapy
9769636|NCT00875485|Experimental|Twinrix Adult Group|Subjects received 2 doses of Twinrix™ Adult intramuscularly according to a 0, 6 month schedule in the primary study
9769637|NCT00875485|Experimental|Twinrix Junior Group|Subjects received 3 doses of Twinrix™ Junior (= half dose Twinrix™ Adult) intramuscularly according to a 0, 1, 6 month schedule in the primary study
9769638|NCT00875550|Active Comparator|Dexmedetomidine Low Dose|
9769639|NCT00875550|Active Comparator|Dexmedetomidine High dose|
9769640|NCT00875563|Experimental|1|Zenith(R) Fenestrated AAA Endovascular Graft
9769641|NCT00875589||Control|Control subjects with no Mild Traumatic Brain Injury (MTBI) and no Post-Traumatic Stress Disorder (PTSD)
9769642|NCT00875589||MTBI|Subject with a diagnosis for Mild Traumatic Brain Injury (MTBI)
9769643|NCT00875615|Experimental|Cisplatin or Carboplatin + Sorafenib|
9769644|NCT00875641||HRV cohort|HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).
9769645|NCT00875641||Concurrent Control cohort|Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).
9769646|NCT00875641||Recent Historical Control cohort|Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.
9769647|NCT00875667|Experimental|Lenalidomide|Lenalidomide
9769648|NCT00875667|Active Comparator|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine
9769649|NCT00875706|Other|Training Feasibility|"4 sites will receive the training intervention to determine the feasibility of the train-the trainer approach.~The educational intervention is included in this arm."
9769650|NCT00875706|Other|Data Collection - Survey|Survey data collection tools will be piloted to assess feasibility of survey administration and development of the survey for future studies. This tools were piloted in sites where the educational intervention was administered.
9769651|NCT00875706|Other|Data Collection - Interview|Interview data collection tools will be piloted to assess feasibility of interview administration and development of the interview protocol for future studies. This tools were piloted in sites where the educational intervention was administered.
9769652|NCT00875797|Active Comparator|parentral glutamine|parenteral glutamine given in central venous line in dose up to 30 g par day
9769653|NCT00875797|Experimental|entral glutamine|enteral glutamine given through gastric tube in a dose up to 30 g per day
9769654|NCT00875836|Experimental|Buspirone|Buspirone
9769655|NCT00875836|Placebo Comparator|Placebo|Placebo
9769656|NCT00875979|Experimental|Trastuzumab emtansine 3.0 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
9769657|NCT00875979|Experimental|Trastuzumab emtansine 3.6 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
9769658|NCT00876018|No Intervention|No intervention|No intervention
9769659|NCT00876018|Experimental|Nutritional supplement|Fortified nutritional powder
9769660|NCT00876018|Placebo Comparator|Placebo|Un-fortified nutritional powder
9769661|NCT00876187|Experimental|Tanezumab 20 mg IV|
9769662|NCT00876187|Experimental|Tanezumab 10 mg IV|
9769663|NCT00876187|Experimental|Tanezumab 5 mg IV|
9769664|NCT00876187|Active Comparator|Naproxen|
9769665|NCT00876187|Placebo Comparator|Placebo|
9769666|NCT00876200|Experimental|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
9769667|NCT00876200|Placebo Comparator|Placebo|Placebo = lactose
9769668|NCT00876265|Experimental|Belotero|
9769669|NCT00876265|Active Comparator|Zyplast|
9769670|NCT00876343|Experimental|1|Fixed dose
9769671|NCT00876343|Experimental|2|Titration dose
9769672|NCT00876343|Placebo Comparator|3|Placebo
9769673|NCT00876395|Experimental|Everolimus + Paclitaxel + Trastuzumab|Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
9769674|NCT00876395|Placebo Comparator|Placebo + Paclitaxel + Trastuzumab|Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
9769675|NCT00876447|Experimental|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
9769676|NCT00876447|Experimental|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
9769677|NCT00876460|Experimental|BIBF 1120 + docetaxel|Low, medium and high dose of BIBF 1120 and 60 mg/m2, 75 mg/m2 docetaxel every 3 weeks
9769678|NCT00876694|Experimental|Indacaterol 300 µg|Indacaterol 300 μg once a day (o.d.) delivered via single dose dry powder inhaler (SDDPI). Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
9769679|NCT00876694|Active Comparator|Salmeterol 50 µg|Salmeterol 50 μg twice a day (b.i.d.) delivered via Diskus®. Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
9769680|NCT00876733||HIV treatment|
9769681|NCT00876915|Experimental|High Risk for VTE recieving dalteparin|Patients assigned at random to receive prophylactic dalteparin injections
9769682|NCT00876915|No Intervention|High Risk for VTE No therapy|No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
9769683|NCT00876915|No Intervention|Low Risk for VTE|Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples
9769684|NCT00876928|Placebo Comparator|Placebo|Subjects with low vitamin D levels and pre-diabetes
9769685|NCT00876928|Experimental|vitamin D|Subjects with low vitamin D levels and pre-diabetes
9769686|NCT00876993|Experimental|Dose Level 0|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 75 mg/m^2 PO
9769687|NCT00876993|Experimental|Dose Level 1|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 125 mg/m^2 PO
9769688|NCT00876993|Experimental|Dose Level 2|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 175 mg/m^2 PO
9769689|NCT00876993|Experimental|Dose Level 3|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 200 mg/m^2 PO
9769690|NCT00876993|Experimental|Dose Level 4|Bevacizmuab 10 mg/kg IV Irinotecan 150 mg/m^2 IV Temozolomide 200 mg/m^2 PO
9769691|NCT00877006|Experimental|Bendamustine and Rituximab (BR)|Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1
9769692|NCT00877006|Active Comparator|R-CHOP/R-CVP|"Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.~R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5~R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5"
9769693|NCT00877032|Experimental|Arm 1|
9784422|NCT01225250|Other|Non-plated cartilagenous graft|15 subjects will be randomized to receive a cartilagenous caudal septal extension fgraft
9784423|NCT01225263|Experimental|Simvastatin and vitamin D|Participants in this arm will receive simvastatin + vitamin D.
9769694|NCT00877058|Experimental|1.Preventive home visit|Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
9769695|NCT00877058|Experimental|2. Senior meetings|The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
9769696|NCT00877058|No Intervention|3. Control group|The control group had access to the ordinary range of services if requested from the urban districts for the aged. The aim of the municipal provision of care for the older persons is to ensure the ability to live as independently as possible. This includes remaining in their homes. When an older person in Sweden has difficulties managing independently, she or he can apply for assistance from the district. The extent of such support is subject to an assessment of needs and includes meals on wheels, help with cleaning and shopping, assistance with personal care, safety alarms and transportation service. The older person are also offered healthcare, provided either by municipal home help or home medical care services.
9769697|NCT00877370|Experimental|ertapenem|subjects will receive ertapenem while receiving CVVHD
9769698|NCT00877383|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9769699|NCT00877383|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9769700|NCT00877448|Experimental|Multimeric-001 250 Mcg|Multimeric-001 250 Mcg in PBS
9769701|NCT00877448|Experimental|Adjuvanted Multimeric-001 250 Mcg|250 Mcg in montanide
9769702|NCT00877448|Placebo Comparator|Phosphate Buffered saline|Non-adjuvanted placebo
9769703|NCT00877448|Placebo Comparator|Adjuvanted PBS|Adjuvant was montanide
9769704|NCT00877448|Experimental|Multimeric-001 500 Mcg|Multimeric-001 in PBS
9769705|NCT00877448|Experimental|Adjuvanted Multimeric-001 500 Mcg|Adjuvant was montanide
9769706|NCT00877448|Experimental|Multimeric-001 125 Mcg|Multimeric-001 in PBS
9769707|NCT00877487|Experimental|SPD489|
9769708|NCT00877487|Placebo Comparator|Placebo|
9769709|NCT00877604|Experimental|TUDCA|tauroursodeoxycholic acid di-hydrate
9769710|NCT00877604|Placebo Comparator|placebo|excipient lactose
9769711|NCT00877773|Experimental|Temsirolimus|Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
9769712|NCT00877799|Experimental|CR845|CR845 administered as a single 15-min i.v. infusion at doses of 0.008 or 0.024 mg/kg on the day after surgery (Cohort 1), or at a dose of 0.040 mg/kg immediately after surgery (Cohort 2)
9769713|NCT00877799|Placebo Comparator|Placebo|Matched placebo administered as a single 15-min i.v. infusion on the day after surgery (Cohort 1), or the immediately after surgery (Cohort 2)
9769714|NCT00877877|Other|Cervarix Group|Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.
9769715|NCT00877890|Experimental|1|
9769716|NCT00877890|Active Comparator|2|
9769717|NCT00877929|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
9769718|NCT00877929|Active Comparator|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
9769719|NCT00878072|Experimental|Famciclovir|
9769720|NCT00878189|Experimental|1|
9769721|NCT00878215|Experimental|Phase 1:Localize Anatomical Points on Liver Surface|-The surgeon will use image-guided surgery equipment to create the mapping with 3-D pictures of the participants liver. Laser range scanning will also be used to take 3-D pictures of the liver surface. The participant will then have planned standard surgery.
9769722|NCT00878215|Experimental|Phase 2: Ceramic bead|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. During the surgery, a ceramic bead will be placed in a pre-operatively determined target location within the tumor using image-guided surgery. Standard surgical procedures will then be used to remove the tumors. Magnetic resonance (MR) images of the resected liver will confirm targeting accuracy.
9769723|NCT00878215|Experimental|Phase 3: Ablative therapy|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. The liver tumors will be ablated using image-guided surgery. Standard surgical procedures will then be used to remove the portion of the liver that has the ablated tumors. The accuracy of the ablation will be confirmed via pathology sectioning.
9769724|NCT00878215|Experimental|Phase 4: Ablative therapy (not liver resection candidates)|-This phase is for patients who otherwise do not qualify to have a portion of their liver to be surgically removed. The surgeon will use image-guidance to create the mapping with 3-D pictures of the liver. The tumors will be ablated using image-guided therapy.
9769725|NCT00878228|Experimental|Study Group|The study group will receive intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).
9769726|NCT00878228|Placebo Comparator|Control Group|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).
9769727|NCT00878436|Experimental|Arm A (120 mg/week)|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~40 mg Panobinostat 3 times per week (120 mg per week) for 2 consecutive weeks with one week rest"
9769728|NCT00878436|Experimental|Arm B (60 mg/week)-Closed to accrual|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~20 mg Panobinostat 3 times per week (60 mg per week) for 2 consecutive weeks with one week rest"
9769729|NCT00878501|Experimental|AZD1386, 90 mg|
9769730|NCT00878501|Experimental|AZD1386, 30 mg|
9769731|NCT00878501|Placebo Comparator|Placebo|
9769732|NCT00878553|Placebo Comparator|Placebo|Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
9769733|NCT00878553|Experimental|10 mg SKP-1041|One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
9769734|NCT00878553|Experimental|15 mg SKP-1041|One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
9769735|NCT00878553|Experimental|20 mg SKP-1041|Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
9769736|NCT00878644|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
9769737|NCT00878644|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
9769738|NCT00878709|Experimental|Neratinib|240 mg orally daily for one year
9769739|NCT00878709|Placebo Comparator|Placebo|orally daily for one year
9769740|NCT00878722|Experimental|Arm A|"PXD101 administered as a 30-minute intravenous (IV) infusion of 1000 mg/m²/d for five consecutive days every 3 weeks.~Idarubicin administered on day 5 (first steps) or days 4 and 5 (later steps). Patients will be treated in a 21-day cycle for a minimum of 2 cycles and a maximum of 6 cycles (depending on cumulated idarubicin dose)."
9769741|NCT00878722|Experimental|Arm B|PXD101 administered by continuous intravenous infusion over 24-48 hours and idarubicin (in the later steps) added after the first 24 hours. The second cycle will start on day 15 but under observation of possible toxicity. Further cycles will be administered q 14 d for up to 6 cycles. The first dose steps will be carried out with PXD101 alone for safety reasons.
9769742|NCT00878800|Experimental|Experimental: PXD101 and doxorubicin (BelDox)|5-day PXD101 IV schedule with dose escalation combined with 1 day doxorubicin dose escalation IV
9769743|NCT00878826|Active Comparator|Enoxaparin 40 mg per day|
9769744|NCT00878826|Active Comparator|Enoxaparin 1 mg per kg daily|
9769745|NCT00878826|Active Comparator|Pre prescribed regimen of Enoxaparin|Current enoxaparin dose at time of first prenatal visit.
9769746|NCT00878878|Experimental|Arm A|
9769747|NCT00878878|Experimental|Arm B|
9769748|NCT00878995|Placebo Comparator|Standard of Care Therapy + Placebo Testosterone|Patients receive standard of care chemotherapy and/or radiation plus placebo testosterone intramuscularly (IM) weekly for 7 weeks.
9769749|NCT00878995|Active Comparator|Standard of Care Therapy + Testosterone|Patients receive standard of care chemotherapy and/or radiation plus testosterone (Testosterone Enanthate 100mg/ml) intramuscularly (IM) weekly for 7 weeks.
9769750|NCT00879034|Experimental|Zoledronic Acid,Pravastatin,and Lonafarnib|Lonafarnib;Zoledronic acid;Pravastatin
9769751|NCT00879060|Experimental|Spironolactone|Experimental group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to experimental group will be initiated on 25mg of spironolactone. If at week 4, serum potassium is <5.5 mmol/L and serum creatinine-baseline creatinine is <0.5 mg/dl, the study drug will be increased to the target dose of 50mg once daily.
9769752|NCT00879060|Placebo Comparator|Placebo Control|Placebo group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to placebo group will be initiated on an inactive placebo pill.
9769753|NCT00879190|Active Comparator|Unasyn (ampicillin/sulbactam)|
9769754|NCT00879190|Active Comparator|Ampicillin/gentamicin|
9769755|NCT00879229|Experimental|Ambrisentan|Participants were randomized to receive ambrisentan treatment at an initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 52 weeks
9769756|NCT00879229|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ambrisentan for 48 weeks, then transition to ambrisentan treatment at the initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 4 weeks.
9769757|NCT00879255|Experimental|Videoteleconferencing CPT|"The experimental arm is the group condition that received the CPT treatment via videoteleconferencing modality as compared to the experimental condition which is via face-to-face traditional modality.~Cognitive Processing Therapy Group Videoteleconference is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference."
9769758|NCT00879255|Active Comparator|Face-to-Face CPT|"The control arm is the group condition that received the CPT treatment via face-to-face traditional modality as compared to the experimental condition which is via videoteleconferencing modality.~Cognitive Processing Therapy Group In-Person is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference."
9769759|NCT00879333|Experimental|Everolimus + BSC|All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
9769760|NCT00879333|Placebo Comparator|Placebo + BSC|All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
9769761|NCT00879359|Experimental|I|
9984297|NCT04249557|Experimental|EIM group|This contains: A 12-week Exercise is medicine teaching class containing 6-18 patients per group (class size may be limited by social distancing policy in Hong Kong), homework are prescribed to participants to encourage regular exercise. The exercise level will be recorded by a tracker and provides feedback to the participants and physical trainer. The physical parameters such as fat percentage and blood pressure level will be feedback to the patients to encourage exercise. (If sports center are closed by the Government, the classes will be conducted online)
9769762|NCT00879398||OAB-Toviaz|All patients who enrolled in this study
9769763|NCT00879411||arterial hypertension|
9769764|NCT00879437|Experimental|valproic acid and radiation, followed by valproic acid and bevacizumab|radiation phase (week 1-6): daily valproic acid and radiation, for approximately 6 weeks post-radiation phase (week 7-10): valproic acid daily maintenance phase (starting week 11): daily valproic acid, and bevacizumab once every 2 weeks; to continue for a maximum duration of 2 years
9769765|NCT00879645|Experimental|Sodium Sulfide - Mild Cohort|Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.
9769766|NCT00879645|Experimental|Sodium Sulfide - Healthy Cohort|Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
9769767|NCT00879645|Experimental|Sodium Sulfide - Moderate Cohort|Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
9769768|NCT00879645|Experimental|Sodium Sulfide - Severe Cohort|Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
9769769|NCT00879658|Experimental|BAF312 10mg (period 1)|
9769770|NCT00879658|Experimental|BAF312 2 mg (period 1)|
9769771|NCT00879658|Experimental|BAF312 0.5 mg (period 1)|
9769772|NCT00879658|Experimental|BAF312 dose between 0.1 to 8 mg period 2|
9769773|NCT00879658|Experimental|BAF312 dose between 0.1 - 8 mg period 2|
9769774|NCT00879658|Placebo Comparator|Placebo (period 1, 2)|
9769775|NCT00879684|Experimental|1|
10203694|NCT05184205|Experimental|Active Intervention|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
9769776|NCT00879697|Active Comparator|Strength training|Patients who performed strength training. The strength training program was composed by 8 exercises for whole body performed at sub-maximal intensity prescribed according to the patients self-perceived effort
9769777|NCT00879697|Active Comparator|Walking training|Patients who performed walking training. The walking training was performed in a treadmill using sub-maximal intensity prescribed based in patients self perceived effort
9769778|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 1|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
9769779|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 1|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
9769780|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 2|"Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks,~4 weeks washout period"
9769781|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 2|"Half the subjects will start with arm (i.e. every other subject in order) Ezetimibe 10 mg by month for 6 weeks,~•4 weeks washout period"
9769782|NCT00879775|Experimental|Caffeine|Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour
10203695|NCT05184205|Sham Comparator|Sham Comparator: Control|Sham comparator
10203696|NCT05181423||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
10203697|NCT05181423||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
10203698|NCT05181332||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
10203699|NCT05181332||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
10203700|NCT05179850||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
10203701|NCT05179850||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
9769783|NCT00879775|Placebo Comparator|Placebo|Intravenous injections of 100ml of normal saline over 1 hour
9784424|NCT01225263|Placebo Comparator|"Placebo Sugar Pill"|"Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill."
9784425|NCT01225289|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
9784426|NCT01225289|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day
9784427|NCT01225354|Experimental|Calcium hydroxylapatite|Subject will be treated at baseline and, if needed, at 2 weeks.
9784428|NCT01225549|Experimental|1|AZD5423 75ug
9784429|NCT01225549|Experimental|2|AZD5423 300ug
9784430|NCT01225549|Active Comparator|3|Budesonide 200 microgram
9784431|NCT01225549|Placebo Comparator|4|Placebo
9784432|NCT01225562|Experimental|1|Oral Treatment
9784433|NCT01225562|Experimental|2|Oral Treatment
9784434|NCT01225562|Placebo Comparator|3|Oral Treatment
9785730|NCT01258855|Experimental|Arm I (ziv-aflibercept and aldesleukin)|Patients receive ziv-aflibercept IV over at least 1 hour in weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9785731|NCT01258855|Experimental|Arm II (aldesleukin)|Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9785732|NCT01258985|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
9785733|NCT01258985|Active Comparator|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of Supervised Home Exercise
9785734|NCT01258998|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9785735|NCT01259011|No Intervention|control|Written information on advance directives and the patient's right to have an advance directive is provided to every patient on the first day of dialysis treatment by a social worker at the clinic. A social worker documents whether the patient has an advance directive, a surrogate decision maker, and/or a Do-Not-Resuscitate (DNR) Order on a Comprehensive Interdisciplinary Assessment form. The social worker encourages patients to complete an advance directive and addresses their questions about life-sustaining treatment options. If completed, the advance directive is placed in the medical record.
9785736|NCT01259011|Experimental|SPIRIT intervention|The SPIRIT intervention is a two-session, 1½ hour-long, structured intervention that is composed of six steps (assessing representations, identifying and exploring gaps and concerns, creating conditions for conceptual change, introducing replacement information, summarizing, and setting goals and planning), presented to both patient and surrogate by a trained nurse interventionist in a face-to-face interview format based on the representational approach.
9785737|NCT01259063|Experimental|Pts who failed or relapsed after intravesical BCG|Phase I: Everolimus will be administered as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be administered at the dose determined in Phase .Everolimus will be continued for 12 months in the patients who achieve a CR or a Partial Response. Patients demonstrating a CR (by cystoscopy and cytology) or a Partial Response at their Cycle 12 cystoscopy will be observed with serial cystoscopies every 3 months.
9785738|NCT01259089|Experimental|Arm I|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9785739|NCT01259102|Experimental|No Rest|BTDS 10 with no application site rest period prior to application of second BTDS
9785740|NCT01259102|Experimental|7-Day Rest|BTDS 10 with 7-day rest period prior to application of second BTDS
9785741|NCT01259102|Experimental|14-Day Rest|BTDS 10 with 14-day rest period prior to application of second BTDS
9785742|NCT01259102|Experimental|21-Day Rest|BTDS 10 with 21-day rest period prior to application of second BTDS
9785743|NCT01259102|Experimental|28-Day Rest|BTDS 10 with 28-day rest period prior to application of second BTDS
9769784|NCT00879814|Experimental|1|rLP2086 vaccine 60 mcg
9769785|NCT00879814|Experimental|2|rLP2086 vaccine 120 mcg
9769786|NCT00879814|Experimental|3|rLP2086 vaccine 200 mcg
9769787|NCT00879814|Active Comparator|4|Tdap vaccine - normal saline - normal saline
9769788|NCT00879879|Experimental|Losartan|50 mg tablets of losartan taken daily by mouth for 1 year
9769789|NCT00879970|Active Comparator|pioglitazone|PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
9769790|NCT00879970|Active Comparator|rosiglitazone|RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
9769791|NCT00879970|Placebo Comparator|TZD placebo|Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
9769792|NCT00879970|Active Comparator|Vitamin D|Active comparator
9769793|NCT00879970|Placebo Comparator|Vitamin D placebo|Placebo Comparator
9769794|NCT00879996|Active Comparator|1|Methadone 10-60 mg per day in 2-4 divided doses for 6 months
9769795|NCT00879996|Experimental|2|Buprenorphine 4-16 mg per day in 2-4 divided doses for 6 months (using tablets of buprenorphine/naloxone:4/1 mg)
9769796|NCT00880009|Experimental|1|Combination of Bosutinib and Letrozole
9769797|NCT00880009|Active Comparator|2|Letrozole
9769798|NCT00880022|Active Comparator|arm compression only|Intervention of arm compression only by Flexitouch System
9769799|NCT00880022|Experimental|arm, trunk and chest compression|Intervention of arm, trunk and chest compression by Flexitouch System
9769800|NCT00880048|Experimental|orvepitant 30 mg|orvepitant 30 mg (low dose)
9769801|NCT00880048|Experimental|orvepitant 60 mg|orvepitant 60 mg (high dose)
9769802|NCT00880048|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 mg and 60 mg dosage forms
9769803|NCT00880087|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
9769804|NCT00880087|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
9769805|NCT00880100|Experimental|Ultrase® MT12|
9769806|NCT00880165|Active Comparator|Arm 1|In-laboratory testing followed by continuous positive airway pressure treatment
9769807|NCT00880165|Active Comparator|Arm 2|Home unattended testing followed by continuous positive airway pressure treatment
9769808|NCT00880191|Experimental|Arm I|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
9769809|NCT00880191|Experimental|Arm II|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.
9769810|NCT00880230|Experimental|Scuba Iliac Stent System|Device: Scuba™ iliac stent
9769811|NCT00880256|Experimental|MBSR|Patients who undergo mindfulness-based stress reduction will fill out measures of IBS severity before and after the mindfulness course.
9769812|NCT00880269|Experimental|Stratum A|patients with refractory acute myelogenous leukemia (AML) initially diagnosed as de novo AML received 60 mg of panobinostat per day on three discontinuous days per week.
9769813|NCT00880269|Experimental|Stratum B|patients with refractory AML initially diagnosed as AML secondary to myelodysplastic syndrome (MDS)/antecedent hematologic disorder (AHD) received 60 mg of panobinostat per day on three discontinuous days per week.
9769814|NCT00880334|Experimental|vandetanib & Docetaxel|vandetanib orally and Docetaxel intravenously
9769815|NCT00880334|Active Comparator|Placebo and Docetaxel|Placebo orally and docetaxel intravenously
9769816|NCT00880360|Experimental|Ontak|Administration of Ontak IV for treatment of epithelial ovarian cancer
9769817|NCT00880399|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
9769818|NCT00880399|Experimental|Orvepitant 30 mg|30 mg/day (low dose)
9769819|NCT00880399|Experimental|Orvepitant 60 mg|60 mg/day (high dose)
9769820|NCT00880425||Participants with continuous headache|
9769821|NCT00880425||Participnts with non-continuous headache|
9769822|NCT00880464|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
9769823|NCT00880555||Arm 1: Non-Dementia Memory Disorder|Elderly patients with non-dementia memory disorder (mild cognitive impairment)
9769824|NCT00880555||Arm 2: Control|Elderly controls without memory impairment
9769825|NCT00880555||Arm 3: Mild Alzheimer Disease|Patients with mild Alzheimer disease (but preserved routine activities of daily living)
9769826|NCT00880568|Experimental|MK-1496 20 mg (21-Day Cycle)|Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle
9769827|NCT00880568|Experimental|MK-1496 40 mg (21-Day Cycle)|Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle
9769828|NCT00880568|Experimental|MK-1496 80 mg (21-Day Cycle)|Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle
9769829|NCT00880568|Experimental|MK-1496 120 mg (21-Day Cycle)|Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle
9769830|NCT00880568|Experimental|MK-1496 20 mg (28-Day Cycle)|Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
9769831|NCT00880568|Experimental|MK-1496 40 mg (28-Day Cycle)|Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
9769832|NCT00880568|Experimental|MK-1496 80 mg (28-Day Cycle)|Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
9769833|NCT00880568|Experimental|MK-1496 100 mg (28-Day Cycle)|Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
9769834|NCT00880568|Experimental|MK-1496 120 mg (28-Day Cycle)|Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
9769835|NCT00880581|Experimental|PF-3512676|Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
9769836|NCT00880607|Active Comparator|Intrathecal morphine|Receives a single dose of intrathecal morphine
9769837|NCT00880607|Experimental|Extended Release Epidural Morphine|Receives DepoDur extended release epidural morphine for pain management
9769838|NCT00880620|Placebo Comparator|Placebo|One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
9769839|NCT00880620|Experimental|IPX066 145 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
9769840|NCT00880620|Experimental|IPX066 245 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
9769841|NCT00880620|Experimental|IPX066 390 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).
9769842|NCT00880685|Experimental|Memantine|Memantine 10-30mg
9769843|NCT00880698|Experimental|HIV-uninfected RotaTeq|HIV-1 uninfected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
9769844|NCT00880698|Placebo Comparator|HIV-uninfected Placebo|HIV-1 uninfected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
9769845|NCT00880698|Experimental|HIV-infected RotaTeq|HIV-1 infected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
9769846|NCT00880698|Placebo Comparator|HIV-1 infected Placebo|HIV-1 infected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
9769847|NCT00880750|Experimental|Lanthanum carbonate granules|Lanthanum carbonate granulated formulation crossover to chewable tablet formulation
9769848|NCT00880750|Experimental|Lanthanum carbonate chewable tablets (Fosrenol)|Lanthanum carbonate chewable table formulation crossover to granulated formulation
9769849|NCT00880763|Experimental|Vaniprevir 200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
9784435|NCT01225731|Experimental|Part 1: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4
9769850|NCT00880763|Experimental|Vaniprevir 600 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
9769851|NCT00880763|Experimental|Vaniprevir 1200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
9769852|NCT00880763|Placebo Comparator|Placebo + peg-IFN + ribavirin|Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
9769853|NCT00880906|Active Comparator|A|Group A receives steroids and PPI, (SOC) and esophageal dilation.
9769854|NCT00880906|Sham Comparator|B|Receives steroids and PPI only- Does not have esophageal dilation.
9769855|NCT00880919|Active Comparator|1|Seroquel XR 150mg oral tablets taken daily for 8 weeks.
9769856|NCT00880919|Active Comparator|2|Seroquel XR 300mg oral tablets taken daily for 8 weeks.
9769857|NCT00880919|Placebo Comparator|3|Equivalent number of placebo oral tablets taken daily for 8 weeks.
9769858|NCT00880997|Experimental|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both groups were tapered off doxazosin or placebo over study weeks 14-17."
9769859|NCT00880997|Placebo Comparator|placebo|A sugar pill to mimic the experiment drug, doxazosin, will be administered in the same manner as the experimental drug through the study duration.
9769860|NCT00881335|No Intervention|control group|
9769861|NCT00881335|Experimental|intervention|Intervention group were given flutter valve mucus clearance devices to do pulmonary function exercise
9769862|NCT00881361|Other|Study cohort|Patients who plan to receive or have received neoadjuvant chemotherapy are eligible. Patients undergo examination for breast and axilla lymph adenopathy and then undergo ultrasound of the axillary nodes at baseline and after completion of neoadjuvant chemotherapy. Within 12 weeks of completing neoadjuvant chemotherapy, patients undergo a mastectomy or lumpectomy (per surgeon discretion) including both sentinel lymph node surgery and axillary lymph node dissection.
9769863|NCT00881465|Experimental|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks. The first session will be held face-to-face to foster rapport. Sessions 1-4 will be held twice weekly; thereafter sessions will be held weekly. Sessions 1-3 are devoted to psychoeducation, treatment discussion, and hierarchy development. Sessions 4-10 involve CBT exercises specific to each youth.
9769864|NCT00881465|Placebo Comparator|Waitlist|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
9769865|NCT00881504|Experimental|"FOLFOX6 and Bevacizumab"|"Intervention = bevacizumab in combination with chemotherapy~Treatment of biliary system carcinoma using Bevacizumab in combination with modified FOLFOX6."
9769866|NCT00881530|Active Comparator|Sitagliptin|100 mg
9769867|NCT00881530|Active Comparator|Metformin|2000 mg
9769868|NCT00881530|Experimental|BI 10773 X mg|lower dose
9769869|NCT00881530|Experimental|BI 10773 Y mg|higher dose
9769870|NCT00881569|Experimental|1|CS-7017 tablets twice daily at strength ranging from 0.5 mg to 0.75 mg
9769871|NCT00881621|Experimental|Lapatinib and Capecitabine|Treatment
9769872|NCT00881647|Experimental|1|Participants will receive an 8-week course of cognitive behavioral therapy for insomnia.
9769873|NCT00881647|No Intervention|2|Participants will be placed on a waitlist for 8 weeks.
9769874|NCT00881712|Experimental|PET positive nodal disease measuring 15 mm or greater|Proton radiation with concomitant chemotherapy
9769875|NCT00881712|Experimental|PET positive nodal disease measuring less than 15 mm|Proton radiation
9769876|NCT00881712|Experimental|Patients considered resectable|Proton radiation plus surgery
9769877|NCT00881751|Experimental|Arm 1: bevacizumab and erlotinib|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28.
9769878|NCT00881751|Active Comparator|Arm 2: sorafenib tosylate|Patients receive oral sorafenib tosylate twice daily on days 1-28.
9769879|NCT00881868|Active Comparator|Clobex Spray|
9769880|NCT00881868|Placebo Comparator|Vehicle spray|
9769881|NCT00881894|Experimental|Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)|Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
9769882|NCT00881894|Experimental|Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)|Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days
9769883|NCT00881959|Experimental|Group 1: Puros Dermis|Experimental treatment group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
9769884|NCT00881959|Active Comparator|Group 2: Alloderm|Control group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
9769885|NCT00882102|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 by vein (IV) over 1-1/2 hours daily for 5 days. Gemtuzumab ozogamicin 3 mg/m^2 by vein on day 5.
9769886|NCT00882115|Experimental|DEP challenge in subjects consuming BSE|DEP will be administered in nostrils of participants who received BSE intervention by drinking 1 cup of liquid containing 1.25 g BSE daily for 4 days, or without consuming BSE.
9769887|NCT00882206|Experimental|Decitabine / Vorinostat|This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
9769888|NCT00882362|Experimental|1|
9769889|NCT00882518|Experimental|1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day)
9769890|NCT00882518|Active Comparator|2-Chlorpromazine|Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)
9769891|NCT00882557|Experimental|A|9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.
9769892|NCT00882557|Experimental|B|Post dialysis dosing
9769893|NCT00882583|Experimental|Dasatinib/Cetuximab/RT|"In Cohort A , there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort A will consist of patients with AJCC stage II (T2N0) and III (T1-2N1) SCCHN of oral cavity, oropharynx, T2N0 hypopharynx, T2N0-1 supraglottic larynx. Treatment will be dasatinib at specific dose level in combination with cetuximab 250mg/m2 IV and radiation therapy (RT) 70Gy at 2Gy/fn."
9769894|NCT00882583|Experimental|Dasatinib/Cetuximab/cisplatin/RT|"In Cohort B, there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort B will include patients with AJCC stage III (T3N0-1) and IV (T1-4N2-3M0, T4N0-1M0) squamous cell carcinoma of Oral Cavity, Oropharynx, Hypopharynx, and Larynx. Treatment will be daily dasatinib at specific dose level, in combination with q 3 week cisplatin 75mg/m2, weekly cetuximab 250mg/m2 IV and RT 70Gy ( 2gy per fraction)."
9769895|NCT00882661|Experimental|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
9769896|NCT00882661|Active Comparator|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
9769897|NCT00882687|Experimental|0.1% Lifitegrast|
9769898|NCT00882687|Experimental|1.0% Lifitegrast|
9769899|NCT00882687|Experimental|5.0% Lifitegrast|
9769900|NCT00882687|Placebo Comparator|Placebo|
9769901|NCT00882713|Experimental|C.E.R.A.|Eligible participants will be administered continuous erythropoietin receptor activator (C.E.R.A.[Mircera]) intravenously (IV) every 4 weeks for 44 weeks. The starting dose of 120, 200, or 360 micrograms (mcg) will be based on the dose of epoetin alfa or beta administered in the week preceding the switch to C.E.R.A. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin (Hb) within a range of +/- 1.0 grams per deciliter (g/dL) of the reference hemoglobin (Hb) concentration and between 10.50 and 12.50 g/dL.
9769902|NCT00882778||activated recombinant human factor VII|Male patients diagnosed with haemophilia A or B with inhibitors, who were prescribed activated recombinant human factor VII (rFVIIa) for at least 30 days. All direction for rFVIIa medication usage was at the sole discretion of the physician in accordance within their usual practice. Data was collected for approximately 6 months of pre-prophylaxis, while the prophylaxis period had no limits.
9769903|NCT00882908|Experimental|TMC435 75 mg 12 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
9769904|NCT00882908|Experimental|TMC435 75 mg 24 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
9769905|NCT00882908|Experimental|TMC435 150 mg 12 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
9769906|NCT00882908|Experimental|TMC435 150 mg 24 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
9769907|NCT00882908|Placebo Comparator|Placebo 24 Wks + PR48|Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.
9769908|NCT00882921||Elaprase|Idursulfase 0.5 mg/kg Weekly
9769909|NCT00882999|Placebo Comparator|Placebo|Injection: Every 4 weeks in the placebo arm for 24 weeks (Weeks 0, 4, 8, 12, 16, and 20) for a total of 6 doses. Every 4 weeks in the LY2127399 arms [4 milligrams (mg) LY2127399 / 12 weeks and 120 mg LY2127399 / 12 weeks] for 24 weeks (except Week 0 and Week 12).
9769910|NCT00882999|Experimental|4 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
9769911|NCT00882999|Experimental|40 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
9769912|NCT00882999|Experimental|120 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
9769913|NCT00882999|Experimental|4 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
9769914|NCT00882999|Experimental|120 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
9769915|NCT00882999|Experimental|12 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
9769916|NCT00883051|Experimental|50 mg Lasmiditan|50 mg lasmiditan administered orally (PO)
9769917|NCT00883051|Experimental|100 mg Lasmiditan|100 mg lasmiditan administered orally (PO)
9769918|NCT00883051|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally (PO)
9769919|NCT00883051|Experimental|400 mg Lasmiditan|400 mg lasmiditan administered orally (PO)
9769920|NCT00883051|Placebo Comparator|Placebo|Placebo administered orally (PO)
9769921|NCT00883090|Experimental|FXIII|All subjects treated with Factor XIII Concentrate (Human) (FXIII)
9769922|NCT00883103|Active Comparator|Lidocaine|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
9769923|NCT00883103|Placebo Comparator|Aqueous gel|Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
9769924|NCT00883116|Experimental|Ixabepilone, 40 mg/m^2, intravenously (IV)|Participants received ixabepilone, 40 mg/m^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
9769925|NCT00883116|Active Comparator|Control chemotherapy (Paclitaxel or Doxorubicin)|Participants received either paclitaxel, 175 mg/m^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m^2.
9769926|NCT00883129|Experimental|Mycophenolate Arm|Participants will receive oral mycophenolate mofetil for 2 years.
9769927|NCT00883129|Experimental|Cyclophosphamide Arm|Participants will receive oral cyclophosphamide for 1 year, followed by placebo for 1 year.
9769928|NCT00883168|Placebo Comparator|placebo|
9769929|NCT00883168|Active Comparator|azelastine Hcl|
9769930|NCT00883168|Active Comparator|fluticasone propionate|
9769931|NCT00883168|Experimental|azelastine Hcl /fluticasone propionate|
9769932|NCT00883233|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
9769933|NCT00883233|Experimental|2|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
9769934|NCT00883233|Experimental|3|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
9769935|NCT00883233|Active Comparator|4|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
9769936|NCT00883246|Other|Atherectomy|All patients enrolled in this single-arm study were treated with directional atherectomy.
9769937|NCT00883337|Experimental|Teriflunomide 7 mg / 14 mg|Teriflunomide 7 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
9769938|NCT00883337|Experimental|Teriflunomide 14 mg / 14 mg|Teriflunomide 14 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extension treatment period).
9769939|NCT00883337|Active Comparator|IFN-β-1a / 14 mg|Interferon β-1a 3 times a week (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
9769940|NCT00883389||Safe Kidney Care|Patients with Chronic Kidney Disease (eGFR < 60 ml/min/1.732)and not expected to need dialysis within 6 months of enrollment
9769941|NCT00883493|Experimental|Quetiapin fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
9769942|NCT00883493|Experimental|Quetiapin fumarate XR+Lithium carbonate|Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
9769943|NCT00883558|Experimental|INSULIN-PH20 NP / Insulin Lispro|"All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump."
9769944|NCT00883675|Experimental|Treatment|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
9769945|NCT00883688|Experimental|Bevacizumab + Lapatinib|"Bevacizumab 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle). Lapatinib Pills of 700 mg/m^2/dose given orally 2 times each day."
9769946|NCT00883740|Experimental|Lyrica|flexible dosing Lyrica 300-450mg/day
9769947|NCT00883740|Placebo Comparator|Placebo|Placebo
9769948|NCT00883753|Experimental|tocilizumab|Participants received tocilizumab 8 mg/kg intravenous (IV), maximum dose not exceeding 800 mg in a single infusion, every 4 weeks for up to 104 weeks or up to 4 weeks after tocilizumab became commercially available in the respective country whichever occurred first.
9769949|NCT00883779|Experimental|1|
9769950|NCT00883779|Placebo Comparator|2|
9769951|NCT00884039|Active Comparator|30 mg anecortave acetate|
9769952|NCT00884039|Active Comparator|15 mg anecortave acetate|
9769953|NCT00884052|Experimental|levetiracetam dose escalation|6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day
9769954|NCT00884065|Experimental|Intervention Group|The intervention group was treated with a single session of DF following the procedure as described by the authors.
9769955|NCT00884065|Placebo Comparator|Control Group|The control group was treated with a single placebo session of DF.
9784436|NCT01225731|Experimental|Part 1: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4
9769956|NCT00884117||Participants Infected with Influenza|Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.
9769957|NCT00884221|Experimental|Highly Purified Menotrophin|
9769958|NCT00884221|Active Comparator|Recombinant FSH|
9769959|NCT00884273|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
9769960|NCT00884273|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin."
9769961|NCT00884286|Experimental|Arm One|Aplidin® given as a 1-hour weekly IV infusion
9769962|NCT00884312|Experimental|Carfilzomib|Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.
9769963|NCT00884325|Experimental|Xyzal|
9769964|NCT00884325|Placebo Comparator|Placebo|
9769965|NCT00884377|Active Comparator|Sodium stibogluconate intravenous|20 mg/kg/day Sodium stibogluconate intravenous
9769966|NCT00884377|Experimental|ThermoMed device|ThermoMed device, single heat treatment at 50 degrees Celsius
9769967|NCT00884390|Experimental|ReFacto AF|
9769968|NCT00884585|Experimental|Cyclosporine Ophthalmic Solution (COS) followed by COS|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
9769969|NCT00884585|Other|Placebo followed by COS|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.
9769970|NCT00884611|Experimental|Predictive Low Glucose Suspend|The pump suspension system consists of the Revel CGM device communicating with a laptop computer that contains the hypoglycemia prediction algorithm. During the 21 night study period, the laptop is placed at the bedside and turned on by the participant at bedtime and off on arising in the morning.The laptop contains a randomization schedule (2:1) that indicats whether the hypoglycemia prediction algorithm will be in operation that night (Predictive Low Glucose Suspend Algorithm ON) or will not be activated (Predictive Low Glucose Suspend Algorithm OFF), to which the participant is blinded.
9769971|NCT00884650|Active Comparator|Oral Analgesic Only|Group 1 will receive oral analgesic only
9769972|NCT00884650|Active Comparator|anesthetic continuous-infusion + oral analgesia|Group 2: anesthetic continuous-infusion device, e.g. intravenous analgesic per pump, with supplemental oral analgesia
9769973|NCT00884741|Active Comparator|Arm I (radiation therapy, temozolomide, placebo)|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide PO QD for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.
9769974|NCT00884741|Experimental|Arm II (radiation therapy, temozolomide, bevacizumab)|Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.
9769975|NCT00884754|Experimental|rigid GlideScope Specific Stylet|
9769976|NCT00884754|Active Comparator|90º curvature, malleable stylet|
9769977|NCT00884793|Experimental|intensification with raltegravir +/- NNRTI or PI|Intensification with raltegravir 400mg PO BID +/- a study PI or NNRTI
9769978|NCT00884806|Experimental|FID 114675A|FID 114675A used for 7 days, per protocol-specified instructions. Silicone hydrogel or hydrogel contact lenses worn bilaterally on a daily wear basis, one brand only.
9769979|NCT00884832|Experimental|Oral Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
9769980|NCT00884832|Placebo Comparator|Oral Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
9769981|NCT00884897|Experimental|Oxytocin|We will purchase OT from PharmaWorld, an international pharmacy located in Switzerland; the preparation of intranasal OT is manufactured by Novartis and sold under the trade name: Syntocinon. We have obtained an IND (number 78,246) for Syntocinon (intranasal oxytocin) manufactured by Novartis.
9784437|NCT01225731|Experimental|Part 1: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4
9769982|NCT00884897|Placebo Comparator|Placebo|We will be purchasing oxytocin placebo nasal spray through LABOSWISS located in Davos, Switzerland and distributed through PharmaWorld. LABOSWISS will manufacture the matching the placebo under GDP guidelines. The placebo will be in every way identical to the oxytocin formulation but will not contain OT.
9769983|NCT00884949|Experimental|BMN 110|Within-patient Dose-Escalation
9769984|NCT00885079|Experimental|Rebamipide|Instillation,4 times/day for 4 weeks
9769985|NCT00885079|Active Comparator|Hyaluronate|Instillation,6 times/day for 4 weeks
9784438|NCT01225731|Experimental|Part 1: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4
9784439|NCT01225731|Placebo Comparator|Part 1: Placebo|Participants receive placebo, SC, at Weeks 0 and 4
9784440|NCT01225731|Experimental|Part 2: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks
9784441|NCT01225731|Experimental|Part 2: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks
9784442|NCT01225731|Experimental|Part 2: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks
9784443|NCT01225731|Experimental|Part 2: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks
9784444|NCT01225731|No Intervention|Part 3: Tildrakizumab 5 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
9784445|NCT01225731|No Intervention|Part 3: Tildrakizumab 25 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
9784446|NCT01225731|No Intervention|Part 3: Tildrakizumab 100 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
9784447|NCT01225731|No Intervention|Part 3: Tildrakizumab 200 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
9784448|NCT01225731|No Intervention|Part 3: Placebo Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
9784449|NCT01225822|Experimental|BIBR 1048 50 mg bis in die(b.i.d)|BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
9784450|NCT01225822|Experimental|BIBR 1048 150 mg b.i.d|BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
9784451|NCT01225822|Experimental|BIBR 1048 225 mg b.i.d|BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
9784452|NCT01225822|Experimental|BIBR 1048 300 mg quaque die(q.d)|BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
9784453|NCT01225822|Active Comparator|Enoxaparin 40 mg subcutaneous(s.c)|placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
9785744|NCT01259115|Experimental|Sequence A|BTDS 10 with ketoconazole 200 mg tablets twice daily in period 1 and BTDS 10 with ketoconazole placebo tablets twice daily in period 2.
9769986|NCT00885092|Other|FID 114675A / RepleniSH|FID 114675A in Period 1; RepleniSH in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
9769987|NCT00885092|Other|RepleniSH / FID 114675A|RepleniSH in Period 1; FID 114675A in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
9769988|NCT00885105|Experimental|Fluzone® Vaccine-Primed Group|Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)
9769989|NCT00885105|Active Comparator|Influenza Vaccine-Naive Group|Participants who have never received influenza vaccine (and not in Study GRC27)
9769990|NCT00885118|Experimental|BI 10773 low dose quaque die (QD)|patient to receive a BI 10773 low dose tablet and a placebo tablet once daily
9769991|NCT00885118|Experimental|BI 10773 mid-low dose QD|patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily
9769992|NCT00885118|Experimental|BI 10773 mid-high dose QD|patient to receive two tablets of BI 10773 middle dose once daily
9769993|NCT00885118|Experimental|BI 10773 high dose QD|patient to receive a BI 10773 high dose tablet and a placebo tablet once daily
9769994|NCT00885118|Placebo Comparator|Placebo|patient to receive two tablets of placebo once daily
9769995|NCT00885170|Experimental|Odanacatib 50 mg|Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
9769996|NCT00885170|Placebo Comparator|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
9769997|NCT00885352|Experimental|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
9769998|NCT00885352|Placebo Comparator|Placebo|Placebo to sitagliptin orally once daily for 26 weeks.
9769999|NCT00885365|Experimental|Bramitob|tobramycin / Bramitob administered 300mg twice a day for 4 weeks
9770000|NCT00885365|Active Comparator|TOBI|tobramycin / TOBI administered 300mg twice a day for 4 weeks
9770001|NCT00885378|Active Comparator|Saxagliptin plus metformin IR|
9770002|NCT00885378|Placebo Comparator|Placebo plus metformin IR|
9770003|NCT00885482|Experimental|Single arm|"Treatment simplification from a standard combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy."
9770004|NCT00885534|Experimental|Chemotherapy|This is a single institution phase II trial in stage III or IV melanoma patients with measurable disease but no prior cytotoxic chemotherapy and not thought to be curable by surgery.Before starting the chemotherapy, you may need to have a fresh biopsy of your tumor. If you have already had a tumor biopsy that we can use, you may not need another biopsy. Your study doctor will review with you the biopsies you have had. We will try to obtain biopsy material that already exists but if we cannot, you will need another biopsy.
9770005|NCT00885638|Placebo Comparator|Placebo|A placebo tablet is given before ingestion of macronutrients
9770006|NCT00885638|Active Comparator|Sitagliptin|Sitagliptin is given before ingestion of macronutrients
9770007|NCT00885677|Active Comparator|Study Group|Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
9770008|NCT00885677|No Intervention|Control Group|Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.
9770009|NCT00885703|Experimental|Stage 1, Fluconazole 1200mg|Participants receive Fluconazole 1200mg induction dose in Stage 1
9770010|NCT00885703|Experimental|Stage 1, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 1
9770011|NCT00885703|Experimental|Stage 1, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 1
9770012|NCT00885703|Active Comparator|Stage 1, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 1
9770013|NCT00885703|Experimental|Stage 2, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 2
9770014|NCT00885703|Experimental|Stage 2, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 2
9770015|NCT00885703|Active Comparator|Stage 2, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 2
9770016|NCT00885742|Experimental|FXIII|All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).
9770017|NCT00885755|Experimental|1|
9770018|NCT00885768||A|patients with renal artery stenosis
9770019|NCT00885846|Active Comparator|Qigong Therapy|
9770020|NCT00885846|Active Comparator|PRT|
9770021|NCT00885846|No Intervention|Control|
9770022|NCT00886015|Experimental|TT Clamp|The TT clamp will be used in trichiasis surgery.
9770023|NCT00886015|Active Comparator|Standard BLTR Technique|Standard BLTR technique will be used in trichiasis surgery.
9770024|NCT00886119|Other|Lotrafilcon B / Omafilcon A|Lotrafilcon B, followed by Omafilcon A
9770025|NCT00886119|Other|Omafilcon A / Lotrafilcon B|Omafilcon A, followed by Lotrafilcon B
9770026|NCT00886145|Other|Vibration and No Vibration|Vibration: Right Leg and No Vibration: Left Leg.
9770027|NCT00886236|Active Comparator|1 Preoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
9770028|NCT00886236|Experimental|2 Preoperative and Postoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)
9770029|NCT00886236|Placebo Comparator|3 Preoperative and Postoperative Placebo Liquid|Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
9770030|NCT00886262|Experimental|Vasopressin|
9770031|NCT00886262|Placebo Comparator|Normal saline placebo|
9770032|NCT00886288||Telmisartan|
9770033|NCT00886288||Telmisartan + hydrochlorothiazide|
9770034|NCT00886340|Active Comparator|Enhanced standard care|
9770035|NCT00886340|Experimental|Lifestyle counseling|
9770036|NCT00886379|Active Comparator|1|Mongolian milk without D
9770037|NCT00886379|Experimental|2|Mongolian milk with vitamin D
9770038|NCT00886379|Experimental|3|Ultra High Temperature (UHT) milk
9770039|NCT00886379|Experimental|4|Milk Substitute
9770040|NCT00886379|Experimental|5|Seasonal D
9770041|NCT00886379|Experimental|6|Daily D
9770042|NCT00886483|Active Comparator|Active neurofeedback|In the active neurofeedback condition, the intervention is active neurofeedback (actual neurofeedback) either twice weekly or three times a week (randomized to frequency), with the same amount of total treatment over 40 sessions, varying only in frequency. Neurofeedback will be via the CyberLearning technology, using videogame race car speed and steering as feedback governed by EEG theta-beta ratio through the interface. the game controller is used in the usual fashion, but maximal speed is capped by the threshold theta-beta ratio, which changes from minute-to-minute by fuzzy logic based on the previous minute's ratio. If theta power exceeds a threshold, the rumble function of the controller comes on as a warning. The feedback is transparent to the patient, who just plays the videogame.
9770043|NCT00886483|Sham Comparator|Sham Neurofeedback|The sham condition will appear identical to the neurofeedback in all aspects: equipment, duration, frequency, and videogame choices. The only difference is that the interface module will be pre-programmed to give random feedback rather than contingent on the participant's brainwave power spectrum.
9770044|NCT00886587|Experimental|11054-010|F# 11054-010 Investigational Device
9770045|NCT00886587|Active Comparator|10495-053|F# 10495-053 Atopiclair
9770046|NCT00886613|Experimental|V212|Participants randomized to receive V212 (heat treated VZV Vaccine)
9770047|NCT00886613|Active Comparator|Zostavax™|Participants randomized to receive Zostavax™ (Zoster Vaccine, live)
9770048|NCT00886613|Placebo Comparator|Placebo|Participants randomized to receive placebo
9770049|NCT00886626|Experimental|Exenatide|Exenatide
9770050|NCT00886626|No Intervention|Control|Control - no intervention
9770051|NCT00886639|Other|First of 2 6-minute-walking test with oxygen|Continuous flow of 2 liters per minute First with oxygen, second with medical air
9770052|NCT00886639|Other|First of 2 6-minute-walking tests with medical air|Medical air is compressed room air. First test with medical air, second with oxygen
9770053|NCT00886704|Active Comparator|Convenience drink with EPA and DHA|Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)
9770054|NCT00886704|Placebo Comparator|Convenience drink without EPA and DHA|Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)
9770055|NCT00886743|Other|Oprelvekin as subcutaneous injection (50 mg/kg once daily)|Open label treatment with oprelvekin
9770056|NCT00886769|Experimental|Canakinumab|Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients>37.5 kg) received two sc injections.
9770057|NCT00886769|Placebo Comparator|Placebo|Patients received a single dose matching placebo of canakinumab on day 1.
9770058|NCT00886795|Experimental|Abatacept|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
9770059|NCT00886821|Experimental|1|
9770060|NCT00886834|Experimental|Misoprostol|Misoprostol 400 micrograms inserted vaginally or buccally, per the participants desire.
9770061|NCT00886834|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
9770062|NCT00886899|Experimental|BridgePoint Medical System|Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire
9770063|NCT00886938|Experimental|rTMS to DLPF, pilot study|rTMS to the dorsolateral prefrontal cortex for patients with tinnitus
9770064|NCT00887068|Experimental|Azacitidine|Azacitidine 32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
9770065|NCT00887068|No Intervention|No Azacitidine|Standard treatment post allogeneic transplant is supportive care only.
9770066|NCT00887159|Active Comparator|Arm A (CE)|Patients receive cisplatin IV over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9770067|NCT00887159|Experimental|Arm B (CE + GDC-0449)|Patients receive cisplatin and etoposide as in Arm A and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
9770068|NCT00887159|Experimental|Arm C (CE + IMC-A12)|Patients receive cisplatin and etoposide as in Arm A and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity.
9770069|NCT00887198|Placebo Comparator|Placebo + prednisone|Placebo plus prednisone
9770070|NCT00887198|Experimental|Abiraterone + prednisone|Abiraterone acetate plus prednisone
9770071|NCT00887224|Experimental|Desvenlafaxine succinate sustained release 50 mg|
9770072|NCT00887224|Placebo Comparator|Placebo|
9770073|NCT00887341|Experimental|1|
9770074|NCT00887341|Active Comparator|2|
9770075|NCT00887354|Experimental|Teriparatide|"20 micrograms (mcg) a day by subcutaneous injection throughout study.~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only."
9770076|NCT00887354|Active Comparator|Risedronate|"35 milligrams (mg) risedronate sodium orally once weekly throughout study.~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only."
9770077|NCT00887432|Experimental|Arm I (cholecalciferol and placebo)|Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.
9770078|NCT00887432|Experimental|Arm II (placebo and cholecalciferol)|Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
9770079|NCT00887458|Active Comparator|Low Dose|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
9770080|NCT00887458|Active Comparator|High Dose|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
9770081|NCT00887471||Children who underwent PITA|Children who underwent partial intracapsular tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
9770082|NCT00887471||Children who underwent T&A|Children who underwent total tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
9770083|NCT00887484|Experimental|Clindoxyl Gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
9770084|NCT00887484|Active Comparator|Epiduo gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
9770085|NCT00887510|Active Comparator|Thiazide First|Participants will receive 25 mg of hydrochlorothiazide (HCTZ) each day for 6 weeks, followed by 25 mg of HCTZ every day plus 4 mg of trandolapril each day for 6 weeks, followed by 4 mg trandolapril each day for 6 weeks.
9770086|NCT00887510|Active Comparator|Trandolapril First|Participants will receive 4 mg of trandolapril each day for 6 weeks, followed by 4 mg of trandolapril for 6 weeks plus 25 mg of HCTZ each day for 6 weeks, followed by 25 mg of HCTZ each day for 6 weeks.
9770087|NCT00887549|Experimental|Pemetrexed|
9770088|NCT00887562|Experimental|Idebenone 900 mg/day|Idebenone 900 mg/day
9770089|NCT00887562|Experimental|Idebenone 2250 mg/day|Idebenone 2250 mg/day
9770090|NCT00887562|Placebo Comparator|placebo|Placebo
9770091|NCT00887575|Experimental|Dose Level I|"Neoadjuvant - Paclitaxel IV (70 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.~Maintenance - Sunitinib PO (25mg) daily"
9770092|NCT00887575|Experimental|Dose Level II|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
9770093|NCT00887575|Experimental|Dose Level III|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 6) day 1 of every cycle and Sunitinib PO (25mg) daily.
9770094|NCT00887588|Experimental|LCZ696|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
9770095|NCT00887588|Active Comparator|Valsartan|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.
9770096|NCT00887640|Experimental|Temsirolimus 25 mg|Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion.
9770097|NCT00887653|Experimental|Raltegravir|This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
9770098|NCT00887679|Experimental|Escitalopram|Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Open label, rater-blinded, prospective, 6-week trial of escitalopram.Subjects received escitalopram 10-20mg. Escitalopram was started at 10mg per day and augmented weekly in 10mg per day increments, the maximum dose being 20mg per day.
9770099|NCT00887744|Other|Aperius Treatment Arm|Single Arm
9785745|NCT01259115|Experimental|Sequence B|BTDS 10 with ketoconazole placebo tablets twice daily in period 1 and BTDS 10 with ketoconazole 200 mg twice daily in period 2.
9785746|NCT01259128|Experimental|SER120 500 ng/day|SER120 Level 1 (500 ng/day)
9770100|NCT00887783|Experimental|B: 66Gy/33F+Navelbine oral 150 mg q3w|"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).~Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization"
9770101|NCT00887783|Active Comparator|A: 60Gy/30F+Navelbine oral 150 mg q3w|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization
9770102|NCT00887809|Experimental|gemcitabine and docetaxel with bevacizumab|Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.
9770103|NCT00887822|Experimental|Bevacizumab, Capecitabine and Cisplatin|Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
9770104|NCT00887822|Placebo Comparator|Placebo, Capecitabine and Cisplatin|Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
9770105|NCT00887926|Experimental|IMC-EB10 5 milligrams/kilogram (mg/kg)|All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
9770106|NCT00887965|Other|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
9770107|NCT00887978|Placebo Comparator|Placebo|Identical placebo tablets to UT-15C, doses were titrated in the same manner
9770108|NCT00887978|Experimental|UT-15C SR|Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.
9770109|NCT00888134|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9770110|NCT00888173|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9770111|NCT00888238|Experimental|Sitagliptin/Sitagliptin/Placebo|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
9770112|NCT00888238|Experimental|Sitagliptin/Placebo/Sitaglipitin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
9770113|NCT00888238|Experimental|Placebo/Sitagliptin/Sitagliptin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
9770114|NCT00888329|Experimental|Aprepitant|40 mg aprepitant
9770115|NCT00888329|Placebo Comparator|Placebo|Placebo
9770116|NCT00888381|Experimental|Adults|Healthy volunteers aged 18 to 59 years
9770117|NCT00888381|Experimental|Older Adults|Healthy volunteers aged 60 years or older
9770118|NCT00888433|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications
9770119|NCT00888433|No Intervention|Control|Maintenance of anti-hypertensive medications with option for cross-over treatment after 6-months
9770120|NCT00888459|Active Comparator|active|Self-help counseling material and 4 mg nicotine lozenges
9770121|NCT00888459|Placebo Comparator|2|self help counseling material and placebo nicotine lozenges
9770122|NCT00888511|Experimental|1|
9770123|NCT00888615|Experimental|Treatment (paclitaxel, elesclomol sodium)|Patients receive paclitaxel IV over 1 hour and elesclomol sodium IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients who are currently on treatment must not be dosed with elesclomol sodium after 12/31/2015. All other study procedures, with the exception of elesclomol sodium administration and paclitaxel administration, should continue in accordance with protocol requirements. Any treatment given after 12/31/2015, including continuation of paclitaxel, will be considered off study.
9784454|NCT01225835|Experimental|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
9770124|NCT00888628|Experimental|Islet transplant|"Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.~For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.~Induction therapy for subsequent transplants will be 2 doses of basiliximab.~All patients will receive Etanercept to promote engraftment."
9770125|NCT00888654|Experimental|B-Dim, Radical Prosatectomy|"B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)~Radical Prostatectomy"
9770126|NCT00888849|Experimental|Stapling|
9770127|NCT00888849|Active Comparator|Suturing|4 layered hand-sutured anastomosis
9770128|NCT00888927|Experimental|Phase 1 Cohort 1|First course: 0.1 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.1 mg/kg over 1 hour every other week
9770129|NCT00888927|Experimental|Phase 1 Cohort 2|First course: 0.3 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.3 mg/kg over 1 hour every other week
9770130|NCT00888927|Experimental|Phase 1 Cohort 3|First course: 1.0 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 1.0 mg/kg over 1 hour every other week
9770131|NCT00888927|Experimental|Phase 2|First course: Maximum tolerated dose once a week over 1 hour for 4 weeks Subsequent courses: Maximum tolerated dose over 1 hour every other week
9770132|NCT00888940|Experimental|ecallantide|
9770133|NCT00888940|Active Comparator|Cyklokapron(R)|
9770134|NCT00888979|Experimental|Nicotrol with Behavioral Counseling|Nicotrol Inhaler: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
9770135|NCT00889005|Experimental|Cognitive Behavioral Therapy|Five sessions of trauma-focused, telephone based cognitive behavioral therapy, followed by assessment and referral to clinical treatment if needed.
9770136|NCT00889005|No Intervention|Waitlist control group|Five weeks without active intervention, followed by assessment and referral to clinical treatment if needed.
9770137|NCT00889187|Experimental|Phase 1 Cohort 1: Photon Rad (30 Gy/12 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 1, a total dose of 30 Gy in 10 fractions (3 Gy/day) was prescribed to the 95% isodose and administered 5 days per week over 12 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
9770138|NCT00889187|Experimental|Phase I Cohort 2: Photon Rad (25 Gy/11 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 2, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 11 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
9770139|NCT00889187|Experimental|Phase I Cohort 3: Photon Rad (25 Gy/5 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 3, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 5 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
9770140|NCT00889187|Experimental|All Phase I: Photon Rad+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~All Phase I participants received the radiation regimen according to the established dose escalation schedule.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
9770141|NCT00889187|Experimental|Phase II: Photon Rad (MTD)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~Phase II participants received the radiation regimen established in the Phase I study (MTD).~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
9770142|NCT00889200|Experimental|Open-label Eszopiclone|Standard dosing of drug for 6 weeks for insomnia
9770143|NCT00889226|Experimental|Pitavastatin Group|
9770144|NCT00889226|Active Comparator|Atorvastatin Group|
9770145|NCT00889252|Experimental|K-Lens|Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug
9770146|NCT00889252|Placebo Comparator|Placebo Lens|Placebo lens
9770147|NCT00889265|Experimental|CopiOs Pericardium Membrane|Subject's study site must exhibit a partially edentulous ridge of the maxilla or mandible with at least one tooth-span in length and less than 5.5mm in its smallest buccolingual dimension as measured by ridge-mapping calipers.
9770148|NCT00889330|Experimental|alcaftadine ophthalmic solution|active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
9770149|NCT00889330|Placebo Comparator|inactive ophthalmic solution vehicle|Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
9770150|NCT00889512|Active Comparator|Luveris Fixed dose|Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
9785747|NCT01259128|Experimental|SER120 750 ng/day|SER120 Level 2 (750 ng/day)
10203702|NCT05179330|Experimental|Group A (no visual feedback-visual feedback)|Participants in group A (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® without visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® plus visual feedback
10203703|NCT05179330|Experimental|Group B (visual feedback-no visual feedback)|Participants in group B (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® plus visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® without visual feedback
10203704|NCT05178784||Active Stimulation|Adults exposed to active external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
10203705|NCT05178784||Sham Stimulation|Adults exposed to sham external Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation during the 8-week blinded treatment phase of the MOOD Clinical Trial (NCT04279522) who enrolled in this EEG substudy
10203706|NCT05178589|No Intervention|Control|During the control condition cycle (no TENS), participants will refrain from using or taking other analgesics, besides ibuprofen.
10203707|NCT05178589|Experimental|One Unit TENS|Participants will use one-unit TENS set-up where the TENS unit has 2 channels.
10203708|NCT05178589|Experimental|Two Unit TENS|Participants will use a two-unit TENS set-up where the TENS unit has 4 channels.
10203709|NCT05178225|Active Comparator|patients with post-COVID-19 syndrome with Mountain spa rehabilitation|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 15 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, for 16 to 18 days
10203710|NCT05178225|Active Comparator|patients with post-COVID-19 syndrome with Mountain spa rehabilitation + supplementation coenzyme Q10|patients with post-COVID-19 syndrome with Mountain spa rehabilitation: 22 patients with post-COVID-19 syndrome, 3-6 months after hospitalization were on Mountain spa rehabilitation (MR) in High Tatras, Tatranská Polianka, Slovakia, 22 patients who will be on spa rehabilitation and at the same time on supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg, for 16 to 18 days
10203711|NCT05178225|Placebo Comparator|healthy control|15 healthy control volunteers (no Covid-19 or other pathologies)
10203712|NCT05178173|Placebo Comparator|Sterile Water|Subject participants will rinse mouth one time for 60 seconds with 20 mL of sterile water.
10203713|NCT05178173|Active Comparator|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 20 mL 27% ethanol plus essential oils.
10203714|NCT05178173|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 20 mL 0.075% Cetylpyridinium Chloride.
9770151|NCT00889512|Experimental|Luveris increasing dose|Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
9770152|NCT00889603||1|
9770153|NCT00889681|Experimental|Ablation|All study subjects will be receive cryo ablation with the experimental devices and, optionally, an Atrial Fibrillation Drug.
9770154|NCT00889707|Experimental|Active Drug|PRX302
9770155|NCT00889707|Placebo Comparator|Placebo|Placebo
9770156|NCT00889720|Other|Smoking cessation tratment including varenicline|
9770157|NCT00889824|Experimental|prosthesis group|balance prosthesis
9770158|NCT00889863|Experimental|Canakinumab|In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
9770159|NCT00889863|Placebo Comparator|Placebo|Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
9770160|NCT00889915|Active Comparator|1|Participants will receive methylphenidate transdermal system.
9770161|NCT00889915|Active Comparator|2|Participants will receive lisdexamfetamine dimesylate.
9770162|NCT00889915|Active Comparator|3|Participants will receive osmotic-release oral system methylphenidate (OROS MPH).
9770163|NCT00889915|Active Comparator|4|Participants will receive mixed amphetamine salts extended release.
9770164|NCT00889928|Experimental|cholecystectomy|transvaginal cholecystectomy
9770165|NCT00890045|Active Comparator|Control graft|Conventional ePTFE hemodialysis graft
9770166|NCT00890045|Experimental|HeRO Vascular Access Device|HeRO Vascular Access Device
9770167|NCT00890084||Group1|
9770168|NCT00890097|Experimental|AL-8309B 1.0%|AL-8309B 1.0% Ophthalmic Solution, 1 drop in each eye twice daily for 30 months, up to a maximum of 36 months
9770169|NCT00890097|Experimental|AL-8309B 1.75%|AL-8309B 1.75% Ophthalmic Solution, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
9770170|NCT00890097|Placebo Comparator|Vehicle|AL-8309B Vehicle, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
9770171|NCT00890162|Active Comparator|Omalizumab|Subjects will receive two doses of Omalizumab while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
9770172|NCT00890162|Placebo Comparator|Placebo|Subjects will receive two doses of placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
9770173|NCT00890201||Normal Gallbladder|"Patients with normal gallbladder (without gallstones) evidenced by preoperative ultrasonography (and postoperative biopsy) submitted to elective gastroesophageal surgery (gastrectomy for gastric cancer, bariatric surgery or esophageal surgery such as Nissen plicature or miotomy for achalasia).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography. Preoperative values of amylase and lipase must be normal."
9770174|NCT00890201||Gallbladder with gallstones|"Patients submitted to elective cholecystectomy for diseased gallbladders (gallbladder with gallstones evidenced by preoperative ultrasound).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography and the preoperative amylase and lipase levels must also be normal."
9784455|NCT01225835|Active Comparator|Follitrophin Alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
9770175|NCT00890396||Active Follow-up|An active follow-up involved the performance of many of the laboratory tests and procedures done during BABY HUG clinical trials study. These included, but not limited to, serial laboratory parameters that were not part of routine clinical care such as Hgb F levels, pitted cell count, Howell-Jolly Body determination, a liver-spleen scan, diethylenetriaminepentaacetic acid (DTPA) glomerular filtration rate (GFR) measurement, creatinine clearance, Cystatin C, urine concentrating ability, transcranial Doppler, and neuropsychological testing.
9770176|NCT00890396||Passive Follow-up|A passive follow-up involved the abstraction of clinical data from the medical record. Results of physical examinations and laboratory tests performed as part of routine clinical care were recorded.
9770177|NCT00890552|Experimental|Lenalidomide+Melphalan+Dexamethasone|Patients received lenalidomide 10 mg/day orally on days 1-21, melphalan 0.18 mg/kg orally on days 1-4, and dexamethasone 40 mg orally once weekly of a 28-day cycle (MDR treatment).
9770178|NCT00890617|Experimental|Prednisone & Cryotherapy|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
9770179|NCT00890656|Experimental|Augmented Hyper-CVAD|Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.
9770180|NCT00890682|Experimental|Sky0402|Injection of Study Drug
9770181|NCT00890682|Placebo Comparator|Placebo|Injection of study drug
9770182|NCT00890695|Active Comparator|Ready to use supplementary food (RUSF)|The RUSF intervention consists of a food paste made of maize, soya, sorghum, vegetable oil, sugar, dried skim milk and vitamin/mineral premix, prepared by VALID Nutrition in collaboration with Insta Products, Kenya in accordance with composition specified by the latest WHO expert consultation in 2008. Children in the intervention arm receive 4 weeks supply of RUSF. The amount supplied is based on the child's weight to give energy supplement of 100kcal per kg per day, equivalent to 25g RUSF per kg per day.
9770183|NCT00890695|No Intervention|Normal diet (standard of care)|For equity, parents or guardians of children in the usual diet arm will be given 2 bags of maize meal(4Kg) for family consumption instead of RUSF. All parents and carers in both arms will also receive standard nutritional advice as specified in the current WHO IMCI handbook.
9770184|NCT00890721|Experimental|SKY0402|During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.
9770185|NCT00890721|Placebo Comparator|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
9770186|NCT00890825|Active Comparator|AZD6244 + Docetaxel|AZD6244 75 mg bd + Docetaxel 75 mg/m^2
9770187|NCT00890825|Placebo Comparator|Placebo + Docetaxel|Placebo + Docetaxel 75 mg/m^2
9770188|NCT00890916|Experimental|Neuroprosthesis System|Receives implanted device for hand function.
9770189|NCT00890929|Experimental|Azacitidine followed by lenalidomide|Dose escalation then dose expansion
9770190|NCT00890981|Other|Arm 1|Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.
9770191|NCT00891020|Experimental|Tocilizumab 8 mg/kg Monotherapy|Participants received Tocilizumab 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
9770192|NCT00891020|Experimental|Tocilizumab 4 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 4 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants not achieving a 20% improvement from baseline in tender and swollen joint counts at Week 8 were to have their dosage increased to 8 mg/kg, per protocol. Beginning at Week 12 dosage increase to 8 mg/kg was at the discretion of the investigator. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
9770193|NCT00891020|Experimental|Tocilizumab 8 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
9770194|NCT00891046|Experimental|Canakinumab|Canakinumab
9770195|NCT00891176|Experimental|Synflorix-Meningitec Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age. 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
9770196|NCT00891176|Experimental|Synflorix-NeisVac-C Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
9784456|NCT01225887|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9784457|NCT01225926|Experimental|Toric T3 - T9|AcrySof IQ Toric IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
10203715|NCT05178134|Active Comparator|The wet formulation of ETVAX.|The wet formulation consists of a liquid suspension of inactivated bacteria (ETEX 21-24) and LCTBA in one vial, freeze-dried dmLT adjuvant in a second vial, and effervescent buffer granules in a separate sachet. Prior to administration, the buffer is dissolved in 150 ml tap water, followed by the addition of the content of the vaccine vial (inactivated bacteria mixed with LCTBA) and reconstituted and diluted adjuvant dmLT from the second vial.
9770197|NCT00891176|Experimental|Synflorix-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
9770198|NCT00891176|Active Comparator|Prevenar-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
9770199|NCT00891202|Experimental|Active|Eliglustat
9770200|NCT00891202|Placebo Comparator|Placebo|Placebo
9770201|NCT00891228|Placebo Comparator|Testosterone Gel 10 g and Nestorone® 0 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
9770202|NCT00891228|Experimental|Testosterone Gel 10 g and Nestorone® 8 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.
9770203|NCT00891228|Experimental|Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
9770204|NCT00891293|Experimental|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
9770205|NCT00891319|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Electrical stimulator~Stimulation to finger and thumb extensors only in response to, and with an intensity proportional to, opening of the contralateral unimpaired hand.~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity.~Therapy sessions are done with the subject being assisted by the CCFES system."
9770206|NCT00891319|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation~Electrical stimulator~Preprogrammed cycles of finger and thumb extensor stimulation repeatedly and automatically open the hand.~Subject instructed to not move the contralateral arm/hand during stimulation.~Therapy sessions are done without the stimulation system."
9770207|NCT00891371|Experimental|lanreotide (Autogel formulation) Autogel 120mg|lanreotide (Autogel formulation) Autogel 120mg
9770208|NCT00891436|Placebo Comparator|Placebo nasal spray|
9770209|NCT00891436|Active Comparator|Fluticasone furoate nasal spray|
9770210|NCT00891462|Experimental|1|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
9770211|NCT00891462|Experimental|2|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
9770212|NCT00891462|Placebo Comparator|3|Inhaled placebo for 12 weeks
9770213|NCT00891527|Experimental|Avastin and/or Gleevec|Patients were all treated with Gleevec (imatinib mesylate) and those without congenital heart disease and those who progressed were also treated with Avastin (bevacizumab).
9770214|NCT00891618|Experimental|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
9770215|NCT00891657|Experimental|SprayShield™|SprayShield™
9770216|NCT00891657|No Intervention|Control|No adhesion barrier administered.
9770217|NCT00891735|Experimental|Ranibizumab 0.5 mg monthly|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
9770218|NCT00891735|Experimental|Ranibizumab 2.0 mg monthly|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.
9770219|NCT00891735|Experimental|Ranibizumab 0.5 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
9770220|NCT00891735|Experimental|Ranibizumab 2.0 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.
9770221|NCT00891774|Experimental|Device|Treatment with EVOLENCE®
9770222|NCT00891813|Experimental|Zemplar (paracalcitol)|
9770223|NCT00891839|Experimental|Bendamustine+Rituximab|Patients receive bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2, and 375 mg/m^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).
9770224|NCT00891878|Experimental|Arm I|Patients receive oral capecitabine twice daily on days 1-14. Patients experiencing disease progression may crossover to arm II at the physician's discretion.
9770225|NCT00891878|Experimental|Arm II|Patients receive oral capecitabine as in arm 1 and oral sunitinib malate once daily on days 1-21.
9770226|NCT00891930|Experimental|Panitumumab|Participants received panitumumab (6 mg/kg starting dose) with irinotecan (starting dose of 180 mg/m²) every 2 weeks (Q2W) during Part 1. Upon radiographically confirmed disease progression, participants proceeded to Part 2 of the study and received treatment with panitumumab (6 mg/kg starting dose) and ganitumab (12 mg/kg starting dose) Q2W.
9770227|NCT00891982|Experimental|CTGel plus BPO wash|Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening
9770228|NCT00891982|Active Comparator|CTGel|Soap Free Cleanser in the morning and CTGel in the evening
9770229|NCT00891995|Experimental|Intensive Treatment|closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
9770230|NCT00891995|Active Comparator|Standard Treatment|home glucose monitoring (2 years)
9770231|NCT00892008||Open-Label|This study was open-label with only one treatment group. Pregabalin was prescribed in accordance with usual clinical practice.
9770232|NCT00892047|Experimental|1: venlafaxine plus aripiprazole|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
9770233|NCT00892047|Experimental|2: Placebo Comparator|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
9770234|NCT00892099|Experimental|High Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol weekly
9770235|NCT00892099|Experimental|Low Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol per month
9770236|NCT00892099|Placebo Comparator|Placebo|Receives no ergocalciferol
9770237|NCT00892151|Experimental|Intended Users of the Software|10 Healthcare Professionals and 40 persons with diabetes (of which 6 were parents/legal guardians of children with diabetes) using a diabetes data management program.
9770238|NCT00892177|Experimental|Arm I|Patients receive bevacizumab on Day 1 and dasatinib on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9770239|NCT00892177|Active Comparator|Arm II|Patients receive bevacizumab on Day 1 and placebo on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9770240|NCT00892281|Other|Oracea® as monotherapy|Oracea as monotherapy
9770241|NCT00892281|Other|Oracea® as add-on therapy|Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides
9770242|NCT00892437|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo +ATV+FTC/TDF for 48 weeks
9770243|NCT00892437|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo +ATV+FTC/TDF for 48 weeks
9770244|NCT00892606|Experimental|Methadone|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
9770245|NCT00892606|Active Comparator|Control|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)
9770246|NCT00892697|Experimental|Arm|15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin
9770247|NCT00892710|Experimental|Pemetrexed/Bevacizumab|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days"
9770248|NCT00892710|Experimental|Pemetrexed/Bevacizumab/Carboplatin|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days~Carboplatin AUC=5 IV every 21 days"
9770249|NCT00892710|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
9770250|NCT00892723|Experimental|Low Dose|
9770251|NCT00892723|Experimental|High Dose|
9770252|NCT00892723|Placebo Comparator|Placebo|
9770253|NCT00892775|Experimental|Priorix-Tetra new WS Group|Subjects received 2 doses of Priorix-Tetra vaccine formulated with new measles and rubella working seeds at Day 0 and Week 12.
9770254|NCT00892775|Experimental|Priorix-Tetra current WS Group|Subjects received 2 doses of Priorix-Tetra vaccine manufactured with current working seed virus at Day 0 and Week 12.
9770255|NCT00892957|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr will be applied to the study suture line.
9770256|NCT00892957|Active Comparator|Manual compression with surgical gauze pads|Dry gauze pads will be positioned to cover the complete study suture line.
9770257|NCT00893074|Other|0, 30, 60, and 120mg dronabinol|0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing
9770258|NCT00893113|Placebo Comparator|Placebo, Then Alfuzosin|Participants first received 1 Placebo tablet once daily for 12 weeks. Participants then received a 10 mg tablet of Alfuzosin daily for 12 weeks.
9770259|NCT00893113|Experimental|Alfuzosin, Then Placebo|Participants first received a 10 mg tablet of Alfuzosin once daily for 12 weeks. Participants then received 1 Placebo tablet once daily for 12 weeks.
9770260|NCT00893152||Group 1|Male veterans (focus groups and individual interviews)
9770261|NCT00893152||Group 2|Female veterans (focus groups and individual interviews)
9770262|NCT00893152||Group 3|Family members of participating veterans (focus groups and individual interviews)
9770263|NCT00893464|Experimental|IXAZOMIB|
9770264|NCT00893737|Experimental|Treximet|Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.
9770265|NCT00893763|Experimental|Pre-intubation CHX|Chlorhexidine applied to oral cavity prior to intubation
9770266|NCT00893763|Active Comparator|Control|No chlorhexidine applied to oral cavity prior to intubation
9770267|NCT00893971|Experimental|1|Inhaled PT001 18 μg
9770268|NCT00893971|Experimental|2|Inhaled PT005 2.4 μg
9770269|NCT00893971|Experimental|3|Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)
9770270|NCT00893971|Experimental|4|PT001 18 μg + PT005 2.4 μg
9770271|NCT00893984|Experimental|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
9770272|NCT00893997|Experimental|PR-1 vaccine|4 injections of 0.5 mg PR1 peptide vaccine every 3 weeks.
9770273|NCT00894127|Experimental|CyPath Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from two cohorts, including (1) high-risk control group comprised of individuals not diagnosed but at high risk for lung cancer (n=102) and, (2) cancer group comprised of individuals with confirmed lung cancer diagnosis (n=26), was labeled in exact manner with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
9770274|NCT00894166|Active Comparator|Nicotine Replacement Therapy Responder|Nicotine Responders
9770275|NCT00894166|Active Comparator|Pre-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches
9770276|NCT00894166|Active Comparator|Pre-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline)
9770277|NCT00894166|Active Comparator|Pre-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to continued use of nicotine patches
9770278|NCT00894166|Active Comparator|Post-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Zyban (bupropion) in combination with nicotine patches
9770279|NCT00894166|Active Comparator|Post-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Chantix (varenicline)
9770280|NCT00894166|Active Comparator|Post-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to continued use of nicotine patches
9770281|NCT00894322|Experimental|Cohort 1: Healthy Participants|A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.
9770282|NCT00894322|Experimental|Cohort 2: Diabetes Participants|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.
9770283|NCT00894322|Placebo Comparator|Cohort 2: Diabetes Participants Placebo|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.
9770284|NCT00894361|Active Comparator|rotating-platform design TKA|patients who were randomized to receive the rotating platform mobile-bearing TKA design
9770285|NCT00894361|Active Comparator|all-polyethylene tibia design TKA|patients who were randomized to receive the all-polyethylene tibial component design
9770286|NCT00894387|Experimental|Aliskiren|Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.
9770287|NCT00894387|Placebo Comparator|Placebo|Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
9770288|NCT00894413|Placebo Comparator|Placebo|
9770289|NCT00894413|Experimental|Tadalafil|Tadalafil 20 mg once per day
9770290|NCT00894465|Experimental|Versed|Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
9770291|NCT00894465|Placebo Comparator|Placebo|Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
9770292|NCT00894504|Experimental|Panitumumab/Gemcitabine/Carboplatin|Systemic therapy
9770293|NCT00894517|Experimental|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
9770294|NCT00894517|Placebo Comparator|Placebo (saline)|Placebo (saline) injected into the prostate on Day 1.
9770295|NCT00894543|Active Comparator|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
9770296|NCT00894543|Placebo Comparator|Placebo|Inactive pill
9770297|NCT00894647|Placebo Comparator|2|placebo cream in 250mg/packet, up to 2 packets applied daily
9770298|NCT00894647|Active Comparator|imiquimod cream|Imiquimod 3.75% cream, 250 mg single-use packets, up to 2 packets applied daily
9770299|NCT00894686|Experimental|All subjects|Assessment of seropersistence of TBE antibodies at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (in Study 700401), as well as antibody response to a second booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL, depending on the subject´s age. Timing of the second booster vaccination will depend on the level of serum TBE antibodies detected at the defined assessment time points. Subjects who are not protected against TBE for an entire further season (NT titer <= 20 and/or ELISA value <=126 VIE U/mL) will be invited to receive the second booster vaccination at either the 40, 48, 60, 72, 84, 96, 108, or 120-month time point.
9770300|NCT00894699|Active Comparator|1|single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
9770301|NCT00894699|Placebo Comparator|2|single dose of sublingual Placebo NanoTab™
9770302|NCT00894738||antipsychotic treated|Children with psychiatric diagnoses who are currently treated with antipsychotic medications.
9770303|NCT00894738||healthy control|Age- and gender-matched children who do not have a psychiatric diagnosis, are not taking antipsychotic medications, and are otherwise healthy.
9770304|NCT00894803|Active Comparator|rt-PA only|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA given over 60 minutes. One out of 6 subjects will be in this group.
9770305|NCT00894803|Experimental|rt-PA and Eptifibatide|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA. This IV dose will be discontinued at 40 minutes. The subject will immediately receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours. Five out of six subjects will be in this group.
9770306|NCT00894933|Experimental|Continuum|Verify the consistency of performance of the AMS CONTINUUM device in facilitating a sustainable anastomosis following a radical prostatectomy using updated Device design elements and Physician training materials on Device implant technique.
9770307|NCT00895011|Placebo Comparator|Placebo|
9770308|NCT00895011|Experimental|Avanafil 100 mg|
9770309|NCT00895011|Experimental|Avanafil 200 mg|
9770310|NCT00895037||1|Patients treated with Refacto AF
9770311|NCT00895154|Active Comparator|General Tutoring Group|Participants will receive general tutoring in the subject of his/her choice.
9770312|NCT00895154|Experimental|Tutoring + Memory Training Group|Participants will receive tutoring and memory training.
9770313|NCT00895180|Experimental|Group 1|Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9770314|NCT00895180|Experimental|Group 2|Patients receive olaratumab IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9770315|NCT00895193|Active Comparator|Apple-pectin 2000mg|Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
9770316|NCT00895193|Active Comparator|Regular Non-enteric coated aspirin 325mg|Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
9770317|NCT00895193|Active Comparator|Apple pectin + aspirin|Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
9770318|NCT00895193|Placebo Comparator|Placebo Comparator|Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
9770319|NCT00895232|Experimental|Cohort I|500 mg dose Venofer over 4 hours
9770320|NCT00895232|Experimental|Cohort II|500 mg Venofer infusion over 4-6 hours on Day 0 and repeated on Day 2 to 7
9770321|NCT00895232|Experimental|Cohort III|500 mg Venofer over 6 hours, followed within 24 hours by 500 mg Venofer over 6 hours
9770322|NCT00895245|Experimental|Arm I|"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients also undergo radiotherapy once daily 5 days a week for up to 7 weeks.~Patients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients then receive oral dexamethasone on days 2-4. Patients with no emesis or requirement for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.~Patients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion."
9770323|NCT00895310|Experimental|Ketoconazole and Hydrocortisone|Ketoconazole 200mg PO TID + Hydrocortisone 20mg PO Qam, 10mg PO Qpm
9770324|NCT00895414|Experimental|Doxorubicin alone first, then Doxorubicin with Enalapril|Patients receive doxorubicin hydrochloride IV over 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2.
9770325|NCT00895414|Experimental|Doxorubicin with Enalapril first, then Doxorubicin alone|Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
9770326|NCT00895453|Active Comparator|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid).
9770327|NCT00895453|Active Comparator|itraconazole + lactobacilli agent|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). Additionally, Lactobacillus vaginal tablets monthly given through 6 days.
9770328|NCT00895453|Active Comparator|classic homeopathy (CH)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
9770329|NCT00895531|Active Comparator|Peripheral Nerve group|Group will receive sciatic catheter placed before or after surgery by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
9770330|NCT00895531|Experimental|Depodur Group|patients will have an L2-L3 epidural placed while they are in the sitting position before or after femoral catheter placement. They will receive 7.5 mg Depodur via the epidural catheter. All of these patients will receive Singular 10 mg and Claritin 10 mg before the epidural Depodur is placed, as per our protocol of patients receiving EREM.
9770331|NCT00895583|Experimental|Group I - Planned transition to sirolimus from tacrolimus|
9770332|NCT00895583|Active Comparator|Group II - Continuation of tacrolimus|
9770333|NCT00895622|No Intervention|Low Risk|No treatment given.
9770334|NCT00895622|Experimental|Intermediate Risk|54 Gy radiotherapy
9770335|NCT00895622|Experimental|High Risk|60 Gy radiotherapy
9770336|NCT00895661|Other|rituximab|single-arm, open-label, interventional
9770337|NCT00895752|Experimental|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
9770338|NCT00895817|Active Comparator|Swallowed fluticasone|
9770339|NCT00895817|Active Comparator|Esomeprazole|
9770340|NCT00895830|Placebo Comparator|1|
9770341|NCT00895830|Experimental|2|0.3mg dose level
9770342|NCT00895830|Experimental|3|1mg dose level
9770343|NCT00895830|Experimental|4|2mg dose level
9770344|NCT00895830|Experimental|5|3mg dose level
9770345|NCT00895843|Active Comparator|Conventional ibuprofen|
9770346|NCT00895843|Experimental|Brufen retard|
9770347|NCT00895895|Placebo Comparator|1|Placebo
9770348|NCT00895895|Experimental|2|SAM-531 1.5 mg
9770349|NCT00895895|Experimental|3|SAM-531 3.0 mg
9770350|NCT00895895|Experimental|4|SAM-531 5.0 mg
9770351|NCT00895895|Active Comparator|5|Donepezil
9770352|NCT00895921|Active Comparator|Aripiprazole|Participants will receive an injection of aripiprazole during the tracer-clamp study.
9770353|NCT00895921|Active Comparator|Olanzapine|Participants will receive an injection of olanzapine during the tracer-clamp study.
9770354|NCT00895934|Experimental|Phase 1 - Dose Finding|Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. Includes cohorts 1-3.
9770355|NCT00895934|Experimental|Phase 2 - Treatment at Selected Dose|Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, gemtuzumab ozogamicin 3 mg/m2/day on days 4 and 8.
9770356|NCT00895947|Experimental|Interferon-alpha|150 international units of interferon-alpha
9770357|NCT00895947|Placebo Comparator|placebo|placebo lozenges
9770358|NCT00896012|Experimental|1. Low-dose tacrolimus arm|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months). All patients will undergo a second protocol biopsy at 12 months.
9770359|NCT00896012|Experimental|2. Rapamune conversion arm:|Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy. Tacrolimus will be withdrawn progressively over a period of 7-10 days. Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued. Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
9770360|NCT00896038|Experimental|Aprepitant|Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant orally daily for 21 days
9770361|NCT00896038|Placebo Comparator|Placebo|Subjects received oral placebo during the 1-week placebo lead-in and then daily for 21 days
9770362|NCT00896051|Experimental|ATV/rtv 300/100 mg (Treatment A)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pre-treatment followed by ATV/rtv 300/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will receive TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
9770363|NCT00896051|Experimental|ATV/rtv 400/100 mg (Treatment B)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pretreatment followed by ATV/rtv 400/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will take TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
9770364|NCT00896064|Experimental|Formulation 1|
9770365|NCT00896064|Experimental|Formulation 2|
9770366|NCT00896168|Experimental|Infliximab + Methotrexate (Moderate RA)|Participants with moderate RA (score greater than 3.2, but less than 5.1 on the disease activity score [DAS] 28) received infliximab 3 milligram per kilogram (mg/kg) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at Week 0, 2, 6, 14 and 22 along with oral MTX IN a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 weeks.
9770367|NCT00896168|Experimental|Infliximab + Methotrexate (Severe RA)|Participants with severe RA (score greater than 5.1 on the DAS 28) received infliximab 3 mg/kg intravenous infusion at Week 0, 2, 6, 14 and 22 along with oral MTX in a stable dose of 7.5 to 20 mg per week (mg/week) equal to the dose used before participation in the study) for 22 weeks.
9770368|NCT00896181|Experimental|Chemoradiation for Nasopharyngeal Carcinoma|"INDUCTION THERAPY: Patients receive docetaxel intravenously (IV) over 60 minutes on Day 1; cisplatin IV over 1 to 3 hours (or carboplatin IV over 30 minutes) on Day 1; and fluorouracil IV continuously over 24 hours on Days 1 to 5. Each cycle is 21 days, with treatment consisting of up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMO-RADIOTHERAPY: Beginning within 3 to 6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5 to 7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1 to 6 in the absence of disease progression or unacceptable toxicity."
9770369|NCT00896233|Experimental|MRE|
9770370|NCT00896298|Active Comparator|1 Leptin|Active Comparator for 4 months, then for 8 months.
9770371|NCT00896298|Placebo Comparator|2 Sugar pill|Placebo for 4 months, then active comparator for 8 months.
9784458|NCT01225926|Active Comparator|IQ SN60WF|AcrySof IQ IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
9784459|NCT01225952|Experimental|Crystalens AO|Bausch & Lomb silicone multi-piece accommodating IOL is a modified plate haptic lens
9770372|NCT00896337|Experimental|ORION|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System.
9770373|NCT00896363|Active Comparator|Active|Parallel Group - High Dose Arm, Low Dose Arm
9770374|NCT00896363|Placebo Comparator|Placebo|Parallel Group
9770375|NCT00896441|Experimental|Depressed patients|Depressed patients assigned in an open-label study of citalopram
9770376|NCT00896441|No Intervention|Controls|Healthy controls used as a comparison (no intervention) group for change in resting-state fMRI over time
9770377|NCT00896454|Experimental|denosumab|Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
9770378|NCT00896480|Experimental|GSK2132231A Group|Subjects, male or female, 18 years of age or older, received up to 24 doses of GSK2132231A intramuscularly in 4 cycles. In Cycle 1 (ending Week 13) 6 doses were administered at 2-week intervals; in Cycle 2 (ending Week 32) 6 doses at 3-week intervals; in Cycle 3 (ending Week 54) 4 doses at 6-week intervals and in Cycle 4 4 doses at 12-week intervals, starting 12 weeks after end of Cycle 3, followed by, after an interruption of treatment of 6 months, 4 doses at 24-week intervals.
9770379|NCT00896532|Placebo Comparator|Placebo|"Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
9770380|NCT00896532|Active Comparator|Alendronate|"Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation."
9770381|NCT00896532|Active Comparator|Teriparatide|Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
9770382|NCT00896532|Experimental|Romosozumab 70 mg QM|"Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
9770383|NCT00896532|Experimental|Romosozumab 140 mg Q3M|"Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
9770384|NCT00896532|Experimental|Romosozumab 140 mg QM|"Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
9770385|NCT00896532|Experimental|Romosozumab 210 mg Q3M|"Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
9770386|NCT00896532|Experimental|Romosozumab 210 mg QM|"Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
9770387|NCT00896649|Experimental|positron emission mammography|questionnaire administration digital mammography positron emission mammography
9770388|NCT00896779|Other|ranibizumab Group 1|Group 1: 3 monthly injections of 0.5mg then prn
9770389|NCT00896779|Other|ranibizumab Group 2|Group 2: 6 monthly injections of 0.5 mg then prn
9770390|NCT00897390|Other|Arm A|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
9770391|NCT00897390|Other|Arm B|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
9770392|NCT00897390|Other|Arm C|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
9770393|NCT00897390|Other|Arm D|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
9770394|NCT00897676|Other|Vehicle first, then Exendin-(9-39)|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
9770395|NCT00897676|Other|Exendin-(9-39) first then Vehicle.|"An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.~."
9770396|NCT00897715|Active Comparator|Interleukin-1 receptor antagonist|active drug
9770397|NCT00897715|Placebo Comparator|Placebo|matching placebo
9770398|NCT00897897|Other|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure receive a treatment with the Philips MRI-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
9770399|NCT00898222|Experimental|aspirin|Low dose daily aspirin in healthy volunteers for two weeks
9770400|NCT00898443|Other|Spinal Anesthetic Group|This group will receive spinal anesthetic for the surgical procedure and will serve as the control group for this study.
9770401|NCT00898443|Experimental|Epidural Anesthetic Group|This is the experimental group for this study.
9770402|NCT00898560|Other|Microginon®|A single oral dose of a combined oral contraceptive containing 30ug ethinyloestradiol and 150ug levonorgestrel (Microginon ®).
9770403|NCT00898560|Experimental|ESL and Microginon®|15-day treatment with ESL 800 mg once daily, with co administration of a single oral dose of Microginin® on Day 14 of the relevant dosing period, to assess impact of ESL on pharmacokinetics of the combined oral contraceptive.
9770404|NCT00898807|Experimental|Citalopram and psychosocial intervention|Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
9770405|NCT00898807|Placebo Comparator|Placebo and psychosocial intervention|Matching placebo, oral, and psychosocial intervention
9770406|NCT00899353|Experimental|Omega 3 supplement|Omega 3 supplement will be added to diet, 3 capsules per day for one month then 6 capsules per day for one month then 9 capsules per day as tolerated
9770407|NCT00899392|Experimental|Electronic Assisted Consent|Standard procedural consent performed by pediatric gastroenterologist plus assistance from computerized emmi module.
9770408|NCT00899392|No Intervention|Control Consent|Standard procedural consent as performed by pediatric gastroenterologists
9770409|NCT00899431|Active Comparator|Group 1: Lenalidomide|Chemotherapy, Plus Lenalidomide - Lenalidomide starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months. Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine). Allopurinol 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
9770410|NCT00899431|Active Comparator|Group 2: No Lenalidomide|Chemotherapy Treatment, No Lenalidomide - Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
9770411|NCT00899470|Experimental|S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)|Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M [fasted]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M [fed]) followed by S/M under fasting conditions (S/M [fasted]) followed by S + M under fed conditions (S + M [fed])
9770412|NCT00899470|Experimental|S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)|Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
9770413|NCT00899470|Experimental|S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)|Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
9770414|NCT00899470|Experimental|S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)|Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)
9770415|NCT00899548||Metastatic breast cancer patients|DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
9770416|NCT00899574|Experimental|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
9770417|NCT00899600|Placebo Comparator|Normal saline|
9770418|NCT00899600|Experimental|Ketamine|
9770419|NCT00899678|Active Comparator|Maintenance High-Dose|Maintenance High-Dose group: 400 mg Certolizumab Pegol for subjects ≥ 40 kg or 200 mg Certolizumab Pegol for subjects 20 to < 40 kg
9770420|NCT00899678|Active Comparator|Maintenance Low-Dose|Maintenance Low-Dose group: 200 mg Certolizumab Pegol for subjects ≥ 40 kg or 100 mg Certolizumab Pegol for subjects 20 to < 40 kg
9770421|NCT00899717|Experimental|A|
9770422|NCT00899717|Placebo Comparator|B|
9770423|NCT00899847|Experimental|Autologous-Allogeneic Peripheral Blood Stem Cell Transplant|Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
9770424|NCT00900029||No HP802 Treatment|Treatment received in Study 802-247-09-015 was HP802
9770425|NCT00900029||No HP802 Vehicle Treatment|Treatment received in Study 802-247-09-015 was HP802 Vehicle
9770426|NCT00900146|Experimental|Canakinumab 5 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 5 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
9770427|NCT00900146|Experimental|Canakinumab 15 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 15 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
9770428|NCT00900146|Experimental|Canakinumab 50 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 50 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
9770429|NCT00900146|Experimental|Canakinumab 150 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 150 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
9770430|NCT00900146|Placebo Comparator|Placebo + Metformin|In 4 month dose finding period as well as during intermediate period, patients received one injection of canakinumab matching placebo monthly and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations).
9770431|NCT00900159|Experimental|eszopiclone|Treatment with eszopiclone
9770432|NCT00900159|Placebo Comparator|matching placebo|Treatment with matching placebo
9770433|NCT00900237|Active Comparator|Eslicarbazepine acetate|Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9
9770434|NCT00900237|Active Comparator|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9
9770435|NCT00900562|Experimental|Arm 1|Zalypsis (PM00104)
9770436|NCT00900601|Experimental|Sacroilliac fusion|Pastient are treated with sacroiliac joint arthrodesis to the sacroiliac joint and symphysis
9770437|NCT00900627|Experimental|1|AZD8931 plus Paclitaxel
9770438|NCT00900627|Placebo Comparator|2|Placebo plus Paclitaxel
9770439|NCT00900666|Placebo Comparator|Saline injection|
9770440|NCT00900666|Experimental|Botulinum toxin injection|
9770441|NCT00900731|Experimental|Indacaterol 150 µg|Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
9770442|NCT00900731|Active Comparator|Tiotropium 18 µg|Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
9770443|NCT00900757|Experimental|Palonosetron|Single Arm trial of Palonosetron for the prevention of RINV in primary malignant glioma patients receiving radiation therapy (RT) and concomitant temozolomide (TMZ)
9770444|NCT00900796||1|Patients diagnosed with active AS who start anti-TNF therapy according to standard clinical practice.
9770445|NCT00900822|Experimental|Straumann Bone Ceramic|StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures
9770446|NCT00900822|Active Comparator|BioOss|BioOss is used as a bone grafting material in sinus augmentation procedure
9770447|NCT00901017|Active Comparator|Straumann BoneCeramic|Straumann BoneCeramic
9770448|NCT00901017|Active Comparator|Bio-Oss|Geistlich Bio-Oss
9770449|NCT00901186|Experimental|RFB002|RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.
9770450|NCT00901186|Active Comparator|Laser photocoagulation|At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
9770451|NCT00901199|Experimental|Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects received Deferasirox (Exjade) and Deferoxamine (DFO) dosing based on the iron overload at baseline.
9770452|NCT00901225|Experimental|G-CSF plus Plerixafor|Patients who were unable to mobilize a minimum number of cells (CD34+ cell count <20 cells/ul)following 5 days of G-CSF mobilization.
9770453|NCT00901316|Experimental|Routine Measures|
9770454|NCT00901316|Experimental|Bleach Baths|
9770455|NCT00901342|Experimental|Sipuleucel-T|Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
9770456|NCT00901394|Experimental|Treatment 1|B12-Folic acid, nitrous oxide
9770457|NCT00901394|Active Comparator|Treatment 2|Nitrous oxide (NO) and placebo
9770458|NCT00901394|Placebo Comparator|Control group|oxygen nitrogen
9770459|NCT00901459|Active Comparator|rTMS 90% MT - Low frequency rTMS|Intervention type: device. Intervention description: low frequency rTMS was administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues using 90% MT (Motor Threshold) 1 Hz rTMS Dose on Superior Frontal Gyrus
9770460|NCT00901459|Active Comparator|Location Control|rTMS Dosing: 90% MT (Motor Threshold) 1 Hz rTNS Location: Motor Cortex
9770461|NCT00901459|Active Comparator|Frequency Control|rTMS Dosing: 90% MT (Motor Threshold) 10 Hz rTNS Location: Superior Frontal Gyrus
9770462|NCT00901485|Experimental|autotitrating NIV|approximately 6 weeks using domiciliary nocturnal autotitrating non-invasive ventilation
9770463|NCT00901485|Active Comparator|Standard non-invasive ventilation|approximately 6 weeks using domiciliary nocturnal standard non-invasive ventilation
9770464|NCT00901576|Experimental|SPD503|
9770465|NCT00901576|Active Comparator|Concerta|
9770466|NCT00901576|Active Comparator|SPD503 + Concerta|
9770467|NCT00901628|Experimental|Periarticular Injection group|Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime
9770468|NCT00901628|No Intervention|No Injection group|usual postoperative care without periarticular injection
9770469|NCT00901901|Experimental|Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)|Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)
9770470|NCT00901901|Active Comparator|Sorafenib (Nexavar, BAY43-9006) + Placebo|Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)
9770471|NCT00901927|Experimental|Bendamustine + Mitoxantrone + Rituximab|Bendamustine starting dose 90 mg/m^2 intravenously (IV) over 30-60 minutes on Days 1 and 2 of each 8-day cycle. Mitoxantrone 10 mg/m^2 IV over 15 minutes on Day 2 of each cycle. Rituximab 375 mg/m^2 IV over several hours on Day 1 of each cycle.
9770472|NCT00902018|Experimental|eltrombopag|10 ITP patients were treated with daily oral eltrombopag 75mg for 2 weeks and complete testing was done at weekly intervals 3 times they then were allowed to receive long-term eltrombopag
9770473|NCT00902018|Experimental|romiplostim|3 of the patients who received eltrombopag were also treated with romiplostim 10 micrograms/kg weekly for 2 weeks with the same complete testing done at weekly intervals three times after a washout period > 1 month they then resumed long-term eltrombopag
9770474|NCT00902018|Sham Comparator|healthy controls|no intervention single blood draw with complete studies
9770475|NCT00902161|Experimental|Propanolol + Placebo > Propanolol + MK0893|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8).
9770476|NCT00902161|Placebo Comparator|Propanolol + MK0893 > Propanolol + Placebo|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8).
9770477|NCT00902174|Experimental|imatinib mesylate|Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.
9770478|NCT00902174|Placebo Comparator|Placebo|Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.
9770479|NCT00902226|Experimental|Escitalopram|
9770480|NCT00902265||desmopressin|"Participants with benign prostate syndrome suffering from nocturia associated with nocturnal polyuria.~Drug given by prescription."
9770481|NCT00902278|Active Comparator|Flulaval|
9770482|NCT00902278|Active Comparator|Fluvirin|
9770483|NCT00902278|Active Comparator|Fluzone|
9770484|NCT00902278|Active Comparator|Fluarix|
9770485|NCT00902278|Active Comparator|Affluria|
9770486|NCT00902304|Active Comparator|Usual care|Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
9770487|NCT00902304|Experimental|Monotherapy (initial monotherapy arm)|Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
9784460|NCT01225952|Active Comparator|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
9784461|NCT01225952|Active Comparator|AMO Tecnis Multifocal|A foldable hydrophobic acrylic IOL,(Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL
9770488|NCT00902304|Experimental|Combination (initial combination therapy arm)|Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
9770489|NCT00902330|Experimental|Arm I (cranial microcurrent electrical stimulation [CES])|Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
9770490|NCT00902330|Sham Comparator|Arm II (sham CES)|Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
9770491|NCT00902486|Experimental|INCB028050 4 mg QD|INCB028050 4mg Once daily (QD)
9770492|NCT00902486|Experimental|INCB028050 7 mg QD|INCB028050 7mg QD
9770493|NCT00902486|Experimental|INCB028050 10 mg QD|INCB028050 10mg QD
9770494|NCT00902486|Placebo Comparator|Placebo|Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.
9770495|NCT00902538|Experimental|Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg|The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.
9836096|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence BCA|B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
10203716|NCT05178134|Active Comparator|The partially dried formulation of selected components of ETVAX.|The partially dried formulation, dmLT and LCTBA are spray-dried and mixed with the buffer granules and stabilizing excipients in a sachet. Prior to administration, the content of the buffer sachet (buffer, dmLT, and LCTBA) is dissolved in 150 ml tap water, followed by the addition of a liquid suspension of inactivated bacteria (ETEX 21-24).
10203717|NCT05177484|Experimental|Ferric maltol|
10203718|NCT05177484|No Intervention|Standard Care|
10203719|NCT05177471||SSc-ILD patients with JAK inhibitors|
10203720|NCT05176132||OBESE (BMI>30)|BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year.
10203721|NCT05176132||CONTROL Normal weight (BMI 20-25)|100 persons with normal weight (BMI 20 - 25 kg/m2) 18 to 60 years of age
10203722|NCT05176132||CONTROL Overweight (BMI 25-30)|100 persons with overweight (BMI 25 - 30 kg/m2) 18 to 60 years of age
10203723|NCT05175820||Dentists|"Graduated from the Faculty of Dentistry,~Continuing/not continuing dental education (master, doctor, doctorate) after graduation,~Working in practice or outpatient clinic, private or public hospital, private polyclinic or public health or university hospital,~Dentists who registered in Turkish Dental Association"
10203724|NCT05174871|Active Comparator|Active control|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months
10203725|NCT05174871|Experimental|Time-Restricted Feeding|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months. During this time, participants will have their feeding time restricted to 8 hours per day.
10203726|NCT05174338||AL and TTR amyloidosis|immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR)
10203727|NCT05172609|Experimental|Exposure Based Implementation Strategy (EBIS)|EBIS is informed by the latest science in exposure theory, borrowing heavily from brief exposure-based treatments that can be delivered in a single session. We anticipate that EBIS will occur in four phases that map on to standard exposure therapy practice for patients with anxiety disorders: psychoeducation, assessment, practice, and relapse prevention; however, the final version will depend on the outcomes of the preparatory phases of this study. Clinicians assigned to the EBIS arm will also receive all elements of IAU.
10203728|NCT05172609|Active Comparator|Implementation as Usual (IAU)|Gold-standard IAU for SSAIs typically comprises pre-implementation preparation, didactic training, knowledge tests, experiential role plays, ongoing expert consultation, and providing certification status to clinicians who attain established benchmarks. Pre-implementation preparation will include provision of materials. Didactic training will occur in two parts: (1) suicide screening and assessment, and (2) Safety Planning Intervention (SPI) use. Part one will consist of materials we previously developed based on community clinician feedback. Part two will follow established SPI guidelines, including didactic training about SPI rationale and evidence base and experiential practice. IAU also will include supports for electronic health record integration (e.g., previously developed templates). After training, clinicians will receive 8 weeks of expert consultation to discuss implementation barriers and receive more role play practice.
10203729|NCT05170997|Active Comparator|Iodine Control|Participants taking an iodine-containing multivitamin or supplement and randomly allocated not to receive milk supply.
10203730|NCT05170997|Active Comparator|No Iodine Control|Participants not taking an iodine-containing multivitamin or supplement and randomly allocated not to receive milk supply.
10203731|NCT05170997|Experimental|Iodine Intervention|Participants taking an iodine-containing multivitamin or supplement and randomly allocated to receive milk supply.
10203732|NCT05170997|Experimental|No Iodine Intervention|Participants not taking an iodine-containing multivitamin or supplement and randomly allocated to receive milk supply.
10203733|NCT05170867|Experimental|Probiotic group|Two capsules of Hafnia alvei HA4597™ probiotic/day (5 x 107 CFU/day) for 60 days
10203734|NCT05170867|Placebo Comparator|Placebo group|Two identical capsules of placebo/day for 60 days
10203735|NCT05167279|Placebo Comparator|JS026/placebo 30 mg|4 patients will be enrolled in this arm.
10203736|NCT05167279|Placebo Comparator|JS026/placebo 100 mg|4 patients will be enrolled in this arm.
10203737|NCT05167279|Placebo Comparator|JS026/placebo 300 mg|8 patients will be enrolled in this arm.
10203738|NCT05167279|Placebo Comparator|JS026/placebo 600 mg|8 patients will be enrolled in this arm.
10203739|NCT05167279|Placebo Comparator|JS026/placebo 1000 mg|8 patients will be enrolled in this arm.
10203740|NCT05167279|Placebo Comparator|JS026/placebo 300 mg + JS016/placebo1200 mg|8 patients will be enrolled in this arm.
10203741|NCT05167279|Placebo Comparator|JS026/placebo 600 mg + JS016/placebo 1200 mg|8 patients will be enrolled in this arm.
10203742|NCT05165472|Experimental|Intervention|Real transcranial magnetic stimulation applied
10203743|NCT05165472|Sham Comparator|Sahm-control|Sham transcranial magnetic stimulation applied
10203744|NCT05163912|Experimental|Intervention|Virtual home intervention
10203745|NCT05163613|Experimental|Patients hospitalized due to PCR-confirmed SARS-Cov-2 infection.|Patients hospitalized due to PCR-confirmed SARS-Cov-2 infection, who were treated with magnetostimulation in addition to a standard therapy. In the study groups, the patients were subjected to magnetic field - magnetostimulation with the use of apparatus Viofor JPS System. The control group included patients receiving a comprehensive treatment without magnetostimulation.
10203746|NCT05156944|Experimental|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including two exercises for daily self-guided therapy.
9770496|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.
9770497|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.
9770498|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)|Participants who meet their blood pressure goals in Period 3 and continued into the 8-week, double-blind Period 4 continued to receive this combination.
9770499|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
9770500|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
9770501|NCT00902564|Experimental|Escitalopram|
9770502|NCT00902577|Experimental|Diagnostic (MRI and PET using FMISO)|Two weeks before initiation of chemoradiotherapy with temozolomide, patients undergo MRI (DSC, DCE,DWI and MRS) and PET scan using FMISO. A subset of 15 patients undergo FMISO PET scans approximately 1 week before chemoradiotherapy.
9770503|NCT00902746|Experimental|NPC-01|Norethisterone, Ethinyl Estradiol
9770504|NCT00902850|Experimental|SofLens Daily Disposable|SofLens Daily Disposable Lenses
9770505|NCT00902850|Active Comparator|Marketed 1 Day Contact Lens|Marketed 1 Day Contact Lens
9770506|NCT00903032|Experimental|Arm 1|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
9770507|NCT00903032|Active Comparator|Arm 2|Patients will receive usual care following ACS hospital discharge
9770508|NCT00903162|Experimental|Letrozole-Leuprolide|Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.
9770509|NCT00903175|Experimental|everolimus 1L/sunitinib 2L|everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)
9770510|NCT00903175|Active Comparator|sunitinib 1L/everolimus 2L|sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment
9770511|NCT00903201|Experimental|Treatment A|20 mg of SB656933
9770512|NCT00903201|Experimental|Treatment B|50 mg of SB656933
9770513|NCT00903201|Experimental|Placebo|Placebo
9770514|NCT00903331|Experimental|ACT-064922|ACT-064922 tablet (macitentan), 10 mg, once daily
9770515|NCT00903331|Placebo Comparator|Placebo|Matching placebo, once daily
9770516|NCT00903344|Experimental|Vitamin D|4000IU Vitamin D3 in tablet taken daily with multivitamin
9770517|NCT00903344|Active Comparator|Multivitamin|Multivitamin with 400IU vitamin D tablet
9770518|NCT00903357|Experimental|Montelukast first, then placebo|The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed by a crossover to 8 weeks of placebo after 2-weeks washout period.
9770519|NCT00903357|Experimental|Placebo first, then Montelukast|The group received placebo medication (ascorbic acid) for 8 weeks followed by a crossover to 8 weeks of active medication (montelukast 4 mg or 5mg once daily) after 2-weeks washout period.
9770520|NCT00903370|Active Comparator|MVS|All participants will undergo mitral valve surgery with ligation/excision of left atrial appendage.
9770521|NCT00903370|Experimental|Ablation|Participants will undergo mitral valve surgery with ligation/excision of left atrial appendage plus surgical ablation with pulmonary vein isolation or biatrial lesion set.
9770522|NCT00903383|Experimental|Low Dose|A low dose of LX3305; daily oral intake for 12 weeks
9770523|NCT00903383|Experimental|Mid Dose|A mid dose of LX3305; daily oral intake for 12 weeks
9770524|NCT00903383|Experimental|High Dose|A high dose of LX3305; daily oral intake for 12 weeks
9770525|NCT00903383|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
9770526|NCT00903409|Experimental|"Simvastatin + Lovaza® (Non-switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers"
9770527|NCT00903409|Experimental|"Simvastatin + Lovaza® (Switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers"
9770528|NCT00903448|Experimental|A|Prilosec OTC
9770529|NCT00903448|Active Comparator|B|Prevacid
9770530|NCT00903617|Experimental|Part A Treatment A|5 mg of GSK256073
9770531|NCT00903617|Experimental|Part A Treatment B|50 mg of GSK256073
9770532|NCT00903617|Experimental|Part A Treatment C|150 mg of GSK256073
9770533|NCT00903617|Placebo Comparator|Part A Treatment D|placebo
9770534|NCT00903617|Placebo Comparator|Part B Treatment A|placebo
9770535|NCT00903617|Active Comparator|Part B Treatment B|1500 mg Niaspan
9770536|NCT00903617|Experimental|Part B Treatment C|x mg dose of GSK256073 based on data from Part A
9770537|NCT00903617|Experimental|Part B Treatment D|optional dose of GSK256073 based on data from Part A
9770538|NCT00903630|Experimental|Phase 1 - Dose Level 1|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 10 mg daily on Days 1-28 every 28 days
9770539|NCT00903630|Experimental|Phase I - Dose Level 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 15 mg daily on Days 1-28 every 28 days
9770540|NCT00903630|Experimental|Phase 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: maximum tolerated dose from Phase I portion of the study (10mg) daily on Days 1-28 every 28 days
9770541|NCT00903682|Experimental|etravirine|etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
9770542|NCT00903682|Active Comparator|efavirenz|efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
9770543|NCT00903695|Experimental|Memory XL|"Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion."
9770544|NCT00903695|Placebo Comparator|placebo|"Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion."
9770545|NCT00903760|Experimental|Decitabine + Clofarabine|Drug delivery intravenously (IV) in alternating series of cycles (Decitabine 20 mg/m^2 for 5 days first 3 cycles, then Clofarabine 10 mg/m^2 five days for next 3 cycles), pattern repeats for up to 24 cycles.
9770546|NCT00903760|Experimental|Decitabine|Decitabine 20 mg/m^2 IV daily for 5 days for a total of 24 courses.
9770547|NCT00903786|Experimental|Perampanel|"Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) [NCT00849212]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest."
9770548|NCT00903877|Experimental|Placebo followed by T3|Participants receive placebo for 4 weeks. Following placebo, participants begin T3 treatment at 25 mcg per day, for 4 weeks. Following this, participants begin T3 treatment at 50 mcg per day, for 4 more weeks.
9770549|NCT00903929|Experimental|Eltrombopag|
9770550|NCT00903968|Experimental|Phase I Dose Level 1|Phase I Dose Level 1 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
9770551|NCT00903968|Experimental|Phase I Dose Level 2|Phase I Dose Level 2 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
9770552|NCT00903968|Experimental|Phase I Dose Level 3|Phase I Dose Level 3 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
9770553|NCT00903968|Experimental|Phase I Dose Level 4|Phase I Dose Level 4 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
9770554|NCT00903968|Experimental|Phase I Dose Level 5|Phase I Dose Level 5 patients received plerixafor 320ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
9770555|NCT00903968|Experimental|Phase I Dose Level 5B|Phase I Dose Level 5B patients received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
9770556|NCT00903968|Experimental|Phase I Dose Level 6|Phase I Dose Level 6 patients received plerixafor 400ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
9770557|NCT00903968|Experimental|All Phase I Participants|All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
9770558|NCT00903968|Experimental|All Phase II Participants|All Phase I participants received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13, bortezomib 1.3 mg/m2 intravenously or subcutaneously days 3, 6, 10, and 13, and dexamethasone 40mg orally days 3, 6, 10, and 13 of each 21 day cycle during induction. In maintenance, participants received plerixafor, bortezomib, and dexamethasone days 1, 8, 15, and 22 of each 35 day cycle. Participants were treated until disease progression or unacceptable toxicity.
9770559|NCT00904007|Experimental|SE Game Cohort|Will receive ISE intervention.
9770560|NCT00904007|No Intervention|Control Cohort|The control cohort will receive identical content online (with no ISE)
9770561|NCT00904033|Active Comparator|Multivitamin|Multivitamin used as control group.
9770562|NCT00904033|Experimental|Exercise|Exercise consisting of progressive walking and resistance band training.
9770563|NCT00904033|Experimental|Calcitriol|Calcitriol pill taken once per week.
9770564|NCT00904033|Experimental|Calcitriol and Exercise|Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
9770565|NCT00904150||1 Menstrual migraine|Caucasian women with a current or past history of menstrual migraine (MM = pure menstrual migraine or menstrually-related migraine) attending the City of London Migraine Clinic
9770566|NCT00904150||2 No migraine|Caucasian women with no personal history of migraine
9770567|NCT00904345|Experimental|Treatment|
9770568|NCT00904371||Patients with arterial hypertention|
9770569|NCT00904488|Active Comparator|Addition of PO Thiazide Diuretic|Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
9770570|NCT00904488|Active Comparator|IV furosemide dose escalation|Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.
9770571|NCT00904618|Experimental|TVT-SECUR|This study arm consisted of 48 women operated from January 2007 to October 2008. All patients underwent the implantation of the TVT-SECUR for the treatment of stress urinary incontinence or stress predominant mixed urinary incontinence. The surgery was done under local anesthesia by one high-volume surgeon.
9770572|NCT00904670|Experimental|Active|
9770573|NCT00904670|Placebo Comparator|Comparator|
9770574|NCT00904722|Experimental|CT-011 in combination with Rituximab|Combination of the immunotherapy drugs, CT-011 and rituximab.
9770575|NCT00904748|Experimental|Test 1|
9770576|NCT00904748|Experimental|Test 2|
9770577|NCT00904748|Active Comparator|Reference|
9770578|NCT00904813|Active Comparator|1. Short-course RT (5x5 Gy) + surgery within 1 week (SRT)|RT=Preoperative radiotherapy Gy=Gray
9770579|NCT00904813|Active Comparator|2. Short-course RT (5x5 Gy) + surgery after 4-8 weeks (SRT-delay)|RT=Preoperative radiotherapy Gy= Gray
9770580|NCT00904813|Active Comparator|3. Long-course RT (25x2 Gy) + surgery after 4-8 weeks (LRT-delay)|RT= Preoperative radiotherapy Gy= Gray
9770581|NCT00904826|Experimental|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.
9770582|NCT00904839|Experimental|BIBF 1120 + mFolfox6|BIBF1120 medium dose twice daily
9770583|NCT00904839|Active Comparator|Bevacizumab + mFolfox6|Bevacizumab 5mg/kg once daily every other week
9784462|NCT01225991|Experimental|Milnacipran, active drug, open-label|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day, or to their maximum tolerated dose in the course of the first week. The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day). Final efficacy assessments will be made at the termination visit, and the study medication will be tapered down following 12 weeks of drug treatment.
9784463|NCT01226043|Experimental|Lantus (insulin glargine) vial & syringe|10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
9784464|NCT01226043|Experimental|Lantus (insulin glargine) SoloSTAR pen|3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
9784465|NCT01226095||Osteoarthritic patients|Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
9784466|NCT01226121|Active Comparator|Day 1 manipulation|Finger manipulation one day following Clostridial collagenase injectable
9770584|NCT00904917|Experimental|Adapted PIP|"Participants (both mother and children) participated in an adapted cognitive family prevention program for the families of children with a depressed African American mother.~The intervention was the Prevention Intervention Project."
9770585|NCT00904917|Active Comparator|Lecture|"Mothers received psychoeducation about depression.~The intervention was psychoeducation."
9770586|NCT00904969|Experimental|AMS Transobturator Male Sling System|
9770587|NCT00904982|Other|1 Usual Care Group/Control|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant and can confirm when medication is taken correctly.
9770588|NCT00904982|Experimental|2Med-eMonitor/Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled.
9770589|NCT00904982|Experimental|3 Incentive Group/Lottery|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant. This group will also be entered into a daily lottery in which he/she can win money. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
9770590|NCT00904982|Experimental|4 Combined Group/Lottery and Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled. Participants in this group will also be entered into a daily lottery. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin medication as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
9770591|NCT00904995|Experimental|Group 1 - Oral|Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
9770592|NCT00904995|Experimental|Group 2 - IV + Oral|Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.
9770593|NCT00905021|Experimental|Exemestane plus Sutent|"All patients enrolled on the study will receive treatment as follows:~Exemestane 25 mg by mouth every day.~Sunitinib 37.5 mg by mouth every day."
9770594|NCT00905034|Experimental|MOAD|Chemotherapy regimen of methotrexate, rituximab, vincristine, pegylated L-asparaginase and dexamethasone (MOAD).
9770595|NCT00905060|Experimental|Protein Peptide-Complex (HSPPC-96)|Patients will receive 4 weekly injections of HSPPC-96 followed by a 5th vaccine injection on the same day of the start of maintenance temozolomide administered 2 weeks (+ 4 days) following vaccine administration #4 on the same day of the start of maintenance temozolomide (Day 36). Monthly vaccine injections will then begin on day 21 (+/- 7 days) of the first 28 day temozolomide cycle (Day 56 of the study), 3 weeks following vaccine administration #5 and will continue every 28 days until depletion of vaccine or progression.
9770596|NCT00905125|Experimental|Arm 2, Fluarix®|Single 0.5 mL intramuscular injection of Fluarix®.
9770597|NCT00905125|Experimental|Arm 1, Fluzone®|Single 0.5 mL intramuscular injection of Fluzone®.
9770598|NCT00905151||HIV Positive|Across-sectional analysis of 200 HIV+ patients with varying levels of kidney function
9770599|NCT00905255|Experimental|Lixisenatide (Two-step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
9770600|NCT00905255|Experimental|Lixisenatide (One-step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to end of treatment.
9770601|NCT00905268|Experimental|Group A: Idebenone|Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
9770602|NCT00905268|Experimental|Group B: Idebenone|Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
9770603|NCT00905268|Experimental|C: Idebenone|Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
9770604|NCT00905268|Placebo Comparator|D: Placebo|placebo
9770605|NCT00905307|Experimental|1|OPC-34712 0.25 mg arm
9770606|NCT00905307|Experimental|2|OPC-34712 low-dose arm
9770607|NCT00905307|Experimental|3|OPC-34712 mid-dose arm
9770608|NCT00905307|Experimental|4|OPC-34712 high-dose arm
9770609|NCT00905307|Placebo Comparator|5|
9770610|NCT00905307|Active Comparator|6|Aripiprazole arm
9770611|NCT00905359|Active Comparator|Aperius™ PercLID™ System|Aperius™ PercLID™ System arm. Patients randomized to this arm will undergo treatment with the Aperius™ PercLID™ System.
9770612|NCT00905359|Active Comparator|Standalone Decompressive Surgery|Patients randomized to this arm will receive Standalone Decompressive Surgery, defined as decompressive surgery without instrumentation or fusion.
9770613|NCT00905424|Experimental|Active|Antidepressant + SPD489
9770614|NCT00905424|Placebo Comparator|Placebo|Antidepressant + placebo
9770615|NCT00905437|Placebo Comparator|Placebo|Placebo as an adjunct to standard of care
9770616|NCT00905437|Active Comparator|Pregabalin|Pregabalin as an adjunct to standard of care
9770617|NCT00905450|Experimental|BOL-303242-X|BOL-303242-X (Mapracorat)
9770618|NCT00905450|Placebo Comparator|Vehicle|Vehicle for BOL-303242-X (Mapracorat)
9770619|NCT00905489|Experimental|Nevirapine IR / Nevirapine XR|In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).
9770620|NCT00905515|Active Comparator|Control Group Cyclosporine|Maintain on Cyclosporine (CsA) at target trough level of 50-250 ng/mL.
9770621|NCT00905515|Active Comparator|Low Trough Level Prograf Group|Convert to Prograf (TAC) at target trough levels of 3.0-5.9 ng/mL.
9770622|NCT00905515|Active Comparator|High Trough Level Prograf Group|Convert to TAC at target trough levels of 6.0-8.9 ng/mL.
9770623|NCT00905554|Experimental|warm water|warm water irrigation during the insertion phase of colonoscopy
9770624|NCT00905554|Active Comparator|air|air insufflation during the insertion phase of colonoscopy
9770625|NCT00905580|Placebo Comparator|Placebo|Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
9770626|NCT00905580|Experimental|Pregabalin|Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later
9770627|NCT00905632|Experimental|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
9770628|NCT00905632|Experimental|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
9770629|NCT00905632|Experimental|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
9770630|NCT00905632|Placebo Comparator|Placebo + SOC|Placebo tid +SOC
9770631|NCT00905827|Experimental|Intervention 1: in person CAMS|In person Collaborative Assessment and Management of Suicidality (CAMS) training for providers
9770632|NCT00905827|Experimental|Intervention 2: e-learning CAMS|Online Collaborative Assessment and Management of Suicidality (CAMS) training for providers
9770633|NCT00905827|No Intervention|Control: no training|Control Group: no training
9770634|NCT00905840|Active Comparator|Titanium Zircon implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
10203747|NCT05156944|No Intervention|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
10203748|NCT05148338|Experimental|Risk intervention group|Comprehensive risk factor management at specialized AF outpatient clinic concerning blood pressure, cholesterol, glycaemic control, physical inactivity, weight control, smoking, alcohol intake and sleep apnea.
9770635|NCT00905840|Placebo Comparator|Titanium Grade IV implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
9770636|NCT00906074||Case|Cases will be defined as patients with elective or emergency abdominal surgery who develop severe surgical site infection (deep incisional or organ cavity type; see Center for Disease Control (CDC) criteria for definition in the Appendix), within 0-30 days of surgery.
9770637|NCT00906074||Control|Surgeon-matched controls will be patients with elective or emergency abdominal surgery who are free of surgical site infection (SSI) after 30 days from the surgery.
9770638|NCT00906087|Other|Cosopt|Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.
9770639|NCT00906165|Active Comparator|1- Immediately provisionalized|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
9770640|NCT00906165|Active Comparator|2- Delayed Loading|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
9770641|NCT00906178|Experimental|CyberSenga|6-module HIV prevention program tailored for adolescents in Uganda
9770642|NCT00906178|No Intervention|Control|"treatment as usual - the sexual health education adolescents currently receive in secondary school"
9770643|NCT00906204|Experimental|Single-dose Thymoglobulin|Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
9770644|NCT00906204|Active Comparator|Divided-dose Thymoglobulin|Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4
9770645|NCT00906243|Experimental|CV9103|CV9103 will be applied intradermally on three (3) or five (5) time points. Treatment with CV9103 is administered over a period of either seven (7) or twenty-three (23) weeks.
9770646|NCT00906282|Experimental|Pemetrexed/Carboplatin|"4 cycles of preoperative treatment (1 Cycle = 21 days):~Pemetrexed: 500 mg/m2 intravenously (IV) for 10 minutes on Day 1 each cycle; Carboplatin: AUC 6.0 by IV on Day 1 each cycle."
9770647|NCT00906347|Active Comparator|Oxytocin augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
9770648|NCT00906347|Active Comparator|Misoprostol augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
9770649|NCT00906373|Active Comparator|Cohort 1, IMC A12 - 10 mg/kg|Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or withdrawal. If any participant experiences a dose-limiting toxicity (DLT), an additional 3 participants will be enrolled at this dose level (for a total of 6). If no further DLTs, enrollment into Cohort 2 will occur.
9770650|NCT00906373|Active Comparator|Cohort 2, IMC A12 20 - mg/kg|Treatment cycles will repeat until there is evidence of PD, toxicity, or withdrawal.
9770651|NCT00906399|Placebo Comparator|Placebo|Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
9770652|NCT00906399|Experimental|Peginterferon Beta-1a Q2W|125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
9770653|NCT00906399|Experimental|Peginterferon Beta-1a Q4W|125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).
9770654|NCT00906425|Active Comparator|Submerged healing|The Straumann Bone Level Implant(s) will be placed using a submerged healing treatment
9770655|NCT00906425|Active Comparator|Trans-mucosal healing|The Straumann Bone Level Implant(s) will be placed using a trans-mucosal healing treatment
9770656|NCT00906503|Experimental|PET/Computed Tomography (CT)|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan; Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
9770657|NCT00906698|Experimental|BIBW 2992 and vinorelbine i.v|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine i.v.
9770658|NCT00906698|Experimental|BIBW 2992 and vinorelbine per os|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine per os.
9770659|NCT00906776|Active Comparator|Emdogain PLUS|Straumann Emdogain in combination with Straumann BoneCeramic
9770660|NCT00906776|Active Comparator|Autogenous bone|Autogenous bone from the patient
10203749|NCT05148338|Active Comparator|Control group|Standard of care. Treatment by cardiologist conform existing guidelines.
9770661|NCT00906789||Radiologists|Radiologists who have certification by the American Board of Radiology
9770662|NCT00906945|Experimental|Dose Level 1|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 240 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
9770663|NCT00906945|Experimental|Dose Level 2|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 320 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
9770664|NCT00906945|Experimental|Dose Level 3|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 420 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
9770665|NCT00906945|Experimental|Dose Level 4|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 560 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
9770666|NCT00906945|Experimental|Dose Level 5|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 750 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
9770667|NCT00906945|Experimental|MTD - Phase II|"G-CSF MTD determined in Phase 1 SQ on Days 1-8~Plerixafor MTD determined in Phase 1 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
9770668|NCT00906958|Experimental|Nexus Flow Generator|Participants were randomised to Nexus Flow Generator group for one night.
10203750|NCT05140174|Experimental|RHIS Informed Psychotherapy|Therapists will be trained in Radical Healing and Internalized Stigma (RHIS) and meet with their clients as part of their usual care for 15 tele-psychotherapy sessions
10203751|NCT05139849|Active Comparator|Intervention|"Adrenaline, vasopressin and steroids arm (intervention)~At randomization~1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR.~1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR~In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the hydrocortisone dos will be reduced daily to 67 ml (200 mg) and 33 ml (100 mg) and then discontinued). Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml (300mg hydrocortisone/ d) for maximum 3 days to prevent retardation of infarct healing."
9770669|NCT00906958|Active Comparator|VPAP Flow Generator 25|Participants were randomised to VPAP Flow Generator 25 group for one night.
9770670|NCT00906971|Active Comparator|Laxatives|Magnesium hydroxide for which the dosage varied according to individual needs (a minimum of 2 ml/kg), and received guidance regarding fiber-rich foods, water and toilet training. Patients attended weekly consultations with a pediatric gastroenterologist.
9770671|NCT00907088|Active Comparator|1|
9770672|NCT00907088|Experimental|2|
9770673|NCT00907101|Experimental|Study Treatment|"Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)~Other Names:~Epiduo® Gel Apply once daily"
9770674|NCT00907153|Experimental|Vitamin D|
9770675|NCT00907153|Placebo Comparator|Placebo|
9770676|NCT00907257|Experimental|Same time of day|5% benzoyl peroxide wash and 0.04% tretinoin gel used at same time of day
9770677|NCT00907257|Active Comparator|Different times of day|5% benzoyl peroxide wash used in the morning and 0.04% tretinoin gel used in the evening
9770678|NCT00907296|Placebo Comparator|Placebo|Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.
9770679|NCT00907296|Experimental|Romosozumab 70 mg: 2 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
9770680|NCT00907296|Experimental|Romosozumab 70 mg: 3 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
9770681|NCT00907296|Experimental|Romosozumab 70 mg: 4 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.
9770682|NCT00907296|Experimental|Romosozumab 140 mg: 2 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
9770683|NCT00907296|Experimental|Romosozumab 140 mg: 3 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
9770684|NCT00907296|Experimental|Romosozumab 140 mg: 4 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.
9770685|NCT00907296|Experimental|Romosozumab 210 mg: 2 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
9770686|NCT00907296|Experimental|Romosozumab 210 mg: 3 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
9770687|NCT00907296|Experimental|Romosozumab 210 mg: 4 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.
9770688|NCT00907335|Experimental|Retin-A Micro|Retin-A Micro 0.04% facial acne treatment used once daily
9770689|NCT00907335|Placebo Comparator|Vehicle Control|Color matched facial gel vehicle control used once daily
9770690|NCT00907374|Active Comparator|Low dose inhibition of RAS|Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria
9770691|NCT00907374|Experimental|Agressive inhibition of the RAS|40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily
9770692|NCT00907426|Experimental|Bimatoprost 0.03% Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
9770693|NCT00907426|Other|Bimatoprost 0.03% Followed by Vehicle|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin.
9770694|NCT00907426|Other|Vehicle Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
9770695|NCT00907478|Experimental|Romiplostim|"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years.~The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L."
9784467|NCT01226121|Active Comparator|Day 2 manipulation|Finger manipulation two days following Clostridial collagenase injectable
9770696|NCT00907517|Experimental|MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 10 mg/m^2 intravenously (IV) on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour continuous intravenous infusion (CIV) on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
9770697|NCT00907517|Experimental|MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 20 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
9770698|NCT00907517|Experimental|MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 40 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
9770699|NCT00907517|Experimental|MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 56 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
9770700|NCT00907517|Experimental|MK-8776 140 mg + Cytarabine 2 g/m^2|Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
9770701|NCT00907621|Experimental|Acupuncture|"Acupuncture with Seirin 020x15 mm sterile acupuncture needle:~Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36 on infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks."
9770702|NCT00907621|No Intervention|Control|"Infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks.~The Control group will have no intervention."
9770703|NCT00907738|Experimental|Vorinostat|
9770704|NCT00907777|Experimental|Pn Group|Subjects receiving GSK 1024850A vaccine.
9770705|NCT00907777|Active Comparator|Prev Group|Subjects receiving Prevenar™ vaccine.
9770706|NCT00907803|Experimental|ST-246 400 mg|ST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days
9770707|NCT00907803|Experimental|ST-246 600 mg|ST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days
9770708|NCT00907803|Placebo Comparator|Placebo|Matching Placebo capsules, Orally Once Daily for 14 days
9770709|NCT00907881||All participants|Participants with type 2 diabetes mellitus (T2DM) who had sulfonylurea treatment added to an on-going regime of oral hypoglycemic agent(s).
9770710|NCT00908011|Active Comparator|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
9770711|NCT00908011|Active Comparator|Standard Care|Increased dose of rosuvastatin to 20mg/day
9770712|NCT00908037|Experimental|eltrombopag plus standard of care|eltrombopag
9770713|NCT00908037|Placebo Comparator|placebo plus standard of care|placebo
9770714|NCT00908076|Active Comparator|amitiza|Amitiza
9770715|NCT00908076|Placebo Comparator|Placebo|Matching Placebo
9770716|NCT00908115||Infanrix Group|Subjects received one dose of Infanrix™ at 2, 4 and 6 months of age (primary vaccination), one dose at 15-18 months of age (booster vaccination) and one dose at 4-6 years of age (booster vaccination).
9770717|NCT00908141|Experimental|Arm I: sargramostim (days1-14)|Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9770718|NCT00908141|Experimental|Arm II: sargramostim (3xweek)|Patients receive GM-CSF SC three times weekly for 4 weeks. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9770719|NCT00908232|Experimental|Stable Disease: VD|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
9784468|NCT01226121|Active Comparator|Day 4 manipulation|Finger manipulation four days following Clostridial collagenase injectable
10203752|NCT05139849|Placebo Comparator|Control|"Adrenaline alone arm (control)~At randomization 1 ml sodium chloride 9 mg/ml (placebo) will be administered as soon as possible after adrenaline during the first five cycle of drug administration during CPR 1 ml sodium chloride 9 mg/ml (placebo) will be administered only during the first cycle of drug administration during CPR~b In the ICU sodium chloride 9 mg/ml (placebo) At 4 hours post ROSC, and then once daily, surviving patients with post-resuscitation shock will receive an infusion of 100 ml for ≤ 7 days. From day 8 post ROSC or when vasopressors are not needed the dos will be reduced daily to 67 ml and 33 ml and then discontinued. Patients with evidence of acute myocardial infarction will receive an infusion of 100 ml for 3 days."
10203753|NCT05132322|Active Comparator|Unlearning Only|Includes educational outreach and audit & feedback.
10203754|NCT05132322|Experimental|Unlearning + Substitution|Includes educational outreach, audit & feedback, and an electronic health record-integrated clinical pathway to support appropriate use of pulse oximetry.
10203755|NCT05131698|Experimental|Patients with advanced unresectable liver cancer|
10203756|NCT05129202||Chemotherapy alone or chemotherapy combined with anti-angiogenesis|patients with Chemotherapy
10203757|NCT05129202||immuntherapy|patients treated with immune checkpoint inhibitor monotherapy or combination therapy.
10203758|NCT05126381||Smoker with taking levamlodipine besylate tablets|The subjects are allowed to smoke during the time taking levamlodipine besylate tablets.
10203759|NCT05126381||Non-smoker with taking levamlodipine besylate tablets|The subjects are not allowed to smoke during the time taking levamlodipine besylate tablets.
10203760|NCT05126381||Smoker with taking metformin sustained-release tablets|The subjects are allowed to smoke during the time taking metformin sustained-release tablets。
9770720|NCT00908232|Experimental|Stable Disease: VDC|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
9770721|NCT00908232|Experimental|Stable Disease: VDL|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
9770722|NCT00908232|Experimental|Complete to Partial Response: VD|Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
9770723|NCT00908310|Other|Omniscan|
9770724|NCT00908349|Other|Oxcarbazepine XR|Open Label Study
9770725|NCT00908375|Active Comparator|Pregabalin|A 75mg pregabalin capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
9770726|NCT00908375|Placebo Comparator|Surgar Pill|One Sugar pill capsule will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 Sugar pill capsules twice a day. The total duration of the treatment will be 3 weeks.
9770727|NCT00908388|Experimental|GORE Conformable TAG® Device Surgical Implant|
9770728|NCT00908466|Experimental|Intravitreal Injection|Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
9770729|NCT00908466|Experimental|Subconjunctival Injection|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
9770730|NCT00908544|Experimental|PHI-patients|"Patients with primary HIV infection (PHI) (see also Eligibility) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir"
9770731|NCT00908544|Experimental|CHI-patients|"Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also Eligibility) intensified by Maraviroc + Raltegravir"
9770732|NCT00908583|Experimental|Phase 1, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day 32. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
9770733|NCT00908583|Experimental|Phase 2, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
9784469|NCT01226420|Experimental|Alefacept|Alefacept iv
9784470|NCT01226459|Experimental|Minoxidil Foam|5% Minoxidil Topical Foam
9784471|NCT01226459|Placebo Comparator|Vehicle Foam|Vehicle Topical Foam
9784472|NCT01226472|Experimental|KW-0761|
9785748|NCT01259245|Experimental|Tai chi + PRP|Tai chi elements in incorporated into the exercise component of standard pulmonary rehabilitation program. The exercise content was totally identical to the PRP group except 15 minutes of Tai Chi exercises was substituted to 15 minutes of relaxation exercise. The 5 forms of Sun Style of Tai Chi were taught.
10203761|NCT05126381||Non-smoker with taking metformin sustained-release tablets|The subjects are not allowed to smoke during the time taking metformin sustained-release tablets.
10203762|NCT05122572|Experimental|Intravenous Injection|Intravenous with or without Intratumoral RT-01 in the treatment of patients with advanced solid tumors combined with or without Nivolumab in the treatment of patients with advanced solid tumors
10203763|NCT05121428||Survey 1|Survey investigating patients' experiences with buprenorphine treatment for Opioid Use Disorder before and during the COVID-19 pandemic
10203764|NCT05121428||Survey 2|Survey investigating the factors that motivate patients to abstain from opioid drug use during buprenorphine treatment for Opioid Use Disorder
10203765|NCT05121428||Survey 3|Survey investigating patients' attitudes towards and experiences with cannabis use during buprenorphine treatment for Opioid Use Disorder.
10203766|NCT05121428||Survey 4|Survey investigating patients' attitudes towards and experiences with cigarettes and e-cigarettes use during buprenorphine treatment for Opioid Use Disorder.
10203767|NCT05121428||Survey 5|Survey investigating patients' attitudes towards and experiences with benzodiazepine use during buprenorphine treatment for Opioid Use Disorder.
10203768|NCT05119400||COVID-19 group|"COVID-19 group will be made up of 30 patients that have a past diagnosis of COVID-19 with confirmed positive SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) PCR (polymerase chain reaction) test in their electronic medical record and were previously hospitalized at NYP/WCM (NewYork Presbyterian/ Weill Cornell Medicine) between March 1 and December 31, 2020 for a minimum of three days.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
9770734|NCT00908583|Experimental|Phase 3, two stages|Patients will receive 1 dose of rituximab and 4 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 23, 26, 30 and 33. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
9770735|NCT00908583|Experimental|Phase 4, single stage|Patients will receive 1 dose of rituximab and 6 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered during the pre-transplant period on days 1, 4, 8, and 11, 14, and 17. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
9770736|NCT00908583|Experimental|Phase 5, single stage|Phase 5 evaluated even greater bortezomib dosing density by eliminating the inter-cycle dosing interval. Phase 5 evaluated eight consecutive doses of bortezomib with one dose of rituximab. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patient will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, 11, 14, 17, 20, and 23. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
9770737|NCT00908596|Experimental|Gadoxetic acid disodium (Primovist/Eovist, BAY86-4873)|Participants received Primovist at a dose of 0.025 mmol/kg body weight (BW) intravenously.
9770738|NCT00908791|Experimental|CLA|open-label, single-institution proof of principle study of oral CLA in patients with newly diagnosed adenocarcinoma of the breast.
9770739|NCT00908830||Cystic fibrosis|Lung transplant patients with cystic fibrosis. Measuring MPA levels in cystic fibrosis lung transplant patients for pharmacokinetic parameters.
9770740|NCT00908830||Non-cystic fibrosis lung transplant|Non-cystic fibrosis lung transplant patients. Non-cystic fibrosis lung transplant patients will have MPA levels drawn after their dose to determine pharmacokinetic parameters.
9770741|NCT00908882|Experimental|Enhanced PTSD Health Buddy and Motivational Interviewing|Veterans with PTSD who smoke are exposed to an intervention which included a 90-day smoking cessation curriculum that is integrated into the PTSD Health Buddy Program and weekly motivational interviewing counseling by a nurse plus usual smoking cessation care
9770742|NCT00908882|No Intervention|Usual PTSD Health Buddy Care|Veteran with PTSD who smoke randomly assigned to this arm received standard of care for smoking cessation and used the standard PTSD Health Buddy
9770743|NCT00908895|Experimental|Radio-radial fixator|Patients are operated on using a radio-radial fixator (Distal radius fixator, Synthes)
9770744|NCT00908895|Active Comparator|Percutaneous pinning|Two K-wires inserted on a percutaneous way (dorsally and from the styloid), with a cast for 6 weeks
9770745|NCT00908908|Experimental|1|
9770746|NCT00908947|Experimental|Overall Study|PTA plus stenting with the LifeStent® Vascular Stent System
9770747|NCT00908960|Experimental|High TFMP: Enoxaparin|Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.
9770748|NCT00908960|No Intervention|High TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.
9770749|NCT00908960|No Intervention|Low TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.
9770750|NCT00909064|Experimental|Arixtra|Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement
9770751|NCT00909090|Active Comparator|Intervention|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
9770752|NCT00909090|Placebo Comparator|Placebo|visually identical placebo
9770753|NCT00909155|Active Comparator|Depressed; Venlafaxine treatment|Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
9770754|NCT00909155|Active Comparator|Depressed; Fluoxetine treatment|Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
9770755|NCT00909155|No Intervention|Control|Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication
9770756|NCT00909181|Experimental|Oxybutynin Gel 56 mg/day|
9770757|NCT00909181|Experimental|Oxybutynin Gel 84 mg/day|
9770758|NCT00909181|Placebo Comparator|Placebo Gel|
9770759|NCT00909220||Current Major Depressive Disorder|Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores > 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
9770760|NCT00909220||Healthy Participants|Another 36 participants with no lifetime psychiatric symptoms and scores < 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.
9770761|NCT00909324|Experimental|Pre-LASIK 0.3% hypromellose|
9770762|NCT00909324|Active Comparator|Post-LASIK 0.3% hypromellose|
9770763|NCT00909363|Experimental|WAS patients receiving Promacta|Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
9770764|NCT00909363|Experimental|WAS patients for blood drawing only|WAS patients not receiving treatment to serve as subjects for platelet parameter studies blood drawing once only
9770765|NCT00909363|Placebo Comparator|healthy children for blood drawing only|healthy children having blood obtained once as controls for platelet parameters study
9770766|NCT00909428|Experimental|Solifenacin Succinate|The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.
9770767|NCT00909480|Experimental|IDet|Individually adjusted insulin detemir once daily + metformin at least 1500 mg/day
9770768|NCT00909480|Active Comparator|IGlar|Individually adjusted insulin glargine once daily + metformin at least 1500 mg/day
9770769|NCT00909532|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
9770770|NCT00909532|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
9770771|NCT00909545|Active Comparator|Isradipine CR 5mg|Isradipine CR 5mg/day
9770772|NCT00909545|Active Comparator|Isradipine CR 10mg|Isradipine CR 10mg/day
9770773|NCT00909545|Active Comparator|Isradipine CR 20mg|Isradipine CR 20mg/day
9770774|NCT00909545|Placebo Comparator|Placebo|Placebo
9770775|NCT00909727|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
9770776|NCT00909727|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
9770777|NCT00909779|Experimental|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
9770778|NCT00909779|Placebo Comparator|Placebo twice daily|Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
9770779|NCT00909792|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
9770780|NCT00909792|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
9770781|NCT00909844|Experimental|Triptorelin|
9770782|NCT00909857|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles
9770783|NCT00909857|Active Comparator|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles
9770784|NCT00909870|Experimental|1|Weekly applications of Dermagraft and compression dressings, in combination with systematic surgical wound debridement.
9770785|NCT00909870|Active Comparator|2|Weekly application of compression dressings only, in combination with systematic surgical wound debridement.
9770786|NCT00910000|Experimental|Dose Level 1A|"Vorinostat: 200 mg taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 100 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
9770787|NCT00910000|Experimental|Dose Level 2A|"Vorinostat: 300mg, taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
9770788|NCT00910000|Experimental|Dose Level 1B|"Vorinostat: 200mg, taken orally twice a day for days 1-3 and days 8-10 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
9770789|NCT00910000|Experimental|Dose Level 1C|"Vorinostat: 200mg, taken orally twice a day for days 1, 2, 8 and 9 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
9770790|NCT00910000|Experimental|Dose Level 1D|"Vorinostat: 300mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
9770791|NCT00910000|Experimental|Dose Level 2D|"Vorinostat: 400mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
9770792|NCT00910039|Experimental|Sunitinib malate|"Oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo neuropsychological battery testing at baseline and periodically during study to assess cognitive function (memory, verbal fluency, visual-motor speed, executive function, and motor dexterity), activities of daily living, and quality of life."
9770793|NCT00910091|Experimental|A- BN 83495- 40mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
10203769|NCT05119400||Comparison group|"The subjects in comparison group will be 30 patients previously hospitalized at NYP/WCM between March 1 and December 31, 2020 for a minimum of three days. The recruited subjects would have undergone hospitalization secondary to a medical diagnosis that was not COVID-19.~Administration of study instruments, including self-report measures of mood, anxiety, post-traumatic stress and adjustment, and objective neuropsychological tests of cognitive function will be done via telephone interview, videoconference interview, and/or Redcap survey for both groups."
9770794|NCT00910091|Active Comparator|B- MA - 160mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
9770795|NCT00910208|Experimental|Patient-controlled analgesia 1 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes
9770796|NCT00910208|Experimental|Patient-controlled analgesia 1.5 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes
9770797|NCT00910208|Active Comparator|Non-Patient-controlled analgesia comparison group|0.1 mg/kg morphine loading dose plus additional analgesia as needed
9770798|NCT00910247|Experimental|eslicarbazepine acetate|Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD
9784473|NCT01226485|Experimental|Taladegib|"Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle.~Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle.~Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors.~Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC)."
9784474|NCT01226511|Experimental|Duloxetine|30-120 mg flexible dosing once daily for 10 weeks. At the end of the 10 week blinded treatment period, participants may participate in an 18 week extension
9784475|NCT01226511|Placebo Comparator|Placebo|Administered once daily for 10 weeks. At the end of the 10 week blinded treatment period, placebo participants receive duloxetine in the 18 week extension
9784476|NCT01226706|Placebo Comparator|Placebos|Placebo injected into the detrusor at Day 1,
9784477|NCT01226706|Experimental|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
9784478|NCT01226719|Experimental|FOLFOXIRI+panitumumab regimen|"All patients will receive the FOLFOXIRI/panitumumab regimen, with drugs administered in the following order:~Panitumumab~Oxaliplatin~Irinotecan~Leucovorin~5-Fluorouracil"
9784479|NCT01226745|Experimental|ONO-4641 0.15 milligram (mg) - 0.15 mg|
9784480|NCT01226745|Experimental|ONO-4641 0.10 mg - 0.10 mg|
9784481|NCT01226745|Experimental|ONO-4641 0.05 mg - 0.05 mg|
9784482|NCT01226745|Experimental|Placebo - ONO4641 0.15 mg|
9784483|NCT01226745|Experimental|Placebo - ONO4641 0.10 mg|
10203770|NCT05118139|Experimental|1.5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 1.5% ENDS products based on their preferred flavor.
9784484|NCT01226745|Experimental|Placebo - ONO4641 0.05 mg|
9784485|NCT01226914|Placebo Comparator|Placebo|For subjects in the placebo group, saline was drawn into the applicator and aerosolized in a similar fashion; it was allowed to remain in the wound during closure.
9784486|NCT01226914|Experimental|Evicel|For subjects in the treatment group, Evicel was applied in the usual manner by study personnel, with 5mL of each component drawn into a two-barrel syringe device and aerosolized using a pedal-controlled inert gas supply.
9784487|NCT01226979|Experimental|HDRBT (High Dose Rectal Brachytherapy)|Radiation: High-dose endorectal brachytherapy The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer. A daily dose of 6.5 Gy over four consecutive days
9784488|NCT01227005|Active Comparator|Whole Blood|Whole Blood plus pooled platelets
9784489|NCT01227005|Active Comparator|Component Therapy|Red blood cells, plasma, platelets
9784490|NCT01227018|Experimental|STA-9090|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9784491|NCT01227044|Active Comparator|NTX + MM/MC|Naltrexone + Medical Management/Medication Coaching
9784492|NCT01227044|Placebo Comparator|Placebo + MM/MC|Placebo plus Medical Management/Medication Coaching
9784493|NCT01227057|Experimental|Arm 1: Cognitive Rehabilitation|Cognitive rehabilitation and exposure therapy for hoarding
9784494|NCT01227057|Active Comparator|Arm 2: Case Management|Case management
9784495|NCT01227252|Experimental|LY2886721|
9784496|NCT01227252|Placebo Comparator|Placebo|
9784497|NCT01227265|Experimental|Preladenant 2 mg|Participants received 2 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
9784498|NCT01227265|Experimental|Preladenant 5 mg|Participants received 5 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
9784499|NCT01227265|Placebo Comparator|Placebo|Participants received preladenant-matching placebo as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extention trial or return for a follow-up visit two (2) weeks later.
9784500|NCT01227278|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
9784501|NCT01227278|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
9784502|NCT01227382|Other|ERCP with Cholangiopancreatoscopy|The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.
9784503|NCT01227395||Azithromycin|Patients taking Azithromycin.
9784504|NCT01227421|Active Comparator|Nitazoxanide, Placebo|300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
9784505|NCT01227421|Active Comparator|Nitazoxanide, Nitazoxanide|Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
9784506|NCT01227421|Placebo Comparator|Placebo|2 placebo tablets twice daily for 5 days
9784507|NCT01227434|Experimental|Surgical Group|PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection as clinical care for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
9785749|NCT01259245|Active Comparator|PRP|PRP is a formal pulmonary rehabilitation program consisted of physical training including warm up and cool down exercise and aerobic exercises in addition to breathing control exercises, safety precautions for physical training, Thera-Band strengthening exercises and overview of COPD management.
9770799|NCT00910273|Experimental|1|etanercept 50 mg/week
9770800|NCT00910299|Experimental|Prasugrel|
9770801|NCT00910299|Active Comparator|Clopidogrel|
9770802|NCT00910429|Experimental|Arm 1|
9770803|NCT00910481|Experimental|Elective IABP Insertion|
9770804|NCT00910481|No Intervention|No Planned IABP Insertion|
9770805|NCT00910520|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
9770806|NCT00910520|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
9770807|NCT00910624|Experimental|BOC + PEG/RBV|Participants who enrolled within 2 weeks after the last dose of PEG/RBV in previous protocol received boceprevir (BOC) + peginterferon/ribavirin (PEG/RBV) for up to 44 weeks followed by 24 weeks post-treatment follow-up. Participants who did not enroll within 2 weeks after the last dose of PEG/RBV in previous protocol received PEG/RBV for 4 weeks followed by BOC + PEG/RBV for up to 44 weeks, with 24 weeks post-treatment follow-up.
9770808|NCT00910663|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by Cellcept® 250 mg Capsule dosed in second period.
9770809|NCT00910663|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
9770810|NCT00910689|Placebo Comparator|1|Optimal Acute Therapy plus Beta Blocker Placebo
9770811|NCT00910689|Active Comparator|2|Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
9770812|NCT00910689|Active Comparator|3|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
9770813|NCT00910689|Active Comparator|4|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)
9770814|NCT00910715|Active Comparator|EM-10 days doxycycline|
9770815|NCT00910715|Active Comparator|EM-doxycycline 15 days|
9770816|NCT00910715|Placebo Comparator|controls|
9770817|NCT00910728|Experimental|1|AZD1480
9770818|NCT00910845|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
9770819|NCT00910845|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
9770820|NCT00910858|Experimental|10 mg Lenalidomide|"Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure.~During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment."
9770821|NCT00910858|Experimental|15 mg Lenalidomide Non-del 5q|Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
9770822|NCT00910871|Experimental|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks in addition to Background Regimen (BR) for the treatment of multi-drug resistant tuberculosis (MDR-TB).
9770823|NCT00910910|Experimental|1 - Lenalidomide|1 - Lenalidomide
9770824|NCT00910910|Active Comparator|2- Chlorambucil|2- Chlorambucil
9770825|NCT00910962|Experimental|Treatment A|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
9770826|NCT00910962|Experimental|Treatment B|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
9770827|NCT00910962|Placebo Comparator|Treatment C|Placebo twice daily for 12 weeks
9770828|NCT00910988|Active Comparator|olanzapine|olanzapine injection in healthy control
9770829|NCT00910988|Active Comparator|ziprasidone|ziprasidone injection in healthy control
9770830|NCT00910988|Placebo Comparator|saline|saline injection in healthy control
9770831|NCT00911144|Experimental|Synflorix Group|Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
9770832|NCT00911144|Active Comparator|Prevenar Group|Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
9770833|NCT00911157|Experimental|Fondaparinux|
9770834|NCT00911157|Other|unfractionated heparin|
9770835|NCT00911170|Placebo Comparator|Placebo|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2, and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus placebo subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
9770836|NCT00911170|Placebo Comparator|Pegfilgrastim|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2 and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus pegfilgrastim 6 mg administered as a single subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
9770837|NCT00911300|Active Comparator|Arm 1: fondaparinux|
9770838|NCT00911300|Active Comparator|Arm 2: unfractionated heparin + Vitamin-K-Antagonist|
9770839|NCT00911495|Experimental|GMI-1070|
9770840|NCT00911508|Active Comparator|Left Atrial Ablation|Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.
9770841|NCT00911508|Active Comparator|Rate or Rhythm Control Therapy|Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.
9770842|NCT00911534|Experimental|1|
9770843|NCT00911534|Placebo Comparator|2|
9770844|NCT00911586|Experimental|Testosterone Undecanoate|Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.
9770845|NCT00911612|Experimental|Colesevelam|Participants received colesevelam 1.875 g twice daily
9770846|NCT00911612|Placebo Comparator|Placebo|Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
9770847|NCT00911625|Active Comparator|0.5 units/kg|Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
9770848|NCT00911625|Experimental|0.25 units/kg|Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
9770849|NCT00911742|Experimental|1 Tramadol Contramid Once A Day|
9770850|NCT00911742|Active Comparator|2 Zytram (R)|
9770851|NCT00911768|Experimental|Korean Red Ginseng group|The brand name of experimental drug is 'Capsule of Korean Red Ginseng Powder'. It consists of the powder of steamed root of Panax ginseng made by Korean Ginseng Corp.
9770852|NCT00911768|Placebo Comparator|Corn-starch powder with ginseng flavor|The placebo of this study is corn-starch powder with Korean Red Ginseng flavor. It has the same shape, color and flavor like experimental drug.
9770853|NCT00911807|Experimental|Cerebrolysin + donepezil|
9770854|NCT00911807|Experimental|Cerebrolysin + placebo|
9770855|NCT00911807|Active Comparator|Donepezil + placebo|
9770856|NCT00911820|Active Comparator|Arm A: PCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally, on days 1 and 8 of each cycle, patients received cisplatin 30 mg/m2 IV over 30 minutes and then irinotecan 65 mg/m2 IV over 30 minutes of each 3-week cycle. Treatment could continue until disease progression or unacceptable toxicity.
9770857|NCT00911820|Active Comparator|Arm B: TPCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally on days 1 and 8 of each cycle, patients received docetaxel 30 mg/m2 IV over 30 minutes followed by cisplatin 25 mg/m2 IV over 30 minutes and then irinotecan 50 mg/m2 IV over 30 minutes of each 3-week cycle.
9770858|NCT00911859|Experimental|Part 1: VMP+Siltuximab 11 mg/kg|Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP (Velcade+Melphalan+Prednisone). Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally (by mouth).
9770859|NCT00911859|Experimental|Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg|Siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
9770860|NCT00911859|Active Comparator|Part 2, Arm B: VMP|Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
9770861|NCT00911898|Experimental|MM-111|
9770862|NCT00911937|Experimental|Fesoterodine|
9770863|NCT00911937|Placebo Comparator|Placebo|
9770864|NCT00911989|Other|Transvaginal Sleeve Gastrectomy|Transvaginal Sleeve Gastrectomy using Steerable Flex Trocar (SFT) for transvaginal endoscope placement (endoscopic visualization)
9770865|NCT00912002|Experimental|MK-0941|MK-0941
9770866|NCT00912015|Experimental|Tramadol OAD 200mg|
9770867|NCT00912015|Experimental|Tramadol OAD 300mg|
9770868|NCT00912015|Experimental|Tramadol OAD 400mg|
9770869|NCT00912015|Other|Tramadol OAD 100mg|Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
9770870|NCT00912028|Active Comparator|senofilcon A|contact lens
9770871|NCT00912028|Active Comparator|lotrafilcon B|contact lens
9770872|NCT00912028|Active Comparator|balafilcon A|contact lens
9770873|NCT00912028|Active Comparator|methafilcon A|contact lens
9770874|NCT00912028|Active Comparator|vifilcon A|contact lens
9770875|NCT00912093|Placebo Comparator|Placebo|Single subcutaneous injection of matching placebo
9770876|NCT00912093|Experimental|Icatibant|Single subcutaneous injection of icatibant, 30 mg
9770877|NCT00912197|Experimental|Oligofructose|Participants received 10g of Oligofructose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals.The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
9770878|NCT00912197|Placebo Comparator|Cellulose and maltodextrin|Participants received 10g of Cellulose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals. Maltodextrin was added to the cellulose supplement. The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
9770879|NCT00912288|Experimental|Dimebon|
9770880|NCT00912288|Placebo Comparator|Placebo|
9770881|NCT00912301|Experimental|NaCDC 500 mg|Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
9770882|NCT00912301|Experimental|NaCDC 1000 mg|Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
9770883|NCT00912301|Placebo Comparator|Placebo|Participants randomized to this arm received a placebo capsule each day for 4 days.
9770884|NCT00912340|Experimental|Trastuzumab|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab and hormone therapy.
9770885|NCT00912340|Experimental|Everolimus|Patients receive everolimus PO daily and continue their most recent hormone therapy. Patients achieving disease progression receive trastuzumab IV over 30-90 minutes once every 3 weeks in combination with everolimus and hormone therapy.
9770886|NCT00912340|Experimental|Trastuzumab and everolimus (ARM REMOVED)|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and everolimus PO daily while continuing to receive their most recent hormone therapy.
9770887|NCT00912405|Experimental|Sinexus Intranasal Splint|Patient receives a drug-coated intranasal splint
9770888|NCT00912509|Active Comparator|30 minute light duration|30 minute treatment with UVX light
9770889|NCT00912509|Active Comparator|45 minute light duration|45 minute treatment with UVX light
9770890|NCT00912743|Experimental|1|MSI - H arm
9770891|NCT00912782|Placebo Comparator|Placebo|Placebo one time per week for 3 weeks
9770892|NCT00912782|Experimental|Cholecalciferol|Vitamin D 200,000 IU per week for 3 weeks
9770893|NCT00912795|Experimental|SMS Turkey|6-week smoking cessation program delivered via daily text messages
9770894|NCT00912795|No Intervention|Brochure control|7-page brochure that provided general information and tips on how to quit smoking
9770895|NCT00912808|Experimental|Donepezil|
9770896|NCT00912808|Placebo Comparator|Sugar Pill|
9770897|NCT00912873|Active Comparator|0.1% Ropivicaine|Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
9770898|NCT00912873|Experimental|0.4% Ropivicaine|Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
9770899|NCT00912912|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
9770900|NCT00912925|Placebo Comparator|Placebo|Patients in the placebo-control group were administered a solution of 100 millimolar (mM) sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
9770901|NCT00912925|Active Comparator|Aldurazyme treatment|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 Units/kg (approximately 0.58 mg/kg = labeled dose) administered intravenously over approximately 4 hours once weekly for 26 weeks.
9770902|NCT00912964|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once a day for 12 weeks.
9770903|NCT00912964|Experimental|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
9770904|NCT00912964|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.
9770905|NCT00912990|Placebo Comparator|Normal saline|Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg
9770906|NCT00912990|Active Comparator|Cisatracurium|Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.
9770907|NCT00913003|Placebo Comparator|Placebo|Group B using saline as a placebo.
9770908|NCT00913003|Active Comparator|Lidocaine|Group A lidocaine infusion and bolus.
9770909|NCT00913068|Experimental|TAP arm|in the experimental arm, the procedure will consist of the staff urologist injecting local anesthetic into the anterior abdominal wall bilaterally from the inside of the abdomen at the end of their surgery
9770910|NCT00913068|Active Comparator|standard post operative pain control|Our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). Some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. Often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction.
9770911|NCT00913081|Experimental|Quercetin 500 mg|Quercetin 500 mg once, administered one hour before 500 mg immediate-release niacin
9770912|NCT00913081|Experimental|Quercetin 1000 mg|Quercetin 1000 mg once, administered one hour before 500 mg immediate-release niacin
9770913|NCT00913081|Experimental|Quercetin 2000 mg|Quercetin 2000 mg once, administered one hour before 500 mg immediate-release niacin
9770914|NCT00913081|Placebo Comparator|Placebo|Placebo once, administered one hour before 500 mg immediate-release niacin
9770915|NCT00913133|Experimental|Desirudin|desirudin 15 mg twice daily for a minimum of 5 days
9770916|NCT00913263|Experimental|2-Hydroxyflutamide|Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
9770917|NCT00913380|Experimental|Low-dose CT|
9770918|NCT00913380|Active Comparator|Standard-dose CT|
9770919|NCT00913458|Experimental|1|etanercept + methotrexate; etanercept + methotrexate
9770920|NCT00913510|Experimental|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
9770921|NCT00913510|Active Comparator|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
9770922|NCT00913523|Experimental|Tampon with GML|Regular and Super Tampon with GML added to the cover
9770923|NCT00913523|Sham Comparator|Tampon without GML|Regular and Super Tampon without GML
9770924|NCT00913523|Sham Comparator|Tampon Normally Used|Type and Size of Tampon Normally Used by Subjects
9770925|NCT00913627|Experimental|1|1 x 600 mg ibuprofen IR/ER-roller compaction caplet
9770926|NCT00913627|Experimental|2|1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
9770927|NCT00913627|Active Comparator|3|1x 220 mg naproxen sodium (Aleve caplet)
9770928|NCT00913627|Placebo Comparator|4|1 x placebo caplet
9770929|NCT00913744|Experimental|Ocriplasmin|
9770930|NCT00913744|Sham Comparator|Sham injection|
9770931|NCT00913770|No Intervention|SC|Standard Care
9770932|NCT00913770|Experimental|SBIRT|Screening, Brief Intervention and Facilitated Referral to Treatment
9770933|NCT00913770|Experimental|SBI+Bup|Screening, Brief Intervention and Buprenorphine initiation
9770934|NCT00913835|Experimental|Olaratumab and Liposomal Doxorubicin|Olaratumab and Liposomal Doxorubicin
9770935|NCT00913835|Active Comparator|Liposomal Doxorubicin: Optional Olaratumab Monotherapy|Liposomal Doxorubicin Monotherapy until disease progression. Upon disease progression the participant had the option to receive Olaratumab monotherapy.
9770936|NCT00913913|Experimental|bevacizumab,IL-2, IFN, DC vaccine|Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
9770937|NCT00913978|Active Comparator|Group 1: VitaHeat|Patients in group one will be warmed perioperatively with the VitaHeat mattress and IV fluid warmers once they are in the operating room.
9770938|NCT00913978|Active Comparator|Group 2: Bair Hugger|Patients in group two will be warmed perioperatively with the upper body bair hugger and IV fluid warmers once they are in the operating room.
9770939|NCT00914069|Experimental|RIVS vascular access|RIVS vascular access
9770940|NCT00914069|Active Comparator|Conventional vascular access|Conventional vascular access
9770941|NCT00914186|Placebo Comparator|Vehicle|
9770942|NCT00914186|Experimental|TS-022 0.005% lotion|
9770943|NCT00914186|Experimental|TS-022 0.010% lotion|
9770944|NCT00914186|Experimental|TS-022 0.020% lotion|
9770945|NCT00914316|Active Comparator|Phase 1-Ranolazine, Phase 2-Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
9770946|NCT00914316|Active Comparator|Phase 1 -Ranolazine, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
9770947|NCT00914316|Active Comparator|Phase 1 -Placebo, Phase 2 -Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
9770948|NCT00914316|Placebo Comparator|Phase 1 -Placebo, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
9770949|NCT00914459|Other|Moroctocog alfa (AF-CC)|Open Label
9770950|NCT00914485|Other|Provider Communication Skills Training|Provider clinical communication training intervention
9770951|NCT00914589|Experimental|FXIII17.5IU/Kg|Recombinant factor XIII at a single dose of 17.5 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
9770952|NCT00914589|Experimental|FXIII35IU/Kg|Recombinant factor XIII at a single dose of 35 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
9770953|NCT00914589|Placebo Comparator|Placebo|Recombinant factor XIII placebo was administered as a single dose via slow i.v. push at a rate not exceeding two mL per minute.
9770954|NCT00914628|Experimental|A|HSV-TK engineering donor Lymphocytes
9770955|NCT00914628|Active Comparator|B|T-cell depleted or T-cell replete strategies
9770956|NCT00914732|Experimental|Group B, liquid, subcutaneous|Group B: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) liquid formulation by the subcutaneous route on Day 0 and 28.
9770957|NCT00914732|Experimental|Group C, liquid, intradermal|Group C: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (2x10^7 TCID50/0.1mL per dose) liquid formulation by the intradermal route on Day 0 and 28.
9770958|NCT00914732|Experimental|Group A, lyophilized, subcutaneous|Group A: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) lyophilized formulation by the subcutaneous route on Day 0 and 28.
9770959|NCT00914810|Experimental|Vitamin D|Cholecalciferol (2000 I.U. daily)
9770960|NCT00914810|Placebo Comparator|Placebo|Placebo capsule (sugar pill daily)
9770961|NCT00914849|Experimental|Arm 1 - Donor|"Day 1~AMD3100 320 ug/kg IV~Leukopheresis~Day 2 (if peripheral blood stem cell (PBSC) collected is not sufficient)~AMD3100 320 ug/kg IV~Leukopheresis"
9770962|NCT00914849|Experimental|Arm 2 - Recipient|"Standard of care and physician choice myeloablative or non-myeloablative chemotherapy with or without total body irradiation (permitted = cyclophosphamide and single dose total body irradiation (TBI) / fludarabine and busulfan / fractionated TBI and cyclophosphamide / fractionated TBI, etoposide, and cyclophosphamide / busulfan and cyclophosphamide / fludarabine, busulfan, and ATGAM~Day 0 = Stem Cell Transplant"
9770963|NCT00914862|Experimental|Children Ramelteon 4 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single 4 mg oral dose of ramelteon.
9770964|NCT00914862|Experimental|Children Ramelteon 8 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single oral 8 mg dose of ramelteon.
9770965|NCT00914862|Experimental|Adolescents Ramelteon 4 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 4 mg ramelteon.
9770966|NCT00914862|Experimental|Adolescents Ramelteon 8 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 8 mg ramelteon.
9770967|NCT00914862|Active Comparator|Healthy Adult Ramelteon 8 mg|Healthy adults (18 to 50 years old) received a single oral dose of 8 mg ramelteon.
9770968|NCT00914927|Experimental|1|
9770969|NCT00914927|Experimental|2|
9770970|NCT00914927|Placebo Comparator|3|
9770971|NCT00914940|Experimental|Arm 1|"CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD."
9770972|NCT00914966|Experimental|CINRYZE|"There were 3 potential dose escalation steps:~Step 1: 1500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 2: 2000 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 3: 2500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks"
9770973|NCT00915005|Experimental|Group 1|"Group 1: Photon Therapy - 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
9770974|NCT00915005|Experimental|Group 2|"Group 2: Proton Therapy - 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
9770975|NCT00915005|Experimental|Group 3|"Group 3: Receives either photon or proton therapy, whichever participant's doctor decides is better, for for 6-7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
9770976|NCT00915005|Experimental|Group 4|"Photon Therapy - Highest practical dose (74 CGE, 66 CGE) radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
9770977|NCT00915018|Experimental|neratinib plus paclitaxel|
9770978|NCT00915018|Active Comparator|trastuzumab plus paclitaxel|
9770979|NCT00915031|Active Comparator|Hypothermia Only OR|Use of Hypothermia Cooling device only in the operating room. Intervention is Hypothermia Cooling Device.
9770980|NCT00915031|Active Comparator|Hypothermia in OR + Recovery|Use of hypothermia cooling device in the operating room and up to five hours after surgery is intervention.
9770981|NCT00915148||Ultrasound examination|Women with prolonged Labour; Primi gravidae, single pregnancy, >37 weeks, fetus alive, cephalic presentation.
9770982|NCT00915278|Experimental|PF-04605412|
9770983|NCT00915343|Experimental|Novel once daily modified release|"Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state"
9770984|NCT00915343|Active Comparator|Conventional TID hydrocortisone|Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.
9770985|NCT00915356|Experimental|1|AZD1305 iv infusion
9770986|NCT00915356|Placebo Comparator|2|Placebo iv infusion
9770987|NCT00915473|Experimental|Active Injection|Subjects randomized to this arm will receive 2.5 mL 0.5% bupivicaine plus 0.5 mL 20 mg methylprednisolone injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
9770988|NCT00915473|Placebo Comparator|Placebo Injection|Subjects randomized to this arm will receive 2.75 mL normal saline plus 0.25 mL 1% lidocaine injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
9770989|NCT00915499|Active Comparator|ASV mode|
9770990|NCT00915499|Active Comparator|CPAP mode|
9770991|NCT00915525|Experimental|botulinum toxin Type A 100U|Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
9770992|NCT00915525|Experimental|botulinum toxin Type A 150U|Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
9770993|NCT00915538|Other|Group 1 / use of pMDI as approved|The intervention in this group will use inhalation from the pMDI containing budesonide/formoterol pMDI 160/4.5 2 inhalations as approved. (FDA approved product information) without a spacer. The pulmonary function tests (PFTs) will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of budesonide /formoterol; pMDI160/5.
9770994|NCT00915538|Experimental|Group 2 / pMDI with Aerochamber Plus|The intervention in this group will use the pMDI budesonide/formoterol 160/4.5 with a valve holding chamber spacer device, Aerochamber Plus which is the intervention being studied The PFTs will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of Symbicort 160/5. This is the intervention to be studied for comparison to the non-spacer inhalations..
9770995|NCT00915551|Experimental|PEP005 (Ingenol Mebutate) gel|
9770996|NCT00915551|Placebo Comparator|Vehicle gel|
9770997|NCT00915590|Experimental|Placebo first, then IL-1RA|It is our intent that 10 patients will complete a course of treatment with placebo, followed by a course of treatment with 5% custom made topical IL-1Ra.
9770998|NCT00915590|Experimental|IL-1RA first, then Placebo|It is our intent that 10 patients will complete a course of treatment with 5% custom made topical IL-1Ra, followed by a course of treatment with placebo
9770999|NCT00915603|Active Comparator|paclitaxel/bevacizumab/everolimus|Systemic Therapy
9771000|NCT00915603|Placebo Comparator|paclitaxel/bevacizumab/placebo|Systemic Therapy
9771001|NCT00915655|Experimental|DRV/rtv (darunavir/ritonavir)|Patients will receive darunavir tablets 2 x 400 mg in combination with ritonavir capsule 100 mg once daily for 48 weeks along with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ie, either zidovudine/lamivudine or abacavir/lamivudine
9771002|NCT00915759|Active Comparator|ProKera|
9771003|NCT00915759|Placebo Comparator|Bandage contact lens|
9771004|NCT00915772|Experimental|Linagliptin + metformin bid|Linagliptin low dose + metformin 500 mg, bid
9771005|NCT00915772|Experimental|Linagliptin+ metformin bid|Linagliptin low dose + metformin 1000 mg bid
9771006|NCT00915772|Active Comparator|Metformin bid|Metformin 1000 mg bid
9784508|NCT01227434|Experimental|Non-surgical group|Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
9784509|NCT01227512|Experimental|Tolvaptan 15-60mg|Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
9784510|NCT01227512|Active Comparator|Fluid Restriction|Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
10203771|NCT05118139|Experimental|2.4% nicotine cartridges|Subjects will self-assign to one of 2 flavor variants of 2.4% ENDS products based on their preferred flavor.
10203772|NCT05118139|Experimental|5% nicotine cartridges|Subjects will self-assign to one of 7 flavor variants of 5% ENDS products based on their preferred flavor.
10203773|NCT05114863|Experimental|Non-menthol smokers|Subjects will be randomized to one of ten product use sequences, such that one of the five IPs (A1,B,C,D,N) will be used in each of the five Test Sessions.
10203774|NCT05114863|Experimental|Menthol smokers|Subjects will be randomized to one of six product use sequences, such that one of the six IPs (A2,E,F,G,H,N) will be used in each of the six Test Sessions.
10203775|NCT05110781|Experimental|Treatment (atezolizumab, surgery, radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Beginning 6 weeks after surgery, patients with residual disease undergo standard of care radiation therapy and receive atezolizumab IV over 30-60 minutes on day 1. Treatment with atezolizumab repeats every 21 days for up to 15 cycles in the absence of disease progression and unacceptable toxicity.
9771007|NCT00915798||Smokers with ADHD|Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
9771008|NCT00915798||Nonsmokers with ADHD|Nonsmokers with ADHD participated in one condition.
9771009|NCT00915798||Control smokers|Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
9771010|NCT00915798||Control nonsmokers|Control nonsmokers participated in one condition.
9771011|NCT00915876|Active Comparator|Paricalcitol|
9771012|NCT00915876|Placebo Comparator|Placebo|
9771013|NCT00915902|Experimental|Omega-3-acid ethyl esters (Lovaza)|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. GlaxoSmithKline supplied the study drug and the placebo. The study drug, Omega-3-acid ethyl esters (Lovaza) was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week treatment period. The study drug contained minimally 1.5 g DHA (docosahexaenoic acid) and 1.86 g EPA (eicosapentaenoic acid).
9771014|NCT00915902|Placebo Comparator|Placebo|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. The corn oil placebo was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week non-treatment (placebo) period.
9771015|NCT00915928|Active Comparator|ACE inhibitor|patients randomized to this arm will be treated with ACE inhibitors after surgery
9771016|NCT00915928|Placebo Comparator|Placebo|patients randomized to this arm will be treated with placebo after surgery
9771017|NCT00915954|Active Comparator|Active Acromegaly|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
9771018|NCT00915954|Active Comparator|Type 2 Diabetes Mellitus(DM)|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
9771019|NCT00915954|Active Comparator|Heathy Controls|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
9771020|NCT00915967|Experimental|Vancomycin|Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
9771021|NCT00915967|Placebo Comparator|Saline|Subjects in the saline group will receive a Saline injection directly into the wound pocket.
9771022|NCT00916006|Experimental|PEP005 gel|PEP005 gel, 0.015% applied once daily for three consecutive days
9771023|NCT00916006|Placebo Comparator|Vehicle gel|Vehicle gel applied once daily for three consecutive days
9771024|NCT00916032|Active Comparator|1|One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
9771025|NCT00916032|Active Comparator|2|One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
9771026|NCT00916058|Experimental|Dose Level 1|Dose Level 1; Bendamustine 30 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
9771027|NCT00916058|Experimental|Dose Level 2|Dose Level 2; Bendamustine 60 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
9771028|NCT00916058|Experimental|Dose Level 3|Dose Level 3; Bendamustine 90 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
9771029|NCT00916058|Experimental|Dose Level 4|Dose Level 4; Bendamustine 120 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
9771030|NCT00916058|Experimental|Dose Level 5|Dose Level 5; Bendamustine 150 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
9771031|NCT00916058|Experimental|Dose Level 6|Dose Level 6; Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
9771032|NCT00916058|Experimental|Phase 2|Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
9771033|NCT00916136|Active Comparator|Cutaneous Traction|Applied by using a strap on boot that attaches to the leg. A rope is attached to the boot. Weight is attached to the rope to use gravity to pull traction. The traction is left in place until patient is taken to surgery for reduction of the femur fracture.
9771034|NCT00916136|Active Comparator|Skeletal Traction|A small incision is made on the inside of the knee and a pin is surgically inserted through the bone. Weights are then attached that will pull traction on the broken femur. This traction pin will stay in until patient is taken to surgery for reduction of the femur fracture.
9771035|NCT00916149|Active Comparator|Levetiracetam|12 individuals with epilepsy, 6 of whom experience infrequent focal epileptiform discharges and 6 of whom experience frequent focal discharges. These individuals will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.
9771036|NCT00916149|Active Comparator|Lamotrigine|12 individuals with epilepsy, 6 of whom experience infrequent generalized discharges and 6 of whom experience frequent generalized discharges. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.
9771037|NCT00916149|No Intervention|No treatment|15 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.
9771038|NCT00916279|Experimental|Lutonix Catheter|
9771039|NCT00916305|Experimental|Modified Audio video|Participants will listen to an audio video modified to mimic noise induced hearing loss after one night at a loud club
9771040|NCT00916305|Active Comparator|Unmodified Audio video|Participants will listen to the same music as the other arm, but only the track with unaltered music.
9771041|NCT00916344|Experimental|Pacemaker therapy|
9771042|NCT00916357|Active Comparator|Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.
9784511|NCT01227551|Experimental|Intratumoral injection|Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).
9771043|NCT00916357|Active Comparator|Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
9771044|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
9771045|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.
9771046|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
9771047|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.
9771048|NCT00916370|Experimental|Core size registry (CSR)|Core size indicates the range of diameters of the stents used.
9771049|NCT00916370|Experimental|Long lesion registry (LLR)|Use of long lesion stents.
9771050|NCT00916383|Experimental|Upper Back|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
9771051|NCT00916383|Experimental|Upper Arm|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
9771052|NCT00916383|Experimental|Side of Torso|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
9771053|NCT00916539|Experimental|Cast that immobilizes the thumb|Cast that immobilizes the thumb
9771054|NCT00916539|Active Comparator|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
9771055|NCT00916578|Experimental|Radiation Therapy + Capecitabine|"Capecitabine 825 mg/m2 twice a day. One of the two daily doses of capecitabine should be taken approximately 2 hours before receiving radiotherapy. The first day of Capecitabine is same day that radiotherapy is started, and last day that Capecitabine is given is last day of radiotherapy. Capecitabine administered only on days patient receives radiation therapy.~Radiation therapy dose 50-57 Gy to initial clinical target volume (CTV, gross disease + tissue at risk for micrometastatic disease including margin around gross disease and draining regional lymphatics)."
9771056|NCT00916617|Experimental|1|5 mg/week
9771057|NCT00916643|Experimental|H.E.L.P. Secura|"The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:~Flushing the system with normal saline.~Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.~Mixing the plasma with an equal volume of acetate buffer containing heparin.~Precipitation of LDL as a complex with heparin.~Removing the LDL-heparin precipitate by continuous circulation through a filter.~Removing heparin with use of a heparin adsorber.~Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.~Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient."
9771058|NCT00916721|Active Comparator|Propranolol|propranolol
9771059|NCT00916721|Placebo Comparator|Placebo|sugar pill
9784512|NCT01227564|Experimental|ACC-001 3 μg/ QS-21 50 μg|
9771060|NCT00916929|Other|Implantable Cardioverter Defibrillator (ICD)|Impedance Monitoring Feature in an Implantable Cardioverter Defibrillator (ICD).
9771061|NCT00916929|Other|Cardiac Resynchronization Therapy (CRT-D)|Impedance Monitoring Feature in a Cardiac Resynchronization Therapy (CRT-D) device.
9771062|NCT00917124|Active Comparator|INVOS|INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
9771063|NCT00917124|No Intervention|CONTROL|The CONTROL arm did not have INVOS or any other cerebral oxygenation monitoring, so interventions to control cerebral oxygenation were not performed.
9771064|NCT00917150|Experimental|OPC-6535 12.5mg|
9771065|NCT00917150|Experimental|OPC-6535 25mg|
9771066|NCT00917150|Experimental|OPC-6535 50mg|
9771067|NCT00917150|Placebo Comparator|placebo|
9771068|NCT00917267|Experimental|1|
9771069|NCT00917267|Active Comparator|2|
9771070|NCT00917384|Experimental|ramucirumab|Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
9771071|NCT00917384|Placebo Comparator|Placebo|Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
9771072|NCT00917462|Experimental|Sorafenib|Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer.
9771073|NCT00917501|Placebo Comparator|Placebo|Placebo to the Omega-3 given in other group taken twice a day.
9771074|NCT00917501|Active Comparator|Omega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA & will be taken twice a day.
9771075|NCT00917553|Experimental|doxycycline monohydrate|
9771076|NCT00917553|Placebo Comparator|Placebo|Placebo
9771077|NCT00917579|Other|Reference|10 mg atorvastatin
9771078|NCT00917579|Experimental|Test|New 10 mg atorvastatin tablet
9771079|NCT00917644|Other|Reference|80 mg atorvastatin tablets
9771080|NCT00917644|Experimental|Test|New 80 mg atorvastatin tablets
9771081|NCT00917735|Experimental|Green tea extract|Green tea extract capsules containing 80.7 % total catechins (51.7 % EGCG)
9771082|NCT00917735|Placebo Comparator|Sugar pill|Placebo capsules containing 50% maltodextrin, 49.5 % cellulose, and 0.5 % magnesium stearate
9771083|NCT00917852|Experimental|GORE Conformable TAG® Thoracic Endoprosthesis|
9771084|NCT00917865|Experimental|FACBC Imaging|Dynamic FACBC PET of primary prostate carcinoma.
9771085|NCT00918125||White educational video|Patients will view an educational video that contains White physicians and patients.
9771086|NCT00918125||African-American educational video|Patients will view an educational video that contains African-American physicians and patients.
9771087|NCT00918125||Usual care|Patients will receive counseling about their condition and treatment options.
9771088|NCT00918138|Experimental|Saxagliptin + Metformin XR + matching Metformin XR placebo|(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
9784513|NCT01227564|Experimental|ACC-001 10 μg/ QS-21 50 μg|
9771089|NCT00918138|Active Comparator|Metformin XR + Metformin XR + matching Saxagliptin placebo|(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
9771090|NCT00918203|Active Comparator|Paclitaxel + Carboplatin|"(Initial 4-6 cycles) Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle (Initial 4-6 cycles) Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants who experience progressive disease may cross over to olaratumab monotherapy."
9771091|NCT00918203|Experimental|Olaratumab + Paclitaxel + Carboplatin|"(Initial 4-6 cycles)~Olaratumab 15 milligrams/kilogram (mg/kg) over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit."
9771092|NCT00918229|Other|balloon implantation|implantation of an absorbable perirectal spacer balloon
9771093|NCT00918255|Experimental|Adalimumab 40 mg qwk|Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
9771094|NCT00918255|Experimental|Adalimumab 40 mg eow|Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
9771095|NCT00918255|Placebo Comparator|Placebo|Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
9771096|NCT00918281|Experimental|Fluciclatide Injection|Fluciclatide Injection
9771097|NCT00918333|Experimental|Treatment (panobinostat and everolimus)|Patients receive panobinostat PO QD or on days 1, 3, 5, 15, 17, and 19 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9771098|NCT00918346|Experimental|Tafluprost 0.0015% preserved formulation|
9771099|NCT00918346|Experimental|Tafluprost 0.0015% unpreserved formulation|
9771100|NCT00918385|Active Comparator|1|High Androgen Receptor (AR) activity
9771101|NCT00918385|Active Comparator|2|Low Androgen Receptor (AR) activity
9771102|NCT00918567|Experimental|Combined therapy|atomoxetine plus behavior therapy
9771103|NCT00918567|Active Comparator|Drug therapy|atomoxetine alone
9771104|NCT00918580|Experimental|1|
9771105|NCT00918671||Medication-overuse headache|Chronic daily headache combined with medication overuse
9771106|NCT00918684|Experimental|Escitalopram|12-week open label with 2 week placebo period (14 weeks total)
9771107|NCT00918723|Experimental|Treatment (induction and maintenance chemotherapy)|"INDUCTION THERAPY: Patients receive vorinostat PO once daily on days 1-5 and 8-12; cyclophosphamide IV over 30-60 minutes and fludarabine phosphate IV over 30-60 minutes on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3 months for 2 years in the absence of disease progression or unacceptable toxicity."
10203776|NCT05110521|Experimental|Intervention (PROMPTS and MENTORS offered)|Health facilities randomized into the Intervention Arm will be offered the MENTORS program, which trains in-facility nurse-mentors to provide health workers with training and mentorship on aspects of basic and emergency obstetric and newborn care. At health facilities in the intervention arm, patients attending antenatal care clinics will be offered the PROMPTS program, which is a digital health platform that connects mothers with information, advice and referrals to care.
10203777|NCT05110521|No Intervention|Control (Routine Care/No PROMPTS or MENTORS OFFERED)|In the control arm, neither the PROMPTS program nor the MENTORS program will be offered during the study period.
10203778|NCT05109117|Experimental|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter^2) of ChapStick Active Performance Unscented will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
10203779|NCT05109117|No Intervention|Control Arm|No treatment will be applied to the assigned control site.
10203780|NCT05106465||Konectom|Participants with a diagnosis of MS or clinically isolated syndrome who are enrolled in Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) and who own a smartphone model compatible with the Konectom platform will be enrolled.
10203781|NCT05105711|Experimental|Primary care providers|Providers who treat 11-12 year old adolescent patients in participating Kaiser Permanente Washington pediatric and family medicine practices.
10203782|NCT05099276|Experimental|Oral TXA|1,950 mg oral tranexmic acid (three capsules of 650 mg) administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
10203783|NCT05099276|Placebo Comparator|Oral placebo|Three capsules of cellulose administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
10203784|NCT05092763|Experimental|FIT4SURGERY Intervention|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls.
10203785|NCT05092763|Active Comparator|Healthy Lifestyle Control|The Healthy Lifestyle Control group engages in their usual activities and receives education about physical activity and a healthy lifestyle for ovarian cancer patients. They receive weekly check in calls.
10203786|NCT05087212|Experimental|plerixafor|Participants will receive the first dose of plerixafor by subcutaneous (SC) injection on the evening of Day 4 (10 to 11 hours (± 1 hour) prior to the start of next day's apheresis). For a maximum of 4 days, patients will continue to receive daily plerixafor in the evening, followed by a morning dose of G-CSF and apheresis for up to a maximum of 4 apheresis or until ≥ 6×106 Cluster of differentiation 34 (CD34) + cells/kg were collected.
10203787|NCT05081479|Experimental|Participants with Lymphoma, Cohort 1|The first dose escalation cohort in the study will be treated at 25% of that target dose level
9771108|NCT00918736|Experimental|hyaluronate injection|All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
9784514|NCT01227564|Placebo Comparator|Placebo- Phosphate buffered saline (PBS)|
9771109|NCT00918749|Active Comparator|150 mg|150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
9771110|NCT00918749|Experimental|75 mg|75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
9771111|NCT00918749|Experimental|100 mg|100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
9771112|NCT00918866|Experimental|Low Pulmonary Arterial Pressure|Subjects with pulmonary arterial pressure (PAP) of < or = to 35 mmHg.
9771113|NCT00918866|Experimental|Elevated Pulmonary Arterial Pressure|Subjects with a PAP of > or = to 35 mmHg.
9771114|NCT00918879|Experimental|1|Saxagliptin
9771115|NCT00918879|Placebo Comparator|2|
9771116|NCT00918931|Experimental|Obatoclax Mesylate|30 mg by vein over 3 hours Days 1-3, 14-day cycle
9771117|NCT00918957|Experimental|TIP (Tobramycin Inhalation Powder)|Tobramycin 28 mg powder. The TIP dose of 112 mg twice a day (bis in diem = b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment.
9771118|NCT00918957|Placebo Comparator|Placebo|Placebo 20 mg powder capsules. The dose regimen for the reference product was inhaling the contents of four capsules twice a day (bis in diem = b.i.d.), in the morning and in the evening for 28 days (on treatment), followed by 28 days of no study treatment (off treatment).
9771119|NCT00919035|Experimental|Torisel|Single Agent Temsirolimus (Torisel®)
9771120|NCT00919061|Experimental|Gemcitabine and Cisplatin plus Sorafenib|This is a non-randomized, open label, single institution, phase II study of gemcitabine and cisplatin plus sorafenib for the treatment of patients with advanced or biliary tract carcinomas naïve to systemic therapy.
9771121|NCT00919100|Other|Standard Care|venipuncture with vapocoolant spray offered
9771122|NCT00919100|Experimental|Buzzy|Vibrating device with cold pack held to arm with tourniquet proximal to venipuncture site, optional distraction cards.
9771123|NCT00919113|Experimental|8 weekly bladder instillations of Uracyst|20 mL Uracyst (2% sodium chondroitin sulfate) per instillation; 8 instillations over a 7-week period
9771124|NCT00919113|Placebo Comparator|8 weekly bladder instillations of inactive control|20 mL inactive control buffer (phosphate-buffered saline); 8 instillations over a 7-week period
9771125|NCT00919126|Experimental|Group A|Xenon 50% (45%-55%) in Oxygen (45%-55%),
9771126|NCT00919126|Experimental|Group B|Xenon 70% (65%-75%) in Oxygen (25%-35%)
9771127|NCT00919126|Active Comparator|Group C|Medical Air in Oxygen (45%-55%)
9771128|NCT00919191|Experimental|Two interventions in split-face model|"Once daily use in a split face model:~Tretinoin gel~Adapalene Benzoyl peroxide"
9771129|NCT00919503|Experimental|Regimen A (PBSCT and BMT)|"CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
9771130|NCT00919503|Experimental|Regimen B (UBCT)|"CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD."
9771131|NCT00919633|Experimental|Group 1: interferon alfa-2b (dose 1)|continuous subcutaneous infusion for 48 weeks
9771132|NCT00919633|Experimental|Group 2: interferon alfa-2b (dose 2)|continuous subcutaneous infusion for 48 weeks
9771133|NCT00919633|Experimental|Group 3: interferon alfa-2b (dose 3)|continuous subcutaneous infusion for 48 weeks
9771134|NCT00919633|Active Comparator|Group 4: peginterferon alfa-2b (1.5 μg/kg)|subcutaneous weekly for 48 weeks
9771135|NCT00919711|Experimental|Denosumab 60 mg|
9771136|NCT00919711|Active Comparator|Risedronate 150 mg QM|
9771137|NCT00919724||HIV-Infected|HIV-infected participants who are not currently receiving antiretroviral medications
9771138|NCT00919724||HIV-Uninfected|HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
9771139|NCT00919763|Experimental|CD 2027|Topical Ointment
9771140|NCT00919763|Placebo Comparator|CD 2027 Vehicle|Topical Ointment
9771141|NCT00919802|Active Comparator|Oxytocin|Oxytocin, 40 IU intranasally, once
9771142|NCT00919802|Placebo Comparator|Saline as a nasal spray|Saline, 4ml intranasally, once
9771143|NCT00919854|Experimental|Darunavir (DRV)+Ritonavir (rtv)|Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg. After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg. Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
9771144|NCT00919867|Active Comparator|A: SPD503 (4mg)|
9771145|NCT00919867|Active Comparator|B: VYVANSE (50mg)|
9771146|NCT00919867|Active Comparator|C: SPD503 (4mg) + VYVANSE (50mg)|
9771147|NCT00919932|Active Comparator|Paper and pen homework|Treatment as usual: therapy homework is completed by paper and pen.
9771148|NCT00919932|Experimental|Text-message homework|Experimental treatment: therapy homework is completed by text messaging.
9771149|NCT00920023|Experimental|SPIO MRI|
9784515|NCT01227577|Experimental|Nilotinib|Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.
9771150|NCT00920075||1 Alendronate for 12 months, post study|Participants earlier were treated with alendronate for 12 months either in an open label study (without control) or double blind study with placebo control. These studies were completed. In this post study evaluation, available participants will be scheduled for one clinic visit to assess their current status of the bone density and no treatment is involved.
9771151|NCT00920140|Experimental|Phase I|"The proposed treatment schedule of GSK1120212 is continuous daily dosing. At the initiation of dosing, a loading dose will be given prior to starting continuous dosing (maintenance dose).~Alterations to the dose and schedule will be based on emerging PK, PD, and tolerability data. The goal will be to define a regimen that is well tolerated and provides adequate PK and PD. This will be the recommended Phase II schedule."
9771152|NCT00920140|Experimental|Phase II|A dose determined by Phase I to further evaulate the safety profile, PK, PD, and clinical activity of GSK1120212.
9771153|NCT00920218|Experimental|GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
9771154|NCT00920218|Experimental|GSK 1437173A F2 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
9771155|NCT00920218|Experimental|Placebo-GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
9771156|NCT00920218|Placebo Comparator|Placebo Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
9771157|NCT00920231|Experimental|Arm 1 initial system|"8 blind subjects are asked to use a prototype computer vision system to determine the challenges facing computer vision based indoor navigation.~Subjects are asked to travel through the hallways of a large hospital from the front entrance to a side entrance. The pathway consists of 9 segments including corners, four-way intersections, and doorways, and the total length of the route was approximately 200 meters. This challenging route was designed to stress the capabilities of the navigation system. It is a route that even sighted persons may find difficult to follow without practice. Pedestrian traffic was present throughout the route and lighting conditions could change in two of the segments where there were windows and doors."
9771158|NCT00920231|Experimental|Arm 2 modified system|The system is redesigned in response to problems identified from the first phase of the study. The redesigned system is tested by a second set of 8 blind subjects in the same indoor path as used in Arm 1.
9771159|NCT00920374|Experimental|Fluarix Adult Group|Subjects who are 18-60 years of age received one dose of Fluarix™
9771160|NCT00920374|Experimental|Fluarix Elderly Group|Subjects who are > 60 years of age received one dose of Fluarix™
9771161|NCT00920426|Experimental|GSK1265744 30 mg|GSK1265744 30 mg
9771162|NCT00920426|Experimental|Placebo|Placebo to match GSK1265744
9771163|NCT00920426|Experimental|GSK1265744 5 mg|GSK1265744 5 mg
9771164|NCT00920439|Experimental|POLIORIX GROUP|Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).
9784516|NCT01227629|Experimental|dabigatran 50 mg twice daily (bid)|Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).
9784517|NCT01227629|Experimental|dabigatran 50 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.
9784518|NCT01227629|Experimental|dabigatran 50 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
9784519|NCT01227629|Experimental|dabigatran 150 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
9784520|NCT01227629|Experimental|dabigatran 150 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
10203788|NCT05081479|Experimental|Participants with Lymphoma, Cohort 2|The second cohort in the study will be treated at 50% of that target dose level
10203789|NCT05081479|Experimental|Participants with Lymphoma, Cohort 3|The third cohort in the study will be treated at 100% of that target dose level only if no DLTs are seen at lower doses.
10203790|NCT05079399||Healthy Control|
10203791|NCT05079399||Diabetes but no retinopathy|
10203792|NCT05079399||Mild non proliferative diabetic retinopathy|
10203793|NCT05079399||Moderate non proliferative diabetic retinopathy|
10203794|NCT05079399||Severe non proliferative diabetic retinopathy|
10203795|NCT05079399||Proliferative diabetic retinopathy|
10203796|NCT05077449|Experimental|XZP-3287+Fulvestrant|
10203797|NCT05077449|Placebo Comparator|Placebo + Fulvestrant|
10203798|NCT05074485|Experimental|Placebo plus nociceptive pain challenge, then anakinra plus nociceptive pain challenge|Pharmacological challenge (with placebo) plus nociceptive pain challenge, then pharmacological challenge (with anakinra) plus nociceptive pain challenge
10203799|NCT05074485|Experimental|Anakinra plus nociceptive pain challenge, then placebo plus nociceptive pain challenge|Pharmacological challenge (with anakinra) plus nociceptive pain challenge, then pharmacological challenge (with placebo) plus nociceptive pain challenge
10203800|NCT05073575|Experimental|Hyaluronic acid Group|Hyaluronic acid gel will be applied to exposed dental roots surfaces, after scaling and root planing therapy
10203801|NCT05073575|Active Comparator|No-hyaluronic acid Group|Only scaling and root planning will be performed on the exposed dental roots surfaces
9771165|NCT00920556|Experimental|Treatment|"5.0 g SRT501 will be administered for 20 consecutive days in a 21 day cycle for a maximum of 12 cycles. SRT501 will be administered at the same time each morning (approximately 15-30 minutes after breakfast) on all dosing days. No SRT501 administration will occur on Day 21 of each cycle.~After the first two cycles of SRT501, any subject who exhibits stable disease or better with SRT501 monotherapy (5.0 g/day) will continue for an additional two cycles. If, after the first two cycles, a subject exhibits PD, that subject will receive bortezomib (1.3 mg/m2 on Day 1, Day 4, Day 8, and Day 11 in a 21 day cycle) in conjunction with SRT501. Bortezomib will be administered prior to breakfast and SRT501 administration.~If after two additional cycles of SRT501 monotherapy (4 cycles total), the subject exhibits a MR or better, they they will remain on SRT501 therapy. If PD or SD are exibited, they are to undergo bortezomib regiment listed above."
9771166|NCT00920647|Other|Control|Untreated Patients
9771167|NCT00920647|Experimental|Idursulfase -IT (1 mg)|monthly using an intrathecal drug delivery device (IDDD)
9771168|NCT00920647|Experimental|Idursulfase-IT (10 mg)|monthly using an intrathecal drug delivery device (IDDD)
9771169|NCT00920647|Experimental|Idursulfase -IT (30 mg)|monthly using an intrathecal drug delivery device (IDDD)
9771170|NCT00920686|Experimental|NXN-188|NXN-188, 600 mg, PRN
9771171|NCT00920686|Active Comparator|sumatriptan succinate 100 mg|Sumatriptan, 100 mg, PRN
9771172|NCT00920686|Placebo Comparator|placebo|matching, PRN
9771173|NCT00920699|Experimental|600 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
9771174|NCT00920699|Experimental|1200 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
9771175|NCT00920699|Experimental|2400 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
9771176|NCT00920790|Experimental|KW-0761|
9771177|NCT00920816|Experimental|A|
9771178|NCT00920816|Active Comparator|B|
9771179|NCT00920829|Active Comparator|A118G A/A with Naltrexone|Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
9771180|NCT00920829|Placebo Comparator|A118G A/A with Placebo|Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks
9771181|NCT00920829|Active Comparator|A118G Any G with Naltrexone|Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
9771182|NCT00920829|Placebo Comparator|A118G Any G with Placebo|Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
9771183|NCT00920855|Experimental|Bendamustine and Bortezomib|Bendamustine in escalating doses of 50, 70 or 90 mg/m^2 as combination therapy with bortezomib at 1.0 mg/m^2/dose administered for up to eight 28 day cycles.
9771184|NCT00920907|Experimental|Ipilimumab (Process B)|Reference
9771185|NCT00920907|Experimental|Ipilimumab (Process C)|Test
9771186|NCT00921024|Experimental|1|CXA-101
9771187|NCT00921024|Active Comparator|2|Ceftazidime
9771188|NCT00921115|Experimental|Arimidex + Faslodex|"Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks.~On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery."
9771189|NCT00921310|Experimental|Phase I Dose Level 1 (pemetrexed + temsirolimus)|"-Dose Level 1~Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle~Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle"
9771190|NCT00921310|Experimental|Phase I Dose Level -1 (pemetrexed + temsirolimus)|"Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
9771191|NCT00921310|Experimental|Phase 2 (pemetrexed + temsirolimus)|"Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.~Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
9771192|NCT00921518|Placebo Comparator|Normal Saline|This group will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
9771193|NCT00921518|Active Comparator|Sodium Bicarbonate|This arm two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
9771194|NCT00921557|Experimental|1A: Alendronate/Alendronate|Participants received alendronate for 96 weeks and calcium carbonate/vitamin D for 144 weeks
9771195|NCT00921557|Experimental|1B: Alendronate/Placebo|Participants received alendronate for 48 weeks followed by placebo for 48 weeks and calcium carbonate/vitamin D for 144 weeks
9771196|NCT00921557|Experimental|2: Placebo/Alendronate|Participants received placebo for 48 weeks followed by alendronate for 48 weeks and calcium carbonate/vitamin D for 144 weeks
9771197|NCT00921687|Experimental|Multifactorial intervention|The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
9771198|NCT00921687|Active Comparator|Education only|Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.
9771199|NCT00921843|Experimental|Methadone 0.1mg/kg|Methadone 0.1mg/kg
9771200|NCT00921843|Experimental|Methadone 0.2mg/kg|Methadone 0.2mg/kg
9771201|NCT00921843|Experimental|Methadone 0.3mg/kg|Methadone 0.3mg/kg
9771202|NCT00921843|Placebo Comparator|Control|No methadone
9771203|NCT00921895|Experimental|Device Testing|Patients with conjunctivitis will be tested with the RPS Adeno Detector IV
9771204|NCT00921934||Vitamin C|Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
9771205|NCT00921947|Experimental|VAX102 IM|VAX102 given as 1 µg intramuscular (i.m.)
9771206|NCT00921947|Experimental|VAX102 SC|VAX102 given as a 2 µg subcutaneous (s.c.) dose
9771207|NCT00922116|Experimental|1|
9771208|NCT00922207|Experimental|1|
9771209|NCT00922207|Experimental|2|
9771210|NCT00922207|Placebo Comparator|3|
9784521|NCT01227629|Experimental|dabigatran 150 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
9784522|NCT01227629|Experimental|dabigatran 300 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
9784523|NCT01227629|Experimental|dabigatran 300 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
9784524|NCT01227629|Experimental|dabigatran 300 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
9784525|NCT01227629|Active Comparator|warfarin|once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0
9784526|NCT01227655|Experimental|BIA 9-1067 25 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
9784527|NCT01227655|Experimental|BIA 9-1067 50 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
9784528|NCT01227655|Placebo Comparator|Placebo|PLC, Placebo
9784529|NCT01227668|Experimental|Aripiprazole|
9784530|NCT01227668|Placebo Comparator|Placebo|
9784531|NCT01227681|Experimental|high dose G-CSF|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
9784532|NCT01227681|Active Comparator|low dose G-CSF|low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
9784533|NCT01227681|Placebo Comparator|placebo|Sodium Chloride (NaCl) 0.9 %
9784534|NCT01227707|Experimental|Single Arm|
9784535|NCT01227785||INCEPTA ICD and CRT-D|ICD and CRT-D indicated patients were included in the study. Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).
9784536|NCT01227824|Experimental|GSK1349572 (N=~394)|GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
9784537|NCT01227824|Active Comparator|raltegravir (N=~394)|raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily
9784538|NCT01227889|Experimental|GSK2118436|Subjects in this arm will receive GSK2118436 150 mg twice daily.
9784539|NCT01227889|Active Comparator|Dacarbazine (DTIC)|Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
9784540|NCT01227889|Experimental|Crossover|Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
9784541|NCT01227902|Experimental|Retigabine IR|Open Label flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
9784542|NCT01227928|Experimental|pazopanib|experimental medication
9784543|NCT01227928|Placebo Comparator|placebo|placebo comparator
9784544|NCT01227954|Other|WBRT with Hippocampal Avoidance|Whole brain radiotherapy (WBRT) with hippocampal avoidance using intensity-modulated radiation therapy (IMRT)
9784545|NCT01227967|Experimental|Combination Therapy|Amantadine, Ribavirin, Oseltamivir
9784546|NCT01227967|Active Comparator|Oseltamivir monotherapy|Oseltamivir
9784547|NCT01227980|Active Comparator|Pexacerfont|Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days
9784548|NCT01227980|Placebo Comparator|Placebo|Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days
10203802|NCT05072093|Experimental|All men in cohort: Black MSM|Prospective cohort of young Black MSM who are followed either in-person at the PRISM Health Research Clinic and/or virtually with remote study visits.
10203803|NCT05066230|Experimental|KSI-301 - Treatment Group A|Intravitreal injection of KSI-301 (5 mg): three initiating doses, and then every 24 weeks through Week 92
10203804|NCT05066230|Sham Comparator|Treatment Group B|Sham injection on the same schedule as Treatment Group A
10203805|NCT05063994|Experimental|Chronocort|Hydrocortisone modified-release capsule - Chronocort®. 63 subjects will be randomised to this group using an interactive response technology (IRT).
10203806|NCT05063994|Active Comparator|Cortef|Immediate-release hydrocortisone capsule (IRHC) - Cortef. 63 subjects will be randomised to this group using an interactive response technology (IRT).
10203807|NCT05063903||Fontan Group|"Fontan Group Inclusion Criteria~be between the ages of 8-50 Having undergone Fontan operation in our hospital or another center Clinical stability of the patients (preserved ventricular function), No change in ongoing drug therapy that adversely affects clinical stability, At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital~Fontan Group Exclusion Criteria:~Inability to access the patient's medical data Neurological and/or genetic musculoskeletal disease Having orthopedic and cognitive problems that prevent testing The patient's and/or family's unwillingness to participate in the study"
10203808|NCT05063903||Control Group|"Control Group Inclusion Criteria:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease Not having orthopedic and cognitive problems that prevent testing The patient's and/or family's willingness to participate in the study"
9771211|NCT00922233|Experimental|Levonorgestrel|0.75 mg of levonorgestrel within 24 hours of sex
9771212|NCT00922272|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
9771213|NCT00922272|Placebo Comparator|Placebo|Placebo
9771214|NCT00922428||Observational group|Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.
9771215|NCT00922441|Experimental|Fimasartan 1|Fimasartan 60 mg group
9771216|NCT00922441|Experimental|Fimasartan 2|Fimasartan 120 mg group
9771217|NCT00922441|Active Comparator|Valsartan|Reference (Valsartan 80 mg) group
9771218|NCT00922480|Active Comparator|2|Losartan group
9771219|NCT00922480|Active Comparator|1|Fimasartan 60mg, 120mg
9771220|NCT00922623|Experimental|Belotero®|
9771221|NCT00922636|Active Comparator|Methylphenidate|Extended-release methylphenidate 18 milligrams per day (mg/day) to 54 mg/day, based on weight, given once daily (QD) and orally (po) as a capsule for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
9771222|NCT00922636|Placebo Comparator|Placebo|
9771223|NCT00922636|Experimental|LY2216684 (0.1 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
9771224|NCT00922636|Experimental|LY2216684 (0.2 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
9771225|NCT00922636|Experimental|LY2216684 (0.3 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
9771226|NCT00922701|Experimental|Peritoneal Dialysis Solution|
9771227|NCT00922766||1.0|
9771228|NCT00922779|Experimental|1|
9771229|NCT00922883|Experimental|Eltrombopag|Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.
9771230|NCT00922935|Experimental|Cresco early loading|The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) at 10 days of post surgery
9771231|NCT00922935|Experimental|Cresco late loading|"Healing caps will be placed until loading. The minimum waiting time is 4 weeks, but not before try ins to ensure a perfect fit. The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) within 42-56 days (6 to 8 weeks) of surgery."
9771232|NCT00922935|Active Comparator|Straumann system late loading|Straumann components loading at 6-8 weeks post surgery
9771233|NCT00922974|Experimental|Radiosurgery/SBRT|
9771234|NCT00922974|Active Comparator|External Beam Radiation Therapy|
9771235|NCT00922987||Lyrica|Adult patients with partial seizures (type of epilepsy). Inclusion criteria according to Summary of Product Characteristics
9771236|NCT00923078|Experimental|Auditory-Visual Train Order|4 weeks (20 sessions) of auditory cognitive training (Brain Fitness) followed by 4 weeks (20 sessions) of visual cognitive training (Insight)
9771237|NCT00923078|Experimental|Visual-Auditory Train Order|4 weeks (20 sessions) of visual cognitive training (Insight) followed by 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness)
9771238|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg|olmesartan medoxomil 20mg / amlodipine besylate 5 mg / hydrochlorothiazide 12.5mg
9771239|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg|
9771240|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg|
9771241|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg|
9771242|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg|
9771243|NCT00923091|Experimental|olmesartan/amlodipine 20mg/5mg|olmesartan medoxomil 20mg / amlodipine besylate 5mg
9771244|NCT00923091|Experimental|olmesartan/amlodipine 40mg/5mg|
9771245|NCT00923091|Experimental|olmesartan/amlodipine 40mg/10mg|
9771246|NCT00923117|Experimental|Bevacizumab resistant patients|Patients who had tumor progression while treated with bevacizumab.
9771247|NCT00923117|Experimental|Bevacizumab naive patients|Patients with progressive tumor who have not been treated with bevacizumab.
9771248|NCT00923130|Experimental|Bevacizumab with Ixabepilone|Bevacizumab 15mg/kg every 3 weeks Ixabepilone given on days 1,2,3,4 and 5 of each three week cycle at a dose of 6mg/m(2)/day
9771249|NCT00923156|Experimental|Aliskiren|In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received aliskiren (150 mg once daily) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site and matching placebo of ramipril capsules.
9771250|NCT00923156|Experimental|Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (Period 2), patients received ramipril 10 mg capsule o.d and matching placebo of aliskiren tablet."
9771251|NCT00923156|Experimental|Aliskiren plus Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (period 2), patients received ramipril (10 mg once daily capsule) and aliskiren (150 mg once daily tablet) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site"
9771252|NCT00923195|Experimental|TBI 600cGy + PBL + HD IL-2+gp100:154-162|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
9771253|NCT00923195|Experimental|TBI 600cGy+PBL+HD IL-2+MART-1:26-35(27L)|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
9771254|NCT00923260|Experimental|Roux-en-Y Gastric Bypass/Omentectomy|Laparoscopic Roux-en-Y Gastric Bypass with omentectomy
9771255|NCT00923260|Active Comparator|Roux-en-Y Gastric Bypass alone|
9771256|NCT00923273|Experimental|Treatment level 1 - 3mg load|Sirolimus 3mg load/1mg/day; Pemetrexed 375mg/m^2
9771257|NCT00923273|Experimental|Treatment level 2 - 6 mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
9771258|NCT00923273|Experimental|Treatment level 3 - 6mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
9771259|NCT00923273|Experimental|Treatment level 4 - 10 mg load|Sirolimus 10mg load/3mg/day; Pemetrexed 500mg/m^2
9771260|NCT00923273|Experimental|Treatment level 5 - 15 mg load|Sirolimus 15mg load/5mg/day; Pemetrexed 500mg/m^2
9771261|NCT00923351|Experimental|Arm A - Participants who did not receive rhIL-7|Six patients with Ewings sarcoma family or tumors (ESFT) participants will receive cytotoxic/lympholytic therapy with cyclophosphamide and fludarabine (if cluster of differentiation 4 (CD4) count > 200 cells/mcl). Participant will receive Tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccine followed by Infusion of 8H9/CD25 depleted autologous lymphocyte infusion on Day 1, followed by Tumor lysate/KLH pulsed dendritic cell vaccine on week 4, 6, 8, 10, and 12.
9771262|NCT00923351|Experimental|Arm B - Participants who received rhIL-7|"Eight patients with rhabdomyosarcoma, fifteen patients with Ewings sarcoma family or tumors (ESFT), two patients with desmoplastic small round cell tumor, and one patient with synovial cell sarcoma participants will receive CYT107 20 mcg/kg/dose subcutaneous (SQ) (approx. 48h prior to vaccine[Day 0]), Tumor lysate/KLH pulsed dendritic cell vaccine followed by Infuse 8H9/CD25 depleted autologous lymphocyte infusion on Day 2, followed by CYT107 20 mcg/kg/dose SQ on days 14, 28 and 42 (± 7 days), and Tumor lysate/KLH pulsed dendritic cell vaccine on Days 16, 30, 44, 56, and 70 (± 7 days).~Apheresis/flow cytometry/delayed type of hypersensitivity (DTH) responses for immune endpoint monitoring (skin tests) will be performed on Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (+/- 7 days) (Arm B); and radiographic studies for clinical restaging will be performed on Week 8 and 20 (Arm A) and Days 42 and 126 (+/- 7 days) (Arm B)."
9771263|NCT00923364|Experimental|Recipients and Healthy Related Donors|Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
9771264|NCT00923481|Experimental|Multi-kinase inhibitor Fostamatinib Disodium (R935788)|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
9771265|NCT00923559|Experimental|Mother-Infant Psychoanalytic treatment;MIP|MIP intervention
9771266|NCT00923559|Active Comparator|TAU at Child Health Centres|Regular nurse visits at Child Health Centres according to Swedish infant health care.
9771267|NCT00923598|Active Comparator|1) 0.1% Ropivicaine on Right Leg|Patients will be randomized ot 0.1% Ropivicaine infusion on the right leg and therefore 0.4% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
9771268|NCT00923598|Active Comparator|2) 0.4% Ropivicaine on Right Leg|Patients will be randomized ot 0.4% Ropivicaine infusion on the right leg and therefore 0.1% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
9771269|NCT00923845|Other|Donors|A sibling who is 6/6 HLA --matched with the recipient. Donors undergo donor lymphocyte harvest and stem cell mobilization and harvest.
9771270|NCT00923845|Other|Recipients|Recipients undergo induction therapy, allogeneic stem cell therapy and GVHD prophylaxis.
9771271|NCT00923910|Other|Donors|Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.
10203809|NCT05062135|Experimental|Morphological analysis of endometrium|"PCOS: Seventeen PCOS subjects underwent two endometrial biopsies after the first P4-treated cycle, the first between days 5-9 of the cycle and the other between days 20-22 (i.e., under P4 treatment) of the cycle.~Controls: Thirteen ovulatory control women under two endometrial biopsies, performed after the first month of luteal P4 treatment, the first between days 5-9 and the second between days 20-22 of the cycle To quantify the parameters of interest, images were captured using a high-resolution camera (AxioCam-MCR, Carl Zeiss) adapted to a light microscope (Axiolab, Carl Zeiss) and adjusted with 40× objective lenses. The images were transmitted to a computer with AxioVision Rel 4.2 software (Carl Zeiss). For assessment of glandular and surface epithelial thickness, cell count, and counting newly formed blood vessels, ten images of each endometrial sample were made for each patient. For VEGF-C determination, the numerical density of blood vessels per mm2 was established"
10203810|NCT05061667|Active Comparator|Group I|Group I will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve paravertebral block which is already proven to be effective in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, paravertebral block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the paravertebral space at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
9771272|NCT00923910|Experimental|Recipients|Participants receive donor lymphocytes and vaccines prepared from donors.
9771273|NCT00923936|Active Comparator|KS;classic/HIV+not improved on antiviral|Kaposi's Sarcoma (KS) in patients who are Human immunodeficiency virus (HIV) Negative, HIV infected with stable disease for one year despite antiretroviral therapy or progressive disease despite 4 months of antiretroviral therapy.
9771274|NCT00923936|Active Comparator|All other advanced HIV-asociated KS|All other patients with advanced acquired immune deficiency syndrome (AIDS)-associated KS
9771275|NCT00923949|Experimental|Pioglitazone|45 mg tablet daily by mouth for six weeks
9771276|NCT00923975|Other|Intended Users of the Software|Young adults, parents/guardians of young people under age 18, and healthcare professionals who work with this population would be intended users of the data management program. The DIDGET World Reports software is used to upload blood glucose results from the DIDGET Blood Glucose Monitoring System so that intended users can identify patterns in their diabetes management.
9771277|NCT00924001|Experimental|Metastatic Melanoma|Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.
9771278|NCT00924040|Experimental|BL22 Immunotherapy|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
9771279|NCT00924053|Experimental|EGT0001474|
9771280|NCT00924053|Placebo Comparator|Placebo|
9771281|NCT00924066|Experimental|Squamous and Nonsquamous participants|"Squamous cell carcinoma is a histologic subtype of cervical cancer. Squamous cell carcinoma of the cervix (80%) is much more common than adenocarcinoma of the cervix.~Non squamous carcinoma is a histologic subtype of cervical cancer. It is the second most common form of cervical cancer; consists of adenocarcinoma, adenosquamous and non squamous (not otherwise specified) subtypes.~All participants in both arms received ixabepilone 6 mg/m^2 x 5 days, each cycle."
9771282|NCT00924118|Experimental|Sodium Nitrite|Dose escalation of sodium nitrite.
10203811|NCT05061667|Experimental|Group II|Group II will consist of randomly assigned patients scheduled for thoracic surgery. These patients will recieve rhomboid block which is being experimented for its efficacy in postoperative pain. After applying standart monitors to the patient and proper positioning in the operating room, rhomboid block will be performed at the planned surgical side using high frequency (8-18 MHz) linear probe of GE Logiq S7 (General Electric Healthcare, Little Chalfont, United Kingdom). 20 ml of 0.25% bupivacaine will be administered into the plane between rhomboid muscle and intercostal muscles, medial to scapula at T5-T6 vertebra levels using a 50 mm 22 G block needle (BBraun, Melsungen, Germany).
10203812|NCT05058560|Experimental|BACE+Tislelizumab|BACE was performed on the first day of the first cycle, and the first 200 mg of tislelizumab was given 3-5 days later.
9771283|NCT00924118|No Intervention|Open Control|Standard therapy
9771284|NCT00924209|Experimental|Stage IIIA lung cancer patients|Non-squamous cell non small cell lung cancer treated with 1250 mg/m^2 gemcitabine dose for two doses on day 1 and day 8 every 21 days,80 mg/m^2 cisplatin day 1 every 21 days for 3 cycles, 7.5 mg/kg bevacizumab on day 1 every 21 days for first 2 cycles only, and 100 mg/m^2 intravenous, and 100 mg/m^2 etoposide intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
9771285|NCT00924287|Experimental|Metastatic Cancer|Cancer that has invaded other parts of the body
9771286|NCT00924313|Experimental|11C-acetate for Prostate Cancer Patients|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
9771287|NCT00924352|Experimental|Ixabepilone + Dasatinib|"Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.~Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD."
9771288|NCT00924404|Experimental|Xylitol|isotonic xylitol for sinus rinse
9771289|NCT00924404|Active Comparator|Saline|saline for sinus rinse
9771290|NCT00924443|Experimental|Clofarabine|Clofarabine 30 mg/m^2/day intravenously over 1 hour for 5 days every 28 to 42 days (one cycle), then 20mg/m^2/day intravenously over 1 hour for 5 days every 29 to 43 days for the second and subsequent cycles, up to a maximum of 3 cycles.
9771291|NCT00924469|Experimental|Abiraterone plus leuprolide plus prednisone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
9771292|NCT00924469|Active Comparator|Leuprolide then abiraterone plus leuprolide plus prednisone|Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.
9771293|NCT00924482|Other|Single Arm - Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
9771294|NCT00924508|Experimental|Patch + cream, patch alone, cream alone|This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.
9771295|NCT00924560|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
9771296|NCT00924560|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).
9771297|NCT00924560|No Intervention|Untreated Control|Participants received no oral contraceptives during the study.
9771298|NCT00924612|Experimental|Fasting (Treatment A)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state
9771299|NCT00924612|Experimental|Very low fat diet (Treatment B)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with very low fat (6-10% fat).
9771300|NCT00924612|Experimental|Low fat diet (Treatment C)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with low fat (20% fat).
9771301|NCT00924612|Experimental|Normal diet (Treatment D)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with normal fat (30% fat).
9771302|NCT00924612|Experimental|High fat diet (Treatment E)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with high fat (50% fat).
9771303|NCT00924638|Active Comparator|Continuous Monitoring|Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
9771304|NCT00924638|No Intervention|Control Arm|Follow-up at the same frequency, but with no Insertable Cardiac Monitor
9771305|NCT00924651|Experimental|Standard Care + EXCAP|Personalized exercise prescription
9771306|NCT00924651|No Intervention|Standard Care|Wait list control
9771307|NCT00924664|Experimental|Tanezumab 20 mg|
9771308|NCT00924664|Experimental|Tanezumab 10 mg|
9771309|NCT00924703|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses dependent on safety and efficacy.
9771310|NCT00924729|Active Comparator|Moxifloxacin 0.5% ophthalmic solution|
9771311|NCT00924729|Active Comparator|Besifloxacin 0.6% ophthalmic suspension|
9771312|NCT00924781|Experimental|MK2578 1 mcg for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment every week (QW).
9771313|NCT00924781|Experimental|1 mcg of MK2578 for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
9771314|NCT00924781|Experimental|MK2578 1 mcg for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
9771315|NCT00924781|Experimental|1 mcg of MK2578 for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
9771316|NCT00924781|Experimental|MK2578 1 mcg for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
9771317|NCT00924781|Experimental|1 mcg of MK2578 for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
9771318|NCT00924820|Experimental|Bevacizumab|Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.
9771319|NCT00924885|Experimental|Thin Follicle Aspiration Needle|Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the RN needle that had an outer diameter of 0.9 mm (20 gauge) and inner diameter of 0.6 mm for the last 50 mm from the tip of the needle and an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg.
9771320|NCT00924885|Active Comparator|Standard Follicle Aspiration Needle|"Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the SN needle that had an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. or the SN with an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the whole length of the needle.~The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg."
9771321|NCT00924898|Experimental|Acute HIV Treatment Group|Single arm, open label study in which all participants received the same study treatment with efavirenz, emtricitabine, and tenofovir DF
9771322|NCT00924950|Active Comparator|Taclonex Ointment/Hydrogel Patch Applied Topically Once Daily|Taclonex ointment once daily used to treat one psoriatic plaque, along with the Hydrogel Patch used once daily.
9771323|NCT00924950|Active Comparator|Taclonex Ointment Topically Once Daily|
9771324|NCT00925002|Active Comparator|Open-Label|
9771325|NCT00925015|Experimental|Cetux/Irin - Dmab 10 mg/kg|After treatment with Cetuximab (Cetux) and Irinotecan (Irin), Dalotuzumab (Dmab) was administered as an intravenous infusion at 10 mg/kg in Cycle 1 on Days 22, 29 and 36; followed in subsequent cycles by treatment with 10 mg/kg on Days 1, 8, 15, 22, 29 and 36. Each cycle was 6 weeks long.
9771326|NCT00925015|Experimental|Cetux/Irin - Dmab 15/7.5 mg/kg|After treatment with Cetux/Irin, Dmab was administered as an intravenous infusion at 15 mg/kg in Cycle 1 on Days 8, 22 and 36; followed in subsequent cycles by treatment with 7.5 mg/kg on Days 8, 22 and 36. Each cycle was 6 weeks long.
9771327|NCT00925015|Experimental|Dmab 10 mg/kg - Cetux/Irin (DDI)|Dmab was administered in each cycle as an intravenous infusion at 10 mg/kg once weekly on Days 1, 22 and 29; followed by treatment with Cetux/Irin. For Drug-Drug Interaction (DDI). Each cycle was 6 weeks long.
9771328|NCT00925054|Experimental|rAvPAL-PEG 0.001 mg/kg|Subjects will start on rAvPAL-PEG 0.001 mg/kg
9771329|NCT00925054|Experimental|rAvPAL-PEG 0.003 mg/kg|Subjects will start on rAvPAL-PEG 0.003 mg/kg
9771330|NCT00925054|Experimental|rAvPAL-PEG 0.01 mg/kg|Subjects will start on rAvPAL-PEG 0.01 mg/kg
9771331|NCT00925054|Experimental|rAvPAL-PEG 0.03 mg/kg|Subjects will start on rAvPAL-PEG 0.03 mg/kg
9771332|NCT00925054|Experimental|rAvPAL-PEG 0.1 mg/kg|Subjects will start on rAvPAL-PEG 0.1 mg/kg
9771333|NCT00925119|Experimental|Atenolol|Participants will receive atenolol for 8 weeks.
9771334|NCT00925132|Experimental|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
9771335|NCT00925288|Active Comparator|Regular schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,2,6 months
9771336|NCT00925288|Experimental|Modified Schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,3,6 months
9771337|NCT00925301|Experimental|Migalastat|Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
9771338|NCT00925301|Placebo Comparator|Placebo|Placebo capsule taken orally QOD for 6 months.
9771339|NCT00925353|Experimental|lidocaine gel|
9771340|NCT00925522|Experimental|Therapy Cool Path Duo Cardiac Ablation System|All patients who are eligible receive cardiac ablation procedure for Ischemic Ventricular Tachycardia
9771341|NCT00925587|Active Comparator|Q2W|Q2W administration of darbepoetin alfa.
9771342|NCT00925587|Active Comparator|QM|QM administration of darbepoetin alfa
9771343|NCT00925600|Placebo Comparator|Placebo|Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
9771344|NCT00925600|Experimental|Denosumab|Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
9771345|NCT00925704|Active Comparator|Calcitriol|
9771346|NCT00925704|Experimental|Lanthanum carbonate + calcitriol|
9771347|NCT00925704|Experimental|Sevelamer carbonate + calcitriol|
9771348|NCT00925756|Experimental|Maraviroc 150 mg, 300 mg, or 600 mg twice daily|"This was a single arm study where Maraviroc was added for 24 weeks.~Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:~150 mg twice daily with strong CYP3A4 inhibitors, including:~Protease inhibitors (except tipranavir/ ritonavir)~Delavirdine~ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin~Darunavir/r + etravirine~300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:~Tipranavir/ ritonavir~Nevirapine~All NRTIs~Enfuvirtide~600 mg twice daily with strong CYP3A4 inducers, including:~Efavirenz, etravirine~rifampin"
9771349|NCT00925769|Experimental|1|
9771350|NCT00925782|Other|Melphalan-Alkeran|Subjects begin with treatment Melphalan and crossover to treatment Alkeran
9771351|NCT00925782|Other|Alkeran-Melphalan|Subjects begin with treatment Alkeran and crossover to treatment Melphalan.
9771352|NCT00925899|Experimental|Melatonin|20 mg
9771353|NCT00925899|Placebo Comparator|Placebo|
9771354|NCT00925938|Experimental|Misoprostol vaginal priming insert (MVPI)|One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
9771355|NCT00925938|Placebo Comparator|MVPI Placebo|One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
9771356|NCT00925990|Experimental|CTS-1027 + ribavirin|Study drug plus ribavirin
9771357|NCT00925990|Experimental|CTS-1027 + placebo|Study drug plus placebo for ribavirin
9771358|NCT00926003|Experimental|Full Computerized Cognitive Training|Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. Each training game become more difficult as the child gains proficiency.
9771359|NCT00926003|No Intervention|Control|Passive Control with no intervention training (computer cognitive games) for 8 weeks.
9771360|NCT00926003|Active Comparator|Limited computerized cognitive training|"Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. In this arm, however, the training games do NOT become progressively more difficult as the child gains proficiency, but rotates randomly among simpler to moderate levels of difficulty for each game. The purpose to to give children int he limited CCRT arm comparable exposure to the cognitive games training as with the full CCRT arm, with the exception of the titrating nature of the game training."
9771361|NCT00926029|Placebo Comparator|Fluoride control -A|Winterfresh Gel
9771362|NCT00926029|Active Comparator|Triclosan/Fluoride - B|Positive control (Total toothpaste)
9771363|NCT00926029|Experimental|Triclosan/fluoride/metal salt- C|test toothpaste
9771364|NCT00926185|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
9771365|NCT00926185|Experimental|0.1% Lifitegrast|Lifitegrast
9771366|NCT00926185|Experimental|1.0% Lifitegrast|Lifitegrast
9771367|NCT00926185|Experimental|5.0% Lifitegrast|Lifitegrast
9771368|NCT00926211|Experimental|Computer-Assisted|Hair harvest using the computer-assisted system
9771369|NCT00926211|Active Comparator|Manual Harvest|Hair harvesting via manual technique
9771370|NCT00926237|Experimental|Sham followed by active 1Hz, then active 10Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 1Hz and then active rTMS at 10 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
9771371|NCT00926237|Experimental|Sham followed by active 10Hz and active 1Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 10 Hz and then active rTMS at 1 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
9771372|NCT00926263|Experimental|10 mg/kg cohort|
9771373|NCT00926263|Experimental|20 mg/kg cohort|
9771374|NCT00926263|Experimental|20/20 mg/kg cohort|
9771375|NCT00926289|Active Comparator|Telmisartan|Telmisartan 80 mg
9771376|NCT00926289|Experimental|Telmisartan/hydrochlorothiazide|Telmisartan80mg/Hydrochlorothiazide25mg
9771377|NCT00926328|Active Comparator|A -Experimental toothpaste|triclosan/copolymer/fluoride toothpaste
9771378|NCT00926328|Placebo Comparator|B - control toothpaste|sodium fluoride only toothpaste (placebo)
9771379|NCT00926367|Experimental|Clinidamycin/ Benzoyl Peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).
9771380|NCT00926367|Active Comparator|Benzoyl peroxide and adapalene|Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene
9771381|NCT00926380|Experimental|denosumab ONLY|
9771382|NCT00926380|Experimental|teriparatide (Forteo®) ONLY|
9771383|NCT00926380|Experimental|denosumab and teriparatide (Forteo®)|
9771384|NCT00926393|Active Comparator|Quetiapine Immediate Release (IR)|Quetiapine 25, 100, 200 and 300 mg
9771385|NCT00926393|Active Comparator|Quetiapine Extended Release (XR)|Quetiapine 50, 200, 300
9771386|NCT00926497|Experimental|Procalcitonin group|Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
9771387|NCT00926497|No Intervention|Standard group|Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters
9771388|NCT00926536|Experimental|C-arm CT + DSA as needed'|In the group of subjects randomized in this group, the image guidance component of the procedure will be conducted by the acquisition of 3D CT-like images during a trans-hepatic arterial injection of iodinated contrast agent for road mapping the tumor feeding vessels and supplemented by DSA as needed by the operating physician as imaging guidance for planning tumor(s) treatment approach.
9771389|NCT00926536|Active Comparator|DSA only|In the group of subjects randomized in this group, present standard of care, i.e DSA imaging only will be used by the operating physician to map out the tumor vessels and used for treatment approach. Additional 3D CT-like images will be obtained, but only used if the operator cannot perform adequate planning using DSA alone.
9771390|NCT00926588|Experimental|Stepped Care|Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
9771391|NCT00926588|No Intervention|Usual Care|Patients receive usual care for pain from their primary care physician
9771392|NCT00926783|Active Comparator|(1) targeted CFAE ablation|
9771393|NCT00926783|Active Comparator|(2) generalized CFAE ablation|
9771394|NCT00926796|Experimental|Regimen B: gemifloxacin plus azithromycin|Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
9771395|NCT00926796|Experimental|Regimen A: gentamicin plus azithromycin|Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.
9771396|NCT00926848|Experimental|PaTH intervention group|"The PaTH intervention group for patients and partners consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions~18 educational sessions. The intervention consisted of patients and partners participating together in a formal cardiac rehabilitation program when typically just patients participate. In addition, partners were asked to make the same healthy eating and exercise changes that patients did to meet guidelines for health."
9771397|NCT00926848|Active Comparator|Usual care group|"The usual care group intervention for patients only consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions and 18 educational sessions~Partners participated in the 18 educational sessions only."
9771398|NCT00926887|Sham Comparator|Placebo Laser|Placebo Laser is an inactive light
9771399|NCT00926887|Active Comparator|Erchonia EML Laser|Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.
9771400|NCT00926952|Experimental|MAL-PDT 90 min incubation, no occlusion|Patients had 2-4 g of Methylaminolevulinate (MAL) spread on the entire face without occlusion and waited 90 minutes prior to photodynamic therapy (PDT) using red light.
9771401|NCT00927069|Experimental|Group A|Patients who have shown an unsatisfactory response to 3 months of etanercept 50 mg twice a week without dose reduction prior to screening.
9771402|NCT00927069|Experimental|Group B|Patients who showed a satisfactory response to 3 months or more of etanercept 50 mg twice a week followed by a loss of response after dose reduction to 50 mg etanercept once a week prior to screening.
9771403|NCT00927069|Experimental|Group A dose increase at Week 12|Patients in group A who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
9771404|NCT00927069|Experimental|Group B dose increase at Week 12|Patients in group B who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
9771405|NCT00927082|Experimental|PEG-IFN 90mcg 24 Wks|Participants received Pegasys (Pegylated interferon alfa-2a [PEG-IFN]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.
9771406|NCT00927082|Experimental|PEG-IFN 180mcg 24 Wks|Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.
9771407|NCT00927082|Experimental|PEG-IFN 90mcg 48 Wks|Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
9771408|NCT00927082|Experimental|PEG-IFN 180mcg 48 Wks|Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
9771409|NCT00927095|Active Comparator|Continuous OC (EE/DROS)|Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)
9771410|NCT00927095|Active Comparator|Intermittent OC (EE/DROS)|Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)
9771411|NCT00927095|Placebo Comparator|Placebo|Continuous daily oral placebo
9771412|NCT00927160||MACE group|Elderly patients admitted to the Mobile Acute Care of the Elderly Unit.
9771413|NCT00927160||Usual Care group|Elderly patients admitted to the general medicine service in the hospital
9771414|NCT00927186|Experimental|Teriparatide|
9771415|NCT00927186|Active Comparator|Zoledronic Acid|
9784549|NCT01227993|Experimental|Finasteride|Participants are treated with 5 mg oral finasteride daily when they have clinically significant subretinal fluid accumulation, defined as any subretinal fluid in the macula with a volume of at least 0.1 microliter and causing visual change such as reduced acuity, metamorphopsia, or microperimetry deficits.
9784550|NCT01228019||All participants|Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)
9784551|NCT01228071|Experimental|40 mg daily dose of testosterone gel 2%|testosterone gel 2%
9784552|NCT01228084|Experimental|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
9784553|NCT01228149|Active Comparator|Diamox/DexaEDO|Patients receive Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy. 7 days preoperatively DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally. Patient will undergo trabeculectomy.
9784554|NCT01228149|Experimental|Cosopt S|Patients receive Cosopt S (dorzolamide/timolol) eye drops starting 28 days before trabeculectomy.
9784555|NCT01228175|Active Comparator|Varenicline|Varenicline
9771416|NCT00927251|Experimental|Model 4296 LV Lead|Non-randomized study
9771417|NCT00927264|Experimental|Behavioral|"Motivational Interviewing Intervention Plus Education~Caregivers will receive a home-based motivational interviewing intervention for ETS reduction plus an educational program for ETS reduction."
9771418|NCT00927264|Active Comparator|Education Only|Caregivers will receive only educational program for ETS reduction.
9771419|NCT00927355|Active Comparator|Pioglitazone|half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician.
9771420|NCT00927355|Placebo Comparator|Placebo|"The other half will be randomized to placebo for 6 months. The placebo pills also start out with one 15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
9771421|NCT00927368|Active Comparator|Ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
9771422|NCT00927368|Active Comparator|Ultrasound guidance needle stimulation|For the ultrasound guidance and needle stimulation arm, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation
9771423|NCT00927368|Active Comparator|Ultrasound guidance+catheter stimulation|For the ultrasound guidance and catheter stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
9771424|NCT00927394|Experimental|Combination Therapy: Aliskiren + Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks
9771425|NCT00927394|Active Comparator|Monotherapy: Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks.
9771426|NCT00927472|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
9771427|NCT00927472|Active Comparator|Nix Creme Rinse|Nix applied to scalp for 10 minutes
9771428|NCT00927485|Experimental|Curcumin|Curcumin
9771429|NCT00927485|Placebo Comparator|Placebo|Placebo (sugar pills)
9771430|NCT00927563|Experimental|Tolcapone|Tolcapone 100-300mg/day
9771431|NCT00927576||Control subjects|Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
9771432|NCT00927576||TBI patients|TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
9771433|NCT00927589|Experimental|1|
9771434|NCT00927758|Active Comparator|Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
9771435|NCT00927758|Active Comparator|Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
9771436|NCT00927758|Active Comparator|Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
9784556|NCT01228175|Placebo Comparator|Microcrystal Cellulose|Microcrystal cellulose placebo
9771437|NCT00927758|Active Comparator|Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
9771438|NCT00927758|Active Comparator|Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
9771439|NCT00927758|Active Comparator|Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
9771440|NCT00927784|Sham Comparator|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media alone (placebo).
9771441|NCT00927784|Experimental|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs in sequential cohorts.
9771442|NCT00927810|Experimental|canakinumab|
9771443|NCT00927823|Experimental|PF-04691502 Treatment|
9771444|NCT00927849|Active Comparator|surgical group lateral sphincterotomy|underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
9771445|NCT00927849|Active Comparator|Glycerin trinitrate group|all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
9771446|NCT00927849|Active Comparator|botulinum toxin injection|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
9771447|NCT00927862|Active Comparator|Standard IWPC warfarin dosing algorithm|Standard International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm.
9771448|NCT00927862|Experimental|Modified IWPC warfarin dosing algorithm|Modified International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm
9771449|NCT00927862|Other|Historical controls|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records database of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic (PG)-guided cohorts (July 2008 through December 2010). Patients ≥18 years old initiating warfarin therapy with a baseline and at least 1 follow-up international normalized prothrombin time ratio (INR) level between days 3-14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG based.
9771450|NCT00927888|Active Comparator|1 - Bupivacaine Block|3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
9771451|NCT00927888|Placebo Comparator|2 - Placebo|Normal saline with Epi 1:100,000 (B block)
9771452|NCT00927901|Experimental|Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate|In treatment period 1, patients received indacaterol maleate 400 μg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 μg; and in treatment period 4, patients received indacaterol acetate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9771453|NCT00927901|Experimental|Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo|In treatment period 1, patients received indacaterol xinafoate 400 μg; in treatment period 2, patients received indacaterol maleate 400 μg; in treatment period 3, patients received indacaterol acetate 400 μg; and in treatment period 4, patients received placebo to indacaterol 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9784557|NCT01228318|Experimental|Zoledronic acid|Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
9771454|NCT00927901|Experimental|Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate|In treatment period 1, patients received indacaterol acetate 400 μg; in treatment period 2, patients received indacaterol xinafoate 400 μg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9771455|NCT00927901|Experimental|Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate|In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 μg; in treatment period 3, patients received indacaterol maleate 400 μg; and in treatment period 4, patients received indacaterol xinafoate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
10203813|NCT05056987|Other|TOTAL30, then AOHP|Lehfilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. The lehfilcon A contact lenses will be worn for approximately 28 days. The senofilcon A contact lenses will be worn for approximately 14 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
10203814|NCT05056987|Other|AOHP, then TOTAL30|Senofilcon A contact lenses worn first, with lehfilcon A contact lenses worn second, as randomized. The senofilcon A contact lenses will be worn for approximately 14 days. The lehfilcon A contact lenses will be worn for approximately 28 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
9771456|NCT00927927|Experimental|SD 0.0002 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg
9771457|NCT00927927|Experimental|SD 0.0012 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg
9771458|NCT00927927|Experimental|SD 0.007 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg
9771459|NCT00927927|Experimental|SD 0.035 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg
9771460|NCT00927927|Experimental|SD 0.175 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg
9771461|NCT00927927|Experimental|SD 0.7 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg
9771462|NCT00927927|Experimental|SD 2.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg
9771463|NCT00927927|Experimental|SD 7.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg
9771464|NCT00927927|Experimental|SD Placebo|Subjects were injected once with placebo
9771465|NCT00927927|Experimental|MD 0.02 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg
9771466|NCT00927927|Experimental|MD 0.3 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg
9771467|NCT00927927|Experimental|MD 1.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg
9771468|NCT00927927|Experimental|MD 1.6 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg
9771469|NCT00927927|Experimental|MD 4.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg
9771470|NCT00927927|Experimental|MD Placebo|Subjects were injected biweekly four times with placebo
9771471|NCT00927940|Experimental|Drug Eluting Stent|All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. A patient with one or two lesions treated with stents of diameter 2.5mm - 3.5mm will be designated in this study.
9771472|NCT00927992||Patients with haemophilia who undergo liver transplantation|Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.
9771473|NCT00928018|Active Comparator|Sirolimus-Containing Regimen|"The Sirolimus containing arm will consist of the following drugs:~Experimental Arm: tacrolimus + sirolimus + low-dose methotrexate~Tacrolimus: Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Sirolimus:Given as a loading oral dose of 12 mg on day -3, then as a daily maintenance dose of 4 mg starting on day -2.~Methotrexate: Administered by intravenous bolus infusion, per institutional standard, at a dose of 5 mg/m2 on days +1, +3 and +6."
9771474|NCT00928018|Active Comparator|Sirolimus-Free regimen|"There are two choices for the Sirolimus free arm:~Control Arm 1: tacrolimus + methotrexate~Tacrolimus:Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Methotrexate:Administered by intravenous bolus infusion at a dose of 5 mg/m2 on days +1, +3 and +6. For patients receiving stem cells from unrelated donors, an additional dose will be given on day +11.~Control Arm 2: cyclosporine + MMF~Cyclosporine: administered orally at a dose of 6 mg/kg based on ABW bid starting on day -3.~MMF:administered at a dose of 3gm daily orally (or intravenously if the patient cannot tolerate oral administration) divided in 2 or 3 doses (bid or tid) depending on physician preference starting on day 3."
9771475|NCT00928057|Experimental|4 mm / 8 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 8mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
10203815|NCT05046444||Unclear diagnosis via conventional methods|The study population consists of carefully chosen patients with potential hematological malignancy, for which current diagnostic methods were not sufficient to provide clear-cut diagnosis and definitive clinical guidance. SIRIUS will be conducted for a total number of 110 patients with inconclusive diagnosis by gold standard techniques for a total of up to nine months after the first enrollment.
9771476|NCT00928057|Experimental|4 mm / 5 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 5mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
9771477|NCT00928070|Experimental|Fesoterodine|
9771478|NCT00928070|Placebo Comparator|Placebo|
9771479|NCT00928083|Experimental|Part A - 50 mg Single Dose|OZ439 Single doses of 50mg (capsules)
9771480|NCT00928083|Experimental|Part A - 100mg Single Dose|OZ439 Single doses of 100mg (capsules)
9771481|NCT00928083|Experimental|Part A - 200mg Single Dose|OZ439 Single doses of 200mg (capsules)
9771482|NCT00928083|Experimental|Part A - 400mg Single Dose|OZ439 Single doses of 400mg (capsules)
9771483|NCT00928083|Experimental|Part A - 400mg Single Dose + Food|OZ439 Single doses of 400mg (capsules) administered with food.
9771484|NCT00928083|Experimental|Part A - 400mg AD Single Dose|OZ439 Single doses of 400mg (aqueous dispersion)
9771485|NCT00928083|Experimental|Part A - 800mg Single Dose|OZ439 Single doses of 800mg (capsules)
9771486|NCT00928083|Experimental|Part A - 800mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
9771487|NCT00928083|Experimental|Part A - 1200mg Single Dose|OZ439 Single doses of 1200mg (capsules)
9771488|NCT00928083|Experimental|Part A - 1600mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
9771489|NCT00928083|Placebo Comparator|Part A - Placebo|Placebo control for Single rising Part A
9771490|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fed|Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
9771491|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fast|Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
9771492|NCT00928083|Experimental|Part C - 200mg AD Multiple Dose|200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
9771493|NCT00928083|Experimental|Part C - 400mg AD Multiple Dose|400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
9771494|NCT00928083|Experimental|Part C - 800mg AD Multiple Dose|800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
9771495|NCT00928083|Placebo Comparator|Part C - Placebo|Placebo control for Multiple rising Part C
9771496|NCT00928135|Active Comparator|7% Hypertonic saline|5 ml of 7% saline twice daily
9771497|NCT00928135|Experimental|Hypertonic xylitol|5 ml of 15% xylitol twice daily
9771498|NCT00928174|Experimental|Single Arm|Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.
9771499|NCT00928187|Active Comparator|Arm A|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
9771500|NCT00928187|Active Comparator|Arm B|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
9771501|NCT00928187|Active Comparator|Arm C|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
9771502|NCT00928200|Experimental|Single Arm|All patients receive Vincristine, Dexamethasone, Doxorubicin, and Cytarabine. Dexrazoxane optional on Day 1. Erwinase is started between Days 3-5 and is given every M-W-F for a total of 10 doses. Patients with CNS 1 or 2 receive Methotrexate intrathecally on Day 15. Patients with CNS 3 receive Triple Intrathecal Therapy (Methotrexate, Cytarabine and Hydrocortisone) on Days 8, 15, and 22.
9771503|NCT00928252|Experimental|Received 18F-fluorocholine PET/CT|IV fluorine-18 labeled methylcholine before PET/CT
9771504|NCT00928304|Experimental|Florbetaben (BAY94-9172)|
9771505|NCT00928395|Active Comparator|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
9771506|NCT00928408||Cinacalcet|
9771507|NCT00928421|Experimental|Varisolve 0.125%|
9771508|NCT00928434|Experimental|DI (Degarelix Intermittent)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.~During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered."
9771509|NCT00928434|Experimental|DC (Degarelix Continuous)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall"
9771510|NCT00928434|Active Comparator|LC (Leuprolide Continuous)|"Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer's labeling directions.~One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer's labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).~On Investigator's discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels."
9771511|NCT00928486|Experimental|Lenalidomide and Dexamethasone|Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance <60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.
9771512|NCT00928512|Experimental|Secukinumab 25mg|Secukinumab 25mg s.c. q4wk
9771513|NCT00928512|Experimental|Secukinumab 75mg|Secukinumab 75mg s.c. q4wk
9771514|NCT00928512|Experimental|Secukinumab 150mg|Secukinumab 150mg s. c. q4wk
9771515|NCT00928512|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c. q4wk
9771516|NCT00928512|Placebo Comparator|Secukinumab Placebo|Secukinumab Placebo s.c. q4wk
9771517|NCT00928564|Active Comparator|Pudendal Block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
9771518|NCT00928564|Placebo Comparator|Placebo|5ml of saline at each block site
9771519|NCT00928642|Experimental|Oral Imatinib plus intravenous gemcitabine|"All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.~All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .~All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy."
9771520|NCT00928668|Experimental|Olodaterol (BI1744) Low|Single dosing of low dose Olodaterol inhaled orally from Respimat Device
9771521|NCT00928668|Experimental|Olodaterol (BI1744) Medium Low|Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device
9771522|NCT00928668|Experimental|Olodaterol (BI1744) Medium High|Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device
9771523|NCT00928668|Experimental|Olodaterol (BI 1744) High|Single dosing of high dose Olodaterol inhaled orally from Respimat Device
9771524|NCT00928668|Placebo Comparator|Placebo|Single dosing of Olodaterol placebo inhaled orally from Respimat Device
9771525|NCT00928694|Active Comparator|1|Fenofibrate U.S. Formulation
9771526|NCT00928694|Active Comparator|2|Fenofibrate UK Formulation
9771527|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_1|50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
9771528|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_2|50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
9771529|NCT00928720|Active Comparator|CES device|Participants will use the device for 60 minutes each day for 8 weeks.
9771530|NCT00928720|Sham Comparator|Sham device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
9771531|NCT00928720|No Intervention|Usual care alone|No intervention; participants will receive usual medical care
9771532|NCT00928746|Other|ATROVENT 42mcg|
9771533|NCT00928772|Active Comparator|Alpha-Stim intervention|One hour Alpha-Stim intervention with sham midazolam
9771534|NCT00928772|Sham Comparator|Sham Alpha-Stim with midazolam|Sham Alpha-Stim intervention with real midazolam administration
9771535|NCT00928772|Placebo Comparator|Placebo|No Alpha-Stim and only topical anesthetics
9771536|NCT00928889|Experimental|Nateglinide 120 mg|Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
9771537|NCT00928889|Active Comparator|Acarbose 50 mg|Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
9771538|NCT00928954|Active Comparator|Gabapentin|Increasing dose to 300 mg four times per day (total of 1200 mg/day)
9771539|NCT00928954|Active Comparator|Memantine|Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
9771540|NCT00929071|Experimental|Pain assessment for Evolence/topical anesthetic|Assess injection pain severity for a one time 1.0 mL injection of Evolence with 0.2 ml of topical anesthetic, applied 30 minutes prior to injection, to the left nasolabial fold of each participant .
9771541|NCT00929071|Experimental|Pain assessment for Evolence/Lidocaine|Assess injection pain severity for a one time 1.0 mL injection of Evolence mixed with 0.18 mL of 2% lidocaine (0.3% final lidocaine-HCl) in the right nasolabial fold of each participant.
9771542|NCT00929110|Experimental|Glycopyrronium bromide 50 μg|Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9771543|NCT00929110|Placebo Comparator|Placebo to glycopyrronium bromide|Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9771544|NCT00929110|Active Comparator|Tiotropium 18 μg|Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9771545|NCT00929162|Experimental|ZD4054 + paclitaxel + carboplatin|ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
9771546|NCT00929162|Placebo Comparator|Placebo + paclitaxel + carboplatin|Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
9771547|NCT00929201|Active Comparator|Sita + Met then Sita/Met FDC|Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
9771548|NCT00929201|Active Comparator|Sita/Met FDC then Sita + Met|Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
9771549|NCT00929240|Active Comparator|Avastin (bevacizumab)|
9771550|NCT00929240|Experimental|Avastin (bevacizumab) + Xeloda (capecitabine)|
9771551|NCT00929305|Placebo Comparator|Placebo laser|inactive laser light
9771552|NCT00929305|Active Comparator|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 milliWatt (mW) of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
9771553|NCT00929331|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
9771554|NCT00929331|Experimental|Fluviral Elderly Group|Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
9771555|NCT00929344|Experimental|Duloxetine|
9771556|NCT00929344|Experimental|Pregabalin|
9771557|NCT00929344|Placebo Comparator|Placebo|
9771558|NCT00929357||1|DMARDs
9771559|NCT00929357||2|Biologics
9771560|NCT00929500|Experimental|MAST program|Mixed Aerobic and Strength Training program (MAST): Each exercise session consisted of 10 minutes of warm-up, 15-30 minutes of interval aerobic training by cycle ergometer according to the program, 20 minutes of strength training exercises, and 10 minutes of cool-down by stretching.
9771561|NCT00929500|No Intervention|UC|Usual Care (UC) with Educational Lectures: No exercise sessions.
9771562|NCT00929526|Experimental|Cervarix Group|subjects received 3 doses of Cervarix™ vaccine in primary vaccination study NCT00316693.
9771563|NCT00929526|Placebo Comparator|Aimmugen Group|subjects received 3 doses of Aimmugen ™ vaccine in primary vaccination study NCT00316693.
9771564|NCT00929578|Placebo Comparator|Placebo|The sterile placebo: Bacteriostatic Sodium Chloride for Injection.
9771565|NCT00929578|Active Comparator|Fluphenazine|This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
9771566|NCT00929643||1|
9771567|NCT00929656|Experimental|Real rTMS|Real rTMS + unimanual paretic UE training
9771568|NCT00929656|Active Comparator|Sham rTMS|Sham rTMS + unimanual paretic UE training
9771569|NCT00929669|Experimental|Pasireotide LAR|80 mg IM once monthly
9771570|NCT00929695|Experimental|Arm I (Low-dose)|Patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
9771571|NCT00929695|Active Comparator|Arm II (Standard-dose)|Patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
9771572|NCT00929708|Experimental|1|AZD3199 low dose
9771573|NCT00929708|Experimental|2|AZD3199 intermediate dose
9771574|NCT00929708|Experimental|3|AZD3199 high dose
9771575|NCT00929708|Active Comparator|4|Formoterol 2x4.5 microgram bid
9771576|NCT00929708|Placebo Comparator|5|Placebo
9771577|NCT00929734|Experimental|Rosuvastatin|
9771578|NCT00929734|Placebo Comparator|Placebo|
9771579|NCT00929773|Active Comparator|Erchonia PL2000 Laser|Low level laser light energy comprised of 1 milliWatts (mW) of red light (635 nm).
9771580|NCT00929773|Placebo Comparator|Placebo laser|inactive light
9771581|NCT00929838|Experimental|Diabetes Knowledge/Information Arm|Subjects randomized to the diabetes knowledge/information arm will complete 12 diabetes education modules over a 12-week period. The educational materials were developed based on guidelines for diabetes education by the American Diabetes Association. The content is based on the principles of the Adult Learning Theory. The information is designed to be relevant, person centered, and presented in a non-threatening manner. The modules are designed to be delivered via telephone in 10-15 minutes, so that the maximum contact time per telephone call including introduction and closing would not exceed 30 minutes.
9771582|NCT00929838|Experimental|Motivation/Behavioral Skills Arm|The motivation/behavioral skills intervention consists of patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks. The behavioral skills training will be focused on 4 behaviors - physical activity, diet, medication adherence, and glucose self-monitoring. Guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks (4 behaviors over 12 weeks).
9771583|NCT00929838|Experimental|Combined Intervention Arm|The combined intervention group will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The behavioral skills training will be focused on 4 behaviors and guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks. The combined intervention group telephone sessions will last for 30 minutes.
9771584|NCT00929838|Sham Comparator|Usual Care Arm|The usual care group will receive weekly telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention. Patients in the usual care group will continue to receive any usual diabetes education provided by the clinic staff; however, they will not receive targeted diabetes knowledge/information, activation, empowerment, or behavioral skills training.
9771585|NCT00929864|Active Comparator|Abatacept|
9771586|NCT00929864|Active Comparator|Adalimumab|
9771587|NCT00929981||Oral Methylprednisolone|
9771588|NCT00929994||Exercise|Following a 3 month non intervention period, participants will participate in Cardiac Rehabilitation, carrying out an exercise program which will last 6 months and combine both resistance and aerobic training.
9771589|NCT00930046|Active Comparator|Ropivacaine group|Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery
9771590|NCT00930046|Placebo Comparator|Normal Saline Group|Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.
9771591|NCT00930059|Experimental|PF-04447943|
9771592|NCT00930059|Placebo Comparator|Placebo|
9771593|NCT00930176|Experimental|Human Coagulation FACTOR X|
9771594|NCT00930293|Experimental|Personalized Depression Care|Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.
9771595|NCT00930293|Active Comparator|Standard Depression Care|Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.
9771596|NCT00930553|Experimental|Previously treated with alemtuzumab|Alemtuzumab 12 mg per day administered through IV, once a day for 3 consecutive days (participants might receive additional cycles of alemtuzumab upon documented evidence of resumed disease activity, but not within same 12-month period)
9771597|NCT00930553|Experimental|Previously treated with interferon beta-1a (Rebif®)|Alemtuzumab 12 mg per day administered through IV, once a day for 5 consecutive days during the first cycle and 12 mg per day administered through IV, once a day for 3 consecutive days during the second cycle, 12 months later. Participants might qualify for as-needed retreatment (12 mg per day administered through IV, once a day for 3 consecutive days) after their second fixed annual cycle.
9771598|NCT00930644|Experimental|teduglutide|0.05 mg/kg/day
9771599|NCT00930761|No Intervention|Control|
9771600|NCT00930761|Experimental|Music therapy|
9771601|NCT00930774|Experimental|FM System|Provision of FM assistive device
9771602|NCT00930774|Experimental|Auditory Training|Provision of auditory training
9771603|NCT00930774|Experimental|FM System and Auditory Training|Provision of FM assistive device and auditory training
9771604|NCT00930774|No Intervention|Standard-of-Care|Standard-of-care informational counseling
9771605|NCT00930813|Experimental|Lutonix Catheter|Paclitaxel coated Balloon Catheter
9771606|NCT00930813|Active Comparator|Standard uncoated Balloon Angioplasty Catheter|uncoated angioplasty balloon
9771607|NCT00930930|Experimental|Cisplatin and Paclitaxel + RAD001|Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks
9771608|NCT00930930|Active Comparator|Cisplatin and Paclitaxel + Placebo|Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks
9771609|NCT00930982|Experimental|Ciprofloxacin Inhale (BAYQ3939)|32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
9771610|NCT00930982|Placebo Comparator|Placebo|Inhalation of matching placebo twice a day
9771611|NCT00931164|Experimental|Sodium oxybate|"The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.~Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy."
9771612|NCT00931242|Experimental|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
9771613|NCT00931268|Other|Macrolane VRF 30|Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.
9771614|NCT00931307|Experimental|Lotrafilcon A|
9771615|NCT00931359|Experimental|Treatment with DTS-G2 System|Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
9771616|NCT00931359|Sham Comparator|Sham treatment|All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.
9771617|NCT00931385|Experimental|BI 1744 (Olodaterol) Low Dose|BI1744 Low Dose once daily
9771618|NCT00931385|Experimental|BI 1744 (Olodaterol) Med Dose|BI 1744 Med Dose once daily
9771619|NCT00931385|Placebo Comparator|Placebo|Placebo once daily
9771620|NCT00931385|Active Comparator|Foradil|Foradil 12 mcg twice daily
9771621|NCT00931411|Experimental|Formulation 609580 20 then 609209|Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
9771622|NCT00931411|Active Comparator|Formulation 609209 then 609580 20|Formulation 609209 cream is applied topically to entire body, twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609580 20 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
9771623|NCT00931463|Active Comparator|Ritonavir-boosted lopinavir and 2N(t)RTI|This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
9771624|NCT00931463|Experimental|Ritonavir-boosted lopinavir and raltegravir|This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.
9771625|NCT00931489|Active Comparator|Wet AMD Patients Responders|Dilated eye exam once a month for 7 months; visual acuity and OCT once a month for 7 months; Lucentis(R)/ranibizumab injection once each month for the Baseline and Month 1-3 visits, then as needed at Month 4 and 5; 3 Tbls. blood draw at Baseline, Month 3 and Month 6 visits.
9771626|NCT00931489|No Intervention|Normal Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
9771627|NCT00931489|Active Comparator|Wet AMD Patients Acute Non-responders|Participants in this Group will have not responded to 4 prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. Dilated eye exam at Month 4; visual acuity and OCT at Months 4-6; injection of anti-VEGF treatment as needed at Months 4 and 5; 3 Tbls. blood draw at Month 4
9771628|NCT00931489|No Intervention|Dry AMD Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
9771629|NCT00931489|Active Comparator|Wet AMD Patients Chronic Non-responderes|Participants in this Group will have not responded to 4 or more prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. One visit at Month 4: Dilated eye exam with visual acuity and OCT; injection of anti-VEGF as needed; 3 Tbls. blood drawn
9771630|NCT00931515|Experimental|NuBac|NuBac device implanted at the L4/5 level
9771631|NCT00931515|Active Comparator|Prodisc-L|Prodisc-L implanted at the L4/5 level.
9771632|NCT00931528|Experimental|Tadalafil|Tadalafil
9771633|NCT00931528|Placebo Comparator|Placebo|Placebo
9771634|NCT00931632|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
9771635|NCT00931632|Placebo Comparator|Placebo|Nitrogen Placebo
9771636|NCT00931710|Experimental|Valsartan/amlodipine/HCTZ|Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.
9771637|NCT00931710|Active Comparator|Losartan/HCTZ|Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.
9771638|NCT00931723|Active Comparator|1|Seroquel XR and Lithium
9771639|NCT00931723|Placebo Comparator|2|Seroquel XR and placebo
9771640|NCT00931762|Experimental|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, with or without food, three times a week on Monday, Wednesday, and Friday for up to 6 treatment cycles (each cycle of 28-days) with dose adjustments possible.
9771641|NCT00931801|Experimental|Intervention Arm No.1|
9771642|NCT00931801|Experimental|Intervention Arm No.2|
9771643|NCT00931801|Active Comparator|Control Arm|Continue baseline regimen
9771644|NCT00931879|Placebo Comparator|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
9771645|NCT00931879|Active Comparator|omega-3-ethyl esters 4g|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
9784558|NCT01228318|Placebo Comparator|Placebo|Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
9784559|NCT01228435|Experimental|ALK-inhibitor naive|No prior exposure to ALK-inhibitor
9784560|NCT01228435|Experimental|ALK-inhibitor pre-treated|Prior exposure to ALK inhibitor
9784561|NCT01228591|Other|Acuvue Advance Plus/ Acuvue Advance|Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.
9784562|NCT01228591|Other|Acuvue Advance/Acuvue Advance Plus|Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.
9784563|NCT01228734|Experimental|Cetuximab + FOLFOX-4|Subjects received cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab was always administered every 7 days with an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions, followed by oxaliplatin 85 mg/m^2 infused over 120 minutes at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA was administered at a dose of 200 mg/m^2 infused over 120 minutes, on Day 1, Day 2, and every 2 weeks and then 5- FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours, on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
9784564|NCT01228734|Active Comparator|FOLFOX-4|Subjects received FOLFOX-4 chemotherapy regimen that consists of a combination of oxaliplatin with 5-FU/FA. Oxaliplatin 85 mg/m^2 infused over 120 minutes was administered first or simultaneously with FA at a dose of 200 mg/m^2 infused over 120 minutes on Day 1, Day 2, and every 2 weeks and then 5-FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
9784565|NCT01228747|Placebo Comparator|Placebo|Matching placebo for 28 weeks
9784566|NCT01228747|Experimental|Levetiracetam|Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks
9784567|NCT01228903|Placebo Comparator|Control|Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
9784568|NCT01228903|Active Comparator|Allopurinol|Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
9784569|NCT01228929|Experimental|Normal|Subjects with no clinical diagnosis or symptoms of dry eye.
9784570|NCT01228929|Experimental|Aqueous Deficiency Dry Eye (ADDE)|Subjects with low tear volume measured by Schirmer's test less than 10 mm.
9784571|NCT01228929|Experimental|Meibomian Gland Dysfunction (MGD)|Subjects having mild to moderate Meibomian Gland Dysfunction by slit lamp evaluation.
9784572|NCT01228968||Volunteers|Volunteers will have a range of body mass index from 19 - 45 kilogram per square meter. In order to fit in the magnetic resonance scanner subjects must weigh less than 300 pounds.
9784573|NCT01229111|Experimental|Treatment (cediranib maleate and modified FOLFOX)|Patients receive cediranib maleate PO QD on days 1-14 and modified FOLFOX6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.
9771646|NCT00931892|Experimental|Low gluten group|Subjects will eat 3g of gluten per day
9771647|NCT00931892|Experimental|High gluten group|Subjects will eat 10g of gluten per day
9771648|NCT00931918|Active Comparator|RCHOP|RCHOP [rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
9771649|NCT00931918|Experimental|Vc-RCHOP|Vc-RCHOP [bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
9771650|NCT00931944|Experimental|KNS-760704 300 mg/day|Open-label KNS-760704 (150 mg Q12H)
9771651|NCT00931996|Experimental|Antipsychotic|Antipsychotic
9771652|NCT00932022|Experimental|trospium chloride XR 60 mg|Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
9771653|NCT00932022|Placebo Comparator|placebo|Placebo capsule taken orally once daily for 14 weeks.
9771654|NCT00932035|Experimental|Arm I (reverse mapping guided axillary lymph node dissection)|Patients receive isosulfan blue dye SC and then undergo reverse mapping-guided axillary lymph node dissection.
9771655|NCT00932035|Active Comparator|Arm II (control)|Patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye SC.
9771656|NCT00932113|Active Comparator|Adalimumab|Dosing will be on day 1 and then weekly. For the injections, dosing will occur according to product recommendations. Patients will receive 80mg adalimumab (2 pre-filled syringes, each with 40mg) on day 1, and then 40mg on week 1 and then every 2 weeks (from week 1 through week 15).
9771657|NCT00932113|Active Comparator|Methotrexate (MTX)|Patients will be dosed according to the CHAMPION study in single weekly doses of methotrexate: 7.5mg at week 0, 10mg at week two, and 15mg at week 4 for all patients. For each subject if the PASI did not decrease by at least 50% from baseline (PASI-50) at week 8, dosing will be increased to 20mg per week; the dose will be maintained at 15mg per week if PASI-50 was achieved at week 8. If PASI-50 was not achieved at week 12, dosing will be increased to 25mg per week; the dose will be maintained at 20mg per week if the PASI-50 was achieved at week 12. All patients on methotrexate will also receive a dietary supplement of oral folate (5mg per week). Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
9771658|NCT00932126|Experimental|1|
9771659|NCT00932165||Exemestane|Patients taking Exemestane Tablets.
9771660|NCT00932282|Active Comparator|12 month maintenance of PnOIT|"Randomized subjects who will stay on the maintenance dose of oral peanut immunotherapy (PnOIT) for 12 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
9771661|NCT00932282|Active Comparator|24 month maintenance of PnOIT|"All subjects will be on the same intervention until Randomization. Randomized subjects who will stay on the maintenance dose of peanut oral immunotherapy (PnOIT) for 24 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
9771662|NCT00932321|Experimental|24 Day NA/EE|Norethindrone acetate 1 mg /ethinyl estradiol 20 mcg for 24 days of each 28 day cycle
9771663|NCT00932321|Active Comparator|21 Day NA/EE|Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg for 21 days of each 28 day cycle
9771664|NCT00932360|Experimental|Active TENS Placebo TENS No TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor
9771665|NCT00932360|Experimental|Placebo TENS Active TENS No TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Participants wore a TENS unit that was turned off for blinding of the outcome assessor
9771666|NCT00932360|Experimental|No TENS Active TENS Placebo TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
9771667|NCT00932360|Experimental|Active TENS No TENS Placebo TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
9771668|NCT00932360|Experimental|Placebo TENS No TENS Active TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
9771669|NCT00932360|Experimental|No TENS Placebo TENS Active TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
9771670|NCT00932373|Experimental|1|
9771671|NCT00932399||Group 1|Underwent a procedure at a VA medical facility in VISN 20 for a lower limb amputation between 1997 and 2008
9771672|NCT00932399||Group 2|No history of lower limb amputation
9771673|NCT00932425|Experimental|Outpatient cardiac monitoring|Patients will be assigned to wear a portable outpatient cardiac telemetry device for 21 days
9771674|NCT00932425|No Intervention|Control|Patients will be discharged home with standard clinical follow-up
9771675|NCT00932438|Experimental|LC Beads loaded with Irinotecan and FOLFOX6|"Device: LC Beads loaded with 100mg Irinotecan~Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician"
9771676|NCT00932438|Active Comparator|FOLFOX6 and Bevacizumab|Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
9771677|NCT00932451|Experimental|PF-0231066|
9771678|NCT00932477|Experimental|Artificial Tear Formulation 1|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
9771679|NCT00932477|Experimental|Artificial Tear Formulation 2|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
9771680|NCT00932477|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
9771681|NCT00932620|Active Comparator|Simvastatin 40 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
9771682|NCT00932620|Active Comparator|Simvastatin 10 mg plus ezetimibe 10 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
9771683|NCT00932646|Experimental|BI1744 (Olodaterol)|Medium Dose once Daily
9771684|NCT00932646|Experimental|BI 1744 (Olodaterol)|Low Dose once Daily
9771685|NCT00932646|Placebo Comparator|Placebo|Placebo once Daily
9771686|NCT00932646|Active Comparator|Foradil|12 mcg twice daily
9771687|NCT00932659||Hemodialysis patients|This is a single arm observational study. The single arm consists of adult hemodialysis patients without a prior history of cardiac arrhythmias who will be implanted with a continuous cardiac monitoring device (REVEAL, Medtronic) for an FDA approved indication.
9771688|NCT00932698|Experimental|Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2|Ixazomib 0.24 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
9771689|NCT00932698|Experimental|Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2|Ixazomib 0.48 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
9771690|NCT00932698|Experimental|Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2|Ixazomib 0.8 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
9771691|NCT00932698|Experimental|Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2|Ixazomib 1.2 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
9771692|NCT00932698|Experimental|Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2|Ixazomib 1.68 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
9771693|NCT00932698|Experimental|Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
9771694|NCT00932698|Experimental|Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2|Ixazomib 2.23 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
9771695|NCT00932698|Experimental|Relapsed and Refractory Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
9784574|NCT01229150|Active Comparator|KRAS Mut 2|KRAS Mutant patients randomized to combination therapy arm
9784575|NCT01229150|Active Comparator|KRAS Mut 1|KRAS Mutant patients randomized to monotherapy arm
9784576|NCT01229150|Active Comparator|WT KRAS 1|Wild-Type KRAS patients randomized to monotherapy arm
9784577|NCT01229150|Active Comparator|WT KRAS 2|Wild-Type KRAS patients randomized to combination therapy arm
9771696|NCT00932698|Experimental|Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
9771697|NCT00932698|Experimental|Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
9771698|NCT00932698|Experimental|Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).
9771699|NCT00932828|Experimental|Peanut oral immunotherapy|Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.
9771700|NCT00932893|Experimental|PF-02341066|
9771701|NCT00932893|Active Comparator|Pemetrexed or Docetaxel|Investigator selection of either pemetrexed or docetaxel as the active comparator
9771702|NCT00933166|Experimental|Lotrafilcon A|Investigational contact lens worn in both eyes for three months
9771703|NCT00933244|Other|High Dose Vitamin D3|"Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days."
9771704|NCT00933244|Other|Low Dose Vitamin D3|"Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.~Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days."
9771705|NCT00933244|Placebo Comparator|Placebo|"Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days."
9771706|NCT00933270|Experimental|SUPERA® Nitinol Stent System|Implantation of SUPERA nitinol stent using the SUPERA® Nitinol Stent System
9771707|NCT00933335|Experimental|Single Arm|Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.
9771708|NCT00933491||Diabetic|Type II Diabetes
9771709|NCT00933491||Control|Non-diabetics
9771710|NCT00933543|Experimental|Visonac cream with PDT|Active treatment, Light dose 37 J/cm2.
9771711|NCT00933543|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 J/cm2.
9771712|NCT00933608|Experimental|memantine|after a period of gradual dose increase from 5 mg/day, participants will be asked to take memantine (20mg/day) for 16 weeks 10 mg in the morning, 10 mg at night
9771713|NCT00933608|Placebo Comparator|Placebo|dose increase to match active drug, after that 1 tablet in the morning, 1 tablet at night, to match active drug
9771714|NCT00933686|Active Comparator|Saizen®|
9771715|NCT00933686|Active Comparator|Placebo + Saizen®|
9771716|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Specificity|Specimens collected from normal apparently healthy individuals at low risk for HIV infection will be tested by the investigational HIV test and FDA-licensed HIV test.
9771717|NCT00933933|No Intervention|ARCHITECT HIV Ag/Ab Combo Sensitivity|Specimen with confirmed positive HIV Antigen, HIV-1 antibody, or HIV-2 antibody will be tested by the investigational HIV test.
9771718|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Reactivity|Specimen collected from individuals at risk for HIV infection will be tested by the investigational HIV test.
9771719|NCT00934024|Other|Abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was abstinent after 5 weeks of varenicline treatment.."
9771720|NCT00934024|Other|Non-abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was participants who continued to smoke after 5 weeks of varenicline treatment."
9771721|NCT00934050|Experimental|ELND005|
9771722|NCT00934089|Experimental|PF-04217329 + placebo|Active study drug + latanoprost vehicle
9771723|NCT00934089|Experimental|PF-04217329 + latanoprost|Active study drug + latanoprost
9771724|NCT00934102|Active Comparator|Lotrafilcon A|Lotrafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
9771725|NCT00934102|Active Comparator|Narafilcon A|Narafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
9771726|NCT00934102|Active Comparator|Galyfilcon A|Galyfilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
9771727|NCT00934128|Experimental|Group 1: BiPAP then Vapotherm|Bilevel positive airway pressure device (BiPAP) then Vapotherm air delivery.
9771728|NCT00934128|Experimental|Group 2: Vapotherm then BiPAP|Vapotherm air delivery then BiPAP.
9784578|NCT01229176|Experimental|Vi-CRM, Adults|Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
9784579|NCT01229176|Active Comparator|Vi-PS, Adults|Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
9784580|NCT01229176|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
9771729|NCT00934141|Experimental|Interest Circle Call + Website|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach.
9771730|NCT00934141|Experimental|Coaching + Website|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
9771731|NCT00934141|Experimental|Full: LS, Coaching, ICC, Website|Learning Session, Coaching, Interest Circle Calls, Website, see descriptions above
9771732|NCT00934141|Experimental|Learning Session + Website|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
9771733|NCT00934362|Other|Lucinactant first, then placebo|Active treatment first, then washout period, then placebo treatment
9771734|NCT00934362|Other|Placebo treatment first, then lucinactant treatment|0.9% NaCl vehicle treatment first, then washout period, then lucinactant treatment
9771735|NCT00934375|Experimental|1|
9771736|NCT00934375|Placebo Comparator|2|
9771737|NCT00934440|Experimental|Dose Escalation: 5-azacitidine|A traditional 3+3 dose escalation trial was implemented. Successive cohorts of patients (3 participants/cohort) received bevacizumab at the standard dose of 10mg/kg in combination with escalating doses of 5-azacitidine. If no dose limiting toxicity (DLT) is seen, subsequent patients will be treated at the next dose level. If one DLT is seen, an additional three patients will be accrued at that dose level. If two or more DLTs are seen at one dose level, then the previous dose level will be chosen for phase IIA. If two DLT's are seen at dose level 1, the trial will end. The standard 5-azacitidine dose is 75mg/m2/day for 7 days. If no DLT is seen at dose level 3, then we will proceed with the phase IIA portion of the study.
10203816|NCT05035901|Experimental|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
10203817|NCT05022173|Experimental|Helmet NIV|Patients randomized to the intervention arm will receive NIV through a phthalate free helmet (CaStar, STARMED) via an ICU ventilator in pressure support (PS) mode.
9771738|NCT00934544|Experimental|Ruxolitinib|5 mg tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
9771739|NCT00934544|Active Comparator|Best Available Therapy (BAT)|"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.~Patients randomized to BAT were eligible to cross over to receive open-label ruxolitinib after a qualifying progression event, if they met the safety criteria. After the primary analysis in January 2011, patients randomized to receive BAT were allowed to cross over to receive ruxolitinib and move to the extension phase of the study without a qualifying progression event."
9771740|NCT00934596|Experimental|Lund de-airing|Lund de-airing technique
9771741|NCT00934596|Active Comparator|Carbon-dioxide insufflation|carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner
9771742|NCT00934622|Experimental|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL)
9771743|NCT00934635|Active Comparator|002|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
9771744|NCT00934635|Active Comparator|003|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
9771745|NCT00934635|Active Comparator|004|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
9771746|NCT00934635|Active Comparator|005|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
9771747|NCT00934635|Active Comparator|006|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
9771748|NCT00934635|Active Comparator|007|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
9771749|NCT00934635|Active Comparator|008|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
10203818|NCT05022173|Active Comparator|Facemask NIV|Patients in the control arm will be randomized to the traditional facemask interface. The facemask group will use the same ICU ventilator being used for the helmet group.
10203819|NCT05012020|Experimental|mHealth Remote Monitoring|Use of the Clinic Portal by Healthcare professionals and use of the Mobile App by patients/caregivers
10203820|NCT05007093|Experimental|Anlotinib hydrochloride|
10203821|NCT05005572|Experimental|Treatment|
10203822|NCT05005572|No Intervention|Control|
10203823|NCT05005182|Experimental|Cohort A (luspatercept)|Patients receive luspatercept SC on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
10203824|NCT05005182|Experimental|Cohort A (luspatercept, hydroxyurea)|Patients receive luspatercept SC on day 1 and hydroxyurea PO on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
10203825|NCT05004428||Type 2 Diabetes Mellitus patients with Chronic Kidney Disease|Canadian patients with type 2 diabetes mellitus data will be collected retrospectively.
9771750|NCT00934635|Other|009|PET Scan PET Scan
9771751|NCT00934635|Active Comparator|001|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
9771752|NCT00934648|Experimental|1|
9771753|NCT00934661|Experimental|Extended Release Epidural Morphine|Four mg (0.4 ml) of EREM will be delivered to the epidural space and flushed with 1 ml of saline
9771754|NCT00934661|Placebo Comparator|Placebo Group|The epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
9771755|NCT00934843|Experimental|Single dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive ONE dose intravenous methylprednisolone (IVMP) prior to heart surgery.
9771756|NCT00934843|Experimental|Two Dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
9771757|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (over 2 days)|Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
9771758|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (over 2 days)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
9771759|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
9771760|NCT00934856|Experimental|MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
9771761|NCT00934856|Experimental|LABC: T-DM1 + Doc (Doublet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
9771762|NCT00934856|Experimental|LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
9771763|NCT00934934|Placebo Comparator|Placebo|Saline will serve as the placebo solution since the active comparator is clear and colourless.
9771764|NCT00934934|Active Comparator|Antifungal|Patient will receive a dose daily for a total of 14 days
9771765|NCT00934947|Placebo Comparator|Sugar pill|
9771766|NCT00934947|Experimental|Propranolol, Propanolol ER|
9771767|NCT00935012|Experimental|Open-Label|
9771768|NCT00935064|Active Comparator|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
9771769|NCT00935064|Placebo Comparator|Placebo|
9771770|NCT00935220|Experimental|linagliptin|Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation
9771771|NCT00935259|Experimental|Simvastatin 40 mg first, then placebo|Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks
9771772|NCT00935259|Placebo Comparator|Placebo first, then simvastatin 40 mg once daily|Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks
9771773|NCT00935272|Experimental|Treatment|Restylane® Treatment
9771774|NCT00935272|No Intervention|Non-Treatment|Non-Treatment Arm
9771775|NCT00935311|Experimental|ABT-712|1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
9771776|NCT00935311|Active Comparator|Hydrocodone/Acetaminophen|2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
9771777|NCT00935311|Placebo Comparator|Placebo|2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
9771778|NCT00935493|Experimental|Guanfacine 0.1 mg po qhs|
9771779|NCT00935493|Experimental|Guanfacine 0.5 mg po qhs|
10203826|NCT04997902|Experimental|PIK3CA-dependent (Cohort 1)|Adult participants with R/M HNSCC whose tumors harbor PI3KCA (activating) mutations and/or amplifications
10203827|NCT04997902|Experimental|HRAS-dependent (Cohort 2)|Adult participants with R/M HNSCC whose tumors have increased HRAS dependency, defined as HRAS overexpression
9771780|NCT00935493|Placebo Comparator|Placebo po qhs|
9771781|NCT00935532|Experimental|exenatide once weekly|
9771782|NCT00935532|Active Comparator|insulin glargine|
10203828|NCT04996823|Experimental|Ipilimumab + Axtinib|Participants will receive treatment with ipilimumab 3 mg/kg IV q3 weeks x 4 doses and axitinib at 5 mg by mouth twice daily. Each cycle is 3 weeks/21 days
9771783|NCT00935584|Other|PACE Study|"The study utilized a quasi-experimental pre-post intervention design. The intervention provided was physician education to improve EMR use and communication.~Physician training in patient-centered EMR use was developed. The conceptual model of patient-centered communication will provide the underlying framework for the training aimed at improving physicians interviewing and communication skills."
9771784|NCT00935701|Experimental|Acupuncture and Acupressure|In Phase 1, 10 children with ASD will receive acupressure for four weeks. At week 5, they will be introduced to acupuncture which will be continued throughout the rest of the study as tolerated. In Phase 2, 40 children with ASD will receive acupressure twice weekly for 12 weeks. Parents will be trained in the acupressure techniques and will be asked to do this daily, at bedtime, and/or as requested by the child or deemed needed by the parent. Children will begin to be assessed for their ability to participate in acupuncture treatment between weeks 5 and 7 at the discretion of the acupuncturist. By week 7, all children will have been introduced to acupuncture/needling. If needling is still refused at this time, acupressure will continue for the remainder of the study.
9771785|NCT00935766|Placebo Comparator|Sugar Pill|4 tabs of placebo dependent on randomization
9771786|NCT00935766|Active Comparator|Omega 3|omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily
9771787|NCT00935792|Experimental|Arm I|Patients receive oral everolimus thrice weekly for 9 weeks and alemtuzumab subcutaneously thrice weekly for 8 weeks.
9771788|NCT00935818|Active Comparator|varenicline and buproprion SR|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
9771789|NCT00935818|Placebo Comparator|varenicline and placebo|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
9771790|NCT00935857|Experimental|Balloon Colonoscopy|Colonoscopy using the single balloon colonoscopy system (novel endoscope to facilitate difficult colonoscopy).
9771791|NCT00935857|Active Comparator|Standard Colonoscopy|Colonoscopy using a standard adult colonoscope
9771792|NCT00935883|Placebo Comparator|Saline|Randomized patients in the drusen or the GA cohort will receive placebo saline infusions as a comparator
9771793|NCT00935883|Active Comparator|Eculizumab|Randomized patients in the drusen or the GA cohort will receive active treatment with eculizumab
9771794|NCT00936065|Active Comparator|Group A|
9771795|NCT00936065|Experimental|Group B|
9771796|NCT00936065|Active Comparator|Group C|
9771797|NCT00936117|Experimental|Posaconazole|Posaconazole 200 mg (liquid) by mouth 3 times per day.
9771798|NCT00936208||Essential hypertensive men and women|
9771799|NCT00936221|Active Comparator|1|AZD6244 in combination with dacarbazine
9771800|NCT00936221|Placebo Comparator|2|Placebo in combination with dacarbazine
9771801|NCT00936299|Active Comparator|Bupropion + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.
9771802|NCT00936299|Placebo Comparator|Placebo + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.
9771803|NCT00936351|Experimental|Arm 1|Mindfulness Meditation
9771804|NCT00936351|Active Comparator|Arm 2|Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support
9771805|NCT00936377|Experimental|Dexmedetomidine, low dose|Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
9771806|NCT00936377|Experimental|Dexmedetomidine, high dose|Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
9771807|NCT00936377|Placebo Comparator|Placebo|Normal saline
9771808|NCT00936455||Telemedicine|Telemedicine evaluated patients
9771809|NCT00936455||Telephone|Telephone evaluated patients
9771810|NCT00936481||Healthy controls|18 years or older with body mass index between 25-45
9771811|NCT00936481||Obstructive Sleep Apnea Group|Age 18 years or older with body mass index between 25 and 45
9771812|NCT00936611|Experimental|LBH589|"30 mg three days a week (Mondays, Wednesdays and Fridays).~1 cycle was 28 days~Dose modifications for attributable toxicities allowed for reduction to:~25 mg, 20 mg three times a week every week~Or 20 mg three times a week every other week. No dose re-escalation was allowed.~The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose."
9771813|NCT00936663|Experimental|Sitagliptin 100 mg daily|sitagliptin 100 mg daily
9771814|NCT00936663|Placebo Comparator|placebo|placebo
9771815|NCT00936702|Experimental|Treatment (carboplatin, paclitaxel, and everolimus)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive everolimus PO QD on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9771816|NCT00936715|Experimental|FTC/TDF|
9771817|NCT00936741|Experimental|Mifepristone|Mifepristone 300mg to 1200mg once daily
9771818|NCT00936858|Experimental|Arm A|RAD001 will be administered orally as once daily dose of 10 mg (one 10mg tablet or two 5mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.
9771819|NCT00936884|Experimental|Methylnaltrexone double-blind|Methylnaltrexone once every other day.
9771820|NCT00936884|Placebo Comparator|Placebo|Placebo once every other day.
9771821|NCT00936884|Other|Methylnaltrexone open-label|Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period.
9771822|NCT00936897|Active Comparator|Ibandronate|Ibandronate 150mg PO QM (tablet)
9771823|NCT00936897|Experimental|Denosumab|denosumab 60mg Subcutaneous Q6M (pre-filled syringe)
9771824|NCT00936910|Experimental|Antifungal lock-treated patients|Intestinal failure and other patients with poor IV access and central line fungal-related infections will receive intravenous systemic antifungal therapy plus the instillation of Ambisome locks into the infected catheter.
9771825|NCT00936975|Experimental|18F-Fluoride PET|Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol
9771826|NCT00937040|Experimental|001|OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
9771827|NCT00937040|Placebo Comparator|002|Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
9771828|NCT00937105|Active Comparator|ReNu Multiplus and lotrafilcon A lenses|ReNu Multiplus contact lens care solution
9771829|NCT00937105|Active Comparator|Clear Care solution and lotrafilcon A lenses|Clear Care Contact Lens Care Solution
9771830|NCT00937118||Injury Management|Patients with full thickness duodenal laceration undergoing laparotomy and surviving more then 72 hours at our level 1 trauma center in the years 1989-2009. Patients requiring pancreaticoduodenectomy were excluded.
9771831|NCT00937157|Other|1|Patients diagnosed with multiple sclerosis who have the presence of at least 1 or more Gd enhancing lesions and/or acute relapse.
9771832|NCT00937235|Experimental|Integrated Treatment|Prolonged Exposure + Varenicline + Medication Management Counseling
9771833|NCT00937235|Active Comparator|Varenicline|Varenicline + Medication Management Counseling
9771834|NCT00937326|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight placebo capsules per day.~Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
9771835|NCT00937326|Active Comparator|Arm1 - 0.25g|"The 0.25g SRT2104 treatment group will be administered one SRT2104 capsules with 7 placebo capsules, for a total of 8 capsules per day.~0.25g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
9771836|NCT00937326|Active Comparator|Arm2 - 0.5g|"The 0.5g SRT2104 treatment group will be administered two SRT2104 capsules with 6 placebo capsules, for a total of 8 capsules per day.~0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
9771837|NCT00937326|Active Comparator|Arm3 - 1g|"The 1g SRT2104 treatment group will be administered four SRT2104 capsules with four placebo capsules, for a total of 8 capsules per day.~1g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
9771838|NCT00937326|Active Comparator|Arm4 - 2g|"The 2g SRT2104 treatment group will be administered eight SRT2104 capsules per day.~2g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
9771839|NCT00937378|Experimental|SER120|
9771840|NCT00937378|Placebo Comparator|Placebo|
9771841|NCT00937391|Experimental|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
9771842|NCT00937404|Experimental|IPV Group|Healthy male or female subjects between, and including, 60 and 90 days of age at the time of the first vaccination, receive 3 doses of Poliorix at 2 (Study Day 0, Visit 1), 3 (Study Month 1, Visit 2) and 4 (Study Month 2, Visit 3) months of age, administered intramuscularly into the upper right side of the thigh.
9771843|NCT00937495|Experimental|Treatment (vorinostat, bortezomib)|Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9771844|NCT00937521|Other|1|Vaccine candidate formulation I
9771845|NCT00937521|Other|2|Vaccine candidate formulation II
9771846|NCT00937521|Other|3|Vaccine candidate formulation III
9771847|NCT00937521|Other|4|Vaccine candidate formulation IV
9771848|NCT00937521|Other|5|Vaccine candidate formulation V
9771849|NCT00937521|Other|6|Vaccine candidate formulation VI
9771850|NCT00937521|Other|7|Control
9771851|NCT00937521|Other|8|Vaccine candidate formulation I with antipyretic
9771852|NCT00937560|Experimental|Bevacizumab + paclitaxel + carboplatin|Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = [glomerular filtration rate + 25] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
9784581|NCT01229176|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
9771853|NCT00937768|Experimental|Arm A (antihormone therapy)|Patients receive leuprolide acetate IM on day 1 OR goserelin acetate SC on day 1. Courses repeat every 3 months for 9 months in the absence of disease progression or unacceptable toxicity.
9771854|NCT00937768|No Intervention|Arm B (no antihormone therapy)|Patients undergo observation every 3 months for 9 months.
9771855|NCT00937794||No treatment|This is a screening study designed to evaluate the behavioral, physical, and neurodevelopmental status in pediatric patients with Hunter syndrome who have early signs and symptoms of CNS involvement and who are currently receiving treatment with Elaprase.
9771856|NCT00937833|Experimental|Urethrovesical Sling|Surgisis Male Sling placed at the time of prostatectomy
9771857|NCT00937833|Active Comparator|Control|Prostatectomy
9771858|NCT00937859|Experimental|SER120|SER120
9771859|NCT00937859|Placebo Comparator|Placebo|
9771860|NCT00937950|Other|HPV-052 study subjects Group|The study group consisted of a subset of HPV-008 (NCT00122681) study subjects (15-25 years old at first study vaccination), who at their last study visit (Visit 10, Month 48) in HPV-008 (NCT00122681) study displayed normal cervical cytology, but were tested positive for oncogenic HPV infection, or were pregnant and hence no cervical sample could be collected at their HPV-008 (NCT00122681) concluding visit.
9771861|NCT00938015||PsA Patients (New)|New patients
9771862|NCT00938015||PsA Patients|CU patients
9771863|NCT00938041|Experimental|Retreatment of NHL with Iodine-131 Anti-B1 Antibody|Patients with non-Hodgkin's lymphoma who previously responded with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy will undergo two phases of study. In the first phase, patients will receive a dosimetric dose of unlabeled Anti-B1 Antibody (450 mg) followed by Anti-B1 Antibody (35 mg) which has been radiolabeled with 5 mCi of Iodine-131. Whole body gamma camera scans will be obtained after the dosimetric dose and data from three imaging time points will be used to calculate a patient-specific dose to deliver the desired total body dose of radiotherapy. In the second phase, patients will receive the therapeutic dose of unlabeled Anti-B1 Antibody (450 mg) followed by 35 mg of Anti-B1 Antibody labeled with the patient-specific dose to deliver the desired whole body dose of radiation. Patients will be treated with thyroid blocking medication at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion.
9771864|NCT00938314|Experimental|NTx®-265 Low Dose|hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
9771865|NCT00938314|Experimental|NTx®-265 Medium Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
9771866|NCT00938314|Experimental|NTx®-265 High Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
9771867|NCT00938314|Placebo Comparator|Saline Placebo|
9771868|NCT00938327||Rotarix Group|Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.
9771869|NCT00938340|Experimental|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
9771870|NCT00938340|Experimental|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
9771871|NCT00938340|Experimental|Walnut oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
9771872|NCT00938340|Experimental|Walnut skins|Separated, ground walnut skins incorporated into inert food carrier
9771873|NCT00938366|Experimental|Cladribine followed by Cladribine + Pantoprazole|Subjects will receive a single dose of cladribine10 milligram (mg) orally on Day 1. After a wash out period of 10-25 days, subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose.
9771874|NCT00938366|Experimental|Cladribine + pantoprazole followed by Cladribine|Subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose. After a wash out period of 10-25 days, subjects will receive a single dose of cladribine 10 mg orally.
9771875|NCT00938392|Experimental|FluNG Aged Group|Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).
9771876|NCT00938392|Experimental|FluNG Fresh Group|Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).
9771877|NCT00938431|Experimental|Lacosamide - Age 5 - 11 years|Cohort 1 (Age 5 - 11 years); up to 8 mg/kg/day
9771878|NCT00938431|Experimental|Lacosamide - (Age 12 - 17 years)|Cohort 2 (Age 12 - 17 years); 12 mg/kg/day.
9771879|NCT00938431|Experimental|Lacosamide (Age 2 - 4 years)|Cohort 3 (Age 2 - 4 years); 12 mg/kg/day.
9771880|NCT00938431|Experimental|Lacosamide (Age 5 - 11 years)|Cohort 4 (Age 5 - 11 years); 12 mg/kg/day.
9771881|NCT00938431|Experimental|Lacosamide (Age 1 month - < 2 years)|Cohort 5 (Age 1 month to < 2 years); 12 mg/kg/day
9784582|NCT01229176|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
9771882|NCT00938457|Experimental|Arm I|Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
9771883|NCT00938470|Experimental|Arm I (combination chemotherapy, radiation therapy, surgery)|Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Patients also receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of the second course, patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity. Approximately 4-12 weeks after completion of radiotherapy, patients undergo surgery.
9771884|NCT00938470|Active Comparator|Arm II (oxaliplatin, fluorouracil, radiation, and surgery)|Patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy and then surgery as in Arm I.
9771885|NCT00938548|Placebo Comparator|Placebo|Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
9771886|NCT00938548|Experimental|Pregabalin|Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later
9771887|NCT00938639|Experimental|CSL425 (15 mcg)|15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
9771888|NCT00938639|Experimental|CSL425 (30 mcg)|30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
9771889|NCT00938704|Active Comparator|1|carboxymethylcellulose 0.5%, glycerin 0.9%
9771890|NCT00938704|Active Comparator|2|sodium hyaluronate 0.18%
9771891|NCT00938717|Placebo Comparator|Placebo|
9771892|NCT00938717|Experimental|290 μg Linaclotide|
9771893|NCT00938782|Active Comparator|Active Monitoring with SEDLine Monitor|Patient group randomized to active monitoring with SEDLine monitor for titration of anesthesia.
9771894|NCT00938782|No Intervention|Blinded monitoring with SeEDLine Monitor|Patient group randomized to blinded monitoring with SEDLine monitor for titration of anesthesia. Data captured but not used for titration of anesthesia.
9771895|NCT00938860|Experimental|Neoral|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
9771896|NCT00938860|Active Comparator|tacrolimus|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
9771897|NCT00938886|Experimental|Naltrexone|50 mg daily naltrexone for 10 weeks
9771898|NCT00938886|Placebo Comparator|Placebo|Daily matched placebo pill
9771899|NCT00938964|Experimental|Lidocaine|Lidocaine infusion for 48 hours
9771900|NCT00938964|Placebo Comparator|Placebo|Normal saline infusion for 48 hours
9771901|NCT00939003|Experimental|Adalimumab|
9771902|NCT00939003|Placebo Comparator|Placebo|
9771903|NCT00939003|Experimental|Open-label Adalimumab|
9771904|NCT00939029|Active Comparator|Active|2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
9771905|NCT00939029|Placebo Comparator|placebo|2 patches (containing non active ingredients) per day for 8 weeks
9771906|NCT00939055|Experimental|StomaphyX|Post-Roux-en-Y revisional surgery using the StomaphyX device.
9771907|NCT00939055|Sham Comparator|Sham Procedure|No intervention
9771908|NCT00939094|Experimental|A|
9771909|NCT00939094|Placebo Comparator|B|
9771910|NCT00939107|Experimental|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
9771911|NCT00939107|Active Comparator|Spinal manipulation|Spinal manipulation in combination with information of clinical findings and advice about back care
9771912|NCT00939120|Experimental|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
9771913|NCT00939120|Placebo Comparator|placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
9771914|NCT00939159|Experimental|LBH589|LBH589 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
9771915|NCT00939185||Azithromycin group|
9771916|NCT00939198|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will be skin tested with Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
9771917|NCT00939211|Experimental|AZD9164 100 mcg First, then Placebo for Spririva|1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
9771918|NCT00939211|Experimental|AZD9164 400 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
9771919|NCT00939211|Experimental|AZD9164 1200 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
9771920|NCT00939211|Active Comparator|Spiriva 18 mcg First, then Placebo for AZD9164|1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
9771921|NCT00939211|Placebo Comparator|Placebo for Spiriva First, then Placebo for AZD9164|1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)
9771922|NCT00939341|Experimental|1|Symbicort Turbuhaler 160/4.5 µg delivered dose
9771923|NCT00939367|Experimental|Test|Torrent's Zolpidem TartrateTablets 10 mg
9771924|NCT00939367|Active Comparator|Reference|Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg
9771925|NCT00939393|Active Comparator|FESS in OR with or without balloons|Functional Endoscopy Sinus Surgery
9771926|NCT00939393|Active Comparator|Balloon sinuplasty in physician office|Balloon Sinuplasty in physician office using Acclarent devices
9771927|NCT00939471|Other|Relieva™ Balloon Sinuplasty™ System|Balloon Dilation of sinus ostium
9771928|NCT00939484|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
9771929|NCT00939510|Experimental|Lenalidomide (RevlimidTM ) and GM-CSF|
9771930|NCT00939523|Experimental|Lapatinib|All participants will be asked to take Lapatinib daily for a total of six months during the research study.
9771931|NCT00939536|Experimental|Torrent's Zolpidem Tartrate Tablets 10 mg|Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
9771932|NCT00939536|Active Comparator|Sanofi-Synthelabo's Ambien® 10 mg Tablets|Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
9771933|NCT00939562|Experimental|doxycycline monohydrate tablet|
9771934|NCT00939562|Active Comparator|doxycycline carragenate tablet|
9771935|NCT00939627|Placebo Comparator|Arm I (cetuximab and placebo)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21.
9771936|NCT00939627|Experimental|Arm II (cetuximab and sorafenib tosylate)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate twice daily on days 1-21.
9771937|NCT00939640|Experimental|Dietary intervention|Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
9771938|NCT00939653|Experimental|Single Arm - Clofarabine with Chemo|All patients receive the same treatment regimen consisting of clofarabine, etoposide, cyclophosphamide, cytarabine, and filgrastim. Up to 4 courses of therapy may be given.
9771939|NCT00939692|Experimental|Torrent Topiramate|tablet containing 25 mg of topiramate (Torrent Pharmaceuticals)
9771940|NCT00939692|Active Comparator|Topamax|tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)
9771941|NCT00939705|Experimental|Torrent Topiramate|
9771942|NCT00939705|Active Comparator|Topamax|
9771943|NCT00939731|Experimental|PIC|
9771944|NCT00939731|Experimental|IRT|
9771945|NCT00939770|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9771946|NCT00939783|Experimental|Dimebon 20 mg TID|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
9771947|NCT00939796|Experimental|Tympanostomy Tube Delivery System (TTDS)|Tympanostomy tube placement with Acclarent tube delivery system
9771948|NCT00939809|Experimental|Treatment (urokinase-derived peptide A6)|Patients receive A6 subcutaneously once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9771949|NCT00939822|Experimental|Simvastatin|40 mg. Simvastatin/day
9771950|NCT00939822|Placebo Comparator|Placebo|Matching Placebo
9771951|NCT00939874|Experimental|Raltegravir|
9771952|NCT00939900|Experimental|aclasta|aclasta group
9771953|NCT00939900|No Intervention|control|control group
9771954|NCT00939952|Active Comparator|ertapenem 500 mg IV x1|All patients will receive ertapenem 500 mg IV once.
9771955|NCT00939991|Experimental|1|Phase I- Bevacizumab will be administered intravenously every other week. Temozolomide will be administered on a continuous daily dosing schedule. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen.
9771956|NCT00940017|Experimental|1|
9771957|NCT00940108|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
9771958|NCT00940108|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
9771959|NCT00940290|Other|GRADE system|A clinical recommendation built and graded with the GRADE working group system
9771960|NCT00940290|Other|SIGN grading system|A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
9771961|NCT00940290|Other|NICE grading system|A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
9771962|NCT00940290|Other|CEBM-Oxford|A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system
9771963|NCT00940316|Experimental|Arm A: Erlotinib + Panitumumab + Irinotecan|Patients receive oral erlotinib hydrochloride once daily on days 1-14, panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
9771964|NCT00940316|Experimental|Arm B: Erlotinib + Panitumumab|Patients receive oral erlotinib hydrochloride once daily on days 1-14 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients receive irinotecan hydrochloride as in arm A.
9771965|NCT00940316|Experimental|Arm C: Erlotinib + Panitumumab|Patients receive erlotinib hydrochloride and panitumumab as in arm B.
9771966|NCT00940342|Experimental|Treated and Relapsed - Group 1|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
9771967|NCT00940342|Experimental|Treated and High-Risk for Progression - Group 2|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
9771968|NCT00940342|Experimental|70 Years of Age and Refused Chemo - Group 3|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
9771969|NCT00940446|Experimental|Insorb staples|Subcuticular Absorbable staples
9771970|NCT00940446|Active Comparator|Control|Metal staple wound closure
9771971|NCT00940485|Experimental|Peginterferon alfa-2a + entecavir|Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
9771972|NCT00940485|Active Comparator|Entecavir|Participants received entecavir 0.5 mg orally once daily for 48 weeks.
9771973|NCT00940537||NAFLD|Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)
9771974|NCT00940537||Non-NAFLD|Non-diabetic, obese with no previous diagnosis of NAFLD
9771975|NCT00940576|Experimental|mare´s milk|oral intake of of 250 ml mare´s milk
9771976|NCT00940576|Placebo Comparator|placebo drink|oral intake of of 250 ml placebo drink
9771977|NCT00940589|Experimental|Circadin|Drug
9771978|NCT00940589|Placebo Comparator|Placebo|drug
9771979|NCT00940602|Experimental|Deferasirox|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
9771980|NCT00940602|Placebo Comparator|Placebo|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
9771981|NCT00940771|Experimental|boosted Atazanavir|Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen
9771982|NCT00940823|Active Comparator|Ahmed FP7 Valve|Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.
9771983|NCT00940823|Active Comparator|Baerveldt-350 Tube|Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.
9771984|NCT00940875|Experimental|1|
9771985|NCT00940875|Active Comparator|2|
9771986|NCT00940888||No treatment: ICD/CRTD-indicated|
9771987|NCT00940901|Experimental|sildenafil|Participants assigned to this arm were given sildenafil 50 mg tablet daily for 16 weeks.
9771988|NCT00940901|Placebo Comparator|placebo|Participants assigned to this arm were given a placebo pill for the first 8 weeks, and then Sildenafil 50 mg for weeks 9-16.
9771989|NCT00940992|Experimental|DER 45 EV Gel, 1%|DER 45 EV Gel, 1% topically applied once daily to face for 12 weeks
9771990|NCT00940992|Placebo Comparator|Vehicle|Placebo Gel applied topically once a day for 12 weeks
9771991|NCT00940992|Experimental|DER 45 EV Gel, 5%|DER 45 EV Gel, 5% applied topically once a day for 12 weeks
9771992|NCT00941005|Experimental|Electroacustimulation|Received electroacustimulation at the wrist using a small, battery-powered electroacustimulation device.
9771993|NCT00941005|Sham Comparator|Control|Received a device that was not turned on.
9771994|NCT00941031|Experimental|Induction Single Dose|"Induction with single injection - Single: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12"
9771995|NCT00941031|Experimental|Induction Monthly Dose|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12"
9771996|NCT00941031|Experimental|Induction Early Loading Dose|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12"
9771997|NCT00941031|Placebo Comparator|Placebo Dose|Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12
9784583|NCT01229176|Active Comparator|PNC13, Older infants|Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
9784584|NCT01229176|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
9771998|NCT00941070|Experimental|Treatment (cisplatin, triapine, radiation therapy)|"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.~Patients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression."
9771999|NCT00941304|Active Comparator|Standard Opioid|Oxycodone 5-mg oral capsule and 2 buccal placebo films
9772000|NCT00941304|Experimental|High Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 1, buccal placebo film, and oral placebo capsule
9772001|NCT00941304|Experimental|Mid Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 2, buccal placebo film, and oral placebo capsule
9772002|NCT00941304|Experimental|Low Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.25-mg modified formulation 2, buccal placebo film, and oral placebo capsule
9772003|NCT00941304|Placebo Comparator|Placebo|Oral placebo capsule and 2 buccal placebo films
9772004|NCT00941330|Experimental|A: Exemestane|ARM A: Patients will be treated with exemestane.
9772005|NCT00941330|Active Comparator|B: Docetaxel and Cytoxan|ARM B: Patients will be treated with docetaxel and cytoxan.
9772006|NCT00941603|Experimental|SCH 900271 15 mg|Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
9772007|NCT00941603|Experimental|SCH 900271 10 mg|Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
9772008|NCT00941603|Experimental|SCH 900271 5 mg|Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
9772009|NCT00941603|Experimental|SCH 900271 2.5 mg|Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
9772010|NCT00941603|Experimental|SCH 900271 1 mg|Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
9772011|NCT00941603|Placebo Comparator|Placebo|Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks
9772012|NCT00941655|Experimental|Surgery + HIPEC + Systemic Chemotherapy|"Surgery -gastric resection, metastasectomy, and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes. Leucovorin 20 mg/m^2 IV and Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours."
9772013|NCT00941655|Experimental|Systemic Chemotherapy Alone|Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours.
9772014|NCT00941668|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
9772015|NCT00941668|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
9772016|NCT00941681|Experimental|Cohort 1: MR 50 mg BID|Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.
9772017|NCT00941681|Experimental|Cohort 2: IR 37.5 mg TID|Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.
9772018|NCT00941681|Experimental|Cohort 3: MR 100 mg BID|Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days
9772019|NCT00941720|Experimental|Busulfan Treatment|
9772020|NCT00941733|Experimental|Drug Eluting Balloon|Intervention: IN.PACT Amphirion™
9772021|NCT00941733|Active Comparator|Standard PTA|Intervention: Standard PTA
9772022|NCT00941798|Experimental|QMF149 Twisthaler® 500/400|QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD)
9772023|NCT00941798|Active Comparator|Mometasone Twisthaler®|Mometasone Twisthaler®, 400 µg QD
9772024|NCT00941863|Experimental|Sorafenib 100 mg (50-mg tablet)|Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
9772025|NCT00941863|Experimental|Sorafenib 200 mg (50-mg tablet)|Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
9772026|NCT00941863|Experimental|Sorafenib 400 mg (50-mg tablet)|Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
9772027|NCT00941863|Experimental|Sorafenib 400 mg (200-mg tablet)|Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet). Treatment were planned until primary completion date (PCD).
9784585|NCT01229176|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
9784586|NCT01229228|Experimental|Naproxen Test (lower dose)|200-mg
9784587|NCT01229228|Experimental|Naproxen Test (upper dose)|400-mg (2 x 200-mg)
9784588|NCT01229228|Active Comparator|Naprosyn 250 mg|
9784589|NCT01229228|Active Comparator|Naprosyn 500 mg|
9772028|NCT00941863|Experimental|Sorafenib 400 mg (Expansion)|Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion. Treatment were planned until primary completion date (PCD). 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib until 18 Sep 2008.
9772029|NCT00941889|Placebo Comparator|Placebo|Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment.
9772030|NCT00941889|Active Comparator|Gardasil|The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at two months and six months after enrollment.
9772031|NCT00941993|Experimental|local anesthesia|tympanic membrane local anesthesia delivery system
9772032|NCT00942084|Active Comparator|Protocol V2&up-Grp1-Acyclo10 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age < 14 days Dosage 10 mg/kg IV q12 Number of Infants 8
9772033|NCT00942084|Active Comparator|Protocol V2&up-Grp2_Acyclo20 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age 14-44 days Dosage 20 mg/kg IV q12 Number of Infants 8
9772034|NCT00942084|Active Comparator|Protocol V2&up-Grp3-Acyclo20 mg/kg IVq8|Gestational Age 30-34 weeks Postnatal Age <45 days Dosage 20 mg/kg IV q8 Number of Infants 4
9772035|NCT00942084|Other|Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h|All patients in protocol V1 were to be dosed with 500 mg/m2 IV q8h. Protocol V1 Group 1: Gestational Age: 23-29 Weeks; PNA: <14 days; Protocol V1 Group 2: Gestational Age: 30-42 Weeks; PNA: <14 days; Protocol V1 Group 3: Gestational Age: 23-29 Weeks; PNA: 14-60 days; Protocol V1 Group 4: Gestational Age: 30-42 Weeks; PNA: 14-60 days
9772036|NCT00942149|Experimental|Daptomycin cohort|
9772037|NCT00942162|Experimental|GSK2132231A GS+ Group|Patients with the pre-specified gene signature (GS), who received intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
9772038|NCT00942162|Experimental|GSK2132231A GS- Group|Patients without the pre-specified gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
9772039|NCT00942162|Experimental|GSK2132231A GS-unknown Group|Patients with unknown gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE_A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
9772040|NCT00942175|Other|Regimen A|Clopidogrel 75 mg QD
9772041|NCT00942175|Other|Regimen B|Clopidogrel 75 mg QD and Lansoprazole 30 mg QD
9772042|NCT00942175|Other|Regimen C|Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD
9772043|NCT00942175|Other|Regimen D|Clopidogrel 75 mg QD and Omeprazole 80 mg QD
9772044|NCT00942175|Other|Regimen E|Clopidogrel 75 mg QD and Esomeprazole 40 mg QD
9772045|NCT00942188|Experimental|0.6 milligrams (mg) LY2189102|
9772046|NCT00942188|Experimental|18 mg LY2189102|
9772047|NCT00942188|Experimental|180 mg LY2189102|
9772048|NCT00942188|Placebo Comparator|Placebo|0.9% Sodium Chloride
9772049|NCT00942266|Experimental|Arm I|Patients receive low-dose oral vorinostat once daily on days 1-3, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV over 46 hours on days 2 and 3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
9772050|NCT00942266|Experimental|Arm II|Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
9772051|NCT00942305|Placebo Comparator|Placebo|"Cohort 1 = 40 mg of matching placebo administered once weekly (QW)~Cohort 2 = 100 mg of matching placebo administered QW~Cohort 3 = 200 mg of matching placebo administered QW~Cohort 4 = 200 mg of matching placebo administered twice weekly (BIW)~Cohort 4A = 100 mg of matching placebo administered BIW"
9772052|NCT00942305|Experimental|Brincidofovir|"Cohort 1 = 40 mg brincidofovir (BCV) administered once weekly (QW)~Cohort 2 = 100 mg BCV administered QW~Cohort 3 = 200 mg BCV administered QW~Cohort 4 = 200 mg BCV administered twice weekly (BIW)~Cohort 4A = 100 mg BCV administered BIW"
9772053|NCT00942357|Experimental|Arm I (cisplatin, radiation therapy, paclitaxel, carboplatin)|Patients receive cisplatin IV on days 1 and 29. Patients also undergo radiation therapy QD, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9772054|NCT00942357|Active Comparator|Arm II (paclitaxel and carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9772055|NCT00942422|Experimental|defined green tea catechin extract / correlative analysis|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9772056|NCT00942448|Experimental|Diclofenac HPBCD s.c. 25mg/ml|
9772057|NCT00942448|Experimental|Diclofenac HPBCD s.c. 50mg/ml|
9772058|NCT00942448|Active Comparator|Diclofenac HPBCD s.c. 75mg/ml|
9772059|NCT00942448|Placebo Comparator|Placebo s.c. (1ml)|
9784590|NCT01229228|Placebo Comparator|Placebo|
9784591|NCT01229254|Experimental|Amiodarone|Participants on betrixaban 30 mg and concomitant baseline amiodarone
9784592|NCT01229254|Experimental|Betrixaban 60 mg|Participants with lower weights
9784593|NCT01229254|Experimental|Betrixaban 90 mg|Participants with higher weights
9784594|NCT01229267|Experimental|V212 Consistency Lot 1|Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
9772060|NCT00942578|Experimental|Single Arm - 4 Drug Combination|A two dose level escalation of Lenalidomide from 15mg to 20mg to 25mg- standard 3+3 dose escalation approach in combination with docetaxel, Bevacizumab and prednisone.
9772061|NCT00942604|Active Comparator|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
9772062|NCT00942604|Placebo Comparator|Vehicle gel|Vehicle gel once daily for 2 consecutive days
9772063|NCT00942708|Other|Fluoxetine|Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
9772064|NCT00942734|Experimental|RAD001 + Erlotinib|RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.
9772065|NCT00942786||No treatment|Consecutive patients undergoing emergency surgery
9772066|NCT00942825|Experimental|A CBP501 +Cisplatin + Pemetrexed|CBP501 25 mg/m2 + Cisplatin 75 mg/m2 + Pemetrexed 500mg/m2
9772067|NCT00942825|Active Comparator|B Cisplatin + Pemetrexed|Cisplatin + Pemetrexed
9772068|NCT00942851|Experimental|active|AH-8 containing topical intervention
9772069|NCT00942851|Placebo Comparator|placebo|topical intervention WITHOUT AH-8
9772070|NCT00942890|Experimental|NMES plus Standard Rehab Protocol|"NMES (EMPI 300PV stimulator) plus standard of care intervention. NMES is to the quadriceps muscle of the residual and intact limb plus rehabilitation. Therapy is 12-wks of NMES home training w/ the EMPI 300PV muscle stimulator. Participants perform training at home for 5days/wk; sessions consisted of 15 to 20 min. of NMES to each leg eliciting15 contractions/leg (10 seconds on:50 seconds off), plus a 5-minute patient treatment log, 5x/wk for 12-wks. Each contraction will be elicited by an electrical impulse generated by a battery-operated device. Two 3 X 5 electrodes are placed over the quadriceps muscle group. Participants will train at 30-40% of MVC during weeks 1-6, and 40-50% of MVC during weeks 7-12; incremental increases will be made at the study visits."
9772071|NCT00942890|Active Comparator|Standard Rehab Protocol|TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
9772072|NCT00942903|Experimental|Compliant HME users|Laryngectomized patients who are currently compliant (24/7) users of a Provox HME
9772073|NCT00942968|Experimental|1|
9772074|NCT00942994|Experimental|Triple Therapy (Aliskiren/Amlodipine/HCTZ)|At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.
9772075|NCT00942994|Active Comparator|Dual Therapy (Aliskiren/Amlodipine)|At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.
9772076|NCT00943072|Experimental|VEGF Trap-Eye|Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
9772077|NCT00943072|Sham Comparator|Sham|Monthly Sham IVT injection until Week 24 Primary Endpoint
9772078|NCT00943098|Experimental|Diclofenac HPBCD s.c. 75mg/ml|
9772079|NCT00943098|Active Comparator|Voltarol 75mg/3ml i.m.|
9772080|NCT00943111|Experimental|Investigational|Eliglustat tartrate
9772081|NCT00943111|Active Comparator|Imiglucerase|
9772082|NCT00943124|Experimental|MK0524B then Simvastatin + MK0524A|"Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).~Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets."
9772083|NCT00943124|Experimental|Simvastatin + MK0524A then MK0524B|"Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.~Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg)."
9772084|NCT00943150|Experimental|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
9772085|NCT00943150|Active Comparator|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
9772086|NCT00943202|Experimental|Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine; Day 42: TIV.
9772087|NCT00943202|Experimental|Group 2: Day 0-H1N1+TIV; Day 21-H1N1|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine + TIV; Day 21: 15 mcg H1N1 vaccine.
9772088|NCT00943202|Experimental|Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1|150 subjects to receive-Day 0: TIV; Day 21: 15 mcg H1N1 vaccine; Day 42: 15 mcg H1N1 vaccine.
9772089|NCT00943202|Experimental|Group 3: Day 0-H1N1; Day 21-H1N1+TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine + TIV.
9772090|NCT00943306|Experimental|lomitapide|Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
9772091|NCT00943319|Experimental|Busulfan and fludarabine|Intravenous busulfan (Busulfan®) in combination with fludarabine
9772092|NCT00943384|Experimental|chronOS Strip|This is a single arm, outcome study for treatment of patients with degenerative disc disease (DDD), with or without stenosis, with interbody fusion, posterolateral pedicle screw system, and the study device (chronOS Strip).
9772093|NCT00943436|Active Comparator|Active males|Males who participate in at least 30 minutes of physical activity on 5 or more days per week for the last month.
9772094|NCT00943436|Active Comparator|Inactive males|Males who participate in less than 1 hour of physical activity per week for the last month.
9772095|NCT00943488|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
9772096|NCT00943488|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
9772097|NCT00943579|Experimental|Kuvan®|Kuvan® (sapropterin) will be administered to all subjects at 20 mg/kg/day for 16 weeks.
9772098|NCT00943592|Experimental|Treatment|
9772099|NCT00943631|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
9772100|NCT00943631|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
9772101|NCT00943670|Experimental|T-DM1 / T-DM1 + pertuzumab|"Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.~From Cycle 4, participants with early progressive disease (demonstrated prior to the end of Cycle 6) could receive combined pertuzumab and trastuzumab emtansine. Pertuzumab was administered after trastuzumab emtansine by IV infusion at a loading dose of 840 mg on Day 1, starting at the cycle after tumor progression was determined, followed by 420 mg IV infusion every 3 weeks in subsequent cycles.~Participants who met criteria for ongoing clinical benefit were allowed to continue study treatment in the absence of disease progression or unacceptable toxicity for up to 1 year."
9772102|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
9772103|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 2)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
9772104|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 3)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
9772105|NCT00943722|Experimental|9- to 15-Year-Old Males (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
9772106|NCT00943722|Experimental|16- to 26-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
9772107|NCT00943735||Fesoterodine arm|subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy
9772108|NCT00943761|Experimental|Vaniprevir 300 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 300 mg twice daily (b.i.d.) in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
9772109|NCT00943761|Experimental|Vaniprevir 600 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 600 mg b.i.d. in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
9772110|NCT00943787|Other|SMBG followed by clamp|One month of self-monitored blood glucose (SMBG) field data was used to calculate measures of glucose variability and risk of hypoglycemia, while the hyperinsulinemic, euglycemic and hypoglycemic clamp procedure was used to evaluate insulin sensitivity and epinephrine response during induced hypoglycemia.
9772111|NCT00943800|Experimental|Good Risks patients|For patients transplanted in remission.
9772112|NCT00943800|Experimental|High Risk Patients eligible for radiation|
9772113|NCT00943800|Experimental|High Risk Patients not eligible for radiation|
9784595|NCT01229267|Experimental|V212 Consistency Lot 2|Participants randomized to receive V212 consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
9772114|NCT00943826|Experimental|Bevacizumab + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
9772115|NCT00943826|Placebo Comparator|Placebo + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.
9772116|NCT00943878|Experimental|Group 3: H1N1+placebo; H1N1+TIV; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); and Day 42, placebo.
9772117|NCT00943878|Experimental|Group 1: H1N1+placebo; H1N1+placebo; TIV|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, trivalent influenza vaccine (TIV).
9772118|NCT00943878|Experimental|Group 2: H1N1+TIV; H1N1+placebo; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, placebo.
9772119|NCT00943878|Experimental|Group 4: TIV+placebo; H1N1+placebo; H1N1|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, trivalent influenza vaccine (TIV) + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, 15 mcg H1N1 vaccine.
9772120|NCT00943904|Experimental|Interstim stimulation|Patients who receive the interstim implant in order to evaluate effectiveness of treatment
9772121|NCT00943917|Experimental|ITCA 650 20 mcg/day|
9772122|NCT00943917|Experimental|ITCA 650 40 mcg/day|
9772123|NCT00943917|Active Comparator|Exenatide Injection|
9772124|NCT00943917|Experimental|ITCA 650 20/20|
9772125|NCT00943917|Experimental|ITCA 650 20/60|
9772126|NCT00943917|Experimental|ITCA 650 40/40|
9772127|NCT00943917|Experimental|ITCA 650 40/80|
9772128|NCT00943917|Experimental|Ex Inj/ITCA 650 40|
9772129|NCT00943917|Experimental|Ex Inj/ITCA 650 60|
9772130|NCT00944021|Experimental|PA-824 50 mg/qd|
9772131|NCT00944021|Experimental|PA-824 100mg/qd|
9772132|NCT00944021|Experimental|PA-824 150mg/qd|
9772133|NCT00944021|Experimental|PA-824 200mg/qd|
9772134|NCT00944021|Active Comparator|Rifafour e-275mg|
9772135|NCT00944034|Experimental|B+R246_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
9772136|NCT00944034|Experimental|B+R246_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
9772137|NCT00944034|Experimental|B+R246_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
9772138|NCT00944034|Experimental|B246_12|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
9772139|NCT00944034|Experimental|B246_18|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
9772140|NCT00944034|Experimental|B246_24|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
9772141|NCT00944034|Experimental|B+R234_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
9772142|NCT00944034|Experimental|B+R234_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
9772143|NCT00944034|Experimental|B+R234_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
9772144|NCT00944034|Experimental|B12 14|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
9772145|NCT00944034|Experimental|B18 20|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
9772146|NCT00944034|Experimental|B24 26|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.
9772147|NCT00944047|Experimental|Intervention Arm|Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
9772148|NCT00944073|Experimental|Group 2: 30 mcg H1N1 Vaccine|300 subjects to receive 30 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
9772149|NCT00944073|Experimental|Group 1: 15 mcg H1N1 Vaccine|300 subjects to receive 15 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
10203829|NCT04983511|Experimental|Electrical Epidural Stimulation Test (EST)|Postpartum women are given EST to predict epidural catheter reactivation for their subsequent procedures (i.e. tubal ligation).
9772150|NCT00944125|Active Comparator|Dual Site LV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
9772151|NCT00944125|Active Comparator|BiV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
9772152|NCT00944450|Active Comparator|1|Sitagliptin anhydrous formulation
9772153|NCT00944450|Active Comparator|2|Sitagliptin monohydrate FMI formulation
9772154|NCT00944554|Placebo Comparator|Placebo|Group given placebo.
9772155|NCT00944554|Experimental|Varenicline|Experimental group given varenicline dosing.
9772156|NCT00944645|Active Comparator|A|MK0524A Source 1 (Phase III manufacturing site)
9772157|NCT00944645|Active Comparator|B|MK0524A Source 2 (commercial manufacturing site)
10203830|NCT04981821|Experimental|GO-EXCAP|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
10203831|NCT04981821|Active Comparator|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
10203832|NCT04979169|No Intervention|Non-adherent control|Subjects who are determined to be non-adherent to screening guidelines and are assigned to usual treatment via randomization in REDCap.
10203833|NCT04979169|Experimental|Non-adherent intervention|Subjects who are determined to be non-adherent to screening guidelines and are assigned to intervention treatment (text messaging) via randomization in REDCap.
10203834|NCT04963569||Albumin|Participants enrolled in the ABC Sepsis trial who have been randomised to 5% Human Albumin Solution as the sole resuscitative fluid in the first 6 hours.
10203835|NCT04963569||Balanced Crystalloid|Participants enrolled in the ABC Sepsis trial who have been randomised to Balanced Crystalloid as the sole resuscitative fluid in the first 6 hours.
10203836|NCT04960722|Active Comparator|Control|autogenous bone graft
10203837|NCT04960722|Experimental|1.5 mg/g OIF/β-TCP|1.5 mg/g OIF/β-TCP
10203838|NCT04960722|Experimental|2 mg/g OIF/β-TCP|2 mg/g OIF/β-TCP
10203839|NCT04960722|Experimental|3 mg/g OIF/β-TCP|3 mg/g OIF/β-TCP
10203840|NCT04945148|Experimental|Metformin|Patients who have been selected with an OXPHOS+ status, will start standard radiotherapy (RT, 60Gy/6 weeks), concomitant TMZ chemotherapy (75mg/m²/day), and metformin by 7 weeks after surgery and adjuvant TMZ + metformin will follow onwards until the 12th cycle of TMZ. Patients still in remission after this time-point will continue metformin alone until progression.
10203841|NCT04937816||EMPA-REG - Placebo|Participants of the EMP-REG OUTCOME study (1245.25) who received placebo.
10203842|NCT04937816||EMPA-REG - Empagliflozin low dose|Participants of the EMPA-REG OUTCOME study (1245.25) who received a low dose of empagliflozin once daily (QD).
10203843|NCT04937816||EMPA-REG - Empagliflozin high dose|Participants of the EMP-REG OUTCOME study (1245.25) who received a high dose of empagliflozin once daily (QD).
10203844|NCT04937816||EMPEROR-Preserved - Empagliflozin|Participants of the EMPEROR-Preserved study (1245.110) who received empagliflozin once daily (QD).
10203845|NCT04937816||EMPEROR-Preserved - Placebo|Participants of the EMPEROR-Preserved study (1245.110) who received placebo once daily (QD).
10203846|NCT04937816||EMPEROR-Reduced - Empagliflozin|Participants of the EMPEROR-Reduced study (1245.121) who received empagliflozin once daily (QD).
10203847|NCT04937816||EMPEROR-Reduced - Placebo|Participants of the EMPEROR-Reduced study (1245.121) who received placebo once daily (QD).
10203848|NCT04934449|Experimental|Hard splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, hard occlusal splints for 6 weeks during sleep
10203849|NCT04934449|Experimental|Hard splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, hard occlusal splints for 6 weeks during sleep
10203850|NCT04934449|Experimental|Soft splint group- 2 mm thicknesss|This group of patients was allocated to use 2 mm-thickness, soft occlusal splints for 6 weeks during sleep
10203851|NCT04934449|Experimental|Soft splint group- 3 mm thicknesss|This group of patients was allocated to use 3 mm-thickness, soft occlusal splints for 6 weeks during sleep
10203852|NCT04906902|Experimental|Acalabrutinib Dose Escalation|"Phase 1 Dose escalation will occur using a 3+3 dose escalation approach, evaluating three separate dose levels.~Acalabrutinib 200mg 2x daily~Acalabrutinib 300mg 2x daily~Acalabrutinib 400mg 2x daily"
9772158|NCT00944658|Placebo Comparator|Placebo|placebo twice a day for 12 weeks, 4 weeks follow up
9772159|NCT00944658|Active Comparator|Apremilast|30 mg twice a day for 12 weeks, 4 weeks follow up
9772160|NCT00944671|Active Comparator|A|Famotidine/antacid combination tablet with water
9772161|NCT00944671|Experimental|B|Famotidine/Antacid EZ Chew tablet without water
9772162|NCT00944671|Experimental|C|Famotidine/Antacid EZ Chew tablet with water
9772163|NCT00944697|Placebo Comparator|Tablets|A placebo tablet to match the active reference treatment
9772164|NCT00944697|Active Comparator|Tablet|Oxycodone Naloxone tablets
9772165|NCT00944710|Active Comparator|Intensified treatment|Weekend atropine 1% with plano lens over the sound eye
9772166|NCT00944710|Active Comparator|Control|Weekend atropine 1%
9772167|NCT00944749|Experimental|Single Arm|
9772168|NCT00945061|Experimental|Intraoperative radiation therapy|Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.
9772169|NCT00945061|Experimental|Intracavitary balloon brachytherapy|Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.
9772170|NCT00945100|Active Comparator|Control|2 hours daily patching
9772171|NCT00945100|Active Comparator|Intensified treatment|42 hours per week of patching (averaging 6 hours daily)
9772172|NCT00945139|Experimental|Single Arm: Doxil and Avastin|Patients receive both agents, doxil and Avastin.
9772173|NCT00945191|Experimental|CS-1008 with paclitaxel and carboplatin|CS-1008 will be administered with paclitaxel and carboplatin.
9772174|NCT00945243|Other|Treatment|Treatment of cervical DDD with the Zero-P device
9772175|NCT00945256|Active Comparator|Young Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
9772176|NCT00945256|Active Comparator|Elderly Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
9772177|NCT00945256|Active Comparator|Young Sodium Nitroprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
9772178|NCT00945256|Active Comparator|Elderly Sodium Nitoprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
9772179|NCT00945256|Active Comparator|Elderly Sodium Nitroprusside and Amino Acid Drink|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally
9772180|NCT00945282|Experimental|Cohort 1|In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
9772181|NCT00945282|Experimental|Cohort 2|In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
9772182|NCT00945295|Active Comparator|Cohort #1|Cohort 1 will receive BoNT-A plus rehabilitation therapy for the duration of the study (for up to 2 injections of BoNT-A).
9772183|NCT00945295|Active Comparator|Cohort #2|Cohort 2 will receive BoNT-A alone
9772184|NCT00945321|Active Comparator|1|aprepitant 165 mg
9772185|NCT00945321|Active Comparator|2|aprepitant 185 mg
9772186|NCT00945321|Experimental|3|fosaprepitant 150 mg
9772187|NCT00945321|Experimental|4|aprepitant with food
9772188|NCT00945334|Experimental|Group 1|Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
9772189|NCT00945334|Experimental|Group 2|Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
9772190|NCT00945477|Experimental|Advanced prostate cancer, treatment, pazopanib|Pazopanib
9772191|NCT00945555||All participants|Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
9772192|NCT00945594|Experimental|Flexible cystoscopy|16F flexible cysto urethroscope (Storz, Culver city, CA)
9772193|NCT00945594|Experimental|Rigid cystoscopy|17F, 70° scope (Storz, Culver city, CA)
9772194|NCT00945659|Active Comparator|Standard Care|"Standard Care constitutes intensified diabetes management, an enrollment criterion for the study, consisting of either continuous subcutaneous insulin infusion (insulin pump) or multiple daily injections using a basal-bolus approach. All patients must be using carbohydrate counting and have prescribed correction factors for targeted insulin bolus dose adjustments."
9772195|NCT00945659|Active Comparator|Continuous Glucose Sensor|Patients will have the same diabetes management regimen as those in the Standard Care group. In addition they will be given a continuous glucose sensor, receive expert instruction in its use, and be guided by a physician and diabetes educator in achieving glycemic benefits through retrospective and real-time interpretation of CGS results and by learning to respond judiciously to the various CGS alarms.
9772196|NCT00945659|Experimental|CGS + Behavior Therapy|Patients in the use group will receive the same medical management as the Continuous Glucose Sensor group above. In addition, they will have 6 scheduled encounters with a behavior therapist that are designed to reduce or eliminate typical behavioral and/or psychological barriers to optimal use of CGS as part of diabetes care.
9784596|NCT01229267|Experimental|V212 Consistency Lot 3|Participants randomized to receive V212 consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
9772197|NCT00945750|Experimental|Sequence 1: FCT with water → CT without water → CT with water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
9772198|NCT00945750|Experimental|Sequence 2: CT without water → CT with water → FCT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
9772199|NCT00945750|Experimental|Sequence 3: CT with water → FCT with water → CT without water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
9772200|NCT00945750|Experimental|Sequence 4: FCT with water → CT with water → CT without water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
9772201|NCT00945750|Experimental|Sequence 5: CT without water → FCT with water → CT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
9772202|NCT00945750|Experimental|Sequence 6: CT with water → CT without water → FCT with water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
9772203|NCT00945815|Experimental|treatment|AraC 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7, 14, 21, 28 acetaminophen 650 mg/d PO Days 7, 14, 21, 28 diphenhydramine 50 mg/d IV Days 7, 14, 21, 28 IT methotrexate 12 mg IT at least 1 wk apart during induction All give 1 cycle
9772204|NCT00945854|Active Comparator|Wholegrain cereal diet|Treatment with a diet based on wholegrain cereals and foods with low glycemic index
9772205|NCT00945854|Active Comparator|Refined cereal diet|Treatment with a diet based on refined cereals and foods with high glycemic index
9772206|NCT00945893|Experimental|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.
9772207|NCT00945893|Placebo Comparator|Placebo|Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
9772208|NCT00945906|Experimental|FXIII|Subjects were administered FXIII Concentrate (Human) by intravenous (IV) infusion approximately every 28 days to maintain a trough FXIII level of approximately 5 to 20%.
9772209|NCT00945945|Experimental|DLX30-PLA|Per the protocol, patients randomized to the duloxetine group were to receive duloxetine for the entire 13-week acute treatment period. Patients were to start at a 30 mg daily (QD) dose of duloxetine for 1 week, then increase to 60 mg QD of duloxetine for the following 12 weeks. However, due to a study drug labeling error, patients randomized to this group received 30 mg of duloxetine for the initial 1-week, but received placebo instead of receiving 60 mg QD of duloxetine for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as DLX30-PLA throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive 30 mg QD of duloxetine during that week, and that did occur per protocol.
9772210|NCT00945945|Placebo Comparator|PLA-DLX60|Per the protocol, patients randomized to the placebo group were to receive placebo for the entire 13-week acute treatment period. Patients were to start on placebo for the first week, then continue on placebo for the following 12 weeks. However, due to a study drug labeling error, patients in this group received placebo for the initial 1-week, but received 60 mg QD of duloxetine instead of receiving placebo for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as PLA-DLX60 throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive placebo that week, and that did occur per protocol.
9772211|NCT00945958|Experimental|SPARC0913|
9772212|NCT00946023|Experimental|Transplant|Non-myeloablative allogeneic bone marrow transplant (BMT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD (graft vs host disease) prophylaxis. Rituximab will be given as post-transplant maintenance.
9772213|NCT00946088|Active Comparator|Progesterone|Progesterone 400mg per vagina qhs.
9772214|NCT00946088|Placebo Comparator|Polyethylene glycol&hydrogenated vegetable oil|Polyethylene glycol&hydrogenated vegetable oil per vagina
9772215|NCT00946101|Active Comparator|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414- Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of influenza virus type A/California/07/2009.
9772216|NCT00946101|Placebo Comparator|Placebo|Placebo - Placebo was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer
9772217|NCT00946153|Experimental|Lenvatinib|
9772218|NCT00946192|Experimental|Estrogen Patch|17Beta-estradiol transdermal patch twice weekly application for 12 months
9772219|NCT00946192|Active Comparator|Estrogen Pill|One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
9772220|NCT00946192|Sham Comparator|Control|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
9772221|NCT00946270|Experimental|Group 3 CC-4047 + Prednisone|CC-4047 0.5 mg orally daily starting on day 1 through 28. Prednisone given during first 3 cycles of therapy. It will be dosed orally at the dose of 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
9772222|NCT00946270|Experimental|Group 1 CC-4047|CC-4047 3.0 mg orally daily starting on day 1 through 21.
9772223|NCT00946270|Experimental|Group 2 CC-4047|CC-4047 0.5 mg orally daily starting on day 1 through 28.
9772224|NCT00946296|Active Comparator|Potassium Iodide|8 drops of Potassium Iodide in a glass of water, by mouth, daily for 7 days prior to operation.
9772225|NCT00946296|No Intervention|No Treatment|The experimental group receives no treatment.
9772226|NCT00946309|Experimental|High Sulforaphane Extract|
9772227|NCT00946309|Placebo Comparator|Placebo|
9772228|NCT00946322|Experimental|Arm 1: CTAP|Couple-Based Treatment for Alcohol Use Disorders and PTSD
9772229|NCT00946348|Experimental|Dronabinol|Dronabinol 10mg or 15 mg
9772230|NCT00946348|Active Comparator|Cannabis|Cannabis cigarette
9772231|NCT00946478|Active Comparator|Pimecrolimus|
9772232|NCT00946478|Sham Comparator|Vehicle cream|
9772233|NCT00946530|Experimental|Bright Light|received bright light
9772234|NCT00946530|Placebo Comparator|Control|received regular light
9772235|NCT00946647|Experimental|Panobinostat + 5-Azacytidine|"In phase I: Panobinostat : Escalating doses starting with 20 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In both phases, dose of 5-Azacytidine was 75 mg/m^2, subcutaneously Daily for Day 1 to Day 7."
9772236|NCT00946647|Active Comparator|5-Azacytidine|"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.~Dose of 5-Azacytidine : 75 mg/m^2 subcutaneously daily from Day 1 to Day 7."
9772237|NCT00946712|Experimental|Arm I (chemo +/- bevacizumab)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes with or without bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients receiving bevacizumab may continue to receive bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
9772238|NCT00946712|Experimental|Arm II (chemo, cetuximab, +/- bevacizumab)|Patients receive paclitaxel and carboplatin with or without bevacizumab as in Arm I. Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients may continue to receive cetuximab with or without bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
9772239|NCT00946881|Experimental|WST11 (TOOKAD® Soluble)|WST11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses
9772240|NCT00946920|Experimental|Degarelix 240 mg/480 mg|
9772241|NCT00946920|Active Comparator|Goserelin acetate|
9772242|NCT00946998|Active Comparator|Sertraline|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
9772243|NCT00946998|Placebo Comparator|Placebo|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
9772244|NCT00947115|Experimental|Cervarix 15-25 years group|Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
9772245|NCT00947115|Experimental|Cervarix 26-45 years group|Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
9772246|NCT00947115|Experimental|Cervarix 46-55 years group|Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
10203853|NCT04906902|Experimental|Acalabrutinib Dose Expansion|"Phase 2~Participants will receive Acalabrutinib at the pre-determined dosage established in Phase 1."
10203854|NCT04894110|Experimental|EO2002 treatment|
10203855|NCT04880733|Experimental|Acupuncture|This arm will receive acupuncture for pain management, and any pain medications will be delayed until after receipt of acupuncture.
10203856|NCT04880733|Active Comparator|Usual Care|This arm will receive usual care for pain management.
9835711|NCT02751424|Experimental|GSK3342830 repeat Dose in Part 2|Enrolled subject will receive repeat escalating dose of GSK3342830. GSK3342830 as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. The escalating doses will be evaluated in three cohorts as G-1000 mg, H-2000 and I-4000 mg. In each cohort 8 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 24 subjects will receive GSK3342830. The starting dose and maximum dose may change based on clinical safety and PK findings in Part 1 or earlier doses in Part 2 respectively.
9835712|NCT02751424|Placebo Comparator|Placebo repeat Dose in Part 2|Enrolled subject will receive repeat escalation dose of placebo. Placebo as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 6 subjects will receive placebo.
9835713|NCT02751450|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
9835714|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
9835715|NCT02751580|Experimental|Health services research (telehealth)|Patients undergo their first post-treatment visit as a virtual telehealth visit using the JeffConnect application downloaded onto their electronic device.
9835716|NCT02751827||Prospective cohort|"Prospective cohort involving patients treated in four distinct centers. Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
9835717|NCT02751827||Retrospective cohort A|"Retrospective cohort of patients treated at the Institut Bergonié (Bordeaux, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
9835718|NCT02751827||Retrospective cohort B|"Retrospective cohort of patients treated at the Centre Antoine Lacassagne(Nice, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
9835719|NCT02751879||Non small cell lung cancer (NSCLC)|patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
9835720|NCT02751931|Experimental|Children (3 to < 12 Years)|Participants aged 3 to < 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg (milligram) [PED25]) on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50], orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 end-of-study (EOS) or end-of-treatment (EOT).
9835721|NCT02751931|Experimental|Adolescents (12 to < 18 Years)|Participants aged 12 to < 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight [PED25] on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50] orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT.
9835722|NCT02751983|Experimental|Treatment as usual plus ACT|Participants in this condition will be enrolled in the ACT for Life intervention and still able to engage in treatment as usual.
9835723|NCT02751983|Active Comparator|Treatment as usual|Participants in this condition will not be enrolled in ACT for Life, but will continue to participate in treatment as usual (e.g., inpatient and outpatient mental health care).
9835724|NCT02752048|Experimental|TAS-205（Low dose group）|Low dose group：Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (6.67-13.33 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
9835725|NCT02752048|Experimental|TAS-205（High dose group）|High dose group: Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (13.33-26.67 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
9835726|NCT02752048|Placebo Comparator|Placebo|Placebo group: Oral administration of tablets for 24 weeks, BID after meal
9835727|NCT02752074|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab + Epacadostat
9772247|NCT00947154|Experimental|Open-label aripiprazol|Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
9772248|NCT00947167|Experimental|Pertuzumab and Erlotinib|
9772249|NCT00947193|Experimental|Ataluren Overall Study|Ataluren was provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren was taken 3 times per day, with dosing based on the participant's body weight. The dose level for ataluren was 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening or 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by an interval of 14 days without treatment.
9772250|NCT00947219|Active Comparator|HairMax LaserComb 2009, 12 Beam|Low Level Laser Medical Device 2009 with 12 laser beams
9772251|NCT00947219|Active Comparator|HairMax LaserComb 2009 9 Beam|Low Level Laser Mecial Device 2009 with 9 laser beams
9772252|NCT00947219|Active Comparator|Control device|The control device appears identical to the active device, but utilizes 9 LED lights instead of laser lights. The randomized devices are blinded to the study investigator and distributed in a blinded manner to the participants.
9772253|NCT00947271|Experimental|DVD 1 plus assessment 1|Participants will view educational DVD 1 and complete the first version of the study assessment.
9772254|NCT00947271|Experimental|DVD 1 plus assessment 2|Participants will view educational DVD 1 and complete the second version of the study assessment.
9772255|NCT00947271|Experimental|DVD 2 plus assessment 1|Participants will view educational DVD 2 and complete the first version of the study assessment.
9772256|NCT00947271|Experimental|DVD 2 plus assessment 2|Participants will view educational DVD 2 and complete the second version of the study assessment.
9772257|NCT00947297|Experimental|HPN-100|Patients who were treated with HPN-100
9772258|NCT00947310|Experimental|A|Standard ICD Programming
9772259|NCT00947310|Experimental|B|High rate cutoff
9772260|NCT00947310|Experimental|C|Long ICD duration delay
9772261|NCT00947349|Experimental|BI 201335 NA low TN|patient to receive a capsule containing low dose of BI 201335 NA/Drug for treatment-naive (TN) patients
9772262|NCT00947349|Experimental|BI 201335 NA high TN|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-naive (TN )patients
9772263|NCT00947349|Experimental|BI 201335 NA high TE|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-experienced (TE) patients
9772264|NCT00947349|Placebo Comparator|Placebo in Treatment Naive (TN) Patients|
9772265|NCT00947427|Placebo Comparator|Placebo|Placebo solution given by subcutaneous injection on monthly basis for 12 months
9772266|NCT00947427|Experimental|Canakinumab|Subcutaneous injection of canakinumab at dose of 2.0 mg/kg given monthly of 12 months
9772267|NCT00947505|Active Comparator|HairMax LaserComb 2009, 7 Beam|Lower level laser phototherapy medical device with 7 laser beams
9772268|NCT00947505|Active Comparator|Control Device|Identical to the Active device, but with 7 LED's instead of lasers
9772269|NCT00947531|Experimental|Cerebrolysin|
9772270|NCT00947531|Placebo Comparator|0.9% Saline Solution|
9772271|NCT00947544|Experimental|HPN-100 and NaPBA|1 week of NaPBA treatment followed by 1 week of HPN-100 treatment.
9784597|NCT01229267|Experimental|V212 High Antigen Lot|Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
9784598|NCT01229267|Placebo Comparator|Placebo|Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
9784599|NCT01229371|Active Comparator|Subjects ≥18 to ≤60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
9784600|NCT01229371|Active Comparator|Subjects >60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
9835728|NCT02752074|Active Comparator|Pembrolizumab + Placebo|Pembrolizumab + Placebo
9835729|NCT02752087|Experimental|U-193 LY900014 Test|LY900014 test dose administered via subcutaneous (SC) injection
9772272|NCT00947661|Experimental|SPARC0912|Test drug
9772273|NCT00947661|Experimental|Reference0912|Reference drug
9772274|NCT00947752|Active Comparator|F1 Glatiramer acetate 20mg/1.0ml|
9772275|NCT00947752|Experimental|F2 Glatiramer acetate 20mg/0.5ml|
9772276|NCT00947765|Experimental|Autologous blood injection group|This is the study group in whom autologous blood injection was injected at lateral epicondylitis site.
9772277|NCT00947765|Active Comparator|Local corticosteroid injection group|This is the control group in whom the commonly used treatment modality-local corticosteroid injection was given at lateral epicondyle site.
9772278|NCT00947856|Experimental|BV Retreatment|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
9772279|NCT00947856|Experimental|BV Extension|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
9772280|NCT00947882|Placebo Comparator|Placebo|
9772281|NCT00947882|Experimental|Degarelix 10 mg|
9772282|NCT00947882|Experimental|Degarelix 20 mg|
9772283|NCT00947882|Experimental|Degarelix 30 mg|
9772284|NCT00948025|Active Comparator|Avance Nerve Graft|Commercially available Avance Nerve Graft for repair of nerve gap
9772285|NCT00948025|Active Comparator|Hollow Tube Conduit|Commercially available hollow tube conduit for repair of nerve gap.
9772286|NCT00948064|Experimental|Vorinostat with Azacitidine|ARM A: Azacitidine 75 mg/m^2/day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Vorinostat 200 mg by mouth three time a day with food for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
9772287|NCT00948064|Experimental|Azacitidine|ARM B: Azacitidine 75 mg/m^2 /day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
9772288|NCT00948090|Experimental|IV Busulfan|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
9772289|NCT00948155|Experimental|Varenicline before placebo|"Drug (Varenicline (Chantix)): Placebo~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21."
9772290|NCT00948155|Experimental|Placebo then Varenicline|"Placebo: Drug Varenicline (Chantix)~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.~Intervention 'Drug (Varenicline (Chantix)): Placebo'"
9772291|NCT00948246||Easyband|Subjects who had the Easyband device implanted laparoscopically.
9772292|NCT00948298|Placebo Comparator|Placebo|
9772293|NCT00948298|Experimental|Vitamin D|
9772294|NCT00948389|Active Comparator|Dasatinib|
9772295|NCT00948389|Active Comparator|Lomustine|
9772296|NCT00948428|Active Comparator|Generic Imiquimod|imiquimod cream, 5%
9772297|NCT00948428|Active Comparator|Aldara™|Aldara™ (imiquimod) cream, 5%
9772298|NCT00948428|Placebo Comparator|Vehicle cream|Vehicle cream (Actavis)
9772299|NCT00948441|Experimental|Group 1|25% ethanol for 12 weeks; wash out period for 4 weeks; heparin lock for 12 weeks
9772300|NCT00948441|Experimental|Group 2|heparin lock for 12 weeks; wash out period for 4 weeks; 25% ethanol lock for 12 weeks
9772301|NCT00948506|Placebo Comparator|1% topical cidofovir|1% topical cidofovir to one side of the face and placebo to the other side of the face
9772302|NCT00948506|Placebo Comparator|3% topical cidofovir|3% topical cidofovir to one side of the face and placebo to the other side of the face
9772303|NCT00948610|Placebo Comparator|Placebo|Placebo-participant will receive placebo saline solution via IV route.
9772304|NCT00948610|Active Comparator|Remicade|Remicade-Participant will be given 10 mg/kg of drug via IV route.
9772305|NCT00948675|Experimental|Pemetrexed + Carboplatin + Pemetrexed|Pemetrexed and Carboplatin followed by Pemetrexed
9772306|NCT00948675|Active Comparator|Paclitaxel + Carboplatin + Bevacizumab|Paclitaxel, Carboplatin, and Bevacizumab followed by Bevacizumab
9772307|NCT00948688|Experimental|Vorinostat, 5-FU, Radiation Therapy|Vorinostat at varying doses; orally, days 1-7, weeks 1-6 5-FU 225 mg/m2/day; intravenous; days 1-5, weeks 1-6 until completion of radiation therapy; Radiation therapy; 180cGy daily Monday-Friday; 28 days of treatment (6 weeks)
9772308|NCT00948766|Experimental|Rivastigmine 13.3 mg/24 h transdermal patch|In the core study, patients were titrated to the rivastigmine 13.3 mg/24 h dose in 2 steps. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-8, patients received rivastigmine 9.5 mg/24 h and placebo. For Weeks 9-24, patients received rivastigmine 13.3 mg/24 h and placebo. In the extension study, all patients were switched to rivastigmine 9.5 mg/24 h for a 4-week titration period and were then titrated up to 13.3 mg/24 h for a further 20 weeks of treatment.
9772309|NCT00948766|Active Comparator|Rivastigmine 4.6 mg/24 h transdermal patch|In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.
9772310|NCT00948792|Active Comparator|Long transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of two hours.
9772311|NCT00948792|Experimental|Short transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of 30 minutes.
9772312|NCT00948818|Experimental|Linaclotide|Linaclotide 290 micrograms
9772313|NCT00948818|Placebo Comparator|Placebo|Matching placebo
9772314|NCT00948857|Experimental|DHEA active treatment|Dehydroepiandrosterone 25 mg tid po
9772315|NCT00948857|Placebo Comparator|DHEA Placebo|Blinded placebo
9772316|NCT00948896|Experimental|1|
9772317|NCT00948896|Experimental|2|
9772318|NCT00948896|Experimental|3|
9772319|NCT00948896|No Intervention|4|
9772320|NCT00948922|Other|A: Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
9772321|NCT00948922|Other|B: Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
9772322|NCT00948922|Other|BE: Group B Expansion|Group B Expansion on Bortezomib Maintenance: Autologous Only.
9772323|NCT00948935|Experimental|Chemotherapy|Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
9772324|NCT00948974|Active Comparator|cognitive therapy|cognitive therapy and exposure
9772325|NCT00948974|Active Comparator|acceptance and committment therapy|acceptance and commitment therapy and exposure
9772326|NCT00949078|Experimental|Open Label Omalizumab Group A|Omalizumab was dosed according to package insert. Patients who have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
9772327|NCT00949078|Experimental|Open Label Omalizumab Group B|Omalizumab was dosed according to package insert. Patients who do not have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
9772328|NCT00949117|Experimental|Arm I- cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
9772329|NCT00949117|Experimental|cyproheptadine HCl & PediaSure or Ensure|Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
9772330|NCT00949234|Other|Open-Label|This was an open-label demonstration project. Therefore, medications were not blinded and participants were made aware of the regimen they received for PEP.
9772331|NCT00949325|Experimental|temsirolimus plus liposomal doxorubicin|Single arm study: Dose escalation of temsirolimus plus constant dose of liposomal doxorubicin.
9772332|NCT00949533|Experimental|Standard Dose|Oseltamivir capsule will be administered orally at a dose of 75 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 milligrams/ milliliter [mg/mL]) based on their body weight with a starting dose of 30 mg BID to a maximum dose of 75 mg BID; for 5 days.
9772333|NCT00949533|Active Comparator|Double Dose|Oseltamivir capsule will be administered orally at a dose of 150 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 mg/mL) based on their body weight with a starting dose of 60 mg BID to a maximum dose of 150 mg BID; for 5 days.
9772334|NCT00949650|Experimental|BIBW 2992|BIBW 2992 tablet once daily until progression
9772335|NCT00949650|Active Comparator|Cisplatin/Pemetrexed|Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles
9772336|NCT00949702|Experimental|Single arm|
9772337|NCT00949715|Active Comparator|RV Mid-Septal Pacing|Pacing lead located in the right ventricle at the middle of the muscle separating the right and left sides of the heart
9772338|NCT00949715|Active Comparator|RV Apical Pacing|Pacing lead located at the bottom of the right ventricle of the heart, in the right ventricular apex
9772339|NCT00949884|Experimental|Olmesartan|Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
9772340|NCT00949884|Placebo Comparator|Placebo followed by Olmesartan|Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks
9772341|NCT00949884|Active Comparator|Losartan|Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks
9772342|NCT00949910|Experimental|Erlotinib|Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.
9772343|NCT00949975|Active Comparator|1|AZD9668 active treatment
9772344|NCT00949975|Active Comparator|2|AZD9668 active treatment
9772345|NCT00949975|Active Comparator|3|AZD9668 active treatment
9772346|NCT00949975|Placebo Comparator|4|AZD9668 placebo treatment
9772347|NCT00950170|Experimental|1|The investigator treats subjects with ReFacto AF in the usual care setting.
9772348|NCT00950235|Other|Usual Care|This arm will receive one additional nutrition counseling session that typically received in the health system. This arm will be compared to our intervention group
9772349|NCT00950235|Experimental|Weight Management Counseling|In-person and group session counseling
9772350|NCT00950248|Active Comparator|Idebenone|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
9772351|NCT00950248|Placebo Comparator|Placebo|Placebo tablets administered orally as five tablets, three times per day with food.
9772352|NCT00950300|Active Comparator|Herceptin IV + Chemotherapy|Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
9835730|NCT02752087|Active Comparator|U-95 LY900014 Reference|LY900014 reference dose administered via SC injection
9835731|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
9772353|NCT00950300|Experimental|Herceptin SC + Chemotherapy|Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
9772354|NCT00950352|Experimental|Citicoline|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
9772355|NCT00950352|Placebo Comparator|Placebo|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
9772356|NCT00950365|Active Comparator|Arm A (pemetrexed)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9772357|NCT00950365|Experimental|Arm B (pemetrexed disodium, erlotinib hydrochloride)|Patients receive pemetrexed disodium IV as in Arm A and erlotinib hydrochloride PO QD on days 2-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9772358|NCT00950599|Experimental|Saxagliptin (2.5 mg)|
9772359|NCT00950599|Experimental|Saxagliptin (5 mg)|
9772360|NCT00950599|Experimental|Saxagliptin (10 mg)|
9772361|NCT00950599|Experimental|Saxagliptin (20 mg)|
9772362|NCT00950599|Experimental|Saxagliptin (40 mg)|
9772363|NCT00950599|Experimental|Saxagliptin (100 mg)|
9772364|NCT00950599|Placebo Comparator|Placebo|
9772365|NCT00950612|Experimental|Group A|
9772366|NCT00950612|Placebo Comparator|Group B|
9772367|NCT00950651|Experimental|1 Tramadol HCl Contramid® Once A Day|
9772368|NCT00950651|Active Comparator|2 Tramadol HCl Twice a day (SR)|
9772369|NCT00950664|Experimental|Dysport® to Botox®|Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
9772370|NCT00950664|Experimental|Botox® to Dysport®|Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
9772371|NCT00950729|Active Comparator|Driving with Running Shoes|
9772372|NCT00950729|Active Comparator|Driving with Plaster cast|
9772373|NCT00950729|Active Comparator|Driving with Aircast|
9772374|NCT00950742|Experimental|BIBW 2992 + Trastuzumab|Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally with fixed weekly infusion doses of 2mg/kg Herceptin. Escalating doses of BIBW 2992 starting at 20mg daily.
9772375|NCT00950755|Experimental|Tositumomab and Iodine I 131 Tositumomab (anti-B1 antibody)|In the first phase (dosimetric dose) patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of Anti B1 Antibody (35 mg) which has been trace-labeled with 5 mCi of Iodine 131. Whole body gamma camera scans will be obtained following the dosimetric dose. Using the dosimetric data, a patient-specific dose of Iodine 131 Anti B1 Antibody to deliver the desired total body dose of radiotherapy will be calculated. In the second phase, (radioimmunotherapeutic dose), patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of 35 mg Anti B1 Antibody labeled with the patient-specific dose of Iodine 131 to deliver a whole body dose of 75 cGy. Patients will be treated with saturated solution potassium iodide, Lugol's solution, or potassium iodide tablets starting at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion of Iodine 131 Anti B1 Antibody.
9772376|NCT00950807|Placebo Comparator|Placebo|Placebo
9772377|NCT00950807|Active Comparator|Tiotropium|Tiotropium
9772378|NCT00950807|Experimental|Arm 1|GSK573719 1000mcg once daily
9772379|NCT00950807|Experimental|Arm 2|GSK573719 500mcg once daily
9772380|NCT00950807|Experimental|Arm 3|GSK573719 250mcg once daily
9772381|NCT00950807|Experimental|Arm 4|GSK573719 125mcg once daily
9772382|NCT00950807|Experimental|Arm 5|GSK573719 62.5 mcg once daily
9772383|NCT00950807|Experimental|Arm 6|GSK573719 250mcg twice daily
9772384|NCT00950807|Experimental|Arm 7|GSK573719 125mcg twice daily
9772385|NCT00950807|Experimental|Arm 8|GSK573719 62.5mcg twice daily
9835732|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
9772386|NCT00950833|Active Comparator|AP-AP Group|subjects from the AP-AP group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015, receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
9772387|NCT00950833|Active Comparator|NAP-pre Group|subjects from the NAP-pre group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015 receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
9772388|NCT00950833|Active Comparator|Unprimed Group|Age-matched subjects from the unprimed group of the NCT00496015 study, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
9772389|NCT00950859|Experimental|GSK1349572 Cohort I|Single Arm, Cohort I
9772390|NCT00950859|Experimental|GSK1349572 Cohort II|Single Arm, Cohort II
9772391|NCT00950872|Experimental|Duet TRS|Subjects receive Duet TRS
9772392|NCT00950911|Experimental|1|
9772393|NCT00950950|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
9772394|NCT00950950|Experimental|Romosozumab|Participants were randomized to receive 3 mg/kg romosozumab administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
9772395|NCT00950963|Experimental|Phone Counseling|The telephone outreach intervention was considered an adjunct to usual care. The study nurse focused on optimizing lipids utilizing published guidelines through phone contact.
9772396|NCT00950963|Active Comparator|Standard Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
9772397|NCT00951015|Experimental|10 mg GSK1349572|subjects will receive GSK1349572 10mg once daily blinded to dose
9772398|NCT00951015|Experimental|25mg GSK1349572|subjects will receive GSK1349572 25mg once daily blinded to dose
9772399|NCT00951015|Experimental|50mg GSK1349572|subjects will receive GSK1349572 50mg once daily blinded to dose
9772400|NCT00951015|Other|efavirenz control|efavirenz will serve as the internal control arm
9772401|NCT00951041|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
9772402|NCT00951041|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
9772403|NCT00951080|Experimental|SNaP Wound Care System|
9772404|NCT00951080|Active Comparator|Traditional NPWT System|
9772405|NCT00951093||Patients assessed for GERD|Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language
9772406|NCT00951171|Experimental|Cervical occulsion|Insemination Eliptosphere catheter filled with 1cc of air for 15 minutes. H/S Eliptosphere by Copper surgical (U.S. Patent No. 5,624,399)
9772407|NCT00951171|Active Comparator|Standard IUI|Insemination with TOmcat catheter
9772408|NCT00951275|Experimental|1|
9772409|NCT00951379|Experimental|Arm I (Pioglitazone Hydrochloride)|Three (3) Pioglitazone 15 mg capsules by mouth once daily for 24 weeks
9772410|NCT00951379|Placebo Comparator|Arm II (Placebo)|Three (3) placebo capsules by mouth once daily for 24 weeks
9772411|NCT00951483|Experimental|Intervention Cohort|Patients will undergo baseline psychological and laboratory tests then receive Quetiapine-XR(Seroquel-XR) with flexible dosing at the discretion of the treating physician based on clinical response and tolerability. The dose range will be from 50-300mg. The total duration of the treatment will be 12 weeks.
9772412|NCT00951483|No Intervention|Healthy Control|Participants without major depressive disorder or anxiety are enrolled as a comparison group without intervention.
9772413|NCT00951496|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
9772414|NCT00951496|Experimental|Arm II (paclitaxel, bevacizumab, carboplatin IP)|Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
9772415|NCT00951496|Experimental|Arm III (paclitaxel IP, bevacizumab, cisplatin IP)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
9772416|NCT00951509||Condition 1 (PC Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
9772417|NCT00951509||Condition 2 (PC Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
9772418|NCT00951509||Condition 3 (VR Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
9772419|NCT00951509||Condition 4 (VR Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
9772420|NCT00951509||Condntion 5 (Real-world driving)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
9772421|NCT00951561|Experimental|Vipon|
9772422|NCT00951561|Active Comparator|Ibuprofen|
9772423|NCT00951665|Experimental|Phase lb Regimen 1|Participants received trastuzumab emtansine (T-DM1) every three weeks (Q3W) + paclitaxel weekly (QW) intravenously.
9772424|NCT00951665|Experimental|Phase Ib Regimen 2|Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.
9772425|NCT00951665|Experimental|Phase Ib Regimen 3|Participants received T-DM1 QW + paclitaxel QW intravenously.
9772426|NCT00951665|Experimental|Phase Ib Regimen 4|Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously.
9772427|NCT00951665|Experimental|Phase IIa Group A|Participants received maximum tolerated dose (MTD) from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW intravenously.
9772428|NCT00951665|Experimental|Phase IIa Group B|Participants received MTD from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW + pertuzumab Q3W intravenously.
9772429|NCT00951808|Active Comparator|Blood Transfusion Trial Cohort|Twenty participants will receive a blood transfusion while in the hospital.
9772430|NCT00951808|Active Comparator|Standard Care Trial Cohort|Twenty participants will not receive a blood transfusion and will receive standard care.
9772431|NCT00951808|Active Comparator|Standard Care Observational Cohort|Approximately 300 participants who are ineligible for or decline the blood transfusion part of the study will participate in the observational portion of the study and receive standard care.
9772432|NCT00951821|Experimental|Concurrent treatment|Concurrent treatment - experimental condition: Adolescent participants and their parents will receive concurrent cognitive behavioral therapy.
9772433|NCT00951821|Active Comparator|Adolescent treatment only|Adolescent treatment only - Active Comparator: Only adolescent participants will receive cognitive behavioral therapy.
9772434|NCT00951899|Experimental|Colesevelam|Treatment with colesevelam hydrochloride in addition to Metformin and Diet
9772435|NCT00951899|Placebo Comparator|Placebo|Treatment with placebo in addition to Metformin and Diet
9772436|NCT00951912|Placebo Comparator|Placebo|10g soy protein isolated powder patch by mouth everyday for 6months
9772437|NCT00951912|Experimental|Daidzein|10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months
9772438|NCT00951912|Experimental|Genistein|10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months
9772439|NCT00952068|Experimental|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
9772440|NCT00952081|Experimental|clevidipine,brain tumor,hypertension|21 or older, Clevidipine in brain tumor resection, epilepsy focus resection during acute hypertension under general anesthesia
9772441|NCT00952120|Experimental|GSUC|Gauze-based wall suction negative pressure wound therapy for 4-5 days
9772442|NCT00952120|Active Comparator|Vacuum-assisted closure|Vacuum-assisted closure (VAC) negative pressure wound therapy using commercially available device (KCI, Inc) for 4-5 days
9772443|NCT00952133|Experimental|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery.
9772444|NCT00952133|Placebo Comparator|Palonosetron only|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Intravenous Palonosetron and Saline solution
9772445|NCT00952211|Active Comparator|CPAP|CPAP at therapeutic pressure
9772446|NCT00952211|Sham Comparator|sub-therapeutic CPAP|CPAP administered at sub-therapeutic pressure
9772447|NCT00952276|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)
9772448|NCT00952276|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)
9772449|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
9772450|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 4|Participants will receive A/H1N1 vaccine formulation 4
9772451|NCT00952276|Placebo Comparator|Placebo Group 5|Participants will receive a placebo vaccine
9772452|NCT00952289|Experimental|Ruxolitinib|Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count > 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
9772453|NCT00952289|Placebo Comparator|Placebo|Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.
9772454|NCT00952315|Active Comparator|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
9772455|NCT00952315|Active Comparator|Lithoclast Select|Lithoclast Select will be used to breakup and remove kidney stone. Duration will be timed and documented.
9772456|NCT00952315|Active Comparator|Cyberwand|The dual probe Cyberwand device will be used to fragment and remove the kidney stone. Duration will be timed and documented.
9772457|NCT00952341|Experimental|Aprepitant (MK-0869)|
9772458|NCT00952341|Placebo Comparator|Standard Therapy|
9772459|NCT00952367||Per-protocol population|In all, 3641 participants were enrolled; however, 38 were excluded because of violation of inclusion/exclusion criteria and 3 participants were excluded for unavailability of nasopharyngeal swab sample. The record presents demographic and result data for 3600 participants in the per-protocol population. These participants completed collection of the nasopharyngeal swab sample, the Epidemiology questionnaire, and 24 hours safety observation.
9772460|NCT00952380|Other|Single Arm|Single arm open-label
9772461|NCT00952393|Other|Pharmacokinetic|This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.
9772462|NCT00952419|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
9772463|NCT00952419|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
9772464|NCT00952419|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
9772465|NCT00952484|Active Comparator|2 mg/kg|2 mg/kg subcutaneous injection three times per week.
9772466|NCT00952484|Active Comparator|3 mg/kg|3 mg/kg subcutaneous injection three times per week.
9772467|NCT00952523|Experimental|Tretinoin & Adapalene-Benzoyl Peroxide|Tretinoin and Adapalene-Benzoyl Peroxide facial gels applied once daily in a split face model
9772468|NCT00952588|Experimental|AZD1152 1200 mg|AZD1152 1200 mg, iv, 7 day infusion monotherapy
9772469|NCT00952588|Active Comparator|LDAC 20 mg|LDAC 20 mg, sc, bd, 10 days (400mg per cycle)
9772470|NCT00952614|Experimental|Retisert for Retinal Vein Occlusion|0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
9772471|NCT00952653|Experimental|DVS SR|
9772472|NCT00952705|Experimental|Q/LAIV-BFS (MEDI8662)|Q/LAIV-BFS (quadrivalent influenza vaccine) (MEDI8662) was supplied in the blow-fill-seal delivery system that delivers a nominal dose of 0.2 mL into a single nostril. Each dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), B/Victoria (B/Malaysia/2506/2004), and B/Yamagata (B/Florida/4/2006).
9772473|NCT00952705|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata was administered intranasally using a Becton Dickinson Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Yamagata (B/Florida/4/2006)
9772474|NCT00952705|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria was administered intranasally using a BD Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Victoria (B/Malaysia/2506/2004).
9772475|NCT00952718|No Intervention|Control|No intervention.
9772476|NCT00952718|Experimental|Inspiratory muscle training|With intervention.
9772477|NCT00952731|Experimental|oral placebo, afimoxifene|4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.
9772478|NCT00952731|Active Comparator|tamoxifen citrate, placebo gel)|Placebo gel applied to the breasts daily. 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules).
9772479|NCT00952822|Experimental|1|ADVATE reconstituted in 2 mL sterile water for infusion
9772480|NCT00952822|Active Comparator|2|ADVATE reconstituted in 5 mL sterile water for infusion
9772481|NCT00952848|Experimental|MC5-A Scramble instrument|Treatment of chronic neuropathic pain with the MC5-A device
9772482|NCT00953017|Active Comparator|Miralax plus Amitiza|106 patients randomized to Miralax plus Amitiza will take one 24mcg gelcap of Amitiza at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
9772483|NCT00953017|Active Comparator|Miralax plus Dulcolax|107 patients randomized to Miralax plus Dulcolax will take two 5mg tablets of Dulcolax at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
9772484|NCT00953017|Active Comparator|Miralax|106 patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
9772485|NCT00953017|Active Comparator|Golytely (polyethylene glycol)|106 patients will take 1 gallon of golytley (Polyethylene glycol) and drink 1/2 of the solution at 4 p.m. The remaining 1/2 of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy
9772486|NCT00953043|Active Comparator|Lubiprostone|Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
9772487|NCT00953043|Placebo Comparator|Placebo|Subjects randomized to this arm received placebo medication for three days.
9772488|NCT00953056|Experimental|Cohort I - RotaTeq™, Adults|Adults randomized to receive a single dose of RotaTeq™.
9772489|NCT00953056|Placebo Comparator|Cohort I - Placebo, Adults|Adults randomized to receive a single dose of matching placebo to RotaTeq™.
9772490|NCT00953056|Experimental|Cohort II - RotaTeq™, Children|Children randomized to receive a single dose of RotaTeq™.
9772491|NCT00953056|Placebo Comparator|Cohort II - Placebo, Children|Children randomized to receive a single dose of matching placebo to RotaTeq™.
9772492|NCT00953056|Experimental|Cohort III - RotaTeq™, Infants|Infants randomized to receive 3 doses of RotaTeq™.
9772493|NCT00953056|Placebo Comparator|Cohort III - Placebo, Infants|Infants randomized to receive 3 doses of matching placebo to RotaTeq™.
9772494|NCT00953121|Experimental|Cohort A-Grade IV No Failure|Recurrent GBM patients who have not previously failed bevacizumab, irinotecan, or carboplatin
9772495|NCT00953121|Experimental|Cohort B-Grade III No Failure|Recurrent Grade 3 malignant glioma patients who have not previously failed either bevacizumab, irinotecan or carboplatin
9772496|NCT00953121|Experimental|Cohort C-Failed Prior Therapy|Recurrent Grade IV GBM patients who have failed prior bevacizumab therapy, but not prior CPT-11 or carboplatin therapies
9784601|NCT01229371|Experimental|Subjects ≥18 to ≤60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
9784602|NCT01229371|Experimental|Subjects >60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
9784603|NCT01229397|Active Comparator|Inflexal V 0.25 mL x 2|
9784604|NCT01229397|Experimental|Inflexal V 0.5 mL x 1|
9784605|NCT01229410|Experimental|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
9784606|NCT01229410|Experimental|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
9784607|NCT01229423|Experimental|LATISSE®|bimatoprost 0.03% (LATISSE®)
9784608|NCT01229436|Experimental|Xiapex Injection|
9784609|NCT01229449|Experimental|Ibuprofen/acetaminophen (lower dose)|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
9784610|NCT01229449|Experimental|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
9784611|NCT01229449|Active Comparator|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
9784612|NCT01229449|Active Comparator|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
9784613|NCT01229449|Placebo Comparator|Placebo|Two placebo tablets
9784614|NCT01229462|Other|Combigan®|One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
9784615|NCT01229462|Active Comparator|Alphagan® and Timolol Concurrent|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
9784616|NCT01229527|Experimental|Remifentanil RS1|
9784617|NCT01229527|Experimental|Remifentanil RS2|
9784618|NCT01229527|Active Comparator|Meperidine|
9784619|NCT01229722|Active Comparator|Beeper|Patients randomized to the control arm (Beeper) will receive the standard of care at each clinic visit. The subjects will bring their HIV medications every 3 weeks (MEMS measure, pill count) and questioned on their adherence to antiretroviral therapy (ART) in the past 7 days. They will not receive any text messages addressing their adherence to ART between each study visit. Their providers will not be receiving any adherence reports but will be asked to assess their adherence at at the start of the trial (Time 1 or T1) and at subsequent clinic visit scheduled according to a frequency defined by standard of care.
9784620|NCT01229722|Experimental|Cell Phone|Participants will receive a text message reminder via ARemind at scheduled intervals, with varying frequency. They will also be subject to a remote adherence assessment, over text messages, interactive voice response (IVR), or a remote pill count with assistance over the phone from a counselor. Those who demonstrate lower adherence rates may receive a call from a counselor.
9784621|NCT01229735|Experimental|Levetiracetam|250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
9784622|NCT01229735|Active Comparator|Topiramate|25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks
9784623|NCT01229891|Placebo Comparator|Plain yogurt drink|daily intake of two bottle (250 mL) plain yogurt drink
9784624|NCT01229891|Experimental|vitamin D-fortified yogurt drink|daily intake of two bottle yogurt drink fortified with 500 IU vitamin D/250 mL
9784625|NCT01229891|Experimental|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 mL
9784626|NCT01230021|Experimental|recombinant factor XIII|
9784627|NCT01230060|Experimental|enVista|enVista One-Piece Hydrophobic Acrylic Intraocular Lens
9784628|NCT01230125|Experimental|Mapracorat|Ophthalmic suspension 3%
9784629|NCT01230125|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
9784630|NCT01230177||Etanercept (genetical recombination)|Among the patients with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy), the patients who will have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
9784631|NCT01230424|Experimental|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
9772497|NCT00953147|Experimental|Ciclesonide HFA 80 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 40 mcg canister, to be administered as 1 puff in each nostril (80 mcg per day).
9772498|NCT00953147|Experimental|Ciclesonide HFA 160 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 80 mcg canister, to be administered as 1 puff in each nostril (160 mcg per day).
9772499|NCT00953147|Placebo Comparator|Placebo once daily|The placebo HFA nasal aerosol is identical to active drug, but does not contain ciclesonide.
9772500|NCT00953160|Experimental|RF treatment|Abdomen, flank or thigh treated with RF device
9772501|NCT00953173||LapBand|Patients who have already consented to receive the LAP-BAND AP® Adjustable Gastric Banding System
9772502|NCT00953199|Experimental|Lidocaine|Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
9772503|NCT00953199|Active Comparator|Normal Saline|The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
9772504|NCT00953212|Active Comparator|Group A|Beta Blockers, Ascorbic Acid and Amiodarone
9772505|NCT00953212|Active Comparator|Group B|Beta Blockers and Ascorbic Acid
9772506|NCT00953212|Active Comparator|Group C|Beta Blockers and Amiodarone
9772507|NCT00953212|Active Comparator|Group D|Beta Blockers alone
9772508|NCT00953225|Experimental|Vitamin D3|4,000 IU vitamin D3 daily for one year
9772509|NCT00953225|Placebo Comparator|Placebo|Placebo daily for one year
9772510|NCT00953290|Experimental|Treated Thigh|The thigh treated with the RF device
9772511|NCT00953290|No Intervention|Untreated Thigh|The untreated thigh
9772512|NCT00953407|Experimental|Nelfilcon A|Nelfilcon A contact lens
9772513|NCT00953407|Active Comparator|Narafilcon A|Narafilcon A contact lens
9772514|NCT00953407|Active Comparator|Etafilcon A|Etafilcon A contact lens
9772515|NCT00953407|Active Comparator|Omafilcon A|Omafilcon A contact lens
9772516|NCT00953407|Active Comparator|Hilafilcon B|Hilafilcon B contact lens
9772517|NCT00953524|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
9772518|NCT00953524|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
9772519|NCT00953524|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Vaccine formulation 3
9772520|NCT00953524|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
9772521|NCT00953576|Experimental|Phase I Dose Level 1 (DL1): KHAD+L (250 mg)|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
9772522|NCT00953576|Experimental|Phase I Dose Level 2 (DL2): KHAD+L (500 mg)|"For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day"
9772523|NCT00953576|Experimental|All Phase I Participants|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: according to the established dose escalation schedule~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
9772524|NCT00953654|Experimental|Strength Training|Lower-body strength training exercise twice weekly for 6 weeks at an intensity progressing from 50% to 75% predicted one-repetition maximum
9772525|NCT00953654|Experimental|Endurance Training|Six-week lower-body dynamic cycling exercise condition completed twice weekly and matched to the strength training arm on total work completed, total time actively engaged in exercise and load progression.
9772526|NCT00953654|No Intervention|Waiting List Control|Waiting list control condition in which participants will maintain their current lifestyle and will not enter a six-week exercise training intervention, but will complete outcome measures along the same time progression as the intervention arms.
9772527|NCT00953667|Experimental|Niacin and Endotoxin|All subjects are expected to have the same interventions- Niacin and Endotoxin.
9772528|NCT00953706|Placebo Comparator|Placebo|Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
9772529|NCT00953706|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
9772530|NCT00953719|Active Comparator|36 mm|36 mm ceramic head on ceramic acetabular liner
9772531|NCT00953719|Other|28 mm ceramic-on-polyethylene|28 mm ceramic-on-polyethylene historical control
9772532|NCT00953745|Active Comparator|Depressed Participants|"Subjects with treatment-resistant depression (TRD) will be administered the Hamilton Depression Rating Scale (HAM-D 17) for entry and will receive escitalopram combined with an adjunctive placebo capsule for 8 weeks.~Subjects who fail to respond will continue to receive escitalopram and additionally change to receive a placebo tablet resembling the active augmentation agent Aripiprazole (ARP) for 2 weeks.~Subjects who fail to respond to escitalopram after the 2 phase placebo treatment will enter the ARP augmentation phase of the study and will receive escitalopram augmentation with ARP.~Subjects will have 3 neuroimaging scans: F-DOPA PET, raclopride PET, and functional MRI conducted after 10 weeks of treatment and repeated after 6 weeks of ARP treatment."
9772533|NCT00953745|No Intervention|Control Participants|Non-depressed, age- and sex-matched subjects without a DSM-IV Axis I diagnosis will serve as controls. They will not receive antidepressant, ARP, or any drug augmentation and will be used as quality control to compare the pre-ARP and post-ARP treatment brain images.
9772534|NCT00953849|Experimental|Arm 1: Celecoxib|Celecoxib treatment prior to surgery
9772535|NCT00953849|Experimental|Arm 2: Calcitriol|Treatment with Calcitriol prior to surgery
9772536|NCT00953849|Experimental|Arm 3: Celecoxib plus Calcitriol|Treatment with Celecoxib plus Calcitriol prior to surgery.
9772537|NCT00953849|No Intervention|Arm 4: No Treatment|no treatment prior to surgery
9772538|NCT00953862|Experimental|Atomoxetine Treatment Arm|Patients who were identified as having adult ADHD on the ACDS were offered an open label treatment trial with atomoxetine, up to 120 mg/day over 10 weeks. Atomoxetine was titrated over a period of four weeks based upon clinical response and observed side-effects. All patients receiving atomoxetine gave written informed consent prior to participation and were assessed for ADHD symptoms via the Adult Investigator Adult ADHD Symptom Rating Scale (AISRS) every 1-2 weeks. All patients received a physical exam, review of systems and routine blood work prior to treatment. Data were analyzed for patients completing at least 2 weeks of atomoxetine therapy. Treatment response was pre-hoc defined as having a >=30% reduction in total AISRS scores from baseline.
9772539|NCT00953927|Experimental|Investigational Vaccine|MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
9772540|NCT00953927|Placebo Comparator|Control Group|Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.
9772541|NCT00954109|Experimental|Exercise|exercise - supervised exercise (treadmill walking or cycle ergometer use)
9772542|NCT00954122|Experimental|Quetiapine XR|Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.
9772543|NCT00954174|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.
9772544|NCT00954174|Experimental|Arm II (paclitaxel, ifosfamide)|Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.
9772545|NCT00954356|Experimental|XPF-001|
9772546|NCT00954356|Placebo Comparator|Placebo|
9772547|NCT00954421|Experimental|Deep Brain Stimulation|Multiple Sclerosis Tremor treated with VIM and VO Deep Brain Stimulation
9772548|NCT00954447|Experimental|Linagliptin|patient receives a tablet with intended final marketed dose
9772549|NCT00954447|Placebo Comparator|Placebo|patient receives a tablet identical to those containing Linagliptin
9772550|NCT00954512|Experimental|Regimen A: FOLFIRI (± Cetuximab) + Robatumumab|Participants with colorectal adenocarcinoma receive FOLFIRI (Irinotecan 180 mg/m^2+ folinic acid 400 mg/m^2+ 5-fluorouracil [5-FU] 400 mg/m^2 bolus followed by 2400 mg/m^2 intravenous [IV] infusion over 46 hours) (± cetuximab initial dose of 400 mg/m^2 IV followed by once-weekly doses of 250 mg/m^2 IV) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 2-week cycle.
9772551|NCT00954512|Experimental|Regimen B: Carboplatin + Paclitaxel + Robatumumab|Participants with non-small cell lung cancer receive carboplatin administered at an area under the curve (AUC) of 6 mg/mL/min IV PLUS paclitaxel 225 mg/m^2 IV PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
9772552|NCT00954512|Experimental|Regimen C: Epirubicin + Cisplatin + 5-FU + Robatumumab|Participants with gastric adenocarcinoma receive epirubicin 50 mg/m^2 IV PLUS cisplatin 60 mg/m^2 IV PLUS 5-FU 200 mg/m^2/day administered via a 21-week continuous IV infusion PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
9772553|NCT00954512|Experimental|Regimen D: Trastuzumab + Robatumumab|Participants with human epidermal growth factor receptor 2 positive (Her2+) breast cancer receive trastuzumab 4 mg/kg IV once every week PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
9772554|NCT00954512|Experimental|Regimen E: mTor Inhibitor (Everolimus) + Robatumumab|Participants with renal cell cancer receive mammalian target of rapamycin (mTor) inhibitor (everolimus) 10 mg orally once per day PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
9772555|NCT00954512|Experimental|Regimen F: Gemcitabine (± Erlotinib) + Robatumumab|Participants with pancreatic adenocarcinoma receive gemcitabine 1000 mg/m^2 IV on Days 1, 8, 15, 22, 29, 36, and 43 in Cycle 1 and on Days 1, 8 and 15 in subsequent cycles (± erlotinib 100 mg per day orally) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle. (Cycle 1 is 8 weeks.)
9772556|NCT00954538|Experimental|Part I, Healthy Participants|Healthy participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
9772557|NCT00954538|Experimental|Part II, HE and AD Participants|HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
9772558|NCT00954538|Experimental|Part III, HE and AD Participants|HE and AD participants will receive two separate IV doses of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
9772559|NCT00954681|Experimental|quetiapine treatment|Open label treatment with quetiapine
9772560|NCT00954707|Placebo Comparator|12m DAPT Group|
9772561|NCT00954707|Active Comparator|30m DAPT Group|
9772562|NCT00954733|Experimental|All participants|All participants, one arterial blood draw
9772563|NCT00954824|Experimental|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
9772564|NCT00954941|Experimental|Group 1: Ondansetron|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
9772565|NCT00954941|Active Comparator|Group 2: Ondansetron + Aprepitant|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
9772566|NCT00954993|Experimental|Vaniprevir 600 mg - 300 mg|For each participant in period 1, 600 mg of Vaniprevir was taken twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg was taken on Day 4. Period 1 was followed by a minimum 30-day, up to approximately 140 day, washout interval. In period 2, 300 mg of Vaniprevir was taken twice daily by each participant on Days 1-3 and a single dose of Vaniprevir 300 mg was taken on Day 4.
9772567|NCT00955032|Experimental|High-Frequency Repetitive Transcranial Magentic Stimulation|High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
9772568|NCT00955032|Sham Comparator|Sham Repetitive Transcranial Magentic Stimulation|Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
9772569|NCT00955110|Experimental|Oxymorphone ER 15 mg|15mg
9772570|NCT00955110|Active Comparator|Oxycodone CR 30 mg|30mg
9772571|NCT00955110|Placebo Comparator|Placebo|
9772572|NCT00955110|Experimental|Oxymorphone ER 30mg|30mg
9772573|NCT00955110|Active Comparator|Oxycodone CR 60mg|60mg
9772574|NCT00955201|No Intervention|Arm 1|Sedentary Control Group
9772575|NCT00955201|Experimental|Arm 2|Aerobic Exercise Group
9772576|NCT00955201|Experimental|Arm 3|Isokinetic Strength Exercise Group
9772577|NCT00955201|Experimental|Arm 4|Combined Aerobic and Isokinetic Strength Exercise Group
9772578|NCT00955253|Experimental|Guanfacine (Day 2) then Placebo (Day 4)|All patients received a single dose of guanfacine on Day 2 and a single dose of placebo on Day 4.
9772579|NCT00955253|Experimental|Placebo (Day 2) then Guanfacine (Day 4)|All patients received a single dose of placebo on Day 2 and a single dose of guanfacine on Day 4.
9772580|NCT00955266|Active Comparator|Calcium Chloride|Calcium chloride, 10mg/kg
9772581|NCT00955266|Placebo Comparator|Placebo|Normal saline
9772582|NCT00955279|Placebo Comparator|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
9772583|NCT00955279|Experimental|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
9772584|NCT00955279|Experimental|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
9772585|NCT00955305|Active Comparator|Arm A (CPB)|Patients receive carboplatin intravenously (IV) over 30 minutes, paclitaxel IV over 3 hours, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab may continue in the absence of disease progression or unacceptable toxicity.
9772586|NCT00955305|Experimental|Arm B (CPB+cixutumumab)|Patients receive carboplatin, paclitaxel, and bevacizumab as in Arm A. Patients also receive cixutumumab (IMC-A12) IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab and cixutumumab may continue in the absence of disease progression or unacceptable toxicity.
9772587|NCT00955357|Experimental|First Add-on|Lacosamide added to first adequate monotherapy (no history of Antiepileptic Drug [AED] polytherapy) and epilepsy diagnosis < or = 24 months at Screening.
9772588|NCT00955357|Experimental|Later Add-on|Lacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis > or = 5 years at Screening.
9772589|NCT00955409|Experimental|ACC-001(3µg) + QS21|ACC-001(3µg) + QS21
9772590|NCT00955409|Experimental|ACC-001(10µg) + QS21|ACC-001(10µg) + QS21
9772591|NCT00955409|Experimental|ACC-001(30µg) + QS21|ACC-001(30µg) + QS21
9772592|NCT00955474|Experimental|Quetiapine|Patients assigned to receive Quetiapine
9772593|NCT00955474|Active Comparator|Quetiapine and SSRI|Patients assigned to receive Quetiapine and SSRI
9772594|NCT00955487|Experimental|Inhaled Nitric Oxide (iNO)|Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
9772595|NCT00955487|Placebo Comparator|Nitrogen (placebo)|Participants will receive nitrogen (placebo) while in the hospital.
9772596|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel twice a day|drug
9772597|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel three times a day|drug
9772598|NCT00955513|Placebo Comparator|placebo|placebo
9772599|NCT00955617|Experimental|Dotarem / Gadovist|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Dotarem in period 1 then with Gadovist in period 2
9772600|NCT00955617|Experimental|Gadovist / Dotarem|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Gadovist in period 1 then with Dotarem in period 2
9772601|NCT00955682|Experimental|Group A|Subjects who received GSK vaccine 134612 in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
9772602|NCT00955682|Active Comparator|Group B|Subjects who received Meningitec™ vaccine in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
9772603|NCT00955708||Implants|Patients successfully implanted with the ACUITY Spiral Lead
9772604|NCT00955721|Experimental|Phase 1: GEMOX + Sorafenib|"Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib.~Gemcitabine: 1000 or 750 mg/m2, IV, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: 100 or 75 mg/m2, IV, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: 200 mg, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
9772605|NCT00955721|Experimental|Phase 2 - RPTD GEMOX + Sorafenib|"Recommended Phase Two Dose (RPTD) of Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib:~Gemcitabine: Recommended Phase II Dose determined from Phase I, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: Recommended Phase II Dose determined from Phase I, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: Recommended Phase II Dose determined from Phase I, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
9772606|NCT00955747|Placebo Comparator|Sugar Substitute Splenda|1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
9772607|NCT00955747|Experimental|Tagatose|15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment
9772608|NCT00955825|Experimental|300 IR|300 IR grass pollen allergen extract tablet
9772609|NCT00955825|Placebo Comparator|Placebo|Pacebo tablet
9772610|NCT00955877|Experimental|DepoDur80|DepoDur will be administered at 80μg/kg (not to exceed 5 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
9772611|NCT00955877|Experimental|DepoDur120|DepoDur will be administered at 120μg/kg (not to exceed 10 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
9772612|NCT00955877|Placebo Comparator|Control|Preservative-free normal saline (2.5ml) will be placed in the L1 laminectomy defect and also dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter prior to wound closure.
9772613|NCT00955903|Experimental|Weight Loss|Participants receive Exercise and Reduced Calorie Diet Interventions
9772614|NCT00955903|Active Comparator|Control|Participants receive Exercise Intervention
9772615|NCT00955903|Active Comparator|Weight Maintenance|Participants receive Exercise and a Weight Maintenance Diet Interventions
9772616|NCT00955916|Experimental|CLAG Regimen with Gleevec®|Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
9772617|NCT00955955|Experimental|6(S)-5-MTHF(Deplin)|"Participants will receive 15 mg/day of Deplin, a medical food, for 8 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
9772618|NCT00955955|Experimental|Placebo/Deplin|"Participants will receive placebo for the first 4 weeks, and then 15 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
9784632|NCT01230424|Placebo Comparator|Sodium Chloride|0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
9784633|NCT01230502|Active Comparator|Group 3: Donor Specific Regulation (DSR) -, standard of care|Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
9784634|NCT01230502|Active Comparator|Group 2 Donor Specific Regulation (DSR) +; standard of care|Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
9772619|NCT00955955|Experimental|Placebo/Placebo|"Participants will receive placebo for both phases of the study.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
9772620|NCT00955968|Experimental|Continue HAART|Continue receiving HAART within 0-42 days after delivery or other pregnancy outcome.
9772621|NCT00955968|Active Comparator|Stop HAART|Stop receiving HAART within 0-42 days after delivery or other pregnancy outcome and resume HAART when protocol specified criteria were met.
9772622|NCT00956020|Experimental|Treatment|Skin injection with platelet rich fibrin matrix on the inner aspect of the upper arm, with biopsies over a period from 30 minutes to 12 weeks after treatment.
9772623|NCT00956085|Experimental|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
9772624|NCT00956254|Experimental|Fentanyl sublingual spray 100 µg|Participants received a single administration of fentanyl sublingual spray 100 µg sublingually.
9772625|NCT00956293|Active Comparator|Control group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.
9772626|NCT00956293|Experimental|Everolimus group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.
9772627|NCT00956540|Experimental|Deflating|Deflating tracheal cuff (total air suction under negative pressure using a syringe) during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support. During ventilatory support the tracheal cuff remain pressurized (30 mmHg).
9772628|NCT00956540|No Intervention|Not deflating|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support
9772629|NCT00956540|Experimental|Deflating 2|Deflating tracheal cuff during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
9772630|NCT00956540|No Intervention|Not deflating 2|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
9772631|NCT00956592|Active Comparator|CMAC Video laryngoscope|Subjects will have their intubation attempted first with the CMAC video laryngoscope
9772632|NCT00956592|Active Comparator|Macintosh blade|Patients will have their first intubation attempted utilizing the conventional Macintosh design laryngoscope blade
9772633|NCT00956631|Other|interlaminar decompression|Commercially available product (mild® Device Kit) used to perform interlaminar decompression
9772634|NCT00956709|Active Comparator|Levobupivacaïne 0,5 %|
9772635|NCT00956709|Active Comparator|Ropivacaïne 0,5%|
9772636|NCT00956761|Experimental|1|
9772637|NCT00956813|Experimental|Arm I|Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
9772638|NCT00956813|Placebo Comparator|Arm II|Patients receive oral placebo bar once daily.
9772639|NCT00956839|Active Comparator|Group A|IM Vitamin D3 3,00,000 Units single dose
9772640|NCT00956839|Active Comparator|Group B|IM vitamin D3 6,00,000 Units single dose
9772641|NCT00956839|Active Comparator|Group C|Oral vitamin D3 500 Units/ day
9772642|NCT00956930|Experimental|Arm I (radioembolization)|Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
9772643|NCT00956930|Experimental|Arm II (transarterial chemoembolization [TACE])|Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
9772644|NCT00956943|Active Comparator|21mg transdermal nicotine + placebo patch|21mg transdermal nicotine + placebo patch
9772645|NCT00956943|Experimental|42mg transdermal nicotine|42mg transdermal nicotine
9772646|NCT00957008|Experimental|A - GWL|Group Weight Loss Program (GWL) - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator.
9772647|NCT00957008|Experimental|B - GWL+SWA|Group weight loss program plus use of the Senseware Armband - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator and wore a SenseWear Armband. The SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
9772648|NCT00957008|Experimental|C - SWA Alone|Use of the senseware armband alone program - The intervention for the SWA Alone group was the SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
9772649|NCT00957008|No Intervention|D - Standard Care|Standard Care - Participants in this group received a self-directed weight loss manual that focused on cognitive and behavior change principles and learning activities based on Active Living Every Day and Healthy Eating Every Day
9772650|NCT00957021|Other|Triathlon® PS Total Knee System|Triathlon® PS Total Knee System
9772651|NCT00957047|Experimental|ESL 400 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I
9772652|NCT00957047|Experimental|ESL 800 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I
9772653|NCT00957047|Experimental|ESL 1200 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I
9772654|NCT00957047|Placebo Comparator|placebo|Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied
9772655|NCT00957047|Experimental|ESL - Part II|All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.
9772656|NCT00957229|Placebo Comparator|Sugar pill|placebo pill by mouth once daily
9772657|NCT00957229|Experimental|GDC-0449|vismodegib 150MG by mouth once daily
9772658|NCT00957242|Active Comparator|warfarin|Oral warfarin titrated to an international normalization ratio (INR) of 2-3
9772659|NCT00957242|Placebo Comparator|placebo|Oral placebo (1mg or 2.5mg)
9772660|NCT00957268|Experimental|Alogliptin 12.5 mg (age 10 to < 14 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
9772661|NCT00957268|Experimental|Alogliptin 25 mg (age 10 to < 14 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
9772662|NCT00957268|Experimental|Alogliptin 12.5 mg (age 14 to < 18 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
9772663|NCT00957268|Experimental|Alogliptin 25 mg (age 14 to < 18 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
9772664|NCT00957268|Experimental|Alogliptin 25 mg (age 18 to 65 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
9772665|NCT00957333||case|ketamine + Cystitis
9772666|NCT00957359|Experimental|Psilocybin|Drug intervention
9772667|NCT00957359|Active Comparator|Niacin|Active control
9772668|NCT00957372|Experimental|ESL 800 mg daily (Part I)|ESL 800mg daily
9772669|NCT00957372|Experimental|ESL 1200 mg daily (Part I)|ESL 1200mg daily
9772670|NCT00957372|Placebo Comparator|placebo (Part I)|placebo
9772671|NCT00957372|Experimental|ESL - Open-label Extension (Part II)|All patients were treated with only ESL during Part II.
9772672|NCT00957424|Other|Overall|Single-armed study
9772673|NCT00957528|Placebo Comparator|Placebo|Weekly placebo treatment for a duration of 5 months.
9772674|NCT00957528|Experimental|Monthly Cycled Testosterone|A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
9772675|NCT00957528|Experimental|Continuous Testosterone|Weekly testosterone treatment for a duration of 5 months
9772676|NCT00957580|Experimental|Regimen 1 (Part 1)|
9772677|NCT00957580|Experimental|Regimen 2 (Part 1)|
9772678|NCT00957580|Experimental|Regimen 3 (Part 1)|
9772679|NCT00957580|Experimental|Regimen 1 (Part 2)|
9772680|NCT00957580|Experimental|Regimen 2 (Part 2)|
9772681|NCT00957593|Active Comparator|Oxytocin|Continuation of oxytocin per protocol once the patient reaches active labor
9772682|NCT00957593|Active Comparator|Oxytocin discontinuation|Oxytocin will be stopped once the patient reaches active labor
9772683|NCT00957658|Other|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem Study Device
9772684|NCT00957671|Experimental|Human Growth Hormone|recombinant human growth hormone (rhGH) self administered daily for one year
9772685|NCT00957684|Experimental|ESL 400 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
9772686|NCT00957684|Experimental|ESL 800 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
9772687|NCT00957684|Experimental|ESL 1200 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
9772688|NCT00957684|Placebo Comparator|placebo|Placebo matching tablets
9772689|NCT00957684|Experimental|ESL - PART II|During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.
9772690|NCT00957723|Other|Triathlon® CR Total Knee System|Participants receive the Triathlon® CR Total Knee System
9772691|NCT00957801|Active Comparator|Testosterone injection|Testosterone enanthate given as a single 100 mg Intramuscular (IM) injection
9772692|NCT00957801|Active Comparator|Testosterone gel|Testosterone topical gel (Androgel 1%) 10 mg administered daily for seven days
9772693|NCT00957801|Active Comparator|Testosterone injection and Medrol 6 day dose pack|Testosterone enanthate given as a single 100mg Intramuscular (IM) injection. Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
9772694|NCT00957801|Active Comparator|Medrol 6 day dose pack|Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
9772695|NCT00957853|Experimental|Group 1: Cetuximab|Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes
9772696|NCT00957853|Experimental|Group 2: IMC-A12|IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.
9772697|NCT00957853|Experimental|Group 3: Cetuximab + IMC-A12|"Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes.~IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3."
9772698|NCT00957905|Experimental|Part A (alvocidib and oxaliplatin)|Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9772699|NCT00957905|Experimental|Part B (alvocidib and FOLFOX)|Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9772700|NCT00957931|Experimental|Mesenchymal stromal cells|
9772701|NCT00957944|Experimental|Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)|Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days
9772702|NCT00957944|Experimental|Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)|Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days
9772703|NCT00957996|Experimental|Peramivir 300 mg|Peramivir 300 mg twice daily
9772704|NCT00957996|Experimental|Peramivir 600 mg|Peramivir 600 mg once daily
9772705|NCT00958035|Experimental|LATISSE®|bimatoprost ophthalmic 0.03% solution
9772706|NCT00958035|Placebo Comparator|Placebo|vehicle sterile solution
9772707|NCT00958074|Experimental|Cohort I (>=65 years old)|200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
9772708|NCT00958074|Experimental|Cohort II (<65 years old)|400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
9772709|NCT00958126|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
9772710|NCT00958126|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
9772711|NCT00958126|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
9772712|NCT00958126|Placebo Comparator|Placebo|Vaccine diluent. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
9772713|NCT00958165|Experimental|EAS-AC|PVI with EAS-AC
9772714|NCT00958191|Other|Trident® X3 Polyethylene Insert|Participants who received the Trident® X3 Polyethylene Insert.
9772715|NCT00958217|Experimental|Cognitive Processing Therapy-Modified|12 individually delivered sessions of Cognitive Processing Therapy-Modified (CPT-M) provided once weekly following initial group delivery of 12 sessions of Integrated Cognitive Behavioral Therapy
9772716|NCT00958217|Active Comparator|Integrated Cognitive Behavioral Therapy|12 individually delivered sessions of Integrated Cognitive Behavioral Therapy (ICBT) once weekly following initial group delivery of 12 sessions of ICBT
9772717|NCT00958217|No Intervention|Integrated Cognitive Behavioral Group Therapy|All participants were enrolled in an initial group-delivered Integrated Cognitive Therapy Group, consisting of 12 sessions over approximately 12 weeks prior to randomization to one of the study individually delivered interventions (CPT-M or ICBT). Individuals who were no longer participating in the study at the end of group sessions were not randomized.
9772718|NCT00958243|Placebo Comparator|Placebo|Placebo
9772719|NCT00958243|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose
9772720|NCT00958243|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose
9784635|NCT01230502|Experimental|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy|"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy:~Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive"
9772721|NCT00958256|Experimental|Bortezomib with Cyclophosphamide and Rituximab|Bortezomib 1.3 mg/m^2 intravenously (IV) on Days 1, 4, 8, and 11 of the cycle; Cyclophosphamide 300 mg/m^2 IV every 12 hours on Days 2, 3, and 4, and Rituximab 375 mg/m^2 IV on Day 1. Mesna 600 mg/m^2 for 3 days, G-CSF 5 micrograms/kg subcutaneously daily for 7 days after last dose of Bortezomib. Cycles repeated every 21 days for up to six cycles.
9772722|NCT00958282|Active Comparator|lisdexamfetamine/Behavior Therapy|lisdexamfetamine 70mg/day plus Behavior Therapy
9772723|NCT00958282|Placebo Comparator|placebo|Placebo Comparator once per day
9772724|NCT00958308|Placebo Comparator|Placebo|Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
9772725|NCT00958308|Active Comparator|BIO-K+ CL-1285|Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
9772726|NCT00958308|Other|BIO-K+ CL-1285® & placebo|One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
9772727|NCT00958334|Experimental|Proellex 25 mg|Two Proellex® 12.5 mg capsules once daily
9772728|NCT00958334|Experimental|Proellex 12.5 mg|One Proellex® 12.5 mg capsules once daily
9772729|NCT00958334|Placebo Comparator|Placebo|Capsule once a day
9772730|NCT00958360|Experimental|Arm 1|Interdisciplinary Low Vision Rehabilitation: Low vision examination, prescription and dispensing of low vision devices, low vision therapy and homework.
9772731|NCT00958360|Active Comparator|Arm 2|Basic Low Vision Care: Low vision examination, prescription and dispensing of low vision devices without low vision therapy or assigned homework.
9772732|NCT00958412|Experimental|Proellex®|25 mg Proellex®
9772733|NCT00958438|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept ) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
9772734|NCT00958438|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
9772735|NCT00958438|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
9772736|NCT00958477|Experimental|EMD 525797|
9772737|NCT00958568|Experimental|Olanzapine and Fluoxetine combination (OFC)|
9772738|NCT00958568|Active Comparator|Fluoxetine|
9772739|NCT00958581|Placebo Comparator|Normal Saline|Patients infused with normal saline before and during the surgical procedure as a placebo.
9772740|NCT00958581|Experimental|Tranexamic acid|Patients receive TXA before and during the surgical case.
9772741|NCT00958581|Experimental|Epsilon Aminocaproic Acid|Patients will receive EACA before and during the surgical case.
9772742|NCT00958711|Experimental|Biologic - Unite Biomatrix|
9772743|NCT00958711|Active Comparator|Saline and Gauze|
9772744|NCT00958724|Experimental|Neratinib and Vinorelbine|Neratinib: 240 mg administered daily by mouth continuously, Vinorelbine: 25 mg/m^2 administered IV on Day 1 and 8 of 21 day cycle
9772745|NCT00958776|Experimental|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
9772746|NCT00958776|Placebo Comparator|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
9772747|NCT00958789|Other|Triathlon TS Knee|Triathlon TS Knee System
9772748|NCT00958828|Other|Nelfilcon A / Narafilcon A|Nelfilcon A contact lenses, then Narafilcon A contact lenses
9772749|NCT00958828|Other|Narafilcon A / Nelfilcon A|Narafilcon A contact lenses, then Nelfilcon A contact lenses
9772750|NCT00958841|Experimental|pasireotide LAR 60mg|Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
9772751|NCT00958880|Placebo Comparator|Sugar Pill|Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy
9772752|NCT00958880|Experimental|Yohimbine Hydrochloride|Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy
9772753|NCT00958919|Experimental|naloxone|
9772754|NCT00958919|Placebo Comparator|normal saline|
9772755|NCT00959049|Experimental|Afluria Cohort A|Age 6 months to < 3 years
9772756|NCT00959049|Experimental|Afluria Cohort B|Age 3 to < 9 years
9772757|NCT00959049|Experimental|Afluria Cohort C|Age 9 to < 18 years
9772758|NCT00959049|Active Comparator|Fluzone Cohort A|Age 6 months to < 3 years
9772759|NCT00959049|Active Comparator|Fluzone Cohort B|Age 3 to < 9 years
9772760|NCT00959049|Active Comparator|Fluzone Cohort C|Age 9 to < 18 years
9772761|NCT00959166|Other|HIV/acute HCV coinfection|Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.
9772762|NCT00959166|Other|HIV mono|HIV-infected individuals without hepatitis C co-infection
9772763|NCT00959192|Experimental|ACC-001 + QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
9772764|NCT00959192|Placebo Comparator|QS-21|Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
9784636|NCT01230554|Experimental|Prism I|Bausch & Lomb daily disposable cosmetic tint contact lens
9784637|NCT01230593|Active Comparator|Hot Compress|"Hot Compress"
9784638|NCT01230593|Active Comparator|Tobrex|"Hot Compress, Tobrex Drops, Tobrex Ointment"
9772765|NCT00959374|Active Comparator|V-loc and Monocryl|Subjects served as their own control, and they were randomized to receive an intervention of a standard closure using 3-0 Monocryl™ on one side of the body and the test closure device, V-Loc 180/90, on the other side. The standard closure technique was agreed on by study investigators for control side, and included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl™ sutures, spaced no further than 2 cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl™ sutures. The test closure side, closure of the deep dermal layer was optional. If deep dermal sutures were used, interrupted 3-0 Monocryl™ sutures were required to be placed no closer than 5 cm apart followed by closure of the intradermal layer with test device, V-Loc 180/90.
9772766|NCT00959647|Experimental|Vismodegib 150 mg|Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.
9772767|NCT00959660|Active Comparator|Exercise Training|Exercise participants will undergo a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
9772768|NCT00959660|Active Comparator|Dietary Intervention|A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb) weight loss per week.
9772769|NCT00959660|Active Comparator|Attention control|Attention control participants will be provided a counseling session regarding general health education at baseline and will be contacted by staff via telephone every 2 weeks to discuss general health status.
9772770|NCT00959660|Active Comparator|Diet and Exercise|A hypocaloric diet will be developed to achieve a 2450 kcal/week deficit in addition to undergoing a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
9772771|NCT00959699|Placebo Comparator|PegIFN-2b + RBV|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA <9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
9772772|NCT00959699|Active Comparator|PegIFN-2b + RBV + Boceprevir|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.
9772773|NCT00959751|Experimental|NXN-188 600 mg|3 x 200 mg capsules, PRN
9772774|NCT00959751|Placebo Comparator|Placebo|3 x 0 mg capsules, PRN
9772775|NCT00959764|Experimental|Oral calcitonin and placebo nasal spray|Intervention: Oral calcitonin tablet (along with placebo intranasal spray)
9772776|NCT00959764|Active Comparator|Intranasal calcitonin & oral placebo|Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).
9772777|NCT00959764|Placebo Comparator|Placebo: tablet & intranasal spray|Intervention: Both oral matching placebo tablets and matching intranasal placebo spray
9772778|NCT00959842|Experimental|Lovaza|Lovaza was given as the only agent; there was no comparator agent or arm
9772779|NCT00959894|Experimental|Etravirine 400 mg once daily|Etravirine 400 mg once daily with fixed dose tenofovir/emtricitabine (Truvada) one tablet once daily
9772780|NCT00959907|Active Comparator|BoNT A1 (4U)|BoNT A1 (4U): Botulinum toxin A (Dysport®)4 units
9772781|NCT00959907|Active Comparator|BoNT-A2 (2U)|BoNT-A2(2U): Botulinum toxin A (Botox®) 2 units
9772782|NCT00959920|Active Comparator|Indwelling foley catheter|Insertion of an indwelling foley catheter when bladder emptying is necessary. The indwelling catheter will remain in place until the time of delivery.
9772783|NCT00959920|Active Comparator|Intermittent straight catheterization|Intermittent straight catheterization will be performed as needed during labor.
9772784|NCT00959946|Experimental|1|In part 1 (phase 1), ascending and descending multiple oral doses of bosutinib + capecitabine. Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14 + bosutinib 200 mg QD; capecitabine 625 mg/m2 BID on days 1-14 + bosutinib 300 mg QD. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID and bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
9772785|NCT00959985|No Intervention|Group 1A|Mild Lymphedema: Only required to meet with the lymphedema physical therapist
9772786|NCT00959985|Active Comparator|Group 1B|Mild Lymphedema: Fitted for compression sleeve
9772787|NCT00959985|Active Comparator|Group 2A|Moderate lymphedema: Fitted with a compression sleeve
9772788|NCT00959985|Active Comparator|Group 2B|Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage
9772789|NCT00960011|Experimental|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
9772790|NCT00960011|Active Comparator|POLYPROPYLENE|Use of Polypropylene mesh for open inguinal hernia repair
9772791|NCT00960063|Experimental|Temozolomide+Irinotecan+Robatumumab|Participants receive temozolomide 100 mg/m^2/day intravenously (IV) on Days 1-5 PLUS irinotecan 10 mg/m^2/day IV on Days 1-5 and Days 8-12 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
9772792|NCT00960063|Experimental|Vincristine+Doxorubicin+Cyclophosphamide+Robatumumab|Participants receive vincristine 2 mg/m^2 (maximum 2 mg) IV on Day 1 PLUS cyclophosphamide 1200 mg/m^2 IV on Day 1 PLUS doxorubicin hydrochloride 75 mg/m^2 IV continuously over 48 hours PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
9772793|NCT00960063|Experimental|Ifosfamide+Etoposide+Robatumumab|Participants receive ifosfamide 1800 mg/m^2 per day IV PLUS etoposide 100 mg/m^2 per day IV on Days 1-5 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
9772794|NCT00960076|Experimental|1|Saxagliptin
9772795|NCT00960076|Active Comparator|2|Metformin Extended Release
9772796|NCT00960115|Experimental|Tecemotide (L-BLP25) + Cyclophosphamide|Active
9772797|NCT00960115|Placebo Comparator|Placebo + Saline|Control
9772798|NCT00960193|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
9772799|NCT00960193|Experimental|Colchicine with Seville Orange Juice|colchicine pharmacokinetics in presence of Seville orange juice
10203857|NCT04878211|Experimental|Ofatumumab - vaccine 2 weeks prior|RMS participants will receive non-live COVID-19 mRNA vaccine at least two weeks prior to start of ofatumumab (20 mg subcutaneous)
10203858|NCT04878211|Experimental|Ofatumumab -vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least four weeks after start of ofatumumab (20 mg subcutaneous)
9772800|NCT00960206|Experimental|Trident®System|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
9772801|NCT00960206|Experimental|ABC System|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
9772802|NCT00960206|Active Comparator|Control|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
9772803|NCT00960323|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
9772804|NCT00960323|Experimental|Colchicine with Atorvastatin|Colchicine pharmacokinetics in the presence of atorvastatin at steady state.
9784639|NCT01230593|Active Comparator|Tobradex|"Hot Compress, Tobradex Drops, Tobradex Ointment"
10203859|NCT04878211|Active Comparator|Interferon or glatiramer acetate - vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least 4 weeks after start of prescribed interferon or glatiramer acetate
10203860|NCT04874922|Experimental|Case group|The case group will first receive standard diabetes training from the hospital. After 28-30. Diabetes training based on Planned Behavior Theory will be given three times between gestational weeks. Each training will take an average of 45 minutes. After that, the data evaluation phase will be started.
10203861|NCT04874922|Other|Control Group|The control group will only receive standart diabetes training from the hospital. Then, only follow-up will be done and the data will be evaluated.
10203862|NCT04873856|Experimental|Intervention group|"Intervention contains:~individual nutritional plan~regular contact~friendly reminder/informal caregiver and~weight dairy."
10203863|NCT04873856|No Intervention|Control Group|Standard of care
10203864|NCT04872686|Experimental|Oral and nasal spray to moderately ill COVID-19 positive patient|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: Single
10203865|NCT04872686|Experimental|Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: hourly for 4 hours in a single day
10203866|NCT04872686|Experimental|Oral and nasal spray to healthy volunteer|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: 3-4 times interval but not more than 4 times a day for 30 days
9772805|NCT00960375|Experimental|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
9772806|NCT00960375|Active Comparator|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide test at the start of each group meeting. StSST groups provide education about smoking and support for quitting.
9772807|NCT00960440|Experimental|Sequence 1|
9772808|NCT00960440|Experimental|Sequence 2|
9772809|NCT00960440|Placebo Comparator|Sequence 3|
9772810|NCT00960440|Placebo Comparator|Sequence 4|
9772811|NCT00960505|Experimental|Alternate day fasting (ADF)|Fast day diet: 25% energy intake, Feast day diet: Ad libitum energy intake (alternating days)
9772812|NCT00960505|Experimental|Calorie restriction (CR)|75% energy intake every day
9772813|NCT00960505|Active Comparator|Control|Usual diet
9772814|NCT00960531|Experimental|ACC-001 (3mcg) + QS-21|ACC-001 (3mcg) + QS-21
9772815|NCT00960531|Experimental|ACC-001 (10mcg) + QS-21|ACC-001 (10mcg) + QS-21
9772816|NCT00960531|Experimental|ACC-001 (30mcg) + QS-21|ACC-001 (30mcg) + QS-21
9772817|NCT00960570|Active Comparator|Efavirenz Alone|Baseline Efavirenz pharmacokinetics.
9772818|NCT00960570|Experimental|Efavirenz with Steady State Fenofibric Acid|Efavirenz pharmacokinetics in the presence of steady state Fenofibric Acid.
9772819|NCT00960622|Experimental|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
9772820|NCT00960622|Active Comparator|Combivir or Trizivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
9772821|NCT00960661|Experimental|Exenatide (BET)|Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)
9772822|NCT00960661|Active Comparator|Insulin Lispro (BBT)|Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)
9772823|NCT00960687|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered 30 minutes after the initiation of a standard breakfast.
9772824|NCT00960687|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered 30 minutes after the initiation of a standard breakfast.
9772825|NCT00960778|Experimental|Women- denicotinized cigarette|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
9772826|NCT00960778|Experimental|Men- denicotinized cigarette|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
9772827|NCT00960778|Experimental|Women -nicotine patch|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
9772828|NCT00960778|Experimental|Men- nicotine patch|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
9772829|NCT00960804|Experimental|Tanezumab 5 mg|
9772830|NCT00960804|Experimental|Tanezumab 10 mg|
9772831|NCT00960804|Placebo Comparator|Placebo|
9772832|NCT00960843|Active Comparator|Conventional Adjustment Group|Subject whose band adjustments will be made via conventional standard of care (e.g., volume, hunger).
9772833|NCT00960843|Active Comparator|Intraband Pressure Arm|Subjects whose band adjustments will be guided by intraband pressure readings.
9772834|NCT00960856|Experimental|Fenofibric Acid 105 mg - Low-Fat Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
9772835|NCT00960856|Experimental|Fenofibric Acid 105 mg - Standard Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a standard breakfast.
9784640|NCT01230710|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once a day for 48 weeks.
9772836|NCT00960856|Experimental|Fenofibric Acid 105 mg - High-Fat/High-Calorie Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
9772837|NCT00960856|Experimental|Fenofibric Acid 105 mg - Fasted State|Fenofibric Acid 105 mg tablet administered after an overnight fast of at least 10 hours
9772838|NCT00960869|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)
9772839|NCT00960869|Active Comparator|EC-Aspirin 325 mg|EC-Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)
9772840|NCT00960934|Experimental|MK-5442 2.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.
9772841|NCT00960934|Experimental|MK-5442 5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.
9772842|NCT00960934|Experimental|MK-5442 7.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.
9772843|NCT00960934|Experimental|MK-5442 10 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.
9772844|NCT00960934|Experimental|MK-5442 15 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.
9772845|NCT00960934|Placebo Comparator|Placebo|Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.
9772846|NCT00960986|Experimental|Duloxetine 60 mg with food|Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks
9772847|NCT00960986|Experimental|Duloxetine 60 mg without food|Duloxetine 60 mg capsule po QD without food for 8 weeks
9772848|NCT00960986|Experimental|Duloxetine 30 mg with food|Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks
9772849|NCT00960986|Experimental|Duloxetine 30 mg without food|Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks
9772850|NCT00960999|Experimental|Single-fraction SBRT (34 Gy)|Single-fraction stereotactic body radiation therapy (SBRT) of 34 Gy
9772851|NCT00960999|Experimental|Multiple-fraction SBRT (48 Gy)|Multiple-fraction stereotactic body radiation therapy (SBRT) given in four daily 12 Gy fractions for a total dose of 48 Gy
9772852|NCT00961051|Experimental|Investigational MPS|Investigational multipurpose disinfecting solution (study MPS)
9772853|NCT00961051|Active Comparator|Predicate MPS|Opti-Free RepleniSH multipurpose disinfecting solution (predicate MPS)
9772854|NCT00961116|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered after an overnight fast of at least 10 hours
9772855|NCT00961116|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
9772856|NCT00961181|Experimental|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
9772857|NCT00961220|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour and apply topical carmustine to the total skin surface (excluding the lips, eyelids, and ulcerated lesions) 1 hour after completing O6-benzylguanine infusion on days 1-2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9772858|NCT00961233|Experimental|inhaled/swallowed budesonide|
9772859|NCT00961233|Active Comparator|viscous/swallowed budesonide|
9772860|NCT00961259|Experimental|Fenofibric Acid 35 mg (1 x 35 mg tab)|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
9772861|NCT00961259|Experimental|Fenofibric Acid 105 mg (3 x 35 mg tab)|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
9772862|NCT00961259|Experimental|Fenofibric Acid 105 mg (1 x 105 mg tab)|1 x 105 mg tablet administered after an overnight fast of at least 10 hours
9772863|NCT00961298|Experimental|Duloxetine|Two weeks of placebo run in followed by 12 weeks of Duloxetine.
9772864|NCT00961311|Experimental|Trial Arm|All patients with systematic ischemic heart disease with stenotic lesions that are amenable to percutaneous treatment.
9772865|NCT00961350|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
10203867|NCT04872686|Placebo Comparator|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled water Dosage form: Oral and Nasal spray will be provided by Distilled water
10203868|NCT04867603|Experimental|Digital PET/CT using [Ga-68]PSMA|Following prostate Standard of Care MRI, eligible participants will receive a single injection of [Ga-68]PSMA followed by digital PET/CT imaging approximately 60 minutes later. PET/CT takes approximately 30-35 minutes, where the participant would lay still on a scanner table.
10203869|NCT04865731|Experimental|Dermaprazole|30 HNC patients who will be using Dermaprazole twice daily for 7 weeks
10203870|NCT04865731|Active Comparator|Aquaphor|15 HNC patients using Aquaphor, the current clinical standard of care
10203871|NCT04860843|Experimental|Local anesthetic TPVB + Local anesthetic PecsII block|Patients will receive a thoracic paravertebral with pecs II block, both with local anesthetic infiltrate.
10203872|NCT04860843|Sham Comparator|Local anesthetic TPVB + Sham PecsII block|Patients will receive a thoracic paravertebral with local anesthetic infiltrate and a pecs II block with saline infiltrate.
10203873|NCT04858789|Experimental|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|The experimental group will receive an 8-session CA-CBI in an online group format.
10203874|NCT04858789|No Intervention|Control|The control (care as usual) group will receive the information about freely available psychological support options. After all the measurements are completed, the control group will be able to receive CA-CBI, too.
10203875|NCT04856293|Experimental|Three Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial, and a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules)
9772866|NCT00961350|Active Comparator|EC Aspirin|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
9772867|NCT00961402|Experimental|Wellness Control|Participants will receive health and wellness information and no exercise information.
9772868|NCT00961402|Experimental|Exercise Intervention|Intervention will include motivational telephone-based intervention to increase exercise to 5 days per week for 30 minutes or more each session.
9772869|NCT00961415|Experimental|Part 1|
9772870|NCT00961415|Experimental|Part 2A|
9772871|NCT00961415|Active Comparator|Part 2B|
9772872|NCT00961441|Experimental|Children 12-16 years old|
9772873|NCT00961441|Experimental|Adults 18-55 years old|
9772874|NCT00961532|Experimental|DDAVP|DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes
9772875|NCT00961571|Experimental|sunitinib and cepecitabine|Administration of sunitinib and capecitabine
9772876|NCT00961636|Experimental|ERN/LRPT|"One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg~tablets daily (2g/40 mg total) for 28 weeks"
9772877|NCT00961636|Experimental|ERN/LRPT then ERN|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.
9772878|NCT00961636|Placebo Comparator|Placebo|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.
9772879|NCT00961649|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
9772880|NCT00961649|Active Comparator|Brinz|Brinzolamide ophthalmic suspension, 1% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
9772881|NCT00961649|Active Comparator|Brim|Brimonidine tartrate ophthalmic solution, 0.2% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
9772882|NCT00961649|Active Comparator|Brinz+Brim|Brinzolamide ophthalmic suspension, 1% and brimonidine tartrate ophthalmic solution, 0.2%: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
9772883|NCT00961662|Experimental|2.5 active|2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
9772884|NCT00961662|Active Comparator|5.0 mid dose|5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
9772885|NCT00961662|Active Comparator|7.5 high dose|7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
9772886|NCT00961896|Active Comparator|LDE225 (applied in parallel with vehicle) [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
9772887|NCT00961896|Placebo Comparator|Vehicle cream (applied in parallel with LDE225 [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
9772888|NCT00961896|Active Comparator|LDE225 0.25% [Part II]|Participants were exposed to topically applied 0.25% LDE225 cream twice daily for 6 weeks.
9772889|NCT00961896|Active Comparator|LDE225 0.75% [Part II]|Participants were exposed to topically applied 0.75% LDE225 cream twice daily where some basal cell carcinomas (BCCs) were teated for 6 weeks and some BCCs were treated for 9 weeks.
9772890|NCT00961961|Other|Lithium plus Fluoxetine Phase I|All participants were started in this arm. Those who met criteria for entry into Phase II were then randomized to one of the two Phase II arms.
9772891|NCT00961961|Other|Lithium plus Placebo Phase I|No participants began their participation on Lithium plus Placebo.
9772892|NCT00961961|Experimental|Lithium plus Fluoxetine Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to continue on both compounds.
9772893|NCT00961961|Placebo Comparator|Lithium plus Placebo Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to switch from Fluoxetine to placebo.
9772894|NCT00962000|Other|600 mL/min|Dialysis Flow Rate Start 600mL/min Subject starting dialysis flow rate set at 600mL/min. ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
9784641|NCT01230749|Experimental|JNJ-41443532 250 mg|Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
9772895|NCT00962000|Other|800 mL/min|Dialysis Flow Rate Start 800mL/min Subject starting dialysis flow rate set at 800mL/min. BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
9772896|NCT00962013|Other|Restoration® Modular|All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.
9772897|NCT00962039|Experimental|Citalopram|Citalopram was initiated at 10 mg daily for one week, with dosage increased to 20 mg daily during week 2, with an optional increase to 40 mg daily at week 4 or thereafter if response was judged to be suboptimal (CGI-I or CGI-S > 2).
9772898|NCT00962039|Placebo Comparator|Placebo|Placebo administered in capsules identical to those containing citalopram using microcrystalline cellulose.
9772899|NCT00962065|Experimental|Low Dose|A low dose of LX4211; daily oral intake for 28 days
9772900|NCT00962065|Experimental|High Dose|A high dose of LX4211; daily oral intake for 28 days
9772901|NCT00962065|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 28 days
9772902|NCT00962078|Other|interval training|interval training in lung transplant candidates
9772903|NCT00962078|Other|Continuous Training|continuous training in lung transplant candidates
9772904|NCT00962091|Experimental|Dose Escalation|A single dose of alisertib 15 mg, oral solution (OS) was administered on Day 1, followed by alisertib 40 mg, powder-in-capsule (PIC), orally, twice a day (BID) on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, was administered on Cycle 2 Day 1 followed by alisertib 40 mg on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Subsequent cycles, alisertib 40 or 50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
9772905|NCT00962091|Experimental|Part A: Relative Bioavailability OS/PIC (Sequence A)|A single dose of alisertib 25 mg, OS, administered on Day 1, followed by alisertib 40 mg PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, administered on Cycle 2 Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles, alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
9772906|NCT00962091|Experimental|Part A: Relative Bioavailability PIC/OS (Sequence B)|A single dose of alisertib 50 mg, PIC, orally administered on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 25 mg, OS, once on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles followed by alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in Cycle 3, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
9772907|NCT00962091|Experimental|Part B: OS Food Effect Fed/Fasted (Sequence A)|Alisertib 35 mg (35 mg = relative bioavailability estimate in Part A as dose of OS that was calculated to yield the area under the concentration time curve of a 50-mg PIC dose): A single dose of alisertib 35 mg oral solution (OS), in fed state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 35 mg administered, OS, in fasted state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg, PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted, based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
9772908|NCT00962091|Experimental|Part B: OS Food Effect Fasted/Fed (Sequence B)|A single dose of alisertib 35 mg, OS, in fasted state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 2 Day 1 alisertib 30 mg, OS administered in fed state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
9772909|NCT00962091|Experimental|Part C: ECT Food Effect Fed/Fasted (Sequence A)|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 40 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Cycle 3 onwards, participants were administered alisertib 40 mg BID ECT on Days 1-7 with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
9772910|NCT00962091|Experimental|Part C: ECT Food Effect Fasted/Fed (Sequence B)|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 mg, ECT, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2, a 23-day cycle. Cycle 3 onwards participants were administered alisertib 40 mg BID ECT on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
9772911|NCT00962104|Experimental|Atomoxetine|
9772912|NCT00962104|Placebo Comparator|Placebo|
9772913|NCT00962208|Experimental|orthokeratology lenses|Children wearing orthokeratology at night for correcting of refractive error will be study group
9772914|NCT00962208|Other|single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
9772915|NCT00962247|Experimental|Sedentary; usual, 25% reduced, 50% reduced|The initial 3 weeks of the study, children were asked to maintain their usual targeted sedentary behaviors (TV, video game, computer use) measured by a television reduction device (TV Allowance). The following 3 weeks children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 25% from the usual sedentary condition using a television reduction device (TV Allowance). The final 3 weeks of the study, children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 50% from the usual sedentary condition using a television reduction device (TV Allowance)
9772916|NCT00962390|Experimental|150mg S-equol|
9772917|NCT00962390|Experimental|50mg S-equol|
9772918|NCT00962390|Experimental|10 mg S-equol|
9772919|NCT00962390|Placebo Comparator|Placebo|
9772920|NCT00962585|Placebo Comparator|Placebo|Placebo
9772921|NCT00962585|Experimental|S-equol 10 mg BID|S-equol 20 mg total daily dose
9772922|NCT00962585|Experimental|S-equol 50 mg BID|S-equol 100 mg total daily dose
9772923|NCT00962585|Experimental|S-equol 150 mg BID|S-equol 300 mg total daily dose
9772924|NCT00962598|Placebo Comparator|Corn Oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
9772925|NCT00962598|Experimental|Omega-3 Fatty Acids|The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
9772926|NCT00962650|Experimental|NOTES Toolbox|Multiple devices designed for trans-orifice use during surgical procedures; used for transvaginal cholecystectomy in this trial
9772927|NCT00962741|Experimental|1|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
9772928|NCT00962754|No Intervention|physician insight fluid balance|physician has insight in fluid balance chart, this is standard practice
9772929|NCT00962754|Experimental|fluid balance data masked to physician|physician no insight in the fluid balance chart
9772930|NCT00962780|Experimental|1|3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
9772931|NCT00962871|Active Comparator|1|
9772932|NCT00962871|Experimental|2|
9772933|NCT00962871|Experimental|3|
9772934|NCT00962871|No Intervention|4|
9772935|NCT00962949|Experimental|Control|Healthy controls
9772936|NCT00962949|Experimental|Postural Tachycardia Syndrome|Patients with Postural Tachycardia Syndrome
9772937|NCT00963105|Experimental|Lenalidomide 5 mg|"Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
9772938|NCT00963105|Experimental|Lenalidomide 10 mg|"Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
9772939|NCT00963105|Experimental|Lenalidomide 15 mg|"Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
9772940|NCT00963157|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
9772941|NCT00963157|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
9772942|NCT00963157|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
9784642|NCT01230749|Experimental|JNJ-41443532 1000 mg|Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
9772943|NCT00963157|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
9772944|NCT00963157|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
9772945|NCT00963235|Experimental|1|
9772946|NCT00963430|Experimental|Group 2: 30 mcg H1N1 vaccine|60 subjects to receive 30 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
9772947|NCT00963430|Experimental|Group 1: 15 mcg H1N1 vaccine|60 subjects to receive 15 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
9772948|NCT00963482|Experimental|Intervention group|Cognitive-behavioural smoking cessation program
9772949|NCT00963482|Other|Control group|Autogenic training
9772950|NCT00963508|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
9772951|NCT00963508|Active Comparator|Nix Crème Rinse|Nix Crème Rinse applied to scalp for 10 minutes
9772952|NCT00963547|Experimental|Pt. 1: MK-2206 45mg, QOD + Trastuzumab|Participants in Part 1 (Pt. 1) receive MK-2206 45 mg every other day (QOD), taken orally. In combination with MK-2206, trastuzumab is administered by intravenous (IV) infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg every 3 weeks (q3wk).
9772953|NCT00963547|Experimental|Pt. 1: MK-2206 60mg, QOD + Trastuzumab|Participants in Pt. 1 receive MK-2206 60 mg QOD, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
9772954|NCT00963547|Experimental|Pt. 1: MK-2206 135mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 135 mg once weekly (QW), taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
9772955|NCT00963547|Experimental|Pt. 1: MK-2206 200mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 200 mg QW, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
9772956|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 500mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the maximum tolerated dose defined in Part 1 (Pt. 1 MTD). MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 500 mg taken orally once daily (QD).
9772957|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 750mg, QD|Participants in Pt. 2 receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 750 mg taken orally QD.
9772958|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 1000mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 1000 mg taken orally QD.
9784643|NCT01230749|Active Comparator|Pioglitazone|Participants will receive pioglitazone 30 mg in morning for 28 days.
9784644|NCT01230749|Placebo Comparator|Placebo|Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.
9784645|NCT01230801|Experimental|BMN 701|IV infusion
9784646|NCT01230814|Experimental|Arm 1|Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
9784647|NCT01230814|Placebo Comparator|Arm 2|Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.
9784648|NCT01230827|Experimental|CNTO 148 (Golimumab)|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response at Week 16 and who are randomly allocated to golimumab, will receive 30 mg per square meter every 4 weeks through Week 48. Patients will continue to receive golimumab 30 mg per square meter after Week 48 in a long-term extension until Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
9784649|NCT01230827|Placebo Comparator|Placebo|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive placebo every 4 weeks through Week 48. However, patients receiving placebo and who will have lack/loss of clinical response will be eligible to receive golimumab 30 mg per square meter every 4 weeks through Week 48. At Week 48, patients do not have a clinical response will begin to receive golimumab 30 mg per square meter in a long-term extension until Week 248 and patients who have a clinical response will be discontinued from the study. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
9784650|NCT01230892|Active Comparator|Nebivolol|
9784651|NCT01230892|Active Comparator|Atenolol|
9784652|NCT01230931|Experimental|Vitagel and Standard of Care|This group of patients will receive the vitagel topical surgical hemostat spray intra-operatively, along with all the other standards of care.
9784653|NCT01230931|Active Comparator|Standard of Care|This group of patients will receive the standard of care for hemostasis in acetabular surgery (electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing). They will not receive the vitagel product.
9784654|NCT01231230|Experimental|fluticasone/salmeterol|participants were treated fluticasone/salmeterol,
9784655|NCT01231230|Experimental|salmeterol|participants were treated with salmeterol
9784656|NCT01231230|Experimental|fluticasone|participants were treated with fluticasone
9772959|NCT00963560|Experimental|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lens (IOL)
9772960|NCT00963560|Active Comparator|Crystalens HD|Bilateral implantation of Crystalens HD Intraocular Lens (IOL)
9772961|NCT00963560|Active Comparator|Crystalens AO|Bilateral implantation of Crystalens AO Intraocular Lens (IOL)
9772962|NCT00963638|Experimental|MagTabSR|
9772963|NCT00963638|Placebo Comparator|Sugar Pill|
9772964|NCT00963677|Experimental|Intubation without difficulty|The patients are not predicted for difficult intubation
9772965|NCT00963677|Experimental|Difficult intubation|The patients will be anticipated for difficult intubation without difficult ventilation
9772966|NCT00963807|Experimental|Treatment|Patients receive docetaxel IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo FDG PET/CT, FLT PET/CT, and thoracic CT at baseline and the end of cycles 1 and 2 and then undergo surgery.
9772967|NCT00963820|Experimental|0.24 mg/m^2|Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate
9772968|NCT00963820|Experimental|0.48 mg/m^2|Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772969|NCT00963820|Experimental|0.80 mg/m^2|Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772970|NCT00963820|Experimental|1.20 mg/m^2|Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period.
9772971|NCT00963820|Experimental|1.68 mg/m^2|Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772972|NCT00963820|Experimental|2.23 mg/m^2|Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772973|NCT00963820|Experimental|2.97 mg/m^2|Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772974|NCT00963820|Experimental|3.95 mg/m^2|Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772975|NCT00963820|Experimental|Relapsed and Refractory (RR)|Ixazomib citrate, 2.97 mg/m^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772976|NCT00963820|Experimental|VELCADE-Relapsed (VR)|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772977|NCT00963820|Experimental|PI naïve|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772978|NCT00963820|Experimental|Carfilzomib|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
9772979|NCT00963859|Experimental|Robotic-assisted laparoscopic surgery|Robotic-assisted laparoscopic extended pelvic lymph node dissection
9772980|NCT00963872|Experimental|Complement Fragment 3A - Small Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
9772981|NCT00963872|Experimental|Complement Fragment A - Larger Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
9772982|NCT00963911|Experimental|Included patients|Screening tests (G8 and VES-13)
9772983|NCT00963924|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
9772984|NCT00963924|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
9772985|NCT00963937|Active Comparator|Sumatriptan 25 mg|
9772986|NCT00963937|Active Comparator|Sumatriptan 50 mg|
9772987|NCT00963937|Placebo Comparator|Placebo|
9772988|NCT00963989|Experimental|Penumbra Device Arm|
9772989|NCT00964028|Experimental|INFANRIX-IPV/HIB M2-M3-M4 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age (M2-M3-M4), administered intramuscularly into the upper right side of the thigh.
9772990|NCT00964028|Experimental|INFANRIX-IPV/HIB M3-M4-M5 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age (M3-M4-M5), administered intramuscularly into the upper right side of the thigh.
9772991|NCT00964158|Experimental|Group A|
9772992|NCT00964223|Experimental|Duac gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
9772993|NCT00964223|Active Comparator|Epiduo gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
9772994|NCT00964353|Active Comparator|Clinically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
9772995|NCT00964353|Experimental|Pharmacogenetically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
9772996|NCT00964366|Experimental|Clindamycin/BPO gel|Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
9772997|NCT00964366|Active Comparator|Dapsone gel|Twice-daily applications of dapsone gel to one side of the face.
9772998|NCT00964392|Experimental|More-Experienced Physicians (MEP)|Physicians who perform greater than or equal to 50 atrial fibrillation ablation procedures per year.
9772999|NCT00964392|Experimental|Less-Experienced Physicians (LEP)|Physicians who perform less than 50 atrial fibrillation ablation procedures per year.
9773000|NCT00964431|Experimental|Indomethacin Test (lower dose)|
9773001|NCT00964431|Experimental|Indomethacin Test (upper dose)|Single dose
9773002|NCT00964431|Active Comparator|Celecoxib 400 mg|
9773003|NCT00964431|Placebo Comparator|Placebo|
9773004|NCT00964496|Active Comparator|Thalidomide Group|
9773005|NCT00964496|Other|Iron-controlled Group|
9773006|NCT00964548|Experimental|Dantrolene (low dose)|
9773007|NCT00964548|Experimental|Dantrolene (high dose)|
9773008|NCT00964678|Experimental|carvedilol|Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI
9773009|NCT00964743|Experimental|Intrathecal DepoCyt and Oral Sorafenib|This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
9773010|NCT00964782|Active Comparator|Sildenafil crossover to placebo|Sildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.
9773011|NCT00964782|Placebo Comparator|Placebo crossover to sidenafil|Patient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.
9773012|NCT00964795|Experimental|Open-label Intravitreal Aflibercept Injection|Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.
9773013|NCT00964860|No Intervention|Brushing Only|Brushing Only with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice
9773014|NCT00964860|Experimental|Brushing + Flossing|Brushing with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice, plus flossing with Glide floss
9773015|NCT00964886|Experimental|Arm 1|desipramine hydrochloride
9773016|NCT00964886|Experimental|Arm 2|cognitive behavioral therapy
9773017|NCT00964886|Experimental|Arm 3|desipramine hydrochloride and cognitive behavioral therapy
9773018|NCT00964886|Placebo Comparator|Arm 4|anticholinergic medication; active placebo
9773019|NCT00965081|Experimental|Duloxetine|
9773020|NCT00965081|Placebo Comparator|Placebo|
9773021|NCT00965094|Experimental|Everolimus|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.
9784657|NCT01231230|Placebo Comparator|placebo inhalation|participants were treated with placebo
9773022|NCT00965094|Active Comparator|Reference Therapy|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.
9773023|NCT00965185|Experimental|Atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
9773024|NCT00965185|Placebo Comparator|placebo|
9773025|NCT00965237|Other|Multifocal CL / Single vision CL + reading glasses|Lotrafilcon B multifocal contact lenses (CL) worn first, with lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
9773026|NCT00965237|Other|Single vision CL + reading glasses / Multifocal CL|Lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn first, with lotrafilcon B multifocal contact lenses (CL) worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
9773027|NCT00965250|Experimental|Thymoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
9773028|NCT00965250|Experimental|Thymic Carcinoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
9773029|NCT00965263|Experimental|Low dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
9773030|NCT00965263|Experimental|High Dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul
9773031|NCT00965341|Active Comparator|Testosterone|Testosterone Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
9773032|NCT00965341|Placebo Comparator|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
9773033|NCT00965419|Experimental|Edivoxetine|All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
9773034|NCT00965458|Experimental|Alefacept|Subjects in this group receive weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
9773035|NCT00965458|Placebo Comparator|Placebo|Subjects in this group received weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
9773036|NCT00965484|Experimental|Genotropin pen|All subjects will receive genotropin pen to use for 2 months.
9773037|NCT00965497|Experimental|Escitalopram|All patients will receive escitalopram 20 mg daily.
9773038|NCT00965523|Experimental|Eribulin Mesylate|
9773039|NCT00965562|Active Comparator|I|Fluoxetine
9773040|NCT00965562|Active Comparator|II|Calcium
9773041|NCT00965562|Placebo Comparator|III|
9773042|NCT00965575|Experimental|Melatonin|Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks
9773043|NCT00965575|Placebo Comparator|Placebos|Subjects will take a placebo 30 minutes before bedtime for four weeks
9773044|NCT00965731|Active Comparator|Erlotinib|
9773045|NCT00965731|Experimental|Erlotinib + PF-02341066|
9773046|NCT00965848|Experimental|Nosocomial Pneumonia|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days.
9773047|NCT00965848|Experimental|Complicated Intra-Abdominal Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated intra-abdominal infections up to maximum of 14 days.
9773048|NCT00965848|Experimental|Complicated Urinary Tract Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated urinary tract infections up to maximum of 10 days.
9773049|NCT00966186|Active Comparator|Standard technique|Proseal laryngeal mask airway was inserted according to the manufacture's instruction manual (insertion with help of index finger insertion)
9773050|NCT00966186|Experimental|Rotational technique|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was fel
9773051|NCT00966238|Experimental|VAX125|HA1 influenza vaccine
9773052|NCT00966264|Active Comparator|LNG-IUS|Levonorgestrel releasing intrauterine system
9773053|NCT00966264|Other|Hysterectomy|Hysterectomy
9773054|NCT00966277|Experimental|Group 1: Dalteparin|Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.
9773055|NCT00966277|No Intervention|Group 2: Control|No study drug.
9773056|NCT00966355|Active Comparator|Terlipressin|treat with terlipressin IV for 5 days and endoscopic treatment
9773057|NCT00966355|Active Comparator|Somatostatin|treat with somatostatin IV for 5 days and endoscopic treatment
9773058|NCT00966355|Active Comparator|Octreotide|treat with octreotide IV for 5 days and endoscopic treatment
9773059|NCT00966433|Experimental|Spontaneous ventilation|Pt's will be allowed to breathe spontaneously through the PLMA during surgery without the assistance of positive pressure ventilation.
9773060|NCT00966433|Experimental|Pressure support ventilation|Pt's will receive positive pressure assistance with each spontaneous breath through the PLMA.
9773061|NCT00966433|Active Comparator|Pressure control ventilation|Pt.'s will be placed on the ventilator and ventilated with pressure control. through the PLMA.
9773062|NCT00966446|Experimental|Unsupervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided.
9773063|NCT00966446|Experimental|Supervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Study staff is in contact with household members during this intervention to ensure compliance.
9773064|NCT00966446|No Intervention|No Intervention|Households do not undergo active MRSA decolonization protocol
9773065|NCT00966550|Active Comparator|Tomato|Tomato with high carb/fat meal
9773066|NCT00966550|Placebo Comparator|Non-Tomato|Non-tomato with high carb/fat meal
9773067|NCT00966641|Experimental|PL 3100|Active experimental drug
9773068|NCT00966641|Active Comparator|Naproxen|Active comparator
9773069|NCT00966693|Experimental|Treatment (lenalidomide, thalidomide, dexamethasone)|"Participants receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Participants also receive dexamethasone PO QD on days 1-4, 9-12, and 17-20 of courses 1-2, and days 1, 8, 15, and 22 of subsequent courses. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Participants who have stable or responding disease to treatment receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants may receive dexamethasone at the discretion of the investigator."
9784658|NCT01231321|Experimental|adalimumab|Adalimumab / pre-filled syringe 40 mg/0.8 ml
9784659|NCT01231334|Active Comparator|Aczone® Gel 5% plus Differin® 0.3% Gel|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
9784660|NCT01231334|Active Comparator|Duac® Topical Gel plus Differin® 0.3% Gel|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
9784661|NCT01231373|Experimental|polidocanol injectable foam, 0.125%|
9784662|NCT01231373|Experimental|polidocanol injectable foam, 0.5%|
9784663|NCT01231373|Experimental|polidocanol injectable foam, 1.0%|
9784664|NCT01231373|Placebo Comparator|Vehicle|
9784665|NCT01231399|Experimental|Arm I|Patients receive fluorouracil IV continuously over 46 hours, leucovorin calcium IV over 2 hours, and oxaliplatin IV over 2 hours on day 1. Patients also receive oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9784666|NCT01231412|Active Comparator|Arm I (MMF and CSP)|Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
9784667|NCT01231412|Experimental|Arm II (MMF, CSP, and Sirolimus)|Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
9784668|NCT01231412|Experimental|Arm 0 (CSP and Sirolimus)|Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
9785750|NCT01259297|Experimental|Aliskiren + Amlodipine|"In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period."
9785751|NCT01259297|Experimental|Aliskiren + Hydrochlorothiazide (HCTZ)|"In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily."
9785752|NCT01259297|Experimental|Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg"
9785753|NCT01259297|Experimental|Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily"
9835733|NCT02752490|Active Comparator|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
10203876|NCT04856293|Experimental|Two Period Treatment Sequence|Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
10203877|NCT04855708|Experimental|Virtual visit|Patients will have 2-week post-operative virtual visit
10203878|NCT04855708|Active Comparator|Office visit|Patients will return to the office for a 2-week post-operative visit
9773070|NCT00966719|Active Comparator|Lactation Consultant|"In hospital meeting with lactation consultant~1 to 3 follow up visits at weekly intervals with lactation consultant"
9773071|NCT00966719|No Intervention|current treatment for jaundice|Babies will receive current standard of care for jaundice (IV fluids and phototherapy)
9773072|NCT00966823|Experimental|Detachable balloon|Intervention: Fetuses treated with endoscopic tracheal occlusion
9773073|NCT00966849|Experimental|Conditional Cash Transfer|Vulnerable households in this arm will receive conditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
9773074|NCT00966849|Experimental|Unconditional Cash Transfer|Vulnerable households in this arm will receive unconditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
9773075|NCT00966849|Other|Control|Vulnerable households in this arm will not receive cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
9773076|NCT00966875|Experimental|3 mg LY2439821 (bDMARD-naive population)|3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)]
9773077|NCT00966875|Experimental|10 mg LY2439821 (bDMARD-naive population)|10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
9773078|NCT00966875|Experimental|30 mg LY2439821 (bDMARD-naive population)|30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
9773079|NCT00966875|Experimental|80 mg LY2439821 (bDMARD-naive population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
9773080|NCT00966875|Experimental|180 mg LY2439821 (bDMARD-naive population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
9773081|NCT00966875|Experimental|80 mg LY2439821 (TNFa-IR population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)]
9773082|NCT00966875|Experimental|180 mg LY2439821 (TNFa-IR population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
9773083|NCT00966875|Placebo Comparator|Placebo (bDMARD-naive population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
9773084|NCT00966875|Placebo Comparator|Placebo (TNFa-IR population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
9773085|NCT00966940|Other|Travoprost-to-tafluprost|Travoprost first, with tafluprost second. Each product dosed for six weeks.
9773086|NCT00966940|Other|Tafluprost-to-travoprost|Tafluprost first, with travoprost second. Each product dosed for six weeks.
9773087|NCT00967005|Experimental|N Acetyl Cysteine|The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
9773088|NCT00967005|Placebo Comparator|Sugar Pill|
9773089|NCT00967018|Experimental|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. For patients treated with goserelin in the previous trials (CS28, CS30 and CS31),a starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to the end of the trial. For patients treated with degarelix in the previous trials, maintenance doses of 80 mg (20 mg/mL) degarelix were continued and were administered as single 4 mL s.c. injections at 28 day intervals to the end of the trial.
9773090|NCT00967044|Experimental|Panobinostat + Everolimus|Panobinostat (LBH589) Plus Everolimus (RAD001)
9773091|NCT00967226|Experimental|propranolol for treatment of hemangiomas|Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
9773092|NCT00967226|Active Comparator|Prednisolone|Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
9773093|NCT00967330|Experimental|1|
9773094|NCT00967330|Active Comparator|2|
9773095|NCT00967343|Experimental|ATIR|
9773096|NCT00967369|Experimental|Arm A (bortezomib, ifosfamide, carboplatin, etoposide)|ARM A: Patients receive bortezomib IV over 5 seconds on days 1 and 4, ifosfamide IV continuously over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on days 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9773097|NCT00967369|Active Comparator|Arm B (ifosfamide, carboplatin, etoposide)|Patients receive ifosfamide, carboplatin and etoposide as in Arm A. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9773098|NCT00967473|Experimental|Toric Intraocular Lens|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Models SN60T9/SN60T8
9773099|NCT00967486|Active Comparator|Routine Shunt|These patients are called routine as the routine method of carotid endarterectomy is used.
9773100|NCT00967486|Active Comparator|Selective Shunt|These patients are selectively used for shunting or not shunting based on systolic pressure < 40mmHg. This group is further used as subgroup analysis.
9773101|NCT00967499|Active Comparator|1|
9773102|NCT00967499|Active Comparator|2|
9773103|NCT00967551|Active Comparator|Micronutrient Sprinkles without zinc|Micronutrient sprinkles without zinc
9773104|NCT00967551|Experimental|Micronutrient sprinkles with zinc|Micronutrient sprinkles with zinc gluconate
9773105|NCT00967616|Active Comparator|FOLFIRI|"Participants who received irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). FOLFIRI was administered by intravenous (IV) injection once every 2 weeks. The FOLFIRI regimen consisted of:~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
9773106|NCT00967616|Experimental|CS7017+FOLFIRI|"Participants who received CS7017 plus irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). Two CS-7017 tablets were administered by mouth (PO) twice a day (BID) every 12 hours. FOLFIRI was administered IV once every 2 weeks. The FOLFIRI regimen consisted of:~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
9773107|NCT00967668|Experimental|ASPIRE-Phone Lifestyle Coaching|Phone-based coaching using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
9773108|NCT00967668|Experimental|ASPIRE-Group Lifestyle Coaching|On-site weekly group visits using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
9773109|NCT00967668|Active Comparator|MOVE! Usual Care|Usual care MOVE!, which consists of weekly on-site group visits that follow MOVE! protocols with unstructured follow-up phone support
9773110|NCT00967694|Experimental|Nitrous oxide administration|All 20 healthy volunteers had their intraocular pressure (IOP) measured at baseline and then after 3, 6, 9, and 12 minutes of nitrous oxide administration, and then after 5, 10, and 15 minutes of breathing room air. There was therefore only one study arm, with each individual serving as their control for baseline and then intervention values of IOP measurement.
9773111|NCT00967798|Experimental|Sitagliptin|"CF patients receiving Sitagliptin.~Intervention: Dose is 100 mg taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
9773112|NCT00967798|Placebo Comparator|Sugar pill|"CF patients receiving placebo.~Intervention: Placebo is taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
9773113|NCT00967941||Ancef|
9773114|NCT00967941||Vancomycin and Cefazolin|
9773115|NCT00967941||Daptomycin and Cefazolin|
9773116|NCT00967993||KRX-0502 (ferric citrate)|"KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day.~Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate.~Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks."
9773117|NCT00968019||Presillion stent|Patients treated with the Presillion stent in up to two de novo coronary artery lesions
9773118|NCT00968071|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 intravenously (IV) over an hour and half daily for 5 days, Gemtuzumab Ozogamicin 3 mg/m^2 IV on day 5.
9773119|NCT00968227|Experimental|Transfusion|
9773120|NCT00968253|Experimental|Phase I: RAD001 + Combination Chemo|"Optimal dose finding of Everolimus (RAD001) beginning dose 5 mg + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Cytarabine (Ara-C) during Cycles 2, 4, 6, & 8.~First chemotherapy combination Hyper-CVAD = Cyclophosphamide, Vincristine, Adriamycin (doxorubicin), and Dexamethasone; Second chemotherapy combination Methotrexate and Ara-C."
9773121|NCT00968253|Experimental|Phase II: MTD RAD001 + Combination Chemo|MTD dose of Everolimus + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Ara-C during Cycles 2, 4, 6, & 8.
9773122|NCT00968344|Experimental|Leucine|3-4 g Leucine added to daily meals during bed rest
9773123|NCT00968344|Placebo Comparator|Placebo|3-4 g Alanine added to daily meals during bed rest
9773124|NCT00968526|Experimental|GSK2340272A 2D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received two doses (2D) of GSK2340272A vaccine, one administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and the other one, administered intramuscularly in the deltoid region of the dominant arm at Day 21.
9773125|NCT00968526|Experimental|GSK2340272A 1D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received a single dose (1D) of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
9773126|NCT00968539|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9784669|NCT01231464|Placebo Comparator|placebo|vehicle placebo nasal spray
9784670|NCT01231464|Experimental|FFNS|fluticasone furoate nasal spray
9773127|NCT00968539|Experimental|GSK2340269A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9773128|NCT00968617|Experimental|MK2578 1.0 mcg/kg|MK2578
9773129|NCT00968617|Experimental|MK2578 2.0 mcg/kg|MK2578
9773130|NCT00968617|Experimental|MK2578 3.6 mcg/kg|MK2578
9773131|NCT00968617|Active Comparator|Darbepoetin alfa|darbepoetin alfa
9773132|NCT00968669|Experimental|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
9773133|NCT00968669|Experimental|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
9773134|NCT00968669|Experimental|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
9773135|NCT00968669|Experimental|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
9773136|NCT00968708|Experimental|Placebo|Alogliptin placebo matching tablets, orally, once daily. Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
9773137|NCT00968708|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and <60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR <30 mL/min). Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
9773138|NCT00968799|Experimental|HIPEC treatment|"Cytoreduction~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).~Perfusion is performed with the open or Coliseum technique for 90 min."
9773139|NCT00968812|Active Comparator|Glimepiride|Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
9773140|NCT00968812|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
9773141|NCT00968812|Experimental|Canagliflozin 300 mg|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
9773142|NCT00968838|Experimental|Non-radiated White Blood Cell Transfusion|Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
9773143|NCT00968838|Experimental|White Blood Cell Transfusion|Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
9773144|NCT00968890|Experimental|Pandemrix+Fluarix and Pandemrix+Placebo|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
9773145|NCT00968890|Experimental|Pandemrix+Placebo and Pandemrix+Fluarix|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
9773146|NCT00968968|Experimental|Arm 1: Lapatinib plus Trastuzumab|
9773147|NCT00968968|Active Comparator|Arm 2: Trastuzumab|
9773148|NCT00968981|Experimental|A|
9773149|NCT00968981|Experimental|B|
9773150|NCT00968981|Experimental|C|
9773151|NCT00969124|Experimental|Third Eye Retroscope|All subjects underwent the same intervention, consisting of examination of the colon using a colonoscope along with the Third Eye Retroscope device, with removal of any polyps that were detected during the procedure.
9773152|NCT00969150|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
9773153|NCT00969150|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
9773154|NCT00969228|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 or 2-month schedule.
9773155|NCT00969228|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 or 2-month schedule.
9773156|NCT00969280|Experimental|Standardized Acupuncture group|
9773157|NCT00969280|Placebo Comparator|Non-acupoint shallow penetration group|
9773158|NCT00969332|Experimental|Omegaven|0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
9773159|NCT00969436|Experimental|Priorix-Tetra Group|Subjects received 2 doses of Priorix-Tetra® vaccine, 1 at Day 0 and 1 at Month 6, administered subcutaneously in the left anterolateral thigh.
9773160|NCT00969436|Experimental|Priorix/ Priorix-Tetra Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix-Tetra® vaccine at Month 6, both administered subcutaneously in the left anterolateral thigh.
9773161|NCT00969436|Active Comparator|Control Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix™ vaccine co-administered with Varilirix™ vaccine at Month 6, administered subcutaneously in the left and right anterolateral thigh.
9784671|NCT01231503|Experimental|RTS,S Neo-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
9784672|NCT01231503|Experimental|RTS,S Neo-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanri xHepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
9784673|NCT01231503|Experimental|RTS,S 6-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 14 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
9784674|NCT01231503|Experimental|RTS,S 6-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
9784675|NCT01231503|Experimental|Engerix-B Neo/RTS,S 6-10-26 Group|Subjects received one dose of Engerix-B (HBV) when ≤ 7 days of age followed by 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E and HBV vaccines were administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
10203879|NCT04844619|Experimental|KDR2-2 group|The patients with NVG will receive 4.0 mg/ml or 16.0mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.
10203880|NCT04836845|Active Comparator|Focus extracorporeal shock wave therapy|
10203881|NCT04836845|Active Comparator|Radial extracorporeal shock wave therapy|
10203882|NCT04836845|Sham Comparator|Sham extracorporeal shock wave therapy|
10203883|NCT04827485|Active Comparator|Gluteal squeeze|Patients behind pressed together during part of the colonoscopy (The technicians arms will be covered with a towel to mask the provider of any pressure being applied)
9773162|NCT00969501|Experimental|EUFLEXXA|ACTIVE CONTROL
9773163|NCT00969540|Active Comparator|Active Mattress Cover|Subjects in this arm will be given the placebo mattress cover followed active mattress cover .
9773164|NCT00969540|Placebo Comparator|Placebo Mattress Cover|Subjects in this arm will be given the active mattress cover followed by the placebo mattress cover.
9773165|NCT00969553|Experimental|BI 6727|Schedule A
9773166|NCT00969618|Experimental|Atomoxetine|
9773167|NCT00969709|Experimental|1|40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
9773168|NCT00969709|Experimental|2|80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
9773169|NCT00969709|Experimental|3|120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
9773170|NCT00969709|Placebo Comparator|4|Matching placebo capsules, oral administration, once daily.
9773171|NCT00969761|Experimental|A. BI 6727-cisplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to cisplatin
9773172|NCT00969761|Experimental|B. BI 6727-carboplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to carboplatin
9773173|NCT00969878|Placebo Comparator|Placebo injection|TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
9773174|NCT00969878|Experimental|TA-CD Vaccination|TA-CD 400 μg will be administered intramuscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
9773175|NCT00970073|Experimental|Delayed CNI Group 1|Thymoglobulin 3mg total, administered on Days 0 and 2 (after transplant), plus MMF and corticosteroids. CNI administration delayed until 10 days post transplant. tacrolimus 3-8 (trough concentration)
9773176|NCT00970073|Experimental|Delayed CNI Group 2|Thymoglobulin 4.5mg total, plus MMF and corticosteroids. CNI therapy delayed until 10 days post transplant.tacrolimus 3-8 (trough concentration)
9773177|NCT00970073|Active Comparator|Early CNI / Control Arm|Standard post liver transplant therapy to include: tacrolimus 8-12 (trough concentration) initiated within 48 hours post-transplant, plus mycophenolate mofetil (MMF) and corticosteroids to be administered within 24 hours after transplant (Day 0).
9773178|NCT00970203|Experimental|Cohort A|"3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
9773179|NCT00970203|Experimental|Cohort B|"3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
9773180|NCT00970268|Experimental|1|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
9773181|NCT00970268|Experimental|2|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
9773182|NCT00970281|Experimental|10 mg Olanzapine|
9773183|NCT00970281|Placebo Comparator|Placebo|
9773184|NCT00970294|Experimental|Health Promotion Program|Supervised exercise, educational sessions, dietary counseling
9773185|NCT00970307|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
9773186|NCT00970307|Active Comparator|INFANRIX HEXA + MENJUGATE GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 3 and 4 months of age, 2 doses of Menjugate® vaccine at 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Menjugate® vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
9773187|NCT00970307|Active Comparator|INFANRIX HEXA + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
9773188|NCT00970320|No Intervention|Control group, RCT2|Participants reporting anal incontinence 6 months postpartum receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
9773189|NCT00970320|Active Comparator|Intervention group, RCT 2|Participants reporting anal incontinence 6 months postpartum receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
9773190|NCT00970320|No Intervention|Control group, RCT3|Women with obsteric anal sphincter injury receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
9773191|NCT00970320|Active Comparator|Intervention group, RCT 3|Women with obsteric anal sphincter injury receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
9773192|NCT00970320|No Intervention|Prevalence Study|1571 primiparae delivering at Ostfold Hospital Trust or St. Olav's Hospital during the period May 2009 to December 2010.
9773193|NCT00970359|Experimental|pts with thyroid cancer with and without BRAF mutation|Patients receive selumetinib orally (PO) twice daily (BID) for 4 weeks. Within 1 month, patients with adequate RAI uptake may receive 131I per standard of care and continue selumetinib until 2 days following 131I.
9773194|NCT00970489|Experimental|Omega-3 fatty acid capsules|
9773195|NCT00970489|Placebo Comparator|Olive Oil capsule|
9773196|NCT00970502|Experimental|erlotinib + celecoxib|
9773197|NCT00970593|Placebo Comparator|OAP-189|
9773198|NCT00970593|Placebo Comparator|2|
9773199|NCT00970632|Placebo Comparator|Placebo|Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
9773200|NCT00970632|Experimental|Tadalafil 5 milligram (mg)|Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
9773201|NCT00970632|Active Comparator|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks
9773202|NCT00970684|Experimental|Bevacizumab, Docetaxel, and Gemcitabine|Treatment repeats every 21 days for up to 6 courses.
9773203|NCT00970814|Active Comparator|Levetiracetam XR|Group received Levetiracetam
9773204|NCT00970814|Placebo Comparator|Sugar Pill|Placebo
9773205|NCT00970853|Active Comparator|Control|Control group
9773206|NCT00970853|Experimental|MOM Program home visiting|Mixed professional support home visiting program.
9773207|NCT00970944|Experimental|Amantadine HCL|100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.
9773208|NCT00970944|Placebo Comparator|Placebo|
9773209|NCT00971048|Experimental|HP828-101|
9773210|NCT00971048|Active Comparator|Standard of Care|For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.
9773211|NCT00971178|Active Comparator|Local Dexmedetomidine|
9773212|NCT00971178|Placebo Comparator|Normal Saline|
9773213|NCT00971178|Active Comparator|IV dexmedetomidine|
9773214|NCT00971204|Experimental|Treatment with HeartLight System|Treatment of paroxysmal atrial fibrillation (PAF) with HeartLight System
9773215|NCT00971243|Experimental|MP-513 Lowest Dose and Metformin|
9773216|NCT00971243|Experimental|MP-513 Low Dose and Metformin|
9773217|NCT00971243|Experimental|MP-513 Medium Dose and Metformin|
9773218|NCT00971243|Experimental|MP-513 High Dose and Metformin|
9773219|NCT00971243|Placebo Comparator|Placebo and Metformin|
9773220|NCT00971282|Experimental|intra-individual comparison|
9773221|NCT00971295|Experimental|Treatment Sequence A|Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
9773222|NCT00971295|Experimental|Treatment Sequence B|Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
9773223|NCT00971321|Experimental|GSK 2340272A F1 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 1 (F1) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
9773224|NCT00971321|Experimental|GSK 2340272A F2 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 2 (F2) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
9773225|NCT00971425|Experimental|Placebo-Pandemrix-Fluarix Group|Subjects received one dose of placebo intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21, and 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day 42.
9773226|NCT00971425|Experimental|Fluarix-Pandemrix-Placebo Group|Subjects received 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid of the non-dominant arm at Day 0 and 21, and 1 dose of placebo intramuscularly in the deltoid of the non-dominant arm at Day 42.
9773227|NCT00971620|Experimental|BTX-A|BTX-A intralesional injection
9773228|NCT00971620|Experimental|Placebo/Saline|Saline intralesional injection
9773229|NCT00971633|Experimental|1|Treatment Sequence A-B-C
9773230|NCT00971633|Experimental|2|Treatment Sequence B-C-A
9773231|NCT00971633|Experimental|3|Treatment Sequence C-A-B
9773232|NCT00971633|Experimental|4|Treatment Sequence A-C-B
9773233|NCT00971633|Experimental|5|Treatment Sequence B-A-C
9773234|NCT00971633|Experimental|6|Treatment Sequence C-B-A
9773235|NCT00971737|Active Comparator|Cyclophosphamide and Vaccine only|Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
9773236|NCT00971737|Experimental|Cyclophosphamide, Vaccine and Trastuzumab|Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
9773237|NCT00971750||Ultrasound Study Group|Patients with no history of gallbladder surgery who are undergoing elective laparoscopic roux-en-Y gastric bypass that have consented to undergo a preoperative transabdominal ultrasound in addition to routine preoperative assessment for surgery.
9773238|NCT00971789|Experimental|Sirolimus Patients|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.
9773239|NCT00971841|Experimental|Paclitaxel|One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
9773240|NCT00971932|Experimental|Cetuximab + Cisplatin/Carboplatin + Fluorouracil (5-FU)|
9773241|NCT00971945|Experimental|Paclitaxel|
9773242|NCT00971997|Experimental|Lispro 50/50|
9773243|NCT00972088|Other|capsule endoscopy|patients eligible according to inclusion criteria who underwent a capsule endoscopy
9773244|NCT00972153|No Intervention|No device used|
9773245|NCT00972153|Sham Comparator|Device attached, not activated|
9773246|NCT00972153|Experimental|Device deployed and activated|
9773247|NCT00972205|Experimental|Paclitaxel and CBT-1|
9773248|NCT00972244|Experimental|1|1mg dapagliflozin
9773249|NCT00972244|Experimental|2|2.5mg dapagliflozin
9773250|NCT00972244|Experimental|3|5mg dapagliflozin
9773251|NCT00972244|Experimental|4|10mg dapagliflozin
9773252|NCT00972244|Placebo Comparator|5|Placebo
9773253|NCT00972283|Experimental|IDeg OD|
9773254|NCT00972283|Active Comparator|IGlar OD|
9773255|NCT00972322|Experimental|MK-8245 50 mg|MK-8245, 50 mg, twice daily for 28 days
9773256|NCT00972322|Placebo Comparator|Placebo|Placebo to MK-8245, 50 mg, twice daily
9773257|NCT00972335|Experimental|Combination Therapy|"Everolimus; this drug will be dosed at 10 mg orally DAILY for the duration of the study.~Bevacizumab; this drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study"
9773258|NCT00972374|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
9773259|NCT00972374|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
9773260|NCT00972374|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
9773261|NCT00972439|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
9773262|NCT00972439|Active Comparator|Ovcon Fe®|Ovcon Fe® is an oral contraceptive that contains less progestin.
9773263|NCT00972478|Experimental|Treatment (combination chemotherapy)|Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
9773264|NCT00972504|Active Comparator|GSK835726 (10mg)|10mg oral dose
9773265|NCT00972504|Active Comparator|GSK1004723 (1000mcg)|1000mcg nasal spray solution
9773266|NCT00972504|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
9773267|NCT00972504|Placebo Comparator|placebo|placebo
9773268|NCT00972517|Experimental|Group A|Subjects receiving alternative dose of GSK23440272A vaccine
9773269|NCT00972530|No Intervention|Activity|Normal activity without restrictions
9773270|NCT00972530|Active Comparator|immobilisation|48 hours postinjection rest
9773271|NCT00972543|Active Comparator|Raptiva|Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
9773272|NCT00972543|Placebo Comparator|Placebo|Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
9773273|NCT00972595|Experimental|A|clinical trial formulation
9773274|NCT00972595|Active Comparator|B|non-U.S. marketed formulation
9773275|NCT00972621|Experimental|Vitrax II|Investigational dispersive viscoelastic
9773276|NCT00972621|Active Comparator|Viscoat|Marketed control dispersive viscoelastic
9773277|NCT00972725|Experimental|GSK732461+Nivaquine Group|Subjects received a single dose of Nivaquine® tablets orally, 2 days prior to receiving a booster dose of the GSK732461 vaccine.
9773278|NCT00972725|Active Comparator|GSK732461 Group|Subjects received a booster dose of the GSK732461 vaccine intramuscularly, in the deltoid region of the non-dominant arm.
9773279|NCT00972777|Experimental|Besifloxacin|0.6% ophthalmic suspension
9773280|NCT00972777|Placebo Comparator|Vehicle|
9773281|NCT00972816|Experimental|3.75_(50)MF59|3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
9773282|NCT00972816|Experimental|7.5_(0) MF59|7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
9773283|NCT00972816|Experimental|7.5_(50) MF59|7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
9773284|NCT00972816|Experimental|7.5_(100) MF59|7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
9773285|NCT00972816|Experimental|15_(0) MF59|15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
9773286|NCT00972816|Experimental|15_(50)MF59|15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
9773287|NCT00972816|Experimental|15_(100) MF59|15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
9773288|NCT00972816|Experimental|30_(0) MF59|30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
9773289|NCT00972959|Experimental|Bortezomib/Dexamethasone/Zoledronic Acid|"For this study, Velcade will be administered at the standard dose of 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle.~Dexamethasone will be administered at a dose of 12 mg/m2 p.o., on days 1-2, 4-5, 8-9 and 11-12 of the same cycle.~Zoledronic acid will be administered at a dose of 4 mg, iv (15-minute infusion), every 28 days for up to 8 cycles, and then every 28 days for the next 18 months"
9773290|NCT00973102|Experimental|Premarin IV|Patients who were randomized to receive a single dose of 0.5 mg/kg Premarin® IV.
9773291|NCT00973102|Placebo Comparator|Placebo|Patients who were randomized to receive a single dose of 0.5 mg/kg placebo. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with hemorrhagic shock.
9773292|NCT00973349|Experimental|3.75_(50)MF59|50% of MF59 with 3.75 µg A/H1N1 antigen
9773293|NCT00973349|Experimental|7.5 w/o MF59|0% of MF59 with 7.5 µg A/H1N1 antigen
9773294|NCT00973349|Experimental|7.5_(50)MF59|50% of MF59 with 7.5 µg A/H1N1 antigen
9773295|NCT00973349|Experimental|7.5_(100)MF59|100% of MF59 with 7.5 µg A/H1N1 antigen
9773296|NCT00973349|Experimental|15 w/o MF59|0% of MF59 with 15 µg A/H1N1 antigen
9773297|NCT00973349|Experimental|15_(50)MF59|50% of MF59 with 15 µg A/H1N1 antigen
9773298|NCT00973349|Experimental|15_(100)MF59|100% of MF59 with 15 µg A/H1N1 antigen
9773299|NCT00973349|Experimental|30 w/o MF59|0% of MF59 with 30 µg A/H1N1 antigen
9773300|NCT00973362|Other|Adjunct (i.e. Normal Pap)|The Adjunct study will evaluate APTIMA HPV Assay clinical performance for detecting high-risk HPV types in female subjects 30+ years of age with negative (NILM) cytology results from routine Pap testing. This will be accomplished by evaluating the assay performance compared to known cervical disease status at baseline and after a 3-year follow-up period. A comparator FDA-Approved HPV DNA test is reported.
9773301|NCT00973362|Other|ASC-US|The ASC-US study will evaluate the APTIMA HPV Assay clinical performance for detecting high-risk HPV types in subjects with ASC-US Pap test results from routine Pap testing and known cervical disease status (based on colposcopic biopsy results). A comparator FDA-Approved HPV DNA test is reported. There is no follow-up period.
9773302|NCT00973479|Experimental|Group I: Placebo + Methotrexate (MTX)|Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
9773303|NCT00973479|Placebo Comparator|Group II: Golimumab + Methotrexate (MTX)|Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
9773304|NCT00973622|Experimental|Smokers|Healthy adult smokers aged 19-55 who are not currently interested in quitting smoking.
9773305|NCT00973622|Experimental|Non-smokers|Healthy adult non-smokers aged 19-55
9773306|NCT00973674|Experimental|Premarin IV|Patients randomized to receive a single dose of 0.5 mg/kg Premarin® IV
9773307|NCT00973674|Placebo Comparator|Placebo|Patients randomized to receive a single dose of placebo IV. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with traumatic brain injury.
9773308|NCT00973700|Experimental|2x7.5adj|Two doses of MF59 adjuvanted (adj) A/H1N1
9773309|NCT00973700|Experimental|7.5adj_1_8|MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
9773310|NCT00973700|Experimental|7.5adj_1_22|MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
9773311|NCT00973700|Experimental|15_1_22|A/H1N1 on study days 1 and 22
9773312|NCT00973700|Experimental|2x15_1_22|Two doses of A/H1N1 (one in each arm) on study days 1 and 22
9773313|NCT00973739|Experimental|Lapatinib|"Lapatinib PO dosed according to age:~Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily~Adults (18 years of age or older): 1,500 mg PO once daily~Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment."
9773314|NCT00973752|Experimental|Experimental|All patients treated on same arm
9773315|NCT00973765|Active Comparator|bactrim DS (800/160) 2 pills po BID x 7 days|active comparator
9773316|NCT00973765|Placebo Comparator|Matched placebo 2 pills po BID x 7 days|placebo
9773317|NCT00973921||Stent deployment evaluation|The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.
9773318|NCT00973973|Experimental|Elagolix 150 mg|Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.
9773319|NCT00973973|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.
9773320|NCT00974051|Active Comparator|Control|Subjects complete the same exercise routine, however no treatment is given at 9:00pm.
9773321|NCT00974051|Experimental|Terbutaline|Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.
9773322|NCT00974051|Experimental|20% Basal Insulin Reduction|All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for six hours.
9773323|NCT00974090|Placebo Comparator|Placebo / Teneli + SU|
9773324|NCT00974090|Experimental|Teneli / Teneli + SU|
9773325|NCT00974142|Experimental|Cyclosporine|
9773326|NCT00974142|Placebo Comparator|Placebo|
9773327|NCT00974220|Placebo Comparator|placebo|nebulized 0.9% saline placebo
9773328|NCT00974220|Experimental|fentanyl|nebulized fentanyl citrate (50 mcg)
9773329|NCT00974233|Experimental|Induction/Maintenance chemotherapy|Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy
9773330|NCT00974246|Experimental|COPD, ECF residents, Advair diskus|open label treatment with Advair diskus in COPD patients
9773331|NCT00974259|Experimental|pBrO2 and ICP management|Treatment protocol based on pBrO2 and ICP values.
9773332|NCT00974259|Active Comparator|ICP management|Treatment protocol based on ICP values only.
9773333|NCT00974311|Experimental|Enzalutamide|Formerly MDV3100
9773334|NCT00974311|Placebo Comparator|Placebo|
9773335|NCT00974350|Experimental|Group 1: SABER-Bupivacaine|2.5 mL SABER-Bupivacaine/Once
9773336|NCT00974350|Experimental|Group 2: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
9773337|NCT00974350|Placebo Comparator|Group 3: SABER-Placebo|2.5 mL or 5.0 mL SABER-Placebo/Once
9773338|NCT00974363|Experimental|Group A|Subjects who received GSK Biologicals' meningococcal vaccine 134612 in the primary vaccination study 109069.
9773339|NCT00974363|Active Comparator|Group B|Subjects who received MencevaxTM ACWY in the primary vaccination study 109069.
9773340|NCT00974376|Experimental|Gabapentin 1200mg/day|1200mg/day of gabapentin for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
9773341|NCT00974376|Placebo Comparator|Placebo|1200mg/day of placebo for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
9773342|NCT00974480|Experimental|Redermic|Cream was applied twice a day every day, morning and evening for 24 weeks.
10203884|NCT04827485|Sham Comparator|Non-squeeze|When the doctor asks for gluteal pressure, a technician will not administer the pressure but their arms will be covered with a towel and the doctor will not know if the pressure is being administered or not.
10203885|NCT04797585|Active Comparator|Laparoscopic supracervical hysterectomy|Minimally invasive procedure to remove a woman's uterus
10203886|NCT04797585|Experimental|Vaginal hysterectomy|Surgical procedure to remove the uterus
10203887|NCT04797520|Other|Treatment|All participants will have placement of ETT confirmed using both Core stethoscope and point-of-care ultrasound
10203888|NCT04784182|Experimental|Synbiotic supplement group|Daily consumption of pills containing prebiotics and probiotics
10203889|NCT04784182|Placebo Comparator|Placebo group|Daily consumption of pills containing maltodextrin
10203890|NCT04783233||Packing with Gelfoam|Tympanoplasty surgery with fascia graft (either transcanal or post-auricular) will be preformed. The middle ear and external canal will then be packed with Gelfoam.
10203891|NCT04783233||Packing with Chitosan succinamide|The surgical intervention and tympanoplasty will be performed as normal. The middle ear and external canal will be packed Chitosan succinamide.
10203892|NCT04769375||Group 1: Pregnant women diagnosed with GDM (first pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their first pregnancy.
10203893|NCT04769375||Group 2:Pregnant women diagnosed with GDM (2nd or 3rd pregnancy)|This group will consist of women with gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
10203894|NCT04769375||Group 3: Healthy pregnant women (first pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their first pregnancy.
10203895|NCT04769375||Group 4:Healthy pregnant women (2nd or 3rd pregnancy)|This group will consist of women who do not have gestational diabetes mellitus according to routine control tests in their second or third pregnancy.
10203896|NCT04751461|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) during an evaluation period, followed by a 4 hour Test Session
9773343|NCT00974480|Active Comparator|Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Hydrating cream was applied to the face in the morning every day for 24 weeks.
9773344|NCT00974480|Active Comparator|Combination of Redermic and Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Redermic was applied every evening when Rejuva-A™ was not applied, as well as every morning.
9773345|NCT00974493|Active Comparator|Oral antibiotics|
9773346|NCT00974493|Active Comparator|Intravenous antibiotics|
9773347|NCT00974675|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
9773348|NCT00974675|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
9773349|NCT00974675|Experimental|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
9773350|NCT00974675|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
9773351|NCT00974818|Experimental|pts getting Mitomycin C (MMC)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of MMC, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
9773352|NCT00974818|Experimental|pts getting Bacillus Calmette-Guerin (BCG)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of either BCG, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
9773353|NCT00974974|Experimental|IPX066|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
9773354|NCT00974974|Active Comparator|IR CD-LD|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
9773355|NCT00975000|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
9773356|NCT00975000|Placebo Comparator|Placebo|Participants received placebo orally once daily for 52 weeks.
9773357|NCT00975130|Experimental|SC-GLM50|In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.
9773358|NCT00975130|Experimental|IV GLM 2 mg/kg + GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.
9773359|NCT00975130|Experimental|GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.
9773360|NCT00975143|Experimental|CIP-Isotretinoin|
9773361|NCT00975143|Active Comparator|Isotretinoin|
9773362|NCT00975156|Experimental|Lokomat Intervention|Lokomat gait training (five days a week for eight weeks for a total of 40 sessions).
9773363|NCT00975156|Active Comparator|Standard of Care|Conventional physical therapy focusing on gait training for five days a week for eight weeks for a total of 40 sessions.
9773364|NCT00975195|Experimental|fluticasone high dose|fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate
9773365|NCT00975195|Experimental|fluticasone medium & low doses|fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate
9773366|NCT00975221|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally BID and were eligible for a dose titration once every 3 weeks during the 12-week dose-titration phase based on corrected total serum calcium concentration and safety assessments. Participants continued to receive cinacalcet for another 16 weeks during the efficacy assessment phase and then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
9773367|NCT00975221|Placebo Comparator|Placebo|Participants received placebo orally twice a day (BID) for 12 weeks during the dose titration phase and for another 16 weeks during the efficacy assessment phase. Participants then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
9773368|NCT00975286|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
9773369|NCT00975286|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
9773370|NCT00975416|Placebo Comparator|Methadone|Intranasal oxytocin administered in the context of cognitive behavioral therapy to methadone dependent outpatients
9773371|NCT00975416|Placebo Comparator|Outpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent outpatients
9773372|NCT00975416|Placebo Comparator|Inpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent inpatients
9773373|NCT00975481|Experimental|dimebon 20 mg|
9773374|NCT00975481|Experimental|dimebon 40 mg|
9773375|NCT00975481|Experimental|dimebon 60 mg|
9773376|NCT00975481|Placebo Comparator|placebo|
9773377|NCT00975481|Active Comparator|alprazolam 1 mg|
9773378|NCT00975481|Active Comparator|alprazolam 3 mg|
9773379|NCT00975507|Experimental|1|ProQuad™ (V221) + Placebo Followed by ProQuad™
9773380|NCT00975507|Active Comparator|2|M-M-R™ II + VARIVAX™
9773381|NCT00975585|Active Comparator|senofilcon A both eyes|soft contact lens worn daily for 2 weeks, with a 2-week replacement regimen.
9773382|NCT00975585|Active Comparator|lotrafilcon B both eyes|soft contact lens worn daily for 4 weeks, with a 4-week replacement regimen
9784676|NCT01231503|Experimental|RTS,S 10-14-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 10, 14 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
9784677|NCT01231503|Experimental|RTS,S 14-26-9M Group|Subjects received 3 doses of RTS,S/AS01E (or GSK257049) at 14 and 26 weeks of age and at 9 months of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
9784678|NCT01231503|Active Comparator|Engerix-B Neo Group|Subjects in this group received one dose of Engerix-B (HBV) ≤ 7 days of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The HBV vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
9784679|NCT01231555|Experimental|GSK2248761 100 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
9784680|NCT01231555|Experimental|GSK2248761 200 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
9784681|NCT01231555|Active Comparator|Efavirenz 600 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
9784682|NCT01231581|Experimental|GSK1120212 plus Gemcitabine|GSK1120212 administered orally plus gemcitabine IV
9784683|NCT01231581|Active Comparator|Placebo plus Gemcitabine|Placebo administered orally plus gemcitabine IV
9784684|NCT01231607|Active Comparator|1mg Finasteride|1mg finasteride active plus dutasteride placebo, by mouth once daily
9773383|NCT00975637|Experimental|140 mg SC|140 mg SC
10203897|NCT04751461|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) during an evaluation period, followed by a 4 hour Test Session
9773384|NCT00975637|Experimental|70 mg SC|70 mg SC
9773385|NCT00975637|Experimental|280 mg SC|280 mg SC
9773386|NCT00975637|Placebo Comparator|210 mg SC|210 mg SC
9773387|NCT00975637|Experimental|Placebo|Placebo
9773388|NCT00975650|Experimental|Test 8.0, Ref 5.0, Test 14.0, Test 11.0|Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;
9773389|NCT00975650|Experimental|Test 11.0, Test 8.0, Ref 5.0, Test 14.0|Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
9773390|NCT00975650|Experimental|Test 14.0, Test 11.0, Test 8.0, Ref 5.0|Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;
9773391|NCT00975650|Experimental|Ref 5.0, Test 14.0, Test 11.0, Test 8.0|Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
9773392|NCT00975676|Experimental|Triptorelin plus tamoxifen|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.
9773393|NCT00975676|Experimental|Triptorelin plus exemestane|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.
9773394|NCT00975715|Experimental|TRI476|Participants received TRI476 based on body weight with titration up to the maintenance dose, in addition to their traditional antiepileptics dosage.
9773395|NCT00975715|Placebo Comparator|Placebo|Participants received placebo to TRI476 without any adjustment to the dosing regimen, in addition to their traditional antiepileptics dosage.
9773396|NCT00975780|Experimental|enhanced oral care|
9773397|NCT00975780|Active Comparator|Usual care|The usual oral care provided at the nursing home
9773398|NCT00975806|Experimental|Cohort A|Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
9773399|NCT00975806|Experimental|Cohorts F and G|Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle
9773400|NCT00975884|Experimental|GSK2340272A (D21) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21 (D21).
9773401|NCT00975884|Experimental|GSK2340272A (M6) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Month 6 (M6).
9773402|NCT00975923|Experimental|Collaborative Group|Quality Improvement Virtual Learning Collaborative with Interactive Teleconferences and Tool Kit
9773403|NCT00975923|Active Comparator|Tool Kit Group|Tool Kit of Evidence-Based Guidelines, Education Seminars, and Aide for Quality Improvement Methods
9773404|NCT00975975|Experimental|Basiliximab|Basiliximab will be given by IV on Day +7 post transplant for recipients of matched unrelated cells. Basiliximab will be given by IV on Day +9 post transplant for recipients of matched related cells.
9773405|NCT00976027|Experimental|Fluzone® High Dose Group|
9773406|NCT00976027|Active Comparator|Fluzone® Group|
9773407|NCT00976183|Experimental|Vorinostat|All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.
9773408|NCT00976209|Experimental|Phenylephrine Hydrochloride Extended Release Tablets, 30 mg|
9773409|NCT00976209|Active Comparator|Phenylephrine Hydrochloride Immediate Release Tablets, 10 mg|
9773410|NCT00976248|Experimental|RAD001|RAD001, oral, 10 mg, daily
9773411|NCT00976274|Placebo Comparator|starch capsule|
9773412|NCT00976274|Experimental|Korea red ginseng|
9773413|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 1|rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
9773414|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 2|rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
9773415|NCT00976391|Active Comparator|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
9773416|NCT00976391|Active Comparator|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
9773417|NCT00976404|Active Comparator|Maraviroc + raltegravir intensification|ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
10203898|NCT04751461|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) during an evaluation period, followed by a 4 hour Test Session
10203899|NCT04751461|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) during an evaluation period, followed by a 4 hour Test Session
9773418|NCT00976404|Experimental|Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine|ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
9773419|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed|Bevacizumab + Pemetrexed
9773420|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab + Pemetrexed + Carboplatin
9773421|NCT00976482||Pacemaker|Patients currently implanted with permanent Pacemaker according to guidelines
9773422|NCT00976495|Experimental|Dapagliflozin|
9773423|NCT00976495|Active Comparator|Hydrochlorothiazide|
9773424|NCT00976508|Experimental|1|
9773425|NCT00976521|Experimental|Local infusion, thrombus aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
9773426|NCT00976521|Experimental|Local infusion, no aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
9773427|NCT00976521|Active Comparator|No local infusion, thrombus aspiration|No local infusion of abciximab, thrombus aspiration.
9773428|NCT00976521|Active Comparator|No local infusion, no aspiration|No local infusion abciximab and no thrombus aspiration
9773429|NCT00976560|Experimental|GW856553|GW856553 7.5 mg BID
9773430|NCT00976560|Placebo Comparator|Placebo|Matching Placebo BID
9773431|NCT00976573|Experimental|Arm I (bevacizumab, paclitaxel, and carboplatin)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9773432|NCT00976573|Experimental|Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)|Patients receive bevacizumab, paclitaxel, and carboplatin as in Arm I. Patients also receive everolimus PO QD on 3 days a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9773433|NCT00976599|Experimental|CP-690,550 + methotrexate|
9773434|NCT00976599|Placebo Comparator|Placebo + methotrexate|
9773435|NCT00976664|Active Comparator|Orthotic group|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
9773436|NCT00976664|Other|Shoe Orthotic Wait group|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.
9773437|NCT00976677|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes (with or without bevacizumab IV over 30-90 minutes) on day 1. Patients also receive placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive placebo (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
9773438|NCT00976677|Experimental|Arm II|Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm I. Patients also receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
9773439|NCT00976703|Active Comparator|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
9773440|NCT00976703|Active Comparator|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
9773441|NCT00976716|Experimental|Celecoxib|
9773442|NCT00976820|Experimental|Arepanrix/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh [for children under (<) 12 months of age]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
9773443|NCT00976820|Experimental|Arepanrix/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
9773444|NCT00976820|Experimental|GSK2340273A/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
9773445|NCT00976820|Experimental|GSK2340273A/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
9773446|NCT00976898|Experimental|Proton Beam Irradiation|This is a single arm study. All study participants will receive proton radiation therapy.
9773447|NCT00976911|Active Comparator|1|
9773448|NCT00976911|Experimental|2|
9773449|NCT00976937|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24 along with placebo matching to sitagliptin 100 milligram (mg) capsule orally QD up to Week 24.
9773450|NCT00976937|Active Comparator|Sitagliptin|Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
9773451|NCT00976950||Patients with HIV-1 infection|
9773452|NCT00976989|Experimental|T+P Concomitant Anthracycline-based chemotherapy|5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
9773453|NCT00976989|Experimental|T+P Sequential Anthracycline-based chemotherapy|FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
9773454|NCT00976989|Experimental|T+P Concomitant Non-Anthracycline chemotherapy|Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
9784685|NCT01231607|Active Comparator|0.02mg Dutasteride|0.02mg dutasteride active plus finasteride placebo, by mouth once daily
9773455|NCT00977080|Active Comparator|IV Paricalcitol|Participants in the IV stratum received intravenous (IV) paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at 0.07 mcg/kg with titration every 2 weeks.
9773456|NCT00977080|Active Comparator|Cinacalcet (at sites with IV paricalcitol)|Participants in the IV stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (doxercalciferol IV 1 mcg 3 times weekly (TIW) at sites in the US and alfacalcidol capsules 0.25 mcg daily at sites in Russia).
9773457|NCT00977080|Active Comparator|Oral paricalcitol|Participants in the oral stratum received oral paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at mcg = IPTH/60 3 times weekly (TIW) with titration every 2 weeks.
9773458|NCT00977080|Active Comparator|Cinacalcet (at sites with oral paricalcitol)|Participants in the oral stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (alfacalcidol capsules 0.25 mcg daily).
9773459|NCT00977106|Experimental|1|
9773460|NCT00977106|Placebo Comparator|2|
9773461|NCT00977106|Experimental|3|
9773462|NCT00977171|Experimental|Droxidopa|
9773463|NCT00977184|Experimental|Real rTMS|
9773464|NCT00977184|Sham Comparator|Sham rTMS|
9773465|NCT00977197|Active Comparator|Pregabalin|"Subjects randomized to this arm will receive the following dosage:~75 mg (one tablet) twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study."
9773466|NCT00977197|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo matching the study drug.
9773467|NCT00977314|Experimental|SoundBite Hearing System|The objective of this study was to assess the safety and effectiveness of the SoundBite hearing system by Sonitus Medical and to support its intended use for the treatment of unilateral hearing loss. The SoundBite hearing system is a Bone Conduction Device (BCD) and is occasionally referred to as such in the protocol and within this report.
9784686|NCT01231607|Active Comparator|0.1mg Dutasteride|0.1mg dutasteride active plus finasteride placebo, by mouth once daily
9773468|NCT00977379|Active Comparator|WBRT Followed by Standard of Care|Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system [CNS] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
9773469|NCT00977379|Experimental|WBRT+Capecitabine Followed by Capecitabine Maintenance|Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).
9773470|NCT00977431|Experimental|Regimen U|BIBW2992 + Radiotherapy
9773471|NCT00977431|Experimental|Regimen M|BIBW2992 + Temozolomide + Radiotherapy
9773472|NCT00977470|Experimental|Erlotinib|Erlotinib 150 mg oral daily
9773473|NCT00977470|Experimental|Erlotinib and Hydroxychloroquine|Erlotinib 150 mg oral daily plus Hydroxychloroquine (HCQ) 1000 mg oral daily
9773474|NCT00977548|Experimental|Erlotinib Treatment|Erlotinib was given as an oral 150 mg daily dose for 16 weeks. The dose was adjusted for diarrhea, rash and pulmonary toxicity.
9773475|NCT00977561|Experimental|Arm A|Figitumumab (CP-751,871) Plus Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
9773476|NCT00977561|Active Comparator|Arm B|Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
9773477|NCT00977613|Other|life style counseling|Treated stage 2 and 3 colorectal cancer patients were counseled to exercise at least to the equivalent of 18 metabolic hours per week and were assessed over 6 months.
9773478|NCT00977665|Experimental|rasagiline mesylate|rasagiline tablet, 1 mg/day for up to 48 weeks.
9773479|NCT00977665|Placebo Comparator|placebo|placebo tablet for up to 48 weeks.
9773480|NCT00977691|Experimental|Cohort 1|PBSC transplant with no post-transplant cyclophosphamide (PT-Cy)
9773481|NCT00977691|Experimental|Cohort 2|PBSC transplant with 50 mg/kg post-transplant cyclophosphamide (PT-Cy)
9773482|NCT00977691|Experimental|Cohort 3|PBSC transplant with 100 mg/kg post-transplant cyclophosphamide (PT-Cy)
9773483|NCT00977704|Active Comparator|Restylane and Perlane|Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
9773484|NCT00977769|Experimental|carbetocin 100 µg|Carbetocin injection, 100µg, single injection
9773485|NCT00977769|Active Comparator|oxytocin 5 u|Oxytocin 5U, injection, single injection
9773486|NCT00977769|Placebo Comparator|placebo (NaCl)|Saline single injection
9773487|NCT00977808|Experimental|Closed-Loop Model Predictive Control (MPC)|Insulin dosing was performed by a model-predictive control (MPC) algorithm.
9773488|NCT00977808|Placebo Comparator|Open-Loop|Insulin dosing was performed by the patient (using their normal routine and personal insulin pump) under a physician's supervision.
9773489|NCT00977938|Placebo Comparator|12m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
9773490|NCT00977938|Active Comparator|30m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
9773491|NCT00978029|Placebo Comparator|Placebo|Matching placebo tablet sublingual, once daily
9773492|NCT00978029|Experimental|SCH 39641 6 Amb a 1-U|6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
9773493|NCT00978029|Experimental|SCH 39641 12 Amb a 1-U|12 Amb a 1-U in an AIT, sublingual, once daily
9773494|NCT00978042|Experimental|VOLUMA® XC Treatment Arm|Participants treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs) at study start. Participants were eligible for re-treatment if applicable.
9773495|NCT00978042|Other|Control Arm_No Treatment then VOLUMA® XC|No treatment for 6 months, then participants were treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs). Participants were eligible for re-treatment if applicable.
9773496|NCT00978068|Active Comparator|Lopinavir/ritonavir (LPV/r) +2 NRTI|Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
9773497|NCT00978068|Active Comparator|Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI|Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)
9773498|NCT00978120|Experimental|H1N1 vaccine high dose|Participants will be stratified according to asthma severity and will receive the high dosage of the H1N1 vaccine.
9773499|NCT00978120|Experimental|H1N1 vaccine low dose|Participants will be stratified according to asthma severity and will receive the low dosage of the H1N1 vaccine.
9773500|NCT00978250|Experimental|5-Fluro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd (100 mg/m(2)) + THU (350 mg/m(2)) administered 5 days/week for 2 weeks in 28-day cycles
9773501|NCT00978341|Experimental|Pregabalin|
9773502|NCT00978341|Other|Placebo|
9773503|NCT00978380|Experimental|A|
9773504|NCT00978432|Experimental|Arm 1a (RAD001 followed by LBH589)|"Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
9773505|NCT00978432|Experimental|Arm 1b (LBH589 followed by RAD001)|"Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
9773506|NCT00978432|Experimental|Doublet (Combination RAD001 and LBH589)|Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.
9784687|NCT01231607|Active Comparator|0.5mg Dutasteride|0.5mg dutasteride active plus finasteride placebo, by mouth once daily
9773507|NCT00978445|Experimental|Home/Standard|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was at home first then in clinic INR and interaction with a care giver.
9773508|NCT00978445|Experimental|Standard/Home|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was an in clinic INR and interaction with a care giver, then the Home protocol was as described.
9773509|NCT00978562|Experimental|Diagnostic (DSC-MRI with ferumoxytol, DCE-MRI with gadolinium)|Patients receive ferumoxytol and gadolinium IV and then undergo DSC-MRI and DCE-MRI. An optional MRI without injection of a contrast agent may be obtained after 20-24 hours at the discretion of the clinician. Patients may receive up to 3 more scans at least 3 weeks apart over up to 2 years.
9773510|NCT00978627|Experimental|IDegAsp OD|
9773511|NCT00978627|Active Comparator|IDet|
9773512|NCT00978731|Experimental|Dasatinib|
9773513|NCT00978757|Experimental|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
9773514|NCT00978757|Placebo Comparator|Placebo|Placebo: saline solution
9773515|NCT00979017|Experimental|Avastin in combination with temozolomide and irinotecan|Avastin 10 mg/kg every 14 days. Temozolomide 200 mg/m2 daily x 5 days in a 28-day cycle. Irinotecan dose depends on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). EIAED 340 mg/m2 every other week and no EIAED 125 mg/m2 every other week. Irinotecan dose also depends on if the patient has the UGT 1A1 polymorphism (7/7). If so, they do not metabolize the irinotecan normally, so these patients will start out at a two dose level reduction. EIAED starting dose will be 275 mg/m2 and no EIAED starting dose will be 75 mg/ m2.
9773516|NCT00979069|Experimental|Aerobic Group|12 weeks of aerobic exercise 3 times a week
9773517|NCT00979069|No Intervention|Control Group|No contact control
9773518|NCT00979121|Active Comparator|Rosuvastatin|"Half of the subjects were randomized to the active drug (Rosuvastatin).~Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.~Duration: drug was administered daily until:~28 days after randomization or 3 days after ICU discharge (whichever comes first),~Discharge from study hospital,~Death"
9773519|NCT00979121|Placebo Comparator|Placebo|"Half of the subjects were randomized to placebo.~10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug."
9773520|NCT00979134|Experimental|Part A|Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)
9773521|NCT00979134|Experimental|Part B|Dose expansion phase, at the RD defined in Part A
9773522|NCT00979134|Experimental|Part C|Expansion phase in patients with FGFR1 and FGFR2 amplified tumours commencing at the RD defined from Part A
9773523|NCT00979199|Other|Non invasive cardiac imaging|Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.
9773524|NCT00979212|Active Comparator|Induction CT+RT|Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
9773525|NCT00979212|Experimental|Induction CT+RT+Panitumumab|Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
9773526|NCT00979303|No Intervention|Control Group|Control Patients - Undergo ablation procedures with radiation/fluoroscopy only
9773527|NCT00979303|Experimental|Study Group|Study Group Patients - Undergo ablation procedures using intracardiac echocardiography and 3D navigational system in addition to radiation.
10203900|NCT04751461|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) during an evaluation period, followed by a 4 hour Test Session
10203901|NCT04751461|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) during an evaluation period, followed by a 4 hour Test Session
10203902|NCT04751461|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) during an evaluation period, followed by a 4 hour Test Session
10203903|NCT04751461|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) during an evaluation period, followed by a 4 hour Test Session
10203904|NCT04751461|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) during an evaluation period, followed by a 4 hour Test Session
10203905|NCT04751461|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) during an evaluation period, followed by a 4 hour Test Session
10203906|NCT04742569||Cohort 1- Exposed/Early Symptomatic|"The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing.~For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day."
10203907|NCT04742569||CoHort 2- Pfizer or Moderna Vaccine|Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series. For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing
9773528|NCT00979407|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9773529|NCT00979407|Experimental|GSK2340274A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9773530|NCT00979420||HIV treatment|
9773531|NCT00979459|Experimental|MK-1006 80 mg DFC|Participants received a single dose of four 20 mg dry filled capsules of MK-1006
9773532|NCT00979459|Experimental|MK-1006 80 mg FCT|Participants received a single dose of two 40 mg film coated tablets of MK-1006
9773533|NCT00979576|Experimental|BIBF 1120 BID + Pemetrexed|Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m^2 pemetrexed once every 3 weeks
9773534|NCT00979576|Experimental|BIBF 1120 BID (RD) + Pemetrexed|PHase II part: Study arm
9773535|NCT00979576|Experimental|BIBF 1120 BID(Placebo) + Pemetrexed|Phase II part: Comparator arm
9773536|NCT00979602|Experimental|GSK2340274A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
9773537|NCT00979602|Experimental|GSK2340273A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
9773538|NCT00979615|Experimental|1|Olopatadine HCL Nasal Spray, 0.6%
9773539|NCT00979615|Active Comparator|2|Azelastine HCl Nasal Spray, 137 mcg
9773540|NCT00979628|Experimental|Basal Plus Regimen|glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
9773541|NCT00979628|Experimental|Basal Bolus|glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
9773542|NCT00979628|Active Comparator|sliding scale regular insulin (SSRI)|sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.
9773543|NCT00979654|Experimental|Sifalimumab (MEDI-545) 500 or 600 milligram (mg)|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
9773544|NCT00979732|Active Comparator|GSE beverage active|grape seed extract beverage 150 mg/BID
9773545|NCT00979732|Placebo Comparator|GSE beverage placebo|grape seed extract placebo beverage 150 mg/BID
9773546|NCT00979745|Experimental|Afamelanotide|
9773547|NCT00979745|Placebo Comparator|Placebo|
9773548|NCT00979875|Experimental|Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart."
9773549|NCT00979940|No Intervention|No atorvastatin|Patients do not receive Atorvastatin prior to PCI in cath lab
9773550|NCT00979940|Experimental|atorvastatin|Atorvastatin 80mg po given prior to PCI in cath lab
9773551|NCT00979953|Experimental|ADL5859|One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days
9773552|NCT00979953|Experimental|ADL5747|One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days
9773553|NCT00979953|Active Comparator|Oxycodone CR|"One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4~One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14"
9773554|NCT00979953|Placebo Comparator|Placebo|Four placebo capsules administered orally BID for 14 days
9773555|NCT00979992|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9773556|NCT00980005|Experimental|Flulaval Group|"subjects received Flulaval™ vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid."
9784688|NCT01231607|Placebo Comparator|Placebo|1mg finasteride placebo plus dutasteride placebo, by mouth once daily
9773557|NCT00980005|Active Comparator|Fluzone Group|"subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid."
9773558|NCT00980018|Experimental|nilotinib|Participants received two 150 [a total of 300 mg at each dosing] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules [a total of 400 mg at each dosing] for patients enrolled prior to Protocol Amendment 1).
9773559|NCT00980044|Experimental|Tramadol 200 mg then placebo|Tramadol 200 mg daily for 1 week then placebo given for 1 week
9773560|NCT00980044|Placebo Comparator|Placebo for two weeks|Medication
9773561|NCT00980044|Experimental|Tramadol 600 mg then placebo|Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
9773562|NCT00980057|Experimental|Adaptive CRT (aCRT) arm|Intervention: Cardiac resynchronization therapy (CRT-D) with Adaptive CRT algorithm ON
9773563|NCT00980057|Active Comparator|Echo-optimized arm|Intervention: Cardiac resynchronization therapy (CRT-D) with standard biventricular pacing (Adaptive CRT algorithm OFF)
9773564|NCT00980148|Experimental|Arm2|Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects
9773565|NCT00980148|Experimental|Arm 1|Azithromycin 1 gm oral single dose; 153 subjects
9773566|NCT00980174|Placebo Comparator|2|Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)
9773567|NCT00980174|Experimental|1|60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.
9773568|NCT00980200|Experimental|C/E/A/B/D|GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
9773569|NCT00980200|Experimental|D/C/E/A/B|GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
9773570|NCT00980200|Experimental|A/B/C/D/E|placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
9773571|NCT00980200|Experimental|B/A/D/E/C|GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
9773572|NCT00980200|Experimental|E/D/B/C/A|GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo
9773573|NCT00980278|Active Comparator|sinus lift plus dental implant|"Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: N/A; only sinus augmentation and dental implant"
9773574|NCT00980278|Experimental|sinus lift plus BRCs and dental implant|"transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant"
9773575|NCT00980330|Experimental|TMC435 100 mg 12 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.
9773576|NCT00980330|Experimental|TMC435 100 mg 24 Wks + PR48|Participants willl receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.
9773577|NCT00980330|Experimental|TMC435 100 mg 48 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
9773578|NCT00980330|Experimental|TMC435 150 mg 12 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.
9773579|NCT00980330|Experimental|TMC435 150 mg 24 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.
9773580|NCT00980330|Experimental|TMC435 150 mg 48 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
9773581|NCT00980330|Placebo Comparator|Placebo 48 Wks + PR48|Participants will receive Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
9773582|NCT00980343|Experimental|Arm I (pre-surgery vismodegib)|"Patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily for 7 days before therapeutic conventional surgery. Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis"
9773583|NCT00980343|Experimental|Arm II (no vismodegib pre-surgery)|"Patients do not receive treatment before therapeutic conventional surgery.~Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
9773584|NCT00980395|Experimental|VCR (Velcade, Cladribine and Rituximab)|"Rituximab 375 mg/m2 IV day1~Cladribine 4 mg/m2 IV over 2 hours days 1-5~Bortezomib 1.3 mg/m2 IV days 1 and 4~Repeat every 28 days for a maximum of 6 cycles"
9773585|NCT00980590|Experimental|Airway Scope|Intubation with Airway Scope
9773586|NCT00980590|Active Comparator|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
9784689|NCT01231620|Experimental|Intravenous (IV) Zanamivir 300mg Twice Daily|300mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
9773587|NCT00980642|Other|General anesthesia|Temperature is measured by Draeger double-sensor and esophageal stethoscope temperature sensor every 5-min during the surgery.
9773588|NCT00980642|Other|Regional anesthesia|Temperature is measured by Draeger double-sensor and Foley catheter temperature sensor every 5-min during the surgery.
9773589|NCT00980655|Experimental|1|
9773590|NCT00980681|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg.
9773591|NCT00980681|Other|Time Of Flight|Each subject will undergo a TOF Magnetic Resonance Angiography
9773592|NCT00980746|Experimental|ESL 400 mg BID|ESL 400 mg twice daily (BID)
9773593|NCT00980746|Experimental|ESL 800 mg QD|ESL 800 mg once-daily (QD)
9773594|NCT00980746|Experimental|ESL 600 mg BID|Eslicarbazepine 600 mg twice daily
9773595|NCT00980746|Experimental|ESL 1200 mg QD|Eslicarbazepine acetate 1200 mg once daily
9773596|NCT00980746|Experimental|ESL 800 mg BID|Eslicarbazepine acetate 800 mg twice daily
9773597|NCT00980746|Placebo Comparator|Placebo|Placebo
9773598|NCT00980785|Placebo Comparator|Placebo|Matching Placebo
9773599|NCT00980785|Experimental|Active|Ramipril 5mg/day
9773600|NCT00980798|Experimental|001|OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks
9773601|NCT00980798|Placebo Comparator|002|Placebo placebo tablet once daily for 16 weeks
9773602|NCT00980980|No Intervention|Arm 1: Usual Care-Active Surveillance|Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+
9773603|NCT00980980|Active Comparator|Arm 2: Targeted Decolonization|Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
9773604|NCT00980980|Active Comparator|Arm 3: Universal Decolonization|Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
9773605|NCT00981019||mortality*incidence*5-year survival*early stage|Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
9773606|NCT00981045|Experimental|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
9773607|NCT00981045|Active Comparator|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
9773608|NCT00981084|Experimental|armodafinil and placebo|All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design
9773609|NCT00981149|Experimental|duloxetine study drug|Drug
9773610|NCT00981149|Placebo Comparator|Placebo|Placebo
9773611|NCT00981175|Experimental|Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo|Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
9773612|NCT00981175|Experimental|Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine|Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
9773613|NCT00981214|Experimental|EUR-1008 (APT-1008)|
9773614|NCT00981227|Experimental|ESL 400 mg twice-daily|ESL 400 mg twice-daily
9773615|NCT00981227|Experimental|ESL 800 mg once-daily|ESL 800 mg once-daily
9773616|NCT00981227|Experimental|ESL 600 mg twice daily|ESL 600 mg twice daily
9773617|NCT00981227|Experimental|ESL 1200 mg once daily|ESL 1200 mg once daily
9773618|NCT00981227|Experimental|ESL 800 mg twice daily|ESL 800 mg twice daily
9773619|NCT00981227|Placebo Comparator|placebo|placebo
9773620|NCT00981253|Experimental|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation with weekly stress management training for 12 weeks.
9773621|NCT00981253|Active Comparator|Standard Cardiac Rehabilitation|Standard cardiac rehabilitation consisting of supervised exercise for 12 weeks.
9773622|NCT00981292|Active Comparator|135mg EGCG|
9773623|NCT00981292|Active Comparator|270mg EGCG|
9773624|NCT00981292|Placebo Comparator|0mg EGCG|
9773625|NCT00981305|Experimental|Lactate-containing Vaginal Lubricant|apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
9773626|NCT00981305|Placebo Comparator|Placebo|apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
9773627|NCT00981409|Experimental|Fondaparinux|
9773628|NCT00981409|Other|unfractionated heparin|
9773629|NCT00981435|Experimental|Artificial Tears|Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
9773630|NCT00981435|Experimental|Non-steroidal anti-inflammatory|Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
9773631|NCT00981435|Experimental|Steroid|Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
9773632|NCT00981461|Active Comparator|LLT Device 2009 9 Beam|HairMax LaserComb
9773633|NCT00981461|Sham Comparator|control device|control device
9773634|NCT00981474|Active Comparator|Control|Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
9773635|NCT00981474|Experimental|Intervention|Blood pressure management based on cerebral autoregulation data.
9773636|NCT00981526|Experimental|A: Telmisartan|(existing Clozapine or Olanzapine treatment) + (Telmisartan)
9773637|NCT00981526|Placebo Comparator|B: Placebo|(existing Clozapine or Olanzapine treatment) + (Placebo)
9773638|NCT00981578|Experimental|ExAblate 2100 Treatment|ExAblate 2100 ablation for the treatment of painful bone metastases.
9773639|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 1|Participants received ChimeriVax™-JE (Japanese Encephalitis) a dose of 3.0 log10 Plaque-forming units (PFU) on Day 0.
9773640|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 2|Participants received ChimeriVax™-JE a dose of 4.0 log10 PFU on Day 0.
9773641|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 3|Participants received ChimeriVax™-JE a dose of 5.0 log10 PFU on Day 0.
9773642|NCT00981630|Placebo Comparator|Placebo|Participants received ChimeriVax diluent, 0.5 mL on Day 0.
9773643|NCT00981669|Experimental|rotavirus vaccine|3 doses with 6 weeks interval
9773644|NCT00981669|Placebo Comparator|placebo|3 doses with 6 weeks interval
9773645|NCT00981682|Experimental|SER120 (desmopressin)|
9773646|NCT00981747|Experimental|All study participants|Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).
9773647|NCT00981799|Experimental|Nelarabine Dose Level 1|The study will begin at Dose Level 1 at 480 mg/m2 Nelarabine (75% of single agent maximum tolerated dose) and 330 mg/m2 Cyclophospamide and will escalate to the next Dose Level if the maximum tolerated dose (MTD) is not exceeded. The first 3 patients will be enrolled into Dose Level 1. If 0/3 experiences dose limiting toxicity (DLT) at a given dose level, then the dose is escalated to the next higher level and 3 more patients are enrolled. If 1/3 experiences DLT at current dose, the up to 3 more patients are accrued at the same dose level. If 2 or more DLTs are observed in a 3-patient or 6-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to 3 additional patients will be enrolled at the next lower dose level (unless 6 patients have already been treated at that prior dose). If the MTD is exceeded at Dose Level 0, the study will be closed.
9773648|NCT00981799|Experimental|Nelarabine Dose Level 2|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 330 mg/m2 Cyclophosphamide.
9773649|NCT00981799|Experimental|Nelarabine Dose Level 3|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 400 mg/m2 Cyclophosphamide
9773650|NCT00981799|Experimental|Nelarabine Dose Level 0|Patients in this arm will be administered Nelarabine 325 mg/m2 (50% of single agent MTD) and 330 mg/2 Cyclophosphamide. Patients will only enter this arm if the MTD at Dose Level 1 has been exceeded. If the MTD is exceeded at Dose Level 0, the study will be closed.
9773651|NCT00981812|Experimental|PEM Breast Biopsy|All patients underwent PEM biopsy.
9773652|NCT00981825|Placebo Comparator|A|fluoride toothpaste control
9773653|NCT00981825|Active Comparator|B|triclosan/fluoride toothpaste
9773654|NCT00982007|Experimental|Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
9773655|NCT00982007|Active Comparator|Cohort 1 (Group B) - Ferrous Sulfate|Oral iron - Ferrous Sulfate tablets
9773656|NCT00982007|Active Comparator|Cohort 2 (Group D) - IV Iron (standard of care)|Other IV iron
9773657|NCT00982007|Experimental|Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
9773658|NCT00982020|Experimental|Olanzapine/standard behavioral weight intervention|
9773659|NCT00982020|Experimental|Olanzapine/intense behavioral weight intervention|
9773660|NCT00982033|Active Comparator|Aliskiren|50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.
9773661|NCT00982033|Placebo Comparator|Placebo|50% of subjects will be randomized to placebo.
9773662|NCT00982072|Active Comparator|prednisolone|prednisolone tablets
9773663|NCT00982072|Experimental|tacrolimus|tacrolimus tablets
9773664|NCT00982137|Experimental|ChimeriVax™-JE then STAMARIL®|Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
9773665|NCT00982137|Experimental|STAMARIL® then ChimeriVax™-JE|Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
9773666|NCT00982137|Experimental|ChimeriVax™-JE and STAMARIL®, then Diluent|Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
9773667|NCT00982137|Experimental|Diluent then ChimeriVax™-JE and STAMARIL®|Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
9773668|NCT00982189|Experimental|Lisinopril|Lisinopril 10mg once daily
9773669|NCT00982189|Placebo Comparator|Lisinopril Placebo|Placebo pill (matched to lisinopril) once daily
9773670|NCT00982189|Experimental|Pravastatin|Pravastatin 20mg once daily
9773671|NCT00982189|Placebo Comparator|Pravastatin placebo|Placebo pill (matched to pravastatin) once daily
9773672|NCT00982228|Experimental|IDeg OD|
9773673|NCT00982228|Active Comparator|IGlar OD|
9773674|NCT00982280|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
9773675|NCT00982319|Experimental|Broccoli sprout extract|Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
9773676|NCT00982319|Placebo Comparator|Mango juice|Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
9773677|NCT00982345|Other|Open label Quetiapine|Open-label Quetiapine XL 50 - 400 mg daily treatment 8 weeks
9773678|NCT00982397|Experimental|Single-chamber detetction|Patients implanted with a Protecta VR-ICD.
9773679|NCT00982397|Experimental|Dual-chamber detection|Patients implanted with a Protecta DR-ICD or CRT-D.
9773680|NCT00982410|Experimental|Arm 1|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
9773681|NCT00982410|Placebo Comparator|Arm 2|educational supportive group
9773682|NCT00982423|Experimental|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
9773683|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Chronic phase|Participants with chronic phase disease continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID).
9773684|NCT00982488|Other|Imatinib, 400 mg BID, Chronic phase|Participants with chronic phase disease received 400 mg of imatinib twice BID.
9773685|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, AP|Participants with advanced phase disease, accelerated phase (AP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
9773686|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, MBP|Participants with advanced phase disease, myeloid blast cell (MBP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
9773687|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, Ph+ ALL|Participants with advanced phase disease, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
9773688|NCT00982553|Experimental|Phase 1_ribavirin|Treatment with Single dose ribavirin (800 mg) administered on day 1
9773689|NCT00982553|Experimental|Phase2_raltegravir|Treatment with Raltegravir (400 mg twice daily) administered from days 15-19
9773690|NCT00982553|Experimental|Phase3_ribavirin+raltegravir|Treatment with Ribavirin (800 mg) and Raltegravir (400 mg) administered day 20
9773691|NCT00982592|Experimental|Arm I (FOLFOX regimen and placebo)|Patients receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil bolus and then IV over 46-48 hours on day 1. Patients also receive placebo PO QD on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
9773692|NCT00982592|Experimental|Arm II (FOLFOX regimen and vismodegib)|Patients receive FOLFOX chemotherapy as in arm I. Patients also receive vismodegib PO on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
9773693|NCT00982644|Experimental|IDeg OD|
9773694|NCT00982644|Active Comparator|IGlar OD|
9773695|NCT00982657|Experimental|Cohort 1|CVX-060 + sunitinib
9773696|NCT00982657|Experimental|Cohort 2|CVX-060 + sunitinib
9773697|NCT00982657|Experimental|Cohort 3|CVX-060 + sunitinib
9773698|NCT00982657|Experimental|Expanded cohort|CVX-060 + sunitinib
9773699|NCT00982657|Experimental|Phase II - Arm A|CVX-060 + sunitinib
9773700|NCT00982657|Active Comparator|Phase II - Arm B|sunitinib alone
9773701|NCT00982865|Experimental|MSC1936369B Regimen 1|Subjects will be administered MSC1936369B (pimasertib) capsules 1 to 120 milligram (mg) orally, once daily (QD) on Days 1 to 5, 8 to 12, 15 to 19 of each 21-day treatment cycle until progressive disease (PD) or intolerable toxicity or investigator/subject decision.
9773702|NCT00982865|Experimental|MSC1936369B Regimen 2|"MSC1936369B Regimen 2 (Without Food Effect): Subjects will be administered MSC1936369B capsules 1 to 255 mg orally QD on Days 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.~MSC1936369B Regimen 2 (With Food Effect): : Subjects will be administered MSC1936369B capsules 90 or 150 mg orally QD on Day 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. Subjects in the Regimen 2 FE cohort were assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Day 1 of Cycle 2."
9773703|NCT00982865|Experimental|MSC1936369B Regimen 3 once daily|Subjects will be administered MSC1936369B capsules 60 to 90 mg orally QD in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
9773704|NCT00982865|Experimental|MSC1936369B Regimen 3 twice daily (BID)|Subjects will be administered MSC1936369B capsules 45 to 75 mg orally BID in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
9773705|NCT00982878|Experimental|Maraviroc|
9773706|NCT00982930|Experimental|Tobramycin Inhalation Powder (TIP)|Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.
9773707|NCT00983073|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
9773708|NCT00983216|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
9773709|NCT00983216|Experimental|Colchicine with Steady-State Ketoconazole|-colchicine pharmacokinetics in presence of steady-state ketoconazole
9773710|NCT00983242|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
9773711|NCT00983242|Experimental|Colchicine with Verapamil HCl ER|colchicine pharmacokinetics in presence of steady-state verapamil
9773712|NCT00983281||Hextend|Patients that received Hextend as part of their fluid resuscitation.
9773713|NCT00983281||Standard of Care|Patients that received standard fluid resuscitation but no Hextend.
9773714|NCT00983294|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
9773715|NCT00983294|Experimental|Colchicine with steady-state Azithromycin|colchicine pharmacokinetics in presence of steady-state azithromycin
9773716|NCT00983307|Experimental|Erlotinib and radiotherapy|Patients will be treated with Erlotinib and hypofractionated radiotherapy.
9773717|NCT00983346|Experimental|All patients|All participants enrolled.
9773718|NCT00983359|Experimental|Treatment (conformal stereotactic radiation therapy)|Patients undergo conformal stereotatic radiation
9773719|NCT00983372|Active Comparator|Colchicine alone|-colchicine baseline pharmacokinetics
9773720|NCT00983372|Experimental|Colchicine with steady-state Diltiazem|-colchicine pharmacokinetics in presence of steady-state diltiazem
9773721|NCT00983385|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol immediate release (IR) tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
9773722|NCT00983476|Experimental|Arm 1|in-person MOVE! SMI
9773723|NCT00983476|Experimental|Arm 2|web-based MOVE! SMI
9773724|NCT00983476|No Intervention|Arm 3|usual care + educational handouts regarding weight loss
9773725|NCT00983489|Active Comparator|counselling|counselling: Breast feeding counselling will be done to mothers
9773726|NCT00983489|Active Comparator|Video demonstration|Video demonstration to mothers on the advantages of exclusive breast feeding
9773727|NCT00983489|No Intervention|Standard Care|Standard care includes the routine care provided to the neonates as per hospital protocol
9773728|NCT00983515|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
9773729|NCT00983515|Experimental|Colchicine with Ritonavir|-colchicine pharmacokinetics in presence of steady-state ritonavir
9773730|NCT00983541|Experimental|All patients|All participants enrolled.
9773731|NCT00983580|Experimental|Arm I (acetylsalicylic acid and eflornithine)|Patients receive acetylsalicylic acid PO once daily and eflornithine PO twice daily on days 1-28.
9773732|NCT00983580|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO three times daily on days 1-28.
9773733|NCT00983619|Experimental|Part A-MEDI-551 0.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773734|NCT00983619|Experimental|Part A-MEDI-551 1 mg/kg|Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773735|NCT00983619|Experimental|Part A-MEDI-551 2 mg/kg|Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773736|NCT00983619|Experimental|Part A-MEDI-551 4 mg/kg|Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773737|NCT00983619|Experimental|Part A-MEDI-551 8 mg/kg|Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9784690|NCT01231620|Experimental|Intravenous (IV) Zanamivir 600mg Twice Daily|600mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
9773738|NCT00983619|Experimental|Part A-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773739|NCT00983619|Experimental|Part B-MEDI-551 6 mg/kg|Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773740|NCT00983619|Experimental|Part B-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773741|NCT00983619|Experimental|Part B-MEDI-551 24 mg/kg|Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
9773742|NCT00983619|Experimental|Part C-MEDI-551 8 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
9773743|NCT00983619|Experimental|Part C-MEDI-551 12 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
9773744|NCT00983619|Experimental|Part D-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.
9773745|NCT00983749|Experimental|Full-pressure ECP|"Patients in the Full-pressure ECP arm receive a 1-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner up to 300mmHg, while assessments are made."
9773746|NCT00983749|Sham Comparator|Sham-pressure ECP|A 1-hour treatment of ECP at an inactive pressure (75mmHg)
9773747|NCT00983801|Experimental|Ixabepilone|
9773748|NCT00983827|Experimental|Aquatic treadmill training|Aquatic treadmill training (ATT) is a pool-based treadmill training that combines the three concepts of unweighting the body, treadmill training, and the resistance effects of water into one modality.
9773749|NCT00983853|Experimental|Part A|The dose of ribavirin used (fixed versus weight-based) is region dependent
9773750|NCT00983853|Experimental|Part B|The dose of ribavirin used (fixed versus weight-based) is region dependent
9773751|NCT00983892|Experimental|CarePartners+|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
9773752|NCT00983892|No Intervention|CarePartners-|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').
9773753|NCT00983905|Active Comparator|Theophylline alone|baseline theophylline kinetics
9773754|NCT00983905|Experimental|Theophylline with steady-state Colchicine|theophylline pharmacokinetics upon administration with colchicine at steady-state
9773755|NCT00983918|Active Comparator|Desflurane|General Anesthesia with Desflurane
9773756|NCT00983918|Active Comparator|Sevoflurane|General Anesthesia with Sevoflurane
9773757|NCT00983918|Active Comparator|Isoflurane|General Anesthesia with Isoflurane
9773758|NCT00983918|Active Comparator|Propofol|General Anesthesia with Propofol
9773759|NCT00983931|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
9773760|NCT00983931|Experimental|Colchicine with Cyclosporine|-colchicine pharmacokinetics in presence of cyclosporine
9773761|NCT00983957|Experimental|BMS-790052 plus Ortho Tri-Cyclen®|
9773762|NCT00983983|Experimental|High fat/high calorie|High fat/high calorie diet: Oxepa
9773763|NCT00983983|Active Comparator|High calorie|High calorie diet: Jevity 1.5
9773764|NCT00983983|Placebo Comparator|Control|Control diet: Jevity 1.0
9773765|NCT00984009|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
9773766|NCT00984009|Experimental|Colchicine with Grapefruit Juice|colchicine pharmacokinetics in presence of grapefruit juice
9773767|NCT00984022|Active Comparator|Iodoform dressing|Iodoform dressing for cutaneous abscess
9773768|NCT00984022|Active Comparator|Aquacel dressing|Aquacel dressing for cutaneous abscess
9773769|NCT00984061|Experimental|colchicine alone|colchicine baseline pharmacokinetics
9773770|NCT00984061|Experimental|colchicine with clarithromycin|colchicine pharmacokinetics in presence of clarithromycin
9773771|NCT00984126|Experimental|Turoctocog alfa|
9773772|NCT00984139|Experimental|Engerix-B Group|Subjects who were vaccinated with 3 doses of Engerix-B in infancy and who received a single challenge dose of Engerix-B , intramuscularly in the deltoid region of the non-dominant arm, at 12-13 years of age (Day 0).
9773773|NCT00984165|Experimental|Donor Lymphocyte Infusion/Radiation|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).
9773774|NCT00984165|Active Comparator|Radiation/No Donor Lymphocyte Infusion|Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).
9773775|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Control|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.
9773776|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Donor|Healthy subjects who donated lymphocytes for infusion on a treatment Arm.
9773777|NCT00984204|Experimental|Treatment arm|
9773778|NCT00984256|Experimental|Drug|"5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge"
9773779|NCT00984256|Placebo Comparator|Control -no prophylaxis|
9773780|NCT00984282|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle
9773781|NCT00984282|Placebo Comparator|Placebo|Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle
9773782|NCT00984295|Experimental|1|ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
9773783|NCT00984295|Experimental|2|ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
9773784|NCT00984295|Active Comparator|3|Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)
9773785|NCT00984308|Experimental|Intervention|The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed
9773786|NCT00984308|Other|Control|The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services
9773787|NCT00984334|Placebo Comparator|Capsules with no active drug|Placebo capsules once daily for three weeks then twice daily for three weeks.
9773788|NCT00984334|Active Comparator|Naloxone SR 2.5 mg capsules|Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
9773789|NCT00984334|Experimental|Naloxone SR 10mg capsules|Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
9773790|NCT00984334|Experimental|Naloxone SR 20 mg capsules|Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
9773791|NCT00984334|Experimental|Naloxone SR 5mg capsules|Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
9773792|NCT00984542|Experimental|Bendamustine|
9773793|NCT00984568|Experimental|Top-Hold|Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
9773794|NCT00984568|Active Comparator|Step-Up|Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
9773795|NCT00984594|Other|Primary injury site|CR-Plug will be placed in the site of the primary injury
9773796|NCT00984594|Other|Backfill site|Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site
9784691|NCT01231620|Active Comparator|Oral Oseltamivir 75mg Twice Daily|75mg oral oseltamivir twice daily plus intravenous placebo zanamivir twice daily
9773797|NCT00984620|Experimental|short arm|patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
9773798|NCT00984620|Experimental|long arm|patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
9773799|NCT00984659|Experimental|FSC|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
9773800|NCT00984659|Experimental|SAL|Salmeterol 50mcg DISKUS twice a day
9773801|NCT00984659|Placebo Comparator|Placebo|Placebo DISKUS twice a day
9773802|NCT00984698|Experimental|Structured Therapy|Cognitive Behavioral Social Rhythm Group Therapy is designed to improve mood and sleep by stabilizing social rhythms, increasing exposure to ambient light, changing dysfunctional bed/bedtime associations, activating the imagery system by changing nightmare content, and challenging dysfunctional automatic thoughts that might contribute to behavioral inactivation and nonadherence to the therapy protocol. There is no discussion of past traumatic events.
9773803|NCT00984698|Active Comparator|Unstructured Therapy|Present Centered Group Therapy includes education about the typical symptoms and features associated with PTSD and MDD, with a focus on how these symptoms affect interpersonal relationships. It uses the group format to decrease isolation, normalize symptoms, and provide the experience of giving and receiving support. Some relaxation training is provided early in therapy. There is no discussion of past traumatic events.
9773804|NCT00984815|Experimental|HZT-501|Open-label treatment with HZT-501
9773805|NCT00984867|Active Comparator|1|Dapagliflozin 10 mg tablet
9773806|NCT00984867|Placebo Comparator|2|Matching placebo tablet
9784692|NCT01231633|Experimental|Group 1|Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
9784693|NCT01231633|Active Comparator|Group 2|Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
9784694|NCT01231646||Lamotrigine|No intervention
9784695|NCT01231646||Valproate|No intervention
9784696|NCT01231659|Experimental|Everolimus + Letrozole|All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.
9784697|NCT01231841|Experimental|rATG + Cyclosporine|Patients receive anti-thymocyte globulin IV daily over 4-24 hours on days 1-5. Beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. Treatment continues in the absence of disease progression or unacceptable toxicity
9784698|NCT01231906|Experimental|Arm A (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV over 1-15 minutes (or as per institutional policies up to 60-minutes) on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 1 and 9."
9784699|NCT01231906|Experimental|Arm B (combination chemotherapy, topotecan hydrochloride)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-30 minutes on days 1-5 in weeks 1 and 9, and over 30-60 minutes on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm A; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and over 30-60 minutes on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 13 and 19."
9784700|NCT01231984|Experimental|4 mm vs. 8 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
9784701|NCT01231984|Experimental|4 mm vs. 12.7 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 12.7mm x 29G Pen Needle (PN) for 12 weeks (Period 1), then switched to the alternate PN for another 12 weeks (Period 2). Order of PN use was randomly determined.
9784702|NCT01232127|Other|Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI|The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
9784703|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
10203908|NCT04742036|Experimental|capivasertib|single-dose and multiple-dose capivasertib as monotherapy (Part A) and then in combination with paclitaxel (Part B)
10203909|NCT04740515|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
10203910|NCT04740515|No Intervention|usual care only|Patients were provided with usual care.
10203911|NCT04736472|Experimental|DPYD/UGT1A1 pharmacogenetic testing|"All patients will be screened for twelve single nucleotide polymorphisms (SNPs) in DPYD: DPYD*2A, *5, *6, *8, *9A, *10, *12, *13, rs2297595, rs115232898, rs67376798, HapB3.~All patients will be screened for two SNPs in UGT1A1: UGT1A1*6, *28."
10203912|NCT04733079|Experimental|E-mail follow-up group|Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging
10203913|NCT04733079|Active Comparator|Usual follow-up group|Adaptation and follow-up of ULT according to referring physician's habits
9773807|NCT00985088|Experimental|GSK2340274A F1_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
9773808|NCT00985088|Experimental|GSK2340274A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
9773809|NCT00985088|Experimental|GSK2340274A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
9773810|NCT00985088|Experimental|GSK2340274A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
9773811|NCT00985088|Experimental|GSK2340273A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
9773812|NCT00985088|Experimental|GSK2340273A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
9773813|NCT00985088|Experimental|GSK2340273A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. Subjects above (>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm.
9773814|NCT00985088|Experimental|GSK2340273A F3_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
9773815|NCT00985114|Experimental|Device|EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
9773816|NCT00985114|Active Comparator|Diet + Lifestyle counseling|Multidisciplinary lifestyle and nutritional counseling for 12 months
9773817|NCT00985140||12 Gy TSEBT|Prospective assignment to receive 12 Gy total skin electron beam therapy (TSEBT) for mycosis fungoides
9773818|NCT00985153|Experimental|1|ProQuad Lot 1
9773819|NCT00985153|Experimental|2|ProQuad Lot 2
9773820|NCT00985153|Experimental|3|ProQuad Lot 3
9773821|NCT00985153|Active Comparator|4|M-M-R II + Varivax
9773822|NCT00985166|Experimental|1|ProQuad + Placebo
9773823|NCT00985166|Active Comparator|2|M-M-R II + Placebo
9773824|NCT00985166|Active Comparator|3|M-M-R II + Varivax
9773825|NCT00985192|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity
9773826|NCT00985231|Experimental|PureVision Multi-Focal contact lenses|
9773827|NCT00985231|Active Comparator|SofLens59 contact lens|
9773828|NCT00985257|Other|Subjects with diabetes|Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
9773829|NCT00985426|Experimental|HEPLISAV-B|0.5 mL HEPLISAV-B and 0.5 mL Placebo
9773830|NCT00985426|Active Comparator|Engerix-B|2.0 mL Engerix-B
9773831|NCT00985439|Experimental|Diclofenac Test (lower dose)|One 18-mg Diclofenac Test Capsule and 1 placebo capsule
9773832|NCT00985439|Experimental|Diclofenac Test (upper dose)|One 35-mg Diclofenac Test Capsule and 1 placebo capsule
9773833|NCT00985439|Active Comparator|Celecoxib 400 mg|
9773834|NCT00985439|Placebo Comparator|Placebo|
9773835|NCT00985465|Experimental|Pn-Pn group|subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
9773836|NCT00985465|Experimental|Zil-Pn group|subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
9773837|NCT00985491|Experimental|Device|All patients will be implanted with the Endobarrier Liner device.
9773838|NCT00985504|Experimental|Duloxetine|
9773839|NCT00985504|Active Comparator|Escitalopram|
9773840|NCT00985517|Experimental|Phase 1: Cohort 1|CERE-120 9.4 x 10^11 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
9773841|NCT00985517|Experimental|Phase 1: Cohort 2|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
9773842|NCT00985517|Experimental|Phase 2: CERE-120|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
9773843|NCT00985517|Sham Comparator|Phase 2: Sham Surgery|Neurosurgical procedure that mimics the procedure for CERE-120 delivery. No injections were administered during sham surgery.
9773844|NCT00985543|Active Comparator|LPV/r 400/100 mg|Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
9773845|NCT00985543|Experimental|LPV/r 200/150 mg|Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
9773846|NCT00985543|Experimental|LPV/r 200/50 mg|Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)
9773847|NCT00985621|Experimental|1|
9773848|NCT00985621|Experimental|2|
9773849|NCT00985621|Active Comparator|3|
9773850|NCT00985621|Placebo Comparator|4|
9773851|NCT00985673|Experimental|Flulaval/placebo/unadjuvanted Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
9773852|NCT00985673|Experimental|Flulaval/placebo/Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
9773853|NCT00985673|Experimental|Flulaval/unadjuvanted Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
9773854|NCT00985673|Experimental|Flulaval/Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
9773855|NCT00985673|Experimental|Unadjuvanted Arepanrix/placebo/Flulaval Group|subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
9773856|NCT00985673|Experimental|Arepanrix/placebo/Flulaval Group|subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
9773857|NCT00985686|Experimental|Study Arm|Arm where participants began the LEAP Project intervention upon recruitment for an 8 week period.
9773858|NCT00985686|Active Comparator|Waitlist Arm|"Arm where participants received the LEAP Project intervention after an 8 week wait period.~At 8 weeks, the results from the wait-list arm (no intervention) were compared to the results of the study arm (intervention completed)."
9773859|NCT00985712|Experimental|HumaPen Luxura|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks
9773860|NCT00985712|Experimental|HumaPen Memoir|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks
9773861|NCT00985725|Experimental|Active|SPD489
9773862|NCT00985725|Placebo Comparator|Placebo|Placebo
9773863|NCT00985751|Experimental|Group 1|
9773864|NCT00985751|Experimental|Group 2|
9773865|NCT00985751|Experimental|Group 3|
9773866|NCT00985751|Experimental|Group 4|
9773867|NCT00985751|Experimental|Control Group|
9773868|NCT00985790|Experimental|GSK2321138A Group|"Subjects aged between 18 and 47 months received the GSK2321138A. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm."
9784704|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
9773869|NCT00985790|Active Comparator|Fluarix Group|"Subjects aged between 18 and 47 months received the Fluarix™ vaccine. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm."
9773870|NCT00985829|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
9773871|NCT00985907|Experimental|Doxil® + Melphalan + Velcade (DMV)|
9773872|NCT00985946|Experimental|panobinostat|This is a single arm trial. All patients will take panobinostat
9773873|NCT00985959|Experimental|Phase I: JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
9773874|NCT00985959|Experimental|Phase I: JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
9773875|NCT00985959|Experimental|Phase I: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
9773876|NCT00985959|Experimental|Phase II: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
9773877|NCT00985985|Experimental|2mg nicotine lozenge|2 mg nicotine lozenge
9773878|NCT00985985|Placebo Comparator|2 mg placebo|2 mg placebo
9773879|NCT00985985|Experimental|4 mg nicotine lozenge|4 mg nicotine lozenge
9773880|NCT00985985|Placebo Comparator|4 mg placebo|4 mg placebo
9773881|NCT00986102|Other|001|doripenem 500mg vial by injection every 8 hours for 5 to 14 days
9773882|NCT00986154|Experimental|heparin/edoxaban tosylate|
9773883|NCT00986154|Active Comparator|heparin/warfarin|
9773884|NCT00986180|Experimental|001|NUCYNTA 50 75 or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
9773885|NCT00986180|Active Comparator|002|Oxycodone IR 5 10 or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
9773886|NCT00986232|Experimental|1|ProQuad (low dose)
9773887|NCT00986232|Experimental|2|ProQuad (middle dose)
9773888|NCT00986232|Experimental|3|ProQuad (high dose)
9773889|NCT00986232|Active Comparator|4|M-M-R II + PUVV
9773890|NCT00986245|Active Comparator|Ropinirole PR QD first, then BID|Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
9773891|NCT00986245|Active Comparator|Ropinirole PR BID first, and then QD|Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing
9773892|NCT00986258|Experimental|Tapentadol Prolonged Release|"Other Names:~Nucynta~Palexia"
9773893|NCT00986349|Experimental|Diabetes|Single Arm
9773894|NCT00986362|Experimental|Ocriplasmin|
9773895|NCT00986362|Placebo Comparator|Placebo|
9773896|NCT00986401|Experimental|Glucophage® then Sanctura XR® (AB)|Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.
9773897|NCT00986401|Experimental|Sanctura XR® then Glucophage® (BA)|Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.
9773898|NCT00986427|Active Comparator|1|Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
9773899|NCT00986427|Placebo Comparator|2|Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
9773900|NCT00986440|Experimental|CS-7017|
9773901|NCT00986440|Placebo Comparator|Placebo|Placebo matching CS-7017
9773902|NCT00986453|Experimental|PlasmaBlade arm|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
9773903|NCT00986453|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
9773904|NCT00986479|Experimental|AZD6765 (150 mg) / Placebo|Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period.
9773905|NCT00986479|Placebo Comparator|Placebo / AZD6765 (150 mg)|Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period.
9773906|NCT00986544|Sham Comparator|Absence of drain|
10203914|NCT04732520|Experimental|Treatment|Patients participating in the treatment group will undergo pulsed electric field (PEF) treatment of a single NSCLC nodule measuring 1 to 4 cm by CT, using the Aliya System. The treatment may be performed endoluminally in conjunction with a diagnostic bronchoscopy, or percutaneously.
9773907|NCT00986544|Active Comparator|Drain|drain positioned in the subhepatic space after laparoscopic cholecystectomy
9773908|NCT00986570|Experimental|Xeomin®|Botulinum Toxin A
9773909|NCT00986583|Other|Statin use group|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
9773910|NCT00986583|Other|non statin use|Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
9784705|NCT01232205|Active Comparator|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
9773911|NCT00986674|Experimental|Arm I (carboplatin, paclitaxel, cetuximab)|Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
9773912|NCT00986674|Experimental|Arm II (carboplatin, paclitaxel, cixutumumab)|Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
9773913|NCT00986674|Experimental|Arm III (carboplatin, paclitaxel, cetuximab, cixutumumab)|Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II.
9773914|NCT00986830|Experimental|Balloon Dilation|Balloon dilation of the maxillary sinuses using the FinESS Sinus Treatment device.
9773915|NCT00986856|Experimental|Fucidin® cream|
9773916|NCT00986856|Placebo Comparator|Fucidin® cream vehicle|
9773917|NCT00986921|Experimental|mifepristone|women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
9773918|NCT00986921|Active Comparator|Osmotic dilator insertion|Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure
9773919|NCT00986973|Experimental|Sapropterin (KUVAN)|All subjects will receive Sapropterin (KUVAN) therapy at a dose of 20/mk/kg/day for four months.
9773920|NCT00986986|Experimental|Active Drug (extended release niacin)|Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
9773921|NCT00986986|No Intervention|Observation|Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
9773922|NCT00987337|Experimental|Arm A|"Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
9773923|NCT00987337|Experimental|Arm B|"Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
9773924|NCT00987337|Placebo Comparator|Arm C|Placebo + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks
9773925|NCT00987389|Experimental|Plasma Exchange with Standard Glucocorticoids|Participants in this arm undergo plasma exchange and take a standard glucocorticoid dose.
9773926|NCT00987389|Active Comparator|No Plasma Exchange with Standard Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a standard glucocorticoid dose.
9773927|NCT00987389|Experimental|Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm undergo plasma exchange and take a reduced glucocorticoid dose.
9773928|NCT00987389|Active Comparator|No Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a reduced glucocorticoid dose.
9773929|NCT00987402|Active Comparator|Plain soap and water|Surgical hand preparation with plain soap and water
9773930|NCT00987402|Active Comparator|Alcohol based hand rubs|Surgical hand preparation with alcohol based alcohol hand rub
9773931|NCT00987415|Active Comparator|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
9773932|NCT00987415|Placebo Comparator|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
9773933|NCT00987467|Experimental|Cyclosporine 0.05% ophthalmic|cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control
9773934|NCT00987480|Experimental|chemotherapy-based cytoreductive regimen plus a CD34+ selected|This phase II trial is designed to investigate the safety and efficacy of a chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease.
9773935|NCT00987558|Experimental|Treatment Sequence A|Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period
9773936|NCT00987558|Experimental|Treatment Sequence B|Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period
9773937|NCT00987623|Experimental|nelfilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
9773938|NCT00987623|Active Comparator|narafilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
9773939|NCT00987727|Experimental|1|carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
9773940|NCT00987727|Active Comparator|2|sodium hyaluronate 0.18% (VISMED® Multi)
9773941|NCT00987831|Experimental|Blood drawing only Group C|Healthy controls, age, sex and ethnicity matched to the active study participants were recruited for two time blood donation as controls for the biomarker studies
9784706|NCT01232205|Placebo Comparator|Control|
9784707|NCT01232296|Experimental|TKI258|capsule
9784708|NCT01232296|Experimental|Sorafenib|tablet
9773942|NCT00987831|Experimental|Group A SLE prospective study|In Group A SLE patients enter with active disease. Any immune suppressant (e.g. methotrexate, azathioprine or mmf) is withdrawn and after blood drawing, depomedrol up to 160 mg IM is given. This may be repeated for a maximum of 160mg up to four times total in the first two weeks. Depomedrol is expected to last 1-3 months, serial biomarkers will be drawn until time of flare, at which time biomarkers will be drawn, patient is defined as meeting endpoint and new treatment initiated. Patients may elect to continue to donate blood samples per protocol up to one year.
9773943|NCT00987831|Experimental|Group B SLE one blood donation|SLE patients who meet the same entry criteria as Group A could elect to donate blood one time and not to continue in the prospective protocol. No extra intervention was performed other than blood draw and medical records review. This allowed an extension of cross sectional comparisons between biomarker changes related to background treatments by combining Group A baseline data with Group B data.
9773944|NCT00987935|Experimental|Nintedanib (BIBF 1120)|Phase I dose escalation and phase II using dose determined in phase I
9773945|NCT00987935|Active Comparator|Sorafenib|Twice daily dosing in phase II
9773946|NCT00987948|Experimental|Maraviroc|
9773947|NCT00988000|Other|Agree to the alternative study invitation|Agree with alternative of telephone consultation (instead of face to face) offered as an initial consultation to new referrals
9773948|NCT00988000|Other|Decline the alternative study invitation|Decline, no respond to the alternative of telephone consultation
9773949|NCT00988000|Other|Comparator|Choose and book
9773950|NCT00988013|Experimental|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day (total of 3Gy).
9773951|NCT00988013|Experimental|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days (for a total of 6Gy).
9773952|NCT00988013|Experimental|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days (for a total of 9Gy).
9773953|NCT00988013|Experimental|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days (for a total of 12Gy).
9773954|NCT00988065|Experimental|Sugammadex 4 mg/kg|Participants were to receive one dose of sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
9773955|NCT00988065|Experimental|Sugammadex 16 mg/kg|Participants were to receive one dose of sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
9773956|NCT00988065|Placebo Comparator|Placebo|Participants were to receive one dose of placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
9773957|NCT00988091|Placebo Comparator|IA-SA|Each participant received a single intra-articular (IA) injection of buffered saline (SA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they could receive a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and be followed for an additional 26 weeks.
9773958|NCT00988091|Experimental|IA-BioHA|Each participant received a single intra-articular (IA) injection of 1.2% sodium hyaluronate (BioHA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they received a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and were followed for an additional 26 weeks.
9773959|NCT00988117|Experimental|Rivastigmine Patch 9.5 cm2|
9773960|NCT00988143|Experimental|Study Group 1|Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)
9773961|NCT00988143|Active Comparator|Study Group 2|Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)
9773962|NCT00988143|Active Comparator|Study Group 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV)
9773963|NCT00988156|Active Comparator|Eslicarbazepine acetate|To receive Eslicarbazepine acetate in addition to concomitant therapy
9773964|NCT00988156|Placebo Comparator|Placebo|To receive placebo in addition to concomitant therapy
9773965|NCT00988169|Experimental|oral erlotinib and pulsed doses of oral AT-101|This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.
9773966|NCT00988208|Experimental|Docetaxel, Prednisone, Lenalidomide (DPL)|25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
9773967|NCT00988208|Experimental|Docetaxel and Prednisone (DP)|Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
9773968|NCT00988221|Experimental|Tocilizumab 10 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
9773969|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
9773970|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
9773971|NCT00988221|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks.
9773972|NCT00988325|Experimental|Oseltamivir 3 mg|infants 3 to <12 months
9773973|NCT00988325|Experimental|Oseltamivir 2.5 mg|infants 1 to <3 months of age
9773974|NCT00988325|Experimental|Oseltamivir 2 mg|infants 0 to 30 days (post natal) of age
9773975|NCT00988351|Active Comparator|PSG CPAP titration then CPAP treatment|Patients diagnosed with sleep apnea will have a continuous positive airway pressure (CPAP) titration with polysomnography (PSG) followed by continuous positive airway pressure (CPAP) Treatment
9773976|NCT00988351|Active Comparator|Auto-Adjusting Positive Airway Pressure|Following diagnosis of obstructive sleep apnea patients will be have auto-adjusting positive airway pressure treatment without a titration.
9773977|NCT00988429|Active Comparator|800 mg QD Eslicarbazepine acetate|tablets
9773978|NCT00988429|Active Comparator|1200 mg QD Eslicarbazepine acetate|tablets
9773979|NCT00988429|Placebo Comparator|Placebo|tablets
9773980|NCT00988442|Experimental|Enhanced nursing telephone support with standard care|Participants received enhanced nursing telephone support plus care as usual.
9773981|NCT00988442|Active Comparator|Standard care|Participants received care as usual.
9773982|NCT00988533|Experimental|0.5% Ivermectin Cream|
9773983|NCT00988559|Experimental|PMED Delivery - groups 1 and 2|Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
9773984|NCT00988559|Experimental|IM injections - groups 5 and 6|Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
9773985|NCT00988559|Experimental|Intralesional delivery - group 3 and 4|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
9773986|NCT00988559|Experimental|Intralesional delivery + imiquimod - group 7|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
9773987|NCT00988598|Active Comparator|PF-04447943|
9773988|NCT00988598|Placebo Comparator|Placebo|
9773989|NCT00988637|Other|1) Vectical™ Ointment and Clobex® Spray|Vectical™ Ointment weekdays & Clobex® Spray weekends regimen
9773990|NCT00988637|Other|2) Clobex® Spray and Vectical™ Ointment|Clobex® Spray morning and Vectical™ Ointment evening regimen
9773991|NCT00988832||Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
9773992|NCT00988858|Experimental|LY2603618 and Pemetrexed|
9773993|NCT00988884|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
9773994|NCT00988884|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
9773995|NCT00989014|Experimental|CD07805/47 0.5% Topical Gel|0.5% Topical Gel
9773996|NCT00989014|Experimental|CD07805/47 0.18% Topical Gel|0.18% Topical Gel
9773997|NCT00989014|Experimental|CD07805/47 0.07% Topical Gel|0.07% Topical Gel
9773998|NCT00989014|Placebo Comparator|CD07805/47 Vehicle Topical Gel|Vehicle Topical Gel
9773999|NCT00989092|Other|Observational Group|Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
9774000|NCT00989092|Active Comparator|21 week treatment group|Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.
9774001|NCT00989157|Experimental|Active drug|All subjects received drug. Single arm.
9774002|NCT00989196|Experimental|Human-cl rhFVIII|
9774003|NCT00989196|Active Comparator|Kogenate FS|
9774004|NCT00989235|Active Comparator|Abatacept (10 mg/Kg)|
9774005|NCT00989235|Active Comparator|Abatacept (5 mg/Kg)|
9774006|NCT00989261|Experimental|Cohort 1; ≥60 years of age|"Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission <12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
9774007|NCT00989261|Experimental|Cohort 2; ≥18 years of age|"Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
9774008|NCT00989287|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9774009|NCT00989287|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9774010|NCT00989573|Placebo Comparator|Placebo|oral administration of placebo once-daily for 8weeks
9774011|NCT00989573|Experimental|OPC-6535 25 mg|oral administration of OPC-6535 25 mg once-daily for 8 weeks
9774012|NCT00989573|Experimental|OPC-6535 50 mg|oral administration of OPC-6535 50mg once-daily for 8 weeks
9774013|NCT00989586|Experimental|Phase I|Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
9774014|NCT00989586|Experimental|Phase II|Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
9774015|NCT00989612|Experimental|GSK2340274A GROUP|Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9774016|NCT00989664|Experimental|open-label single arm|Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
9774017|NCT00989768|Experimental|Botulinum toxin type - A|Dysport® compared to Botox®
9774018|NCT00989781|Experimental|PCOS women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
9774019|NCT00989781|Experimental|Normal women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
9774020|NCT00989833|Active Comparator|A|budesonide 400yg + terbutaline 0.4 mg as-needed
9774021|NCT00989833|Active Comparator|B|placebo + terbutaline 0.4 mg as-needed
9774022|NCT00989833|Active Comparator|C|placebo + budesonide/formoterol 160/4.5 yg as-needed
9774023|NCT00989911|Experimental|Bosentan|Bosentan
9774024|NCT00989950|Experimental|Daytrana 9 hr wear|
9774025|NCT00989950|Experimental|Daytrana 10 hr wear|
9774026|NCT00989950|Experimental|Daytrana 11 hr wear|
9774027|NCT00989950|Experimental|Daytrana 12 hr wear|
9774028|NCT00989963|Experimental|Maximum Tolerated Dose (MTD)|Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.
9774029|NCT00989963|Experimental|Low Fixed Dose|The low dose group will receive 60µg twice a day(b.i.d.)
9774030|NCT00989963|Experimental|High Fixed Dose|Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,
9774031|NCT00989989|Experimental|Adjunctive treatment|Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.
9774032|NCT00989989|Experimental|Monotherapy treatment|Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.
9774033|NCT00989989|Active Comparator|Laser control|Active laser treatment plus sham intravitreal injections.
9784709|NCT01232452|Experimental|Pemetrexed + Cisplatin + Cixutumumab|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
9784710|NCT01232452|Active Comparator|Pemetrexed + Cisplatin|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
9784711|NCT01232465||IVF|those individuals undergoing conventional IVF to inseminate their retrieved eggs
9784712|NCT01232465||ICSI|those individuals whose eggs were fertilized via intracytoplasmic sperm injection (ICSI)
9784713|NCT01232491|Active Comparator|Control|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
9784714|NCT01232491|Experimental|Dietician|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects received dietary consultation according to local standard during 3 face-to-face meetings and 3 phone contacts. Insulin doses were individually adjusted.
9784715|NCT01232504|Experimental|rhGM-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
9784716|NCT01232504|Active Comparator|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
9774034|NCT00990093|Experimental|test intermittent catheter|CH 12 hydrophilic coated catheter
9774035|NCT00990093|Experimental|intermittent catheter|CH 12 hydrophilic coated catheter
9774036|NCT00990106|Active Comparator|prazosin hydrochloride|"prazosin Pfizer Minipress~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
9774037|NCT00990106|Placebo Comparator|placebo|"placebo~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
9774038|NCT00990184|Experimental|Colesevelam Hydrochloride|
9774039|NCT00990236|Active Comparator|Enoxaparin 30 mg BID|standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
9774040|NCT00990236|Experimental|Enoxaparin dose adjusted based on TEG|enoxaparin dose modified based on TEG results
9774041|NCT00990249|Experimental|Busulfan + Clofarabine + Stem Cell Transplant|"Busulfan test dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.~Clofarabine 40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors.~Stem cell infusion on Day 0."
9774042|NCT00990288|Experimental|Hemostatic Matrix|2 vials of Floseal applied once at the end of surgery
9774043|NCT00990288|No Intervention|Control|No intervention.
9774044|NCT00990314|Experimental|B.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, B.I.D (twice a day dosing)
9774045|NCT00990314|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, q.i.d (four times a day dosing)
9774046|NCT00990340|Active Comparator|Tev-Tropin® needle-free|needle-free injection method (T-jet®)for 14 days before cross-over to other arm
9774047|NCT00990340|Active Comparator|Tev-Tropin® by Needle-syringe|needle-syringe injection method for 14 days before cross-over to other arm
9774048|NCT00990509|Experimental|Albumin|
9774049|NCT00990509|Placebo Comparator|Placebo|
9774050|NCT00990561|Active Comparator|Twice Daily Ultravate|Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
9774051|NCT00990561|Active Comparator|Once daily Ultravate|Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
9774052|NCT00990652|Experimental|Bortezomib + Temozolomide|Patients receive an injection of bortezomib 1.7mg/m^2 on days 1, 4 and 8. Patients then undergo their standard of care surgery on day 8 or 9 to remove the tumor. Once recovered from surgery, patients receive combination treatment with temozolomide and bortezomib in periods called cycles (1 cycle = 28 days). Temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle, and bortezomib injections are given on days 7 and 21 of each cycle.
9774053|NCT00990665|Experimental|CRT-D and LV lead|
9774054|NCT00990704|Experimental|Paricalcitol|2 mcg adjusted by +/- 1 mcg, up to a maximum of 7 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
9774055|NCT00990704|Active Comparator|Maxacalcitol|5 or 10 mcg adjusted by +/- 2.5 mcg, up to a maximum of 20 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
9774056|NCT00990769|Experimental|"High-normal BIS (Lighter anesthesia)"|Depth of anesthesia is titrated to a BIS of 55-60
9774057|NCT00990769|Experimental|"Low-normal BIS (Deeper anesthesia)"|Depth of anesthesia is maintained at a BIS level of 40-45
9774058|NCT00990782|Experimental|Single Arm|PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.
9774059|NCT00990821|Experimental|Part I, Panel A|100 mg MK-0517 (nonpolysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant
9774060|NCT00990821|Experimental|Part I, Panel B|100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant
9774061|NCT00990821|Experimental|Part I, Panel C|40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant
9774062|NCT00990821|Experimental|Part II|2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam
9774063|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 1|125 mg aprepitant → 90 mg MK-0517 (PS80)
9774064|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 2|40 mg MK-0517 (non-PS80) → 125 mg aprepitant
9774065|NCT00990821|Experimental|Part III, Panel 2|40 mg MK-0517 (non-PS80)
9774066|NCT00990821|Experimental|Part IV|40 mg MK-0517 (non-PS80 formulation)
9774067|NCT00990821|Experimental|Part V, Treatment Sequence 1|125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)
9774068|NCT00990821|Experimental|Part V, Treatment Sequence 2|100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant
9774069|NCT00990821|Experimental|Part V, Treatment Sequence 3|115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)
9774070|NCT00990821|Experimental|Part V, Treatment Sequence 4|125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)
9774071|NCT00990821|Experimental|Part V, Treatment Sequence 5|100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)
9774072|NCT00990821|Experimental|Part V, Treatment Sequence 6|115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant
9774073|NCT00990938|Placebo Comparator|Saline|If randomized to placebo the patient will receive a subcutaneous injection once per week for 4 weeks
9774074|NCT00990938|Experimental|IMO-2125|If randomized to receive the experimental treatment, IMO-2125, the patient will receive a subcutaneous injection once per week for 4 weeks
9774075|NCT00991029|Active Comparator|clopidogrel|Patients assigned to clopidogrel in addition to aspirin
9774076|NCT00991029|Placebo Comparator|placebo|Patients assigned to placebo in addition to aspirin
9774077|NCT00991081|Active Comparator|Standard treatment|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling.~A self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail~A standard 8-week course of genetically-tailored pharmacotherapy~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~Participants with the A2 allele (CC) were assigned to receive bupropion"
9774078|NCT00991081|Experimental|Genetic feedback plus standard treatment|"In addition to the standard treatment, participants in this arm received the following interventions:~Genetic feedback, verbal - During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment~Genetic feedback, printed - After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype"
9774079|NCT00991276|Experimental|pregabalin|
9774080|NCT00991276|Placebo Comparator|placebo|
9774081|NCT00991276|Active Comparator|pramipexole|
9774082|NCT00991289|Experimental|NTZ/PEG/RBV|Participants received nitazoxanide (NTZ) alone for 4 weeks followed by 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment.
9774083|NCT00991302|Experimental|CAP-IT|"Participants received the modified CAP-IT adherence intervention in addition to standard care.~Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)"
9774084|NCT00991302|No Intervention|Standard care|Participants received standard care.
9774085|NCT00991341|Active Comparator|Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
9774086|NCT00991341|Active Comparator|Longer-storage red blood cell units|Red blood cell units stored >= 21 days
9774087|NCT00991406|Experimental|Arm 1: FES|Case-control study: pre- and post-stimulation (FES).
9774088|NCT00991458|Experimental|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
9774089|NCT00991458|Experimental|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
9774090|NCT00991458|Placebo Comparator|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
9774091|NCT00991510|Experimental|Reference/Test/Test|"The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
9774092|NCT00991510|Experimental|Test/Reference/Reference|"The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
9774093|NCT00991809|Experimental|Alfentanil|Subjects received a series of acute alfentanil administrations each session (15 mcg/kg IM per session), with sessions spaced at 3-4 day intervals.
9774094|NCT00991809|Active Comparator|Diphenhydramine|Subjects received a series of acute diphenhydramine administrations each session (25 mg IM per session), with sessions spaced at 3-4 day intervals.
9774095|NCT00991939|Experimental|High dose pulse dexamethasone|
9774096|NCT00991939|Active Comparator|Standard prednisone therapy|
9774097|NCT00991952|Experimental|Arm A (irinotecan hydrochloride, alvocidib)|Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9774098|NCT00991952|Active Comparator|Arm B (irinotecan hydrochloride)|Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9774099|NCT00992017|Experimental|H1N1 vaccine|Pregnant women enrolled received two doses of H1N1 vaccine, administered 21 days apart.
9774100|NCT00992056|Experimental|Metoprolol/Nebivolol|Metoprolol/Nebivolol: Metoprolol 50 mg titrated to 100 mg then nebivolol 5 mg titrated to 10 mg
9774101|NCT00992056|Experimental|Nebivolol/Metoprolol|Metoprolol 50 mg titrated to 100 mg then Nebivolol 5 mg titrated to 10 mg
9774102|NCT00992108|Active Comparator|Lidocaine|lidocaine injection group
9774103|NCT00992108|Experimental|Botulinum|
9774104|NCT00992186|Experimental|Carlumab|
9774105|NCT00992225|Experimental|LY573636-sodium|
9774106|NCT00992264|Experimental|Message Tone|"Prescriptive or Motivational~Persons are randomized to receive intervention content written in either a prescriptive or motivational tone."
9774107|NCT00992264|Experimental|Testimonials|Persons are randomized to receive a personally tailored testimonial or not.
9774108|NCT00992264|Experimental|Navigation|"Dictated or Non-Dictated~Persons are randomly assigned to be able to freely navigate the website or to have their navigation of the website pre-determined based on their baseline readiness to quit smoking."
9774109|NCT00992264|Experimental|Proactive Outreach|"Email or No-Email communication~Persons are randomized to receive periodic email reminders to return to the intervention website or not."
9774110|NCT00992394|Other|Arm 1|Subjects randomized to arm 1 stop their etanercept treatment on entry into the study and may be retreated by etanercept 50 mg once weekly after medical review and agreement between the subject and the investigator
9774111|NCT00992394|Other|Arm 2|Subjects randomized to arm 2 in which subjects continue on treatment with etanercept at 25 mg once weekly, but with the option to have their drug treatment increased to 50 mg once weekly after medical review and agreement between the subject and the investigator
9774112|NCT00992407|Experimental|Risperidone long acting injectables|
9774113|NCT00992407|Active Comparator|Risperidone tablets|
9774114|NCT00992433|Experimental|Group 2, 30 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
9774115|NCT00992433|Experimental|Group 1, 15 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.
9774116|NCT00992446|Experimental|Treatment (chemotherapy, ASCT, bortezomib, vorinostat))|All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
9774117|NCT00992459|Experimental|Buphenyl (NaPBA) /HPN 100 Placebo|Subjects in Arm A were randomly assigned to receive NaPBA + HPN 100 placebo for 2 weeks and then crossed over to receive HPN 100 + NaPBA Placebo for 2 weeks.
9774118|NCT00992459|Experimental|HPN-100/NaPBA Placebo|Subjects in Arm B were randomly assigned to receive HPN-100 + NaPBA placebo for 2 weeks and then crossed over to receive NaPBA + HPN 100 placebo for 2 weeks.
9774119|NCT00992511|Experimental|GSK2340272A New 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
9774120|NCT00992511|Experimental|GSK2340272A New 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9774121|NCT00992511|Experimental|GSK2340272A INI 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
9774122|NCT00992511|Experimental|GSK2340272A INI 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the Initial process-manufactured (INI 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
9774123|NCT00992589|Experimental|Rabeprazole sodium 5 mg|
9774124|NCT00992589|Experimental|Rabeprazole sodium 10 mg|
9774125|NCT00992589|Placebo Comparator|Placebo|
9774126|NCT00992602|Experimental|Treatment (liposomal cytarabine, high-dose methotrexate)|See Detailed Description
9774127|NCT00992719|Active Comparator|Group 3: Non-pregnant Women: 15 mcg H1N1 Vaccine|100 non-pregnant women to receive 15 mcg inactivated H1N1 vaccine.
9774128|NCT00992719|Experimental|Group 2: Pregnant Women: 30 mcg H1N1 Vaccine|100 pregnant women to receive 30 mcg inactivated H1N1 vaccine.
9774129|NCT00992719|Experimental|Group 1: Pregnant Women: 15 mcg H1N1 Vaccine|100 pregnant women to receive 15 mcg inactivated H1N1 vaccine.
9774130|NCT00992784|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
10203915|NCT04732520|No Intervention|Control|Patients declining to participate in the treatment arm may self-select to participate in an observational control arm.
9774131|NCT00992784|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
9774132|NCT00992784|Active Comparator|Fluarix young Group|Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine
9774133|NCT00992836|Experimental|Influenza A (H1N1) 2009 monovalent vaccine|All participants received two doses of the H1N1 influenza virus vaccine, administered 21 days apart.
9774134|NCT00992927|Experimental|CPIHD|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
9774135|NCT00992927|Active Comparator|CRIHD|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
9774136|NCT00992992|Experimental|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Tositumomab and Iodine I 131 Tositumomab followed by CHOP
9774137|NCT00993031|Experimental|Group A|ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
9774138|NCT00993031|Active Comparator|Group B|ZDV 300mg/3TC 150mg/EFV 600mg
9774139|NCT00993044|Experimental|Single Arm|
9774140|NCT00993148|Experimental|Maraviroc plus darunavir/ritonavir|Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
9774141|NCT00993187|Experimental|Sitagliptin/Metformin FDC|Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
9784717|NCT01232504|Active Comparator|rhG-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
9784718|NCT01232556|Experimental|1|Inotuzumab ozogamicin+rituximab
10203916|NCT04728282|Experimental|RTSA with subscapularis repair|
10203917|NCT04728282|Active Comparator|RTSA without subscapularis repair|
10203918|NCT04722926||PJI|Patients having had a PJI
9774142|NCT00993187|Active Comparator|Glimepiride|Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.
9774143|NCT00993200|Active Comparator|Warfarin, control|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by usual care dosing.
9774144|NCT00993200|Experimental|Warfarin: PERMIT|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by warfarin pharmacogenetic dosing (warfarin dosing using genetic information incorporated into the PERMIT algorithm).
9774145|NCT00993226|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
9774146|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
9774147|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
9774148|NCT00993226|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
9774149|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
9774150|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
9774151|NCT00993265|Experimental|N-acetylcysteine (NAC)|Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated to 2400 mg. They will receive NAC in addition to the medication regimen they are on at enrollment.
9774152|NCT00993265|Placebo Comparator|Placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
9774153|NCT00993291|No Intervention|Baseline frequency|Baseline DBS frequency
9774154|NCT00993317|Placebo Comparator|Placebo of CDP870+MTX|
9774155|NCT00993317|Experimental|CDP870 200mg+MTX|
9774156|NCT00993421|Placebo Comparator|placebo|
9774157|NCT00993421|Experimental|LY377604 (75 mg)|
9774158|NCT00993421|Active Comparator|sibutramine (30 mg)/metoprolol (200 mg)|
9774159|NCT00993421|Experimental|LY377604 (40 mg)/sibutramine (30 mg)|
9774160|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (30 mg)|
9774161|NCT00993421|Experimental|LY377604 (15 mg)/sibutramine (30 mg)|
9774162|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (15 mg)|
9774163|NCT00993473|Experimental|Lantus (insulin glargine)|Lantus given as basal insulin once a day in the morning by subcutaneous injection
9774164|NCT00993473|Active Comparator|NPH insulin|Neutral Protamine Hagedorn (NPH) human insulin given as basal insulin either once or twice per day generally in the morning and /or at bedtime by subcutaneous injection
9774165|NCT00993499|Experimental|BIBW 2992 + Sirolimus|Dose escalation of the combination BIBW 2992 plus Sirolimus.
9774166|NCT00993616|Experimental|Treatment|Patients receive belinostat IV over 30 minutes on days 1-5 and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are clinically responding or who, in the opinion of their physician, would continue to benefit from treatment may continue treatment beyond 6 courses.
9774167|NCT00993655|Active Comparator|IV carboplatin + IV paclitaxel|ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
9774168|NCT00993655|Active Comparator|IP cisplatin + IV/IP paclitaxel|ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)
9774169|NCT00993655|Active Comparator|IP carboplatin + IV/IP paclitaxel|ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles
9774170|NCT00993668|Placebo Comparator|Placebo|Placebo
9774171|NCT00993668|Experimental|Cimzia|Certolizumab pegol
9774172|NCT00993798|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
9774173|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
9774174|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
9774175|NCT00993798|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
9774176|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
9774177|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
9774178|NCT00993824|Placebo Comparator|Welchol then Placebo|3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
9774179|NCT00993824|Placebo Comparator|Placebo then Welchol|Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
9774180|NCT00993915||Main group|Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications
9774181|NCT00993928|Experimental|Arm A: Home-based sleep intervention with Device #1|Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
9774182|NCT00993928|Active Comparator|Arm B: Home-based sleep intervention with Device #2|Participants will listen to a pre-recorded mp3 device #2 before retiring to sleep. At the end of the study, participants assigned to pre-recorded mp3 device #2 will be offered pre-recorded mp3 device #1 for their own use.
9774183|NCT00993954|Experimental|Nurse Reduction|Patients randomized to reduction by nurse.
9774184|NCT00993954|Active Comparator|Physician Reduction|Patients randomized to treatment by Emergency Department Physician in traditional ED manner
9774185|NCT00993967|Experimental|Idebenone|1350 mg/day or 2250 mg/day for patients weighing ≤45 kg or >45 kg, respectively.In case of poor tolerability, dose reduction to 450 mg/day or 900 mg/day, respectively, were allowed.
9774186|NCT00994110|Experimental|SOM230|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
9774187|NCT00994110|Placebo Comparator|placebo|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
9774188|NCT00994123|Experimental|Phase 1: Dose-Escalation|Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
9774189|NCT00994123|Active Comparator|Phase 2: Control|Erlotinib (daily)
9774190|NCT00994123|Experimental|Phase 2: Treatment|MM-121 (QOW IV) and erlotinib (daily PO)
9774191|NCT00994175|Experimental|Pioglitazone, Then Placebo|Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.
9774192|NCT00994175|Experimental|Placebo, Then Pioglitazone|Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.
9774193|NCT00994214|Experimental|BIM 23A760 1 mg|
9774194|NCT00994214|Experimental|BIM 23A760 2 mg|
9774195|NCT00994214|Experimental|BIM 23A760 4 mg|
9774196|NCT00994214|Experimental|BIM 23A760 6 mg|
9774197|NCT00994240|Active Comparator|ED&C times 3 cycles|
9774198|NCT00994240|Active Comparator|ED & C times 1 cycle|
9774199|NCT00994279|Active Comparator|Arm 1: Yoga Intervention|Yoga Intervention
9774200|NCT00994279|Active Comparator|Arm 2: Educational Wellness Group|Educational Wellness Group
9774201|NCT00994318|Experimental|FCM (high ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
9774202|NCT00994318|Experimental|FCM (low ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
9774203|NCT00994318|Active Comparator|Oral Iron|Ferrous sulphate 100 mg iron twice daily, continuous
9774204|NCT00994422|Experimental|0.5% ivermectin cream|
9774205|NCT00994422|Placebo Comparator|vehicle control|
9774206|NCT00994448|Experimental|Bupropion|
9774207|NCT00994448|Placebo Comparator|Placebo (sugar pill)|
9774208|NCT00994461|Experimental|Celecoxib|
9774209|NCT00994461|Active Comparator|Loxoprofen|
9774210|NCT00994461|Placebo Comparator|Placebo|
9774211|NCT00994604|Experimental|broccoli sprout extract|This a before and after treatment study. The subjects will consumer broccoli sprout extract (BSE) for two weeks (14d). Lung function and Chest CT will be performed before and after BSE consumption.
9774212|NCT00994643|Experimental|Treatment (Interleukin Therapy, Monoclonal Antibody)|Patients receive interleukin-2 SC twice weekly and rituximab IV once weekly in weeks 5-8 and 25-28. Courses repeat every 4 weeks for up to 7 months in the absence of disease progression or unacceptable toxicity.
9774213|NCT00994682|Active Comparator|Pioglitazone|After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
9774214|NCT00994682|Placebo Comparator|Placebo|After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
9774215|NCT00994760||GENISIS|
9774216|NCT00994890|Experimental|Tanezumab 2.5 mg|
9774217|NCT00994890|Experimental|Tanezumab 5 mg|
9774218|NCT00994890|Experimental|Tanezumab 10 mg|
9774219|NCT00994929|Experimental|Neumega (Oprelveken, Interleukin 11)|Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
9774220|NCT00995007|Active Comparator|Group 2|Sequential Group (carboplatin followed by vandetanib)
9774221|NCT00995007|Active Comparator|Group 1|Combo Group (both drugs together)
9774222|NCT00995020|Experimental|SWETZ|The intervention administered in this arm is the straight wire excision of the transformation zone, a electrosurgical method to perform a cone biopsy using a 1 cm straight wire of 0.20 mm wire. The activated wire is used in much the same way as a cold knife or laser beam fashioning the surgical specimen to achieve two centimeters cm at cervical canal..
9774223|NCT00995020|Active Comparator|LLETZ cone|The intervention administered in this arm is the large loop excision of transformation zone as a cone biopsy, performed using a large loop electrode of 2 cm depth, applied to the cervix to achieving two centimeters at cervical canal .
9774224|NCT00995072|Experimental|Arm A|Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
9774225|NCT00995072|Experimental|Arm B|Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
9774226|NCT00995085|Experimental|Metadoxine SR|Metadoxine is a pyrolate salt of Pyridoxine
9774227|NCT00995215|Experimental|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
9774228|NCT00995345|Experimental|Dose 1: KRP-104 40 mg|Tablet, once-daily for 24 weeks
9774229|NCT00995345|Experimental|Dose 2: KRP-104 80 mg|Tablet, once-daily for 24 weeks
9774230|NCT00995345|Experimental|Dose 3: KRP-104 100 mg|Tablet, once-daily for 24 weeks
9774231|NCT00995345|Experimental|Dose 4: KRP-104 20/120mg|Tablet, once-daily for 24 weeks (dose switch from 20 to 120 mg at week 12)
9774232|NCT00995345|Placebo Comparator|Placebo|Tablet, once-daily for 24 weeks
9774233|NCT00995371|Active Comparator|Vertos mild® Minimally-Invasive Lumbar Decompression|Patients in the Vertos mild® treatment group will be treated by appropriately trained physicians in accordance with the product labeling and indications for use.
9774234|NCT00995371|Active Comparator|Epidural Steroid Injection|Patients in the Epidural Steroid Injection (ESI) group will have ESI performed by appropriately trained physicians in accordance with product labeling and indications for use.
9774235|NCT00995410|Experimental|PA32540 tablet|325 mg enteric coated (EC) ASA and 40 mg omeprazole to be taken by mouth once daily
9774236|NCT00995436|Active Comparator|Extraoral anchorage|The intervention is the placement of Headgear, to be worn 100 hours per week
9774237|NCT00995436|Active Comparator|Miniscrews|The intervention is the of miniscrews to supplement anchorage
9774238|NCT00995436|Active Comparator|Nance palatal arch|Anchorage supplemented by Nance palatal arch fixing molars together with an arch
9774239|NCT00995449|Experimental|KB003 70 mg|
9774240|NCT00995449|Experimental|KB003 200 mg|
9774241|NCT00995449|Experimental|KB003 600 mg|
9774242|NCT00995449|Placebo Comparator|Placebo|
9774243|NCT00995475|Experimental|Inhaled corticosteroid, Then placebo|FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks. After a washout period of 2 weeks, they then received FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks.
9784719|NCT01232556|Active Comparator|2|Investigator's choice of (1) rituximab+gemcitabine, or (2) rituximab+bendamustine
9784720|NCT01232569|Experimental|Tocilizumab 162 mg sc|Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
9774244|NCT00995475|Placebo Comparator|Placebo control, Then inhaled corticosteroid|FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks. After a washout period of 2 weeks, they then received FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks.
9774245|NCT00995488|Experimental|ABI-007|ABI-007 combined with Carboplatin, and Gemcitabine
9774246|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
9774247|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
9774248|NCT00995501|Active Comparator|Intensive Glucose Control, placebo, Light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
9774249|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
9774250|NCT00995501|Active Comparator|Intensive Glucose Control, Placebo, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
9774251|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
9774252|NCT00995501|Active Comparator|Conventional Glucose Control, Placebo, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
9774253|NCT00995501|Placebo Comparator|Conventional Glucose Control, Placebo, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
9784721|NCT01232569|Placebo Comparator|Placebo sc|Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
9784722|NCT01232738|Experimental|rasagiline|Treated for 12 months with rasagiline 2mg orally, once daily.
9784723|NCT01232790|Experimental|Group A: Intervention/Placebo|Group A first receives the commercially available sustained release form of N-acetylcysteine, then the matching placebo capsules both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
9784724|NCT01232790|Placebo Comparator|Group B: Placebo/Intervention|Group B first receives the placebo and then receives a commercially available sustained release form of N-Acetylcysteine. In each arm, the capsules are both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
9774254|NCT00995553|Experimental|Cognitive Remediation|A 48-session working memory focused cognitive remediation program is conducted. Training tasks have been selected from 3 software programs, PSS CogRehab, BrainTrain, and custom made N-back tasks.
9774255|NCT00995553|Placebo Comparator|Computer Skills|This is a 48-session, time matched comparison group in which participants practice keyboarding skills and the fundamentals of Microsoft Office Word, Powerpoint, and Excel programs.
9774256|NCT00995566||Thelin Registry Patients|
9774257|NCT00995670|Experimental|Sevoflurane and Glucose|"Endothelial function will be measured via forearm blood flow (FBF). Subjects may get I/R injury (ischemia) without glucose or sevoflurane (placebo); I/R with glucose only (glucose trial); I/R with sevoflurane only (sevo trial); I/R with glucose and sevoflurane (combo trial). Baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Glucose: 5% dextrose will be infused at 12 ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 1 hr to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent I/R injury.~Sevoflurane: 1 minimum alveolar concentration (MAC) for 20 min (after 1 hr glucose and before I/R) 26 volunteers were studied 67 times in this arm."
9774258|NCT00995670|Experimental|Vitamin C and Glucose|"To determine if vitamin C can restore the impairment of the endothelium (FBF) caused by the glucose (dextrose infusion). All subjects received glucose and I/R injury (ischemia), either with or without vitamin C. Control baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Vitamin C: 1 gm iv bolus injection 5 min before I/R injury 16 volunteers were studied 25 times in this arm."
9774259|NCT00995670|Experimental|Statins and Glucose|"Volunteers ingested a 40 mg simvastatin (statin) pill for the two evenings prior to study day and the morning of the study to determine the effect of simvastatin on modulating the I/R injury during hyperglycemia (high glucose). Volunteers were studied with statin alone and with statin and glucose.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Statin: 40 mg of simvastatin 17 volunteers were studied 31 times in this arm."
9774260|NCT00995709|Experimental|AIN457C 300 mg every 2 week dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
9774261|NCT00995709|Experimental|AIN457C 300 mg monthly dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
9774262|NCT00995709|Placebo Comparator|Placebo|Placebo was administered in 2 s.c. injections every 2 weeks
9774263|NCT00995722|Experimental|Prednisone + Pyridostigmine|Corticosteroid
9774264|NCT00995722|Placebo Comparator|Placebo + Pyridostigmine|Matched, inactive substance
9774265|NCT00995761|No Intervention|biweekly schedule|docetaxel 40mg/m2 on day 1,15 every 4weeks cisplatin 40mg/m2 on day 1,15 every 4weeks
9774266|NCT00995774|Experimental|Robotic then Conventional|robotic arm therapy first, conventional therapy second
9774267|NCT00995774|Experimental|Conventional then Robotic|conventional therapy first, robotic therapy second
9774268|NCT00995865|Active Comparator|High dose|
9774269|NCT00995865|Active Comparator|Mid Dose|
9774270|NCT00995865|Placebo Comparator|Placebo|NaCl Injectable 0.9%
9774271|NCT00995904|Experimental|Treatment A, then Treatment B, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
9774272|NCT00995904|Experimental|Treatment A, then Treatment C, then Treatment B|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
9774273|NCT00995904|Experimental|Treatment B, then Treatment A, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
9774274|NCT00995904|Experimental|Treatment B, then Treatment C, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
9774275|NCT00995904|Experimental|Treatment C, then Treatment A, then Treatment B|"Study visits were separated by 3-7 day intervals.~Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4"
9774276|NCT00995904|Experimental|Treatment C, then Treatment B, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
9774277|NCT00995930|Placebo Comparator|Placebo|subcutaneous (SQ) monthly
9774278|NCT00995930|Experimental|ACZ885|150 mg SQ monthly
9774279|NCT00996034|Experimental|Healthy Smoker|There is only one arm to the study. All subjects will receive NicVax, [123I]5-I-A-85380,and Nicotine bitartrate.
9774280|NCT00996125|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
9774281|NCT00996125|Experimental|Placebo Group|Subjects received 3 doses of placebo. Placebo vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
9774282|NCT00996164|Experimental|flibanserin 100 mg|flibanserin 100mg po qd
9774283|NCT00996164|Placebo Comparator|Placebo|placebo 1 tab po qd
9774284|NCT00996203|Experimental|1|
9774285|NCT00996216|Experimental|Open-label eltrombopag|Open-label eltrombopag with dose titrations to support adequate platelet counts.
9774286|NCT00996281|Experimental|Azilsartan Medoxomil and Chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks.~For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg."
9774287|NCT00996281|Active Comparator|Olmesartan Medoxomil and Hydrochlorothiazide QD|"Participants in the United States:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg.~Participants in Europe:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg."
9774288|NCT00996307|Experimental|3.75_(50)MF59|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
9774289|NCT00996307|Experimental|7.5_(0)MF59|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
9774290|NCT00996307|Experimental|7.5_(50)MF59|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
9774291|NCT00996307|Experimental|15_(0)MF59|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
9774292|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 1|"Arm 1, Level 1: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 15 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
9774293|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 2|"Arm 1, Level 2: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 20 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
9774294|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 2, Level 1|"Arm 1, Level 2: Irinotecan intravenously at 50 mg/m2 + Temsirolimus intravenously at 25 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
9774295|NCT00996372|Experimental|flibanserin 100mg|flibanserin 100mg po qd
9774296|NCT00996372|Placebo Comparator|placebo|placebo one tablet po qd
9774297|NCT00996437|Placebo Comparator|Saline Injection|Saline injection at baseline, 4 and 8 weeks
9774298|NCT00996437|Active Comparator|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
9774299|NCT00996476|Experimental|TMC12/PR24 50 mg|Participants received TMC435 50 mg once daily with PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24 Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
9774300|NCT00996476|Experimental|TMC12/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
9774301|NCT00996476|Experimental|TMC24/PR24 50 mg|Participants received TMC435 50 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435, PR) at Week 24. All other participants continued PR until Week 48.
9774302|NCT00996476|Experimental|TMC24/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
9774303|NCT00996476|Experimental|PR48 Control|Participants received PegIFNa-2a and ribavirin (PR) for 48 weeks (PR48 control group)
9774304|NCT00996489|Experimental|Coaptite|
9774305|NCT00996580|Experimental|DR-103|"Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;~21 days combination therapy of 25 mcg EE/150 mcg LNG followed by;~21 days combination therapy of 30 mcg EE/150 mcg LNG followed by;~7 days of 10 mcg EE."
9774306|NCT00996593|Experimental|open-label, single arm|
9774307|NCT00996606|Experimental|Tocilizumab in Active RA|Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.
9774308|NCT00996632|Experimental|A|Patients were operated using an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
9774309|NCT00996632|Active Comparator|B|Patients were operated using a conventional diarthermy knife
9774310|NCT00996658|Experimental|Linagliptin|Linagliptin tablets once daily
9774311|NCT00996658|Placebo Comparator|Placebo|Placebo tablets once daily
9774312|NCT00996736|Active Comparator|Topical Natamycin|
9774313|NCT00996736|Experimental|Topical Voriconazole|
9774314|NCT00996775|Active Comparator|standard care only|standard care only - harmful effects of alcohol use and NIAAA limits
9774315|NCT00996775|Experimental|Brief alcohol intervention|Group receiving brief alcohol intervention
9774316|NCT00996801|Placebo Comparator|Placebo|Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
9774317|NCT00996801|Experimental|MK-5442 5 mg|Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
9774318|NCT00996801|Experimental|MK-5442 7.5 mg|Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
9774319|NCT00996801|Experimental|MK-5442 10 mg|Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
9774320|NCT00996801|Experimental|MK-5442 15 mg|Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
9774321|NCT00996801|Active Comparator|Alendronate 70 mg|Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
9774322|NCT00996840|Experimental|Cohort 1 - SB-681323 Intravenous 3mg|3mg SB-681323 Intravenous administration, infused over 4 hours
9774323|NCT00996840|Experimental|Cohort 2 - SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
9774324|NCT00996840|Experimental|Cohort 3 - SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
9774325|NCT00996840|Experimental|Cohort 4 - SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
9774326|NCT00996840|Experimental|Combined Placebo|Placebo to match intervention
9774327|NCT00996892|Experimental|Dose Escalation Stage 1: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams [mg]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
9774328|NCT00996892|Experimental|Dose Escalation Stage 1A: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
9774329|NCT00996892|Experimental|Dose Escalation Stage 1B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
9774330|NCT00996892|Experimental|Dose Expansion Stage 2: Cobimetinib + Pictilisib|Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
9774331|NCT00996892|Experimental|Dose Expansion Stage 2A: Cobimetinib + Pictilisib|Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.
9774332|NCT00996892|Experimental|Dose Expansion Stage 2B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.
9774333|NCT00996918|Experimental|Bapineuzumab 0.5 mg/kg|bapineuzumab
9774334|NCT00996918|Experimental|Bapineuzumab 1.0 m/kg|bapineuzumab
9774335|NCT00996931|Experimental|Lenalidomide|
9774336|NCT00996944|Experimental|Ropinirole IR|
9774337|NCT00996944|Placebo Comparator|Placebo|
9774338|NCT00996996|Experimental|open-label, single arm|Tositumomab and Iodine I 131 Tositumomab
9774339|NCT00997035|Active Comparator|Oral Voriconazole|
9774340|NCT00997035|Placebo Comparator|Placebo|
9774341|NCT00997113|Active Comparator|Propofol|propofol only for deep procedural sedation
9774342|NCT00997113|Active Comparator|Propofol/alfentanil|Propofol with alfentanil for deep procedural sedation
9774343|NCT00997126|Active Comparator|Propofol|Propofol 1m g/kg IV followed by 0.5 mg/kg IV prn sedation
9774344|NCT00997126|Active Comparator|Alfentanil|Sedation using alfentanil 10 ug/kg followed by 5 ug/kg prn sedation
9774345|NCT00997204|Experimental|Icatibant- Naive Treatment Phase|Single subcutaneous injection of icatibant, 30 mg
9774346|NCT00997204|Experimental|icatibant- Self administration Phase|Single subcutaneous injection of icatibant, 30 mg
9774347|NCT00997243|Experimental|5-azacytidine and Lintuzumab|"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC(subcutaneous)daily on days 1-7.~Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7."
9774348|NCT00997321|Active Comparator|Propofol|propofol 1 milligram per kilogram intravenous bolus followed by 0.5 millligrams per kilogram as needed for mooderate procedural sedation
9774349|NCT00997321|Active Comparator|Ketamine|ketamine 1 milligram per kilogram followed by 0.5 millgram per kilogram as needed for moderate procedural sedation
9774350|NCT00997334|Experimental|Erlotinib|Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.
9774351|NCT00997373|Experimental|Letrozole|letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
9774352|NCT00997373|No Intervention|control|no treatemtn prior to hysterectomy
9774353|NCT00997425|Experimental|Door Cover/Floor Cover|Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)
9774354|NCT00997438|Experimental|MS - Secondary Progressive|1200 mg of Lipoic acid supplement
9774355|NCT00997438|Experimental|MS - Relapsing Remitting|1200mg of Lipoic acid supplement
9774356|NCT00997438|Experimental|Healthy Controls|1200 mg of Lipoic acid supplement
9774357|NCT00997516|Experimental|SILS appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
9774358|NCT00997516|Active Comparator|Conventional laparoscopic appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
9774359|NCT00997555|Experimental|bronchoscopy intervention group|Group undergoing scheduled bronchoscopy.
9774360|NCT00997555|No Intervention|Control group|Standard treatment without scheduled bronchoscopy.
9774361|NCT00997594|Active Comparator|Adrenal radiofrquency (RF) ablation|Patients who wll receive adrenal RF ablation.
9774362|NCT00997594|Active Comparator|Abdominal RF ablation other than adrenal gland|Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
9774363|NCT00997620|Placebo Comparator|Placebo|Placebo treatment given as a once daily dose intranasally.in subjects with active seasonal allergic rhinitis.
9774364|NCT00997620|Experimental|Fluticasone Furoate|IFluticasone Furoate 110 mcg given intranasly once daily in am as an active treatment of seasonal allergic rhinitis
9774365|NCT00997672|Experimental|Lithium CARBONATE 150 and/or 300 mg|
9774366|NCT00997672|Placebo Comparator|Placebo|Placebo comparator
9774367|NCT00997893|Experimental|Estradiol/Medroxyprogesterone Acetate|1 mg/d oral Estradiol pill and 0 mg/d oral placebo pill for 12 weeks, followed by 10 mg/d oral medroxyprogesterone acetate (MPA) pill, for 10 days.
9774368|NCT00997893|Experimental|Soy Phytoestrogen|55 mg/twice daily oral Novasoy®/Soy Phytoestrogen pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
9774369|NCT00997893|Placebo Comparator|Placebo|0 mg tablet/twice daily oral placebo pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
9774370|NCT00997932|Other|Complete Cohort|The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 hours of vaginal delivery.
9774371|NCT00997984|Experimental|Extended-release Guanfacine Hydrochloride (SPD503) AM|
9774372|NCT00997984|Experimental|placebo|
9774373|NCT00997984|Experimental|SPD503 PM|
9774374|NCT00998010|Experimental|Experimental|Patients receive bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide on days 1-42.Patients undergo external-beam fractionated regional radiotherapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.2-6 weeks after radiotherapy, patients receive bortezomib IV on days 1, 4, 8, and 11 and oral temozolomide on days 1-5.Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9774375|NCT00998023|Experimental|Mynx VCD|Mynx Vascular Closure Device
9774376|NCT00998023|Active Comparator|AngioSeal VCD|AngioSeal Vascular Closure Device
9774377|NCT00998049|Experimental|Plerixafor|"Plerixafor 160mg/kg/dose by IV on days 5-8~Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8."
9774378|NCT00998205|Other|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
9774379|NCT00998296|Experimental|BIBW 2992 + BIBF 1120|This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
9774380|NCT00998309||Azithromycin SR|Patients taking Azithromycin.
9774381|NCT00998335|Active Comparator|Insulin detemir only|Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
9774382|NCT00998335|Experimental|Insulin detemir plus aspart|After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
9774383|NCT00998374||Pyloric-sparing vs. non-pyloric sparing|Pyloric: SG & DS Non-pyloric: RYGB
9774384|NCT00998400|No Intervention|Clinical Management|Control group
9774385|NCT00998400|Experimental|CBT + WBT|Patients treated with Cognitive-Behavioral Therapy in combination with Well-Being Therapy and lifestyle modification
9774386|NCT00998426|Experimental|All study participants|Study procedures will occur one timebetween post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
9774387|NCT00998517|Active Comparator|Soy/peanut fortified spread|
9774388|NCT00998517|Experimental|Milk fortified corn/soy blend|
9774389|NCT00998517|Active Comparator|Supplementary Plumpy®|
9774390|NCT00998582|Active Comparator|Abacavir|Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
9774391|NCT00998582|Experimental|Tenofovir|Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
9774392|NCT00998660|Experimental|Patients receiving an Activa RC implant|
9774393|NCT00998764|Experimental|Bapineuzumab 0.5 mg/kg|
9774394|NCT00998790|Experimental|AMS AdVance Sling Group|European Male subjects >40 years old who were implanted with the AMS AdVance Male Sling to treat Stress Urinary Incontinence.
9774395|NCT00998868||hemiplegia|patients with hemiplegia, without other musculoskeletal disorders of the shoulder
9774396|NCT00998881|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
9774397|NCT00998881|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
9774398|NCT00998946|Experimental|Pralatrexate|"Participants received pralatrexate at an initial dose of 30 mg/m^2, as IV push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline on Days 1, 8 and 15 of a 4-week cycle (weekly for 3 weeks with 1 week of rest) until criteria for discontinuation per protocol were met. The initial dose of 30 mg/m^2 may be reduced to 20 mg/m^2 weekly, permitted per protocol defined criteria. If pralatrexate 20 mg/m^2/week was not tolerated, pralatrexate had to be discontinued. Dose re-escalation was not allowed once dose reduction was done.~Participants had dietary supplement of vitamin B12 and folic acid along with pralatrexate. Vitamin B12, given as 1mg IM, within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days post last dose of pralatrexate. Folic acid was given 1mg daily, orally, for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days post last dose of pralatrexate."
9774399|NCT00998985|Experimental|400 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
9774400|NCT00998985|Experimental|600 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
9774401|NCT00998985|Experimental|800 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
9774402|NCT00998985|Experimental|400 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
9774403|NCT00998985|Experimental|600 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
9774404|NCT00998985|Experimental|800 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
9774405|NCT00998985|Experimental|200 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
9774406|NCT00998985|Experimental|100 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
9774407|NCT00998985|Experimental|50 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
9774408|NCT00998985|Experimental|200 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
9774409|NCT00998985|Experimental|100 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
9774410|NCT00998985|Experimental|50 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
9774411|NCT00998985|Experimental|30 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
9774412|NCT00998985|Experimental|10 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo
9774413|NCT00999037|Experimental|Renvela|Daily renvela with meals for 12 weeks
9774414|NCT00999037|Placebo Comparator|placebo|
9774415|NCT00999102|Experimental|Nebivolol, followed by Metoprolol|Participants first received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 9-16 in total).
9774416|NCT00999102|Experimental|Metoprolol, followed by Nebivolol|Participants first received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 9-16 in total)
9774417|NCT00999141|Experimental|FS VH S/D 4 s-apr|One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
9774418|NCT00999141|No Intervention|Standard of Care (SoC)|Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
9774419|NCT00999167|Experimental|HPN-100|
9774420|NCT00999167|Placebo Comparator|Placebo|
9774421|NCT00999466|Experimental|1|AZD8848 (30 μg PILOT part and 60 μg MAIN part)
9774422|NCT00999466|Placebo Comparator|2|Placebo
9774423|NCT00999518|Experimental|Group 1|
9774424|NCT00999518|Experimental|Group 2|
9774425|NCT00999518|Experimental|Group 3|
9774426|NCT00999518|Experimental|Group 4|
9774427|NCT00999518|Placebo Comparator|Group 5|
9774428|NCT00999544|Experimental|Placebo aprepitant/0 mg oxycodone IN PO|Placebo aprepitant/Placebo oxycodone IN/PO
9774429|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 15 IN 0 PO|Placebo aprepitant/ oxycodone 15 IN 0 PO
9774430|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 30 IN 0 PO|Placebo aprepitant/ oxycodone 30 IN 0 PO
9774431|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 20 PO|Placebo aprepitant/ oxycodone 0 IN 20 PO
9774432|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 40 PO|Placebo aprepitant/ oxycodone 0 IN 40 PO
9774433|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 0 PO|Aprepitant 40 mg/ oxycodone 0 IN 0 PO
9774434|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 20 PO|Aprepitant 40 mg/ oxycodone 0 IN 20 PO
9774435|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 40 PO|Aprepitant 40 mg/ oxycodone 0 IN 40 PO
9774436|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 15 IN 0 PO|Aprepitant 40 mg/ oxycodone 15 IN 0 PO
9774437|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 30 IN 0 PO|Aprepitant 40 mg/ oxycodone 30 IN 0 PO
9774438|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 0 PO|Aprepitant 200 mg/ oxycodone 0 IN 0 PO
9774439|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 20 PO|Aprepitant 200 mg/ oxycodone 0 IN 20 PO
9774440|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 40 PO|Aprepitant 200 mg/ oxycodone 0 IN 40 PO
9774441|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 15 IN 0 PO|Aprepitant 200 mg/ oxycodone 15 IN 0 PO
9774442|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 30 IN 0 PO|Aprepitant 200 mg/ oxycodone 30 IN 0 PO
9774443|NCT00999596||FFDM (Full Field Digital Mammography)|Mammograms from the Philips Digital System
9774444|NCT00999687|Experimental|Indigo naturalis extract in oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
9774445|NCT00999687|Placebo Comparator|Olive oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
9774446|NCT00999713|Experimental|Calfactant|Endotracheal calfactant administration
9774447|NCT00999713|Placebo Comparator|Placebo (air)|Endotracheal air administration
9774448|NCT00999804|Experimental|24-week arm|Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
9774449|NCT00999804|Active Comparator|12-week arm|Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
9774450|NCT00999830|Experimental|IPH 2101 0.2 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
9774451|NCT00999830|Experimental|IPH2101 2.0 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
9774452|NCT00999908|Experimental|Indacaterol 150 μg-tiotropium 18 μg-placebo|Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9774453|NCT00999908|Experimental|Tiotropium 18 μg-placebo-indacaterol 150 μg|Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9774454|NCT00999908|Experimental|Placebo-indacaterol 150 μg-tiotropium 18 μg|Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9774455|NCT00999921|Experimental|Tamoxifen|10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months
9774456|NCT00999921|Experimental|Evening Primrose Oil|1000 mg daily for 3 months
9774457|NCT01000025|Active Comparator|PF-00299804|Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9774458|NCT01000025|Placebo Comparator|Placebo|Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9774459|NCT01000051|Experimental|Eltrombopag|Starting dose 50 mg/day orally for 8 weeks
9774460|NCT01000051|Placebo Comparator|Placebo|Once a day orally for 8 weeks
9774461|NCT01000064|Active Comparator|Vyvanse|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
9774462|NCT01000064|Placebo Comparator|Placebo|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
9774463|NCT01000155|Experimental|Vorinostat|Patients received vorinostat in a pulsed fashion, once a day for 3 consecutive days every week to a maximum dose of 400 mg per dose (1200 mg/wk), for 12 to 16 weeks at the maximum dose. The first 3 patients were enrolled in an intrapatient dose escalation schedule of 100 mg/d, then 200 mg/d, each for 3 consecutive days a week for 4 weeks, and then 400 mg/d, 3 consecutive days per week for 16 weeks. The last 2 patients were enrolled to receive 400 mg/d, 3 consecutive days per week for 12 weeks, without an initial dose escalation.
9774464|NCT01000285|Experimental|Arm 1|"Bortezomib 1.0 mg/m2 intravenous (IV) Days 1-4~Etoposide 50 mg/m2/d 96 hour continuous intravenous infusion (CIVI) on Days 1-4~Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4~Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4~Prednisone 60 mg/m2/d PO on Days 1-5~Cyclophosphamide 375 mg/m2 IV on Day 5~Raltegravir 400 mg PO twice per day (BID) every day starting with cycle 2 therapy for the entire duration of the cycle.~Cycles will be repeated every 21-28 days for 2 cycles beyond best response, or a maximum of 6 cycles."
9774465|NCT01000311|Experimental|MenACWY-CRM + Routine Vaccines|"Infants received 3 doses of MenACWY-CRM at 2, 4 and 6 months as a infant series vaccination and a toddler dose at 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months."
9774466|NCT01000311|Experimental|Routine Vaccines|"Infants received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months.~In addition subjects were offered a dose of MenACWY-CRM at 18 months as a benefit of participating in this study. However, blood was not drawn for immunogenicity analysis after this dose."
9774467|NCT01000324|Experimental|Twinrix Group|Pooled group of subjects from groups who were vaccinated with either Lot 1, Lot 2 or Lot 3 of Twinrix in the primary study according to a 0, 1, 6-Month schedule
9774468|NCT01000337|Active Comparator|sevoflurane|Volatile anesthetic
9774469|NCT01000337|Active Comparator|Propofol|Intravenous anesthetic
9774470|NCT01000376|Experimental|Group 1|
9774471|NCT01000376|Experimental|Group 2|
9774472|NCT01000480|Experimental|Pemetrexed|Pemetrexed and cisplatin are given as induction therapy followed after by pemetrexed and cisplatin with concurrent radiotherapy.
9784725|NCT01232829|Experimental|Treatment (RO4929097)|"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies."
9784726|NCT01232868|Other|Age 25-40|Trivalent Influenza vaccine given to age 25-40
9784727|NCT01232868|Other|Age ≥65|Trivalent Influenza vaccine given to age≥65
9784728|NCT01232894|Experimental|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
9784729|NCT01232894|Active Comparator|Long-acting beta2-agonist|Participants' current long-acting beta2-agonist (LABA) bronchodilator therapy
9784730|NCT01232920|Active Comparator|Methotrexate|
9784731|NCT01232920|Active Comparator|Mycophenolate mofetil|
9784732|NCT01232946|Experimental|Iiraglutide|Type 2 diabetic subjects will be assigned to 3 months of treatment with 1.8mg liraglutide administered once daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
9784733|NCT01232946|Experimental|insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
9784734|NCT01232946|Experimental|Liraglutide plus insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with a combination of liraglutide and insulin detemir in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
9784735|NCT01233050|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
9784736|NCT01233050|Active Comparator|Iodine Povacrylex/74% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
9784737|NCT01233076|Other|Nelfilcon A / Narafilcon B|Nelfilcon A worn first, with narafilcon B worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
9784738|NCT01233076|Other|Narafilcon B / Nelfilcon A|Narafilcon B worn first, with nelfilcon A worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
9784739|NCT01233232|Placebo Comparator|1|Placebo dose
9784740|NCT01233232|Experimental|2|Treatment arm AZD5069 50mg
9784741|NCT01233232|Experimental|3|Treatment arm AZD5069 80mg
9784742|NCT01233258|Experimental|Arm 1: rFVIII on demand first CS/EP then CS/ADJ|Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
9784743|NCT01233258|Experimental|Arm 2: rFVIII on demand first CS/ADJ then CS/EP|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
9784744|NCT01233258|Experimental|Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
9784745|NCT01233258|Experimental|Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
9784746|NCT01233258|Experimental|Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
9784747|NCT01233258|Experimental|Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
9784748|NCT01233284|Experimental|tiotropium low dose once daily|once daily, delivered by the Respimat® inhaler
9784749|NCT01233284|Experimental|tiotropium medium dose once daily|once daily, delivered by the Respimat® inhaler
9784750|NCT01233284|Experimental|tiotropium high dose once daily|once daily, delivered by the Respimat® inhaler
9784751|NCT01233284|Placebo Comparator|Placebo once daily|once daily, delivered by the Respimat® inhaler
9784752|NCT01233518|Other|Single arm study|Patients will receive cCTA, ICA, FFR, and cFFR per protocol.
9784753|NCT01233609|Active Comparator|Valproic Acid|Subjects who receive valproic acid
9784754|NCT01233609|Placebo Comparator|Placebo|Subjects who receive placebo
9774473|NCT01000493|Experimental|Orvepitant 60 mg|60 mg/day
9774474|NCT01000493|Placebo Comparator|Placebo|
9774475|NCT01000506|Active Comparator|Mepolizumab 750mg|Mepolizumab 750mcg i.v. every 4 weeks
9774476|NCT01000506|Active Comparator|Mepolizumab 250mg|Mepolizumab 250mcg i.v. every 4 weeks
9774477|NCT01000506|Active Comparator|Mepolizumab 75mg|Mepolizumab 75mcg i.v. every 4 weeks
9774478|NCT01000506|Placebo Comparator|Placebo|Placebo saline every 4 weeks i.v.
9774479|NCT01000610|Experimental|single arm|
9774480|NCT01000636|Experimental|Metvix PDT|
9774481|NCT01000649|Experimental|FE 202158 1.25|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 1.25 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
9774482|NCT01000649|Experimental|FE 202158 2.5|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 2.5 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
9774483|NCT01000649|Experimental|FE 202158 3.75|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 3.75 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
10203919|NCT04717505||Healthy Control Group|Demographic information ( age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor).
10203920|NCT04717505||Rheumatological Condition Group|Demographic information (diagnosis, age, gender, occupation, weight, height) of all participants in the study will be recorded first. The cognitive functions of all participants within the scope of the study will be evaluated in the Standardized Mini Mental Test; The 10 Meter Walk Test for dual task assessments will be applied in 3 different ways, with a portable gait device with wearable sensors: 1-single task conditions, 2-dual task conditions (motor + cognitive), 3-dual task conditions (motor + motor). In addition, in order to evaluate their health status, only the case group will be applied Arthritis Impact Measurement Scales 2 (questionnaire) and Visual Analogue Scale for pain assessment.
10203921|NCT04713020|Experimental|Effectiveness of Application Education Intervention|This study hopes that through the intervention of mobile device education programs, it can provide patients with easy access and repeated viewing and learning. It can replace traditional leaflet health education and reduce the workload of clinical nurses. It is hoped that it can effectively improve the self-care knowledge of stroke patients, improve self-efficacy, reduce the symptoms of depression, and increase the satisfaction of education and guidance. Eventually, patients can be prevented from recurring from stroke, and they can coexist peacefully with stroke and have a good quality of life.
10203922|NCT04713020|Other|genaral care|Give patients routine care
9774484|NCT01000649|Placebo Comparator|PLCBO|Patients in the arm received an intravenous infusion for up to 7 days of placebo.
9774485|NCT01000662|Active Comparator|ARM 1 daily boost|Radiation Therapy
9774486|NCT01000662|Active Comparator|ARM 2 weekly boost|Radiation Therapy
9774487|NCT01000727|Experimental|Darapladib 160 mg|Single daily oral tablet
9774488|NCT01000727|Placebo Comparator|Placebo|Single daily oral tablet
9774489|NCT01000805|Experimental|Duloxetine|
9774490|NCT01000805|Placebo Comparator|Placebo|
9774491|NCT01000818|Experimental|Period 1|MK0518
9774492|NCT01000818|Experimental|Period 2|famotidine + MK0518
9774493|NCT01000818|Experimental|Period 3|omeprazole + MK0518
9774494|NCT01000961|Experimental|RP103 Q12H|
9774495|NCT01000961|Active Comparator|Cystagon® Q6H|
9774496|NCT01000974|Experimental|Hiberix Group|Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
9784755|NCT01233687|Experimental|AMG 102 and erlotinib|Combination of AMG 102 and erlotinib
10203923|NCT04712305||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
10203924|NCT04712305||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
10203925|NCT04712123||relapse due to S. aureus|patients having had an initial infection due to S. aureus and who present a relapse with persistence of S. aureus
10203926|NCT04707885|Experimental|ECochG monitoring|For those randomized to the experimental group, the CI surgery will proceed in a standard fashion. However, the surgeon will utilize ECochG-guided monitoring by placing the external device coil and processor over the receiver/stimulator of the implanted components. Also, a sound applicator (i.e. speaker) will be placed in the external auditory canal by the surgeon. During electrode insertion the surgeon will utilize the ECochG feedback to adjust insertion if needed. That is, once the electrode has been inserted at least 75% (75% of the electrode contacts inside the cochlea), the surgeon may proceed to full insertion if indicated during ECochG feedback or may modify and/or cease electrode insertion if indicated by the ECochG feedback in attempts to preserve RH.
9774497|NCT01000974|Active Comparator|ActHIB Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
9774498|NCT01000974|Active Comparator|Pentacel Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
9774499|NCT01000987|Experimental|varenicline|varenicline 1mg/day or 2mg/day
9774500|NCT01000987|Placebo Comparator|placebo|placebo
9774501|NCT01001052|Experimental|Colcrys™ - young subjects (18-30 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
9774502|NCT01001052|Experimental|Colcrys™ - elderly subjects (≥60 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
9774503|NCT01001078|Active Comparator|I-Gel supraglottic airway device|Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
9774504|NCT01001078|Active Comparator|LMA Supreme supraglottic airway device|Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
9774505|NCT01001078|Active Comparator|Standard endotracheal tube|A Standard endotracheal tube will be inserted in case both other airway devices (LMA Supreme and iGel) devices fail to provide adequate ventilation.
9774506|NCT01001104|Experimental|0.75 mg LY2189265|
9774507|NCT01001104|Experimental|0.5 mg LY2189265|
9774508|NCT01001104|Experimental|0.25 mg LY2189265|
9774509|NCT01001104|Placebo Comparator|Placebo|
9774510|NCT01001169|Experimental|GSK2340274A_F1 6M-9Y GROUP|Healthy male or female Japanese children, between and including 6 months to 9 years of age, who received two doses of GSK2340274A vaccine (formulation 1), administered intramuscularly into the deltoid region of the arm (intramuscularly into the anterolateral part of the thigh for subjects below 12 months of age at the entry of the study), according to 0, 21-day schedule. Within this group, enrolment of subjects was stratified by age into two subgroups, from 6 to 35 months and from 3 to 9 years.
9774511|NCT01001169|Experimental|GSK2340274A_F2 10Y-17Y GROUP|Healthy male or female Japanese children, between and including 10 to 17 years of age, who received two doses of GSK2340274A vaccine (formulation 2), administered intramuscularly into the deltoid region of the arm, according to 0, 21-day schedule.
9774512|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
9774513|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
9774514|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
9774515|NCT01001195|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
9774516|NCT01001208|Experimental|Etanercept Plus Methotrexate|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received active methotrexate titrated as follows: 7.5 mg per week (3 capsules) for weeks 1 and 2, 10 mg per week (4 capsules) for weeks 3 and 4, and then up to 15 mg per week (6 capsules) or the maximum tolerated dose for the remainder of the 24-week treatment period.
9774517|NCT01001208|Active Comparator|Etanercept Plus Placebo|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received oral placebo that was the same number of capsules per week as the methotrexate dosing regimen.
9774518|NCT01001221|Experimental|Cabazitaxel + gemcitabine|"Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.~On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel."
9774519|NCT01001299|Experimental|Single arm|
9774520|NCT01001325|Experimental|Seasonal influenza vaccination|Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification
9774521|NCT01001325|Placebo Comparator|Placebo|0.5 mL normal saline
9774522|NCT01001377|Active Comparator|Cetuximab|"Cetuximab 400 mg/m^2 as an initial dose, followed by 250 mg/m^2 intravenously (IV) every 7 days.~Participants were treated until disease progression, intolerability, withdrawal of consent, or death."
9774523|NCT01001377|Experimental|Panitumumab|Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
9774524|NCT01001403|Experimental|nafamostat|The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
9774525|NCT01001403|Placebo Comparator|Control|The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
9774526|NCT01001429|Active Comparator|Propofol|propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
9774527|NCT01001429|Experimental|dexmedetomidine infusion|Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.
9774528|NCT01001442|Experimental|BT062|BT062 was to be administered as single-dose IV infusions via a 0.22 μm in-line filter preferably in a forearm vein, according to medically accepted procedures on Days 1, 8, and 15 of each 28-day cycle. Alternatively BT062 may have been administered through a central venous line or a peripherally inserted central catheter (PICC). Other administration routes were only to be allowed after approval from Biotest. Each subject was to be monitored carefully for the effects of exposure to BT062. No subject was to have received more than 3 doses of BT062 per 28-day treatment cycle.
9774529|NCT01001494|Experimental|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation
9774530|NCT01001494|Experimental|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation
9774531|NCT01001494|Placebo Comparator|Placebo|Placebo
9774532|NCT01001520|Placebo Comparator|Placebo (Sugar Pill)|11-day placebo-controlled medication period
9774533|NCT01001520|Active Comparator|Tolcapone|11-day phase, tapered dosing scheduled (Day 1: 100mg three times daily, Days 2-8: 200mg three times daily, Day 9: 200mg twice daily, Day 10: 200mg once daily, Day 11: 100mg once daily); oral dosing; medication is encapsulated by the University of Pennsylvania's Investigational Drug Service (IDS)
9774534|NCT01001546|Experimental|Arm 1|Internet-based smoking cessation
9774535|NCT01001546|Other|Arm 2|Clinic-based smoking cessation
9774536|NCT01001559||Deplin + antidepressant|Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
9774537|NCT01001559||Antidepressant alone|SSRI or SNRI alone
9774538|NCT01001572|Active Comparator|Valsartan 160 mg|One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
9774539|NCT01001572|Experimental|Valsartan/amlodipine 160/5 mg|One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks
9774540|NCT01001572|Other|Single-Blind Run-In Valsartan 160 mg|Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.
9774541|NCT01001598|Other|danazol|Subjects with either Fanconi anemia or Dyskeratosis congenita
9774542|NCT01001702|Experimental|Oral Aripiprazole|Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
9774543|NCT01001767|Active Comparator|Lovaza|Lovaza 1 gram by mouth twice a day for 24 weeks.
9774544|NCT01001767|Placebo Comparator|Placebo|Placebo capsule by mouth twice a day x 24 weeks.
9774545|NCT01001806|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
9774546|NCT01001806|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
9774547|NCT01001806|Active Comparator|Nevanac|One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
9774548|NCT01001832|Active Comparator|Subcutaneous (SC) abatacept, 125 mg|
9774549|NCT01001832|Active Comparator|Intravenous (IV) abatacept, 125 mg|
9774550|NCT01001910|Experimental|Treatment (pemetrexed disodium, carboplatin)|Patients receive pemetrexed disodium IV over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
9774551|NCT01001975|Experimental|SPF Testing|Following Food and Drug Administration (FDA) guidelines for SPF testing, exposure control and product-protected site erythema responses are scored after 16 to 24 hours post-exposure to full spectrum light (Ultraviolet B radiation [UVB] and UVA).
9774552|NCT01001975|Experimental|UVA Protection Testing|Determination of Ultraviolet A Protection Factor (PFA). Following FDA guidelines, test sites exposed to UVA are scored for pigmentation responses 2 to 4 hours post-exposure.
9774553|NCT01001988|Experimental|Study group|Participants received a single dose of JE-CV administered in Study JEC02. In Study JEC05 there were yearly visits with blood samples taken for immunogenicity assessment.
9774554|NCT01002105|Experimental|Baclofen|The study was a double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations.
9774555|NCT01002105|Other|Psychosocial intervention|Intervention of the addition of placebo to low-intensity psychosocial intervention program. This was the control group
9774556|NCT01002118|Placebo Comparator|Placebo|4 capsules inert oil Placebo each day for 16 weeks
9774557|NCT01002118|Active Comparator|Omega-3 Fatty Acid Ethyl Esters|4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
9774558|NCT01002287|Experimental|SprayShield Adhesion Barrier|SprayShield Adhesion Barrier
9774559|NCT01002287|Sham Comparator|Control|Good Surgical Technique Alone
9774560|NCT01002339|Experimental|Tacrolimus with rapid steroid withdrawal|Basiliximab induction. Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
9774561|NCT01002339|Active Comparator|Tacrolimus with steroids minimization|Basiliximab induction.Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
9774562|NCT01002339|Experimental|CsA with steroid minimization|Basiliximab induction. Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
9774563|NCT01002456|Other|Level 1: site-specific information|provide site-specific information on nonadherence
9774564|NCT01002456|Other|Level 2: site-, patient-specific info|provide site- and patient-specific information on nonadherence
9774565|NCT01002482|Experimental|CGAO-based Glucose Control|Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.
9774566|NCT01002482|Active Comparator|Standard-Care Glucose Gontrol|Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.
9774567|NCT01002547|Placebo Comparator|Arm 1|Diabetic with proven NASH by biopsy
9774568|NCT01002547|Active Comparator|Arm 2|Diabetic with proven NASH by biopsy
9774569|NCT01002547|Other|Arm 3|Diabetic with proven NASH by biopsy
9774570|NCT01002573|Experimental|ibuprofen|Ibuprofen, 10 mg/kg
9774571|NCT01002573|Active Comparator|Acetaminophen|Acetaminophen, 10mg/kg
9774572|NCT01002742|Experimental|Placebo|Corticosteroids with placebo
9774573|NCT01002742|Experimental|Mycophenolate Mofetil|Corticosteroids with Mycophenolate Mofetil
9774574|NCT01002755|Experimental|Treatment (lenalidomide, ofatumumab)|Participants receive ofatumumab IV over 4 hours on days 1, 8, 15, and 22 of course 1, day 1 of courses 2-6, and day 1 of every even course beginning course 8. Beginning day 9 of course 1, participants also receive lenalidomide PO daily. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9774575|NCT01002989||All eligible patients|"Subjects assessed for hypertension, were subjected to the measurement of ankle brachial index (ABI) by two methods:~Doppler~WatchBP Office oscillometric The order for performing the two methods was randomized."
9774576|NCT01003067|No Intervention|No Mesh|
9774577|NCT01003067|Experimental|Mesh Implementation|
9774578|NCT01003080|Experimental|TKA with the Aquamantys for hemostasis|This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.
9774579|NCT01003080|Active Comparator|TKA without the Aquamantys for hemostasis|This group will receive total knee arthroplasty using the standard treatment for hemostasis.
9774580|NCT01003106|Experimental|BRVO- Ranibizumab 0.5mg alone|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation.
9774581|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab with laser|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
9774582|NCT01003106|Experimental|BRVO- Ranibizumab 2.0mg alone|Branch retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
9774583|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
9774584|NCT01003106|Experimental|CRVO- Ranibizumab 0.5mg alone|Central retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation
9774585|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab with laser|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
9774586|NCT01003106|Experimental|CRVO- Ranibizumab 2.0mg alone|Central retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
9774587|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
9774588|NCT01003184|Experimental|1|
9774589|NCT01003184|Active Comparator|2|
9774590|NCT01003210|Experimental|Homeopathic ear drops|Commercially available homeopathic ear drops
9774591|NCT01003210|No Intervention|standard therapy|standard therapy for otitis media, no ear drops
9774592|NCT01003249|Active Comparator|Baclofen, Then Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
9774593|NCT01003249|Placebo Comparator|Placebo, Then Baclofen|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
9774594|NCT01003275|Active Comparator|Paricalcitol followed by placebo|Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
9774595|NCT01003275|Active Comparator|Placebo followed by paricalcitol|Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
9774596|NCT01003288|Experimental|Pandemic influenza H1N1 vaccine|Influenza vaccine
9984298|NCT04248751|Experimental|Graft-Augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin. Then, the graft will be delivered to the subacromial space and positioned over the bursal surface of the suprasinatus tendon, ensuring that the lateral edge of the implant will overlap with the head of the humerus. The graft will be fixed with tendon and bone staples.
9984299|NCT04248751|Active Comparator|Non-augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin.
9984300|NCT04246008|Experimental|Neuromuscular training group|This group will receive a 60-min neuromuscular training sessions twice a week, for 10 weeks until the completion of twenty sessions
9984301|NCT04246008|Active Comparator|Conventional training group|This group will receive a 60-min convencional cardiac rehabiliation session twice a week, for 10 weeks until the completion of twenty sessions
9984302|NCT04238845|Active Comparator|SMC + Vitamin A alone|Children under SMC Coverage, receiving AQSP and Vitamin A supplementation alone
9774597|NCT01003301|Experimental|Omalizumab|Active treatment: Experimental This arm will receive treatment with omalizumab at the dose FDA-approved for the treatment of allergic asthma.
9774598|NCT01003301|Placebo Comparator|Placebo|This arm will receive treatment with a placebo injections based on the FDA-approved dosing schedule approved for omalizumab for the treatment of allergic asthma.In general injection number and frequency are determined by a subject's weight and IgE level.
9984303|NCT04238845|Experimental|SMC+ Vitamin A + Plumpy'Doz|Children under SMC Coverage, receiving AQSP + Vitamin A plus Plumpy'Doz supplementation
9984304|NCT04238845|Experimental|SMC+ Vitamin A + Zinc|Children under SMC Coverage, receiving AQSP + Vitamin A plus Zinc supplementation
9774599|NCT01003418|Experimental|GSK2340272A Group 1|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-28 day schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
9774600|NCT01003418|Experimental|GSK2340272A Group 2|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-4 month schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
9774601|NCT01003639|Active Comparator|Acetazolamide|Acetazolamide given in escalating doses
9774602|NCT01003639|Placebo Comparator|Sugar pill|"Given in escalating dose (number of pill)"
9774603|NCT01003769|Experimental|Treatment (lenalidomide in combination with AT-101)|Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.
9774604|NCT01003886||Open Label|Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS
9774605|NCT01003899|Experimental|afatinib (BIBW 2992)|patient to receive afatinib(BIBW 2992) po QD in an open-label manner
9774606|NCT01003938|Experimental|topotecan and erlotinib|Topotecan 0.4 mg/m^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
9774607|NCT01003990|Experimental|Atazanavir|
9774608|NCT01003990|Experimental|Atazanavir/Ritonavir|
9774609|NCT01003990|Active Comparator|Lopinavir/Ritonavir|Ritonavir-boosted Lopinavir (LPV/RTV 400/100 mg) administered twice a day (BID) with Tenofovir/ Emtricitabine (TDF/FTC).
9774610|NCT01004003|Experimental|BIBF 1120|Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
9774611|NCT01004003|Active Comparator|Sorafenib|
9774612|NCT01004029|Placebo Comparator|Vehicle|Castor Oil
9774613|NCT01004029|Active Comparator|Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL|HPC 250 mg/mL in oil
9774614|NCT01004042|Active Comparator|Depressed subjects|Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
9774615|NCT01004042|Active Comparator|Non Depressed subjects|Subjects with no diagnosis of depression
9774616|NCT01004107|Experimental|Radiesse Injectable Dermal Filler|Device: Radiesse Injectable Dermal Filler
9774617|NCT01004107|Active Comparator|Delayed Treatment|Cross over to treatment with Radiesse Injectable Dermal Filler at 3 Months
9774618|NCT01004146|Placebo Comparator|Control group|Patients assigned to the control group were educated on the proper technique of using the incentive spirometer and were instructed to use it for 3 breaths once per day to become able to use the device properly and consistently.
9774619|NCT01004146|Experimental|Experimental Group|Patients assigned to the experimental group were instructed to use the spirometer by inhaling as slowly and deeply as possible in a set of 10 times and to repeat the process at least 5 times every day until the day of surgery.
9774620|NCT01004159|Experimental|cetuximab with irinotecan|
9774621|NCT01004172|Experimental|carboplatin, bevacizumab, trastuzumab (if HER2+)|"Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.~carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle~bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle~trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only~*8mg/kg loading dose in cycle 1 for some participants~HER-2: human epidermal growth factor receptor 2"
9774622|NCT01004185|Experimental|High Dose|2.0 - 4.8 g/day Asacol dependent on body weight
9774623|NCT01004185|Experimental|Low Dose|1.2 - 2.4 g/day Asacol dependent upon body weight
9774624|NCT01004250|Experimental|Study Treatment|
9774625|NCT01004354|Experimental|Vitamin D|
9774626|NCT01004393|Experimental|Methylnaltrexone bromide|A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.
9774627|NCT01004406|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent
9774628|NCT01004406|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
9774629|NCT01004432|Experimental|Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX|All enrolled and dosed participants receive golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks + Methotrexate (MTX) from Week 0 to Week 12.
9774630|NCT01004432|Experimental|Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX|Participants, who do not achieve Disease Activity Score in 28 joints (DAS28) good response at Week 16, will be randomly assigned to receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48, along with placebo matched to golimumab intravenous infusion (IV) at Week 16, 20, 28, 36, and 44.
9774631|NCT01004432|Experimental|DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX|Participants, who do not achieve DAS28 good response at Week 16, will be randomly assigned to receive golimumab 2 milligram per kilogram (mg/kg) intravenous infusion (IV) + MTX, at Week 16, 20, 28, 36 and 44, along with placebo matched to golimumab SC injection every 4 weeks from Week 16 to Week 48.
9774632|NCT01004432|Experimental|OL Group 1: Golimumab 50 mg SC + MTX|Participants, who achieve DAS28 good response at Week 16, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48.
9774633|NCT01004432|Experimental|OL Study Extension Group: Golimumab 50 mg SC + MTX|Participants who complete the main study (Week 0 to Week 52), do not meet lack of efficacy criteria, and participate in the OL study extension, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 52 to Week 72.
9774634|NCT01004614|Experimental|Cohort 1|24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.
9774635|NCT01004614|Active Comparator|Cohort 2|24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water
9774636|NCT01004705|Experimental|Fixed Dose Combination Pill|Once daily oral dose of combination of acetylsalicylic acid, simvastatin, and ramipril (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 or 10 mg ramipril)
9774637|NCT01004705|Active Comparator|Simvastatin|Once daily oral dose of Simvastatin 40 mg
9774638|NCT01004718|Experimental|Fludeoxyglucose F18 (FDG) PET/CT scans|Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
9774639|NCT01004744|Experimental|Presurgical oral anastrozole|1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.
9774640|NCT01004770|Experimental|1 (AH113111 Injection)|
9774641|NCT01004770|Active Comparator|2 (Visipaque Injection)|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
9774642|NCT01004822|Experimental|Active Drug|Weekly infusions of CVX-241 at specified doses
9774643|NCT01004848|Experimental|Peer-Led Lifestyle Education on Weight Loss|"Project HEED (Help Educate to Eliminate Diabetes), a community-based, peer-led weight loss program for overweight adults with pre-diabetes.~The intervention group will participate in an 8-session course held over a 10-week period. Project HEED (Help Educate to Eliminate Diabetes), led by trained peer educators, aims to help participants lose weight, thereby preventing their progression to diabetes."
9774644|NCT01004848|Placebo Comparator|Delayed Intervention|The control group will be offered the chance to participate in the 8-session course 1 year after enrollment into the trial.
9774645|NCT01004939||fondaparinux prescribed subjects|fondaparinux prescribed subjets
9774646|NCT01004991|Experimental|All patients|subjects will receive azacytidine dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose RCHOP
9774647|NCT01005251|Experimental|60 mg|PPI+lesogaberan (AZD3355) 60 mg bid
9774648|NCT01005251|Experimental|120 mg|PPI+lesogaberan (AZD3355) 120 mg bid
9774649|NCT01005251|Experimental|180 mg|PPI+lesogaberan (AZD3355) 180 mg bid
9774650|NCT01005251|Experimental|240 mg|PPI+lesogaberan (AZD3355) 240 mg bid
9774651|NCT01005251|Placebo Comparator|Placebo|PPI+ Placebo
9774652|NCT01005290|Experimental|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
9774653|NCT01005290|Active Comparator|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
9774654|NCT01005316||Cohort A: Non-Sensitized|"Cohort A will include participants who are alloantibody Luminex(TM) LABScreen. There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen. Non-sensitized recipients receive steroid-free maintenance immunosuppression:~Induction Therapy (anti-T cell antibody induction)~Tacrolimus (Prograf®)~Mycophenolate Mofetil- MMF (CellCept®)."
9774655|NCT01005316||Cohort B: Sensitized|"Cohort B will include participants who are alloantibody positive (Sensitized) as determined by Luminex LabScreen for Class I or Class II with specificities identified by single antigen testing.~There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen.~Sensitized recipients receive:~Induction Therapy (anti-T cell antibody induction)~Intraoperative plasma exchange/pheresis~Short-term post-operative plasmapheresis~Post-transplant course of intravenous immunoglobulin (IVIG) therapy~Maintenance corticosteroids (Prednisone)~Tacrolimus (Prograf®)~Mycophenolate Mofetil-MMF (CellCept®)."
9774656|NCT01005329|Experimental|Treatment (IMRT, cisplatin,bevacizumab,carboplatin,paclitaxel)|Patients undergo pelvic IMRT once daily, 5 days a week, for 5 weeks. Patients may also undergo optional nodal boost radiotherapy and/or vaginal brachytherapy boost. Patients also receive concurrent cisplatin IV over 1 hour on days 1 and 29 and bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Beginning 4-6 weeks after completing IMRT, cisplatin, and bevacizumab, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment with carboplatin and paclitaxel repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9774657|NCT01005355|Experimental|IMC-1121B|Participants receiving IMC-1121B intravenously
9774658|NCT01005407|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
9774659|NCT01005407|Active Comparator|Engerix-B(1)|1.0 mL Engerix-B
9774660|NCT01005459|Active Comparator|tetracaine 2mg|
9774661|NCT01005459|Active Comparator|Bupivacaine 2 mg|
9774662|NCT01005576|Experimental|Conditioning regimen|Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
9774663|NCT01005602|Experimental|Digoxin Dosing per Nomogram|Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
9774664|NCT01005602|Other|Standard Digoxin Dosing|This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.
9774665|NCT01005680|Experimental|Pemetrexed plus Cisplatin|
9774666|NCT01005680|Active Comparator|Gemcitabine plus Cisplatin|
9774667|NCT01005706|Active Comparator|Tacrolimus Withdrawal Arm|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
9774668|NCT01005706|Active Comparator|Tacrolimus Minimization Arm|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
9774669|NCT01005719|Experimental|Zegerid|Participants receiving Zegerid (omeprazole/sodium bicarbonate) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
9774670|NCT01005719|Active Comparator|Prevacid®|Participants receiving Prevacid® (lansoprazole) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
9774671|NCT01005719|No Intervention|No treatment|Participants receiving No treatment in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants took approximately 2 oz of water once daily for 7 days.
9784756|NCT01233726|Experimental|T-DIET PLUS DIABET IR|Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
9784757|NCT01233726|Active Comparator|ISOSOURCE PROTEIN FIBRE|Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
9784758|NCT01233726|Active Comparator|GLUCERNA SELECT|Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
9784759|NCT01233817|Experimental|Spinal muscular atrophy|Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program.
9784760|NCT01233869|Experimental|Cohort A|
9784761|NCT01233869|Experimental|Cohort B|
9784762|NCT01233869|Placebo Comparator|Cohort C|
9784763|NCT01233921|Experimental|Arm I (palifermin)|Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.
9784764|NCT01233921|Active Comparator|Arm II (no palifermin)|Patients do not receive palifermin.
9784765|NCT01233999|Placebo Comparator|Botox|single-drug dosage comparison cross-over study
9784766|NCT01234207|Active Comparator|Randomized Order of Interventions 1|Randomized to first wear standard, non-free-form, non-customized PAL spectacles, then second, crossover to wear individually customized free-form surfaced PAL spectacles
9784767|NCT01234207|Active Comparator|Randomized Order of Interventions 2|Randomized to first wear individually customized free-form surfaced PAL spectacles, then second, crossover to wear standard, non-free-form, non-customized PAL spectacles
9784768|NCT01234337|Experimental|Sorafenib (Nexavar, BAY43-9006) + Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
9784769|NCT01234337|Placebo Comparator|Placebo + Capecitabine|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
9784770|NCT01234350||FIRMAGON|
9784771|NCT01234350||GnRH Agonist|
9784772|NCT01234402|Experimental|Ramucirumab DP + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
9784773|NCT01234402|Experimental|Icrucumab + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
9785754|NCT01259297|Experimental|Amlodipine + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily"
9774672|NCT01005810|Active Comparator|N-Acetylcysteine|
9774673|NCT01005810|Placebo Comparator|Placebo|
9774674|NCT01005875|Experimental|Radiation followed by Sorafenib|Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
9774675|NCT01005888|Experimental|C1INH-nf First, then Placebo|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
9774676|NCT01005888|Experimental|Placebo First, then C1INH-nf|Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.
9774677|NCT01005901|Experimental|Glycopyrronium bromide|Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
9774678|NCT01005901|Placebo Comparator|Placebo|Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
9774679|NCT01005966|Other|Run in|Placebo
9774680|NCT01005966|Experimental|Sodium Fluoride Toothpaste|Sodium fluoride toothpaste
9774681|NCT01005966|Active Comparator|Amine Fluoride Toothpaste|Amine Fluoride
9774682|NCT01005966|Other|675ppmf toothpaste|Dose response
9774683|NCT01005966|Active Comparator|Sodium monofluorophosphate/sodium fluoride Toothpaste|Sodium monofluorophosphate/sodium fluoride Toothpaste
9774684|NCT01005966|Placebo Comparator|0 ppmf toothpaste|
9774685|NCT01006122|Placebo Comparator|Placebo|
9774686|NCT01006122|Active Comparator|PF-03654746|At the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
9774687|NCT01006135||COPD patients|
9774688|NCT01006252|Experimental|Tasisulam-sodium|Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
9774689|NCT01006252|Active Comparator|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
9774690|NCT01006291|Experimental|IDeg OD FF|
9774691|NCT01006291|Experimental|IDeg OD|
9774692|NCT01006291|Experimental|IGlar OD|
9774693|NCT01006356|Experimental|Hydromorphone hydrochloride (HCl) oral osmotic system (OROS)|Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.
9774694|NCT01006369|Experimental|FOLFOX6 + Bevacizumab + Hydroxychloroquine|"Arm A: FOLFOX6 + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 5 mg/kg in 100 cc Normal Saline every 14 days on day one.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
9774695|NCT01006369|Experimental|XELOX + Bevacizumab + Hydroxychloroquine|"Arm B: XELOX + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 7.5 mg/kg in 100 cc Normal Saline every 21 days.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
9774696|NCT01006538|Experimental|Arm A (treatment)|Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.
9774697|NCT01006538|Active Comparator|Arm B (control):|Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.
9774698|NCT01006590|Experimental|1|Saxagliptin 5 mg
9774699|NCT01006590|Active Comparator|2|Metformin 500 -1000 mg
9774700|NCT01006603|Experimental|1|Saxagliptin 5 mg
9774701|NCT01006603|Active Comparator|2|Glimepiride 1 - 6 mg
9774702|NCT01006616|Experimental|Navarixin 10 mg|Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally once daily (QD) for up to 2 years
9774703|NCT01006616|Experimental|Navarixin 30 mg|Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years
9774704|NCT01006616|Experimental|Navarixin 50 mg|Participants receive navarixin 50 mg, as two navarixin 10 mg capsules and one navarixin 30 mg capsule, administered orally QD for up to 2 years
9774705|NCT01006616|Placebo Comparator|Placebo|Participants receive placebo to navarixin, as three placebo capsules, administered orally QD for up to 2 years
9774706|NCT01006629|Experimental|palivizumab|palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections
9774707|NCT01006655|Placebo Comparator|placebo, adenosine challenge test|Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
9774708|NCT01006655|Active Comparator|Qvar, adenosine challenge test|Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
9774709|NCT01006707|Other|Ondansetron, then Placebo|Some participants received ondansetron pretreatment during the second session, and then placebo during the third session.
9774710|NCT01006707|Other|Placebo, then Ondansetron|Some participants received placebo pretreatment during the second session, and then ondansetron pretreatment during the third session.
9774711|NCT01006889|Experimental|Exenatide (twice daily)|Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
9774712|NCT01006967|Active Comparator|ActiveStep|Subjects will use the ActiveStep treadmill as part of their physical therapy program for balance
9774713|NCT01006967|Active Comparator|Standard physical therapy|Subjects will receive a standard physical therapy program for gait and balance.
9774714|NCT01006980|Experimental|Vemurafenib|
9774715|NCT01006980|Active Comparator|Dacarbazine|
9785755|NCT01259297|Experimental|HCTZ + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily"
9774716|NCT01007032|Experimental|Cixutumumab|Participants receive IV cixutumumab every 2 or 3 weeks. A cycle equals 6 weeks, with radiological evaluation of tumor response after each cycle. After 1st cycle, pts with a complete response (CR), PR, or SD continue to receive cixutumumab cohort dose and schedule disease progression. 3 pts enroll in each cohort. Starting dose in Cohort 1 is 6 mg/kg every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10 mg/kg every 2 weeks) occurs at least 3 pts in Cohort 1 completes 1 cycle of therapy. Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not proceed until at least 3 pts have completed one cycle of therapy in Cohort 2. Pts enroll in Cohort 4 once at least 3 pts have completed once cycle of therapy in Cohort 3; pts in Cohort 4 receive 20 mg/kg every 3 weeks.
9774717|NCT01007071|Experimental|Growth hormone|Subjects randomized to growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Dose adjustments based on serum insulin-like growth factor-1 (IGF-1) levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 standard deviation (SD) to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
9774718|NCT01007071|Placebo Comparator|Placebo|Subjects randomized to placebo for 16 weeks. As noted above, placebo subjects will be initiated on a daily subcutaneous injection, with dose changes based on changes in active drug subjects.
9774719|NCT01007110|Active Comparator|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA)
9774720|NCT01007110|Placebo Comparator|Placebo|soy/corn oil placebo
9774721|NCT01007123|Experimental|A3309 low dose|Administered once daily for the duration of the study
10203927|NCT04707885|No Intervention|Control Group|For those randomized to the control group, they will receive their CI per the standard of care. That is, all procedures that take place during a routine CI surgery will be the same for those in the control group. As such, no ECochG monitoring will be performed. However, all study surgeons will be asked to adhere to soft surgical principles (non-traumatic cochlear opening, slow electrode insertions) to enhance HP outcomes even in the absence of intraoperative ECochG monitoring. Further, the standard of care for cochlear implantation is to perform full electrode insertions with all electrode contacts inside of the cochlea. Thus, for subjects in the control group, surgeons will be asked to perform full electrode insertions.
10203928|NCT04707183|Placebo Comparator|Control Arm|1.0mg/kg/hr IV lidocaine infusion
9774722|NCT01007123|Experimental|A3309 intermediate dose|Administered once daily for the duration of the study.
9774723|NCT01007123|Experimental|A3309 high dose|Administered once daily for the duration of the study
9774724|NCT01007123|Placebo Comparator|Placebo|Administered once daily for the duration of the study
9774725|NCT01007136|Experimental|tDCS and occupational therapy|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
9774726|NCT01007136|Sham Comparator|Sham and occupational therapy|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
9774727|NCT01007149|Experimental|Omalizumab|Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
9774728|NCT01007149|Placebo Comparator|Placebo|Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.
9774729|NCT01007253|Other|FF/PL, PL/OLO, FF/OLO, PL/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and~placebo (PL) nasal spray and PL eye drops (PL/PL)."
10203929|NCT04707183|Experimental|Treatment Arm|10 mL of 2% lidocaine via ESPB
10203930|NCT04703205|Experimental|ivermectin|Ivermectin group: Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state) subjects take the study drug (3 mg tablet of ivermectin) at the dose of the study drug taken once per body weight of the subject.
10203931|NCT04703205|Placebo Comparator|placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state) the control drug (ivermectin placebo tablet) at the dose of the study drug taken once per body weight of the subject.
10203932|NCT04697212|Experimental|Healthcare team- + patient-directed intervention|Team education and patient tool
10203933|NCT04697212|Active Comparator|Healthcare team-directed intervention|Team education
10203934|NCT04681365||Simulation Suite|Participating staff will use BubblePAPR and evaluate its function in the non-clinical simulation suite, ensuring that simulated tasks appropriate to role can be undertaken safely whilst wearing the Bubble
10203935|NCT04681365||Low-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered low risk (ie non-COVID-19).
10203936|NCT04681365||High-Risk Clinical Environment|Participating staff will use BubblePAPR and evaluate its function in the usual clinical environments (wards, ICUs or Emergency Departments) but with patients who are considered high risk (ie suspected or confirmed COVID-19).
10203937|NCT04680598||high HBV-DNA group|patients with HBV-DNA >500 IU/ml
10203938|NCT04680598||low HBV-DNA group|patients with HBV-DNA≤500 IU/ml
10203939|NCT04677920|Experimental|Healthy Cookie Group|All participants in the study
10203940|NCT04677244|Experimental|Portal vein blood sample|
10203941|NCT04676711|Experimental|GFH312|
10203942|NCT04676711|Placebo Comparator|Placebo|
10203943|NCT04676334|Experimental|Rucaparib|Rucaparib administered at dose and schedule last taken in parent study, or per investigator decision
10203944|NCT04640727||open reduction and internal fixation|open reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
10203945|NCT04640727||closed reduction and internal fixation|closed reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
9774730|NCT01007253|Other|PL/OLO, FF/OLO, PL/PL, FF/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL), and~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)."
9774731|NCT01007253|Other|FF/OLO, PL/PL, FF/PL, PL/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO)."
9774732|NCT01007253|Other|PL/PL, FF/PL, PL/OLO, FF/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO)."
9774733|NCT01007396|Other|new healthcare workers|doctors and nurses who were newly hired in 2008 at the Samsung Medical Center
9774734|NCT01007435|Experimental|(A) Tocilizumab 8 mg/kg + placebo to methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
9774735|NCT01007435|Experimental|(B) Tocilizumab 8 mg/kg + methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
9774736|NCT01007435|Experimental|(C) Tocilizumab 4 mg/kg + methotrexate|Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
9774737|NCT01007435|Active Comparator|(D) Placebo to tocilizumab + methotrexate|Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.
9774738|NCT01007448|Experimental|Bexarotene 150 milligrams (mg)/square meter (m^2)/day|Participants will receive bexarotene 150 mg/m^2/day once daily for 24 weeks.
9774739|NCT01007448|Experimental|Bexarotene 300 mg/m^2/day|Participants will receive bexarotene 300 mg/m^2/day once daily for 24 weeks.
9774740|NCT01007526|Experimental|CCRT plus VIDL|CCRT followed by VIDL chemotherapy Concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation
9774741|NCT01007552|Experimental|Gemcitabine, Capecitabine and Bevacizumab|Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
9774742|NCT01007591|Active Comparator|LEO 80190 ointment|
9774743|NCT01007591|Active Comparator|Hydrocortisone 10 mg/g ointment|
9774744|NCT01007643|Experimental|Wii Fit (TM) Interactive Video Game|Wii Fit (TM) Interactive Video Game
9774745|NCT01007643|Active Comparator|Traditional Home Exercise Program|Traditional Home Exercise Program
9774746|NCT01007656|Experimental|GD Antrodia camphorata|"GD Antrodia Camphorata is the extract from mycelium of the fungus Antrodia Camphorata which is an endemic species in Taiwan. According to the literatures, mycelium of Antrodia camphorata is beneficial to health. Moreover, the study product GD Antrodia Camphorata has been approved by Department of Health, Taiwan as a health supplement (approval number A00124)."
9774747|NCT01007812|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week, followed by Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week.
9774748|NCT01007812|Other|Comfilcon A / Lotrafilcon B|Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week, followed by Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week.
9774749|NCT01007838|Experimental|Chronic kidney disease progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
9774750|NCT01007838|Sham Comparator|Chronic kidney disease sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
9774751|NCT01007838|Experimental|Healthy controls progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
9774752|NCT01007838|Sham Comparator|Healthy controls sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
9774753|NCT01007916|Other|Lotrafilcon B / Habitual|Lotrafilcon B contact lenses worn first, with habitual contact lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
9774754|NCT01007916|Other|Habitual / Lotrafilcon B|Habitual contact lenses worn first, with lotrafilcon B lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
9774755|NCT01007942|Experimental|Everolimus + vinorelbine + trastuzumab|Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
9774756|NCT01007942|Placebo Comparator|placebo + vinorelbine + trastuzumab|Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only
9774757|NCT01007994|Active Comparator|New Medication|A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.
10203946|NCT04639414|Experimental|Combined treatment with Empagliflozin and Semaglutide|Combined treatment with Empagliflozin, film-coated tablet, 10mg once daily and Semaglutide, colourless solution in pre-filled pen, 1mg once weekly
9774758|NCT01007994|No Intervention|Control|Subjects in the control group will continue to take their medications as usual.
9774759|NCT01008059|Experimental|Alfentanil|Alfentanil (0.5-1 mg IV bolus) followed 3 hours later or simultaneously by 1-4 mg oral deuterium-labeled (d3) alfentanil on each study visit.
9774760|NCT01008150|Active Comparator|Arm 1: paclitaxel + trastuzumab then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
9774761|NCT01008150|Experimental|Arm 2: paclitaxel + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
9774762|NCT01008150|Experimental|Arm 3: paclitaxel + trastuzumab + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
9774763|NCT01008150|Experimental|Arm 3 NR: paclitaxel+trastuzumab+neratinib|Non-randomized: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
9774764|NCT01008280|Experimental|Baclofen|baclofen 10 mg po tid
9774765|NCT01008280|Placebo Comparator|Placebo|placebo given tid
9774766|NCT01008319|Active Comparator|Traditional Administration|The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5). If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
10203947|NCT04639414|Experimental|Empagliflozin monotherapy|Empagliflozin, film-coated tablet, 10mg once daily and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
9774767|NCT01008319|Experimental|Stair-Step Administration|The stair-step protocol the dose of clomiphene citrate would be increased without administering progestin and inducing a period. This would eliminate the days of progestin (10 days) and the waiting for the period (usually 3 to 7 days) and finally waiting to start clomiphene citrate on cycle day 3 at the earliest (3 more days) for a total of up to 20 days difference for the 100 mg dose of clomid. If they did not ovulate on 100mg, then the process repeats and another 20 days before they start 150mg. Therefore, the time to ovulation and pregnancy may be reduced, and hopefully pregnancy, by using the stair-step protocol. This method utilizes ultrasound monitoring for follicle development before increasing the dose of clomiphene citrate.
9774768|NCT01008410|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
9774769|NCT01008410|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
10203948|NCT04639414|Placebo Comparator|Placebo|Placebo matching Empagliflozin (film-coated tablet, once daily) and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
10203949|NCT04637841|Active Comparator|Diabetes Mellitus Kinesiology Taping Group|Kinesiology tape will be applied to the left foot of the participants in diabetes mellitus group.
10203950|NCT04637841|Active Comparator|Kinesiology Taping Control Group|Kinesiology tape will be applied to the left foot of the healthy participants in the control group.
10203951|NCT04637841|Active Comparator|Diabetes Mellitus Myofascial Release Group|Myofascial Release Technique will be applied to the right foot of the participants in diabetes mellitus group.
10203952|NCT04637841|Active Comparator|Myofascial Release Control Group|Myofascial Release Technique taping will be applied to the right foot of the healthy participants in the control group.
10203953|NCT04630990||Participants Treated With Elagolix|Participants will receive Elagolix according to the local label.
10203954|NCT04620993||Group 1: pregnant women with pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy and have pelvic girdle pain.
10203955|NCT04620993||Group 2:pregnant women without pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy but have not pelvic girdle pain.
10203956|NCT04620993||Group 3: healthy women|This group will consist of healthy women who have not been pregnant.
9774770|NCT01008423|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
9774771|NCT01008423|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
9774772|NCT01008449|Active Comparator|Absorbable Subcuticular Surgical Suture|Patients in this arm will receive absorbable subcuticular suture for wound closure of cesarean deliveries.
9774773|NCT01008449|Active Comparator|Surgical staples|Patients in this arm will receive surgical staples for wound closure.
9774774|NCT01008462|Experimental|Treatment (autologous HCT, donor HCT)|See Detailed Description
9774775|NCT01008475|Experimental|Safety part: EMD 525797 250 mg + Standard of Care (SoC)|EMD 525797 250 mg in combination with cetuximab and irinotecan
9774776|NCT01008475|Experimental|Safety part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
9774777|NCT01008475|Experimental|Safety part: EMD 525797 750 mg + SoC|EMD 525797 750 mg in combination with cetuximab and irinotecan
9774778|NCT01008475|Experimental|Safety part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg in combination with cetuximab and irinotecan
9774779|NCT01008475|Experimental|Randomized part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
9774780|NCT01008475|Experimental|Randomized Part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg (or dose as defined by safety monitoring committee (SMC)] in combination with cetuximab and irinotecan.
9774781|NCT01008475|Other|Randomized Part: SoC|Cetuximab and irinotecan
9774782|NCT01008553|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
9774783|NCT01008553|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
9774784|NCT01008553|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
9774785|NCT01008605|Experimental|Caverject Impulse|representative users
9774786|NCT01008618|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will be continued for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
9835734|NCT02752490|Experimental|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
9774787|NCT01008618|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
9774788|NCT01008618|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
9774789|NCT01008696|Experimental|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
9774790|NCT01008696|Active Comparator|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
9774791|NCT01008748|Experimental|Smoking Cessation Treatment|Nicotine replacement therapy (NRT), self-help materials, + brief in-person and telephone counseling, all conducted in Spanish. Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
9774792|NCT01008904|Experimental|Supportive care (magnesium oxide)|Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.
9774793|NCT01008943|Experimental|1|
9774794|NCT01008995|Experimental|001|placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
9774795|NCT01008995|Experimental|002|placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16
9774796|NCT01009034||12 male HIV-positive patients|Male HIV-positive patients who have been receiving stable antiretroviral therapy that includes maraviroc for a minimum of three months.
9774797|NCT01009047|Experimental|Paliperidone extended-release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
9774798|NCT01009047|Active Comparator|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
9774799|NCT01009060|Experimental|GSK239512|Repeat dose.
10203957|NCT04613362|Experimental|TENACITY Telehealth Cognitive Behavioral Therapy|Six sessions of standardized Cognitive Behavioral Therapy for patients with diagnosed chronic migraine headaches will be delivered by a clinical health psychologist via telehealth platform. All patients have access to a set of standardized educational, headache self-management materials.
10203958|NCT04613362|Active Comparator|Usual Care Outpatient Cognitive Behavioral Therapy Face to Fa|Usual care Cognitive Behavioral Therapy will be delivered by clinical health psychologists for patients with diagnosed chronic migraines face to face at the VAMC outpatient clinics. All patients have access to a set of standardized educational, headache self-management materials.
10203959|NCT04612075||All patients referred to fast track clinical pathway for HNC cancer|MRI as part of staging, including a 5-minute additional sequence.
10203960|NCT04612075||Patients with locally advanced HNC|FDG-PET/MRI
10203961|NCT04608903|Experimental|Sulforaphane Group|Administration of 4g L-Sulforaphane per day, for 2 months and after the washout period (2 months) the groups will be crossed and will receive the same amount of placebo as the other group for 2 months.
10203962|NCT04608903|Placebo Comparator|Placebo Group|Administration of 4g of corn starch colored with chlorophyll, per day, for 2 months and then after the washout period (2 months) the groups will be crossed and will receive the same amount of sulfarophane as the treatment group.
10203963|NCT04607616|Experimental|3 baselines sessions Treatment As Usual (TAU)|Patients received 3 baseline sessions before interactive guidance therapy
9774800|NCT01009060|Placebo Comparator|Placebo|Repeat dose. Placebo to match GSK239512
9774801|NCT01009086|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
9774802|NCT01009086|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
10203964|NCT04607616|Experimental|4 baselines sessions TAU|Patients received 4 baseline sessions before interactive guidance therapy
10203965|NCT04607616|Experimental|5 baselines sessions TAU|Patients received 5 baseline sessions before interactive guidance therapy
10203966|NCT04607616|Experimental|6 baselines sessions TAU|Patients received 6 baseline sessions before interactive guidance therapy
10203967|NCT04607616|Experimental|7 baselines sessions TAU|Patients received 7 baseline sessions before interactive guidance therapy
10203968|NCT04607616|Experimental|8 baselines sessions TAU|Patients received 8 baseline sessions before interactive guidance therapy
10203969|NCT04605484|Experimental|Posoleucel|Arm 1: Regimen A
10203970|NCT04605484|Experimental|Posoleucel and Placebo|Arm 2: Regimen B
10203971|NCT04605484|Placebo Comparator|Placebo|Arm 3: Regimen A
10203972|NCT04581499|Experimental|DynamiCare Motivation Support Program|Intervention Group members will receive 32 weeks of remote Contingency Management (CM; financial motivational incentives), Recovery Coaching, substance testing, appointment reminding/tracking, and in-app Cognitive Behavioral Therapy (CBT). After 32 weeks, coaching, testing, appointment tracking and CBT will continue until an overall 12 months in the project is completed.
9774803|NCT01009086|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
9774804|NCT01009099|Experimental|Arm 1|exercise training with breathing retraining
9774805|NCT01009099|Active Comparator|Arm 2|exercise training
9774806|NCT01009138|Experimental|Diabetes-Specific CBT (DS-CBT)|Cognitive Behavioral Intervention (Group) focusing on Diabetes-Specific Problems
9774807|NCT01009138|Active Comparator|Standard Diabetes Education|Standard Diabetes Education Lessons will be given to quantify the unspecific antidepressive Effects of Participation in Group Sessions with social Contact and Acquisition of Knowledge.
9774808|NCT01009203|Experimental|Temsirolimus and Erlotinib|Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days
9774809|NCT01009281|Experimental|AIN457|
9774810|NCT01009333|Experimental|Low InterStim rate setting at 5.2 Hz|
9774811|NCT01009333|Experimental|Medium InterStim rate setting at 14 Hz|
9774812|NCT01009333|Experimental|High InterStim rate setting at 25 Hz|
9774813|NCT01009346|Experimental|RAD001|Daily RAD001 in combination with weekly cetuximab and cisplatin/ carboplatin on Day 1, 8 of each 28 day cycle.
9774814|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9774815|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9774816|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9774817|NCT01009463|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
9774818|NCT01009515|Experimental|Chemotherapy Combination|Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.
9774819|NCT01009554|Experimental|Potassium Oxylate|1.5% potassium oxalate sensitive mouthwash
9774820|NCT01009554|Active Comparator|Sodium Fluoride|Sodium Fluoride Dentifrice
9774821|NCT01009580|Experimental|IDegAsp BID|
9774822|NCT01009580|Experimental|BIAsp 30 BID|
9774823|NCT01009619|Experimental|Azithromycin|250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
9774824|NCT01009619|Placebo Comparator|Placebo|PLacebo daily for 5 days, followed by placebo three times a week (Mon.-Wed.-Fri.) until end of study.
9774825|NCT01009645|Experimental|Fact Only|The educational message used will contain facts only.
9774826|NCT01009645|Experimental|Fact and Myth|The educational material seen by this arm will contain facts and myths only.
9774827|NCT01009645|Experimental|Fact, Myth, Why|The educational material seen by this arm will contain myths, facts, and refutations of the myths.
9774828|NCT01009645|Placebo Comparator|Control|This arm will receive fact/myth educational materials originally developed and used by the CDC.
9774829|NCT01009762|Placebo Comparator|Saline|Sterile saline for injection is used as placebo arm. It is administered i.m. in the same way as for the active vaccine, week 0, 2, 4, 8.
9774830|NCT01009762|Active Comparator|AFO-18 vaccine|the intervention is injection of the experimental therapeutic peptide vaccine (AFO-18) consisting of 18 peptides in CAF01 adjuvant intra muscularly (i.m.) week 0, 2, 4, 8
9774831|NCT01009814|Experimental|BMS-663068 600 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8.
9774832|NCT01009814|Experimental|BMS-663068 1200 mg QHS + RTV 100 mg QHS|All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni [QHS]) from Day 1 to Day 8.
9774833|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 1200 mg and RTV 100 mg Q12H from Day 1 to Day 8.
9774834|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg QAM|All participants received BMS-663068 1200 mg Q12H and RTV 100 mg every 24 hours in the morning (quaque ante meridiem [QAM]) from Day 1 to Day 8.
9774835|NCT01009814|Experimental|BMS-663068 1200 mg Q12H|All participants received BMS-663068 1200 mg Q12H from Day 1 to Day 8.
9774836|NCT01009840|Experimental|IV busulfan|Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
9774837|NCT01009918|Experimental|Arm I lisinopril|Patients receive oral lisinopril once daily.
9774838|NCT01009918|Experimental|Arm II Coreg CR®|Patients receive oral Coreg CR® once daily.
9774839|NCT01009918|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily.
9774840|NCT01009983|Experimental|Arm 1|Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.
9774841|NCT01010009|Experimental|Resveratrol 250mg|
9774842|NCT01010009|Experimental|Resveratrol 500mg|
9774843|NCT01010009|Placebo Comparator|Placebo|
9774844|NCT01010061|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
9774845|NCT01010061|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
9774846|NCT01010061|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
9774847|NCT01010126|Experimental|Treatment (temsirolimus, bevacizumab)|Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9774848|NCT01010204|Experimental|Varenicline|We will be comparing Varenicline to placebo in a double-blind placebo controlled, randomized study.
9774849|NCT01010204|Placebo Comparator|Placebo|We will be using placebo in a randomized, controlled, and blinded trial to compare to varenicline in subjects with bipolar disorder.
9774850|NCT01010217|Experimental|Haploidentical related|Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day
9774851|NCT01010217|Experimental|1 Antigen Mismatch Related or Unrelated|Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.
9774852|NCT01010217|Experimental|Matched Unrelated Donor (MUD)|Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide
9774853|NCT01010230|Placebo Comparator|LMHF mechanical stimulation placebo device|The placebo device is identical in appearance and function to the active platform; except when activated, it emits the same sound as the active device but does not deliver the vibration.
9774854|NCT01010230|Active Comparator|LMHF mechanical stimulation|"Low magnitude, high frequency mechanical stimulation device (vibrating) platform"
9774855|NCT01010282|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
9774856|NCT01010282|Experimental|Artificial Tears Formulation 1|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
9774857|NCT01010282|Experimental|Artificial Tears Formulation 2|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
9774858|NCT01010399|Experimental|Boosted Lexiva with Lovaza|
9774859|NCT01010477|Experimental|Nicotine Nasal Spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. . Nasal spray will be used from the TQD through the end of Week 20.
9774860|NCT01010477|Placebo Comparator|Placebo nasal spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Nasal spray will be used from the TQD through the end of Week 20.
9774861|NCT01010503|Experimental|Single Arm|
9774862|NCT01010555|Active Comparator|lotrafilcon B|Lotrafilcon B contact lens randomly assigned to one eye, with balafilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
9774863|NCT01010555|Active Comparator|balafilcon A|Balafilcon A contact lens randomly assigned to one eye, with lotrafilcon B contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
9774864|NCT01010555|Active Comparator|senofilcon A|Senofilcon A contact lens randomly assigned to one eye, with enfilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
10203973|NCT04581499|Other|Untreated or Routine Care Control Group|Control participants will receive substance tests at the same frequency as Intervention participants, and the same incentive amounts for tests as treatment participants. Controls' payments, however, will not be contingent on positive/negative results, but rather only on valid, on-time submission. Controls will not receive coaching, CBT or rewards for appointments.
10203974|NCT04579939|Experimental|Experimental|All 10 participants will go through the experimental arm receiving the dextrose candy oral glucose tolerance test.
10203975|NCT04579549|Experimental|Repeat Testing for SARS-CoV-2|Anyone over the age of 5yrs old with consent to provide a saliva sample for SARS-CoV-2 assay will be eligible to participate. Assay takes 20 minutes.
10203976|NCT04579029|Experimental|Surgical Cohort|"Patients randomised to the surgical group will undergo near infrared spectroscopy imaging to assess suitability and plan the surgical procedure.~Limb measurements with perometry and bio-impedance spectroscopy will be performed at baseline. Under general anaesthetic multiple LVA bypass procedures will be performed on the affected arm. Near infrared spectroscopy imaging will be used throughout. One week after discharge the patient will return for the bandages to be removed and the wounds inspected for any evidence of infection before renewing the bandage. Again, two weeks after surgery, the patient will return for inspection of wound and removal of sutures. It is at this point that the surgical patients will be returned into a standard lymphoedema compression garment, fitted by the research nurse. Thereafter, standard follow up (Bilateral) measurements and checks will be done at 1 month, 3 months, 6 months and 1 year."
10203977|NCT04579029|No Intervention|Non-surgical cohort|"The main intervention for the non-surgical group largely encompasses limb measurements with perometry and bio-impedance spectroscopy at baseline before a compression garment is applied. The compression garments will be measured and fitted by a trained lymphoedema specialist and will be given the standard advice as is best practice for such patients currently. This cohort will likewise be followed up at 1 month, 3 months, 6 months and 1 year and undergo perometry readings and measurements with comparable collection of data.~For patients in both surgical and non-surgical groups, the compression garments will be measured and fitted by a trained lymphoedema specialist and they will be given the standard advice as is best practice for such patients currently. For each patient key details of the surgical technique, garment specification, imaging results and perometry/BIS measurements will be recorded on a study specific form for subsequent entry onto the database."
9774865|NCT01010555|Active Comparator|enfilcon A|Enfilcon A contact lens randomly assigned to one eye, with senofilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
9774866|NCT01010568|Experimental|Ofatumumab and Bendamustine|Ofatumumab and Bendamustine
9774867|NCT01010633|Experimental|Loteprednol Etabonate|Loteprednol etabonate
9774868|NCT01010633|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate
9774869|NCT01010750|Active Comparator|LDX + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
9774870|NCT01010750|Active Comparator|MAS-IR + LDX Placebo|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
9774871|NCT01010750|Placebo Comparator|Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
9774872|NCT01010763|Experimental|M2a Magnum|Total HIp Arthroplasty using with the M2a Magnum Large Metal Articulation is an ultra-high performance metal-on-metal articulation with a big ball (greater than or equal to 38mm) in acetabulums as small as 44mm.
9774873|NCT01010763|Active Comparator|M2a Taper|Total Hip Arthroplasty using with the M2a Taper Acetabular System consists of a titanium outer shell with cobalt chromium (Co-Cr-Mo) metallic liner, which articulates with with a cobalt chromium (Co-Cr-Mo) modular femoral head.
9774874|NCT01010776|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
9774875|NCT01010854|Experimental|VPA FEC100|Valproic Acid with FEC100
9774876|NCT01010867|Experimental|Lactobacillus plantarum|There is a single intervention arm in this study. Target accrual for the intervention is 30 subjects. Subjects receive supplementation with Lactobacillus plantarum strains 299 and 299v.
9774877|NCT01010906|Experimental|Mild Hepatic Insufficiency (HI)|Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
9774878|NCT01010906|Experimental|Healthy Control to Mild HI|Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir
9774879|NCT01010906|Experimental|Moderate HI|Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
9774880|NCT01010906|Experimental|Healthy Control to Moderate HI|Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir
10203978|NCT04577209|Experimental|Pediatric Patients|Participants undergoing anesthesia-related aerosol generating medical procedures (AGMPs) and pediatric otolaryngologic surgeries will have a local exhaust ventilation system to the exposure seen by the medical providers during the AGMPs and surgeries.
10203979|NCT04562740|Experimental|ABLUMINUS DES|"ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.~Sirolimus drug dosage on the ABLUMINUS DES drug eluting stent system is determined by Concept Medical to deliver the optimal dose of sirolimus to the abluminal surface of the BTK lesions."
10203980|NCT04561453||Resected Biliary Duct Cancer|
9774881|NCT01010906|Experimental|Severe HI|Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
9774882|NCT01010906|Experimental|Healthy Control to Severe HI|Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
9784774|NCT01234402|Active Comparator|Capecitabine*|"Crossover Study:~* At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given.~Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant."
9784775|NCT01234467|Experimental|Bendamustine, Rituximab|This is a single arm intervention where patients will receive bendamustine at a dose of 120 mg/m^2 infused over 60 minutes in days 1 and 2 of each 21 day cycle along with rituximab 375 mg/m^2 after bendamustine on day 1 of each cycle. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 at baseline were allowed to receive bendamustine at a dose of 90 mg/m^2 daily with a dose increase to 120 mg/m^2 daily if their ECOG improved.
9784776|NCT01234480|Experimental|Participants with Cervical Disease|Participants positive for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
9784777|NCT01234480|Experimental|Participants without Cervical Disease|Participants negative for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
9835735|NCT02752633|Experimental|Study subjects|Following a 7 day washout period all patients receive allopurinol (400 mg/day) as a single daily dose for 2 weeks. Following another 7 day washout period all participants receive febuxostat, 80 mg/day as a single daily dose, for 2 weeks.
10203981|NCT04560127|Experimental|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
10203982|NCT04545112|Experimental|XABG|
10203983|NCT04544098|Experimental|PRRT with 177Lu-DOTATATE|Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration.
10203984|NCT04540068||Patients with Lumbar Disc Herniation|Patients with a lumbar disc herniation on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
10203985|NCT04540068||Patients with Lumbar Spinal Stenosis|Patients with a lumbar spinal stenosis on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
10203986|NCT04529473|Placebo Comparator|Placebo|1 capsule per day, consumed orally, before breakfast for the duration of the study.
9774883|NCT01010932|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
9774884|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 160 μg|160 μg once daily
9774885|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 80 μg|80 μg once daily
9774886|NCT01010971|Placebo Comparator|Placebo|Placebo
9774887|NCT01010984|Experimental|Transcatheter Arterial Chemoembolization|TACE using LC beads loaded with Doxorubicin
9774888|NCT01011049|Experimental|Group 1: Fluzone ID After Fluzone ID|Participants will receive Fluzone intradermal (ID) following Fluzone ID in Study FID31
9774889|NCT01011049|Experimental|Group 2: Fluzone IM After Fluzone ID|Participants will receive Fluzone intramuscular (IM) following Fluzone ID in Study FID31
9774890|NCT01011049|Experimental|Group 3: Fluzone IM After Fluzone IM|Participants will receive Fluzone intramuscular (IM) following Fluzone IM in Study FID31
9774891|NCT01011049|Experimental|Group 4: Fluzone ID After Fluzone IM|Participants will receive Fluzone intradermal (ID) following Fluzone intramuscular (IM) in Study FID31
9774892|NCT01011075|Experimental|Imatinib mesylate + Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
9774893|NCT01011153||All Dermatologists|
9774894|NCT01011179|Experimental|Internet-based JIA Self-Management Program|
9774895|NCT01011179|Active Comparator|Attention Control Group|
9774896|NCT01011218|Experimental|BBT-I + Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~Armodafinil 150 mg/day by mouth."
9774897|NCT01011218|Experimental|Behavioral placebo + Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~Armodafinil 150 mg/day by mouth."
9774898|NCT01011218|Sham Comparator|BBT-I without Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~No pharmaceutical intervention."
9774899|NCT01011218|Placebo Comparator|Behavioral placebo without Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~No pharmaceutical intervention."
9774900|NCT01011283|Active Comparator|1|
9774901|NCT01011283|Active Comparator|2|
9774902|NCT01011309|Experimental|LEISH-F2 + MPL-SE vaccine|Recombinant three antigen Leishmania polyprotein + MPL-SE adjuvant
10203987|NCT04529473|Experimental|Eubacterium hallii|1 capsule per day, consumed orally, before breakfast for the duration of the study.
9774903|NCT01011309|Active Comparator|Sodium stibogluconate (SSG)|20 mg/kg/day IV for 20 days
9774904|NCT01011335|Experimental|Active Vaccine|Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
9774905|NCT01011335|Placebo Comparator|Placebo with Alum|
9774906|NCT01011335|Placebo Comparator|Saline Placebo|
9774907|NCT01011387|Other|NPWT system|Negative pressure wound therapy
9774908|NCT01011413|Active Comparator|600 milligram (mg) Efavirenz|Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
9774909|NCT01011413|Experimental|400mg Efavirenz|Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
10203988|NCT04518345|Experimental|Treatment (dubermatinib)|"FLT3 AML WITH RELAPSED/REFRACTORY DISEASE:~INDUCTION: Patients receive dubermatinib PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission."
10203989|NCT04518033|Experimental|Face covering use|Participants will be provided various commercially available face coverings
10203990|NCT04516876|Experimental|Camp-based bimanual intensive training(BIT)|
10203991|NCT04516473||Experimental/Body Contouring Intervention|These are participants who have self-selected to undergo an abdominal body contouring procedure within the course of the study.
9774910|NCT01011439|Experimental|Milciclib Maleate (PHA-848125AC)|100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
9774911|NCT01011465|Experimental|Oxytocin|One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol
9774912|NCT01011465|Placebo Comparator|Placebo|The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray
9774913|NCT01011465|Experimental|Social Support|Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks
9774914|NCT01011465|Placebo Comparator|No Social Support|Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.
9774915|NCT01011465|Other|Female Gender|Effects of oxytocin and social support are examined among women versus men
9774916|NCT01011465|Other|Male Gender|Consider effects of oxytocin and social support in men versus women
9774917|NCT01011556|Active Comparator|20 mcg Subcutaneous Teriparatide|Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
9774918|NCT01011556|Experimental|30 mcg Transdermal Teriparatide|Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
9774919|NCT01011556|Experimental|50 mcg Transdermal Teriparatide|Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
9774920|NCT01011556|Experimental|80 mcg Transdermal Teriparatide|Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
9774921|NCT01011673|Active Comparator|Ketorolac|Ketorolac 30mg IVSS
9774922|NCT01011673|Active Comparator|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
9774923|NCT01011738||Cohort|
9774924|NCT01011816|Experimental|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
9774925|NCT01011816|Placebo Comparator|Saline|One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
9774926|NCT01011829|Active Comparator|Varenicline|"Varenicline:~0.5 mg daily for days 1-3~0.5 mg twice daily for days 4-7~1 mg twice daily from day 8 until end of week 8."
9774927|NCT01011829|Placebo Comparator|Placebo|8 weeks of daily matching oral placebo in tablet form
9774928|NCT01011868|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose daily
9774929|NCT01011868|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose daily
9774930|NCT01011868|Placebo Comparator|placebo|Patients receive placebo to match BI 10773 daily
9774931|NCT01011894|Experimental|pts getting lenalidomide|Patients with intermediate or high-risk chronic lymphocytic leukemia (≥ 65 years old) will receive lenalidomide until disease progression at the 20mg dose level (recognizing that progression at this dose requires non-protocol alternate therapy) or unacceptable toxicity.
9774932|NCT01011907|Experimental|varenicline|Drug: varenicline (Chantix) 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
9774933|NCT01011907|Placebo Comparator|placebo|Drug: placebo for varenicline 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
9774934|NCT01011933|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood and archived tumor tissue samples are collected for biomarker studies.
9774935|NCT01011946|Experimental|Positron Emission Mammography|
9774936|NCT01012037|Experimental|linagliptin low dose|linagliptin low dose twice daily
9774937|NCT01012037|Placebo Comparator|placebo|placebo matching linagliptin
9774938|NCT01012037|Experimental|linagliptin medium dose|linagliptin medium dose once daily
9774939|NCT01012089|Experimental|Daptomycin|Pediatric patients on hemodialysis or peritoneal dialysis with suspected or confirmed infection and who were receiving standard of care antibiotics were also eligible to receive a single dose of daptomycin 5mg/kg IV. Serial blood draws were obtained to assess daptomycin pharmacokinetics
9774940|NCT01012219|Experimental|Period 1|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
9774941|NCT01012219|Experimental|Period 2|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
9774942|NCT01012219|Experimental|Period 3|
9774943|NCT01012245||patients with glaucoma and ocular hypertension|
9774944|NCT01012258|Experimental|Cetuximab|All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course
9774945|NCT01012297|Experimental|Arm I Gem+Doce+Placebo|Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.
9774946|NCT01012297|Experimental|Arm II Gem+Doce+Bev|Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.
9774947|NCT01012323|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.
9774948|NCT01012336|Experimental|Aprepitant|
9774949|NCT01012362|Experimental|Optimum Tolerated Dose Determination|"Patient receives assigned dose level:~Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2."
9774950|NCT01012362|Experimental|Optimum Tolerated Dose Confirmation|Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.
9774951|NCT01012388|Experimental|Radiesse|
9774952|NCT01012440|Experimental|Beast cancer subjects|Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods
9774953|NCT01012492|Experimental|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
9774954|NCT01012622|Experimental|OROS Methylphenidate Hydrochloride|
9774955|NCT01012661|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).
9774956|NCT01012661|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face.
9774957|NCT01012674|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
9774958|NCT01012713|Experimental|Open-Label Treatment|All patients will receive treatment with Clobex Spray, Vectical Ointment, and Excimer Laser
9774959|NCT01012739|Experimental|Indacaterol 150μg-placebo-Indacaterol 60μg-Indacaterol 120μg|In treatment period 1, patients received indacaterol 150 μg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 μg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9774960|NCT01012739|Experimental|Indacaterol 60μg-Indacaterol 150μg-Indacaterol 120μg-placebo|In treatment period 1, patients received indacaterol 60 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 μg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 μg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9774961|NCT01012739|Experimental|Indacaterol 120μg-Indacaterol 60μg-placebo-Indacaterol 150μg|In treatment period 1, patients received indacaterol 120 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 μg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 μg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9784778|NCT01234649|Experimental|Metformin XR plus liraglutide|Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
9784779|NCT01234649|Active Comparator|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
9774962|NCT01012739|Experimental|Placebo-Indacaterol 120μg- Indacaterol 150μg- Indacaterol 60μg|In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 μg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 μg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
9774963|NCT01012765|Experimental|Indacaterol - placebo - tiotropium|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
9774964|NCT01012765|Experimental|Placebo - Tiotropium - Indacaterol|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
9774965|NCT01012765|Experimental|Tiotropium - indacaterol - placebo|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
9984305|NCT04238715|Experimental|E7090 140 mg|Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.
9774966|NCT01012765|Experimental|Placebo - indacaterol - tiotropium|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
9784780|NCT01234675|Experimental|milnacipran|Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
9984306|NCT04237857||LSG|Chinese patients who received laparoscopic sleeve gastrectomy at Prince of Wales Hospital, The Chinese University of Hong Kong for more than 36 months
9984307|NCT04236609|Active Comparator|Abluminus DES+ sirolimus- eluting stents (SES)|Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).
9774967|NCT01012765|Experimental|Indacaterol - tiotropium - placebo|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
9774968|NCT01012765|Experimental|Tiotropium - placebo - indacaterol|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
9774969|NCT01012921|Active Comparator|Bio-Gide® membrane|Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
9774970|NCT01012921|Experimental|MembraGel|MembraGel The Straumann membrane is a synthetic degradable barrier membrane
9774971|NCT01012947|Experimental|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
9774972|NCT01012947|Experimental|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
9774973|NCT01012947|Experimental|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
9774974|NCT01012947|Experimental|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
9774975|NCT01012947|Experimental|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
9774976|NCT01012973|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
9774977|NCT01012973|Sham Comparator|Sham treatment|Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.
9774978|NCT01012999|Experimental|Intranasal sufentanil, pain relief|Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period
9774979|NCT01013194|Experimental|Treated patients|Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.
9774980|NCT01013194|No Intervention|Control patients|Cirrhotic patients on Standard therapy.
9774981|NCT01013207|Experimental|Nexus (S9) CPAP device|"Fifty subjects with obstructive sleep apnea (OSA), established on CPAP therapy (≥ 6 months) were recruited into this study. These patients use their CPAP device every night while sleeping to treat their OSA.~Nexus (S9) is a new CPAP device with improved humidification system (heated tube and climate control), reduced noise, improved comfort of breathing and new user interface. During the study, patients will use this CPAP every night in place of their own CPAP for a period of 4 weeks. Compliance data from the Nexus will then be compared to the patient's usual CPAP pre trialling Nexus and post trialling Nexus."
9774982|NCT01013285|Experimental|bevacizumab, temozolomide, external beam radiation|
9774983|NCT01013350||Never Exposed to Cladribine|All participants who received placebo matched to cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826 , NCT00641537, NCT00938366 and NCT00725985).
9774984|NCT01013350||Exposed to Cladribine|All participants who received cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826, NCT00641537, NCT00938366 and NCT00725985).
9774985|NCT01013597|Experimental|LBH589|
9774986|NCT01013740|Experimental|Lapatinib + Vinorelbine|Lapatinib + Vinorelbine
9774987|NCT01013740|Active Comparator|Lapatinib + Capecitabine|Lapatinib + Capecitabine
9774988|NCT01013753|Experimental|Olodaterol (BI 1744) low|Low dose inhaled orally once daily from the Respimat inhaler
9774989|NCT01013753|Experimental|Olodaterol (BI 1744) very low|Very low dose inhaled orally once daily from the Respimat inhaler
9774990|NCT01013753|Experimental|Olodaterol (BI 1744) medium|Medium dose inhaled orally once daily from the Respimat inhaler
9774991|NCT01013753|Experimental|Olodaterol (BI 1744) high|High dose inhaled orally once daily from the Respimat inhaler
9774992|NCT01013753|Active Comparator|Formoterol 12 mcg|12mcg inhaled twice daily from the Aerolizer inhaler
9774993|NCT01013753|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
9774994|NCT01013792|Experimental|Non-adherent Wound Dressing|The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
9774995|NCT01013792|Active Comparator|Tegaderm Matrix Dressing with PHI|A commercial wound dressing to be used per manufacturer's instructions for use.
9774996|NCT01013844|Active Comparator|Solo Learning|Participant learning alone (without partner).
9774997|NCT01013844|Active Comparator|Dyadic Learning|Participant and partner learning together.
9774998|NCT01013870|Experimental|MTBI subjects randomized to drug|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the treatment arm of the phase II drug trial of atorvastatin. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for seven days and started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving a placebo.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
9784781|NCT01234675|Placebo Comparator|placebo|Drug: placebo 45-day placebo treatment before or after crossover to milnacipran
9784782|NCT01234714||Major liver resection|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (>=3 segments).
9784783|NCT01234766|Experimental|Single Arm|Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
9774999|NCT01013870|Placebo Comparator|MTBI subjects randomized to placebo|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the placebo arm of the phase II drug trial of atorvastatin. These subjects will receive a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
9775000|NCT01013883||systolic dysfunction|patients having left ventricular systolic dysfunction on echocardiography
9775001|NCT01013883||distolic heart failure|patients with clinical heart failure and preserved LV systolic dysfunction
9775002|NCT01013961|Active Comparator|Arm A (standard dose)|"Patients receive alemtuzumab subcutaneously (SC) on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and standard-dose rituximab 375 mg/m^2/week intravenously (IV) on days 8, 15, 22, and 29 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and standard-dose rituximab IV on days 3, 10, 17, and 24. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
9775003|NCT01013961|Experimental|Arm B (low dose)|"Patients receive alemtuzumab SC on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and low-dose rituximab at 20 mg/m^2 IV on days 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC and low-dose rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
9775004|NCT01014013|Experimental|ertapenem sodium (MK0826)|ertapenem sodium
9775005|NCT01014013|Active Comparator|ceftriaxone sodium|ceftriaxone sodium
9775006|NCT01014091|Experimental|GSK2340272A F1 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
9775007|NCT01014091|Experimental|GSK2340272A F1 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
9775008|NCT01014091|Experimental|GSK2340272A F2 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
9775009|NCT01014091|Experimental|GSK2340272A F2 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
9775010|NCT01014091|Experimental|GSK2340272A F3 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
9775011|NCT01014091|Experimental|GSK2340272A F3 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
9775012|NCT01014143|Placebo Comparator|Fluoride toothpaste|Negative control
9775013|NCT01014143|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste
9775014|NCT01014143|Active Comparator|Chlorhexidine Oral Rinse|Positive Control mouthrinse
9775015|NCT01014169|No Intervention|Usual care|Mothers in the control group will receive the nursing discharge newborn information from the nurse practitioner [sometimes via a Spanish interpreter, if required] according to current standard of care, which includes verbal information and written handouts.
9775016|NCT01014169|Experimental|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of the discharge envelope using their language of preference when receiving the standard newborn information.
9775017|NCT01014208|Experimental|OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with ofatumumab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with ofatumumab. All subjects will receive the same ofatumumab regimen and dose.
9775018|NCT01014208|Active Comparator|RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with rituximab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with rituximab. All subjects will receive the same rituximab regimen and dose.
9775019|NCT01014351|Experimental|Paclitaxel/Carboplatin/Everolimus|Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
9775020|NCT01014390|Experimental|WallFlex Biliary RX FC Stent System|The WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
9775021|NCT01014403|Experimental|enoxaparin 30 mg SQ q12 hours|Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.
9775022|NCT01014403|Placebo Comparator|placebo|vehicle administered sq q 12 hours
9775023|NCT01014442|Experimental|Mycophenolate Mofetil; Cystic Fibrosis|Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
9775024|NCT01014442|Experimental|Mycophenolate Mofetil; Other|Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
9775025|NCT01014455|Experimental|CO reminder|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
9775026|NCT01014455|Placebo Comparator|no CO reminder|a brief intervention that recommends fasting but does not mention that CO will be checked
9775027|NCT01014533|Placebo Comparator|Placebo|After 3 nights in the UM sleep lab and randomization, this arm receives placebo for one week. They then return to the sleep lab for the same procedures.
9775028|NCT01014533|Active Comparator|Gabapentin|After spending 3 baseline nights in the UM sleep lab, alcohol dependent subjects are randomized. This arm receives gabapentin . On nights 1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8-10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.
9775029|NCT01014585|Placebo Comparator|1|Placebo tablets administered orally twice daily
9775030|NCT01014585|Experimental|2|Milnacipran tablets administered orally twice daily
9775031|NCT01014624|Experimental|Prasugrel|Prasugrel 10mg administered for 7 days followed by a Washout Period up to 12 days.
9775032|NCT01014624|Active Comparator|Clopidogrel|Clopidogrel 75mg administered for 7 days followed by a 12 day Washout Period up to 12 days.
9775033|NCT01014689|Active Comparator|Adapalene 0.1% / BPO 2.5% gel|
9775034|NCT01014689|Placebo Comparator|Adapalene 0.1% / BPO 2.5% Vehicle Gel|
9775035|NCT01014728|Active Comparator|Intravenous anesthesia|Intravenous anesthesia with propofol for endoscopic sinus surgery
9775036|NCT01014728|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane for endoscopic sinus surgery
9775037|NCT01014741|Experimental|Ibutilide arm|
9775038|NCT01014741|Placebo Comparator|Placebo arm|
9775039|NCT01014871|Other|intra-individual comparison|
9775040|NCT01014910|Active Comparator|Continuous pulse oximetry monitoring|Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
9775041|NCT01014910|Active Comparator|Intermittent pulse oximetry monitoring|Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
9775042|NCT01014936|Experimental|MSC2156119J Regimen 1|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.
9775043|NCT01014936|Experimental|MSC2156119J Regimen 2|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.
9775044|NCT01014936|Experimental|MSC2156119J Regimen 3|Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.
9775045|NCT01014975|Experimental|20 mg Plasmin (Human)|20 mg of Plasmin (Human)
9775046|NCT01014975|Experimental|40 mg Plasmin (Human)|40 mg of Plasmin (Human)
9775047|NCT01014975|Experimental|80 mg Plasmin (Human)|80 mg of Plasmin (Human)
9775048|NCT01014988|Other|Single Arm|A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir in an expedited manner. This study design also facilitates the provision of safety data on a real-time basis, if necessary.
9775049|NCT01015118|Experimental|BIBF 1120|patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
9775050|NCT01015118|Placebo Comparator|Placebo|patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
9775051|NCT01015131|Experimental|All Participants|18F-FLT-PET imaging
9775052|NCT01015170|Experimental|Bupropion HCl|Up to 8 week of bupropion SR (150mg BID) + counseling.
9775053|NCT01015287|Experimental|Non pre-treatment|A placebo oral loading dose is given at the time of diagnosis and a 60 milligrams (mg) oral loading dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.
9775054|NCT01015287|Experimental|Split Loading Dose|A 30 mg oral loading dose of prasugrel is given at diagnosis and a 30 mg oral dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days
9775055|NCT01015326||Expert Interviews|Expert cohort consists of providers with expertise in administering epidermal growth factor receptor inhibitors (EGFRI) or treating patients with EGFRI-associated skin toxicities. Experts will be asked open-ended questions about symptoms and issues as they relate to HRQL in patients with EFGRI skin toxicities. Experts will then be presented with a pool of potential items and will be asked through interview and questionnaire to relate items according to how common and how important they are when occurring in patients with this condition.
9775056|NCT01015326||Patient Interviews|Patient cohort will consist of those treated with an epidermal growth factor receptor inhibitor (EGFRI) and referred to a specialized dermatology clinic for skin rash management. Patients will be asked open-ended questions about symptoms and issues as they relate to their HRQL to elicit personal experiences about how EGFRI skin toxicities and its treatment affects patients. Patients will be asked through interview and questionnaire to rate items according to how often they are experienced and how important they are to the patient.
9775057|NCT01015443|Experimental|Investigational Arm|Tecemotide (L-BLP25) + Single low dose cyclophosphamide + Best supportive care (BSC)
9775058|NCT01015443|Placebo Comparator|Control Arm|Saline + Placebo + Best supportive care (BSC)
9775059|NCT01015534|Experimental|Whole brain irradiation plus Temozolomide|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
9775060|NCT01015534|Active Comparator|Whole brain irradiation|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks
9775061|NCT01015560|Experimental|treatment|MLN1202 8mg/kg IV Days 1, 15, 29 given as 1 6 week cycle
9775062|NCT01015586|Experimental|Lamotrigine|Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
9775063|NCT01015586|Placebo Comparator|Placebo|Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
9775064|NCT01015612|Experimental|Medtronic CoreValve® System Implantation|Patients with symptomatic severe aortic stenosis who have an elevated surgical risk
9775065|NCT01015638|Experimental|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
9775066|NCT01015638|Active Comparator|Clindamycin phosphate and BPO 2.5% gel|Once Daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel.
9775067|NCT01015677|Experimental|MK-6913 75 mg|MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and Stage 2)
9775068|NCT01015677|Active Comparator|17-β estradiol 1 mg|17β-estradiol 1 mg tablet and matching placebo for MK-6913 75 mg capsule once daily for 4 weeks (Stage 1 and Stage 2)
9775069|NCT01015677|Placebo Comparator|Placebo|Matching placebo for MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and State 2)
9775070|NCT01015677|Experimental|MK-6913 25 mg|MK-6913 25 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 2)
9775071|NCT01015703|Experimental|CoVaccine HT|
9775072|NCT01015768|Experimental|Test eye|Uses ReNu Multiplus as multipurpose soaking solution
9775073|NCT01015768|Active Comparator|Control|A new lens (PureVision) is soaked for 2 hours in non-preserved saline
9775074|NCT01015781|Experimental|Arm 1|Progressive Tinnitus Management
9775075|NCT01015781|Other|Arm 2|Wait List Control
9775076|NCT01015807|Placebo Comparator|Placebo|Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
9775077|NCT01015807|Active Comparator|TAP (Bupi)|2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
9775078|NCT01015807|Active Comparator|Clo-TAP (Bupi + Clon)|2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
9775079|NCT01015820|Experimental|Cancer group|Participants in this group had pathologically confirmed pancreatic adenocarcinoma. They received an EGD with EUS. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
9775080|NCT01015820|Other|Control group|Participants in this group were without pancreatic adenocarcinoma. Participants in the control group received an EGD with EUS for the indication of abdominal pain. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
9775081|NCT01015976|Experimental|Post bariatric surgery|Roux en Y bariatric surgery
9775082|NCT01015976|Other|Control|No surgery
9775083|NCT01016015|Experimental|Treatment (cixutumumab and temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9775084|NCT01016067|Experimental|INFUSE/MASTERGRAFT|Patients received INFUSE/MASTERGRAFT granules with rigid internal fixation.
9775085|NCT01016067|Active Comparator|Autograft bone|Patients received autograft bone with rigid internal fixation.
9784784|NCT01234831|Other|Active Screening|Patients randomized to active screening will have two nasal swabs collected daily for 3 days, for both nucleic acid amplification and culture (CHROMagar)assays.
9784785|NCT01234831|Other|Passive Screening|Patients randomized to passive screening will not actively be identified for testing but may be tested using culture-based algorithm by care team.
9784786|NCT01234870|Experimental|Ischemic heart disease patients|Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
9784787|NCT01234883|Experimental|multiple electrolyte solution|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
9784788|NCT01234883|Active Comparator|saline|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
9784789|NCT01234922|Experimental|Arm I|Patients receive oral benazepril hydrochloride once daily on days 1-7.
9784790|NCT01234922|Experimental|Arm II|Patients receive oral lisinopril once daily on days 1-7.
9784791|NCT01234922|Experimental|Arm III|Patients receive oral ramipril twice daily on days 1-7.
9784792|NCT01234922|Experimental|Arm IV|Patients receive oral losartan potassium once daily on days 1-7.
9784793|NCT01235195|Active Comparator|Sertraline 50 mg capsules|
9784794|NCT01235195|Active Comparator|Sertraline 50 mg tablet|
9784795|NCT01235234|Experimental|CF101 0.1 mg|
9784796|NCT01235234|Experimental|CF101 1 mg|
9784797|NCT01235234|Placebo Comparator|Placebo|
9784798|NCT01235338|Experimental|LDX (SPD489) + Venlafaxine XR (Effexor XR)|
9784799|NCT01235338|Experimental|Venlafaxine XR + LDX|
9784800|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 carriers|Clopidogrel for CYP2C19*2 gene carriers
9784801|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 non-carriers|Clopidogrel for CYP2C19*2 gene NON-carriers
9784802|NCT01235377|Active Comparator|Favor Chlorthalidone|Providers randomized to Favor Chlorthalidone will have agreed to prescribe chlorthalidone for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
9784803|NCT01235377|Active Comparator|Favor Hydrochlorothiazide|Providers randomized to Favor Hydrochlorothiazide will have agreed to prescribe hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
9784804|NCT01235403|Experimental|Lacosamide|Flexible dosing between 200mg/day and 400mg/day
9784805|NCT01235442|Experimental|etanercept and clobetasol|Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
9784806|NCT01235442|Experimental|etanercept|Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks
9784807|NCT01235507|Experimental|Single Arm|
9775086|NCT01016106|Active Comparator|AA pts AD and IV|African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
9775087|NCT01016106|Active Comparator|AA patients (controls)|African American patients with no personal or family history of ichthyosis vulgaris or atopy. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
9775088|NCT01016262|Experimental|MAX-002|
9775089|NCT01016262|Placebo Comparator|Placebo|
9775090|NCT01016262|Active Comparator|Canasa®|
9775091|NCT01016483|Experimental|Safety Run-in Part: Regimen 1|Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).
9775092|NCT01016483|Experimental|Safety Run-in Part: Regimen 2|Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).
9775093|NCT01016483|Active Comparator|Phase II: Arm 1 (Gemcitabine + Placebo)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.
9775094|NCT01016483|Experimental|Phase II: Arm 2 (Gemcitabine + Pimasertib)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.
9775095|NCT01016600|Experimental|Cohort 1|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 25 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
9775096|NCT01016600|Experimental|Cohort 2|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 50 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
9775097|NCT01016600|Experimental|Cohort 3|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
9775098|NCT01016600|Experimental|Phase II|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 (dose determined in Phase I) mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
9784808|NCT01235546|Placebo Comparator|Placebo and standard of care|250 cc normal saline
9775099|NCT01016652|Other|etafilcon A multifocal / etafilcon A sphere|period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.
9775100|NCT01016652|Other|etafilcon A sphere / etafilcon A multifocal|period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.
9775101|NCT01016678|Other|Active, Active, Active, Placebo|One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order. First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
9775102|NCT01016678|Other|Active, Active, Placebo, Active|This is another of the five treatment arms. One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
9775103|NCT01016678|Other|Active, Placebo, Active, Active|Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo. The final two migraines treated will be with Active study drug.
9775104|NCT01016678|Other|Placebo, Active, Active, Active|One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
9775105|NCT01016678|Other|Active, Active, Active, Active|One fifth of the subject will treat all their migraines with Active Treximet.
9775106|NCT01016691|Experimental|High Dose Drug Device/ bimatoprost 0.03%|drug device containing 65 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
9775107|NCT01016691|Experimental|Low Dose Drug Device / bimatoprost 0.03%|drug device containing 45 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
9775108|NCT01016691|Other|Placebo Device / bimatoprost 0.03%|placebo drug device worn over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
9775109|NCT01016769|Experimental|Temsirolimus + Weekly Paclitaxel + Carboplatin|"In Part 1 (Phase I) of the study, the primary endpoint is to establish the phase II recommended dose for the combination of temsirolimus + weekly paclitaxel + carboplatinPart 1 (Phase I) features a standard 3 + 3 phase I dose escalation design. Up to 3 dose levels are planned in the Phase I portion of the study.~In Part 2 (Phase II) of the study, the primary endpoint is to determine the objective response rate (CR or PR) after two cycles (approximately 6 weeks) of treatment with the combination of temsirolimus + weekly paclitaxel + carboplatin as palliative therapy for recurrent or metastatic HNSCC. A two-stage design will be employed."
9775110|NCT01016834|Other|Sumavel(R) DosePro(R)|Single arm study (Sumavel DosePro)
9775111|NCT01016873|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
9775112|NCT01016873|Sham Comparator|Sham 16 Gy IRay|Sham 16 Gy IRay + PRN Lucentis®
9775113|NCT01016873|Experimental|24 Gy IRay|24 Gy IRay + PRN Lucentis®
9775114|NCT01016873|Sham Comparator|Sham 24 Gy IRay|Sham 24 Gy IRay + PRN Lucentis®
9775115|NCT01016912|Experimental|Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
9775116|NCT01016912|Experimental|Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
9775117|NCT01016912|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
9775118|NCT01016912|Experimental|Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)|Non-Responder
9775119|NCT01016912|Experimental|Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Non-Responder
9775120|NCT01016938||Group I|This is a pilot study and there is only one group.
9775121|NCT01016964|Sham Comparator|Sham Device|Sham device
9775122|NCT01016964|Active Comparator|LLT Device 2009 12 Beams|HairMax LaserComb 2009 model 12 beam
9775123|NCT01016977|Active Comparator|Duac & taz|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
9775124|NCT01016977|Active Comparator|Acanya & taz|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
9775125|NCT01017003|Experimental|1|0.6mg colchicine tablet
9775126|NCT01017003|Experimental|2|colchicine 0.6mg q12 hours for 10 days
9775127|NCT01017029|Active Comparator|Immediate introduction of everolimus|
9775128|NCT01017029|Experimental|Delayed introduction of everolimus|delayed introduction) + Cyclosporin + steroids
9775129|NCT01017042|Experimental|colchicine|colchicine 1.2mg by mouth initially then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
9775130|NCT01017120|Experimental|1|Tazarotene foam, 0.1%
9775131|NCT01017120|Placebo Comparator|2|Vehicle Foam
9775132|NCT01017146|Experimental|1|Tazarotene foam, 0.1%
9775133|NCT01017146|Placebo Comparator|2|Vehicle Foam
9775134|NCT01017237|Active Comparator|Dex plus midazolam|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
9775135|NCT01017237|Active Comparator|Dex plus midazolam and ketamine|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
9775136|NCT01017250|Experimental|Stereotactic Radiosurgery|Avastin and Radiosurgery
9775137|NCT01017497|Experimental|1mm margin|GTV expanded by 1 mm
9775138|NCT01017497|Experimental|3mm margin|GTV expanded by 3 mm
9775139|NCT01017536|Placebo Comparator|Placebo|Thirteen subjects received placebo vaccine that did not contain any AERAS-402.
9775140|NCT01017536|Experimental|Investigational Vaccine|Thirteen subjects received active vaccine 3 x 10^10 vp AERAS-402.
9775141|NCT01017549|Other|Treatment|This is a single arm study where all patients are treated with FDA cleared electronic brachytherapy treatment.
9775142|NCT01017575|Experimental|Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
9775143|NCT01017575|Experimental|Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
9775144|NCT01017575|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
9775145|NCT01017575|Experimental|Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)|Non-Responder
9775146|NCT01017575|Experimental|Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Non-Responder
9775147|NCT01017601|Experimental|Arm I|Patients receive a single dose of Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
9775148|NCT01017601|Placebo Comparator|Arm II|Patients receive a single dose of placebo IV over 1 hour on day 1.
9775149|NCT01017653|Experimental|Panitumumab and irinotecan|
9775150|NCT01017731|Experimental|IMC-1121B|"Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period.~For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab [10 milligrams per kilogram (mg/kg)] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between."
9775151|NCT01017874|Experimental|Pemetrexed + Cisplatin + Gefitinib|
9775152|NCT01017874|Active Comparator|Gefitinib|
9775153|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9775154|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9775155|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9775156|NCT01017952|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
9775157|NCT01018030|Experimental|FFNS 110 mcg QD|
9775158|NCT01018030|Experimental|FFNS 110 mcg BID|
9775159|NCT01018030|Placebo Comparator|Placebo Nasal Spray|
9775160|NCT01018056|Experimental|D-serine (glutamate agonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive D-serine for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
9775161|NCT01018056|Experimental|Riluzole (glutamate antagonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive riluzole for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
9775162|NCT01018056|Placebo Comparator|Placebo|12 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive placebo for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
9775163|NCT01018095|Active Comparator|Single dose|Metronidazole 2 gm single dose
9775164|NCT01018095|Active Comparator|7 day dose|Metronidazole 500 mg dose x 7 days
9775165|NCT01018134|Experimental|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered once daily to affected area
9775166|NCT01018134|Experimental|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered twice daily to affected area
9775167|NCT01018134|Experimental|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered once daily to affected area
9775168|NCT01018134|Experimental|Desoximetasone 0.25% twice daily|Desoximetasone topical spray 0.25% administered twice daily to affected area
9775169|NCT01018134|Placebo Comparator|Vehicle once daily|Vehicle administered to affected areas once daily
9775170|NCT01018134|Placebo Comparator|Vehicle twice daily|Vehicle administered to affected areas twice daily
9775171|NCT01018186|Experimental|Fluticasone furoate/GW642444|
9775172|NCT01018186|Active Comparator|Fluticasone propionate|
9775173|NCT01018264|Experimental|solifenacin succinate (VESIcare)|
9775174|NCT01018264|Placebo Comparator|placebo|
9775175|NCT01018394|Active Comparator|nicotine lozenges|40 subjects will be assigned to receive nicotine lozenges for 8 weeks. They will use the nicotine lozenges ad lib, up to 8 lozenges per day.
9775176|NCT01018394|Active Comparator|tobacco free snuff|41 subjects will receive tobacco free snuff for 8 -12 weeks. The tobacco-free snuff will be used ad lib - as needed.
9775177|NCT01018420|Experimental|Colchicine|
9775178|NCT01018420|Active Comparator|Moxifloxacin|
9775179|NCT01018511|Placebo Comparator|Placebo|Participants received 3 tablets once a day for 12 weeks. Placebo tamsulosin hydrochloride oral controlled absorption system (OCAS) 0.4 mg tablet; Placebo fixed dose combination (FDC) tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
9775180|NCT01018511|Active Comparator|TOCAS 0.4 mg|Participants received 3 tablets once a day for 12 weeks. Tamsulosin hydrochloride OCAS (TOCAS) 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
9775181|NCT01018511|Experimental|FDC 0.4 mg/6 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
9775182|NCT01018511|Experimental|FDC 0.4 mg/9 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
9775183|NCT01018680|Placebo Comparator|Placebo|
9775184|NCT01018680|Experimental|Duloxetine|
9775185|NCT01018732|Experimental|I: MenACWY-CRM vaccine|Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
9775186|NCT01018732|Experimental|II: Licensed Polysaccharide Meningococcal vaccine|Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
9775187|NCT01018732|Experimental|III: Meningococcal Naive|Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.
9775188|NCT01018862|Active Comparator|MP03-36 (0.15% solution)|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
9775189|NCT01018862|Active Comparator|MP03-33 (0.10% solution)|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
9775190|NCT01018862|Placebo Comparator|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
9775191|NCT01018953|Experimental|BIM 23A760|This dose adaptive study is planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed are 1, 2, 4, 6 and 8 mg, however, the maximum starting dose will be 4 mg. The starting dose of the first cohort will be 1 mg; the first cohort will include at least five patients. After the first fifteen patients have been treated for 4 weeks, the results will be reviewed by a Data Review Committee. An extension phase (Part B) is planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).
9775192|NCT01018979|Experimental|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
9775193|NCT01018979|Experimental|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
9775194|NCT01018992|Placebo Comparator|Placebo|Adult women with DSM-IV defined PTSD will receive matching placebo for 6 weeks
9775195|NCT01018992|Experimental|GSK561679|Adult women with DSM-IV-defined PTSD will receive GSK561679 at a fixed dose of 350 mg/day for 6-weeks
9775196|NCT01019135|Active Comparator|Women-Only Cardiac Rehabilitation|The women-only CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format, wherein participants engage in on-site female-only group exercise sessions, as well as female-only group education sessions.
9775197|NCT01019135|Active Comparator|Co-ed Cardiac Rehabilitation|The traditional hospital-based co-ed CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format.
9784809|NCT01235546|Experimental|Azithromycin and Standard of care|500 mg Azithromycin in 250 cc normal saline
9775198|NCT01019135|Active Comparator|Home-Based Cardiac Rehabilitation|In the monitored home-based programs, patients attend an intake appointment where an exercise test is performed as the basis for exercise prescription. Patients are given written guidelines for aerobic conditioning based on their treadmill test. Patients are cautioned about symptoms, and taught how to check their heart rate during walking sessions. Patients are provided with reading materials regarding CVD, risk factors and lifestyle modification. These are discussed with an allied health professional from the home-based CR program by telephone during weekly scheduled telephone calls.
9775199|NCT01019252|Experimental|CBT for ADHD first, then follow-up|Participants received Cognitive Behavioral Therapy following randomization.
9775200|NCT01019252|No Intervention|Wait list first, then CBT for ADHD|Cross-over: Participants were assigned to a wait list after the initial assessment. They received Cognitive Behavioral Therapy after the 4 month assessment.
9775201|NCT01019317|Experimental|Cytarabine + Fludarabine|Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.
9775202|NCT01019369|Experimental|Self Administration of DMPA|Self administration of subcutaneous depot medroxyprogesterone acetate
9775203|NCT01019369|Active Comparator|Clinic administration of DMPA|Clinic administration (routine care) of DMPA
9775204|NCT01019486|Experimental|Type 1 Diabetic Subjects|Regadenoson 400mcg slow IV bolus to identify assess myocardial blood flow (MBF). Stratified by coronary calcium score of below 100 or greater than score of 100 for low and high risk individuals respectively.
9775205|NCT01019486|Active Comparator|Nondiabetic Subjects|Regadenoson myocardial perfusion imaging (MPI) Intervention: Regadenoson (400mcg slow IV bolus) stress to assess myocardial blood flow (MBF) and MPI to identify occult coronary artery disease (CAD). These individuals serve as an active control with higher risk non-diabetic individuals with scores greater than 100.
9775206|NCT01019694|Experimental|Combivent Respimat 20/100 microgram(mcg)|patient to take 1 inhalation 4 times a day
9775207|NCT01019694|Active Comparator|Combivent CFC-MDI 36/206 microgram-mcg|patient to take 2 inhalations 4 times a day
9775208|NCT01019694|Active Comparator|Atrovent HFA 42 mcg + Albuterol HFA|patient to take 2 inhalations of each 4 times a day
9775209|NCT01019707|Placebo Comparator|Sugar pill|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
9775210|NCT01019707|Active Comparator|Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
9775211|NCT01019928|Experimental|First AZD1386, then washout, then placebo|
9775212|NCT01019928|Experimental|First placebo, then washout, then AZD1386|
9775213|NCT01020006|Active Comparator|Gemcitabine|Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
9775214|NCT01020006|Experimental|PCI-27483 + Gemcitabine|"Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion.~Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion."
9775215|NCT01020019|Experimental|Lofexidine and Dronabinol|Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
9775216|NCT01020019|Placebo Comparator|Placebo|Lofex. matched placebo Dronabinol placebo
9775217|NCT01020123|Experimental|1|AZD1656
9775218|NCT01020123|Experimental|2|AZD1656
9775219|NCT01020123|Experimental|3|AZD1656
9775220|NCT01020123|Experimental|4|AZD1656
9775221|NCT01020123|Experimental|5|AZD1656
9775222|NCT01020123|Placebo Comparator|6|
9775223|NCT01020123|Active Comparator|7|Glipizide administered to 1 group of patients
9775224|NCT01020305|Experimental|Temsirolimus + Bicalutamide|"Temsirolimus 25 mg administered intravenously (IV) once weekly for 12 weeks~Casodex (bicalutamide) administered 50 mg/day orally (PO)"
9775225|NCT01020435|Active Comparator|Spinal Manipulation High Velocity|This non-rotary upper cervical procedure uses an impulse thrust with a controlled depth (high velocity). The participant's head is supported by a specially designed cushion and the doctor usually approaches the participant from in front of his or her head to contact soft tissue over the atlas transverse process, posterior to the lateral mass or occasionally on the C2 lamina or spinous process, with the pisiform process of one hand. The thrust is delivered by a contraction of the triceps muscles of both arms, which straightens the arms and applies the thrust to the participant.
9775226|NCT01020435|Placebo Comparator|Sham Spinal Manipulation|The sham assessment procedures will be similar to the active group. It has been developed and validated by Vernon et al.
9775227|NCT01020448|Experimental|Triptorelin (Decapeptyl®) 22.5 mg|
9775228|NCT01020474|Placebo Comparator|Placebo|
9775229|NCT01020474|Experimental|drug-pregabalin|
9775230|NCT01020487|Experimental|Part 1: Paricalcitol|Participants received a single 3 µg dose of paricalcitol capsules on Study Day 1.
9775231|NCT01020487|Placebo Comparator|Part 2: Placebo|Participants received placebo capsules three times a week (TIW) for 12 weeks during the double-blind treatment phase. From Weeks 12 to 24 participants received open-label paricalcitol at an initial dose of 1 µg three times a week. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target Kidney Disease Outcomes Quality Initiatives (KDOQI) target levels.
9775232|NCT01020487|Experimental|Part 2: Paricalcitol|Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
9775233|NCT01020526|Experimental|Pregabalin|
9775234|NCT01020591|Active Comparator|Osteopathic evaluation|osteopathic evaluation of motion and tissue mobility
9775235|NCT01020591|Experimental|Osteopathic evaluation with treatment|osteopathic evaluation of motion and tissue mobility followed by osteopathic manual therapy release of the tight or restricted tissues
9775236|NCT01020773|Active Comparator|SBT group|In the SBT group, the patients underwent a 1 hr SBT with inspiratory PS of 7 cmH2O with other settings remaining constant (FiO2, PEEP, trigger sensitivity). The patients who tolerated the SBT underwent immediate extubation.
9775237|NCT01020773|No Intervention|no-SBT group|In no-SBT group, as soon as a patient met readiness criteria, he or she underwent extubation without SBT process.
9775238|NCT01020786|Experimental|Pemetrexed + Carboplatin|After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.
9775239|NCT01020799|Experimental|AZD7268|The AZD7268 15 mg BID arm consisted of 3 AZD7268 5 mg capsules dosed orally in the morning and evening. In addition, 2 placebo tablets to match encapsulated escitalopram tablets were dosed orally in the morning only.
9775240|NCT01020799|Placebo Comparator|Placebo|The placebo arm consisted of 3 placebo capsules to match AZD7268 capsules dosed orally in the morning and evening. In addition, 2 placebos to match encapsulated escitalopram tablets were dosed orally in the morning only.
9775241|NCT01020799|Active Comparator|Escitalopram|The escitalopram 20 mg QD arm consisted of 3 placebo to match AZD7268 capsules dosed orally in the morning and evening. In addition, during Week 1, one encapsulated 10-mg escitalopram tablet and 1 placebo to match encapsulated escitalopram tablet were dosed orally in the morning only. During Weeks 2 through 4, two encapsulated 10-mg escitalopram tablets were dosed orally in the morning only.
9775242|NCT01020812|Experimental|Stereotactic body radiotherapy (SBRT)|"SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction"
9775243|NCT01020838|Experimental|Florbetaben (BAY94-9172)|
9775244|NCT01020877|Experimental|1|Metronidazole Vaginal Gel
9775245|NCT01020877|Active Comparator|2|MetroGel-Vaginal®
9775246|NCT01020981||Group 1|Michigan State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
9775247|NCT01020981||Group 2|Indiana State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
9775248|NCT01021007|Placebo Comparator|A|control mouthrinse
9775249|NCT01021007|Experimental|B|new prototype mouthrinse
9775250|NCT01021020|Experimental|1|Colchicine (fasted)
9775251|NCT01021020|Experimental|2|Colchicine (fed)
9775252|NCT01021020|Active Comparator|3|Colchicine/Probenecid (fasted)
9775253|NCT01021111|Experimental|Activity Training with Feedback|Subject is tested prior to training and retested with feedback training designed to modify the mechanics of landing during jumping and running activities
9775254|NCT01021137||TBI & Blast|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure and a diagnosis of mild TBI
9775255|NCT01021137||Blast Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure without TBI
9775256|NCT01021137||TBI Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with a history of mild TBI and no blast exposure
9775257|NCT01021137||Healthy Controls|Age and gender matched control participants with no complaints of dizziness and/or imbalance or history of TBI or blast exposure
9775258|NCT01021137||Excluded|Participants who did not meet inclusion criteria, did not return to complete evaluation, and/or were excluded from data analysis.
9775259|NCT01021215|Experimental|Arm I: Zileuton|Zileuton 1200 mg twice orally twice a day on days 1-6.
9775260|NCT01021215|Experimental|Arm II: Zileuton and Celecoxib|Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.
9775261|NCT01021293|Experimental|Poliorix Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
9775262|NCT01021293|Active Comparator|Control Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.
9775263|NCT01021306|Active Comparator|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner.
9775264|NCT01021306|Active Comparator|Dental Care & Self Care|Intraoral splints are removable orthopedic appliances fabricated of hard acrylic resin positioned between the remaining teeth of the patient. They are designed in theory to support the function of the TMJ and relieve associated pain. Stabilization splints are believed to function by stabilizing the intracapsular structure of the TMJ, reducing activity of masticatory muscles, distributing occlusal forces, and reducing bruxism (teeth grinding).
9775265|NCT01021306|Sham Comparator|Sham AMCT & Self Care|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
9775266|NCT01021306|Placebo Comparator|Self-care only group|All patients will be offered the self-care checklist of homecare approaches at baseline. Self-care only participants successfully completing the 6 months assessment will be given the option for RIST or AMCT for one month.
9775267|NCT01021332|Experimental|Total Group|Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
9775268|NCT01021423|Experimental|Lenalidomide|Lenalidomide - 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
9775269|NCT01021423|Experimental|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
9775270|NCT01021553|Placebo Comparator|placebo|placebo
9775271|NCT01021553|Active Comparator|50 mg|50 mg GSK557296
9775272|NCT01021553|Active Comparator|150 mg|150 mg GSK557296
9775273|NCT01021618|Active Comparator|Vasodilator-exercise stress|Four-minute infusion of dipyridamole (0.56 mg/kg) followed by symptom-limited exercise; injection of technetium-99m labeled radiopharmaceutical at peak hyperemia or peak exercise followed by SPECT myocardial perfusion imaging
9775274|NCT01021618|Experimental|Exercise-vasodilator stress|Symptom-limited exercise followed by a bolus intravenous injection of regadenoson (0.4 mg/5 mL) in patients failing to achieve a standard clinical endpoint; injection of technetium-99m labeled radiopharmaceutical 15 seconds after administration of regadenoson (or at peak exercise if regadenoson not administered) followed by SPECT myocardial perfusion imaging.
9775275|NCT01021683||Itraconazole|Participants who have been receiving itraconazole will be observed prospectively. Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
9775276|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg QD|Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
9775277|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg BID|Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
9775278|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 50 mg BID|Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
9775279|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
9775280|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg BID|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
9775281|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
9775282|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 150 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
9775283|NCT01021748|Experimental|MK-2206 100 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
9775284|NCT01021748|Experimental|MK-2206 135 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
9775285|NCT01021761|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
9775286|NCT01021761|Active Comparator|Nevanac|Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
9775287|NCT01021761|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
9775288|NCT01021813|Experimental|Suvorexant|After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to <65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
9775289|NCT01021813|Placebo Comparator|Placebo|After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.
9775290|NCT01021852|Experimental|MK-6096 2.5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for overnight polysomnography (PSG) recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive dose-matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
9775291|NCT01021852|Experimental|Placebo/MK-6096 2.5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
9775292|NCT01021852|Experimental|MK-6096 5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
9784810|NCT01235598|Other|Placebo followed by Certolizumab Pegol (CZP)|Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
9784811|NCT01235598|Experimental|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40
9785756|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily"
9775293|NCT01021852|Experimental|Placebo/MK-6096 5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
9775294|NCT01021852|Experimental|MK-6096 10 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
9775295|NCT01021852|Experimental|Placebo/MK-6096 10 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
9785757|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily"
9785758|NCT01259375|Experimental|All patients|All participants who received Amrubicin.
9775296|NCT01021852|Experimental|MK-6096 20 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
9775297|NCT01021852|Experimental|Placebo/MK-6096 20 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
9775298|NCT01021878|Experimental|icodextrin|glucose sparing alternative dialysis solution
9775299|NCT01021878|Active Comparator|dextrose|dianeal, Control group, standard treatment
9775300|NCT01021956|Experimental|WST11 (STAKEL)|Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².
9775301|NCT01022073||Globus Pallidus interna Group|Cohort of subjects who received DBS-GPi as part of the CSP 468 intervention trial, and still have their device working and in place.
9775302|NCT01022073||Subthalamic Nucleus Group|Cohort of subjects who received DBS-STN as part of the CSP 468 intervention trial, and still have their device working and in place.
9775303|NCT01022112|Experimental|TA-7284-Low|
9775304|NCT01022112|Experimental|TA-7284-Low-middle|
9775305|NCT01022112|Experimental|TA-7284-High-middle|
9775306|NCT01022112|Experimental|TA-7284-High|
9775307|NCT01022112|Placebo Comparator|Placebo|
9775308|NCT01022190|Experimental|Drug: Etoricoxib (Arcoxia, MSD), 90 mg.|Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.
9775309|NCT01022203|Experimental|Structured Approach Therapy|Couple-Based Intervention called Structured Approach Therapy provides skills training to couple so they can reduce PTSD.
9775310|NCT01022203|Active Comparator|PTSD Family Education|Couple-Based Education called PTSD Family Education teaches couple about PTSD symptoms, related problems, and treatment.
9775311|NCT01022242|Placebo Comparator|Placebo|Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
9775312|NCT01022242|Experimental|PXL01|PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
9775313|NCT01022307||Group 1: no history of TBI|184 participants with no history of traumatic brain injury (TBI).
9775314|NCT01022307||Group 2: with a history of TBI|28 patients with a history of TBI. Most of these patients had suffered mild TBI.
9775315|NCT01022359|Active Comparator|Tesio Catheter|Patients randomised to receive the established catheter type in use at our centre [control]
9775316|NCT01022359|Active Comparator|LifeCath|Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)
9775317|NCT01022424|Experimental|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
9775318|NCT01022502|Active Comparator|refined indigo naturalis ointment|Refined indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
9775319|NCT01022502|Active Comparator|crude indigo naturalis ointment|Crude indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
9785759|NCT01259388|Experimental|Lithium|"Lithium-treatment phase~Lithium Carbonate: Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time."
9785760|NCT01259388|No Intervention|Observation|During observation subjects continue on their standard of care disease modifying agent (or no agent at all if judged not appropriate by the treating physician).
9775320|NCT01022567|Active Comparator|Operative treatment|Regular open appendicectomy
9775321|NCT01022567|Active Comparator|Antibiotic treatment|Ertapenem 1 g i.v. x 1 three days
9775322|NCT01022580|Active Comparator|Infasurf surfactant (ONY, Inc.)|Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.
9775323|NCT01022580|Sham Comparator|Sham (No Treatment)|"Infants already receiving inhaled nitric oxide will receive Sham (no treatment) doses on study days 0,2,4,6, and 8."
9775324|NCT01022762|Active Comparator|repaglinide|1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
9775325|NCT01022762|Active Comparator|gliclazide|80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
9775326|NCT01022853|Experimental|BIBF 1120 and BI 6727|Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
9775327|NCT01022996|Experimental|RAD001|"Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason.~A treatment cycle consisted of 28 days."
9836097|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence CAB|C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
9666200|NCT04642053|Experimental|Delayed Treatment|The Delayed Treatment Group serves as a control during the period in which participants are waiting to begin treatment. A delayed treatment onset is employed to control for maturation effects. Participants in the Delayed Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin after an 8-week delay following the diagnostic evaluation.
9666201|NCT04641962|Experimental|Phase 2: low dose ASP0367|Participants will receive ASP0367 once daily in the morning for 2 weeks.
9666202|NCT04641962|Experimental|Phase 2: high dose ASP0367|Participants will receive ASP0367 once daily in the morning for 2 weeks.
9666203|NCT04641962|Placebo Comparator|Phase 2: Placebo|Participants will receive placebo once daily in the morning for 2 weeks.
9666204|NCT04641962|Experimental|Phase 3: ASP0367|Participants will receive ASP0367 once daily in the morning for up to 52 weeks.
9666205|NCT04641962|Placebo Comparator|Phase 3: Placebo|Participants will receive placebo once daily in the morning for up to 52 weeks.
9666206|NCT04641962|Experimental|Open Label Extension: ASP0367|Participants will receive ASP0367 once daily in the morning for 24 weeks.
9666207|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
9666208|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
9666209|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
9666210|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
9666211|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
9666212|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
9666213|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
9666214|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
9666215|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
9666216|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
9666217|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
9666218|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
9666219|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
9666220|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
9666221|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
9666222|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
9775328|NCT01023022||Medtronic CareLink® Network|"Patients with implanted Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices, who will be monitored by the Medtronic CareLink® System.~The System consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website."
9775329|NCT01023035|Experimental|Treated/Not Randomized|Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
9775330|NCT01023035|Experimental|Ribavirin Dose Reduction|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
9775331|NCT01023035|Experimental|Erythropoietin Use|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
9775332|NCT01023061|Experimental|Treatment (antihormone therapy and radiation therapy)|Patients receive abiraterone acetate and prednisone daily for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9775333|NCT01023074|No Intervention|Non-MS Control|Non-MS control group
9775334|NCT01023074|Active Comparator|MS: Auditory Training|MS group receiving auditory training
9775335|NCT01023074|Placebo Comparator|MS: Control Activity|MS group not receiving auditory training, doing control activity
9775336|NCT01023178|Active Comparator|Vivelle-Dot|17Beta Estradiol - transdermal
9775337|NCT01023178|Active Comparator|Premarin|Conjugated estrogens
9775338|NCT01023178|Active Comparator|Estrace|17beta Estradiol
9775339|NCT01023217|Experimental|Adefovir plus Entecavir|Adefovir + Entecavir for 104 weeks
9775340|NCT01023217|Active Comparator|Adefovir plus Lamivudine|Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
9775341|NCT01023256|Experimental|Group 1: MOR103, experimental|Biological: MOR103 0.3 mg/kg or placebo
9775342|NCT01023256|Experimental|Group 2: MOR103, experimental|Biological: MOR103 1.0 mg/kg or placebo
9775343|NCT01023256|Experimental|Group 3: MOR103, experimental|Biological: MOR103 1.5 mg/kg or placebo
9775344|NCT01023269|Other|ON / OFF|Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.
9775345|NCT01023269|Other|OFF / ON|Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.
9775346|NCT01023308|Experimental|Panobinostat + Bortezomib + Dexamethasone|
9775347|NCT01023308|Placebo Comparator|Placebo + Bortezomib + Dexamethasone|
9775348|NCT01023477|Experimental|Chloroquine Standard Dose (500mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
9775349|NCT01023477|Experimental|Chloroquine Low Dose (250mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
9775350|NCT01023516|Experimental|1|
9775351|NCT01023516|Placebo Comparator|2|
9775352|NCT01023568|Active Comparator|Macintosh blade|Intubation with Macintosh blade laryngoscope
9775353|NCT01023568|Active Comparator|Glidescope|Intubation with Glidescope laryngoscope
9775354|NCT01023568|Active Comparator|Truview PCD|Intubation with the Truview PCD laryngoscope
9775355|NCT01023581|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
9775356|NCT01023581|Experimental|Alogliptin 25 QD|Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
9775357|NCT01023581|Experimental|Alogliptin 12.5 BID|Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
9775358|NCT01023581|Active Comparator|Metformin 500 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
9775359|NCT01023581|Active Comparator|Metformin 1000 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
9775360|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 500 BID|Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
9775361|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 1000 BID|Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
9775362|NCT01023659|Active Comparator|Bupropion + motivational emails|participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
9775363|NCT01023659|Active Comparator|Varenicline + motivational emails|participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
9775364|NCT01023659|Active Comparator|Motivational emails|participants receive weekly motivational emails for 12 weeks.
9775365|NCT01023672|Other|Armodifinil|150-250 mg armodafinil by mouth daily
9775366|NCT01023711|Other|Inactivated H1N1 Vaccine|Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
9775367|NCT01023724|Active Comparator|bromfenac 0.09%|bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
9775368|NCT01023724|Active Comparator|Acuvail|Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
9775369|NCT01023776|Other|live monovalent H1N1 vaccine|A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
9775370|NCT01023789|Experimental|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation in the treatment of coronary artery disease
9775371|NCT01023815|Experimental|Group A -Once-a-day regimen|"Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12.~Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL.~Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning."
9775372|NCT01023815|Experimental|Group B - Steroid Withdrawal group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12.~Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks."
9775373|NCT01023815|Active Comparator|Group C - Standard twice-a-day group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12.~Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning."
9775374|NCT01023815|Experimental|Not Randomized Population (NRP)|"NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as not randomized patients (NRP) and described with respect to baseline characteristics, treatment and outcome variables."
9775375|NCT01023841|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
9775376|NCT01023841|Placebo Comparator|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
9775377|NCT01023958|Experimental|single arm|open label
9775378|NCT01024010|Experimental|Arm A (PCO, closed to accrual as of 8/23/2011)|Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9775379|NCT01024010|Experimental|Arm B (PCO with ofatumumab consolidation)|Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9775380|NCT01024036|Experimental|Siltuximab+best supportive care (BSC)|Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
9775381|NCT01024036|Placebo Comparator|Placebo+BSC|Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.
9775382|NCT01024231|Experimental|Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
9775383|NCT01024231|Experimental|Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
9775384|NCT01024231|Experimental|Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
9775385|NCT01024231|Experimental|Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
9775386|NCT01024231|Experimental|Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
9775387|NCT01024231|Experimental|Cohort 6: BMS-936558 (1 mg/kg)|BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
9775388|NCT01024231|Experimental|Cohort 7: BMS-936558 (3 mg/kg)|BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
9775389|NCT01024231|Experimental|Cohort 8: Nivolumab+Ipilimumab|"Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks~Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks"
9775390|NCT01024244|Placebo Comparator|0 milligrams (mg) Placebo|Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
9775391|NCT01024244|Experimental|100 mg LY2599506|Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
9775392|NCT01024244|Experimental|200 mg LY2599506|Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
9775393|NCT01024244|Experimental|400 mg LY2599506|Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
9775394|NCT01024244|Experimental|200 mg LY2599506 once daily|Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
9775395|NCT01024296|Experimental|Gastric Bypass Surgery Patients|Surgical site closure using Port Close device
9775396|NCT01024309|Active Comparator|Mini-Posterior Approach|Mini-Posterior surgical approach for total hip arthroplasty
9775397|NCT01024309|Experimental|Direct Anterior Approach|Direct Anterior surgical approach for total hip arthroplasty
9775398|NCT01024335|Active Comparator|Naltrexone and placebo|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
9775399|NCT01024335|Experimental|Naltrexone and dronabinol|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
9775400|NCT01024387|Experimental|AMG 479|Patients receive AMG 479 at a dose of 18 mg/kg administered IV on day 1 (± 3 days) of every 3-week cycle. Treatment should continue until disease progression, unacceptable toxicity or withdrawal of consent.
9775401|NCT01024465|Experimental|ReShape Duo Balloon|Patients seeking weight loss with a starting BMI in the 30-40 range, received the ReShape Duo Balloon
9775402|NCT01024569|Experimental|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
9775403|NCT01024569|No Intervention|Comparison Wait-List Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
9775404|NCT01024686|Experimental|p52-p36- GAP Vaccine|"p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.~p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
9775405|NCT01024686|No Intervention|Infectivity Control|Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum
9775406|NCT01024686|Experimental|p52-p36- GAP Vaccine + Infectivity Challenge|"p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
9775407|NCT01024738|Placebo Comparator|Fluoride toothpaste|negative control toothpaste
9775408|NCT01024738|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste (Total toothpaste)
9775409|NCT01024738|Active Comparator|Chlorhexidine Oral Rinse|positive control oral rinse
9775410|NCT01024751|Experimental|Bausch & Lomb Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
9775411|NCT01024751|Active Comparator|Ciba's Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
9775412|NCT01024855|Experimental|RevitaLens OcuTec Multipurpose Solution (Investigational MPS)|
9775413|NCT01024855|Active Comparator|Opti-Free RepleniSH Multipurpose Solution (MPS, Control)|
9775414|NCT01024920|Experimental|Nintedanib (BIBF 1120)|Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
9775415|NCT01024920|Active Comparator|sunitinib|Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
9775416|NCT01024946|Experimental|Pts getting everolimus|This is a multicenter, open label, phase II study of everolimus as a second or third line therapy for the treatment of advanced malignant pleural mesothelioma, which will also evaluate Merlin/NF2 loss as a biomarker to predict sensitivity to everolimus. Patients who have disease progression after one or two prior chemotherapy regimens will be eligible. In the first stage of this design, 19 patients will be accrued. If 6 or less patients among the first 19 patients show clinical benefit, then the study will be terminated and declared negative. If 7 or more patients show clinical benefit, than an additional 20 patients will be accrued to the second stage. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.
9775417|NCT01024959|Experimental|PCA3 Assay|
9775418|NCT01024972|Experimental|Dantrolene|Dantrolene 1.25mg/kg IV every 6 hours x 7 days
9775419|NCT01024972|Placebo Comparator|Placebo|Equiosmolar volume (5% Mannitol)
9775420|NCT01025037|Other|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement at the rotator cuff repair site
9775421|NCT01025076|Experimental|StomaphyX Group|"Primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy.~Patients also demonstrate a weight regain of 15% of excess body weight loss."
9775422|NCT01025154|Experimental|Clofarabine, Cytarabine + Idarubicin|Induction Cycle: Clofarabine 20 mg/m^2 intravenous (IV) daily for 5 days; Idarubicin 10 mg/m^2 IV daily for 3 days; Cytarabine 1 g/m^2 IV daily for 5 days
9775423|NCT01025193|Experimental|Belimumab|Belimumab will be administered intravenously at a dose of 10mg/kg on days 0, 14, 28 and every 28 days for up to 52 weeks to normalize alloantibody levels in sensitized patients awaiting kidney transplantation. Subjects who are not able to undergo transplantation before the end of the treatment period will have final follow-up evaluation 8 weeks after the last dose of belimumab is administered.
9775424|NCT01025232|Active Comparator|4 Week Re-treatment|Subjects can receive re-treatment every 4 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Subjects will go no longer than 12 weeks without treatment.
9775425|NCT01025232|Active Comparator|6 Week Re-treatment|Subjects can receive re-treatment every 6 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab. Subjects will go no longer than 12 weeks without treatment.
9775426|NCT01025284|Experimental|Part A LY2523355|8 milligrams per square meter (mg/m²) per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 5, 9 of each 21-day cycle, until disease progression or unacceptable toxicity.
9775427|NCT01025284|Experimental|Part B LY2523355|5 or 6 mg/m² per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 2, 3 plus granulocyte colony-stimulating factor (G-CSF) support administered subcutaneously beginning on Day 4 of each 21-day cycle, until disease progression or unacceptable toxicity.
9775428|NCT01025336|Other|23vPS Naive|Group 1.1 13vPnC/13vPnC Group 1.2 13vPnC/23vPS Group 2 23vPS/13vPNC
9775429|NCT01025336|Other|Prior 23vPS>/= 5 years|Group 1 13vPnC/13vPnC Group 2 23vPS/13vPnC
9775430|NCT01025427|Experimental|Elite controller|Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
9775431|NCT01025453|Experimental|Pts getting Temsirolimus and Sorafenib|We propose a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). A maximum of 36 subjects will be evaluated during the study. Restaging scans, with evaluation of response, will be done every 2 cycles (8 weeks of treatment). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 4 weeks, or at the discretion of the treating physician or patient.
9775432|NCT01025635|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
9775433|NCT01025635|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
9775434|NCT01025752|Experimental|Arm 1|Ten session IVR-based cognitive behavior therapy intervention for chronic low back pain
9775435|NCT01025752|Active Comparator|Arm 2|Ten session face to face cognitive behavior therapy for chronic low back pain
9775436|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
9775437|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
9775438|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.
9775439|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
9775440|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.
9775441|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
9775442|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
9775443|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.
9775444|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 1|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
9775445|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 2|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
9775446|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 3|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
9775447|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 4|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
9775448|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 5|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
9775449|NCT01025791|Placebo Comparator|Panel C, Mild/Moderate Hypertension, Sequence 6|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na
9775450|NCT01025817|Experimental|Everolimus (EVR) & low dose of tacrolimus|Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was < 3 ng/mL, or reduced if the trough level was > 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.
9775451|NCT01025817|Active Comparator|Mycophenolate mofetil & standard dose tacrolimus|Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
9775452|NCT01025830|Experimental|Generic|generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)
9775453|NCT01025830|Active Comparator|Brand|3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)
9775454|NCT01025843|Experimental|Pbo → 5 mg → Candesartan → 24 mg → 38 mg|Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
9775455|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Candesartan → Pbo|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
9775456|NCT01025843|Experimental|1 mg → Candesartan → Pbo → 24 mg → 38 mg|1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
9775457|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Pbo → Candesartan|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
10203992|NCT04516473||Control/Post Massive Weight Loss Matched Control|"These are participants who have similar characteristics to the body contouring intervention group, but they will not undergo any surgical procedure during the course of the study.~The addition of this matched control group with a similar degree of excess skin but who will not be undergoing body contouring surgery will control for any changes in physical function which may occur without any intervention within the testing sessions. This group will also control for any learning effects between testing sessions."
10203993|NCT04515472|Active Comparator|Healthy Volunteer Male|Healthy male currently on no testosterone treatment
9775458|NCT01025843|Experimental|Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan|Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
9775459|NCT01025843|Experimental|2 mg→Pbo → Candesartan → Pbo fed→38 mg|2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
9775460|NCT01025843|Experimental|2 mg→Candesartan→Pbo→Candesartan fed→38 mg|2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
10203994|NCT04515472|Active Comparator|Healthy Volunteer Female|Healthy female currently on no estrogen treatment
10203995|NCT04515472|Active Comparator|MTF group|MTF transgender currently on estrogen treatment
10203996|NCT04515472|Active Comparator|FTM group|FTM transgender group currently on testosterone treatment
9775461|NCT01025843|Experimental|2 mg → 8 mg → 18 mg → 2 mg fed → Pbo|2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
9775462|NCT01025843|Experimental|Candesartan→8 mg→ 18 mg →2 mg fed→38 mg|Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
9775463|NCT01025843|Experimental|Candesartan→Pbo → 12 mg → 24 mg→38 mg|Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
9775464|NCT01026012|Experimental|Combined Protocol|patient with submaximal symptom limited maximal exercise testing will also be administered regadenoson pharmacological stress test.
9775465|NCT01026038|Experimental|1|1 dose (0.5 mL), IM of 13vPnC vaccine.
9775466|NCT01026103|Experimental|Tri Staple|This is a single arm study.
9775467|NCT01026142|Active Comparator|A: Capecitabine + Trastuzumab|
9775468|NCT01026142|Experimental|B: Capecitabine + Trastuzumab + Pertuzumab|
9775469|NCT01026181||LSG|Laparoscopic Sleeve Gastrectomy
10203997|NCT04513106|Experimental|Advance care planning programme|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
10203998|NCT04513106|Placebo Comparator|Attention control|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
10203999|NCT04512079|Active Comparator|Prophylactic Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min)
9775470|NCT01026181||LRYGB|Laparoscopic Roux-en-Y Gastric Bypass
9775471|NCT01026181||LAGB|Laparoscopic Adjustable Gastric Banding
9775472|NCT01026194|Placebo Comparator|Placebo / Teneli + Pio|
9775473|NCT01026194|Experimental|Teneli / Teneli + pio|
9775474|NCT01026324|Experimental|Treatment (dinaciclib)|Patients receive dinaciclib IV over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
9775475|NCT01026389|Active Comparator|Gadovist|Patient received contrast-enhanced MRA with Gadovist
9775476|NCT01026389|Experimental|Dotarem, interventional|Patients received contrast-enhanced MRA with Dotarem
10204000|NCT04512079|Active Comparator|Full Dose Enoxaparin|Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
9775477|NCT01026402|Experimental|AZD2014|AZD2014 dose escalation phase in Part A and expansion phase in Part B.
9775478|NCT01026454|Active Comparator|acyclovir|acyclovir 400 mg orally twice daily
10204001|NCT04512079|Experimental|Apixaban|Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
9775479|NCT01026454|Active Comparator|valacyclovir|valacyclovir 1.5 g orally twice daily
9775480|NCT01026493|Experimental|Phase I: Dose Level 1|ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days
9775481|NCT01026493|Experimental|Phase I: Dose Level 2a|ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days
9775482|NCT01026493|Experimental|Phase I: Dose Level 2b|ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days
9775483|NCT01026493|Experimental|Phase I: Dose Level 3|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
9775484|NCT01026493|Experimental|Phase II: Arm 1/BEV-NAIVE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
9775485|NCT01026493|Experimental|Phase II: Arm 2/BEV-NAIVE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
9775486|NCT01026493|Experimental|Phase II: Arm 1/BEV-FAILURE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
9775487|NCT01026493|Experimental|Phase II: Arm 2/BEV-FAILURE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
9775488|NCT01026623|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60-70 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9775489|NCT01026792|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. For complete responders, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or for 2 courses after complete response criteria are first met. For other patients, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9775490|NCT01026805||Hysteroscopic Morcellator|11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.
10204002|NCT04511247|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
9775491|NCT01026818|Experimental|Tadalafil daily [5 milligrams (mg)]|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
9775492|NCT01026818|Experimental|Tadalafil on demand (20 mg)|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
9775493|NCT01026818|Placebo Comparator|Placebo|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
9775494|NCT01026831|Experimental|Tafluprost|Preservative-free tafluprost
9775495|NCT01026831|Active Comparator|timolol maleate|Preservative-free timolol maleate
9775496|NCT01026844|Experimental|Erlotinib plus hydroxychloroquine|erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day
9775497|NCT01026844|Experimental|Hydroxychloroqine|hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day
9775498|NCT01026909|Experimental|Injection|Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
9775499|NCT01026909|No Intervention|Control|Patients will be enrolled in physical therapy
9775500|NCT01026948||Propess and Monica AN24 care package|Women who are eligible and consent to recruitment will receive the Propess and Monica AN24 care package for outpatient induction of labour
9775501|NCT01026974|Experimental|4rMenB|Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.
9775502|NCT01026974|Experimental|4rMenB+OMV NZ|Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.
9775503|NCT01026974|Experimental|Naive_4042|Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.
9775504|NCT01026974|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.
9775505|NCT01027000|Experimental|Treatment (Combination of chemotherapy and transplant)|See detailed description
9775506|NCT01027195|Placebo Comparator|Standard Bovie Electrocautery|Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.
9775507|NCT01027195|Experimental|Bipolar Radiofrequency|Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (<100 degrees Celsius) than standard Bovie electrocautery.
9775508|NCT01027273|Experimental|Peer-Led Stroke Recurrence Prevention Education|The intervention group will participate in a 6-session course held over a 6-week period. The Prevent Return of Stroke Workshop, led by trained peer educators, aims to help participants control the risk factors for stroke, thereby preventing recurrence of strokes.
9775509|NCT01027273|Placebo Comparator|Usual Care (Delayed Intervention)|The control group will be offered the chance to take part in the 6-week session intervention after 12 months after enrollment into the trial.
9775510|NCT01027286|Experimental|Vitagel|
9775511|NCT01027286|No Intervention|Control|No Vitagel used.
9775512|NCT01027351|Experimental|5rMenB|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
9775513|NCT01027351|Experimental|5rMenB+OMV NZ|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
9775514|NCT01027351|Experimental|3rMenB|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
9775515|NCT01027351|Experimental|3rMenB+OMV NZ|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
9775516|NCT01027351|Experimental|Naive_4042|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
9666223|NCT04639531|Experimental|Orientation and Mobility Training with VR-IOMSs|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from Virtual Reality-base Intelligent O&M Specialists (VR-IOMSs). VR-IOMSs are intelligent, computer-controlled automatic O&M skill training programs in virtual streets.
9666224|NCT04639531|Active Comparator|Orientation and Mobility Training with COMS|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from human Certified O&M Specialists (COMS) in real streets
9666225|NCT04639531|Placebo Comparator|No Orientation and Mobility Training|Low vision subjects with Orientation and Mobility (O&M) difficulties watching low vision education videos and discuss low vision issues not related to O&M with COMSs.
9775517|NCT01027351|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.
9775518|NCT01027364|Experimental|Fixed Weekly Interval|"50 IU/kg rFIXFc via intravenous (IV) injection once every 7 days initially, then at a dose indicated by the participant's baseline pharmacokinetic (PK) assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial weekly dose of rFIXFc (50 IU/kg) were to be made based on baseline PK assessments, occurrence of spontaneous bleeding episodes, and the trough levels, which were to be monitored at Weeks 4, 16, 26, and 39.~Prior to the first dose of rFIXFc, participants in the Sequential PK subgroup were to receive a single dose of 50 IU/kg BeneFIX administered IV in the clinic, followed by PK sampling. A single dose of 50 IU/kg rFIXFc was administered following a 120-hour washout from BeneFIX, followed by PK sampling for a baseline PK profiling. At Week 26 (±1 week) subjects were to receive a single dose of 50 IU/kg rFIXFc for repeat PK profiling."
9775519|NCT01027364|Experimental|Individualized Interval|100 IU/kg rFIXFc via IV injection once every 10 days initially, then at an interval derived from the baseline PK assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial 10-day interval were to be made based on baseline PK assessments and trough levels, which were monitored at Weeks 4, 16, 26, and 39.
9775520|NCT01027364|Experimental|On Demand|20 to 100 IU/kg rFIXFc via IV injection, or the dose indicated by the participant's baseline PK to target a plasma level of 20% to 100%, as needed for the treatment of mild to severe bleeding episodes
9775521|NCT01027364|Experimental|Surgery|The surgical period and dosing are dependent on the type of surgery the participant undergoes. Participants who started the study in one of the other treatment arms prior to surgery will return to the original treatment arm. Participants who joined the study in the Surgery arm will be assigned to one of the other treatment arms following post-operative rehabilitation.
9775522|NCT01027416|No Intervention|No Intervention|
9775523|NCT01027416|Active Comparator|Tamoxifen|Tamoxifen 20 mg orally 1x/day for 4 weeks
9775524|NCT01027468|Experimental|group 1|bevacizumab intravitreal injection
9775525|NCT01027559|Active Comparator|Depressed Group: CBT|Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
9775526|NCT01027559|No Intervention|Healthy Control Group|Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.
9775527|NCT01027559|Active Comparator|Depressed Group: SRT|Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
9775528|NCT01027598|Experimental|Erlotinib + Pazopanib|"Erlotinib: 150 mg orally daily~Pazopanib: 600 mg orally daily"
9775529|NCT01027598|Placebo Comparator|Erlotinib + Placebo|"Erlotinib: 150 mg orally daily~Placebo: orally daily"
9775530|NCT01027650|Experimental|Stage 1 Cohort 1|AGN208397 intravitreal injection 75 ug on Day 1.
9775531|NCT01027650|Experimental|Stage 1 Cohort 2|AGN208397 intravitreal injection 300 ug on Day 1.
9775532|NCT01027650|Experimental|Stage 1 Cohort 3|AGN208397 intravitreal injection 600 ug on Day 1.
9775533|NCT01027650|Experimental|Stage 1 Cohort 4|AGN208397 intravitreal injection 900 ug on Day 1.
9775534|NCT01027650|Experimental|Stage 2 Arm 1|AGN208397 intravitreal injection 600 ug on Day 1.
9775535|NCT01027650|Experimental|Stage 2 Arm 2|AGN208397 intravitreal injection 450 ug on Day 1.
9775536|NCT01027650|Experimental|Stage 2 Arm 3|AGN208397 intravitreal injection 300 ug on Day 1.
9775537|NCT01027650|Active Comparator|Stage 2 Arm 4|Dexamethasone 700 ug intravitreal implant on Day 1.
9775538|NCT01027754|Experimental|Varenicline|Drug treatment in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
9775539|NCT01027754|Placebo Comparator|Placebo|Matched placebo capsules in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
9775540|NCT01027780|Active Comparator|Mindfulness-Based Stress Reduction|Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
9775541|NCT01027780|No Intervention|Wait-list control|Wait-list control participants were offered MBSR training after completion of their primary assessments periods.
9775542|NCT01027793|Active Comparator|Tretinoin|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
9775543|NCT01027793|Active Comparator|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.
9775544|NCT01027806|Active Comparator|Montelukast|
9775545|NCT01027806|Placebo Comparator|Placebo|
9775546|NCT01027819|Active Comparator|Mobile bearing|Mobile bearing type between polyethylene insert and tibial component MB type will be randomly used in total knee arthroplasty
9775547|NCT01027819|Active Comparator|Fixed bearing|Fixed bearing type between polyethylene insert and tibial component FB type will be randomly used in total knee arthroplasty
9775548|NCT01027845|Experimental|10Pn Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of Synflorix (10Pn) vaccine, administered intramuscularly on alternating (left/right) sides of the anterolateral thigh and DPT KAKETSUKEN Syringe (DTPa) vaccine administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm. Both vaccines were administered at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
9775549|NCT01027845|Active Comparator|DTPa Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of the DPT KAKETSUKEN Syringe (DTPa) vaccine, administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
9775550|NCT01027871|Experimental|LY2605541 Dosing Algorithm 1|Participants took both LY2605541 and their pre-study insulin for first several days
9775551|NCT01027871|Experimental|LY2605541 Dosing Algorithm 2|Participants took only LY2605541 with first dose doubled
9984308|NCT04236609|Active Comparator|XIENCE Everolimus-Eluting Stents (EES)|Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).
9775552|NCT01027871|Active Comparator|Insulin glargine|
9775553|NCT01027884|Placebo Comparator|Placebo|Placebo 900 mg/day
9666226|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 14.
9666227|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14 28.
9666228|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 14.
9666229|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|Two doses of High-dose vaccine at the schedule of day 0, 14, 28.
9775554|NCT01027884|Experimental|Idebenone|Idebenone 900 mg/day
9984309|NCT04235257|Experimental|Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
9775555|NCT01027897|Experimental|Doripenem group|Patients will receive doripenem for the treatment of their infection
9784812|NCT01235689|Experimental|Tight Control Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI < 150, hs-CRP, < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI < 150, hs-CRP < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone during the preceding week."
9784813|NCT01235689|Active Comparator|Clinically Driven Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine.~Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified failure criteria using less stringent criteria:~At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI < 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI < 200, and absence of prednisone during the preceding week."
9784814|NCT01235715|Active Comparator|Evicel|Evicel is a fibrin sealant used for hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical. It has been shown to stop bleeding in 2 minutes or less. Evicel is a combination of a biologic activated component containing human fibrinogen and topical thrombin that functions on wet, actively bleeding tissue. It is a bioresorbable and biocompatible agent.
9784815|NCT01235715|No Intervention|no evicel|Patients will receive standard treatment for bleeding as practiced at the Hospital for Special Surgery.
9784816|NCT01235728|Experimental|Treatment Sequence 1|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
9784817|NCT01235728|Experimental|Treatment Sequence 2|Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
9784818|NCT01235728|Experimental|Treatment Sequence 3|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
10204003|NCT04511247|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
9784819|NCT01235728|Experimental|Treatment Sequence 4|Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
9984310|NCT04235257|Experimental|Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
10204004|NCT04511234|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
10204005|NCT04511234|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
10204006|NCT04508582||Women with Pre-eclampsia|De novo hypertension after 20 weeks gestation with evidence of end organ dysfunction.
10204007|NCT04508582||Women with Pregnancy-induced hypertension|De novo hypertension after 20 weeks gestation without evidence of end organ dysfunction.
10204008|NCT04508582||Healthy pregnant controls|Low risk women at booking as per NICE guidelines without any medical condition throughout pregnancy
10204009|NCT04505384|Experimental|Left bundle branch pacing|Left bundle branch pacing
10204010|NCT04505384|Active Comparator|Biventricular pacing|Biventricular pacing
10204011|NCT04504955||Atopic Dermatitis|Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible
10204012|NCT04491617|Active Comparator|Standard Opioid Protocol (Control)|Standard postoperative medications (opioids and non-opioids) are prescribed upon discharge after surgery
10204013|NCT04491617|Experimental|Restrictive Opioid Protocol (Intervention)|Only non-opioid analgesics (i.e. ibuprofen and acetaminophen) are prescribed upon discharge after surgery. Patients are allowed to request an opioid prescription if they so desire
10204014|NCT04488055|Experimental|Crisis Line Facilitation (CLF)|This single-session intervention addresses the individuals' perceived barriers and facilitators of crisis line use during periods of suicidal crisis.
10204015|NCT04488055|Active Comparator|Enhanced Usual Care (EUC)|Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with the NSP Lifeline and a list of outpatient mental health and substance use resources and encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms.
10204016|NCT04482933|Experimental|Experimental: HSV G207|All subjects will receive G207 at 1 x 10^8 plaque-forming units (pfu), intratumorally via controlled rate infusion through up to 4 silastic catheters over a 6 hour period. The subject will then receive a single 5 Gy dose of radiation to the tumor within 24 hours of virus inoculation.
10204017|NCT04475497|Experimental|Blood mangement group|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels <11.0. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
10204018|NCT04475497|Active Comparator|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
10204019|NCT04460690|Experimental|Rapid Onsite COVID-29 Testing|Community participants provide a saliva sample for a simple test to detect high concentrations of SARS-CoV-2 in saliva with assays that require no specialized equipment and can be completed in one hour.
9775556|NCT01027910|Experimental|PCI-24781 without mandated GCSF|PCI-24781 in combination with doxorubicin without mandated GCSF
9775557|NCT01027910|Experimental|PCI-24781 with mandated GCSF|PCI-24781 in combination with doxorubicin with mandated GCSF
9775558|NCT01027949|Experimental|Oral Treprostinil|Subjects from previous studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405), TDE-PH-301 (NCT00325442), TDE-PH-302 (NCT00325403), or TDE PH-308 (NCT00887978). Subjects were instructed to take the appropriate amount of 0.125, 0.25, 0.5, 1, and/or 2.5 mg tablets based upon their prescribed dose. Investigators were instructed to increase the dose of oral treprostinil in the absence of dose limiting drug-related AEs to ensure each subject received the optimal clinical dose throughout the study
9775559|NCT01028014|Active Comparator|Pseudoephedrine|Pseudoephedrine 120mg extended release tablets
9775560|NCT01028014|Active Comparator|Solifenacin|Solifenacin 5mg capsule
9775561|NCT01028014|Active Comparator|Tamsulosin|Tamsulosin 0.4mg capsule
9775562|NCT01028014|Active Comparator|Imipramine|Imipramine 25mg tablet
9775563|NCT01028014|Active Comparator|Cyclobenzaprine|Cyclobenzaprine 10mg tablet
9775564|NCT01028014|Placebo Comparator|Lactose capsules|Sham
9775565|NCT01028027|Experimental|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension
9775566|NCT01028027|Active Comparator|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension
9775567|NCT01028053|Experimental|Flutemetamol (18F) Injection|Flutemetamol (18F) Injection
9775568|NCT01028131|No Intervention|Control|Participants randomized by the computer into this condition will only view the 20-minute video clips of music and tv videos.
9775569|NCT01028131|Experimental|Computerized brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model (ask, advise, assess, assist & arrange) and Motivational Interviewing.
9775570|NCT01028131|Experimental|Contingency Management Alone|Participants randomized by the computer into this condition will view a 20-minute music and tv video clip after completing the brief assessment. The research assistant will then briefly describe the CM process, with some time to discuss questions regarding procedure to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
9775571|NCT01028131|Experimental|Combined Brief Intervention and CM|Combined intervention. Participants in this condition will receive both the brief intervention and the brief description of the CM process.
9775572|NCT01028222|Experimental|Nilotinib|400 mg twice daily
9775573|NCT01028222|Active Comparator|DTIC|850 mg/m2 IV every 3 weeks
9775574|NCT01028352|Other|Duloxetine|
9775575|NCT01028378|Experimental|Topography-guided LASIK|Topography-guided LASIK for Myopia or Hyperopia
9775576|NCT01028391|Experimental|Sitagliptin + Pioglitazone|
9775577|NCT01028391|Active Comparator|Pioglitazone + Placebo|
9775578|NCT01028560|Active Comparator|No immunotherapy, receive standard of care asthma treatment|This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
9775579|NCT01028560|Experimental|Allergen immunotherapy|This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
9775580|NCT01028651||Portopulmonary hypertension|
9775581|NCT01028677|Experimental|intranasal spray with oxytocin|Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
9775582|NCT01028677|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.
9775583|NCT01028820|Experimental|Open-Label, Flexible-Dose Aripiprazole|This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
9775584|NCT01028911|Experimental|PF-03654746|
9775585|NCT01028911|Placebo Comparator|Placebo|
9775586|NCT01028937|Experimental|Hyperopia|The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.
9775587|NCT01029054|Experimental|carfilzomib, lenalidomide w/dexamethasone|"Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level~Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study"
9775588|NCT01029262|Experimental|Arm #1 - Lenalidomide plus placebo|Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and < 60 mL/min.
9775589|NCT01029262|Placebo Comparator|Arm #2 - placebo|Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.
9775590|NCT01029340|Experimental|Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS|Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
9775591|NCT01029340|Experimental|Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)|Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
9775592|NCT01029340|Experimental|Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ|Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
9775593|NCT01029340|Experimental|Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP|Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
9775594|NCT01029340|Experimental|Arm 5: Recombinant Factor VIII by CS/EP|Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
9775595|NCT01029353|Active Comparator|Randomized Trial: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
9775596|NCT01029353|Active Comparator|Randomized Trial: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
9775597|NCT01029353|Active Comparator|Preference Cohort: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
9775598|NCT01029353|Active Comparator|Preference Cohort: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
9784820|NCT01235728|Experimental|Treatment Sequence 5|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
9775599|NCT01029366|Experimental|CART-19 CLL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
9775600|NCT01029366|Experimental|CART-19 ALL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
9775601|NCT01029392|Experimental|Required Vitamin D|Those children whose Vitamin D level was low (<30 ng/mL) are given Vitamin D supplementation
9775602|NCT01029392|No Intervention|Normal Vitamin D|Those children whose Vitamin D level was normal (50-80 ng/mL) did not receive Vitamin D supplementation
9775603|NCT01029405|Active Comparator|1. AN2728 Ointment B|2%, administered twice daily
9775604|NCT01029405|Placebo Comparator|2. AN2728 Ointment B Vehicle|
9775605|NCT01029405|Active Comparator|3. AN2728 Ointment B|2%, administered once daily
9775606|NCT01029405|Active Comparator|4. AN2728 Ointment B|0.5%, administered twice daily
9775607|NCT01029405|Active Comparator|5. AN2728 Ointment B|0.5%, administered once daily
9775608|NCT01029535|Experimental|Juvederm® VOLUMA™|Juvederm® VOLUMA™ injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.
9775609|NCT01029587|Experimental|Eculizumab|Patients will receive eculizumab in conjunction with systemic anticoagulation before and after kidney transplant operation
9775610|NCT01029652|Experimental|Canakinumab 150 mg|"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive re-dose of study drug on demand upon occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after previous dose. Patients completing 12 weeks core study were allowed to continue treatment in another 12-week extension for any new gout flare on demand with same treatment as assigned in core study.~After completing the first extension, patients were offered to enter second extension study, whereby all patients were treated open-label on demand with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in core study. Patients completing first 12 weeks extension study were allowed to continue to be treated in another single-arm, open-label 48 weeks extension when all patients from both treatment arms received canakinumab on demand"
9775611|NCT01029652|Active Comparator|Triamcinolone acetonide 40 mg|"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.~Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period Triamcinolone acetonide was not to be administered in the 48-week session."
9775612|NCT01029691|Experimental|Positive Airway Pressure (compliant)|This arm was women who used auto-titrating positive airway pressure (APAP) for at least 4 hours per night
9775613|NCT01029691|No Intervention|Standard care|
9775614|NCT01029691|Experimental|Positive Airway Pressure (non-compliant)|No one was assigned to this arm, but for results data quality purposes, women assigned to PAP who were explicitly non-compliant (used less than 4 hours per night), were analyzed separately from women who were compliant with the PAP assignment.
9775615|NCT01029704|Experimental|EGT0001442|
9775616|NCT01029704|Placebo Comparator|Placebo|
9775617|NCT01029730|Experimental|Bendamustine/Bortezomib/Rituximab|Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
9775618|NCT01029782|Active Comparator|IV cefazolin plus oral probenecid and placebo cephalexin|
9775619|NCT01029782|Active Comparator|Oral cephalexin and saline IV plus probenecid placebo|
9775620|NCT01029795|Experimental|LY2599506|Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
9784821|NCT01235728|Experimental|Treatment Sequence 6|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
9775621|NCT01029795|Active Comparator|Glyburide|Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
9775622|NCT01029886|Experimental|1|
9775623|NCT01029886|Active Comparator|2|
9775624|NCT01029912|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) Electrical Stimulator
9775625|NCT01029912|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) Electrical Stimulator
9775626|NCT01029925|Experimental|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart.
9775627|NCT01030133|Active Comparator|Real TMS|Participants in the real Transcranial Magnetic Stimulation (TMS) group will receive real stimulation across all interventions; the operator role Real TMS and receiver role Real TMS. rTMS will be used to stimulate the left prefrontal cortex using two Neuronetics TMS machines with figure-8, iron core coils at 10Hz and at 110% of resting motor threshold [5 second trains following each trial (25 trials per visit)].
9775628|NCT01030133|Sham Comparator|Sham TMS|Participants in the sham Transcranial Magnetic Stimulation (TMS) group will receive sham stimulation across all interventions; the operator role Sham TMS and receiver role Sham TMS. Sham Stimulation involves 5 second trains of 10Hz rTMS in pairs alternating between real TMS and eSham TMS (randomly ordered). All sham treatment will be delivered with a specially designed, manufacture-provided sham TMS coil that looks and sounds identical to a real TMS coil but no magnetic current is transferred to the participant.
9775629|NCT01030133|Other|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
9775630|NCT01030289|Active Comparator|real tDCS First Visit|On the First Visit, A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
9775631|NCT01030289|Sham Comparator|sham tDCS First Visit|On the First Visit, For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
9775632|NCT01030289|Active Comparator|real tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
9775633|NCT01030289|Sham Comparator|sham tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
9775634|NCT01030406|Active Comparator|40/0mg taken first|8x oxycodone/niacin 5/0mg tablets
9775635|NCT01030406|Active Comparator|80/0mg taken first|8x oxycodone/niacin 10/0mg tablets
9775636|NCT01030406|Experimental|40/240mg taken first|8x oxycodone/niacin 5/30mg tablets
9775637|NCT01030406|Experimental|80/480mg taken first|8x oxycodone/niacin 10/60mg tablets
9775638|NCT01030406|Placebo Comparator|0/0mg taken first|Placebo
9775639|NCT01030458|Experimental|amlodipine plus valsartan|In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.
9666230|NCT04636333|Experimental|Middle-dose vaccine (> 59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14, 28.
9666231|NCT04636333|Experimental|High-dose vaccine (> 59 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
9666232|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 14.
9666233|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Three dose regimen|Three doses of middle-dose placebo at the schedule of day 0, 14, 28.
9666234|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 14.
9775640|NCT01030458|Active Comparator|hydrochlorothiazide plus bisoprolol|In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol
9775641|NCT01030523|Experimental|Short Implants|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
9775642|NCT01030523|Active Comparator|Long Implants|ASTRA TECH Implants System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)
9775643|NCT01030536|Experimental|CAT-8015 20 microgram per kilogram (mcg/kg)|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
9775644|NCT01030536|Experimental|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
9775645|NCT01030536|Experimental|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
9784822|NCT01235728|Experimental|Treatment Sequence 7|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
9984311|NCT04232202|Experimental|Laser|After extraction, Er:YAG and Nd:YAG lasers used for degranulation, disinfection, deepithelialization, clot stabilization and photobiomodulation.
9984312|NCT04232202|Active Comparator|Control|Standard extraction procedure.
9984313|NCT04229797|Active Comparator|Comparator|Extraction of the unerupted third molars before distalization of mandibular first molar using Mandibular buccal shelf mini-screws.
9984314|NCT04229797|Experimental|Intervention|Leaving the unerupted third molars and distalizing using Mandibular buccal shelf mini-screws.
9984315|NCT04228822|Experimental|Low carb diet intervention group|Low carbohydrate diet defined as 25-35% of total energy intake
9984316|NCT04228822|No Intervention|Control|Standard diet defined as 45-65% total energy intake
9984317|NCT04228276|Experimental|Active rTMS|Receive active rTMS
9984318|NCT04228276|Sham Comparator|Sham rTMS|Receive sham rTMS
10204020|NCT04456244||Group 1:Transtibial Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
10204021|NCT04456244||Group 2:Transfemoral Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
10204022|NCT04450654|Experimental|Gamunex-C IVIG|Gamunex-C IVIG dosed at 2g/kg will be given on week 0 and week 4.
10204023|NCT04450654|Placebo Comparator|Placebo|Albumin in a 1% solution at an equivalent volume to the corresponding Gamunex-C IVIG dose will be given at week 0 and week 4.
10204024|NCT04445493||Device: MindRhythm Harmony|Passive recording of the head pulse
10204025|NCT04438304|Experimental|Intervention|64Cu-SARTATE will be administered at a fixed administration dose of 200 MBq (5.4 mCi) given as a single bolus intravenous injection.
10204026|NCT04437485|Experimental|eIMPACT-DM intervention|eIMPACT-DM is a 6-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for diabetes risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Good Days Ahead, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers (PCPs).
10204027|NCT04437485|Active Comparator|Active Control|Active Control (AC) consists of depression education (study staff), symptom monitoring (study staff), and primary care for depression (clinical staff).
10204028|NCT04436224|Experimental|hydromorphone|NS 40ML+ hydromorphone(10mg , 2mg:2ml），IV-Pump，maintenance dose 0.50mg/h
10204029|NCT04436224|Active Comparator|fentanyl|NS 40ML+ fentanyl(0.5mg, 0.1mg:2ml），IV-Pump，maintenance dose 0.08-0.2mg/h
9666235|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
9666236|NCT04636333|Placebo Comparator|Middle-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
9666237|NCT04636333|Placebo Comparator|High-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
9666238|NCT04636177|Active Comparator|Standard Physiotherapy Rehabilitation (SPR)|Sessions are individually-tailored and based on the Guide to Physical Therapy Practice 3.0 consisting of 1) therapeutic exercise, 2) balance and proprioception, 3) strength training, and 4) use of modalities (e.g., heat/cold pack). Patients will be given a structured Home Exercise Program (HEP) with prescribed exercises for home. SPR participants will be allocated a VR headset for recreational use.
9666239|NCT04636177|Experimental|Pain Rehabilitation Virtual Reality (PRVR)|Sessions will follow the same guidelines as SPR, with half of the physiotherapy (PT) sessions delivered in virtual reality (VR). VR in PT will engage participants in a series of immersive games customized to align with individual PT needs. Patients in the PRVR arm will be given a structured HEP to practice prescribed exercises at home with integrated VR activities. PRVR participants will be allocated a VR headset for use in PT sessions and with HEP.
9666240|NCT04631848||ULTRASCORE™ Focused Force PTA Balloon|
9666259|NCT04629274|Experimental|Test of Imotopes® candidates on blood cells of patients with stabilized NMO|To test in vitro the binding of different Imotopes® to class II HLA antigens on PBMC isolated from patients presenting a diagnosed and stabilized neuromyelitis optica spectrum disorders, as well as their ability to generate a cytolytic response directed against the immune cells involved in the maintenance and triggering of the disease (i.e. non-cytolytic T cells recognising the same epitopes and antigen presenting cells (APC) presenting the same epitopes).
9666260|NCT04626804|Experimental|1 Test the usability, perceptions, and acceptability of R/S|Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. . The primary outcome is a caregiver-assessed measure usability.
9666261|NCT04624698|Experimental|Implantation|Subjects will undergo cataract surgery and then implantation of the iStent Inject trabecular micro-bypass device.
9666262|NCT04623671|Active Comparator|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
9666263|NCT04623671|Placebo Comparator|Placebo|Matching placebo solution
9666264|NCT04623216|Experimental|Sabatolimab 400mg|Safety cohort 1: Participants in this arm will receive sabatolimab 400mg intravenously every 4 weeks.
9666265|NCT04623216|Experimental|Sabatolimab 800mg|Safety cohort 2: Participants in this arm will receive sabatolimab 800mg intravenously every 4 weeks.
9666266|NCT04623216|Experimental|Sabatolimab + Azacitidine|Expansion cohort 3: Participants in this arm will receive sabatolimab at the recommended dose for expansion in combination with azacitidine.
9666267|NCT04623216|Experimental|Sabatolimab|Expansion cohort 4: Participants in this arm will receive sabatolimab at the recommended dose for expansion.
9775646|NCT01030536|Experimental|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
9775647|NCT01030536|Experimental|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
9775648|NCT01030653|Experimental|Voriconazole low dose first then high dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
9775649|NCT01030653|Experimental|Voriconazole high dose first then low dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
9775650|NCT01030666|Experimental|doxycycline|"The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
9775651|NCT01030666|Placebo Comparator|placebo|"The patients of the control group will take placebo once a day for 7 days after regenerative therapy of an infrabony defect~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
9775652|NCT01030718|Experimental|dasatinib (CML-CP)|CML - Chronic Phase
9775653|NCT01030718|Experimental|dasatinib (CML-AP/BP)|CML - Accelerated Phase and Blast Phase
9775654|NCT01030718|Experimental|dasatinib (Ph+ ALL)|Ph+ Acute Lymphoblastic Leukemia
9775655|NCT01030783|Experimental|tivozanib (AV-951)|
9775656|NCT01030783|Active Comparator|sorafenib|
9775657|NCT01030822|Experimental|Group A|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
9775658|NCT01030822|Experimental|Group B|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
9775659|NCT01030822|Experimental|Group C|Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.
9775660|NCT01030861|Active Comparator|teplizumab|Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
9775661|NCT01030861|Placebo Comparator|Placebo infusion|Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.
9775662|NCT01030874|No Intervention|Usual Rehabilitation Care|Usual rehab care
9775663|NCT01030874|Experimental|Experimental Treatment/Medication Review|Treatment for, and prevention of, orthostatic hypotension
9775664|NCT01030952|Experimental|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
9775665|NCT01030952|Active Comparator|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
9775666|NCT01030965|Experimental|GSK573719 125mcg|125mcg once-daily via novel dry powder inhaler
9775667|NCT01030965|Experimental|GSK573719 250mcg|250mcg once-daily via novel dry powder inhaler
9775668|NCT01030965|Experimental|GSK573719 500mcg|500mcg once-daily via novel dry powder inhaler
9775669|NCT01030965|Placebo Comparator|Placebo|once-daily via novel dry powder inhaler
9775670|NCT01031004|Experimental|narafilcon B|contact lens
9775671|NCT01031004|Active Comparator|etafilcon A|contact lens
9775672|NCT01031043|Experimental|Topical Bethanechol|patients will be given either 5 mg (first phase) or 10 mg (second phase) of bethanechol in 1 ml of solution containing an absorption enhancer. Administration will be performed by throat spray device
9784823|NCT01235728|Experimental|Treatment Sequence 8|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
9775673|NCT01031069|Experimental|HIV+/Cervarix Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
9775674|NCT01031069|Active Comparator|HIV+/Gardasil Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
9775675|NCT01031069|Experimental|HIV-/Cervarix Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
9775676|NCT01031069|Active Comparator|HIV-/Gardasil Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
9775677|NCT01031095|Experimental|Low dose intracoronary heparin|Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
9775678|NCT01031095|Active Comparator|Standard treatment arm|Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
9775679|NCT01031134|Experimental|Shared Decision Making|1 in person session followed by 2 telephone calls 1 and 2 weeks later.
9775680|NCT01031134|Active Comparator|Usual Care|Physician Usual Care of depressed patients.
9775681|NCT01031381|Other|Rad001/Bevacizumab|Patients will receive RAD001 by mouth everyday and Bevacizumab IV every 14 days until clinical progression.
9775682|NCT01031420|Experimental|dose dense MVAC|standard doses of MVAC given every 14 days x 3.
9775683|NCT01031446|Experimental|Treatment|
9775684|NCT01031498|Active Comparator|Ondansetron: Standard of Care|Standard of care, Ondansetron 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
9775685|NCT01031498|Experimental|Palonosetron Group 1 (5 Days)|Palonosetron once a day 0.25 mg IV injection for 5 days, given over 30 seconds, 30 minutes before chemotherapy treatment.
9775686|NCT01031498|Experimental|Palonosetron Group 2 (3 Days)|Palonosetron once a day 0.25 mg IV injection on Days 1, 3, and 5 of chemotherapy treatment, given over 30 seconds, 30 minutes before chemotherapy treatment.
9775687|NCT01031537|Other|FSME-IMMUN 0.5mL Baxter|FSME-IMMUN 0.5mL Baxter is non-US licensed vaccine for tick-borne encephalitis virus. The FSME-IMMUN 0.5mL Baxter is available as 0.5mL in a pre-loaded vaccine syringe. All participants received active vaccine using a rapid immunization schedule, with vaccine administration on Days 0, 14, 161 and 245. Participants that tested seropositive for tick-borne encephalitis virus or subjects that developed positive viral neutralizer titers after the 3rd or 4th vaccine were given a booster of FSME-IMMUN 0.5mL Baxter vaccine at 3, 6 and 9 years after enrollment.
9775688|NCT01031680|Experimental|1|Dapagliflozin 10 mg tablet
9775689|NCT01031680|Placebo Comparator|2|Matching placebo tablet
9775690|NCT01031706|Experimental|Hypertonic saline|6% NaCl, 4 ml TID via eFlow
9775691|NCT01031706|Placebo Comparator|Placebo|0.12% x 4ml via eFlow nebulizer
9775692|NCT01031810|Other|tranylcypromine|patients will receive treatment with tranylcypromine
9775693|NCT01031836|Experimental|MEDI-545 1.0 mg/kg|Cohort 1
9775694|NCT01031836|Experimental|MEDI-545 3.0 mg/kg|Cohort 2
9775695|NCT01031836|Experimental|MEDI-545 10.0 mg/kg|Cohort 3
9775696|NCT01031836|Experimental|MEDI-545 100 mg|Cohort 4
9775697|NCT01031836|Experimental|MEDI-545 600 mg|Cohort 5
9775698|NCT01031836|Experimental|MEDI-545 1,200 mg|Cohort 6
9775699|NCT01031914|Experimental|Paced Breathing Sleep/Wake detection|All subjects enrolled will have oobstructive sleep apnea (OSA) and will be current Continuous Positive Airway Pressur (CPAP) users.
9775700|NCT01031953|Experimental|Fosaprepitant|
9775701|NCT01031979|Experimental|Yohimbime Group|Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.
9775702|NCT01031979|Placebo Comparator|Placebo Group|Patients will take a placebo one hour before first imaginal exposure in PE.
9775703|NCT01032018|Active Comparator|Referred Care|Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
9775704|NCT01032018|Experimental|Stepped Care|Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.
9775705|NCT01032044|Active Comparator|Standard endoscopic evaluation|Standard high-definition white light endoscopy guided evaluation
9775706|NCT01032044|Experimental|pCLE-guided evaluation|Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
9775707|NCT01032070|Experimental|Erlotinib|Erlotinib was administered orally at a dose of 85 mg/m^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
9775708|NCT01032070|Active Comparator|Etoposide|Etoposide 50 mg/m^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
9775709|NCT01032135|Active Comparator|1-MI-IOP Engaged|Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
9775710|NCT01032135|Experimental|2-MI-IOP Non-Engaged|Randomized to treatment as usual, and do not attend.
9775711|NCT01032135|Active Comparator|3-MI-PC Engaged|Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
9775712|NCT01032135|Experimental|4-MI-PC Non-engaged|Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
9775713|NCT01032174||Azithromycin SR|Acute Bacterial Maxillary Sinusitis
9775714|NCT01032174||Amoxiclav 1000 mg|Acute Bacterial Maxillary Sinusitis
9775715|NCT01032200|Experimental|Arm I - Armodafinil|Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
9775716|NCT01032200|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
9775717|NCT01032239|Active Comparator|ITB therapy|Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
9775718|NCT01032239|No Intervention|Best Medical Treatment (BMT)|Use one or a combination oral antispastic medication.
9775719|NCT01032291|Experimental|lenalidomide plus cetuximab|Combination therapy of lenalidomide plus cetuximab
9775720|NCT01032291|Experimental|lenalidomide|Single agent therapy of lenalidomide
9775721|NCT01032330|No Intervention|Observation|Patients randomized to the observation group will receive no treatment (other than refractive correction).
9775722|NCT01032330|Active Comparator|Occlusion Therapy|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
9775723|NCT01032382|Active Comparator|Paromomycin Alone Treatment|
9775724|NCT01032382|Active Comparator|WR 279,396|
9775725|NCT01032538||Patients with knee osteoarthritis|Patients with knee osteoarthritis that are about to get an operation with oxford unicondylar knee
9775726|NCT01032629|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
9775727|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 100 mg|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
9775728|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 300 mg|Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
10204030|NCT04436224|Active Comparator|Butorphanol|NS 40ML+ butorphanol(10mg, 1mg:1ml），IV-Pump，maintenance dose 0.7-10mg/kg/h
10204031|NCT04433988|Placebo Comparator|Control group|100 patients will receive standard treatment plus placebo
9775729|NCT01032694||Z-max treated group|Patients with Community-Acquired Pneumonia
9775730|NCT01032694||Amoxiclav treated group|Patients with Community-Acquired Pneumonia
9775731|NCT01032733|Experimental|Lifestyle Counseling|In the experimental condition, participants attended a group-based weight management session plus three supervised exercise sessions each week.
9775732|NCT01032733|Placebo Comparator|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss.
9775733|NCT01032759|Active Comparator|Memantine|
9775734|NCT01032759|Placebo Comparator|Placebo|Placebo
9775735|NCT01032837|Experimental|Oseltamivir standard dose 5 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
10204032|NCT04433988|Experimental|Pentoxifylline group|100 patients will receive standard treatment plus pentoxifylline 1200 mg/day
10204033|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
10204034|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
10204035|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 3|100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
9775736|NCT01032837|Experimental|Oseltamivir standard dose 10 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 10 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 10 days.
9775737|NCT01032837|Experimental|Oseltamivir high dose 5 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
9775738|NCT01032837|Experimental|Oseltamivir high dose 10 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 10 days. Children aged 1- 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 10 days.
9775739|NCT01032850|Experimental|Arm 1: Sorafenib & Capecitabine|Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)
9775740|NCT01032889|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9775741|NCT01032889|Experimental|Deoxycholic acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9775742|NCT01032889|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9775743|NCT01032915|Experimental|AIN457 300mg s.c weekly for 3 weeks|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
9775744|NCT01032915|Experimental|AIN457 300mg s.c at baseline and Week 2|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
9775745|NCT01032915|Experimental|AIN457 150mg s.c at baseline and Week 2|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
9775746|NCT01032915|Placebo Comparator|Placebo s.c weekly for 3 weeks|Placebo s.c weekly for 3 weeks then every 2 weeks
9775747|NCT01032928|Experimental|Respiratory Phase Training|Chronically dysphagic, medically stable patients at least 6 months post treatment for head and neck cancer with non-optimal respiratory-swallowing patterns participated in up to 8 sessions of respiratory phase training to learn an optimal respiratory - swallow phase pattern
9775748|NCT01032954|Active Comparator|"125 to 170 IU of 'Botulinum toxin' "|group with intervention of 125 to 170 IU of 'Botulinum toxin'
9775749|NCT01032954|Active Comparator|171 to 210 IU of 'Botulinum toxin'|Patients who have received 171 to 210 IU of 'Botulinum toxin'
9775750|NCT01032954|Active Comparator|211 to 250 IU of Botulinum toxin|Patients who have received 211 to 250 U of Botulinum toxi'
9775751|NCT01032993|Active Comparator|Coenzyme Q10|600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
9775752|NCT01032993|Placebo Comparator|Placebo|Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
9775753|NCT01033019|Experimental|LDE225 0.75%|Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
9775754|NCT01033019|Placebo Comparator|Vehicle|Participants topically applied matching placebo cream twice daily for 6 weeks.
9775755|NCT01033032|Experimental|Amrubicin Phase I/II|Systemic therapy with amrubicin
9775756|NCT01033071|Experimental|Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD|
9775757|NCT01033071|Experimental|Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD|
9775758|NCT01033071|Active Comparator|Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD|
9775759|NCT01033136|Experimental|MCET-V|Multiple Channel Exposure Therapy -Veterans (MCET-V) is a 12-session cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks. It is an integrated treatment designed to target panic and PTSD symptoms simultaneously.
9775760|NCT01033136|Active Comparator|CPT|Cognitive Processing Therapy (CPT) is a 12-session cognitive-behavioral treatment for persons with PTSD. It is a gold-standard cognitive behavioral intervention designed to target PTSD symptoms.
10204036|NCT04422847|Experimental|intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
10204037|NCT04422847|No Intervention|control group|The standard procedure without the 3D obturator.
10204038|NCT04419467|Experimental|CSL346 (low dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
10204039|NCT04419467|Experimental|CSL346 (high dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
10204040|NCT04419467|Placebo Comparator|Placebo|Administered as a single IV loading dose followed by SC infusions
10204041|NCT04414722|Placebo Comparator|Concurrent control yogurt and amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
10204042|NCT04414722|Placebo Comparator|Control yogurt taken 4 hours after amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
10204043|NCT04414722|Active Comparator|Concurrent BB-12 yogurt and amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
9666268|NCT04623216|Experimental|Sabatolimab (adolescent cohort)|Adolescent safety cohort (cohort 5): ≥12 to < 18 year old adolescent participants in this arm will receive sabatolimab at the recommended dose for expansion.
9666269|NCT04623177||Anticoagulation|Patients receiving an anticoagulant dose (equal or higher than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
9666270|NCT04623177||Thromboprophylaxis|Patients receiving a prophylactic dose (lower than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
9666271|NCT04623177||No heparin|Patients receiving no anticoagulant drug within the first 48 hours after the ICU admission
9666272|NCT04621526|Active Comparator|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
9666273|NCT04621526|Active Comparator|dexmedetomidine- propofol|patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
9666274|NCT04619355||TVC K-Registry|
9666275|NCT04617587|Experimental|Early Intervention|All the enrolled preterm infants are assigned to receive the early neurodevelopmental intervention during the NICU stay.
9666276|NCT04616170|Active Comparator|Usual care|Patients in this arm will be randomized to the routine positioning instructions given at the time of crowning of the fetal vertex during vaginal delivery.
9666277|NCT04616170|Experimental|Hip extension|Patients in this arm will be randomized to hip extension at the time of crowning of the fetal vertex during vaginal delivery.
9666278|NCT04616014|Other|ORMD-0801 QD|8 mg QD, daily, in the morning
9666279|NCT04616014|Other|ORMD-0801 BD|8 mg BD, daily in the morning and in the evening
9666280|NCT04615689||Infants with febrile urinary tract infection|The investigators will recruit infants hospitalized for acute febrile urinary tract infection. Before starting antibiotics treatment, The investigators will collect feces with the informed consents from infants' parents.
9666281|NCT04615689||Healthy infants|The investigators will recruit healthy controls from the clinics for routine check up with the informed consents from infants' parents.
9666282|NCT04614116|Other|Biopsy without cold induction|Participants will undergo a fat biopsy after the first scan, without cooling
9666283|NCT04614116|Other|Biopsy with cold induction|Participants will undergo a fat biopsy after the second scan, with cooling
9666284|NCT04613570|Experimental|Yearly endoscopy|Upper gastrointestinal endoscopy every year (12-16 months)
9666285|NCT04613570|Other|Endoscopy every 3 years|Upper gastrointestinal endoscopy every three years (32-40 months)
9666286|NCT04612322||Patients undergoing coronary microvascular function assessment|
9666287|NCT04609111|Active Comparator|No aspirin|To start prasugrel monotherapy before the index percutaneous coronary intervention (PCI) and to change into clopidogrel monotherapy at 1-month after the PCI.
9666288|NCT04609111|Active Comparator|1-month DAPT|To start dual antiplatelet therapy comprising of aspirin and prasugrel before the index percutaneous coronary intervention (PCI) and to change into aspirin monotherapy at 1-month after the PCI.
9666289|NCT04607837|Experimental|Etrasimod 2 mg|
9666290|NCT04607837|Placebo Comparator|Placebo|
9666291|NCT04607174||Pathologic group|At least 20 participants with various neurologic or orthopaedic conditions (for example, hemiparesis post-stroke, multiple sclerosis, traumatic knee injuries, knee osteoarthritis) will be enrolled.
9666292|NCT04606459|Active Comparator|Optimal medical therapy|"Optimal medical therapy consisting of acetyl salicylic acid, statins, beta-blockers, calcium channel-antagonists, ranolazine will be administered at the discretion of the physician as recommended by the most recent European Society of Cardiology (ESC) guidelines.~Long-acting nitrates will not be administered unless for patients with fractional flow reserve (FFR)<0.8 or with previously reported good response. Short-acting nitrates may be administered in patients in whom concomitant epicardial spasm is suspected, but they have no documented effect on microvascular angina."
9666293|NCT04606459|Experimental|Coronary sinus reducer|The device being studied is the Neovasc Reducer™ System. Each patient in the Reducer group will be implanted with a single Reducer according to the instructions for use.
9666294|NCT04601857|Experimental|futibatinib and pembrolizumab (Cohort A)|Patients with UC and FGFR3 mutation or FGFR1-4 fusion/rearrangement.
9666295|NCT04601857|Experimental|futibatinib and pembrolizumab (Cohort B)|All other patients than in Cohort A with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors).
9666296|NCT04600466||Retrospective Non-Hispanics|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
9666297|NCT04600466||Retrospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
9666298|NCT04600466||Prospective Non-Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
9666299|NCT04600466||Prospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
9775761|NCT01033227|No Intervention|No drug|No study drug administered
9775762|NCT01033227|Experimental|Sodium nitrite injection, USP|Administration if sodium nitrite injection, USP
9775763|NCT01033240|Experimental|Safety Cohort 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
9775764|NCT01033240|Experimental|Safety Cohort 2 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (4 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
9775765|NCT01033240|Active Comparator|Safety Cohort 3 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (6 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
9775766|NCT01033240|Experimental|Treatment Group 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 1: CS-1008 (6 mg/kg [or as determined] loading, 2 mg/kg/week maintenance) + sorafenib twice daily (N=50)
9775767|NCT01033240|Experimental|Treatment Group 2 with CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 2: CS-1008 (6 mg/kg [or as determined] loading, 6 mg/kg/week [or maximum tolerated dose {MTD}] maintenance) + sorafenib twice daily (N=50)
9775768|NCT01033240|Experimental|Treatment Group 3 with Sorafenib Alone|Sorafenib. Treatment Group 3: sorafenib twice daily (N=50)
9775769|NCT01033383|Placebo Comparator|3 placebo capsules|3 placebo capsules qd
9775770|NCT01033383|Experimental|1 cranberry capsule & 2 placebo capsules|1 active cranberry capsule and 2 placebo capsules qd
9775771|NCT01033383|Experimental|2 cranberry capsules & 1 placebo capsule|2 active cranberry capsules and 1 placebo capsules qd
9775772|NCT01033383|Experimental|3 cranberry capsules|3 active cranberry capsules qd
9775773|NCT01033422|Experimental|CF101 1mg|CF101 1mg orally q12 hours
9775774|NCT01033422|Placebo Comparator|Placebo|matching placebo orally q12 hours
9775775|NCT01033422|Experimental|CF101 2mg|CF101 2mg orally q12 hours
9775776|NCT01033448|Experimental|Single arm|
9775777|NCT01033487|Placebo Comparator|Placebo|
9775778|NCT01033487|Active Comparator|active comparator|
9775779|NCT01033487|Experimental|PF-03635659|
9775780|NCT01033565|Experimental|Natrol|Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days
9775781|NCT01033643|Experimental|MK-3614 0.25 mg (Panel A)|Participants received 0.25 mg of MK-3614 twice daily (BID) every 12 hours orally for 10 days.
9775782|NCT01033643|Experimental|MK-3614 0.50/0.25 mg (Panel B)|Participants received 0.50 mg of MK-3614 in the morning (AM) and 0.25 mg of MK-3614 in the evening (PM) 12 hours apart orally for 10 days.
9775783|NCT01033643|Experimental|MK-3614 0.50/0.25 mg (Panel C Repeat)|Participants were to receive 0.75 mg of MK-3614 BID every 12 hours orally for 10 Days. Per protocol amendment, the Panel B dose was repeated, and participants received instead 0.50 mg of MK-3614 in the AM, and 0.25 mg of MK-3614 in the PM, 12 hours apart orally for 10 days.
9775784|NCT01033643|Experimental|MK-3614 0.50 mg (Panel D)|Participants received 0.50 mg of MK-3614 three times a day (TID) orally every 8 hours on Day 1 followed by a wash out period for Days 2, 3 and 0.50 mg of MK-3614 every 12 hours orally for 10 days (Days 4-13).
9775785|NCT01033643|Experimental|MK-3614 0.50 mg (Panel E)|Participants were to receive orally 0.50 mg of MK-3614 BID every 12 hours on Day 1 followed by 3 doses (0.50/0.50/0.25 mg) of MK-3614 each 8 hours apart on Day 2; three doses of 0.50 mg of MK-3614 8 hours apart on Days 3,4; and 0.75 mg of MK-3614 BID every 12 hours on Days 5-14. No participants were enrolled in this group.
9775786|NCT01033643|Placebo Comparator|Placebo (All Panels)|Participants received a dose matched placebo orally according to randomization.
9784824|NCT01235741|Experimental|Group A|Pramlintide+Metreleptin
9784825|NCT01235741|Placebo Comparator|Group B|Placebo
9784826|NCT01235793|Experimental|DRBEAT Regimen|
9784827|NCT01235897|Experimental|Maximum tolerated dose|
9784828|NCT01235910|Other|1|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
9784829|NCT01235923|Active Comparator|three times weekly Epo|Epo 400 units/kg three times weekly given subcutaneously for 4 weeks
9784830|NCT01235923|Active Comparator|weekly Epo|1,200 units/kg given once a week subcutaneously for 4 weeks
9784831|NCT01235949|Experimental|Group IIBU|Immediate ibuprofen group: subjects receiving immediate ibuprofen treatment after each primary vaccine dose
9784832|NCT01235949|Active Comparator|Group DIBU|Delayed ibuprofen group: subjects receiving delayed ibuprofen treatment after each primary vaccine dose
9784833|NCT01235949|Active Comparator|Group NIBU|No ibuprofen group: subjects receiving no prophylactic ibuprofen treatment after each primary vaccine dose
9784834|NCT01235949|Experimental|Group IPARA|Immediate paracetamol group: subjects receiving immediate paracetamol treatment after each primary vaccine dose
9784835|NCT01235949|Experimental|Group DPARA|Delayed paracetamol group: subjects receiving delayed paracetamol treatment after each primary vaccine dose
9784836|NCT01235949|Active Comparator|Group NPARA|No paracetamol group: subjects receiving no prophylactic paracetamol treatment after each primary vaccine dose
9784837|NCT01235949|Experimental|Group IIBU-IIBU|1/3 of the subjects from the primary IIBU group receiving immediate ibuprofen treatment after booster vaccination
9775787|NCT01033734|Experimental|Single arm|
9775788|NCT01033747|Experimental|Deferasirox|Deferasirox group consists of all participants who were initially randomized to 10 and 20 mg/kg/day deferasirox orally daily in the main study and remained on the same treatment during the comparative prolongation study (NCT00379483) and at the beginning of the 5-year non-comparative study
9775789|NCT01033747|Experimental|Deferasirox Crossover|Deferasirox Crossover group consists of participants who were initially randomized to 40 mg/kg/day deferoxamine (DFO)subcutaneously in the main study and comparative prolongation study and crossed over to 5mg/kg/day to 30 mg/kg/day deferasirox orally daily at the beginning of the 5-year non-comparative extension study
9775790|NCT01033773|Other|Diabetes education and medication management|All enrolled patients received the intervention. There was no comparative arm. The analysis was done as pre and post.
9775791|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 mcg once daily
9775792|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily
9775793|NCT01033825|Placebo Comparator|HFA Nasal Aerosol placebo|HFA Nasal Aerosol Placebo once daily
9775794|NCT01033825|Experimental|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
9775795|NCT01033825|Placebo Comparator|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
9775796|NCT01033825|Active Comparator|Placebo HFA plus Dexamethasone 6 mcg|Placebo HFA plus Dexamethasone 6 mg once daily
9775797|NCT01033825|Active Comparator|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mg once daily
9775798|NCT01033851|Active Comparator|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is an 8-week group intervention that trains participants in mindfulness meditation techniques.
9775799|NCT01033851|Active Comparator|Stress Management Education|Stress Management Education (SME) is an 8-week group intervention that educates participants about stress physiology and health lifestyle changes.
9775800|NCT01033864|Experimental|MMF, Prednisone|Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
9775801|NCT01033864|Active Comparator|EC-MPS|Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.
9775802|NCT01033942|Experimental|FTC/TDF as PrEP|Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
9775803|NCT01033942|Placebo Comparator|Placebo Pill Control|Blinded administration of placebo pill; HIV behavioral intervention
9775804|NCT01033942|Active Comparator|No Pill Control|Subjects receive HIV behavioral intervention but no pill.
9775805|NCT01034111|Experimental|Sitagliptin|Sitagliptin as add-on therapy to a stable dose of metformin
9775806|NCT01034137|Experimental|Tocilizumab + Methotrexate|Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
9775807|NCT01034137|Active Comparator|Tocilizumab + Placebo Methotrexate|Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
9775808|NCT01034137|Active Comparator|Methotrexate + Placebo Tocilizumab|Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.
9775809|NCT01034163|Experimental|Panobinostat (PAN)|Participants received 45 mg orally 3 times a week (TIW), every other week (QOW),
9775810|NCT01034163|Placebo Comparator|Placebo|Participants received matching placebo to PAN TIW, QOW.
9775811|NCT01034176|Active Comparator|Levofloxacin|Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days
9775812|NCT01034176|Placebo Comparator|placebo|placebo identical to levofloxacin drug daily for 30 days
9775813|NCT01034358|Experimental|Human Papillomavirus Vaccine|The Gardasil HPV vaccine was administered in 3 doses: baseline, 2 months, and 6 months.
9775814|NCT01034397|Experimental|1|
9775815|NCT01034397|Placebo Comparator|2|
9775816|NCT01034462|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
9775817|NCT01034462|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
9775818|NCT01034527|Experimental|Neuromuscular Training|Combination of exercises and phases designed to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
9775819|NCT01034527|No Intervention|Speed Training|Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
9775820|NCT01034540|Experimental|POM3|POM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment
9775821|NCT01034540|Placebo Comparator|Placebo|Placebo for the first six weeks of treatment. POM3 for the second six weeks of treatment
10204044|NCT04414722|Active Comparator|BB-12 yogurt taken 4 hours after amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
9775822|NCT01034553|Experimental|Arm I|Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.
9775823|NCT01034579|Other|Rebif® Cohort|
9775824|NCT01034579|Other|Copaxone® Cohort|
9775825|NCT01034592|Experimental|Lenalidomide|Subjects will initially receive lenalidomide 2.5 mg, and may escalate up to 2.5 mg/wk up to 5 mg 3x/wk, depending toxicity and response.
9775826|NCT01034631|Active Comparator|Combination Arm A: Everolimus + BNC105P|Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
9775827|NCT01034631|Active Comparator|Sequential Arm B:Everolimus followed by BNC105P Monotherapy|"Sequential Arm B: Everolimus 10 mg, 21 day cycle~Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy."
9775828|NCT01034657|Experimental|LBH589|During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
9775829|NCT01034657|Experimental|LBH589 + Epoetin Alfa|During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.
9775830|NCT01034709||Symptomatic|Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms
10204045|NCT04414722|Other|Amoxicillin-clavulanate|Amoxicillin-clavulanate 875 mg-125 mg oral tablet
10204046|NCT04411771|Experimental|Extended Assessment - Given shCBT|"The extended assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).~In the primary analysis, only patients given shCBT are included"
9775831|NCT01034709||Asymptomatic|Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms
9775832|NCT01035047|No Intervention|Inpatient Care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
9775833|NCT01035047|Experimental|CDU-CMR Protocol|Patients will be transferred to the clinical decision unit and undergo a stress cardiac MRI evaluation.
9775834|NCT01035060||Older Adult|Healthy Men and Women Over 70 Years of Age
9775835|NCT01035060||Young Adult|Healthy Men and Women Aged 18-30 Years
9775836|NCT01035099|Experimental|Titrated dose Letrozole|Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
9775837|NCT01035099|Active Comparator|Fixed dose Letrozole|Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
9775838|NCT01035138|Experimental|Drug: semagacestat|
9775839|NCT01035151|Active Comparator|Delayed Control|Women in the delayed control condition received culturally sensitive smoking cessation written materials at week 1, and mailed materials at week 6, 12, and 18. At the end of the study (i.e., after the 12 month data collection), participants were offered counseling, nicotine patches, and community health worker contacts.
10204047|NCT04411771|Active Comparator|Screening Assessment - Suitable for shCBT but given BI|"The screening assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.~In the primary anaysis, only patients suited for shCBT are included, as decided from an algorithm based on data from their screening."
10204048|NCT04411771|Experimental|Extended Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomized to Extended Assessment are included, regardless of if they start shCBT or BI"
9775840|NCT01035151|Experimental|Experimental|Women in neighborhoods randomized to the S2S received 24-week bundled multi-level intervention. Individual-led strategies were led by paid community health workers (CHWs). The CHWs provided 1:1 contact to reinforce social support, and enhanced self-efficacy with cessation attempts. A certified smoking cessation counselor led behavioral group sessions using the S2S handbook based on the PHS Guidelines. The weekly group sessions were initiated during the 1st week of the intervention, with a total of 6 group sessions over a 6-week period. Transdermal nicotine patches were offered to participants who set a quit date. Within the 24-week study period, the neighborhood tenant association, in partnership with study staff, implemented at least two neighborhood level anti-smoking activities
9775841|NCT01035229|Experimental|Everolimus + Best Supportice Care (BSC)|Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
9775842|NCT01035229|Placebo Comparator|Placebo + Best Supportive Care|Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
9775843|NCT01035255|Experimental|LCZ696|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
10204049|NCT04411771|Active Comparator|Screening Assessment - All patients|"Same as the other arm marked as Active comparator, but for the purpose of a secondary analysis all patients randomized to Screening Assessment are included, regardless of if they are suiteble for shCBT or not."
10204050|NCT04410341|Placebo Comparator|Placebo group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet once daily for 12 weeks
9775844|NCT01035255|Active Comparator|Enalapril|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period
9775845|NCT01035333|Experimental|orlistat 60mg|Patients assigned to treatment group for up to 6 months of therapy.
9775846|NCT01035346|Experimental|A|
9775847|NCT01035346|Placebo Comparator|B|
9775848|NCT01035463|Experimental|Treatment (stem cell transplantation)|"PRE-CONDITIONING (patients with CD20+ NHL): Patients receive rituximab IV per standard of care.~PREPARATIVE REGIMEN: Patients receive carmustine IV on day -6, etoposide IV BID and cytarabine IV BID on days -5 through -2, and melphalan IV on day -1.~AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: Patients undergo stem cell infusion on day 0.~MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant, patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity."
9775849|NCT01035606|Experimental|Goal-oriented Attention Regulation Training|training in goal-directed attention regulation
9775850|NCT01035606|Active Comparator|Education|brain health education
9775851|NCT01035606|Experimental|Technology-assisted Goal-directed Self-Regulation Training|computer-assisted training in goal-directed attention regulation
9775852|NCT01035658|Experimental|Dose Level 1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
9775853|NCT01035658|Experimental|Dose Level -1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
9775854|NCT01035658|Experimental|Dose Level 1 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
9775855|NCT01035658|Experimental|Dose Level 2 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
9775856|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F1 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 1 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
9775857|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
9775858|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 3D GROUP|Subjects received 3 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0, Day 21 and Day 182 (booster).
9775859|NCT01035749|Experimental|AREPANRIX-UNADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ unadjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
9775860|NCT01035788|Experimental|Mindfulness-Based CBCT|Mindfulness Based Cognitive Behavioral Conjoint Therapy for PTSD
9775861|NCT01035788|Active Comparator|CBCT Communication Skills|CBCT for PTSD - Communication Skills
9775862|NCT01035905|Experimental|Nelfilcon A|Nelfilcon A contact lens
9775863|NCT01035905|Active Comparator|Narafilcon A|Narafilcon A contact lens
9775864|NCT01036009|No Intervention|Group I: Observation|Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.
9775865|NCT01036009|Experimental|Group II: Intervention|Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.
9775866|NCT01036022|Experimental|Group 2|ASACOL 800mg t.i.d.
9775867|NCT01036022|Experimental|Group 1|GSK1399686 at 3-4 dose levels
10204051|NCT04410341|Experimental|Vildagliptin group|Escitalopram 20 mg tablet once daily for 12 week plus Vildagliptin 50mg tablet once daily for 12 weeks
10204052|NCT04383938|Experimental|Safety Lead In|Patients with advanced solid tumors. Up to 3 dose levels evaluated.
10204053|NCT04383938|Experimental|Expansion 1|Patients with advanced gastric cancer.
10204054|NCT04383938|Experimental|Expansion 2|Patients with advanced urothelial/bladder cancer.
10204055|NCT04383938|Experimental|Expansion 3|Patients with advanced NSCLC.
10205338|NCT02698163|Experimental|Nanodiamond reinforced Gutta Percha|For all the patients in the treatment arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, Nanodiamond gutta percha (NDGP) in the middle third, and again with gutta percha at the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
10205339|NCT02680067|Experimental|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
9775868|NCT01036022|Experimental|Group 3|Placebo
9775869|NCT01036321|Active Comparator|Purified Isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler. 40 mg daily.
9775870|NCT01036321|Placebo Comparator|Methyl cellulose blend|Placebo.
9775871|NCT01036438|Placebo Comparator|Mepilex product|
10204056|NCT04380753|Experimental|Treatment Arm|Subjects will be enrolled and will receive AMG 510 PO QD.
10204057|NCT04375514|Experimental|ARO-ENaC|ARO-ENaC Inhalation
9775872|NCT01036438|Active Comparator|Mepilex Ag|
9775873|NCT01036490|No Intervention|Control|Control group
9775874|NCT01036490|Experimental|Exercise|Exercise Group
9775875|NCT01036529|Experimental|Precision Spinal Cord Stimulator|Spinal Cord Stimulation
9775876|NCT01036529|Active Comparator|Back Surgery|Discectomy, laminotomy, laminectomy, foraminotomy, fusion with or without instrumentation
9775877|NCT01036594|Experimental|Ketoconazole + Hydrocortisone|"po = oral tid = 3 times per day qam = every morning qom = every evening bid = twice daily~1 cycle = 28 days~Ketoconazole: 200mg during first week of study (run-in phase), then 400mg po tid~Hydrocortisone 20mg po qam and 10mg po qpm: If participant has ≥ 30% Prostate-specific antigen (PSA) decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by Prostate Specific Antigen Working Group (PSAWG) criteria) is documented. After that, drug will be discontinued. If participant has < 30% PSA decline at 12 week evaluation, participant goes off study."
9775878|NCT01036594|Experimental|Ketoconazole + Dexamethasone|"Ketoconazole: 400mg po tid~Dexamethasone 0.5mg po bid: If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
9775879|NCT01036724||Carto 3|Those subjects whose cases use the CARTO 3 EP Navigation System.
9775880|NCT01036724||NAVX|Those subjects whose cases use the NAVX(TM) EP Navigational System.
9775881|NCT01036802|Active Comparator|Warfarin|Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
9775882|NCT01036802|Placebo Comparator|Placebo|matching active products
9775883|NCT01037088|Experimental|Mild dose cannabis|3.53% THC by weight
9775884|NCT01037088|Experimental|Low dose cannabis|1.29% THC by weight
9775885|NCT01037088|Placebo Comparator|Placebo cannabis|placebo marijuana
9775886|NCT01037114|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the first long-term follow-up NCT00289718 and this long-term follow-up.~A challenge dose of the Havrix or Engerix-B vaccines can be administered in this study based on serology results at each time point."
9775887|NCT01037127|Experimental|Cohort A|Subjects who have had previous treatment with a BRAF inhibitor.
9775888|NCT01037127|Experimental|Cohort B|Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.
9775889|NCT01037192|Experimental|Vanco once daily|Subject receives vancomycin 30 mg/kg dose
9775890|NCT01037192|Active Comparator|Vanco twice daily|Subject receives vancomycin 15 mg/kg twice daily
9775891|NCT01037218|Experimental|Udenafil 50 mg|50 mg Udenafil tablet plus 100 & 150 mg placebo tablets
10204058|NCT04375514|Placebo Comparator|Placebo|Sterile normal saline (0.9% NaCl)
10204059|NCT04374019|Experimental|Arm C: Ivermectin|Ivermectin
10204060|NCT04374019|Experimental|Arm D: Camostat Mesilate|Camostat Mesilate
10204061|NCT04374019|Experimental|Arm E: Artemesia annua|Artemesia annua tea or coffee
10204062|NCT04374019|Experimental|Arm F: Artesunate|Artesunate
10204063|NCT04357730|No Intervention|Control|Patients randomized to Control arm will receive no study medication; the treatment will be standard of care according to the institution's protocol for ARDS.
9775892|NCT01037218|Experimental|Udenafil 100 mg|100 mg Udenafil tablet plus 50 & 150 mg placebo tablets
9775893|NCT01037218|Experimental|Udenafil 150mg|150 mg Udenafil tablet plus 50 & 100 mg placebo tablets
9775894|NCT01037218|Placebo Comparator|Placebo|50, 100 & 150 mg placebo tablets
9775895|NCT01037244|Placebo Comparator|Placebo|
9775896|NCT01037244|Experimental|Udenafil 50 mg|
9775897|NCT01037244|Experimental|Udenafil 100 mg|
9775898|NCT01037244|Experimental|Udenafil 150 mg|
9775899|NCT01037309|Experimental|PRO044, cohort 1|Subcutaneous injection of 0.5 mg/kg on day 1, 8, 15, 22 and 29.
9775900|NCT01037309|Experimental|PRO044, cohort 2|Subcutaneous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29.
9775901|NCT01037309|Experimental|PRO044, cohort 3|Subcutaneous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29.
9775902|NCT01037309|Experimental|PRO044, cohort 4|Subcutaneous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29.
9775903|NCT01037309|Experimental|PRO044, cohort 5|Subcutaneous injection of maximally 10 mg/kg on day 1, 8, 15, 22 and 29
9775904|NCT01037309|Experimental|PRO044, cohort 6|Subcutaneous injection of maximally 12 mg/kg on day 1, 8, 15, 22 and 29
10204064|NCT04357730|Experimental|Alteplase-50 bolus|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Re-bolusing of Alteplase, at the same dose, is permitted in those patients who show an initial transient response. The repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
10204065|NCT04357730|Experimental|Alteplase-50 bolus plus drip|Patients randomized to Alteplase-50 plus drip group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Immediately following this initial Alteplase infusion, a drip of 2 mg/hr of Alteplase will be initiated over the ensuing 24 hours (total 48 mg infusion).
10204066|NCT04344678|Placebo Comparator|Control group|Escitalopram 20 mg tablet plus one placebo tablet
10204067|NCT04344678|Experimental|Sildenafil group|Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet
10204068|NCT04338399|Experimental|Buparlisib & Weekly Paclitaxel|"Drug: Patients will receive 100 mg (2 x 50 mg) buparlisib hard gel capsule administered orally, once daily starting on Day 1 of Treatment Cycle 1, Drug: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle.~Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason."
9775905|NCT01037309|Experimental|PRO044, cohort 7|Intravenous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29
9775906|NCT01037309|Experimental|PRO044, cohort 8|Intravenous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29
9775907|NCT01037309|Experimental|PRO044, cohort 9|Intravenous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29
9775908|NCT01037413|Experimental|EXC 001|
9775909|NCT01037413|Placebo Comparator|Placebo|
9775910|NCT01037452|Experimental|Combination product|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet
9775911|NCT01037452|Active Comparator|PPI alone|Lansoprazole
9775912|NCT01037452|Active Comparator|Antacid alone|Calcium carbonate/magnesium hydroxide
9775913|NCT01037452|Placebo Comparator|Placebo|Placebo
9775914|NCT01037790|Experimental|Arm 1 - Metastatic breast cancer|"Metastatic breast cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
9775915|NCT01037790|Experimental|Arm 2 - Metastatic colorectal cancer that harbors the Kras or BRAF mutation|"Metastatic colorectal cancer that harbors the Kras or BRAF mutation~PD-0332991 Given orally, 125 mg QD on a 21-day"
9775916|NCT01037790|Experimental|Arm 3 - Advanced or metastatic esophageal and/or gastric cancer|"Advanced or metastatic esophageal and/or gastric cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
9775917|NCT01037790|Experimental|Arm 4 - Cisplatin-refractory, unresectable germ cell tumors|"Cisplatin-refractory, unresectable germ cell tumors~PD-0332991 Given orally, 125 mg QD on a 21-day"
9775918|NCT01037790|Experimental|Arm 5 - CCND1amplification, CDK4/6mutation, CCND2amplification, OR other functional G1/S alterations|"Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.~PD-0332991 Given orally, 125 mg QD on a 21-day"
9775919|NCT01037881|Experimental|LEO 29102 0.03 mg/g cream|
9775920|NCT01037881|Experimental|LEO 29102 0.1 mg/g cream|
9775921|NCT01037881|Experimental|LEO 29102 0.3 mg/g cream|
9775922|NCT01037881|Experimental|LEO 29102 1.0 mg/g cream|
9775923|NCT01037881|Experimental|LEO 29102 2.5 mg/g cream|
9775924|NCT01037881|Placebo Comparator|LEO 29102 cream vehicle|
9775925|NCT01037881|Active Comparator|Elidel® cream (pimecrolimus) 10 mg/g|
9775926|NCT01037985|Experimental|EXC 001|
9775927|NCT01037985|Placebo Comparator|Placebo|
9775928|NCT01038128|Experimental|Memantine|Memantine, 10-40 mg daily
9775929|NCT01038297|Experimental|EXC 001|
9775930|NCT01038297|Placebo Comparator|Placebo|
9775931|NCT01038323|Experimental|CBT and milnacipran|Subjects randomized to this group will receive a combination of eight telephone sessions of Cognitive Behavior Therapy (CBT) and a 21-week regimen of milnacipran.
9775932|NCT01038323|Placebo Comparator|CBT and placebo|Subjects randomized to this arm will receive a series of eight telephone sessions of Cognitive Behavioral Therapy (CBT) along with a 21-week regimen of a placebo(sugar pill)medication.
9775933|NCT01038323|Active Comparator|Educational with milnacipran|Subjects randomized to this group will receive a series of eight educational phone calls regarding fibromyalgia along with a 21-week regimen of milnacipran.
9775934|NCT01038336|Experimental|Multimedia HLPP|Multimedia Hearing Loss Prevention Program (HLPP)
9775935|NCT01038336|Active Comparator|Hearing Conservation Brochure|Hearing Conservation Brochure (HCB)
9775936|NCT01038336|No Intervention|Standard-of-Care|Standard-of-Care (SoC)
9775937|NCT01038427|Experimental|Test|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
9775938|NCT01038427|Active Comparator|Reference|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
9775939|NCT01038427|Placebo Comparator|Placebo|Placebo nasal spray administered once daily for 14 days.
9775940|NCT01038557|Active Comparator|Refrigerated RBCs 0-14 days old|Standard, refrigerated RBC units stored up to 14 days
9775941|NCT01038557|Active Comparator|Refrigerated RBCs 15-42 days old|Standard, refrigerated RBC units stored 15-42 days
9775942|NCT01038557|Experimental|Frozen RBCs|RBC units stored frozen at -80 degrees Celsius, then thawed and deglycerolized using the ACP 215.
9775943|NCT01038609|Placebo Comparator|Placebo|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
9775944|NCT01038609|Active Comparator|Acetaminophen|1 dose of 1 placebo capsule (for morphine extended release) plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
9775945|NCT01038609|Active Comparator|Morphine Extended Release|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 morphine extended release capsule, administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
9775946|NCT01038609|Active Comparator|Morphine Extended Release / Acetaminophen|1 dose of 1 morphine extended release capsule plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
10204069|NCT04338399|Active Comparator|Weekly Paclitaxel|Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
10204070|NCT04326335|Active Comparator|Felt-tip marking|
10204071|NCT04326335|Experimental|Felt-tip marking + 3D printed ostomy button|
10204072|NCT04319237||All Participants|
9775947|NCT01038609|Experimental|Hydrocodone/Acetaminophen Extended Release|1 dose of 1 hydrocodone/acetaminophen extended release tablet plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
9775948|NCT01038635|Experimental|5-Azacytidine + Lenalidomide|5-Azacytidine 75 mg/m^2 by vein daily x 5 days on days 1 to 5. Lenalidomide starting dose 10 mg orally daily x 5 days on days 6 to 10.
9775949|NCT01038687|Experimental|A3309 15 mg|Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.
9775950|NCT01038687|Experimental|A3309 20 mg|Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.
9775951|NCT01038687|Placebo Comparator|Placebo|Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.
9775952|NCT01038713|Experimental|Resectable; plastic stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a plastic biliary stent to relieve their biliary obstruction.
9775953|NCT01038713|Experimental|Resectable; uncovered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
9775954|NCT01038713|Experimental|Resectable; fully covered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
9775955|NCT01038713|Experimental|Unresectable; uncovered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
9775956|NCT01038713|Experimental|Unresectable; fully covered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
9775957|NCT01038778|Experimental|Treatment (entinostat, aldesleukin)|"Patients receive entinostat PO every 2 weeks beginning on day -14 and high-dose aldesleukin IV every 8 hours on days 1-5 and 15-19. Cycles repeat every 84 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients with evidence of tumor shrinkage may receive up to 3 cycles of high-dose aldesleukin therapy. Patients with stable disease by RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two cycles will receive only entinostat until disease progression is documented."
9775958|NCT01038856|Experimental|+JAK2V61F mutation|Patients with MPN diagnoses and polycythemia vera who also have a confirmed JAK2V617F mutation
9775959|NCT01038869|Experimental|Azelaic acid 15% (Finacea)|Open label pilot study, Topical gel to be appiled twice daily for 16 weeks
9775960|NCT01038921|Experimental|Melatonin|Melatonin 8mg one hour before bedtime for 10 weeks
9775961|NCT01038921|Placebo Comparator|Placebo|Placebo administered 1 hour before bedtime for 10 weeks
9775962|NCT01039207|Experimental|Treatment (rilotumumab)|Patients receive rilotumumab IV over 30-60 minutes on days 1 and 14. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
9775963|NCT01039376|Experimental|ARM A: Ofatumumab|300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)
9775964|NCT01039376|Other|ARM B: Observation and assessments as per Arm A|Disease status assessments to determine subject response or progression performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria
9775965|NCT01039428|Experimental|HS219|
9775966|NCT01039428|Placebo Comparator|Placebo|
10204073|NCT04311463|Experimental|Paroxetine hydrochloride followed by PAXIL|
9775967|NCT01039467|Active Comparator|Managed Ventricular Pacing|Managed Ventricular Pacing group: programmed on
9775968|NCT01039467|Active Comparator|Search AV+|Search AV+: programmed on
9775969|NCT01039519|Experimental|ganetespib 200 mg/m^2|Ganetespib (STA-9090) 200 mg/m^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
9775970|NCT01039584|Placebo Comparator|Placebo|vehicle of the test product; applied intravaginally once within 48 hours of randomization
9775971|NCT01039584|Experimental|Test Product|Butoconazole Nitrate Vaginal Cream; applied intravaginally once within 48 hours of randomization
9775972|NCT01039584|Active Comparator|Reference Product|Gynazole 1 Vaginal Cream; applied intravaginally once within 48 hours of randomization
9775973|NCT01039675|Experimental|GSK573719/GW642444|
9775974|NCT01039675|Placebo Comparator|Placebo|
9775975|NCT01039688|Experimental|5 mg BID CP-690,550|
9775976|NCT01039688|Experimental|10 mg BID CP-690,550|
10204074|NCT04311463|Experimental|PAXIL followed by paroxetine hydrochloride|
10204075|NCT04308434|Experimental|CSD190601-11|Subjects will self-assign to flavor variant CSD190601-11 of 1.5% ENDS products based on their preferred flavor.
10204076|NCT04308434|Experimental|CSD190601-12|Subjects will self-assign to flavor variant CSD190601-12 of 1.5% ENDS products based on their preferred flavor.
10204077|NCT04308434|Experimental|CSD190601-13|Subjects will self-assign to flavor variant CSD190601-13 of 1.5% ENDS products based on their preferred flavor.
10204078|NCT04308434|Experimental|CSD190601-14|Subjects will self-assign to flavor variant CSD190601-14 of 1.5% ENDS products based on their preferred flavor.
10204079|NCT04308434|Experimental|CSD190601-15|Subjects will self-assign to flavor variant CSD190601-15 of 1.5% ENDS products based on their preferred flavor.
10204080|NCT04308434|Experimental|CSD190601-16|Subjects will self-assign to flavor variant CSD190601-16 of 1.5% ENDS products based on their preferred flavor.
10204081|NCT04308434|Experimental|CSD190601-17|Subjects will self-assign to flavor variant CSD190601-17 of 1.5% ENDS products based on their preferred flavor.
10204082|NCT04308434|Experimental|CSD190601-21|Subjects will self-assign to flavor variant CSD190601-21 of 3.0% ENDS products based on their preferred flavor.
10204083|NCT04308434|Experimental|CSD190601-22|Subjects will self-assign to flavor variant CSD190601-22 of 3.0% ENDS products based on their preferred flavor.
10204084|NCT04308434|Experimental|CSD190601-23|Subjects will self-assign to flavor variant CSD190601-23 of 3.0% ENDS products based on their preferred flavor.
10204085|NCT04308434|Experimental|CSD190601-24|Subjects will self-assign to flavor variant CSD190601-24 of 3.0% ENDS products based on their preferred flavor.,
9775977|NCT01039688|Active Comparator|methotrexate|
9775978|NCT01039792|Placebo Comparator|Placebo|Placebo
9775979|NCT01039792|Experimental|Active|Active Methyl B12
9775980|NCT01040052|Experimental|Study Group|
9775981|NCT01040130|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
9775982|NCT01040130|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
9775983|NCT01040130|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler
9775984|NCT01040169|Placebo Comparator|Nupro C Prophylaxis paste|Fluoride Free
9775985|NCT01040169|Experimental|ProClude Prophylaxis paste|Arginine
9775986|NCT01040208|Experimental|flibanserin 50 mg to 100 mg qhs|Patient to receive one tablet of flibanserin 50 mg and one tablet of flibanserin placebo qhs for 14 days then will receive 2 flibanserin tablets of 50 mg qhs
9775987|NCT01040208|Experimental|flibanserin 100 mg qhs|Patient to receive 2 flibanserin tablets of 50 mg qhs
10204086|NCT04308434|Experimental|CSD190601-25|Subjects will self-assign to flavor variant CSD190601-25 of 3.0% ENDS products based on their preferred flavor.
10204087|NCT04308434|Experimental|CSD190601-26|Subjects will self-assign to flavor variant CSD190601-26 of 3.0% ENDS products based on their preferred flavor.
9775988|NCT01040208|Experimental|placebo 2 tablets qhs|Patient to receive 2 placebo tablets of 50 mg qhs
9775989|NCT01040260|Experimental|Contingency management|Use of tangible rewards for verified abstinence
9775990|NCT01040260|Active Comparator|Counseling plus nicotine patches|Counseling plus nicotine patches
9775991|NCT01040351|Experimental|1: Hydrosalpinx needle aspiration|After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .
9775992|NCT01040351|No Intervention|2. no aspiration|IVF-ET is done without prior aspiration of hydrosalpingeal fluid
9775993|NCT01040403|Experimental|olodaterol (BI 1744) low and placebo|low dose inhaled olodaterol orally once daily from the Respimat inhaler
9775994|NCT01040403|Experimental|olodaterol (BI 1744) low and low tio|low dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
9775995|NCT01040403|Experimental|olodaterol (BI 1744) low and medium tio|low dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
10204088|NCT04308434|Experimental|CSD190601-27|Subjects will self-assign to flavor variant CSD190601-27 of 3.0% ENDS products based on their preferred flavor.
9775996|NCT01040403|Experimental|olodaterol (BI 1744) low and high tio|low dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
9775997|NCT01040403|Experimental|olodaterol (BI 1744) high and placebo|high dose inhaled olodaterol orally once daily from the Respimat inhaler
9775998|NCT01040403|Experimental|Olodaterol (BI 1744) high and low tio|high dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
9775999|NCT01040403|Experimental|Olodaterol (BI 1744) high and medium tio|high dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
9776000|NCT01040403|Experimental|Olodaterol (BI 1744) high and high tio|high dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
9776001|NCT01040689|Placebo Comparator|Placebo|olodaterol placebo and/or Tiotropium placebo inhaled once daily
9776002|NCT01040689|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
9776003|NCT01040689|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
9776004|NCT01040689|Active Comparator|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
9776005|NCT01040728|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
9776006|NCT01040728|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
9776007|NCT01040728|Active Comparator|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
9776008|NCT01040728|Placebo Comparator|Placebo|Olodaterol placebo and/or Tiotropium placebo inhaled once daily
9776009|NCT01040780|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
9776010|NCT01040780|Active Comparator|Gefitinib|250 mg every 24 hours by mouth
9776011|NCT01040793|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
9776012|NCT01040793|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
9776013|NCT01040793|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler
9776014|NCT01040819|Experimental|Pioglitazone 15 mg|Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
9776015|NCT01040819|Experimental|Pioglitazone 30 mg/d|Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
9776016|NCT01040832|Experimental|Cetuximab plus EMD 1201081|
9776017|NCT01040832|Active Comparator|Cetuximab monotherapy|
9776018|NCT01040845|Experimental|Oral Contraceptive with Colchicine then Placebo|
9776019|NCT01040845|Placebo Comparator|Oral Contraceptive with Placebo then Colchicine|
9776020|NCT01040858|Experimental|Cognitive Strategies Training|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study). Cognitive Strategies training consisted of interactive didactic presentations, in-class discussions, and activities that introduced participants to a variety of cognitive strategies and external aids.
10204089|NCT04305678|Experimental|Single Arm|Patients with a biopsy proven diagnosis of eosinophilic fasciitis
10204090|NCT04296565|Other|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
9776021|NCT01040858|Placebo Comparator|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
9776022|NCT01040871|Experimental|VR-CAP|VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
9776023|NCT01040871|Active Comparator|R-CHOP|R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
9776024|NCT01041209|Experimental|BPS|BPS guidance
9776025|NCT01041209|Active Comparator|Guideline|Enforced guidelines
9784838|NCT01235949|Experimental|Group IIBU-DIBU|1/3 of the subjects from the primary IIBU group receiving delayed ibuprofen treatment after booster vaccination
9784839|NCT01235949|Experimental|Group IIBU-NIBU|1/3 of the subjects from the primary IIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
9784840|NCT01235949|Experimental|Group DIBU-IIBU|1/3 of the subjects from the primary DIBU group receiving immediate ibuprofen treatment after booster vaccination
9784841|NCT01235949|Experimental|Group DIBU-DIBU|1/3 of the subjects from the primary DIBU group receiving delayed ibuprofen treatment after booster vaccination
9784842|NCT01235949|Experimental|Group DIBU-NIBU|1/3 of the subjects from the primary DIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
9784843|NCT01235949|Experimental|Group NIBU-IIBU|1/3 of the subjects from the primary NIBU group receiving immediate ibuprofen treatment after booster vaccination
9784844|NCT01235949|Experimental|Group NIBU-DIBU|1/3 of the subjects from the primary NIBU group receiving delayed ibuprofen treatment after booster vaccination
9784845|NCT01235949|Active Comparator|Group NIBU-NIBU|1/3 of the subjects from the primary NIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
9784846|NCT01235949|Experimental|Group IPARA-NPARA|subjects from the primary IPARA group receiving no paracetamol treatment after booster vaccination
9784847|NCT01235949|Experimental|Group DPARA-IPARA|subjects from the primary DPARA group receiving immediate paracetamol treatment after booster vaccination
9784848|NCT01235949|Experimental|Group NPARA-IPARA|subjects from the primary NPARA group receiving immediate paracetamol treatment after booster vaccination
9784849|NCT01235975|Experimental|Group A|
9784850|NCT01235975|Active Comparator|Group B|
9784851|NCT01236001||Vimpat® treatment|Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.
9784852|NCT01236053||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.
9784853|NCT01236105|Experimental|6 mg LY2624803 Alone Morning Dosing|Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast.
9784854|NCT01236105|Experimental|6 mg LY2624803 Morning Dosing + Activated Charcoal|Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola.
9784855|NCT01236105|Experimental|6 mg LY2624803 Alone Evening Dosing|Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast.
9784856|NCT01236118|Experimental|30 milligrams (mg) LY2439821|Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
9784857|NCT01236118|Experimental|80 mg LY2439821|Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
9784858|NCT01236118|Experimental|160 mg LY2439821|Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
9784859|NCT01236170||Group 1|Veterans with spinal cord injury or amputated limbs who use a wheelchair as their primary source of mobility
9784860|NCT01236196|Experimental|Arm 1 - Telephone CBT|telephone cognitive behavior therapy for pain management
9784861|NCT01236196|Active Comparator|Arm 2 - telephone education|telephone pain education
9784862|NCT01236300|Experimental|Cellvizio system|
9784863|NCT01236326|Active Comparator|LESS-DN|
9784864|NCT01236326|Active Comparator|Conventional LDN|
9784865|NCT01236339|Experimental|TIPS|TIPS with GORE® VIATORR® TIPS Endoprosthesis
9776026|NCT01041248|Experimental|Tocilizumab|Single arm open label study. In this arm patient will receive 8mg/kg of Tocilizumab q 2 weeks iv.
9776027|NCT01041274|Experimental|Citalopram|Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.
9776028|NCT01041274|Placebo Comparator|Placebo|Participants will receive a daily dose of placebo for 12 months.
9776029|NCT01041287|Active Comparator|Nebivolol/ Metoprolol|"Subjects were randomized to nebivolol for 3 months. They crossed over to take 3 months of metoprolol succinate. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
9776030|NCT01041287|Active Comparator|Metoprolol/Nebivolol|"Subjects were randomized to metoprolol succinate for 3 months. They crossed over to take 3 months of nebivolol. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
9776031|NCT01041404|Experimental|Trastuzumab, Fluoropyrimidine, Cisplatin|Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
9776032|NCT01041404|Active Comparator|Fluoropyrimidine, Cisplatin|Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
9776033|NCT01041417|Experimental|GM-CSF|Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
9776034|NCT01041417|Placebo Comparator|Placebo|Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
9776035|NCT01041495|Experimental|cyclobenzaprine ER|
9776036|NCT01041495|Placebo Comparator|placebo|
9776037|NCT01041521|Experimental|Lovaza (omega three fatty acid)|"Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.~Other Names:~Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules"
9776038|NCT01041521|No Intervention|sugar pill|"Dietary Supplement: sugar pill~2 capsules given twice daily Arms: sugar pill"
9776039|NCT01041573|Experimental|IC51 0.5 mL|Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
9776040|NCT01041573|Experimental|IC51 0.25 mL|Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
9776041|NCT01041573|Active Comparator|Havrix 720|Havrix®720 0.5 ml im. at day 0 and month 7
9776042|NCT01041573|Active Comparator|Prevnar|Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13
9776043|NCT01041638|Experimental|Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)|Patients receive sargramostim SC or IV over 2 hours on days 0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin PO BID on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9776044|NCT01041781|Experimental|Arm I|Patients receive gemcitabine hydrochloride* IV on days 1 and 8 OR pemetrexed disodium* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
9776045|NCT01041781|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride* OR pemetrexed disodium* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
9776046|NCT01041859|Experimental|Tapentadol Extended Release (ER)|
9776047|NCT01041859|Placebo Comparator|Placebo|
9776048|NCT01041976|Experimental|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
9776049|NCT01041976|Placebo Comparator|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
9776050|NCT01042093|Active Comparator|ROP/EPI/TOR/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
9776051|NCT01042093|Active Comparator|ROP/EPI/TOR|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)
9776052|NCT01042093|Active Comparator|ROP/EPI/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
9776053|NCT01042093|Active Comparator|ROP/EPI|Ropivacaine 5mg/ml (49.25ml) Epinephrine 1 mg/ml (0.5 ml)
9776054|NCT01042145|Active Comparator|Prednisone|Prednisone, 2mg/kg for 3 days
9776055|NCT01042145|Active Comparator|Dexamethasone|Dexamethasone, 0.6mg/kg for one day, then placebo for 2 days
9776056|NCT01042158|Other|Tadalafil and ambrisentan upfront therapy|This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD).
9776057|NCT01042236|Experimental|Arm 1|
9776058|NCT01042288|Experimental|Carboplatin/Pemetrexed/Panitumumab|Systemic Therapy
9776059|NCT01042366|Experimental|Vaccine co-cultured with melanoma cells|Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance
9776060|NCT01042366|Experimental|Vaccine pulsed with tumor cell lysates|Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance
9776061|NCT01042366|Experimental|Vaccine fused with tumor cells|Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance
9776062|NCT01042392|Active Comparator|Ramipril|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
9776063|NCT01042392|Experimental|Aliskiren|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal ): At visit 4, part of the patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
9776064|NCT01042392|Placebo Comparator|Placebo to Ramipril|In period III (double-blind withdrawal ): At visit 4, part of patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4).
9776065|NCT01042392|Placebo Comparator|Placebo to Aliskiren|In period III (double-blind withdrawal ): At visit 4, part of the patients from Aliskiren arm received placebo to Aliskiren for 1 day. The study ended at visit 5 (48 hours later than visit 4).
9776066|NCT01042496|Active Comparator|Bipolar Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC) before and after treatment with Lamotrigine.
9776067|NCT01042496|Active Comparator|Control Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
9776068|NCT01042509|Experimental|Alemtuzumab and rituximab|Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.
9776069|NCT01042535|Experimental|Treatment (vaccine therapy, 1-methyl-d-tryptophan)|Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9776070|NCT01042600|Active Comparator|Endotracheal intubation|Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication
9776071|NCT01042600|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
9776072|NCT01042613|Other|Group A|Research participants are randomly assigned into group A (Accuvein AV300 assisted intravenous catheter insertion)
9776073|NCT01042613|Other|Group B|(standard technique of insertion of the intravenous cannula)
9776074|NCT01042678|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
9776075|NCT01042678|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
9776076|NCT01042678|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
10204091|NCT04296565|Experimental|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
10204092|NCT04295005||All patients who started an Empagliflozin therapy|
10204093|NCT04295005||All patients who started a DPP-4 inhibitor therapy|
10204094|NCT04295005||All patients who started a Sitagliptin therapy|
10204095|NCT04295005||All patients who started a GLP-1 receptor agonist therapy|
10204096|NCT04294290|Experimental|hCT-MSC infusion|
10204097|NCT04255108||Men/Women who meet the inclusion/exclusion criteria|
10204098|NCT04254562|Experimental|Experimental Group: HYPE Services|The experimental arm will receive the HYPE intervention for 12 months.
10204099|NCT04254562|Active Comparator|Control Group: Enhanced Academic Services as Usual|"The control arm will receive a special personalized packet of resources available on campus and off-campus within a 10-mile radius, as enhanced academic services as usual."
10205340|NCT02680067|Experimental|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
9776077|NCT01042678|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
9776078|NCT01042678|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
9776079|NCT01042678|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
9776080|NCT01042795|Experimental|Continuous Daily Dosing of Sunitinib|
9776081|NCT01042938|Active Comparator|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
9776082|NCT01042938|Placebo Comparator|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
9776083|NCT01042977|Experimental|1|dapagliflozin 10 mg tablet
9776084|NCT01042977|Placebo Comparator|2|matching placebo tablet
9776085|NCT01043094|Experimental|Pitavastatin 4mg renal impaired|Subjects with severe renal impairment (glomerular filtration rate [GFR] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
9776086|NCT01043094|Active Comparator|Pitavastatin 4mg healthy subjects|Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
9776087|NCT01043133|Experimental|Intervention group|
9776088|NCT01043133|No Intervention|Control Group|
9776089|NCT01043146|Active Comparator|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
9776090|NCT01043146|Placebo Comparator|placebo|intravenous 0.9 % NaCl
9776091|NCT01043185|Experimental|A|AZD3355 30 mg
9776092|NCT01043185|Experimental|B|AZD3355 90 mg
9776093|NCT01043185|Experimental|C|AZD3355 120 mg
9776094|NCT01043185|Experimental|D|AZD3355 240 mg
9776095|NCT01043185|Placebo Comparator|E|Placebo
9776096|NCT01043393|Experimental|Psoriasis involving 10-15% BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of 10-15% of their body surface area.
9776097|NCT01043393|Experimental|Psoriasis involving >15% of BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of >15% of their body surface area.
9776098|NCT01043432||Moderate/severe TBI and history of suicidal behavior Group 1|Moderate/severe TBI and history of suicidal behavior
9776099|NCT01043432||Moderate/Severe TBI and no history of suicidal behaviorGroup|Moderate/Severe TBI and no history of suicidal behavior
9776100|NCT01043432||No TBI and a history of suicidal behavior Group 3|No TBI and a history of suicidal behavior
9776101|NCT01043432||No TBI and no history of suicidal behavior Group 4|No TBI and no history of suicidal behavior
9776102|NCT01043523||Group 1|
9776103|NCT01043562||Pediatric ICD pts|Inclusion criteria for study participants included: 1) weight ≤60 kg, 2) new or existing ICD system, and 3) clinically necessary assessment of the defibrillation efficacy of the ICD system. Transvenous systems utilized a high-voltage ICD coil with active-fixation lead attached to the right ventricular endocardial surface, whereas non-transvenous systems depended upon a high-voltage shocking coil placed within the pericardial, subcutaneous or pleural space. To be included in the post-shock pacing portion of the study, adequate sinus and AV node function had to be present at baseline. Exclusion criteria included 1) tenuous hemodynamic status felt to warrant abbreviation of the defibrillation efficacy testing or 2) inability to induce fibrillation during defibrillation threshold testing (DFT).
9776104|NCT01043640|Experimental|Transplant Patients|Includes patients who received allogeneic stem cell transplantation following treatment plan of Campath-1H, cyclophosphamide, cyclosporine A, mycophenolate mofetil, and busulfan.
9776105|NCT01043653||Maryland Assessment of Recovery in Serious Mental Illness|Individuals with serious mental illness treated in mental health outpatient programs
9776106|NCT01043705||CIED replacement with CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with a CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
9776107|NCT01043705||CIED replacement with ICD and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD and the TYRX Anti-bacterial envelope, with or without lead revision.
9776108|NCT01043705||CIED replacement with ICD or CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD or CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
9984319|NCT04226209|Experimental|PSSE|Physiotherapeutic Scoliosis-Specific Exercises PSSE group will receive corrective exercise for scoliosis
9776109|NCT01043705||CIED replacement w/ CRT & no TYRX|(Retrospective Case-Control Arm) Patients who have undergone CIED replacement with a CRT and no TYRX Anti-bacterial envelope, with or without lead revision/addition.
9776110|NCT01043705||CIED replacement w/ CRT & TYRX vs. Case Match Arm|Patients who have undergone CIED replacement with a CRT and TYRX Anti-bacterial envelope, with or without lead revision/addition. Cohort is TYRX Case, Matched to Retrospective Case-Control Arm)
9776111|NCT01043874|Experimental|Nilotinib|400 mg BID
9776112|NCT01043926|Experimental|Participants with Moderate Hepatic Insufficiency (Part I)|Participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
9776113|NCT01043926|Experimental|Healthy Participants (Part I)|Healthy participants matched to participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
9776114|NCT01043926|Experimental|Participants with Mild Hepatic Insufficiency (Part II)|Participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
9776115|NCT01043926|Experimental|Healthy Participants (Part II)|Healthy participants matched to participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
9776116|NCT01043939|Active Comparator|Purple Grape Juice First|After 4 week run-in period, drink 6 ounces of purple grape juice twice daily, then 4 week washout, week 12 drink 6 ounces of clear apple juice for 4 weeks twice daily
9776117|NCT01043939|Active Comparator|Apple Juice First|After 4 week run-in period, drink 6 ounces of clear apple juice twice daily, then 4 week washout, week 12 drink 6 ounces of purple grape juice for 4 weeks twice daily
9776118|NCT01044030|Experimental|Xylitol syrup|
9776119|NCT01044030|Placebo Comparator|Placebo|
9776120|NCT01044212|Active Comparator|Docusate|Docusate is the standard of care regimen
9776121|NCT01044212|Experimental|Bowel medications|Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
9776122|NCT01044264|Active Comparator|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Test product
9776123|NCT01044264|Active Comparator|DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Reference product
9776124|NCT01044264|Placebo Comparator|Placebo|
9776125|NCT01044290|Experimental|Outlook Intervention|"Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy."
9776126|NCT01044290|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
9776127|NCT01044290|No Intervention|Treatment as Usual|"Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window."
9776128|NCT01044303|Experimental|Myfortic Escalation|Participants EC-MPS dose was escalated to a minimum daily dose of 1440mg or equivalent, with the maximum dose never exceeding the manufacturer's recommendations.
9776129|NCT01044433|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.
9776130|NCT01044459|Experimental|Aclidinium Bromide 200 µg|aclidinium bromide, inhaled, 52 weeks of treatment
10204100|NCT04247308|Experimental|experimental group|"Sensory stimulations (ATVV) will be consisting of Soft lullaby between of 30-40 dB for Auditory, Gentle stroking massage in supine position(upper and lower limb)for Tactile, Visual Stimulations with Black and white card (distance of 8-10 in), gentle rocking (vertical and horizontal direction) for the stimulation of vestibular system and oral stimulation including stocking cheeks, lips, jaw and tongue, rubbing gum.Each stimulation will be given for 3 minutes.~Movement therapy will include: Guided range of motion: flexion-extension movements of lower limb (bicycle riding pattern). Hand should be placed around knee joint. Care must be taken as PI consist the cartilaginous joints at wrist and ankle. Anti gravity movements in prone (neck and spinal extension), Anti gravity movements in sitting (supported) and Upright positioning for 3min each"
10204101|NCT04247308|Active Comparator|control group|receives routine care from the nursing team as well as daily maternal care, such as being held in the mother's arms
10204102|NCT04237753|Active Comparator|MyHealthebladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
10204103|NCT04237753|Active Comparator|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
10204104|NCT04225988|Experimental|Extended-release tacrolimus|Kidney transplant recipients will receive extended-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
10204105|NCT04225988|Active Comparator|Immediate-release tacrolimus|Kidney transplant recipients will receive immediate-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
10204106|NCT04221958||Electrocardiogram (ECG) Mapping|Participants will have 10 superficial electrode-patches placed on their chest in two vertical columns of 5 electrode-patches. The channels V1-V5 will be connected to one of the columns. The channel V6 will be connected to each of the electrode-patches in the second column ad recordings will be taken for approximately 2 minutes on each electrode-patch. ECG readings will be recorded.
10205341|NCT02650414|Experimental|CART22 cells|"Subjects <50kg will receive 0.2-1 x 107 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x106 CART22 cells/kg~Day 2, 30% fraction: 0.6-3x106 CART22 cells/kg~Day 3, 60% fraction: 1.2-6x106 CART22 cells/kg~Subjects ≥50kg will receive 1-5x108 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x107~Day 2, 30% fraction: 0.3-1.5x108~Day 3, 60% fraction: 0.6-3x108"
10205342|NCT02610374|Other|Cohort A|HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
10205343|NCT02610374|Other|Cohort B|HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
9776131|NCT01044459|Experimental|Aclidinium Bromide 400 µg|aclidinium bromide, inhaled, 52 weeks of treatment
9776132|NCT01044498|Experimental|Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)|Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
9776133|NCT01044498|Other|Ortho-Novum® 1/35 (Group 2)|Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
9776134|NCT01044537|Placebo Comparator|Placebo|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
9776135|NCT01044537|Experimental|PF-04937319|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
9776136|NCT01044576||Multiple Sclerosis|Patients with relapsing-remitting or secondary progressive multiple sclerosis
9776137|NCT01044589|Experimental|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft
9776138|NCT01044589|Active Comparator|Overlapping Sphincter Repair|Control
9776139|NCT01044693|Placebo Comparator|Placebo capsule|Placebo capsule
9776140|NCT01044693|Experimental|Nebivolol 5 mg|Nebivolol 5 mg capsule
9776141|NCT01044693|Active Comparator|Metoprolol tartrate 50 mg|Metoprolol tartrate 50 mg single oral dose
9776142|NCT01044693|Active Comparator|Sildenafil 25 mg|Sildenafil 25 mg single oral dose
9776143|NCT01044706|Experimental|Bicalutamide 50 mg Tablet|Bicalutamide 50 mg Tablet
9776144|NCT01044706|Active Comparator|Casodex® 50 mg Tablet|Casodex® 50 mg Tablet
9776145|NCT01044732|Experimental|Group A - COLO, then TER|"Complete examination with standard colonoscope (COLO) followed by complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope"
9776146|NCT01044732|Active Comparator|Group B - TER, then COLO|"Complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (COLO) alone"
9776147|NCT01044745|Experimental|Treatment (Rituximab and allogeneic HCT transplant)|"CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0."
9776148|NCT01044758|Experimental|aMCI_62.5mg drug first, then placebo|"Amnestic MCI:~62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
9776149|NCT01044758|Experimental|aMCI_Placebo first, then 62.5mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)"
9776150|NCT01044758|Experimental|aMCI_125mg drug first, then placebo|"Amnestic MCI:~125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
9776151|NCT01044758|Experimental|aMCI_Placebo first, then 125mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)"
9776152|NCT01044758|Experimental|aMCI_250mg drug first, then placebo|Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)
9776153|NCT01044758|Experimental|aMCI_Placebo first, then 250mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)"
9776154|NCT01044758|Placebo Comparator|Control_Placebo first, then placebo|"Healthy control:~placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
9776155|NCT01044771|Other|change from tenofovir to raltegravir|"Single arm study:~Tenofovir containing nucleoside backbone changed over to raltegravir in all patients"
9776156|NCT01044862|Active Comparator|Aromatase Inhibitors (AI)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
9776157|NCT01044862|Active Comparator|Clomiphene Citrate (CC)|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
9776158|NCT01044862|Active Comparator|Follicle Stimulating Hormone (FSH)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
9776159|NCT01044966|Experimental|ITV DepoCyt + Temozolomide|Patients will undergo an induction phase of intraventricular (ITV) DepoCyt, using the dosage determined from the Phase I portionPatients with stable disease (clinically and radiographically), not exhibiting systemic toxicity, will undergo a three month consolidation phase of ITV DepoCyt, for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues. Oral metronomic Temozolomide dosing of 75 mg/m2 daily for 21 days followed by 7 days off will be given throughout the Induction, Consolidation, and Maintenance Phases of the ITV DepoCyt described above.
9776160|NCT01045031||Controls|"Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper (Krone) and one in an Austrian bicyclist journal (Bicyclist Sports). The controls were matched according to age, sex and years of education"
9984320|NCT04226209|No Intervention|Control|Control group will be taken to the queue list.
9776161|NCT01045031||marathon athletes|Runners participating in the 2008 Wachau half marathon (21,2 km) and the Vienna City marathon (42,5 km) as well as bicyclists participating at the Corinthian marathon (180km). Inclusion criteria:1) participation in at least one of these 3 marathons in the preceding two years,2)still in continuous training during the recruitment phase (at least 2 hours/week), 3) aged over 60. Exclusion criteria:(a) present or past exposure to neurotoxic substances (b) if they did not speak German as their native language (c) diseases that markedly affect CNS functions (d) manifest cardiovascular disease, (e) chronic alcoholism (daily alcohol intake > 60 g or diagnosed history of alcoholism) and (f) unwillingness to give informed consent.
9776162|NCT01045057|Experimental|Puncture Set and Flexible Protector|Provox Vega Puncture Set is used to create the primary puncture and insert the prosthesis during total laryngectomy
9776163|NCT01045096|Experimental|Dexlansoprazole 15 mg QD|
9776164|NCT01045096|Experimental|Dexlansoprazole 30 mg QD|
9776165|NCT01045096|Experimental|Dexlansoprazole 60 mg QD|
9776166|NCT01045122|Other|Propofol|Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
9776167|NCT01045122|Other|Dexmedetomidine|Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
9776168|NCT01045135||first time delivery|Women giving birth to their first child
9776169|NCT01045161|Experimental|1|Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
9776170|NCT01045161|Experimental|2|Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
9776171|NCT01045161|Placebo Comparator|3|Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks
9776172|NCT01045174|Active Comparator|Breath-Actuated Nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer.
9776173|NCT01045174|Active Comparator|Conventional continuous-ouput nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer
9776174|NCT01045187|Other|endometrial cancer|Patients are treated with electronic brachytherapy for an FDA cleared indication.
9776175|NCT01045265||Raltegravir treated men|Single group study of seminal plasma pharmacokinetics of raltegravir in men receiving chronic raltegravir therapy
9776176|NCT01045421|Experimental|MLN8237 (Alisertib)|MLN8237 administered as an enteric-coated tablet (ECT)
9776177|NCT01045447|Experimental|IDegAsp OD|
9776178|NCT01045447|Active Comparator|IGlar OD|
9776179|NCT01045460|Experimental|ASCT + MILs|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.
9784866|NCT01236339|Active Comparator|LVP|"Large Volume Paracentesis~*A subject may be crossed-over from large volume paracentesis to TIPS with GORE® VIATORR® TIPS Endoprosthesis if the subject has completed their six month study visit and has met the criteria for cross-over (LVP failure)."
9784867|NCT01236352|Experimental|Phase 1 (Cohort 1): BMS-911543 (5 mg)|BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
9784868|NCT01236352|Experimental|Phase 1 (Cohort 2): BMS-911543 (10 mg)|BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
9776180|NCT01045460|Experimental|ASCT + MILs + vaccine|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.
9776181|NCT01045499|Experimental|laparoscopic gastric banding|Adolescent patients who have undergone laparoscopic adjustable gastric banding. Weight, BMI, and co-morbidity data will be compared to patient's pre-operative values.
9776182|NCT01045551|Experimental|Apremilast 20 mg (twice per day)|All subjects will receive Apremilast 20mg taken orally twice per day.
9776183|NCT01045707|Experimental|IDegAsp OD|
9776184|NCT01045707|Experimental|IGlar OD|
9776185|NCT01045798|Experimental|Caspofungin|caspofungin acetate
9776186|NCT01045798|Placebo Comparator|Placebo|normal saline
9776187|NCT01045967|Experimental|Invesigational Test Product|Lansoprazole 30 mg delayed-release Capsules
9776188|NCT01045967|Active Comparator|Reference Listed Drug|Prevacid® 30 mg delayed-release Capsules
9776189|NCT01045993|Active Comparator|1|Heat device
9776190|NCT01045993|Sham Comparator|2|Placebo arm
10204107|NCT04212364|Experimental|Peer Education|"During Session 1, participants will be trained in Peer Education and how to use Nasal Narcan. They will be given two Nasal Narcan kit that includes 2 doses. One kit if for their use and one kit is to give someone in their social network after they have trained them in how to use it.~A week after Session 1, participants will be scheduled for Session 2.~During session 1 and 2 participants, Index participants will be taught information and skills pertaining to overdose prevention and response and how to train network members in overdose prevention and response.~At the 2nd session, index participants will be given 1 coupon to give to 1 member from their social network to attend Session 3.~Session 3 will be a dyad session where Index participants will use their peer mentors' skills to train their network member in overdose prevention and response.~Index participants will also be invited to up to 3 Booster Session (monthly) after they complete Sessions 1-3."
10204108|NCT04212364|Active Comparator|Standard of care|"Participants randomized to this condition will participate in one 1-hour session. This session will be an individual session where the participant will meet with a trained staff member in a private room at the Lighthouse.~This session will be standard overdose prevention and response information. Participants will also be trained in Narcan administration. Participants will be given 1 nasal Narcan kit.~At the end of this session, participants will be asked to refer a network member to the study for survey visits"
9776191|NCT01045993|Active Comparator|3|Marketed analgesic
9776192|NCT01045993|Placebo Comparator|4|(Oral) Placebo comparator
9776193|NCT01046084|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
9776194|NCT01046084|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
9776195|NCT01046110|Experimental|IDeg OD|
10204109|NCT04207879||weight loss group|Dynamic changes in body composition, biochemical metabolomics and gut microbiome will be reported among overweight and obese patients.
10204110|NCT04197934|Experimental|Dose escalation (WSD0922-FU)|Patients receive WSD0922-FU PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10204111|NCT04197934|Experimental|Dose expansion Cohort I (WSD0922-FU)|Patients with GBM/AA receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9776196|NCT01046110|Experimental|DPP-IV inhibitor|
9776197|NCT01046136|Active Comparator|Mucinex|
9776198|NCT01046136|Placebo Comparator|placebo|
9776199|NCT01046253|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
9776200|NCT01046253|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
10204112|NCT04197934|Experimental|Dose expansion Cohort II (WSD0922-FU, surgery)|Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10204113|NCT04197934|Experimental|Dose expansion Cohort III (WSD0922-FU)|Patients with NSCLC LM receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10204114|NCT04195750|Experimental|Belzutifan|Participants receive 120 mg of belzutifan orally once daily (QD)
9776201|NCT01046396|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
9776202|NCT01046396|Active Comparator|Differin® Lotion 0.1%|Adapalene Lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
9776203|NCT01046565|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
9776204|NCT01046565|Active Comparator|Differin® Lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face
9776205|NCT01046643|Active Comparator|Estrogen followed by Placebo|Estrogen treatment with Estradiol (E2) followed by Placebo.
9776206|NCT01046643|Active Comparator|Progesterone followed by Placebo|Progesterone (P10) treatment followed by Placebo.
9776207|NCT01046643|Active Comparator|Placebo followed by Estrogen|Placebo followed by Estrogen treatment with Estradiol (E2)
9776208|NCT01046643|Active Comparator|Placebo followed by Progesterone|Placebo followed by Progesterone (P10) treatment.
9776209|NCT01046669|Sham Comparator|Control|Standard medical care for septic shock
9776210|NCT01046669|Experimental|Treatment|Two (2) PMX cartridges will be administered approximately 24 hours apart plus standard medical care for septic shock
9776211|NCT01046682|Active Comparator|Salsalate|
9776212|NCT01046682|No Intervention|Usual care|
9784869|NCT01236352|Experimental|Phase 1 (Cohort 3): BMS-911543 (20 mg)|BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
9784870|NCT01236352|Experimental|Phase 1 (Cohort 4): BMS-911543 (40 mg)|BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
9776213|NCT01046695|Active Comparator|TENS Unit|"This arm will be adding the use of the TENS unit for 48 hours in addition to standard care for their post operative pain control.~Patient's primary area of postoperative pain was determined by nursing personnel. Four electrodes were placed on or around the area of maximum pain. The TENS unit was turned on, 1 of 5 frequency patterns selected and the impulse turned up until the patient could feel the impulse. The location of the electrodes, the pattern, and/or the intensity of the TENS unit were adjusted until the patient achieved maximum comfort with the sensation."
9776214|NCT01046695|No Intervention|Control Arm|This arm will have standard care for their post operative pain control.
9776215|NCT01046877|Experimental|Tympanostomy Tube placement|Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
9776216|NCT01046903||1|
9776217|NCT01047007|Experimental|Part 1:MK-1775 65 mg BID|Participants received 65 mg of MK-1775 administered orally twice a day (BID) on Days 1-5 of a 21-day cycle.
9776218|NCT01047007|Experimental|Part 2 A1:MK-1775 20 mg BID+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally BID on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle.
9776219|NCT01047007|Experimental|Part 2 A2:MK-1775 20 mg QD+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally once a day (QD) on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle.
9776220|NCT01047007|Experimental|Parts 2B +3:MK-1775+5-FU+CDDP|Participants were to receive 20 mg or 65 mg of MK-1775 administered either BID or QD on Days 1-5 of a 21-day cycle; 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle; and 60 mg/m^2 to 100 mg/m^2 of CDDP administered as an IV infusion on Day 1.
9776221|NCT01047189|Experimental|1|Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
9776222|NCT01047189|Active Comparator|2|Generic clindamycin 1% gel plus tretinoin 0.025% cream
9776223|NCT01047241|Experimental|Intranasal sufentanil/ketamine|Intranasal combination of sufentanil and ketamine. Dose of sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.
9776224|NCT01047293|Experimental|All patients|All participants enrolled.
9776225|NCT01047306||No Treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
9776226|NCT01047332|Active Comparator|Uncovered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (uncovered type).
9776227|NCT01047332|Experimental|Partially Covered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (partially covered type).
9776228|NCT01047345|Experimental|9vHPV Vaccine|Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
9776229|NCT01047345|Placebo Comparator|Placebo|Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
9776230|NCT01047358||ajuvant group|adjuvant setting after two to three years of tamoxifen
9776231|NCT01047358||palliative group|palliative setting after progression of disease with anti-estrogen therapy
9776232|NCT01047436|Experimental|ArTiMist (artemether sublingual spray)|
9776233|NCT01047436|Active Comparator|Intravenous Quinine|
9784871|NCT01236352|Experimental|Phase 1 (Cohort 5): BMS-911543 (80 mg)|BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
9784872|NCT01236352|Experimental|Phase 1 (Cohort 6): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
9784873|NCT01236352|Experimental|Phase 1 (Cohort 7): BMS-911543 (160 mg)|BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
9784874|NCT01236352|Experimental|Phase 1 (Cohort 8): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
9784875|NCT01236352|Experimental|Phase 1 (Cohort 9): BMS-911543 (240 mg)|BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
9784876|NCT01236352|Experimental|Phase 1 (Cohort 10): BMS-911543 (320 mg)|BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
9784877|NCT01236352|Experimental|Phase 2 (Cohort 11): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
9784878|NCT01236352|Experimental|Phase 2 (Cohort 12): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
9784879|NCT01236365|Experimental|Atorvastatin|
9784880|NCT01236365|Placebo Comparator|Placebo|
9784881|NCT01236378|Experimental|sirolimus|Subjects must be taking sirolimus (1 mg tablet formulation) with or without concomitant medications, unless specifically excluded below, for prophylaxis of renal rejection.
9784882|NCT01236391|Experimental|Participants received PCI-32765 560 mg daily|Participants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.
9784883|NCT01236521|Experimental|Arm 1: Pharmacological (MED)|Subjects in the Pharmacological (MED) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
9776234|NCT01047475|Active Comparator|MB-6+FOLFOX4|MB-6 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
9776235|NCT01047475|Placebo Comparator|Placebo+FOLFOX4|Placebo, 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
9776236|NCT01047527|Active Comparator|8 weeks transdermal nicotine|8 weeks of transdermal nicotine
9776237|NCT01047527|Active Comparator|24 weeks transdermal nicotine|24 weeks of transdermal nicotine
9776238|NCT01047527|Experimental|52 weeks transdermal nicotine|52 weeks of transdermal nicotine
9776239|NCT01047553|Experimental|1|Formoterol 9 μg/dose
9776240|NCT01047709|Experimental|positional therapy|Avoidance of supine positioning.
9776241|NCT01047709|No Intervention|Control|Position ad lib.
9776242|NCT01047839|Experimental|>=2 months to <3 years|IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
9776243|NCT01047839|Experimental|>=3 to <12 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
9776244|NCT01047839|Experimental|>=12 to <18 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
9776245|NCT01048099|Experimental|PRO Onc Assay and Treatment|Blood specimens tested for circulating tumor cells followed by systemic treatment based on assay results with either trastuzumab or pertuzumab
9776246|NCT01048242|Experimental|Ramelteon|Ramelteon 8 mg oral before bedtime
9776247|NCT01048242|Placebo Comparator|sugar pill|
9776248|NCT01048333|Experimental|Formoterol, then Salmeterol, then Placebo|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
9776249|NCT01048333|Experimental|Salmeterol, then Palcebo, then Formoterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
9776250|NCT01048333|Experimental|Placebo, then Formoterol, then Salmeterol|Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
9776251|NCT01048333|Experimental|Formoterol, then Placebo, then Salmeterol|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
9776252|NCT01048333|Experimental|Salmeterol, then Formoterol, then Placebo|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
9776253|NCT01048333|Experimental|Placebo, then Salmeterol, then Formoterol|Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
9776254|NCT01048424|Experimental|Paced respiration|Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
9776255|NCT01048424|Placebo Comparator|Control|Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
9776256|NCT01048502|Experimental|Fenofibrate (Tricor) (145 mg/day)|Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
9776257|NCT01048502|Placebo Comparator|Placebo|Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
9776258|NCT01048502|Experimental|Lovaza (900 mg/day)|Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
9776259|NCT01048502|Experimental|Lovaza (3,600 mg/day)|Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
9776260|NCT01048541|Active Comparator|SpeediCath catheter|Standard treatment
9776261|NCT01048541|Experimental|Test product|
9776262|NCT01048593|Experimental|Dose 1|114ug
9776263|NCT01048593|Experimental|Dose 2|513ug
9776264|NCT01048593|Experimental|Dose 3|684ug
9776265|NCT01048606|Active Comparator|Placeco + exercise|Placebo (no phytoestrogen): Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) Exercise (three 1h-sessions/week)
9776266|NCT01048606|Active Comparator|Phytoestrogens without exercise|Phytoestrogens (70mg/day of soy isoflavone) Without exercise (no structured exercise session)
9776267|NCT01048606|Experimental|Phytoestrogens + exercise|Phytoestrogens (70 mg/day soy isoflavone) Exercise (1h-sessions 3 times/week)
9776268|NCT01048606|No Intervention|Placebo without exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) No exercise
9776269|NCT01048658|Active Comparator|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
9776270|NCT01048658|Placebo Comparator|No Sevoflurane|Subject receives standard of care drug regimens for anesthesia with this procedure.
10204115|NCT04195750|Active Comparator|Everolimus|Participants receive 10 mg of Everolimus orally once daily (QD)
10204116|NCT04180436|Experimental|morbidly obese patients with BMI ≥ 40|Morbidly obese patients with BMI ≥ 40
10204117|NCT04180436|Experimental|Patients operated by gastric bypass|Patients operated by gastric bypass for over a year and with stable weight
10204118|NCT04180436|Experimental|Patients operated by sleeve gastrectomy|Patients operated by sleeve gastrectomy for over a year and with stable weight
10204119|NCT04180436|Experimental|Control group: non-operated subjects|Control group: non-operated subjects but with an age and a BMI corresponding to those of the patients of the 2 operated groups.
10204120|NCT04179890||Uncommon mutation cohort|Patients with non-small-cell lung cancer (NSCLC)
10204121|NCT04179890||Sequencing cohort|Patients with non-small-cell lung cancer (NSCLC)
10204122|NCT04175509|Active Comparator|Rectal acetaminophen|Patients will receive two 650mg suppositories rectally of acetaminophen for a total dose of 1300mg at the end of surgery.
10204123|NCT04175509|Active Comparator|Intravenous acetaminophen|Patients will receive one dose of 1000mg of acetaminophen, administered intravenously, at the end of surgery.
9776271|NCT01048671||Antiretroviral combination therapy including raltegravir|Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
9776272|NCT01048697|Experimental|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
9776273|NCT01048788|Experimental|OPC|
9776274|NCT01048866|Experimental|flurbiprofen 8.75 mg lozenge|Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
9776275|NCT01048866|Placebo Comparator|placebo lozenge|Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
9776276|NCT01048879|Other|ECMO alone|Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy (patients were already receiving oseltamivir and ECMO due to an illness)- Procedure/Surgery: pharmacokinetic blood sampling
9776277|NCT01048879|Other|CVVHD Alone|"Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir (Patients were already receiving oseltamivir and CVVHD as a result of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
9776278|NCT01048879|Other|CVVHD + ECMO|"Patient receiving oseltamivir and ECMO and CVVHD (patients were already receiving oseltamivir, ECMO, and CVVHD as part of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
9776279|NCT01048905|Experimental|Treatment: L-glutamine|Patients will receive an 8-week course of oral L-glutamine 10 grams TID
9776280|NCT01048944|Active Comparator|Bupropion SR|150 mg bid bupropion SR
9776281|NCT01048944|Active Comparator|Nicotine Patch|21mg, 14mg, 7mg
9776282|NCT01048944|Placebo Comparator|Placebo Patch and Placebo Pill|Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.
9776283|NCT01048944|No Intervention|Delayed-quit control|Smoke for 67 days while others have quit, then quit.
9776284|NCT01049009|Active Comparator|Nebivolol followed by Metoprolol XL|Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
9776285|NCT01049009|Active Comparator|Metoprolol XL followed by Nebivolol|Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
9776286|NCT01049217|Experimental|Active drug|
9776287|NCT01049217|Placebo Comparator|Control|
9776288|NCT01049243|Other|Fluocinonide Cream 0.1%|Fluocinonide Cream 0.1% open label
9776289|NCT01049308||Heart Failure|veteran population with documented heart failure
9776290|NCT01049334|Experimental|flurbiprofen 8.75 mg lozenge|Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
9776291|NCT01049334|Placebo Comparator|Placebo lozenge|Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
9776292|NCT01049360|Experimental|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
9776293|NCT01049360|Experimental|Aclidinium 400 μg / formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
9776294|NCT01049360|Experimental|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID)
10205344|NCT02610374|Other|Cohort C|HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
9776295|NCT01049360|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily
9776296|NCT01049360|Placebo Comparator|Placebo|Placebo twice-daily
9776297|NCT01049373|Experimental|Lymphdiaral Basistropfen (HDC)|HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
9776298|NCT01049373|Placebo Comparator|Placebo Solution|10 drops t.i.d. for 15 weeks
9776299|NCT01049412|Experimental|LY2605541 First, Then Insulin Glargine|Participants received LY2605541 for 8 weeks, followed by insulin glargine for 8 weeks.
9776300|NCT01049412|Active Comparator|Insulin Glargine First, Then LY2605541|Participants received insulin glargine for 8 weeks, followed by LY2605541 for 8 weeks.
9776301|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
9776302|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
9776303|NCT01049503|Active Comparator|Caries-active 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
9776304|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
9776305|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
9776306|NCT01049503|Active Comparator|Caries-inactive 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
9776307|NCT01049581|Experimental|pediatric aquatic therapy|The children of the PAT group participated in a 1 hour/time, twice-per-week, 12-week, PAT program in addition to conventional rehabilitation programs
9776308|NCT01049581|No Intervention|conventional therapy|The children included in the control group continued with their original rehabilitation programs
9776309|NCT01049776|Experimental|Pazapanib (GW786034)|
9776310|NCT01049802|Experimental|Active rTMS|Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
9776311|NCT01049802|Placebo Comparator|Sham rTMS|Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
9776312|NCT01049919|Experimental|Concentrated bone marrow aspirate (cBMA)|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
9776313|NCT01049919|Sham Comparator|Placebo control (sham)|Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
9776314|NCT01049945|Experimental|Arm I|Patients receive dexamethasone orally or IV on days 1, 8, 15, and 22; bendamustine hydrochloride IV over 30 minutes on days 1 and 2; and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9776315|NCT01049984|Experimental|Rasagiline 1 mg|Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
9776316|NCT01049984|Placebo Comparator|Placebo|Participants took a matching placebo tablet once daily for 18 weeks.
9776317|NCT01050062||Micombi® Combination Tablet AP|
9776318|NCT01050062||Micombi® Combination Tablet BP|
9776319|NCT01050153|Active Comparator|Control (standard of care)|Dalteparin sodium 5000IU subcutaneously daily
9776320|NCT01050153|Experimental|TEG-guided thromboprophylaxis|Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
9776321|NCT01050205|Active Comparator|Current Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Current intervention Arm in which case they will receive the intervention immediately."
9776322|NCT01050205|Active Comparator|Delayed Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Delayed Intervention Arm in which case they will receive delayed intervention at 6 months."
9776323|NCT01050231|Experimental|Robotic group (Type I)|Type I Robotic Therapy (Functional activities first) Participants in this group will participate in functional/task-oriented multi-joint training with the BONES robot first, followed by individual joint training with the BONES robot. A one-week break was provided between interventions.
9776324|NCT01050231|Active Comparator|Robotic group (Type II)|Type II Robotic Therapy (Individual joints first) Participants in this group will participate in individual joint training with the BONES robot first, followed by functional/task-oriented multi-joint training with the BONES robot. A one-week break was provided between interventions.
9776325|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 100 mg|Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
9776326|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 200 mg|Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
9776327|NCT01050257|Experimental|Oseltamivir Open Label|Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.
9776328|NCT01050530|Experimental|OPC-41061|
9776329|NCT01050530|Placebo Comparator|Placebo|
9776330|NCT01050543|Experimental|Sugammadex|
9776331|NCT01050543|Active Comparator|Neostigmine|
9776332|NCT01050569|Active Comparator|VLNC Cigarette|Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
9776333|NCT01050569|Active Comparator|Nicotine Patch|21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
9776334|NCT01050569|Experimental|VLNC Cigarette plus Nicotine Patch|Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
9776335|NCT01050582|Experimental|Risperidone|Risperidone as per local prescribing practices
9776336|NCT01050582|Experimental|Other atypical antipsychotic drugs|Other atypical antipsychotic drugs as per local prescribing practices
9776337|NCT01050634||Observational|
9776338|NCT01050647|Active Comparator|17-hydroxyprogesterone caproate|Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
9776339|NCT01050647|Placebo Comparator|Castor oil injections|Weekly injections of Caster Oil (placebo)
9776340|NCT01050660|Active Comparator|3 gm/kg/day intravenous lipid emulsion|
9776341|NCT01050660|Experimental|Intravenous Fat Emulsion-restricted|
9776342|NCT01050673|Active Comparator|VERSAJET|Excision with VERSAJET™ Hydrosurgery System
9776343|NCT01050673|Active Comparator|Conventional Therapy|Conventional operating room excision will consist of sharp instrumentation and electrocautery techniques, with the use of pulse lavage at the investigator's discretion. The type of sharp instrumentation, together with the brand of pulse lavage will be recorded.
9776344|NCT01050764|Experimental|T-reg Cell Infusion after Allogeneic Stem Cell Transplant|
9776345|NCT01050790|Experimental|Aza Len Lymphapheresis SCT ALI|Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.
9776346|NCT01050816|Experimental|Chondron implantation|ankle cartilage defect patients who had CHONDRON transplantation
9776347|NCT01050907|Experimental|Miltefosine|2.5 mg/kg/day for 28 days
9776348|NCT01050946|Other|Haploidentical/cord transplant|Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
9776349|NCT01050998|Experimental|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
9776350|NCT01050998|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
9776351|NCT01050998|Experimental|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
9776352|NCT01050998|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
9776353|NCT01050998|Placebo Comparator|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
9776354|NCT01051063|Experimental|Partial Remission Group|Adult patients in partial remission post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
9776355|NCT01051063|Experimental|Complete Remission Group|Adult patients in complete remission with incomplete blood count recovery post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
9776356|NCT01051310|Experimental|CoreValve|
9776357|NCT01051323||1|
9776358|NCT01051349|Experimental|BIIB019|Participants received BIIB019, 150 mg subcutaneous injection every 4 weeks up to Week 288.
9776359|NCT01051440|Placebo Comparator|Placebo|Subjects will receive placebo for lisdexamfetamine.
9776360|NCT01051440|Active Comparator|Lisdexamfetamine|Subjects will start with 20 mg per day of lisdexamfetamine and may increase to a maximum of 40 mg.
9776361|NCT01051466|Experimental|Duloxetine|
9776362|NCT01051466|No Intervention|Healthy Participants|
9776363|NCT01051518|Experimental|CoreValve|
9776364|NCT01051557|Experimental|Treatment (temsirolimus and perifosine)|"PHASE I: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and perifosine PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive temsirolimus and perifosine as in phase I. Some patients may also undergo cytoreductive surgery."
9776365|NCT01051570|Experimental|Carboplatin, RAD 001 & Prednisone|"Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle~RAD 001: 5 mg Orally daily, starting from Day 2 continuously~Prednisone 5 mg Orally twice daily, continuously"
9776366|NCT01051596|Experimental|ABT-888 and temozolomide|Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
9776367|NCT01051661|Experimental|Arepanrix 2D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
9776368|NCT01051661|Experimental|Arepanrix 2D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
9776369|NCT01051661|Experimental|Arepanrix 1D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
9776370|NCT01051661|Experimental|Arepanrix 1D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
9776371|NCT01051661|Experimental|GSK2340273A 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
9776372|NCT01051661|Experimental|GSK2340273A 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
9776373|NCT01051739||Group 1|glaucoma
9776374|NCT01051739||Group 2|normal
9776375|NCT01051778|Experimental|enoxaparin 40 mg plus low dose aspirin|
9776376|NCT01051778|Active Comparator|Heparin calcium 5,000 U twice daily plus low dose aspirin|
9776377|NCT01051791|Experimental|Everolimus 10 mg daily|"The study of the efficacy of everolimus will proceed in two stages after the method of Simon1. In the first stage 15 patients will be accrued and treated. If 9 or fewer patients show clinical benefit the study will be terminated. If 10 or more patients show clinical benefit the study will proceed to the second stage, accruing an additional 26 patients. If the second stage is complete and a total of 29 or more patients show clinical benefit among the 41 patients treated, the treatment CBR for will be considered high enough to warrant further study. Conversely, if the evaluation of everolimus concludes at the first stage, or if 28 or fewer patients experience a clinical benefit after completing the second stage, the therapy will not be considered for further study.~1"
9776378|NCT01051817|Experimental|AIN457|
9776379|NCT01051817|Placebo Comparator|Placebo|
9776380|NCT01051856|Active Comparator|SEAMGUARD with bioabsorbable staple|In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
9776381|NCT01051856|Active Comparator|TissueLink with radiofrequency ablation|After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.
9776382|NCT01051960|Experimental|ambrisentan|ambrisentan dosed at either 5mg or 10mg orally once per day
10205345|NCT02597075|Active Comparator|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
9776383|NCT01051986|Active Comparator|SVG group|"patients who underwent off-pump coronary artery bypass using saphenous vein composite grafting based on the left internal thoracic artery~use saphenous vein as a composite graft connected to the left internal thoracic artery"
9776384|NCT01051986|Active Comparator|RITA group|"patient who underwent off-pump coronary artery bypass using right internal thoracic artery composite grafting based on the left internal thoracic artery~use right internal thoracic artery as a composite graft connected to the left internal thoracic artery"
9776385|NCT01052012|Experimental|Active: SABER-Bupivacaine|SABER-Bupivacaine
9776386|NCT01052012|Active Comparator|Comparator: Bupivacaine HCl|Bupivacaine HCl
9776387|NCT01052012|Placebo Comparator|Placebo: SABER-Placebo|SABER-Placebo
9776388|NCT01052038|Placebo Comparator|Group 1 Placebo|Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
9776389|NCT01052038|Active Comparator|Group 2: Dexamethasone 0.05mg/kg|Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
9776390|NCT01052038|Active Comparator|Group 3:Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
9776391|NCT01052077|Experimental|Brexipiprazole + ADT|OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
9776392|NCT01052077|Placebo Comparator|Placebo + ADT|Placebo + ADT
9776393|NCT01052103|Experimental|LY2140023|
9776394|NCT01052103|Placebo Comparator|Placebo|
9776395|NCT01052116|Active Comparator|Soy Isoflavone|Oral isoflavone supplement (100 mg/day)
9776396|NCT01052116|Placebo Comparator|Placebo|Matching placebo
9776397|NCT01052207||Critically Ill Patients|Evaluation of Oxidative Stress, Glucocorticoid Receptor function, and Adrenal Insufficiency amongst critically ill pediatric patients. Serum, and when available endotracheal samples, will be obtained within 24 hours of admission and at 5 days provided patients are 1) still in the PICU and 2) blood draws and endotracheal aspirates are part of their standard of care. Endotracheal aspirates will be sent on day 14, 21, and 28 provided patients are intubated and require suctioning as part of their standard of care.
9776398|NCT01052207||Healthy Controls|Healthy controls will be evaluated and defined as those who do not have any chronic medical condition, are not on steroids (inhaled or oral), and have not received steroids or etomidate in the last month. Given the time and need for multiple lab draws low dose adrenocorticotropin (ACTH) testing will not be done in healthy patients, nor will tracheal aspirate samples be obtained.
9776399|NCT01052272|Active Comparator|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
9776400|NCT01052272|Active Comparator|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
9776401|NCT01052272|Active Comparator|Ramipril and Allopurinol|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. It is anticipated that the starting dose of each drug will be initiated in hospital and that the second dose will be implemented prior to discharge from the hospital. The starting dose of Allopurinol is 300 mg daily.
9776402|NCT01052272|Active Comparator|Candesartan cilexetil and Allopurinol|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. The starting dose of Allopurinol is 300 mg daily.
9776403|NCT01052428|Active Comparator|Toprol XL|beta 1 receptor blockade; generic name metoprolol succinate
9776404|NCT01052428|Placebo Comparator|Placebo|Pill that looks like Toprol XL but does not have the active ingredients
9776405|NCT01052480|Experimental|Plasma and Standard Care|Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies (Anti-Influenza Immune Plasma) in addition to standard care.
9776406|NCT01052480|Active Comparator|Standard Care|Participants will receive standard care.
9776407|NCT01052493|Experimental|2mg PP 1420|PP 1420 single dose, subcutaneous
9776408|NCT01052493|Experimental|4mg PP 420|PP 1420 single dose, subcutaneous
9776409|NCT01052493|Experimental|8mg PP 1420|PP 1420 single dose, subcutaneous
9776410|NCT01052493|Placebo Comparator|Placebo|0.9% saline
9776411|NCT01052545|Experimental|Arm 1- Intervention: Audit-Feedback|Baseline surveillance for the clinical outcomes will begin in year 1 at the intervention site and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will occur during year 2 of the study at the intervention site. Feedback will be delivered to individual health care providers at the intervention site during year 2.Unit-level audit feedback will be delivered at the intervention site during years 2 and 3 of the study. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the intervention site in years 2 and 3 of the project.
10205346|NCT02597075|Active Comparator|Arm B:|Standard therapy
10205347|NCT02586675|Experimental|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
10205348|NCT02582905|Placebo Comparator|Placebo|Matching placebo given beginning at 1 capsule BID increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
10205349|NCT02582905|Experimental|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
9776412|NCT01052545|No Intervention|Arm 2- Control|At the control site, baseline surveillance for the clinical outcomes will begin in year 1 at the and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will not occur at the control site. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the control site in year 3 of the project.
9776413|NCT01052662|Experimental|Memantine 30mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
9776414|NCT01052662|Experimental|Memantine 15mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
9776415|NCT01052662|Placebo Comparator|Memantine 0mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Matching placebo capsule was started on week 2. The placebo capsules were given on a twice a day schedule until week 12 and then discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
9776416|NCT01052701|Active Comparator|Ribavirin plus Abacavir|Ribavirin plus Abacavir Administration intervention
9776417|NCT01052701|Active Comparator|Ribavirin alone|Ribavirin alone administration
9776418|NCT01052714|No Intervention|Usual Care|Control group with time-matched study visits
9776419|NCT01052714|Active Comparator|Lifestyle Balance|Weight management group education and individual counseling
9776420|NCT01052714|Other|Usual Care then Lifestyle Balance|Participants originally randomized to Usual Care, allowed to change over to Lifestyle Balance at month 6 per their request.
9776421|NCT01052779|Experimental|Ferumoxytol|Participants received an IV injection of ferumoxytol (510 milligrams [mg], 17 milliliters [mL]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
9776422|NCT01052779|Active Comparator|Iron Sucrose|"Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g."
9776423|NCT01052831|Active Comparator|Naltrexone|For the first four weeks of the study, participants were administered naltrexone at 50mg per day. Participants not in response at week 4 were increased to 100mg per day for the remaining four weeks of the study.
9776424|NCT01052831|Placebo Comparator|Placebo|Participants received the placebo treatment which looked identical to active study medication.
9776425|NCT01052844|Placebo Comparator|Control group|"Placebo:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
9776426|NCT01052844|Experimental|Gabapentin|"Gabapentin 300mg:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
9776427|NCT01052948||Cohort 1|All persons who newly start one of the dopamine agonists (DA) after start of eligibility period
9776428|NCT01052948||Cohort 2|All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.
9776429|NCT01052948||Cohort 3|All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.
9776430|NCT01052948||Cohort 4|healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists
9776431|NCT01053000|Experimental|Lt. Arm Tazorac/Rt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Left arm only and then receive ALA- PDT Treatment to both arms
9776432|NCT01053000|Experimental|Rt. Arm Tazorac/Lt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Right arm only and then receive ALA- PDT Treatment to both arms
9776433|NCT01053013|Experimental|Macrobead Implantation|patients will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
9776434|NCT01053078|Experimental|Naltrexone|
9776435|NCT01053078|Placebo Comparator|Placebo|
9776436|NCT01053156|Placebo Comparator|Placebo pill|All patients will be on placebo for 3 months in this crossover study.
9776437|NCT01053156|Experimental|Minocycline|All patients will be on minocycline for 3 months in this crossover trial.
9776438|NCT01053247|Experimental|Test|Test product that contains the active pharmaceutical ingredient
9776439|NCT01053247|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
9776440|NCT01053247|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
9776441|NCT01053312|Experimental|1 flutemetamol|
9776442|NCT01053429||observational cohort|
9776443|NCT01053507|Active Comparator|Treximet|In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
9776444|NCT01053507|Placebo Comparator|Placebo|In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
9776445|NCT01053663|Experimental|1|
9784884|NCT01236521|Experimental|Arm 2: Behavioral treatment (CBT)|Veterans randomized to behavioral treatment arm (CBT) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
9784885|NCT01236534|Active Comparator|Lubiprostone|
9784886|NCT01236534|Placebo Comparator|Sugar pill|
9784887|NCT01236573|Experimental|Group 1 - CD8 + TIL expressing IL-12 1x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of interleukin-12 (IL-12) gene-transduced tumor infiltrating lymphocytes (TIL).
9784888|NCT01236573|Experimental|Group 2 - CD8 + TIL expressing IL-12 3x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784889|NCT01236573|Experimental|Group 3 - CD8 + TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784890|NCT01236573|Experimental|Group 4- CD8+TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784891|NCT01236573|Experimental|Group 5 - Bulk TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784892|NCT01236573|Experimental|Group 6 - Bulk TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784893|NCT01236573|Experimental|Group 7- Bulk TIL expressing IL-12 1x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784894|NCT01236573|Experimental|Group 8 - Bulk TIL expressing IL-12 3x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784895|NCT01236573|Experimental|Group 9 - Bulk TIL expressing IL-12 1x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784896|NCT01236573|Experimental|Group 10- Bulk TIL expressing IL12 3x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784897|NCT01236573|Experimental|Group 11 - Bulk TIL expressing MTD 1x10^9 (Phase 2)|Maximum tolerated dose (MTD). Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
9784898|NCT01236742|Experimental|single-vision glasses and ortho-k lenses|Children who are currently wearing ortho-k lenses at night for correction of refractive errors will be switched to wear single-vision glasses for the first 7 months and then switched back to ortho-k lenses for the next 7 months
9784899|NCT01236742|Active Comparator|ortho-k lenses|Children who are currently wearing ortho-k lenses at night for the correction of refractive errors will continue with the current treatment and serve as the first control group
10205350|NCT02582905|Experimental|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
10205351|NCT02572843|Experimental|MEDI4736|Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.
9776446|NCT01053741|Experimental|Seminal Fluid then Normosol|2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.
9776447|NCT01053741|Experimental|Normosol then Seminal Fluid|2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.
9776448|NCT01053819|Experimental|Etanercept|open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
9776449|NCT01053897|Experimental|GBT009|
9776450|NCT01053897|Placebo Comparator|Placebo|
9776451|NCT01053962|Experimental|SP-304 0.3 mg|SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.
9776452|NCT01053962|Experimental|SP-304 1.0 mg|SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.
9776453|NCT01053962|Experimental|SP-304 3.0 mg|SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days
9776454|NCT01053962|Experimental|SP-304 9.0 mg|SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.
9776455|NCT01053962|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 14 consecutive days
9776456|NCT01053988|Experimental|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9776457|NCT01053988|Experimental|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
9776458|NCT01053988|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
9776459|NCT01053988|Placebo Comparator|Placebo|Placebo
9776460|NCT01053988|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9776461|NCT01054079|Experimental|Treatment (cinacalcet hydrochloride)|Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
9776462|NCT01054144|Experimental|Response Adapted Therapy|Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
9776463|NCT01054170|Experimental|AZD9668|
9776464|NCT01054170|Placebo Comparator|Placebo|
9776465|NCT01054183|Experimental|Intubation using GlideScope Ranger|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team A to use the GlideScope Ranger for all intubations on that day.
9776466|NCT01054183|Active Comparator|intubation using direct laryngoscopy|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team B. Team B will do intubations using direct laryngoscopy only that day.
9776467|NCT01054209|No Intervention|A: standard care, no warming|Control arm. Full standard care. No mattress warming. May receive warmed fluids if standard practise for clinician
9776468|NCT01054209|Active Comparator|B: electric warming mattress|Warming with warming mattress
9776469|NCT01054222|Other|Fesoterodine 4 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
9776470|NCT01054222|Other|Fesoterodine 8 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
9776471|NCT01054300|Experimental|Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg|Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
9776472|NCT01054300|Experimental|Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo|Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
9776473|NCT01054300|Experimental|Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg|Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
9776474|NCT01054300|Experimental|Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo|Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
9776475|NCT01054339|Experimental|Low dose|rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg
9776476|NCT01054339|Experimental|Middle dose|rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg
9776477|NCT01054339|Experimental|High dose|rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg
9776478|NCT01054404|Active Comparator|Furosemide|Furosemide 0.3 mg/kg
9776479|NCT01054404|Placebo Comparator|Placebo|Up to 5 mL saline
9776480|NCT01054443|Placebo Comparator|Placebo|Participants received placebo tablets orally once a day for 42 days.
9776481|NCT01054443|Experimental|Lusutrombopag 0.5 mg|Participants received 0.5 mg lusutrombopag orally once a day for 42 days.
9776482|NCT01054443|Experimental|Lusutrombopag 0.75 mg|Participants received 0.75 mg lusutrombopag orally once a day for 42 days.
9776483|NCT01054443|Experimental|Lusutrombopag 1.0 mg|Participants received 1.0 mg lusutrombopag orally once a day for 42 days.
9776484|NCT01054456|Experimental|All Participants: Palonosetron 0.25 mg/5 mL|Participants will receive palonosetron 0.25 milligram (mg) per (/) 5 milliliter (mL) intravenous injection 30 minutes prior to receiving a low emetogenic chemotherapy (LEC) agent on Day 1.
9776485|NCT01054560|Experimental|SOLITAIRE™ Device|The SOLITAIRE™ Device (investigational device) is the experimental arm
9776486|NCT01054560|Active Comparator|MERCI® Device|The MERCI® Device (control device) is commercially available.
9776487|NCT01054573|Experimental|Telaprevir + Standard Treatment|Telaprevir 750 mg orally (by mouth) every 8h for 12 weeks plus standard treatment. Standard treatment is 180 mcg subcutaneous (under the skin) injection pegylated interferon (Peg-IFN) alfa-2a and 1000-1200 mg twice daily ribavirin (RBV) for 48 weeks.
9776488|NCT01054586||HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI|Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.
9776489|NCT01054599|Experimental|Memantine|Subjects will randomly assigned to take either a placebo or memantine for 13 weeks. The assignment will be double-blind, neither the study members nor the subject will know if he/she is taking memantine or a placebo.
9776490|NCT01054599|Placebo Comparator|Sugar Pill|Subjects will be randomly assigned to take either memantine or a placebo. The study is double-blind, and neither the study members nor the subject will know if he/she is taking memantine or a placebo.
9776491|NCT01054625|Experimental|zalutumumab 4 mg/kg|zalutumumab 4 mg/kg iv single infusion week 1,3, 4 and 5
9776492|NCT01054625|Experimental|zalutumumab 8 mg/kg|zalutumumab 8 mg/kg iv single infusion week 1, 3, 4 and 5
9776493|NCT01054625|Experimental|zalutumumab 16 mg/kg|zalutumumab 16 mg/kg iv single infusion week 1, 3, 4 and 5
9776494|NCT01054703|Experimental|Ethmoid Sinus Spacer placement|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
9776495|NCT01054729|Experimental|Sofosbuvir 100 mg+PEG+RBV|Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
9776496|NCT01054729|Experimental|Sofosbuvir 200 mg+PEG+RBV|Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
9776497|NCT01054729|Experimental|Sofosbuvir 400 mg+PEG+RBV|Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
9776498|NCT01054729|Active Comparator|Placebo+PEG+RBV|Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
9776499|NCT01054742||Standard of Care PegIntron Plus Ribavirin [Part 2]|Participants who had relapsed during Part 1 of the study, had detectable HCV-RNA on Day 1 of Part 2 of the study, and who were re-treated during Part 2 of the study with standard of care PegIntron plus ribavirin for 48 weeks.
9776500|NCT01054768|Experimental|alpha-lipoic acid and acetyl-L-carnitine|alpha-lipoic acid and acetyl-L-carnitine1400 mg tablet twice a day for 6 months.
9776501|NCT01054768|Placebo Comparator|Placebo|1400 mg placebo tablet twice a day for 6 months.
9776502|NCT01054820|Experimental|FLECTORA Patch (diclofenac epolamine topical patch) 1.3%|One patch applied every 12 hours
9776503|NCT01054846|Experimental|Helmet and helmet education|Each participant preschool child received a free bicycle Bell helmet, manufactured by Bell Sports Inc., Rantoul IL, USA. In addition, classroom bicycle helmet education was provided to all participant children and their caregivers, consisting of a video on rules of biking and the importance of proper helmet use and a classroom melon drop demonstration with and without a helmet to participants and their caregivers.
9776504|NCT01054846|Active Comparator|Helmet education|Each child did not receive a bicycle Bell helmet but the child and his/her caregiver was given bicycle helmet education package as above.
9776505|NCT01054885|Experimental|Fluticasone Furoate Inhalation Powder|Inhaled Corticosteroid (ICS)
9776506|NCT01054885|Experimental|FF Inhalation Pwdr|Inhaled Corticosteroid (ICS)
9776507|NCT01054885|Experimental|Fluticasone Furoate/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9776508|NCT01054885|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9776509|NCT01054885|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
9776510|NCT01054885|Placebo Comparator|Placebo|Placebo
9776511|NCT01054911|Experimental|Sunitinib pill|Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.
9776512|NCT01054976|Experimental|Galantamine|
9776513|NCT01055028|Experimental|Regimen A / Treatment 1|"Participants were to receive paclitaxel 200 mg/m² intravenously over 3 hours every 21 days followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
9776514|NCT01055028|Experimental|Regimen B / Treatment 2|"Patients were to receive paclitaxel 90 mg/m² weekly x 3 of a 28-day cycle followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
9776515|NCT01055067|Experimental|Tivantinib (ARQ 197)|3 capsules of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles
9776516|NCT01055132|Other|Etafilcon A toric contact lens/Nelfilcon A toric|Etafilcon A toric contact lens first, then nelfilcon A toric second
9776517|NCT01055132|Other|Nelfilcon A toric/ Etafilcon A toric|Nelfilcon A toric contact lens first, then etafilcon A toric toric second
9776518|NCT01055171|Active Comparator|Propranolol|Patients will receive Propranolol in this condition.
9776519|NCT01055171|Placebo Comparator|Placebo|Patient to receive placebo in this condition.
9776520|NCT01055184|Experimental|2009 H1N1 Vaccine|Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
9776521|NCT01055197|Experimental|PCI|Prophylactic Cranial Irradiation (PCI)
9776522|NCT01055197|Experimental|PCI + Consolidation RT|Prophylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
9776523|NCT01055223||Type 2 diabetes subjects|Type 2 diabetes subjects
9776524|NCT01055262|Experimental|Heatwrap 1|Experimental heatwrap device for the lower back
9784900|NCT01236742|Other|single-vision glasses|Children who are currently wearing single-vision spectacles in the daytime for correcting their refractive errors will continue with the current treatment and serve as the second control group
9776525|NCT01055314|Experimental|Group 1 (chemotherapy, radiation therapy, cixutumumab)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.
9776526|NCT01055314|Experimental|Group 2 (chemotherapy, radiation therapy, temozolomide)|Patients receive vincristine sulfate, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1, 4, 20, 23, 47, and 50.
9776527|NCT01055457|Experimental|Experimental Multi-Purpose Solution|contact lens care solution
9776528|NCT01055457|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
9776529|NCT01055496|Experimental|Arm 1 (R-CVP)|Subjects in arm 1 will be enrolled in dose escalation cohorts that will initially evaluate an escalating dose of cyclophosphamide in combination with set doses of inotuzumab ozogamicin, vincristine, prednisone, and rituximab.
9776530|NCT01055496|Experimental|Arm 2 (R-GDP)|Subjects in arm 2 will be enrolled in dose escalation cohorts that will initially evaluate escalating doses of gemcitabine and/or cisplatinum in combination with set doses of inotuzumab ozogamicin, dexamethasone, and rituximab.
9776531|NCT01055613|Experimental|Experimental multi-purpose solution|Multi-purpose contact lens care solution.
9776532|NCT01055613|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution.
9776533|NCT01055639|Active Comparator|In-person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT). ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
9776534|NCT01055639|Experimental|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT). Sessions were delivered via videoconferencing system. ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
9776535|NCT01055704|Experimental|Methylnaltrexone|
9776536|NCT01055704|Experimental|Codeine|
9776537|NCT01055704|Experimental|Methylnaltrexone + codeine|
9776538|NCT01055704|Placebo Comparator|Placebo|
9776539|NCT01055769|Other|Group 1|Subjects will accept Linezolid OS 600 MG first, after 4 days wash-out, then will accept Linezolid tablet 600 MG.
9776540|NCT01055769|Other|Group 2|Subjects will accept Linezolid tablet 600 MG first, after 4 days wash-out, then will accept Linezolid OS 600 MG.
9776541|NCT01055782|Experimental|With endoguide|Colonoscopy completed with endoguide
9776542|NCT01055782|No Intervention|Without endoguide|Colonoscopy completed without endoguide
9776543|NCT01055834|Experimental|Eszopiclone 3 mg tablet|
9776544|NCT01055834|Experimental|Eszopiclone 1 mg tablet|
9776545|NCT01055886|Active Comparator|Nicotine Patch|Nicotine patch given pre-quit attempt at weeks 4 through 6
9776546|NCT01055886|Placebo Comparator|placebo patch|placebo patch given pre-quit from weeks 4 through 6
9776547|NCT01056016|No Intervention|Wait-list control|Wait-list control group
9776548|NCT01056016|Experimental|ADHD Collaborative Intervention|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.
9776549|NCT01056107|Experimental|ROSE-010 30 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
9776550|NCT01056107|Experimental|ROSE-010 100 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
9776551|NCT01056107|Experimental|ROSE-010 300 mcg|A glucagon-like peptide-1 (GLP-1) analogue. A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
9776552|NCT01056107|Placebo Comparator|Placebo|Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
9776553|NCT01056198|Active Comparator|Santyl|2 mm Santyl applied once daily
9776554|NCT01056198|Sham Comparator|Control|Daily gauze and optional sharp debridement
9776555|NCT01056263||Non-Interventional Study|Subjects participating in this observational study originally participated in study A4061012 [NCT00076011], and may have also have participated in study A4061008 [NCT00828919].
9776556|NCT01056276|Experimental|Treatment|Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
9776557|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|
9776558|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|
9776559|NCT01056289|Placebo Comparator|Placebo|
9776560|NCT01056302||Group 1|15 patients who underwent surgical repair of mandibular fractures at San Francisco VA Medical Center
9776561|NCT01056328|Experimental|St. Jude Medical Cardiac Ablation System|
9776562|NCT01056328|Active Comparator|FDA approved Open Irrigated Radio Frequency Ablation System|
9776563|NCT01056341|Experimental|Propranolol oral solution|
9776564|NCT01056341|Placebo Comparator|Placebo|
9776565|NCT01056380|Active Comparator|Nitazoxanide|
10204124|NCT04173000|Experimental|Intervention|All adolescent/parent dyads enrolled at each practice will have access to the meHealth for ADHD software without medication continuity tools prior to being given access to the medication continuity tools.
9776566|NCT01056380|Placebo Comparator|Placebo|
9776567|NCT01056484|Experimental|Meditation|Mindfulness Based Relapse Prevention for Alcohol Dependence intervention + Standard of Care therapy
9776568|NCT01056484|Other|Wait-list control|Standard of Care therapy only
9776569|NCT01056510|Experimental|A|
9776570|NCT01056510|Experimental|B|
9776571|NCT01056523|Experimental|Ribavirin-Cytarabine arabinoside|Ribavirin will be given orally bid according to a dose escalation scheme daily for 28 days of a 28 day cycle Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle
10204125|NCT04171635||Patients with transfusional iron overload|The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).
10204126|NCT04171635||Healthy subjects|Healthy control subjects over the age of 21 with no known hematological or liver disease and no contraindications for MRI
9776572|NCT01056536|Experimental|Structured intervention + free condoms|The subjects will receive a structured intervention on STI's and will be offered free condoms
10204127|NCT04170920|Experimental|Mobile Health Application Intervention|"LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
10204128|NCT04168385|Experimental|Maralixibat|Participants will all receive Maralixibat oral solution
10204129|NCT04158024|No Intervention|Volatile Anesthetic Control|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
10204130|NCT04158024|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique in addition to the standard of care Volatile Anesthetic Treatment.
10204131|NCT04148105|Placebo Comparator|Placebo|Implement standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway.
10204132|NCT04148105|Experimental|Experimental|Administer 100 mg cilostazol, twice daily for 14 days. In addition, implement the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days, and the standard aneurysmal subarachnoid treatment pathway.
10204133|NCT04147351|Experimental|Atezolizumab+bevacizumab+pemetrexed+carboplatin or cisplatin|
9776573|NCT01056536|Active Comparator|Free condoms|Subjects will be offered free condoms at the end of the pre-travel consultation
9776574|NCT01056536|No Intervention|No intervention|The topic of STI's will not be actively discussed during the pretravel consultation
9776575|NCT01056601|Experimental|Pancreatic Cancer Patients|Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
9776576|NCT01056640|Experimental|Home Telemonitoring|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line. This device has video monitoring which allows a real time face to face interaction with the provider. This allows for an individualized home care plan based upon multiple concerns which have not been adequately studied.
9776577|NCT01056640|Active Comparator|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required. It also includes home health care, timely post-hospital outpatient visits, a nurse generated phone call progress report within one business day of hospital dismissal, and standard clinic phone triage during business hours. It also involves a 24 hour nurse triage line for questions. Patients will be informed of the general options currently available to patients including the above as well as options for care in extended hours and at Mayo Express care.
9776578|NCT01056653|Experimental|Group A Teal|Standard Dose - Two intervention home visits (at 4 and 6 months of age)
10204134|NCT04140396|Placebo Comparator|Placebo Comparator|Participants will receive placebo infusion consisting of normal saline
10204135|NCT04140396|Active Comparator|Active Comparator|Participants will receive a lidocaine infusion
10204136|NCT04130711|Other|TEST 1: Visual virtual Conditions|"50 subjects (30 healthy volunteers and 20 patients after stroke)~3 different situations of vibration applications, without EGG neurofeedback session"
10204137|NCT04130711|Other|TEST 2: Standard EEG|"20 subjects (healthy volunteers)~3 separate electroencephalographic recording conditions without Neurofeedback"
10204138|NCT04130711|Other|TEST 3: Neurofeedback Training Stroke Patients|"26 patients after stroke~12 neurofeedback sessions spread over 6 weeks according to the feedback modality that will be drawn (visual or visuo-vibratory)"
9776579|NCT01056653|Experimental|Group B Purple|High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
9776580|NCT01056653|Sham Comparator|Group C Yellow|Comparison Group - One home visit, information only (at 4 months of age)
9776581|NCT01056718|Other|Nebivolol treatment|10 week open label nebivolol treatment.
9776582|NCT01056822|Active Comparator|1|Mycophenolate mofetil
9776583|NCT01056822|Experimental|2|Miycophenolate sodium
9776584|NCT01056913|Other|NITI CAR27 (ColonRing)|
9776585|NCT01057017|Experimental|intervention|"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
9776586|NCT01057225|Experimental|Arm I|Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
9776587|NCT01057251|Experimental|1|
9776588|NCT01057251|Placebo Comparator|2|
9776589|NCT01057277|Experimental|RAD001(Afinitor)|Radiation 47 days Cisplatin day 1,8,15,22,29,36,43 RAD001 Day 1 according to assigned group to day 47
9776590|NCT01057381|Active Comparator|Dexmedetomidine 0.75 mcg/kg|Intraoperative administration for analgesia.
9776591|NCT01057381|Active Comparator|Dexmedetomidine 1mcg/kg|Intra-operative administration of dexmedetomidine 1 mcg/kg for analgesia
9776592|NCT01057381|Active Comparator|Morphine 50 mcg/kg|Intra-operative administration of morphine 50 mcg/kg for analgesia
9776593|NCT01057381|Active Comparator|Morphine 100mcg/kg|Intra-operative administration of morphine 100mcg/kg for analgesia
9776594|NCT01057394|Active Comparator|Radiofrequency Ablation|PVI using RF ablation
9776595|NCT01057394|Experimental|Visually Guided Ablation|PVI using visually guided ablation with an endoscopic ablation system
9776596|NCT01057433|Experimental|Pitavastatin|Healthy adult subjects
9776597|NCT01057589|Experimental|Pemetrexed + Cisplatin + Cetuximab|"Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m^2) intravenous (IV) infusion and as a 250 mg/m^2 IV weekly dose thereafter.~As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter."
9776598|NCT01057693|Experimental|pregabalin (Lyrica)|
9776599|NCT01057693|Placebo Comparator|Placebo|
9776600|NCT01057810|Experimental|Ipilimumab|
9776601|NCT01057810|Placebo Comparator|Placebo|
9776602|NCT01057862|Experimental|Naltrexone|
9776603|NCT01057862|Placebo Comparator|Placebo|
9776604|NCT01057888|Experimental|Autodialer|Autodialer reminder/recall
9776605|NCT01057888|Experimental|Letters|Mailed reminder letters
9776606|NCT01057888|No Intervention|Controls|Controls
9776607|NCT01057901|Experimental|Flibanserin 100 mg|Flibanserin 100 mg administered at bedtime
9776608|NCT01057901|Placebo Comparator|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
9776609|NCT01058005|Experimental|Natalizumab|
9776610|NCT01058005|Active Comparator|Interferon Beta-1a|
9776611|NCT01058005|Active Comparator|Glatiramer Acetate|
9776612|NCT01058070|Experimental|Implantable Device|Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)
9776613|NCT01058096|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
9776614|NCT01058096|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
9776615|NCT01058239|Experimental|Rituximab plus Bortezomib|This is a single arm trial adding the new drug bortezomib to the standard drug rituximab
9776616|NCT01058265|Experimental|Integrative|Integrative Medical care is defined as a comprehensive medical evaluation that emphasizes wellness and healing of the whole person as major goals above and beyond suppression of a specific somatic disease. The patient is viewed as a whole person with mind and spirit as well as body and these dimensions are incorporated into diagnosis and treatment plans. An integrative medicine evaluation includes four aspects of health: physical, emotional, mental and spiritual health. Maximum improvement in health is achieved by addressing each aspect through an integrated treatment plan. The evaluation generally takes 90-120 minutes.
9776617|NCT01058265|Active Comparator|Standard|Standard general medical evaluation.
9776618|NCT01058304|Experimental|Group Physical Therapy for Knee OA|Group Physical Therapy for Knee OA
9776619|NCT01058304|Active Comparator|Individual Physical Therapy for Knee OA|Individual Physical Therapy for Knee OA
9776620|NCT01058356||IBD research group in KASID|KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.
9776621|NCT01058395|Experimental|800 mg loading then 200 mg Q12|Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.
9776622|NCT01058395|Experimental|800 mg loading then 400 mg Q12|Minocycline 800 mg. loading followed by 400 mg. Q 12 hours.
9776623|NCT01058421|Experimental|Intensive physical therapy|four week intervention of daily intensive physical therapy
9776624|NCT01058421|Active Comparator|control group|
9776625|NCT01058655|Experimental|Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
9784901|NCT01236755|Experimental|ortho-k lenses|Children were switched to wear ortho-k lenses for 7 months after wearing single-vision glasses for 7 months
9776626|NCT01058655|Experimental|Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
9776627|NCT01058655|Experimental|Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
9776628|NCT01058655|Experimental|Phase II: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
9776629|NCT01058668|Experimental|Cariprazine (3-6 mg/day)|Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
9776630|NCT01058668|Experimental|Cariprazine (6-12 mg/day)|Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
9776631|NCT01058668|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
9776632|NCT01058707|Experimental|MLN0128 QD|MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
9776633|NCT01058707|Experimental|MLN0128 QW|MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
9776634|NCT01058707|Experimental|MLN0128 QDx3d QW|MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
9776635|NCT01058707|Experimental|MLN0128 QDx5d QW|MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
9776636|NCT01058707|Experimental|MLN0128 5 mg QD|MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
9776637|NCT01058707|Experimental|MLN0128 30 mg QW|MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
9776638|NCT01058707|Experimental|MLN0128 40 mg QW|MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
9776639|NCT01058863|Experimental|Albuterol Spiromax® 90 mcg|A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
9776640|NCT01058863|Experimental|Albuterol Spiromax® 180 mcg|A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
9776641|NCT01058863|Active Comparator|ProAir® HFA 90 mcg|A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
9776642|NCT01058863|Active Comparator|ProAir® HFA 180 mcg|A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
9776643|NCT01058863|Placebo Comparator|Placebo Inhaler|Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
9776644|NCT01058941|Experimental|Lipoic acid and Omega-3 fatty acids|Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two lipoic acid (LA) capsules per day in the morning. Total daily dose of study drug: 675 mg DHA, 975 mg EPA, 600 mg LA.
9776645|NCT01058941|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two placebo LA capsules per day in the morning.
9776646|NCT01058993|Experimental|AMD3100 or plerixafor|SINGLE arm study with increasing doses of Plerixafor
9776647|NCT01059175|Experimental|CRT With Dual Site LV Pacing|Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
9776648|NCT01059175|Active Comparator|Standard CRT|Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
9776649|NCT01059305|Experimental|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
9776650|NCT01059318|Experimental|Everolimus|"All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks."
9776651|NCT01059344|Experimental|Mesalamin|4.8g Mesalamin (800mg tablet)
9776652|NCT01059344|Placebo Comparator|Placebo|4.8g Placebo to Mesalamin (800 mg tablet)
9784902|NCT01236768|Experimental|AG200-15|Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
9784903|NCT01236768|Active Comparator|Levora|oral contraceptive containing 150mcg of LNG and 30mcg of EE
9784904|NCT01237041|Experimental|Niacin First|Subjects receive niacin 500mg hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive placebo hourly for 4 hours on day 2 at (7:30am, 8:30am, 9:30am, and 10:30am).
9784905|NCT01237041|Experimental|Placebo First|Subjects receive placebo hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive niacin hourly for 4 hours on day 2 (at 7:30am, 8:30am, 9:30am, and 10:30am).
9784906|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 250mg|Subjects received Niacin 250 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
9784907|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 500mg|Subjects received Niacin 500 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
9776653|NCT01059357|Experimental|Transoral Robotic Surgery (TORS)|Transoral Robotic Surgery (TORS) using the Da Vinci Robotic Surgical System
9776654|NCT01059435|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.
9776655|NCT01059435|Experimental|Romosozumab|Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.
9776656|NCT01059526||Patients naive to KALBITOR|HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
9776657|NCT01059526||Patients non- naive to KALBITOR|HAE patients that have been treated with KALBITOR prior to enrollment in the study
9776658|NCT01059539|Experimental|Cariprazine 3-12 mg/day for 16 weeks|Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.
9776659|NCT01059565|Experimental|AZLI|Participants were randomized to receive AZLI for up to 24 weeks and may have continued to receive AZLI during the open-label phase for up to an additional 24 weeks.
9776660|NCT01059565|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match AZLI for up to 24 weeks and may have switched to AZLI during the open-label phase for up to 24 weeks.
9776661|NCT01059617|Experimental|Flulaval/Arepanrix Group|subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
9776662|NCT01059617|Experimental|Flulaval/Unadjuvanted Arepanrix Group|subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
9776663|NCT01059617|Experimental|Placebo/Arepanrix Group|subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
9776664|NCT01059617|Experimental|Placebo/Unadjuvanted Arepanrix Group|subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
9776665|NCT01059630|Active Comparator|Bendamustine Alone|Participants will receive bendamustine 120 milligrams per meter square (mg/m^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.
9776666|NCT01059630|Experimental|Obinutuzumab + Bendamustine|"Induction phase: Participants will receive bendamustine 90 mg/m^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.~Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first)."
9776667|NCT01059643|Experimental|LY2523355|
9776668|NCT01059682|Experimental|Dalcetrapib|
9776669|NCT01059682|Placebo Comparator|Placebo|
9776670|NCT01059760|Other|Fasting Day First|28±4 hours of water-only fasting followed by 28±4 hours fed
9776671|NCT01059760|Other|Fed Day First|28± 4 hours fed followed by 28± 4 hours of fasting
9776672|NCT01059773|Experimental|Immediate Methotrexate Cessation|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
9776673|NCT01059773|Active Comparator|Gradual Reduction of Methotrexate|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.
9776674|NCT01059799|Experimental|IDeg OD|
9776675|NCT01059799|Active Comparator|IGlar OD|
9836098|NCT02769065|Experimental|SRD: Cohort 18: TAK-071 120 mg|TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
9776676|NCT01059812|Experimental|IDegAsp BID|
9776677|NCT01059812|Active Comparator|BIAsp 30 BID|
9776678|NCT01059825|Placebo Comparator|Placebo|Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
9776679|NCT01059825|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
9776680|NCT01059825|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
9776681|NCT01059825|Experimental|Ertugliflozin 10 mg|Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
9776682|NCT01059825|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
9776683|NCT01059825|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
9776684|NCT01059851|Experimental|Participants with Severe Renal Impairment (Part I)|"Participants with severe renal impairment will receive a~single dose of 20 mg open-label suvorexant during Part I of the~study."
9776685|NCT01059851|Experimental|Healthy Participants (Severe Impairment Controls) (Part I)|Healthy participants matched to participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
9776686|NCT01059851|Experimental|Participants with Moderate Renal Impairment (Part II)|Participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
9776687|NCT01059851|Experimental|Healthy Participants (Moderate Impairment Controls) (Part II)|Healthy participants matched to participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
9776688|NCT01059851|Experimental|Participants with Mild Renal Impairment (Part II)|Participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
9776689|NCT01059851|Experimental|Healthy Participants (Mild Impairment Controls) (Part II)|Healthy participants matched to participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
9776690|NCT01059864|Experimental|Arm 1|
9776691|NCT01059864|Experimental|Arm 2|
9776692|NCT01059877|Active Comparator|1072nm Infrared Photobiomodulation|Received treatment for dementia with transcranial 1072nm infrared light stimulation.
9776693|NCT01059877|Placebo Comparator|Placebo|Placebo device simulated transcranial photobiomodulation
9776694|NCT01059903|Experimental|Rotigotine PR2.2.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
9776695|NCT01059903|Experimental|Rotigotine PR2.1.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
9776696|NCT01059929|Active Comparator|Dexmedetomidine|Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
9776697|NCT01059929|Active Comparator|Propofol|Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
9776698|NCT01059994|Placebo Comparator|placebo sildenafil young|Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.
9776699|NCT01059994|Experimental|sildenafil young|Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.
9776700|NCT01059994|Placebo Comparator|placebo sildenafil older|Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.
9776701|NCT01059994|Experimental|sildenafil older|Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.
9776702|NCT01060007|Experimental|Neoadjuvant radiation followed by FOLFOX|"Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.~FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).~If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days."
9776703|NCT01060020|Experimental|Sildenafil 40mg or 80mg|A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (<50%) EF.
9776704|NCT01060059||exenatide|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide.
9776705|NCT01060059||basal insulin|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin.
9776706|NCT01060072|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5% ophthalmic suspension
9776707|NCT01060072|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ophthalmic suspension
9776708|NCT01060098||Rheumatoid arthritis|Participants with Rheumatoid arthritis
9776709|NCT01060098||Ankylosing spondylitis|Participants with Ankylosing spondylitis
9776710|NCT01060098||Psoriatic arthritis|Participants with Psoriatic arthritis
9776711|NCT01060111|Experimental|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
9776712|NCT01060111|Experimental|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
9776713|NCT01060111|Experimental|Topiramate Slow and Propranolol Booster|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion. Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
9776714|NCT01060124|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl D-trans|
9776715|NCT01060150|Experimental|OROS Methylphenidate HCl|
9776716|NCT01060345|Experimental|Women with Ductal Carcinoma in Situ|Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E
9776717|NCT01060384|Experimental|Phase 1/Phase II|All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
9776718|NCT01060540|Experimental|CR+G|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus genetic testing for type 2 diabetes
9776719|NCT01060540|Active Comparator|CR+EYE|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus eye disease counseling
9776720|NCT01060553|Experimental|Arm 1|The treatment program consisted of 24 semi-individualized acupuncture treatments over 12 weeks. It combines front and back treatments to avoid point fatigue (tolerance due to frequent use). The front treat-ment uses 11 needles, bilateral at acupuncture points LR3, PC6, HT7, ST36, SP6, and one at Yintang; the back treatment uses 14 needles, bilateral at points GB20, and BL14, 15, 18, 20, 21, and 23. There are 15 other points from which the flexibly prescribed points could be chosen
9776721|NCT01060553|No Intervention|wait list control|subjects were put on a wait list control. due to small numbers completing in both groups, the data from the wait list who completed acupuncture are combined with the experimental treatment group for analysis.
9776722|NCT01060592|Experimental|Stoma Adjustment at Surgery|The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
9776723|NCT01060592|No Intervention|Historic|Weight loss profile over time for 50 patients in the first 12 months after surgery as derived from historic control records. Band adjustments are made in a heuristic fashion during the year after surgery using the experience of surgeon alone
9776724|NCT01060670|Experimental|Dermal Replacement Device|Device: INTEGRA® Dermal Regeneration Template
9776725|NCT01060670|Active Comparator|Moist Wound Therapy|0.9% Saline gel
9776726|NCT01061008|Experimental|Handgrip exercise|Handgrip exercise - patients allocated to this intervention will carry out an eight week post operative progressive handgrip exercise training program
9776727|NCT01061008|Active Comparator|Treatment as usual|
9776728|NCT01061177|Experimental|Nilotinib|This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.
9776729|NCT01061333|Experimental|Placebo|Placebo
9776730|NCT01061333|Experimental|Montelukast|Montelukast
9776731|NCT01061333|Experimental|Nedocromil|Nedocromil
9776732|NCT01061333|Experimental|Mometasone|Mometasone
9776733|NCT01061359||Non-Interventional Study|Chemotherapy containing Epirubicin
9776734|NCT01061385|Experimental|ReShape Intragastric Balloon|Patients receiving the ReShape Intragastric Balloon
9776735|NCT01061385|Other|Control Arm|Weight loss using behavior modification (diet and exercise counseling) alone
9776736|NCT01061476|Other|Single arm - Sleep apnea|"Participants with sleep apnea will be recruited for the study. Each participant will undergo 3 sleep studies to assess the effect of the Provent™ device. Participants will only use the device while they are in the sleep laboratory. They will not use the device at home between sleep studies .~Baseline sleep study (No device) - Assess the effects of no Provent™ on sleep apnea severity.~Treatment sleep study (Provent™ device used) - Assess the effects of Provent™ on sleep apnea severity~Physiology sleep study (Provent™ on/off) - Assess the physiological effects of the Provent™ device on breathing during sleep."
9776737|NCT01061528|Experimental|New Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
9776738|NCT01061528|Active Comparator|Standard Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
9776739|NCT01061567||Male and female patients with Parkinson's disease|
9776740|NCT01061606|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9776741|NCT01061671|Active Comparator|simvastatin|40 mgms of simvastatin daily
9776742|NCT01061671|Placebo Comparator|placebo|Matched placebo pill daily
9776743|NCT01061710||varenicline (Champix®)|Subjects who have been retreated with varenicline within 52 weeks and have been enrolled to varenicline protocol A3051109.
9776744|NCT01061723|Placebo Comparator|Placebo|Placebo (for sarilumab) weekly (qw) for 12 weeks.
9776745|NCT01061723|Experimental|Sarilumab 100 mg q2w|Sarilumab 100 mg Subcutaneous (SC) injection alternating with placebo every other week (q2w) for 12 weeks.
9776746|NCT01061723|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks.
9776747|NCT01061723|Experimental|Sarilumab 100 mg qw|Sarilumab 100 mg SC injection qw for 12 weeks.
9776748|NCT01061723|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks.
9776749|NCT01061723|Experimental|Sarilumab 150 mg qw|Sarilumab 150 mg SC injection qw for 12 weeks.
9776750|NCT01061736|Experimental|Part A: SAR 100 mg qw|Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
9776751|NCT01061736|Experimental|Part A: SAR 150 mg qw|Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
9776752|NCT01061736|Experimental|Part A: SAR 100 mg q2w|Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
9776753|NCT01061736|Experimental|Part A: SAR 150 mg q2w|Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
9776754|NCT01061736|Experimental|Part A: SAR 200 mg q2w|Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
9776755|NCT01061736|Placebo Comparator|Part A: Placebo qw|Placebo (for sarilumab) qw on top of MTX for 12 weeks.
9776756|NCT01061736|Experimental|Part B Cohort 1: Non-selected Doses|Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
9776757|NCT01061736|Experimental|Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
9776758|NCT01061736|Experimental|Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
9776759|NCT01061736|Experimental|Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)|Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
9776760|NCT01061775|Experimental|Exenatide|5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
9776761|NCT01061866|Experimental|Thalidomide|Open-labeled preliminary trial
9776762|NCT01062009|No Intervention|Control group|No intervention
9776763|NCT01062009|Active Comparator|Low dose group|250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
9776764|NCT01062009|Active Comparator|Medium dose group|500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
9776765|NCT01062009|Active Comparator|High dose group|750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
9776766|NCT01062061||VARIVAX|Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.
9776767|NCT01062074||Korean Participants Vaccinated with GARDASIL|Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
10204139|NCT04117815||study group|"Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen No alopecia of any reason (up-front) No overt cognitive impairment and fluent in German Written informed consent Age 18 and older"
9776768|NCT01062113|Experimental|Celecoxib 400mg|
9776769|NCT01062113|Experimental|Celecoxib 200mg|
9776770|NCT01062113|Placebo Comparator|Placebo|
9776771|NCT01062165|Experimental|Capsofungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
9776772|NCT01062230|Experimental|All patients|All participants enrolled.
9776773|NCT01062256|Placebo Comparator|Placebo|Placebo
9776774|NCT01062256|Experimental|Guaifenesin|Guaifenesin
9776775|NCT01062256|Experimental|Buckwheat Honey|Buckwheat Honey
9776776|NCT01062269|Active Comparator|Cholestyramine 4 grams|
9776777|NCT01062269|Active Comparator|Cholestyramine 12 grams|
9776778|NCT01062269|Placebo Comparator|Tang|
9776779|NCT01062308|Experimental|Taping|The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
9776780|NCT01062308|Active Comparator|Sham Taping|This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.
9776781|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 2.5 mg/day|Radiation therapy (RT), concurrent temozolomide (TMZ), and concurrent RAD001 2.5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
9776782|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 5 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
9776783|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 10 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
9776784|NCT01062399|Active Comparator|Ph II: RT + TMZ|Radiation therapy and concurrent temozolomide followed by post-radiation temozolomide
9776785|NCT01062399|Experimental|Ph II: RT + TMZ + RAD001|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
9776786|NCT01062555|Active Comparator|Phase I Arm 1|CSA and MMF
9776787|NCT01062555|Active Comparator|Phase I Arm 2|FK and MMF
9776788|NCT01062555|Active Comparator|Phase II Arm 1|Low CNI and MMF
9776789|NCT01062555|Active Comparator|Phase II Arm 2|Rapa and MMF
9776790|NCT01062568|Experimental|Obese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
9776791|NCT01062568|Experimental|Nonobese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
9776792|NCT01062763|Experimental|addition of spironolactone|spironolactone is added to previous antihypertensive treatment
9776793|NCT01062763|Placebo Comparator|Placebo|Addition of placebo
9776794|NCT01062841|Active Comparator|Intervention: Targeted Infection Control|Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
9776795|NCT01062841|No Intervention|Control|Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.
9776796|NCT01062893|Placebo Comparator|0 mls saline injected|NO SALINE INJECTED
9776797|NCT01062893|Active Comparator|15 mls saline|15ML SALINE ADMINISTERED EPIDURALLY
9776798|NCT01062971|Active Comparator|A|IOP Dorzolamide-Timolol-Brimonidine group
9776799|NCT01062971|Active Comparator|B|IOP dorzolamide-timolol group
9776800|NCT01063036|Experimental|Entecavir + Tenofovir|
9776801|NCT01063049|Active Comparator|Nulytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
9776802|NCT01063049|Experimental|Gatorade/Miralax + Placebo|Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
9776803|NCT01063049|Experimental|Gatorade/Miralax + Bisacodyl|Gatorade 64 oz (1/2 gallon), Miralax 306 g and Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and Bisacodyl 10 mg at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
9776804|NCT01063062|Experimental|tocilizumab|Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
9776805|NCT01063075|Experimental|Cetuximab and Carboplatin (D)|"Group D:~Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on week 1,day 1. Carboplatin area under the curve (AUC=5) administered I.V on week 1,day 1.~Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1.~After 1 cycle, participants may then receive cetuximab as determined by clinical exam or radiological imaging studies until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants were placed into Group D only."
9776806|NCT01063075|Experimental|Cetuximab and Carboplatin (C)|"Group C: Cycle 1 (4 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
9776807|NCT01063075|Experimental|Cetuximab and Carboplatin (B)|"Group B:~Cycle 1 (3 weeks, single-agent cetuximab):~400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011,any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
9776808|NCT01063075|Experimental|Carboplatin and Cetuximab (A)|"Group A:~Cycle 1 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1.~After 7 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
9776809|NCT01063153|Experimental|Concerta|Open-Label Concerta (Osmotic Release Methylphenidate)
9776810|NCT01063153|No Intervention|Control group|Healthy subjects without ADHD will be assessed using EEG.
9776811|NCT01063283|Active Comparator|Group A|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
9776812|NCT01063283|Active Comparator|Group B|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin+Pemetrexed+Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
9776813|NCT01063348|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine - 600mg tablets by mouth (dosing 1200mg - 3000mg qd)
9776814|NCT01063348|Placebo Comparator|Placebo|Matching placebo taken daily
9776815|NCT01063595|Experimental|Octaplas LG|Participants received 1200 mL of Octaplas LG intravenously once.
9776816|NCT01063595|Active Comparator|Octaplas SD|Participants received 1200 mL of Octaplas SD intravenously once.
9776817|NCT01063712|Other|Nit-Occlud PDA-R|Interventional, prospective clinical study, non randomized.
9776818|NCT01063764|Experimental|Levetiracetam|Open-label, single-arm
9776819|NCT01063829|Experimental|Dose regimen 1|60 mg AIC246, one tablet per day
9776820|NCT01063829|Experimental|Dose regimen 2|120 mg AIC246, one tablet per day
9776821|NCT01063829|Experimental|Dose regimen 3|240 mg AIC246, one tablet per day
9776822|NCT01063829|Other|Placebo|Placebo arm
9776823|NCT01063855|Experimental|Dapoxetine + PDE5I|Dapoxetine 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
9776824|NCT01063855|Placebo Comparator|Placebo + PDE5I|Placebo tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
9776825|NCT01063868|Experimental|001|Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 52 weeks
9776826|NCT01063868|Active Comparator|002|Oxycodone controlled release (CR) 20 30 40 50 mg twice daily for 52 weeks
9776827|NCT01063881|Experimental|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity may be increased after 4 weeks to 60mg taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
9776828|NCT01063907|Experimental|Phase 1: Cohort 1|Cohort 1: KW 2478 130 mg/m^2 and Bortezomib 1.0 mg/m^2
9776829|NCT01063907|Experimental|Phase 1: Cohort 2|Cohort 2: KW 2478 130 mg/m^2 and Bortezomib 1.3 mg/m^2
9776830|NCT01063907|Experimental|Phase 1: Cohort 3|Cohort 3: KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
9776831|NCT01063907|Experimental|Phase 1: Cohort 4|Cohort 4: KW 2478 175 mg/m^2 and Bortezomib 1.3 mg/m^2
9776832|NCT01063907|Experimental|Phase 2|KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
9776833|NCT01063972|Experimental|Experimental 1|Experimental: 1 Centralized disease management
9776834|NCT01063972|Experimental|Experimental 2|Experimental: 2 Counseling alone
9776835|NCT01064076|Experimental|S-ICD System|This is a single arm study
9776836|NCT01064167|Experimental|Tranexamic Acid group|
9776837|NCT01064167|Placebo Comparator|Control group|
9776838|NCT01064284|Active Comparator|PLASMA DERIVED Factor VIII|Plasma-derived vWF/FVIII
9776839|NCT01064284|Active Comparator|rFVIII|Recombinant FVIII
9776840|NCT01064297||Women exposed to lamotrigine during pregnancy|
9776841|NCT01064310|Experimental|pazopanib followed by sunitinib|800mg pazopanib orally for 10 weeks followed by 50mg sunitinib orally for 10 weeks
9776842|NCT01064310|Experimental|sunitinib followed by pazopanib|50mg sunitinib orally for 10 weeks followed by 800mg pazopanib orally for 10 weeks
9776843|NCT01064323|Other|Intermittent leg compression|Intermittent leg compression daily for 3 hrs a day for 4 weeks
9776844|NCT01064362||Prophylaxis following major orthopedic surgery|Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.
9776845|NCT01064401|Experimental|Daclizumab High Yield Process 150 mg SC|Daclizumab High Yield Process (DAC HYP) 150mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks
9776846|NCT01064401|Active Comparator|IFN β-1a 30 µg IM|Interferon beta-1a (IFN β-1a) 30 µg IM once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks
9776847|NCT01064414|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
9776848|NCT01064414|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
9776849|NCT01064414|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks.
9776850|NCT01064531||MIS Femoral Neck Stem|Subject will be randomized to either MIS or Synergy implant.
9776851|NCT01064531||Synergy Hip System|Subject will be randomized to either Synergy or MIS implant.
9776852|NCT01064622|Active Comparator|Arm I (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients are unblinded and may crossover to arm II.
9776853|NCT01064622|Experimental|Arm II (gemcitabine hydrochloride and vismodegib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9776854|NCT01064687|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
9776855|NCT01064687|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
9776856|NCT01064687|Active Comparator|Exenatide|"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
9784908|NCT01237041|Experimental|Dose-Establishing Study 2 Niacin 500mg|Subjects received Niacin 500 mg hourly for 4 doses (administered at 7:30am, 8:30am, 9:30am, and 10:30am).
9776857|NCT01064687|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC), once weekly for 26 weeks~LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
9776858|NCT01064713|Experimental|Tesetaxel|Therapy initiated at a flat dose of 40 mg for subjects in Cohort A and at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.
9776859|NCT01064739|Experimental|Study Diet +/- fava beans|Participants underwent testing while on a methylxanthine-free diet providing 150 mEq sodium and 75 mEq potassium per day. The study involved a longitudinal design where the participants served as their own controls. Subjects consumed the standard fixed sodium diet on study day one. On study day two, participants ate 100 g of puréed fava beans and pods with study diet at breakfast (0800hr) and lunch (1200hr).
9984321|NCT04223037|Active Comparator|Day 0，7 immunization shedule|Japanese Encephalitis Vaccine produced by Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) and Japanese Encephalitis Vaccine produced by Liaoning Chenda CO.,LTD Dosage form: 0.5mL/vial Two Dose injection with 7 days interval
9776862|NCT01064830|Active Comparator|topical cyclosporine suspension|apply 2 drops to 2 target nails under occlusion daily for 20 weeks
9776863|NCT01064830|Placebo Comparator|vehicle|apply to target nails daily under occlusion daily for 20 weeks
9776864|NCT01064856|Experimental|Double-blind (DB) Adalimumab|Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.
9776865|NCT01064856|Placebo Comparator|Double-blind Placebo|Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.
9776866|NCT01064856|Experimental|Double-blind Adalimumab / Open-label Adalimumab|Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.
9776867|NCT01064856|Placebo Comparator|Double-blind Placebo / Open-label Adalimumab|Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.
9784909|NCT01237054|Experimental|Imaging in MGUS, SMM, and MM|Participants will have three imaging studies on separate days: a standard positron emission tomography/computed tomography scan (18-FDG PET/CT), a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT), and magnetic resonance imaging (DCE-MRI).
9784910|NCT01237080|Experimental|Fastrach|50 persons beeing intubated using the Fastrach.
9784911|NCT01237080|Experimental|GlideScope|50 persons beeing intubated using the GlideScope.
9784912|NCT01237197|Experimental|Exenatide, then Open-Label Exenatide|Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
9784913|NCT01237197|Placebo Comparator|Placebo, then Open Label Exenatide|Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.
9784914|NCT01237223|Placebo Comparator|Placebo|In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.
9776868|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.005%|bimatoprost ophthalmic sterile solution 0.005%
9776869|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.015%|bimatoprost ophthalmic sterile solution 0.015%
9776870|NCT01064882|Active Comparator|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03%
9776871|NCT01065350|Active Comparator|Propofol|As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
9776872|NCT01065350|Experimental|Ketofol|"As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose."
9776873|NCT01065428||Weaning failure|Weaning failure:(1) failed SBT; (2) reintubation and /or resumption of support following successful extubation; or (3) die 48h following extubation.
9776874|NCT01065428||Weaning successful|Weaning successful:extubation and the absence of ventilatory support 48 h following the extubation
9776875|NCT01065480|Active Comparator|Live Teleconference Supervision|Clinicians from participating substance abuse treatment programs receive live supervision by MI trainer via teleconference while in session with client.
9776876|NCT01065480|Active Comparator|Taped Review Supervision|Clinicians from participating substance treatment programs audio record session with client and receive supervision after the session by MI trainer.
9776877|NCT01065506|Active Comparator|Standard Care plus Wellness Program|
9776878|NCT01065506|Active Comparator|Standard Care plus Exercise Program|
9776879|NCT01065558|Experimental|Ecopipam 12.5 - 200 mg/day|Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
9776880|NCT01065571|Experimental|carrageenan-free diet with placebo|This is the experimental arm in which subjects will be on a no-carrageenan diet and receive placebo capsules. This will test whether the no carrageenan diet leads to longer relapse-free interval for patients with ulcerative colitis.
9776881|NCT01065571|Active Comparator|carrageenan-free diet w/ carrageenan|The carrageenan-free diet with carrageenan supplement will mimic the carrageenan normally consumed in the diet. The study will permit blinded comparison of carrageenan-free vs. carrageenan consumption.
9776882|NCT01065597|Experimental|Nonconvulsive electrotherapy|Open label single arm study of nonconvulsive electrotherapy
9776883|NCT01065714|Experimental|Hydrogel vehicle|Parallel designed study. Split body treatment
9776884|NCT01065714|Active Comparator|Eucerin Lotion|Parallel study design. Split body study.
9776885|NCT01065766||All participants|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin
9776886|NCT01065844|Experimental|Nelfinavir|1250 mg Nelfinavir twice daily Monday-Sunday
9776887|NCT01066000|Experimental|Mircera|
9776888|NCT01066026|Experimental|Metallic cannula|Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool
9776889|NCT01066026|Active Comparator|Standard needle|Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.
9776890|NCT01066039|Experimental|Bisoprolol|
9776891|NCT01066052|Experimental|r-hGH|Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
9776892|NCT01066052|No Intervention|Historical Control|This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.
9776893|NCT01066104|Placebo Comparator|Xolair placebo|Xolair placebo 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg) ). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
9984322|NCT04223037|Experimental|Day 0，28 immunization shedule|Japanese Encephalitis Vaccine produced by IMBCAMS Dosage form: 0.5mL/vial Two Dose injection with 28 days interval
9776894|NCT01066104|Active Comparator|Xolair (omalizumab)|Xolair (omalizumab) 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
9776895|NCT01066143|Experimental|Seroquel XR|
9776896|NCT01066156|Experimental|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
9776897|NCT01066364|Placebo Comparator|Placebo (sugar) pill|Six tablets per day (identical to colesevelam)
9776898|NCT01066364|Experimental|Colesevelam arm|3.75 grams per day
9776899|NCT01066520|Experimental|Traumeel S ointment|Traumeel S ointment 2 g, 3 times daily topical during 14 days
9776900|NCT01066520|Experimental|Traumeel S gel|Traumeel S gel 2 g, 3 times daily topical during 14 days
9776901|NCT01066520|Active Comparator|Diclofenac gel|Diclofenac gel 2 g, 3 times daily topical during 14 days
9776902|NCT01066546|Experimental|Dimebon|
9776903|NCT01066585|Experimental|0.5% Ivermectin Cream|
10204140|NCT04117815||reference group|"For the purpose of comparison, a reference sample will be included in the study applying to the following inclusion criteria:~Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen Refuse to undergo scalp cooling Patients who have been excluded for the study group for the reason of migraine Written informed consent Age 18 and older~Patients from the reference group complete the same survey as the study group. Group comparisons will be adjusted for baseline body image and reasons for refusal."
10204141|NCT04117360||Dentofacial Disharmony Patients|Dentofacial disharmony patients who are seeking jaw surgery in UNC oral and maxillofacial surgery department and are seen in UNC orthodontic dentofacial disharmony clinic.
9776904|NCT01066585|Placebo Comparator|Vehicle control|
9776905|NCT01066624|Active Comparator|0.9% Sodium Chloride irrigation solution|Standard of care for prevention and management of oral mucositis (0.9% Sodium Chloride irrigation solution): Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study.
9776906|NCT01066624|Active Comparator|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion. After patients are done with the cryotherapy they will follow the standard of care for prevention and management of oral mucositis until the end of the study.
9776907|NCT01066624|Active Comparator|Calcium phosphate (Caphosol) mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
9776908|NCT01066780|Experimental|Group A: ClearVoice Medium|Chronic use of ClearVoice MEDIUM for two weeks followed by chronic use of ClearVoice HIGH for two weeks.
9776909|NCT01066780|Experimental|Group B: ClearVoice High|Chronic use of ClearVoice HIGH for two weeks followed by chronic use of ClearVoice MEDIUM for two weeks.
9776910|NCT01066793||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6
9776911|NCT01066819||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.
9776912|NCT01066871|Experimental|Sprifermin (AS902330) 10 mcg|
9776913|NCT01066871|Experimental|Sprifermin (AS902330) 30 mcg|
9776914|NCT01066871|Experimental|Sprifermin (AS902330) 100 mcg|
9776915|NCT01066871|Placebo Comparator|Placebo|
9785761|NCT01259401|Experimental|SIP group|The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
10204142|NCT04111549|Experimental|Home-based telehealth GOALS|Participants in this arm will receive the GOALS intervention via in-home video telehealth.
10204143|NCT04111549|Active Comparator|In-person GOALS|Participants in this arm will receive the GOALS intervention in the traditional in-person format.
10204144|NCT04103073||Study group|The patient with OSAS 35-70 years of age, clinically stabile, symptoms such as snoring, breathing cessations, and daytime sleepiness, and polysomnographic evidence consistent with mild (5<apnea hypopnea index (AHI)< 15) to moderate (16 < AHI < 30) OSAS.
10204145|NCT04095429|Experimental|Expect Respect Support Group|"Experimental: Expect Respect Support Group Expect Respect is a program intended to create safe, trauma-informed space for young people who have been exposed to violence, to promote positive bystander intervention and healthy relationship skills, to alter norms that foster TDV/SV perpetration, and reduce violence perpetration through weekly support groups with students at elevated risk for such perpetration. Youth with prior history of exposure to violence are invited to in-school gender specific support groups that take place over 24 in-classroom sessions.~Expect Respect addresses violence perpetration prevention with youth already exposed to violence by recognizing violence as a problem that is fueled by gender norms that promote dominance and challenging the need to control and exert power in relationships especially with the use of violence, while simultaneously strengthening emotion regulation, social skills, and connectedness."
10204146|NCT04095429|Active Comparator|Enhanced Usual Care|Comparator: Enhanced Usual Care The control arm will receive enhanced usual care. Enhanced care means that the investigators will ensure each school has information, resource lists, and connection to services for individual youth who are referred to the study, including warm referrals to victim service agencies, behavioral health services, as well as resources (e.g., assistance with food insecurity, and so forth).
10205352|NCT02560805|Experimental|Veterans|Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.
9776916|NCT01066897|Experimental|Pramipexole|Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.
9776917|NCT01066897|No Intervention|Healthy Controls|Non depressed, non-intervention comparison group
9776918|NCT01066923|Experimental|Daily ASA, Active cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, aspirin immediately post exercise
9776919|NCT01066923|Experimental|Daily ASA, Active cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, placebo immediately post exercise
9776920|NCT01066923|Experimental|Daily ASA, Passive cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
9776921|NCT01066923|Experimental|Daily ASA, Passive cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
9776922|NCT01066923|Experimental|Daily placebo, active cool, Acute ASA|Two weeks of daily placebo prior to exercise, active cooling following exercise, aspirin immediately post exercise
9776923|NCT01066923|Experimental|Daily placebo, active cool, Acute placebo|Two weeks of daily placebo prior to exercise, active cooling following exercise, placebo immediately post exercise
9776924|NCT01066923|Experimental|Daily placebo, Passive cool, Acute ASA|Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
9776925|NCT01066923|Placebo Comparator|Daily placebo, Passive cool, Acute placebo|Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
9776926|NCT01067105|Experimental|ciclesonide|ciclesonide HFA 160 μg once daily
9776927|NCT01067144|Placebo Comparator|Control|Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively
9776928|NCT01067144|Experimental|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
9776929|NCT01067326|Active Comparator|Aliskiren|150 mg Aliskiren once daily for a period of 4 months.
9776930|NCT01067326|Placebo Comparator|Placebo|1 pill per day by mouth for 4 months.
9776931|NCT01067339|Experimental|Darapladib|Subjects randomized to this arm will receive a darapladib tablet, 160 mg, by mouth, once per day for 6 months.
9776932|NCT01067339|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a placebo tablet matching the study drug, once per day for 6 months.
9776933|NCT01067352|Experimental|Group A (A1)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
9776934|NCT01067352|No Intervention|Group A (A2)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
9776935|NCT01067352|No Intervention|Group B|Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
9776936|NCT01067456|No Intervention|Dedicated CT arm|Subjects in this arm will continue to receive standard of care - that is the dedicated CT protocol to rule out either aortic dissection or acute coronary syndrome or pulmonary embolism.
9776937|NCT01067456|Experimental|Comprehensive Cardiothoracic CT arm|The intervention consisted in a change of the routine CT protocol (as in dedicated CT protocol) to a comprehensive cardiothoracic CT protocol which includes changes in contrast injection and coverage to enable evaluation of the presence of acute coronary syndrome/aortic dissection/pulmonary embolism in a single scan.
9776938|NCT01067469|Experimental|Standard Dose Bevacizumab|Bevacizumab 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
9776939|NCT01067469|Experimental|Low Dose Bevacizumab + Lomustine|Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
9776940|NCT01067508|Experimental|Fiji Water|Participants are asked to consume one liter of this silicon-rich water daily for three months.
9776941|NCT01067508|No Intervention|Aquafina Water|Participants are asked to drink one liter of this deionized water daily for three months.
9776942|NCT01067716|Experimental|Refractive Error|
9776943|NCT01067768|Experimental|Daily review|In the intervention group a nurse reviewed daily, by using a checklist designed for this study, the indications and pertinence of the catheter. If it was not indicated she asked the doctor to order the removal of the catheter, but the doctor would make the final decision.
9776944|NCT01067768|No Intervention|Routine care|In the control group, the attending team would remove the catheter as routine, without any suggestion by the research protocol.
9776945|NCT01067781|Experimental|1|Two vaccination regimen with an LT patch (no swabbing)
9776946|NCT01067781|Experimental|2|Two vaccination regimen with an LT patch (with swabbing)
9776947|NCT01067781|Placebo Comparator|3|Two vaccination regimen with a placebo patch (no swabbing)
9776948|NCT01067781|Placebo Comparator|4|Two vaccination regimen with a placebo patch (with swabbing)
9776949|NCT01067846|Experimental|DCS and Cognitive Behavioral Therapy|Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
9776950|NCT01067846|Placebo Comparator|Placebo and Cognitive Behavioral Therapy|Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
9776951|NCT01067976|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw [0.1 ml/kg bw] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
9776952|NCT01068158|Experimental|0.5% Ivermectin Cream|Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
9776953|NCT01068158|Placebo Comparator|Vehicle control|Up to 4 ounces of topical control applied to hair and scalp on day 1.
9776954|NCT01068262|Experimental|Panel A - Odanacatib|Panel A - Healthy male subjects receiving Odanacatib
9776955|NCT01068262|Placebo Comparator|Panel A - Placebo|Panel A - Healthy male subjects receiving placebo
9776956|NCT01068262|Experimental|Panel B - Odanacatib|Panel B - Healthy female subjects receiving Odanacatib
9776957|NCT01068262|Placebo Comparator|Panel B - Placebo|Panel B - Healthy female subjects receiving placebo
9776958|NCT01068418|Experimental|Vitamin D3|15000IU of vitamin D3 daily: open-label, single-arm
9776959|NCT01068509|Experimental|Non-randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs. The 6-8 injections contained ~ 60 × 10^6 dendritic cells. Following evaluation after the first dose, participants received additional injections as described for the randomized Cvac group below.
9776960|NCT01068509|Experimental|Randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs every 4 weeks for 24 weeks (7 doses at Weeks 8, 12, 16, 20, 24, 28, and 32), and then every 8 weeks for 24 weeks (3 doses at Weeks 40, 48, and 56). The 6-8 injections contained ~ 60 × 10^6 dendritic cells.
9776961|NCT01068509|No Intervention|Observational standard of care|Participants in this group did not receive any treatment during the study.
9776962|NCT01068548|No Intervention|Arm 1|pre-implementation of computer based intervention
9776963|NCT01068548|Experimental|Arm 2|post-implementation of computer based length of stay clinical reminder
9776964|NCT01068600|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9776965|NCT01068600|Placebo Comparator|Placebo|"Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9776966|NCT01068626|Active Comparator|Rosuvastatin|
9776967|NCT01068626|Placebo Comparator|Placebo for Rosuvastatin|
9776968|NCT01068652|Active Comparator|Detemir + Met|Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.
9776969|NCT01068652|Active Comparator|BIAsp 30 + Met|Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
9776970|NCT01068665|Experimental|IDeg 200 U/mL OD|
9776971|NCT01068665|Active Comparator|IGlar OD|
9776972|NCT01068678|Experimental|IDeg 3 times weekly (3TW)|
9776973|NCT01068678|Active Comparator|IGlar OD|
9776974|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
9776975|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)|Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
9776976|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
9776977|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)|Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
9776978|NCT01068730|Other|Treatment A|500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
9776979|NCT01068730|Other|Treatment B|500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
9776980|NCT01068730|Other|Treatment C|1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
9776981|NCT01068730|Other|Treatment D|1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
9776982|NCT01068743|Other|Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.
9776983|NCT01068743|Other|Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.
9776984|NCT01068743|Other|Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.
9776985|NCT01068743|Other|Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.
9776986|NCT01068769|Experimental|Regorafenib|Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle
9776987|NCT01068821|Active Comparator|Egg crate foam mattress|Patients will be placed on egg-crate foam mattress instead of a gel pad by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
9776988|NCT01068821|Active Comparator|Gel pad|Patients will be placed on gel pad instead of egg-crate foam mattress by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
9776989|NCT01068860|Experimental|Canakinumab 150 mg + Metformin|Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
9776990|NCT01068860|Placebo Comparator|Placebo + Metformin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
9776991|NCT01068860|Experimental|Canakinumab 150 mg + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
9776992|NCT01068860|Placebo Comparator|Placebo + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
9776993|NCT01068860|Experimental|Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
9776994|NCT01068860|Placebo Comparator|Placebo + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
9785762|NCT01259401|Active Comparator|Control group|The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care
9776995|NCT01068860|Experimental|Canakinumab 150 mg + Insulin|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
9776996|NCT01068860|Placebo Comparator|Placebo + Insulin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
9776997|NCT01068860|Experimental|Canakinumab 150 mg in patients with IGT|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
9776998|NCT01068860|Placebo Comparator|Placebo in patients with IGT|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
9776999|NCT01068873|Experimental|open label single arm|Drug: lopinavir/ritonavir plus maraviroc
9777000|NCT01068912|Experimental|1: Experimental|Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days
9777001|NCT01068912|Experimental|2: Experimental|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
9777002|NCT01068912|Placebo Comparator|Placebo|Placebo
9777003|NCT01068964|Experimental|0.03% Bimatoprost/0.5% Timolol in Same Bottle|Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
9777004|NCT01068964|Active Comparator|0.03% Bimatoprost and 0.5% Timolol in Separate Bottles|Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
9777005|NCT01069003|Placebo Comparator|Placebo Arm|Subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
9777006|NCT01069003|Active Comparator|Thienopyridine Therapy|Subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
9777007|NCT01069003|Other|Surveillance Arm|Non randomized subjects followed through 24 months
9777008|NCT01069172|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery group (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device. If necessary, ultrasound (U/S) phacoemulsification will also be applied to facilitate removal of the crystalline lens during cataract surgery.
9777009|NCT01069172|Active Comparator|CCC Surgery|For the continuous curvilinear capsulorhexis (CCC) group (CCC Surgery), subjects will receive the standard of care for CCC and U/S phacoemulsification surgery to facilitate removal of the crystalline lens during cataract surgery.
9777010|NCT01069185|Experimental|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
9777011|NCT01069185|Other|Routine endotracheal suctioning|Endotracheal suctioning every two hours
9777012|NCT01069289|Experimental|1|Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
9777013|NCT01069289|Active Comparator|2|Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily
9777014|NCT01069315|Experimental|Normal saline and High pressure|Irrigation with normal saline delivered at high pressure
9777015|NCT01069315|Experimental|Soap solution and High pressure|Irrigation with soap solution delivered at high pressure
9777016|NCT01069315|Experimental|Normal saline and Low pressure|Irrigation with saline solution delivered at low pressure
9777017|NCT01069315|Experimental|Soap solution and Low pressure|Irrigation with soap solution delivered at low pressure
9777018|NCT01069341|Other|Treatment|All subjects enrolled received treatment with identical dosage of Ranibizumab
9777019|NCT01069354|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
9777020|NCT01069354|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
9777021|NCT01069419||Cimzia|All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC
9777022|NCT01069484|Experimental|Postpartum pelvic floor muscle training|Beyond a customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the participants are given supervised pelvic floor muscle group training led by physiotherapists once a week. In addition, the participants train every day at home, with at least 3 sets of 8-12 contractions. Training period is 4 months.
9777023|NCT01069484|No Intervention|Control|Beyond the customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the control group participants received no further intervention. They were not discouraged from doing PFMT on their own.
9777024|NCT01069510|Placebo Comparator|Placebo|Patients will receive placebo
9777025|NCT01069510|Experimental|Spironolactone|Spironolactone 25 mg daily
9777026|NCT01069523|Placebo Comparator|Placebo|Patients will be started on 1 mg of guanfacine extended release matching placebo tablets at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
9777027|NCT01069523|Experimental|Guanfacine Extended Release|Patients will be started on 1 mg of guanfacine extended release at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
9777028|NCT01069562|Active Comparator|MANUAL|In the manual group isoflurane was administered using Tech 7 vapouriser. The dial setting was controlled by the anesthesiologist to achieve and maintain a BIS of 50 during anesthesia.
9777029|NCT01069562|Experimental|IAADS group|In this group, liquid isoflurane was injected into the circuit using a syringe pump controlled by the IAADS system.The IAADS system has the algorithm to regulate the rate of infusion of isoflurane such that BIS is achieved and maintained at 50 during anesthesia.
9777030|NCT01069627|Experimental|1|
9777031|NCT01069705|Experimental|Tobramycin Inhalation Powder (TIPnew)|Participants received four capsules of 28 mg TIPnew (112 mg), inhaled twice a day (b.i.d.) in the morning and the evening given in a cycle of 28 days on treatment followed by 28 days off treatment for three consecutive cycles.
9777032|NCT01069900|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride [NaCl solution]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
9777033|NCT01069900|Active Comparator|Comparator Ertapenem|Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
9777034|NCT01069939|Experimental|Esomeprazole 20mg|Esomeprazole 20mg once daily oral
9777035|NCT01069939|Placebo Comparator|Placebo|Placebo once daily oral
9777036|NCT01070043|Experimental|Amlodipine 5mg/Valsartan 80 mg|During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.
9777037|NCT01070043|Active Comparator|Valsartan 160 mg|In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.
9777038|NCT01070043|Other|Run-In Valsartan 80 mg|During run-in period, oral valsartan 80 mg once daily for 4 weeks.
9777039|NCT01070095|Experimental|Electronic Asthma Action Plan System|Electronic Asthma Action Plan System (eAAPS)
9777040|NCT01070173||Short Stature|Poor linear growth
9777041|NCT01070173||Poor Weight Gain (Failure-To-Thrive)|Poor Weight Gain
9777042|NCT01070173||Isolated Gastrointestinal Symptoms|No growth symptoms
9777043|NCT01070303|Experimental|Adalimumab 40 mg every other week or every week|
9777044|NCT01070316|Experimental|Everolimus|Subjects will be administered study drug if they meet study criteria after 4 weeks of baseline phase. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily.
9777045|NCT01070329|Experimental|Duloxetine|
9777046|NCT01070329|Placebo Comparator|Placebo|
9777047|NCT01070381|Other|nelfilcon A / ocufilcon D|Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
9777048|NCT01070381|Other|ocufilcon D / nelfilcon A|Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
9777049|NCT01070394|Experimental|LDX Treatment|Eligible participants received 12 weeks of open-label treatment. Those on treatment prior to baseline underwent a 7-day (for amphetamine or methylphenidate) or 28-day (for atomoxetine or other medications) washout period prior to initiating LDX treatment. The starting dose was 30mg/day, which could be titrated up by 20mg/day during visits 2-6 (for a maximum dose of 70mg/day). At discretion of investigator, the dose could be down-titrated by 20mg/day during visits 4-6. Once the dose was optimized (after visit 6), the dose was maintained for 8 weeks.
9777050|NCT01070550||Cohort|Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.
9777051|NCT01070693|Experimental|Prolene Hernia System device|Inguinal hernia repair either with a bilayer mesh (PHS)
9777052|NCT01070693|Experimental|Lichtenstein|Inguinal hernia repair with the Lichtenstein technique
9777053|NCT01070784|Experimental|1|
9777054|NCT01070784|Active Comparator|2|
9777055|NCT01070810|Placebo Comparator|1|50 ml D5W
9777056|NCT01070810|Experimental|2|200mg Thiamine in 50ml D5W
9777057|NCT01070888|Experimental|Budesonide/Formoterol first|This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.
9777058|NCT01070888|Active Comparator|Budesonide first|This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.
9777059|NCT01070979|Experimental|Estradiol acetate (E3A)|
9777060|NCT01070979|Active Comparator|Estradiol|
9777061|NCT01070979|Active Comparator|Conjugated equine estrogens (CEE):|
9777062|NCT01071044|Active Comparator|Lisdexamfetamine Dimesylate|Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
9777063|NCT01071044|Placebo Comparator|Sugar pill|"Matching Placebo 30, 50 or 70 mg"
9777064|NCT01071070|Active Comparator|Group 1|Initial dosing based on a formula of intact parathyroid hormone value/80 (where intact parathyroid hormone value is the baseline value in pg/mL).
9777065|NCT01071070|Active Comparator|Group 2|Dose determined by US paricalcitol injection package insert dosing instructions (starting dose at 0.04 microgram/kg)
9777066|NCT01071083|Active Comparator|natalizumab|
9777067|NCT01071083|Placebo Comparator|IV placebo|
9777068|NCT01071083|Active Comparator|interferon β-1a, glatiramer acetate, or methylprednisolone|
9777069|NCT01071096|Active Comparator|OnabotulinumtoxinA|Minimum dose of 155 international units (U) OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
9777070|NCT01071096|Placebo Comparator|Saline|155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
9777071|NCT01071200|Experimental|A|Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)
9777072|NCT01071200|Active Comparator|B|Subjects treated with r-hFSH alone
9777073|NCT01071252|Experimental|AIN457 1x25mg|
9777074|NCT01071252|Experimental|AIN457 3x25mg|
9777075|NCT01071252|Experimental|AIN457 3x75mg|
9777076|NCT01071252|Experimental|AIN457 3x150mg|
9777077|NCT01071252|Placebo Comparator|Placebo|
9784915|NCT01237223|Active Comparator|Aliskiren 150 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
9784916|NCT01237223|Active Comparator|Amlodipine 2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
9984323|NCT04222660|Experimental|Type 2 diabetes without neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
9777078|NCT01071278||Patients treated within a disease management program|Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
9777079|NCT01071278||Patients treated outside a disease management program|Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
9777080|NCT01071317|Experimental|Comprehensive care|Reinforcement of diagnosis, education, medications, and referral
9777081|NCT01071317|Active Comparator|Typical care|Usual care
9777082|NCT01071356|Experimental|Intensive MI|9 hours of Motivational Interviewing + outpatient substance abuse treatment
9777083|NCT01071356|Active Comparator|Single session MI|1.5 hours of Motivational Interviewing + 8 hours of time equivalent nutrition classes +outpatient substance abuse treatment
9777084|NCT01071395|Experimental|Amantadine|Amantadine 100mg tab BID or TID for duration of study
9777085|NCT01071395|Placebo Comparator|Placebo|Placebo one tab BID or TID for duration of study
9777086|NCT01071512|Experimental|Tysabri|Natalizumab 300 mg IV every 4 weeks
9777087|NCT01071538|Experimental|Buprenorphine|Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
9777088|NCT01071798||Main Analysis Set|Participants who received at least one cycle of rituximab
9777089|NCT01071915|Experimental|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
9777090|NCT01071954|Experimental|Romiplostim|Participants received romiplostim administered by subcutaneous injection once a week. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of between 50 x 10^9/L and 200 x 10^9/L.
9777091|NCT01072006||Control Group|Control group without traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD)
9777092|NCT01072006||PTSD Group|PTSD (not TBI)
9777093|NCT01072006||TBI Group|TBI (no PTSD)
9777094|NCT01072006||TBI+PTSD Group|Combined TBI history and PTSD
9777095|NCT01072032|Experimental|Low-Reward|Low-Reward Anklebot training Group: The low reward-feedback group receives the Anklebot training with only immediate feedback on target successes, without cumulative scores and with minimal social interaction with the research team.
9777096|NCT01072032|Active Comparator|High-Reward|High-Reward Anklebot training Group: The high-reward group receives cumulative scores and abundant social interaction and are eligible for prizes during each training session and at completion of the study
9777097|NCT01072136|Placebo Comparator|Placebo|Placebo.
9777098|NCT01072136|Experimental|Azithromycin/Cefixime|A single dose of cefixime 400 mg (1 tablet oral at 400 mg) and azithromycin 1 gram (2 tablets oral at 500 mg each).
9777099|NCT01072149|Experimental|50mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9777100|NCT01072149|Experimental|100mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9777101|NCT01072149|Experimental|200mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
9777102|NCT01072149|Placebo Comparator|placebo|placebo
9777103|NCT01072188|Active Comparator|ProClude Prophylaxis paste-A|Arginine Bicarbonate prophylaxis paste
9777104|NCT01072188|Placebo Comparator|Nupro-M Prophylaxis paste -B|Control prophylaxis paste (Fluoride free - placebo)
9777105|NCT01072201|Experimental|Total toothpaste|Triclosan/copolymer/fluoride toothpaste
9777106|NCT01072201|Placebo Comparator|Ultrabrite toothpaste|Fluoride Toothpaste
9777107|NCT01072331|Experimental|MP-513 10 mg, once a day, for 4 weeks|
9777108|NCT01072331|Experimental|MP-513 20 mg, once a day, for 4 weeks|
9777109|NCT01072331|Placebo Comparator|Placebo of MP-513|
9777110|NCT01072344|Experimental|Chamomile Extract|Pharmaceutical grade oral chamomile extract.
9777111|NCT01072344|Placebo Comparator|Placebo|Pharmaceutical grade lactose monohydrate.
9777112|NCT01072357|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 milliliter (mL) (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
9777113|NCT01072357|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% sodium chloride (NaCl). Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
9777114|NCT01072396|Active Comparator|18 mcg tiotropium|Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
9777115|NCT01072396|Placebo Comparator|Placebo|Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
9777116|NCT01072396|No Intervention|Control|Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
9777117|NCT01072409|Other|Single Arm|Single arm design
9777118|NCT01072448|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9777119|NCT01072448|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
9777120|NCT01072500|Active Comparator|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
9777121|NCT01072500|Active Comparator|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
9777122|NCT01072539||Patients who have approved indications of Tygacil|"Approved indications of Tygacil~-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia"
9777123|NCT01072617|Experimental|Safety of rTMS in schizophrenia patients|Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
9777124|NCT01072630|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
9777125|NCT01072630|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
9777126|NCT01072630|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
9777127|NCT01072643|Experimental|Dexmedetomidine|To study safety of DEX with regard to effect on PVR; There will be 3 study groups (n=8 per group). The groups will be based on DEX doses as follows- Group 1 - Bolus 1 mcg/kg followed by infusion 0.7 mcg/kg/hr Group 2 - Bolus 1.5 mcg/kg followed by infusion 1.05 mcg/kg/hr Group 3 - Bolus 2 mcg/kg followed by infusion 1.4 mcg/kg/hr
9777128|NCT01072656|Active Comparator|Treatment group|Active stimulation and programmed to the settings found to be optimal during the titration process.
9777129|NCT01072656|Sham Comparator|Control group|IPG is set to ON but the voltage is set to 0V.
9777130|NCT01072669|Active Comparator|ambrisentan|"drug arm~use of ambrisentan in limited scleroderma patients with raynaud's to evaluate digital microvascular flow"
9777131|NCT01072669|Placebo Comparator|sugar pill|those getting sugar pill to evaluate if the active drug improves digital microvascular flow in limited scleroderma patients
9777132|NCT01072773|Experimental|Bortez/Cyc/Dex|Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
9777133|NCT01072877|Experimental|Polidocanol injectable foam 0.125%|Polidocanol injectable foam 0.125%
9777134|NCT01072877|Experimental|Polidocanol injectable foam 0.5%|Polidocanol injectable foam 0.5%
9777135|NCT01072877|Experimental|Polidocanol injectable foam 1.0%|Polidocanol injectable foam 1.0%
9777136|NCT01072877|Experimental|Polidocanol injectable foam 2.0%|Polidocanol injectable foam 2.0%
9777137|NCT01072877|Placebo Comparator|Vehicle|Injection of vehicle comparator
9777138|NCT01072929|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
9777139|NCT01072929|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
9777140|NCT01072929|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
9836099|NCT02769065|Experimental|SRD: Cohort 19: TAK-071 160 mg|TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
9777141|NCT01073020|Active Comparator|Gastric Band vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) laparoscopic placement of an adjustable gastric band (LAGB) or 2) treatment with an intensive medical and weight management (IMWM) program.~LAGB will be placed using the pars flaccida technique. The Allergan laparoscopic band LAP BAND system will be utilized. LAGB ports will be placed in subcutaneous pockets in the right upper abdomen.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
9777142|NCT01073020|Active Comparator|RYGB vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) Roux-en-Y gastric bypass (RYGB) surgery or 2) treatment with an intensive medical and weight management (IMWM) program.~RYGB will be performed using a 75 cm antecolic, ante-gastric Roux limb created with a 50 cm pancreaticobiliary limb. A 15-20 cc gastric pouch will be created lying along the lesser curve of the stomach, with division of the vagal trunks at the lower border of the pouch.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
9777143|NCT01073163|Experimental|Bendamustine with Rituximab|Participants were administered bendamustine intravenous (IV) infusion at 90 mg/m^2 on Days 1 and 2 of each 28-day cycle, and rituximab IV infusion at 375 mg/m^2 on Day 1 of each 28-day cycle.
9777144|NCT01073267|Experimental|TSEBT|Total Skin Electron Beam Therapy (TSEBT) to dose of 12 Gy
9777145|NCT01073293|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
9777146|NCT01073293|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
9777147|NCT01073449||Cardiac device|All patients implanted with a cardiac device, pacemaker(PM)or Implantable Cardioverter Defibrillator (ICD)
9777148|NCT01073462||Paricalcitol IV|Participants with chronic kidney disease stage 5 with secondary hyperparathyroidism and cardiac morbidity received intravenous (IV) paricalcitol (Zemplar) prescribed according to current practice with regards to dose, population and indication for up to 2 years.
9777149|NCT01073566|Experimental|Finesse|Finesse Insulin Delivery Patch
9777150|NCT01073566|Active Comparator|Usual injection device|Pen/Syringe
9777151|NCT01073605|Active Comparator|Genotonorm A|Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
9777152|NCT01073605|Active Comparator|Genotonorm B|Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
9777153|NCT01073605|Active Comparator|Genotonorm C|Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day
9777154|NCT01073618||A.|Patients who are indicated for VFEND according to drug package insert.
9777155|NCT01073631||1|Patients who are indicated for use of voriconazole tablet.
9777156|NCT01073657|Experimental|Supported Education|Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
9777157|NCT01073657|Active Comparator|General Peer Support|Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.
9777158|NCT01073865|Experimental|1|"Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days).~One oral tamoxifen 20 mg tablet also will be taken daily"
9777159|NCT01073865|Active Comparator|2|Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.
9777160|NCT01073930|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy."
9777161|NCT01073930|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
9777162|NCT01073943|Experimental|PicoPrep|"Day Before method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy."
9777163|NCT01073943|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
9777164|NCT01074008|Experimental|ABT-450/r (50/100 mg) once daily (QD) + pegIFN/RBV|Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9777165|NCT01074008|Experimental|ABT-450/r (100/100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9777166|NCT01074008|Experimental|ABT-450/r (200/100 mg) once daily (QD) + pegIFN/RBV|Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
10204147|NCT04083274|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
9777167|NCT01074008|Experimental|ABT-072 (100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9777168|NCT01074008|Experimental|ABT-072 (300 mg) once daily (QD) + pegIFN/RBV|Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9777169|NCT01074008|Experimental|ABT-072 (600 mg) once daily (QD) + pegIFN/RBV|Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9777170|NCT01074008|Experimental|ABT-333 (400 mg) twice a day (BID) + pegIFN/RBV|Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9777171|NCT01074008|Experimental|ABT-333 (800 mg) twice daily (BID) + pegIFN/RBV|Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9836100|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil Placebo|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.
10204148|NCT04083274|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
10204149|NCT04075110|Placebo Comparator|Control group|50 patients will receive metformin 2000mg/daily (Control group)
10204150|NCT04075110|Experimental|Montelukast group|50 patients will receive a combination of metformin 2000 mg/daily and montelukast (10 mg /day).
10204151|NCT04074668||Type 1 Diabetes|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
10204152|NCT04074668||Healthy Controls|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
10204153|NCT04065321||Control group|250 patients will be assigned into control group.
10204154|NCT04065321||Trial group|250 patients will be assigned into trial group.
9777172|NCT01074008|Placebo Comparator|Placebo + pegIFN/RBV|Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
9777173|NCT01074034|Experimental|AV Therapy Assessment group|appropriate system performance of the atrial and ventricular tachyarrhythmia therapies in the ASSURE device
9777174|NCT01074047|Experimental|Azacitidine|Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
9777175|NCT01074047|Active Comparator|Conventional Care Regimen|Conventional Care Regimen
9777176|NCT01074099|Active Comparator|Control|CABG only
9777177|NCT01074099|Experimental|BMAC enhanced CABG|Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
9777178|NCT01074125|Experimental|1 g/day|1 g/day KRX-0502 (ferric citrate)
9777179|NCT01074125|Experimental|6 g/day|6 g/day KRX-0502 (ferric citrate)
9777180|NCT01074125|Experimental|8 g/day|8 g/day KRX-0502 (ferric citrate)
9777181|NCT01074164|Placebo Comparator|Control group|This group of subjects will serve as the control group and will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids.
9777182|NCT01074164|Experimental|Accu-patch pellet|This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
9777183|NCT01074177|Experimental|BIBW 2992|BIBW 2992 Taken orally once a day
9777184|NCT01074216|Experimental|vitamin D, vitamin D3|This is a Phase II study involving Stage IV colorectal cancer patients with serum vitamin D deficiency, to determine the ability to correct vitamin D deficiency and to maintain serum vitamin D levels (25-hydroxy vitamin D) once achieved.
9777185|NCT01074229|Placebo Comparator|Placebo|sterile normal saline as placebo
9777186|NCT01074229|Active Comparator|Drug .5% Ropivacaine|Instillation of 20 cc of 0.5% ropivacaine
9777187|NCT01074229|Active Comparator|20 cc of 0.25% ropivacaine|Instillation of 20 cc of 0.25% ropivacaine
9777188|NCT01074242||Rotateq|Korean Infants vaccinated with Rotateq in usual practice. The Rotateq vaccination series consists of 3 ready-to-use liquid (oral) doses with the first dose to be administered at age 6-12 weeks and subsequent doses to be administered at 4 to 10-week intervals.
10204155|NCT04061720|Experimental|Enhanced Chronic Care|Enhanced Chronic Care provides ongoing, phone-based motivational interventions and interpersonal support to promote readiness to quit, with facilitated access to evidence-based smoking treatment.
10204156|NCT04061720|Active Comparator|Standard Care|Standard Care provides phone-based brief advice to quit once per year.
10204157|NCT04059003||Sensitivity group|100 patients will be assigned into sensitivity group according to the actual situation of them.
9777189|NCT01074255||Korean Participants Treated With EMEND (aprepitant)|Participants receiving EMEND on Treatment Days 1, 2, and 3 concomitantly with a corticosteroid and a 5-hydroxytryptamine 3 (5-HT3) antagonist.
9777190|NCT01074268|Experimental|IDeg OD|
10204158|NCT04059003||Drug resistance group|100 patients will be assigned into drug resistance according to the actual situation of them.
9777191|NCT01074268|Active Comparator|IDet|
9777192|NCT01074307|Experimental|Low Dose Bisoprolol|
9777193|NCT01074307|Experimental|High Dose Bisoprolol|
9777194|NCT01074450|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
9777195|NCT01074450|Active Comparator|2|Mirapex® 0.25 mg Tablets
9777196|NCT01074463|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
9777197|NCT01074463|Active Comparator|2|Mirapex® 0.25 mg Tablets
9777198|NCT01074554|Experimental|Antibiotic Regimen|"The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.~All four drugs are given concomitantly."
9777199|NCT01074554|Placebo Comparator|Placebo Regimen|The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
9777200|NCT01074658||severe aortic valve stenosis|elderly patients with severe aortic valve stenosis requiring treatment
9777201|NCT01074931||Lopinavir/ritonavir group|This study is a non-interventional, observational study in which lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of China market authorization with regards to dose, population and indication. It is planned to enroll approximately 100 patients in total.
9777202|NCT01074944|Experimental|Twice Daily (BID) Dose Regimen|Patients will receive either 50 mg BID or 100 mg BID
10204159|NCT04058535|Experimental|ALT-L9|Intravitreal injection of ALT-L9 50 ul, every 4 weeks
10204160|NCT04058535|Active Comparator|Eylea|Intravitreal injection of Eylea 50 ul, every 4 weeks
10204161|NCT04055025|Other|Sleeve gastrectomy operated patients|Six test days in a randomized, patient-blinded, cross-over design
10204162|NCT04054973|Experimental|L-arginine and Kuvan|Open-label single arm study, all participants will be in this group
10204163|NCT04050410|Experimental|Moxonidine|Patients will receive a single oral dose of moxonidine 0.4 mg.
10204164|NCT04050410|Placebo Comparator|Placebo|Patients will receive a single oral dose of placebo.
10204165|NCT04046575|Experimental|IMRT + Carboplatin + Paclitaxel|Concurrent chemoradiation will consist of hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) for 3 weeks with carboplatin and paclitaxel for 3 cycles every 7 days. Endoscopy and (optional) PET/CT within 6-8 weeks post-completion of chemoradiation.
10205353|NCT02560805|Experimental|Control|Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.
9777203|NCT01074944|Experimental|Once Daily (QD) Dose Regimen|Patients will receive either 100 mg QD or 200 mg QD
9777204|NCT01075048|Experimental|Phase 2: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
9777205|NCT01075048|Placebo Comparator|Phase 2: Placebo, cetuximab, irinotecan|Placebo in combination with irinotecan and cetuximab
9777206|NCT01075048|Experimental|Phase 1: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
9777207|NCT01075074|Active Comparator|Ropivacaine 0.05%|Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side
9777208|NCT01075074|Placebo Comparator|Normal Saline|Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.
9777209|NCT01075074|Active Comparator|Ropivacaine 0.25%|Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side
9777210|NCT01075087|Placebo Comparator|Placebo|(control group) will receive sterile normal saline in the block
9777211|NCT01075087|Active Comparator|Active comparator|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
9777212|NCT01075100|Experimental|Weekly Ixabepilone +carboplatin|Subjects will receive ixabepilone and carboplatin on Days 1 and 8 of each 21-day cycle.
9777213|NCT01075152|Experimental|Earlier HIV Therapy|HIV therapy initiated at 7-13 days of cryptococcal meningitis diagnosis. HIV therapy consisting of a nucleoside with lamivudine and efavirenz.
9777214|NCT01075152|Active Comparator|Deferred HIV Therapy|"HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week).~HIV therapy consisting of a nucleoside with lamivudine and efavirenz."
9777215|NCT01075178||Palivizumab-treated subjects (CASES)|HSCHD infants, <2 yrs old at first dose of palivizumab
9777216|NCT01075178||Non-palivizumab-treated subjects (CONTROLS)|HSCHD infants, <2 yrs old that did not receive palivizumab
9777217|NCT01075191||HIV-infected participants|"HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.~Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (three 133 mg/33 mg capsules twice daily or two 200 mg/50 mg tablets twice daily)."
9777218|NCT01075204||Clarithromycin modified release|Patients with upper or lower respiratory tract infection were administered clarithromycin modified release 500 mg once daily for 7 days and then followed for a further 3 days, per routine clinical practice.
9777219|NCT01075217|Experimental|Isovue 250 (iopamidol)|
9777220|NCT01075217|Active Comparator|Visipaque 270 (iodixanol)|
9777221|NCT01075243|Experimental|Paracetamol 1000mg|Paracetamol 1000mg
9777222|NCT01075243|Experimental|Paracetamol 650 mg|Paracetamol 650 mg
9777223|NCT01075243|Placebo Comparator|Placebo|Placebo
9777224|NCT01075256|Active Comparator|5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste.
9777225|NCT01075256|Active Comparator|7.5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste.
9777226|NCT01075256|Placebo Comparator|Placebo toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with placebo toothpaste.
9777227|NCT01075282|Experimental|LY2189265 1.5 mg|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
9777228|NCT01075282|Experimental|LY2189265 0.75 mg|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
9777229|NCT01075282|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
9777230|NCT01075321|Experimental|Arm I|Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
9777231|NCT01075347|Active Comparator|Autologous serum use|Patients treated with additional 20% autoserum after diabetic vitrectomy or penetrating keratoplasty
9777232|NCT01075347|Placebo Comparator|Non-autologous serum use|Patients treated with traditional medication(0.1% betamethasone, 0.3% gentamicin and 0.4% tropicamide eye drops application 4 times daily) after diabetic vitrectomy or penetrating keratoplasty
9777233|NCT01075399|Experimental|[F 18]HX4|[F18]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.
9777234|NCT01075412|Experimental|Group 2|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
9777235|NCT01075412|Experimental|Group 1|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
9777236|NCT01075516||Standard Follow Up|ICD patients followed through periodic in-hospital visits
9777237|NCT01075516||Remote Follow Up|ICD patients followed with remote transmitters (Merlin@Home) that periodically communicate correct system functioning
9777238|NCT01075646|Experimental|Ropivacaine|After a bolus administration of Ropivacaine a perfusion ot the same anesthetic is initiated through an elastomeric wound during 48 hours
9777239|NCT01075646|Placebo Comparator|saline solution|After a bolus administration of saline solution a perfusion ot saline solution is initiated through an elastomeric wound during 48 hours
9777240|NCT01075685|Experimental|Web-based alcohol programme|"Participants could log on to their account and access the programme whenever they wanted to.~They received automated email reminders inviting them to use follow-up tools, especially the diary in order to register their alcohol intake on the previous week:~4 weeks after starting the programme, so that they would take advantage of the monitoring stage in case they had not spontaneously done so.~2 weeks later for 6-week follow-up."
9777241|NCT01075685|Placebo Comparator|Minimum information|Participants could log on to their account and access the programme whenever they wanted to. At 6 week follow-up they received an automated email reminder inviting them to use the diary in order to register their alcohol intake on the previous week.
9777242|NCT01075763|Experimental|Treatment arm - Rebif®|Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)
9777243|NCT01075763|Placebo Comparator|Placebo arm|Subjects in this arm received placebo
9777244|NCT01075815|Experimental|rFSH + rhLH|Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.
9777245|NCT01075815|Active Comparator|rFSH|rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.
9777246|NCT01075971|Experimental|Buprenorphine hydrochloride|
9777247|NCT01075984|Active Comparator|POS IV 200 mg single dose (Cohort 0)|POS 200 mg IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
9777248|NCT01075984|Placebo Comparator|Dextrose 5% in water (Cohort 0)|Placebo IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
9777249|NCT01075984|Experimental|POS IV 200 mg BID (Cohort 1)|POS 200 mg IV infused over 1.5 hours BID on Day 1, followed by POS 200 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 1)
9777250|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 2)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 2). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
9777251|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 3)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 5, then by POS 200 mg oral TID or POS 400 mg oral BID through Day 28, or POS 200-300 mg IV once daily as required (Cohort 3). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
9777252|NCT01076010|Experimental|Sorafenib crossover to tivozanib.|The subjects who failed sorafenib (had Response Evaluation Criteria in Solid Tumors [RECIST] - defined progressive disease) on the parent protocol AV-951-09-301 will be offered tivozanib hydrochloride on Protocol AV- 951-09-902.
9777253|NCT01076010|Experimental|First line tivozanib.|The subjects who were randomized to tivozanib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability in Protocol AV-951-09-301.
9777254|NCT01076010|Active Comparator|First line sorafenib.|The subjects who were randomized to sorafenib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability were to be offered long-term access to sorafenib.
9777255|NCT01076036|Experimental|CorPath 200 System|Robotic-assisted PCI with the CorPath 200
9777256|NCT01076049|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, the preferred irrigation solution was chosen by the site's emergency department physician(s).
9777257|NCT01076049|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
9777258|NCT01076075|Active Comparator|placebo/pioglitazone|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
9777259|NCT01076075|Experimental|Sitagliptin|Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone
9777260|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 500 mg|Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
9777261|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 850 mg|Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
9777262|NCT01076088|Active Comparator|Metformin 500 mg|Metformin 500 mg twice daily for 24 weeks.
9777263|NCT01076088|Active Comparator|Metformin 850 mg|Metformin 850 mg twice daily for 24 weeks.
9777264|NCT01076088|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
9777265|NCT01076088|Placebo Comparator|Placebo|Matching placebo tablets for 24 weeks.
9777266|NCT01076153||Patients with respiratory tract infection|Thai patients with upper or lower respiratory tract infections on Klacid MR.
9777267|NCT01076166||Children with lower respiratory tract infection|Thai children with lower respiratory tract infections on Klacid Granules for Oral Suspension
9777268|NCT01076179||Human Immunodeficiency Virus (HIV)-Infected Participants|HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists
9777269|NCT01076192||Moderate-to-severe chronic plaque psoriasis|Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice
9777270|NCT01076205||Adalimumab|Adults with moderate to severe active rheumatoid arthritis (RA) who initiated adalimumab therapy during routine clinical care.
9777271|NCT01076231|Experimental|Arm I|"Patients undergo proton beam radiotherapy over 5.5-7.5 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and days 29-33.Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 4-6 weeks after completion of chemoradiotherapy, patients may undergo surgical resection or additional chemoradiotherapy."
9777272|NCT01076244|Other|Minimally invasive lumbar decompression|
9784917|NCT01237223|Active Comparator|Amlodipine 5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
9784918|NCT01237223|Experimental|Aliskiren/amlodipine 150/2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
9784919|NCT01237223|Experimental|Aliskiren/amlodipine 150/5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
9777273|NCT01076270|Experimental|Filgrastim and plerixafor for PBSC mobilization|"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.~After completion of study treatment, donors are followed up 1 day after the last stem cell donation."
9777274|NCT01076283|Active Comparator|Baclofen|Baclofen 10 mg three times a day (t.i.d.) for 8-10 days
9777275|NCT01076283|Placebo Comparator|Cyproheptadine|Cyproheptadine 2 mg t.i.d. for 8-10 days
9777276|NCT01076335|Experimental|Neoadjuvant Hormones + Docetaxel|Neoadjuvant Hormonal Therapy plus Docetaxel followed by Radical Prostatectomy
9777277|NCT01076400|Experimental|Part 1: MK-1775 + topotecan/cisplatin|Part 1: Dose escalation study. MK-1775 capsules will be administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
9777278|NCT01076400|Experimental|Part 2: MK-1775 + topotecan/cisplatin|Part 2: MK-1775 capsules will be administered at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
9777279|NCT01076400|Placebo Comparator|Part 2: Placebo to MK-1775 + topotecan/cisplatin|Part 2: Placebo to MK-1775 capsules will be administered twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
9777280|NCT01076452|Active Comparator|STN|Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
9777281|NCT01076452|Active Comparator|GPi|Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
9777282|NCT01076504|Experimental|Amrubicin/Carboplatin with Pegfilgrastim|Systemic therapy
9777283|NCT01076543|Experimental|Treatment (lenalidomide, temsirolimus)|Patients receive lenalidomide PO on days 1-21 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 2 courses may continue therapy for up to 52 weeks.
9777284|NCT01076647|Experimental|IDeg 3TW|
9777285|NCT01076647|Active Comparator|IGlar OD|
9777286|NCT01076686||Bupivacaine and low dose SKY0402|
9777287|NCT01076686||Bupivacaine and high dose SKY0402|
9777288|NCT01076686||Bupivacaine|
9777289|NCT01076686||High dose SKY0402|
9777290|NCT01076959||Humira|The sponsor was required to include all patients diagnosed with rheumatoid arthritis and who were treated Humira in routine medical practice during the review period by the PMDA. The safety analysis set included all patients who met all eligibility criteria and received at least one dose of Humira. The full analysis set included all patients who were treated with Humira for at least 2 weeks and had complete DAS 28 assessments at baseline and at least one other time point.
9777291|NCT01076972||Lopinavir/ritonavir group|All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
9777292|NCT01076985||Lopinavir/ritonavir group|All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
9777293|NCT01077024|Experimental|Smoking-cessation treatment + substance treatment as usual|
9777294|NCT01077024|No Intervention|Substance-treatment as usual|Treatment as usual is outpatient stimulant-dependence treatment as typically provided by the participating site.
9777295|NCT01077050|Other|SciBase III|Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.
9777296|NCT01077063|Active Comparator|paracentesis|cutting and draining procedure for malignant ascites
9777297|NCT01077063|Active Comparator|Pleurx catheter|a catheter drainage system the subject uses himself/herself.
9777298|NCT01077076|Experimental|Zegerid OTC Capsules|20 mg omeprazole and 1100 mg sodium bicarbonate
9777299|NCT01077076|Active Comparator|Prilosec OTC™ tablets containing 20 mg-equivalent omeprazole|20.6 mg omeprazole-magnesium complex.
9777300|NCT01077076|Placebo Comparator|Placebo|Inert substance
9777301|NCT01077128||Patients with psoriasis|All eligible patients with psoriasis treated with Adalimumab
9777302|NCT01077154|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once every 4 weeks for 6 months followed by placebo subcutaneous injections once every 3 months for 4.5 years.
9777303|NCT01077154|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneous injections once every 4 weeks for 6 months followed by denosumab 120 mg subcutaneous injections once every 3 months for 4.5 years.
9777304|NCT01077193|Other|Gastric Plication Surgery|
9777305|NCT01077258||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
9777306|NCT01077271||Premature infants 33 - 35 wGA prophylaxed with palivizumab|Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)
9777307|NCT01077284|Experimental|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
9777308|NCT01077284|Active Comparator|Allopurinol|Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
9777309|NCT01077284|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 6 months.
9777310|NCT01077310|Active Comparator|Intramuscular naltrexone|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
9777311|NCT01077310|Placebo Comparator|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
9777312|NCT01077323||Exenatide Initiators|
9777313|NCT01077323||Other Antidiabetic Drug Initiators|
9777314|NCT01077323||Non-Diabetes Cohort|
9777315|NCT01077362|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 40. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
9777316|NCT01077362|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 40. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
9777317|NCT01077362|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
9777318|NCT01077375|Placebo Comparator|Placebo|Placebo tablets, twice a day, oral administration
9777319|NCT01077375|Experimental|Milnacipran|Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses.
9777320|NCT01077401|Experimental|Ranibizumab 0.5mg|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
9777321|NCT01077401|Experimental|Ranibizumab 2.0 mg|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
9984324|NCT04222660|Experimental|Type 2 diabetes with neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
10204166|NCT04044209|Experimental|Patients receiving nivolumab and ivosidenib|"Patients who meet eligibility criteria will initiate therapy with the IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.~On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle. Patient will be treated until progression, transplant or unacceptable toxicity. The patient will be continually monitored on therapy and will undergo scheduled response assessments to evaluate response."
10204167|NCT04003389|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
10204168|NCT04003389|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
10204169|NCT04003389|Placebo Comparator|placebo|Participants will receive placebo for 52 weeks.
10204170|NCT03998813|Experimental|Locoregional analgesia by femoral triangle catheterization|
10204171|NCT03998813|Active Comparator|Tissue infiltration|
10204172|NCT03990363|Experimental|High Dose|High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300
10204173|NCT03990363|Experimental|Intermediate Dose|Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300
10204174|NCT03990363|Experimental|Low Dose|Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300. As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at Visit 9.
10204175|NCT03990363|Experimental|Allopurinol alone (0/300 mg)|Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300
10204176|NCT03990363|Placebo Comparator|Placebo (0/0 mg)|Placebo (mg) in 3 steps_0/0
10204177|NCT03979794|Experimental|Be-WEL Intervention|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
10204178|NCT03979794|No Intervention|Standard Care|Standard Care consists of the standard care patients typically receive from their medical team.
10204179|NCT03960463|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
10204180|NCT03960463|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
10204181|NCT03955978|Experimental|TSR-042 and Brachytherapy|"Patients will receive four doses of TSR-042. The first dose is given 21 days prior to the first planned brachytherapy fraction. The second dose is given 21 (+3) days later, corresponding to the time of brachytherapy fraction #1. The third dose is given 21 (+3) days after dose 2, corresponding to the time of brachytherapy fraction #4. The fourth dose is given 21 (+3) days after dose corresponding to 1 weeks after brachytherapy fraction #6.~Brachytherapy will consist of 6 weekly fractions of 6 Gy per fraction (total 36Gy)"
9777322|NCT01077518|Experimental|Ofatumumab and Bendamustine (Arm A)|Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
9777323|NCT01077518|Active Comparator|Bendamustine (Arm B)|Up to 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
9777324|NCT01077544|Experimental|Group 1|1 year to < 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
9777325|NCT01077544|Experimental|Group 2|>= 10 years to <18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
9777326|NCT01077596||New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006|All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.
9777327|NCT01077622|Experimental|2000 mg dose|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
9777328|NCT01077713|Experimental|1|
9777329|NCT01077713|Experimental|2|
9777330|NCT01077739|Experimental|Avastin (bevacizumab) + standard of care|
9777331|NCT01077804||Varivax vaccinated children|Children who are members of Kaiser Permanente Medical Care Program (KPMCP) and who received a first dose of the varicella vaccine, Varivax, in 1995 between the ages of 12 and 23 months.
9777332|NCT01077856||Pre-Vaccine|Registry, survey, and HPV status data from 2004-2006
9777333|NCT01077856||Post-Vaccine|Registry, survey, and HPV status data from 2011-2012
9777334|NCT01077921|Experimental|Propranolol|Drug arm
9777335|NCT01077921|Placebo Comparator|Sugar pill|Placebo arm
9777336|NCT01077960|Experimental|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
9777337|NCT01077973|Experimental|Treatment A|
9777338|NCT01077973|Active Comparator|Treatment B|
9777339|NCT01077973|Placebo Comparator|Treatment C|
9777340|NCT01078090||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 5 years.
9777341|NCT01078116||Patients with Rheumatoid Arthritis|Eligible rheumatoid arthritis patients treated with adalimumab according to the approved Summary of Product Characteristics (SmPC) in European Union
9777342|NCT01078155||Participants with Active Rheumatoid Arthritis (RA)|Participants (women and men) with active early and long-standing RA according to American College of Rheumatology revised criteria from 1987 were prescribed adalimumab in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. The decision to prescribe or not to prescribe an anti-TNF was taken prior to a participant's enrollment in the study.
9777343|NCT01078168|Active Comparator|Acitretin|oral, 30 mg per day, day 1-28
9777344|NCT01078168|Placebo Comparator|Placebo|oral, day 1-28
9777345|NCT01078220||3-Dose Safety Population (Primary)|Females between ages 9 to 26 at receipt of the first dose of GARDASIL who are members of the participating MCOs and have completed the 3-dose regimen of GARDSIL vaccination with 12 months.
9777346|NCT01078220||Pregnancy Safety Population|Females who received at least one dose of GARDASIL during pregnancy.
9777347|NCT01078220||Autoimmune Safety Population|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
9777348|NCT01078220||Any Dose Safety Population (Secondary)|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
9777349|NCT01078233||Raltegravir Cohort|Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.
9777350|NCT01078233||Historical Cohort|Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.
9777351|NCT01078233||Concurrent Cohort|Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.
9777352|NCT01078246||Raltegravir Cohort Only|Participants with HIV-1 infection who received raltegravir (RAL) on or after 12 October 2007 (the market authorization date in the United States) (Raltegravir Cohort). These participants contributed data to the Raltegravir Cohort only.
9777353|NCT01078246||Historical and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received RAL on or after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Historical and Raltegravir Cohorts only.
9777354|NCT01078246||Historical Cohort Only|Participants with HIV-1 infection who received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort). These participants contributed data to the Historical Cohort only.
9777355|NCT01078246||Historical and Concurrent Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Historical and Concurrent Cohorts only.
9777356|NCT01078246||Concurrent Cohort Only|Participants with HIV-1 infection who received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Concurrent Cohort only.
9777357|NCT01078246||Concurrent and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 2) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Concurrent and Raltegravir Cohorts only.
9777358|NCT01078246||Historical, Concurrent and Raltegravir Cohorts|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), 2) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 3) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to all three cohorts.
9777359|NCT01078298|Experimental|varenicline|
9777360|NCT01078298|Placebo Comparator|placebo|placebo
9777361|NCT01078363|Active Comparator|ramipril|ramipril, 5mg starting dose to maximum dose of 20mg daily dose for one year.
9777362|NCT01078363|Placebo Comparator|Placebo|Sugar pill manufactured to mimic ramipril 5mg starting dose , increasing to 20mg daily for one year.
9777363|NCT01078376|Experimental|Cohort 1: Healthy Adults (18 years to 45 years old)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
9777364|NCT01078376|Experimental|Cohort 1: Adolescents (≥12 to <17 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
9777365|NCT01078376|Experimental|Cohort 2: Children (≥6 to <12 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
9777366|NCT01078376|Experimental|Cohort 3: Children (≥1 to <6 years old)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
9777367|NCT01078389|Experimental|Febuxostat 40 mg or 80 mg|Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
9777368|NCT01078389|Placebo Comparator|Placebo|Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
9777369|NCT01078402||Single patients group: RA, PsA and AS|Single patients group with: Active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)
9777370|NCT01078441|Experimental|Treatment (combination chemotherapy)|Patients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9777371|NCT01078545||Adv. PCa patients with LUTS treated with GnRH analogue|Patients with advanced prostate cancer and lower urinary tract symptoms treated with GnRH analogue Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine)
9777372|NCT01078558||Patients with rheumatic disease|Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
9777373|NCT01078571||RA patients in treatment with adalimumab (Humira)|RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks
9777374|NCT01078584||Hypertensive Participants|Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days.
9777375|NCT01078623|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
9777376|NCT01078623|Placebo Comparator|Placebo|Placebo twice daily
9777377|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
10204182|NCT03949491|Experimental|3-D virtual planning and medical modeling of breast|"3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction.~Preoperative CT-Angiogram of the abdominal wall~Volumetric analysis preformed~3D printed models made~Pre operative BREAST-Questionnaires given~Free tissue transfer performed: Operative/Dissection Time Recorded~Flap/Abdominal donor site complications recorded~Standard Digital Photography and Harris Scoring~BREAST-Questionnaires given at 3, 6 months"
10204183|NCT03930186|Experimental|Apremilast|After a 5-day titration, participants received 30 mg apremilast tablets orally twice daily (BID) for up to 32 weeks in addition to their existing topical therapy. At week 16 participants were permitted to decrease their use of topical therapy at their own discretion under the direction of their physician.
9777378|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
9777379|NCT01078623|Experimental|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
9777380|NCT01078675|Experimental|1|
9777381|NCT01078753|Experimental|Desmopressin|During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of <75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
9777382|NCT01078753|Placebo Comparator|Placebo|Participants received matching placebo tablets during treatment periods I and II according to the same efficacy criteria as participants in the Desmopressin treatment group.
10204184|NCT03911973|Experimental|Talazoparib + Gedatolisib|"Talazoparib + Gedatolisib~Dose Level -1: Gedatolisib 150mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 1: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 2: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 1.00 mg/orally qd, Days 1-28"
10204185|NCT03910972|Experimental|Part A, Group A (Sm-TSP-2/Alhydrogel 10 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
9777383|NCT01078805||FORTEO (teriparatide)-treated|FORTEO-treated
9777384|NCT01078909|Experimental|300mg Fish Oil (EPA + DHA) Supplement|
9777385|NCT01078909|Experimental|600mg Fish Oil (EPA+DHA) Supplement|
9777386|NCT01078909|Experimental|900mg Fish Oil (EPA + DHA) Supplement|
9777387|NCT01078909|Experimental|1800mg Fish Oil (EPA + DHA) Supplement|
9777388|NCT01078909|Placebo Comparator|Placebo|
9777389|NCT01078922|Experimental|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
9777390|NCT01078974|Experimental|pomalidomide, dexamethasone, rituximab|"Drug: pomalidomide Taken orally once a day~Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15~Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15"
9777391|NCT01079130|Experimental|Indacaterol 18.75 µg|"Indacaterol 18.75 µg once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9777392|NCT01079130|Experimental|Indacaterol 37.5 µg|"Indacaterol 37.5 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9777393|NCT01079130|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9777394|NCT01079130|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9777395|NCT01079130|Active Comparator|Salmeterol|"Salmeterol 50 µg twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9777396|NCT01079130|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
9777397|NCT01079143|Experimental|Certican EMT+|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
9777398|NCT01079143|Experimental|Certican EMT-|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
9777399|NCT01079143|Active Comparator|Neoral EMT+|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
9777400|NCT01079143|Active Comparator|Neoral EMT-|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
10204186|NCT03910972|Experimental|Part A, Group B (Sm-TSP-2/Alhydrogel 10 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
10204187|NCT03910972|Experimental|Part A, Group C (Sm-TSP-2/Alhydrogel 30 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
10204188|NCT03910972|Experimental|Part A, Group D (Sm-TSP-2/Alhydrogel 30 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
10204189|NCT03910972|Experimental|Part A, Group E (Sm-TSP-2/Alhydrogel 100 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
10204190|NCT03910972|Experimental|Part A, Group F (Sm-TSP-2/Alhydrogel 100 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
10204191|NCT03910972|Active Comparator|Part A, Group G (HBV)|Hepatitis B Vaccine
10204192|NCT03910972|Experimental|Part B, Group H (Sm-TSP-2/Alhydrogel +/- AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, with or without AP 10-701, dose and formulation determined in Part A
10204193|NCT03910972|Active Comparator|Part B, Group I (HBV)|Hepatitis B Vaccine
10204194|NCT03899701|Experimental|PEC I and PEC II block|Ultrasound guided nerve block group.
10204195|NCT03899688|Experimental|test site|The space obtained underneath the sinus mucosa will be filled with the xenograft without protecting the antrostomy with a collagen membrane in the test sites. Bone to implant contact was measured at the turned and machined surface.
10204196|NCT03899688|Active Comparator|control site|The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites. Bone to implant contact was measured at the turned and machined surface.
9777401|NCT01079182||Ankylosing spondylitis|Participants with ankylosing spondylitis
9777402|NCT01079195||Single Patient group with Hypertension|Single Patient group with Hypertension
9777403|NCT01079234|Experimental|Flex + insulin aspart|
9777404|NCT01079234|Experimental|Fixed + insulin aspart|
9777405|NCT01079234|Active Comparator|IGlar + insulin aspart|
9777406|NCT01079299|Experimental|IPC plus standard compression|
9777407|NCT01079299|Active Comparator|Standard compression alone|
9777408|NCT01079390|Experimental|High dose acupuncture|six needle applied during acupuncture
9777409|NCT01079390|Experimental|Low dose acupuncture|two needles will be applied.
9777410|NCT01079390|Placebo Comparator|placebo acupuncture|sham acupuncture treatment will be applied
9777411|NCT01079663|Experimental|Chlorhexidine chip (Periochip®)|PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
9777412|NCT01079663|Placebo Comparator|Placebo chip|Placebo Chip Placebo Chips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
9777413|NCT01079741|Experimental|Dose-escalation component|Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen and Montanide will be held constant.
9777414|NCT01079741|Active Comparator|Phase II is the randomized component.|The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
9777415|NCT01079806|Active Comparator|Entecavir|Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
9777416|NCT01079806|Placebo Comparator|Placebo|Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
9777417|NCT01079832|Experimental|Arm I: CyberKnife Radiosurgery|Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
9777418|NCT01079936|Experimental|Lenalidomide + High-Dose Melphalan|Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.
9777419|NCT01079949|Experimental|r-hLH + r-hFSH|
9777420|NCT01079949|Active Comparator|r-hFSH|
9777421|NCT01079962|Experimental|Bisoprolol|
9777422|NCT01079962|Active Comparator|Atenolol|
9777423|NCT01079988|Experimental|Cyclosporin|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
9777424|NCT01079988|Experimental|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
9777425|NCT01079988|Experimental|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
9777426|NCT01079988|Experimental|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
9777427|NCT01079988|Experimental|Systemic corticosteroids/methotrexate|"Corticosteroid starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%.~Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks."
9777428|NCT01080118|Other|control group|Control group, taught with a standard Macintosh laryngoscope
9777429|NCT01080118|Experimental|Study group|Study group taught with the Airtraq video laryngoscope
9777430|NCT01080131|Experimental|Canakinumab 150 mg|"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to receive open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year, for a total duration of 18 months."
9784920|NCT01237301|Experimental|CGM Group|Wear an unblinded CGM for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use real time continuous glucose monitoring (rt CGM).
9784921|NCT01237301|Active Comparator|SMBG Group|Use SMBG 4 to 7 times a day for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use structured self monitoring blood glucose (stSMBG) and periodic, blinded continuous glucose monitoring (CGM).
9777431|NCT01080131|Active Comparator|Triamcinolone acetonide 40 mg|"Participants received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to switch to open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year. Triamcinolone acetonide was not to be administered in the second extension study."
9777432|NCT01080196|Experimental|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
9777433|NCT01080196|No Intervention|TRADITIONAL|"The TRAD group will perform their lower extremity resistance exercise for 15 minutes per session with isotonic weight machines and cuff weights as part of their multicomponent exercise fall reduction program (MCERFP). The progression of the 3 x/week, 12 week TRAD program will be determined as a relative function of their 1 repetition maximum (1RM) weight that can be lifted in a safe and successful manner. The 1RM will be measured before the 12 week training program and every 2 weeks thereafter. A target resistance workload (i.e., weight level) commensurate with 60-70% of the 1RM of the knee and hip extensors will be calculated bi-monthly and 3 sets of 15 repetitions of 3-4 different knee and hip exercises will be used over a 15 minute time period."
9777434|NCT01080209|Experimental|Brimo PS DDS® 400 μg (2 implants)|Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study.
9777435|NCT01080209|Experimental|Brimo PS DDS® 400 μg (1 implant)|Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study.
9777436|NCT01080209|Experimental|Brimo PS DDS® 200 μg (2 implants)|Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study.
9777437|NCT01080209|Experimental|Brimo PS DDS® 200 μg (1 implant)|Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study.
9777438|NCT01080209|Experimental|Brimo PS DDS® 100 μg (1 implant)|Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study.
9777439|NCT01080209|Experimental|Brimo PS DDS® 50 μg (1 implant)|Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study.
9777440|NCT01080209|Sham Comparator|Sham|Patients who received sham in a previous study.
9777441|NCT01080248|Experimental|Arm 1 (gemcitabine & pazopanib)|"Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.~Pazopanib 800 mg PO daily of each 28 day cycle."
9777442|NCT01080261|Experimental|PROMUS Element|everolimus-eluting coronary stent
9777443|NCT01080300|Experimental|Gabapentin Extended Release|Active treatment
9777444|NCT01080300|Other|Placebo|Placebo
9777445|NCT01080326|Experimental|Endoscopic Translumenal Omental Patch|Patients with the clinical diagnosis of a perforated viscus who are scheduled to undergo surgical exploration will be recruited. The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix the Endoscopic Translumenal Omental Patch in place.
9777446|NCT01080391|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.
9777447|NCT01080391|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone (CRd)|Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.
9777448|NCT01080625|Experimental|phenylephrine|100 mcg of phenylephrine is administered at the time of reperfusion
9777449|NCT01080625|Experimental|epinephrine|10 mcg of epinephrine is administered iv at the time of reperfusion
9777450|NCT01080625|Placebo Comparator|control|10 ml of normal saline is administered at the time of reperfusion
9777451|NCT01080677|Placebo Comparator|Placebo|Participants will receive placebo to match caffeine/propranolol (single dose)
9777452|NCT01080677|Experimental|Low dose|Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)
9777453|NCT01080677|Experimental|High dose|Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)
9777454|NCT01080716|Experimental|Part 1/Arm 1 of Study: WRSS1 vaccine|WRSS1 is a live attenuated S. sonnei vaccine candidate derived from the Mosely strain of S.sonnei
9777455|NCT01080716|Placebo Comparator|Part 1/Arm 2 of Study: Placebo vaccine|Placebo
9784922|NCT01237327|Active Comparator|1|
9784923|NCT01237327|Experimental|2|
9777456|NCT01080716|Experimental|Part 2/Arm 1 of Study: S. sonnei 53G|10 volunteers from Study Arm 1/Part 1 (WRSS1 vaccine) plus 4 alternates from Arm 1/Part 1 are given 53G S. sonnei
9777457|NCT01080716|Active Comparator|Part 2/Arm 2 of Study: S sonnei 53G|10 subjects (naïve controls) plus 4 alternates are give 53G S sonnei
9777458|NCT01080794|Active Comparator|Double rTMS|High frequency rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
9777459|NCT01080794|Active Comparator|M1 Active rTMS + DLPFC Sham rTMS|High frequency stimulation of the primary motor cortex (M1) and sham stimulation of the dorsolateral prefrontal cortex (DLPFC).
9777460|NCT01080794|Active Comparator|DLPFC Active rTMS + M1 Sham rTMS|High frequency stimulation of the dorsolateral prefrontal cortex (DLPFC) and sham stimulation of the primary motor cortex (M1).
9777461|NCT01080794|Sham Comparator|Double Sham rTMS|Sham rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
9777462|NCT01080807|Experimental|150 mg/day armodafinil|
9777463|NCT01080807|Placebo Comparator|Matching placebo|
9777464|NCT01080976||Primary Care Physicians|
9777465|NCT01080976||Diabetologists|
9777466|NCT01081041|Experimental|Safety Lead-In (cetuximab manufactured by ImClone)|"Cycle 1:~Week 1 - Cetuximab 400 milligrams per square meter (mg/m^2) on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
9777467|NCT01081041|Experimental|Cetuximab manufactured by ImClone|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
9777468|NCT01081041|Experimental|Cetuximab manufactured by Boehringer Ingelheim|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
9777469|NCT01081132|Experimental|Extended-release Guanfacine HCl|
9777470|NCT01081132|Placebo Comparator|Placebo|
9777471|NCT01081145|Experimental|Extended-release Guanfacine HCl|
9777472|NCT01081145|Placebo Comparator|Placebo|
9784924|NCT01237340|Experimental|Saizen®|
9777473|NCT01081249|Experimental|Placebo then Oxytocin|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
9777474|NCT01081249|Experimental|Oxytocin then placebo|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
9784925|NCT01237353|Experimental|betaine hydrochloride and rabeprazole|
9784926|NCT01237587|Experimental|Duloxetine|"Blinded treatment period: 30mg or 60mg once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
9784927|NCT01237587|Placebo Comparator|Placebo|"Blinded treatment period:Placebo once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
9784928|NCT01237678|Experimental|IMGN901 with carboplatin and etoposide|Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
9784929|NCT01237678|Active Comparator|Carboplatin and Etoposide|Patients will receive Carboplatin and etoposide for up to 6 cycles.
9784930|NCT01237821|Active Comparator|BenzaClin|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
9784931|NCT01237821|Active Comparator|effaclar|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
9784932|NCT01237899|Experimental|1 mg LY2623091|Daily by mouth for 7 days.
9784933|NCT01237899|Experimental|10 mg LY2623091|Daily by mouth for 7 days.
9784934|NCT01237899|Experimental|25 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of 100 mg based on safety and tolerability data. The 25 mg LY2623091 was administered daily by mouth for 7 days.
9784935|NCT01237899|Experimental|0.3 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of up to 200 mg. The 0.3 mg LY2623091 was determined based on an interim analysis after the third dose level and was administered daily by mouth for 7 days.
9784936|NCT01237899|Placebo Comparator|Placebo|Daily by mouth for 7 days.
9784937|NCT01237899|Active Comparator|50 mg Eplerenone|Daily by mouth for 7 days.
9784938|NCT01237951|Experimental|GemBuMel|"Gemcitabine 1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.~Busulfan 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan area under curve (AUC) 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.~Melphalan 60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.~Palifermin 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~Palifermin 60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.~Dexamethasone 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.~Stem Cell Transplant: On Day 0, stem cells returned to body by vein over 30-60 minutes."
9784939|NCT01238120|Active Comparator|Placebo and Home-Based Exercise|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
9784940|NCT01238120|Active Comparator|Ibuprofen 200mg BID, Home-Based Exercise|200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
9784941|NCT01238120|Placebo Comparator|Placebo|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
9784942|NCT01238120|Active Comparator|Ibuprofen 200 mg BID|200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
9784943|NCT01238172|Experimental|Arm A - MEAL Program Intervention|Patients will receive dietary education and telephone counseling sessions over 24 months.
9784944|NCT01238172|Experimental|Arm B - Prostate Cancer Foundation Booklet|Patients receive information about diet, nutrition, exercise and cancer. Patients also receive regularly scheduled newsletters.
9784945|NCT01238341||Pancreatobiliary disease|Patients who have altered gastric anatomy who need an ERCP with an overtube for evaluation of pancreatobiliary disease.
9784946|NCT01238471|Experimental|Propranolol|Oral propranolol for premature infants allocated to this arm by randomization
9784947|NCT01238471|Placebo Comparator|Oral sucrose 5%|Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization
9777475|NCT01081301|Experimental|Living with Hope Program|Receive Living with Hope Program
9777476|NCT01081626|Experimental|Group I: Chronic Low dose Protocol|Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
9777477|NCT01081626|Experimental|Group II: Low dose Protocol|Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.
9777478|NCT01081665||Chronic Kidney Disease|All eligible patients treated with IV Paricalcitol (Zemplar)
9777479|NCT01081678|Placebo Comparator|Placebo|Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
9777480|NCT01081678|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
9777481|NCT01081678|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
9777482|NCT01081678|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
9777483|NCT01081769|Experimental|Paliperidone Palmitate|paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter
9777484|NCT01081769|Active Comparator|Oral Antipsychotics|oral antipsychotics daily treatment according to local label for maximally 24 months
9777485|NCT01081795|Experimental|Topiramate (JNS019) 50 mg|In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
9777486|NCT01081795|Experimental|Topiramate 100 mg|In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
9777487|NCT01081795|Placebo Comparator|Placebo|In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.
9777488|NCT01081834|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
9777489|NCT01081834|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
9777490|NCT01081834|Experimental|Placebo/Sitagliptin|In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
9777491|NCT01081873||Advanced prostate cancer participants|Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
9777492|NCT01081912|Active Comparator|Hydrocodone Bitartrate Capsules|Hydrocodone Bitartrate Controlled-Release Capsules
9777493|NCT01081912|Placebo Comparator|Placebo comparator|
9777494|NCT01082081|Experimental|Paracetamol 1000 mg|Paracetamol 1000 mg
9777495|NCT01082081|Experimental|Paracetamol 500 mg|Paracetamol 500 mg
9777496|NCT01082081|Placebo Comparator|Placebo|Placebo
9777497|NCT01082159|Other|lumbar decompression|Percutaneous lumbar decompression with mild® Device Kit.
9777498|NCT01082211|Experimental|Partial Breast Re-Irradiation|Partial Breast Re-Irradiation (PBrI) 3D-Conformal External Beam 1.5 Gy x 15 (BID) to 45 Gy Total
9777499|NCT01082328|Experimental|Kuvan®|
9777500|NCT01082367|Experimental|TOBI (tobramycin inhaled solution)/Placebo|Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
9777501|NCT01082367|Placebo Comparator|Placebo/TOBI|Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).
9777502|NCT01082380|Experimental|1|
9777503|NCT01082575||Major Surgery|Oxygen Monitoring
9777504|NCT01082588|Active Comparator|pravastatin|pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks
9777505|NCT01082588|Placebo Comparator|Placebo|placebo, once a day, shortly after baseline for 12 consecutive weeks
9777506|NCT01082614|No Intervention|Standard fluid management|standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
9777507|NCT01082614|Experimental|Goal directed therapy|Intraoperative fluid management guided by stroke volume variation determined by arterial pressure pulse wave contour analysis
9777508|NCT01082640|Placebo Comparator|Placebo|Placebo-matching capsules, orally, twice daily for up to 12 months.
9777509|NCT01082640|Experimental|Febuxostat 30 mg BID|Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.
9777510|NCT01082640|Experimental|Febuxostat 40/80 mg QD|Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was <6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.
9777511|NCT01082874|Experimental|Active Clonidine and Active ASA|
9777512|NCT01082874|Experimental|Active Clonidine and Placebo ASA|
9777513|NCT01082874|Experimental|Placebo Clonidine and Active ASA|
9777514|NCT01082874|Placebo Comparator|Placebo Clonidine and Placebo ASA|
9777515|NCT01082939|Experimental|CFAR|CFAR: Cyclophosphamide 250 mg/m^2/day intravenous (IV) Days 3-5, Fludarabine 25 mg/m^2/day IV Days 3-5, Alemtuzumab 30 mg IV Days 1, 3 and 5 over 2-4 hours, repeated every four weeks for a total of 6 planned cycles, and Rituximab Cycle 1 (Week 1): 375 mg/m^2/day IV Day 2 over 4- 6 hours, Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV Day 2 over 4- 6 hours.
9777516|NCT01082952||Asthmatic patients|
9777517|NCT01082952||Non asthmatic patients|
9777518|NCT01082965|Experimental|Treatment|
9777519|NCT01082965|Placebo Comparator|Placebo|
9777520|NCT01083121||Adalimumab|Participants who were prescribed with adalimumab per approved prescribing information of adalimumab in Korea.
9777521|NCT01083160||Non responders to other anti-TNF|Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
9777522|NCT01083173||Participants with HIV-1 infection|Participants treated with Kaletra (lopinavir/ritonavir 200 mg/50 mg and 100 mg/25 mg) tablet
9777523|NCT01083186||Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism|Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)
9777524|NCT01083199|Experimental|CONTINUUMTM|
9836101|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.
9777525|NCT01083316|Experimental|Single Arm - Investigational|"Induction:~Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
9777526|NCT01083368|Experimental|Arm 1: Combination of temsirolimus and AVASTIN|Patients receive temsirolimus IV over 30-60 minutes once weekly and bevacizumab IV over 30-90 minutes once every two weeks . Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
9777527|NCT01083485|Experimental|Tablets Oxycodone Naloxone (OXN)|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)
9777528|NCT01083485|Active Comparator|Oxycodone|Oxycodone PR 20mg or 10mg (twice a day) BID for 2.5 days (total 5 dosages)
9777529|NCT01083576|Active Comparator|Paromomycin Alone Treatment|Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days
9777530|NCT01083576|Active Comparator|WR 279,396|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days
9777531|NCT01083602|Experimental|panobinostat + bortezomib & dexamethasone|panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
9777532|NCT01083628|Experimental|Group CBT for Depression with MoodText'|Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content
9777533|NCT01083628|Active Comparator|Group CBT for Depression|Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression
9777534|NCT01083641|Experimental|Estrogen Therapy|Estrogen therapy
9777535|NCT01083654|Active Comparator|Standard Treatment Counseling|Standard Treatment (ST) will consist of 12 weeks of open-label varenicline and smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
9777536|NCT01083654|Experimental|Culturally-Tailored Treatment|The Culturally-Tailored Treatment will consist of 12 weeks of open-label varenicline and culturally-tailored (for American Indians) smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
9777537|NCT01083667|Experimental|Pyrimethamine|Open label. Only one arm will receive the intervention.
9777538|NCT01083680||Participants with Crohn's Disease (CD)|Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.
9777539|NCT01083693||Rheumatoid, Psoriatic Arthritis, Ankylosing Spondylitis|Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, patients with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.
9777540|NCT01083706|Experimental|Treatment (chemotherapy)|Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9777541|NCT01083732|Experimental|dabigatran etexilate|treatment with dabigatran oral solution as a single dose
9777542|NCT01083758|Other|LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)|
9777543|NCT01083810||therapy-naive|Patients who had not received prior antiretroviral drug therapy
9777544|NCT01083810||pre-treated|Patients that had previously received antiretroviral therapy, but are protease inhibitor naive
9777545|NCT01083810||non-B|Patients infected with non-B subtypes of HIV-1
9777546|NCT01083849||Paricalcitol|Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
9777547|NCT01083901|Experimental|Resistance training with Acetaminophen|Acetaminophen
9777548|NCT01083901|Experimental|Resistance Training with ibuprofen|Ibuprofen
9777549|NCT01083901|Placebo Comparator|placebo|Placebo
9777550|NCT01083979|Experimental|Liposomes|Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments.
9777551|NCT01084005|Experimental|linagliptin|patients receive linagliptin 5 mg tablets once daily
9777552|NCT01084005|Placebo Comparator|placebo|patients receive placebo tablets matching linagliptin 5 mg once daily
9777553|NCT01084083|Experimental|Group 1|After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
9777554|NCT01084083|Experimental|Group 2|After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.
9777555|NCT01084135|Experimental|Rivastigmine- Liquid form|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
9777556|NCT01084135|Placebo Comparator|Liquid placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
9777557|NCT01084148|Experimental|V0034CR01B|cream
9777558|NCT01084148|Placebo Comparator|V0034 CR 01B vehicle|cream
9777559|NCT01084174|Experimental|Active SLIT/Placebo OIT|These subjects will receive peanut powder given orally and placebo extract given sublingually.
9777560|NCT01084174|Experimental|Active OIT/Placebo SLIT|These subjects will receive peanut extract given sublingually and placebo powder given orally.
9777561|NCT01084239|No Intervention|Standard of care|Subjects in this arm (50% of the total cohort) continued to receive standard non-invasive evaluation of acute chest pain symptoms in the emergency department - mostly comprising of, but not limited to - exercise treadmill test, stress test with imaging and stress echocardiography.
9777562|NCT01084239|Experimental|Cardiac CT|Subjects in this arm (50% of the total cohort) were randomized to receive a cardiac computed tomography scan as part of the initial evaluation of acute chest pain symptoms, upon presentation to the emergency department.
9777563|NCT01084278|Experimental|Healthy|Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
9777564|NCT01084278|Experimental|Mild renal impairment|Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
9777565|NCT01084278|Experimental|Moderate renal impairment|Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.
9777566|NCT01084278|Experimental|Severe renal impairment|Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.
9777567|NCT01084278|Experimental|End stage renal disease (ESRD)|Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
9777568|NCT01084499|Experimental|Femara First, Then Peratra (Sequence 1)|Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.
9777569|NCT01084499|Experimental|Peratra First, Then Femara (Sequence 2)|Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.
9777570|NCT01084538||End stage chronic kidney disease|Secondary hyperparathyroidism defined as intact PTH > 300 pg/mL
9777571|NCT01084551|Experimental|SPM 962 4.5|started at 2.25 mg/day to 4.5 mg/day for 13 weeks
9777572|NCT01084551|Experimental|SPM 962 6.75|started at 2.25 mg/day to 6.75 mg/day for 13 weeks
9777573|NCT01084551|Placebo Comparator|placebo|for 13 weeks
9777574|NCT01084603|Experimental|Oral Nicotine 1|One oral administration of 1 mg nicotine
9777575|NCT01084603|Experimental|Oral Nicotine 2|Two oral administrations of 1 mg nicotine
9777576|NCT01084603|Experimental|Oral Nicotine 4|Four oral administrations of 1 mg nicotine
9777577|NCT01084603|Active Comparator|NiQuitinTM Nicotine Lozenge 4 mg|One 4 mg marketed nicotine lozenge
9777578|NCT01084603|Active Comparator|Nicorette® Gum 4 mg|One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
9777579|NCT01084655|Experimental|Phase 1: Orteronel 200 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 200 milligram (mg), tablets, orally, twice daily (BID) starting from Day 1 along with docetaxel 75 milligram per square meter (mg/m^2), infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
9777580|NCT01084655|Experimental|Phase 1: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Day 1 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
9777581|NCT01084655|Experimental|Phase 2: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Cycle 1 Day 15 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets, orally, twice daily from Day 1 up to Day 21 of each 21-day treatment cycle until disease progression or end of treatment (EOT).
9777582|NCT01084668||Adalimumab|Participants with moderate to severe chronic plaque psoriasis treated with adalimumab after biologic disease modifying anti-rheumatic drug (BDMARD) failure
9777583|NCT01084707|Experimental|Oral Nicotine 24-SA|2 Self-administrations of Experimental Nicotine once every hour
9777584|NCT01084707|Experimental|Oral Nicotine 24|2 administrations of Experimental Nicotine by study personnel once every hour
9777585|NCT01084707|Experimental|Oral Nicotine 48|2 administrations of Experimental Nicotine by study personnel once every 30 minutes
9777586|NCT01084707|Active Comparator|NiQuitin™ Lozenge 4 mg|1 NiQuitin™ lozenge, administered by study personnel once every hour
9777587|NCT01084707|Active Comparator|Nicorette® Gum 4 mg|1 piece Nicorette® gum, chewed for 30 minutes once every hour
9777588|NCT01084759|Experimental|Etoposide and Testosterone|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.
9777589|NCT01084772|Other|VISIONAIRE Instrumentation|TKA with VISIONAIRE instrumentation
9777590|NCT01084772|Other|Standard Instrumentation|TKA with standard instrumentation
9777591|NCT01085006|Experimental|Tranexamic acid|
9777592|NCT01085006|Placebo Comparator|normal saline infusion|
9777593|NCT01085045|Experimental|Inhaled PT003 (Dose 1)|PT003 MDI Dose 1
9777594|NCT01085045|Experimental|Inhaled PT003 (Dose 2)|PT003 MDI Dose 2
9777595|NCT01085045|Experimental|Inhaled PT005 (Dose 1)|PT005 MDI Dose 1
9777596|NCT01085045|Experimental|Inhaled PT005 (Dose 2)|PT005 MDI Dose 2
9777597|NCT01085045|Placebo Comparator|Inhaled Placebo|Placebo MDI
9777598|NCT01085045|Active Comparator|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Tiotropium Bromide inhalation powder
9777599|NCT01085045|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
9777600|NCT01085045|Experimental|Inhaled PT001 (Dose 1)|PT001 MDI Dose 1
9777601|NCT01085136|Active Comparator|Investigator's choice of chemotherapy|Patients will be treated with investigator's choice of chemotherapy
9777602|NCT01085136|Experimental|BIBW 2992 and Paclitaxel|Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2
9777603|NCT01085201|Experimental|Stage 1|12-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
9777604|NCT01085201|Experimental|Stage 2|24-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
9777605|NCT01085201|Experimental|Stage 3|24-hour infusion to adults with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
9777606|NCT01085201|Experimental|Stage 4|24-hour infusion to children with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
9777607|NCT01085201|Experimental|Stage 2B|48-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
9777608|NCT01085214|Experimental|AZD6244 (Selumetinib) Treatment|Participants receive AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9777609|NCT01085318|Active Comparator|Arm 1 MS Patients|Rebif 44 tiw
9777610|NCT01085318|No Intervention|Arm 2 Healthy Control|
9777611|NCT01085331|Experimental|Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI|
9777612|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI|Planned, not performed
9777613|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI|Planned, not performed
9777614|NCT01085344|Experimental|Factor VIII|escalating dose Factor VIII
9777615|NCT01085357|Experimental|CyPass Micro-Stent + Cataract Surgery|Subjects receive the CyPass Micro-Stent at the conclusion of their cataract surgery
9777616|NCT01085357|Active Comparator|Cataract Surgery Only|Subjects do not receive the CyPass Micro-Stent at the conclusion of their cataract surgery
9777617|NCT01085500|Experimental|Simulation Curriculum|General surgery residents will undergo a simulation-based educational curriculum (Mastery Learning TEP Curriculum) on TEP hernia repair
9777618|NCT01085500|Other|Current Practice|General surgery residents will undergo current practice of learning how to perform the TEP repair in the operating room under direct supervision of the staff surgeon without any simulation pre-training.
9777619|NCT01085513|Active Comparator|Patients|Patients previously indicated for manometry
9777620|NCT01085513|Active Comparator|Healthy volunteers|Healthy volunteers
9777621|NCT01085591|Experimental|CB-183,315, 125 mg|125 milligrams (mg) CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
9777622|NCT01085591|Experimental|CB-183,315, 250 mg|250 mg CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
9777623|NCT01085591|Active Comparator|Vancomycin, 125 mg|125 mg vancomycin administered orally four times a day for 10 days.
9777624|NCT01085630|Experimental|Arm I|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9777625|NCT01085630|Active Comparator|Arm II|Patients undergo observation until disease progression.
9777626|NCT01085682|Active Comparator|Lifestyle counseling|
9777627|NCT01085682|Active Comparator|Standard care|
9777628|NCT01085734|Active Comparator|Group 1|Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema
9777629|NCT01085734|Active Comparator|Group 2|Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema
9777630|NCT01085760|Experimental|Vancomycin 125 mg orally 4 times a day|The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
9777631|NCT01085760|Experimental|Vancomycin 250 mg orally 4 times a day|
9777632|NCT01085760|Experimental|Metronidazole 250 mg orally 3 times a day|
9777633|NCT01085760|Experimental|Metronidazole 500 mg orally 3 times a day|
9777634|NCT01085786|Active Comparator|14-day sequential treatment|One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and metronidazole for 7 days.
9777635|NCT01085786|Experimental|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
9777636|NCT01085812|Experimental|2|40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
9777637|NCT01085812|Placebo Comparator|1|Matching placebo capsules, oral administration, once daily dosing.
9777638|NCT01085825|Active Comparator|Manual Vacuum Aspiration|
9777639|NCT01085825|Active Comparator|Electric Vacuum Aspiration|
9777640|NCT01085903|Active Comparator|normal subjects|Normal subjects are persons without stroke who receive baseline, CPS, Post CPS and Follow up interventions.
9777641|NCT01085903|Active Comparator|stroke subjects|Stroke subjects are persons who have had a stroke affecting the right hemisphere and are subject to neglect or dysphagia who receive modafinil, placebo, baseline, CPS, Post CPS and Follow up interventions.
9777642|NCT01085968|Experimental|PD Subjects|PD subjects who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
9777643|NCT01085968|Active Comparator|Control Subjects|Age matched controls who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
9777644|NCT01086033||Humira|Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.
9777645|NCT01086150|Other|Healthy control patients|Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
9777646|NCT01086150|Other|Type I or Type II diabetes with painful diabetic neuropathy|18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
9777647|NCT01086150|Other|patients with non-painful diabetic peripheral neuropathy|18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
9777648|NCT01086215||Limb Ischemia|Patients presenting with limb ischemia for treatment
9777649|NCT01086215||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
9777650|NCT01086215||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
9777651|NCT01086215||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment
9777652|NCT01086228||XIENCE V / PROMUS stent|Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
9777653|NCT01086358|Active Comparator|Triptan|Arm 1 subjects began with their prescribed triptan
9777654|NCT01086358|Active Comparator|Treximet 85Mg-500Mg Tablet|Arm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)
9777655|NCT01086384|Experimental|Fluticasone furoate/GW642444|
9777656|NCT01086384|Experimental|fluticasone furoate|
9777657|NCT01086410|Active Comparator|FF/444 Dose B|Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
9777658|NCT01086410|Active Comparator|FF/444 Dose A|Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
9777659|NCT01086410|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
9777660|NCT01086410|Active Comparator|Prednisolone|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study
9777661|NCT01086423|Experimental|INFANRIX-IPV+HIB 1 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.
9777662|NCT01086423|Experimental|INFANRIX-IPV+HIB 2 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.
9777663|NCT01086423|Active Comparator|INFANRIX-HIB+POLIORIX GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.
9777664|NCT01086475|Experimental|D-cycloserine|Subjects randomized to D-cycloserine will be administered 50 mg 30 minutes prior to each of ten Social Skills Training Sessions
9777665|NCT01086475|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive placebo pill 30 minutes prior to each of ten Social Skills Training Sessions
9777666|NCT01086540|Experimental|Rituximab+PAH SOC|"Rituximab (1000 mg) will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
9777667|NCT01086540|Placebo Comparator|Placebo + PAH SOC|"Placebo will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
9777668|NCT01086605|Experimental|Arm I|Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9777669|NCT01086605|Experimental|Arm II|Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9777670|NCT01086761|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
9777671|NCT01086761|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
9777672|NCT01086761|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
9777673|NCT01086761|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
9777674|NCT01086761|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
9777675|NCT01086761|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
9777676|NCT01086852|Experimental|FACTOR X|Human Coagulation Factor X
9777677|NCT01086969|Experimental|Study Group|Participants in three age cohorts - Children: 2 - 11 years of age; Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age will be enrolled.
9784948|NCT01238536|Experimental|Epidural Steroid injection|"Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.~Intervention: Epidural steroid with local anesthetic injection~2cc of .25 - 1% lidocaine and glucocorticoid (Kenalog 40-120 mg, depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg)"
9784949|NCT01238536|Active Comparator|Epidural local anesthetic injection|Intervention: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
9784950|NCT01238549||Spinal Cord Injury|Participants with SCI
9784951|NCT01238575|Experimental|Extended-release guanfacine|
9784952|NCT01238575|Placebo Comparator|Inactive placebo|
9784953|NCT01238588|Other|Sevelamer Carbonate (Renvela)|Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
9784954|NCT01238640|Experimental|Code STD|"An experimental 2 mg nicotine product coded STD"
9784955|NCT01238640|Experimental|Code STE|"An experimental 2 mg nicotine product coded STE"
9784956|NCT01238640|Active Comparator|Nicorette Microtab|A comparative 2 mg marketed nicotine product called Nicorette Microtab
9784957|NCT01238822|Placebo Comparator|Placebo|
9784958|NCT01238822|Active Comparator|Low Dose Methylphenidate|Low dose: 18 mg methylphenidate
9784959|NCT01238822|Active Comparator|Medium Dose Methylphenidate|Medium Dosage: 36 mg if more than 50 kg and 27 mg if less than 50 kg
9784960|NCT01238822|Active Comparator|High Dose Methylphenidate|54 mg if more than 50 kg and 36 mg if less than 50 kg
9784961|NCT01238835|Experimental|TAVR-TA|Transcatheter valve replacement with transapical access
9784962|NCT01238848|Experimental|Hypertonic|Nebulized hypertonic saline (sodium chloride 3%) + albuterol
9784963|NCT01238848|Active Comparator|Normal|Normal saline (sodium chloride 0.9%) + albuterol
9784964|NCT01238861|Placebo Comparator|Eosinophilic phenotype (EOS+) Placebo|EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
9784965|NCT01238861|Experimental|EOS+ Benralizumab (2 mg)|EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
9784966|NCT01238861|Experimental|EOS+ Benralizumab (20 mg)|EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
9777678|NCT01087489|Experimental|4% lidocaine|Eyes were anesthetized with 0.5% proparacaine and then with three cotton swabs soaked in 4% liquid lidocaine applied with moderate pressure to the site of the injection inferotemporally to the limbus. Each participant was assigned to have this prep during one of the consecutive study visits if unilateral or in one eye if patient requires bilateral injections given the same day
9777679|NCT01087489|Experimental|3.5% ophthalmic lidocaine gel|Eye was anesthetized with 0.5% proparacaine and then with 3.5% ophthalmic lidocaine gel applied to the surface of the eye. Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day.
9777680|NCT01087502|Experimental|Linagliptin|52 weeks treatment
9777681|NCT01087502|Placebo Comparator|Placebo|First 12 weeks of treatment
9777682|NCT01087502|Active Comparator|Glimepiride|Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)
9777683|NCT01087528|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
9777684|NCT01087541|No Intervention|Control|Usual clinical health care
9777685|NCT01087541|Experimental|Intervention|Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )
9777686|NCT01087723|Experimental|Bivalirudin|Given immediately upon enrollment as an intravenous (IV) bolus of 0.75 mg/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continuously until completion of PCI, at which time the infusion was reduced to 0.25 mg/kg/h for at least 4 hours. An optional PCI-dose infusion of 1.75 mg/kg/h was also permitted for up to 4 hours at the discretion of the operator.
9777687|NCT01087723|Active Comparator|Standard of Care: Heparins with Optional GPI|"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of STE-ACS, not including bivalirudin: UFH (100 international units/kg [IU/kg] without GPI and 60 IU/kg with GPI). Any of the following approved GPIs were used either as a routine strategy or as a bail out: eptifibatide (two 180-micrograms/kilogram [μg/kg] IV boluses with a 10-minute [min] interval followed by an infusion of 2.0 μg/kg/min for 72-96 hours); tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18-24 hours); or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours [maximum dose of 10 μg/min]).~For this study, the control consisted of treatment with UFH or low molecular weight heparin (LMWH) with or without GPI and is referred to as heparins with optional GPI."
9777688|NCT01087736|Experimental|Topiramate|Participants will be randomly assigned to either the topiramate arm or placebo arm. Neither the participant nor the researchers will know which arm the participant is in. Participants in the topiramate arm will be ingesting daily doses of topiramate that will gradually increase to a maximum, and then taper off.
9777689|NCT01087736|Placebo Comparator|Placebo|The Drug Product Services Laboratory at UCSF will purchase and supply our lab with USP or NF grade topiramate study capsules and matching placebo capsules. Randomization will be done by a consulting biostatistician, who will be the only one to know which participants are assigned to placebo. Dosing will follow the same procedures as with topiramate in that arm of the study. If adverse events occur, there will be a procedure in place for unblinding only that participant.
9777690|NCT01087762|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
9777691|NCT01087762|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
9777692|NCT01087762|Placebo Comparator|Placebo|"Matching Placebo to CZP injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16.~After 24 weeks, all subjects were randomized to active treatment with CZP 200 mg Q2W or CZP 400 mg Q4W."
9777693|NCT01087762|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9784967|NCT01238861|Experimental|EOS+ Benralizumab (100 mg)|EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
9777694|NCT01087762|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9777695|NCT01087762|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9777696|NCT01087762|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9777697|NCT01087775|Experimental|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
9777698|NCT01087788|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
9777699|NCT01087788|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
9777700|NCT01087788|Placebo Comparator|Placebo|"Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.~After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W)."
9777701|NCT01087788|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9777702|NCT01087788|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9777703|NCT01087788|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9777704|NCT01087788|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
9777705|NCT01087801|Active Comparator|ChiRhoStim|Human Secretin for Injection
9777706|NCT01087801|Placebo Comparator|Placebo|Saline for Injection
9777707|NCT01087814|Active Comparator|efavirenz|
9777708|NCT01087814|Experimental|over-encapsulated efavirenz|
9777709|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
9777710|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
9784968|NCT01238861|Placebo Comparator|Non-eosinophil phenotype (EOS-) Placebo|EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
9784969|NCT01238861|Experimental|EOS- Benralizumab (100 mg)|EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
9784970|NCT01238900||benign biliary strictures|All patients who have a medical indication for an ERCP to place a stent in their benign biliary strictures
9777711|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
9777712|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
9777713|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
9777714|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
9777715|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
9777716|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
9777717|NCT01087918|Experimental|First RAGT, then strength training|16 sessions of 45 minutes of robot-assisted gait training 4 times a week in first intervention period and 16 sessions of 45 minutes of strength training 4 times a week in second intervention period.
9777718|NCT01087918|Experimental|First strength training, then RAGT|16 sessions of 45 minutes of strength training 4 times a week in first intervention period and 16 sessions of 45 minutes of robot-assisted gait training 4 times a week in second intervention period.
9777719|NCT01087931|Active Comparator|Bupivacaine|This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
9777720|NCT01087931|Placebo Comparator|Saline|This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.
9777721|NCT01087944|Experimental|1|"Peginterferon via auto-injector device.~All participants will receive Peginterferon in a cross-over design."
9777722|NCT01087944|Active Comparator|2|"Peginterferon via pre-filled syringe.~All participants will receive Peginterferon in a cross-over design."
9777723|NCT01087957|Active Comparator|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
9777724|NCT01087957|Active Comparator|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
9777725|NCT01087970|Experimental|Triplet Combination Therapy|"Cycle 1:~Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1"
9777726|NCT01087996|Experimental|Auto-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
9777727|NCT01087996|Experimental|Allo-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
9777728|NCT01088048|Experimental|Idelalisib + Rituximab|"Participants with chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL) will receive treatments as follows:~Cohort 1a: Idelalisib (IDELA) 100 mg orally twice daily (BID) on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 intravenously (IV) on Days 1, 8, 15 & 22, Cycles 1 & 2~Cohort 2a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2~Cohort 3e: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2~Cohort 4a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle, starting Cycle 2 Day 1 with the 5th dose of rituximab + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2"
9777729|NCT01088048|Experimental|Idelalisib + Rituximab + Bendamustine|"Participants with CLL, iNHL and mantle cell lymphoma (MCL) will receive treatments as follows:~Cohort 3a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 70 mg/m^2 IV on Days 1 & 2 of each 28-day cycle from Cycles 1 - 6~Cohort 5c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6"
9777730|NCT01088048|Experimental|Idelalisib + Bendamustine|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 1b: IDELA 100 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 2b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3f: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3g: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 70 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 4b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle starting Cycle 2, Day 3 (after the Cycle 2 bendamustine dosing) + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6"
9777731|NCT01088048|Experimental|Idelalisib + Ofatumumab|"Participants with CLL will receive treatments as follows:~Cohort 3c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + ofatumumab 12 doses (300 mg (Day 1 or Day 2, Dose 1), followed 1 week later by 1,000 mg weekly for 7 doses (Doses 2 - 8), followed 5 weeks later by 1,000 mg every 4 weeks for 4 doses (Doses 9 - 12))"
9777732|NCT01088048|Experimental|Idelalisib + Fludarabine|"Participants with CLL will receive treatments as follows:~Cohort 3d: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + fludarabine 40 mg/m^2 orally on Days 1 - 5 of each 28-day cycle, Cycles 1 - 6"
9777733|NCT01088048|Experimental|Idelalisib + Everolimus|"Participants with MCL will receive treatments as follows:~Cohort 5a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + everolimus 10 mg orally once daily on Days 1 - 28 of each 28-day cycle"
9777734|NCT01088048|Experimental|Idelalisib + Bortezomib|"Participants with MCL will receive treatments as follows:~Cohort 5b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bortezomib 1.3 mg/m^2 subcutaneously on Days 1, 8 & 15 of each 28-day cycle"
9777735|NCT01088048|Experimental|Idelalisib + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + chlorambucil 10 mg/m^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
9777736|NCT01088048|Experimental|Idelalisib + Rituximab + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + chlorambucil 10 mg/m^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
9784971|NCT01238991|Experimental|ACC-001 (3 micrograms) + QS-21|Active vaccine dose of 3 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
9784972|NCT01238991|Experimental|ACC-001 (10 micrograms) + QS-21|Active vaccine dose of 10 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
9777737|NCT01088048|Experimental|Idelalisib + Rituximab + Lenalidomide|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 7a: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 5 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles~Cohort 7b: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 10 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles~Cohort 7c: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 20 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles"
9777738|NCT01088243|Experimental|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
9777739|NCT01088243|Placebo Comparator|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
9777740|NCT01088295|Experimental|Telmisartan|Telmisartan 40mg po daily for 24 weeks
9777741|NCT01088399||Somatropin replacement treatment|Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
9777742|NCT01088399||No treatment|Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.
9777743|NCT01088412||Treated|Participants treated with somatropin for improvement of growth
9777744|NCT01088412||Untreated|Untreated participants with presence or history of neoplastic disease evaluated for endocrine or growth disorder or with any SHOX deficiency related disorder
9777745|NCT01088438|Experimental|Contextualization workshop|A four-hour course on contextualization.
9777746|NCT01088438|No Intervention|Control|No intervention
9777747|NCT01088464|Experimental|Cohort 1|
9777748|NCT01088464|Experimental|Cohort 2|
9777749|NCT01088464|Experimental|Cohort 3|
9777750|NCT01088503||ADP receptor inhibitor treatment|Participants admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
9777751|NCT01088529|Experimental|AA+LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.
9777752|NCT01088529|Experimental|LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
9777753|NCT01088672|Other|Acute Ischemic Stroke|Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
9777754|NCT01088711|Experimental|Healthy Omarigliptin|Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
9777755|NCT01088711|Placebo Comparator|Healthy Placebo|Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
9777756|NCT01088711|Experimental|T2D Omarigliptin|Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
9777757|NCT01088711|Placebo Comparator|T2D Placebo|Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
9777758|NCT01088984|Experimental|Bendamustine|Bendamustine 90 or 120 mg/m^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.
9777759|NCT01088997|Experimental|High Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
9777760|NCT01088997|Experimental|Low Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
9777761|NCT01089023|Experimental|1|
9777762|NCT01089062|Other|Treatment A, then Treatment B, then Treatment C|"The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
9784973|NCT01238991|Experimental|ACC-001 (30 micrograms) + QS-21|Active vaccine dose of 30 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
9784974|NCT01239043|Experimental|Menomune® vaccine group|Participants received Menomune® vaccine in MTA29 (NCT00874549)
9784975|NCT01239043|Experimental|Menactra® vaccine group|Participants received Menactra® vaccine in trial MTA29 (NCT00874549)
9784976|NCT01239056||Pancreatic Pseudocysts|All adult patients who have a clinical indication to undergo an endoscopic drainage of a pancreatic pseudocyst.
9777763|NCT01089062|Other|Treatment A, then Treatment C, then Treatment B|"The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
9777764|NCT01089062|Other|Treatment B, then Treatment A, then Treatment C|"The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
9777765|NCT01089062|Other|Treatment B, then Treatment C, then Treatment A|"The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
9777766|NCT01089062|Other|Treatment C, then Treatment A, then Treatment B|"The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
9777767|NCT01089062|Other|Treatment C, then Treatment B, then Treatment A|"The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
9777768|NCT01089127|Experimental|Indacaterol 18.75 μg|Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
9777769|NCT01089127|Experimental|Indacaterol 37.5 μg|Patients inhaled indacaterol 37.5 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
9777770|NCT01089127|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
9777771|NCT01089127|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
9777772|NCT01089127|Active Comparator|Salmeterol 50 μg|Patients inhaled salmeterol 50 μg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
9777773|NCT01089127|Placebo Comparator|Placebo|Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
9777774|NCT01089231|Placebo Comparator|Placebo - healthy subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
9777775|NCT01089231|Placebo Comparator|Placebo - hyperlipedemic subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
9777776|NCT01089231|Experimental|Fish oil - hyperlipidemic subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
9777777|NCT01089231|Experimental|Fish oil - healthy subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.
9777778|NCT01089361|Placebo Comparator|Normal saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
9777779|NCT01089361|Experimental|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
9777780|NCT01089413||Cohort|
9777781|NCT01089504|Active Comparator|Phenobarbital|Phenobarbital, 4-5 mg/kg/day, for 4 months
9777782|NCT01089504|Placebo Comparator|Placebo|Placebo in a volume equivalent to active drug for 4 months
9777783|NCT01089517|Active Comparator|Lucentis|
9777784|NCT01089517|Experimental|E10030 low dose plus Lucentis|
9777785|NCT01089517|Experimental|E10030 high dose plus Lucentis|
9777786|NCT01089543|Experimental|Rabeprazole 10 mg|
9777787|NCT01089543|Experimental|Rabeprazole 20 mg|
9777788|NCT01089543|Experimental|Rabeprazole 40 mg|
9777789|NCT01089543|Placebo Comparator|Placebo|
9777790|NCT01089556|Experimental|Duloxetine|"Initial Treatment:~Duloxetine 30 milligram (mg) daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week~Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks"
9777791|NCT01089556|Experimental|Pregabalin+Duloxetine|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 300 mg (150 mg twice daily) daily for 8 weeks~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks"
9777792|NCT01089556|Experimental|Pregabalin|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 450 mg (300 mg in the morning, 150 mg in the evening) daily for 1 week~Pregabalin 600 mg (300 mg twice daily) daily for 7 weeks"
9777793|NCT01089556|Experimental|Duloxetine + Pregabalin|"Initial Treatment:~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 60 mg daily for 8 weeks~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks"
9777794|NCT01089569|Active Comparator|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
9777795|NCT01089569|Active Comparator|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
9777796|NCT01089569|Active Comparator|Exenatide + Insulin Glargine|"Exenatide: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study~+ Insulin Glargine: 0.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results"
9777797|NCT01089582||AD patients|
9777798|NCT01089595|Active Comparator|Nilotinib|Nilotinib 400 mg po bid
9777799|NCT01089595|Active Comparator|Nilotinib + Imatinib|Nilotinib 400 mg BID with Imatinib 400 mg daily
9777800|NCT01089608|Placebo Comparator|Unifluid|Eye drops in Single Dose Unit
9777801|NCT01089608|Experimental|Azithromycin|Eye drops Single dose unit
9777802|NCT01089647|Active Comparator|budesonide and montelukast|treatment arm
9777803|NCT01089647|Placebo Comparator|placebo|sugar pill, salt water nasal spray
9777804|NCT01089725|Placebo Comparator|Placebo|
9777805|NCT01089725|Experimental|2.5 mg tanezumab SC and placebo IV|
9777806|NCT01089725|Experimental|5 mg tanezumab SC and placebo IV|
9777807|NCT01089725|Experimental|10 mg tanezumab SC and placebo IV|
9777808|NCT01089725|Experimental|10 mg tanezumab IV|
9777809|NCT01089751|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
9777810|NCT01089751|Placebo Comparator|Placebo|Placebo once daily on an empty stomach for 14 weeks.
9777811|NCT01090011|Experimental|combination arm|patients to receive medium BIBW 2992 once daily plus biweekly cetuximab infusion at low, median and high dose level
9777812|NCT01090011|Experimental|sequential arm|patients to receive BIBW 2992 once daily, upon progression add biweekly cetuximab
9784977|NCT01239121|Experimental|HIE-Enhanced Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
10204197|NCT03883828|Experimental|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
10204198|NCT03883828|No Intervention|Control|Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.
10204199|NCT03878485|Experimental|Stereotactic MRI-guided Adaptive Radiotherapy|-Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
10204200|NCT03854227|Experimental|Dose Escalation|Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis
10204201|NCT03854227|Experimental|Non small cell lung cancer monotherapy|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
10204202|NCT03854227|Experimental|Urothelial carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
10204203|NCT03854227|Experimental|Head and neck squamous cell carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
10204204|NCT03854227|Experimental|Non small cell lung cancer PF-06939999 plus docetaxel|Participants will receive PF-06939999 on a continuous basis in combination with docetaxel
10204205|NCT03854227|Experimental|Non small cell lung cancer dose finding|Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel
10204206|NCT03835819|Experimental|IMGN853 + Pembrolizumab|"Pembrolizumab is administered intravenously once every 3 weeks~IMGN853 is administered intravenously once every 3 weeks"
10204207|NCT03819842|No Intervention|Aphakic Measure only|Eye measured in aphakic state only
10204208|NCT03819842|Active Comparator|Pseudophakic measure|Eye measured in aphakic state then again in pseudophakic state with toric IOL using the ORA System. Pseudophakic measurement obtained will provide data about placement of toric iol and the surgeon will use that data to rotate the iol if necessary.
10204209|NCT03817463||Patients with T2DM|
10204210|NCT03808272|Experimental|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System
10204211|NCT03805737|Experimental|Indoor Daylight PDT Therapy|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will be exposed to natural sunlight through a window for 2 hours. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
10204212|NCT03805737|Active Comparator|FDA Approved Standard Light Therapy Treatment|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
9777813|NCT01090050|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Sumatriptan/Naproxen Sodium will treat daily with 1 tablet Sumatriptan 85mg / Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Sumatriptan/Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue.
9777814|NCT01090050|Active Comparator|Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Naproxen Sodium will treat daily with 1 tablet Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Naproxen Sodium will be provided with 14 tablets of Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue.
9777815|NCT01090076|Experimental|Abound|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
9777816|NCT01090076|Placebo Comparator|Placebo|Placebo comparator that contains none of the active ingredients
9777817|NCT01090102|Experimental|Mesalamine|
9777818|NCT01090102|Placebo Comparator|Placebo|
9777819|NCT01090180|Experimental|Arm 1: Dexamethasone|Dexamethasone (oral)
9777820|NCT01090180|Placebo Comparator|Arm 2: Placebo|Placebo (inactive)
9777821|NCT01090310|Experimental|AIN457 300mg every 2 weeks|AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
9777822|NCT01090310|Experimental|AIN457 300 mg every 4 weeks|AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
10204213|NCT03787849|Active Comparator|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction . After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
9777823|NCT01090310|Experimental|AIN457 150 mg every 4 weeks|AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
9777824|NCT01090310|Placebo Comparator|Placebo|Placebo s.c. every 2 weeks
9777825|NCT01090323|Experimental|ICL670|
9777826|NCT01090414|Experimental|Idelalisib|Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.
9777827|NCT01090427|Experimental|Ustekinumab Half-standard Dosage|Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
10204214|NCT03787849|Active Comparator|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
9777828|NCT01090427|Experimental|Ustekinumab Standard Dosage|Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
9777829|NCT01090427|Experimental|Placebo|Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.
9777830|NCT01090453|Experimental|GSK2202083A Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2202083A vaccine, co-administered with Prevenar 13® at 2, 4 and 12 months of age. The GSK2202083A and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
9777831|NCT01090453|Active Comparator|Infanrix hexa Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® and Menjugate® at 2, 4 and 12 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the right and upper left sides of the thigh, respectively and the Menjugate® vaccine was administered intramuscularly in the lower left thigh. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
10204215|NCT03781440|Experimental|Bilateral ESP catheter with Lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
10204216|NCT03781440|Placebo Comparator|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
10204217|NCT03777319|Experimental|Spironolactone|Twelve subjects will be prescribed a standard clinical dose of spironolactone of 1 mg/kg/day. The spironolactone will be provided as suspension.
10204218|NCT03777319|Active Comparator|Prednisolone|Twelve subjects will be prescribed a standard clinical dose of prednisolone of 0.75 mg/kg/day or weekend dosing per sites standard of care. The prednisolone will be provided will be provided as suspension.
10204219|NCT03770052|Experimental|0.25mg robeglitazone add-on group|0.25mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
10204220|NCT03770052|Active Comparator|0.5mg robeglitazone add-on group|0.5mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
10204221|NCT03765099|Experimental|Animal-Assisted Interactions|Children and their caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
9777832|NCT01090479|No Intervention|Control|This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
9777833|NCT01090479|Experimental|2% Chlorhexidine cloth|This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.
9777834|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 1)|
9777835|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 2)|
9777836|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 1)|
9777837|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 2)|
9777838|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 1)|
9777839|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 2)|
9777840|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 1)|
9777841|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 2)|
9777842|NCT01090739|Experimental|TOPAS|TOPAS Treatment for Fecal Incontinence
9777843|NCT01090752|Placebo Comparator|Pioglitazone|placebo-controlled, randomized, cross-over study
9777844|NCT01090752|Placebo Comparator|Metformine|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
9777845|NCT01090765|Experimental|TRC105 1 mg/kg every 2 weeks|Intravenous infusion at 1 mg/kg every 2 weeks
9777846|NCT01090765|Experimental|TRC105 3 mg/kg every 2 weeks|Intravenous infusion at 3 mg/kg every 2 weeks
9777847|NCT01090765|Experimental|TRC105 10 mg/kg every 2 weeks|Intravenous infusion at 10 mg/kg every 2 weeks
9777848|NCT01090765|Experimental|TRC105 10 mg/kg weekly|Intravenous infusion at 10 mg/kg weekly
9777849|NCT01090765|Experimental|TRC105 15 mg/kg every 2 weeks|Intravenous infusion at 15 mg/kg every 2 weeks
9777850|NCT01090765|Experimental|TRC105 20 mg/kg every 2 weeks|Intravenous infusion at 20 mg/kg every 2 weeks
9777851|NCT01090921|Experimental|Single-Arm|Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
9777852|NCT01090973|Experimental|Oral drug treatment|LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26.
9777853|NCT01091103|Experimental|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
9777854|NCT01091116|Experimental|Double dose MEN16132 0.125 mg|Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.
9777855|NCT01091116|Experimental|Double dose MEN16132 0.25 mg|Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.
9777856|NCT01091116|Experimental|Double dose MEN16132 0.5 mg|Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.
9777857|NCT01091116|Experimental|Single dose MEN16132 0.5 mg|Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.
9777858|NCT01091116|Placebo Comparator|Placebo|Intra-articular administration of two doses of Placebo at 2-week interval.
9777859|NCT01091155|Experimental|ColonRing TM|
9777860|NCT01091168|Experimental|arm A: Vinflunine|Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.
9777861|NCT01091168|Active Comparator|arm B: Alkylating agent of physician choice|Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.
9777862|NCT01091246|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
9777863|NCT01091246|Experimental|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])
9984325|NCT04222660|Experimental|Normal subjects, aged match with no symptoms of diabetes|Healthy, aged matched control subjects will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
9777864|NCT01091246|Experimental|FluMist/B/Victoria|FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004]).
9777865|NCT01091259|Experimental|Irinotecan with Bevacizumab|Irinotecan is administered every 3 weeks at a dose of 175 mg/m^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
9777866|NCT01091363|Experimental|deep cultural arm|deep cultural therapy
9777867|NCT01091363|Active Comparator|standard arm|brief cessation counseling
9777868|NCT01091428|Experimental|Alisertib (Phase 1 - Ovarian cancer)|Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
9777869|NCT01091428|Experimental|Alisertib (Phase 1 - Breast cancer)|Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
9777870|NCT01091428|Experimental|Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2)|Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
9777871|NCT01091428|Experimental|Paclitaxel 80 mg/m^2 (Phase 2)|Paclitaxel 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
9777872|NCT01091454|Experimental|Treatment (cisplatin and brostallicin)|Patients receive cisplatin IV over 2 hours on day 1 and brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9777873|NCT01091519||Toviaz(fesoterodine) plus educational materials|
9777874|NCT01091519||Toviaz(fesoterodine) alone|Toviaz(fesoterodine) without additional educational materials
9777875|NCT01091662|Experimental|eslicarbazepine acetate 1600 mg|Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD(Day 0) to 1200 mg once a day(Week 2) to 1600 mg QD (Weeks 3-18) and may taper down from 1600 mg to 800 mg QD 3 days after the Week 18 visit.
9777876|NCT01091662|Experimental|eslicarbazepine acetate 1200 mg|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day0) to 800 mg QDweek2) to 1200 mg QD(weeks 3-18) and may taper down from 1200 mg to 600 mg QD 3 days after the Week 18 visit.~Subjects may continue in an open-label extension study with a starting dose of 1200 mg QD, or taper off their previous antiepileptic drugs during weeks 2-8."
9777877|NCT01091675|Experimental|etoricoxib|All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
9777878|NCT01091948|Active Comparator|Fiberoptic Intubation|Subjects will be intubated with the Fiberoptic laryngoscope.
9777879|NCT01091948|Active Comparator|GlideScope® Video Laryngoscope|Subjects will be intubated with the GlideScope® Video Laryngoscope.
9777880|NCT01091974|Experimental|1 - CBT-I + placebo|CBT-I and placebo
9777881|NCT01091974|Experimental|2 - CBT-I + Armodafinil|CBT-I + Armodafinil
9777882|NCT01091974|Placebo Comparator|3 - Placebo only|Placebo only
9777883|NCT01091974|Experimental|4 - Armodafinil only|Armodafinil only
9777884|NCT01092182|Experimental|Group A - Burkitt lymphoma Low Risk Arm|Burkitt lymphoma Low Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
9777885|NCT01092182|Experimental|Group B - Burkitt lymphoma High Risk Arm|Burkitt lymphoma High Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
9777886|NCT01092182|Experimental|Group C - DLBCL high risk arm|Diffuse large B-cell lymphoma (DLBCL) high risk arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
9777887|NCT01092195|Active Comparator|Cohort 1|Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
9777888|NCT01092195|Active Comparator|Cohort 2|Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
9777889|NCT01092195|Active Comparator|Cohort 3|Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
9777890|NCT01092338|Active Comparator|4000IU|Subjects in this arm take a daily dose of 4000IU of Vitamin D3
9777891|NCT01092338|Active Comparator|7000IU|Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3
9777892|NCT01092364|Experimental|Cell phone intervention|Behavioral lifestyle intervention for weight loss, delivered by cell phone.
9777893|NCT01092364|Experimental|Personal counseling intervention|Behavioral lifestyle intervention for weight loss, delivered by personal counseling.
9777894|NCT01092364|No Intervention|Advice only|Advice only control group.
9777895|NCT01092442||Retrospective Patients|Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.
9777896|NCT01092442||Prospective Patients|Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.
9777897|NCT01092507|Experimental|JE-CV Group|Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
9777898|NCT01092507|Active Comparator|SA14-14-2 vaccine Group|Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)
9777899|NCT01092546|Experimental|Arm 1|
9777900|NCT01092559|Experimental|nitric oxide via GeNO Nitrosyl system|Nitric Oxide via GeNO Nitrosyl system
9777901|NCT01092637||Cooled|Child was allocated standard intensive care plus moderate whole body hypothermia treatment within 6 hours of birth
9777902|NCT01092637||Non-cooled|Child was allocated standard intensive care only within 6 hours of birth
9777903|NCT01092663|Active Comparator|Colesevelam HCl: 3 tablets, 2x/day|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
9777904|NCT01092663|Active Comparator|Colesevelam plus Sitagliptin|"Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks."
9777905|NCT01092676|Active Comparator|Regular Ibuprofen Dosing|Regular Ibuprofen Dosing throughout 4 days of study
9777906|NCT01092676|Active Comparator|PRN Ibuprofen dosing|As needed Ibuprofen dosing
9777907|NCT01092702|Other|Varenicline|Everyone on study will receive Varenicline daily for 12 weeks
9777908|NCT01092728|Active Comparator|Group 1: Completely Resectable|Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).
9777909|NCT01092728|Active Comparator|Group 2: Unresectable|100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment).
9777910|NCT01092767|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|Valiant Thoracic Stent Graft with the Captivia Delivery System
9777911|NCT01092780|Experimental|MK-7288 10mg/Pbo/MK-7288 20mg/Modafinil|Participants received single doses of study drug in the following order: MK-7288 10 mg in Treatment Period 1, Placebo (Pbo) in Treatment Period 2, MK-7288 20 mg in Treatment Period 3 and Modafinil 200 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
9777912|NCT01092780|Experimental|MK-7288 20mg/MK-7288 10mg/Modafinil/Pbo|Participants received single doses of study drug in the following order: MK-7288 20 mg in Treatment Period 1, MK-7288 10 mg in Treatment Period 2, Modafinil 200 mg in Treatment Period 3 and Placebo in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
9777913|NCT01092780|Experimental|Modafinil/MK-7288 20mg/Pbo/MK-7288 10mg|Participants received single doses of study drug in the following order: Modafinil 200 mg in Treatment Period 1, MK-7288 20 mg in Treatment Period 2, Placebo in Treatment Period 3 and MK-7288 10 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
9777914|NCT01092780|Experimental|Pbo/Modafinil/MK-7288 10 mg/MK-7288 20mg|Participants received single doses of study drug in the following order: Placebo in Treatment Period 1, Modafinil 200 mg in Treatment Period 2, MK-7288 10 mg in Treatment Period 3 and MK-7288 20 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
9777915|NCT01092832|Experimental|Active voriconazole|All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
9777916|NCT01092910|Experimental|Esteem Implant|Subjects are implanted with the Esteem Totally Implantable Hearing System
9777917|NCT01092923|Experimental|Air/Oxygen|Sevoflurane with Air/Oxygen Mix
9777918|NCT01092923|Experimental|sevoflurane in N2O/O2|
9784978|NCT01239121|Active Comparator|Optimal Medication Reconciliation without HIE|Optimal Medication Reconciliation without Health Information Exchange (HIE) for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
9784979|NCT01239121|Other|Pilot HIE-Enhanced Outpatient Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans seen as outpatients in Geriatrics Primary care clinic
9784980|NCT01239160|Experimental|Advanced PCD|The use of an advanced PCD device to reduce and maintain limb volume
10204222|NCT03765099|Active Comparator|Usual Care|Children and their caregivers randomly assigned to the usual care group will receive usual care which may include play therapy, music therapy or visits with a social worker during their visits to the hospital.
10204223|NCT03762265|Experimental|Experimental|
9784981|NCT01239160|Active Comparator|Simple PCD|The use of the Simple PCD is to reduce and maintain limb volume
9784982|NCT01239316|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
10204224|NCT03762265|Placebo Comparator|Placebo|
9784983|NCT01239342|Experimental|Arm I (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who are progression free after 1 year may receive a 12 week study drug supply of Akt inhibitor MK2206.
10204225|NCT03759951|Experimental|Control|No intervention. Participated only in measurements at baseline, at 6 months and at 12 months.
9784984|NCT01239342|Experimental|Arm II (everolimus)|Patients receive everolimus PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
10204226|NCT03759951|Experimental|DoIT-1|Participated in a supervised 1-year workout exercise training program once per week and in measurements at baseline, at 6 months and at 12 months.
10204227|NCT03759951|Experimental|DoIT-2|Participated in a supervised 1-year workout exercise training program twice per week and in measurements at baseline, at 6 months and at 12 months.
10204228|NCT03759951|Experimental|DoIT-3|Participated in a supervised 1-year workout exercise training program thrice per week and in measurements at baseline, at 6 months and at 12 months.
10204229|NCT03740100|Other|Open single arm|Bimiralisib capsules orally
10204230|NCT03729427|Experimental|Treatment Arm|ESP Block
10204231|NCT03729427|No Intervention|Control Arm|Standard of Care
10204232|NCT03728582|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be verb naming therapy in a sentence context. This will be followed by sham tDCS plus speech-language therapy after a 2 month washout period.
9777919|NCT01093014|Experimental|Arm 1: High-force muscle stimulation|High-force muscle stimulation
9777920|NCT01093014|Experimental|Arm 2: Low-force muscle stimulation|Low-force muscle stimulation
9777921|NCT01093014|Experimental|Arm 3: Sequential low-force and high-force muscle stimulation|Sequential low-force and high-force muscle stimulation
9777922|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
9777923|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
9777924|NCT01093183|Experimental|Treatment (lenalidomide and cyclophosphamide)|Patients receive lenalidomide PO QD on days 1-21 and cyclophosphamide PO QD on days 1-28. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response.
9777925|NCT01093222|Experimental|Treatment (sorafenib tosylate and erlotinib hydrochloride)|Patients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9777926|NCT01093417|Placebo Comparator|Placebo|Participants that have been randomized into this arm will receive placebo pills.
9777927|NCT01093417|Active Comparator|Vitamin D 4000 IU|Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.
9777928|NCT01093469|Experimental|Aquaphor Healing Ointment|Aquaphor Healing Ointment three times daily to atopic dermatitis
9777929|NCT01093469|Active Comparator|Atopiclair Nonsteroidal Cream|Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis
9777930|NCT01093469|Active Comparator|EpiCream Skin Barrier Emulsion|EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis
9777931|NCT01093482||mechanically ventilated patients|"Patients who are admitted to the participating intensive care units and require invasive mechanical ventilation (endotracheal tube or tracheostomy) for more than 12 hours.~Patients who are admitted to the participating intensive care units and require non-invasive mechanical ventilation (Bilevel positive airway pressure (BIPAP) or continuous positive airway pressure (CPAP) with nasal or facial mask) for more than 1 hour."
9777932|NCT01093521|Experimental|100 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2
9777933|NCT01093521|Experimental|200 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2
9777934|NCT01093534|Placebo Comparator|Placebo|Participants received 2 placebo tablets once daily for 12 weeks.
9777935|NCT01093534|Experimental|Solifenacin 5 mg|Participants received one 5 mg solifenacin tablet and one placebo tablet, once daily for 12 weeks.
9777936|NCT01093534|Experimental|Solifenacin 10 mg|Participants received two 5 mg solifenacin tablets once daily for 12 weeks.
9777937|NCT01093573|Experimental|Dose Level 1|Aza at 75 mg/m2 D1-7 & Midostaurin 25 mg BID D 8-21
9777938|NCT01093573|Experimental|Dose Level 2|Aza at 75 mg/m2 D1-7 & Midostaurin 50 mg BID D 8-21
9777939|NCT01093573|Experimental|Dose Level 3|Azacitidine 75 mg/m2 IV D1-7 & Midostaurin 75 mg PO BID D 8-21
9777940|NCT01093586|Experimental|Arm I|PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
9777941|NCT01093599|Active Comparator|Quit Line Only|Control Participants will call the Wisconsin Tobacco Quit Line intervention including phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
9777942|NCT01093599|Active Comparator|Quit Line plus MTS|Participants in the study group will receive the Quit Line intervention (talk to a Quit Line Counselor, receive quit smoking materials and get 4 weeks of nicotine patches) and also receive 4 weeks of training in mindfulness meditation through the mindfulness for smokers intervention.
9777943|NCT01093625|Experimental|Narafilcon B Contact Lens|Investigational Silicone Hydrogel Contact Lens
9777944|NCT01093625|Active Comparator|Spectacles|
9777945|NCT01093651|Experimental|DPPIV inhibition|Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
9777946|NCT01093651|Placebo Comparator|Placebo|Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
9777947|NCT01093690|Experimental|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5
9777948|NCT01093690|Placebo Comparator|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
9777949|NCT01093755|Active Comparator|dexlansoprazole|Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
9777950|NCT01093755|Active Comparator|omeprazole|Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
9777951|NCT01093794|Experimental|1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 500 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin"
9777952|NCT01093794|Experimental|2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin~Co-administration of 50 mg sitagliptin and 500mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet"
9777953|NCT01093794|Experimental|3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500mg metformin"
9777954|NCT01093794|Experimental|4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500 mg metformin~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet"
9777955|NCT01093885|Other|open label: medication Ambrisentan|"Open label study of Ambrisentan.~Ambrisentan will begin at 5mg daily for the first month.~Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week. Subjects will continue their present dose and schedule of disease modifying/antifibrotic medication for the duration of the study.~** Dose escalation was attempted however none of the patients were able to increase. Therefore all subjects remained on 5 mg daily throughout the study. 12 patients on mycophenolate mofetil, 2 on mycophenolic acid and one on methotrexate"
9777956|NCT01093976|Experimental|Dronabinol|Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks
9777957|NCT01094106|Active Comparator|Ropivacaine 0,75%|Postoperative wound infusion 15 mg /h / 48h
9777958|NCT01094106|Placebo Comparator|NaCl 0,9%|Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h
9777959|NCT01094119|Active Comparator|Bair Hugger heated blanket|Patients will be warmed during surgery with the Bair Hugger heated blanket.
9777960|NCT01094119|Active Comparator|LMA PerfecTemp system|Patients will be warmed during surgery with the PerfecTemp heated pad .
9777961|NCT01094171|Experimental|Poliorix Group|Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age. All vaccines were administered intramuscularly in the anterolateral side of the left thigh (Poliorix) and the right thigh (Infanrix).
9777962|NCT01094184|Experimental|Bevacizumab 10 mg/kg Q2W|Participants will receive bevacizumab at a dose of 10 milligrams per kilogram (mg/kg) every 2 weeks (Q2W) as intravenous infusion along with paclitaxel every week (Q1W) or docetaxel every 3 weeks (Q3W) as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
9777963|NCT01094184|Experimental|Bevacizumab 15 mg/kg Q3W|Participants will receive bevacizumab at a dose of 15 mg/kg Q3W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
9777964|NCT01094288|Experimental|Alisertib + Docetaxel|"Alisertib in escalating dose (10-40 mg), enteric-coated tablets (ECT), orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 along with docetaxel 60-75 mg/m^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable adverse events (AEs) or withdrawal of consent.~The starting alisertib dose is 10 mg, orally, twice daily (total 20 mg/day)."
9777965|NCT01094301|Experimental|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
9777966|NCT01094522|Experimental|Methadone|One half the Study patients will be randomized to receive a loading dose of IV methadone, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
9777967|NCT01094522|Active Comparator|Morphine|One half the Study patients will be randomized to receive a loading dose of IV morphine, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
9777968|NCT01094548|Experimental|Tecemotide (L-BLP25) plus single low dose cyclophosphamide|
9777969|NCT01094548|Experimental|Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide|
9777970|NCT01094574|Active Comparator|Alfentanil|Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
9777971|NCT01094574|Active Comparator|Propranolol|Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
9777972|NCT01094574|Placebo Comparator|Placebo|Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
9777973|NCT01094704|Experimental|Hypertonic Saline - 1 hour|sodium chloride (7%); mucociliary clearance measured 1 hour post dose
9777974|NCT01094704|Experimental|Hypertonic Saline - 4 hours|sodium chloride (7%); mucociliary clearance measured four hours post-dose.
9777975|NCT01094717|Experimental|acitretin and active excimer laser|patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions.
9777976|NCT01094717|Experimental|acitretin and sham excimer laser|Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of body psoriasis lesions.
9777977|NCT01094717|Experimental|tazarotene and active excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and excimer (active) laser to randomly assigned left or right side of body psoriasis lesions.
9777978|NCT01094717|Experimental|tazarotene and sham excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and sham excimer laser to randomly assigned left or right side of body psoriasis lesions.
9777979|NCT01094730|Other|galyfilcon A prototype/marketed galyfilcon A|The galyfilcon A prototype lens worn daily for 12-16 days during the first period then the marketed galyfilcon A lens worn daily for 12-16 days during the second period.
9777980|NCT01094730|Other|marketed galyfilcon A/galyfilcon A prototype|The marketed galyfilcon A lens worn daily for 12-16 days during the first period then the galyfilcon A prototype lens worn daily for 12-16 days during the second period; during each period.
9777981|NCT01094743|Other|galyfilcon A prototype lens / lotrafilcon B lens|The galyfilcon A prototype lenses will be worn during the first period and lotrafilcon B lenses will be worn during the second period. Each period consists of daily lens wear for one week.
9777982|NCT01094743|Other|lotrafilcon B lens / galyfilcon A prototype lens|The lotrafilcon B lenses will be worn during the first period and galyfilcon A prototype lenses will be worn during the second period. Each period consists of daily lens wear for one week.
9777983|NCT01094782|Active Comparator|Healthy - True Acupuncture|Healthy volunteers with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7.This group received true acupuncture treatment (the needles punctured the skin).
9777984|NCT01094782|Sham Comparator|Healthy - Sham Acupuncture|Healthy with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
9777985|NCT01094782|No Intervention|Healthy - No Treatment|Healthy volunteers with no neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
9777986|NCT01094782|Active Comparator|Pain - True Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received true acupuncture treatment (the needles punctured the skin).
9777987|NCT01094782|Sham Comparator|Pain - Sham Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
9777988|NCT01094782|No Intervention|Pain - No Treatment|Volunteers with radiating neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
9777989|NCT01094808|Experimental|Pregabalin 75 mg|Subjects randomized to this arm received a single dose of pregabalin 75 mg orally
9777990|NCT01094808|Experimental|Pregabalin 200 mg|Subjects randomized to this arm received a single dose of pregabalin 200 mg orally
9777991|NCT01094808|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo medication orally
9777992|NCT01094886|Experimental|001|Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
9984326|NCT04218838|Active Comparator|CornerLoc SI Joint Stabilization Group|Patient will receive the CornerLoc minimally invasive SI Joint Stabilization procedure. This procedure will be performed in an outpatient surgery center under local sedation or general anesthesia, and normally takes around 45 minutes. During the procedure, the physician will make two small incisions in the patient's lower back to access the SI joint, and place four small cadaveric bone grafts into the SI joint to help stabilize the SI joint.
9777995|NCT01095094|Experimental|Arm I|Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.
9777996|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 1|
9777997|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 2|
9777998|NCT01095510|Experimental|500 U CINRYZE (10-25 kg body weight)|Single IV dose of 500 U CINRYZE
9777999|NCT01095510|Experimental|1000 U CINRYZE (10-25 kg body weight)|Single IV dose of 1000 U CINRYZE
9778000|NCT01095510|Experimental|1000 U CINRYZE (>25 kg body weight)|Single IV dose of 1000 U CINRYZE
9778001|NCT01095510|Experimental|1500 U CINRYZE (>25 kg body weight)|Single IV dose of 1500 U CINRYZE
9778002|NCT01095653|Experimental|Group 1|
9778003|NCT01095653|Experimental|Group 2|
9778004|NCT01095653|Experimental|Group 3|
9778005|NCT01095666|Experimental|Group 1|
9778006|NCT01095666|Experimental|Group 2|
9778007|NCT01095666|Experimental|Group 3|
9778008|NCT01095757|Other|Plerixafor + Chemo and G-CSF|Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
9778009|NCT01095796|Experimental|Stribild|Stribild plus placebo to match Atripla
9778010|NCT01095796|Active Comparator|Atripla|Atripla plus placebo to match Stribild
9778011|NCT01095835|Experimental|PEG-IFN48|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
9778012|NCT01095835|Experimental|PEG-IFN96|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
9778013|NCT01095835|Experimental|PEG-IFN+LAM96|Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).
9778014|NCT01095887|Experimental|eculizumab|Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.
9778015|NCT01095978||Acute upper respiratory tract diseases, bronchitis, pneumonia|
9778016|NCT01096017|Experimental|1|Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler®
9778017|NCT01096017|Experimental|2|salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI
9778018|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 1 Group|Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.
9778019|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 2 Group|Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.
9778020|NCT01096160|Experimental|Panel A: MK-8266 BID, 1 mg/Placebo|MK-8266 1 mg (0.7 mg in the morning [AM] + 0.3 mg in the evening [PM]), or as matching placebo BID.
9778021|NCT01096160|Experimental|Panel B: MK-8266 BID, 1.8 mg/Placebo|MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
9778022|NCT01096160|Experimental|Panel C: MK-8266 TID, 1.8 mg/Placebo|MK-8266 TID, 1.8 mg (0.6 mg every 6 hours [q6hr]), or as matching placebo TID.
9778023|NCT01096160|Experimental|Panel D: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
9778024|NCT01096160|Experimental|Panel E: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.
9778025|NCT01096186|Other|Open Label IPX066|Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.
9778026|NCT01096290|Experimental|Lubiprostone 24mcg BID for 30 days|Active medication
9778027|NCT01096290|Placebo Comparator|Placebo|Placebo, matched, blinded
9778028|NCT01096316|Experimental|Intervention|"The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:~enhanced education of patients and providers~engagement of patients~depression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation."
9778029|NCT01096316|No Intervention|Usual Care|Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.
9778030|NCT01096342|Experimental|Treatment|Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9778031|NCT01096446|Experimental|Higher Infusion|Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
9778032|NCT01096446|Other|Standard Infusion|Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
9778033|NCT01096550|Experimental|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
9778034|NCT01096550|Active Comparator|Outpatient|Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
9778035|NCT01096589|Experimental|Arm 1 - 3M Coban 2|3M Coban 2 - 2 apps/wk
9778036|NCT01096589|Experimental|Arm 2 - 3M Coban 2|3M Coban 2 - 3 apps/wk
9778037|NCT01096589|Experimental|Arm 3 - 3M Coban 2|Arm 3 - 3M Coban 2 - 5 apps/wk
9778038|NCT01096589|Active Comparator|Arm 4 - Comprilan|Comprilan short-stretch bandage 5 apps/wk
9778039|NCT01096667|Placebo Comparator|Placebo|Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
9778040|NCT01096667|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
9778041|NCT01096667|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
9778042|NCT01096667|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
9778043|NCT01096667|Active Comparator|HCTZ 12.5mg|HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days
9778044|NCT01096680|Experimental|SPD489 20 mg|
9778045|NCT01096680|Experimental|SPD489 50 mg|
9778046|NCT01096680|Experimental|SPD489 70 mg|
9778047|NCT01096680|Active Comparator|Armodafinil|
9778048|NCT01096680|Placebo Comparator|Placebo|
9778049|NCT01096771|Experimental|ClinOleic 20%|96 hour continuous infusion.
9778050|NCT01096771|Active Comparator|Intralipid 20%|96 hour continuous infusion.
9778051|NCT01096784|Active Comparator|rhIGF-I/rhIGFBP-3|Continuous IV Infusion
9778052|NCT01096784|No Intervention|Control|The comparator group will receive no treatment with rhIGF-1/rhIGFBP-3
9778053|NCT01096810|Experimental|TBL 12|TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression
10204233|NCT03728582|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. Language therapy will be verb naming therapy in a sentence context. This will be followed by active tDCS plus speech-language therapy after a 2 month washout period.
9778054|NCT01096823|Experimental|Iyengar Yoga|
9778055|NCT01096823|No Intervention|Waitlist Control|
9778056|NCT01096849|Experimental|plazomicin (10 mg/kg)|Patients received two intravenous (IV) infusions daily for 5 consecutive days: 10 milligrams per kilogram (mg/kg) plazomicin followed by placebo.
9778057|NCT01096849|Experimental|plazomicin (15 mg/kg)|Patients received two IV infusions daily for 5 consecutive days: 15 mg/kg plazomicin followed by placebo.
9778058|NCT01096849|Active Comparator|levofloxacin|Patients received two IV infusions daily for 5 consecutive days: placebo followed by 750 milligrams (mg) levofloxacin.
9778059|NCT01096875|Active Comparator|Atorvastatin|Hydroxymethylglutaryl-CoA Reductase Inhibitors
9778060|NCT01096875|Placebo Comparator|Placebo|Atorvastatin like pill
9778061|NCT01096992|Experimental|Phase 1 20 mg/m^2|Bendamustine, Fludarabine + Rituximab
9778062|NCT01096992|Experimental|Phase 2|Bendamustine 30 mg/m^2 by vein (fixed), Days 1,2,3 + Fludarabine + Rituximab
9778063|NCT01096992|Experimental|Phase 1 30 mg/m^2|Bendamustine, Fludarabine + Rituximab
9778064|NCT01096992|Experimental|Phase 1 40 mg/m^2|Bendamustine, Fludarabine + Rituximab
9778065|NCT01096992|Experimental|Phase 1 50 mg/m^2|Bendamustine, Fludarabine + Rituximab
9778066|NCT01097044|Experimental|Afamelanotide|Dose: 16 mg implant; release of 16 mg over 7 to 10 days Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
9778067|NCT01097044|Placebo Comparator|Placebo|Dose: 16 mg implant; Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
9778068|NCT01097057|Experimental|Treatment (rituximab, etoposide, carboplatin, ifosfamide)|Patients receive rituximab IV on day 1, etoposide IV on days 2-4, carboplatin IV on day 3, and ifosfamide IV on day 3 over 24 hours. Patients also receive G-CSF SC once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.
9778069|NCT01097304|Experimental|Treatment (ursodiol)|Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
9778070|NCT01097330|Active Comparator|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia
9778071|NCT01097330|Active Comparator|Amiodarone|amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.
9778072|NCT01097343|Active Comparator|75 mg clopidogrel|
9778073|NCT01097343|Active Comparator|150 mg clopidogrel|
9778074|NCT01097395|Active Comparator|Standard Weight-Based Ribavirin Dosing|1000 mg daily in patients weighing <75 kg and 1200 mg daily in patients weighing ≥ 75 kg
9778075|NCT01097395|Experimental|Concentration-Controlled Ribavirin Dosing|Dose adjusted based on first dose AUC0-12
9778076|NCT01097421||Patient with parkinsons disease|
9778077|NCT01097460|Experimental|MM-111 + Herceptin|MM-111 will be combined with Herceptin
9778078|NCT01097577|Experimental|pregabalin|Oral Pregabalin 75 mg capsule twice daily administered prior to PRK and continued for 5 days
9778079|NCT01097577|Placebo Comparator|Placebo|Oral placebo capsule (Lactose) twice daily administered prior to PRK and continued for 5 days
9778080|NCT01097616|Experimental|Suvorexant HD|Drug
9778081|NCT01097616|Experimental|Suvorexant LD|Drug
10204234|NCT03693768|Experimental|Health coaching ARM|Participants in this ARM will undergo health coaching for 4 months.
10204235|NCT03687814|Experimental|Low FODMAP diet plus PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).
10204236|NCT03687814|Sham Comparator|Sham diet plus PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax).
10204237|NCT03686683|Experimental|Treatment Group: Sipuleucel-T|Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion. Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals.
10204238|NCT03686683|No Intervention|Control Arm: Active Surveillance|Subjects randomized to the control arm will be followed on Active Surveillance described in the schedule of events.
9778082|NCT01097616|Placebo Comparator|Placebo|Placebo Comparator
9778083|NCT01097629|Experimental|Suvorexant HD|Drug
9778084|NCT01097629|Experimental|Suvorexant LD|Drug
9778085|NCT01097629|Placebo Comparator|Placebo|Placebo Comparator
9778086|NCT01097642|Active Comparator|Ixabepilone|Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.
9778087|NCT01097642|Experimental|Ixabepilone plus Cetuximab|Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.
9778088|NCT01097655||HIV-infected Participants|"HIV-infected participants starting with Kaletra tablets.~Participants included 3 subgroups:~antiretroviral therapy (ART) treatment-naïve participants starting with Kaletra tablets~participants receiving their first protease inhibitor (PI)-containing regimen (apart from Kaletra) pretreated with any non nucleoside reverse transcriptase inhibitor (NNRTI)-containing or nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen~participants pretreated with a PI-containing regimen (apart from Kaletra)."
9778089|NCT01097668|Experimental|Intradermal injection|Injections will be given by the intradermal route
9778090|NCT01097668|Experimental|Subcutaneous injection|Injections will be given by the subcutaneous route
9778091|NCT01097694|Active Comparator|Imatinib mesylate|Group on active imatinib treatment
9778092|NCT01097694|Placebo Comparator|Placebo|Group on Placebo treatment
9778093|NCT01097707|Experimental|1mg LY500307|
9778094|NCT01097707|Experimental|3mg LY500307|
9778095|NCT01097707|Experimental|10mg LY500307|
9778096|NCT01097707|Experimental|25mg LY500307|
9778097|NCT01097707|Placebo Comparator|Placebo|
9778098|NCT01097785|Active Comparator|Simvastatin|40 mg Simvastatin 1 pill every day for 30 days
9778099|NCT01097785|Placebo Comparator|Placebo|Placebo cap 1 pill every day for 30 days
9778100|NCT01097863|Experimental|nelfilcon A, modified inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
9778101|NCT01097863|Experimental|nelfilcon A, no inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
9778102|NCT01097863|Active Comparator|nelfilcon A, inversion indicator|Nelfilcon A commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for one week.
9778103|NCT01097915||PROP taste sensitivity|"PROP Sensitive and non sensitive individuals are defined as Tasters and Non-tasters, respectively. Taster are further divided in Super-taster who perceived PROP as extremely bitter and Medium tasters who perceived PROP as moderately bitter."
9778104|NCT01098006|Other|Immune tolerant patients Group|Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
9778105|NCT01098006|Other|HBeAg positive Group|HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
9778106|NCT01098006|Other|Inactive carriers Group|Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
9778107|NCT01098006|Other|HBeAg negative Group|HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
9778108|NCT01098097||Peginterferon alpha and ribavirin|Peginterferon alpha and ribavirin will be administered at the discretion of the treating physician, in accordance per label according to local guidelines for all participating countries.
9778109|NCT01098162||Vimpat®|Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.
9778110|NCT01098240|Experimental|Active Treatment|CP-601,927
9778111|NCT01098240|Placebo Comparator|Placebo|Placebo
9778112|NCT01098253|Experimental|Adherence Intervention|Factors affecting adherence to oral hypoglycemic agents and antidepressants were addressed using a problem solving process.
9778113|NCT01098253|No Intervention|Usual Care|
9778114|NCT01098266|Experimental|A: NGR-hTNF + BIC|NGR-hTNF plus Best Investigator's Choice
9778115|NCT01098266|Placebo Comparator|B: Placebo+BIC|Placebo plus Best Investigator's Choice
9778116|NCT01098305|Active Comparator|Varenicline|
9778117|NCT01098305|Placebo Comparator|Placebo|
9778118|NCT01098318|Experimental|Rhodiola rosea|Herbal extract
9778119|NCT01098318|Active Comparator|Sertraline|Conventional anti-depressant
9778120|NCT01098318|Placebo Comparator|Sugar pill|Lactose monohydrate
9778121|NCT01098422|Experimental|Yttrium-90 Radioactive Resin Microspheres|Yttrium-90 Radioactive Resin Microspheres
9778122|NCT01098461|Active Comparator|albiglutide 15mg weekly|once weekly subcutaneous injection of albiglutide 15mg
9778123|NCT01098461|Active Comparator|albiglutide 30mg weekly|once weekly subcutaneous injection of albiglutide 30mg
9778124|NCT01098461|Active Comparator|albiglutide 30mg every other week|subcutaneous injection of 30mg albiglutide every other week
9778125|NCT01098461|Placebo Comparator|placebo|once weekly subcutaneous injection of placebo to match albiglutide
9778126|NCT01098474|Experimental|SB692342 2 dose Group|Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.
9778127|NCT01098474|Experimental|SB692342 1 dose Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.
9784985|NCT01239355|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9784986|NCT01239381|Experimental|SBRT-Proton|Stereotactic body radiotherapy by proton radiation
9784987|NCT01239394|Other|ofatumumab|single-arm, open-label, interventional
9784988|NCT01239472|No Intervention|tacrolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone.
10204239|NCT03681223|Active Comparator|Restorelle® Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Restorelle® sacrocolpopexy
10204240|NCT03681223|Experimental|Vertessa® Lite Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Vertessa® Y sacrocolpopexy
10204241|NCT03673709|No Intervention|Individual Antenatal Care (usual care)|Women are provided antenatal care services on a first come, first serve basis and listen to a health lecture. They meet individually with a midwife for a physical assessment. Women complete laboratory tests (including HIV testing) at their first visit. Congruent with the new WHO recommendations, individual antenatal care consists of 8 antenatal care visits and 2 postnatal visits at 1 week and 6 weeks.
10204242|NCT03673709|Experimental|Group Antenatal Care (intervention)|Women have the same number of visits as those in individual care. Their first antenatal care (intake) and first postnatal visit is done individually (identical to individual care). Women in group care bypass the waiting area and have a 2-hour visit with the same provider in a group of 8-12 women at a similar stage of pregnancy. Women assess their blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
10204243|NCT03635983|Experimental|Combination|NKTR-214 + Nivolumab
10204244|NCT03635983|Experimental|Monotherapy|Nivolumab
10204245|NCT03626337||Hospital-based cohort|100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
10204246|NCT03626337||Community-based cohort|Sex-, age- and regionally matched comparison group
10204247|NCT03600649|Experimental|Myxoid Liposarcoma|Twice-daily administration of oral seclidemstat
10204248|NCT03600649|Experimental|Sarcomas with FET-family translocations, including demoplastic small round cell tumors|Twice-daily administration of oral seclidemstat
10204249|NCT03600649|Experimental|Ewing sarcoma, combination therapy|Twice daily administration of seclidemstat in combination with cyclophosphamide and topotecan
10204250|NCT03600103|No Intervention|Control|Participants will receive standard of care.
10204251|NCT03600103|Experimental|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
10204252|NCT03597295|Experimental|INCMGA00012|
10204253|NCT03583814|Active Comparator|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
10204254|NCT03583814|Active Comparator|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
10204255|NCT03583814|No Intervention|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
10204256|NCT03569865|Experimental|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
9778128|NCT01098474|Active Comparator|Control Menjugate Group|Subjects received three doses of the control Menjugate™ vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.
9778129|NCT01098474|Experimental|SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group|"Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomintantly with the last two doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered instramuscularly in the right arm, on a 0, 1, 2 months schedule.~All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose."
9778130|NCT01098474|Experimental|SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
9778131|NCT01098474|Active Comparator|Control Tritanrix + Prevnar + Polio Sabin Group|Subjects received three doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
9778132|NCT01098487|Experimental|Open Label|Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).
9778133|NCT01098500||Cancer patients|Adults (age ≥18 years) with at least two ICD-9 codes for a particular cancer within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code
9778134|NCT01098539|Active Comparator|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
9778135|NCT01098539|Active Comparator|sitagliptin|albiglutide matching placebo + sitagliptin
9778136|NCT01098578|Experimental|Floseal|Received 1 syringe of Floseal for treatment of posterior epistaxis.
9778137|NCT01098747|Experimental|Treatment A|
9778138|NCT01098747|Active Comparator|Treatment B|
9778139|NCT01098747|Active Comparator|Treatment C|
9778140|NCT01098747|Placebo Comparator|Treatment D|
10204257|NCT03569865|Experimental|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
10204258|NCT03569865|Placebo Comparator|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
10204259|NCT03561220|Active Comparator|IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
10204260|NCT03561220|Active Comparator|Proton Therapy Standard of Care|As this trial is pragmatic, all treatment will be standard of care.
10204261|NCT03561220|Experimental|Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.
10204262|NCT03561220|Experimental|Hypofractionated Proton therapy|60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.
10205354|NCT02557672|Active Comparator|Fresh frozen plasma|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
9784989|NCT01239472|Active Comparator|everolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone, and converted for everolimus, mycophenolate sodium, and prednisone 90 days after renal transplantation.
9784990|NCT01239511|Placebo Comparator|Placebo group|placebo capsule 2# t.i.d./day
9784991|NCT01239511|Experimental|Treatment Group A|150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
9784992|NCT01239511|Experimental|Treatment Group B|300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
9784993|NCT01239511|Experimental|Treatment Group C|450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
9785763|NCT01259427|Experimental|Arm 1: Ending Self Stigma|Ending Self Stigma (ESS): Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
9778141|NCT01098812|Active Comparator|Control IOL|Approved Intraocular control lens
9778142|NCT01098812|Experimental|Toric IOL|Investigational Toric IOL
9778143|NCT01098812|Experimental|Higher Cylinder Toric IOL|Investigational Toric IOLs with higher cylinder powers.
9778144|NCT01098851||Obstructive Sleep Apnea|Surgery patients at high risk for Obstructive Sleep Apnea
9778145|NCT01098851||Surgery Patients|Surgery patients at low risk for Obstructive Sleep Apnea
9778146|NCT01099111||Irritable Bowel Syndrome|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
9778147|NCT01099111||Ulcerative Colitis|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
9778148|NCT01099111||Crohn's Disease|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
9778149|NCT01099111||Colo Rectal Cancer|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
9778150|NCT01099111||Control: Normal Subjects|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
9778151|NCT01099202|Experimental|Procrit|Starting dose 40,000 units subcutaneously once a week with chemotherapy.
9778152|NCT01099202|No Intervention|No Procrit|No intervention.
9778153|NCT01099215|Other|PVS-10200|Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.
9778154|NCT01099267||Lenalidomide|No intervention was given during this extension study which gathered survival information on participants of study NCT00065156 (Celgene study CC-5013-MDS-003). During the CC-5013-MDS-003 study, participants initially took a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle. The study was amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.
9778155|NCT01099358|Experimental|Cetuximab and Cisplatin (D)|"Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.~100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.~After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
9778156|NCT01099358|Experimental|Cetuximab and Cisplatin (C)|"Cycle 1 (4 weeks, combination therapy):~100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks combination therapy):~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
9778157|NCT01099358|Experimental|Cetuximab on Cisplatin (B)|"Cycle 1:~400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.~Cycle 2:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~Cycle 3 + :~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
9778158|NCT01099358|Experimental|Cisplatin on Cetuximab (A)|"Cycle 1:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.~Cycle 2 +:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.~After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
9778159|NCT01099397||PEAR Participants|All participants eligible for PEAR study. Each participant will be have fasting and oral glucose tolerance test data collected.
9778160|NCT01099449|Experimental|Arm I|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy comprising leucovorin calcium, fluorouracil, and oxaliplatin).
9778161|NCT01099449|Placebo Comparator|Arm II|Patients receive placebo IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy).
9778162|NCT01099449|Experimental|Arm III|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and placebo IV over 30 minutes immediately after oxaliplatin administration (part of FOLFOX chemotherapy).
9778163|NCT01099475|Experimental|Pringle manoeuvre 15 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 2 cycles of 15 minutes of hepatic inflow occlusion will be applied each followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
9778164|NCT01099475|Experimental|Pringle manoeuvre 30 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 1 cycle of 30 minutes of hepatic inflow occlusion will be applied followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
9778165|NCT01099579|Experimental|Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg|Patients weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by patient's weight on the day of first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
9778166|NCT01099579|Experimental|Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg|Patients weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
9778167|NCT01099579|Experimental|Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg|Patients weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
9778168|NCT01099618|Active Comparator|Metformin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
9778169|NCT01099618|Active Comparator|Sitagliptin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
9836102|NCT02769065|Experimental|SRD: Cohort 20: TAK-071 40 mg+Donepezil|TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
10204263|NCT03556683|Experimental|Hypertonic Saline|Subjects will inhale hypertonic saline before having a Mucociliary Clearance (MCC) scan
10204264|NCT03547115|Experimental|voruciclib|Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level and disease type (AML or B-cell malignancies)
10204265|NCT03538223|Experimental|"Radioterapy+Melomics-Health Listening"|"The musical content is composed by an algorithm (named Melomics-Health) with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context."
10204266|NCT03538223|Experimental|Radiotherapy+Individualized Listening|The musical content is based on the patient's preferred music (chosen by patients with the support of the music therapist) with the purpose of acting psychologically and physiologically on the person. Patients will undergo to music listening for 15 minutes before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
10204267|NCT03538223|Other|Radiotherapy+No Music Listening|Patients will undergo the standard treatment (radiotherapy) without music support.
10204268|NCT03515304|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
9836103|NCT02769065|Experimental|SRD: Cohort 21: TAK-071 60 mg+Donepezil|TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.
10204269|NCT03515304|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
10204270|NCT03501368|Experimental|Trametinib + Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
10204271|NCT03490513|Placebo Comparator|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
10204272|NCT03490513|Experimental|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
10204273|NCT03471728||Irritable Bowel Syndrome|Patients with Irritable Bowel Syndrome with Constipation (IBS-C) who have used linaclotide for the first time
10204274|NCT03471728||Chronic Constipation|Patients with Chronic Constipation (CC) (excluding constipation due to organic diseases) who have used linaclotide for the first time
10204275|NCT03463148||1|Men/Women who meet the inclusion/exclusion criteria of this protocol.
10204276|NCT03463057|Other|Atezolizumab|18 cycles atezolizumab followed by 12 months of observation
10204277|NCT03462979|Experimental|Open Results with home testing|Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 8 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 8 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine samples and complete a questionnaire.Additionally, participants will be given 4 stool test kits, with instructions that they may use these at times of their choosing and will report results and reasons for test use, if any. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
10204278|NCT03462979|No Intervention|Blinded (sample collection only)|Participants in the blinded arms will not be given a test kit but will be given sample collection materials. During the period from week 8 to week 30 of the study, participants will be contacted a total of 6 times at random intervals, instructed to collect urine samples, and complete a questionnaire. Participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit. After completion of sample collection, all participants will be unblinded and notified of the results once the samples have been processed.
10204279|NCT03459729|Experimental|Antitumor B|ATB will be administered on an outpatient basis.
10204280|NCT03456635|No Intervention|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
10204281|NCT03456635|Experimental|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
10204282|NCT03448653|Experimental|Colonoscopy with NBI|
10204283|NCT03440697||Aortopathy- Closed to external enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
10204284|NCT03440697||Syndromic- Open to external enrollment|"Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS)~•positive genetic testing and/or a previous cardiac study required to be eligible"
10204285|NCT03440697||Aortopathy with Positive Genetic Results- Open to Enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
10204286|NCT03440697||Aortic Valve Disease- Closed to enrollment|Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
10204287|NCT03440697||Family Members- Open to external enrollment|"Family members of eligible subjects~•Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time"
10204288|NCT03440697||Controls- Closed to external enrollment|Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
10204289|NCT03429582|Active Comparator|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
10204290|NCT03429582|Experimental|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
10204291|NCT03429582|Experimental|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
10204292|NCT03404596|Experimental|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
10204293|NCT03387137|Experimental|Group 1: RSV 6120/∆NS2/1030s Vaccine|RSV-seropositive children will receive a single dose of 10^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
10204294|NCT03387137|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
10204295|NCT03387137|Experimental|Group 2: RSV 6120/∆NS2/1030s Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
10204296|NCT03387137|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
9984327|NCT04218838|Active Comparator|SI Joint Steroid Injections Group|Patient will receive an injection of steroid medication directly into their SI joint. The area around the SI joint will be numbed with an injection of local anesthetic and then ultrasound guidance will be used to guide the needle of steroid medication directly into the SI joint. This procedure will be performed in the physician's office or an outpatient surgery center, and normally takes around 30 minutes.
10204297|NCT03342027|Experimental|Bupropion + Positively Smoke Free|Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation bupropion--used for smoking cessation
10204298|NCT03342027|Experimental|Bupropion + Standard of Care|Standard of Care--brief advice to quit provided in a standardized format bupropion--used for smoking cessation
9778170|NCT01099618|Placebo Comparator|Placebo|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
9778171|NCT01099631|Experimental|Salmonella typhimurium 10 to the 5th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
9778172|NCT01099631|Experimental|Salmonella typhimurium 10 to the 6th -- Level 2|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
9778173|NCT01099631|Experimental|Salmonella typhimurium 10 to the 7th -- Level 3|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
9778174|NCT01099631|Experimental|Salmonella typhimurium 10 to the 8th - Level 4|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
9778175|NCT01099631|Experimental|Salmonella typhimurium 10 to the 9th - Level 5|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
9778176|NCT01099631|Experimental|Salmonella typhimurium 10 to the 10th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
9778177|NCT01099709|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
9778178|NCT01099709|Active Comparator|Original OxyContin® (OXY) 10 mg|Original OxyContin® (OXY) 10 mg x 1 dose
9778179|NCT01099761|Experimental|ACE-031 0.5 mg/kg q4wk|
9778180|NCT01099761|Experimental|ACE-031 1.0 mg/kg q2wk|
9778181|NCT01099761|Placebo Comparator|Placebo|
9778182|NCT01099774|Experimental|Bimatoprost 0.03% Formulation B Ophthalmic Solution|Bimatoprost 0.03% Formulation B Ophthalmic Solution
9778183|NCT01099774|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% Ophthalmic Solution
9778184|NCT01099917|Experimental|Maitake|This is a phase II trial examining hematopoietic response in MDS patients.
9778185|NCT01099969|Experimental|Glidescope with non-styletted Endotrol ETT|The patients in this arm will be intubated using a Glidescope videolaryngoscope with non-styletted Endotrol endotracheal tube (ETT).
9778186|NCT01099969|Active Comparator|Glidescope with styletted regular ETT|The patientsin this arm will be intubated using the glidescope videolaryngoscope and regular endotracheal tube (ETT) with gliderite stylet.
9778187|NCT01099969|Experimental|McGrath with non-styletted Endotrol ETT|The patients in this arm will be intubated using McGrath videolaryngoscope and non-styletted Endotrol endotracheal tube (ETT).
9984328|NCT04213365|Other|cognitive stimulation and adapted physical activity|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
9984329|NCT04212884||PLWH|PLWH followed up at the five participating HIV centers
10204299|NCT03342027|Experimental|Placebo + Positively Smoke Free|Placebo--matched to bupropion Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation
10204300|NCT03342027|Placebo Comparator|Placebo + Standard of Care.|Placebo--matched to bupropion Standard of Care--brief advice to quit provided in a standardized format
10204301|NCT03330561|Experimental|PRS-343|
10204302|NCT03321513|Active Comparator|Aflibercept Group|2.0 mg intravitreous aflibercept
10204303|NCT03321513|Experimental|Bevacizumab + Deferred Aflibercept Group|1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
10204304|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
10204305|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
9984330|NCT04212884||HIV-uninfected individuals|Age and sex-matched HIV-uninfected individuals
9984331|NCT04212013|Experimental|Ibrutinib/Rituximab|All subjects meeting eligibility criteria will receive rituximab: 375 mg/m^2 on days 1, 8, 15 and 22 on cycle 1.
10204306|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
10204307|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
10204308|NCT03225482|Experimental|ME-CCT|8-week Motivationally Enhanced Compensatory Cognitive Training group
10204309|NCT03225482|Active Comparator|SC|8-week Goal-focused Supportive Contact group
10204310|NCT03224624|Experimental|self-management|Participants will be taught to monitor blood pressure and make limited adjustments to their medications
10204311|NCT03224624|No Intervention|usual care|Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.
10204312|NCT03208504|Experimental|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
9778188|NCT01099969|Active Comparator|McGrath with with styletted regular ETT|The patients receiving this arm will be intubation using McGrath videolaryngoscope and regular endotracheal tube (ETT) with Gliderite stylet.
9778189|NCT01100034||1|pediatric patients with plaque psoriasis on etanercept
9778190|NCT01100073||Patients with Parkinson's disease|Early and advanced Parkinson's disease patients
9778191|NCT01100086|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
9778192|NCT01100086|Active Comparator|Original OxyContin® (OXY)10 mg|Original OxyContin® (OXY)10 mg x 1 dose
9778193|NCT01100112|Experimental|Budesonide|Budesonide-MMX 9 mg tablet
9778194|NCT01100242|Experimental|Arm 1: VELCADE and Sorafenib|Patients will be given VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 & 11 and sorafenib at a dosage of 200 mg orally twice per day. One full course is comprised of 21 days.
9778195|NCT01100255|Active Comparator|Group A|0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
9778196|NCT01100255|Active Comparator|Group B|IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes
9778197|NCT01100268|Experimental|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
9778198|NCT01100307|Experimental|pegaptanib sodium|
9778199|NCT01100307|Sham Comparator|sham injection|
9778200|NCT01100320|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
9778201|NCT01100320|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
9778202|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules crushed and mixed in solution and administered orally at each patient's stable dose, given either once daily or twice daily.
9778203|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily
9778204|NCT01100502|Experimental|Brentuximab vedotin|brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
9778205|NCT01100502|Placebo Comparator|Placebo|placebo every 3 weeks by IV infusion
9778206|NCT01100528|Experimental|Arm I|Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
9778207|NCT01100567|Placebo Comparator|Placebo platform|Randomized to stand on placebo platform for 10 minutes/day
9778208|NCT01100567|Active Comparator|Low-magnitude mechanical stimulation|Randomized to stand on LMMS platform 10 minutes/daily
9778209|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Juice|
10204313|NCT03132415|Experimental|Get Connected|Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.
10204314|NCT03132415|Active Comparator|Non-tailored HIV Test Locator|Participants randomized to the control condition will be directed to a testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.
10204315|NCT03131934|Experimental|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
10204316|NCT03128385|Experimental|Intensive CIT Model Program|"In day camp model, the therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Adventure Camp that decorating the treatment place as the adventure world and the participants take role as a warrior. This novel design is mean to enhance and motivate the engagement of participation."
9778210|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Sauce|
9778211|NCT01100723|Experimental|Computer directed dosing decisions|This study will be an open-label, non-randomized, single arm design. Patients will have their mineral and bone disorders managed by the computer directed algorithm. The computer algorithm will make recommendations for dosing active vitamin D and cinacalcet. The doses of these medications recommended by the algorithm will then be prescribed to the subjects participating in the study unless overridden by the patients primary attending nephrology for other clinical or safety concerns. At any time in the study, subjects may be on neither, one, or both of these medication depending on their laboratory results and the output recommendations of the algorithm.
9778212|NCT01100762|Experimental|Single Group|10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
9778213|NCT01100853|Active Comparator|Extended release VIVITROL injection 380 mg, 24 weeks|Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
9778214|NCT01100853|Placebo Comparator|VIVITROL placebo injection, 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
9778215|NCT01100931|Experimental|YM155 in Solid Tumors|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
9778216|NCT01100944|Experimental|Therapy in Thymic Malignancies|PXD101 (Belinostat) will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression. A conventional 3+3 dose escalation design was used with up to 3 additional patients added if one patient exhibited a dose limiting toxicity (DLT). Dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT.
9778217|NCT01101022|Active Comparator|SPD489|
9778218|NCT01101022|Placebo Comparator|Placebo|
9778219|NCT01101035|Experimental|Febuxostat|Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.
9778220|NCT01101035|Active Comparator|Allopurinol|Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but <60 mL/min).
10204317|NCT03128385|Experimental|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
10204318|NCT03125928|Experimental|Investigational Arm|
10204319|NCT03111875|Active Comparator|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An Multi-Position Upper Body Warming Blanket forced-air cover will be positioned over an appropriate non-operative site, but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further.
10204320|NCT03111875|Experimental|Aggressive thermal management|"Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using an Multi-Position Upper Body and Full Access Underbody Warming Blankets forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature."
10204321|NCT03101917|Experimental|Visual assessment of electrode insertion|This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
10204322|NCT03101917|Experimental|Camera assessment of electrode insertion|This arm will include the next 6 participants. In this group, a tube with a camera will be inserted past the ear drum, by making a small hole in the ear drum, to see the electrode as it goes into the cochlea.
10204323|NCT03086369|Experimental|Phase1b: Olaratumab 15 mg/kg + Nab-paclitaxel + Gemcitabine|Participants received intravenous (IV) infusions of olaratumab 15 milligrams per kilogram (mg/kg), nab-paclitaxel 125 milligrams per meter square (mg/m^2) and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
10204324|NCT03086369|Experimental|Phase1b: Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of olaratumab 20 mg/kg, nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
10204325|NCT03086369|Experimental|Phase1b (cohort expansion): Olaratumab 20 mg/kg + Nab-paclitaxel + Gemcitabine|"Following a protocol amendment, cohort expansion arm was added in phase 1b with new participants enrolled to confirm the safety of the olaratumab 20 mg/kg dose prior to opening the Phase 2. Participants received intravenous infusions of olaratumab 20 mg/kg, nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met."
10204326|NCT03086369|Experimental|Phase 2: Olaratumab + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of olaratumab 20 mg/kg loading dose on days 1, 8, 15 of cycle 1 followed by 15 mg/kg on days 1, 8, 15 of all subsequent cycles, in combination with nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
10204327|NCT03086369|Placebo Comparator|Phase 2: Placebo + Nab-paclitaxel + Gemcitabine|Participants received intravenous infusions of placebo, nab-paclitaxel 125 mg/m^2 and gemcitabine 1000 mg/m^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
10204328|NCT03084081|Active Comparator|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
10204329|NCT03084081|Experimental|CryoPen|Single freeze treatment consists of one five-minute freeze
10204330|NCT03084081|Experimental|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
9778221|NCT01101061|Experimental|Romosozumab|Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.
9778222|NCT01101061|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
9778223|NCT01101100|Experimental|AMG 827|AMG 827
9778224|NCT01101165|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
9778225|NCT01101165|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
9778226|NCT01101178|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
9778227|NCT01101178|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
9778228|NCT01101191|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
9778229|NCT01101191|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
9778230|NCT01101308|Experimental|Reformulated OXY 10 mg (Totowa)|Reformulated OXY 10 mg (Totowa) x 1 dose
9778231|NCT01101308|Active Comparator|Reformulated OXY 10 mg (Wilson)|Reformulated OXY 10 mg (Wilson) x 1 dose
9778232|NCT01101321|Experimental|Reformulated OXY 80 mg (Totowa)|Reformulated OXY 80 mg (Totowa) x 1 dose
9778233|NCT01101321|Active Comparator|Reformulated OXY 80 mg (Wilson)|Reformulated OXY 80 mg (Wilson) x 1 dose
9778234|NCT01101334|Experimental|CS-7017 plus erlotinib|
9778235|NCT01101334|Active Comparator|erlotinib|
9778236|NCT01101477|Active Comparator|Titration by target effect site concentration (Cet) 0.5μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
9778237|NCT01101477|Active Comparator|Titration by Cet 0.2μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
9778238|NCT01101477|Active Comparator|Titration by Cet 0.1μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
9778239|NCT01101542||Cervarix Group|Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.
9778240|NCT01101750|Other|Liver and Kidney Transplant Patient Arm|Standard of Care Intervention: Participants on this arm receive Gardasil vaccine and have a history of liver or kidney transplant.
9778241|NCT01101841|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
9778242|NCT01101841|Placebo Comparator|Placebo capsules|Sugar pill
9778243|NCT01101867|Experimental|Aspart flexible dose|aspart dose determined based upon carbohydrate intake.
9778244|NCT01101867|Active Comparator|Aspart fixed dose|fixed meal dose of aspart (based upon weight or total daily insulin dose)
9778245|NCT01101880|Experimental|Treatment (chemotherapy and colony stimulating factor)|"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.~CONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.~Treatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity."
9778246|NCT01101958|Other|Chartis System-EBV Treatment|Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
9778247|NCT01101971|Experimental|first year medical students|
9778248|NCT01101997|Experimental|Experimental: Abdomen Treatment Group|All subjects were treated on the abdomen with the CoolSculpting system.
9778249|NCT01102218|Experimental|erythropoietin plus pentoxifylline|
9778250|NCT01102218|Active Comparator|erythropoietin alone|
9778251|NCT01102231|Experimental|A|Chemoradiotherapy
9778252|NCT01102257|Experimental|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:~2000 mg EPA 1000 mg DHA"
9778253|NCT01102257|Placebo Comparator|Olive Oil|Gel Capsule
9778254|NCT01102270|Active Comparator|Eszopiclone|Eszopiclone 3mg prior to sleep (1 night)
9778255|NCT01102270|Placebo Comparator|Sugar Pill|Sugar Pill (placebo) prior to sleep (1 night)
9778256|NCT01102374|Experimental|High Dose Vitamin D|100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
9778257|NCT01102374|Active Comparator|Standard Dose Vitamin D|12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
9778258|NCT01102413|Experimental|Monofer|Injections or infusions
9778259|NCT01102413|Active Comparator|Iron Sulphate|Oral intake
9778260|NCT01102426|Experimental|Plitidepsin+Dexamethasone|plitidepsin + dexamethasone combination
9836237|NCT02777125|Active Comparator|Albuterol Breath Actuated Nebulizer|Subjects randomized to BAN were evaluated for proper breath actuation technique. For subjects unable to coordinate breath actuation, the RT attached an appropriately sized mask to the device, changed the setting to continuous nebulization and returned upon completion of the treatment. Albuterol dosing was based upon the subject's weight and presenting symptom severity. Children presenting in the mild and moderate severity category weighing less than 20kg, received 2500mcg of albuterol. Children weighing more than 20kg, received 2500mcg of albuterol if their presentation met mild severity criteria, or 5000mcg if they met moderate criteria.
9836238|NCT02777242|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate administered subcutaneously once each week. Auto-injection of QST 50 mg or 75 mg or 100 mg [Device: QuickShot® Testosterone (QST)]
9836239|NCT02777268|Experimental|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
9836240|NCT02777268|Experimental|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
9836241|NCT02777268|Experimental|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
9836242|NCT02777268|Experimental|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
9836243|NCT02777268|Active Comparator|Hydrocortisone|1 (10 mg) tablet
9836244|NCT02777333|Experimental|Simulation training|Addition of simulation training during usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
9836245|NCT02777333|No Intervention|Non-simulation/Routine training|Usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
9921845|NCT00831740|Experimental|Speech Therapy|
9921846|NCT00831740|Active Comparator|ACT NoW Visitor|
9921847|NCT00831818||1|Mothers of healthy infants who breastfeed on demand
9921848|NCT00831818||2|Mothers of healthy infants who do not breastfeed
9921849|NCT00831857||Group A|Treatment with sunitinib.
9921850|NCT00831857||Group B|Treatment with bevacizumab and interferon
9921851|NCT00831883|Experimental|Partner Specific IMB|partner-specific HIV risk reduction intervention
9921852|NCT00831883|Placebo Comparator|HLS|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
9921853|NCT00831896|Experimental|1|TAK-701
9921854|NCT00831909||1|All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department, Pneumology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of January 2009 to the end of March 2009. Patients diagnosed, or even treated, in other departments within the same hospital or in another hospital are susceptible to be included in the study if full access to the patient's medical record is made available.
9921855|NCT00831922|Experimental|1|masitinib (AB1010) 3 mg/kg/day
9921856|NCT00831922|Experimental|2|masitinib (AB1010) 6 mg/kg/day
9921857|NCT00831935||Depressed|Depressed individuals, as identified by their referring physician.
9921858|NCT00831935||Non-depressed|Non-depressed individuals, confirmed to be non-depressed by the Centers for Epidemiological Studies Depression Scale (CES-D).
9921859|NCT00831948||Mitochondrial disease|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques
9921860|NCT00831961||1|Patients randomized to gatifloxacin (Zymar)
9921861|NCT00831961||2|Patients randomized to moxifloxacin (Vigamox)
9921862|NCT00831961||3|Patients randomized to ofloxacin (Ocuflox)
9921863|NCT00831961||4|Patients randomized to azithromycin (AzaSite)
9921864|NCT00831974|Experimental|2|masitinib (AB1010) 6 mg/kg/day
9921865|NCT00831974|Experimental|1|masitinib (AB1010) 3 mg/kg/day
9921866|NCT00832013|Active Comparator|1|"Propofol 1 % at a dose of 4mg/kg will be administered intravenously via a standard Medex Protégé® 3010 (Medex-A Furon. Healthcare Company, Duluth, GA, USA) infusion pump at a constant rate determined by the randomization schedule. Fresh gas flow will be maintained at 6 l/min throughout the induction procedure with the FiO2 increased to 0.5. Full cardiovascular, respiratory and EEG monitoring will continue during induction of anesthesia.~Once the loading dose of propofol has been delivered the propofol infusion will be maintained at a rate of 200mcg/kg/min or as determined by the attending anesthesiologist whilst the end-point respiratory responses are observed."
9921867|NCT00832013|Active Comparator|2|Same procedure as above. These subjects will be stratified by age and randomized, using the Biased Coin Design (BCD) principle to determine the infusion rate of propofol for delivery of the induction dose.
9921868|NCT00832026||Sleep apnea|Patients with diagnosed obstructive sleep apnea
9921869|NCT00832039|Active Comparator|SelPCT|Patient receives sodium-selenite; causal therapy is guided by a PCT based algorithm.
9836246|NCT05350150|Experimental|Auricular Vagal Nerve Stimulation|Patients will undergo a standard EPS with 4 catheters. Following the standard EPS, patients will be hooked up a Parasym device to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve, EPS will be repeated.
9836247|NCT05350137|Active Comparator|Group A: 100% oxygen|After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen.
9836248|NCT05350137|Experimental|Group B: Carbon dioxide|After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide.
9836249|NCT05350124|Experimental|Group 1|Vitamin C (200 mg) capsule, and vitamin E (400 IU) capsule every day for 12 weeks.
9836250|NCT05350124|Experimental|Group 2|Vitamin C (200 mg) capsule, and placebo every day for 12 weeks.
9836251|NCT05350124|Experimental|Group 3|Vitamin E (400 IU) capsule, and placebo every day for 12 weeks.
9836252|NCT05350124|Experimental|Group 4|Placebo capsule (2 pills) every day for 12 weeks.
9836253|NCT05350111|Other|group supported through group education and telemedicine tools|the group of this pilot study will be compared to conventional obesity clinic
9836254|NCT05350098|Experimental|A dietary intervention of plant-protein based diets|
9836255|NCT05350098|Active Comparator|A dietary intervention of control diets|
9836256|NCT05350085|Experimental|Remazolam besylate Group|Use remazolam besylate as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
9836257|NCT05350085|Active Comparator|Midazolam Group|Use midazolam as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
9836258|NCT05350072|Experimental|Arm A|ianalumab
9836259|NCT05350072|Placebo Comparator|Arm B|placebo
9836260|NCT05350059|Experimental|High Intensity Focused Ultrasound (HIFU) treatment to breast cancer|High-Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer prior to surgical resection
9836261|NCT05350046|Experimental|Physically active adults|A cohort of physically-active adults will use ear-worn prototype devices and established gold standard and comparator devices during rest periods, physical activity, and various activities of daily living.
9836262|NCT05350033|Experimental|Active-Active|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h) and in Phase 2 (5 sessions, intersession time-24h).
9836263|NCT05350033|Experimental|Active-Sham|Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
9836264|NCT05350033|Experimental|Sham-Active|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and active-tDCS at 2 mA during 20 min in Phase 2 (5 sessions, intersession time-24h).
9836265|NCT05350033|Sham Comparator|Sham-Sham|Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
9836266|NCT05350020|Experimental|Solu-Cortef® in deltoid muscle|Solu-Cortef® in deltoid muscle
9836267|NCT05350020|Experimental|Solu-Cortef® in thigh muscle|Solu-Cortef® in thigh muscle
9836268|NCT05350020|Experimental|Hydrocortisone 100mg/ml in deltoid muscle|Hydrocortisone 100mg/ml in deltoid muscle
9836269|NCT05350020|Experimental|Hydrocortisone 100mg/ml in thigh muscle|Hydrocortisone 100mg/ml in thigh muscle
9836270|NCT05349994|No Intervention|Control|Standard amount of physical therapy at surgical wards in an urban hospital, corresponding to 1.75 physiotherapy employment on weekdays divided on four wards with a total of approx. 40-48 patients.
9836271|NCT05349994|Experimental|Intervention|Extended physiotherapy with an extra 0.5 employment on weekdays, leading to 1-2 physiotherapy session per day for the study participants in the intervention group.
9836272|NCT05349981|Experimental|Lyric self-replacement|This cohort of experienced Lyric patients are required to meet the candidacy criteria to be eligible for the self-replacement procedure. They will also be required to demonstrate proficiency with the self-replacement procedure before proceeding with independent self-replacement.
9836273|NCT05349968|Experimental|Dose 5 mg|
9836274|NCT05349968|Experimental|Dose 20 mg|
9836275|NCT05349968|Experimental|Dose 40 mg|
9836276|NCT05349955|Experimental|Intensive guideline algorithm implementation|The guideline algorithm intervention is based on '2019 ESC/EASD Guidelines, 2020 ADA guideline and 2020 CDS guideline on diabetes'. Briefly, SGLT2i or GLP-1RA will be used in priority in subjects with high risk of ASCVD.
9836277|NCT05349955|Active Comparator|Conventional guideline algorithm implementation|The guideline intervention is based the guidance which the local physicians followed through self learning and education. Briefly, the use of SGLT2i or GLP-1RA will be decided by local physicians.
9836278|NCT05349942|Experimental|Intraoral scanning and data acquisition|
9836279|NCT05349929|Experimental|Ibuprofen|Ibuprofen(Gelofen) 400mg capsules, Dana pharma company, every 6hours
9836280|NCT05349929|Experimental|Anahil|Bromelain(Anahil) 200 mg capsules, Permon Amin Health Company,every 6hours
9836281|NCT05349916|Experimental|Control|
9836282|NCT05349916|Experimental|Isomaltodextrin Low Dose|
9836283|NCT05349916|Experimental|Isomaltodextrin High Dose|
9836284|NCT05349916|Experimental|GPC partially digestible maltodextrin|
9836285|NCT05349916|Experimental|Resistant Starch Type 4|
9836286|NCT05349903|Experimental|Rice flour|Rapidly digestible control
9836287|NCT05349903|Experimental|Alternanoligosaccharide 15|
9836288|NCT05349903|Experimental|Waxy potato starch|
9836289|NCT05349903|Experimental|Combination of waxy potato starch and epigallocatechin gallate (EGCG)|
9836290|NCT05349903|Experimental|Combination of chickpea flour and epigallocatechin gallate (EGCG)|
9836291|NCT05349903|Experimental|Inulin|
9836292|NCT05349890|Experimental|CDX-1140 + TCR-T + Pembro|Patients will receive CDX-1440, TCR-T, and pembrolizumab.
9836293|NCT05349877|Experimental|Expressive writing|Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.
9836294|NCT05349877|Experimental|Self-affirmation|Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination.
9836295|NCT05349877|Placebo Comparator|Placebo|Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week.
9836296|NCT05349864|Experimental|PF-07284890 Sequence 1|"PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
9836297|NCT05349864|Experimental|PF-07284890 Sequence 2|"PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
9836298|NCT05349851||Renal failure patiens|Patients with advanced renal failure
9836299|NCT05349838|Experimental|DTG/RPV FDC Regimen|One combined Dolutegravir 50mg /Rilpivirine 25mg FDC tablet taken orally once daily
9836300|NCT05349838|Active Comparator|Continued ART Regimen|Patients will continue the current boosted PI regimen (or other antiretroviral combination) for 48 weeks. Patients will then be switched to one combined Dolutegravir/Rilpivirine FDC tablet taken orally once daily for 48 weeks.
9836301|NCT05349825||Patients with Hypertensive episode|50 individuals presenting with a hypertensive episode (patients under 60, >140/90 mmHg, patients over 60, >150/90 mmHg, according to the JNC8 guidelines) while under losartan treatment
9836302|NCT05349825||Patients with controlled hypertension|50 patients whose blood pressure was regulated while receiving losartan treatment and who were admitted to the ED for reasons other than hypertensive episode. The eligible patients matching the inclusion and exclusion criteria were recruited for the study.
9836303|NCT05349799|Experimental|TEOSYAL RHA® 1|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, not further treated with TEOSYAL® PureSense Redensity 1 during the skin redensification phase."
9836304|NCT05349799|Experimental|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 with a needle|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, further treated with TEOSYAL® PureSense Redensity 1 using a needle during the skin redensification phase."
9836305|NCT05349799|Experimental|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 with a cannula|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, further treated with TEOSYAL® PureSense Redensity 1 using a cannula (optional for perioral lines) during the skin redensification phase."
9836306|NCT05349786|Experimental|Intervention Group|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
9836307|NCT05349786|No Intervention|Non-Intervention Group|The individuals in the control group, were pre-tested, evaluated at the first, second, and third months, and followed up in the process without any intervention. Patients were reminded that they should continue their routine medical treatment and not start any physical activity program.
9836308|NCT05349773||endoscopic left radial artery harvesting|single group of 32 patients listed for coronary artery bypass surgery with endoscopic radial artery harvesting.
9785847|NCT01261390|Placebo Comparator|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide ~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
9836309|NCT05349760|Experimental|AMB-05X|AMB-05X will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
10205527|NCT05205720|Experimental|NB group|"Celiac plexus block (CPB) was added to the postoperative analgesia plan.~CPB: the target nerve is located in the retroperitoneal space, embedded in the fat in front of the aorta, and distributed in a network along the anterolateral wall of the aorta, just at the beginning of the celiac trunk. During direct vision (anterior) block, first expose the upper edge of the pancreas, palpate the abdominal aorta and abdominal trunk, and palpate the pulsation of the common hepatic artery and splenic artery at the level of the abdominal trunk. Use a 25g 6cm puncture needle with an extension tube and a syringe pumped back by an assistant to form a negative pressure, then the needle is inserted into the fat on both sides of the abdominal aorta. If there is no blood or fluid outflow, slowly inject 10ml of 0.5% ropivacaine each side. After pulling out the needle, observe whether there is damage and bleeding. If necessary, use low-energy electrocoagulation to stop bleeding."
10205528|NCT05205720|No Intervention|GC group|The same analgesic plan as the experimental group, except that CPB is not performed.
9998256|NCT01516489|Experimental|$10 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $10 at PVAMC.
10205529|NCT05205694||Late COVID-19 and PERIO|Participants in the late convalescent stage of COVID-19 with diagnosed periodontitis
10205530|NCT05205694||PERIO non COVID-19|Participants with diagnosed periodontitis and no history of COVID-19
10205531|NCT05205694||Late COVID-19 non PERIO|Participants in the late convalescent stage of COVID-19 without periodontitis
10205532|NCT05205694||Non PERIO non COVID-19|Participants with no history of COVID-19 and without periodontitis
10205533|NCT05205668|Experimental|F-652 Dosage Level 1|IL-22 fusion protein administered intravenously
10205534|NCT05205668|Placebo Comparator|Placebo|Placebo administered intravenously
10205535|NCT05205668|Experimental|F-652 Dosage Level 2|IL-22 fusion protein administered intravenously
10205536|NCT05205655|Active Comparator|positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
9799267|NCT01654887|Active Comparator|Chest X-Ray|CXR first followed by LUS second
9799268|NCT01655043|Experimental|coronary artery disease patients|Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
9799269|NCT01655069|Experimental|Children Treated with Placebo in 905-CL-076|Male and female children aged 5 to less than 12 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
9799270|NCT01655069|Experimental|Children Treated with Solifenacin in 905-CL-076|Male and female children aged 5 to less than 12 years old who received solifenacin in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
9799271|NCT01655069|Experimental|Adolescents Treated with Placebo in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
9799272|NCT01655069|Experimental|Adolescents Treated with Solifenacin in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received solifenacin in Study 905- CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
9799273|NCT01655329||Standard chest radiographs|The radiologists will be viewing two groups of chest images. The first group are standard chest radiographs.
9799274|NCT01655329||Modified chest radiographs|This group of chest radiographs will be presented with the modified image. The modified image is intended to increase the visibility of tubes, lines and wires on chest radiographs
9799275|NCT01655381|Experimental|Tocilizumab|Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
9799276|NCT01655498|Experimental|Vaginal Bowel Control|A vaginal bowel control system intended to manage fecal incontinence.
9799277|NCT01655563|Active Comparator|Standard Dosing Arm|Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
9799278|NCT01655563|Experimental|Pharmacogenetic Arm|"Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.~CYP3A5 non-expressor starting dose:~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours~CYP3A5 expressor starting dose:~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours"
9799279|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 20 mg/m2|DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
9799280|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 30 mg/m2|DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
9836310|NCT05349760|Placebo Comparator|Placebo|Placebo will be administered every 4 weeks for 24 weeks (for 6 treatments in total).
9836311|NCT05349734|Experimental|overbody blanket|
9836312|NCT05349734|Active Comparator|underbody blanket|
9836313|NCT05349721|Experimental|PTC857|"Participants will receive PTC857 during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants have the option to receive open-label PTC857 in the Long-term Extension Period for 28 weeks."
9836314|NCT05349721|Active Comparator|Placebo|"Participants will receive matching placebo during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants have the option to receive open-label PTC857 in the Long-term Extension Period for 28 weeks."
9836315|NCT05349708|Experimental|Participant|Patients who were sent home with the intervention post-surgery
9836316|NCT05349708|No Intervention|Historical controls|
9836317|NCT05349682|Experimental|GAE and MRI treatment arm|GAE is geniculate artery embolization.
9836318|NCT05349669|No Intervention|Conventional CPB|Elective cardiopulmonary bypass (CPB) procedures with an expected time >120 minutes for each extracorporeal procedure.
9836319|NCT05349669|Experimental|CPB with Jafron|Elective cardiopulmonary bypass (CPB) procedures with Jafron use with an expected time >120 minutes for each extracorporealprocedure.
9836320|NCT05349656|Experimental|trans muscular quadratus lumborum (TQL) block|after induction of general anesthesia (GA), the participant will be placed in the lateral position, and a high-frequency linear ultrasound probe (5-13 MHz) will be placed on the anterior iliac crest. The Petit's triangle (formed of the iliac crest inferiorly and the borders of external abdominal oblique anteriorly and latissimus dorsi (LD) posteriorly) will be identified and then Tracing dorsally from Petit's triangle, the external oblique, and the internal oblique are seen disappearing into an aponeurosis as the quadratus lumborum (QL) appears beneath the LD (anteriorly), and going farther dorsally, the QL, erector spinae, and psoas major (PM) muscles around the transverse process of lumbar vertebra L4 are seen. A 22-gauge needle will be inserted using an in-plane technique along the posterior edge of the probe in the anteromedial direction. The needle tip will be placed between the QL muscle and the PM muscle, then 0.5 ml/kg of 0.25% bupivacaine will be injected.
9836321|NCT05349656|Experimental|Pericapsular nerve group (PENG) block|After induction of GA, the participant will be in the supine position. A linear high-frequency ultrasound probe (5-13MHz) will be initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees; In this view, the ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle Will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution of 0.25% bupivacaine will be injected in 5-mL increments while observing for an adequate fluid spread in this plane for a total volume of 0.5 ml/kg.
9836322|NCT05349643|Experimental|AMB-05X|Subjects will receive an injection of AMB-05X once every 4 weeks for 24 weeks (for 6 treatments total). Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose.
9836323|NCT05349630|Placebo Comparator|Healthy individuals - pre-iron|"Five healthy participants will be enrolled. Baseline echocardiography and exercise data prior to oral iron supplementation will be obtained as part of the parent study to this study (NCT05272514)."
9836324|NCT05349630|Active Comparator|Healthy individuals - post-iron|The same five healthy participants will complete echocardiography and exercise testing after taking 30 days of oral iron supplementation.
9836325|NCT05349617|Experimental|Group 1 - PXVX0317|
9836326|NCT05349617|Placebo Comparator|Group 2 - Placebo|
9836327|NCT05349604|Experimental|Garlic extracts|Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)
9836328|NCT05349604|Placebo Comparator|placebo|As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.
9836329|NCT05349591|No Intervention|Control|The Participants in this arm receive islet transplant only and no cePolyTregs.
9836330|NCT05349591|Experimental|Treatment|Participants will receive cePolyTregs (target 400-1600 million, with a minimal acceptable dose of 100 million) two weeks post islet transplant and will be followed for 1 year after cePolyTregs infusion to assess the safety and preliminary efficacy of cePolyTregs therapy.
9836331|NCT05349578|Other|Tissue|conventional RUT using biopsied tissue
9836332|NCT05349578|Experimental|Swab|RUT using swab
9836333|NCT05349565|Active Comparator|CONVENTIONAL PHYSICAL THERAPY|
9836334|NCT05349565|Experimental|MUSCLE ENERGY TECHNIQUE|
9836335|NCT05349552||Chest Wall Type|The lesion is directly adjacent (less than 1cm) or overlapped with the chest wall.
9836336|NCT05349552||Peripheral Type|The lesion is more than 1cm away from the chest wall and more than 2cm away from the bronchial tree.
9836337|NCT05349552||Central Type|The lesion is less than 2cm away from the bronchial tree.
9836338|NCT05349552||Ultral-central Type|The lesion is directly adjacent or overlapped with the mediastinal structure.
9836339|NCT05349539||Healthy Subjects|Cohort of healthy subjects as control.
9836340|NCT05349539||Patients with Parkinson's disease|Cohort of patients with Parkinson's disease
9836341|NCT05349526||stenotic carotid|patients with a stenotic carotid
9836342|NCT05349526||non stenotic carotid|patients with non stenotic carotid
9836343|NCT05349513|Experimental|Interventionnal arm|Administration of the experimental questionnaire ESSME in patient's environment.
9836344|NCT05349500|Experimental|OA CARE|Participants assigned to the OA CARE intervention will receive a 12-month Medical Membership to a local YMCA and participate in a 12-week weight loss program. Participants will also work with an OA CARE Navigator, who, in partnership with their primary care provider (PCP), will identify any additional programs or resources that may help them manage their osteoarthritis (OA) symptoms.
9836345|NCT05349500|Placebo Comparator|Usual Care|Participants assigned to this group will receive no additional treatment from the study for about 12 months.
9836346|NCT05349487|Experimental|SpeakFree Hands Free Heat Moisture Exchanger (HEM) Valve Group|Participants will be fitted to use a hand free HME device over their stoma in order to communicate with a voice prosthesis for one month. The participants will also serve as their own control performing voicing and speech tasks using digital occlusion and digital depression HME.
9836347|NCT05349474|Experimental|Metformin Treatment|Metformin 500 mg tablets up to 2,000 mg (4 tablets) a day divided into two doses. Patients will start on 500 mg Qday and a titration to maximum dose will be attempted during the first 30 day period of the study.
9836348|NCT05349474|Placebo Comparator|Placebo Treatment|Placebo tablets identical to metformin 500 mg tablets divided into two doses. Patients will be started on 1 tablet a day and a titration to maximum dose (4 tablets) will be attempted during the first 30 day period of the study.
9836349|NCT05349461|Active Comparator|Complete contact|
9836350|NCT05349461|Active Comparator|Incomplete contact|
9836351|NCT05349448|Active Comparator|solo group|hyalase plus 6 mg dexamethasone
9836352|NCT05349448|Active Comparator|dex plus hyalase group|hyalase plus dexmedtemodine plus 6 mg dexamethasone
9836353|NCT05349435|Experimental|Cohort 1 Dose Level 1|Drug: Fezagepras and sodium PBA
9836354|NCT05349435|Experimental|Cohort 2 Dose Level 2|Drug: Fezagepras and sodium PBA
9836355|NCT05349422|Experimental|Intervention Group|
9836356|NCT05349422|No Intervention|Usual Care Group|Usual Care Clinical Decision Support (CDS) Tools
9836357|NCT05349409|Experimental|Treatment group|SHR-A1811, Fluzoparib
9836358|NCT05349396|Experimental|Eszopiclone Test Product T-1|Participants will receive one tablet of the Test T-1 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
9836359|NCT05349396|Experimental|Eszopiclone Test Product T-2|Participants will receive one tablet of the Test T-2 formulation containing Eszopiclone 3mg. The tablets will be taken with water and in a fasting condition.
9836360|NCT05349396|Active Comparator|Eszopiclone Referent Product|Participants will receive one tablet of the marketed reference formulation containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
9836361|NCT05349383||Antibody-Drug Conjugate (ADC)|Sepsis-related toxicities induced by antibody-drug conjugate(ADC). Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by ADC, with a chronology compatible with the drug toxicity Intervention: Drug: ADC
9836362|NCT05349383||Common cancer drug therapies other than ADC|"Sepsis-related toxicities induced by Common cancer drug therapies other than ADC.~Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by Common cancer drug therapies other than ADC, with a chronology compatible with the drug toxicity~Intervention:~Drug: Chemotherapy, targeted therapy, immunotherapy and so on."
9836363|NCT05349370|Experimental|All patients|All patients receive the same intervention/sampling protocol
9836364|NCT05349357|Active Comparator|Group A|TENS, Stretching exercises, ROM exercises Sliding neural mobilization to femoral, sciatic, tibial nerve
9836365|NCT05349357|Active Comparator|Group B|TENS, Stretching exercises, ROM exercises Tensioner neural mobilization to femoral, sciatic, tibial nerve
9836366|NCT05349344|Experimental|Aerobic Circuit Training|Each session consists of 5 minutes of warming up,20 minutes of aerobic exercises with brief resting periods, followed by 5 minutes to cool down.
9836367|NCT05349344|Active Comparator|outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
9836368|NCT05349331|Experimental|Resection group|Surgical resection group: The patients underwent liver cancer resection and were followed up regularly after surgery.
9836369|NCT05349331|No Intervention|Non-surgical resection group|Stop hepatic artery interventional therapy (chemoembolization/infusion chemotherapy), continue the original targeted and immunotherapy for no more than 1 year
9836370|NCT05349318|Active Comparator|Hyperbaric Oxygen Therapy active arm|The protocol comprises of 60 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive HBOT twice a week.
9836371|NCT05349318|Sham Comparator|Sham active arm|The protocol comprises of 60 consecutive Sham sessions, 5 sessions per week within a three months' period. Then there will be a maintenance period for 6 months in which the participants will receive Shan sessions twice a week.
10205537|NCT05205655|Experimental|negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
10205538|NCT05205642|Experimental|Patients recovering from COVID-19|Pediatric and adult patients recovering from COVID-19 with or without complaints.
9836374|NCT05349266|Experimental|ThisCART19A 2×10^6 cells/kg for dose level 1|Patients will receive 2×10^6 cells/kg of ThisCART19A
9836375|NCT05349266|Experimental|ThisCART19A 3×10^6 cells/kg as dose level 2|Patients will receive 3×10^6 cells/kg of ThisCART19A
9836376|NCT05349266|Experimental|Patients will receive 4×10^6 cells/kg as dose level 3|Patients will receive 4×10^6 cells/kg of ThisCART19A
9836377|NCT05349253|Experimental|Garlic extracts|Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)
9836378|NCT05349253|Placebo Comparator|placebo|As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.
9836379|NCT05349240|Experimental|Study Intervention|All subjects will receive treatment with the study device.
9836380|NCT05349227|Experimental|Intervention Group|In addition to standard of care services at the participant's respective health system, and study specific collection of clinical, PRO, and wearable data, as well as microbiome specimens, individuals randomized to the intervention group will receive immediate enrollment to a 6-month digital health coaching program followed by 6 months monitoring via PRO, wearable, and clinical data collection. They will collect fecal microbiome samples at baseline (study enrollment) and month 6 following enrollment.
9836381|NCT05349227|Other|Wait List Control Group|In addition to standard of care services, individuals in the wait list control will be monitored via the collection of PRO, clinical, and wearable data for the first 6 months, along with fecal microbiome collection at study enrollment baseline (study enrollment) and month 6. At month 6 these individuals will be enrolled into the 6-month digital health coaching program, during which clinical, PRO and wearable data will continue to be collected. At the completion of the 6-month coaching these individuals will come off study and will not receive additional follow-up.
9836382|NCT05349214|Experimental|Arm A|ianalumab exposure level 1
9836383|NCT05349214|Experimental|Arm B|ianalumab exposure level 2
9836384|NCT05349214|Placebo Comparator|Arm C|placebo
9836385|NCT05349201||Adult R/R DLBCL cohort: KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL])
9836386|NCT05349201||Adult R/R DLBCL cohort: YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL])
9836387|NCT05349201||ALL pediatric and young adult cohort: KYMRIAH|Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) ( refractory, in relapse post transplant or in second or later relapse
9836388|NCT05349188|Experimental|Melatonin 3 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 3 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 3mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 3 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 3 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
9836389|NCT05349188|Active Comparator|Melatonin 0.5 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 0.5 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 0.5 mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 0.5 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 0.5 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
9836390|NCT05349188|Placebo Comparator|Placebo Pill|"Individuals will receive a kit with medication adherence devices containing the placebo pills in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the placebo. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive the placebo, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The placebo will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
9836391|NCT05349175|Experimental|Cohort A|Receives AIR device feedback beginning immediately after training
9836392|NCT05349175|Experimental|Cohort B|Receives AIR device feedback beginning 2 months after training
9836393|NCT05349175|Experimental|Cohort C|Receives AIR device feedback beginning 4 months after training
9836394|NCT05349149|Experimental|Tocilizumab|Participants will receive one 30 min intravenous infusion of tocilizumab/Actemra® (Roche). The dose will be 8 mg/kg bodyweight or a maximum of 800mg. Tocilizumab is dissolved in 100 mL 0.9% saline.
9836395|NCT05349149|Placebo Comparator|Saline|As placebo, participants will receive one 30 min intravenous infusion of 100 mL 0.9% saline.
9836396|NCT05349136|Experimental|Synchronous telerehabilitation group|Synchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
9836397|NCT05349136|Experimental|Asynchronous telerehabilitation group|Asynchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
10205539|NCT05205616|Placebo Comparator|Reciprocating saw|The traditional surgical instrument used for cutting bilateral sagittal split osteotomies
10205540|NCT05205616|Active Comparator|Sonopet ultrasonic saw|This instrument is being compared to the reciprocating saw
10205541|NCT05205603|Placebo Comparator|Biologics group|"Biologics including infliximab and vedolizumab. infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks."
10213403|NCT04097262|Experimental|Cross-Price Elasticity|"The price of fruit will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
9836398|NCT05349136|No Intervention|Control group|Conventional physiotherapy
9836399|NCT05349123|Experimental|Intervention|Home-based pulmonary rehabilitation that includes health coaching with mindful breathing module
9836400|NCT05349123|Active Comparator|Control|Home-based pulmonary rehabilitation that includes health coaching
9836401|NCT05349110||Gastroenterology patients|"Patient receiving a colonoscopy because of regular care will be considered eligible for inclusion if at least one diminutive colorectal polyp is encountered during the colonoscopy. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.~Colonoscopies will be executed using Fujifilm endoscopy systems (Fujifilm® Corporation, Tokyo, Japan), using Pentax endoscopy systems (Pentax Medical®, Hamburg, Germany), and using Olympus endoscopy systems (Olympus®, Tokyo, Japan)."
9836402|NCT05349097|Experimental|SAD cohort 1|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of 30mg IMG-004 oral capsule(s) or a single dose of matching placebo. Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
9836403|NCT05349097|Experimental|SAD cohort 2|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
9836404|NCT05349097|Experimental|SAD cohort 3(FE cohort)|Participants in the food-effect cohort will be admitted to the clinic on the first Baseline (Day -1) and remain domiciled until Day 8 in the fasted condition period. After completing the safety follow-up in fasted period, and after safety information for at least 24 hours in the sentinel participants at a higher dose level has been reviewed by the PI/designee, the same participants will be readmitted to the clinic on the second Baseline (fed period). Participants will take IMG-004 under the fed condition and domiciled 7 days after administration. The schedule of events will follow the same procedure in the fasted condition period.
9836405|NCT05349097|Experimental|SAD cohort 4|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
9836406|NCT05349097|Experimental|SAD cohort 5|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
9921870|NCT00832039|Active Comparator|SelKon|Patient receives sodium-selenite; causal therapy is not guided by a PCT based algorithm.
9998257|NCT01516489|Experimental|$20 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $20 at PVAMC.
9836407|NCT05349097|Experimental|SAD cohort 6|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
9836408|NCT05349097|Experimental|MAD cohort 1|Each participant who meets confirmation of eligibility and completion of a screening phase will be randomized to receive active or placebo drug orally for 8 days. Participants will be admitted on Day -1 ,domiciled until Day 13 and complete the safety follow-up on Day22.
9836409|NCT05349097|Experimental|MAD cohort 2|Each participant who meets confirmation of eligibility and completion of a screening phase will be randomized to receive active or placebo drug orally for 8 days. Participants will be admitted on Day -1 ,domiciled until Day 13 and complete the safety follow-up on Day22.
9836410|NCT05349097|Experimental|MAD cohort 3|Each participant who meets confirmation of eligibility and completion of a screening phase will be randomized to receive active or placebo drug orally for 8 days. Participants will be admitted on Day -1 ,domiciled until Day 13 and complete the safety follow-up on Day22.
9836411|NCT05349084|Other|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
9836412|NCT05349071|Experimental|methylprednisolone group|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
9836413|NCT05349071|Active Comparator|physiological saline group|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
9836414|NCT05349058||ICI patients|Patients receiving an Immune Checkpoint Inhibitor as treatment for their malignancy
9836415|NCT05349045||an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group|
9836416|NCT05349032|Other|Meriva|120 mg of curcumin in Meriva.
9836417|NCT05349032|Other|Longvida|120 mg of curcumin Longvida.
9836418|NCT05349032|Other|NovaSol|120 mg of curcumin NovaSol
9836419|NCT05349032|Other|CurcElite|120 mg of curcumin CurcElite
9836420|NCT05349032|Other|UltaCur|120 mg of curcumin Ultracur
9836421|NCT05349019||Part A/Sub Cohort A1|15 healthy participants 18-35 years of age
9836422|NCT05349019||Part A/Sub Cohort A2|15 healthy participants 65-80 years of age
9836423|NCT05349019||Part A/Sub Cohort A3|Control group age and sex matched to the PD participants in Part B of the study
9836424|NCT05349019||Part B|60 participants with a confirmed diagnosis of Parkinson's disease and a heterozygous G2019S mutation in the LRRK2 gene
9836425|NCT05349006|Experimental|Azathioprine|"Azathioprine, dose related to weight (100 mg for <50 kg, 150 mg 50-100 kg, 200 mg for >100 kg), oral, daily~Associated to oral corticosteroid, prednisone : 40 mg per day during three months, and progressively tapered during three months until stop (- 30 mg during 15 days, 20mg during 15 days, 15 mg during 15 days, 10 mg during 15 days, 5 mg during 15 days and introduction of hydrocortisone 20 mg + Stop prednisone; hydrocortisone 20mg during 15 days, Stop hydrocortisone)"
9836426|NCT05349006|Placebo Comparator|Placebo|"Placebo, once a day, oral, number of caps related to weight~Associated to oral corticosteroid: prednisone 40 mg per day during three months and progressively tapered during three months until stop (- 30 mg during 15 days, 20mg during 15 days, 15 mg during 15 days, 10 mg during 15 days, 5 mg during 15 days and introduction of hydrocortisone 20 mg + Stop prednisone; hydrocortisone 20mg during 15 days, Stop hydrocortisone)"
9836427|NCT05348993|Experimental|50 mg dose of G03-52-01|150 subjects randomized to 50 mg of G03-52-01
9836428|NCT05348993|Experimental|100 mg dose of G03-52-01|150 subjects randomized to 100 mg of G03-52-01
9836429|NCT05348993|Placebo Comparator|Placebo|75 subjects randomized to placebo
9836430|NCT05348980|Active Comparator|Phenylephrine 4mg|Inj Phenylephrine HCL 04 mg as Group P4.
9836431|NCT05348980|Active Comparator|Phenylephrine 8mg|Inj Phenylephrine HCL 08 mg as Group P8.
9836432|NCT05348967|No Intervention|Control|Ketogenic diet
9836433|NCT05348967|Experimental|TECADRIOL|Ketogenic diet plus a food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
9836434|NCT05348954|Experimental|Sexual dysfunction of women|Sexual dysfunction of women
9836435|NCT05348954|Experimental|Quality of sexual life|Quality of sexual life
9836436|NCT05348941|No Intervention|Control|Hypocaloric balanced diet
9836437|NCT05348941|Experimental|TECADRIOL|Hypocaloric balanced diet plus a food supplement with D-chiro-inositol and alpha-lactalbumin
9836438|NCT05348928||With oral ascorbic acid|1 g ascorbic acid orally
9836439|NCT05348928||Without oral ascorbic acid|No oral ascorbic acid is taken
9836440|NCT05348915|Experimental|Inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
9836441|NCT05348889|Experimental|Dose Escalation|Open label, single arm trial where 1A46 will be administered
9836442|NCT05348876|Experimental|Darolutamide (BAY1841788)|Participants with high-risk nmCRPC will receive darolutamide.
9836443|NCT05348863|Experimental|SPARK app|Access to the SPARK app which will provide support for a healthier diet and increased physical activity as well as daily monitoring of blood glucose levels.
9836444|NCT05348863|No Intervention|Control arm|Standard care i.e., the routine treatment program for GDM delivered by the care provider.
9836445|NCT05348850||Study Group|"Athletes with patellofemoral pain syndrome will be selected Muscle contractile properties and functional performance will be assessed for athletes with patellofemoral pain syndrome .~Data will be collected from all athletes regarding age, gender, training intensity running experience and previous injuries.~By the end of the assessment it will be detected if muscle contractile properties of vastus medialis and vastus lateralis is a determinant factor that influence functional performance in runners with patellofemoral pain syndrome."
9836446|NCT05348837||Subthalamic nucleus (STN) DBS|Patients undergoing evaluation for subthalamic nucleus DBS implantation will be included in this group.
9836447|NCT05348837||Globus pallidus interna (GPi) DBS|Patients undergoing evaluation for globus pallidus interna DBS implantation will be included in this group.
9836448|NCT05348824|Experimental|Moringa oleifera|
9836449|NCT05348824|Active Comparator|Sodium hypochlorite|
9836450|NCT05348811|Experimental|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, Day 1, every 3 weeks (Q3W). The maximum of 6 times.~Sintilimab will be given on Day 1, 200 mg i.v. Q3W.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment."
9836451|NCT05348798||Ultra endurance athletes|Individual participating in ultra endurance sports (events exceeding 6 hours) including running, cycling, triathlon, swimming and Nordic skiing. Participants are above 18 years of age and volunteer to participate in this web-based survey.
9785848|NCT01261390|Sham Comparator|Sham PAP (Sham)|"In addition to receiving CMT, participants in this treatment arm will receive a sham-CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.~The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up~1-month follow up~3-month follow up~6-month follow up~9-month follow up (will not occur if on a 6-month follow-up protocol)~It is estimated that each in-person follow-up adherence visit with the PAP specialist would last ~30 minutes."
9785849|NCT01261390|Active Comparator|Active PAP with RT Support (Active-Beh)|"In addition to receiving CMT, participants will receive active-PAP. The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up (FU)~1-month FU~3-month FU~6-month FU~9-month FU (12-month follow-up protocol only)~All visits will take place with a PAP specialist. All follow-up visits will be anchored to the initial PAP set-up visit. At these visits, using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. Each follow-up visit with the PAP specialist will last 30 minutes."
9785850|NCT01261390|Active Comparator|Active PAP with Behavioral Modification (Active+Beh)|"In addition to receiving CMT and active-PAP, participants will have behavioral intervention sessions to promote PAP adherence. The treatment visit schedule is outlined below:~Visits with Behavioral Interventionist (in addition to active-PAP treatment visits):~PAP Initial Set-Up (in-person, 1-hr)~1-week follow-up (FU) (in-person, 1-hr)~1-month FU~2-month FU~3-month FU~5-month FU~8-month FU (12-month follow-up protocol only)~All follow-up visits will be anchored to the initial PAP set-up visit. PAP treatment visits will occur as outlined in the active-PAP arm.~All behavioral intervention visits will be 30-min phone calls, unless otherwise noted. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training."
9785851|NCT01261559|No Intervention|Standard CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
9785852|NCT01261559|Experimental|Chrysalis CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.
9785853|NCT01261611|Experimental|Dysport NG|"500U (1mL) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.~250U (0.5mL), 500U (1mL) or 750U (1.5mL) administered as intramuscular injection on day 1 of treatment cycle 3.~250U (0.5mL), 500U (1mL), 750U (1.5mL) or 1000U (2mL) administered as intramuscular injection on day 1 of treatment cycle 4 and 5."
9785854|NCT01261611|Active Comparator|Dysport|500U (1mL) injected as intramuscular injection on day 1 of treatment cycle 1.
9785855|NCT01261611|Placebo Comparator|Placebo|1mL administered as, intramuscular injection on day 1 of treatment cycle 1.
9785856|NCT01261624|Experimental|Givinostat 1.0 mg/kg daily|
9785857|NCT01261624|Experimental|Givinostat 1.5 mg/kg daily|
9785858|NCT01261780|Sham Comparator|Sham device|Sham therapy device to area of painful chemotherapy induced peripheral neuropathy (CIPN) for 45 minutes daily x 10 days
9998258|NCT01516489|Experimental|$5 Voucher-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
9785859|NCT01261780|Active Comparator|MC-5A treatment|MC-5A therapy to the area of painful CIPN for 45 minutes daily for a total of 10 days.
9785860|NCT01261793|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
9785861|NCT01261793|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles
9785862|NCT01261793|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
9785863|NCT01261819|Experimental|transurethral laparoscope|These patients had cystoscopy performed with the transurethral laparoscope.
9785864|NCT01261819|Active Comparator|Traditional cystoscopy|"These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard."
9785865|NCT01261975|Experimental|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial microincision
9785866|NCT01261975|Active Comparator|Coaxial Small Incision Cataract Surgery|2.75 mm standard incision
9785867|NCT01262027|Experimental|Dovitinib|A complete treatment cycle defined as 28 days or 4 weeks (+/- 2 days). Patients receive a single daily oral dose of 500 mg of dovitinib for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule).
9785868|NCT01262092|Active Comparator|Gabapentin|Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
9785869|NCT01262092|Placebo Comparator|Placebo|Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening
9785870|NCT01262105|No Intervention|No device|
9785871|NCT01262105|Experimental|Device deployed|
9785872|NCT01262118|Experimental|CP-690,550 (tasocitinib) 10 mg twice daily (BID)|
9785873|NCT01262118|No Intervention|Healthy Volunteers|No intervention
9921871|NCT00832039|Placebo Comparator|PlacPCT|Patient receives placebo; causal therapy is guided by a PCT based algorithm.
9785874|NCT01262131|Active Comparator|Resonator Protocol A|
9785875|NCT01262131|Active Comparator|Resonator Protocol B|Application of magnetic fields using the Resonator device Protocol B
9785876|NCT01262131|Placebo Comparator|Inactive Resonator|
9785877|NCT01262287|Experimental|dutasteride|dutasteride (1 mg oral daily dose) for 8-week treatment period
9785878|NCT01262287|Placebo Comparator|Placebo|placebo daily for 8-week treatment period
9785879|NCT01262352|Experimental|Treatment Sequence 1|Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2.
9785880|NCT01262352|Experimental|Treatment Sequence 2|Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2.
9785881|NCT01262365|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
9785882|NCT01262365|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
9785883|NCT01262365|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
9785884|NCT01262456|Experimental|Desmopressin 50 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
9785885|NCT01262456|Experimental|Desmopressin 75 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
9785886|NCT01262456|Placebo Comparator|Placebo Double-Blind / Desmopressin 100 μg Open-Label|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
9785887|NCT01262547|Experimental|Dermabrasion-Micrografting|Dermabrasion-Micrografting
9785888|NCT01262547|Active Comparator|Dermabrasion alone|Dermabrasion alone
9785889|NCT01262547|No Intervention|Control|Control
9785890|NCT01262560|Active Comparator|Supportive Care|Standard supportive care
9785891|NCT01262560|Experimental|Liquid Manuka Honey|Manuka honey in liquid form
9785892|NCT01262560|Experimental|Lozenge Manuka Honey|Manuka honey in lozenge form
9785893|NCT01262573|Experimental|Barbed|Vaginal cuff closure with barbed suture
9785894|NCT01262573|Active Comparator|Smooth|Vaginal cuff closure with smooth suture
9785895|NCT01262599|Sham Comparator|Sham PEMF Device|Patients will receive inactive device
9785896|NCT01262599|Active Comparator|PEMF Device|Patients will receive Ivivi Torino II PEMF Device
9785897|NCT01262638|Experimental|ETC-1002 120 mg (Group 1)|Subjects with hypercholesterolemia and normal triglycerides
9785898|NCT01262638|Experimental|ETC-1002 80 mg (Group 2)|Subjects with hypercholesterolemia and normal triglycerides
9785899|NCT01262638|Experimental|ETC-1002 40 mg (Group 3)|Subjects with hypercholesterolemia and normal triglycerides
9785900|NCT01262638|Experimental|Placebo (Group 4)|Subjects with hypercholesterolemia and normal triglycerides
9785901|NCT01262638|Experimental|ETC-1002 120 mg (Group 5)|Subjects with hypercholesterolemia and elevated triglycerides
9785902|NCT01262638|Experimental|ETC-1002 80 mg (Group 6)|Subjects with hypercholesterolemia and elevated triglycerides
9785903|NCT01262638|Experimental|ETC-1002 40 mg (Group 7)|Subjects with hypercholesterolemia and elevated triglycerides
9785904|NCT01262638|Experimental|Placebo (Group 8)|Subjects with hypercholesterolemia and elevated triglycerides
9785905|NCT01262651|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
9836452|NCT05348785|Experimental|BIIB122 225 mg|Participants will receive BIIB122, 225 mg tablets, by mouth, once daily (QD) for up to a minimum of 48 weeks and a maximum of 144 weeks.
9836453|NCT05348785|Placebo Comparator|BIIB122 225 mg-Matching Placebo|Participants will receive BIIB122, 225 mg-matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.
9836454|NCT05348772|Active Comparator|AmnioPul-02 Dose level 1|AmnioPul-02 Dose level 1
9836455|NCT05348772|Active Comparator|AmnioPul-02 Dose level 2|AmnioPul-02 Dose level 2
9836456|NCT05348772|Active Comparator|AmnioPul-02 Dose level 3|AmnioPul-02 Dose level 3
9836457|NCT05348733||Patients diagnosed with CKD and T2D|Patients who are newly prescribed finerenone under routine treatment conditions.
9836458|NCT05348720||COVID-19 ICU survivor|COVID-19 patients admitted to ICU between the 1st of March 2020 and the 30rd of May 2021, who survived ICU stay and still alive 18 months after ICU discharge.
9836459|NCT05348720||Relatives|Relative of those COVID-19 patients enrolled in the 'COVID-19 ICU survivor' cohort
9836460|NCT05348707||Pre Covid 19 cohort|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2019 to 16th March 2020."
9836461|NCT05348707||Per Covid 19 cohort year 1|"Infant hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2020 to 16th March 2021. The need to recruit patients for an additional per-covid year (from 17th March 2021 to 16th March 2022) will be evaluated after the data from the first 2 years of recruitment are available."
9836462|NCT05348707||Per Covid 19 cohort, year 2|"Infants hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2021 to 16th March 2022. The need to recruit patients for this additional cohort will be evaluated after the data from the first 2 years of recruitment are available and analyzed."
9836463|NCT05348694|Active Comparator|Pendulum WBF-038|Pendulum WBF-038, a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
9836464|NCT05348694|Placebo Comparator|Pendulum Placebo|Pendulum Placebo containing Magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
9836465|NCT05348681|Experimental|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
9836466|NCT05348681|Placebo Comparator|Placebo|Placebo: 4 placebo tablets once daily for 12 weeks
10213404|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm A|Combination of nivolumab and relatlimab.
9836468|NCT05348655||Pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2019-2020 winter epidemic"
9836469|NCT05348655||Per Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, and 2023-2024 epidemic. The need for continuation of the study will be reassessed after each season"
9836470|NCT05348642|Experimental|Experimental group receiving pasteurized Akkermansia muciniphila|pasteurized Akkermansia muciniphila - daily oral dose
9836471|NCT05348616||pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2013-2020 winter epidemic"
9921872|NCT00832039|Placebo Comparator|PlacKon|Patient receives placebo; causal therapy is not guided by a PCT based algorithm.
10213405|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm B|Treatment by nivolumab alone.
10213406|NCT04092166|No Intervention|Controlled|Participants will have no intervention.
10213407|NCT04092166|Other|Cardiac Rehab Exercise: Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
10213408|NCT04088591|Experimental|Treatment arm|The study drug is ascorbic acid is 200mg/kg/day divided over 4 doses per day and delivered in 50 ml of 5% dextrose in water intravenously over a total duration of 96 hours.
10213409|NCT04088591|Placebo Comparator|Placebo arm|The placebo is 50ml of 5% dextrose in water and will be administered 4 doses per day over a total duration of 96 hours
10213410|NCT04087057||Observational (interview, medical records review)|Patients complete questionnaires and participate in an interview to answer questions about information patients received before starting chemotherapy, any medical problems after surgery that could have been related to the start of the chemotherapy, how chemotherapy affected patients' life, and anything else patients may remember between the time when the breast surgery ended and the first dose of chemotherapy started. Patients' medical records are also reviewed.
10213411|NCT04078178|Other|Randomized Crossover|The primary outcome of this study will be objective measures of cognitive performance measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline, crossover, and the end of study. Subjects will receive 1200 mg Niagen and PBO dispensed in randomized blocks. All subjects will receive both.
10213412|NCT04067609|Experimental|patients receiving dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
10213413|NCT04067609|Placebo Comparator|placebo|100mL of normal saline (placebo) immediately upon the subjects' arrival to the Post Anesthesia Care Unit (PACU) after leaving the operating room from their scheduled c-section
10213414|NCT04061980|Experimental|Arm I (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10213415|NCT04061980|Experimental|Arm II (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD and binimetinib PO BID as in arm I. Patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10214062|NCT01632930|Experimental|Results of urinary PCA3 test will be available|In this arm, physicians will have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion is likely to be influenced by urinary PCA3 test results
9785906|NCT01262651|Placebo Comparator|Placebo (GA-0034)|Placebo Comparator: Placebo (GA-0034) Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol: propylene glycol (50:50)
9785907|NCT01262677|Experimental|pregabalin CR 330 mg|
9785908|NCT01262677|Experimental|pregabalin CR 165 mg|
9785909|NCT01262677|Placebo Comparator|Placebo|
9785910|NCT01262755||African Americans|Consists of 450 African Americans living in the zip code surrounding Temple Hospital between the ages of 18 and 80.
9785911|NCT01262820|Experimental|Single Intervention|Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
9785912|NCT01262846|Active Comparator|Fluzone SD|Fluzone® Standard dose
9785913|NCT01262846|Experimental|Fluzone® High dose|Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
9785914|NCT01262872|Experimental|10PP-HD 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.
9785915|NCT01262872|Active Comparator|Prevnar13 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.
9785916|NCT01262872|Experimental|10PP-LD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
9799281|NCT01655693|Active Comparator|Best Standard of Care|Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
9800432|NCT01687296|Active Comparator|oral prednisone/placebo inhalation solution|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily
9800433|NCT01687387|Experimental|IPH2102 at 1 mg/kg|lirilumab (IPH2102/BMS986015) at 1 mg/kg
9785917|NCT01262872|Experimental|10PP-HD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
9785918|NCT01262872|Active Comparator|Synflorix 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
9785919|NCT01262872|Active Comparator|Prevnar13 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
9785920|NCT01262872|Experimental|10PP-HD 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
9785921|NCT01262872|Active Comparator|Synflorix 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
9785922|NCT01262898|Experimental|GSK962040 (10 mg)|GSK962040 10 mg
9785923|NCT01262898|Experimental|GSK962040 (50 mg)|GSK962040 50 mg
9785924|NCT01262898|Experimental|GSK962040 (125 mg)|GSK962040 125 mg
9785925|NCT01262898|Experimental|Placebo|Placebo
9785926|NCT01262976|Experimental|HIV(+)-HA/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
9785927|NCT01262976|Placebo Comparator|HIV(+)-HA/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
9785928|NCT01262976|Experimental|HIV(+)-TN/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
9785929|NCT01262976|Placebo Comparator|HIV(+)-TN/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
9785930|NCT01262976|Experimental|HIV(-)/GSK692342|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
9785931|NCT01262976|Placebo Comparator|HIV(-)/Placebo|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
9785932|NCT01262989|Active Comparator|tamsulosin Reference|Reference drug administration followed by Test drug administration
9785933|NCT01262989|Active Comparator|tamsulosin Test|Test drug administration followed by Reference drug administration
9785934|NCT01263015|Experimental|Dolutegravir (N=~394):|Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
9785935|NCT01263015|Active Comparator|Atripla (N=~394):|Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily
9785936|NCT01263054|Experimental|TransDiscal System|Kimberly-Clark TransDiscal System in addition to standard medical management
9785937|NCT01263054|Other|Medical Management|Standard medical management
9785938|NCT01263093|Experimental|Clopidogrel First, Then LY2216684 + Clopidogrel|"Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1).~Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
9785939|NCT01263093|Experimental|LY2216684 + Clopidogrel First, Then Clopidogrel|"Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
9921873|NCT00832052|Experimental|Cohort 1|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
9785940|NCT01263106|Experimental|Theophylline, LY2216684 + Theophylline|Period 1: single 200-milligram (mg) theophylline oral dose on Day 1; Washout period of at least 7 days; Period 2: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3
9785941|NCT01263106|Experimental|LY2216684 + Theophylline, Theophylline|Period 1: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3; Washout period of at least 7 days; Period 2: single 200-mg theophylline oral dose on Day 1
9785942|NCT01263119|Experimental|Warfarin, LY2216684 + Warfarin|Period 1: Single 10-milligram (mg) warfarin oral dose on Day 1; Washout Period of at least 14 days; Period 2: 18-mg LY2216684 oral dose, once daily on Days 1 to 12, with single 10-mg warfarin oral dose coadministered on Day 3.
9785943|NCT01263132|Experimental|F0434|
9785944|NCT01263132|Active Comparator|Gabapentin|
9800434|NCT01687387|Experimental|IPH2102 at 0.1 mg/kg|lirilumab (IPH2102/BMS986015) at 0.1 mg/kg
9800435|NCT01687387|Placebo Comparator|Placebo (Normal saline solution)|Normal saline solution
9836472|NCT05348616||Per-Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, 2023-2024 and 2024-2025 epidemics. The need for continuation of the study will be reassessed after each season."
9836473|NCT05348603|No Intervention|No Intervention|*No intervention.
9836474|NCT05348603|Experimental|Traditional Letter Only|*A mailed letter will invite the patient to set up a research profile in their patient portal.
9836475|NCT05348603|Experimental|Direct to Patient Message Only|*An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research.
9836476|NCT05348603|Experimental|Chatbot Only|*A real-time, interactive chatbot on the patient portal will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests.
9836477|NCT05348603|Experimental|Banner Only|"*Banner-type advertisements will appear during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
9836478|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research."
9836479|NCT05348603|Experimental|Traditional Letter + Chatbot|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
9836480|NCT05348603|Experimental|Traditional Letter + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
9836481|NCT05348603|Experimental|Direct to Patient Message + Chatbot|"An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
9836482|NCT05348603|Experimental|Direct to Patient Message + Banner|"An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
9836483|NCT05348603|Experimental|Chatbot + Banner|"A real-time, interactive chatbot will encourage research participation and direct patients to learn more about clinical trial opportunities and trials that match their interests; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care will inform patients of research opportunities."
9836484|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message + Chatbot|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests."
9836485|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
9921874|NCT00832052|Experimental|Cohort 2|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
9921875|NCT00832052|Experimental|Cohort 3a|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
9921876|NCT00832052|Experimental|Cohort 3b|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
9785945|NCT01263197|Experimental|LY2216684, albuterol, LY2216684+albuterol|LY2216684 as an 18 milligram (mg) oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
9785946|NCT01263197|Experimental|albuterol, LY2216684+albuterol, LY2216684|Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
9785947|NCT01263197|Experimental|LY2216684+albuterol, LY2216684, albuterol|LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
9785948|NCT01263197|Experimental|LY2216684, propranolol, LY2216684+propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
9785949|NCT01263197|Experimental|propranolol, LY2216684+propranolol, LY2216684|Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
9785950|NCT01263197|Experimental|LY2216684+propranolol, LY2216684, propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
9785951|NCT01263223|Experimental|LY2216684, placebo, LY or placebo|"Period 1: 18 milligrams (mg) LY2216684 administered orally once daily on Days 1-4~Period 2: placebo administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
9785952|NCT01263223|Experimental|Placebo, LY2216684, placebo or LY|"Period 1: placebo administered orally once daily on Days 1-4~Period 2: 18 mg LY2216684 administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
9785953|NCT01263301|Active Comparator|carotid duplex for hemolytic patients wtih SSS|assigned intervention:carotid duplex
9785954|NCT01263301|Active Comparator|carotid duplex for nonhemolytic patients with SSS|
9785955|NCT01263314|Experimental|Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
9785956|NCT01263314|Experimental|Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
9785957|NCT01263314|Experimental|Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
9785958|NCT01263314|Placebo Comparator|Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)|Placebo to MK-8266 single dose
9785959|NCT01263314|Experimental|Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
9785960|NCT01263314|Experimental|Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
9785961|NCT01263314|Experimental|Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
9785962|NCT01263314|Placebo Comparator|Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)|Placebo to MK-8266 single dose
9785963|NCT01263444|Experimental|Azarga|Brinzolamide 1% / timolol 0.5% Fixed Combination administered as 1 drop in study eye(s) twice a day (8:00 AM and 8:00 PM) for 12 weeks, at a 5 minute interval from the habitual prostaglandin monotherapy.
9785964|NCT01263470|Placebo Comparator|Placebo|
9785965|NCT01263470|Experimental|Alogliptin 6.25 mg QD|
9785966|NCT01263470|Experimental|Alogliptin 12.5 mg QD|
9785967|NCT01263470|Experimental|Alogliptin 25 mg QD|
9785968|NCT01263470|Experimental|Alogliptin 50 mg QD|
9785969|NCT01263470|Active Comparator|Voglibose 0.2 mg TID|
9785970|NCT01263483|Active Comparator|Voglibose 0.2 mg TID|
9785971|NCT01263483|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
9785972|NCT01263483|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
9785973|NCT01263496|Experimental|Alogliptin 6.25 mg QD|
9785974|NCT01263496|Experimental|Alogliptin 12.5 mg QD|
9785975|NCT01263496|Experimental|Alogliptin 25 mg QD|
9785976|NCT01263496|Experimental|Alogliptin 50 mg QD|
9785977|NCT01263496|Active Comparator|Voglibose 0.2-mg TID|
9785978|NCT01263509|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
9785979|NCT01263509|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
9921877|NCT00832052|Experimental|Cohort 4|
9785980|NCT01263561|Active Comparator|trabeculectomy|trabeculectomy filtering surgery
9785981|NCT01263561|Experimental|ExPRESS|ExPRESS miniature glaucoma drainage device
9785982|NCT01263639|Experimental|Intervention Group, biosketch card|The investigators aim to improve the patient-physician relationship and improve patient satisfaction by providing a biosketch card of the attending orthopaedic trauma surgeon to the patient. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
9785983|NCT01263639|Active Comparator|Control group, standard care|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The control group will receive the usual/standard care as provided to all orthopaedic trauma admission patients without receiving a biosketch card."
9785984|NCT01263665|Experimental|25cm Gore VIABAHN|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
9785985|NCT01263691|Active Comparator|BioThrax|BioThrax, 0.5 mL AVA per dose
9785986|NCT01263691|Experimental|AV7909 Formulation 1|0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
9785987|NCT01263691|Experimental|AV7909 Formulation 2|0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
9785988|NCT01263691|Experimental|AV7909 Formulation 3|0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
9785989|NCT01263691|Experimental|AV7909 Formulation 4|0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
9785990|NCT01263691|Placebo Comparator|Control|Saline control
9785991|NCT01263704|Experimental|Rituximab plus Fludarabine and Cyclophosphamide|Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.
9785992|NCT01263717|Experimental|Tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
9785993|NCT01263717|Placebo Comparator|Placebo (inactive injection)|Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
9785994|NCT01263782|Experimental|Carboplatin + Pemetrexed|"The chemotherapy will be Carboplatin (AUC 6) and Pemetrexed (500 mg/m2) every 3 weeks for 4 cycles.~Then maintenance Pemetrexed (500 mg/m2 every 3 weeks) will be administered until disease progression or excessive toxicity.~If patients are randomized into one of the arms with a biologic therapy, patients will take the chemotherapy prescribed above, but will also receive the biologic therapy during the same time period."
9785995|NCT01263782|Experimental|Chemo (Carbo/Peme) + Bevacizumab|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Bevacizumab 15 mg/kg by vein on day 1 of each 21 day cycle.
9785996|NCT01263782|Experimental|Chemo (Carbo/Peme)|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
9785997|NCT01263782|Experimental|Chemo (Carbo/Peme) + Cixutumumab|"Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.~Cixutumumab 20 mg/kg by vein on day 1 of each 21 day cycle."
9785998|NCT01263873|Active Comparator|Mallinckrodt (ETT)|Artifical Airway Device
9785999|NCT01263873|Experimental|Parker Flex Tip (ETT)|Artifical Airway Device
9786000|NCT01263925|Experimental|Alprostadil|Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
9786001|NCT01263925|Active Comparator|Pentoxifylline|Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
9786002|NCT01263938|Other|Atorvastatin|
9786003|NCT01264016|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use an investigational blood glucose monitoring system.
9786004|NCT01264081|Experimental|Lapatinib|Lapatinib will be administered as an oral dose of 500 mg twice daily in the morning and evening one hour before or after meals.
9786005|NCT01264380|Experimental|1|
9786006|NCT01264380|Experimental|2|
9786007|NCT01264380|Experimental|C|
9786008|NCT01264419|Experimental|Silk Road Embolic Protection System|Eligible subjects who are to receive a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
9786009|NCT01264601|Experimental|Single Dose|This arm will receive TIV as 2 doses, the first of which will be normal saline administered at approximately 10% of the total age appropriate dose volume, followed 30 minutes later by the full age appropriate dose. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
9786010|NCT01264601|Experimental|Graded Challenge|Subjects in this arm will receive TIV by standard 10%/90% 2-step graded challenge split of the age appropriate dose, separated by 30 minutes. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
9786011|NCT01264614|Experimental|Early stage dementia|Individuals with early stage dementia who attended a Adult Day Care Program at least twice a week. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
9786012|NCT01264614|Active Comparator|Normative older adults|Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
9786013|NCT01264705|Experimental|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
9786014|NCT01264705|Experimental|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
9786015|NCT01264705|Experimental|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
9786016|NCT01264718|No Intervention|Control|After randomization to the control group, minority low-income parents of uninsured, Medicaid/CHIP-eligible children received only traditional Medicaid/Children's Health Insurance Program (CHIP) outreach and enrollment.
9786017|NCT01264718|Experimental|Parent Mentors|After randomization to the Parent Mentor group, minority low-income parents of uninsured Medicaid/CHIP-eligible children received face-to-face instruction and guidance from Parent Mentors on obtaining and keeping Medicaid/CHIP for their child; getting a doctor, dentist, and pharmacist; and addressing social determinants of health.
9786018|NCT01264770|Experimental|Dosing Group A|Oral treatment and subcutaneous injection
9786019|NCT01264770|Experimental|Dosing Group B|Oral treatment and subcutaneous injection
9786020|NCT01264770|Experimental|Dosing Group C|Oral treatment and subcutaneous injection
9786021|NCT01264770|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection
9786022|NCT01264770|Placebo Comparator|Dosing Group E|Oral treatment and subcutaneous injection
9786023|NCT01264887|Experimental|Tapentadol Prolonged Release|Participants allocated to this treatment arm can be flexibly dosed between 100 to 250 mg tapentadol twice daily (50 and 100 mg tablets to be dispensed).
9786024|NCT01264939|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
9786025|NCT01264939|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
9786026|NCT01265056|Placebo Comparator|Sugar Pill|Placebo
9786027|NCT01265056|Experimental|Gabapentin|Gabapentin
9786028|NCT01265394|Experimental|(18F) Flutemetamol|
9786029|NCT01265420|Experimental|Injectable clostridial collagenase|Patients with thumb 1st web contracture secondary to Dupuytren's disease will be treated with 0.58mg of collagenase
9786030|NCT01265446|Experimental|Lidocaine 8mg +CPC 2mg|one single dose
9786031|NCT01265446|Active Comparator|Lidocaine 1mg + CPC 2mg|one single dose
9786032|NCT01265459|Experimental|Durolane 3ml|Durolane 3 ml is an Intraarticular hyaluronic acid
9786033|NCT01265459|Experimental|Durolane 4.5|Durolane 4.5 is an Intraarticular hyaluronic acid
9786034|NCT01265459|Experimental|Durolane 6 ml|Durolane 6 ml is an Intraarticular hyaluronic acid
9786035|NCT01265498|Active Comparator|Obeticholic acid|obeticholic acid
9786036|NCT01265498|Placebo Comparator|Placebo|Placebo
9786037|NCT01265511|Placebo Comparator|Placebo|Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
9786038|NCT01265511|Active Comparator|SCY-635 600 mg|SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
9786039|NCT01265524|Active Comparator|CLP|Investigational drug: 15 g CLP per day given as capsules
9786040|NCT01265524|Placebo Comparator|Placebo|Placebo, capsules
9786041|NCT01265537|Experimental|Low target tacrolimus (Advagraf)|"This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and low-target Advagraf."
9786042|NCT01265537|Active Comparator|Standard target tacrolimus (Advagraf)|"This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and standard target Advagraf."
9786043|NCT01265550|Other|Medical Treatment Group|Omeprazole or Omeprazole + baclofen or Omeprazole + desipramine
9786044|NCT01265550|Other|Surgical Treatment Group|Laparoscopic nissen fundoplications
9786045|NCT01265550|Other|Placebo Medical Treatment Group|Omeprazole + placebo
9786046|NCT01265563|Placebo Comparator|NAC placebo and Silibin placebo|Drug: N-acetylcysteine placebo and Drug: Silibin placebo
9786047|NCT01265563|Experimental|NAC active and Silibin placebo|Drug: N-acetylcysteine and Drug: Silibin placebo
9786048|NCT01265563|Experimental|NAC placebo and Silibin active|Drug: N-acetylcysteine placebo and Drug: Silibin active
9786049|NCT01265563|Experimental|NAC active and Silibin active|Drug: N-acetylcysteine active and Drug: Silibin active
9786050|NCT01265563|Experimental|NAC active and High-dose Silibin active|Drug: N-acetylcysteine active and Drug: Silibin higher dose active
9786051|NCT01265615|Active Comparator|Paricalcitol treatment|6-8 μg daily per os (orally) without special diet
9786052|NCT01265615|Active Comparator|Calcitriol treatment|2-4 μg daily orally under with dietary restrictions of vitamin D
9786053|NCT01265615|Active Comparator|Cholecalciferol|alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
9786054|NCT01265615|Other|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
9786055|NCT01265667|Experimental|CF101 2 mg|CF101 2mg oral tablets
9786056|NCT01265667|Placebo Comparator|Placebo|Placebo oral tablets
9786057|NCT01265719||Latanoprost-treatment group|
9786058|NCT01265719||Non-topical prostaglandin analogue treatment group|
9786059|NCT01265797|Active Comparator|Cranial Electrostimulator|wears active cranial electrostimulation device for 20 minutes daily for 28 days
9786060|NCT01265797|Sham Comparator|Sham device|wears sham device for 20 minutes daily for 28 days
9799282|NCT01655719|Experimental|Pioglitazone Treatment|"If eligible, subjects can participate in 1 or both parts of this study as follows:~Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.~Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment."
9799283|NCT01655823|Placebo Comparator|Placebo (twice daily)|Placebo for injection (1 ml volume), twice a day for four consecutive days.
9799284|NCT01655823|Experimental|Low dose Tetrodotoxin (twice daily)|Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
9799285|NCT01655823|Experimental|Mid-range dose of Tetrodotoxin (twice daily)|Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
9799286|NCT01655823|Experimental|Max dose Tetrodotoxin (once daily)|Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
9799287|NCT01655823|Experimental|Max dose Tetrodotoxin (twice daily)|Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
9799288|NCT01655901|Experimental|Active video gaming|Playing Kinect
9799289|NCT01655901|Experimental|Passive video gaming|Playing Xbox 360
9799290|NCT01655901|Experimental|Resting|Stay seated on a comfortable chair
9786061|NCT01265823|Experimental|Adalimumab|
9786062|NCT01265875|Other|human secretin|intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
9786063|NCT01265953|Experimental|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of sulforaphane (SFN) daily, 2 capsules (1 capsule B.I.D.) daily
9786064|NCT01265953|Placebo Comparator|Placebo capsules|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
9786065|NCT01265966||Moderate Sedation|Children undergoing moderate sedation for procedures.
9786066|NCT01265966||Deep Sedation|Children undergoing deep sedation for procedures.
9786067|NCT01265992||Paricalcitol capsules|Patients with secondary hyperparathyroidism associated with Stage 3 - 5 CKD and not yet on dialysis and prescribed paricalcitol capsules in accordance with the terms of the marketing authorization in Sweden.
9786068|NCT01266018|Experimental|Cohort 1: Sensitive Disease|"Cohort 1 comprised subjects with sensitive disease, defined as subjects who were treated with 1 previous line of chemotherapy and maintained an appropriate response for 90 days or more. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
9786069|NCT01266018|Experimental|Cohort 2: Refractory Disease|"Cohort 2 comprised subjects with refractory disease, defined as subjects who either (a) were treated with 1 previous line of chemotherapy and either had no response or progressed < 90 days after completing treatment or (b) required third-line therapy, i.e., had completed 2 previous lines of chemotherapy, regardless of response. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
9786070|NCT01266070|Experimental|Dovitinib|500 mg/day on a 5 day on, 2 day off schedule
9786071|NCT01266122|No Intervention|HIV/STI voluntary counseling and testing|Participants enrolled in the control arm will receive study assessments only.
9786072|NCT01266122|Experimental|Behavioral intervention|Participants enrolled in the experimental condition will receive 4 group sessions and 4 individual sessions over 3 months. This intervention focuses on psychosocial concerns and HIV risk for MSM in India.
9786073|NCT01266148|Experimental|Everolimus|Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
9786074|NCT01266148|Experimental|Control|Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
9786075|NCT01266161|Experimental|Ibuprofen 600 mg extended release|
9786076|NCT01266161|Placebo Comparator|Placebo|
9786077|NCT01266265||Tyvaso|The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.
9786078|NCT01266265||Control|The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.
9921878|NCT00832065||Patients With Sleep Apnea and Low Testosterone|Adult male patients between 18-70 years of age with nely diagnosed OSAS documented by all night polysomnography(PSG)
9921879|NCT00832143|No Intervention|1|Usual Care
9921880|NCT00832143|Experimental|2|Referral Card with one-to-one counseling
9786079|NCT01266291|Other|Treatment with Sabril (vigabatrin)|This is a single arm study. All subjects who are eligible for treatment will begin taking vigabatrin (Sabril) during the third month of the study. Treatment will be in accordance with the FDA-approved prescribing information: upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
9786080|NCT01266317|Experimental|Combined PEX, Rituximab and Steroids|"Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator.~Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5.~Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13."
9786081|NCT01266447|Experimental|Treatment (veliparib, topotecan hydrochloride, filgrastim)|Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9786082|NCT01266460|Experimental|Treatment (ADXS11-001)|Patients receive live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001 IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9786083|NCT01266590|Experimental|LY2216684 + digoxin|Two oral 0.5-milligrams (mg) (two 0.25-mg tablets) doses of digoxin separated by 12 hours on Day 1, followed by once daily 0.25-mg (single 0.25-mg tablet) dose of digoxin on Days 2-14. Daily oral 18-mg (two 9-mg tablets) doses of LY2216684 on Days 8-14.
9786084|NCT01266603|Experimental|HDIL-2 + recMAGE-A3 + AS15|HDIL-2 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle. recMAGE-A3 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
9786085|NCT01266642|Experimental|Arm I (HF-WBI)|Patients undergo HF-WBI comprising external beam RT 5 days a week for approximately 3 weeks.
9786086|NCT01266642|Active Comparator|Arm II (CF-WBI)|Patients undergo CF-WBI comprising external beam RT 5 days a week for approximately 5 weeks.
9786087|NCT01266850|Active Comparator|Group 1, RotaTeq® x 3|2, 4 and 6 months of age: RotaTeq®
9786088|NCT01266850|Experimental|Group 5, Rotarix®, RotaTeq® x2|2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
9786089|NCT01266850|Active Comparator|Group 4, Rotarix® x 2|2 and 4 months of age: Rotarix®
9786090|NCT01266850|Experimental|Group 2, RotaTeq®, Rotarix® x 2|2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
9786091|NCT01266850|Experimental|Group 3, RotaTeq® x 2, Rotarix®|2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
9786092|NCT01266876|Placebo Comparator|Placebo|Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
9786093|NCT01266876|Experimental|Alirocumab 150 mg Q4W|Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
9786094|NCT01266876|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
9786095|NCT01266876|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
9786096|NCT01266876|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
9786097|NCT01266902|Experimental|Rilpivirine|Rilpivirine 25 mg once daily
9786098|NCT01266967|Experimental|Single Arm|Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
9786099|NCT01266993|Experimental|Nimenrix Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Nimenrix vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Nimenrix vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
9786100|NCT01266993|Experimental|Menjugate Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Menjugate vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Menjugate vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
9786101|NCT01267019|Experimental|Arm 1: vivo augmentation|social cognitive training with in vivo augmentation
9786102|NCT01267019|Active Comparator|Arm 2: social cognitive|social cognitive training
9786103|NCT01267019|Active Comparator|Arm 3: non-social skills|non-social skills training
9786104|NCT01267045|Experimental|Arm 1|Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction course
9786105|NCT01267045|No Intervention|Arm 2|Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
9786106|NCT01267136|Experimental|Capital® with Codeine Suspension|
9786107|NCT01267136|Active Comparator|Tramadol suspension|
9786108|NCT01267175|Experimental|X54 pump|All subjects transferred from current pump to X54
9786109|NCT01267201|Experimental|POS formulation #1|
9786110|NCT01267201|Experimental|POS formulation #2|
9786111|NCT01267201|Active Comparator|commercial tablet|
9786112|NCT01267227|Active Comparator|High Dose|Pterostilbene 125 mg twice daily
9786113|NCT01267227|Active Comparator|Low Dose|Pterostilbene 50 mg twice daily
9786114|NCT01267227|Active Comparator|Low Dose Combination|Pterostilbene 50 mg/Grape Extract 100 mg twice daily
9786115|NCT01267227|Placebo Comparator|Placebo|Matching placebo twice daily
9786116|NCT01267240|Experimental|Arm I (capecitabine, vorinostat)|Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9786117|NCT01267253|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9786118|NCT01267266|Experimental|Arm I (saracatinib)|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9786119|NCT01267266|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Upon progression, patients may crossover to arm I.
9786120|NCT01267279|Placebo Comparator|Placebo|
9786121|NCT01267279|Experimental|Zoledronic Acid|
9786122|NCT01267292|Experimental|Buspirone plus Methylphenidate|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
9786123|NCT01267292|Placebo Comparator|Placebo for Buspirone plus Methylphenidate|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
9786124|NCT01267422|Experimental|rAAV2-ND4|injection
9786125|NCT01267656|Experimental|Lubricating and Rewetting Drops|Lubricating and Rewetting Drops, after one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week.
9786126|NCT01267656|Active Comparator|AMO Blink Contacts Lubricant Eye Drops|AMO Blink Contacts Lubricant Eye Drops, After one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week
9786127|NCT01267864|Active Comparator|Metoclopramide|Metoclopramide 10mg IVSS
9786128|NCT01267864|Active Comparator|Ketorolac|Ketorolac 30mg IV
9836486|NCT05348603|Experimental|Traditional Letter + Chatbot + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests.~AND~*Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
9786129|NCT01267864|Active Comparator|Valproate|1gm IV
9786130|NCT01267929|Experimental|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months. The mirror neurons stimulation based VCD program that contained four volumes. The first volume includes activities activities for improving balance in sitting position. The second volume includes activities of sitting to standing. The third volume includes activities for improving balance in standing position. The last one includes activities of sideway walking. The running time of each volume is 30 minutes. The children had been practicing for two weeks per volume. Their parents were trained for practicing their children by VCD program at home and were asked to complete daily record of children's activities. The children were scheduled to meet a pediatric physical therapist once a week to monitor possible side effects.
9786131|NCT01267929|Active Comparator|The conventional physical therapy|The children receive manual physical therapy regularly at the hospital once a week for first two months and twice a month for last four months. The conventional physical therapy technique in this study derive from the manual technique including the Bobath concept, stretching exercise and functional training for 30-45 minutes at a time.
9786132|NCT01267994|Experimental|Single Arm-Open Label|Single Arm-Open Label use of Anakinra
9786133|NCT01268046|Experimental|Young postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
9786134|NCT01268046|Experimental|Older postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
9786135|NCT01268046|Placebo Comparator|Young postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
9786136|NCT01268046|Placebo Comparator|Older postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
9786137|NCT01268059|Active Comparator|Carboplatin/Paclitaxel|Carboplatin/paclitaxel regimen (carboplatin area under the plasma concentration-time curve [AUC] of 6 milligram per milliliter into minute [mg/mL*min], and paclitaxel 200 milligram per square meter [mg/m^2]) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal. Subjects were enrolled from North America/European Union (EU) and Japan regions.
9786138|NCT01268059|Experimental|Carboplatin/Paclitaxel + MEDI-575|Carboplatin/paclitaxel regimen (carboplatin AUC = 6 mg/mL*min, and paclitaxel 200 mg/m^2) followed by MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575. Subjects were enrolled from North America/European Union (EU) and Japan regions.
9786139|NCT01268098|Experimental|25 µg dose|25 µg
9786140|NCT01268098|Experimental|50 µg dose|50 µg
9786141|NCT01268111|Experimental|Vitamin D|ERgocalcifoerol 50,000 units q weekly for 8 weeks
9786142|NCT01268111|Placebo Comparator|Placebo|
9786143|NCT01268150|Experimental|Experimental|
9786144|NCT01268189|Experimental|Burn wound patients with donor sites|Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
9786145|NCT01268267|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using an investigational blood glucose monitoring system (development name Ninja 2).
9786146|NCT01268293|Experimental|1|
9786147|NCT01268306|Experimental|B+L Biotrue MPS and B+L PureVision|Successful contact lens wearers switched to B&L BioTrue MPS while wearing B+L PureVision lenses
9786148|NCT01268488|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.
9786149|NCT01268501|Experimental|Lotrafilcon B multifocal|Lotrafilcon B multifocal contact lenses worn bilaterally for 3 weeks on a daily wear basis
9786150|NCT01268527|Experimental|Cohort 1|Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
9786151|NCT01268527|Experimental|Cohort 2|Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
9786152|NCT01268553|Experimental|Active treatment|This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.
9786153|NCT01268566|Experimental|MEDI-575, 25 mg/kg|MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
9786154|NCT01268644|Experimental|active open label Leptin|Active open label Leptin for type 1 Diabetes
9786155|NCT01268683|Experimental|Glyburide for Injection|This arm is administered a glyburide bolus followed by continuous infusion of glyburide for 72 hours
9786156|NCT01268891|Placebo Comparator|Placebo|
9786157|NCT01268891|Experimental|Azilect®|
9786158|NCT01268943|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9786159|NCT01268943|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9786160|NCT01268943|Experimental|1400mg|capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9786161|NCT01268943|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9786162|NCT01269047|Experimental|Pramlintide + Insulin Group|These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
9786163|NCT01269047|Experimental|Exenatide + Insulin Group|This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
9786164|NCT01269047|Active Comparator|Insulin monotherapy|This group will be on their regular insulin therapy.
9786165|NCT01269125|Active Comparator|Endometriosis, leuprolide, IVF|Women with stage II endometriosis received GnRH-a (leuprolide) prior to an IVF attempt.
9786166|NCT01269125|Active Comparator|Endometriosis, IVF|Women with mild endometriosis who underwent an IVF attempt without prior administration of GnRH-a.
9786167|NCT01269125|Active Comparator|Tubal infertility, IVF|Women with tubal infertility underwent an IVF attempt.
10205542|NCT05205603|Experimental|5-ASA group|"5-ASA combined with biologics (including infliximab and vedolizumab). infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks.~mesalazine: at a dose of 4-6g/d systemic or topical therapy"
10205543|NCT05205525||Restrictive antibiotic strategy|
9786168|NCT01269346|Experimental|1|
9786169|NCT01269372|Other|PillCam Colon 2 and Standard Colonoscopy|All subjects received Capsule Endoscopy (CE) using the PillCam Colon 2 followed by a standard colonoscopy.
9786170|NCT01269385|Experimental|Arm I|Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
9786171|NCT01269736|Experimental|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
9786172|NCT01269736|No Intervention|Control|Usual in-service education for nurses
9786173|NCT01269801|Active Comparator|Botox Cosmetic|onabotulinumtoxinA for injection
9786174|NCT01269801|Active Comparator|JUVÉDERM|JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
9786175|NCT01269918|Active Comparator|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
10205544|NCT05205525||Aggressive (immediate) antibiotic strategy|
10214063|NCT01632930|Active Comparator|Results of urinary PCA3 test will not be available|In this arm, physicians will not have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion will therefore not be influenced by urinary PCA3 test results
9786176|NCT01269918|Active Comparator|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
9786177|NCT01270126|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
9786178|NCT01270126|No Intervention|Sham stimulation (placebo condition)|A clicking sound was presented and the same electrode montage set-up was used during rtACS- and placebo-stimulation, except that placebo patients received no current (stimulator turned off)
9786179|NCT01270139|Experimental|Nano group|60 patients in Nano group were treated with transplantation of nanoparticles (NP), particularly with a bioengineered patch that was grown with allogenous stem cells pre-cultivated in the medium with NP. After the admission, patients were examined with QCA, and allocated to the trial. The implantation of the patch onto the artery was undergone by the minimally invasive cardiac surgery (MICS CABG) with fixation of the graft to the epicardial myocardium. MICS CABG implies a beating-heart multi-vessel heart surgery performed through several small incisions under direct vision through an anterolateral mini-thoracotomy in the 4th-6th intercostal spaces. The patients can expect high quality of life resuming all everyday activities within a few weeks of their operation. NP were activated with NIR laser at 7 days after the intervention. Patients were treated with bolus of bivalirudin on the day of NP detonation.
9786180|NCT01270139|Active Comparator|Ferro group|60 patients in Ferro group were managed with transplantation of iron-bearing nanoparticles (NP), particularly with intracoronary infusion of allogenous stem cells or CD68 targeted micro-bubbles pre-cultivated in the medium with iron-bearing NP. Cells and/ or micro-bubbles were infused with QCA- and IVUS-guidance to the target coronary artery via micro-catheter on the day of admission. The destruction of CD68 targeted micro-bubbles was obtained by using a Sonos 5500 machine with an S3 transducer operating in ultraharmonic mode (transmit, 1.3MHz/ receive, 3.6 MHz) with a mechanical index of 1.5 and a depth of 4 cm. The AXIOM Artis dBC (Siemens) magnetic navigation system was used for precise delivery of NP to the atheroma through two permanent computer-controlled external magnets generating a navigational magnetic field of 0.08 Tesla in any direction. NP were detonated with NIR laser under the protection of anti-platelet therapy.
9786181|NCT01270139|Other|Stenting control|In case of control group (stenting control), XIENCE V stent was implanted to 60 patients. Patients with a single de novo native coronary stenosis of less than 12 mm lesion length, more than 50% stenosis and reference diameter of 3.0 mm as assessed by online QCA were stented by a single stent of 3.0 x 18 mm. The procedure of implantation had to be performed according to common interventional practices including the administration of intracoronary nitroglycerine 0.2 mg of glycerol trinitrate or isosorbide dinitrate and intra-arterial heparin (50-100 U/kg body weight). Predilation with a conventional balloon catheter was recommended before DES deployment according to the manufacturer's recommendation. The protocol recommended the study stent should cover 2 mm of non-diseased tissue on either side of the target lesion. Postdilatation was allowed with a balloon that was shorter than was the study device.
10205545|NCT05205460|Experimental|Home-based telehealth exercise training|After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes). Then, the participants will start a home-based telehealth exercise training program (30minutes/session, 3 sessions/week for 12weeks, with a total of 36 sessions) combined with heart rate sensing clothes. Exercise type: brisk walking, jogging, or stationary ergometer exercise.
9786182|NCT01270256|Active Comparator|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
9786183|NCT01270256|Placebo Comparator|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
9786184|NCT01270321|Experimental|Arm A (Everolimus alone)|CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression
10205546|NCT05205460|Active Comparator|Education and self-exercise|"After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes).~Then, the patients will receive weekly reminders and monthly outpatient follow-ups during the exercise program."
9786185|NCT01270321|Experimental|Arm B (Pasireotide alone)|CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression
9786186|NCT01270321|Experimental|Arm C (Everolimus + Pasireotide)|CURRENTLY CLOSED TO ACCRUAL
9786187|NCT01270464|Placebo Comparator|Placebo|Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
9786188|NCT01270464|Experimental|Reslizumab - 0.3 mg/kg|0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses
9786189|NCT01270464|Experimental|Reslizumab - 3.0 mg/kg|3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
9786190|NCT01270503|Experimental|Menactra® Group 1|Participants aged 2 to 11 on enrollment
9786191|NCT01270503|Experimental|Menactra® Group 2|Participants aged 12 to 17 on enrollment
9786192|NCT01270503|Experimental|Menactra® Group 3|Participants aged 18 to 55 on enrollment
9786193|NCT01270516|Placebo Comparator|Control, to be given saline solution|Intervention: This group will be given saline (30 ml every 12 hours) for 10 days
9786194|NCT01270516|Experimental|EPA, eicosapentaenoic acid|This group will be given 1000 mg EPA every 12 hours for 10 days
9786195|NCT01270516|Experimental|HMB, hydroxymethylbutyrate|This arm will be given HMB (1500 mg) every 12 hours for 10 days.
9786196|NCT01270516|Experimental|EPA and HMB|Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.
9786197|NCT01270529|Experimental|CKD Stages 1-4|
9786198|NCT01270529|Experimental|ESRD on Dialysis|
9786199|NCT01270529|Experimental|Kidney Transplant recipients|
10205547|NCT05205434|Experimental|Synchronous telerehabilitation program (Video conference)|Participants will exercise program at home for an average of 30 minutes a day, 3 days a week, under the supervision of a physiotherapist via synchronized video conference. The program will continue for 8 weeks. The exercise program will consist of physical exercises (aerobic and strength exercises) along with breathing exercises and an educational program. Physical exercises will be adjusted in 3 different difficulty levels: sitting, standing with or without support.
10205548|NCT05205434|Experimental|Asynchronous telerehabilitation programme (Mobil app.)|The same exercises as in the synchronous telerehabilitation program will be done at the same frequency. Participants will watch the videos sent by the investigator via the mobile application and then do the exercises at home. The participants will meet with the investigator once a week to an update exercise program.
10205549|NCT05205434|No Intervention|Control|Participants in this group will only receive an educational program
10205550|NCT05205421|Experimental|Oncolytic Virus Injection(RT-01)|RT-01 will be administered either intravenously or with a combination of intravenously and intratumorally; intravenously dosage: 1 x 10^10 TCID50; intratumorally: 7×10^8 TCID50/mL;
10205551|NCT05205395||Women with stress incontinence|Women with urodynamic stress incontinence (USI) scheduled for mid-urethral sling surgery in the urogynecological department of a tertiary referral center were recruited.
10214064|NCT01601522|Experimental|Oral Immunotherapy with placebo antihistamines|500 mg Peanut Protein with placebo antihistamines
9786200|NCT01270542|Experimental|Avastin Injection Group (AIG)|Subjects in this group will get single 0.05 mL intravitreal injection of bevacizumab 1.25 mg 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
9786201|NCT01270542|Sham Comparator|Sham Injection Group (SIG)|Subjects in this group will get a sham injection 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
9786202|NCT01270555|Experimental|Bupropion|
9786203|NCT01270620|Active Comparator|Propofol|Patients will receive propofol as general anesthetics.
9786204|NCT01270620|Active Comparator|Desflurane|Patients will receive desflurane as general anesthetics.
9786205|NCT01270659|Experimental|Low-FBT|Subject will receive FBT and placebo at a low dose
9786206|NCT01270659|Experimental|High-FBT|Subject will receive the high dose regimen of FBT and a high dose placebo
9786207|NCT01270659|Active Comparator|Low control|"Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl placebo"
9786208|NCT01270659|Active Comparator|High control|"Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl placebo"
9786209|NCT01270711||Cabergoline users|cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
9786210|NCT01270802|Active Comparator|Tenofovir/emtricitabine/efavirenz|Tenofovir/emtricitabine/efavirenz
9786211|NCT01270802|Experimental|Tenofovir/emtricitabine plus raltegravir|Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir
9786212|NCT01270828|Experimental|Pregablain CR tablet 82.5 to 660mg|
9786213|NCT01270828|Placebo Comparator|Placebo|
9786214|NCT01270841|Placebo Comparator|Placebo|Placebo
9786215|NCT01270841|Active Comparator|Testim (topical testosterone)|Testim (topical testosterone)
9786216|NCT01270841|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
9786217|NCT01270841|Experimental|Androxal 25 mg|Androxal 25 mg/day
9786218|NCT01270867|Active Comparator|Merci Retriever|Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
9786219|NCT01270867|Experimental|Trevo Stentriever|Trevo Retriever is a second generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke. The Trevo Retriever is a type of stent, specifically design to allow for clot integration into the device. The clot in the retriever is then removed and blood flow is restored.
9786220|NCT01270880|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9786221|NCT01270958|Experimental|TREATMENT|50 adult patients with Perennial Allergic Rhinities treated with Avamys.
9786222|NCT01270971|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
9786223|NCT01270971|Placebo Comparator|Solution Vehicle|Solution Vehicle
9786224|NCT01271010|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants received rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
9786225|NCT01271036|Experimental|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
9786226|NCT01271244|Active Comparator|PTSD Depression Group|Escitalopram 10-20 mg/day
9786227|NCT01271244|Active Comparator|Major Depression Group|Escitalopram 10-20 mg/day
9786228|NCT01271413|Experimental|Adaptive cognitively stimulating activities|
9786229|NCT01271413|Active Comparator|Non-adaptive cognitively stimulating activities|
9786230|NCT01271452|Active Comparator|Vistabel®|botulinum toxin type A (Vistabel®)
9786231|NCT01271452|Active Comparator|Bocouture®|botulinum toxin type A (Bocouture®)
9786232|NCT01271504|Active Comparator|Phase Ib: Cohort 1,2, and 3|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
9786233|NCT01271504|Active Comparator|Phase II: Arm 1; E7050 + Sorafenib|Phase II: Arm 1; E7050 + 400 mg Sorafenib Arm 2; 400 mg Sorafenib
9786234|NCT01271543|Active Comparator|MacIntosh group|
9786235|NCT01271543|Experimental|Shikani optical stylet|
9786236|NCT01271686|Experimental|0.01% bimatoprost|bimatoprost 0.01% one time per day at bedtime for 4 weeks.
9786237|NCT01271712|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
9786238|NCT01271712|Placebo Comparator|Placebo|Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
9786239|NCT01271725|Experimental|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
9786240|NCT01271725|Experimental|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
9786241|NCT01271725|Experimental|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
9786242|NCT01271803|Experimental|DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786243|NCT01271803|Experimental|DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786244|NCT01271803|Experimental|DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9921881|NCT00832156|Experimental|1|wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
9786245|NCT01271803|Experimental|DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786246|NCT01271803|Experimental|DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786247|NCT01271803|Experimental|DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786248|NCT01271803|Experimental|DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786249|NCT01271803|Experimental|DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786250|NCT01271803|Experimental|DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786251|NCT01271803|Experimental|Cobimetinib Monotherapy (100 mg or 60 mg)|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786252|NCT01271803|Experimental|CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786253|NCT01271803|Experimental|CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
9786254|NCT01271855|Placebo Comparator|Glycerin suppository|Women assigned to this arm receive a glycerin suppository (placebo) every 8 hours after delivery during the first 24 hours postpartum
9786255|NCT01271855|Experimental|Belladonna and opioid suppository|Women assigned to this arm receive a belladonna and opioid (B&O) suppository every 8 hours after delivery during the first 24 hours postpartum
9786256|NCT01271868|Experimental|IB1001|
9799291|NCT01656031|Experimental|high-dose cytarabine and clofarabine|high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days
9799292|NCT01656161|Experimental|Triptorelin embonate 22.5 mg|Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
9799293|NCT01656187|Experimental|Memantine, Then Placebo|Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.
9921882|NCT00832156|Other|2|control wound site; application of mesh graft alone
9786257|NCT01271907|Experimental|Cohort 0|Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
9786258|NCT01271907|Experimental|Cohort 1|2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
9786259|NCT01271907|Experimental|Cohort 2|1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells
9786260|NCT01271933|Experimental|Pregabalin|
9786261|NCT01271933|Placebo Comparator|Placebo|
9786262|NCT01271946|Other|Diagnostic Procedure|
9786263|NCT01272011|Experimental|Phase 1 Arm (Pilot)|Individuals were exposed to intermittent hypoxia and locomotor training to establish our interventions (set up lab, train personnel, develop study protocols/interventions, etc)
9786264|NCT01272011|Experimental|Phase 2 Arm (LTF)|Individuals were exposed to 10 days of intermittent hypoxia to determine the effect of this intervention on ventilatory long-term facilitation, as measured by minute ventilation
9786265|NCT01272011|Other|Phase 3 Arm (Ventilatory Loading)|Individuals were exposed to 10 days of intermittent hypoxia to determine changes in ventilatory loading.
9786266|NCT01272076||Dry AMD and geographic atrophy|Patients diagnosed with dry AMD and geographic atrophy
9786267|NCT01272180|Experimental|ABCWY+OMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart."
9786268|NCT01272180|Experimental|ABCWY+qOMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart."
9786269|NCT01272180|Active Comparator|rMenB+OMV|"Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart."
9996764|NCT01503047|Placebo Comparator|Placebo group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.
10205552|NCT05205356||Neonates and Parents/Caregivers|"Providers caring for newborns that meet eligibility criteria will approach parents to assess interest. The VIGOR study staff will remotely contact parents to complete consent for genomic sequencing (GS). We will also invite 1 additional primary caregiver (e.g. father, co-mother etc.) to participate even if that caregiver is not biologically related to the child.~We will administer surveys at baseline enrollment to assess sociodemographics, obstetrical history, family genetic history & mental health; within 1 week of disclosure of findings to assess satisfaction & mental health; & at 3 & 6 months to further assess mental health & newborn clinical outcomes. We will approach a subset of the families for qualitative interviews to assess satisfaction with VIGOR & receipt of GS results with their physician in more detail."
10205553|NCT05205356||Clinicians|Following focus groups at each of the participating sites to assess the feasibility & needs of each site, the care teams will receive basic training in genomics and how to disclose GS results with VIGOR support. Study orientation will be completed as part of the training. Focus groups will be conducted within 1 year post implementation & again between year 4 & the completion of the study, to assess feasibility & appropriateness of VIGOR. We will administer brief surveys to the care providers before & after receipt of genomic education to assess their baseline knowledge & comfort with genomic medicine in newborns. Surveys will be repeated within a week of disclosure to families regarding feedback on the process & satisfaction with VIGOR. After approximately 3-5 disclosure events, study staff will approach the clinical care team members to participate in a qualitative interview to assess their perspectives in more depth.
10205554|NCT05205343|Other|Standard of Care|"questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery.~The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete."
10205555|NCT05205343|Other|Control group|"questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery.~The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete."
10205556|NCT05205330|Experimental|30 mg (Dose Level 1)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 30 mg twice a day for 14 days
10205557|NCT05205330|Experimental|90 mg (Dose Level 2)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days
10205558|NCT05205330|Experimental|180 mg (Dose Level 3)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 180 mg twice a day for 14 days
10205559|NCT05205317|Experimental|vaginal repair + metformin|CSD patients were treated with vaginal repair of CSD in combination with metformin (Boke, 500 mg, Wanhui Shuanghe, Beijing, China) as an oral medicine (abbreviated as VR + metformin). In the group of VR + metformin, the patients start oral metformin from one month before the operation to 6 months after the operation. The dose is 500mg twice a day. The detailed procedure of VR has been described in investigators' previous study.
10205560|NCT05205317|Active Comparator|vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
10205561|NCT05205291||Parkinson's disease patients|18 patients with Parkinson's disease who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer [11C]PBR28 before and four hours after administration of LPS (1 ng/Kg)
9786270|NCT01272180|Active Comparator|MenACWY|"Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later."
9786271|NCT01272193|Experimental|IDegAsp OD|
9786272|NCT01272193|Active Comparator|IGlar OD|
9786273|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)|
9786274|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)|
9786275|NCT01272219|Placebo Comparator|Liraglutide Placebo, no Pre-diabetes|
9786276|NCT01272219|Experimental|Liraglutide 3.0mg, Pre-diabetes|
9786277|NCT01272219|Placebo Comparator|Liraglutide Placebo, Pre-diabetes|
9786278|NCT01272232|Experimental|Lira 3.0 mg|
9786279|NCT01272232|Experimental|Lira 1.8 mg|
9786280|NCT01272232|Experimental|Placebo|
9786281|NCT01272245|Experimental|Omacetaxine and Cytarabine|Omacetaxine 1.25 mg/m2 SQ every 12 hours x 3 days + Cytarabine 20 mg SQ x 7 days of 4-7 week cycle.
9786282|NCT01272284|Other|Altis® SIS|Subjects enrolled with Altis® SIS
9786283|NCT01272388|Active Comparator|Tadalafil|
9786284|NCT01272388|Placebo Comparator|Placebo|
9786285|NCT01272583|Other|Sequence A (sitagliptin→placebo)|Cross-over, both arms reveived the same intervention in different order.
9786286|NCT01272583|Other|Sequence B (placebo→sitagliptin)|Cross-over, both arms reveived the same intervention in different order.
9786287|NCT01272635|Experimental|Azythromycin (APRIL) and Prednisolone (OCELOT)|
9786288|NCT01272635|Experimental|Azythromycin (APRIL) and Placebo (OCELOT)|
9786289|NCT01272635|Experimental|Placebo (APRIL) and Prednisolone (OCELOT)|
9786290|NCT01272635|Placebo Comparator|Placebo (APRIL) and Placebo (OCELOT)|
9786291|NCT01272661|Active Comparator|Enhanced Curriculum|New Enhanced Breastfeeding Curriculum with 11 brief modules
9786292|NCT01272661|Active Comparator|Enhanced Curriculum+Breastfeeding Doula|"Enhanced Curriculum + mother selects a support person to learn about breastfeeding with her and support her postpartum (breastfeeding doula)"
9786293|NCT01272661|Active Comparator|Enhanced Curriculum +Father Support|Enhanced Curriculum+ mother provides father-friendly information about breastfeeding to her partner plus an invitation to an educational group for fathers
9786294|NCT01272804|Experimental|PF-04937319|
9786295|NCT01272804|Placebo Comparator|Placebo|
9786296|NCT01272830|Experimental|oral Apatone®B|An amalgam of Vitamins C & K3
9786297|NCT01272830|Placebo Comparator|Placebo|Oral capsule of similar appearance and taste without Apatone®B
9786298|NCT01272869|Active Comparator|Sensura|SenSura is the reference product and the product is already commercially available
9786299|NCT01272869|Experimental|Morfeus|The test product is the product with the proposed new filter (Morfeus)
9786300|NCT01272882|Experimental|Adults with ARDS or ALI|Adults with PaO2/FiO2 ratio less than 300. Consented patients will be placed on EIT monitor. The only intervention is the addition of Electrical Impedance Tomography monitoring using the Chest belt with 16 electrodes connected to the EIT device. No changes to standard patient care will occur other than collecting EIT monitor data.
9786301|NCT01272908|Experimental|Single arm|
9786302|NCT01272921|Active Comparator|Bupivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
9786303|NCT01272921|Active Comparator|Ropivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
9786304|NCT01272934|Placebo Comparator|Placebo|
9786305|NCT01272934|Experimental|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%
9786306|NCT01272947|Experimental|Diclofenac sodium topical gel 1%|
9786307|NCT01272947|Placebo Comparator|placebo|
9921883|NCT00832169|Experimental|1|
9921884|NCT00832182|Experimental|Insulin aspart and neutral protamine Hagedorn insulin|
9921885|NCT00832195|Experimental|1|Footwear with motion controlling elements built into construction in order to reduce pronation of the foot and ankle during running.
9786308|NCT01272960|Active Comparator|Interval Insertion|Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
9786309|NCT01272960|Experimental|Post-Placental Mirena Insertion|Will receive Mirena insertion within 10 minutes of delivery of placenta
9786310|NCT01272999||1|Otitis media cases
9786311|NCT01273038|Active Comparator|SenSura|The reference product is the CE marked and launched SenSura product which is commercially available
9786312|NCT01273038|Experimental|Morfeus|The test product is the product with the proposed new Morfeus filter
9786313|NCT01273155|Active Comparator|Normal Function-Belinostat 1000 mg/m(2)|Normal Liver Function was defined as bilirubin ≤Upper Limit of Normal (ULN) and aspartate aminotransferase (AST) ≤ ULN.
9786314|NCT01273155|Experimental|Mild Dysfunction-Belinostat 750 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
9786315|NCT01273155|Experimental|Mild Dysfunction-Belinostat 1000 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
9786316|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 500 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
9786317|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 750 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
9786318|NCT01273155|Experimental|Severe Dysfunction-Belinostat 250 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
9786319|NCT01273155|Experimental|Severe Dysfunction-Belinostat 350 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
9786320|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
9786321|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
9786322|NCT01273181|Experimental|Ph II:Anti-MAGE TCR PBL MTD+HD IL-2|"Phase II:Anti-MAGE A3/12 TCR PBL MTD + HD IL-2, Melanoma, RCC~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
9786323|NCT01273181|Experimental|Ph II:Anti-MAGE A3/12 TCR PBL MTD|"Phase II: Anti-MAGE A3/12 TCR PBL MTD + HD-IL2 Other Cancer~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
9786324|NCT01273207|Experimental|Inhaled Cyclosporine in HSCT Participants|Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week
9786325|NCT01273519||RA, PsA, AS|Participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) prescribed Humira (adalimumab) in the usual manner and in accordance with the terms of the local marketing authorization with regards to dose, population and indication.
9786326|NCT01273597||End-stage kidney disease with secondary hyperparathyroidism|Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
9786327|NCT01273623|Experimental|Patients with PAD|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
9786328|NCT01273766|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.
9836487|NCT05348603|Experimental|Direct to Patient Message + Chatbot + Banner|"An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
9836488|NCT05348603|Experimental|Traditional Letter + Direct to Patient Message + Chatbot + Banner|"A mailed letter will invite the patient to set up a research profile in their patient portal; AND~An e-mail sent to the patient will inform the patient that there is a message pending in their patient portal regarding opportunities to participate in research; AND~A real-time, interactive chatbot will encourage research participation and direct patients to learn more about research opportunities and trials that match their interests; AND~Banner-type advertisements during routine viewing and use of of the patient's portal for their our medical/clinical care inform patients of research opportunities."
9836489|NCT05348577|Experimental|capivasertib + docetaxel|Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.
9836490|NCT05348577|Placebo Comparator|placebo + docetaxel|Participants receive placebo in combination with docetaxel and steroids on a background of ADT.
9836491|NCT05348564|Experimental|Direct contact|Study team contact of family members
9836492|NCT05348564|No Intervention|Indirect contact|Proband initiated contact of family members
9836493|NCT05348538|Experimental|Medication review with follow up or MaJ? for the acronym in french|All the pharmacists accepting to participate in the study will perform the intervention.
9836494|NCT05348499||People with T1D participating in the NHS funded pilot of HCL therapy|"The questionnaires to be administered to people with type 1 diabetes, over 3 months after starting hybrid closed loop insulin pump therapy as part of the NHS pilot are:~Gold Score~Patient health questionnaire-9 (PHQ-9)~Diabetes distress score-T1~Hypoglycaemia confidence scale~INSPIRE survey~EQ5D5L~Diabetes Treatment Satisfaction Questionnaire (DTSQs) and Diabetes Treatment Satisfaction Questionnaire change (DTSQc) version~Bespoke questionnaire using domains that are important to people with diabetes~System usability scale~Approximately 15 participants with type 1 diabetes will be asked to participate in semi-structured qualitative interviews at >3 months after the person with type 1 diabetes starts the HCL."
9836495|NCT05348499||Partners of people with T1D participating in the NHS funded pilot of HCL therapy|"Partners of people with type 1 diabetes will be invited to complete three validated questionnaires that have been specifically developed for partners and one bespoke questionnaire:~Diabetes distress score - partner~Hypoglycaemia confidence scale - partner~INSPIRE - partner~Bespoke questionnaire~Approximately 15 partners of people with type 1 diabetes will be asked to participate in semi-structured qualitative interviews at >3 months after the person with type 1 diabetes starts the HCL."
9836496|NCT05348486|Experimental|Dose escalation|Dose escalated radiotherapy protocol: 75,9 - 79,2 Gy in 33 fractions GTV hypoxic or any hypoxic LN > 2cm - PTV (0mm): dose 75,9 - 79,2 Gy/33 (Contours must be subtracted and reduce by 3mm in case of close relation to the skin, bones or large blood vessels) GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
9836497|NCT05348486|No Intervention|Standard fractionation|Standard fractionation regimen: 70 Gy/54 Gy in 33 fractions GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 GTV LN bulky (> 3cm) - PTV (5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
9836498|NCT05348473|Active Comparator|alpha group|In this group, tips of the seton will be tied as alpha-shaped
9836499|NCT05348473|Sham Comparator|Beta group|The tips of the seton in this group will be overlapped and tied. There is no palpable free ends.
9836500|NCT05348473|Experimental|Comfort group|Knotless seton will be applied
9836501|NCT05348460|Other|Ketone - Placebo treatment|Patients will first receive a supplemental drink containing a ketone ester before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the placebo treatment.
9786329|NCT01273766|No Intervention|control arm|blood tested on healthy patients
9786330|NCT01273766|No Intervention|correlative|treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
9786331|NCT01273805|Experimental|Hydroxychloroquine 400 mg b.i.d.|Patients received 400 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
9786332|NCT01273805|Experimental|Hydroxychloroquine 600 mg b.i.d.|Patients received 600 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
9786333|NCT01273818|Active Comparator|gentamicin|80 mg gentamicin topical application intraoperatively
9786334|NCT01273818|Active Comparator|Cefazolin|Application of 1000 mg cefazolin intra venously 1 hour before surgery
9786335|NCT01273818|Active Comparator|gentamicin and cefazolin|1000 mg cefazolin application 1 hour before surgery and topical 80 mg gentamicin intraoperatively
9786336|NCT01273857|Sham Comparator|Control|Subjects will undergo standard staged-procedures without cell infusion
9786337|NCT01273857|Experimental|Cell infusion|Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
9786338|NCT01273883|Experimental|Magnesium first, then placebo|Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.
9786339|NCT01273883|Placebo Comparator|Placebo first, then magnesium|Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.
9786340|NCT01273896|Experimental|STA-9090|This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
9786341|NCT01274182|Experimental|GP2013|
9786342|NCT01274182|Active Comparator|MabThera|
9786343|NCT01274182|Active Comparator|Rituxan|
9786344|NCT01274338|Experimental|Arm A (HIP)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
9786345|NCT01274338|Experimental|Arm B (HDI)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
9786346|NCT01274338|Experimental|Arm C (LIP)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
9786347|NCT01274338|Experimental|Arm D (HIP; Pediatric)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
9799294|NCT01656187|Experimental|Placebo, Then Memantine|Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.
9799295|NCT01656200|Experimental|Vaccine|Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
9836502|NCT05348460|Other|Placebo - Ketone treatment|Patients will first receive a placebodrink before performing the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time after receiving the supplemental drink containing a ketone ester.
9836503|NCT05348447|Experimental|Cryoanalgesia with standard of care pain control|subjects will receive standard of care pain control + cryoanalgesia in the intercostal spaces during routine surgery
9836504|NCT05348447|Active Comparator|Standard of care pain control|subjects will receive standard of care pain control only
9836505|NCT05348434||patients with maxillofacial deformities|10 patients with maxillofacial deformities (trauma patients, war injuries, patients with pre-existing maxillofacial tumours, and meucrmycotic patients)
9836506|NCT05348421|Experimental|the ultrasound-guided fascia transversalis plane block|The TFPB will be performed while the participant is in the supine position. a high-frequency linear ultrasound probe (5-13 MHz) will be placed transversely in the midaxillary line between the iliac crest and the costal margin. After the external oblique, internal oblique, transversus abdominis muscle, and quadratus lumborum (QL) muscle will be identified.
9836507|NCT05348421|Experimental|The ultrasound guided Pericapsular Nerve Group block|while the participant is in the supine position, a linear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees; In this view, the ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed.
9836508|NCT05348408|Active Comparator|platelet rich plasma|patients will be injected perineural platelet rich plasmawith 1.5 to 3 ml around each affected nerve
9836509|NCT05348408|Sham Comparator|contact group|only medical treatment in form of opioid and NSAIDs will be used
9836510|NCT05348395|Experimental|Experimental diet|The experimental diet will provide 15% of calories from saturated fat and 14% of calories from fructose with a goal of providing 1.25x total energy needs
9836511|NCT05348382|Experimental|Intradermal acupuncture group|Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster.
9836512|NCT05348382|Sham Comparator|Sham intradermal acupuncture group|Sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling.
9836513|NCT05348356|Experimental|Nirogacestat Open-Label|All participants will receive open-label nirogacestat
9836514|NCT05348343|Other|Autocontrolled Arm|The subject will be treated with both the experimental treatment and the active comparator.
9836515|NCT05348330|Experimental|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
9836516|NCT05348330|Active Comparator|Costo-transverse ligament block|Under ultrasound guidance the continuous costo-transverse ligament block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
9836517|NCT05348317|Experimental|MI-CBT Teletx|The intervention consists of an initial 30-60 min phone-delivered Engagement session that focuses on MI to help participants build self-efficacy and motivation to engage and to empower them to plan change and use Elicit-Provide-Elicit (EPE) to address treatment barriers (e.g., stigma, appeal, accessibility). Participants will then complete up to 8 ~50 minute Teletx weekly sessions via videoconference (or phone if needed). The intervention is highly patient-centered, by meeting and assessing patients where they are including in their unique context (i.e. rural community), helping them identify reasons and motivations for change, and centered around their goals (e.g. substance use reduction or abstinence).
9836518|NCT05348304|No Intervention|Control|Hypocaloric diet
9836519|NCT05348304|Experimental|EUDIAMET|Hypocaloric diet plus a supplementation with myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
9836520|NCT05348291|Active Comparator|Ventilation tubes|Ventilation tube surgery
9836521|NCT05348291|No Intervention|Active monitoring|Active monitoring of patients, with the possibility to cross over to other arm if deemed necessary.
9836522|NCT05348278|No Intervention|standard of care|standard of care including hand and foot care, avoid friction
9836523|NCT05348278|Experimental|urea cream|use 10% urea cream apply at both hands and feet twice a day from time of starting capecitabine
9921886|NCT00832195|Active Comparator|2|Footwear with standard neutral stabilization elements for the foot and ankle during running.
10214065|NCT01601522|Placebo Comparator|Double Placebo|Placebo (Oat flour) and placebo antihistamines
10214066|NCT01601522|Active Comparator|Oral Immunotherapy with H1 and H2 antihistamines|500 mg Peanut Protein with Dosage of desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) and ranitidine be 5ml (15mg/ml=75 mg) po bid.
10214067|NCT01599494|Experimental|Single-Dose MK-8962 + recFSH|
10214068|NCT01599494|Active Comparator|Reference Group recFSH only|
10214069|NCT01590862|Active Comparator|Deep Brain Stimulation On|We will assess Reward Motivation behavior with Deep Brain Stimulation on.
10214070|NCT01590862|No Intervention|Deep Brain Stimulation Off|We will assess Reward Motivation behavior with Deep Brain Stimulation off.
10214071|NCT01566175|Experimental|Neovasc coronary sinus reducer|open label: Neovasc coronary sinus reducer
10214072|NCT01518517|Experimental|GRASPA|"Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).~GRASPA® administration takes place as below:~for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)~for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)"
9836524|NCT05348265|Active Comparator|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
9836525|NCT05348265|Experimental|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
9836526|NCT05348252|Experimental|Interventional group (Patient Journey App)|The interventional group will receive all information and instructions on discontinuing PPI use through the Patient Journey App.
9836527|NCT05348252|Active Comparator|Control group (Conventional Care)|The control group will receive all information and instructions on discontinuing PPI use through email as a digital information folder.
9836528|NCT05348239|Experimental|Oral Chlorophyllin arm|Participants will receive oral Sodium Copper Chlorophyllin at a dose of 750mg once daily (OD) on an empty stomach.
9836529|NCT05348213|Experimental|R-ICE+X|
9836530|NCT05348200|Active Comparator|Monad 1 cream|Topical cream applied to the peri-anal area twice daily for seven days.
9836531|NCT05348200|Active Comparator|Monad 2 cream|Topical cream applied to the peri-anal area twice daily for seven days.
9836532|NCT05348200|Active Comparator|Monad 3 cream|Topical cream applied to the peri-anal area twice daily for seven days.
9836533|NCT05348200|Experimental|Combination-CITI-002 (low dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
9836534|NCT05348200|Experimental|Combination-CITI-002 (high dose) cream|Topical cream applied to the peri-anal area twice daily for seven days.
9836535|NCT05348187|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Colorectal Cancer (CRC) and Non-small Cell Lung Cancer (NSCLC) tissue. The therascreen KRAS RGQ PCR Kit is intended to aid in the identification of cancer patients who may be eligible for treatment with AMG 510.
9836536|NCT05348174|Active Comparator|Virtual Reality Assisted Guided Imagery (VRAGI )|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR guided imagery on VR Head Mounted Displays (Meta Quest 2). They will experience video content and the accompanying guided imagery and nature soundscapes.
9836537|NCT05348174|Sham Comparator|Virtual Reality No Guided Imagery or other audio ( VR No GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the immersive VR visual content on VR Head Mounted Displays (Meta Quest 2) but will not experience the accompanying guided imagery narration or nature soundscapes.
9836538|NCT05348174|Active Comparator|Laptop Assisted Guided Imagery (Laptop AGI)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience video content and the accompanying guided imagery and nature soundscapes on a laptop.
9836539|NCT05348174|Sham Comparator|Laptop no Guided Imagery or other audio (Laptop no GI or other audio)|20 participants will be randomized to this arm. Participants in this arm will experience the VR content on laptops. They will not receive the VRHMDs. They will experience only the video content on a laptop and will no experience the accompanying guided imagery or nature soundscapes.
9836540|NCT05348161|Other|Anti-HER2 & Immunotherapy|Advancd gastric cancer patients received anti-HER2 & immunotherapy ± chemotherapy
9836541|NCT05348161|Other|Anti-HER2|Advancd gastric cancer patients received anti-HER2 ± chemotherapy.
9836542|NCT05348148|Active Comparator|Oral Levocetirizine|Patients in Levocetirizine group will use oral antihistamine (Levocetirizine) only
9836543|NCT05348148|Active Comparator|Combined Intranasal Mometasone Furoate with oral Levocetirizine|Patients in combined Intranasal Mometasone Furoate with oral Levocetirizineintranasal group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine)
9996765|NCT01503060|Placebo Comparator|Group 1|"Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
9996766|NCT01503060|Active Comparator|Group 2|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
9786348|NCT01274338|Experimental|Arm E (HDI; Pediatric)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
9786349|NCT01274338|Experimental|Arm F (LIP; Pediatric)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
9786350|NCT01274351|Experimental|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
9786351|NCT01274520|Experimental|Experimental: Hypothermic Machine Perfusion Group|The Medtronic Portable Bypass System (PBS®) with Model 550 Bioconsole and the BioCal® blood temperature control module will be used for machine perfusion of liver grafts. These products are commercially available and used in clinical practice for cardiopulmonary bypass and extracorporeal membrane oxygenation. The Medtronic system utilizes an atraumatic centrifugal pump that can deliver the flow rates approximating portal venous flow in human livers, and it has modules for online membrane oxygenation, and electronic flow measurement.
9786352|NCT01274520|No Intervention|Matched control group|The proposed study is a matched cohort design. Subjects will be matched with 24 historical control patients who received similar cold stored ECD grafts. Subjects will be matched on known covariates including donor age, donation after cardiac death, steatosis, both warm and cold ischemia times, recipient age, MELD score and disease etiology. Additional analyses will be performed on historical control blood and/or tissue samples previously collected and stored in the study's sample repository.
9786353|NCT01274585|Sham Comparator|No active treatment|
9786354|NCT01274585|Experimental|stimulation/treatment|
9786355|NCT01274637|Experimental|low molecular weight heparin|Prophylactic-dose (5000 IU/0.2ml)low molecular weight heparin (LMWH), administered subcutaneously once daily in pre-filled glass syringes for 10 days (+/- 3 days) for a total of 10 (+/-3) study drug injections.
9786356|NCT01274637|No Intervention|Control Group|No treatment control group.
9786357|NCT01274715|Experimental|Behavioral Health Coaching arm|This is a single-arm, pilot study of a health behavior coaching intervention to consist of 12 sessions of coaching over a 3 month period. There is no control arm for this pilot study.
9786358|NCT01274897|Experimental|MenACWY-CRM|Subjects received one dose of MenACWY-CRM conjugate vaccine.
9786359|NCT01274897|Placebo Comparator|Placebo|Subjects received the saline placebo.
9786360|NCT01275053|Experimental|Leptin|
9786361|NCT01275066|Placebo Comparator|Placebo|
9786362|NCT01275066|Experimental|BMN 110 Weekly|
9786363|NCT01275066|Experimental|BMN 110 Every Other Week|
9786364|NCT01275092|Experimental|CorPath robotic-assisted PCI|CorPath 200 robotic-assisted PCI
9786365|NCT01275131|Active Comparator|Stage 1: Insulin aspart first, then insulin aspart-rHuPH20|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
9786366|NCT01275131|Active Comparator|Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
9786367|NCT01275131|Active Comparator|Stage 3: Insulin aspart first, then insulin aspart + rHuPH20|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp.~After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp."
9799296|NCT01656252|Experimental|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine twice daily on Days 1, 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
9836544|NCT05348148|Active Comparator|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|The other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline)
9836545|NCT05348135|Active Comparator|Functional strength training|
9836546|NCT05348135|Active Comparator|Cognitive training|
9836547|NCT05348135|Active Comparator|Combined treatment|
9836548|NCT05348135|Placebo Comparator|Conventional physical therapy|
9836549|NCT05348122|Experimental|TG103, 15 mg,Q2W|TG103 (15 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
9836550|NCT05348122|Experimental|TG103, 22.5 mg,Q2W|TG103 (22.5 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
9836551|NCT05348122|Placebo Comparator|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
9836552|NCT05348122|Experimental|TG103, 7.5 mg,QW|TG103 (7.5 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
9836553|NCT05348122|Experimental|TG103, 15 mg,QW|TG103 (15 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
9836554|NCT05348122|Placebo Comparator|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
9836555|NCT05348109||well fininshed cases|
9836556|NCT05348096|Experimental|Low-dose ibrutinib|Patients will receive ibrutinib 140mg/day PO in combination with oral itraconazole (100mg/day) continuously for six months.
9836557|NCT05348083||ESPB|A prospective cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided ESPB at T9 level at the end of surgery.
9836558|NCT05348083||p-QLB|A historical cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided p-QLB at the end of surgery.
9836559|NCT05348070||Operated Non-Ruptured Endometrioma Group|It consists of patients who were found to have endometrioma in their clinical follow-ups and decided to operate as a result of the evaluations. The patients were operated under elective conditions.
9836560|NCT05348070||Operated Ruptured Endometrioma Group|Rupture of endometrioma, which is a rare gynecological emergency. This group consists of endometrioma patients requiring urgent/subacute operation such as acute abdominal pain, hemodynamic instability, intra-abdominal bleeding. The patients were operated after completing the necessary preparations
9836561|NCT05348057|Experimental|Ivabradine group|The starting dose is 5 mg twice a day. After 2 weeks of treatment, if the patient's resting heart rate continues to be higher than 70 beats per minute, increase the dose to 7.5 mg twice a day. If the patient's resting heart rate continues to be less than 50 beats per minute or symptoms related to bradycardia occur, reduce the dose to 2.5 mg
9836562|NCT05348057|No Intervention|The control group|
9836563|NCT05348044|Experimental|Res-ET intervention|Res-ET will include a 6-week remote (Zoom) home-group-delivered IMST exercise intervention of approximately 20 minutes a session consisting of a warmup and 3 bouts of 5 sets x 6 inspiratory maneuvers using an IMST training device (POWERBreathe) and 1 min recovery between each set (inspiration to rest ratio taken from Craighead 2021). The intensity of the IMST maneuvers will begin at 40% of MIP during week one, 50% of MIP during week two, and 60% of MIP during weeks three through six. Participants will remotely perform Res-ET intervention 4 times per week in a group setting (Zoom). During the intervention multiple opportunities to engage in a group training session will be available and a recording of an IMST session will be available for viewing if the participant is unable to attend a live group session. Each week the CEP will record participation rates and accelerometry data in REDcap. Group conversations and motivation will be encouraged during live training sessions.
9836564|NCT05348018|Experimental|"test group"|"test group which accessed SGs during a four-week test period in addition to conventional lectures"
9836565|NCT05348018|No Intervention|"control group"|"control group which benefited solely from conventional lectures"
9786368|NCT01275131|Active Comparator|Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp .~After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp."
9786369|NCT01275144|Experimental|LY2216684+lorazepam, placebo+lorazepam|Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
9786370|NCT01275144|Experimental|Placebo+Lorazepam, LY2216684+Lorazepam|Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
9786371|NCT01275170|Experimental|Panel A Mild Renal Impairment|Participants with an eGFR of >50 to <80 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
9786372|NCT01275170|Experimental|Panel B Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel A and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
9786373|NCT01275170|Experimental|Panel C Moderate Renal Impairment|Participants with an eGFR of 30 to 50 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
9786374|NCT01275170|Experimental|Panel D Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel C and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
9786375|NCT01275170|Experimental|Panel E Severe Renal Impairment|Participants with an eGFR <30 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
9786376|NCT01275170|Experimental|Panel F Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel E and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
9786377|NCT01275170|Experimental|Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)|Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).
9786378|NCT01275170|Experimental|Panel H Healthy Volunteers|A subset of healthy control participants were matched specifically to participants in Panel G and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
9786379|NCT01275196|Experimental|Nilotinib|
9786380|NCT01275196|Active Comparator|Imatinib|
9786381|NCT01275222|Experimental|Phase l: RAD001 20mg/week|RAD001 20 mg was given once a week.
9786382|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 600mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 600mg/day.
9786383|NCT01275222|Experimental|Phase l: RAD001 5mg/day + Glivec 600mg/day|RAD001 5 mg was given in combination with Glivec/Gleevec 600mg/day.
9786384|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 800mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 800mg/day.
9786385|NCT01275222|Experimental|Phase ll - Stratum l (first-line resistant/refractory): RAD001 2.5mg/day + Glivec 600mg/day|All first-line resistant/refractory patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day.
9786386|NCT01275222|Experimental|Phase ll - Stratum ll: (post second-line therapy): RAD001 2.5mg/day + Glivec 600mg/day|All post-second-line patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day
9786387|NCT01275300|Placebo Comparator|Placebo phase I|Subjects were given 5 days of placebo. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of placebo. Urine was collected sequentially for analysis. The same subjects came back for cross-over study and were assigned to Aspirin group. There was a 2-week washout period between each treatment.
9786388|NCT01275300|Active Comparator|Aspirin phase I|Subjects were given 5 days of 81 mg aspirin. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of aspirin or placebo. Urine was collected sequentially for analysis.
9786389|NCT01275300|Active Comparator|Aspirin phase II|In phase II study, subjects were given 5 days of 81 mg aspirin. On day 6, they were given a single dose of niacin (600 mg) administered 24 hours after the last dose of aspirin. Urine was collected sequentially for analysis
9786390|NCT01275313|Experimental|Custom-Fitted Lightweight Wheelchair & Cushion|Receive a new custom-fitted lightweight wheelchair, skin protection cushion and wheelchair skills training
9786391|NCT01275313|Other|Cushion Only|Receive a skin protection cushion and wheelchair training, but remain in facility-issued wheelchair
9786392|NCT01275339|Active Comparator|Tadalafil in Diabetic Cohort|
9786393|NCT01275339|Placebo Comparator|Placebo in Diabetic Cohort|
9786394|NCT01275339|Active Comparator|Tadalafil in Non-Diabetic Cohort|
9786395|NCT01275339|Placebo Comparator|Placebo in Non-Diabetic Cohort|
9786396|NCT01275365|No Intervention|Placebo/Low Protein|Placebo injections weekly; 0.8 g/kg/day protein
9786397|NCT01275365|No Intervention|Placebo/High Protein|Placebo injections weekly; 1.3 g/kg/day protein
9786398|NCT01275365|Other|Testosterone/Low Protein|Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
9786399|NCT01275365|Other|Testosterone/High Protein|Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
9786400|NCT01275430|Experimental|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
9786401|NCT01275430|Active Comparator|"Blind Placement"|"PICCs will be placed blindly, without the use of any tip location/positioning device."
9786402|NCT01275586|Experimental|Tasigna|Following enrollment each subject will initially receive the drug Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily.
9786403|NCT01275625|Experimental|Treatment|Single arm study of combivir and maraviroc for 48 weeks
9786404|NCT01275664|Experimental|Treatment (granisetron, dexamethasone, aprepitant)|Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.
9786405|NCT01275755|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally every day (QD) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
9786406|NCT01275755|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally QD for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-milligrams (mg) ADL5945 capsule orally QD for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally QD for 1 week.
9786407|NCT01275833|Experimental|Device programming modifies AV timing|DDD-40-BiV
9786408|NCT01275833|No Intervention|Device programming allows intrinsic AV timing.|VVI-40-RV
9786409|NCT01276041|Experimental|pertuzumab in combination with trastuzumab and paclitaxel|This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.
9786410|NCT01276106|Experimental|AC-201, 25mg|25mg BID for 24 weeks
9786411|NCT01276106|Experimental|AC-201, 50mg|50mg BID for 24 weeks
9786412|NCT01276106|Experimental|AC-201, 75mg|75mg BID for 24 weeks
9786413|NCT01276106|Placebo Comparator|Placebo|Placebo BID for 24 weeks
9786414|NCT01276171|Active Comparator|Ultrasound|Participants will place arterial line using ultrasound technique
9786415|NCT01276171|Active Comparator|Doppler|Participants will place arterial line using doppler technique
9786416|NCT01276171|Active Comparator|Palpation|Participants will place arterial line using palpation technique
9836566|NCT05348005|No Intervention|No TENS unit use|All subjects will start with 3 months of no TENS use and diary tracking
9786417|NCT01276184|No Intervention|Usual Care|Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
9786418|NCT01276184|Experimental|SMS Text Message|Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.
9786419|NCT01276197|Experimental|Arm 1: Story-Telling DVD|Participant will receive a DVD with informational and story-telling components
9786420|NCT01276197|Active Comparator|Arm 2: Non-Storytelling DVD|Participant will receive an informational DVD
9786421|NCT01276223|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week to allow for tapering of the steroid exposure.
9786422|NCT01276223|Placebo Comparator|Vehicle|Difluprednate vehicle, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week.
9786423|NCT01276236|Experimental|Treatment Arm (Maraviroc)|The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen.
9786424|NCT01276288|Active Comparator|Reference 1|administration of BI 10773 once daily for 5 days (20 patients)
9786425|NCT01276288|Active Comparator|Reference 2|administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)
9786426|NCT01276288|Active Comparator|Reference 3|administration of torasemide (TOR) once daily for 4 days (10 patients)
9786427|NCT01276288|Experimental|Test 1|administration of BI 10773 + HTC once daily for 5 days (10 patients)
9786428|NCT01276288|Experimental|Test 2|administration of BI 10773 + TOR once daily for 5 days (10 patients)
10205562|NCT05205291||Healthy controls|6 healthy controls who will undergo clinical assessment, and PET/MR imaging of TSPO using the tracer [11C]PBR28 before and four hours after administration of LPS (1 ng/Kg)
9786429|NCT01276301|Experimental|Reference|single dose BI 10773
9786430|NCT01276301|Active Comparator|Test|single dose BI 10773 + single dose verapamil
9786431|NCT01276314|Experimental|anti- TNF-a treatment|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks"
9786432|NCT01276314|Active Comparator|control group|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose."
9996767|NCT01503060|Active Comparator|Group 3|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
9996768|NCT01503060|Active Comparator|Group 4|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
9786433|NCT01276327|Experimental|1 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
9786434|NCT01276327|Experimental|2 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
9786435|NCT01276327|Experimental|3 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
9786436|NCT01276327|Experimental|4 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
9786437|NCT01276353|Experimental|1|
9786438|NCT01276353|Active Comparator|2|
9996769|NCT01503073|Active Comparator|Real stimulation|real NIBS
10205563|NCT05205278|Experimental|training group|Group 1 (n=21) was the training group and, in addition to the routine volleyball training programmes, an 8-week (3 days/week) progressive core stability training programme was applied.
10205564|NCT05205278|No Intervention|control group|Group 2 (n=21) was the control group, and they only engaged in routine volleyball training: no core stability training was given.
10205565|NCT05205239|Experimental|Systemic sclerosis|
10205566|NCT05205200|Experimental|Cohort 1A|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1316 (anti-PD-L1) and endocrine therapy.
10205567|NCT05205200|Active Comparator|Cohort 1B|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with endocrine therapy.
9786439|NCT01276379|Experimental|FOLFIRI (m) or FOLFOX-6 (m) + cetuximab|FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.
9786440|NCT01276457|Experimental|Upper everolimus blood target + very low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
9836567|NCT05348005|Active Comparator|TENS unit use|All subjects will then have 3 months of TENS use during episodes of endometriosis pain flare and diary tracking.
9996770|NCT01503073|Sham Comparator|Sham stimulation|sham NIBS
10205568|NCT05205200|Experimental|Cohort 2A|In this cohort, a patient would receive SHR1316 (anti-PD-L1) combined with nab-paclitaxel.
9786441|NCT01276457|Active Comparator|Standard everolimus blood target + low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
9786442|NCT01276509|Placebo Comparator|Placebo-SC Injection|Placebo delivered SC, 3 doses separated by 4 weeks.
9786443|NCT01276509|Experimental|Drug Dose level 1- SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.
9786444|NCT01276509|Experimental|Drug Dose level 2-SC injection|Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.
9786445|NCT01276509|Experimental|Drug Dose level 3- SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.
9786446|NCT01276535|Experimental|Erchonia MLS + Erchonia THL|"The Erchonia® MLS contains 5 independent diodes: 4 each emitting 17 milliwatt (mW) 635 nanometers (nm) of red laser light and the fifth diode emitting 17 mW, 405 nm of blue laser light.~The Erchonia THL is a single diode pulsed laser that emits 4.9 milliwatts (mW) of red 635 nanometer (nm) light."
9786447|NCT01276639|Experimental|Active Treatment 10 mg BID|
9786448|NCT01276639|Experimental|ActiveTreatment 5 mg BID|
9786449|NCT01276639|Placebo Comparator|Placebo Treatment|
9786450|NCT01276652|Active Comparator|Environmental modification|Subjects assigned to this group receive the environmental modification intervention for 48 hours beginning the morning after enrollment.
9786451|NCT01276652|No Intervention|Usual care (randomized)|"Usual care is provided for the first 48 hours. Subsequently, in the initial protocol, subjects received 48 hours of the environmental modification intervention so long as they remained in the ICU during this time. The opportunity to receive the Delayed intervention was later removed from the protocol."
9786452|NCT01276652|No Intervention|Usual care (observational)|Usual care was provided.
9836568|NCT05347992||Standard of Care|Cohort(1) of the study will collect longitudinal blood samples from participants who are on the standard of care treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
10205569|NCT05205200|Active Comparator|Cohort 2B|In this cohort, a patient would single nab-paclitaxel.
10205570|NCT05205200|Other|Cohort 2C|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with fulvestrant.
10205571|NCT05205187||Healthy group|Healthy people in the community.
10205572|NCT05205187||Non-Borrmann IV group|Patients with Borrmann types I, II and III gastric cancer.
10205573|NCT05205187||Borrmann IV group|Patients with Borrmann type IV gastric cancer.
10205574|NCT05205161|Experimental|Part A (Dose Escalation): Dose Level (DL)-1|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205575|NCT05205161|Experimental|Part A (Dose Escalation): DL1|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205576|NCT05205161|Experimental|Part A (Dose Escalation): DL2|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205577|NCT05205161|Experimental|Part A (Dose Escalation): DL3|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205578|NCT05205161|Experimental|Part A (Dose Escalation): DL4|Participants with advanced R/R B-NHL will receive AZD0466 on day 1 , day 4, day 8 day 15, day 22 of cycle 1 and day 1, day 8 day 15, day 22 of cycle 2 and beyond until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205579|NCT05205161|Experimental|Part B (Dose Expansion): Cohort B1 (R/R MCL)|Participants with advanced R/R MCL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205580|NCT05205161|Experimental|Part B (Dose Expansion): Cohort B2 (R/R FL or MZL)|Participants with advanced R/R FL or MZL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205581|NCT05205161|Experimental|Part B (Dose Expansion): Cohort B3 (R/R DLBCL)|Participants with advanced R/R DLBCL will receive AZD0466 at the recommended phase 2 dose (RP2D) until maximum 2 years or until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention, whichever occurs first.
10205582|NCT05205135||Caregivers|Caregivers of persons with dementia supported by the Carer Matters programme
10205583|NCT05205135||Nurses|Ward nurses who collaborate with the Carer Matters team
10205584|NCT05205135||Programme facilitators|Facilitators of programmes organised through Carer Matters
10205585|NCT05205135||Care Support Nurses|Nurses trained to deliver support and assistance as part of Carer Matters Programme
10205586|NCT05205135||Community partners and hospital leaders|Key policy makers and community leaders who partner with the Carer Matters programme to ensure its success
9786453|NCT01276756|Active Comparator|Standard of care|Group A: comprises 50 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
9786454|NCT01276756|Experimental|Triple therapy|Group B: comprises 50 treatment-naive chronic HCV patients who will receive oral Nitazoxanide 500 mg twice daily for 4 weeks (lead-in phase) followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
9786455|NCT01276821|Placebo Comparator|Standard Treatment|L-Epinephrine and Normal Saline (0.9%)
9786456|NCT01276821|Active Comparator|Study Treatment|L-Epinephrine and Hypertonic Saline (3%)
9786457|NCT01276847|Experimental|Ustekinumab|
9786458|NCT01276847|Active Comparator|Etanercept|
9786459|NCT01276847|No Intervention|No treatment|
9786460|NCT01276860|Other|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
9786461|NCT01277042|Experimental|Cervarix Group|Subjects received a 3-dose vaccination course of the Cervarix™ vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
9786462|NCT01277042|Active Comparator|Engerix Group|Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
9786463|NCT01277081|Active Comparator|Paracetamol hot drink|Hot drink containing paracetamol
9786464|NCT01277081|Active Comparator|Paracetamol tablets|Paracetamol tablets
9786465|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg).|Control Nerve Block. IV Dexamethasone (4 mg).
9786466|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
9786467|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
9786468|NCT01277159|Experimental|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
9836569|NCT05347992||Biologics|Cohort(2) of the study will collect longitudinal blood samples from participants who are on biologics treatment for Systemic lupus erythematosus (SLE) based on Cohort specific inclusion criteria
9786469|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
9786470|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
9786471|NCT01277302|Experimental|Ranibizumab 0.5 mg PRN - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
9786472|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - non-randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
9786473|NCT01277341|Experimental|2% Twice a day|Bepotastine Besilate Nasal Spray 2% Twice a day
9786474|NCT01277341|Experimental|3% Twice a day|Bepotastine Besilate Nasal Spray 3% Twice a day
9786475|NCT01277341|Experimental|4% Twice a day|Bepotastine Besilate Nasal Spray 4% Twice a day
9786476|NCT01277341|Placebo Comparator|Placebo|Placebo nasal spray
9786477|NCT01277354|Active Comparator|Cognitive Processing Therapy|Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
9786478|NCT01277354|Placebo Comparator|Waitlist|Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
9786479|NCT01277510|Placebo Comparator|Placebo|Participants received standard of care and placebo once daily for 30 weeks during the double-blind phase. During the open-label phase, participants received cinacalcet with standard of care for an additional 30 weeks. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks up to Week 54 to a maximum dose of 4.2 mg/kg.
9786480|NCT01277510|Experimental|Cinacalcet|Participants received standard of care and cinacalcet once daily for 30 weeks during the double-blind phase. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks until Week 24 to a maximum dose of 4.2 mg/kg. During the open-label phase participants continued to receive cinacalcet with standard of care for an additional 30 weeks.
9786481|NCT01277523|Experimental|A|
9786482|NCT01277523|Experimental|B|
9786483|NCT01277523|Placebo Comparator|C|
9786484|NCT01277549||Non-mobilized donors|In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.
9786485|NCT01277549||G-CSF mobilized donors|In this arm the collection efficiency of CD34+ cells will be studied.
9786486|NCT01277601|Experimental|TDF+Peg-IFN 48 Weeks|TDF plus Peg-IFN for 48 weeks
9786487|NCT01277601|Experimental|TDF 48 Weeks + Peg-IFN 16 Weeks|TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
9786488|NCT01277601|Active Comparator|TDF 120 Weeks|TDF monotherapy for 120 weeks
9786489|NCT01277601|Active Comparator|Peg-IFN 48 Weeks|Peg-IFN monotherapy for 48 weeks
9786490|NCT01277666|Placebo Comparator|Placebo|orally administered
9786491|NCT01277666|Experimental|GSK1605786A 500mg once daily|orally administered
9786492|NCT01277666|Experimental|GSK1605786A 500mg twice daily|orally administered
9786493|NCT01277718|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.
9786494|NCT01277718|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.
9786495|NCT01277744|Experimental|HIPEC + Cisplatin|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions. Cisplatin 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the Cisplatin.
9786496|NCT01277757|Experimental|Treatment (Akt inhibitor MK-2206)|Akt Inhibitor MK-2206 mg orally once a week on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9799297|NCT01656252|Experimental|Phase II- Sequence A|Cytarabine twice daily on Days 1, 3 and 5. Eltrombopag(dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
9996771|NCT01503099||Active ITB|Patients with active intestinal tuberculosis (ITB)
9786497|NCT01277783|Experimental|Endocardial Left Ventricular pacing|All patients will undergo the intervention, and are followed at 1, 3, 6, and 12 months (minimum) and biannually thereafter until 1 year after enrollment of the last patient.
9786498|NCT01277861|Active Comparator|FENTANYL|FENTANYL
9786499|NCT01277861|Placebo Comparator|SALINE|SALINE
9786500|NCT01277887|Active Comparator|Cognitive-Behavioral Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
9786501|NCT01277887|Placebo Comparator|Smoking Cessation Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
9786502|NCT01278030|No Intervention|Control group|Patients will be implanted according to the standard of care with the LV lead in the traditional LV lead position.
9786503|NCT01278030|Experimental|3D echo-guided LV lead placement group|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.
9786504|NCT01278160|Experimental|BIAsp 30 (2:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 2/3 and 1/3 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
9786505|NCT01278160|Experimental|BIAsp 30 (1:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 1/2 and 1/2 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
9786506|NCT01278173|Other|Sabril|
9786507|NCT01278303|Other|Treatment of Aortic Wall Injury|Repair of aortic wall injury with covered CP Stents
10205587|NCT05205135||Other clinicians (e.g. Social workers, Physiotherapists, doctors)|Other clinicians who refer caregivers to the Carer Matters programme
10205588|NCT05205122|Experimental|Infants with primary congenital glaucoma|
9786508|NCT01278342|Active Comparator|Sandostatin LAR high dose Alone|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with controlled GH and IGF-I after 3 months of Sandostatin LAR monotherapy continued to receive Sandostatin LAR 40 mg i.m. every 28 days for an additional 4 months.
9786509|NCT01278342|Experimental|Sandostatin LAR high dose + Pegvisomat|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR40 mg every 28 days in combination with weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for a further 4 months
9786510|NCT01278342|Experimental|Sandostatin LAR high dose + Cabergoline|"All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR 40 mg every 28 days in combination with weekly cabergoline for a further 4 months, with cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
9836570|NCT05347979|Experimental|Dabigatran Etexilate (NIMP) and Relacorilant (IMP)|Following an overnight fast, participants will receive 75 mg dabigatran etexilate on Day 1, 400 mg dose of relacorilant QD on Days 3 to 13, and 75 mg dabigatran etexilate on Day 12. On Day 12, dabigatran etexilate will be dosed at approximately the same time as the relacorilant dose.
10205589|NCT05205096|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
10205590|NCT05205083|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
10205591|NCT05205070|Experimental|Rosnilimab (ANB030)|ANB030 biological humanized monoclonal antibody, SC injections every 4 weeks
9786511|NCT01278394|Experimental|Group 1|AN2690 Solution, 5.0%
9786512|NCT01278407|Placebo Comparator|Placebo - Confirmatory Phase|Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.
9786513|NCT01278407|Experimental|Donepezil 5 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.
9786514|NCT01278407|Experimental|Donepezil 10 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.
9786515|NCT01278407|Experimental|Placebo to Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
10205592|NCT05205070|Placebo Comparator|Placebo solution|Placebo solution, SC injections every 4 weeks
10205593|NCT05205018|Experimental|Motivational Interviewing Arm|This Arm will receive a remote intervention (via videacalls) based on motivational interviewing to improve self-care. The intervention will be delivered seven time over 12 months.
10205594|NCT05205018|No Intervention|Standard care Arm|This Arm will receive the standard of care.
10205595|NCT05204979||Misopristol|Group A: vaginal misoprostol will be taken Group B: sublingual misoprostol will be taken
9786516|NCT01278407|Experimental|Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
9786517|NCT01278485||Sulphonylurea (SU) Monotherapy or SU + Metformin|Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
9786518|NCT01278615|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity
9786519|NCT01278745|Experimental|Rituximab|Rituximab induction/conventional immunosuppression
9786520|NCT01278745|Placebo Comparator|Rituximab Placebo|Rituximab Placebo / conventional immunosuppression
9786521|NCT01278797|Active Comparator|Telmisartan/Amlodipine Fixed Dose|Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
9786522|NCT01278797|Active Comparator|Amlodipine Monocomponent|Amlodipine Monocomponent 10mg tablet once daily
9786523|NCT01278862|Experimental|DVS veneer|veneer made by CAD/CAM method
9786524|NCT01278862|Active Comparator|Conventional veneer|Veneer made by laboratory technician
9786525|NCT01278927|Active Comparator|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief (10 minute) personalized introduction to the home-based exercise intervention. On Day 30 post hematopoietic cell transplantation (HCT), participants will meet briefly with the same interventionist when possible. To minimize contamination across intervention conditions, participants randomized to Exercise will be provided with only general advice regarding stress management (i.e., to continue using any techniques they currently use to manage stress). The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant.
9786526|NCT01278927|Active Comparator|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief standardized introduction to the self-administered intervention. On Day 30 post HCT, the interventionist will meet with the participant to answer any questions about the intervention, encourage the continued use of stress management techniques as recommended, and monitor for any adverse reactions to use of the techniques. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
9786527|NCT01278927|Active Comparator|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions. On Day 30 post HCT, the same interventionist will meet with the participant briefly to answer any questions about the interventions, encourage the continued use of the interventions as recommended, and monitor for any adverse reactions. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
9786528|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive a digital video disc (DVD). The interventionist will briefly discuss the topics of the DVD and elicit questions. To minimize contamination across intervention conditions, participants randomized to the control group will be provided with only general advice about exercise and stress management during treatment (i.e., to maintain any usual patterns of exercise to the extent possible and to continue using any techniques they currently use to manage stress).
9786529|NCT01278953|Experimental|TactiCath|Catheter ablation to treat paroxysmal AF using the TactiCath catheter with contact force capability
9786530|NCT01278953|Active Comparator|Control|Catheter ablation to treat paroxysmal AF using a catheter with no contact force sensing capability
9786531|NCT01279044|Active Comparator|1|HIV testing with adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
9786532|NCT01279044|Placebo Comparator|2|HIV testing with information only
9786533|NCT01279057|Experimental|Test|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
9786534|NCT01279057|Active Comparator|Reference|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
9786535|NCT01279057|Placebo Comparator|Placebo|Placebo nasal spray administered once daily for 14 days.
9786536|NCT01279070|Experimental|REPYFLEC cognitive remediation training|REPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
9786537|NCT01279070|Active Comparator|Leisure group|"Leisure group is a stimulating activity focused on socialization through group dynamics, board games, coffee and talk."
9786538|NCT01279109|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building healthy lifestyle skills and reciprocal social ties between the intervention group members
9786539|NCT01279109|Active Comparator|Home visit|Home visits focused on preventable infant injuries
9799298|NCT01656252|Experimental|Phase II- Sequence B|Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
9836571|NCT05347966|Other|Brain Health PRO|
9786540|NCT01279187|Experimental|Teriparatide|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
9786541|NCT01279187|Placebo Comparator|Control|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
9786542|NCT01279200|Active Comparator|Urinary LH Kits|Patients randomized to this arm will monitor ovulation with home-based urinary LH kits (Ovulation Predictor Kits, OPK's).
9786543|NCT01279200|Active Comparator|Midcycle ultrasound + hCG injection|Patients randomized to this arm will undergo ovulation monitoring with midcycle ultrasound and receive hCG injection if evidence of a mature size follicle.
9786544|NCT01279265|Active Comparator|Nutramigen Lipil with Enflora|Formula with probiotics (Lactobaccillus Rhamnosus GG)
9786545|NCT01279265|Placebo Comparator|Nutramigen A+|Hypoallergenic formula without probiotics (Lactobaccillus Rhamnosus GG)
9786546|NCT01279317|Experimental|vinegar co-ingestion|25 ml vinegar is added to glucose containing beverage
9786547|NCT01279317|Placebo Comparator|Placebo co-ingestion|25 ml vinegar is substituted by 25 ml water
9786548|NCT01279343|Experimental|Foley Bulb plus Misoprostol|
9786549|NCT01279343|No Intervention|Misoprostol|
9786550|NCT01279447|Sham Comparator|Placebo|A sham infrapatellar block performed under US guidance with normal saline
9786551|NCT01279447|Experimental|Infrapatellar nerve block|An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
9786552|NCT01279564|Experimental|ETview|ETview TVT endotracheal tube
9786553|NCT01279564|Sham Comparator|Control|Endotracheal tube
9786554|NCT01279681|Active Comparator|Arm A [fluoropyrimidine + bevacizumab (BEV)]|Patients receive either 5FU/LV or Capecitabine, plus BEV. 5FU/LV + BEV is comprised of 5FU IV over 46-48 hours, LV calcium IV over 2 hours, and BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Capecitabine + BEV is comprised of capecitabine PO BID on days 1-14 and BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9786555|NCT01279681|Experimental|Arm B [fluoropyrimidine/oxaliplatin (OXAL) + BEV]|Patients receive either mFOLFOX7 plus BEV, or Capecitabine + OXAL (XELOX) plus BEV. mFOLFOX7 + BEV is comprised of OXAL IV over 2 hours, LV calcium IV over 2 hours, and 5FU IV over 46-48 hours on day 1. Patients also receive BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. XELOX + BEV is comprised of OXAL IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Patients also receive BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9786556|NCT01279850||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
9786557|NCT01279954|Experimental|open-label abatacept first, then 5 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)
9786558|NCT01279954|Experimental|open-label abatacept first, then 10 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)
9786559|NCT01280058|Experimental|Arm I (wild-type reovirus, carboplatin, paclitaxel)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9786560|NCT01280058|Experimental|Arm II (carboplatin, paclitaxel)|Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
9786561|NCT01280110|Active Comparator|Preserved (BAK 0.006%) lubricating drop|One group will receive preserved lubricating drops 4 times a day for 1 month.
9786562|NCT01280110|Active Comparator|Preservative-free lubricating drops|The second group will receive preservative-free lubricating drops 4 times a day for 1 month.
9786563|NCT01280123|Experimental|15 mg pioglitazone|15 mg pioglitazone
9786564|NCT01280123|Experimental|45 mg pioglitazone|45 mg pioglitazone
9786565|NCT01280123|Placebo Comparator|Matching Placebo|Placebo
9786566|NCT01280201|Experimental|Pazopanib|
9786567|NCT01280266|Experimental|Amlodipine-Udenafil (AU) arm|Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
9786568|NCT01280266|Experimental|Udenafil-Amlodipine (UA) arm|Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks
9786569|NCT01280357|Active Comparator|Monitor Philips 50XM (K954351)|CTG Fetal Monitor If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
9786570|NCT01280357|Experimental|Monica AN24 (K101801)|EHG Fetal Monitor
9786571|NCT01280409|Placebo Comparator|Placebo|Compounded placebo
9786572|NCT01280409|Experimental|Metformin|Compounded metformin as the intervention
9786573|NCT01280552|Experimental|ICT-107|Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
9786574|NCT01280552|Placebo Comparator|Control|Autologous dendritic cells that have not been pulsed with antigens
9786575|NCT01280591|Experimental|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|
9786576|NCT01280591|Experimental|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|
9786577|NCT01280591|Active Comparator|Naproxen sodium 440 mg (BAYH6689)|
9786578|NCT01280591|Active Comparator|DPH 50 mg|
9786579|NCT01280604|Experimental|Intervention 'Fenofibrate 54mg'|Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
9786580|NCT01280604|No Intervention|Control 'Fenofibrate 160mg'|Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).
9786581|NCT01280617|Experimental|Thymoglobulin 1.25mg/kg dose|The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.
9786582|NCT01280617|Experimental|Thymoglobulin 0.75mg/kg dose|The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.
9786583|NCT01280656||Conventional Interferon Plus Ribavirin|Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
9786584|NCT01280656||Peginterferon Alfa-2a Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
9786585|NCT01280656||Peginterferon Alfa-2b Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
9786586|NCT01280695|Placebo Comparator|Placebo|Placebo capsule once daily
9786587|NCT01280695|Experimental|MSDC-0602 100 mg|MSDC-0602 capsule 100 mg once daily
9786588|NCT01280695|Experimental|MSDC-0602 250 mg|MSDC-0602 capsule 250 mg once daily
9786589|NCT01280695|Experimental|MSDC-0602 500 mg|MSDC-0602 capsule 500 mg once daily
9786590|NCT01280695|Active Comparator|Pioglitazone 45 mg|Pioglitazone capsule 45 mg once daily
9786591|NCT01280721|Experimental|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
9786592|NCT01280812|Experimental|PA intervention and Maintenance plus|3-month physical activity intervention and 6-month maintenance intervention-Plus program
9786593|NCT01280812|Experimental|PA intervention and Maintenance regular|3-month physical activity intervention and 6-month maintenance - Regular program
9786594|NCT01280812|Active Comparator|Pedometer|Non-intervention group
9786595|NCT01280903|Experimental|STAR Intervention|Staying Active with Arthritis Intervention
9786596|NCT01280903|Placebo Comparator|Attention-Control|Senior Health Information Intervention
9786597|NCT01280942|No Intervention|Control|Patients admitted to 4 GHWs designated as controls. Nurses will not be notified when patients on these GHWs satisfy the EWS algorithm. They will also not wear the wireless sensor devices.
9786598|NCT01280942|Experimental|Nurse notification of EWS alert|Patients admitted to 4 GHWs designated as intervention wards at BJH. Nurses will be notified when patients on these wards satisfy the EWS algorithm. Some patients will be asked to wear the wireless remote sensors.
9786599|NCT01280955|Experimental|Transplant Recipients|Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
9786600|NCT01280968|Experimental|NIC002 Vaccine in Aluminum hydroxide|4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
9786601|NCT01280968|Placebo Comparator|Placebo Vaccine - Aluminum hydroxide|4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
9786602|NCT01280981|Experimental|Tranexamic acid|Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).
9786603|NCT01281007|Experimental|Famciclovir 125 mg|1 tablet every 12 hours for 5 days
9786604|NCT01281007|Active Comparator|Aciclovir 200 mg|1 tablet every 4 hours (excluding nocturnal dose) for 5 days
9786605|NCT01281189|Experimental|Dexpramipexole|
9786606|NCT01281189|Placebo Comparator|Placebo|
9786607|NCT01281202|Active Comparator|CPP-109 Vigabatrin Tablets|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received 3 CPP-109 Vigabatrin 500 mg Tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Individual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
9786608|NCT01281202|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received Vigabatrin matching placebo tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Indivdiual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
9786609|NCT01281306|Experimental|VAL + AHU 400 mg|Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
9786610|NCT01281306|Experimental|VAL + AHU 200 mg|Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
9786611|NCT01281306|Experimental|VAL + AHU 100 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
9786612|NCT01281306|Experimental|VAL + AHU 50 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
9786613|NCT01281306|Experimental|VAL 320 mg|Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
9996772|NCT01503099||Controls India|Healthy subjects serving as controls
9786614|NCT01281306|Experimental|LCZ 400 mg|Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
9786615|NCT01281306|Experimental|Placebo|Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
9786616|NCT01281475|Experimental|Levodopa|Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
9786617|NCT01281475|Placebo Comparator|Placebo|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa, so it is not expected to have any effect.
9786618|NCT01281501|Active Comparator|Conventional|Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
9786619|NCT01281501|Experimental|Pantoprazole|Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
9786620|NCT01281839|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
9786621|NCT01281839|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
9786622|NCT01281865|Experimental|Treatment (everolimus and imatinib mesylate)|Patients receive everolimus PO once daily and imatinib mesylate PO once daily on days 1-28. Course repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and tumor tissue sample collection at baseline and periodically during study for correlative biomarker and protein expression studies.
9786623|NCT01281917|Experimental|Velcade plus Temsirolimus|"Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)~Treat for up to 6 cycles, cycles are 35 days long."
9786624|NCT01281956|Experimental|Placebo Then PRX|Subjects are administered Placebo x3 months followed by PRX (selective 5HT1A agonist) x3 months
9786625|NCT01281956|Experimental|PRX Then Placebo|Subjects are administered PRX (selective 5HT1A agonist) x3 months followed by Placebo x3 months
9786626|NCT01281969|Experimental|Group A|Drug: Gamunex Intravenous Immunoglobulin 2.0 gm/kg total, IV (in the vein), over 2 days
9786627|NCT01281969|Placebo Comparator|Group B|Drug: Placebo Normal saline, IV (in the vein), over 2 day
9786628|NCT01282086||Adults requiring anesthesia for surgery|Adult patients requiring general anesthesia for surgery
9786629|NCT01282138|Experimental|Patanol|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
9786630|NCT01282138|Placebo Comparator|Tears Naturale II|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
9786631|NCT01282164|Experimental|Study patients|patients with growth hormone deficiency or hypothalamic-pituitary disorders underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).
9786632|NCT01282164|Active Comparator|Control|"The control group will consist of healthy volunteers matched to the study group for age, gender, Body mass index (BMI) and estrogen status. Note: Allegheny site is not enrolling in the control group.~Control subjects underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT)."
9786633|NCT01282203||Adults requiring anesthesia for surgery|This post-marketing observational study will be conducted in a prospective, multi-centre format. It is a non-interventional, observational study in which Sevorane is prescribed for adult patients undergoing general surgery for induction and maintenance of anesthesia in the usual manner in accordance with the terms of the local marketing authorization. Sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist. No additional procedures (other than standard of care) shall be applied to the patients. Each patient will be observed from the start of anesthesia through anesthesia end. Markers of myocardial ischemia will be detected up to the first 24 hours after anesthesia (if available). Additionally the correlation between the experience and training background of anesthesiologists and patient related outcomes of general anesthesia with Sevorane as a single anesthetic will be assessed.
9786634|NCT01282229|Active Comparator|LANAP Quadrant|Treated with LANAP
9786635|NCT01282229|No Intervention|Modified Widman Flap|Quadrant treated with Modified Widman Flap surgery
9836572|NCT05347953||Single arm|Patients with self-reported symptoms of positional dependent palpitations
9786636|NCT01282229|No Intervention|Scaling and Root Planing|Quadrant treated with scaling and root planing alone
9786637|NCT01282229|No Intervention|Coronal Debridement|Quadrant treated with coronal debridement
9786638|NCT01282242|Experimental|IV rt-PA|open-label
9786639|NCT01282294||ETN PROtect|There is only 1 cohort in this case series
9786640|NCT01282372||Participants with moderate to severe rheumatic disease|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received adalimumab in accordance with approved label
9786641|NCT01282424|Experimental|Idelalisib|Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.
9786642|NCT01282463|Active Comparator|Docetaxel|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
9786643|NCT01282463|Experimental|Docetaxel + Ramucirumab DP|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
9836573|NCT05347940|Experimental|Study group (A)|Study group (A):15 patient received traditional physical therapy program in addition to motor imagery in form of mirror therapy.
9836574|NCT05347940|Experimental|Study group (B)|Study group (B):15 patient received traditional physical therapy program only.
9836575|NCT05347927||Test group|will receive water resistante padding and a cast
9836576|NCT05347927||Control group|will receive traditional non-water resistante padding and cast
9836577|NCT05346120|Experimental|Intervention|Single IV infusion of 6 million cells/kg allogeneic marrow stromal cells (MSCs) lasting approximately 30 minutes
9836578|NCT05346120|Placebo Comparator|Placebo controlled|PlasmaLyte A supplemented with 5% HSA
9836579|NCT05343962||Parkinson's Disease (PD)|Subjects with a medical diagnosis and currently cursing with Parkinson's Disease (PD)
9836580|NCT05343962||Diabetes Mellitus type I and II (DM I/II)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
9836581|NCT05343962||SARS Covid-19 Infection (COVID-19)|Subjects with a medical diagnosis and currently cursing or who have cursed at some point in the past with SARS Covid-19 Infection (COVID-19)
9836582|NCT05343962||Chronic obstructive pulmonary disease (COPD)|Subjects with a medical diagnosis and currently cursing with Chronic obstructive pulmonary disease (COPD).
9836583|NCT05343962||Stroke (ST)|Subjects with a medical diagnosis and who have cursed at some point with Stroke, either ischemic or hemorrhagic (ST)
9836584|NCT05343962||Healthy population (HP)|Healthy population (HP). No chronic or acute conditions declared.
9836585|NCT05343286|Experimental|APAP group: adapted and personalized physical activity|12 weeks of adapted and personalized physical activity
9836586|NCT05343286|Active Comparator|APA group: adapted physical activity|12 weeks of generic physical activity
9836587|NCT05343286|Sham Comparator|Control group: no physical activity|no physical activity
9836588|NCT05339581|Experimental|IMRT combined with PD-1 Blockade and Lenvatinib|"Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.~Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk."
9836589|NCT05339581|Active Comparator|PD-1 Blockade and Lenvatinib|Participants receive PD-1 Blockade (Pembrolizumab，Sintilimab， Camrelizumab，Tislelizumab) 200 mg intravenously on day 1 of a 21-day treatment cycle until >42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until >7 days before liver transplantation.
9836590|NCT05339308|Experimental|Experimental|Magnesium oil application
9836591|NCT05339308|Placebo Comparator|Control|Natural mineral-free oil application
9836592|NCT05338593||prolonged veno-venous extracorporeal membrane oxygenation|Critically affected patients treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO). Based on severe acute respiratory distress syndrome (ARDS) and prolonged therapy for more than 2 weeks.
9836593|NCT05337553|Experimental|taldefgrobep alfa|weight based 35 mg/50 mg weekly subcutaneous injection
9836594|NCT05337553|Placebo Comparator|Placebo|matching weight based 35 mg/50 mg weekly subcutaneous injection
9836595|NCT05337436||All patients receive conventional dialysis treatment at enrollment|All patients receive conventional dialysis treatment at enrollment
9836596|NCT05337280|Experimental|Imagio OA/US|Imagio OA/US Imaging
9836598|NCT05336903|Experimental|APP-led model of care for chronic pain management|The APP-led model of care involves integrating an APP as the first point of contact within an interprofessional chronic pain clinic setting. This is in contrast to the usual physician- or nurse practitioner-led model of care.
9836599|NCT05336227|Experimental|Immediate Start - Virtual Reality Exergaming|12 weeks of virtual reality active video gaming using immersive commercially available equipment, with adapted games for people to play in the seated position. Maintain normal eating/nutritional behaviors.
9836600|NCT05336227|No Intervention|Wait-list Control|Maintain habitual physical activity levels for 12 weeks, before receiving the same intervention. Maintain normal eating/nutritional behaviors.
9836601|NCT05336006|Experimental|High-intensity aerobic training with high protein diet - Group A|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
9836602|NCT05336006|Placebo Comparator|Control group - Group B|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
9836603|NCT05335616|Experimental|"Intervention Guideline"|Participants are given written information (a hypothetical new guideline).
9836604|NCT05335616|Experimental|"Intervention Treatment fee item"|Participants are given written information about a hypothetical new treatment fee item.
9836605|NCT05335005|Experimental|MK-2060|MK-2060 administered via intravenous (IV) infusion on days 1, 3, and 5 during the first week and on day 8 during the second week.
9836606|NCT05334979|Other|Kidney stone formers|12 stone-forming subjects will be enrolled in this arm.
10205596|NCT05204966|Other|Infant with suspected dysphagia|For newborns and infants who satisfy the inclusion and exclusion criteria, after taking a video of a bottle feeding, we try to develop an evaluation of swallowing disorder through artificial intelligence-based analysis. The developed evaluation will be verified for validity by comparing it with NOMAS (and VFSS if possible), and the correlation with future development will be analyzed through the relationship with the 1st and 2nd year correctional Bailey Developmental Evaluation.
10205597|NCT05204953||1|patients diagnosed to have myelodysplastic syndrome
10205598|NCT05204953||2|healthy control subjects
10205599|NCT05204914|Other|Supra glottic airway devices|
10205600|NCT05204901|Experimental|Magnetic tracking|This is the only arm of the study. All 12 participants will undergo the insertion of the magnetic-tipped guidewire into their nasogastric tube after its correct placement is confirmed by chest X-ray.
10205601|NCT05204862|Experimental|TU2218 Phase 1a|Escalating doses of TU2218 orally administered daily for two weeks followed by one week of rest for up to seventeen 21-day cycles
9836607|NCT05334979|Other|Non-kidney stone formers|12 non-stone-forming subjects will be enrolled in this arm.
9836608|NCT05334732|Experimental|Sisters Informing Sisters Sessions|The intervention is peer-based and in concert with our theoretical model, builds upon positive role-modeling of the survivor coach to the patient, addresses behavioral expectations/capacities, and uses Motivational Interviewing (MI) techniques. The intervention includes a culturally relevant coach's manual and a patient workbook that will be used to facilitate the coaching sessions.
9836609|NCT05334732|No Intervention|Enhanced Usual Care|Women in the EUC arm will receive usual care that includes standardized information in the public domain (NCI treatment information booklet). This booklet was chosen to provide women with national-level recommendations regarding treatment recommendations.
9836610|NCT05334199|Experimental|Biodegradable stent treatment group|Biodegradable stent treatment group
9836611|NCT05334017|Active Comparator|Xylometazoline|Xylometazoline 0,1% as nasal solution given immediately prior to nasal intubation
9836612|NCT05334017|Active Comparator|Cocaine|Cocaine 4% as nasal solution given immediately prior to nasal intubation
9996773|NCT01503099||CD India|Patients with active Crohn's Disease (CD) in India
9836614|NCT05332509|Experimental|C-BRACE/SCO|The patient is first fitted during 2 months with the C-BRACE orthosis, them, after 2 weeks wash-out period, the patient is fitted with its Stance Controlled Orthosis (SCO).
9836615|NCT05332509|Other|SCO/C-BRACE|The patient is using its Stance controlled orthosis (SCO) during 2 months, then, after 2 weeks wash-out period, the patient is fitted with the C-BRACE orthosis.
9836616|NCT05332457|Active Comparator|Arm A|"Phase I : Participants will undergo first CPET (Day 0) at trough concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at peak concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index < 0.8 at peak level of BB, (2) Resting HR < 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
9836617|NCT05332457|Active Comparator|Arm B|"Phase I : Participants will undergo first CPET(Day 0) at peak concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at trough concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index < 0.8 at peak level of BB, (2) Resting HR < 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
9836618|NCT05331404|Experimental|Presbycusis|Patients with presbycusis who receive rehabilitation with hearing aids
9836619|NCT05331404|Active Comparator|Aged control group|Aged control group: 15 subjects with normal or near-normal hearing thresholds
9836620|NCT05331404|Active Comparator|Young control group|Young control group: 15 subjects with normal hearing thresholds
9836621|NCT05330442|No Intervention|CoCM alone|In the CoCM alone arm, participants will have access to treatment as usual from the CM.
9836622|NCT05330442|Experimental|CoCM+WET|In the CoCM+WET intervention arm, patients will be encouraged to receive WET.
9921887|NCT00832208|Active Comparator|Ambisome control:|Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21
9996774|NCT01503099||Active PTB|Patients with active pulmonary tuberculosis (PTB)
10205602|NCT05204862|Experimental|TU2218 Food Effect|A MTD of TU2218 orally administered under fasting condition on -Day 2, followed by the same dose orally administered with meals on -Day 1 and then continued without meals for two weeks followed by one week of res for up to seventeen 21-day cycles
9996775|NCT01503099||CD Norway|Patients with active Crohn's Disease (CD) in Norway
10205603|NCT05204862|Experimental|TU2218 + Anti-PD-1 antibody Phase 1b|Escalating doses of TU2218 in combination with anti-PD-1 antibody up to seventeen 21-day cycles
10205604|NCT05204862|Experimental|TU2218 Phase 2a|TU2218 at a RP2D orally administered daily for two weeks followed by on week of rest for up to seventeen 21-day cycles
10205605|NCT05204862|Experimental|TU2218 + Anti-PD-1 antibody Phase 2b|TU2218 at a RP2DC in combination with anti-PD-1 antibody up to seventeen 21-day cycles
10205606|NCT05204836|Experimental|Zoledronic Acid Injection|Participants will receive 1 dose of 5 mg/100 mL intravenous zoledronic acid
10205607|NCT05204836|Placebo Comparator|Placebo|Participants will receive 1 dose 100 ml Saline.
10205608|NCT05204810|Experimental|Night_1dosis|"anticoagulation at dialysis start~blood sampling 5min after start dosis, and at 1h, 4h and 8h after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
9836623|NCT05330026|Experimental|Yoga practitioner|"The RUSI protocol for taking measurements with ultrasound for physiotherapists will be followed. Three measurements of each of the explorations will be made with the average of the three, pausing for 30 seconds between each repetition.~Three variables will be analyzed: diaphragm thickness, its rate of contraction, and diaphragmatic excursion, all of them at rest, ujjayi breathing, and pursed-lip breathing."
9836624|NCT05330026|Active Comparator|Non yoga practitioner|"Each subject will have previously received (one week before taking the measurements) the instructions where the main researcher will have shown him what calm diaphragmatic breathing is like, as well as forced breathing at maximum inspired volume with neutral breathing, yoga breathing (ujjayi ) and pursed-lip breathing. During that week prior to taking measurements, the subjects should practice each breath for 20 minutes a day in order to have a good awareness of how to perform them correctly.~The RUSI protocol for taking measurements with ultrasound for physiotherapists will be followed. Three measurements of each of the explorations will be made with the average of the three, pausing for 30 seconds between each repetition.~Three variables will be analyzed: diaphragm thickness, its rate of contraction, and diaphragmatic excursion, all of them at rest, ujjayi breathing, and pursed-lip breathing."
9984767|NCT03746756|Experimental|SBIRT as Usual|The follow-up team will (a) contact participants within 24-48 hours to collect additional locator information and mailing a schedule card for the next interview, (b) receipt information in a management information system (MIS), (c) assign each case to a follow-up case tracker, (d) verify locator data, (e) conduct outreach for unverified cases and discussing them at weekly meetings, (f) mail thank-you cards to participants and collaterals, (g) schedule follow-up appointments, (h) mail 3 and 6 week post-enrollment flyers, (i) implement returned-mail procedures, (j) call participants 6 weeks before appointment to confirm date and location (phone vs. research office), (k) conduct outreach for unconfirmed cases and review them at weekly meetings, (l) complete follow-up interviews and scheduling next appointments, and (m) implement a no-show protocol.
9984768|NCT03746756|Experimental|SBIRT + RMC-PC|Patients will receive SBIRT plus the RMC protocol. The Linkage Manager (LM) will: 1) provide personalized feedback to participants about the status of their condition based on responses from the Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3), 2) help participants resolve ambivalence about their dependence and moving them toward a commitment to change by accessing additional care, 3) address existing barriers to treatment, 4) schedule an assessment, and 5) facilitate reentry and engagement. The LM will stay in contact 2-3 times per week for two weeks to ensure that individuals both initiate and remain engaged in treatment.
9836627|NCT05327920||Participants Receiving Upadacitinib|Participants receiving upadacitinib for Rheumatoid Arthritis
9984769|NCT03740035||Prostate Cancer Patients|Prostate cancer patients that who have been actively receiving care through Wake Forest Baptist Comprehensive Cancer Center and/or satellite clinics over the past two-year period will be using an eHealth for Sedentary Behavior.
9984770|NCT03739034|Experimental|Lifestyle Medicine|Patients presenting for lifestyle medicine treatment to prevent, arrest or reverse chronic lifestyle related diseases.
9836633|NCT05325385||OHCA attended by ambulance service|All adults attended by ambulance service where time of collapse and initial rhythm is known.
9836634|NCT05325255|Experimental|Maitland mobilization with myofascial trigger point release group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Ischemic Compression technique: on subscapularis trigger points for 90 secs thrice a week for 2 weeks.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
9836635|NCT05325255|Active Comparator|Maitland mobilization alone group|"Maitland technique: caudal, anteroposterior (AP), and posteroanterior (PA) glides 5 sets of 2-3 glides per second of Grade III and IV for 30 seconds with a rest interval of 30 second between sets.~Stretching exercises in direction of abduction, external rotation (ER), internal rotation (IR), and flexion. 6 repetitions of each stretch for 10 seconds Cold pack for 20 mins"
9836636|NCT05320718|Experimental|erector spinae plane block|A needle is inserted until the tip contacted the T5 transverse process under ultrasound guidance. After confirming the needle tip position, 20 ml of 0.5% ropivacaine was injected in the plane between the erector spinae muscles and transverse process. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
9836637|NCT05320718|Active Comparator|thoracic paravertebral block|A needle is inserted into the paravertebral space. After confirming the needle tip position, 20 ml of 0.5% ropivacaine is injected in the paravertebral space. A catheter is inserted through the needle and then connected to a Programmed Electronic Postoperative Analgesia Pump with a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery.
9786644|NCT01282463|Experimental|Docetaxel + Icrucumab|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
9786645|NCT01282476|Experimental|Panobinostat/Rituximab|single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
9786646|NCT01282710||Pregnant, In Labor|
9786647|NCT01282723||Pregnant, In Labor|
9786648|NCT01282801|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
9786649|NCT01282801|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
9786650|NCT01282814|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules.
9786651|NCT01282814|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
9786652|NCT01282866|Experimental|HS treatment|Treatment with HS handpiece
9786653|NCT01283009|Placebo Comparator|Arm 1: Inactive substance|Inactive substance
9786654|NCT01283009|Active Comparator|Arm 2: Methylprednisolone|Methylprednisolone
9786655|NCT01283022|Experimental|MVI 200|MVI 200 mcg vaginal insert
9786656|NCT01283035|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
9786657|NCT01283139|Experimental|Sifalimumab 200 milligram (mg)|Sifalimumab 200 milligram (mg) will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
9786658|NCT01283139|Experimental|Sifalimumab 600 mg|Sifalimumab 600 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
9786659|NCT01283139|Experimental|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
9786660|NCT01283139|Placebo Comparator|Placebo|Placebo matching to sifalimumab will be administered intravenously at a fixed dose every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
9786661|NCT01283152|Active Comparator|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|
9786662|NCT01283152|Other|Lactulose|Per standard of care
9786663|NCT01283282|Active Comparator|Clopidogrel/Placebo|Subjects were randomized to clopidogrel 75 mg daily for 6 weeks. Then immediately transitioned to a placebo daily for 6 weeks.
9786664|NCT01283282|Active Comparator|Placebo/Clopidogrel|Subjects were randomized to a placebo daily for 6 weeks. Then immediately transitioned to clopidogrel 75 mg daily for 6 weeks.
9786665|NCT01283321|Experimental|Group A: RiaSTAP|Human fibrinogen concentrate
9786666|NCT01283321|Active Comparator|Group B: apheresis platelets|single apheresis unit
9786667|NCT01283334|Experimental|A|Treatment arm with carboplatin, cetuximab and RAD001
9786668|NCT01283386|Experimental|FCR-lite|Rituximab, fludarabine, and cyclophosphamide
9921888|NCT00832208|Experimental|Ambisome test|Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)
9786669|NCT01283386|Active Comparator|LR Therapy|Rituximab and chlorambucile
9786670|NCT01283464|Active Comparator|Retinol|Retinol 1.0% cream
9786671|NCT01283464|Active Comparator|Tretinoin|Tretinoin 0.02% cream
9786672|NCT01283516|Experimental|LDK378 750 mg: Arm 1A and Arm 1B|NSCLC patients previously treated with an ALK inhibitor
9786673|NCT01283516|Experimental|LDK378 750 mg: Arm 2|NSCLC patients not previously treated with an ALK inhibitor
9786674|NCT01283516|Experimental|LDK378 750 mg: Arm 3|Patients with other tumors that are ALK positive other than NSCLC
9786675|NCT01283542|Experimental|Pasireotide LAR|All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks
9786676|NCT01283555|Experimental|User-Filled Applicator|
9786677|NCT01283555|Other|Prefilled applicator|
9786678|NCT01283581|Experimental|Delafloxacin|300 mg IV (intravenous) every 12 hours for 5-14 days
9786679|NCT01283581|Active Comparator|Vancomycin|15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
9786680|NCT01283581|Active Comparator|Linezolid|600 mg IV every 12 hours for 5-14 days
9786681|NCT01283971|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
9786682|NCT01283971|Active Comparator|Adalimumab + Methotrexate|Adalimumab 40 mg SC every 2 weeks + Placebo to tocilizumab IV every 4 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
9786683|NCT01284062|Experimental|Arm 1|200 mg PF-05230917, Anrukinzumab active dose level
9786684|NCT01284062|Experimental|Arm 2|400 mg PF-05230917, Anrukinzumab active dose level
9786685|NCT01284062|Experimental|Arm 3|600 mg PF-05230917, Anrukinzumab active dose level
9786686|NCT01284062|Placebo Comparator|Arm 4|Matching placebo - administered at matching dose level 200 mg, 400 mg or 600 mg.
9786687|NCT01284114|Active Comparator|Aliskiren|
9786688|NCT01284127||Deferiprone|All patients must have MRI evidence of superficial siderosis and be treated with deferiprone according to standard of care guidelines.
9786689|NCT01284140|Experimental|Sleep promotion protocol|Behavioral: 48 hours of sleep and circadian rhythm promotion including timed light exposure.
9921889|NCT00832221|Active Comparator|1|
9921890|NCT00832221|Active Comparator|2|
9984771|NCT03736954|Experimental|ICU doulas intervention|specially trained ICU doulas will provide critically ill intubated patients with early psychological support on a daily basis
9836640|NCT05319353|Experimental|Cohort 1: Maribavir 400 or 200 mg|Participants with greater than (>=) 12 to less than (<) 18 years of age will receive maribavir 400 milligrams (mg) (2*200 mg tablets) twice daily (BID) based on body weight >= 25 kilogram (kg) or 200 mg tablet BID based on body weight < 25 kg orally for up to 8 weeks treatment period (Day 0/Week 0 to Day 56/Week 8). The dosing regimen will be based on the participant's body weight and may be updated over the course of the study based on the internal interim analyses on PK, safety, and tolerability of at least 5 participants in each cohort.
9836641|NCT05319353|Experimental|Cohort 2: Maribavir 400 or 200 mg|Participants with >= 6 to < 12 years of age will receive maribavir 400 mg (2*200 mg tablets) BID based on body weight >= 25 kg or 200 mg tablet BID based on body weight 10-25 kg orally for up to 8 weeks treatment period (Day 0/Week 0 to Day 56/Week 8). The dosing regimen will be based on the participant's body weight and may be updated over the course of the study based on the internal interim analyses on PK, safety, and tolerability of at least 5 participants in each cohort.
9836642|NCT05319353|Experimental|Cohort 3: Maribavir|Participants with 0 to < 6 years of age will receive maribavir based on PK modeling.
9836643|NCT05314166|Experimental|"focused attention group"|"focused attention group: adult subjects practicing face-to-face focused attention meditation."
9836644|NCT05314166|Active Comparator|"contemplation group"|"contemplation group: adult subjects practicing face-to-face contemplation meditation."
9836645|NCT05312879|Experimental|Phase 2: VX-147|Participants will be randomized to receive different dose levels of VX-147.
9836646|NCT05312879|Placebo Comparator|Phase 2: Placebo|Participants will receive placebo matched to VX-147.
9836647|NCT05312879|Experimental|Phase 3: VX-147|Participants will receive VX-147 with the dose to be based on the outcome of Phase 2.
9836648|NCT05312879|Placebo Comparator|Phase 3: Placebo|Participants will receive placebo matched to VX-147.
9836649|NCT05309577|Active Comparator|Caregiver Intervention|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors for 6 weeks, into an electronic tablet or device; and behavioral self monitoring + motivational interviewing health coaching.
9836650|NCT05309577|Active Comparator|Enhanced Usual Care|Participants randomized to this condition will receive the written education provided to all participants, along with weekly check-in calls.
9836651|NCT05308238|Experimental|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
9836652|NCT05308238|Active Comparator|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
9836653|NCT05305053||high-risk noncardiac surgery patients for preoperative Multidisciplinary Team (MDT) discussion|observation of MDT in 11 hospitals
9836654|NCT05303571||Monodof|monofocal and EDOF lens
9836655|NCT05303571||Bidof|Bifocal and EDOF lens
9836656|NCT05303051|Experimental|Study Population|The investigators will conduct an electronic medical record (EMR) query of individuals in the University of California, San Francisco (UCSF) primary care clinics without a prior diagnosis of DM and who are undergoing, or who have recently undergone, a lab measured HBA1c before or after 1 month of enrollment. sample size estimation for testing the estimated AUROC in the validation sample vs. the null value of AUC 0.7. The investigators will target an enrollment of 5006 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.07 (i.e. AUROC = 0.76 [95%CI 0.725, 0.795]). The investigators assume that ~4% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
9836657|NCT05303051|Experimental|Alternative Sample Group|The investigators also aim to perform a sensitivity analysis to estimate the DNN performance in a target general population without a diabetes diagnosis. The investigators will recruit patients from the UCSF EHR system without a history of diabetes, no prior HBA1c measured, and no history of known diabetic risk factors. The investigators will target an enrollment of 1000 subjects in order to obtain a pre-specified AUROC 95% confidence interval width of 0.18 (i.e. AUROC = 0.76 [95%CI 0.67, 0.85]). The investigators assume that ~3% of the cohort will have undiagnosed diabetes based on national prevalence estimates.
9836658|NCT05302544|Experimental|"with mixed reality training group"|2 Mixed Reality sessions per week for 8 weeks in addition to motor activities usually performed
9921891|NCT00832234|Experimental|BDR|
9984772|NCT03734705|Experimental|Imaginal Exposure Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about their worst-case scenario regarding discarding a possession (i.e., imaginal exposure).
9984773|NCT03734705|Sham Comparator|Neutral Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about what they would do if they had a day off work or school.
9786690|NCT01284140|Active Comparator|Usual care|Behavioral: 48 hours of usual care.
9786691|NCT01284244|Experimental|Uresta|
9786692|NCT01284244|Sham Comparator|Silastic vaginal ring|
9786693|NCT01284296|Experimental|Digital block|
9786694|NCT01284335|Experimental|Gemcitabine plus LY573636|
9786695|NCT01284335|Experimental|Docetaxel plus LY573636|
9786696|NCT01284335|Experimental|Temozolomide plus LY573636|
9786697|NCT01284335|Experimental|Cisplatin plus LY573636|
9786698|NCT01284335|Experimental|Erlotinib plus LY573636|
9786699|NCT01284361|Experimental|30 cm Intermittent Catheter|Intervention was the test of a 30 cm catheter compared to standard commercial 40 cm catheter in a cross-over design.
9786700|NCT01284361|Active Comparator|40 cm Intermittent Catheter|Active comparator 40 cm commercial catheter was compared to experimental 30 cm catheter in a cross-over design.
9786701|NCT01284426||Chronic urticaria|Chronic urticaria, Natural history
9786702|NCT01284517|Experimental|Lurasidone 20-120 mg flexible dose|
9786703|NCT01284517|Placebo Comparator|Placebo|
9786704|NCT01284621|Experimental|BI 10773|1 tablet per days for 5 days, oral administration with 240 mL water for each treatment
9786705|NCT01284621|Other|Ramipril|1 tablet on day 1 and 2 tablets per day on day 2-5, oral administration with 240 mL water for each treatment
9786706|NCT01284621|Other|BI 10773 + Ramipril|1 tablet BI 10773 and 1 tablet on day 1 and 2 tablets ramipril per day on day 2-5, oral administration with 240 mL water for each treatment
9786707|NCT01284634|Experimental|GWP42003 200 milligrams (mg)/day Dose|Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
9786708|NCT01284634|Experimental|GWP42003 400 mg/day Dose|Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
9786709|NCT01284634|Experimental|GWP42003 800 mg/day Dose|Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
9786710|NCT01284634|Experimental|Placebo|Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
9786711|NCT01284959|Experimental|risperidone|Drug: risperidone 3mg, PO two times Groups: risperidone
9786712|NCT01284959|Placebo Comparator|placebo|drug: lactose, PO 3 times group: placebo
9786713|NCT01284959|Experimental|paliperidone ER|drug : Paliperidone ER 6mg PO, two times group: paliperidone ER
9786714|NCT01285024|No Intervention|Control|No Vitagel used during total hip arthroplasty
9786715|NCT01285024|Experimental|Vitagel|Vitagel applied just prior to closure during total hip arthroplasty
9786716|NCT01285050|Other|pre post ART|HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)
9786717|NCT01285076||All Enrolled Participants|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU + MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist, or family practice doctor.
9786718|NCT01285310|Experimental|Apremilast 30 mg|
9786719|NCT01285310|Experimental|Apremilast 20 mg|
9786720|NCT01285310|Placebo Comparator|Placebo|
9786721|NCT01285323|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
9786722|NCT01285323|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
9786723|NCT01285349|Experimental|Couple-based HIV prevention|7-session couple-based HIV/STI risk reduction intervention (CSTI)
9786724|NCT01285349|Active Comparator|Individual HIV/STI Prevention|7-session individual HIV/STI intervention comparison condition (ISTI) provided to the index participant alone, which is identical in content to the CSTI.
9786725|NCT01285349|Placebo Comparator|Couple Wellness Promotion|7-session couple-based stress reduction intervention (CSR) that serves as an attentional control condition.
9786726|NCT01285401|Experimental|VigantOL® oil|VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
9786727|NCT01285401|Placebo Comparator|Placebo|Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
9786728|NCT01285401|Experimental|Rebif|Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L
9786729|NCT01285427||DNA loci (SeCore vs. SSP UniTray platforms)|
9786730|NCT01285492|Experimental|QVA149|QVA149 110/50 μg once a day (o.d)
9786731|NCT01285492|Active Comparator|Tiotropium|tiotropium 18 μg o.d.
9786732|NCT01285518|Experimental|Treatment|
9786733|NCT01285518|Placebo Comparator|Placebo|0.9% w/v sodium chloride injection, USP
9799299|NCT01656304|Experimental|Treatment (monoclonal antibody, antiangiogenesis)|Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
9836659|NCT05302544|Active Comparator|"without mixed reality training group"|group: only motor activities usually performed
9836660|NCT05299723|Experimental|Phase A - open label single-arm|"All Phase A participants randomized to the home-based CC intervention will be use a light visor to administer bright light therapy in the morning for 30 minutes after waking up (BLT), and use orange-colored glasses for blue light blocking at night from 8:00 pm until going to sleep (BLB)."
9836661|NCT05299723|Experimental|Phase B - active CC treatment|For all Phase B participants randomized to the active CC group, BLT will occur each morning after awakening and will last for 30 minutes and BLB at night from 8:00 pm until going to sleep throughout the 4-week intervention period. Participants in the CC group will also receive a sleep hygiene education.
9836662|NCT05299723|Active Comparator|Phase B - sleep hygiene education control group|All Phase B participants randomized to the control group will receive a sleep hygiene education alone at the start of the 4 week monitoring period.
9836663|NCT05299099|Experimental|IN-C006 inj.|IN-C006 inj. 1970 mL
9836664|NCT05299099|Active Comparator|RCN301|RCN301 1820 mL
9836665|NCT05297305|Active Comparator|Onlay Component-Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
9836666|NCT05297305|Active Comparator|Inlay Component-Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
9836667|NCT05296746|Experimental|Responder (ROR-low)|Ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years
9836668|NCT05296746|Other|Non-responder (ROR-medium/high)|"Adjuvant chemotherapy. 3 regimens are permitted.~Regimen 1:~- Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 90 mg/m2) and Cyclophosphamide 600 mg/m2 day 1 every 14/21 days for 4 cycles, followed by Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks.~Regimen 2:~- Docetaxel 75-100 mg/m2 IV day 1 and Cyclophosphamide 600 mg/m2 day 1 every 21 days for 4-6 cycles.~Regimen 3:~- Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks followed by Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 90 mg/m2) and Cyclophosphamide 600 mg/m2 day 1 every 14/21 days for 4 cycles.~Then, patients will receive ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years"
9836669|NCT05295498|Experimental|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 6 sessions (three sessions in two consecutive days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
9836670|NCT05295498|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
9836671|NCT05293834|Experimental|VRAPT intervention group|"Data collection process:~Pre-intervention (t0): patients self-reports and staff observation;~VRAPT: 8-16 weeks;~Post-intervention (t1): patients self-reports, staff observations, and qualitative interview with participants and VRAPT therapists conducted by research staff;~Follow-up 12 weeks after completion of the intervention (t2): patients self-reports and staff observations."
9984774|NCT03734523||Pilot Group: 12 week study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for 12 weeks. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
9996776|NCT01503099||Controls Norway|Healthy subjects serving as controls in Norway
9836679|NCT05286593|Other|Normal volunteers|Normal participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
9836680|NCT05286593|Other|Clinical patients|Clinical patients participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
9836681|NCT05286593|Other|Infarcts|Infarct participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
9836682|NCT05285488|Experimental|"focused attention group"|adult subjects practicing focused attention meditation
9786734|NCT01285609|Experimental|Ipilimumab + Paclitaxel and Carboplatin|"Ipilimumab + Active Chemo Backbone~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
9786735|NCT01285609|Placebo Comparator|Placebo + Paclitaxel and Carboplatin|"Placebo + Active Chemo Backbone~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
9786736|NCT01285635|Active Comparator|Docetaxel Alone|
9786737|NCT01285635|Experimental|Pulse Dose AT-101 Arm|
9786738|NCT01285635|Experimental|Metronomic AT-101 Arm|
9786739|NCT01285713|Experimental|5% Dextrose (D5) in Normal Saline (NS)|10cc/kg D5NS, followed by 30cc/kg NS
9786740|NCT01285713|Active Comparator|Normal Saline (NS)|10cc/kg NS, followed by 30cc/kg NS
9786741|NCT01285791||patients undergoing laparoscopic adjustable gastric banding|morbid obese patients undergoing laparoscopic adjustable gastric banding will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased.
9786742|NCT01285791||patients undergoing laparoscopic sleeve gastrectomy|morbid obese patients undergoing laparoscopic sleeve gastrectomy will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
9786743|NCT01285791||patients undergoing laparoscopic gastric bypass|morbid obese patients undergoing laparoscopic gastric bypass will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
9786744|NCT01285843|Active Comparator|Quadra Group|
9786745|NCT01285843|Active Comparator|AMIStem Group|
9786746|NCT01285908|No Intervention|Baseline|Baseline values measured at various tilt angles, so that each participant may serve as their own control.
9786747|NCT01285908|Placebo Comparator|Saline infusion|Subjects received a saline IV infusion as a placebo, while measurements were taken at various tilt angles.
9786748|NCT01285908|Active Comparator|Norepinephrine Infusion|Subjects were given an norepinephrine infusion at various tilt angles, while measurements were taken.
9786749|NCT01285960|Experimental|ExAblate treatment UF V2|ExAblate MRgFUS Treatment
9786750|NCT01286012|Active Comparator|SFP in liquid bicarbonate|
9786751|NCT01286012|Placebo Comparator|Placebo: Conventional Liquid Bicarbonate|Control concentrate lacking SFP does not contain SFP (total iron = 0)
9786752|NCT01286077|Experimental|bortezomib|bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
9786753|NCT01286077|No Intervention|Non-treated control|no treatment, observation only
9786754|NCT01286129|Active Comparator|Allergic asthmatic|Subjects with allergic asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
9786755|NCT01286129|Active Comparator|Allergic rhinitic without asthma|Subjects with allergic rhinitis without asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
9786756|NCT01286168|Experimental|Antisepsis Side|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
9786757|NCT01286168|Other|Control Side|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
9786758|NCT01286259|Experimental|Intervention Arm|
9786759|NCT01286311|Experimental|Direct-to-patient tailored cardiovascular risk message system|Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
9786760|NCT01286311|No Intervention|Control|
9786761|NCT01286324|Experimental|Chamomile High Grade Extract|Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet
9786762|NCT01286324|Placebo Comparator|Placebo Tablet|Contained lactose
9786763|NCT01286402|Experimental|Bupropion SR (sustained release)|Group receiving bupropion SR medication
9786764|NCT01286402|Placebo Comparator|Placebo|
9786765|NCT01286441|Placebo Comparator|Placebo|Placebo for East Indian Sandalwood Oil ointment administered topically twice daily
9786766|NCT01286441|Active Comparator|10% EISO|East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily
9786767|NCT01286441|Active Comparator|20% EISO|East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily
9786768|NCT01286441|Active Comparator|30% EISO|East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily
9786769|NCT01286454|Experimental|A|4 mg fesoterodine IR beads in capsule under fasting condition
9786770|NCT01286454|Experimental|B|4 mg fesoterodine 10% coated ER beads in capsule under fasting condition
9786771|NCT01286454|Experimental|C|4 mg fesoterodine 15% coated ER beads in capsule under fasting condition.
9786772|NCT01286454|Experimental|D|4 mg fesoterodine 20% coated ER beads in capsule under fasting condition.
9786773|NCT01286454|Experimental|E|4 mg fesoterodine ER tablets under fasting condition.
9786774|NCT01286454|Experimental|F|4 mg fesoterodine TBD % coated ER beads in capsule under fed condition.
9786775|NCT01286480|Experimental|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
9786776|NCT01286480|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies. Time-pressured clinic visits limit the opportunity to discuss many of the topics noted above.
9786777|NCT01286493|Experimental|Rabies vaccines on day 0 and 3|Cell culture Rabies vaccines on day 0 and 3
9786778|NCT01286558|Experimental|80mg telmisartan and 5mg amlodipine FDC|once daily
9786779|NCT01286558|Active Comparator|40mg telmisartan and 5mg amlodipine FDC|once daily
9786780|NCT01286740|Experimental|FTC/RPV/TDF|Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
9786781|NCT01286753|Experimental|Tyrosine Kinase Inhibitor (TKI) Naive|Vemurafenib in participants naive to any prior systemic TKI therapy.
9786782|NCT01286753|Experimental|TKI Experienced|Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).
9786783|NCT01286779|Experimental|BAX 326|
9786784|NCT01286805|Experimental|Lumbar Plexus Blockade + CSE|The study group will receive a lumbar plexus blockade with 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, followed by a combined spinal-epidural.
9786785|NCT01286805|Placebo Comparator|Control Group|The control group will receive only a combined spinal-epidural.
9786786|NCT01286818|Experimental|FOLFIRI plus Ramucirumab (IMC-1121B)|
9786787|NCT01286870|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
9786788|NCT01286987|Experimental|Talazoparib|
9786789|NCT01287013|Other|Cone Beam CT|Procedure performed with Xperguide cone-beam Computed Tomography (CT) navigation
9786790|NCT01287013|Other|Conventional CT|Procedure performed with Conventional Computed Tomography (CT) image guidance
9786791|NCT01287039|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
9786792|NCT01287039|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
9786793|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - AM dosing|FF(100mcg)/Vilanterol(25mcg) in the morning (approx 09.00) for 14 days (± 2 days).; placebo in evening (approx 21.00) for 14 days (± 2 days).
9836683|NCT05285488|Active Comparator|"Contemplation group"|adult subjects practicing contemplation meditation
9836684|NCT05284760|Experimental|Part A, Sequence 1: Treatment B + Treatment A + Treatment C|Soticlestat T3 mini-tablets 300 milligram (mg), orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836685|NCT05284760|Experimental|Part A, Sequence 2: Treatment A + Treatment C + Treatment B|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836686|NCT05284760|Experimental|Part A, Sequence 3: Treatment C + Treatment B + Treatment A|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T3 mini-tablets 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836687|NCT05284760|Experimental|Part A, Sequence 4: Treatment B + Treatment C + Treatment A|Soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836688|NCT05284760|Experimental|Part A, Sequence 5: Treatment A + Treatment B + Treatment C|Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836689|NCT05284760|Experimental|Part A, Sequence 6: Treatment C + Treatment A + Treatment B|Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9921892|NCT00832286|Experimental|Cipro|At Week 12, subjects will receive a 3-day course of oral Ciprofloxacin 500 mg every 12h.
9921893|NCT00832312|Experimental|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml) injected into the knee joint
9799300|NCT01656395|Experimental|MK-1029 10 mg|Participants receive MK-1029 10 mg tablets once daily (QD) for 12 weeks
9799301|NCT01656395|Experimental|MK-1029 30 mg|Participants receive MK-1029 30 mg tablets QD for 12 weeks
9799302|NCT01656395|Experimental|MK-1029 60 mg|Participants will receive MK-1029 two 30 mg tablets QD for 12 weeks
9799303|NCT01656395|Experimental|MK-1029 150 mg|Participants will receive MK-1029 150 mg tablets QD for 12 weeks
9799304|NCT01656395|Active Comparator|Montelukast 10 mg|Participants will receive Montelukast 10 mg tablets QD for 12 weeks
9799305|NCT01656395|Placebo Comparator|Placebo|Participants will receive Placebo tablets QD for 12 weeks
9836690|NCT05284760|Experimental|Part B, Sequence 1: Treatment E + Treatment D + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836691|NCT05284760|Experimental|Part B, Sequence 2: Treatment D + Treatment F + Treatment E|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836692|NCT05284760|Experimental|Part B, Sequence 3: Treatment F + Treatment E + Treatment D|Soticlestat T4 300 mg tablets, crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836693|NCT05284760|Experimental|Part B, Sequence 4: Treatment E + Treatment F + Treatment D|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836694|NCT05284760|Experimental|Part B, Sequence 5: Treatment D + Treatment E + Treatment F|Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836695|NCT05284760|Experimental|Part B, Sequence 6: Treatment F + Treatment D + Treatment E|Soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.
9836696|NCT05284487|Active Comparator|Group 1: Jalosome® Soothing gel|"Jalosome® soothing gel ((L-Acetyl Carnitine chloridrate, Allantoin, Hydrogenated phosphatidylcholine, Sodium Hyaluronate) will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
9836697|NCT05284487|Placebo Comparator|Group 2: Placebo|"Placebo will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
9836698|NCT05283395|Other|Netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%|
9836699|NCT05283265||Intracranial patients|All participants with epilepsy undergoing intracranial monitoring for clinical purposes will be approached to participate in an experiment that is recording-only and an experiment that involves stimulation with simultaneous recording.
9836700|NCT05279937|Experimental|Prolotherapy|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
9836701|NCT05279937|Active Comparator|Control|10mL of 1% Lidocaine (Control)
9836702|NCT05277909|Experimental|The expert assessment of shoulder impairments and individualised treatment plan|Participants randomised to the Intervention group will be referred to an expert assessment of their shoulder impairments at the Shoulder Sector, Vejle Hospital - Orthopaedic Department. The expert assessment will be performed by experienced specialists (e.g. physician and physiotherapist) who are specialised in shoulder diagnostics using x-ray, ultrasound, anamnesis/history and standard clinical tests such as Neers, Hawkins, Jobe´s Empty Can, Painful Arc and Resisted External Rotation. The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan. The individualised treatment plan will typically contain a referral to physiotherapeutic treatment at the municipality or private practice, receive specialised physiotherapeutic rehabilitation at Vejle Hospital, get an ultrasound guided corticosteroid injection in the shoulder or offer surgery.
9836703|NCT05277909|Active Comparator|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|Participants randomised to the Control comparator group will receive a pamphlet from the secretary and perform the exercises at home. This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment. The purpose is to stimulate circulation, improve shoulder function (mobility), increase muscle strength and reduce shoulder pain. The program consists of three warm-up exercises (arm swing, shoulder rolling and scapula-back pocket exercise) followed by three stretching exercises for the breast and shoulder area. Furthermore the pamphlet includes a tissue treatment and four strength exercises for the shoulder (external rotation, extension and flexion of the shoulder and diagonal pull apart). Mobility (with 5-10 repetitions), stretching exercises (in 30 seconds) and tissue treatments will be performed twice a day, while the strength exercises will be performed once a day with 3x12 repetitions.
9786794|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - PM dosing|Placebo in morning (approx 09.00) for 14 days (± 2 days); FF(100mcg)/Vilanterol(25mcg) in evening (approx 21.00) for 14 days (± 2 days).
9786795|NCT01287065|Placebo Comparator|Placebo|Placebo given in morning (approx 09.00) and in evening (approx (21.00) for 14 days (± 2 days).
9786796|NCT01287078|Experimental|Inhaled Cyclosporine in Lung Transplant and HSCT Recipients|Subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.
9786797|NCT01287104|Experimental|Pre-Bone Marrow Transplant (BMT) Prep Regimen|Pre-bone marrow transplant (BMT) Prep Regimen with Stem Cell and natural killer (NK) Cell Infusions coupled with Induction therapy
9786798|NCT01287117|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
9786799|NCT01287117|Experimental|Omalizumab 75 mg|Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period.
9786800|NCT01287117|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period.
9786801|NCT01287117|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
9786802|NCT01287195|Experimental|Oral OKT3|Participants with ulcerative colitis will receive Oral OKT3 given with Omeprazole once daily for 30 days.
9786803|NCT01287208|Active Comparator|Unblinded activity monitor|Subjects wear the activity device and can see the data on the device and on a website where the data is uploaded.
9786804|NCT01287208|Placebo Comparator|Blinded activity monitor|Subjects wear a blinded activity device and cannot see the activity on the device and cannot log on to the website where the data gets uploaded.
9786805|NCT01287221|Active Comparator|Rifampicin|Subjects randomized to this arm will receive 300 mg Rifampicin two times a day for 12 months.
9786806|NCT01287221|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo capsules twice daily for 12 months. The capsules will contain riboflavin (vitamin B2).
9786807|NCT01287364|Experimental|ciclesonide HFA followed by mometasone|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily in first intervention period, followed by a 7-14 day washout period, after which the second intervention of mometasone nasal inhalation 200 μg once daily will be administered.
9786808|NCT01287364|Active Comparator|mometasone followed by ciclesonide HFA|mometasone nasal inhalation 200 μg once daily in first intervention period followed by a 7-14 day washout period after which the second intervention of ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily will be administered
9786809|NCT01287377|Experimental|Pre-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
9786810|NCT01287377|Active Comparator|Post-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients are encouraged to start using their patches ON their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
9786811|NCT01287377|Active Comparator|Telephone Counseling and no patches sent|Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls.
9786812|NCT01287403|Placebo Comparator|Refined wheat flour|A negative control flour to serve as a reference.
9786813|NCT01287403|Active Comparator|Esterase wholegrain wheat flour|Wholegrain wheat flour treated with esterases to release phenolics (positive control for phenolic acids)
9786814|NCT01287403|Experimental|Wholegrain wheat flour|Flour with unknown response
9786815|NCT01287403|Experimental|Liquid whole grain wheat flour|Test flour with unknown response.
9786816|NCT01287403|Experimental|Wholegrain barley flour|Test flour with unknown response.
9786817|NCT01287403|Experimental|Liquid wholegrain barley flour|Test flour with unknown response.
9786818|NCT01287416|Experimental|Applied Suicide Intervention Skills Training (ASIST)|"ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The training is designed for anyone (especially those in a position of trust), from professionals and volunteers to members of the community. Participants range from those in caring roles to people concerned about family members or friends. The theory is that suicide can be pre¬vented with the help of prepared caregivers. ASIST is designed to help all caregivers become more willing, ready and able to help persons at risk. Just as CPR skills make physical first aid possible, training in suicide intervention develops the skills used in suicide first aid."
9786819|NCT01287416|Active Comparator|Resilience Retreat|The two days will be divided into cultural activities, sharing circles, small group discussions, story telling and dance. Two First Nations community leaders will be identified to lead each of the two retreats.
9799306|NCT01656395|Experimental|MK-1029 1 mg or 3 mg|Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
9921894|NCT00832312|Placebo Comparator|Saline|Injection of 1cc of saline into the knee joint
9836704|NCT05277571|Experimental|UCB1381 dosing regime 1 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
9836705|NCT05277571|Experimental|UCB1381 dosing regime 2 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
9836706|NCT05277571|Experimental|UCB1381 dosing regime 3 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
9836707|NCT05277571|Experimental|UCB1381 dosing regime 4 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
9836708|NCT05277571|Experimental|UCB1381 dosing regime 5 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
9836709|NCT05277571|Experimental|UCB1381 dosing regime 6 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
9836710|NCT05277571|Experimental|UCB1381 dosing regime 7 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
9836711|NCT05277571|Experimental|UCB1381 dosing regime 8 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
9836712|NCT05277571|Experimental|UCB1381 dosing regime 9 in Part B|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
9836713|NCT05277571|Placebo Comparator|Placebo iv Arm Part A|Participants will be randomized to receive a single dose of placebo iv to maintain the blinding.
9836714|NCT05277571|Placebo Comparator|Placebo sc Arm Part A|Participants will be randomized to receive a single dose of placebo sc to maintain the blinding.
9836715|NCT05277571|Placebo Comparator|Placebo iv Arm Part B|Participants will be randomized to receive repeated doses of placebo iv to maintain the blinding.
9836716|NCT05275673|Experimental|Group A - NFE2L2 Mutation, Dosing Cohort 1|sapanisertib 3 mg once daily (QD)
9836717|NCT05275673|Experimental|Group A - NFE2L2 Mutation, Dosing Cohort 2|sapanisertib 2 mg twice daily (BID)
9836718|NCT05275673|Experimental|Group B - NFE2L2 Wild-Type, Dosing Cohort 1|sapanisertib 3 mg QD
9836719|NCT05275673|Experimental|Group B - NFE2L2 Wild-Type, Dosing Cohort 2|sapanisertib 2 mg BID
9836720|NCT05274620|Other|IntelliCare|8 weeks of IntelliCare
9836721|NCT05274620|Other|Control|Historical controls
9836722|NCT05273359|Active Comparator|Benralizumab Intervention|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
9836723|NCT05273359|Placebo Comparator|Benralizumab Placebo|15 subjects (>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
9836724|NCT05273359|Other|Comparison (control) group; no intervention|15 subjects (<150 eosinophils/microliter) will not receive any intervention.
9836725|NCT05273307|Experimental|Miracle Fruit|Participants will receive 1 Miracle Fruit Farm miracle fruit cube by mouth three times a day before meals
9836726|NCT05273307|Placebo Comparator|Miracle Fruit Placebo|Participants will receive 1 placebo cube by mouth three times a day before meals
9836727|NCT05272579|Experimental|FFT treatment|Treatment with fecal filtrate transfer in saline solution administered by nasogastric tube
9836728|NCT05272579|Placebo Comparator|Placebo Treatment|Treatment with saline solution administered by nasogastric tube
9836729|NCT05272566||Infants|"30 healthy, term infants are recruited for 2 purposes:~To study the development of gut bacteria and viruses over time~To use as donors in a separate trial"
9836730|NCT05272566||Mothers|"30 healthy pregnant women are recruited along with their infants~To compare gut bacteria and viruses with those of their children~To screen for disease transferrable by breastfeeding"
9836731|NCT05267613|Active Comparator|Nexium - high dose|Arm 1 (High dose = Healing dose)
9836732|NCT05267613|Active Comparator|Nexium - Low dose|Arm 2 (Low dose = ½ healing dose)
9836733|NCT05266482|Experimental|Intervention group|Next to the usual care, patients also get the opportunity to download and read a personal report.
9836734|NCT05266482|No Intervention|Control group|Patients will receive the usual care.
9996777|NCT01503112||Patients starting incretin treatments|Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
9836736|NCT05265039|Experimental|Cognitive Processing Therapy (CPT)|
9836737|NCT05265039|Active Comparator|Relaxation Training (RT)|
9996778|NCT01503138|Experimental|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
9836739|NCT05263557|Experimental|DHEA|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
9836740|NCT05263557|Experimental|11KA4|Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
9836741|NCT05263232|Experimental|Natural office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with wide transparent windows under natural daylight.
9836742|NCT05263232|Experimental|Artificial office light|Over 4.5 days, participants will stay inside in an office room from 8:00 to 17:00h with shielded windows under artificial light.
9836743|NCT05263206|Experimental|Dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) on top of non-sedative antihistamine and moisturizer
9836744|NCT05263206|Placebo Comparator|Placebo|Loading dose administered SC, followed by SC Q2W on top of non-sedative antihistamine and moisturizer
9836745|NCT05261425|Active Comparator|Monocryl (FDA Approved) buried running|Upper extremity primary surgical wound closure via suture with Monocryl (FDA Approved) buried running
9786820|NCT01287520|Experimental|LY2090314/pemetrexed/carboplatin|"Part A, Cycle 1 (28 days): Intravenous doses of LY2090314 starting at 10 milligram (mg) were given on Day 1 followed by 10 mg LY2090314, 500 milligram per square meter (mg/m^2) pemetrexed (intravenous dose), and 5 or 6 area under the concentration-time curve (AUC) intravenous dose of carboplatin on Day 8.~Part A, Cycle 2 (21 days): Pemetrexed and carboplatin given on Day 1 at the same dose administered in Cycle 1.~Part A, Cycle 3 (21 days) and beyond: LY2090314, Pemetrexed and carboplatin were given on Day 1 at the same dose administered in Cycle 1. LY2090314 doses were escalated until the maximum tolerated dose (MTD) was reached.~Part B: Dose determined in Part A was administered. Participants were allowed to continue the combination treatment if they were receiving therapeutic benefit until they fulfilled one of the criteria for discontinuation."
9786821|NCT01287754|Experimental|Single Arm|
9786822|NCT01287832|Active Comparator|High dose vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
9786823|NCT01287832|Experimental|High-dose daptomycin|Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
9786824|NCT01287897|Placebo Comparator|Placebo- SC injection|
9786825|NCT01287897|Experimental|Drug Dose level 1 - SC injection|
9786826|NCT01287897|Experimental|Drug Dose level 2 - SC injection|
9786827|NCT01288027|Experimental|Alglucosidase Alfa|
9786828|NCT01288053|Experimental|Allogeneic Stem Cell Therapy|Allogeneic Stem Cell Therapy will be performed after conditioning
9786829|NCT01288079|Experimental|1|TC-5214, 1 mg BID
9786830|NCT01288079|Experimental|2|TC-5214, 4 mg BID
9786831|NCT01288079|Active Comparator|3|Duloxetine 60 mg Q Day
9786832|NCT01288079|Placebo Comparator|4|Placebo
9786833|NCT01288209|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
9786834|NCT01288209|Experimental|TMC435 100 mg 24 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin ( PR) for 24 weeks (Wks). Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
9786835|NCT01288287||Week 12 Disease Activity Score (DAS) Responders|Patients achieving a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
9786836|NCT01288287||Week 12 Disease Activity Score (DAS) Non-Responders|Patients who fail to achieve a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
9786837|NCT01288430|Experimental|DS-2248|"Study Part 1: DS-2248 oral capsule(s) of increasing strength in a dose escalation study in subjects with advanced solid tumors, administered once daily in 21-day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression is observed.~Study Part 2: DS-2248 oral capsule(s) dose of 4.5 mg/m^2, in subjects with non-small cell lung cancer who have developed acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors or whose tumors carry an ALK translocation and are resistant to ALK inhibitor therapy, administered once daily in 21 day-cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed."
9786838|NCT01288443|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
9786839|NCT01288443|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
9786840|NCT01288443|Experimental|Alirocumab 100 mg Q2W|Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
9786841|NCT01288443|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
9786842|NCT01288443|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
9786843|NCT01288443|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
9786844|NCT01288469|Placebo Comparator|Placebo + Atorvastatin 80 mg|Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.
9786845|NCT01288469|Experimental|Alirocumab + Atorvastatin 10 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.
9786846|NCT01288469|Experimental|Alirocumab + Atorvastatin 80 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.
9786847|NCT01288521|Experimental|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
9786848|NCT01288521|Experimental|Tacrolimus alone, Then Tacrolimus + Ketoconazole|The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
9786849|NCT01288534|Experimental|Radiation Treatment|
9836746|NCT05261425|Active Comparator|Monocryl buried interrupted|Upper extremity primary surgical wound closure via suture with Monocryl buried interrupted
9836747|NCT05261425|Active Comparator|Monocryl not buried interrupted|Upper extremity primary surgical wound closure via suture with Monocryl not buried interrupted
9836748|NCT05261425|Active Comparator|Monocryl not buried running|Upper extremity primary surgical wound closure via suture with Monocryl not buried running
9836749|NCT05261425|Active Comparator|Gut (FDA Approved) not buried interrupted|Upper extremity primary surgical wound closure via suture with Gut (FDA Approved) not buried interrupted
9836750|NCT05261425|Active Comparator|Nylon (FDA Approved) not buried interrupted|Upper extremity primary surgical wound closure via suture with Nylon (FDA Approved) not buried interrupted
9836751|NCT05261425|Active Comparator|Nylon not buried running|Upper extremity primary surgical wound closure via suture with Nylon not buried running
9836752|NCT05260645|Experimental|Experimental group|Intervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
9836753|NCT05260645|No Intervention|Control group|I declare that I will not change my lifestyle during the study process.
9836754|NCT05259930|No Intervention|Chronic gastrointestinal disease (IBD and liver cirrhotic patients)|Liver cirrhotic patients to receive best practice nutritional assessment and supports
9836755|NCT05259930|Experimental|branched-chain amino acid (BCAA)|Liver cirrhotic patients to receive best practice nutritional assessment and supports in addition to a 12-week course of BCAA supplementation
9836756|NCT05259930|No Intervention|Healthy Control|Controls attending gastroenterology outpatient or endoscopy services with no chronic inflammatory GI disease.
9836757|NCT05259917|Placebo Comparator|Placebo|
9836758|NCT05259917|Experimental|KVD900 600 mg|
9836759|NCT05259917|Experimental|KVD900 300 mg|
9836760|NCT05259527|Experimental|Vitamin D Replacement|Participants will receive prescribed oral vitamin D2 to achieve a serum vitamin D level between 30 ng/mL to 50 ng/mL.
9836761|NCT05259527|Active Comparator|Standard of Care|Participants will receive standard-of-care advice to take over the counter vitamin D.
9836762|NCT05259436|Experimental|Caregiver-Child Intervention|Investigators will examine the immediate psychosocial, behavioral, and child biologic response to three caregiver-child interventions depending on site of enrollment. Each interventions contain overlapping core elements, but also contribute unique facets, allowing us to examine overall intervention effects, as well as unique settings (e.g. home vs. clinic) and delivery effects (1:1 vs. group), providing insight for future direction.
9836763|NCT05259436|Active Comparator|Enhanced Primary Care|Navigational services for social need resources.
9836764|NCT05257850|Active Comparator|Fan first|Patients use the fan first and high-flow nasal therapy thereafter
9836765|NCT05257850|Active Comparator|High-flow nasal therapy first|Patients use high-flow nasal therapy first and the fan thereafter
9836766|NCT05257590|Experimental|Nivolumab + CVM-1118|"1 Cycle = 28 days~Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.~CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID.~Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3~Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
9836767|NCT05256355|Other|MSUS novices|Measurement of competence
9836768|NCT05256355|Other|MSUS intermediates|Measurement of competence
9836769|NCT05256355|Other|MSUS experts|Measurement of competence
9836770|NCT05256108|Experimental|Cebranopadol 600 µg|Single oral dose of 6 capsules containing 3 cebranopadol 200 µg tablets and placebo
9836771|NCT05256108|Experimental|Cebranopadol 1000 µg|Single oral dose of 6 capsules containing 5 cebranopadol 200 µg tablets and placebo
9836772|NCT05256108|Active Comparator|Oxycodone 40 mg|Single oral dose of 6 capsules containing 2 oxycodone 20 mg and placebo
9836773|NCT05256108|Active Comparator|Tramadol 600 mg|Single oral dose of 6 capsules containing 6 tramadol 100 mg tablets
9836774|NCT05256108|Placebo Comparator|Placebo|Single oral dose of 6 capsules containing placebo
9836775|NCT05254431|Experimental|Exercise|The Experimental Design is a randomized trial of Moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls
9836776|NCT05254431|No Intervention|Usual Care|Participants in the control group will be instructed to maintain their routine activity level for 12 weeks
9836777|NCT05253001|Experimental|study group|use mobile chatbot approach to improve prenatal education
9836778|NCT05253001|Placebo Comparator|controp group|a traditional approach to prenatal education
9921895|NCT00832351|Experimental|1|Early mobilisation within 24 hours after admittance to hospital
9921896|NCT00832351|No Intervention|2|Mobilisation after 24 but within 48 hours from admittance to hospital
9921897|NCT00832364|Experimental|1|U0279 and Injectable Biologic
9836779|NCT05250388||Patient group|"Patients aged 18-40 years with symptomatic unilateral traumatic anterior shoulder instability, due to dislocation or subluxation, scheduled for arthroscopic Bankart repair.~The study is not interventional but observational, examining biomechanical and proprioceptive conditions in patients' unstable shoulders before and after the surgical procedure."
9836780|NCT05245071|Experimental|Tusamitamab ravtansine|Tusamitamab ravtansine dose will be administered on Day 1 via IV infusion and repeated once every 2 weeks. The duration of 1 cycle will be 14 days (1 administration of tusamitamab ravtansine per cycle).
9836781|NCT05244876|Experimental|Experimental group|Intervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
9836782|NCT05244876|No Intervention|Control group|I declare that I will not change my lifestyle during the study process.
9921898|NCT00832364|Placebo Comparator|2|Placebo and Injectable Biologic
9921899|NCT00832403||polytetrafluoroethylene|
9786850|NCT01288612|Active Comparator|Sedated Endoscopy|Sedated esophagogastroduodenoscopy with biopsy
9786851|NCT01288612|Active Comparator|Transnasal Endoscopy at Hospital Unit|Unsedated transnasal endoscopy at hospital unit.
9786852|NCT01288612|Active Comparator|Transnasal Endoscopy at Mobile Unit|Unsedated transnasal endoscopy in mobile research van
9786853|NCT01288729|Experimental|Group 1 - Steel Cathetar, then Teflon|Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
9786854|NCT01288729|Experimental|Group 2 - Teflon Cathetar, the Steel|Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
9786855|NCT01288781|Experimental|Acetazolamide|Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
9786856|NCT01288781|Placebo Comparator|Placebo|Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
9786857|NCT01288807|Experimental|Treatment|Titrated Milnacipram doses
9786858|NCT01288833|Experimental|Close focus HD NBI Colonoscopy System|Use of close focus to make optical diagnosis
9786859|NCT01288833|No Intervention|Current HD NBI Colonoscopy System|Use of standard focus for optical diagnosis
9786860|NCT01288859|Experimental|encapsulated curcumin|
9786861|NCT01288859|Experimental|encapsulated curcumin + PQG|PQG means Piperine, Quercetin and Genistein
9786862|NCT01288859|Active Comparator|free cocoa polyphenol|
9786863|NCT01288859|Placebo Comparator|control|
9786864|NCT01288859|Experimental|encapsulated cocoa polyphenols|
9786865|NCT01288859|Active Comparator|free curcumin|Subjects will consume bread added with free curcumin
9786866|NCT01288911|Experimental|Enzalutamide|Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
9786867|NCT01288911|Active Comparator|Bicalutamide|Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
9786868|NCT01288937|Experimental|Milnacipran|Patients will receive Milnacipran
9786869|NCT01288937|Placebo Comparator|Placebo|Patients will receive Placebo
9786870|NCT01288976||MitraClip Therapy|Patients treated with the MitraClip System.
9786871|NCT01288976||Medical Management|Patients with MR managed non-surgically based on standard hospital clinical practice.
9786872|NCT01288976||Mitral Valve Surgery|Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
9786873|NCT01288989|Experimental|IMC-3C5|Participants receiving IMC-3C5 intravenously
9786874|NCT01289015|Experimental|NAFT-600 ( naftin 2 % gel)|
9786875|NCT01289015|Placebo Comparator|Placebo|
9786876|NCT01289028|Experimental|Nilotinib|nilotinib 400 mg twice daily (bid).
9786877|NCT01289041|Experimental|All Patients|
9786878|NCT01289067|Other|Satraplatin, Single Arm|
9786879|NCT01289080|Active Comparator|Group 1|subjects with normal renal function
9786880|NCT01289080|Active Comparator|Group 2|severely renally impaired subjects
9786881|NCT01289119|Placebo Comparator|Placebo|Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
9786882|NCT01289119|Experimental|Alogliptin Monotherapy|Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
9786883|NCT01289119|Other|Metformin|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
9786884|NCT01289119|Experimental|Metformin + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
9786885|NCT01289119|Other|Pioglitazone|Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
9786886|NCT01289119|Experimental|Pioglitazone + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
9786887|NCT01289210|Other|VTX-2337 plus radiation|
9786888|NCT01289275|Experimental|Telephone Counseling|Up to 5 proactive counseling sessions
9996779|NCT01503138|No Intervention|Standard community health education program|The community health education programme consists of two group sessions with one on the topic of osteoporosis and one on dietary therapy based on the concepts of Chinese medicine.
9786889|NCT01289275|Experimental|Nicotine Patches|8 weeks of nicotine patches
9786890|NCT01289275|Experimental|Telephone Counseling + Patches|5 proactive sessions, 8 weeks patches
9786891|NCT01289275|Active Comparator|Brief hospital counseling|brief in hospital counseling, no proactive sessions or patches
9786892|NCT01289353|Experimental|ChemoRT|Concurrent Carboplatin and Radiotherapy
9786893|NCT01289392|Active Comparator|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard treatment
9786894|NCT01289392|Active Comparator|Oral Appliance|Alternative treatment for obstructive sleep apnea patients
9786895|NCT01289392|Active Comparator|Physical Exercise|Aerobic and resistance physical exercises
9786896|NCT01289418||Health care workers in Québec|Health care workers from CHUQ hospitals
9786897|NCT01289418||Health care workers in Toronto|Health care workers from the Mount Sinai Hospital
9786898|NCT01289418||Health care workers in Halifax|Health care workers from the Queen Elizabeth Hospital
9786899|NCT01289431|Experimental|Mapracorat|
9786900|NCT01289431|Placebo Comparator|Mapracorat Vehicle|
9786901|NCT01289457|Experimental|Clofarabine + Idarubicin + Cytarabine|Phase I: Clofarabine Starting dose 15 mg/m2 by vein for 5 days (days 1-5) + Idarubicin 10 mg/m2 by vein on day 1-3 + Cytarabine 1 g/m2 by vein on day 1-5.
9786902|NCT01289457|Experimental|Group 1 CIA|Phase II, Group 1 CIA (Clofarabine + Idarubicin + Cytarabine): Clofarabine Maximum Tolerated Dose (MTD) based on Phase I by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
9786903|NCT01289457|Experimental|Group 2 FLAI|Phase II, Group 2 FLAI (Fludarabine + Idarubicin + Cytarabine): Fludarabine 30 mg/m2 by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
9786904|NCT01289522|Experimental|cetuximab|Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according
9786905|NCT01289548|No Intervention|control|patients (both donors and recipients) had a deflated cuff placed on the left lower limb for 30 min
9786906|NCT01289548|Experimental|donor|Donors receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; recipients only have a deflated blood pressure cuff around their leg for 30 minutes.
9786907|NCT01289548|Experimental|recipient|recipients receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; donors only have a deflated blood pressure cuff around their leg for 30 minutes.
9786908|NCT01289574|Placebo Comparator|Vehicle control cream|
9786909|NCT01289574|Experimental|0.025% ASC-J9 cream|
9786910|NCT01289574|Experimental|0.1% ASC-J9 cream|
9786911|NCT01289639|Placebo Comparator|Placebo|matching placebo 1 po qd
9836783|NCT05241366|Experimental|Transcranial Magnetic Stimulation + usual treatment with SSRIs|"Transcranial Magnetic Stimulation + SSRIs The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over right dorsolateral prefrontal cortex with a total of 1500 each session.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
9836784|NCT05241366|Sham Comparator|Sham TMS coil + usual treatment with SSRIs|"The sham TMS coil group will be comprised of 10 patients, sham TMS stimulation will be performed with the B-65 coil, which has similar sound and scalp contact to those experienced during active stimulation. The duration of treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
9836785|NCT05239585|Experimental|Remote EEG monitoring|All subjects will pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
9996780|NCT01503151|Placebo Comparator|Placebo|repeated trials of a dot-probe task and repeated trials of an interpretation task, both not intended to change threat-related biases patterns.
9996781|NCT01503151|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
9996782|NCT01503151|Experimental|Interpretation Bias Modification (IBM)|Interpretation training intended to facilitating a more benign interpretation bias
10205609|NCT05204810|Experimental|Night_2doses|"anticoagulation split over dialysis start and halfway dialysis (after 4h)~blood sampling 5min after start dosis, and at 1h, 4h (1 sample before and 1 sample after the extra anticoagulant dosis) and 8h after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
10205610|NCT05204797|Experimental|Robot-assisted UKA|Unicompartmental knee replacement (Journey II UKA, Smith and Nephew, USA) positioned via CORI surgical system (Smith & Nephew, USA).
9836791|NCT05237362|Experimental|Intervention|Receives the Saga Stories health promotion talk as well as take-home material
9836792|NCT05237362|No Intervention|Control|Receives standard health promotion talk
9836793|NCT05236231|Experimental|Treatment Sequence ABC|Participants will receive single oral dose of fixed dose combination (FDC) of macitentan/tadalafil under fasting conditions in (test) (Treatment A) Treatment Period 1 followed by single oral dose of FDC of macitentan/tadalafil under fed conditions (test) (Treatment B) in Treatment Period 2 and then single oral dose of macitentan/tadalafil under fasting conditions (reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
9836794|NCT05236231|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
10205611|NCT05204797|Active Comparator|Standard technique UKA|Unicompartmental knee replacement (Journey II UKA, Smith and Nephew, USA) positioned via standard technique.
10205612|NCT05204771||Normal foetus|All pregnant women reffered for 3rd trimester routine ultrasound examination without any fetal abnormality
9836795|NCT05236231|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
9836796|NCT05236231|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment C in Treatment Period 2 and Treatment B in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
9836797|NCT05236231|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and Treatment A in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
9836798|NCT05236231|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1 followed by Treatment A in Treatment Period 2 and Treatment C in Treatment Period 3. There will be a wash-out period of at least 12 days between Day 1 of subsequent treatment period.
9836799|NCT05233956|Experimental|LNG IUS|Levonorgestrel intrauterine system
9836800|NCT05233956|Active Comparator|COC|Combined oral contraceptives with ferrous fumarate tables in regimen
10205613|NCT05204758|Experimental|Study arm|Patients receive afatinib and TCM. TCM recipe was chosen from three essential TCM formulas, including Bai He Gu Jin Tang (yin nourishing), Wen Dan Tang (phlegm reducing), and Qing Shang Fang Fen Tang (heat clearing). The packages contained 1.6 g TCM preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of TCM preparations with each meal three times a day, for a total of nine packages per day. Administration of TCM was initiated at the same time as afatinib and continued for a total of three months.
10205614|NCT05204758|Placebo Comparator|Control arm|Patients receive afatinib and placebo. Placebo without the medical ingredients was prepared to be similar to the weight, color, smell, taste, and packaging of the TCM formulas. The packages contained 1.6 g placebo preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of placebo preparations with each meal three times a day, for a total of nine packages per day. Administration of placebo was initiated at the same time as afatinib and continued for a total of three months.
10205615|NCT05204745||Case|Subjects with subjective gait impariment according to questionnaire answers.
10205616|NCT05204745||Control|Subjects without subjective gait impariment according to questionnaire answers.
10205617|NCT05204719|Experimental|Continuous Positive Airway Pressure|
10205618|NCT05204719|No Intervention|No Continuous Positive Airway Pressure|
10205619|NCT05204693|Sham Comparator|Start with: Concentric (normal) cycling|
10205620|NCT05204693|Experimental|Start with: Eccentric cycling|
9836801|NCT05229263|Experimental|Healthy volunteers|
9836802|NCT05229263|Experimental|CKD patients|
9836803|NCT05225415|Active Comparator|CT1812 300 mg|CT1812 300 mg
9836804|NCT05225415|Active Comparator|CT1812 100 mg|CT1812 100 mg
9836805|NCT05225415|Placebo Comparator|Placebo|Placebo
10205621|NCT05204680|Experimental|Aerobic Exercise|"The participant will work with the physical therapist on an exercise regimen and first session will be supervised with the therapist. Exercise protocols will include a 15-minute warmup and cooldown session as well. To allow for increased participation and accessibility, the means of aerobic exercise will not be restricted and any safe mechanism of exercise will be allowed e.g., treadmill, stationary bike, etc.~Subjects will be provided an activity monitor (Phillips HealthBand Monitor) for the duration of study participation and receive training on how to use it, including marking events with start and stop of exercise sessions and tracking heart rate. The device can track type of activity as well as cardio fitness index and VO2max."
10205622|NCT05204667|Experimental|Methocarbamol 380 mg/paracetamol 300 mg (4 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 4 times/day up to 7 days (i.e., every 6 hours±1 hour).
9836806|NCT05223803|Active Comparator|Best systemic therapy (BST) + primary prostate radiation (XRT)|
9836807|NCT05223803|Active Comparator|BST + XRT + SABR metastasis-directed therapy (MDT)|
9836808|NCT05223231|Experimental|LBL-019|singal -arm
9836809|NCT05221658|Experimental|Arm A|As first-line therapy
9836810|NCT05221658|Experimental|Arm B1|EGFR H score ≥ 200, as third-line or above therapy
9996783|NCT01503151|Experimental|Attention and interpretation biases modification|Attention and interpretation training intended to direct cognitive biases away from threat stimulus.
9996784|NCT01503177|Experimental|Treatment (viral therapy)|Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
9836811|NCT05221658|Experimental|Arm B2|EGFR H score <200, as third-line or above therapy
9836812|NCT05221021|Active Comparator|Vaginal Estradiol with placebo oral pill|Patient will receive 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
9836813|NCT05221021|Active Comparator|Oral Mirabegron with placebo vaginal cream|Patient will receive 50 milligrams oral Mirabegron once daily and placebo vaginal cream (Medisca's VersaPro Cream Base) once nightly for two weeks then three times per week
9836814|NCT05220670|Experimental|HIIT Group|This group receives a training in which intervals of intense work and periods of active rest are combined using a cycle ergometer with an intensity of 85-95% of the maximum heart rate [MHR], followed by intervals of active rest of 3 minutes duration. at 50-70% MCF.
9836815|NCT05220670|Experimental|MICT Group|The participants will perform a training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be controlled individually.
9836816|NCT05220670|No Intervention|Control Group|The participants will receive advice on the general positive effects of the regular practice of physical activity, and will be given the guide of recommendations for the promotion of physical activity.
9836817|NCT05219968|Experimental|LYR-210|Single administration of LYR-210 drug matrix (7500 μg)
9836818|NCT05219968|Sham Comparator|Sham procedure control|Single mock administration procedure
9836819|NCT05219812|Experimental|Group 1 (BAY2395840 - placebo)|Participants will be randomly assigned to treatment regimen of double-blind BAY2395840, and after an interim single blind period for washout will switch to double-blind placebo.
9836820|NCT05219812|Experimental|Group 2 (Placebo - BAY2395840)|Participants will start with a treatment regimen of double-blind placebo, and after an interim single blind period for washout will switch to double-blind BAY2395840.
9836821|NCT05219552|Experimental|Intervention group- lactation support and unconditional cash transfers|Women in this arm will receive personal lactation support from a professional lactation specialist at 5 time points: pregnancy and at 2-weeks, 4-weeks, 6-weeks and 3-months postpartum. Women in the intervention group will also receive monthly unconditional cash transfers of 10,000 Kenyan shillings sent directly to a a mobile phone-based money transfer service accounts associated with their personal cell phone.
10205623|NCT05204667|Active Comparator|Methocarbamol 380 mg/paracetamol 300 mg (6 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 6 times/day up to 7 days (i.e., every 4 hours±1 hour).
10205624|NCT05204641|Active Comparator|Fecal microbiota transplant|"Pretreatment with rifaximin 3x 400 mg PO for 7 days Fecal Microbiota Transfer from healthy donor during colonoscopy. Assessments in clinical scales: 30 days, 90 days and 12 months: Unified Parkinson Disease Rating Scale, Constipation Assessment Scale, Parkinson Disease Questionnaire-39, Non- Motor Symptoms Questionnaire, Gastrointestinal Dysfunction Scale for Parkinson Disease.~Assessment of levodopa/benserazide 100+25 mg tablet before and 90 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention"
9836822|NCT05219552|No Intervention|Control group- standard care|The women enrolled in the control arm will receive standard care at a clinic similar to, but distinct from, the intervention site.
9836823|NCT05215535|Experimental|MRI group|An abbreviated MRI of the liver/abdomen
9836824|NCT05215535|Active Comparator|CT group|A combined single venous and 3 min equilibrium phase CT of the abdomen/liver
9836825|NCT05215353|Experimental|Music Therapy (MT)|MT is a non-pharmacological, evidence-based intervention, in which board-certified music therapists engage patients in personally tailored experiences with music to achieve therapeutic goals. Patients will receive a workbook with materials for each session These experiences range from music-guided relaxation to more active forms of musical engagement, including singing and improvising music.
9836826|NCT05215353|Active Comparator|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) is an evidence-based, nonpharmacological intervention delivered by licensed mental health providers. Informed by the cognitive behavior model of anxiety, CBT focuses on the relationship between thoughts, behaviors, and emotions and how thoughts and behaviors can exacerbate or reduce anxiety.
9984775|NCT03734523||Study Group: 6 month study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for six months. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
9984776|NCT03733119|Experimental|Akt/ERK inhibitor ONC201|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9836829|NCT05211505|Experimental|WO 2707|Formulation containing WO 2707 for intravaginal application
10205625|NCT05204641|Placebo Comparator|Autotransplant|"Pretreatment with rifaximin 3x 400 mg PO for 7 days Autotransplant of patients own microbiota collected in screening period during colonoscopy.~Assessments in clinical scales: 30 days, 90 days and 12 months: Unified Parkinson Disease Rating Scale, Constipation Assessment Scale, Parkinson Disease Questionnaire-39, Non- Motor Symptoms Questionnaire, Gastrointestinal Dysfunction Scale for Parkinson Disease.~Assessment of levodopa/benserazide 100+25 mg tablet before and 90 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention"
9836831|NCT05206500|Other|Symptomatic Patients with low Colony Count|Patients with positive urinalysis, symptomatic, and Urine Culture Colony Count <10,000 to be treated based on Next Generation Sequencing result.
9836832|NCT05206422|Experimental|ADHF patients|ADHF patients with insufficient response to diuretics treated with the Doraya catheter
9836833|NCT05203965|Experimental|FHP; Mavoglurant-Placebo|Family History Positive (FHP) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
9836834|NCT05203965|Experimental|FHP; Placebo-Mavoglurant|Family History Positive (FHP) or alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
9836835|NCT05203965|Experimental|FHN; Mavoglurant-Placebo|Family History Negative (FHN) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
9836836|NCT05203965|Experimental|FHN; Placebo-Mavoglurant|Family History Negative (FHN) for alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
9836837|NCT05203939|Experimental|Cohort 1 (Low Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation or RHO mutations subgroup
9836838|NCT05203939|Experimental|Cohort 2 (Mid Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation or RHO mutations subgroup
9836839|NCT05203939|Experimental|Cohort 3 (High Dose)|Biallelic autosomal recessive NR2E3 mutations subgroup or Autosomal dominant NR2E3 mutation or RHO mutations subgroup
9836840|NCT05201183|Experimental|Fludarabine + Total Marrow Irradiation|Fludarabine will be administered sequentially after the administration of TMI. TMI will be delivered on Days -10, -9, -8, -7, and -6 (1.4-2.2 gray (GY)/fraction, twice a day) followed by fludarabine on Days -5, -4, -3, -2, and -1 (150 mg/m2, 30 mg/m2/day)
9836841|NCT05200598||Mild psoriasis|
9836842|NCT05200598||Moderate psoriasis|
9836843|NCT05200598||Severe psoriasis not receiving systemic therapy|
9836844|NCT05200598||Severe psoriasis receiving systemic therapy with genetic-engineering biological drugs|
9836845|NCT05200598||Patients without psoriasis|
9836846|NCT05199779|Experimental|Self-Compassion Intervention (SCI)|First, participants will be taught to implement a 20-second self-compassion induction via video recording. Second, participants will be taught to choose a cue that will precede their daily use of the self-compassion induction. Participants will document the cue they chose, and will be emailed a record of their selected cue, along with the recording and transcript of the self-compassion induction that they can refer back to for reference. Third, participants will be asked to use the self-compassion induction as much as they can and at least once during their daily routine following exposure to their chosen cue.
9836847|NCT05199779|Active Comparator|Finger-Tapping Active Control (AC)|The active control will receive the same procedures as described above, except for receiving a different video containing different instructions describing a finger-tapping exercise. The videos will be virtually identical in length, quality, instructor/their outfit, and lighting.
9836848|NCT05199701|Other|Screening Subjects|Screening Subjects
9836849|NCT05199701|Other|Subjects recommended for biopsy|Subjects recommended for biopsy
9836850|NCT05196776|Experimental|Portable, Handheld Device|Patients will receive a point-of-care ultrasound using a handheld, portable ultrasound device.
9836851|NCT05196776|Active Comparator|Traditional, Cart-based Ultrasound|Patients will receive a point-of-care ultrasound using a traditional, cart-based ultrasound machine.
10205626|NCT05204628|Experimental|XZP-3621|Participants will receive XZP-3621 tablets orally at a dose of 500 mg QD with food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
10205627|NCT05204628|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
10205628|NCT05204550|Experimental|intranasal heparin|"Unfractionated heparin (UFH) 1400u each nostril (as heparin solution 5,000u/ml, 140 microL/actuation, Two actuations each nostril) Three times daily via a plastic nasal inhalator device (APTAR, UK) for 10 days.~This is a maximal dose per day of UFH of 8400u. ie 700 x 2 actuations per nostril (1400 x2) 3 times per day (1400x2x3 = 8400u)"
10205629|NCT05204550|Placebo Comparator|intranasal saline|Comparator 0.9% saline (as saline solution, 140 microlitres/actuation, Two actuations each nostril) Three times daily via a plastic nasal inhalator device(APTAR, UK) for 10 days.
9836852|NCT05195918|Active Comparator|EGCG + Nintedanib|Patients enrolled in this group will be given oral capsule EGCG 400 mg daily with doctor provided Nintedanib for 12 weeks. If no safety concerns, enrollment will begin into the higher dose group EGCG 600 mg with Nintedanib.
9836853|NCT05195918|Active Comparator|EGCG + Pirfenidone|Patients enrolled in this group will be given oral capsule EGCG 400 mg daily with doctor provided Pirfenidone for 12 weeks. If no safety concerns, enrollment will begin into the higher dose group EGCG 600 mg with Pirfenidone.
9836854|NCT05195918|Placebo Comparator|Placebo + Pirfenidone or Nintedanib|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided Pirfenidone or Nintedanib.
9836855|NCT05195866|Active Comparator|Group A - CRP POCT|Participants assigned to Group A will take C-reactive protein (CRP) point of care test (POCT) during a check-up with their healthcare worker (HCW). The assistant investigator will attend the child's consultation with the local HCW and complete the case report form (CRF). Consequently, the CRP result will be recorded in the CRF, which will be the basis for choosing a treatment, depending on its result.
9836856|NCT05195866|No Intervention|Group B - Usual care|HCWs will also consult children who have been randomised to Group B. The assistant investigator will complete the CRF for these children, but the CRP POCT will not test them. They will receive the treatment prescribed by the HCW as usual care
9836857|NCT05192603|Experimental|Dietary intervention with Low FODMAP|The participants are given oral and written instructions on which diet that contains low contents of FODMAP.
9836858|NCT05192603|Experimental|Dietary intervention with SSRD|The participants are given oral and written instructions on which diet that contains SSRD.
9836859|NCT05192226|Experimental|Counterfactual Strategy Intervention|After participants finish describing past events where they were unable to participate or engage in physical activity and have identified barriers which impacted their events they just described, participants will be randomly assigned to conditions. Participants in the counterfactual strategy condition will engage in counterfactual strategies on barriers they believe they could have reasonably acted on to increase physical activity in their described event(s) that would have led to a better outcome. After identifying the counterfactual strategies, participants will then select three counterfactual strategies they just identified that they could use at some point in the upcoming week, any obstacles to using that counterfactual strategy, ways to overcome those obstacles, their intention to use the counterfactual strategy over the next week, and how likely they think the counterfactual strategy would have happened and led to the better outcome.
9836860|NCT05192226|No Intervention|Control|Participants will be asked to describe past events where they were unable to participate or engage in physical activity. All participants will walk through the NIMHD framework with a researcher and be guided to identify barriers at various domains and levels of influence, which impacted their events they just described. After barrier identification, participants will be asked to select three barriers to talk aloud and list out additional details about the barriers identified.
9836861|NCT05191446|Experimental|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|For participants randomized to SAT, consistent with stepped care, treatment will begin with lower intensity services that are stepped up, if necessary, at a predefined time point. Step 1 consists of three motivational interviewing (MI)sessions delivered every 2 weeks. At the 3-month assessment, those with non-response to MI, defined as continued unhealthy alcohol use in the prior 14 days, will be referred to on site physician managed addiction specialty services (Step 2) for higher intensity services.
9836862|NCT05191446|Active Comparator|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
9984777|NCT03733119|Experimental|Akt/ERK inhibitor ONC201, methionine-restricted diet|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Participants also receive methionine-restricted diet PO on days 1-5, 8-12, and 15-19. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9984778|NCT03728127|Experimental|DicaBr group and nuts (DCBN)|Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
9984779|NCT03728127|Active Comparator|DicaBr group (DCB)|Brazilian cardioprotective diet
9984780|NCT03724669|Placebo Comparator|waiting list|
9836867|NCT05183633||One single trial|
9836868|NCT05182580|Experimental|Intervention Group|Autonomous AI results are used to evaluate if the participant needs to see the retina specialist (positive result) or not (negative result).
9836869|NCT05182580|No Intervention|Control Group|All participants see the retina specialist irrespective of the results of their autonomous AI evaluation.
9921900|NCT00832429|Experimental|Diagnostic (SLN localization and biopsy)|Patients receive technetium Tc 99m sulfur colloid ID and then undergo lymph node mapping and SLN biopsy.
9921901|NCT00832442||Beta blocker|
9921902|NCT00832442||Placebo|
9984781|NCT03724669|Experimental|Benzodiazepines and Z-drugs knowledge|
9984782|NCT03724305|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
9984783|NCT03724305|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
9836870|NCT05181657|Experimental|LinkUP Active intervention|"The counselor will present basic evidence-based COVID-19 information on SARS-CoV-2 biology and epidemiology, testing and the safety and efficacy of available COVID-19 vaccines. The counselor will also address COVID-19 misinformation (e.g., that COVID is no worse than the flu), and COVID-19 disinformation (e.g., that COVID vaccines include a tracking device).~The LinkUP active intervention combines education, motivational interviewing (MI), problem-solving, and ongoing support from peer counselors. Through an open discussion with one of OnPoint's peer counselors who are trained in MI, the counselor will present evidence-based COVID-19 information. Next, the counselor will attempt to identify the participant's concerns about COVID-19 and vaccination in an attempt to tip their decisional balance."
9836871|NCT05181657|Placebo Comparator|LinkUP Control Condition (didactic intervention)|As described above, the control condition is a one-way sharing of COVID-19 information presented by an OnPoint counselor. The counselor will be instructed to answer any questions the participant may have but will not engage in motivational interviewing counseling. The same educational materials used in the LinkUP intervention module will be used for this session and it will be completed within 45 minutes.
9836872|NCT05180786|Experimental|Stroke Participants|Single intervention session
9836873|NCT05180318|Placebo Comparator|0.9% saline preadministration group|0.9% saline will be given intravenously 24-36 hours before operation and immediately after operation
9836874|NCT05180318|Experimental|Esketamine preadministration group|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
9836875|NCT05179603|Experimental|Cohort A: (sub study 01) classic Hodgkin lymphoma (cHL)|SAR444245 and pembrolizumab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9836876|NCT05179551|Experimental|Proximal Medial Gastrocnemius Recession Surgery|Patients will be operated with Proximal Medial Gastrocnemius Recession Surgery (PMGR) ad modum Barouk.
9836877|NCT05179447|Experimental|Molecular profile based treatment|Determination of the integrated genomic-pathologic profile to determine adjuvant treatment: observation for POLE-mutated profile; vaginal brachytherapy for intermediate profile; chemo-radiotherapy for p53-abnormal profile.
9836878|NCT05179447|Active Comparator|Radiotherapy|Adjuvant vaginal brachytherapy for intermediate risk (stage I A with G3 or stage I B with G1-2) and external beam pelvic radiotherapy for high-intermediate risk (stage I B with G3, or stage II) (standard treatment)
9836879|NCT05178576|Experimental|Arm 1|ctDNA positive Gevokizumab for 1 year (maximum of 13 cycles)
9836880|NCT05177991|Active Comparator|Liposomal Bupivacaine (Exparel)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
9836881|NCT05177991|Active Comparator|Bupivacaine (Marcaine)|The bilateral TAP block will be performed by the department of anesthesia under ultrasound guidance using 20cc of local anesthetic per side. Additional local anesthetic will be supplied by the surgeon at the incision sites.
9836882|NCT05177770|Experimental|SRF617 in combination with etrumadenant and zimberelimab|All patients will receive SRF617 administered in combination with etrumadenant (AB928) and zimberelimab (AB122).
9836883|NCT05174702||Percutaneous surgery|Patient will have a percutaneous hallus valgus surgery
9836884|NCT05174702||conventional surgery|Patient will have a conventional hallus valgus surgery
9836885|NCT05173532|Experimental|Balance Training|Static and dynamic balance and gait stability training exercises are performed with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
9836886|NCT05173532|Active Comparator|Breathing and Stretching Exercises|Patients perform static stretches for all major muscle groups while performing diaphragmatic breathing with supervision by a physical therapist or physical therapist assistant for 30 minutes, 3 times per week, for 8 weeks.
9836887|NCT05170958|Experimental|Evaluation of LBL-024 Phase I/II study in patients with advanced solid tumors|Starting from the dose A , And then dose B, dose C, doseD, doseE, and dose F Q3W.
9984784|NCT03723928|Active Comparator|Arm I (usual care)|Patients will have imaging studies (modality and frequency per treating physician, however at a minimum frequency of every 12 weeks) alone or in conjunction with STMs (frequency determined by treating physician). Patients will continue with usual care disease monitoring for up to 312 weeks in the absence of disease progression.
9984785|NCT03723928|Experimental|Arm II (serum tumor directed disease monitoring)|Patients undergo disease specific serum tumor marker evaluation (CEA and either CA 15-3 or CA 27.29, whichever were tested at Step 1 Registration and Step 2 Registration) every 4-8 weeks (starting from randomization) without imaging until an elevation of at least one disease specific STM. In the event of an elevated STM, the patient will have imaging within 4 weeks to evaluate for disease progression. Patients continue with STMDDM for up to 312 weeks in the absence of disease progression.
9921903|NCT00832468|Placebo Comparator|sham ear acupressure|
9786912|NCT01289639|Experimental|Fenofibrate|micronized fenofibrate 200 mg 1 po qd
9786913|NCT01289639|Experimental|Pioglitazone|pioglitazone 30 mg po qd
9786914|NCT01289665|Experimental|Lubricating Gel|
9786915|NCT01289665|Active Comparator|Water|
9799307|NCT01656395|Experimental|Montelukast 10 mg + MK-1029|Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
9799308|NCT01656408|Experimental|Panel A: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
9799309|NCT01656408|Experimental|Panel B: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
9799310|NCT01656408|Experimental|Panel C: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
9799311|NCT01656408|Experimental|Panel D: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
9799312|NCT01656408|Experimental|Panel E-Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
9799313|NCT01656408|Experimental|Panel F - Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
9799314|NCT01656408|Experimental|Panel G - Healthy - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
9799315|NCT01656408|Experimental|Panel H - Crossover|MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
9799316|NCT01656408|Experimental|Panel I - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
9799317|NCT01656408|Experimental|Panel J - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
9799318|NCT01656460|Experimental|Stereotactic radiation Arm 1|"Dose Levels/total Dose~1 16 Gy"
9799319|NCT01656460|Experimental|Stereotactic radiation Arm 2|2 20 Gy
9799320|NCT01656460|Experimental|Stereotactic radiation Arm 3|3 24 Gy
9799321|NCT01656460|Experimental|Stereotactic radiation Arm 4|4 28 Gy
9799322|NCT01656486|Experimental|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
9799323|NCT01656629|Active Comparator|teriparatide|teriparatide 20 mcg sq for 3 months
9799324|NCT01656629|Active Comparator|Alendronate|70 mg po weekly for 3 months
9799325|NCT01656629|Active Comparator|calcium and vitamin D|calcium 630 mg vitamin D 500 units daily for 3 months
9799326|NCT01656733|Experimental|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
9799327|NCT01656733|Placebo Comparator|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
9799328|NCT01656759|No Intervention|Control Group|Control group. Will not receive the fibrin spray.
9799329|NCT01656759|Active Comparator|Treatment Group--Evicel Fibrin Spray|"Patient will receive the fibrin spray after implantation of device but before the wound is closed.~Patients will be randomized to receive spray or not and postop parameters measured."
9799330|NCT01656772|Active Comparator|Manual Lasso navigation|Use of conventional manual navigation techniques with the Lasso catheter
9799331|NCT01656772|Experimental|Vdrive Lasso navigation|Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter
9799332|NCT01656850|Experimental|Almond diet first, then NCEP Diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
9799333|NCT01656850|Experimental|NCEP diet first, then Almond diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
9799334|NCT01656889|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
9799335|NCT01656889|Placebo Comparator|Vehicle|Vehicle Control (fibrinogen solution & thrombin solution without cells)
9799336|NCT01656967|Experimental|AMBU Aura-I/aScope 2|First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
9799337|NCT01656967|Experimental|LMA Fastrach|The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
9799338|NCT01657019|Experimental|Lisdexamfetamine dimesylate|
9799339|NCT01657032|Experimental|Lactobacillus GG and Smectite|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~smectite, dose 3 g, once daily orally until diarrhea stopped"
9921904|NCT00832468|Experimental|ear acupressure|
9921905|NCT00832481|Active Comparator|Repaglinide,tablet|
9921906|NCT00832481|Active Comparator|Metformin, tablet|
9921907|NCT00832546|Placebo Comparator|1|Placebo
9921908|NCT00832546|Experimental|2|Powder in solution
9921909|NCT00832546|Experimental|3|
9921910|NCT00832559|Experimental|CVA21|CVA21
9921911|NCT00832611|Experimental|Experimental: Group A Anastomotic Coupler|Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
9921912|NCT00832663|Experimental|NSAID|receive NSAID
9984786|NCT03720704||GORE VIABAHN VBX Balloon Expandable Endoprosthesis|The GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted according to the institution standard of practice in patients needing preservation of peripheral vessels due to multiple pathologies and conditions.
9984787|NCT03719183||Acute Myeloid Leukemia (AML) group|"Patients who are diagnosed as Acute Myeloid Leukemia based on peripheral blood, bone marrow aspiration and immunophenotyping and fulfill WHO criteria for diagnosis.~Fluorescent in Situ Hybridization (FISH) Panels for AML, Multiplex FISH (M-FISH) and Conventional Cytogenetics Studies will be performed for AML patients."
9984788|NCT03718637|Active Comparator|Control|Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.
9984789|NCT03718637|Experimental|Experimental|Identical surgical treatment plus Smith & Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
9984790|NCT03717935|Experimental|Essential Amino Acid (EAA) Supplement|4 weeks: Essential Amino Acid Supplement- 15g 2/day
9984791|NCT03717935|Placebo Comparator|Placebo|4 weeks: Placebo- 15g 2/day
9836898|NCT05167825|Experimental|Macitentan|Participants will receive oral dose of macitentan based on age and weight through Week 52.
9836899|NCT05166980|Experimental|FePP-Q5S|Salt fortified with iron in the form of ferric pyrophosphate (at 1.3 mg of iron per gram of salt) plus ethylenediaminetetraacetic acid (EDTA) as an enhancer of absorption, zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the FePP-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
9836900|NCT05166980|Experimental|eFF-Q5S|Salt fortified with iron in the form of encapsulated ferrous fumarate (at 1.3 mg of iron per gram of salt), zinc in the form of zinc oxide (at 1.4 mg of zinc per gram of salt), vitamin B12 (at 0.6 ug of vitamin B12 per gram of salt), folic acid (at 52 ug per gram of salt) and iodine (at 30 mg of iodine per gram of salt). Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the eFF-Q5S will deliver an average of 6.0 mg of iron, 6.4 mg of zinc, 2.8 ug of vitamin B12, 241 ug of folic acid, and 138 mg of iodine to each participating woman per day.
9836901|NCT05166980|Active Comparator|Iodized Salt|Iodized salt containing 30 mg of iodine per gram of salt. Mean intake of discretionary salt among women of reproductive age in the study area is 4.6 grams per day. Therefore, the iodized salt will deliver an average of 138 mg of iodine to each participating woman per day.
9836902|NCT05166395|Experimental|Er:YAG laser Group|The study is a split-scar model. Participants will have half of their lesion receive a total of three sessions using 2940 nm Er:YAG laser spaced over a 4-week study participation interval.
9836903|NCT05166395|No Intervention|Control (No Intervention) Group|The study is a split-scar model. Participants will serve as their own control and have half of their lesion receive no intervention.
9836904|NCT05166109|Experimental|Vamorolone 500mg/day [250mg if <50kg body weight]|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
9836905|NCT05166109|Placebo Comparator|Placebo|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
9836906|NCT05163353|Experimental|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
9984792|NCT03716921|Experimental|Short antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 3 weeks
9984793|NCT03716921|No Intervention|Long antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care
9996785|NCT01503203|Experimental|Wii Group|This group will do the same training of the Prime Group. However will do also Physical Virtual Training using Nintendo Wii and Wii Balance Board. The physical virtual training going to applied during thirty minutes.
9996786|NCT01503203|Active Comparator|Prime Group|This group will do strength exercises and core training.
9996787|NCT01503216|Experimental|cholecalciferol|Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
9996788|NCT01503216|Experimental|Ergocalciferol|Ergocalciferol 2000 IU per day for 8 weeks
9996789|NCT01503216|Placebo Comparator|Placebo|Placebo for 8 weeks
9786916|NCT01289678|Experimental|interleukin-2|interleukin-2 therapy during lymphocyte recovery
9786917|NCT01289782|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
9786918|NCT01289782|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
9786919|NCT01289821|Experimental|Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)|On Day 1, participants received 85 mg/m^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.
9786920|NCT01289847|Experimental|Gammaplex|
9786921|NCT01289912|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
9786922|NCT01289912|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
9786923|NCT01289990|Experimental|BI 10773 low (drug naive)|BI 10773 tablets once daily
9786924|NCT01289990|Experimental|BI 10773 high (drug naive)|BI 10773 tablets once daily
9786925|NCT01289990|Placebo Comparator|Placebo (drug naive)|Placebo tablets matching BI 10773 / Sitagliptin once daily
9786926|NCT01289990|Active Comparator|Sitagliptin 100mg (drug naive)|Sitagliptin once daily
9786927|NCT01289990|Experimental|BI 10773 low (pioglitazone)|BI 10773 tablets once daily
9786928|NCT01289990|Experimental|BI 10773 high (pioglitazone)|BI 10773 tablets once daily
9786929|NCT01289990|Placebo Comparator|Placebo (pioglitazone)|Placebo tablets matching BI 10773 once daily
9786930|NCT01289990|Experimental|BI 10773 low (metformin)|BI 10773 tablets once daily
9786931|NCT01289990|Experimental|BI 10773 high (metformin)|BI 10773 tablets once daily
9786932|NCT01289990|Placebo Comparator|Placebo (metformin)|Placebo tablets matching BI 10773 once daily
9786933|NCT01289990|Experimental|BI 10773 low (metformin+sulfonylurea)|BI 10773 tablets once daily
9786934|NCT01289990|Experimental|BI 10773 high (metformin+sulfonylurea)|BI 10773 tablets once daily
9786935|NCT01289990|Placebo Comparator|Placebo (metformin+sulfonylurea)|Placebo tablets matching BI 10773
9786936|NCT01290029|Experimental|Cinacalcet|Participants received a single, oral dose of 0.25 mg/kg cinacalcet.
9786937|NCT01290068|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, bilateral implantation
9786938|NCT01290068|Experimental|ReSTOR +3 Toric|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
9786939|NCT01290068|Active Comparator|Monofocal|Monofocal IOL, bilateral implantation
9786940|NCT01290094|Experimental|Single Arm|
9786941|NCT01290224|Experimental|Supportive Care|See Detailed Description
9786942|NCT01290237|Experimental|Vancomycin loading dose|Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
9786943|NCT01290237|Active Comparator|Control|No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.
9786944|NCT01290263|Experimental|Amgen 386|Cohort A will assess recurrent Glioblastoma Multiforme (GBM) patients who receive AMG 386 monotherapy at 30mg/kg every week. As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study. None of these patients had achieved stable disease or response at their initial evaluation after 1-2 months of study therapy. Therefore, study investigators and sponsor agreed that the level of single-agent anti-tumor activity associated with AMG386 for recurrent glioblastoma patients is most likely insufficient to satisfy the stopping rule for low efficacy outlined in Section 14.5 for Cohort A.
9786945|NCT01290263|Experimental|Amgen 386 and Bevacizumab|Cohort B will assess recurrent Glioblastoma Multiforme(GBM) patients who receive AMG 386 plus bevacizumab. Because the maximum tolerated dose of this combination therapy has not yet been established, a 3x3 Phase I study was used to determine the maximum tolerated dose. As of June 6, 2014, the MTD was determined to be AMG386 30 mg/kg administered intravenously every week(dose level +1) in combination with bevacizumab at 10mg/kg administered intravenously every other week. As of July 25, 2014 the Cohort B, Phase II portion of the study was opened to accrual.
9786946|NCT01290315|Experimental|Ferric Carboxymaltose (FCM)|Intravenous iron
9786947|NCT01290315|Active Comparator|Iron Sucrose / Iron Dextran|Intravenous iron
9786948|NCT01290341|Experimental|NAFT-600 ( naftin 2 % gel)|Topical; applied once daily for two weeks
9786949|NCT01290341|Placebo Comparator|Placebo|Topical; applied once daily for two weeks.
9786950|NCT01290445||Exposed|Infants exposed in utero to varenicline
9786951|NCT01290445||Unexposed|infants exposed in utero to cigarette smoke from maternal smoking
9786952|NCT01290445||Reference|infants not exposed in utero to either varenicline or cigarette smoke from maternal smoking
9836907|NCT05163353|Other|Delayed treatment with diluted Radiesse|Delayed injection of Décolleté Wrinkles with diluted Radiesse
9921913|NCT00832663|Placebo Comparator|Placebo|receive placebo
9786953|NCT01290484|Experimental|Open Label|Sildenafil oral tablet three times daily
9786954|NCT01290523|Experimental|Yttrium-90 liver radioembolization|Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)
9786955|NCT01290536|Experimental|Yttrium-90 liver radioembolization|
9786956|NCT01290601|Experimental|Cohort 1 Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
9786957|NCT01290601|Active Comparator|Cohort 1-Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
9786958|NCT01290601|Experimental|Cohort 2 Tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
9786959|NCT01290601|Active Comparator|Cohort 2 Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
9786960|NCT01290614|Experimental|Pharmacist intervention|
9786961|NCT01290614|Active Comparator|Control - usual care|Patients assigned to control will continue to receive care from their VA provider.
9786962|NCT01290627||Knee Prosthesis LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
9786963|NCT01290627||Knee Prosthesis Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
9786964|NCT01290627||Control|Subjects with normal knees
9786965|NCT01290640||TC3 TKA|Subjects implanted with a DePuy fixed-bearing Total Condylar III (TC3) TKA
9786966|NCT01290640||PFC RP TC3 TKA|Subjects implanted with a DePuy PFC Rotating Platform TC3 TKA
9786967|NCT01290666||GORE® BIO-A® Fistula Plug|All patients in study receive the GORE® BIO-A® Fistula Plug.
9786968|NCT01290679|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
9786969|NCT01290679|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks
9786970|NCT01290731|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24 (PR 24). Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than (<) 1.2 log10 IU/mL detectable or undetectable of at Week 4, and undetectable HCV RNA levels at Week 12. All other participants will continue PR until Week 48 (PR 48).
9786971|NCT01290757|Experimental|Dabigatran etexilate 150 mg (T)|Capsugel (T), oral administration
9786972|NCT01290757|Experimental|Dabigatran etexilate 150 mg (R)|Qualicaps (R), oral administration
9786973|NCT01290796|Other|Ajust Adjustable Single-Incision Sling|Urinary incontinence sling
9786974|NCT01290874|Experimental|Tiotropium|Tiotropium bromide will be evaluated as a treatment for asthma.
9786975|NCT01290874|Active Comparator|Salmeterol or Formoterol|Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
9786976|NCT01290887|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.
9786977|NCT01290913|Experimental|omalizumab, oral desensitization|Patients receive omalizumab along with oral peanut desensitization.
9786978|NCT01290952|Experimental|Off-pump bypass surgery|Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable, but not mandatory, a heart positioner
9786979|NCT01290952|Active Comparator|On-pump bypass surgery|coronary artery bypass graft with cardiopulmonary bypass (CPB/CAB)
9786980|NCT01290978|Active Comparator|ChloraPrep|Applied ChloraPrep on the application site per manufacturer's instruction
9786981|NCT01290978|Active Comparator|DuraPrep|Apply DuraPrep to the application site per manufacturer's instruction
9786982|NCT01291017|Experimental|PD0332991|PD0332991 125 mg PO days 1 - 21
9786983|NCT01291056|Active Comparator|Clomphine|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
9786984|NCT01291056|Placebo Comparator|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
9786985|NCT01291108|Experimental|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.
9786986|NCT01291108|Experimental|AGN-210669 + bimatoprost|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.
9786987|NCT01291108|Experimental|AGN-210669 + bimatoprost vehicle|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
9786988|NCT01291108|Active Comparator|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.
9786989|NCT01291108|Experimental|bimatoprost + AGN-210669|bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.
9786990|NCT01291108|Other|bimatoprost + bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
9786991|NCT01291160|Experimental|Epiflo Treatment|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
9786992|NCT01291160|Sham Comparator|Sham Device|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
9786993|NCT01291173|Experimental|SPD489 30 mg|
9786994|NCT01291173|Experimental|SPD489 50 mg|
9786995|NCT01291173|Experimental|SPD489 70 mg|
9786996|NCT01291173|Placebo Comparator|Placebo|
9786997|NCT01291225|Other|Playground|"The playground arm of the study will consist of playground audits and KAP surveys about playground safety in both Chillicothe and Circleville, Ohio.~The intervention is Playground Safety Renovations and Development."
9786998|NCT01291225|Other|Farms|The Farm Arm will consist of farm audits with safety checklists and KAP surveys about farm safety. The intervention is a Safety Educational Campaign.
9786999|NCT01291277|Active Comparator|Ligation: 1-week interval|Endoscopic variceal ligation performed at 1-week intervals
9787000|NCT01291277|Active Comparator|Ligation 2-week interval|Endoscopic variceal ligation performed at 2-week intervals
9787001|NCT01291498|Other|HIFU Treatment|High Intensity Focused Ultrasound. This is not a comparative study
9787002|NCT01291784|Experimental|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
9787003|NCT01292005|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
9787004|NCT01292005|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
9787005|NCT01292057|Active Comparator|Aripiprazole|Medication
9787006|NCT01292057|Placebo Comparator|Sugar pill|
9787007|NCT01292135|Experimental|PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)|
9787008|NCT01292135|Experimental|PCI-32765 plus bendamustine/rituximab (BR)|
9787009|NCT01292187|Experimental|Oral calcitonin at dinner-or bedtime|Intervention: Oral calcitonin at dinnertime or oral calcitonin at bedtime. Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. Randomization to active or placebo was done 2:1. After randomization, further randomization was done to divide each arm into two groups, one in which dosing was at dinnertime and the other in which dosing was at bedtime to determine if food affected efficacy or safety.
9787010|NCT01292187|Experimental|Oral placebo at dinner- or bedtime|Intervention: oral placebo at dinnertime or oral placebo at bedtime
9787011|NCT01292226|Experimental|Mycophenolate Mofetil Monotherapy|Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
9787012|NCT01292239|Experimental|TMC435 100 mg 12 Wks + PR 24/48|Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
9787013|NCT01292239|Experimental|PBO 12 Wks + PR 48|Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
9787014|NCT01292252|Experimental|Treatment|Forteo, Terapeptide 20 ug subcutaneous injection
9787015|NCT01292252|Placebo Comparator|Control|Saline placebo
9787016|NCT01292304|Experimental|Tolvaptan|Tolvaptan 15 mg tablet once daily for 7 days followed by Tolvaptan 30 mg (two 15 mg tablets) once daily according to efficacy and tolerability
9787017|NCT01292447|Placebo Comparator|Control Group|Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.
9787018|NCT01292447|Experimental|Study Group|Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.
9787019|NCT01292473|Experimental|Placebo|Placebo subcutaneously (sc) every 4 weeks
9787020|NCT01292473|Experimental|Omalizumab 75 mg|Omalizumab 75 mg sc every 4 weeks
9787021|NCT01292473|Experimental|Omalizumab 150 mg|Omalizumab 150 mg sc every 4 weeks
9787022|NCT01292473|Experimental|Omalizumab 300 mg|Omalizumab 300 mg sc every 4 weeks.
9787023|NCT01292486|Experimental|Patients with multiple myeloma|Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.
9787024|NCT01292538|Experimental|Erchonia GLS 532nm|532nm green laser light therapy.
9787025|NCT01292538|Sham Comparator|Placebo laser|Sham light output with no therapeutic benefit
9787026|NCT01292603|Experimental|1|
9787027|NCT01292603|Experimental|2|
9787028|NCT01292603|Experimental|3|
9921914|NCT00832689|Experimental|1|
10205630|NCT05204524|Experimental|Subjected arm|"temozolomide for injection (once a day, with a fixed dose of 200 mg (body surface area ≤1.7m2) or 300 mg (body surface area > 1.7 m2), for 5 days, with 21 days as a cycle) combined with epirubicin (60 mg/m2 21-day scheme).~Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months."
10205631|NCT05204511|Experimental|Post-COVID/Long-COVID endurance training group|Participants affected by Post-COVID/Long-COVID that carry out a 12-week thrice weekly endurance training intervention
10205632|NCT05204511|Experimental|Post-COVID/Long-COVID concurrent training group|Participants affected by Post-COVID/Long-COVID that carry out a 12-week thrice weekly concurrent training intervention
10205633|NCT05204511|No Intervention|Post-COVID/Long-COVID control group|Participants affected by Post-COVID/Long-COVID that don't carry out an exercise intervention
9787029|NCT01292629|Experimental|Investigational intraocular lens|iSert 251 intraocular lens
9787030|NCT01292642|Experimental|Treatment|Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.
9787031|NCT01292746|Experimental|Erchonia ML Scanner (MLS)|Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light
9787032|NCT01292798|Experimental|0.5mg and 2.0mgRanibizumab|Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
10205634|NCT05204498|Experimental|Education plan|"Education plan and adherence to exercise Educational talk about the importance of exercise as an important strategy to change dyspnea at the start of the study.~Twice a week, corresponding to the days that do not attend the sessions of pulmonary rehabilitation, calls will be made with a duration of 15 minutes each, in the calls will encourage and guide the practice of physical activity and breathing exercises"
10205635|NCT05204498|No Intervention|control|"A survey will be conducted at week 8 of monitoring where adherence to exercise is measured during the 8-week study.~At the end of week 8, patients will be referred to the pulmonary rehabilitation unit in order to evaluate the anthropometric parameters, assess dyspnea with the modified Medical Research Council scale, the hospital anxiety and depression scale, the Saint George respiratory questionnaire, the pulmonary information needs questionnaire and the 6-minute walk test again."
10205636|NCT05204472|Experimental|Burst DBS first, Tonic DBS second|10 days of Burst-stimulation followed by 10 days of active tonic stimulation (Burst-DBS -> tonic-DBS)
10205637|NCT05204472|Active Comparator|Tonic DBS first, Burst DBS second|10 days of active tonic stimulation followed by 10 days of Burst-stimulation (tonic-DBS -> Burst-DBS)
10205638|NCT05204433||normal control|healthy volunteers
10205639|NCT05204433||adenoma|pathologically reported colorectal adenoma
10205640|NCT05204433||colorectcal cancer|pathologically reported colon cancers
9787033|NCT01292837|Experimental|Levetiracetam|Twice daily (morning and evening) orally
9787034|NCT01292876|Other|Extracellular Matrix|Implantation of Extracellular Matrix
9787035|NCT01292928|Experimental|Stent|Stent implantation into SFA/PPA
10205641|NCT05204433||High risk group|pathologically reported inflammatory bowel diseases
10213416|NCT04059757|Experimental|Fecal Microbiota Transplantation (FMT)|"One dose of FMT equal to 30 capsules will be administered on day 1 of a 28 day cycle. Steroids and routine GVHD prophylaxis medications and antibiotics may be administered concurrently with FMT therapy.~Participants will be followed for 28 days following completion of the FMT dose or protocol defined outcome.~aGVHD will be treated as per standard of care."
10213417|NCT04056104|Experimental|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters
10213418|NCT04055246|Experimental|Prebiotic|Participants receive prebiotics containing fiber bar to consume 2x daily for 1 week.
10213419|NCT04055246|Placebo Comparator|Placebo|Participants receive placebo bar containing no added prebiotics to consume 2x daily for 1 week.
10213420|NCT04049279|Active Comparator|BiMobile standard cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
10213421|NCT04049279|Active Comparator|BiMobile larger cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
10213422|NCT04049279|Active Comparator|Avantage standard cement|25 patients will receive a cemented THA with an Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
10213423|NCT04047589||Subjects|Cancer patients with curable or previously treated malignancies
10213424|NCT04047589||Providers|Physicians seeing patients in the outpatient clinics at the IU Simon Cancer Center
10213425|NCT04046731|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive NMBAs during surgery in order to determine Negative Predictive Values and Non-Irritant Concentrations.
10213426|NCT04042077|Experimental|Delafloxacin|Delafloxacin IV, with the option to switch to delafloxacin oral
9787036|NCT01293006|Experimental|Suvorexant first, then placebo|"During Period 1, participants <65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening and participants ≥65 years of age were administered a 30-mg oral dose of~suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening."
9787037|NCT01293006|Experimental|Placebo first, then suvorexant|"During Period 1, participants <65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening and participants ≥65 years of age received one placebo tablet matching~suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening."
9787038|NCT01293032|Experimental|Group 1 (RS < 11)|"Patients with a Recurrence Score (RS) less than 11 (RS <11) are assigned to Group 1, neoadjuvant hormonal therapy either tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
9787039|NCT01293032|Experimental|Group 2 Arm 1 (RS 11-25)|"Patients with an intermediate RS (11-25) assigned to Group 2. Randomized to Arm 1, neoadjuvant hormonal therapy as in Group 1.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
9787040|NCT01293032|Experimental|Group 2 Arm 2 (RS 11-25)|"Patients with an intermediate RS(11-25) assigned to Group 2. Randomized to Arm 2, neoadjuvant chemotherapy 6-8 courses of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
9787041|NCT01293032|Experimental|Group 3 (RS > 25)|"Patients with a high RS (> 25) assigned to Group 3, neoadjuvant chemotherapy as in Group 2 Arm 2.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
9787042|NCT01293084|Experimental|7% saline|5 mL of 7% saline was inhaled once over a 20 minute period.
9787043|NCT01293084|Placebo Comparator|0.12% saline|5mL 0.12% saline inhaled once during 20 minutes
9787044|NCT01293240|Experimental|Lotrafilcon B|
9787045|NCT01293396|Active Comparator|Biphasic Insulin Aspart 30|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
9787046|NCT01293396|Active Comparator|Biphasic Insulin Aspart 70|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
9787047|NCT01293396|Active Comparator|Insulin Aspart|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
9787048|NCT01293539|Other|Intraocular Retinoblastoma Patients|Single group assignment of patients with intraocular retinoblastoma, unilateral or bilateral.
9787049|NCT01293695|Active Comparator|Hypnosis|Receives 5 weeks of hypnotic relaxation therapy
9787050|NCT01293695|Placebo Comparator|Structured Attention|Meets with therapist for five weekly sessions, but receives no hypnotic relaxation therapy
9787051|NCT01293825|Experimental|Medication Adherence Bipolar Disorder|There was only one group in this study. All participants received the study drug Ziprasidone.
9787052|NCT01293968|Experimental|5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg|
9787053|NCT01293968|Active Comparator|100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg|
9787054|NCT01294098|No Intervention|PCA only|this group will only get a pain control anesthesia pump to use for post-operative pain
9787055|NCT01294098|Experimental|PCA and femoral nerve block|this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
9787056|NCT01294098|Experimental|PCA + hematoma block|patient will receive hematoma block during surgery
9787057|NCT01294150|Active Comparator|UroLift System|The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
9799340|NCT01657032|Placebo Comparator|Lactobacillus GG and Placebo|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~placebo (glucose), dose 3 g, once daily orally until diarrhea stopped"
9836908|NCT05162807|Experimental|Palliative Care Education|The intervention arm will view a psychoeducational video on palliative care.
9787058|NCT01294150|Sham Comparator|Cystoscopy|The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
9787059|NCT01294150|Active Comparator|Crossover|Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
9787060|NCT01294163|Experimental|Xenon|
9787061|NCT01294163|Active Comparator|Sevoflurane|
9787062|NCT01294163|Active Comparator|Total intravenous anaesthesia|
9787063|NCT01294241|Experimental|Oleogel-S10|The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
9787064|NCT01294241|Other|Non-adhesive wound dressing|Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
9787065|NCT01294267|Other|Circulatory Support System|Percutaneous use of left ventricular assist device, Impella 2.5 Circulatory Support System to facilitate mapping and ablation of ongoing VT by maintaining near-normal hemodynamics, reducing myocardial workload and preservice organ perfusion.
9787066|NCT01294306|Experimental|Treatment (Akt inhibitor MK2206, erlotinib hydrochloride)|Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9787067|NCT01294319|Experimental|Sedentary young adults, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
9787068|NCT01294319|Experimental|Endurance-trained young athletes, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
9787069|NCT01294319|Experimental|Sedentary young adults, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
9787070|NCT01294319|Experimental|Endurance-trained young athletes, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
9787071|NCT01294319|Experimental|Sedentary young adults, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
9787072|NCT01294319|Experimental|Endurance-trained young athletes, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
9787073|NCT01294319|Experimental|Sedentary young adults,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
9787074|NCT01294319|Experimental|Endurance-trained young athletes,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
9787075|NCT01294358|Experimental|Gemcitabine Dose Escalation|gemcitabine dose escalation
9787076|NCT01294371||Leuprorelin|"Patients with genital endometriosis received leuprorelin (Lucrin Depot®) in accordance with the respective marketing authorization/manufacturer's directions. All participants received leuprorelin for up to 6 months intramuscularly at a dose of 3.75 mg once a month. If intramuscular administration was not possible, leuprorelin was injected subcutaneously at a dose of 3.75 mg once a month. The first injection was to be carried out on the 3rd day of a menstrual period.~Accepted options for add-back therapy included: monophasic combined low-dose products for hormonal replacement therapy; combined oral contraceptives; and, if use of hormones was not possible, phytoestrogens with calcium products."
9787077|NCT01294384|Experimental|New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
9787078|NCT01294384|Experimental|New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
9787079|NCT01294384|Active Comparator|Refresh Tears®|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
9787080|NCT01294397|Experimental|Etanercept + Denosumab|Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
9787081|NCT01294423|Experimental|1|Dapagliflozin 5 mg
9787082|NCT01294423|Experimental|2|Dapagliflozin 10 mg
9787083|NCT01294423|Placebo Comparator|3|
9787084|NCT01294436|Experimental|Open label treatment|
9836909|NCT05162807|Placebo Comparator|Attention Control|The control arm will view an educational video on nutrition as an attention control.
9787085|NCT01294449||MADIT-CRT ICD|
9787086|NCT01294449||MADIT-CRT CRT-D|
9787087|NCT01294462|Experimental|1|Ticagrelor (AZD6140)
9787088|NCT01294462|Active Comparator|2|Clopidogrel
9787089|NCT01294514||Healthy Volunteers|Healthy volunteers ASA Class 1
9787090|NCT01294553||rosiglitazone/metformin group|Korean subjects who are administered rosiglitazone/metformin according to the prescription information
9787091|NCT01294579|Experimental|ofatumumab and bendamustine|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase and 1000 mg IV every 2 months for 2 years.~Bendamustine 90 mg/m2 was given on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)"
9787092|NCT01294592|Active Comparator|Dutasteride plus tamsulosin|Dutasteride plus tamsulosin arm + lifestyle advice
9787093|NCT01294592|Experimental|Watchful waiting with escalation to tamsulosin|Watchful waiting with escalation to tamsulosin
9787094|NCT01294644|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9787095|NCT01294644|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9787096|NCT01294644|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9787097|NCT01294683|Experimental|Sequence 1: MK-0524B 2g/40g→MK-0524A 2g + Simvastatin 40 mg|After a 2-week placebo run-in, participants received extended release (ER) niacin/laropiprant (N/LRPT) 1 g/20 mg combination tablet (MK-0524B) once daily for 4 weeks, then ERN/LRPT/Simvastatin (SIM) 2 g/40 mg combination tablet once daily for 8 weeks. Participants then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks.
9787098|NCT01294683|Experimental|Sequence 2: MK-0524A 2g + Simvastatin 40 mg→ MK-0524B 2g/40g|After a 2-week placebo run-in, participants received ERN/LRPT 1 g (MK-0524A) co-administered with SIM 20 mg once daily for 4 weeks then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks. Participants then received ERN/LRPT/SIM 2 g/40 mg combination tablets (MK-0524B) once daily for 8 weeks.
9787099|NCT01294709|Experimental|Telcagepant/ Placebo|Participants receive single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 1 and single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
9787100|NCT01294709|Experimental|Placebo/Telcagepant|Participants receive single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 1 and a single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
9787101|NCT01294748|Experimental|MiStent DES|The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
9787102|NCT01294748|Active Comparator|Endeavor DES|The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
10205642|NCT05204394|Experimental|VM-1500A-LAI 600mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 600mg i / m Q4W injections with the background of oral 2NRTIs QD.
10205643|NCT05204394|Experimental|VM-1500A-LAI 900mg|20mg Elpida® 2 weeks run-in period followed by VM-1500A-LAI 900mg i / m Q4W injections with the background of oral 2NRTIs QD.
10205644|NCT05204394|Other|Standard or Care|Any approved 1st line oral HIV treatment regimen
10205645|NCT05204355||Scleroderma|Patients with Scleroderma will be imaged with UTE MRI to compare MRI with CT for identifying Interstitial Lung Disease
10205646|NCT05204355||Scleroderma ILD|Patients with Scleroderma ILD who are initiating treatment will be imaged using hyperpolarized 129Xe MRI to assess treatment efficacy.
10205647|NCT05204329|Active Comparator|Low dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the lowest dose level.
10205648|NCT05204329|Active Comparator|Medium dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the medium dose level.
10205649|NCT05204329|Active Comparator|High dose of allogenic MSC drops|Escalating doses of allogenic MSC eye drops will be assigned at the high dose level.
10205650|NCT05204316|Experimental|Participants|Participants will provide spoken narratives on their headache disorder
10205651|NCT05204303||Patients with symptoms of LPR and objective evidence of GORD|
10205652|NCT05204303||Patients with symptoms of LPR and no objective evidence of GORD|
10205653|NCT05204303||Healthy volunteers|
10205654|NCT05204277|Active Comparator|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
10205655|NCT05204277|Active Comparator|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA)
10205656|NCT05204277|Active Comparator|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
10205657|NCT05204277|Active Comparator|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
10205658|NCT05204277|Active Comparator|In-office bleaching + Remineralization|In-office bleaching was applied followed by MI-Paste Plus®
10205659|NCT05204277|Active Comparator|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
10205660|NCT05204277|Active Comparator|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by inoffice bleaching and lastly MI-Paste Plus®
10205661|NCT05204277|No Intervention|Control|no treatment (control)
10205662|NCT05204173|Experimental|Intraperitoneal|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
10205663|NCT05204121|Experimental|Elpida 40 mg once weekly|elsulfavirine 40mg orally once weekly for 8 weeks
10205664|NCT05204121|Experimental|Elpida 80 mg once weekly|elsulfavirine 80mg orally once weekly for 8 weeks
10205665|NCT05204121|Experimental|Elpida 160 mg once weekly|elsulfavirine 160mg orally once weekly for 8 weeks
10205666|NCT05204108||Contrast-enhanced Ultrasonography|To evaluate the diagnostic accuracy of CEUS for the preoperative staging of bladder cancer, which would benefit the implementation of efficient therapeutic strategies.
10205667|NCT05204095||Referral group|The patients with severe cataracts in this group need a referral to a higher-level hospital for further treatment.
10205668|NCT05204095||Observation group|The patients with mild cataracts or transparent lenses in this group do not need a referral to a higher-level hospital for further treatment and keep regular examinations.
9836910|NCT05162144|Experimental|Proximal Medial Gastrocnemius Recession Surgery|All patients included in the Cohort Study will recieve this PMGR-surgery
9836911|NCT05160168|Experimental|Dose Escalation|Participants with unresectable or metastatic GIST who will receive orally administered THE-630.
9836912|NCT05160168|Experimental|Expansion Cohort 1|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib, regorafenib and ripretinib who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
9836913|NCT05160168|Experimental|Expansion Cohort 2|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib and 0-1 additional lines of therapy in the advanced/metastatic setting, who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
9836914|NCT05160168|Experimental|Expansion Cohort 3|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib (including in the adjuvant setting) and who have not received additional systemic therapy for advanced GIST, who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
9836915|NCT05158296|Experimental|QR-421a 180/60 µg|180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
9836916|NCT05158296|Experimental|QR-421a 60/60 µg|60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
9836917|NCT05158296|Sham Comparator|Sham-procedure|Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
9836918|NCT05158153|Experimental|ORKID Bundled Intervention|
9996790|NCT01503242|Experimental|Treatment (monoclonal antibody, chemo, TBI, transplant)|Patients receive 90Y-BC8 Ab IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and allogeneic peripheral blood stem cell transplant on day 0. Patients also receive graft-vs-host disease prophylaxis comprising cyclosporine PO BID on days -3 to 56 with taper to day 180 or on days -3 to 100 with taper to 180; and mycophenolate mofetil IV or PO BID on days 0-27, or 0-40 with taper to 96.
9996791|NCT01503255|Experimental|cognitive behavioral group therapy|
9996792|NCT01503255|Active Comparator|health education group|
9836923|NCT05152147|Active Comparator|Arm A|Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
9836924|NCT05152147|Experimental|Arm B|Zanidatamab plus physician's choice of CAPOX or FP
9836925|NCT05152147|Experimental|Arm C|Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP
9921915|NCT00832715|Experimental|EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA)
9921916|NCT00832728|Active Comparator|ELAD|ELAD Therapy + Standard of Care
9836926|NCT05149820|Active Comparator|Nudge Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
9836927|NCT05149820|Active Comparator|Nudge Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
9836928|NCT05149820|Active Comparator|Preference Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
9836929|NCT05149820|Active Comparator|Preference Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
9836930|NCT05149352|Active Comparator|Treatment as usual (TAU)|Participants will receive an evidence-based psychotherapeutic intervention combined with/or pharmacotherapy (TAU)
9836931|NCT05149352|Experimental|Treatment as usual (TAU) + Trauma-focused therapy (TFT)|Participants will receive 6 to 10, 60-90 minute TFT sessions delivered over a period of 12 weeks, in addition to TAU.
9836932|NCT05149131||mCSPC patients in the province of Alberta|mCSPC patients who initiated and received at least one dose of guideline recommended life-prolonging therapy for mCSPC (docetaxel, abiraterone, enzalutamide, apalutamide, or ADT alone) from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff, inclusive.
9996793|NCT01503268|Active Comparator|Percutaneous ablation|
9996794|NCT01503268|Active Comparator|Surgical ablation|
9996795|NCT01503268|Active Comparator|DCCV|Direct current cardioversion
9996796|NCT01503281|Experimental|Hospital-based exercise program|Exercise monitored at the hospital
9836937|NCT05145361|Experimental|B001 injection|Subjects randomized to this arm will receive B001 twice, at day 1 and day 15, up to the end of the study.
9836938|NCT05145361|Placebo Comparator|Placebo|Subjects randomized to this arm will receive Placebo twice, at day 1 and day 15, up to the end of the study.
9836939|NCT05144854|Experimental|ONO-4538 + ipilimumab + chemotherapy|
9836940|NCT05144854|Active Comparator|Chemotherapy|
9836941|NCT05142605||Cohort 1: Meaning-Centered Grief Therapy/MCGT|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
9836942|NCT05142605||Group 2: Supportive Psychotherapy /SP|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
9836943|NCT05142605||Group 3: Enhanced usual care/EUC|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
9836944|NCT05142241|Experimental|Treatment (talazoparib, temozolomide)|Patients receive talazoparib PO QD on days 1-28 and temozolomide PO QD on days 2-6 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9836945|NCT05141253|Experimental|RD133 treatment group|"Administration of RD133 Three dose groups of 1.0×10^6 CAR-T/kg, 3.0×10^6 CAR-T/kg, and 6.0×10^6 CAR-T/kg RD133 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.~RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of RD133 will be infused in a single infusion within 30 minutes on day 0."
9996797|NCT01503281|Experimental|Home-based exercise program|Participants perform exercise at home
10205669|NCT05204069|Experimental|Three-dimensional screening for visual disorders using the RetinoMax Device|Instillation of cyclopentolate of 3 drops of cyclopentolate at T0',T5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
9836950|NCT05138471|Experimental|tDCS Active vs TENS Active|
9836951|NCT05138471|Experimental|tDCS Active vs TENS Placebo|
9836952|NCT05138471|Placebo Comparator|tDCS Placebo vs TENS Placebo|
9836953|NCT05137691|Experimental|Experimental|Adapted NHS weight management 1:1 programme. Low carbohydrate dietary focus, enhanced behaviour change via telehealth, daily step target supported by pedometers
9836954|NCT05137691|Active Comparator|Active comparator NHS 1:1 weight management programme|12 week NHS 1:1 weight management programme
9836955|NCT05135091|Experimental|NRTX-1001 (Stage 1)|Up to 10 subjects.
9836956|NCT05135091|Experimental|NRTX-1001 (Stage 2)|Up to 20 subjects.
9836957|NCT05135091|Sham Comparator|Sham Comparator (Stage 2)|Up to 10 subjects.
9836958|NCT05132569|Experimental|SAR442168|Tolebrutinib oral daily dose from baseline until Week 130
9836959|NCT05132569|Placebo Comparator|Placebo|Matching placebo oral daily dose only for DB period
9836960|NCT05131399|Experimental|Self-comparison|"Patients will be fitted with 2 types of ankle foot orthoses, alternately, divided into 4 phases, in the following order:~Phase A1: Standard Plastic ankle foot orthosis Phase B1: carbon medical device ankle foot orthosis Phase A2: Standard Plastic ankle foot orthosis Phase B2: carbon medical device ankle foot orthosis Each patient is his own comparator. For all patients, the total duration of the study will be the same, and will correspond to 12 weeks."
9836961|NCT05130801|Experimental|MRI and pHLIP® ICG|All study participants in Phase I will receive pre-operative MRI and mpMRI scans, a pre-operative injection of pHLIP ICG, and NIRF imaging during surgery (intra-operatively). During phase IIa of the study, if pHLIP® ICG NIRF imaging indicates tumor in areas outside of the planned resection area, biopsy samples will be taken from these areas and submitted for pathological analysis.
9836962|NCT05130463||Patients diagnosed with type 2 diabetes mellitus|
9836963|NCT05130047|Experimental|Aldafermin (NGM282)|Aldafermin (NGM282) is an investigational medication. It is an engineered analog of FGF-19 which reduces synthesis of bile acids and diarrhea caused by elevated bile acids. Participants receive aldafermin (NGM282) 1 mg given by subcutaneous injection once daily for 28 days.
9836964|NCT05130047|Placebo Comparator|Placebo|A placebo looks exactly like the study drug but contains no active ingredients. It is used to learn if the effects seen are truly from the study drug. Participants receive placebo solution matching aldafermin (NGM282) given by subcutaneous injection once daily for 28 days.
9836965|NCT05129735|Experimental|Meal replacement shake|Teatis meal replacement shake
9836966|NCT05128773|Experimental|Amcenestrant with tamoxifen-matching placebo arm|Amcenestrant dose, once daily, continuously. Tamoxifen-matching placebo, once daily, continuously.
9836967|NCT05128773|Active Comparator|Tamoxifen with amcenestrant-matching placebo|Tamoxifen dose, once daily, continuously. Amcenestrant-matching placebo, once daily, continuously.
9836968|NCT05126992||AZD1222|at least one dose of AZD1222
9836969|NCT05126992||comparator|non vaccinated
9836970|NCT05124041|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis
9836971|NCT05124041|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma
9836972|NCT05122728||Concussed Cohort|Concussed active duty Service Members and physically active civilians who have been cleared to RTD/A.
9836973|NCT05122728||Non-Concussed Cohort|Sex, age, occupation, and physical activity matched active duty Service Members and physically active civilians who have not sustained a concussion.
9836974|NCT05121558|Experimental|Yoga|Participants will receive twice weekly yoga over the course of 8 weeks.
9836975|NCT05121558|Experimental|Education control (EC)|Participants will receive twice weekly education over the course of 8 weeks
9836976|NCT05121558|Active Comparator|Usual care (UC)|8 weeks of usual care
9836977|NCT05120271|Experimental|GPC3 positive solid tumors|One time i.v. administration of BOXR1030 after completion of cyclophosphamide and fludarabine lymphodepleting chemotherapy
9836978|NCT05114590|Experimental|Soliqua 100/33|Soliqua 100/33 (Insulin glargine 100 Units/ml /lixisenatide 33 μg/mL) once daily for 16 weeks.
9836979|NCT05113953|Experimental|Low Dose: 200 mg Total Daily Dose (TDD) of Centanafadine|200 mg TTD of centanafadine will be administered as 1x 100 mg tablet and 1 placebo tablet twice daily (BID) 4-6 hours apart.
9836980|NCT05113953|Experimental|High Dose: 400 mg Total Daily Dose (TDD) of Centanafadine|400 mg TTD of centanafadine will be administered as 2x 100 mg tablets twice daily (BID) 4-6 hours apart.
9836981|NCT05113953|Placebo Comparator|Placebo|Placebo will be administered as 2 placebo tablets twice daily (BID) 4-6 hours apart.
9836982|NCT05113901|Active Comparator|Methylprednisolone taper|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM <90° at 8 weeks
9836983|NCT05113901|Placebo Comparator|Placebo taper|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM <90° at 8 weeks
9836984|NCT05113498|Experimental|(-)-Epicatechin|(-)-Epicatechin supplementation
9836986|NCT05107609|Experimental|Self-Compassion Intervention|Participants will be guided through an acute, 30-minute self-compassion intervention consisting of psychoeducation, guided loving-kindness meditation, compassionate imagery and a compassionate writing activity.
9836987|NCT05107609|No Intervention|Resting Control Intervention|Participants will be asked to sit quietly and independently for 30 minutes. They can read neutral magazines provided or their own reading/writing material, but will be asked not to use outside electronic devices or communicate with anyone external.
9836988|NCT05107115|Experimental|Rilzabrutinib dose A|dose A
9836989|NCT05107115|Experimental|Rilzabrutinib dose B|dose B
9836990|NCT05107115|Experimental|Rilzabrutinib dose C|dose C
9836991|NCT05107115|Placebo Comparator|Placebo|Matching placebo
9836992|NCT05106309|Experimental|Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditions|Oral Dose
9836993|NCT05106309|Experimental|Part B: Single doses of CVL-231 target release formulation under fasted and fed conditions|Oral Dose
9996798|NCT01503281|No Intervention|Control|Control Group participants maintained their usual levels of daily activity, with no additional exercise components.
9996799|NCT01503307||Prenatal/Postpartum CHD Diagnosis|parent of a baby (prenatal or postpartum)who was recently found to have a heart defect.
9836996|NCT05104567|Experimental|Cohort A (Sub-study 01): 2-3L ESCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9836997|NCT05104567|Experimental|Cohort B1 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS ≥1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9836998|NCT05104567|Experimental|Cohort B2 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS < 1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9836999|NCT05104567|Experimental|Cohort B3 (Sub-study 02): 2-4L GC/GEJ Post PD1/PD-L1 non-MSI-H|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9837000|NCT05104567|Experimental|Cohort C (Sub-study 03): 2-3L HCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9837001|NCT05104567|Experimental|Cohort D1 (Sub-study 04): 3-6L CRC non-MSI-H any RAS|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9837002|NCT05104567|Experimental|Cohort D2 (Sub-study 04): 3-6L CRC non-MSI-H RAS wild type|SAR444245 is administered every 3 weeks on Day 1 of each cycle (21 days per cycle) and cetuximab is administered on Day 1, Day 8 and Day 15 of each cycle until progressive disease.
9837003|NCT05104515|Experimental|OVM-200|"2 mg/mL OVM-200 solution. Proposed dose levels for Phase 1a: 250, 500, and 1000 μg. The planned doses may be adjusted based on SRC recommendations. Following review of the data, 1 additional dose level may be added up to a maximum of 2000 μg.~The dose level for Phase 1b will be selected following review of the data from Phase 1a and will not exceed the dose safely administered in Phase 1a."
9837004|NCT05103904|Experimental|Treatment (Lenvatinib)|Patients receive lenvatinib PO QD. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the protocol therapy
9837005|NCT05102253|Experimental|TEAS+DCEAS group|Subjects assigned to TEAS+DCEAS group will receive TEAS+DCEAS in addition to routine care.
9837006|NCT05102253|Other|Wait-list control: Routine care group|Subjects assigned to this group will continue their current routine care as usual.
9837007|NCT05101746|Experimental|Nitric oxide group|Participants in this group will receive Nitric Oxide (NO) while undergoing Cardiopulmonary bypass (CPB)
9837008|NCT05101746|Active Comparator|Standard of care cardiopulmonary bypass procedure|Participants in this group will receive standard of care
9996800|NCT01503320|Experimental|Enteral glutamine|
9996801|NCT01503320|Placebo Comparator|Placebo|
9837009|NCT05097326|Active Comparator|Mifepristone|Participants will be given mifepristone with insertion of the cervical Cook balloon for labor induction
9837010|NCT05097326|Active Comparator|Misoprostol|Participants will be given misoprostol with insertion of the cervical Cook balloon for labor induction
9837011|NCT05097287|Experimental|Dupilumab|Dupilumab administered every 2 weeks (Q2W) after an initial loading dose (2 injections) on Day 1
9837012|NCT05097287|Placebo Comparator|Placebo|Matching placebo administered Q2W after an initial loading dose (2 injections) on Day 1
9837013|NCT05096273|Experimental|CPT- Pain relief lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectations. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
9837014|NCT05096273|Experimental|CPT- Pain sensitivity lotion|During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectation. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
9837015|NCT05096273|Active Comparator|ReACT for PNES- Booster therapy sessions|After completing the 12 therapy sessions, half of the participants will be randomized to receive 2 booster therapy sessions, 3 months and 9 months after the 12th ReACT treatment session.
9837016|NCT05096273|Experimental|ReACT for PNES- No Booster therapy sessions|After completing the 12 ReACT treatment sessions, half of the participants will be randomized to not receive the 2 booster therapy sessions.
9837017|NCT05096273|No Intervention|Healthy Control|Healthy controls are matched to participants with PNES based on age (+ or - 1 year), gender, race and family income. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
9837018|NCT05096247|Experimental|Treatment with RF Device|Subjects in this arm of the study will be treated with the radiofrequency device, and will receive up to 4 treatments on the face.
9837019|NCT05096247|Experimental|Treatment with IPL and RF Device|Subjects treated in this arm of the study will receive 2 treatments with just the radiofrequency device and then 2 treatments with both the radiofrequency and the IPL laser.
9998259|NCT01516489|Experimental|$50 Lottery-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will have a 1 in 10 chance of being mailed a voucher that can be exchanged for $50 at PVAMC.
9837021|NCT05093270|Experimental|Part A Dose Escalation (Single Ascending Dose)|Up to 5 dose levels of BGB-23339 or Placebo
9837022|NCT05093270|Experimental|Part B Dose Escalation (Multiple Ascending Dose)|Up to 4 dose levels of BGB-23339 or placebo based on data collected in Part A
9837023|NCT05093270|Experimental|Part C Dose Escalation (Multiple Ascending Dose in Chinese Subjects Sub-study)|Up to 2 dose levels of BGB-23339 or placebo based on data collected in Part A and B (conducted in China only)
9837024|NCT05093270|Experimental|Part D (Food-Effect Study)|Three single dose levels of BGB-23339 under different feeding conditions
9837027|NCT05092646|Placebo Comparator|Control Group|Single dose, 2.0 mL of 0.9% normal saline, administered via intra-articular injection administered to the affected tibiotalar joint.
9837028|NCT05092646|Experimental|Investigational Group|"Biological/Vaccine: Axolotl Ambient~Axolotl Ambient is an allogeneic amniotic intraarticular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.~Other Names:~• CA20"
9837029|NCT05090995|Active Comparator|Self-Monitoring and Feedback|The intervention consists of subjects wearing a PPG device for 6 weeks. Subjects will monitor their own health and report their sleep behaviors daily during this time. On weeks two, four, and six subjects will receive personalized health feedback based on the PPG device data and sleep diaries.
9837030|NCT05090995|Placebo Comparator|Self-Monitoring|The intervention consists of subjects wearing a PPG device for 6 weeks. Subjects will monitor their own health and report their sleep behaviors daily during this time.
9837031|NCT05088369|Experimental|SAD Cohorts 1 to 4: Participants receiving HM201|Each SAD cohort participant will be randomized to receive 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg); 0.12 mg/kg (20 nmol/kg).
9837032|NCT05088369|Placebo Comparator|SAD Cohorts 1 to 4: Participants Receiving Placebo|Each SAD cohort participant will be randomized to receive placebo.
9837033|NCT05088369|Experimental|MAD Cohorts 1 to 4: Participants Receiving HM201|Each MAD cohort participant will be randomized to receive a once a week dose of 1 of 4 escalating doses (0.01 mg/kg (2 nmol/kg); 0.03 mg/kg (5 nmol/kg); 0.06 mg/kg (10 nmol/kg), 0.12 mg/kg (20 nmol/kg) for 4 weeks.
9837034|NCT05088369|Placebo Comparator|MAD Cohorts 1 to 4: Participants Receiving Placebo|Each MAD cohort participant will be randomized to receive placebo once a week for 4 weeks.
9921917|NCT00832728|Other|Standard of Care|Hospital based standard of care for acute liver failure
9837035|NCT05086237|Experimental|Basic reminder|Participants will be sent a basic text message reminder of their missed well-child visit. The exact wording of the text message will be finalized once the open trial is complete.
9837036|NCT05086237|Experimental|Detailed reminder|Participants will be sent a text message reminder of their missed well-child visit that mentions the importance of well-child visits and/or includes the provider/clinic name. The exact wording of the text message will be finalized once the open trial is complete.
9837037|NCT05086237|No Intervention|Treatment as usual|This group will receive treatment as usual, which involves no text messaging follow-up.
9837038|NCT05083130|No Intervention|standard care|Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites
10205670|NCT05204069|Active Comparator|Non-standardized device for usual vision disorders|Screening device for usual vision disorders, performed by the school doctor during the usual prevention visit, with the tools used in the school doctor's current practice, non-standardized, according to his preference
10205671|NCT05204056|Experimental|Group A|Twenty patients who were given intraoperative joint cavity infusion therapy using 20ml tranexamic and 40ml iced normal saline.
9837039|NCT05083130|Experimental|prone position|prone position group will have a special intervention team who visits patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day
9837040|NCT05081557||Participants Receiving Upadacitinib|Participants receiving upadacitinib for atopic dermatitis.
9837041|NCT05081232|Experimental|Umbilical Cord Allograft Recipients|Male patients undergoing Robot Assisted Radical Prostectomy with bilateral nerve sparing technique will remain eligible to receive allograft during the surgery.
9837042|NCT05080491|Experimental|Determination of thyroid profile and neuropsychological assessment|
9837043|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS) plus antihistamines (AH1)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) plus antihistamines (AH1) for 4 weeks
9837044|NCT05080322|Experimental|on-demand intranasal corticosteroid (INS)|the patients will be treated with on-demand intra-nasal corticosteroid (INS) for 4 weeks
9837045|NCT05080322|Active Comparator|maintenance intranasal corticosteroid (INS)|the patients will be treated with intra-nasal corticosteroid(INS) maintenance therapy for 4 weeks
9984794|NCT03715751|Active Comparator|ASV|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted to target the same minute ventilation achieved prior to any change in Vt. Patients will then be switched to ASV mode. The percentage minute volume (%minVol) will be adjusted to target the same minute ventilation as was achieved before the change. Settings will be maintained for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
10205672|NCT05204056|Experimental|Group B|Twenty patients who were given 20ml of iced normal saline, 20ml of iced cocktail and 20ml of tranexamic
10205673|NCT05204056|Active Comparator|Control group|Twenty patients were given joint cavity infusion therapy with 20ml tranexamic only as the control group
10205674|NCT05204043|Experimental|Peter Hess® sound massage|Peter Hess® sound massage using bowls dedicated to this technique.
10205675|NCT05204043|Experimental|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation.
9837051|NCT05078034|Active Comparator|HFNO|High Flow Nasal Oxygen alone
9837052|NCT05078034|Active Comparator|H-NIV|Helmet Non-Invasive ventilation for a minimum of 12 hours per day with HFNO between sessions
9837053|NCT05075187||Participants diagnosed with Frontotemporal Dementia|Participants diagnosed with Frontotemporal Dementia
10205676|NCT05204030|Experimental|Narrative|The intervention condition will present narrative-focused messages about HPV and the HPV vaccine that includes important parent focused exemplar language and cultural norms on Twitter told through stories and characters (i.e., pseudo-parents).
10205677|NCT05204030|Active Comparator|Non-Narrative|The non-narrative condition will present scientific-focused messages about HPV and the HPV vaccine that includes important information relayed with numbers and facts.
9837056|NCT05067790|Experimental|Higher Dose Nusinersen|There will be two groups of participants previously treated with risdiplam in the study (nusinersen-naive group and nusinersen-experienced group), who will receive HD nusinersen, administered as 2 loading doses of 50 milligrams (mg) each, approximately 2 weeks apart, followed by maintenance doses of 28 mg approximately every 4 months.
9837057|NCT05063396|Active Comparator|opioid free anesthesia|opioid free anesthesia
9837058|NCT05063396|Placebo Comparator|Opioid-sparing anesthesia|Opioid-sparing anesthesia
9837059|NCT05062317|Experimental|ctDNA (Low Risk)|Will receive less intense chemotherapy, such as capecitabine or 5-fluorouracil.
9837060|NCT05062317|Experimental|ctDNA (High Risk)|Will receive more intense chemotherapy. This may include resuming the chemotherapy you received before surgery (for example, FOLFOX [5-fluorouracil, leucovorin and oxaliplatin] or FOLFIRI [5-fluorouracil, leucovorin and irinotecan] with or without bevacizumab)
10205678|NCT05204004|Experimental|Sunrise|Participants under investigation for OSA will use both devices (Sunrise solution and overnight polygraphy) simultaneously for a single overnight sleep study. Participants randomised to the 'Sunrise' arm will receive their treatment decision based on the Sunrise solution.
9837062|NCT05061420|Experimental|Cohort A1 (sub study 01) treatment- naïve|Participants with HNSCC, who are treatment-naïve for R/M disease and have a PD-L1 Combined Positive Score (CPS) ≥1, will receive pembrolizumab followed by SAR444245. Both drugs administered by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles.
9921918|NCT00832754|Experimental|RDT+ACT group|RDT+ACT group (ACT offered to RDT positive cases only)
10205679|NCT05204004|Active Comparator|Polygraphy|Participants under investigation for OSA will use both devices (Sunrise solution and overnight polygraphy) simultaneously for a single overnight sleep study. Participants randomised to the 'polygraphy' arm will receive their treatment decision based on the polygraphy.
9787103|NCT01294787|Experimental|indacaterol and glycopyrronium bromide (QVA149)|QVA149 delivered once daily via single-dose dry powder inhaler.
9787104|NCT01294787|Placebo Comparator|placebo|Placebo, delivered once daily via single-dose dry powder inhaler.
9787105|NCT01294787|Active Comparator|tiotropium|Tiotropium delivered once daily via HandiHaler® device.
9787106|NCT01294800|Experimental|Preladenant 2 mg|Participants will receive preladenant 2 mg taken orally twice daily (BID), one tablet in the morning and one tablet in the evening, for 12 weeks.
9787107|NCT01294800|Experimental|Preladenant 5 mg|Participants will receive preladenant 5 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
9787108|NCT01294800|Experimental|Preladenant 10 mg|Participants will receive preladenant 10 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
9787109|NCT01294800|Placebo Comparator|Placebo|Participants will receive a placebo to preladenant tablet taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
9787110|NCT01294917|Experimental|Investigational MPS|AMO Investigational MPS.
9787111|NCT01294917|Active Comparator|Clear Care|Peroxide-based lens care regimen.
9787112|NCT01294917|Active Comparator|Opti-Free RepleniSH|Multi-purpose disinfecting solution (Alcon).
9787113|NCT01295034|Placebo Comparator|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
9787114|NCT01295034|Experimental|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
9799341|NCT01657162|Experimental|Alendronate|Participants received 70 milligrams (mg) of alendronate orally once per week beginning on Day 2 for up to 24 months after participating in Study BA058-05-003 during which participants received abaloparatide 80 micrograms (mcg) SC or abaloparatide-matching placebo daily for 18 months.
9799342|NCT01657253|Experimental|PRO-148|"PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day"
9799343|NCT01657253|Active Comparator|Systane®|"Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day"
9799344|NCT01657266|Experimental|PRO-155|"Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
9799345|NCT01657266|Active Comparator|Nevanac|"Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension~Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
9799346|NCT01657292|Experimental|Oleogel-S10 ointment|Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
9799347|NCT01657292|Other|Octenilin® wound gel|Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
9799348|NCT01657305|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
9799349|NCT01657305|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
9799350|NCT01657344||ED Patients|All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED.
9799351|NCT01657370|Placebo Comparator|Placebo|MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
9799352|NCT01657370|Experimental|MK-1602 1 mg|MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
9799353|NCT01657370|Experimental|MK-1602 10 mg|MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
9799354|NCT01657370|Experimental|MK-1602 25 mg|MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
9837063|NCT05061420|Experimental|Cohort A2 (sub study 02) treatment-naive|Participants with HNSCC, who are treatment-naïve for R/M disease and have a PD-L1 Combined Positive Score (CPS) ≥1, will receive pembrolizumab followed by cetuximab and then SAR444245. All drugs administered by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle with additional cetuximab dosing on days 8 and 15 of each cycle. Pembrolizumab and SAR444245 dosing continues for up to 35 cycles. Cetuximab dosing continues until progressive disease.
9837064|NCT05061420|Experimental|Cohort B1: (sub study 04) PD1/PD-L1 and platinum-based treatments|Participants with HNSCC who have received treatment with a PD1/PD-L1-based regimen & platinum-based regimen and have failed no more than 2 regimens for R/M disease, will receive pembrolizumab followed by SAR444244. Both drugs administered IV infusion on Day 1 of each 21-day treatment cycle for up to 35 cycles
9837065|NCT05061420|Experimental|Cohort B2: (sub study 05) cetuximab- naïve|Participants with R/M HNSCC, who are cetuximab-naïve, have received treatment with a platinum-based regimen, and have failed no more than 2 regimens for R/M disease, will receive treatment with cetuximab followed by SAR444245. Cetuximab IV will be given on days 1, 8, and 15 of each 21 day. SAR444245 will be administered by IV infusion on Day 1 of each 21-day treatment cycle. Dosing of both drugs is to continue until disease progression, unacceptable toxicity, or withdrawal of consent.
10205680|NCT05203926|Experimental|Crohn's disease (CD) subjects|These subjects will then undergo T1 and STIR sequence MRI of SI joints (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis.
10205681|NCT05203913|Experimental|Experimental arm|This arm consists in treatment with cisplatin + nab-paclitaxel + nivolumab during radiotherapy on bladder followed by nivolumab alone after the end of radiotherapy
10205682|NCT05203848|Experimental|Dance program intervention|The community dance program (CDP) will be developed to promote older adults' physical and mental well-being through dancing. The contents of the program are developed based on the literature review (Rossberg-Gempton & Poole, 2008). The CDP will be delivered over a period of 8 weeks.
9837069|NCT05055752|Other|PL-ASA capsule, then IR-ASA tablet|One PL-ASA 325 mg capsule, 14 day washout then one IR-ASA 325 mg tablet
9837070|NCT05055752|Other|IR-ASA tablet, then PL-ASA capsule|One IR-ASA 325 mg tablet, 14 day washout, then one PL-ASA 325 mg capsule,
9998260|NCT01516489|Experimental|$500 Raffle-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be entered into a raffle in which 1 randomly chosen patient (out of about 100 patients) will be mailed a check in the amount of $500.
10205683|NCT05203848|Placebo Comparator|Control group|There will be no dance intervention among control group participants.
9837073|NCT05051527||Legalon®|Legalon® 140 mg
9837074|NCT05051033|Active Comparator|Surgical mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery.
10205684|NCT05203809||Observation group|Group of participants wearing continuous temperature monitoring device
10205685|NCT05203783|Active Comparator|Control Group|The control group will receive only McKenzie exercises for 7 days.
10205686|NCT05203783|Experimental|Experimental Group|The experimental group will receive Kinesio tape application in addition to McKenzie exercises for 7 days.
10205687|NCT05203770||CBP+mOUD|Chronic Back pain participants taking opioids and classified in the opioid misuse disorder group
10205688|NCT05203770||CBP+O|Chronic Back pain participants taking opioids and without opioid misuse disorder group
10205689|NCT05203770||CBP-O|Chronic Back pain participants not taking opioids
10205690|NCT05203770||Healthy Controls|Healthy control without pain or taking opioids.
10205691|NCT05203757|Experimental|Conventional CT-arthrogram + CBCT arthrogram|"Conventional CT-arthrogram + CBCT arthrogram (CBCT in the minutes following the conventional CT arthrogram).~Routine care (arthroCT) and CBCT of ankle."
10205692|NCT05203744|Experimental|Standard Dose (200 mg)|Participants will receive the standard 200 mg tafenoquine dose (200 mg daily for 3 days) followed by 200 mg weekly for two weeks to check for tolerability and adverse effects.
10205693|NCT05203744|Experimental|Low Monthly Dose (600 mg)|"The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose."
10205694|NCT05203744|Experimental|High Monthly Dose (800 mg)|The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose
10205695|NCT05203731|Experimental|Exercise Group|Participants who will be randomized to moderate intensity exercise after extinction (Day 1)
10205696|NCT05203731|Sham Comparator|Seated group|Participants who will be randomized to sitting after extinction (Day 1)
10205697|NCT05203666||degenerative lumbar spinal stenosis|All patients treated in 2019 with a percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
10205698|NCT05203627|Experimental|Arm I (telehealth session, guidebook)|Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.
10205699|NCT05203627|Active Comparator|Arm II (standard nutritional support)|Patients receive standard nutritional support.
10205700|NCT05203614|Other|Household Contribution|Do something thoughtful or nice for your caregiver that would provide them with tangible support
10205701|NCT05203614|Other|Outside Contribution|Do something outside your home/household that contributes to the larger society
10205702|NCT05203614|Other|Control|Keep track of your daily activities
10205703|NCT05203588|Experimental|Experimental group|Patients in this group are received denosumab (60 mg) subcutaneously at one week and 26 weeks after the lumbar fusion surgery, combined with receiving daily calcium (≥1·0 g) and vitamin D (≥400 IU).
10205704|NCT05203588|Sham Comparator|Control group|Patients in this group are only received daily calcium (≥1·0 g) and vitamin D (≥400 IU) after the lumbar fusion surgery.
10205705|NCT05203575|No Intervention|Control|Control condition
10205706|NCT05203575|Experimental|Weekly nudge in Cycle 2|Weekly nudge intervention in Cycle 2
10205707|NCT05203575|Experimental|Fast-forwarding|Fast-forwarding interventions in both Cycles
9837075|NCT05051033|Active Comparator|Transcatheter edge-to-edge repair|In the transcatheter edge-to-edge repair arm, patients will be treated with a commercially-approved edge-to-edge mitral repair device.
9837076|NCT05050942|Experimental|CAM2029|
9837077|NCT05050942|Active Comparator|Octreotide LAR or lanreotide ATG|
9984795|NCT03715751|Active Comparator|Lung Protective Ventilation|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted (while leaving the Vt at 6cc/kg) to achieve the same minute ventilation. Patients will then be maintained on their current lung protective ventilation settings for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
9984796|NCT03710538|No Intervention|[Placebo + Sedentary]|1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
9984797|NCT03710538|Experimental|[Snack effect + Sedentary]|2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
9984798|NCT03710538|Experimental|[Placebo + Exercise]|3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
9837083|NCT05047185|Other|Low dose|BID low dose of PHA-022121
9837084|NCT05047185|Other|High dose|BID high dose of PHA-022121
9837085|NCT05047185|Other|Placebo|BID placebo
9837086|NCT05045937||COVID-19 patients treated with Ivermectin|This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
9837087|NCT05045937||COVID-19 patients declining Ivermectin and wanting traditional treatment|This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
9837090|NCT05044195|Experimental|aQIV|Adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains
9837091|NCT05044195|Active Comparator|Comparator QIV|Non-adjuvanted comparator QIV containing 2 influenza type A strains and 2 influenza type B strains
9837092|NCT05043883|Experimental|Single Group|Index EP Procedure: Ablation of atrial fibrillation
9837093|NCT05042492|No Intervention|Group 1: SC (moveUP)|In group 1: moveUP (class 1, CE-marked, medical device) is being used as the rehabilitation solution after TKA. It has become a valid digital rehabilitation solution and is recognised by the Belgian government as mobile health application in rehabilitation of hip and knee arthroplasty surgeries. It's a full service with daily personalized and individualized follow up by certified physical therapists and certified health care providers. The use of tele-rehabilitation for TKA patients has been internationally recognized with the 2018 John N. Insall Award during the American Knee Society Meeting
9837094|NCT05042492|Experimental|Group 2: SC (moveUP) with 10 days of geko|In group 2: Next to SC (moveUP), the application of a single gekoTM device is used on the operated leg after surgery (day 0). This device will be worn for 24 hours and at least 8 hours from day 1 until day 10.
9837095|NCT05041803|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
9837098|NCT05039710|Experimental|Cohort 1: JNJ-75220795 or Placebo|Participants will receive single subcutaneous (SC) dose of JNJ-75220795 Dose 1 or matching placebo on Day 1 in Cohort 1.
9837099|NCT05039710|Experimental|Cohort 2: JNJ-75220795 or Placebo|Participants will receive single SC dose of JNJ-75220795 Dose 2 or matching placebo on Day 1 in Cohort 2.
9837100|NCT05037032|Active Comparator|Study drug naltrexone hydrochloride|50 mg Naltrexone PO
9837101|NCT05037032|Placebo Comparator|Matching placebo for naltrexone hydrochloride|Matching placebo for Study Drug Naltrexone
9837102|NCT05036785|Active Comparator|Suture removal at 7 days|Suture removal at 7 days post skin surgery
9837103|NCT05036785|Active Comparator|Suture removal at 10 days|Suture removal at 10 days post skin surgery
9837104|NCT05035654|Experimental|Treatment Arm A: LYR-220 Design 1|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
9837105|NCT05035654|Experimental|Treatment Arm B: LYR-220 Design 2|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
9837106|NCT05035654|Sham Comparator|Treatment Arm C: Bilateral sham procedure control|Bilateral sham procedure control
9984799|NCT03710538|Experimental|[Snack + Exercise]|4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
9984800|NCT03709368|Experimental|RANAS|Hardware CLTS+PHAST RANAS (contextualized)
9837109|NCT05034874|Experimental|IXT-m200|Anti-methamphetamine monoclonal antibody, dose levels of 1.5 and 3 g
9837110|NCT05034874|Placebo Comparator|Placebo|Saline
9984801|NCT03709368|Experimental|Mini-RANAS|Hardware CLTS+PHAST mini-RANAS (norms)
9837112|NCT05029726|Experimental|Investigational|Patients will undergo regional ESPB with bupivacaine plus clonidine in the holding area of the OR immediately prior to surgery. 30mL of 0.25% bupivacaine/1:200,000 epinephrine/50mcg clonidine will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
9837113|NCT05029726|Placebo Comparator|Control|Patients will receive a placebo injection of normal saline via the same ESPB technique. 30ml of normal saline will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
9837114|NCT05029050|Experimental|Dexmedetomidine (D)|Continuous intravenous infusion of dexmedetomidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
9837115|NCT05029050|Experimental|Clonidine (C)|Continuous intravenous infusion of clonidine 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
9837116|NCT05029050|Placebo Comparator|Placebo (P)|Continuous intravenous infusion of saline 0.4 μg/kg/hour from the start of cardiopulmonary bypass and during surgery, followed by 0.2 μg/kg/hour until discharge from the ICU or 24 hours postoperatively, whichever happens first.
9837117|NCT05028582|Active Comparator|ARQ-154 Foam 0.3%|ARQ-154 Foam 0.3%
9837118|NCT05028582|Placebo Comparator|ARQ-154 Vehicle|ARQ-154 Vehicle
9984802|NCT03709368|Active Comparator|Control|Hardware CLTS+PHAST Placebo
9984803|NCT03706976|Experimental|CTOM|
9984804|NCT03705962|Experimental|Antibiotic|Subjects will be injected locally at the wound cavity (i.e. fracture site, surrounding soft tissue which include muscle, and subcutaneous space) with 80mg/40mL of tobramycin after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
9984805|NCT03705962|Placebo Comparator|Normal Saline|Subjects will be injected locally with 40 mL 0.9% NS after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
9984806|NCT03705338||Electroencephalography|Electroencephalography (EEG) for induction and emergence in pediatric patients under general anesthesia with propofol.
9984807|NCT03705286|Active Comparator|PVC-ETT|Polyvinylchloride endotracheal tube
9787115|NCT01295112|Sham Comparator|Group 1|Active bevacizumab (Avastin®) and Sham Ozurdex®
9787116|NCT01295112|Active Comparator|Group 2|Active bevacizumab (Avastin®) and Active Ozurdex®
9787117|NCT01295216|Experimental|Intervention|Pre-hypertensive subjects who receive mHealth support for 12 months
9787118|NCT01295216|No Intervention|Control|Individuals who receive the usual primary health care
9787119|NCT01295281|Experimental|LoFric POBE 2.0 - PVC|First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
9787120|NCT01295281|Experimental|LoFric PVC - POBE 2.0|First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.
9787121|NCT01295320|Experimental|GSK1437173A Group|Subjects who received 2 doses of HZ vaccine in the intermediate dose study group in study 108494 (NCT00434577). No treatment was given in this current study (NCT01295320).
9787122|NCT01295515|Experimental|Interferon treatment|Interferon treatment The intervention is administration of Pegylated Interferon Alpha 2b (PEGINTRON) weekly for four weeks
9787123|NCT01295580|Active Comparator|ARTZ sodium hyaluronate|The comparator product, ARTZ, is manufactured by Seikagaku Corporation, Japan. Subjects randomized to the ARTZ group were administered five weekly intra-articular injections (2.5 ml, NASHA 25 mg). ARTZ is a sterile, viscoelastic nonpyrogenic solution of purified, high molecular weight (620,000-1,170,000 daltons) sodium hyaluronate having a pH of 6.8-7.8. The sodium hyaluronate is extracted from chicken combs.
9787124|NCT01295580|Active Comparator|DUROLANE hyaluronic acid|The investigational product was provided in pre-filled syringes containing stabilized non-animal hyaluronic acid (20 mg/mL). Only one injection was given for those subjects randomized to the DUROLANE group, followed by 4 sham injections. DUROLANE is free from products of animal origin and is manufactured by Q-Med AB Corporation.The sham injection procedure was same as the active injection, except that they were subcutaneous and an empty syringe was used.
9787125|NCT01295671|Active Comparator|Sugar-Sweetened Beverages|Provision of beverages: Sugar-sweetened beverages
9787126|NCT01295671|Experimental|Artificially-sweetened Beverages|Provision of beverages: Artificially-sweetened beverages
9787127|NCT01295671|Experimental|Unsweetened Beverages|Provision of beverages: Unsweetened beverages
9787128|NCT01295710|Active Comparator|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
9787129|NCT01295710|Placebo Comparator|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
9787130|NCT01295814|Experimental|adalimumab|Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
9787131|NCT01295814|Placebo Comparator|Inactive drug|Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
9787132|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.
9787133|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.
9787134|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)|During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.
9787135|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.
9787136|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.
9787137|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.
9787138|NCT01295827|Experimental|MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
9799355|NCT01657370|Experimental|MK-1602 50 mg|MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
9787139|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
9787140|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q2W (Part B)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
9787141|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
9787142|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
9787143|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
9787144|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 2 mg/kg Q3W. No participants were enrolled in this arm.
9787145|NCT01295827|Experimental|NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 5 mg/kg Q3W. No participants were enrolled in this arm.
9787146|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 10 mg/kg Q3W. No participants were enrolled in this arm.
9787147|NCT01295840|No Intervention|CRT therapy|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
9787148|NCT01295879|Experimental|Ergocalciferol|Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
9787149|NCT01295905|Experimental|delefilcon A|Investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
9787150|NCT01295905|Active Comparator|narafilcon B|Commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
9787151|NCT01296035|Experimental|Panitumumab and Gemcitabine|Panitumumab and Gemcitabine
9787152|NCT01296152|Experimental|Depo-medroxyprogesterone acetate (DMPA)|At study entry/ Day 0, subjects will receive depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
9787153|NCT01296191|Active Comparator|VIGAMOX|Subjects undergoing cataract surgery, randomized to the VIGAMOX group Generic name is moxifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
9787154|NCT01296191|Active Comparator|Besivance|Subjects scheduled for cataract surgery, randomized to the Besivance group Generic name is besifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
9787155|NCT01296347|No Intervention|Saline|Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.
9787156|NCT01296347|Experimental|ketamine|Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
9787157|NCT01296360|Active Comparator|>14 months to <2 years|IXIARO 0.25 ml i.m. (milliliter, intramuscular)
9787158|NCT01296360|Active Comparator|>3 years - <18 years|IXIARO 0.5 ml i.m (milliliter, intramuscular)
9787159|NCT01296412|Experimental|Sitagliptin +/- glimepiride|Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
9787160|NCT01296412|Active Comparator|Liraglutide|Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
9787161|NCT01296542|Active Comparator|VIGAMOX|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
9787162|NCT01296542|Active Comparator|Besivance|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
9787163|NCT01296568|Experimental|LY2603618|"Single 250 milligram (mg) intravenous dose of LY2603618 containing carbon-14-labeled LY2603618 ([^14C]LY2603618).~After the completion of a minimum 7-day washout period, participants may receive additional doses of LY2603618 in combination as follows:~Gemcitabine 1000 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 with 230 mg LY2603618 being administered on Days 2, 9 and 16 of a 28-day cycle OR~Pemetrexed 500 mg/m^2 on Day 1 and 275 mg LY2603618 on Day 2 of a 21-day cycle~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
9787164|NCT01296646|Active Comparator|Arm 1|Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
9787165|NCT01296646|Active Comparator|Arm 2|Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
9787166|NCT01296646|Active Comparator|Arm 3|Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
9787167|NCT01296646|Active Comparator|Arm 4|Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions
9787168|NCT01296672|Experimental|Finasteride|Finasteride 5mg tablets every day by mouth for 3 months
9787169|NCT01296672|Placebo Comparator|Placebo|Placebo 5mg tablet every day by mouth for 3 months
9787170|NCT01296698|Placebo Comparator|Placebo|0 mg Oral NRT, up to 4 times per hour for 12 weeks
9787171|NCT01296698|Experimental|Nicotine|1 mg Oral NRT, up to 4 times per hour for 12 weeks
9787172|NCT01296763|Experimental|Irinotecan, Cisplatin, Olaparib, then add Mitomycin-C|A 3+3 dose escalation design will be used starting with dose 1. The maximally tolerated dose is defined as the highest dose for which at most 1 out of 6 patients experiences a DLT. We will use 3 patients per dose cohort. If 0 of 3 patients have a DLT (see section 5a) then the escalation will be continued at the next dose level. If 1 of 3 patients have a DLT then three more patients will be enrolled at this dose. If 1 of 6 patients has a DLT then the dose escalation will continue. If 2 or more of the first 3 patients, or >2 of 6 patients treated have a DLT at the dose level, we will reduce the dose to the previous dose level of Olaparib for the phase 2 and then test Mitomycin C (phase 1 dose 5). If DLTs are observed at our dose 1 regimen, we will reduce the duration of Olaparib from day 1 and day 8 to just day 1 (dose level -1) and we will not test Mitomycin C in the trial.
9787173|NCT01296815|No Intervention|HAART|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
9787174|NCT01296815|Experimental|HAART+ Bevacizumab injection|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.
9787175|NCT01296841|No Intervention|Standard encounter|"Standard in-house clinical visit between patient and physician."
9787176|NCT01296841|Experimental|Telemedicine Encounter|Remote clinical appointment between patient and physician.
9787177|NCT01296932|Experimental|Patients with relapsed CLL|Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
9787178|NCT01297062|Experimental|Exenatide|
9787179|NCT01297062|Placebo Comparator|Placebo|
9787180|NCT01297062|Active Comparator|Moxifloxacin|
9787181|NCT01297244|Experimental|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
9787182|NCT01297270|Active Comparator|PegIFN/RBV|48 weeks
9787183|NCT01297270|Experimental|BI 201335 for 24 weeks|BI 201 335 QD dosing in combination with IFN/RBV
9787184|NCT01297270|Experimental|BI201335 for 12 weeks|BI 201335 QD doing in combination with PEFG IFN/RBV
9787185|NCT01297270|Placebo Comparator|Placebo|
9787186|NCT01297283|Experimental|Leadless ECG first|Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device
9984808|NCT03705286|Experimental|EVAC-PU-ETT|Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
9984809|NCT03704285||Propofol|Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
9984810|NCT03702179|Experimental|Durvalumab + Tremelimumab|"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.~Two weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder."
9984811|NCT03698487|No Intervention|Retrospective Chart Review|"Specifically, it consists of:~A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).~A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
9984812|NCT03698487|Active Comparator|Intervention|"A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
9837131|NCT05024994|Experimental|E7820|Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
9837132|NCT05021640|Experimental|Cohort 1 DCR-AUD|Single dose, subcutaneous administration of 80 mg of DCR-AUD (HV)
9837133|NCT05021640|Placebo Comparator|Cohort 1 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
9837134|NCT05021640|Experimental|Cohort 2 DCR-AUD|Single dose, subcutaneous administration of 240 mg of DCR-AUD (HV)
9837135|NCT05021640|Placebo Comparator|Cohort 2 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
9837136|NCT05021640|Experimental|Cohort 3 DCR-AUD|Single dose, subcutaneous administration of 480 mg of DCR-AUD (HV)
9837137|NCT05021640|Placebo Comparator|Cohort 3 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
9837138|NCT05021640|Experimental|Cohort 4 (OPTIONAL) DCR-AUD|Single dose, subcutaneous administration of 960 mg of DCR-AUD (HV)
9837139|NCT05021640|Placebo Comparator|Cohort 4 (OPTIONAL) DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
9837140|NCT05020665|Experimental|Intensive Chemotherapy + Entospletinib (ENTO)|Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with entospletinib (ENTO).
9837141|NCT05020665|Placebo Comparator|Intensive Chemotherapy + Placebo|Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with the matching placebo.
9984813|NCT03697148|Experimental|Diagnostic (mpMRI)|Patients undergo mpMRI within 3 months prior to schedule surgery.
9984814|NCT03696537|Experimental|Fludarabine + Total Marrow Irradiation|
9984815|NCT03695380|Experimental|Arm A: Cobimetinib - Niraparib|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1, Cohort 1.
9837148|NCT05018806|Experimental|Rilzabrutinib|Rilzabrutinib BID or TID
9837149|NCT05018806|Placebo Comparator|Placebo|Matching placebo
9837156|NCT05015426|Experimental|Dose Level -1|"Dose Level -1 may be used as a de-escalation dose level due to Dose Limiting Toxicities (DLTs) from Dose Level 1~Participants will receive 1.0 x 106 cells/kg (0.75-1.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion"
9837157|NCT05015426|Experimental|Dose Level 1|Participants will receive 5.0 x 106 cells/kg (3.75-6.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
9837158|NCT05015426|Experimental|Dose Level 2|Participants will receive 2.5 x 107 cells/kg (1.875-3.125 x 107 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
9787187|NCT01297283|Active Comparator|Programmer ECG first|Measurements of pacing thresholds are done first with the support of the programmer ECG
9787188|NCT01297309|Experimental|NPSP558|titration of 25, 50, 75 or 100 μg
9787189|NCT01297322|Active Comparator|Manual compression|Using manual compression to reach hemostasis
9787190|NCT01297322|Experimental|VASCADE™ Vascular Closure System|The Cardiva VASCADETM Vascular Closure System (VCS) is indicated for the percutaneous closure of common femoral artery access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular catheterization procedures utilizing 6 Fr or 7 Fr procedural sheaths.
9787191|NCT01297335|Experimental|Intrathecal Clonidine|Subject will receive one time Clonidine injection via lower lumber interspace. Clonidine (Duraclon), 100 μg/ml, 1.5 ml will be diluted to 2 ml with preservative free saline, and total of 150 μg will be delivered. Supine and sitting blood pressures and heart rate will be measured at 10 minute intervals until 60 minutes after clonidine administration, then at 15 minutes for next 3 hours.
9787192|NCT01297348||Lybrel®|Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).
9787193|NCT01297348||Other OCs containing 20μg of ethinyl estradiol|Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
9787194|NCT01297465|Active Comparator|Gonal-f® Plus Pergoveris®|
9787195|NCT01297465|Experimental|Pergoveris®|
9787196|NCT01297491|Experimental|Squamous BKM120 100mg qd|Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.
9787197|NCT01297491|Experimental|Non-Squamous BKM120 100mg qd|Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.
9787198|NCT01297504||Palivizumab|Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
9787199|NCT01297517|Experimental|Brinzolamide/Brimonidine|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
9787200|NCT01297517|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
9787201|NCT01297517|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months
9787202|NCT01297595|Experimental|crizotinib|
9787203|NCT01297920|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 3 times a day for 3 months
9787204|NCT01297920|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each eye 3 times a day for 3 months
10205708|NCT05203575|Experimental|Fast-forwarding with weekly nudge in Cycle 2|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 2
9787205|NCT01297920|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each eye 3 times a day for 3 months
9787206|NCT01297959|Experimental|E-101 Solution 300 GU/mL|Participants will receive E-101 Solution at porcine myeloperoxidase (pMPO) concentration of 300 guaiacol units per milliliter (GU/mL) applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
9787207|NCT01297959|Placebo Comparator|Placebo (Saline solution)|Participants will receive placebo (saline solution) matched to E-101 Solution applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
9787208|NCT01297985|Experimental|BRIDGES Intervention|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a 10-week course to an 8-week course, meeting for 2 1/2 hours once a week.
9787209|NCT01297985|No Intervention|Comparison Wait-list Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend the BRIDGES program after their final research interview.
9787210|NCT01298063|Experimental|Afatinib Group A, B (2), D|healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib
9787211|NCT01298063|Experimental|Afatinib Group B (3), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib
10205709|NCT05203575|Experimental|Weekly nudge in Cycle 1|Weekly nudge intervention in Cycle 1
10205710|NCT05203575|Experimental|Weekly nudge|Weekly nudge interventions in both Cycles
10205711|NCT05203575|Experimental|Fast-forwarding with weekly nudge in Cycle 1|Fast-forwarding interventions in both Cycles, plus weekly nudge intervention in Cycle 1
10205712|NCT05203575|Experimental|Full intervention|All interventions applied in all Cycles
10205713|NCT05203575|Experimental|Fast-forwarding in Cycle 1|Fast-forwarding intervention in Cycle 1
9787212|NCT01298063|Experimental|Afatinib Group B (1), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib
9787213|NCT01298128|Experimental|NuvaRing|NuvaRing for IVF pre-treatment
9787214|NCT01298128|Active Comparator|Combined oral contraceptive pill|OCP for IVF pre-treatment
9787215|NCT01298141|Experimental|Replagal®|All eligible patients may receive Replagal produced by the bioreactor process (AF Replagal) on this treatment plan until AF Replagal is commercially available for the patient, the patient's participation is discontinued, or the study is discontinued, whichever comes first.
9787216|NCT01298167|Active Comparator|Cyanoacrylate Superior/Inferior|This arm contains data from only the Cyanoacrylate used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast Absorbing Gut suture.
9787217|NCT01298167|Active Comparator|Fast Absorbing Gut Suture Superior/Inferior|This arm contains data from only the Fast Absorbing Gut Suture used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast absorbing gut suture.
9787218|NCT01298193|Experimental|Aprepitant|"Observational phase (first cycle):~Day 0 (Dexamethasone 8mg) Day 1 (5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg) + Chemotherapy (Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 ).~Days 2 and 3 (Dexamethasone 16 mg).~If not complete response:~Efficacy phase (second cycle):~Day 0 (Dexamethasone 8mg) Day 1 (Aprepitant: 125 mg,5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2, Tropisetron: 5 mg, Dexamethasone 12 mg)+ Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 .~Days 2 and 3 (Aprepitant: 1 capsule of 80 mg daily, Dexamethasone 8 mg)."
9787219|NCT01298219|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
9787220|NCT01298219|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
9787221|NCT01298323|Active Comparator|Vandetanib Control|Control - treatment 300mg vandetanib opel label
9787222|NCT01298323|Experimental|Experimental|Experimental - treatment 300mg vandetanib opel label
9787223|NCT01298362||AIs as first line therapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as first line therapy for 12 months.
9787224|NCT01298362||AIs after chemotherapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as maintenance therapy for 12 months after initial treatment with anthracycline- and/or taxane-based chemotherapy (chemotherapy treatment duration: 1-6 months).
9787225|NCT01298492|Experimental|Open-Label Treatment|Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008
9787226|NCT01298518|Experimental|PF-04620110|
9787227|NCT01298518|Placebo Comparator|placebo|
9787228|NCT01298531|Active Comparator|etanercept|Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
9787229|NCT01298531|Placebo Comparator|etanercept-placebo|Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.
9787230|NCT01298544|Other|All subjects|
9787231|NCT01298570|Active Comparator|Regorafenib + FOLFIRI|regorafenib 160 mg + FOLFIRI
9787232|NCT01298570|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
9787233|NCT01298596|Experimental|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
9787234|NCT01298596|Experimental|Loop Electrosurgical Excision Procedure|Loop Electrosurgical Excision Procedure (LEEP) uses a low-voltage electrified wire loop to cut out diseased part of cervix
9787235|NCT01298648||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
9787236|NCT01298661|Other|Healthy Young Subjects|Subjects apparently healthy, with age of 18 to 27 years old.
9787237|NCT01298661|Other|Healthy Elderly subjects|Subjects apparently healthy, with age of 60 to 75 years old.
9787238|NCT01298661|Other|COPD Patients|Patients with clinical and spirometric diagnosis of COPD
9787239|NCT01298700|Experimental|Bimatoprost 0.01% Ophthalmic Solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
9837159|NCT05015426|Experimental|Dose Level 3|Participants will receive 1.0 x 108 cells/kg (0.75-1.25 x 108 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
9837160|NCT05015426|Experimental|Treatment at Maximum Tolerated Dose|Participants will receive Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells at the dose determined to be the Maximum Tolerated Dose, administered as a single infusion
9837161|NCT05013645|Experimental|Sterilized probiotic (LfQi601)|Sterilized probiotic topically administered.
9837162|NCT05013645|Placebo Comparator|Gel control product|Inactive placebo.
9837163|NCT05013073|Experimental|Experimental Arm|All patients will be enrolled in a single arm and download the mobile application ASTHMAxcel ED to their smartphones.
9984816|NCT03695380|Experimental|Arm B: Cobimetinib - Niraparib - Atezolizumab|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib QD on Days 1-28 at the established doses for the triplet regimen in Stage 1,Cohort 2 plus atezolizumab by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.
9984817|NCT03695380|Experimental|Cohort 1 - Cobimetinib - Niraparib|"Stage 1 - Patients in Cohort 1 will be treated with cobimetinib plus niraparib.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle."
9998261|NCT01516489|No Intervention|Stage 2 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
9837170|NCT05011565||Fontan Group|"Fontan Group Inclusion Criteria~be between the ages of 8-50~Having undergone Fontan operation in our hospital or another center~Clinical stability of the patients (preserved ventricular function),~No change in ongoing drug therapy that adversely affects clinical stability,~At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital~Fontan Group Exclusion Criteria:~Inability to access the patient's medical data~Neurological and/or genetic musculoskeletal disease~Having orthopedic and cognitive problems that prevent testing~The patient's and/or family's unwillingness to participate in the study"
9837171|NCT05011565||Control Group|"Control Group Inclusion Criteria:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease~Not having orthopedic and cognitive problems that prevent testing~The patient's and/or family's willingness to participate in the study"
9837173|NCT05008627||Doffing PPE with verbal instructions and monitor|The subject will remove the PPE according to verbal instructions by a monitor
9837174|NCT05008627||Doffing PPE without verbal instructions|The subject will remove the PPE independently without a monitor
10205714|NCT05203575|Experimental|Full in Cycle 1|Fast-forwarding and weekly nudge interventions in Cycle 1
9984818|NCT03695380|Experimental|Cohort 2 - Cobimetinib - Niraparib - Atezolizumab|"Stage 1 - Patients in Cohort 2 will be treated with cobimetinib plus niraparib and atezolizumab.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.~Atezolizumab: Patients will also receive atezolizumab administered as an IV infusion at a fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle."
9984819|NCT03688243||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
9837177|NCT05007899|Active Comparator|Daily|Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning.
9837178|NCT05007899|Experimental|Alternate Day|Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning.
9984820|NCT03688243||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
9984821|NCT03688243||Cohort 3|Subjects with GA enrolled in another trial
9837179|NCT05007652|Experimental|multiple myeloma cohort (KRN125)|
9837180|NCT05007652|Active Comparator|multiple myeloma cohort (KRN8601)|
9837181|NCT05007652|Experimental|malignant lymphoma cohort|
9984822|NCT03684655|Experimental|[18F]F-AraG|"radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
9984823|NCT03682250||Patients with type 1 diabetes with a high cardiovascular risk|
9984824|NCT03671330|Experimental|Ribociclib|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal experimental arm:~Letrozole + Ribociclib~PK Cohort: Open-label ribociclib + Letrozole treatment combination.~For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
9984825|NCT03671330|Placebo Comparator|Ribociclib Placebo|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal control arm:~Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
9984826|NCT03671304|Experimental|Just-in-time Adaptive Intervention|Participants will receive a Fitbit Versa and instructions on its use. The study design is not a traditional randomized controlled trial in which participants are randomized to either the intervention or control group. Instead the study utilizes a microrandomized design. This is a within-subjects design in which participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
9984827|NCT03669523|Experimental|Denosumab-nivolumab combination|Both drugs to be continued until progression or unacceptable toxicity and for a maximum of two years
9998262|NCT01516502|Active Comparator|laser to acupoint|
9998263|NCT01516502|Sham Comparator|sham laser to acupoint|
9998264|NCT01516502|Active Comparator|laser to trigger point|
9837191|NCT05006079|Placebo Comparator|Placebo drug|Lactose, administered both at 9:30 am and 12:00 pm
9998265|NCT01516502|Sham Comparator|sham laser to trigger point|
10205715|NCT05203562|Active Comparator|Control group I|Patients with complete mole treated by evacuation of using suction curettage followed by conservative follow up
10205716|NCT05203562|Experimental|Prophylactic letrozole group II|Patients with complete mole treated by evacuation of using suction curettage followed by 5mg daily letrozole for 10 days followed by conservative follow up
10205717|NCT05203549||Gastric cancer patients|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
10205718|NCT05203510|Experimental|Treprostinil|"Participants will receive parenteral treprostinil at an initial dose of 1.25 nanograms (ng)/kilogram (kg)/minute (min) (or 0.625 ng/kg/min, if initial dose is not tolerated) either intravenously (IV) or subcutaneously (SC).~Based on Month 6 mPAP assessment or earlier at Investigator's discretion and after a target dose is reached, participants may transition to oral treprostinil 3 times daily (TID) and continue up-titration in dose towards further reduction of mPAP or participants may continue up-titration of parenteral treprostinil until Month 12. Following completion of all Month 12 assessments, at Investigator's discretion, participants may transition from parenteral to oral treprostinil TID and continue up-titration for further reduction of mPAP. Treprostinil therapy (parenteral or oral) may continue, as tolerated, towards the goal of further reduction of mPAP until Month 36."
10205719|NCT05203497|Experimental|The tested injected doses of 99mTc-ZHER2:41071 500 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose.~Subjects withdrawn from the study for any reason will be replaced."
10205720|NCT05203497|Experimental|The tested injected doses of 99mTc-ZHER2:41071 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose.~Subjects withdrawn from the study for any reason will be replaced."
10205721|NCT05203484|Experimental|Multielectrode mapping|Participants assigned to the Multielectrode Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with either a Pentaray or Octaray catheter (Biosense Webster; each 45 catheters, randomly allocated). Catheter ablation of potential diastolic pathways and Scar homogenisation will be performed with a irrigated 3.5mm tip catheter (QDot; Biosense Webster).
9837192|NCT05006079|Active Comparator|Morphine alone|15mg immediate-release oral morphine, administered both at 9:30 am and 12:00 pm
9837193|NCT05006079|Active Comparator|Alprazolam alone|0.25mg oral alprazolam, administered at both 9:30 am and 12:00 pm
9837194|NCT05006079|Active Comparator|Morphine then alprazolam|15mg oral morphine administered at 9:30 am, then 0.25mg oral alprazolam administered at 12:00 pm
9837195|NCT05006079|Active Comparator|Alprazolam then morphine|0.25mg oral alprazolam administered at 9:30 am, then 15mg oral morphine administered at 12:00 pm
9837196|NCT05006079|Active Comparator|Morphine+alprazolam simultaneously|morphine 15mg + 0.25mg alprazolam at 9:30 am, then morphine 15mg + 0.25mg alprazolam at 12:00 pm
9837197|NCT05005663|Active Comparator|group A|patients younger than 2 years
9837198|NCT05005663|Active Comparator|group B|patients older than 2 years
9984828|NCT03668951|Experimental|Buccal DEX 2 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
9984829|NCT03668951|Experimental|Intranasal DEX 3 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
9837201|NCT04998604|Experimental|Dupilumab|Dosing every 2 weeks (Q2W)
9837202|NCT04998604|Experimental|Omalizumab|Dosing Q2W or every 4 weeks (Q4W)
9837203|NCT04996056|Experimental|TNX-1300|TNX-1300 Intravenous injection 200 mg once over 2 mins
9837204|NCT04996056|Other|Usual Care|Usual Care per the Emergency Department protocol for treating Cocaine Intoxication
9837205|NCT04993599|Experimental|Pediatric patients|<Intervention> The participants(Pediatric patients) mainly interact with the social robot which is controlled by the researcher behind the scene
9837206|NCT04993599|Experimental|Carers|<Intervention> The participants(Carers) interact with the social robot and watch how their child interact with the robot which is controlled by the researcher behind the scene
9837207|NCT04984681|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based stress reduction sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
9837208|NCT04984681|Other|Usual Care|The control condition will continue receiving usual care or standard of care.
9984830|NCT03668951|Experimental|Intranasal DEX 4 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
9837210|NCT04982237|Experimental|AK104+chemotherapy± bevacizumab|AK104 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
9837211|NCT04982237|Placebo Comparator|Placebo+chemotherapy± bevacizumab|Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
9837212|NCT04981613|Experimental|Experimental group|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
9837213|NCT04981613|No Intervention|Control group|irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
9984831|NCT03665207|Experimental|Tight glucose control|Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
9984832|NCT03665207|Active Comparator|Liberal glucose control|Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
9984833|NCT03664765|Active Comparator|Intervention exercise arm|daily oropharyngeal and respiratory muscle exercises
9984834|NCT03664765|Sham Comparator|Control arm|Daily sham exercises
9984835|NCT03663829||Participants RA who have received a TNFi|
9984836|NCT03663829||Participants with RA who have received abatacept|
9837220|NCT04977271|Experimental|Treatment Group|"Starting dose of oral venlafaxine immediate release (IR) 37.5 mg BID, to be taken with food. The dosing will be increased at a rate of 75mg per week for 3 weeks, to reach a desired dose of 300mg per day, taken as 150mg BID.~For patients with hepatic impairment, severe renal impairment, or end-stage kidney disease, the starting dose is 37.5 mg once daily, and the dose is increased by increments of 37.5 mg per day, to a maximum of 187.5 mg per day, taken as 93.75 mg BID."
9837221|NCT04977271|No Intervention|Control Group|No intervention will be provided for this group
9984837|NCT03663335|Experimental|Arm 1/Cohort 1|CFZ533 dose A+ MMF + Corticosteroids
9984838|NCT03663335|Experimental|Arm 2/Cohort 1|CFZ533 dose B + MMF + Corticosteroids
9984839|NCT03663335|Active Comparator|Arm 3/Cohort 1|Control/Standard of Care: TAC + MMF + Corticosteroids
9984840|NCT03663335|Experimental|Arm 1/Cohort 2|CFZ533 dose C + MMF ± Corticosteroids
9984841|NCT03663335|Active Comparator|Arm 2/Cohort 2|Tac + MMF ± Corticosteroids
9837229|NCT04964375|Experimental|ABSK043|"Dose escalation of oral ABSK043 with a starting dose of 200mg once daily will be guided byBOIN escalation rules based on safety data until an MTD has been identified or a RDE. For each dose,In the escalation part, sequential cohorts of patients will receive an oral dose of ABSK043 in repeated 28-day cycles. Starting dose level will be 200 mg QD. Cohort 3 on 800mg will be switched to 400mg BID.Then, patients will continuously receive ABSK043 （total daily dose） in repeated 28-day cycles.For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043 at the RDE in repeated 28-day cycles."
9837230|NCT04963296|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.
9837231|NCT04963296|Placebo Comparator|Placebo|Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.
9984842|NCT03662672|Experimental|Rib-raising Intervention|We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
9984843|NCT03662672|Sham Comparator|Sham Intervention|We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
9984844|NCT03661996|Experimental|Breg Cooling Control Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Breg ice water pump.
9837235|NCT04963140|Experimental|Intervention|Intervention subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm signals when an increased risk of exacerbation is detected and subjects shall modify their treatment based on the action plan prescribed by the study doctor at enrolment and used for the self-management of their asthma
9837236|NCT04963140|Sham Comparator|Control|Control subjects will monitor their lung function daily by Forced Oscillation Technique (FOT) device. The embedded algorithm used in the intervention arm is disabled. Subjects will follow the action plan prescribed by the study doctor at enrolment for the self-management of their asthma
9837237|NCT04961034|Other|classic KPE|the classic management of biliary atresia as described
9837238|NCT04961034|Other|modified KPE|we added 2 sutures posterior, one on each side and two anterior. this will hang the jejunal loop to promote tension free anastomosis
9837239|NCT04960748|Experimental|intervention|7-sesson group intervention that uses dyadic instruction, role playing and group sharing and discussion to reduce internalized stigma, improve disclosure decision making and healthy living, and teach advocacy skills
9837240|NCT04960748|No Intervention|wait-list control|Participants will not receive the intervention until all follow-up data has been collected.
9984845|NCT03661996|Experimental|Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
9984846|NCT03661996|Experimental|Shortened Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
9667519|NCT03486704|Active Comparator|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
9984847|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 2% Lidocaine|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
9984848|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 1% Lidocaine|Subject receives 1% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
9984849|NCT03659799|Active Comparator|Aspart - 60-minutes postprandial exercise|
9837249|NCT04958811|Experimental|Tiragolumab plus atezolizumab and bevacizumab|Tiragolumab 600mg IV will be administered together with atezolizumab 1200mg IV and bevacizumab 15mg/kg IV every 3 weeks (q3w) until progressive disease or unacceptable toxicity.
9837250|NCT04955990|Experimental|Participants with PAH|Participants with pulmonary arterial hypertension (PAH) who newly initiate any PAH therapy(ies) at the index date (date when a participant starts the first new PAH therapy after baseline assessments) in a routine clinical setting, either as first-line therapy, as replacement therapies, as concomitant with other PAH therapies, or have already been receiving macitentan 10 milligrams (mg) for at least 3 months prior to the index date. The primary data source for this study will be the medical records of each participant.
9837251|NCT04954326|Experimental|S95014 lyophilizate|Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.
9787240|NCT01298700|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
9787241|NCT01298752|Experimental|Mapracorat|Mapracorat ophthalmic suspension
9787242|NCT01298752|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
9787243|NCT01298765|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
9787244|NCT01298778|Placebo Comparator|Standard of care|Spinal consists of duramorph 150 mcg combined with fentanyl and bupivacaine in conjunction with placebo capsules 2 PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
9787245|NCT01298778|Active Comparator|Acetaminophen and increased dose of Duramorph|Spinal consists of duramorph 300 mcg combined with fentanyl and bupivacaine in conjunction with Acetaminophen 1 Gm PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
9787246|NCT01298999|Experimental|YF476|YF476 (gastrin-receptor antagonist)
9787247|NCT01298999|Placebo Comparator|Placebo|Placebo pill (identical in appearance to YF476 pills)
9787248|NCT01299025|No Intervention|Control|Participants allocated as controls receive no treatment. They may be physically active as usual.
9787249|NCT01299025|Experimental|Training with Nintendo Wii Fit|Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week
9787250|NCT01299038|Active Comparator|Group 1|Rosuvastatin 20mg taken orally once a day for 4 weeks
9787251|NCT01299038|Active Comparator|Group 2|Rosuvastatin 40mg taken orally once a day for 4 weeks
9787252|NCT01299077||Lumbar disc degenerative disease|Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition
9787253|NCT01299090|Experimental|Treatment Group|All subjects enrolled were in the treatment group.
9787254|NCT01299103|Active Comparator|Single Treatment|Treatment of facial wrinkle with one treatment only
9787255|NCT01299103|Active Comparator|Double Treatment|Treatment of facial wrinkle with two treatments
9787256|NCT01299103|Active Comparator|Triple treatment|Treatment of facial wrinkle with three treatments
9787257|NCT01299116|Other|Preference SARC|Participants received one of a variety of oral contraceptives or DMPA
9787258|NCT01299116|Experimental|Randomized LARC|"Participants receive one of the following interventions:~Implanon® or Nexplanon®; ParaGard®; Mirena®"
9787259|NCT01299116|Active Comparator|Randomized SARC|Participants received one of a variety of oral contraceptives or DMPA
9787260|NCT01299272|Experimental|LY2216684 + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization continued their current dose of LY2216684 for another 24 weeks. Participants who completed this period or discontinued early were randomized to abrupt (placebo for 2 weeks) or tapered (12 mg LY2216684 for 4 days, 6 mg LY2216684 for 4 days, then placebo for 6 days) discontinuation of LY2216684."
9787261|NCT01299272|Placebo Comparator|Placebo + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization were tapered from their LY2216684 dose to placebo following the regimen of 12 mg for 7 days, 6 mg for 7 days, and placebo for the remaining 22 weeks. Participants who completed this period or discontinued early continued to receive placebo for an additional 2 weeks"
9787262|NCT01299285|Experimental|LY3009104|Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
9787263|NCT01299376|Experimental|L50/H12.5/A5→L50/H12.5/A5|One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
9787264|NCT01299376|Active Comparator|L50/H12.5→L50/H12.5/A5|One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension
9787265|NCT01299389|Experimental|Paliperidone palmitate|
9787266|NCT01299389|Placebo Comparator|Placebo|
9787267|NCT01299454|Active Comparator|Normal|
9787268|NCT01299454|Active Comparator|Mild|
9787269|NCT01299454|Active Comparator|Moderate|
9787270|NCT01299454|Active Comparator|Severe|
9787271|NCT01299480|Experimental|Group 1|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
9787272|NCT01299480|Experimental|Group 2|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
9787273|NCT01299480|Experimental|Group 3|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
9787274|NCT01299480|Experimental|Group 4|rLP2086 at visits 1 and 3, saline at visits 2 and 5
9787275|NCT01299480|Experimental|Group 5|rLP2086 at visits 3 and 5, saline at visits 1 and 2
9787276|NCT01299571||Dutasteride|Patients administrated dutasteride at the site
9787277|NCT01299584||Remifentanil|Patients administrated remifentanil at the site
9787278|NCT01299610|Experimental|GW870086 2.0% &amp; 0.2%|GW870086 2.0%, GW870086 0.2% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
9787279|NCT01299610|Experimental|GW870086 2.0% & FP 0.05%|GW870086 2.0%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
9787280|NCT01299610|Experimental|GW870086 0.2% & FP 0.05%|GW870086 0.2%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
9787281|NCT01299727|Experimental|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
9787282|NCT01299727|Experimental|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
9787283|NCT01299727|Experimental|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
9787284|NCT01299766|Experimental|Behavior Activation|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
9787285|NCT01299766|Placebo Comparator|Supportive Therapy (ST)|ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
9787286|NCT01299805|Experimental|Vortioxetine|Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.
9787287|NCT01299805|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.
9787288|NCT01299896|Active Comparator|Usual Care|Participants will continue to receive all the care currently offered in the VAPHS, including medications for smoking cessation and use of the in-person or telephone counseling options for quit smoking classes. For veterans with a co-pay, incurred fees with be reimbursed.
9787289|NCT01299896|Active Comparator|Coordinated Care|A CTQ Coordinator will coordinate the delivery of smoking related care.
9787290|NCT01299909|Active Comparator|Mindfulness Training for Smokers|MTS participants will receive 8 classes of training in mindfulness meditation, access to the MTS website, and 2 weeks of nicotine patches.
9787291|NCT01299909|Active Comparator|Integrated Training for Smokers|ITS participants will receive 8 classes of training in smoking cessation strategies, access to the Freedom From Smoking online program, and 2 weeks of nicotine patches.
9787292|NCT01299909|Other|Quitline|Quitline participants will consist of participants who elect not to participate in the high-intensity treatments (Mindfulness Training for Smokers; Integrated Training for Smokers. This Quitline group is a Non-Randomized, Treatment as Usual group.
9787293|NCT01299961|Experimental|Subcutaneous Abatacept|All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.
9787294|NCT01300052|Experimental|AN2728 ointment, 2%|AN2728 ointment, 2%
9787295|NCT01300052|Placebo Comparator|Ointment Vehicle|Ointment Vehicle
9787296|NCT01300065|Experimental|Experimental- Soflens|Bausch & Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.
9787297|NCT01300065|Active Comparator|Marketed - Soflens|Bausch & Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.
9787298|NCT01300234|Experimental|A (TDF tablets)|Tenofovir disoproxil fumarate (TDF) tablets
9787299|NCT01300234|Active Comparator|B (ADV tablets)|Adefovir dipivoxil (ADV) tablets
9787300|NCT01300247|Experimental|Obinutuzumab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6), fludarabine (25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6), and cyclophosphamide (250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6).
9787301|NCT01300247|Experimental|Obinutuzumab + Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6) and bendamustine (90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6).
9787302|NCT01300260|Experimental|LY2189265 then Placebo|"LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
9998266|NCT01516515|Placebo Comparator|placebo, gel|placebo comparator
9787303|NCT01300260|Experimental|Placebo then LY2189265|"Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
9787304|NCT01300286|Experimental|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
9787305|NCT01300338|Experimental|Blood pressure with telemetry|Home blood pressure monitor with telemetry
9787306|NCT01300338|Active Comparator|Blood pressure without telemetry|Home blood pressure self monitor without telemetry.
9787307|NCT01300351|Experimental|Fulvestrant 500mg|Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
9787308|NCT01300351|Active Comparator|Fulvestrant 250mg|Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
9787309|NCT01300455|Experimental|Suvorexant (40 mg)|In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.
9787310|NCT01300455|Placebo Comparator|Placebo|In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.
9787311|NCT01300546|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period, subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue of persistent or recurring headache.
9787312|NCT01300546|Active Comparator|Naproxen Sodium|In Treatment Period, subjects randomized to Naproxen Sodium 500mg will be provided with 14 tablets of Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue of persistent or recurring headache.
9787313|NCT01300559|Experimental|Treatment Group|Tissuelink device plus Unipolar electrocautery will be used in this arm of the study.
9787314|NCT01300559|No Intervention|No treatment|Unipolar electrocautery without Tissuelink device will be used in this arm of the study.
9787315|NCT01300572|Experimental|Y-90-BC8 & Allogeneic Transplant|"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180."
9787316|NCT01300624|Experimental|Verb Network Strengthening Treatment|Verb Network Strengthening Treatment (VNeST) tasks involve the retrieval of nouns related to a target verb. For example, for the verb measure, participants would come up with people who measure and what they measure (e.g., carpenter/lumber, chef/sugar). They would then answer questions related to why, where, and when these things might occur (e.g., for carpenter/measure, they might say to get the right length of board, (why) at a construction site, (where) and when building a house (where). Cues and assistance are provided to the participants when they are unable to complete any given task. As the participants improve, cues are reduced.
9799356|NCT01657370|Experimental|MK-1602 100 mg|MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
9799357|NCT01657461|Experimental|IV t-PA with Solitaire™ revascularization device|Dual IV tPA therapy and adjunctive treatment with the Solitaire revascularization device
9799358|NCT01657461|Active Comparator|IV t-PA|Infusion of intravenous tissue plasminogen activator (IV t-PA)
9787317|NCT01300650|Experimental|Anakinra|
9787318|NCT01300728|Experimental|intravenous immunoglobulin (IVIG)|IVIG (NewGam 10%)at 0.4 g/kg
9787319|NCT01300728|Placebo Comparator|Saline solution|0.9% saline solution
9787320|NCT01300741|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with galyfilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
9787321|NCT01300741|Active Comparator|Galyfilcon A|Galyfilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
9787322|NCT01300767|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with balafilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
9787323|NCT01300767|Active Comparator|Balafilcon A|Balafilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
9787324|NCT01300819|Placebo Comparator|Placebo|
9787325|NCT01300819|Experimental|Rotigotine|
9787326|NCT01300923|Active Comparator|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
9787327|NCT01300923|No Intervention|Autism Spectrum Disorder|This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization.
9787328|NCT01300949|Active Comparator|Glaucoma|154 glaucoma, ocular hypertension and glaucoma suspect patients will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
9787329|NCT01300949|Active Comparator|Controls|125 patients with no eye diseases will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).
9787330|NCT01300949|Active Comparator|Age-Related Macular Degeneration (ARMD)|35 retina patients with age-related macular degeneration (ARMD) will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
9787331|NCT01301001|Placebo Comparator|Placebo oral capsule|Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
9787332|NCT01301001|Active Comparator|Gabapentin|Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
9787333|NCT01301027|Active Comparator|Pioglitazone|15 mg/day pioglitazone for 2 weeks, then 30 mg/day for remaining 24 weeks
9787334|NCT01301027|Placebo Comparator|Placebo|1 placebo pill a day matching the pioglitazone treatment for 26 weeks
9787335|NCT01301066|Experimental|Pitavastatin 4 mg QD|
9787336|NCT01301066|Active Comparator|Pravastatin 40 mg QD|
9787337|NCT01301079|Active Comparator|Ketamine|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), remifentanil (1 μg/kg), and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group ketamine received remifentanil (0.4 μg/kg/min) and ketamine (5 μg/kg/min).~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
9787338|NCT01301079|Placebo Comparator|Saline|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), 1 μg/kg remifentanil, and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group saline received remifentanil (0.4 μg/kg/min) and saline solution.~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
9787339|NCT01301092|Experimental|Part A: LY2189265 intravenous|Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.
9787340|NCT01301092|Experimental|Part B: LY2189265 subcutaneous, intravenous|Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
9787341|NCT01301092|Experimental|Part C: LY2189265 subcutaneous, intramuscular|Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
9787342|NCT01301183|Experimental|Rh IGF-1 + Transdermal estradiol|RhIGF-1 with transdermal 17-beta estradiol
9787343|NCT01301183|Placebo Comparator|Placebo + Transdermal estradiol|Placebo and transdermal 17-beta estradiol
9787344|NCT01301274|Active Comparator|Hypotonic|Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids.
9787345|NCT01301274|Experimental|Isotonic|Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids.
9787346|NCT01301391|Experimental|Milciclib|Milciclib Maleate capsules
9787347|NCT01301456|Placebo Comparator|Treatment Arm 1 (Stage 1A)|
9787348|NCT01301456|Experimental|Treatment Arm 2 (Stage 1A)|
9787349|NCT01301456|Experimental|Treatment Arm 3 (Stage 1A)|
9787350|NCT01301456|Experimental|Treatment Arm 4 (Stage 1A)|
9787351|NCT01301456|Placebo Comparator|Treatment Arm 5 (Stage 1B)|
9787352|NCT01301456|Experimental|Treatment Arm 6 (Stage 1B)|
9787353|NCT01301456|Experimental|Treatment Arm 7 (Stage 1B)|
9787354|NCT01301456|Experimental|Treatment Arm 8 (Stage 1B)|
9787355|NCT01301456|Placebo Comparator|Treatment Arm 9 (Stage 2)|
9787356|NCT01301456|Experimental|Treatment Arm 10 (Stage 2)|
9787357|NCT01301456|Experimental|Treatment Arm 11 (Stage 2)|
9787358|NCT01301456|Experimental|Treatment Arm 12 (Stage 2)|
9787359|NCT01301456|Experimental|Treatment Arm 13 (Stage 2)|
9787360|NCT01301508|Experimental|AN2898 ointment, 1%, vs. ointment vehicle|"AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
9787361|NCT01301508|Experimental|AN2728 ointment, 2%, vs. ointment vehicle|"AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
9787362|NCT01301625||MitraClip Implant|Eligible patients undergoing a MitraClip procedure in Australia and New Zealand
9787363|NCT01301729|Experimental|Trastuzumab|Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.
9787364|NCT01301742|Active Comparator|BI 10773|Subject to receive one single dose BI 10773
9787365|NCT01301742|Experimental|BI 10773 plus gemfibrozil|Subject to receive one single dose BI 10773 plus 600 mg gemfibrozil bid for 5 days
9787366|NCT01301833|Experimental|teneligliptin|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
9787367|NCT01301833|Experimental|teneligliptin and glinide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
9787368|NCT01301833|Experimental|teneligliptin and biguanide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
9787369|NCT01301833|Experimental|teneligliptin and alpha-glucosidase inhibitor|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor
9787370|NCT01301950|Active Comparator|TruMatch® Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch® Personalized Solutions (Custom Patient Instrumentation)
9787371|NCT01301950|Active Comparator|Conventional Total Knee Replacement|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments
9787372|NCT01302041|Experimental|Enzalutamide|Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.
9787373|NCT01302054|Experimental|Fesoterodine|
9787374|NCT01302054|Placebo Comparator|Placebo|
9787375|NCT01302067|Experimental|Fesoterodine 8mg|
9787376|NCT01302067|Experimental|Fesoterodine 4mg|
9787377|NCT01302067|Placebo Comparator|Placebo|
9787378|NCT01302080||Sertraline-treated|enrolled subjects beginning treatment for one of the study qualifying disorders with sertraline
9787379|NCT01302080||psychotherapy only|enrolled subjects beginning treatment for one of the study qualifying disorders with psychotherapy
9787380|NCT01302119|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
9787381|NCT01302119|Placebo Comparator|Solution Vehicle|Solution Vehicle
9787382|NCT01302366|Experimental|Sea cucumber extract|TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.
9787383|NCT01302379|Active Comparator|Metformin + lifestyle intervention|
9787384|NCT01302379|Active Comparator|Placebo + lifestyle intervention|
9787385|NCT01302379|Active Comparator|Metformin + standard dietary guidelines|
9984850|NCT03659799|Active Comparator|Aspart - 120-minutes postprandial exercise|
9984851|NCT03659799|Active Comparator|FiAsp - 60-minutes postprandial exercise|
9984852|NCT03659799|Active Comparator|FiAsp - 120-minutes postprandial exercise|
9984853|NCT03657368|Experimental|Low tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 6 ml/ kg predicted body weight, and PEEP = 5 cm water (H2O).
9984854|NCT03657368|Experimental|Low tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 6 ml/kg predicted body weight, and PEEP = 8 cm H2O.
9984855|NCT03657368|Experimental|High tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 5cm H2O.
9998267|NCT01516515|Active Comparator|SR-T100 with 2.3% of SM, gel|2.3% of SM in Solanum undatum plant extract
9787386|NCT01302379|Placebo Comparator|Placebo + standard dietary guidelines|
9787387|NCT01302392|Active Comparator|Best Supportive Care|
9787388|NCT01302392|Experimental|Carfilzomib|
9787389|NCT01302418||Symptomatic|Individuals with signs and symptoms of an acute respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
9787390|NCT01302483|Experimental|Kovacaine Nasal Spray|3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
9787391|NCT01302483|Active Comparator|Lidocaine Injection|.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
9787392|NCT01302548|Experimental|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
9787393|NCT01302548|Active Comparator|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
9787394|NCT01302691|Experimental|L50/H12.5/A5|Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
9787395|NCT01302691|Active Comparator|L50 + A5|Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
9787396|NCT01302743|Active Comparator|Metformin|oral extended-release Metformin 1000 mg once a day for 90 days
9787397|NCT01302743|Experimental|Cinnamon Bark|Cinnamon Bark 1000 mg once a day for 90 days
9787398|NCT01302743|Experimental|Cinnulin PF|Cinnulin PF 500 mg once a day for 90 days
9787399|NCT01302808|Experimental|Cohort 1 (Erlotinib plus Romidepsin (8 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
9787400|NCT01302808|Experimental|Cohort 2 (Erlotinib plus Romidepsin (10 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
9787401|NCT01302808|Experimental|Cohort 3 (Erlotinib plus Romidepsin (10 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
9787402|NCT01302808|Experimental|Cohort 4 (Erlotinib plus Romidepsin (8 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
9787403|NCT01302834|Active Comparator|IMRT + Cisplatin|Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin
9787404|NCT01302834|Active Comparator|IMRT + Cetuximab|Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab
9787405|NCT01302860|Experimental|Canakinumab|Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.
9787406|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
9787407|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule placebo to HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
9787408|NCT01302938|Experimental|Tolterodine ER|
9787409|NCT01302938|Placebo Comparator|Placebo|
9787410|NCT01302964|Experimental|Mirtazapine|The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.
9787411|NCT01302964|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
9787412|NCT01303068|Experimental|CF patients, 13C urea breath test kit|CF patients with Pseudomonas infection tested with 13C urea breath test
9787413|NCT01303068|Active Comparator|Healthy controls, 13C urea breath test kit|Healthy subjects using 13C urea breath test kit
9787414|NCT01303159|Experimental|Radiofrequency probe (ENDOHPB)|"Intervention:~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment"
9787415|NCT01303172|Active Comparator|Gemcitabine chemotherapy|Patients in the control arm will receive normal standard of care - up to 12 cycles of Gemcitabine. Dosing of Gemcitabine is as per the normal prescribing information for pancreatic cancer.
9787416|NCT01303172|Experimental|IMM-101 in addition to gemcitabine|"Patients in the experimental arm will receive IMM-101 in addition to the current standard of care, namely chemotherapy (Gemcitabine). The treatment regimen with IMM-101 will be every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~For patients in the active group, chemotherapy (Gemcitabine) will begin at least 14 days after first dose of IMM-101.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Patients who complete the Main Study and who provide informed consent are eligible to participate in a long term treatment Sub-Study (IMM-101-002A)"
9787417|NCT01303224|Experimental|Ibodutant low dose|Oral tablet, to be given once daily in fasting conditions.
9787418|NCT01303224|Experimental|Ibodutant intermediate dose|Oral tablet, to be given once daily in fasting conditions.
9787419|NCT01303224|Experimental|Ibodutant high dose|Oral tablet, to be given once daily in fasting conditions.
9787420|NCT01303224|Placebo Comparator|Placebo|Oral tablet, to be given once daily in fasting conditions.
9787421|NCT01303380|Experimental|Canakinumab|
9799359|NCT01657617|Experimental|Radiation Therapy|Boost Stereotactic Body Radiation Therapy (SBRT)
9837252|NCT04954326|Active Comparator|S95014 liquid|Liquid S95014 is provided as 3.750 U per 5 mL solution in a single use vial to obtain a 750 U/mL solution for single use.
9837253|NCT04952701|Active Comparator|Control Lens|All subjects will wear control lenses for two weeks and then will wear Test lenses for two weeks.
9837254|NCT04952701|Experimental|Test Lens|After wearing control lenses for two weeks, all subjects will wear test lenses for two weeks.
9837255|NCT04952597|Experimental|Arm A: Ociperlimab + Tislelizumab|Ociperlimab + tislelizumab + cCRT for 4 cycles followed by ociperlimab + tislelizumab
9837256|NCT04952597|Experimental|Arm B: Tislelizumab|Tislelizumab + cCRT for 4 cycles followed by tislelizumab alone
9837257|NCT04952597|Experimental|Arm C: Concurrent Chemoradiotherapy (cCRT)|cCRT for 4 cycles
9837258|NCT04951518||Van Positive|Large Vessel Occlusion Positive
9837259|NCT04951518||Van Negative|Large Vessel Occlusion Negative
9984856|NCT03657368|Experimental|High tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 8cm H2O.
9837261|NCT04949828||Participants on CREON|
9984857|NCT03651648|Experimental|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
9837264|NCT04947800|Experimental|Arm A: 12 week intervention, 8 week control|Electro acupuncture (EA) intervention will be administered for 12 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 8 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
9837265|NCT04947800|Experimental|Arm B: 8 week intervention, 12 week control|Electro acupuncture (EA) intervention will be administered for 8 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 12 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
9921919|NCT00832754|Active Comparator|Clinical judgement+ACT group|Clinical judgement+ACT group (ACT offered to all suspected cases of malaria by clinical judgement)
9921920|NCT00832806|Active Comparator|1|Extended IVR (integrated voice response technology) vs. no extended IVR
9787422|NCT01303406|Placebo Comparator|Placebo|"Following the body weight, patients will be allocated to one of the following regimen:~Placebo Patients < 45 kg - 3 tablets 3 times a day with meals~Placebo Patients > 45 kg - 5 tablets 3 times a day with meals"
9787423|NCT01303406|Experimental|idebenone|"Following the body weight, patients will be allocated to one of the following regimen:~Idebenone Patients < 45 kg - 3 tablets 3 times a day with meals~Idebenone Patients > 45 kg - 5 tablets 3 times a day with meals"
9787424|NCT01303419|Experimental|CE-BMRI|Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
9787425|NCT01303445|Active Comparator|Treatment A|Aggrenox alone
9787426|NCT01303445|Experimental|Treatment B|Aggrenox and omeprazole
9787427|NCT01303445|Active Comparator|Treatment C|Omeprazole alone
9787428|NCT01303445|Experimental|Treatment D|Aggrenox and omeprazole
9787429|NCT01303510|Experimental|Group A|Adults from 18 to 60 years old inclusive
9787430|NCT01303510|Experimental|Group B|Elderly subjects aged over 60 years
9787431|NCT01303627|Active Comparator|ultiva,remifentanil,opioid,analgesic|Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
9787432|NCT01303627|No Intervention|control|Control:Remifentanil stopped at the end of the surgery
9787433|NCT01303744|Experimental|CHF 5074 1x|oral tablet, multidose
9787434|NCT01303744|Experimental|CHF 5074 2x|oral tablet, multidose
9787435|NCT01303744|Experimental|CHF 5074 3x|oral tablet, multidose
9787436|NCT01303744|Placebo Comparator|Placebo|placebo, oral tablet, multidose
9787437|NCT01303835|Experimental|Naltrexone|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
9787438|NCT01303835|Placebo Comparator|Placebo|Randomized patients received placebo to be taken every night before bed.
9787439|NCT01303861|Active Comparator|varenicline|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
9787440|NCT01303861|Active Comparator|Nicotine Patches only|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
9984858|NCT03651648|Sham Comparator|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
9984859|NCT03650413|Experimental|UTTR1147A|All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
9984860|NCT03646058|Placebo Comparator|Placebo|2 placebo pills sublingual during 28 days
9787441|NCT01303861|Active Comparator|Nicotine Patches with Nicotine Inhaler|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
9787442|NCT01303861|Active Comparator|varenicline with bupropion|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.
9787443|NCT01303939|Other|Glaucoma Patients|Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
9787444|NCT01303939|Other|Control Patients|Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
9787445|NCT01303965|Experimental|Open Label, Single Arm|Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance
9787446|NCT01304082|Placebo Comparator|normal saline|
9787447|NCT01304082|Active Comparator|lidocaine|
9787448|NCT01304082|Experimental|alkalinized lidocaine|
9787449|NCT01304147|Experimental|Ketamine|Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
9787450|NCT01304147|Placebo Comparator|Placebo|Subjects randomized to this arm will receive intranasal saline.
9787451|NCT01304238||lepirudin|lepirudin treated subjects
9837266|NCT04947800|Experimental|Arm C: 4 week intervention, 16 week control|Electro acupuncture (EA) intervention will be administered for 4 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 16 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
9984861|NCT03646058|Experimental|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
9984862|NCT03646058|Experimental|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
9837269|NCT04946344|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 3 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant will be prescribed an individual walking prescription by the exercise leader, which will be adjusted accordingly, as each participant progresses throughout the 3 months. The exercise will be of moderate intensity. Alternate forms of aerobic exercise, such as but not limited to stationary bike, elliptical trainer, or treadmill walking, can be used in place of over-ground walking. This choice could be based on participant preference, the limitations of the exercise facility, or the participant's pain level.
9837270|NCT04946344|Active Comparator|Attention Control|The attention control intervention will cover an 3 month period. There will be two face to face group meetings over the 3 months, with one meeting each at months 1 and 3; and during the other months (month 2) participants will receive a combination of text messages, emails, and phone calls based on continued monitoring of participant needs and delivered via their preferred mode of contact.
9837271|NCT04945733|Experimental|Amivantamab: Gastric Cancer (GC) Cohorts|Participants in Phase 2a GC cohorts will receive intravenous (IV) infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight less than (<) 80 kilograms (kg) will receive IV infusion of amivantamab 1,050 milligrams (mg) and participants with body weight greater than or equal to (>=) 80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). Phase 2b GC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
9837272|NCT04945733|Experimental|Amivantamab: Esophageal Cancer (EC) Cohorts|Participants in Phase 2a EC cohorts will receive IV infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight <80 kg will receive IV infusion of amivantamab 1,050 mg and participants with body weight >=80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle). Phase 2b EC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
9837273|NCT04945707|Active Comparator|Arm 1|Ferric derisomaltose (Monoferric®) 1000 mg X 1 (for subject <50 kg, 20 mg/kg X1)
9837274|NCT04945707|Placebo Comparator|Arm 2|Normal Saline
9837275|NCT04945356|Experimental|upper limb virtual training|6-week virtual training of the affected upper limb using the Physiotec application
9998268|NCT01516528||All|All subjects enrolled in the study
9787452|NCT01304238||danaparoid|danaparoid treated subjects
9787453|NCT01304238||argatroban|argatroban treated subjects
9787454|NCT01304238||fondaparinux|fondaparinux treated subjects
9787455|NCT01304277|Experimental|Replagal® (0.2 mg/kg, IV, EOW)|"Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)~Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF"
9787456|NCT01304329|Experimental|treatment A, reference|1 tablet BI 10773, oral administration with 240 ml water
9787457|NCT01304329|Experimental|treatment B, reference|1 tablet simvastatin, oral administration with 240 ml water
9787458|NCT01304329|Experimental|treatment C, test|1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water
9787459|NCT01304407|Other|RTS Subjects, Calcium Isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
9787460|NCT01304498|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
9787461|NCT01304498|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
9787462|NCT01304589|Experimental|Milnacipran|This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.
9787463|NCT01304641||Atorvastatin Initiators|
9787464|NCT01304641||Simvastatin Initiators|
9787465|NCT01304693|Experimental|ESBA1008|ESBA1008 solution, single intravitreal injection
9787466|NCT01304693|Active Comparator|LUCENTIS|Ranibizumab 0.5 mg, single intravitreal injection
9787467|NCT01304706|Experimental|Fluocinolone Acetonide|
9787468|NCT01304940||PTSD group|Individuals in this group meet criteria for PTSD as defined by DSM-IV
9787469|NCT01304940||trauma control group|individuals in this group do not meet criteria for any Axis I diagnosis as defined by DSM-IV
9787470|NCT01305044|Experimental|Tai Chi Chih|The Tai Chi Chih classes were 60 minutes sessions, held three times a week, over twelve weeks. The classes were led by an instructor who was certified and licensed in the Tai Chi Chih form.
9787471|NCT01305044|Active Comparator|Health Education Classes|Health Education classes were 60 minute sessions that occurred three times a week, over twelve weeks. These classes were taught by specialists in the class topic and focused on topics related to aging (e.g., sleep quality, nutrition, pain, etc.).
9787472|NCT01305200|Placebo Comparator|Arm I (placebo)|Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
9787473|NCT01305200|Experimental|Arm II (supersaturated calcium phosphate rinse)|Patients rinse and gargle with supersaturated calcium phosphate rinse over 1 minute QID beginning on the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
9787474|NCT01305213|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9787475|NCT01305213|Experimental|Arm II (bevacizumab, fosbretabulin tromethamine)|Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9787476|NCT01305239||Postmenopausal ER+ patients treated by Aromasin.|
9787477|NCT01305252|Active Comparator|tadalafil alone|tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
9787478|NCT01305252|Active Comparator|tadalafil and treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.
9787479|NCT01305265|Active Comparator|intervention|Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer
9787480|NCT01305265|No Intervention|control|endotracheal tube cuff will be inflated using standard technique
9787481|NCT01305356|Experimental|Augment® Injectable Bone Graft|Standard rigid fixation + Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
9787482|NCT01305356|Active Comparator|Autologous bone graft|Standard Rigid Fixation + Autologous bone graft
9787483|NCT01305408|Placebo Comparator|Placebo|Participants began taking placebo to match armodafinil and following the same titration procedure. Treatment was administered for a total of 8 weeks.
9787484|NCT01305408|Experimental|Armodafinil 150 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. Treatment was administered for a total of 8 weeks.
9787485|NCT01305473||Sepramesh Group|
9787486|NCT01305564|Experimental|Denali inferior vena cava filter|All subjects enrolled will receive the Denali vena cava filter.
9787487|NCT01305577|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9998269|NCT01516554|Experimental|Testosterone undecanoate|
9787488|NCT01305577|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9787489|NCT01305577|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
9787490|NCT01305655|Experimental|Glucarpidase arm|In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.
9787491|NCT01305772|Experimental|Surgery|Patients who underwent surgery after research PET/CT scans and subsequent radiation therapy with panitumumab administration
9787492|NCT01305772|Active Comparator|Radiation Therapy|Patients who underwent radiation therapy only, in conjunction with panitumumab therapy.
9787493|NCT01305811|Experimental|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
9787494|NCT01305811|Active Comparator|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
9787495|NCT01305941|Experimental|Everolimus +Vinorelbine + trastuzumab|daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab
9787496|NCT01306032|Experimental|Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
9787497|NCT01306032|Experimental|Triple-negative Breast Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
9787498|NCT01306032|Experimental|BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
9787499|NCT01306032|Experimental|BRCA- positive Ovarian Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
9787500|NCT01306032|Experimental|Non-Hodgkin's: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
9787501|NCT01306032|Experimental|Non-Hodgkin's: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
9787502|NCT01306058|Experimental|Sorafenib & TRC105 in Hepatocellular CA|CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day
9787503|NCT01306162|Experimental|A: Dabigatran alone (Reference)|Capsule, oral administration with 240 mL water
9787504|NCT01306162|Experimental|B: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
9998270|NCT01516554|Placebo Comparator|Sugar pill|
9787505|NCT01306162|Experimental|C: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
9787506|NCT01306162|Experimental|D: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
9998271|NCT01516567|Experimental|DA-EPOCH-R|6 courses of Dose Adjusted-EPOCH-Rituximab
9984863|NCT03645759|Experimental|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
9837278|NCT04943874|Other|Technology Based Intervention 1|
9837279|NCT04943874|Other|Technology Based Intervention 2|
9837280|NCT04943861|Active Comparator|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
9837281|NCT04943861|Other|Usual Care|There is no peer navigation within usual care.
9837282|NCT04943510|Experimental|Physical exercices arm|three randomizations will be used to determine the order of the tests that will be proposed to the subjects: on the one hand for the exercise modalities (match, anaerobic, aerobic) and, on the other hand, for the exercise modalities included in the anaerobic and aerobic exercise families: Anaerobic agility / anaerobic - linear sprints Aerobic - shuttle / aerobic - linear
9984864|NCT03645759|Active Comparator|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
9984865|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery online/phone survey.
9984866|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery online/phone survey.
9984867|NCT03645239||Control (non-Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Twenty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
9984868|NCT03645239||Experimental (Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Fifty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
9984869|NCT03641755|Experimental|Olaparib + Sapacitabine|"Olaparib will be administered orally twice daily for each 28-day cycle~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle~Olaparib will be given at a predetermined dose~Sapacitabine will be given at a predetermined dose"
9837291|NCT04938973|Experimental|NIF-Guided RAMIE using ICG Dye (Experimental Arm)|The patient will undergo NIF-guided RAMIE using ICG dye using the standard Ivor-Lewis approach. This will be a two-stage operation involving a first stage through a 5-port robotic approach through the abdomen to achieve a proximal gastrectomy and D2 nodal dissection. A feeding jejunostomy would not be inserted, as per the enhanced recovery pathway for esophagectomy. In addition, the vascularization of the conduit can be confirmed using the near-infrared camera of the robot with the ICG dye. The second stage of the operation will involve a 4-port robotic approach through the right chest to achieve thoracic nodal dissection, esophagectomy, and a hand-sewn anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein. During this second stage of the operation, NIF with ICG dye will be used to visualize the vascular supply of the gastric conduit, and assess the gastric conduit for any perfusions to potentially reduce anastomotic leaks.
9837292|NCT04938973|Active Comparator|Open Transthoracic Esophagectomy (OTE)|The patient will undergo OTE using the standard Ivor-Lewis approach. This is a two-stage operation involving a first stage through laparotomy, proximal gastrectomy, D2 nodal dissection, and insertion of feeding jejunostomy. The second stage of the operation will involve a right thoracotomy, thoracic nodal dissection, esophagectomy, and a stapled anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein.
9837293|NCT04938908|Experimental|Ophthalmic probiotic|1 active drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
9837294|NCT04938908|Placebo Comparator|Placebo|1 placebo drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
9837295|NCT04938908|Experimental|Opthalmic Probiotic + Oral Probiotic|1 active drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
9837296|NCT04938908|Experimental|Oral Probiotic|1 placebo drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
9837297|NCT04938089||ICS|Irregular compliant smoker
9837298|NCT04938089||RCS|Regular compliant smoker
9837299|NCT04938089||ICN|Irregular compliant non-smoker
9837300|NCT04938089||RCN|Regular compliant non-smoker
9837301|NCT04936230|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9837302|NCT04936230|Experimental|Arm B (atezolizumab, SBRT)|Patients receive atezolizumab as in Arm A. Patients also undergo SBRT for 3 fractions over 2 weeks in the absence of disease progression or unacceptable toxicity.
9837303|NCT04934969|Experimental|Use of lavender and peppermint essential oils pre and post|passive inhalation of either peppermint and lavender essential oil with pre and post test measure
9837304|NCT04934670|Experimental|T-Guard|Participants will be administered four doses of T-Guard intravenously for a 4-hour period every other day
9837305|NCT04934670|Active Comparator|Ruxolitinib|Participants will take ruxolitinib twice daily for continuous daily dosing
9837309|NCT04932850|Experimental|Active|"3 active cohorts are involved into study: Cohort 1 (48 mg), Cohort 2 (100 mg) and Cohort 3 (400 mg).~Each cohort is composed of two groups. The subjects enrolled in the first group of each cohort (groups 1, 3 and 5 for Cohorts 1, 2 and 3, respectively) will be sentinel subjects and will be treated one at the time at 48 h intervals in order to evaluate possible treatment-related adverse events."
9837310|NCT04932850|Placebo Comparator|Placebo|Placebo will be administered to 2 subjects for each cohort.
9837311|NCT04927650||Screening|Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.
9984870|NCT03641287|Experimental|Arm I (aerobic exercise)|Participants meet with exercise physiologist for 1, 60 minute session. Participants then receive individualized exercise prescription with goal of moderate aerobic exercise over 150 minutes per week at home for up to 24 weeks. Participants also receive telephone-based motivational support by exercise physiologist weekly for 24 weeks.
9984871|NCT03641287|Active Comparator|Arm II (habitual level of physical activity)|Participants maintain habitual levels of physical activity and receive general education material about ovarian cancer and survivorship for 24 weeks. After 24 weeks, participants are offered exercise intervention.
9984872|NCT03639064|Experimental|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
9984873|NCT03639064|Experimental|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
9984874|NCT03639064|Experimental|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
9984875|NCT03638999|Active Comparator|Intervention Group - Ketorlac (NSAID)|Subjects will receive a one-time intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
9998177|NCT01515800|Experimental|Text message reminder|Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
9837319|NCT04925050|Active Comparator|Drug VB0004|Experimental, Single Ascending dose , Multiple Ascending dose in healthy subjects and naive patients with mild or moderate hypertension with low cardiovascular risk
9837320|NCT04925050|Placebo Comparator|Placebo|Matching Placebo for VB0004
9837327|NCT04920422||Metastatic colorectal cancer patients.|Medical history data of all patients with at least 1 treatment with regorafenib will be collected retrospectively.
9837328|NCT04918875||Patients 12 years of age or older with suspected or confirmed COVID-19, deemed to require oxygen.|
9837329|NCT04918290|Experimental|Tegaderm Left|After general anesthesia is administered, Tegaderm will be placed on the left eye and Transpore will be placed on the right eye
9837330|NCT04918290|Experimental|Transpore Right|After general anesthesia is administered, Transpore will be placed on the right eye and Tegaderm will be placed on the left eye.
9837333|NCT04914897|Experimental|Cohort A1: Non-small cell lung cancer 1rst line therapy with Tumor proportion score > 50%|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
9837334|NCT04914897|Experimental|Cohort A2: Non-small cell lung cancer 1rst line therapy with Tumor proportion score 1-49%|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
9837335|NCT04914897|Experimental|Cohort A3: Non-small cell lung cancer 1rst line therapy|SAR444245 + pembrolizumab on day 1 of a 21 day treatment cycle (up to 35 cycles) Carboplatin/cisplatin on day 1 of a 21-day treatment cycle (up to 4 cycles) Pemetrexed on day 1 of a 21-day treatment cycle (until progressive disease or intolerability)
9837336|NCT04914897|Experimental|Cohort B1: Non-small cell lung cancer 2/3rd line therapy|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
9837337|NCT04914897|Experimental|Cohort B2: Non-small cell lung cancer squamous 2/3rd line therapy|SAR444245 + pembrolizumab (up to 35 cycles), and nab-paclitaxel (up to 6 cycles) on day 1 of a 21-day treatment cycle.
9837338|NCT04914897|Experimental|Cohort C1: :Mesotheloma 2/3rd line therapy|SAR444245 + pembrolizumab, on day 1 of a 21-day treatment cycle (up 35 cycles).
9837339|NCT04913519|Experimental|SAD Cohorts 1 -3 TDM-105795 topical solution|Single dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01%
9837340|NCT04913519|Placebo Comparator|Placebo for TDM-105795 topical solution|Single dose administration of Placebo forTDM-105795 Topical Solution
9837341|NCT04912648||Women age 18 years and older|"baseline anthropometry~bloods for metabolic phenotype; targeted and nontargeted Metabolomics~saliva and urine for steroid Metabolomics~bioimpedance~muscle biopsy for transcriptomics"
9837342|NCT04911062|Experimental|Cohort 1: Bupivacaine HCl|Bupivacaine HCl without epinephrine, via injection into the surgical site.
9787507|NCT01306162|Experimental|E: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
9787508|NCT01306175|Experimental|Digoxin alone (Reference)|Tablet, oral administration with 240 mL water
9787509|NCT01306175|Experimental|Digoxin plus BI 10773 (Test)|Tablets, oral administration with 240 mL water
9787510|NCT01306201||In-patient Volunteers|In-patients from the hospital who choose to participate in the study
9787511|NCT01306214|Experimental|BI 10773 low dose|BI 10773 low dose once daily
9787512|NCT01306214|Experimental|BI 10773 high dose|BI 10733 high dose once daily
9787513|NCT01306214|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
9787514|NCT01306253|Experimental|Elderly|Elderly subjects aged over 60 years
9787515|NCT01306253|Experimental|Adults|Adults from 18 to 60 years old inclusive
9787516|NCT01306292|Experimental|SonoVue|Ultrasound contrast agent under development
9787517|NCT01306292|Placebo Comparator|Placebo|normal saline 0.9% for injection used as the comparator
9787518|NCT01306305|Experimental|Elderly|Elderly subjects aged over 60 years
9787519|NCT01306305|Experimental|Adults|Adults from 18 to 60 years old inclusive
9787520|NCT01306331|Active Comparator|Conceptrol|100 mg (4% concentration) of nonoxynol-9 in 2.5 mL volume of gel
9787521|NCT01306331|Experimental|Amphora|Citric acid USP, potassium bitartrate USP, and L-lactic acid USP
9787522|NCT01306617|Experimental|ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
9787523|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
9787524|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.
9787525|NCT01306643|Experimental|Idelalisib|
9787526|NCT01306656|Experimental|Group 1|10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
9787527|NCT01306656|Placebo Comparator|Group 2|Placebo plus a multivitamin with 400 IU vitamin D
9787528|NCT01306877|Experimental|EEA Hemorrhoid and Prolapse Stapling Set|
9787529|NCT01306877|Active Comparator|Endosurgery Proximate PPH03 Stapling Set|
9787530|NCT01306890||sipuleucel-T|
9787531|NCT01306942|Experimental|Dasatinib + trastuzumab + paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg once daily (QD) (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
9799360|NCT01657760|Placebo Comparator|placebo|Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
9799361|NCT01657760|Active Comparator|citalopram infusion|40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
9799362|NCT01657799|Experimental|Veliparib 200 mg BID + WBRT|Participants received veliparib 200 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
9799363|NCT01657799|Experimental|Veliparib 50 mg BID + WBRT|Participants received veliparib 50 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
9799364|NCT01657799|Placebo Comparator|Placebo BID + WBRT|Participants received placebo twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
9799365|NCT01657877|Experimental|CSP/SMFP Dentifrice|Dentifrice containing high fluoride content as SMFP and CSP
9799366|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 1|Dentifrice containing high fluoride content as SMFP and no CSP
9799367|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 2|Dentifrice containing low fluoride content as SMFP and no CSP
9799368|NCT01657877|Active Comparator|CSP Dentifrice|Dentifrice containing CSP but no fluoride
9799369|NCT01657877|Placebo Comparator|Placebo Dentifrice|Dentifrice containing no CSP and no fluoride
9799370|NCT01657903|Experimental|NaF/KNO3 toothpaste, Low RDA|Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
9799371|NCT01657903|Experimental|NaF/KNO3 toothpaste, Medium RDA|Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
9799372|NCT01657903|Active Comparator|NaF/KNO3 toothpaste|Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
9799373|NCT01657903|Placebo Comparator|No fluoride/KNO3 toothpaste|Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.
9799374|NCT01658020|Experimental|DW224|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
9799375|NCT01658020|Active Comparator|Avelox|Moxifloxacin 400mg tablet P.O. once daily for 7days
9799376|NCT01658059|Experimental|group 1|homeopathic remedy first , placebo second
9998178|NCT01515800|No Intervention|No text message reminder|Patients receive standard follow-up care.
9787532|NCT01306968|No Intervention|Standard TBI Care|Routine post-concussive symptoms (PCS) care as practiced within Departments of Defense (DoD)
9787533|NCT01306968|Experimental|HBO2 Group|Routine PCS care supplemented with hyperbaric oxygen (HBO2) at the dose of 1.5 ATA for 60 minutes administered over 40 sessions given daily Monday through Friday
9787534|NCT01306968|Sham Comparator|Sham Group|Routine PCS care supplemented with an otherwise identical sham hyperbaric air exposure at 1.2 atmospheres absolute (ATA)
9787535|NCT01306968|No Intervention|PTSD With no History of TBI|Subjects who have been diagnosed with PTSD but have no diagnosed or suspected brain injuries. This group does not receive HBO2.
9787536|NCT01307007|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
9787537|NCT01307007|Active Comparator|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
9787538|NCT01307020|Placebo Comparator|Placebo|
9787539|NCT01307020|Active Comparator|Ibuprofen|
9787540|NCT01307020|Active Comparator|TRAM.HCl high dose|
9787541|NCT01307020|Active Comparator|TRAM.HCl low dose|
9787542|NCT01307020|Active Comparator|DKP-TRIS high dose|
9787543|NCT01307020|Active Comparator|DKP-TRIS low dose|
9787544|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl low dose|
9787545|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl high dose|
9787546|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl low dose|
9787547|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl high dose|
9787548|NCT01307098|Experimental|Sebelipase alfa 0.35 mg/kg|Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
9787549|NCT01307098|Experimental|Sebelipase alfa 1 mg/kg|Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
9787550|NCT01307098|Experimental|Sebelipase alfa 3 mg/kg|Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.
9787551|NCT01307111|Experimental|Misoprostol|Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.
9787552|NCT01307111|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
9787553|NCT01307267|Experimental|Portion A|PF-05082566 single agent in patients with advanced cancer
9787554|NCT01307267|Experimental|Portion B|PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma
9787555|NCT01307319|Experimental|BDP HFA 80 mcg/day|Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
9787556|NCT01307319|Experimental|BDP HFA 160 mcg/day|Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
9787557|NCT01307319|Placebo Comparator|Placebo nasal aerosol once daily|Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.
9787558|NCT01307397|Experimental|Vemurafenib|Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
9787559|NCT01307423|Experimental|Apremilast 20mg|Apremilast 20mg twice daily, orally
9787560|NCT01307423|Experimental|Apremilast 30mg|Apremilast 30mg twice daily, orally
9787561|NCT01307423|Placebo Comparator|Placebo + 20mg Apremilast|Placebo + 20mg Apremilast tablets administered twice daily
9787562|NCT01307423|Placebo Comparator|Placebo + 30mg Apremilast|Placebo + 30mg Apremilast tablets administered twice daily
9787563|NCT01307449|Experimental|Older Group on PREVNAR|Participants between the ages of 60-89 received PREVNAR
9787564|NCT01307449|Experimental|Younger Group on PREVNAR|Participants between the ages of 25-40 years received PREVNAR
9787565|NCT01307449|Experimental|Older Group on PNEUMOVAX|Participants between the ages of 60-89 received PNEUMOVAX
9787566|NCT01307449|Experimental|Younger Group on PNEUMOVAX|Participants between the ages of 25-40 years received PNEUMOVAX
9787567|NCT01307462|Experimental|Treatment (BOS therapy)|Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
9787568|NCT01307501|Other|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. No more than 3 tumors in 1 lung can be treated in a single session, and no more than 5 total lung tumors (across both lungs) can be treated during the study.
9799377|NCT01658059|Experimental|group 2|placebo first, homeopathic remedy second
9787569|NCT01307579|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC > 100-500/uL following the nadir or the next chemotherapy course begins.
9787570|NCT01307579|Active Comparator|Arm II (fluconazole)|Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.
9787571|NCT01307618|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
9787572|NCT01307618|Experimental|Arm II (vaccine therapy, IL-12)|Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
9787573|NCT01307748|Experimental|stress reducing aroma|aroma with reported stress reducing effects
9787574|NCT01307748|Placebo Comparator|Placebo aroma 1|
9787575|NCT01307748|Placebo Comparator|Placebo aroma 2|
9787576|NCT01307891|Experimental|Abraxane + Tigatuzumab|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.
9787577|NCT01307891|Experimental|Abraxane alone|Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.
9787578|NCT01307930|Experimental|Anidulafungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
9787579|NCT01307956|Experimental|Treatment (panitumumab, chemotherapy, radiation)|Patients receive panitumumab IV over 1 hour on day 1. Patients also receive oxaliplatin IV and leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1 (FOLFOX chemotherapy). Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Within 24 hours of the start of chemotherapy, patients undergo radiation therapy 5 days a week for 5.5 weeks. Patients then undergo surgery within 6-8 weeks after completion of radiation therapy. Patients with residual disease receive 4 additional courses of FOLFOX chemotherapy on days 1, 15, 29, and 42.
9787580|NCT01308008|Experimental|Functional exercise- home physical activity|On-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with telephonic behavioral support
9787581|NCT01308008|Active Comparator|Flex and tone- home health education|Initial on-site flex and toning program continued on follow-up along with health education
9787582|NCT01308060|Experimental|Botulinum Toxin type A|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
9787583|NCT01308060|Placebo Comparator|Placebo|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
9787584|NCT01308294|Experimental|2 vaccine injections in 1 limb|9 patients initially planned: patients received peptides with IMP321/LAG-3Ig and Montanide in 2 injections sites at 5 cm distance from each other 2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
9787585|NCT01308294|Experimental|2 vaccine injections in distinct limbs|Groupe2: 2 vaccine injections in different limb should include 9 patients that were initially planned: patients received the same vaccine in 2 syringes injected each in a distinct limb (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
9787586|NCT01308294|Experimental|"2 vaccine injections in distinct limbs"|Groupe3: 2 vaccine injections in distinct limb should include 9 patients that were initially planned; due to premature trial termination, no patients could be enrolled. Patients of this group should have received the same vaccine but without the MHC class II peptide (MAGE-A3)
9787587|NCT01308424|Experimental|BTL TML HSV|
9787588|NCT01308424|Placebo Comparator|Matching Placebo|
9787589|NCT01308450||Single Arm, Non ADHD Control Group|Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.
9787590|NCT01308476||SMS group|
9787591|NCT01308476||control group|
9787592|NCT01308567|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
9787593|NCT01308567|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
9787594|NCT01308567|Active Comparator|Docetaxel 75 mg/m^2|Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
9787595|NCT01308580|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
9799378|NCT01658072|Experimental|Peri-Articular Injection|
9799379|NCT01658072|Active Comparator|Epidural Patient Controlled Analgesia (Epidural PCA)|
9787596|NCT01308580|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
9787597|NCT01308619|Active Comparator|Oracea®|Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
9787598|NCT01308619|Active Comparator|placebo|placebo
9787599|NCT01308736|Active Comparator|varenicline|
9787600|NCT01308736|Placebo Comparator|placebo pill|
9787601|NCT01308749|Placebo Comparator|Placebo|Intervention: Drug: placebo
9787602|NCT01308749|Active Comparator|Oxytocin|Intervention: Drug: Syntocinon® Nasal Spray
9787603|NCT01308762|Experimental|IMM-101|"Patients received an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28. Doses used were:~'Heat killed whole cell M. obuense (IMM-101) 0.1 mg', 'Heat killed whole cell M. obuense (IMM-101) 0.5 mg', or 'Heat killed whole cell M. obuense (IMM-101) 1.0 mg'"
9787604|NCT01308788||aqueous suppressant|aqueous suppressant treated
9787605|NCT01308788||aqueous outflow|aqueous outflow treated
9787606|NCT01308814|Placebo Comparator|Placebo|Placebo patches for 12 months and placebo pills for 12 days every 2 months.
9787607|NCT01308814|Experimental|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
9787608|NCT01308840|Experimental|Panitumumab|Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
9787609|NCT01308853|Other|Macrolane|Open label
9787610|NCT01308918||GlideScope DLT intubation|Patients having a thoracic surgery (non cardiac) via either thoracoscopy or thoracostomy. Patients were all 18 years old or over, and have read, understood and signed an informed consent at the preoperative evaluation or on surgery morning.
9787611|NCT01309100|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens.
9787612|NCT01309100|Active Comparator|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens.
9787613|NCT01309100|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens.
9787614|NCT01309165|Experimental|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
9787615|NCT01309165|Active Comparator|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
9787616|NCT01309204|Experimental|Brinz/Brim|Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
9787617|NCT01309204|Active Comparator|Brinz+Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
9787618|NCT01309243|Experimental|FTC/RPV/TDF|
9787619|NCT01309243|Experimental|EFV/FTC/TDF|
9787620|NCT01309269||Cohort|
9787621|NCT01309282||Rituximab|Sero-positive [Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm
9787622|NCT01309308|Experimental|The membranes swept group|This group will have a sweeping of the membranes after the 38th of gestation at hospital, in order to reduce the latency period until labor. Sweeping of the membranes is done by the insertion of examiners finger between the decidua and fetal membranes and by the circular movement of the finger, the membranes are detached from the decidua.
9787623|NCT01309308|Sham Comparator|No sweeping group|This group will not have sweeping of the membranes, will only have vaginal ultrasound
9787624|NCT01309360|Active Comparator|group A : 40ml Prilocaine 1%|40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
9787625|NCT01309360|Active Comparator|group B : 30ml Prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
9787626|NCT01309360|Active Comparator|group C : 20ml Prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
9799380|NCT01658150|Experimental|isradipine|open label
9998179|NCT01515813|Experimental|Arm A: Pravastatin sodium alone for 24 weeks|One 40 mg tablet of Pravastatin sodium taken orally once daily for 24 weeks starting at week 0 and ending at week 24.
9787627|NCT01309386|Experimental|Tapentadol ER|Tapentadol extended-release (ER) (JNS024ER) oral tablets 100 to 400 milligram (mg) daily for 8 weeks (maximum dose could be up to 500 mg daily), as per Investigator's discretion.
9787628|NCT01309386|Active Comparator|Morphine SR|Morphine sustained-release (SR) oral tablets 30 to 120 mg daily for 8 weeks (maximum dose could be up to 140 mg daily), as per Investigator's discretion.
9787629|NCT01309451|Active Comparator|Bevacizumab alone|
9787630|NCT01309451|Active Comparator|Combined group|Bevacizumab plus Ozurdex
9787631|NCT01309646|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
9787632|NCT01309646|Active Comparator|Infanrix IPV Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
9787633|NCT01309659|Experimental|Immediate Intervention Group|Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
9787634|NCT01309659|Experimental|Wait List Control|Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up
9787635|NCT01309737|Experimental|Active Treatment 10 mg BID|
9787636|NCT01309737|Experimental|Active Treatment 5 mg BID|
9787637|NCT01309737|Placebo Comparator|Placebo Treatment|
9787638|NCT01309802|No Intervention|placebo|no intervention
9787639|NCT01309802|Active Comparator|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
9787640|NCT01309828|Experimental|Azilsartan Medoxomil + Chlorthalidone|United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
9787641|NCT01309828|Active Comparator|Olmesartan Medoxomil + Hydrochlorothiazide|United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
9787642|NCT01309841|Experimental|1|Oral treatment
9787643|NCT01309841|Experimental|2|Oral treatment
9787644|NCT01309841|Placebo Comparator|3|Oral treatment
9787645|NCT01309867|Experimental|Investigational Toric Lens|Bausch + Lomb investigational toric contact lenses
9787646|NCT01309867|Active Comparator|PureVision Toric Lens|Currently marketed Bausch + Lomb PureVision toric contact lenses
9787647|NCT01309880|Active Comparator|Air Optix Aqua|Ciba Vision daily wear contact lens
9787648|NCT01309880|Experimental|Test Lens|Investigational silicone hydrogel contact lens
9787649|NCT01309893|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel contact lens for 1 week; then issued Air Optix Aqua Lens for 1 week.
9787650|NCT01309893|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens for 1 week; then issued Investigational Lens for 1 week.
9787651|NCT01309906|Experimental|Investigational lens|Bausch & Lomb investigational silicone hydrogel lens
9787652|NCT01309906|Active Comparator|Air Optix Aqua lens|Ciba Vision Air Optix Aqua contact lens
9787653|NCT01309919|Active Comparator|IUD Arm|Subjects who receive an IUD within 48 hours of delivery (vaginal or cesarean birth)
9787654|NCT01309919|Other|Diary Arm|Subjects who will not have an IUD placed postpartum; they may use another form of contraception, or no form at all
9787655|NCT01309997|Experimental|Arm I (enzyme inhibitor)|Patients receive imatinib mesylate PO QD for 6 months in the absence of progression of sclerosis or unacceptable toxicity.
9787656|NCT01309997|Experimental|Arm II (monoclonal antibody)|Patients receive rituximab IV on days 1, 8, 15, and 22. A second treatment cycle is repeated at 3 months for a total of 8 doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.
9787657|NCT01310036|Experimental|Erlotinib|Erlotinib 150 mg daily
9787658|NCT01310075|Experimental|Alloderm Mesh|Alloderm Mesh - 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
9787659|NCT01310075|Experimental|Surgimend Mesh|Surgimend Mesh - 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
9787660|NCT01310075|No Intervention|Control (no mesh)|
9787661|NCT01310127|Experimental|Bromday|Patients receiving Bromday self-administered one drop of bromfenac 0.09% daily as a topical ophthalmic drop three days prior to cataract surgery, on the day of cataract surgery and 21 days post operatively.
9787662|NCT01310127|Active Comparator|Nevanac|Patients in this arm self-administered nepafenac topical ophthalmic drops three times daily beginning 3 days prior to cataract surgery, on the day of surgery and for 21 days postoperatively in addition to usual cataract procedure.
9787663|NCT01310179|Experimental|Ad/PNP and fludarabine monophosphate|Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate). Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
9787664|NCT01310231|Active Comparator|Metformin|Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
9787665|NCT01310231|Placebo Comparator|Placebo|Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
9787666|NCT01310400|Experimental|Inflexal 0.5 mL|
9787667|NCT01310400|Experimental|Inflexal 0.25 mL|
10205722|NCT05203484|Active Comparator|Point-by-Point Mapping|Participants assigned to the Point-by-Point Mapping arm will undergo VT ablation within 48 hours after baseline evaluation. The Mapping procedure will be performed with a QDot catheter (Biosense Webster). Catheter ablation of potential diastolic pathways and scar homogenisation will also be performed with the QDot catheter.
9787668|NCT01310400|Experimental|Agrippal 0.25 mL|
9787669|NCT01310413|Experimental|Influenza A (H5N1) adjuvanted 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
9787670|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
9787671|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
9787672|NCT01310413|Placebo Comparator|Placebo 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
9837343|NCT04911062|Experimental|Cohort 2: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
9837344|NCT04911062|Experimental|Cohort 3: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
10205723|NCT05203471|No Intervention|Historical controls|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study prior to launching the integrated care intervention.
9787673|NCT01310413|Placebo Comparator|Placebo 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
9787674|NCT01310413|Placebo Comparator|Placebo 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
9787675|NCT01310413|Experimental|Placebo/Influenza A (H5N1) adjuvanted Group|Subjects in this group were those who were administered the saline placebo solution in the Blinded Phase of the study (either in the Placebo 6-<36M, Placebo 3-<9Y or Placebo 9-<18Y Group). These were subjects aged at enrolment between 6 months and 18 years, 18 years excluded, who had received 2 doses of saline placebo at Days 0 and 21 in the Blinded Phase of the study, as per described in the descriptions of the Placebo 6-<36M, Placebo 3-<9Y and Placebo 9-<18Y groups. After consenting to participating to the Unblinded Phase of the study, these subjects received in addition 2 doses of Influenza A (H5N1) Virus monovalent vaccine at Days 385 (Day U0) and Day 385 + 21 days (Day U21). Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. Dose 1 of was administered in the deltoid region of the non-dominant arm and Dose 2 in the deltoid region of the dominant arm.
9998180|NCT01515813|Experimental|Arm B: EFV/FTC/TDF plus Pravastatin sodium at week 13|EFV/FTC/TDF once daily for 24 weeks starting at week 0 and ending at week 24 plus pravastatin sodium (80 mg)once daily for 12 weeks starting at week 13 ending at week 24.
9787676|NCT01310582|Active Comparator|Desflurane|During the surgery the subjects were given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
9787677|NCT01310582|Active Comparator|Sevoflurane|During the surgery the subjects were given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
9787678|NCT01310699|Experimental|High Definition NBI Colonoscopy|Use of high definition narrow band imaging colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
9787679|NCT01310699|Placebo Comparator|High Definition White Light Colonoscopy|Use of high definition white light colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
9787680|NCT01310777|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
9787681|NCT01310777|Active Comparator|Brinz|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
9787682|NCT01310777|Active Comparator|Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months
9787683|NCT01310855|Active Comparator|Cediranib & Gefitinib|Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
9787684|NCT01310855|Placebo Comparator|Cediranbib & placebo|Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
9787685|NCT01310868|Experimental|5-ALA and Gliadel wafers|This is a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Gliadel wafers) in the surgical management of patients with GBM.
9787686|NCT01311024||Sibling vaccinated with PCV GSK1024850A|"Older sibling of a child vaccinated with Pneumococcal conjugate vaccine GSK1024850A in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
9787687|NCT01311024||Control-vaccinated sibling|"Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
9787688|NCT01311102|Experimental|2% Lidocaine liquid|1.33cc of 2% liquid lidocaine infused in endo cervix and endometrium
10205724|NCT05203471|Active Comparator|Integrated care|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study after launching the integrated care intervention. Only patients who provide informed consent and enroll in the study will be treated with our integrated care model. All other patients with a participating primary care provider will be treated using a standard care model and will not be considered study participants.
10205725|NCT05203432|Experimental|Red Light Intervention|Repeated Low-Level Red-Light Therapy
10205726|NCT05203432|Active Comparator|Low concentration atropine|0.01% atropine
9787689|NCT01311102|Placebo Comparator|Normal Saline|1.33cc of normal saline infused in endo cervix and endometrium
10205727|NCT05203367|Experimental|BAR 502|Each subject will receive an oral single-dose of BAR 502.
10205728|NCT05203367|Placebo Comparator|Placebo|Each subject will receive an oral single-dose of placebo.
10205729|NCT05203354|Active Comparator|NB-UVB group|Patients who receive Narrowband ultraviolet B phototherapy
10205730|NCT05203354|Active Comparator|Acitretin group|Patients who receive acitretin
10205731|NCT05203354|No Intervention|Control group|It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level
9787690|NCT01311362||CYP2C19 wild type|"CYP2C19 wild type =extensive metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
9787691|NCT01311362||CYP2C19 mutant|"CYP2C19 *2/*2 or *2/*3 or *3/*3 = poor metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
9787692|NCT01311505|Active Comparator|A|Test
9787693|NCT01311505|Active Comparator|B|Reference
9787694|NCT01311557|Experimental|Adacel Vaccine Group 1|Participants enrolled at 10 to < 11 years of age
9787695|NCT01311557|Experimental|Adacel Vaccine Group 2|Participants enrolled at 11 to < 12 years of age
9787696|NCT01311648|Experimental|PTPs 0-12 years|Previously treated patients (PTPs) aged below 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (EDs) in main study - Part A. Participants having reached at least 50 EDs in main study - Part A were offered participation in an open label extension study (optional). Participants who transitioned from main study - Part A to the extension study received BAY81-8973, 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study).
9787697|NCT01311648|Experimental|PUPs/MTPs 0-<6 years|Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days (EDs) with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development in main study - Part B. Participants having reached at least 50 EDs in main study - Part B were offered participation in an open label extension study and received BAY81-8973 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study); participants who developed an inhibitor in main study - Part B were offered participation in open label extension study and received Immune Tolerance Induction (ITI) treatment with BAY81-8973 until successful eradication of the inhibitor, or until failure, for approximately 18 months.
9787698|NCT01311661|Experimental|Olodaterol medium daily dose|Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
9787699|NCT01311661|Experimental|Olodaterol high daily dose|Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases
9787700|NCT01311674|Active Comparator|Schedule 1- Standard dose primary vaccination series|Schedule 1 subjects received 20 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
9787701|NCT01311674|Experimental|Schedule 2 - High dose primary vaccination series|Schedule 1 subjects received 40 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 60, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
9787702|NCT01311687|Experimental|Pomalidomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
9787703|NCT01311687|Active Comparator|High-Dose Dexamethasone|Participants received 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.
9787704|NCT01311895|Experimental|H2O|2 mg IV hydromorphone administered over 2-3 minutes as initial dose
9787705|NCT01311895|Experimental|1+1|"1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the following question: Do you want more pain medication?"
9787706|NCT01312038|Experimental|simethicone|125 mg tablet
9787707|NCT01312038|Placebo Comparator|placebo|chewable calcium tablet
9787708|NCT01312129|Experimental|Sulfasalazine|Sulfasalazine 1500 mg
9787709|NCT01312129|Placebo Comparator|Placebo|Placebo capsule x 3 doses 12 hours apart
9787710|NCT01312181|Active Comparator|HealthCall +Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
9787711|NCT01312181|Active Comparator|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
9787712|NCT01312181|Placebo Comparator|HIV/AIDS health education - DVD control|HIV/AIDS health education - DVD control. The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
9787713|NCT01312233|Active Comparator|Medical Care|Conventional medical care alone
9787714|NCT01312233|Active Comparator|Dual Care|Unlinked co-occurrence of conventional medical care and chiropractic care
9787715|NCT01312233|Active Comparator|Shared Care|Co-management of medical care and chiropractic care
9787716|NCT01312272|Placebo Comparator|Inactive nasal spray|A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
9787717|NCT01312272|Experimental|Intranasal Oxytocin|Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
9787718|NCT01312389|Experimental|Phase 2: Arm A|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions.
9787719|NCT01312389|Experimental|Phase 2: Arm B|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions, administered in combination with intravenous Ampligen.
9787720|NCT01312389|Experimental|Phase 1|3 patients will be enrolled receiving the vaccine (tumor lysate/Montanide) plus Ampligen using a 3+3 approach. If no DLTs in the first three subjects, we will move to phase II; if one 1/3 subject develops DLTs, we will enroll 3 additional subjects; if 2/6 subjects develop DLTs, we will discontinue the study. Following completion of run---in phase I (3 or 6 subjects), we will transition to Phase 2.
9787721|NCT01312467|Experimental|Prevention (metformin hydrochloride)|Patients receive metformin hydrochloride PO QD during week 1 and then BID during weeks 2-12. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
9787722|NCT01312519|Active Comparator|Manual bone marrow sampling device|Hollow needle with a t-shaped handle manually pushed into the bone for the purpose of bone marrow aspiration and core biopsy collection. Manual Bone Marrow Sampling Device.
9787723|NCT01312519|Active Comparator|OnControl Bone Marrow System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest. OnControl Bone Marrow Biopsy and Aspiration System.
9787724|NCT01312675|Experimental|Group A|S.A.F.E.BT plus Standard of Care therapy
9787725|NCT01312675|No Intervention|Group B|Standard of Care therapy alone
9787726|NCT01312766|Experimental|hMG-IBSA|New hMG preparation.
9787727|NCT01312766|Active Comparator|Menopur|
9787728|NCT01312779|Other|All subjects receive implant|Subjects serve as own control
9787729|NCT01312805|Active Comparator|CHICA Control|This arm received CHICA without the asthma module
9787730|NCT01312805|Experimental|CHICA Asthma Module|This arm received the CHICA asthma module
9787731|NCT01312818|Experimental|Chemotherapy|Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)
9787732|NCT01312844|Experimental|Scopolamine|Patients receiving IV scopolamine at ECT treatment
9787733|NCT01312844|Placebo Comparator|Placebo|Patients receiving IV placebo at ECT treatment
9787734|NCT01312909|Experimental|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
9787735|NCT01312909|Experimental|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
9787736|NCT01312909|Placebo Comparator|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
9787737|NCT01312948|Experimental|Prototype mask|
9787738|NCT01312961|Placebo Comparator|Placebo (for Dupilumab)|Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
9787739|NCT01312961|Experimental|Dupilumab 300 mg qw|Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
9787740|NCT01313039|Experimental|AZD6244|
9787741|NCT01313078|Experimental|Pegaspargase in women with cancer|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
9787742|NCT01313117|Experimental|Alpha lipoic acid|Oral administration three times daily (morning, mid-day, night)
9799381|NCT01658228|Other|Donepezil Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
9799382|NCT01658228|Other|Placebo Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
9799383|NCT01658228|Other|Citalopram|An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
9799384|NCT01658228|Other|Venlafaxine|For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
9799385|NCT01658436|Experimental|BEZ235 300 mg/400 mg bid (Stage 1)|Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
9799386|NCT01658514|Experimental|Met DR|One dose of 1000 mg metformin delayed-release
9799387|NCT01658514|Active Comparator|Met XR|One dose of 1000 mg metformin extended-release
9799388|NCT01658514|Placebo Comparator|Placebo|One dose of Placebo
9837345|NCT04911062|Experimental|Cohort 4 (optional), Group A: HTX-011|HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
9837346|NCT04911062|Active Comparator|Cohort 4 (optional), Group B: Bupivacaine HCl|Bupivacaine HCl without epinephrine, via injection into the surgical site.
9837347|NCT04909606|Experimental|Nurse-led prevention program|Patients will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
9837348|NCT04909606|Active Comparator|Standard of care|Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)
9837349|NCT04906616|No Intervention|Control Comparison|Standard of care, e.g. regular HIV care plus brief advice on alcohol use
9837350|NCT04906616|Experimental|Mlambe Intervention|A couples-based intervention to reduce problematic drinking and improve economic and HIV outcomes.
9837351|NCT04903626|Experimental|Participants Treated With Glecaprevir/Pibrentasvir for 8 weeks|Participants treated once daily with oral tablets of glecaprevir/pibrentasvir for 8 weeks.
9837352|NCT04902469|Experimental|Pleasant Odor|Participants in this condition will sniff the olfactory cue they rate as both pleasant (>5 on the 1-9 scale) and the most intense following cigarette cue exposure. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated as pleasant.
9837353|NCT04902469|Other|Odor Blank|Participants in this condition will sniff a neutral olfactory cue (odor blank) following cigarette cue exposure.
9984876|NCT03638999|Placebo Comparator|Placebo Group - Normal Saline|Subjects in the control group will receive a one-time 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
9984877|NCT03635021|Experimental|Sequence 1|FOLFOX regimen panitumumab FOLFIRI regimen bevacizumab
9837356|NCT04902300||Adolescent|adolescent attending high school
9837357|NCT04901806|Experimental|Phase 1 Dose Escalation|
9837358|NCT04901806|Experimental|Phase 2 Cohort Expansion|
9837359|NCT04901169|Experimental|Angiotensin II (Giapreza)|Giapreza (synthetic human angiotensin II), initiated at 5 ng/kg/min and titrated to between 1.25 ng/kg/min and 40 ng/kg/min, administered by continuous intravenous infusion.
9837360|NCT04901169|Placebo Comparator|Saline|Sterile 0.9% saline, initiated and titrated at an equivalent volume infusion rate to the study drug, administered by continuous intravenous infusion.
9837361|NCT04900220|Active Comparator|Betamethasone|betamethasone
9837362|NCT04900220|Active Comparator|Methylprednisolone|methylprednisolone
10205732|NCT05203341|Placebo Comparator|Placebo|Participants will receive placebo to NBI-1065845 orally once a day.
10205733|NCT05203341|Experimental|NBI-1065845 Low Dose|Participants will receive low-dose NBI-1065845 orally once a day.
10205734|NCT05203341|Experimental|NBI-1065845 High Dose|Participants will receive high-dose NBI-1065845 orally once a day.
10205735|NCT05203302|Experimental|Late Adult Cochlear Implant (LateAdultCI)|Post-lingually implanted adults, 18+ years
10205736|NCT05203302|Experimental|Early Child Cochlear Implant (EarlyChildCI)|Early implanted children, ages 7-17 years
10205737|NCT05203302|Experimental|Early Adult Cochlear Implant (EarlyAdultCI)|Early implanted adults, ages 18 to 35 years
10205738|NCT05203302|Experimental|Cochlear Implant (CI)|CI children, ages 7-17 years, with aided residual hearing (bimodal/contralateral, electric+acoustic/ipsilateral)
10205739|NCT05203302|Active Comparator|Normal Hearing Children (NHC)|Ages 7-17 years, Control Group
10205740|NCT05203302|Active Comparator|Normal Hearing Adults (NHA)|18+ years, Control Group
10205741|NCT05203263|Experimental|Condition 1|Application of the prototype (810A-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
10205742|NCT05203263|Experimental|Condition 2|Application of the prototype (810B-v1) at Day 0, Day 1, Day 2, Day 3, Day 4 and Day 5.
9837363|NCT04899089|Experimental|Video Game Training Condition|Participants complete an 8 week long computerized cognitive training intervention. Participants play the games for 45 minutes, three times per week.
9837364|NCT04899089|Active Comparator|Trivia Training Condition|Participants complete an 8 week long computerized trivia training. Participants complete the trivia training for 45 minutes, three times per week.
9837365|NCT04897750|Experimental|Active|a target dose of intranasal sufentanil 0,5 mcg/kg + ketamine 0,5 mg/kg, (2-4 puffs) and an additional dose if needed as premedication before placement of a PVC for induction of anaesthesia.
9837366|NCT04897607|Active Comparator|Treatment Plan Option 1 (Standard Care)|Standard smoking cessation counseling will be offered + participant choice of nicotine patches or varenicline. Participants are also free to decline either medication.
9837367|NCT04897607|Experimental|Treatment Plan Option 2 (Precision Pharmacotherapy)|Standard smoking cessation counseling will be offered + a recommendation to take either the nicotine patch or varenicline based on the results of the NMR test. Regardless of the recommendation, it would still remain the participant's choice to be prescribed either nicotine patches or varenicline. Participants are also free to decline either medication.
10205743|NCT05203263|Experimental|Condition3|Application of the prototype (810A-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
10205744|NCT05203263|Experimental|Condition 4|Application of the prototype (810C-v1) at Day 0, Day 7, Day 14, Day 21, Day 28 and Day 35.
10205745|NCT05203263|Active Comparator|Condition 5|Application of the prototype (810C-v1) at Day 0, Day 14, Day 28, Day 42, Day 56 and Day 70.
10205746|NCT05203250||Brain tumors, skull base tumors, spinal cord tumors|NEUROPARTICLE
10205747|NCT05203250||Ocular melanomas|
10205748|NCT05203250||Head and Neck tumors|
10205749|NCT05203250||Tumors of thorax and/or abdomen|GI-Particle
10205750|NCT05203250||Pelvic tumors|GYN-Particle
10205751|NCT05203250||Sarcomas and tumors of limbs|SarTAP-Particle
10205752|NCT05203250||Pediatric tumors|
9837368|NCT04897256|Experimental|Turning Boot Camp Group|Participants in the treatment group will attend supervised, 1-hour classes, 3 times per week for 6 weeks, one-on-one with the same exercise trainer, overseen by a physical therapist investigator.
9837369|NCT04897256|No Intervention|No Intervention Control Group|Participants in this group will be tested at baseline and 6 weeks later. They will go about their normal daily life during the 6 week period.
9984878|NCT03635021|Experimental|Sequence 2|FOLFOX regimen bevacizumab FOLFIRI regimen panitumumab
9984879|NCT03634124|Experimental|interventional group|
9984880|NCT03633461|Active Comparator|OC-02 (simpinicline) spray spray, 11.1 mg/ml|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
9984881|NCT03633461|Placebo Comparator|Placebo|Placebo (vehicle) nasal spray
9984882|NCT03628560|Experimental|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
9984883|NCT03628560|Experimental|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
9984884|NCT03628560|Experimental|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
9837377|NCT04895696|Experimental|Afimetoran: Dose 1|
9837378|NCT04895696|Experimental|Afimetoran: Dose 2|
9837379|NCT04895696|Experimental|Afimetoran: Dose 3|
9837380|NCT04895696|Placebo Comparator|Placebo|
9984885|NCT03628560|Experimental|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
9984886|NCT03628560|Active Comparator|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
9984887|NCT03628209|Experimental|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
9837386|NCT04887194|Experimental|Phase 1, Part 1: Sitravatinib monotherapy (DDI cohort)|To evaluate the potential for drug-drug interactions (DDI) with sitravatinib monotherapy. To determine the effect of sitravatinib on the pharmacokinetics (PK) of midazolam (CYP3A4 probe substrate), warfarin (CYP2C9 probe substrate), dextromethorphan (CYP2D6 probe substrate), rosuvastatin (BCRP probe substrate), and digoxin (P-gp probe substrate).
9837387|NCT04887194|Experimental|Phase 1, Part 1: Sitravatinib monotherapy (QTc cohort)|To evaluate the QTc prolongation risk for sitravatinib in patients with advanced/metastatic solid tumors via C-QTc modeling.
9837388|NCT04887194|Experimental|Phase 1, Part 2: Combination Therapy (both DDI and QTc cohorts)|To evaluate safety and tolerability of Sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.
9837389|NCT04886232|Experimental|VP1 Lido US - NC|Injection to the left cheek via needle and to the right cheek via canula
9837390|NCT04886232|Experimental|VP1 Lido US - CN|Injection to the left cheek via canula and to the right cheek via needle
9837391|NCT04886232|Active Comparator|Restylane Lyft Lidocaine - NC|Injection to the left cheek via needle and to the right cheek via canula
9837392|NCT04886232|Active Comparator|Restylane Lyft Lidocaine - CN|Injection to the left cheek via canula and to the right cheek via needle
9837394|NCT04882917|Experimental|Experimental: Dose Escalation Cohort (Part 1A): M4076 Monotherapy|Participants will receive M4076 film coated tablet at escalated doses orally, once daily under fasting condition until disease progression, death, Adverse events (AEs) leading to discontinuation of study intervention(s), or withdrawal of consent, whichever occurs first.
9667520|NCT03486704|Experimental|Face to Face VRRS plus active tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
9837395|NCT04882917|Experimental|Experimental: Preliminary Food Effect Assessment Cohort (Part 1B): M4076|Participants in food effect assessment will receive M4076 at the dose and schedule determined as recommended dose for expansion (RDE) in Part 1A. A single dose of M4076 will be administered on Day -7 under a fed or fasted condition, followed by a 1-week washout period.
9837396|NCT04879589|Experimental|SC ATRS-2002|3 different dosages [25mg (0.13mL) , 75mg (0.4mL) and 200mg (1.05mL)] will be tested as single SC injection into the abdomen.
9837397|NCT04879589|Active Comparator|Oral Abiraterone Acetate|A single dose of 1000mg of commercially available oral formulation of abiraterone acetate will be administered to enrolled participants in Cohort 4
9787743|NCT01313182|Active Comparator|3M Skin and Nasal Antiseptic|Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
9787744|NCT01313182|Active Comparator|Bactroban Nasal|Mupirocin calcium ointment, 2%
9787745|NCT01313208|Placebo Comparator|Placebo|"Participants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks.~All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period."
9787746|NCT01313208|Experimental|Etanercept|"Participants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks.~All participants continued their DMARD treatment throughout the 24-week study period."
9787747|NCT01313221|Active Comparator|Etanercept 50 mg BIW|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
9787748|NCT01313221|Experimental|Etanercept 50 mg QW + Topical|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
9787749|NCT01313286|Experimental|LY2608204 Reference, LY2608204 Test|Single oral 80 mg dose of LY2608204 reference formulation in period 1; single oral 80 mg dose of LY2608204 test formulation in period 2. There is a washout period of at least 14 days between dosing periods.
9787750|NCT01313286|Experimental|LY2608204 Test, LY2608204 Reference|Single oral 80 mg dose of LY2608204 test formulation in period 1; single oral 80 mg dose of LY2608204 reference formulation in period 2. There is a washout period of at least 14 days between dosing periods.
9787751|NCT01313299|Experimental|Dysport 500 U|
9787752|NCT01313299|Experimental|Dysport 1000 U|
9787753|NCT01313299|Placebo Comparator|Placebo|
9787754|NCT01313312|Experimental|Total Dysport®|A total of 254 subjects in the open label study received between 1 and 5 intramuscular (i.m) injections of Dysport® according to their individual needs, for a period of up to 12 months. All subjects were administered an appropriate dosage of Dysport® (1000 Units [U] or 500 U) on Day 1 of treatment Cycle 1. At each study visit from Week 12 onwards, subjects were assessed to determine whether a subsequent treatment cycle was required and treatment cycles were administered at intervals of a minimum of 12 weeks apart depending on the subject's safety and efficacy response. From Cycle 2 onwards, a total dose of 1500 U could be administered in subjects requiring treatment with Dysport® in their shoulder and other upper limb muscles. Subjects who showed improvement in their upper limb during the first two treatment cycles were able to receive concomitant injections of Dysport® 500 U into at least one calf muscle, from Cycle 3 onwards as long as the total dose did not exceed 1500 U.
9787755|NCT01313494|Experimental|Roflumilast|Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
9787756|NCT01313494|Placebo Comparator|Placebo|Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
9787757|NCT01313507|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).
9787758|NCT01313520|Experimental|Infliximab|3 mg/kg of Infliximab intravenous infusion
9787759|NCT01313520|Placebo Comparator|Placebo|saline via intravenous infusion
9787760|NCT01313559|Active Comparator|Cohort A (pasireotide)|Patients receive pasireotide IM once every 4 weeks
9787761|NCT01313559|Experimental|Cohort B (pasireotide and everolimus)|Patients receive pasireotide as in cohort A and everolimus PO QD
9787762|NCT01313624|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
9787763|NCT01313624|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
9787764|NCT01313637|Experimental|GSK573719/GW642444|125/25mcg
9787765|NCT01313637|Experimental|GSK573719|125mcg
9787766|NCT01313637|Experimental|GW642444|25mcg
9787767|NCT01313637|Placebo Comparator|Placebo|Placebo
9787768|NCT01313650|Experimental|GSK573719/GW642444|62.5/25mcg
9787769|NCT01313650|Experimental|GSK573719|62.5mcg
9787770|NCT01313650|Experimental|GW642444|25mcg
9787771|NCT01313650|Placebo Comparator|Placebo|Placebo
9787772|NCT01313663|Experimental|Pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
9787773|NCT01313663|Active Comparator|Pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
9787774|NCT01313676|Experimental|fluticasone furoate/vilanterol|Combination of both products in one inhaler
9787775|NCT01313676|Experimental|fluticasone furoate|comparator of individual component
9787776|NCT01313676|Experimental|vilanterol|comparator of individual component
9787777|NCT01313676|Placebo Comparator|placebo|once daily via inhaler
9787778|NCT01313728|Experimental|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
9787779|NCT01313728|Active Comparator|Tretinoin Gel Alone|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
9787780|NCT01313767|Experimental|Meditoxin®|Botulinum toxin type A
9787781|NCT01313767|Active Comparator|Botox®|Botulinum Toxin type A
9787782|NCT01313780|Experimental|'Oxycodone/Naloxone'|Trade name is Targin(fixed combination drug).
9787783|NCT01313780|Active Comparator|Oxycodone|Trade name is Oxycontin(single compound).
9787784|NCT01313858||Participants with Rheumatoid Arthritis|Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.
9787785|NCT01313858||Participants with Psoriatic Arthritis|Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.
10205753|NCT05203250||Mobile spine and sacral tumors|
9984888|NCT03626922|Experimental|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
9984889|NCT03626922|Experimental|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
9984890|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
9984891|NCT03625141|Experimental|Cohort 1- cobimetinib and atezolizumab|Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
9984892|NCT03625141|Experimental|Cohort 2 - cobimetinib, atezolizumab and vemurafenib|Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
9984893|NCT03622658|Placebo Comparator|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeks
9837405|NCT04868916||Participants with X-Linked Retinitis Pigmentosa (XLRP)|Participants with confirmed diagnosis of XLRP associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR) in the Japanese population will be enrolled in the study and the data will be collected and observed. The primary data source for this study will be the medical records of each participant.
9984894|NCT03622658|Experimental|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeks
9984895|NCT03621475|Experimental|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
9837408|NCT04866589|Experimental|Distribution of free face masks|Face masks will be handed out for free to all customers entering the grocery stores.
9837409|NCT04866589|No Intervention|Control|Business as usual.
9837414|NCT04863950|Experimental|Imipramine Hydrochloride/Lomustine|
9837415|NCT04863794|Experimental|RO7248824|In Part 1 of the study RO7248824 and [89Zr]-labeled RO7248824 will be administered as a single bolus IT injection following a standard IT Administration procedure. In Part 2 of the study, it is planned to test up to 3 additional IT procedures. This part is tentative with regard to its conduct and the number of procedures that may be tested.
9837416|NCT04863625|Experimental|Experimental group|748 students from two secondary schools for the intervention group will be selected and participated in a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).
9837417|NCT04863625|No Intervention|Control group|748 students from two secondary schools for the control group will selected and receive t their school's regular curriculum.
9837418|NCT04863014|Experimental|evinacumab|Randomized 1:1
9837419|NCT04863014|Placebo Comparator|Placebo|Randomized 1:1
9837420|NCT04862689|Experimental|Experimental|Adult subjects clinically indicated for non-emergent percutaneous coronary intervention (PCI) as a stand-alone procedure or following non-emergent diagnostic angiography performed during the same procedure that, in the physician's estimation, requires prolonged balloon inflation with distal perfusion.
9837421|NCT04860700|Experimental|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9837424|NCT04854967|Experimental|De-implementation Intervention|"The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an unlearning component targeting provider and patient education and 3) a substitution component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing)."
9837425|NCT04854967|No Intervention|Usual Care|The patient receives usual care from their assigned clinical provider.
9837433|NCT04851964|Experimental|Tezepelumab|Tezepelumab subcutaneous injection, in an accessorized pre-filled syringe.
9837434|NCT04851964|Placebo Comparator|Placebo|Placebo subcutaneous injection, in an accessorized pre-filled syringe.
9837435|NCT04850573|Experimental|EAA|Participants in this arm will take part in eight weekly thirty minute sessions of equine facilitated learning where they interact with a horse and learn basic horsemanship skills.
9837436|NCT04850573|No Intervention|Control|
9837437|NCT04849169|Experimental|Experimental Arm|Adult subjects who experience a perforation of a coronary vessel during percutaneous coronary intervention (PCI) and require management of hemorrhage until a definitive treatment is determined.
9787786|NCT01313858||Participants with Ankylosing Spondylitis|Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.
9787787|NCT01313884|Experimental|Combination Therapy|"Regimen A alternating with Regimen B every 21 days~Regimen A:~Cytoxan 1200mg/m2~Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2~Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg~Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle~Regimen B:~Irinotecan 50 mg/m2/day x 5 days~Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free"
9787788|NCT01313897|Experimental|Velcade for Anti-MM therapy|Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
9787789|NCT01313910|Experimental|ImmunoLin®|8-week treatment course
9787790|NCT01313936|Experimental|15 mCi/kg of 131I-MIBG|The first cohort for safety will be 3-6 patients treated with vincristine and irinotecan and 15 mCi/kg of 131I-MIBG.
9787791|NCT01313936|Experimental|18 mCi/kg of 131I-MIBG|The second cohort will be 3-6 patients at the same doses of vincristine and irinotecan and 18 mCi/kg of 131I-MIBG.
9787792|NCT01314001|Placebo Comparator|Placebo (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
9787793|NCT01314001|Active Comparator|Varenicline (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
9787794|NCT01314001|Active Comparator|Transdermal Nicotine (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
9787795|NCT01314001|Placebo Comparator|Placebo (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
9787796|NCT01314001|Active Comparator|Varenicline (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
9787797|NCT01314001|Active Comparator|Transdermal Nicotine (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
9787798|NCT01314014|Experimental|Imexon|Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.
9787799|NCT01314105|Experimental|BIBF 1120 L+ Carboplatin + PLD|BIBF 1120 (100 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
9787800|NCT01314105|Experimental|BIBF 1120 M + Carboplatin + PLD|BIBF 1120 (150 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
9787801|NCT01314105|Experimental|BIBF 1120 H + Carboplatin + PLD|BIBF 1120 (200 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
9787802|NCT01314261|Experimental|ABT-267 (5 mg) once daily + pegIFN/RBV|Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
9787803|NCT01314261|Experimental|ABT-267 (50 mg) once daily + pegIFN/RBV|Participants were given 50 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
9998181|NCT01515813|Experimental|Arm C: Pravastatin sodium + EFV/FTC/TDF for 24 weeks|Participants will be administered Pravastatin sodium once daily for 24 weeks starting at week 0 and ending at week 24 plus EFV/FTC/TDF once daily for 24 weeks starting week 0 and ending at week 24.
9787804|NCT01314261|Experimental|ABT-267 (200 mg) once daily + pegIFN/RBV|Participants were given 200 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
9787805|NCT01314261|Placebo Comparator|Placebo + pegIFN/RBV|Participants were given matching placebo to ABT-267 once daily in combination with pegIFN/RBV for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
9787806|NCT01314313|Experimental|PIIA - SAPIEN XT|PIIA is operable group
9787807|NCT01314313|Active Comparator|Control: SAVR|SAVR (surgical aortic valve replacement) is the control arm
9787808|NCT01314417|Experimental|Methotrexate|400 μg/100 μL injection
9787809|NCT01314443|Experimental|Placebo + Smoking Cessation|Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
9787810|NCT01314443|Experimental|Supplement + Smoking Cessation|Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
9787811|NCT01314443|Experimental|Placebo + Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
9787812|NCT01314443|Experimental|Supplement+Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
9787813|NCT01314716|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
9787814|NCT01314716|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
9787815|NCT01314742|Experimental|Biotene OralBalance® gel Arm|Biotene OralBalance® gel contains antibacterial active ingredients: lactoperoxidase, lysozyme and lactoferrin. These enzymes occur naturally in the human milk and colostrum and have mimicking properties of the human saliva activity in vivo.
9787816|NCT01314742|Placebo Comparator|Sterile Water Arm|Sterile Water moisten cotton tipped applicator
9787817|NCT01314872|Placebo Comparator|Part 1: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine extended release (ER) capsule, taken orally each morning, for 8 weeks.
9787818|NCT01314872|Experimental|Part 1: vibegron 3 mg|Participants received one vibegron 3 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
9787819|NCT01314872|Experimental|Part 1: vibegron 15 mg|Participants received one vibegron 15 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
9787820|NCT01314872|Experimental|Part 1: vibegron 50 mg|Participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
9787821|NCT01314872|Experimental|Part 1: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
9787822|NCT01314872|Active Comparator|Part 1: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 8 weeks.
9787823|NCT01314872|Experimental|Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg|Participants received one vibegron 50 mg tablet and one placebo matching vibegron tablet, taken orally each morning, for 8 weeks. They also received one tolterodine ER 4 mg capsule for the first 4 weeks and one placebo matching tolterodine ER capsule for the second 4 weeks, both taken orally each morning.
9787824|NCT01314872|Placebo Comparator|Part 2: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
9787825|NCT01314872|Experimental|Part 2: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
9787826|NCT01314872|Active Comparator|Part 2: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 4 weeks.
9787827|NCT01314872|Experimental|Part 2: vibegron 100 mg + tolterodine ER 4 mg|Participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 4 weeks.
9787828|NCT01314872|Experimental|Extension Study: vibegron 50 mg|Participants in Base Study/Part 1 who received vibegron 50 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 3 mg received vibegron 50 mg in the Extension Study. Also, participants in Base Study/Part 1 who received vibegron 50 mg + tolterodine ER for 4 weeks, followed by vibegron 50 mg alone for 4 weeks, remained on vibegron 50 mg in the Extension Study. In the extension, participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
9787829|NCT01314872|Experimental|Extension Study: vibegron 100 mg|Participants in Base Study/Part 1 or Part 2 who received vibegron 100 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 15 mg received vibegron 100 mg in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
9787830|NCT01314872|Experimental|Extension Study: tolterodine ER 4 mg|Participants in Base Study/Part 1 or Part 2 who received tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received placebo also received tolterodine ER 4 mg in the Extension Study. In the extension, participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 52 weeks.
9787831|NCT01314872|Experimental|Extension Study: vibegron 100 mg + tolterodine ER 4 mg|Participants in Base Study/Part 1 who received vibegron 100 mg + tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 2 who received placebo were assigned to the vibegron 100 mg + tolterodine ER 4 mg arm in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 52 weeks.
9787832|NCT01314911|Experimental|Oseltamivir|
9787833|NCT01314911|Placebo Comparator|Placebo|
9787834|NCT01314963|Experimental|Intraoperative handheld Gamma Camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC)
9787835|NCT01314963|Active Comparator|Gamma probes (GP)|Standard of care intraoperative gamma probes (GP) currently in use.
9787836|NCT01315002|Active Comparator|Nicotine Patch|Transdermal nicotine patch
9787837|NCT01315002|Placebo Comparator|Placebo patch|Placebo patch
9787838|NCT01315028|Experimental|Psychological Therapy|Cognitive Interpersonal Therapy (CIT) was a psychological therapy which emphasised assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive-behavioural and interpersonal strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
9787839|NCT01315028|Active Comparator|Treatment As Usual|All participants continued to receive their usual care from their local community mental health team and other psychological therapies were not withheld during the conduct of the trial.
9787840|NCT01315132|Experimental|Allogeneic Transplantation|Matched Sibling Allogeneic Transplantation
9517806|NCT03302754|Other|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
9787841|NCT01315145|Active Comparator|Percutaneous Lumbar Decompression|Patients receiving percutaneous decompression using the mild® Device Kit.
9787842|NCT01315145|Active Comparator|Lumbar Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
9787843|NCT01315158|Active Comparator|Propofol+Benzo/Opioids|"If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
9837438|NCT04848220|Experimental|Stage A (Dose Cohort 1) and Stage B (Dose Group 1)|
9837439|NCT04848220|Experimental|Stage A (Dose Cohort 2) and Stage B (Dose Group 2)|
9517807|NCT03302728|Experimental|Lenalidomide & brentuximab vedotin|Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg
9517808|NCT03302715|Experimental|Mucosal biopsies|Only blood samples and mucosal biopsies
9787844|NCT01315158|Active Comparator|Propofol Alone|"The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~Induction Dose: 2-2.5 mg/kg~Maintenance Dose: 0.1-0.2 mg/kg/min"
9787845|NCT01315236|Experimental|LAI 590 mg QD|LAI 590 mg QD
9787846|NCT01315236|Placebo Comparator|Placebo|placebo QD
9787847|NCT01315249|Experimental|QVA149|Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
9787848|NCT01315249|Active Comparator|fluticasone/salmeterol|Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).
9787849|NCT01315574|Active Comparator|Latanoprost (Xalatan)|7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
9787850|NCT01315574|Active Comparator|Travoprost (Travatan Z)|7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.
9787851|NCT01315665|Experimental|Healthy volunteers|100 grams of raw broccoli sprouts once daily for 5 consecutive days
9787852|NCT01315665|Experimental|Subjects with cystic fibrosis|100 grams of raw broccoli sprouts once daily for 5 consecutive days
9787853|NCT01315678|Experimental|Arikayce™|Arikayce™ is liposomal amikacin for inhalation
9787854|NCT01315678|Active Comparator|TOBI®|TOBI® is tobramycin inhalation solution
9787855|NCT01315847|Experimental|Healthy Participants (Part I)|Baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 megabecquerel [MBq]) was performed in healthy participants; this PET data served as the baseline for both Period 1 and 2 of Part I. Subsequently in study Part I, Period 1 the healthy participants received a single 1120 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~3 hours post telcagepant dose. In Part I, Period 2 the healthy participants received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part I Period 1 and 2 was to be at least 1 week.
9787856|NCT01315847|Experimental|Participants with Migraine (Part III)|In study Part III, Period 1 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine during a migraine attack (ictal phase). Later in Part III, Period 1 the participants with an ongoing migraine attack (ictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. In Part III, Period 2 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine, however, without a migraine attack ongoing (interictal phase). Later in Part III, Period 2 participants with migraine without a migraine attack ongoing (interictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part III Period 1 and 2 was to be at least 1 week.
9787857|NCT01316042|Placebo Comparator|sugar pill|2 pills per day for 12 months
9787858|NCT01316042|Active Comparator|Metformin|2 212.5mg pill/day for 12 months
9787859|NCT01316055|Active Comparator|Healthy: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
9787860|NCT01316055|Active Comparator|Mild renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
9787861|NCT01316055|Active Comparator|Moderate renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
9787862|NCT01316211|Active Comparator|coflex™|Implantation of coflex™ device in assigned patients
9787863|NCT01316211|Active Comparator|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.
9787864|NCT01316224||Moderate or severe plaque psoriasis|Participants with moderate or severe plaque psoriasis treated with adalimumab
9787865|NCT01316263|Experimental|PDGFRα mutation negative|Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
9787866|NCT01316263|Experimental|PDGFRα mutation positive|Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.
9787867|NCT01316276|Experimental|LAI|590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).
9787868|NCT01316302|Experimental|Pristiq|Flexible dose, 50-100mg QD
9787869|NCT01316302|Placebo Comparator|Placebo|Matching placebo
9787870|NCT01316315|Experimental|Active|N6022 - 5 mg
9787871|NCT01316315|Placebo Comparator|Placebo|Placebo
9787872|NCT01316341|Experimental|BI10773 low dose Per Os(p.o.)|patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo
9787873|NCT01316341|Placebo Comparator|Placebo|patient to receive two placebos
9787874|NCT01316341|Experimental|BI10773 high dose Per Os(p.o.)|patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo
9787875|NCT01316380|Experimental|tiotropium 5 mcg|once daily delivered via Respimat inhaler
9787876|NCT01316380|Experimental|tiotropium 2.5 mcg|once daily delivered via Respimat inhaler
9787877|NCT01316380|Placebo Comparator|placebo|once daily delivered via Respimat inhaler
9517809|NCT03302702|Other|Exercise program|Treatment group
9517810|NCT03302689|Experimental|Ropivacaine|TAP-block with Ropivacaine Solution
9517811|NCT03302689|Experimental|Levobupivacaine|TAP-block with Levobupivacaine Solution
9787878|NCT01316419||Patients with essential hypertension|
9787879|NCT01316510|Active Comparator|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
9787880|NCT01316510|Placebo Comparator|Placebo|A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).
9787881|NCT01316575|Experimental|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
9787882|NCT01316575|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
9787883|NCT01316614|Experimental|With Stylet & Without Stylet|There will only be one arm in this study. This arm will undergo EUS-guided FNA with the use of a stylet for half of their FNA passes and without a stylet for the other half. Patients will be exposed to an equal number of passes with and without a stylet. Each pass will be individually assessed by a skilled cytopathologist who is blinded to the technique used. We will compare the adequacy of both techniques to determine whether or not a stylet leads to a higher diagnostic accuracy rate in patients with solid lesions.
9787884|NCT01316692|Experimental|MLN8237|Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9787885|NCT01316770|Placebo Comparator|Placebo Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with saline (placebo). { UPDATE: drug(generic) was administered at what time pt, dose of drug, route administration, frequency}
9787886|NCT01316770|Experimental|Dexamethasone Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with dexamethasone {UPDATE: drug (generic) was administered at what time pt, dose of drug, route administration, frequency}
9787887|NCT01316887|Experimental|GSK573719/GW642444|125/25 mcg once-daily
9787888|NCT01316887|Experimental|GSK573719|125 mcg once-daily
9787889|NCT01316887|Placebo Comparator|Placebo|inactive
9787890|NCT01316900|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
9787891|NCT01316900|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
9787892|NCT01316900|Experimental|GW642444|25 mcg once-daily
9787893|NCT01316900|Active Comparator|tiotropium bromide|18 mcg once-daily
9787894|NCT01316913|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
9787895|NCT01316913|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
9787896|NCT01316913|Experimental|GSK573719|125 mcg once-daily
9787897|NCT01316913|Active Comparator|tiotropium bromide|18 mcg once-daily
9787898|NCT01316926|Active Comparator|Paxil CR Reference|Reference drug administration followed by test drug administration
9787899|NCT01316926|Active Comparator|Paxil CR Test|Test drug administration followed by Reference drug administration
9787900|NCT01316939|Placebo Comparator|Placebo|Placebo
9787901|NCT01316939|Experimental|GSK1605786A once daily|500 milligrams once daily
9787902|NCT01316939|Experimental|GSK1605786A twice daily|500 milligrams twice daily
9787903|NCT01317004|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
9787904|NCT01317004|Active Comparator|Multiple Sclerosis Disease Modifying Treatment (MS DMT)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
9787905|NCT01317030||Contact Lens Wear|Senofilcon A Lenses, using Sensitive Eyes Saline Solution and/or Biotrue Multipurpose Solution
9787906|NCT01317030||Non-Contact Lens Wear|
9787907|NCT01317095|Active Comparator|Wire closure is the intervention|Patients will have their sternum closed using stainless steel wires.
9787908|NCT01317095|Active Comparator|Rigid fixation|Patients will have their sternum closed by rigid fixation using Starnalock plates.
9837440|NCT04848220|Placebo Comparator|Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)|
9984896|NCT03621475|Experimental|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
9984897|NCT03620968|No Intervention|Group 1|Control, no intervention
9984898|NCT03620968|Experimental|Group 2|Intervention before surgery (cognitive training)
9984899|NCT03620968|Experimental|Group 3|Intervention Before and after surgery (cognitive training)
9984900|NCT03620942|Experimental|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
9984901|NCT03620942|Active Comparator|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
10205754|NCT05203211||Men who have undergone icsi from ejaculated semen|
9837448|NCT04846933||HGSOC patients treated with Neoadjuvant chemotherapy (NACT)|"Diagnostic laparoscopy followed with 3-4 cycles of platinum-taxane NACT and interval debulking surgery (IDS). Treatment response is monitored with FDG PET/CT. IDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines).~Digital H&E slides and WGS, RNAseq are obtained from performed surgeries including relapse operations/ascites drainages. Patients are followed with longitudinal ctDNA sampling."
9837449|NCT04846933||HGSOC patients treated with primary debulking surgery (PDS)|PDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines). Digital H&E slides and WGS, RNAseq obtained from PDS and possible relapse operations/ascites drainages when performed. Patients are followed with longitudinal ctDNA sampling.
9837450|NCT04846400|Experimental|ssNPA|self-supporting nasopharyngeal airway to be used nightly for approximately 8 weeks.
9837451|NCT04845282|Experimental|Graded Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with a gradation of protein over the 12 week study duration.
9837452|NCT04845282|Active Comparator|RDA Protein plus Resistance Training|This group will participate in a progressive resistance training program and will be instructed to consume a diet with the recommended daily allowance of protein over the 12 week study duration.
9837453|NCT04844749|Experimental|Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a day|32mg of VERU-111 26mg of VERU-11
9837454|NCT04844749|Active Comparator|Active control alternative androgen receptor targeting agent|The alternative androgen receptor targeting agent will be administered according to the dosing instructions in the current product prescribing information.
9837455|NCT04844450|Experimental|Single Ascending Dose (SAD)|Participants in cohorts 1-5 and cohorts 3a-5a will receive subcutaneous (SC) injection of single dose (Part A) of JNJ-75220795 or matching placebo.
9837456|NCT04844450|Experimental|Multiple Ascending Dose (MAD)|Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo.
9921921|NCT00832806|Active Comparator|2|Extended IVR (integrated voice response technology) vs. no extended IVR
9921922|NCT00832832|Experimental|Eyelid closure|Eyelids will be closed after administration of eye drop
10205755|NCT05203211||Men who have undergone icsi from testicular sperm|
10205756|NCT05203185|Experimental|Post-pilot Group|Full time employed Emergency Department providers will use the new CDS tool, Pulmonary Embolism Risk Kalculator (PERK), which includes nudges to improve use and will be integrated into the electronic medical record and will be accessible for 6 months
10205757|NCT05203185|No Intervention|Pre-pilot Group|Full time employed Emergency Department providers used a CDS tool, Pulmonary Embolism Calculator (PE CALC), without nudges to improve use, to reduce unnecessary imaging in the diagnosis of pulmonary embolism (PE) in the emergency department (ED).
10205758|NCT05203172|Experimental|Binimetinib only treatment|For those participants receiving binimetinib treatment in parent studies
10205759|NCT05203172|Experimental|Encorafenib only Treatment|For those participants receiving encorafenib only treatment in parent studies
10205760|NCT05203172|Experimental|Encorafenib & Binimetinib Treatment|For those participants receiving encorafenib & binimetinib treatment in parent studies.
10205761|NCT05203172|Experimental|Treatment of Encorafenib & Binimetinib & Ribociclib|For those participants receiving treatment of encorafenib & binimetinib & ribociclib in parent studies
10205762|NCT05203172|Experimental|Treatment of Encorafenib & Binimetinib & Cetuximab|For those participants receiving treatment of encorafenib & binimetinib & cetuximab in parent studies
10205763|NCT05203146|Experimental|Arm A (PIMPmyHospital)|Participants that will use the mHeath PIMPmyHospital tool during the semi-simulation-based scenario.
10205764|NCT05203146|Active Comparator|Arm B (Conventional methods)|Participants that will use conventional methods (i.e., without mobile app support) during the semi-simulation-based scenario.
10205765|NCT05203133|Experimental|Baseline Assessment (Days -5 to -1)|Participants will complete a a 5-day baseline assessment in which habitual energy intake (remote food photography method) and exercise energy expenditure will be monitored.
10205766|NCT05203133|Experimental|Energy Balance (Days 1 to 5)|Participants will be provided with all food intake for five days, to provide an energy intake of 54 kcal/kg FFM/day. On days 1, 3 and 5, participants will complete aerobic (cycling) exercise at ~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy balance (energy availability = 45 kcal/kg of FFM/day, required for weight maintenance.
10205767|NCT05203133|Experimental|Energy Deficit (Days 6-11)|Participants will be provided with all food intake for five days, to provide an energy intake of 19 kcal/kg FFM/day. On days 6, 8 and 10, participants will complete aerobic (cycling) exercise at ~60% VO2peak to expend15 kcal/kg FFM. This will achieve a state of energy deficit (energy availability = 10 kcal/kg of FFM/day) resulting in ~2.5 kg of weight-loss.
10205768|NCT05203120|Experimental|Proton Arm|All patients in the study will receive proton therapy with 67.5 Gray/15 fractions(fx) /5fx per week .
10205769|NCT05203068|Experimental|Recombinant tuberculosis allergen (CFP10-ESAT6)|RTA (CFP10-ESAT6) 0.2 µg/0.1 mL RTA given intradermally on the middle of the forearm
9837457|NCT04844424|Experimental|Part 1A: Treatment Sequence ABC|Participants will receive a single oral Dose 1 of milvexian as direct compression (DC) tablets under fasting conditions (Treatment A) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as roller compacted (RC) tablets under fasting conditions (Treatment B) in Treatment Period 2 and then a single oral Dose 1 of milvexian Phase 2 oral capsules under fasting conditions (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837458|NCT04844424|Experimental|Part 1A: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837459|NCT04844424|Experimental|Part 1A: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837460|NCT04844424|Experimental|Part 1A: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment B in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837461|NCT04844424|Experimental|Part 1A: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 and then Treatment C in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837462|NCT04844424|Experimental|Part 1A: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1 followed by Treatment B in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period during Part 1A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837463|NCT04844424|Experimental|Part 1B: Treatment Sequence DEF|Participants will receive a single oral Dose 1 of milvexian as DC oral tablets under fed conditions (Treatment D) in Treatment Period 1, followed by a single oral Dose 1 of milvexian as RC oral tablets under fed conditions (Treatment E) in Treatment Period 2 and then a single oral Dose 1 of milvexian as Phase 2 oral capsules under fed conditions (Treatment F) in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837464|NCT04844424|Experimental|Part 1B: Treatment Sequence EFD|Participants will receive Treatment E in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837465|NCT04844424|Experimental|Part 1B: Treatment Sequence FDE|Participants will receive Treatment F in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837466|NCT04844424|Experimental|Part 1B: Treatment Sequence DFE|Participants will receive Treatment D in Treatment Period 1, followed by Treatment F in Treatment Period 2 and then Treatment E in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837467|NCT04844424|Experimental|Part 1B: Treatment Sequence EDF|Participants will receive Treatment E in Treatment Period 1, followed by Treatment D in Treatment Period 2 and then Treatment F in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837468|NCT04844424|Experimental|Part 1B: Treatment Sequence FED|Participants will receive Treatment F in Treatment Period 1, followed by Treatment E in Treatment Period 2 and then Treatment D in Treatment Period 3 on Day 1 of each Treatment Period during Part 1B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9921923|NCT00832832|Active Comparator|No eyelid closure|Eyelids will not be closed after eye drop instillation
9787909|NCT01317160|No Intervention|Routine care: Plaster Cast Treatment|Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
9787910|NCT01317160|Experimental|Intermittent pneumatic compression (IPC)|Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.
9787911|NCT01317199|Experimental|Phase 1: Dose-escalation of Muscadine Plus Grape Skin Extract|Muscadine Plus Grape Skin Extract (MPX): Phase I Dose-escalation starts at 500mg daily for 1 cycle (28 days), then increased to 1000mg for 2nd cycle, then increased to 2000mg daily for 3rd cycle, then increased to 3000mg daily for 4th cycle, then increased to maximum dose of 4000mg daily for final cycle. Pills given by mouth once daily for 28 days per cycle.
9787912|NCT01317199|Placebo Comparator|Phase 2: Placebo control|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
9787913|NCT01317199|Experimental|Phase 2: Low-dose MPX|Randomly-assigned participants receive low-dose (500mg) MPX
9787914|NCT01317199|Experimental|Phase 2: High-dose MPX|Randomly-assigned participants receive high-dose (4000mg) MPX
9787915|NCT01317277|Experimental|Personalized Reminder Texting (iTAB) + Psychoeducation|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications.
9787916|NCT01317277|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications. They will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
9787917|NCT01317472|Experimental|Dexlansoprazole|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
9787918|NCT01317472|Placebo Comparator|Sugar pill|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
9787919|NCT01317550|Experimental|Armodafinil + Placebo|Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks
9787920|NCT01317550|Experimental|Minocycline + Placebo|Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks
9787921|NCT01317550|Experimental|Armodafinil + Minocycline|Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks
9787922|NCT01317550|Placebo Comparator|Placebos|Placebo Capsules orally once/day for 10 weeks
9787923|NCT01317615|Experimental|RAD001 plus paclitaxel/carboplatin|Participants received RAD001 5 mg orally once daily in combination with carboplatin and paclitaxel for a maximum 4 cycles or until discontinuation.
9787924|NCT01317641|Experimental|ODM-201 Phase I|
9787925|NCT01317641|Experimental|ODM-201 Phase II Dose 1|
9787926|NCT01317641|Experimental|ODM-201 Phase II Dose 2|
9787927|NCT01317641|Experimental|ODM-201 Phase II Dose 3|
9787928|NCT01317667|Experimental|Group 1|RVEc vaccine 20 μg/dose x 3 doses
9787929|NCT01317667|Experimental|Group 2|RVEc vaccine 50 μg/dose x 3 doses
9787930|NCT01317667|Experimental|Group 3|RVEc vaccine 100 μg/dose x 1 dose
9787931|NCT01317797|Experimental|Namilumab 150 mg|Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
9787932|NCT01317797|Experimental|Namilumab 300 mg|Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
9787933|NCT01317797|Placebo Comparator|Placebo|Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.
9787934|NCT01317901|Experimental|TRU-016+bendamustine+rituximab|Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.
9787935|NCT01317940|Experimental|Group A (Newly Diagnosed Subjects)|
9787936|NCT01317940|No Intervention|Standard of Care Group A|
9787937|NCT01317940|Experimental|Group B (Early Survivors)|
9787938|NCT01317940|No Intervention|Observation Only - Group B|
9787939|NCT01317940|No Intervention|Group C (Siblings of Group A)|
9787940|NCT01318018||Magnetic Seizure Therapy Group|Patients receiving magnetic seizure therapy for depression
9787941|NCT01318018||Electroconvulsive Therapy Group|Patients receiving electroconvulsive therapy for depression
9787942|NCT01318070|Experimental|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD|
9787943|NCT01318070|Experimental|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
9787944|NCT01318070|Active Comparator|Pioglitazone (15mg or 30mg ) QD|
9787945|NCT01318083|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride QD or BID|
9787946|NCT01318083|Active Comparator|Alogliptin 25 mg QD and Glimepiride QD or BID|
9787947|NCT01318083|Active Comparator|Glimepiride 1, 2, 3 or 4 mg QD or BID|
9787948|NCT01318109|Active Comparator|Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID|
9787949|NCT01318109|Active Comparator|Alogliptin 25mg QD and metformin 500mg BID or 750mg TID|
9787950|NCT01318109|Active Comparator|Metformin 500mg BID or 750mg TID|
9787951|NCT01318122|Active Comparator|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD|
9787952|NCT01318122|Active Comparator|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
9837469|NCT04844424|Experimental|Part 2A: Treatment Sequence GH|Participants will receive twice daily (BID) oral Dose 1 of milvexian DC oral tablets (Treatment G) in Treatment Period 1, followed by BID oral Dose 1 of milvexian Phase 2 oral capsule (Treatment H) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
9837470|NCT04844424|Experimental|Part 2A: Treatment Sequence HG|Participants will receive Treatment H in Treatment Period 1, followed by Treatment G in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2A. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
9837471|NCT04844424|Experimental|Part 2B: Treatment Sequence IJ|Participants will receive BID oral Dose 2 of milvexian DC oral tablet (Treatment I) in Treatment Period 1, followed by BID oral Dose 2 of milvexian Phase 2 oral capsule (Treatment J) in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
9837472|NCT04844424|Experimental|Part 2B: Treatment Sequence JI|Participants will receive Treatment J in Treatment Period 1, followed by Treatment I in Treatment Period 2 up to Day 5 in each Treatment Period during Part 2B. There will be a wash-out period of more than 5 days between the evening dose of Day 5 of Treatment Period 1 and the morning dose of Day 1 of Treatment Period 2.
9837473|NCT04844424|Experimental|Part 3A: Treatment Sequence KLM|Participants will receive single oral Dose 1 of milvexian as oral Tablet 1 under fasting conditions (Treatment K) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fasting conditions (Treatment L) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 2 oral capsules under fasting conditions (Treatment M) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837474|NCT04844424|Experimental|Part 3A: Treatment Sequence LMK|Participants will receive Treatment L in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 of each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837475|NCT04844424|Experimental|Part 3A: Treatment Sequence MKL|Participants will receive Treatment M in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837476|NCT04844424|Experimental|Part 3A: Treatment Sequence KML|Participants will receive Treatment K in Treatment Period 1, followed by Treatment M in Treatment Period 2 and then Treatment L in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9787953|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID|
9787954|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID|
9787955|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID|
9787956|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID|
9787957|NCT01318278|Active Comparator|Dopamine treatment|Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
9787958|NCT01318278|Active Comparator|Vasopressin treatment|Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
9787959|NCT01318278|No Intervention|Comparison Arm|Infants who did not require vasopressor support for hypotension during the first 24 hours of life
9787960|NCT01318356|Experimental|Cognitive behavioral therapy|
9787961|NCT01318356|Experimental|Doxycycline|
9787962|NCT01318356|Placebo Comparator|Placebo|
9787963|NCT01318382|Experimental|TOF-Watch SX®|Participants who have undergone elective open or laparoscopic abdominal surgery, received general anesthesia, received at least one dose of non-depolarizing neuromuscular blocker and had the extent of their recovery from NMB monitored by a TOF-Watch SX®.
9787964|NCT01318408|Experimental|Levetiracetam|Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.
9787965|NCT01318499|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
9787966|NCT01318499|Active Comparator|Nepafenac 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
9787967|NCT01318499|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
9787968|NCT01318512||Chronic Kidney Disease|Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.
9787969|NCT01318538|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
9787970|NCT01318538|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
9787971|NCT01318577|Experimental|Investigational Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses.
9787972|NCT01318577|Active Comparator|Clear Care Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses
10205770|NCT05203055|Experimental|monotherapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 48 consecutive weeks. Patients will stop the treatment whenever HBsAg is eliminated, and those without HBsAg elimination after 48 dosages will enter the group of best treatment. The patients will be followed up for another 24 weeks after treatment.
10205771|NCT05203055|Experimental|continuous combination therapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 48 consecutive weeks, plus continuous oral NA. Patients will stop the treatment whenever HBsAg is eliminated, and those without HBsAg elimination after 48 dosages will enter the group of best treatment. The patients will be followed up for another 24 weeks after treatment.
10205772|NCT05203055|Experimental|pulse combination therapy group|Peginterferon alpha-2b injection is given subcutaneously at a dosage of 180μg/w for 8 consecutive weeks and cessation for 4 weeks,plus continuous oral NA. Patients will discontinue the treatment at any time if they are recovery, and those without HBsAg elimination after 48 dosages will enter the group of best treatment.The patients will be followed up for another 24 weeks after treatment.
10205773|NCT05203042||prediabetes|
10205774|NCT05203042||diabetes|
10205775|NCT05203029|Experimental|Aerobic exercises|The warm-up for 5 minutes; stretching exercises include stretching the neck to the sides, stretching the muscles of the shoulder girdle, back, and legs for 10 minutes; resistance exercises for 15 minutes, which will initially be applied in a light and weight-bearing manner, and in each session, according to the patient's progress, using free lightweights; light aerobic exercise for 10 minutes standing, sitting and lying down by controlling patients' heartbeat; cool down for 5 minutes.
10205776|NCT05203029|Experimental|Laughter yoga|Breathing techniques for 20 minutes including deep breathing, diaphragmatic breathing, tap on immune-boosting centers like thymus; laughter concert for 20 minutes such as laughter for no reason, childish movements, release the inner child; and laughter meditation for 5 minutes.
10205777|NCT05203029|Active Comparator|Yoga|Meditation and deep breathing for 10 minutes; physical posture for 15 minutes; 15 minutes relaxation exercises; and 5 minutes mindfulness practices.
9837477|NCT04844424|Experimental|Part 3A: Treatment Sequence LKM|Participants will receive Treatment L in Treatment Period 1, followed by Treatment K in Treatment Period 2 and then Treatment M in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837478|NCT04844424|Experimental|Part 3A: Treatment Sequence MLK|Participants will receive Treatment M in Treatment Period 1, followed by Treatment L in Treatment Period 2 and then Treatment K in Treatment Period 3 on Day 1 in each Treatment Period during Part 3A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837479|NCT04844424|Experimental|Part 3B: Treatment Sequence NOP|Participants will receive single oral Dose 1 of milvexian oral Tablet 1 under fed conditions (Treatment N) in Treatment Period 1, followed by single oral Dose 1 of milvexian oral Tablet 2 under fed conditions (Treatment O) in Treatment Period 2 and then single oral Dose 1 of milvexian Phase 2 oral capsule under fed conditions (Treatment P) in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837480|NCT04844424|Experimental|Part 3B: Treatment Sequence OPN|Participants will receive Treatment O in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837481|NCT04844424|Experimental|Part 3B: Treatment Sequence PNO|Participants will receive Treatment P in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837482|NCT04844424|Experimental|Part 3B: Treatment Sequence NPO|Participants will receive Treatment N in Treatment Period 1, followed by Treatment P in Treatment Period 2 and then Treatment O in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837483|NCT04844424|Experimental|Part 3B: Treatment Sequence ONP|Participants will receive Treatment O in Treatment Period 1, followed by Treatment N in Treatment Period 2 and then Treatment P in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837484|NCT04844424|Experimental|Part 3B: Treatment Sequence PON|Participants will receive Treatment P in Treatment Period 1, followed by Treatment O in Treatment Period 2 and then Treatment N in Treatment Period 3 on Day 1 in each Treatment Period during Part 3B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837485|NCT04844424|Experimental|Part 4 A: Treatment Sequence QRS|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablets under fasting conditions (Treatment Q) in Treatment Period 1, followed by single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment R) in Treatment Period 2 and then single oral Dose 1 of milvexian as Phase 3 oral tablets under fed conditions (Treatment S) in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9921924|NCT00832845|Experimental|CBSST plus treatment as usual|Subject randomized to the CBSST Group arm will attend 2 hour weekly Cognitive Behavioural Social Skills therapy sessions for 9 months. They will also be attending follow-up assessments q 4 months.
10205778|NCT05203016||caesarean sections|
10205779|NCT05203016||Plastic surgery|
10205780|NCT05203016||Maxillofacial surgery|
10205781|NCT05203003||Adult patients who are included in the CONFIRM phase III trial|
10205782|NCT05202990|Experimental|Fecal Microbiota Transplantation by Stool capsules|Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool capsules
10205783|NCT05202990|Experimental|Fecal Microbiota Transplantation by enema|Patients receiving fecal microbiota transplantation from a healthy donor in 3 times after inclusion and randomisation (Month 0 - Month 1 - Month 2) using frozen stool enemas.
10205784|NCT05202977|Experimental|SinocrownTM Transcatheter Aortic Valve Replacement System|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
10205785|NCT05202951||Patients with hemophilia|all adult patients follow-upin Hospital for hemophilia
10205786|NCT05202925|Experimental|Musical Training|All subjects in the intervention group will receive a weekly 45-minute lesson, one-to-one musical training for 52 weeks.
10205787|NCT05202912|Other|Cohort A(Food effect)|
10205788|NCT05202912|Other|Cohort B(Single dose)|
10205789|NCT05202886|Experimental|Liver from deceased donors|This study included all consecutive subjects with chronic liver disease who underwent LT for the first time with a deceased donor liver
10205790|NCT05202847|Experimental|pulsed radiofrequency ablation to modified points group|pulsed radiofrequency ablation aimed at the adjusted target point of Park et al. under C-arm guidance
10205791|NCT05202847|Active Comparator|pulsed radiofrequency ablation to conventional points group|pulsed radiofrequency ablation aimed at conventional target point under C-arm guidance
10205792|NCT05202821|Active Comparator|group of 20 participants receiving fluoride varnish|*Group (I): patients will receive Fluoride varnish ttt.
10205793|NCT05202821|Experimental|group of 20 participants receiving PR-G Barrier coat|*Group (II): patients will receive PR-G Barrier coat
10205794|NCT05202821|Active Comparator|group of 20 participants receiving MI Paste (CPP-ACP)|*Group (III): Patients will receive MI Paste (CPP-ACP)
10205795|NCT05202782|Experimental|Treatment (zanubrutinib and CAR T-cell therapy)|"LEAD- IN PHASE: Patients receive zanubrutinib PO BID for 7-14 days in the absence of disease progression or unacceptable toxicity.~CAR T-CELL THERAPY: Patients receive standard of care CAR T-cell therapy IV at 4 weeks.~MAINTENANCE PHASE: Patients receive zanubrutinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity."
10205796|NCT05201651|Experimental|Creatine|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
10205797|NCT05201651|Placebo Comparator|Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
10205798|NCT05198492||Patients with hospitalizations or emergency room visits due to acute coronary syndromes|Data on hospitalization for acute coronary syndromes were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
10205799|NCT05198492||Patients with hospitalizations or emergency room visits due to atrial fibrillation|Data on hospitalization for atrial fibrillation were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
10205800|NCT05198492||Patients with hospitalizations or emergency room visits due to kidney diseases|Data on hospitalization for kidney diseases were obtained and extracted from the National Health Fund reports. In the present analysis, we used data from patients registered as residents in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020. The set of variables that were subjected to the analysis included demographic features and ICD-10 codes. The diagnosis was based on reports obtained from to the National Health Fund, and these reports have not been reviewed with patient hospital documentation.
9787973|NCT01318694|Experimental|Treatment Arm A|"Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):~Participants with a viral load below the level of detection (< LOD) at Week 4 stop study treatment after 24 weeks~Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment"
9787974|NCT01318694|Experimental|Treatment Arm B|Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)
9787975|NCT01318694|Experimental|Treatment Arm C|Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks
9787976|NCT01318694|Active Comparator|Treatment Arm D|ALV Placebo with PEG and RBV for 48 weeks
9787977|NCT01318733|Experimental|CD07805/47 Gel 0.5%|
9787978|NCT01318811|Active Comparator|Dilute heparin|Arm A will receive dilute heparin delivered as an intravenous infusion proximal to the dialysis filter.
9787979|NCT01318811|Active Comparator|Standard concentrated heparin|Arm B will receive standard concentrated heparin and will be delivered as an intravenous infusion proximal to the dialysis filter.
9787980|NCT01318876||BC Children's and Women's Hospital, Vancouver.|
9787981|NCT01318876||University of British Columbia, Vancouver.|
9787982|NCT01318876||Health care workers in Halifax|
9787983|NCT01318876||Health care workers from CHUQ hospitals|
9787984|NCT01318876||Health care workers from Toronto|
9787985|NCT01318876||Centre hospitalier et universitaire de Sherbrooke|
9787986|NCT01318876||The Ottawa General Hospital, Ottawa|
9799389|NCT01658579|Experimental|HOE901-U300 Morning Then Evening|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
9799390|NCT01658579|Experimental|HOE901-U300 Evening Then Morning|HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
9799391|NCT01658579|Active Comparator|Lantus Morning Then Evening|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
9799392|NCT01658579|Active Comparator|Lantus Evening Then Morning|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
9799393|NCT01658657|Experimental|PRA-guided therapy|Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
9799394|NCT01658657|Active Comparator|Fixed-dose combination treatment-guided therapy|Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
9799395|NCT01658735|Active Comparator|H-Wave Device|H-Wave Device with Usual Care
9799396|NCT01658735|Active Comparator|TENS|Transcutaneous electrical nerve stimulation (TENS) Device with Usual Care
9799397|NCT01658735|Sham Comparator|Sham Electrotherapy|Sham Device plus Usual Care.
9799398|NCT01658839|Experimental|Travoprost|Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days
9800436|NCT01687400|Experimental|Decitabine|Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.
10205801|NCT05198492||Patients who died due to cardiovascular diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
9787987|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
9787988|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
9787989|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were not treated with any other proteasome inhibitor (PI). Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
9787990|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until PD or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were previously treated with any other PI. Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
9787991|NCT01318915|Experimental|Induction (Rituximab and ATG)|Study participants will undergo induction with rituximab and ATG and an initial maintenance therapy with tacrolimus, mycophenolate mofetil (MMF) and sirolimus. MMF will be discontinued on day 12. Participants will be evaluated for eligibility for tacrolimus withdrawal which must be initiated between weeks 26 and 38. Tacrolimus withdrawal must be completed in no fewer than 4 weeks and no more than 8 weeks. Then after at least 26 weeks on sirolimus monotherapy, participants will be evaluated for eligibility for sirolimus withdrawal which must be initiated between weeks 56 and 88. Sirolimus withdrawal must be completed in no fewer than 12 weeks and no more than 26 weeks.
9787992|NCT01318967|Placebo Comparator|PAH|PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
9787993|NCT01318967|Active Comparator|MRI after furosemide|After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
9787994|NCT01319045|Experimental|Iloprost|Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
9787995|NCT01319110|Experimental|CoenzymeQ10|Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
9787996|NCT01319110|Placebo Comparator|Placebo|Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). Placebo will be given through pre-existing NG or OG tube.
9787997|NCT01319318||Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
9787998|NCT01319383|Experimental|Open Label, Translational Research|Vorinostat will be administered to all eligible participants in each step of each phase (period) of the study
9787999|NCT01319422|Experimental|Pomalidomide 2 mg/d on 28 days/28 day cycle|
9788000|NCT01319422|Experimental|Pomalidomide 4 mg/d on 21 days/28 day cycle|
9788001|NCT01319500||Yasmin|"Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC Yasmin"
9788002|NCT01319500||Other OCs|"Users of OCs except Yasmin (Other OCs)"
9788003|NCT01319539|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
9788004|NCT01319552|Other|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
9788005|NCT01319552|Experimental|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
9788006|NCT01319617|Experimental|SENSIMED Triggerfish|
10205802|NCT05198492||Patients who died due to neoplasm diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
10205803|NCT05198492||Patients who died due to kidney diseases|Data on mortality were collected from the National Statistical Office in Poland. These include information on all the deaths recorded in the Podlaskie, Lubelskie, Podkarpackie, Świetokrzyskie, and Warminsko-Mazurskie voivodeships from January 1, 2011 to December 31, 2020 The records included sex and age of people who had died, and the causes of deaths were classified according to codes in the International Classification of Diseases-10th Revision (ICD-10).
10205804|NCT05198466|Active Comparator|Active E-Stim|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
10205805|NCT05198466|Sham Comparator|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
10205806|NCT05197543||BRRA group|Rupture risk of asymptomatic AAAs in this group was estimated using Biomechanical rupture rist assessment (BRRA). BRRA considers an AAA as a pressure vessel and estimates its risk of rupture by comparing its wall stress to wall strength
10205807|NCT05197543||Maximal diameter group|Rupture risk of asymptomatic AAAs in this group was estimated by a classical approach based on a maximal diameter.
9788007|NCT01319721|Active Comparator|Group LCAG|After extensive excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft for repairing the conjunctival defect.
9788008|NCT01319721|Active Comparator|Group AMG|After excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then an amniotic membrane graft for repairing the conjunctival defect.
9788009|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation A (Formulation A)|Parallel-Group Phase (PGP): cyclosporine ophthalmic emulsion Formulation A
9788010|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation B (Formulation B)|PGP: cyclosporine ophthalmic emulsion Formulation B
9788011|NCT01319773|Other|Formulation A and cyclosporine ophthalmic emulsion 0.05%|Paired-Eye Phase (PEP): cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion 0.05%
9788012|NCT01319773|Other|Formulation B and cyclosporine ophthalmic emulsion 0.05%|PEP: cyclosporine ophthalmic emulsion Formulation B and cyclosporine ophthalmic emulsion 0.05%
9788013|NCT01319773|Experimental|Formulation A and Formulation B|PEP: cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion Formulation B
9788014|NCT01319799||Surgical aortic valve replacement|Single observational study. Count of microembolic signals during open heart surgery and measurement of properative vs postoperative levels of markers in cerebrospinal fluid of neuronal damge.
9788015|NCT01319812|Experimental|Astron Stent Group|"Participants indicated for stenting in iliac atherosclerotic lesions.~Intervention: Device: Astron Stents"
9788016|NCT01319812|Experimental|Pulsar Stent Group|"Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.~Intervention: Device: Pulsar Stents"
9788017|NCT01319851|Experimental|Alefacept|Pediatric subjects with non-malignant diseases (NMD) will receive pre-conditioning with alefacept 0.5 mg/kg/dose i.v. with the first dose split on days -40 and -39 and the remaining doses given on days -33, -26, -19, and -12 (e.g. weekly for 5 doses).
9788018|NCT01319877||First Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a first line therapy.
9788019|NCT01319877||Second Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a second line therapy.
9788020|NCT01319929|Experimental|LY2828360 then Placebo|80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
9788021|NCT01319929|Experimental|Placebo then LY2828360|Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
9788022|NCT01319994|Experimental|Metformin|Metformin 850mg TDS (12 weeks)
9788023|NCT01319994|Placebo Comparator|Placebo|Placebo 850mg TDS (12 weeks)
9788024|NCT01320033|Experimental|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.
9788025|NCT01320033|Active Comparator|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.
9788026|NCT01320033|Placebo Comparator|Placebo|Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.
9788027|NCT01320085|Experimental|BRAFV600 mutant, 45mg bid MEK162|BRAFV600 mutant, 45mg bid MEK162
9788028|NCT01320085|Experimental|NRAS mutant, 45mg bid MEK162|NRAS mutant, 45mg bid MEK162
9788029|NCT01320085|Experimental|BRAFV600 mutant, 60mg bid MEK162|BRAFV600 mutant, 60mg bid MEK162
9788030|NCT01320137|Other|Allergy Group|Subjects with ages ranging from 18-45 years and inclusive, presenting symptomatic allergy to birch pollen.
9788031|NCT01320137|Other|Control Group|Subjects with ages ranging from 18-45 years and inclusive, with no known allergies.
9788032|NCT01320150||PPP and Non-PPP|Study Subjects with PPP and without PPP at followup
9788033|NCT01320202|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
9788034|NCT01320202|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
9788035|NCT01320293|Experimental|Adalimumab 40mg|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] Dose administered every other week for 6 months
9788036|NCT01320553|Experimental|SPARC1102 I|1334H 0.15% eye drops will be administered in both eyes at 3 occasions
9788037|NCT01320553|Experimental|SPARC1102 II|1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
9788038|NCT01320553|Experimental|SPARC1102 III|1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
9788039|NCT01320553|Placebo Comparator|Vehicle|Placebo eye drops (solution)will be administered in both eyes at 3 occasions
9788040|NCT01320722|Experimental|Vitamin D|Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.
9788041|NCT01320722|Experimental|Probenecid|Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).
9788042|NCT01320722|Experimental|Allopurinol|Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).
9788043|NCT01320722|Placebo Comparator|Placebo- Vitamin D|Placebo soft gel once per week for 8 weeks.
9788044|NCT01320722|Placebo Comparator|Placebo- Uric Acid|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).
9788045|NCT01320735||Advanced PCa|Participants with advanced PCa
9788046|NCT01320826||Physician colonoscopists|"All primary care physicians (family physicians and general internists) who perform colonoscopies were approached to voluntarily participate in the APC-Endo study.~All patients having a colonoscopy done by an APC-Endo study physician endoscopist were approached at the time of their endoscopy to consent to the post procedure telephone survey."
9788047|NCT01320943|Experimental|Stop TDF|Participants randomized to this arm will stop TDF therapy at baseline.
9788048|NCT01320943|Active Comparator|Continue TDF|Participants randomized to this arm will continue TDF therapy.
9788049|NCT01321073|Experimental|DelIVery for Pulmonary Arterial Hypertension Single Arm|All subjects were enrolled for implantation of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection.
9788050|NCT01321151|Placebo Comparator|Sugar Pill|Placebo control
9788051|NCT01321151|Experimental|Resveratrol|Intervention
9788052|NCT01321177|Experimental|Integrated Treatment|Integrated program of treatments and services delivered by a coordinated team of providers.
9788053|NCT01321177|Active Comparator|Community Care|Standard mental health treatments and services offered at the local agency.
9788054|NCT01321437|Experimental|Axitinib|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 14-21 days after completion of treatment. Beginning 28-56 days after surgery, patients receive axitinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
9788055|NCT01321541|Experimental|Pixantrone + Rituximab|Pixantrone and Rituximab
9788056|NCT01321541|Active Comparator|Gemcitabine + Rituximab|Gemcitabine and Rituximab
9788057|NCT01321554|Experimental|Lenvatinib (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
9788058|NCT01321554|Placebo Comparator|Placebo (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
9788059|NCT01321554|Experimental|Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
9788060|NCT01321554|Experimental|Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
9788061|NCT01321606|Experimental|Arm 1: Probiotic|subjects will be given a capsule formulation of a 1x10^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
9788062|NCT01321606|Placebo Comparator|Arm 2: Placebo|Placebo identical to the active product will be given
9788063|NCT01321710|Active Comparator|Dietary information & standard care|"Mothers in this arm receive dietary information aimed at reducing postpartum sleep disturbance.~Infants in this arm receive no intervention beyond standard immunization care."
9788064|NCT01321710|Experimental|Sleep hygiene & standard care|"Mothers in this arm receive a sleep hygiene intervention aimed at improving their postpartum sleep.~Infants in this arm receive standard immunization care."
9788065|NCT01321710|Experimental|Sleep hygiene & acetaminophen|"Mothers in this arm receive a sleep hygiene intervention aimed at improving postpartum sleep.~Infants in this arm receive an acetaminophen intervention (12.5mg per kg infant weight, 1 dose 30 minutes prior to immunization and q4-6h thereafter, for a total of 5 doses) to minimize sleep disturbance following immunization."
9788066|NCT01321723|Experimental|PTH analog tablet|PTH(1-31) 5 mg tablet, once daily
9788067|NCT01321723|Placebo Comparator|Placebo|Placebo matching tablet, once daily
9788068|NCT01321723|Active Comparator|Forsteo|Forsteo (teriparatide) 20 mcg SC Injection, once daily
9788069|NCT01321749|Experimental|RIPC+stroke secondary prevension|"Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.~Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)"
9517812|NCT03302676|Active Comparator|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.~Daily registrations in a patient dairy."
9788070|NCT01321749|No Intervention|stroke secondary prevention|Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)
9788071|NCT01321879|Experimental|Telavancin|10 or 7.5 mg/kg intravenous daily
9788072|NCT01322009|Experimental|Drug|Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.
9788073|NCT01322009|Placebo Comparator|Placebo|Placebos will be prepared for the two experimental drugs and administered at identical time periods.
9788074|NCT01322022|Experimental|Parent Training|Behavioral Intervention
9788075|NCT01322022|Active Comparator|Parent Education|5 Sessions of individual parent education
9788076|NCT01322048|Experimental|Adrenergic Blockade|Propranolol and Clonidine
9788077|NCT01322048|Placebo Comparator|Placebo|Placebo
9788078|NCT01322347|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
9788079|NCT01322347|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
9788080|NCT01322360|Other|Morphine Sulfate|oral solution (10 mg/5 mL or 20 mg/5 mL) or tablets (15 mg or 30 mg)given based on based on the current pediatric prescribing guidelines
9788081|NCT01322386|Experimental|Oral Vancomycin|Vancocin
9788082|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF"
9788083|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF placebo|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF placebo"
9788084|NCT01322490|Placebo Comparator|Placebo Control|PROSTVAC V/F Placebo + GM-CSF Placebo
9788085|NCT01322594|Experimental|MEDI2338 10 MG|MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
9788086|NCT01322594|Experimental|MEDI2338 30 MG|MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
9788087|NCT01322594|Experimental|MEDI2338 100 MG|MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
9788088|NCT01322594|Experimental|MEDI2338 300 MG|MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
9788089|NCT01322594|Experimental|MEDI2338 1000 MG|MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
9788090|NCT01322594|Placebo Comparator|Placebo|Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
9788091|NCT01322607|Other|Arm 1: High-Intensity Program|High-intensity treadmill-based exercise
9788092|NCT01322607|Other|Arm 2: Low-Intensity Program|Low-intensity lifestyle intervention (group exercise)
9788093|NCT01322633||Pantoprazole|Patients who received treatment with pantoprazole tablets for at least 240 days within a 12-month period from 2000 through 2003.
9788094|NCT01322633||Other proton pump inhibitors|Patients who received treatment with any other proton pump inhibitor for at least 240 days within a 12-month period from 1996 through 2003.
10205808|NCT05196087||NIP IT!|Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival/fresh tumor specimens will be collected for banking and future research purposes.
10205809|NCT05195801||Group with local anesthesia|The group that did not apply general anesthesia
9788095|NCT01322815|Experimental|Chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
10205810|NCT05195801||Group with Sevoflurane|The Sevoflurane used for maintenance of general anesthesia
10205811|NCT05195801||Group with Propofol|The Propofol (IV) used for maintenance of general anesthesia
10205812|NCT05190211|Experimental|Telerehabilitation Group (TG)|
10205813|NCT05190211|Experimental|Video Group (VGr)|
10205814|NCT05185960|Experimental|ALLSWEET®|ALLSWEET® will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
10205815|NCT05185960|Experimental|ALLSWEET® consumed with sucrose|ALLSWEET® and sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
9788096|NCT01322815|Experimental|GI-4000 and bevacizumab|maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
9788097|NCT01322841|Active Comparator|CHICA Diagnosis Module|This arm had the CHICA screening module turned on
9788098|NCT01322841|Placebo Comparator|CHICA Placebo|This arm had CHICA but no additional module
9788099|NCT01322945||Endonasal surgery|Single cohort of patients undergoing endonasal surgery
9788100|NCT01323010|Experimental|Albuterol - Experimental|Albuterol dosages during the first hour include 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
10205816|NCT05185960|Active Comparator|Sucrose|Sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
10205817|NCT05185713||Ctrl HPV (-)|Patients with normal cervix and HPV negative
10205818|NCT05185713||Ctrl HPV (+)|Patients with normal cervix and HPV positive
9788101|NCT01323010|Active Comparator|Albuterol - Control|Albuterol dosages during the first hour include either 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg).
9998182|NCT01515826|Experimental|VIGADEXA Gel|VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
10205819|NCT05185713||LSIL group|Patients with low-grade squamous Intraepithelial lesion
10205820|NCT05185713||HSIL group|Patients with high-grade squamous Intraepithelial lesion
10205821|NCT05185713||ICC group|Patients newly diagnosed invasive cervical cancer
10205822|NCT05184244||Participants with CP|Children with CP
9517813|NCT03302676|No Intervention|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
9788102|NCT01323140|Experimental|TMTS treatment|Following a lead-in dose-proportionality phase (Days 1-2) and a site-to-site bioavailability phase (Days 2-9), subjects were dosed for efficacy analysis beginning on Day 9 at dose level B (a single 48 cm2 testosterone matrix transdermal system). Based on pharmacokinetic (PK) analysis of blood samples drawn on Day 16, on Day 22 subjects could be dose-titrated up to dose level C (one 28 cm2 plus one 48 cm2 TMTS), down to dose level A (one 28 cm2 TMTS), or remain at dose level B. Subjects at all dose levels were pooled for primary efficacy analysis on Days 29/30.
9788103|NCT01323153|Experimental|Dalcetrapib|
9788104|NCT01323153|Placebo Comparator|Placebo|
9788105|NCT01323192|Experimental|JNS001|
10205823|NCT05183620|Other|Nocturnal erection measurement|Overnight measurements of the temperature of the penile skin and outer thigh will be performed, while simultaneously the penile circumference and rigidity is determined by RigiScan measurements
10205824|NCT05183581|Other|Visually aroused erection (naked, clothing, blankets)|"Randomisation of the order of visually aroused erection will be conducted:~Naked - Naked & Blanket - Clothing & Blanket~Naked - Clothing & Blanket - Naked & Blanket~Naked & Blanket - Naked - Clothing & Blanket~Naked & Blanket - Clothing & Blanket - Naked~Clothing & Blanket - Naked - Naked & Blanket~Clothing & Blanket - Naked & Blanket - Naked"
9788106|NCT01323192|Placebo Comparator|Placebo|
9788107|NCT01323270|Experimental|rLP2086|rLP2086 and Repevax
9788108|NCT01323270|Placebo Comparator|Saline and Repevax|Saline and Repevax
9788109|NCT01323387|Other|Treatment|Interbody fusions with Anterior Plating
9788110|NCT01323478|Experimental|Vortioxetine|
9788111|NCT01323517|Experimental|Ipilimumab, Melphalan and Dactinomycin|This is a single-institution phase II trial with a primary outcome of progression free survival (PFS).
9788112|NCT01323530|Experimental|Dose-escalation Phase (Phase 1b)|Participants with advanced and/or metastatic tumors will receive eribulin mesylate as a 2 to 5 min Intravenous (IV) bolus or infusion in two different schedules (Schedule 1 [1.2, 1.6, 2.0 mg/m2], given on Day 1 only, and Schedule 2 [0.7, 1.1, 1.7 mg/m^2], given on Days 1 and 8) and oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles) in both schedules. If maximum tolerated dose (MTD) is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m^2 bid on Days 1-14 (21-day cycles) depending on the Dose limiting toxicities (DLTs) observed and/or pharmacokinetic (PK) data when available. Based on the data and safety monitoring board review of dose escalation phase data (DLTs that will be observed in first cycle), Dose-Confirmation Phase (Phase 2) will may get initiated.
9788113|NCT01323530|Experimental|Dose-confirmation Phase (Phase 2)|Participants with advanced and/or metastatic tumors will receive Eribulin mesylate at the MTD for the selected schedule of dose escalation phase based on safety/PK data.
9788114|NCT01323582|Active Comparator|erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
9788115|NCT01323582|Experimental|Azithromycin|The dose of Azithromycin was determined based on our dose response curve obtained on 10 healthy subjects who were given three different doses of Azithromycin, 50 mg, 100 mg and 133 mg and underwent breath testing to determine the gastric emptying half-time. These doses were determined based on a maximum safe dosage per day of Azithromycin of 400 mg given the medication would then be administered three times daily before meals. The appearance of the medication (azithromycin) and administration period was then identical to that of Erythromycin, i.e. 5ml elixir administered orally three times a day half an hour prior to meals. The total daily dosage of Azithromycin was determined after obtaining the dose- response analysis.
9788116|NCT01323595|Experimental|Celecoxib|Celecoxib will be given for 6 days after surgery
9788117|NCT01323595|Placebo Comparator|Sugar pill|Sugar pill for 6 days after surgery.
9788118|NCT01323621|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
9788119|NCT01323621|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
9788120|NCT01323634|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
9788121|NCT01323634|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
9788122|NCT01323647|Experimental|Group A|Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
9788123|NCT01323647|Active Comparator|Group B|Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.
9788124|NCT01323660|Experimental|GSK573719/GW642444 125/25|125mcg/25mcg nDPI
9788125|NCT01323660|Experimental|GSK573719/GW642444 62.5/25|62.5mcg/25mcg nDPI
9788126|NCT01323660|Experimental|GSK573719/ 125|125mcg nDPI
9788127|NCT01323660|Experimental|GSK573719 62.5|62.5mcg nDPI
10205825|NCT05183516|Experimental|Tdap|Open label study, no placebo comparator
10205826|NCT05181787||AF|Patients with AF
10205827|NCT05181787||AF and stroke|Patients with AF complicated with stroke
9517814|NCT03302663|Other|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
9788128|NCT01323660|Experimental|GW642444 25|25mcg nDPI
9788129|NCT01323660|Placebo Comparator|Placebo|Plb nDPI
9788130|NCT01323673|Active Comparator|Clobetasol Propionate 0.05%|
9788131|NCT01323673|Placebo Comparator|Vehicle|
9788132|NCT01323777|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
9788133|NCT01323790|Experimental|1|Oral treatment
9788134|NCT01323790|Experimental|2|Oral treatment
9788135|NCT01323790|Placebo Comparator|3|Oral treatment
9788136|NCT01323855|Experimental|Part 1: Severe Renal Impairment|Participants with severe CRI, defined as creatinine clearance of <30 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
9788137|NCT01323855|Experimental|Part 2: Moderate Renal Impairment|Participants with moderate CRI defined as creatinine clearance of ≥30 and <50 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
9788138|NCT01323855|Experimental|Part 2: Mild Renal Impairment|Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m^2, were treated with a single tablet of 5 mg preladenant, administered orally
9788139|NCT01323855|Experimental|Part 1: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
9788140|NCT01323855|Experimental|Part 2: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
9788141|NCT01323920|Experimental|Velcade/Tac/MTX|"Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m^2 IV~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid~Drug: Methotrexate. Methotrexate 15 mg/m^2 IV"
9788142|NCT01323946|Experimental|GSK1562902A 6 to 12 M Group|Subjects between 6 and 12 months of age (6 to 12 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
9788143|NCT01323946|Experimental|GSK1562902A 12 to 24 M Group|Subjects between 12 and 24 months of age (12 to 24 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
9788144|NCT01323946|Experimental|GSK1562902A 24 to 36 M Group|Subjects between 24 and 36 months of age (24 to 36 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
9788145|NCT01323959|Experimental|BOOSTRIX POLIO GROUP|Healthy subjects who had received one booster dose Boostrix™ Polio vaccine in the NCT01277705 study received one additional booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
9788146|NCT01323959|Experimental|BOOSTRIX+POLIORIX GROUP|Healthy subjects who had received one booster dose of the co-administered Boostrix™ and Poliorix™ vaccines in the NCT01277705 study received one booster dose Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
9788147|NCT01323959|Experimental|REVAXIS GROUP|Healthy subjects who had received one booster dose of Revaxis® vaccine in the NCT01277705 study received one booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
9788148|NCT01323972|Experimental|GSK 257049-Lot 1 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1 (formulation 1 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
9788149|NCT01323972|Experimental|GSK 257049-Lot 2 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 2 (formulation 2 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
9788150|NCT01323972|Experimental|GSK 257049-Lot 3 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 3 (formulation 3 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
9788151|NCT01323972|Experimental|GSK 257049-Pilot Group|Healthy male or female children aged 5 to 17 received 3 doses of the GSK 257049 vaccine from the pilot scale (pilot formulation of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
9788152|NCT01323998||5ARI monotherapy|Patients with BPH receiving 5ARI monotherapy
9788153|NCT01323998||AB monotherapy|Patients with BPH receiving AB monotherapy
9788154|NCT01323998||Early combination (5ARI + AB) therapy|Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
9788155|NCT01323998||Delayed combination (5ARI + AB) therapy|Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
9788156|NCT01324024|Experimental|Lisdexamfetamine, then placebo|Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
9788157|NCT01324024|Experimental|Placebo, then Lisdexamfetamine|Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.
9788158|NCT01324102|Active Comparator|1. Yoga therapy|The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
9788159|NCT01324102|No Intervention|2. Wait list|The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.
9788160|NCT01324128|Experimental|PA21 (2.5 g tablet)|
9788161|NCT01324128|Active Comparator|Sevelamer carbonate|
9788162|NCT01324128|Other|PA21-1 (1.25 g tablet)|
9788163|NCT01324141|Experimental|1/Chemo + Radiation|Chemo + Radiation
9788164|NCT01324232|Placebo Comparator|Placebo|
9788165|NCT01324232|Experimental|AVP-923-45|
9788166|NCT01324232|Experimental|AVP-923-30|
9788167|NCT01324232|Experimental|AVP-923-20|
9788168|NCT01324271|Experimental|Tympanostomy tube placement|placement of tympanostomy tube under local anesthesia in office/clinic setting
9788169|NCT01324310|Experimental|Romidepsin and ketoconazole|"Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Ketoconazole 400 mg oral once daily on Days 4-8"
9788170|NCT01324323|Experimental|Romidepsin and rifampin|"Romidepsin 14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Rifampin 600 mg oral once daily on Days 4-8"
9788171|NCT01324349|Experimental|Veriset Hemostatic Patch|Veriset Hemostatic Patch
9788172|NCT01324349|Active Comparator|Fibrin Sealant (TachoSil®)|Fibrin Sealant (TachoSil®)
9788173|NCT01324388|Experimental|LY2189265 + Lisinopril|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
9788174|NCT01324388|Placebo Comparator|Placebo + Lisinopril|"Placebo: 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
9788175|NCT01324388|Experimental|LY2189265 (Treatment 1)/Metoprolol + LY2189265 (Treatment 2)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 1 of Treatment 1 and on Day 5 of Treatment 2 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 1 of Treatment 1 to Day 1 of Treatment 2 in Part 2 of the study)."
9788176|NCT01324388|Experimental|Metoprolol + LY2189265 (Treatment 2)/LY2189265 (Treatment 1)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 5 of Treatment 2 and on Day 1 of Treatment 1 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 7 of Treatment 2 to Day 1 of Treatment 1 in Part 2 of the study)."
9837486|NCT04844424|Experimental|Part 4A: Treatment Sequence RSQ|Participants will receive Treatment R in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837487|NCT04844424|Experimental|Part 4A: Treatment Sequence SQR|Participants will receive Treatment S in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837488|NCT04844424|Experimental|Part 4A: Treatment Sequence QSR|Participants will receive Treatment Q in Treatment Period 1, followed by Treatment S in Treatment Period 2 and then Treatment R in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837489|NCT04844424|Experimental|Part 4A: Treatment Sequence RQS|Participants will receive Treatment R in Treatment Period 1, followed by Treatment Q in Treatment Period 2 and then Treatment S in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837490|NCT04844424|Experimental|Part 4A: Treatment Sequence SRQ|Participants will receive Treatment S in Treatment Period 1, followed by Treatment R in Treatment Period 2 and then Treatment Q in Treatment Period 3 on Day 1 of each Treatment Period during Part 4A. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9921925|NCT00832845|Active Comparator|Treatment as Usual Group|Subjects randomized to the Treatment as Usual Group Arm will continue with their regular psychiatric treatment for 1 year. Like the CBSST Group Arm, they will have follow up assessments q 4 months. After completing the Treatment as Usual Group arm, they will automatically continue on with the CBSST Group Arm.
9921926|NCT00832884|Active Comparator|Group 1A|Lacosamide, IV, 50 mg, once, 30 minutes
9667521|NCT03486704|Active Comparator|Face to Face VRRS plus placebo tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
9788177|NCT01324401|No Intervention|Control|The subjects randomized to the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination. These subjects are then offered to cross-over to active treatment.
9921927|NCT00832884|Active Comparator|Group 2A|Lacosamide, IV, 100 mg, once, 30 min
9984902|NCT03620903|Experimental|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:~Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;~Maintenance I (1 cycle = 56 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);~Maintenance II (1 cycle = 84 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);"
9984903|NCT03618550|Experimental|pembrolizumab plus GVD|"Part 1: Patients will receive 2-4 cycles of pembrolizumab plus GVD~Part 2: an additional 25 patients will be enrolled onto an expansion cohort. On the expansion, patients who achieve CR to 4 cycles of pembro-GVD will receive 13 cycles of pembrolizumab maintenance (instead of HDT/ASCT)."
9984904|NCT03615521|Experimental|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
9984905|NCT03615521|Experimental|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.~3 Session for 6 weeks."
9984906|NCT03615521|Experimental|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.~3 session for 6 weeks."
9984907|NCT03611868|Experimental|APG-115+Pembrolizumab open label, two-part phase Ib/II|single arm dose escalation and dose expansion
9984908|NCT03611153|Experimental|Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
9984909|NCT03611153|Placebo Comparator|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
9984910|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values > 52 ng/l or troponin values > 14 ng/l and dynamic change > 20% will undergo coronary angiography
9984911|NCT03606967|Experimental|Arm I (neoantigen vaccine, durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 for 2 cycles at the discretion of the treating physician.~PART B: Patients receive personalized synthetic long peptide vaccine and poly-ICLC SC on days 1, 4, 8, 15, 22, 50, and 78 in the absence of disease progression or unacceptable toxicity. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9998183|NCT01515826|Active Comparator|VIGADEXA Solution|VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
9998184|NCT01515839|Experimental|Supplement intervention|Dietary Supplement: Multivitamin, Omega 3 Supplement, Brain and Memory Formula
9667523|NCT03474718|Experimental|Group A|At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
9667524|NCT03474718|Experimental|Group B|At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
9667525|NCT03473340|Experimental|Pirfenidone Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
9667526|NCT03473340|Placebo Comparator|Placebo Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
9667527|NCT03471221|Experimental|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
9667528|NCT03471221|No Intervention|Control Group|Participants randomized to the Control Group will receive usual medical care.
9667529|NCT03469609|Experimental|Perioperative mucous fistula refeeding|Perioperative mucous fistula refeeding between enterostomy creation and enterostomy closure
9667530|NCT03469609|No Intervention|No mucous fistula refeeding|No perioperative mucous fistula refeeding
9788178|NCT01324401|Experimental|Peanut OIT|The subjects randomized to the active treatment group will receive defatted peanut flour per protocol.
9788179|NCT01324440|Experimental|V710 without MAA|
9788180|NCT01324440|Active Comparator|V710 with MAA|
9788181|NCT01324453|Experimental|Post conditioning + PCI|
9788182|NCT01324453|Active Comparator|Standard PCI|
9788183|NCT01324518|Experimental|Low dose of ORM-12741|
9788184|NCT01324518|Experimental|High dose of ORM-12741|
9788185|NCT01324518|Placebo Comparator|Placebo|
9788186|NCT01324570|Experimental|Overall BTDS|Buprenorphine transdermal system
9788187|NCT01324622|Active Comparator|Laminectomy|Control
9788188|NCT01324622|Active Comparator|Laminoplasty|Treatment group
9788189|NCT01324687||Control|Group without access to telemedicine in the home for acute care issues.
9788190|NCT01324687||Telemedicine care|Cohort with access to telemedicine in the home for acute care issues.
9788191|NCT01324700|Active Comparator|High severity group: Escitalopram|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into escitalopram group.
9788192|NCT01324700|Active Comparator|Low severity group: Escitalopram|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into escitalopram group.
9788193|NCT01324700|Placebo Comparator|High severity group: Placebo|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into placebo group.
9788194|NCT01324700|Placebo Comparator|Low severity group: Placebo|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into placebo group.
9788195|NCT01324830|Experimental|arm A|14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
9788196|NCT01324830|Experimental|arm B|5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
9788197|NCT01324882|Experimental|Study Arm|This is the group who will have a colonoscopy with the Olympus Technically Improved Colonoscope.
9788198|NCT01324882|Active Comparator|Control|This is the group who will have a colonoscopy with the traditional colonoscope Olympus CF-H180.
9799399|NCT01658904|Experimental|Cohort 1- CFZ 20 mg/m^2 (Day 1,2)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
9799400|NCT01658904|Experimental|Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
9921928|NCT00832884|Active Comparator|Group 3A|Lacosamide, IV, 150 mg, once, 30 min
9788199|NCT01324947|Experimental|Pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
9788200|NCT01324999|Experimental|Sarcoid Associated Pulm. Hypertension|Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.
9788201|NCT01325181|Active Comparator|Low-fluence PDT with Verteporfin|Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
9788202|NCT01325181|Active Comparator|Ranibizumab|Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered
9788203|NCT01325207|Experimental|intravenous trastuzumab infusions|A Phase I single dose study (H0407g) of intravenous trastuzumab infusions ranging from 10-500 mg resulted in dose-dependent pharmacokinetics (PK) with serum clearance of trastuzumab decreasing with an increasing dose at doses <250 mg. PK modeling of trastuzumab concentration-time data from 7 patients that were administered doses of 250 mg and 500 mg had in a mean halflife of 5.8 days (range 1-32 days).
9788204|NCT01325311|Experimental|Arm I (cholecalciferol, genistein)|Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
9788205|NCT01325311|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
9788206|NCT01325337|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788207|NCT01325337|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788208|NCT01325337|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788209|NCT01325337|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788210|NCT01325337|Active Comparator|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
9788211|NCT01325350|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788212|NCT01325350|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788213|NCT01325350|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788214|NCT01325350|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
9788215|NCT01325350|Active Comparator|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
9788216|NCT01325428|Experimental|Afatinib once daily (OD)|Patients receive afatinib monotherapy once daily until progression of their disease
9788217|NCT01325493|Placebo Comparator|Normal Saline|Normal Saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
9788218|NCT01325493|Active Comparator|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
9921929|NCT00832884|Active Comparator|Group 4A|Lacosamide, IV, 200 mg, once, 30 min
9921930|NCT00832884|Active Comparator|Group 1B|Lacosamide, IV, 50 mg, once, 15 min
9517626|NCT03304587|Experimental|Arm 1: Bright blue-green light|"Bright blue-green light (~515nm; 12,000 lux) for 30 minutes once a day.~For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory~On 2 randomly selected days, the participants will wear a light meter during wake time"
9788219|NCT01325532|Experimental|Active CES|"Active CES: The FW-100 Cranial Stimulator headset was placed on the scalp over the two dorsolateral prefrontal cortex areas. The power knob was turned to maximum setting. The waveform contains a 15000Hz square wave carrier from 0-4 mAmp. The first 15Hz modulating signal provides 50msec of on and 16.7msec of off time (total 66.7msec, 50% duty cycle). A second 500Hz modulating signal changes the on time series of 15000Hz pulses (750 pulses/50msec) into 25 smaller bursts of 15 pulses of the 15000Hz carrier signal, for 375 pulses in 50msec. The consecutive positive burst and off time is followed by an opposite negative burst and off time, balancing the current component to zero. Output voltage ranges from 0-40V, positive and negative. CES automatically shut off after 20 mins."
9788220|NCT01325532|Sham Comparator|Sham CES|Shame CES: The sham devices were modified to not deliver current to the headset. The current from the active device departs from the posts at the top of the device into the headsets, creating a loop when the headset is worn by the subject with the wet electrode sponges. This loop is eliminated in the sham devices by wrapping wire around the posts, thus containing the loop within the device, with no electricity leaving the headsets. This approach allows the loop to be maintained, and therefore all of the device's green and yellow amperage lights still light up, protecting the blind.
9788221|NCT01325584|Experimental|Omegaven (compassionate use)|This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.
9788222|NCT01325623|Other|Model 106 VNS Therapy System|Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.
9788223|NCT01325701|Experimental|PCI-32765: 560 mg|Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.
9788224|NCT01325701|Experimental|PCI-32765: 840 mg|Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.
9788225|NCT01325714|Experimental|Arm 1: PAVeD Intervention|In the experimental arm, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
9788226|NCT01325714|Active Comparator|Arm 2: Enhanced Usual Care|In the comparison arm, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
9788227|NCT01325792||GORE® BIO-A® Tissue Reinforcement|Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
9788228|NCT01325870|Experimental|ACD-CPR +ITD|Active Compression Decompression CPR with the ResQPRO device and ResQPOD ITD device.
9788229|NCT01325870|Experimental|S-CPR + ITPR|
9788230|NCT01325870|Active Comparator|S-CPR|
9788231|NCT01326026|Experimental|IDeg Simple|
10205828|NCT05181176|Experimental|Coffee|The coffee group was instructed to consume 2 cups of coffee a day, the amount that was previously described as beneficial in epidemiological studies and safe for children and adolescence. Each cup of coffee contains 250 ml of coffee, which contains approximately 80 mg of caffeine. The children were allowed to add milk to the coffee and sweeten it with artificial sweetener
9788232|NCT01326026|Experimental|IDeg Step wise|
10205829|NCT05181176|Experimental|Green Tea|The green tea group will be instructed to drink 3 cups (230CC) of Chinese green tea (Wissotzky Tea Israel Ltd). Each tea bag contains 500 g of fine dried herb parts. Each cup contains 84 mg total catechin and 32 mg caffeine. The participants were instructed to leave the tea bag for 2 minutes before drinking.
9788233|NCT01326481|Experimental|Single|All patients received TRC105 + capecitabine
9788234|NCT01326533|Experimental|hydroxychloroquine|Thirteen weeks of daily hydroxychloroquine following FSIGTT testing
9788235|NCT01326533|Placebo Comparator|Placebo|Thirteen weeks of daily placebo following FSIGTT testing
9788236|NCT01326546|Experimental|Therapeutic HBV vaccine+Entecavir|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
9788237|NCT01326546|Placebo Comparator|placebo+Entecavir|Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
9788238|NCT01326702|Experimental|Treatment (veliparib, bendamustine hydrochloride, rituximab)|"Patients receive veliparib PO BID on days 1-7 and bendamustine hydrochloride IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
9788239|NCT01326728||Allogeneic Stem Cell Transplant|Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells)
9788240|NCT01326780|Experimental|1.2% Facial Cream|1.2% JNJ 10229570-AAA
9788241|NCT01326780|Experimental|2.4% Facial Cream|2.4% JNJ 10229570-AAA
9788242|NCT01326780|Experimental|3.6% Facial Cream|3.6% JNJ 10229570-AAA
9788243|NCT01326780|Placebo Comparator|0% Facial Cream|Vehicle control
9788244|NCT01326910|Experimental|19306-127|Experimental Topical cream applied twice daily (or as needed)
9788245|NCT01326910|Other|19306-137|Marketed Topical cream applied twice daily (or as needed)
9788246|NCT01326962|Experimental|Single Arm|
9788247|NCT01327053|Experimental|LDE225 200 mg|The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
9788248|NCT01327053|Experimental|LDE225 800 mg|The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
9788249|NCT01327157|Placebo Comparator|Visual Analog Scale (VAS)|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final~VAS and dental cleaning at the first query.~VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment)."
9800437|NCT01687413|Experimental|Radiotherapy|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
9921931|NCT00832884|Active Comparator|Group 2B|Lacosamide, IV, 100 mg, once, 15 min
9788250|NCT01327157|Experimental|Occlusal adjustment|In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.
9788251|NCT01327274|Experimental|Treatment Arm|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed. After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted. After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
9788252|NCT01327300|Active Comparator|Mesalamine|This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
9788253|NCT01327300|Placebo Comparator|Placebo|This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
9788254|NCT01327313|Experimental|EMD525797 250 milligram (mg)|
9788255|NCT01327313|Experimental|EMD525797 500 mg|
9788256|NCT01327313|Experimental|EMD525797 1000 mg|
9788257|NCT01327313|Experimental|EMD525797 1500 mg|
9788258|NCT01327339||Subjects eligible for REQUIP prescription|Male and female subjects who were considered appropriate to be prescribed REQUIP according to the prescribing information will be included in this study.
9788259|NCT01327482|Experimental|All|All patients were part of the intervention arm, as this was a pharmacokinetic study. All women took Raltegravir 400mg orally, twice daily for 3 weeks.
9788260|NCT01327495|Placebo Comparator|Arm 1: Placebo|Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
9921932|NCT00832884|Active Comparator|Group 3B|Lacosamide, IV, 150 mg, once, 15 min
10205830|NCT05181176|Placebo Comparator|Herbal tea|The control group consumed 3 cups a day of Wissotzky- kid drink (Wissotzky Tea Israel Ltd), which is a drink that is marketed for children containing an infusion of fruits and plants. Each tea bag contains 2.7 gr plants parts with no evidence of polyphenols or caffeine.
10205831|NCT05180032|Experimental|Romosozumab group|Romosozumab (evenity) administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18
10205832|NCT05180032|Placebo Comparator|Control group|Placebo administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18
10205833|NCT05179629|Active Comparator|Group M = M-TAPA group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
10205834|NCT05179629|No Intervention|Group C = Control group|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group. 100 mg tramadol will be performed for rescue analgesia."
10205835|NCT05179434|Experimental|Retrograde graft reperfusion|Kidney transplantation with retrograde venous reperfusion of renal graft followed by arterial reperfusion
10205836|NCT05179434|Active Comparator|conventional antegrade perfusion|Kidney transplantation with conventional arterial reperfusion of renal graft (without retrograde venous reperfusion)
10205837|NCT05178342|Other|CA-4948 treatment|Single-arm design. all patients are treated with IMP
10205838|NCT05178017|Experimental|Participants|Individuals with Irritable Bowel Syndrome (IBS)
10205839|NCT05176054|Experimental|Experimental group|Researchers will conduct the health service program for the experimental group.
10205840|NCT05176054|No Intervention|Contrast group|The contrast group will be receiving the routine care only.
10205841|NCT05175833|Experimental|Oral probiotics|oral gel containing Streptococcus salivarius K12 (2 billion live bacilli) and Lactobacillus brevis CD2 (4 billion live bacilli). During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
10205842|NCT05175833|Placebo Comparator|Oral placebo|oral gel containing placebo. During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
10205843|NCT05174949|Experimental|Anodal stimulation|Anodal stimulation targeting hemisphere
10205844|NCT05174949|Experimental|Cathodal stimulation|Cathodal one at the contralesional hemisphere
10205845|NCT05174949|Experimental|Sham stimulation|Sham stimulation to the brain
10213427|NCT04042077|Active Comparator|Best Available Therapy|"Cardiothoracic / related leg SSI~Vancomycin IV~Linezolid IV, with the option to switch to linezolid oral.~In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice~Abdominal SSI~Piperacillin/Tazobactam IV, OR~Tigecycline IV~In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice."
10213428|NCT04040530||Cryoablation|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with CT-guided cryoablation at Odense University Hospital in the period from 1/6-2019 to 1/6-2021.
10213429|NCT04040530||Partial nephrectomy|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with partial nephrectomy at Odense University Hospital or Zealand University Hospital in the period from 1/6-2019 to 1/6-2021.
10213430|NCT04040192|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied once daily (QD)
10213431|NCT04040192|Placebo Comparator|Vehicle|Vehicle ointment applied once daily (QD)
10213432|NCT04037020||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa.
10213433|NCT04031560|Experimental|Experimental|Integrative treatment
9788261|NCT01327495|Active Comparator|Arm 2:1.25g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
9788262|NCT01327495|Active Comparator|Arm 3: 2.5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
9788263|NCT01327495|Active Comparator|Arm 4: 5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
9788264|NCT01327495|Active Comparator|Arm 5: 10g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
9788265|NCT01327495|Active Comparator|Arm 6: 15g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
9788266|NCT01327508|Experimental|TRIGEN SURESHOT Distal Targeting|TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
9788267|NCT01327508|Active Comparator|Standard Nailing Instrumentation.|Free-hand technique utilizes x-rays to find screw holes
9984912|NCT03606967|Active Comparator|Arm II (durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each remaining cycle.~PART B: Patients receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9998185|NCT01515852|Other|Stress level after general anesthesia|
9788268|NCT01327547|Experimental|1.0|
9788269|NCT01327547|Placebo Comparator|2|
9788270|NCT01327573|Experimental|Eculizumab|"eculizumab will be given in addition to standard immunosuppression regimen (oral tacrolimus or equivalent, MMF [mycophenolate mofetil~], prednisone)"
9788271|NCT01327573|No Intervention|no additional therapy|patients in this arm will receive standard immunosuppression regimen (oral tacrolimus or equivalent, MMF, prednisone only, no additional therapy
9788272|NCT01327599|Experimental|DUOTRAV®|Travoprost 0.004%+Timolol 0.5% ophthalmic solution, 1 drop to the study eye(s) once a day at 8:00 PM for 12 weeks
9998186|NCT01515852|Other|Stress level after local anesthesia|
9788273|NCT01327612|Experimental|Conatumumab Monotherapy|Participants will continue to receive conatumumab every 2 weeks (Q2W) or every 3 weeks (Q3W) at the same dose and regimen as at the conclusion of the parent study.
9788274|NCT01327612|Experimental|Conatumumab + Ganitumab|Participants will receive conatumumab and ganitumab by intravenous infusion at the same dose and regimen as at the conclusion of the parent study.
9788275|NCT01327612|Experimental|Ganitumab Monotherapy|Participants will continue to receive ganitumab Q3W or every 4 weeks (Q4W) at the same dose and regimen as at the conclusion of the parent study.
9788276|NCT01327612|Experimental|Conatumumab + mFOLFOX6 ± Bevacizumab|Participants will continue to receive conatumumab by intravenous infusion in addition to modified FOLFOX6 chemotherapy with or without bevacizumab.
9788277|NCT01327651|Active Comparator|Daily dosing|Participants will receive oral FTC/TDF daily.
9788278|NCT01327651|Experimental|Time-driven dosing|Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
9788279|NCT01327651|Experimental|Event-driven dosing|Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.
9788280|NCT01327677|Active Comparator|Pro re nata (PRN) fentanyl|A nurse can give the patient up to 3 doses of fentanyl intravenously (through a vein) each hour whenever a patient indicates that he or she is in pain.
9788281|NCT01327677|Active Comparator|Intravenous Patient-controlled Analgesia (IVPCA) fentanyl|Fentanyl will be given with a Patient Controlled Analgesia (PCA) pump.
9788282|NCT01327703|Experimental|Panzytrat® 25,000|
9788283|NCT01327703|Active Comparator|Kreon® 25,000|
9788284|NCT01327846|Experimental|Canakinumab Dose 50 mg|"Pivotal Phase:~Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
9788285|NCT01327846|Experimental|Canakinumab Dose 150 mg|"Pivotal Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
9788286|NCT01327846|Experimental|Canakinumab Dose 300 mg|"Pivotal Phase:~Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy.~Extension phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
9788287|NCT01327846|Placebo Comparator|Placebo|"Pivotal Phase:~Blinded matching placebo quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
9788288|NCT01327885|Experimental|Arm A|
9788289|NCT01327885|Active Comparator|Arm B|
9921933|NCT00832884|Active Comparator|Group 4B|Lacosamide, IV, 200 mg, once, 15 min
9921934|NCT00832897|Sham Comparator|Eyedrop|
9788290|NCT01327963|Experimental|Transoral Incisionless Fundoplication|"Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0).~With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GastroEsophageal Junction (GEJ) below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications."
9788291|NCT01327976|Active Comparator|vBloc (Active Device)|The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
9788292|NCT01327976|Sham Comparator|Sham (Non-active Device)|The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
9788293|NCT01327989||Solitaire™ FR device|Eligible subjects treated with the Solitaire™ FR device.
9788294|NCT01328002|Experimental|Milnacipran|oral administration, twice daily dosing
9788295|NCT01328002|Placebo Comparator|Placebo|oral administration, twice daily dosing
9788296|NCT01328041|Experimental|dolutegravir|dolutegravir plus background antiretroviral therapy optimised at Day 8
9788297|NCT01328054|Experimental|lapatinib/placebo|This is a crossover study where subjects will receive placebo that mimics lapatinib for 2 days and lapatinib for 2 days. Subjects will not know when they are receiving placebo vs. lapatinib.
9788298|NCT01328080|Experimental|Targeted UV-B (Left)|Targeted UV-B on left side of the scalp.
9788299|NCT01328080|Experimental|Targeted UV-B (Right)|Targeted UV-B on right side of the scalp.
9788300|NCT01328158||Lopinavir/Ritonavir|Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated
9788301|NCT01328184|Experimental|Reference|multiple doses of Microgynon
9788302|NCT01328184|Active Comparator|Test|multiple doses of Microgynon + BI 10773
9788303|NCT01328249|Experimental|Doxorubicin and cyclophosphamide followed by eribulin mesylate|
9788304|NCT01328366||Participants with severe psoriasis|The participants had severe disease as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and had not responded to standard systemic therapies.
9788305|NCT01328379|Active Comparator|Dalfampridine-ER 5mg|5mg, twice daily
9788306|NCT01328379|Active Comparator|Dalfampridine-ER 10mg|10mg, twice daily
9788307|NCT01328379|Placebo Comparator|Placebo|placebo, twice daily
9788308|NCT01328405|Experimental|Air-Q LMA|Air-QⓇ intubating laryngeal mask (Mercury Medical, Clearwater, Fl.)
9788309|NCT01328405|Experimental|Proseal LMA|LMA-Proseal TM (LMA North America, San Diego, Ca.)
9788310|NCT01328431|No Intervention|Standard Care|Subjects receive a brochure for the state's Smokers' Quitline only.
9788311|NCT01328431|Experimental|SBIRT+NRT|Subjects receive a 6 week course of NRT, a motivational Brief Negotiated Interview, and a facilitated referral to the state's Smokers' Quitline.
9788312|NCT01328444|Experimental|GSK 573719 + GW642444 125/25|125mcg/25mcg nDPI
9788313|NCT01328444|Experimental|GSK 573719 +GW642444 62.5/25|62.5mcg/25mcg nDPI
9788314|NCT01328444|Experimental|GSK 573719 125|125mcg nDPI
9788315|NCT01328444|Experimental|GSK 573719 62.5|62.5 mcg nDPI
9788316|NCT01328444|Experimental|GW 642444 25|25mcg nDPI
9788317|NCT01328444|Placebo Comparator|Plb|Plb nDPI
9788318|NCT01328496|Other|Research Arm|"Participant with high-risk hematologic malignancies undergoing Hematopoietic Cell Transplantation, who do not have a suitable Human Leukocyte Antigen -matched related/sibling donor, Matched Unrelated Donor or Killer immunoglobulin receptors ligand mismatched haploidentical donor identified, will receive a single UCB unit.~Intervention: Preparative Regimen"
9788319|NCT01328496|Other|Observation Arm|"Patients requiring two UCB units will be eligible for UCBT01 on the observational arm.~Intervention: Preparative Regimen"
9788320|NCT01328535|Experimental|Treatment (individualized chemotherapy)|Patients with an established biorhythm receive TMZ PO on recommended day for 5 days. Treatment repeats every 21-42 days until disease progression or unacceptable toxicity. Patients without an established biorhythm receive TMZ PO on days 1-5. Courses repeat every 28 days until disease progression or unacceptable toxicity.
9788321|NCT01328548||Nursing Home Elderly Cases|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.
9921935|NCT00832897|Active Comparator|Crosslinking|The patients will be submitted to corneal collagen crosslinking, by use riboflavin eyedrop with UVA light.
9921936|NCT00832910||Rheumatoid Arthritis group1|This group had patients with rheumatoid arthritis
9921937|NCT00832910||2|
9837491|NCT04844424|Experimental|Part 4B: Treatment Sequence TU|Participants will receive single oral Dose 1 of milvexian as Phase 3 oral tablet under fed conditions (Treatment T) in Treatment Period 1, followed by single oral Dose 2 of milvexian as Phase 3 oral tablet under fed conditions (Treatment U) in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837492|NCT04844424|Experimental|Part 4B: Treatment Sequence UT|Participants will receive Treatment U in Treatment Period 1, followed by Treatment T in Treatment Period 2 on Day 1 of each Treatment Period during Part 4B. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837493|NCT04844424|Experimental|Subpart 4A: Treatment Sequence VW|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive milvexian tablet dispersed in water without a sweetener orally via syringe (Treatment V) in Treatment Period 1, followed by milvexian tablet dispersed in water with sucralose sweetener orally via syringe (Treatment W) in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
9837494|NCT04844424|Experimental|Subpart 4A: Treatment Sequence WV|All participants of Subpart 4A will undertake a mandatory taste assessment on Day 5 of period 3 or Day 15 before the discharge and will receive Treatment W in Treatment Period 1, followed by Treatment V in Treatment Period 2. Participants will cleanse their palates using 2 rinse of mineral water and one unsalted cracker and wait for a time interval of at least 1-2 hours from start of dosing before the next taste round.
9788322|NCT01328548||Nursing Home Elderly Controls|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.
9788323|NCT01328548||Community dwelling seniors|Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.
9788324|NCT01328574|Experimental|Single Arm - TRC105 in Urothelial Carcinoma|TRC105 15 mg/kg/dose every two weeks
9788325|NCT01328717|Experimental|Intended Users of the System|Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
9788326|NCT01328743|No Intervention|Treatment as usual|Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
9788327|NCT01328743|Experimental|Brief Alcohol Intervention|Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls
9788328|NCT01328756|Experimental|Lisdexamfetamine Dimesylate|
9788329|NCT01328769|Active Comparator|Febuxostat|Investigational
9788330|NCT01328769|Placebo Comparator|Placebo|Placebo
9788331|NCT01328782|Active Comparator|The group receiving oral pain medicine|This group will receive Oxycodone with Acetaminophen orally
9788332|NCT01328782|Active Comparator|The group receiving bupivacaine and oral pain medicine|This group will receive an intra-articular shot during surgery and will then be sent to the recovery room to receive pain medication as needed.
9788333|NCT01328782|Active Comparator|The group receiving ropivacaine and oral pain medicine|This group will receive an intra-articular shot of ropivacaine during surgery and will be sent to the recovery room to receive pain medicine as needed.
9788334|NCT01328873|Experimental|Laboratory testing|All patients will receive the lab testing on bronchoscopy specimens
9788335|NCT01328951|Experimental|Early Erlotinib|Participants will receive blinded erlotinib as 150 mg PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
9788336|NCT01328951|Placebo Comparator|Late Erlotinib|Participants will receive blinded placebo tablets PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive second-line erlotinib as 150 mg PO once daily until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
9788337|NCT01328964||Children Ages 4-11 with asthma|Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy
9788338|NCT01329029|Active Comparator|Roflumilast|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
9788339|NCT01329029|Placebo Comparator|Placebo|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
9788340|NCT01329185|Placebo Comparator|Placebo|Eligible consenting kidney transplant donors who are randomized to receive placebo will be given 1 placebo in morning and 1 in evening for 14 days prior to transplant date
9788341|NCT01329185|Experimental|Valganciclovir|Eligible consenting kidney transplant donors who are randomized to the experimental arm of the study will receive 450mg of Valganciclovir twice a day for 14 days prior to the transplant date
9788342|NCT01329198|Active Comparator|Delayed Activation - Deep Brain Stimulation (DBS)|"Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
9921938|NCT00832923|No Intervention|Routine IMPACT DC care|Participants receive standard asthma education as routine for IMPACT DC
9921939|NCT00832923|Experimental|Enhanced care PEPAC Intervention|
9788343|NCT01329198|Active Comparator|Immediate Activation - Deep Brain Stimulation (DBS)|"Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency & severity, while limiting potential stimulation-induced side-effects.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
9788344|NCT01329263|Experimental|Nonmenthol|Participants switch from menthol to non-menthol cigarettes.
9788345|NCT01329263|No Intervention|Menthol|Participants smoke own brand of menthol cigarettes.
9788346|NCT01329328|No Intervention|CONTROL|NO VIBRATION EXERCISE
9788347|NCT01329328|Experimental|VIBRATION EXERCISE|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIOS, MILAN, ITALY
9788348|NCT01329328|Experimental|VIBRATION EXERCISE PLUS RADIOFREQUENCY ADMINISTRATION|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIO, MILAN, ITALY PLUS LOCAL ADMINISTRATION OF RADIOFREQUENCY
9788349|NCT01329380||Adalimumab|Participants with ankylosing spondylitis (AS) receiving treatment with adalimumab (Humira) as prescribed by their physician.
9788350|NCT01329419||adefovir dipivoxil|Patients administrated adefovir at the site
9788351|NCT01329562|Active Comparator|Treximet|"Subjects randomized to Group A will be provided with 1 tablet of Treximet to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
9788352|NCT01329562|Placebo Comparator|Placebo|"Subjects randomized to Group B will be provided with 1 tablet of placebo to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
9788353|NCT01329679|Experimental|Energy Drink|Energy drink, 2 oz twice daily for 7 days
9788354|NCT01329679|Placebo Comparator|Placebo|Water, lime juice and cherry flavoring, 2 oz twice daily for 7 days
9788355|NCT01329848||discomfort symptoms|level of discomfort symptoms while performing near work
9788356|NCT01329900|Experimental|Ofatumumab + Stem Cell Collection|Ofatumumab 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8. Ifosfamide 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously. Etoposide 150 mg/m2 by vein over 2 hours every 12 hours for 6 doses. Mesna 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts). Mesna 2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide). After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose. G-CSF 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis. Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
9788357|NCT01329939|Experimental|Obese atopic asthmatics, montelukast|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
9788358|NCT01329939|Placebo Comparator|Lean atopic asthmatics, placebo|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
9788359|NCT01329939|Active Comparator|Lean atopic asthmatics, montelukast|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
9788360|NCT01329939|Placebo Comparator|Obese atopic asthmatics, Placebo|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
9788361|NCT01329978|Experimental|SOF+PEG+RBV 12 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
9788362|NCT01329978|Experimental|SOF+PEG+RBV 24 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
9788363|NCT01329978|Experimental|SOF+PEG+RBV 12 week/Rerandomization Group|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.
9788364|NCT01330017|Experimental|PE 10 mg|
9788365|NCT01330017|Experimental|PE 20 mg|
9788366|NCT01330017|Experimental|PE 30 mg|
9788367|NCT01330017|Experimental|PE 40 mg|
9788368|NCT01330017|Placebo Comparator|Placebo|
9788369|NCT01330030|Experimental|Drug Selegiline|6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
9788370|NCT01330030|Placebo Comparator|Matching placebo|matching placebo worn 24 hours for 8 weeks
9788371|NCT01330043|Active Comparator|Non-extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks"
9788372|NCT01330043|Experimental|Extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks~24 additional weeks of CBT"
9788373|NCT01330108|Experimental|Ambrisentan|patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
9788374|NCT01330134|Experimental|lidocaine onto skin prior to lidocaine subcutaneous injection|1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
9788375|NCT01330134|Active Comparator|lidocaine subcutaneous injection alone|1% lidocaine subcutaneous injection alone by standard approach
9788376|NCT01330290||Neupro® Treatment|Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
9788377|NCT01330303|Active Comparator|tamsulosin - Reference|Reference drug administration followed by Test drug administration
9788378|NCT01330303|Active Comparator|tamsulosin - Test|Test drug administration followed by Reference drug administration
9788379|NCT01330316|Experimental|BI 201335 for 24 weeks|BI 201335 once daily dose for 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
9788380|NCT01330355|Experimental|Besivance|Besifloxacin 0.6% ophthalmic suspension
9788381|NCT01330355|Active Comparator|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution
9788382|NCT01330381|Experimental|prucalopride|drug
9788383|NCT01330381|Placebo Comparator|Placebo|
9788384|NCT01330381|Active Comparator|PEG 4000|4-20g administered as an oral solution once daily
9788385|NCT01330394|Sham Comparator|sham-tDCS control|simulate control for transcranial Direct Current Stimulation
9788386|NCT01330394|Active Comparator|active tDCS|active transcranial Direct Current Stimulation
9788387|NCT01330420|Experimental|Relaxation Response Resiliency Program for Depression|"The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients."
9788388|NCT01330433|No Intervention|No CoSeal Surgical Spray|A patient randomized to the No CoSeal Surgical Spray group will not have CoSeal Surgical Spray applied at the end of their first staged procedure.
9788389|NCT01330433|Experimental|CoSeal Spray Group|CoSeal Spray will be applied at the end of the first staged procedure in patients randomized to the experimental group.
9788390|NCT01330459|Active Comparator|Hydrocodone/acetaminophen|"Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
9998187|NCT01515878|Experimental|Dialysis with BVT|Dialysis using the BVT monitor biofeedback called Hemocontrol
9788391|NCT01330459|Placebo Comparator|Placebo|"Subject will receive placebo 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
9788392|NCT01330628|Experimental|Laser atherectomy and PTA|laser, then balloon angioplasty
9788393|NCT01330628|Active Comparator|Balloon angioplasty|
9788394|NCT01330914||Gastric Bypass Surgery Patients|Obese men and women undergoing gastric bypass surgery
9788395|NCT01330953|Placebo Comparator|Placebo|Single intravenous placebo dose.
9788396|NCT01330953|Experimental|30 mg LY2928057 (Cohort 1)|Day 1: single 30-milligram (mg) LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 30-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 30-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 30 mg LY2928057.
9788397|NCT01330953|Experimental|100 mg LY2928057 (Cohort 2)|Day 1: single 100-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 100-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 100-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 100 mg LY2928057.
9788398|NCT01330953|Experimental|300 mg LY2928057 (Cohort 3)|Day 1: single 300-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 300-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 300-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 300 mg LY2928057.
9788399|NCT01330953|Experimental|1000 mg LY2928057 (Cohort 4)|Day 1: single 1000-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 1000-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 1000-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 1000 mg LY2928057.
9799401|NCT01658904|Experimental|Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
9799402|NCT01658943|Experimental|Arm I (mFOLFOX regimen)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and fluorouracil IV over 46-48 hours on days 1-2 and 15-16.
9799403|NCT01658943|Experimental|Arm II (Akt inhibitor MK2206 and selumetinib)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, and selumetinib PO daily on days 1-28.
9799404|NCT01658995|Active Comparator|Post ESI implant - Doxycycline|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received Doxycycline 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
9799405|NCT01658995|Placebo Comparator|Post ESI implant - Placebo|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received placebo 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
9921940|NCT00832962||1|Adult Rh negative pregnant patients from 7 selected centers (SAINT ANTOINE hospital, CHU Marseille, CHU Nantes, CHU Lille, LOUIS MOURIER Hospital, SAINT VINCENT-PAUL Hospital, CH POISSY)
9984913|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:~Disease onset as metastatic or unresectable disease.~First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
9788400|NCT01330966|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
9788401|NCT01331005|Placebo Comparator|Placebo|Placebo will be given three times per day for one year
9788402|NCT01331005|Active Comparator|nepafenac 0.1% drops|Nepafenac drops will be given three times per day for one year
9788403|NCT01331083|Experimental|PX-866|
9788404|NCT01331109|Experimental|Milnacipran|oral administration, twice daily dosing
9788405|NCT01331161|Experimental|Older group|Participants between the ages of 60-79
9788406|NCT01331161|Experimental|Younger group|Participants between the ages of 25-40
9788407|NCT01331213|Active Comparator|Pregabalin|Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
9788408|NCT01331213|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo orally.
9788409|NCT01331239|Experimental|Part l: Core cohort|Participants took an ascending dose of LCI699 (osilodrostat) from 2mg bid or 5 mg bid, up to 30 mg bid and participated in Part I of this study. 4 patients in this cohort moved to Part II of the study
9788410|NCT01331239|Experimental|Part II Core: Expansion cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Expansion of this study. These patients were all newly enrolled into the phase II part of the study
9788411|NCT01331239|Experimental|Part II Core: Follow-up cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Follow-up of this study. These patients were patients who transferred from Part I Core phase of the study
9788412|NCT01331291|Experimental|Arm A|Patients who are surgical candidates. Participants are given oral bosutinib, 400mg daily, for 7-9 days prior to resection. After at least 10 days elapsed post-operatively, bosutinib dosing was resumed.
9788413|NCT01331291|Experimental|Arm B|Patients that are not surgical candidates. Participants are given oral bosutinib, 400 mg daily in 28 day cycles until disease progression, intolerability or withdrawal of consent.
9788414|NCT01331304|Other|Li + APT|Study participants will take lithium in addition to any other medications recommended by the study physician.
9788415|NCT01331304|Other|QTP + APT|Study participants will take quetiapine in addition to any other medications recommended by the study physician.
9788416|NCT01331408|Experimental|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks
9788417|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
9788418|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
9788419|NCT01331681|Active Comparator|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
9788420|NCT01331694||COPD|copd patients 65 years and older
9788421|NCT01331824|Experimental|Amrubicin|35 mg/m2/day intravenously
9788422|NCT01331837|Active Comparator|Etanercept|
9788423|NCT01331837|Experimental|Tocilizumab|
9788424|NCT01332019|Experimental|peginterferon beta-1a Q4W|125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
9788425|NCT01332019|Experimental|peginterferon beta-1a Q2W|125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
9788426|NCT01332071|Active Comparator|Avandamet test product|Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2
9788427|NCT01332071|Active Comparator|Avandamet reference product|Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2
9788428|NCT01332123|Experimental|Alignment perturbations|The following modifications will be applied to the prostheses: increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
9788429|NCT01332149|Experimental|300 mg/day pregabalin (Lyrica)|Patient take pregabalin capsule twice a day
9788430|NCT01332149|Placebo Comparator|Placebo|
9788431|NCT01332188|Experimental|AC-170 0.05%|
9788432|NCT01332188|Experimental|AC-170 0.1%|
9788433|NCT01332188|Experimental|AC-170 0.24%|
9788434|NCT01332188|Placebo Comparator|AC-170 0%|
9788435|NCT01332227|Experimental|Atazanavir/Ritonavir + Raltegravir|Atazanavir + Ritonavir (heat-stable) + Raltegravir
9788436|NCT01332227|Other|Atazanavir/Ritonavir + Tenofovir/Emtricitabine|"Reference~Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine"
9788437|NCT01332253|Experimental|Intravenous Ibuprofen|
9788438|NCT01332253|Placebo Comparator|Normal Saline|
9788439|NCT01332292|Active Comparator|COHORT 1 RANDOMISATION A|(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
9788440|NCT01332292|Placebo Comparator|COHORT 1 RANDOMISATION B|(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
9788441|NCT01332292|Active Comparator|COHORT 2 RANDOMISATION A|(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
9788442|NCT01332292|Placebo Comparator|COHORT 2 RANDOMISATION B|(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
9788443|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 600 mg|GEn (XP13512/GSK1838262) 600 mg
9788444|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1200 mg|GEn (XP13512/GSK1838262) 1200 mg
9788445|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1800 mg|GEn (XP13512/GSK1838262) 1800 mg
9788446|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 2400 mg|GEn (XP13512/GSK1838262) 2400 mg
9788447|NCT01332305|Placebo Comparator|Placebo|Placebo
9788448|NCT01332318|Placebo Comparator|Placebo|XP13512 Placebo + Diphenhydramine Placebo
9788449|NCT01332318|Experimental|XP13512 1200 mg|XP13512 1200 mg/day + Diphenhydramine Placebo
9788450|NCT01332318|Experimental|XP13512 1800 mg|XP13512 1800 mg/day + Diphenhydramine Placebo
9788451|NCT01332318|Active Comparator|Placebo + Diphenhydramine|XP13512 Placebo + 50 mg Diphenhydramine
9788452|NCT01332331|Experimental|Low Dose Ambrisentan|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
9788453|NCT01332331|Experimental|High Dose Ambrisentan|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
9788454|NCT01332357||Fluticasone propionate/salmeterol combination ED MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
9788455|NCT01332357||Fluticasone propionate/salmeterol combination OP MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
9788456|NCT01332435||Early 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
9788457|NCT01332435||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)
9788458|NCT01332461||COPD Patients|Patients over the age of 40 with a COPD-related hospital or ER visit
9788459|NCT01332487||Early initiation of 5ARI therapy|Patients starting 5ARI therapy within 30 days of initiating AB therapy
9788460|NCT01332487||Delayed initiation of 5ARI therapy|Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy
9788461|NCT01332500||adult migraineurs with/without aura|Adult migraine patients >18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
9788462|NCT01332578|Experimental|Test Product|Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
9788463|NCT01332578|Active Comparator|Paracetamol tablet|Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
9517815|NCT03302663|Other|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
9788464|NCT01332630|Experimental|TPI 287|TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, Dexamethasone 10 mgby vein may be given 30-60 minutes prior to treatment with TPI 287, Benadryl 12.5-25 mg IV push over 30-60 minutes, and Ranitidine 1mg/kg IV over 30-60 minutes.
9788465|NCT01332721|Experimental|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
9788466|NCT01332851|Experimental|Promoting First Relationships (PFR)|"PFR is a strengths-based 10 week in-home parenting intervention based on attachment theory. Each week has a theme for discussion, an activity, and time for joining - checking in with the parent, listening to their concerns and establishing a positive, supportive relationship. The sessions include handouts which focus on the content area covered that day and applying a topic to their relationship with their child. The provider also videotapes playtime between parent and child. On alternate weeks, the provider watches the video with the parent, reflecting on both the parent's and the child's needs. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent identify her own feelings and needs around parenting."
9788467|NCT01332851|Active Comparator|Resource & Referral|This condition consists of 1) Resource and Referral assistance provided over the phone, and 2) Local Services Resource Packet. The participant receives a phone call from a Resource and Referral Specialist to conduct a needs assessment to identify the particular needs or concerns of the family (such as housing needs, mental health, tangible goods). If a need is identified, the Referral and Referral Specialist will provide the family with local information regarding the stated need. The R&R provider makes two follow-up check in calls with the families. In addition, families can call the Research and Referral Specialist if additional needs arise. The resource packet includes information organized by type of need or resource. These packets are updated regularly as services change over time.
9788468|NCT01332981||Cohort|
9788469|NCT01332994|Experimental|1|
9788470|NCT01332994|Experimental|2|
9788471|NCT01333033|Experimental|Arm I (FOLFOX regimen)|Patients receive modified FOLFOX-6 therapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-5. Treatment repeats every 14 days for 3 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreased by >= 35%) receive 3 additional courses of FOLFOX-6 therapy and undergo concurrent RT (3D-conformal or intensity-modulated) once daily, 5 days a week, for approximately 6 weeks. Patients without responsive disease (tumor metabolic activity did not decrease by 35%) cross over to Arm II during RT.
9788472|NCT01333033|Experimental|Arm II (carboplatin + paclitaxel + radiation)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 2 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreases >= 35%) continue to receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly for 5 weeks and undergo RT (3D-conformal or intensity-modulated) once a day, 5 days a week, for approximately 6 weeks. Patients without responsive disease (metabolic activity did not decrease by 35%) cross over to Arm I during RT
9788473|NCT01333059|Experimental|Experimental Group|"In this arm Fentanyl and Midazolam was replaced with placebo (normal saline) during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the placebo drug (normal saline). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the placebo drug (normal saline), was started. The switch Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol"
9788474|NCT01333059|Active Comparator|Control Group|"In this arm, midazolam and fentanyl were administered during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the control drug (midazolam). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the control drug (fentanyl), was started. The switch to Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol."
9788475|NCT01333072|Active Comparator|Risperidone|Atypical antipsychotic
9788476|NCT01333072|Active Comparator|Aripiprazole|Atypical antipsychotic
9788477|NCT01333098|Experimental|mifepristone|1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)
9788478|NCT01333111|Experimental|Prophylaxis, high dose (trial duration 52 weeks)|
9788479|NCT01333111|Experimental|Prophylaxis, low dose (trial duration 52 weeks)|
9788480|NCT01333111|Experimental|On-demand (trial duration 28 weeks)|
9921941|NCT00832962||2|Adult Rh negative pregnant patients from 6 selected centers (Tenon hospital, Jean VERDIER Hospital, La Pitie-Salpetriere Hospital, Cochin Hospital, Robert Debre Hospital, BICHAT Hospital)
9921942|NCT00832988||Pacemaker patients|Patients who are implanted with a SJM Zephyr™ DR device for a standard pacing indication will be eligible
9984914|NCT03601728|Experimental|Enhanced Monitoring Program|Four weeks prior to the scheduled (elective) surgery, participants will receive a 60-minute in person education session how to increase the level of physical activity. This will be followed by 4 weeks of keeping this level of physical activity, which will be monitored and supported by personalized interactive prompts delivered by a smartwatch. This approach is called personalized prehabilitation.
9788481|NCT01333189|Experimental|RELOAD: Weight-bearing biofeedback exercise|RELOAD participants participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games. These biofeedback training sessions were provided in addition to the standard of care rehabilitation that the CONTROL group received. Total dose of exercise across groups was matched.
9788482|NCT01333189|Active Comparator|CONTROL: Standard of care exercise|CONTROL participants were provided two weeks of home rehabilitation (6 visits) by a physical therapist. Patients then progressed to outpatient rehabilitation, consisting of 4 weeks of treatment for a total of 6 weeks of standard of care rehabilitation. Total dose of exercise across groups was matched.
9788483|NCT01333397|Experimental|Dysport RU 20 U|
9984915|NCT03601728|No Intervention|Regular Monitoring Program|Participants randomized to this arm will receive standard perioperative care.
9788484|NCT01333397|Experimental|Dysport RU 50 U|
9788485|NCT01333397|Experimental|Dysport RU 75 U|
9788486|NCT01333397|Active Comparator|Dysport (Azzalure) 50 U|
9788487|NCT01333397|Placebo Comparator|Placebo|
9788488|NCT01333475|Experimental|TAC1:MK-2206 & AZD6244 in Pts with Colorectal Ca|Cycle = 28 days:MK-2206:90 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 75 mg PO QD (every day) MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
9788489|NCT01333475|Experimental|TAC1A:MK-2206 & AZD6244 in Pts with Colorectal Ca|"Cycle = 28 days:MK-2206:135 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 100 mg PO QD~MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression."
9788490|NCT01333488|No Intervention|Conventional Therapy|
9788491|NCT01333488|Experimental|Hypothermia|Subjects will have their core body temperatures lowered to 34C.
9788492|NCT01333488|Experimental|Hypothermia plus supplemental magnesium sulfate infusion|
9788493|NCT01333501|Experimental|Fingolimod|0.5 mg in capsules for oral administration once daily
9788494|NCT01333501|Active Comparator|Interferon beta 1b|250 μg injected s.c. every other day
9788495|NCT01333527|Experimental|Group A (early ROM)|Group A (early ROM) will use the sling for comfort only
9788496|NCT01333527|Active Comparator|Group B (usual care)|Group B (usual care) will be immobilized in a sling for 6 weeks.
9788497|NCT01333592|Experimental|KAD-1229|
9788498|NCT01333722|Placebo Comparator|Placebo|placebo, 1 oral tablet every 12 hours
9788499|NCT01333722|Experimental|Hydrocodone/Acetaminophen Extended Release|hydrocodone/acetaminophen extended release, 1 oral tablet every 12 hours
9788500|NCT01333813|Experimental|Engerix-B Kinder Group|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 7-8 years of age.
9788501|NCT01333865|Experimental|Memantine (Namenda) Treatment|
9788502|NCT01333943|Experimental|Experimental|Saphenous (Adductor Canal) Nerve Block
9788503|NCT01333943|Active Comparator|Control|Femoral Nerve Block
9788504|NCT01333956|Placebo Comparator|Control|Patients will receive 0mg of pregabalin
9788505|NCT01333956|Experimental|50mg Arm|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.
9788506|NCT01333956|Experimental|100mg Arm|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
9788507|NCT01333956|Experimental|150mg Arm|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
9788508|NCT01334086|Experimental|Aprepitant|
9788509|NCT01334125|Experimental|Metformin|Metformin 1000 mg once daily by mouth for 9 months
9788510|NCT01334125|Placebo Comparator|Placebo|2 capsules once daily by mouth for 9 months
9788511|NCT01334216|Active Comparator|CHICA Smoking Cessation Module|This arm had the CHICA smoking cessation module turned on
9788512|NCT01334216|Placebo Comparator|CHICA Placebo|This arm had CHICA without the smoking cessation module
9984916|NCT03601507|Experimental|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
9984917|NCT03600142|No Intervention|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare a woman (and her partner, if present) for HIV testing. For anyone who tests positive for HIV, counseling should help the woman/couple to accept an HIV test result and discuss implications for treatment.
9788513|NCT01334229|Experimental|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
9788514|NCT01334229|Placebo Comparator|Placebo|Placebo for 6 weeks
9788515|NCT01334515|Experimental|Disease measured by standard radiographic criteria|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
9788516|NCT01334515|Experimental|Disease evaluable only by I-MIBG or BM histology|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
9788517|NCT01334554|Experimental|Sildenafil|Sildenafil 20 mg three times a day
9788518|NCT01334554|Placebo Comparator|Placebo|placebo
9998188|NCT01515878|No Intervention|Conventional dialysis|Conventional dialysis without blood volume tracking or similar therapies
10205846|NCT05173350|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
10205847|NCT05173350|Active Comparator|Active Comparator|The active comparator group does not receive the full set of RETAIN intervention activities.
10205848|NCT05172050|Experimental|Group 1: Raloxifene 60 mg|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing 60 mg of the active substance or placebo), a single daily oral dose of raloxifene 60 mg was administered; the treatment was taken by the patients for two weeks.
10205849|NCT05172050|Experimental|Group 2: Raloxifene 120 mg|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing 60 mg of the active substance or placebo), a single daily oral dose of raloxifene 120 mg was administered; the treatment was taken by the patients for two weeks.
10205850|NCT05172050|Placebo Comparator|Group 3: Placebo.|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing placebo), a single daily oral dose of placebo (2 capsules guarantee the blinding design) was administered; the treatment was taken by the patients for two weeks.
10205851|NCT05171608|Experimental|Ultrasound-based protocol group (USP)|Preoperative intravenous (IV) fluid therapy is order according to the result of the preoperative ultrasound scans of the inferior vena cava and the lungs (2 hours and 30 minutes before surgery)
10205852|NCT05171608|No Intervention|Conventional fluid therapy|Preoperative IV fluid therapy (isotonic, balanced crystalloid infusion, if any) is determined by the discretion of the attending anesthesiologist.
10205853|NCT05167981|Experimental|RETAIN Programming|The experimental group receives the full set of RETAINWORKS intervention activities.
10205854|NCT05167981|No Intervention|Control|The control group receives information and referral to partner services.
10205855|NCT05167370|Experimental|Amifostine|
10205856|NCT05166057|Experimental|Telerehabilitation Group (TG)|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
10205857|NCT05166057|Experimental|Video Group (VGr)|After 1 session of online simultaneous exercise training in the company of a physiotherapist via a smart phone videoconference to the VGr group, an exercise video including the exercises will be sent and the participants will be asked to do exercises 3 days a week. The cases will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
10205858|NCT05166057|Experimental|Standard pulmonary rehabilitation group (SGr)|The SGr group will be applied the pulmonary rehabilitation program with supervision in the hospital 2 days a week, and participants will be asked to do exercises at home for 1 day. The exercise period will be 8 weeks for both groups.
10205859|NCT05164094|Experimental|mRNA-1189 Dose Level 1|Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
10205860|NCT05164094|Experimental|mRNA-1189 Dose Level 2|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
10205861|NCT05164094|Experimental|mRNA-1189 Dose Level 3|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
10205862|NCT05164094|Placebo Comparator|Placebo|Participants will receive 1 IM injection of study drug-matching placebo on Days 1, 57, and 169.
10213434|NCT04031560|No Intervention|Control|The control group (62 patients) will not receive any type of add-on psychotherapy.
10213435|NCT04027777|Experimental|Aktiia.product-P0|Main study arm including 85 subjects
10213436|NCT04027777|Experimental|Aktiia.product-P0 Diabetics|Second study arm including 40 diabetic patients
10213437|NCT04027777|Experimental|Aktiia.product-P0 Aged|Thirs study arm including 40 patients aged 65+
10213438|NCT04027075|Experimental|Intervention|This group will be asked to use the Rewire app daily in the month following the baseline assessment. This group will also receive services as usual from the Department of Youth Services.
9517816|NCT03302663|Other|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
9788519|NCT01334710|Experimental|Sorafenib and OSI-906|This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients.
9788520|NCT01334723||Acute Urinary Retention|This subset of the Integrated Health Care Information Solutions (ICHIS) benign prostate hyperplasia (BPH) study population was used to assess acute urinary retention as a clinical outcome.
9788521|NCT01334723||Prostate Surgery|This subset of the ICHIS BPH study population was used to assess surgery as a clinical outcome.
9788522|NCT01334827|Other|Formulations|high volume gel; low volume gel; vaginal film
9788523|NCT01334918|Experimental|Single Photon Emission Computed Tomography (SPECT)|"Resting SPECT imaging was performed prior to regadenoson stress SPECT~imaging. Imaging was conducted with one of two radiotracers (99mTc sestamibi or tetrofosmin). Regadenoson 0.4 mg was administered prior to stress SPECT as a single bolus injection."
9788524|NCT01334918|Experimental|Multidetector Computed Tomography (MDCT)|Multidetector Computed Tomography (MDCT), composed of CCTA and regadenoson CTP. Regadenoson stress CTP was performed prior to rest CCTA/CTP imaging. Regadenoson 0.4 mg was administered prior to stress CTP as a single bolus injection. The rest CCTA/CTP was performed at least 30 minutes after completion of the stress CTP, after resolution of any symptoms brought on by the regadenoson infusion and after the participant's heart rate had returned to baseline.
9788525|NCT01334944|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.
9788526|NCT01334957|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.
9788527|NCT01335009|Experimental|MORAb-004, 2 mg/kg|Biologic (monoclonal antibody)
9788528|NCT01335009|Experimental|MORAb-004, 4 mg/kg|Biologic (monoclonal antibody)
9788529|NCT01335061|Other|BeneFIX|
9788530|NCT01335191|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.
9788531|NCT01335191|Placebo Comparator|Placebo|Two subcutaneous injections of placebo at Day 0 and Week 3.
9788532|NCT01335204|Experimental|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
9788533|NCT01335230||10 HIV mono-infected subjects|10 subjects infected with HIV only
9788534|NCT01335230||10 HCV mono-infected subjects|10 subjects infected with HCV only
9788535|NCT01335230||10 HIV/HCV co-infected subjects|10 subjects infected with both HIV and HCV
9788536|NCT01335230||10 control subjects|10 subjects without HIV, HCV, or both
9788537|NCT01335308|Active Comparator|Standard Care with Education Materials|Measure height and weight only. usual care
9788538|NCT01335308|Experimental|Moderate Dose Motivational Interviewing|MI delivered by PCP, 4 sessions
9788539|NCT01335308|Experimental|Higher Dose Motivational Interviewing|MI delivered by PCP, 4 sessions plus MI delivered by RD, 6 sessions
9788540|NCT01335464|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
9788541|NCT01335464|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
9788542|NCT01335477|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
9788543|NCT01335477|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
9788544|NCT01335542|Active Comparator|Epidural Pathway (PCEA+FNB)|
9788545|NCT01335542|Active Comparator|Peri-Articular Injection|
9921943|NCT00833001||1|GYNECARE PROLIFT+M* Pelvic Floor Repair System
9921944|NCT00833014|Experimental|I|
9921945|NCT00833066|Placebo Comparator|Placebo|
9788546|NCT01335620|Other|Tenofovir/Emtricitabine and Raltegravir|"Single arm study~tenofovir/emtricitabine 245/200 mg once daily and raltegravir 400 mg twice daily"
9788547|NCT01335698|Experimental|Stage 1: Atazanavir + Ritonavir|Participants received atazanavir powder orally (dosed by weight: 5 to <10 kg=150 mg, 5 to <10 kg=200 mg, 10 to <15 kg=200 mg, 15 to <25 kg=250 mg, 25 to <35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to <25 kg=80 mg, 25 to <35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to <35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to <35 kg=100 mg)
9788548|NCT01335724|Experimental|Diclofenac diethylamine 1.16% gel|
9788549|NCT01335724|Placebo Comparator|placebo gel|
9788550|NCT01335750|Experimental|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
9788551|NCT01335750|Experimental|Multipurpose Solution #2|OptiFree Replenish Multipurpose Solution
9788552|NCT01335750|Experimental|Multipurpose Solution #3|Ciba ClearCare Multipurpose Solution
9788553|NCT01335750|Active Comparator|Multipurpose Solution #4|Saline Solution
9788554|NCT01335789|Active Comparator|Oxytocin|intranasal administration
9788555|NCT01335789|Placebo Comparator|saline|intranasal administration
9788556|NCT01335867|Experimental|Vigabatrin|Vigabatrin titrated to 3 grams daily for 8 weeks
9788557|NCT01335867|Placebo Comparator|Placebo|Identical placebo daily for three weeks
9788558|NCT01335932|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by either IV ganciclovir or oral valganciclovir once daily until hospital discharge
9788559|NCT01335932|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by either IV normal saline or oral placebo once daily until hospital discharge
9788560|NCT01335971|Active Comparator|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
9788561|NCT01335971|Active Comparator|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
9788562|NCT01335971|Placebo Comparator|Placebo|Microcrystalline cellulose
9788563|NCT01336023|Experimental|IDeg|
9788564|NCT01336023|Experimental|IDegLira|
9788565|NCT01336023|Experimental|Lira|
9788566|NCT01336140|Experimental|Aminophylline|75 mg of intravenous aminophylline.
9788567|NCT01336140|Placebo Comparator|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
9788568|NCT01336205|Experimental|1|Oral Treatment
9788569|NCT01336205|Active Comparator|2|Oral treatment
9788570|NCT01336296|Active Comparator|Myfortic preload|Initiation of mycophenolic acid (Myfortic) 2 weeks prior to transplantation (with Simulect induction at time of transplant)
9788571|NCT01336296|Active Comparator|Myfortic standard|mycophenolic acid (Myfortic) at time of transplant with Thymoglobulin induction
9788572|NCT01336413|Active Comparator|Arm 1|Pregnenolone
9788573|NCT01336413|Placebo Comparator|Arm 2|Placebo
9788574|NCT01336569|Experimental|DuoTrav|Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks
9788575|NCT01336608|Experimental|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
9788576|NCT01336608|Experimental|vilanterol|Inhaled long acting beta-agonist
9788577|NCT01336608|Placebo Comparator|placebo|Placebo
9788578|NCT01336647|Experimental|Group A|Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.
9788579|NCT01336647|Experimental|Group B|Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.
9788580|NCT01336647|Placebo Comparator|Group C|Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.
9788581|NCT01336712|Experimental|Myeloablative Haploidentical Transplant|Haplo transplant
9788582|NCT01336738|Placebo Comparator|Placebo|Matching placebo for PF-04991532 and Sitagliptin
9788583|NCT01336738|Experimental|150 mg PF-04991532|
9788584|NCT01336738|Experimental|450 mg PF-04991532|
9788585|NCT01336738|Experimental|750 mg PF-04991532|
9788586|NCT01336738|Active Comparator|Sitagliptin 100 mg|
9788587|NCT01336764|Experimental|Active|individual coping self-statements and stimulus guided paced breathing.
9788588|NCT01336764|Sham Comparator|Control|Coping self statements and breathing retraining will be replaced with undirected passive behaviors such as listening to music.
9788589|NCT01336803|Experimental|Feraheme|Intravenous injection of Feraheme, 5 mg Fe/kg
9921946|NCT00833066|Experimental|gpASIT 25|
9788590|NCT01336894|Active Comparator|Arm I (SR+Brachytherapy)|Patients undergo sublobar resection comprising either a wedge resection or anatomical segmentectomy with or without intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
9788591|NCT01336894|Experimental|Arm II (SBRT)|Patients undergo 3 fractions of stereotactic body radiation therapy at 2-8 days apart.
9788592|NCT01336933|Experimental|Treatment|"A Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) B Treatment: Pralatrexate (P)~A cycles (CEOP) of the treatment regimen are 14 days, followed by  B cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.~Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation."
9788593|NCT01336959|Experimental|Open Label - BCT197 Part A|10mg single dose of BCT197
9788594|NCT01336959|Experimental|BCT197 Part B|Single dose of 50mg BCT197
9788595|NCT01336959|Placebo Comparator|BCT 197 Placebo Part B|Single dose of matching placebo to 50mg BCT197
9788596|NCT01336972|Experimental|Group A - eGFR > 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
9788597|NCT01336972|Experimental|Group B - eGFR 30 to 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
9788598|NCT01336972|Experimental|Group C - eGFR < 30 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
9788599|NCT01337050|Experimental|A|PF-03446962
9799406|NCT01659021|Experimental|Idelalisib+ofatumumab|"Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
9921947|NCT00833066|Experimental|gpASIT 100|
9921948|NCT00833066|Experimental|gpASIT 400|
9921949|NCT00833079|Experimental|Tacrolimus 0.1% Taro|Tacrolimus 0.1% manufactured by Taro applied for 14 days
9921950|NCT00833079|Active Comparator|Protopic - Tacrolimus 0.1%|Protopic, Tacrolimus 0.1% applied for 14 days
9921951|NCT00833079|Placebo Comparator|Vehicle|Tacrolimus vehicle applied for 14 days
9921952|NCT00833118||Intubation|
9788600|NCT01337076|Other|cochlear implant|
9788601|NCT01337089|Experimental|Non-comparative, open-label Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
9788602|NCT01337115|Active Comparator|Continuous femoral nerve block (CFNB)|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
9788603|NCT01337115|Experimental|Single shot SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h
9788604|NCT01337167|Experimental|V419|V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
9788605|NCT01337167|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
9788606|NCT01337297|Placebo Comparator|sham-tDCS|the electrodes are positioned in the same manner as the active-tDCS, activated for 20 s (time to climb ramp of the current until reach the current intensity used in the experiment), enough to produce the sensation of itch, and turned off until the end of the session.
9788607|NCT01337297|Experimental|active-tDCS|low-intensity transcranial Direct Current Stimulation (tDCS)applied over the dorsolateral prefrontal cortex
9788608|NCT01337336||COPD patients with comorbid depression/anxiety|Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged >40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.
9788609|NCT01337596|Experimental|Single dose 1 milligram (mg) LY2951742|Administered single subcutaneous injection
9788610|NCT01337596|Experimental|Single dose 5 mg LY2951742|Administered single subcutaneous injection
9788611|NCT01337596|Experimental|Single dose 25 mg LY2951742|Administered single subcutaneous injection
9788612|NCT01337596|Experimental|Single dose 75 mg LY2951742|Administered single subcutaneous injection
9788613|NCT01337596|Experimental|Single dose 200 mg LY2951742|Administered single subcutaneous injection
9788614|NCT01337596|Experimental|Single dose 600 mg LY2951742|Administered single subcutaneous injection
9788615|NCT01337596|Placebo Comparator|Single dose placebo|Administered single subcutaneous injection
9788616|NCT01337596|Placebo Comparator|Multiple dose placebo|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
9788617|NCT01337596|Experimental|150 mg LY2951742|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
9788618|NCT01337635|Active Comparator|Standard dose vitamin D|Treatment with cholecalciferol 400 IU daily at home.
9788619|NCT01337635|Active Comparator|High dose vitamin D|Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
9788620|NCT01337674|Experimental|Panel A: MK-4618 + Met → PBO + Met|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
9788621|NCT01337674|Experimental|Panel A: PBO + Met → MK-4618 + Met|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
9788622|NCT01337674|Experimental|Panel B: MK-4618 + Amlo → PBO + Amlo|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
9788623|NCT01337674|Experimental|Panel B: PBO + Amlo → MK-4618 + Amlo|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
9788624|NCT01337687|Experimental|Oxytocin|
9788625|NCT01337687|Placebo Comparator|Placebo|
9788626|NCT01337700|Experimental|Milnacipran|
9788627|NCT01337700|Placebo Comparator|Placebo|
9788628|NCT01337739|Placebo Comparator|Placebo Comparator|Continuous infusion of placebo during operative procedure
9788629|NCT01337739|Active Comparator|Active Comparator|Administration of Dexmedetomidine
9788630|NCT01337960|Experimental|Arm 1|Seated robot training group. Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
9788631|NCT01337960|Experimental|Arm 2|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
9788632|NCT01337960|Active Comparator|Arm 3|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
9788633|NCT01337973|Experimental|Arm 1: MI-CBT|MI-CBT (six sessions during acute treatment phase integrating motivational interviewing and cognitive behavioral approaches)
9788634|NCT01337973|Experimental|Arm 2: MI-CBT+CC|MI-CBT+CC (acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention)
9788635|NCT01337973|Active Comparator|Arm 3: E-TAU|E-TAU (enhanced treatment as usual - includes brief session and provision of resources)
9788636|NCT01337986|Active Comparator|Group B: Dalfampridine First|Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
9788637|NCT01337986|Active Comparator|Group A: Dalfampridine Second|Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks
9788638|NCT01338012|Experimental|sipuleucel-T|Men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. Subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions.
9788639|NCT01338025|Active Comparator|Arm A, non-suppressive HAART regimen|"In Step 1, subjects were randomized to continue their non-suppressive HAART regimen.~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
9788640|NCT01338025|Active Comparator|Arm B, 3TC or FTC monotherapy|"In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider).~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
9788641|NCT01338298|Active Comparator|Aripiprazole|
9788642|NCT01338298|Placebo Comparator|Placebo|
9788643|NCT01338415|Experimental|bosentan 2mg/kg b.i.d.|Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
9788644|NCT01338415|Experimental|bosentan 2mg/kg t.i.d.|Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
10205863|NCT05163925||EUROSETS ECMOLIFE SYSTEM|"Thirty consecutive patients that require ECLS and who receive the EUROSETS ECMOLIFE SYSTEM will be included. ECMOLIFE System is a perfusion system enabling operation and monitoring of extracorporeal circulation. ECMOLIFE System operates, powers, controls and regulates ECMOLIFE Centrifugal Pump which represents the disposable blood pump. ECMOLIFE System, when used in combination with ECMOLIFE Centrifugal Pump, is suitable for full or partial cardiac, circulatory and pulmonary support.~ECMOLIFE System is composed by an active programmable console (ECMOLIFE Console), a bearing-less motor driver (ECMOLIFE Motor driver), and sensors for blood parameters detection (flow rate, pressure, temperature, SvO2 and Hb). The console is equipped with an integrated back-up which in case of primary unit failure may be operated in combination with a back-up motor driver and flowmeter (besides, the ECMOLIFE system includes an Heater cooler device)."
10205864|NCT05159869|Experimental|Experimental|After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia. Persons randomized to the User-Led Meaningful Activity intervention group will begin the treatment protocol right after randomization. The intervention will consist of 3-4 sessions lasting 60-90 minutes each in which participants receive feedback from the neuropsychological assessment, identify the basis/topic of the activity plan, receive dementia psychoeducation, and map out an activity gradation plan. A brief cognitive screening tool will be re-administered at six months and 12 months. The neuropsychological battery that was administered at baseline will be re-administered 12 months later. Follow-up will also involve solicitation of feedback from the person with dementia and his or her caregiver regarding participants' participation in the study.
9788645|NCT01338493||lumbar spinal arthroplasty + Maverick™|Patients requiring total disc replacement
9788646|NCT01338506|Experimental|COPE Therapy|Combined prolonged exposure therapy for PTSD with cognitive behavioral therapy for substance use disorder.
9788647|NCT01338506|Active Comparator|Treatment as usual|CBT for substance use disorder.
9788648|NCT01338610|Experimental|ESBA105|ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks
9788649|NCT01338610|Placebo Comparator|Vehicle|ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks
10205865|NCT05159869|Active Comparator|Wait-List Control|"After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia (i.e., mild dementia). Those who meet criteria will be randomly assigned. Persons randomized to the wait-list control group will begin the treatment protocol after four months' time."
10205866|NCT05156879|Experimental|Aspirin|Aspirin Enteric-coated Tablets，75mg/day，24 weeks
10205867|NCT05156879|Active Comparator|Drospirenone ethinyl estradiol|Drospirenone ethinyl estradiol，one tablet/day for 21 consecutive days, 28 days as a cycle of use，24 weeks
10205868|NCT05156619||Cohort#1|new annual breast cancer cases and cases of recurrence at Hadassah University hospital between 2018-2021 (700)
10205869|NCT05156619||Cohort#2|Retrospective study - all clinical trial patients in the Sharett institute of oncology between 1.1.12-30.6.21 (300)
10205870|NCT05156619||Cohort#3|all newly diagnosed recurrent/metastatic disease during the study period (200)
9788650|NCT01338649|Active Comparator|Bright White|Exposure to bright white light treatment.
9788651|NCT01338649|Placebo Comparator|Dim red light|Exposure to dim red light treatment.
9788652|NCT01338792|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive oxaliplatin IV over 2 hours and pemetrexed disodium IV on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9788653|NCT01338818|Experimental|Ritalin LA|All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).
9788654|NCT01338857|Experimental|Sorafenib (Nexavar)|Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
9788655|NCT01338870|Placebo Comparator|Placebo|Placebo for PF-04991532 and sitagliptin
9788656|NCT01338870|Experimental|25 mg PF-04991532|
9788657|NCT01338870|Experimental|75 mg PF-04991532|
9788658|NCT01338870|Experimental|150 mg PF-04991532|
9788659|NCT01338870|Experimental|300 mg PF-04991532|
9788660|NCT01338870|Active Comparator|Sitagliptin 100 mg|
9788661|NCT01338987|Active Comparator|Arm1 First Transplt/males/leuprolide/+/-FLT Imaging|"Males randomized to leuprolide for first transplant.~[18F]fluorothymidine (FLT) imaging"
9788662|NCT01338987|Active Comparator|Arm2 First Transplt/males/No Leuprolide/+/- FLT Imaging|"Males not receiving leuprolide for first transplant~[18F]fluorothymidine (FLT) imaging"
10205871|NCT05156203|Experimental|T-1301 Capsules|T-1301 Capsules will be administered orally QD or BID in a 28-day cycle (21 days on treatment followed by 7 days off treatment) in sequential cohorts.
10205872|NCT05153863|Experimental|Single Arm C-Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
10205873|NCT05153629|No Intervention|Standard care|Participants will follow standard care until the ureteral stent is removed
10205874|NCT05153629|Experimental|TENS device|Participants will use the TENS device until the ureteral stent is removed
9788663|NCT01338987|Experimental|Arm3 First Transplt/females/leuprolide+/- FLT Imaging|"Females receiving leuprolide for first transplant.~[18F]fluorothymidine (FLT) imaging"
9788664|NCT01338987|Experimental|Arm4-Second Transplt/leuprolide and FLT Imaging|Second transplant with leuprolide and [18F]fluorothymidine (FLT) imaging
9788665|NCT01338987|No Intervention|Healthy Volunteer - Arm 5|Healthy Volunteer
9788666|NCT01339000|Experimental|Arm A -Sequence 1 Immunizations|Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)
9788667|NCT01339000|Experimental|Arm B - Sequence 2 Immunizations|Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7
9788668|NCT01339013|Active Comparator|AnaConDa|
9921953|NCT00833131|Experimental|1|25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.
10205875|NCT05148104||Patients receiving shoulder arthroplasty|Patients receiving shoulder arthroplasty that have an intact glenoid prior to the procedure. Ideally the glenoid surface should be visible and intact during imaging.
10205876|NCT05146544||No limitation of exercise performance capacities|normal maximal oxygen uptake (greater than or equal to 80% of the reference value)
10205877|NCT05146544||Limitation of exercise performance capacities|reduced maximal oxygen uptake (less than 80% of the reference value).
10205878|NCT05146349|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
10205879|NCT05146349|No Intervention|Control|The control group does not receive the full set of RETAIN intervention activities.
10205880|NCT05144308|Experimental|Patients operated with a TECNIS® Eyhance Toric II 1-piece posterior chamber lens|For at least one eye : Planned cataract surgery with placement of a TECNIS® Eyhance Toric II 1-piece posterior chamber lens
10205881|NCT05143736||Modeling cohort|The population enrolled at the intensive care unit of Zhujiang Hospital of Southern Medical University in Guangdong Province, China will be used as a modeling cohort.For the patients in this cohort, the nasal and fecal specimens and related clinical information will collected to construct the prediction model.
10205882|NCT05143736||validation cohort|The population enrolled at the intensive care unit of Dongguan People's Hospital in Guangdong Province, China will be used as a validation cohort.
10205883|NCT05140538|Active Comparator|Group 1|SRP + Biorepair Total Protective Repair toothpaste for home oral hygiene twice a day
10205884|NCT05140538|Experimental|Group 2|SRP + Biorepair Total Protective Repair toothpaste + Biorepair mouthwash (3 in 1) for home oral hygiene twice a day
10205885|NCT05136560|No Intervention|Placebo|normal saline
10205886|NCT05136560|Experimental|low dose dexamethasone|0.1 mg/kg dexamethasone iv once per day, for 1 or 2 days
10205887|NCT05136560|Experimental|high dose dexamethasone|0.2 mg/kg dexamethasone iv once per day, for 1 or 2 days
10205888|NCT05136456|Active Comparator|SHR1459 Low Dose|Drug: SHR1459 SHR1459 oral 24weeks
10205889|NCT05136456|Active Comparator|SHR1459 High Dose|Drug: SHR0302 SHR1459 oral 24 weeks
10205890|NCT05136456|Placebo Comparator|Placebo|Drug: Placebo Placebo oral 24 weeks
10205891|NCT05134454|Experimental|Extended ECG investigation|Participants will undergo 24-48 hours of continuous ECG recording and at least two long-term continuous ambulatory ECG recordings with a duration of 14 days each.
10205892|NCT05134454|No Intervention|Standard of care|Participants will undergo 24-48 hours of continuous ECG recording.
10205893|NCT05130073||Observational (PET/CT, medical data review, follow-up)|Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients' medical records are received. Patients are followed up for 5 years.
10205894|NCT05129163|Placebo Comparator|Exercise|The control group received weekly one-hour group exercise training for 3 months.
9788669|NCT01339052|Experimental|Cohort 1: Surgical subjects|"Subjects scheduled for surgery~BKM120: 100 mg once daily, orally, for 8-12 days prior to surgery~Surgery: Surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
9788670|NCT01339052|Experimental|Cohort 2: Non-surgical subjects|"Subjects not candidates for surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
9788671|NCT01339091|Experimental|Dalbavancin|
9788672|NCT01339091|Active Comparator|Vancomycin with possible switch to oral linezolid|
9788673|NCT01339247|Active Comparator|Paxil CR Reference|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
9788674|NCT01339247|Active Comparator|Paxil CR Test|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2
9788675|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-cycle 1|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
9788676|NCT01339260|Active Comparator|Palonosetron+dexamethasone-cycle 1|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
9788677|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-multicycle extension|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
10205895|NCT05129163|Experimental|Exercise and nutrition|The intervention group had weekly one-hour group exercise training the same as the control and an additional weekly one-hour group nutrition session for 3 months.
10205896|NCT05125523|Experimental|Sirolimus for Injection (Albumin Bound)|"Stage 1：Multiple doses of Sirolimus for Injection (Albumin Bound) will be administered intravenously.~Stage 2：RP2D of Sirolimus for Injection (Albumin Bound) as determined during stage 1 will be administered intravenously."
10205897|NCT05124678|Experimental|Fast/intermediate acetylators|"Participants in this arm have fast/intermediate acetylator status from NAT2 genotyping.~In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 10mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
10205898|NCT05124678|No Intervention|Slow acetylators|"Participants in this arm have a slow acetylator status from NAT2 genotyping. They will receive the standard of care. In the Intensive phase (Month 1-2) of treatment, they will receive; Oral Isoniazid 5mg/kg/day + Rifampicin, Ethambutol and Pyrazinamide at standard dose.~In the continuation phase (Month 3 - 6 ) of treatment, they will receive; Oral Isoniazid 5mg/kg/day +Rifampicin at standard dose"
10205899|NCT05123807|Other|Cytoreductive surgery|
10205900|NCT05123365|Experimental|Dose Level 1 (DL1)|"Patients take N-Acetylcysteince 600 mg orally twice daily.~This is the starting dose level for the study."
10205901|NCT05123365|Experimental|Dose Level 2 (DL2)|"Patients take N-Acetylcysteince 1200 mg orally twice daily.~If DL1 is well tolerated, the next cohort will progress to this dose level."
10205902|NCT05123365|Experimental|Dose Level 3 (DL3)|"Patients take N-Acetylcysteince 1800 mg orally twice daily.~If DL2 is well tolerated, the next cohort will progress to this dose level."
10205903|NCT05119777|Experimental|HArmonyCa Injectable Gel|HArmonyCa injected at the discretion of the Treating Investigator (TI) to the midface for initial treatment and an optional touch-up treatment 14 days later
10205904|NCT05118230||Inclisiran Cohort|patients treated with inclisiran in certain special territories in China
10205905|NCT05118230||SoC Historical Cohort|patients treated with standard of care (SoC) in routine clinical practice from EMR database
10205906|NCT05113667|Experimental|Clinical pharmacist-led services|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program
10205907|NCT05113667|No Intervention|Control group|Usual care
10205908|NCT05113199|Experimental|Virtual Dignity Therapy|
10205909|NCT05112198|Experimental|Noona web-based symptom tracking tool|In addition to usual care for their disease, patients interact with Noona system and system questioners to record their symptoms over a period of 6 months.
10205910|NCT05112198|No Intervention|Usual Care|Participants will receive the standard of care for their disease
10205911|NCT05108805|Experimental|YESCARTA in the Outpatient Setting|Participants will receive YESCARTA therapy in the outpatient setting
10205912|NCT05106192|Experimental|Cutaneous T-cell lymphomas (CTCL) Participants|"The first plaque will be treated using standard of care topical bexarotene or nitrogen mustard for participants with CTCL (cutaneous T-cell lymphomas)~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
10205913|NCT05106192|Experimental|Cutaneous B-cell lymphomas (CBCL) Participants|"The first plaque will be treated using standard of care intralesional TAC (triamcinolone acetonide) using a syringe/needle with participants with CBCL (cutaneous B-cell lymphomas).~The second plaque will be treated using a needle-free injector system.~After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded."
10205914|NCT05101564|Experimental|IC1:Alpelisib|Integrative subtype IC1, Treatment (14 days, - 2 or + 7 days): Take assigned alpelisib pills, 300 mg (two 150 mg tablets) with food, once daily by mouth
10205915|NCT05101564|Active Comparator|IC1:Tamoxifen|Integrative subtype 1, Treatment (14 days, -2 to +7 days): Take assigned tamoxifen pills, 20 mg once daily by mouth
10205916|NCT05101564|Experimental|IC2:Infigratinib|Integrative subtype 2, Treatment (18 days, - 2 to +3 days): Take assigned infigratinib pills, 100 mg once daily by mouth in the morning
10205917|NCT05101564|Active Comparator|IC2:Tamoxifen|Integrative subtype 2, Treatment (18 days, - 2 to +3 days): Take assigned tamoxifen pills, 30 mg once daily by mouth
10205918|NCT05101564|Active Comparator|IC6:Infigratinib|Integrative subtype 2, Treatment (18 days, - 2 to +3 days): Take assigned tamoxifen pills, 30 mg once daily by mouth
9788678|NCT01339260|Active Comparator|Palonosetron+dexamethasone-multicycle extension|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
9788679|NCT01339273|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
9788680|NCT01339273|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
9788681|NCT01339299|Experimental|recombinant luteinizing hormone|150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)
9788682|NCT01339299|Active Comparator|recombinant human chorionic gonadotrofin|25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )
9788683|NCT01339390|Experimental|Arm 1: MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
9788684|NCT01339390|Active Comparator|Arm 2: MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the primary care provider (PCP) to determine if the person would benefit from a weight loss program, and to refer them to MOVE! if they and the patient agree that it would be beneficial. The MOVE! program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
9788685|NCT01339403||HIV infected|No study specific intervention, non-interventional trial
9788686|NCT01339403||HIV-uninfected|No study specific intervention, non-interventional trial
9788687|NCT01339416||HIV infected cohort|HIV infected patients in the HIV cohorts at the three participating hospitals
9788688|NCT01339429|Experimental|simplified Negative Pressure Wound Therapy|The simplified Negative Pressure device will be placed on subjects selected from the hospital ward and meeting the eligibility criteria.
9788689|NCT01339559|Experimental|Brivaracetam|Brivaracetam with a maximum of 200 mg/day
9788690|NCT01339832||Cohort|
9788691|NCT01339858|Experimental|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 600 mg of NAC. Dosing will begin at 600 mg/d and titrated up over 5 weeks until a maximum dose of 3600 mg/d is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose.
9788692|NCT01339858|Placebo Comparator|Sugar Pill|matched placebo
9788693|NCT01339897|Active Comparator|5 mg/N6022|Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
9788694|NCT01339897|Placebo Comparator|Placebo|Injectable formulation normal saline
9788695|NCT01339897|Active Comparator|10mg/N6022|Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
9788696|NCT01339897|Active Comparator|20mg/N6022|Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
9788697|NCT01339910|Experimental|Reduced Intensity Conditioning (RIC)|One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
9788698|NCT01339910|Active Comparator|Myeloablative Conditioning Regimen (MAC)|One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
9788699|NCT01339923|Experimental|B_2h3h5_11|Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
9788700|NCT01339923|Experimental|B_3h5_11|Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
9788701|NCT01339923|Experimental|B_68_11|Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
9984918|NCT03600142|Experimental|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions. If a male partner is present with the women, he may also be enrolled and participate in the first two counseling sessions together with the woman.
9984919|NCT03598894||Case NDHT|Healthy non-dipping hypertensives 'NDHT' (24h mean wake SBP >145mmHg at baseline and a decline of <10% between mean day time and night time systolic pressures)
9788702|NCT01339923|Experimental|B_02_2_5|Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
9788703|NCT01339923|Experimental|B_02_6_10|Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
9984920|NCT03598894||Control NT|matched healthy normotensives 'NT' (24h mean wake SBP <120mmHg)
10205919|NCT05101564|Active Comparator|IC6:Tamoxifen|Integrative subtype 6, Treatment (18 days, - 2 to +3 days): Take assigned tamoxifen pills, 30 mg once daily by mouth
10205920|NCT05101564|Experimental|IC9: Amcenestrant|Integrative subtype 9, Amcenestrant 200 mg
10205921|NCT05101564|Active Comparator|IC9: Letrozole|Integrative subtype 9, Letrozole 2.5 mg
9837495|NCT04844424|Experimental|Part 5: Treatment Sequence XYZ|Participants will receive a single oral Dose 1 of milvexian as DC whole tablets under fasting conditions (Treatment X) in Treatment Period 1 followed by a single oral Dose 1 of milvexian as DC tablets dispersed in water and then mixed with apple sauce under fasting conditions (Treatment Y) in Treatment Period 2 and then a single oral Dose 1 of milvexian as DC tablets dispersed in water administered through a nasogastric (NG) tube under fasting conditions (Treatment Z) in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837496|NCT04844424|Experimental|Part 5: Treatment Sequence YZX|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837497|NCT04844424|Experimental|Part 5: Treatment Sequence ZXY|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837498|NCT04844424|Experimental|Part 5: Treatment Sequence XZY|Participants will receive Treatment X in Treatment Period 1 followed by Treatment Z in Treatment Period 2 and then Treatment Y in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837499|NCT04844424|Experimental|Part 5: Treatment Sequence YXZ|Participants will receive Treatment Y in Treatment Period 1 followed by Treatment X in Treatment Period 2 and then Treatment Z in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837500|NCT04844424|Experimental|Part 5: Treatment Sequence ZYX|Participants will receive Treatment Z in Treatment Period 1 followed by Treatment Y in Treatment Period 2 and then Treatment X in Treatment Period 3 on Day 1 of each Treatment Period during Part 5. There will be a wash-out period of 5 days between Day 1 of adjacent treatment periods.
9837501|NCT04840823|Experimental|Enoxacin 200mg twice daily|Enoxacin 200mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 1 active 200mg enoxacin tablet and 2 placebo tablets per dose.
9837502|NCT04840823|Experimental|Enoxacin 400mg twice daily|Enoxacin 400mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 2 active 200mg enoxacin tablets and 1 placebo tablet per dose.
9837503|NCT04840823|Experimental|Enoxacin 600mg twice daily|Enoxacin 600mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 3 active 200mg enoxacin tablets per dose.
9984921|NCT03598894||Control DHT|matched dipping hypertensives 'DHT' (24h mean wake SBP >145mmHg and a decline of >10% between mean day time and night time systolic pressures)
9837505|NCT04840121|Active Comparator|Study Group - AdhesioRT|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the study group will proceed with frozen embryo transfer cycle according window of implantation determined by AdhesioRT.
9921954|NCT00833131|Active Comparator|2|Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.
9921955|NCT00833144||1|Congestive Heart Failure
9921956|NCT00833144||2|Patients without congestive heart failure
10205922|NCT05101564|Experimental|Typical risk: Amcenestrant|Integrative subtypes 3, 4, 7, 8, Amcenestrant 200 mg
10205923|NCT05101564|Experimental|Typical risk: Amcenestrant + Letrozole|Integrative subtypes 3, 4, 7, 8 , Drug: Amcenestrant 200 mg, Drug: Letrozole 2.5 mg
10205924|NCT05101564|Active Comparator|Typical risk: Letrozole|Integrative subtypes 3, 4, 7, 8, Drug: Letrozole 2.5 mg
10205925|NCT05099679|Other|Psychosocial intervention + Cardiac Rehab Services|Cognitive Behavioral Therapy + Cardiac Rehab
10205926|NCT05098756|Experimental|Art therapy group|Experimental group received 8-week art therapy. Art therapy uses different themes and materials to art-making.
10205927|NCT05098756|No Intervention|No intervention group|No intervention group maintain the institution's original daily routine and participation in activities.
10205928|NCT05096546||Group I|"20 years old or older (regardless of sex)~Outpatients~Newly-diagnosed with dry eye disease (DED) within 6 months prior to signing the informed consent under hospital-based practice in Taiwan"
10205929|NCT05096546||Group II|"20 years old or older (regardless of sex)~Outpatients~Patients who had undergone cataract surgery and~was suspected to have dry eye disease (dry eye evaluations conducted based on the routine practice) within 6 months prior to signing the informed consent or~was diagnosed with dry eye disease within 6 months prior to signing the informed consent"
10205930|NCT05094440|Experimental|Immediate Treatment|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur over eight weeks and will be supplemented with a weekly guide and links to DBT worksheets. The intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program.
10205931|NCT05094440|Active Comparator|Waitlist and Delayed Treatment|Waitlist control whereby outpatients will wait 8 weeks to receive the intervention and then receive the Pocket Skills webapp (subsequent 8 weeks). The waitlist period and subsequent intervention will be delivered in conjunction with treatment as usual which includes standard psychosocial care (e.g., assessments, group, and individual programming) as part of the Addictions Program.
10205932|NCT05091931||Guidance® UTI Pathway|Guidance® UTI testing pathway with antibiotic sensitivity and microbial testing results reporting to a clinical lead specialist at the urology office within 14 hours of lab receipt. Treatment based on local standard clinical antibiotic selection with or without empiric therapy.
10205933|NCT05091931||Traditional Diagnostic Pathways|Local standard clinical practice pattern for UTI testing (e.g., urine analysis, urine culture and sensitivities or molecular testing as available) Treatment based on local standard clinical antibiotic selection with or without empiric therapy
9788704|NCT01339923|Experimental|BC_35_12|Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
9788705|NCT01339923|Experimental|C_35_12|Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
10205934|NCT05090514|Experimental|Reading and Growth Mindset Intervention Group|Parents and students receive a packet of age-appropriate books and educational materials on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
10205935|NCT05090514|Active Comparator|Wait-list Control Group|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read.
9788706|NCT01339936|Experimental|Investigational eye drop|Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
9788707|NCT01340014|Other|AZARGA/COSOPT|1 drop AZARGA instilled in each eye twice a day for 7 days, followed by 1 drop COSOPT instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
9788708|NCT01340014|Other|COSOPT/AZARGA|1 drop COSOPT instilled in each eye twice a day for 7 days, followed by 1 drop AZARGA instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
9788709|NCT01340027|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
9788710|NCT01340027|Active Comparator|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks
9788711|NCT01340027|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
9788712|NCT01340027|Active Comparator|Solifenacin 2.5 mg|Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks
9788713|NCT01340027|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg tablets orally once a day for 12 weeks
9788714|NCT01340027|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 10 mg tablets orally once a day for 12 weeks
9788715|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 25 mg|Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
9788716|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 50 mg|Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
9788717|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 25 mg|Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
9788718|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
9788719|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 25 mg|Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
9788720|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 50 mg|Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
9788721|NCT01340053|Placebo Comparator|Placebo|Capsule that is identical in size and color to other treatments
9788722|NCT01340053|Experimental|Low Dose|10 mg capsule of tenapanor
9788723|NCT01340053|Experimental|Mid Dose|30 mg capsule of tenapanor
9788724|NCT01340053|Experimental|High Dose|100 mg capsule of tenapanor
9788725|NCT01340066|Experimental|UISH001|
9788726|NCT01340066|Placebo Comparator|Matching placebo|
9788727|NCT01340144||PFC Sigma PS TKA|one group received primary TKA using the PFC Sigma PS TKA
9788728|NCT01340144||PFC Sigma HP PS TKA|One group received primary TKA using the PFC Sigma HP PS TKA.
9788729|NCT01340196|Experimental|sequence 1|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through day 22 (morning dose on day 22 only)
9788730|NCT01340209|Experimental|Tiotropium Respimat (low dose)|Tiotropium low dose once daily delivered with Respimat inhaler
9788731|NCT01340209|Experimental|Tiotropium Respimat (high dose)|Tiotropium high dose once daily delivered with Respimat inhaler
9788732|NCT01340209|Placebo Comparator|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
9788733|NCT01340300|Active Comparator|Exercise training|Exercise training with exercise physiologist
9788734|NCT01340300|Active Comparator|Exercise training with metformin|Exercise training with exercise physiologist with oral metformin
9788735|NCT01340300|Active Comparator|Metformin|Metformin
9788736|NCT01340300|Active Comparator|Control|Educational information
9788737|NCT01340482|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)
10205936|NCT05089799||Patients|"Older adults 60 years old or older They are referred to the day care hospital for memory problems or frailty and may present with various cognitive, behavioural, mental and physical disorders.~Persons in this group are diverse in socio-cultural levels. The investigators expect to include 100 patients (N = 100). Each patient will test 1 out of the 5 use cases, so 20 patients will test the same use case (n = 20)."
10213439|NCT04027075|No Intervention|Services as usual|This group will receive services as usual from the Department of Youth Services.
9788738|NCT01340495|Experimental|Proton Radiation|Radiation therapy with proton beam
9788739|NCT01340586|Experimental|Group A: Apixaban|
9788740|NCT01340586|Experimental|Group B: Apixaban|
9788741|NCT01340625|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)
9788742|NCT01340625|Active Comparator|Reference Listed Drug|Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)
9921957|NCT00833157|Experimental|Glucosamine|
9921958|NCT00833157|Experimental|Ibuprofen|
9788743|NCT01340651|Experimental|Ruxolitinib 25 mg SR/10, 15, or 20 mg IR|Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD. At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily. Participants who continued to demonstrate benefit in the opinion of the investigator could remain on ruxolitinib IR until the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition.
9788744|NCT01340664|Experimental|Canagliflozin 50 mg bid|Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
9788745|NCT01340664|Experimental|Canagliflozin 150 mg bid|Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
9788746|NCT01340664|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 18 weeks
9788747|NCT01340768|Experimental|Sitagliptin|Sitagliptin 100mg taken orally once daily with or without metformin
9788748|NCT01340768|Active Comparator|Sulfonylurea Therapy|Usual sulfonylurea therapy with or without metformin
9788749|NCT01340794|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9788750|NCT01340872|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
9788751|NCT01340872|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
9788752|NCT01340898|Experimental|Nimenrix 3+1 Group|Subjects, male and female, received 4 doses of Nimenrix™ vaccine (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
9788753|NCT01340898|Experimental|Nimenrix 1+1 Group|Subjects, male and female, received 2 doses of Nimenrix™ vaccine (1 dose at 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
9788754|NCT01340898|Experimental|Nimenrix Control Group|Subjects, male and female, received 1 dose of Nimenrix™ at 15-18 months of age and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
9788755|NCT01340937|Experimental|V419 Lot A|V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
9788756|NCT01340937|Experimental|V419 Lot B|V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
9788757|NCT01340937|Experimental|V419 Lot C|V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
9921959|NCT00833157|Placebo Comparator|Placebo|
9788758|NCT01340937|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age
9788759|NCT01340976|Experimental|LY2787106 Dose Escalation|Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles.
9788760|NCT01340976|Experimental|10 mg/kg LY2787106|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
9788761|NCT01340976|Experimental|10 mg/kg LY2787106+Iron|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
9788762|NCT01341067||Basal insulin, approved oral medications|
9788763|NCT01341301|Experimental|Allogeneic HSCT|"CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28."
9788764|NCT01341444|Experimental|Prevena Incision Management System|Negative Pressure Therapy Device
9788765|NCT01341444|Placebo Comparator|Standard of Care for Surgical Incisions|Sterile gauze and a non-penetrable barrier
9788766|NCT01341457|Experimental|LY2603618 + Gemcitabine|"Gemcitabine 1000 milligrams per meter squared (mg/m^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.~Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met."
9788767|NCT01341470|Experimental|Single IV dose LY2495655|Single 70 milligram (mg) dose LY2495655 administered intravenously (IV)
9788768|NCT01341470|Experimental|Multiple SC dose 17.5 mg LY2495655|17.5 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
9788769|NCT01341470|Experimental|Multiple SC dose 140 mg LY2495655|140 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
9788770|NCT01341470|Experimental|Multiple SC dose 420 mg LY2495655|420 mg dose of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
9788771|NCT01341470|Placebo Comparator|Single IV dose placebo|Single Placebo dose administered intravenously (IV)
9788772|NCT01341470|Placebo Comparator|Multiple SC dose placebo|Placebo dose administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
9788773|NCT01341639|Experimental|PR5I|V419 + RotaTeq + Prevenar 13 + ProQuad
9788774|NCT01341639|Active Comparator|INFANRIX™ hexa|INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad
9788775|NCT01341652|Experimental|pTVG-HP vaccine with GM-CSF|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
9788776|NCT01341652|Active Comparator|GM-CSF alone|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
9788777|NCT01341730|Active Comparator|Atorvastatin 20 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg group is to take atorvastatin 20 mg and take follow up PET CT in 3 months"
9788778|NCT01341730|Experimental|Atorvastatin 20 mg + Pioglitazone 30 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg + Pioglitazone 30 mg group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months"
9788779|NCT01341782|Experimental|Paricalcitol|Participants received paricalcitol at an initial dose of 2 µg, and maxacalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 1 µg based on protocol-specified criteria up to a maximum of 7 µg.
9788780|NCT01341782|Active Comparator|Maxacalcitol|Participants received maxacalcitol at an initial dose of 5 µg (iPTH < 500 pg/mL at Screening) or 10 µg (iPTH ≥ 500 pg/mL at Screening), and paricalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 2.5 µg based on protocol-specified criteria up to a maximum of 20 µg.
9788781|NCT01341912|Experimental|Human-cl rhFVIII|Recombinant FVIII derived from a human cell line.
9788782|NCT01341977|Experimental|Alcon MPDS|Alcon Multi-Purpose Disinfecting Solution (MPDS)
9788783|NCT01341977|Active Comparator|ReNu Fresh Multi-Purpose Solution|ReNu Fresh Multi-Purpose Solution
9788784|NCT01341990|Experimental|FID 114675A|Multi-purpose disinfecting solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
9788785|NCT01341990|Active Comparator|ReNu MultiPlus|Multi-purpose solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
9788786|NCT01342029|Experimental|Ranolazine|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
9788787|NCT01342029|Placebo Comparator|Placebo|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
9788788|NCT01342081|Experimental|1|DE-111 ophthalmic solution
9788789|NCT01342081|Active Comparator|2|Tafluprost ophthalmic solution 0.0015%
9788790|NCT01342081|Active Comparator|3|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
9788791|NCT01342094|Experimental|DE-111 ophthalmic solution|DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.
9788792|NCT01342094|Active Comparator|Timolol ophthalmic solution 0.5%|Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes.
9788793|NCT01342107|Experimental|FID 114675A|Contact lens soaked overnight in an investigational multi-purpose disinfecting solution randomly assigned to one eye, with contact lens removed directly from the blister pack assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
9788794|NCT01342107|Active Comparator|Blister Pack|Contact lens removed directly from the blister pack randomly assigned to one eye, with contact lens soaked overnight in an investigational multi-purpose disinfecting solution assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
9788795|NCT01342172|Experimental|Lenalidomide|capsules for oral administration
9788796|NCT01342211|Placebo Comparator|Treatment A|
9788797|NCT01342211|Experimental|Treatment B|
9788798|NCT01342211|Experimental|Treatment C|
9788799|NCT01342211|Experimental|Treatment D|
9788800|NCT01342211|Experimental|Treatment E|
9788801|NCT01342341|Experimental|Parafon Forte first, then Placebo|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).
9788802|NCT01342341|Placebo Comparator|Placebo first, then Parafon Forte|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).
9788803|NCT01342367|Experimental|Oral Androgen Therapy|Subjects will receive two oral hormonal drugs (bicalutamide with dutasteride or bicalutamide with finasteride)
9788804|NCT01342445|Experimental|lisdexamfetamine dimesylate|All participants will be assessed across five conditions (baseline, placebo, 30-mg, 50-mg, & 70-mg) in a double-blind, crossover design
9788805|NCT01342458|Experimental|Intervention Group|Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
9788806|NCT01342458|No Intervention|Control Group|During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.
10205937|NCT05089799||Informal carers or family caregivers|"This group includes persons who accompany patients during the hospital visit, such as family members (spouses or children) and friends.~They provide support to the patient with various frequency and intensity (occasional / regular / continuous).~Persons in this group are diverse in age and socio-cultural levels. They may also suffer from physical and/or psychological disorders.~The investigators expect to include 100 informal or family caregivers (N = 100). Each one will test 1 out of the 5 use cases, so 20 informal or family caregivers will test the same use case (n= 20)."
10205938|NCT05089799||Professionals|"All categories of professionals working in the day care hospital. Persons in this group belong to different professional categories (administrative, health, technical). They have different levels of proximity with the public and have various positions in the hospital.~The investigators expect to include 50 professionals."
10205939|NCT05087823|Experimental|Lipid, Glucose, and Mixed Meal Challenges|Participants will take part in three different meal challenges on three separate days with approximately two weeks in between. The first meal challenge is the lipid challenge, the second meal challenge is the glucose challenge and third meal challenge is the mixed-meal challenge.
10205940|NCT05085834|Experimental|Zinc gluconate|Patients received Zinc gluconate 45 mg capsules orally twice daily for 24 weeks.
10205941|NCT05085834|Placebo Comparator|Placebo|Patients received Zinc gluconate Placebo capsules orally twice daily for 24 weeks.
10205942|NCT05083910|Experimental|Oxytocin Group|The oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord
10205943|NCT05083910|Experimental|Oxytocin+Intrauterine Misoprostol|The oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity
10205944|NCT05083910|Experimental|Carbetocin|100-mg carbetocin was intravenously administered immediately after birth of the baby
10205945|NCT05083780|Experimental|mFORFIRINOX, Chlorphenesin Carbamate, Hydroxychloroquine|
10205946|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Monotherapy)|HMBD-002 administered as a 60-minute IV infusion as a monotherapy. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.
10205947|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Combination Therapy)|"HMBD-002 administered as a 60-minute IV infusion at escalating doses in combination with pembrolizumab. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.~Pembrolizumab will be administered as a 30-minute IV infusion at a dose of 200 mg on Day 1 of every 21-day cycle."
10205948|NCT05082610|Experimental|Part 2 - Dose Expansion (Monotherapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion as a monotherapy in patients with TNBC or NSCLC.
10205949|NCT05082610|Experimental|Part 2 - Dose Expansion (Combination Therapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion in combination with pembrolizumab at the standard labeled dose in patients with TNBC or NSCLC.
10205950|NCT05080647|Active Comparator|Mightier Child Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more play each week) for the 8-week duration. Parents in the Child Play condition will be advised specifically to not play Mightier for the 8-week duration of the study.
10205951|NCT05080647|Experimental|Mightier Child and Parent Play|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration. Additionally, parents in the Child and Parent Play condition will be encouraged to play Mightier games at least once a week (totalling 15 minutes or more of play each week) for the 8-week duration.
9788807|NCT01342471|Active Comparator|30-min walk|"Instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Participants were permitted to exercise in one long bout (30 min) or divide the exercise into multiple bouts as long as the bout length was 10 min or greater."
9984922|NCT03598608|Experimental|Part A: Favezelimab Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
9788808|NCT01342471|Experimental|TV commercial stepping|"Instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (~9 or 10), short (~3-5 min) bouts, conveniently incorporated into their daily TV viewing time."
9788809|NCT01342484|Experimental|linagliptin low dose|linagliptin low dose for children once daily
9788810|NCT01342484|Experimental|linagliptin high dose|linagliptin high dose for children once daily
9788811|NCT01342484|Placebo Comparator|placebo|matching placebo for each linagliptin dose once daily
9788812|NCT01342510|Experimental|Lidocaine|Lidocaine 50 mg in a 10 cc syringe
9788813|NCT01342510|Experimental|Magnesium|Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe
9788814|NCT01342510|Experimental|Lidocaine/Magnesium|Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe
9788815|NCT01342510|Placebo Comparator|Control|0.9% saline in a 10 cc syringe
9788816|NCT01342523|Experimental|No CIS/No loz/No Email/Lite Website/Brief Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, No nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
9788817|NCT01342523|Experimental|CIS/No loz/No email/Lite Website/Brief booklet|"This arm of the project will address the following question:~Does the following treatment provide efficacy relative to others:~CIS calls, no NRT lozenge, no motivational email, Lite website, Brief mailed booklet"
9788818|NCT01342523|Experimental|no CIS/Loz/No email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services achieve effectiveness compared to others:~No CIS phone counseling, NRT lozenge, no motivational email, lite website, brief mailed booklet"
9788819|NCT01342523|Experimental|No CIS/no loz/email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence:~No CIS counseling calls, no NRT lozenge, motivational emails, lite website, brief mailed booklet."
9788820|NCT01342523|Experimental|No CIS/No loz/No email/Full website/Brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence?~No CIS counseling, no NRT lozenge, no motivational email, full website, brief mailed booklet"
9788821|NCT01342523|Experimental|No CIS/No loz/No email/lite website/full booklet|"This arm seeks to answer the question:~Does this combination of services achieve efficacy compared to others:~No CIS counseling, no NRT lozenge, no motivational email, lite website, full mailed booklet"
9788822|NCT01342523|Experimental|CIS/Loz/No email/Lite website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
9788823|NCT01342523|Experimental|CIS/No loz/Emails/Lite Website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, motivational emails, lite website, brief mailed booklet"
9788824|NCT01342523|Experimental|CIS/No loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, full website, brief mailed booklet"
9788825|NCT01342523|Experimental|CIS/No loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, lite website, full mailed booklet"
9788826|NCT01342523|Experimental|No CIS/Loz/emails/Lite Website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
9788827|NCT01342523|Experimental|No CIS/Loz/No emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
9788828|NCT01342523|Experimental|No CIS/Loz/No emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
9788829|NCT01342523|Experimental|no CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
9984923|NCT03598608|Experimental|Part A: Favezelimab Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
9788830|NCT01342523|Experimental|no CIS/no loz/emails/lite web/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
9788831|NCT01342523|Experimental|no CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
9788832|NCT01342523|Experimental|CIS/loz/emails/lite website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
9788833|NCT01342523|Experimental|CIS/loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
9788834|NCT01342523|Experimental|CIS/loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
9788835|NCT01342523|Experimental|CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
9788836|NCT01342523|Experimental|CIS/no loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
9788837|NCT01342523|Experimental|CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
9788838|NCT01342523|Experimental|No CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
9788839|NCT01342523|Experimental|No CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
9788840|NCT01342523|Experimental|No CIS/loz/no emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
9788841|NCT01342523|Experimental|no CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
9788842|NCT01342523|Experimental|CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
9788843|NCT01342523|Experimental|CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
9788844|NCT01342523|Experimental|No CIS/loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
9788845|NCT01342523|Experimental|CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
9788846|NCT01342523|Experimental|CIS/Loz/no Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
9788847|NCT01342523|Experimental|CIS/Loz/Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
9788848|NCT01342549|Active Comparator|Arm 1|sodium valproate
9788849|NCT01342549|Active Comparator|Arm 2|naltrexone
9788850|NCT01342640|Experimental|Single Arm|
9788851|NCT01342666|Experimental|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
9788852|NCT01342666|Placebo Comparator|Cucumber consumption|Daily consumption of 300g of cucumber.
9788853|NCT01342757|Experimental|Arm I|"Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study."
9788854|NCT01342770|Experimental|Treatment (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
9788855|NCT01342796|Experimental|Arm 1|
9788856|NCT01342796|Active Comparator|Arm 2|
9788857|NCT01342887|Experimental|Treatment (immunosuppression, enzyme inhibitor, and chemo)|Patients receive cyclosporine IV continuously on days 5-9. Patients also receive pravastatin sodium PO every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity.
9799407|NCT01659021|Active Comparator|Ofatumumab|"Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
9799408|NCT01659125|Experimental|OCFighter|OCFighter
9799409|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.
9799410|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.
9788858|NCT01342913|Experimental|Fluticasone Furoate/Vilanterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)
9788859|NCT01342913|Active Comparator|Fluticasone Propionate/Salmeterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA
9788860|NCT01342926|Experimental|GSK933776 3 mg/kg|3 mg/kg administration of GSK933776 via intravenous infusion
9788861|NCT01342926|Experimental|GSK933776 6 mg/kg|6 mg/kg administration of GSK933776 via intravenous infusion
9788862|NCT01342926|Placebo Comparator|Placebo|Placebo via intravenous infusion
9788863|NCT01342926|Experimental|GSK933776 15 mg/kg|15 mg/kg administration of GSK933776 via intravenous infusion
9788864|NCT01342965|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
9788865|NCT01342965|Active Comparator|Chemotherapy|Participants received gemcitabine 1250 mg/m^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.
9788866|NCT01343004|Placebo Comparator|Placebo|Placebo identical in appearance to BA058 study drug
9788867|NCT01343004|Experimental|BA058 80 mcg (abaloparatide)|
9788868|NCT01343004|Active Comparator|teriparatide|Blinded until after randomization, then open-label
9788869|NCT01343043|Experimental|Cohort 1 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
9788870|NCT01343043|Experimental|Cohort 2 treated with NY-ESO-1 T Cells|Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
9788871|NCT01343043|Experimental|Cohort 3 treated with NY-ESO-1 T Cells|High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine as the lymphodepleting chemotherapy.
9788872|NCT01343043|Experimental|Cohort 4 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen as the lymphodepleting chemotherapy.
9788873|NCT01343056|Active Comparator|Office Staff follow up education|"A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up.~The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment."
9788874|NCT01343056|Active Comparator|Peer follow up education|"A person with diabetes trained as a peer shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment."
9837506|NCT04840121|Active Comparator|Control Group - Standard of Care|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the control group will proceed with the first frozen embryo transfer cycle as per standard of care. In the event of unsuccessful implantation (negative serum pregnancy test), participants will proceed with subsequent frozen embryo transfer cycle according to window of implantation determined by AdhesioRT.
9837507|NCT04838756|Experimental|Intervention arm|AI-integrated mammography screening
9837508|NCT04838756|Experimental|Control arm|Conventional mammography screening (standard of care)
9837509|NCT04837547|Experimental|Arm 1: Subjects with Diffuse Intrinsic Pontine Glioma (DIPG).|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
9837510|NCT04837547|Experimental|Arm 2: Relapsed/Refractory Neuroblastoma (NB)|"This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT:~Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg~The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects)."
9984924|NCT03598608|Experimental|Part A: Favezelimab Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
9837512|NCT04828161|Experimental|ensovibep active treatment arm 1|Phase 2 / Part A: ensovibep active treatment arm 1
9837513|NCT04828161|Experimental|ensovibep active treatment arm 2|Phase 2 / Part A: ensovibep active treatment arm 2
9837514|NCT04828161|Experimental|ensovibep active treatment arm 3|Phase 2 / Part A: ensovibep active treatment arm 3
9837515|NCT04828161|Placebo Comparator|Placebo|Phase 2 / Part A: Placebo
9837516|NCT04828161|Experimental|ensovibep|Phase 3/ Part B: ensovibep active treatment
9837517|NCT04828161|Placebo Comparator|Placebo Comparator|Phase 3/ Part B: Placebo
9837518|NCT04827056|Experimental|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
9837519|NCT04827056|Experimental|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
9837520|NCT04827056|Placebo Comparator|Placebo|Placebo and study drug will look exactly the same in order to maintain the double-blind; study drug and placebo are administered exactly the same.
9984925|NCT03598608|Experimental|Part B: cHL-Combination Therapy|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the recommended Phase 2 dose (RP2D) of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
9837523|NCT04825522|No Intervention|Control|Participants will not be receiving vancomycin.
9837524|NCT04825522|Active Comparator|Vancomycin|For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
9837526|NCT04822883|Experimental|Dose-escalation - RL-007|Each cohort will include a single dose-strength. Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
9837527|NCT04822883|Placebo Comparator|Dose-escalation - matching Placebo|Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.
9984926|NCT03598608|Experimental|Part B: DLBCL-Combination Therapy|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
9788875|NCT01343056|Active Comparator|Usual Care|ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
10205952|NCT05080335|Active Comparator|TRANS-gender female instructor, with videos (TV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a TRANS-gender woman with extensive experience as an educator on transgender health
9788876|NCT01343056|Active Comparator|Educator support follow up|A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment. The diabetes educator uses behavioral goal setting as an education intervention. The educator calls patient to determine goal attainment. That is the intervention.
9788877|NCT01343082|Experimental|1|DE-111 ophthalmic solution
9788878|NCT01343095|No Intervention|Usual Care|Usual Care between 10pm-6am
9788879|NCT01343095|Active Comparator|Earplugs|Application of foam earplugs from 10pm-6am nightly for seven nights or until ICU discharge.
9788880|NCT01343095|Active Comparator|Earplugs and Headphones|Foam Earplugs and Noise canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge.
9788881|NCT01343160|Other|GORE VIABIL® Biliary Endoprosthesis|Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
9788882|NCT01343251||HeRO Graft|patients who are evaluated and receive a HeRO Graft implant for hemodialysis
9788883|NCT01343251||Control|control group of non-HeRO patients who are evaluated but do not receive a HeRO Graft for any reason
9788884|NCT01343277|Experimental|Trabectedin|
9788885|NCT01343277|Active Comparator|Dacarbazine|
9788886|NCT01343368|Experimental|Interventional - Received Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
9788887|NCT01343368|Active Comparator|Observational Arm|Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
9788888|NCT01343407|Experimental|MK-1029 60 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
9788889|NCT01343407|Experimental|MK-1029 500 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
9788890|NCT01343407|Placebo Comparator|Placebo|Part II - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
9788891|NCT01343485|No Intervention|Control, standard care for HPV vaccine|Study participants in control sites will receive standard care for HPV vaccine administration and follow-up per PPFA protocol
9788892|NCT01343485|Experimental|Intervention, computer reminder system|Study participants in the intervention sites will receive standard care for HPV vaccine administration per PPFA protocol, reminder messages for subsequent vaccination appointments, and real-time determination of financial assistance for HPV vaccine.
9788893|NCT01343667|Other|GFRS EPD|Carotid artery stenting with Gore Flow Reversal System embolic protection device
9788894|NCT01343667|Other|GEF EPD|Carotid artery stenting with Gore Embolic Filter embolic protection device
9788895|NCT01343693||Anterior cervical discectomy and fusion|Any subject with DDD, tumor, deformity ot trauma to the cervical spine in which the investigator determines the subject will require an ACDF using the MaxAn Plate.
10205953|NCT05080335|Active Comparator|CIS-gender female instructor, with videos (CV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
10205954|NCT05080335|Active Comparator|CIS-gender female, with NO videos (CN)|Didactic materials do NOT use short videos of transgender youth [until AFTER completion of the POST outcome measures]; lesson is led by a CIS-gender woman with extensive experience as an educator on transgender health
10205955|NCT05080335|No Intervention|No intervention control|Subjects randomized to this arm will complete the baseline assessment and the post assessment thirty days later, but just *before* receiving the intervention (TV).
10205956|NCT05079841|Experimental|Intrapartum nipple stimulation|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or stimulate by hand (intervention) to induce labor.
10205957|NCT05079841|Active Comparator|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor.
10205958|NCT05079594|No Intervention|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, when the baby starts to cry, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
10205959|NCT05079594|Experimental|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb. It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvey Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies. In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position.
9788896|NCT01343823|Active Comparator|ecallantide 10mg|Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
9788897|NCT01343823|Placebo Comparator|placebo|Administered as two SC 3 mL injections
9788898|NCT01343823|Active Comparator|ecallantide 60mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
9788899|NCT01343823|Active Comparator|ecallantide 30mg|Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.
9788900|NCT01343888|Active Comparator|PegIFN/RBV|PegIFN/RBV for 48 weeks
9788901|NCT01343888|Experimental|BI 201335 for 12 or 24 weeks|BI 201335 once daily low dose for 12 or 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
9788902|NCT01343888|Active Comparator|Placebo and PegIFN/RBV|Placebo (oral) once daily plus PegIFN/RBV (subcutaneous injection/oral) for 24 weeks, followed by PegIFN/RBV alone up to Week 48.
9788903|NCT01343901||Bevacizumab|Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.
9788904|NCT01344057|Other|Sub unit, Inactivated, MF59C.1 Adjuvanted Influenza Vaccine|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
9788905|NCT01344161|Placebo Comparator|Lactose|
9788906|NCT01344161|Experimental|Vitamin D|
9788907|NCT01344356|Other|Benign Tumors|Benign head and neck tumors will be treated with SBRT
9788908|NCT01344356|Other|Malignant Tumors|Malignant Head and Neck Tumors will be treated with SBRT.
9788909|NCT01344369|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)
9788910|NCT01344369|Active Comparator|Reference Listed Drug|FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)
9788911|NCT01344447|Experimental|Arm 1|
9788912|NCT01344460|Experimental|Arm 1|
9788913|NCT01344538|Experimental|Ginger Root Extract|
9788914|NCT01344538|Placebo Comparator|Lactose Capsule|
9788915|NCT01344616|No Intervention|usual clinical care|usual clinical care with no intervention
9788916|NCT01344616|Experimental|lifestyle counseling|computer-based clinical support to patient
9788917|NCT01344629|Experimental|Telmisartan80mg/Amlodipin5mg FDC|single-dose, four-period replicated crossover design
9788918|NCT01344629|Experimental|Telmisartan80mgtab + Amlodipin5mg tab|single-dose, four-period replicated crossover design
9788919|NCT01344759|Active Comparator|Propofol|
9788920|NCT01344759|Active Comparator|Dexmedetomidine|
9788921|NCT01344824|Other|Single Arm Trial|Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride
9788922|NCT01344876|Experimental|OPB-51602|OPB-51602 1, 2, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle
9788923|NCT01345019|Active Comparator|Zoledronic acid|Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
9788924|NCT01345019|Experimental|Denosumab|Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
9788925|NCT01345058|Experimental|Lacosamide + Low-Dose Levetiracetam|Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.
9788926|NCT01345058|Other|Control Group (High-Dose Levetiracetam)|Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam >1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.
9788927|NCT01345123|Experimental|Decision Aid with Health Coaching|
9788928|NCT01345123|Experimental|Decision Aid only|
9788929|NCT01345123|No Intervention|No condition specific support|
9788930|NCT01345162|Other|ketorolac|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then Ketorolac postoperative 10mg 1cp x 3/die, from the day of surgery for 4 days after surgery.
9788931|NCT01345162|Other|acetaminophene+tramadol|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then postoperative Patrol (acetaminophene 325mg+tramadol 37,5mg) 1cp x 3/die for 4 days after surgery.
9788932|NCT01345188|Active Comparator|Ranolazine|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
9788933|NCT01345188|Placebo Comparator|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
9788934|NCT01345253|Experimental|Belimumab|10mg/kg
9788935|NCT01345253|Placebo Comparator|Placebo|placebo
9788936|NCT01345292|Experimental|12027-027|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
9788937|NCT01345292|Active Comparator|310158077046|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
9788938|NCT01345292|Placebo Comparator|037000003212|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
9788939|NCT01345318|Experimental|Open-label Treatment|
9788940|NCT01345513||Solid Tumor Cancer|
9788941|NCT01345591|Experimental|Fat Grafting|Twenty (20) subjects who have had severe facial trauma, 18 years of age and older enrolled to clinical trial will receive Fat grafting intervention procedure
9788942|NCT01345630|Experimental|Maraviroc|Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
9788943|NCT01345630|Active Comparator|Emtricitabine/tenofovir|Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
9788944|NCT01345669|Experimental|Afatinib (BIBW 2992)|Once daily
9788945|NCT01345669|Placebo Comparator|Placebo|Once daily
9788946|NCT01345682|Experimental|Afatinib (BIBW 2992)|Once daily
9788947|NCT01345682|Active Comparator|Methotrexate|Weekly
9788948|NCT01345721|Experimental|MenACWY (2 primary + 1 booster dose)|Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
9788949|NCT01345721|Experimental|MenACWY (1 primary + 1 booster dose)|Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
9788950|NCT01345721|Experimental|MenC (1 primary dose)+MenACWY (1 booster dose)|Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.
9788951|NCT01345929|Experimental|CXA-201 as treatment for cUTI|CXA-201 IV infusion (1500mg q8) for 7 days
9788952|NCT01345929|Active Comparator|Levofloxacin as treatment for cUTI|Levofloxacin IV infusion (750mg qd) for 7 days
9788953|NCT01346059|Placebo Comparator|Saline|The saline arm will receive normal saline through the catheter as a placebo.
9788954|NCT01346059|Experimental|Vancomycin|The vancomycin arm will receive vancomycin solution through the catheter.
9788955|NCT01346072|Other|Tolvaptan|Single arm study
9788956|NCT01346085|Experimental|CNI-free single-group|
9788957|NCT01346176|Experimental|Positive default|Patients in this arm will receive AD forms where specific life-extending interventions will be provided unless patients specifically opt-out from such selections
9788958|NCT01346176|Experimental|Negative default|Patients in this arm will receive AD forms where specific life-extending interventions will not be provided unless patients specifically opt-into such selections
9788959|NCT01346176|Experimental|Forced Choice|Patients in this arm will receive AD forms in which they must actively choose whether to receive each intervention.
9788960|NCT01346189|Active Comparator|Physician Incentives|"(with adherence feedback)~Quarterly payments to physician combined based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL with daily patient statin adherence information made available."
9788961|NCT01346189|Active Comparator|Patient Incentives|"(with adherence feedback)~Quarterly payments to patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL."
9788962|NCT01346189|Active Comparator|Physician and Patient Combined Incentives|"(with adherence feedback)~Quarterly payments shared evenly by physician and patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL. Physicians will receive daily information about patients' statin adherence."
9788963|NCT01346189|No Intervention|Usual Care|
9788964|NCT01346267|Experimental|Arm I- Real Acupressure bands|Patients wear Sea-Band acupressure wristbands on each wrist beginning approximately 30 minutes prior to the first cisplatin-containing chemotherapy course and continually for 24 hours after the last chemotherapy dose (acute phase), and for a maximum of 7 days or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients also receive standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.
9788965|NCT01346267|Sham Comparator|Arm II- Placebo Acupressure Bands|Patients wear placebo wristbands on each wrist and receive standard of care anti-emetic prophylaxis during chemotherapy as patients in arm I.
9788966|NCT01346293|Experimental|Study Group 1|Participants will receive concomitantly a dose of DTap-IPV, a dose of M-M-R®II, and a dose of VARIVAX® vaccine on Day 0
9788967|NCT01346293|Experimental|Study Group 2|Participants will receive concomitantly a dose of DAPTACEL®, a dose of IPOL®, a dose of M-M-R®II, and a dose of VARIVAX® vaccines on Day 0
9788968|NCT01346293|Experimental|Study Group 3|Participants will receive concomitantly a dose of DTap-IPV with or without a dose of M-M-R®II and a dose of VARIVAX® on Day 0
9788969|NCT01346293|Experimental|Study Group 4|Participants will receive concomitantly a dose of DAPTACEL® vaccine, a dose of IPOL® vaccine with or without a dose of M-M-R®II and a dose of VARIVAX® vaccines on Day 0
9788970|NCT01346371|Placebo Comparator|Refresh Tears® eye drops|Must add drops twice a day every day during trial enrollment.
9788971|NCT01346371|Experimental|Bepreve® 1.5% solution|Must add drops twice a day every day while enrolled in trial.
9788972|NCT01346397||cyclosporine group|cyclosporine group - after alemtuzumab induction cyclosporine was administered
9788973|NCT01346397||tacrolimus group|tacrolimus group - after alemtuzumab induction tacrolimus was administered
9788974|NCT01346410|Experimental|A|Stereotactic Radiation to Pancreas
9788975|NCT01346475|Active Comparator|valacyclovir|
9788976|NCT01346475|Experimental|high dose valacyclovir|
9788977|NCT01346488||Adalimumab|Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).
9788978|NCT01346501||Adalimumab|"Participants with Rheumatoid Arthritis (RA) who continued adalimumab treatment after completion of study M06-859, participated in the observational period of studies P12-069 and P12-707.~Other name for adalimumab is Humira."
9788979|NCT01346501||Non-adalimumab|Patients who discontinued adalimumab treatment after completion of the study M06-859.
9788980|NCT01346514|Experimental|Arm 1: Addiction/Housing Case Management(AHCM)|The AHCM condition provided individual case management, delivered at the VA and in the community, designed to assist homeless Veterans with SUD issues who may be unable to take advantage of housing opportunities available in the VA due to difficulty navigating multiple services and maintaining stability with respect to SUD and co-occurring mental health conditions.
9788981|NCT01346514|Active Comparator|Arm 2: Housing Support Group(HSG)|The HSG condition involved a weekly drop-in housing support group.
9788982|NCT01346540|Experimental|BIBF 1120|VEGF inhibitor
9788983|NCT01346540|Placebo Comparator|Placebo|BIBF 1120 placebo
9788984|NCT01346592|Active Comparator|aTIV (6 to <72 months)|Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
9788985|NCT01346592|Active Comparator|Comparator TIV (6 to <72 months)|Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
9788986|NCT01346592|Active Comparator|TIV (6 to <72 months)|Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
9788987|NCT01346683|Experimental|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
9788988|NCT01346696|Experimental|OsseoSpeed™ TX implants|OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.
9788989|NCT01346774|Experimental|Cranberry powder capsules|"TheraCran® cranberry: based upon proanthocyanidin content, the four cranberry capsules are equivalent to two 8-ounce servings of cranberry juice.~Participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food."
9788990|NCT01346774|Placebo Comparator|Placebo capsules|Placebo: participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.
9788991|NCT01346839|Experimental|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
9799411|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.
9799412|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.
9799413|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.
9788992|NCT01346839|No Intervention|Usual Care Control|"The usual care at MEDVAMC consists of providers using an advanced EHR and its notification system (the View Alert system) that immediately alerts providers about clinically significant events. The system relies primarily on computerized notification (alerts) displayed prominently through a View Alert window that is displayed in the EHR every time a provider signs on or switches between patient records. The system does not require providers to read alerts, and providers do have an option of ignoring the View Alert window to bypass it. At SWHS there is a navigation program for patients who have received a cancer diagnosis by tissue biopsy. However, currently there is no routine tracking of patients if they do not show for their scheduled appointments and tests at SWHS."
9788993|NCT01346852||Pediatric participants|Pediatric participants (age 4 to 17) with a diagnosis of asthma
9788994|NCT01346852||Adult participants|Adult participants (age 18 and older) with a diagnosis of asthma
9788995|NCT01346969|Active Comparator|Group 1|
9788996|NCT01346969|Placebo Comparator|Group 2|
9788997|NCT01346969|Placebo Comparator|Group 3|
9788998|NCT01346969|Placebo Comparator|Group 4|
9788999|NCT01347008|Active Comparator|Sildenafil citrate|Oral Sildenafil citrate, 50mg, b.i.d.
9789000|NCT01347008|Placebo Comparator|Sugar pill|Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.
9789001|NCT01347034|Active Comparator|External Beam Radiation Therapy (RT)|Arm A - University of Florida - External Beam Radiation Therapy (RT) - As outlined in Intervention Description
9789002|NCT01347034|Experimental|External Beam RT + DC Injection|Arm B - Moffitt Cancer Center - External Beam RT + Autologous Dendritic Cells (DC) Injection - As outlined in Intervention Description
9789003|NCT01347060||Medicare-eligible subjects with asthma|Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.
9789004|NCT01347073|Experimental|HPN-100|Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months
9789005|NCT01347086|Experimental|BI 207127 NA (low dose)|Single dose of BI 207127 NA
9789006|NCT01347086|Placebo Comparator|Matching placebo (low dose)|Single dose of matching placebo
9789007|NCT01347086|Experimental|BI 207127 NA (medium dose)|Single dose of BI 207127 NA
9789008|NCT01347086|Placebo Comparator|Matching placebo (medium dose)|Single dose of matching placebo
9789009|NCT01347086|Experimental|BI 207127 NA (high dose)|Single dose of BI 207127 NA
9789010|NCT01347086|Placebo Comparator|Matching placebo (high dose)|Single dose of matching placebo
9789011|NCT01347112|Active Comparator|Varenicline|varenicline 1.0 mg twice daily for 12 weeks
9789012|NCT01347112|Placebo Comparator|Sugar Pil|Varenicline look alike sugar pill twice daily for 12 weeks
9789013|NCT01347255|Experimental|LEO 90100 cutaneous spray ointment|LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).
9789014|NCT01347255|Active Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone|Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
9789015|NCT01347255|Placebo Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle|LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.
9789016|NCT01347255|Active Comparator|Daivobet® Ointment|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
9789017|NCT01347307|Other|SBRT for Benign Extradural Spine Tumors|Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
9789018|NCT01347307|Other|SBRT for Vertebral/Paraspinal Metastases|Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
9789019|NCT01347333|Other|liver metastases|Oligometastases (1-3) with aggregate tumor diameter < 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
9789020|NCT01347333|Other|Primary Liver Tumors|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
9789021|NCT01347541|Experimental|Stepped care|Combination of behavioral therapy and drug therapy
9789022|NCT01347541|Active Comparator|Standard care provided to injured trauma survivors|
9789023|NCT01347554|Active Comparator|Xience V stent group|Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction
9789024|NCT01347554|Active Comparator|Endeavor resolute group|Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction
9789025|NCT01347580|Experimental|Ticagrelor|Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
9789026|NCT01347580|Experimental|Placebo|Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
10205960|NCT05079594|Experimental|Mother Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks. Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks. The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it. It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements.
9789027|NCT01347710|Experimental|Flurpiridaz F18|Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization
9789028|NCT01347762|Experimental|Nabilone|nabilone titrated to 2 mg daily
9789029|NCT01347762|Placebo Comparator|Placebo|Placebo
9789030|NCT01347788|Experimental|Cohort 1|Dose level 0: cabozantinib 40 mg daily
9789031|NCT01347788|Experimental|Cohort 2|Dose level -1: cabozantinib 20 mg daily
9789032|NCT01347788|Experimental|Expansion cohort|Dose level 0: cabozantinib 40 mg daily
9789033|NCT01347866|Experimental|Arm D: PF-05212384 + PD-0325901|
9789034|NCT01347866|Experimental|Arm C: PF-05212384 + irinotecan|
9789035|NCT01347879|Experimental|Visonac cream with PDT|active treatment with light dose of 37 Joule/cm2
9789036|NCT01347879|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 Joule/cm2
9789037|NCT01347931|Experimental|NIOV System|Noninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
10205961|NCT05072236|Placebo Comparator|normal saline|intravenous 5 mL normal saline 1 minute before bronchoscopic insertion
10205962|NCT05072236|Experimental|etomidate|intravenous etomidate 0.15 mg/kg 1 minute before bronchoscopic insertion
10205963|NCT05072236|Active Comparator|lidocaine|intravenous lidocaine 1.5 mg/kg 1 minute before bronchoscopic insertion
10205964|NCT05070169||Early Surgical Fixation|Prospective cohort of patients with intertrochanteric fractures with DOAC (direct oral anticoagulation) therapy undergoing early surgical fixation (within 24 hours).
10205965|NCT05070169||Delayed Surgical Fixation|Retrospective control group of patients with intertrochanteric fractures with DOAC medication who underwent delayed surgical fixation (≥48 hours) from January 2014 to December 2018.
10205966|NCT05067244|Experimental|MDMA assisted psychotherapy|Participants will undergo a 2-month course of CPT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered ini two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
9789038|NCT01347931|Active Comparator|Standard Oxygen Therapy|Supplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.
9789039|NCT01348087|Experimental|AFQ056 100 mg (Bid)|All patients initiated treatment with AFQ056 at a starting dose of 25 milligram (mg) twice daily. The dose was titrated from 25mg bid to 50mg bid, 75mg bid and 100mg bid at weekly intervals. Dose adjustments (up- and down titrations) were permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose not to exceed 100mg bid.
9789040|NCT01348100|Experimental|Iloperidone 50 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
9789041|NCT01348100|Experimental|Iloperidone 125 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
9799414|NCT01659255|Experimental|Tirabrutinib 400 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.
9984927|NCT03598608|Experimental|Part B: iNHL-Combination Therapy|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).
9837530|NCT04821115|Experimental|Low intensity choc waves therapy (Experimental group)|The patients will use the device with a real applicator.
9837531|NCT04821115|Sham Comparator|Sham group|The patients will use the device with a sham applicator. Instead of a focusing lens, the applicator will have an internal foam piece that will dissipate the energy of the shockwave. Hence, the sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted
9837532|NCT04820881||Case Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
9837533|NCT04820881||Control Group|Measurement of cerebrovascular reactivity and oxygen metabolism before and after a single dose of 50mg sildenafil citrate. Diffusion tensor imaging, other structural imaging and cognitive testing will also be completed.
9837534|NCT04817501||Breast cancer|At least eighty five subjects with breast cancer
9837535|NCT04817501||Ovarian cancer|At least 32 subjects with ovarian cancer
9837536|NCT04817501||Endometrial Cancer|At least 33 subjects with endometrial cancer
9837537|NCT04817501||Healthy control|30 healthy volunteers
9837538|NCT04817501||Suspected malignant tumor non-verified|Patients with suspected malignant tumor, which was not verified by biopsy. Nubmber of patients to be defined
9984928|NCT03598608|Experimental|Part B: cHL-Monotherapy|Participants with cHL receive the RP2D of favezelimab by IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to approximately 2 years).
9984929|NCT03592407|Experimental|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
9984930|NCT03589339|Experimental|NBTXR3 activated by SABR followed by anti-PD-1 monotherapy|Intratumoral injection of NBTXR3 followed by SABR followed by monotherapy with nivolumab or pembrolizumab
9984931|NCT03586895|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
9837543|NCT04814225|Experimental|Pea Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
9837544|NCT04814225|Experimental|Pea & Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
9837545|NCT04814225|Experimental|Oat Protein Powder|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
9837546|NCT04814225|Active Comparator|Whey Protein Isolate|Participants will be instructed to mix the IP with 250 mL room temperature water once/day for 12 weeks.
9837547|NCT04809883||observational study of gastric and pyloric motor function measured with Endoflip|observational study of gastric and pyloric motor function measured with Endoflip during fasting and postprandial periods There is NO intervention
9837548|NCT04809324|Experimental|Gross examination|measurement of the surgical margins will be done by the surgeon in the operating room using sterile scale after resection of the primary tumor .
9837549|NCT04809324|Active Comparator|Frozen section|frozen section examination of surgical margins will be done by the pathologist.
9984932|NCT03586258|Experimental|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
9837551|NCT04807205|Experimental|Elite IQ Laser|The Elite IQ will be used on multiple areas of the body such as, but not limited to, the face, legs, and arms.
9984933|NCT03586258|Sham Comparator|Healthy Volunteers|Healthy Controls
9837553|NCT04803786||Transition from Xyrem to Xywav|
9984934|NCT03584516|Experimental|Part 1 : Dose determination of itacitinib|itacitinib administered in combination with corticosteroids.
9837556|NCT04800263|Experimental|SHR-1905 Dose Level 1|SHR-1905 Dose level 1
9837557|NCT04800263|Experimental|SHR-1905 Dose Level 2|SHR-1905 Dose level 2
9837558|NCT04800263|Experimental|SHR-1905 Dose Level 3|SHR-1905 Dose level 3
9837559|NCT04800263|Experimental|SHR-1905 Dose Level 4|SHR-1905 Dose level 4
9837560|NCT04800263|Experimental|SHR-1905 Dose Level 5|SHR-1905 Dose level 5
9789042|NCT01348100|Experimental|Iloperidone 250 mg crystalline formulation - Phase B|Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
9789043|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase B|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
9789044|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
9789045|NCT01348100|Experimental|Iloperidone 500 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
9789046|NCT01348100|Experimental|Iloperidone 625 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
9789047|NCT01348139|Experimental|1|AZD3199 800 µg inhaled via single inhaler device (SID), single dose
9789048|NCT01348139|Experimental|2|AZD3199 880 µg inhaled via SID, single dose
9789049|NCT01348139|Experimental|3|AZD3199 1400 µg inhaled via SID, single dose
9789050|NCT01348139|Experimental|4|AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose
9789051|NCT01348139|Experimental|5|AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose
9789052|NCT01348139|Placebo Comparator|6|Placebo inhaled via Turbuhaler inhaler and SID, single dose
9789053|NCT01348165|Experimental|BI 137882 Dose 1|Powder for oral solution
9789054|NCT01348165|Experimental|BI 137882 Dose 2|Powder for oral solution
9789055|NCT01348165|Experimental|BI 137882 Dose 3|Powder for oral solution
9789056|NCT01348165|Experimental|BI 137882 Dose 4|Powder for oral solution
9789057|NCT01348165|Experimental|BI 137882 Dose 5|Powder for oral solution
9789058|NCT01348165|Experimental|BI 137882 Dose 6|Powder for oral solution
9789059|NCT01348165|Experimental|BI 137882 Dose 7|Powder for oral solution
9789060|NCT01348165|Experimental|BI 137882 Dose 8|Powder for oral solution
9789061|NCT01348165|Experimental|BI 137882 Dose 9|Powder for oral solution
9789062|NCT01348165|Placebo Comparator|Placebo|Powder for oral solution
9789063|NCT01348347|Experimental|Volasertib|Patient to receive low, middle and high doses of Volasertib IV
9789064|NCT01348425|Experimental|Longer Stents|
9789065|NCT01348425|Experimental|Shorter Stents|
9789066|NCT01348490|Experimental|Ruxolitinib 5 mg|Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
9789067|NCT01348542|Active Comparator|Trazodone|
9789068|NCT01348542|Active Comparator|Cognitive Behavioral Therapy|
9789069|NCT01348607|Experimental|Arm I - methylphenidate hydrochloride|Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
9789070|NCT01348607|Experimental|Arm II -modafinil|Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
9789071|NCT01348607|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
9789072|NCT01348698||Adrenal Gland Neoplasm|To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells. Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor.
9789073|NCT01348763|Experimental|Truvada, Darunavir/r and Maraviroc|Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
9789074|NCT01348776|Experimental|Hair2Go (Mē)|Subjects treated with Hair2Go (Mē) Device
9789075|NCT01348789|Experimental|Hair2Go (Mē)|Treatment with Hair2Go (Mē)device
9799415|NCT01659255|Experimental|Tirabrutinib 500 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.
9799416|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.
9799417|NCT01659255|Experimental|Tirabrutinib 300 mg Twice Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.
9799418|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.
9799419|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.
9799420|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.
9799421|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.
9799422|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.
9799423|NCT01659255|Experimental|Tirabrutinib 480 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.
9799424|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.
9799425|NCT01659255|Experimental|Tirabrutinib 240 mg Twice Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.
9799426|NCT01659268|Experimental|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
9799427|NCT01659268|Other|Exhibition-dialogued class|Students will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, each subgroup composed of 4-5 students will go to the and practical activity in skill lab using the low-fidelity mannequin for 35 minutes.
9799428|NCT01659320|Experimental|Minocycline|Open label treatment using minocycline.
9799429|NCT01659567||Chronic Hepatitis C|Participants with chronic hepatitis C, treated with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) according to the current standard of care and in line with current summaries of product characteristics/local labelling, will be observed for up to 96 weeks.
9799430|NCT01659736|Experimental|TMS Therapy|TMS treatment
9799431|NCT01659736|Sham Comparator|TMS-Sham|This is a sham TMS condition
9799432|NCT01659853|Experimental|Overall Study|"In this crossover study of CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15%, 70 subjects were randomly assigned to treatment sequence.~During Period 1 (15 days), 35 subjects received topical CD07805/47 gel 0.5% in the morning and topical CD07805/47 gel vehicle in the evening, and 35 received topical azelaic acid gel twice daily according to FDA approved prescribing information. Subjects crossed over to the other treatment in Period 2 (15 days)."
9789076|NCT01348828|Other|Single Arm|All patients meet study criteria receives a single use Ventana Fenestrated System, which requires administration of intravascular contrast. Catheter advancement is performed under fluoroscopic guidance and Ventana Fenestrated System is placed.
9789077|NCT01348854|Experimental|Natural Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.
9789078|NCT01348854|Experimental|Post Cataract with Residual Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.
9789079|NCT01349036|Experimental|PLX3397-Cohort 1|10 patients with recurrent glioblastoma who require reoperation will be treated with PLX3397 for 7 days prior to surgery and their tumor tissue will be evaluated for pharmacokinetic levels and pharmacodynamic effects.
9789080|NCT01349036|Experimental|PLX3397-Cohort 2|30 patients will be orally dosed with PLX3397 continuously on 28 day cycles.
9789081|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397 (RP2D)|Subjects will be dosed at the recommended Phase 2 dose (RP2D)
9789082|NCT01349049|Experimental|oral dose of 800 mg/day of PLX3397|Level 0
9789083|NCT01349049|Experimental|oral dose of 1000 mg/day PLX3397|Level 1
9789084|NCT01349049|Experimental|oral dose of 1200 mg/day PLX3397|Level 2
9789085|NCT01349049|Experimental|oral dose of 1400 mg/day PLX3397|Level 3
9789086|NCT01349049|Experimental|oral dose of 2000 mg/day PLX3397|Level 4
10205967|NCT05063500|Experimental|Experimental group|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
10205968|NCT05063500|Active Comparator|Control group|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
10205969|NCT05062655|Experimental|Drug reconciliation|Drug reconciliation and transmission to pharmacist
10205970|NCT05062655|No Intervention|standard|
10205971|NCT05060172|Experimental|Bloomlife MFM-Pro|
9789087|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397|Level 5
9789088|NCT01349049|Experimental|oral dose of 4000 mg/day PLX3397|Level 6
9789089|NCT01349049|Experimental|oral dose of 5000 mg/day PLX3397|Level 7
9789090|NCT01349114|Active Comparator|aliskiren 300 mg once daily for 12 weeks|aliskiren 300 mg daily
9789091|NCT01349114|Placebo Comparator|Sugar pill/ placebo|Patients were double-blind placebo-controlled randomized to either aliskiren 300 mg once daily or sugar pill/ placebo
9789092|NCT01349140|Experimental|Nerve Block|The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.
9789093|NCT01349192|Experimental|Treatment|Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.
9789094|NCT01349192|No Intervention|Observational|Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
9789095|NCT01349231|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of ketamine.
10205972|NCT05056350|Other|Assessment of the feasibility and impact of a back-to-work support program|questionnaires, back to work coaching
10205973|NCT05050981||HT|Women using hormone replacement therapy (estrogen only or oestrogen and progestin) for treating climacteric symptoms.
10205974|NCT05050981||SSRI|Women using selective serotonin reuptake inhibitors for treating climacteric symptoms.
9789096|NCT01349465|Other|Group 1: TMC 435 - Patients With SVR at LPVPS|Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
9789097|NCT01349465|Other|Group 2: TMC 435 - Patients With No SVR at LPVPS|Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
9789098|NCT01349491|Experimental|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
9789099|NCT01349491|Placebo Comparator|Placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.
9789100|NCT01349569|Experimental|Myeloma Vaccine, Prevnar, & Lenalidomide|Lenalidomide will be continued on the same dose as was being administered prior to the study. The allogeneic myeloma vaccine and Prevnar-13 vaccine will be given on four days over the course of the study.
10205975|NCT05050981||Control group|Women not using hormone replacement therapy or selective serotonin reuptake inhibitors
10205976|NCT05047692|Experimental|Group 1: Low dose|The subject will receive a single dose of AdCLD-CoV19-1(5.0x10^10VP) as an intramuscular injection.
10205977|NCT05047692|Experimental|Group 2: High dose|The subject will receive a single dose of AdCLD-CoV19-1(1.0x10^11VP) as an intramuscular injection.
10205978|NCT05043311|Experimental|Experimental: 20 µg dose, 18-59 years of age (phase 1/2)|
10205979|NCT05043311|Experimental|Experimental: 20 µg dose, ≥60 years of age (phase 1/2)|
10205980|NCT05043311|Experimental|Experimental: 40 µg dose, 18-59 years of age (phase 1/2)|
10205981|NCT05043311|Experimental|Experimental: 40 µg dose, ≥60 years of age (phase 1/2)|
10205982|NCT05043311|Placebo Comparator|Placebo Comparator: Placebo, 18-59 years of age (phase 1/2)|
10205983|NCT05043311|Placebo Comparator|Placebo Comparator: Placebo, ≥60 years of age (phase 1/2)|
10205984|NCT05043285|Experimental|20 µg dose, 18-59 years of age (phase 1/2)|
9984935|NCT03584516|Experimental|Part 1 : Dose expansion of itacitinib|itacitinib administered in combination with corticosteroids or corticosteroids alone.
9984936|NCT03584516|Placebo Comparator|Part 2 : itacitinib recommended dose from part 1|itacitinib or placebo administered in combination with corticosteroids
9837565|NCT04799275|Experimental|Arm I (oral azacitidine, R-miniCHOP)|Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486 PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity.
9837566|NCT04799275|Active Comparator|Arm II (R-miniCHOP)|Patients receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9984937|NCT03584477|Active Comparator|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
9984938|NCT03584477|Active Comparator|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
9837569|NCT04797650|Experimental|CTP-543, 8 mg BID|Oral tablet for 24 weeks
9837570|NCT04797650|Experimental|CTP-543, 12 mg BID|Oral tablet for 24 weeks
9837571|NCT04797650|Placebo Comparator|Placebo, BID|Oral tablet for 24 weeks
9837572|NCT04797429|Experimental|intervention group|The intervention group will receive antidiabetic therapy according to the current guidelines but with the additional opportunity to use the peer support IMS tool. Peer support and moderation of the intervention group will be provided by moderators. Moderators will be supervised by a dietitian.
9837573|NCT04797429|Active Comparator|control group|The control group receives the antidiabetic therapy according to the current guidelines, but without having access to the IMS tool. This means that participants receive medical treatment by their practitioner according to the Austrian recommendations.
9837574|NCT04795622|Experimental|Treatment Ulthera System|
9837575|NCT04795622|Other|Delayed-treatment Ulthera System|
10205985|NCT05043285|Experimental|20 µg dose, ≥60 years of age (phase 1/2)|
9837577|NCT04794491|Experimental|Open-Label Conversion and Treatment Optimization|Conversion from Xyrem to XYWAV, maintaining the dose and regimen of any concomitant anticataplectics or stimulants unchanged throughout study.
9837578|NCT04792021|Active Comparator|N-acetylcysteine (NAC)|Patients receiving N-acetylcysteine (NAC)
9837579|NCT04792021|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
9837580|NCT04790864|Experimental|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|
9837581|NCT04790864|Active Comparator|Online large-group one-session treatment with post-treatment control exercise|
9837582|NCT04787939|Experimental|Early Feeding Arm|Early Feeding Group
10205986|NCT05043285|Experimental|40 µg dose, 18-59 years of age (phase 1/2)|
10205987|NCT05043285|Experimental|40 µg dose, ≥60 years of age (phase 1/2)|
10205988|NCT05043285|Placebo Comparator|Placebo, 18-55 years of age (phase 1/2)|
9789101|NCT01349660|Experimental|BKM120/Bevacizumab|"Phase I:~BKM 120 orally (PO) once daily (dose is 60mg or 80mg). Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks~Phase II:~BKM 120 orally (PO) once daily - dose is optimal dose determined in Phase I. Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks"
9789102|NCT01349673|Experimental|Budesonide Foam|Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
9789103|NCT01349790|Experimental|NewGam|Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
9789104|NCT01349803|Experimental|PT005 MDI|PT005 MDI
9789105|NCT01349803|Experimental|PT001 MDI|PT001 MDI
9789106|NCT01349803|Experimental|PT003 MDI|PT003 MDI
9789107|NCT01349803|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
9789108|NCT01349816|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
9789109|NCT01349816|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
9789110|NCT01349816|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
9789111|NCT01349816|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
9789112|NCT01349816|Experimental|PT001|PT001 MDI
9789113|NCT01349816|Experimental|PT005|PT005 MDI
9789114|NCT01349829|Experimental|HAVpur|
9789115|NCT01349829|Active Comparator|Havrix|
9789116|NCT01349920||Infliximab 5 mg/kg|Infliximab treatment and endoscopy.
9789117|NCT01349933|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive 200 mg Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9789118|NCT01349972|Experimental|Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride)|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
9789119|NCT01349972|Active Comparator|Arm II (cytarabine, daunorubicin hydrochloride)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
9789120|NCT01350102|Active Comparator|Bacitracin wound care dressing alone|Bacitracin wound care dressing alone
10205989|NCT05043285|Placebo Comparator|Placebo, ≥60 years of age (phase 1/2)|
10205990|NCT05042115|Experimental|Education in pain neurosciences and clinical hypnosis|Pain neuroscience education and clinical hypnosis
9789121|NCT01350102|Active Comparator|Bacitracin with Vit C|Bacitracin wound care dressing with Vitamin C supplementation
9789122|NCT01350102|Active Comparator|AmeriGel® wound care dressing alone|AmeriGel® wound care dressing alone
9789123|NCT01350102|Active Comparator|AmeriGel® with Vit C|AmeriGel® wound care dressing with Vitamin C supplementation
9789124|NCT01350115|Active Comparator|LDE225|Participants received 400 mg once daily.
9789125|NCT01350115|Placebo Comparator|Placebo|Participants received matching placebo.
9789126|NCT01350128|Experimental|PT001 MDI (Dose 1)|PT001 MDI
9789127|NCT01350128|Experimental|PT001 MDI (Dose 2)|PT001 MDI
9789128|NCT01350128|Experimental|PT001 MDI (Dose 3)|PT001 MDI
9789129|NCT01350128|Experimental|PT001 MDI (Dose 4)|PT001 MDI
9789130|NCT01350128|Active Comparator|Ipratropium Bromide HFA Inhalation Aerosol|Ipratropium Bromide HFA Inhalation Aerosol
9789131|NCT01350128|Placebo Comparator|Placebo MDI|PT001 Placebo MDI
9789132|NCT01350141|Placebo Comparator|Treatment A|
9789133|NCT01350141|Experimental|Treatment B|
9789134|NCT01350141|Experimental|Treatment C|
9789135|NCT01350245|Experimental|TJU 2 Step Regimen|All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.
9789136|NCT01350271|Placebo Comparator|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
9789137|NCT01350271|Active Comparator|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
9789138|NCT01350271|Experimental|Mebendazole polymorph C 500 mg|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
9789139|NCT01350336|Experimental|Alair|Alair system
9789140|NCT01350388|Active Comparator|Febuxostat|80 mg/day of febuxostat for 24 weeks
9789141|NCT01350388|Placebo Comparator|Placebo|1 placebo tablet per day for 24 weeks
9789142|NCT01350401|Experimental|NY-ESO-1/LAGE-1 and HLA-A*02 Positive Subjects|
9789143|NCT01350414||Alair Group|Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)
9789144|NCT01350453|Experimental|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
9789145|NCT01350453|Active Comparator|Standard Care|Participants received their usual care which included home exercises
9789146|NCT01350479||MRSA colonized|Residents with history of MRSA in the past year
9789147|NCT01350479||Not MRSA colonized|Residents without history of MRSA in the past year
9789148|NCT01350492|Experimental|Arm 1|Resistance exercise training
9789149|NCT01350492|No Intervention|Arm 2|Waitlist Control
9789150|NCT01350505|Experimental|All subjects|13 minutes of light at night (2 hours after bedtime)
9789151|NCT01350544|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
9799433|NCT01659866|Other|Cipro-susceptible|Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
9800438|NCT01687413|Active Comparator|Radiotherapy, cisplatin|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)~Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
9800439|NCT01687478|Experimental|Olanzapine + Fluoxetine|"Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
9800440|NCT01687478|Placebo Comparator|Placebo + Fluoxetine|"Placebo matches the Olanzapine tablet for blinding.~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
9800441|NCT01687595|Experimental|HerpV 240 μg + QS-21 50 μg|Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1. At Week 24, participants who completed treatment period 1 will receive a booster dose of combination of HerpV 240 μg and QS-21 50 μg in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
9800442|NCT01687595|Placebo Comparator|Placebo|Participants will receive a placebo injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1 and at Week 24 in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
9800443|NCT01687673|Experimental|Treatment|Combination temsirolimus plus sorafenib
9800444|NCT01687712|Experimental|AFOLIA|One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
9800445|NCT01687712|Active Comparator|Gonal-f® RFF|One subcutaneous injection of 225IU Gonal-f® RFF (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
9800446|NCT01687790|Experimental|molecular breast imaging|
9800447|NCT01687972|Active Comparator|Sutures|
9800448|NCT01687972|Active Comparator|Insorb Staples|
9800449|NCT01687998|Experimental|Evacetrapib|Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
9800450|NCT01687998|Placebo Comparator|Placebo|Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
9800451|NCT01688037|Experimental|NBI-98854 50 mg|NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
9800452|NCT01688037|Experimental|NBI-98854 100 mg and 50 mg|NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
9800453|NCT01688037|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
9789152|NCT01350544|Experimental|treatment advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.
9789153|NCT01350804|Experimental|AIN457 10mg/kg - 75 mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
9789154|NCT01350804|Experimental|AIN457 10mg/kg - 150 mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
9789155|NCT01350804|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
9789156|NCT01350804|Active Comparator|Abatacept|Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).
9789157|NCT01350947|Experimental|All patients|All participants enrolled.
9789158|NCT01350973|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 12 weeks.
9789159|NCT01350973|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 12 weeks.
9789160|NCT01350973|Experimental|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.
9789161|NCT01350999|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 52 weeks.
9789162|NCT01350999|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 52 weeks.
9789163|NCT01350999|Active Comparator|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.
9789164|NCT01351025|Experimental|Arm A: atorvastatin / placebo|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated atorvastatin at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at the week 4 visit. At week 20, atorvastatin was stopped for a 4-week washout period.~At week 24, placebo was started for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the placebo dose was doubled at week 28. At week 44, the placebo was stopped to allow for another 4-week washout period."
9789165|NCT01351025|Experimental|Arm B: placebo / atorvastatin|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated placebo for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the dose of placebo was doubled at the week 4 visit. At week 20, the placebo was stopped for a 4-week washout period.~At week 24, atorvastatin was started at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at week 28. At week 44, atorvastatin was stopped to allow for another 4-week washout period."
9789166|NCT01351064|Experimental|CHICA ADHD Module|This arm received The CHICA ADHD Module
9789167|NCT01351064|No Intervention|CHICA ADHD Control|This arm received CHICA without the ADHD module
9789168|NCT01351077|Experimental|CHICA DevScreen Module|This arm will get the CHICA Developmental Screening Module
9789169|NCT01351077|No Intervention|CHICA DevScreen Control|This arm will get CHICA without the developmental screening module
9789170|NCT01351090|Experimental|Ketorolac tromethamine (5%)|
9789171|NCT01351090|Experimental|Ketorolac tromethamine (15%)|
9789172|NCT01351090|Placebo Comparator|Placebo|
9789173|NCT01351337|Other|intraoperative functional monitoring|intraoperative functional monitoring
9789174|NCT01351350|Experimental|MLN0128P 30 mg QW|MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9789175|NCT01351350|Experimental|MLN0128P 40 mg QW|MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9789176|NCT01351350|Experimental|MLN0128P 6 mg QD×3d QW|MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9800454|NCT01688050|Experimental|Endovascular Repair|
9837583|NCT04785989|Active Comparator|Group A: Healthy volunteers|Healthy volunteers are defined as people without a history of cancer
9837584|NCT04785989|Experimental|Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
9837585|NCT04785989|Experimental|Group B subset-2: Treatment naïve CLL patients with low disease burden|Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.
9837586|NCT04785989|Experimental|Group C:Treatment naïve CLL patients with high systemic disease burden|Treatment naïve CLL patients with high systemic disease burden
9837587|NCT04784533|Experimental|Part A, Period 1 - Low dose|8 mg BID CTP-543 for 24 weeks
9837588|NCT04784533|Experimental|Part A, Period 1 - High dose|12 mg BID CTP-543 for 24 weeks
9837589|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from low dose|Dose reduction for a maximum of 24 weeks for those previously receiving 8 mg BID
9837590|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from low dose|Placebo for a maximum of 24 weeks for those previously receiving 8 mg BID
9837591|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from high dose|Dose reduction for a maximum of 24 weeks for those previously receiving 12 mg BID
9837592|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from high dose|Placebo for a maximum of 24 weeks for those previously receiving 12 mg BID
9837593|NCT04784533|Experimental|Part B - Low dose|8 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
9837594|NCT04784533|Experimental|Part B - High dose|12 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
9837595|NCT04782856|Active Comparator|Single therapy|"Levothyroxine (LT4) and placebo (a look-alike inactive substance, a sugar pill) Patients in the LT4 group will be started at a dose of 1.6 mcg/Kg (52 The VCU Investigational Pharmacy will over-encapsulate LT4 plus placebo, in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation."
9837596|NCT04782856|Experimental|Combination therapy|"Liothyronine/levothyroxine (LT3/LT4) combination therapy. LT4/LT3 group will have 25 mcg of LT4 substituted with 5 mcg LT3 twice daily, to mimic the average daily T3 production form the thyroid The VCU Investigational Pharmacy will over-encapsulate LT4 plus 5 mcg LT3 in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation. No changes will be made in LT3."
9837597|NCT04781387|Experimental|CRS3123 200 milligram|"CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
9837598|NCT04781387|Experimental|CRS3123 400 milligram|"CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.~Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm."
9837599|NCT04781387|Active Comparator|Vancomycin 125 milligram|Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.
10205991|NCT05042115|Active Comparator|Education in pain neurosciences and clinical hypnosis plus Osteopathic manipulative treatment|Pain neuroscience education and clinical hypnosis, associated with osteopathic manipulative treatment
10205992|NCT05040295|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single 30 milligrams (mg) ritlecitinib intact adult capsule during the first period, three 10 mg ritlecitinib pediatric capsules during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
10205993|NCT05040295|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive three 10 mg ritlecitinib pediatric capsules during the first period, a single 30 mg intact adult capsule during the second period and 30 mg ritlecitinib spray congealed beads in the third period.
10205994|NCT05038124|Experimental|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction. Active sparing of the intended surgical approach will be incorporated into the radiation plan by creating an avoidance structure. Surgical stabilization will proceed within 1 week of completion of radiotherapy. Pathologic specimens will be obtained intraoperatively via existing surgical access for histologic and molecular analysis. An optional research MRI with perfusion will be performed within 30 days prior to radiation simulation and within one-week after radiation therapy using 3T scanner. If patients receive radiation simulation at a non-MSK Manhattan site, MRI with Perfusion will not be performed.
10205995|NCT05037942|Experimental|Blood flow-restricted exercise at 40% limb occlusion pressure (BFR-40)|Participants in BFR-40 will perform a lower-body exercise protocol under BFR set to 40% of the participants' relative limb occlusion pressure.
10205996|NCT05037942|Experimental|Blood flow-restricted exercise at 80% limb occlusion pressure (BFR-80)|Participants in BFR-80 will perform the same lower-body BFR exercise protocol as BFR-40; however, the occlusion pressure will be set to 80% of the participants' relative limb occlusion pressure.
10205997|NCT05037942|No Intervention|Control for BFR-40|Participants randomised to BFR-40 will perform the same exercise protocol without BFR with the contralateral leg.
10205998|NCT05037942|No Intervention|Control for BFR-80|Participants randomised to BFR-80 will perform the same exercise protocol without BFR with the contralateral leg.
9984939|NCT03584477|Active Comparator|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
9837603|NCT04779879|Active Comparator|Sotrovimab (Gen1)|Part A (double-blinded) participants will be randomized to receive 500 mg of an IV infusion of Sotrovimab Gen 1 material or 500 mg of an IV infusion of VIR-7831 Gen 2 material
9837604|NCT04779879|Active Comparator|Sotrovimab (Gen2)|"Part B (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or by IM injection~Part C (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or 250 mg by IM injection"
9837605|NCT04776980|Experimental|Ferumoxytol Infused MRI|Ferumoxytol is an iron replacement product that is FDA approved to treat iron deficiency anemia in patients with chronic kidney disease (CKD). In this study, ferumoxytol is used to quantify tumor-associated macrophages. The infused dose would be 5mg/kg.
9837606|NCT04776213|Experimental|Mavenclad®|
9837607|NCT04774536|Experimental|CRISPR_SCD001 Drug Product|CRISPR_SCD001 Drug Product (autologous CD34+ cell-enriched population that contains cells modified by the CRISPR-Cas9 ribonucleoprotein) dose will be ≥3.0×106 CD34+ cells/kg recipient weight for each subject and the upper limit cell dose is 20 ×106 CD34+ cells/kg.
9984940|NCT03580616|Experimental|L-Serine|L-Serine 15 grams orally twice a day as tolerated for 6 months
9837609|NCT04773522|Experimental|Talquetamab|Participants will receive talquetamab injection subcutaneously (SC) in 3 cohorts: Cohort 1 and Cohort 2 as 2 step-up doses and Cohort 3 as 3 step-up doses followed by a treatment dose.
9837611|NCT04771299|Active Comparator|Cariprazine|1.5mg of Cariprazine added to their current treatment for 6 week period
9837612|NCT04771299|Placebo Comparator|Placebo|Matching placebo added to their current treatment for 6 week period.
9837613|NCT04770909|Experimental|Combined|Weekly incentives for dietary self-monitoring and weight loss
9837614|NCT04770909|Experimental|Dietary self-monitoring|Weekly incentives for dietary self-monitoring
9837615|NCT04770909|Experimental|Weight loss|Weekly incentives for weight loss
9837616|NCT04770909|No Intervention|Control|
9837617|NCT04766918|Experimental|High molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with high molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
9837618|NCT04766918|Active Comparator|Low molecular weight hyaluronic acid|Ultrasound-guided hydrodissection with low molecular weight hyaluronic acid between carpal tunnel and median nerve (total 2 times with one-week interval)
9837619|NCT04763226|Experimental|Part A Furosemide|
9837620|NCT04763226|Experimental|Part B (SAD)|Single Ascending Dose (SAD)
9837621|NCT04762758|Experimental|PXT3003|Liquid oral solution, 10 mL twice a day, morning and evening with food
9837622|NCT04762758|Placebo Comparator|Placebo|Liquid oral solution, 10 mL twice a day, morning and evening with food
9837623|NCT04757675|Experimental|0.3 SK iv|0.3 μg/kg intravenous injection s-ketamin
9837624|NCT04757675|Experimental|0.5 SK iv|0.5 μg/kg intravenous injection s-ketamin
9837625|NCT04757675|Experimental|2 SK in|2 μg/kg intranasal s-ketamin
9837626|NCT04757675|Experimental|1 SK in + 1 DEX in|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
9837627|NCT04757675|Experimental|0.5 SK in + 2 DEX in|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
9837628|NCT04757246|Other|Cohort 1|Stable outpatients without implantable devices
9837629|NCT04757246|Other|Cohort 2|Stable outpatients with Boston Scientific pacemakers or defibrillators with Heart Logic capability
9837630|NCT04757246|Other|Cohort 3|Stable outpatients with implantable CardioMEMS devices
9837631|NCT04755712|Experimental|ropivacaine in quadratum lumburum block 2|Ropivacaine will be administrated in perineural in quadratum lumburum block 2 after the caesarian.
9837632|NCT04755712|Active Comparator|Intrathecal morphine|Morphine will be administrated in intrathecal
9984941|NCT03580317|Experimental|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
9837634|NCT04753931|Experimental|Sensory Training in addition to Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
9837635|NCT04753931|Experimental|Bobath Training|Exercises will be applied to the individuals participating in the study 3 days a week, 8 weeks, and 24 sessions in total. Exercises will be applied after the conventional therapy sessions.
9837636|NCT04752475|Experimental|Lasix (furosemide)|Furosemide 20 mg, oral, once daily for 5 days
9837637|NCT04752475|Placebo Comparator|Placebo|Identical-appearing placebo, oral, once daily for 5 days
9837638|NCT04751812|Active Comparator|High-pain standard|Patients grading pain associated with venous cannulation >=2.0 allocated to standard treatment.
9837639|NCT04751812|Experimental|High-pain extra|Patients grading pain associated with venous cannulation >2.0 allocated to extra treatment.
9837640|NCT04751812|Active Comparator|Low-pain standard|Patients grading pain associated with venous cannulation to <2.0 allocated to standard treatment.
9837641|NCT04751812|Experimental|Low-pain opioid-free|Patient grading pain associated with venous cannualation to <2.0 allocated to opioid-free anesthesia.
10205999|NCT05033054|Placebo Comparator|Group 1: Placebo EffCaMgCitrate + Placebo Dapagliflozin|Group 1 will receive a Placebo form the Effervescent CaMgCitrate and a Placebo form of the Dapagliflozin twice a day.
10206000|NCT05033054|Experimental|Group 2: EffCaMgCitrate + Placebo Dapagliflozin|Group 2 will receive the medication EffCalMgcitrate 480mg (total dosage per day) and Placebo Dapagliflozin twice a day.
10206001|NCT05033054|Experimental|Group 3: Dapagliflozin + Placebo EffCaMgCitrate|Group 3 will receive the medication Dapagliflozin10mg (total dosage per day) and Placebo Effervescent CaMgCitrate twice a day.
10206002|NCT05031949|Experimental|Hyperbaric oxygen therapy plus Camrelizumab|Subjects receive Camrelizumab intravenous at the dose 3mg/kg on Day 1 every 3 weeks, and breath pressurized (0.25 MPa) 100% oxygen (O2) indirectly by a head hood or mask for 60 minutes in multiplace chambers at Day 1 of every week.
9837646|NCT04749615|Placebo Comparator|No PAI + ACB & IPACK|Control: saline injection (same injection technique and volumes as described for the active intervention, of normal saline)
9837647|NCT04749615|Active Comparator|PAI + ACB & IPACK|Active intervention: Periarticular injection: one deep injection prior to cementation and then a second more superficial injection prior to closure. The deep injection will consist of bupivacaine 0.25% with 1:200,000 epinephrine, 30 cc; morphine, 8 mg/ml, 1cc; methylprednisolone, 40 mg/ml, 1 ml; cefazolin, 500 in 10 ml; normal saline, 22cc. The superficial injection will be 20 ml 0.25% bupivacaine
9837648|NCT04748601|Placebo Comparator|Placebo|
9837649|NCT04748601|Experimental|Qudexy XR|
9837650|NCT04747431|Experimental|Cohort 1|"Drug: PBFT02 Dose 1: 3.3 x 10^10 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
9837651|NCT04747431|Experimental|Cohort 2|"Drug: PBFT02 Dose 2: 1.1 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
10206003|NCT05029154|Experimental|Exercise|Patients in the exercise group will perform interval training 3 days per week.
10206004|NCT05029154|Placebo Comparator|Attention Control|Physical activity education and physical activity monitoring.
10206005|NCT05028517|Experimental|FMF Connect Intervention + Coaching|Participants receive the FMF Connect mobile health app plus text-based coaching to support continued use of the app and individualized goal setting.
10206006|NCT05028517|Experimental|FMF Connect Intervention (no coaching)|Participants receive the FMF Connect mobile health app. They do not receive coaching.
10206007|NCT05028517|No Intervention|Waitlist comparison group|Participants receive the FMF Connect mobile health app at the conclusion of the study.
10206008|NCT05017415|Experimental|Standard toilet chair (hip angle 90°)|uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.
10206009|NCT05017415|Experimental|Toilet chair with decreased hip angle|uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.
10206010|NCT05017246|Active Comparator|Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA)|"Standard of care at Washington University School of Medicine/Barnes-Jewish Hospital~Day of surgery: preoperative tylenol, gabapentin, celebrex, and epidural dosing per standard protocol.~Intraoperative: dexamethasone and epidural bupivacaine~Day of surgery postoperative: hydromorphone PCA, toradol, ibuprofen, tylenol, epidural bupivacaine~Postoperative: hydromorphone PCA, ibuprofen, oxycodone"
10206011|NCT05017246|Experimental|Intrathecal morphine with intraoperative lidocaine infusion|"Day or surgery: tylenol, gabapentin, celebrex, and preoperative intrathecal morphine one time injection (150mcg)~Intraoperative: dexamethasone and lidocaine infusion 1 mg/kg ideal body weight~Day of surgery postoperative: toradol, ibuprofen, tylenol~Postoperative: ibuprofen, oxycodone, and hydromorphone prn"
10206012|NCT05014542|Experimental|Acupuncture Group|Participants in Acupuncture group will get acupuncture treatments to their symptomatic knee/knees according to the study protocol. Acupuncture will be provided to participants in three cycles, each three weeks duration, with frequency three times weekly. Period between the cycles is three weeks long. Participants will get acupuncture as adjunctive therapy to conventional medical treatment (analgesic therapy) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
10206013|NCT05014542|Active Comparator|Control Group|Participants in Control group will get their standard conventional treatment (analgesics) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
9837652|NCT04747431|Experimental|Optional Cohort 3|"Drug: PBFT02 Dose 3: 2.2 x 10^11 GC/g* Single dose of PBFT02, via intra cisterna magna~*GC/g: gene copy per gram of estimated brain weight"
9837653|NCT04746911|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 4 weeks
9837654|NCT04746833|Experimental|SUMMIT|Participants randomized to the experimental intervention will participate in a Motivational Interviewing (MI) session lasting between 30 and 60 minutes with study psychologist. All MI sessions will be audiotaped using a VA-approved digital recorder and transcribed verbatim. Participants will subsequently be shown how to access SUMMIT via a set of unique anonymized login credentials and to navigate the components of SUMMIT on one or more devices, depending on their preference. They will then be trained on how to complete the outcome surveys.
9837655|NCT04746833|Placebo Comparator|control|Participants randomized to the control intervention will use an eHealth comparator: My Pain Diary: Chronic Pain Management (iPhone, Android). This app includes a pain monitoring functioning only, and thus will only minimally overlap, if at all, with SUMMIT's components. Control participants will not participate in a MI session. Participants will download the app and be shown how to use the My Pain Diary app and trained how to complete the outcome surveys
9837656|NCT04746638|Experimental|Prostate cancer|At least five (5) evaluable subjects with prostate cancer.
9837657|NCT04746638|Experimental|Breast cancer|At least five (5) evaluable subjects breast cancer.
9837658|NCT04746274|Experimental|Online large-group one-session multicomponent positive psychological intervention|
9837659|NCT04746274|Active Comparator|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|
9837660|NCT04746274|No Intervention|Waitlist Control Group|
10206014|NCT05013255|Active Comparator|Pioglitazone 15mg Dose|Subjects will be given PIO 15mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
10206015|NCT05013255|Active Comparator|Pioglitazone 30mg Dose|Subjects will be given PIO 30mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
9984942|NCT03580317|Placebo Comparator|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
9984943|NCT03580317|Active Comparator|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
9984944|NCT03580317|Sham Comparator|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
9984945|NCT03579966|Experimental|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day
9837667|NCT04740827|Active Comparator|Atogepant 60 mg|Taken once daily
9837668|NCT04740827|Placebo Comparator|Placebo|Taken once daily
9984946|NCT03570606||HA Paste in Spine|"Evaluation of HA Paste in spinal fusion procedures~o Spinal cage filling"
9984947|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
9837671|NCT04739761|Experimental|Trastuzumab Deruxtecan|Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
10206016|NCT05013255|No Intervention|No Drug|Subjects will be assigned to a no drug control group based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
9837673|NCT04733937|Active Comparator|a2 Group|The infant group consuming a2 Platinum® stage 1 infant formula
9837674|NCT04733937|Active Comparator|Control Group|The infant group consuming conventional, A1 and A2 β-casein containing stage 1 infant formula
9837675|NCT04733937|No Intervention|breast feeding|
9837676|NCT04733638||Pre-Viz ICH VOLUME|Patient data collected prior to Viz ICH VOLUME implementation, utilized as a control data set
9837677|NCT04733638||Post-Viz ICH VOLUME|Patient data collected post-Viz ICH VOLUME implementation
9837678|NCT04731311|Other|Usability Evaluation of the BrightGo system|Participants with rate the device in each of 4 usability evaluation sessions.
9837679|NCT04729959|Experimental|Group I (tocilizumab, atezolizumab, FSRT)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes (dependent upon the results of the Safety Run-In) on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days in the absence of disease progression or unacceptable toxicity. Starting 4 weeks from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
10206017|NCT05004051||Patients who are booked for and then subsequently have undergone endovascular repair.|
10206018|NCT05004051||Patients with infrarenal AA without indications for repair undergoing serial monitoring|
10206019|NCT05003076|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
10206020|NCT05003076|Experimental|Methamphetamine Then Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
10206021|NCT05002374|Experimental|Experimental Group|
10206022|NCT05002374|Active Comparator|Control Group|
10206023|NCT05001139|Experimental|Relizema ecofoam|Reizema ecofoam for 42 days, 2 times per day
10206024|NCT04997915||Critical COVID-19|Critical COVID-19 patients admitted to the ICU
9837680|NCT04729959|Experimental|Group II, Arm I (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes (dependent upon the results of the Safety Run-In) on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9837681|NCT04729959|Experimental|Group II, Arm II (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3-5 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab IV over 60 minutes with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9837682|NCT04728815|Experimental|CAMS to Maintenance|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
9837683|NCT04728815|Experimental|CAMS to CAMS|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
9837684|NCT04728815|Experimental|CAMS to DBT|Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
9837685|NCT04728815|Experimental|TAU to Maintenance|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
9837686|NCT04728815|Experimental|TAU to CAMS|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
9837687|NCT04728815|Experimental|TAU to DBT|Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.
9837688|NCT04728815|Experimental|DBT Only|Subject Assigned to DBT for Phase 1, continuing up to 16 weeks.
9984948|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures~o Spinal cage filling"
9984949|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
9837691|NCT04726566||Arthroscopic stabilization|Patient will have an anatomical surgery of chronic lateral ankle instability under arthroscopy
9837692|NCT04726163|No Intervention|Tele-expertise|Basal-bolus insulin treatment with adaptation of insulin doses according to continuous glucose measurement
9837693|NCT04726163|Experimental|Standard|Standard treatment and adaptation of insulin doses according to the usual management of the unit
9837694|NCT04722341|Experimental|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
9837695|NCT04722341|Active Comparator|Control|More than equal to a 12-hour daily eating period
9837696|NCT04722172|Experimental|Acalabrutinib Combined With Obinutuzumab|Patients will receive acalabrutinib for a minimum of 13 cycles and maximum 26 cycles and Obinutuzumab will be administered during Cycles 2-7. This will be followed by treatment-free observation through the 65th cycle. Patients who progress during the observation period, per iwCLL criteria, will receive 13 cycles of acalabrutinib in combination with obinutuzumab in the retreatment phase of this study.
9984950|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures~o Spinal cage filling"
9984951|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
9984952|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:~o High tibial osteotomies with fixation"
9984953|NCT03564132|Experimental|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
9837702|NCT04716309|Active Comparator|VLP|Open reduction and volar locking plate
9837703|NCT04716309|Active Comparator|CRPP|Closed reduction and percutaenous K-wires/pins
9837704|NCT04715906|Experimental|UP-Caregiver Group|Unified Protocol (UP) Caregiver Group will receive the UP for Transdiagnostic Treatment of Emotional Disorders for Caregivers intervention via telehealth using Zoom for a minimum of 4 up to 8 sessions ideally within 8 weeks.
9984954|NCT03564132|Placebo Comparator|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
9984955|NCT03563690|Experimental|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
9837707|NCT04713995|Other|All Study Participants|"Enrolled with: AxSpA diagnosis, HLA-B27 positive, mASDAS > or = 1.3 and HLA-B27 positive. Will complete surveys online or on an app, about mental and physical health and how they are doing, submits and collection of samples (blood, stool, saliva, urine, fasting blood test at local lab). Receives results of some of the analysis of samples. Participants that qualify and complete the first set of samples can be eligible for the 3 and 6 month longitudinal follow-up collection kits.~All participants receive dietary recommendations based on samples collected and the analysis of the microbiome."
9984956|NCT03563690|Experimental|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
9984957|NCT03563690|Experimental|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
9984958|NCT03563690|Experimental|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
9984959|NCT03563690|Sham Comparator|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
10206025|NCT04994938|Experimental|Peer led diet and exercise intervention|participation in two-times per week diet and exercise peer led interventions.
10206026|NCT04989101|Active Comparator|Nigelle Group|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
10206027|NCT04989101|No Intervention|Placebo Group|Follow-up should be done weekly for 1 month.
10206028|NCT04986930|Experimental|SBRT+mFOLFIRINOX|"Stereotactic body radiotherapy: 3500 cGy (5 fractions)~mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2"
9837716|NCT04705662|Other|Ferrous Sulphate|This is a single arm study, all participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
9837721|NCT04701073|No Intervention|"Control group usual care"|Promotion of physical activity and taking usual medicines for pain relief
9837722|NCT04701073|Experimental|Intervention group : lumbar belt|wearing the LombaStab belt during 3 months in addition to usual care (promotion of physical activity and taking usual medicines for pain relief).
9837723|NCT04700449|Experimental|CBP-307 capsules|CBP-307 capsules oral administration.
9837724|NCT04700449|Placebo Comparator|Placebo capsules|Placebo capsules oral administration.
9837725|NCT04699773|Experimental|LITT with Hypofractionated RT|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 25Gy/10 fractions.
9837726|NCT04698460|Experimental|Hybrid coronary revascularization (HCR)|Patients with multi-vessel CAD randomized to hybrid coronary revascularization
9837727|NCT04698460|Active Comparator|Conventional coronary artery bypass grafting (CABG)|Patients with multi-vessel CAD randomized to conventional CABG
9837728|NCT04697407|Experimental|MS Patients|Patients with MS at any stage and for any type of MS : MS at the onset of the disease, Clinically isolated syndrome (CIS), Relapsing-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS)
9837729|NCT04697407|Active Comparator|non MS Patients|Patients with a neurological and immunological disease except MS.
9837730|NCT04697407|Active Comparator|Healthy volunteers|
9837731|NCT04696809|Experimental|Japanese Participants with Relapsed or Refractory Multiple Myeloma (MM)|Japanese participants with relapsed or refractory MM will receive Teclistamab subcutaneously (SC) at three dose levels. Cohort 1 will receive Teclistamab at Dose 1 and Dose 2 (step-up doses) prior to the first treatment dose on Day 1 followed by Dose 3 on Days 1,8, and 15 of a 21-day cycle. Cohort 2 will receive Teclistamab at Dose 1 and Dose 4 (step up doses) prior to the first treatment dose on Day 1 followed by Dose 5 on Days 1,8, and 15 of a 21-day cycle. Cohort 3 will receive Teclistamab at Dose 1, Dose 4, and Dose 5 (step up doses) prior to the first treatment dose on Day 1 followed by Dose 6 on Days 1,8, and 15 of a 21-day cycle in the Phase 1 part. In Phase 2 part, participants will receive Teclistamab SC at Dose 1 and Dose 4 (step up doses) up to 8 days prior to the first treatment dose on Day 1 followed by Dose 5 on Days 1,8,15, and 22 of a 28-day cycle.
9837732|NCT04696029|Experimental|Difluoromethylornithine (DFMO)|study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study.
9837733|NCT04695860|Experimental|Open label Burosumab|Burosumab Q4W, 1mg/kg body weight s.c.
9837734|NCT04695678||residents and staff of all nursing homes in Solingen|each study participant receives a single nasal/pharyngeal swab
9837735|NCT04695678||staff of one single nursing home in Solingen|each study participant receives a weekly nasal/pharyngeal swab for six months
9921960|NCT00833183|Active Comparator|25 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
9984960|NCT03563690|Active Comparator|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
9837737|NCT04694001|Other|Hemiplegia due to Cerebrovascular Accident (CVA)|
9984961|NCT03558945|Experimental|Personalized neoantigen vaccine|"Patients will receive radical surgery and at least one circle of post-operative chemotherapy.~Personalized neoantigen vaccines will be injected on day 1 of weeks 1, 3, 5, 7, 9, short interval or 1-2 months after the end of their post-operative chemotherapy, and two boosts will be on day 1 of weeks 12, 20.~Vaccines will be given in a total volume of up to 1.0ml/shot consisting of 0.3mg peptide+0.5mg ployICLC injected subcutaneously into two to four separate sites of the subject's thighs.~Patients will be called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit."
9837739|NCT04690868|Experimental|ARM 1|Period 1 : Reference Drug(AD-2131) Period 2 : Test Drug(AD-213-A)
9837740|NCT04690868|Experimental|ARM 2|Period 1 : Test Drug(AD-213-A) Period 2 : Reference Drug(AD-2131)
9984962|NCT03558945|No Intervention|Conventional treatment|Patients will receive radical surgery and conventional post-operative chemotherapy.
9984963|NCT03556488||Pediatric CAP|Patients with a clinical diagnosis of CAP and radiographic evidence of lung consolidation, hospitalized in the Pediatric Unit.
9984964|NCT03555877|Experimental|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
9984965|NCT03555877|Active Comparator|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
9837746|NCT04690699|Experimental|Arm 1: Lerapolturev and Anti-PD-1/L1 Therapy|Subjects will be treated with a combination of lerapolturev and an FDA-approved anti-PD-1/L1 therapy, the choice of which will be determined based on the solid tumor cancer of interest and specified in the associated tumor specific appendix.
9837749|NCT04684719|Experimental|Whole Blood|Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care.
9837750|NCT04684719|Active Comparator|Standard Care|Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service.
9837752|NCT04683029|Experimental|Group A: Guselkumab|Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Guselkumab Dose 2 and IV injection of placebo at long-term extension (LTE) Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
9837753|NCT04683029|Placebo Comparator|Group B: Placebo|Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Placebo and IV injection of Guselkumab Dose 1 at LTE Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
9837754|NCT04682366|Experimental|Tamsulosin|Patients in this arm will receive 10 days of 0.4 mg of oral tamsulosin once daily starting 5 days pre-operatively and continuing until all pills are completed.
9837755|NCT04682366|Placebo Comparator|Placebo|Patients in this arm will receive 10 days of identical-appearing placebo once daily starting 5 days pre-operatively and continuing until all pills are completed.
9837756|NCT04682223|Experimental|Aphasia Remote Therapy (ART)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done remotely with a speech-language pathologist through an online platform using therapy applications. Participants will be provided with teletherapy kits (including an Internet hotspot if needed) to complete the therapy tasks."
9837757|NCT04682223|Active Comparator|In-Clinic Therapy (I-CT)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done in person with a speech-language pathologist at the UofSC Aphasia Lab."
9837758|NCT04680585|Other|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
9837759|NCT04680585|Experimental|MOVIN|Enhanced Usual Care plus MOVIN Care Platform. The MOVIN Care Platform is virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
9837760|NCT04677569|Experimental|ALIS + Background Regimen|Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg, once daily.
9837761|NCT04677569|Placebo Comparator|ELC + Background Regimen|Participants will be administered ELC (empty liposome control), a visually matching placebo to ALIS (amikacin liposome inhalation suspension), once daily. Participants will also be administered azithromycin 250 mg and ETH (ethambutol) 15 mg/kg, once daily.
9837762|NCT04677543|Active Comparator|ALIS + Background Regimen (Azithromycin + Ethambutol)|Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
9837763|NCT04677543|Placebo Comparator|ELC + Background Regimen (Azithromycin + Ethambutol)|Participants will be administered ELC (empty liposome control), a matching placebo to ALIS, once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
9984966|NCT03555396|Experimental|Intervention|Subjects will receive an intervention is based off of current evidence-based practices and will consist of activities designed to strengthen support within the couple to improve adherence to antiretroviral therapy.
9984967|NCT03555396|Active Comparator|Standard of Care|Standard of Care is the comparison arm that consists of care currently provided at the AIDS Center. Subjects will receive a consultation with a healthcare provider every three months, prescription refills, and blood draws for viral load and CD4 testing.
9984968|NCT03547739|Active Comparator|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
9984969|NCT03547739|Active Comparator|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
9984970|NCT03547739|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
9837769|NCT04665089|Active Comparator|Erythromycin arm|The erythromycin arm (n=40) receives, in addition to the standard antimicrobial therapy, erythromycin 1 g three times per day intravenously: each gram is diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
9837770|NCT04665089|Placebo Comparator|Placebo arm|The placebo arm (n=40) receives, in addition to the standard antimicrobial therapy, isotonic saline, intravenously, 20 ml diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
9984971|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
9837772|NCT04660526|Experimental|Intervention (Enhanced Standard of Care)|Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
9837773|NCT04660526|No Intervention|Control (Standard of Care)|Usual care, continuing standard quality improvement effort
9837774|NCT04654988|Experimental|Immunsuppression|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and Azathioprine: 2 mg/kg daily for 12 months
9837775|NCT04654988|Placebo Comparator|Placebo|placebo matching prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months and placebo matching azathioprine: 2 mg/kg daily for 12 months
9837778|NCT04652557|Experimental|Fampridine SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 82 days depending on the individual scheduling of each subject."
9837779|NCT04652557|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
9837784|NCT04647721|Experimental|Left side Radiesse® / Right side Restylane®|
9837785|NCT04647721|Experimental|Left side Restylane® / Right side Radiesse®|
9837786|NCT04646226|Active Comparator|fistula surgically placed|Randomized group to have surgically placed fistula for permanent hemodialysis access
9837787|NCT04646226|Active Comparator|graft surgically placed|Randomized group to have surgically placed graft for permanent hemodialysis access
9837788|NCT04645953|Experimental|1mg AZ010|Single orally-inhaled dose
9837789|NCT04645953|Experimental|3mg AZ010|Single orally-inhaled dose
9837790|NCT04645953|Experimental|Placebo|Single orally-inhaled dose
9837791|NCT04645823|Active Comparator|Spinal fentanyl|Using a combined spinal epidural technique a single dose of 20 µg of fentanyl diluted into 2 ml with NaCl 0.9 % will be injected into the CSF at lower lumbar interspace. An epidural catheter is left in place for subsequent analgesic doses.
9837792|NCT04645823|Experimental|Epidural lidocaine and fentanyl|Using a catheter in the epidural space in the lower lumbar interspace a single dose of lidocaine (80 mg) and fentanyl (100 µg) is given. The epidural catheter is left in place for subsequent analgesic doses.
9984972|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
9984973|NCT03535857|Active Comparator|Unilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
9984974|NCT03535857|Experimental|Bilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
9837796|NCT04644068|Experimental|Module 1: AZD5305 Monotherapy|AZD5305 Monotherapy
9837797|NCT04644068|Experimental|Module 2: AZD5305 + Paclitaxel|AZD5305 + Paclitaxel
9837798|NCT04644068|Experimental|Module 3: AZD5305 + Carboplatin with or without Paclitaxel|AZD5305 + Carboplatin with or without Paclitaxel
9837799|NCT04644068|Experimental|Module 4: AZD5305 + Trastuzumab Deruxtecan|AZD5305 + T- Dxd
9837800|NCT04644068|Experimental|Module 5 AZD5305 + Datopotamab Deruxtecan|AZD5305 + Dato-DXd
9837801|NCT04641442|Experimental|MAS825|Experimental drug
9837802|NCT04641442|Placebo Comparator|Placebo|matching placebo
9837803|NCT04640545|Experimental|LBL-007+Toripalimab+Axitinib Tablets|"Study Part A： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv；~Study Part B： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv+Axitinib Tablets 5mg + Axitinib Tablets 1mg"
9984975|NCT03534466|Experimental|intervention group|Baby treadmill + conventional physical rehabilitation training
9984976|NCT03534466|Active Comparator|positive control group|Conventional physical rehabilitation training only
9984977|NCT03534167|Experimental|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
9984978|NCT03534167|No Intervention|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
9837808|NCT04636008|Experimental|Experimental arm|Sintilimab+Hypofractionated radiotherapy
9837809|NCT04634773|Experimental|Group 1: Early Degeneration ('Disease')|Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
9837810|NCT04634773|Active Comparator|Group 2: No Degeneration ('Healthy')|Those who have posterior subluxation of the humeral head and show no signs of degeneration.
9837811|NCT04633447|Experimental|Guselkumab|Participants will receive guselkumab dose 1 intravenously (IV) at week 0, 4, and 8 and guselkumab dose 2 subcutaneously (SC) every 4 weeks (q4w) from week 12 through week 48. This will be in combination with a protocol specified 26-week GC taper. Participants of the long-term extension (LTE) period will continue to receive subcutaneous (SC) injections q4w starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a Giant cell arteritis (GCA) flare, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
9837812|NCT04633447|Experimental|Placebo|Participants will receive matching placebo IV at week 0, 4 and 8 and matching placebo SC q4 weeks from week 12 through week 48. This will be in combination with a protocol-specified 26-week GC taper. Participants of the LTE period will continue to receive SC injections q4w starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a GCA flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
9984979|NCT03527576|Active Comparator|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
9984980|NCT03527576|Placebo Comparator|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
10206029|NCT04986930|Active Comparator|mFOLFIRINOX|-mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
9984981|NCT03527498|Experimental|intervention group|Baby treadmill + physical rehabilitation training
9984982|NCT03527498|Active Comparator|positive control group|Physical rehabilitation training only
9837817|NCT04631432||Study participation|All participants will complete the same protocol
10206030|NCT04984421|Active Comparator|Basic|All schools will receive the HSS program. Schools randomly assigned to group 1 will receive implementation strategy bundle 1 (Basic).
9837819|NCT04630808|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
9837820|NCT04630808|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
9837821|NCT04630353|Experimental|HB-201 Intratumorally on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
10206031|NCT04984421|Experimental|Enhanced|All schools will receive the HSS program. Schools randomly assigned to group 2 will receive implementation strategy bundle 1+2 (Enhanced).
10206032|NCT04984330|Experimental|selinexor/ dexamethasone (Sd)|"Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity~Dexamethasone~• 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23"
9837822|NCT04630353|Experimental|HB-201 Intravenously on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
9837823|NCT04630353|Experimental|HB-201 Intratumorally 7 to 14 days before chemoradiation|Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype.
9837824|NCT04630197|Experimental|e-CBT|16 weekly sessions will be conducted through OPTT and consist of approximately 30 slides and interactive therapist videos. The content and format will mirror in-person CBT for OCD. The connection between thoughts, behaviours, emotions, physical reactions, and the environment will be a focus. Moreover, mindfulness, body scanning, self-care, goal setting, thinking errors, the 5-part model, thought records, and ERP will be incorporated. Slides will highlight different topics each week and include general information, an overview of skills, and homework on that topic. The homework will be submitted through OPTT and reviewed by therapists with personalized feedback provided within 3 days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. After each completion of the e-CBT program, participants will be interviewed to investigate their experience using OPTT and their perception of how the treatment went.
9837825|NCT04628858||Primary group|
9837826|NCT04625023||Cohort of BC patients|Stage-mixed cohort of at least 500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.
9837827|NCT04622774|Experimental|IMGC936|Single-arm. IMGC936 administered every 3 weeks.
9837828|NCT04622345|Experimental|VSJ-110 Solution|
9837829|NCT04622345|Placebo Comparator|Placebo Solution|
9837830|NCT04622254|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection.
9837831|NCT04622254|Experimental|MP: NT201 (incobotulinumtoxinA): LCL, Placebo: GFL/ HFL|Intramuscular injection.
9837832|NCT04622254|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection.
9837833|NCT04622254|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection.
9837834|NCT04621604|Experimental|Patients|
9837836|NCT04616235|Placebo Comparator|CON|This group will do intense aerobic exercise without concomitant IL-6R blockade
9837837|NCT04616235|Active Comparator|BLOCK|This group will do intense aerobic exercise with concomitant IL-6R blockade
9837838|NCT04615325|Experimental|Single ascending dose stage|Patients will receive a single dose of RO7303359, in multiple escalating cohorts (A-D)
9837839|NCT04615325|Experimental|Expansion cohort stage|Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.
9837840|NCT04615325|Experimental|Optional cohort E|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
9837841|NCT04615325|Experimental|Optional cohort F|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
9837842|NCT04613154|Active Comparator|Magnesium|Given 1000 mg oral magnesiumcitrate once daily (4*250mg) during the day of surgery and the next 6 Days.
9837843|NCT04613154|Placebo Comparator|Placebo|Given placebo once daily during the day of surgery and the next 6 Days.
9984983|NCT03526510|Active Comparator|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
9837845|NCT04609280|Experimental|Reduced C/L elective nodal volume|All patients will receive the reduced C/L elective nodal volume as described. Treatment will be delivered via IMRT/VMAT or PBPT.
9984984|NCT03526510|Experimental|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
9984985|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
9837848|NCT04608617||Pre-Viz|Pre-Viz LVO implementation patient data utilized as a control data set
9837849|NCT04608617||Post-Viz|Patient data collected post-Viz LVO implementation
9837850|NCT04606901|Active Comparator|Sugammadex|Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.
9837851|NCT04606901|Active Comparator|Neostigmine/Glycopyrrolate|Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade
9837852|NCT04606771|Experimental|Arm A|"Savolitinib 300 mg oral QD~Osimertinib 80 mg oral QD"
9837853|NCT04606771|Experimental|Arm B|"Savolitinib 300 mg oral QD~Placebo to Osimertinib 80mg oral QD"
9837854|NCT04603521||Hypertrophic cardiomyopathy (HCM)|Survival after Myectomy Operation
9984986|NCT03523585|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
9984987|NCT03523585|Active Comparator|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
9984988|NCT03523585|Active Comparator|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
9984989|NCT03522584|Experimental|Treatment (tremelimumab, durvalumab, HIGRT, SBRT)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
9984990|NCT03517722|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
9837860|NCT04594694|Active Comparator|Treatment A: BZF 200 mg IR|Bezafibrate (BZF): 200 mg IR Ocaliva (OCA) Placebo Bezafibrate (BZF) 400 mg Placebo
9837861|NCT04594694|Active Comparator|Treatment B: BZF 400 mg SR|Bezafibrate (BZF): 400 mg SR Ocaliva (OCA) Placebo Bezafibrate (BZF) 200 mg Placebo
9837862|NCT04594694|Experimental|Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 200 mg IR Bezafibrate (BZF) 400 mg Placebo
9837863|NCT04594694|Experimental|Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 400 mg SR Bezafibrate (BZF) 200 mg Placebo
9837864|NCT04594434|Experimental|protocol EMDR + SB / SMP protocol (adjusted)|"Association of a positive memory with the recommended therapy based on EMDR."
9837865|NCT04594434|Active Comparator|protocol EMDR (standard).|"recommended therapy based on EMDR."
9984991|NCT03517722|Experimental|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
9837867|NCT04591392|Experimental|Device|ASD closure with the reSept ASD Occluder
9837868|NCT04589585|Experimental|DiVeRt treatment|DiVeRt device to be used in the single arm
9837869|NCT04587999|Experimental|bladder stimulation|
9837870|NCT04587999|Active Comparator|Quick wee|
9837871|NCT04585958|Experimental|Treatment (trastuzumab deruxtecan, olaparib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9837872|NCT04585308|Experimental|Single arm|Patients with severe native aortic valve stenosis who meet the commercially approved indications for TAVR.
9984992|NCT03517098|Experimental|The ERAS group|Patients will be treated with the ERAS pathway
9984993|NCT03517098|Other|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
9984994|NCT03511625|Experimental|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
9984995|NCT03511625|Active Comparator|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
9984996|NCT03508765|Experimental|rsfMRI + Neurocognitive Tests|Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
9837878|NCT04579094||1/elderly dependent persons|
9837879|NCT04579094||2/healthcare workers (HCW)|
10206033|NCT04981223|Experimental|ExactVu Imaging|"EV29L transducer will be inserted in the subject's rectum. Cine sweeps will be performed to save images of:~The entire prostate from posterior to anterior (may require 2 sweeps to cover base and apex)~The peripheral zone using the highest zoom setting (30mm depth) on the system (may require 2 sweeps to cover base and apex). Analysis of these images will be performed after surgery but before prostatectomy"
10206034|NCT04980638|Experimental|ER004|Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor binding domain fusion protein.
9984997|NCT03500354|Experimental|Nutrient|Nutrient drink
9984998|NCT03499314|Experimental|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
9984999|NCT03499314|Placebo Comparator|Sham Stimulation|20 ×20-minute sessions sham tDCS
9837885|NCT04573946|Placebo Comparator|Vitamin D placebo + fish oil placebo|
9837886|NCT04573946|Active Comparator|Vitamin D placebo + fish oil|
9837887|NCT04573946|Active Comparator|Vitamin D + fish oil placebo|
9837888|NCT04573946|Active Comparator|Vitamin D + fish oil|
9837889|NCT04573751|Sham Comparator|Standard therapy|No intracoronary epinephrine and verapamil
9837890|NCT04573751|Active Comparator|Epinephrine|Intracoronary bolus epinephrine injection requires two ampoules each of 1:1,000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline solution (to 20 μg/mL epinephrine solution); therefore, a 5-mL syringe contains 100 μg of epinephrine. Intracoronary epinephrine will be administered at a dose of 100 μg and at a lower dose of 80 μg in patients with blood pressure >160 mmHg
9837891|NCT04573751|Active Comparator|Verapamil|Intracoronary verapamil is administered at a dose of 0.5 mg.
9837892|NCT04573751|Active Comparator|Epinephrine + verapamil|Intracoronary administration of epinephrine at a dose of 80-100 μg and verapamil at a dose of 0.5 mg.
9837893|NCT04573205|Experimental|> 50 years|"Healthy individuals > 50 years of age divided into age groups 50-59 years, 60-69 years and >70 years, approximately 20 participants in each group.~Vaccinated with 4 doses FSME immune Adult intramuscular injection according to the recommended primary vaccine Schedule in Sweden for individuals > 50 years of age, at time 0, 1, 2 and 7 months."
9837894|NCT04573205|Active Comparator|< 40 years|Healthy individuals < 40 years of age. Vaccinated with 3 doses FSME immune Adult intramuscular injection according to the standard recommended primary vaccine at time 0, 1, and 7 months.
9837895|NCT04573101|No Intervention|Before intervention|Participants answer questionnaire before any stimulus is given.
9837896|NCT04573101|No Intervention|After intervention|Participants answer questionnaire after the series of stimulus is given.
9837897|NCT04573101|Experimental|N1 (Ney - Improvisation- Saba Re)|Improvisation with Ney, on Saba maqam on Re.
9837898|NCT04573101|Experimental|O1 (Oud - Improvisation- Saba Re)|Improvisation with Oud, on Saba maqam on Re.
9837899|NCT04573101|Experimental|Q1(Qanun - Improvisation- Saba Re)|Improvisation with Qanun, on Saba maqam on Re.
9837900|NCT04573101|Experimental|N2 (Ney - Improvisation- Saba Sol)|Improvisation with Ney, on Saba maqam on Sol.
9837901|NCT04573101|Experimental|O2 (Oud - Improvisation- Saba Sol)|Improvisation with Oud, on Saba maqam on Sol.
9837902|NCT04573101|Experimental|Q2 (Qanun - Improvisation- Saba Sol)|Improvisation with Qanun, on Saba maqam on Sol.
9837903|NCT04573101|Experimental|N3 (Ney - Improvisation- Kurd Re)|Improvisation with Ney, on Kurd maqam on Re.
9837904|NCT04573101|Experimental|O3 (Oud - Improvisation- Kurd Re)|Improvisation with Oud, on Kurd maqam on Re.
9837905|NCT04573101|Experimental|Q3 (Qanun - Improvisation- Kurd Re)|Improvisation with Qanun, on Kurd maqam on Re.
9837906|NCT04573101|Experimental|N4 (Ney - Improvisation- Kurd Sol)|Improvisation with Ney, on Kurd maqam on Sol.
9837907|NCT04573101|Experimental|O4 (Oud - Improvisation- Kurd Sol)|Improvisation with Oud, on Kurd maqam on Sol.
9837908|NCT04573101|Experimental|Q4 (Qanun - Improvisation- Kurd Sol)|Improvisation with Qanun, on Kurd maqam on Sol.
9837909|NCT04573101|Experimental|N5 (Ney - Known music- Kurd Re)|Known music with Ney, on Kurd maqam on Re. (El Rabii)
9837910|NCT04573101|Experimental|O5 (Oud - Known music- Kurd Re)|Known music with Oud, on Kurd maqam on Re. (El Rabii)
9837911|NCT04573101|Experimental|Q5 (Qanun - Known music- Kurd Re)|Known music with Qanun, on Kurd maqam on Re. (El Rabii)
9837912|NCT04573101|Experimental|N6 (Ney - Known music- Kurd Sol)|Known music with Ney, on Kurd maqam on Sol. (El Rabii)
9837913|NCT04573101|Experimental|O6 (Oud - Known music- Kurd Sol)|Known music with Oud, on Kurd maqam on Sol. (El Rabii)
9985000|NCT03498495|Experimental|SMART Intervention|
10206035|NCT04980573|Experimental|Intervention|Participants receive a bottle of plant-based oil to inhale twice daily for 14 days.
10206036|NCT04980573|Placebo Comparator|Placebo|Participants receive a bottle of inert oil to inhale twice daily for 14 days.
9789177|NCT01351350|Experimental|MLN0128P 7 mg QD×3d QW|MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9789178|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9789179|NCT01351350|Experimental|MLN0128P 9 mg QD×3d QW|MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9789180|NCT01351350|Experimental|MLN0128P 10 mg QD×3d QW|MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9789181|NCT01351350|Experimental|MLN0128P 7 mg QD×5d QW|MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
9789182|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW HER2-|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
9789183|NCT01351350|Experimental|MLN0128PH 8 mg QD×3d QW HER2+|MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
9789184|NCT01351376|Placebo Comparator|Placebo|CDT + inactive LLL
9789185|NCT01351376|Active Comparator|LLL combined with CDT|CDT + active LLL
9789186|NCT01351415|Experimental|Bevacizumab + Standard of Care|Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
9789187|NCT01351415|Active Comparator|Standard of Care|Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
9789188|NCT01351480|Other|abatacept|open label use of abatacept for 12 months
9789189|NCT01351623|Experimental|Carfilzomib|A single arm, open-label, single institution phase 2 clinical trial is planned.
9789190|NCT01351740|Experimental|Switch|switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
9789191|NCT01351740|Active Comparator|Continuation|continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
9789192|NCT01351753|Active Comparator|Metformin|
9789193|NCT01351753|Experimental|Metformin + Orlistat|
9789194|NCT01351753|Experimental|Metformin + Topiramate|
9789195|NCT01351753|Experimental|Topiramate|
9789196|NCT01351753|Experimental|Metformin + Topiramate + Orlistat|
9789197|NCT01351753|Placebo Comparator|Placebo|
9789198|NCT01351766|Experimental|Behavioral Activation for Smoking|"Eight 60-minute group sessions over an eight-week period. Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after treatment sessions have ended.~Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level."
9789199|NCT01351805|Experimental|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
9789200|NCT01351805|Experimental|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
9789201|NCT01351805|Placebo Comparator|placebo|Subjects will receive placebo pill.
9789202|NCT01351805|Experimental|Vitamin D and Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
9789203|NCT01352117|Active Comparator|Arm A: ART alone or with delayed ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks. Arm A participants who experienced KS progression on ART alone could receive ET in addition to EFV/FTC/TDF in Step 2 of the study.
9789204|NCT01352117|Experimental|Arm B: ART with immediate ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks with immediate ET for up to 16 weeks.
9789205|NCT01352182|Experimental|Pioglitazone hydrochloride|Pioglitazone hydrochloride treatment group
9789206|NCT01352182|No Intervention|Normal standard care|Normal standard care control group
9789207|NCT01352221|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
9789208|NCT01352221|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
9837914|NCT04573101|Experimental|Q6 (Qanun - Known music- Kurd Sol)|Known music with Qanun, on Kurd maqam on Sol. (El Rabii)
9837915|NCT04573101|Experimental|N7 (Ney - Known music- Saba Re)|Known music with Ney, on Saba maqam on Re. (Howa Sahih)
9837916|NCT04573101|Experimental|O7 (Oud - Known music- Saba Re)|Known music with Oud, on Saba maqam on Re. (Howa Sahih)
9837917|NCT04573101|Experimental|Q7 (Qanun - Known music- Saba Re)|Known music with Qanun, on Saba maqam on Re. (Howa Sahih)
9837918|NCT04573101|Experimental|N8 (Ney - Known music- Saba Sol)|Known music with Ney, on Saba maqam on Sol. (Howa Sahih)
9837919|NCT04573101|Experimental|O8 (Oud - Known music- Saba Sol)|Known music with Oud, on Saba maqam on Sol. (Howa Sahih)
9837920|NCT04573101|Experimental|Q8 (Qanun - Known music- Saba Sol)|Known music with Qanun, on Saba maqam on Sol. (Howa Sahih)
9985001|NCT03498495|No Intervention|Usual Care|
9837922|NCT04572035|Experimental|Exercise only|Undergraduate peer-facilitators part of a curricular kinesiology program will facilitate a personalized group-based exercise program adapted to the participant's abilities, teach participants how to exercise, and gauge exercise intensity in a safe manner (26). The CANMAT guidelines will be implemented, with the program consisting of supervised group-based moderate-intensity exercise sessions lasting 30-minutes (plus 10-minutes for warm-up and cool-down), 3 times weekly, for a period of 10-weeks. Participants will start exercising at a low intensity and progressively increase until they are consistently exercising at a moderate intensity. As a result of the uncertainty surrounding the pandemic, the intervention will be conducted either via a virtual platform or in-person at the Exercise and Health Psychology Lab, depending on the health and safety restrictions applicable to when the student enrolls and begins their program.
9837923|NCT04572035|Experimental|Exercise + Self-compassion|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks).
9837924|NCT04572035|Experimental|Exercise + Behavioural Coaching|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting).
9837925|NCT04569864|Experimental|Mild hypothermia (30-32°C)|During aortic hemiarch replacement, mild hypothermia (30-32°C) will be used during circulatory arrest.
9837926|NCT04569864|Active Comparator|Moderate hypothermia (26-28°C)|During aortic hemiarch replacement, moderate hypothermia (26-28°C) will be used during circulatory arrest.
9985002|NCT03496844|No Intervention|Routine F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who have had an F-18 fluciclovine-PET/CT scan for routine standard of care for biochemical recurrence. These patients would be asked to participate in the study only if there is a need for a standard of care bone biopsy.
10206037|NCT04974346|Experimental|study arm|"External beam radiotherapy:~Pelvic and para-aortic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~High dose rate(HDR) Brachytherapy. The dose of high-risk clinical target volume(HR CTV) D90 or Point A should be 85Gy+/-10%. The dose of intermediate-risk clinical target volume(IR CTV) D98 should be 60Gy at least."
9837928|NCT04567602||Participants with PAH|Participants with confirmed diagnosis of pulmonary arterial hypertension (PAH) will be enrolled in the study and the data will be collected and observed to describe the application of European ESC/ERS guidelines and related 6th WSPH proceedings on risk assessment and related treatment strategy, in clinical practice.
9985003|NCT03496844|Active Comparator|Research F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who would not ordinarily obtain an Axumin-PET scan for routine standard of care but have a need for bone biopsy. This will include patients with metastatic castrate resistant prostate cancer. For example, a patient with known lymph node recurrence of prostate cancer and suspicious finding on a bone scan would be asked to participate in the study and get a F-18 fluciclovine-PET/CT scan prior to the standard of care bone biopsy.
9837930|NCT04565990|Experimental|Selexipag|Participants will receive selexipag tablets twice daily with the dose strength corresponding to their individual maximum tolerated dose (iMTD) from the parent study.
10206038|NCT04974346|Active Comparator|control arm|"External beam radiotherapy:~Pelvic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~HDR Brachytherapy. The dose of HR CTV D90 or Point A should be 85Gy+/-10%. The dose of IR CTV D98 should be 60Gy at least."
9837932|NCT04564417|Experimental|Monotherapy dose escalation: W0180|Participants will receive W0180 in a 21-day cycle until the maximum tolerated dose (MTD)/ recommended dose for expansion (RDE) for the single-agent identified.
9837933|NCT04564417|Experimental|Combination dose escalation: W0180+Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) followed by W0180 in a 21-day Cycle until the MTD in combination is identified or an RDE in combination is established.
9837934|NCT04564417|Experimental|Dose expansion|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion Q3W followed by an RDE dose of W0180 in a 21-day cycle.
10206039|NCT04969094|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
10206040|NCT04969094|Active Comparator|MMBI|Participation in a multi-modality balance intervention
9837937|NCT04562935||Pediatric intensive care|Children admitted to a pediatric intensive care unit before one year of age and admitted for to days or more and treated with mechanical ventilation and alive at follow
9837938|NCT04558476|Experimental|Convalescent Plasma|2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
9837939|NCT04558476|Other|Standard of care|Standard of care according the last gold standards
10206041|NCT04969081|Active Comparator|treatment as usual|usual substance use treatment
9837941|NCT04554173||surgical resection neurogenic tumors|
9837942|NCT04553120|Experimental|Alternating treatments condition - 10 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
9837943|NCT04553120|Experimental|Alternating treatments condition - 9 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
9837944|NCT04553120|Experimental|Alternating treatments condition - 13 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
9837945|NCT04553120|Experimental|Alternating treatments condition - 12 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
9837946|NCT04549428|Experimental|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1,200 mg by intravenous infusion every 21 days on an outpatient basis until progression, intolerance or loss of clinical benefit, according to the its approved prescribing information. Palliative radiation therapy will be delivered concomitant to the 2nd dose of atezolizumab as a single fraction of 8 Gy
9837947|NCT04548752|Experimental|Arm A (olaparib, pembrolizumab)|Patients receive olaparib PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 19, patients receive olaparib PO BID on days 1-42 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9837948|NCT04548752|Active Comparator|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9837949|NCT04546750||Patients without Varicose Veins|Individuals who do not have varicose veins of lower legs: C0, C1 classes according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
9837950|NCT04546750||Patients with Varicose Veins|Individuals who have varicose veins of lower legs: C2 Ep class according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
9985004|NCT03496636|Experimental|Ovarian tissue transplant|Transplantation of ovarian tissue into the abdomen. Only for patients who have previously frozen ovarian tissue
9837952|NCT04544800|Experimental|Use of Splint for UADT Visualization|Use of device to view UADT
9837953|NCT04542382|Experimental|Placebo and Rosuvastatin|Subjects will be dosed with placebo tablet and Rosuvastatin 10mg tablet
9837954|NCT04542382|Experimental|Eltrombopag and Rosuvastatin|Subjects will be dosed with Eltrombopag 75mg tablet and Rosuvastatin 10mg tablet
9837955|NCT04541407|Experimental|Exon 19 deletions or L858R point mutations in exon 21|Will include patients with exon 19 deletions or L858R point mutations in exon 21 of the epidermal growth factor receptor (EGFR) gene. Temozolomide plus Osimertinib will be the study drug combination administered. Osimertinib will be given at a fixed dose of 80 mg daily for dose level 1, with a potential to increase to 160 mg daily for dose level 2. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level.
9837956|NCT04541407|Experimental|Patients with anaplastic lymphoma kinase (ALK) fusions|Will include patients with anaplastic lymphoma kinase (ALK) fusions. Temozolomide plus Lorlatinib will be the study drug combination administered. Lorlatinib will be given at a fixed dose of 100 mg daily. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level depending on tolerability.
9985005|NCT03496597||Patients|type 1 diabetes patients
9837958|NCT04540003|Experimental|Access to School Based Health Centre|Of the eight school in the intervention arm, four schools will be linked to a school based health center (SBHC) at Sprucecourt or Nelson Mandela Park Public Schools (established in partnership with the department of Pediatrics at St. Michael's hospital) and four schools will be linked to a SBHC at Parkdale Public School (established in partnership with St. Joseph's Health Centre). SBHC pediatricians will attend School Support Team (SST) meetings at all intervention schools and students with developmental concerns identified at the SST meetings will be referred to the SBHC.
9921961|NCT00833183|Active Comparator|37 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
9985006|NCT03496597||Healthy controls|non diabetic control subjects of the same age
9837959|NCT04540003|No Intervention|Control Arm: Standard of care|Of the eight schools assigned to the control condition, four will be in the South East area of the city closer to Nelson Mandela Park PS and four will be in the South West area of the city closer to St. Josephs Health Center. The eight schools will be subject to standard of care which is: when a child is identified by the SST (no pediatrician present), students identified with developmental concerns are advised to access a pediatric/developmental assessment in the community.
9837960|NCT04538664|Experimental|Arm A: Amivantamab + Chemotherapy|"Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.~Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles.~Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3."
9837961|NCT04538664|Experimental|Arm B: Chemotherapy Alone|"Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.~Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles."
9985007|NCT03496597||Dyslipidemic controls|non-diabetic control participants with familial dyslipidemia
9985008|NCT03495674|Experimental|Group I (FITBIT, cycling)|Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.
9985009|NCT03495674|Active Comparator|Group II (FITBIT, information)|Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.
9837965|NCT04532645||Patients with BRCA mutated ovarian cancer|BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
9837966|NCT04529655||Sepsis|Patients admitted to the ICU with sepsis will be enrolled and monitored at time sequential time points during their treatment
9837967|NCT04527900|Experimental|Concurrent chemoradiation|Concurrent carboplatin and paclitaxel and IMPT (Intensity Modulated Proton Therapy)
9837968|NCT04527315||COVID-19 ICU Patients|
9837969|NCT04527315||Control|
9985010|NCT03492476|Experimental|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
9985011|NCT03492476|Active Comparator|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
9985012|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.
9985013|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring.
10206042|NCT04969081|Experimental|treatment as usual plus referral to work focused program|usual substance use treatment plus referral to a competitive or non-competitive work-focused program
10206043|NCT04961645|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants will have two study visits. During the first visit, participants will have an fMRI scan to identify the OPA location in each individual participant. During the second visit, participants will receive rTMS. Each visit lasts approximately 90 minutes.
9837976|NCT04524910||mCNV patients|Adult Canadian patients diagnosed with myopic choroidal neovascularization (mCNV) and naïve for anti-VEGF treatment
9837977|NCT04521088||visitors of the outpatient clinic for COVID-19|visitors of the outpatient clinic for COVID-19
9837978|NCT04520217|Experimental|4% Imipramine Cream on UVB-Treated Areas|"2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.~2g of base cream will be applied to the UVB-treated areas on volar forearm and back.~No cream will be applied to a UVB-treated area on the back"
9837979|NCT04518995|Experimental|CTP-543, 8 mg BID|Oral tablet for 24 weeks
9837980|NCT04518995|Experimental|CTP-543, 12 mg BID|Oral tablet for 24 weeks
9837981|NCT04518995|Placebo Comparator|Placebo, BID|Oral tablet for 24 weeks
9837982|NCT04518917||Parkinson disease plus dementia|Participants will have a diagnosis of Parkinson disease plus dementia.
9837983|NCT04517461||Head and neck free flap surgery patients|Patients undergoing head and neck microvascular free flap surgery at Skåne University Hospital, Lund, Sweden.
10206044|NCT04957342|Active Comparator|Sutures|Patients assigned to Sutures group will not have the allograft placed on the donor site. One current clinical standard of practice is to place sutures on donor site. Patients assigned to Sutures group will have sutures placed on donor site.
10206045|NCT04957342|Experimental|Allograft and Sutures|Patients assigned to Allograft and Sutures will have allograft placed and secured with sutures on the donor site.
9837986|NCT04510766||Part A|Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions
9837987|NCT04510766||Part B|"FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for liquid biopsy will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent~(1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of liquid biopsy for future analysis."
9837988|NCT04510727|Experimental|OCT Guided C&D Group|Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C&D.
10206046|NCT04956796||Group A|At the beginning of Phase 1, participants from Group A will be exposed to the video airway library in addition to the conventional airway training. At the beginning of Phase 2, participants will continue with conventional airway training only. Each phase will last for 1 month.
9837989|NCT04508309|Experimental|Cecolin® at 0 and 6 months|Two doses of Cecolin® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
9837990|NCT04508309|Experimental|Cecolin® at 0 and 12 months|Two doses of Cecolin® given at 0 and 12 months with blood draw at baseline, prior to second dose and one-month post second dose
9837991|NCT04508309|Experimental|Cecolin® at 0 and 24 months|Two doses of Cecolin® given at 0 and 24 months with blood draw at baseline, prior to second dose and one-month post second dose
9837992|NCT04508309|Active Comparator|Gardasil® at 0 and 6 months|Two doses of Gardasil® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
9837993|NCT04508309|Other|Gardasil® at 0 and Cecolin® at 24 months|One dose of Gardasil® at 0 months and one dose of Cecolin® at 24 months with blood draw at baseline, prior to second dose and one-month post second dose.
9837994|NCT04508023|Experimental|Rivaroxaban|Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).
9837995|NCT04508023|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.
9837996|NCT04507646|Experimental|True auricular acupuncture|Effective auricular acupuncture
9837997|NCT04507646|Sham Comparator|Sham auricular acupuncture|Ineffective auricular acupuncture
9837998|NCT04507022|Experimental|HRT Plus Aromatase Inhibitor|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups:~Group A (HRT plus AI): will be given aromatase inhibitor for 5 days only (2.5 mg twice daily), along with the oral 6 mg E2. Then, daily intramuscular (IM) P in oil (100 mg IM P) will be started in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
9837999|NCT04507022|Active Comparator|HRT Only|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups Group B (HRT only): will be administered daily intramuscular (IM) P in oil (100 mg IM P) in addition to the daily dose of oral 6 mg E2.~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
9838000|NCT04504175|Experimental|Acute|Acute phase: ketamine infusions twice a week for 4 weeks
9838001|NCT04504175|Experimental|Continuation|Continuation: for remitters/ responders, 4 weeks of weekly ketamine infusions
9838002|NCT04502615|Experimental|Sand|Participants perform 5 single leg hops onto a Sand surface from a 30cm height
9838003|NCT04502615|Active Comparator|Artificial grass|Participants perform 5 single leg hops onto a grass surface from a 30cm height
9838004|NCT04502615|Active Comparator|Firm Ground|Participants perform 5 single leg hops onto a firm ground surface from a 30cm height
9838005|NCT04501822||Covid19 pneumonia patients|The study includes men and women ≥18 years old with documented COVID-19 pneumonia
9838006|NCT04501614|Experimental|Ponatinib|Ponatinib tablet or age appropriate formulation (AAF) in combination with chemotherapy backbone, orally, once daily in both reinduction block and consolidation block (35 days each including 29 days of treatment followed by rest period from chemotherapy for a minimum of 6 days consisting of daily ponatinib only) in Phase 1 to determine RP2D. In Phase 2 participants will receive ponatinib at RP2D in combination with chemotherapy backbone at RP2D determined in Phase 1.
9789209|NCT01352286|Experimental|Autologous Genetically modified T cells|Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose >0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
9789210|NCT01352442|Experimental|AcuFocus Corneal Inlay|The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
9789211|NCT01352468|Experimental|Multifaceted Cognitive Training|Cognitive Training with 4 different tasks each of which gets progressively more difficult as children obtain proficiency.
9789212|NCT01352468|Sham Comparator|Sham Cognitive Training|Cognitive Training with 4 different tasks which does not get progressively more difficult throughout training
9789213|NCT01352507|Experimental|Tadalafil then Sildenafil|"20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED)."
9789214|NCT01352507|Active Comparator|Sildenafil then Tadalafil|"100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED."
10206047|NCT04956796||Group B|At the beginning of Phase 1, participants from Group B will be exposed to the conventional airway training only. At the beginning of Phase 2, the participants in Group B will be exposed to the video airway library. Each phase will last for 1 month.
10206048|NCT04953910|Experimental|Group B: Moderate hepatic impairment|Cancer participants with moderate hepatic impairment [total bilirubin > 1.5x - 3x upper limit of normal (ULN); any aspartate aminotransferase (AST) level]
9789215|NCT01352546|Experimental|BOTOX|intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.
9789216|NCT01352585||JAK2 Positive Participants|
9789217|NCT01352585||JAK2 Negative Participants|
9789218|NCT01352598|Other|Stereotactic Body Radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
9789219|NCT01352637|Placebo Comparator|Placebo + Prolonged Imaginal Exposure|Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
9789220|NCT01352637|Placebo Comparator|Placebo + VR exposure|Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
9789221|NCT01352637|Active Comparator|DCS + Prolonged Imaginal Exposure|Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
9789222|NCT01352637|Active Comparator|DCS+VR exposure|Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment
9789223|NCT01352715|Experimental|Arm A: LPV/r plus RAL|Participants were administered LPV/r plus RAL orally twice daily throughout follow-up.
9789224|NCT01352715|Experimental|Arm B: LPV/r plus best available NRTIs|"Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs (listed below) throughout follow-up-~FTC/TDF orally twice daily~ABC/3TC/ZDV orally twice daily~ABC/3TC orally once daily~3TC/ZDV orally twice daily~ABC 300mg orally twice daily or 600 mg once daily~3TC orally twice daily~ZDV orally twice daily"
9789225|NCT01352741|Experimental|Tapentadol Prolonged Release|Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
9789226|NCT01352741|Active Comparator|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.
9789227|NCT01352793|Experimental|rLP2086 vaccine|rLP2086 vaccine
9789228|NCT01352793|Other|control|The control treatment will be HAVRIX vaccine at month 0 and 6 and a normal saline injection at month 2.
9789229|NCT01352845|Experimental|rLP2086|
9789230|NCT01352845|Placebo Comparator|Control|Steril normal saline solution
9789231|NCT01353079|Experimental|Short Ragweed Pollen Allergenic Extract|
9789232|NCT01353079|Placebo Comparator|Glycero-COCAs|
9789233|NCT01353144|No Intervention|esomeprazole|esomeprazole (40 mg/day) for 8 weeks
10206049|NCT04953910|Experimental|Group C: Severe hepatic impairment|Cancer participants with severe hepatic impairment (> 3x ULN; any AST level)
10206050|NCT04953910|Active Comparator|Group A: Normal hepatic function|Cancer participants with normal hepatic function (total bilirubin ≤ ULN; AST ≤ ULN)
10206051|NCT04953897|Experimental|Group A: Severe Renal Impairment|Cancer participants with severe renal impairment not requiring dialysis (creatinine clearance [CLcr] <30 mL/min/1.73m^2)
10206052|NCT04953897|Active Comparator|Group B: Normal Renal Function|Cancer participants with normal renal function (CLcr ≥80 mL/min/1.73m^2)
9789234|NCT01353144|Active Comparator|esomeprazole plus aspirin|esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks
9789235|NCT01353196||stenosis|carotid stenosis
9789236|NCT01353196||no stenosis|no stenosis
9789237|NCT01353222|Experimental|DN24-02|Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
9789238|NCT01353222|Other|Standard of Care|Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
9789239|NCT01353274||Patients with hypertension|
9789240|NCT01353495|Experimental|APM Graft (BIOTAPE XMTM|graft applied to wound q 3 weeks for 12 weeks
9789241|NCT01353495|Active Comparator|standard wound care|Wound debridement and gels and foams applied to wound weekly for 12 weeks.
9985014|NCT03489291|Experimental|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
9985015|NCT03489018|Active Comparator|Full dose PCV13 (2p+1 schedule)|Full dose PCV13 administration in 2p+1 schedule
9838009|NCT04498416||Group 1 Post-Traumatic Stress Disorder (PTSD)|children with an identified traumatic history
9838010|NCT04498416||Group 2 Pathology|children with psychological follow-up treatment for a psychiatric disorder, without traumatic history;
9838011|NCT04498416||Group 3 Control|children without traumatic experience and without psychiatric or psychological follow-up treatment.
9838012|NCT04497844|Experimental|Niraparib with Abiraterone Acetate plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: niraparib 200 milligrams (mg), abiraterone acetate (AA) 1000 mg plus prednisone 5 mg once daily.
9838013|NCT04497844|Experimental|AA plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: matching placebo for Niraparib along with AA 1000 mg plus prednisone 5 mg once daily.
9838014|NCT04497116|Experimental|RP-3500 alone|"Phase 1:~Multiple doses of RP-3500 for oral administration alone"
9838015|NCT04497116|Experimental|Expansion cohorts with RP-3500|"Phase 2:~Expansion cohorts with RP-3500"
9838016|NCT04497116|Experimental|RP-3500 with Talazoparib or Gemcitabine|"Phase 1:~Multiple doses of RP-3500 for oral administration in combination with talazoparib or gemcitabine"
9838017|NCT04497116|Experimental|RP-3500 in children|"Phase 1:~Multiple doses of RP-3500 for oral administration alone given in children"
9985016|NCT03489018|Experimental|40% dose PCV13 (2p+1 schedule)|Fractional (40%) dose PCV13 administration in 2p+1 schedule
9985017|NCT03489018|Experimental|20% dose PCV13 (2p+1 schedule)|Fractional (20%) dose PCV13 administration in 2p+1 schedule
9838020|NCT04495634|Experimental|Head Trauma or Brain Bleed|Medically stable patients who have undergone conventional head CT imaging undergo imaging within 24 hours using the s-HCT system.
9838021|NCT04494360||Healthy Participants|Healthy participants (men and women) who have, or are likely to have, NAFLD will be enrolled in the study.
9838022|NCT04492839|Experimental|Intestial adsorbent arm|This is a single arm study, all participants will receive the class IIa intestinal adsorbent medical device
9985018|NCT03489018|Active Comparator|Full dose PCV10 (2p+1 schedule)|Full dose PCV10 administration in 2p+1 schedule
9985019|NCT03489018|Experimental|40% dose PCV10 (2p+1 schedule)|Fractional (40%) dose PCV10 administration in 2p+1 schedule
9838028|NCT04487314||Patients without Chronic Venous Disease|Individuals who do not have signs of chronic venous diseases of lower legs according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
9838029|NCT04487314||Patients with Chronic Veinous Disease|Individuals who have signs of chronic venous diseases of lower legs according to CEAP classification (telangiectases, varicose veins, venous edema, skin hyperpigmentation, lipodermatosclerosis, venous ulcer).
9838030|NCT04487080|Experimental|Treatment Arm A (Open-label): Amivantamab and Lazertinib|Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.
9838031|NCT04487080|Active Comparator|Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib|Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.
9838032|NCT04487080|Experimental|Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib|Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.
9838033|NCT04486755|Experimental|Dose Level 1|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 20 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
9838034|NCT04486755|Experimental|Dose Level 2|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 16 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
9838035|NCT04486755|Experimental|Dose Level 3|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
9838036|NCT04486261|Experimental|High-intensity strength training|"16 weeks of high-intensity strength training two times per week.~Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient)~Interventions:~Other: high-intensity strength training Drug: Usual care"
9838037|NCT04486261|No Intervention|Control|"Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient).~Intervention:~Drug: Usual care"
9838038|NCT04485754|Experimental|Telemedicine FU|Telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
9838039|NCT04485754|Active Comparator|Office FU|Office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
9838040|NCT04479852|Experimental|SP-624|Daily oral capsule, 20 mg/day
9838041|NCT04479852|Placebo Comparator|Placebo|Daily oral capsule
9985020|NCT03489018|Experimental|20% dose PCV10 (2p+1 schedule)|Fractional (20%) dose PCV10 administration in 2p+1 schedule
9838043|NCT04465669|Active Comparator|Orsiro|Implantation of a Orsiro® biolimus a9 eluting coronary stent (drug-eluting stent, DES)
9838044|NCT04465669|Active Comparator|Resolute Integrity|Implantation of a Resolute Integrity® zotarolimus eluting coronary stent (drug-eluting stent, DES)
9985021|NCT03489018|Active Comparator|Full dose PCV10 (3p+0 schedule)|The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.
9838046|NCT04464564|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
9838047|NCT04464564|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
9838048|NCT04459507||Participants With Palmoplantar pustulosis (PPP)|Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
9998189|NCT01515904||Control|Approximately 50% of attendees choose not to book into the STOMP program, for reasons including difficulty attending the frequent appointments due to distance or inability to leave work early. This population will serve as the control group for the evaluation. Control participants will be recruited from the community through posters in the hospital
9838050|NCT04457492|Experimental|Acute Facial Nerve Injury with Intact Facial Nerve|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
9838051|NCT04457492|Experimental|Facial Nerve Grafting After Surgical Excision|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
9838052|NCT04457492|No Intervention|Standard of Care Group|"No FES~Assessments will be taken at the same intervals as the interventions group."
9838053|NCT04453163|Experimental|RAAC program|"If the patient is under the RAAC group, he/she will then be received in consultation by a RAAC specialist nurse, between the anesthesia / radiology consultation and the intervention. This RAAC nurse will explain the procedure and show him/her an information video on vertebroplasty. Information about managing anxiety and pain will also be provided. In addition, the day after the patient leaves the clinic, the RAAC nurse will call him/her to inquire."
9838054|NCT04453163|Other|Standard management program|"If the patient is under the control group, he/she will be taken care of according to the standard protocol after a surgery in percutaneous vertebroplasty. The patient will not have a consultation with the specialized nurse."
9838055|NCT04452045|Experimental|SweetDreams|Access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
9838056|NCT04452045|No Intervention|Waitlist Control|Wait list condition with future access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
9838059|NCT04449510|Other|E-liquid pH 5, 7, or 9|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned e-liquid pH.
9838060|NCT04449510|Other|1 of the other 2 remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 assigned e-liquid pH.
9838061|NCT04449510|Other|Remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining assigned e-liquid pH.
9838062|NCT04449432|Experimental|GROWell (Interactive Obesity Treatment Approach)|With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four components: (1) personalized goal setting, (2) daily support and educational messages, (3) self-monitoring of behavior with tailored feedback, and (4) skills training. Each component aligns with the self- regulatory processes shown in previous studies to be necessary for behavior change. All interactions with participants are via text using a cell phone.
9838063|NCT04449432|Active Comparator|Attention Support Control|The attention control will be delivered using text messaging to reduce the potential placebo effect that interacting with our mHealth system may have on pregnancy weight gain and postpartum weight loss. Information will be provided to control group participants that is specific to pregnancy, labor, delivery, and early infancy, but not to diet. Texts are specific to the participant's partner, pregnancy, employment, and breastfeeding plans/status.
9838064|NCT04447131||COVID-19|Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).
9838065|NCT04447131||Healthy Individuals|Asymptomatic and with negative SARS-CoV-2 serology
9838066|NCT04447131||Respiratory symptoms but negative for COVID-19|Negative for SARS-CoV-2. But with respiratory symptoms
9985022|NCT03479476|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
9985023|NCT03479476|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
9985024|NCT03478488|Experimental|KN035|"KN035 plus Gemcitabine & oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.~Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
9838070|NCT04445519|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily to both eyes
9838071|NCT04445519|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
9838072|NCT04445519|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
9838073|NCT04445233||COV Participants|COVID-positive index cases (COV): Participants who are greater than or equal to 18 years of age who test positive for COVID-19 by positive NP swab
9838074|NCT04445233||COV-HC Participants|Household contact of COVID-positive index case (COV-HC): Household contacts greater than 1 year of age currently living in the same home as the COVID-positive index case
9985025|NCT03478488|Active Comparator|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
9985026|NCT03478215|Experimental|Mesenchymal Stromal Stem Cells Infusion|"Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.~Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
9985027|NCT03478215|Placebo Comparator|Placebo Infusion|Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.
9985028|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
9985029|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
9838093|NCT04442373||Patients undergoing THR with no known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment in THR patients
9838094|NCT04442373||Patients undergoing THR with known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment before and after THR in patients with bone neoplasm
9838095|NCT04441892|Experimental|QTc Meter|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device
9838096|NCT04441892|Experimental|QTc Meter - Healthy Controls|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device.
9838097|NCT04440592|Experimental|MT-7117|Oral tablet of MT-7117 once a day.
9838098|NCT04440592|Placebo Comparator|Placebo|Oral tablet of placebo once a day.
9838099|NCT04440501|No Intervention|Standard education (Control)|Standard education regarding the gluten free diet by the nutritionist will be provided.
9838100|NCT04440501|Experimental|Virtual Reality Program to teach gluten free diet|"Virtual Reality Goggles and education regarding the gluten free diet will be provided.~This group will receive VIRTUE, and watch a VR educational video, and play Chaos Café, which will be administered by a research team member. This group will be prescribed to take home the VIRTUE headset and play modules for 15 minutes per week until the 6-8 month follow up.~The VIRTUE technology will track frequency of game playing to control for adherence to the prescription."
9985030|NCT03471338|Experimental|Experimental Group|Patients benefit cognitive rehabilitation
9985031|NCT03471338|Sham Comparator|Standard Psychological care|Patients do not benefit cognitive rehabilitation
9838103|NCT04435626|Experimental|Arm 1_BAY94-8862|Adult patients receive BAY94-8862
9838104|NCT04435626|Placebo Comparator|Arm 2_Placebo|Adult patients receive placebo
9838105|NCT04433338|Experimental|Intervention group|"Participants in the intervention group will follow a low-calorie diet during 14 days before undergoing surgery. The diet will consist of both meal replacements and regular foods.~For women, the diet provides ± 900 kcal, 50 grams of carbohydrates, 85 grams of protein, 30 grams of fat and 25 grams of fibres.~For men, the diet provides ± 1000 kcal, 55 grams of carbohydrates, 100 grams of protein, 30 grams of fat and 30 grams of fibres."
9838106|NCT04433338|No Intervention|Control group|Participants in the control group can eat according to the standard nutritional advices provided by their dietitian. These advices are intended to educate participants on the recommended eating pattern after surgery.
9985032|NCT03468556|Experimental|test drug|2 tabs of SNP-610
9985033|NCT03468556|Placebo Comparator|placebo|2 tabs of placebo
9985034|NCT03467386|Experimental|Treatment (TMLI, cyclophosphamide)|Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.
9985035|NCT03466866|Experimental|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
9838111|NCT04432493|Experimental|Active TMS|Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
9838112|NCT04432493|Placebo Comparator|Sham TMS|Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
9838113|NCT04432285||Deep Brain Stimulation (GPi-DBS)|Patients with cervical dystonia (CD) who were operated at Oslo University Hospital between June 2004 and December 2017 with a DBS-device targeting the GPi bilaterally, and who have been treated with chronic GPi-DBS for a minimum of 3 years.
9838114|NCT04432285||Botulinum toxin treatment|CD patients who for a minimum of 3 years have received treatment with botulinum neurotoxin (BoNT) injections at regular intervals (minimum 12 injection cycles) and still are receiving them (Age- and gender matched to the GPi-DBS group)
9985036|NCT03466866|Active Comparator|Intensive Diabetes Education|In-home diabetes education
10206053|NCT04949022|Experimental|Hybrid closed loop system|Initiation of 780G insulin pump. First two weeks run-in-phase in open loop Manual mode, followed by a12 month study phase with advanced hybrid closed loop Auto mode.
10206054|NCT04947202||Safil Mesh|
9838118|NCT04430959|Experimental|Candesartan first then Placebo|4 weeks of candesartan with crossover to the other.
9838119|NCT04430959|Placebo Comparator|Placebo first then Candesartan|4 weeks of placebo with crossover to the other.
9838120|NCT04430101|Active Comparator|Negative WB radiographs and stress fluoroscopy|"Cohort 1~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Negative stress fluoroscopy: the midfoot is tested stable"
9838121|NCT04430101|Active Comparator|Negative WB radiographs / positive stress fluoroscopy|"Cohort 2~Negative weight bearing radiographs:~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.~Positive stress fluoroscopy: manual testing reveals midfoot instability"
9838122|NCT04430101|Other|Surgical cohort (Cohort 3)|Patients with positive weightbearing radiographs will be operated on with minimally invasive technique and followed up as an independent cohort.
9838123|NCT04423757|Experimental|BI 1358894|
9838124|NCT04423757|Placebo Comparator|Placebo|
10206055|NCT04940351|Experimental|GROUP - A: PIEZOCISION GROUP|This group will receive piezocision using piezotome inbetween the roots of mandibular anteriors after the placement of initial arch wire.
9838125|NCT04421196|No Intervention|Standard multimodal analgesic pathway with opioids|"This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.~The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) & Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr"
9838126|NCT04421196|Experimental|Modified multimodal analgesic pathway without opioids|"This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.~The modified multimodal analgesic regimen utilizes the following medications:~includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr"
10206056|NCT04940351|Experimental|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive Micro-Osteoperforation using orthodontic mini-implants and mini-implant screw driver after the placement of initial arch wire.
9789242|NCT01353508|Experimental|LCZ696 to Valsartan - Heart Failure (HF) cohort|Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
9789243|NCT01353508|Experimental|Valsartan to LCZ696 - HF Cohort|Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
9789244|NCT01353508|Experimental|LCZ696 to Valsartan - Hypertension (HTN) cohort|Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
9789245|NCT01353508|Experimental|Valsartan to LCZ696 - HTN cohort|Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.
9789246|NCT01353586|Experimental|nMARQ™ System|The nMARQ™ System (Circular and Crescent Mapping and Ablation Catheters as well as the Multi-Channel Radiofrequency Generator) as part of the Multi-Electrode Irrigated Pulmonary Vein (PV) Isolation System will serve as a treatment method for subjects undergoing radiofrequency catheter ablation for drug refractory, symptomatic Paroxysmal Atrial Fibrillation (PAF). The study later included a Subpopulation Neurological Assessments (SNA) substudy which is a prospective, non-randomized, controlled, acute assessment to compare subjects treated with the nMARQ™ System against control subjects treated with the NAVISTAR® THERMOCOOL® Irrigated Tip Catheter.
9789247|NCT01353664|Experimental|Romidepsin|This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
9789248|NCT01353703|Experimental|INFANRIX HEXA 6-10-14 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.
9789249|NCT01353703|Active Comparator|INFANRIX HEXA 2-4-6 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.
9789250|NCT01353859|Experimental|Single Arm|
9789251|NCT01353898|Experimental|MK-1972 50 mg once daily (Part I)|Ten capsules containing a total daily dose of 50 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
9789252|NCT01353898|Experimental|MK-1972 200 mg once daily (Part I)|Ten capsules containing a total daily dose of 200 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
9789253|NCT01353898|Experimental|MK-1972 800 mg once daily (Part I)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
9789254|NCT01353898|Experimental|MK-1972 25 mg twice daily (Part I)|Ten capsules containing a total daily dose of 25 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
9789255|NCT01353898|Experimental|MK-1972 100 mg twice daily (Part I)|Ten capsules containing a total daily dose of 100 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
9789256|NCT01353898|Placebo Comparator|Placebo twice daily (Part I)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part I)
9789257|NCT01353898|Experimental|MK-1972 800 mg twice daily (Part II)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part II)
9789258|NCT01353898|Placebo Comparator|Placebo twice daily (Part II)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part II)
9789259|NCT01353911|Experimental|Grazoprevir 100 mg|TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
9789260|NCT01353911|Experimental|Grazoprevir 200 mg|TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
9789261|NCT01353911|Experimental|Grazoprevir 400 mg|TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
9789262|NCT01353911|Experimental|Grazoprevir 800 mg|TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
9789263|NCT01353911|Active Comparator|Boceprevir 800 mg|TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.
9789264|NCT01353911|Experimental|Grazoprevir 400 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
9789265|NCT01353911|Experimental|Grazoprevir 800 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
9789266|NCT01353911|Experimental|OL Grazoprevir 100 mg|TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
9789267|NCT01353963||1|
9789268|NCT01353976|Experimental|Econazole Nitrate Foam 1%|Study medication
9789269|NCT01353976|Placebo Comparator|Vehicle Foam|Placebo medication
9789270|NCT01354015|Experimental|Use of messaging system|Use of DRMS
9789271|NCT01354015|No Intervention|Usual Care|Usual Care
9789272|NCT01354028|Experimental|Massage therapy|Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
9789273|NCT01354028|No Intervention|No massage therapy|This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.
9789274|NCT01354106|Experimental|3M Kind Removal Silicone Tape|"investigational medical Silicone tape, 1 x 1.5 sample, applied on time, worn for 24 hours."
9789275|NCT01354106|Other|3M Micropore Medical Tape|"Commercially available Medical Paper Tape, 1 x 1.5 sample, applied on time, worn for 24 hours. Study Control."
9789276|NCT01354132|Active Comparator|n-acetyl-cysteine|N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks
9789277|NCT01354132|Placebo Comparator|Placebo|matching effervescent tablets in water 2 in am and 1 in pm
9789278|NCT01354145|Experimental|Chondroitin sulfate (Condrosan)|CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
9789279|NCT01354145|Active Comparator|Celecoxib|CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
9789280|NCT01354197||All ICU admission patients|All ICU admission to surgical intensive care unit at cohort time
9789281|NCT01354223|Experimental|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
9789282|NCT01354223|Active Comparator|ocufilcon B contact lens|Randomized to ocufilcon B contact lens worn in a daily wear, daily disposable mode
9789283|NCT01354314|Experimental|Fluconazole|Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine
9789284|NCT01354314|Experimental|Paroxetine|Paroxetine 20 mg orally once per day; placebo in place of fluconazole
9789285|NCT01354314|Experimental|Paroxetine and Fluconazole|Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
9789286|NCT01354314|Placebo Comparator|Placebo|Placebo in place of both fluconazole and paroxetine
9789287|NCT01354353|Active Comparator|Aripiprazole|Part A: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 21). Part B: Continue current prescribed dosing regimen (≤ 30 milligrams [mg]/day ) -- Study Day 1 to discharge (Study Day 23, 25 or 28 based on adaptive design)
9789288|NCT01354353|Experimental|Part A: 160 mg LY2140023|Administered orally, twice daily (BID) for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
9789289|NCT01354353|Experimental|Part A: 240 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
9789290|NCT01354353|Experimental|Part A: 320 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
9789291|NCT01354353|Experimental|Part A: 400 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
9789292|NCT01354353|Experimental|Part A: 480 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
9789293|NCT01354353|Experimental|Part B: LY2140023|If doses up to or equal to 400 mg BID are not tolerated, Part B of the study may be started. The dose of LY2140023 will be titrated in the same participant from highest dose that was tolerated in Part A, with the intention to reach a dose of 480 mg LY2140023.
9789294|NCT01354444|Active Comparator|Carvedilol|Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.
9789295|NCT01354444|Placebo Comparator|Placebo|Non active substance
9789296|NCT01354496|Experimental|Cohort 1 - LY2409021 reference form|A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state
9789297|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fed|Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
9789298|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
9789299|NCT01354496|Experimental|Cohort 2 - LY2409021 low test form fasted|Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state
9789300|NCT01354496|Experimental|Cohort 2 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
9789301|NCT01354496|Experimental|Cohort 2 - LY2409021 high test form fasted|Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state
9789302|NCT01354652|Experimental|entecavir|"Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
9800455|NCT01688102|Active Comparator|Oral Vitamin D3|Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of oral vitamin D.
9985037|NCT03465384|Active Comparator|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
9838129|NCT04420845|Other|Intervention|
9985038|NCT03465384|Experimental|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
9985039|NCT03462511|No Intervention|Control Group|Dyads randomized to the control group will receive standard care and education handouts.
9985040|NCT03462511|Experimental|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
9838133|NCT04419168|Experimental|cCBT|Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
9838134|NCT04419168|Experimental|m-Education|Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
9838135|NCT04419168|No Intervention|Convenience Comparison|Not participating in the intervention. Participants will complete the baseline questionnaire battery only and we will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.
9985041|NCT03459781|Experimental|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
9985042|NCT03459781|Active Comparator|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
9838138|NCT04413461|Experimental|TENS|
9838139|NCT04413461|Placebo Comparator|TENS Sham|
9985043|NCT03458546|Experimental|Roflumilast and R-CHOP|
9985044|NCT03454997|Active Comparator|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
9838142|NCT04410224|Experimental|ASN004 ascending doses|Patients will receive escalating doses of ASN004 to identify the best dose for further study.
9985045|NCT03454997|Active Comparator|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
9985046|NCT03454191|Experimental|Erector spinae plane block|
9985047|NCT03454191|Placebo Comparator|Placebo|
9985048|NCT03452007|Experimental|Bladder Mapping and Training|Individuals already implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
9838147|NCT04408755|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
9838148|NCT04408755|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
10206057|NCT04939545|Experimental|Experimental Intervention Ropivacain|Ropivacain Fresenius 0.2% is a solution for infusion/ injection and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter (ICC) between parietal pleura and fascia endo-thoracica at the level of surgical incision for a maximum of 72 hours at an initial standard flow rate setting of 6 ml/h using 2 mg/ml ropivacaine. In case pain exceeds 7 on NRS later than 2 hours after skin closure the flow rate will be adjusted on 8 ml/h. Furthermore, Ropivacain Fresenius 0.2% will be provided in a 20 ml glass vial for flushing the infusion line and subpleural administration.
10206058|NCT04939545|Placebo Comparator|Control Intervention Placebo|Placebo (NaCl 0.9% B. Braun) is an isotonic solution for infusion and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter (ICC) between parietal pleura and fascia endo-thoracica at the level of surgical incision for a maximum of 72 hours at an initial standard flow rate setting of 6 ml/h using NaCl 0.9%. In case pain exceeds 7 on NRS later than 2 hours after skin closure the flow rate will be adjusted on 8 ml/h. Furthermore, NaCl 0.9% will be provided in a 20 ml glass vial for flushing the infusion line and for subpleural administration, which will be prepared by the hospital pharmacy.
10206059|NCT04936607|Experimental|Personnalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; >18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio <2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
9838154|NCT04397276|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
9838155|NCT04397276|Experimental|Part 2: Dose Expansion|Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.
9838156|NCT04397263|Experimental|Guselkumab|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.
9985049|NCT03451708|Experimental|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
10206060|NCT04936607|Active Comparator|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
9838164|NCT04394546|Experimental|Device Group|Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
9838165|NCT04394546|Active Comparator|Control Group|Randomized to non-vitamin K oral anticoagulant (NOAC)
10206061|NCT04933708|Experimental|Labor Podcast Group|"1) Labor Podcast Group - Women randomized to this arm will receive access to a link to download six HUP physician created labor podcasts in addition to usual care during labor, delivery, and postpartum~o Podcast topics: Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth~LAS-10 and Birth Satisfaction survey - Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~EPDS - Women will receive this survey on postpartum day 7 via method they desire"
9838167|NCT04391114|Active Comparator|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to Transurethral Resection of the Prostate (TURP) and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
9838168|NCT04391114|Active Comparator|Top-Down HoLEP|"The Top-Down HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve, with anticipated improved continence [8]. A variation of this method is also being explored in Japan (termed the en-bloc technique with anteroposterior dissection HoLEP) [9]. The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique."
10206062|NCT04933708|No Intervention|Usual Care|"2. Usual care Women randomized to this arm will receive usual care during labor, delivery, and postpartum with the following exceptions:~LAS-10 and Birth Satisfaction survey Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~EPDS Women will receive this survey on postpartum day 7 via method they desire"
9838170|NCT04383340|Experimental|Mother-Infant Transaction Program|Four sessions were delivered to the mothers one-on-one based on a manualized protocol while the infants were still in the neonatal intensive care units. These coaching sessions included psychological care for the mother and topics on recognizing premature infant's characteristics, understanding and recognizing signs of infant stress and infant's engagement and disengagement cues, principles of graded stimulation, and how to optimize interactions and avoid over-stimulating the infant.
9838171|NCT04383340|Active Comparator|Treatment as usual|For this group, infants and mothers received standard hospital care following the initial baseline assessment; these mothers were invited to ask questions about recommended ways to take care of their infants, but no specific knowledge or skills targeted by the adapted MITP program were taught
10206063|NCT04932733|Experimental|Elderly isometric exercise|Quadriceps isometric exercise.
9935800|NCT03198351||Cohort I|Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
9935801|NCT03198351||Cohort II|Pregnant women with MS not exposed to teriflunomide during the current pregnancy
9935802|NCT03198351||Cohort III|Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen
10206064|NCT04932733|Active Comparator|Young isometric exercise|Quadriceps isometric exercise.
10206065|NCT04932590|Experimental|Patients|Patients less than 2 years old admitted in the pediatric intensive care unit of the Armand-Trousseau hospital, under invasive mechanical ventilation and in whom a volume expansion is planned by the attending physicians.
10206066|NCT04929483|Experimental|BIO89-100 - 15 mg QW|
10206067|NCT04929483|Experimental|Experimental: BIO89-100 - 30 mg QW|
10206068|NCT04929483|Experimental|Experimental: BIO89-100 - 44 mg Q2W|
10206069|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo QW|
10206070|NCT04929483|Placebo Comparator|Placebo Comparator: Placebo Q2W|
10206071|NCT04929379|Experimental|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
10206072|NCT04929379|Placebo Comparator|Placebo|Inactive tablets identical to fenofibrate
10206073|NCT04926090|Experimental|Emotional Support Plan - Clinician Guided (ESP-C) + (Bi)Weekly Monitoring|This will involve brief assessment visits throughout the fall semester, without prompting to use the ESP-C. Visits will be weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
10206074|NCT04926090|Experimental|Emotional Support Plan - Clinician Guided (ESP-C) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will also participate in brief assessment visits conducted weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
10206075|NCT04926090|Experimental|Emotional Support Plan - Self Guided (ESP-S) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt. They will be asked to complete questionnaires weekly for the first 6 weeks and then biweekly for the remaining 9 weeks of the term.
9789303|NCT01354652|Active Comparator|lamivudine|"Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
9789304|NCT01354652|No Intervention|no NRTI group|hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence
9789305|NCT01354691|Experimental|ladostigil hemitartrate|Ladostigil capsules 80 mg
9789306|NCT01354691|Placebo Comparator|Placebo|Placebo capsules
9789307|NCT01354938||Acute Exacerbation of Chronic Bronchitis (AECB)|Participants with a diagnosis of chronic bronchitis and signs and symptoms of an acute exacerbation who were prescribed Klaricid XL (500 mg of modified release clarithromycin) at a dose of one tablet once a day or two tablets once a day based on physician's decision of severity of symptoms per routine clinical care.
9789308|NCT01354964|Experimental|Vitamin D|Participants received weekly oral vitamin D drops using a weight-based calculated dosage for up to six months.
9789309|NCT01354964|Placebo Comparator|Placebo|Participants received weekly oral placebo drops (similar in taste and appearance to vitamin D) for up to six months.
9799434|NCT01659866|Active Comparator|Cipro-resistant|"Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~ceftriaxone 500 mg intramuscularly 2 hours before the procedure~gentamicin 2mg/kg intramuscularly 2 hours before the procedure~amikacin 5 mg/kg intramuscularly 2 hours before the procedure~aztreonam 500 mg intramuscularly 2 hours before the procedure~imipenem 500 mg intramuscularly 2 hours before the procedure~ceftriaxone 2000 mg intravenously 1 hour before the procedure~gentamicin 2 mg/kg intravenously 1 hour before the procedure~amikacin 5mg/kg intravenously 1 hour before the procedure~aztreonam 2000 mg intravenously 1 hour before the procedure~imipenem 1000 mg intravenously 1 hour before the procedure"
9799435|NCT01659996|Experimental|Menactra Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® at 15 to 18 months of age.
9799436|NCT01659996|Experimental|Menactra and Pentacel Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed (Pentacel®) concomitantly at 15 to 18 months of age.
9799437|NCT01659996|Active Comparator|Pentacel Vaccine Group|Participants will receive only Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Pentacel®) at 15 to 18 months of age.
9799438|NCT01660022|Experimental|OZ439 100mg|100mg OZ439 single oral dose
9799439|NCT01660022|Experimental|OZ439 100 mg + PQP 160mg|100mg OZ439 single oral dose + 160mg Piperaquine single oral dose
9799440|NCT01660022|Experimental|OZ439 100 mg + PQP 480mg|100mg OZ439 single oral dose + 480mg Piperaquine single oral dose
9799441|NCT01660022|Experimental|OZ439 100 mg + PQP 1440mg|100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
9799442|NCT01660022|Experimental|OZ439 300mg|300mg OZ439 single oral dose
9799443|NCT01660022|Experimental|OZ439 300 mg + PQP 1440mg|300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
9799444|NCT01660022|Experimental|OZ439 800mg|800mg OZ439 single oral dose
9799445|NCT01660022|Experimental|OZ439 800 mg + PQP 1440mg|800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
9799446|NCT01660022|Placebo Comparator|Placebo|Placebo
9799447|NCT01660191|Active Comparator|Pitavastatin 4mg|Pitavastatin 4mg tablet by mouth once daily for 12 weeks
9799448|NCT01660191|Active Comparator|Atorvastatin 20mg|Atorvastatin 20mg tablet by mouth once daily for 12 weeks
9799449|NCT01660191|Active Comparator|rosuvastatin 5 mg|rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
9799450|NCT01660230|Active Comparator|6 µg/kg 3K3A-APC, single-dose|Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
9799451|NCT01660230|Active Comparator|30 µg/kg 3K3A-APC, single-dose|Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
9985050|NCT03451708|Experimental|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
9799452|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, single-dose|Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
9799453|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, single-dose|Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
9799454|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, single-dose|Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
9799455|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, single-dose|Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
9799456|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
9985051|NCT03451708|Experimental|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
9985052|NCT03451708|Experimental|OKS and gait|Effect of OKS on gait and balance
9838172|NCT04381559|Experimental|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
9838173|NCT04381559|Active Comparator|Applied Relaxation|In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response. AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety. This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition. Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety. However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
9838174|NCT04381429|Active Comparator|Group 1: A-F-A-F|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid).~Each treatment period will last 3 months."
9838175|NCT04381429|Active Comparator|Groupe 2: F-A-F-A|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP)."
9838176|NCT04378699|Experimental|SMR Sensory Motor Rhythm (12-15 Hz)|3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region
9838177|NCT04378699|Experimental|the alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
9985053|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
9838179|NCT04372628|Active Comparator|Group 1 - Lopinavir/Ritonavir|Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)
9838180|NCT04372628|Placebo Comparator|Control Group|Placebo unmatched orally twice daily for 14 days
9838181|NCT04372563||healthy|Healthy patients with normal aortic dimensions
9838182|NCT04372563||ascending aortic dilation 45-55, operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves operated on
9838183|NCT04372563||ascending aortic dilation 45-55, non operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves non operated
9838184|NCT04372251|Active Comparator|Sinus tarsi approach (STA)|Patients randomized to this arm are operated with plate osteosynthesis via the sinus tarsi approach
9838185|NCT04372251|Active Comparator|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Patients randomized to this arm are operated with percutaneous reduction of the fracture and osteosynthesis with screws, assisted by subtalar arthroscopy
9985054|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
9985055|NCT03449095|Experimental|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
9838188|NCT04369612|Active Comparator|Standard of care|Standard follow-up after kidney transplantation during the first 7-8 post-transplant weeks
9838189|NCT04369612|Experimental|Home-based monitoring|Every second visit will be performed without patients actually visiting the hospital. They take a capillary blood sample themselves, send it to the lab and get a telecom follow-up by treating physician the same day.
9838190|NCT04367090|Experimental|Pyrotinib and docetaxel plus trastuzumab|
9985056|NCT03449095|No Intervention|Control Beverage Administration|Participants consume a non-alcoholic beverage
9838197|NCT04356261|Placebo Comparator|Control PNF|Personalized Normative Feedback on non-alcohol/health related topics delivered in all weekly rounds (active control)
9838198|NCT04356261|Active Comparator|Light Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 33% of weekly rounds
9838199|NCT04356261|Active Comparator|Heavy Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 67% of weekly rounds
9838200|NCT04350606|Experimental|PF-006462700 group|All enrolled participants will be administrated PF-006462700.
9838201|NCT04349319|Other|Digital preoperative planning|To use digital preoperative planning software
9789310|NCT01354990||Participants treated with sitagliptin|
9789311|NCT01355068|Active Comparator|Treatment A|Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
9789312|NCT01355068|Experimental|Treatment B|Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)
9789313|NCT01355081|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.
9789314|NCT01355081|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.
9789315|NCT01355081|Placebo Comparator|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.
9789316|NCT01355159|Experimental|Folic Acid 4 mg|Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
9789317|NCT01355159|Placebo Comparator|Placebo|Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo
9789318|NCT01355224|No Intervention|No risk feedback|No obesity risk information given (control)
9789319|NCT01355224|Experimental|Genetic risk feedback|Only personal genetic risk information provided
9789320|NCT01355224|Experimental|Lifestyle risk feedback|Only personal lifestyle risk information provided
9789321|NCT01355224|Experimental|Both genetic or lifestyle risk feedback|Personal genetic and lifestyle information provided
9789322|NCT01355289|Placebo Comparator|Placebo (Core Study)|Placebo, will be administered orally, once daily for up to 21 days.
9789323|NCT01355289|Active Comparator|Avatrombopag 10 mg (Core Study)|Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.
9789324|NCT01355289|Active Comparator|Avatrombopag 20 mg (Core Study)|Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.
9789325|NCT01355289|Active Comparator|Avatrombopag 30 mg (Core Study)|Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.
9789326|NCT01355289|Experimental|Avatrombopag (Open-Label Extension)|Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
9789327|NCT01355302|Experimental|Phase Ib: Cohort 1 and 2 and 3|"Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine~Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine"
9789328|NCT01355302|Active Comparator|Phase II: Arm 1; E7050 + cisplatin+ capecitabine|Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine
9789329|NCT01355419||obstructive sleep apnea, CPAP|moderate to severe obstructive sleep apnea requiring CPAP therapy
9789330|NCT01355458|Experimental|CD07805/47 gel|
9789331|NCT01355458|Placebo Comparator|Placebo|
9789332|NCT01355471|Experimental|CD07805/47 gel|
9789333|NCT01355471|Placebo Comparator|Placebo|
9789334|NCT01355484|Experimental|GTx-024|subject will receive GTx-024 treatment for the duration of the trial
9789335|NCT01355484|Placebo Comparator|Placebo|subject will receive placebo for the duration of the trial
9789336|NCT01355497|Experimental|GTx-024 3mg once daily|subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial
9789337|NCT01355497|Placebo Comparator|placebo|subjects will be randomized to receive matching placebo once daily for the duration of the trial
9789338|NCT01355523|Active Comparator|Melatonin|6 mg oral melatonin daily
9789339|NCT01355523|Placebo Comparator|Placebo|6 mg oral placebo daily
9789340|NCT01355575|Experimental|Rifaximin for 6-weeks followed by 6-week observation period|All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.
9789341|NCT01355588|Experimental|Ketorolac Tromethamine|
9789342|NCT01355588|Experimental|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|
9789343|NCT01355588|Experimental|Ketorolac Tromethamine with 5% Lidocaine HCl|
9789344|NCT01355588|Experimental|Ketorolac Tromethamine with 6% Lidocaine HCl|
9789345|NCT01355627|Experimental|TachoSil®|
9789346|NCT01355627|Active Comparator|Current practice group|
9789347|NCT01355705|Experimental|Amrubicin + Lenalidomide + Dexamethasone|"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.~Concurrent therapeutic medications:~Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14~Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)~Other drugs:~Aspirin: 81 or 325 mg daily oral~Pegfilgrastim subcutaneous on Day 2"
9789348|NCT01355796|Experimental|Aerosolized Hypertonic xyltiol|Aerosolized xylitol (5 ml) twice daily for 14 days
9789349|NCT01355796|Active Comparator|Hypertonic saline|Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
9789350|NCT01355978|Experimental|Noninvasive Open Ventilation System|Portable noninvasive open ventilator & nasal interface.
9789351|NCT01356147|Sham Comparator|Sham placebo|No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
9789352|NCT01356147|Active Comparator|Dornase alfa|Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
9789353|NCT01356277|Experimental|Multi-component Intervention|"Multi-component Intervention consisting of:~Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~text message, email, or visual cue dose reminders"
9789354|NCT01356277|No Intervention|Attention control|Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.
9789355|NCT01356407|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day before the colonoscopy."
9789356|NCT01356407|Active Comparator|PEG-ELS|PEG-ELS was used according to the approved labeled dosage and administration instructions. Only received one dose of 2 boxes (6 packets), administrated on the day of colonoscopy examination.
9789357|NCT01356498|Experimental|q2 RCT|Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
9789358|NCT01356498|Experimental|q4 RCT|Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
9789359|NCT01356498|Experimental|Placebo in RCT|Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
9789360|NCT01356589||Cohort|
9789361|NCT01356602|Experimental|Canakinumab, pre-filled syringes (PFS)|Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
9789362|NCT01356602|Active Comparator|Canakinumab, lyophilizate (LYO)|The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
9789363|NCT01356602|Active Comparator|Triamcinolone Acetonide|The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
9789364|NCT01356628|Experimental|PD-0332991|PD-0332991 in the Treatment in Patients with Advanced Hepatocellular Carcinoma
9789365|NCT01356940|Active Comparator|dalfampridine ER 10mg bid-placebo|4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control
9789366|NCT01356940|Placebo Comparator|placebo-dalfampridine ER 10mg bid|placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid
9789367|NCT01356966|Experimental|Tetrahydrobiopterin + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily
9789368|NCT01356966|Placebo Comparator|Placebo + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily
9789369|NCT01357135||Metformin + Sitagliptin|Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.
9789370|NCT01357135||Metformin + Sulfonylurea|Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.
9789371|NCT01357135||Sitagliptin +/- Other Antihyperglycemic Medication|Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.
9789372|NCT01357148||Participants treated with sitagliptin phosphate/metformin HCl|
9789373|NCT01357161|Experimental|Part 1: MK-1775 225 mg + paclitaxel +carboplatin|During the open-label run-in, participants receive 225 mg MK-1775 twice daily (BID) starting on Day 1 of Cycle 1 (cycle=21 days) for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (area under the curve [AUC] 5).
9789374|NCT01357161|Experimental|Part 2: MK-1775 225 mg + paclitaxel +carboplatin|During Part 2, participants receive 225 mg MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
9789375|NCT01357161|Placebo Comparator|Part 2: Placebo + paclitaxel +carboplatin|During Part 2, participants receive matched placebo to MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive placebo in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
9789376|NCT01357239|Experimental|25 mg bid|
9789377|NCT01357239|Experimental|50 mg bid|
9789378|NCT01357239|Experimental|100 mg bid|
9789379|NCT01357239|Placebo Comparator|Placebo|
9789380|NCT01357356|Experimental|SER120 (750 ng/day)|SER120 (750 ng/day)
9789381|NCT01357356|Experimental|SER120 (1000 ng/day)|SER120 (1000 ng/day)
9789382|NCT01357356|Experimental|SER120 (1500 ng/day)|SER120 (1500 ng/day)
9789383|NCT01357356|Placebo Comparator|Placebo|Placebo
9789384|NCT01357512|Experimental|MRI done|Subjects with MRI prior prostate biopsies
9789385|NCT01357512|No Intervention|no MRI|No MRI before prostate biopsies
9789386|NCT01357525|Other|Stereotactic Body Radiotherapy|
9799457|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
10206076|NCT04925843||Patients undergoing liver transplant for end-stage liver disease|The investigators propose to conduct a retrospective cohort study to explore the association between fibrinogen concentration and intraoperative bleeding in patients who underwent a liver transplant between July 2008 and January 2021.
10206077|NCT04922697|Experimental|Prevention (educational videos, questionnaires)|Participants watch 2 educational videos during week 3 regarding air pollution, health effects, and personal preventive health behaviors to reduce air pollution exposure. Participants will use wearable air pollution sensors. Participants will complete questionnaires at weeks 1 and 5.
10206078|NCT04920292|Experimental|Single Dose of 100mg Oxfendazole versus Placebo|8 participants will receive a single oral dose of 100mg of oxfendazole. 2 participants will receive a single oral dose of placebo.
10206079|NCT04920292|Experimental|Single Dose of 400mg Oxfendazole versus Placebo|8 participants will receive a single oral dose of 400mg of oxfendazole. 2 participants will receive a single oral dose of placebo.
10206080|NCT04920292|Experimental|Multiple Doses of 400mg Oxfendazole versus Placebo|"8 participants will receive multiple oral doses of 400mg of oxfendazole on 5 consecutive days.~2 participants will receive multiple oral doses of placebo on 5 consecutive days."
10206081|NCT04917614|Active Comparator|group teas|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at Hegu (LI4), Neiguan (PC6), and Zusanli (St 36) with an electronic acupuncture device.
10206082|NCT04917614|Sham Comparator|Control Group|In the sham group, the patients were connected to the electronic acupuncture, but electronic stimulation was not applied.
10206083|NCT04917029|Active Comparator|Active:Group A|Group A: receive 40 ml bupivacaine 0.25% +5 ml placebo in FICB perineurally in generally anaesthetized patients with intravenous infusion of 0.5 µg/kg/h of Dexmedetomidine.
10206084|NCT04917029|Active Comparator|(Group B|Group B: receive FICB with dexmedetomidine 80µg diluted in 5 ml normal saline and 40 ml bupivacaine 0.25% added perineurally in generally anaesthetized patients without dexmedetomidine infusion.
10206085|NCT04914637|Active Comparator|interlaminar epidural steroid injection plus dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. Also, dry needling will be applied to the active trigger points for the patients in this group.~Interlaminar epidural steroid injection will be applied at week 0, while dry needling will be applied in 3 sessions per week (week 0, week 1, week 2). The first session of the dry needling will be in the same day with interlaminar epidural steroid injection."
9789387|NCT01357551|Experimental|Maintenance intervention|Participants receive a theoretically-informed maintenance intervention for 42 weeks, followed by 14 weeks of no intervention contact to examine sustainability. The maintenance intervention involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
9789388|NCT01357551|No Intervention|Usual care|Participants receive usual care for 56 weeks
9789389|NCT01357564|Experimental|Tailored Activity Program|Occupational therapists assess the person's home environment, preserved capabilities, daily routines, interests and the caregiver's readiness and ability to use activities. Activities are developed that reflect the Veteran's previous or current interests and are modified to match their preserved capabilities without taxing the most impaired areas of cognition (e.g., memory, new learning). TAP-VA provides caregivers with the knowledge and skills to use activities. The overall goal is to provide predictability, familiarity, and structure in the daily life of the Veteran and establish a level of environmental stimulation appropriate to that person's abilities.
9789390|NCT01357564|Active Comparator|Attention Control|Caregivers in this group receive bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers are provided important information about dementia and strategies for disease management. Each telephone contact begins with a brief overview of the specific purpose of the session, followed by a description of the key facts about the session topic, and concludes with a question and answer period. The attention control group intervention is delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
9789391|NCT01357577|Experimental|Arm 1: TAU + CBT|The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
9789392|NCT01357577|No Intervention|Arm 2: TAU|"The no intervention group will receive treatment as usual (TAU)."
9789393|NCT01357616|Experimental|AZARGA|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
9789394|NCT01357616|Active Comparator|AZOPT + Timolol|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in the affected eye(s), followed by Timolol 0.5% ophthalmic solution, 1 drop instilled in the affected eye(s). Approximately 10 minutes separated the 2 instillations. The study drugs were instilled twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
9789395|NCT01357655|Active Comparator|Arm 1: Dasatinib|
9789396|NCT01357655|Experimental|Arm2: Dasatinib + BMS-833923|Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response
9789397|NCT01357720|Experimental|Quinvaxem|
9789398|NCT01357720|Active Comparator|Tritanrix Hib/HepB + Quinvaxem|
9789399|NCT01357850|Experimental|GSK716155 (3.75mg)|GSK716155 (3.75mg)
9789400|NCT01357850|Experimental|GSK716155 (15mg)|GSK716155 (15mg)
9789401|NCT01357850|Experimental|GSK716155 (30mg)|GSK716155 (30mg)
9789402|NCT01357850|Placebo Comparator|GSK716155-matched placebo|GSK716155-matcued placebo
9789403|NCT01357889|Active Comparator|process 2 albiglutide|albiglutide 30mg from process 2 drug substance
9789404|NCT01357889|Active Comparator|process 3 albiglutide|albiglutide 30mg from process 3 drug substance
9789405|NCT01357915|Experimental|GSK149203A S- Group|Male subjects who received 3 doses of GSK Biologicals' candidate GSK149203A vaccine according to a 0-1-6 month schedule in the primary study 108890 (NCT00435396).
9789406|NCT01357915|Other|GSK149203A S+ Group|Male subjects who were assessed as being naturally infected with Cytomegalovirus (CMV) at the screening visit of the primary study 108890 (NCT00435396).
9789407|NCT01357980|Experimental|Dysport 750 U (15 injection sites)|
9789408|NCT01357980|Placebo Comparator|Placebo (15 injection sites)|
9789409|NCT01357980|Experimental|Dysport 750 U (30 injection sites)|
9789410|NCT01357980|Placebo Comparator|Placebo (30 injection sites)|
9789411|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 75 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
9789412|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
9789413|NCT01358175|Placebo Comparator|Placebo|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
9789414|NCT01358266|Active Comparator|Ophthalmic solution low dose|
9789415|NCT01358266|Active Comparator|Ophthalmic solution medium dose|
9789416|NCT01358266|Active Comparator|Ophthalmic solution high dose|
9789417|NCT01358331|Experimental|MK-8353 100 mg twice daily (BID)|100 mg capsules administered orally twice daily for 28 days for each cycle
9789418|NCT01358331|Experimental|MK-8353 200 mg BID|200 mg capsules administered orally twice daily for 28 days for each cycle
9789419|NCT01358331|Experimental|MK-6353 300 mg BID|300 mg capsules administered orally twice daily for 28 days for each cycle
9789420|NCT01358331|Experimental|MK-8353 350 mg BID|350 mg capsules administered orally twice daily for 28 days for each cycle
9789421|NCT01358331|Experimental|MK-8353 400 mg BID|400 mg capsules administered orally twice daily for 28 days for each cycle
9789422|NCT01358331|Experimental|MK-8353 800 mg BID|800 mg capsules administered orally twice daily for 28 days for each cycle
9789423|NCT01358357|Experimental|Lurasidone 20-80 mg flexible dose|
9789424|NCT01358357|Placebo Comparator|Placebo|
9789425|NCT01358526|Experimental|OXN|Oxycodone/Naloxone Controlled-release Tablets (OXN)
9789426|NCT01358526|Placebo Comparator|Placebo|Placebo tablets to match OXN
9789427|NCT01358578|Experimental|AIN457 150mg|AIN457 150mg
9789428|NCT01358578|Experimental|AIN457 300mg|AIN457 300mg
9789429|NCT01358578|Placebo Comparator|Placebo|Placebo
9789430|NCT01358578|Active Comparator|Etanercept|Etanercept
9789431|NCT01358578|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
9789432|NCT01358578|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase
9789433|NCT01358708|Experimental|LACTEOL® 340 mg|
9789434|NCT01358708|Placebo Comparator|PLACEBO|
9789435|NCT01358721|Experimental|Arm 1: BMS-936558|
9789436|NCT01358721|Experimental|Arm 2: BMS-936558|
9789437|NCT01358721|Experimental|Arm 3: BMS-936558|
9789438|NCT01358721|Experimental|Arm 4: BMS-936558|(treatment naive)
9789439|NCT01358734|Experimental|Lenalidomide in combination with azacitidine|Repeated cycles of azacitidine 75 mg/m^2/day subcutaneous (SC) on Days 1-7 and lenalidomide 50 mg/day by mouth (PO) on Days 8-28 followed by a 14-day break plus best supportive care
9789440|NCT01358734|Experimental|Lenalidomide - single agent|Lenalidomide 50 mg PO daily for 28 days for the first 2 cycles and lenalidomide 25 mg daily for 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg daily PO plus best supportive care
9789441|NCT01358734|Experimental|Azacitidine-single agent|Repeated cycles of azacitidine 75mg/m^2/day subcutaneous on Days 1-7 followed by a 21-day break plus best supportive care
9789442|NCT01358760|Placebo Comparator|Placebo|
9789443|NCT01358760|Experimental|0.25% DHEA|
9789444|NCT01358760|Experimental|0.5% DHEA|
9789445|NCT01358825|Experimental|Infanrix hexa Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034.
9789446|NCT01358825|Experimental|Infanrix-IPV/Hib Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib™ (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034.
9789447|NCT01358864|Active Comparator|Placebo/PegIFN/RBV|patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
9789448|NCT01358864|Experimental|BI201335 12 weeks|patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
9789449|NCT01358864|Experimental|BI201335 24 weeks|patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
9789450|NCT01358968|Experimental|LY2603618|"Single 50 milligrams (mg) oral dose of desipramine on day 1 of study period 1. Single 275 mg intravenous infusion over one hour of LY2603618 followed by single 50 mg oral dose of desipramine on day 1 of study period 2. Participants may then receive additional doses of LY2603618 in combination as follows: 1000 milligrams per square meter (mg/m²) intravenous administration over 30 minutes of gemcitabine on days 1, 8 and 15 and 230 mg intravenous dose of LY2603618 on days 2, 9 and 16 of 28-day cycles OR 500 mg/m² intravenous administration over 10 minutes of pemetrexed on day 1 and 275 mg intravenous dose of LY2603618 on day 2 of 21-day cycles.~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
9799458|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
9799459|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, q12h for 5 doses|Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
9985057|NCT03441958|Experimental|ECT-001 (UM171) expanded cord blood|"Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy.~The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.~Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
9838206|NCT04349111|Other|Experimental: Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
9985058|NCT03440736|Active Comparator|Secukinumab 300 mg s.c.|Patients in arm A receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24)
9985059|NCT03440736|Experimental|Secukinumab 300 mg s.c. and lifestyle intervention|Arm B: Patients in arm B receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24). In addition they participate in a lifestyle intervention program.
9985060|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 18 months
9985061|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
9838211|NCT04344873|Experimental|Older Adult participants|Older adult participants (ages 55-75) will be assessed for arterial function using FMD analysis, PWV calculations, T Cell phenotyping, and proportion of inflammatory biomarkers after injections of placebo and abatacept.
9985062|NCT03439254|Placebo Comparator|Placebo|Placebo for up to 18 months
9985063|NCT03439124|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
10206086|NCT04914637|Sham Comparator|interlaminar epidural steroid injection plus sham dry needling|"Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered same as the arm titled interlaminar epidural steroid injection plus dry needling. The only difference in the interventions in this arm is that dry needling is applied without penetrating the skin. The blunt tip of the needle will be used in sham intervention.~Interlaminar epidural steroid injection will be applied at week 0, while sham dry needling will be applied in 3 sessions per week (week 0, week 1, week 2)"
9838223|NCT04338022|Experimental|Evobrutinib + Teriflunomide matched Placebo: DB Period|
9838224|NCT04338022|Active Comparator|Teriflunomide + Evobrutinib matched Placebo: DB Period|
9838225|NCT04338022|Experimental|Evobrutinib: Open-Label Extension Period|
9838226|NCT04336189|Active Comparator|SP + DP placebo every 4 weeks|
9838227|NCT04336189|Active Comparator|DP + SP placebo every 4 weeks|
9838228|NCT04336189|Active Comparator|SP + DP given every 4 weeks|
9921962|NCT00833183|Active Comparator|25 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
9838229|NCT04335240|Experimental|Music Therapy Intervention|"This protocol is a Family Centered Care Music Therapy Intervention. The methodologies will provide early intervention from the first days of hospitalization in NICU and consist of music therapy sessions both active (parental chant, live music and lullaby) and receptive (listening to recorded tracks). The music therapy accompanies the newborn and the parents during the hospitalization and focuses its attention on the emotional-relational care, according to the different needs that they will develop over time.Therapy sessions will be performed starting from three times per week, on three different days of the week, during the entire hospitalization of the enrolled infants. After discharge music therapy treatment will be performed once a week until twelve months of corrected age.~Stress level of infants and parents and neurobehavioral and neurological development of children will be assessed."
9838230|NCT04335240|No Intervention|No music therapy intervention|Music therapy is not administered in this group. Control group (no music therapy). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
9985064|NCT03439124|Active Comparator|IV standard-of-care cephalosporin|"Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
9838232|NCT04332497|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
9838233|NCT04332497|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
9838234|NCT04332497|Active Comparator|Group ISCB = ISCB group|In group ISCB, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
9838235|NCT04331301|Active Comparator|vapoenucleation group|Group A
9838236|NCT04331301|Active Comparator|needlescopic enucleation|group B
9838237|NCT04328558|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
9838238|NCT04328558|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
9985065|NCT03436368|Active Comparator|CSA group|Continuous Spinal Anesthesia
9838240|NCT04322981|Experimental|Community Pharmacist-Led|Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.
9838241|NCT04322981|Active Comparator|Academic hepatology|Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.
9985066|NCT03436368|Active Comparator|GA group|General Anesthesia
9838251|NCT04311567|Experimental|Tofacitinib|Oral tablet tofacitinib 5 mg BID for 48 weeks
9838252|NCT04311567|Active Comparator|Methotrexate|Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks
9838253|NCT04310007|Experimental|Arm A (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
9838254|NCT04310007|Experimental|Arm B (cabozantinib S-malate, nivolumab)|Patients receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
9838255|NCT04310007|Active Comparator|Arm C (standard chemotherapy,cabozantinib S-malate, nivolumab)|See Detailed Description
9838256|NCT04307992|Experimental|Intervention|Device: ANEUFIX
9838257|NCT04307953|Experimental|AZD0530|
9838258|NCT04307953|Experimental|Placebo/AZD0530|
9838259|NCT04307225||CABG|Patients whom has undergone CABG surgery for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
9838260|NCT04307225||PCI|Patients whom has undergone PCI for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
9985067|NCT03426306|Experimental|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
9985068|NCT03425500|Experimental|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
9985069|NCT03425500|Active Comparator|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
9985070|NCT03424343||cancer survivor, parents, sibling|
10206087|NCT04914637|Other|interlaminar epidural steroid injection only|Only interlaminar epidural steroid injection will be administered to patients in this arm with the same method as in the other arms (one session, week 0). No dry needling or sham dry needling will be used.
9838266|NCT04301843|Experimental|Eflornithine (DFMO)|"In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.~Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed.~DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study."
9838267|NCT04301154|Experimental|Arm 1 (n=10): HIVIS DNA / MVA-CMDR|"Arm 1 (n=10) will receive 1500 micrograms (0.5ml) HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.~Participants who have been randomized to receive HIVIS DNA and MVA-CMDR alone (ARM 1) will be administered Cervarix after week 72, the last study follow-up visit, if required."
9838268|NCT04301154|Experimental|Arm 2 (n=10): HIVIS DNA + Cervarix/ / MVA-CMDR|Arm 2 (n=10) will receive 0.5 ml of Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
9838269|NCT04301154|Experimental|Arm 3 (n=5): Cervarix|Arm 3 (n=5) will receive 0.5 ml of Cervarix by IM needle injection at weeks 0, 4 and 24.
10206088|NCT04914195|Experimental|Leuprolide acetate 3.75 mg Depot (Luprodex)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
9838271|NCT04301076|Experimental|Treatment (lenalidomide, EPOCH)|"INDUCTION THERAPY: Patients receive lenalidomide PO QD on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients also receive doxorubicin hydrochloride IV continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients with CR, PR, or SD may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity."
9838272|NCT04300855|Experimental|Sunphenon® 90D|Participants will be administered a standardized formulation of whole Green Tea Catechin for 24 months. The daily dose of Green Tea Catechin will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
9838273|NCT04300855|Placebo Comparator|Placebo|Participants will be administered a placebo for 24 months. The daily dose of placebo will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
9838274|NCT04298567||Treatment|Female and male patients with a diagnosis of CAD or symptomatic PAD will be enrolled within 4 weeks after the decision for treatment with rivaroxaban 2.5mg [BID] plus ASA 75mg [OD] has been made by the investigator.
9838275|NCT04298086|Experimental|Exercise Treatment and Plant-Based Diet|Will consist of structured exercise treatment plus a calorie-restricted plant-based diet. Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service. Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention. If a patient is temporarily unable to complete supervised sessions as a result of unforeseen circumstances, patients may be assigned low intensity unsupervised training sessions per EP/PI discretion
10206089|NCT04914195|Active Comparator|Leuprolide acetate 3.75 mg Depot (Lucrin)|Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29
10206090|NCT04909502|Experimental|EHP-101 Once a day (OD)|
10206091|NCT04909502|Experimental|EHP-101 Twice a day (BID)|
10206092|NCT04905433|Experimental|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
10206093|NCT04905433|Active Comparator|cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
10206094|NCT04903132||Longhauler's Syndrome Cohort|Subject's with longhaulers
10206095|NCT04903132||Control Cohort|Control cohort will not have had a known case of COVID-19 or Longhauler's syndrome
10206096|NCT04903132||COVID Control Cohort|Subjects who have had COVID-19 but no known Longhauler's syndrome
10206097|NCT04903119|Experimental|Level 1|Patients in this group will receive 100mg Nilotinib PO BID.
9838276|NCT04298086|Active Comparator|Physical activity and nutrition counseling|Patients will receive a home-based, general physical activity program and nutrition counseling. Specifically, all patients assigned to the counseling arm will receive a study kit which includes an activity tracker, heart rate monitor, scale, and tablet. Treadmills may also be provided to patients in the counseling arm if they do not already have access to one.
9985071|NCT03422536|Experimental|Arm I (ficlatuzumab)|Patients receive ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9838278|NCT04291001|Active Comparator|ENG Implant alone|Women will receive a contraceptive implant in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
9838279|NCT04291001|Active Comparator|ENG Implant plus oral UPA|Women will receive a contraceptive implant and oral UPA the same day in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
9985072|NCT03422536|Experimental|Arm II (ficlatuzumab, cetuximab)|Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9838281|NCT04288778|Experimental|Canagliflozin + Metformin Hydrochloride Immediate Release (IR)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.
9985073|NCT03420482|Experimental|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
9985074|NCT03420482|Placebo Comparator|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
9838284|NCT04287218|Experimental|TG-iConquerFear|The participant is guided through the web-based sessions by minimum weekly contact with an experienced therapist (estimated ½ hour/week for 10 weeks). The therapist will motivate, answer questions and give feedback on written material and exercises.
9838285|NCT04287218|Active Comparator|Augmented treatment as usual|"The control group is described as augmented treatment as usual (aTAU), since the diagnostic telephone interview exceeds standard treatment. Further more, the participants will be referred to a website with a non-guided, publicly available E-learning program in cancer rehabilitation hosted by the Region of Central Jutland (livogkraeft.rm.dk). In addition to written material the website includes self-help instructions for meditation."
9838286|NCT04281849|No Intervention|Usual care|Patients in the usual care arm will receive educational material from the Heart Failure Society of America (HFSA) with the current recommendations for exercise for patients with heart failure.
9838287|NCT04281849|Experimental|BAMS-HF Program|
9838288|NCT04276441||Non- Atrial Fibrillation (AF) Cohort|Participants without a history of AF will be randomly assigned into the study to either an Apple Watch/iPhone group or an iPhone group only.
9838289|NCT04276441||Atrial Fibrillation (AF) Cohort|Participants with a diagnosis of AF taking a direct oral anti-coagulant (DOAC) for at least 30 days will be randomly assigned to Apple Watch/iPhone group or iPhone group only.
9838290|NCT04273945|Active Comparator|Macitentan 10 milligrams (mg) + Placebo|Participants will receive macitentan 10 mg once daily (qd) orally for 4 weeks in open-label Run-in phase prior to randomization (only for participants who are Endothelin Receptor Antagonist [ERA] treatment-naive. Other participants will bypass the Run-in period and go directly to randomization). Double-blind Treatment Period: participants will receive macitentan 10 mg qd for 8 weeks and matching placebo of macitentan 37.5 mg for 4 weeks (Uptitration) and matching placebo of macitentan 75 mg thereafter orally up to End of Double-Blind Treatment period (EDBT). Treatment Extension Period: After EDBT, participants will receive macitentan 37.5 mg qd and macitentan 75 mg matching placebo orally for 4 weeks (Uptitration), followed by open-label macitentan 75 mg qd orally for 2 years.
9838291|NCT04273945|Experimental|Macitentan 75 mg + Placebo|Participants will receive macitentan 10 mg qd orally for 4 weeks in open-label Run-in phase prior to randomization (only for ERA treatment-naive. Other participants will bypass the Run-in period and go directly to randomization). Double-blind Treatment Period: participants will receive macitentan 37.5 mg for 4 weeks (Uptitration) and 75 mg qd along with matching placebo for macitentan 10 mg orally up to EDBT. Treatment Extension Period: After EDBT, participants will receive macitentan 75 mg qd and macitentan 37.5 mg matching placebo orally for 4 weeks (Uptitration), followed by open-label macitentan 75 mg qd orally for 2 years.
9985075|NCT03416088|Experimental|Beverage consumption|Drink 300ml red wine (alcohol concentration:12.5%), 300ml coffee (caffeine concentration 72 mg), or 300ml water.
9985076|NCT03416088|Experimental|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading.
9985077|NCT03416088|Experimental|Body motion|Exercise and body postural changes.
9789451|NCT01358981|Experimental|LY2881835|"One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).~There is a washout period of at least 5 days between periods (doses)."
9789452|NCT01358981|Placebo Comparator|placebo|"One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.~There is a washout period of at least 5 days between periods (doses)."
9789453|NCT01359007|Experimental|FOLFIRINOX|Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
9789454|NCT01359046|Experimental|silver SPC|Subjects randomized to receive silver-impregnated SPC.
9789455|NCT01359046|Active Comparator|standard SPC|subjects randomized to receive standard SPC.
10206098|NCT04903119|Experimental|Level 2|Patients in this group will receive 200mg Nilotinib PO BID.
10206099|NCT04903119|Experimental|Level 3|Patients in this group will receive 300mg Nilotinib PO BID.
10206100|NCT04903119|Experimental|Level 4|Patients in this group will receive 400mg Nilotinib PO BID.
9789456|NCT01359150|Experimental|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).|CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
9789457|NCT01359150|Placebo Comparator|Treatment Group 2:Placebo CP-690,550 (100 subjects).|Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
9789458|NCT01359371||Peer telephone cessation counseling|The cohort is 131 veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital follow up volunteer peer telephone cessation counseling
9789459|NCT01359410|Active Comparator|Stapled transection with mesh reinforcement|Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
9789460|NCT01359410|No Intervention|Stapled transection without mesh reinforcement|
9789461|NCT01359449|Experimental|Menactra® Vaccine Group|Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
9789462|NCT01359449|Active Comparator|Menjugate® Vaccine Group|Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.
9789463|NCT01359592|Active Comparator|PET Negative: R-CHOP|R-CHOP x 3 Cycles
9789464|NCT01359592|Experimental|PET Positive: IFRT +Zevalin|Standard IFRT+ Zevalin IV per ABW
9789465|NCT01359644|Experimental|Treatment A: PSI-7977 + Daclatasvir|Genotype 1a or 1b
9789466|NCT01359644|Experimental|Treatment B: PSI-7977 + Daclatasvir|Genotype 2 or 3
9789467|NCT01359644|Experimental|Treatment C: PSI-7977 + Daclatasvir|Genotype 1a or 1b
9789468|NCT01359644|Experimental|Treatment D: PSI-7977 + Daclatasvir|Genotype 2 or 3
9789469|NCT01359644|Experimental|Treatment E: PSI-7977 + Daclatasvir + Ribavirin|Genotype 1a or 1b
9789470|NCT01359644|Experimental|Treatment F: PSI-7977 + Daclatasvir+ Ribavirin|Genotype 2 or 3
10206101|NCT04899700|Placebo Comparator|WLE-LCI|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with WLE. Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
10206102|NCT04899700|Active Comparator|LCI-WLE|First endoscopist will perform an optical diagnosis of recurrence of post-polypectomy scar with Linked Color Imaging (LCI). Then a second diagnosis will be performed by the same endoscopist with blue light imaging (BLI)
10206103|NCT04894773|Experimental|Imaginary Resisted Exercises|Handgrip exercises with the imagination of resistance in hand by getting feedback in VR Box will be given as an intervention. Stretching will be given at the beginning and the end of each session. This will include imaginary resistance exercises for handgrip by using Virtual Reality Box. Five types of different resistances will be imagined by patients by watching their own videos in VR box, which will be recorded on day one to make them familiar with the resistive objects and the resistance experienced from them by asking patients to perform 15-15 repetitions of each object. Every imaginary resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
9789471|NCT01359644|Experimental|Treatment G: PSI-7977 + Daclatasvir|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
9789472|NCT01359644|Experimental|Treatment H: PSI-7977 + BMS-790052 + Ribavirin|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
9789473|NCT01359644|Experimental|Treatment I: PSI-7977 + Daclatasvir|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
9789474|NCT01359644|Experimental|Treatment J: PSI-7977 + Daclatasvir + Ribavirin|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
9789475|NCT01359735|Active Comparator|HP802-247|allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
9789476|NCT01359735|Active Comparator|Bacitracin Ointment|bacitracin antibiotic ointment
10206104|NCT04894773|Experimental|Physical Resisted Exercises|Handgrip exercises with physical resistance in hand will be given as an intervention. Stretching will be given at the beginning and the end of the session. 5 different types of resistances will be given to patients for making themselves familiarize themselves with the type of resistance applied by each object, that they will experience in further sessions, by asking them to perform 15-15 repetitions of each object. Every physical resistance exercise will have 15 repetitions. After performing exercises, the participants will ask to perform Finger-to-Nose Test and Purdue Pegboard Test.
10206105|NCT04893759|Experimental|APG-1252|
10206106|NCT04892771||Experimental group|Patients who have honored two consultations per year for two years.
10206107|NCT04892771||Control group|Patients who have not honored two consultations per year for two years.
9789477|NCT01359748|Other|Wrist Size <= 14.25 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
9789478|NCT01359748|Other|Wrist Size >=14.26 <16.50 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
9789479|NCT01359748|Other|Wrist size >=16.5 <17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
9789480|NCT01359748|Other|Wrist Size >=17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
9789481|NCT01359904|Active Comparator|high dialysate bath|additive is put in the dialysate to increase the concentration of glucose to 10mmol/l
9789482|NCT01359904|No Intervention|Standard dialysate glucose concentration|Standard 5.5 mmol/L dialysate glucose concentration.
9789483|NCT01359943|Experimental|secukinumab 10 mg/kg i.v. loading|secukinumab 10mg/kg i.v. loading at Weeks 0, 2 and 4, and placebo s.c. at weeks 0, 1, 2, 3 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
9789484|NCT01359943|Experimental|secukinumab 150 mg s.c. loading|secukinumab 150mg s.c. loading at Weeks 0, 1, 2, 3 and 4, and placebo i.v. at weeks 0, 2 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
9789485|NCT01359943|Placebo Comparator|placebo|placebo at Weeks 0, 1, 2, 3, 4, 8 & 12, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 16
9789486|NCT01359956|Experimental|A1|combination chemotherapy without interferon
9789487|NCT01359956|Experimental|A2|combination chemotherapy with interferon
9789488|NCT01359956|Active Comparator|B1|single agent dacarbazine without interferon
9789489|NCT01359956|Experimental|B2|single agent dacarbazine plus interferon
9789490|NCT01360021|Active Comparator|1 Symbicort/inhaler|Symbicort BA MDI 2x160/4.5 μg twice daily
9789491|NCT01360021|Active Comparator|Symbicort/inhaler|Symbicort AC pDMI 2x160/4.5 μg twice daily
9789492|NCT01360021|Active Comparator|Budesonide/inhaler|Budesonide AC pMDI 2x160 μg twice daily
9789493|NCT01360229|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
9789494|NCT01360229|Active Comparator|Randomized Subjects receive real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
9789495|NCT01360398|Other|Cohort|COPD male and female patients between 40 and 85 years of age, recruited among the patients of the Southampton General Hospital and referring practices.
9789496|NCT01360450|Experimental|Treatment|Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
9789497|NCT01360450|Placebo Comparator|Control|Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally
9789498|NCT01360554|Experimental|A|Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
9789499|NCT01360554|Active Comparator|B|Blinded active comparator (erlotinib) + blinded placebo PF-00299804
9789500|NCT01360632|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
9789501|NCT01360632|Placebo Comparator|Phase A|Drug: Placebo + ADT
9789502|NCT01360645|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
9789503|NCT01360645|Placebo Comparator|Phase A|Intervention: Drug: Placebo + ADT
9789504|NCT01360762|Experimental|Pentamidine Secondary Prophylaxis (PSP)|"Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period."
9789505|NCT01360840|Placebo Comparator|Placebo + Standard of care (SoC)|
9789506|NCT01360840|Experimental|EMD 525797 750 mg + SoC|
9789507|NCT01360840|Experimental|EMD 525797 1500 mg + SoC|
9789508|NCT01360866|Experimental|OPC-34712 (Brexpiprazole) and Escitalopram|OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day
9789509|NCT01360866|Experimental|OPC-34712 and Fluoxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day
9789510|NCT01360866|Experimental|OPC-34712 and Paroxetine CR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day
9789511|NCT01360866|Experimental|OPC-34712 and Sertraline|OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day
9789512|NCT01360866|Experimental|OPC-34712 and Duloxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day
9789513|NCT01360866|Experimental|OPC-34712 and Venlafaxine XR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day
9789514|NCT01360996|Experimental|3 mg DRSP/20 μg EE--normal weight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~Normal weight -BMI 18-24.9 kg/ m2"
9789515|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Overweight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 25-29.9 kg/ m2"
9789516|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Grade 1 obese|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 30-34.9 kg/ m2"
9789517|NCT01361009||pramipexole group|It's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
9789518|NCT01361048|Active Comparator|oral metronidazole|control arm
9789519|NCT01361048|Experimental|neo penotran forte|neo penotran forte vaginal suppository twice a day for 7 days
9789520|NCT01361048|Experimental|neo penotran forte once a day|neo penotran forte vaginal suppository once a day for 7 days
9789521|NCT01361113|Other|Single Arm Neoadjuvant Pazopanib|Pazopanib 800 mg PO once daily for 8 weeks
9789522|NCT01361126|Experimental|On-demand|The routine prophylactic therapy interval is targeted at every 7 days.
9789523|NCT01361126|Experimental|Prophylactic|On-demand subjects will receive rIX-FP only for the treatment of a bleeding episode.
9789524|NCT01361178|No Intervention|Transplant patients who do not receive SQ IVIG|Patients participating in the observational arm of the study who do not need to receive IgG replacement.
9789525|NCT01361178|Active Comparator|Transplant patients who receive SQ IVIG|Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.
9789526|NCT01361217|Experimental|Fluoxetine DDI|Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
9789527|NCT01361308|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
9789528|NCT01361308|Placebo Comparator|Placebo Capsules|Placebo Capsules
9789529|NCT01361464|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib orally twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9789530|NCT01361568|Experimental|CR845|Peripheral kappa opioid receptor agonist
9789531|NCT01361568|Placebo Comparator|Placebo|Matched Placebo
9789532|NCT01361594|Active Comparator|Intensive insulin treatment|Intensive insulin treatment (BG target: 100-140 mg/dL)
9789533|NCT01361594|Active Comparator|Conventional insulin treatment|Conventional insulin treatment (BG target: 141-180 mg/dl)
9789534|NCT01361607|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
9789535|NCT01361607|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
9789536|NCT01361620|Other|Aspirin|All subjects took 7-10 days of 81 mg aspirin
9789537|NCT01361633|Experimental|Medication|250 mg d-cycloserine
9789538|NCT01361633|Placebo Comparator|Sugar Pill|
9789539|NCT01361711|Experimental|Treatment (monoclonal antibody therapy)|Patients receive alemtuzumab SC three times a week in weeks 1-18 and ofatumumab IV over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and 17.
9789540|NCT01361854|Experimental|polysomnography for suspicion of SDB|adults, suspects of suffering from sleep disordered-breathing, who must undergo a diagnostic polysomnography
9789541|NCT01361867|Other|Robot-induced perturbations|The subject walks on a treadmill with his/her legs strapped to a robotic system (Lokomat by Hocoma AG) that generates mechanical perturbations aimed to modify the subject's walking pattern.
9799460|NCT01660230|Placebo Comparator|Matching Placebo, 0.9% NaCl in water|Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)
9799461|NCT01660256|Experimental|OPC-12759 ophthalmic solution|OPC-12759 ophthalmic solution
9799462|NCT01660256|Placebo Comparator|Placebo|OPC-12759 ophthalmic solution 0%
9799463|NCT01660256|Active Comparator|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
9799464|NCT01660321|Experimental|Natroba|Natroba (Spinosad) Topical Suspension, 0.9%
9799465|NCT01660334||Voriconazole|Subjects who are treated with voriconazole
9799466|NCT01660412|Active Comparator|pH altered first|The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
9799467|NCT01660412|Active Comparator|Standard of Care first|The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.
9799468|NCT01660672|Other|LEVETIRACETAM|Open label, dose escalation to optimal dose.
9799469|NCT01660698|Placebo Comparator|Placebo|maltodextrin powder
9799470|NCT01660698|Active Comparator|Probiotic|probiotic blended in maltodextrin
9799471|NCT01660711|Experimental|FOLFIRINOX chemotherapy|"5FU 2400 mg/m2 IV over 48 hours Irinotecan 180 mg/m2 IV day 1 Oxaliplatin 85 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1~Cycles administered every 14 days for 4 cycles before and 4 cycles after surgery."
9799472|NCT01660737||PASCALLERG® tablets in patients with hay fever|Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.
9799473|NCT01660763|Experimental|Sufentanil NanoTab PCA System/15 mcg|
9789542|NCT01361919|Experimental|Feedback During CPR Training and Testing|"A feedback defibrillator (ZOLL R series) will be used at teaching, immediate testing and 12 week (retention) testing. A simulation manikin with an attached accelerometer pad on its sternum will be used to collect CPR performance data. Subjects will be told to perform compressions on top of the accelerometer pad and will be taught to use and follow the audio and visual feedback to optimize their CPR performance. After training, the raw data collected by the accelerometer will be used as a demonstration and training tool, to correct the subjects' performance by visually demonstrating the difference between ideal and suboptimal CPR performance. Testing will be carried out with the use of a feedback defibrillator."
9789543|NCT01361919|Active Comparator|Feedback during CPR Training Not Testing|"A feedback defibrillator will be used for teaching, with a standard no feedback defibrillator used at immediate and 12 week (retention) testing to assess if the techniques the students' learned during training are transferable to devices without feedback. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest."
9789544|NCT01361919|Placebo Comparator|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
9789545|NCT01362049|Active Comparator|'Eligible' Subject Group - STAB|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
9789546|NCT01362049|Active Comparator|'Ineligible' Subject Group - STAB|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
9789547|NCT01362049|Active Comparator|'Eligible' Subject Group - MSI|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
9789548|NCT01362049|Active Comparator|'Ineligible' Subject Group -MSI|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
9789549|NCT01362062||RA Cohort|Participants with active RA who had an inadequate clinical response to current non-biologic disease modifying anti-rheumatoid drug (DMARD) and/or anti-tumor necrosis factor (anti-TNF) therapy being treated with tocilizumab according to the routine clinical practice and in line with prescribing information will be observed for a total duration of 12 months.
9789550|NCT01362127|Active Comparator|Radiochemotherapy|Arm I: Radiochemotherapy + Surgery
9789551|NCT01362127|Active Comparator|Chemotherapy|Arm II: Chemotherapy + surgery
9789552|NCT01362140|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg every three weeks (Q3W) for 24 weeks in the double-blind treatment period, and continued to receive darbepoetin alfa 500 µg Q3W during the active treatment period for an additional 48 weeks.
9789553|NCT01362140|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection every 3 weeks (Q3W) for 24 weeks during the double-blind treatment period. From week 25 participants received darbepoetin alfa 500 µg Q3W during the active treatment period for 48 weeks.
9789554|NCT01362192|Other|532 nm KTP Laser Treatment|
9789555|NCT01362205|Experimental|Dexmedetomidine|Dexmedetomidine titrated to achieve predefined goals on selected components of the MINDS score using the minimum amount of medication possible. Blinded study medication will be started at a rate determined by the MINDS score. The maximum infusion rate is 1.4 μg/kg per hour. Uncontrolled SAWS/D symptoms, will be treated with open label lorazepam according to the MINDS score algorithm. Persistent SAWS/D symptoms despite maximum infusion rate of study medication treatment limiting symptoms while receiving higher infusion rates of study medication, ancillary therapies will be administered according to the MINDS score algorithm, at the discretion of the treating physician.
9789556|NCT01362205|Placebo Comparator|Placebo|Blinded placebo study drug administration in equal volume per hour as active study medication arm.
9789557|NCT01362244|Experimental|Treatment Periods 1-8|Part A comprises eight outpatient visits (Visits 1 - 8). For six of these visits, subjects will receive a dose of either 750 mg mepolizumab or placebo. Dosing occurs in four week intervals. Assessment for entry into Part B will take place at the last visit in Part A (Visit 8). Subjects not eligible for Part B will have study exit procedures performed and be discontinued.
9789558|NCT01362244|Other|Run In period|10-14 day run in period to assess the patients suitability for entry into Part A of the trial.
9789559|NCT01362244|No Intervention|Treatment periods 9-13|Subjects eligible for Part B will attend the clinic for up to 5 more outpatient visits (Visits 9 - 13) for assessments. Visits occur every four weeks. There is no dosing in Part B. At the point when each subject meets Study Exit criteria, study exit procedures will be performed and the subject will exit the study.
9838294|NCT04271475|Experimental|Macitentan|Participant will receive macitentan at a dose of 10 milligram (mg) once daily (OD) for 4 weeks, followed by a dose of macitentan 37.5 mg for another 4 weeks and continue with the target dose of macitentan 75 mg. Participants who have reached the target dose of 75 mg, completed the Double-blind (DB) period up to Week 28 (either on treatment or in Post-treatment observation period [PTOP]) at minimum, may be eligible for transitioning into the Open label (OL) extension period once all participants have completed the DB part of the study, or earlier if they experienced a Clinical event committee (CEC) confirmed clinical worsening event.
9838295|NCT04271475|Experimental|Placebo|Participants will receive placebo tablets matching the macitentan 10 mg, macitentan 37.5mg and macitentan 75 mg tablets, respectively. Participants who completed the DB period as per protocol either on treatment or in PTOP are eligible for transitioning to the OL extension period and will receive macitentan 75 mg after an 8-week double-dummy uptitration (macitentan 10 mg for 4 weeks, followed by 37.5 mg for another 4 weeks).
9838296|NCT04269902|Active Comparator|Arm I (delayed V-O)|Treatment begins once 2018 IWCLL indications are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
9838297|NCT04269902|Experimental|Arm II (early V-O)|Treatment begins as soon as eligibility criteria are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
9985078|NCT03410394||registry of endocrine tumors|"Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.~Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23~Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24~Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
9985079|NCT03410355|Experimental|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
9985080|NCT03410355|Active Comparator|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
9985081|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Within this cohort, some patients will have high pain score recorded (persistent pain) during the follow-up evaluations at 4 and 6 months.
9985082|NCT03406897|Active Comparator|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
9985083|NCT03406897|Active Comparator|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
9838304|NCT04264000|Experimental|platelet-rich plasma|The perineural injection with PRP is a potential treatment for peripheral entrapment neuropathy
9838305|NCT04264000|Active Comparator|5% dextrose|The perineural injection of 5% dextrose is a novel management for peripheral entrapment neuropathy
9838306|NCT04260659|Active Comparator|Opioid liberal group|
9838307|NCT04260659|Experimental|Opioid free group|
9838308|NCT04259775|Active Comparator|Automated Insulin Dose Adjustment (AIDA)|Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
9838309|NCT04259775|Active Comparator|Control|Standard Care - change in therapy settings effected a regularly scheduled patients visits
9985084|NCT03406351||Asthma|
9838311|NCT04258397|Active Comparator|Experimental, pirfenidone|"Pirfenidone 267 mg capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
9838312|NCT04258397|Placebo Comparator|Placebo, pirfenidone|"Pirfenidone placebo capsules~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
10206108|NCT04892420|Active Comparator|Group DX|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia
10206109|NCT04892420|Active Comparator|Group DM|The patients receive 20 ml plain bupivacaine(0.5%)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
10206110|NCT04892420|Active Comparator|Group M|The patients receive 20 ml plain bupivacaine(0.5%)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
10206111|NCT04892420|Placebo Comparator|Group C|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
10206112|NCT04887896|Experimental|GS500 flexible dose|3, 2, or 4 GS500 capsules 2 times per day
10206113|NCT04887896|Placebo Comparator|Placebo flexible dose|3, 2, or 4 placebo capsules 2 times per day
10206114|NCT04887766|Active Comparator|Active|GS300: Three (3) GS300 capsules [approximately 0.65 grams (g)] two (2) times per day ingested 10 minutes (min) before meals (i.e., lunch and dinner) - total of 3.9 g per day
10206115|NCT04887766|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day 10 min before meals (i.e., lunch and dinner)
10206116|NCT04886895|Experimental|Let's Move Intervention|Let's Move intervention will be administered and videotaped for 20 infant/caregiver dyads. Therapy will occur weekly (30-60 minutes per session) for 16 weeks, alternating between clinic and home (video telehealth) sessions. Each month, there will be two clinic-based sessions followed by 2 telehealth-based sessions
9985085|NCT03406351||Healthy|Matched controls
9985086|NCT03399617|Active Comparator|Standard Care+MNPs|Participants will receive standard health care services provided by the Ministry of Health, including micronutrient powders (MNPs). Children 6 months old will receive 1 gram of powdered micronutrients for 60 days every 6 months until 24 months of age.
9838313|NCT04258059|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
9838314|NCT04258059|Sham Comparator|Inactive UV Device|A device that appears identical to the active comparator device except the lamp will not emit germicidal UV.
9838315|NCT04254939|Experimental|CS3007(BLU-285)|
9838316|NCT04252690|Experimental|Mobiderm|MOBIDERM® autofit : auto-adjustable compression stocking
9838317|NCT04251117|Experimental|GNOS-PV02 + INO-9012 + Pembrolizumab|"First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured.~GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI."
9838318|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 17 and 19 lb BPW|Participants will be randomized to both 17 and 19 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
9838319|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 19 and 17 lb BPW|Participants will be randomized to both 19 or 17 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
9838320|NCT04248816|Experimental|Usual Care|Standard of care
9838321|NCT04248816|Experimental|Opt-out|Facilitated outreach and opt-out framing
9838322|NCT04248816|Experimental|Opt-out + Incentive|Facilitated outreach and opt-out framing plus a financial incentive
9985087|NCT03399617|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive Small Quantity Lipid-based Supplements (SQ-LNS) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
9985088|NCT03399617|Experimental|SPOON behavioral change strategy+MNPs|Participants will receive micronutrient powders (MNPs) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of MNPs will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities.
9985089|NCT03399552|Experimental|Avelumab|The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.
10206117|NCT04883554|Experimental|Olfactory therapy group|"The therapeutic group takes place in specific stages on a weekly basis and lasts approximately 45 minutes. The group consists of a maximum of 6 patients of approximately the same age. The therapists leading the therapeutic group choose in advance the smells that will be offered to patients, based on one odor for each of the following categories: food and woody / flowery. The odors circulate between the participants of the group (patients and therapists), on wipes of blotting paper soaked in the bottles and soaked in the odors. The first step of the therapeutic group is olfactory perception: this is the moment when the odors selected for the session are presented to the patients. Each scent goes around the patients and therapists, three times and without verbalization. Therefore, patients can express their feelings through drawing or writing on distributed sheets. .~In a second step, called rendering, patients are asked to express what they think of the smell presented."
10206118|NCT04883554|Active Comparator|Body therapy group|"The therapeutic group takes place according to very specific stages at a weekly frequency and lasts 1 hour. The group is made up of a maximum of 6 patients.~This workshop includes three times divided equally over a period of 1 hour:~Kinesic time or time to set the body in motion (20 min):~These techniques involve lying on the floor on a mat and approaching the movement slowly. The movements are suggested by the patients and then imitated by the rest of the group.~Kinesthetic time: time of slow movements (20 min):~During this time, the patient is asked to find a period of calm close to immobility without imposing the instruction. They are asked to touch the different parts of the body as slowly as possible in isolation, starting and ending in the center of the body.~Talk time (20 min):~Patients are invited to verbalize what they felt bodily"
9838326|NCT04239846|Experimental|AC-701|AC-701 Topical Gel 0.3%
9838327|NCT04239846|Placebo Comparator|Placebo|Placebo Gel
10206119|NCT04882553|Experimental|Incremental inspiratory effort|"Every participant will be subjected to a stepwise incremental inspiratory effort:~Ventilated~Baseline spontaneous breathing with deep anesthesia (minimal alveolar concentration 1.5)~Spontaneous breathing with PEEP 10 and deep anesthesia (minimal alveolar concentration 1.5)~Spontaneous breathing with PEEP 0 and deep anesthesia (minimal alveolar concentration 1.5)~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0)~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +7cmH2O~Spontaneous breathing with PEEP 0 and moderate anesthesia (minimal alveolar concentration 1.0) and added inspiratory threshold of +15cmH2O"
9838332|NCT04234347|Active Comparator|Long Axis approach|Utilize the longitudinal orientation when placing an USGPIV.
9838333|NCT04234347|Active Comparator|Short axis approach|Utilize the transverse orientation when placing an USGPIV.
9838334|NCT04233476|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg frequency:single dose
9838337|NCT04233060|Experimental|CS3005|
9921963|NCT00833183|Active Comparator|37 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
9838338|NCT04231877|Experimental|Treatment (polatuzumab vedotin, combination chemotherapy)|Patients receive rituximab IV on day 1, polatuzumab vedotin IV on day 1, prednisone PO BID on days 1-5, etoposide IV on days 1-4, doxorubicin IV on days 1-4, and cyclophosphamide IV on day 5. Patients also receive filgrastim SC 24-72 hours after the last dose of each treatment cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9838339|NCT04231708|Placebo Comparator|placebo stressor, sham rTMS|Placebo stressor (lactose) + sham (inactive) rTMS over the left dlPFC
9838340|NCT04231708|Experimental|placebo stressor, active rTMS|Placebo stressor (lactose) + active 10Hz rTMS over the left dlPFC
9838341|NCT04231708|Experimental|active stressor, sham rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + sham (inactive) rTMS over the left dlPFC
9838342|NCT04231708|Experimental|active stressor, active rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + active 10Hz rTMS over the left dlPFC
9838343|NCT04225078|Experimental|Treatment Sequence 1: Treatment ADBC|Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
9838344|NCT04225078|Experimental|Treatment Sequence 2: Treatment BACD|Participants will receive Treatment B on Day 1 of treatment period 1 followed by Treatment A on Day 1 of treatment period 2 then Treatment C on Day 1 of treatment period 3 and then Treatment D on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
9838345|NCT04225078|Experimental|Treatment Sequence 3: Treatment CBDA|Participants will receive Treatment C on Day 1 of treatment period 1 followed by Treatment B on Day 1 of treatment period 2 then Treatment D on Day 1 of treatment period 3 and then Treatment A on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
9838346|NCT04225078|Experimental|Treatment Sequence 1: Treatment DCAB|Participants will receive Treatment D on Day 1 of treatment period 1 followed by Treatment C on Day 1 of treatment period 2 then Treatment A on Day 1 of treatment period 3 and then Treatment B on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
9985090|NCT03399396|Experimental|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
9838348|NCT04223323|Experimental|Intervention|The intervention arm consists of daily consumption of the investigator's intervention snack over the course of 12 weeks.
9838349|NCT04223323|Placebo Comparator|Isocaloric Control|The control arm consists of daily consumption of an isocaloric snack over the course of 12 weeks.
9838350|NCT04223141|Experimental|Study group|Robot-assisted laparoscopic resection of sigmoid colon with colorectal anastomosis constructed by the double purse-string technique
9985091|NCT03399396|Experimental|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
9985092|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
9985093|NCT03395366|Active Comparator|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
9985094|NCT03395366|No Intervention|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
9985095|NCT03395210|Experimental|PRN1008 Daily|"Part A approximately 60 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension.~Part B approximately 25 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension"
10206120|NCT04876677|Experimental|CHF5993|Beclometasone Dipropionate (BDP) 100 μg/inhalation + Formoterol Fumarate (FF) 6 μg/inhalation + Glycopyrronium Bromide (GB) 12.5 µg/inhalation
10206121|NCT04876300||Menotropin Cohort|
10206122|NCT04874194|Experimental|Treatment (omacetaxine, venetoclax)|Patients receive omacetaxine SC BID on days 2-3 or 2-4, and venetoclax PO on days 1-7, 1-10 or 1-14. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9838359|NCT04210219|Experimental|JNJ-64264681: Dose Escalation and Expansion|Participants will receive oral administration of JNJ-64264681 capsule at a dose assigned by the sponsor Study Evaluation Team (SET), based on the available safety, pharmacokinetics, and pharmacodynamics data in dose escalation treatment group (Part 1); and recommended Phase 2 dose (RP2D) determined in Part 1 in cohort expansion treatment group (Part 2).
10206123|NCT04874012|Placebo Comparator|Placebo|Participants into the placebo group will receive the same treatment regimen, but with packets of the same appearance and size containing only vehicle.
10206124|NCT04874012|Active Comparator|Taurine|Participants will receive 6 gy taurine divided into twice/day orally administration for 12 weeks.
10206125|NCT04869917|Experimental|In-person intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid which reviews information about the benefits and risks of intensive lifestyle intervention and metformin
10206126|NCT04869917|Experimental|Automated intervention|Participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent by Erie's health education department using their existing secure text messaging platform.
10206127|NCT04869917|Experimental|In-person intervention + automated intervention|Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid. Additionally, participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent by Erie's health education department using their existing secure text messaging platform.
10206128|NCT04869917|Placebo Comparator|Usual Care|Usual care includes no additional intervention above the care routinely provided at the clinical partner site, Erie Family Health Center.
10206129|NCT04866602|Experimental|Atoguanil|Atovaquone 500 mg + Proguanil 348 mg
10206130|NCT04866602|Active Comparator|Malarone®|Atovaquone 1000 mg + Proguanil HCl 400 mg
10206131|NCT04865874|Experimental|PPV-GDT|Intra-operative fluid-therapy based (lactated Ringer) on continous PPV monitoring (target ≤5.8%)
9789560|NCT01362270|Experimental|Verum Acupuncture|Subjects will receive acupuncture using real acupuncture needles.
9789561|NCT01362270|Sham Comparator|Sham acupuncture|Subjects will receive sham acupuncture therapy using the Streitberger needle at the same points and on the same schedule as patients in the treatment group. Streitberger needles are blunt tipped and retract into themselves rather than penetrating the skin.
9789562|NCT01362296|Experimental|GSK1120212|Oral once daily
9789563|NCT01362296|Active Comparator|docetaxel|IV once every 3 weeks
9789564|NCT01362322|Experimental|BOOSTRIX NEW GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a new syringe presentation (prefilled syringes from a different manufacturer) in the deltoid of the non-dominant arm, at Day 0.
9789565|NCT01362322|Active Comparator|BOOSTRIX PREV GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a previous syringe presentation (single dose vial or a prefilled disposable syringe without a needle) in the deltoid of the non-dominant arm, at Day 0.
9789566|NCT01362348|Experimental|pazopanib eye drops|pazopanib topical ocular administration
9789567|NCT01362439|Experimental|Paliperidone ER|
9789568|NCT01362491|Experimental|Treatment A|
9789569|NCT01362491|Active Comparator|Treatment B|
9789570|NCT01362491|Placebo Comparator|Treatment C|
10206132|NCT04865874|Active Comparator|Zero balance|Intra-operative fluid-therapy (lactated Ringer) based on 1:1 compensation of urinary output
10206133|NCT04859517|Experimental|ADG20|Participants will be dosed on Day 1 with ADG20 IM
9789571|NCT01362517|Experimental|Quinvaxem|
9789572|NCT01362530|Experimental|Aprepitant Regimen|"Cycle 1:~Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg).~Optional Cycles 2-6:~Open-label aprepitant administered in the same manner as in Cycle 1."
9789573|NCT01362530|Placebo Comparator|Control Regimen|Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
9789574|NCT01362608|Experimental|Canakinumab and placebo matching to triamcinolone acetonide|ACZ885H
9789575|NCT01362608|Active Comparator|Triamcinolone acetonide 40 mg|ACZ885H
9789576|NCT01362686|Experimental|Donepezil|See intervention note.
9789577|NCT01362686|Experimental|Galantamine|See intervention note.
9789578|NCT01362686|Experimental|Rivastigmine|See intervention note.
9789579|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg days 10, 12, and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
9789580|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen B|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle Regimen B: Cycle 1: 4 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen B: Cycle 1: 35mcg/kg days 18, 20, and 22. Cycles 2-4: (Days 6, 8, and 10), for a maximum of six treatment cycles."
9789581|NCT01362790|Experimental|Phase 2 Peritoneal Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5 and 9 of 38 day cycle Cycles 2-6: 4 mg/m^2 on day 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen B: Cycle 1: 35 mcg/kg or 25 mcg/kg days 18, 20 and 22. Cycles 2-4: Days 6, 8, and 10, for a maximum of six treatment cycles."
9789582|NCT01362790|Experimental|Phase 2 Pleural Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
9789583|NCT01362790|Experimental|Mesothelioma Positive Ca Dose De-escalation Pilot Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
9799474|NCT01660763|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
9799475|NCT01660802|Experimental|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
9799476|NCT01660802|Sham Comparator|Sham|Sham administered in the study eye on Day 1.
10206134|NCT04859517|Placebo Comparator|Placebo|Participants will be dosed on Day 1 with placebo IM
10206135|NCT04858152|Experimental|Experimental Arm: Transplantation of hair follicles to non-hair bearing areas affected by vitiligo|Punch biopsies will be used to extract hair follicles from area on participant's body that is not affected by vitiligo and has hair growth. The follicles will then be transplanted into an area of the body affected by vitiligo that is hairless.
10206136|NCT04858074|Experimental|Active medication- PECKO-D|Participants will be randomly allocated to experimental drug
10206137|NCT04858074|Placebo Comparator|Placebo|Corn-Starch will be administered as placebo agent
10206138|NCT04857398|Experimental|Insulin icodec|The participants will receive an individualised weekly dose of subcutaneously (s.c.) insulin icodec for 6 weeks
10206139|NCT04856202|Active Comparator|Intervention|A trained facilitator will schedule two facilitated Respecting Choices interviews with the patient and preferably, if the patient agrees, in the presence of a caregiver or relative.
10206140|NCT04856202|No Intervention|Control|Care as usual
10206141|NCT04848428|Experimental|Online Mindfulness-based intervention|Four weekly sessions are planned. The first session will focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
9789584|NCT01362790|Experimental|Phase 2 Pancreatic Adenocarcinoma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
9789585|NCT01362790|Experimental|Phase 2 Lung Adenocarcinoma Pilot Expansion Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
10206142|NCT04848428|Active Comparator|Online standardized education|In addition to usual care, the CG will have access to one 15-minute standardized educational online session on persistent post-surgical pain, how pain and stress may interact and their potential impact on recovery.
9789586|NCT01362894|Other|nelfilcon A / etafilcon A|Nelfilcon A lenses worn first, with etafilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
9789587|NCT01362894|Other|etafilcon A / nelfilcon A|Etafilcon A lenses worn first, with nelfilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
9789588|NCT01362907|Other|Delefilcon A / etafilcon A|Delefilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
9789589|NCT01362907|Other|Etafilcon A / delefilcon A|Etafilcon A contact lenses worn first, with delefilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
9789590|NCT01362946|Experimental|Reward-Emphasized treatment|This treatment consisted of behavior therapy modified to match the unique learning styles of children with CPCU. This was accomplished by emphasizing rewards and de-emphasizing punishments. This treatment was administered using a summer treatment program.
9789591|NCT01362946|Active Comparator|Standard treatment|This treatment consisted of standard behavior therapy, in which reward and punishment components were used in a balanced manner, as is typically done in outpatient settings. This treatment was administered using a summer treatment program.
9789592|NCT01362959|Experimental|Nicotine patch|
9789593|NCT01362959|Placebo Comparator|Control patch|The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.
9789594|NCT01363011|Experimental|E/C/F/TDF (Cohort 1)|"Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country."
9789595|NCT01363011|Experimental|COBI+PI+2 NRTI (Cohort 2)|"Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country."
9789596|NCT01363050|Experimental|Ketorolac tromethamine|
9789597|NCT01363076|Experimental|Ketorolac Tromethamine (15 mg)|Ketorolac Tromethamine - single dose (15 mg) administered intranasally (IN) for subjects weighing <50 kg.
9789598|NCT01363076|Experimental|Ketorolac Tromethamine (30 mg)|Ketorolac Tromethamine - single dose (30 mg) administered intranasally (IN) for subjects weighing ≥50 kg.
9789599|NCT01363128|Experimental|Treatment (hyper-CVAD, ofatumumab)|"COURSES 1, 3, 5, 7: Patients receive hyper-CVAD comprising cyclophosphamide IV over 3 hours every 12 hours on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 15 minutes on days 4 and 11; and dexamethasone IV over 30 minutes or PO QD on days 1-4 and 11-14. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 11 of courses 1 and 3.~COURSES 2, 4, 6, 8: Patients receive high-dose methotrexate IV over 2 hours and then over 22 hours on day 1 and cytarabine IV over 2 hours every 12 hours on days 2-3. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 8 of courses 2 and 4.~Treatment repeats every 21-28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may receive maintenance therapy for an additional 30 months."
9789600|NCT01363258|Experimental|Care-resistant mouth care (MOUTh)|These nursing home residents with dementia receive mouth care from study personnel who use strategies to reduce care-resistant behavior (Managing Oral Hygiene Using Threat Reduction or MOUTh) while providing evidence-based mouth care.
9789601|NCT01363258|Active Comparator|Evidence Base Mouth Care|Nursing home residents with dementia received mouth care from study personnel who were trained in evidence-based mouth care only.
9789602|NCT01363297|Experimental|Inotuzumab Ozogamicin|
9789603|NCT01363349|Experimental|CYP-1020|Dose titration 15-35mg/day for 6 months
9789604|NCT01363349|Active Comparator|Risperidone|Dose titration 2-6mg/day for 6 months
9789605|NCT01363388|Placebo Comparator|Placebo|
9789606|NCT01363388|Experimental|CCX168|Active study medication
9789607|NCT01363440|Active Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
9789608|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
9789609|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
9789610|NCT01363479|Experimental|Oral palonosteron plus dexamethasone|Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
9789611|NCT01363479|Active Comparator|I.V. palonosetron plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
9789612|NCT01363492|Experimental|Replagal 0.2 mg/kg every other week (EOW)|
9789613|NCT01363661|Experimental|Molsidomine|Coruno (molsidomine 16 mg tablet; per os; once daily)
9789614|NCT01363661|Placebo Comparator|Placebo|Placebo (16 mg tablet; once a day)
9789615|NCT01363700|Experimental|1|
9789616|NCT01363700|Placebo Comparator|2|
9789617|NCT01363700|Active Comparator|3|
9789618|NCT01363713|Experimental|1|
9789619|NCT01363765|Experimental|Xpert MTB/Rif|Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
9789620|NCT01363765|Active Comparator|Sputum smear|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining
9789621|NCT01363843|Experimental|treatment|"Induction therapy - Modified FOLFOX6 - Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours - Repeat q14 days x 8 cycles~Concurrent Chemoradiation~50.4 Gy Radiation in 28 fractions (45 Gy IMRT, 5.4 Gy 3D conformal boost)~Surgery"
9789622|NCT01363908|Experimental|SPD602 (26 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks
9789623|NCT01363908|Experimental|SPD602 (36 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
9789624|NCT01363908|Experimental|SPD602 (16 mg/kg)|A single dose given in the initial pharmacokinetic phase.
9789625|NCT01363986|Experimental|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.
9789626|NCT01363999|Experimental|A|RO5317116/F01 bilayer tablet
9789627|NCT01363999|Experimental|B|RO5317116/F03 bilayer tablet
9789628|NCT01363999|Experimental|C|RO5317116/F04 active-coated tablet
9789629|NCT01363999|Experimental|D|RO4607381/F49 tablet
9789630|NCT01364090|Active Comparator|Standard Treatment Duration (24 weeks)|Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
9789631|NCT01364090|Experimental|Shortened Treatment Duration (12 Weeks)|Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).
9789632|NCT01364207|Experimental|Caffeinated Coffee 1st Visit, Decaffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of caffeinated coffee on their first visit and 8 oz cup of decaffeinated coffee on their second visit.
9789633|NCT01364207|Experimental|Decaffeinated Coffee 1st Visit, Caffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of decaffeinated coffee on their first visit and 8 oz cup of caffeinated coffee on their second visit.
9789634|NCT01364233|Other|MotifMesh|Condensed polytetrafluoroethylene (cPTFE, MotifMESH) mesh
9789635|NCT01364259|Placebo Comparator|Placebo|Placebo and SRS
9789636|NCT01364259|Experimental|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
9789637|NCT01364298|Experimental|Gabapentin/B-complex|
9789638|NCT01364298|Active Comparator|Pregabalin|
9789639|NCT01364389|Experimental|ACZ885|On day 1, patients received a single intravenous dose of ACZ885 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of ACZ885 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
9789640|NCT01364389|Experimental|AIN457|On day 1, patients received a single intravenous dose of AIN457 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of AIN457 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
9789641|NCT01364389|Other|Prednisone|On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
9789642|NCT01364428|Experimental|IDeg 200 U/mL|
9789643|NCT01364428|Experimental|IDeg 100 U/mL|
10206143|NCT04845919|Experimental|5-ALA mediated sonodynamic therapy|
9838362|NCT04209569|Active Comparator|NIPP|The NIPP group is a standard social behavior change (SBCC) intervention that tackles a set of underlying causes of malnutrition, with the potential to have both a curative and preventative impact on child malnutrition. The approach in this group/arm involves training and pragmatic behavior change education reinforced by practical activities over a 12-week period to both men and women in selected communities. It aims to utilize easy, viable and accessible solutions within the community that can be used to improve and protect household health and nutrition. The 12-week lesson plans for the circles are divided into 3 components, i) hands-on behavior change sessions that focus on the key pre-identified causes of malnutrition to improve awareness and practice ii) micro-gardening for improved household nutrition security and iii) participatory cooking demonstrations to stimulate improvements in nutritional status and care practices.
9838363|NCT04209569|Experimental|NIPP+|In addition to establishing the circles and implementing the three NIPP components also implemented in the NIPP arm, those randomized to the NIPP+ arm will be provided access to innovations to allow and encourage the households and communities to translate the knowledge into positive practices. The innovations and access to vendors who sell innovations will be made available during the training to the NIPP+ volunteers who will provide trainings and access to vendors during the circle meetings. Most of the additions will be made accessible at a subsidized/low cost. The NIPP+ officers from the program will support NIPP+ volunteers in collaboration with agricultural extension officers.
9838364|NCT04209569|No Intervention|Control|No Intervention
9838366|NCT04203823|Experimental|Algorithm Testing|"The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm~The study population will be enrolled as 2 separate cohorts to test each algorithms individually"
9838367|NCT04202991||COPD with pain|People with COPD who also report pain more often than not over the previous 3 months
9838368|NCT04202991||COPD with no pain|People with COPD who do not report pain more often than not over the previous 3 months
9838369|NCT04197635|Active Comparator|Dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive dapagliflozin 10 mg per day.
9838370|NCT04197635|Placebo Comparator|Placebo identical to dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive placebo (one tablet a day orally).
9838371|NCT04193306|Experimental|Alirocumab|alirocumab 150 mg s.c. every 2 weeks, for 48 weeks
9838372|NCT04193306|Placebo Comparator|Placebo|placebo s.c. every 2 weeks, for 48 weeks
9838373|NCT04193046|Other|Participants with PH and non-PH|Blood samples will be collected for biomarker analysis from new (incident) and existing (prevalent) participants who undergo right heart catheterization (RHC). Participants will be categorized into non-PH or PH based on the results of the RHC and those who are found to have PH will be further classified into the different groups of PH. A transthoracic echocardiography (TTE) will be performed if not done previously.
9838374|NCT04191785|Experimental|plasmatic NGAL and MRI|
9838375|NCT04188665|Experimental|MASL treated|Patients treated with lozenge containing MASL
9838376|NCT04188665|Placebo Comparator|Placebo treated|Patients treated with lozenge without MASL
9838377|NCT04186247|Other|Standard of Care|SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
9838378|NCT04186247|Experimental|Standard of Care + Antibiotics|"SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.~Azithromycin (weeks 4-12)~Metronidazole (weeks 4-12)"
9838379|NCT04181515|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor (lactose), sham rTMS (inactive coil)
9838380|NCT04181515|Active Comparator|placebo stressor, active rTMS|placebo stressor (lactose), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
9838381|NCT04181515|Active Comparator|stressor, sham rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), sham rTMS (inactive coil)
9838382|NCT04181515|Active Comparator|stressor, active rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
9838383|NCT04181255|Experimental|Curosurf|
9838384|NCT04181255|Placebo Comparator|Sham (air)|
9838385|NCT04181060|Active Comparator|Arm A (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9921964|NCT00833209|Experimental|1|Patients with Medication Overuse Headache (MOH)
9921965|NCT00833209|Sham Comparator|2|controls suffering from migraine
9789644|NCT01364467|Placebo Comparator|Placebo|Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
9789645|NCT01364467|Active Comparator|Guaifenesin|
9789646|NCT01364558|Experimental|Diazepam Nasal Spray Suspension|Diazepam Nasal Suspension - 10 mg
9789647|NCT01364558|Experimental|Diazepam Nasal Spray Solution|Diazepam Nasal Spray Solution - 10 mg
9789648|NCT01364558|Active Comparator|Diazepam injection|Diazepam injection IV - 5 mg
9789649|NCT01364584|Experimental|Exenatide|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months
9789650|NCT01364584|Placebo Comparator|Placebo|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of placebo for 2.5 months
9789651|NCT01364623|Experimental|Low dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.24% testosterone gel to deliver a single dose of 300 μg of testosterone per nostril, for a total dose of 600 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 1 (Low dose testosterone nasal gel, single dose)
9789652|NCT01364623|Experimental|Medium dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 2 (Medium dose testosterone nasal gel, single dose)
9789653|NCT01364623|Experimental|High dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.72% testosterone gel to deliver a single dose of 900 μg of testosterone per nostril, for a total dose of 1800 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 3 (High dose testosterone nasal gel, single dose)
9789654|NCT01364623|Experimental|Medium dose TBS-2 multiple doses|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2 (Multi-dose group) (Medium dose testosterone nasal gel, multiple dose)
9789655|NCT01364649|Experimental|Vortioxetine|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
9789656|NCT01364649|Active Comparator|Escitalopram|Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
9789657|NCT01364727|Experimental|Amrubicin|Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
9789658|NCT01364740|Experimental|PMP-300E, In-Lab PSG|PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
9838386|NCT04181060|Experimental|Arm B (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9838387|NCT04180969|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil
9838388|NCT04180969|Experimental|placebo stressor, active rTMS|placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
9838389|NCT04180969|Experimental|active stress, sham rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil
9838390|NCT04180969|Experimental|active stress, active rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
9838391|NCT04180215|Experimental|Ph I, Group 1|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
9838392|NCT04180215|Experimental|Ph I, Group 2|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
9838393|NCT04180215|Experimental|Ph I, Group 3|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
9838394|NCT04180215|Experimental|Ph I, Group 4|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
9838395|NCT04180215|Experimental|Ph II, Group A|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
9838396|NCT04180215|Experimental|Ph II, Group B|Patients with HPV 16+ HNSCC who are eligible to receive immune checkpoint inhibitor as part of standard of care.
9838397|NCT04180215|Experimental|Ph II, Group C|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
9838398|NCT04180215|Experimental|Ph II, Group D|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
9838399|NCT04180215|Experimental|Ph II, Group E|Patients with HPV 16+ HNSCC who are eligible to receive immune checkpoint inhibitor as part of standard of care.
9838400|NCT04180215|Experimental|Ph II, Group F|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
9838401|NCT04180215|Experimental|Ph I, Group 5|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
9838402|NCT04180215|Experimental|Ph I, Group 6|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy
9838403|NCT04180215|Experimental|Ph I, sub-study|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy
10206144|NCT04843579|Experimental|Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)|"Selinexor~• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.~Dexamethasone~Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.~Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).~Clarithromycin~Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.~Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.~Pomalidomide~Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.~Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle."
10206145|NCT04840979|Experimental|Cognitive Impairment|Subjects diagnosed with Alzheimer's disease (AD) or mild cognitive impairment (MCI) will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo a 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
10206146|NCT04840979|Active Comparator|No Cognitive Impairment|Healthy volunteers who are cognitively normal will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo an 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
9838407|NCT04174859||NVAF patients|Start treatment with rivaroxaban at the discretion of physician.
9838408|NCT04172675|Experimental|Cohort 1: Erdafitinib|Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ [CIS], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.
9838409|NCT04172675|Active Comparator|Cohort 1: Investigators Choice|Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC)/hyperthermic MMC. Participants who are randomized to gemcitabine or MMC/hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.
9838410|NCT04172675|Experimental|Cohort 2|Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.
9838411|NCT04172675|Experimental|Cohort 3|Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.
9921966|NCT00833209|Sham Comparator|3|controls without any neurological disease
10206147|NCT04826419|Active Comparator|Non-invazive ozone therapy in a group|ozone therapy
10206148|NCT04826419|No Intervention|Control group|control groups do not take ozone therapy
10206149|NCT04822766|Active Comparator|Chemotherapy|
10206150|NCT04822766|Experimental|Allogeneic Hematopoietic Cell Transplantation|Time of transplant procedure The best available treatments of AML
10206151|NCT04821375|Experimental|Bazedoxifene plus conjugated estrogens immediately|Immediate receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
9921967|NCT00833222||Full Term Infants|Infants born between 37 4/7 weeks and 42 3/7 weeks gestation.
9799477|NCT01660815|Experimental|Healthy Volunteers|Cognitively normal, healthy volunteers at least 45 years of age.
9799478|NCT01660893|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and oxymetazoline HCl 0.05%
9799479|NCT01660893|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
9799480|NCT01660893|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
9799481|NCT01660906|Experimental|Dasatinib (100 mg)|
9799482|NCT01661062|Experimental|Cone Beam CT|All patients will be included in the treatment arm of this study. For the purposes of this study patients will get CT scans every day for the length of their radiation therapy (in order to assess if CT every day provides additional information compared with CT scans performed less frequently). Although the exact amount of radiation patients get will be determined by their doctor, it is expected that they will get approximately 7 weeks, approximately 35 total cone beam CT scans.
9799483|NCT01661088|Experimental|Study Treatment|"Patients will receive FOLFIRINOX x 6 followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine (1g/m^2) on days 1, 8, 22, 29.~Intensity-modulated radiotherapy (IMRT): The prescribed dose was 50.0Gy in 2.0Gy per fraction.~Patients without metastatic disease will be offered surgical exploration."
9799484|NCT01661114|Experimental|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
9799485|NCT01661140|Experimental|Methotrexate (MTX) Tapering Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
9799486|NCT01661140|Active Comparator|Methotrexate (MTX) Maintenance Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
9799487|NCT01661179|Experimental|Vandetanib 300mg|300 mg/day vandetanib
9799488|NCT01661205|Experimental|AtriCure Bipolar System combined with a catheter ablation|Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
9799489|NCT01661270|Placebo Comparator|Placebo|Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
9799490|NCT01661270|Experimental|Aflibercept|Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
9799491|NCT01661283|Experimental|Arm A|All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days
9799492|NCT01661595|Active Comparator|Sildenafil / Placebo|50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
9799493|NCT01661595|Active Comparator|Tadalafil / Placebo|10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
9799494|NCT01661595|Active Comparator|Placebo / Sildenafil|Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
9799495|NCT01661595|Active Comparator|Placebo / Tadalafil|Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
9799496|NCT01661621|Experimental|Group 1|Antimuscarinics (Detrusitol 4 mg QD)
9799497|NCT01661621|Experimental|Group 2|α-blockers (Doxazosin 4 mg QD)
9799498|NCT01661686|Active Comparator|Insertion of a partially covered SEMS|
9799499|NCT01661686|Active Comparator|Insertion of a Fully covered SEMS|
9789659|NCT01364870|Active Comparator|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
9789660|NCT01364870|Placebo Comparator|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
9789661|NCT01364870|No Intervention|Standard Care|"Subjects randomized to Standard Care will be given no TENS unit."
9789662|NCT01364896||Inflammatory bowel disease, Immunosuppressive agent|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid immunosuppressive agent
9789663|NCT01364922|Experimental|Open-label Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 2 tablets twice daily
9789664|NCT01364922|Experimental|Double-blind Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 1 tablet twice daily
9789665|NCT01364922|Placebo Comparator|Double-blind Placebo|Placebo, 1 tablet twice daily
9789666|NCT01365039|Experimental|Test lens|Test contact lens will be worn on a daily disposable wear basis.
9789667|NCT01365039|Active Comparator|SofLens lens|The currently marketed Bausch + Lomb SofLens daily disposable contact lens. Worn on a daily disposable wear basis.
9789668|NCT01365052|Experimental|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|
9789669|NCT01365052|Placebo Comparator|Placebo|
9789670|NCT01365091|Experimental|Arm 1: Treatments A,B/B,A|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."
9789671|NCT01365091|Experimental|Arm 2: Treatments C,D/D,C|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."
9789672|NCT01365091|Experimental|Arm 3: Treatments E, F/F,E|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."
9789673|NCT01365091|Experimental|Arm 4: Treatments G,H/H,G|"Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."
9789674|NCT01365130|Experimental|real drug|patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity
9789675|NCT01365273|No Intervention|Bridal Veil together with staples|Standard of care. Bridal Veil is fixed over the graft with staples.
9789676|NCT01365273|Active Comparator|Mepitel One|Device, dressing
9789677|NCT01365455|Experimental|AIN457 150 mg|AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
9789678|NCT01365455|Experimental|AIN457 300 mg|AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
9799500|NCT01661712|Active Comparator|Transcutaneous electrical stimulation|One night of transcutaneous electrical stimulation (electrical current titrated according to skin sensation)
9799501|NCT01661712|Sham Comparator|Sham stimulation|One night of sham stimulation (no electrical current)
9838412|NCT04171440|Experimental|Minimally Invasive Pancreaticoduodenectomy|Patients that undergo pancreaticoduodenectomy through small incisions with state-of-the-art robotic-assisted technology.
10206152|NCT04821375|Other|Bazedoxifene plus conjugated estrogens wait list|After a 6-month waiting period, receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
10206153|NCT04819113|Experimental|Nimenrix|Nimenrix
10206154|NCT04814953||Basal cell carinoma patients|Patients with basal cell carcinoma in history (up to 10 years before inclusion) with or without squamous cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
9838416|NCT04164082|Experimental|Treatment (pembrolizumab, gemcitabine hydrochloride)|"INDUCTION: Patients receive pembrolizumab IV over 25-40 minutes on day 1 of cycles 1-4. Patients also receive gemcitabine hydrochloride intravesically on days 1, 8 and 15 of cycles 1 and 2. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 5, patients with no evidence of disease after induction receive pembrolizumab IV over 25-40 minutes and gemcitabine intravesically on day 1. Treatment repeats every 3 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity."
9838417|NCT04164069|Experimental|Prevention (dasatinib, mFOLFOX, bevacizumab)|Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.
9838418|NCT04162470|Experimental|REGN3918|Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 [NCT03946748] or R3918-PNH-1853)
9838419|NCT04154774|Experimental|Group 1: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive single oral dose of apalutamide on Day 1 under fasted condition.
9838420|NCT04154774|Experimental|Group 2: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive single oral dose of apalutamide on Day 1 under fasted condition.
9838421|NCT04150276|Active Comparator|ZEEP during awakening|ZEEP will be used during emergence preoxygenation and awakening.
9838422|NCT04150276|Active Comparator|PEEP during awakening|PEEP is maintained throughout emergence preoxygenation and awakening.
9838423|NCT04145531|Experimental|JZP-458|"Part A (IM JZP-458) of the study will have 2 IM cohorts:~Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and~Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule~Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose.~Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit."
10206155|NCT04814953||Squamous cell carcinoma patients|Patients with squamous cell carcinoma in history (up to 10 years before inclusion) with or without basal cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
9838425|NCT04145115|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9838426|NCT04143594|Experimental|Lenacapavir, F/TAF, and TAF|"Induction: Participants will receive oral lenacapavir 600 mg, 600 mg, and 300 mg at Days 1, 2, and 8, respectively. Participants will also begin oral daily emtricitabine/tenofovir alafenamide (F/TAF) 200/25mg from Day 1 onwards for a total of 28 weeks. On Day 15 participants will receive subcutaneous (SC) lenacapavir 927 mg.~Maintenance: Participants will receive SC lenacapavir 927 mg at Week 28 and every 26 weeks. Participants will discontinue oral daily F/TAF 200/25 mg at Week 28 and begin taking oral daily TAF 25 mg.~May require oral weekly bridging if an SC injection of GS-6207 cannot be administered for any reason within the protocol visit window.~Participants willing to continue the study beyond Week 80 will continue to receive SC lenacapavir 927 mg every 6 months (26 weeks) and oral daily TAF 25 mg from Week 80 onwards."
9838427|NCT04143594|Experimental|Lenacapavir, F/TAF, and BIC|"Induction: Participants will receive oral lenacapavir 600 mg, 600 mg, and 300 mg at Days 1, 2, and 8, respectively. Participants will also begin oral daily F/TAF 200/25 mg from Day 1 onward for a total of 28 weeks. On Day 15 participants will receive SC lenacapavir 927 mg.~Maintenance: Participants will receive SC lenacapavir 927 mg at Week 28 and every 26 weeks. Participants will discontinue oral daily F/TAF 200/25 mg at Week 28 and begin oral daily bictegravir (BIC) 75 mg.~May require oral weekly bridging if an SC injection of GS-6207 cannot be administered for any reason within the protocol visit window.~Participants willing to continue the study beyond Week 80 will continue to receive SC lenacapavir 927 mg every 6 months (26 weeks) and oral daily bictegravir (BIC) 75 mg from Week 80 onwards."
9921968|NCT00833222||Preterm Infants|Infants born between 32 4/7 weeks and 35 3/7 weeks gestation.
9921969|NCT00833235||Patients with dry eye|No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.
10206156|NCT04814953||Patients with actinic keratoses|Patients with actinic keratosis in history (up to 10 years before inclusion) with or without basal cell carcinoma or squamous cell carcinomas but no other skin cancers (melanoma or non-melanoma skin cancer)
10206157|NCT04814316||Study group|Patients with gastroesophageal reflux or gastroesophageal reflux disease who will use lansoprazole.
10206158|NCT04814316||Control group|Healty volunteers who will not use lansoprazole.
10206159|NCT04812067|Experimental|TTHX1114 weekly x 5|TTHX1114 via IC injection weekly x 5
10206160|NCT04808505|Experimental|Cipaglucosidase Alfa/Miglustat -treated ERT-experienced subjects experiencing clinical decline|
10206161|NCT04808505|Experimental|Cipaglucosidase Alfa/Miglustat treated ERT-naïve subjects|
10206162|NCT04808505|No Intervention|Approved rhGAA-treated ERT-naive subjects|
10206163|NCT04806919|No Intervention|Control group: Amelgen ® 400 mg BID|Continue daily dose progesteron
10206164|NCT04806919|Experimental|Intervention group: Amelgen ® 400 mg TID|Increase daily progesteron dose
10206165|NCT04806854|Experimental|LUM-201 (1.6 mg/kg/day)|
10206166|NCT04806854|Experimental|LUM-201 (3.2 mg/kg/day)|
10206167|NCT04805671|Experimental|ADG20 IM|Participants will be dosed on Day 1 with ADG20 IM
9789679|NCT01365455|Placebo Comparator|placebo|placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
9789680|NCT01365455|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
9789681|NCT01365455|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
9789682|NCT01365468|Experimental|Everolimus (RAD001)|enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.
9789683|NCT01365481|Experimental|valsartan|Valsartan starting dose: ≥18 kg to <35 kg is 40 mg, ≥35 kg to <80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to <35 kg is 80 mg, ≥35 kg to <80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
9789684|NCT01365494|Active Comparator|Group A-Zagreb|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
9789685|NCT01365494|Active Comparator|Group B-Essen|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)
9789686|NCT01365507|Experimental|IDegAsp Simple|
9789687|NCT01365507|Experimental|IDegAsp Step wise|
9789688|NCT01365546|Experimental|human VWF/FVIII concentrate|
9789689|NCT01365585||Sildenafil ≥20mg three times daily|Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH
9789690|NCT01365611|Experimental|Ketorolac tromethamine|
9789691|NCT01365624|Experimental|Ketorolac tromethamine|
9789692|NCT01365650|Experimental|Ketorolac Tromethamine|
9789693|NCT01365650|Experimental|Oxymetazoline Hydrochloride|
9789694|NCT01365650|Experimental|Fluticasone Propionate|
9789695|NCT01365793|Experimental|Rapid rehydration using 0.45% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.45% saline will be used as the replacement fluid for this arm.
9789696|NCT01365793|Experimental|Rapid rehydration using 0.9% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.9% saline will be used as the replacement fluid.
9789697|NCT01365793|Experimental|Slower rehydration using 0.45% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fluid bolus) with 0.45% saline used as the replacement fluid.
9789698|NCT01365793|Experimental|Slower rehydration using 0.9% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fuid bolus) with 0.9% saline used as the replacement fluid.
9789699|NCT01365819|Placebo Comparator|Sugar pill|Placebo
9789700|NCT01365819|Experimental|Varenicline|Varenicline (Chantix (R))
10206168|NCT04805671|Placebo Comparator|Placebo IM|Participants will be dosed on Day 1 with placebo IM
9789701|NCT01365845|Active Comparator|1|Conventional photon plan
9789702|NCT01365845|Experimental|2|3D-Proton/Conventional plan or 3D-proton only
9985096|NCT03393884|Experimental|NACT + GEN-1|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. GEN-1 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
10206169|NCT04804332|Experimental|EXPECTANT MANAGEMENT|No treatment will be offered.
10206170|NCT04804332|Experimental|OPERATIVE HYSTEROSCOPY|Operative hysteroscopy using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) is performed.
10206171|NCT04802655|Experimental|Exergame Group (EG)|In addition to routine NDT training, Structured Exergame Program for upper extremity and trunk control will be applied in this group. Xbox one - Kinect supported video games will be selected for video-game based exergame program. The Video games to be included in the Exergame program will be selected by Analytical Hierarchy Process. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
10206172|NCT04802655|Active Comparator|Activity Based Exercise Group (AG)|In addition to routine NDT training, Goal Directed Activity Based Exercises for upper extremity and trunk will be applied to this group. Program will consist 40 minutes of exergame sessions and 15 sessions total. Sessions will be applied 2 times a week, and It is planned to complete in 8 weeks.
10206173|NCT04801797|Experimental|Standard of Care (Conventional Induction)|"Randomized participants will receive cytarabine and idarubicin [or daunorubicin) per standard of care as follows:~Induction: cytarabine on days 1-7 and idarubicin (or daunorubicin) on days 1-3 of induction.~Second Induction (if needed): Cytarabine on days 1-5 and idarubicin (or daunorubicin) on days 1-2 of re-induction.~Consolidation (if needed): If < 60 years, cytarabine days 1,3,5 of consolidation cycles, and if ≥60 years, cytarabine days 1-5 of consolidation cycles~Those with secondary or therapy-related AML can receive liposomal daunorubicin and cytarabine (Vyxeos) per standard of care as follows:~Induction: Liposomal daunorubicin and cytarabine (Vyxeos) on Days 1,3, 5 of induction.~Second Induction (if needed): Liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of re-induction Consolidation (if needed): liposomal daunorubicin and cytarabine (Vyxeos) on days 1,3 of consolidation cycles"
9789703|NCT01365910|Experimental|Treatment (enzyme inhibitor)|Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9789704|NCT01366196|Placebo Comparator|Control Group (C)|Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.
9789705|NCT01366196|Experimental|Pregabalin Group (P)|Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.
9789706|NCT01366209|Active Comparator|Active Arm|
9789707|NCT01366209|Placebo Comparator|Placebo Arm|
9789708|NCT01366443||women pregnant|Healthy pregnant women between 15 or greater weeks gestation reporting with signs or symptoms of rupture of membranes.
9789709|NCT01366495|Experimental|On-site Rapid HIV Testing|On-site rapid testing conducted by research staff co-located for the purposes of this study at the probation/parole office.
9789710|NCT01366495|No Intervention|Off-site Referral for HIV Testing|Off-site referral for rapid HIV testing at a community health center or HIV testing clinic
9789711|NCT01366495|Experimental|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
9789712|NCT01366495|No Intervention|Treatment as Usual|Passive referral to HIV community treatment provider.
9789713|NCT01366521|Experimental|Mepolizumab 250 mg subcutaneous (SC)|250 mg subcutaneous (SC)
9789714|NCT01366521|Experimental|Mepolizumab 125 mg subcutaneous (SC)|125 mg subcutaneous (SC)
9789715|NCT01366521|Experimental|Mepolizumab 12.5 mg subcutaneous (SC)|12.5 mg subcutaneous (SC)
9789716|NCT01366521|Experimental|Mepolizimab 75 mg intravenously (I.V.)|75 mg intravenously (I.V.)
9789717|NCT01366534|Experimental|Ad35.CS.01 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
9789718|NCT01366534|Experimental|GSK257049 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
9789719|NCT01366534|Experimental|Control Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.
9789720|NCT01366638|Experimental|Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
9789721|NCT01366638|Experimental|Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
9789722|NCT01366638|Experimental|Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
9789723|NCT01366846|Experimental|Peanut avoidance after continuous peanut consumption|These participants were the peanut consumption group of the ITN032AD (LEAP) study
9789724|NCT01366846|Experimental|Continued peanut avoidance|These participants were the peanut avoidance group of the ITN032AD (LEAP) study
9789725|NCT01366885|Experimental|Intervention during pregnancy|5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.
9789726|NCT01366976|Placebo Comparator|Placebo|
9789727|NCT01366976|Active Comparator|Acetaminophen|Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period
9789728|NCT01367080|Experimental|A Group|"1st administration - DWETR10~2nd administration - DWETR25"
9789729|NCT01367080|Experimental|B Group|"1st administration - DWETR25~2nd administration - DWETR10"
9789730|NCT01367119|Active Comparator|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic prior to electroconvulsive therapy (ECT).
9838428|NCT04143594|Experimental|Lenacapavir and F/TAF|"Participants will receive oral lenacapavir 600 mg at Day 1 and Day 2. On Day 3, participants will begin oral daily lenacapavir 50 mg. Participants will begin oral daily F/TAF 200/25 mg from Day 1 onwards.~Participants willing to continue the study beyond Week 80 will continue to receive oral daily lenacapavir 50 mg and oral daily F/TAF 200/25 mg from Week 80 onwards."
9838429|NCT04143594|Active Comparator|B/F/TAF|Participants will receive oral daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg at Day 1 and throughout their participation in the study.
9985097|NCT03393884|Active Comparator|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
9838432|NCT04140825||Group 1|Subjects>=18 years old will measure as a minimum FOT and spirometry.
9838433|NCT04133636|Experimental|JNJ-68284528|Single group assignment-After lymphodepletion, JNJ-68284528 will be administered as single infusion to participants in cohort A (Progressive disease after 1-3 prior lines of therapy), cohort B (Early relapse after front-line), cohort C (Relapsed/refractory multiple myeloma after PI, IMiD, anti-CD38, and anti- BCMA therapy), cohort D (Less than CR after ASCT front-line therapy; some participants will be administered JNJ-68284528 followed by lenalidomide), cohort F (Newly diagnosed multiple myeloma [NDMM] with standard risk [international staging system {ISS} Stage I and II] and after initiation of therapy). Participants in cohort E (NDMM, transplant not planned, high risk disease) will first be administered with quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd), followed by lymphodepletion and JNJ-68284528, followed by consolidation regimen of lenalidomide.
9838434|NCT04129502|Experimental|TAK-788 Group (Arm A)|TAK-788 160 milligram (mg), capsules, orally, once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
9838435|NCT04129502|Active Comparator|Platinum-based Chemotherapy Group (Arm B)|Pemetrexed 500 milligram per meter square (mg/m^2) plus cisplatin 75 mg/m^2, infusion, IV, once on Day 1 of 21-day cycle pemetrexed 500 mg/m^2 plus carboplatin, infusion, IV, once at a dose calculated to produce area under curve (AUC) of 5 milligram*minute per milliliter (mg*min/mL) on Day 1 of 21-day cycle until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria. Pemetrexed/cisplatin or pemetrexed/carboplatin will be repeated every 3 weeks for 4 cycles, followed by maintenance treatment with pemetrexed 500 mg/m^2, on Day 1 of a 21-day cycle thereafter.
9838437|NCT04127656|Experimental|Amino Acid-Based Experimental Study Formula|Single-Arm Study
9838438|NCT04126005||Cohort 1 (Age < 18 Months)|"In-home visits every 2 months~Clinic assessments every 6 months"
9838439|NCT04126005||Cohort 2 (Age ≥ 18 Months - 3 Years)|"In-home visits every 4 months~Clinic assessments every 6 months"
9838440|NCT04126005||Cohort 3 (Age > 3 - 5 Years)|"In-home visits every 6 months~Clinic assessments every 6 months"
9838441|NCT04126005||Cohort 4 (Age > 5 Years)|"In-home visits every 12 months~Clinic assessments every 12 months"
9838442|NCT04126005||Cohort 5 (Deceased)|• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.
9838443|NCT04119414|Experimental|S&S + LFLS Group|300 expecting couples totaling 600 participants will be completing the S&S program followed by the LFLS Program.
9838444|NCT04115527|Active Comparator|Standard lymphadenectomy|Standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes harvested during the pancreaticoduodenectomy with CHILD's digestive reconstruction
9838445|NCT04115527|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, para-aortic lymph nodes (No16) is included, in particular No 16b1 lymph nodes (Lymph nodes along the psterior side of the pancreas between the aorta and inferior vena cava).
9838446|NCT04114227|Active Comparator|Acceptance and Commitment Therapy|Participants will learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors.
9838447|NCT04114227|Active Comparator|Supportive Psychotherapy|Participants will talk about their experiences to date.
9838448|NCT04108208|Experimental|Apalutamide 240 milligram (mg) plus ADT|Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
9789731|NCT01367119|Active Comparator|Methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic prior to electroconvulsive therapy.
9789732|NCT01367158|Experimental|3ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
9789733|NCT01367158|Experimental|2ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
9789734|NCT01367158|Experimental|3ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
9789735|NCT01367158|Experimental|2ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
9838449|NCT04108208|Placebo Comparator|Placebo plus ADT|Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
9985098|NCT03386162|Experimental|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
9985099|NCT03386162|Active Comparator|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
9838452|NCT04102644||Pregnant Women|Up to 15,000 pregnant women and their fetuses/newborns (including a pilot phase of up to 500 participant pairs)
9985100|NCT03376867||Healthy volunteers|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
9985101|NCT03376867||Volunteers with chronic pain|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
9985102|NCT03375710|Experimental|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
9838456|NCT04101877|Experimental|Avastin|bevacizumab 25 mg/ml, intravitreal administration, 0.05 ml (1.25 mg)
9838457|NCT04101877|Active Comparator|Eylea|aflibercept 40 mg/ml, intravitreal administration, 0.05 ml (2 mg)
9838458|NCT04101149||Group 1|Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.
9838461|NCT04090398|Experimental|Arm I (paclitaxel, radium Ra 223 dichloride)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and radium Ra 223 dichloride IV over 1 minute on day 1. Treatment with radium Ra 223 dichloride repeats every 28 days for 6 cycles and treatment with paclitaxel repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9838462|NCT04090398|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9838465|NCT04079712|Experimental|Treatment (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
9838466|NCT04077463|Experimental|Phase 1 (monotherapy dose escalation): Lazertinib|Participants will receive Lazertinib monotherapy orally once daily (QD) in 21-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. The subsequent doses of Lazertinib will be assigned by the Study Evaluation Team (SET) according to the dose escalation strategy by Bayesian logistic regression model (BLRM).
9838467|NCT04077463|Experimental|Phase 1b (combination): Lazertinib and Amivantamab|Participants will receive Lazertinib and Amivantamab, after the safety of RP2D of Lazertinib is confirmed in the Phase 1, in 28-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. This phase will start enrolling participants after the safety of Amivantamab is confirmed in Japanese participants in Study 61186372EDI1001 (NCT02609776).
9838468|NCT04077463|Experimental|Phase 1b (combination): Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP)|Participants will receive Lazertinib starting dose administered orally once daily (QD) in combination with Amivantamab, and doses of platinum-based chemotherapy (carboplatin and pemetrexed) per standard of care according to local guidance in a 21-day cycle for 4 cycles followed by maintenance with Lazertinib, Amivantamab and pemetrexed until disease progression or unacceptable toxicities.
9838469|NCT04077463|Experimental|Phase 1b (expansion) Cohort A: Lazertinib and Amivantamab|"This cohort A will further characterize the safety, tolerability, and preliminary antitumor activity of Lazertinib and Amivantamab based combinations within specific NSCLC population who have progressed after osimertinib and subsequent platinum-based chemotherapy, and platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR TKI is allowed if administered prior to osimertinib. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter."
9838470|NCT04077463|Experimental|Phase 1b (expansion) Cohort B: Lazertinib and Amivantamab|This Cohort B will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants previously treated with advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
9838471|NCT04077463|Experimental|Phase 1b (expansion) Cohort C: Lazertinib and Amivantamab|This Cohort C will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants with uncommon EGFR mutations. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
9838472|NCT04077463|Experimental|Phase 1b (expansion) Cohort D: Lazertinib and Amivantamab|Cohort D will seek to validate one or both potential biomarker strategies (next generation sequencing [NGS] and Immunohistochemical [IHC]), previously identified in Cohort E of Study 61186372EDI1001, in participants with osimertinib-relapsed, but chemotherapy-naive, EGFR Exon19del or L858R mutated NSCLC. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
9838473|NCT04077359|Experimental|nephrographic phase CT|the nephrographic phase will be evaluated alone by a radiologist blinded to the remaining series
9838474|NCT04077359|Active Comparator|gold standard|all series (unenhanced, corticomedullary, nephrographic and excretory phase) will be evaluated by a radiologist not involved in the experimental arm
9838475|NCT04074161|Experimental|Semaglutide|Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
9838476|NCT04074161|Placebo Comparator|Placebo (semaglutide)|Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
9838477|NCT04074161|Active Comparator|Liraglutide|Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
9838478|NCT04074161|Placebo Comparator|Placebo (liraglutide)|Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
9985103|NCT03373071|Experimental|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
9985104|NCT03369431|Other|Vivomixx, then placebo|This group starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
9838481|NCT04067778|Experimental|Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
9838482|NCT04067778|Other|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
9838483|NCT04061330|Experimental|Ketamine Group|
9838484|NCT04061330|Active Comparator|Opioid group|
9838485|NCT04060680|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
9838486|NCT04057898|Experimental|MN-166|Subjects will take MN-166 10 mg capsules, up to 50 mg twice a day for 12 months.
9838487|NCT04057898|Placebo Comparator|placebo|Subjects will take up to 5 matching placebo capsules twice a day for 12 months.
10206174|NCT04801797|Experimental|Investigational (Venetoclax and Azacitidine)|Participants will receive azacitidine on days 1-7 and venetoclax daily for up to (3) three 28-day study cycles and evaluated for response or benefit. If benefit/response is achieved, azacitidine on days 1-7 and venetoclax on days 1-28 (or less if deemed necessary per protocol) will be given in repeating 28-day cycles until benefit/response is no longer achieved or until patient proceeds to transplantation.
10206175|NCT04800094|Experimental|Investigational Ultrasound Imaging for Liver Fat Quantification|
10206176|NCT04797390|Active Comparator|Advanced Pneumatic Compression Device (APCD)|Daily self-administered treatment with the Flexitouch® Plus system (FT)
9838488|NCT04057391||QT Scanner in comparison to mammography|Women who have experience with both technologies (QT Scanner/Breast mammography
9985105|NCT03369431|Other|Placebo, then Vivomixx|This group starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
9985106|NCT03369249|Experimental|Link2CARE|This arm is comprised of participants randomized to the 4-session Link2CARE intervention.
9985107|NCT03369249|No Intervention|Standard of Care|This arm is comprised of participants who will not receive the 4-session Link2CARE intervention.
10206177|NCT04797390|Active Comparator|Usual Care|Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
9985108|NCT03367962|Experimental|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a [18F]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
9838494|NCT04050683|Experimental|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Right Atrial Pressure (RAP) ≥ 15mmHg or change in RAP ≥ 10 mmHg or Peak Systolic Right Ventricular (PSRV) Pressure ≥ 46 mmHg
9838495|NCT04050683|Active Comparator|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Normal hemodynamic parameters
10206178|NCT04796194|Experimental|LTX-315 in combination with pembrolizumab|"LTX-315 will be injected directly into the selected tumor lesion(s) at Days 1, 2, 3, 8, 15, 22, and 29. The maximum number of injections given per dosing day is 8 (5 mg each for a maximum total of 40 mg per day); the number of injections required per lesion depends on lesion size. The maximum total number of LTX-315 injections during the study will be 56 (up to 8 injections per day on each of 7 dosing days).~Pembrolizumab will be dispensed and administered as an IV infusion."
9838498|NCT04048616|Active Comparator|whey protein isolate + KHCO3|1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3
9789736|NCT01367158|Experimental|3ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of the same in current study
9789737|NCT01367158|Experimental|2ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of Tdap in current study
9789738|NCT01367158|Experimental|3ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of the same in current study
9789739|NCT01367158|Experimental|2ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of Tdap in current study
9789740|NCT01367158|Active Comparator|3B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of the same in current study
9789741|NCT01367158|Active Comparator|2B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of Tdap in current study
9789742|NCT01367158|Active Comparator|1ACWY|One dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine followed by one dose of placebo and one dose of Tdap in current study
9789743|NCT01367236|Active Comparator|standard care|"treatment with:~atazanavir 300 mg daily~ritonavir 100 mg daily~tenofovir 245 mg daily*~emtricitabine 200 mg daily* * as the fixed dose combination Truvada™"
9789744|NCT01367236|Active Comparator|Novel therapeutic approach|"darunavir 800 mg daily~ritonavir 100 mg daily~lamivudine 300 mg daily**~abacavir 600 mg daily**~maraviroc 150 mg once daily ** as the fixed dose combination Kivexa ™"
9789745|NCT01367249|Experimental|Bromfenac Ophthalmic Solution|Bromfenac ophthalmic solution 0.07% one drop into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
9789746|NCT01367249|Placebo Comparator|Placebo|One drop of placebo into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
9789747|NCT01367262|Experimental|Radiolabeled LY2886721|Single 25 milligram (mg) oral dose containing 80 microCuries of radiolabeled LY2886721
9789748|NCT01367275|Experimental|Brivanib + Irinotecan|Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m^2 on Day 1.
9789749|NCT01367444|Experimental|SAR422459 (Dose 1)|Starting dose of SAR422459 given through subretinal injection
9789750|NCT01367444|Experimental|SAR422459 (Dose 2)|Escalating dose of SAR422459 given through subretinal injection
9789751|NCT01367444|Experimental|SAR422459 (Dose 3)|Maximum tolerated dose (MTD) of SAR422459 given through subretinal injection
9789752|NCT01367457||Patients that received treatment with Temsirolimus|Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
9789753|NCT01367665|Experimental|Vismodegib - Locally Advanced|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
9789754|NCT01367665|Experimental|Vismodegib - Metastatic|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
9799502|NCT01661764|Active Comparator|rs174535 (GG), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
9799503|NCT01661764|Placebo Comparator|rs174535 (GG), placebo|Oleic Acid
9799504|NCT01661764|Active Comparator|rs174535 (GT), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
9799505|NCT01661764|Placebo Comparator|rs174535 (GT), placebo|Oleic Acid
9799506|NCT01661764|Active Comparator|rs174535 (TT), fish oil supplement|Eicosapentanoic acid and docosahexanoic acid
9799507|NCT01661764|Placebo Comparator|rs174535 (TT), placebo|Oleic Acid
9799508|NCT01661790|Experimental|Bevacizumab & Cisplatin|Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
9799509|NCT01661790|Active Comparator|Cisplatin|Cisplatin 30mg by intrapleural given every two weeks
9800456|NCT01688102|Active Comparator|Ultraviolet Light|Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of narrow band UVB.
9800457|NCT01688141|No Intervention|Control|Usual care
9789755|NCT01367704|Active Comparator|Control School|Control schools (where the coaches do not receive the Coaching Boys into Men (CBIM) training until following academic year 'wait list control')
10206179|NCT04792268|Experimental|Electronic clinical decision support|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm. An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~Automated electronic decision support will be provided as a combination of visual prompts on the individual patient's dashboard, accessed by clinicians when they view a patient record on the electronic health record supplemented by an email sent to the NHS Trust email account addresses of the participating ward clinician(s).~Alerts will include locally approved guideline-based recommendations for clinician-led monitoring and management of dysglycaemia and known diabetes, tailored to the individual patient based upon reported HbA1c values."
9789756|NCT01367704|Experimental|Intervention School|Intervention schools (where coaches receive the CBIM training at start of sports season)
9789757|NCT01367834|Experimental|Growth Hormone|Subjects in the somatotropin (growth hormone, GH) arm will receive GH injections from 12-24 months of life.
9789758|NCT01367834|No Intervention|Control|Subjects will receive no GH or placebo.
9789759|NCT01367847|Active Comparator|Helping the Noncompliant Child (HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
9789760|NCT01367847|Experimental|Technology-Enhanced HNC (TE-HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
9789761|NCT01367860|Active Comparator|OMicro|This group will be formed by randomization, which gets out surgery to open microdiscectomy
9789762|NCT01367860|Experimental|SJet|This group will be formed by randomization, and receive the discectomy procedure addressed by the technique of Percutaneous Diskectomy SpineJet
9789763|NCT01367886|Other|Fesoterodine|Females with overactive bladder symptoms will be given Fesoterodine 4 mg. daily for six weeks.
9789764|NCT01368042||Chronic Kidney Disease, Secondary Hyperpathyroidism|All eligible participants treated with paricalcitol iv according to the approved Summary of Product Characteristics (SmPC)
9789765|NCT01368081|Experimental|BI 10773 low dose|BI 10773 low dose tablet once daily
9789766|NCT01368081|Experimental|BI 10773 high dose|BI 10773 high dose tablet once daily
10206180|NCT04792268|No Intervention|Treatment as usual|Clinicians will not have access to eCDSS on wards recruited to this arm and will deliver care as usual.
10206181|NCT04789551||Multiple Sclerosis Stable Conditions|Multiple sclerosis patients presenting for a routine clinic visit.
9789767|NCT01368081|Active Comparator|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
9789768|NCT01368211|Active Comparator|Mirasol first, then Reference|This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
9789769|NCT01368211|Active Comparator|Reference first, then Mirasol|This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).
9789770|NCT01368263|Experimental|Group 1 (Ki67 <10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.
9789771|NCT01368263|Experimental|Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
9789772|NCT01368263|Experimental|Group 3 (E2 > 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
9789773|NCT01368276|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 consecutive days followed by 14 days of rest, in 28-day treatment cycles for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
9789774|NCT01368276|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered at a concentration of 10⁸ plaque forming units (PFU)/mL injected into 1 or more skin or subcutaneous tumors on Days 1 and 15 of each 28-day cycle for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
9789775|NCT01368406|Experimental|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
9789776|NCT01368406|No Intervention|treatment as usual|patients were on regular visits on psychiatrist
9789777|NCT01368432|Placebo Comparator|Placebo|Daily for 12 weeks
9789778|NCT01368432|Experimental|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks
9838499|NCT04048616|Active Comparator|whey protein isolate + microcrystalline cellulose|1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules
9838500|NCT04048616|Active Comparator|maltodextrin powder + KHCO3|isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3
9838501|NCT04048616|Placebo Comparator|maltodextrin powder + microcrystalline cellulose|isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules
9985109|NCT03367962|Experimental|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a [18F]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
9985110|NCT03367962|Experimental|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a [18F]F-AraG PET-CT scan.
9985111|NCT03360214|Other|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
9985112|NCT03360214|Other|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
9985113|NCT03360214|Other|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
9985114|NCT03360214|Other|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
9838508|NCT04040790|Experimental|Healthy volunteers|15 healthy volunteers for trials with passive artificial iris
9985115|NCT03359408|No Intervention|Care as usual|Care as usual, no intervention, just observation of natural change/ trajectories over time
9838512|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 1|Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
9838513|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 2|Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
9838514|NCT04033445|Placebo Comparator|Induction Study 1: Placebo IV|Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
9838515|NCT04033445|Experimental|Induction Study 2: Guselkumab IV|Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
9838516|NCT04033445|Placebo Comparator|Induction Study 2: Placebo IV|Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
9838517|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 1|Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).
9838518|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 2|Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).
9838519|NCT04033445|Placebo Comparator|Maintenance Study: Placebo SC|Participants will receive matching placebo SC q4w.
9838520|NCT04033432|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on day 1. Treatment repeats every 14 days for cycles 1-6 and then every 21 days for subsequent cycles. Patients may continue to receive sEphB4-HSA treatment until no longer clinically benefiting (PCWG3), unacceptable toxicity, treatment delay >= 4 weeks, or prohibitive illness/change in patient?s condition, or patient decides to withdraw from study.
9838521|NCT04033354|Experimental|A|HLX10 + chemotherapy (carboplatin nab paclitaxel)
9517817|NCT03302663|Other|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
9838522|NCT04033354|Placebo Comparator|B|Placebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy
9838523|NCT04030247|Experimental|Plant Sterol|South Asian participants with moderate cardiovascular disease risk will receive standard of care in addition to the plant sterol supplement to take twice daily for 3 months.
9838524|NCT04029688|Experimental|Dose Escalation: Solid Tumors: Idasanutlin Single Agent|
9838525|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Venetoclax|
9838526|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Cyclophosphamide + Topotecan|
9838527|NCT04029688|Experimental|AML: Idasanutlin + Venetoclax|
9838528|NCT04029688|Experimental|AML: Idasanutlin + Fludarabine + Cytarabine|
9838529|NCT04029688|Experimental|ALL: Idasanutlin + Venetoclax|
9838530|NCT04028063|Experimental|doxorubicin with AGEN1884 and AGEN2034|Doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1884 and anti-PD-1 antibody AGEN2034. Doxorubicin dosing is standard at 75 mg/m2 via Bolus with prior Dexrazoxane. AGEN2034 - 300 mg IV over 60min with infusion pump. AGEN1884 - 1 mg/kg IV over 90 min (-10 /+20 min) with infusion pump, within 30 minutes (0 / +20) of completion of AGEN2034.
9838531|NCT04027998||Carpal tunnel syndrome|group of carpal tunnel syndrome patients
9838532|NCT04027998||Control group|group of healthy controls
9985116|NCT03359408|Experimental|Dementia Care Management (DCM)|"Subjects in this arm will be provided with Dementia Care Management adapted to the intersectoral setting."
9838534|NCT04027894|Experimental|Rifamycin SV MMX plus ORT|Each tablet contains 200mg Rifamycin SV MMX for oral administration
9838535|NCT04027894|Placebo Comparator|Placebo tablets plus ORT|Placebo tablets identical to Rifamycin tablets with respect to size, taste and appearance.
9838536|NCT04026984|Experimental|Rifamycin SV MMX plus ORT|One tablet contains 50 mg Rifamycin SV-MMX® plus standard of care Oral Rehydration Therapy (ORT). Two 50mg tablets will be administered twice daily.
9838537|NCT04026984|Placebo Comparator|Placebo tablets plus ORT|Matching placebo tablets plus standard of care Oral Rehydration Therapy (ORT)
10206182|NCT04789551||Multiple Sclerosis Acute Flare Up|Multiple sclerosis patients admitted to the hospital with acute symptoms.
10206183|NCT04789551||Control patients|Patients without any immunological diseases who present for elective surgery.
9838540|NCT04025216|Experimental|Dose Escalation Arm1: Solid Tumors|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
10206184|NCT04788888|Experimental|Navitor Transcatheter Aortic Valve, FlexNav Delivery System|Navitor valve implantation, FlexNav Delivery system (small and large) and and Navitor Loading System (small and large)
10206185|NCT04788576||Patients with heart failure with preserved ejection fraction (HFpEF)|Subject with preserved ejection fraction (ejection fraction > 50%) and with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF ≥5 or 2-4 with abnormal stress test or invasive hemodynamic test)
10206186|NCT04785638|Experimental|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
10206187|NCT04785625|Experimental|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
10206188|NCT04785625|Placebo Comparator|Placebo implant|Placebo collagen-matrix implant
10206189|NCT04784429|Experimental|MPK|Microprocessor controlled knee
10206190|NCT04784429|Active Comparator|NMPK|Non-microprocessor controlled knee
10206191|NCT04783987||Healthy Control Group|Walking Assessments will be practised under dual and single task conditions.
9789779|NCT01368497|Experimental|Entecavir and peginterferon|Entecavir for 8 weeks followed by 40 weeks of both entecavir and peginterferon
9789780|NCT01368536|Experimental|Valturna|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.
9789781|NCT01368536|Active Comparator|Valturna + Amlodipine|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.
9789782|NCT01368536|Active Comparator|Valturna + chlorthalidone|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.
9789783|NCT01368562|Experimental|Methylnaltrexone|Participants will receive single dose of MNTX 0.15 milligrams per kilogram (mg/kg) subcutaneously (SC). Subsequent dosing could be adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability.
10206192|NCT04783987||Case Group|Walking Assessments will be practised under dual and single task conditions.
10206193|NCT04779307|Experimental|Induction Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of ≥30 kg were included in this arm.
9789784|NCT01368614|Experimental|AVAPS-AE|AVAPS-AE Mode of ventilation
9789785|NCT01368614|Active Comparator|Respironics OmniLab Advanced BiPAP S mode|OmniLab Advanced BiPAP S Mode of ventilation
9789786|NCT01368614|Active Comparator|Respironics OmniLab Advanced CPAP mode|OmniLab Advanced CPAP Mode of ventilation
9789787|NCT01368653|Active Comparator|Standard treatment|In this arm, smokers receive a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help them quit smoking
9789788|NCT01368653|Experimental|Standard treatment+practice quitting|In this arm, participants receive standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling.
9789789|NCT01368653|Experimental|Very low nicotine cigarettes|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this group. Those assigned to this group will receive a 6-week supply of cigarettes that contain tobacco with very low levels of nicotine (in regular or menthol flavors) to smoke instead of regular cigarettes containing nicotine. This treatment is designed to help people stop smoking after slipping (returning to smoking) during an attempt to stop smoking
10206194|NCT04779307|Experimental|Induction Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of >15 to <30 kg were included in this arm.
10206195|NCT04779307|Experimental|Induction Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of 10 to 15 kg were included in this arm.
9838541|NCT04025216|Experimental|Dose Escalation Arm 2: Multiple Myeloma|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
9838542|NCT04024761|Experimental|CIML NK|"CIML NK will be administered intavenously on day 0~Fludarabine will be administered as one-hour IV infusion once daily for 3 doses beginning on day -5.~Cyclophosphamide will be administered as 2-hour IV infusion on days -5 and -4."
9838543|NCT04021238|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with suspected kidney cancer and planned surgery will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
9838544|NCT04015141|Experimental|Perampanel|Participants aged 1 month to less than 18 years with pediatric epileptic syndrome (Cohort 1) or aged 1 month to less than 2 years with POS (Cohort 2) will receive perampanel oral suspension or perampanel tablets, once daily up to 56 weeks.
9985117|NCT03359239|Experimental|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
9838546|NCT04013841|Experimental|Oral preparation|The bowel preparation prior to colorectal resection will be conducted using oral-agents
9838547|NCT04013841|Experimental|Enema preparation|The bowel preparation prior to colorectal resection will be conducted using rectal enema
9838548|NCT04010461|Experimental|TMS to dlPFC, without a concurrent task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are in a resting state
9838549|NCT04010461|Experimental|TMS to vertex, without concurrent task|TMS (intermittent theta burst stimulation) will be applied to the cerebral vertex, when subjects are in a resting state
9838550|NCT04010461|Experimental|TMS to dlPFC, during task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are engaged in the n-back working memory task
9985118|NCT03355066|Experimental|Part 1A: Dose Escalation|Cohorts of subjects with advanced solid tumors will receive increasing doses (10, 20, 40, 60, 80, 120, 160, or 200 mg) of SM08502, administered orally, once daily, following 28-day treatment cycles. If the maximum tolerated dose (MTD) is not determined at the 200 mg dose, dosing will continue at 50 mg/dose increments until an MTD is determined. Cohorts will include approximately 1 to 6 subjects according to an accelerated escalation design and safety requirements for expansion of subject numbers. For the purpose of dose escalation and de-escalation, the dose of SM08502 and regimen may be modified based on the type of dose limiting toxicities (DLTs) observed and following data review and discussions between the Sponsor and Investigators.
9985119|NCT03355066|Experimental|Part 1B: Dose Finding|Indications eligible for Part 1B include castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), endometrial cancer, or ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Initially, two cohorts of 6-24 subjects will be evaluated comparing 2 different doses and schedules of SM08502 (30 mg daily and 40 mg 5 days on and 2 days off), administered orally following 28-day treatment cycles. If appropriate, alternative doses and schedules may be evaluated depending on the results.
9838553|NCT04006223||11C-PIB or 18F-florbetapir PET/MR|Patients suspected of or diagnosed with systemic amyloidosis will be scanned by 11C-PIB or 18F-florbetapir PET/MR twice. One is before biopsy and treatment, and the other is after at least half a year of treatment.
9838554|NCT04003584||Minimally Invasive Cardiac Bypass patients|
9838555|NCT04003584||Traditional Sternotomy Cardiac Bypass patients|
9838557|NCT04001933|Experimental|Intervention Arm|CPOP Intervention (see below).
9838558|NCT04001933|No Intervention|Control Arm|Usual care.
9838559|NCT03996395||Infants|Infants, 4-4.5 months of age at enrollment
9838568|NCT03985761|Experimental|Home Telerehabilitation_Motivation Enhanced HTme|The Home Telerehabilitation Motivation Enhanced (HTme) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTme group will use three simulations that will provide the user with eight to twelve levels of gradually increasing difficulty and complexity. A screen announces each level change and the graphics for each new level change substantially. Scoring opportunities increase at each new level.
9838569|NCT03985761|Active Comparator|Home Telerehabilitation_Unenhanced (HTu)|The Home Telerehabilitation Motivation Enhanced (HTu) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTu group will use three simulations. Difficulty will be increased utilizing an adaptive control algorithm that increases difficulty based on performance. Difficulty changes are extremely incremental making them imperceptible for most subjects. Graphics and scoring do not change as difficulty level changes.
9789790|NCT01368653|No Intervention|Advice and encouragement only|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this condition. Those in this arm will receive advice and encouragement to try to stop smoking again after they have slipped (returned to smoking) during a stop smoking attempt.
9789791|NCT01368809|Active Comparator|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
9789792|NCT01368809|Placebo Comparator|Saline Solution|Saline Solution 2 ml at induction, 1-2 ml boluses as needed
9789793|NCT01368835|Experimental|Ulthera treatment|
9789794|NCT01368874|Active Comparator|Group A|Ulthera® System treatment of the submental and submandibular regions at two treatment depths, and the lower neck region at one treatment depth.
9789795|NCT01368874|Active Comparator|Group B|Ulthera® System treatment of skin above the jawline, as well as the submental, submandibular and lower neck regions.
9789796|NCT01368874|Active Comparator|Group C|Ulthera® System treatment of the submental, submandibular, and the lower neck regions at two treatment depths.
9789797|NCT01368900|Experimental|Ulthera System Treatment|Ulthera treatment to the upper face.
9789798|NCT01368965|Experimental|Ulthera® System treatment|
9789799|NCT01369030||Deplin®|Subjects with depression who have been prescribed Deplin® daily.
9789800|NCT01369069|Experimental|IV insulin drip with target glucose 80 mg/dL - 130 mg/dL|The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
9789801|NCT01369069|Active Comparator|Sub Q insulin to keep glucose less than 180 mg/dL|This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL
9789802|NCT01369108|Experimental|Flowable composite|Flowable composite
9789803|NCT01369108|Active Comparator|Conventional composite|Highly filled conventional composite restorative
9789804|NCT01369199|Experimental|Peginterferon and entecavir|A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.
9789805|NCT01369225|Experimental|0.5 mg/kg AAB-003|
9789806|NCT01369225|Experimental|1 mg/kg AAB-003|
9789807|NCT01369225|Experimental|2 mg/kg AAB-003|
9789808|NCT01369225|Experimental|4 mg/kg AAB-003|
9789809|NCT01369225|Experimental|8 mg/kg AAB-003|
9789810|NCT01369329|Placebo Comparator|001|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
9789811|NCT01369329|Experimental|002|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
9789812|NCT01369329|Experimental|003|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
9789813|NCT01369342|Placebo Comparator|Placebo IV|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
10206196|NCT04779307|Experimental|Maintenance Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
10206197|NCT04779307|Experimental|Maintenance Period: Participants ≥30 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
9789814|NCT01369342|Experimental|Ustekinumab 130 milligram (mg)|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
10206198|NCT04779307|Experimental|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
10206199|NCT04779307|Experimental|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
10206200|NCT04779307|Experimental|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
10206201|NCT04779307|Experimental|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
10206202|NCT04777994|Experimental|Monotherapy Dose Escalation|ABBV-CLS-484 will be administered as a monotherapy in subjects with solid tumors
10206203|NCT04777994|Experimental|Combination Dose Escalation|ABBV-CLS-484 will be administered in combination with Programmed Cell Death-1 Inhibitor in subjects with solid tumors
10206204|NCT04777994|Experimental|Monotherapy Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC)
10206205|NCT04777994|Experimental|Combination Expansion|ABBV-CLS-484 will be administered at the determined recommended dose in combination with Programmed Cell Death-1 Inhibitor in subjects with locally advanced or metastatic, relapsed or refractory gastric or GEJ adenocarcinoma
10206206|NCT04775654|Experimental|Supplement|Participants consume 455mg of blackcurrant extract standardized to contain 50mg anthocyanins in a 2-capsule dose for 70 days.
10206207|NCT04775654|Placebo Comparator|Placebo|Participants consume 2 capsules of microcrystalline cellulose for 70 days.
10206208|NCT04772079|Experimental|Active treatment (BMS-986165) standard dose|
9789815|NCT01369342|Experimental|Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
9789816|NCT01369355|Placebo Comparator|001|Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
9789817|NCT01369355|Experimental|002|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
10206209|NCT04772079|Experimental|Active treatment (BMS-986165) half-standard dose|
10206210|NCT04772079|Placebo Comparator|Placebo|
9789818|NCT01369355|Experimental|003|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
9789819|NCT01369355|Experimental|004|Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
9789820|NCT01369355|Experimental|005|Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
9789821|NCT01369355|Placebo Comparator|006|Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.
9789822|NCT01369433|Experimental|tivozanib renal cell carcinoma (RCC)|Subjects who participated in a Phase 2 monotherapy study in RCC and showed tolerability and clinical benefit will be allowed access to tivozanib (AV-951).
9789823|NCT01369433|Experimental|tivozanib + temsirolimus|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + temsirolimus combination.
9789824|NCT01369433|Experimental|tivozanib + paclitaxel|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + paclitaxel combination.
9789825|NCT01369433|Experimental|tivozanib solid tumors - QTC|Subjects who participated in a Phase 1 and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951).
9789826|NCT01369433|Experimental|tivozanib + capecitabine|After Ph 1b study tolerable to Tivo + Xeloda®
9789827|NCT01369433|Experimental|tivozanib Advanced RCC|After biomarker study tolerable to Tivo
9789828|NCT01369485|Active Comparator|Active Treatment group|VERV™ System
9789829|NCT01369485|Sham Comparator|Sham Treatment Group|Sham version of (VERV™ System)
9789830|NCT01369498|Experimental|Simtuzumab 200 mg|Participants in Stage 1 of study will receive simtuzumab 200 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
10206211|NCT04766099|No Intervention|Standard Treatment|Standard bedside coaching by labor and delivery staff
10206212|NCT04766099|Experimental|Educational Video|Patients will watch the provided coaching video in addition to standard bedside coaching by labor and delivery staff
10206213|NCT04762225|Experimental|RPTR-168|Escalating doses of RPTR-168 as a monotherapy in HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
10206214|NCT04761770|Experimental|Geriatric participants with various blood disorders|"Geriatric assessment (GA) pre-transplant~Risk-adapted allocation of conditioning intensity based on GA~GA-directed, longitudinal supportive care management"
10206215|NCT04756583|Experimental|Intervention|
10206216|NCT04756583|No Intervention|Control|
10206217|NCT04756063|Experimental|Ascorbic Acid (AA)|The first intravenous dosage of 1500mg of AA in 100mL of normal saline (NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
10206218|NCT04756063|Placebo Comparator|Placebo|The first intravenous dosage of placebo (100 mL of NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
10206219|NCT04755231|Experimental|PanOptix IOL|AcrySof IQ PanOptix Presbyopia Correcting IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery
10206220|NCT04754113|Experimental|prone position|patients from supine to prone for at least 3 hours than re-supine
10206221|NCT04747730|Experimental|Transcendental Meditation training|The intervention of the project is the teaching and learning of Transcendental Meditation technique. The technique involves the use of a sound (mantra) to effortlessly allow the mind to settle down to a state of inner calm. It is a simple, natural and effortless practise, and unlike other meditation strategies, it does not involve concentration or control of the mind. The practice does not require any religion, philosophy, or change in lifestyle. Once learned the technique, participants will practice it twice a day, 20 minutes every morning and 20 minutes in the afternoon.
10206222|NCT04747730|No Intervention|control|no intervention
10206223|NCT04746378||extracorporeal shockwave lithotripsy|Patients that are included in the study and undergo a shockwave lithotripsy. The pre- and postoperative assessment remains the same across groups
10206224|NCT04746378||uretero(reno)scopy|Patients that are included in the study and undergo a semirigid or flexible uretero(reno)scopy. The pre- and postoperative assessment remains the same across groups
10206225|NCT04746378||percutaneous nephrolithotomy|Patients that are included in the study and undergo a percutaneous nephrolithotomy. The pre- and postoperative assessment remains the same across groups
10206226|NCT04745455|Other|Cow's milk based infant formula containing prebiotics, probiotics and postbiotics|
9789831|NCT01369498|Experimental|Simtuzumab 700 mg|Participants in Stage 1 of study will receive simtuzumab 700 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
9789832|NCT01369498|Experimental|Simtuzumab 200 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
9789833|NCT01369498|Experimental|Simtuzumab 700 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
9789834|NCT01369511|Placebo Comparator|Placebo|Administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
9789835|NCT01369511|Experimental|35 mg LY2495655|LY2495655: 35 milligrams (mg) administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
9789836|NCT01369511|Experimental|105 mg LY2495655|LY2495655: 105 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
9789837|NCT01369511|Experimental|315 mg LY2495655|LY2495655: 315 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
9789838|NCT01369615|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride controlled-release tablets
9789839|NCT01369680|Experimental|Ketamine 0.25 mg/kg/dose|The first three subjects were administered 0.25 mg/kg/dose oral ketamine.
9789840|NCT01369680|Experimental|Ketamine 0.5 mg/kg/dose|The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.
9789841|NCT01369680|Experimental|Ketamine 1 mg/kg/dose|The third group of three subjects were administered 1 mg/kg/dose oral ketamine.
9789842|NCT01369680|Experimental|Ketamine 1.5 mg/kg/dose|The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.
9789843|NCT01369706|Other|Hand-held metal detector|Exposure to two hand-held metal detectors
9789844|NCT01369732|Placebo Comparator|Saline group|We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
9789845|NCT01369732|Experimental|erythropoietin group|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
9789846|NCT01369745|Active Comparator|Prednisolone|Prednisolone 2.7 mg daily for 12 weeks
9789847|NCT01369745|Active Comparator|dipyridamole|Dipyridamole 360 mg daily for 12 weeks
9789848|NCT01369745|Active Comparator|prednisone|Prednisone 5 mg daily for 12 weeks
9789849|NCT01369745|Experimental|Z102 (2.7/360)|Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks
9789850|NCT01369745|Placebo Comparator|placebo|Placebo daily for 12 weeks
9789851|NCT01369758|Experimental|Intrauterine pathology, myomectomy|Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
9789852|NCT01369784||refractory/relapsed LDCBG|patients with refractory/relapsed diffuse large B-cell lymphoma
9789853|NCT01369849|Experimental|Treatment (Akt inhibitor MK2206, bendamustine, rituximab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22 (days 1, 8, 15, 22, and 29 of course 1); rituximab IV on day 1 (day 8 of course 1); and bendamustine hydrochloride IV over 30-60 minutes on days 1-2 (days 8-9 of course 1). Treatment repeats every 28 days (35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease progression or unacceptable toxicity.
9789854|NCT01369875|Experimental|Standard Young TIL|"Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
9789855|NCT01369875|Experimental|ECCE Young TIL|"Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
9789856|NCT01369888|Experimental|IL-15 following Young TIL (0.25 mcg)|0.25 mcg/kg/day x 10
9789857|NCT01369888|Experimental|IL-15 following Young TIL (0.50 mcg)|0.50 mcg/kg/day x 10
9789858|NCT01369888|Experimental|IL-15 Following Young TIL (1 mcg)|1 mcg/kg/day x 10
9789859|NCT01369888|Experimental|IL-15 Following Young TIL (2 mcg)|2 mcg/kg/day x 10
9789860|NCT01370005|Experimental|BI 10773 low dose|BI 10773 low dose once daily
9789861|NCT01370005|Experimental|BI 10773 high dose|BI 10773 high dose once daily
9789862|NCT01370005|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
9789863|NCT01370018|Experimental|alpha-1 proteinase inhibitor in HIV|HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor
9789864|NCT01370083|Experimental|Stroke: TPPT|Adults with dysphagia post stroke (within 4-16 weeks of onset) who have radiographically confirmed difficulties with thin liquid bolus control. Individuals will complete 24 sessions of tongue-pressure-profile training over 8-12 weeks.
9789865|NCT01370083|Active Comparator|Stroke: TPSAT Control|Individuals with dysphagia (within 4-16 weeks post stroke) who demonstrate difficulties with thin liquid control on videofluoroscopy. Individuals will complete 24 sessions of tongue-pressure strength-and-accuracy training over 8-12 weeks.
9789866|NCT01370174|Active Comparator|Induced Step Training (IST)|The IST group will receive waist-pulls in both the left and right lateral directions by a motorized pulling system to produce stepping.
9789867|NCT01370174|Active Comparator|Hip Strength Training (HST)|The HST group will have muscle strength training, to include hip abduction (AB) and adduction (AD) resistance exercises.
9789868|NCT01370174|Active Comparator|Combined Induced Step and Hip Strength Training|This training group consists of combined induced step training (IST) and hip AB-AD strength training (HST).
9789869|NCT01370174|Placebo Comparator|Standard Flexibility and Relaxation (SFR)|The SFR group will perform a flexibility and relaxation program involving minimal-intensity exercises.
9985120|NCT03355066|Experimental|Part 2: Expansion|"Part 2 will evaluate the recommended Part 2 dose and schedule of SM08502, as determined in Part 1B, in 6 cohorts of subjects. The indications to be evaluated include subjects with advanced and/or metastatic CRPC, NSCLC, TNBC, CRC, endometrial cancer, and ovarian cancer for which histologic or cytologic confirmation of malignancy was obtained at diagnosis. Each cohort will enroll approximately 20 subjects.~Approximately 10 subjects enrolled in Part 2 will be included in a food effect sub-study to assess the preliminary effect of a high-fat, high-calorie meal on the PK of SM08502."
9985121|NCT03352765|Experimental|rituximab, bendamustine & melphalan and ASCT|This is a phase I study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts. Patients who are deemed inevaluable will be replaced for the primary objective. Patients will be considered inevaluable if they don't receive one dose of conditioning regimen and are removed from the study.
9985122|NCT03350620|Experimental|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
9985123|NCT03350620|Experimental|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
9985124|NCT03350620|Placebo Comparator|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
9985125|NCT03350594|Active Comparator|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.~There will be free exchanges along the lines between therapist and family, within the family and between therapists.~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
9985126|NCT03350594|Experimental|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
9985127|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
9838582|NCT03964454|Experimental|SC + BFI|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives contingent on observed breastfeeding.
9838583|NCT03964454|Active Comparator|SC|Participants randomized into Standard Care (SC) will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
9985128|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
9985129|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
9838586|NCT03963960|Experimental|Hemodialysis with low dialysate flow|
9838587|NCT03963960|Active Comparator|Conventional triweekly high-flow hemodialysis|
9838588|NCT03959709|Experimental|Prepectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
9838589|NCT03959709|Active Comparator|Subpectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
9985130|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
9985131|NCT03344744||Control|Healthy volunteers
9838592|NCT03955913||Participants with Urothelial Cancer,selected FGFR aberrations|Participants with urothelial cancer (UC) will be evaluated for the prevalence of positive results of selected fibroblast growth factor receptor (FGFR) aberrations and will be assessed for eligibility status for erdafitinib studies. The primary data source for this study will be the medical records of each participant.
9838601|NCT03945162|Experimental|0.7 mg/cm^2 TLD-1433 Bladder infusion and Photodynamic Therapy|A single instillation of TLD-1433 (at the therapeutic dose of 0.7 mg/cm^2) will be infused intravesically into the bladder for approximately 60 minutes. Photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. Two treatment procedures will be performed, a primary treatment at Day 0 and a secondary treatment at Day 180 post primary treatment.
9921970|NCT00833235||Patients with no history of dry eye|No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.
9789870|NCT01370213|Experimental|CD34 Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and filgrastim mobilized CD34+ selected peripheral blood stem cell graft from the same donor.
9789871|NCT01370213|Experimental|TCRα/β Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and same donor TCR α/β-depleted cells infusion.
9789872|NCT01370265|Active Comparator|Regadenoson, then Adenosine|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
9789873|NCT01370265|Active Comparator|Adenosine, then Regadenoson|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
9789874|NCT01370317|Experimental|MK-1029|
9789875|NCT01370317|Placebo Comparator|Placebo|
9789876|NCT01370356|Active Comparator|Varenicline Tartrate|
9789877|NCT01370356|Placebo Comparator|Placebo|
9789878|NCT01370369|Experimental|Single Testosterone Dose (Inner Thigh)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the inner thigh followed by a seven day washout period.
9789879|NCT01370369|Experimental|Single Testosterone Dose (Abdomen)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the abdomen followed by a seven day washout period.
9789880|NCT01370369|Experimental|Single Testosterone Dose (shoulder/upper arm)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the shoulder/upper arm.
9789881|NCT01370369|Experimental|Testosterone 1.25|Subjects received testosterone gel 2% at dose of 1.25 mL (one stroke) applied once daily for 10 consecutive days to the shoulder/upper arm.
9789882|NCT01370369|Experimental|Testosterone 2.50|Subjects received testosterone gel 2% at dose of 2.50 mL (two strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
9789883|NCT01370369|Experimental|Testosterone 3.75|Subjects received testosterone gel 2% at dose of 3.75 mL (three strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
9789884|NCT01370408|Experimental|Palonosetron|"All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation~Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO"
9789885|NCT01370460|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.
9789886|NCT01370460|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
9789887|NCT01370499|Experimental|LY2216684 + SSRI|"LY2216684: 12 milligrams (mg) or 18 mg, administered orally, once daily for 52 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI).~During the open-label phase, all participants started at the 12 mg dose and could have the dose increased to 18 mg after the first week of treatment. During the first 12 weeks, participants were allowed (at scheduled or unscheduled visits) to decrease their dose to 12 mg based on response. After a decrease in dose to 12 mg, participants could have had an increase back up to 18 mg at any scheduled visit based on response and tolerability. After 12 weeks of treatment, participants maintained a stable dose.~Open-label treatment was followed by a 1-week abrupt discontinuation phase. Participants who either completed study visits through Week 52 or discontinued early from the study for any reason returned 1 week later for follow-up visit. Participants did not receive LY2216684 but continued their SSRI treatment at a stable dose."
9789888|NCT01370525|Experimental|Esomeprazole 20 mg|
9789889|NCT01370525|Placebo Comparator|Placebo|
9789890|NCT01370538|Experimental|Esomeprazole 20 mg|
9789891|NCT01370538|Placebo Comparator|Placebo|
9789892|NCT01370564|Other|Daily diuretic adjustment|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
9789893|NCT01370616|Experimental|Ertapenem sodium|Participants received 1.0 g intravenous (IV) ertapenem sodium as a single daily dose at Hour 0 infused over a 30-minute interval , and IV piperacillin/tazobactam-matching placebo at Hours 8 and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
9921971|NCT00833274|Experimental|1|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
9789894|NCT01370616|Active Comparator|Piperacillin/tazobactam sodium|Participants received 4.5 g IV piperacillin/tazobactam at Hours 0, 8, and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
9789895|NCT01370629||All participants|Participants treated with vernakalant IV in acute care and inpatient hospital settings
9789896|NCT01370642|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
9789897|NCT01370642|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
9789898|NCT01370642|Active Comparator|Control Arm|Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
9789899|NCT01370655|Experimental|MK-7145 6 mg (Treatment A)|MK-7145 3 mg (three x 1-mg MK-7145 capsules administered orally) and placebo to HCTZ (two 12.5-mg capsules) then three x 1-mg MK-7145 capsules 4 hours later, daily for 4 weeks.
9789900|NCT01370655|Experimental|MK-7145 3 mg (Treatment B)|MK-7145 3 mg (one 2mg MK-7145 and one MK-7145 placebo capsule) then one 1-mg MK-7145 capsule and two MK-7145 placebo capsules 4 hours later and placebo to HCTZ (2 capsules once daily) daily for 4 weeks.
9789901|NCT01370655|Active Comparator|Hydrochlorothiazide 25 mg (Treatment C)|HCTZ 25 mg (two 12.5-mg capsules) and placebo to MK-7145 (one 3-mg capsule) then placebo for MK-7145 (one 3-mg capsule) 4 hours later daily for 4 weeks.
9789902|NCT01370655|Placebo Comparator|Placebo (Treatment D)|Placebo to MK-7145 (2 x 3-mg capsules) and placebo to HCTZ 25 mg (2 capsules) then placebo to MK-7145 (2 x 3-mg capsules) 4 hours later daily for 4 weeks
9789903|NCT01370694|Experimental|MK-8808 Combination Therapy|Participants received MK-8808 375 mg/m^2 intravenously (IV) + cyclophosphamide 750 mg/m^2 IV + vincristine 1.4 mg/m^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.
9789904|NCT01370733|Experimental|Active sTMS|Treatment with the NEST-1 Device
9789905|NCT01370733|Sham Comparator|Sham|Treatment with a sham (inactive) device, identical in sound and appearance to the NEST-1 Device
9789906|NCT01370837|Experimental|Healthy controls|
9789907|NCT01370837|Experimental|Diabetes|Patients with diabetes mellitus without polyneuropathy.
9789908|NCT01370837|Experimental|Polyneuropathy|Patients with diabetes and polyneuropathy.
9789909|NCT01370863|Experimental|SPD557|
9789910|NCT01370863|Placebo Comparator|Placebo|
9789911|NCT01371006|Experimental|BI201335 low dose Efavirenz|low dose Efavirenz
9789912|NCT01371006|Experimental|BI201335 high dose Efavirenz|normal dose Efavirenz
9789913|NCT01371032|Active Comparator|Video-Miller laryngoscope|using the screen (Video laryngoscopy group)
9789914|NCT01371032|Active Comparator|Direct laryngoscopy|without use the screen (Direct laryngoscopy group)
9789915|NCT01371110|Active Comparator|Ketamine|Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
9789916|NCT01371110|Sham Comparator|Midazolam|Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
9789917|NCT01371539|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B contact lenses worn first, with comfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
9789918|NCT01371539|Other|Comfilcon A / Lotrafilcon B|Comfilcon A contact lenses worn first, with lotrafilcon B contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
9789919|NCT01371552|Experimental|delefilcon A|Part 1: Delefilcon A contact lenses, followed by filcon II 3 contact lenses and narafilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
9789920|NCT01371552|Active Comparator|filcon II 3|Part 1: Filcon II 3 contact lenses, followed by narafilcon A contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
9789921|NCT01371552|Active Comparator|narafilcon A|Part 1: Narafilcon A contact lenses, followed by filcon II 3 contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
9789922|NCT01371565|Experimental|mifepristone|
9789923|NCT01371643|Active Comparator|Medical treatment by Octreotide LAR|Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery
9789924|NCT01371643|Active Comparator|Surgical debulking followed by Octreotide LAR|Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured
9789925|NCT01371656|Experimental|Arm I (levofloxacin)|Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.
9789926|NCT01371656|No Intervention|Arm II (standard of care)|Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
9789927|NCT01371708|Experimental|Desvenlafaxine Succinate Sustained-Release|
9789928|NCT01371721|Experimental|Desvenlafaxine Succinate Sustained-Release|
9789929|NCT01371734|Experimental|Experimental Arm 1 - high dose|
9789930|NCT01371734|Experimental|Experimental Arm 2 - low dose|
9789931|NCT01371734|Placebo Comparator|Placebo Arm|
9789932|NCT01371747|Experimental|Stratum 1: 8.4 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L (milliequivalent)
9789933|NCT01371747|Experimental|Stratum 1: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
9789934|NCT01371747|Experimental|Stratum 1: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
9789935|NCT01371747|Experimental|Stratum 2: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
9789936|NCT01371747|Experimental|Stratum 2: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
9789937|NCT01371747|Experimental|Stratum 2: 33.6 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
9789938|NCT01371786|Experimental|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
9789939|NCT01371786|Active Comparator|mometasone|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
9789940|NCT01371825|Experimental|Open-Label Sebelipase Alfa|Participants received intravenous (IV) infusions of sebelipase alfa during the open-label treatment. Participants initially received 0.35 milligrams (mg)/kilogram (kg) qw and escalated to 1 mg/kg qw after demonstrating acceptable safety and tolerability during at least 2 infusions. One participant initiated treatment under a Temporary Use Authorization prior to enrollment, wherein the participant's dose was gradually escalated from 0.2 to 1 mg/kg over 4 weeks; the participant started the study at this dose. Participants on treatment for 96 weeks and on stable qw dosing for 24 weeks could be switched to an every other week (qow) dosing schedule. In the event of protocol-defined disease progression at any time during treatment, a participant could receive a dose increase from 1 to 3 mg/kg qw and, if necessary, a dose increase to 5 mg/kg qw with Safety Committee approval. Participants dosed qow who met dose-escalation criteria were reverted to qw dosing or escalated to 1 or 3 mg/kg qow.
9789941|NCT01371838|Experimental|Ceftaroline|
9789942|NCT01371838|Active Comparator|Ceftriaxone plus placebo|
9789943|NCT01371851|Experimental|Doxazosin|Doxazosin extended release will be administered initially at 4 mg/day. On day 8 the dose is increased to 8 mg/day and the participant is maintained on the study until the end of the trial.
9789944|NCT01371851|Placebo Comparator|Placebo|Participants will be maintained on placebo (cellulose) throughout the trial.
9789945|NCT01371877|Experimental|Vitamin D3 4000 IU|"Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 4000 IU daily."
9789946|NCT01371877|Active Comparator|Vitamin D3 600 IU|"Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 600 IU daily"
9789947|NCT01371994|Experimental|Solifenacin succinate|Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
9789948|NCT01371994|Placebo Comparator|Placebo|Participants received matching placebo tablets once a day for 12 weeks.
9789949|NCT01372085|Experimental|Part A: 25 mg RF|A single 25 mg dose of LY2584702 RF
9789950|NCT01372085|Placebo Comparator|Part A: Placebo|Placebo taken orally
9789951|NCT01372085|Experimental|Part B: Sequence 1|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
9789952|NCT01372085|Experimental|Part B: Sequence 2|Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
9789953|NCT01372085|Experimental|Part B: Sequence 3|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
9789954|NCT01372085|Experimental|Part B: Sequence 4|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
9789955|NCT01372150|Experimental|DVS SR|
9789956|NCT01372150|Other|Fluoxetine|Active control for assay sensitivity
9789957|NCT01372150|Experimental|Placebo|
9789958|NCT01372202|Active Comparator|Arm A|Paclitaxel with Cisplatin along with Radiotherapy and followed by Esophagectomy
9789959|NCT01372202|Active Comparator|Arm B|Cisplatin or Oxaliplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
9789960|NCT01372202|Active Comparator|Arm C|Cisplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
9921972|NCT00833300|Active Comparator|1|Haloperidol
9838602|NCT03942211|Experimental|Selexipag 200 micro gram (μg)|Study intervention will be up-titrated to allow each participant to reach their individual maximum tolerated dose (iMTD), in the range of 200 μg to1600 μg (ie, 1 to 8 tablets) twice daily/once daily. Dosing frequency will be twice daily, except for participants with moderate hepatic impairment (Child-Pugh Class B) or who are concomitantly taking (a) moderate CYP2C8 inhibitor(s), who receive study intervention once daily. The dose will be up-titrated by the investigator/delegate in 200 μg twice daily/once daily increments at weekly intervals during scheduled TCs until reaching the iMTD. If the dose regimen is not well tolerated or symptoms cannot be fully managed with symptomatic treatment, the duration of the titration step can be prolonged to 2 weeks. If needed, the dose can be reduced by 200 μg twice daily/once daily.
9838603|NCT03942211|Placebo Comparator|Placebo|The comparator will be administered similarly to the experimental intervention.
9985132|NCT03343054|Experimental|talazoparib|0.75 mg/day or 1.0 mg/day
9985133|NCT03336866|Placebo Comparator|Placebo|Normal saline
9985134|NCT03336866|Experimental|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
9985135|NCT03336411|Active Comparator|mHealth|
9985136|NCT03336411|Experimental|Personalized mHealth|
10206227|NCT04739475|Other|Non surgical Periodontal Therapy NPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
9838609|NCT03936257|Placebo Comparator|Breast milk|group receiving breastfeeding
9838610|NCT03936257|Active Comparator|infant formula conventional BIO|infant formula with conventional whey BIO
9838611|NCT03936257|Active Comparator|infant formula BIO TrueGreen|infant formula with whey BIO TrueGreen
9985137|NCT03335345|Other|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
9985138|NCT03335345|Other|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
9838614|NCT03923725|Experimental|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
9838615|NCT03923725|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
9838616|NCT03923725|Experimental|Artesunate-mefloquine+Piperaquine (AS-MQ+PPQ)|Triple ACTs
9838617|NCT03923725|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs
9838618|NCT03923270|No Intervention|Thoracic Radiotherapy plus Durvalumab|This Arm is a standard of care Arm. Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 13 doses
9838619|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 4 doses and 75mg intravenously of Tremelimumab every 4 weeks for up to 4 doses
9838620|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and Olaparib|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg orally of Olaparib twice a day
9838621|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg Tremelimumab IV x 1 (single dose)
9985139|NCT03335163|Experimental|ENG Implant Users|Healthy women using an ENG implant for at least 12 months and no greater than 36 months will be administered a 6 week titration schedule of topiramate to a max dose of 200mg bid by the final week.
9985140|NCT03332173|Experimental|Zanubrutinib|Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity
9985141|NCT03328676|Experimental|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
9985142|NCT03328676|Placebo Comparator|placebo oil|Patients in the control group will receive placebo.
9985143|NCT03324711|Other|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
9838627|NCT03922139|Experimental|Botox|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
9985144|NCT03324477|Experimental|preload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.
10206228|NCT04739371|Experimental|Insulin|40 participants will receive 40 IUs of intranasal insulin about 30 minutes before consuming an ad libitum lunch.
9921973|NCT00833300|Active Comparator|2|Olanzapine
9921974|NCT00833326|Experimental|ARRY-334543 + docetaxel + prophylactic growth factors|
9921975|NCT00833339|Experimental|1|mifepristone
9921976|NCT00833339|Placebo Comparator|2|
9921977|NCT00833352|Experimental|1|Right ventricular lead located in Mid Septum
9921978|NCT00833352|Active Comparator|2|Right ventricular lead located in Apex
10206229|NCT04739371|Placebo Comparator|Placebo|40 participants will receive 40 IUs of intranasal saline about 30 minutes before consuming an ad libitum lunch.
10206230|NCT04737876|Experimental|BX002-A|BX002-A: 1 mL liquid for multiple dose oral administration
10206231|NCT04737876|Placebo Comparator|Placebo|Placebo: 1 mL liquid for multiple dose oral administration
10206232|NCT04737122|Experimental|LM-061 single agent escalation|The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. The subject in single agent dose levels will be administered multiple oral doses of LM-061 once daily.
9921979|NCT00833378|Active Comparator|Period 2|Treatment B
9789961|NCT01372254|Active Comparator|Standard smoking cessation|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
9789962|NCT01372254|Experimental|BA for substance abusing smokers|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
9789963|NCT01372384|Experimental|Single Arm|
9789964|NCT01372410|Active Comparator|Tiotropium|18 mcg, inhaled long acting muscarinic antagonist
9789965|NCT01372410|Experimental|GSK573719|inhaled medication
9789966|NCT01372410|Placebo Comparator|Placebo|inactive/excipients only
9789967|NCT01372462|Experimental|NIOV - Room air|Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
9789968|NCT01372462|Experimental|NIOV - Oxygen|Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
9789969|NCT01372462|Active Comparator|Nasal Cannula Oxygen|Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
9789970|NCT01372462|No Intervention|No treatment|Control arm. Subjects exercise without using supplemental oxygen or NIOV.
9789971|NCT01372501|Experimental|Experimental: Device|All patients will be implanted with the Endobarrier Liner device
9789972|NCT01372605|Experimental|Collaborative depression care|Measurement-Based Care: Decision support from paraprofessional to HIV medical provider around initiating and monitoring antidepressant treatment.
9789973|NCT01372605|Other|Enhanced usual care|Usual care. Enhanced through pre-study training of providers, provision of psychiatric diagnostic information at enrollment to HIV provider, and availability of best-practices guidelines for reference in clinic.
9789974|NCT01372748|Active Comparator|Standard CPR|American Heart Association (AHA)recommended cardiopulmonary resuscitation (CPR) of 30 compressions with brief pause for 2 ventilations
9789975|NCT01372748|Experimental|Continuous chest compressions|Continuous compression CPR
9789976|NCT01372774|Active Comparator|Arm I - WBRT|Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
9789977|NCT01372774|Experimental|Arm II - SRS|Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
9789978|NCT01372813|Other|Clear Cell Renal Carcinoma|Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived growth factor and glucose transporter 1. Patients received ZD6474 300 mg/day by mouth daily on days 1-28.
9789979|NCT01372995|Experimental|Enteral vitamin D3 50,000 IU|An arm where subjects receive 50,000 IU of Vitamin D for 5 days.
9789980|NCT01372995|Experimental|Enteral Vitamin D3 100,000 IU|Arm where subjects receive 100,000 IU of Vitamin D for 5 days
9789981|NCT01372995|Placebo Comparator|Inactive Substance|Arm where patients receive inactive substance for 5 days.
9789982|NCT01373164|Experimental|Phase 1b: 80 mg Galunisertib + Gemcitabine|"Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
9789983|NCT01373164|Experimental|Phase 1b: 160 mg Galunisertib + Gemcitabine|"Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
9789984|NCT01373164|Experimental|Phase 1b: 300 mg Galunisertib + Gemcitabine|"Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
9921980|NCT00833378|Active Comparator|Period 1|Treatment A
9921981|NCT00833378|Active Comparator|Period 3|Treatment C
10206233|NCT04737122|Experimental|LM-061 combination escalation|The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. The subjects in combination dose levels will be administered multiple oral doses once daily of LM-061 and Toripalimab fixed dose injections every 3 weeks
10206234|NCT04734015|Experimental|Together Overcoming Diabetes (TOD) curriculum|"A randomized waitlist control trial (RCT) design will be employed with 140 family dyads (adult caregiver and youth) randomly assigned to the Intervention group (Group A): Together Overcoming Diabetes (TOD).~Group A participant dyads will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months."
9985145|NCT03324477|Experimental|coload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .
9838633|NCT03910621|Experimental|Miglustat|Miglustat is administered three times a day as an oral capsule
10206235|NCT04734015|No Intervention|Waitlist Control|"A randomized waitlist control trial (RCT) design will be employed with 140 family dyads (adult caregiver and youth) randomly assigned to the Waitlist Control group (Group B). Waitlist family dyads will not initially receive the intervention. They will be monitored via assessment of applicable biometric, psychosocial and behavioral outcomes at baseline, 3-months into intervention delivery, 6 months after baseline (post intervention), 12 months, 18 months, and 24 months.~Waitlist participant dyads will begin to receive the intervention program (TOD) approximately 24 months (2 years) after enrollment in the RCT."
10206236|NCT04732806|No Intervention|Treatment as usual|
9838636|NCT03910101|Active Comparator|Hand surgery and intensive rehabilitation|"The surgical treatment for reducing spasticity comprises lengthening of tendons, muscle release and occasionally correction of deformities. Lengthening of a tendon or releasing a muscle from its insertion, results in relaxation of the whole muscle-tendon unit. Hence, the spasticity is not gone, but reduced in strength.~The tendon lengthening procedures is performed by a stair-step incision technique followed by reattachment in the lengthened position using a side-to-side, cross-stich technique. The load to failure of the sutured tendon is approximately 200Newton, which gives a sufficient safety margin for early active mobilization of the tendons involved. This suture technique thus enables active training directly after surgery.~Postoperative rehabilitation includes wrapping and a custom-made splint, for day and night use, muscle activation and passive stretching 2-4 times per day without the splint."
9838637|NCT03910101|Active Comparator|Botulinum toxin injections|Botulinum toxin injections are given in spastic muscles of the upper extremity. Dosage and number of injections per muscle vary depending on the degree and extent of spasticity. For optimal effect on hand function, botulinum toxin is accompanied by the treatment of individualized exercise and splinting when needed.
9838638|NCT03908359|Active Comparator|traditional cataract surgery|Central anterior continuous capsulorhexis opening (5-6 mm)+ lens irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit)
9838639|NCT03908359|Experimental|minimal invasive lens surgery|Peripheral capsulorhexis opening (1.0-1.5 mm)+lens irrigation/aspiration
9838640|NCT03907657|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with Von-Hippel Lindau disease will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
10206237|NCT04732806|Experimental|Intervention|Six months of ad lib Mightier play in home
10206238|NCT04731896|No Intervention|Late Amniotomy|Initiating induction of labor with oxytocin infusion followed by amniotomy 4-6 hours later
9838643|NCT03906110||C-Cares|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) Materials and FIT kits.
9838644|NCT03906110||C-Cares Plus|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) materials, FIT kids, and personalized one-on-one education and coaching.
9838645|NCT03904693|Experimental|FDC therapy + Placebo macitentan + Placebo tadalafil|Subjects to receive FDC macitentan/tadalafil (macitentan 10 mg and tadalafil 40 mg) plus matching placebos for the two other study treatments.
9838646|NCT03904693|Active Comparator|Macitentan mono-therapy + Placebo tadalafil + Placebo FDC|Subjects to receive macitentan 10 mg plus matching placebos for the two other study treatments.
9838647|NCT03904693|Active Comparator|Tadalafil mono-therapy + Placebo macitentan + Placebo FDC|Subjects to receive tadalafil 40 mg (2 x 20 mg) plus matching placebos for the two other study treatments.
9838648|NCT03901963|Experimental|Daratumumab + Lenalidomide|Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
9838649|NCT03901963|Active Comparator|Lenalidomide|Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
9838650|NCT03900598|Experimental|Part 1 (Dose Escalation): JNJ-67856633|Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.
9838651|NCT03900598|Experimental|Part 2 (Cohort Expansion): JNJ-67856633|Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
9838652|NCT03898479|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
9838653|NCT03897621|Experimental|tranexamic acid|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
10206239|NCT04731896|Active Comparator|Early Amniotomy|Early amniotomy initiating induction of labor followed by oxytocin infusion 30 minutes later
10206240|NCT04731610|Other|Post-operative radiotherapy|Tumour resection followed by radiotherapy.
10206241|NCT04731610|Other|Surveillance after tumour resection|Tumour resection
10206242|NCT04729907|Experimental|BIIB058 28 mg (Prior Maintenance Dose 28 mg)|Participants who received maintenance dose of 28 milligram (mg) nusinersen in study 232SM203 (NCT04089566), will receive maintenance dose of 28 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
9789985|NCT01373164|Experimental|Phase 2: Recommended dose of Galunisertib + Gemcitabine|"Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
9789986|NCT01373164|Experimental|Phase 2: Placebo + Gemcitabine|"Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
9799510|NCT01661881|Experimental|RB/RC|"Patients received 3 cycles of outpatient RB (rituximab 375 mg/m2 day 1, bendamustine 90 mg/m2 days 1 and 2 of a 4-week cycle), followed by interim CT restaging. Patients with progressive disease (PD) went off study. Those with stable disease (SD) or better went on to receive three cycles of inpatient RC (rituximab 375 mg/m2 day 1, cytarabine 3 g/m2 every 12 h for 4 doses). The cytarabine was dose reduced to:~2 g/m2 for age >60 years old, creatinine 114.9-176.8 lmol/l (for patients ≤60 years old), and pre-existing neurotoxicity;~1.5 g/m2 for age >60 years old AND creatinine 114.9-176.8 lmol/l, or for age >60 years old AND pre-existing neurotoxicity;~1 g/m2 for age > 60 years old AND creatinine 114.9-176.8 lmol/l AND pre-existing neurotoxicity.~Stem cell mobilization and collection, ASCT and post-transplantation supportive care were performed per institutional standard and not as part of this study."
9799511|NCT01661933|Experimental|Necator americanus, gluten challenge|Single arm, vertical.
9799512|NCT01661946|Active Comparator|Ranibizumab|intravitreal injection of 0.5mg ranibizumab in usual fashion
9799513|NCT01661946|Active Comparator|Bevacizumab|intravitreal injection of 1.25mg bevacizumab in usual fashion
9799514|NCT01661972|Experimental|Phase 1: Capecitabine and Aflibercept|A standard 3+3 dose escalation format will be used. Capecitabine will start at 850mg/m2 to be given on days 1-14 and off days 15-21. If tolerated, the dose will then be escalated to 1000mg/m2 for the next cohort, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
9799515|NCT01661972|Experimental|Phase 2: Capecitabine and Aflibercept|Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single, Phase 2 arm
9799516|NCT01662024|Experimental|Endoscopic gastric restrictive procedure|Restrict gastric size by approximating tissue endolumenally via an incisionless/per-oral approach.
9799517|NCT01662063|Experimental|SC TCZ QW|Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
9799518|NCT01662063|Experimental|SC TCZ Q2W|Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
9799519|NCT01662115|Active Comparator|Nicotine gum|100 subjects who will actually get the intervention medication
9799520|NCT01662115|Sham Comparator|regular chewing gum|100 subjects who will be part of a control group
9799521|NCT01662115|No Intervention|No gum|100 subjects who will not get neither the intervention nor the placebo gum.
9799522|NCT01662297|Active Comparator|Quetiapine|Veterans remaining on quetiapine for insomnia.
9799523|NCT01662297|Active Comparator|Trazodone|Veterans switching from quetiapine to trazodone for the treatment of insomnia.
9799524|NCT01662310|Experimental|Paliperidone: Run-in or Stabilization phase|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) once daily for 8 weeks. Dose will be increased from milligram per day (3 mg/day) after 5 days based on Investigator's discretion, up to maximum of 12 mg/day.
9799525|NCT01662310|Experimental|Paliperidone: Double blind (DB) phase|Participants who transitioned from run-in or stabilization phase received 3 to 12 mg fixed dose of paliperidone ER oral tablet once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
9799526|NCT01662310|Active Comparator|Placebo: DB phase|Participants who transitioned from run-in or stabilization phase received matching placebo to paliperidone ER once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
9838654|NCT03897621|Placebo Comparator|Normal saline|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
9838655|NCT03897127|Active Comparator|Standard arm|
9838656|NCT03897127|Experimental|Investigational arm|
9789987|NCT01373229|Experimental|Lenalidomide + Plerixafor+ Rituximab|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.~Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~Cohort 1: 0.24 mg/kg~Cohort 2: 0.32 mg/kg~Cohort 3: 0.42 mg/kg~Cohort 4: 0.54 mg/kg~Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~Subjects will then continue single agent lenalidomide until disease progression."
9789988|NCT01373242|Experimental|Peanut ( liquid peanut extract) SLIT|All subjects will receive peanut SLIT upon enrollment for at least the first 48 months. After the desensitization DBPCFC after at least 48 months of treatment, subjects will be randomized off treatment from 1 to 17 weeks. Subjects will then undergo another DBPCFC.
9789989|NCT01373294|Experimental|A: Combination Arm|"Bacille Calmette-Guerrin (BCG) and lenalidomide.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer. This group received BCG + lenalidomide)"
9789990|NCT01373294|Active Comparator|B: Control Arm|"Bacille Calmette-Guerrin (BCG) only.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer.~This group was not eligible to receive the combination of BCG + lenalidomide."
9789991|NCT01373346|Experimental|Long limb Roux-en Y reconstruction|Long limb Roux-en Y reconstruction means that the length of Roux limb and biliopancreatic limb are longer than conventional reconstruction method after gastrectomy.
9789992|NCT01373450|Experimental|OXM → Lg-0.6 → Pbo → Lg-1.2|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
9789993|NCT01373450|Experimental|Lg-0.6 → Pbo → OXM → Pbo|Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
9789994|NCT01373450|Experimental|Pbo → OXM → Lg-0.6 → Pbo|Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
9789995|NCT01373450|Experimental|Lg-0.6 → OXM → Pbo → Lg-1.2|Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
9789996|NCT01373450|Experimental|OXM → Pbo → Lg-0.6 → Pbo|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
9789997|NCT01373450|Experimental|Pbo → Lg-0.6 → OXM → Lg-1.2|Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
9789998|NCT01373489|No Intervention|Usual Care|The usual care group received the current standards of care at the study clinics.
9789999|NCT01373489|Experimental|Technology Assisted Case Management|The TACM group used the FORA 2-in-1 Telehealth system for diabetes management intervention to link a case manager to patients with poorly controlled type 2 diabetes in real time.
9790000|NCT01373580|Experimental|Raindrop|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
9790001|NCT01373671|Other|Mammography exam|Siemens DBT scan
9790002|NCT01373918|Experimental|low dose intravenous fat emulsion|Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
9790003|NCT01373918|Active Comparator|standard dose intravenous fat emulsion|Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
9790004|NCT01373931|Experimental|OC + LY2216684 First, Then OC + Placebo|28-day lead-in period of Ortho Cyclen (OC; 28-day packet), followed by randomization to OC administered orally once daily for 28 days + 18 milligrams (mg) of LY2216684 administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days.
9790005|NCT01373931|Experimental|OC + Placebo First, Then OC + LY2216684|28-day lead-in period of OC (28-day packet), followed by randomization to OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + 18 mg of LY2216684 administered concomitantly orally once daily for 21 days.
9790006|NCT01374087|Experimental|Brachytherapy + Triptorelin 22.5 mg|Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
9790007|NCT01374087|Active Comparator|Brachytherapy|Brachytherapy: Low or high dose rate.
9790008|NCT01374178|Experimental|LY2963016|A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
9790009|NCT01374178|Active Comparator|Lantus|A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
9790010|NCT01374217|Experimental|Tadalafil|Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)
9790011|NCT01374269|Experimental|Excercise|One group will be assigned to protocolized back pain exercise, three times a week for 4 weeks. This program is carried out by physiotherapists from participating institutions who wish to participate in research and who will be given a training which will standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. Treatment, type of exercises, exercise tolerance and adverse reactions will be registered
9790012|NCT01374269|Active Comparator|NSAID|Naproxen 500 mg per day by 10 days or Celecoxib 200 mg per day by 10 days and Acetaminophen 1,5 a 2 g as rescue
9838657|NCT03896945|Placebo Comparator|Placebo|Placebo capsules will be administered orally twice a day over a 15-week period.
9838658|NCT03896945|Experimental|AVP-786|AVP-786 capsules will be administered orally twice a day over a 15-week period.
9985146|NCT03322293|Active Comparator|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
10206243|NCT04729907|Experimental|BIIB058 50/28 mg (Prior Maintenance Dose 12 mg)|Participants who received maintenance dose of 12 mg nusinersen in study 232SM203 (NCT04089566), will receive loading dose of 50 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
10206244|NCT04725994|Other|Group 1|
10206245|NCT04725994|Other|Group 2|
9985147|NCT03322293|Experimental|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
9985148|NCT03322293|Experimental|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
9985149|NCT03322033|Experimental|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
9985150|NCT03321552|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
10206246|NCT04725305|Experimental|BiZact|A bipolar electrosurgical device that employs radiofrequency(RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger
9838665|NCT03893565|Experimental|GSK2831781-Double blind phase|Eligible participants will receive GSK2831781 intravenously in the double blind induction phase at different dose levels. Participants identified as Responders at Week 10 will then receive GSK2831781 subcutaneously during the double-blind ETP from Week 14 until Week 26
9838666|NCT03893565|Experimental|GSK2831781- Open label phase|Eligible participants will receive GSK2831781 intravenously in the open label induction phase. Participants identified as Non-Responders at Week 10 will receive GSK2831781 from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
9838667|NCT03893565|Placebo Comparator|Placebo matching GSK2831781- Double blind phase|Eligible participants will receive Placebo in the double blind induction phase Participants identified as Responders at Week 10 will continue to receive Placebo subcutaneously during the double-blind ETP from Week 14 until Week 26.
9838668|NCT03887780||Treatment|Rivaroxaban treatment-naïve patients, at least 18 years of age and presenting with NVAF will be considered eligible for participation in this study only after the decision to treat with rivaroxaban has been made by the treating physician.
9838669|NCT03886467|Active Comparator|Nutrition Education|Households will participate in community-based nutrition education program specifically targeting child nutrition and milk consumption, in addition to general community development activities
9838670|NCT03886467|No Intervention|Control|community development activities only.
10206247|NCT04725305|Active Comparator|Standard of care|In electrocautery tonsillectomy (or diathermy) electric current from a radiofrequency generator is passed through the tissue between two electrodes. The resulting high temperature (400º-600ºC) cuts the tissue and simultaneously seals the blood vessels
10206248|NCT04721769|Active Comparator|Endoscopic strip craniectomy with the use of lateral osteotomies|Patients will have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
10206249|NCT04721769|Experimental|Endoscopic strip craniectomy without the use of lateral osteotomies|Patients will NOT have lateral osteotomies incorporated into their surgical procedure following suturectomy of the fused sagittal suture.
10206250|NCT04720456|Experimental|SHAPE with Sonazoid|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at The Children's Hospital of Philadelphia (CHOP) will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent Sonazoid® (perfluorobutane microbubbles) will be performed during a single visit. A dose of three vials with 16 μL each of microbubbles will be prepared. An infusion of the ultrasound contrast agent at the rate of 0.18 mL/kg/hour will be co-infused with an infusion of saline at the rate of 120 mL/hour resulting in an effective dosage of 1.44 μL microbubbles/kg/hour as per the FDA approved IND through an IV line in a peripheral vein. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
9838675|NCT03879733|Experimental|Intervention group|The group of childcare centers that will receive the intervention during 10 months from sept 2018 - June 2019
9838676|NCT03879733|Other|Wait-list control|"Will receive no intervention and continue with business as usual during the primary intervention period Sept. 2018 - June 2019.~Will receive the intervention from Sept. 2019 - June 2020."
9838677|NCT03879512|Experimental|Active vaccination arm|All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
9838682|NCT03871907|Active Comparator|Digital technology|standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week
9838683|NCT03871907|No Intervention|Control|standard cardiac rehabilitation program
9921982|NCT00833391|Experimental|GSK1838262 arm|Each subject will participate in five dosing sessions separated by at least seven days. Subjects will receive a single dose of current formulation of GSK1838262 or one of the four new formulations of GSK1838262 at each dosing session in random sequence.
9921983|NCT00833404|Experimental|Smoking Cessation|8-week nicotine patch regimen
9838684|NCT03871829|Active Comparator|Arm A: Carfilzomib+Dexamethasone (Kd)|Participants will receive carfilzomib 20 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1 and then 70 mg/m^2 on Days 8 and 15 of Cycle 1 and thereafter on Days 1, 8, 15 of Cycle 2 onwards. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
9838685|NCT03871829|Experimental|Arm B: Dara-SC in combination with Kd (DKd)|Participants will receive daratumumab subcutaneous (Dara-SC) 1800 mg by SC injection on Days 1, 8, 15, 22 for Cycle 1 and 2, Days 1 and 15 for Cycle 3-6, Day 1 for Cycle 7 onwards. Participants will receive carfilzomib 20 mg/m^2 IV on Cycle 1 Day 1 and then 70 mg/m^2 on Day 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
9838686|NCT03871816||Participants with Metastatic Prostate Cancer|Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.
9985151|NCT03319927|Experimental|Integrated pest management|The intervention consists of an integrated pest management (IPM) educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for child care center directors and providers on IPM policies and practices including the providers' practices and beliefs. The workshop includes IPM videos, IPM Toolkit, and IPM toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
10206251|NCT04720456|Active Comparator|SHAPE with Lumason|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at CHOP will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent LUMASON® (sulfur hexafluoride lipid-type A microspheres) will be performed during a single visit. Two doses of 0.03 mL/kg (or 2.4 mL maximum) as per package labeling will be prepared and mixed with saline at a 1:10 dilution in a 50 ml bag of saline. The diluted preparation of Lumason will be through an IV line in a peripheral vein up to 4 mL/min using an infusion setup. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
9838689|NCT03865979|Active Comparator|Intervention Arm|"Subject CT images assessed by Viz RECRUIT software in real time analysis All subjects in which the Viz RECRUIT software is utilized will be identified per cohort described below per PI confirmation of ENRICH Trial status/Study ID.~Cohort A: Subjects with imaging data Cohort B: Subjects with imaging data and ultimately enrolled as part of the ENRICH Trial"
9838690|NCT03865979|No Intervention|Control Arm|Subjects enrolled as part of the ENRICH Trial prior to Viz RECRUIT software activation
9985152|NCT03319927|Active Comparator|Physical activity|The intervention consists of a physical activity educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for the child care center directors and providers on physical activities center policies and best practices over 7 months. The workshop includes a Physical Activity Toolkit and toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
9985153|NCT03317405|Experimental|Cohort I (endoxifen hydrochloride)|Participants apply endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
10206252|NCT04720456|Experimental|Longitudinal SHAPE|SHAPE will be used to monitor subjects identified in the initial examination as having portal hypertension for up to 18 months. These subjects will undergo laboratory testing every 6 months as a part of their clinical standard of care. During these times the SHAPE examination will also be repeated using the same ultrasound contrast agent and infusion methodologies (including dosages) as during the initial study.
10206253|NCT04716699|Experimental|Health services research (lidocaine, surgery)|Patients receive bolus lidocaine IV per standard of care. After intubation, patients receive another infusion of lidocaine IV over 4 hours or until the end of surgery. Patients also undergo collection of blood and tumor samples at the start of surgery and hourly afterwards until a total of 4 samples are collected.
10206254|NCT04714749|Experimental|Endovenous treatment|Endovenous treatment with cyanoacrylate glue
9838696|NCT03854058||OHS or elevated OHS-risk (stages 0-IV)|"stage 0: OHS-risk (OSA / no hypercapnia)~stage I: obesity associated hypoventilation (intermittent hypercapnia during sleep, arterial carbon dioxide partial pressure (PaCO2) or transcutaneous carbon dioxide partial pressure (PtcCO2) morning ~ evening), bicarbonate < 27 mmol/L awake)~stage II: obesity associated hypoventilation (intermittent hypercapnia during sleep, PaCO2 or PtcCO2 morning > evening, bicarbonate ≥ 27 mmol/L awake)~stage III: OHS (hypercapnia, carbon dioxide partial pressure (PCO2) > 45 mmHg awake)~stage IV: OHS with end organ damage (hypercapnia , PCO2 > 45 mmHg awake, cardiometabolic comorbidities)~diagnostic tests: magnetic phrenic nerve stimulation, diaphragmatic ultrasound"
9838697|NCT03847649|Active Comparator|Cohort 1: High Risk|
9838698|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm A|
9838699|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm B|
9838700|NCT03846947|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
9921984|NCT00833404|No Intervention|Wait List Control|Smoking as usual
9790013|NCT01374425|Experimental|Bevacizumab + mFOLFOX6|Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
9790014|NCT01374425|Experimental|Bevacizumab + FOLFIRI|Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
9790015|NCT01374438|Experimental|MSDC-0160 capsules|MSDC tablets contained in #00 capsules
9790016|NCT01374438|Placebo Comparator|Placebo capsules|Placebo tablets contained in #00 capsules
9790017|NCT01374451|Experimental|Paseriotide LAR + Everolimus|everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
9790018|NCT01374451|Experimental|Everolimus|everolimus 10 mg once daily po alone
9790019|NCT01374490|Experimental|Crofelemer|
9790020|NCT01374568|Active Comparator|sitagliptin|Sitagliptin
9790021|NCT01374568|Placebo Comparator|Placebo|Placebo
9790022|NCT01374802|Experimental|BI 201335|capsule for oral administration
9790023|NCT01374802|Experimental|Darunavir 400 mg|tablet for oral administration
9790024|NCT01374802|Experimental|Ritonavir 100 mg|tablet for oral administration
9790025|NCT01374906|Experimental|10 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
9790026|NCT01374906|Experimental|30 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
9790027|NCT01374919|Other|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
9790028|NCT01374971|Other|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks with arthroscopic synovial tissue biopsy pre- and post-treatment.
9790029|NCT01375010|Placebo Comparator|Group A|Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
9790030|NCT01375010|Experimental|Group B|2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
9790031|NCT01375049|Experimental|Aztreonam for Inhalation Solution (AZLI)|Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
9790032|NCT01375075|Experimental|30 milligrams (mg) LY2484595|Administered orally once daily for 12 weeks
9790033|NCT01375075|Experimental|100 mg LY2484595|Administered orally once daily for 12 weeks
9790034|NCT01375075|Experimental|500 mg LY2484595|Administered orally once daily for 12 weeks
9790035|NCT01375075|Placebo Comparator|Placebo|Administered orally once daily for 12 weeks
9790036|NCT01375075|Active Comparator|10 mg Atorvastatin|Administered orally once daily for 12 weeks
10206255|NCT04712942|Experimental|pevonedistat + azacitidine|pevonedistat in combination with azacitidine
10206256|NCT04712942|Other|azacitidine monotherapy|administration of azacitidine monotherapy
10206257|NCT04712175||Patients with SARS-CoV-2 infection|
9790037|NCT01375075|Experimental|100 mg LY2484595 + 10 mg Atorvastatin|Administered orally once daily for 12 weeks
9790038|NCT01375127||Subjects from Study A3921009|
10206258|NCT04712175||Patients without SARS-CoV-2 infection|
10206259|NCT04710875|Active Comparator|Na-lactate|Iv infusion of sodium D/L lactate
10206260|NCT04710875|Placebo Comparator|Sodium chloride|Iv infusion of Sodium chloride
10206261|NCT04709978||Pneumonia|Participants will be over the age of 65 and diagnosed with pneumonia in the UW Emergency Department.
10206262|NCT04709705|Experimental|Cryopreserved platelets|Cryopreserved platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
10206263|NCT04709705|Active Comparator|Liquid stored platelets|Liquid stored platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
9790039|NCT01375127||Subjects from Study A3921030|
9790040|NCT01375140|Experimental|Ruxolitinib + Lenalidomide|Ruxolitinib 15 mg orally twice daily continuously + Lenalidomide orally 5 mg/day on days 1-21, followed by 7 days of no therapy (28-day cycle). Prednisone will be added for patients who have not responded after 3 cycles of therapy. Prednisone 30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
9790041|NCT01375205|Active Comparator|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
9790042|NCT01375205|Experimental|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
9790043|NCT01375374|Experimental|Lacosamide|commercial 50 mg (pinkish) and 100 mg (yellow) tablets
9790044|NCT01375491|Experimental|Doxycycline|Participants with DM2 receiving doxycycline 100mg BID
9790045|NCT01375491|Placebo Comparator|Placebo|Pills prepared identical to doxycycline.
9790046|NCT01375569|Experimental|TRC105 in Liver Cancer|TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
9790047|NCT01375608|Other|decitabine|active treatment
9790048|NCT01375660|Placebo Comparator|Arm 1|Placebo: One capsule weekly
9790049|NCT01375660|Experimental|Arm 2|50K vitamin D2: One capsule weekly
9790050|NCT01375673|Experimental|Exercise|Exercise: Walking Strength Training Bicycling
9790051|NCT01375673|No Intervention|Usual Care|Usual Care
10206264|NCT04708145|Experimental|Group 1|"Study eyes without PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if DRSS level is 47 or worse as determined by the treating investigator.~Subjects may be evaluated every 8 weeks if a 2-step DRSS level worsening compared to the last protocol-scheduled 16-week visit occurs, the DRSS level is 53 or worse, or if a subject has active PDR. Visits can continue every 8 weeks until there is no active PDR, and the DRSS improves to the level observed at the visit before the subject began being seen at 8-week intervals. Thereafter, visits will continue at 16 week intervals."
10206265|NCT04708145|Experimental|Group 2|"Study eyes with PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if the neovascular disease process is active and stable (not new or worse) as determined by the treating investigator. If the neovascular disease is inactive, no treatment will be given.~If new or worsening neovascularization develops, subjects may be seen and treated every 8 weeks until the neovascular disease is stable or inactive, at which time the interval between visits will increase to 16 weeks."
10206266|NCT04699786|Active Comparator|Arm A|Participants randomized to Arm A will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document.
9790052|NCT01375751|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
9790053|NCT01375751|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790054|NCT01375751|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790055|NCT01375764|Active Comparator|Ezetimibe|Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
9790056|NCT01375764|Experimental|Evolocumab + Ezetimibe|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
9790057|NCT01375764|Experimental|Evolocumab 280 mg|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790058|NCT01375764|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790059|NCT01375764|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790060|NCT01375777|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
9790061|NCT01375777|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
9790062|NCT01375777|Active Comparator|Ezetimibe|Participants received 10 mg ezetimibe orally once a day for 12 weeks.
9790063|NCT01375777|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9790064|NCT01375777|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9790065|NCT01375777|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9790066|NCT01375777|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790067|NCT01375777|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790068|NCT01375777|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790069|NCT01375946|Experimental|AG200-15 location|The subject will wear AG200-15 for 7 days and be exposed to one of 5 external conditions (normal, treadmill, cold water, whirlpool, dry sauna).
9790070|NCT01376037|Placebo Comparator|inactive placebo laser device|The inactive placebo laser device looks identical to the active laser device, but does not emit any therapeutic light output.
9790071|NCT01376037|Active Comparator|Erchonia ML Scanner (MLS)|The Erchonia ML Scanner (MLS) is a low level laser light therapy device comprising 4 independent rotating diodes, each emitting 17mW 635nm of red laser light. The diodes are mounted in scanner devices positioned 120 degrees apart from each other, tilted at a 30 degree angle. The Erchonia® MLS is activated for 20 minutes per arm during which time the 4 rotating diodes create a spiraling circle pattern that is totally random and independent from the others. These patterns overlap each other to guarantee total coverage within the target area. The total laser energy the test subject is exposed to per treated arm is approximately 3.94 joules per square centimeter. Six procedures are administered evenly across 2 weeks.
9790072|NCT01376050|Active Comparator|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
9790073|NCT01376050|Placebo Comparator|Placebo Laser|Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.
9790074|NCT01376089|Other|Arm 1-Iodixanol|
9790075|NCT01376089|Active Comparator|Arm 2-Iopamidol|
9790076|NCT01376167|Experimental|Tafenoquine 50mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 50mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
9790077|NCT01376167|Experimental|Tafenoquine 100mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 100mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
9790078|NCT01376167|Experimental|Tafenoquine 300mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
9790079|NCT01376167|Experimental|Tafenoquine 600mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 600mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
9790080|NCT01376167|Active Comparator|Primaquine 15mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15.
9790081|NCT01376167|Placebo Comparator|Chloroquine only|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered.
9790082|NCT01376167|Experimental|Tafenoquine 300mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
9790083|NCT01376167|Active Comparator|Primaquine 15mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15
9790084|NCT01376167|Placebo Comparator|Chloroquine only (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered
9790085|NCT01376245|Experimental|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
9790086|NCT01376245|Placebo Comparator|placebo|matching placebo
9790087|NCT01376297|Experimental|Netupitant and Palonosetron plus dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
9790088|NCT01376297|Active Comparator|Aprepitant and Palonosetron plus dexamethasone|Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.
9790089|NCT01376310|Experimental|Cohort A|Subjects on GSK1120212 Monotherapy who have been treated less than 24 weeks in their parent study.
9790090|NCT01376310|Experimental|Cohort B|Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.
9790091|NCT01376349|Experimental|Arm I low dose DHEA|Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
9790092|NCT01376349|Experimental|Arm II high dose DHEA|Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
9790093|NCT01376349|Placebo Comparator|Arm III placebo|Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
9790094|NCT01376362|Experimental|Interferon gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
9790095|NCT01376388|Experimental|GSK573719/GW642444|125/25mcg
9790096|NCT01376557|Experimental|Treatment A|
9790097|NCT01376557|Experimental|Treatment B|
9790098|NCT01376557|Experimental|Treatment C|
9790099|NCT01376557|Experimental|Treatment D|
9790100|NCT01376557|Placebo Comparator|Placebo|
9790101|NCT01376700|Experimental|ADVATE - Prophylactic Regimen|Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
9790102|NCT01376804|Experimental|Valganciclovir|Participants received a once daily oral dose (solution or tablets) of valganciclovir starting within 10 days of kidney transplant for up to 200 days post-transplant. Dose (in milligrams) was calculated using the algorithm [7 * Body Surface Area * Creatinine Clearance].
9790103|NCT01376908|Experimental|Kuvan® + Phe-restricted diet|Subjects will be treated with Kuvan® tablets once daily along with Phe-restricted diet therapy.
9790104|NCT01376908|Other|Phe-restricted diet alone|Subjects will follow a Phe-restricted diet alone.
9790105|NCT01377012|Experimental|AIN457 10mg/kg-75mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
9790106|NCT01377012|Experimental|AIN457 10mg/kg-150mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
9790107|NCT01377012|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24
10206267|NCT04699786|Active Comparator|Arm B|Participants randomized to Arm B will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document.
10206268|NCT04697901|Experimental|Active Stimulation|Active tDCS stimulation will be applied.
10206269|NCT04697901|Sham Comparator|Sham Stimulation|Sham tDCS stimulation will be applied.
10206270|NCT04693598|Experimental|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the lower dose (N=3 participants)
10206271|NCT04693598|Experimental|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|Participants will receive a single infusion at the higher dose (N=3 participants)
10206272|NCT04688177||smokers|cigarette smokers male 20 ≤ age ≤ 45 years old female 20 ≤ age ≤ 55 years old
10206273|NCT04688177||never smokers|age and gender-matched non-smokers
10206274|NCT04685590|Experimental|Treatment|Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb). Quercetin (Q) will be given as (4) 250 mg capsules daily (total 1000 mg daily) for the same 2 consecutive days (Thorne Research). Both are administered orally.
9790108|NCT01377194|Experimental|1|40mg Levomilnacipran ER
9790109|NCT01377194|Experimental|2|80mg of Levomilnacipran ER
9790110|NCT01377194|Placebo Comparator|3|Placebo
9790111|NCT01377233|Experimental|Zicronapine open-label lead-in 10 mg daily|
9790112|NCT01377233|Experimental|Zicronapine 10 mg daily|
9790113|NCT01377233|Experimental|Zicronapine 20 mg once weekly|
9790114|NCT01377233|Experimental|Zicronapine 30 mg once weekly|
9790115|NCT01377233|Experimental|Zicronapine 45 mg once weekly|
9790116|NCT01377389|Experimental|Ipilimumab + ADT|Ipilimumab 10 mg/kg intravenous (IV) Weeks 5, 9, 13, and 17 plus Androgen Depravation Therapy (ADT) of either Leuprolide 7.5 mg intramuscular (IM) , Goserelin 3.6 mg subcutaneous (SQ) or Degarelix 80 mg SQ once a month for 8 months beginning Week 1.
9790117|NCT01377402||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
9790118|NCT01377467|Experimental|Denosumab|60 mg denosumab s.c. at baseline and after 6 months
9790119|NCT01377467|No Intervention|Control|No treatment
9790120|NCT01377480|Experimental|Posaconazole|Posaconazole (POS) 400 mg (10 mL) oral suspension twice daily for 60 days
9790121|NCT01377480|Placebo Comparator|Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days
9790122|NCT01377480|Experimental|Posaconazole + Benznidazole|Posaconazole 400 mg (10 mL) oral suspension twice daily for 60 days and benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
9790123|NCT01377480|Active Comparator|Benznidazole + Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days and benznidazole 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
9790124|NCT01377584|Experimental|Patients in the Couple-oriented intervention|Patients randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with their partner and participate in an individual telephone follow-up session.
9790125|NCT01377584|Other|Patients in Usual Care|Patients will not attend any intervention sessions.
9790126|NCT01377584|Experimental|Patients in the Patient-oriented intervention|Patients randomly assigned to the patient-oriented (PT) group will attend two face to face sessions and participate in a telephone follow-up session.
9790127|NCT01377584|Experimental|Partners in the Couple-oriented intervention|Partners randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with the patient and participate in an individual telephone follow-up session.
9790128|NCT01377584|Other|Partners in Usual Care|Partners will not attend any intervention sessions.
9790129|NCT01377584|Experimental|Partners in the Patient-oriented intervention|Partners randomly assigned to the patient-oriented (PT) group will not attend any intervention sessions.
9790130|NCT01377623|Placebo Comparator|Placebo group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
9790131|NCT01377623|Experimental|Dexmedetomidine group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
9790132|NCT01377636|Experimental|Isoproterenol, BIS, forearm test|30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
9790133|NCT01377844|Experimental|EGT0001442|EGT0001442 capsule, 20 mg, daily, 96 weeks
9790134|NCT01377844|Placebo Comparator|Placebo|Placebo
9790135|NCT01377922|Placebo Comparator|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
9790136|NCT01377922|Experimental|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
9790137|NCT01377987|Experimental|Acetazolamide|
9790138|NCT01377987|Placebo Comparator|Sugar pill|
9790139|NCT01378104|Experimental|80% dosage group of peginterferon alfa 2a|This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
9790140|NCT01378104|Active Comparator|100% dosage group of peginterferon alfa 2a|These group patients would be treated with standard dose 180 ug/week for 48 weeks.
9790141|NCT01378117|Experimental|Sitagliptin + SSI prn|Sitagliptin once daily plus supplemental doses of lispro if needed using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with GFR 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
9790142|NCT01378117|Experimental|Sitagliptin and glargine+ SSI|Sitagliptin 50-100 mg per oral once a day and SubCutaneous (SQ) glargine insulin once daily + correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with glomerular filtration rate (GFR) 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
9790143|NCT01378117|Active Comparator|Glargine and Lispro + SSI|Glargine once daily and lispro before meals supplemental insulin lispro as needed for elevated blood glucose using sliding scale insulin (SSI)
9790144|NCT01378195|Experimental|CBT-based|CBT-based program (Cognitive Behavioral Therapy) with video, workbook, and website
9790145|NCT01378195|Active Comparator|Educational/Resources Materials|Educational/Resources Materials: video, workbook, and website.
9790146|NCT01378221||Group 1|cardiac surgery patients age 65 years and less
9790147|NCT01378221||Group 2|cardiac surgery patients aged 75 years and over
9790148|NCT01378273|Placebo Comparator|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
9790149|NCT01378273|Experimental|Epo 1000 U/kg followed by 400 U/kg|Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.
9790150|NCT01378299|Experimental|Arm 1: Testosterone Cypionate|All patients who qualify for the study will receive testosterone cypionate
9790151|NCT01378325|Experimental|Phenylephrine|PHenylephrine infusion started at 0.75 microgram per kg per mL started at spinal injection till delivery
10206275|NCT04685590|Placebo Comparator|Placebo|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
9790152|NCT01378325|Placebo Comparator|Saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
9790153|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 12.5 mg|
9921985|NCT00833456||1|Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
9921986|NCT00833456||2|Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
9790154|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 25 mg|
9790155|NCT01378377|Experimental|Pimasertib 75 mg+Temsirolimus 25 mg|
10206276|NCT04685525|Experimental|Mycobiome Supporting Diet|Participants will be able to abide by the allowed and disallowed foods in MSD diet for at least four consecutive weeks prior to conditioning and up to 10 days after transplant. Participants will maintain a diary of foods they consume and any adverse effects they are experiencing and will self- collect fecal samples 28 days before transplant, 2 days before transplant and 10 days after transplant
10206277|NCT04680910|Experimental|Propofol infusion - moderate dose|Serial propofol infusions to maximally and safely induce unconsciousness and EEG slow waves while minimizing burst suppression.
10206278|NCT04680910|Active Comparator|Propofol infusion - low dose|Serial propofol infusions to safely induce unconsciousness while minimizing EEG slow waves and burst suppression.
10206279|NCT04676737|No Intervention|Group 1 DWEK/DSO|Study subjects in Group 1 will undergo DWEK/ DSO and will not receive any TTHX1114
10206280|NCT04676737|Experimental|Group 2 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 2 will receive TTHX1114 (5 injections) and undergo DWEK/ DSO
10206281|NCT04676737|Experimental|Group 3 TTHX1114 in combination with DWEK/DSO|Study subjects in Group 3 will receive TTHX1114 (1 injection) and undergo DWEK/ DSO
10206282|NCT04676737|Experimental|Group 1a|Study subjects in Group 1a will consist of subjects in Group 1 if not recovered from DWEK/ DSO by Day 84 and will receive TTHX1114 (5 injections)
10206283|NCT04676737|Experimental|Group 3a|Study subjects in Group 3a will consist of subjects who had participated in in Group 3 if not recovered from DWEK/ DSO by the median time observed in Group 2 and will receive TTHX1114 (4 injections)
9790156|NCT01378416|Experimental|1|
10206284|NCT04676191|Experimental|Patients with sleep disorders, cardiorespiratory or neuromuscular disorders|
10206285|NCT04671615||Patients with metastatic, HR+/HER2- breast cancer.|Patients who initiated first or subsequent lines of treatment with palbociclib
10206286|NCT04670848|Experimental|Patients suspected of suffering from sleep apnea|
10206287|NCT04670848|Experimental|Healthy volunteers|
9790157|NCT01378429|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
9790158|NCT01378429|Placebo Comparator|Placebo|
9790159|NCT01378520|Experimental|ketoconazole|600 mg ketoconazole
9790160|NCT01378520|Placebo Comparator|inert powder|inert powder in capsule
9790161|NCT01378858|Experimental|Varenicline treatment as usual (TAU)|Subjects in the TAU arm will self administer varenicline for 12 weeks.
9790162|NCT01378858|Experimental|Varenicline directly observed therapy|Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
9790163|NCT01378962|Experimental|Single Arm|
9790164|NCT01378975|Experimental|Cohort 1: Previously Untreated Participants|Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
9799527|NCT01662336||Lopinavir/Ritonavir + KASA|Patients were treated according to the standard of care provided by their respective study sites. Treatments with LPV/r and participation in the KASA program were according to the decision of the treating physician and the participant, and were not affected in any way by their decision to participate in the study.
9799528|NCT01662362|Other|Testing Donor Specimens with ESA Chagas|Test blood donor specimens that are ABBOTT PRISM Chagas Repeatedly Reactive with ESA Chagas. Donors will be asked to return for a follow-up blood draw.
9799529|NCT01662440|Active Comparator|R/JE - Conv|Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
9790165|NCT01378975|Experimental|Cohort 2: Previously treated Participants|Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
9790166|NCT01378988|Experimental|Dose level 1|Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
9790167|NCT01378988|Experimental|Dose level 2|Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
9790168|NCT01379183|Active Comparator|Erythromycin|Erythromycin 200 mg i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
9790169|NCT01379183|Placebo Comparator|Placebo|Matching placebo i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
9790170|NCT01379222|Experimental|ENGAGE PAS De Novo Subjects|The Endurant Stent Graft System Bifurcated device is administered to patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair, per the FDA approved Instructions For Use (IFU).
9790171|NCT01379508|Experimental|telbivudine|telbivudine 600 mg tablet orally (p.o.) once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with tenofovir 300 mg tablets p.o. once daily for the remaining weeks of treatment. The investigator was to initiate tenofovir add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive telbivudine monotherapy
9790172|NCT01379508|Active Comparator|tenofovir|tenofovir 300 mg tablets p.o. once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with telbivudine 600 mg tablet p.o. once daily for the remaining weeks of treatment. The investigator was to initiate telbivudine add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive tenofovir monotherapy
9790173|NCT01379521|Experimental|everolimus + TACE|everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
9790174|NCT01379521|Placebo Comparator|placebo + TACE|Placebo by mouth + transcatheter arterial chemoembolization (TACE)
9790175|NCT01379534|Experimental|TKI258|1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status
9790176|NCT01379573|Experimental|Pregnant women with previous child with cardiac neonatal lupus|400 mg/day Hydroxychloroquine
9790177|NCT01379625|Active Comparator|Medium Chain Triglyceride (MCT)|Subjects randomized to consume 20% of energy from MCT
9790178|NCT01379625|Experimental|Triheptanoin|Subject randomized to consume 20% of energy from triheptanoin.
9790179|NCT01379651|Experimental|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of food antigen
9790180|NCT01379651|No Intervention|control|controls were kept on an egg-free diet for 6 months
9790181|NCT01379664|Experimental|Isoflurane|Isoflurane is to be administered to patients in this arm during surgery
9790182|NCT01379664|Experimental|Sevoflurane|Sevoflurane is to be administered to patients in this arm during surgery
9790183|NCT01379703||Single patients group|Single HIV-1 infected patients group
9790184|NCT01379768|Active Comparator|Lotrafilcon A|Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
9790185|NCT01379768|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
9790186|NCT01379768|No Intervention|No lens wear|No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
9790187|NCT01379924|Experimental|Young Parents Program plus Parenting/Life Skills modules|In addition to receiving standard medical and social services for young parents and their children, patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
9790188|NCT01379924|Active Comparator|Young Parents Program usual care|Patients receive regular standard of care without modules.
9790189|NCT01379937|Experimental|GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
9790190|NCT01379937|Experimental|GSK1562902A Formulation 1 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
9790191|NCT01379937|Active Comparator|GSK1562902A Formulation 2 - Havrix / Havrix Jr Group|Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
9790192|NCT01379937|Active Comparator|Havrix / Havrix Jr Group|Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
9790193|NCT01379963||Cohort|
9790194|NCT01380080|Experimental|Arm A: Empiric|Study treatment for Arm A participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral treatment as soon as possible following randomization and within no more than 3 days following randomization plus a 4-drug anti-tuberculosis treatment (ATT) regimen (defined as rifampin/isoniazid/ethambutol/pyrazinamide) as soon as possible following randomization and within no more than 7 days following initiation of antiretroviral therapy. After 2 months (or 8 weeks), the 4-drug ATT will be followed with 4 months (or 16 weeks) of 2-drug ATT (defined as rifampin/isoniazid). All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only
9790195|NCT01380080|Experimental|Arm B: IPT|Study treatment for Arm B participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral therapy as soon as possible following randomization and within no more than 3 days following randomization and of initiating anti-TB treatment (ATT) only when indicated according to local standard practice and at the discretion of the site investigator. All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only. Pyridoxine is provided by the sites to all participants while they are receiving isoniazid (INH).
9790196|NCT01380093|Placebo Comparator|Placebo|
9790197|NCT01380093|Active Comparator|MS Contin (morphine sulfate, controlled release)|
9790198|NCT01380093|Experimental|EMBEDA (morphine sulfate / naltrexone hydrochloride)|
9790199|NCT01380106|Active Comparator|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
9790200|NCT01380106|Active Comparator|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle
9790201|NCT01380145|Experimental|recMAGE-A3 Protein + AS15 Adjuvant|Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
9799530|NCT01662440|Experimental|R/JE - Acc|Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
9799531|NCT01662440|Active Comparator|R - Conv|Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
9799532|NCT01662440|Active Comparator|JE - Conv|Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.
9799533|NCT01662492|Experimental|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
9799534|NCT01662492|Experimental|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
9799535|NCT01662492|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
9799536|NCT01662505|Experimental|Volasertib|Patient to receive escalating dose of volasertib
9799537|NCT01662531|Experimental|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
9799538|NCT01662583|Experimental|Educational Text Message|Educational text message reminder
9799539|NCT01662583|Experimental|Plain Text Message|plain text message reminder
9799540|NCT01662583|Other|Written reminder only|written reminder at time of vaccination
9799541|NCT01662635||ALK-BREAK APART|"We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.~For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods."
9799542|NCT01662648|Experimental|Paliperidone ER: Lack of efficacy|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.
9799543|NCT01662648|Experimental|Paliperidone ER: Lack of tolerability, compliance or other|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.
9799544|NCT01662752|Other|Indocyanine green|Indocyanine green is used for intraoperative identification of sentinel lymph nodes in patients with early colonic cancer using near infrared laparoscopic imaging
9799545|NCT01662765|Experimental|Surgery|"Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium.~Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination."
9838704|NCT03840382|Experimental|Tele-PrEP Intervention|The telemedicine intervention will allow participants to discuss HIV prevention and PrEP with PrEP specialists at an academic medical center via videoconference from their local community based organization (CBO). During the intervention, participants will gain information related to HIV and PrEP, view a video to improve motivation for engagement in PrEP related care, and receive resources to address barriers to care.
9985154|NCT03317405|Placebo Comparator|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
9985155|NCT03316196|Experimental|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
9985156|NCT03316196|Sham Comparator|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
9985157|NCT03315039|Experimental|Liposomal annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
9838709|NCT03835416|Experimental|WL-Control|0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability.
9838710|NCT03835416|Experimental|WL-Protein|>30 g of high quality protein per meal, 1.2 g protein/kg body weight/day. Fourteen servings of high quality (30 g/serving) protein (lean meats, low fat dairy products) provided to participants each week to increase compliance.
9985158|NCT03311126|Experimental|Bendamustine + Obinutuzumab (BO)|"Induction chemoimmunotherapy (28 day cycles):~Bendamustine 90 mg/m2 IV days 1 & 2 every 28 days X 4-6 cycles~Obinutuzumab:~Cycle 1: 100 mg IV day 1, 900 mg IV day 2, 1000 mg IV days 8 & 15~Cycles 2-6: 1000 mg IV day 1~Consolidation phase:~Obinutuzumab 1000 mg IV weekly X 4 doses~Maintenance phase (8 week cycles):~Obinutuzumab 1000 mg IV on day 1 of cycles 1-8"
9985159|NCT03308045|Experimental|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
9985160|NCT03299959|Experimental|Agili-C|
9838714|NCT03821870||Standard treatment|Standard first line treatment
9838715|NCT03821233|Experimental|ZW49|
9838716|NCT03816345|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
10206288|NCT04668365|Experimental|Zanubrutinib Combined With Standard Chemotherapy|"A: For the first-line treatment:~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 6 cycles for patients with CD79A/CD79B genetic abnormality.~Zanubrutinib combined with Rituximab for the 7 cycle.~B: For R/R DBCLC:~Rituximab, 375mg/m2, Intravenous administration on day 0, combined with regimen: GemOx(Gemcitabine, Oxaliplatin)/ DHAP(Cisplatin, Cytarabine, Dexamethasone)/ ICE(Ifosfamide, Etoposide, Carboplatin)/ GDP(Gemcitabine, Cisplatin, Dexamethasone): repeated every 3 weeks, up to 5 cycles.~Zanubrutinib, 160mg twice daily continuous oral administration from 2 to 5 cycles for patients with CD79A/CD79B genetic abnormality.~Maintenance treatment: Zanubrutinib, 160mg twice daily continuous oral administration for 12 months."
9838718|NCT03811769|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
9838719|NCT03811769|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best medical treatment
10206289|NCT04667039|Experimental|GNR-067|Ranibizumab
9985161|NCT03299959|Active Comparator|Surgical Standard of Care (SSOC)|
9985162|NCT03297281|Experimental|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
10206290|NCT04667039|Active Comparator|Lucentis®|Ranibizumab
10206291|NCT04665596|Experimental|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
10206292|NCT04665479|Experimental|Intervention group|A total of 30 children with any progressively declining (acute or chronic) life-threatening diagnosis per parent report (aged 8 to 17) and their primary parent caregivers will be recruited as a dyad. Dyads will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
10206293|NCT04664998|Active Comparator|Male participants|200 male participants whose partners are enrolled in the parent study (Kampala Women's Bone study). All male participants will undergo the same study procedures at each visit, such as HIV and STI testing, and urine tenofovir testing if on PrEP.
10206294|NCT04664998|Active Comparator|Female participants|300 female participants from the parent study (Kampala Women's Bone study) will be enrolled to recruit their male sexual partner(s). All female participants will receive HIV testing, STI testing, and urine tenofovir testing (if on PrEP) at quarterly visits.
10206295|NCT04660864|Experimental|Rhinochill|Treatment with nasal cavity cooling 10 minutes during three consecutive migraine attacks.
10206296|NCT04657523|Experimental|Investigational Ultrasound Imaging for Liver Fat Quantification|
10206297|NCT04656678|Experimental|DynaCAD / UroNAV|This is a single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. UroNav is a stereotaxic accessory for image-guided interventional and diagnostic procedures of the prostate gland. It provides 2D and 3D visualization of Ultrasound (US) images and the ability to fuse and register these images with those from other imaging modalities such as Magnetic Resonance (MR), Computed Tomography, etc. It also provides the ability to display a simulated image of a tracked insertion tool on a computer monitor screen that shows images of the target organ and the current and the projected future path of the interventional instrument. DynaCAD 5.0 is an image analysis and planning system that will provide off station, pre planning and review of interventional study data. It interfaces with the Uronav 4.0 fusion guidance system.
9985163|NCT03297281|Active Comparator|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
9985164|NCT03296813|Active Comparator|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
9985165|NCT03296813|Active Comparator|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:~1 mg oral torsemide = 2-4 mg oral furosemide~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
9838725|NCT03802435|Experimental|Two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc 5% dextrose (3 months interval)
9838726|NCT03802435|Active Comparator|One-session of ultrasound-guided PIT|one-session of ultrasound-guided PIT with 10cc 5% dextrose and 10cc normal saline separately (3 months interval)
9838727|NCT03802435|Placebo Comparator|Two-session of ultrasound-guided nerve hydrodissection|two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
9985166|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis >60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL <1.8, HbA1c <6.0, blood pressure <140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
9985167|NCT03294590|Experimental|Oral health text messages (OHT)|Participants in this arm will receive the OHT parent targeted text messages to reduce caries and improve oral health behaviors among low income families visiting community-based, urban pediatric clinics.
9838730|NCT03799432|Experimental|TF-CBT Learning collaborative + COAST-IS|In addition to participating in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls, organizations will receive additional training and tailored implementation support.
9838731|NCT03799432|Active Comparator|TF-CBT Learning collaborative|Organizations will participate in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls.
9838732|NCT03797482||Intra-operative tumour tissue biopsies|Intra-operative tumour tissue biopsies will be collected for all patients
9838733|NCT03797196|Active Comparator|group 1|standard tacrolimus with mycophenolate mofetil
9838734|NCT03797196|Experimental|group 2|low dose tacrolimus with everolimus
9838735|NCT03796468|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
9838736|NCT03796468|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best treatment medical
9838737|NCT03795675|Experimental|Meniere's Disease/Vestibular Schwannoma|Individuals diagnosed with Meniere's disease and undergoing labyrinthectomy or diagnosed with vestibular schwannoma and undergoing surgical excision via translabyrinthine approach for treatment will receive cochlear implant at the time of surgery.
9838738|NCT03795298|Experimental|WATCHMAN FLX|WATCHMAN FLX implant including modified post-implant drug regimen.
9838739|NCT03795298|Active Comparator|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
9838740|NCT03793738|Active Comparator|anterior component separation|The anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath.
9838741|NCT03793738|Active Comparator|posterior component separation|The posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles.
9838742|NCT03793673|Other|Standard Care: Standard appointments|"Usual in-person medical appointments. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
9838743|NCT03793673|Other|Standard Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
9838744|NCT03793673|Other|CoYoT1 Care: Standard Appointment|"In-person - medical appointments with provider and/or team. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
9838745|NCT03793673|Other|CoYoT1 Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
9985168|NCT03294590|Active Comparator|Child wellness text messages (CWT)|Participants in this arm will receive the CWT parent targeted text messages to improve child wellness (e.g., reading time, safety) among low income families visiting community-based, urban pediatric clinics.
9985169|NCT03291847|Experimental|Buprenorphine-naloxone treated|Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
9921987|NCT00833508|Experimental|Test arm|Patients undergoing preoperative chemoradiotherapy will have their exercise capacity measured before and after chemoradiotherapy.
9790202|NCT01380184|Experimental|Ridaforolimus 40 mg|In Part 1 (Days 1-19), participants received ridaforolimus (MK-8669) 40 mg via oral enteric-coated tablet on Day 1; followed by no study treatment on Days 2-7; followed by two weekly sequences (Days 8-19) consisting of 5 consecutive days of ridaforolimus 40 mg and 2 consecutive days off study treatment. Following Part 1, participants underwent at least a 2-day study treatment washout prior to starting Part 2. In Part 2, participants received a weekly treatment regimen consisting of 5 consecutive days (Days 1-5) of ridaforolimus 40 mg via oral enteric-coated tablet and 2 consecutive days (Days 6-7) off study treatment. This weekly treatment regimen was repeated every subsequent week for the remainder of participation in Part 2.
9790203|NCT01380197|Active Comparator|Randomizing particiipants to Morphine|Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
9790204|NCT01380197|Active Comparator|Randomization to Nubain|Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
9790205|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 420 microliters daily
9790206|NCT01380327|Placebo Comparator|Placebo|Placebo administered sublingually not to exceed the maximally tolerated dose of either 1.) 420 microliters daily (placebo - low dose randomization) or 2.) 840 microliters twice daily (placebo - high dose randomization)
9790207|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 840 microliters taken twice daily
9790208|NCT01380366|Other|Patients consent to rHGH study|Patients consent to be given growth hormone (rHGH) for their short bowel syndrome.
9790209|NCT01380379|Experimental|Life skills and self-defense training|Women will participate in a therapeutic group which covers education, skills, and empowerment activities.
9790210|NCT01380535|Experimental|ECP Methoxsalen + Standard of Care|Participants receive methoxsalen administered via ECP in addition to standard of care
9790211|NCT01380535|Active Comparator|Standard of Care|Participants receive standard of care only
9790212|NCT01380639|Experimental|Rehabilitation with vibration training|
9790213|NCT01380639|No Intervention|Rehabilitation without vibration training|
9790214|NCT01380691|Experimental|LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc|"Period 1: 18 milligrams (mg) LY2216684 (LY) administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic (Alc) beverage (with an alcohol dose of 0.6 grams per kilograms [g/kg] for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching (Pl-Match) alcoholic beverage, taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
9790215|NCT01380691|Experimental|Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
9790216|NCT01380691|Experimental|LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc|"Period 1: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
9790217|NCT01380691|Experimental|Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
9790218|NCT01380730|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
9790219|NCT01380730|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
9790220|NCT01380730|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9790221|NCT01380730|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9790222|NCT01380730|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9790223|NCT01380730|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790224|NCT01380730|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790225|NCT01380730|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9790226|NCT01380743|Experimental|Cohort 1, Duvoglustat 50 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 50 milligram (mg) oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
9790227|NCT01380743|Experimental|Cohort 2, Duvoglustat 100 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 100 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
9790228|NCT01380743|Experimental|Cohort 3, Duvoglustat 250 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 250 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
9790229|NCT01380743|Experimental|Cohort 4, Duvoglustat 600 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 600 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
9790230|NCT01380769|Experimental|CRLX101|
9790231|NCT01380769|Other|Best supportive care|
9790232|NCT01380782|Experimental|Bevacizumab Naive|Bevacizumab naive subjects
9790233|NCT01380782|Experimental|Prior Bevacizumab|Patients previously treated with bevacizumab
9790234|NCT01380834|Active Comparator|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
10206298|NCT04656496|Experimental|NOURISH-T+|NOURISH-T+ targets parents as agents of change by providing intensive parent skills training emphasizing role modeling of positive health behaviors to foster the development of healthy eating and physical activity in pediatric cancer survivors. The NOURISH-T+ group will have 6 weekly, 1-1.5 hour, manualized sessions delivered using video-conferencing. There will be 2 additional brief sessions where the child will participate along with their parent to promote child engagement. Additionally, there will be one session with a pediatric oncology dietician based out of Nicklaus Children's Hospital who will discuss personalized nutritional strategies. Brief booster sessions at 2-, 4-, 8-, and 10- months will maximize retention and follow-up participation. NOURISH-T+ content is theory-based, manualized, and builds upon strengths of our prior work with NOURISH-T (our pilot) and NOURISH (our work with otherwise healthy overweight and obese children).
9790235|NCT01380834|Placebo Comparator|Placebo group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
9790236|NCT01380899||PD Parkinson´s Disrease|We are studying the presence of alpha-synuclein in the epidermis and dermis besides the end nerve terminal. We have several reports until now, and we are following the study because we wish to convince the academic and scientific society over the utility of this study to be close to the molecular diagnosis of this kind of disease.
9790237|NCT01380899||AP Atypical Parkinsonism|with neurodegenerative disease (proteinopathies) and secondary AP.
9790238|NCT01380899||Control group|Subjects without neurodegenerative disease and apparently good health status with an age that matches the problems groups
9790239|NCT01380990|Experimental|Gene Therapy|Infusion of autologous EFS-ADA LV CD34+ cells
9790240|NCT01380990|Other|Historical Control Group|Historical data from ADA-SCID patients who were treated with Hematopoietic Stem Cell Transplantation (HSCT)
9790241|NCT01381016|Other|Group 1 - Normal Weight|"Group 1: Normal weight (BMI 18-25 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
9790242|NCT01381016|Experimental|Group 2 - Obese|"Group 2: Obese (BMI >30 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
9790243|NCT01381068|Experimental|Monitored Arm|The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
9985170|NCT03291847|Active Comparator|Methadone treated|Participants receiving methadone treatment for opioid use disorder during pregnancy
9921988|NCT00833534|Experimental|Group I (consolidation phase)|Patients receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
9790244|NCT01381068|Placebo Comparator|Control Arm|The end tidal CO2 sensor is placed in th respiratory circuit. The monitor is covered so the resuscitation team can not see the display. The resuscitation team is instructed to provide ventilation according to clinical judgment.
9790245|NCT01381120|Experimental|VESIcare + Narcotic Painkiller|VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
9790246|NCT01381120|Active Comparator|Narcotic Painkiller|Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
9790247|NCT01381172|Experimental|Treatment|The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.
9790248|NCT01381172|Other|Control|The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.
9790249|NCT01381406||COPD patients|Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
9790250|NCT01381471||COPD|Patients with a diagnosis code of COPD
9790251|NCT01381549|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
9790252|NCT01381549|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
9790253|NCT01381549|Active Comparator|imipenem-cilastatin|500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
9790254|NCT01381562|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
9790255|NCT01381562|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
9790256|NCT01381562|Active Comparator|Meropenem 1G|q8h administered via IV infusion, plus saline placebo
9790257|NCT01381575|Experimental|Cervarix 1 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
9790258|NCT01381575|Active Comparator|Cervarix 2 Group|Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Day 0, at Month 1 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
9790259|NCT01381575|Experimental|Cervarix 3 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 12, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
9790260|NCT01381692|Active Comparator|Arm I (rituximab, bortezomib, dexamethasone)|Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9790261|NCT01381692|Experimental|Arm II (temsirolimus, rituximab, bortezomib, dexamethasone)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9790262|NCT01381718|Experimental|Arm I|Participants receive modafinil orally (PO) once daily (QD) on days 1-42.
9790263|NCT01381718|Placebo Comparator|Arm II|Participants receive placebo PO QD on days 1-42.
9790264|NCT01381861|Experimental|Carotuximab (TRC105) alone|Single arm, open label Carotuximab (TRC105) alone therapy dosed at 10 mg/kg administered intravenously over 1 to 4 hours on days 1, 8, 15 and 22 of each 28 day cycle
9790265|NCT01381874|Experimental|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
9790266|NCT01381874|Experimental|Abiraterone acetate + Prednisone/Prednisolone + Exemestane|Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
9790267|NCT01381874|Experimental|Exemestane|Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
9790268|NCT01381900|Experimental|Canagliflozin 100mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
9790269|NCT01381900|Experimental|Canagliflozin 300mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
9790270|NCT01381900|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
10206299|NCT04656496|Active Comparator|EUC - Brief NOURISH-T+|The EUC condition (Brief NOURISH-T+) engages parents in one information session moderated by a USF-based interventionist using videoconferencing. Session content is taken from the publicly available We Can! Manual. Parents in this group will receive nationally available web-based brochures on pediatric overweight/obesity on two occasions during the 6 weeks that NOURISH-T+ families participate in the study. Check-ins will take place at 2-, 4-, 8-, and 10- months post-intervention.
10206300|NCT04653610||HIV-infected individuals|
9790271|NCT01381926|Experimental|Exenatide then Placebo|"Study participants in phase1 will receive the study drug, exenatide, at a dose of 5mg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the dose of exenatide will be increased to 10mg subcutaneously twice daily before meals for one month. During the third month of the study, no study medication will be given and this will serve as a wash out period prior to the second phase of the study (placebo). During the fourth and fifth months, study participants will get placebo alternatives to exenatide 5mg and exenatide 10mg, respectively, subcutaneously twice daily before meals."
9790272|NCT01381926|Active Comparator|Placebo then Exenatide|"Study participants in phase1 will receive the saline placebo, at a dose of 5mcg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the saline placebo will be increased to 10mcg subcutaneously twice daily before meals for one month. During the third month of the study, no treatment will be given and this will serve as a wash out period prior to the second phase of the study. During the fourth month study participants will receive Exenatide 5mcg twice daily with meals. During the fifth month, study participants will receive exenatide 10mcg, subcutaneously twice daily before meals."
9790273|NCT01381952|Experimental|Reduced radiation dose (ClarityIQ)|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology
9790274|NCT01381952|Active Comparator|Normal radiation dose (AlluraXper)|Normal dose DSA with conventional X-ray technology.
9790275|NCT01382108||Normal participants|
9790276|NCT01382108||Meibomian Gland Dysfunction|
9790277|NCT01382186||Purposive Sampling|Purposive sampling was used to identify a sample of 33 Veterans who have been Personally Authenticated for the SM feature on MHV. Participants were recruited from each site (Tampa, Boston). Women were purposively recruited to ensure females were represented in data findings.
9790278|NCT01382186||Random Sampling|Random sampling was used to conduct a quantitative survey with 819 veterans to explore their experiences using secure messaging.
9790279|NCT01382212|Experimental|Paricalcitol|Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.
9790280|NCT01382225|Experimental|Sodium Hyaluronate|Sodium Hyaluronate Ophthalmic Solution, 0.18%, 1-2 drops instilled in each eye 3-6 times a day for 14 days
9790281|NCT01382225|Placebo Comparator|Vehicle|Inactive ingredients, 1-2 drops instilled in each eye 3-6 times a day for 14 days
9790282|NCT01382251||Patient|Patients undergoing ambulatory surgery
9790283|NCT01382251||Caregiver|Spouse, family members, or friends identified as the patient's primary source of support in the community.
9790284|NCT01382303|Active Comparator|Pentoxifylline|Pentoxifylline 400mg three times a day
9790285|NCT01382303|Placebo Comparator|Placebo|placebo tablet
9790286|NCT01382446|Active Comparator|Standard Oral Care Regimen|Current oral care protocol includes the use of 1.5% H2O2-coated swabs every four hours, toothbrushing with toothpaste every 12 hours, and use of continuous subglottic suction apparatus.
9790287|NCT01382446|Experimental|Chlorhexidine Oral Care Regimen|This study will compare our current oral care practice with the use of Chlorhexidine Gluconate 0.12% (Peridex, 3M Corporation) Twice daily in addition to regularly scheduled oral care as a means to decrease the incidence of VAP utilizing evidence-based strategies.
9790288|NCT01382602|Experimental|AMDC-USR|Subjects received 1 or 2 treatments of 150 million AMDC-USR delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded. Subjects were followed for 2 years after initial AMDC-USR treatment.
9790289|NCT01382602|Placebo Comparator|Placebo|Subjects received 1 or 2 treatments of placebo delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded and could elect to receive open-label AMDC-USR treatment. Subjects that received unblinded AMDC-USR treatment were followed for 2 years after initial placebo treatment.
9790290|NCT01382719|Placebo Comparator|Placebo|Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
9790291|NCT01382719|Experimental|bremelanotide arm 1|Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
9790292|NCT01382719|Experimental|bremelanotide arm 2|Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
9790293|NCT01382719|Experimental|bremelanotide arm 3|High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
9790294|NCT01382901|Experimental|Intravenous (IV) Iron|
9790295|NCT01382901|Placebo Comparator|Placebo|
9921989|NCT00833534|Experimental|Group II (consolidation phase)|Patients receive lenalidomide as in group I. Patients also receive rituximab IV once on the day before the start of lenalidomide and then once between days 25-30, 50-55, and 75-80 for a total of 4 doses in the absence of disease progression or unacceptable toxicity.
10206301|NCT04653610||HIV-seronegative healthy volunteers|
10206302|NCT04652622|Experimental|Intervention arm|Participants will receive 4 hours of exposure to the Mindful Garden digital therapeutic platform in addition to standard care
9790296|NCT01382940|Experimental|Rituximab|Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
9790297|NCT01383005||Kaletra (LPV/r) QD as First Kaletra Treatment|HIV-infected participants treated with lopinavir/ritonavir once daily (LPV/r QD) from ≥3 months to <2 years who had not been treated with any of the following: LPV/r twice daily (BID), a protease inhibitor, or a ritonavir-boosted protease inhibitor.
9790298|NCT01383005||Kaletra (LPV/r) QD from Kaletra BID|HIV-infected participants treated with LPV/r from ≥3 months to <2 years who had initiated on LPV/r BID and at any time within this period (but at least 3 months before inclusion in the study) had changed dosing from BID to QD.
9790299|NCT01383018||AMS penile prosthesis receipients|Men for whom an AMS penile prosthesis is recommended
9790300|NCT01383096|Active Comparator|Cohort 1 - Treatment A: OZ439 800mg PIB, fed|OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.
9790301|NCT01383096|Experimental|Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.
9790302|NCT01383096|Experimental|Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.
9790303|NCT01383096|Experimental|Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted|Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
9790304|NCT01383096|Experimental|Cohort 1 - Treatement B: OZ439 800mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
9790305|NCT01383096|Experimental|Cohort 1 - Treatment C:OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
9790306|NCT01383096|Experimental|Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted|Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.
9790307|NCT01383096|Experimental|Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.
9790308|NCT01383096|Experimental|Cohort 2 - Treatement F: OZ439 800 mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
9790309|NCT01383096|Experimental|Cohort 2 - Treatement G: OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
9790310|NCT01383096|Experimental|Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.
9790311|NCT01383161|Active Comparator|Curcumin|Theracurmin (180mg/day)
9790312|NCT01383161|Placebo Comparator|Placebo|Sugar Pill
9790313|NCT01383174|Experimental|Peer Support Program|Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
9790314|NCT01383174|No Intervention|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the peer support program.
9790315|NCT01383200|Active Comparator|Tetracaine R/Lidocaine L|Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
9921990|NCT00833573||1|For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
9790316|NCT01383200|Active Comparator|Tetracaine L/Lidocaine R|Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.
9790317|NCT01383213|Experimental|CPAP (group A)|group A will be treated with CPAP using a helmet, initial PEEP of 10 cmH20 and an FiO2 set in order to maintain SpO2 ≥92%
9790318|NCT01383213|Active Comparator|oxygen therapy (group B)|group B (standard treatment) will be treated with oxygen therapy by Venturi mask with an FiO2 set in order to maintain SpO2 ≥92%.
9790319|NCT01383317|Active Comparator|RIPC|A tourniquet on the thigh will be inflated to 300 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
9790320|NCT01383317|Sham Comparator|Sham RIPC|A tourniquet on the thigh will be inflated to 15 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
9790321|NCT01383356|Experimental|Linagliptin/Metformin medium dosecombo|patient to receive a single medium dose combination tablet containing Linagliptin and Metformin once daily
9790322|NCT01383356|Active Comparator|Linagliptin plus Metformin medium dose|patient to receive two individual tablets: Linagliptin and Metformin (medium dose)
9790323|NCT01383421||Participants With RA Receiving Adalimumab|"Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.~All participants were offered to participate in the PSP while treated with ADA for their RA."
9790324|NCT01383486|Experimental|Naproxen Sodium ER (BAYH6689) or Advil IR|Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
9790325|NCT01383499|Experimental|Treatment A|patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler
9790326|NCT01383499|Experimental|Treatment B|patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler
9790327|NCT01383499|Experimental|Treatment C|patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler
9790328|NCT01383499|Placebo Comparator|Treatment D|patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler
9790329|NCT01383616|Active Comparator|Unipedicular kyphoplasty|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
9790330|NCT01383616|Active Comparator|Bipedicular Kyphoplasty group|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.
9790331|NCT01383707|Experimental|Bevacizumab + mFOLFOX-6|Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
9790332|NCT01383720|Experimental|Lotus Valve System|Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis
9790333|NCT01383759|Experimental|Bortezomib/Dexamethasone (BD) , STC & Maintenance BD|This is a pilot study to gain information and estimate the toxicity/tolerability of 1-3 cycles of BD, followed by HDM/ASCT, and maintenance therapy with BD in patients with MIDD associated with multiple myeloma and AL amyloidosis.
9790334|NCT01383928|Experimental|Phase 1: Ixazomib 3 mg or 3.7 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
9790335|NCT01383928|Experimental|Phase 2: Ixazomib 3 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 2. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
9790336|NCT01383954|Other|Diclofenac gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
9790337|NCT01383993|Experimental|1.0|Immunocompromised children aged 2 to <15 and 12 to <15 years weighing <50 kg who are at high risk for systemic fungal infection.
9790338|NCT01383993|Experimental|2.0|Immunocompromised children aged 12 to <15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
9790339|NCT01384019|Experimental|DP-TA|distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
9790340|NCT01384019|Placebo Comparator|c-PCI|conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction
9790341|NCT01384292|Experimental|1 (part A and B)|Oral treatment
9790342|NCT01384292|Experimental|2 (part A and B)|Oral treatment
9790343|NCT01384292|Placebo Comparator|3 (part A only)|Oral treatment
9790344|NCT01384539|Experimental|Cholecalciferol|Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months
9790345|NCT01384539|Experimental|Calcitriol|Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months
9790346|NCT01384591|Experimental|Losartan and placebo N-acetylcysteine|losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
9985171|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
9985172|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
9996802|NCT01503346|Experimental|herbal medicine|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
9996803|NCT01503359|Experimental|Dietary Supplement: Sarcosine|Sarcosine Group
9996804|NCT01503359|Placebo Comparator|Placebo|Control Group
9838753|NCT03786003|Experimental|VATS|Video-assisted thoracoscopic surgery
9838754|NCT03786003|Active Comparator|Thoracotomy|Open surgery
9996805|NCT01503372|Experimental|Arm A: FLO + Pazopanib|
9996806|NCT01503372|Active Comparator|Arm B: FLO|
9996807|NCT01503385|Experimental|Celecoxib|"Combination of and concurrent radiotherapy Cisplatin/etoposide with or without Celecoxib.~Intervention: Drug: Celecoxib"
9838758|NCT03782415|Experimental|MN-166 and temozolomide|Part 1: Combination treatment of MN-166 60 mg/day (30 mg twice a day) for 28 days and temozolomide 150 mg/m² on Days 1-5 of 28-day cycle. Part 2: Open-label, fixed-dose MN-166 and temozolomide combination treatment for 6 cycles until disease progression, unacceptable tolerability and/or toxicity or loss of life.
9996808|NCT01503398|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
9996809|NCT01503398|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
9838761|NCT03773302|Experimental|Infigratinib (BGJ398) 125 mg|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
9996810|NCT01503424|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
9996811|NCT01503424|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
9996812|NCT01503437|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
9996813|NCT01503437|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
9996814|NCT01503450|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
9996815|NCT01503450|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
9996816|NCT01503463|No Intervention|Usual Care|Patients in the control group receive usual care delivered by their primary care physicians and cardiologists. Usual care consists of regular visits to the specialist or primary care clinics every time a medication change is required, or a medical examination is needed.
9996817|NCT01503463|Experimental|Home telemonitoring of patients with CHF|
9996818|NCT01503476|Experimental|Healthy volunteers|healthy volunteers
9838762|NCT03773302|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.
10206303|NCT04652622|No Intervention|Control Arm|Participants will be monitored over a 4 hour period of standard care interventions
9790347|NCT01384591|Placebo Comparator|Placebo losartan and placebo N-acetylcysteine|Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
9790348|NCT01384591|Experimental|N-acetylcysteine and placebo losartan|N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
9790349|NCT01384734|Experimental|Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir|Treatment Group 1
9790350|NCT01384734|Experimental|Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir|Treatment Group 2
9790351|NCT01384734|Experimental|Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir|Treatment Group 3
9790352|NCT01384734|Experimental|Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir|Treatment Group 4
9790353|NCT01384734|Active Comparator|Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir|Treatment Group 1 (reference arm)
9790354|NCT01384760|Active Comparator|Lifestyle modification program|"At the 1st session, the dietitian carried out a complete behavioral assessment, with emphasis on patient's current eating and lifestyle patterns, specific eating-related behaviors, knowledge of risks associated with current eating patterns, and concerns and feelings about specific lifestyle changes. In the subsequent follow up visit, the dietitian reviewed the 7-day food diaries to ensure nutritional adequacy and treatment compliance, and also offered recommendations for controlling caloric intake.~Patients were encouraged to see an exercise instructor who designed an individualized suitable exercise regime with cardiovascular and resistance exercises for the patients to perform at home. Subjects were encouraged to perform 30-minute aerobic exercise 2-3 times a week."
9790355|NCT01384760|Placebo Comparator|Simple lifestyle advice|Subjects in control group received simple lifestyle advice from a clinician at baseline and month 6. This was a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects were encouraged to perform regular 30-minute exercise 2 to 3 times per week. This was to resemble routine clinical practice.
9790356|NCT01384877|Experimental|Lidocaine|Lidocaine
9790357|NCT01384877|Placebo Comparator|Placebo (D5W)|Placebo first as compared with lidocaine first
9790358|NCT01385098|Experimental|Vitamin D3 and Calcium|Dietary supplement of vitamin D3 and calcium
9790359|NCT01385137|Experimental|Arm I|Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
9790360|NCT01385137|Placebo Comparator|Arm II|Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
9790361|NCT01385189|Experimental|Cohort 1|10 μg Na-GST-1/Alhydrogel vs. 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
9790362|NCT01385189|Experimental|Cohort 2|30 μg Na-GST-1/Alhydrogel vs. 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
9790363|NCT01385189|Experimental|Cohort 3|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
9790364|NCT01385189|Experimental|Cohort 4|100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
9790365|NCT01385189|Experimental|Cohort 5|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
9790366|NCT01385202|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
9790367|NCT01385293|Experimental|Study arm|BKM120 at 100mg orally daily
9790368|NCT01385306|Experimental|AlphaCore System|non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System
9790369|NCT01385371|Experimental|SCH 697243|
9790370|NCT01385371|Placebo Comparator|Placebo|
9790371|NCT01385566|Active Comparator|Full Dose Subcutaneous|Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
9790372|NCT01385566|Experimental|1/3 Dose Subcutaneous|Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
10206304|NCT04642820|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
10206305|NCT04642820|Experimental|MethamphetamineThen Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
10206306|NCT04639024|Experimental|ADCT-301 Infusion|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
10206307|NCT04635735|Experimental|Ipilimumab After Stem Cell Transplantation|The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.
10206308|NCT04634279|Experimental|Collaborative Care Plus|Intervention is administered to patients in this arm. Care to be delivered via collaborative care. The supplement intervention adds family involvement in care and Caring Contacts, a suicide prevention method.
10206309|NCT04634279|No Intervention|Control|Patients in this arm will receive enhanced usual care.
10206310|NCT04632069|Experimental|NAC + taVNS|NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
9790373|NCT01385566|Experimental|Full Dose Intradermal|Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
9790374|NCT01385566|Experimental|1/3 Dose Intradermal|Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
9790375|NCT01385566|Experimental|1/10 Dose Intradermal|Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
9790376|NCT01385566|Experimental|1/27 Dose Intradermal|Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
9790377|NCT01385579|No Intervention|usual care|Patients assigned to the usual care arm may be referred for colorectal cancer screening by their providers per usual health center protocol and practice. They receive no additional outreach by the preventive care care manager.
9790378|NCT01385579|Experimental|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit
9790379|NCT01385644|Experimental|1*10^6 MSC / kg|Placental MSC
9790380|NCT01385644|Experimental|2*10^6 MSC / kg|Placental MSC
9790381|NCT01385696|Experimental|group A|Genuair first, HandiHaler second
9790382|NCT01385696|Experimental|group B|HandiHaler first, Genuair second
9790383|NCT01385748|Active Comparator|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablets, once de day, every day up to 8 weeks
9790384|NCT01385748|Active Comparator|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
10206311|NCT04629599|Experimental|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
9790385|NCT01385748|Placebo Comparator|Placebo Lauriad®|Placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
9790386|NCT01385995|Active Comparator|Continuous Positive Airway Pressure (CPAP)|
9790387|NCT01385995|Sham Comparator|Sham-Continuous Positive Airway Pressure (CPAP)|
9790388|NCT01386008|Other|enfilcon A + senofilcon A|Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
9790389|NCT01386528|Experimental|Patients enrolled in trial|New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
9790390|NCT01386554|Experimental|80 U Acthar|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) two times per week
9790391|NCT01386554|Placebo Comparator|1.0 mL Placebo|Placebo (1.0 mL) two times per week
9790392|NCT01386554|Experimental|40 U Acthar|Acthar (Repository Corticotropin Injection) 40 U (1.0 mL) two times per week
9790393|NCT01386606|Experimental|Androxal 6.25 mg|Androxal 6.25 mg/day
9790394|NCT01386606|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
9790395|NCT01386606|Experimental|Androxal 25 mg|Androxal 25 mg/day
9790396|NCT01386606|Active Comparator|AndroGel|AndroGel 5G topical testosterone
9790397|NCT01386632|Active Comparator|DCA (dichloroacetate) Treatment|DCA orally 12.5mg/kg or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
9790398|NCT01386632|Placebo Comparator|Placebo|Placebo orally or per G-tube BID for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
9790399|NCT01386645|Active Comparator|Low GI diet|low glycemic index diet
9790400|NCT01386645|Placebo Comparator|High GI diet placebo|high glycemic index diet plus placebo
9790401|NCT01386645|Active Comparator|High GI diet NAC|high glycemic index diet plus N-acetylcysteine
9985173|NCT03289585||Hidradenitis Suppurativa Cohort|Patients with Hidradenitis Suppurativa (ages 18-99 years old) will be asked to complete a series of questionnaires on how Hidradenitis Suppurativa impacts quality of life.
9985174|NCT03289325|Experimental|DEX group|The active drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
9838765|NCT03764501|Active Comparator|Image fusion group (Image fusion)|Use image fusion system during surgery (Image fusion, ZedTrauma, LEXI Co., Ltd.)
9838766|NCT03764501|No Intervention|Control group (ZedTrauma)|only use 3D preoperative planning (Zed Trauma, LEXI Co., Ltd.)
9985175|NCT03289325|Placebo Comparator|CTRL group|The placebo drug (normal saline, or 0.9% sodium chloride for injection) will be administered in the same rate and volume for a same duration as that in the DEX group.
9985176|NCT03288025|Experimental|Nutrition and Exercise|5 days a week of moderate exercise and biweekly diet counseling on Low Glycemic Index/ Mediterranean Diet for 12 weeks.
9838769|NCT03758261|Other|Erector Spinae Nerve Block|Erector Spinae nerve block
9838770|NCT03758261|Other|Paravertebral Nerve Block|Paravertebral nerve block
9838771|NCT03756077||Primary diagnosis and staging|Patients suspected of or diagnosed with prostate cancer who want a differential diagnosis and staging by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT before treatment
9838772|NCT03756077||Evaluation of recurrence|Patients with a history of prostate cancer and elevated PSA level after treatment, who need to determining whether or not there are recurrences/metastatic lesions and its locations by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
9838773|NCT03752034|Experimental|Muscle Fiber Fragments (MFF)|Participants undergoing rotator cuff repair will have autologous muscle tissue harvested. The tissue will be processed to obtain Muscle Fiber Fragments (MFFs) and administered via direct injection into the supraspinatus muscle belly.
9985177|NCT03288025|No Intervention|Standard of Care|Counseling at baseline on diet as recommended by USDA and on the benefits of regular aerobic exercise.
9985178|NCT03286010|Experimental|Intervention|Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).
9996819|NCT01503476|Experimental|symptomatic patients|symptomatic patients with known or suspected gastro esophageal reflux disease
9996820|NCT01503502|Experimental|flumatinib 400mg qd|
10206312|NCT04629599|Active Comparator|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
9838779|NCT03743766|Experimental|Relatlimab|"Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1).~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
9838780|NCT03743766|Experimental|Nivolumab|"Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks.~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
9838781|NCT03743766|Experimental|Relatlimab + Nivolumab|Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
9838782|NCT03742635|Experimental|GMA Assessment|"Conduct General Movements Assessment (GMA) in-person/via-telemedicne (real-time) and recorded (standard of care)"
10206313|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus pyrazinamide|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.
10206314|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus bedaquiline|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.
10206315|NCT04629378|Active Comparator|Rifafour standard of care treatment|Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
10206316|NCT04628572||Cohort 1|Eligible adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice
10206317|NCT04617353|Experimental|Plasma|(the treatment of sterno-mediastinitis was carried out using a combined method of air-plasma flow and NO therapy)
9838791|NCT03735628|Experimental|Dose escalation|"Copanlisib:~45 mg (dose level -1) or 60 mg (dose level 1) on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
9790402|NCT01386788||Smoke Inhalation patients|Closed space fire, Soot deposits, Altered mental status Blood specimen before intravenous antidote treatment (cyanide measurement) Known delay between end of smoke exposure and blood sampling
9790403|NCT01386944||Neupro® Treatment|Routine treatment (1,2,3 mg/24 h) as per approved label in the European Union (EU).
9790404|NCT01386970|Active Comparator|HIV-negative|This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
9790405|NCT01386970|Active Comparator|HIV-infected|This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
9790406|NCT01386983||Early 5ARI Initiation|Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
9790407|NCT01386983||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)
10206318|NCT04617353|Other|Standard therapy|(patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage)
9790408|NCT01387022|Experimental|Tenofovir, lamivudine and efavirenz|
9790409|NCT01387022|Active Comparator|Zidovudine, lamivudine and efavirenz|
9790410|NCT01387074||botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
9790411|NCT01387139|Active Comparator|Ketamine Alone|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
9790412|NCT01387139|Experimental|Ketamine Co-Administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
10206319|NCT04616183|Experimental|Arm A (ERK1/2 inhibitor LY3214996, cetuximab)|Patients receive ERK1/2 inhibitor LY3214996 PO QD on days 1-28 and cetuximab IV over 1-2 hours on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10206320|NCT04616183|Experimental|Arm B (ERK1/2 inhibitor LY3214996, cetuximab, abemaciclib)|Patients receive ERK1/2 inhibitor LY3214996 and cetuximab as in Arm A. Patients also receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10206321|NCT04615819|Experimental|Arm 1|KTFT
9790413|NCT01387178||COPD patients - risk analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).
9790414|NCT01387178||COPD patients - cost analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).
9790415|NCT01387230|Experimental|GSK573719|active drug
9790416|NCT01387230|Placebo Comparator|Placebo|no active drug
9790417|NCT01387269|Experimental|100 mg QD|Anamorelin HCL 100 mg will be administered daily
9790418|NCT01387269|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
9790419|NCT01387282|Active Comparator|100 mg QD|Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.
9790420|NCT01387282|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
9790421|NCT01387347|Active Comparator|Thymosin Beta 4|RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
9790422|NCT01387347|Placebo Comparator|Placebo|The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
9790423|NCT01387464|Experimental|ISV-303|
9790424|NCT01387464|Active Comparator|Bromday™|
9799546|NCT01662765|Active Comparator|Conservative|"Conservative treatment described as follow:~Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus.~postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry."
10206322|NCT04615819|Experimental|Arm 2|PN
10206323|NCT04615806|Experimental|NIR-ICG|After positioning,Indocyanine green（ICG） dye (Yichuang Pharmaceutical, Liaoning, China) stored at a dose of 25 mg in a small bottle was diluted with 5 ml sterile water. Then, 2 ml of this solution was added to 8 ml sterile water in a dis-posable dressing bowl, resulting in a final concentration of 1.25 mg/ml.
10206324|NCT04615806|No Intervention|Control|This group of patients received only conventional radical resection of esophageal cancer without Indocyanine green injection.
10206325|NCT04611022|Experimental|Patients Eligible for HPV Vaccine|
10206326|NCT04608318|Experimental|I (Ibrutinib)|Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.
10206327|NCT04608318|Experimental|VG (Obinutuzumab + Venetoclax)|12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone
9790425|NCT01387516|Experimental|Motivational Intervention|Motivational Interviewing (MI) will be a 60-90 minutes individual session.The focus is on establishing rapport and building motivation. The counselor explores youth's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancy, and perceptions of self-efficacy. A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
9790426|NCT01387516|Active Comparator|Relaxation Intervention|The Relaxation Therapy intervention is a 60-90 minute individual session. The session encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and as a whole is really a meditation protocol.
9790427|NCT01387516|Experimental|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) Intervention is administered during two 90 minute group sessions. The focus is on the interrelationship between thoughts, feelings, and behaviors. It is used to address specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
9790428|NCT01387516|Active Comparator|Self-Help Programming|"Self Help intervention is administered during two 90 minute group sessions. The intervention modules are based on the principles of Nicotine Anonymous (NicA), to provide those who use nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. Elements incorporated in this intervention include the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
9790429|NCT01387542|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
9790430|NCT01387581||Without MelaFind|Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
9790431|NCT01387581||With MelaFind|Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion
9790432|NCT01387581||Experts Without MelaFind|PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
9790433|NCT01387594|Experimental|Cohort 1|Interventions prior to treatment. Control arm
9790434|NCT01387594|Experimental|Cohort 2|Interventions prior to and after 3 monthly injections
9790435|NCT01387607|Experimental|Pregabalin|
9790436|NCT01387607|Placebo Comparator|Placebo|Matched placebo
9790437|NCT01387672|Active Comparator|Nitrol|Nitroglycerin Ointment 2% USP
9790438|NCT01387672|Active Comparator|Nitro-Dur|Nitroglycerin Extended Release Patch 160mg
9790439|NCT01387672|Active Comparator|Nitrostat 1|Nitroglycerin 0.3mg Sublingual Tablet
9790440|NCT01387672|Active Comparator|Nitrostat 2|Nitroglycerin 0.6mg Sublingual Tablet
9790441|NCT01387672|Active Comparator|ISMO|Isosorbide Mononitrate 20mg Oral Tablet
9790442|NCT01387672|Placebo Comparator|Placebo|Placebo Ointment
9790443|NCT01387737|Experimental|TA-7284-Low|
9790444|NCT01387737|Experimental|TA-7284-High|
9790445|NCT01387789||Scheduled to start adalimumab therapy|Patients diagnosed with rheumatoid arthritis for at least 3 months that previously had not received prior anti-TNF agents.
9790446|NCT01387815||Topical/Traditional Systemic Agent|Participants who initiated treatment with a new topical agent that was not used before or already being treated with topical agent and not responding, thereby requiring a change of treatment type, frequency, or dose and all participants who initiated treatment with a new systemic agent that was not used before alone or in combination with topical agents.
9790447|NCT01387815||Adalimumab|Participants treated with adalimumab alone or in combination with topical agents.
9790448|NCT01387932|Experimental|HepaSphere/QuadraSphere TACE|HepaSphere/QuadraSphere TACE
9790449|NCT01387932|Active Comparator|Conventional TACE|Conventional TACE
9790450|NCT01388166||Patients with COPD|
9790451|NCT01388335|Experimental|warfarin + enzastaurin|"On Day 1 of Period 1, a single 5-milligram (mg) oral dose of warfarin will be given, followed by at least a 7-day washout.~Period 2: 500 mg enzastaurin administered orally once daily for at least 19 consecutive days and 5 mg warfarin administered as a single oral dose on Day 15.~Safety Extension: Participants are allowed to continue receiving enzastaurin alone until disease progression or other discontinuation criteria are met."
9790452|NCT01388361|Experimental|IDeg (non-randomised)|
9790453|NCT01388361|Experimental|IDeg + IAsp|
9790454|NCT01388361|Experimental|IDeg + liraglutide|
9790455|NCT01388478|Experimental|R(+)pramipexole|Each study participant will be given the active study drug, R-pramipexole. There is no placebo arm.
9790456|NCT01388530|Experimental|trigeminal nerve stimulation|Open label treatment with trigeminal nerve stimulation in an 8-week trial.
9790457|NCT01388543|Active Comparator|CYP3A5 Expressors|A pre-screening genetic test determines CYP3A5 expressor status
9790458|NCT01388543|Active Comparator|CYP3A5 Non-expressors|A pre-screening genetic test determines CYP3A5 non-expressor status
9790459|NCT01388647|Experimental|Eribulin, carboplatin, and trastuzumab|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
9790460|NCT01388777|Experimental|Cryoablation|Cryoablation therapy followed by re-imaging then complete surgical resection.
9790461|NCT01388790|Experimental|Cetuximab plus cisplatin plus S-1|
9790462|NCT01388816|Placebo Comparator|Placebo capsule|
9790463|NCT01388816|Experimental|DRL-17822 50 mg|
9790464|NCT01388816|Experimental|DRL-17822 150 mg|
9790465|NCT01388816|Experimental|DRL-17822 300 mg|
9790466|NCT01388907|Experimental|Prevadh film|Patient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
9790467|NCT01388907|Active Comparator|Ringer solution|Patients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
9790468|NCT01388946|Active Comparator|Ropivacaine 0.75|Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
9790469|NCT01388946|Placebo Comparator|Normal saline|Continuous infusion of normal saline 2 ml/h for 24 hours
9790470|NCT01388985|Active Comparator|Standard vaccination schedule|One injection will be given on three different days (day 0, day 7 and day 21 or 28)
9790471|NCT01388985|Experimental|Accelerated vaccination schedule|Two injections will be given on the same day (day 0 and day 7): one on each forearm.
9790472|NCT01389076|Experimental|Treatment arm|Low dose methotrexate and Bexxar
9790473|NCT01389102|Placebo Comparator|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
9790474|NCT01389102|Placebo Comparator|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
9790475|NCT01389102|Placebo Comparator|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
9790476|NCT01389102|Active Comparator|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
9790477|NCT01389102|Active Comparator|Estradiol transdermal two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
9790478|NCT01389102|Active Comparator|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
9790479|NCT01389128|Active Comparator|Control Group|Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
9790480|NCT01389128|Experimental|Intervention Group|Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: pelvic mobility , lumbosacral massage and warm shower.
9790481|NCT01389232|Experimental|SeriScaffold® Surgical Scaffold|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
9790482|NCT01389245|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
9790483|NCT01389258|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
9790484|NCT01389284|Experimental|Naproxen Sodium ER (BAYH6689)|1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
9790485|NCT01389284|Active Comparator|Naproxen Sodium IR (Aleve, BAYH6689)|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
9790486|NCT01389284|Placebo Comparator|Placebo|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
9790487|NCT01389323|Experimental|Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin|
9790488|NCT01389596|Placebo Comparator|Placebo|
9790489|NCT01389596|Experimental|Pregabalin Level 1 (max 150 mg/day)|
9790490|NCT01389596|Experimental|Pregabalin Level 2 (max 600 mg day)|
9790491|NCT01389752|Experimental|LY2216684 without Charcoal, then with Charcoal|Period 1: Single 18-mg (milligram) (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg (gram/kilogram) of Activated Charcoal. Periods will be separated by a minimum of 7 days.
9790492|NCT01389752|Experimental|LY2216684 with Charcoal, then without Charcoal|Period 1: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg of Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Periods will be separated by a minimum of 7 days.
9790493|NCT01389765|Experimental|LY2216684 administered in fasted then fed state|Period 1: Single 18-mg (milligram) oral dose of LY2216684 administered in fasted state. Period 2: Single 18-mg oral dose of LY2216684 administered in fed state. Periods will be separated by a minimum of 7 days.
9790494|NCT01389765|Experimental|LY2216684 administered in fed then fasted state|Period 1: Single 18-mg oral dose of LY2216684 administered in fed state. Period 2: Single 18-mg oral dose of LY2216684 administered in fasted state. Periods will be separated by a minimum of 7 days.
9790495|NCT01389856|Experimental|1|Bosentan
9790496|NCT01389856|Placebo Comparator|2|Matching placebo
9790497|NCT01389882|Experimental|ventilator assist|
9790498|NCT01389973|Experimental|Open-label: ustekinumab 90 mg|
9790499|NCT01389973|Experimental|Double-blind: ustekinumab 45 mg|
9790500|NCT01389973|Experimental|Double-blind: ustekinumab 90 mg|
9790501|NCT01389973|Experimental|Double-blind: ustekinumb 180 mg|
9790502|NCT01389973|Placebo Comparator|Double-blind: placebo|
9921991|NCT00833573||2|For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.
9838792|NCT03735628|Experimental|Dose expansion|"Copanlisib:~Recommended phase 2 dose established in the phase 1b part on Day 1, Day 8 and Day 15 (28 day cycle)~Nivolumab:~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
9985179|NCT03286010|No Intervention|Control|Participants in the control group will be eligible to participate in the study, but cannot participate because there are no groups within their geographical region. They will be offered the W@H program after their 26-week follow up.
9985180|NCT03279289|Experimental|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
9985181|NCT03279289|Active Comparator|Group B|FOLFIRI + aflibercept
9985182|NCT03276533|Experimental|Intravenous saline, dexmedetomidine and lidocaine|
9985183|NCT03276533|Experimental|Intravenous saline, dexmedetomidine, lidocaine and combination|
9985184|NCT03276533|Experimental|Intravenous saline,dexmedetomidine plus lidocaine|
9985185|NCT03276533|Experimental|Intravenous saline, dexmedetomidine combined with lidocaine|
10206328|NCT04608318|Experimental|VI (Venetoclax + Ibrutinib)|15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles
9838801|NCT03709732||Spinal cord injury|Persons with a spinal cord injury. No intervention
9838802|NCT03709732||Caregivers spinal cord injury|Caregivers for persons with a spinal cord injury. No intervention
9838803|NCT03709732||Controls for patients|Control group for patient cohort. No intervention
9838804|NCT03707340||Breast Cancer Pts with hyposexual desire disorder/HSDD|
9838805|NCT03707184|Experimental|Diagnostic (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 intravenously (IV) over 30 seconds and undergo PET/CT scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy.
9838806|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 20mg|Apremilast 20mg Twice Daily (BID)
9838807|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 30mg|Apremilast 30mg Twice Daily (BID)
9838808|NCT03701763|Placebo Comparator|Administration of Placebo|Placebo tablet Twice Daily (BID)
9838809|NCT03701516|Experimental|TEST/CONTROL|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Test/Control sequence.
10206329|NCT04606693|No Intervention|Patients with negative diagnosis of SAHS|Patients with low risk or negative diagnosis of SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit
10206330|NCT04606693|Other|Patients with positive diagnosis of SAHS|Patients with intermediate or high risk of SAHS and positive diagnosis
10206331|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 1|PF-07248144 Monotherapy Escalation
10206332|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 2|PF-07248144 Monotherapy Escalation
10206333|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 3|PF-07248144 Monotherapy Escalation
10206334|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 4|PF-07248144 Monotherapy Escalation
10206335|NCT04606446|Experimental|1B Combination Dose Finding Arm level 1|PF-07248144 with Fulvestrant Combination Dose Finding
10206336|NCT04606446|Experimental|1B Combination Dose Finding Arm Level 2|PF-07248144 with Fulvestrant Combination Dose Finding
10206337|NCT04606446|Experimental|1C Combination Dose Finding Arm Level 1|PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
10206338|NCT04606446|Experimental|1C Combination Dose FInding Arm Level 2|PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
9838810|NCT03701516|Experimental|CONTROL/TEST|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Control/Test sequence.
9838811|NCT03701165|Other|Snoring cohort.|Subjects will undergo two nights of polysomnography. The first night will be a baseline recording. The next night subjects will use the DryMouth Shield during the polysomnography.
9838812|NCT03696017||Group 1|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse opioids (40 patients per group).
9838813|NCT03696017||Group 2|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse benzodiazepines (BZD) (40 patients per group).
9838814|NCT03696017||Group 3|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse BZD/opioid (40 patients per group).
9838815|NCT03692052|Experimental|AG-348|Participants with alpha or beta thalassemia received AG-348 50 mg twice daily (BID), orally up to Week 6. Following Week 6, depending on the participants' safety and hemoglobin (Hb) concentrations, they could undergo one potential dose-level increase from 50 to 100 mg BID. After completion of the Core Period of 24 weeks, participants were eligible to continue to receive AG-348 in the Extension Period which is up to 10 years.
9838816|NCT03691129|Experimental|Yoga participant groups|Yoga participant groups will practice elderly yoga for four months. We will collect their blood before and after their participation in the elderly yoga program. There will be two subgroups which are Advanced group and Beginner group.
10206339|NCT04606446|Experimental|2A Monotherapy Dose Expansion Arm|PF-07248144 Monotherapy Dose Expansion
10206340|NCT04606446|Experimental|2B Combination Dose Expansion Arm|PF-07248144 with either Fulvestrant or Letrozole + Palbociclib Dose Expansion
10206341|NCT04606069|Experimental|Active Arm|Regadenoson will be given intravenously as 5 ug/kg loading dose (up to 400 mg/patient) over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
10206342|NCT04606069|Placebo Comparator|Control Arm|The same volume of saline will be given intravenously for 30 mins followed by a continuous infusion for 6 hours.
10206343|NCT04603846|Experimental|Combined treatment group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
10206344|NCT04603742|Experimental|Anakinra IV|Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
10206345|NCT04603742|Placebo Comparator|Normal Saline IV|Patients in the placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
9985186|NCT03271190|Experimental|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills and application in selected leisure activities (music or Spanish lessons, and videogames) over 4 months.
9985187|NCT03271190|Active Comparator|ENGAGE DISCOVERY|Educational program about brain and healthy aging complemented by learning of new information with videogames, documentaries and group discussions over 4 months.
9790503|NCT01390038|Experimental|Simpliciti™ Shoulder System|The Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.
9790504|NCT01390064|Experimental|Initial Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
9790505|NCT01390064|Active Comparator|Escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
9790506|NCT01390064|Active Comparator|De-escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms
9790507|NCT01390077|Experimental|Nitisinone|all subjects will receive open-label nitisinone
9790508|NCT01390220|Experimental|USL261|intranasal midazolam 5mg
9790509|NCT01390220|Experimental|Placebo|Intranasal placebo
9790510|NCT01390233|Active Comparator|Urinary Balloon Catheter Only|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
9790511|NCT01390233|Active Comparator|Prepadil Only|Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
9790512|NCT01390233|Experimental|Combined Urinary Catheter & Prepidil Gel|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. Prepidil gel will be inserted through the catheter into the lower uterine segment, in a dose equivalent to manufacturer's recommendation. No oxytocin or other intervention will commence until 6 hours after insertion of the catheter and administration of prepidil gel (even if catheter is spontaneously expelled). After 6 hours, digital exam will be performed and Bishop score recorded. If no active labor, standardized protocol of oxytocin will commence.
9790513|NCT01390246|Active Comparator|Bupropion SR + cessation counseling|"Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose Bupropion SR 150 mg tablet orally BID for a total medication treatment of 12 full weeks.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
9799547|NCT01662778|Active Comparator|Monodisperse FP 1.5um|50 mg of monodisperse Fluticasone Propionate delivered as 1.5 microns aerosol followed by AMP PC20 challenge test
9985188|NCT03262935|Experimental|(vic-)trastuzumab duocarmazine|SYD985, every 3 weeks (Q3W)
9985189|NCT03262935|Active Comparator|Physician's choice|"Lap/Cap~T/Cap~T/Vino~T/Eri"
9996821|NCT01503502|Experimental|flumatinib 600 mg qd|
9996822|NCT01503502|Active Comparator|imatinib|
9790514|NCT01390246|Placebo Comparator|Placebo + cessation counseling|"Placebo and smoking cessation counseling Subjects received matching Bupropion SR placebo tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (matched placebo tablets orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose matching Bupropion SR placebo tablet orally BID for a total medication treatment of 12 full weeks of therapy.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
9790515|NCT01390259|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
9790516|NCT01390259|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
9790517|NCT01390272|Experimental|Titration Intervention|"The intervention arm includes three levels of resource intensity targeted to improve patients' systolic blood pressure (SBP) [top number of blood pressure measurement].~Medium/level 1 resource intensity: a registered nurse (RN) will provide monthly tailored behavioral support telephone calls + home BP monitoring.~High/level 2 resource intensity: a pharmacist will provide monthly tailored behavioral support telephone calls + home BP monitoring + pharmacist-directed medication management.~Booster (low) resource intensity: a licensed practical nurse (LPN) will provide non-tailored behavioral support telephone calls every two months to patients whose SBP comes under control."
9790518|NCT01390272|Active Comparator|LPN Control|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months (identical to booster (low) resource intensity component of the titrated intervention). The control arm will utilize the same procedures as the booster level for intervention patients for whom SBP comes under control.
9790519|NCT01390298||Observational|Adult patients scheduled for elective unicompartmental or total knee replacement surgery or total hip replacement will be consented to participate
9790520|NCT01390389|Experimental|CoQ10|"Subjects who meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed are assigned to this arm and administered the Coenzyme Q10 intervention. CoQ10 dosing guidelines:~Visit 1 (Baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of Baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
9790521|NCT01390389|No Intervention|Control|Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
9790522|NCT01390402|Experimental|NK Infusion + Chemotherapy|Fludarabine 40 mg/m2 intravenous (IV) daily for 4 days, immediately followed by Busulfan 130 mg/ m2 IV every 24 hours and NK cell infusion IV.
9790523|NCT01390428|Experimental|Part 1-Mild Hepatic Impairment (HI)|Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
9790524|NCT01390428|Experimental|Part 1-Healthy Matched to Mild HI|Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
9790525|NCT01390428|Experimental|Part 2-Moderate HI|Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
9790526|NCT01390428|Experimental|Part 2-Healthy Matched to Moderate HI|Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
9790527|NCT01390428|Experimental|Part 3-Severe HI|Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
9790528|NCT01390428|Experimental|Part 3-Healthy Matched to Severe HI|Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
9790529|NCT01390441|Experimental|Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MK-8808 (500 mg/m^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
9790530|NCT01390441|Active Comparator|Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MabThera® (500 mg/m^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
9790531|NCT01390441|Experimental|Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
9799548|NCT01662778|Active Comparator|Monodisperse FP 6.0um|50 mg of monodisperse Fluticasone Propionate delivered as 6.0 microns aerosol followed by AMP PC20 challenge test
9799549|NCT01662778|Placebo Comparator|Placebo STAG|No active drug, just solvent delivered from STAG followed by AMP PC20 challenge test
9799550|NCT01662778|Active Comparator|MDI FP|Fluticasone Propionate , Metered dose inhaler, 250 mg dose followed by AMP PC20 challenge test
9985190|NCT03258996|Experimental|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
10206346|NCT04601779|Other|Cluster I|Cluster I is randomized to start the VIPP-PUF intervention phase January 1, 2022
10206347|NCT04601779|Other|Cluster II|Cluster II is randomized to start the VIPP-PUF intervention phase May 1, 2022
10206348|NCT04601779|Other|Cluster III|Cluster IiI is randomized to start the VIPP-PUF intervention phase September 1, 2022
10206349|NCT04599218|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as an ultrasound guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy.
10206350|NCT04599101|Other|Nasal suction devices: Nose Frida and Bulb|Nose Frida nasal suction device and bulb syringe suction device to clear nasal secretions
10206351|NCT04594980|Other|Minimally invasive TLIF|Patients will undergo a single level decompression and fusion using a minimally invasive technique. Followed posterior screw fixation is mandatory.
10206352|NCT04594980|Other|Open TLIF|Patients will undergo a single level decompression and fusion using an open traditional technique. Followed posterior screw fixation is mandatory.
10206353|NCT04591353|Experimental|"Investigational group (PENG Block group)"|Participants in the pericapsular nerve group block (PENG) arm will receive a PENG block preoperatively in the block area placed under direct ultrasound guidance as follows: Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area Anatomical landmarks identified using ultrasound and skin will be numbed using 2-3 cc of 2% lidocaine. Long acting local anesthetic, a bolus of 25 cc of 0.5 % Bupivacaine will be injected lateral to iliopubic eminence (IPE). A Curvilinear low frequency (2-5 MHz) ultrasound probe will be used to identify landmarks. A 22 G, 10 cm needle will be inserted using in-plane technique and advanced to target site (17).
10206354|NCT04591353|Active Comparator|Control group|"Control group participants will be transferred to the block area preoperatively, and care will proceed as if they were receiving injection.~Patients will be placed in the supine position resting comfortably. Standard noninvasive monitors will be applied, and oxygen will be administered via nasal cannula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area. The ultrasound probe will be used to identify the iliopubic eminence (IPE). Only skin will be numbed using 2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected."
10206355|NCT04590833|Experimental|Aerobic exercise group|
10206356|NCT04590833|Placebo Comparator|Attention control group|
10206357|NCT04590300|Other|Schizophrenia|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
10206358|NCT04590300|Other|Bipolar disorder|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
10206359|NCT04587622|Experimental|Group 1 - Healthy subjects with normal hepatic function|Healthy subjects with normal hepatic function - Control
10206360|NCT04587622|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment: Child-Pugh A (Score 5-6)
10206361|NCT04587622|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment: Child-Pugh B (Score 7-9)
10206362|NCT04587622|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment: Child-Pugh C (Score 10-15)
10206363|NCT04581395|Other|Not pretreated|Succinylcholine administration with no Rocuronium pre-treatment
10206364|NCT04581395|Active Comparator|Pre-treated 1 minute before succinylcholine administration|Succinylcholine administration 1 minute following Rocuronium pre-treatment
10206365|NCT04581395|Active Comparator|Pre-treated 2 minutes before succinylcholine administratjion|Succinylcholine administratjion 2 minutes following Rocuronium pre-treatment
10206366|NCT04579900|Experimental|Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
10206367|NCT04579900|Active Comparator|Non Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
9790532|NCT01390441|Active Comparator|Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
9790533|NCT01390441|Experimental|Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
9790534|NCT01390584|Experimental|ABVD + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.~ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks."
9790535|NCT01390584|Experimental|ABVD + BEACOPP + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.~BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks."
9790536|NCT01390649|Experimental|IgPro10|
9790537|NCT01390779|Experimental|SENSIMED Triggerfish|All subjects enrolled in the trial were housed in a sleep laboratory for 24 hours, during which they underwent SENSIMED Triggerfish recording on one randomly selected eye.
9790538|NCT01390818|Experimental|MSC1936369B and SAR245409 once daily|
9790539|NCT01390818|Experimental|MSC1936369B and SAR245409 twice daily|
9790540|NCT01390844|Experimental|Boceprevir|PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
9790541|NCT01390844|Active Comparator|Control|PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.
9790542|NCT01390857||Pediatric patients prescribed valaciclovir|Pediatric patients with chickenpox prescribed valaciclovir during study period.
9790543|NCT01390870||Patient Survey|Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
9790544|NCT01390909||Medicaid patients with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
10206368|NCT04578106|Experimental|Omission of surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Adjuvant period: If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB,patients will be eligible to omit loco-regional surgery. Whole breast radiotherapy without nodal radiotherapy will then be performed. Trastuzumab and pertuzumab FDC will be continued to complete 1 year of treatment and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
10206369|NCT04578106|No Intervention|Surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Surgery: If invasive tumor cells and/or in situ disease are identified, patients will undergo surgery. Adjuvant period: All patients will continue with Trastuzumab-emtansine (T-DM1) completing 1 year of treatment (14 cycles) and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
9838817|NCT03691129|No Intervention|Non-Yoga participant groups|Non-Yoga participant groups will not practice yoga for four months and will be used as the control. We will collect their blood before and after the elderly yoga program. There will be two subgroups which are Elderly group and Young group.
9985191|NCT03258996|Active Comparator|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
9790545|NCT01390909||Medicaid patients with well-controlled epilepsy|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
9790546|NCT01390909||Medicaid patients with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
9985192|NCT03254394|Placebo Comparator|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
10206370|NCT04576949|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
10206371|NCT04576949|Experimental|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
10206372|NCT04576949|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
10206373|NCT04573140|Experimental|Phase I adult (Stratum 1)|A maximum of 28 adult patients will be enrolled in dose-escalation study using the BOIN design with an initial embedded accelerated titration design (ATD).
9838824|NCT03684694|Experimental|Phase 1: Dose-Escalation of ADCT-402|A standard 3+3 dose escalation design will be used. The dose-limiting toxicity (DLT) period will be the 21 days following the first dose of ibrutinib. The dose escalation cohort will receive loncastuximab tesirine for Cycle 1 and 2 (3 weeks each) with concurrent ibrutinib (concomitant therapy) daily. Participants may continue to receive treatment up to 1 year after Cycle 1 Day 1 (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a frozen liquid.
9838825|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in Non-GCB DLBCL|Participants with non-germinal center B-cell diffuse large B-cell lymphoma (Non-GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
9838826|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in GCB DLBCL|Participants with germinal center B-cell diffuse large B-cell lymphoma (GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
9838827|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in MCL|Participants with mantle cell lymphoma (MCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
9838828|NCT03679468|Sham Comparator|Cognitive Rehab & Sham Exercise|Cognitive Rehabilitation by computer based brain tasks, and Sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
9838829|NCT03679468|Sham Comparator|Sham Cognitive Rehab & Sham Exercise|Sham cognitive Rehabilitation will consist of basic internet searches and learning to use a computer, and sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
9838830|NCT03679468|Sham Comparator|Sham Cognitive rehab & Aerobic Exercise|Sham cognitive rehabilitation will consist of basic internet searches and learning to use a computer, and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
9838831|NCT03679468|Active Comparator|Cognitive Rehab & Aerobic Exercise|Cognitive Rehabilitation by computer based brain tasks and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
9838832|NCT03679260|Experimental|Arm A|Carbohydrate restricted diet and phone counseling with dietitian. After 6 months, patients will crossover to a non-restricted diet.
9838833|NCT03679260|Experimental|Arm B|Non-restricted diet and after 6 months, patients will crossover to a carbohydrate restricted diet and phone counseling with dietitian
10206374|NCT04570657|Experimental|MEDI3506 Dose 1|Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
9838834|NCT03675152|Experimental|Soft spinal brace|Soft spinal brace used 23 hours a day for 4 months.
9790547|NCT01390909||Patients in a private health plan with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
9790548|NCT01390909||Patients in a private health plan with well-controlled epileps|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
9838835|NCT03675152|Active Comparator|thoracolumbar orthosis|Thoracolumbar orthosis used 23 hours a day for 4 months.
9838836|NCT03674593|Experimental|Mitral valve chordae prosthesis|"Patients of this group receive mitral valve chordae replacement performed in five stages:~Measure the required length of the chordae.~Forming loops.~Fixation of the loop group to the papillary muscles.~Fixation of chordal loops to the free edge of the valve.~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse."
9838837|NCT03674593|Active Comparator|Mitral valve chordae translocation|"The technique of translocation of secondary chordae:~The method consists essentially of three stages:~Selection of the secondary chordae.~Fixation of secondary chordae to the free edge of the valve.~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
9985193|NCT03254394|Active Comparator|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
9985194|NCT03253809|Experimental|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.~ECG signals will be saved digitally for analysis"
9838840|NCT03658096|Active Comparator|Healthy volunteer|
9838841|NCT03658096|Active Comparator|DRUJ instability patients|
9838842|NCT03658083||Thoracotomy|Individuals referred for a lung resection via thoracotomy with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
9838843|NCT03658083||Robotic-assisted thoracic surgery|Individuals referred for a lung resection via robotic-assisted thoracic surgery with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
9838844|NCT03654742|Active Comparator|ECTE/Electrosurgery|Extracapsular tonsillectomy (ECTE) with monopolar electrosurgery
9838845|NCT03654742|Experimental|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
9838846|NCT03654742|Experimental|ICTE/Coblator|Intrapsular tonsillectomy (ICTE) with coblator
9838847|NCT03652051|Experimental|AZR-MD-001 Low Dose|AZR-MD-001 Low Dose will be dosed up to once daily.
9838848|NCT03652051|Experimental|AZR-MD-001 Mid Dose|AZR-MD-001 Mid Dose will be dosed up to once daily.
9838849|NCT03652051|Experimental|AZR-MD-001 High Dose|AZR-MD-001 High Dose will be dosed up to once daily.
9838850|NCT03652051|Sham Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
9838851|NCT03650556|Experimental|Ablation|Enrolled subjects who had the investigational catheter inserted into their vasculature for pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE).
9985195|NCT03252314||Subjects with ruptured aneurysms|
9985196|NCT03247205|Experimental|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
10206375|NCT04570657|Experimental|MEDI3506 Dose 2|Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
10206376|NCT04570657|Placebo Comparator|Placebo|Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
10206377|NCT04570384|Active Comparator|IV L-Citrulline (Turnobi) Arm|Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
9838857|NCT03639311|Experimental|Participants receiving Injection CAB LA plus RPV LA|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections will be administered 1 month after initial loading dose (CAB LA 600 mg plus RPV LA 900 mg), with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available. HAART therapy will be initiated within 8 weeks after the last Q2M injection.
9838858|NCT03639311|Experimental|Participants receiving Oral DTG plus RPV|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose of the DTG 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available.
9838859|NCT03639194|Experimental|Part A: ABBV-011 Dose Escalation|ABBV-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared.
9838860|NCT03639194|Experimental|Part B: ABBV-011 Dose Expansion|ABBV-011 via intravenous administration at dose regimen(s) that will not exceed the maximum tolerated dose determined in Part A.
9838861|NCT03639194|Experimental|Part C: ABBV-011 + Budigalimab Escalation and Expansion|ABBV-011 via intravenous administration at various doses and dosing regimens starting at least 1 dose level below the recommended single-agent dose of ABBV-011 for Part B plus Budigalimab via intravenous administration at fixed doses and various dosing regimens.
9838862|NCT03639194|Experimental|Part D: ABBV-011 Dose Evaluation for Japan|ABBV-011 via intravenous administration will be administered every 3 weeks (Q3wk), on Day 1 of each 21-day cycle or alternate dosing regimens.
9838863|NCT03628716|Experimental|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
9838864|NCT03625921|Experimental|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
9838865|NCT03625921|Active Comparator|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
9790549|NCT01390909||Patients in a private health plan with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
9790550|NCT01390948|Experimental|Bevacizumab + TMZ Young Patient Cohort (YPC)|Participants aged greater than or equal to (>/=) 6 months and less than (<) 3 years will receive 10 milligrams per kilogram (mg/kg) Bevacizumab every 2 weeks and 150 to 200 milligrams per meter squared (mg/m^2) of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
9790551|NCT01390948|Experimental|Main Cohort: Chemoradiation + Bevacizumab + TMZ|Participants will receive a total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle. Bevacizumab will be given concomitantly at a dose of 10 mg/kg every 2 weeks throughout the entire treatment period.
9790552|NCT01390948|Active Comparator|Main Cohort: Chemoradiation + TMZ|Participants will receive a total dose of 54 Gy units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
9790553|NCT01391000|Experimental|Laser CO2|
9790554|NCT01391000|Active Comparator|TENS|
9790555|NCT01391013|Experimental|Monotherapy|Monotherapy: darunavir/ritonavir (DRV/r) will be administered for 48 weeks.
9790556|NCT01391013|Experimental|Combination therapy|DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
9790557|NCT01391130|Experimental|LY2510924 + Sunitinib|LY2510924: 20 milligram administered subcutaneously once daily, given every day of the 6 week cycle. Sunitinib: 50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
9790558|NCT01391130|Active Comparator|Sunitinib|50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
9790559|NCT01391273|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
9790560|NCT01391273|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
9790561|NCT01391286|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
9790562|NCT01391286|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
9790563|NCT01391299|Active Comparator|botulinum toxin Type A (40 Units)|Botulinum toxin Type A 40 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
9790564|NCT01391299|Active Comparator|botulinum toxin Type A (30 Units)|Botulinum toxin Type A 30 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
9790565|NCT01391299|Placebo Comparator|placebo (Normal saline)|Placebo (Normal saline) injected into bilateral forehead and frown line areas on Day 1.
9790566|NCT01391312|Active Comparator|botulinum toxin Type A|Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
9790567|NCT01391312|Placebo Comparator|placebo (Normal Saline)|Normal Saline (placebo) injected into the glabellar region on Day 0.
9790568|NCT01391325|Other|Allopurinol|Treatment.
9790569|NCT01391364|Experimental|SofLens in investigational solution|Bausch + Lomb SofLens daily disposable contact lens packaged in an investigational storage solution.
9790570|NCT01391364|Active Comparator|SofLens in currently marketed solution|SofLens daily disposable contact lens packaged in currently marketed storage solution.
9790571|NCT01391468|Placebo Comparator|Placebo|cornstarch
9790572|NCT01391468|Experimental|Probiotics|probiotics
9790573|NCT01391507|Placebo Comparator|Placebo|
9790574|NCT01391507|Experimental|20 mg COR-1|
9790575|NCT01391507|Experimental|80 mg COR-1|
9790576|NCT01391507|Experimental|160 mg COR-1|
9790577|NCT01391546|Experimental|ZOSTAVAX intramuscular (IM) route|Single dose of 0.65 mL via IM injection
9790578|NCT01391546|Active Comparator|ZOSTAVAX subcutaneous (SC) route|Single dose of 0.65 mL via SC injection
9790579|NCT01391559|Experimental|arformoterol|beta-2 agonist bronchodilator
9790580|NCT01391559|Active Comparator|salmeterol|beta-2 agonist bronchodilator
9790581|NCT01391611|Experimental|Pazopanib arm|
9790582|NCT01391663|Experimental|Alogliptin 12.5 mg QD|
9790583|NCT01391663|Experimental|Alogliptin 25 mg QD|
9790584|NCT01391663|Experimental|Alogliptin 50 mg QD|
9790585|NCT01391793|Active Comparator|Adjuvant dexamethasone|
9790586|NCT01391793|Placebo Comparator|Placebo|
9790587|NCT01391819|Other|Study cohort|Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.
9790588|NCT01391832|Sham Comparator|Sham rTMS|Sham Treatment Intervention: Device: Repetitive Transcranial Magnet Stimulation (sham treatment)
9790589|NCT01391832|Active Comparator|active rTMS|"Active Repetitive Transcranial Magnet Stimulation treatment~Intervention: Device: Active rTMS of dorsolateral pre-frontal cortex"
9790590|NCT01391858|Active Comparator|pregabalin|pregabalin (lyrica)
9790591|NCT01391858|Placebo Comparator|placebo|placebo
9790592|NCT01392053|No Intervention|Control group|Control Group (CG) that will receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group
9790593|NCT01392053|Experimental|Massage Group|Massage Group (GM):receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation
9790594|NCT01392183|Experimental|Pazopanib|Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
9790595|NCT01392183|Experimental|Temsirolimus|Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
9790596|NCT01392300|Experimental|DB IncobotulinumtoxinA (Xeomin) (400 U)|IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
9790597|NCT01392300|Placebo Comparator|DB Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
9790598|NCT01392326|Experimental|Group 1|Secukinumab (75mg)
9790599|NCT01392326|Experimental|Group 2|Secukinumab (150 mg)
9790600|NCT01392326|Placebo Comparator|Group 3|
9790601|NCT01392378|Experimental|Group 1|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
9790602|NCT01392378|Experimental|Group 2|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
9790603|NCT01392378|Experimental|Group 3|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
9790604|NCT01392378|Experimental|Group 4|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
9790605|NCT01392378|Experimental|Group 5|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
9790606|NCT01392443|Experimental|Ruxolitinib|Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count >200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.
9790607|NCT01392469|Experimental|Imatinib + Bosentan + Sildenafil|Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.
9790608|NCT01392495|Experimental|QTI571|Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
9790609|NCT01392547|Experimental|rFVIIa|
9790610|NCT01392547|Experimental|vatreptocog alfa|
9790611|NCT01392560|Experimental|BI 10773|Oral once daily
9790612|NCT01392573|Experimental|IDegLira + metformin|IDegLira was injected subcutaneously once daily for 26 weeks.
9790613|NCT01392573|Experimental|IDeg + metformin|IDeg was injected subcutaneously once daily for 26 weeks.
9790614|NCT01392625|Active Comparator|Autologous hMSCs|Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
9790615|NCT01392625|Active Comparator|Allogeneic hMSCs|Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
9790616|NCT01392677|Experimental|Dapagliflozin 10 mg tablet|
9790617|NCT01392677|Placebo Comparator|matching placebo tablet|
9790618|NCT01392703|Other|Dasatinib, 100 mg as tablets + water|Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
9790619|NCT01392703|Other|Dasatinib, 100 mg as liquid + water|Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
10206378|NCT04570384|Placebo Comparator|Placebo Arm|Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
10206379|NCT04568902|Experimental|Dose Escalation Part: H3B-6545 300 mg|Participants will receive H3B-6545 300 milligram (mg) tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
9790620|NCT01392703|Other|Dasatinib, 100 mg as tablets in orange juice + water|Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
9790621|NCT01392742||Cohort|
9790622|NCT01392859|Experimental|Initial Treatment: Levocetirizine(LCT)|Group 1 will begin with active Levocetirizine(LCT) 0.5 mg/ml oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and placebo will be provided for 5-8 days.
9790623|NCT01392859|Experimental|Initial Treatment: Placebo|Group 2 will begin with placebo oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and active Levocetirizine(LCT) 0.5 mg/ml will be provided for 5-8 days.
9790624|NCT01392963|Experimental|Botox, Then Placebo|At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
9790625|NCT01392963|Experimental|Placebo, Then Botox|At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).
9790626|NCT01392989|Experimental|Allogeneic Cytokine-induced Killer Cells (CIK)|Target dose of ≥ 5 x 10e6 CD34+ cells/kg of recipient body weight plus an additional 2 x10e9 mononuclear cells.
9790627|NCT01393106|Experimental|Idelalisib|Participants will receive up to 300 mg of idelalisib twice daily.
9790628|NCT01393132|Experimental|Thymosin Beta 4 eye drops|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
9790629|NCT01393132|Placebo Comparator|Vehicle Control|It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.
9790630|NCT01393158|Experimental|20 mg BID|Patients dosed with 20 mg orally of Apremilast BID for 3 months.
9790631|NCT01393158|Experimental|30 mg BID|Patients dosed with 30 mg orally of Apremilast BID for 6 months.
9790632|NCT01393301|Experimental|Behavioral Intervention Arm|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
9790633|NCT01393301|Other|Control Arm|Enhanced Treatment as Usual (ETAU); enhanced standard smoking cessation treatment and nicotine replacement therapy (NRT).
9799551|NCT01662791|Experimental|Case Group|All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day (BID) for 14 days. Subjects in the case group were in the study for 3 months.
9799552|NCT01662791|No Intervention|Control Group|This arm consisted of subjects with Parkinson's Disease who had not experienced significant weight loss. These patients were in the study for one day.
9799553|NCT01662856|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
9799554|NCT01662856|Active Comparator|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
9799555|NCT01662882|Experimental|AD Subjects|
9799556|NCT01662882|Experimental|MCI|MCI (mild cognitive impairment)
10206380|NCT04568902|Experimental|Dose Escalation Part: H3B-6545 450 mg|Participants will receive H3B-6545 450 mg tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
9799557|NCT01662882|Experimental|Healthy Controls|
9799558|NCT01662895|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
9799559|NCT01662895|Placebo Comparator|Normal Saline|0.9% sodium chloride
9799560|NCT01662908|Experimental|edoxaban tosylate|
9799561|NCT01662908|Active Comparator|heparin/warfarin|
9799562|NCT01662960|Experimental|Mirror therapy|4 weeks of home-based mirror therapy. Participants practiced making movements with mirrored visual feedback of the low-functioning arm.
9799563|NCT01662960|Active Comparator|Divider therapy|4 weeks of home-based divider therapy (control therapy to mirror therapy; mirror replaced by a divider). Participants practiced making movements with no visual feedback of the low-functioning arm.
9799564|NCT01662986|Active Comparator|18 mcg tiotropium bromide|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
9985197|NCT03246932|Experimental|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
9985198|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
9790634|NCT01393392|Experimental|Intensive, tailored intervention|Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
9790635|NCT01393392|Active Comparator|Control Intervention|Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
9790636|NCT01393405|Active Comparator|Methotrexate|25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
9790637|NCT01393405|Placebo Comparator|Placebo|Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
9790638|NCT01393444|Experimental|Direct Brain Interface Users|"All participants enrolled in the study will undergo Implantation of ECoG sensors on the brain surface to record neural activity. There is no control group. There are no other arms."
9790639|NCT01393457|Active Comparator|ldopa + ropinirole low dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d
9790640|NCT01393457|Active Comparator|ldopa + ropinirole high dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d
9790641|NCT01393457|Active Comparator|ldopa|levodopa/carbidopa 800/200 mg/d
9790642|NCT01393457|Placebo Comparator|placebo|Placebo
9790643|NCT01393600|Experimental|NBI-98854 12.5 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.~Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
9790644|NCT01393600|Experimental|NBI-98854 50 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.~Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
9790645|NCT01393613|Experimental|Dose 3 OPC 34712|Higher dose, tablet, once daily, for six weeks
9790646|NCT01393613|Experimental|Dose 2 OPC 34712|Middle dose, tablet, once daily, for six weeks
9790647|NCT01393613|Experimental|Dose 1 OPC 34712|Lower dose, tablet, once daily, for six weeks
9790648|NCT01393613|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
9790649|NCT01393626|Placebo Comparator|Placebo BID|
9790650|NCT01393626|Experimental|5mg BID|
9790651|NCT01393626|Experimental|10mg BID|
9790652|NCT01393704|Active Comparator|High Volume Dilute Vasopressin|20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
9985199|NCT03246932|Active Comparator|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
9985200|NCT03244163|Experimental|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
9985201|NCT03244163|Active Comparator|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
9985202|NCT03242174||Traditional Obstetrical Prenatal Care|Pregnant women receiving traditional obstetrical prenatal care and delivering in a hospital will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
9985203|NCT03242174||Prenatal Care from Midwife|Pregnant women receiving prenatal care from a midwife and delivering at the birth center will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
9985204|NCT03230318|Experimental|derazantinib|Oral administration
9985205|NCT03228563|Experimental|Probiotics|Taking two capsules of probiotics twice daily for 12 months.
9790653|NCT01393704|Active Comparator|Low volume dilute vasopressin|20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
9799565|NCT01662986|Placebo Comparator|placebo|Patient to receive one placebo inhalation powder capsule daily (in the morning) via HandiHaler
9838866|NCT03621735|Other|Sham then Active|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
9838867|NCT03621735|Other|Active then Sham|"Active: Bimodal auditory-somatosensory stimulation~Sham: Sham Bimodal auditory-somatosensory stimulation~Subjects receive both an active treatment and a sham treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
9838868|NCT03619213|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
9838869|NCT03619213|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
9838870|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
9838871|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
9838872|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
9838873|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
9838874|NCT03611738|Experimental|Phase I Dose Escalation|"The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg, 300 mg, and 450 mg), plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore, four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).~Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m^2 docetaxel"
9838875|NCT03611738|Experimental|Phase Ib Dose Expansion|Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.
9985206|NCT03228563|No Intervention|Healthy control|Healthy volunteers were: no hypertension (Blood pressure<140/90mmHg), no diabetes (Glucose AC 70~100mg/dl), no hyperlipidemia (Cholesterol Total 130~200mg/dL、Triglyceride<150mg/dL), no urinary protein (-) and normal renal function (eGFR>90), after signing the consent form, the stool samples will be collected.
9985207|NCT03227081|No Intervention|Sleep|Sleep
10206381|NCT04568902|Experimental|Antihistamine Prophylactic Administration Part|Participants will receive prophylactic treatment with non-sedating systemic antihistamine, orally, once from Cycle 1 Day 1 until Cycle 1 Day 28, followed by H3B-6545 450 mg tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
10206382|NCT04568902|Experimental|Randomization Part|Participants will be randomized in 1:1 ratio to receive H3B-6545 450 mg, tablets, orally, once daily in 28 days cycle either with non-sedating systemic antihistamine prophylactic administration from Day 1 until Day 28 of Cycle 1 OR without antihistamine prophylactic administration until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
10206383|NCT04567719||Changes in Taste Perception After Exposure to Chemotherapy|A total of 20 participants with histologically-proven MIBC planning to receive pre-surgery chemotherapy followed by radical cystectomy will be recruited.
10206384|NCT04566692|Experimental|Treatment-experienced Cohort|Treatment-experienced participants will receive IGSC 20% at 2 different dosing frequencies using a subcutaneous (SC) infusion pump during 2 treatment periods (16 weeks per treatment period). In treatment period 1, treatment-experienced participants will receive 16 weekly IGSC 20% doses from Week 0 to Week 15. For participants entering study on intravenous immune globulin (IVIG), IGSC 20% will be dosed at 1.37 times the equivalent weekly dose and participants entering on subcutaneous immunoglobulin (SCIG) will receive the same milligram/kilogram (mg/kg) equivalent weekly dose as given prior to entry, without using a dose adjustment factor (DAF). In treatment period 2, treatment-experienced participants will receive biweekly IGSC 20 % (i.e, IGSC 20% every 2 weeks) for a total of 9 doses, with the first IGSC 20% dose administered at Week 16 and the final dose given at Week 32.
9985208|NCT03227081|Experimental|Sleep Deprivation|Sleep Deprivation
9985209|NCT03219827|Experimental|Patients allergic to wasp venom|"Patient with major allergic reaction to wasp venom.~Blood samples collection at visit 1, at visit 2 (4 weeks after visit 1), at visit 3 (one year after treatment onset)~After visit 1, an allergen-specific immunotherapy will be conducted as part of the classical patient care program."
9985210|NCT03219827|Experimental|Patients allergic to penicillin|"Patient with major allergic reaction to penicillin.~- Blood samples collection at visit 1 and at visit 2 (4 weeks after visit 1= end of study, none treatment will be evaluated in this arm)"
9985211|NCT03215940|Active Comparator|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
9985212|NCT03215940|Active Comparator|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
9985213|NCT03215940|Placebo Comparator|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
9838888|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza®|"Group A:~4 grams Lovaza®, 2 grams twice a day (BID). 2 grams by mouth daily, AM and PM 8,000 mgs CUR Curcumin C3 complex® tablets, divided into 2 doses. 4 grams by mouth, twice a day, AM and PM."
9838889|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza® +Placebo|"Group B:~2 grams Lovaza®, 1 gram twice a day, AM and PM. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs twice a day, AM and PM.~1 placebo capsule twice a day, AM and PM."
9838890|NCT03598309|Active Comparator|Placebo only|Placebo: Two matching placebo capsules twice a day (BID), taken by mouth, AM and PM
9790654|NCT01393717|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses. Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
9790655|NCT01393730|Experimental|Abiraterone+prednisone+dutasteride|Abiraterone acetate 1000mg orally once per day + prednisone 5mg orally once per day for two months, followed by abiraterone 1000mg orally once per day + prednisone 5mg orally once per day + dutasteride 3.5mg orally once per day in 28-day cycles until symptomatic or radiographic progression
9790656|NCT01393743|Experimental|Perampanel|Participants received 6 tablets (initially 1 tablet of 2-mg perampanel plus 5 tablets of perampanel matched placebo) and up-titrated weekly in 2-mg increments to a target dose range of 8 mg per day maintaining the blind with administration of 6 tablets per day of either perampanel/placebo.
9790657|NCT01393743|Placebo Comparator|Placebo|Participants received 6 tablets of perampanel matched placebo, once a day.
9790658|NCT01393821|Experimental|Arm I (lotion)|Patients apply menadione topical lotion BID for 28 days.
9790659|NCT01393821|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo lotion BID for 28 days.
9790660|NCT01393899|Placebo Comparator|Placebo BID|
9790661|NCT01393899|Experimental|5mg BID|
9790662|NCT01393899|Experimental|10mg BID|
9790663|NCT01393964|Experimental|Arm 1: Lenalidomide + Dexamethasone +Elotuzumab|Severe Renal Impairment
9790664|NCT01393964|Experimental|Arm 2: Lenalidomide + Dexamethasone +Elotuzumab|End-stage renal disease
9790665|NCT01393964|Experimental|Arm 3: Lenalidomide + Dexamethasone +Elotuzumab|Normal renal function
9790666|NCT01393990|Experimental|LY2228820|"The study had 4 parts, dose-escalation (Part A), 2 dose-confirmation (Parts B and C), and a tumor-specific expansion for metastatic breast cancer (Part D).~Part A: Participants received escalating doses of 10, 20, 40, 65, 90, 120, 160, 200, 300, 420 and 560 milligrams (mg) of LY2228820 every 12 hours on Days 1 through 14 of a 28-day cycle.~Part B: Participants received 420 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle. Participants received midazolam orally 2 days before the first dose and again after the morning dose of study drug on Day 8 during the first cycle of treatment.~Part C: Participants received 300 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle.~Part D: Participants received 200 mg and 300 mg of LY2228820 in combination with tamoxifen."
9790667|NCT01394003|Experimental|LY2584702|"Oral dose escalation starting at 25 milligrams (mg), daily for 28 day cycles in Part A; oral dose escalation starting at 50 mg, twice daily for 28 day cycles in Part B; oral dose with schedule determined by Parts A and B will be administered in Part C (dose confirmation).~Part A: Participants received 25 mg, 50 mg, 100 mg and 200 mg once daily (QD) and 300 mg twice daily (BID) of LY2584702 capsule, for a 28-day cycle during Part A of the study until the criteria for maximum tolerated dose (MTD) were met.~Part B: Participants received 50 mg, 75 mg and 100 mg LY2584702 orally as a capsule, twice daily (BID) for a 28-day cycle during Part B of the study until the criteria for maximum tolerated dose (MTD) were met."
9790668|NCT01394081|Experimental|Enhanced Engagement and Enrollment (EEE)|Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
9790669|NCT01394081|Active Comparator|Administrative Outreach (AO)|Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).
9790670|NCT01394159|Active Comparator|22G ProCore biopsy needle|Using the 22G ProCore needle for sampling pancreatic mass lesions, the tissue obtained will be compared to the standard FNA needle.
9790671|NCT01394159|Active Comparator|22G standard FNA needle|Using the 22G standard fine needle aspiration needle (FNA) for sampling pancreatic mass lesions, the tissue obtained will be compared to the 22 G ProCore needle.
9790672|NCT01394185|Active Comparator|Low Dose Dronabinol, High Dose Dronabinol, and placebo|Participants were administered dronabinol (0 mg/day, 120mg/day and 240mg/day) for 12 days each in a random order
9790673|NCT01394250|Experimental|Buzzy|If randomized to Buzzy®, the nurse will demonstrate the cold pack and the device just prior to the IV cannulation procedure. The device will be applied with a Velcro strap 5 centimeters proximal to the site of IV cannulation; it will remain in place until the IV cannula is inserted and secured. All nurses that work during the study hours will be trained on the device prior to beginning the study. Training includes direct one-one training with the device including return demonstration.
9790674|NCT01394250|Active Comparator|Topical Lidocaine 4% Cream|If randomized to topical lidocaine cream, subjects will have the cream placed on two or more potential IV sites as soon as possible after the consent procedure is complete. These subjects will undergo IV placement no less than 30 minutes after the cream is applied.
9790675|NCT01394276||Tocilizumab|Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra [Tocilizumab (TCZ)] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
9790676|NCT01394510|Experimental|N-acetylcysteine dose study|Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
9790677|NCT01394523|Active Comparator|Caudal epidural|The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.
9790678|NCT01394523|Active Comparator|Rectus sheath|The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.
9790679|NCT01394523|Active Comparator|Local|The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.
9790680|NCT01394614||Narcoleptics exposed to A/H1N1 vaccine|Adjuvanted (ASO3) A/H1N1 pandemic vaccine
9790681|NCT01394614||Narcoleptics unexposed to A/H1N1 vaccine|Narcoleptic subjects who were unexposed (non-vaccinated or vaccinated after onset) to adjuvanted (ASO3) A/H1N1 pandemic vaccine.
9790682|NCT01394627|Experimental|Eplerenone|hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)
9790683|NCT01394627|Placebo Comparator|placebo|hypoglycemia of 50 mg/dl plus placebo
9790684|NCT01394692|Active Comparator|intraoperative MRI|tumor resection with intraoperative MRI-guidance
9790685|NCT01394692|Active Comparator|conventional group|standard microsurgical tumor resection
9790686|NCT01394705|No Intervention|Standard of Care|standard of care (office provider exercise counseling)
9799566|NCT01662999|Experimental|A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)|Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
9838891|NCT03597607|Experimental|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
9838892|NCT03597607|Experimental|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
9838893|NCT03581409|Experimental|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
9838894|NCT03581409|Experimental|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
9985214|NCT03209687|Experimental|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
9985215|NCT03209687|No Intervention|Routine care|This group will receive the routine care for luteal phase support
9838897|NCT03574779|Experimental|Cohort A: 1-2 prior lines of therapy (TSR-042, Bevacizumab, and Niraparib)|PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered 500 milligrams (mg) on Day 1 every 3 weeks (Q3W) for 4 cycles (each cycle is 21 days), followed by 1000 mg every 6 weeks (Q6W) beginning on Cycle 5 Day 1 until progressive disease (PD) or toxicity. Bevacizumab administered 15 milligram per kilogram (mg/kg) every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day until PD or toxicity.
9838898|NCT03574779|Active Comparator|Cohort C: Arm 1: Participants receiving platinum plus taxane|Participants are expected to receive 1 run-in cycle (up to 5 weeks) of carboplatin-paclitaxel during pre-screening. After confirmation that the tumor is homologous recombination-deficient (HRd). Participants will then be randomized to three 21-day cycles of platinum-taxane doublet chemotherapy (carboplatin plus paclitaxane). After interval debulking surgery (IDS), all participants will receive up to three 21-day cycles of adjuvant platinum-taxane doublet chemotherapy (and optional bevacizumab for participants deemed high-risk; third cycle is optional) followed by niraparib (and optional bevacizumab or bevacizumab biosimilar for participants deemed high- risk) maintenance treatment.
9838899|NCT03574779|Experimental|Cohort C: Arm 2: Participants receiving neoadjuvant Niraparib|Participants are expected to receive 1 run-in cycle (up to 5 weeks) of carboplatin-paclitaxel during pre-screening. After confirmation that the tumor is HRd, participants will be randomized to three 21-day cycles of neoadjuvant niraparib therapy. After IDS, all participants will receive up to three 21-day cycles of adjuvant platinum-taxane doublet chemotherapy (and optional bevacizumab for participants deemed high-risk; third cycle is optional) followed by niraparib (and optional bevacizumab or bevacizumab biosimilar for participants deemed high- risk) maintenance treatment.
9838900|NCT03566667|Active Comparator|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
9838901|NCT03566667|Other|Standard care|Usual standard care
9838902|NCT03556800|Experimental|0.5 gm of EstroCream (VML-0203)|
9838903|NCT03556800|Experimental|0.75 gm of EstroCream (VML-0203)|
9838904|NCT03556800|Experimental|1.25 gm of EstroCream (VML-0203)|
9838905|NCT03556800|Active Comparator|1.25 EstroGel|
9985216|NCT03208868|Active Comparator|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
9985217|NCT03208868|Active Comparator|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
9985218|NCT03208036|Experimental|TDCS|TDCS offered concurrent with working memory focused cognitive training
9838909|NCT03551886|Experimental|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
9985219|NCT03208036|Sham Comparator|Sham|Sham stimulation offered concurrent with working memory focused cognitive training
9985220|NCT03206645|Experimental|Carboplatin/Paclitaxel + PTC596|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; Unesbulin PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
9985221|NCT03203876|Experimental|Part One Combination Therapy|Lirilumab and Nivolumab
9838910|NCT03551886|Active Comparator|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
9838911|NCT03547037|Experimental|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
9838912|NCT03547037|Experimental|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
9838913|NCT03546374|Experimental|Primary Cohort|Patients with a history of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal atrial fibrillation) who are undergoing concomitant cardiac surgery
9838914|NCT03539536|Experimental|Telisotuzumab vedotin|Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.
9985222|NCT03203876|Experimental|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
9985223|NCT03203642|Experimental|Treatment Group|50mg tesevatinib administered once daily for up to 24 months.
9985224|NCT03203642|Placebo Comparator|Control Group|Matching placebo administered once daily for up to 24 months.
9985225|NCT03202069|Experimental|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
9985226|NCT03202069|Experimental|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
9985227|NCT03201198|Experimental|Active Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
9985228|NCT03201198|Sham Comparator|Chair exercises|The Chair exercise intervention includes chair exercises, behavioral relaxation and health education.
9985229|NCT03196024|Experimental|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
9985230|NCT03196024|Active Comparator|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
9985231|NCT03191240|Experimental|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
9985232|NCT03191240|Placebo Comparator|Normal saline|Additional normal saline intravenous injection for 2 times
9985233|NCT03180294|Experimental|Bupropion 150 mg|One Bupropion 150 mg XL capsule by mouth (PO) in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule daily for 8 weeks; one placebo capsule daily for one 1 week (titration off).
9985234|NCT03180294|Experimental|Bupropion 300 mg|One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)
9985235|NCT03180294|Placebo Comparator|Placebo|One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)
9838934|NCT03536312|No Intervention|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
9838935|NCT03536312|Other|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
9838938|NCT03534687|Experimental|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to ~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
9838939|NCT03534687|No Intervention|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
9838941|NCT03532217|Experimental|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"Within 60 days after the last chemo, patients will start a priming dose of PROSTVAC-V, and subsequent doses of PROSTVAC- F (weeks 0, 2, 5, 8, 11, 14, and 17). During Treatment A phase, subjects should receive nivolumab intravenously on Day 1 of each cycle every 3 weeks for 6 doses. Ipilimumab on Day 1 of each cycle every 3 weeks for 2 doses.~Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered starting approximately week 21 by intramuscular injection for a total of 6 treatments every 28 days +/-7 days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is Treatment B. In the event the DNA vaccine production is delayed, patients will receive single agent nivolumab every 4 weeks beginning week 21 until the vaccine is ready"
9838943|NCT03522740|Active Comparator|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
9790687|NCT01394705|Experimental|Intervention|The intervention group received a personalized exercise prescription (using the FITT principles) and wore an accelerometer up to 7days/week (most waking hours) and logged their activity by regularly (3 times a week) uploading the device for a period of 3 months, use of the internet was supervised by a parent or guardian. Their activity was monitored via the online BodyMedia site on a regular basis by study personnel and feedback was provided at least once a week through email and/or phone calls
9790688|NCT01394718|Placebo Comparator|Saline Placebo|Control subjects will receive saline as placebo at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
9790689|NCT01394718|Experimental|Intravenous Acetaminophen|Subjects will receive the first dose of intravenous (IV) acetaminophen (at 15 mg/kg, with maximum doses based on patient age and weight) at the time of skin closure intra-operatively and will continue to receive IV acetaminophen for 42 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
9790690|NCT01394939|Experimental|Single Agent_ Cohort 1|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: Recombinant Vaccinia Granulocyte-Macrophage Colony-Stimulating Factor (RAC VAC GM-CSF) Cohort 1: JX-594 3 x 10^8 plaque forming unit (pfu), Days 1, 8,15, 22, and 29"
9790691|NCT01394939|Experimental|Single Agent_Cohort 2|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: RAC VAC GM-CSF Cohort 2: JX-594 1 x 10^9 pfu, Days 1, 8,15, 22, and 29"
9790692|NCT01394939|Experimental|Combination_Cohort 3|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF Irinotecan: 180 mg/m2 IV every 2 weeks. JX-594 3 x 10^8 pfu Day 1,8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
9790693|NCT01394939|Experimental|Combination_Cohort 4|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF JX-594 1 x 10^9 pfu Day1, 8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
9790694|NCT01394952|Experimental|1.5 mg Dulaglutide|Administered once weekly, subcutaneously
9790695|NCT01394952|Placebo Comparator|Placebo|Administered once weekly, subcutaneously
9790696|NCT01394978|Other|Control|No treatment.
9790697|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant with standard surgical closure|Standard surgical closure (suturing or stapling of visible air leaks incurred during resection of lung parenchyma) plus Progel Pleural Air Leak Sealant.
9790698|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant without standard surgical closure|Progel Pleural Air Leak Sealant without standard surgical closure (without suturing or stapling of visible air leaks incurred during resection of lung parenchyma).
9790699|NCT01394991|Experimental|001|Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
9790700|NCT01394991|Experimental|002|Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
9790701|NCT01395017|Active Comparator|Group 1|One arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD).
9790702|NCT01395017|Placebo Comparator|Group 2|The other arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus matched placebo by mouth once daily (QD).
9790703|NCT01395030|Experimental|18F-fluoromethylcholine PET/CT|Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.
9790704|NCT01395043|Other|TAP-catheter|Each patient receives bilateral TAP-catheters preoperatively.
9790705|NCT01395277|Experimental|High Flavanol first then Low Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with high flavanol content and 2) before and 2 hours following consumption of a beverage with low flavanol content."
9790706|NCT01395277|Experimental|Low Flavanol first then High Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with low flavanol content and 2) before and 2 hours following consumption of a beverage with high flavanol content."
9790707|NCT01395316|Experimental|Alemtuzumab|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
9838944|NCT03522740|No Intervention|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
9790708|NCT01395329|Active Comparator|Nebivolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Nebivolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of nebivolol.
9790709|NCT01395329|Active Comparator|Metoprolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Metoprolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of Metoprolol.
9790710|NCT01395329|Placebo Comparator|Placebo|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of placebo. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of placebo.
9790711|NCT01395368||Brain Speed Test|Brain Speed Test
9790712|NCT01395394|Experimental|BH4 Non-Responders|Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
9790713|NCT01395394|Experimental|Healthy Controls|Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
9790714|NCT01395394|Experimental|BH4 Responders|Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
9790715|NCT01395524|Experimental|NKTR-118 12.5mg|
9790716|NCT01395524|Experimental|NKTR-118 25mg|
9790717|NCT01395524|Placebo Comparator|Placebo|
9790718|NCT01395537|Experimental|Lapatinib With Carboplatin and Paclitaxel|
9790719|NCT01395758|Experimental|tivantinib (ARQ 197) plus erlotinib arm|"Eligible subjects will be randomly assigned to receive erlotinib plus tivantinib (ARQ 197).~Treatment will be open-label and continue until progression of disease, unacceptable toxicity, or another discontinuation criterion is met."
9790720|NCT01395758|Active Comparator|Chemotherapy arm|Investigator's choice of single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered in 3-week cycles according to the approved label until disease progression or unacceptable toxicity. Subjects who discontinued chemotherapy can be switched to the crossover arm (tivantinib plus erlotinib) and continue treatment until disease progression or unacceptable toxicity.
9790721|NCT01395784|Placebo Comparator|Placebo Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
9790722|NCT01395784|Experimental|PIO 15 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
9790723|NCT01395784|Experimental|PIO 45 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
9790724|NCT01395797|Placebo Comparator|Placebo - Heroin|Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
9790725|NCT01395797|Experimental|PIO low dose - Heroin|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
9790726|NCT01395797|Experimental|PIO high dose - Heroin|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
9790727|NCT01395797|Placebo Comparator|Placebo - Nicotine|Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
9790728|NCT01395797|Experimental|PIO Low Dose - Nicotine|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
9790729|NCT01395797|Experimental|PIO High Dose - Nicotine|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
9790730|NCT01395810|Experimental|Prophylaxis, high dose (once weekly)|
9790731|NCT01395810|Experimental|Prophylaxis, low dose (once weekly)|
9790732|NCT01395810|Experimental|On-demand|
9790733|NCT01395810|Experimental|Prophylaxis, high dose (every second week)|
9790734|NCT01395823|Other|ergocalciferol supplementation|
9790735|NCT01395823|Placebo Comparator|placebo|
9790736|NCT01395888|Experimental|Relovair|Inhaled long-acting bronchodilator and corticosteroid combination
9790737|NCT01395888|Active Comparator|Tiotropium|Inhaled long-acting anticholinergic
9790738|NCT01395901|Experimental|Palonosetron and placebo to Ondansetron|Intervention: Drug: Palonosetron
9790739|NCT01395901|Active Comparator|Ondansetron and placebo to Palonosetron|Intervention: Drug: Comparator: Ondansetron
9790740|NCT01395914|Experimental|100 mg QD|100 mg yellow coated, oval tablet; oral administration once daily
9790741|NCT01395914|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
9790742|NCT01395966|Active Comparator|DF289|Ear drops
9790743|NCT01395966|Active Comparator|DF277|Ear drops
9790744|NCT01395966|Experimental|DF289 plus DF277|Ear drops
9790745|NCT01396005|Experimental|Methadone + boceprevir|Participants receive standard methadone maintenance therapy (20-150 mg tablets, liquid, or disket, orally, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7)
9790746|NCT01396005|Experimental|Buprenorphine/naloxone + boceprevir|Participants receive standard buprenorphine/naloxone maintenance therapy (8/2-24/6 mg, tablets, sublingual, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7
9790747|NCT01396044|Experimental|Electronic checklist|Electronic checklist
9790748|NCT01396044|Experimental|Verbal prompting|Verbal prompting with written checklist
9985236|NCT03179930|Experimental|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
9985237|NCT03169881|Experimental|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
9985238|NCT03169881|Placebo Comparator|Placebo|Equal volume normal saline for IV administration, or sham dosing
9985239|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
9985240|NCT03158051|Experimental|Intervention|Telephone health coaching, home blood pressure monitoring, individualized goal setting, and tailored educational materials
9838950|NCT03519256|Experimental|Nivolumab monotherapy|
9838951|NCT03519256|Experimental|Nivolumab + BCG|
9838952|NCT03519256|Experimental|Nivolumab + BMS-986205|
9838953|NCT03519256|Experimental|Nivolumab + BMS-986205 + BCG|
9838954|NCT03510741|Active Comparator|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
9838955|NCT03510741|Active Comparator|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
9838956|NCT03510741|Active Comparator|Placebo|Placebo added to TAU
9838957|NCT03510741|Active Comparator|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
9985241|NCT03158051|No Intervention|Usual clinical care|Usual care arm participants will receive routine hypertension clinical care per their primary care provider.
9985242|NCT03151408|Experimental|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
9985243|NCT03151408|Placebo Comparator|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
9985244|NCT03147222|Experimental|Fracture Care at Home|A trained FFC coach will visit each caregiver and fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
9985245|NCT03146078||Primary Cohort|"Participants with baseline visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and stable fixation and clinically determined [on Octopus 900 Pro] kinetic visual field III4e area 10° or more in the study eye (primary cohort) will be enrolled into the longitudinal natural history study"
9985246|NCT03146078||Secondary Cohort|"Participants with baseline visual acuity ETDRS letter score of 53 or less [approximate Snellen equivalent 20/100 or worse] or unstable fixation or clinically determined [on Octopus 900 Pro] kinetic visual field III4e area less than 10°in the study eye (secondary cohort) will be enrolled in the cross-sectional baseline study"
9838964|NCT03505983|Active Comparator|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
9838965|NCT03505983|Active Comparator|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
9838966|NCT03505983|Active Comparator|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
9838967|NCT03503513|Experimental|Gentamicin sulfate|
9838968|NCT03500835|Experimental|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
9838969|NCT03500835|Experimental|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
9838970|NCT03500835|Experimental|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
9838971|NCT03500016|Experimental|Acute exercise and exercise training|"Euglycemic-hyperinsulinemic clamp before and after 8 weeks supervised exercise training. Before exercise training the participants will also do an acute exercise on 1 hour with muscle biopsies taken before and after exercise and then again 4 hours into recovery."
9838972|NCT03494348|No Intervention|Cruciate Retaining Polyethylene (CR)|This is the standard Polyethylene articular surface
9838973|NCT03494348|Active Comparator|Medial Congruent Polyethylene (MC)|The intervention here will be the MC articular surface. This is the new Polyethylene articular surface with a more congruent medial side and a more flat lateral side which should better resemble natural anatomy.
9985247|NCT03145298|Experimental|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
9985248|NCT03145298|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
9921992|NCT00833599||1: NIRFLI with ICG|1) Persons affected with lymphatic or lympho-vascular disorders, 2) Family members (affected or unaffected) of persons affected with lymphatic or lympho-vascular disorders and 3) Health, normal persons (Controls) that participate at one of the clinical sites in both the lymphatic function imaging with indocyanine green and the Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) system, as well, as the genetic analysis portion of the study.
9790749|NCT01396057|Experimental|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
9790750|NCT01396057|Sham Comparator|Dexamethasone|Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
9790751|NCT01396070|Experimental|Brentuximab vedotin|Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks
9790752|NCT01396083|Experimental|Ranibizumab|
9790753|NCT01396083|Active Comparator|Standard of Care|
9790754|NCT01396148|Experimental|Children with GIST|children ages 6yrs-<18yrs
9790755|NCT01396148|Experimental|Young adults with GIST|young adults ages 18yrs-<21 yrs
9790756|NCT01396161|Experimental|30 mg PF-05175157 or Placebo QD|
9790757|NCT01396161|Experimental|100 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
9790758|NCT01396161|Experimental|200 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
9790759|NCT01396161|Experimental|100 mg PF-05175157 or Placebo BID|Planned dose might be modified based on emerging safety and PK data.
9790760|NCT01396161|Experimental|xxx mg PF-05175157|Dose will be determined based on results obtained from Arms 1 to 4.
9790761|NCT01396187|Experimental|Treatment|
9790762|NCT01396187|Placebo Comparator|Placebo|
9790763|NCT01396226|Experimental|1|A single dose of AZD2927 administered as an iv infusion
9790764|NCT01396226|Placebo Comparator|2|A single dose of placebo administered as an iv infusion
9790765|NCT01396239|Experimental|AVI-4658 (Eteplirsen)|"50 mg/kg eteplirsen for 28 weeks~30 mg/kg eteplirsen for 28 weeks"
9790766|NCT01396239|Placebo Comparator|Placebo / Delayed Treatment|"3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.~3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks."
9790767|NCT01396265|Experimental|Afatinib alone (Reference)|Tablet, Oral administration with 240 mL of water
9790768|NCT01396265|Experimental|Rifampicin + Afatinib (Test)|Tablet, Oral administration with 240 mL of water
9790769|NCT01396317|Experimental|Tocilizumab|This is a single-arm study. All subjects will receive the active study treatment for 12 months, and will then be evaluated for 3 months of long-term follow-up.
9790770|NCT01396382|Experimental|68Ga-DOTATATE PET|Patients will receive a 68Ga-DOTATATE PET scans
9790771|NCT01396395|Experimental|Standard treatment plus nicorandil|The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors [(ACEIs] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
9790772|NCT01396395|Other|Standard treatment|
9790773|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] High Dose|Higher Dose, tablet, once daily, for six weeks
9790774|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Middle Dose|Middle Dose, tablet, once daily, for six weeks
9790775|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Low Dose|Lower Dose, tablet, once daily, for six weeks
9790776|NCT01396421|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
9790777|NCT01396434||Prevenar 13 patients|
9790778|NCT01396447|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks.
9790779|NCT01396447|Experimental|Cariprazine 0.75 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
9790780|NCT01396447|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
9790781|NCT01396447|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
9790782|NCT01396486|Active Comparator|Omega-3/Placebo|Combination Omega-3 and Placebo treatment.
9790783|NCT01396486|Active Comparator|Placebo/Inositol|Combination Placebo and Inositol treatment.
9790784|NCT01396486|Active Comparator|Omega-3/Inositol|Combination Omega-3 and Inositol treatment.
9790785|NCT01396512|Experimental|IMOJEV™ Vaccine Group|Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
9790786|NCT01396512|Active Comparator|CD.JEVAX ™ Vaccine Group|Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0
9790787|NCT01396525|Experimental|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|
9790788|NCT01396551|Experimental|Transponder implantation|Implantation of anchored Beacon transponder in the lung
9790789|NCT01396837|Experimental|RedDress Wound Care System (RD1)|RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
9790790|NCT01397071|Active Comparator|Ground Beef Patty with Avocado|Test burgers with fresh avocado added just prior to consumption
9790791|NCT01397071|Active Comparator|Ground Beef Patty without Avocado|Test burgers
9790792|NCT01397084|Other|esomeprazole 20 mg|esomeprazole 20 mg
9790793|NCT01397253|No Intervention|(Usual) MedTrak system of PCP notification|MedTrak, the information system used by the University of Pittsburgh Medical Center (UPMC), currently notifies PCPs when patients are admitted and discharged from the hospital.
9790794|NCT01397253|Experimental|Automated communication tools|An enhanced version of MedTrak (the present system of PCP notification). Electronic medical record links will be developed and used to allow automated communication with the PCP.
9790795|NCT01397409|Experimental|Stage 1: AGN-150998 4.2 mg|Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.
9838983|NCT03492177|Experimental|open label selexipag|The first dose of selexipag (Uptravi) will be administered in the evening of Day 1 and will be based on the body weight. Thereafter selexipag will be administered twice daily (morning and evening). Selexipag will be up-titrated during the first 12 weeks, with weekly increments equal to the starting dose until the participants reach their individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline weight category is achieved (which will be 8-fold of the corresponding starting dose). Up-titration is followed by a stable maintenance treatment period from Week 12 to Week 16, at the maximum tolerated dose. Thereafter, participants will be treated with selexipag as long as the treatment is beneficial to the participants, as per investigator's decision.
9838984|NCT03485326||Safety|Safety
9985249|NCT03141671|Experimental|GnRH + Bicalutamide|"GnRH agonist injection monthly or every 3 months for 6 months~Bicalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
9985250|NCT03141671|Experimental|GnRH+Abiraterone+Apalutamide+Prednisone|"GnRH agonist injection monthly or every 3 months for 6 months~Abiraterone acetate by mouth once/day for 6 months~Prednisone by mouth once/day for 6 months~Apalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
9985251|NCT03137173|Experimental|ceftobiprole medocaril|Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
9985252|NCT03137173|Active Comparator|vancomycin+aztreonam|Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
9985253|NCT03133559||Cohort 1|Patients infected with HIV off antiretroviral therapy
9985254|NCT03133559||Cohort 2|Patients infected with HIV experiencing virologic control, but with blunted immunologic recovery
9985255|NCT03133559||Cohort 3|Matched healthy volunteers
9985256|NCT03129828|Experimental|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
9838993|NCT03473743|Experimental|Phase 1b: Dose Escalation|Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
9838994|NCT03473743|Experimental|Phase 2: Dose Expansion|The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
9838995|NCT03472495|Active Comparator|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
9838996|NCT03472495|Active Comparator|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR <110 (Diltiazem Injectable Product)
9838997|NCT03451851|Experimental|Part 1 Group 1: Guselkumab|Participants in Part 1a (age greater than or equal to (>=) 12 - less than (<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose >=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) Phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
9838998|NCT03451851|Placebo Comparator|Part 1 Group 2: Placebo for Guselkumab|Participants in Part 1a (age >= 12 - <18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose >=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
9838999|NCT03451851|Active Comparator|Part 1 Group 3: Etanercept|Participants in Part 1a (age >= 12 - <18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
9839000|NCT03451851|Experimental|Part 2: Guselkumab|Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter.
9839005|NCT03435796|Other|Participants exposed to Gene-modified (GM) T cell therapy|
9839006|NCT03434717|Experimental|Control (high distress)|Control group receiving care as usual
9839007|NCT03434717|Experimental|Individualised rehabilitation|"Patients with high distress receive the intervention individualized rehabilitation including evaluation of individual needs and based on that physical, psychological or social interventions to promote rehabilitation."
9839008|NCT03434717|Experimental|Control group (low distress)|Control group receiving care as usual
9839012|NCT03433170|Experimental|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
9839013|NCT03433170|Active Comparator|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
9985257|NCT03129061|Experimental|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline [18F]F-AraG PET/CT scan and another [18F]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
9985258|NCT03129061|Experimental|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline [18F]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second [18F]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
9985259|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
9985260|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
9985261|NCT03117751|Experimental|B-ALL and B-LLy, Low-risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL-class fusion. Blinatumomab will be given to patients with certain genetic subtypes and those with Down syndrome.~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase® or Rylaze™), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, thioguanine, methotrexate, dexamethasone, blinatumomab."
9839023|NCT03426878|Active Comparator|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
9839024|NCT03426878|Experimental|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
9839025|NCT03425643|Experimental|NAC + Neoadjuvant/Adjuvant Pembrolizumab|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, IV; given on cycle day 1]."
9839026|NCT03425643|Placebo Comparator|NAC + Neoadjuvant/Adjuvant Placebo|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1] in combination with platinum doublet NAC, consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1]."
9839027|NCT03422328|Experimental|Open-label macitentan 10 mg|10 mg macitentan film coated tablet, administered orally once daily
9839028|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
9839029|NCT03417115||Advanced breast cancer - Her2 positive|Patients with HER2-positive advanced breast cancer
9839030|NCT03417115||Advanced breast cancer - triple negative|Patients with triple negative advanced breast cancer
9839031|NCT03417115||Advanced breast cancer - HR positive, Her2 negative|Patients with HR positive, Her2 negative advanced breast cancer
9839032|NCT03417115||Early breast cancer - HER2 positive|Patients with HER2 positive early breast cancer
9839033|NCT03417115||Early breast cancer - triple negative|Patients with triple negative early breast cancer
9839034|NCT03417115||Early breast cancer - HR positive, HER2 negative|Patients with HR positive, HER2 negative early breast cancer
9839037|NCT03409328|Experimental|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
9790796|NCT01397409|Experimental|Stage 1: AGN-150998 3.0 mg|Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.
9790797|NCT01397409|Experimental|Stage 1: AGN-150998 2.0 mg|Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.
9790798|NCT01397409|Experimental|Stage 1: AGN-150998 1.0 mg|Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.
9790799|NCT01397409|Experimental|Stage 2: AGN-150998 4.2 mg|Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
9790800|NCT01397409|Experimental|Stage 2: AGN-150998 3.0 mg|Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
9790801|NCT01397409|Active Comparator|Stage 2: ranibizumab 0.5 mg|Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
9790802|NCT01397409|Experimental|Stage 3: AGN-150998 2.0 mg|Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
9790803|NCT01397409|Experimental|Stage 3: AGN-150998 1.0 mg|Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
9790804|NCT01397409|Active Comparator|Stage 3: ranibizumab 0.5 mg|Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.
9790805|NCT01397422|Placebo Comparator|Treatment A|
9790806|NCT01397422|Active Comparator|Treatment B|Low dose ADS-5102 (amantadine extended release)
9790807|NCT01397422|Active Comparator|Treatment C|A mid-dose ADS-5102 (amantadine extended release)
9790808|NCT01397422|Active Comparator|Treatment D|High dose ADS-5102 (amantadine extended release)
9790809|NCT01397448|Experimental|E3810 5 mg|
9790810|NCT01397448|Experimental|E3810 10 mg|
9790811|NCT01397448|Active Comparator|Teprenone 150 mg|
9790812|NCT01397461|Experimental|ozenoxacin 1% cream|1% cream
9790813|NCT01397461|Placebo Comparator|ozenoxacin placebo|cream
9790814|NCT01397461|Active Comparator|retapamulin 1% ointment|1% ointment
9790815|NCT01397591|Experimental|Ofatumumab with Bortezomib|Ofatumumab was given intravenously on cycle 1 day 1 at a dose of 300mg, followed by a cycle 1 day 8 dose of 1000mg. During cycles 2 through cycle 6, Ofatumumab was given at a dose of 1000mg on day 1 of each cycle, with no dosing on any other day of the cycle. Bortezomib was given intravenously at a dose of 1.6mg/m2 on days 1, 8, and 15 of each cycle, following the Ofatumumab infusion, if given.
9790816|NCT01397617|Experimental|NobelActive Internal|NobelActive Internal implant
9790817|NCT01397617|Experimental|NobelActive External|NobelActive External implant
9790818|NCT01397617|Active Comparator|NobelReplace Tapered Groovy|NobelReplace Tapered Groovy implant
9790819|NCT01397656|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations followed by cross-over to CPR with Continuous Compressions
9790820|NCT01397656|Active Comparator|CPR with Continuous Compressions|Continuous Chest Compressions without ventilation followed by CPR 30:2 (30 chest compressions to 2 ventilations)
9790821|NCT01397747||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
9790822|NCT01397786|Experimental|OPC-34712|
9790823|NCT01397825|Experimental|Safety Lead-in|Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
9790824|NCT01397825|Experimental|Dose Escalation, Alisertib 30 mg|Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
9790825|NCT01397825|Experimental|Dose Escalation, Alisertib 40 mg|Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
9790826|NCT01397825|Experimental|Dose Escalation, Alisertib 50 mg|Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
9790827|NCT01397825|Experimental|Phase 2: Alisertib|Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV on Days 1 & 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
9790828|NCT01397851|Experimental|Treatment: Insecticide-treated net|Smallholder farmers in the treatment group are informed that they won a raffle, and receive a free insecticide-treated net
9790829|NCT01397851|No Intervention|Control|Smallholder farmers in the control group are informed that they had a chance to win an insecticide-treated mosquito net in a raffle, but did not end up winning
9790830|NCT01397890|Other|1|Add-on treatment
9790831|NCT01397890|Other|2|Add-on treatment
9790832|NCT01398059|Experimental|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
9790833|NCT01398059|Experimental|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
9790834|NCT01398059|Experimental|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
9790835|NCT01398176|Experimental|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
9790836|NCT01398176|Experimental|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
9790837|NCT01398280|Experimental|Aminocaproic Acid (ACA)|Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
9790838|NCT01398280|Placebo Comparator|Vehicle cream|Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
9790839|NCT01398358|No Intervention|Usual Head Start Exposure|Children will attend their usual Head Start classroom and receive the usual educational interventions provided in that classroom.
9790840|NCT01398358|Experimental|Parents of Preschoolers Series (POPS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention.
9790841|NCT01398358|Experimental|POPS + Incredible Years Series (IYS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention. In the classroom, children also receive a series of lessons about emotional and behavioral self-regulation delivered by a trained mental health specialist. The parents also are invited to classes about child behavioral and emotional self-regulation delivered by a mental health specialist.
9790842|NCT01398410|Experimental|Rabeprazole 5 mg|
9790843|NCT01398410|Experimental|Rabeprazole 10 mg|
9790844|NCT01398475|Experimental|LY3009104 Reference Formulation|8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
9790845|NCT01398475|Experimental|LY3009104 Test Formulation 1|8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
9790846|NCT01398475|Experimental|LY3009104 Test Formulation 2|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
9839038|NCT03409328|No Intervention|Waitlist|The control condition will be a waitlist.
9985262|NCT03117751|Experimental|B-ALL and B-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5%, LLy patients who don't qualify for complete response at end of Remission Induction and all patients with ETP and T/M MPAL. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD >5%. Blinatumomab will be given to patients with residual disease at the end of induction (≥0.01% and <1%), certain genetic subtypes and Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase® or Rylaze™), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, thioguanine, methotrexate, dexamethasone, doxorubicin"
9985263|NCT03117751|Experimental|B-ALL and B-LLy, High-risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy (chimeric antigen receptor [CAR] T cells). Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard-risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy. Blinatumomab will be given to patients who are not able to receive CAR T cell therapy and patients with certain genetic subtypes and those with Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase® or Rylaze™), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, dexamethasone, clofarabine, thioguanine, methotrexate."
9985264|NCT03117751|Experimental|T-ALL and T-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5% and all patients with ETP and T/M MPAL and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD ≥ 5%.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase® or Rylaze™), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine, thioguanine."
9839043|NCT03406273|Experimental|≥ 5 years of age|Cerebral Spinal (CS) radiation
9839044|NCT03406273|Experimental|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
9839045|NCT03406273|Experimental|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
9839050|NCT03393520|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
9839051|NCT03393520|Experimental|AVP-786; Dose 1|Participants will receive AVP-786 (Dose 1) capsules administered twice a day over a 12-week period.
9839052|NCT03393520|Experimental|AVP-786; Dose 2|Participants will receive AVP-786 (Dose 2) capsules administered twice a day over a 12-week period.
9839053|NCT03392376|Experimental|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.~Other name: Serenase"
9839054|NCT03392376|Placebo Comparator|Normal Saline|Saline (0,9%)
9839064|NCT03381183|Experimental|Phase 1 - Dose Escalation|Six patients will be enrolled at Dose Level 1 with IRX-2 230 units/day in combination with cyclophosphamide and durvalumab and treated sequentially at least 1 week apart. If less than 2 out of 6 patients have DLTs in Dose Level 1, the dose will be escalated to administration of IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab as Dose Level 2. If 2 of 6 patients have DLTs, stop accrual and re-evaluate. In the next safety phase, six patients at IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab will be enrolled and treated sequentially (at least 1 week apart). If DLT occurs in less than 2 of 6 patients during the first 6 weeks of treatment, enrollment can continue in the dose expansion phase at Dose Level 2. If DLT is observed in 2 of 6 patients, accrual will be stopped and Dose Level 1 will resume in the dose expansion phase.
9790847|NCT01398475|Experimental|LY3009104 Test Formulation 2 + Meal|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.
9790848|NCT01398514|Experimental|Active medication|Escitalopram 10mg/day
9790849|NCT01398514|Placebo Comparator|Placebo|Matched pill placebo
9790850|NCT01398566|Experimental|SuperBetter Play|members of this group will play SuperBetter for 6 weeks (averaging 10 min per day of play for 6 week period)
9790851|NCT01398787|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear
9790852|NCT01398787|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear
9790853|NCT01398943|Experimental|COPD Patients|"Patients with COPD~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
9790854|NCT01398943|Experimental|Controls|"Healthy age- and sex- matched controls~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
9790855|NCT01398956|Experimental|Levetiracetam|Twice daily (morning and evening) orally
9790856|NCT01398982|Placebo Comparator|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
9790857|NCT01398982|Experimental|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
9799567|NCT01662999|Experimental|A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin|Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
9799568|NCT01662999|Experimental|B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
9799569|NCT01662999|Experimental|B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
9799570|NCT01662999|Experimental|C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
9799571|NCT01662999|Experimental|C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
9799572|NCT01663012|Experimental|Drug: Etirinotecan pegol|145 mg/m2 dose
9799573|NCT01663103|Experimental|Rilonacept|12 weeks of treatment with rilonacept
9799574|NCT01663103|Placebo Comparator|Placebo|Twelve weeks of treatment with placebo
9799575|NCT01663233|Experimental|LCZ696 and amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.
9799576|NCT01663233|Active Comparator|Amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.
9799577|NCT01663259|Experimental|Cetuximab|
9790858|NCT01399008|Experimental|Arhalofenate 400 mg|Arhalofenate 400 mg plus allopurinol 300 mg
9790859|NCT01399008|Experimental|Arhalofenate 600 mg|Arhalofenate 600 mg plus allopurinol 300 mg
9790860|NCT01399008|Active Comparator|Allopurinol|Placebo plus Allopurinol 300 mg
9790861|NCT01399047|Active Comparator|Mycophenolate Mofetil|
9790862|NCT01399047|Placebo Comparator|Placebo liquid|
9790863|NCT01399099|Experimental|All Study Participants|Half of the abdomnioplasty incision was treated with the embrace device. Half of the abdomnioplasty incision was treated according to the investigator's standard of care. Participant served as his own control.
9790864|NCT01399125|Experimental|Rivastigmine patch|Once-daily target patch size 10 cm²
9790865|NCT01399125|Active Comparator|Rivastigmine capsules|Twice-daily target dose of 6 mg oral capsule
9790866|NCT01399190||Bevacizumab|Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.
9790867|NCT01399229||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
9790868|NCT01399229||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
9790869|NCT01399229||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
9790870|NCT01399268|Experimental|Steroid|Hydrocortisone 100 mg IV Q 8hrs x3
9790871|NCT01399268|Placebo Comparator|Control|Saline IV Q8hr x3
9790872|NCT01399372|Active Comparator|Chemotherapy|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.
9790873|NCT01399372|Experimental|Chemotherapy + Low-Dose WBRT|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.
9790874|NCT01399593|Experimental|Eculizumab|Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
9790875|NCT01399593|No Intervention|Standard of Care|Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
9790876|NCT01399619|Experimental|BI201335 12W|patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
9790877|NCT01399619|Experimental|BI 201335 24W|patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
9790878|NCT01399619|Experimental|BI 201335 24 W|patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks
9790879|NCT01399697|Experimental|A|
9790880|NCT01399697|Active Comparator|B|
9790881|NCT01399723|Experimental|Amoxicillin 45mg/kg 12 hourly|
9790882|NCT01399723|Active Comparator|Benzyl Penicillin 50,000IU/kg 6 hourly|
9790883|NCT01399736|Active Comparator|FFR-guided revascularisation strategy|In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of >0.80 will not be treated.
9790884|NCT01399736|Placebo Comparator|randomised to guidelines group|In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
9790885|NCT01399788|Active Comparator|1.0|Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
9790886|NCT01399788|Active Comparator|2.0|Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
9790887|NCT01399827|Active Comparator|Omega-3 Fatty Acids|1060 mg EPA Omega-3 Fatty Acids
9790888|NCT01399827|Placebo Comparator|Placebo|
9790889|NCT01399866|Placebo Comparator|Placebo|50 mg capsule,single dose, twice, one week apart, by mouth
9790890|NCT01399866|Active Comparator|D-cycloserine|50 mg capsule,single dose, twice, one week apart, by mouth
9790891|NCT01399905|Experimental|High carbidopa followed by low carbidopa|450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks
9790892|NCT01399905|Experimental|Low carbidopa followed by high carbidopa|75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day
9790893|NCT01400113|Experimental|Asenapine|This group received 10mg asenapine sl x 1 dose
9790894|NCT01400113|Placebo Comparator|Placebo|This group received placebo sl x 1 dose
9790895|NCT01400139|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
9790896|NCT01400243|Placebo Comparator|Placebo Patch|Placebo patch for 15-day quit period
9790897|NCT01400243|Active Comparator|Nicotine Patch|7 mg Habitrol nicotine patch-15 day quit period
9790898|NCT01400412|Experimental|MVC Arm: DRV/r + MVC + FTC + TDF placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Maraviroc 150 mg PO QD + Emtricitabine 200 mg PO QD + Placebo for Tenofovir disoproxil fumarate PO QD
9790899|NCT01400412|Experimental|TDF Arm: DRV/r + TDF + FTC + MVC placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Emtricitabine 200 mg PO QD + Tenofovir disoproxil fumarate 300 mg PO QD + Placebo for Maraviroc PO QD
9790900|NCT01400425|Experimental|Subjects with Progressive Cognitive Decline|Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
9790901|NCT01400451|Experimental|Ipilimumab + Vemurafenib|
9790902|NCT01400477|Experimental|DMXB-A-SR|Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR), 3-2, 4 dimethoxybenzylidene anabaseine sustained release (GTS-21)
9790903|NCT01400477|Placebo Comparator|Arm #2: Placebo Comparator|Inert capsule to resemble active drug.
9790904|NCT01400503|Experimental|Siltuximab|Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.
9790905|NCT01400516|Experimental|Teriparatide|The participants who are in treatment arm received teriparatide 20 μg, subcutaneous injection, 1 injection per day, with a biologic for 12 months. A second year of teriparatide was offered to all interested participants. All participants received daily 1000 milligrams (mg) of calcium citrate, 800 IU of vitamin D and a Tumor Necrosis Factor (TNF) antagonist.
9790906|NCT01400516|Other|Control Arm|The participants randomized to the control arm had the same testing as those in the treatment arm and were offered teriparatide, if determined to be effective in healing bone erosions, after the first 12 months. All participants received daily 1000 mg of calcium citrate, 800 IU of vitamin D and a TNF antagonist.
9790907|NCT01400698|Experimental|Saizen® (Continuous or intermittent treatment)|
9790908|NCT01400698|Experimental|Saizen® (Observed and then continuous or no treatment)|
9790909|NCT01400698|Other|Observation only|
9790910|NCT01400815|Experimental|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
9790911|NCT01400815|Active Comparator|Active Control Cigarette|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette."
9790912|NCT01400841|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
9790913|NCT01400880||Pregnant|In Labor
9790914|NCT01400893|Experimental|CRRT + SCD|Patients with a diagnosis of AKI requires CRRT will be randomized
9790915|NCT01400893|No Intervention|CRRT alone|Patients with a diagnosis of AKI requires CRRT will be randomized
9790916|NCT01400906|Placebo Comparator|3 periods cross-over study|Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
9790917|NCT01400919|Experimental|Protégé™ EverFlex™ and GPS™ Self-Expanding Stent Systems|The objective of the study is to confirm the safety and effectiveness of the Protégé EverFlex and Protégé GPS Self-Expanding Stent Systems in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
9790918|NCT01400932|Experimental|GI148512 (Benzoyl Peroxide 3% Gel)|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
9790919|NCT01400932|Placebo Comparator|vehicle gel|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
9790920|NCT01400958|Active Comparator|A: Nuvigil®|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
9799578|NCT01663272|Experimental|cabozantinib with gemcitabine|The Study Treatment Period will consist of continued treatment during which time patients will receive cabozantinib and gemcitabine until either disease progression or the occurrence of unacceptable drug-related toxicity
9799579|NCT01663363|Experimental|wavefront-guided LASIK|LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System.
9839065|NCT03381183|Experimental|Phase 2 - Dose Expansion|14 patients will be enrolled at the recommended dose level from the dose finding phase for a total enrollment of 20 patients; however, investigators will replace patients with any missing tumor sample collection and continue enrollment until there are at least 20 pre- and post-treatment paired tumors (i.e. minimum 2 of 3 tumors per patient). The 6 patients treated at the recommended dose in the dose finding phase of the study will be counted as a part of the dose expansion patient population,
9839066|NCT03380351||SCDIC interventions|Careful detail the intervention components and the implementation strategies (i.e., the mechanisms by which the interventions are being delivered in usual care) being developed by the consortium.
9839067|NCT03380351||SCDIC control groups|Careful detail the control conditions of each of the SCDIC sites for each of the interventions being developed.
9839068|NCT03377699|Experimental|Insulin Degludec|Insulin Degludec once daily and Insulin Aspart 2-4 times daily
9839069|NCT03377699|Active Comparator|Insulin Determir|Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily
9839070|NCT03377023|Experimental|Phase 1 - Dose Escalation|"Nivolumab + Ipilimumab + Nintedanib dose escalation.~Nivolumab: 3 mg/kg IV Q2 weeks.~Ipilimumab: 1 mg/kg Q6 weeks.~Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =100 mg).~Nintedanib Level 0:150 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =150 mg)~Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg).~Nintedanib Level 2: 150 mg PO BID Days 1-14 (Daily dose = 300 mg).~Nintedanib Level 3: 200 mg PO BID Days 1-14 (Daily dose = 400 mg)."
9839071|NCT03377023|Active Comparator|Phase 2 - Arm A|"Arm A: Newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
9839072|NCT03377023|Active Comparator|Phase 2 - Arm B|"Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.~Nivolumab + Ipilimumab + Nintedanib at RP2D."
10206385|NCT04566692|Experimental|Treatment-naïve Cohort|Treatment-naïve participants will receive a loading dose of 150 mg/kg/day IGSC 20% for 5 consecutive days (Week 0, Days 1 to 5) followed by weekly maintenance infusions of 150 mg/kg IGSC 20% starting Week 1 (Day 8) through Week 32. IGSC 20% infusion will be administered using an SC infusion pump.
9985265|NCT03117751|Experimental|T-ALL and T-LLy, High-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard-risk T-ALL but are discontinued in Reintensification therapy.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase® or Rylaze™), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine, thioguanine.."
9985266|NCT03117751|Experimental|ALL, CEP72 T/T, Vincristine|"Patients with the CEP72 rs904627T/T genotype (~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m^2 or 1 mg/m^2 of vincristine after Continuation Week 1. Patients in low- risk will complete vincristine in Week 49 and those in standard/high-risk will complete in Week 101.~Intervention: vincristine."
9985267|NCT03117751|Experimental|ALL, CEP72 C/T or C/C, Vincristine|"Patients with either a CEP72 rs904627 C/T or C/C genotype (~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (2 mg/m^2 per dose except during Reinduction I and Reinduction II when 3 weekly doses of 1.5 mg/m^2 will be given) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment. Patients at low-risk will complete vincristine in Week 49.~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
9985268|NCT03111030|Experimental|ProacTive SCI|Individualized physical activity coaching sessions
9985269|NCT03111030|No Intervention|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
9839080|NCT03369223|Experimental|Part 1A: BMS-986249|
9839081|NCT03369223|Experimental|Part 1B: BMS-986249 + nivolumab (nivo)|
9839082|NCT03369223|Experimental|Part 2A Arm C: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
9839083|NCT03369223|Experimental|Part 2A Arm D: ipilimumab + nivo then nivo|Previously untreated unresectable stage III-IV melanoma
9839084|NCT03369223|Experimental|Part 2A Arm F: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
9839085|NCT03369223|Experimental|Part 2B Cohort 1: BMS-986249 + nivo|Advanced or intermediate hepatocellular carcinoma (HCC)
9839086|NCT03369223|Experimental|Part 2B Cohort 2: BMS-986249 + nivo|Metastatic castration-resistant prostate cancer (CRPC)
9839087|NCT03369223|Experimental|Part 2B Cohort 3: BMS-986249 + nivo|Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
9839088|NCT03369223|Experimental|Part 2A Arm A: BMS-986249 + nivo then nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
9839089|NCT03369223|Experimental|Part 2A Arm B: BMS-986249 + nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
9839090|NCT03369223|Experimental|Part 2A Arm E: Nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
9985270|NCT03110107|Experimental|Part 1A: Monotherapy (BMS-986218)|
9985271|NCT03110107|Experimental|Part 1B: Combination Therapy (BMS-986218 + Nivolumab)|
9985272|NCT03110107|Experimental|Part 2A: Monotherapy (BMS-986218 OR Ipilimumab)|
9839100|NCT03365687|Active Comparator|Vitamin D|Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
9839101|NCT03365687|Placebo Comparator|Placebo|Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
9839102|NCT03364400|Experimental|VT1021|Escalating doses of VT1021 to determine RP2D
9839103|NCT03362502|Experimental|PF-06939926|
9839108|NCT03342144||Participants Receiving Venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
9839109|NCT03342144||Participants Receiving Venetoclax + Rituximab|Participants with CLL receiving venetoclax in combination with rituximab.
9839110|NCT03342144||Participants Receiving Venetoclax + Obinutuzumab|Participants with CLL receiving venetoclax in combination with obinutuzumab.
9839111|NCT03337087|Experimental|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|"PHASE Ia: Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.~PHASE Ib/II: Patients receive liposomal irinotecan IV over 90 minutes and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity."
9985273|NCT03110107|Experimental|Part 2B: Monotherapy (BMS-986218)|
9985274|NCT03110107|Experimental|Part 2C: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
9985275|NCT03110107|Experimental|Part 2D: Expansion Combination Therapy (BMS-986218 + Nivolumab)|
9839115|NCT03329950|Experimental|CDX-1140|Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.
9839116|NCT03329950|Experimental|CDX-1140 and CDX-301|Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.
9839117|NCT03329950|Experimental|CDX-1140 and pembrolizumab|Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
9839118|NCT03329950|Experimental|CDX-1140 and chemotherapy|Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.
9985276|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
9985277|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
9985278|NCT03100149|Experimental|Part 1: RO7046015 High Dose|Participants will receive RO7046015 at high dose level as intravenous infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.
9985279|NCT03100149|Experimental|Part 1: RO7046015 Low Dose|Participants will receive RO7046015 at low dose level as intravenous infusion Q4W up to 52 weeks in Part 1.
9985280|NCT03100149|Placebo Comparator|Part 1: Placebo|Participants will receive placebo as intravenous infusion Q4W up to 52 weeks in Part 1.
9985281|NCT03100149|Experimental|Part 2: RO7046015 High Dose|Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
9985282|NCT03100149|Experimental|Part 2: RO7046015 Low Dose|Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
9839126|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
9839127|NCT03314337|No Intervention|Distal Pancreatectomy without pancreatic stent|
9839128|NCT03314337|Experimental|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
9985283|NCT03100149|Experimental|Part 3: RO7046015 Low Dose|Part 2 RO7046015 low dose group participants and high dose group participants will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 5 years in Part 3.
9985284|NCT03098797|Experimental|Experimental: Elamipretide|Patients will be randomized to receive 12 weeks of elamipretide in one of the two treatment periods. All subjects will receive 12 weeks of elamipretide and 12 weeks of placebo.
9985285|NCT03098797|Placebo Comparator|Placebo|Patients will be randomized to receive 12 weeks of placebo in one of the two treatment periods. All subjects will receive 12 weeks of placebo and 12 weeks of elamipretide.
10206386|NCT04558346|Placebo Comparator|Placebo|"Placebo (40ug/kg) will be self-administered twice daily for 14 days.~ONLY THE PART B (ACUTE) SUBJECTS WILL BE RANDOMIZED AND MAY RECEIVE PLACEBO."
10206387|NCT04558346|Experimental|Ghrelin (OXE-103)|"OXE-103 (40ug/kg) will be self-administered twice daily for 14 days.~PART A (POST-ACUTE) SUBJECTS WILL BE OFFERED EXPERIMENTAL TREATMENT WITHOUT RANDOMIZATION.~PART B (ACUTE) SUBJECTS WILL BE DOUBLE-BLIND RANDOMIZED TO EXPERIMENTAL OR PLACEBO TREATMENT."
9790921|NCT01400958|Placebo Comparator|B: Placebo|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent EBRT and TMZ, there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
9790922|NCT01400971||MOSAIc Participants|Participants enrolled in Multinational Observational Study Assessing Insulin use (MOSAIc) who had complete treatment data during the study.
9790923|NCT01401010|Active Comparator|Doripenem 500 mg|pharmacokinetics/pharmacodynamics
9790924|NCT01401010|Active Comparator|Doripenem 1000 mg|pharmacokinetics/pharmacodynamics
9790925|NCT01401023|Experimental|Clostridium difficile Patient|Open non-comparative trial
9790926|NCT01401062|Experimental|Arm 1 (Fresolimumab 1 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
9790927|NCT01401062|Experimental|Arm 2 (Fresolimumab 10 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
9790928|NCT01401101|Experimental|PTSD Care Management (PCM)|PCM has six intervention components: 1) patient education, 2) patient screening and written feedback of screening information to primary care clinicians, 3) clinician education on practice guidelines , 4) structured feedback between primary care and mental health clinicians, 5) continuity of patient care, and 6) a resource guide detailing available community services where the FQHC has established reciprocal referrals. All of the intervention components will be implemented through the CM, except for the clinician education component, which will combine onsite and online continuing medical education (CME)-accredited sessions.
9790929|NCT01401101|Placebo Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition consists of only the clinician education and patient screening without written feedback.
9790930|NCT01401153|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
9790931|NCT01401153|Experimental|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.
9790932|NCT01401166|Experimental|Cohort 1: SC (SID) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
9799580|NCT01663402|Placebo Comparator|Placebo|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.
10206388|NCT04558138|Experimental|Discharge day of surgery|Patient discharges day of surgery and given surveys to complete at home on post operative day (POD) #1 and #7.
10206389|NCT04558138|No Intervention|Discharge post operative day 1|Patient Discharges POD #1 and completes survey prior to discharge. Patient given surveys to complete POD #7 at home.
10206390|NCT04551417|Active Comparator|Dorsal onlay graft urethroplasty|
10206391|NCT04551417|Experimental|Ventral onlay graft urethroplasty|
10206392|NCT04549376|Experimental|PVP-I 0.4% NI|Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
10206393|NCT04549376|Experimental|PVP-I 0.5% NI|Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
10206394|NCT04549376|Experimental|PVP-I 0.6% NI|Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
10206395|NCT04549376|Experimental|PVP-I NS 0.5% NS|Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
10206396|NCT04549376|Experimental|PVP-I 0.6% NS|Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
10206397|NCT04549376|Placebo Comparator|DW NI|Arm-6 will receive distilled water through nasal irrigation
10206398|NCT04549376|Placebo Comparator|DW NS|Arm-7 will receive distilled water through nasal spray
10206399|NCT04545151|Experimental|Verapamil SR|Eligible participants will be randomised into the Verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
10206400|NCT04545151|Placebo Comparator|Placebo|"Eligible participants will be randomised into the placebo arm and receive instructions on frequency of administration (daily intake).~40 participants on the control arm are expected to complete the trial."
10206401|NCT04542603|Experimental|treatment naivete women with stage 1-4 newly diagnosed ovarian|
10206402|NCT04539431||Retrospective|The cases with glioma will be identified in the databases of hospital, the material will be preliminarily evaluated in order to see if there is sufficient tissue left for analysis.
10206403|NCT04539431||Prospective|A blood sample for molecular analyses will be collected in all the cases, CSF samples will be taken only if recommended by the normal surgical routine.
10206404|NCT04538989|Experimental|RZ358 Cohort 1|
10206405|NCT04538989|Experimental|RZ358 Cohort 2|
10206406|NCT04538989|Experimental|RZ358 Cohort 3|
10206407|NCT04538989|Experimental|RZ358 Cohort 4|
10206408|NCT04538599|Experimental|RD13-01 cell infusion|
9985286|NCT03097497|Experimental|Physiotherapy re-education program|Physiotherapy re-education program based on the pre-activation of the transverse abdominal muscle, performed with progressive difficulty and supervised at all times by an expert physiotherapist. The intervention will last 4 weeks, with two weekly sessions of 30-35 minutes each. Sessions will be held individually.
9985287|NCT03097497|Active Comparator|Conventional treatment by GP|"Will follow conventional treatment prescribed by the general practitioner in a primary care consultation. This conventional treatment is based on the clinical guidlines of the Institut Català de la Salut~http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf"
9985288|NCT03096067|Active Comparator|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
9985289|NCT03096067|Experimental|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
9985290|NCT03095313|Experimental|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
9985291|NCT03092635|Experimental|OPC|During weeks 1- 12, subjects will take one OPC tablet in the morning and in the evening, about 12 hours apart.
9985292|NCT03092011|Experimental|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
9839144|NCT03297125||Eligible Subjects|All enrolled subjects undergoing Optune therapy.
9985293|NCT03092011|Active Comparator|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
9985294|NCT03091660|Active Comparator|Arm I (BCG solution)|INDUCTION: Patients receive TICE BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive TICE BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
9985295|NCT03091660|Experimental|Arm II (Tokyo-172 strain BCG solution)|INDUCTION: Patients receive Tokyo-172 strain BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
9985296|NCT03091660|Experimental|Arm III (Tokyo-172 strain BCG solution with priming)|PRIME: Patients receive Tokyo-172 strain BCG vaccine once ID. INDUCTION: Within 21 days, patients receive Tokyo-172 strain BCG solution as in Arm II. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution as in Arm II.
9985297|NCT03090295|Experimental|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
9985298|NCT03086655|Experimental|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
9985299|NCT03086655|Other|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
9839154|NCT03275350|Active Comparator|XR-NTX|Extended-release naltrexone
9839155|NCT03275350|Active Comparator|TAU|Treatment as usual
9839156|NCT03272347|Experimental|Islatravir 0.25 mg|Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
9839157|NCT03272347|Experimental|Islatravir 0.75 mg|Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
9839158|NCT03272347|Experimental|Islatravir 2.25 mg|Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
9839159|NCT03272347|Active Comparator|Doravirine, Tenofovir, Lamivudine|Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and doravirine, tenofovir, lamivudine consisting of 100 mg DOR + 300 mg 3TC + 300 mg tenofovir disoproxil fumarate (TDF) for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only doravirine, tenofovir, lamivudine QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
9839162|NCT03266770|Other|RELIEF stent placement|After meeting the inclusion criteria and being consented, patients will have the RELIEF stent inserted in the ureter during cystoscopy per standard of care for ureteral stent placement.
9839163|NCT03258632|No Intervention|Usual Care|Under usual care, when a patient screens positive on the AUDIT-C administered at intake, a provider (social worker, nurse) provides Brief Intervention (BI), i.e., tells the patient that problems are associated with alcohol use, and about recommended drinking limits; notes the patient as ready to change drinking or not, and as agreeing to treatment or not. If the patient agrees to treatment, specialty addiction services are notified.
9839164|NCT03258632|Experimental|Intervention|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
9985300|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
9985301|NCT03081052|Active Comparator|Lung transplant with iNO|
9985302|NCT03081052|Active Comparator|Lung transplant with iEPO|
9839172|NCT03254758|Experimental|Mesenchymal stem cell|"Phase 1 Dose escalation : low Mid High Single administalation of ADR-001~Phase 2 The recommended dose of ADR-001"
9839173|NCT03254732|Experimental|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
9985303|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iNO|
9985304|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iEPO|
9985305|NCT03080935|Experimental|Evolocumab|Single arm study administering Evolocumab.
9985306|NCT03079024|Experimental|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
9985307|NCT03079024|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
9985308|NCT03079024|No Intervention|Treatment as Usual (TAU)|Treatment as Usual
9839180|NCT03250832|Experimental|Part 1a: TSR-033 monotherapy dose escalation|Part 1a will evaluate TSR-033 at ascending doses (20 milligrams [mg], 80 mg and 240 mg) every 2 weeks. Cohorts will be enrolled sequentially and will initially follow a 3+3 design at a starting dose of 20 mg.
9839181|NCT03250832|Experimental|Part 1b: TSR-033 monotherapy PK/PDy characterization|Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
9839182|NCT03250832|Experimental|Part 1c: TSR-033+dostarlimab combination dose escalation|Participants will be administered ascending doses of TSR-033 in combination with dostarlimab 500 mg every 3 weeks. Planned dose levels of TSR-033 include 80 and 240 mg.
9839183|NCT03250832|Experimental|Part 2 Cohort A: TSR-033+dostarlimab combination|Part 2 Cohort A will evaluate the preliminary activity of TSR-033 in combination with dostarlimab in anti-PD-1 naive participants with third and fourth line MSS-CRC. TSR-033 will be administered every 2 weeks and dostarlimab every 6 weeks.
9839184|NCT03250832|Experimental|Part 2 Cohort B1: TSR-033+dostarlimab with mFOLFOX6|Part 2 Cohort B1 will evaluate the preliminary activity of TSR-033 administered every 2 weeks (Q2W) in combination with dostarlimab administered every 6 weeks (Q6W) along with mFOLFOX6 and bevacizumab (standard of care [SOC]) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFIRI, with or without biologics.
9839185|NCT03250832|Experimental|Part 2 Cohort B2: TSR-033+dostarlimab with FOLFIRI|Part 2 Cohort B2 will evaluate the preliminary activity of TSR-033 in combination with FOLFIRI and bevacizumab (SOC) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFOX, with or without biologics.
9839186|NCT03246906|Experimental|Arm I (mycophenolate mofetil, cyclosporine, sirolimus)|Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.
9921993|NCT00833599||2: Genetic Analysis Only|Family members of an affected subject from Group 1. Subjects in Group 2 can be either affected or unaffected and will provide a blood or saliva sample for the genetic analysis portion of the study, but will not undergo lymphatic function imaging with ICG and the NIRFLI system. Group 2 individuals are not required to travel to one of the clinical sites in order to participate in the study.
9985309|NCT03078855|Experimental|Vitamin D plus rituximab|
9985310|NCT03078855|Placebo Comparator|Placebo plus rituximab|
9985311|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
9985312|NCT03072251||Anyone|Any individual may complete this survey
9985313|NCT03071601|Experimental|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
9985314|NCT03071601|Experimental|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
9985315|NCT03070327|Experimental|BCMA Targeted CAR T Cells with or without Lenalidomide|
9790933|NCT01401166|Experimental|Cohort 1: IV then SC (SID) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
9790934|NCT01401166|Experimental|Cohort 2: SC (Vial) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
9790935|NCT01401166|Experimental|Cohort 2: IV then SC (Vial) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
9790936|NCT01401257|Experimental|PXT3003 Low dose|Oral Liquid formulation, 1/100, bid, 12 months
9790937|NCT01401257|Experimental|PXT3003 Intermediate dose|Oral Liquid formulation, 1/50, bid, 12 months
9790938|NCT01401257|Experimental|PXT3003 High dose|Oral Liquid formulation, 1/10, bid, 12 months
9790939|NCT01401257|Placebo Comparator|Placebo|Oral Liquid formulation, bid, 12 months
9790940|NCT01401283|Active Comparator|Study group|intraoperative guidance of hemodynamics by measures of cardiac index and pulse pressure variation, measurement of cardiac output and pulse pressure variation, hemodynamic optimization according to cardiac index and pulse pressure variation
9790941|NCT01401283|No Intervention|Control group|hemodynamic management according to institutional clinical standards
9790942|NCT01401322|Experimental|Lenalidomide 50 mg/day x 28 days|Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.
9790943|NCT01401361|Experimental|Treatment Arm|Atrial Flutter RF Ablation treatment with the Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement.
9790944|NCT01401452||Participants with psoriasis and at least one co-morbid disease|Participants with moderate to severe plaque psoriasis with at least one co-morbid disease and/or symptom such as hypertension, psoriatic arthritis confirmed by a rheumatologist or other appropriate specialist, obesity, diabetes, metabolic syndrome or depression
9790945|NCT01401465|Experimental|Ciclesonide Nasal Aerosol|74 mcg ciclesonide nasal aerosol once daily
9790946|NCT01401465|Active Comparator|Mometasone Nasal Spray|200 mcg mometasone aqueous nasal spray once daily
9790947|NCT01401478||Stage 5 Chronic Kidney Disease|Planned for Zemplar administration due to secondary hyperparathyroidism
9790948|NCT01401517|Placebo Comparator|Placebo|Microcrystalline cellulose NF at 60 mg/capsule, BID
9790949|NCT01401517|Experimental|40 mg Sodium Nitrite|40 mg dose, BID
9790950|NCT01401517|Experimental|80 mg Sodium Nitrite|80 mg dose, BID
9790951|NCT01401530|Experimental|E7777|
9790952|NCT01401543|Active Comparator|5 mg LY2452473 + 5 mg Tadalafil|5-mg LY2452473 oral capsule and 5-mg tadalafil oral tablet, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
9790953|NCT01401543|Experimental|LY900010 (particle size #1)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
9790954|NCT01401543|Experimental|LY900010 (particle size #2)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
9790955|NCT01401543|Experimental|LY900010 (particle size #3)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
9790956|NCT01401582|No Intervention|care as usual|care as usual, no intervention, just observation of natural change/ trajectories over time
9790957|NCT01401582|Experimental|Implementation of Dementia Care Manager|"Subjects in this arm will be provided with a specialised Dementia Care Manager to be included in a subsidiary support system"
9790958|NCT01401595|Experimental|Night Eaters|Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
9800458|NCT01688141|Active Comparator|Enhanced Management|Practices randomised to the intervention group will be offered an enhanced level of CKD disease management led by clinical nurse specialists based on an intervention previously piloted in high risk patients. Here, high risk patients identified will be invited to a CKD clinic for tailored management of bp and proteinuria and referral as needed.
9921994|NCT00833612|No Intervention|Control arm of study|
10206409|NCT04537598|Active Comparator|patient controlled analgesia|30 patients will receive only postoperative IV PCA alone for postoperative analgesia.
10206410|NCT04537598|Active Comparator|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia.
9790959|NCT01401595|No Intervention|Control Subjects|"At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls."
9790960|NCT01401647|Active Comparator|Amiodarone|Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.
9790961|NCT01401647|Active Comparator|Lidocaine|IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.
9790962|NCT01401647|Placebo Comparator|Normal saline|IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.
9790963|NCT01401699|Experimental|Optical Frequency Domain imaging System|Optical Frequency Domain Imaging (OFDI) balloon based imaging
9790964|NCT01401842|Experimental|Strengthening Exercise|Lumbar ext. high intensity progressive resistance exercise
9790965|NCT01401842|Active Comparator|Stabilization Exercise|Low intensity core stabilization exercise
9790966|NCT01401907|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
9790967|NCT01401907|No Intervention|Standard of Care|Subjects receives standard of care
9790968|NCT01401959|Experimental|Cohort A: Triple-negative breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
9790969|NCT01401959|Experimental|Cohort B: ER/PR+ /HER2- breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
9790970|NCT01401959|Experimental|Cohort C: HER2+ breast cancer|"Eribulin 1.4 mg/m^2 intravenously (IV)~Trastuzumab 6mg/kg intravenously (IV)"
9790971|NCT01402011|Experimental|25% dextrose in shoulder entheses|25% dextrose and .1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
9790972|NCT01402011|Active Comparator|.1% lidocaine in shoulder entheses|.1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
9790973|NCT01402011|Placebo Comparator|.1% lidocaine subcu. above shouldr enth.|.1% lidocaine injected subcutaneously above the shoulder entheses (ligament and tendon insertions on the periosteum).
9790974|NCT01402050|Active Comparator|FOLEY BALLOON|Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
9790975|NCT01402050|Active Comparator|CERVIDIL|
9790976|NCT01402063|Experimental|radiation plus PPX(CT2103|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ intravenous PPX every week x 6 weeks for a total of 6 treatments"
9790977|NCT01402063|Active Comparator|radiation + Temozolomide|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days"
9790978|NCT01402102|Experimental|Aged garlic powder|
9790979|NCT01402102|Placebo Comparator|Placebo|
9790980|NCT01402115|Experimental|Polycan|Polycan 150mg for 12 weeks
9790981|NCT01402115|Placebo Comparator|Placebo|Placebo 15mg for 12 weeks
9790982|NCT01402128|Experimental|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
9790983|NCT01402128|Placebo Comparator|Placebo|Placebo for 12 weeks
9790984|NCT01402141|Experimental|Chungkookjang|
9790985|NCT01402141|Placebo Comparator|Placebo|
9790986|NCT01402284|Experimental|Carfilzomib, Lenalidomide, Dexamethasone|Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year
9790987|NCT01402375|Experimental|Hydrocodone (first trial)|Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
9790988|NCT01402375|Active Comparator|Codeine (first trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
9790989|NCT01402375|Experimental|Oxycodone (for second trial)|Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
9790990|NCT01402375|Active Comparator|Codeine (for second trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
9790991|NCT01402375|Experimental|Oxycodone (third trial)|Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
9790992|NCT01402375|Active Comparator|Hydrocodone (third trial)|Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
9790993|NCT01402427|Active Comparator|Verapamil|
9790994|NCT01402427|Placebo Comparator|Placebo|
10206411|NCT04536077|Experimental|CDX-1140 Monotherapy|Patients randomized to the CDX-1140 monotherapy arm will receive a single IV infusion at a dose of 1.5 mg/kg, with surgery to follow 7-12 days after administration of CDX-1140.
10206412|NCT04536077|Experimental|CDX-1140 + CDX-301|Patients randomized to the CDX-301 + CDX-1140 arm will receive CDX-301 at 75 mcg/kg/day as a subcutaneous injection every day for 5 days (Days 1-5) with CDX-1140 IV at 1.5 mg/kg on Day 8 +/-1 day. Surgery will be 7-12 days after administration of CDX-1140.
10206413|NCT04530344|Experimental|Cohort A : ruxolitinib cream|Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
10206414|NCT04530344|Placebo Comparator|Cohort A : Vehicle|Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
9790995|NCT01402492|Experimental|BUP4+XR-NTX|4mg buprenorphine plus naltrexone for 8 weeks of treatment
9790996|NCT01402492|Experimental|BUP16+XR-NTX|16mg buprenorphine plus naltrexone for 8 weeks of treatment
9790997|NCT01402492|Active Comparator|PLB+XR-NTX|naltrexone for 8 weeks of treatment
9790998|NCT01402544|Other|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year
9790999|NCT01402570|Experimental|Glutathione supplement|All subjects will be taking a glutathione supplement.Glutathione is a naturally occuring antioxidant and a nonessential amino acid.
9791000|NCT01402700|Experimental|Visi-Pro™ Balloon Expandable Stent System|The objective of the study is to confirm the safety and effectiveness of the Visi-Pro stent in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
9791001|NCT01402817|Experimental|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
9791002|NCT01402869|Experimental|Prilocaine|30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
10206415|NCT04530344|Experimental|Cohort B : roxolitinib cream|Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.
9791003|NCT01402869|Experimental|Lidocaine|30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
9791004|NCT01402869|No Intervention|No local anesthetic|30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control
10206416|NCT04528134|Experimental|Extended Contact RMGI Varnish/5% Sodium Fluoride Varnish|This group will receive extended contact (XT) varnish on their upper left and lower right teeth, and traditional 5% sodium fluoride varnish on their upper right and lower left teeth.
10206417|NCT04528134|Experimental|Placebo Varnish/Extended Contact RMGI Varnish|This group will receive placebo varnish on their upper left and lower right teeth, and extended contact (XT) varnish on their upper right and lower left teeth.
10206418|NCT04528134|Active Comparator|5% Sodium Fluoride Varnish/Placebo Varnish|This group will receive traditional 5% sodium fluoride varnish on their upper left and lower right teeth, and placebo varnish on their upper right and lower left teeth.
9791005|NCT01402908|Experimental|PI-88|Arm 1
9791006|NCT01402908|Placebo Comparator|Placebo|Arm 2
9791007|NCT01402947|Experimental|Ciprofloxacin + MMX placebo|
9791008|NCT01402947|Experimental|MMX Mesalazine/mesalamine + Ciprofloxacin|
9791009|NCT01402986|Placebo Comparator|Placebo, Q2W - Cohort 1|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
9791010|NCT01402986|Experimental|Tralokinumab 300 mg, Q2W - Cohort 1|Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
9791011|NCT01402986|Placebo Comparator|Placebo, Q2/4W - Cohort 2|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
9791012|NCT01402986|Experimental|Tralokinumab 300 mg, Q2/4W - Cohort 2|Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
9791013|NCT01403051|Experimental|Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.
10206419|NCT04518501|Experimental|study group|Fuzuloparib Capsules plus table Arsenic Trioxide po
10206420|NCT04518046|Experimental|Phase 1: Dose Escalation|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment.
10206421|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort A|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment
10206422|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort B|Patients with favorable-risk RCC with clear cell component for first-line treatment.
10213440|NCT04022239|Experimental|Schedule I (non-lymphoma)|Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.
10213441|NCT04022239|Experimental|Schedule II (lymphoid malignancies)|Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.
10213442|NCT04012996|Experimental|Investigational|Two-level prodisc C SK and/or prodisc C Vivo
10213443|NCT04012996|Active Comparator|Control|Two-level Mobi-C device
10213444|NCT04010539|Active Comparator|Gepotidacin|Subjects will receive Gepotidacin orally at the study site during the Baseline (Day 1) visit followed by self-administration of a second oral dose as an outpatient 6 to 12 hours after the first dose.
9985316|NCT03069326|Experimental|Cohort A: Ruxolitinib and Thalidomide|After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
9985317|NCT03069326|Experimental|Cohort B: Ruxolitinib and Thalidomide|"A cohort expansion, for patients with baseline thrombocytopenia, will enroll 35 additional patients~After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs."
9985318|NCT03068663|Experimental|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: at consultations after inclusion in the study~faeces: day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
10206423|NCT04511533|Experimental|Treatment Arm|The recommended dosage of dacomitinib is 45 mg taken orally once a day at approximately the same time each day, until disease progression, participant refusal/lost to follow-up, or unacceptable toxicity occurs.
9791014|NCT01403051|Experimental|Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.
9791015|NCT01403064|Experimental|Open Label ALD518|
9791016|NCT01403064|Experimental|ALD518 Dose 1|
9791017|NCT01403064|Experimental|ALD518 Dose 2|
9791018|NCT01403064|Placebo Comparator|Placebo|
9791019|NCT01403090|Experimental|Angel Catheter|
9791020|NCT01403116|Experimental|Oral testosterone undecanoate (TU)|"Treatment Period 1: 100 mg capsules, BID, with food~Treatment Period 2: One of the following dosages:~100 mg BID~150 mg BID~100 mg BID~100 mg and 150 mg BID~150 mg capsules BID~Safety Follow-up Phase:~Initial dose: ~84 doses Maintenance dose-Titrated dose: ~96 doses Safety follow-up at maintenance dose: ~540 doses"
9791021|NCT01403116|Active Comparator|topical testosterone gel|"Treatment Period 1: 5 g of 1% transdermal T-gel applied QD~Treatment Period 2:~2.5 g of 1% transdermal T-gel applied QD~5 g of 1% transdermal T-gel applied QD~7.5 g of 1% transdermal T-gel applied QD~10 g of 1% transdermal T-gel applied QD~Safety Follow-up Phase:~Initial dose: ~42 doses Maintenance dose-Titrated dose: ~48 doses Safety follow-up at maintenance dose: ~270 doses"
9791022|NCT01403246|Experimental|Lenalidomide with Chlorambucil|
9791023|NCT01403376|Experimental|Teriflunomide 7 mg|Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
9791024|NCT01403376|Experimental|Teriflunomide 14 mg|Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
9791025|NCT01403376|Active Comparator|IFN-β-1|Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months
9791026|NCT01403441|Experimental|Radiosurgical Neuromodulation|Bilateral Radiosurgical Neuromodulation using the Cyberknife
9791027|NCT01403584|Experimental|AutoVPAP with addition of AutoEPAP|This arm will receive conventional device modified to enable algorithm for automatically applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
9791028|NCT01403584|Active Comparator|AutoVPAP without addition of AutoEPAP|This arm will receive conventionally applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
9791029|NCT01403610|Experimental|Cohort 1|Subjects received TH-302 single dose at 575 mg/m2 or placebo administered preoperative in a 2:1 randomization and were then administered 240 mg/m2 of TH-302 post-operative.
9791030|NCT01403610|Experimental|Cohort 2|Surgical subjects will receive TH-302 at 340 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
9791031|NCT01403610|Experimental|Cohort 3|Surgical or Non-Surgical subjects will receive TH-302 at 480 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
9791032|NCT01403610|Experimental|Cohort 4|Non-surgical subjects will receive a dose up to 670 mg/m2 of TH-302
9791033|NCT01403805|Experimental|Oral care and vaccines|Oral care and pneumococcal plus influenza vaccines
9791034|NCT01403805|Active Comparator|Vaccine|Influenza vaccine only
9791035|NCT01403987|Active Comparator|Control Arm|Control group will receive standard teaching by the Residency Program regarding management of ascites and performance of paracentesis.
9791036|NCT01403987|Experimental|Intermediate Education Arm|In addition to the teaching provided by the residency program, the intermediate education group will receive a dedicated lecture by a gastroenterology fellow designed to teach consensus guidelines and their rationale in management of ascites. They will also receive a pocket card noting specific indications for paracentesis, and a brief summary of guidelines.
9791037|NCT01403987|Experimental|"Intensive Education Arm (Pager Arm)"|This group will receive the residency teaching, the specialist lecture, the pocket card, and have access to a pager carried by a gastroenterology fellow for personal assistance in performing paracentesis.
9791038|NCT01404039|Experimental|Motor Learning (ML) sighted|"In this arm, subject will perform motor Learning with visual feedback - ML sighted.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
9800459|NCT01688310|Active Comparator|Open surgical circumcision|Open surgical techniques, which are commonly used for circumcision in Mozambique, require good surgical skills and minor complications are common.
10206424|NCT04508413|Other|KB295|
10206425|NCT04506853|Other|Study Procedure|
10206426|NCT04506775|Experimental|Wrist one|Wrist one will have both the ViTrack wrist cuff on one wrist
9839187|NCT03246906|Experimental|Arm II (cyclosporine, sirolimus, cyclophosphamide)|Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.
9985319|NCT03068663|Experimental|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery~faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
9839189|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
9839190|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
9985320|NCT03066440|Placebo Comparator|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
9985321|NCT03066440|Experimental|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
9839193|NCT03233542|Experimental|Panic Disorder: CBT|Participants with Panic Disorder randomized to this arm will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
9839194|NCT03233542|No Intervention|Panic Disorder: Waiting list|After the pre-treatment testing session, participants with Panic Disorder randomized to this arm will wait a length of time equivalent to that for the pre/post-treatment duration for the Panic Disorder: Cognitive Behaviour Therapy arm (approx. 3 months), before returning to the post-treatment assessment. After completing all the study procedures, participants in this arm receive also the manualised Cognitive Behaviour Therapy treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
9839195|NCT03233542|Other|Anxious Control Group: CBT|All participants in the Anxious Control Group will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for their diagnosed anxiety disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
9839196|NCT03232073|Experimental|Ponesimod|20 mg administered orally once daily
9985322|NCT03061903|Experimental|Prevena|Subjects will receive PREVENA after surgery.
9985323|NCT03061903|Active Comparator|Aquacel|Subjects will receive AQUACEL Ag after surgery.
9985324|NCT03061643|Experimental|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
9985325|NCT03061630|Experimental|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
9985326|NCT03059030|Experimental|Subjects with thrombocytopenia secondary to cirrhosis|Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
9985327|NCT03057002||HCM Group|HCM patients will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
9985328|NCT03057002||Control Group|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
9985329|NCT03055390|Placebo Comparator|Control|They received two ml of normal saline intravenously as a placebo
9985330|NCT03055390|Active Comparator|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
9985331|NCT03055390|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
9985332|NCT03054298|Active Comparator|Cohort 1|Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells
9985333|NCT03054298|Active Comparator|Cohort 2|Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells
9985334|NCT03054298|Active Comparator|Cohort 3|PERMANENTLY CLOSED
9985335|NCT03054298|Active Comparator|Cohort 4|PERMANENTLY CLOSED
10206427|NCT04506775|Active Comparator|Wrist Two|Wrist two and the radial artery catheter in the opposite wrist.
10206428|NCT04504422|Experimental|Primary motor cortex|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
10206429|NCT04504422|Experimental|Left dorsolateral prefrontal cortex|The anodic electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
10206430|NCT04504422|Experimental|Ventromedial prefrontal cortex|The anodic electrode is positioned in the ventromedial prefrontal cortex (Fpz) and the cathode electrode on the left dorsolateral prefrontal cortex (F4). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
9985336|NCT03054298|Active Comparator|Cohort 5|Single dose of 1-3x107 huCART-meso cells/m2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2. Subjects in Cohort 5 may be enrolled in parallel to Cohort 6.
9985337|NCT03054298|Active Comparator|Cohort 6|Dose of 1-3x107 huCART-meso cells/m2 via IV infusion on Day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Cohort 6 was activated with Protocol V6. Enrollment into Cohort 6 will occur in parallel with Cohort 5.
9839213|NCT03216967|Active Comparator|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
9839214|NCT03216967|Experimental|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
9839215|NCT03207945|Experimental|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C <50mg/dl will remain on the same 75mg dose throughout the trial.
9839216|NCT03207945|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
9985338|NCT03054298|Active Comparator|Cohort 7|a single dose of 1-3x107 huCART-meso cells/m2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. Infusion #1 for the first three subjects in Cohort 7 will be staggered by at least 21 days to allow for the assessment of DLTs. Enrollment into Cohort 7 will occur in parallel with Cohort 5 and Cohort 6.
9985339|NCT03039140|Experimental|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
9985340|NCT03038802|Active Comparator|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
9985341|NCT03038802|Experimental|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
9985342|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
9985343|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
9985344|NCT03028740|Placebo Comparator|Placebo|Participants received cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
9985345|NCT03028740|Experimental|Cenicriviroc 150 mg|Participants received cenicriviroc, 150 milligrams (mg), tablet, orally, once daily for up to approximately 40 months.
9839225|NCT03197194|Experimental|A : Alteplase|Intravenous injection of Alteplase and one tablet of placebo
9839226|NCT03197194|Active Comparator|B : Acetylsalicylic Acid|one tablet of Acetylsalicylic Acid and one dose of IV placebo
9985346|NCT03022097|Experimental|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
9985347|NCT03022097|Experimental|Experimental 2|Aclidinium bromide 400 μg
9985348|NCT03022097|Active Comparator|Comparator|Formoterol fumarate 12 μg
9985349|NCT03022097|Placebo Comparator|Placebo|Placebo
9985350|NCT03020251|Active Comparator|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
9985351|NCT03020251|Experimental|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
9985352|NCT03015142||New image-guidance software|Patients in this group had spine surgery with new image-guidance software application.
9839236|NCT03186508|Active Comparator|Optimize Sleep (OS)|Optimize Sleep will focus exclusively on enhancing sleep by using effective behavioral strategies. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
9839237|NCT03186508|Active Comparator|Optimize Sleep-Plus (OS-Plus)|OS-Plus will focus on enhancing sleep and targeted eating (decreasing sugar-sweetened beverages and sweet and salty snack foods) and activity (increasing physical activity and decreasing TV viewing) behaviors. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
9791039|NCT01404039|Experimental|Motor Learning (ML) blind|"In this arm, subject will perform motor Learning without visual feedback - ML blind.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
9791040|NCT01404039|Placebo Comparator|Motor Learning (ML) control group|In this arm, subject will perform simple hand movements - control group. There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session.
9791041|NCT01404039|Experimental|Somatosensory Learning (SL sighted)|"In this arm, subject will perform sensory Learning with visual feedback - SL sighted.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
9791042|NCT01404039|Experimental|Somatosensory Learning (SL blind)|"In this arm, subject will perform sensory Learning without visual feedback - SL blind.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
9791043|NCT01404039|Experimental|Somatosensory Activation (S activation)|"In this arm, subject will receive simple sensory stimulation over their left index finger - Sactivation.~There will be an anticipated total of 10 subjects in this experimental arm.This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
9791044|NCT01404039|Placebo Comparator|Somatosensory Learning (SL) control group|"In this arm,the subjects will not receive any somatosensory input (SL control group).~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
9791045|NCT01404039|Experimental|Observational Task (OT) - real|In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
9791046|NCT01404039|Placebo Comparator|Observational Task (OT) - control group|In this arm, the subjects will perform a controlled observational task - observation of geometric shapes. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
9791047|NCT01404039|Experimental|Mental Imagery (MI) - real|In this arm, the subjects will perform mental imagery - mental imagery of finger movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
9791048|NCT01404039|Placebo Comparator|Mental Imagery (MI) - control group|In this arm, the subjects will perform a controlled task - simple mental calculation. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
9791049|NCT01404039|Experimental|transcranial direct current stimulation - tDCS real|tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. 15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session.
9791050|NCT01404039|Placebo Comparator|transcranial direct current stimulation - tDCS sham|"tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. The stimulation will be stopped after 30seconds.~15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session."
9791051|NCT01404078|Active Comparator|SD Polycap without potassium|Single dose polycap without pottasium
9791052|NCT01404078|Experimental|DD Polycap plus potassium|Double Dose polycap with potassium
9791053|NCT01404208|Active Comparator|D-Cycloserine|
9791054|NCT01404208|Placebo Comparator|Sugar Pill|
9839243|NCT03170518|Experimental|Single-blind run-in Period: Placebo|Participants will receive 1 placebo tablet matching canagliflozin 100 milligram (mg) once-daily during the 2-week single-blind placebo run-in period.
9839244|NCT03170518|Experimental|Double-blind Treatment Phase: Canagliflozin or Placebo|Canagliflozin 100 mg/matching placebo once-daily during first 12 weeks. At Week 13, participants who have glycated hemoglobin (HbA1c) of greater than or equal to (>=)7.0 percent (%), estimated glomerular filtration rate (eGFR) >=60 milliliter/minute/1.73 meter square (mL/min/1.73 m^2) will be re-randomized to either remain on canagliflozin 100 mg/matching placebo or up-titrate to canagliflozin 300 mg/matching placebo till Week 52.
10206431|NCT04504422|Sham Comparator|Sham stimulation|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA during first 30 seconds, decreases to 0 mA over 30 seconds, and then stops supplying for 19 minutes.
10206432|NCT04503317|Experimental|active acupuncture low level laser and aerobic exercise|active acupuncture, low level laser and aerobic exercise
9839245|NCT03168880|Active Comparator|A|weekly Paclitaxel chemotherapy at the dose of 100 mg/m2/week for 8 weeks as a 1-hour infusion and AC/EC (60/600 or 90/600) / 3 weekly.
9839246|NCT03168880|Experimental|B|weekly Paclitaxel at 100mg /m2/week + weekly Carboplatin AUC-2 as an infusion over 60 minutes and AC/EC (60/600 or 90/600)/ 3 weekly.
10206433|NCT04503317|Active Comparator|aerobic exercise|aerobic exercise
10206434|NCT04503109|Other|Nalu SCS System|All eligible subjects will receive the Nalu Neurostimulation System
9985353|NCT03012672|Experimental|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
9985354|NCT03012672|Experimental|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9985355|NCT03011775|Experimental|Pioglitazone + Standard Care|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
9985356|NCT03011775|Other|Standard Care|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
10206435|NCT04502381|Experimental|Intervention arm|The study participants in the intervention arm will receive nebulization with amphotericin B deoxycholate (10 mg twice a day every alternate day, as described below) along with intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
10206436|NCT04502381|Active Comparator|Conventional arm|Participants will receive treatment with only intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
10206437|NCT04500821|Experimental|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
9839254|NCT03145181|Experimental|Part 1: Dose Escalation (IV)|Participants will receive Teclistamab intravenously (IV).
9839255|NCT03145181|Experimental|Part 2: Dose Expansion (IV)|Participants will receive Teclistamab IV.
9839256|NCT03145181|Experimental|Part 1: Dose Escalation (SC)|Participants will receive Teclistamab subcutaneously (SC).
9839257|NCT03145181|Experimental|Part 2: Dose Expansion (SC)|Participants will receive Teclistamab SC.
9839258|NCT03144232|Experimental|Active rTMS|10 Hz rTMS applied to the left DLPFC
9839259|NCT03144232|Sham Comparator|Sham rTMS|Sham rTMS applied to the left DLPFC
9839260|NCT03138369|Experimental|Vestibular nerve stimulation|Usage of wearable vestibular nerve stimulator that non-invasively stimulates the vestibular nerves by administering a small electrical current through the skin behind the ears. Should be worn up to one hour a day and at least 5 hours a week.
9839261|NCT03138369|Sham Comparator|Sham vestibular nerve stimulation|Usage of wearable control device that appears identical to active device. Instead of stimulating the vestibular nerves this device will discharge its battery into an internal resistor. Should be worn up to one hour a day and at least 5 hours a week.
10206438|NCT04496986||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
9839265|NCT03101007|Experimental|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
9839266|NCT03101007|Active Comparator|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
9839267|NCT03099733|Experimental|concussion|patients who present to ED with concussion
9839272|NCT03095066|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
9839273|NCT03095066|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
9839274|NCT03092895|Experimental|SHR-1210+Apatinib(Arm A）|
9839275|NCT03092895|Experimental|SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）|
9839282|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
9985357|NCT03011346|Active Comparator|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
9839285|NCT03074045|Experimental|Test|LCS16 (Low-dose LNG IUS)
9839286|NCT03074045|Active Comparator|Reference|COC (Yarina)
9839287|NCT03072927||MILD|All Medicare patients treated with MILD as reported via CPT® Code 0275T (or successor code(s)).
9839288|NCT03072927||Interspinous Process Decompression|All Medicare patients treated with interspinous process decompression (CPT Code 22869 or 22870, or successor code(s)) for the treatment of LSS with NC.
9985358|NCT03011346|Active Comparator|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
9985359|NCT03007485|No Intervention|Standard of Care|Standard pulmonary rehabilitation
9985360|NCT03007485|Experimental|Intervention|Telehealth delivered pulmonary rehabilitation
9985361|NCT02998476|Experimental|Group A Parsaclisib (no prior BTK inhibitor)|Parsaclisib in subjects who were not previously treated with a BTK inhibitor.
9985362|NCT02998476|Experimental|Group B Parsaclisib (prior BTK inhibitor)|Parsaclisib in subjects who were previously treated with a BTK inhibitor.
9985363|NCT02998047|Experimental|IV infusion of Lintuzumab AC225|"Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg and 1.5 μCi/Kg or de-escalation to 0.25 μCi/Kg.~1 cycle = 28 days, up to 3 to 8 cycles (depending on the cohort)."
9985364|NCT02996110|Active Comparator|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab
9985365|NCT02996110|Experimental|Nivolumab + Relatlimab|Nivolumab + Relatlimab
9985366|NCT02996110|Experimental|Nivolumab + BMS-986205|Nivolumab + BMS-986205
9985367|NCT02996110|Experimental|Nivolumab + BMS-813160|Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
9985368|NCT02994043|Active Comparator|MBRP|
9985369|NCT02994043|Active Comparator|RP|
9985370|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
9985371|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
9839304|NCT03036098|Experimental|Arm A: Investigational immunotherapy|
9839305|NCT03036098|Active Comparator|Arm B: Standard of care chemotherapy|
9839306|NCT03036098|Experimental|Arm C: Investigational immunotherapy|
9839307|NCT03036098|Active Comparator|Arm D: Standard of care chemotherapy|
9839308|NCT03034902|Experimental|Combined EEG and fNIRS|EEG is electroencephalography. fNIRS is functional near infrared spectroscopy. The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured.
9791055|NCT01404234|Experimental|Open-label AZLI|Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
9791056|NCT01404260|Experimental|Gemcitabine +Carboplatin +Gefitinib|Arm A: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, Gefitinib 250mg/d every cycle d15-25, and Gefitinib 250mg/d from d15 of last cycle until disease progression
9791057|NCT01404260|Active Comparator|Gemcitabine +Carboplatin|Arm B: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum4 cycles, observation until disease progression
9791058|NCT01404325|Experimental|Quadruple low level IS regimen|quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
9791059|NCT01404325|Experimental|Centre specific triple IS regimen|centre specific CNI-based triple drug immunosuppression (IS)
9791060|NCT01404429|Active Comparator|Methotrexate 7.5 mg per week|
9791061|NCT01404429|Experimental|Methotrexate 15 mg per week|
9791062|NCT01404559|Active Comparator|Prosthetic foot 1 (Ossur Variflex)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 1 (Ossur Variflex).
9791063|NCT01404559|Active Comparator|Prosthetic foot 2 (Ossur Ceterus)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 2 (Ossur Ceterus).
9791064|NCT01404559|Active Comparator|Prosthetic foot 3 (Endolite Elite Blade)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 3 (Endolite Elite Blade).
9791065|NCT01404559|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
9791066|NCT01404572|Active Comparator|Atazanavir + 10% aspartame|
9791067|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame|
9791068|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame and sucralose|
9791069|NCT01404611|Active Comparator|DF289|Ear drops
9791070|NCT01404611|Active Comparator|DF277|Ear drops
9791071|NCT01404611|Experimental|DF289 plus DF277|Ear drops
9791072|NCT01404650|Experimental|AUY922|
9799581|NCT01663402|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels >=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were <25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were <15 mg/dL (0.39 mmol/L).
9799582|NCT01663506||Cohort|
9799583|NCT01663532|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks
9799584|NCT01663532|Placebo Comparator|Placebo|Matching placebo
9799585|NCT01663623|Placebo Comparator|Placebo plus azathioprine|Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.
9799586|NCT01663623|Experimental|Belimumab 10 mg/kg plus azathioprine|Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.
9799587|NCT01663636||SMS Vaccine|Mothers will be sent an SMS message reminding them to come for their scheduled vaccines 1 week prior to the date of 2nd and 3rd doses
9799588|NCT01663636||Usual care|Mothers under usual care will serve as a control
9791073|NCT01404923|Experimental|meteospasmyl|
9791074|NCT01404923|Active Comparator|standard of care|
9791075|NCT01404936|Experimental|Interferon-2A + Chemotherapy|Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)
9791076|NCT01404949|Experimental|Tretinoin and Arsenic Trioxide|This is a multicenter, phase II trial to study the efficacy of combined tretinoin and ATO in the treatment of newly diagnosed APL in an effort to reduce or eliminate the amount of standard chemotherapy required for long-term remission.
9791077|NCT01404988|Experimental|Telephone-Delivered BI|Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
9791078|NCT01404988|Experimental|Telephone-Delivered BEI|Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
9791079|NCT01404988|Placebo Comparator|Telephone-Delivered API|Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
9791080|NCT01405027|Other|Group A - HCEE|Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor. HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
9791081|NCT01405027|Other|Group B - Community Sites|Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
9791082|NCT01405053|Active Comparator|Rufinamide|
9791083|NCT01405053|Active Comparator|Any other approved AED|
9791084|NCT01405196|Other|10 mg of PF-04236921|
9791085|NCT01405196|Other|50 mg of PF-04236921|
9791086|NCT01405196|Other|200 mg of PF-04236921|
9791087|NCT01405196|Other|Placebo|
9791088|NCT01405313|Experimental|Modified ASV|Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
9791089|NCT01405313|Active Comparator|Conventional ASV|Conventional ASV This is the current (predicate) ASV algorithm.
9791090|NCT01405456|Experimental|Eplerenone and Lifestyle|First 6 months: eplerenone 50mg daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: same (eplerenone open label during second 6 months)
9791091|NCT01405456|Placebo Comparator|Placebo and Lifestyle|First 6 months: placebo pill daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: eplerenone (open label) 50mg daily along with continued lifestyle modification
9791092|NCT01405469|Experimental|Peroral Endoscopic Myotomy|Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment
9791093|NCT01405508|Experimental|Placebo tablets / Brivaracetam bolus|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
9791094|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV bolus|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"
9791095|NCT01405508|Experimental|Placebo tablets / Brivaracetam infusion|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
9791096|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV infusion|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
9985372|NCT02972801||Testicular tissue biopsy|Testicular biopsy
9791097|NCT01405560|Experimental|Vaniprevir 24 Week Arm|Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment
9791098|NCT01405742|Experimental|Arm A|"The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds."
9791099|NCT01405742|Experimental|Arm B|"The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds"
9791100|NCT01405768|Active Comparator|Lidocaine Arm|Women in this arm will receive plain lidocaine with epinephrine injected into their cervix prior to the LEEP procedure.
9791101|NCT01405768|Experimental|Buffered Lidocaine|Women in this arm will receive sodium bicarbonate buffered lidocaine mixed with epinephrine injected into their cervix prior to the LEEP procedure.
9791102|NCT01405794|Experimental|32ppm Oral Silver|14 Days Active Silver Solution
9791103|NCT01405794|Placebo Comparator|Sterile Water|No Silver Nanoparticles
9791104|NCT01405820|Active Comparator|Natalizumab 300 mg Intravenous (IV) Every 4 Weeks|Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
9791105|NCT01405820|Experimental|Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks|Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
9791106|NCT01405820|Experimental|Natalizumab 300 mg IV Every 12 Weeks|Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
9791107|NCT01405820|Experimental|Natalizumab 300 mg SC Every 12 Weeks|Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
9791108|NCT01405820|Experimental|Natalizumab 150 mg IV Every 12 Weeks|Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
9791109|NCT01405820|Experimental|Natalizumab 150 mg SC Every 12 Weeks|Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
9791110|NCT01405898|Experimental|Beetroot Juice|
9791111|NCT01405898|Placebo Comparator|Nitrate-free beetroot juice|
9791112|NCT01405911|Placebo Comparator|Placebo|Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
9791113|NCT01405911|Experimental|Sitagliptin 25 mg|Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
9791114|NCT01405911|Experimental|Sitagliptin 50 mg|Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.
9791115|NCT01405924|Experimental|Fosaprepitant 150 mg|Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy
9791116|NCT01405937|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
9791117|NCT01405937|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
9791118|NCT01405950|Experimental|Dose Level 1|
9791119|NCT01405950|Experimental|Dose Level 2|
9791120|NCT01405950|Experimental|Dose Level 3|
9791121|NCT01405950|Experimental|Dose Level 4|
9791122|NCT01406015|Active Comparator|Spironolactone|
9791123|NCT01406015|Placebo Comparator|Placebo|
9791124|NCT01406223|Active Comparator|varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
10213445|NCT04010539|Active Comparator|Ceftriaxone plus Azithromycin|Subjects will receive a single IM dose of Ceftriaxone plus a single oral dose of Azithromycin at the study site during the Baseline (Day 1) visit.
9791125|NCT01406223|Active Comparator|NRT (nicotine patches only)|21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
10213446|NCT04009668|Experimental|adalimumab|Adalimumab dose every other week (study weeks 0, 2, 4, 6, and 8), subcutaneously
10213447|NCT04008238|Experimental|Biomarker analysis|This study is a single arm study with biomarker analysis
10213448|NCT04001803|Experimental|Subjects with HIV infection|HIV-infected subjects receiving CAB LA+RPV LA will be included in this arm.
10213449|NCT03995017|Experimental|Safety Lead In|"Rucaparib 600 milligrams twice daily~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~Nivolumab 480 milligrams intravenous every 4 weeks~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients~1 cycle= 28 days"
10213450|NCT03995017|Experimental|Cohort A|"Rucaparib 600 milligrams twice daily~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~Nivolumab 480 milligrams intravenous every 4 weeks~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~1 cycle= 28 days"
9791126|NCT01406223|Active Comparator|varenicline + bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus bupropion at a dose of 150mg once per day. Subsequently, the dose of varenicline will be 1 mg twice per day and the dose of bupropion will be 150 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline and bupropion, smokers in this group will also receive placebo patches.
9791127|NCT01406223|Placebo Comparator|Post-quit NRT|Nicotine patches at 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
9791128|NCT01406444|Active Comparator|rhIGF-1 followed by Risedronate|Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
9791129|NCT01406444|Active Comparator|Risedronate|Risedronate 35mg PO once weekly for 12 months
9791130|NCT01406444|Placebo Comparator|Placebo|Placebo for 12 months
9791131|NCT01406574|Experimental|OPB-31121 p1|Phase1 step
9791132|NCT01406574|Experimental|OPB-31121 p2|Phase2 step
9791133|NCT01406652|Active Comparator|One-stage bursectomy|Bursectomy with debridement and primary closure of the wound during one surgical intervention
9791134|NCT01406652|Experimental|Two-stage bursectomy|Bursectomy with debridement and left open. Wound closure in a second step and in a second surgery.
9791135|NCT01406717|Experimental|SPIL1033|
9791136|NCT01406717|Placebo Comparator|Placebo|
9791137|NCT01406795|Experimental|Venous Stent Arm|The study is a single treatment arm study and the venous stent will be placed in all eligible participants.
9791138|NCT01406873|Active Comparator|Mexiletine|20 subjects will be randomized (assigned) to receive Mexiletine. Mexiletine is available on the market for the treatment of cardiac arrhythmias, but it is not currently approved for the treatment of myotonia or myotonic dystrophy.
9791139|NCT01406873|Placebo Comparator|Sugar pill|20 subjects will be randomized (assigned) to receive placebo (sugar pill). This control group is necessary to definitely establish the antimyotonic efficacy and safety of mexiletine.
9791140|NCT01406938|Experimental|AIN457150 mg- Induction period Only(IPO)|secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
9791141|NCT01406938|Experimental|AIN457 300 mg - IPO|secukinumab- 2 x 150mg injections per dose
9791142|NCT01406938|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
9791143|NCT01406938|Experimental|AIN457 300 mg FI|2 s.c. secukinumab 150 mg injections
9791144|NCT01406938|Experimental|AIN457 150 mg- Start of relapse (SoR)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
9791145|NCT01406938|Experimental|AIN457 300 mg- SoR|2 s.c. secukinumab 150 mg injections
9791146|NCT01406990||Aspirin 81 mg|Women with CAD taking 81 mg aspirin.
9791147|NCT01407068|Experimental|AA4500|AA4500 collagenase clostridium histolyticum
9791148|NCT01407094|Active Comparator|Sertraline|SSRI monotherapy
9791149|NCT01407094|Placebo Comparator|Placebo|Placebo control
9791150|NCT01407094|Active Comparator|Bupropion|BupropionXL
9791151|NCT01407107|Experimental|Nitroglycerin|Dose escalation trial of Nitroglycerin
9791152|NCT01407276|Experimental|Part 1: Mild Renal Impairment (Panel A)|
9791153|NCT01407276|Experimental|Part 1: Control to Match Panel A (Panel B)|
9791154|NCT01407276|Experimental|Part 1: Moderate Renal Impairment (Panel C)|
9791155|NCT01407276|Experimental|Part 1: Control to Match Panel C (Panel D)|
9791156|NCT01407276|Experimental|Part 1: Severe Renal Impairment (Panel E)|
9791157|NCT01407276|Experimental|Part 1: Control to Match Panel E (Panel F)|
9791158|NCT01407276|Experimental|Part 2: End-stage Renal Disease needing hemodialysis (Panel G)|
9791159|NCT01407276|Experimental|Part 2: Control to Match Panel G (Panel H)|
9791160|NCT01407354|Experimental|Lokomat Training|Lokomat robotic assisted treadmill training Lokomat Treadmill Training
9791161|NCT01407354|Active Comparator|Aquatic Therapy|Aquatic exercise therapy
9791162|NCT01407367||Phase I and Phase II|"Phase I (First 100 participants):~Medical alert bracelet/necklace, Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs~Phase II (Next 250 participants):~Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs"
9791163|NCT01407523|Experimental|Levetiracetam|Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
9791164|NCT01407575|Experimental|Buprenorphine|0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks
9791165|NCT01407575|Placebo Comparator|Placebo|matching placebo- sublingual- over the course of 8 weeks
9791166|NCT01407926||Nurse-Led Mental Health Promotion Group|Interprofessional nurse-led strategy involving regular home visits over 6 months by an RN and PSW. The RN will conduct a comprehensive health assessment and screen clients for risk factors for depression and other chronic conditions, implement health promotion strategies to address this risk factors and enhance health, review their medications, conduct in-home exercise , refer clients to other health services
9791167|NCT01407952|Other|HydroCoil Embolic System|Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
9791168|NCT01407952|Other|Control|Aneurysm treatment using bare platinum coil(s)
9791169|NCT01408030|Placebo Comparator|Placebo spray|sterile saline
9791170|NCT01408030|Active Comparator|Bevacizumab spray|bevacizumab 1%
9791171|NCT01408030|Active Comparator|Estriol spray|Estriol 0.1%
9791172|NCT01408030|Active Comparator|Tranexamic acid spray|tranexamic acid 10%
9791173|NCT01408043|Experimental|Treatment (stem cell supermobilization)|Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
9791174|NCT01408147|Active Comparator|Treatment Group|This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
9791175|NCT01408147|No Intervention|Standard WIC care|The control group will received Standard Care as provided through WIC.
9791176|NCT01408277|Active Comparator|Santyl|2mm Santyl applied once daily.
9791177|NCT01408277|Active Comparator|Control|Standard Care
9791178|NCT01408303|Placebo Comparator|Olive Oil|olive oil: 4 g/day + prescription statin
9791179|NCT01408303|Experimental|Epanova, 2 g|omega-3-carboxylic acids, 2g/day + prescription statin
9791180|NCT01408303|Experimental|Epanova, 4 g|omega-3-carboxylic acids, 4g/day + prescription statin
9791181|NCT01408329|Sham Comparator|Control|Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.
9791182|NCT01408329|Experimental|Hypoxic intervention|Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.
9791183|NCT01408459|Active Comparator|Tomato product|Motivational telephone counseling weekly
9791184|NCT01408459|Placebo Comparator|Control|No Motivation telephone Counseling
9791185|NCT01408485|Experimental|Treatment Arm|Radio-frequency cardiac ablation for treatment of isthmus-dependant atrial flutter using the Therapy™ Cool Flex™ Irrigated Ablation System
9791186|NCT01408537|Experimental|JEVAC|JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year
10213451|NCT03995017|Active Comparator|Cohort B|"Rucaparib 600 milligrams twice daily~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy~1 cycle= 28 days"
10213452|NCT03986047|Experimental|Thermal care|Participants will be asked to wear a heat wrap over the lower lumbar spine, during the day for 8 hours on 7 consecutive days. The Thermal care group will also receive education by a physiotherapist on acute low back pain management.
9791187|NCT01408563|Experimental|Fludarabine/Melphalan/TBI|All patients receive same therapy
9791188|NCT01408576|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles
9791189|NCT01408576|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles
9791190|NCT01408628|Experimental|Internet Insulin Education|"Single arm study; intervention represented by subjects' participation in 4 synchronous (live) interactive Internet classes."
9791191|NCT01408706|Active Comparator|Miller enema air tip|The Miller enema air tip rectal balloon is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy.
9791192|NCT01408706|Active Comparator|Radiadyne Immobilizer|The Radiadyne Immobilizer Treatment Device is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy
9791193|NCT01408719|Experimental|5g LMW beta glucan|5 gram low molecular weight barley beta-glucan diet for 35 days
9791194|NCT01408719|Experimental|3g HMW beta glucan|3 gram high molecular weight barley beta-glucan diet for 35 days
9791195|NCT01408719|Experimental|3g LMW beta glucan|3 grams of low molecular weight beta-glucan diet for 35 days
9791196|NCT01408719|Placebo Comparator|Control|control diet containing negligible amount of beta glucan
9985373|NCT02970318|Experimental|Acalabrutinib (ACP-196)|Acalabrutinib (ACP-196) Monotherapy
9791197|NCT01408732|Experimental|Standard Treatment then Sclerotherapy Intervention|"The standard treatment group will continue their pre-study standard treatment methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks"
9791198|NCT01408732|Experimental|Sclerotherapy Intervention then Standard Treatment'|This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks
9791199|NCT01408862||controls|Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture
9985374|NCT02970318|Active Comparator|Rituximab Plus Idelalisib or Bendamustine|Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
9985375|NCT02964559|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9985376|NCT02960997|Experimental|Sirolimus, then Placebo|Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.
9985377|NCT02960997|Placebo Comparator|Placebo, then Sirolimus|Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.
10206439|NCT04496986||Cardiovascular Surgical Patients Postoperative Exam|All remaining participants without preoperative dysphagia will be seen for a postoperative exam performed within 48 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow up clinic visit.
9985378|NCT02951104|Experimental|USCOM|
9985379|NCT02950493|Other|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.
9985380|NCT02949128|Experimental|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks for 26 weeks in the Initial Evaluation Period.~After the Initial Evaluation Period, participants could enter an Extension Period and receive ravulizumab until the product registration or approval (in accordance with country-specific regulations) or for up to 4.5 years, whichever occurs first."
10206440|NCT04477564||Unprovoked proximal deep vein thrombosis|
10206441|NCT04477564||Provoked distal deep vein thrombosis|
10206442|NCT04477564||age-matched control group with no history of vein thrombosis|
9839327|NCT02988960|Experimental|Escalating Arm 1: ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
9839328|NCT02988960|Experimental|Escalating Arm 2: ABBV-927|Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
9839329|NCT02988960|Experimental|Escalating Arm 3: ABBV-927+ABBV-181|Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
9839330|NCT02988960|Experimental|Escalating Arm 4: ABBV-927+ABBV-181|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
9839331|NCT02988960|Experimental|Escalating Arm 5 (Japan): ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
9839332|NCT02988960|Experimental|Escalating Arm 6 (Japan): ABBV-927+ABBV-181|Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
9839333|NCT02988960|Experimental|Expansion Arm A: ABBV-927|Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
9839334|NCT02988960|Experimental|Expansion Arm B: ABBV-927+ABBV-181|Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
9839335|NCT02988960|Experimental|Expansion Arm C: ABBV-927+ABBV-181|Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
9839336|NCT02984384|Active Comparator|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
9985381|NCT02947217|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
9985382|NCT02947217|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
9839337|NCT02984384|Active Comparator|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
10206443|NCT04476797|Experimental|Arm A Active GC4711|
10206444|NCT04476797|Placebo Comparator|Arm B Placebo|
10206445|NCT04472182|Experimental|Fluoride varnish with xylitol coated calcium and phosphate|
10206446|NCT04472182|Active Comparator|Conventional Fluoride varnish|
10206447|NCT04467905|Placebo Comparator|Placebo|Patients will receive a total of 200 μL of placebo ((i.e. 100 μL in each nostril) via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
10206448|NCT04467905|Experimental|Etripamil|Patients will receive a total of 200 μL of etripamil Nasal spray 70 mg via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
9921995|NCT00833625|Experimental|PET/CT Scan + Biomarkers Testing|"PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).~Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis."
9921996|NCT00833651||tacrolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
9921997|NCT00833651||sirolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
9921998|NCT00833651||Healthy controls|Age, gender- and race-matched individuals, not on immunosuppressive medications
9921999|NCT00833716|Experimental|A|
9922000|NCT00833729|Experimental|etanercept|Single armed study
9922001|NCT00833742|Experimental|1|ISTDP therapy was provided
10213453|NCT03986047|Experimental|Thermal care + exercises|In addition to heat wrap and pain management education as for Thermal care group, participants of this group will be asked to perform exercises at home over 7 days, targeted on functional capacity, lumbar mobility, and slight contraction of trunk muscle (posture and/or cognitive).
10213454|NCT03986047|Sham Comparator|Control|Participants in the control group will receive the same education program as those of the two other groups. A sham non-heating wrap will be used to control for potential supportive and sensory influence of the heat wrap.
10213455|NCT03980314|Active Comparator|Arm A (Process C)|
10213456|NCT03980314|Experimental|Arm B (Process D)|
9839344|NCT02977299|Experimental|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
9839345|NCT02977299|Experimental|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
9839346|NCT02977299|Experimental|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
9839347|NCT02975895|Other|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
9839348|NCT02975895|Other|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
9985383|NCT02944071|Experimental|(Ranger & Ranger LE) and Ranger DCB|"The working length is 80cm and 135cm for Ranger DCB catheter and 90 cm and 150cm for Ranger SL and Ranger LE DCB catheter.~Multiple interventions:~Prior to or during Index Procedure:~Prior to treatment of the index limb, successful (< 30% residual stenosis) treatment of ipsilateral iliac inflow lesions may be performed~Prior to treatment of the index limb, successful treatment of the arteries of the non-index limb may be performed~Prior to treatment of the index limb, absence of clinical complications such as embolism, thrombosis, severe dissection, vessel rupture must be confirmed."
9985384|NCT02926079||Pregnant women diagnosed with gestational diabetes|
9985385|NCT02926079||Pregnant women with normal pregnancy|
9985386|NCT02924480|Active Comparator|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
9985387|NCT02924480|Placebo Comparator|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
9985388|NCT02924064|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
9839359|NCT02966886|Active Comparator|Participants with 10-15 degrees of glenoid retroversion|
9839360|NCT02966886|Active Comparator|Participants with >15 degrees of glenoid retroversion|
9839363|NCT02952846|No Intervention|Before algorithm|Observational
9839364|NCT02952846|Experimental|After algorithm|Algorithm for tapering of analgosedation
9839365|NCT02943408|Experimental|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
9839366|NCT02943408|Active Comparator|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
9985389|NCT02924064|Placebo Comparator|Placebo|Placebo for 24 weeks in combination with metformin
9985390|NCT02920788|Experimental|Veteran Mild TBI Group - GOALS Intervention|Veterans ages 18+ with chronic mild TBI, to undergo GOALS cognitive training as an intervention.
9985391|NCT02920788|Active Comparator|Veteran Mild TBI - Treatment as Usual|Veterans ages 18+ with chronic mild TBI, matched by demographic and clinical criteria to the GOALS group, to receive the standard clinical care.
9985392|NCT02920788|No Intervention|Veteran Non TBI - No Treatment|Veterans ages 18+ with no history of TBI, to undergo Neuropsychologic evaluation and MR Imaging with no intervention.
9839371|NCT02932410|Experimental|Macitentan|Macitentan is administered once daily via oral route. Children less than (<) 2 years old (y.o.) will be assigned as a cohort to the macitentan group without randomization. The dose will be adjusted to the participant's age (for those < 2 y.o.) or to the participant's body weight (for those greater than or equal to (>=) 2 y.o.). single-arm extension period (SAEP) will start at end of core period (EOCP) visit and ends at end of study (EOS) visit.
9839372|NCT02932410|Other|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with pulmonary arterial hypertension (PAH) non-specific treatment and/or up to two PAH-specific medications excluding macitentan and intravenous/subcutaneous (IV/SC) prostanoids.
9985393|NCT02917993|Experimental|Itacitinib + osimertinib|
9985394|NCT02916706|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
9985395|NCT02916706|Placebo Comparator|Placebo|Placebo for 24 weeks
9985396|NCT02909777|Experimental|CUDC-907|"CUDC-907 orally administered~CUDC-907 once daily for 5 consecutive days per week followed by two days without dosing~Dose level assigned at registration~Pre-dose pharmacokinetic blood sample will be collected~Dose escalation will follow a standard 3+3 design"
9839377|NCT02923466|Experimental|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
9839378|NCT02923466|Experimental|Selection of VSV-IFNβ-NIS Monotherapy|VSV-IFNβ-NIS will be administered either intratumorally, intravenously or with a combination of intratumorally and intravenously as a single dose on day 1.
9839379|NCT02923466|Experimental|VSV-IFNβ-NIS and avelumab|"VSV-IFNβ-NIS will be administered as determined in arm 2 as a single dose on day 1.~Avelumab will be administered intravenously every 2 weeks starting on day 1."
9839380|NCT02915198|Experimental|Metformin|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
9839381|NCT02915198|Placebo Comparator|Placebo|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
9839382|NCT02915185|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
9839383|NCT02915185|Experimental|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
9839384|NCT02914600|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 432 weeks
9839385|NCT02914600|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 432 weeks
9839386|NCT02914600|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg for up to 432 weeks
9839387|NCT02914600|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 432 weeks
9839388|NCT02914600|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 432 weeks
9985397|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
9922002|NCT00833742|No Intervention|2|People referred but never seen
9922003|NCT00833768|Active Comparator|Sevelamer carbonate|
9922004|NCT00833768|Placebo Comparator|Placebo|
9985398|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
9791200|NCT01408888|Experimental|LY2189265, Sitagliptin + LY2189265|A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
9791201|NCT01408888|Experimental|Sitagliptin + LY2189265, LY2189265|100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
9791202|NCT01408901|Experimental|A: GM-CSF + supervised treadmill exercise therapy|
9791203|NCT01408901|Active Comparator|B: GM-CSF + attention control group|
9791204|NCT01408901|Active Comparator|C: placebo + supervised exercise therapy|
9791205|NCT01408901|Placebo Comparator|D: placebo + attention control group|
9791206|NCT01408914|No Intervention|RIF 600|
9791207|NCT01408914|Experimental|RIF 900|
9791208|NCT01408914|Experimental|RIF 1200|
9791209|NCT01408992|Experimental|FMHT|All community people will be interviewed with Thai Five Minute Hearing Test questionnaire and will be tested with an audiometry.
9791210|NCT01409096|Active Comparator|Pregnenolone|This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.
9791211|NCT01409096|Placebo Comparator|Placebo|The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks.
9791212|NCT01409213||All Enrolled Participants|
9791213|NCT01409239|Active Comparator|Subcutaneous Insulin|
9791214|NCT01409239|Experimental|Intravenous insulin|
9791215|NCT01409382|Active Comparator|Lifestyle counseling|Daily brisk walking plus a carbohydrate-restricted diet
9791216|NCT01409382|No Intervention|Standard follow-up|Prenatal care will proceed according to the routine.
9791217|NCT01409434|Other|Follow-Up Arm|All patients are recruited for inclusion in the Follow-Up Arm, which is the sole arm of the study. The Follow-Up Arm includes a one time study visit in which study interventions are performed. The Follow-Up Arm involves patients from the parent study who were enrolled in the follow-up study. The intervention in the Follow-Up Arm is the Oral Glucose Tolerance Test.
9791218|NCT01409564|Experimental|Cilostazol|Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
9791219|NCT01409564|Placebo Comparator|Placebo|Placebo group means dementia patients group receiving donepezil with placebo.
9791220|NCT01409707|Experimental|Healthy lifestyles sessions|Healthy lifestyles sessions is a structured 9-12 session intervention that provides education about a variety of health-related topics. Each therapy session was 50-60 minutes long. Sessions included the provision of information, discussing participants' understanding of information, and answering questions about the information provided.
9791221|NCT01409707|Experimental|Trauma-focused exposure therapy|Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
9791222|NCT01409707|Experimental|Motivational enhancement + trauma-focused exposure therapy|A one session, 90 min. trauma-focused motivational enhancement therapy session was provided prior to starting the trauma-focused exposure therapy. Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
9791223|NCT01409811|Experimental|Treatment (zoledronic acid)|"Patients receive a single dose of zoledronic acid 4 mg IV over 15 minutes on day 1. Patients then undergo planned definitive surgery (lumpectomy or mastectomy) on day 10-23. Tissue and blood samples from the initial biopsy and definitive surgery are collected to measure changes in biomarkers of tumor growth and metastasis, immunologic function, and the expression of genes important to breast cancer progression and metastasis.~zoledronic acid: Given IV~laboratory biomarker analysis: Correlative studies~therapeutic conventional surgery: Undergo definitive lumpectomy or mastectomy"
9791224|NCT01409837|Placebo Comparator|Sugar pill|Started with Placebo until the crossover.
9791225|NCT01409837|Experimental|Lisinopril|Started with Lisinopril until the crossover
9791226|NCT01409915|Experimental|Sagramostim (Leukine)|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
9791227|NCT01409915|Placebo Comparator|Control Group|Saline -- placebo comparator. Given as a subcutaneous injection.
9800460|NCT01688310|Experimental|Gomco clamp with tissue adhesive|Coupling removal of the foreskin with the Gomco clamp followed by wound sealing with tissue adhesive results in a procedure that can be performed by generalist doctors using the same technique in all age groups.
9839389|NCT02914561|Experimental|Filgotinib 200 mg (Induction Study)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
9839390|NCT02914561|Experimental|Filgotinib 100 mg (Induction Study)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 10 weeks
9839391|NCT02914561|Placebo Comparator|Placebo (Induction Study)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
9839392|NCT02914561|Experimental|Maintenance Study|Participants who meet response or remission criteria at Week 10 will continue into the Maintenance Study and receive filgotinib and/or placebo for 48 weeks.
9985399|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
9985400|NCT02889900|Experimental|combination of cediranib and olaparib|Open label
9985401|NCT02882022|Experimental|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
9985402|NCT02881554|Experimental|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.~In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.~In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
9985403|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
9985404|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
9985405|NCT02875158|Active Comparator|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
9839400|NCT02909647|Active Comparator|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
9839401|NCT02909647|Active Comparator|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
9839402|NCT02908906|Experimental|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), IV every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous [SC] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4 to evaluate additional doses.
9839403|NCT02906202|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene)
9839407|NCT02879630||Obese Patients|Obese patients (patients whose weight is >190% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by adjusted body weight as part of their routine care.
9839408|NCT02879630||Non-obese Patients|Normal weigh patients (patients whose weight is 80-120% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by total body weight as part of their routine care.
9839409|NCT02876315|Experimental|Redoxon VI|2 film coated tablets Redoxon VI oral intake daily for 12 weeks
9839410|NCT02876315|Placebo Comparator|Placebo|2 film coated tablets placebo oral intake daily for 12 weeks
9839411|NCT02874898|Active Comparator|Heavy marijuana use|Heavy marijuana users with PTSD
9839412|NCT02874898|Active Comparator|No marijuana use|Non-marijuana users with PTSD
10206449|NCT04466163|Experimental|Schema Therapy and the Healthy Adult|For this study the ST-HA protocol outlined by Broersen & Claassen (2019) will be followed, consisting of ten one-and-a-half hour individual sessions across ten weeks with daily homework assignments (30-60 minutes). The ST-HA protocol is based on three pillars, aimed at improving self-compassion, well-being and positive affect. First psycho-education about compassionate affect regulation is given and patients learn to recognize the importance of self-caring behavior in stimulating the soothing- affect system to buffer against stress. The second pillar of the ST-HA protocol concerns the development of personal values and committed action as well as getting insight in values of important others. The third pillar concerns developing self-compassion
9839413|NCT02869425|Experimental|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
9839414|NCT02869425|Placebo Comparator|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
10206450|NCT04466163|No Intervention|Baseline|Outcome variables will be measured repeatedly in a pre-treatment baseline condition (2-5 weeks). Patients are randomly assigned to a pre-treatment/baseline phase. In the present study a restricted randomisation is chosen (Heyvaert & Onghena, 2014a). A minimum length of the phases is decided a priori in order to prevent for the assignment of too few measurements per phase and to ensure that the full treatment protocol can be offered
9839415|NCT02863380|Experimental|Individualized rTMS (transcranial magnetic stimulation)|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks."
9839416|NCT02863380|Active Comparator|Classical rTMS (transcranial magnetic stimulation)|rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
9839417|NCT02863380|Active Comparator|Classical tDCS (transcranial direct current stimulation)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
9839418|NCT02860364|Experimental|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
9839419|NCT02860364|Active Comparator|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
9985406|NCT02875158|Experimental|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
9985407|NCT02873819|Experimental|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
9985408|NCT02873819|Placebo Comparator|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
10206451|NCT04462965|Experimental|Test group|Toripalima Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
10206452|NCT04462965|Placebo Comparator|Placebo group|Placebo Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
9839425|NCT02853305|Experimental|Pembrolizumab + ST Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS standard therapy (ST) chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin at an area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
9839426|NCT02853305|Experimental|Pembrolizumab (Pembro)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses.
9922005|NCT00833807|Experimental|Nab-paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
9922006|NCT00833820|Active Comparator|A|Patients receiving real rTMS
10206453|NCT04458103|Experimental|prospective interventional cohort|The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will receive an RVAD (either the ProtekDuo or Impella RP) prior to or during LVAD implantation.
10206454|NCT04458103|No Intervention|retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be age and sex matched with the enrolled prospective interventional patients.
10206455|NCT04436991||Amoxicillin-clavulanate|Administration of amoxicillin-clavulanate as standard care therapy (4x or 6x 1g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
9791228|NCT01409928|Experimental|Lap-Band|Placement of the LAP-BAND® system will be performed laparoscopically under general anesthesia, using the pars flaccida technique. The device will be placed by surgeons from the University of Texas Southwestern Medical Center Obesity Management Program at Children's Medical Center Dallas. Surgeons will be fully trained in the placement of the LAP-BAND® device, in accordance with FDA approval of the device for the placement in adults. As is current practice in adults undergoing the procedure, incidentally discovered hiatal hernias are repaired at the time of band placement, to reduce the incidence of post-operative reflux. Children receive prophylactic antibiotics, and are observed overnight after surgery. Patients are generally discharged from the hospital the next day. The band will initially be left empty at the end of the placement procedure.
9791229|NCT01409993|Experimental|sildenafil Aim 1|sildenafil 25 mg p.o. tid
9791230|NCT01409993|Placebo Comparator|placebo Aim 1|matching placebo p.o. tid
9791231|NCT01409993|Experimental|sildenafil Aim 2|sildenafil 25 mg p.o. tid
9791232|NCT01409993|Placebo Comparator|placebo Aim 2|matching placebo p.o. tid
9791233|NCT01410058||Nevirapine|HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
9791234|NCT01410058||Efavirenz|HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
9791235|NCT01410084|Experimental|Vitamin D3|100,000 IU vitamin D3 once monthly
9791236|NCT01410084|Placebo Comparator|Vitamin E|400 IU vitamin E once monthly
9791237|NCT01410097|Experimental|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
9791238|NCT01410097|Placebo Comparator|Diabetes Support and Education (DSE)|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
9791239|NCT01410110|Experimental|Cognitive Training + Work Therapy|"Cognitive Training using auditory and visual Positscience software 5 hours/per week for 13 weeks.~Work Therapy for 15 hours per week at half minimum wage doing entry level duties at medical center job sites, supervised by regular medical center staff."
9791240|NCT01410110|Active Comparator|Work Therapy Only|Same work therapy but for 20 hours per week.
9791241|NCT01410227|Experimental|PK 80 Arm (minimum of 22 subjects with severe VWD)|PK assessment (80 IU/kg rVWF) + 12-month treatment period
9791242|NCT01410227|Experimental|PK 50 Arm (14 subjects with type 3 VWD)|Two single-blinded PK assessments (50 IU/kg rVWF + rFVIII/placebo) + 12-month treatment period
9791243|NCT01410227|Experimental|PK 50 Only Arm (minimum of 7 subjects with type 3 VWD)|PK assessment (50 IU/kg rVWF) only, no treatment of bleeding episodes
9791244|NCT01410227|Experimental|Treatment Only (up to 7 subjects independent of VWD subtype)|Treatment of bleeding episodes for a total of 12 months
9791245|NCT01410240|Active Comparator|Standard of Care (SoC)|SoC: conventional hemostatic techniques such as cautery and manual compression
9791246|NCT01410240|Experimental|FLOSEAL + Standard of Care (SoC)|"FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.~SoC: conventional hemostatic techniques such as cautery and manual compression"
9791247|NCT01410344|Other|Allogeneic Transplant|One regimen from either reduced-intensity conditioning (RIC) (Fludarabine and Busulfan; or Fludarabine and Melphalan) or myeloablative conditioning (MAC) (Busulfan and Fludarabine; or Cyclophosphamide and Total Body Irradiation) will be administered prior to allogeneic hematopoietic cell transplantation (HCT).
9791248|NCT01410357|Experimental|Targeted Training in Illness Management (TTIM)|Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
9791249|NCT01410357|No Intervention|Treatment As Usual (TAU)|Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.
9791250|NCT01410409|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
9791251|NCT01410409|Active Comparator|MEDIC + TKR|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
9791252|NCT01410409|Active Comparator|Observational Cohort|If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.
9791253|NCT01410448|Active Comparator|Immediate Everolimus (IE)|Everolimus was started within 48 hours after graft reperfusion at a starting dose of 0.75 mg twice daily in combination with low-dose cyclosporine and steroids for 3 months.
9791254|NCT01410448|Experimental|Delayed Everolimus|The standard dose of mycophenolate sodium was administered within 48 hours after graft reperfusion in combination with a full dose of cyclosporine and steroids. After28 +/- 4 days of treatment, mycophenolate sodium was discontinued and everolimus was introduced at a starting dose of 0.75 mg twice daily for 3 months.
9791255|NCT01410474|Experimental|2-18 years|
9791256|NCT01410552|Other|ICD or CRT-D with PARAD+|only 1 arm is the study: all patients implanted with ICD or CRT-D with PARAD+ enabled, no comparator
9791257|NCT01410565|Active Comparator|Apaziquone|
9791258|NCT01410565|Placebo Comparator|Placebo|Placebo
9791259|NCT01410604|Experimental|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
9791260|NCT01410604|Placebo Comparator|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
9791261|NCT01410773|Experimental|Intended Users of the System|Untrained subjects with diabetes (at least 70% of subjects will be insulin users) use an investigational blood glucose monitoring system (Ninja 2) to self-test capillary blood obtained from fingerstick and palm.
9800461|NCT01688336|Experimental|FOLFIRINOX|FOLFIRINOX given to all subjects
9922007|NCT00833820|Sham Comparator|B|patients receiving sham stimulation
9791262|NCT01410812|Experimental|Suggested Tying|Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.
10206456|NCT04436991||Piperacillin-tazobactam|Administration of piperacillin-tazobactam as standard care therapy (4x 4g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
10206457|NCT04436991||Temocillin|Administration of temocillin as standard care therapy (2x or 3x 2g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
9791263|NCT01410812|Experimental|Forced Tying|Receives same treatment as the control group. However, in addition to receiving the cash, they also receive 4 iTunes audio novels for a loaned iPod that they will only have access to at the gym. They are told they may only listen to these novels only when at the gym in order to increase their attendance.
9791264|NCT01410812|Experimental|Control|Control group of participants who do not receive any intervention but are weighed at the beginning and end of a 10 week period and receive weekly emails asking them about their exercise. They also receive the equivalent cash value of 4 iTunes audio novels
9791265|NCT01411085|Experimental|Risperidone + Desipramine|All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
9791266|NCT01411137|Experimental|IPX066|Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
9791267|NCT01411215||RA, AS|Rheumatoid arthritis patients Ankylosing spondylitis patients
9791268|NCT01411228|Experimental|60 Units/kg|
9791269|NCT01411228|Experimental|30 Units/kg|
9791270|NCT01411319|Experimental|LEAD Radiation Therapy|Participants in this group will receive the LEAD Radiation Therapy on Day 1 followed by 38 daily standard IMRT beginning Day 2.
9791271|NCT01411488|Experimental|Fecal Management System- Company 1|80 adult patients to be randomly assigned to receive a fecal management system by Bard Medical
9791272|NCT01411488|Active Comparator|Fecal Management System- Company 2|80 adult patients to be randomly assigned to receive a fecal management system by ConvaTec
9791273|NCT01411501|Experimental|Acupuncture at ST25 and BL25|the points formula of back-shu point combination with front-mu point.
9791274|NCT01411501|Experimental|Acupuncture at LI11 and ST37|the points formula of He-points
9791275|NCT01411501|Experimental|Acupuncture at ST25, BL25, LI11 and ST37|the formula of He-point,back-shu point and front-mu point
9791276|NCT01411501|Active Comparator|medicine|oral use of mosapride citrate
9791277|NCT01411527||Cross- sectional cohort|Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children
9791278|NCT01411527||Longitudinal cohort|"209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).~116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children."
9791279|NCT01411592|Active Comparator|Multilink|RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system [A/B primer and Multilink-Automix] with Metal/Zirconia primer)
9791280|NCT01411592|Active Comparator|Panavia 21 TC|RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
9799589|NCT01663714|Experimental|open-label, single arm|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
9799590|NCT01663727|Experimental|A|Paclitaxel + Bevacizumab [Avastin]
9799591|NCT01663727|Experimental|B|Paclitaxel + Placebo
9799592|NCT01663740|Experimental|Cohort A: Partcipants who Received Valganciclovir|Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
9799593|NCT01663740|No Intervention|Cohort B: Untreated Participants|Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.
9799594|NCT01663779|Experimental|Ultrasound radial artery catheter|Ultrasound guided radial artery catheterization.
9799595|NCT01663779|Active Comparator|Palpation based artery catheterization|Blind insertion of radial artery catheterization
9799596|NCT01663857|Experimental|Phase 1b (Cohort 1) LY2228820 200 milligrams (mg)|"Cohort 1: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3..~Cohort 1: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
9799597|NCT01663857|Experimental|Phase 1b (Cohort 2) LY2228820 300 mg|"Cohort 2: Cycles 1-6 (21 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Cohort 2: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
9922008|NCT00833872|Experimental|LEO 22811 solution|
9922009|NCT00833872|Placebo Comparator|placebo solution|
9839427|NCT02853305|Active Comparator|ST Chemotherapy (Chemo)|Participants receive ST chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin at AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
9985409|NCT02872467|Experimental|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
9839429|NCT02850874|Experimental|HIPEC|Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
9839430|NCT02850874|Other|Historical Control|Case-matched historical controls will have received neoadjuvant chemotherapy with gemcitabine prior to open pancreaticoduodenectomy (PD) by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy (SCT) with gemcitabine will be administered for 6 mo (including period of neoadjuvant therapy) according to established institutional protocol.
9839431|NCT02843568|Active Comparator|Standard of Care|"Subjects undergo four-dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning. Subjects undergo laboratory biomarker analysis, including spirometry, diffusion capacity (DLCO), and lung volumes (FEV, FEV1). Subjects complete a self-assessment, RTOG defined acute evaluation toxicity evaluation, RTOG late toxicity evaluation, and constitutional assessment.~Radiation doses between 60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation schemes are utilized. Treatment volumes are at the discretion of the treating radiation oncologist and should follow standard of care."
9839432|NCT02843568|Experimental|Pulmonary Function Damage Reduction|All criteria and specifications in the standard of care arm are applicable for this arm, including the same 4DCT scans, and laboratory biomarker analysis. Subjects randomized to this arm of the trial will have the same prescribed radiation dose to the tumor volume and held to the same radiation dose criteria as the subjects in the standard of care arm (60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation). The fundamental difference will be radiation doses for these subjects will be redistributed away from regions predicted to cause the greatest reduction in pulmonary function if damaged.
9985410|NCT02872467|Placebo Comparator|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
9985411|NCT02866695|Other|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
9985412|NCT02863445|Active Comparator|LNG-ECx1|Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
9985413|NCT02863445|Experimental|LNG-ECx2|Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
9985414|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
9985415|NCT02859337|Active Comparator|UPA-ECx1 followed by ECx2|Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.
9985416|NCT02859337|Experimental|UPA-ECx2 followed by ECx1|Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
9985417|NCT02859337|Other|UPA-ECx1 Normal BMI/weight|Ulipristal acetate 30mg orally x 1 dose. timing of dosage depends on follicle measurements. This is to obtain a normal BMI control group.
9985418|NCT02854436|Experimental|Niraparib|Participants will receive 300 milligram (mg) niraparib (3 capsules*100 mg) orally once daily.
9839443|NCT02827838|Experimental|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
9839449|NCT02815618||Infants delivered by elective caesarean|Infants to be measured immediately after birth and on their second day of life.
9839450|NCT02815618||Infants on mechanical ventilation|Infants to be measured while changing ventilator settings to normalize arterial pCO2.
9839451|NCT02815618||Infants on ventilatory support|Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
9922010|NCT00833885|Other|1|Control
9922011|NCT00833885|Other|2|Masks
9922012|NCT00833885|Other|3|Masks and Hygiene
9791281|NCT01411696||All Participants|Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.
9791282|NCT01411774|Active Comparator|Cognitive-behavioral therapy plus pill placebo|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with pill placebo taken 1 hour before the session.
9791283|NCT01411774|Experimental|Cognitive-behavioral Therapy plus d-cycloserine|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with d-cycloserine taken 1 hour before the session.
9791284|NCT01411839|Experimental|Cognitive-Behavioral Therapy (CBT-AD)|This arm type is a cognitive-behavioral therapy program intervention for issues of medication adherence and depression. The intervention is a therapy program intervention involves 10-weekly or biweekly sessions, with 2 booster session, and focused on psychoeducation, behavioral activation, cognitive restructuring, and problem-solving. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms.
9791285|NCT01411839|No Intervention|Control-Standard Care|Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms. The participants in the control arm are followed and matched to a participant in the intervention arm.
9791286|NCT01411852|Experimental|0.9% Sodium Chloride 250 mL bolus|0.9% Sodium Chloride 250 mL bolus - A large bore IV will be placed and a 250cc bag of normal saline (NS) will be hung. If IV placement is difficult, NS can be given through an intraosseous line. Using small bags versus large bags will physically limit the amount of fluid given to patients in the experimental group. The requirement to change the smaller bags of fluid and recheck the pulse or blood pressure will limit the amount of fluid given. The procedure will continue until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
9791287|NCT01411852|Active Comparator|0.9% Sodium Chloride 2000 mL bolus|0.9% Sodium Chloride 2000 mL bolus - The treatment of the control group will be consistent with traditional Prehospital Trauma Life Support and Advanced Trauma Life Support guidelines which recommend early aggressive fluid resuscitation. An intravenous line (IV) will be placed and a 1000cc bag of normal saline will be hung. If IV placement is difficult, fluid can be given through an intraosseous line. This procedure will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
9791288|NCT01411891|No Intervention|Control|Patients assigned to this study group will not have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
9791289|NCT01411891|Experimental|Chlorhexidine impregnated patch.|Patients assigned to this study group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
9791290|NCT01411917|Experimental|TAP block group|Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
9791291|NCT01411917|Placebo Comparator|Placebo|Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.
9791292|NCT01411995|Experimental|2% Lidocaine gel|Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal
9791293|NCT01411995|Placebo Comparator|Water based lubricant|Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal
9791294|NCT01412021||Humira|Participants with juvenile idiopathic arthritis who received Humira (adalimumab).
9791295|NCT01412060|Experimental|Cariprazine - Open-label Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
9791296|NCT01412060|Experimental|Placebo - Double-blind Treatment Phase|Participants received placebo orally once a day for 26 to 72 weeks.
9791297|NCT01412060|Experimental|Cariprazine - Double-blind Treatment Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks
9791298|NCT01412086||All Participants|Healthy volunteers. No treatment (intervention) was received.
9791299|NCT01412151|Other|Creatine monohydrate|single arm long-term open label follow-up
9791300|NCT01412164|Experimental|Firehawk|Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
9791301|NCT01412229|Experimental|Treatment|"nab-paclitaxel 100mg/m2~Carboplatin area under curve (AUC)2 (IV)~Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks"
9791302|NCT01412281|Experimental|Group A - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
9791303|NCT01412281|Active Comparator|Group B - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
9791304|NCT01412281|Experimental|Group C - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
9791305|NCT01412281|Active Comparator|Group D - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
9791306|NCT01412372|Experimental|Placebo|This arm will include those who are randomized to the placebo
9791307|NCT01412372|Experimental|Mesalamine|This arm is for subjects randomized to the study drug, Mesalamine
9985419|NCT02847728||Single Arm Design|The study encompasses a single arm design with 417 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 772 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.
9985420|NCT02846571|Other|Human Pancreatic Islet Transplantation|Islet transplantation into the anterior chamber of the eye single arm
9839455|NCT02794337|Active Comparator|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
9839456|NCT02794337|Experimental|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
9985421|NCT02840799|Experimental|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
9985422|NCT02840799|Placebo Comparator|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
9839459|NCT02785120|Experimental|High dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
9839460|NCT02785120|Experimental|Middle dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
9839461|NCT02785120|Experimental|Low dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
9985423|NCT02834793|Experimental|Perampanel up to 8 mg/day|"During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.~Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A."
9985424|NCT02834793|Placebo Comparator|Matching placebo|"During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.~During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion."
9839464|NCT02773485|Active Comparator|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
9839465|NCT02773485|Experimental|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
9791308|NCT01412424|Experimental|Octreotide capsules|Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
9791309|NCT01412541|Experimental|Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter
9791310|NCT01412541|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
9791311|NCT01412554||Longitudinal Insulin Sensitivity|The participants were examined using the hyperinsulinaemic isoglycaemic glucose clamp technique which is the gold standard to assess insulin sensitivity.
9791312|NCT01412710|Experimental|4000 IU group|This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.
9791313|NCT01412710|Experimental|6000 IU group|This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.
9791314|NCT01412801|Experimental|HIVneg|HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.
9791315|NCT01412801|Experimental|HIVposCD4HIGH|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count >350 cells/µL received one dose of Group B streptococcus vaccine.
9791316|NCT01412801|Experimental|HIVposCD4LOW|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but > 50 cells/µL received one dose of Group B streptococcus vaccine
9791317|NCT01412866|Experimental|EDSS with CO monitor|Web-based electronic decision support system (EDSS) with carbon monoxide (CO) monitor and health-checklist
9791318|NCT01412866|Active Comparator|EDSS without CO monitor|Web-based electronic decision support system (EDSS) with health-checklist only
9791319|NCT01412879|Experimental|Arm I|Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.
9791320|NCT01412879|Experimental|Arm II|Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.
9791321|NCT01412918|Experimental|Tinnitus|"Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device."
9791322|NCT01412918|No Intervention|No tinnitus|Individuals without tinnitus will also be masked with the device.
9791323|NCT01412944|Experimental|AIN457 subcutaneous (s.c.)|During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
9791324|NCT01412944|Experimental|AIN457 I.V.|During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
9791325|NCT01412957|Experimental|Panitumumab + BSC|Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.
9791326|NCT01412957|Other|BSC Alone|Participants received best supportive care until disease progression, withdrawal of consent, or death.
9791327|NCT01412983|Experimental|Bausch & Lomb Test Lens|Bausch + Lomb investigational soft contact lens
9791328|NCT01412983|Active Comparator|Ciba Vision soft contact lens|Ciba Vision Air Optix Aqua soft contact lens
9791329|NCT01413087|Experimental|8 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 8 mg of BC-819
9791330|NCT01413087|Experimental|12 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 12 mg of BC-819
9791331|NCT01413178|Experimental|Busulfan + Melphalan|Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
9791332|NCT01413178|Experimental|Melphalan|High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.
9985425|NCT02832271|Active Comparator|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
9985426|NCT02832271|Placebo Comparator|placebo group|placebo fro women with ultrasound confirmed endometriosis
9839474|NCT02763202|No Intervention|Usual Care Group|Participants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
9839475|NCT02763202|Experimental|CHS-TS Group|Participants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
9985427|NCT02830204|Experimental|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
9985428|NCT02827032|Experimental|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
9985429|NCT02825836|Experimental|TL-895 80/160 mg QD in R/R Participants|Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9985430|NCT02825836|Experimental|TL-895 300 mg QD in R/R Participants|Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9985431|NCT02825836|Experimental|TL-895 600 mg QD in R/R Participants|Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9985432|NCT02825836|Experimental|TL-895 300 mg BID in R/R Participants|Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9839481|NCT02759588|Experimental|GL-ONC1|
9839482|NCT02758184|Experimental|ROTEM Group|Patients who are randomized to receive ROTEM
9839483|NCT02758184|Other|Control Group|Patients who are randomized not to receive ROTEM
9839485|NCT02751710|Experimental|Whole-body FDG PET-CT alone|
9839486|NCT02751710|No Intervention|Conventional breast cancer staging|Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen & pelvis
9791333|NCT01413191|Experimental|CixutumumabTreatment|Cixutumumab 10 mg/kg intravenous (IV) over 1 hour on days 1 and 15 for 4 week courses.
9791334|NCT01413204|Experimental|TA-7284 Low|
9791335|NCT01413204|Experimental|TA-7284 High|
9791336|NCT01413204|Placebo Comparator|Placebo|
9791337|NCT01413360|Experimental|HD Vitamin C|High dose vitamin C
9791338|NCT01413503|Experimental|131I-MIBG|Patients received 131I-MIBG 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) diluted in 25 ml of normal saline. Patients were infused intravenously through a patient's peripheral or central line over 120 minutes
9791339|NCT01413516|Placebo Comparator|Placebo Control|Smoking cessation counseling with placebo comparator
9791340|NCT01413516|Active Comparator|Experimental: Varenicline|Smoking cessation counseling with varenicline
9791341|NCT01413542|Placebo Comparator|Placebo then sitagliptin (DPP4 inhibition) group 1|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to bradykinin and substance P are studied after administration of placebo or sitagliptin (DPP4 inhibition).
9791342|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then placebo group 1|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to substance P and bradykinin are studied after administration of sitagliptin (DPP4 inhibition) or placebo
9791343|NCT01413542|Placebo Comparator|Placebo then sitagliptin group 2|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to glucagon-like peptide-1 and brain natriuretic pepdie are studied after administration of placebo or sitagliptin (DPP4 inhibition).
9791344|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then comparator group 2|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to glucagon-like peptide and brain natriuretic peptide are studied after administration of placebo or sitagliptin (DPP4 inhibition).
9791345|NCT01413750|Experimental|Arm I (paclitaxel, carboplatin, vorinostat)|Patients receive paclitaxel IV over 3 hours, and carboplatin IV over 30 minutes on day 0. Patients also receive vorinostat PO once daily on days -2 to 2.
9791346|NCT01413750|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
9791347|NCT01413958|Experimental|Phenylephrine|
9791348|NCT01413958|Placebo Comparator|Placebo|
9791349|NCT01414010|Active Comparator|Prebiotic|
9791350|NCT01414010|Active Comparator|Probiotic|
9791351|NCT01414010|Active Comparator|Antibiotic|
9791352|NCT01414010|No Intervention|Control|Control group, no intervention given.
9791353|NCT01414036|Active Comparator|Enhanced Traditional Care control|This arm will receive a low literacy smoking cessation educational brochure, a list of hospital and community resources for smoking cessation, in addition to usual care.
9791354|NCT01414036|Experimental|Patient Navigation|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
9791355|NCT01414075|Experimental|Arm A + E (Participants on HD): Roxadustat Only, No Iron|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally 3 times weekly (TIW) for 12 weeks.
9791356|NCT01414075|Experimental|Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
9791357|NCT01414075|Experimental|Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with approximately 60 mg IV iron (ferric gluconate complex in sucrose injection [for example, Ferrlecit®] or equivalent) once a week for 12 weeks.
9791358|NCT01414075|Experimental|Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on PD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
9791359|NCT01414114|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) administered by intravenous bolus injection at the end of each hemodialysis session for 12 weeks. The starting dose was 5 mg and may have been titrated every 4 weeks based on the preceding serum parathyroid hormone (PTH) and corrected calcium (cCa) levels to a maximum dose of 20 mg per hemodialysis session in order to achieve the targeted PTH range while maintaining serum calcium within an acceptable range.
9791360|NCT01414153|Experimental|Monotherapy|4.0 mg iSONEP followed by sham injection; given monthly intravitreously for 4 months
9922013|NCT00833950|Experimental|narrow band noise|Phase out in narrow band noise tinnitus patients
9791361|NCT01414153|Experimental|0.5 mg iSONEP & Lucentis/Avastin/Eylea|0.5 mg iSONEP and 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
9791362|NCT01414153|Experimental|4.0 mg iSONEP & Lucentis/Avastin/Eylea|4.0 mg iSONEP followed by 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
9791363|NCT01414153|Active Comparator|Lucentis or Avastin or Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea followed by a sham injection; given monthly intravitreously for 4 months
9791364|NCT01414205|Experimental|Obinutuzumab 1000 mg|Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
9791365|NCT01414205|Experimental|Obinutuzumab 2000 mg|Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
9791366|NCT01414244|Active Comparator|Glutamine supplementation|Glutamine
9791367|NCT01414244|Placebo Comparator|Placebo|Whey protein powder
9791368|NCT01414257||Methotrexate (MTX)|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis.
9791369|NCT01414413|Experimental|Home assessment and initiation of ART|"Participants with a positive home-based HIV test result will receive a home visit from a study nurse who will complete the following on the first home visit:~Confirmatory fingerprick HIV testing~TB symptom screening~ART eligibility assessment (Word Health Organization clinical staging, sampling of blood for measurement of CD4 count and treatment education)~At a second home visit (within 5 days), participants who are ART eligible (as defined in National ART guidelines) will be initiated onto ART (using National Treatment Programme ART regimens).~Following home initiation of ART, participants in the intervention arm will receive detailed counselling from the study nurse about the need to attend their first 2-week follow-up appointment at the primary health care clinic that serves their household's residence. They will receive a referral slip detailing the date, time and place of their appointment."
9791370|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor. HIV care, including ART, will be started from the primary care clinic.
9791371|NCT01414426|Experimental|Arm I (chemoprevention)|Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
9791372|NCT01414426|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
9791373|NCT01414634|Experimental|ETIMS 1x10^3|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^3 cells.
9791374|NCT01414634|Experimental|ETIMS 1x10^5|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^5 cells.
9791375|NCT01414634|Experimental|ETIMS 1x10^7|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^7 cells.
9791376|NCT01414634|Experimental|ETIMS 1x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^8 cells.
9791377|NCT01414634|Experimental|ETIMS 5x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10^8 cells.
9791378|NCT01414634|Experimental|ETIMS 1x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^9 cells.
9791379|NCT01414634|Experimental|ETIMS 2.5x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10^9 cells.
9791380|NCT01414634|Experimental|ETIMS 3x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10^9 cells.
9791381|NCT01414738|Experimental|Radiation|Whole-Brain Radiotherapy
9791382|NCT01414855|Experimental|obinutuzumab + CHOP|Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.
9791383|NCT01415232|Experimental|Ultrasound measurement|Ultrasound using the Sonosite S-Nerve® US system (SonoSite, Bothell,WA) to measure depth to epidural space in morbidly obese parturients.
9791384|NCT01415349|Experimental|SSP-002358 alone|
9791385|NCT01415349|Experimental|SSP-002358 + omeprazole|SSP-002358 + omeprazole
9791386|NCT01415401|Experimental|AZARGA|Brinzolamide 1% / timolol 0.5% maleate fixed combination, 1 drop self-administered in study eye(s) twice daily for 8 weeks (8AM and 8PM)
9791387|NCT01415427|Experimental|BMN 110 Weekly|BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
9791388|NCT01415427|Experimental|BMN 110 Every Other Week|BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.
9791389|NCT01415440|Experimental|Psychostimulant|30-70 mg capsule of Lisdexamfetamine once daily for 12 weeks
9791390|NCT01415440|Placebo Comparator|Placebo|30-70 mg capsule of placebo (sugar pill) once daily for 12 weeks
9839487|NCT02750358|Experimental|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
9985433|NCT02825836|Experimental|TL-895 900 mg QD in R/R Participants|Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9985434|NCT02825836|Experimental|TL-895 100 mg BID in R/R Participants|Participants received TL-895 100 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9839490|NCT02740218||Psoriasis patients|Single cohort of psoriasis patients treated with OTEZLA (apremilast)
9839491|NCT02721732|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or toxicity. Patients with clinical response or disease stabilization may continue treatment for up to an additional 12 months.
9839492|NCT02721459|Experimental|Dose Escalation|Escalating Doses of XL888 with Vemurafenib plus Cobimetinib.
9985435|NCT02825836|Experimental|TL-895 150 mg BID in R/R Participants|Participants received TL-895 150 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9985436|NCT02825836|Experimental|TL-895 150 mg BID in Treatment Naïve Participants|Participants received TL-895 150 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
9985437|NCT02816983||SBRT for oligometastatic prostate cancer|
9985438|NCT02811263|Active Comparator|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)
9985439|NCT02811263|Placebo Comparator|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age
9985440|NCT02810457|Experimental|FKB238 / paclitaxel / carboplatin|"Drug: FKB238:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
9985441|NCT02810457|Active Comparator|Avastin / paclitaxel / carboplatin|"Drug: Avastin:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
9985442|NCT02798185||Former NFL Players|120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
9985443|NCT02798185||Former College Football Players|60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
9839502|NCT02698579||Participants treated with Lenti-D|Partcipants who have received Lenti-D Drug Product in a parent clinical study (bluebird bio-sponsored clinical trial) and who meet the eligibility criteria for the study LTF-304.
9985444|NCT02798185||Control Group|60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.
9985445|NCT02797964|Experimental|Open label|
9985446|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
9985447|NCT02795442|Experimental|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
9985448|NCT02795442|Experimental|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
9985449|NCT02787005|Experimental|Cohort 1: PD-L1 positive with measurable disease|Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
9985450|NCT02787005|Experimental|Cohort 2: PD-L1 negative with measurable disease|Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
9985451|NCT02787005|Experimental|Cohort 3: Bone metastases with non-measurable disease|Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
9839514|NCT02677870|Other|Diet treatment|In part 1 of the study, patients will not receive any medication. Each patient will DIET treatment alone. They will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week. Based on these diaries, average weekly Phe intake and Phe tolerance will be calculated and recorded.
9839515|NCT02677870|Active Comparator|Standard dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin dihydrochloride (Kuvan) or high-dose saproterin dihydrochloride (Kuvan)  groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Standard-dose saproterin dihydrochloride will be 20mg/kg (rounded up to the nearest 100mg) provided in the form of 100mg tablets. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
9839516|NCT02677870|Experimental|High dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin or high-dose saproterin groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
9839517|NCT02674750|Experimental|Group A|Group A: MYC translocation+ and/or MYC gene copy number gain by FISH
9839518|NCT02674750|Experimental|Group B|Group B: MYC expression in > 40% of tumor cells by IHC
9839519|NCT02674750|Experimental|Group C|Group C: MYC translocation- by FISH, and MYC expression in < 40% of tumor cells, and no MYC gene copy number gain by FISH
9985452|NCT02787005|Experimental|Cohort 4: RECIST 1.1-measureable disease|Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
9985453|NCT02787005|Experimental|Cohort 5: Bone metastases only or bone-predominant disease|Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
9985454|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
9985455|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
9985456|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
9985457|NCT02768597|Active Comparator|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
9839526|NCT02663102||Fluarix Tetra Group|Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
9985458|NCT02768597|Active Comparator|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
9985459|NCT02768597|Active Comparator|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
9985460|NCT02768597|Active Comparator|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
9985461|NCT02760485|Experimental|itacitinib + ibrutinib|
9839538|NCT02652455|Experimental|PD-1, CD137 and Adoptive Cell Therapy|"Combination Therapy and Immunotherapy as described in intervention descriptions.~Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.~Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment."
9791391|NCT01415453|Experimental|Retinitis Pigmentosa|Subject will have retinitis pigmentosa and will be legally blind in one or both eyes
9791392|NCT01415518|Other|1|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
9791393|NCT01415518|Other|2|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
9791394|NCT01415531|Experimental|1|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
9791395|NCT01415531|Placebo Comparator|2|Dose-matched placebo
9791396|NCT01415583|Placebo Comparator|Saline|Placebo is described in chart
9791397|NCT01415583|Experimental|Dexamethasone|Dexamethasone is described in chart
9791398|NCT01415908|Active Comparator|Control Group|
9791399|NCT01415908|Experimental|Investigational Group|
9791400|NCT01415921|Experimental|Pyridostigmine Bromide|Forced titration protocol 15-60 mg every 8 hours as tolerated
9791401|NCT01415921|Placebo Comparator|Placebo|Matching placebo forced titration 15-60 mg as tolerated
9791402|NCT01415934|No Intervention|Continue Statins|Participant will continue on statins as per usual
9791403|NCT01415934|Experimental|Discontinue statins|Participant will stop taking their statin drugs
9791404|NCT01415960|Experimental|Leuprolide acetate 22.5 mg depot|Leuprolide acetate 22.5 mg depot administered twice, 3 months apart
9791405|NCT01416025|Experimental|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
9791406|NCT01416025|No Intervention|Standard dosing|Standard doses of voriconazole will be used
9791407|NCT01416129|Active Comparator|Active Comparator: Prosthetic socket standard of care|
9791408|NCT01416129|Active Comparator|Active Comparator: Prosthetic brimless socket|
9791409|NCT01416142|Active Comparator|Spectacles|The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)
9791410|NCT01416142|Experimental|PureVision2 HD contact lenses|Currently marketed Bausch + Lomb PureVision2 HD contact lenses
9791411|NCT01416155|Experimental|natalizumab|300 mg intravenous (IV) infusions of natalizumab every 4 weeks until product is approved in Japan or development is discontinued in Japan, whichever comes first.
9791412|NCT01416181|Experimental|natalizumab|In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
9791413|NCT01416181|Experimental|Placebo|In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
9791414|NCT01416194||Bazedoxifene|
9791415|NCT01416194||Primary Comparator|
9791416|NCT01416194||Secondary Comparator|
9791417|NCT01416389|Experimental|LY2523355 + pegfilgrastim or filgrastim|LY2523355: Five milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Pegfilgrastim or Filgrastim: Dosage is determined by standard of care and is administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
9791418|NCT01416389|Active Comparator|ixabepilone|Forty milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
9791419|NCT01416441|Experimental|Aripiprazole|Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.
9791420|NCT01416571|Experimental|Influenza A (H5N1) Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
9791421|NCT01416584|No Intervention|Usual Care Control|Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
9791422|NCT01416584|Experimental|Methadone Contingency Group|Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
9791423|NCT01416584|Experimental|Methadone & Abstinence Contingency|Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).
9791424|NCT01416610||All Participants|Participants with chronic hepatitis C, Genotype 2, 3, 1 or 4, undergoing an opioid maintenance therapy
9791425|NCT01416636|Active Comparator|Treprostinil sodium low dose - Arm I|"Arm I (low dose):~Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
9800462|NCT01688466|Experimental|0.5 mg/day with Dose Escalation|0.5 mg/day with Dose Escalation by 0.5 mg/day increments every 2 weeks to a maximum of 2.0 mg/day
9985462|NCT02757989|Experimental|Patients with donor|Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
9985463|NCT02757989|No Intervention|Patients without donor|Patients without a matched donor
9985464|NCT02754856|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.
9985465|NCT02750605|Experimental|Drug eluting balloon angioplasty|Intervention with DEB angioplasty in long lesions of crural arteries
9985466|NCT02750605|Active Comparator|Plain old balloon angioplasty|Intervention with plain old balloon angioplasty POBA in long lesions of crural arteries
9985467|NCT02746809|Experimental|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
9985468|NCT02745535|Experimental|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
9985469|NCT02742883|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for up to 104 days. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached, but not exceeding 12.0 g/kg/d Atengenal or 0.4 mg/kg/d Astugenal.
9839549|NCT02638701|Experimental|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
9839550|NCT02631733|Experimental|Treatment (liposomal irinotecan, veliparib)|Patients receive liposomal irinotecan IV over 90 minutes on days 1 and 15 and veliparib PO BID on days 5-12 and 19-25 or 3-12 and 17-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Within 2-6 days prior to beginning liposomal irinotecan treatment, patients may optionally receive FMX IV and undergo MRI at baseline and 24 hours after FMX infusion.
9985470|NCT02740699|Other|Moderate to high intensity treatment|Participants will receive 20-40 mg once daily Rosuvatain, or Participants will receive 40-80 mg once daily of Atrovastin.
9985471|NCT02738853|Experimental|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
9985472|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
9985473|NCT02730312|Experimental|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
9985474|NCT02729701|Experimental|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
9985475|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for R-PDAC|Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
9839561|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
9839564|NCT02611037|Experimental|Chemoperfusion + Questionnaire|"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m^2), methotrexate (100 mg/m^2) and gemcitabine (1000 mg/m^2).~Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.~Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire."
9839566|NCT02609776|Experimental|Part 1:Amivantamab Monotherapy+Combination Dose Escalations|The first cohort of participants will receive intravenous (IV) infusions of Amivantamab 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of Amivantamab once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and Amivantamab on Cycle 1 Day 1 (C1D1) prior to initiation of Amivantamab (C1D1) at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter, on 28-day Amivantamab treatment cycle. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with standard of care carboplatin and pemetrexed.
9839567|NCT02609776|Experimental|Part 2:Amivantamab Monotherapy+Combination Dose Expansion|Participants will receive IV infusion of Amivantamab as monotherapy at Phase 2 dose (RP2D) regimen or in combination lazertinib at the recommended Phase 2 combination dose (RP2CD) regimen as determined in Part 1. The purpose of dose expansion is to further evaluate safety, tolerability, pharmacokinetic, and to assess preliminary efficacy in monotherapy and combination therapy cohorts.
9839572|NCT02590523|Experimental|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
9839573|NCT02590523|Experimental|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
9839574|NCT02590523|Placebo Comparator|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
9839577|NCT02582879||Patient with CLL/SLL|Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.
9839578|NCT02582125|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
9985476|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for BR-PDAC|Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
9985477|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
9985478|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.~+topical testosterone treatment for >1 year"
9985479|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
9985480|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
9985481|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
9985482|NCT02717650|Experimental|A-STEP|Study A) A-STEP Study Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).
9985483|NCT02717650|Experimental|A-STEP (New Protocol)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
9985484|NCT02717650|Active Comparator|CPET cycle ergometer (Gold Standard)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
9985485|NCT02713126|Placebo Comparator|Placebo|Subjects will undergo cardiac exercise training and receive oral placebo capsules three times per day for 12 weeks while wearing an accelerometer
9985486|NCT02713126|Active Comparator|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive oral sodium nitrite capsules three times per day for 12 weeks while wearing an accelerometer
9985487|NCT02711826|Active Comparator|Maintenance CNI based immunosuppression therapy group|"Standard of care~(N=7 participants in this group)"
9985488|NCT02711826|Experimental|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (550 ± 450 x 10^6). After receiving at least 300X10^6 polyTregs infusion, eligible subjects will start mammalian Target of Rapamycin (mTOR) inhibitor.~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued.~(N=7 participants in this group)"
9985489|NCT02705911|Experimental|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
9985490|NCT02705911|Active Comparator|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
9985491|NCT02705911|No Intervention|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
9985492|NCT02704312|Experimental|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
9985493|NCT02692768|Active Comparator|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
9985494|NCT02692768|Active Comparator|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
9985495|NCT02692768|Active Comparator|Control|This group will receive standard of care with no music therapy intervention
9985496|NCT02684253|Experimental|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
9985497|NCT02684253|Experimental|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
9985498|NCT02683473||Infants|Infants aged 1-3 months
9985499|NCT02683356|Active Comparator|OCT-guided PCI|OCT before and after Stent implantation
9985500|NCT02683356|Active Comparator|Angiography-guided PCI|OCT after Stent implantation
9985501|NCT02681406|No Intervention|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
9791426|NCT01416636|Experimental|Treprostinil sodium high dose - Arm II|"Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
9791427|NCT01416805|Experimental|Computerized Cognitive Behavioral Therapy|
9791428|NCT01416805|Active Comparator|Treatment as Usual|
9791429|NCT01417000|Experimental|Cy/GVAX + CRS-207|200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
9791430|NCT01417000|Experimental|Cy/GVAX|200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16; GVAX (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1, 4, 7, 10, 13, 16.
9791431|NCT01417026|Active Comparator|Intranasal Oxytocin|"Intranasal oxytocin (Trade name: Syntocinon)~Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril).~Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
9791432|NCT01417026|Placebo Comparator|Intranasal Placebo|"Intranasal placebo~The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril).~Placebo will be imported from Victoria Pharmacy Zurich- Switzerland."
9791433|NCT01417078|Experimental|Diazepam Nasal Spray|
9791434|NCT01417104|Active Comparator|Aliskiren|Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
9791435|NCT01417104|Placebo Comparator|Placebo|Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)
9791436|NCT01417156|Experimental|All patients|
9791437|NCT01417195|Experimental|Menopur and Bravelle combination|The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
9791438|NCT01417195|Active Comparator|Menopur alone|The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
9791439|NCT01417234||SNaP® Wound Care System|
9791440|NCT01417455||Rheumatoid Arthritis|Active Rheumatoid Arthritis patients
9791441|NCT01417455||Ankylosing Spondylitis|Active Ankylosing Spondylitis
9791442|NCT01417455||Controls|Healthy donors age and sex matched to the patients
9791443|NCT01417481|Active Comparator|Glycine|Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
9791444|NCT01417481|Placebo Comparator|Placebo|Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
9791445|NCT01417741|No Intervention|Standard Therapy Only|Patients will not receive acupuncture. Standard anti-emetic therapy will be given.
9791446|NCT01417741|Experimental|Acupuncture Plus Standard Therapy|Bilateral P6 acupuncture applied after anesthesia induction and removed at the termination of the surgery. Patients will also receive standard anti-emetic therapy.
9791447|NCT01417780|Active Comparator|AB103 0.25 mg/kg|
9791448|NCT01417780|Active Comparator|AB103 0.5 mg/kg|
9791449|NCT01417780|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride)
9791450|NCT01417936|Experimental|Sym004|
9791451|NCT01418001|Experimental|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|This will be a multicenter single arm phase IB/II trial to evaluate the clinical safety and efficacy of gemcitabine/docetaxel and pazopanib in the neoadjuvant treatment of soft tissue sarcoma.
9791452|NCT01418209|Active Comparator|Low-dose 17-ß-estradiol with progesterone taper|
9791453|NCT01418209|Active Comparator|Venlafaxine XR|
9791454|NCT01418209|Placebo Comparator|Placebo|
9791455|NCT01418339|Experimental|Aripiprazole|Aripiprazole was administered orally once a week (QW) for 8 weeks in a double-blind manner. Participants randomized to aripiprazole received aripiprazole tablets at a starting dose of 52.5 milligrams (mg) QW on Day 0. At Week 1, according to the investigator's discretion based on efficacy and tolerability, the dose of aripiprazole could remain at 52.5 mg QW or could be increased to 77.5 mg QW. The dose could be increased to 110 mg QW as early as Week 2. For the remainder of the study (up to Week 8), the dose was to be adjusted up and down among these three dose levels, as determined by the investigator.
9791456|NCT01418339|Placebo Comparator|Placebo|Participants randomized to placebo received aripiprazole-matching placebo, tablet, orally, QW for 8 weeks in a double-blind manner.
9791457|NCT01418352|Placebo Comparator|Matching Placebo|Participants received aripiprazole matching placebo, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
9791458|NCT01418352|Experimental|Aripiprazole 52.5 mg|Participants received aripiprazole 52.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
9791459|NCT01418352|Experimental|Aripiprazole 77.5 mg|Participants received aripiprazole 77.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
9791460|NCT01418352|Experimental|Aripiprazole 110 mg|Participants received aripiprazole 110 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
9791461|NCT01418365|Experimental|Metronidazole + MMX placebo|
10206458|NCT04435288|Active Comparator|TNFi-induction group|"The patients in the TNFi-induction group will receive golimumab at a standard dose of 50 mg subcutaneously (SC) every 4 weeks (with matching methotrexate (MTX)-placebo). In case of potential intolerance or toxicity to MTX-placebo, the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX-placebo will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
10214073|NCT01518517|Active Comparator|reference L-asparaginase|"For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).~•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).~NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)~•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles)."
10214074|NCT01496118|Experimental|Carfilzomib and Panobinostat|"Phase I:~Carfilzomib: cycle 1 - Dose is 20 mg/m^2 IV on day 1; 27 or 36 or 45 or 56 mg/m^2 IV on Days 8, 9, 15, 16 cycle 2 to progression - 27 or 36 or 45 or 56 mg/m^2 IV on days 1, 2, 8, 9, 15, 16~Panobinostat: cycle 1 and cycle 2 to progression - 20 mg or 30 mg on days 1, 3, 5, 15, 17, 19~Phase II:~Carfilzomib and Panobinostat: Dose is optimal dose determined in Phase I"
9791462|NCT01418365|Experimental|Metronidazole + MMX Mesalazine/mesalamine|
9791463|NCT01418378|Active Comparator|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
9791464|NCT01418378|Active Comparator|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
9791465|NCT01418482|Experimental|Mepilex Border Ag|Mepilex Border Ag, a silver dressing will be used
9791466|NCT01418703|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
9791467|NCT01418703|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
9791468|NCT01418937|Experimental|HPV Group|
9791469|NCT01419015|Experimental|TAVI-TF Approach|Transcatheter aortic valve implantation and transfemoral approach. SAPIEN XT NovaFlex delivery system will be used.
9791470|NCT01419028||Patients with perinatal and/or infantile onset HPP|Patients with a confirmed diagnosis of perinatal or infantile onset hypophosphatasia (HPP)
9791471|NCT01419080||Peripheral Arterial Disease (PAD) patients|Patients with new onset or exacerbation of peripheral artery (PA) symptoms.
9799598|NCT01663857|Experimental|Phase 2 (Arm A) LY2228820 200 mg|"Arm A: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm A: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
9799599|NCT01663857|Placebo Comparator|Phase 2 (Arm B) Placebo|"Arm B: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm B: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind."
9799600|NCT01663896||Single or multi vessel disease|Pre- and post-PCI fractional flow reserve (FFR) and OCT were performed in participants.
9799601|NCT01663922|Experimental|St John's Wort, then Boceprevir|D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
9799602|NCT01663922|Experimental|Boceprevir, then St John's Wort|D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD
9799603|NCT01663935|Other|Levodopa/carbidopa 4mg/kg/day|Treatment drug taken orally three times daily
9799604|NCT01663987|Active Comparator|18 mcg tiotropium|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
9799605|NCT01663987|Placebo Comparator|Placebo|Patient to receive one placebo capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
9799606|NCT01664039|Experimental|TRAVATAN|Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
9799607|NCT01664039|Active Comparator|LUMIGAN|Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
9799608|NCT01664052|Experimental|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
9800463|NCT01688466|Experimental|0.5 mg/day without Dose Escalation|0.5 mg/day without Dose Escalation
9800464|NCT01688596|No Intervention|No Treatment|"The No Treatment group includes patients undergoing laparoscopic hysterectomy without local infiltration of bupivacaine."
10213457|NCT03972527|Active Comparator|Active Device Treatment Cohort|The MuReva Phototherapy System consists of Light Control Unit and a Mouthpiece Cable Assembly. Subjects will begin device treatment photobiomodulation sessions on the first day of radiotherapy (RT) treatment. They will receive once-daily investigative device photobiomodulation treatments prior to radiation therapy (RT) with their assigned Mouthpiece for 5 days per week for the duration of their CRT treatment. Each device treatment session will last up to 5 minutes, not including up to 5 additional minutes for treatment breaks. All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period. Each patient will be assigned their own Mouthpiece Cable Assembly.
9517854|NCT03302260|No Intervention|Control|Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
9791472|NCT01419171|Experimental|OMEGA™ Monorail Coronary Stent System|
9791473|NCT01419184|Experimental|Daptomycin|4 milligrams per kilogram (mg/kg) daptomycin administered intravenously (IV) once a day until end of antibiotic therapy for complicated skin and skin structure infections (cSSSI) or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
9791474|NCT01419184|Active Comparator|Vancomycin|Vancomycin was reconstituted per the manufacturer's instructions and was dosed per investigator's discretion and was administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occured first. Investigators treated participants according to their usual decision-making and discretion
9791475|NCT01419197|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
9791476|NCT01419197|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
9791477|NCT01419236|Experimental|Testosterone Solution 2% 60 milligrams (mg)|Testosterone Solution 2% 60 mg applied topically once daily with possible 1-time titration to 30 milligrams per day (mg/day) or 90 mg/day for 16 weeks
9791478|NCT01419236|Placebo Comparator|Placebo|Placebo solution applied topically once daily for 16 weeks
9791479|NCT01419249|Other|Retrospective cohort|
9791480|NCT01419275|Experimental|Moyamoya|Approximately 60 Moyamoya patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
9791481|NCT01419275|Experimental|Acute stroke|Approximately 60 acute stroke patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
9791482|NCT01419275|Experimental|Healthy participants|Approximately 30 healthy participants will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
9791483|NCT01419275|Experimental|Diagnosis unspecified|Approximately 60 participants with diagnosis unspecified will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
9791484|NCT01419314|Experimental|Splinting application|Participants will be asked to wear a pair of LE night splints for the duration of the study (6 weeks) at night/during sleep only.
9791485|NCT01419314|Placebo Comparator|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study.
9791486|NCT01419535|Experimental|Mifepristone, then Placebo|Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.
9791487|NCT01419535|Experimental|Placebo, then Mifepristone|Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.
9791488|NCT01419626|No Intervention|Negative Control|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste.
9791489|NCT01419626|Sham Comparator|Device with Water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
9791490|NCT01419626|Experimental|Device with Mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
9791491|NCT01419639|Experimental|RAD001|RAD001 taken orally continuously until disease progression or unacceptable toxicity, dosed according to age
9791492|NCT01419665|Experimental|GP2013|Type: Biological/Vaccine
9791493|NCT01419665|Active Comparator|rituximab|Type: Biological/Vaccine
9791494|NCT01419717|Experimental|Denosumab|Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.
9791495|NCT01419769|Experimental|AXIOS Stent and Delivery System|
9791496|NCT01419795|Experimental|Arm I (lenalidomide, rituximab)|Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
9791497|NCT01419795|Active Comparator|Arm II (lenalidomide)|Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.
9791498|NCT01419977|Placebo Comparator|Placebo|Normal saline solution
9791499|NCT01419977|Experimental|Dalteparin|5000 unites subcutaneously, Other Name: Fragmin
9839612|NCT02519309|Experimental|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
9839613|NCT02519309|Experimental|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
9839614|NCT02519309|No Intervention|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
9985502|NCT02681406|Experimental|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
9985503|NCT02681406|Experimental|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
9985504|NCT02681406|Experimental|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
9985505|NCT02666794|Active Comparator|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 20 micrograms sufentanil, followed by the placement of the epidural catheter
9985506|NCT02666794|Active Comparator|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
9985507|NCT02664753|Experimental|L-Carnitine group|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Intervention: 56 days of weight-adjusted L-Carnitine treatment"
9985508|NCT02664753|Placebo Comparator|Placebo then open group|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Intervention: 10 days of intravenous placebo (isotonic saline)"
9985509|NCT02663739||Aortic Dissection|Treating patients with acute complicated Stanford Type B aortic dissection with the Zenith® TXD
9985510|NCT02657707|Experimental|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
9985511|NCT02656550|Experimental|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
9985512|NCT02655055|Experimental|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
9985513|NCT02655055|No Intervention|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
9985514|NCT02649738|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
9985515|NCT02642094|Experimental|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
9985516|NCT02636569|Active Comparator|diclofenac once daily|Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
9985517|NCT02636569|Placebo Comparator|placebo|The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
9996823|NCT01503528|Active Comparator|Motor Sparing Nerve Block|Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
9667542|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
9667543|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
9839635|NCT02503657|Placebo Comparator|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
9839636|NCT02503657|Other|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
9985518|NCT02636322|Experimental|Arm I (RLI WITH EPOCH)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
9996824|NCT01503528|Experimental|Peri-Articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
9839651|NCT02469220|Experimental|Low FODMAP diet|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement low in FODMAPS are administered in a blinded fashion.
9839652|NCT02469220|Active Comparator|Standardized FODMAP|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement with FODMAPS are administered in a blinded fashion.
9839653|NCT02469220|No Intervention|Control|Watchful waiting. No diets or food supplements are administered
9996825|NCT01503554|Experimental|Social Worker + Pharmacist Intervention|Intervention arm offering enhanced services from a social worker and a pharmacist post-discharge
10206459|NCT04435288|Active Comparator|csDMARD-Step-up group|"The patients in the csDMARD-Step-up group will start with oral methotrexate (MTX) at a weekly dose of 15 mg for 4 weeks (with matching TNFi-placebo injections). In case of potential intolerance or toxicity to MTX , the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
10206460|NCT04429919|Experimental|AP-325|25 mg capsule for oral use, 4 capsules (100 mg) once daily in the morning before meals
10206461|NCT04429919|Placebo Comparator|Placebo|4 capsules once daily in the morning before meals
10206462|NCT04427033||CHL & MHL (18 years and older)|CHL= conductive hearing loss MHL= mixed hearing loss
10206463|NCT04427033||CHL & MHL (5 to 17 years)|
10206464|NCT04427033||SSD (5 years and older)|SSD= single sided deaffness
10206465|NCT04425720|Active Comparator|Standard Of Care|Patients without wearable monitoring technology undergoing routine standard of care at the hospital.
9839662|NCT02446132|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 52-week period
9839663|NCT02446132|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 52-week period
9839664|NCT02446132|Experimental|AVP-786 (dose 3)|AVP-786 dose 3; capsules administered twice a day over a 52-week period
10206466|NCT04425720|Experimental|Monitored|Patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary
10206467|NCT04423744|Experimental|Intervention ABCD|"Intervention A:~Day 1 and 2: Supra-therapeutic dose of BAY1817080, three times daily (tid) Day 3: Supra-therapeutic dose of BAY1817080 and placebo to moxifloxacin, once~Intervention B:~Day 1 and 2: therapeutic dose of BAY1817080 and placebo to BAY1817080, tid Day 3: therapeutic dose of BAY1817080, placebo to BAY1817080 and placebo to moxifloxacin, once~Intervention C:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and moxifloxacin, once~Intervention D:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and placebo to moxifloxacin, once~Subjects will receive intervention A, B, C and D sequentially. The washing-out period between each intervention is at least 14 days"
10206468|NCT04423744|Experimental|Intervention BCDA|Subjects will receive intervention B, C, D and A sequentially. The washing-out period between each intervention is at least 14 days
10206469|NCT04423744|Experimental|Intervention CDAB|Subjects will receive intervention C, D, A and B sequentially. The washing-out period between each intervention is at least 14 days
10206470|NCT04423744|Experimental|Intervention DABC|"Subjects will receive intervention D, A, B and C sequentially. The washing-out period between each intervention is at least 14 days~Note: the intervention sequences in this and above arms are examples, the actual order of intervention may differ from these examples"
10206471|NCT04421170|Experimental|Intervention Group|Participants from the intervention group will receive CBT based smoking cessation. It provides both mandatory information of evidence-based and guideline-based smoking cessation interventions, and optional information about quitting benefits, tips for quitting et al. The app will be available for the participants in the intervention group until 26-week post-quit date follow-up. After this period, the app will automatically stop the data collection, but they can continue to use it if they want. As the participants progressed through the study, smoking cessation related information will be gradually reduced until 12 weeks after quit date, and follow-up messages will be sent at 16, 20 and 26 weeks after quit date. Participants from intervention group can also seek for help at any time by text or WeChat, or make a phone call.
10206472|NCT04421170|No Intervention|Control group|Participants from the control group will only receive information of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the outcomes between two groups, continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 2, 3, 4, 8, 12, 16, 20 and 26 points after quit date by ePRO software. Biochemically verified continuously abstinence will also be checked if they have reported continuous smoking abstinence at week 26 points after quit date.
10206473|NCT04419532|Experimental|Dose Escalation (DS-1055a)|Participants will be enrolled into groups with each group receiving an increased dose from the previous group as safety assessments permit in order to determine the optimal dose for safety and tolerability.
9839667|NCT02440854||Patients with non-small cell lung cancer (NSCLC) treated with afatinib|Patients with advanced/metastatic non-small cell lung cancer (NSCLC) in Greece treated with afatinib. Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib. Patients were observed in the context of the study until the end of study participation, defined as a maximum of 48 months after afatinib treatment initiation or until disease progression, death, withdrawal of consent, unacceptable toxicity, study completion or physician's decision whichever occurred earlier.
9985519|NCT02636322|Experimental|Arm II (RLI WITH R-CHOP)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
9985520|NCT02625090|Experimental|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
9985521|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
9985522|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
9985523|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
9985524|NCT02617277|Experimental|Dose Schedule A|In Schedule A, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib).
9985525|NCT02617277|Experimental|Dose Schedule B|In Schedule B, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
9985526|NCT02617277|Experimental|Dose Schedule C|In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
9996826|NCT01503554|Experimental|Usual Care|Patients receiving usual care will have a medication reconciliation performed by a physician or nurse during their hospital stay. No further support or interventions are provided post discharge.
9996827|NCT01503567||Subjects 6 to 18 years old without inhibitors|
9996828|NCT01503567||Subjects 6 to 18 years old with inhibitors|
10206474|NCT04413123|Experimental|Cabozantinib|"Eligible patients will be enrolled and receive treatment with~Cycle 1-4 (cycles of 21 days)~Cabozantinib predetermined protocol dosage po daily~Nivolumab predetermined protocol dosage via IV every 3 weeks~Ipilimumab predetermined protocol dosage via IV every 3 weeks~After the first four cycles of therapy,~Cabozantinib determined protocol dosage po daily~Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)"
10206475|NCT04409509|Experimental|CSL312|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
10206476|NCT04409509|Placebo Comparator|Placebo|CSL312 diluent administered intravenously
9667544|NCT03464669||Control group|Absence of prenatal education
10206477|NCT04407962|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
10206478|NCT04407962|No Intervention|Control group|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
10206479|NCT04402749||Nephrectomy|Patients underwent nephrectomy
9985527|NCT02617277|Experimental|Dose Schedule D|In Schedule D, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 (adavosertib) being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
9839706|NCT02369016|Experimental|Copanlisib (BAY 80-6946)|patients with rituximab-refractory iNHL
9839707|NCT02368405|Active Comparator|Control|Control group will receive standard of care
9839708|NCT02368405|Experimental|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
9839709|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
9839710|NCT02367040|Experimental|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
9839711|NCT02367040|Placebo Comparator|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
9839712|NCT02365597|Experimental|Erdafitinib (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression.
9985528|NCT02612038|Experimental|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
9985529|NCT02612038|Sham Comparator|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
9985530|NCT02603328|Active Comparator|Treatment|Atorvastatin 80mg OD (optimal dose). Treatment dose will be de-escalated to 40mg based on reported adverse events.
9985531|NCT02603328|Placebo Comparator|Placebo|Identically looking capsules containing no active ingredient
9985532|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
9985533|NCT02578368|Experimental|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
9985534|NCT02578368|Active Comparator|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1~For PD-L1 positive disease (CPS ≥ 5), nivolumab can be added according to SmPC:~Nivolumab 240 mg i.v. for 30 min, d1, repeated every two weeks (q15d)"
9996829|NCT01503567||Subjects above18 years old without inhibitors|
9996830|NCT01503567||Subjects above 18 years old with inhibitors|
9839724|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters >/= 12 mm, treated with mechano-chemical ablation (MOCA)
9839725|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
9839726|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
9839727|NCT02344498||Urban|HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
9839728|NCT02344498||Rural|HBV patients in Harar. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
9839738|NCT02328872|Experimental|Intervention (HPV Arm)|"Molecular testing for HPV with partial genotyping for types 16/18, with referral of the HPV16/18-positive group for diagnostic evaluation, and secondary randomisation of women testing positive for other oncogenic HPV infection (not 16/18), to either image-read cytology screening or dual-stained (DS) cytology testing with p16/Ki67 - the HPV arm. Screening performed 5 yearly."
9996831|NCT01503580|Experimental|antimuscarinic drug|
9996832|NCT01503593|No Intervention|Alveolar ridge dimensions|Control group - Only extraction teeth
9667545|NCT03457896|Experimental|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:~• Neratinib daily + Trastuzumab weekly until disease progression"
9667546|NCT03457896|Experimental|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:~• Neratinib daily + Cetuximab weekly until disease progression"
9667547|NCT03457493|Experimental|Healthy Controls, DPA-714-PET/MRI|
9667548|NCT03457493|Experimental|Early Parkinson's Disease, DPA-714-PET/MRI|
9667549|NCT03449069|Experimental|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
9667550|NCT03446027|No Intervention|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
9667551|NCT03446027|Experimental|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
9667552|NCT03444298|Placebo Comparator|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Neutral Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
9667553|NCT03444298|Active Comparator|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
9667554|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: RMS|Pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS) will receive eribulin mesylate administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 milligrams per meters squared (mg/m^2). Participants will continue study therapy until progression of disease (per Response Evaluation Criteria In Solid Tumors [RECIST] 1.1), intolerable toxicity, or withdrawal of consent.
9667555|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: NRSTS|Pediatric participants with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
9667556|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: EWS|Pediatric participants with Ewing sarcoma (EWS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
9667557|NCT03434379|Experimental|Atezolizumab + Bevacizumab|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator
9667558|NCT03434379|Active Comparator|Sorafenib|Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator
9667559|NCT03427047|Active Comparator|MyKnee with single use Efficiency Instrument|Patients randomized in this group will undergo Total Knee Arthroplasty utilizing patient matched cutting blocks and single use instruments. Customization will be by a CT scan of patients knee.
9667560|NCT03427047|Active Comparator|Stryker Navigational with conventional metal instruments|Patients randomized in this group will undergo Total Knee Arthroplasty with conventional metal instruments. CT scan are not utilized with this arm.
9667561|NCT03424122|Experimental|Treatment A|Parsaclisib + Rituximab
9667562|NCT03424122|Experimental|Treatment B|Parsaclisib + Bendamustine + Rituximab
9667563|NCT03424122|Experimental|Treatment C|Parsaclisib + Ibrutinib
9667565|NCT03420209|Experimental|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
9667566|NCT03420209|No Intervention|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
9667567|NCT03417986|Experimental|Group 1a: TEP 26 mg daily for 4d|
9667568|NCT03417986|Experimental|Group 1b: TEP 52 mg daily for 4d|
9667569|NCT03417986|Experimental|Group 2: TEP 26 mg daily for 54d|
9667570|NCT03417570|Experimental|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap.
9667571|NCT03417570|Experimental|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap
9839739|NCT02328872|Active Comparator|Control (LBC Arm)|"Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the LBC arm. Screening performed 2.5 yearly."
9985535|NCT02575963|Experimental|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.~Experimental: Phase 2~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
9985536|NCT02573376|Other|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
9985537|NCT02573376|Other|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
9985538|NCT02568553|Experimental|Treatment (blinatumomab, lenalidomide)|"INDUCTION: Patients receive blinatumomab IV continuously on days 1-56 and lenalidomide PO on days 29-49 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving response including stable disease receive blinatumomab IV continuously on days 1-7 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receiving response including stable disease after completion of Consolidation receive lenalidomide PO on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
9985539|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
9985540|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.~In general all proximal humerus fractures were operated except minimally or undisplaced."
9839746|NCT02318784|Experimental|Carfilzomib|"Carfilzomib will be administered as intravenous (IV) infusion over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of each 28-day cycle.~Cycle 1: First two doses of Carfilzomib 20 mg/m2 IV; subsequent doses at 56 mg/m2 IV~Cycle 2 onwards: Carfilzomib 56 mg/m2 IV"
9985541|NCT02563691|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
9996833|NCT01503593|Experimental|Alverolar ridge dimension|Extraction of teeth and implant a bone substitute
9996834|NCT01503619||Basic science (biomarker analysis)|DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
9996835|NCT01503658|Experimental|Clopidogrel+Aspirin|Clopidogrel on Day 1, Aspirin on Day 2 - Day 14, Clopidogrel + Aspirin Day 15, Aspirin on Day 16 - Day 28, Clopidogrel + Aspirin Day 29
9996836|NCT01503671|Experimental|Atorvastatin|Atorvastatin 40 mg/day for high inflammation CAPD patient
9996837|NCT01503671|No Intervention|No intervention arm|Placebo arm without intervention
9996838|NCT01503684||Patients with sepsis|Patients who are admitted to ICU with the diagnosis of sepsis
9996839|NCT01503723||Patients with acute lung injury|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure
9996840|NCT01503736|Placebo Comparator|Placebo|
9996841|NCT01503736|Experimental|4g/day|Ferric Citrate for a total daily dose of 4g
9996842|NCT01503736|Experimental|6g/day|Ferric Citrate for a total daily dose of 6g
9996843|NCT01503762|Experimental|Mirror Therapy Group|Mirror Therapy Group
9996844|NCT01503762|Sham Comparator|Control Group|Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ...
9996845|NCT01503775||TRUFILL® DCS Orbit Galaxy|
9996846|NCT01503788|Active Comparator|periprocedural sedation with midazolam|periprocedural sedation with IV midazolam 5-10 minutes before diagnostic lumbar puncture
9667572|NCT03416933|Experimental|Biological|
9839765|NCT02307331|Other|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
9839766|NCT02307331|Other|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
9839767|NCT02307331|Other|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
9839768|NCT02307331|Other|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
9839772|NCT02278185|Experimental|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
9839773|NCT02278185|Active Comparator|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
9839782|NCT02254642|Experimental|Ischemic preconditioning arm|Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
9839783|NCT02254642|Other|Control patients|Usual surgery assigned to control patients
9839785|NCT02234219|Active Comparator|Circular Anastomosis|
9839786|NCT02234219|Active Comparator|Heart-shaped Anastomosis|
9985542|NCT02556450|Experimental|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
9985543|NCT02556450|No Intervention|Control group|Only background treatment
9985544|NCT02552511||Exposure|Perinatal factors exposure
9985545|NCT02551991|Experimental|nal-IRI + 5-FU/LV + oxaliplatin|
9985546|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
9985547|NCT02551003|Experimental|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
9839796|NCT02217891||participants from existing MSK protocol 12-245|"Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings.~Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling."
9985548|NCT02551003|Active Comparator|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
9985549|NCT02550054|Experimental|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
9985550|NCT02550054|Placebo Comparator|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
9839800|NCT02208375|Experimental|Arm I (olaparib, vistusertib)|CONTINUOUS AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 5-28 of course 1 and alone on days -3 to -1 of week -1) and vistusertib PO BID on days 1-28 (alone on days 1-4 of week 1).
9839801|NCT02208375|Experimental|Arm II (olaparib, vistusertib)|INTERMITTENT AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 3-28 on course 1 and alone on days -5 to -3 of week -1) and vistusertib 4 PO BID for 2 days on and 5 days off (alone on days 1-2 of week 1).
9839802|NCT02208375|Experimental|Arm III (olaparib, capivasertib)|INTERMITTENT AZD5363 DOSING: Patients receive olaparib PO BID on days 1-28 (on days 5-28 of course 1 and alone on days -3 to -1 of week -1) and capivasertib PO BID for 4 days on and 3 days off (alone on days 1-4 of week 1).
9985551|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
9985552|NCT02539225|Experimental|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
9985553|NCT02539225|Active Comparator|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
9985554|NCT02535650|Experimental|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
9985555|NCT02528500|Experimental|TAMBE Device|Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
9791500|NCT01420016|Active Comparator|Prioritized Clinical Decision Support|The Prioritized Clinical Decision Support (CDS) intervention is a protocol driven CDS system linked within the EMR that identifies patients with high cardiovascular risk and provides tailored, prioritized decision support to the provider and patient at the point of care. The CDS was printed at intervention sites. It i) compiled most recent lab data (A1c, SBP, and LDL), BMI, smoking status, and aspirin use, (ii) calculated a 10-year risk for stroke or heart attack, (iii) prioritized clinical domains based on the absolute risk reduction for each component, (iv) compiled information related to renal and liver function, creatine kinase level, and previous diagnoses (CHF, CVD, DM), and (v) provided recommendations for intensification of therapy for A1c, SBP and/or LDL if not at goal.
9791501|NCT01420016|No Intervention|Usual Care|Providers in the usual care arm did not have access to the prioritized clinical decision support tool.
9791502|NCT01420068||All patients|All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.
9791503|NCT01420081|Experimental|B|PI3K Basal, IV Compound
9791504|NCT01420081|Experimental|C|PI3K Activated, Oral Compound
9791505|NCT01420081|Experimental|F|Japanese lead in cohort, IV compound
9791506|NCT01420146|Experimental|Zr89-trastuzumab PET/CT|Zr89-trastuzumab PET/CT single arm
9791507|NCT01420289|Experimental|HPIPC|High Pressure Intermittent Pneumatic compression (HPIPC)to be performed for 45 minutes twice daily
9791508|NCT01420289|Active Comparator|Excercise|Walking on a graded treadmill for 45 minutes once daily
9791509|NCT01420536|Experimental|Canine Guidance|"Complete dentures adjusted with mutually protected articulation in which the vertical and horizontal overlap of the canine teeth disengage the posterior teeth in the excursive movements of the mandible (The Glossary of Prosthodontic Terms. J. Prosthet. Dent., 94(1): 10-92)"
9791510|NCT01420536|Sham Comparator|Bilateral Balanced Occlusion|Complete dentures as conventionally adjusted: anterior and posterior teeth presented bilateral contact in excentric positions
9791511|NCT01420549|Experimental|Rosuvastatin + Ezetimibe|Participants received Rosuvastatin 10 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Rosuvastatin 20 mg+ Ezetimibe 10mg tablet orally once daily for more 4 weeks.
9791512|NCT01420549|Active Comparator|Simvastatin + Ezetimibe|Participants received Simvastatin 20 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Simvastatin 40 mg + Ezetimibe 10mg tablet orally once daily for more 4 weeks.
9791513|NCT01420627|Experimental|Adagen/EZN-2279|Patients started on Adagen and crossed over to experimental EZN-2279 treatment after at least a 3 week Lead-in Period on Adagen
9791514|NCT01420653|Experimental|Maxigesic 325|Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
9791515|NCT01420653|Active Comparator|Acetaminophen|Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
9791516|NCT01420653|Active Comparator|Ibuprofen|Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
9791517|NCT01420653|Placebo Comparator|Placebo|Placebo tablets, every 6 hours, orally
9791518|NCT01420679|Experimental|Pralatrexate|Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
9791519|NCT01420679|No Intervention|Observation|Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.
9791520|NCT01420848|Active Comparator|Auriculotherapy Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem)."
9791521|NCT01420848|Placebo Comparator|Placebo Group|Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
9791522|NCT01420848|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
9791523|NCT01421017|Experimental|IMQ+RT|"This arm has been closed as of 6/4/2014.~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
9791524|NCT01421017|Experimental|CTX/IMQ/RT|"Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
9791525|NCT01421017|Experimental|CTX/RT|"For patients with only non-skin metastatic sites~First cycle (Cycle 1):~Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
9791526|NCT01421134|Experimental|Lurasidone|Lurasidone 20, 40 or 60 mg
9791527|NCT01421134|Placebo Comparator|Placebo|Placebo
9996847|NCT01503788|No Intervention|No intervention|Participants will undergo the diagnostic lumbar puncture as routinely practiced
9985556|NCT02527681|Experimental|Ceftobiprole|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
9985557|NCT02526017|Experimental|Phase 1a Monotherapy Dose Escalation|Cabiralizumab administered at 2 mg/kg every 2 weeks (Q2W), 4 mg/kg Q2W and 6 mg/kg Q2W in participants with any solid tumor.
9985558|NCT02526017|Experimental|Phase 1a Combination Therapy Dose Escalation|Nivolumab 3 mg/kg Q2W + cabiralizumab at the following doses: 1 mg/kg, 2 mg/kg, 4 mg/kg, and 6 mg/kg Q2W. Also nivolumab 3 mg/kg + cabiralizumab 4 mg/kg every 3 weeks (Q3W). Participants with any solid tumor.
9985559|NCT02526017|Experimental|Phase 1b Combination Therapy Dose Expansion|The expansion phase would use the recommended dose determined in Phase 1a: cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Q2W. Participants are enrolled for the following advanced cancer types: non-small cell lung cancer (anti-programmed cell death 1 [PD1] targeted drug naïve), non-small cell lung cancer (prior treatment with anti-PD-1), pancreatic cancer, ovarian cancer, renal cell cancer, glioblastoma, and melanoma.
9985560|NCT02520362||Postmenopausal Women|Postmenopausal Women
9985561|NCT02520362||Women with post menopausal osteoporosis|Women with post menopausal osteoporosis
9839820|NCT02193009|Experimental|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
9839821|NCT02193009|Active Comparator|Move More, behavioral intervention|Aimed at physical activity promotion
9985562|NCT02520362||Prolia for unapproved indications|Patients who receive Prolia for unapproved indications
9985563|NCT02520362||Men with osteoporosis|Men with osteoporosis treated with denosumab
9985564|NCT02516657|Experimental|Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
9985565|NCT02510625|Active Comparator|Bankart repair|Arthroscopic bankart repair
9985566|NCT02510625|Experimental|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
9985567|NCT02502435||Patients with Night-Eating Syndrome|Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
9985568|NCT02502435||Matched Healthy Controls|Healthy volunteers; 18-65 years of age; eating <25% of their caloric intake after dinner; no nocturnal ingestions
9985569|NCT02501993||Screening cohort|All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
9985570|NCT02500849|Experimental|Cohort 1:|target busulfan AUC levels: 8,000 µM*min (+/- 1,000)
9985571|NCT02500849|Experimental|Cohort 2:|busulfan AUC levels: 12,000 µM*min (+/- 1,000)
9985572|NCT02489591|No Intervention|Control|No oral appliance (control) first, oral appliance (BluePro oral appliance or other device) second
9839834|NCT02154529|Experimental|Arm 1: Tesevatinib 150 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 150 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
9839835|NCT02154529|Experimental|Arm 2: Tesevatinib 250 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 250 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
9839836|NCT02154529|Experimental|Arm 3: Tesevatinib 300 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 300 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
9839837|NCT02154529|Experimental|Arm 4: Tesevatinib 350 mg PO QD + Trastuzumab 8 mg/kg IV|Tesevatinib in combination with Trastuzumab: tesevatinib 350 mg PO QD in combination with trastuzumab 8 mg/kg IV initially then 6 mg/kg IV every 3 weeks thereafter.
9839838|NCT02154490||S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
9791528|NCT01421147|Experimental|LY2963016 + Insulin Lispro|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
9791529|NCT01421147|Active Comparator|Lantus + Insulin Lispro|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
9791530|NCT01421186|Experimental|Phase 1 dose escalation|"Part A: MOR03087 dose escalation; biweekly treatment~Part B: MOR03087 dose escalation; weekly treatment~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone~For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment."
9791531|NCT01421186|Experimental|Phase 2a confirmatory cohorts|"Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.~For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment."
9791532|NCT01421225|Active Comparator|Standard Insulin Pump Therapy first, then Closed Loop|Standard therapy day 1, Closed-Loop therapy day 2.
9791533|NCT01421225|Active Comparator|Closed Loop first, then Standard Insulin Pump Therapy|Closed-loop therapy day 1, standard therapy day 2.
9791534|NCT01421277||Participants Enrolled in Protocol Version (V)1.1|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study.
9791535|NCT01421277||Participants Enrolled in Protocol V2|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study.
9791536|NCT01421303||AS patients who are working and treated with Enbrel|
9791537|NCT01421342|Active Comparator|Switching: Bupropion-SR|Switching: Bupropion-SR
9791538|NCT01421342|Active Comparator|Augmenting: Antidepressant + Bupropion-SR|Augmenting: Antidepressant + Bupropion-SR
9791539|NCT01421342|Active Comparator|Augmenting: Antidepressant + Aripiprazole|Augmenting: Antidepressant + Aripiprazole
9791540|NCT01421355|Experimental|Atazanavir 300 mg BID|Atazanavir 300 mg BID for 4 days.
9791541|NCT01421459|Experimental|LY2963016 + OAMs|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) [alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)] administered per standard of care for 24 weeks
9791542|NCT01421459|Active Comparator|Lantus + OAMs|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
9791543|NCT01421472|Experimental|MM-121 (SAR256212) + paclitaxel|2 week run-in of MM-121 followed by MM-121 + dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
9791544|NCT01421472|Active Comparator|Paclitaxel only|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
9791545|NCT01421498|Experimental|5.0% Lifitegrast|Lifitegrast
9791546|NCT01421498|Placebo Comparator|Placebo|Placebo
9791547|NCT01421511|Experimental|TR-701 FA|• TR-701 FA IV followed by TR-701 FA tablets
9791548|NCT01421511|Active Comparator|Linezolid|• Linezolid IV followed by Linezolid Tablets
9791549|NCT01421589|Experimental|Growth Hormone|
9791550|NCT01421641|Active Comparator|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle.
9791551|NCT01421641|Active Comparator|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip (this amount of lidocaine will be measured out prior to procedure)
9791552|NCT01421654|Experimental|Fixed Mode + Acclimate|S9 Elite flow generator with Acclimate feature activated.
9791553|NCT01421654|Active Comparator|Fixed Mode only|S9 Elite Flow Generator with Fixed Mode only
9791554|NCT01421667|Experimental|Brentuximab vedotin+rituximab|
9791555|NCT01421667|Experimental|Brentuximab vedotin|
9791556|NCT01421719|Experimental|botulinum toxin treatment|botulinum toxin treatment Injection of Botox into urinary bladder for neurogenic symptoms.
9791557|NCT01422070||Patients admitted to the Study Units|Consecutive adult patients consecutively admitted to the Study Units during one month (either from 7th November to 4th December 2010, or from 16th January to 12th February 2012)
9839839|NCT02154490||S1400A Arm II (CLOSED TO ACCRUAL 4/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
9839840|NCT02154490||S1400A Arm III (MEDI4736)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
9839841|NCT02154490||S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9839842|NCT02154490||S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
9839843|NCT02154490||S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9839844|NCT02154490||S1400C Arm I (palbociclib)|Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9839845|NCT02154490||S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
9839846|NCT02154490||S1400C Arm III (palbociclib)|Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9839847|NCT02154490||S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9839848|NCT02154490||S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
9839849|NCT02154490||S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)|Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9839850|NCT02154490||S1400E Arm I (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
9839851|NCT02154490||S1400E Arm II (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
9839852|NCT02154490||S1400F (durvalumab, tremelimumab)|Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
9839853|NCT02154490||S1400G (talazoparib)|Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9839854|NCT02154490||S1400I Arm I (nivolumab, ipilimumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9839855|NCT02154490||S1400I Arm II (nivolumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9791558|NCT01422135|Experimental|Abdomen, Buttock, Upper Torso|"Patch was placed on abdomen, buttock then the upper torso excluding breast.~Intervention: AG200-15 patch"
9791559|NCT01422135|Experimental|Abdomen, Upper Torso, Buttock|"Patch was placed on abdomen, upper torso excluding breast then the buttock.~Intervention: AG200-15 patch"
9791560|NCT01422135|Experimental|Buttock, Abdomen, Upper Torso|"Patch was placed on the buttock, abdomen, then the upper torso excluding breast.~Intervention: AG200-15 patch"
9791561|NCT01422135|Experimental|Buttock, Upper Torso, Abdomen,|"Patch was placed on the buttock, upper torso excluding breast then the abdomen~Intervention: AG200-15 patch"
9791562|NCT01422135|Experimental|Upper Torso, Abdomen, Buttock|"Patch was placed on the upper torso excluding breast, abdomen then buttock.~Intervention: AG200-15 patch"
9791563|NCT01422135|Experimental|Upper Torso, Buttock, Abdomen|"Patch was place on the upper torso excluding breast, buttock, then abdomen.~Intervention: AG200-15 patch"
9791564|NCT01422161|Experimental|Botulinum Toxin commonly known as BOTOX®|Some subjects will receive BOTOX® injections. Subject will not be informed of what injection they received.
9791565|NCT01422161|Placebo Comparator|Placebo|Some subject will receive a safe Placebo injection. Subjects will not be informed of what injection they have received.
9791566|NCT01422187|Experimental|Taliglucerase alfa 30 units/kg|Subjects randomized to receive 30 units/kg
9791567|NCT01422187|Experimental|Taliglucerase alfa 60 units/kg|Subjects randomized to 60 units/kg
9791568|NCT01422200|Experimental|Subcutaneous|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once
9791569|NCT01422200|Active Comparator|Intramuscular|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once
9791570|NCT01422213|Placebo Comparator|Placebo|
9791571|NCT01422213|Experimental|Vortioxetine 10 mg|
9791572|NCT01422213|Experimental|Vortioxetine 20 mg|
9791573|NCT01422226|Experimental|Experimental active comparator|"Drug: Misoprostol~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion"
9791574|NCT01422226|Placebo Comparator|Placebo comparator|"Other: Placebo~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion"
9791575|NCT01422239|Experimental|Tailored behavioral counseling|"The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. The last 5 counseling sessions will be based on perceived risks of quitting."
9791576|NCT01422239|Active Comparator|Standard behavioral counseling|"The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual."
9791577|NCT01422304|Experimental|Sugammadex|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive sugammadex and placebo to neostigmine, and participants assigned to planned spontaneous recovery will receive sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
9791578|NCT01422304|Experimental|Usual Care|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive neostigmine and placebo to sugammadex, and participants assigned to planned spontaneous recovery will receive placebo to sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
9791579|NCT01422369|Experimental|All Subjects|pitavastatin 4 mg
9791580|NCT01422382|Experimental|All Subjects|There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
9985573|NCT02489591|Experimental|Oral appliance|oral appliance (BluePro oral appliance or other device) first, no oral appliance (control) second
9985574|NCT02483637|Experimental|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
9985575|NCT02482233|Experimental|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)~the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)~veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
9985576|NCT02482233|Active Comparator|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
9985577|NCT02481674|Experimental|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
9839861|NCT02149277|Active Comparator|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
9839862|NCT02149277|Placebo Comparator|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
9985578|NCT02481674|Placebo Comparator|Placebo|A placebo control will be administered via monthly intravenous infusions
9985579|NCT02479919|Experimental|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
9985580|NCT02479919|Active Comparator|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
9839866|NCT02143466|Experimental|AZD6094|AZD9291 in combination with AZD6094
9839867|NCT02143466|Experimental|Selumetinib|AZD9291 in combination with selumetinib
9839868|NCT02143466|Experimental|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
9839869|NCT02143466|Experimental|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
9839870|NCT02139605|Active Comparator|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
9839871|NCT02139605|Experimental|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
10206480|NCT04401865|Experimental|Pulsed, Accelerated|5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
10206481|NCT04401865|Active Comparator|Conventional|4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
9985581|NCT02479919|Sham Comparator|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
9985582|NCT02476916|Experimental|AG-348 50 mg BID|Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
9839874|NCT02125864|Experimental|Aflibercept|There is only one arm. Plasma VEGF is investigated in the same patient before and after intravitreal Aflibercept injection.
9985583|NCT02476916|Experimental|AG-348 300 mg BID|Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
9985584|NCT02476734||Diffuse Large B-cell Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
9985585|NCT02476734||Follicular Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
9985586|NCT02470897|Experimental|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 8.0Gy escalated dose"
9985587|NCT02470897|Active Comparator|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 7.5Gy conventional dose"
9839880|NCT02120807|Experimental|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
9985588|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
9985589|NCT02459067|Experimental|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
10206482|NCT04401150|Experimental|Vitamin C|Vitamin C: 50 mg/kg of weight administered intravenously every 6 hours for 96 hours (16 doses).
9791581|NCT01422408|Experimental|Supportive care (fluocinonide cream)|Patients apply topical fluocinonide cream BID in weeks 1-2 and QD in weeks 3-4.
9791582|NCT01422434|Active Comparator|LEO 90105 ointment|LEO 90105 ointment applied once daily for 4 weeks.
9791583|NCT01422434|Active Comparator|Dovonex® ointment|Applied twice daily for 4 weeks.
9791584|NCT01422434|Active Comparator|Rinderon® - DP ointment|Applied once daily for 4 weeks
9791585|NCT01422538|Active Comparator|Group A|Subjects will receive Ulthera® System alone.
9791586|NCT01422538|Active Comparator|Group B|Sculptra® only
9791587|NCT01422538|Active Comparator|Group C|Sculptra® treatment followed by Ultherapy™ treatment
9791588|NCT01422720|Experimental|Eslicarbazepine Acetate tablets (800 mg)|
9791589|NCT01422824||Cohort|
9791590|NCT01422876|Experimental|BI 10773/linagliptin FDC (high dose)|Patients receive BI 10773/linagliptin FDC (high dose) once daily
9791591|NCT01422876|Experimental|BI 10773/linagliptin FDC (low dose)|Patients receive BI 10773/linagliptin FDC (low dose) once daily
9791592|NCT01422876|Active Comparator|BI 10773 (high dose)|Patients receive BI 10773 (high dose) once daily
9791593|NCT01422876|Active Comparator|BI 10773 (low dose)|Patients receive BI 10773 (low dose) once daily
9791594|NCT01422876|Active Comparator|Linagliptin|Patients receive linagliptin once daily
9791595|NCT01422889||ION Registry|The ION Registry population was designed to collect real world safety and clinical outcomes data. There were 1120 subjects were enrolled, however 9 subjects did not receive a study stent therefore 1111 subjects were eligible for follow up.
9791596|NCT01422915|Experimental|colestipol treatment|2 grams morning and bedtime for 180 days
9791597|NCT01423084|Experimental|MenB Lot 1|MenB vaccine Lot 1: 2 doses administered 1 month apart
9791598|NCT01423084|Active Comparator|MenB Lot 2|MenB vaccine Lot 2: 2 doses administered 1 month apart
9791599|NCT01423162|Experimental|Drink with Vit C then drink without Vit C|Fortified oat drink with vitamin C on day 1 followed by fortified oat drink without vitamin C on day 2
9791600|NCT01423162|Experimental|Drink without Vit C then drink with Vit C|Fortified oat drink without vitamin C on day 1 followed by fortified oat drink with vitamin C on day 2
9791601|NCT01423253|Experimental|Lurasidone 20, 40, 60 mg|Lurasidone 20, 40, or 60 mg/day flexibly dosed
9791602|NCT01423604|Experimental|Capecitabine and ruxolitinib|
9791603|NCT01423604|Placebo Comparator|Capecitabine and placebo|
9791604|NCT01423617|Active Comparator|Zenoctil|
9791605|NCT01423617|Placebo Comparator|Placebo|
9791606|NCT01423760|Experimental|Tecemotide (L-BLP25)|
9791607|NCT01423760|Other|Observational|
9791608|NCT01423773|Other|Lotrafilcon A test/lotrafilcon A control|Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
9791609|NCT01423773|Other|Lotrafilcon A control/lotrafilcon A test|Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
9791610|NCT01423812|Experimental|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily to Darunavir 800mg plus Ritonavir 100mg once-daily
9791611|NCT01423812|Active Comparator|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
9791612|NCT01423916|Active Comparator|Arm 1 (OPC-34712, placebo)|Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
9791613|NCT01423916|Active Comparator|Arm 2 (OPC-34712, placebo)|Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
9791614|NCT01423916|Active Comparator|Arm 3 (moxifloxacin, placebo)|Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
9791615|NCT01423916|Active Comparator|Arm 4 (moxifloxacin, placebo)|Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
9791616|NCT01424033|Experimental|N-Acetylcysteine|This is an open label trial, all patient will be entered into one treatment arm.
9791617|NCT01424072|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
9791618|NCT01424072|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
9791619|NCT01424072|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
9791620|NCT01424189|Experimental|ReSTOR Toric IOL|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
9791621|NCT01424189|Active Comparator|ReSTOR IOL|AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
9791622|NCT01424215|Experimental|ICG injection with Spyscope imaging|Indocyanine Green (ICG)
9791623|NCT01424215|No Intervention|Standard Critical View Technique|50 patients will be randomized to the no treatment arm. These patients will not get ICG injection but rather will have the standard technique for laparoscopic cholecystectomy performed including the critical view technique to expose the important structures prior to clipping and division.
9791624|NCT01424228|Placebo Comparator|Placebo|Placebo 2 mg tablet once daily before breakfast
9791625|NCT01424228|Active Comparator|prucalopride|Prucalopride 2 mg once daily before breakfast
9791626|NCT01424293|Experimental|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
9791627|NCT01424306|Experimental|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days.
9791628|NCT01424306|Experimental|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days.
9791629|NCT01424306|Experimental|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days.
9791630|NCT01424397|Experimental|SB-705498|Experimental
9791631|NCT01424397|Active Comparator|Fluticasone Propionate|Active Comparator
9791632|NCT01424397|Placebo Comparator|Placebo|Placebo Comparator
9791633|NCT01424397|Experimental|SB-705498+FP|Experimental
9791634|NCT01424501|Experimental|Group A|Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
9791635|NCT01424501|Placebo Comparator|Group B|Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
9791636|NCT01424501|Experimental|Group C|Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
9791637|NCT01424501|Placebo Comparator|Group D|Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
9791638|NCT01424501|Experimental|Group E|Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
9791639|NCT01424501|Placebo Comparator|Group F|Subjects from TB-naive cohort will receive 2 doses of physiological Saline.
9791640|NCT01424514|Experimental|SB-705498|
9791641|NCT01424514|Placebo Comparator|Placebo|
9791642|NCT01424566|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 2 or 7 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%)flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
9791643|NCT01424566|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
9791644|NCT01424644|Placebo Comparator|Placebo + Tdap + HPV|This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
9791645|NCT01424644|Experimental|MenACWY-CRM + Tdap + HPV|This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
9791646|NCT01424670|Experimental|Delamanid + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive 100 mg delamanid orally BID (morning and evening) + OBR for 2 months, followed by 200 mg delamanid QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
9791647|NCT01424670|Placebo Comparator|Placebo + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive placebo orally BID (morning and evening) + OBR for 2 months followed by placebo QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
9791648|NCT01424722|Experimental|ST Monitoring Feature|ST segment continous monitoring feature enabled and programmed ON
9791649|NCT01424813|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
9791650|NCT01424813|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
9791651|NCT01424930|Experimental|Abiraterone+prednisone (low-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
9791652|NCT01424930|Experimental|Abiraterone+prednisone (high-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
9791653|NCT01424943|Experimental|Stepping Stones Triple P|10-15 sessions of Level 4 Standard Stepping Stones Triple P delivered in family homes
9791654|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
9985590|NCT02455791|Experimental|Ultrasound-Guided Biopsy of Tumor Site|Ultrasound-guided biopsy of the tumor site performed before scheduled surgery.
9985591|NCT02454855|Experimental|"Group Melatonin"|standard anticancer treatment + 3-month of melatonin supplementation
9985592|NCT02454855|Placebo Comparator|"Group Placebo"|standard anticancer treatment + placebo (3 months)
9985593|NCT02450331|Experimental|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
9985594|NCT02450331|No Intervention|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
9985595|NCT02445222|Other|Previously treated CAR-T patients|Patients who previously were exposed to lentiviral-based CART cell therapy
9985596|NCT02442973||Control group (CG):|Standard practice group
9985597|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
9985598|NCT02427620|Experimental|Treatment (ibrutinib, rituximab, consolidation chemotherapy)|"PART I (IBRUTINIB PLUS RITUXIMAB): Patients receive ibrutinib PO QD on days 1-28 and rituximab IV over 6-8 hours on days 1, 8, 15, and 22 of cycle 1 and then over 4 hours on day 1 of cycles 3-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve complete response.~PART II (CONSOLIDATION THERAPY): Patients receive rituximab IV over 6 hours on day 1; dexamethasone PO or IV on days 1-4; cyclophosphamide IV over 3 hours BID on days 2-4; doxorubicin hydrochloride IV over 15-30 minutes on day 5; and vincristine sulfate IV over 15-30 minutes on day 5 of cycles 1, 3, 5, and 7. Patients also receive rituximab IV over 6 hours on day 1; methotrexate IV over 24 hours on day 2; and cytarabine IV over 2 hours BID on days 3 and 4 of cycles 2, 4, 6, and 8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
9985599|NCT02427581|Experimental|Arm 1 - personlized synthetic long peptide vaccine|"Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.~The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.~The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
9985600|NCT02423525|Experimental|Afatinib|Afatinib tablets are taken by mouth. Dose Level 1: 80 mg every 4 days Dose Level 2: 120 mg every 4 days Dose Level 3: 180 mg every 4 days Dose Level 4: 280 mg every 7 days
9839907|NCT02098538|Experimental|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
9985601|NCT02417415|Experimental|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
9839909|NCT02089269||Cohort 1|2,200 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
9839910|NCT02089269||Cohort 2|125 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention
9985602|NCT02417415|Sham Comparator|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
9996848|NCT01503801|Experimental|inhaled nitric oxide|The preterm infants in the experimental group inhaled nitric oxide
9996849|NCT01503801|Active Comparator|oxygen|The preterm infants enrolled but subjected to routine respiratory support.
10206483|NCT04401150|Placebo Comparator|Control|Normal saline (0.9% NaCl) or dextrose 5% in water (D5W) in a volume to match the vitamin C.
10206484|NCT04399473||Control group: Usual PT Care|
10206485|NCT04399473||Experimental group: PNE + Usual PT Care|Participants in this arm will receive PNE education in addition to Usual PT Care
10206486|NCT04388852|Experimental|Treatment (valemetostat, ipilimumab)|Patients receive valemetostat PO QD on days 1-21 and ipilimumab IV over 90 minutes on day 1 of cycles 1 and 3. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10206487|NCT04386811|Experimental|Calcitriol|
10206488|NCT04386811|Placebo Comparator|Placebo|
10206489|NCT04386538|Experimental|Low Starch Diet (LSD)|Participants will receive the low starch diet program: restricts the daily amount of ingested rich starch food, to a reduction of at least 40% compared to usual daily individual starch intake.
10206490|NCT04386538|Active Comparator|Control|Participants will receive dietary counselling based on general recommendations for healthy eating.
10206491|NCT04384341|Experimental|Haemophilic patients|Blood sampling Bone Densitometry (BMD)
10206492|NCT04384341|Other|Healthy volunteers|Bone Densitometry (BMD)
10206493|NCT04382313|Placebo Comparator|the adequate hydration group guided by Vigileo|The hydration speed is adjusted according to SVV or SV by Vigileo
10206494|NCT04382313|No Intervention|the control group|The routine hydration regimen is adopted, perioperative saline ≤500 ml hydration
10206495|NCT04381143|Active Comparator|Aspirin|Aspirin tablet 100mg daily
10206496|NCT04381143|Placebo Comparator|Matching Placebo|Placebo tablet 1 pill daily
10206497|NCT04380519|Experimental|RPH -104 80 mg|Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy
10206498|NCT04380519|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
10206499|NCT04380519|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy
10206500|NCT04379336|Experimental|Bacille Calmette-Guérin (BCG)|Participants will receive an intradermal injection of 0.1ml of the suspended BCG vaccine which accounts for 0.075mg of attenuated Mycobacterium bovis. BCG-Vaccin SSI [Statens Serum Institut], Danish strain 1331.
10206501|NCT04379336|Placebo Comparator|Placebo|The placebo used for this study is 0.9% Sodium Chloride (NaCl). Participants that are randomized to the control arm will receive a placebo injection of 0.1ml 0.9% NaCl, which is the same volume and has the same colour as the suspended BCG vaccine.
9985603|NCT02400736|Experimental|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) competitive employment: IPS assists participants to enter into competitive jobs; 2) eligibility based on client choice, i.e. zero exclusion; 3) integration of IPS and treatment team, i.e. the PACT; 4) patient-centered job match for competitive employment; 5) personalized benefits counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) rapid job search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) job development: IPS specialists build an employer network based on Veterans' interests; 8) time-unlimited and individualized support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
9985604|NCT02400736|Active Comparator|Treatment as Usual Vocational Rehabilitation/Transitional Work (TAU-VR)|Treatment as Usual Vocational Rehabilitation includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW) which involves 1) time-limited set-aside work experiences: short-term transitional work experiences in a brokered or set-aside work setting; 2) no strict entrance criteria other than general medical clearance; 3) limited integration of TW and clinical Services; 4) not patient-centered: TW jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) personalized benefits counseling; 6) limited job search: TW specialists provide variable and limited guidance for competitive job search; 7) no job development: TW specialists do not engage in community based job development; 8) time limited: The TW specialist does not provide long-term follow-up after the first job is obtained.
9839914|NCT02062489|Active Comparator|Tamoxifen|20mg(2#)/day, PO, daily, five years
9839915|NCT02062489|Placebo Comparator|Placebo|2#/day, PO, daily, five years
9839916|NCT02060721|Experimental|Macitentan|Macitentan 10mg, oral tablet, once daily
9985605|NCT02391324|Experimental|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
9985606|NCT02391324|Experimental|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
9985607|NCT02391324|Experimental|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
9985608|NCT02391324|No Intervention|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
9985609|NCT02374112|Experimental|Experimental|Creatine supplementation
9985610|NCT02374112|Placebo Comparator|Control|Placebo supplementation
9985611|NCT02369653|Experimental|Apixaban|"Children aged 1 to <18 years weighing 6 to <35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days.~Children aged 1 to <18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects < 5years and < 35 kg may be administered 0.5-mg tablets only"
9985612|NCT02369653|Placebo Comparator|No systemic anticoagulant prophylaxis|No systemic anticoagulant prophylaxis
9985613|NCT02356861|Active Comparator|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
9667573|NCT03416010|No Intervention|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
9985614|NCT02356861|Sham Comparator|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
9985615|NCT02354079|Other|genetic analysis|
9996850|NCT01503814|No Intervention|Control (Usual Care)|Control
10206502|NCT04377659|Experimental|Intubation/Mechanical Ventilation|Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
10206503|NCT04377659|Experimental|Respiratory Support|In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)
10206504|NCT04371666|Experimental|Arm A|pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
10206505|NCT04371666|Experimental|Arm B|matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
10206506|NCT04369573|Active Comparator|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
9839949|NCT01929928||Surgical Patients|
9839950|NCT01929902||Surgical Patients|
9985616|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
9985617|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
9985618|NCT02350205|Experimental|Treatment (SASS)|All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).
9985619|NCT02350205|Active Comparator|Control (split-thickness autograft)|All patients will receive both SASS and Split-thickness autograft (paired samples).
9985620|NCT02348112||Altis Sling|Subjects will have an Altis sling placed to treat stress urinary incontinence.
9985621|NCT02348112||Transobturator or Retropubic Sling|Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.
9985622|NCT02346838|Experimental|Inulin|Participants will receive 10 g of inulin powder each day for 6 weeks.
10206507|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20
10206508|NCT04369014|Experimental|etomidate|
10206509|NCT04369014|Experimental|propofol|
10206510|NCT04364152|Experimental|PD patients with freezing of gait, internal strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
10206511|NCT04364152|Experimental|PD patients with freezing of gait, external strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
10206512|NCT04364152|Experimental|PD patients without freezing of gait, internal strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
9839967|NCT01878617|Experimental|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
9839968|NCT01878617|Experimental|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
9839969|NCT01878617|Experimental|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
9839970|NCT01878617|Experimental|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
9839971|NCT01878617|Experimental|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
9839972|NCT01878617|Experimental|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
9839973|NCT01878617|Experimental|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
9922014|NCT00833963||Participants Treated With Trastuzumab|Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
9839974|NCT01878617|Experimental|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
9985623|NCT02346838|Placebo Comparator|Placebo|Participants will receive 10 g of maltodextrin each day for 6 weeks.
9985624|NCT02335424|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to 24 months.
9985625|NCT02333708||GCA group|
9985626|NCT02333708||Inflammatory syndrome (without GCA) group|
9985627|NCT02333708||Without inflammatory syndrome and without GCA group|
9985628|NCT02326974|Experimental|T-DM1 and Pertuzumab|T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy.
9985629|NCT02314988|Active Comparator|Intervention|Subjects will receive tranexamic acid on the surgical wound.
9985630|NCT02314988|Placebo Comparator|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
9985631|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
9985632|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
9985633|NCT02299999|Experimental|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
9985634|NCT02299999|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
9985635|NCT02299999|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
9985636|NCT02299999|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
9985637|NCT02293109|Experimental|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
9985638|NCT02284568|Placebo Comparator|Placebo|once daily oral dose
9985639|NCT02284568|Experimental|Laquinimod 0.6 mg|1 capsule containing 0.6 mg laquinimod and 2 capsules containing placebo were administered orally once daily for at least 48 weeks.
9985640|NCT02284568|Experimental|Laquinimod 1.5 mg|3 capsules containing 0.5 mg laquinimod were administered orally once daily for at least 48 weeks. However this arm was discontinued as of 01 January 2016 and no participants reached the 48 week timeframe.
9985641|NCT02271243||Subject with suspected MBI|
9985642|NCT02271243||Subjects without suspected MBI|
9985643|NCT02270034|Experimental|Cohort crizotinib|Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
9985644|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
9985645|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
9985646|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
9839999|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
9840000|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
9985647|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
9985648|NCT02228525|Experimental|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
9840021|NCT01821781|Experimental|Preparative|
9840025|NCT01808183||supracondylar humerus fractures|All members of the study will have near Infrared spectroscopy pads placed on their injured and uninjured arms as a part of this study.
10206513|NCT04364152|Experimental|PD patients without freezing of gait, external strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
10206514|NCT04364152|Experimental|Healthy elders, internal strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
9791655|NCT01425190|Experimental|Cohort 1: Children 17 to ≥13 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
9791656|NCT01425190|Experimental|Cohort 2: Children <13 to ≥7 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
9791657|NCT01425190|Experimental|Cohort 3: Children <7 to ≥3 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
9791658|NCT01425203|Experimental|RGT BOC + PR|Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
9791659|NCT01425203|Placebo Comparator|PBO + PR (Control)|Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
9791660|NCT01425203|Experimental|Crossover Arm|Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.
9791661|NCT01425229||Bosentan|Haplotypes of CYP2C9 and OATP1B1 characterisation of CYP2C9 (CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910)) and OATP1B1 (SLCO1B1*15 (rs2306283, rs4149056))
9791662|NCT01425268|Experimental|AeroForm Tissue Expansion|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
9791663|NCT01425268|Active Comparator|Saline Tissue Expansion|Saline Tissue Expansion inflated by needle injections of saline
9791664|NCT01425281|Active Comparator|XIENCE™|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
9791665|NCT01425281|Experimental|ABSORB BVS™|Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
9791666|NCT01425307|No Intervention|Standard Therapy|Standard Therapy of monthly transfusions
9791667|NCT01425307|Experimental|Treatment Arm|Hydroxyurea will be provided as capsules or liquid
9791668|NCT01425359|Placebo Comparator|Placebo|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks."
9791669|NCT01425359|Experimental|Ranolazine|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks."
9791670|NCT01425463|Experimental|Ferrous (II) Glycine Sulphate Complex|Ferrous (II) Glycine Sulphate Complex treatment with 567.7 mg three times a day (t.i.d.) for 12 weeks plus Placebo to Polyferose.
9791671|NCT01425463|Active Comparator|Polyferose|Polyferose treatment with 150 mg twice daily (b.i.d) for 12 weeks plus Placebo to Ferrous (II) Glycine Sulphate Complex.
9791672|NCT01425528|Experimental|Kuvan Cohort 1|This cohort will be enrolled first. Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid. This cohort will begin at a dose of 20mg/kg/day.
9791673|NCT01425528|Experimental|Kuvan Cohort 2|Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place. Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
9799609|NCT01664052|Experimental|ESS 305/ESS 505 (Essure, BAY1454032/Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
9799610|NCT01664078|Experimental|InCraft® - AAA stent graft system|Intervention: Endovascular AAA repair using the InCraft device
9799611|NCT01664091|Experimental|TE-ADM with PMRT|Participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling placed during the same surgery. This was followed by post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months, if adjuvant chemotherapy was required. The prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. Permanent reconstruction was performed at least 5 months after completion of PMRT.
9840029|NCT01785420|Experimental|Drug Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
9840030|NCT01785420|Placebo Comparator|Control|A 90 minute intravenous infusion of saline as placebo
9985649|NCT02227238|Experimental|DTG arm|Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
9985650|NCT02227238|Active Comparator|LPV/RTV arm|Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
9985651|NCT02195986|Experimental|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
9985652|NCT02195986|Active Comparator|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
9985653|NCT02195986|Placebo Comparator|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
9985654|NCT02183883|Experimental|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
9985655|NCT02177292|Experimental|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
9985656|NCT02158507|Experimental|Combination of Veliparib + Lapatinib|Lapatinib will be administered as a tablet at a dosage of 1250 mg/day continuously for 28 days starting on Day 1 of each cycle. Veliparib will be administered as a capsule at a dosage of 200 mg every 12 hours for 28 days starting on Day 2 of each cycle. A cycle of therapy is defined as 28 days. Treatment is administered on an outpatient basis. Patient response will be evaluated every 8 weeks according to the current Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and performance of relevant scans and/or x-rays.
9985657|NCT02146950||LCS12|New users of LCS12
9985658|NCT02146950||Mirena|New users of Mirena
9840041|NCT01734928|Experimental|Pomalidomide, Bortezomib and Low Dose Dexamethasone|4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
9840042|NCT01734928|Active Comparator|Bortezomib and Low Dose Dexamethasone|1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day [≤ 75 years old]or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
9985659|NCT02146950||Copper IUD|New users of copper IUDs
9985660|NCT02146950||Kyleena|New users of Kyleena
9985661|NCT02146950||Other hormonal IUD (OHIUD)|New users of other hormonal IUDs (e.g. Levosert, Fibroplant)
9985662|NCT02128958|Experimental|CF102|orally q12h
9985663|NCT02128958|Placebo Comparator|Placebo tablets of CF102|orally q12h
9985664|NCT02094625|Experimental|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
9985665|NCT02094625|No Intervention|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
9985666|NCT02087423|Experimental|MEDI4736|see below
9985667|NCT02086448|No Intervention|Obese, SDB negative|No intervention, observational comparison group
10206515|NCT04364152|Experimental|Healthy elders, external strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
10206516|NCT04362813|Experimental|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
9985668|NCT02086448|Active Comparator|Obese, SDB postive, CPAP|Therapeutic CPAP
10206517|NCT04362813|Placebo Comparator|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
9985669|NCT02086448|Sham Comparator|Obese, SDB postive, sham-CPAP|Sham (non-therapeutic) CPAP
9840054|NCT01709539|Experimental|Diagnostiskt Centrum|Investigation at the primary care center followed by further investigation at Diagnostiskt Centrum, Kristianstad General Hospital
9840055|NCT01709539|No Intervention|Existing diagnostic procedures|Investigation at the primary care center followed by further investigation at Helsingborg General Hospital
9840056|NCT01704859|Placebo Comparator|Vitamin D placebo + fish oil placebo|
9840057|NCT01704859|Active Comparator|Vitamin D placebo + fish oil|
9840058|NCT01704859|Active Comparator|Vitamin D + fish oil placebo|
9840059|NCT01704859|Active Comparator|Vitamin D + fish oil|
9840063|NCT01689103|Experimental|Alliance Feedback to Therapist|Alliance feedback provided to therapist
9840064|NCT01689103|Placebo Comparator|No alliance feedback to therapist|No alliance feedback provided to therapist
9840065|NCT01685814|Active Comparator|single stem cell transplant, 3-year lenalidomide maintenance|Arm A
9840066|NCT01685814|Experimental|tandem autologous transplant, lenalidomide maintenance|Arm B
9840067|NCT01685814|Active Comparator|allogeneic stem cell transplant, lenalidomide maintenance|Arm C
9840068|NCT01685814|Experimental|tandem autologous transplant|Arm D
10206518|NCT04360616||MG+|the lesion could detected by mammography
10206519|NCT04360616||US+|the lesion could detected by breast ulrtasound
9791674|NCT01425632|Experimental|TAU-284 Low|
9791675|NCT01425632|Experimental|TAU-284 High|
9791676|NCT01425632|Placebo Comparator|Placebo|
9791677|NCT01425723|Experimental|On-Demand|The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
9791678|NCT01425723|Experimental|Prophylaxis|Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.
9791679|NCT01425749|Experimental|Arm A|Intramuscular injections of recMAGE-A3 + AS15 ASCI.
9791680|NCT01425749|Experimental|Arm B|Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
9791681|NCT01425801|Experimental|LAS100977 0.625 μg|Single-dose LAS100977 0.625 μg, during double-blind treatment period
9791682|NCT01425801|Experimental|LAS100977 1.25 μg|Single-dose LAS100977 1.25 μg, during double-blind treatment period
9791683|NCT01425801|Experimental|LAS100977 2.5 μg|Single-dose LAS100977 2.5 μg, during double-blind treatment period
9791684|NCT01425801|Active Comparator|Salbutamol|Single-dose salbutamol 400 μg, during double-blind treatment period
9791685|NCT01425801|Placebo Comparator|Placebo|Placebo to LAS100977, and placebo to salbutamol
9791686|NCT01425801|Experimental|LAS100977 0.313 μg|Single-dose LAS100977 0.313 μg, during double-blind treatment period
9791687|NCT01425814|Experimental|Arm #2|Single dose, double blind treatment period
9791688|NCT01425814|Experimental|Arm #3|Single dose, double blind treatment period
9791689|NCT01425814|Experimental|Arm #4|Single dose, double blind treatment period
9791690|NCT01425814|Active Comparator|Arm #5|Single dose, double blind treatment period
9791691|NCT01425814|Placebo Comparator|Arm #6|Single dose, double blind treatment period
9791692|NCT01425814|Experimental|Arm #1|Single dose, double blind treatment period
9791693|NCT01425853|Experimental|Chondroitin/Glucosamine (Droglican)|"Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.~Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX."
9791694|NCT01425853|Active Comparator|Celecoxib|Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
9791695|NCT01425879|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9791696|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 via nebulizer (eFlow®)
9791697|NCT01426009|Active Comparator|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium bromide via (Spiriva® Handihaler®)
9791698|NCT01426009|Active Comparator|Ipratropium bromide Inhalation Solution|Ipratropium bromide Inhalation Solution via Handihaler® DPI
9791699|NCT01426009|Placebo Comparator|Placebo EP-101|Placebo
9791700|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 via nebulizer (eFlow®)
9791701|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 via nebulizer (eFlow®)
9791702|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 via nebulizer (eFlow®)
9791703|NCT01426191||xinzhijun|1.5-3.0g,iv,bid or tid for 5-12 days
9791704|NCT01426217|No Intervention|Control|Control arm using standard of care operating room procedures and equipment
9791705|NCT01426217|Experimental|Problem Solving Innovations (PSI) Experimental|Implementation of the passive bundle including HubScrub and DocIt
9791706|NCT01426230||Open Label|"Cohort by age-~- Patients >70 Yrs old"
9791707|NCT01426230||Open label|"Cohort by age-~- Patients < 70 Yrs old"
9791708|NCT01426269|Placebo Comparator|Placebo|Subjects will receive placebo during phase 2 (week 12 - week 52)
9791709|NCT01426269|Other|Doxycycline and Metronidazole|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
9791710|NCT01426269|Active Comparator|Doxycycline|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
9791711|NCT01426347|Placebo Comparator|placebo group|"RA Patients with vitamin D deficiency will be randomized to placebo and active intervention arms.~Patients in the placebo arm will receive I placebo pill per week for 16 weeks. After completing this arm, they will cross-over to the active treatment arm."
9791712|NCT01426347|Active Comparator|Ergocalciferol|Patients with vitamin D deficiency will be randomized to either active or placebo group. In the active group, patients will receive ergocalciferol 50,000 IU per week for 16 weeks.
9791713|NCT01426360|Experimental|strontium chloride/potassium nitrate dentifrice|
9791714|NCT01426360|Placebo Comparator|control dentifrice|
9791715|NCT01426373|Experimental|Deoxycholic Acid 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9791716|NCT01426386|Experimental|5.2 µg|
9791717|NCT01426386|Experimental|6.9 µg|
9791718|NCT01426386|Experimental|8.6 µg|
9791719|NCT01426386|Experimental|10.3 µg|
9791720|NCT01426386|Experimental|12.1 µg|
9791721|NCT01426386|Active Comparator|11 µg FbM (150 IU)|
9791722|NCT01426412|Experimental|LY3015014 intravenously (IV)|A single dose of LY3015014 up to 10.0 milligrams per kilogram (mg/kg) administered IV
9791723|NCT01426412|Experimental|LY3015014 IV Japanese|Single dose of LY3015014 10.0 mg/kg administered IV to Japanese participants. Added per protocol amendment effective October, 2012.
9791724|NCT01426412|Placebo Comparator|Placebo IV|Administered IV once only
9791725|NCT01426412|Experimental|LY3015014 subcutaneously (SC)|A single dose of LY3015014 up to 3.0 mg/kg administered SC
9985670|NCT02086448|Other|Obese, SDB postive, sleep hygiene|Sleep hygiene information and local sleep resources
9985671|NCT02078206|Experimental|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
9985672|NCT02078206|No Intervention|Treatment as usual|
9985673|NCT02061319|Experimental|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
9840077|NCT01657383||Hepatopancreaticobiliary (HPB) Surgery Patients|Patients undergoing surgical HPB procedures
9985674|NCT02061319|No Intervention|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
9985675|NCT02039830|Experimental|Group physiotherapy|12 weekly treatment visit + daily home exercise program
9985676|NCT02039830|Active Comparator|Individual one-on-one physiotherapy|12 weekly treatment visit + daily home exercise program
9985677|NCT02036931||Metal on Polyethylene articulation|G7 cup with Metal on Polyethylene articulation (MOP)
9985678|NCT02036931||Ceramic on Polyethylene articulation|G7 cup with Ceramic on Polyethylene articulation (COP)
9985679|NCT02036931||Ceramic on Ceramic articulation|G7 cup with Ceramic on Ceramic articulation (COC)
9985680|NCT02027948|Experimental|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
9840085|NCT01637051|Other|Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock|The tibial component has a monoblock design
9840086|NCT01637051|Other|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|The tibial component has a modular design
9985681|NCT02026908|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
9985682|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.~No interventions."
9985683|NCT02013297|Experimental|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
9985684|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
9985685|NCT01998841|Experimental|Mutation Carriers: Crenezumab|"Study Period A: Participants will receive Crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: Participants will be offered the opportunity to continue to receive blinded study drug until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
9985686|NCT01998841|Placebo Comparator|Mutation Carriers: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All mutation carriers entering Study Period B will, receive Crenezumab until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
9840107|NCT01590628|Experimental|NiCord|NiCord: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
10206520|NCT04360330|Experimental|Preoperative SABER|"Experimental: Preoperative Stereotactic Ablative Breast Radiotherapy (SABER). Phase I study testing up to 4 dose levels.~Non-experimental: Participants will undergo standard partial mastectomy and axillary surgery as per discretion of treating physician 4 to 6 weeks (+ at most 1 week delay) after preoperative SABER is completed."
9791726|NCT01426412|Experimental|LY3015014 SC + Statin|A single dose of LY3015014 up to 3 mg/kg administered SC in addition to participant's dose of statin
9791727|NCT01426412|Placebo Comparator|Placebo SC|Administered SC once only
9791728|NCT01426425|Experimental|Cryoablation|Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.
9791729|NCT01426438|Experimental|Arm A: Extended-release niacin with aspirin|
9791730|NCT01426438|Experimental|Arm B: Fenofibrate|
9791731|NCT01426581|Experimental|Educational Intervention A|Intervention: Teach to Goal
9791732|NCT01426581|Experimental|Educational Intervention B:|Brief Intervention
9791733|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 1|Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks
9791734|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 2|Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks
9791735|NCT01426789|Experimental|Secukinumab|10 mg/kg intravenous (I.V.)
9791736|NCT01426789|Placebo Comparator|Placebo|Placebo I.V.
9791737|NCT01426828|Other|Arm A|"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of KLH only vaccine."
9791738|NCT01426828|Other|Arm B|Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)
9791739|NCT01426854|Active Comparator|Nepafenac|Nepafenac Ophthalmic Suspension, 0.1%, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
9791740|NCT01426854|Placebo Comparator|Placebo|Nepafenac Vehicle, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
9791741|NCT01426867|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each affected eye 3 times a day for 7 days
9791742|NCT01426867|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each affected eye 3 times a day for 7 days
9791743|NCT01426867|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each affected eye 3 times a day for 7 days
9791744|NCT01426958|Active Comparator|treatment A|1 tablet afatinib single dose
9791745|NCT01426958|Experimental|treatment B|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
9791746|NCT01426958|Experimental|treatment C|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
9791747|NCT01427296|Active Comparator|OsmoPrep Tablets|
9791748|NCT01427296|Active Comparator|HalfLytely and Bisacodyl Tablet|
9791749|NCT01427309|Experimental|High Dose Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
9791750|NCT01427309|Active Comparator|Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of the Trivalent Inactivated Influenza vaccine
9791751|NCT01427504|Experimental|Sequence 1a|Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.
9791752|NCT01427504|Experimental|Sequence 1b|Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.
10206521|NCT04360265||ABO-102|Participants from prior interventional trials involving the administration of ABO-102.
10206522|NCT04358133|Experimental|Chlorhydrate de morphine|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
10206523|NCT04358133|Placebo Comparator|NaCl 0,9%|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
9791753|NCT01427504|Experimental|Sequence 2a|Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.
9791754|NCT01427504|Experimental|Sequence 2b|Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.
9791755|NCT01427504|Experimental|Sequence 3a|Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.
9791756|NCT01427504|Experimental|Sequence 3b|Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.
9791757|NCT01427517|Experimental|NAC in PD|single intravenous administration of N-acetylcysteine in PD patients
9791758|NCT01427517|Experimental|NAC in GD|single intravenous administration of N-acetylcysteine in GD patients
9791759|NCT01427517|Experimental|NAC in controls|single intravenous administration of N-acetylcysteine in control subjects
9791760|NCT01427595|Experimental|Metformin, progesterone , estrace|12 weeks Metformin oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (2X) oral estrace, 0.5-1 mg once a day for seven days (2X)
9791761|NCT01427608|Active Comparator|Sertraline + Olanzapine|Randomized to continue with sertraline and olanzapine under double-blind conditions.
9791762|NCT01427608|Placebo Comparator|Sertraline + Placebo|Randomized to continue with sertraline and substitute placebo for olanzapine under double-blind conditions.
9791763|NCT01427738|Experimental|Arm A: Topical GV solution|Topical GV 0.00165% solution (5 mL swish and gargle for 1 minute and expectorate [spit] 2 times per day [BID]) for 14 days
9791764|NCT01427738|Active Comparator|Arm B: Nystatin oral suspension|Nystatin oral suspension (5 mL of 100,000 units/mL swish for 1 minute and swallow 4 times per day [QID]) for 14 days
9791765|NCT01427751|Active Comparator|Ozurdex®|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
9791766|NCT01427751|Active Comparator|Lucentis®|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
9791767|NCT01427803|Experimental|Arm 1|
9791768|NCT01427881|Experimental|Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126."
9791769|NCT01427907|Experimental|Phoslyra - Calcium Acetate Oral Solution|The investigational compound is calcium acetate oral solution (COS) or Phoslyra. It is a pale, light greenish-yellow clear liquid with a characteristic black cherry odor and flavor for oral ingestion. Each 5 mL of COS contains 667 mg calcium acetate equal to 169 mg of elemental calcium. Each subject will follow their usual prescription.COS will be taken either prior to or during meals and snacks.
9791770|NCT01427907|Active Comparator|Sevelamer Carbonate|Sevelamer carbonate is an anion exchange resin that binds phosphate in the gastrointestinal tract and is a buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients. Each film-coated tablet of sevelamer carbonate (trade name Renvela™) contains 800 mg of sevelamer carbonate on an anhydrous basis. Subjects will receive sevelamer tablets according to their prescription.
9791771|NCT01427920|Experimental|Subject-driven titration BIAsp 30 (BID) + metformin|The subjects performed the titration of BIAsp 30 dose.
9791772|NCT01427920|Active Comparator|Investigator-driven titration BIAsp 30 (BID) + metformin|The investigator performed the titration of BIAsp 30 dose.
9791773|NCT01427933|Experimental|Ramucirumab and Eribulin|"Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle~Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
9791774|NCT01427933|Active Comparator|Eribulin Monotherapy|Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle
9791775|NCT01427972|Experimental|0.2 milligrams (mg) LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
9791776|NCT01427972|Experimental|1.5 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
9791777|NCT01427972|Experimental|10 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
9791778|NCT01427972|Active Comparator|50 mg Eplerenone|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
9791779|NCT01428024|Experimental|Restylane Lip Volume|Submucosal injections with Restylane Lip Volume. Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
9791780|NCT01428024|Experimental|Restylane Lip Refresh|Submucosal injections with Restylane Lip Refresh. Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
9791781|NCT01428063|Experimental|Daclatasvir + Asunaprevir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule or 200-mg tablet, by mouth twice daily + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
9791782|NCT01428063|Experimental|Daclatasvir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, (two 30-mg tablets or one 60-mg tablet, by mouth once daily) + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
9791783|NCT01428063|Experimental|Daclatasvir + Asunaprevir|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule, by mouth twice daily for 24 weeks
9791784|NCT01428076|Experimental|High Dose Polidocanol Endovenous Microfoam|
9791785|NCT01428076|Experimental|Medium Dose Polidocanol Endovenous Microfoam|
9791786|NCT01428115||Patients with severe active Crohn's disease|Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.
9791787|NCT01428128|Experimental|Arsenic Trioxide|
9791788|NCT01428193|Experimental|Flutamide, estrace, progesterone|"For flutamide, subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission."
9791789|NCT01428219|Experimental|Cabozantinib (XL184)|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
9791790|NCT01428245|Experimental|Progesterone, estrace|"oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days~oral estrace, 0.5-1 mg once a day for seven days"
9791791|NCT01428258|Experimental|GMP Diet/GMP Medical Foods|The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
9791792|NCT01428258|Active Comparator|AA Diet/AA Medical Foods|The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.
9791793|NCT01428336|Active Comparator|Patients|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
9791794|NCT01428336|Active Comparator|Volunteers|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
9791795|NCT01428453|Experimental|250mg rilapladib|Experimental drug
9791796|NCT01428453|Placebo Comparator|placebo|Placebo comparator
9791797|NCT01428583|Experimental|oxycodone HCl and naltrexone HCl extended-release capsules|
9791798|NCT01428661|Experimental|tasimelteon|
9791799|NCT01428661|Placebo Comparator|placebo|
9791800|NCT01428713|Active Comparator|Group A-Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
9791801|NCT01428713|Active Comparator|Group B-Combined oral contraceptive pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
9791802|NCT01428882|Active Comparator|Midazolam balanced propofol sedation|2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
9791803|NCT01428882|Placebo Comparator|Single-agent propofol sedation|2 ml saline followed by continuous propofol iv infusion
10206524|NCT04353739|Experimental|Immediate Treatment (IT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
10206525|NCT04353739|Active Comparator|Delay Treatment (DT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
9791804|NCT01429051|Experimental|Intranasal Fentanyl Spray (INFS)|All participants were step-wise titrated to an effective dose of 50, 100, 200 or 400 μg INFS in the Titration Phase (I). Participants titrated to 200 or 400 μg INFS in the Titration Phase were randomized to an 8-spray sequence in the Efficacy Phase (II); 6 BTP episodes were treated with 400 μg INFS and 2 BTP episodes with placebo in a random sequence. Participants entered the Tolerability Phase (III) either directly from the Titration Phase (with an effective dose of 50 or 100 μg) or from the Efficacy Phase (400 μg) and continued with this specific dose, unless adjustment was needed, for a total treatment time of 12 weeks.
9791805|NCT01429064|Experimental|ODM-201|
9791806|NCT01429077|Active Comparator|Levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
9791807|NCT01429077|Placebo Comparator|Inactive pill|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
9791808|NCT01429259|Experimental|Meropenem 3 hour prolonged infusion|All 30 participants will receive meropenem as a 3 hour infusion.
10206526|NCT04351945||Blood test|Patients will have a blood test to define hormone levels.
9791809|NCT01429272|Placebo Comparator|Placebo & Placebo|Placebo for minocycline & placebo for aspirin
9791810|NCT01429272|Active Comparator|minocycline & aspirin|Minocycline 100mg PO BID for 6 weeks & Aspirin 81 mg PO BID for 6 weeks
9791811|NCT01429285|Experimental|Hydromorphone|Hydromorphone protocol
9791812|NCT01429285|Active Comparator|Usual care|Usual care
9791813|NCT01429298|Experimental|Hydromorphone|2 mg of IV dilaudid will be administered over 2-3 minutes as initial dose.
9791814|NCT01429298|Active Comparator|Usual care|The attending physician administers whatever IV opioid he/she deems appropriate in whatever dose he/she chooses for initial dosing
9791815|NCT01429350|Active Comparator|IV rtPA|IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
9791816|NCT01429350|Experimental|IV rtPA and IA Penumbra System|Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
9791817|NCT01429441|Experimental|Ocriplasmin|
9791818|NCT01429441|Sham Comparator|Sham injection|
9791819|NCT01429454|Placebo Comparator|Soybean-Corn Blend Capsule|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
9791820|NCT01429454|Experimental|Omega 3 long chain fatty acid|The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
9791821|NCT01429532||Group I|1.8-mm-incision-size phacoemulsification system
9791822|NCT01429532||Group II|2.2-mm-incision-size phacoemulsification system
9791823|NCT01429532||Group III|3.0-mm-incision-size phacoemulsification system
9791824|NCT01429584|Active Comparator|0.25% bupivacaine|interscalene nerve block with 0.25% bupivacaine
9791825|NCT01429584|Active Comparator|0.125% bupivacaine|interscalene nerve block with 0.125% bupivacaine
9791826|NCT01429623|Experimental|ladostigil hemitartrate|10mg ladostigil base
9791827|NCT01429623|Placebo Comparator|Placebo Control|drug product excipients
9791828|NCT01429792|Experimental|Single Arm|
9791829|NCT01429987|Experimental|plecanatide 0.3 mg|Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
9791830|NCT01429987|Experimental|plecanatide 1.0 mg|Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
9791831|NCT01429987|Experimental|plecanatide 3.0 mg|Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
9791832|NCT01429987|Placebo Comparator|Placebo|Subjects receive placebo for 12 consecutive weeks
9791833|NCT01430091|Active Comparator|Prasugrel clinical formulation|A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
9791834|NCT01430091|Experimental|Prasugrel (ODT) - on tongue|A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
9791835|NCT01430091|Experimental|Prasugrel (ODT) - apple juice|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
9791836|NCT01430091|Experimental|Prasugrel (ODT) - chewed|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
9791837|NCT01430091|Experimental|Prasugrel (ODT) - under tongue|A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
9791838|NCT01430104|Experimental|Teriparatide + Aspara-CA + Alfarol|Aspara-CA 600 milligrams (mg) and Alfarol 1.0 microgram (µg) administered orally once daily throughout the study. Teriparatide 20 µg administered subcutaneously once daily for 28 days during the Treatment Period.
9791839|NCT01430130|Experimental|All Study Participants|Half of the revised incision was treated with the embrace device. Half of the revised incision was treated according to the Investigator's standard of care. Participant served as his/her own control.
9791840|NCT01430169|Experimental|AA4500|"collagenase clostridium histolyticum (AA4500) contains purified collagenase AA4500 (clostridium histolyticum) consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.~2 injections of AA4500 0.58 mg were administered 24 hours apart."
9791841|NCT01430182|Experimental|Methadone 0.2 mg/kg|0.2 mg/kg methadone by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
9791842|NCT01430182|Active Comparator|Morphine 0.2 mg/kg|0.2 mg/kg morphine by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
9791843|NCT01430299|Other|Demineralized Bone Matrix|a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space
9791844|NCT01430299|Other|rh-BMP2|A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2
9791845|NCT01430325|Sham Comparator|Sea Level Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion"
9791846|NCT01430325|Experimental|Sea Level Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion"
9791847|NCT01430325|Sham Comparator|Altitude Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion"
9791848|NCT01430325|Experimental|Altitude Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion"
9791849|NCT01430403|Experimental|Omalizumab|Participants receive active omalizumab (Xolair®) injections and a placebo Flovent® Diskus® (fluticasone) inhaler. Each participant will receive omalizumab (Xolair®) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. In addition, all participants receive standardized specialist asthma care.
9791850|NCT01430403|Experimental|Inhaled Corticosteroid Boost Therapy (ICS)|Participants in this group, the Inhaled Corticosteroid (ICS) boost arm, receive active ICS and placebo omalizumab (Xolair®) injections. Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone will be used. In addition, all participants receive standardized specialist asthma care.
9791851|NCT01430403|Placebo Comparator|Placebo|The placebo group receive placebo omalizumab (Xolair®) injections and placebo Flovent® Diskus® (fluticasone) inhaler. In addition, all participants receive standardized specialist asthma care.
9791852|NCT01430442|Experimental|Treatment A: Rimegepant, 10 mg|Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
9791853|NCT01430442|Experimental|Treatment B: Rimegepant, 25 mg|Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
9791854|NCT01430442|Experimental|Treatment C: Rimegepant, 75 mg|Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
9791855|NCT01430442|Experimental|Treatment D: Rimegepant, 150 mg|Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
9791856|NCT01430442|Experimental|Treatment E: Rimegepant, 300 mg|Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
9791857|NCT01430442|Experimental|Treatment F: Rimegepant, 600 mg|Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
9791858|NCT01430442|Placebo Comparator|Treatment P: Rimegepant Placebo-Matching Capsules|Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
9985687|NCT01998841|Placebo Comparator|Non-carriers of Mutation: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All non-mutation carriers entering Study Period B will continue to receive Placebo, until the results of the study are known and post trial access to Crenezumab is started or development of Crenezumab is discontinued."
9985688|NCT01987973|Active Comparator|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
9985689|NCT01987973|Experimental|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
9985690|NCT01982630|Experimental|Part 1: MK-8521 64/120 μg/day|Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.
9985691|NCT01982630|Experimental|Part 1: MK-8521 34/72 μg/day|T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14.
9985692|NCT01982630|Active Comparator|Part 1: Liraglutide 0.6/1.2/1.8 mg/day|T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.
9985693|NCT01982630|Placebo Comparator|Part 1: Placebo for MK-8521|T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.
9985694|NCT01982630|Experimental|Part 2: MK-8521 64/120/180/240/300 µg/day-T2DM|T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.
9985695|NCT01982630|Active Comparator|Part 2: Liraglutide 0.6/1.2/1.8 mg/day-T2DM|T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.
9985696|NCT01982630|Placebo Comparator|Part 2: Placebo for MK-8521-T2DM|T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.
9985697|NCT01982630|Experimental|Part 2: MK-8521 64/120 µg/day-Non-Diabetic Overweight/Obese|Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14.
9985698|NCT01982448|Experimental|Arm A: Cisplatin|Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
9985699|NCT01982448|Experimental|Arm B: Paclitaxel|Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
9985700|NCT01951469|Experimental|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) chemotherapy or Pemetrexed (D1)+nedaplatin (D1) chemotherapy, every 28 days
9985701|NCT01951469|Active Comparator|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
9985702|NCT01940809|Experimental|Arm A1 (ipilimumab, dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
9840143|NCT01547468|Active Comparator|Intravenous Opioids|
9840144|NCT01547468|Experimental|Femoral Nerve Catheterization|
9922015|NCT00833963||Participants Treated With Trastuzumab and Pertuzumab|Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
9922016|NCT00833963||Participants Treated With Ado-Trastuzumab Emtansine|Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
9922017|NCT00834015|Other|Experimental|combined strength and aerobic training
9985703|NCT01940809|Experimental|Arm A2 (dabrafenib, trametinib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
9985704|NCT01940809|Experimental|Arm B1 (ipilimumab, trametinib)|Patients receive trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
9840158|NCT01506141|Experimental|Idursulfase-IT|Idursulfase-IT will be administered once monthly and weekly IV infusions of Elaprase at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
9985705|NCT01940809|Experimental|Arm B2 (trametinib, nivolumab, ipilimumab)|Patients receive trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
9985706|NCT01940809|Experimental|Arm C1 (ipilimumab, dabrafenib)|Patients receive dabrafenib PO BID for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
9985707|NCT01940809|Experimental|Arm C2 (dabrafenib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
9985708|NCT01940809|Experimental|Arm D1 (ipilimumab)|Patients receive ipilimumab IV over 90 minutes Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
9985709|NCT01940809|Experimental|Arm D2 (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses
9985710|NCT01937247|Placebo Comparator|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
9985711|NCT01937247|Active Comparator|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
9985712|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
9985713|NCT01891747|Experimental|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab & temozolomide.
9985714|NCT01879228|Experimental|Sitagliptin|The dose of sitagliptin (Januvia®) 100 mg tablet will be taken orally each morning for 6 months.
9985715|NCT01879228|Placebo Comparator|Placebo|Placebo tablet will be taken orally each morning for 6 months.
10206527|NCT04349371|Experimental|CQ group|Participants will receive CQ supply for 3 months. Patients will receive a supply of 36 -- 250 mg tabs or placebo that will last 3 months (enough for taking two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
9840176|NCT01485861|Experimental|Phase Ib: Ipatasertib 400 mg + abiraterone|Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
9840177|NCT01485861|Experimental|Phase Ib: Apitolisib 30 mg + abiraterone|Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
9840178|NCT01485861|Experimental|Phase II: Ipatasertib 400 mg + abiraterone|Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
9840179|NCT01485861|Experimental|Phase II: Ipatasertib 200 mg + abiraterone|Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
9840180|NCT01485861|Placebo Comparator|Phase II: Placebo + abiraterone|Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
9922018|NCT00834028||1|patients with hepatocellular carcinoma receive transcatheter arterial chemoembolization
9922019|NCT00834054||Double-lung transplanted patients|
9922020|NCT00834093|Experimental|Biological/Vaccine|'Epstein-Barr Virus Specific Immunotherapy' given intravenously on Days 1 and 14
9922021|NCT00834145|Experimental|1|Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.
9922022|NCT00834145|No Intervention|2|Routine medical treatment
9791859|NCT01430442|Active Comparator|Treatment G: Sumatriptan 100 mg|Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
9791860|NCT01430455|Experimental|Tranylcypromine|Active, open-label tranylcypromine treatment
9791861|NCT01430468|Experimental|Glenoid Positioning System|For the patients randomized to the GPS group, the surgeon will be given the GPS patient specific instrumentation and a model of the glenoid surface showing the exact placement and fit of the GPS alignment instruments.
9791862|NCT01430468|No Intervention|Standard Group|Each surgeon will use their standard methods of pre-operative planning using the pre-operative x-rays and CT scan.
9516874|NCT03311438|Other|Oral health intervention program|Oral Health intervention program: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
9791863|NCT01430559|Other|Meloxicam|
9791864|NCT01430559|Placebo Comparator|Placebo|2 Placebo capsules once a day for 12 weeks
9791865|NCT01430585|Experimental|A|
9791866|NCT01430585|Experimental|B|
9791867|NCT01430585|Active Comparator|C|
9791868|NCT01430611|Experimental|Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine|
9791869|NCT01430611|Active Comparator|Lanzhou Institute Meningococcal A+C Polysaccharide Vaccine|
9791870|NCT01430624|Experimental|PPRS video|Prevention of post sexual assault stress
9791871|NCT01430624|Active Comparator|PIRI video|Pleasant imagery and relaxation instruction
9791872|NCT01430624|No Intervention|Standard care|Treatment as usual
9791873|NCT01430741|Other|Implementation as Usual Case Management|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar"
9791874|NCT01430741|Other|Implementation as Usual Veterans|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar. Staff then deliver MISSION to Veterans."
9791875|NCT01430741|Experimental|Getting to Outcomes Case Management|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform.
9791876|NCT01430741|Experimental|Getting to Outcomes Veterans|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform, that guides staff while delivering MISSION to Veterans.
9791877|NCT01430754|Experimental|tasimelteon|20 mg tasimelteon capsules
9791878|NCT01430754|Placebo Comparator|Placebo|Placebo capsules
9791879|NCT01430819|Experimental|Fluzone® Vaccine Group|Participants will receive the Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
9791880|NCT01430819|Active Comparator|Fluzone® High-Dose Vaccine Group|Participants will receive the Influenza Virus Vaccine, Fluzone® High-Dose 2011-2012 Formulation.
9791881|NCT01431014|Active Comparator|"Dexamethasonelow-dose"|5mg
9791882|NCT01431014|Experimental|"Dexamethasonehigh-dose"|15mg
9791883|NCT01431079|Experimental|Health belief model based education|This experimental arm will provide an educational intervention designed to modify constructs of health belief model regarding HPV vaccine acceptability.
9840181|NCT01485861|Experimental|Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone|"Participants will receive Ipataseritib 400 mg once daily in the AM for Cycle 1 day 1-18. On Day 19, Ipataseritib 400 mg will be switched to PM dosing for the remainder of the Cycle 1.~Prednisone 5 mg starts in the PM of Cycle 1 day 8 and taken BID thereafter for the remainder of the study treatment Abiraterone 1000mg once a day starts on Cycle1 day 12 in the AM and should be taken at the same time as Ipataseritib. Starting from cycle 1 day 19, Ipataseritib and Abiraterone are dosed in PM at should be taken together at the same time each day until cycle 2 day 1. Starting from Cycle 2 Day 1, Participants may choose to take Ipatasertib and Abiraterone in either the AM or PM; however, they should be taken together at approximately the same time each day.~Participants will receive the study treatment until disease progression or intolerable toxicity."
9985716|NCT01829958|Experimental|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
9985717|NCT01829958|Experimental|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
9985718|NCT01813370||Pts with prostate cancer|Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
9985719|NCT01805271|Experimental|Everolimus|1 or 2 tablets/day (i.e.5 or 10 mg/day )
9985720|NCT01805271|Placebo Comparator|Placebo|1 or 2 tablets/day
9985721|NCT01783041|Placebo Comparator|5% dextrose|Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
9985722|NCT01783041|Experimental|L-carnitine|Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
9985723|NCT01781728|Active Comparator|RT naive|
9985724|NCT01781728|Active Comparator|Previous RT|
9996851|NCT01503814|Experimental|Intervention|"Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a2+2model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable"
9996852|NCT01503827|Experimental|WBRT|Patients will receive WBRT after local treatment. A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
9996853|NCT01503827|No Intervention|Observation|No Intervention
10206528|NCT04349371|Placebo Comparator|Placebo group|Participants will receive placebo supply for 3 months. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
10206529|NCT04344392|Other|Dysphagic hemiplegic patients|Dysphagic patients with hemiplegia as assessed by clinical examination
10206530|NCT04344392|Other|Control|Volunteers which do not have an active swallowing dysfunction.
9996854|NCT01503840|Active Comparator|Sugammadex|
9996855|NCT01503840|Placebo Comparator|Sodium chloride solution|
9996856|NCT01503866|Experimental|20 mg bardoxolone methyl|
9996857|NCT01503892|Placebo Comparator|Placebo|The control group will receive placebo pill twice daily for twelve months.
9996858|NCT01503892|Active Comparator|Metanx|Metanx group will receive one pill twice daily for twelve months.
9996859|NCT01503905|Active Comparator|Docetaxel plus epirubicin|
9996860|NCT01503905|Active Comparator|docetaxel plus epirubicin plus cyclophosphamide|
9996861|NCT01503918|Experimental|Valaciclovir/Aciclovir|
9996862|NCT01503918|Experimental|Valganciclovir/Ganciclovir|
9996863|NCT01503918|No Intervention|control|
9996864|NCT01503931||Alcohol-dependent patients|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no other psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
10206531|NCT04335981|Experimental|FT-CC and Swallow Exercises|
10206532|NCT04335981|Active Comparator|Swallow Exercises|
10206533|NCT04334304|Active Comparator|Posterior Stabilized TKA without robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA without robot-assistance
10206534|NCT04334304|Experimental|Posterior Stabilized with robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA with robot-assistance
10206535|NCT04334304|Experimental|Bicruciate retaining TKA without robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA without robot-assistance
10206536|NCT04334304|Experimental|Bicruciate retaining TKA with robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA with robot-assistance
10206537|NCT04332211|Experimental|Pseudoephedrine Group|Patients randomized to pseudoephedrine prior to hyperbaric therapy
9996865|NCT01503931||Healthy control subjects|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
9996866|NCT01503957|Placebo Comparator|Saline solution|Nasal spray
9996867|NCT01503957|Experimental|Nasya|Thixotropic nasal spray suspension
9791884|NCT01431079|Active Comparator|Knowledge-based education|This comparison arm will provide education based on knowledge regarding HPV vaccine acceptability.
9791885|NCT01431105|Experimental|Atorvasatin|Atorvastatin dose titration to maximum tolerated dose
9791886|NCT01431131|Active Comparator|Intrasocket graft|Positive control
9791887|NCT01431131|Experimental|Intrasocket plus facial overlay graft|Intrasocket cancellous allograft plus a facial overlay bovine xenograft
9791888|NCT01431144|Active Comparator|Connective tissue autograft|A connective tissue autograft harvested from the palate was grafted onto the facial of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
9791889|NCT01431144|Experimental|connective tissue allograft|An acellular dermal matrix allograft was grafted on the facial surface of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
9791890|NCT01431170|Experimental|Besivance Treatment Group|Besivance™ ophthalmic suspension, 0.6%
9791891|NCT01431170|Active Comparator|Polytrim Treatment Group|Polytrim ophthalmic solution
9791892|NCT01431209|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9791893|NCT01431274|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
9791894|NCT01431274|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
9791895|NCT01431274|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
9791896|NCT01431274|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
9791897|NCT01431274|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
9791898|NCT01431287|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
9791899|NCT01431287|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
9791900|NCT01431287|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
9791901|NCT01431287|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
9791902|NCT01431287|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
9791903|NCT01431300|Active Comparator|0.03 mmol/kg|FDA-approved dose for lower extremity arterial imaging
9791904|NCT01431300|Experimental|0.02 mmol/kg|
9791905|NCT01431300|Experimental|0.01 mmol/kg|
10206538|NCT04332211|Placebo Comparator|Placebo Group|Patients randomized to placebo prior to hyperbaric therapy
10206539|NCT04331041|Experimental|MR-guided SBRT + Defactinib|"Participants in this study will receive 5 fractions of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) and seventeen 21-day cycles of defactinib (beginning on Day 2 of radiation).~Participants who are candidates for surgical resection will undergo standard of care surgery at 2 weeks post-end of SBRT (+/- 1 weeks) or 12 weeks post-end of SBRT (+/- 1 week). These participants will discontinue defactinib the day prior to the operation and will resume taking it for the remainder of the 17 cycles 4 to 6 weeks after surgery. Participants who are not candidates for surgical resection will continue to receive defactinib uninterrupted. All participants should receive 17 cycles of defactinib unless they experience disease progression or intolerable toxicity."
9791906|NCT01431313|Experimental|Inhaled Nitrite|Sodium Nitrite Inhalation Solution (AIR001) 45mg dosage with one subsequent escalation dosage of 90mg based on tolerability.
9799612|NCT01664104||RA Participants|Participants with moderate or severe RA who are under tocilizumab treatment in routine clinical practice (in accordance with the local label) will be observed for 6 months from the start of treatment.
9799613|NCT01664117||bDMARD Monotherapy|Patients with moderate to severe rheumatoid arthritis (RA) will be treated with bDMARD (biologic disease-modifying antirheumatic drug) monotherapy under routine clinical practice conditions at rheumatology clinics
9799614|NCT01664130|Experimental|Treatment (SBRT)|Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.
9799615|NCT01664247|Experimental|IDeg + Lira|
9799616|NCT01664247|Experimental|Placebo + Lira|
9799617|NCT01664494||Capecitabine|Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
9799618|NCT01664533||Erlotinib|Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg.
9799619|NCT01664559|Placebo Comparator|Placebo with 1cc normal saline IM|If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.
9799620|NCT01664559|Experimental|Toradol, 30mg in 1cc IM|If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.
9799621|NCT01664624|Experimental|Roflumilast + alogliptin|Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.
9799622|NCT01664624|Experimental|Alogliptin alone|Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.
9799623|NCT01664624|Experimental|Roflumilast alone|Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.
9799624|NCT01664624|Active Comparator|Exenatide|Exenatide 5 μg subcutaneous injection twice a day for 11 days.
9799625|NCT01664741|Active Comparator|Nicotine patch - transdermal|21 mg nicotine patch
9799626|NCT01664741|Placebo Comparator|Placebo NRT|Matching placebo patch
9799627|NCT01664741|No Intervention|Healthy non-smoker comparison|Demographically-matched women and men who have never smoked
9799628|NCT01664793|Experimental|Intervention Group Year 1|The 4 Pillars Immunization Toolkit along with donated vaccines for early season vaccination, staff education and support.
9922023|NCT00834158|Active Comparator|TACE|perform TACE only
9922024|NCT00834158|Experimental|TACE+PVE|perform TACE and PVE sequentially
9791907|NCT01431339|Active Comparator|Vancomycin with possible switch to oral linezolid|
9791908|NCT01431339|Experimental|Dalbavancin|
9791909|NCT01431391|Experimental|Arm 1: Sipuleucel-T followed by ADT|Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
9791910|NCT01431391|Experimental|Arm 2: ADT followed by sipuleucel-T|Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.
9791911|NCT01431521|Experimental|MK-4074|Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
9791912|NCT01431521|Placebo Comparator|Placebo for MK-4074|Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
9791913|NCT01431521|Experimental|Pioglitazone|Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
9791914|NCT01431521|Placebo Comparator|Placebo for pioglitazone|Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
9791915|NCT01431534|Experimental|Ridaforolimus 22 mg/m^2|Participants receive 22 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
9791916|NCT01431534|Experimental|Ridaforolimus 28 mg/m^2|Participants receive 28 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
9791917|NCT01431534|Experimental|Ridaforolimus 33 mg/m^2|Participants receive 33 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
9791918|NCT01431573|Experimental|Wake Therapy + light box +/- lithium|"Bipolar patients must take lithium; others do not take lithium~all patients are hospitalized for a week during which they do not sleep on alternating nights~for six weeks, including the week in the hospital all patients sit in front of bright lights at specified times and for specified durations"
9791919|NCT01431638|Experimental|Canakinumab 150mg|Canakinumab 150mg in prefilled syringe subcutaneously
9791920|NCT01431716|Experimental|EFI/ACT-385781A|EFI/ACT-385781 administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump
9791921|NCT01431755|Other|Restylane SubQ|
9791922|NCT01431755|Other|Restylane SubQ Lidocaine|
9791923|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-600mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.
9791924|NCT01431794|Active Comparator|Phase II-Arm A:Gem,nab-paclitaxel,LDE225|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
9791925|NCT01431794|Active Comparator|Phase II-Arm B:Gem,nab-paclitaxel|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
9791926|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-400mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.
9791927|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-800mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.
9791928|NCT01431846|No Intervention|Discharge Patient|Eight patients who were being discharged from Denver VA Medical Center for cardiac care to their primary care providers were recruited at the time of discharge and completed an interview two weeks following their discharge. Patients were asked to describe their transition to home and identify barriers and facilitators of this process, their understanding of their medical condition, new medications prescribed, timeliness of follow-up visit with their PCP and knowledge of signs/symptoms in which they should seek medical attention.
9791929|NCT01431846|No Intervention|Providers|Three providers who refer patients to the Denver VA Medical Center for cardiac care were interviewed to identify barriers and facilitators from their perspective of following-up with patients after their hospitalization at Denver VAMC. Additionally, the same information was asked of providers who participated in two focus groups in the Grand Junction VA.
9791930|NCT01431846|Experimental|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
9791931|NCT01431950|Experimental|FF 100mcg once daily|Inhaled corticosteroid (ICS)
9791932|NCT01431950|Experimental|FF 200mcg once daily|Inhaled corticosteroid
9791933|NCT01431963|Experimental|Lamotrigine|No comparison.
9791934|NCT01431976|Experimental|Lamotrigine|No comparison
9985725|NCT01779557|Experimental|Huaren peritoneal dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
9791935|NCT01431989|Active Comparator|Test formulation|Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.
9791936|NCT01431989|Active Comparator|Reference formulation|Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2
9791937|NCT01432015|Active Comparator|Fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3
9791938|NCT01432015|Active Comparator|Aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1
9791939|NCT01432145|Experimental|6MP/MTX|6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week
9791940|NCT01432171|Experimental|Arm I (lacosamide)|Participants receive lacosamide PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
9791941|NCT01432171|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
9791942|NCT01432236|Experimental|Pregabalin|Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
9791943|NCT01432236|Placebo Comparator|Placebo|Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
9791944|NCT01432262|Experimental|Group 1|=> 65 years of age
9791945|NCT01432262|Experimental|Group 2|50 to 64 years of age
9791946|NCT01432275|Experimental|ADC, Then Comparator, Then ADC With Calculator|Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
9791947|NCT01432275|Experimental|Comparator, Then ADC, Then ADC With Calculator|Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
9791948|NCT01432327|Placebo Comparator|Control group|This group receives no kind of feedback during the intervention period. The participants wear the SenseWear Armband for 4 weeks and results of the intervention are discussed after the 4 week intervention period.
9791949|NCT01432327|Experimental|Step Group|This group receives feedback about the daily amount of steps by means of a pedometer.
9791950|NCT01432327|Experimental|Display Group|Participants receive real time feedback on their energy expenditure, minutes of physical activity and step count by means of the SenseWear Display
9791951|NCT01432327|Experimental|Coaching Group|Participants receive real-time feedback on their energy expenditure, step count and minutes of physical activity by means of the SenseWear Display and weekly meet with a Personal Coach to discuss their progress
9791952|NCT01432366||Rheumatoid arthritis patients treated with SC anti-TNF|
9791953|NCT01432379||botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
9791954|NCT01432405|Experimental|Pioglitazone and exenatide|Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
9791955|NCT01432405|Experimental|Pioglitazone|Pioglitazone 45 mg daily orally for 12 months
9791956|NCT01432444|Experimental|OPC-14597|Aripiprazole IM depot injection 300 mg or 400 mg.
9791957|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 50 mg/day|
9791958|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 100 mg/day|
9791959|NCT01432457|Placebo Comparator|Placebo|
9791960|NCT01432535|Active Comparator|Healthy Participants|Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
9791961|NCT01432535|Experimental|Participants with Moderate Renal Impairment|Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
9791962|NCT01432535|Experimental|Participants with Severe Renal Impairment|Participants with severe renal impairment defined as having a creatinine clearance test value of <30 mL/min/1.73 m^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
9791963|NCT01432561|Experimental|Cysteamine bitartrate|Cysteamine bitartrate, 500mg once a day, three days.
9791964|NCT01432574|Experimental|Gardasil Vaccine|Vaccine Administration: A total of 3 injections (shots) at 3 separate visits.
9791965|NCT01432600|Experimental|A: Dose Escalation of Cyclophosphamide|"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:~Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
9791966|NCT01432600|Active Comparator|B: Pomalidomide and Dexamethasone|"Randomized Phase II - Pomalidomide high dose dexamethasone:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
9985726|NCT01779557|Active Comparator|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
9791967|NCT01432600|Active Comparator|C: Pomalidomide/Dexamethasone/Cyclophosphamide|"Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Cyclophosphamide 400 mg PO days 1, 8, 15.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
9791968|NCT01432600|Other|D: Crossover|Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
9791969|NCT01432626|Experimental|Stress Induced Cardiomyopathy Patients|Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
9791970|NCT01432730|Experimental|Gefapixant 600 mg>Placebo|Gefapixant, 600 mg, twice daily (BID), taken orally for 2 weeks followed by a 2-week washout period and then placebo to gefapixant, BID, taken orally for 2 weeks.
9791971|NCT01432730|Experimental|Placebo>Gefapixant 600 mg|Placebo to gefapixant BID, taken orally for 2 weeks followed by a 2-week washout period and then gefapixant, 600 mg, BID, taken orally for 2 weeks.
9791972|NCT01432756|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 3-month follow-up assessment.
9791973|NCT01432756|Experimental|Let's Talk Worskite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
9791974|NCT01432886|Experimental|1|
9791975|NCT01432938|Experimental|Warfarin first, then Dulaglutide + Warfarin|A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).
9791976|NCT01432938|Experimental|Dulaglutide + Warfarin first, then Warfarin|A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).
9791977|NCT01432951|Experimental|Enzastaurin|"Enzastaurin 500 mg, four 125-mg tablets administered orally once daily for 14 days. Dosing is held for 3 days, and resumes on Day 18. Participants may continue receiving optional enzastaurin for an additional 2 to 4 weeks.~Safety Extension: Participants had the option to continue receiving enzastaurin until disease progression or discontinuation criteria are met, as per the investigator's assessment."
9791978|NCT01433016|Experimental|Octanaote Breath Test|A Octanoate breath test will be performed on this single arm population
9791979|NCT01433042|Experimental|capsule endoscopy|
9791980|NCT01433055|Active Comparator|Minocycline|
9791981|NCT01433055|Placebo Comparator|Sugar Pill|
9791982|NCT01433081|Active Comparator|Magnesium sulfate infusion|Administration of magnesium suflate
9791983|NCT01433081|Placebo Comparator|Placebo|.9 normal saline infusion
9791984|NCT01433107|Experimental|Terbinafine|Drug
9791985|NCT01433107|Placebo Comparator|Placebo|Drug
9791986|NCT01433159|Experimental|HP011-101|
9791987|NCT01433159|Active Comparator|Various|Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
9791988|NCT01433172|Experimental|Phase I Vaccinations|Participants enrolled in the Phase I trial will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note for the phase I portion: the use of steroid medication is to be avoided for 4 weeks prior to the initiation of vaccine therapy and during the vaccine treatment period.
9791989|NCT01433172|Active Comparator|Phase II Arm A Vaccinations|Arm A participants will receive GM.CD40L cells vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
9791990|NCT01433172|Active Comparator|Phase II Arm B Vaccinations|Arm B participants will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
9791991|NCT01433250|Experimental|AIN 457 Core|(10mg/kg i.v.). AIN 457 core study /AIN 457 Extension
9791992|NCT01433250|Experimental|AIN457 Placebo Core|(10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension
9791993|NCT01433263|Experimental|30mg/kg BYM338|
9791994|NCT01433263|Placebo Comparator|Placebo / late 30mg/kg BYM338|
9791995|NCT01433354|Experimental|AFQ056 Treatment|All patients will initiate treatment with AFQ056 at a starting dose of 25 mg b.i.d. The dose will be titrated from 25 mg b.i.d to 50 mg b.i.d., 75 mg b.i.d. and 100 mg b.i.d. at weekly intervals. Dose adjustments (up- and down-titrations) will be permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose, not to exceed 100 mg b.i.d.
9791996|NCT01433549|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
9799629|NCT01664793|No Intervention|Control Group Year 1|Control sites will not receive assistance with increasing influenza vaccination in Year 1, they will follow guidelines for usual care.
9985727|NCT01752920|Experimental|Low Dose Group|Patients who received derazantinib orally at dose levels from 25 mg every other day (QOD) - 200 mg daily (QD) on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
9985728|NCT01752920|Experimental|Middle Dose Group|Patients who received derazantinib orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
9985729|NCT01752920|Experimental|High Dose Group|Patients who received derazantinib orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
9985730|NCT01752920|Experimental|Expanded Cohort Group|Patients who received derazantinib orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
9985731|NCT01750619||Mucosal tumors of the colon|Patients who received endoscopic treatment for noninvasive mucosal tumors of the colon.
9985732|NCT01750619||Nonampullary tumors of the duodenum|Patients who received endoscopic treatment for noninvasive mucosal tumors of the duodenum.
9840229|NCT01387763|Active Comparator|PegIntron <= 60 years|In patients <= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
9840230|NCT01387763|Active Comparator|Pegasys <= 60 years|In patients <= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
9840231|NCT01387763|Active Comparator|PegIntron > 60 years|In patients < 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
9840232|NCT01387763|Active Comparator|Pegasys > 60 years|In patients > 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
9840233|NCT01387763|Active Comparator|Hydroxyurea > 60 years|Capsule Hydrea 500-2000 mg orally QD or BID
9985733|NCT01750619||Ampullary tumors|Patients who received endoscopic treatment for noninvasive ampullary tumors.
9985734|NCT01744093|Active Comparator|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
9985735|NCT01744093|Placebo Comparator|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
9840237|NCT01375114|Experimental|Panax Ginseng|Panax ginseng 400 mg by mouth twice a day from Day 1-29 for first 30 participants in Part 1. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
9840238|NCT01375114|Experimental|Ginseng (Part 2)|Panax ginseng 400 mg by mouth twice a day from Day 1-29. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
9840239|NCT01375114|Placebo Comparator|Placebo (Part 2)|Oral placebo twice daily for 4 weeks. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
9985736|NCT01740297|Experimental|Phase 1b: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque-forming units (PFU)/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until complete response (CR), all injectable tumors had disappeared, confirmed disease progression per the modified immune-related response criteria (irRC), or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab administered intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
9985737|NCT01740297|Active Comparator|Phase 2: Ipilimumab|Participants received ipilimumab 3 mg/kg intravenously every 3 weeks for a total of 4 infusions starting at week 1.
9996868|NCT01503970|Experimental|Chondrocyte implantation|
9996869|NCT01503983|Experimental|Trastuzumab+Oxaliplatine+capecitabine|Patient takes Trastuzumab (initial dose 8 mg/kg and a maintenance dose 6 mg/kg) anda oxaliplatin (dose 130mg/m2) during the first day os cycle and them Capecitabine (dose 2000 mg/m2)during 14 days in cycle of 21 days.
9996870|NCT01503996||glaucoma|hospitalized glaucoma patients
9996871|NCT01503996||controls|hospitalized patients without glaucoma
9516875|NCT03311425|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
9516876|NCT03311425|Placebo Comparator|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
9791997|NCT01433549|Other|Senofilcon A / Lotrafilcon B|Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
9791998|NCT01433731|Placebo Comparator|placebo for SHAPE (SHP-141)|placebo for SHAPE (SHHP-141) topical gelled solution
9791999|NCT01433731|Experimental|SHAPE (SHP-141) 0.1%BID|SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
9792000|NCT01433731|Experimental|SHAPE (SHP-141) 0.5% BID|SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
9792001|NCT01433731|Experimental|SHAPE (SHP-141) 1.0% BID|SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
9792002|NCT01433913|Experimental|Arm I (metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 4-12 weeks.
9792003|NCT01433913|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-12 weeks.
9792004|NCT01433978|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, once daily and allow to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
9792005|NCT01433978|Active Comparator|Eltrombopag (Core Study)|Eltrombopag will be administered orally as 25 mg, 50 mg, or 75 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 50 mg eltrombopag once daily and allow to have their dose titrated up (maximum dose of 75 mg eltrombopag) or down (minimum dose of 25 mg eltrombopag) depending on their response to study drug.
9792006|NCT01433978|Experimental|Avatrombopag (Open-label Extension)|Participants who meet the eligibility requirements for the Open-label Extension (OLE) Phase or who discontinue the Core Study early because of lack of treatment effect will be eligible to continue into the OLE Phase for up to 104 weeks of open-label avatrombopag therapy. Participants who enter the OLE from the Core Study will receive a starting dose of open-label avatrombopag which will be determined by the last dose of study drug at the End of Treatment (EOT) Visit (Visit 22) of the Core Study. Participants who discontinue the Core Study early because of lack of treatment effect and enter the OLE will receive open-label avatrombopag at a starting dose of 20 mg once daily of open-label avatrombopag.
9792007|NCT01433991|Experimental|Phase 1B|Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.
9792008|NCT01433991|Experimental|Phase 2 Cohort 1 Arm A:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.
9792009|NCT01433991|Experimental|Phase 2 Cohort 1 Arm B:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1*4 mg capsule + 2*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).
9792010|NCT01433991|Experimental|Phase 2 Cohort 2 Arm C:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.
9792011|NCT01433991|Experimental|Phase 2 Cohort 2 Arm D:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.
9792012|NCT01434030|Other|Behavioral Observer|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
9792013|NCT01434121|Active Comparator|High Dose Ascorbic Acid|Subject receives a high dose of infused Vitamin C
9792014|NCT01434121|Active Comparator|Low Dose Ascorbic Acid|Subject receives a low dose of infused Vitamin C
9792015|NCT01434121|Placebo Comparator|Placebo|Subject receives an infusion of saline
9840255|NCT01349881|Placebo Comparator|eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.
9840256|NCT01349881|Experimental|Eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
9840257|NCT01349881|Experimental|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
9840258|NCT01349881|Experimental|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
9840259|NCT01330446|Experimental|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
9840260|NCT01330446|Placebo Comparator|Placebo|1 Placebo by mouth every morning for a 28 day cycle.
9985738|NCT01740297|Experimental|Phase 2: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ PFU/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until CR, all injectable tumors had disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
9985739|NCT01738009|Experimental|Induction of flow limitation|Flow limitation will be induced by sustained reductions in continuous positive airway pressure during sleep
9985740|NCT01729754|Experimental|Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
9985741|NCT01729754|Experimental|Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
9985742|NCT01729754|Placebo Comparator|Placebo|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
9985743|NCT01729754|Active Comparator|Etanercept 50 mg|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.
9985744|NCT01718743|Experimental|Treatment (ixazomib citrate, lenalidomide)|Beginning 60-180 days post-transplant, patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9985745|NCT01684826|Experimental|ClarityIQ|Angiographic run with new algorithm and low dose (50% dose)
9985746|NCT01684826|Experimental|AlluraXper|Angiographic run with predecessor algorithm and dose (100% dose)
9985747|NCT01672242|Experimental|HFNC|High Flow Nasal Cannula (HFNC) oxygen.
9985748|NCT01672242|Experimental|CPAP|Continuous Positive Airway Pressure (CPAP)
9985749|NCT01668784|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9985750|NCT01668784|Active Comparator|Arm 2: Everolimus|Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9996872|NCT01504009|Experimental|Muscle strength|
9996873|NCT01504022|No Intervention|Control group.|Control group.
10206540|NCT04331041|Active Comparator|MR-guided SBRT|-Participants in this study will receive 5 fractions of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT)
10206541|NCT04330274||Group 1|Unilateral transtibial amputee
10206542|NCT04330274||Group 2|Unilateral transfemoral amputee
10206543|NCT04323553||ESBL E.coli strains from 24 contact-index patients|48 ESBL-E. coli strains from 24 contact-index patients
10206544|NCT04320680|Other|lupus cohort follow up|it is a descrption lupus patients study
10206545|NCT04314115|Active Comparator|Mindfulness|A brief intervention in mindfulness will be administered
9840281|NCT01297400|Experimental|Investigational Drug, MW-III|Investigational Drug, MW-III
9840282|NCT01297400|Active Comparator|Standard of care|Silvadene® Cream 1% [Silver Sulfadiazine]
9840283|NCT01295645|Experimental|Standard of Care + Cidofovir|Cidofovir 0.5 mg/kg IV 3 x week for 4 weeks
9840284|NCT01295645|Active Comparator|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
10206546|NCT04314115|Active Comparator|Systemic therapy|A brief systemic therapy intervention will be administered
10206547|NCT04314115|Active Comparator|Cognitive behavioral therapy and positive psychology|A brief intervention of traditional cognitive behavioral therapy with positive psychology elements will be administered
10206548|NCT04314115|No Intervention|Waiting list|Waiting list, as a control group
9840287|NCT01283997|Placebo Comparator|Placebo Group|1 dose on first day of induction therapy, then every 12 hours for 10 weeks.
9840288|NCT01283997|Experimental|Minocycline Group|200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks.
9840299|NCT01254864|Experimental|Abiraterone Acetate + Prednisone (AP)|Abiraterone Acetate at 1000 mg orally each day, given in combination with 5 mg of Prednisone orally twice daily.
9840300|NCT01254864|Experimental|Group 1: AP + Sunitinib|AP (Abiraterone Acetate + Prednisone) Plus Sunitinib; Randomized from AP group to receive Sunitinib if disease worsens. Assignment to crossover group AP + Dasatinib with further disease progression.
9840301|NCT01254864|Experimental|Group 2: AP + Dasatinib|AP (Abiraterone Acetate + Prednisone) Plus Dasatinib; Randomized from AP group to receive Dasatinib if disease worsens. Assignment to crossover group AP + Sunitinib with further disease progression.
10206549|NCT04312542||SRP with minocycline HCl microspheres|Participants in this cohort received the intervention of minocycline HCl microspheres, 1 mg in the interventional phase of the trial.
10206550|NCT04312542||SRP without minocycline HCl microspheres|Participants in this cohort did not have minocycline HCl microspheres, 1 mg administered during the interventional phase of the trial.
9516877|NCT03311399|Experimental|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
9792016|NCT01434186|Experimental|Arm 1: Saxagliptin +Metformin XR/IR|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg
9792017|NCT01434186|Placebo Comparator|Arm 2: Placebo +Metformin XR/IR|Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg
9792018|NCT01434290|Experimental|5 Fractions|36.25 Gy IMRT in 5 fractions over two and a half weeks
9792019|NCT01434290|Experimental|12 Fractions|51.6 Gy IMRT in 12 fractions over two and a half weeks
9792020|NCT01434342|Experimental|Arm I - Quitline|"Participants receive a letter from their physician advising them to quit smoking, and undergo a 15-30-minute smoking-cessation counseling session by a trained research staff.~The participants are educated and motivated about the importance of quitting smoking, and cancer-specific quitting issues. They will be called by Quitline in 2-3 days and receive a fact sheet about benefits of SC for cancer patients.~Participants receive 8 weeks of nicotine replacement patches and up to 5 proactive telephone calls over a 12-week period.~Participants also learn behavioral tips and coping skills."
9792021|NCT01434342|No Intervention|Arm II - Usual Care|"Participants receive a letter from their physician advising them to quit smoking, the importance of quitting smoking for cancer patients, and a copy of the National Cancer Institute's Clearing the Air smoking cessation booklet. Participants also receive standard of care from their oncology and other treatment providers which may or may not include nicotine replacement therapy."
9792022|NCT01434472|Experimental|Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)|Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).
9792023|NCT01434641|Other|low-dose stress MPI SPECT|Patients will receive a low-dose stress/high-dose rest protocol. Subject results are compared to archived patients undergoing a standard protocol./
9792024|NCT01434654||Non Neuro-HAART (low CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
9792025|NCT01434654||Neuro-HAART (high CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
9792026|NCT01434667|Active Comparator|APOE Genotype Non-Disclosure|Subjects will receive Alzheimer's disease risk disclosure. This assessment is based on age and MCI status alone.
9985751|NCT01658683|Experimental|Exercise Facilitator Intervention|The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
9985752|NCT01658683|No Intervention|Usual Care|Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention & Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
10206551|NCT04312386|Experimental|A new 4-week lunch menu|Optimized lunch menu with 30% lower greenhouse gas emissions, nutritionally adequate
10206552|NCT04310839||outpatient left laparoscopic colectomy|Left laparoscopic laparoscopic colectomy patient managed on an outpatient basis
10206553|NCT04309773|Experimental|Bezafibrate in addition to standard UDCA therapy|"Bezafibrate (400mg) in addition to standard 15-20 mg/kg/day UDCA therapy (experimental arm)"
10206554|NCT04309773|Placebo Comparator|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate in addition to standard 15-20 mg/kg/day UDCA therapy
10206555|NCT04306211|Active Comparator|Facial mask|facial mask for oxygen delivery
10206556|NCT04306211|Experimental|SuperNO2VA|SuperNO2VA is CPAP device to deliver oxygen with nasal mask rather than with facial mask
10206557|NCT04300998||older lymphoma patients|This is a prospective observational cohort where 18 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory high-grade B-cell lymphoma will undergo serial comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
10206558|NCT04300998||older patients with lymphoma and other lymphoid malignancies|This is a prospective observational cohort where 100 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory lymphoma and lymphoid malignancies will undergo comprehensive geriatric assessment, aging biomarker analysis, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
10206559|NCT04300998||older patients with myeloma and other plasma cell disorders|This is a prospective observational cohort where 60 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory plasma cell disorders will undergo
10213458|NCT03972527|Sham Comparator|Sham Device Treatment Cohort|The MuReva Phototherapy System (or sham control) is a Light Control Unit and a Mouthpiece Cable Assembly. The sham control Mouthpiece Cable Assembly will appear identical to the active Mouthpiece Cable Assembly, and will be used in the same manner as the active cohort. However, the sham control device will be configured where the mouthpiece will not emit any light at any time during the study. The same Light Control Unit will be used with sham and active Mouthpiece Cable Assemblies. Each patient will be assigned their own Mouthpiece Cable Assembly.
9792027|NCT01434667|Experimental|APOE Genotype Disclosure|Subjects will receive both APOE genotype and Alzheimer's disease risk disclosure. The assessment is based on age, MCI status, and genotype.
9792028|NCT01434680|Experimental|MenC-CRM LIQ (Liquid Formulation)|Subjects received 1 injection of MenC-CRM vaccine,liquid formulation.
9792029|NCT01434680|Experimental|MenC-CRM ROS (Rosia)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy
9792030|NCT01434680|Active Comparator|MenC-CRM EMV (Emeryville)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA
9792031|NCT01434693|Experimental|TSO 500|
9792032|NCT01434693|Experimental|TSO 2500|
9792033|NCT01434693|Experimental|TSO 7500|
9792034|NCT01434693|Placebo Comparator|Placebo|single dose
9792035|NCT01434810|Experimental|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
9792036|NCT01434810|Active Comparator|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
9792037|NCT01434823|Experimental|Intervention - nocturnal coverage|Nocturnal coverage from intensivists will be randomized by week. The weeks that have intensivists in the MICU during the 7pm to 7am shift are the intervention weeks.
9792038|NCT01434823|No Intervention|Control - standard of care|The weeks that are not randomized, the intervention arm will retain the current standard of care in the HUP MICU: attending intensivist availability by phone (home call).
9792039|NCT01435018|Experimental|ET+ART|Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
9792040|NCT01435018|Experimental|BV+ART|Bleomycin and Vincristine (BV) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
9792041|NCT01435018|Active Comparator|PTX+ART|Paclitaxel (PTX) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
9792042|NCT01435031|Other|CTO Treatment|"Subjects receiving at least 1 of the following for the treatment of CTO:~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~HT PROGRESS and/or HT PILOT guide wires in recanalization~MINI-TREK Coronary Dilatation Catheter in predilatation"
9792043|NCT01435122|Experimental|Axitinib Administration|"The investigational drug used in this study is axitinib, and is available as tablets.~You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to make up the dose but instead continue taking your next dose as planned.~Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit."
9792044|NCT01435174|Experimental|Ranolazine|End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
9792045|NCT01435265|Active Comparator|Normal Nurse Education|Subjects receive normal nurse education materials provided by their physician.
9792046|NCT01435265|Experimental|Additional Nurse Education-|Subjects will receive additional nurse education beyond the normal education materials provided by their physician
9792047|NCT01435304|Experimental|Hemobag®|Hemobag® method of returning residual CPB blood (study group)
9792048|NCT01435304|No Intervention|cell saver|Standard method of returning the residual pump volume to the patient as washed, centrifuged cells (control group)
9792049|NCT01435356|Active Comparator|recMage-A3 + AS15 ASCI|MAGE-A3 positive patients treated with recMAGE-A3 + AS15 ASCI
9792050|NCT01435356|Placebo Comparator|Placebo|MAGE-A3 positive patients treated with placebo
9792051|NCT01435382|Experimental|Group A|
10206560|NCT04299867||< 34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
10213459|NCT03943849|Experimental|Particulate bone graft plus autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside. The isolated dental pulp will be mixed with hydrated particulate bone graft, and the mixture will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
10213460|NCT03943849|Active Comparator|Particulate bone graft|Hydrated particulate bone graft will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
9792052|NCT01435382|Experimental|Group B|
9792053|NCT01435382|Experimental|Group C|
9792054|NCT01435382|Experimental|Group D|
9792055|NCT01435460|Experimental|Alrex|Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
9792056|NCT01435460|Active Comparator|Patanol|Ophthalmic solution containing olopatadine, 0.1%
9792057|NCT01435512|Experimental|Group|PTSD-Focused Cognitive Behavioral Therapy for Partner Violence
9792058|NCT01435512|No Intervention|Waitlist|Control group - no intervention
9792059|NCT01435577|Experimental|Tapentadol intravenous|Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
9792060|NCT01435577|Placebo Comparator|Matching placebo intravenous|Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
9792061|NCT01435603|Active Comparator|Standard Lifestyle Advice|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
9799630|NCT01664806|No Intervention|Coag mode 30 Watts Power|Elective laparoscopic cholecystectomy will be performed with 30 Watts power coag mode which is current standard of care.
9792062|NCT01435603|Experimental|Advice Plus Lifestyle Intervention|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.
10206561|NCT04299867||34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
10206562|NCT04294628|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10206563|NCT04294459|Experimental|Phase 1|Isatuximab dose level 1 or dose level minus 1 depending on predefined unacceptable toxicities observed.
9922025|NCT00834184|Experimental|A|nikkomycin Z 250 mg BID versus placebo BID x 14 days
9922026|NCT00834184|Experimental|B|nikkomycin Z 500 mg BID versus placebo BID x 14 days
10206564|NCT04294459|Experimental|Phase 2: Cohort A|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with living donor.
10206565|NCT04294459|Experimental|Phase 2: Cohort B|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with no living donor cleared for donation.
10206566|NCT04291885|Experimental|Avelumab|6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
10206567|NCT04291885|Placebo Comparator|Placebo|6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
10206568|NCT04289779|Experimental|Treatment Arm|Cabozantinib 40 mg orally daily x 9 weeks plus Atezolizumab 1200 mg every 3 weeks x 3 doses
10206569|NCT04288830|Experimental|TCMMMRT First|Participants will perform an instructor-led mind-body exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home practice will be logged. At the completion of the TCMMMRT Condition, participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week for a total of 8 weeks. Home exercise will be logged.
10206570|NCT04288830|Active Comparator|Aerobic Exercise First|Participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home exercise will be logged. At the completion of the aerobic exercise condition, participants will perform an instructor-led mind-body exercise regimen 1 day per week for a total of 8 weeks. Home practice will be logged.
10206571|NCT04286867|Experimental|Alcohol Moderation Group 1|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
10206572|NCT04286867|Active Comparator|Alcohol Moderation Group 2|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
10206573|NCT04285242||Participants with Cancer|Assessments and observations for up to 40 days with one overnight hospital stay.
10206574|NCT04285242||Healthy Volunteers - Group A|Assessments and observations for up to 2 days with one overnight hospital stay.
10206575|NCT04285242||Healthy Volunteers - Group B|Assessments and observations for up to 2 days.
10206576|NCT04284657|No Intervention|ARM I: Control group|Standard therapy alone
10206577|NCT04284657|Active Comparator|ARM II: PRAVASTATIN|Standard therapy and PRAVASTATIN 40 mg QD
10206578|NCT04284657|Active Comparator|ARM III: PRAV + Sodium Citrate|Standard therapy and PRAVASTATIN 40 mg QD and Sodium Citrate (up to 30 mL TID)
10206579|NCT04275843|Active Comparator|Traditional Diet|Unprocessed/minimally processed whole foods.
10206580|NCT04275843|Active Comparator|Modern Diet|Multi-ingredient, ultra-processed formulations of the traditional diet.
10206581|NCT04271748|Experimental|Time Restricted Feeding|Subjects will be required to fast for 16 consecutive hours daily for 4 weeks. The registered dietitian will provide subjects counseling on the intermittent fasting regimen.
10206582|NCT04263831|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be two dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 1.0x10^6 IU/m^2/day. Cohort 2: 1.25x10^6 IU/m^2/day."
10206583|NCT04254770|Active Comparator|ADA (American Dental Association) approved Manual Toothbrush|
10206584|NCT04254770|Experimental|Marketed Power Toothbrush|
10206585|NCT04254133||Case Ascertainment|Men with metastatic prostate cancer
10206586|NCT04254133||Family Recruitment|Male relatives of men with metastatic prostate cancer found to have a germline DNA Repair Gene mutation
10206587|NCT04249388||Decliners of Pulmonary Rehabilitation|No intervention, just observation
10206588|NCT04249219|Experimental|E-Cigarette Ads|All individuals in the study will see the same e-cigarette advertisements presented in a random order.
10206589|NCT04243499|Experimental|IV ICT01 Monotherapy|Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
10206590|NCT04243499|Experimental|IV ICT01 + IV Pembrolizumab|A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion
9792063|NCT01435616|Experimental|LY2605541|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks
9792064|NCT01435616|Active Comparator|Glargine|Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks
9792065|NCT01435655|Experimental|open|tafamidis
9792066|NCT01435759|Experimental|Antidepressant + SPD489 10 mg|
9792067|NCT01435759|Experimental|Antidepressant + SPD489 30 mg|
9792068|NCT01435759|Experimental|Antidepressant + SPD489 50 mg|
9792069|NCT01435759|Experimental|Antidepressant + SPD489 70 mg|
9792070|NCT01435759|Placebo Comparator|Antidepressant + Placebo|
9792071|NCT01435772|Experimental|BMN 701 20mg/kg|BMN 701 20mg/kg IV every other week
9792072|NCT01435772|Experimental|BMN 701 10mg/kg|BMN 701 10mg/kg IV every other week
9792073|NCT01435772|Experimental|BMN 701 5mg/kg|BMN 701 5mg/kg IV every other week
9792074|NCT01435798|Placebo Comparator|0% MTD Dex|0% MTD Dextromethorphan
9792075|NCT01435798|Experimental|25% MTD Dex|25% MTD Dextromethorphan
9792076|NCT01435798|Experimental|50% MTD Dex|50% MTD Dextromethorphan
9792077|NCT01435798|Experimental|100% MTD Dex|100% MTD Dextromethorphan
9792078|NCT01435824|Active Comparator|Water as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml water and orally administered in a fasting state.
9792079|NCT01435824|Experimental|Human milk as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml human milk and orally administered in a fasting state.
9792080|NCT01435928|Experimental|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
9792081|NCT01435928|Placebo Comparator|Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
9792082|NCT01436006||CT scan|patient with cancer
9792083|NCT01436045|Experimental|Insulin glulisine|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
9792084|NCT01436045|Placebo Comparator|Saline|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
9792085|NCT01436071|Experimental|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
9792086|NCT01436071|Placebo Comparator|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
9792087|NCT01436110|Experimental|Fluticasone furoate 50 mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
9792088|NCT01436110|Active Comparator|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ ACCUHALER
9792089|NCT01436110|Placebo Comparator|Placebo|Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER
9792090|NCT01436149|Experimental|Antidepressant + SPD489|
9792091|NCT01436149|Placebo Comparator|Antidepressant + Placebo|
9792092|NCT01436162|Experimental|Antidepressant + SPD489|
9792093|NCT01436162|Placebo Comparator|Antidepressant + Placebo|
9792094|NCT01436175|Experimental|SPD489 + Antidepressant|
9792095|NCT01436201|Experimental|Digoxin + Dulaglutide|"Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.~Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15."
9792096|NCT01436266|Active Comparator|Misoprostol|400 mcg buccally 2 hours prior to procedure
9792097|NCT01436266|Placebo Comparator|Placebo (Folic acid)|Two 1-mg tablets buccally 2 hours prior to procedure
9792098|NCT01436279|Experimental|Mifepristone + misoprostol|Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
9792099|NCT01436279|Active Comparator|Osmotic dilators|Placed 20-24 hours prior to procedure
9792100|NCT01436305|Active Comparator|Tac maintenance|"Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)"
9792101|NCT01436305|Experimental|Belatacept maintenance|"Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)"
9792102|NCT01436305|Experimental|Basiliximab induction/Short-term Tac|"Short term = 3 months~Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)"
9922027|NCT00834184|Experimental|C|nikkomycin Z 750 mg BID versus placebo BID x 14 days
9922028|NCT00834184|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
9840305|NCT01246869|Experimental|All Participants|All enrolled participants will complete three imaging sessions on separate days, beginning with a research MRI, then a PET scan with FDG and [15O]water, and a PET scan with FMISO. The two PET scans will be in any order on different days within one week of each other, and preferably on consecutive days. The research MRI will be within 14 days of the first PET scan.
9985753|NCT01627093||Observational (questionnaire, medical chart review)|Patients complete questionnaires over 30 minutes before treatment begins, at each visit during treatment, and again at all follow-up visits related to treatment. Patients also have their medical records reviewed.
9985754|NCT01622998|Active Comparator|Standard transdermal NRT group (UC)|10 week standard transdermal nicotine replacement therapy patch protocol
9985755|NCT01622998|Experimental|Titrated transdermal NRT group (EXP)|10 week titrated transdermal nicotine replacement therapy patch dose regimen based on smoking history with the option to increase dose, if withdrawal symptoms are unmanageable.
9985756|NCT01599741|Experimental|ClarityIQ|Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.
9985757|NCT01599741|Active Comparator|AlluraXper|Normal dose DSA with conventional X-ray imaging technology.
9985758|NCT01597583|Experimental|Use of MobileMedMinder|
9985759|NCT01597583|No Intervention|Usual care|
9985760|NCT01595620|Active Comparator|THC 0.01 mg/kg|
9985761|NCT01595620|Placebo Comparator|Placebo|
9985762|NCT01595620|Active Comparator|THC 0.03 mg/kg|
9985763|NCT01593852|Active Comparator|Regular X-ray dose settings|For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
9985764|NCT01593852|Experimental|Reduced X-ray dose settings|For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing
9985765|NCT01591629|Placebo Comparator|Placebo and Placebo|
9985766|NCT01591629|Experimental|Active Naloxone and Placebo|
9985767|NCT01591629|Placebo Comparator|Placebo and Active Delta-9-THC|
9985768|NCT01591629|Experimental|Active Naloxone and Active Delta-9-THC|
9985769|NCT01564537|Experimental|Ixazomib + Lenalidomide + Dexamethasone|Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to end of treatment (EOT) projected at 80 months.
9985770|NCT01564537|Placebo Comparator|Placebo + Lenalidomide + Dexamethasone|Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to EOT projected at 80 months.
9985771|NCT01538966|Active Comparator|High dose SRL + weekly Pegvisomant|"High dose of SRL monthly~Octreotide LAR 30mg~Lanreotide 120mg~Weekly Pegviosmant (40-120mg/week)"
9985772|NCT01538966|Active Comparator|Low dose SRL + daily Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Daily Pegviosmant (15-60mg/day)"
9840326|NCT01221415||Interscalene Ultrasound|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
9840327|NCT01221415||Interscalene Nerve Stimulator|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
9840328|NCT01221415||Popliteal Ultrasound|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
9840329|NCT01221415||Popliteal Nerve Stimulator|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
9840330|NCT01221415||Femoral Ultrasound|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
9840331|NCT01221415||Femoral Nerve Stimulator|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
9985773|NCT01538966|Active Comparator|Low dose SRL + weekly Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Weekly Pegviosmant (40-120mg/week)"
9985774|NCT01536275|No Intervention|Early parenteral nutrition|Parenteral nutrition supplements insufficient enteral nutrition from admission to ICU according to the current standard of care per center
9985775|NCT01536275|Experimental|Late parenteral nutrition|Parenteral nutrition will be withheld during the first 7 days of ICU stay
9985776|NCT01525069|Experimental|Arm A (HAI FUDR alone)|"14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
9840339|NCT01210365|Experimental|furosemide (40 mg) +amiloride (10 mg)|One group of patients will receive furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow the tablet in whole form on an empty stomach with some liquid.
9840340|NCT01210365|Active Comparator|Lasix ®|One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
9840346|NCT01198067|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO on days 1-28 or 1-21. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
9922029|NCT00834223|Other|Aquashunt|Open label, all subjects receive device.
9922030|NCT00834262||A|
9922031|NCT00834301|Experimental|Treatment Arm|
9840348|NCT01187199|Experimental|Carboplatin Group|Carboplatin: Starting dose AUC 2 by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
9840349|NCT01187199|Experimental|Paclitaxel Group|Paclitaxel: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
9840350|NCT01187199|Experimental|Sorafenib Group|Sorafenib: Starting dose 200 mg by mouth daily for a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
9840351|NCT01180361||Active SLE patients|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
9840352|NCT01180361||Psoriatic arthritis|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Diagnosed according to criteria described by McGonagle et al (McGonagle, D., Conaghan, P.G., and Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.)
9840353|NCT01180361||Normal controls|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Healthy volunteers. Not on corticosteroids.
9840354|NCT01180361||Active RA patients|Age 18-65, male and female, no methotrexate or statin therapy in prior 3 months. Not on biological therapies. satisfy at least 4 of the 7 revised criteria (1987) for the classification of RA
9840355|NCT01176474|Experimental|Nivolumab and Peptide Vaccine|"Cohorts 1 through 3: Participants will receive nivolumab with the peptide vaccine within 8 days after their first apheresis procedure.~Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody Nivolumab (BMS-936558). Level 1: 1 mg/kg Nivolumab + peptide vaccine. Level 2: 3 mg/kg Nivolumab + peptide vaccine. Level 3: 10 mg/kg Nivolumab + peptide vaccine."
9840356|NCT01176474|Experimental|Nivolumab and Ipilimumab|Cohorts 4 and 5. Participants will receive their first dose of nivolumab with ipilimumab within 28 days after screening blood draws. Both drugs will be given. Cohort 4: nivolumab 1mg/kg plus ipilimumab 3mg/kg. Cohort 5: nivolumab 3mg/kg plus ipilimumab 1mg/kg.
9985777|NCT01525069|Experimental|Arm B (HAI FUDR + gemcitabine)|"Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.~Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 & B3~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
9985778|NCT01525069|Experimental|Arm C (HAI FUDR + gemcitabine + oxaliplatin)|"Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.~Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
9985779|NCT01515306|Experimental|Part A: ramucirumab (IMC-1121B) and paclitaxel|Experimental: Part A: ramucirumab (IMC-1121B) and paclitaxel Cycle 1: paclitaxel administered on Day 1 of 2-week cycle. Cycle 2 and beyond : ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.
9985780|NCT01515306|Experimental|Part B: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.~Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4- week cycle.~*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A."
9985781|NCT01515098|Experimental|Blueberry Group|37 grams of dehydrated blueberries daily for 6 months
9840376|NCT01154920|Experimental|PCC Group + RT|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT)
9840377|NCT01154920|Experimental|PCC Group + RT + Chemotherapy|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT) + Chemotherapy
9840378|NCT01154920|Experimental|C-TPF Group + RT|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT)
9840379|NCT01154920|Experimental|C-TPF Group + RT + Chemotherapy|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT) + Chemotherapy
9985782|NCT01515098|Placebo Comparator|Placebo Group|37 grams of dextrose powder daily for 6 months
9985783|NCT01515098|No Intervention|Reference Group|No intervention
9985784|NCT01513187|Experimental|Pazopanib + interferon|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
9985785|NCT01464268|Active Comparator|Riboflavin drops every minute|Administration of riboflavin every 2 minutes for the duration of UV exposure.
9985786|NCT01464268|Active Comparator|Riboflavin drops every 2 minutes|Administration of riboflavin every 1 minute for the duration of UV exposure.
9985787|NCT01433965|Experimental|Phase I Dose Escalation|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
9985788|NCT01431157|Active Comparator|Nasal oxygen|Nocturnal nasal oxygen
9985789|NCT01431157|Placebo Comparator|No nasal oxygen|
9985790|NCT01423851|Experimental|Intervention: Drug: NS-018|In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.
9985791|NCT01397929|Experimental|Drug: BAL101553 at MTD|
9985792|NCT01397929|Experimental|Drug: BAL101553 at 50% of MTD|
9985793|NCT01385176|Experimental|Therapy|"Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.~The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.~Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
9985794|NCT01385176|Sham Comparator|Control|"Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
9985795|NCT01370447|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 50 milligrams (mg) at Day 1, 50 mg twice daily for 13 days, 100 mg on Day 15, and 100 mg twice daily until Day 28; either by mouth with a meal or via their G-tube with feeds. In the absence of clinical or laboratory indications of any safety concerns, participants will receive 100 mg EPI-743 three times daily until end of study.
9985796|NCT01366404||FFR|Patients who had FFR measurement
9985797|NCT01364480|Experimental|Brain-Machine Interface Users|All participants enrolled in the study will undergo Implantation of NeuroPort Arrays in the motor cortex. There is no control group.
9985798|NCT01360593|Other|Gem, Xeloda, SBRT|
9985799|NCT01354977|Experimental|Resveratrol|Each participant will receive a 28 days' supply of resveratrol capsules on day 0.
9985800|NCT01354431|Experimental|Arm 1: nivolumab - 0.3 mg/kg|
9985801|NCT01354431|Experimental|Arm 2: nivolumab - 2.0 mg/kg|
9985802|NCT01354431|Experimental|Arm 3: nivolumab - 10.0 mg/kg|
9985803|NCT01334606|Experimental|Nano: 4mm x 32G Pen Needle|Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
9985804|NCT01334606|Experimental|Short: 8mm x 31G Pen Needle|Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
9985805|NCT01317875|Experimental|Stratum -1|Participants with baseline Platelet counts of 75-99 x10^9/L
9985806|NCT01317875|Experimental|Stratum -2|Participants with baseline Platelet counts of 50-74 x10^9/L
9985807|NCT01233297|Active Comparator|Antibiotics|Azithromycin (10 mg/kg once a day for 3 days)
9985808|NCT01233297|Placebo Comparator|Placebo|Placebo mixture (once a day for 3 days)
9985809|NCT01226732|Experimental|Dose Level 1|Hsp90 Inhibitor AUY922: 22mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
9985810|NCT01226732|Experimental|Dose Level 2|Hsp90 Inhibitor AUY922: 28mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
9985811|NCT01226732|Experimental|Dose Level 3|Hsp90 Inhibitor AUY922: 40mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
9985812|NCT01226732|Experimental|Dose Level 4|Hsp90 Inhibitor AUY922: 55mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
9985813|NCT01226732|Experimental|Dose Level 5|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
9985814|NCT01226732|Experimental|Dose Level 6|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1250mg/m2 PO BID d 1-14 of 21-day cycles
10206591|NCT04243356|Experimental|Nurse Encounter Group|Nurses that are assigned to this group will be asked to take surveys before and immediately following the post-ICU clinic encounter with a patient that they had cared for in the ICU during a follow-up care visit with the former ICU - patient.
10206592|NCT04243356|Other|Nurse Control Group|Nurses assigned to this group will only complete surveys and will not see a former patient in a post-ICU visit.
9840430|NCT01123018||Older Adults|Persons over age 60 Participants will complete the Memtrax memory screening test
9840431|NCT01113476|Experimental|Nab-paclitaxel, Gemcitabine + Bevacizumab|Starting doses of Nab-paclitaxel 50 mg/m^2, Bevacizumab 5 mg/kg + fixed dose of Gemcitabine 1000 mg/m^2
9985815|NCT01216683|Experimental|Arm A then Arm D (Induction with Bendamustine + Rituximab; Continuation with Rituximab)|"Arm A (induction): Patients receive rituximab intravenously (IV) on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm D (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
9985816|NCT01216683|Experimental|Arm B then Arm E (Induction with Bendamustine + Rituximab + Bortezomib; Continuation with Rituximab)|"Arm B (induction): Patients receive rituximab IV on day 1; bortezomib IV on days 1, 4, 8, and 11; and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm E (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab as in arm D."
9985817|NCT01216683|Experimental|Arm C then Arm F (Induction with Bendamustine+Rituximab; Continuation with Lenalidomide + Rituximab)|"Arm C (induction): Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm F (continuation): Immediately after completing induction therapy, patients who have stable disease or better at time of post-induction restaging receive oral lenalidomide on days 1-21. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, these patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
9985818|NCT01194362||45 specimens collected from BAV patients|
9985819|NCT01194362||45 specimens collected from TAV patients|
9985820|NCT01194362||15 specimens collected from CABG pts|
9985821|NCT01186133||DESSIAN|consecutive patients receiving CYPHER stent
9985822|NCT01186133||K-XIENCE|consecutive patients receiving Xience stent
9985823|NCT01186133||GENOUS|consecutive patients receiving GENOUS stent
9985824|NCT01186133||ELEMENT|consecutive patients receiving PROMUS-ELEMENT stent
9985825|NCT01186133||PRIME|consecutive patients receiving XIENCE-PRIME stent
9985826|NCT01186133||NOBORI|consecutive patients receiving NOBORI stent
9985827|NCT01186133||INTEGRITY|consecutive patients receiving RESOLUTE-INTEGRITY stent
9985828|NCT01186133||XPEDITION|consecutive patients receiving XIENCE-XPEDITION stent
9985829|NCT01186133||BIOMATRIX|consecutive patients receiving BIOMATRIX stent
9985830|NCT01186133||CILOTAX|consecutive patients receiving CILOTAX stent
9985831|NCT01186133||DEB|consecutive patients receiving Drug eluting balloon
9985832|NCT01186133||DESYNE|consecutive patients receiving DESYNE stent
9516878|NCT03311399|Experimental|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
9985833|NCT01186133||PREMIER|consecutive patients receiving PROMUS-PREMIER stent
9840457|NCT01052168|Active Comparator|Speed Group|The Speed Group, (n=20) will train in laparoscopic suturing on the validated FLS suturing model until the expert level of speed (i.e. task duration < 70 seconds) has been achieved on two consecutive attempts.
9840458|NCT01052168|Experimental|Motion Group|The Motion Group, (n=20) will train in laparoscopic suturing until expert levels of motion (pathlength 6700 and smoothness 560) have been achieved.
9840459|NCT01052168|Experimental|Speed and Motion Group|The Speed and Motion Group (n=20) will train in laparoscopic suturing until expert levels of speed AND motion have been achieved.
9985834|NCT01186133||ORSIRO|consecutive patients receiving ORSIRO stent
9985835|NCT01186133||ONYX|consecutive patients receiving ONYX stent
9985836|NCT01186133||BVS|consecutive patients receiving Bioresorbable Vascular Scaffold
9985837|NCT01186133||BVS AMI|consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
9985838|NCT01186133||Ultimaster|consecutive patients receiving Ultimaster stent
9985839|NCT01186133||Synergy|consecutive patients receiving Synergy stent
9985840|NCT01186133||Biofreedom|consecutive patients receiving Biofreedom stent
9985841|NCT01186133||Firehawk|consecutive patients receiving Firehawk stent
9985842|NCT01186133||DESyne X2|consecutive patients receiving DESyne X2 stent
9922032|NCT00834314|Experimental|Vacuum-pack|see Interventions
9922033|NCT00834314|Active Comparator|Abdominal dressing|see Interventions
9792103|NCT01436357|Experimental|Arm A (Stage I and II)|Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
9792104|NCT01436357|Placebo Comparator|Arm B (Stage I and II)|Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
9792105|NCT01436370|Experimental|Group 1 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
9792106|NCT01436370|Experimental|Group 2|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
9792107|NCT01436370|Experimental|Group 2 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
9792108|NCT01436370|Experimental|Group 1|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
9792109|NCT01436435|Experimental|Jetstream Atherectomy System|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention including Atherectomy utilizing the Jetstream Atherectomy System with or without adjunctive therapy.
9792110|NCT01436500|Experimental|5 mg ifetroban, Type 1|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
9792111|NCT01436500|Placebo Comparator|Placebo, Type 1|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.
9792112|NCT01436500|Experimental|5 mg ifetroban, Type 2|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
9792113|NCT01436500|Experimental|15 mg ifetroban, Type 1|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
9792114|NCT01436500|Experimental|15 mg ifetroban, Type 2|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
9792115|NCT01436500|Experimental|50 mg ifetroban, Type 1|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
9792116|NCT01436500|Experimental|50 mg ifetroban, Type 2|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
9792117|NCT01436500|Experimental|150 mg ifetroban, Type 2|60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
9792118|NCT01436500|Placebo Comparator|Placebo, Type 2|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.
9792119|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
9792120|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
9799631|NCT01664806|Experimental|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform Elective laparoscopic cholecystectomy. which is the experimental arm of the study's mode.
9799632|NCT01664858|Active Comparator|3T CMR-guided management|Patient to be managed according to the results of 3T CMR imaging
9799633|NCT01664858|Active Comparator|SPECT-guided management|Patients to be managed according to the results of SPECT
9799634|NCT01664858|Active Comparator|NICE-guidelines based management|"Patients will be receive NICE-guidelines based management and will receive the imaging strategy specified by NICE according to their pre-test likelihood of having CHD.~10-29% - CT calcium score +/- CT coronary angiography; 30-60% - SPECT; 61-90% - X-Ray coronary angiography"
9799635|NCT01664897|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9799636|NCT01664923|Experimental|Enzalutamide|Enzalutamide 160 mg/day orally
9799637|NCT01664923|Active Comparator|Bicalutamide|50 mg/day orally
9799638|NCT01664949|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
9799639|NCT01664949|Active Comparator|OPTIVE™|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
9799640|NCT01664975|Experimental|GDPT regimen|GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
9799641|NCT01664975|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
9799642|NCT01665040|Experimental|Neurostimulation for chronic pain|Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
9799643|NCT01665053|Active Comparator|Promus Element Plus|PROMUS Element Plus is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
9922034|NCT00834327|Experimental|1|aplindore 0.05 mg MR total daily dose
9792121|NCT01436643|Experimental|Fluoxetine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
9792122|NCT01436643|Experimental|Venlafaxine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
9792123|NCT01436643|Experimental|Citalopram and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg
9792124|NCT01436799|Experimental|Desflurane|anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane
9792125|NCT01436799|Active Comparator|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model
9792126|NCT01437098|Experimental|MDT-2111 CoreValve TAVI|Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.
9792127|NCT01437124||Ceramic on metal THA|Those who have received a ceramic on metal total hip replacement
9792128|NCT01437267|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
9792129|NCT01437267|Active Comparator|PNC13, Older infants|Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
9792130|NCT01437267|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
9792131|NCT01437267|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
9792132|NCT01437267|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
9792133|NCT01437267|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
9792134|NCT01437319|Active Comparator|lotrafilcon A, comfilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
9792135|NCT01437319|Active Comparator|lotrafilcon A, balafilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
9792136|NCT01437397|Experimental|1|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg
9792137|NCT01437397|Experimental|2|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg
9792138|NCT01437397|Active Comparator|3|Aclidinium monotherapy 400 μg
9792139|NCT01437397|Active Comparator|4|Formoterol monotherapy 12 μg
9792140|NCT01437397|Placebo Comparator|5|Placebo
9792141|NCT01437449|Experimental|Cisplatin + Docetaxel + Cetuximab|Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
9792142|NCT01437488|Experimental|Cabazitaxel|Cabazitaxel following platinum-based chemotherapy
9792143|NCT01437501|Experimental|Broccoli Sprout Extract Beverage|
9792144|NCT01437501|Placebo Comparator|Placebo beverage|
9792145|NCT01437540|Experimental|1|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
9792146|NCT01437540|Active Comparator|2|Inhaled formoterol fumarate 12 μg, twice per day
9792147|NCT01437605|Active Comparator|A: recMAGE-A3 + AS15|ASCI injections without Poly IC:LC
9792148|NCT01437605|Active Comparator|B: recMAGE-A3 + AS15 + Poly IC:LC|ASCI injections with Poly IC:LC
9792149|NCT01437852|Experimental|StrataGraft skin tissue|"All subjects enrolled in this study will receive StrataGraft tissue. Will randomly assign treatment regimens to the two comparable study treatment sites pre-identified as A or B. A sealed randomization envelope will be supplied to the clinical site along with the shipment of clinical tissue. Neither the surgeon nor scrubbed operating room personnel will be informed of the randomization until completion of surgical excision. The treatment sites A or B will be randomized to receive either StrataGraft skin tissue or autograft using a 1:1 ratio.~Two comparable areas of healthy skin will be pre-identified by the clinical staff as donor sites A or B. The randomization assignment will be identical as that above for the treatment sites. For example, if treatment site A is randomized to receive an autograft, donor site A will be designated the donor site for autografting"
9792150|NCT01437878|Experimental|iloprost|single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
9792151|NCT01437878|Placebo Comparator|placebo|matching placebo using the power disc-6 with I-neb AAD system
9792152|NCT01437943|Active Comparator|Aliskiren|Aliskiren 150 mg daily for 180 days
9792153|NCT01437943|Placebo Comparator|Placebo|Placebo identical to Aliskiren drug daily for 180 days
9792154|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 250/50 ug|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
9792155|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 100/50 ug|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
9792156|NCT01437995|Active Comparator|Fluticasone Diskus alone 250 ug|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
9792157|NCT01438008|Experimental|Sucrose 24% po|"24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution"
9792158|NCT01438008|Placebo Comparator|Placebo po|"The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings"
9792159|NCT01438060|Experimental|Aripiprazole (BMS-337039)|Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140)
9792160|NCT01438060|Placebo Comparator|Placebo|Double blind Acute Phase (Week 1 to Week 10)
9792161|NCT01438151|Experimental|Remicade|Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
9516879|NCT03311399|No Intervention|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
9792162|NCT01438177|Experimental|Velcade+Cyclophosphamide+Chloroquine|"VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.~Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.~Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.~Each cycle is 42 days in length."
9792163|NCT01438229|Experimental|renal artery ablation|Catheter-based RF ablation in renal artery
9792164|NCT01438294|Active Comparator|Aerobic exercise|The aerobic training will be done on the treadmill with heart monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.
9792165|NCT01438294|Experimental|Video game|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( reflex ridge- Adventure).
9792166|NCT01438307|Experimental|Schedule A|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
9792167|NCT01438307|Experimental|Schedule B|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
9792168|NCT01438411|Other|Cholic Acid|Active drug
9792169|NCT01438424|Experimental|Entecavir, 1.0 mg, with or without lamivudine|
9792170|NCT01438476|Experimental|IV Pain Management|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
9792171|NCT01438476|Experimental|Epidural Pain Management|Thoracic epidurals placed preoperatively in either holding area or in operating room. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
9792172|NCT01438489|Experimental|Anifrolumab (MEDI-546) 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
9792173|NCT01438489|Experimental|Anifrolumab (MEDI-546) 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
9792174|NCT01438489|Placebo Comparator|Matching Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
9792175|NCT01438541|Experimental|Window|WindowTM is a protective layer that may reduce the shear and friction on the skin and may help to prevent skin breakdown. Window TM provides instant tack adhesion that minimizes the requirement of extra pressure in order to fixate well. The product does not leave residues and the adhesion level does not increase over time.
9792176|NCT01438710|Experimental|LCP-Tacro|LCP Tacro tables for once daily oral administration
9792177|NCT01438710|Experimental|Prograf|Tacrolimus capsules for twice daily oral administration
9792178|NCT01438814|Experimental|linagliptin + metformin|patients to receive linagliptin +metformin QD
9792179|NCT01438814|Active Comparator|metformin|patients to receive metformin BID
9792180|NCT01438840|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
9516880|NCT03311386||Patients in AIS receiving actilyse|the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
9792181|NCT01438840|Placebo Comparator|Placebo (Core Study)|Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.
9799644|NCT01665053|Experimental|SYNERGY|SYNERGY is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
9799645|NCT01665092|Placebo Comparator|Control|Normal saline
9799646|NCT01665092|Experimental|Carnitine Low|Levo-Carnitine 6g
9985843|NCT01186133||Sierra|consecutive patients receiving Sierra stent
9985844|NCT01186133||Tansei|consecutive patients receiving Tansei stent
9985845|NCT01162109|Placebo Comparator|Severe sepsis without zinc|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
9985846|NCT01162109|Experimental|Zinc in severe sepsis|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
9985847|NCT01162109|Experimental|Healthy Volunteers receiving zinc|Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours. PK in sepsis patients and healthy volunteers will be compared.
9985848|NCT01152541|Active Comparator|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
9985849|NCT01152541|Active Comparator|Riboflavin/dextran|Administration of Riboflavin/dextran every 2 minutes for the duration of UV exposure.
9985850|NCT01112072|Active Comparator|Intacs combined with CXL|Intacs placement followed by collagen crosslinking with UV light and riboflavin
9985851|NCT01112072|Active Comparator|Intacs followed by CXL|Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later
9985852|NCT01107717|Experimental|Triple Therapy|initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
9840482|NCT01015222|Experimental|Dasatinib, Bevacizumab + Paclitaxel|"Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15~Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation."
9985853|NCT01107717|Active Comparator|conventional therapy|sequential addition of metformin, glyburide and basal insulin
9985854|NCT01104350|Experimental|Radiotherapy and Concurrent Gemcitabine Chemotherapy|This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.
9985855|NCT01085097|Placebo Comparator|Placebo|Participants will receive 2 capsules of placebo matching to laquinimod orally once daily (QD) for 24 weeks, MMF 500 mg tablet orally twice daily (BID) for the first week then 1 gram (g) BID from Week 2 to Week 28, and MP 500 mg/day intravenously (IV) from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
9985856|NCT01085097|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 mg and 1 capsule of placebo matching to laquinimod orally QD for 24 weeks, MMF 500 mg tablet orally BID for the first week then 1 g BID from Week 2 to Week 28, and MP 500 mg/day IV from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
9985857|NCT01085097|Experimental|Laquinimod 1 mg|Participants will receive 2 capsules of laquinimod 0.5 mg orally QD for 24 weeks, MMF 500 mg tablet orally BID for the first week then 1 g BID from Week 2 to Week 28, and MP 500 mg/day IV from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
9985858|NCT01064063|Active Comparator|AGC knee|Patients were randomised to receive an AGC Cruciate Retaining cement knee. This is the control group in the study; the AGC is the gold standard of Biomets' knee products.
9985859|NCT01064063|Experimental|Vanguard CR|Patients were randomised to receive a Vanguard Cruciate Retaining Knee from the Vanguard system which encompasses concepts used in the AGC family of knees. The Vanguard is specifically designed to give greater knees stability through use of more anatomic patello-femoral kinematics.
9985860|NCT01025089|Experimental|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
9985861|NCT01003496|Active Comparator|Treatment as Usual (TAU)|
9985862|NCT01003496|Experimental|TAU + Long-Term Recovery Management (LTRM)|
9792182|NCT01438840|Experimental|Avatrombopag (Open-Label Extension)|Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.
9792183|NCT01438957|Placebo Comparator|Placebo|Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
9792184|NCT01438957|Experimental|Dexmedetomidine 0.067 mcg/kg|Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
9792185|NCT01438957|Experimental|Dexmedetomidine 0.25 mcg/kg|Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
9792186|NCT01438957|Experimental|Dexmedetomidine 0.5 mcg/kg|Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
9792187|NCT01438957|Experimental|Dexmedetomidine 1.0 mcg/kg|Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
9792188|NCT01438996|Experimental|NVGH Vi-CRM/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study
9792189|NCT01438996|Experimental|Vi-PS/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study
9792190|NCT01438996|Experimental|NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults
9792191|NCT01439009|Experimental|Tolvaptan|15 mg
9792192|NCT01439009|Placebo Comparator|Placebo|Placebo
9792193|NCT01439035|Experimental|MGH OFDI imaging|OFDI imaging
9792194|NCT01439074|Active Comparator|Mepilex Ag|Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
9792195|NCT01439074|Active Comparator|Silver Sulphadiazine Ag cream|SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.
9792196|NCT01439087|Experimental|OFDI imaging|OFDI imaging
9792197|NCT01439126|Active Comparator|Subjects on KAPVAY™ (clonidine hydrochloride)|Subjects in the KAPVAY™ arm receive their optimal dose of KAPVAY™ for the 26-week randomized-withdrawal period (Period 3)
9792198|NCT01439126|Placebo Comparator|Subjects on Placebo|Subjects in placebo arm tapered off optimal dose of KAPVAY™ (ie, Period 2 Maintenance Dose) at weekly intervals in decrements of 0.1 mg/day until reaching dose of 0 mg/day; subjects then receive only placebo for the rest of the study
9985863|NCT00982982|Active Comparator|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes"
9516881|NCT03311360||drug-coated balloon|patients with vertebral artery origin stenosis treated with drug-coated balloons
9792201|NCT01439204|Active Comparator|Abatacept (BMS-188667) manufactured at Lonza, NH facility|
9792202|NCT01439204|Experimental|Abatacept (BMS-188667) manufactured at Devens, MA facility|
9792203|NCT01439282|Experimental|Eribulin + Capecitabine|
9792204|NCT01439360|Experimental|D-QIV|Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
9792205|NCT01439360|Active Comparator|Control|In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).
9792206|NCT01439373|Experimental|GSK2336805|Study Part 1
9792207|NCT01439373|Placebo Comparator|Placebo|Study Part 1
9792208|NCT01439373|Experimental|GSK2336805 + pegylated interferon alfa-2a + ribavrin|Study Part 2
9792209|NCT01439373|Active Comparator|Placebo + pegylated interferon alfa-2a + ribavirin|Study Part 2
9792210|NCT01439555|Experimental|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
9792211|NCT01439568|Experimental|LY2510924 + Carboplatin + Etoposide|"LY2510924: 20 milligram (mg) administered once daily as a subcutaneous(SC) injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
9792212|NCT01439568|Active Comparator|Carboplatin + Etoposide|"Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
9792213|NCT01439581|Experimental|Patients on mapping systems|
9792214|NCT01439581|Active Comparator|Patients not on mapping systems|
9792215|NCT01439594|Experimental|MGH OFDI Imaging|OFDI imaging
9792216|NCT01439620|Experimental|OFDI imaging|Subject will swallow an OFDI capsule and images will be obtained using MGH Optical Frequency Domain Imaging (OFDI) imaging system.
9792217|NCT01439633|Experimental|MGH OFDI marking and imaging|OFDI imaging
9792218|NCT01439672|Experimental|Insulin Sensitivity|Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity.
9792219|NCT01439711|Experimental|letrozole + MRI + surgery|Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.
9792220|NCT01439724|Placebo Comparator|Placebo|Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
9792221|NCT01439724|Experimental|Low Level Laser Therapy|The investigators used a Low Level Laser Therapy, diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
9792222|NCT01439815|Placebo Comparator|Placebo Nasal Spray|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
9792223|NCT01439815|Active Comparator|Fluticasone Propionate|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
9792224|NCT01439854|Placebo Comparator|Placebo|this arm is control
9792225|NCT01439854|Experimental|Dapagliflozin|Interventional arm
9792226|NCT01439867|Experimental|Cinacalcet|"Prior to the partial clinical hold, the starting dose was 0.25 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 4.2 mg/kg) based on plasma intact parathyroid hormone (iPTH), corrected serum calcium levels obtained monthly, and adverse signs and symptoms.~After the partial clinical hold the starting dose was 0.20 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 2.5 or 60 mg, whichever was lower) based on plasma iPTH, corrected serum calcium levels obtained monthly, weekly monitoring of ionized calcium levels, and adverse signs and symptoms.~All participants also received standard of care, which may have included vitamin D sterols."
9792227|NCT01439880|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product [all-IP] period.
9792228|NCT01439880|Experimental|Evolocumab + SOC|Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
9792229|NCT01439945|Experimental|Arm I|Patients receive a low-dose of magnesium oxide orally (PO) daily (QD).
9792230|NCT01439945|Experimental|Arm II|Patients receive a high-dose of magnesium oxide PO QD.
9792231|NCT01439945|Placebo Comparator|Arm III|Patients receive a low-dose of placebo PO QD.
9792232|NCT01439945|Placebo Comparator|Arm IV|Patients receive a high-dose of placebo PO QD.
9792233|NCT01439971|Experimental|1|
9792234|NCT01439971|Experimental|2|
9792235|NCT01439971|Experimental|3|
9792236|NCT01439971|Experimental|4|
9792237|NCT01439971|Experimental|5|
9792238|NCT01440049||Eplerenone|
9792239|NCT01440101|Experimental|Double-blind Natalizumab 300 mg|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
9792240|NCT01440101|Placebo Comparator|Double-blind Placebo|IV infusions of placebo over 60 minutes every 4 weeks for 20 weeks
9792241|NCT01440101|Experimental|Open-label Natalizumab|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
9985864|NCT00982982|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
9985865|NCT00962988|Experimental|Cost-Free Group|
9985866|NCT00962988|Other|Prescription Only Group|
9840495|NCT00929214|Experimental|Standard Therapy + Local Therapy|Systemic Standard Therapy (chemotherapy and/or endocrine therapy) + Local Therapy (surgery and/or radiation)
9985867|NCT00949312||Stage II unresected Colon Cancer|
9985868|NCT00937586||Newly diagnosed patients|Patients with newly diagnosed prostate cancer.
9985869|NCT00920621|Experimental|Vitamin D treatment|vitamin D treatment plus prenatal multivitamins
9985870|NCT00920621|Placebo Comparator|placebo|placebo plus prenatal multivitamins
9985871|NCT00916747|Experimental|Treatment arm|All patients will receive zoledronic acid, pravastatin and lonafarnib
9985872|NCT00883597||Controls|Patients with ileostomy.
9985873|NCT00883597||Standard Sepsis Treatment|Patients with ileostomy and sepsis
9985874|NCT00856947|Active Comparator|Vitamin D|Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
9985875|NCT00856947|Placebo Comparator|Placebo|Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
9985876|NCT00828308|Experimental|Ixabepilone|"Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.~Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study***"
9985877|NCT00824252||Spousal Support|Questionnaire for Head and Neck Cancer Patients + Spouses
9985878|NCT00768820|Experimental|1|
9799647|NCT01665092|Experimental|Carnitine Medium|Levo-Carnitine 12 g
9799648|NCT01665092|Experimental|Carnitine High|Levo-Carnitine 18 g
9799649|NCT01665157|Experimental|low-residue diet package (Enimaclin®)|Low-residue diet package with normal amount 2L PEG-ELS
9799650|NCT01665157|Placebo Comparator|Self-controlled diet|Self-controlled diet with normal amount of 2L PEG-ELS
9799651|NCT01665157|Experimental|Low-residue diet (Enimaclin®) package|Low-residue diet package with low volume 1.5L PEG-ELS
9799652|NCT01665170|Placebo Comparator|Placebo|Placebo arm
9799653|NCT01665170|Active Comparator|Verum|Verum arm - Pascoflair 425mg
9799654|NCT01665430|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous infusion every 4 weeks up to 104 weeks.
9799655|NCT01665508|Experimental|Nebivolol|Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
9799656|NCT01665599|Experimental|Testosterone gel (FE 999303)|"Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations.~Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion."
9799657|NCT01665768|Experimental|Everolimus and Rituximab|Everolimus daily for one year and IV rituximab four times during that year.
9799658|NCT01665807|Experimental|Nurse-administered IM|Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
9799659|NCT01665807|Experimental|Self-administered intradermal|Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
9799660|NCT01665807|Active Comparator|Repeat self-administration intradermal|Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
9799661|NCT01665872|Experimental|Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention co-facilitated by mental health clinician and a Community Mental Health Ambassador (peer).
9799662|NCT01665872|Active Comparator|Standard of care - Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention administered by mental health clinician.
9799663|NCT01665911|Other|Arm 1|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
9799664|NCT01665911|Other|Arm 2|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
9799665|NCT01665911|Other|Arm 3|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
9799666|NCT01665911|Other|Arm 4|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
9799667|NCT01665911|Active Comparator|Arm 5|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
9799668|NCT01665950|Experimental|Simvastatin-Simvastatin|Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
9799669|NCT01665950|Experimental|Placebo->Simvastatin|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
9799670|NCT01665950|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
9799671|NCT01666002|Experimental|Treatment|"st visit: Patient will come into clinic for initial laser treatment with Nd:YAG 1064 nm laser fitted with special handpiece.~nd visit: 2 weeks after initial laser treatment, patient will be seen for second treatment with Nd:YAG 1064 nm laser fitted with special handpiece."
9799672|NCT01666002|No Intervention|Placebo|"st visit: For the control group, no treatment will be given.~nd visit: 2 weeks after initial visit, patient will be seen for second visit"
9792242|NCT01440283|Experimental|Treatment|"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen will be eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients will begin the planning process for abdominal irradiation.~Interventions: Intensity Modulated Radiation Therapy (IMRT)"
9792243|NCT01440322|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lenses with color worn in both eyes on a daily wear, monthly replacement basis for 3 months
9792244|NCT01440322|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear, monthly replacement basis for 3 months
9792245|NCT01440374|Experimental|Part 1, Open Label|100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
9792246|NCT01440374|Experimental|Part 2, eltrombopag arm|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
9792247|NCT01440374|Experimental|Part 2, placebo arm|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
9792248|NCT01440374|Experimental|part 3 extension|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
9792249|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Adult Group|Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
9792250|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Elderly Group|Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
9792251|NCT01440543|Experimental|Water/CO2|water immersion during colonoscope insertion and CO2 insufflation during colonoscope withdrawal
9792252|NCT01440543|Experimental|Water/Air|Water immersion during colonoscope insertion and air insufflation during colonoscope withdrawal
9792253|NCT01440543|Experimental|CO2/CO2|CO2 insufflation during both colonoscope insertion and withdrawal
9792254|NCT01440543|No Intervention|Air/Air|room air insufflation during both colonoscope insertion and withdrawal
9792255|NCT01440569|Experimental|COBI-boosted DRV|Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
9792256|NCT01440634|Other|supervised exercise|It consists of six months of supervised, intermittent track walking to near maximal leg pain or discomfort three days per week. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month.
9792257|NCT01440634|No Intervention|Standard of Care|Patients will be observed during the time of the study, no intervention will be applied. Patients are allowed to do their regular activity at home.
9792258|NCT01440647|Experimental|NIPPV|Extubation to NIPPV (nasal intermittent positive pressure ventilation)
9792259|NCT01440647|Active Comparator|CPAP|After extubation this arm was placed on CPAP (continuous positive airway pressure) and was not offered NIPPV in the first month on life
9792260|NCT01440764|Experimental|F(40), then Saline, then IV.F|"On Test Day 1, participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
9792261|NCT01440764|Experimental|IV.F, then F(40), then Saline|"On Test Day 1, participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes."
9792262|NCT01440764|Experimental|Saline, then F(40), then IV.F|"On Test Day 1, participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 3), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
9792263|NCT01440764|Experimental|F(80), then Saline, then Saline|"On Test Day 1, participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
9998190|NCT01515904||STOMP|12-17 yrs. Patients in the program have severe complex obesity defined as children and youth who have a BMI >95th %ile for their age and gender in addition to one of the following: at least one significant obesity-related co-morbidity requiring specialty care (e.g. type 2 diabetes), other co-existing chronic illness impacted by obesity (e.g. CNS tumor, post-organ transplant), or a BMI ≥99th percentile for their age and gender
9792264|NCT01440764|Experimental|Saline, then F(80), then Saline|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
9792265|NCT01440764|Experimental|Saline, then Saline, then F(80)|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes."
9792266|NCT01440803|Active Comparator|Teriparatide (Forteo)|Daily injection of Teriparatide for treatment of idiopathic osteoporosis
9792267|NCT01440803|Placebo Comparator|Placebo saline injection|Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.
9792268|NCT01440816|Experimental|Cohort A: Tavo-EP|Patients in Cohort A received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, after which they proceeded to definitive treatment (surgery and/or radiation therapy) which started between 2 and 4 weeks after the first injection.
9792269|NCT01440816|Experimental|Cohort B: Tavo-EP|Patients in Cohort B received up to 4 cycles (3 daily treatments on Days 1, 5, and 8, per cycle) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, with 12 planned weeks between each cycle, lasting up to 12 months.
9792270|NCT01440881|Active Comparator|Nesiritide|infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours
9792271|NCT01440881|Placebo Comparator|Placebo|infuses at 0.01MCG/KG/min for 48 hours
9792272|NCT01440920|Experimental|Cohort 1|0.3 mg
9792273|NCT01440920|Experimental|Cohort 2|1 mg
9792274|NCT01440920|Experimental|Cohort 3|3 mg
9792275|NCT01440946|Experimental|rFIXFc Prophylaxis|"At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated."
9792276|NCT01440959|Experimental|TKI258|
9792277|NCT01440972|Active Comparator|Exercise without PBFR|
9792278|NCT01440972|Experimental|exercise with PBFR|
9792279|NCT01441037|Experimental|Danazol|Single arm in which danazol is administered orally at 800 mg daily for 2 years.
9792280|NCT01441063|Experimental|Tocilizumab|Tocilizumab 8 mg/kg on Day 1 of a 14 day cycle a maximum of 6 cycles. If indicated, zidovudine (AZT) and valganciclovir (VGC) will be administered concurrently with tocilizumab, with day 1 of the cycle being the day tocilizumab is administered.
9792281|NCT01441076|Experimental|Anakinra|Treatment with Anakinra 100mg subcutaneous daily with option to escalate dose up to 300mg subcutaneous daily
9792282|NCT01441102|Experimental|Dextromethorphan hydrobromide|
9792283|NCT01441180|Experimental|Phase 1|Participants (N =10) will receive GS-7977 QD in combination with RBV for a total of 24 weeks. The study team will perform an interim evaluation of data and safety at the end of 12 weeks of treatment.
9792284|NCT01441180|Active Comparator|Phase 2 Arm A|(N =25) 24 weeks of GS-7977 QD in combination with weight based RBV (1000 mg for participants weighing <75 kg and 1200 mg for participants weighing ≥75kg)
9792285|NCT01441180|Active Comparator|Phase 2 Arm B|(N = 25): 24 weeks of GS-7977 QD with low dose RBV (600mg).
9792286|NCT01441245|Experimental|Continuous furosemide infusion|The group that received the continuous infusion of furosemide (cIV), consisted of 30 patients;
9792287|NCT01441245|Experimental|Intermittent furosemide infusion|The group that received the bolus infusion of furosemide (iIV), consisted of 27 patients
9792288|NCT01441401||Gabapentin|Peadiatric subjects taking Gabapen Tablets and syrup.
9792289|NCT01441414|Experimental|ARM A|PF-04856884 in combination with AG-013736
9792290|NCT01441414|Active Comparator|ARM B|AG-013736 alone
9792291|NCT01441440|Experimental|venlafaxine ER 75 mg/day (fixed dose)|
9792292|NCT01441440|Experimental|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|
9792293|NCT01441440|Placebo Comparator|Placebo|
9792294|NCT01441466||Group without isolation|Patients in this arm are nursed together (in the same room) independent of viral agent.
9922035|NCT00834327|Experimental|2|aplindore 0.1 mg MR total daily dose
9985879|NCT00708994|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
9985880|NCT00708994|Placebo Comparator|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
9985881|NCT00695981|Active Comparator|Rotator cuff repair|Surgery following a 3 months period of active non-operative treatment
9985882|NCT00695981|Active Comparator|Conservative treatment|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
9985883|NCT00691223||Experimental|Individuals with Goltz syndrome and their first degree relatives.
9985884|NCT00682318|Experimental|Fish oil|Omega-3 polyunsaturated fatty acids (n-3 PUFA)
9985885|NCT00682318|Active Comparator|Safflower Oil|Omega-6 polyunsaturated fatty acids (n-6 PUFA)
9985886|NCT00680901|Experimental|CapeOx plus Lapatinib|CapeOx plus Lapatinib
9840518|NCT00897117||Resectable non-small cell lung cancer|Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
9985887|NCT00680901|Placebo Comparator|CapeOx plus Placebo|CapeOx plus Placebo
9985888|NCT00678730|Active Comparator|1|"Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or joint.~Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or joint.~Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or joint."
9840521|NCT00888680|Experimental|BGC20-1531 200 mg|
9840522|NCT00888680|Experimental|BGC20-1531 400mg|
9840523|NCT00888680|Placebo Comparator|Lactose|
9985889|NCT00678730|Placebo Comparator|2|small amount of ethanol, (quarter teaspoon), with no THC
9985890|NCT00667251|Active Comparator|Lapatinib|Plus taxane based chemotherapy
9985891|NCT00667251|Active Comparator|Trastuzumab|Plus taxane based chemotherapy.
9985892|NCT00654264|Other|1|Patients will have water immersion on first day and sitting in a tub without water on the second day.
9985893|NCT00654264|Other|2|Patients will sit in a tub without water on the first day and have water immersion on the second day.
9985894|NCT00637013|Active Comparator|Acromioplasty|Acromioplasty + physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
9985895|NCT00637013|Active Comparator|Physiotherapy|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
9985896|NCT00602459|Active Comparator|Arm A (rituximab, fludarabine phosphate)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: Patients receive rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5.
9985897|NCT00602459|Experimental|Arm B (rituximab, fludarabine phosphate, lenalidomide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
9985898|NCT00602459|Experimental|Arm C (rituximab, fludarabine phosphate, cyclophosphamide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 4 hours on days 1 (50mg/m^2) and 3 (325 mg/m^2) of course 1 and on day 1 (500 mg/m^2) of all subsequent courses. Patients then receive fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) followed by cyclophosphamide (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) IV piggyback over 30 minutes on days 1-3.
9998191|NCT01515917|Experimental|Citicoline and Omega-3|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
9998192|NCT01515917|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
9840543|NCT00813566|Experimental|All Participants|All participants will receive multi-tracer PET scans at up to 3 time points: baseline, at the conclusion of standard of care chemoradiation, and at the time of documented recurrence within two years.
9840546|NCT00800514|Experimental|active|
9840551|NCT00788125|Experimental|Dasatinib with Ifosfamide, Carboplatin, Etoposide|
9840556|NCT00776035||heart failure|Obesity related Heart failure population
9840560|NCT00745134|Experimental|Arm I (curcumin)|Patients undergo radiation therapy 5 days a week for a total of 28 fractions. Patients also receive capecitabine PO BID on the days of radiation therapy and curcumin PO BID in weeks 1-11.5.
9840561|NCT00745134|Active Comparator|Arm II (placebo)|Patients undergo radiation therapy and receive capecitabine as in Arm I. Patients also receive placebo PO BID in weeks 1-11.5.
9985899|NCT00602459|Experimental|Arm D (rituximab, fludarabine, cyclophosphamide, lenalidomide)|Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m^2) on day 1 and fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) and cyclophosphamide IV (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
9985900|NCT00600015|Experimental|Combination Therapy|Erlotinib + Sorafenib
9985901|NCT00600015|Placebo Comparator|Placebo|Erlotinib + Placebo
9985902|NCT00552591|Experimental|1|Family Heart Health Program
9985903|NCT00552591|No Intervention|2|Usual Care
9985904|NCT00500071|Experimental|1|
9985905|NCT00447122|Experimental|treatment 1|Gemcitabine 1000mg/m2 with lapatinib 1000mg/d weekly x 3 weeks
9840570|NCT00715442|Experimental|Sunitinib + Nephrectomy|Sunitinib 50 mg by mouth daily for 28 consecutive days. Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
9985906|NCT00447122|Experimental|treatment 2|Gemcitabine 1000mg/m2 with lapatinib 1500mg/d weekly X 3 weeks
9840572|NCT00708045|Experimental|All patients|All participants enrolled.
9840573|NCT00707213|Experimental|All Participants|All Participants will be assessed by FDG-PET to identify possible sites of infection
9985907|NCT00447122|Experimental|treatment 3|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1000 mg/d
9985908|NCT00447122|Experimental|treatment 4|gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 on days 1 and 14 of a 28-day cycle with lapatinib 1500 mg/d
9985909|NCT00430040|Experimental|carvedilol|carvedilol
10206593|NCT04240392|Experimental|Collaborative Care (CC)|The CC team includes an obstetrical provider and a nursing case manager. The obstetrician will see all participants, initially to discuss preferences for addiction treatment, buprenorphine, methadone (MAT) or no MAT. The obstetrician will see participants every 1-2 weeks, as needed and will provide prenatal care. The care team will meet at least monthly and review the participants' status. For research purposes, the CM will obtain informed consent, collect and enter results of the urine drug screen (UDS) into a database. At enrollment and at 26 and 34 weeks' gestation the care manager will ask participants to complete an assessment battery of self-reported measures.
9985910|NCT00430040|Active Comparator|lisinopril|lisinopril
9985911|NCT00382252|Experimental|18F-FDG PET/CT + RFA|"18F-FDG PET/CT: I.V. injection of 5 to 15 mCi (185 to 555 MBq) of 18F-FDG. Capture time of 60 to 90 minutes. Acquisition of images: A whole body CT scan with normal breathing will be performed for attenuation correction with 5mm thick slices. A whole body PET acquisition of 6 or 7 steps will be done from the upper third of the thighs to the base of the skull. PETC/CT performed at inclusion, 1 month et 3 months after RFA.~RFA: Treatment procedure: the location under scanner allows to place the electrode in the center of the tumor. The treatment then lasts 15 to 20 minutes.~CT scanner: The CT examination will be performed in spiral acquisition without or after injection of contrast medium (70 ml at 2 or 3 ml/sec). On a 16-slice scanner, the examination is performed with 1.25 mm slices every 0.9. Constants generally used 120kV, 350 mA. Ct scanner performed at inclusion, 48H post-RFA, 1 month, 3 months, 6, 9 and 12 months after RFA."
9985912|NCT00353483||Tissue, blood, and bone marrow (optional) collection|"Undergo neoadjuvant systemic therapy~initial surgery for sentinel lymph node biopsy/portacath placement~definitive cancer surgery (if applicable)~when portacath is removed (1 year, if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis~Undergo Adjuvant Systemic Therapy~initial surgery for a sentinel lymph node biopsy/portacath placement~when portacath is removed (1 year, if available)~If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.~Undergone neoadjuvant systemic therapy~during definitive cancer surgery/portacath removal (if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis"
9985913|NCT00324805|Active Comparator|Arm I (chemotherapy)|"Patients receive one of the following. For all, treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~REGIMEN 1: Vinorelbine ditartrate 30 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV over 60 minutes on day 1 REGIMEN 2: Docetaxel 75 mg/m2 IV and cisplastin 75 mg/m2 IV on day 1 REGIMEN 3: Gemcitabine hydrochloride 1200 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV on day 1 REGIMEN 4 (non-squamous histology only): Pemetrexed disodium 500mg/m2 IV and cisplatin 75 mg/m2 IV on day 1"
9840595|NCT00571389||Cancer Cohort|The first cohort of patients to be enrolled for this study will be adults (males and females) with histological proven solid tumors of any stage, seen for routine cancer care at participating community cancer clinic sites. Patients on clinical trials with experimental study drugs will be allowed to participate in this observational prospective study.
9840596|NCT00571389||Healthy Volunteer Cohort|Healthy volunteers make up the second, smaller study population for this observational biospecimen laboratory study. Healthy volunteers serve primarily to aid in the proficiency, quality control and/or optimization of study procedures, experimental design assay development, and for device/equipment validation.
9840597|NCT00571389||COVID-19 Disease Cohort|Due to the COVID-19 pandemic and the consequent amendment to aid in the research response, study subjects with COVID-19 disease may participate in all aspects of this protocol, but depending on their disease state, infection timeline, and age, participation may be limited to only one component, procedure, and/or type of biospecimen collection. Age is a very important criteria, as pediatric subjects (5-17 years old) will only be eligible to participate in minimally invasive biospecimen collection procedures.
9985914|NCT00324805|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive chemotherapy as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 1 year.
9985915|NCT00310180|Experimental|Group 1 (Oncotype DX recurrence score =< 10)|Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.
9985916|NCT00310180|Experimental|Group 2, Arm I (experimental)|Patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
9985917|NCT00310180|Active Comparator|Group 2, Arm II (standard)|Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
9985918|NCT00310180|Experimental|Group 3 (Oncotype DX recurrence score >= 26)|Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in group two who are assigned to receive both types of treatment.
9985919|NCT00309985|Experimental|Androgen-Deprivation Therapy and Docetaxel|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9985920|NCT00309985|Active Comparator|Androgen-Deprivation Therapy alone|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration) alone.
9985921|NCT00290251|Active Comparator|ulipristal acetate -20 mg|20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
9985922|NCT00290251|Active Comparator|ulipristal acetate - 10 mg|10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
9985923|NCT00290251|Placebo Comparator|Placebo|Placebo taken daily for three menstrual cycles or up to 102 days
9985924|NCT00290251|No Intervention|Pre-ulipristal acetate 10 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 10 mg arm
9985925|NCT00290251|No Intervention|Pre-ulipristal acetate 20 mg|Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 20 mg arm
9985926|NCT00290251|No Intervention|Pre-placebo|Subjects were studied during one baseline cycle without any intervention before entering placebo arm
9985927|NCT00214916|Active Comparator|A|conventional insulin therapy (using Actrapid IV)
9985928|NCT00214916|Experimental|B|intensive insulin therapy (using actrapid IV)
9985929|NCT00066963|No Intervention|Counseling Only|Counseling Only
9985930|NCT00066963|Experimental|FV every 12mo for 24mo + Counsel|Preventive fluoride varnish every 12mo for 24mo plus Counseling
9985931|NCT00066963|Experimental|FV every 6mo for 24mo + Counseling|Preventive fluoride varnish every 6mo for 24mo plus Counseling
9985932|NCT00055731|Experimental|Chemotherapy|
9985933|NCT00055731|Active Comparator|Without Chemotherapy|
9985934|NCT01397487|Other|one single arm|All patients are included to complete a biopsy of half part of the embryos
9985935|NCT01397500|Active Comparator|Genotropin|"6 months Genotropin (open treatment)~Daily dose:~Male < 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female < 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks."
9985936|NCT01397500|Active Comparator|Testosterone undecannoate|18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
9985937|NCT01397500|No Intervention|control group|No Intervention.
9985938|NCT01397513|Active Comparator|Aspirin 75mg|
9985939|NCT01397513|Active Comparator|Aspirin 320mg|
9985940|NCT01397539|Experimental|BIIB037|A single dose of BIIB037 by intravenous infusion.
9985941|NCT01397539|Placebo Comparator|Placebo|A single dose of placebo matching BIIB037 by intravenous infusion.
9985942|NCT01397565|Active Comparator|Laparoscopic cholecystectomy|Patients in this arm will undergo conventional laparoscopic cholecystectomy
9985943|NCT01397565|Experimental|Minilaparoscopic cholecystectomy|Patients in this arm will undergo laparoscopic cholecystectomy using minilaparoscopic instruments
9985944|NCT01397604|No Intervention|Saline Placebo|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects."
9985945|NCT01397604|Placebo Comparator|SE Vehicle|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~The SE (squalene) vehicle contains the oil emulsion in which the GLA-SE is solubilized."
9985946|NCT01397604|Active Comparator|GLA-AF|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-AF contains the study drug in an aqueous solution."
9985947|NCT01397604|Active Comparator|GLA-SE|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-SE contains the study drug in a squalene oil emulsion."
9985948|NCT01397630|Experimental|Accelerated Oxytocin Titration|
9840648|NCT00360646||Subjects with liver injury|
9840649|NCT00360646||Subjects without liver injury|
9985949|NCT01397630|Active Comparator|Gradual Oxytocin Titration|
9985950|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
9985951|NCT01397643|Other|Operative|Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.
9985952|NCT01397669|Other|HIV infection and non HIV infection|
9985953|NCT01397708|Experimental|INXN-1001 in combination with INXN-2001|Intratumoral injections of INXN-2001 (Ad-RTS-hIL-12) at a constant dose in combination with inter-cohort escalating doses of INXN-1001 (activator ligand).
9985954|NCT01397734|Experimental|Cohort 1|Patients who are receiving Imatinib as part of their standard of care therapy for CML.
9840656|NCT00345930||2|Individuals without drug induced liver disease
9516882|NCT03311360||bare metal stent|patients with vertebral artery origin stenosis treated with bare metal stent
9840657|NCT00345930||1|Individuals with drug induced liver disease
9985955|NCT01397734|Experimental|Cohort 2|Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
9985956|NCT01397734|Experimental|Cohort 3|Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
9985957|NCT01397773||Hemodialysis group|Patients on chronic hemodialysis program
9985958|NCT01397773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
9985959|NCT01397773||Pre-dialysis group|Patients with chronic kidney disease stage-4
9985960|NCT01397773||Control group|Healthy subjects
9985961|NCT01397799|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
9985962|NCT01397812||1|"Subjects will comprise of patients who are the recipients of a heart transplant within the previous 12 months and are scheduled for a routine endomyocardial biopsy.~Subjects will provide breath samples for the Heartsbreath test using the BreathScanner 1.0. Optionally subjects will provide breath samples using the BreathLink point of care system."
9985963|NCT01397838|Experimental|Pro-Bone|
9985964|NCT01397864||Hereditary Angioedema|
9985965|NCT01397877|Experimental|stratum 1|Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
9985966|NCT01397903||Group 1|"Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study.~The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment)."
9985967|NCT01397942|Experimental|Diet intervention - Ancient vegatables|A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
9516883|NCT03311347|Experimental|100%O2 breathing|Primary aim, item 1
9985968|NCT01397942|No Intervention|Control Nordic diet|A diet habitually consumed in the Nordic countries
9985969|NCT01397942|Experimental|Diet intervention - Modern Vegetables|A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
9985970|NCT01397955||Group 1|Drug (incl. Placebo)
9985971|NCT01397981|Experimental|Walking modification|Changing kinematics for walking
9985972|NCT01397994|Active Comparator|Nicorandil test arm|Nicorandil is given with atenolol therapy.
9840695|NCT00329043|Experimental|Sunitinib + Hormonal Ablation Before Prostatectomy|Sunitinib Malate 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles. LHRH Agonist intramuscular injection either monthly for 3 months or in a single 3-month dose. Radical prostatectomy after completion of Sunitinib and LHRH agonist.
9985973|NCT01397994|Active Comparator|Atenolol control arm|Atenolol 50 mg OD is given.
9985974|NCT01398007|No Intervention|Conventional syringe|Conventional syringe
9985975|NCT01398007|Experimental|Camouflage syringe|The camouflage syringe is divided into three parts: head, body and tail. Head consists of bristles to apply topical anesthesia. The body holds the normally used conventional syringe and presents with a slot to check the aspiration results. The tail hides the conventional syringe loaded with the local anesthetic solution. This syringe is made up of cold-cure acrylic with a colorful toy-like look.
9985976|NCT01398020|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep prior to colonoscopy.
9985977|NCT01398020|Experimental|2L Bi-Peglyte|Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
9985978|NCT01398033|Active Comparator|Drug-coated balloon|"pre-dilatation of the target lesion with a non-coated balloon.~treatment of the target lesion with the paclitaxel-coated balloon"
9985979|NCT01398033|Placebo Comparator|non-coated balloon|Treatment of the target lesion with plain balloon angioplasty.
9985980|NCT01398046|Active Comparator|Dasatinib|
10206594|NCT04240392|Active Comparator|Extension for Community Healthcare Outcomes (ECHO)|ECHO is a remote education model that provides mentorship and guided practice and participation in a learning community, via video conferencing. The practice members who participate in ECHO will include obstetricians and nurses as well as other members of the care team who wish to join. Providers are given access to a password-protected website containing the recorded sessions, a discussion board, and resource library. CME credits are available for each session and can motivate providers to attend.
9516884|NCT03311347|Experimental|Air breathing|Primary aim, item 1
9985981|NCT01398046|Experimental|Dasatinib plus Rabeprazole|
9985982|NCT01398046|Experimental|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|
9985983|NCT01398072|Active Comparator|Moxifloxacin|
9985984|NCT01398072|Active Comparator|Azithromycin|
10206595|NCT04237181|Other|Acute diarrhoea or colitis presumed to be of infectious origin|
9985985|NCT01398072|Active Comparator|Doxycycline|
9985986|NCT01398072|Placebo Comparator|Placebo|
10206596|NCT04232618||FIND cohort|Evaluation of biomarkers in serum samples from 500 people with suspected TB from non-African countries provided by FIND diagnostic biorepository.
10206597|NCT04232618||Phase 1|Evaluate the basic 3-marker multi-biomarker test (MBT) signature in 150 participants across three African sites. This will be used to lock down the final MBT signature to be used in the next phase of testing.
10206598|NCT04232618||Phase 2|Enrolment of 750 participants across three African sites using the locked down MBT signature from phase 1.
9985987|NCT01398085|Active Comparator|Radioactive iodine (RAI) ablation Arm|Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq
9985988|NCT01398085|No Intervention|No Radioactive iodine (No-RAI) ablation|Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation
10206599|NCT04231409|Active Comparator|WaveWriter Settings|WaveWriter Programming
10206600|NCT04231409|Active Comparator|Conventional Settings|Conventional Programming
10206601|NCT04227470|Experimental|Experimental: HBM9161, 340mg|HBM 9161 injection, 340mg, weekly administered by subcutaneous for a period of 4 weeks.
10206602|NCT04227470|Experimental|Experimental: HBM9161, 680mg|HBM 9161 injection, 680mg, weekly administered by subcutaneous for a period of 4 weeks.
10206603|NCT04226352|Experimental|Dose 1|60 mg DXM a day for 28 days
10206604|NCT04226352|Experimental|Dose 2|300 mg DXM every 2 weeks for 28 days.
9985989|NCT01398098|Experimental|COLOKIT®|
9840713|NCT00200200|Active Comparator|1|Bevacizumab in addition to HAI plus systemic chemotherapy
9840714|NCT00200200|Experimental|2|HAI plus systemic chemotherapy alone
9840715|NCT00199862|Experimental|Radio-labeled huA33 Antibody|"Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .~Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.~Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure."
9922036|NCT00834327|Experimental|3|aplindore 0.25 mg MR total daily dose (to include short titration)
9985990|NCT01398111|Active Comparator|Treatment R2|
9985991|NCT01398111|Active Comparator|Treatment R1|
9985992|NCT01398111|Placebo Comparator|Placebo|
9985993|NCT01398111|Experimental|Treatment T|
9985994|NCT01398137||Ragweed allergic subjects|
10206605|NCT04226352|Experimental|Dose 3|300mg DXM once, with 60mg DXM daily afterwards
10206606|NCT04224974|Experimental|Other: Usual Care|
10206607|NCT04224974|Experimental|Behavioral: Usual Care + EASE Intervention-psy|EASE Intervention = EASE-psy + EASE-phys
10206608|NCT04224090||Congenita coronary abnormalities (CAA)|"All the coronary arteries were differing from the definition of normal: when do not arise from the appropriate sinus of Valsalva (right or left) and not present a proper course and termination."
10206609|NCT04222816|Active Comparator|Lithium carbonate|Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
10206610|NCT04222816|Experimental|Add-on Sodium chloride|Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.
9840716|NCT00187668||African American|Must self identify as African American with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
9840717|NCT00187668||Cuacasian|Must self identify as Caucasian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
9840718|NCT00187668||Hispanic|Must self identify as Hispanic with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
9840719|NCT00187668||Asian|Must self identify as Asian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
9985995|NCT01398150|Placebo Comparator|Sweetened Beverage|looks like and is given in the same way as the experimental treatment but contains no active ingredient
9985996|NCT01398150|Experimental|Cranberry Beverage|15 ounce bottle of cranberry beverage consumed daily for 70 days
9985997|NCT01398163|Experimental|1 = Tested product|
9985998|NCT01398163|Active Comparator|2 = Control product|
9985999|NCT01398163|No Intervention|3 = No product|
9986000|NCT01398189|Experimental|clozapine|patients with refractory schizophrenia or schizoaffective disorder
9986001|NCT01398202|Active Comparator|Vitamin D3 (20 microgram/day)|
9986002|NCT01398202|Active Comparator|25-hydroxyvitamin D (7 microgram/day)|
9986003|NCT01398202|Active Comparator|25-hydroxyvitamin D3 (20 micogram/day)|
9986004|NCT01398202|Placebo Comparator|Placebo|
9986005|NCT01398215||transvaginal NOTES|
9986006|NCT01398228|Other|Group 1|Group 1 will receive quality improvement initiatives first, after 6 months of baseline initiation.
9986007|NCT01398228|Other|Group 2|Group 2 will receive quality improvement initiatives second, after 6 months of the intervention initiation for Group 1.
9986008|NCT01398228|Other|Group 3|Group 3 will receive quality improvement initiatives third, after 6 months of the intervention initiation for Group 2.
9986009|NCT01398228|Other|Group 4|Group 4 will receive quality improvement initiatives forth, after 6 months of the intervention initiation for Group 3.
9986010|NCT01398241|Experimental|Active|
9986011|NCT01398241|Placebo Comparator|Placebo|
9986012|NCT01398254|Other|TRA|Transradial Access
9986013|NCT01398254|Other|TFA|Transfemoral Access
9986014|NCT01398267|Experimental|1|
10206611|NCT04222387|Experimental|Participants with hair dye|Hair dye product with pPD Type Aromatic Amines used up to 1 month before
9840740|NCT00107289|Experimental|Radiation|
9986015|NCT01398267|Placebo Comparator|2|
9986016|NCT01398293|Experimental|A|
9986017|NCT01398293|Experimental|B|
9986018|NCT01398293|Active Comparator|C|
9986019|NCT01398293|Placebo Comparator|D|
9986020|NCT01398306||Group A|Patients with clear cell renal cell carcinoma with metastases.
9986021|NCT01398306||Group B|Patients with low grade neuro-endocrine tumours with metastases.
9986022|NCT01398319|Other|Group Brief Alcohol Intervention|The number of alcohol related incidents for the year prior the initiation of the BAI will be compared to the number of alcohol related incidents when Airmen were exposed to the BAI
9986023|NCT01398332||Aortic pathologies|Indication for aortic endovascular stent graft repair
9986024|NCT01398345|Active Comparator|Exercise and Respiratory Training|
9986025|NCT01398371|Active Comparator|Stable digoxin therapy|Participants need to have been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation.
9986026|NCT01398371|Experimental|Digoxin withdrawal|Participants will receive a placebo for 4 weeks.
9986027|NCT01398384|Active Comparator|Nitric Oxide|nitric oxide for inhalation
9986028|NCT01398384|Placebo Comparator|Placebo|inhalation gas
9986029|NCT01398423|Active Comparator|Active control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
9986030|NCT01398423|Experimental|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
9986031|NCT01398436|Experimental|Catheter tip in right atrium|In this group a central venous catheter will be advanced for its entire length unless arrhythmias develop.Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography.
9986032|NCT01398436|No Intervention|Catheter tip in superior vena cava|In this group a central venous catheter will be inserted for 15 cm in accordance with standard practice. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
9986033|NCT01398449|Experimental|B|After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI)
9986034|NCT01398449|Active Comparator|A|After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only
9986035|NCT01398462|Experimental|CWP232291|
9986036|NCT01398488|Active Comparator|Conventional Patient education|Conventional Patient education by health care professionals.
9986037|NCT01398488|Experimental|Patient education via Tablet computer|Patient education after lung transplantation via Tablet computers. An electronic patient questionnaire via tablet computer will be collected in addition.
9986038|NCT01398501|Experimental|Post-SCT Sorafenib|Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.
9986039|NCT01398527|No Intervention|LTC Osteoporosis Toolkit Only|Homes will receive the LTC osteoporosis toolkit only and will be required to attend an online webinar to outline the toolkit contents.
9986040|NCT01398527|Active Comparator|Educ sessions & LTC Osteoporosis toolkit|LTC homes will receive the LTC osteoporosis toolkit, on line webinar. Three educational sessions lead by an osteoporosis expert will also take place, 1 on-site visit and 2 webinars.
9986041|NCT01398540|Experimental|elderly|subjects are at least 60 years old (with no upper age limit), receiving 2 immunisations with IXIARO
9986042|NCT01398540|Experimental|young|subjects 18 to 40 years old, receiving 2 immunisations with IXIARO
9986043|NCT01398553|Experimental|Armeo Spring|
9986044|NCT01398553|Active Comparator|conventional physiotherapy|
10206612|NCT04221061|Other|Non-surgical candidates|In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).
9986045|NCT01398579|Active Comparator|Group A|Group A: WLE followed by AFI followed by NBI followed by pCLE.
9986046|NCT01398579|Active Comparator|Group B|Group B: WLE followed by NBI followed by AFI followed by pCLE.
9986047|NCT01398592|Experimental|Vildagliptin|Experimental
9986048|NCT01398592|Active Comparator|Sitagliptin|Active comparator (drug)
9986049|NCT01398605|Experimental|moderate exercise training|
9986050|NCT01398605|Experimental|intensive exercise training|
9986051|NCT01398605|No Intervention|Control|
9986052|NCT01398618|Experimental|4M-RMP|adult household contacts with latent tuberculosis infection receiving 4-month rifampicin preventive therapy
9986053|NCT01398618|Active Comparator|9M-INH|adult household contact with latent tuberculosis infection receiving 9-month isoniazid preventive therapy
9986054|NCT01398631||Study Group|All included patients presented with chest pain at the emergency room within the inclusion period.
9986055|NCT01398644|Active Comparator|Phlebotomy -intervention phlebotomy|Patients are treated with phlebotomy if ferritin level >50 ug/l
9986056|NCT01398644|Experimental|Erythrocytapheresis|Patients are treated with erythrocytapheresis if serum ferritin level >50ug/l
10206613|NCT04221061|Other|Surgical candidates|In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.
10206614|NCT04220671|Experimental|Intervention|Standard dose measles vaccine, 0.5 ml
9986057|NCT01398657|Experimental|Adjuvant Androgen-Deprivation Therapy|Cryotherapy with Short-term Adjuvant Androgen-Deprivation Therapy
10206615|NCT04220671|Placebo Comparator|Control|Saline injection, 0.5 ml
9986058|NCT01398657|No Intervention|No adjuvant therapy|Cryotherapy without any adjuvant therapy
9986059|NCT01398670|Experimental|Lispro arm|Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
9986060|NCT01398670|Active Comparator|Humalog® arm|Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
9986061|NCT01398696|Active Comparator|Patient Information Leaflets|Patient Information Leaflets (PIL) is given to the patient during consultation
9986062|NCT01398696|Placebo Comparator|usual consultation without PIL|no particular intervention during consultation for the patient.
9986063|NCT01398709|Active Comparator|Slow rewarming strategy|Slow rewarming strategy (0.24 degrees C/min)
9986064|NCT01398709|Active Comparator|Fast rewarming strategy|Fast rewarming strategy (0.5 degrees C/min)
9986065|NCT01398722|Active Comparator|Intensive insulin therapy|Intensive insulin therapy(Blood glucose target: 110-150 mg/dL)
9986066|NCT01398722|Active Comparator|Conventional insulin therapy|Conventional insulin therapy(Blood glucose target: 150-180 mg/dl)
9986067|NCT01398748|Active Comparator|Intranasal GSH 100mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
9986068|NCT01398748|Active Comparator|Intranasal glutathione 200mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
9986069|NCT01398748|Placebo Comparator|Saline intranasal delivery|Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
9986070|NCT01398748|No Intervention|Watchful waiting|No intervention, watchful waiting only (n=4)
9986071|NCT01398761|Experimental|Intervention|nurses, residents, PAs, and attendings from the two pilot services
9986072|NCT01398878|No Intervention|Traditional work schedule|Residents in the intensive care unit perform overnight shifts in excess of 24 hrs every fourth night
9986073|NCT01398878|Active Comparator|Intervention work schedule|Residents in the Intensive Care Unit perform shifts less than 16 hours in length and have at least 8 hours off between shifts
9986074|NCT01398891|Experimental|Positive Psychology Exercises|
10206616|NCT04219033||with postoperative cognitive dysfunction|
10206617|NCT04219033||without postoperative dysfunction|
10206618|NCT04200365|Experimental|Itacitinib|
10206619|NCT04197336|Sham Comparator|Control Arm|27 participants enrolled in the procedure arm. Participants randomized to the control arm will follow the same screening. Pre-procedure assessment will take the same pre-procedure meds. Procedure day, interventional radiologist will determine radial or groin access. After the participant and procedure area are prepped, participants will be under standard moderate sedation medications; all participants will receive lidocaine & a skin nick to their groin or their wrist as determined by the operating physician. Participant will have a blind fold placed & their hearing damped either with ear plugs or noise cancelling headphones. Participants randomized to the control arm will not receive other procedural intervention. Procedural team will follow a prescribed simulated protocol. Participants randomized to the control arm will be given under skin lidocaine and receive a skin nick on the wrist or groin.
10214075|NCT01451502|Experimental|Unlicensed Umbilical Cord Blood Infusion|"All patients will be registered in OnCore under this protocol as well as the specific treatment protocol.~Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride~Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines.~Infusion of minimally manipulated unlicensed UCB units:~vital signs Monitoring during and after UCB infusion:~Management of infusion reactions~Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines."
9986075|NCT01398904||Body dysmorphic disorder (BDD) Participants|Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
9986076|NCT01398904||Healthy Controls|Males and females 18 years of age or older with ability to provide informed consent and understand study staff.
9986077|NCT01398917|Active Comparator|short-term stenting|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
9986078|NCT01398917|Active Comparator|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
9986079|NCT01398930|Active Comparator|Group I was treated with etoricoxib|
9986080|NCT01398930|Active Comparator|Group II was treated with acupuncture and etoricoxib|
9986081|NCT01398930|Sham Comparator|Group III was treated with sham acupuncture and etoricoxib.|
9986082|NCT01398969|Experimental|Fresh FMT|Participants in this arm will receive Fresh FMT via rectal administration. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
9986083|NCT01398969|Experimental|Frozen-and-Thawed FMT|Participants in this arm will receive Frozen-and-Thawed FMT via rectal administration. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
9986084|NCT01398995|Experimental|90 minutes|Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
9986085|NCT01398995|Experimental|60 minutes|Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
9986086|NCT01398995|Experimental|30 minutes|Basal insulin infusion reduced to normal 30 minutes prior to exercise
9986087|NCT01398995|Experimental|Start|Basal insulin infusion reduced to 50% of normal at the start of exercise
9986088|NCT01399021|Other|Flat Davol drain|both arms will have flat davol drains placed at the end of the parotidectomy surgery
9986089|NCT01399034||MicroRNA study|Obese group (+ periodontitis group) Non-obese group (+ periodontitis group)
9986090|NCT01399034||DNA methylation study|Periodontitis group Healthy periodontium group
9986091|NCT01399073||Patients with Neglect|
9986092|NCT01399073||Patients with Hemianopsia|
9986093|NCT01399073||Healthy age-matched controls|
9986094|NCT01399086||Fulvestrant|
9986095|NCT01399112|Experimental|Electronic Decision Support System|The Electronic Decision Support System (EDSS) is a 5-module computer program aimed to assess, motivate, educate, solicit preferences, and provide feedback and referrals for people with severe mental illness. The program provides: a) a personalized assessment of the individual's smoking, b) information to improve knowledge of smoking risks and treatment benefits, c) interactive exercises to personalize the impact of smoking, improve attitudes about quitting, and increase self-efficacy for seeking smoking cessation treatment, and d) a video patient vignette to develop social norms for smoking cessation treatment and increase self-efficacy. Usability testing among people with severe mental illness established that the system was comprehensible, easy to use, and took 30-90 minutes to complete.
9986096|NCT01399112|Active Comparator|thetruth.com website|"Participants who are assigned to use the web-based thetruth.com website will be asked to navigate through the website as they wish. The home page of thetruth.com site has links to access video games, fact sheets, and videos that highlight negative aspects of cigarettes or tobacco companies. Thetruth.com website is not structured and participants can utilize whatever aspects of the website they wish and in any order they wish to view them.~Individuals will use the computer with a research staff member present who can provide assistance if needed. The sections of the two programs website that are used and the time spend on each portion of the program will be recorded. Participants who use TheTruth.com will be given a referral for assistance in quitting smoking if requested."
9986097|NCT01399138|Experimental|Blueberry Powder|A blueberry smoothie will be consumed at the breakfast and dinner meals.
9986098|NCT01399138|Placebo Comparator|Placebo|A placebo smoothie will be consumed at the breakfast and dinner meals.
9986099|NCT01399151|Experimental|Vitamin D - Treatment 1|400 IU/day Vitamin D
9986100|NCT01399151|Experimental|Vitamin D- Treatment 2|2,000 IU/day Vitamin D
9986101|NCT01399151|Experimental|Vitamin D- Treatment 3|5,000 IU/day Vitamin D
9986102|NCT01399164|Experimental|Fortified Bread|A single serving of 14C-B12 fortified bread
9986103|NCT01399203||percutaneous coronary intervention|The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention
9986104|NCT01399216|Experimental|Fucoidan supplement|
9986105|NCT01399216|Placebo Comparator|Placebo|
9998272|NCT01516580|Active Comparator|LMB chemo|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²~in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
9986106|NCT01399242|Active Comparator|Certican, prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
9986107|NCT01399242|No Intervention|Tacrolimus,Prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
9986108|NCT01399255|Experimental|Listro™ Arm|Insulin Lispro (Listro™); 100 U/mL, DispoPen 3.0 mL.
9986109|NCT01399255|Active Comparator|Humalog® Arm|Insulin Lispro (Humalog®; 100 U/mL), Humalog® Kwik Pen™ 3.0 mL.
9986110|NCT01399281||Biologics alone or methotrexate alone|This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,
9986111|NCT01399281||Biologics and MTX|JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics
9986112|NCT01399281||NSAIDs and/or steroid injections alone|This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.
9996874|NCT01504022|Experimental|Telecare, self monitoring, lifestyle counseling|Patients in the intervention group will measure their blood pressure with home blood pressure monitor which is linked to a secured website. Patients will measure as recommended in the European guidelines of hypertension. This includes 2 measurements in the morning and two times in the evening on 7 consecutive days every month. The measurements of the first day will be discarded. These measurements will be forwarded to the web-based system, which will be managed by the nurse practitioner and the research doctor. At least every month patients are contacted about the state of their condition. If needed, antihypertensive medication is added of adjusted by the nurse practitioner or research doctor under the supervision of one consultant physician. Tailored lifestyle advices are given every month.
9996875|NCT01504035|Experimental|Hemostatic putty plus Lidocaine (Orthostat-L)|
9996876|NCT01504035|Active Comparator|Hemostatic putty (Orthostat)|
9996877|NCT01504048|Experimental|Chromoendoscopy|
9996878|NCT01504061|Experimental|Mederma Ultra Gel|
9996879|NCT01504061|Active Comparator|Mederma N&I|
9996880|NCT01504074||Patients suffering on CME secondary to cataract surgery|
9996881|NCT01504087||patinet with deep venous thrombosis|patient with deep venous thrombosis by ultrasonography as case; patient with no deep venous thrombosis by ultrasonography as control
9996882|NCT01504087||patient without deep venous thrombosis|
9996883|NCT01504100||femoral internal rotation|
9996884|NCT01504100||no femoral internal rotation|
9996885|NCT01504113||Study 1 goup|Patients who are planned to receive targeted agents
9996886|NCT01504113||Study 2 case group|Patients who have received targeted therapy
9996887|NCT01504113||study 2 control group|Psoriasis patients without target therapy
9996888|NCT01504126|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9996889|NCT01504139|Experimental|hCG in the late follicular phase + luteal phase|
9996890|NCT01504139|Experimental|hCG in the follicular phase + luteal phase|
9996891|NCT01504139|Experimental|LH in the luteal phase|
9986113|NCT01399307|Other|Elective Liposuction|
9986114|NCT01399320|Experimental|cyanoacrylate dressing,excesion|we excise the sinus tip then apply cyanoacrylate dressing and watch for healing
9986115|NCT01399333|Active Comparator|Group 1|full liquid diet utilizing meal replacements with PDCAAS of 1.0
9986116|NCT01399333|Active Comparator|Group 2|full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99
9986117|NCT01399333|Active Comparator|Group 3|full liquid diet utilizing protein supplement with a PDCAAS less than 0.5
9986118|NCT01399346|Experimental|1 bolus of insulin aspart 18 IU|Subcutaneous administration of insulin aspart as one bolus of 18 IU at one injection site.
9986119|NCT01399346|Experimental|9 bolus of insulin aspart a 2 IU|Subcutaneous administration of insulin aspart as 9 separately and simultaneously applied bolus of 2 IU at 9 separate injection sites
9986120|NCT01399359||Women who decide not to take a SERM|Women participate in the counseling session, questionnaire 1, and questionnaire 2, and the online questionnaire.
9986121|NCT01399359||Women who decide to take a SERM|Women participate in the counseling session, questionnaire 1 and questionnaire 2.
9986122|NCT01399450|Experimental|paliperidone add on|paliperidone add on
9986123|NCT01399463|Experimental|DEB + BMS|Paclitaxel drug-eluting balloon (DEB) dilatation and bare metal stenting
9986124|NCT01399463|Active Comparator|Stenting with commonly used Drug Eluting Stents (DES)|
9986125|NCT01399476|Experimental|Endoscopic Myotomy|
9986126|NCT01399489|Experimental|Exercise training|Individuals randomized to this arm get 48 sessions of personal training in a state of the art fitness facility
9986127|NCT01399489|No Intervention|Control|Individuals in the control arm are expected to continue to live normally, following their doctor's advice but not engage in any formal exercise training.
9986128|NCT01399502|Active Comparator|Self-help advice|Each email will contain a self-help strategy for coping with depressive symptoms. The email will contain information about why the strategy will be effective, tips for implementing the strategy and overcoming barriers, and how to set a goal to implement the strategy. Strategies are based on previous research published by the trial co-ordinators.
9986129|NCT01399502|Placebo Comparator|Depression information|Each email will contain different information about depression, such as symptoms, risk factors, prevalence.
9986130|NCT01399515|Active Comparator|Valproic acid|
9986131|NCT01399515|No Intervention|Control|
9986132|NCT01399528||Beaumont Hospital, Dublin, Ireland|
9986133|NCT01399528||St. James' Hospital, Dublin, Ireland|
9986134|NCT01399528||Hôpital Erasme, Brussels, Belgium|
9986135|NCT01399528||Duke Medical Centre, North Carolina, USA|
9986136|NCT01399528||The Institute of Neurology/University College London, UK|
9986137|NCT01399541||Under and over 65 years|
9986138|NCT01399554|No Intervention|Assessment Only|
9986139|NCT01399554|Experimental|Weekly Exercise Counseling Intervention|
9986140|NCT01399567|Experimental|Algorithm|The NH pain management algorithm is a series of decision-making tools that begins with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain. The algorithm is coupled with intense diffusion strategies (e.g., education, consultation, boosters) to increase adoption of these evidence-based practices
9986141|NCT01399567|Active Comparator|Control|Control sites received staff education for pain assessment and management comprised of four one-hour classes
9986142|NCT01399606|Experimental|BF2.649|
9986143|NCT01399632|Experimental|High Fat and Low Carbohydrate Diet|
9986144|NCT01399632|Experimental|Low Fat and High Carbohydrate Diet|
9986145|NCT01399645|Experimental|Liraglutide-Metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day until the end of the study.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
9986146|NCT01399645|Experimental|Insulin-Metformin|"Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU. The patients will be taught to increase their insulin dose by 1 unit each day until achieving an FPG ≤ 7.0 mmol/L.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
9986147|NCT01399749|Experimental|Autologous ASC implantation|Treatment with autologous ASC
9986148|NCT01399749|Active Comparator|Autologous Chondrocytes implantation|Treatment with autologous chondrocytes
9986149|NCT01399762||mechanical recanalization|Patients with acute stroke being treated with endovascular devices for mechanical recanalization (no restriction to specific endovascular devices)
9986150|NCT01399775|Experimental|immediate implantation|Immediately after tooth extraction, dental implant is inserted.
9986151|NCT01399775|Other|Delayed implantation|Four months after extraction, Dental implant is inserted.
9986152|NCT01399801|Experimental|hemodynamicaly guided LV lead placement|optimized left ventricular lead placement
9986153|NCT01399801|Active Comparator|Standard lead placement|Standard LV lead placement with no measurements to guide LV lead placement
9986154|NCT01399814|Active Comparator|standard fluid regimen group|perioperative fluid treatment
9986155|NCT01399814|Experimental|restricted fluid regimen group|perioperative fluid treatment
9986156|NCT01399840|Experimental|Arm 1: BMN 673|Arm 1 will enroll patients with either AML or MDS
9986157|NCT01399840|Experimental|Arm 2: BMN 673|Arm 2 will enroll patients with either CLL or MCL
9986158|NCT01399853|Experimental|160U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
9986159|NCT01399853|Experimental|320U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
9986160|NCT01399853|Experimental|640U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
9986161|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in children (12-36months)|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
9986162|NCT01399853|Experimental|160U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
9986163|NCT01399853|Experimental|320U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
9986164|NCT01399853|Experimental|640U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
9986165|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in infants (from 6 to 11 months|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
9986166|NCT01399853|Placebo Comparator|0/0.5ml placebo in children (from 12 to 36 months old)|0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
9986167|NCT01399853|Placebo Comparator|0/0.5ml placebo in infants (from 6 to 11 months old)|0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28
9986168|NCT01399879||Healthy Volunteers|
9986169|NCT01399931||Early-stage Hodgkin Lymphoma Patients|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy
9986170|NCT01399957||pwMS prescribed dalfampridine-ER|Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.
9986171|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Conventional in Office Care
9986172|NCT01399970|Experimental|Mobile Teleconsultation Arm (MTA)|Mobile Teledermatology Care
9986173|NCT01399983||pulmonary hypertension|patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
9986174|NCT01399996|Placebo Comparator|Yogurt smoothie without probiotic.|
9986175|NCT01399996|Experimental|Probiotic added post fermentation.|
9986176|NCT01399996|Experimental|Probiotic added pre-fermentation.|
9986177|NCT01399996|Experimental|A capsule containing the probiotic.|
9986178|NCT01400009|Placebo Comparator|Placebo|Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
9986179|NCT01400009|Active Comparator|Vitamin D|Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
9986180|NCT01400022|Active Comparator|Cortisone|
9986181|NCT01400022|Experimental|UVA1 phototherapy|
9986182|NCT01400035||test group, control group|"Test group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg, intravenous infusion of Cavinton 30mg once a day.~Control group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg once a day."
9986183|NCT01400048|Active Comparator|Aloe vera effervescent tablet (AVH200)|
9986184|NCT01400048|Placebo Comparator|Placebo|
9986185|NCT01400061||normal|body mass index: 19-24
9986186|NCT01400061||overweight|body mass index: 25-29
9986187|NCT01400061||obesity|body mass index: 30-40
9986188|NCT01400061||modbid obes|body mass index: over 40
9986189|NCT01400074|Active Comparator|Nilotinib|400 mg twice daily
9986190|NCT01400074|Active Comparator|Imatinib|400 mg twice daily
9986191|NCT01400087|Active Comparator|Cap-attached Colonoscopy|
9986192|NCT01400087|Placebo Comparator|Regular colonoscopy|
9986193|NCT01400100|Experimental|Octreotide|Study patients receive after randomization a single shot of 5 mL 500 µg Octreotide in the gastroduodenal artery at the time of its transection.
9986194|NCT01400100|Placebo Comparator|Control|Control patients receive after randomization a single shot of 5 mL 0,9% NaCL solution in the gastroduodenal artery at the time of its transection.
9986195|NCT01400152|Active Comparator|Passive warming with additional active warming|
9986196|NCT01400152|No Intervention|Passive warming|
9986197|NCT01400165|Active Comparator|Desyrel/Teva-Trazodone|Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
9986198|NCT01400165|Active Comparator|Visken/Teva-Pindolol|Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
9986199|NCT01400165|Active Comparator|Seroquel/Teva-Quetiapine|Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
9986200|NCT01400191|Active Comparator|Homozygote wildtype OCT1|
9986201|NCT01400191|Active Comparator|Heterozygote OCT1|
9986202|NCT01400191|Active Comparator|Homozygote OCT1 variant|
9986203|NCT01400204||MDMA|poly drug users that used MDMA at New Years Eve
9986204|NCT01400204||Other Drugs|poly drug users that used drugs at New Years Eve, but not MDMA
9986205|NCT01400204||Alcohol|poly drug users that used no drugs at New Years Eve, but did consume alcohol
9986206|NCT01400217||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
9986207|NCT01400217||IPDI SP HFA-BDP|Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
9986208|NCT01400217||IPDA SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
9986209|NCT01400217||IPDA EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
9986210|NCT01400217||IPDS SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
9986211|NCT01400217||IPDS EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date
9986212|NCT01400230||CCTA-IVUS-FFR|Patients suspected ischemic heart disease by the symptom and CCTA and undergone IVUS and FFR in the Cath Lab with CAG enrolled consecutively.
9986213|NCT01400282|Other|Sequence 1|Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks)
9986214|NCT01400282|Other|Sequence 2|Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks)
9986215|NCT01400295||coronary angiography|The investigators reviewed all consecutive patients who were undergoing coronary angiography
9986216|NCT01400308|Active Comparator|Chlorhexidine + Mupirocin|"Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)."
9986217|NCT01400308|Experimental|Prontoderm|Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
9986218|NCT01400321||Distal region|Patients with loss of tooth in the premolar and molar region of the atrophied mandible
9986219|NCT01400321||aesthetic zone|Patients with loss of tooth within the aesthetic zone (canine to canine)
9986220|NCT01400334||Ischemic Cardiomyopathy|Subjects with ischemic cardiomyopathy [pre-enrollment left ventricular ejection fraction ≤0.35, with coronary artery disease documented by cardiac catheterization, a history of definite myocardial infarction, or reversible ischemia on nuclear imaging] who are considered eligible to receive an implantable cardiac defibrillator for the primary prevention of sudden cardiac death.
9986221|NCT01400360|Active Comparator|invasive|After proof of perfusion relevant CVS in interventional therapy should be performed as best possible combination from TBA and intraarterial vasodilators additional to the conventional treatment.
9986222|NCT01400360|No Intervention|conventional|After proof of perfusion relevant CVS only conventional treatment should be performed (no intraarterial therapy).
10206620|NCT04197336|Active Comparator|Bariatric Embolization Procedure|27 subjects will be enrolled in the bariatric embolization(BM) procedure arm. BM procedure will be performed under moderate sedation. Procedure will take 1.5 hr to 3 hr subject will be placed on the X-ray fluoroscopy table. Radial or femoral vascular access will be achieved using a small gauge needle, dilated over a guidewire to accommodate a 5 French vascular sheath. Standard catheters, 3 dimensional imaging will be acquired of the stomach, the arteries supplying the fundus arising off the celiac vessel. Microcatheter into the left gastric and/or gastroepiploic arteries supplying the fundus and small calibrated spheres will be infused until stasis of anterograde arterial flow is achieved, with particular care to avoid infusion of non-target arteries. The left gastric and/or gastroepiploic arteries will be embolized. Repeat 3 dimensional imaging: assess bead distribution and fundal coverage. Subject will be monitored in the recovery room and will be observed overnight.
10206621|NCT04193527|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ (123I) ioflupane. Single photon emission computed tomography (SPECT) imaging will be performed between 3 to 6 hours post-injection and will last approximately 20 minutes to 1 hour.
10206622|NCT04189731||supra-scapular block|Patient will have a short ISB (between 2h and 4h) relayed by a supra-scapular block (SSB) long (72h) through the placement of a perineural catheter thus allowing a continuous diffusion of Naropein® by an elastomeric pump
10206623|NCT04187040|Active Comparator|3-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 3-step hand hygiene technique.
10206624|NCT04187040|Active Comparator|6-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 6-step hand hygiene technique.
10206625|NCT04185311|Experimental|Treatment (talimogene laherparepvec, nivolumab, ipilimumab)|Participants receive talimogene laherparepvec intratumorally on days 1, 22, and 36, nivolumab IV over 60 minutes on days 1, 15, 29, and 43, and ipilimumab IV over 90 minutes on days 1 and 43 in the absence of disease progression or unacceptable toxicity.
10206626|NCT04184375|Experimental|TONIC|"The cognitive stimulation sessions are carried out using Liliane Israël's TRAIN YOUR MEMORY software, and are divided into two parts: the first part is essentially cognitive and the second relates to the daily life of the Bipolar patient.~This training method consists of combining two means of intervention, pedagogical action and psychotherapeutic effect. It aims to stimulate, develop and strengthen the basic mechanisms underlying memory phenomena (sensory acuity, attention, associations, structuring, executive functions, spatial and temporal landmarks, associative recruitment). It is presented in the form of exercises divided into eight modules."
10206627|NCT04184375|No Intervention|Control|The usual practice consists of interviews with the psychiatrist with the possibility of home visits by the nurse.
10206628|NCT04182334|Experimental|Slow Tempo Music|Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.
10206629|NCT04182334|Sham Comparator|Attention Control|One-hour sessions consisting of a silence track twice daily delivered through noise-cancelling headphones for up to 7 days.
10206630|NCT04179968|Experimental|Patients with suspected prostate cancer|Patients with suspected prostate cancer who have at least one PI-RADS 5 lesion, or at least one PI-RADS 4 lesion and PSA ≥10 nanograms/milliliter (ng/mL), on standard of care mpMRI of the prostate, who are scheduled for biopsy or radical prostatectomy
10206631|NCT04174716|Experimental|IDX-1197|Patient will be receive IDX-1197HCl once daily for 28 continuous days
10206632|NCT04161248|Experimental|Venetoclax + R-GDP|
9986223|NCT01400373|No Intervention|Control|Patients in the control group standard advanced cardiac life support care. Patients that achieve return of spontaneous circulation will be treated with hypothermia according to current guidelines upon arrival at the intensive care unit.
9986224|NCT01400373|Experimental|Intervention|Intra-arrest trans-nasal cooling with RhinoChill will be initiated during advanced cardiac life support. In patients achieving return of spontaneous circulation, trans-nasal cooling will continue until systemic cooling is started at the intensive care unit.
9986225|NCT01400386|Experimental|Soluble coffee 1|
9986226|NCT01400386|Experimental|Soluble coffee 2|
9986227|NCT01400386|Experimental|Soluble coffee 3|
9986228|NCT01400386|Experimental|Soluble coffee 4|
9986229|NCT01400438|Experimental|patients group with Herceptin|Patients beginning Herceptin in adjuvant after chemotherapy
9986230|NCT01400438|Active Comparator|Control group|patient not beginning Herceptin after chemotherapy : control group
9986231|NCT01400490|Placebo Comparator|Olive Oil 6 grams/day|
9986232|NCT01400490|Active Comparator|DHA 1800 mg/day|
9986233|NCT01400490|Active Comparator|EPA 1800 mg/day|
9986234|NCT01400490|Active Comparator|Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day|
9986235|NCT01400542||OSAS +|Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
10206633|NCT04160910|Active Comparator|5-hydroxytryptophan|"Dosage of 5-hydroxytryptophan will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
10206634|NCT04160910|Placebo Comparator|Placebo|"Dosage of placebo will be determined by weight:~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
10206635|NCT04155580|Experimental|Part 1|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
10206636|NCT04155580|Experimental|Part 2|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) as a single agent or in combination with ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
10206637|NCT04155580|Experimental|Part 3|ASTX660 at the recommended dose for expansion identified in Part 2 + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
10206638|NCT04155333|Experimental|Active anodal stimulation|active anodal stimulation at F3, cathode placed on contralateral bicep
10206639|NCT04155333|Experimental|Active cathodal stimulation|active cathodal stimulation at F3, anode placed on contralateral bicep
10206640|NCT04155333|Sham Comparator|Sham stimulation|sham stimulation that will be counterbalanced between subjects such that half will receive sham stimulation configured as condition 1 (anode F3, cathode bicep) and half will receive condition 2 (cathode F3, anode bicep)
10206641|NCT04150783||Unilateral Cleft Lip Nasal Deformity (uCLND)|uCLND patients who are scheduled to undergo surgical treatment for nasal obstruction as standard of care.
10206642|NCT04150783||Healthy Subjects|Existing data from healthy subjects with no prior symptoms of nasal obstruction used to create normative ranges for comparison to uCLND cohort.
9986236|NCT01400542||OSAS -|Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
9986237|NCT01400555|Experimental|001|Cohort 1 Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
9986238|NCT01400555|Experimental|002|Cohort 2 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
9986239|NCT01400555|Experimental|003|Cohort 3 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
9986240|NCT01400555|Experimental|004|Cohort 4 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
9986241|NCT01400568|Experimental|LPS challenge and fluticasone propionate|In case LPS induced airway inflammation is reproducible, the effect of a single high dose of inhaled fluticasone propionate will be assessed after a 4-week wash-out period.
9986242|NCT01400581|Experimental|Collaborative Care [CC] Intervention|The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
9986243|NCT01400581|No Intervention|Usual Care|Observational
9986244|NCT01400607|Active Comparator|Neocartilage Implant|Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
9986245|NCT01400607|Other|Microfracture|Standard of care cartilage repair technique.
9986246|NCT01400620|Experimental|Active oral rinse|Oral rinse containing botanical extracts
9986247|NCT01400620|Placebo Comparator|Placebo rinse|
9986248|NCT01400633||001|decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
9986249|NCT01400646|Experimental|Rivaroxaban + Warfarin Concomitant Therapy Phase|Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for >= 2 to <= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
9986250|NCT01400646|Experimental|Warfarin Monotherapy Phase|Warfarin monotherapy 10 mg/day for >=2 to <=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.
9986251|NCT01400659|Active Comparator|CARB Counting|For CARB counting, insulin dose will be calculated according to the carbohydrate content of the test meal (1 carb unit = 10 g carbohydrate). The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient.
9986252|NCT01400659|Active Comparator|CFP counting|For CFP counting, insulin dose will be calculated according the carbohydrate content (1 carb unit = 10 g carbohydrate) as well as fat/protein content (1 FPU = 100 kcal from fat and protein) of the meal. The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient. The insulin-to-FPU ratio is the same as the insulin to carb ratio.
9996892|NCT01504139|Active Comparator|vaginal progesterone and estradiol in the luteal phase|
9922037|NCT00834327|Experimental|4|aplindore 0.5 mg MR total daily dose (to include short titration)
9922038|NCT00834327|Placebo Comparator|5|Placebo
9986253|NCT01400672|Experimental|DIPG Patients Receiving Vaccine|Patients with diffuse intrinsic pontine glioma (DIPG) receiving radiation therapy, Tumor Lysate Vaccine (dose of 4 x 10^6 cells divided into 2 doses then every 4 weeks for up to 1 year) and Imiquimod (5% Aldara cream at a total dose of 12.5 mg) topically at each site prior to and 24 hours after vaccination.
9986254|NCT01400711|Active Comparator|ERAS patients|Patients planned to undergoing major intrabdominal surgery, following the ERAS perioperative care.
9986255|NCT01400711|Active Comparator|Control patients|Patients planned to undergo major intrabdominal surgery, following the conventional perioperative care.
9986256|NCT01400724|Experimental|Inofolic NRT|
9986257|NCT01400737|Experimental|ibuprofen|The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
10206643|NCT04150692|Experimental|Arm 1: Dara-SC Re-Escalation|-Re-escalation will include weekly dosing for two 4-week cycles (8 doses, Days 1, 8, 15, and 22 of each 28-day cycle) followed by dosing every-other-week thereafter (Days 1 and 15 of each 28-day cycle). Patients will remain on study treatment until meeting clinical progression.
10206644|NCT04150692|Active Comparator|Arm 2: Dara-SC|-Continued subcutaneous daratumumab and and hyaluronidase-fihj (1,800mg/30,000U, [Dara-SC])
9986258|NCT01400750|Active Comparator|Ciproxin-inhaled Colistin|oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months
9986259|NCT01400750|Active Comparator|Tobramycine for inhalation (TIS)|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
9986260|NCT01400789|Experimental|ListroMix 50/50®|Insulin Lispro/ insulin Lispro protamine ( ListroMix 50/50®; 100 U/mL), DispoPen 3.0 mL.
9986261|NCT01400789|Active Comparator|Humalog Mix50/50®|Insulin Lispro/ insulin Lispro protamine (Humalog Mix50/50® ; 100 U/mL), Humalog Mix 50/50® Kwik PenTM 3.0 mL.
9986262|NCT01400802|Experimental|Listro Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Listro Mix75/25®; 100 U/mL), DispoPen 3.0 mL.
9986263|NCT01400802|Active Comparator|Humalog Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Humalog® Mix75/25TM; 100 U/mL), Humalog Mix 75/25® Kwik PenTM 3.0 mL.
9986264|NCT01400828|Experimental|Bilastine|Intervention: Drug: Bilastine
9986265|NCT01400828|Active Comparator|Desloratadine|Intervention: Drug: Desloratadine
9986266|NCT01400828|Placebo Comparator|Placebo|Intervention: Drug: Placebo
9986267|NCT01400854||Effentora®|Single group prospective treatment cohort
9986268|NCT01400867|Experimental|Ceftaroline fosamil|
9986269|NCT01400867|Active Comparator|Comparators|Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam
9986270|NCT01400945|Experimental|S-Pantoprazole|Experimental drug: AGSPT201 Tab. (contain S-Patoprazole) Active comparator: Pantoloc Tab. (contain pantoprazole)
9986271|NCT01401036|Active Comparator|Nobori|subjects receiving Biolimus A9 eluting stent implantation
9986272|NCT01401036|Sham Comparator|Uncoated stents|subjects receiving uncoated stent implantation
9986273|NCT01401075|Active Comparator|doxifluridine|oral chemotherapy with the 5-FU prodrug doxifluridine
9986274|NCT01401075|Experimental|doxifluridine + mistletoe extract|oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
9986275|NCT01401088|Experimental|Artificial drainage implant|Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
9986276|NCT01401114||Group 1|Drug (incl. Placebo)
9986277|NCT01401127||Type 1 Diabetes|Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
10206645|NCT04149145|Experimental|M4344+Niraparib|all PARP resistant, recurrent ovarian cancer
10206646|NCT04140773|Experimental|D-serine group|Oral administration of 2g D-serine per day, for 6 weeks.
10206647|NCT04140773|Placebo Comparator|Placebo group|Oral administration of 2g Placebo (Mannitol) per day, for 6 weeks.
9922039|NCT00834353||Pulmonary tuberculosis patients|Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs
9922040|NCT00834379|Experimental|Pravastatin|Pravastatin 40 mg Tablet (test) dosed in first period followed by Pravachol® 40 mg Tablet (reference) dosed in second period
9922041|NCT00834379|Active Comparator|Pravachol®|Pravachol® 40 mg Tablet (reference) dosed in first period followed by Pravastatin 40 mg Tablet (test) dosed in second period
9922042|NCT00834392|No Intervention|Control|
9922043|NCT00834392|Experimental|Exercise|
9922044|NCT00834457|Active Comparator|2A|co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg po(Trizivir)one tablet twice daily(BID)for 96 weeks
9922045|NCT00834457|Active Comparator|2B|co-formulated abacavir 600mg/3TC 300mg orally (as Kivexa) one tablet daily plus fixed dose lopinavir 133.3mg/ritonavir 33.3mg orally (as Aluvia) four tablets daily for 96 weeks
9922046|NCT00834470|Experimental|Atropine|Atropine 0.01mg/kg IV
9922047|NCT00834470|Placebo Comparator|Normal saline|Same volume of atropine
10206648|NCT04136548|Experimental|Fentanyl|Fentanyl will be administered intravenously during one visit.
10206649|NCT04136548|Placebo Comparator|Placebo|Placebo (saline) will be administered intravenously during one visit.
10206650|NCT04131907|Experimental|Optilume™ BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
9922048|NCT00834496||1|"Our experience with the use of Sirolimus is delineated below. About 15% to 20% of our patients are currently switched to Sirolimus.Indications for conversion from calcinurin inhibitors (CNIs) to Sirolimus more than 90 days post liver transplantation include:~CNI renal toxicity.~Hepatic fibrosis on biopsy.~CNI neurologic toxicity.~Post transplant diabetes. Any of the above 4 indications makes a patient a candidate for conversion from CNIs to Sirolimus at or > 90 days after liver transplantation."
9922049|NCT00834509||Obstructive Sleep Apnea (OSA)|OSA participants will be treated with a CPAP/APAP treatment, per standard clinical care.
9922050|NCT00834509||Control|Control participants will not receive APAP/CPAP treatment, if not diagnosed with OSA.
9922051|NCT00834548||1|WB-MRA standard protocol
9922052|NCT00834548||2|WB-MRA hybrid protocol
10206651|NCT04131907|Sham Comparator|Sham Device|The Sham Device is a 21 Fr Optilume BPH, Prostatic Pre-dilation Catheter within the sheath.
9792295|NCT01441466||group with isolation|Patients in this arm are nursed separately until the test result of the PCR (polymerase chain reaction) for viral agents is known (within 24-48 hrs). RS-positive patients are nursed separately (separate room) from RS-negative patients
9792296|NCT01441492|Experimental|No Drains|Patients who will not receive intraperitoneal drainage following pancreas resection.
10206652|NCT04131907|Experimental|Pharmacokinetics Optilume Arm|A single arm of 15 non-randomized subjects will be treated in the pharmacokinetics (PK) arm. These subjects will be treated with the Optilume BPH Catheter System
10206653|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method A|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method A
10206654|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method B|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method B
10206655|NCT04123938|Experimental|Pea Protein|Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
10206656|NCT04123938|Active Comparator|Whey Protein|Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
10206657|NCT04123938|Placebo Comparator|Maltodextrin|Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
10206658|NCT04118231|Experimental|Dry needling|
9792297|NCT01441492|Experimental|Drains|Patients who will receive drains, the standard of care treatment, following pancreas resection.
10206659|NCT04118231|No Intervention|Control group|
10206660|NCT04117802|Experimental|Maple|
9792298|NCT01441570|Active Comparator|Nebivolol|
9792299|NCT01441570|Active Comparator|Metoprolol Succinate|
9792300|NCT01441596|Experimental|arm A: Afatinib monotherapy|Afatinib monotherapy: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
9792301|NCT01441596|Experimental|arm B: Afatinib in combination with vino|Afatinib 40 mg per day, continuous treatment, in combination with vinorelbine Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course.
9792302|NCT01441596|Active Comparator|arm C: investigator's choice of treatmen|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
9792303|NCT01441635|Experimental|Cohort 4 Elagolix 400 mg QD|Participants received elagolix 400 mg once a day (QD) for 3 months.
9792304|NCT01441635|Experimental|Cohort 4 Elagolix 100 mg BID|Participants received elagolix 100 mg twice a day (BID) for 3 months.
9792305|NCT01441635|Placebo Comparator|Cohort 4 Placebo|Participants received placebo to elagolix BID for 3 months.
9792306|NCT01441635|Experimental|Cohort 1 Elagolix 200 mg BID|Participants received elagolix 200 mg twice a day for 3 months.
9792307|NCT01441635|Placebo Comparator|Cohort 1 Placebo|Participants received placebo to elagolix twice a day for 3 months.
9792308|NCT01441635|Placebo Comparator|Cohort 3 Elagolix 200 mg BID + LD E2/NETA|Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.
9792309|NCT01441635|Experimental|Cohort 5 Elagolix 600 mg QD|Participants received elagolix 600 mg once a day for 3 months.
9792310|NCT01441635|Experimental|Cohort 2 Elagolix 300 mg BID|Participants received elagolix 300 mg twice a day for 3 months.
9792311|NCT01441635|Experimental|Cohort 2 Placebo|Participants received placebo to elagolix BID for 3 months.
9792312|NCT01441635|Experimental|Cohort 6 Elagolix 300 mg BID + CEP|Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.
9792313|NCT01441765|Active Comparator|CT-011|CT-011 3 mg/kg for 4 cycles of 6 weeks
9792314|NCT01441765|Active Comparator|CT-011 with DC/RCC fusion vaccine|CT-011 with DC/RCC fusion vaccine for subjects undergoing nephrectomy, resection of tumor tissue, or aspiration of malignant effusion
9792315|NCT01441843|Active Comparator|Lorazepam|Lorazepam 4mg/4ml
9792316|NCT01441843|Placebo Comparator|NaCl 0.9%|NaCl 0.9% 4ml
9792317|NCT01441882|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9792318|NCT01441960|Experimental|Succinylcholine first, then Rocuronium|Cross-over randomized controlled, assessor blinded clinical trial.
9792319|NCT01441960|Experimental|Rocuronium first, then succinylcholine|Cross-over randomized controlled, assessor blinded clinical trial.
9792320|NCT01441973|Experimental|Elotuzumab, 20 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1: Days 1 and 8. Cycle 2 and beyond: Day 1 only.
9792321|NCT01441973|Experimental|Elotuzumab, 10 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1 and 2: Days 1, 8, 15, and 22. Cycle 3 and beyond: Days 1 and 15.
9792322|NCT01442038|Experimental|Ranolazine|
9792323|NCT01442038|Placebo Comparator|Placebo|
9792324|NCT01442064|Experimental|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
9792325|NCT01442103|Experimental|Device, dressing|Normlgel Ag is an opaque, amorphous hydrogel containing a high water content, water soluble polymer chains and an antimicrobial silver compound.
9792326|NCT01442129|Experimental|MPC Intramyocardial injection|Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
9792327|NCT01442129|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
9792328|NCT01442155||Capecitabine + Oxaliplatin|Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.
10206661|NCT04117802|Placebo Comparator|Placebo|
9792329|NCT01442181|Active Comparator|Minimally Invasive Surgery|Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
9792330|NCT01442181|Active Comparator|Medical Therapy|Patients are treated with rhythm and rate control medications.
9792331|NCT01442376|Experimental|Palonosetron 10 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
9792332|NCT01442376|Experimental|Palonosetron 20 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
9792333|NCT01442376|Active Comparator|Ondansetron|"Ondansetron and placebo to Palonosetron~Drug:~Comparator: Ondansetron"
9792334|NCT01442493|Experimental|Patient-Centered Methadone Treatment|Patient-Centered Methadone Treatment alters the rules and staff roles in methadone treatment as usual in an attempt to increase treatment retention and improve patient outcomes.
9792335|NCT01442493|Active Comparator|Methadone Treatment as Usual|Methadone treatment provided as usual in the U.S.
9792336|NCT01442675|Experimental|Meningococcal vaccine Group|Participants must have received Menactra vaccine 4 to 6 years prior to enrollment
9792337|NCT01442688|Experimental|Amoxicillin + MMX placebo|
9792338|NCT01442688|Experimental|Amoxicillin + MMX mesalazine/mesalamine|
9792339|NCT01442714|Experimental|Azacitidine plus Lenalidomide|Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.
9792340|NCT01442844|Active Comparator|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
9792341|NCT01442844|No Intervention|No intervention|No intervention will be performed. Subject will receive dressings that are standard of care.
9792342|NCT01443026|Experimental|Lycopene|Lycopene 30 mg/day
9792343|NCT01443026|Placebo Comparator|Placebo|Placebo
9792344|NCT01443078|Experimental|pemetrexed plus cisplatin, vinorelbine and docetaxel|This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
9792345|NCT01443130|Experimental|Chloroquine IPT|300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
9792346|NCT01443130|Experimental|Chloroquine Prophylaxis|300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.
9792347|NCT01443130|Active Comparator|SP IPT|300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
9792348|NCT01443364|Experimental|Certolizumab pegol|
9792349|NCT01443403|Placebo Comparator|Placebo|Participants received placebo orally once daily for 28 days.
9792350|NCT01443403|Experimental|Naldemedine 0.1 mg|Participants received 0.1 mg naldemedine orally once daily for 28 days.
9792351|NCT01443403|Experimental|Naldemedine 0.2 mg|Participants received 0.2 mg naldemedine orally once daily for 28 days.
9792352|NCT01443403|Experimental|Naldemedine 0.4 mg|Participants received 0.4 mg naldemedine orally once daily for 28 days.
9792353|NCT01443442|Active Comparator|Bepreve|1.5% bepotastine besilate, drops, twice per day, for two weeks
9792354|NCT01443442|Active Comparator|Alrex|treatment with 0.2 % loteprednol etabonate, drops, four times per day
9792355|NCT01443494|Experimental|NE group|Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
9792356|NCT01443546|Active Comparator|hCG|standard dose of hCG for ovulation trigger
9792357|NCT01443546|Active Comparator|Lupron Trigger|Leuprolide acetate 2 mg ovulation trigger
9792358|NCT01443546|Experimental|Dual Trigger|Lupron and hCG combined ovulation trigger
9792359|NCT01443845|Experimental|1|Roflumilast
9792360|NCT01443845|Placebo Comparator|2|Placebo
9792361|NCT01443858|Active Comparator|Placebo + Nicotine Patch|Subjects in this group will take placebo meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Placebo meclizine will be administered in two doses each day.
9792362|NCT01443858|Experimental|25mg Meclizine + Nicotine Patch|Subjects in this group will take 25mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
9792363|NCT01443858|Experimental|50mg Meclizine + Nicotine Patch|Subjects in this group will take 50mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
9792364|NCT01444027|No Intervention|Attention Control|"This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group."
9792365|NCT01444027|Experimental|Intervention Group 1 (Face to Face)|This group receives Problem Solving Therapy in face to face visits.
9792366|NCT01444027|Experimental|Intervention Group 2 (Video)|This group receives Problem Solving Therapy via video.
9792367|NCT01444287|Placebo Comparator|Spectacles No Lenses|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
9792368|NCT01444287|Experimental|narafilcon B|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
9792369|NCT01444287|Active Comparator|polymacon|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
9792370|NCT01444287|Active Comparator|lotrafilcon A|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
9792371|NCT01444300|Experimental|Dalfampridine|
9792372|NCT01444300|Placebo Comparator|Placebo|
10206662|NCT04111627|Experimental|Aerobic exercise plus Duloxetine|Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.
10206663|NCT04111094||HF|Diagnosed heart failure as described by recent guidelines. Inclusion criteria will be applied: i) minimum one symptom typical of HF: positive physical examination (e.g., bilateral oedema, increased jugular pressure) or positive clinical history (e.g., orthopnoea, history of coronary vascular disease, history of arterial hypertension, exposition to cardiotoxic drug/radiation, diuretic use); b-type natriuretic peptide (BNP) or N-terminal pro-BNP levels ≥35 or ≥125 pg/ml, respectively; and iii) classification as New York Heart Association (NYHA) functional class 2 or 3. There is no prespecified inclusion criterion with respect to left ventricular ejection fraction as congestive symptoms and prevalence of kidney dysfunction are comparable in patients with HF across the left ventricular ejection fraction spectrum.
10206664|NCT04111094||Diabetes|Diagnosed diabetes mellitus, with/without treatment
10206665|NCT04111094||Hypertension|Diagnosed hypertension, with/without treatment
9792373|NCT01444378|Experimental|Absolute Pro® and Pro LL® Peripheral Stent Systems|
9792374|NCT01444391|Experimental|Tympanostomy Tube Placement|
9792375|NCT01444417|Experimental|Romiplostim|Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
9792376|NCT01444417|Placebo Comparator|Placebo|Participants received weekly subcutaneous placebo for 24 weeks.
9792377|NCT01444430|Experimental|1|Symbicort
9792378|NCT01444430|Active Comparator|2|budesonide
9792379|NCT01444456||Cohort 1: Darbepoetin alfa|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) to treat symptomatic anemia according to routine institutional practice.
9792380|NCT01444456||Cohort 2: Any ESA|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) or another erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia according to routine institutional practice.
9792381|NCT01444651|Active Comparator|Tadalafil|20 mg Tadalafil tablet taken by mouth once a day for 3 months
9792382|NCT01444651|Placebo Comparator|Placebo|Placebo tablet taken by mouth once a day for 3 months
9792383|NCT01444716|Experimental|Treatment (ofatumumab)|Participants receive ofatumumab IV over 4 hours once a week for 4 weeks, then monthly thereafter. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
9792384|NCT01444742|Experimental|Clofarabine + Cytarabine|"Induction:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)"
9792385|NCT01444781|Experimental|Study Group 1|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of DTaP-IPV-Hep B-PRP~T vaccine + one dose of Prevenar™
9792386|NCT01444781|Active Comparator|Study Group 2|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
9792387|NCT01444781|Experimental|Study Group 3|Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP~T + one dose of Prevenar™.
9792388|NCT01444898|Experimental|Exenatide|All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
9792389|NCT01444911|Experimental|Vaginal Renewal Program|
9792390|NCT01444911|Active Comparator|Standard of care|This will consist of still vaginal dilator and/or lubricant.
9792391|NCT01444924|Experimental|Bupivicaine|TAP block with bupivicaine/epinephrine placed prior to surgery.
9792392|NCT01444924|Placebo Comparator|Placebo|TAP block with placebo placed prior to surgery
9792393|NCT01445028|Experimental|Primary, high-risk retinal detachment|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
9792394|NCT01445028|Experimental|Recurrent RD associated with PVR|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
9792395|NCT01445080|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9792396|NCT01445171|Other|Study Valve|Subjects act as own control
10206666|NCT04109690|Experimental|CPX-351|Phase I will evaluate the safety and tolerability of CPX-351 (44mg/m2 of daunorubicin and 100mg/m2 of cytarabine) administered on 2 days (day 1 and day 5) to determine the Phase II dose. Phase II will evaluate the efficacy of the RP2D.
10206667|NCT04103567|Experimental|Biological collection|"Fecal samples collected at different times : During inclusion consultation with surgeon, after neoadjuvant treatment and before surgery,~In parallel to this fecal collection, standardized clinical data will be entered into a database"
10206668|NCT04102111|Experimental|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily for 12 weeks.
10206669|NCT04102111|Placebo Comparator|Placebo|Participants will receive oral tablets of matching placebo twice daily for 12 weeks.
10206670|NCT04099264|Experimental|Intervention group: Personalized music|This arm will receive an intervention which will be personalized music. It will be provided by Music Care application (https://www.music-care.com/fr).
9841091|NCT02777554|Experimental|Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD|Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.
9841092|NCT02777554|Experimental|Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID|Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.
9841093|NCT02777554|Experimental|Part 2: Sequence 1|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal."
9841094|NCT02777554|Experimental|Part 2: Sequence 2|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal."
9841095|NCT02777554|Experimental|Part 2: Sequence 3|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions."
9841096|NCT02777554|Experimental|Part 2: Sequence 4|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions."
9841097|NCT02777749|Active Comparator|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~Adductor Canal Block (ACB)"
9841098|NCT02777749|Active Comparator|Periarticular SB|50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
9841099|NCT02777749|Active Comparator|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
9841100|NCT02777827|Experimental|Abediterol dry powder inhaler 0.156 μg|Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)
9841101|NCT02777827|Experimental|Abediterol dry powder inhaler 2.5 μg|Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).
9841102|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.05μg|Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).
9841103|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.156 μg|Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).
9841104|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 2.5μg|Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).
9841105|NCT02777827|Placebo Comparator|Placebo|Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).
9841106|NCT02777918|Experimental|Intervention|6 recipes will be sent by post every 2 weeks for a 12 week period. Dietary recommendations will also be provided at the start of the intervention period to increase the relevance of the recipes.
9841107|NCT02777918|No Intervention|Control|Dietary recommendations will be provided at the start of the study period, such that the intervention regards the recipes, not the recommendations
9841108|NCT02777931|Experimental|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
9841109|NCT02777931|Placebo Comparator|Placebo|Matching placebo capsules.
10206671|NCT04099264|Active Comparator|Control: Audio Books|Control will consist of audio books.
10206672|NCT04090203|Experimental|Boiled Peanut Powder|Boiled Peanut Powder
10206673|NCT04087395|Experimental|RHA®4 with new anesthetic agent|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
10206674|NCT04087395|Experimental|RHA®4-Lidocaine|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
10206675|NCT04085887|Experimental|Cohort 1-0.006 Panitumumab-IRDye800|Dose: 0.006 Panitumumab-IRDye800 (mg/kg)
10206676|NCT04085887|Experimental|Cohort 2-0.25 Panitumumab-IRDye800|Dose: 0.25 Panitumumab-IRDye800 (mg/kg)
10206677|NCT04085887|Experimental|Cohort 3-0.50 Panitumumab-IRDye800|Dose: 0.50 Panitumumab-IRDye800 (mg/kg)
10206678|NCT04085887|Experimental|Cohort 4-1.0 Panitumumab-IRDye800|Dose: 1.0 (with max cap dose 50 mg) Panitumumab-IRDye800 (mg/kg)
10206679|NCT04082429|Experimental|Arm 1: No prophylaxis|Haemophilia A (HA) and haemophilia B (HB) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension phase, this group will receive treatment with concizumab.
10206680|NCT04082429|Experimental|Arm 2: Concizumab prophylaxis|HA and HB patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
10206681|NCT04082429|Experimental|Arm 3: Concizumab prophylaxis|The HA patients enrolled into the concizumab phase 2 trial NN7415-4255 (explorer 5) will be offered enrolment into this arm.
10214076|NCT01415674|Experimental|Arm A: Afatinib 40mg per os daily|Patients randomized to the arm A will take a single oral dose of Afatinib from Day 1, for 14 to 28 days, depending on the date of surgery. The number of dosing days will be chosen so that patients are off treatment for a maximum of 7 days before surgery.
10214077|NCT01415674|No Intervention|Arm B : No pre operative treatment|
10206682|NCT04082429|Experimental|Arm 4: Concizumab prophylaxis|"Arm 4 will include patients previously on prophylaxis with factor products with a minimum of 24 weeks observation in NN7415-4322 (explorer 6) (at least 30 HA and 30 HB patients).~In addition, arm 4 will also include: 1) Patients who were randomised to arms 1 and 2 before the treatment pause. 2) HA patients who were in NN7415-4255 (explorer 5) at the time of the treatment pause, and who have now completed explorer 5. 3) On demand patients included after arms 1 and 2 are closed."
10206683|NCT04074785|Experimental|Safety Run-In|Abemaciclib 150 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
9841110|NCT02777944|Experimental|Intervention|Access to Motivate: a web-based intervention, in addition to Usual Care
9841111|NCT02777944|No Intervention|Control|Usual Care
9841112|NCT02777970|Experimental|Tramadol/Dexketoprofen|"Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;~Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose."
9841113|NCT02777970|Active Comparator|Tramadol/Paracetamol|"Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;~Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.~."
9841114|NCT02777970|Placebo Comparator|Placebo|"Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;~Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose."
9841115|NCT02778074|Experimental|Internet Cognitive Behavioural Therapy|Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
9841116|NCT02778074|Placebo Comparator|Moderated discussion forum|In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.
9841117|NCT02778100|Experimental|Nasal Glucagon (NG) - Common Cold|Cohort 1 - Nasal Glucagon (NG) administered once in participants with a common cold.
9841118|NCT02778100|Experimental|Nasal Glucagon (NG) - Symptom-Free|Cohort 1 - NG administered once in participants who have recovered from a common cold.
9841119|NCT02778100|Experimental|NG - Common Cold+Oxymetazoline|Cohort 2 - NG administered once in participants with a common cold who are taking oxymetazoline.
9841120|NCT02778113|Experimental|Nasal Glucagon (NG) - 0.5 mg|Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
9841121|NCT02778113|Experimental|NG - 1.0 mg|Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
9841122|NCT02778113|Experimental|NG - 2.0 mg|Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
9841123|NCT02778113|Active Comparator|SC Glucagon 1 mg|Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
9841124|NCT02778152|Experimental|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
9841125|NCT02778555||Sample 1|In Sample 1 (N=186), our 14-item Daily PCS was administered daily for 14 days to replicate the 3-factor structure at the daily level, and to select the ideal 5 items for a brief Daily PCS.
9841126|NCT02778555||Sample 2|In Sample 2 (N=209), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14.
9841127|NCT02778555||Sample 3|In Sample 3 (N=318), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14. In addition, assessments of pain, mood, activity, sleep, energy level, and positive affect were administered daily for the 14-day period.
9841128|NCT02778867|Active Comparator|1-Food Elimination Diet (1FED)|Participants eliminate milk from the diet in Phase 1
9841129|NCT02778867|Active Comparator|6-Food Elimination Diet (6FED)|Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1
9841130|NCT02778867|Other|1FED Non-Responders (6FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2
9841131|NCT02778867|Other|6FED Non-responders (SGC)|Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2
9841132|NCT02778880|Experimental|Ketamine|Ketamine 1.5 mg/kg intranasally for one dose
9841133|NCT02778880|Active Comparator|Fentanyl|Fentanyl 2 mcg/kg intranasally for one dose
9841134|NCT02778932||Intubation|General anesthesia including intubation and muscle relaxation
9841135|NCT02778932||Laryngeal Mask|General anesthesia including laryngeal mask without muscle relaxation
9841136|NCT02779075|Placebo Comparator|Saline|0.9% NaCL (saline) intravenously for 6 hours.
9841137|NCT02779075|Active Comparator|Exendin-9,39|Exendin-9,39 intravenously for 6 hours.
9841138|NCT02779166|Experimental|Intervention|Received 400mg celecoxib prior to surgery
9841139|NCT02779166|Placebo Comparator|Placebo|Received placebo pill prior to surgery
9841140|NCT02779491|Experimental|Intervention for two weeks|Receipt of the mobile phone application for two weeks
9841141|NCT02779491|No Intervention|Control for two weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
9841142|NCT02779491|Experimental|Intervention for four weeks|Receipt of the mobile phone application for four weeks
9841143|NCT02779491|No Intervention|Control for four weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
9986278|NCT01401127||Participants without diabetes|Participants without diabetes or evidence of impaired glucose regulation
9986279|NCT01401140|Active Comparator|St Thomas|
10206684|NCT04074785|Experimental|Abemaciclib with Bevacizumab|Abemaciclib 100 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
10206685|NCT04073862|Other|Stepped-Care TF-CBT|The study participants will receive Stepped-Care Trauma-Focused Cognitive-Behavioral-Therapy (SC-TF-CBT).
9841144|NCT02779543|Active Comparator|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
9841145|NCT02779543|Active Comparator|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
9841146|NCT02779543|Active Comparator|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
9841147|NCT02780115|Experimental|Cohort 1: Vehicle Control|Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
9841148|NCT02780115|Experimental|Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A|Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
9841149|NCT02780115|Experimental|Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B|Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
9841150|NCT02780115|Experimental|Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C|Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
9841151|NCT02780115|Experimental|Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C|Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.
9841152|NCT02780167|Experimental|Cohort 1|10 mg of PF-04965842 QD
9841153|NCT02780167|Experimental|Cohort 2|30 mg of PF-04965842 QD
9841154|NCT02780167|Experimental|Cohort 3|100 mg of PF-04965842 QD
9841155|NCT02780167|Experimental|Cohort 4|200 mg of PF-04965842 QD
9841156|NCT02780167|Placebo Comparator|Cohort 5|placebo QD
9841157|NCT02780349|Experimental|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
9841158|NCT02780388|Placebo Comparator|Placebo|Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
9841159|NCT02780388|Experimental|VIB4920 75 mg|Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
9841160|NCT02780388|Experimental|VIB4920 500 mg|Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
9841161|NCT02780388|Experimental|VIB4920 1000 mg|Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
9841162|NCT02780388|Experimental|VIB4920 1500 mg|Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.
9841163|NCT02780622|Experimental|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
9841164|NCT02780622|Experimental|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
9841165|NCT02780661|Experimental|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre [ml]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
9922053|NCT00834600|Experimental|HCTZ , ARB|Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
9986280|NCT01401140|Experimental|Custodiol|
9986281|NCT01401179|Active Comparator|cefazolin|
9841166|NCT02780661|Experimental|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
9841167|NCT02780687|Experimental|Afatinib|
9841168|NCT02780700|Experimental|Nintedanib|
9841169|NCT02780700|Experimental|Nintedanib plus capecitabine|
9841170|NCT02780713|Experimental|AZD9496|"This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.~Treatment period 1 will assess AZD9496 Variant A: 100mg.~Treatment period 2 will assess AZD9496 Reference: 100mg.~Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5"
9841171|NCT02780765|Experimental|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
9841172|NCT02780765|Active Comparator|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
9841173|NCT02780856|Other|Sound and unsound teeth|Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System
9841174|NCT02780869|Experimental|Investigational|HEMOBLAST Bellows
9841175|NCT02780869|Active Comparator|Control|Absorbable gelatin sponge, USP with thrombin
9841176|NCT02781051|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
9841177|NCT02781311|Experimental|Setipiprant|Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
9841178|NCT02781311|Placebo Comparator|Placebo|Two placebo tablets BID at 12-hour intervals for 24 weeks.
9841179|NCT02781311|Active Comparator|Finasteride|Finasteride 1 mg tablet, orally, once daily for 24 weeks.
9841180|NCT02781324|Experimental|Ultrasonic Bone Scalpel Group|Surgeons will use the ultrasonic bone scalpel, to their discretion, along with standard of care manual devices when performing the posterior spinal fusion.
9841181|NCT02781324|Active Comparator|Standard of Care Group|Surgeons will use, to their discretion, only standard of care manual devices when performing the posterior spinal fusion.
9841182|NCT02781454|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 4 weeks.
9841183|NCT02781454|Active Comparator|Mexiletine, 600 milligrams|Mexiletine, 600 milligrams by mouth per day for 4 weeks.
9841184|NCT02781454|Placebo Comparator|Placebo|Placebo, by mouth per day for 4 weeks.
9841185|NCT02781480|Experimental|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
9841186|NCT02781480|Experimental|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
9841187|NCT02781480|Experimental|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
9841188|NCT02781558|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
9841189|NCT02781558|Experimental|SOF/VEL + RBV|SOF/VEL FDC + RBV for 12 weeks
9841190|NCT02781571|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
9841191|NCT02781610|Other|ERR-10|ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
9841192|NCT02781610|Other|ERR-14|ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
9841193|NCT02781610|Other|NERR-14|NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
9841194|NCT02781610|Other|NERR-21|NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
9841195|NCT02781649|Experimental|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
9841196|NCT02781649|Experimental|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
9841197|NCT02781649|Experimental|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
9841198|NCT02781818|Experimental|Triamcinolone Acetonide 10mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 10mg/mL solution.
9986282|NCT01401179|Active Comparator|cefazolin plus erythromycin|cefazolin, erythromycin
9841199|NCT02781818|Experimental|Triamcinolone Acetonide 40mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 40mg/mL solution.
9841200|NCT02781818|Placebo Comparator|Normal Saline Placebo|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of sterile normal saline solution.
9841201|NCT02781844|Experimental|A/B or B/A|Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2
9841202|NCT02781844|Experimental|C/B or B/C|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2
9841203|NCT02781844|Experimental|D/E or E/D|Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2
9841204|NCT02781844|Experimental|F/E or E/F|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2
9841205|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
9841206|NCT02782169|Active Comparator|Pregabalin|
9841207|NCT02782169|Placebo Comparator|Placebo|
9841208|NCT02782325|Active Comparator|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
9841209|NCT02782325|Placebo Comparator|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
10206686|NCT04072432|Experimental|Cohort 1|120 mg, single IV infusion in healthy volunteers and subjects CKD Stage 3-4
10206687|NCT04072432|Experimental|Cohort 2|240 mg, single IV infusion in healthy volunteers and subjects CKD Stage 3-4
10206688|NCT04072432|Experimental|Cohort 3|360 mg, single IV infusion in healthy volunteers and subjects CKD Stage 3-4
10206689|NCT04069585|Experimental|RHA® Redensity with new anesthetic agent|"Split-face injection of RHA® Redensity with new anesthetic agent in the perioral rhytids on one side of the mouth and RHA® Redensity with lidocaine in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
10206690|NCT04069585|Experimental|RHA® Redensity with lidocaine|"Split-face injection of RHA® Redensity with lidocaine in the perioral rhytids on one side of the mouth and RHA® Redensity with new anesthetic agent in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
9841210|NCT02782364||Faecal Incontinence: fast-fill measurement first|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will undergo fast-fill measurement first.
9841211|NCT02782364||Faecal Incontinence: step-wise measurement first.|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will have step-wise measurement first.
10206691|NCT04067713||PARADIGM-D|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Docetaxel with androgen deprivation therapy (ADT).
9841212|NCT02782377||Pelvic Floor Dysfunction|"Observational study where patients with pelvic floor dysfunction undergo three AAR measurements. One at baseline, one with the catheter alongside and a third with the rectal balloon inflated. No intervention is performed~Note, that initial inclusion of Squeeze parameters was detailed in error, these were not compared in this study and were compared in previous study"
9986283|NCT01401179|Active Comparator|cefazolin plus clarithromycin|
10206692|NCT04067713||PARADIGM- A|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Androgen Receptor Signalling Inhibitor (ARSI) drugs with androgen deprivation therapy (ADT).
10206693|NCT04063215|Experimental|HB-adMSC|HB-adMSCs will be infused three times over a six week period, spaced 14 days apart
10206694|NCT04062058|Experimental|Total Neoadjuvant Chemoradiotherapy|Total neoadjuvant chemoradiotherapy arm receives intensity-modulated neoadjuvant chemoradiotherapy (45Gy in 25 fractions) concurrently with oral S-1(40-60mg/m2, orally twice daily every weekday) followed by six cycles of SOX neoadjuvant chemotherapy and surgery
10206695|NCT04055753||Doxorubicin|
10206696|NCT04055753||Doxil|
10206697|NCT04055454|Experimental|MV-LASV low dose: treatment group A|In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.
10206698|NCT04055454|Experimental|MV-LASV high dose: treatment group B|In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.
10206699|NCT04055454|Placebo Comparator|Placebo: treatment group C|In total 12 participants will receive placebo treatment on day 0 and 28.
10206700|NCT04053452|Experimental|GBS Patients|
10206701|NCT04053452|Active Comparator|Controls|
9841213|NCT02782676|Experimental|Investigational Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
9841214|NCT02782676|Active Comparator|Approved Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
9841215|NCT02782741|Experimental|avalglucosidase alfa (GZ402666)|Administered intravenously every 2 weeks
9841216|NCT02782741|Active Comparator|alglucosidase alfa (GZ419829)|Administered intravenously every 2 weeks
9841217|NCT02782780|Experimental|CBTi|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep as well as to work with the patient toward altering sleep habits to increase sleep propensity and regularity. Specifically, participants will receive 8 weekly individual sessions of CBTi according to the VA CBTi protocol. The investigators will follow the semi-structured approach to treatment described in the VA CBTi protocol, which allows the case conceptualization to drive the order in which treatment components are introduced.
9841218|NCT02782780|No Intervention|Monitor Only|Study participants who are randomized to the Monitor Only (MO) control group will be followed for 8 weeks of usual care (i.e., they will be advised to continue doing whatever they were doing to manage their GWI and insomnia symptoms without change dosage or frequency of treatment). Participants randomized to the Monitor Only condition will have the option of receiving CBTi delivered by telephone, at no cost to them, upon completion of post-study procedures.
9841219|NCT02782923|Experimental|s-ACDFwith STISIM|Single-level anterior cervical discectomy fusion
9841220|NCT02782923|Experimental|m-ACDF with STISIM|Multi-level anterior cervical discectomy and fusion
9841221|NCT02782923|Experimental|CDR with STISIM|Cervical disc replacement
9841222|NCT02782923|Experimental|PCLF with STISIM|Posterior laminectomy and fusion
9841223|NCT02782923|Experimental|PCD with STISIM|Posterior cervical decompression procedure
9841224|NCT02782923|Sham Comparator|Control Group with STISIM|
9841225|NCT02783027|Experimental|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
9841226|NCT02783027|No Intervention|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
9841227|NCT02783066|Experimental|"PulseFlow group"|Eligible subjects will try a new offloading boot for 4 weeks
9841228|NCT02783170|Other|Simultaneous vaccination arm|In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
9841229|NCT02783170|Other|Sequential vaccination arm|In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
9841230|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
9841231|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
9841232|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
9841233|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
9841234|NCT02783573|Experimental|Lanabecestat 20 milligrams (mg)|Participants received Lanabecestat 20 mg film-coated tablets orally once daily until week 156.
9841235|NCT02783573|Experimental|Lanabecestat 50 mg|Participants received Lanabecestat 50 mg film-coated tablets orally once daily until week 156.
9841236|NCT02783573|Experimental|Placebo/ Lanabecestat 20 mg|Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156.
9841237|NCT02783573|Experimental|Placebo/ Lanabecestat 50 mg|Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156.
9841238|NCT02783599|Experimental|Olaratumab + Doxorubicin|"Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle).~Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle).~Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles)."
9841239|NCT02783599|Experimental|Olaratumab + Radiotherapy Addendum|"Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy.~Radiotherapy addendum was not implemented."
9841240|NCT02783729|Experimental|Lemborexant 5 milligrams (mg)|Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night
9516885|NCT03311321|Placebo Comparator|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
9516886|NCT03311321|Experimental|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
9516887|NCT03311295|Experimental|ARTO System|
9841241|NCT02783729|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night
9841242|NCT02783729|Active Comparator|Zolpidem tartrate|Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night
9841243|NCT02783729|Placebo Comparator|Placebo|Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night
9841244|NCT02783768|Experimental|E-cigarette first|Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
9841245|NCT02783768|Experimental|Sham first|Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
9841246|NCT02783820|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
10206702|NCT04053335||Cohort 1: Multicomponent Physician Performance Peer-Comparison|Cohort 1 (2 groups): Runs July 2019 - December 2020 - Inova/Signature Parters and Sentara/Sentara Quality Care Network
10206703|NCT04053335||Cohort 2: Multicomponent Physician Performance Peer-Comparison|Cohort 2 (2 groups): Runs November 2019 - April 2021 - Ballad Health and Carilion Clinic
9841247|NCT02783820|Placebo Comparator|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
9841248|NCT02783820|Experimental|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
9841249|NCT02783820|Placebo Comparator|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
9841250|NCT02783820|Experimental|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
9841251|NCT02783820|Placebo Comparator|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
9841252|NCT02783898|Experimental|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
9841253|NCT02783898|No Intervention|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
9841254|NCT02783911|Experimental|Mineral Trioxide Aggregate|Subject with pulpotomy treated with MTA MTA paste (< 1gm) will be placed on pulp orifice once for the life of the primary teeth
9841255|NCT02783911|Experimental|Ferric Sulfate|Subject with pulpotomy treated with FS FS paste (<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth
9841256|NCT02783950|Other|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
9841257|NCT02783950|No Intervention|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
9841258|NCT02784106|Placebo Comparator|Placebo: Double-Blind Treatment Period|
9841259|NCT02784106|Experimental|M2951: Double-Blind Treatment Period|
9841260|NCT02784106|Experimental|Placebo/M2951: Open Label Extension Period|
9841261|NCT02784106|Experimental|M2951/M2951: Open Label Extension Period|
9841262|NCT02784275|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
9841263|NCT02784275|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
9841264|NCT02784275|Experimental|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
9841265|NCT02784275|Placebo Comparator|Dose D|Placebo
9841266|NCT02784431|Experimental|Contour Neurovascular System placement|Treatment of intracranial aneurysm with the Contour Neurovascular System device.
9841267|NCT02784444|Active Comparator|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
9841268|NCT02784444|Active Comparator|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
9841269|NCT02784444|Active Comparator|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
10206704|NCT04053335||Cohort 3: Multicomponent Physician Performance Peer-Comparison|Cohort 3 (2 groups): Runs March 2020 - August 2021 - Health Care Associates Virginia/Virginia Care Partners and Virginia and Commonwealth University Health System
10206705|NCT04047433|Experimental|women with external anal sphincter injury|The study cohort will be composed of women undergoing vaginal delivery and diagnosed with external anal sphincter injury after a vaginal delivery.
10206706|NCT04047433|Experimental|women without external anal sphincter injury|The control group will be women who had a vaginal delivery without any clinically apparent perineal laceration
10206707|NCT04040751|Experimental|CARE-CITE Carepartner|This study arm consists of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
10206708|NCT04040751|Active Comparator|Control Carepartners|"Carepartners (CP) receiving customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The CP will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
10214078|NCT01408615||All Enrolled Participants|Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program.
9841270|NCT02784444|Placebo Comparator|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
9841271|NCT02784548|Experimental|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
9841272|NCT02784587|Experimental|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
9841273|NCT02784613|Experimental|Ospemifene open label|60 mg ospemifene daily for 20 weeks
9841274|NCT02784834|Experimental|Dimethyl fumarate (DMF)|"Cohort 1: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 2 x 28 day cycles.~Cohort 2: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 1 week, then escalating to the assigned dose of (240mg PO BID for the remainder of 2 x 28 day cycles.~Cohort 3: dimethyl fumarate 120 mg PO BID for 1 week, then escalate to the dose of 360mg PO BID for the remainder of 2 x 28 day cycles."
9841275|NCT02784925|Other|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
9841276|NCT02785159|Experimental|IDP-118 Lotion|Lotion
9841277|NCT02785159|Active Comparator|Tazorac Cream|Cream
9841278|NCT02785159|Active Comparator|IDP 118 Vehicle Lotion|Lotion
9841279|NCT02785159|Active Comparator|IDP-118 Vehicle Cream|Cream
9841280|NCT02785172|Experimental|IDP-118 Lotion|Lotion
9841281|NCT02785172|Active Comparator|Ultravate Cream|Cream
9841282|NCT02785172|Active Comparator|IDP-118 Vehicle Lotion|Lotion
9841283|NCT02785172|Active Comparator|IDP-118 Vehicle Cream|Cream
9841284|NCT02785185|Experimental|IDP-122 Lotion|Lotion
9841285|NCT02785185|Active Comparator|Ultravate Cream|Cream
9841286|NCT02785185|Active Comparator|IDP-122 Vehicle Lotion|Lotion
9841287|NCT02785185|Active Comparator|IDP-122 Vehicle Cream|Cream
9841288|NCT02785354||NOAC|New oral anticoagulant groups
9841289|NCT02785354||VKA|VKA group
9841290|NCT02785406|Experimental|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
9841291|NCT02785406|Placebo Comparator|Placebo|Subjects will receive placebo once daily at 10 PM.
9922054|NCT00834600|Active Comparator|Conventional antihypertensive therapy|All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
9922055|NCT00834665|Experimental|hTERT/GM-CSF+PCV, T cell infusion|ARM A = hTERT/GM-CSF+PCV, T cell infusion
9922056|NCT00834665|Experimental|GM-CSF+PCV, T cell infusion,GM-CSF+PVC|ARM B GM-CSF+PCV, T cell infusion,GM-CSF+PVC
10206709|NCT04040751|Experimental|CARE-CITE Stroke Survivor|This study arm consists of stroke survivors of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
10206710|NCT04040751|Active Comparator|Control Stroke Survivors|"Stroke survivors (SS) receiving customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The CP will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
10206711|NCT04038333||Children|Interviewees are parents or grandparents of children aged between 6 to 59 months.
10206712|NCT04038333||Elderly|Interviewees are the elderly aged 60 years old or above.
10206713|NCT04038333||Chronic disease patients|Interviewees are adult patients with chronic diseases aged below 60 years old.
10206714|NCT04038333||Vaccination and health care personnel|Interviewees are vaccination and health care personnel in each study site.
10206715|NCT04029012|Experimental|Penthrox|methoxyflurane inhaler (Penthrox) to be used 5 minutes (+/- 1 minutes) before procedure, and continuously breathing in the inhaler throughout the procedure.
10206716|NCT04026711|Active Comparator|MitoQ|MitoQ 40 mg per day for 12 weeks
10206717|NCT04026711|Placebo Comparator|Placebo|placebo daily for 12 weeks
10206718|NCT04024917|Experimental|Coherence cardiac|
10206719|NCT04024917|Active Comparator|Standard care|
10206720|NCT04023240|Experimental|68Ga-FAPI PET/CT|Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
10206721|NCT04021537|Experimental|non-invasive nerve stimulation a|Electrical stimulation will be delivered to a location at the ear.
10206722|NCT04021537|Active Comparator|non-invasive nerve stimulation b|Electrical stimulation will be delivered to a location at the ear.
10206723|NCT04017819|Active Comparator|Healthy volunteers (Group 1)|Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
10206724|NCT04017819|Experimental|Patients with newly diagnosed lung cancer (Group 2)|Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
10206725|NCT04017819|Experimental|Patients with lung cancer undergoing non-surgical tx (Group 3)|Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of [18F]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart, each of which will be followed by undergoing a [18F]-C-SNAT4 PET/CT scan)
10214079|NCT01371630|Experimental|Treatment (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description
9841292|NCT02785432|Sham Comparator|Sham low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 0 watts for a total of 0 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint. The contact head applicator will be used if soft tissue contact is tolerable. Otherwise, the non-contact head will be utilized.
9841293|NCT02785432|Active Comparator|Active low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. This equates to standard acceptable dosing of 6-10 j/cm2 over the larger area of treatment. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Areas for administration and contact will otherwise be consistent with the sham group.
9841294|NCT02785458|No Intervention|Usual Care|Subjects will receive the current standard of care.
9841295|NCT02785458|Experimental|EMC2 Strategy|Subjects will receive the EMC2 Strategy. See description of strategy below.
9841296|NCT02785588|Other|3.0 T Neonatal MRI scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
9841297|NCT02785770|Experimental|PF-04447943 low dose|25 mg of PF-04447943
9841298|NCT02785770|Experimental|PF-04447943 high dose|100 mg of PF-04447943
9841299|NCT02785770|Placebo Comparator|Placebo|Matching placebo for PF-04447943
9841300|NCT02785770|Active Comparator|Moxifloxacin|400 mg of moxifloxacin
9841301|NCT02785900|Experimental|33A + HMA|33A plus azacitidine or decitabine
9841302|NCT02785900|Active Comparator|placebo + HMA|placebo plus azacitidine or decitabine
9841303|NCT02785913|Experimental|Arm I (GDC-0032)|Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9841304|NCT02785939|Experimental|Arm I - Palbociclib|"Participants receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
9841305|NCT02785939|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~Closed to accrual 12/18/2015"
9841306|NCT02785939|Experimental|Arm III - Palbociclib re-reg|"Participants in Arm II eligible for re-registration receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
9841307|NCT02786004|Experimental|Full Field Digital Mammography|2-dimensional breast imaging
9841308|NCT02786004|Experimental|Digital Breast Tomosynthesis|3-dimensional breast imaging
9841309|NCT02786134|Experimental|low-dose methotrexate (LDM)|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
9841310|NCT02786134|Experimental|placebo|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
9841311|NCT02786355|Other|Maximum bimanual compression|Squeeze through Frova bougie with maximum bimanual compression
9841312|NCT02786355|Other|Normal bimanual compression|Squeeze through Frova bougie with normal bimanual compression
9516888|NCT03311282|Experimental|Feeding Bottle 0m+|10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.
9841313|NCT02786719|Experimental|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
9841314|NCT02786771|Experimental|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
9841315|NCT02786771|Experimental|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
9841316|NCT02786810|Other|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
9922057|NCT00834691||1|Patients with anemia and systolic heart failure
10206726|NCT04017520||Mother-infant dyads|"200 mother-infant dyads enrolled at delivery and followed longitudinally at regularly scheduled well child checks (4, 16, 24, and 48- weeks) at a primary care outpatient pediatric clinic affiliated with an academic medical center. Eligible mothers will be those who plan to breast feed for 16 weeks and infants born at term (37-42 weeks). The cohort will be divided post-hoc into atopic and non-atopic groups based on the primary outcome measure (described below).~No intervention will be administered."
10206727|NCT04014842|Other|RapidShock|
9792397|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) once daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
9792398|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
9792399|NCT01445301|Active Comparator|CLDM 1% gel twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
9792400|NCT01445535|Experimental|siplizumab + EPOCH (combo chemo) + rituximab|siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
9792401|NCT01445548|Experimental|Sirolimus|"Participants initially received a 20 μL (440 μg) intravitreal injection sirolimus in the study eye at baseline and every two months thereafter unless contraindicated.~As of September 2012, sirolimus intravitreal injections were no longer administered to participants."
9792402|NCT01445613|Other|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
9792403|NCT01445626||All participants|Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.
9792404|NCT01445652|Experimental|nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily disposable basis a minimum of five days per week, eight hours per day, for six months
9792405|NCT01445652|Active Comparator|Spectacles|Spectacles per current prescription worn a minimum of five days per week, eight hours per day, for six months
9792406|NCT01445678|Experimental|CXA-201 and Metronidazole as treatment for cIAI|
9792407|NCT01445678|Active Comparator|Meropenem as treatment for cIAI|
9792408|NCT01445730|Experimental|After fructose feeding|After 3 month fructose diet 75 g/day
9792409|NCT01445769|Experimental|Ruxolitinib|Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.
9792410|NCT01445821|Active Comparator|Cyclophosphamide rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. Peripheral blood stem cells (PBSC) will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
9792411|NCT01445821|Experimental|Cyclophosphamide rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 mg/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
9792412|NCT01445847|Active Comparator|Lidocaine|Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
9792413|NCT01445847|Placebo Comparator|Placebo|Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.
9792414|NCT01445873||PAH patients receiving Sitaxentan|
9792415|NCT01445886|Experimental|Indigo Naturalis Extract in Oil|A 5-ml eye drop bottles contain indigo naturalis powder mixed with olive oil, and the concentration was 200 ug indirubin per ml. Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
9792416|NCT01445886|Active Comparator|Calcipotriol solution|Calcipotriol solution (Daivonex® scalp solution, calcipotriol 50 ug/ml) was purchased from LEO Pharmaceutical Products, Ltd. (Ballerupt, Denmark) and also distributed into 5-ml eye drop bottles for this trial.Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
9792417|NCT01445951|Experimental|Technosphere® Insulin with MedTone C Inhaler|Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
9922058|NCT00834691||2|Patients with systolic heart failure but without anemia
10206728|NCT04013126|Experimental|endometriosis|Women who undergoing surgery for removal of endometriosis implants
10206729|NCT04013126|Active Comparator|non-endometriosis|Women who undergoing surgery for removal of benign masses in the pelvis
10206730|NCT04011540|Experimental|Intervention|Participants will receive a personalized digital data dashboards throughout the two-month study period.
10206731|NCT04011540|No Intervention|Usual Care|Usual care
10206732|NCT04007198|Experimental|EQ001|EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
10206733|NCT04007198|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
10206734|NCT04002063|Experimental|CBT-D augmented with CBT MobileWork-V|Patients randomized to this condition will receive CBT-D as usual plus access to CBT MobileWork-V, a comprehensive tailored smartphone app for CBT skills practice for OEF/OIF Veterans.
9792418|NCT01445951|Active Comparator|Aspart Group|Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
9792419|NCT01445951|Experimental|Technosphere ® Insulin-Gen2 Group|Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
9792420|NCT01446003|Experimental|MK-8457-Placebo Sequence|Participants received MK-8457 100 mg twice daily (BID) for 10 days followed by Placebo for 10 days. Each treatment was separated by a 10-day washout.
9792421|NCT01446003|Experimental|Placebo-MK-8457 Sequence|Participants received Placebo for 10 days followed by MK-8457 100 mg BID for 10 days. Each treatment was separated by a 10-day washout.
9792422|NCT01446042|Experimental|TBS-1 - b.i.d.|5.5 mg per nostril of 4.5% TBS-1 BID
9792423|NCT01446042|Experimental|TBS-1 - t.i.d.|5.5 mg per nostril of 4.5% TBS-1 TID
9792424|NCT01446159|Experimental|MEDI-573 10 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
9792425|NCT01446159|Experimental|MEDI-573 30 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
9792426|NCT01446159|Experimental|MEDI-573 45 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
9792427|NCT01446159|Experimental|Aromatase Inhibitor|Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
9792428|NCT01446237|Experimental|Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%|open label - no comparator; only Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%
9792429|NCT01446289|Experimental|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
9792430|NCT01446289|Placebo Comparator|Placebo|Pregnant women who received one injection of saline solution.
9792431|NCT01446419|Experimental|Intracept Treatment|
9792432|NCT01446419|Sham Comparator|Sham Treatment|
9792433|NCT01446666||HCC high-risk group|"Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (>=2.33)~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive)."
9792434|NCT01446705||No Exchange|Patients in this arm will represent Veterans seen at the Indianapolis VA Medical Center (VAMC) for whom information exchange has not been activated.
9792435|NCT01446705||Enrolled in Exchange|"Patients in this arm will represent Veterans seen at the Indianapolis VAMC for whom information exchange has been activated by the patient choosing to opt-in."
9792436|NCT01446809|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
9792437|NCT01446809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
9792438|NCT01446874|Experimental|Pre-operative brushing (Pilot Portion)|-Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
9792439|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Esophageal Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
9792440|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Lung Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
9792441|NCT01446913|Active Comparator|Standard Intervention group|This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.
9792442|NCT01446913|Active Comparator|Enhanced CPAP intervention|This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.
9792443|NCT01446913|No Intervention|Usual Care|This group usual care after TIA/stroke and a sleep study at the end of the study.
9792444|NCT01446965|Experimental|Wearable defibrillator|subjects in the Device Group will receive a LifeVest® wearable cardioverter-defibrillator (manufacturer: ZOLL Medical Corporation) plus guideline-directed medical therapy for post-myocardial infarction patients
9792445|NCT01446965|No Intervention|Conventional treatment|subjects in the Control Group will only receive guideline-directed medical therapy for post-myocardial infarction patients
9792446|NCT01447017|Experimental|DPK-060 2% ear drops|DPK-060 2% ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
9792447|NCT01447017|Placebo Comparator|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
9792448|NCT01447121|Experimental|Intended Users of the System|Untrained subjects with diabetes use an investigational blood glucose monitoring system (Tatsu/Tradewind Investigational BG Monitoring System) to self-test capillary blood obtained from fingerstick.
9792449|NCT01447225|Experimental|MM-121 plus Gemcitabine|escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
9792450|NCT01447225|Experimental|MM-121 plus Carboplatin|carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
9792451|NCT01447225|Experimental|MM-121 plus Pemetrexed|pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
9841317|NCT02786836|Experimental|13C-Methacetin Testing|All patients enrolled into the ALFSG Registry with the duration of illness <26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.
9841318|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
9841319|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
9841320|NCT02786901|Placebo Comparator|Vehicle Gel|Vehicle
9841321|NCT02786927|Experimental|ELLIPTA - HANDIHALER; HANDIHALER Questionnaire Version 1|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
9841322|NCT02786927|Experimental|ELLIPTA - HANDIHALER; Questionnaire Version 2|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
9841323|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 1|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
9841324|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 2|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
9841325|NCT02786953|Experimental|Sleep Promotion|Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.
9841326|NCT02786953|No Intervention|Usual Care|Usual Care
9841327|NCT02787057|Experimental|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
9841328|NCT02787057|Active Comparator|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
9841329|NCT02787083|Experimental|Mirabegron|These patients will receive mirabegron 50mg tablets daily for 12 weeks.
9841330|NCT02787083|Placebo Comparator|Placebo|These patients will receive placebo tablets daily for 12 weeks.
9841331|NCT02787291|Other|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
9841332|NCT02787304|Experimental|SHP626 5 Milligram (mg)|Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
9841333|NCT02787304|Experimental|SHP626 10 Milligram (mg)|Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
9841334|NCT02787304|Experimental|SHP626 20 Milligram (mg)|Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
9841335|NCT02787304|Placebo Comparator|Placebo (PBO)|Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
9841336|NCT02787564|Experimental|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
9841337|NCT02787564|No Intervention|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
9922059|NCT00834691||3|Patients with at least moderate chronic renal failure, with or without anemia and without systolic heart failure.
9922060|NCT00834704|Other|1|Dose determination
9922061|NCT00834730|Active Comparator|Ketamine|Ketamine 2mg/kg IV
9922062|NCT00834730|Experimental|N2O gas|50%-70% N2O gas inhalation
9922063|NCT00834782||IOP|Measuring IOP
9922064|NCT00834821|Experimental|1|Participants will undergo the Child Life and Attention Skills (CLAS) Program.
9922065|NCT00834821|Active Comparator|2|Participants will undergo parent focused training (PFT).
9922066|NCT00834821|No Intervention|3|Participants will receive a list of referrals for clinical services as needed, including professional organizations, support groups, and the community mental health system.
9922067|NCT00834847|Experimental|Pravastatin fast|Test product under fasting conditions dosed in first period followed by either test or reference product dosed under fed conditions in second and third periods
9922068|NCT00834847|Experimental|Pravastatin|Test product under fed conditions dosed in first period followed by either test product dosed under fasting conditions or reference product dosed under fed conditions in second and third periods
9922069|NCT00834847|Active Comparator|Pravachol®|Reference product under fed conditions dosed in first period followed by test product dosed under either fed or fasted conditions in second and third periods
9922070|NCT00834860|Active Comparator|CHC, HCC|100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
9922071|NCT00834860|Active Comparator|CHC, LC|100 naïve CHC patients without malignancy
9922072|NCT00834925|No Intervention|standard dose diltiazem|
9922073|NCT00834925|Experimental|low dose diltiazem|
9922074|NCT00834938||1|Patients with DM2 undergoing RYGB with remission of DM2
9922075|NCT00834938||2|Patients with DM2 undergoing RYGB without remission of DM2
10206735|NCT04002063|Active Comparator|CBT-D|Patients randomized to CBT-D will receive CBT-D as usual only.
9792452|NCT01447225|Experimental|MM-121 plus Cabazitaxel|escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
9792453|NCT01447407|Active Comparator|NDV-3 vaccine with alum IM|300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM
9792454|NCT01447407|Active Comparator|NDV-3 vaccine without alum IM|300 ug Als3 in PBS per dose, one dose administered IM
9792455|NCT01447407|Placebo Comparator|Placebo IM|0.5 mg Al as alum in PBS per dose, one dose administered IM
9792456|NCT01447407|Active Comparator|NDV-3 vaccine without alum ID|30 ug Als3 in PBS per dose, one dose administered ID
9792457|NCT01447420|Experimental|Peginterferon Alfa-2a Plus Ribavirin|
9792458|NCT01447433|Experimental|Calcium+D|Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
9792459|NCT01447433|Placebo Comparator|Control|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
9792460|NCT01447446||Dual Therapy: Peg-IFN Alfa-2a + Ribavirin|Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.
9792461|NCT01447446||Dual Therapy: Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
9792462|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
9792463|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
9792464|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
9792465|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
9792466|NCT01447511|Other|CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
9792467|NCT01447511|Other|CYP2C9*1B/*1B Haplotype|Individuals with the CYP2C9*1B/*1B haplotype have two CYP2C9*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
9792468|NCT01447511|Other|CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
9792469|NCT01447511|Other|CYP2C9*2/*3 Genotype|Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
9792470|NCT01447511|Other|CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
9792471|NCT01447576|Experimental|OPC-34712 + ADT|Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
9792472|NCT01447706|Active Comparator|Paclitaxel|Standard dosing paclitaxel: 80 mg/m2 QW intravenously)
9792473|NCT01447706|Experimental|MM-121 (SAR256212) + Paclitaxel|administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses
9792474|NCT01447849|Active Comparator|Lubiprostone 24 mcg Twice a day|Both controls and patients with chronic constipation will receive 1 week of therapy with lubiprostone and one week of placebo.
9792475|NCT01447849|Placebo Comparator|Placebo|Both controls and patients with chronic constipation will receive placebo pills twice daily for one week in cross over design
9792476|NCT01447888|Experimental|150% Oral Morphine Equivalent (OME)|Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients
9792477|NCT01447888|Active Comparator|Control|Standard perioperative dosing, which does not currently account for patients' baseline opiate use.
9792478|NCT01447914|Experimental|ARQ 197 Treatment (Tivantinib)|Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.
9792479|NCT01447927|Experimental|Arm I|Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
9792480|NCT01447927|Placebo Comparator|Arm II|Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
9799673|NCT01666119|Experimental|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
9799674|NCT01666197|Experimental|diclofenac potassium 25 mg tablet|
9841338|NCT02787655|Experimental|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
9841339|NCT02787655|Active Comparator|Cognitive Training Only Group|Cognitive Training Only Group. For this arm of the intervention, randomized participants followed the same guidelines as the cognitive component of the AE+CT group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the AE+CT group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
9841340|NCT02787681|Experimental|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
9841341|NCT02787694|Experimental|Factor Targeted Walking Training|Individuals undergo 5x 2 week periods of targeted training based upon evaluation of walking factor results
9841342|NCT02787863|Experimental|COPD with Prevenar-13 (1)|33 patients with COPD. Standard therapy with Prevenar-13.
9841343|NCT02787863|Experimental|Asthma with Prevenar 13 (2)|34 patients with asthma. Standard therapy with Prevenar 13.
9841344|NCT02787863|Experimental|COPD with Pneumo-23 (3)|25 patients with COPD. Standard therapy with Pneumo-23.
9841345|NCT02787863|Experimental|Asthma with Pneumo-23 (4)|25 patients with asthma. Standard therapy with Pneumo-23.
9841346|NCT02787863|Experimental|COPD with Pneumo-23/Prevenar-13 (5)|32 patients with COPD. Standard therapy, vaccinated with pneumococcal polysaccharide vaccine/pneumococcal conjugate vaccine (PPV23/PCV13).
9841347|NCT02787863|Experimental|Asthma with Pneumo-23/Prevenar-13 (6)|18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
9841348|NCT02787863|Experimental|COPD with Prevenar-13/Pneumo-23 (7)|25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
9841349|NCT02787863|Experimental|Asthma with Prevenar-13/Pneumo-23 (8)|27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
9841350|NCT02788019|Experimental|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
9841351|NCT02788019|Active Comparator|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
9841352|NCT02788097|Experimental|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
9841353|NCT02788097|Active Comparator|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
9841354|NCT02788175|Experimental|HIV-infected Adults on cART|HIV-infected Adults (age 18 - 65) on CART with suppressed viremia
9841355|NCT02788188|Experimental|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
9841356|NCT02788188|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
9841357|NCT02788188|Experimental|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
9841358|NCT02788188|Experimental|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
9841359|NCT02788188|Experimental|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
9841360|NCT02788188|Experimental|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
9841361|NCT02788188|Experimental|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
9841362|NCT02788201|Experimental|Treatment Regimen|Treatment regimen selected by CO eXpression ExtrapolatioN (COXEN) model
9516889|NCT03311282|Experimental|Feeding Bottle 4m+|10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.
9841363|NCT02788279|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
9841364|NCT02788279|Experimental|Cobimetinib + Atezolizumab|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
9792481|NCT01448044|Experimental|BMS-790052 + PegIFNα-2a + Ribavirin|"BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response"
9792482|NCT01448044|Placebo Comparator|Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin|"Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks"
9792483|NCT01448057|Experimental|Combination Product|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
9792484|NCT01448057|Active Comparator|Paracetamol tablets|Paracetamol (500 mg) tablets
9792485|NCT01448213|Active Comparator|Fluorometholone 0.1% Solution|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
9792486|NCT01448213|Active Comparator|Prednisolone acetate 1% Solution|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
9792487|NCT01448356|Experimental|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity"
9792488|NCT01448421|Experimental|Keystone Heart Embolic Deflection Device|Protected Transcatheter Aortic Valve Replacement
9792489|NCT01448447|Experimental|Sole method|patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS
9792490|NCT01448447|Experimental|Boost|patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS
9792491|NCT01448486|No Intervention|Standard of Care HAART|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).
9792492|NCT01448486|Experimental|Raltegravir|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
9792493|NCT01448525|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
9792494|NCT01448525|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
9792495|NCT01448616|No Intervention|Run-in Phase|Women will first participate in a run-in phase with twice daily swabbing.
9792496|NCT01448616|Experimental|Study Drug Phase: TDF|Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
9792497|NCT01448616|Experimental|Study Drug Phase: Vaginal TFV Gel|Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
9792498|NCT01448616|Placebo Comparator|Study Drug Phase: Double Placebo|Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
9792499|NCT01448707|Experimental|Darunavir monotherapy|Darunavir (DRV) + ritonavir (rtv): 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal. Following the primary efficacy analysis after Week 48, patients who entered the study with a nadir CD4+ count of <200 cells/μL will also receive 2 N[t]RTIs (ie, triple therapy) as soon as possible
9792500|NCT01448707|Active Comparator|Triple therapy containing darunavir|Darunavir (DRV) + ritonavir (rtv) + 2 N[t]RTIs: 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal in combination with 2 N[t]RTIs (an investigator-selected dual combination of either abacavir (ABC), lamivudine (3TC), zidovudine (AZT), tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)
9792501|NCT01448824|Experimental|Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo|"Period 1: Participants will receive either 100 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive either 1800 mg LY2484595 tablets or placebo tablets QD by mouth on Days 1 through 14 of Period 2."
9792502|NCT01448824|Experimental|Part 1 (Cohort B): 300 mg LY2484595, Placebo|Participants will receive either 300 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
9792503|NCT01448824|Experimental|Part 1 (Cohort C): 600 mg LY2484595, Placebo|Participants will receive either 600 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
9792504|NCT01448824|Experimental|Part 1 (Cohort D): 1200 mg LY2484595, Placebo|Participants will receive either 1200 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
9792505|NCT01448824|Experimental|Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole|"Period 1: Participants will receive 100 milligrams (mg) LY2484595 tablet by mouth on Day 1 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive 400 mg ketoconazole tablets once daily (QD) by mouth on Days 1 through 14 of Period 2. Participants will receive 100 mg LY2484595 tablet by mouth on Day 5 of Period 2."
9792506|NCT01448850|Placebo Comparator|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
9792507|NCT01448850|Experimental|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
9516890|NCT03311282|Experimental|Feeding Bottle 6m+|10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.
9792508|NCT01449006|No Intervention|Standard of care HAART regimen|Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
9792509|NCT01449006|Experimental|Maraviroc|Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.
9792510|NCT01449240||No treatment|Approximately 5 adults (equal to or not less than 18yrs old) and 5 children (equal to or not over 18yrs old)
9792511|NCT01449266|Other|Dotarem®-injected patients|Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
9792512|NCT01449279|Experimental|Ipilimumab Treatment + Radiation Therapy|Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments. Palliative radiation therapy to 1 to 2 sites of disease will start within 5 days of the first ipilimumab dose. Subjects will have follow up visits 2 to 4 weeks after the last ipilimumab dose and then every 3 months (±2 weeks) thereafter until progression of disease.
9792513|NCT01449305|Experimental|Nanoone Woman Underwear|"Nanoone negative ion of textiles, which is health material specifically designed for human body, in short distance and long time to produce negative ion, the human body really needed, it can neutralize free radical in the human body."
9792514|NCT01449370|Experimental|Arm A|TAK-117 administered once a day orally
9792515|NCT01449370|Experimental|Arm B|TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
9792516|NCT01449370|Experimental|Arm C|TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
9792517|NCT01449461|Experimental|Brigatinib 30 mg QD/60 mg QD|Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (Approximately up to 7.3 years).
9792518|NCT01449461|Experimental|Brigatinib 90 mg QD|Brigatinib 90 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years).
9792519|NCT01449461|Experimental|Brigatinib 120 mg QD/60 mg BID|Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
9792520|NCT01449461|Experimental|Brigatinib 90 mg QD-180 mg QD|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.
9799675|NCT01666197|Placebo Comparator|placebo|
9841365|NCT02788279|Active Comparator|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
9841366|NCT02788357|Experimental|Atomoxetine with motor training|40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
9841367|NCT02788357|Placebo Comparator|Placebo with motor training|Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays
9841368|NCT02788474|Placebo Comparator|placebo|
9841369|NCT02788474|Experimental|nintedanib|
9841370|NCT02788513|Experimental|BI 425809 dose 1|
9841371|NCT02788513|Experimental|BI 425809 dose 2|
9841372|NCT02788513|Experimental|BI 425809 dose 3|
9841373|NCT02788513|Experimental|BI 425809 dose 4|
9841374|NCT02788513|Placebo Comparator|Placebo|
9841375|NCT02788656|Experimental|Group A|Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
9841376|NCT02788656|Active Comparator|Group B|"Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device)."
9841377|NCT02788747|Experimental|4 mg elamipretide|4 mg elamipretide once daily for 28 consecutive days
9841378|NCT02788747|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
9841379|NCT02788747|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
9841380|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
9841381|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
9841382|NCT02789033|Active Comparator|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
9841383|NCT02789033|Active Comparator|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
9841384|NCT02789033|Placebo Comparator|Placebo|Placebo in the same pharmacological presentation
9841385|NCT02789111|Active Comparator|Alvimopan|12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
9841386|NCT02789111|Placebo Comparator|Placebo|Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
9792521|NCT01449461|Experimental|Brigatinib 180 mg QD/90 mg BID|Brigatinib 180 mg, once daily or 90 mg, BID, tablets, orally in each cycle of 28 days (Approximately up to 7.3 years).
9792522|NCT01449461|Experimental|Brigatinib 240 mg QD/120 mg BID/300 mg QD|Brigatinib 240 mg, QD or 120 mg, BID or 300 mg once daily, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
9792523|NCT01449513|Active Comparator|PEP005 Gel 0.05%|active ingredient of PEP005: Ingenol mebutate
9792524|NCT01449513|Placebo Comparator|Placebo Gel|Vehicle of PEP005 Gel
9792525|NCT01449526|Experimental|B&L Investigational Contact Lens|The Bausch + Lomb investigational silicone hydrogel contact lens
9792526|NCT01449526|Active Comparator|B&L PureVision Contact Lens|The Bausch + Lomb PureVision silicone hydrogel contact lens
9792527|NCT01449630|Experimental|LY3031207|Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally.
9792528|NCT01449630|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.
9792529|NCT01449630|Active Comparator|Celecoxib|Single 400mg dose of celecoxib administered orally on one occasion.
9799676|NCT01666210|Active Comparator|Dexamethasone Punctum Plug|Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
9799677|NCT01666210|Placebo Comparator|Placebo Vehicle Punctum Plug|Placebo punctum plug insertion
9799678|NCT01666314|Other|Placebo + Orteronel 200 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 (28 days) followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
9799679|NCT01666314|Experimental|Orteronel 200 mg (Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
9799680|NCT01666314|Other|Placebo + Orteronel 300 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
9799681|NCT01666314|Experimental|Orteronel 300 mg (Japan)|Orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
9799682|NCT01666314|Other|Placebo + Orteronel 200 mg (Ex-Japan)|"Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles outside of Japan (Ex-Japan) for up to 3.1 years.~Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study."
9799683|NCT01666314|Experimental|Orteronel 200 mg (Ex-Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
9799684|NCT01666314|Other|Placebo + Orteronel 400 mg (Ex-Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
9799685|NCT01666314|Experimental|Orteronel 400 mg (Ex-Japan)|Orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
9799686|NCT01666444|Experimental|PLD 40 mg/m2 plus VTX-2337|The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
9799687|NCT01666444|Active Comparator|PLD 40 mg/m2 plus placebo|The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only.
9799688|NCT01666652|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
9799689|NCT01666652|Experimental|TDENV-PIV AS01E1|1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
9799690|NCT01666652|Experimental|TDENV-PIV AS03B1|1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
9799691|NCT01666652|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
9841387|NCT02789176||Outpatient Enrollees|This is a cohort of 150 subjects who were previously enrolled in the Neonatal Seizure Registry, a multi-center association of institutions across the United States, They were contacted to participate in the study after discharge from the Neonatal Intensive Care Unit (NICU) but prior to the prospective follow up. They were asked to take part in all prospective follow up surveys at 12, 18, & 24 months of age.
9841388|NCT02789176||NICU Enrollees|This is a cohort of 150 subjects who were enrolled in the study prior to discharge from the NICU. They were asked to complete surveys prior to discharge from the NICU, returned to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, & completed the follow surveys at 12, 18, & 24 months of age.
9841389|NCT02789410|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
9841390|NCT02789410|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
9841391|NCT02790073|Other|SNF472|SNF472 for calciphylaxis
9841392|NCT02790437|Experimental|Treatment IdeS|IdeS intravenous infusion
9841393|NCT02790463|No Intervention|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
9841394|NCT02790463|Active Comparator|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
9841395|NCT02790606|Experimental|Covera(TM) Vascular Covered Stent|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
9841396|NCT02790736|Experimental|Propranolol|Propranolol 40 mg capsule, given once after fear activation procedure
9841397|NCT02790736|Placebo Comparator|placebo capsule|Placebo capsule, given once after fear activation procedure
9841398|NCT02790788|Experimental|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
9841399|NCT02790788|Placebo Comparator|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
9841400|NCT02791191|Experimental|Dose 1 LY3202626|3 mg LY3202626 given orally once daily for 52 weeks.
9841401|NCT02791191|Experimental|Dose 2 LY3202626|12 mg LY3202626 given orally once daily for 52 weeks.
9841402|NCT02791191|Experimental|Placebo|Placebo given orally once daily for 52 weeks.
9841403|NCT02791269|Experimental|HBeAg Negative Participants|HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
9841404|NCT02791269|Experimental|HBeAg Positive Participants|HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
9841405|NCT02791308|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
9841406|NCT02791308|Active Comparator|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
9841407|NCT02791308|Placebo Comparator|Vehicle Cream|Cream vehicle of the test product (Actavis)
9841408|NCT02791399|No Intervention|Control|Treatment as usual
9841409|NCT02791399|Experimental|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
9841410|NCT02791438|Experimental|Azilsartan 2.5 - 20 mg (Weight < 50 kg)|Following a 2-week placebo run-in period, azilsartan 2.5 mg (titrated as needed to the highest dose of 20 mg) was administered orally once daily before or after breakfast, for the participants weighing < 50 kg.
9841411|NCT02791438|Experimental|Azilsartan 5 - 40 mg (Weight ≥ 50 kg)|Following a 2-week placebo run-in period, azilsartan 5 mg (titrated as needed to the highest dose of 40 mg) was administered orally once daily before or after breakfast, for the participants weighing ≥ 50 kg.
9841412|NCT02791490|Experimental|Sitagliptin|Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day [b.i.d.]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
9841413|NCT02791490|Placebo Comparator|Placebo|Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
9516891|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 0m+|10 infants aged 0-4 weeks (+/- 7 days)
9841414|NCT02791516|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a month for 6 months.
9841415|NCT02791516|Experimental|Romosozumab|Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.
9841416|NCT02791659|Active Comparator|Left lateral decubitus|In this group, the position will be assigned to Left lateral decubitus during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
9792530|NCT01449682|Active Comparator|Ozurdex PRN|0.7 mg intravitreal DEX implant at Visit 1 then PRN for duration of trial (48 weeks) if evidence of fluid on OCT
9792531|NCT01449682|Active Comparator|Ozurdex Q16 weeks|0.7 mg intravitreal DEX implant at Visit 1 then Q16 weeks
9792532|NCT01449708|No Intervention|Balanced Anesthesia|Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
9792533|NCT01449708|Active Comparator|NoNarc TIVA|Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine
9792534|NCT01449721|No Intervention|Control|Standard medical care by the primary treatment team.
9792535|NCT01449721|Experimental|Interventional arm|Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization
9792536|NCT01449747|Active Comparator|study group|sitagliptin hypo-response patients
9792537|NCT01449747|Sham Comparator|control group|sitagliptin response patients
9792538|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 1 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
9792539|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 2 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
9792540|NCT01449812|Active Comparator|CONTROL GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
9792541|NCT01449864|Experimental|Proton RT|Subjects receive proton radiation
9792542|NCT01449929|Experimental|dolutegravir 50mg once daily (OAD)|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
9792543|NCT01449929|Active Comparator|darunavir 800mg OAD in combination with ritonavir 100mg OAD|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
9792544|NCT01449955|Placebo Comparator|Placebo (e.g., sugar pill)|15 mg Placebo will be administered once, in pill form.
9792545|NCT01449955|Active Comparator|Rapamycin|15 mg of Rapamycin will be administered once, in pill form.
9792546|NCT01450007|Experimental|Dexamethasone block|Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
9792547|NCT01450007|Active Comparator|Dexamethasone IV|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
9792548|NCT01450007|Placebo Comparator|Placebo|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline
9792549|NCT01450098|Experimental|Cohort A: Fixed Sequence of Meal Conditions|LY2484595 (evacetrapib): 200 milligrams (mg) of LY2484595 administered orally, one time only, as an SDSD-PG tablet given with no food. There was a washout of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with low-fat breakfast. There was another washout period of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with high-fat breakfast.
9792550|NCT01450098|Experimental|Cohort B: Comparison of Randomized Treatments|LY2484595 (evacetrapib): 100 mg of LY2484595 administered orally as an RF tablet given with a low-fat breakfast. There was a washout period of at least 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low-fat breakfast. There was another washout of at least 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low-fat breakfast.
9792551|NCT01450137|Experimental|Tocilizumab|Tocilizumab 8mg/kg every 4 weeks until week 52.
9792552|NCT01450137|Placebo Comparator|Placebo|Placebo every 4 weeks until week 52.
9792553|NCT01450189|Active Comparator|Standard Counseling Arm|The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
9841417|NCT02791659|Experimental|Prone|In this group, the position will be assigned to Prone during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
9841418|NCT02791763|Experimental|Daprodustat in ND participants|Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams [mg] as recommended) dose once daily for 52 weeks.
9841419|NCT02791763|Active Comparator|Epoetin beta pegol in ND participants|Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram [µg] as recommended) dose once every 2 or 4 weeks for 52 weeks.
9841420|NCT02791763|Experimental|Daprodustat in PD participants|Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.
9841421|NCT02791893|Experimental|VNS device|Vagus Nerve Stimulation (VNS) hand held device - subjects to utilize the VNS hand held device for 20 weeks total, putting it on the skin overlying the vagus nerve in their neck and then turning it on for 120 second periods three times a day. The device is programmed to deliver only 6 bouts of stimulation per day - one to each side of the neck three times a day
9841422|NCT02791893|Placebo Comparator|Inactive device|Inactive hand held device - subjects to utilize the inactive device for 10 weeks and then will receive the VNS device for the next 10 weeks.
9841423|NCT02791906|Experimental|ISMN Only|Patients receive only ISMN
9841424|NCT02791906|Experimental|ISMN AND Vitamin C|Patients receive both ISMN and Vitamin C
9841425|NCT02791945|Experimental|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
9841426|NCT02791945|Placebo Comparator|Placebo|Placebo capsules daily - up to 3200 mg
9841427|NCT02792049|Experimental|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
9841428|NCT02792049|Active Comparator|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
9841429|NCT02792062|Experimental|TAK-385 40 mg (Group A)|A single oral dose of TAK-385 40 milligram (mg) (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
9841430|NCT02792062|Experimental|TAK-385 40 mg (Group B)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
9841431|NCT02792062|Experimental|TAK-385 40 mg (Group C)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
9841432|NCT02792062|Experimental|TAK-385 40 mg (Group D)|A single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
9841433|NCT02792062|Experimental|TAK-385 40 mg (Group E)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
9516892|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 4m+|10 infants aged 4 months (+/- 10 days)
9841434|NCT02792062|Experimental|TAK-385 40 mg (Group F)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
9841435|NCT02792192|Experimental|Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC)|Participants will receive atezolizumab 1200 mg IV infusion q3w, for a maximum of 32 doses or 96 weeks of therapy, whichever comes first.
9922076|NCT00835016|Experimental|Early psychosocial stimulation (LTP)|The 10 session of Early psychosocial stimulation (LTP)will be delivered to depressed mothers in the intervention group
9986284|NCT01401192|Experimental|TS positive cohort & Gem/Cis Tx arm|Among TS expression positive patients, some will be randomized to Gem/cis therapy
9986285|NCT01401192|Active Comparator|TS+ cohort & Pem/Cis arm|Among patients with TS+, randomised to Pem/cis chemotherapy
9841436|NCT02792192|Experimental|Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. Optional BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
9841437|NCT02792192|Experimental|Cohort 2: Atezolizumab + BCG (BCG-relapsing NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
9841438|NCT02792192|Experimental|Cohort 3: Atezolizumab + BCG (BCG-naive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
9841439|NCT02792218|Experimental|OMB 20 mg|Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
9841440|NCT02792218|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
9841441|NCT02792231|Experimental|OMG 20 mg|"Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1~,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide-matching placebo, taken orally once daily"
9841442|NCT02792231|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
9841443|NCT02792517|Experimental|Erenumab + Estrogen/Progestin Contraceptive|"Participants received a combination oral contraceptive for 3 28-day cycles during the study.~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider."
9841444|NCT02792699|Experimental|ABP 798 / ABP 798|Participants received ABP 798 on days 1 and 15 (dose 1) and a second dose of ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
9841445|NCT02792699|Active Comparator|Rituximab (US) / ABP 798|Participants received rituximab (United States [US] formulation) on days 1 and 15 (dose 1) and transitioned to receive ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
9841446|NCT02792699|Active Comparator|Rituximab (EU) / Rituximab (EU)|Participants received rituximab (European Union [EU] formulation) on days 1 and 15 (dose 1) and a second dose of rituximab (EU formulation) at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
9841447|NCT02792777||Interviews|Interview participants will be recruited from 3 different care settings: an acute care visit (in the emergency department), a post-acute care visit (within 1 week of a hospital discharge), and a routine primary care visit. Target sample size within each healthcare setting is 30 patients, which is the anticipated number needed for thematic saturation. The total recruitment goal for this cohort is 90-120 participants.
9986286|NCT01401192|Active Comparator|TS negative cohort & Pem/Cis Tx arm|Among patients with TS-, some will be randomised to Pem/cis Tx arm
9799692|NCT01666652|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
9799693|NCT01666730|Experimental|Treatment (metformin hydrochloride, FOLFOX)|Patients receive metformin hydrochloride PO BID on days 1-14 and FOLFOX therapy comprising leucovorin calcium IV over 120 minutes, fluorouracil IV continuously over 46 hours, and oxaliplatin IV over 120 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9799694|NCT01666782|Experimental|High-Dose Influenza Vaccine|
9799695|NCT01666782|Active Comparator|Standard Trivalent Influenza Vaccine|
9799696|NCT01666912|Active Comparator|6 week postpartum contraceptive implant|randomized to receive contraceptive implant at normal 6 week postpartum visit
9799697|NCT01666912|Experimental|Immediate postpartum contraceptive implant|randomized to receive contraceptive implant prior to leaving the hospital postpartum
9799698|NCT01666951|Experimental|LCP-Tacro|LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
9799699|NCT01666951|Active Comparator|Prograf|Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
9799700|NCT01667029|Experimental|sulfasalazine|1 g oral twice daily for 2 weeks
9799701|NCT01667029|Placebo Comparator|placebo|oral placebo pill twice daily for two weeks.
9799702|NCT01667107|Experimental|Posaconazole - CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
9799703|NCT01667107|Experimental|Posaconazole - Non-CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
9799704|NCT01667224|Experimental|Actiponin|Actiponin(extract of Gynostema pentaphyllum, 450mg/day) for 12weeks
9799705|NCT01667224|Placebo Comparator|Placebo|Placebo(450mg/day) for 12weeks
9799706|NCT01667250|Active Comparator|GammaCore Active Device|Subjects will use an Active GammaCore Device
9799707|NCT01667250|Sham Comparator|GammaCore Sham Device|Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study.
9799708|NCT01667406|Experimental|Kisspeptin-54, 1.6 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 1.6 nmol/kg
9799709|NCT01667406|Experimental|Kisspeptin-54, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
9799710|NCT01667406|Experimental|Kisspeptin-54, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
9799711|NCT01667406|Experimental|Kisspeptin-54, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
9799712|NCT01667406|Experimental|Kisspeptin-54 OHSS, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
9799713|NCT01667406|Experimental|Kisspeptin-54 OHSS, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
9799714|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 9.6 nmol/kg
9799715|NCT01667406|Experimental|Kisspeptin-54 OHSS, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
9799716|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + 9.6|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of Kisspeptin, dose of 9.6 nmol/kg 10 hours later
9799717|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + saline|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of saline10 hours later
9799718|NCT01667419|Experimental|Cohort 1 Vemurafenib|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
9799719|NCT01667419|Placebo Comparator|Cohort 1 Placebo|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
9986287|NCT01401192|Experimental|TS negative cohort & Gem/Cis Tx arm|Among patients with TS-, some will be randomised to Gem/Cis Tx arm
9792554|NCT01450189|Active Comparator|Behavioral Intervention Arm only|Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
9792555|NCT01450189|Active Comparator|Behavioral Intervention plus ARV|The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
9792556|NCT01450306|Experimental|D-cycloserine plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
9792557|NCT01450306|Placebo Comparator|Placebo plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
9792558|NCT01450319|Experimental|Cetuximab|
9792559|NCT01450397|Other|XIAFLEX|XIAFlEX
9792560|NCT01450540|Active Comparator|Group 1|REMStar auto A-Flex
9792561|NCT01450540|Experimental|Group 2|modified REMstar Auto A-Flex with AGPAP
9792562|NCT01450631|Active Comparator|Standard Dressing|Standard-of-care includes coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™) consistent with the national standard for dressing Cesarean section incisions.
9792563|NCT01450631|Experimental|Prevena™ (PIMS)|PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period.
9792564|NCT01450683|Experimental|Itraconazole|600 mg/day oral (PO)
9792565|NCT01450696|Active Comparator|Capecitabine + Cisplatin + Herceptin (6 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
9792566|NCT01450696|Experimental|Capecitabine + Cisplatin + Herceptin (10 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
9792567|NCT01450761|Experimental|Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Ipilimumab: IV solution, Intravenous (IV), 10 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
9792568|NCT01450761|Placebo Comparator|Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Placebo matching Ipilimumab: IV solution, IV, 0 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
9792569|NCT01450787||diabetics|diabetics
9792570|NCT01450787||non diabetics|non diabetics
9792571|NCT01450800|Active Comparator|Nitrofurantoin|Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
9792572|NCT01450800|Placebo Comparator|Placebo|Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
9792573|NCT01450813|Sham Comparator|Group 1|Saline 0.06 ml/kg
9792574|NCT01450813|Active Comparator|Group 2|Rocuronium 0.2 mg/kg
9792575|NCT01450813|Active Comparator|Group 3|Rocuronium 0.4 mg/kg
9792576|NCT01450813|Active Comparator|Group 4|Rocuronium 0.6 mg/kg
9792577|NCT01450826|Active Comparator|aprepitant+ondansetron|On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
9792578|NCT01450826|Active Comparator|ondansetron|On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
9792579|NCT01450943|Active Comparator|Standard of care|debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape
9792580|NCT01450943|Experimental|Dermagraft|debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
9792581|NCT01450943|Experimental|Oasis|debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
9792582|NCT01451164|Experimental|High dose|
9792583|NCT01451164|Experimental|Mid dose|
9792584|NCT01451164|Experimental|Low dose|
9792585|NCT01451164|Placebo Comparator|Placebo|
9792586|NCT01451203|Placebo Comparator|PBO + MTX|Participants who received placebo subcutaneously every two weeks (Q2W) at Weeks 0, 2, and 4; followed by placebo subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
9792587|NCT01451203|Experimental|CZP + MTX|Participants who certolizumab pegol (CZP) subcutaneously at a loading dose of CZP 400 mg every 2 weeks (Q2W) at Weeks 0, 2, and 4; followed by a dose of CZP 200 mg subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
9792588|NCT01451385|Experimental|COV795|Participants receive 2 tablets of COV795 every 12 hours for up to 35 days
9792589|NCT01451398|Experimental|TI inhalation powder|Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
9792590|NCT01451398|Placebo Comparator|Technosphere powder|Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
9792591|NCT01451411|Experimental|Conivaptan hydrochloride|
9792592|NCT01451411|Placebo Comparator|Placebo|
9792593|NCT01451424|Experimental|Proellex 12 mg PK group|Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.
9792594|NCT01451424|Experimental|Proellex 12 mg per protocol|Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
9792595|NCT01451424|Experimental|Proellex 6 mg per protocol|Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
9792596|NCT01451424|Experimental|Proellex 3 mg per protocol|Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
9792597|NCT01451424|Experimental|24 mg Proellex|24 mg vaginal Proellex daily for 16 weeks
9792598|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 30 mg QD|Participants received MK-8242 30 mg once daily (QD) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
9792599|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 60 mg QD|Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
9792600|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg QD|Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
9792601|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg QD|Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
9792602|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg BID|Participants received MK-8242 120 mg twice daily (BID) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.
9792603|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 170 mg BID|Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.
9792604|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 210 mg BID|Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.
9792605|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg BID|Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.
9792606|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 300 mg BID|Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
9792607|NCT01451541|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37mcg once daily
9792608|NCT01451541|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg once daily
9792609|NCT01451541|Placebo Comparator|Placebo|
9792610|NCT01451554|Active Comparator|Portion Control Intervention|Individuals will be given a portion control plate and dietary counseling
9792611|NCT01451554|Placebo Comparator|Usual Care|Provided with self-help booklets on diet and exercise.
9792612|NCT01451606|Placebo Comparator|Placebo pill|A pill that looks like the active drug, but does not contain any active ingredients.
9792613|NCT01451606|Active Comparator|Duloxetine|The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
9792614|NCT01451632|Experimental|Part 1: MM-121 + cetuximab|increasing doses of weekly MM-121 + weekly cetuximab
9792615|NCT01451632|Experimental|Part 2: MM-121 + cetuximab + irinotecan|increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
9792616|NCT01451645|Other|placebo|daily placebo dosing for 16 weeks with background allopurinol therapy
9792617|NCT01451645|Active Comparator|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks with background allopurinol therapy
9792618|NCT01451749|Experimental|Shenwu Capsule|"Shenwu Capsule:1 capsule contains 451 mg of Shenwu extracts. 5 capsules/time, 3 times/day for 6 months.~Placebo: Placebo identical to donepezil tablets,1 placebo tablet/time, 1 time/day for 6 months."
9792619|NCT01451749|Active Comparator|Donepezil|"Donepezil: 1 tablet contains 5 mg of donepezil, 1 tablet/time, 1time/day for 6 months.~Placebo: Placebo identical to shenwu capsules,5 placebo capsules/time,3 times/day for 6 months"
9792620|NCT01451762|Placebo Comparator|Placebo|.9 normal saline IV
9792621|NCT01451762|Active Comparator|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
9792622|NCT01451762|Active Comparator|50 mg diphenhydramine IV|50 mg diphenhydramine IV administered before surgery
9792623|NCT01451775|Experimental|Treatment A|high dose of empagliflozin after overnight fasting for at least 10 h
9841448|NCT02792777||Concept Mapping|Concept mapping participants will be recruited from existing clinical and research databases for 3 separate concept mapping groups, each with a target of 20 patients. The total recruitment goal for this cohort is 60 people.
9841449|NCT02792829|Experimental|Lenvatinib 11 mg (suspension formulation)|"Arm 1 will have 2 sequences:~Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg)~Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)"
9841450|NCT02792829|Experimental|Lenvatinib 11 mg (2 vs 5 capsules)|"Arm 2 will have 4 sequences:~Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE~Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER~Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE~Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER"
9841451|NCT02792829|Experimental|Lenvatinib 23 mg|"Arm 3 will have 2 sequences:~Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation~Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation"
9841452|NCT02792959|Experimental|Functional imaging|A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
9841453|NCT02793128|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
9841454|NCT02793154|Experimental|Part A: Exenatide|Part A is a single arm design and all subjects will receive 10 mcg subcutaneous injection (SC) of exenatide twice daily for 5 days
9841455|NCT02793154|Experimental|Part B: Albiglutide|In Part B, half of the subjects will be randomized to receive albiglutide: On Day 1: Once weekly SC injection at 30 mg for 4 weeks From Week 5, Day 1: Dose will be increased to 50 mg once weekly SC injection for 4 weeks
9841456|NCT02793154|Active Comparator|Part B: Exenatide|"In Part B, half of the subjects will be randomized to receive exenatide: On Day 1: Twice daily SC injection at 5 mcg for 4 weeks.~From Week 5, Day 1: Dose will be uptitrated to 10 mcg twice daily SC injection for 4 weeks"
9841457|NCT02793232|Experimental|Single Ascending Dose Crossover|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
9841458|NCT02793232|Experimental|Multiple Ascending Dose|Multiple dose administration to Healthy Subjects in parallel cohorts (PF-06751979).
9841459|NCT02793232|Experimental|Multiple Dose Elderly|Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
9841460|NCT02793622|Active Comparator|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
9841461|NCT02793622|Active Comparator|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
9841462|NCT02793674|Other|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher & Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
9841463|NCT02793674|Other|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
9841464|NCT02793817|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|dosed BID
9841465|NCT02793817|Placebo Comparator|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
9841466|NCT02793856|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 1 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
9841467|NCT02793856|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
9841468|NCT02793856|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 4 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
9841469|NCT02793947|Experimental|Peri-incisional injection|A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
9841470|NCT02793947|No Intervention|Control (no injection)|Femur fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
9841471|NCT02794103|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment throughout the hydrotherapy session.
9841472|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
9841473|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
9841474|NCT02794246|Experimental|Single Arm|
9841475|NCT02794441|Experimental|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
9841476|NCT02794441|Placebo Comparator|Placebo|Matched oral solution in same volume per kg as dexamethasone
9841477|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo AZ MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily (QD) for 28 days and Placebo AZ MDI taken as two inhalations twice daily (BD) for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
9841478|NCT02794480|Experimental|Placebo AZ MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive AZ MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
9841479|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo GSK MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily for 28 days and Placebo GSK MDI taken as two inhalations twice daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period.
9841480|NCT02794480|Experimental|Placebo GSK MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive GSK MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
9841481|NCT02794597|No Intervention|Opioid Medication-Assisted Treatment only|Usual care - Opioid Medication Assisted Treatment
9841482|NCT02794597|Experimental|Intervention|Peer led, behavioral sexual health intervention: Sexual Health Initiative for Navigation and Empowerment (SHINE).
9841483|NCT02794727|Sham Comparator|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
9841484|NCT02794727|Active Comparator|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
9841485|NCT02794727|No Intervention|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
9841486|NCT02794766|Experimental|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
9841487|NCT02794766|Active Comparator|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
9841488|NCT02794766|Placebo Comparator|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
9841489|NCT02794844|Experimental|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.~No other ARM will be studied."
9841490|NCT02794870|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants received a single dose of the RSV LID ΔM2-2 1030s vaccine at study entry (Day 0).
9841491|NCT02794870|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
9841492|NCT02794974|Experimental|with perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
9841493|NCT02794974|Experimental|without perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)
9841494|NCT02795117|Experimental|Test product|
9841495|NCT02795117|Active Comparator|Reference product|
9841496|NCT02795117|Placebo Comparator|Placebo product|
9841497|NCT02795767|Experimental|Cohort A: 1.5 mg/kg Emicizumab QW|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
9841498|NCT02795767|Experimental|Cohort B: 3 mg/kg Emicizumab Q2W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
9841499|NCT02795767|Experimental|Cohort C: 6 mg/kg Emicizumab Q4W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
9841500|NCT02795780|Experimental|Follow-up Flortaucipir PET Scan|
9841501|NCT02795819|Experimental|Cohort minus 1 (-1)|Participants take 10 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
9841502|NCT02795819|Experimental|Cohort 1|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
9841503|NCT02795819|Experimental|Cohort 2|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
9841504|NCT02795819|Experimental|Cohort 3A|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
9841505|NCT02795819|Experimental|Cohort 3B|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
9841506|NCT02795819|Experimental|Cohort 4A|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
9841507|NCT02795819|Experimental|Cohort 4B|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
9841508|NCT02795832|Experimental|Cohort 1a|ZPL-5212372 1% w/w Ointment BID
9841509|NCT02795832|Placebo Comparator|Cohort 1b|Placebo Ointment BID
9841510|NCT02795832|Experimental|Cohort 2a|ZPL-5212372 1% w/w Ointment BID
9841511|NCT02795832|Placebo Comparator|Cohort 2b|Placebo Ointment BID
9841512|NCT02795832|Experimental|Cohort 3a|ZPL-5212372 1% w/w OIntment BID
9841513|NCT02795832|Placebo Comparator|Cohort 3b|Placebo Ointment BID
9841514|NCT02796092|Active Comparator|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
9841515|NCT02796092|Experimental|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
9841516|NCT02796144|Active Comparator|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
9841517|NCT02796144|Active Comparator|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
9841518|NCT02796144|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
9841519|NCT02796300|Active Comparator|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
9841520|NCT02796300|Active Comparator|Palindrome Group|This group will have dialysis using the Palindrome catheter.
9841521|NCT02796352|Experimental|High dose bolus interleukin-2 (HD IL2)|
9841522|NCT02796560|Experimental|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
9841523|NCT02796560|Experimental|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
9841524|NCT02796625|Experimental|Painful Stimuli|Participants will be exposed to painful heat
9841525|NCT02796651|Experimental|Formoterol 6 μg|Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
9841526|NCT02796651|Experimental|Formoterol 12 μg|Participants received formoterol fumarate 12 μg administered via Pressair BID.
9841527|NCT02796651|Experimental|Formoterol 24 μg|Participants received formoterol fumarate 24 μg administered via Pressair BID.
9841528|NCT02796651|Placebo Comparator|Placebo|Participants received placebo to formoterol fumarate administered via Pressair BID.
9841529|NCT02796651|Experimental|Formoterol 20 μg|Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
9841530|NCT02796651|Experimental|Formoterol 40 μg|Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
9841531|NCT02796664|Experimental|Ginseng|
9841532|NCT02796664|Placebo Comparator|Placebo|
9841533|NCT02796677|Experimental|AB/FF 400/12 μg BID|Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
9841534|NCT02796677|Experimental|AB 400 μg BID|Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
9841535|NCT02796677|Experimental|FF 12 μg BID|Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
9841536|NCT02796677|Experimental|TIO 18 μg QD|Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
9841537|NCT02796755|Experimental|Riluzole Arm|Participants will take a daily oral dose of 100 mg of riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
9841538|NCT02796755|Placebo Comparator|Placebo Arm|Participants will take a daily oral dose of 100 mg of a placebo that appears identical to riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
9841539|NCT02796924|Experimental|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
9841540|NCT02796963|Experimental|Immediate Intervention|Men will be exposed immediately to a comprehensive intervention promoting HIV testing.
9841541|NCT02796963|Experimental|Delayed Intervention|Men will be exposed to a comprehensive intervention promoting HIV testing after a delay period.
9841542|NCT02797054|Experimental|Tailored Intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
9841543|NCT02797054|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
9841544|NCT02797054|Other|Usual Care|Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
9841545|NCT02797080|Experimental|interferon γ-1b|ACTIMMUNE® will be administered 3 times per week (TIW) by subcutaneous (SC) injection.
9841546|NCT02797132|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A (<14 kg): Participants weighing less than (<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part A (>=14 kg): Participants weighing greater than or equal to (>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part B (<14 kg): Participants weighing <14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.~Part B (>=14 kg): Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B."
9841547|NCT02797171|Experimental|Group 1|Participants will receive 10 mg/kg of VRC01 at Months 0, 2, 4, and 6.
9841548|NCT02797171|Experimental|Group 2|Participants will receive 30 mg/kg of VRC01 at Months 0, 2, 4, and 6.
9841549|NCT02797171|Experimental|Group 3|Participants will receive 30 mg/kg of VRC01LS at Months 0, 3, and 6.
9841550|NCT02797171|Experimental|Group 4|Participants will receive 30 mg/kg of VRC01 at Month 0.
9841551|NCT02797171|Experimental|Group 5|Participants will receive 30 mg/kg of VRC01LS at Month 0.
9841552|NCT02797522|Experimental|NHV Participants: Cohort 1|NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.
9841553|NCT02797522|Experimental|NHV Participants: Cohort 2|NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.
9841554|NCT02797522|Experimental|NHV Participants: Cohort 3|NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.
9841555|NCT02797522|Experimental|NHV Participants: Cohort 4|NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.
9841556|NCT02797522|Experimental|NHV Participants: Cohort 5|NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.
9841557|NCT02797522|Experimental|NHV Participants: Cohort 6|NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.
9841558|NCT02797522|Placebo Comparator|NHV Participants: Placebo|NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.
9841559|NCT02797522|Experimental|CHB Participants: Cohort 3b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
9841560|NCT02797522|Experimental|CHB Participants: Cohort 4b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
9841561|NCT02797522|Experimental|CHB Participants: Cohort 3c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.
9841562|NCT02797522|Experimental|CHB Participants: Cohort 4c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.
9841563|NCT02797613|Experimental|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
9841564|NCT02797613|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
9841565|NCT02797678|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week. Participants will then be crossed over and will wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week
9841566|NCT02797678|Sham Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week. Participants will then wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week.
9841567|NCT02797808|Experimental|Children with OCD|Children with obsessive compulsive disorder, not currently on medication for OCD
9841568|NCT02797808|Active Comparator|Healthy Control Children|Children without obsessive compulsive disorder
9841569|NCT02797821|Experimental|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
9841570|NCT02797821|Experimental|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
9841571|NCT02797821|Experimental|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
9841572|NCT02798211|Active Comparator|Group 1|secukinumab 300mg s.c. injection
9841573|NCT02798211|Active Comparator|Group 2|secukinumab 150 mg s.c. injection
9841574|NCT02798211|Placebo Comparator|Group 3|Placebo s.c. injection
9841575|NCT02798289|Experimental|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
9841576|NCT02798315||Participants With Hepatitis C Virus (HCV) Genotype 1 or 4|"Participants with HCV genotype 1 or 4 receiving paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
9922077|NCT00835016|Active Comparator|Waiting group|Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
9922078|NCT00835029|Active Comparator|Clotrimazole varnish|Clotrimazole in a slow release varnish treatment
9922079|NCT00835029|Active Comparator|Clotrimazole troches|Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
9922080|NCT00835107|Experimental|Ziprasidone|
9922081|NCT00835107|Placebo Comparator|Sugar pill|
9922082|NCT00835250|Active Comparator|Laparoscopy|Laparoscopic cholecystectomy
9922083|NCT00835250|Experimental|Transumbilical|Transumbilical endoscopic cholecystectomy
9922084|NCT00835250|Experimental|Transvaginal|Transvaginal endoscopic cholecystectomy
9922085|NCT00835289|Placebo Comparator|Placebo (corn oil)|Each participant will be taking 3 capsules of a matching placebo (corn oil).
9922086|NCT00835289|Experimental|PUFA (Omax3)|Omax3[TM] (Cenestra Health), or dietary supplement: n-3 polyunsaturated fatty acids, is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3[TM].
9922087|NCT00835302|Experimental|Manipulation + Exercise Group|Cervicothoracic manipulation and ROM exercises
9922088|NCT00835315||3|patients with psoriasis , patients with atopic dermatitis and healthy patients.
9922089|NCT00835393|Experimental|1|
9841577|NCT02798354|Experimental|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
9841578|NCT02798354|Experimental|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
9841579|NCT02798354|Experimental|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
9841580|NCT02798380|Experimental|HTS-519 Insert|Active treatment
9841581|NCT02798627|Experimental|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
9841582|NCT02798627|Placebo Comparator|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
9841583|NCT02798835|Active Comparator|Adductor Canal block|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
9841584|NCT02798835|Active Comparator|Adductor canal block with dexamethasone|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
9841585|NCT02798835|Active Comparator|Adductor canal catheter|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
9841586|NCT02798861||CAP assessment|Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes
9841587|NCT02798952|Experimental|HBV Group|Subjects received a single challenge dose of Engerix-B Kinder.
9841588|NCT02798978|Experimental|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
9841589|NCT02798978|Experimental|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
9841590|NCT02798978|Experimental|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
9841591|NCT02799069|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
9841592|NCT02799069|Active Comparator|MAL Cream|Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
9841593|NCT02799069|Placebo Comparator|Vehicle|Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
9841594|NCT02799082|Placebo Comparator|Vehicle|Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
9841595|NCT02799082|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
9841596|NCT02799290|No Intervention|CONTROL|No intervention
9841597|NCT02799290|Experimental|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
9841598|NCT02799290|Experimental|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
9841599|NCT02799381|Active Comparator|Optimized Medical Treatment (OMT)|Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.
9922090|NCT00835393|Active Comparator|2|
9922091|NCT00835419|Experimental|1|P276-00 investigational product (small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor)
9516893|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 6m+|10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)
9516894|NCT03311243|Experimental|β-Thalassemia major (TM- β)|
9516895|NCT03311243|Active Comparator|Systemically healthy controls|
9792624|NCT01451775|Experimental|Treatment B|high dose of empagliflozin after a standardised high fat breakfast
9792625|NCT01451775|Experimental|Treatment C|low dose empagliflozin after overnight fasting for at least 10 h
9792626|NCT01451814|Experimental|Positive psychotherapy|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
9792627|NCT01451814|Active Comparator|Standard treatment|6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition
9792628|NCT01451827|Experimental|Tolvaptan MR 50 mg|Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
9792629|NCT01451827|Experimental|Tolvaptan MR 80 mg|Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
9792630|NCT01451827|Experimental|Tolvaptan IR 60/30 mg|Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
9792631|NCT01451827|Placebo Comparator|Placebo|Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
9792632|NCT01451931|Experimental|Point-of-care Ultrasound|Patient with suspected urolithiasis will receive ultrasonography performed in the emergency department. Perform ultrasonography in the ED (physician).
9792633|NCT01451931|Experimental|Radiology Ultrasound|Patient with suspected urolithiasis will receive diagnostic ultrasonography in the radiology department. Diagnostic ultrasound completed in the radiology department at time 0.
9792634|NCT01451931|Experimental|Radiology CT|Patient with suspected urolithiasis will receive computed tomography in the radiology department. Computed tomography of abdomen completed in the radiology department at time 0.
9792635|NCT01451983||ASD with PTEN|Individuals with autism spectrum disorder who are also found to have a PTEN mutation.
9792636|NCT01451983||ASD no PTEN macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation with a large head circumference.
9792637|NCT01451983||ASD no PTEN no macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation without a large head circumference.
9792638|NCT01451983||Siblings|Siblings of individuals with autism spectrum disorders.
9792639|NCT01451996|Other|Claritin ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
9792640|NCT01451996|Other|Zyrtec ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
9792641|NCT01452126|Experimental|Ropivacaine|Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
9792642|NCT01452191|Active Comparator|Injury Prevention Briefing and facilitation|Children's Centres will be given an Injury Prevention Briefing which offers guidance on best evidence on reducing fire related injuries in the home, and facilitation by the research team to support implementation of the IPB
9792643|NCT01452191|Active Comparator|Injury Prevention Briefing only|Children's Centres will be given an Injury Prevention Briefing (IPB) , which offers guidance on best evidence on reducing fire related injuries in the home.
9792644|NCT01452191|No Intervention|Usual Care|
9792645|NCT01452269|Experimental|Immediate intervention group|This arm will receive the intervention immediately following baseline data collection.
9792646|NCT01452269|Experimental|Delayed intervention group|This arm will receive the intervention one year following the immediate intervention group.
9792647|NCT01452347|Experimental|Dabigatran etexilate|Patient dose dependent on screening CrCl levels and TT
9792648|NCT01452347|Active Comparator|warfarin|warfarin doses to maintain INR levels
9792649|NCT01452412|Experimental|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
9792650|NCT01452412|Placebo Comparator|Placebo|placebo dosage/frequency equivalent to sodium bicarbonate
9792651|NCT01452425|Experimental|Tourniquet|Inflation of a tourniquet
9792652|NCT01452529|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
9792653|NCT01452529|Placebo Comparator|Placebo|Placebo to match hydrocodone bitartrate once daily tablets
9792654|NCT01452789|Experimental|sublingual buprenorphine|This is the group that received active sublingual buprenorphine and placebo for oral morphine
9792655|NCT01452789|Active Comparator|oral morphine|This is the group that received active oral morphine and placebo for sublingual buprenorphine
9792656|NCT01452919|Experimental|LY2140023/LY2140023|"Open label phase: 40 milligram (mg) LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Current dose level at randomization will remain constant through the double blind phase.~Double blind phase: 40 mg or 80 mg LY2140023 administered orally; given twice daily for up to 3 weeks."
9792657|NCT01452919|Placebo Comparator|LY2140023/Placebo|"Open label phase: 40 mg LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time.~Double blind phase: placebo administered orally; given twice daily for up to 3 weeks."
9792658|NCT01453023|Active Comparator|Fluticasone Furoate|One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
9792659|NCT01453023|Experimental|Fluticasone Furoate/Vilanterol|One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
9792660|NCT01453036|Active Comparator|Conventional AOC group|The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks
9922092|NCT00835445||1|Asthmatics with polyps
9792661|NCT01453036|Active Comparator|Mutation test group|Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
9792662|NCT01453036|Active Comparator|Conventional AOM group|The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
9792663|NCT01453049|Experimental|fix dose of rosiglitazone/glimepiride|4mg/1mg, 4mg/2mg, 4mg/4mg
9792664|NCT01453049|Active Comparator|glimepiride|1mg, 2mg, 4mg
9792665|NCT01453075|Experimental|Arm 1: valacyclovir|Assigned patients will take 1.5 mg po valacyclovir twice daily
9792666|NCT01453075|Placebo Comparator|Arm 2: placebo|Assigned patients will receiving matching placebo twice daily
9792667|NCT01453153|Active Comparator|Gemcitabine|Gemcitabine + Placebo
9792668|NCT01453153|Experimental|PEGPH20|PEGPH20+Gemcitabine
9792669|NCT01453166|Experimental|Group 1|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
9792670|NCT01453166|Experimental|Group 2|Group B received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
9792671|NCT01453166|Experimental|Group 3|Group C received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
9792672|NCT01453205|Active Comparator|Rituximab+ ICE/DHAP|Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
9792673|NCT01453205|Experimental|MEDI-551 2 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
9792674|NCT01453205|Experimental|MEDI-551 4 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
9792675|NCT01453296|Active Comparator|COHORT 1 (RANDOMISATION AB or BA)|"8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
9799720|NCT01667419|Experimental|Cohort 2 Vemurafenib|Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
9799721|NCT01667419|Placebo Comparator|Cohort 2 Placebo|Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
9799722|NCT01667432||Peginterferon alfa-2a|Participants received peginterferon alfa-2a (PEGASYS®) 180 µg subcutaneously in the abdomen or thigh once weekly for 12 weeks.
9799723|NCT01667471|Experimental|RoActemra/Actemra|
9922093|NCT00835445||2|Non-asthmatics with polyps
9799724|NCT01667536|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
9841600|NCT02799381|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.
9841601|NCT02799472|Experimental|GSK3196165 + MTX arm|Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
9841602|NCT02799472|Placebo Comparator|Placebo + MTX arm|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
9841603|NCT02799667|Active Comparator|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
9841604|NCT02799667|Experimental|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
9841605|NCT02799745|Active Comparator|Enzalutamide|Participants received 160-milligrams (mg) enzalutamide administered as four 40-mg capsules, orally once daily for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow-up period, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
9841606|NCT02799745|Other|Active Surveillance (AS)|Participants did not receive any study treatment in this arm but were on continued active surveillance (AS) for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow up, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
9841607|NCT02799784|Experimental|Sequence 1: UMEC/VI 62.5/ 25 mcg|Subjects will receive UMEC/VI 62.5/25 mcg (as one inhalation) administered QD via the ELLIPTA Inhaler for 8 weeks followed by a washout period of 3 weeks
9841608|NCT02799784|Experimental|Sequence 2: TIO/OLO 5/5 mcg|Subjects will receive TIO/OLO 5/5 mcg (as 2 inhalations of 2.5/2.5 mcg per inhalation) administered QD via the RESPIMAT inhaler for 8 weeks followed by a washout period of 3 weeks
9841609|NCT02800148|Experimental|Azelaic acid foam|
9841610|NCT02800148|Active Comparator|Finacea Foam|
9841611|NCT02800148|Placebo Comparator|Placebo Foam|
9792676|NCT01453296|Active Comparator|COHORT 2 (RANDOMISATION AB or BA)|"5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
9792677|NCT01453348|Active Comparator|Group 1|This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' alone on the different visits.
9792678|NCT01453348|Active Comparator|Group 2|This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
9792679|NCT01453348|Active Comparator|Group 3|This group will receive only MenACWY-CRM.
9792680|NCT01453361|Experimental|Vigil™ Vaccine|Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
9792681|NCT01453374|Experimental|VIVITROL|380 mg IM injection
9792682|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 1)|
9792683|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 2)|
9792684|NCT01453413|Other|People with type 2 diabetes|People with type 2 diabetes who were in attendance at a diabetes conference were asked for their perceived Blood Glucose (BG) value. Then, after staff measured BG on a Blood Glucose meter, subjects were informed of their BG value.
9792685|NCT01453439|Experimental|Cognitive Behavioral Therapy|Group receiving Cognitive-Behavioral Therapy
9792686|NCT01453439|Active Comparator|Supportive Psychotherapy|Group receiving Supportive Psychotherapy
9792687|NCT01453569|Experimental|sodium oligo-mannurarate 900mg|
9792688|NCT01453569|Experimental|sodium oligo-mannurarate 600mg|
9792689|NCT01453569|Placebo Comparator|Placebo|
9792690|NCT01453595|Experimental|BEZ235|"This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:~Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).~Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235."
9792691|NCT01453725|Experimental|Golimumab→Golimumab|In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
9792692|NCT01453725|Placebo Comparator|Placebo→Golimumab|In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)
9792693|NCT01453855|Experimental|Travoprost 0.003%|Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
9792694|NCT01453855|Active Comparator|TRAVATAN|Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
9792695|NCT01453894|Experimental|Reminder and Outreach Intervention|Participants randomized to this arm will receive the Reminder and Outreach intervention.
9792696|NCT01453894|No Intervention|Usual Care Control Group|Patients assigned to this arm will receive usual care.
9792697|NCT01453998|Experimental|GSK217744 Group 1|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
9799725|NCT01667549|Experimental|1M0.5|"Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
9799726|NCT01667549|Experimental|1M1.5|"Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.~Intervention: Timing of Diet and Flavor Experience"
9792698|NCT01453998|Experimental|GSK217744 Group 2|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
9792699|NCT01453998|Active Comparator|Infanrix hexa Group|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
9792700|NCT01454063|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
9792701|NCT01454063|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
9792702|NCT01454076|Experimental|Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg|Ixazomib 2.5 milligram (mg), capsule B, orally, once on Day 1 and 15 along with ketoconazole 400 mg, tablets, orally, once daily from Day 12 to 25 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
9792703|NCT01454076|Experimental|Arm 2: Ixazomib 4 mg Capsule A or B|Ixazomib 4 mg, capsule A, orally, once on Day 1 followed by ixazomib 4 mg, capsule B once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, once on Day 1 followed by ixazomib 4 mg, capsule A once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
9792704|NCT01454076|Experimental|Arm 3: Ixazomib 4 mg Fasted or Fed|Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
9792705|NCT01454076|Experimental|Arm 4: Ixazomib 4 mg + Rifampin 600 mg|Ixazomib, 4 mg, capsule B, orally, once on Day 8 along with rifampin 600 mg, capsule, orally, once daily from Day 1 to 14 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
9792706|NCT01454076|Experimental|Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg|Ixazomib, 2.5 mg, capsule B, orally, once on Day 6 along with clarithromycin, 500 mg, tablet, orally, twice daily from Day 1 to 16 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
9792707|NCT01454102|Experimental|Arm A: Nivolumab + Gemcitabine + Cisplatin|"Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
9792708|NCT01454102|Experimental|Arm B: Nivolumab + Pemetrexed + Cisplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
9792709|NCT01454102|Experimental|Arm C: Nivolumab + Paclitaxel + Carboplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles"
9792710|NCT01454102|Experimental|Arm D: Nivolumab + Bevacizumab maintenance|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity"
9792711|NCT01454102|Experimental|Arm E: Nivolumab + Erlotinib|"Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity"
9792712|NCT01454102|Experimental|Arm F: Nivolumab|Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
9792713|NCT01454102|Experimental|Arm G: Nivolumab + Ipilimumab|"In Squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered until PD or discontinuation due to toxicity"
9799727|NCT01667549|Experimental|3M0.5|"Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
9799728|NCT01667549|No Intervention|Control|Mothers will not receive the intervention.
9792714|NCT01454102|Experimental|Arm H: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
9792715|NCT01454102|Experimental|Arm I: Nivolumab + Ipilimumab|"In squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
9792716|NCT01454102|Experimental|Arm J: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
9792717|NCT01454102|Experimental|Arm K: Nivolumab|"In squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks"
9792718|NCT01454102|Experimental|Arm L: Nivolumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks"
9792719|NCT01454102|Experimental|Arm M: Nivolumab|"NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks"
9792720|NCT01454102|Experimental|Arm N: Nivolumab + Ipilimumab|"In subjects with any histology (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
9792721|NCT01454102|Experimental|Arm O: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
9792722|NCT01454102|Experimental|Arm P: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
9792723|NCT01454102|Experimental|Arm Q: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
9792724|NCT01454102|Experimental|Arm R: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
9792725|NCT01454102|Experimental|Arm S: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
9792726|NCT01454284|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
9792727|NCT01454284|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
9792728|NCT01454362|Experimental|Electronic cigarette|We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
9792729|NCT01454362|Active Comparator|Nicotine Inhalator|The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
9792730|NCT01454401|Other|Weekly LeucoPatch treatment|Weekly treatment of diabetic foot ulcers with LeucoPatch
10206736|NCT03998527|Experimental|Non-Disabled (ND) and Spinal Cord Injured (SCI) controls|The ND Control group (n=6) and SCI Control group (n=6) will be used to assess related values as acute effects of transcutaneous electrical spinal cord stimulation (TcESCS) itself and will not receive any training intervention. The ND group will receive baseline assessments, then up to 12 (4-Respiratory function, 4-Arm function, and 4-Trunk function) TcESCS mapping experiments, followed by repeating the assessments in the presence of TcESCS. The investigators will decide which stimulation type should be used for the post-mapping assessments.
10214080|NCT01358669|Active Comparator|Denosumab|In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant
10214081|NCT01358669|Placebo Comparator|Placebo|Placebo
10214082|NCT01350934|Experimental|Fosamax Plus|Participants received alendronate 70 mg plus vitamin D3 5600 IU in a combination tablet (FOSAMAX PLUS D) once weekly for 6 months (base study), and then once weekly for another 6 months (extension study).
10214083|NCT01350934|Active Comparator|Calcitriol|Participants received calcitriol 0.25 μg once daily orally for 6 months (base study), and then once daily orally for another 6 months (extension study).
10214084|NCT01330576|Placebo Comparator|Standard treatment of care at normothermia|Control group: Standard treatment of care at normothermia
10214085|NCT01330576|Experimental|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
9841612|NCT02800213|Experimental|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
9841613|NCT02800213|Active Comparator|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
9841614|NCT02800356|Experimental|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
9841615|NCT02800356|Experimental|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
9841616|NCT02800642|Experimental|Intravitreal (IVT) aflibercept|Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept
9841617|NCT02800928|Experimental|CERC-501|Administered orally once daily, 10mg daily, 8 days
9841618|NCT02800928|Placebo Comparator|Placebo|Administered orally daily, 8 days
9841619|NCT02801006|Experimental|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
9841620|NCT02801006|Active Comparator|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
9841621|NCT02801370|Experimental|OTO-201|
9841622|NCT02801370|Sham Comparator|Control|
9841623|NCT02801396|Active Comparator|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
9841624|NCT02801396|Active Comparator|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
9841625|NCT02801396|Active Comparator|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
9841626|NCT02801396|Active Comparator|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
9841627|NCT02801396|Active Comparator|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
9841628|NCT02801396|Active Comparator|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
9841629|NCT02801578|Experimental|Ibrutinib|"Participants take Ibrutinib capsules by mouth every day for 3, 28 day cycles.~During Cycle 1, participants receive the highest dose of Ibrutinib by taking 3 capsules each day. During Cycle 2, participants receive the second-highest dose and will take 2 capsules each day. During Cycle 3, participant takes the lowest dose of Ibrutinib and takes 1 capsule each day."
9841630|NCT02801617|Experimental|Sequence 1 (PRO-067)|"study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
9841631|NCT02801617|Active Comparator|Sequence 2 (GAAP Ofteno®)|"study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
9841632|NCT02801669|Experimental|DU-176b 15 mg group|DU-176b orally administered at a dose of 15 mg once daily.
9841633|NCT02801669|Placebo Comparator|Placebo group|Placebo orally administered once daily.
9841634|NCT02801877|Experimental|IntelliCare Hub recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and receive coaching for the 8 week IntelliCare program.
9841635|NCT02801877|Experimental|IntelliCare Hub recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and independently use the IntelliCare program for 8 weeks.
9841636|NCT02801877|Experimental|IntelliCare Hub no recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and receive coaching for the 8 week IntelliCare program.
9841637|NCT02801877|Experimental|IntelliCare Hub no recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and independently use the IntelliCare program for 8 weeks.
9792731|NCT01454414|Experimental|Permethrin Impregnated Uniforms|Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
9792732|NCT01454414|No Intervention|Placebo|Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).
9792733|NCT01454505|Experimental|Stage B/AL-53817|Stage B: AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
9792734|NCT01454505|Placebo Comparator|Stage B/Vehicle|Stage B: Vehicle nasal spray, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
9792735|NCT01454531|Experimental|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
9792736|NCT01454570|Experimental|Powered Exoskeleton|persons with SCI trained to use a powered exoskeleton to ambulate overground
9792737|NCT01454583||Aliskiren|Patients getting Aliskiren at baseline
9792738|NCT01454583||ACE-I/ARB|Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
9792739|NCT01454583||No RAS-inhibition|Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)
9792740|NCT01454596|Experimental|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of epidermal growth factor receptor (EGFRv)III Chimeric antigen receptor (CAR) transduced peripheral blood lymphocytes (PBL) + aldesleukin
9792741|NCT01454596|Experimental|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + maximum tolerated dose (MTD) of anti-EGFRvIII CAR transduced PBL established in Phase I + aldesleukin
9792742|NCT01454726|Experimental|experimental group|receiving both Diaoshi Jifa therapy and the Western medical treatment.
9792743|NCT01454726|Other|control group|receiving the Western medical treatment alone.
9792744|NCT01454739|Experimental|On-Demand|The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
9792745|NCT01454739|Experimental|Prophylaxis|Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.
9792746|NCT01454778|Experimental|Paclitaxel|
9792747|NCT01454791|Experimental|Diclofenac Sodium Topical Gel first then Placebo|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
9792748|NCT01454791|Placebo Comparator|Placebo first then Diclofenac Sodium Topical Gel|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
9792749|NCT01454830|Experimental|Tailored|Tailored, or individualized, intervention addressing patient education, skills training, and cognitive perceptions
9792750|NCT01454830|Active Comparator|Usual care|The comparison group, usual care, includes the standard of care delivered to all newly-diagnosed OSA persons proceeding to CPAP treatment
9792751|NCT01454934|Experimental|Arm A|
9792752|NCT01454934|Active Comparator|Arm B|
9792753|NCT01454947|Experimental|SA, AJ, PC|Participants are given all 3 interventions.
9792754|NCT01454947|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
9792755|NCT01454947|Experimental|SA, PC|Participants receive the Suggested Alternative and Peer Comparison interventions, but not the Accountable Justification intervention.
9792756|NCT01454947|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternative intervention.
9792757|NCT01454947|Experimental|Peer Comparison (PC)|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
10206737|NCT03998527|Experimental|Spinal Cord Injured (SCI) intervention groups|The respiratory training (RT) group (n=6) will receive the respiratory training intervention only); the transcutaneous electrical spinal cord stimulation (TcESCS) group (n=6) will receive transcutaneous spinal cord stimulation only; TcESCS + RT group (n=6) will receive TcESCS combined with RT; TcESCS + Arm Training (AT) group (n=6) will receive TcESCS combined with AT; and TcESCS + Trunk Training (TT) group (n=6) will receive TcESCS combined with TT.
10206738|NCT03995238|Experimental|Error-augmentation training|A 4-week, 8 session, treadmill-based gait training program, with error-augmentation of step asymmetry delivered on a split-belt treadmill. Each training session will adhere to the same schedule. During the training blocks on the treadmill, the belt under the limb with the shorter step length will be set at 3/4 of the pre-intervention over-ground self-selected walking speed while the belt under the limb with the longer step length will be set to 1/2 of the fast belt speed (2:1 ratio between belts).
10206739|NCT03995238|Experimental|Error-correction training|A 4-week, 8 session, treadmill-based gait training program, with error-correction of step asymmetry delivered with an auditory metronome signal while walking on a treadmill. During each training block, the metronome will be set to overcorrect stance time asymmetry through use of asymmetrical metronome tones, 2:1 ratio.
10206740|NCT03995238|Active Comparator|Supervised waking|A 4-week, 8 session, treadmill-based supervised walking program. The active comparator group will participate in a supervised treadmill walking program of the same frequency and duration, to the two experimental groups.
10206741|NCT03981731|Experimental|Cardiac coherence|
10206742|NCT03969433|Experimental|Phase I|Data collections are performed with TMSi Porti system and CTG (reference)
10206743|NCT03969433|Experimental|Phases II-III-IV|Data collections are performed with the Bloomlife sensor and CTG (reference)
10206744|NCT03968653|Experimental|Debio 0123|"Participants will receive Debio 0123 as monotherapy (Day -3), orally, daily for 3 days during Cycle 1 then in combination with carboplatin intravenous infusion from Cycle 2 onwards.~Depending on pharmacokinetics (PK) and safety results from previous cohorts, the Debio 0123 dosing regimen may be modified for subsequent cohorts."
10206745|NCT03962543|Experimental|Mirdametinib (PD-0325901)|Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m^2 (maximum dose of 4 mg) by mouth twice daily
10214086|NCT01304511||Participants Treated|Women undergoing controlled ovarian COH for ART
9792758|NCT01454947|Experimental|Suggested Alternatives (SA)|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
9792759|NCT01454947|Experimental|Accountable Justification (AJ)|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
9792760|NCT01454947|No Intervention|Education Control|Participants do not receive any of the 3 interventions.
9792761|NCT01455012|Experimental|Rotigotine|Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)
9792762|NCT01455012|Placebo Comparator|Placebo|Placebo
9792763|NCT01455064||Type 1 or 2 diabetes, MDI or pump|
9792764|NCT01455181|Experimental|NPSP558|
9799729|NCT01667562|Experimental|Erlotinib|Erlotinib will be administered as a single daily oral dose of 150 milligrams until disease progression, death or unacceptable toxicity.
9799730|NCT01667562|No Intervention|Diagnostic Phase|Participants with advanced or metastatic NSCLC were tested for EGFR mutations. Participants who did not have an EGFR mutation were excluded from the study.
9799731|NCT01667679|Experimental|OPTINOSE SUMATRIPTAN and Placebo|20 mg OPTINOSE SUMATRIPTAN Powder Delivered Intranasally With the Bi-directional Device nasally and Placebo Tablet
9799732|NCT01667679|Active Comparator|100mg Sumatriptan and OPTINOSE Placebo|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
9799733|NCT01667731|Experimental|SOF+RBV 12 Weeks (GT 2/3, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
9799734|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 2/3, TE)|Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
9799735|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 1, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.
9799736|NCT01667796|Experimental|Vitamin D3|Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.
9799737|NCT01667848|Experimental|group B: Insufflation with warm gas|Insufflation with warmed, humidified carbon dioxide insufflation during laparoscopic cholecystectomy using the optitherm® device attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
9799738|NCT01667848|Experimental|group A: Insufflation with cold gas|group A: Insufflation with cold gas during laparoscopic cholecystectomy, the use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A
9799739|NCT01667900|Experimental|0.5 mg Dulaglutide (Part A-Healthy)|0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
9799740|NCT01667900|Experimental|0.75 mg Dulaglutide (Part A-Healthy)|0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
9799741|NCT01667900|Experimental|1.5 mg Dulaglutide (Part A-Healthy)|1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
9799742|NCT01667900|Placebo Comparator|Placebo (Part A-Healthy)|Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
9799743|NCT01667900|Experimental|0.5 mg Dulaglutide (Part B-T2DM)|0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
9799744|NCT01667900|Experimental|0.75 mg Dulaglutide (Part B-T2DM)|0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
9799745|NCT01667900|Experimental|1.5 mg Dulaglutide (Part B-T2DM)|1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
9799746|NCT01667900|Placebo Comparator|Placebo (Part B-T2DM)|Placebo administered to participants with T2DM once weekly SQ for 4 weeks
9799747|NCT01667926|Experimental|Ketamine|Subject will receive 6 infusions of ketamine over three weeks.
9799748|NCT01667926|Placebo Comparator|Placebo|Subjects will receive 6 infusions of normal saline over 3 weeks.
9799749|NCT01667978|Experimental|PI|Study group with PI: atazanavir ritonavir
9799750|NCT01667978|Placebo Comparator|Control|o PI therapy, control group
9799751|NCT01668004|Experimental|GLM 50 mg|GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months
9799752|NCT01668017|Experimental|Part 1: Pimasertib 30mg in Solid Tumor|
9799753|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in Solid Tumor|
9799754|NCT01668017|Experimental|Part 1: Pimasertib 60 mg in Solid Tumor|
9799755|NCT01668017|Experimental|Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)|
9799756|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in HCC|
9799757|NCT01668030|Experimental|Bacitracin on left, Enzymatic agent on right|Subjects were randomized to receive enzymatic agent on right side of face and bacitracin on left.
9799758|NCT01668030|Experimental|Bacitractin on right, enzymatic agent on left|Subjects were randomized to receive enzymatic agent on left side of face and bacitracin on right.
9799759|NCT01668173|Experimental|AUY922|This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
9799760|NCT01668355|Experimental|SMI-PACT|Patient Aligned Care Team (PACT) medical home model to address the physical healthcare needs of individuals with serious mental illness
9799761|NCT01668355|No Intervention|Usual Care|Usual Primary Care
9799762|NCT01668537|Experimental|Group 1|LF formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
9799763|NCT01668537|Experimental|Group 2|FD formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
9841638|NCT02801942|Experimental|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
9841639|NCT02801942|Experimental|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
9841640|NCT02802111|Experimental|Albuterol 5 mg first, then levalbuterol 2.5 mg|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
9841641|NCT02802111|Experimental|Levalbuterol 2.5 mg first, then albuterol 5 mg|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
9841642|NCT02802241|Experimental|open-label placebo|
9841643|NCT02802241|Experimental|double-blind placebo|
9841644|NCT02802241|Experimental|double-blind peppermint oil|
9841645|NCT02802241|No Intervention|no additional treatment|
9841646|NCT02802319|Experimental|Test: Porcine Xenograft (Zcore)|Ridge preservation bone grafting surgery with porcine xenograft (Zcore)
9841647|NCT02802319|Active Comparator|Active Control: Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting surgery with bovine xenograft (Bio-Oss)
9841648|NCT02802345|Experimental|Nintedanib + placebo matching sildenafil|
9841649|NCT02802345|Active Comparator|Nintedanib + Sildenafil|
9841650|NCT02802449|Placebo Comparator|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
9841651|NCT02802449|Active Comparator|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
9841652|NCT02802501|Experimental|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
9841653|NCT02802501|Active Comparator|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
9841654|NCT02802501|Placebo Comparator|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
9922094|NCT00835471|Experimental|1|Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
9922095|NCT00835471|Active Comparator|2|Erlotinib
9922096|NCT00835523||OHSS risk|
9922097|NCT00835562|Experimental|Osteosynthesis|
9922098|NCT00835562|Experimental|Non-surgical|
9516896|NCT03311217|Experimental|Intervention group|Healthy retail strategies will be implemented in tribally owned convenience stores in these communities. Specific strategies include pricing discounts, promotional signage, incorporation of new product, and placement of healthier items on shelves.
9922099|NCT00835562|Experimental|Hemiarthroplasty|
9792765|NCT01455194|Active Comparator|CIC 160|Two puffs of 40 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 160 mcg)
9792766|NCT01455194|Active Comparator|CIC 320|Two puffs of 80 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 320 mcg)
9792767|NCT01455194|Active Comparator|CIC 640|Two puffs of 160 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 640 mcg)
9792768|NCT01455415|Experimental|1: Pregabalin|
9792769|NCT01455415|Placebo Comparator|2: Placebo|
9792770|NCT01455428|Experimental|Lyrica (pregabalin)|
9792771|NCT01455428|Placebo Comparator|Placebo|
9792772|NCT01455519|Placebo Comparator|Sugar pill|Subjects may receive a pill with no medicine.
9792773|NCT01455519|Active Comparator|Hydromorphone ER|Subjects received study drug: Hydromorphone ER
9792774|NCT01456000|Experimental|EAS-AC (HeartLight)|Treatment with the EAS-AC.
9792775|NCT01456000|Active Comparator|Control Arm Ablation|Treatment with standard ablation.
9792776|NCT01456039|Experimental|Romidepsin|Patients will receive romidepsin intravenously for 4 hours on Days 1, 8, and 15 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, severe adverse events, or consent withdrawal.
9792777|NCT01456052|Experimental|Low Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally once daily (QD).
9792778|NCT01456052|Experimental|High Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally three times daily (TID).
9792779|NCT01456052|Placebo Comparator|Placebo|Matching placebo administered orally.
9792780|NCT01456130|Experimental|Alogliptin|Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
9792781|NCT01456143|Experimental|HRME with proflavine|High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.
9792782|NCT01456169|Active Comparator|Azilsartan medoxomil 40 mg|Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
9792783|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/12.5 mg|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
9792784|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/25 mg|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
9792785|NCT01456195|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
9792786|NCT01456195|Experimental|Fasiglifam 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
9792787|NCT01456195|Experimental|Fasiglifam 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
9792788|NCT01456221|Experimental|omega 3 and an hypocaloric diet|Participants will receive a supplement containing omega 3: Docosahexaenoic acid (DHA) and EPA fatty acids together with an hypocaloric diet.
9792789|NCT01456221|Placebo Comparator|Placebo|Participants will receive a supplement containing sunflower oil with an hypocaloric diet.
9792790|NCT01456299|Placebo Comparator|Control|The control group, which received an infusion of normal saline.
9792791|NCT01456299|Active Comparator|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
9792792|NCT01456299|Active Comparator|Remifentanil 2|"Remifentanil 2: The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml."
9792793|NCT01456494|Experimental|Teach-to-Goal|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
9922100|NCT00835627|Active Comparator|sertraline|flexible dose sertraline
9792794|NCT01456494|Experimental|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
9792795|NCT01456780|Active Comparator|Zylet|Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
9792796|NCT01456780|Active Comparator|Lotemax|Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
9792797|NCT01456780|Placebo Comparator|B+L Advanced Eye Relief Lubricant Drop|Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.
9792798|NCT01456897|Experimental|OPC-34712|
9792799|NCT01456936|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
9792800|NCT01456936|Active Comparator|varenicline|
9792801|NCT01456936|Active Comparator|bupropion|
9792802|NCT01456936|Active Comparator|Nicotine Replacement Therapy Patch|
9792803|NCT01456949|Other|Single Arm|Cryoablation
9792804|NCT01456962||Raltegravir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with raltegravir (RAL)
9792805|NCT01456962||Atazanavir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with ritonavir (RIT)-boosted atazanavir (ATZ)
9792806|NCT01457014|Active Comparator|servo ventilation auto mode|Inspiratory and expiratory pressures automatically determined by the servo ventilation device.
9792807|NCT01457014|Active Comparator|Continuous positive airway pressure|Airway pressure delivered at a constant pressure level.
9792808|NCT01457014|Active Comparator|servo ventilation manual|Inspiratory and expiratory pressures automatically determined by the servo ventilation device with mandatory minimal inspiratory minus expiratory pressure difference.
9792809|NCT01457118|Experimental|NKTR-102|
9792810|NCT01457196|Other|Sequencing Arm|
9792811|NCT01457339|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
9792812|NCT01457339|Placebo Comparator|Placebo|
9792813|NCT01457352|Experimental|SPARC0921|
9792814|NCT01457352|Placebo Comparator|Placebo0921|
9792815|NCT01457417|Experimental|75 milligram (mg) DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
9792816|NCT01457417|Experimental|150 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
9792817|NCT01457417|Experimental|300 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
9792818|NCT01457417|Experimental|600 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
9792819|NCT01457417|Experimental|300 mg DKN-01 Part B|Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
9792820|NCT01457430|Experimental|Icatibant|Open-label study
9792821|NCT01457521|Active Comparator|Therapeutic|Ibuprofen
9792822|NCT01457521|Active Comparator|Prophylactic|Ibuprofen
9792823|NCT01457573|Experimental|One (single arm)|All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg (1 tab) and Solifenacin (Vesicare) 5 mg (1 tab) orally at the same time.
9792824|NCT01457703|Active Comparator|BMI ≥30 kg/m2|"Group 2:~BMI ≥30 kg/m2~History of regular menstrual cycles every 25-40 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
9792825|NCT01457703|Experimental|BMI 18-25 kg/m2|"BMI 18-25 kg/m2~History of regular menstrual cycles every 25-35 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
9792826|NCT01457846|Experimental|AZD4547|AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
9792827|NCT01457846|Active Comparator|Paclitaxel|Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
9841655|NCT02802514|Experimental|With Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Week 9) and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
9841656|NCT02802514|Experimental|Without Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 and exenatide placebo on Day 4 followed by a post-dose MRI scan. In session 2, Day 1 (Week 9) subject will undergo off-therapy MRI scan. Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
9841657|NCT02802514|Experimental|With Off therapy MRI in S1:Exenatide-S1 & Albiglutide-S2|In session 1, Day 1 subject will undergo off-therapy MRI scan Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan In session 2, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 (Week 9) and exenatide placebo Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
9841658|NCT02802514|Experimental|Without Off therapy MRI in S1: Exenatide-S1 & Albiglutide-S2|In session 1, subject will receive single dose each of albiglutide placebo on Day 1 and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. In session 2, subject will undergo off-therapy MRI scan on Day 1 (Week 9). Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI scan.. There will be 6-9 week washout period between Session 1 and Session 2
9841659|NCT02802735|Experimental|Part 1: Apremilast 20 mg|A single oral dose of 20 mg apremilast.
9841660|NCT02802735|Experimental|Part 1: Apremilast 30 mg|A single oral dose of 30 mg apremilast.
9841661|NCT02802735|Experimental|Part 1: Apremilast 40 mg|A single oral dose of 40 mg apremilast.
9841662|NCT02802735|Experimental|Part 2: Apremilast 30 mg BID|30 mg apremilast orally twice a day (BID) for 14 days.
9841663|NCT02802735|Placebo Comparator|Part 2: Placebo|Matching placebo orally twice a day for 14 days.
9841664|NCT02802865|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7
9841665|NCT02802865|Experimental|Letrozole + Clomiphene|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7
9516897|NCT03311217|No Intervention|Control group|No intervention will be implemented in the stores in the control communities.
9841666|NCT02802878|Experimental|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
9841667|NCT02802878|Active Comparator|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
9841668|NCT02803138||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablets; 1000 or 1200 mg divided twice a day) up to 24 weeks
9841669|NCT02803164|Other|Vacuum-assisted dressing|Eligible subjects will receive negative pressure wound therapy during surgery.
9841670|NCT02803164|Other|Historical control group for comparison|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
9841671|NCT02803229|Placebo Comparator|Placebo|matched Placebo arm
9841672|NCT02803229|Experimental|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
9841673|NCT02803749|Experimental|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
9841674|NCT02803749|Placebo Comparator|Placebo|Flexible dosage placebo for 12 weeks.
9841675|NCT02804178|Experimental|ATR-101|Ascending dose levels of ATR-101 beginning with 125 mg by mouth twice per day up to 1000 mg twice per day.
9841676|NCT02804399|Experimental|all subjects|subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
9841677|NCT02804594|Active Comparator|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
9841678|NCT02804594|Placebo Comparator|Placebo|placebo three times daily
9922101|NCT00835627|Active Comparator|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions
9792828|NCT01457885|Experimental|CloBu4 regimen|After pre-conditioning with CloBu4 (Clofarabine/Busulfan x 4), subjects will receive a peripheral blood stem cell transplant
9792829|NCT01457924|Experimental|Cohort 1|Placebo and one dose of Ofatumumab 3mg over 24 weeks
9792830|NCT01457924|Experimental|Cohort 2|Two doses of Ofatumumab 3mg over 24 weeks
9792831|NCT01457924|Experimental|Cohort 3.1|Two doses of Ofatumumab 30mg over 24 weeks
9792832|NCT01457924|Experimental|Cohort 3.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 30mg over 24 weeks
9792833|NCT01457924|Experimental|Cohort 4.1|Two doses of Ofatumumab 60mg over 24 weeks
9792834|NCT01457924|Experimental|Cohort 4.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 60mg over 24 weeks
9792835|NCT01457924|Experimental|Cohort 5.1|Six doses of Ofatumumab 60mg over 24 weeks
9792836|NCT01457924|Experimental|Cohort 5.2|Conditioning dose of Ofatumumab 3mg at randomization, six doses of Ofatumumab 60mg over 24 weeks
9792837|NCT01457950|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
9792838|NCT01457950|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
9792839|NCT01457950|Experimental|Arm 3|open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
9792840|NCT01458106|Experimental|All participants|"PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated."
9792841|NCT01458119|Experimental|Migalastat|Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
9792842|NCT01458132||Subjects who experienced seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and experienced seizure
9792843|NCT01458132||Subjects who did not experience seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and did not experience seizure
9792844|NCT01458171|Experimental|IgPro20|
9792845|NCT01458210|Experimental|Ortho-Cyclen (OC) Alone (Period 1); OC+Dulaglutide (Period 2)|"Ortho-Cyclen (OC) (0.25 milligram [mg] norelgestromin [NGMN] + 0.035 mg ethinyl estradiol [EE] [active tablets] for 21 days + non-active tablets for 7 days): A 28-day course of OC consists of 0.25 mg NGMN and 0.035 mg EE (active tablets), administered orally, once per day for 21 days, then non-active tablets, administered orally, once per day for 7 days. Participants received the first 28-day course (Lead-in) followed by 2 subsequent 28-day courses (Periods 1 and 2, respectively). Following the Lead-in period, the Period 1 sample was taken during the first 28-day course and the Period 2 sample was taken during the second 28-day course.~Dulaglutide: A single, 1.5-mg subcutaneous injection on Day 19 of Period 2."
9792846|NCT01458249|Experimental|eribulin mesylate 1.4 mg/m^2|
9792847|NCT01458275|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
9792848|NCT01458275|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
9792849|NCT01458275|Placebo Comparator|Placebo|
9792850|NCT01458288|Experimental|TG-0054 (3.14 mg/kg)|TG-0054 (3.14 mg/kg)
9792851|NCT01458327|Experimental|3,4-methylenedoxymethamphetamine (MDMA)-assisted therapy|125 mg and 62.5 mg MDMA and therapy
9792852|NCT01458366|Experimental|Bendamustine 70mg/m^2|Level 1: Bendamustine 70mg/m^2 Ofatumumab, Carboplatin, and Etoposide
9792853|NCT01458366|Experimental|Bendamustine 50mg/m^2|Level -1: Bendamustine 50mg/m^2 Ofatumumab, Carboplatin, and Etoposide
9792854|NCT01458366|Experimental|Bendamustine 90mg/m^2|Level 2: Bendamustine 90mg/m^2 Ofatumumab, Carboplatin, and Etoposide
9792855|NCT01458366|Experimental|Bendamustine 120mg/m^2|Level 3: Bendamustine 120mg/m^2 Ofatumumab, Carboplatin, and Etoposide
9792856|NCT01458366|Experimental|Phase II MTD|Phase II: Bendamustine at MTD from Phase I, Ofatumumab, Carboplatin, and Etoposide
9792857|NCT01458392|Experimental|Dalantercept|dalantercept
9792858|NCT01458418|Experimental|Montelukast 10 mg/day|Subjects will receive two 5mg tablets of Montelukast/day.
9792859|NCT01458418|Experimental|Montelukast 5mg/day|Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
9792860|NCT01458418|Placebo Comparator|placebo|Subjects will receive two placebo tablets per day.
9792861|NCT01458522|Active Comparator|fPHT 20mg|fPHT treatment arm, a bolus of 20 mg PE/kg will be administered at a rate of no greater than 75 mg PE/minute. If a further bolus is required, 5 mg PE/kg will be administered. The daily maintenance dose for fPHT will be 5 mg PE/kg divided into 2 doses.
9516898|NCT03311204|Experimental|Microblepharon Exfoliation|This treatment is provided using BlephEx tool from Optimed Pty Ltd.
9799764|NCT01668602|Experimental|Cohort 1 - FastFES Training|Participants with chronic stroke in Cohort 1 will receive 18 training sessions of FastFES (fast treadmill walking with electrical stimulation).
9841679|NCT02804750|Experimental|Group 1: Low-dose Group|100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
9841680|NCT02804750|Experimental|Group 2: High-dose Group|250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
9841681|NCT02804763|Placebo Comparator|Placebo|Placebo in a specified sequence for a total of 24 weeks
9841682|NCT02804763|Experimental|DZP dose 1|Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
9841683|NCT02804763|Experimental|DZP dose 2|Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
9841684|NCT02804763|Experimental|DZP dose 3|Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
9841685|NCT02805179|Experimental|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
9841686|NCT02805309|Experimental|Exercise & Cognitive Behavioral Int.|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program and cognitive behavioral interventions.
9841687|NCT02805309|Experimental|Exercise Alone|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program, without cognitive behavioral interventions.
9841688|NCT02805309|Active Comparator|Attention Control Education Program|Participants will receive telephone-based education sessions from a study health professional.
9841689|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
9841690|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
9841691|NCT02805660|Experimental|Phase 1: Dose Escalation - 50 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
9841692|NCT02805660|Experimental|Phase 1: Dose Escalation - 70 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
9841693|NCT02805660|Experimental|Phase 1: Dose Escalation - 90 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
9841694|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 1|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with no/low programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
9841695|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 2|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with high programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
9841696|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 3|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent with clinical benefit response followed by progression of disease were included in this cohort.
9841697|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 4|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent who had progression of disease ≤ 16 weeks after initiation of treatment were included in this cohort.
9841698|NCT02805790|Experimental|Elamipretide, Then Placebo|Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks.
9841699|NCT02805790|Placebo Comparator|Placebo, Then Elamipretide|Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks.
9841700|NCT02805907|Experimental|Intervention Group (IG)|Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
9841701|NCT02805907|Placebo Comparator|Control Group (CG)|Placebo in a presentation with an identical appearance taken weekly by the oral route
9516899|NCT03311204|Experimental|Eyelid cleansing using Lid Hygenix|Foam-based hypoallergenic cleanser used as a control treatment in this study.
9841702|NCT02805972|Experimental|Naloxone, then Placebo|4 mg / 0.1 ml Naloxone at visit 1, followed by 0.1 ml saline (Placebo) at visit 2 (with a washout period in between the two visits)
9841703|NCT02805972|Experimental|Placebo, then Naloxone|0.1 ml saline (Placebo) at visit 1, followed by 4 mg / 0.1 ml Naloxone at visit 2 (with a washout period in between the two visits)
9841704|NCT02806024|Experimental|Treatment Arm (Tranexamic Acid, or TXA)|Patients will be randomized to treatment or placebo arms preoperatively. In our treatment arm of pregnant patients with suspected placenta accreta or at high risk for placenta accreta, patients will receive 1 gram intravenous TXA administered over 10 minutes immediately after delivery of the infant. The drug will be prepared and ready to hang at the beginning of the case. The study drug will be administered only once.
9922102|NCT00835627|Active Comparator|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions
9516900|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
9516901|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
9516902|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
9516903|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
9799765|NCT01668602|Experimental|Cohort 2 - FastFES and Fast Walking|Participants with chronic stroke in Cohort 2 who complete 3 sessions of FastFES and 3 sessions of fast walking.
9799766|NCT01668628||Incident PD patients|First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study
9799767|NCT01668628||Prevalent PD patients|Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months
9799768|NCT01668628||Prevalent HD patients|Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months
9799769|NCT01668654|Experimental|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
9799770|NCT01668667|Active Comparator|GSK1838262 600 mg|Once-daily dose with food in the evening at approximately 5 PM
9799771|NCT01668667|Active Comparator|GSK1838262 450 mg|Once-daily dose with food in the evening at approximately 5 PM
9799772|NCT01668667|Active Comparator|GSK1838262 300 mg|Once-daily dose with food in the evening at approximately 5 PM
9799773|NCT01668667|Placebo Comparator|GSK1838262 placebo match|Once-daily dose with food in the evening at approximately 5 PM
9799774|NCT01668719|Active Comparator|Arm I (bortezomib, lenalidomide, dexamethasone)|"INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).~MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9799775|NCT01668719|Experimental|Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab)|"INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9799776|NCT01668797|Placebo Comparator|Placebo|Placebo comparator for 52 weeks
9799777|NCT01668797|Experimental|Brexpiprazole (OPC-34712)|Brexpiprazole (OPC-34712) for 52 weeks
9799778|NCT01668836|Experimental|men with resveratrol|12 men will receive a pill with 500mg of resveratrol daily for 30 days
9799779|NCT01668836|Experimental|women with resveratrol|12 women will receive a pill with 500mg of resveratrol daily for 30 days
9799780|NCT01668836|Active Comparator|men with caloric restriction|12 men will follow a 1000 calories per day diet for 30 days
9799781|NCT01668836|Active Comparator|women with caloric restriction|12 women will follow a 1000 calories per day diet for 30 days
9799782|NCT01668966|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
9799783|NCT01669096|Experimental|GSK 692342 Group|Healthy male and female subjects, between and including 18 to 50 years of age, who received 2 doses of GSK 692342 vaccine administered intramuscularly in the deltoid region of the arm, at Days 0 and 30.
9799784|NCT01669122|Experimental|Prototype 1|4mg nicotine lozenge administered orally as a single dose treatment per subject
9799785|NCT01669122|Experimental|Prototype 2|4mg nicotine lozenge administered orally as a single dose treatment per subject
9799786|NCT01669122|Experimental|Prototype 3|4mg nicotine lozenge administered orally as a single dose treatment per subject
9799787|NCT01669122|Active Comparator|Reference Therapy|4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment per subject.
9799788|NCT01669174|Experimental|BYM338|
9799789|NCT01669174|Placebo Comparator|Placebo|
9799790|NCT01669343|Other|Post-menopausal Women Using Adjuvant Letrozole|Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants
9799791|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose baseline|Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4
9799792|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) Double dose|Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8
9799793|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose|4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12
9799794|NCT01669434|Experimental|ACEI continuation|Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
9799795|NCT01669434|Experimental|ACEI omission|Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.
9841705|NCT02806024|Placebo Comparator|Placebo Arm|Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
9841706|NCT02806232|Experimental|Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
9841707|NCT02806232|Experimental|Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
9841708|NCT02806232|Experimental|Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg|Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
9841709|NCT02806232|Experimental|Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg|Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
9841710|NCT02806232|Experimental|Part 1, Cohort 5: Levo Praziquantel 30 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
9841711|NCT02806232|Experimental|Part 1, Cohort 6: Levo Praziquantel 45 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
9841712|NCT02806232|Experimental|Part 1, Cohort 7: Levo Praziquantel 60 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
9841713|NCT02806232|Experimental|Part 2, Cohort 8: Levo Praziquantel 50 mg/kg|Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
9841714|NCT02806232|Experimental|Part 2, Cohort 9: Levo Praziquantel 50 mg/kg|Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
9841715|NCT02806414|Experimental|Ivermectin|All subjects will be treated with topical ivermectin daily for up to 12 weeks.
9841716|NCT02806505|Experimental|Peginterferon alfa-2a 135 microgram (mcg)|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
9841717|NCT02806505|Experimental|Peginterferon alfa-2a 90 mcg|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
9841718|NCT02806544|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily
9841719|NCT02806713|Placebo Comparator|no phenazopyridine|Patients not receiving phenazopyridine (standard of care)
9841720|NCT02806713|Experimental|phenazopyridine|Patients receiving phenazopyridine
9841721|NCT02806726|Experimental|iDesign 1.3-PRESBY|iDesign 1.3-PRESBY in one eye of subject (experimental) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
9841722|NCT02806726|Active Comparator|iDesign 1.3|iDesign 1.3 in one eye of subject (control) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
9841723|NCT02806869|Experimental|Arm #1 - Fasting State, 2 study visits|"Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
9841724|NCT02806869|Experimental|Arm #2 - Fed State, 2 study visits|"Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
9841725|NCT02806895|Placebo Comparator|Placebo|Once daily dosing
9841726|NCT02806895|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
9841727|NCT02806908|Placebo Comparator|Placebo|Once daily dosing
9841728|NCT02806908|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
9841729|NCT02806947|Experimental|Sirolimus|Sirolimus, a steroid-free therapy, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
9841730|NCT02806947|Active Comparator|Prednisone|Prednisone, standard of care therapy for GVHD, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
9841731|NCT02806973|Experimental|Nasal Glucagon (NG) - Treatment 1|One dose of 3 milligram (mg) NG administered in one of four study periods.
9841732|NCT02806973|Experimental|NG - Treatment 2|Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods.
10206746|NCT03949361||Patients starting glucocorticoids|Patients starting a glucocorticoid therapy measuring primary and secondary endpoints before and after at least 4 weeks of treatment.
10206747|NCT03949361||Patients stopping glucocorticoids|Patients stopping a glucocorticoid therapy measuring primary and secondary endpoints before weaning off glucocorticoids and after a period of at least 3 months.
10206748|NCT03948295|Experimental|Lipid Challenge Intervention|Participants of all weights will receive the lipid challenge intervention.
10214087|NCT01286207|Experimental|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
10214088|NCT01286207|Experimental|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
9841733|NCT02806973|Experimental|NG - Treatment 3|Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods.
9841734|NCT02806973|Experimental|NG - Treatment 4|Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.
9841735|NCT02806986|Experimental|IGSC 20%|13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%
9841736|NCT02807259|Experimental|Multi-level intervention|This is a cluster-randomised controlled trial design. The unit of randomisation is village.
9841737|NCT02807259|Other|Control|The intervention will rolled out to all participating villages after 24 months.
9841738|NCT02807376|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's standard of care stapler
9841739|NCT02807376|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
9841740|NCT02807402||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
9841741|NCT02807623|Experimental|Ibuprofen|Randomized and double blinded study participants assigned to Group A intervention will receive an oral NSAID of ibuprofen 800 mgs three times a day for 48 hours.
10206749|NCT03946761|Experimental|Cancer goggle system|"The surgical procedure will be performed according to standard practice, with the exception of microdosing of ICG & visualization of biliary/liver anatomy using the cancer goggles system~The surgeon will start with a peripherally injected microdose of 0.02 mg of ICG & will inject an additional 0.02mg every 5 minutes until a noticeable fluorescent change in the liver is observed. If a change is not observed after 0.14 mg has been injected then the microdosing regimen will stop. Output video from the cancer goggles will be recorded and saved for post-surgical analysis.~Following resection of the liver parenchyma, the portal area and the cut surface of the liver will be analyzed for the identification of bile ducts leaks with or without cancer goggles."
10206750|NCT03946423|Experimental|Sleeve Gastrectomy & Lifestyle Intervention|
9841742|NCT02807623|Placebo Comparator|Placebo|Randomized and double blinded study participants assigned to Group B intervention will receive an oral placebo three times a day for 48 hours starting immediately after influenza vaccine receipt.
9841743|NCT02807623|Experimental|Compound Exercise of Push-ups|Randomized study participants assigned to Group C will perform an exercise intervention of push-ups immediately after influenza vaccine receipt.
9841744|NCT02807844|Experimental|Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W
9841745|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W
9841746|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W
9841747|NCT02807844|Experimental|Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W
9841748|NCT02807844|Experimental|Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W
9841749|NCT02807844|Experimental|Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W
9841750|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)
9841751|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)
9841752|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)
10206751|NCT03946423|Active Comparator|Lifestyle Intervention|
10206752|NCT03922321|Experimental|RVT-1401|RVT-1401 680 milligrams (mg) weekly for two weeks followed by 340 mg weekly for four weeks, administered subcutaneously
9841753|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)
9841754|NCT02807857|Other|Patients' heart failure and non-heart failure|No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians
9841755|NCT02807948|Other|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
9841756|NCT02808052|Experimental|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives a single 200-mg dose of Minocin (minocycline) for Injection except for the hemodialysis therapy/end stage renal disease cohort, which receives two 200-mg doses.
9841757|NCT02808130||group H|"Group H: normolipidemic+ periodontally healthy individuals The healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
9841758|NCT02808130||Group G|"Group G: normolipidemic + gingivitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
9922103|NCT00835627|Active Comparator|Standard care|community care / treatment as usual: routine follow up with existing providers
9922104|NCT00835653||1|patients with a carpal tunnel syndrome
9922105|NCT00835653||2|patients without a carpal tunnel syndrome
10206753|NCT03921255|Active Comparator|TAF Incongruent (TAF-INC)|Active condition (TAF-INC) cognitive bias modification for interpretations (CBM-I), incorporates an obsessional thought meant to elicit either moral or likelihood TAF, followed by a sentence incongruent to TAF bias and meant to reduce the impact of the previous statement. Before moving on, participants must fill-in and correctly solve a key word important in the interpretation of the sentence. Participants then must correctly solve a short yes/no comprehension question to ensure understanding of the scenario.
10214089|NCT01286207|Active Comparator|Standard Care|Standard care at onset of migraine attack
9841759|NCT02808130||Group CP|"Group CP: normolipidemic + generalized chronic periodontitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
9841760|NCT02808130||Group HH|"Group HH: hyperlipidemic + periodontally healthy individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
9841761|NCT02808130||Group HG|"Group HG: hyperlipidemic + gingivitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
9841762|NCT02808130||group HCP|"Group HCP: hyperlipidemic + generalized chronic periodontitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
9841763|NCT02808312|Experimental|Cohort 1: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
9841764|NCT02808312|Experimental|Cohort 1: Normal Hepatic Function|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
9841765|NCT02808312|Experimental|Cohort 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
9841766|NCT02808312|Experimental|Cohort 2: Normal Hepatic Function|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
9841767|NCT02808312|Experimental|Cohort 3: Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
9841768|NCT02808312|Experimental|Cohort 3: Normal Hepatic Function|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
9841769|NCT02808338|Active Comparator|Philips BiPAP AutoSV Advanced System One|"The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.~P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto"
9841770|NCT02808338|Experimental|Modified Philips BiPAP ASV|The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
9841771|NCT02808338|Active Comparator|ResMed S7 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16"
9841772|NCT02808338|Active Comparator|ResMed S9 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off"
9841773|NCT02808429|Experimental|Placebo|
9841774|NCT02808429|Experimental|Atacicept 25 mg|
9841775|NCT02808429|Experimental|Atacicept 75 mg|
9841776|NCT02808819|Other|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
9841777|NCT02808819|Other|Benralizumab Arm B|Benralizumab administered subcutaneously every 8 weeks
9841778|NCT02808975|Placebo Comparator|Placebo|"Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week~Period B: Weeks 13-14- 1 SC injection each week~Period C: Weeks 15-23- 1 SC injection each week"
9841779|NCT02808975|Active Comparator|Adalimumab|"Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week~Period B: Weeks 13-14- 1 SC 40 mg injection each week~Period C: Weeks 15-23- 1 SC 40 mg injection each week"
9841780|NCT02809053|Experimental|SAIT101|
9841781|NCT02809053|Active Comparator|MabThera®|
9841782|NCT02809183|Placebo Comparator|Placebo-BID|Administered twice daily (BID) for 14 days
9841783|NCT02809183|Experimental|TRC101 (1.5g BID)|Administered twice daily (BID) for 14 days
9841784|NCT02809183|Experimental|TRC101 (3g BID)|Administered twice daily (BID) for 14 days
9841785|NCT02809183|Experimental|TRC101 (4.5g BID)|Administered twice daily (BID) for 14 days
9841786|NCT02809183|Experimental|TRC101 (6g QD)|Administered once daily (QD) for 14 days
9841787|NCT02809183|Placebo Comparator|Placebo-QD|Administered once daily (QD) for 14 days
9841788|NCT02809430|Experimental|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
9841789|NCT02809833||Tocilizumab for RA in Routine Practice|Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.
9841790|NCT02809846|Active Comparator|Quell Device|Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
9841791|NCT02809846|Sham Comparator|Sham Quell Device|Identical to Active Comparator, but provides sub-therapeutic electronic stimulation.
9841792|NCT02809859|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
9841793|NCT02809911|Other|Sham of Provant|Sham of Provant Therapy System
9841794|NCT02809911|Other|Active Provant|Active Provant Treatment
9841795|NCT02809976|Experimental|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
9841796|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
9841797|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
9841798|NCT02810340|Experimental|MCV-5 with adjuvant|Received a single intramuscular injection of Adjuvanted MCV-5.
9841799|NCT02810340|Experimental|MCV-5 without adjuvant|Received a single intramuscular injection of Non-Adjuvanted MCV-5.
9841800|NCT02810340|Active Comparator|Menactra®|Received a single intramuscular injection of Menactra.
9841801|NCT02810392|Active Comparator|Intranasal Insulin|Intranasal Insulin (20 IU BID): Humulin insulin packaged is in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
9841802|NCT02810392|Placebo Comparator|Intranasal Saline|Intranasal saline: Saline is packaged in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
9841803|NCT02810509||Short-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days < 90 days"
9841804|NCT02810509||Long-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days ≥ 90 days"
9841805|NCT02810873|Experimental|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
9841806|NCT02810873|Experimental|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
9841807|NCT02810951|Experimental|FCX-007|"In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.~In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.~All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results.~One wound in each target wound pair will be used as control for efficacy and safety evaluations."
9841808|NCT02810964|Experimental|Sulforaphane Nutraceutical|The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
9841809|NCT02810964|Placebo Comparator|Identical-appearing Placebo|The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
9841810|NCT02811159|Experimental|Telapristone Acetate 12 mg|Telapristone acetate 12 milligrams (mg), orally, once daily for two 18-weeks courses (Treatment Courses 1 and 2) separated by an off-drug interval (ODI).
9841811|NCT02811302|Other|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
9841812|NCT02811419|Active Comparator|i-scan|Inspection with i-scan surface enhancement
9841813|NCT02811419|Active Comparator|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
9922106|NCT00835744|Placebo Comparator|A|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
9922107|NCT00835744|Active Comparator|B|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle.
9922108|NCT00835757||1|Diabetic peripheral neuropathy
9922109|NCT00835757||2|Healthy controls
9922110|NCT00835783||FUO|Patients with fever of unknown origin undergoing FDG-PET/CT as part of work-up.
9922111|NCT00835783||BUO|Patients with bacteremia of unknown origin undergoing FDG-PET/CT as part of work-up.
9922112|NCT00835783||VGI|Patients with vascular graft infections undergoing FDG-PET/CT as part of work-up.
9922113|NCT00835809||Acute respiratory diseases.|Patient admit in emergency or intensive care unite with acute respiratory insufficiency.
9922114|NCT00835822|Experimental|A|Arm treated with Investigational product.
9922115|NCT00835822|Placebo Comparator|B|Arm treated with placebo.
9922116|NCT00835835|Placebo Comparator|Control group|The placebo group did not receive treatment during the matched period yet did undergo all assessments. The MS Placebo group received equal treatment following the study intervention period.
9922117|NCT00835835|Experimental|Combination Treadmill training group|Subjects randomized to Combination therapy received 20 minutes of Lokomat assisted treadmill training followed by up to 20 minutes of BWS treadmill training (without robotic assistance) twice a week.
9922118|NCT00835848|Active Comparator|Exenatide|25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
9922119|NCT00835848|Placebo Comparator|Saline|Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
9922120|NCT00835887|Experimental|1|Treatment with low dose flavanoids
9922121|NCT00835887|Experimental|2|Treatment with high dose flavanoids
9922122|NCT00835939|Active Comparator|25% Dextrose and 1% Lidocaine|
9922123|NCT00835939|Placebo Comparator|Lidocaine|
9922124|NCT00835952|Experimental|ATX-101|
9922125|NCT00835965|Active Comparator|Active Comparator|Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting
9922126|NCT00835965|Placebo Comparator|Placebo Comparator|Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting
9922127|NCT00836030||A|
9922128|NCT00836043||Group 1|
9922129|NCT00836082|Experimental|Cohort 1 (N=10)|Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
9922130|NCT00836082|Experimental|Cohort 2 (N=10)|Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
9922131|NCT00836082|Experimental|Cohort 3 (N=10)|Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
9922132|NCT00836082|Experimental|Cohort 4 (N=10)|Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
9922133|NCT00836108|Sham Comparator|1|spontaneous
9922134|NCT00836108|Experimental|2|coordinating arm elevation with inspiration
9922135|NCT00836108|Experimental|3|coordinating arm elevation with expiration
9922136|NCT00836121||tumor|
9922137|NCT00836134|Experimental|1|rectus sheath block
9922138|NCT00836134|Active Comparator|2|local anesthetic infiltration
9922139|NCT00836147|Placebo Comparator|1|250 ng dose
9922140|NCT00836147|Active Comparator|2|250 ng dose
9922141|NCT00836160||1|
9922142|NCT00836160||2|
9922143|NCT00836173|Experimental|RICE followed by GARD|"RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, for 3 cycles.~GaRD treatment: After RICE treatment, gallium nitrate will be given continuously over a 7 day period. In addition rituximab will be given on day 1 of each cycle. Dexamethasone will be given for the first 4 days of each cycle. The length of each cycle is 21 days."
9922144|NCT00836199|Placebo Comparator|Placebo vaccine|
9922145|NCT00836199|Experimental|NicVAX vaccine|
9986288|NCT01401205||shoulder arthroscopic surgery group|the patients who undergo the elective shoulder arthroscopic surgery of rotator cuff repair
9841814|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
9841815|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
9841816|NCT02811640||Study Participants|Adults with chronic kidney disease who will have a PD catheter inserted at the Ottawa Hospital
10206754|NCT03921255|Placebo Comparator|TAF Congruent (TAF-CON)|Maintenance/Control condition (TAF-CON) CBM-I, differs in that participants are provided with a sentence congruent with TAF bias. Again, participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
10206755|NCT03921255|Placebo Comparator|Stress Management Psychoeducation|In the stress management psychoeducation (SMP) psychoeducation about stress and stress management are provided, similar in length to the obsessional thought and interpretations presented in the TAF-INC and TAF-CON. Like the other conditions there is a key word to solve, and participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
10206756|NCT03919773|Active Comparator|Treatment IVIG Arm|IVIG (Gammunex-C) infusion (0.4 gm/kg) every week for 4 weeks, then every 2 weeks for 8 weeks (12 weeks total).
9841820|NCT02811965|No Intervention|Control|Pressure mapping is performed without a heel offloading intervention applied.
9841821|NCT02811965|Experimental|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
9841822|NCT02811965|Experimental|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
9841823|NCT02811965|Experimental|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
9841824|NCT02811965|Experimental|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
9841825|NCT02811965|Experimental|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
9841826|NCT02811965|Experimental|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
9841827|NCT02812160|Active Comparator|Spatz3 Adjustable Balloon|Spatz3 Adjustable Balloon with Dietary and exercise counselling
9841828|NCT02812160|No Intervention|Control|Dietary and Exercise counselling
9841829|NCT02812186|Other|Deep to Moderate NMB|This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
9841830|NCT02812186|Other|Moderate to Deep NMB|This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.
9841831|NCT02812238|Experimental|Arm 1|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
9841832|NCT02812238|Experimental|Arm 2|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
9841833|NCT02812342|Experimental|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
9841834|NCT02812771|Experimental|Efinaconazole|Efinaconazole
9841835|NCT02813070|Experimental|Healthy volunteers|185 MBq [18F] Flutemetamol
9841836|NCT02813070|Experimental|Mild cognitive impairment|185 MBq [18F] Flutemetamol
9841837|NCT02813070|Experimental|Alzheimer's Disease|185 MBq [18F] Flutemetamol
9841838|NCT02813265|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
9841839|NCT02813265|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
9841840|NCT02813421|Experimental|CGM Informed|CGM data was available for use when determining starting insulin pump doses.
9841841|NCT02813421|No Intervention|Control|CGM data will remain secure and not used. Starting insulin pump doses will be made by standard of care.
9841842|NCT02813551|Experimental|Torsemide|Torsemide 20 mg daily for 5 days
9841843|NCT02813551|Placebo Comparator|Placebo|Placebo 20 mg daily for 5 days
9841844|NCT02813577|Other|Lutonix® 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
9986289|NCT01401218||thoracic aortic surgery group|patients who underwent thoracic aortic surgery
10206757|NCT03919773|Placebo Comparator|Treatment Albumin Arm|albumin infusion (0.4 gm/kg) every week for 4 weeks then every 2 weeks for 8 weeks (12 weeks total) during
10206758|NCT03919370||Cerebral ischemia|Patients undergoing planned surgery for carotid stenosis
10206759|NCT03919370||Reperfusion|Patients undergoing cerebral trombectomy.
10206760|NCT03919214|Other|QardioArm and Messaging System|Participants will self-monitor their blood pressure using the Qardio Bluetooth device and obtain 3 separate blood pressure measurements per week (2 morning, 1 evening) for 12 weeks. An automated messaging system for blood pressure management will be triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg. This automated message will be sent to the participant's primary care provider, with copies to the participant and the primary medical oncologist.
10206761|NCT03911713|Active Comparator|Ivacaftor|Participants received IVA 150 milligrams (mg) orally every 12 hours (q12h) in the treatment period for 12 weeks.
10206762|NCT03911713|Experimental|VX-561: 25 mg|Participants received VX-561 25 mg orally daily (qd) in the treatment period for 12 weeks.
10206763|NCT03911713|Experimental|VX-561: 50 mg|Participants received VX-561 50 mg orally qd in the treatment period for 12 weeks.
10206764|NCT03911713|Experimental|VX-561: 150 mg|Participants received VX-561 150 mg orally qd in the treatment period for 12 weeks.
10206765|NCT03911713|Experimental|VX-561: 250 mg|Participants received VX-561 250 mg orally qd in the treatment period for 12 weeks.
10206766|NCT03910153|Placebo Comparator|Placebo - (Age 30-50 years)|
10206767|NCT03910153|Experimental|MSPrebiotic - (Age 30-50 years)|
10206768|NCT03910153|Placebo Comparator|Placebo - (Aged 70 years and above)|
10206769|NCT03910153|Experimental|MSPrebiotic - (Aged 70 years and above)|
9841845|NCT02813681|Active Comparator|US-epidural SVD|US-epidural SVD group - participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity
9841846|NCT02813681|Sham Comparator|(US sham- epidural SVD)|US sham- epidural SVD group- participants who received US examination process but with the monitor turned off.
9841847|NCT02813681|Placebo Comparator|SVD without an Epidural|Spontaneous vaginal delivery without an Epidural group The purpose of the control group is to serve as a baseline.
9841848|NCT02813694|Experimental|lefamulin|oral lefamulin, 600mg
9841849|NCT02813694|Active Comparator|Moxifloxacin|oral moxifloxacin, 400mg
9841850|NCT02814175|Active Comparator|Part 1: MTX Escalated Dose|Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
9841851|NCT02814175|Experimental|Part 1: ADA + MTX|Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
9841852|NCT02814175|Active Comparator|Part 2: MTX Escalated Dose|Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
9841853|NCT02814175|Active Comparator|Part 2: ADA + MTX Escalated Dose|Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
9841854|NCT02814175|Experimental|Part 2: ADA|Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
9841855|NCT02814175|Experimental|Part 2: ADA ew + MTX|Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew
9841856|NCT02814227|Experimental|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
9841857|NCT02814279|Active Comparator|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
9841858|NCT02814279|Experimental|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
9841859|NCT02814448|Active Comparator|CO2 standard cryotherapy- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
9841860|NCT02814448|Active Comparator|CO2 standard cryotherapy- single freeze|Single freeze treatment consists of one five-minute freeze
9841861|NCT02814448|Active Comparator|CryoPen- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
9841862|NCT02814448|Active Comparator|CryoPen- single freeze|Single freeze treatment consists of one five-minute freeze
9841863|NCT02814448|Experimental|Thermocoagulator|Single heat application at 100 ºC for 40 seconds
9841864|NCT02814565|Experimental|Cyclobenzaprine HCl 15 mg|Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.
9841865|NCT02814565|Placebo Comparator|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.
9841866|NCT02814643|Experimental|Benralizumab|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
9841867|NCT02814643|Placebo Comparator|Placebo|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
9841868|NCT02814656|Experimental|Cohort 1, AZD8871 300 μg or placebo|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
9841869|NCT02814656|Experimental|Cohort 2, AZD8871 600 μg or placebo|In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
9841870|NCT02814656|Experimental|Cohort 3, AZD8871 900 μg or placebo|In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
9841871|NCT02814838|Experimental|Ladarixin|Ladarixin oral capsule
9841872|NCT02814838|Placebo Comparator|Placebo|Placebo oral capsule
9841873|NCT02814890|Experimental|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
9841874|NCT02814890|Active Comparator|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
9841875|NCT02815293|Experimental|AGN-195263|
9841876|NCT02815293|Placebo Comparator|Vehicle|
9841877|NCT02815644|Experimental|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
9841878|NCT02815670|Experimental|Idarucizumab|
9841879|NCT02815709|Experimental|Treatment 1 Oliceridine|
9841880|NCT02815709|Experimental|Treatment 2 Oliceridine|
9841881|NCT02815709|Experimental|Treatment 3 Oliceridine|
9841882|NCT02815709|Placebo Comparator|Placebo|
9841883|NCT02815709|Active Comparator|Morphine|
9841884|NCT02815735|Experimental|comfilcon A|Participants wear comfilcon A lens for 4 weeks during the cross over study.
9841885|NCT02815735|Active Comparator|lotrafilcon B|Participants wear lotrafilcon B lens for 4 weeks during the cross over study.
9986290|NCT01401231|Experimental|Behavioral Activation|Behavioral activation psychotherapy
9986291|NCT01401231|Placebo Comparator|Usual Care|Continued care as usual
9841886|NCT02815982|Experimental|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework is assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
9841887|NCT02815982|Active Comparator|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
9841888|NCT02816138|Experimental|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
9841889|NCT02816346|Experimental|Cohort 1: target dose of 500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 510, 717, 588, and 567 CFU)."
9841890|NCT02816346|Experimental|Cohort 2: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 817 CFU), since the attack rate of shigellosis for Cohort 1 was below the protocol target of 60%."
9841891|NCT02816346|Experimental|Cohort 3: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 913 CFU. Although the target dose was the same as Cohort 2, the safety monitoring committee felt that the per-protocol a priori definition of shigellosis was too restrictive and that increasing the dose above 1000 CFU may lead to unnecessarily high toxicity."
9841892|NCT02816346|Experimental|Cohort 4: target dose of 1500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) since the attack rate of shigellosis for Cohort 2 and 3 was below the protocol target of 60%."
9841893|NCT02816346|Experimental|Cohort 5: target dose of CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1150 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) as the final confirmatory cohort since it was felt that the disease rate and profile of Cohort 4 was appropriate."
9841894|NCT02816398|Experimental|Treatment|Interventional use of experimental Ellipsys catheter system for percutaneous creation of an arteriovenous fistula
9841895|NCT02816710|Experimental|IVC Preoperative group|Conbercept injection before vitrectomy
9841896|NCT02816710|Experimental|IVC Postoperative group|Conbercept injection at the end of vitrectomy
9841897|NCT02816710|Experimental|IVC Pre- and Post-operative group|First conbercept injection before vitrectomy and second at the end of operation.
9841898|NCT02816723|Experimental|Mindfulness|mindfulness/meditation/movement training
9516904|NCT03311178|Experimental|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
9841899|NCT02816723|Active Comparator|Brain Health|Brain Health education class
9841900|NCT02817087|Active Comparator|repetitive Transcranial Magnetic Stimulation -On|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.
9841901|NCT02817087|Sham Comparator|repetitive Transcranial Magnetic Stimulation -Off|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.
9841902|NCT02817516|Experimental|Part 1: TAK-828 15 milligram (mg)|TAK-828 15 mg, solution (0.2 milligram per milliliter [mg/mL] or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
9841903|NCT02817516|Experimental|Part 1: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
9841904|NCT02817516|Experimental|Part 1: TAK-828 75 mg|TAK-828 75 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
9841905|NCT02817516|Experimental|Part 1: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
9841906|NCT02817516|Experimental|Part 2: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
9841907|NCT02817516|Experimental|Part 2: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
9841908|NCT02817516|Placebo Comparator|Part 1: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
10206770|NCT03879642|Experimental|REDCHiP|10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
9841909|NCT02817516|Placebo Comparator|Part 2: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-14 in healthy Japanese participants.
9841910|NCT02817555|Active Comparator|Epoetin alfa|Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
9841911|NCT02817555|Active Comparator|Darbepoetin alfa|"Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase."
9922146|NCT00836212|Experimental|LPV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
10206771|NCT03879642|No Intervention|Waitlist|10 week no intervention to provide waitlist control condition
10206772|NCT03878134|Active Comparator|Patients|750 male or female, 18 and older patients
10206773|NCT03876054||Spinal cord stimulation (SCS)|Subjects using Abbott SCS systems
10206774|NCT03876054||Dorsal root ganglion stimulation (DRG)|Subjects using Abbott DRG system
10206775|NCT03864081|Other|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
10206776|NCT03852459|Experimental|Active Arm|S-Ibuprofen Topical Gel 5%
10206777|NCT03852459|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
10206778|NCT03849768|Experimental|HS-10296|110mg PO once daily
10206779|NCT03849768|Active Comparator|Gefitinib|250mg PO once daily
10206780|NCT03842163||Patients with LVH of unknown etiology|
10206781|NCT03828799|Experimental|Folfirinox-R|Folfirinox + regorafenib
10206782|NCT03826459|Active Comparator|Locked Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.
10206783|NCT03826459|Experimental|Non-Locking Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
10206784|NCT03824808|Active Comparator|Treatment group|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
10206785|NCT03824808|Placebo Comparator|Control group|0.9% Sodium Chloride Injection
10206786|NCT03824639|Experimental|Exercise group|Structured exercise
10206787|NCT03824639|Active Comparator|Control group|Health education
10214090|NCT01263769|Experimental|Axitinib|Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.
10214091|NCT01227187|Experimental|Xigris|Drotrecogin alfa activated (Xigris) used as anticoagulant in patients treated with hemodialysis.
10214092|NCT01222247|Active Comparator|Betamethasone|A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart
10214093|NCT01222247|Placebo Comparator|Placebo|A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
10214094|NCT01211405|Active Comparator|Low dose MDMA|Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
10214095|NCT01211405|Active Comparator|Medium dose MDMA|Participants will receive 75 mg MDMA on each of two blinded experimental sessions
10214096|NCT01211405|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.
10214097|NCT01183520|Active Comparator|90 grams of Salmon|Subjects will consume 90 grams of salmon twice a week for 4 weeks
9841912|NCT02817594||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
9841913|NCT02817763|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
9841914|NCT02817763|Experimental|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
9841915|NCT02817776|Experimental|Treatment group|Pulmonary vein isolation (PVI) by RF ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
9841916|NCT02817828|Experimental|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP tablet
9841917|NCT02817841|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive
9841918|NCT02817906|Experimental|ITI-007|9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks.
9841919|NCT02817906|Placebo Comparator|Placebo|Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
9841920|NCT02818036|Experimental|naltrexone|single 50mg dose of naltrexone
9841921|NCT02818036|Placebo Comparator|sugar pill|single sugar pill
9841922|NCT02818114|Experimental|PEET|Peer support interventions as an adjunct to prolonged exposure
9841923|NCT02818244|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
9841924|NCT02818244|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
9841925|NCT02818244|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
9841926|NCT02818244|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
9841927|NCT02818244|Active Comparator|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
9841928|NCT02818569|Experimental|Oral Dexmedetomidine, Then Placebo|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.
9841929|NCT02818569|Experimental|Placebo, Then Oral Dexmedetomidine|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .
9841930|NCT02818777|Experimental|cannabidiol|"GWP42003-P oral solution, is purified cannabidiol (purity of ≥98%, 100 mg/ml cannabidiol in sesame oil with anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring).~Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day."
9841931|NCT02818998|Experimental|Aflibercept 2 mg fixed|Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks
9841932|NCT02818998|Experimental|Aflibercept 2 mg flexible|Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week
9841933|NCT02818998|Experimental|Aflibercept 2 mg PRN|Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)
9841934|NCT02819011|Experimental|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
9841935|NCT02819011|Active Comparator|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
9841936|NCT02819284|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
9841937|NCT02819284|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
9841938|NCT02819297|Experimental|BLI400 Laxative|BLI400 Laxative
9841939|NCT02819297|Placebo Comparator|Placebo|BLI400 placebo
9841940|NCT02819310|Experimental|BLI400 Laxative|BLI400 Laxative
9841941|NCT02819323|Experimental|BLI800 high dose|BLI800 bowel preparation (high dose)
9841942|NCT02819323|Experimental|BLI800 low dose|BLI800 bowel preparation (low dose)
9841943|NCT02819323|Active Comparator|PEG-ELS|PEG based bowel preparation
9841944|NCT02819479|Experimental|Low-dose Intra-arterial Bevacizumab|A single intra-arterial targeted dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
9841945|NCT02819557|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
10206788|NCT03821129|Other|GORE® CARDIOFORM Septal Occluder|Single Arm Commercially available GORE® CARDIOFORM Septal Occluder
10206789|NCT03817905|Experimental|Patient navigator|Participant meets the patient navigator at their colonoscopy appointment and discusses any problems they experienced in getting the colonoscopy done. Participant will tell navigator in their own words their experience and whether they faced any barriers to scheduling and colonoscopy completion.
10206790|NCT03808610|Experimental|Experimental (venetoclax, vincristine, cyclophosphamide)|See Detailed Description.
10206791|NCT03807310|Experimental|Group Long-drink|"83 COPD patients will receive:~Targeted nutrient supplementation (Long-drink) once daily~Counselling once monthly"
10206792|NCT03807310|Placebo Comparator|Group Placebo|"83 COPD patients will receive:~Isocaloric placebo supplement once daily~Counselling once monthly"
10206793|NCT03807310|No Intervention|Healthy control group|30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will only perform a subset of baseline measurements and will not be included in the intervention.
10206794|NCT03797560|Experimental|Ba-Duan-Jin group|"Ba-Duan-Jin therapy: The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital.~Placebo pregabalin capsules: Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks."
10206795|NCT03797560|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
10206796|NCT03797404||Mepolizumab|Patients receiving mepolizumab
9792862|NCT01458522|Experimental|LCM 400mg|LCM treatment arm, a bolus of 400 mg will be administered over 30 minutes. If a further bolus is required, 200 mg will be administered. Regardless of whether the subject received a rebolus, he or she will begin receiving a maintenance dose 12 hours after the initial dose. The daily maintenance dose will be the same as the total bolus (400 mg or 600 mg) divided into 2 doses.
9792863|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
9792864|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
9792865|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
9792866|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
9792867|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
9792868|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.
10206797|NCT03797404||Patients w/o mepolizumab (retrospective)|Retrospective control group of patients not exposed to mepolizumab, included in the COBRA cohort and the ASMATHERM protocol, who had 2 sets of biopsies and BAL within a 6 to 12 month-interval, without change in their treatment. Clinical data for this patients are available at inclusion and after 12 months.
9792869|NCT01458561|Experimental|BioFoam Surgical Matrix|Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct
10206798|NCT03781141|Experimental|Absorbable suture|Wound closure with absorbable suture.
9792870|NCT01458561|Active Comparator|Gelfoam Plus|Control of bleeding using Gelfoam Plus as a surgical adjunct
9792871|NCT01458574|Placebo Comparator|Placebo Comparator|
10206799|NCT03781141|Active Comparator|Non-absorbable suture|Wound closure with non-absorbable suture.
9792872|NCT01458574|Experimental|CP-690,550 5 mg Arm|
9792873|NCT01458574|Experimental|CP-690,550 10 mg Arm|
9792874|NCT01458587|Experimental|ALA|
10206800|NCT03779269|Experimental|color meditation|only color meditation
9792875|NCT01458587|Placebo Comparator|Vehicle|
9792876|NCT01458639|Experimental|Technegas|Technegas V SPECT imaging with Technetium-99m (Tc-99m) labeled carbon particles; approximately 1.1 milliCuries of Technegas, compared with the results of Xenon-133 ventilation scan
9792877|NCT01458639|Active Comparator|Xenon-133|Xenon-133 ventilation Planar imaging compared with the results of the Technegas scan.
10206801|NCT03779269|Experimental|Sound meditation|Only sound mediation
10206802|NCT03779269|Experimental|Color and sound combined meditation|Combined group
10206803|NCT03779269|No Intervention|Control group|Only control group
10206804|NCT03760029|Other|Study arm|All subjects in this study will be observed for 24-30 months.
10206805|NCT03758508|Active Comparator|HFO|Continuous high flow oxygen through nasal cannula for 45 hours; longer if the clinical need persists
10206806|NCT03758508|Active Comparator|NIV/HFO|Alternating noninvasive ventilation (3 hours) and high flow oxygen through nasal cannula (3 hours) for 45 hours; longer if the clinical need persists
10206807|NCT03752892|Experimental|intervention -1-leg cycle training|Primary aerobic training component one-legged, partitioned, cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
10206808|NCT03752892|Active Comparator|usual care - 2-leg cycle training|Primary aerobic training component conventional two-legged cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
9792878|NCT01458951|Experimental|tofacitinib 10 mg BID|
9792879|NCT01458951|Placebo Comparator|Placebo BID|
9792880|NCT01458990|Experimental|PPI inititation|Adding 40mg omeprazole QD for 14 days
9792881|NCT01458990|Active Comparator|PPI withdrawal|The intervention here is systematically withdrawing chronic PPI for 14 days
9792882|NCT01459016|Experimental|Imaging Biomarkers|
9792883|NCT01459068|No Intervention|Waitlist-Control|Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
9792884|NCT01459068|Experimental|Common Elements Treatment Approach|Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.
9792885|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
9792886|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
9792887|NCT01459588|Active Comparator|Carboxymethylcellulose Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
9792888|NCT01459588|Active Comparator|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
9792889|NCT01459614|Experimental|GTX-C|"Each cycle is 21 days (2 weeks Tx + 1 week off). Xeloda given days 1-14, Gemcitabine, Taxotere, and Cisplatin given days 4 and 11.~For expansion cohort, each cycle is 28 days (2 weeks of Tx + 2 weeks off)"
9792890|NCT01459653||Only 1 group|Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
9792891|NCT01459705|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
9792892|NCT01459705|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
9792893|NCT01459705|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
9792894|NCT01459718|Experimental|Deferasirox / Deferasirox + Deferoxamine (DFO)|During Phase A, the induction treatment at entry, participants received Deferasirox -DFO combination. During Phase B, when participants transitioned to less intensive chelation therapy, participants received Deferasirox monotherapy.
9792895|NCT01459783|Active Comparator|Dementia care management in person|The dementia care management protocol will be delivered via face-to-face interactions in participants' homes or in mutually convenient locations between a trained care manager and the care recipient/informal family caregiver dyad, supplemented by telephone.
9792896|NCT01459783|Active Comparator|Dementia care management telephone only|The dementia care management protocol will be delivered via telephonic meetings only. Assessment, education, counseling, and social support procedures as well as referral and follow-ups will follow the same procedural content as stipulated for the face-to-face intervention, however, contact will not be planned in person.
9792897|NCT01459796|Experimental|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 51.
9792898|NCT01459796|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 51.
9792899|NCT01459913|Experimental|Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)|Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
9792900|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
9986292|NCT01401244|Experimental|Norditropin®|
9986293|NCT01401244|Active Comparator|Genotropin®|
9986294|NCT01401270|No Intervention|Treatment Group A|Standard Care
9841946|NCT02819726|Experimental|SAIT101|In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.
9841947|NCT02819726|Active Comparator|Rituxan|In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.
9841948|NCT02819726|Active Comparator|MabThera|In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.
9841949|NCT02819973|Experimental|Educational Video 1|African American/ Black Video
9841950|NCT02819973|Experimental|Educational Video 2|Caucasian Video
9841951|NCT02819973|Experimental|Usual Care (no video) 3|Standard Care/ No video
9841952|NCT02820038|Active Comparator|Other CMI Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
9841953|NCT02820038|Experimental|Other CMI & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
9841954|NCT02820038|Experimental|Drug Facts Boxes Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
9841955|NCT02820038|Experimental|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
9841956|NCT02820181|Experimental|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
9841957|NCT02820181|Active Comparator|traditional tracheostomy tie|those with traditional tracheostomy tie
9841958|NCT02820298|Experimental|Group 1 - Bexagliflozin dosed in fed state, then in fasted state|Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.
9841959|NCT02820298|Experimental|Group 2 - Bexagliflozin in fasted state, then in fed state|Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.
9841960|NCT02820324|Experimental|Treatment 1 Oliceridine|
9841961|NCT02820324|Experimental|Treatment 2 Oliceridine|
9841962|NCT02820324|Experimental|Treatment 3 Oliceridine|
9841963|NCT02820324|Placebo Comparator|Treatment 4 Placebo|
9841964|NCT02820324|Active Comparator|Treatment 5 Morphine|
9841965|NCT02820597|Experimental|Intervention|Cryoablation with the ClariFix device
9841966|NCT02820844|Experimental|GSK1358820 Injection 100 U|"Initially, subjects will receive a single (double-blind) treatment with GSK1358820 (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment with GSK1358820 (open-label). A third treatment with GSK1358820 (open-label) may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
9841967|NCT02820844|Placebo Comparator|Placebo Injection|"Initially, subjects will receive a single (double-blind) treatment with Placebo (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment, this time with open-label GSK1358820. A third treatment with open-label GSK1358820 may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
9841968|NCT02820870|Experimental|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
9841969|NCT02820870|No Intervention|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
9841970|NCT02821104||Healthy Adolescents|Healthy non Hispanic white adolescents
9841971|NCT02821338|Active Comparator|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
9841972|NCT02821338|Active Comparator|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
9841973|NCT02821403|Experimental|Young adults|adults without presbyopia who aged 18-35 years
9841974|NCT02821403|Experimental|Middle-aged adults|adults with presbyopia who aged over 40 years
9841975|NCT02821416|Experimental|Benralizumab|Benralizumab administered subcutaneously
10214098|NCT01183520|Active Comparator|180 grams of salmon|Subjects will consume 180 grams of salmon twice a week for 4 weeks
9841976|NCT02821416|Placebo Comparator|Placebo|Placebo administered subcutaneously
9841977|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
9841978|NCT02821715|Active Comparator|Modafinil + placebo|3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks
9841979|NCT02821715|Experimental|THN102 300/3|3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks
9841980|NCT02821715|Experimental|THN102 300/27|3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks
9841981|NCT02821819|Experimental|Random start ovarian stimulation|"Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.~Interventions:~Random start ovarian stimulation~Gonadotrophins: Urinary FSH 150-225 IU/d~GnRH antagonists: Cetrorelix 0,25 mg/d~GnRH agonist for triggering: Triptorelin 0,2 mg single dose"
9841982|NCT02821910|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
9841983|NCT02821910|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
9841984|NCT02821910|Experimental|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
9841985|NCT02821962|Experimental|Sedentary prompts (VTAP)|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
9841986|NCT02821962|No Intervention|Usual care|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks.
9841987|NCT02822222|Experimental|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
9841988|NCT02822222|Placebo Comparator|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
9841989|NCT02822235||Crohn's Disease|Participants with diagnosis of moderate to severe Crohn's disease (CD) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and CD at Day 1 were followed up for 12 months in prospective phase.
9841990|NCT02822235||Ulcerative Colitis|Participants diagnosed with diagnosis of moderate to severe ulcerative colitis (UC) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and UC at Day 1 were followed up for 12 months in prospective phase.
9841991|NCT02822287|Experimental|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
9841992|NCT02822599|Active Comparator|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
9841993|NCT02822599|Placebo Comparator|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
9841994|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
9841995|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
9841996|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
9841997|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
9841998|NCT02822794|Experimental|SOF/VEL FDC + RBV 12 weeks|SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
9841999|NCT02822794|Experimental|SOF/VEL FDC + RBV 24 weeks|SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
10206809|NCT03748069||Influenza positive CAPIV|All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
10206810|NCT03748069||Influenza negative CAPIV|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza
10206811|NCT03745612|Experimental|TRF|Time restricted feeding
10206812|NCT03745612|Active Comparator|CER|continuous energy restriction
10206813|NCT03740919|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 units per milliliter (U/mL) insulin lispro (Humalog) administered subcutaneously (SC), 0 to 2 minutes before each meal with once or twice daily basal insulin. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
10206814|NCT03740919|Experimental|LY900014|Participants received 100 U/mL LY900014 administered SC, 0 to 2 minutes before start of the meal.
10206815|NCT03740919|Experimental|LY900014 Postmeal|Participants received 100 U/mL LY900014 administered SC, up to 20 minutes after the start of the meal.
9842000|NCT02822885|Experimental|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
9986295|NCT01401270|Experimental|Treatment Group B|100% probability of winning a prize with each draw and has 3 prize categories
9986296|NCT01401270|Experimental|Treatment Group C|31% probability of winning and has 3 prize categories
10206816|NCT03740542|Active Comparator|Esophagectomy with Pyloroplasty|Esophagectomy with Pyloroplasty
10206817|NCT03740542|Experimental|Esophagectomy without Pyloroplasty|Esophagectomy without Pyloroplasty
10206818|NCT03737591||Healthy individuals|Healthy individuals
9792901|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
10206819|NCT03737591||Patients with Colorectal cancer|Stage I-IV colorectal cancer patients
9792902|NCT01459913|Experimental|Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
10206820|NCT03737591||Patients with Colorectal Adenomas|Patients with Colorectal Adenomas
10206821|NCT03737565||Coronary Artery Disease|
10206822|NCT03726047|No Intervention|Control|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately after and 24 hours later (without visual feedback).
10206823|NCT03726047|Experimental|Exercise|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.
10214099|NCT01183520|Active Comparator|270 Grams of Salmon|Subjects will consume 270 grams of salmon twice a week for 4 weeks
9792903|NCT01460225|Experimental|Treatment|24 micrograms of lubiprostone twice daily for one week.
9792904|NCT01460290|Experimental|Asenapine|12-weeks of open-label asenapine treatment
9792905|NCT01460303|Experimental|OPTION-vf patient controlled catheter|"Patients who fail postop bladder challenge and are randomized to OPTION-vf arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
9792906|NCT01460303|Active Comparator|Transurethral catheter w/leg bag|"Patients who fail postop bladder challenge and are randomized to indwelling catheter with leg bag arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
9792907|NCT01460342|Placebo Comparator|Placebo|Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
9792908|NCT01460342|Experimental|Tadalafil|Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
9792909|NCT01460368|Experimental|Part A: LY2409021|Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of 300 milligrams (mg) LY2409021 administered orally. Participants enrolled in Part A will not be allowed to participate in Part B.
9792910|NCT01460368|Experimental|Part B: LY2409021|300 milligrams (mg) LY2409021 administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
9792911|NCT01460368|Placebo Comparator|Part B: Placebo|Administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
9792912|NCT01460368|Active Comparator|Part B: Moxifloxacin|400 milligrams (mg) Moxifloxacin administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
9792913|NCT01460381|Experimental|LY2216684 + Quinidine (CYP2C19 poor metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 poor metabolizer (PM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 was administered on Day 1.~Period 2 (Days 8-15): 300 mg quinidine sulfate controlled release was administered orally, once daily on Days 8-15. Additionally, a single, oral dose of 18 mg LY2216684 was administered on Day 11."
9792914|NCT01460381|Experimental|LY2216684 (CYP2C19 extensive metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 extensive metabolizer (EM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 administered on Day 1.~Period 2 (Days 8-15): EM participants did not participate in this period."
9792915|NCT01460407|Experimental|LY2216684 + Clarithromycin|Participants will receive a single 18-mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
9792916|NCT01460446|Experimental|Aviva Expert blood glucose meter|Participants used the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
9792917|NCT01460446|Active Comparator|Aviva Nano blood glucose meter|Participants used the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
9792918|NCT01460628|Experimental|Armodafinil|Armodafinil is the drug being tested.
9792919|NCT01460719|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9792920|NCT01460732|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
9792921|NCT01460875|Experimental|Treatment (interferon therapy)|Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
9842001|NCT02822950|Other|Ceftazadime/avibactam|Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours [other antibiotics can also be administered as needed]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.
9842002|NCT02823080|Active Comparator|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
9842003|NCT02823080|No Intervention|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
9842004|NCT02823431|Active Comparator|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
9842005|NCT02823431|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
9842006|NCT02823470|Experimental|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
9842007|NCT02823470|Experimental|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
9842008|NCT02823600|Other|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
9842009|NCT02823964|Experimental|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
9842010|NCT02824224|Experimental|Tamoxifen|Tamoxifen 10mg tablet by mouth twice daily for 7 days
9842011|NCT02824224|Placebo Comparator|Placebo|Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
9842012|NCT02824432|Experimental|TAK-085 2g|A dose of 2 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered once a day immediately after meal.
9842013|NCT02824432|Experimental|TAK-085 4g|A dose of 4 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered twice a day immediately after meal.
9842014|NCT02824562|Other|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
9842015|NCT02824562|Other|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group. The participants will complete an outcome assessment within 30 days of the last group session."
9842016|NCT02824913|Experimental|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
9842017|NCT02824913|Placebo Comparator|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
9842018|NCT02825212|Experimental|Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|"Participants treated with either Harvoni or Epclusa~Harvoni 90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.~Epclusa 400mg/100mg 400mg/100mg FDC once daily"
9842019|NCT02825251|Experimental|Faster-acting insulin aspart CSII|
9842020|NCT02825251|Active Comparator|NovoRapid® CSII|
9842021|NCT02825550|Experimental|Hepatoma treated using Taiwan ACE Beads|The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.
9842022|NCT02825680|Active Comparator|Enhanced NCP Support|Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
9842023|NCT02825680|Experimental|LEAP Intervention|Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
9842024|NCT02825849|Experimental|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
10206824|NCT03724110||Pre-Telestroke|Retrospective collection of defined metrics for all TIA patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
10206825|NCT03724110||Post-Telestroke|Prospective collection of defined metrics for all TIA patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
10206826|NCT03719495||Cohort 1|Pre-menopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
10206827|NCT03719495||Cohort 2|Postmenopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
10206828|NCT03719495||Cohort 3|Pre-menopausal women initiating tamoxifen after standard of care local-regional therapy after surgery +/- radiation.
9842025|NCT02825849|No Intervention|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
9922147|NCT00836212|Experimental|EFV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
9922148|NCT00836225|Experimental|A|50 mg ISIS 388626 vs Placebo, s.c. injection
9922149|NCT00836225|Experimental|B|100 mg ISIS 388626 vs Placebo, s.c. injection
9922150|NCT00836225|Experimental|C|200 mg ISIS 388626 vs Placebo, s.c. injection
9922151|NCT00836225|Experimental|D|400 mg ISIS 388626 vs Placebo, s.c. injection
9922152|NCT00836225|Experimental|AA|50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
9922153|NCT00836225|Experimental|BB|100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
9922154|NCT00836225|Experimental|AAA|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
9922155|NCT00836225|Experimental|BBB|100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
9922156|NCT00836225|Experimental|CCC|200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
9922157|NCT00836225|Experimental|FFF|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
9922158|NCT00836238||Questionnaire + Fall Risk Assessment|Physical Function Interview + Physical Function Tests + Symptom Assessment Interview
9922159|NCT00836251||H218O and 2H2O|schizophrenia
9922160|NCT00836264||Morphine T & A|"Subjects ages 4-18 years of age who have a Tonsillectomy and Adenoidectomy and receive morphine for pain control and who have also enrolled in the CAG study at CHOP, A Study of the Genetic Causes of Complex Pediatric Disorders (GCPD study), as approved by the CHOP IRB, 2006-7-4886."
9922161|NCT00836290|Experimental|Pre-release|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
9922162|NCT00836290|Experimental|Post-release|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
9922163|NCT00836290|No Intervention|Control|Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study.
9922164|NCT00836303|No Intervention|Control|Patients of physicians randomly assigned to the control group received usual care
9922165|NCT00836303|Experimental|Intervention Group|This group will receive the behavioral intervention.
9922166|NCT00836329|Experimental|Intensive Glucose Management|Participants will receive intensive glucose management.
9922167|NCT00836329|Active Comparator|Traditional Glucose Management|Participants will receive a traditional method of glucose management.
9922168|NCT00836368|Experimental|MaxiGamma|
9922169|NCT00836381|Experimental|Tolterodine ER|Tolterodine ER 4mg once daily
9922170|NCT00836381|Placebo Comparator|Placebo|Placebo once daily
9922171|NCT00836394|Experimental|Intervention Group|Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
9922172|NCT00836394|No Intervention|Control|Will follow daily habitual activities
9922173|NCT00836420||liver|patients with acute liver failure
9922174|NCT00836446|Active Comparator|Group 1|20 min. physical activity routine
9922175|NCT00836446|Experimental|Group 2|40 min. aerobic physical activity routine
9922176|NCT00836459|No Intervention|Control|
9922177|NCT00836459|Experimental|Mini Booster|
9922178|NCT00836459|Experimental|Full Booster|
9922179|NCT00836485|Experimental|1|Ketotifen 4.0% Patch
9922180|NCT00836485|Placebo Comparator|2|Placebo Patch
9922181|NCT00836485|Active Comparator|3|Pataday(TM)
9922182|NCT00836485|Placebo Comparator|4|Placebo eye drops
9935055|NCT04236414|Experimental|Cohort A: ≥12 to <18 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
9935056|NCT04236414|Experimental|Cohort B: ≥3 to <12 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
9935057|NCT04236414|Experimental|Cohort C: ≥6 months to <6 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart. Patients in Cohort C will receive a predetermined number of each sprinkle capsule strength (15 and 19.5 mg,) to make up the required dose. Olaparib sprinkle capsules will be administered to the child by the parent/caregiver. Patients in Cohort C are not required to fast including PK sampling days. The dispensed granules should be swallowed whole and not chewed, crushed, dissolved or divided, and should be consumed within 30 minutes of preparation.
9986297|NCT01401270|Experimental|Treatment Group D|100% probability of winning and has 7 prize categories
9842026|NCT02825966|Other|AUDICOR then LifeVest then AUDICOR|First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
9842027|NCT02825992|Other|AcQMap System|All patients who underwent catheter ablation using the AcQMap System
9842028|NCT02826421|Experimental|UltraSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
9842029|NCT02826421|Active Comparator|iTec Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
9842030|NCT02826421|Active Comparator|iSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
9842031|NCT02826421|Active Comparator|Monarch III D Manual IOL Delivery System|Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
9842032|NCT02826603|Experimental|Secukinumab|Secukinumab
10206829|NCT03719495||Cohort 4|Pre-menopausal women initiating ovarian suppression plus aromatase inhibition after surgery +/- radiation.
10206830|NCT03719495||Cohort 5|Postmenopausal women initiating endocrine therapy with aromatase inhibition after standard of care surgery +/- radiation.
9842033|NCT02826603|Active Comparator|Ustekinumab|Ustekinumab
9842034|NCT02826694|Other|Well infant, whole exome sequencing|Healthy infants and their parents enrolled in the study prenatally will participate. After the infant is born saliva sample will be collected for DNA extraction and whole exome sequencing will be done.
9842035|NCT02826694|Other|Diagnosed, whole exome sequencing|Infants and children with diagnosed conditions whose parents enroll in the study and consent to having their child sequenced will have saliva samples obtained and whole exome sequencing will be done on extracted DNA.
9842036|NCT02826798|Experimental|VBI-1501A: 0.5µg with adjuvant|0.5µg CMV vaccine with adjuvant
9842037|NCT02826798|Experimental|VBI-1501A: 1.0µg with adjuvant|1.0µg CMV vaccine with adjuvant
9842038|NCT02826798|Experimental|VBI-1501A: 2.0 µg with adjuvant|2.0 µg CMV vaccine with adjuvant
9842039|NCT02826798|Experimental|VBI-1501: 1.0µg without adjuvant|1.0µg CMV vaccine without adjuvant
9842040|NCT02826798|Placebo Comparator|Placebo|Buffer/sucrose used for VBI-1501 suspension
9842041|NCT02827500|Active Comparator|ivabradine|Active Comparator: ivabradine
9842042|NCT02827500|Placebo Comparator|usual care|Placebo Comparator: usual care
9842043|NCT02827708|Experimental|Semaglutide|
9842044|NCT02827708|Placebo Comparator|Placebo|
9842045|NCT02828020|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
10206831|NCT03712891|Experimental|Patients receiving coffee postoperatively|Patients who self-identify as coffee drinkers and receive coffee postoperatively
10206832|NCT03712891|No Intervention|Patients not receiving coffee postoperatively|Patients who self-identify as coffee drinkers and do not receive coffee postoperatively
10206833|NCT03708315|Active Comparator|Order 1|Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)
10206834|NCT03708315|Placebo Comparator|Order 2|Subjects will be given a sublingual film of placebo.
10214100|NCT01146418|Experimental|Corifollitropin alfa 150 μg|Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
9842046|NCT02828020|Experimental|Ubrogepant 100 mg|2 Ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
9842047|NCT02828020|Placebo Comparator|Placebo|2 placebo-matching ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take 2-placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
9842048|NCT02828111|Experimental|Patidegib gel 2% - Cohort 1|Patidegib gel 2%, applied topically, once daily for 12 weeks (Cohort 1)
9842049|NCT02828111|Experimental|Patidegib gel 4% - Cohort 2|Patidegib gel 4%, applied topically, once daily for 12 weeks (Cohort 2)
9842050|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 1|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 1)
9842051|NCT02828111|Experimental|Patidegib gel 2% - Cohort 3|Patidegib gel 2%, applied topically, twice daily for 12 weeks (Cohort 3)
9842052|NCT02828111|Experimental|Patidegib gel 4% - Cohort 4|Patidegib gel 4%, applied topically, twice daily for 12 weeks (Cohort 4)
9842053|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 2|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 2)
9842054|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 3|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 3)
9842055|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 4|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 4)
9842056|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio < 1.78
9842057|NCT02828137||Intermediate NLR group|1.78 < Neutrophil-to-Lymphocyte (NLR) Ratio < 3.90
9842058|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio > 3.90
9842059|NCT02828241|Experimental|DFD-04 Ointment|DFD-04 (Itraconazole) Ointment
9842060|NCT02828241|Placebo Comparator|Placebo Ointment|Placebo Ointment
9842061|NCT02828267|No Intervention|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
9842062|NCT02828267|Experimental|BNI|In the BNI arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
9842063|NCT02828267|Active Comparator|BNI plus standard booster|In the BNI plus standard booster arm, patients will receive the 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. The messages will be standard messages for all those in this arm.
9842064|NCT02828267|Active Comparator|BNI plus personalized booster|In the BNI plus personalized booster arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a text focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
9842065|NCT02828358|Experimental|Treatment (azacitidine, combination chemotherapy)|See Detailed Description
9842066|NCT02828436|Experimental|Spinal Cord Stimulation|Boston Scientific Precision Spectra System
9842067|NCT02828436|Other|Exercise Intervention|If subject cannot tolerate Spinal Cord stimulation they will be assigned this arm
9842068|NCT02828644|Active Comparator|EVO Multitasking|EVO Multitasking is a digital intervention that requires subjects to navigate a character through a game-like space, while collecting objects, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
9842069|NCT02828644|Active Comparator|EVO Words|EVO Words is a digital intervention that requires subjects to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
9842070|NCT02829034|Active Comparator|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
9842071|NCT02829034|Placebo Comparator|Placebo|Placebo by mouth twice per day
9842072|NCT02829138|Placebo Comparator|Non-genetic Group|General Nutrition related to Omega-3 fats: Individuals in this group will be provided with only general nutrition information related to omega-3 fats and health.
9842073|NCT02829138|Experimental|Genetic Group|Genetic information and Omega-3 fat intake: Individuals in this group will be provided with general nutrition information related to omega-3 fats and health, as well as their personal genetic information for a common gene variant related to omega-3 fatty acid metabolism.
9842074|NCT02829294|Experimental|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
9842075|NCT02829307|Experimental|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
9842076|NCT02829320|Experimental|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
9842077|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
9842078|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
9842079|NCT02829775|Experimental|Interferon Alfa-2A in Cancer Participants|Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
9842080|NCT02829944|Experimental|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
9842081|NCT02829944|Placebo Comparator|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
9842082|NCT02829983|Active Comparator|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
9842083|NCT02829983|Placebo Comparator|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
9842084|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.005% QD|trabodenoson 6.0% / latanoprost 0.005% QD FDC
9842085|NCT02829996|Experimental|trabodenoson 3.0% /latanoprost 0.005% QD|trabodenoson 3.0% / latanoprost 0.005% QD FDC
9842086|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.0025%QD|trabodenoson 6.0% /latanoprost 0.0025% QD FDC
9842087|NCT02829996|Active Comparator|latanoprost 0.005% QD|latanoprost 0.005% ophthalmic solution QD
9842088|NCT02829996|Active Comparator|latanoprost 0.0025% QD|latanoprost 0.0025% ophthalmic solution QD
9842089|NCT02830074|Experimental|The BEST Program|a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + patient Education + ongoing Support and Training)
9842090|NCT02830074|Active Comparator|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
9842091|NCT02830087|Active Comparator|220 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 220 mmHg.
9842092|NCT02830087|Active Comparator|250 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 250 mmHg
9842093|NCT02830087|Active Comparator|275 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 275 mmHg
9842094|NCT02830087|Active Comparator|300 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 300 mmHg
9842095|NCT02830087|Active Comparator|325 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 325 mmHg
9842096|NCT02830087|Active Comparator|350 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 350 mmHg
9842097|NCT02830438|Experimental|Shear wave elastography group|Patients referred for kidney biopsy will then undergo shear wave elastography measurements.
9842098|NCT02830776|Experimental|Treatment group|This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).
9842099|NCT02830880|Experimental|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
9842100|NCT02830893|Experimental|The LARA Therapy|The LARA arm of this study will use the LARA system while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. LARA is a system that facilitates patients to perform high amounts of arm movement with the affected upper extremity. Study participants are able to actively propel themselves in the unit.
9842101|NCT02830893|Active Comparator|The Standard Therapy|The control arm of this study will use a standard wheelchair while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. Study participants will have no exposure to LARA and they will use a standard wheelchair. They will use their unaffected upper and lower extremities to propel themselves in the unit.
9842102|NCT02831257|Experimental|AZD2014|"18 patients will be enrolled in this study in a single stage.~AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.~One cycle will consist of 28 days (1 cycle = 28 days)."
9842103|NCT02831387|Experimental|0.017% P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution TID for 28 days.
9842104|NCT02831387|Placebo Comparator|Placebo|P-321 Ophthalmic Solution Placebo TID for 28 days.
9842105|NCT02831569|Experimental|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
9842106|NCT02831660|Experimental|idarucizumab|
9842107|NCT02831816|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
9842108|NCT02831816|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
9842109|NCT02831816|Placebo Comparator|ZP Vehicle|ZP without IPA
9842110|NCT02831855|Experimental|CP-690,550 and methotrexate|Open-label tofacitinib tablet and blinded methotrexate capsule
9986298|NCT01401270|Experimental|Treatment Group E|31% probability of winning and has 7 prize categories
9842111|NCT02831855|Placebo Comparator|CP-690,550 and placebo|open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
9842112|NCT02831998|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
9842113|NCT02831998|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
9842114|NCT02831998|Placebo Comparator|ZP Vehicle|ZP without IPA
9842115|NCT02832037|Experimental|BI 425809 dose 1|
9842116|NCT02832037|Experimental|BI 425809 dose 2|
9842117|NCT02832037|Experimental|BI 425809 dose 3|
9842118|NCT02832037|Experimental|BI 425809 dose 4|
9842119|NCT02832037|Placebo Comparator|Placebo|
9842120|NCT02832115|Experimental|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
9842121|NCT02832115|Placebo Comparator|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
9842122|NCT02832154|Experimental|Supportive Care|Patients complete an initial online questionnaire lasting about 25-30 minutes. Patients complete an internet-delivered PA program during weeks 3-8. Each week consists of didactic material and 20-30 minutes of daily online exercises.
9842123|NCT02832284|Experimental|iNod System|Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
9842124|NCT02832375|Experimental|Experimental: stannous fluoride|Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million [ppm] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
9842125|NCT02832375|Active Comparator|Standard: sodium monofluorophosphate|Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
9842126|NCT02832622||MPP Programming|This post-market study was designed to characterize the real-world use of MPP technology in patients indicated for CRT device implant. Therefore in order to adequately characterize MPP, data from subjects with MPP programmed continuously or for at least 3 months prior to the final follow-up are reported as the MPP programming group.
9986299|NCT01401270|Experimental|Treatment Group F|usual prize contingency management with a 50% probability of winning from 3 prize categories
9986300|NCT01401296|Active Comparator|Wait-list group|Subjects receive access to deprexis after eight weeks
9842127|NCT02832674|Experimental|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
9842128|NCT02833077|Experimental|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
9842129|NCT02833077|Other|No Treatment then JUVÉDERM VOLUMA® XC|No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.
9842130|NCT02833350|Experimental|Cohort 1: GDC-0853 High Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
10206835|NCT03700970|Experimental|TAP block with liposomal bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
9842131|NCT02833350|Experimental|Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
9842132|NCT02833350|Experimental|Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
9842133|NCT02833350|Active Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
9842134|NCT02833350|Placebo Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab Placebo|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
9842135|NCT02833350|Experimental|Cohort 2: GDC-0853 High Dose|Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
9996893|NCT01504152||patients who received HSCT at MSKCC between 2005-2010|A self-administered patient questionnaire will be used to collect data that will assess the prevalence of international travel after HSCT and travel related morbidity and exposure risks among HSCT recipients.
9842136|NCT02833350|Placebo Comparator|Cohort 2: GDC-0853 Placebo|Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
9842137|NCT02833415|Experimental|Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
9842138|NCT02833415|Placebo Comparator|Placebo|Placebo one tablet daily for 3 months
9842139|NCT02833844|Experimental|Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
9842140|NCT02833844|Placebo Comparator|Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
9842141|NCT02833857|Experimental|Etelcalcetide|Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.
9842142|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
9842143|NCT02833948|Active Comparator|ASA + Clopidogrel|ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
9842144|NCT02833948|Experimental|Rivaroxaban + ASA|Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
9842145|NCT02833974|Experimental|GSK2245035 20 ng|Participants will receive 20 ng of GSK2245035 Nasal spray solution (1 spray=10 ng GSK2245035 per actuation per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
9842146|NCT02833974|Placebo Comparator|Placebo|Participants will receive placebo Nasal spray solution (1 spray per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
9842147|NCT02834247|Experimental|Part 1: Advanced Solid Tumors|TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
9842148|NCT02834247|Experimental|Nivolumab Fixed Dose Cohort|After RP2D of TAK-659 has been identified, based on evaluation of combination with weight-based dose of nivolumab (3 mg/kg), RP2D may be evaluated in combination with a fixed dose of 240 mg IV nivolumab after discussion between investigator and sponsor for all types of advanced solid tumors. For single-agent nivolumab, fixed dose is expected to have equal exposure, safety, and efficacy as weight-based (3 mg/kg) dose. If nivolumab fixed dose is evaluated with TAK-659 RP2D, 3 participants will be initially enrolled into cohort. Following evaluation of safety, efficacy, and any available PK data, along with discussions between investigator and sponsor, 3 additional participants may be enrolled into cohort for a total of 3 to 6 participants. If >=1 out of 6 participants experiences dose-limiting toxicity (DLT) in Cycle 1, or significant safety issues are seen in Cycle 2 and beyond, re-evaluation of TAK-659 RP2D when administered with a fixed dose of nivolumab is permitted.
9842149|NCT02834247|Experimental|Part 2: Metastatic Triple-negative Breast Cancer (TNBC)|Participants with metastatic TNBC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
9842150|NCT02834247|Experimental|Part 2: Metastatic Non-small Cell Lung Cancer (NSCLC)|Participants with metastatic NSCLC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1.disease or unacceptable toxicity. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
9842151|NCT02834247|Experimental|Part 2: Metastatic HNSCC|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
9842152|NCT02834390|Experimental|Quizartinib 20 mg/day|"Participants who received 20 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
9842153|NCT02834390|Experimental|Quizartinib 40 mg/day|"Participants who received 40 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
9922183|NCT00836524||1|Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
9842154|NCT02834624|Active Comparator|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
9842155|NCT02834624|Active Comparator|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
9842156|NCT02834663|Experimental|Lucentis|Patients were administered 0.5-mg IVR injections monthly for 6 months.
9842157|NCT02834806|Experimental|BioNIR drug eluting stent system|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
9842158|NCT02834819|Experimental|Hypertonic Saline|Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed.
9842159|NCT02834819|No Intervention|No treatment|"Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed."
9842160|NCT02835092|Active Comparator|Self-directed Control|
9842161|NCT02835092|Experimental|Take Shape For Life Program|
9842162|NCT02835092|Experimental|Medifast Direct Program|
9842163|NCT02835274|Experimental|Ring mode followed by Unrestricted mode|omni-directional stimulation followed by unrestricted Mode stimulation
9842164|NCT02835274|Active Comparator|Unrestricted mode followed by ring mode|Unrestricted Mode stimulation followed by omni-directional stimulation
9842165|NCT02835339|Active Comparator|MgSO4 4g load, 1g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
9842166|NCT02835339|Experimental|MgSO4 6g load, 2g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
9842167|NCT02835495|Experimental|Lifestyle Weight Loss|"Behavioral: HELP Vets Intervention~Lifestyle intervention consisting of 24 weekly group meetings led by a Veteran community health worker and 3 individual sessions with a nutritionist/diabetes educator"
9842168|NCT02835495|Active Comparator|Enhanced Usual Care|"Behavioral: Individual Education Program~Standard care consisting of 2 individual sessions with a nutritionist/diabetes educator and a monthly newsletter"
9842169|NCT02835625|Active Comparator|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.~Women selected for further assessment (positive screening exam) will be recalled."
9842170|NCT02835625|Active Comparator|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
9842171|NCT02835677|Experimental|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
9842172|NCT02835820|Experimental|Ketogenic Diet Group|Ketogenic meals (3 meals/day, 7 days/week x 12 weeks) prepared and delivered to participants.
9842173|NCT02835820|No Intervention|Patient Choice Diet|Control.
9842174|NCT02835846|Experimental|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
9842175|NCT02836496|Experimental|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
9842176|NCT02836496|Placebo Comparator|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
9842177|NCT02836613|Active Comparator|Galcanezumab Reference|Single dose of 240 milligrams (mg) galcanezumab (LY2951742) administered subcutaneously (SC) by manual prefilled syringe (PFS).
9842178|NCT02836613|Experimental|Galcanezumab Test|Single dose of 240 mg galcanezumab (LY2951742) administered SC by autoinjector.
9842179|NCT02836652|Experimental|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
9842180|NCT02836652|Active Comparator|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
9842181|NCT02836769|Experimental|Rehabilitation Consult (RC)|Pilot testing: single group pre-post design
9842182|NCT02836873|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
9842183|NCT02836873|Placebo Comparator|Placebo tablets|Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
9842184|NCT02836990|Active Comparator|Prevena|Prevena Incision Management System for vascular surgical groin wounds
9842185|NCT02836990|Active Comparator|Dermabond|Dermabond for vascular surgical groin wounds
9842186|NCT02837237|Experimental|KBP-5074|Single oral dose
9842187|NCT02837328|Experimental|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
9842188|NCT02837328|Placebo Comparator|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
9842189|NCT02837731|Experimental|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of < 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
9842190|NCT02837731|No Intervention|Control|No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.
9842191|NCT02837744||Axiostat®|Size: 3.5 cm X 3.5 cm
9842192|NCT02837913|Experimental|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
9842193|NCT02837913|Placebo Comparator|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
9842194|NCT02837952|Active Comparator|Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
9842195|NCT02837952|Placebo Comparator|Placebo|Placebo
9842196|NCT02838017|Experimental|Tissue Adhesive|Tissue Adhesive will be placed over subcuticular suture closure.
9842197|NCT02838017|Active Comparator|Steri-Strips|Sterile strips will be placed over subcuticular suture closure.
9842198|NCT02838134|Experimental|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
9842199|NCT02838134|Sham Comparator|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
9842200|NCT02838407|Other|Total group|All enrolled subjects, male or female aged between 6 months included and less than 6 years at the time of enrollment, who visited the hospital with suspected chronic lower respiratory tract infections (LRTIs) and who had an indication for bronchoalveolar lavage (BAL).
9842201|NCT02838420|Experimental|Alectinib|Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.
9842202|NCT02838420|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.
9842203|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 5)|Participants were applied 50 milligrams (mg) of KX2-391 Ointment 1% topically on face or scalp in 25 centimeter square (cm^2) treatment area, once daily for 5 consecutive days.
9842204|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 3)|Participants were applied 50 mg of KX2-391 Ointment 1% topically on face or scalp in 25 cm^2 treatment area, once daily for 3 consecutive days.
9842205|NCT02838901|Experimental|Beet It Beetroot Juice|70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
9842206|NCT02838901|Placebo Comparator|Beet It Beetroot Juice Placebo|70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.
9842207|NCT02839200|Experimental|ACT-541468 5 mg|Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
9842208|NCT02839200|Experimental|ACT-541468 10 mg|Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
9842209|NCT02839200|Experimental|ACT-541468 25 mg|Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
9842210|NCT02839200|Experimental|ACT-541468 50 mg|Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
9842211|NCT02839200|Active Comparator|Zolpidem|Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
9842212|NCT02839200|Placebo Comparator|Placebo|Each subject receives two placebo capsules, once daily in the evening for 4 weeks
9842213|NCT02839330|Experimental|Group A|aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
9842214|NCT02839330|Experimental|Group B|aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
9842215|NCT02839330|Experimental|Group C|aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
9842216|NCT02839330|Placebo Comparator|Group D|Placebo; receive 2 doses (on Day 1 and Day 22)
9842217|NCT02839681|Experimental|1/Safety Run-in Arm|Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
9842218|NCT02839681|Experimental|2/Phase 2 Arm|Subjects will be dosed with anetumab ravtansine at the recommended phase 2 dose (dose level 1 if no more than 1 dose limiting toxicity (DLT) occurred in the safety run-in arm, or at dose level -1 otherwise)
9842219|NCT02839746||Dabigatran|Patients switched from vitamin K antagonist (VKA) to dabigatran
9842220|NCT02839772|Active Comparator|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
9842221|NCT02839772|Experimental|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
9842222|NCT02839798|Experimental|sTMS active|Treatment with the NEST Device
9842223|NCT02839876|Experimental|Intravenous acetaminophen|Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
9842224|NCT02839876|Active Comparator|Oral acetaminophen|Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
9842225|NCT02839889|Placebo Comparator|Placebo|Placebo once daily for two weeks
9842226|NCT02839889|Active Comparator|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
9842227|NCT02839902|Experimental|TAK-085 4g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.
9842228|NCT02839902|Experimental|Control Group|Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.
9842229|NCT02840097|Experimental|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
9922184|NCT00836537|Experimental|1|
9922185|NCT00836537|Active Comparator|2|
9842230|NCT02840097|Experimental|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
9842231|NCT02840097|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
9842232|NCT02840253|Experimental|NIRS|Non-invasive near infrared spectroscopy to assess changes in tissue and cerebral oxygenation.
9842233|NCT02840461|Experimental|Ivermectin Cream, 1%|test product, manufactured by Actavis Laboratories UT, Inc.
9842234|NCT02840461|Active Comparator|SoolantraTM (ivermectin) Cream, 1%|reference product, manufactured by Galderma Laboratories, L.P.
9842235|NCT02840461|Placebo Comparator|Placebo/Vehicle cream|Placebo, manufactured by Actavis Laboratories UT, Inc.
9842236|NCT02840474|Experimental|Part A: VRC01LS (40 mg/kg)|VRC-HIVMAB080-00-AB (VRC01LS) - (40 mg/kg) - administered intravenously (IV) at Day 0
9842237|NCT02840474|Experimental|Part B: VRC07-523LS (40 mg/kg)|VRC-HIVMAB075-00-AB (VRC07-523LS) - (40 mg/kg) - administered IV at Day 0
9922186|NCT00836550|Active Comparator|Control|The participants spoke with a live counselor prior to answering the knowledge measure
9922187|NCT00836550|Experimental|Video|
9922188|NCT00836563||Forearm Arteriovenous Loop Graft|
9922189|NCT00836576|Experimental|1|
9922190|NCT00836576|Active Comparator|2|
9922191|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 1)|
9922192|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 2)|
9922193|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 3)|
9922194|NCT00836628|Experimental|experimental|
9922195|NCT00836654|Active Comparator|1 Catumaxomab|Patient received Catumaxomab and paracentesis
9922196|NCT00836654|No Intervention|2:|Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm
9922197|NCT00836667|Experimental|1|
9922198|NCT00836667|Active Comparator|2|
9922199|NCT00836771|Placebo Comparator|Materna infant formula 1|milk based infant formula powder
9922200|NCT00836771|Experimental|Materna infant formula 2|Probiotic supplemented infant formula
9922201|NCT00836771|Experimental|Materna infant formula 3|Prebiotic supplemented infant formula
9922202|NCT00836771|Experimental|Materna infant formula 4|Prebiotic+ Probiotic supplemented infant formula
9922203|NCT00836771|Other|Human milk|Human Milk
9922204|NCT00836784|Experimental|1|
9922205|NCT00836784|Experimental|2|
9922206|NCT00836797||1 Case with scaffold|This group of patients will be having a placement of PLGA bioscaffold in the alveolar socket after teeth extraction
9922207|NCT00836797||2 Control without scaffold|The Alveolar socket will be left to heal and no treatment/scaffold placement will be done
9922208|NCT00836823|Experimental|Alpha blocker|Alfuzosin 10mg
9922209|NCT00836836|Experimental|1|Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
9922210|NCT00836836|No Intervention|2|"No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.~At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment.~This group will not receive any dietetic input"
9922211|NCT00836849|Experimental|1|
9922212|NCT00836849|Active Comparator|2|
9922213|NCT00836862||Arteriovenous Fistula|
9922214|NCT00836914|Active Comparator|CAL-101|
9922215|NCT00836914|Placebo Comparator|Placebo|
9922216|NCT00836940|Placebo Comparator|1|
9922217|NCT00836940|Experimental|2|GRC 8200-25mg OD
9922218|NCT00836940|Experimental|3|GRC 8200-50mg OD
9922219|NCT00836940|Experimental|4|GRC 8200-50mg BD
9922220|NCT00836940|Experimental|5|GRC 8200-100mg OD
9922221|NCT00836992||Control|Patient's QOL assessments data is not shared with the physician, nurse, and/or nurse practitioner and the patient
9922222|NCT00836992||Active|Patient's QOL assessments data is shared with the physician, nurse, and/or nurse practitioner and the patient immediately prior to the on-treatment visit.
9922223|NCT00837005||1|Patients with suspected CAD
9922224|NCT00837005||2|Patients with known CAD and suspected ischemia.
9922225|NCT00837018|Experimental|Physical exercise program|45 min, 3 times a week
9922226|NCT00837044|Active Comparator|1|Treximet, cognitive testing
9922227|NCT00837044|Placebo Comparator|2|Placebo, Cognitive testing
9922228|NCT00837057|Other|early crrt, late crrt|
9922229|NCT00837070|Experimental|1|Percutaneous zygapophyseal cyst rupture
9922230|NCT00837109|Experimental|1|Imagery Rescripting Nightmare Treatment
9922231|NCT00837109|Active Comparator|2|Treatment-as-usual in the Trauma Recovery Program
9922232|NCT00837135|Experimental|All Subjects|Screening for Eligibility into Trial
9922233|NCT00837135|Experimental|ARM A|GI-4000 Vaccine
9922234|NCT00837135|Experimental|ARM B|GI-4000 Vaccine + Activated T Cells
9922235|NCT00837135|Experimental|After GI-4000 Vaccine #4|GI-4000 Monthly - For those with incomplete removal of tumor GI-4000 Monthly + Chemotherapy - For those with complete removal of tumor
9842238|NCT02840721|Experimental|PF-06480605|PF-06480605 500 mg IV Q2W X 7 doses
9842239|NCT02840916|Experimental|verum laser acupuncture|verum laser acupuncture
9842240|NCT02840916|Sham Comparator|sham laser acupuncture|sham laser acupuncture (no laser output)
9842241|NCT02841033|Experimental|Daratumumab|Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month.
9842242|NCT02841046|Other|group cardiac index|the treatment scheme of goal-directed fluid therapy(GDFT) use cardiac index（CI） as the primary judgment in group cardiac index,Patients in group cardiac index received a therapy with the goal of CI was no less than 2.5L•min-1•m-2 .
9842243|NCT02841046|Experimental|group Stroke Volume Variation|the treatment scheme of goal-directed fluid therapy(GDFT) use Stroke Volume Variation（SVV）and cardiac index（CI）as the primary judgment in group Stroke Volume Variation,Patients in group Stroke Volume Variation received a therapy with SVV was less than 12% and CI was no less than 2.5L•min-1•m-2 .
9842244|NCT02841189|Other|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
9842245|NCT02841241|Experimental|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
9842246|NCT02841267|Active Comparator|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
9842247|NCT02841267|Active Comparator|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
9842248|NCT02841267|Active Comparator|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
9842249|NCT02841397|Experimental|Test group|All subjects will be enrolled into the test group and will receive Masimo Pulse CO-Oximeter for measurement of various physiological parameters.
9842250|NCT02841449|Experimental|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL])
9842251|NCT02841449|Experimental|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL).
9842252|NCT02841709|Experimental|Sequence 1|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
9842253|NCT02841709|Experimental|Sequence 2|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
9922236|NCT00837174|Experimental|Combination Vorinostat + Bortezomib|Six cycle combination therapy with vorinostat and bortezomib.
9922237|NCT00837187|Active Comparator|Intravenous dexmedetomidine|Dexmedetomidine is administered intravenously
9996894|NCT01504165|Experimental|Group 1|Healthy volunteers: matched subjects with normal renal function
9996895|NCT01504165|Experimental|Group 2|Mild renal impaired subjects
9792922|NCT01460901|Experimental|GD2 CAR modified Tri-virus CTL infusion|A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant.
9792923|NCT01460927|Other|TriActive+ RF|Healthy male or female subjects 30-60 years of age, having at least two facial sub-areas (left peri-orbital, right peri-orbital or peri-oral) with visible lines/wrinkles and elastosis, which correlate to a score of 2-6 on the Fitzpatrick Classification of Wrinkling and Degree of Elastosis.
9792924|NCT01460940|Experimental|Lenalidomide and Panobinostat|In the phase I trial, three patients will be enrolled at each dose level, starting at dose level 1 using a standard 3 + 3 dose escalation phase I design.
9792925|NCT01461005|Experimental|Dynamic Stabilization System|Dynamic Stabilization System (DSS) System
9792926|NCT01461044||Cohort|
9792927|NCT01461057|Experimental|Pertuzumab 840/420 mg|Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
9792928|NCT01461057|Experimental|Pertuzumab 840/840 mg|Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
9792929|NCT01461096|Experimental|Quadrivalent HPV Vaccine|Participants were prescribed the quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
9792930|NCT01461096|Placebo Comparator|Placebo Vaccine|Participants were prescribed the placebo vaccine at baseline and Weeks 8 and 24.
9792931|NCT01461369|Experimental|Diclofenac Capsules 35 mg bid|
9792932|NCT01461369|Experimental|Diclofenac Capsules 35 mg tid|
9792933|NCT01461369|Placebo Comparator|Placebo Capsule|
9792934|NCT01461473|Active Comparator|Positive Airway Pressure|Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).
9792935|NCT01461473|Active Comparator|Oral Appliance|Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).
9792936|NCT01461499|Active Comparator|Direct renin inhibitor|
9792937|NCT01461499|Active Comparator|Angiotensin receptor blockers|
9792938|NCT01461538|Experimental|Brentuximab vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
9792939|NCT01461538|Experimental|Brentuximab vedotin 2.4 mg/kg|Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
9792940|NCT01461538|Experimental|Brentuximab vedotin 1.2 mg/kg|Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
9792941|NCT01461551|Experimental|Sevoflurane|
9792942|NCT01461551|Experimental|Propofol|
9792943|NCT01461551|Experimental|Combine of sevoflurane and propofol|
9792944|NCT01461655|Placebo Comparator|Topical retinoid - Placebo|
9792945|NCT01461655|Active Comparator|Topical retinoid-NSAID|
9792946|NCT01461668|Experimental|Retapamulin|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
9792947|NCT01461668|Placebo Comparator|Placebo|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
9792948|NCT01461707|Experimental|Mobile app plus activity monitor group|Participants in the group will receive the mobile phone-based physical activity program and an activity monitor
9792949|NCT01461707|Active Comparator|Activity monitor group|Participants in the group will receive an activity monitor
9792950|NCT01461733|Experimental|amiodarone|standard dose amiodarone
9792951|NCT01461733|Placebo Comparator|placebo|
9792952|NCT01461811|Experimental|DAILIES® AquaComfort Plus® Toric|Nelfilcon A toric contact lenses (with comfort additives) worn in both eyes on a daily wear, daily disposable basis for three months
9792953|NCT01461811|Active Comparator|Focus® DAILIES® Toric|Nelfilcon A toric contact lenses worn in both eyes on a daily wear, daily disposable basis for three months
9792954|NCT01461824|Active Comparator|150 mg DMPA|Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM
9792955|NCT01461824|Experimental|104mg DMPA|Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM
9842254|NCT02841709|Experimental|Sequence 3|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
9842255|NCT02841709|Experimental|Sequence 4|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
9842256|NCT02841709|Experimental|Sequence 5|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
9842257|NCT02841787|Experimental|Individual Internet Intervention (III)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered individually by 2 clinical psychologists.~(iCBT for late life depression without social network included.)"
9842258|NCT02841787|Experimental|Internet Intervention+Peer Supp.(II+PS)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered with peer support; group moderation was provided by 2 clinical psychologists.~(iCBT for late life depression with social network included.)"
9842259|NCT02841787|No Intervention|Waitlist Control (WLC)|Waiting period, no intervention administered. WLC participants received access to the III following the 8-week waiting period.
9842260|NCT02842060|Experimental|myDEx Intervention|The proposed intervention will consist of a 6-session web-based program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, YMSM will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help YMSM consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
9842261|NCT02842060|Active Comparator|Non-tailored HIV Prevention|The investigators will create a 6-session web-based attention-control comparison to match myDEx in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites.
9842262|NCT02842073|Experimental|Naltrexone and Buproprion|Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
9842263|NCT02842086|Experimental|F/TAF|F/TAF+ F/TDF placebo for at least 96 weeks
9842264|NCT02842086|Experimental|F/TDF|F/TDF+ F/TAF placebo for at least 96 weeks
9842265|NCT02842086|Experimental|Open-label|Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment for 96 weeks.
9996896|NCT01504165|Experimental|Group 3|Moderate renal impaired subjects
10206836|NCT03700970|Active Comparator|TAP block with regular bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of 0.25% bupivacaine injected on each side.
9996897|NCT01504165|Experimental|Group 4a|First group of Severe renal impaired subjects
9842266|NCT02842086|Experimental|Open-Label Extension|Participants who remain on study at Open-label Week 96 will have the option to continue on open-label F/TAF treatment in the Open-label extension phase for 144 weeks.
9996898|NCT01504165|Experimental|Group 4b|Second group of severe renal impaired subjects
10206837|NCT03697980||HVAD|
10206838|NCT03692494|Experimental|Unilateral vocal fold paralysis standard of care voice therapy|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques.
10206839|NCT03692494|Experimental|Unilateral paralysis standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
10206840|NCT03692494|Experimental|Parkinson's disease standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
10206841|NCT03686345|Experimental|Core binding factor acute myeloid leukemia (CBF-AML)|Patients must have an unequivocal diagnosis of de novo-CBFL, prior to start midostaurin, documented by rearrangement of Core Binding Factor (CBF) genes, namely AML1-ETO and CBFB-MYH11. The experimental arm involves the administration of Midostaurin orally 50 mg (two 25 mg tablets) twice a day, from the end of induction chemotherapy, for 14 days. Patients should take Midostaurin at approximately 12 hours intervals. During all consolidation cycles, Midostaurin 50 mg (two 25 mg tablets) is administered orally twice a day, on days 8-21. Patients in complete remission after 3 cycles of remission consolidation therapy, will receive Midostaurin continuation therapy for 12 months. Midostaurin 50 mg (two 25 mg tablets) will be given orally twice a day for 12 months.
10206842|NCT03684590|Active Comparator|Standard opioid administration|Intraoperative opioid will be administered by guiding standard practice
10206843|NCT03684590|Experimental|ANI-guided opioid administration|Intraoperative opioid will be administered based on the analgesia nociceptive index (ANI)
9842267|NCT02842151|Other|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
9842268|NCT02842242|Experimental|Open Label|MYK-461
9842269|NCT02842736|Experimental|Endometrial Cryoablation|
9842270|NCT02843178|Experimental|1: distributed, targeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
9842271|NCT02843178|Active Comparator|2: lump sum, targeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
9842272|NCT02843178|Active Comparator|3: distributed, untargeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
9996899|NCT01504178|Experimental|duloxetine|The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.
9842273|NCT02843178|Active Comparator|4: lump sum, untargeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
9842274|NCT02843529|Experimental|Prodromal AD (MCI)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~MCI participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
9842275|NCT02843529|Experimental|Preclinical AD (cognitively normal)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~Cognitively normal participants at risk will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
9842276|NCT02843659|Experimental|BMS-931699|Subcutaneous weekly injection + daily oral placebo tablets
9842277|NCT02843659|Experimental|BMS-986142|Daily oral tablets + subcutaneous placebo (weekly) injection
9842278|NCT02843659|Placebo Comparator|Placebo|Weekly subcutaneous placebo injection +daily oral placebo tablets
9842279|NCT02844439|Experimental|Glioblastoma|The single arm design assessing progression-free survival at 6 months (PFS-6) in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
9842280|NCT02844543|Experimental|Athletes|Participants will be evaluated using the EYE-SYNC eye-tracking device, Desktop Eye-Tracker, and Sport Concussion Assessment Tool (SCAT-3) tool.
9842281|NCT02844569|Experimental|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
9842282|NCT02844569|Active Comparator|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
9922238|NCT00837187|Experimental|Intranasal administration|Dexmedetomidine is administered intranasally
9516905|NCT03311152|Experimental|HCC-free cirrhotic patients|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
9792956|NCT01461824|Experimental|75mg DMPA|Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM
9792957|NCT01461863|Active Comparator|protein calorie supplement|250 gm daily of specially designed porridge plus standard multivitamin
9792958|NCT01461863|Placebo Comparator|Multivitamin|Standard multivitamin control
9792959|NCT01461928|Other|Maintenance II Period Observation Only|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
9792960|NCT01461928|Experimental|Maintenance II Period Rituximab|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
9792961|NCT01461980|Active Comparator|MCV4 + Tdap+ rLP2086|Group 1 - MCV4 + Tdap + rLP2086
9792962|NCT01461980|Active Comparator|MCV4 + Tdap + saline|Group 2, MCV4 + Tdap+ saline
9792963|NCT01461980|Placebo Comparator|Saline + saline + rLP2086|Group 3- rLP2086 + saline
9792964|NCT01461993|Active Comparator|Group 1|rLP2086 + Gardasil
9792965|NCT01461993|Placebo Comparator|Group 2|rLP2086 and saline
9792966|NCT01461993|Active Comparator|Group 3|Saline + Gardasil
9792967|NCT01462045|Experimental|Exercise Group|Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
9792968|NCT01462045|No Intervention|Control Group|Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
9792969|NCT01462045|No Intervention|Base Group|Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.
9842283|NCT02844582|Experimental|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9842284|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
9842285|NCT02844998|Active Comparator|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
9842286|NCT02844998|Experimental|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
9842287|NCT02844998|Sham Comparator|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
9842288|NCT02845336|Experimental|Celecoxib|Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
9842289|NCT02845336|Active Comparator|Control|Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)
9842290|NCT02845375|Placebo Comparator|PLACEBO|Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
9842291|NCT02845375|Other|NEOSTIGMINE|intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
9842292|NCT02845375|Experimental|SUGAMMADEX|intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
9842293|NCT02845674|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
9842294|NCT02845700|Active Comparator|Perceptual Retraining Treatment (PRT)|"The Perceptual Retraining Treatment will involve systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor). Each training session will consist of 4 training blocks."
9842295|NCT02845700|Placebo Comparator|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the PRT. Following the one-month assessment, they will be given the option to complete the PRT.
9842296|NCT02845752|Active Comparator|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
9842297|NCT02845752|Placebo Comparator|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
9842298|NCT02846233|Active Comparator|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
9842299|NCT02846233|No Intervention|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
9842300|NCT02846324|Experimental|GBT440 600 mg Dose|Parts A and B
9842301|NCT02846324|Experimental|GBT440 900 mg Dose|Part A
9842302|NCT02846324|Experimental|GBT440 1500 mg Dose|Part B
9842303|NCT02846324|Placebo Comparator|Placebo|Parts A and B
9842304|NCT02846415|Experimental|PID group|Experimental group receiving the Play Intervention for Dementia
9842305|NCT02846415|No Intervention|Wait-list control group|Participants will receive usual care offered by the day care centre, including health and social services, and meals, etc.
9842306|NCT02846558|Experimental|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
9842307|NCT02846558|Experimental|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
9842308|NCT02846558|Placebo Comparator|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
9842309|NCT02846558|No Intervention|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index < 25 kg/m^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
9842310|NCT02846714|Experimental|FLARE intervention|All FLARE participants enrolled will receive the intervention
9842311|NCT02846740|Experimental|Adjunctive CES|CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
9842312|NCT02846740|Sham Comparator|Sham control CES|For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.
9842313|NCT02846779|Active Comparator|Low intensity|All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
9842314|NCT02846779|Experimental|Moderate intensity|Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program. The pharmacist will also provide limited follow-up with the participant's provider. Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
9842315|NCT02846779|Experimental|High intensity|Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up. The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist. Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
9842316|NCT02846792|Experimental|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9842317|NCT02847169|Active Comparator|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
9842318|NCT02847169|Active Comparator|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
9842319|NCT02847182|Experimental|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
9842320|NCT02847182|Placebo Comparator|Placebo Infusion|Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor.
9842321|NCT02847260|Experimental|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
9842322|NCT02847494|Active Comparator|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
9842323|NCT02847494|Active Comparator|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
9842324|NCT02847650|Placebo Comparator|Placebo|
9842325|NCT02847650|Experimental|PF-06649751|
9842326|NCT02847858|Experimental|Health-E You App Participants|
9842327|NCT02847858|No Intervention|Control Group|
9922239|NCT00837226||Study group-Bariatric procedure performed|
9922240|NCT00837226||Control group: No bariatric procedures|
9922241|NCT00837239|Experimental|Gemcitabine + HuaChanSu|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off + HuaChanSu 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
9842328|NCT02848079|Experimental|combined TAS-102 and oxaliplatin|"Combination treatment with TAS-102 and oxaliplatin. Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional 3+3 design. The subjects in Part 2 were treated with dose level 3.~Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle."
9842329|NCT02848222|Experimental|Twice Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
9842330|NCT02848222|Experimental|Once Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
9842331|NCT02848222|Sham Comparator|Twice Daily Application of warm washcloth|Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
9842332|NCT02848313|Experimental|Intermediate AMD - HRD without GA|"Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy [GA]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen.~Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
9842333|NCT02848313|Experimental|Intermediate AMD with NCGA|"Participants had 1 eye with intermediate AMD with noncentral geographic atrophy [NCGA]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area[DA]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography [SD-OCT]).~Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
9842334|NCT02848326|Placebo Comparator|Placebo|Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
9842335|NCT02848326|Experimental|Atogepant 10 mg QD|Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
9842336|NCT02848326|Experimental|Atogepant 30 mg QD|Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
9842337|NCT02848326|Experimental|Atogepant 30 mg BID|Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
9996900|NCT01504178|Placebo Comparator|positive control (L-Dopa)|The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.
9842338|NCT02848326|Experimental|Atogepant 60 mg QD|Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
9842339|NCT02848326|Experimental|Atogepant 60 mg BID|Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
9842340|NCT02848599|Active Comparator|morphine|The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
9842341|NCT02848599|Active Comparator|levobupivacaine|Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).
9842342|NCT02848651|Experimental|Atezolizumab|Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
9842343|NCT02848664||Dysphagia retraining with device|Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device
9842344|NCT02848729|Experimental|Treatment A: Oral Acetaminophen|Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6
9842345|NCT02848729|Experimental|Treatment B: IV Acetaminophen|Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.
9842346|NCT02848833||JARDIANCE|T2DM with JARDIANCE
9842347|NCT02849080|Experimental|Semaglutide flexible dosing (3, 7 or 14 mg)|
9842348|NCT02849080|Active Comparator|Sitagliptin 100 mg|
9842349|NCT02849184|Experimental|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
9842350|NCT02849184|Placebo Comparator|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
9842351|NCT02849418|Experimental|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
9842352|NCT02849418|Placebo Comparator|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
9842353|NCT02849509||Switch Patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
9842354|NCT02849509||New Patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
9842355|NCT02849678|Active Comparator|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
9842356|NCT02849678|Active Comparator|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
9842357|NCT02849704|Experimental|Chronic Pancreatitis (CP) Subjects|"CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.~Subjects will take Creon36™ for 9 days.~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1)."
9842358|NCT02849704|No Intervention|Healthy Controls|Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.
9842359|NCT02849938|No Intervention|Control Group|Usual care
9842360|NCT02849938|Experimental|Telemedicine Group|TytoCare Device
9842361|NCT02850068|Experimental|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
9842362|NCT02850159|Experimental|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
9842363|NCT02850159|Active Comparator|rTMS group|high-frequency rTMS and sham tDCS
9842364|NCT02850276|Experimental|Pyridostigmine|30mg PO three times a day
9842365|NCT02850601|Experimental|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
9842366|NCT02850601|Active Comparator|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
9842367|NCT02850965|Experimental|BI 695501|
9842368|NCT02850965|Active Comparator|Humira|
9842369|NCT02850978||Spiolto|Patient with COPD to received Spiolto
9842370|NCT02851069||Participants with Hepatitis C Virus Genotype 1 (HCV + GT1)|ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] with or without dasabuvir [250 mg twice daily]), and with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks in HCV + GT1 participants.
9842371|NCT02851108|Experimental|AS-AQ-MB|Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
9842372|NCT02851108|Active Comparator|AS-AQ-PQ|Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
9842373|NCT02851615|Other|SCThrive|SCThrive Intervention for Adolescents with SCD - 6 week self-management group
9842374|NCT02851615|No Intervention|Attention Control|6 weekly 15-20 minute individual phone calls on educational topics. No interventions are included in this arm.
9842375|NCT02851823|Active Comparator|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
9842376|NCT02851823|Experimental|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
9842377|NCT02852005|Experimental|Group 1: MVA/HIV62B + Placebo|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
9842378|NCT02852005|Experimental|Group 2: MVA/HIV62B + AIDSVAX B/E|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
9842379|NCT02852005|Experimental|Group 3: MVA/HIV62B + Placebo|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
9842380|NCT02852005|Experimental|Group 4: MVA/HIV62B + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
9842381|NCT02852005|Experimental|Group 5: Placebo + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
9842382|NCT02852265|Experimental|COC users or new starts|Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.
9842383|NCT02852330|Experimental|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
9842384|NCT02852434|Experimental|Self-administered Gel|Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
9842385|NCT02852434|Active Comparator|Paracervical Block|Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement
9996901|NCT01504178|Placebo Comparator|negative control|The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.
9996902|NCT01504191|Experimental|Internet-based CBT|Randomized patients with symptoms of anxiety and/or depression after MI will participate in an Internet-based CBT-program.
9516906|NCT03311152|Experimental|HCC-positive cirrhotic patients|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
9792970|NCT01462084|Experimental|Adaptive Servo-Ventilation (ASV) then BiLevel PAP|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual. ASV adjusts to the breathing events the individual is experiencing and provides enough PAP to resolve the breathing event. This is a crossover study, so all patients enter both treatment groups.
9792971|NCT01462084|Experimental|Bi-Level PAP then Adaptive Servo-Ventilation (ASV)|Bi-level pressure delivers two pressures, IPAP and EPAP. Both pressures are fixed and do not adjust based on the individuals breathing events. This is a crossover study, so all patients enter both treatment groups.
9792972|NCT01462110|Experimental|0.15% ethyl lauroyl arginate HCl-containing mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (19415-154-1) for 30 seconds - repeat twice daily for four weeks.
9792973|NCT01462110|Sham Comparator|5% hydroalcohol mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 5% hydroalcohol mouthrinse (W002194-0221P) for 30 seconds - repeat twice daily for four weeks.
9792974|NCT01462162||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.
9792975|NCT01462227|Experimental|Naltrexone (higher dose)|Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
9792976|NCT01462227|Experimental|Naltrexone (lower dose)|Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
9792977|NCT01462253|Experimental|Clofarabine, Cyclophosphamide|"Clofarabine concentrate for solution for infusion should be filtered using a 0.2 micron filter and diluted to a final concentration between 0.15 mg/mL and 0.4 mg/mL with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS), or 5% dextrose injection (D5W) USP or EP prior to infusion.~Cyclophosphamide should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of cyclophosphamide may be injected intravenously without further dilution or may be infused following further dilution: Dextrose Injection, USP (5% dextrose), Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride), 5% Dextrose and Ringer's Injection."
9792978|NCT01462266|Experimental|Sitagliptin|Sitagliptin 100 mg once daily
9792979|NCT01462266|Placebo Comparator|Placebo|Placebo to sitagliptin once daily
9792980|NCT01462279|Experimental|Thiamine|Open label - 200mg IV
9792981|NCT01462292|Experimental|GSK2402968 3 mg/kg/week|3 mg/kg/week of investigational product
9792982|NCT01462292|Experimental|GSK2402968 6 mg/kg/week|6 mg/kg/week of investigational Product
9792983|NCT01462292|Experimental|Placebo to match GSK2402968 3 mg/kg/week|Placebo
9792984|NCT01462292|Experimental|Placebo to match GSK2402968 6 mg/kg/week|Placebo
9792985|NCT01462305|Experimental|goLITE|light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
9792986|NCT01462305|Active Comparator|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
9792987|NCT01462318|Experimental|DAC HYP|"DAC HYP 150 mg by a subcutaneous (SC) injection using the pre-filled syringe (PFS) every 4 weeks for 24 weeks followed by a 20-week washout period. After completion of the washout period, participants may resume monthly DAC HYP 150 mg using the PFS for up to 3 additional years.~Participants in the TP-DI sub-study will receive probe-drug cocktail administration at Weeks 43 and 53. The probe-drug cocktail consists of oral midazolam 5 mg, caffeine 200 mg, S-warfarin 10 mg, vitamin K 10 mg, omeprazole 40 mg, and dextromethorphan 30 mg. The oral vitamin K is used to counteract warfarin's anticoagula nt effect prophylactically."
9792988|NCT01462344|Experimental|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
9792989|NCT01462344|Experimental|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
9792990|NCT01462344|Active Comparator|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
9792991|NCT01462344|Active Comparator|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
9792992|NCT01462357|Experimental|Cervarix 2 dose Group|Subjects who received 2 doses of Cervarix vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
9792993|NCT01462357|Experimental|Gardasil 2 dose Group|Subjects who received 2 doses of Gardasil vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
9792994|NCT01462357|Experimental|Gardasil 3 dose Group|Subjects who received 3 doses of Gardasil vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
9842386|NCT02853032|Active Comparator|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
9842387|NCT02853032|Placebo Comparator|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
9842388|NCT02853123|Experimental|Tiotropium + Olodaterol|Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
9842389|NCT02853123|Active Comparator|Tiotropium|
9842390|NCT02853318|Experimental|Treatment (pembrolizumab, bevacizumab, cyclophosphamide)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1 and cyclophosphamide PO QD on days 1-21. Treatment repeats every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity. Patients without evidence of disease progression may continue treatment in the absence of disease progression or unacceptable toxicity.
9842391|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence A-capsules, B-RC, C-HSWG|Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
9842392|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence C-HSWG, A-capsules, B-RC)|Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
9842393|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence B-RC, C-HSWG, A-capsules)|Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
9842394|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence DE-fasted followed by fed|Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
9842395|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence ED-fed followed by fasted|Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
9842396|NCT02853435|Experimental|Part 2a: Gepotidacin 1500 mg (RC or HSWG)- Japanese subjects|Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
9842397|NCT02853435|Experimental|Part 2b: Gepotidacin 1500 mg (RC or HSWG)- Chinese subjects|Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
9842398|NCT02853760|Experimental|Outdoor mountain hiking (M)|"First part of the intervention: an uphill walking phase on single trails and forest roads in a sparse forest with view on the mountainous region around Innsbruck for 6 km in around 1.5 hours together with the test leader. Regarding the walking intensity, the participants were instructed to choose a brisk without overspending pace (average speed: 4 km/h).~In the second part of the intervention, the participants were walking downhill on the same track for around 70 minutes back to the starting point to respond to the post-test (average speed: 5.2 km/h)."
9922242|NCT00837239|Experimental|Gemcitabine + Placebo|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle) + Placebo 500 ml saline only administered as a 2 hour infusion by central line.
9922243|NCT00837278||1 IVF|Pregnancies conceived with the use of assisted reproductive technologies. This is defined as a pregnancy conceived with all gametes being handled outside of the body.
9922244|NCT00837278||2 Control|Spontaneously conceived pregnancies.
9922245|NCT00837291|Experimental|CF101 1 mg BID|
9922246|NCT00837291|Placebo Comparator|Placebo|Placebo tablets BID
10206844|NCT03681210||Patients implanted with HVAD System|Patients intended to be implanted with a HVAD for use as destination therapy are eligible for enrollment into the DT PAS and must be consented for the study prior to the HVAD implant.
10206845|NCT03674567|Experimental|Part 1a: Monotherapy Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy.
10206846|NCT03674567|Experimental|Part 1b: Combination Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 in combination with pembrolizumab.
10206847|NCT03674567|Experimental|Part 2a: Monotherapy Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy; additional subjects in each cohort may be enrolled in Stage 2.
10206848|NCT03674567|Experimental|Part 2b: Combination Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 in combination with pembrolizumab; additional subjects in each cohort may be enrolled in Stage 2.
10206849|NCT03672643|Other|single arm|Crizotinib
10214101|NCT01146418|Active Comparator|recFSH 300 IU|Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
9792995|NCT01462435|Experimental|Diclofenac Test (lower dose)|
9792996|NCT01462435|Experimental|Diclofenac Test (upper dose)|
9792997|NCT01462435|Active Comparator|Celecoxib|
9792998|NCT01462435|Placebo Comparator|Placebo|
9792999|NCT01462565|Experimental|All subjects|Subjects enter the study already taking current marketed FLOLAN (epoprostenol sodium) and continue for 4 weeks (run-in). At baseline, they will be swopped to the new thermo stable formulation of epoprostenol sodium for 4 weeks (or longer if they continue in the extension phase of the study).
9793000|NCT01462695|Experimental|Treatment (sunitinib)|Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
9793001|NCT01462773|Experimental|Treatment (enzyme inhibitor, interferon therapy)|Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22 and recombinant interferon alfa-2b SC on days 1, 3, and 5 (days 1 and 3 only in week 4 course 1) of weeks 1-4. Treatment repeats every 5 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
9793002|NCT01462812|Active Comparator|Sumatriptan|
9793003|NCT01462812|Placebo Comparator|Matching placebo|
9793004|NCT01462877|Other|Fenofibrate arm|
9793005|NCT01462929|Experimental|Aclidinium bromide|Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
9793006|NCT01462929|Active Comparator|Tiotropium|Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
9793007|NCT01462929|Placebo Comparator|Placebo|Placebo comparator administered during 6 weeks of treatment
9793008|NCT01462942|Experimental|Aclidinium/Formoterol 400/6 μg|24 week, double blind treatment period
9793009|NCT01462942|Experimental|Aclidinium/Formoterol 400/12 μg|24 week, double blind treatment period
9793010|NCT01462942|Experimental|Aclidinium monotherapy 400 μg|24 week, double blind treatment period
9793011|NCT01462942|Active Comparator|Formoterol monotherapy 12 μg|24 week, double blind treatment period
9793012|NCT01462942|Placebo Comparator|Placebo|24 week, double blind treatment period
9793013|NCT01463007|Experimental|Radiation|AccuBoost APBI- 34.0 Gy in 10fx
9793014|NCT01463007|Experimental|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
9793015|NCT01463033|Active Comparator|Levetiracetam|66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
9793016|NCT01463033|No Intervention|No Intervention Control|60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.
9793017|NCT01463098|Experimental|Part A: E2006 1.0 mg|
9793018|NCT01463098|Experimental|Part A: E2006 2.5 mg|
9793019|NCT01463098|Experimental|Part A: E2006 5.0 mg|
9793020|NCT01463098|Experimental|Part A: E2006 10.0 mg|
9793021|NCT01463098|Experimental|Part A: E2006 25.0 mg|
9793022|NCT01463098|Experimental|Part A: E2006 50.0 mg|
9793023|NCT01463098|Experimental|Part A: E2006 100 mg|
9793024|NCT01463098|Experimental|Part A: E2006 200 mg|
9793025|NCT01463098|Experimental|Part B: Zolpidem 10 mg|
9793026|NCT01463098|Experimental|Part B: E2006 Matched Placebo or Zolpidem Matched Placebo|
9793027|NCT01463098|Experimental|Part A: E2006 Matched Placebo|
9793028|NCT01463098|Experimental|Part B: E2006 2.5 mg|
9793029|NCT01463098|Experimental|Part B: E2006 10 mg|
9793030|NCT01463098|Experimental|Part B: E2006 25 mg|
9793031|NCT01463111|Other|Mood stabilizer|Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
9793032|NCT01463202|Active Comparator|DMPA postpartum|Depot medroxyprogesterone acetate postpartum
9793033|NCT01463202|Active Comparator|DMPA at 4-6 weeks after delivery|Depot medroxyprogesterone acetate at 4-6 weeks after delivery
9793034|NCT01463267|Active Comparator|Device 2 passive|Device 2 will NOT remind patients to take medications
9793035|NCT01463267|Active Comparator|Device 2 active|Device 2 will remind patients to take medications
9793036|NCT01463267|Active Comparator|Device 1 active|Device 1 will remind patients to take their medications
9842399|NCT02853760|Active Comparator|Indoor treadmill walking (T)|"To ensure that all physical parameters were simultaneous to the outdoor mountain hiking condition, the distance, the difference in height, the average inclination of the track, and the time needed for the outdoor mountain hiking situation were measured in a pilot study.~First part: uphill walking, inclination: 10%, time: 1.5 hours, and speed: 4 km/h (resulting in 600 m difference in height). In accordance to possible differences in outdoor speed, the participants were allowed to change the treadmill's speed in a small range (3.8 to 4.2 km/h) to adapt to the wording brisk without overspending. Second part of the intervention contained 70 minutes of level walking on the same treadmills (5.2 km/h, 6km)."
9842400|NCT02853760|No Intervention|Sedentary control condition (C)|The sedentary control situation was located in a quiet room at the university with access to computers. The participants were allowed to use the computers, to read, and to talk, but had to remain in a sedentary position. To control for possible differences in affective response due to the daytime, the sedentary control condition contained the same timing of the measurements than the intervention condition. Sociodemographic data were collected for 5 to 10 minutes in this condition using a web-based questionnaire.
9842401|NCT02853929|Experimental|dTpa Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
9842402|NCT02853929|Active Comparator|Control Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
9842403|NCT02854059|Experimental|Treatment IdeS (0.25 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of safety and efficacy in 3 patients receiving 0.25 mg/kg there will be a potential to increase the IdeS dose to 0.5 mg/kg for the remaining 3 patients.
9842404|NCT02854059|Experimental|Treatment IdeS (0.50 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.50 mg/kg).
9842405|NCT02854527|Experimental|R1 (Reference 1) Digoxin|1 tablet (0.25 mg) digoxin as single dose
9842406|NCT02854527|Experimental|R2 Furosemide|0.1 mL (1 mg) furosemide oral solution as single dose
9842407|NCT02854527|Experimental|R3 Metformin hydrochloride|0.1 mL (10 mg) metformin oral solution as single dose
9842408|NCT02854527|Experimental|R4 Rosuvastatin|1 tablet (10 mg) rosuvastatin as single dose
9842409|NCT02854527|Experimental|T (Test)|1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
9842410|NCT02854540|Experimental|Hand A (iontophoresis) vs. Hand B (no treatment)|During the treatment period, participants will be asked to treat one hand with the hydrogel electrode-based iontophoresis device. Participants will also be asked to leave the other hand untreated.
9922247|NCT00837304||UC|Patients with known ulcerative colitis
9793037|NCT01463267|Placebo Comparator|Device 1 Passive|Device 1 will NOT remind patients to take medications.
9793038|NCT01463306|Experimental|Open|Pregabalin open label flexible dose
9793039|NCT01463358|Other|DDI30|Control group based only on backup pacing with lower rate 30 ppm
9793040|NCT01463358|Active Comparator|DDD60|Treatment arm based on full pacing support (60 Lower Rate)
9793041|NCT01463384|Active Comparator|Minocycline|Subjects will be administered 50mg minocycline twice daily.
9793042|NCT01463527|Experimental|Open Capnography|
9793043|NCT01463527|Placebo Comparator|Capnography Blind|
9793044|NCT01463631|Experimental|LY3007113|Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
9793045|NCT01463683|Experimental|V232-2XP SC|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
9793046|NCT01463683|Active Comparator|V232-1XP SC|1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
9793047|NCT01463683|Experimental|V232-2XP IM|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6
9793048|NCT01463696|Experimental|MK-8242 60 mg BID|In Cycle 1, participants received MK-8242 60 mg administered orally (PO) twice a day (BID) on Days 1-6 and PO once daily (QD) in the morning on Day 7 of the 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 60 mg PO BID on Days 1-7 of each 21-day cycle.
9793049|NCT01463696|Experimental|MK-8242 120 mg BID|In Cycle 1, participants received MK-8242 120 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 120 mg PO BID on Days 1-7 of each 21-day cycle.
9793050|NCT01463696|Experimental|MK-8242 170 mg BID|In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
9793051|NCT01463696|Experimental|MK-8242 250 mg BID|In Cycle 1, participants received MK-8242 250 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 250 mg PO BID on Days 1-7 of each 21-day cycle.
9793052|NCT01463696|Experimental|MK-8242 300 mg BID|In Cycle 1, participants received MK-8242 300 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 300 mg PO BID on Days 1-7 of each 21-day cycle.
9793053|NCT01463696|Experimental|MK-8242 350 mg BID|In Cycle 1, participants received MK-8242 350 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 350 mg PO BID on Days 1-7 of each 21-day cycle.
9793054|NCT01463696|Experimental|MK-8242 400 mg BID|In Cycle 1, participants received MK-8242 400 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 400 mg PO BID on Days 1-7 of each 21-day cycle.
9793055|NCT01463696|Experimental|MK-8242 500 mg BID|In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
9793056|NCT01463878|Experimental|Glycerna|Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
9793057|NCT01463878|Active Comparator|Control - Jevity|The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.
9793058|NCT01463982|Experimental|Oratecan and Capecitabine|"Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
9793059|NCT01464021||Adalimumab|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
9842411|NCT02854605|Experimental|GS-9674 30 mg|GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
9842412|NCT02854605|Experimental|GS-9674 100 mg|GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
9842413|NCT02854605|Placebo Comparator|Placebo|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
9842414|NCT02854631|Experimental|Selonsertib + Prednisolone|Selonsertib + prednisolone for 28 days
9842415|NCT02854631|Placebo Comparator|Prednisolone|Selonsertib placebo + prednisolone for 28 days
9842416|NCT02854800|Experimental|Weekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per week. As part of the current study, they received 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
9842417|NCT02854800|Experimental|Biweekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once bi-weekly. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
9842418|NCT02854800|Experimental|Monthly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per month. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
9842419|NCT02855086|Experimental|50 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
9842420|NCT02855086|Experimental|100 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
9842421|NCT02855164|Experimental|LJN452 10 μg|Tropifexor (LJN452) Part A
9842422|NCT02855164|Experimental|LJN452 30 μg|Tropifexor (LJN452) Part A
9842423|NCT02855164|Experimental|LJN452 60 μg|Tropifezor (LJN452) Parts A + B
9842424|NCT02855164|Experimental|LJN452 90 μg|Tropifexor (LJN452) Parts A + B
9842425|NCT02855164|Placebo Comparator|Placebo A+ B|Placebo Parts A + B
9842426|NCT02855164|Experimental|LJN452 140 μg|Tropifexor (LJN452) Part C
9842427|NCT02855164|Experimental|LJN452 200 μg|Tropifexor (LJN452) Part B
9842428|NCT02855164|Placebo Comparator|Placebo C|Placebo Part C
9842429|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
9842430|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
9842431|NCT02855359|Experimental|denintuzumab mafodotin + RCHP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
9842432|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP or RCHP|Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP
9842433|NCT02855359|Active Comparator|RCHOP|Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
9842434|NCT02855437|Active Comparator|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
9842435|NCT02855437|Active Comparator|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
9842436|NCT02855450|Experimental|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
9842437|NCT02855450|Placebo Comparator|Vehicle|Ophthalmic Placebo solution
9842438|NCT02855541|Experimental|Cycling intervention|Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
9842439|NCT02855567|Active Comparator|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
9516907|NCT03311139||AF and ACS patients: No PCI|Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention
9516908|NCT03311139||AF and ACS patients: PCI without stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)
9516909|NCT03311139||AF and ACS patients: PCI with stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)
9842440|NCT02855567|Sham Comparator|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
9922248|NCT00837317|Experimental|1|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
9842441|NCT02856035|Experimental|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional sessions up to 60 total; Phase IV: follow-up testing at 3 months after-treatment ends"
9842442|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
9516910|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
9842443|NCT02856490|Active Comparator|vSculpt with Vibration Only|vSculpt genital device used in vibration mode only.
9842444|NCT02856490|Active Comparator|vSculpt with Vibration and Light|vSculpt genital device used in vibration and light mode.
9842445|NCT02856490|Active Comparator|InTone Device|InTone genital device using electric muscle stimulation only.
9842446|NCT02856555|Experimental|Firsocostat 5 mg|Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
9842447|NCT02856555|Experimental|Firsocostat 20 mg|Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
9842448|NCT02856555|Experimental|Placebo|Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
9842449|NCT02856802|Experimental|DFN-02|Participants self-administered a single-dose of DFN-02 (sumatriptan 10-mg/100 μL nasal spray) intranasally within one hour of an acute migraine pain episode.
9842450|NCT02856802|Other|Placebo|Participants self-administered a single-dose of DFN-02 placebo nasal spray matching DFN-02 intranasally within one hour of an acute migraine pain episode.
9922249|NCT00837343|Experimental|Quetiapine Fumarate arm|Quetiapine Fumarate arm
9922250|NCT00837356|Experimental|Advate®/turoctocog alfa|
9922251|NCT00837369|Experimental|1|RTPE studies (resting and following Regadenoson 400 ug IV bolus injection) will be performed during a continuous infusion of lipid encapsulated microbubbles (Definity, Lantheus Medical Imaging) to qualitatively and quantitatively examine wall motion and myocardial contrast enhancement.
9922252|NCT00837382|Experimental|1|MEDVAMC Nightmare Treatment
9922253|NCT00837382|Experimental|2|Videoconferencing nightmare Treatment
9922254|NCT00837395||premenstual asthma|women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period
9922255|NCT00837408||Cases|Individuals with Type 2 Diabetes
9922256|NCT00837408||Controls|Individuals without Type 2 Diabetes
9922257|NCT00837421||sepsis|sepsis survivors
9922258|NCT00837460|Experimental|rehabilitation|Bilateral and unilateral prehension oriented rehabilitation to enhance prehension.
9922259|NCT00837499||Mexican Women from Mexico|
9922260|NCT00837499||Mexican-American Women in U.S.|
9922261|NCT00837499||African-American Women in U.S.|
9922262|NCT00837538||Back pain|Persons with back pain and supposed instability of lumbar spine
9922263|NCT00837551|Placebo Comparator|1 Placebo cream|0% cream 12 patients
9922264|NCT00837551|Active Comparator|2. Cream|0.5% WBI-1001 cream 12 patients
9922265|NCT00837551|Active Comparator|3. Cream|1.0% WBI-1001 cream 12 patients
9922266|NCT00837564|Experimental|CBASP|CBASP psychotherapy
9922267|NCT00837564|Experimental|Escitalopram|Escitalopram pharmacotherapy and clinical management
9922268|NCT00837603|Active Comparator|Training|Ergometer Training
9922269|NCT00837603|No Intervention|2|Counseling
9922270|NCT00837642||ART (Assited reproductive technologies)|In participants born after IVF will be performed a transthoracic echocardiography
9922271|NCT00837642||Control|In participants naturally conceived will be performed a transthoracic echocardiography
9922272|NCT00837655|Experimental|1|Sevelamer intervention
9842451|NCT02856828|Experimental|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
9842452|NCT02856828|No Intervention|Control Group|Standard intraoperative imaging will be used intraoperatively
9842453|NCT02856880|Experimental|Test zinc-IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 milliliter (mL) water for 60 seconds(s) followed by rinse with 10mL water
9842454|NCT02856880|Experimental|Test zinc non- IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
9842455|NCT02856880|Active Comparator|Positive control Toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
9842456|NCT02856880|Active Comparator|SLS Negative Control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
9842457|NCT02856880|Active Comparator|non-SLS negative control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
9842458|NCT02857283|Experimental|Filtered Air, then Ozone|Participants in this arm will first receive filtered clean air followed by ozone
9842459|NCT02857283|Experimental|Ozone, then Filtered Air|Participants in this arm will first receive ozone followed by filtered clean air
9842460|NCT02857816|Other|NURO System PTNM Therapy|Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.
9842461|NCT02858050||MEMs Cap Real-Time Monitoring|Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
9842462|NCT02858050||MEMs Cap Without Real-Time Monitoring|Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
9842463|NCT02858076|Active Comparator|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
9842464|NCT02858076|Active Comparator|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
9842465|NCT02858180|Experimental|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
9842466|NCT02858180|Experimental|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
9842467|NCT02858349|Experimental|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
9842468|NCT02858362|Experimental|Cohort 1: SMT C1100 Formulation 1|Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
9842469|NCT02858362|Experimental|Cohort 2: SMT C1100 Formulation 2|Participants received 1 g SMT C1100 formulation 2 orally twice-daily for at least 48 weeks.
9842470|NCT02858362|Experimental|Cohort 3: SMT C1100 Formulation 1|Participants in this cohort had previously received SMT C1100, but were not eligible for Cohorts 1 or 2. Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
9842471|NCT02858401|Experimental|Vesatolimod 1 mg (Cohort 1)|Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
9842472|NCT02858401|Experimental|Vesatolimod 2 mg (Cohort 2)|Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
9842473|NCT02858401|Experimental|Vesatolimod 4 mg (Cohort 3)|Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
9842474|NCT02858401|Experimental|Vesatolimod 6 mg (Cohort 4)|Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
9842475|NCT02858401|Experimental|Vesatolimod 8 mg (Cohort 5)|Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
9842476|NCT02858401|Experimental|Vesatolimod 10 or 12 mg (Cohort 6)|Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
9842477|NCT02858401|Experimental|Vesatolimod 12 mg (Optional Cohort 7)|Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
9842478|NCT02858401|Experimental|Vesatolimod 6 mg with an acidic solution (Optional Cohort 8)|Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
9842479|NCT02858401|Experimental|Vesatolimod up to 12 mg (Cohort 9)|Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
9842480|NCT02858401|Placebo Comparator|Placebo (Cohorts 1-9)|Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen
9842481|NCT02858440|Experimental|DTPa-IPV/Hib Group|All subjects receive three doses of primary vaccination of the study vaccine, Infanrix-IPV/Hib (DTPa-IPV/Hib), at 3, 4.5 and 6 months of age and a single dose of booster vaccination at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
9842482|NCT02858492|Experimental|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
9842483|NCT02858492|Experimental|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
9842484|NCT02858713|Experimental|App as intervention + Enstilar©|Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
9842485|NCT02858713|No Intervention|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
9516911|NCT03311100||Lung cancer|
9842486|NCT02858726|Experimental|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
10206850|NCT03659721|Experimental|FACAM|Intervention participants are assigned a support person (health nurse or a family therapist) who will offer support to the family until the child starts school at age 6. Intensity is up to 37 hours the first year followed by up to 10 hours of support each of the following years. The support person will offer individualized support to the family depending on the needs of the family. The support person will attend midwife consultations and help the pregnant woman to attend consultations with e.g. GP, midwife, or social worker. All intervention participants will also receive either an individual or group-based (COS-P)attachment based intervention during pregnancy and the first months of the child's life.
10214102|NCT01144416|Experimental|Single injection of 150 µg SCH 900962 (MK-8962)|Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
9793060|NCT01464190|Experimental|PA21|
9793061|NCT01464190|Active Comparator|Sevelamer carbonate|
9793062|NCT01464229|Experimental|Iloperidone addition to SSRI antidepressant|
9793063|NCT01464229|Placebo Comparator|Placebo addition to standard SSRI antidepressant|
9793064|NCT01464255|Experimental|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
9793065|NCT01464255|Active Comparator|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
9793066|NCT01464307|Experimental|IncobotulinumtoxinA (Xeomin) 400 Units|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
9793067|NCT01464307|Placebo Comparator|Placebo Comparator Arm|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
9793068|NCT01464333||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
9793069|NCT01464346|Experimental|Enlite sensor, Abdomen/Abdomen|Subjects wearing 2 Enlite sensors in Abdomen
9793070|NCT01464346|Experimental|Enlite sensor, Abdomen/Buttock|Subjects wearing 2 Enlite sensors in Abdomen/Buttock
9793071|NCT01464346|Experimental|Enlite sensor, Buttock/Buttock|Subjects wearing 2 Enlite sensors in Buttock/Buttock
9793072|NCT01464359|Experimental|Patients with Acute Myelogenous Leukemia|Patients with chemotherapy refractory Acute Myelogenous Leukemia (AML) after a double T-cell depleted (TCD) umbilical cord blood (UCB) transplantation where the smaller unit is activated overnight in interleukin-2 (IL-2). IL-2 will be given three times weekly for 6 doses beginning on days+3 and days +60 to expand UCB-derived natural killer (NK) cells in vivo.
9793073|NCT01464424|Other|TRAVATAN, then LUMIGAN|Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
9793074|NCT01464424|Other|LUMIGAN, then TRAVATAN|Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks
9793075|NCT01464619|Experimental|Delayed Intervention|Those assigned to the delayed intervention arm will receive enhanced mental health referrals, monthly follow-up phone calls, and will be assigned to the parenting intervention 3-4 months after enrollment.
9793076|NCT01464619|Experimental|Intervention|Caregivers assigned to the intervention arm will be assigned to the Incredible Years parenting intervention immediately after enrollment. They will also receive enhanced mental health referrals and monthly follow-up phone calls.
9793077|NCT01464697|Experimental|oral micronized progesterone|Oral micronized progesterone is Prometrium 300 mg at bedtime daily
9793078|NCT01464697|Placebo Comparator|Placebo Comparator|Placebo
9793079|NCT01464775|Experimental|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopy
9793080|NCT01464775|Active Comparator|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopy
9793081|NCT01464788|Experimental|Low dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
9793082|NCT01464788|Experimental|High dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
9793083|NCT01464788|Active Comparator|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
9793084|NCT01464827|Experimental|Group A|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
9793085|NCT01464827|Experimental|Group B|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
9793086|NCT01464827|Experimental|Group C|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
9793087|NCT01464827|Experimental|Group D|Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
9793088|NCT01464827|Experimental|Group E|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
9793089|NCT01464827|Experimental|Group F|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
9793090|NCT01464827|Experimental|Group G|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
9842487|NCT02858726|Experimental|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
9842488|NCT02858726|Experimental|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
9842489|NCT02858726|Placebo Comparator|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
9842490|NCT02859142|Experimental|Augmented Treatment|"Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.~Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
9842491|NCT02859142|Active Comparator|Standard Treatment w/ placebo|"Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits in addition to placebo pills identical in appearance to varenicline~Placebo pills (identical to varenicline)~NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
9842492|NCT02859246|Other|Mucinex|600 mg of Mucinex 2 times a day.
9842493|NCT02859324|Experimental|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
9842494|NCT02859441|Experimental|E10030 and Ranibizumab|Intravitreal injections of E10030 and Ranibizumab
9842495|NCT02859454|Experimental|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
9842496|NCT02859597|Experimental|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
9842497|NCT02859597|Active Comparator|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
9842498|NCT02860130|Experimental|Prismocitrate 18|
9842499|NCT02860130|Active Comparator|No Regional Anticoagulation of CRRT Circuit|
9842500|NCT02860286|Experimental|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
9842501|NCT02860507|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
9842502|NCT02860507|Experimental|sugammadex|Sugammadex 4mg/kg
9842503|NCT02860546|Experimental|TAS-102 + Nivolumab|Participants received a dose of 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice per day (BID) within 1 hour after completion of morning and evening meals, in 4-week cycle. In each 4-week cycle, TAS-102 was administered for 2 weeks, as 5 days a week with 2 days rest, followed by a 14-day rest. Also participants received 3 milligrams per kilogram per dose (mg/kg/dose) Nivolumab intravenous (I.V) infusion over 60 minutes every 14 days (on Day 1 and Day 15 of each 4-week cycle).
9842504|NCT02860845|Experimental|Boric acid and probiotics|Boric acid with L.gasseri and L.rhamnosus
9842505|NCT02860845|Active Comparator|Antibiotic/Antifungal|Antibiotic: Clindamicine Antifungal: Clotrimazol
9842506|NCT02860988|Experimental|MCCC Treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
9842507|NCT02860988|No Intervention|MCCC Comparison|Participants in this condition did not receive reentry services related to responsible parenting, economic stability and mobility, or healthy marriage and relationships.
9842508|NCT02861118||Cohort 1: Crohn's Disease|Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
9842509|NCT02861118||Cohort 2: Ulcerative Colitis|Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.
9842510|NCT02861131|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
9842511|NCT02861131|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
9842512|NCT02861534|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose will be uptitrated to 5 mg and to 10 mg.
9842513|NCT02861534|Placebo Comparator|Placebo|Participants receive a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose will be uptitrated to 5 mg and to 10 mg.
9842514|NCT02861586|Experimental|Treatment Group A; MV-CHIK low|"60 subjects will receive i.m. vaccinations with MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9842515|NCT02861586|Active Comparator|Treatment Group A/C; Priorix®|"20 subjects will receive i.m. vaccinations with Priorix® on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9922273|NCT00837655|Active Comparator|2|Calcium carbonate
10206851|NCT03659721|Active Comparator|Care as Usual|Families in the control group receive the usual care that is offered to families in the target group. This includes consultations with e.g. a midwife, social worker, medical doctor, and health visitor. If needed, CAU families can receive e.g. extra home visits or family therapy.
10206852|NCT03655067|Experimental|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
10206853|NCT03655067|No Intervention|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
10206854|NCT03654131|Active Comparator|MWA|Percutaneous ultrasound-guided MWA or open surgery MWA. The patient is fully anesthetized during the treatment.
10206855|NCT03654131|Active Comparator|SBRT|3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.
10206856|NCT03652454|Experimental|micro-osteoperforation|Propel device (ABD) Micro-osteoperforations were performed in the keratinized tissue. Micro-osteoperforations were 1.5 mm in diameter and 3-7 mm in depth.
10206857|NCT03652454|Other|conventional treatment|conventional fixed appliance treatment
10206858|NCT03650673|Other|Diagnostic Test: Identification of subgroups of patients with|
10206859|NCT03647488|Experimental|Run-in part: capmatinib + spartalizumab|Participants (enrolled in the run-in part) were treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
10206860|NCT03647488|Experimental|Randomized part: capmatinib+spartalizumab|Participants (enrolled in the randomized part) treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
10206861|NCT03647488|Active Comparator|Randomized part: docetaxel|Participants (enrolled in the randomized part) treated with docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
10206862|NCT03644927|Experimental|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual.."
10206863|NCT03644927|Active Comparator|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
9842516|NCT02861586|Experimental|Treatment Group B; MV-CHIK low|"60 subjects will receive i.m. vaccinations with placebo on study day 0. MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9842517|NCT02861586|Active Comparator|Treatment Group B/D; Priorix®|"20 subjects will receive i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9842518|NCT02861586|Experimental|Treatment Group C; MV-CHIK high|"60 subjects will receive i.m. vaccinations with MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9842519|NCT02861586|Experimental|Treatment Group D; MV-CHIK high|"60 subjects will receive i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9842520|NCT02861586|Experimental|Measles Booster Group 1|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9842521|NCT02861586|Experimental|Measles Booster Group 2|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
9842522|NCT02861664|Experimental|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
9842523|NCT02861664|Active Comparator|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
9842524|NCT02861807|Experimental|Active stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to 2.0 milliamps (mA) and guided meditation practice.
9842525|NCT02861807|Sham Comparator|Sham brain stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to ramp up to 2.0 milliamps (mA) and then ramp down to 0.0 mA and guided meditation practice.
9842526|NCT02861937|No Intervention|healthy|"Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)"
9842527|NCT02861937|Active Comparator|chronic gingivitis|"Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm and more than to 25% sites with the gingival bleeding present (BOP)~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
9842528|NCT02861937|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
9842529|NCT02862080|Experimental|no intervention; then no intervention; then cathode tsDCS + Ekso; then Ekso; then cathode tsDCS+Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
9842530|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then cathode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
9842531|NCT02862080|Experimental|no intervention; then no intervention; then anode tsDCS + Ekso; then Ekso; then anode tsDCS + Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
9922274|NCT00837668||sarcoidosis|sarcoidosis patients undergoing clinical bronchoscopy
9516912|NCT03311100||Central Nervous System Cancers|
9922275|NCT00837681||lung disease|hematopoietic stem cell transplantation (HSCT)
9922276|NCT00837733|Experimental|Biopsy catheter|Biopsy catheter (Pipelle de Cornier, Prodimed, Neuilly-en-Thelle, France
10206864|NCT03641092|Experimental|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
10206865|NCT03641092|Active Comparator|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
9516913|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
9516914|NCT03311100||Skin cancers|
9922277|NCT00837746||1|Women taking risedronate for 5 years
9922278|NCT00837772|Active Comparator|Arm 1|Usual standard cutting guide for TKA (Total Knee Arthroscopy)
10206866|NCT03635164|Experimental|Dose Escalation and Expansion|"Part 1 of this trial will use a traditional 3+3 design will be used for this trial (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level). Dose escalation will occur as long as there are minimal dose limiting toxicities.The expectation is that 9 patients will be enrolled to the trial during part 1.This is based on the expectation that all dose levels are safe (i.e. patients will not experience DLTs at all dose levels). The range of patients needed will be 6-12 patients.~Part 2 of this trial will be an expansion cohort. A total of 8 additional patients will be enrolled at the dose level determined to be the MTD in part 1 of the study. These 8 patients will be used to confirm that the MTD is a safe combination, as well as provide additional patients to investigate the efficacy for the treatment combination.~Note: Standard of care surgery will follow 3-6 weeks after medication and radiation treatment."
10206867|NCT03632759|Experimental|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
10206868|NCT03632759|Experimental|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
10206869|NCT03623139|Active Comparator|Standard nutritional education|Control group
10206870|NCT03623139|Experimental|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
10206871|NCT03623113|Experimental|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
10206872|NCT03623113|Experimental|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
10206873|NCT03623113|Active Comparator|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
10206874|NCT03618537|Experimental|ixazomib|"Enrolled patients will receive ixazomib at a fixed dose of 4mg on days~1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities."
10206875|NCT03615105|Experimental|Radiation, Thiotepa & Cyclophosphamide|
10206876|NCT03615105|Experimental|Busulfan, Fludarabine & Melphalan|
10206877|NCT03615105|Experimental|Clofarabine, Thiotepa & Melphalan|
10206878|NCT03614923|Experimental|Etokimab 300 mg + 150 mg Q4W|Participants received a 300 mg loading dose of etokimab administered by subcutaneous injection at Week 0 then 150 mg etokimab by subcutaneous injection every 4 weeks (Q4W) up to Week 12 (Weeks 4, 8, and 12). Participants also used mometasone furoate nasal spray (MFNS) of 2 actuations (50 μg/actuation) in each nostril twice daily (BID).
10206879|NCT03614923|Experimental|Etokimab 300 mg + 150 mg Q8W|Participants received a 300 mg loading dose of etokimab administered by subcutaneous injection at Week 0 then etokimab 150 mg by subcutaneous injection every 8 weeks (Q8W) up to Week 12 and placebo at Weeks 4 and 12. Participants also used MFNS of 2 actuations (50 μg/actuation) in each nostril BID.
10206880|NCT03614923|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks up to Week 12. Participants also used MFNS of 2 actuations (50 μg/actuation) in each nostril BID.
10206881|NCT03613532|Experimental|Venetoclax|"This study has three periods: 1) Screening 2) Treatment with venetoclax + FluBu2 chemotherapy and transplantation and 3) Post-Transplant follow up.~Dose escalations begin in level I with dose cohorts and rules for escalation/de-escalation.~Part 1 dose escalation will occur using a 3+3 approach. Post-transplant period includes routine follow-up.~Venetoclax: 6-7 total doses based on level assigned~Busulfan: given 2x daily for 4 days~Fludarabine: given 1x daily for 4 days~Part 2 post-transplant period includes therapy with azacitidine and venetoclax. Dose escalation will occur using a 10+10 approach.~Venetoclax: 14 doses for 8-12 cycles based on level assigned~Azacitidine: 5 doses for 8-12 cycles based on level assigned~Part 3 post-transplant period includes therapy with oral decitabine/cedazuridine and venetoclax. Dose escalation will occur using a 10+10 approach.~Venetoclax: 14 doses for 8 cycles~Decitabine/cedazuridine: 3 doses for 8 cycles"
10206882|NCT03610997|Other|Photorefractive keratectomy|The children will undergo PRK in the affected eye(s) using previously derived formulas for PRK.
10206883|NCT03601702||EmboTrap ® II Device|The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
10206884|NCT03594422|Experimental|HQP1351 30mg|30 mg QOD
10206885|NCT03594422|Experimental|HQP1351 40mg|40 mg QOD
10206886|NCT03594422|Experimental|HQP1351 50mg|50 mg QOD
10206887|NCT03594422|Experimental|HQP1351 20mg|20 mg QOD (For minor)
10206888|NCT03583099|Experimental|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
10206889|NCT03583099|Active Comparator|COPD Education|Practice clinicians will receive basic COPD education only.
10206890|NCT03580278|Experimental|Cohort 1:75 mg ABY-035/AFO2|Cohort 1: 75 mg ABY-035/AFO2, once daily for 14 days
9842532|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then anode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
9842533|NCT02862106|Experimental|εPA-44 900μg group-placebo|These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
9842534|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
9842535|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
9842536|NCT02862106|No Intervention|Follow-up group-placebo|These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only
9842537|NCT02862106|No Intervention|Follow-up group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
9842538|NCT02862106|No Intervention|Follow-up group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
9842539|NCT02862535|Experimental|Cohort 1: ADX|Participants will receive andecaliximab (ADX) 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
9842540|NCT02862535|Experimental|Cohort 2: ADX + S-1 + Cisplatin|Participants will receive ADX 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle in combination with S-1 orally twice daily plus cisplatin chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice, and/or the in-country label) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
9842541|NCT02862535|Experimental|Cohort 3: ADX + S-1 + Oxaliplatin|Participants will receive ADX 1200 mg every 3 weeks on Day 1 of each 21-day treatment cycle in combination with chemotherapy (S-1 80 mg/day to 120 mg/day according to the body surface area orally twice daily for first 14 days of 21 day cycle plus oxaliplatin 100 mg/m^2) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study.
9922279|NCT00837772|Experimental|Arm 2|Otismed MRI generated cutting guide for TKA
9922280|NCT00837785|Experimental|1|240 mg (two 120 mg capsules) twice a day
10206891|NCT03580278|Experimental|Cohort 2: 150 mg ABY-035/AFO2|Cohort 2: 150 mg ABY-035/AFO2 once daily for up to 28 days
10206892|NCT03579160|Experimental|0.25% Timolol gel applied to full-thickness skin graft|"During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
10206893|NCT03579160|Active Comparator|Standard of Care dressings|"FTSG surgery as per SOC~After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
10206894|NCT03577587|Experimental|Verum|Silitidil for 21 days
10206895|NCT03577587|Placebo Comparator|Placebo|Placebo for 21 days
10206896|NCT03577587|No Intervention|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
10206897|NCT03556696|Experimental|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
10206898|NCT03556696|Active Comparator|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
10206899|NCT03554187|Experimental|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Interventions :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
10206900|NCT03554187|Placebo Comparator|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Intervention(s) :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
10206901|NCT03540277|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
10214103|NCT01144416|Active Comparator|Daily 300 IU recFSH|Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
10214104|NCT01140048||All Enrolled Participants|All participants who completed Protocol 272 and were enrolled in Protocol 374
9516915|NCT03311100||Sarcomas|
9842542|NCT02862535|Experimental|Cohort 4: ADX + Nivolumab|Participants will receive ADX 800 mg every 2 weeks followed by chemotherapy (nivolumab 3 mg/kg) on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
10206902|NCT03540277|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
10206903|NCT03540277|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program.
10206904|NCT03539796|Experimental|Dural puncture epidurals (DPE)|Dural puncture epidurals for cesarean section.
10206905|NCT03539796|Active Comparator|Traditional epidurals (EPI)|Traditional epidurals (EPI) for cesarean section.
9842543|NCT02862548|Experimental|TAF|TAF for 48 weeks
9842544|NCT02862548|Active Comparator|TDF-Containing Regimens|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
9842545|NCT02862548|Experimental|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF for an additional 144 weeks.
9842546|NCT02862574|Experimental|Andecaliximab 300 mg|Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
9842547|NCT02862574|Experimental|Andecaliximab 150 mg|Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
9842548|NCT02862574|Placebo Comparator|Placebo|Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
9842549|NCT02862574|Experimental|Open-Label Extension|On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
9842550|NCT02862600|Experimental|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
9842551|NCT02862730|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient. The predictive low glucose suspend system will run through the artificial pancreas controller in predictive low glucose suspend mode and utilize the patient's optimized basal rates, correction factor, and carb ratio, but it will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
9842552|NCT02862730|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in dual hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
9842553|NCT02862730|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
9842554|NCT02862730|Active Comparator|Sensor Augmented Pump Therapy arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient with subject's insulin pump and glucose sensor, if he/she typically uses one. Subjects will still wear a heart rate monitor uploading to a smart phone.
9922281|NCT00837785|Experimental|2|240 mg (two 120 mg capsules) three times a day
10206906|NCT03539796|Active Comparator|Combined-spinal epidural technique (CSE)|Combined-spinal epidural technique (CSE) for cesarean section.
10206907|NCT03531736|Experimental|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
10206908|NCT03527537|Active Comparator|20% cutoff group|Treatment intervention will be initiated with insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
10206909|NCT03527537|Active Comparator|40% cutoff group|Treatment intervention will be initiated with insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
9922282|NCT00837798||No history of AF|Patient should not have had a documented history of AF for a period of 3 months prior to enrollment.
9922283|NCT00837837|Experimental|Chlorpheniramine|Chlorpheniramine dose by body weight.
9922284|NCT00837850|Active Comparator|1|
9922285|NCT00837850|Active Comparator|2|
9922286|NCT00837863|Experimental|1|ALTU-238
9922287|NCT00837863|Experimental|2|ALTU-238
9922288|NCT00837863|Experimental|3|ALTU-238
9922289|NCT00837863|Active Comparator|4|Nutropin AQ
9922290|NCT00837889||decompensated heart failure patients|
9922291|NCT00837889||chronic heart failure patients|
9922292|NCT00837889||healthy controls|
9842555|NCT02862912|Experimental|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
9842556|NCT02862912|Active Comparator|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
9842557|NCT02863198|Active Comparator|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
9842558|NCT02863198|No Intervention|non endometrial injury|non endometrial injury was done only for patient of the control group
9842559|NCT02863263|Other|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
9842560|NCT02863263|Other|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
9842561|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
9842562|NCT02863328|Experimental|14 mg oral semaglutide|
9842563|NCT02863328|Active Comparator|25 mg empagliflozin|
9842564|NCT02863354|Experimental|Q4WKS|"Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections) through week 48. Following week 48, aflibercept 2 mg every 12 weeks through week 96.~If NV or PDR are worse per pre-specified criteria at week 60, or at any study visit thereafter, the subject will be treated every 4 weeks through the end of the study."
9842565|NCT02863354|Experimental|Q12WKS|"Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval through week 48. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.~At week 52, aflibercept 2 mg every 4 weeks (defined as 28 days (+ 7 days) and at least 21 days between injections) for subjects with visible retinal non-perfusion. If retinal non-perfusion has completely resolved at week 72, aflibercept every 12 weeks through end of study. For subjects without retinal non-perfusion at week 52, aflibercept 2 mg every 12 weeks through the end of study."
9842566|NCT02863419|Experimental|Oral Semaglutide|
9842567|NCT02863419|Active Comparator|Liraglutide|
9842568|NCT02863419|Placebo Comparator|Placebo|
9842569|NCT02863575|Experimental|Ibuprofen/Caffeine|Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
9842570|NCT02863575|Active Comparator|Ibuprofen|Ibuprofen 400 mg
9842571|NCT02863575|Placebo Comparator|Placebo|Placebo comparator
9842572|NCT02864069|Experimental|Walking Intervention|
9842573|NCT02864069|Experimental|Cognitive Training Intervention|
9842574|NCT02864069|Experimental|Combined Intervention|
9842575|NCT02864082|Experimental|PAT-001 0.1%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
9922293|NCT00837915|Experimental|1|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy
9516916|NCT03311100||Urothelial cancer|
9842576|NCT02864082|Experimental|PAT-001 0.2%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.
9842577|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.1% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
9842578|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.2% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
9842579|NCT02864316|Experimental|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
9842580|NCT02864316|Experimental|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
9842581|NCT02864342|Active Comparator|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
9842582|NCT02864342|Placebo Comparator|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
9842583|NCT02864355|Active Comparator|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
9842584|NCT02864355|No Intervention|Usual Care|Standard of care will be used to manage blood pressures.
9842585|NCT02864368|Experimental|5-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
9922294|NCT00837915|Active Comparator|2|(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
10206910|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
10206911|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
10206912|NCT03513445|Experimental|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
10206913|NCT03513445|No Intervention|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
10206914|NCT03511118||Tranexamic acid (TXA)|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206915|NCT03511118||labetalol|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206916|NCT03511118||metformin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206917|NCT03511118||nifedipine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206918|NCT03511118||clindamycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206919|NCT03511118||oxycodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206920|NCT03511118||azithromycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206921|NCT03511118||escitalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206922|NCT03511118||sertraline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206923|NCT03511118||ondansetron|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
9842586|NCT02864368|Experimental|21-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
9842587|NCT02864368|Experimental|5-day TMZ: Safety Cohort|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine. Vaccine components A and B were administered separately, with a delay between them, to determine if it was an individual component or a combination of the components that resulted in adverse reactions.
9842588|NCT02864368|Experimental|5-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
9842589|NCT02864368|Experimental|21-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
9842590|NCT02864381|Experimental|Andecaliximab + Nivolumab|Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
9842591|NCT02864381|Active Comparator|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
9842592|NCT02864394|Experimental|Pembrolizumab|Participants with NSCLC receive pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
9842593|NCT02864394|Experimental|Docetaxel|Participants with NSCLC receive Docetaxel 75 mg/m^2 IV over 1 hour Q3W until disease progression, toxicity, investigator's decision to discontinue, or consent withdrawal.
9842594|NCT02864706|Experimental|EVEROLIMUS|patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
9842595|NCT02864706|Active Comparator|Control|patients received standard CsA, MMF and corticosteroids
9842596|NCT02864732|Experimental|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
9842597|NCT02864732|Experimental|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
9842598|NCT02865343|Active Comparator|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
9842599|NCT02865343|Placebo Comparator|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
9842600|NCT02865434|Experimental|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842601|NCT02865434|Experimental|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842602|NCT02865434|Experimental|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9516917|NCT03311100||Hepatocarcinoma|
9842603|NCT02865434|Experimental|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842604|NCT02865434|Experimental|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842605|NCT02865434|Experimental|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842606|NCT02865434|Experimental|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842607|NCT02865434|Experimental|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842608|NCT02865434|Experimental|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
9842609|NCT02865434|Experimental|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
9842610|NCT02865434|Experimental|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
9842611|NCT02865499|Experimental|acarbose|all participants will receive acarbose
9842612|NCT02865538|Placebo Comparator|BAY3427080 Placebo|
9842613|NCT02865538|Experimental|50mg BAY3427080|
9842614|NCT02865538|Experimental|100mg BAY3427080|
9842615|NCT02865538|Experimental|150mg BAY3427080|
9842616|NCT02865538|Experimental|300mg BAY3427080|
9842617|NCT02865590|Experimental|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
9842618|NCT02865590|Active Comparator|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
9842619|NCT02865720|Experimental|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
9842620|NCT02865720|Experimental|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
9842621|NCT02865811|Experimental|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.~If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.~If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)~Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV~Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
9842622|NCT02866175|Experimental|Edoxaban Regimen|Participants will be randomized to receive edoxaban 60 mg once-daily or 30 mg once-daily and clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5 mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) used.
9842623|NCT02866175|Active Comparator|Vitamin K Antagonist Regimen|Participants will be randomized to receive VKA in combination with clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) and aspirin (100 mg once-daily, for a minimum of 1 month and up to 12 months duration.
9842624|NCT02866643|Experimental|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
9842625|NCT02866643|Active Comparator|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
9842626|NCT02866942|Experimental|Asthma|LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2+
9842627|NCT02867059|Experimental|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
9842628|NCT02867059|Experimental|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
9842629|NCT02867150|Experimental|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
9842630|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
9842631|NCT02867202|Experimental|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two or three months to re-evaluate the uterine adhesions.
9842632|NCT02867202|Experimental|intrauterine device Plus Foley Catheter|Intrauterine Contraceptive Device Plus Foley Catheter are inserted into the uterine after hysteroscopic adhesiolysis. Foley Catheter is removed after three days while intrauterine device is removed at the second hysteroscopy. Uterine adhesions are judged again at the second hysteroscopy.
9842633|NCT02867605|Other|Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|Single Arm study
9842634|NCT02867618|Experimental|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
9842635|NCT02867709|Experimental|Ubrogepant 25 mg|1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
9842636|NCT02867709|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
9842637|NCT02867709|Placebo Comparator|Placebo|1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
9842638|NCT02867995|No Intervention|Control|No glaucoma drop aid control
9842639|NCT02867995|Active Comparator|Eye Drop Aids|Participants could be placed into one of the drop aid groups (Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, or the Simply Touch Eye Drop Applicator)
9842640|NCT02868216|Experimental|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
9842641|NCT02868216|No Intervention|Without management training|No anger management training
9842642|NCT02868229|Experimental|COR-001|
9842643|NCT02868229|Placebo Comparator|Placebo|
9842644|NCT02868242|Experimental|LDV/SOF|Participants will receive LDV/SOF 90/400 mg fixed dose combination (FDC) (1x 90/400 mg tablet or 4 x 22.5/100 mg tablets based on swallowability assessment during screening) for 12 weeks.
9842645|NCT02868281|Experimental|Subjects recruited at ACT centers|For the subjects who will be recruited in the ACT centers, they will be treated based on the ACT score. If ACT score are = 25 for >=3 months then step-down the treatment; if ACT score >=20, <25 or ACT=25 for <3 months then there will be no change and if ACT score less than (<=) 19 then step-up the treatment.
9842646|NCT02868281|Active Comparator|Subjects recruited in the control centers|For subjects who will be recruited in the control centers, they will be treated based on doctor's subjective judgment.
9842647|NCT02868554|No Intervention|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
9842648|NCT02868554|Experimental|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
9842649|NCT02868554|Experimental|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
9842650|NCT02869295|Experimental|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
9842651|NCT02869334|Experimental|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
9842652|NCT02869334|Experimental|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
9842653|NCT02869334|Sham Comparator|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
9842654|NCT02869438|Experimental|Benralizumab arm|Benralizumab administered subcutaneously
9842655|NCT02869438|Placebo Comparator|Placebo arm|Placebo administered subcutaneously
10206924|NCT03511118||Ciprofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206925|NCT03511118||Doxycycline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206926|NCT03511118||Levofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
9842656|NCT02869451|Experimental|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
9842657|NCT02869893|Other|Healthy Participants|MRCP with Secretin and MR elastography will be performed on all participants.
9842658|NCT02870101|Other|Intervention|Performance of three nucleic acid amplification tests (NAATs) to detect Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from swabs collected from the pharynx and rectum. Assays include: Nucleic acid amplification test 1 for NG and CT; Nucleic acid amplification test 2 for NG and CT; and, Nucleic acid amplification test 3 for NG and CT.
9842659|NCT02870205|Experimental|GSP 301 NS|
9842660|NCT02870205|Active Comparator|GOM-NS|
9842661|NCT02870205|Active Comparator|GMM-2 NS|
9842662|NCT02870205|Placebo Comparator|GSP 301 placebo NS|
9842663|NCT02870283|Active Comparator|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 3rd step.~Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
9842664|NCT02870283|Active Comparator|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
10206927|NCT03511118||Methylphenidate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206928|NCT03511118||Sumatriptan|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206929|NCT03511118||Citalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206930|NCT03511118||Cyclobenzaprine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206931|NCT03511118||Furosemide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206932|NCT03511118||Gabapentin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206933|NCT03511118||Hydrochlorothiazide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206934|NCT03511118||Hydroxyurea|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206935|NCT03511118||Rosuvastatin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206936|NCT03511118||Topiramate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206937|NCT03511118||Trazodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206938|NCT03511118||Valganciclovir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206939|NCT03511118||Venlafaxine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
9842665|NCT02870283|Active Comparator|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
9842666|NCT02870309|Experimental|Alpha-1 MP|Participants received 8 IV infusions of 60 mg/kg Alpha-1 MP administered weekly at an infusion rate not exceeding 0.08 mL/kg/min over approximately 15 minutes, up to Week 8.
9842667|NCT02870933|Experimental|subject|this arm will receive Transepicardial with Transseptal CD 133+ Implantation
9842668|NCT02870933|No Intervention|control|this arm will not receive Transepicardial with Transseptal CD 133+ Implantation
9842669|NCT02870972|Experimental|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
9842670|NCT02870972|Experimental|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
9842671|NCT02870972|Experimental|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
9842672|NCT02870972|Placebo Comparator|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
9842673|NCT02870972|Experimental|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
9842674|NCT02871011|Placebo Comparator|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
9842675|NCT02871011|Experimental|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
9842676|NCT02871128|Experimental|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
9842677|NCT02871128|Placebo Comparator|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
9842678|NCT02871128|Active Comparator|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
9842679|NCT02871375|Other|DT1 MF, then Habitual|Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
9842680|NCT02871375|Other|Habitual, then DT1 MF|Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
9842681|NCT02871440|Experimental|Eye drop 1|Omega 3
10206940|NCT03511118||Verapamil|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206941|NCT03511118||Remdesivir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
9842682|NCT02871440|Active Comparator|Eye drop 2|Optive Advanced
9842683|NCT02871440|Active Comparator|Eye drop 3|Optive
9842684|NCT02871479|Experimental|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
10206942|NCT03511118||Anakinra|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
9842685|NCT02871479|Placebo Comparator|Placebo cream|The vehicle cream
9842686|NCT02871479|Experimental|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
9842687|NCT02871492|Experimental|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
9842688|NCT02871492|Placebo Comparator|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
10206943|NCT03511118||Tocilizumab|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206944|NCT03511118||Fluvoxamine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
10206945|NCT03502187|Active Comparator|Primary Care Management (PCM)|Non-specific LBP, where the cause for the pain cannot be determined, accounts for ninety percent of LBP cases.(Koes, et al, 2006) Reducing pain and continuing daily activity to prevent deconditioning are the primary therapy goals of PCM. Traditional PCM treatment of LBP will include advice/information on self-care options, over-the-counter analgesics, heat application, and remaining active.(Chou, et al., 2007; Koes, et al, 2010) Despite evidence that physical activity is effective, limiting activity remains common; individuals cite pain or re-injury fear as a limiting factor.( Lethem, et al., 1983; Poirandeau, et al., 2006; Steenstra, et al., 2016)
10206946|NCT03502187|Experimental|NeuromuscularElectricalStimulation(NMES)|Rehabilitation requires activation of deep stabilizing muscle groups in the lumbopelvic region. Traditional exercises specific for these muscles are hard to teach with poor compliance. NMES is effective in stimulating these muscles, (Porcari, et al., 2005; Glaser, et al., 2001) resulting in enhanced activation, and improved performance. (Coghlan, et al., 2011) NMES devices are programmed to exercise core muscles through a series of stimulated muscle contractions. Concurrent muscle stimulation of the abdominal wall and lumbar paraspinal area has been shown to be most effective to maximally activate deep lumbar stabilizers in LBP patients. (Baek, et al., 2016) NMES provides as much pain relief as transcutaneous electric nerve stimulation (TENS) in LBP subjects. (Moore SR, Shurman J, 1997)
10206947|NCT03502187|Experimental|Progressive Exercise Plan (PEP)|The literature suggests that this intervention may be of benefit in military personnel with subacute LBP. (Chou, et al., 2007;Marshall PW, Murphy BA, 2006) Meta-analysis showed evidence that graded-activity exercise improved patient outcomes in subacute LBP; however, evidence for other exercise programs were inconsistent. (Hayden, et al., 2005) A strengthening program involving the trunk and abdomen muscles showed clinical reductions in low back pain and disability with high adherence. (Kendall, et al., 2015) Systematic reviews were unable to support any one type of exercise over another. The use of pain-relieving modalities combined with muscle strengthening, such as home-based electrotherapy or progressive exercise, could reduce pain and improve function more rapidly.
9842689|NCT02871492|Active Comparator|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
9842690|NCT02871570|Experimental|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
9842691|NCT02871570|Experimental|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
10206948|NCT03498014|Active Comparator|Prescription as standard|
9842692|NCT02871635|Experimental|BI 695501|
9842693|NCT02871635|Active Comparator|HUMIRA + BI 695501|
10206949|NCT03498014|Experimental|Pharmacogenetic-guided prescription|
10206950|NCT03483220||cases|patients with cannabis use disorder
10206951|NCT03475004|Experimental|Combination Therapy|"Cohort A: Patients will start with 7-day run-in of binimetinib on day -7 of cycle 1 only. Pembrolizumab and bevacizumab will then be added to binimetinib on cycle 1 day +1. Cycle 1 will end on day 21. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.~Cohort B: Patients will be treated with pembrolizumab, bevacizumab, and binimetinib together on day 1 of all cycles including cycle 1. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles."
10206952|NCT03474887||DIGI-Throat|Patients choosing to seek primary care through an online consultation with chief complaint sore throat.
10206953|NCT03474887||DIGI-Resp|Patients choosing to seek primary care through an online consultation with chief complaint cough/common cold/influenza.
10206954|NCT03474887||DIGI-Dysuria|Patients choosing to seek primary care through an online consultation with chief complaint dysuria.
10206955|NCT03474887||PHYSI-Throat+CONTROL-Throat|"Patients choosing to seek primary care through physical consultation with chief complaint sore throat.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of sore throat."
10206956|NCT03474887||PHYSI-Resp+CONTROL-Resp|"Patients choosing to seek primary care through physical consultation with chief complaint cough/common cold/influenza.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of cough/common cold/influenza."
9842694|NCT02871739|Experimental|DA viewing with SPI Feedback|Group 1 receives three decision aids and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
9842695|NCT02871739|Experimental|DA viewing with no SPI Feedback|Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
9842696|NCT02871739|Experimental|Webinar with SPI Feedback|Group 3 receives an online, interactive webinar that focuses on SDM skills in clinical encounters and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
9842697|NCT02871739|Experimental|Webinar with no SPI Feedback|Group 4 receives an online, interactive webinar that focuses on SDM skills in clinical encounters. This group does not receive any feedback from the SPI.
9842698|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
9842699|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
9842700|NCT02872012|Experimental|Cryoanesthesia Device -7 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
9842701|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
9842702|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
9842703|NCT02872012|Active Comparator|Lidocaine|"Participants randomized to this arm will have their other eye receive anesthesia via the current standard of care treatment method (lidocaine) prior to receiving an intravitreal injection.~Lidocaine: Lidocaine will be applied to the non-cryoanesthesia eye."
9842704|NCT02872103|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
9842705|NCT02872103|Placebo Comparator|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
9842706|NCT02872142|Experimental|Albutein 5%|Plasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant.
9842707|NCT02872285|Experimental|LYC-30937-EC 25 mg PO once daily (QD)|LYC-30937-EC 25 mg by mouth once daily for 12 weeks
9842708|NCT02872285|Placebo Comparator|Matching Placebo PO QD|Placebo enteric coated (EC) by mouth once daily for 12 weeks
9842709|NCT02872311|Active Comparator|High Dose Influenza Vaccine|This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
9842710|NCT02872311|Active Comparator|Adjuvanted Influenza Vaccine|This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
10206957|NCT03474887||PHYSI-Dysuria+CONTROL-Dysuria|"Patients choosing to seek primary care through physical consultation with chief complaint dysuria~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of dysuria."
9998273|NCT01516580|Experimental|LMB chemo + Rituximab|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
10206958|NCT03461848|Experimental|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
10206959|NCT03461848|Active Comparator|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
10206960|NCT03461458|Experimental|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
10206961|NCT03461458|Experimental|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
10206962|NCT03458247|Active Comparator|Abiraterone acetate standard dose|1000 mg/day
10206963|NCT03458247|Experimental|Abiraterone acetate escalated dose|2000 mg/day
10206964|NCT03450733||Previously Implanted (Group 1)|Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
10206965|NCT03450733||Control (Group 2)|Control, non-implanted subjects
10206966|NCT03447262|Experimental|VX-659/TEZ/IVA TC|Participants from parent studies VX17-659-102 (NCT03447249) or VX17-659-103 (NCT03460990) were administered VX-659 240 milligrams (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the TC treatment period for up to 96 weeks in the current study VX17-659-105.
10206967|NCT03441061|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 8. Treatment repeats every 21-28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
10206968|NCT03432819|Experimental|Siempre Seguiré|We will conduct a small randomized controlled trial (RCT), testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
10206969|NCT03432819|No Intervention|Control|Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
10206970|NCT03428165|Other|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
10206971|NCT03428165|No Intervention|spontaneous|
10206972|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
10206973|NCT03417180|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
10206974|NCT03417180|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
10206975|NCT03417180|Experimental|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
10206976|NCT03402789|Experimental|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
10206977|NCT03402789|Placebo Comparator|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
10206978|NCT03390725|Experimental|A Healthy School Start Plus intervention|The intervention consists of 4 components given to all participants in the experimental group: 1) A health information brochure regarding child's health; 2) Motivational Interviewing with the parents by the school nurse concerning the child; 3) classroom activities for the children with home assignments; and 4) a web-based self-test of type-2 diabetes risk by parents with recommendation to contact primary health care in case of elevated risk.
10206979|NCT03390725|Active Comparator|Control|Treatment as usual in school health services plus the health information brochure regarding child's health (component 1 of the intervention)
10206980|NCT03389399||Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days|This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
10206981|NCT03380078|Active Comparator|Standard|Programs assigned to the Standard condition will receive standard EBI training only
9996903|NCT01504191|No Intervention|Treatment as usual (TAU)|"Control: After randomization patients with symptoms of anxiety and/or depression after MI will participate in the treatment as usual (TAU).~Reference: A reference group without depressive or anxiety symptoms will participate in the treatment as usual (TAU)."
9842711|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+HD|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
9842712|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine +Adj|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
9842713|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+Recomb|This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
9842714|NCT02872857|Placebo Comparator|Placebo|
9842715|NCT02872857|Experimental|8mg galantamine twice daily|
9842716|NCT02872857|Experimental|12mg galantamine twice daily|
9842717|NCT02872909|Active Comparator|low irradiance LED PDT|Ambulight LED portable PDT treatment
9842718|NCT02872909|Active Comparator|conventional higher irradiance LED|Conventional LED hospital based standard PDT treatment
9842719|NCT02872935|Placebo Comparator|Placebo: Normal Saline|1ml of Normal Saline will be given intravenously with the administering of the spinal dose
9842720|NCT02872935|Experimental|Glycopyrrolate group|1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
9842721|NCT02873104|Active Comparator|Treatment|truSculpt rf device, therapeutic settings
9986301|NCT01401296|Experimental|Deprexis|Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.
9986302|NCT01401335|Other|Trauma counseling|
9842722|NCT02873104|Sham Comparator|Sham|truSculpt rf device, non-therapeutic settings
9842723|NCT02873208|Experimental|ALKS 3831|Oral tablet, daily dosing
10206982|NCT03380078|Experimental|TEAMS Leadership Institute (TLI) ONLY|Programs assigned to the TLI ONLY condition will receive standard EBI training for providers and leaders will participate in TLI.
9842724|NCT02873221|Active Comparator|Usual Care|Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
9842725|NCT02873221|Experimental|Ubrogepant 50 mg|Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
9996904|NCT01504230||health older adults|
10206983|NCT03380078|Experimental|Motivational Enhancement (TIPS for Training) ONLY|Programs assigned to the TIPS ONLY condition will receive enhanced TIPS EBI training for providers.
10206984|NCT03380078|Experimental|TIPS + TLI|Programs assigned to the TIPS + TLI condition will receive TIPS EBI training for providers and leaders will participate in TLI
10206985|NCT03365791|Experimental|PDR001+LAG525|PDR001 and LAG525 administered via i.v. infusion over 30 minutes once every 3 weeks (Q3W). LAG525 was given first followed by PDR001.
10206986|NCT03361345|Experimental|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
10206987|NCT03361345|Sham Comparator|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
10206988|NCT03342196|Experimental|Thiotepa + Fludarabine + Melphalan + KGF|Melphalan 100 mg/m2 on day -8 Thiotepa 10 mg/kg on day -7 Fludarabine 160 mg/m2 in divided doses given on days -6, -5, -4 and -3. Keratinocyte Growth Factor (KGF) 60mcg/kg IV on day -11, -10, and -9 and 0, +1, and +2.
10206989|NCT03331354|Active Comparator|Self-help resources|a self-help vocational manual
10206990|NCT03331354|Experimental|Compass|a distant learning vocational program
10206991|NCT03331289|Placebo Comparator|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
10206992|NCT03331289|Active Comparator|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
10206993|NCT03331289|Active Comparator|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
10206994|NCT03331289|Active Comparator|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
10206995|NCT03323749|Experimental|Part 1: Elamipretide|40 mg (0.5mL) elamipretide subcutaneous (SC) daily
10206996|NCT03323749|Placebo Comparator|Part 1: Placebo|Placebo SC daily
10206997|NCT03323749|Experimental|Part 2: Elamipretide open label|Elamepretide 40 mg (0.5 mL) SC daily
10206998|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Epacadostat|Participant received pembrolizumab 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, twice daily (BID) in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
10206999|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Placebo|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat matching placebo tablets, orally, BID in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
10207000|NCT03322566|Experimental|Pembrolizumab + Epacadostat|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, BID in each 21 day cycle for up to 35 cycles.
10207001|NCT03322540|Experimental|Pembrolizumab + Epacadostat|Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.
10207002|NCT03322540|Active Comparator|Pembrolizumab + Placebo|Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.
10214105|NCT01077817||Esophageal Cancer Cases|Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
9516918|NCT03311074|Experimental|Strimvelis treatment receivers|Approximately 15 subjects with ADA-SCID who were previously received Strimvelis will be included in the analysis and a total of 5 blood samples will be collected from each subject at approximately annual interval.
9842726|NCT02873221|Experimental|Ubrogepant 100 mg|Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
9842727|NCT02873286|Experimental|Group 1 - Single Low Dose / Booster|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
9842728|NCT02873286|Experimental|Group 2 - Two Low Doses|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
9842729|NCT02873286|Experimental|Group 3 - Single High Dose / Booster|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
9842730|NCT02873286|Experimental|Group 4 - Two High Doses|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
9842731|NCT02873286|Experimental|Group 5 - Placebo|First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)
9842732|NCT02873338|Active Comparator|Control (idarubicin+cytarabine)|"Induction:~Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)~Reinduction:~Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)~Consolidation:~• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)"
9922295|NCT00837928|Experimental|Bendamustine and Fractionated stereotactic radiotherapy|Bendamustine 40 mg/m2 and will be administered IV on days 1,2,and 3 prior to surgery on each day of SRT (Sterotactic radiation therapy). Laboratory biomarker analysis will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. Pharmacokinetic samples will not be collected from patients who begin SRT on day 1). Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine) Stereotactic fractionated radiation therapy starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri). Concurrent Bendamustine is administered on Days of Stereotactic Radiotherapy (Arm 1: 40 mg/m2/ Day; Arm 2: 50 mg/m2/day).
9922296|NCT00837941|Experimental|1|sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride
9922297|NCT00837941|Experimental|2|sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride
9922298|NCT00837941|Experimental|3|sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin
9842733|NCT02873338|Experimental|Dociparstat 0.125 mg/kg|"Induction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)~Reinduction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)~Consolidation:~Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)~Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)"
9842734|NCT02873338|Experimental|Dociparstat 0.25 mg/kg|"Induction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)~Reinduction:~Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)~Consolidation:~Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)~Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)"
10207003|NCT03321188|Experimental|HIPEC + adjuvant IV chemotherapy|"HIPEC~HIPEC will be administered intraoperatively one time only.~*HIPEC cisplatin will be administered at rate of 100 milligram per meter squared (mg/m2)~Administration of HIPEC will have a duration of 90 minutes.~Adjuvant IV chemotherapy~IV Paclitaxel~Dose: 80mg/m2 IV over 1 hour~Schedule: Days 1, 8 and 15~Cycle Length: 3 weeks (21 days)~IV Carboplatin~Dose: Area under the curve (AUC) 6 IV~Schedule: Day 1~Cycle Length: 3 weeks (21 days)"
10207004|NCT03320902|Active Comparator|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
10207005|NCT03320902|No Intervention|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
10207006|NCT03315026|Experimental|Siltuximab|Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).
9842735|NCT02873377|Experimental|Enhanced Care|"Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling & Smoking Quitline Referral. Participants in the Enhanced Care intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
9842736|NCT02873377|Active Comparator|Standard Care|"Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The Standard Care group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
9986303|NCT01401374||Vitiligo Patients|patients with vitiligo vulgaris
9986304|NCT01401374||Controls|Individuals without vitiligo vulgaris
9986305|NCT01401387|Active Comparator|Standard treatment|Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
10207007|NCT03314987|Active Comparator|intervention group|Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks
10207008|NCT03314987|Placebo Comparator|placebo group|Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks
10213461|NCT03939585|Experimental|NK/γδ T cell-enriched cell therapy product|"This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors.~27 days post transplant, the participant's donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs).~Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable.~Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant.~Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution."
10213462|NCT03936699|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
10213463|NCT03936699|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
10213464|NCT03932461|Active Comparator|Vacuum assisted closure|The VAC® Abdominal Dressing System (KCI Vacuum Assisted Closure, San Antonio, TX, USA) will be used. Intestines, including lateral aspects, are covered by the visceral protective layer. The first layer of foam is placed in the laparostoma on the visceral protective layer and must extend below the fascia at a distance of 5 cm from the facial opening. Above this, a minimum of one piece of foam is folded and placed in the laparostoma. Finally, the laparostoma will be covered by the occlusive drape. A circular opening of approximately 5 cm in diameter will be created in the drape where the connection tubes to the vacuum pump will be placed. Simultaneously while applying the negative pressure of 125 mmHg, the wound edges are approximated manually towards the midline. Each dressing change must be performed in the operation theatre with the patient in general anesthesia and muscle relaxation.
9842737|NCT02873429||Integrative Medicine (Complementary /Alternative)Group|Patients receiving chiropractic care, acupuncture, massage therapy, or meditation training for chronic pain
9842738|NCT02873429||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management, injections, etc.) for chronic pain.
9842739|NCT02873481|Experimental|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
9842740|NCT02873481|No Intervention|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
9996905|NCT01504230||Osteoporosis participants|
9842741|NCT02873585|Experimental|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
9842742|NCT02873689|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
9842743|NCT02873689|Experimental|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
9842744|NCT02873702|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
9922299|NCT00837941|Experimental|4|sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride
10207009|NCT03311308|Active Comparator|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years; after the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
10207010|NCT03311308|Experimental|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, twice a day, for nine weeks; after the first three doses, pembrolizumab dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
10207011|NCT03307564|Experimental|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments
10207012|NCT03292133|Experimental|EGF816 + Gefitinib|"All patients will receive gefitinib orally once daily~EGF816 will be administered orally once daily~Participant will be requested to maintain a medication diary of each dose of medication"
10207013|NCT03280797|Other|Control|
10207014|NCT03280797|Other|Rheumatoid arthritis patients|
10207015|NCT03278600|Experimental|site-specific therapy|standard treatments of sites of origin
10207016|NCT03278600|Active Comparator|standard empiric chemotherapy|standard empiric chemotherapy
10207017|NCT03276481||Multiple Myeloma|Participants with multiple myeloma undergoing autologous hematopoietic cell transplantation (HCT) after a high dose melphalan conditioning regimen
10207018|NCT03270111|Experimental|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
10207019|NCT03270111|Experimental|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
10207020|NCT03267589|Experimental|Cohort A|Intervention: MEDI9447 (CD73) + durvalumab
10207021|NCT03267589|Experimental|Cohort B|Intervention: MEDI0562 (OX40) + durvalumab
10207022|NCT03267589|Experimental|Cohort C|Intervention: MEDI0562 (OX40) + tremelimumab combination
10207023|NCT03261674|Experimental|CBTI|Patients in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBT-I)
10207024|NCT03261674|Experimental|ABTI|Arousal-Based Therapy for Insomnia (ABT-I)
10207025|NCT03255096|Experimental|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
10207026|NCT03255096|Experimental|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
10207027|NCT03240601|Sham Comparator|Subthreshold|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will briefly ramp up to the lowest intensity that is first detected by the participant and then ramped down to a level no longer detected by the participant. Participants will continue their locomotor training.
10207028|NCT03240601|Experimental|Active|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will ramp up slowly to a level that produces parasthesia (tingling) throughout the lower extremity. This intensity will be applied for 30 minutes while participants continue their locomotor training.
10207029|NCT03238794|Active Comparator|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
10207030|NCT03238794|Active Comparator|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
10207031|NCT03233139|Experimental|Cemiplimab|Part 1
10207032|NCT03233139|Experimental|Cohort A|Part 2
10207033|NCT03233139|Experimental|Cohort B|Part 2
10207034|NCT03233139|Experimental|Cohort C|Part 2
10207035|NCT03221751|Experimental|Prazosin|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
10207036|NCT03221751|Placebo Comparator|Placebo|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
10207037|NCT03191084|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
10207038|NCT03191084|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
10207039|NCT03189719|Experimental|Pembrolizumab + SOC|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) plus standard of care (SOC) chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
10207040|NCT03189719|Placebo Comparator|Placebo + SOC|Participants receive placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
9842745|NCT02873702|Experimental|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
9842746|NCT02873702|Experimental|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
9986306|NCT01401387|Active Comparator|Preventive treatment|Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
9842747|NCT02873702|Experimental|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
9842748|NCT02873754|Experimental|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
9986307|NCT01401400||(Peg) interferon|Patients who are treated for at least 12 weeks with (peg-)interferon for chronic hepatitis B
9986308|NCT01401413|Placebo Comparator|1|placebo control nightly
9842749|NCT02873923||Patients with a metastatic soft tissue sarcoma|All patients included in eligible clinical trials of the meta-analysis
9842750|NCT02873936|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
9842751|NCT02873936|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)
9842752|NCT02873936|Placebo Comparator|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
9842753|NCT02874066|Experimental|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
9986309|NCT01401413|Active Comparator|2|8 mg ramelteon nightly
9986310|NCT01401426|Active Comparator|Single incision laparoscopic vertical sleeve gastrectomy|Active Comparator Patients in this group will undergo laparoscopic vertical sleeve gastrectomy through a single periumbilical incision.
9986311|NCT01401426|Active Comparator|Five port laparoscopic vertical sleeve gastrectomy|Patients in this group will undergo conventional laparoscopic vertical sleeve gastrectomy using 5 small incisions.
9842754|NCT02874092|Active Comparator|Rheumatoid Arthritis|-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks
9842755|NCT02874092|Active Comparator|Osteoarthritis|-Diagnosis of osteoarthritis made by physician.
9842756|NCT02874404|Experimental|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9842757|NCT02874404|Experimental|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9922300|NCT00837941|Experimental|5|sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin
9986312|NCT01401491|Active Comparator|clozapine + fluvoxamine|
10207041|NCT03184233|Other|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
10207042|NCT03184233|Active Comparator|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.~No rapid ventricular pacing is applied perioperatively."
10207043|NCT03184155|Experimental|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
10207044|NCT03184155|Placebo Comparator|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
10207045|NCT03166371|Experimental|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
10207046|NCT03166371|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
10207047|NCT03164486|Experimental|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
10207048|NCT03163095|Active Comparator|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
10207049|NCT03163095|Sham Comparator|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
10207050|NCT03161912||DME/naïve|patients with pre-treatment in diabetic macular edema (DME)
10207051|NCT03161912||DME/pre-treatment|patients without pre-treatment in DME
10207052|NCT03161912||RVO/pre-treatment|Macular edema secondary to RVO with prior treatment
10207053|NCT03161912||RVO/naïve|Macular edema secondary to RVO without prior treatment
10207054|NCT03160118|Other|Seasonal,quadrivalent,influenza vaccine|1 vaccine will be administered to all participants, namely Alfa-Rix Tetra 2016-2017
10207055|NCT03155997|Experimental|150 mg Abemaciclib + Endocrine Therapy|Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
10207056|NCT03155997|Other|Endocrine Therapy|Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
10207057|NCT03154151|Experimental|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders and survivors process any traumatic experiences they lived through during their WTC recovery work and exposure.
10207058|NCT03154151|Active Comparator|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders and survivors work through any life problems they might currently be experiencing.
10207059|NCT03153670|Experimental|fMRI-based programming|DBS patients will undergo fMRI scanning while on different stimulation settings. The results will be fed to the programming clinician (movement disorder neurologist) to aid the conventional programming process at the clinician's discretion.
10207060|NCT03149809|Active Comparator|Behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
10207061|NCT03149809|Active Comparator|Drug Therapy|Daily solifenacin drug therapy
10207062|NCT03143504||Single arm.|All participants in the same arm.
10207063|NCT03138564|Experimental|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
9842758|NCT02874404|Experimental|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9842759|NCT02874534|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
9842760|NCT02874534|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
9842761|NCT02874794|Experimental|LCZ696 (sacubitril/valsartan)|minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
9842762|NCT02874794|Active Comparator|Enalapril|minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
9842763|NCT02874846|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
10207064|NCT03138564|Active Comparator|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
9842764|NCT02874846|Placebo Comparator|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
9842765|NCT02874924|Experimental|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
9842766|NCT02874924|Placebo Comparator|Placebo|Placebo taken once daily for 8 weeks
9842767|NCT02874924|Experimental|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
9842768|NCT02875028|Experimental|Vorapaxar|subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
9842769|NCT02875028|Placebo Comparator|Placebo|subjects will be treated with 4 empty lactose-starch capsules
9842770|NCT02875080|Experimental|OPC-34712 disintegrating tablet with water|OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
9842771|NCT02875080|Experimental|OPC-34712 disintegrating tablet without water|OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
9842772|NCT02875080|Experimental|OPC-34712 conventional tablet with water|OPC-34712 (4 mg) conventional tablet is administered with water.
9842773|NCT02875340|Experimental|VAL401 treatment|Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).
9842774|NCT02875366|Placebo Comparator|Placebo|Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
9842775|NCT02875366|Experimental|LUM/IVA|LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
9842776|NCT02875392|Experimental|Fucoidan use|FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
9842777|NCT02875392|Placebo Comparator|placebo pills|placebo capsule 6 per day (before breakfast and supper)
9842778|NCT02875613|Experimental|Avelumab|Avelumab 10mg/kg IV infusion on days 1 and 15 of 28-day cycle
9842779|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
9842780|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
9842781|NCT02875834|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
9842782|NCT02875977|Experimental|Experimental Counseling|Patients randomized to this arm receive experimental counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout and a 4-minute educational video.
9842783|NCT02875977|Active Comparator|Standard Counseling|Patients randomized to this arm receive standard counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout.
9842784|NCT02876055|Active Comparator|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
9922301|NCT00837941|Experimental|6|sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride
9922302|NCT00837954|Active Comparator|1|distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
9922303|NCT00837954|Active Comparator|2|distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
9922304|NCT00837954|Active Comparator|3|distal and proximal Anastomosis Lyostypt®
10207065|NCT03104400|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg orally once a day (QD) and matching placebo to adalimumab by subcutaneous injection every other week (EOW) for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
10207066|NCT03104400|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg orally once a day and matching placebo to adalimumab by subcutaneous injection every other week for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
10207067|NCT03104400|Active Comparator|Adalimumab|"Period 1: Participants receive adalimumab 40 mg by subcutaneous injection every other week and matching placebo to upadacitinib orally QD for 56 weeks.~Period 2: Participants continue to receive adalimumab 40 mg every other week."
9842785|NCT02876055|Active Comparator|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the post-anesthesia care unit (PACU) with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
9842786|NCT02876055|Experimental|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
9842787|NCT02876159|Experimental|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
9842788|NCT02876159|Experimental|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
9842789|NCT02876575|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
9842790|NCT02876601|Active Comparator|Defibrotide/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
9842791|NCT02876601|Placebo Comparator|Placebo/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
9842792|NCT02876601|Other|Defibrotide/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
9842793|NCT02876601|Other|Placebo/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
9842794|NCT02876757||5ARI Users|
9842795|NCT02876757||Non 5ARI users|
9842796|NCT02876887|Active Comparator|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
9842797|NCT02876887|Placebo Comparator|Placebo|Three servings per day of placebo beverages for six months.
9842798|NCT02876900|Experimental|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
9842799|NCT02876900|Experimental|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
9842800|NCT02876900|Placebo Comparator|Placebo transdermal patch|Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches
9842801|NCT02876926|Experimental|"Enhanced home-based testing"|"These participants will download a study-specific smartphone app (eTEST), and receive home-based HIV test kits in the mail every 3 months. These kits will have been fit with sensors that enable remote detection of when the kit was opened. Qualified HIV test counselors (QHTC) will then follow up with these participants within 24 hours of receiving notification that the test has been opened to conduct routine counseling, offer referrals for other services, and connect those with reactive results with follow-up care."
9842802|NCT02876926|Active Comparator|Home-based testing alone|These participants will receive a typical home-based test for HIV in the mail every 3 months, but no phone-based follow-up will be provided.
9842803|NCT02876926|Sham Comparator|Reminders for clinic-based testing|Participants in this condition will receive a letter in the mail every 3 months reminding them to be tested at a local clinic for free.
9842804|NCT02877004|Active Comparator|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
9842805|NCT02877004|Active Comparator|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
9842806|NCT02877004|Active Comparator|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
9842807|NCT02877082|Experimental|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
9842808|NCT02877095|Experimental|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
9922305|NCT00837954|Active Comparator|4|distal and proximal Anastomosis Surgicel®
9842809|NCT02877485|Active Comparator|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
9842810|NCT02877485|Active Comparator|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
9842811|NCT02877680|Experimental|Intervention|Smartphone app for parents to track adolescents' strength behaviors related to living with and managing type 1 diabetes, including regular feedback to parents and training about how to recognize and reinforce positive behaviors in teens.
9842812|NCT02877680|No Intervention|Usual Care|Usual diabetes care and study-related data collection, without use of app during the study period. They will be offered an opportunity to try the app and share their feedback with the study team after completing follow-up data collection.
9842813|NCT02877927|Experimental|Omadacycline|Omadacycline tablets
9842814|NCT02877927|Active Comparator|Linezolid|Linezolid tablets
10207068|NCT03104400|Placebo Comparator|Placebo / Upadacitinib 15 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 15 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
9842815|NCT02878057|Experimental|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
9842816|NCT02878213|Experimental|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
9842817|NCT02878330|Placebo Comparator|Placebo|Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
9842818|NCT02878330|Experimental|MEDI8897 50 mg|Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
9842819|NCT02878382|Other|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
9842820|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
9842821|NCT02878486|Experimental|Group 1|Subjects will have clinic visits, home visits, and telephone visits. Subjects will be asked to wear a wrist monitor (Jawbone Up) for duration of the study, will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
9842822|NCT02878486|Active Comparator|Group 2|Subjects will make clinic visits. At home visits, subjects will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
9842823|NCT02878590|Experimental|BONGO DEVICE|All participants that qualify will receive the intervention of the Bongo device
9842824|NCT02879318|Active Comparator|Gemcitabine plus Nab-Paclitaxel|Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Days 1, 8, 15 Q28 days.
9842825|NCT02879318|Experimental|Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab|"Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 8, 15 Q28 days.~plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity."
9842826|NCT02879383|Experimental|DMR Procedure|Subjects randomized to the DMR procedure are unblinded at 24 weeks and followed for an additional 24 weeks.
9842827|NCT02879383|Sham Comparator|Sham Procedure|Subjects are unblinded at 24 Weeks. Sham subjects to cross over to receive DMR treatment at 24 Weeks and followed up for additional 24 weeks.
9842828|NCT02879578|Experimental|Valbenazine (Children)|Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.
9842829|NCT02879578|Experimental|Valbenazine (Adolescents)|Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.
9842830|NCT02879578|Experimental|Valbenazine (Adults)|Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
9842831|NCT02879747|Active Comparator|Interventional|Unchanged dose Genotropin
9842832|NCT02879747|Active Comparator|Interventional 2|reduced dose 50% Genotropin
9842833|NCT02879812|Experimental|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
9842834|NCT02879812|Active Comparator|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
9842835|NCT02879994|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9842836|NCT02880137|Experimental|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
10207069|NCT03104400|Placebo Comparator|Placebo / Upadacitinib 30 mg|"Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 30 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
9842837|NCT02880176|Experimental|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.~Subjects will use Fitbit Zip to track step counts"
9842838|NCT02880176|No Intervention|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
9842839|NCT02880189|Other|Single|All subjects will be receiving the Orbera Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
9842840|NCT02880228|Experimental|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
9842841|NCT02880254|Active Comparator|Kurbo only|use of app plus standard of care
9842842|NCT02880254|Active Comparator|Kurbo plus PHC|use of app, personal health coach and standard of care
9842843|NCT02880475|Experimental|OXN prolonged release tablet 5/2.5mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
9842844|NCT02880475|Experimental|OXN prolonged release tablet 20/10mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
9842845|NCT02880514|Experimental|PROPEL Mini Sinus Implant|Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
9842846|NCT02880514|Active Comparator|Balloon Sinus Dilation Alone|In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement
9842847|NCT02880761|Experimental|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
9842848|NCT02880761|No Intervention|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
9842849|NCT02880852|Experimental|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
9842850|NCT02880865|Experimental|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
9842851|NCT02880865|Experimental|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
9842852|NCT02881008|Experimental|Arm A|Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period
9842853|NCT02881008|Experimental|Arm B|Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period
9842854|NCT02881008|Experimental|Arm C|Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period
9842855|NCT02881008|Active Comparator|Arm D|Entecavir 0.5 mg daily for 24 weeks
9842856|NCT02881008|Experimental|Arm E|Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period
9842857|NCT02881008|Experimental|Arm F|Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period
9842858|NCT02881047|Experimental|rAblative Fractional Laser for Sclerotic GVHD-Associated Joint|"Range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb"
9842859|NCT02881112|Experimental|Active Treatment Arm|Treatment with Provant Therapy System
9842860|NCT02881567|Experimental|Daclizumab|
9842861|NCT02881658|Experimental|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
9922306|NCT00837993||Survival Analysis|Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.
9986313|NCT01401491|Placebo Comparator|clozapine + placebo|
10207070|NCT03104374|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
10207071|NCT03104374|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
10207072|NCT03104374|Placebo Comparator|Placebo then Upadacitinib 15 mg|"Period 1: Participants receive placebo once daily for 24 weeks followed by upadacitinib 15 mg once daily for 32 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
10207073|NCT03104374|Placebo Comparator|Placebo then Upadacitinib 30 mg|"Period 1: Participants receive placebo once daily for 24 weeks followed by upadacitinib 30 mg once daily for 32 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
10214106|NCT01077817||Comparison Sample (Case-Cohort)|Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.
9986314|NCT01401504|Experimental|ASP3026|
9996906|NCT01504243||Control|normal person under medical examination
9996907|NCT01504243||sepsis|SIRS plus inflammation
10214107|NCT01077817||Non-treated Comparators|Participants who did not initiate treatment of osteoporosis with a study drug
10214108|NCT01077817||Alendronate|Participants initiating treatment for osteoporosis with alendronate
9842862|NCT02881658|Placebo Comparator|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
9842863|NCT02881775|Experimental|rTMS and exercise, then Sham rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
9842864|NCT02881775|Sham Comparator|Sham rTMS and exercise, then rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
9842865|NCT02881840|Experimental|14C-APD421|
9842866|NCT02881957|Placebo Comparator|Control|Placebo control (simple oral syrup)
9842867|NCT02881957|Experimental|Vitamin D3|Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)
9842868|NCT02881996|Experimental|IV tylenol|Post-operatively, all patients will be placed on a standard patient/nurse controlled analgesia (PCA) according to our pain service protocol which included ketorolac. A 3 hours after first dose of ketorolac, patients in the acetaminophen arm will then receive scheduled 10mg/kg of IV acetaminophen every 6hrs for a total of 3 days in between doses of ketorolac. PCA Pumps will be discontinued with the return of bowel function and transition to oral intake in all patients as per the current protocol. If a patient in the acetaminophen arm is transitioned off of PCA prior to 3 days, IV acetaminophen will be stopped at that time as well. Patients in the control group only may receive oral/rectal acetaminophen as needed for treatment of fevers.
9842869|NCT02881996|Active Comparator|No IV tylenol|Same as above without IV tylenol.
9842870|NCT02882152|Experimental|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
9842871|NCT02882152|Active Comparator|Morphine|intrathecal morphine
9842872|NCT02882633|Active Comparator|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
9842873|NCT02882633|Active Comparator|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
9842874|NCT02882711|Experimental|ketamine|
9842875|NCT02882854|Experimental|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
9842876|NCT02882854|Placebo Comparator|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
9842877|NCT02883244|Experimental|Soft-Picks Advanced|Device: Curved Soft-Picks
9842878|NCT02883244|Active Comparator|Floss|Device: Waxed tape floss
9842879|NCT02883452|Active Comparator|Cohort 1: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
9842880|NCT02883452|Experimental|Cohort 2: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
9842881|NCT02883452|Experimental|Cohort 3: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
9842882|NCT02883452|Experimental|Cohort 4: CT-P13 SC 240 mg|CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
9842883|NCT02883452|Experimental|Arm 1: CT-P13 SC 120/240 mg|CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
9842884|NCT02883452|Active Comparator|Arm 2: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)
9842885|NCT02884089|Placebo Comparator|Placebo + Metformin|Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
9842886|NCT02884089|Experimental|Abemaciclib + Metformin|Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
9842887|NCT02884089|Placebo Comparator|Placebo + Iohexol|Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
9842888|NCT02884089|Experimental|Abemaciclib + Iohexol|Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
9842889|NCT02884414|Experimental|Cutaneous Stimulation|Cutaneous stimulation and/or feedback. This stimulation and/or feedback may be visual, auditory, tactile (e.g. vibratory, temperature), or haptic and is completely external.
9842890|NCT02884427|Experimental|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
9842891|NCT02884427|Experimental|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
9842892|NCT02884427|Placebo Comparator|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
9842893|NCT02884492|Experimental|Cognitive impairment|Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
9842894|NCT02884492|Active Comparator|No cognitive impairment|Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
9842895|NCT02885012|Experimental|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
9842896|NCT02885012|Experimental|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
9842897|NCT02885025|Active Comparator|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
9922307|NCT00838019|Experimental|Cord blood|
10214109|NCT01077817||Etidronate|Participants initiating treatment for osteoporosis with etidronate
9842898|NCT02885025|Active Comparator|Broccoli Sprout Extract + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
9842899|NCT02885025|Active Comparator|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray"
9842900|NCT02885025|Placebo Comparator|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
9842901|NCT02885181|Experimental|GS-9876 - 30 mg|GS-9876 30 mg + filgotinib placebo for 12 weeks
9842902|NCT02885181|Experimental|GS-9876 - 10 mg|GS-9876 10 mg + filgotinib placebo for 12 weeks
9842903|NCT02885181|Experimental|Filgotinib|Filgotinib + GS-9876 placebo for 12 weeks
9842904|NCT02885181|Placebo Comparator|Placebo|GS-9876 placebo + filgotinib placebo for 12 weeks
9842905|NCT02885246||Influenza Virus Positive Group|The group included specimen samples with a laboratory confirmed diagnosis of influenza A and/or B, reported in the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) database of Panama, from January 2011 to December 2017.
9842906|NCT02885350|Active Comparator|Spinal fentanyl|20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
9842907|NCT02885350|Experimental|Epidural fentanyl|100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
9842908|NCT02885350|Active Comparator|Spinal sufentanil|5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
9842909|NCT02885350|Experimental|Epidural sufentanil|20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.
9922308|NCT00838032|Experimental|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
9922309|NCT00838032|Active Comparator|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
9922310|NCT00838045|Experimental|Akreos TL intraocular lens|Bausch & Lomb Akreos TL intraocular lens
9922311|NCT00838058|Experimental|Part1; controlled release formulation 4; 250 mg|one 250 mg controlled release tablet, once in the morning, in fasted state
9922312|NCT00838058|Experimental|Part1; controlled release formulation 4; 500 mg|2x250 mg, once in the morning, in fasted state
9922313|NCT00838058|Experimental|Part 1; controlled release formula 4; 1000 mg|4x250 mg tabs, once in the morning, in fasted state
9922314|NCT00838058|Experimental|Part 1; controlled release formulation 4; 500 mg FED|2x250 mg, once in the morning , in fed state
9922315|NCT00838058|Experimental|Part 2; IR formulation 500mg|4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
9922316|NCT00838058|Experimental|Part 2; IR formulation, 500 mg FED|4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
9922317|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FASTED|2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
9922318|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FED|2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
9922319|NCT00838071|Experimental|IGIV-HB Grifols|
9922320|NCT00838084|Experimental|LY2811376 Part 1|LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods.
9922321|NCT00838084|Placebo Comparator|Placebo Part 1|once a day or twice a day for 1 day in up to 3 periods.
9922322|NCT00838084|Experimental|LY2811376 - Part 2 low dose|Single dose of LY2811376, dose determined by part 1
9922323|NCT00838084|Experimental|LY2811376 - Part 2 high dose|Single dose of LY2811376, dose determined by part 1
9922324|NCT00838084|Placebo Comparator|Placebo Part 2|single dose
9922325|NCT00838149|Active Comparator|Glutamine|Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
9922326|NCT00838149|Placebo Comparator|Whey Protein|"Whey Protein:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
9922327|NCT00838175||1|All pts. who have undergone percutaneous intervention who received a suture-mediated closure of the venous access site will be screened for eligibility for this research trial.
9842910|NCT02885506|Experimental|Cohort 1|Oral administration of P218 capsules 10 mg
9842911|NCT02885506|Experimental|Cohort 2|Oral administration of P218 capsules 30 mg
9842912|NCT02885506|Experimental|Cohort 3|Oral administration of P218 capsules 100 mg
9842913|NCT02885506|Experimental|Cohort 4|Oral administration of P218 capsules 250 mg
9842914|NCT02885506|Experimental|Cohort 5|Oral administration of P218 capsules 500 mg
9842915|NCT02885506|Experimental|Cohort 6|Oral administration of P218 capsules 750 mg
9842916|NCT02885506|Experimental|Cohort 7|Oral administration of P218 capsules 1000 mg
9842917|NCT02885506|Placebo Comparator|Cohort 8 - Pooled Placebo|Oral administration of P218 matching placebo
9842918|NCT02885506|Experimental|Fed - Fasted|Oral administration of P218 capsules 250 mg Under fed then fasted conditions.
9842919|NCT02885506|Experimental|Fasted - Fed|Oral administration of P218 capsules 250 mg Under fasted then fed conditions.
9842920|NCT02885636|Experimental|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
9842921|NCT02885636|Placebo Comparator|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
9842922|NCT02886234|Experimental|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
9842923|NCT02886234|Active Comparator|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
9793091|NCT01464827|Experimental|Group H|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
9793092|NCT01464827|Experimental|Group I|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
9793093|NCT01464827|Experimental|Group J|Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
9842924|NCT02886338|Experimental|capsule endoscopy examination|Capsule endoscopic examination for the esophagus, stomach and duodenum.
9842925|NCT02886494|Active Comparator|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
9842926|NCT02886494|Placebo Comparator|Matched vehicle|Matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
9842927|NCT02886624|Experimental|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
9842928|NCT02886702|Experimental|Test|Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)
9842929|NCT02886702|Active Comparator|Reference|TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)
9842930|NCT02886702|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
9842931|NCT02886715|Experimental|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
9842932|NCT02886715|Active Comparator|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
9842933|NCT02886715|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
9842934|NCT02886728|Experimental|Filgotinib 200 mg + MTX|Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
9842935|NCT02886728|Experimental|Filgotinib 100 mg + MTX|Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg
9842936|NCT02886728|Experimental|Filgotinib 200 mg Monotherapy|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX
9842937|NCT02886728|Active Comparator|MTX Monotherapy|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
9842938|NCT02886923|Experimental|Test/Control Sequence|Subjects will wear the Hioxifilcon A Test contact lens and then the Hioxifilcon A with Cosmetic Ring Control contact lens for approximately three to four hours at each of the two measurement visits.
9842939|NCT02886923|Active Comparator|Control/Test Sequence|Subjects will wear the Hioxifilcon A with Cosmetic Ring Control contact lens and then the Hioxifilcon A Test contact lens for approximately three to four hours at each of the two measurement visits.
9842940|NCT02887183|Other|LCZ696(sacubitril/valsartan)|"Subjects received sacubitril/valsartan (LCZ696) on Day 1. The initial dose was determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available were: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).~Titration of the dosage were performed per USPI at 2 to 4 week intervals as clinically tolerated until maximal tolerated or target dosage was achieved. Target dosage was sacubitril/valsartan 97/103 mg twice daily."
9922328|NCT00838188||1|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
9922329|NCT00838188||2|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
9842941|NCT02887404|Experimental|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
9842942|NCT02887404|Active Comparator|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
9842943|NCT02887521|Experimental|Pulmonary Rehabilitation (PR)|Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
9842944|NCT02887521|Active Comparator|Standard of Care|Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
9842945|NCT02887989|Experimental|Virtual Reality|Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
9842946|NCT02887989|Sham Comparator|'Health and Wellness Channel'|Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
9842947|NCT02888080|Experimental|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
9842948|NCT02888080|Placebo Comparator|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
9842949|NCT02888093|Experimental|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
9842950|NCT02888093|Experimental|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
9842951|NCT02888106|Active Comparator|Arm A|PEG IFN alfa-2a 180 µg for 48 weeks
9842952|NCT02888106|Experimental|Arm B|Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
9842953|NCT02888106|Experimental|Arm C|Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
9842954|NCT02888106|Experimental|Arm D|Myrcludex B 2 mg for 48 weeks
9842955|NCT02888106|Experimental|Arm E|Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
9842956|NCT02888106|Experimental|Arm F|Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks
9842957|NCT02888171|Experimental|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
9842958|NCT02888171|Active Comparator|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
9842959|NCT02888665|Experimental|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
9842960|NCT02888691|Experimental|Low Carbohydrate Diet|< 100 grams of carbohydrate per day
9842961|NCT02888691|Experimental|High Carbohydrate Diet|> 250 grams of carbohydrate per day
9842962|NCT02888756|Experimental|iHIVARNA-01|Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
9842963|NCT02888756|Active Comparator|TriMix|Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
9842964|NCT02888756|Placebo Comparator|Placebo|Water for injection 3 vaccinations, two weeks interval
9842965|NCT02889289|Experimental|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
9842966|NCT02889393|Experimental|Standard of Care followed by Teduglutide|"Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure."
10214110|NCT01077817||Ibandronate|Participants initiating treatment for osteoporosis with ibandronate
9793094|NCT01464827|Experimental|Group K|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
9793095|NCT01464827|Experimental|Group L|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
9793096|NCT01464827|Experimental|Group M|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
9793097|NCT01464827|Experimental|Group N|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
9793098|NCT01464840||15 minutes|500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
9793099|NCT01464840||30 minutes|500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
9793100|NCT01464840||60 minutes|500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
9793101|NCT01464879|Experimental|Testosterone 2.50 mL (hand)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
9793102|NCT01464879|Experimental|Testosterone 1.25 mL (applicator)|Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.
9793103|NCT01464879|Experimental|Testosterone 2.50 mL (applicator)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
9793104|NCT01464879|Experimental|Testosterone 3.75 mL (applicator)|Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.
9793105|NCT01464931|Experimental|Denosumab|Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
9793106|NCT01464996|Experimental|Adhesive OptiBond XTR|Adhesive OptiBond XTR will include composite restorations placed using the dental adhesive OptiBond XTR.
9793107|NCT01464996|Active Comparator|Adhesive OptiBond FL|Adhesive OptiBond FL will include composite restorations placed using the dental adhesive OptiBond FL.
9793108|NCT01465022|Active Comparator|Study Arm A|Study Arm A is one of two interventions (Combined estrogen-progestin pill)
9793109|NCT01465022|Active Comparator|Study Arm B|Study Arm B is one of two interventions (Progestin-only pill)
9793110|NCT01465048|Experimental|Plasmodium falciparum sporozoites 2sites|2,500 sporozoites intradermally
9793111|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1 site|2,500 sporozoites intramuscularly
9793112|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1site|25,000 sporozoites intramuscularly
9793113|NCT01465178|Active Comparator|2000 IU vitamin D3|Cholecalciferol 2,000 IU capsules
9793114|NCT01465178|Placebo Comparator|Placebo|Non-matching placebo, gelatin filled capsules
9793115|NCT01465191|Experimental|50 micrograms (mcg) spinal morphine|Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section
9793116|NCT01465191|Experimental|100 micrograms spinal morphine|Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section
9793117|NCT01465191|Experimental|150 micrograms spinal morphine|Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section
9793118|NCT01465334|Experimental|Treatment Naive|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
9800465|NCT01688596|Active Comparator|Bupivacaine|"The Bupivacaine Arm includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc."
9842967|NCT02889393|Experimental|Teduglutide followed by Standard of Care|"Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure"
9842968|NCT02889510|Other|liraglutide|7-week subcutaneous liraglutide treatment once daily
9842969|NCT02889510|Other|placebo|7-week subcutaneous placebo treatment once daily.
9842970|NCT02889562|Active Comparator|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
9842971|NCT02889562|Active Comparator|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
9842972|NCT02889796|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
9842973|NCT02889796|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
9842974|NCT02889796|Active Comparator|Adalimumab|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
9842975|NCT02889796|Experimental|Placebo to Filgotinib 200 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
9842976|NCT02889796|Experimental|Placebo to Filgotinib 100 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
9842977|NCT02889796|Placebo Comparator|Placebo Never Received Filgotinib|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.
9842978|NCT02889861|Experimental|Regimen 1|IMCgp100 (77 kDa bi-specific protein) weekly dosing regimen (QW)
9842979|NCT02890303|Experimental|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture & Vitreous Loss (4% or less)
9842980|NCT02890381|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
9842981|NCT02890381|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
9842982|NCT02890992|Experimental|Cohort 1 - Alirocumab 30 mg Q2W: <50 kg|"Period 1: Participants with body weight less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT).~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
9842983|NCT02890992|Experimental|Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg|"Period 1: Participants with body weight greater than or equal to (>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
9842984|NCT02890992|Experimental|Cohort 2 - Alirocumab 40 mg Q2W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still < 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
9842985|NCT02890992|Experimental|Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130."
9922330|NCT00838188||Breast - feeding first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
9842986|NCT02890992|Experimental|Cohort 3 - Alirocumab 75 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
9842987|NCT02890992|Experimental|Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
9842988|NCT02890992|Experimental|Cohort 4 - Alirocumab 150 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48."
9842989|NCT02890992|Experimental|Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48."
9842990|NCT02891070|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
9842991|NCT02891070|Active Comparator|DuraSeal Dural Sealant|DuraSeal Dural Sealant, single use treatment, intraoperative
9842992|NCT02891174|Active Comparator|Ibuprofen followed by acetaminophen|Ibuprofen administered immediately post-partum, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours followed by acetaminophen, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours.
9842993|NCT02891174|Active Comparator|Acetaminophen followed by ibuprofen|Acetaminophen administered immediately post-partum, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours followed by ibuprofen, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours.
9922331|NCT00838188||Bottle first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
9922332|NCT00838188||Way of feeding|Each infant is evaluated twice, once after breastfeeding and once after bottle feeding of breast milk using a Premature Nipple & Ring (Ross Products Division, Columbus OH, USA). In this way, each infant serves as its own control. REE is recorded for 20 minutes after each meal
9922333|NCT00838214|Experimental|budesonide|3mg capsules 3x/day for 6 months
9922334|NCT00838214|Active Comparator|prednisone|5mg tablet, 40mg starting dose titrated to 10mg over 3 months
9922335|NCT00838227|Experimental|One arm|Study withdrawn due to lack of funds.
9922336|NCT00838240|Experimental|Arm I|Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
9922337|NCT00838240|Experimental|Arm II|Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
9842994|NCT02891200|Experimental|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
9842995|NCT02891200|Experimental|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
9842996|NCT02891408|Experimental|Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg|Participants with mild hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
9842997|NCT02891408|Experimental|Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
9842998|NCT02891408|Experimental|Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg|Participants with moderate hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
9842999|NCT02891408|Experimental|Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
9843000|NCT02891408|Experimental|Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg|Participants with severe hepatic impairment will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
9843001|NCT02891408|Experimental|Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
9843002|NCT02891408|Experimental|Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg|Participants with mild hepatic impairment will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
9843003|NCT02891408|Experimental|Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg|Matched normal hepatic function participants to mild hepatic impairment participants, will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
9843004|NCT02891629|Experimental|Device use in Healthy volunteers|10 healthy volunteers will be recruited
9843005|NCT02891629|Experimental|Device use in ALS patients|5 ALS patients in early stages will be recruited
9843006|NCT02891681|Experimental|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
9843007|NCT02891681|Experimental|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
9843008|NCT02891850|Experimental|Riociguat|PDE5i treatment will be stopped and riociguat treatment initiated following a defined washout period with a starting dose of 1 mg riociguat TID followed by an 8 weeks dose adjustment phase according to the approved riociguat dose adjustment scheme.
9843009|NCT02891850|Active Comparator|PDE-5i|Patients will continue to receive PDE5i treatment as well as other standard of care treatments at the discretion of the investigator up to Week 24. Patients in the experimental and active comparator treatment arms follow the same visit schedule.
9843010|NCT02891863|Experimental|Acute Testing|Single-arm study - all subjects who meet the I&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
9843011|NCT02891915|Active Comparator|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
9843012|NCT02891915|Active Comparator|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
9843013|NCT02892019|Active Comparator|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
9843014|NCT02892019|Active Comparator|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
9843015|NCT02892110|Experimental|Varenicline|2 mg daily
9843016|NCT02892110|Placebo Comparator|Placebo|2 mg daily
9843017|NCT02892344|Experimental|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
9843018|NCT02892344|Active Comparator|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
9843019|NCT02892409|Active Comparator|Clarithromycin + Amoxicillin + Bismuth + Lansoprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
9843020|NCT02892409|Experimental|Clarithromycin + Amoxicillin + Bismuth + TAK-438|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
9843021|NCT02892422|Experimental|Flexible-dose of Lu AF35700|
9843022|NCT02892448|Active Comparator|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
9922338|NCT00838253|Experimental|1|
9922339|NCT00838253|Experimental|2|
9922340|NCT00838253|Experimental|3|
9922341|NCT00838253|Placebo Comparator|4|
9922342|NCT00838266|Experimental|1|Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
9922343|NCT00838266|Placebo Comparator|2|Antiplaque mouthrinse containing non-active component
9922344|NCT00838292|Active Comparator|ART: food|ART + food supplementation + nutrition counseling
9793119|NCT01465334|Experimental|Relapsed/Refractory|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
9793120|NCT01465347|Experimental|TSC 0.25 mg/kg for 9 or 18 doses|This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.
9793121|NCT01465386|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9793122|NCT01465412|Experimental|Mild Hepatic Impaired (HI) Part 1|Participants with mild chronic liver disease enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
9793123|NCT01465412|Active Comparator|Healthy to Match Mild HI Part 1|Healthy volunteers with normal hepatic function matched to participants with mild chronic liver disease by race, age, BMI, and gender, enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
9793124|NCT01465412|Experimental|Moderate HI Part 2|Participants with moderate chronic liver disease enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
9793125|NCT01465412|Active Comparator|Healthy to Match Moderate HI Part 2|Healthy volunteers with normal hepatic function matched to participants with moderate chronic liver disease by race, age, BMI, and gender, enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
9793126|NCT01465464|Experimental|Orantinib|
9793127|NCT01465464|Placebo Comparator|Placebo|
9793128|NCT01465659|Experimental|Temozolomide 100 mg/m2 and Pazopanib 400 mg|Temozolomide 100 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
9793129|NCT01465659|Experimental|Temozolomide 75 mg/m2 and Pazopanib 400 mg|Temozolomide 75 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
9793130|NCT01465659|Experimental|Temozolomide 150 mg/m2 and Pazopanib 400 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
9793131|NCT01465763|Experimental|tofacitinib 10 mg BID|
9793132|NCT01465763|Placebo Comparator|Placebo|
9793133|NCT01465802|Experimental|Cohort I|Arm A: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline placebo orally BID for 4 weeks Arm B: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline 100 mg orally BID for 4 weeks
9793134|NCT01465802|Experimental|Cohort II|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
9793135|NCT01465802|Experimental|Cohort III|Cohort III is an interrupted dosing schedule of dacomitinib in the first cycle only
9793136|NCT01465841|Experimental|Embolization with the PC 400 coils|
9793137|NCT01465958|Active Comparator|Intravenous GAMUNEX-C|
9793138|NCT01465958|Experimental|Subcutaneous GAMUNEX-C|
9793139|NCT01465997|Experimental|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
9793140|NCT01465997|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)
9793141|NCT01466062|Experimental|Palivizumab|15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
9793142|NCT01466075|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the Apollo Evolution Investigational BG Monitoring System.
9793143|NCT01466127|Placebo Comparator|Placebo|Matched nasal spray placebo.
9793144|NCT01466127|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
9793145|NCT01466153|Active Comparator|Rituximab + Bendamustine|Rituximab was administered by IV infusion as 375 mg/m^2 on Day 2 of Cycle 1 and then 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
9793146|NCT01466153|Experimental|MEDI-551 2 mg/kg + Bendamustine|MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
9793147|NCT01466153|Experimental|MEDI-551 4 mg/kg + Bendamustine|MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
10207074|NCT03098654|Experimental|Enhanced Intervention|"Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:~Community mobilization activities to inform community members of available services~Support at the local health center to aid clinicians in managing uncontrolled cases of DM and HTN, including training for clinical staff, glucometers/test strips, and BP monitors.~HIV counseling and serial rapid HIV testing~Blood glucose and blood pressure testing~DM/HTN medications as needed~Personalized diet and lifestyle counseling for all participants with elevated glucose or BP that includes education, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose/BP."
10207075|NCT03098654|No Intervention|Control|Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
9843023|NCT02892448|Active Comparator|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
9843024|NCT02892448|Active Comparator|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
9843025|NCT02892513|Experimental|Active Stimulation|Participants will have active percutaneous auricular neurostimulation for 5 days during and after elective surgery.
9843026|NCT02892513|Sham Comparator|Sham Percutaneous Neurostimulation|Participants will have inactive device worn for 5 days during and after elective surgery.
9843027|NCT02892734|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
9843028|NCT02892760|Experimental|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
9843029|NCT02893878||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in approximately 10 volunteer practices.
9843030|NCT02893878||Vaccinated_Non GSK Group|Volunteered subjects who received Non-GSK influenza vaccination in approximately 10 volunteer practices.
9843031|NCT02893878||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or Non-GSK not known) in approximately 10 volunteer practices.
9843032|NCT02894502|Experimental|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
9843033|NCT02894502|Experimental|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
9843034|NCT02894502|No Intervention|Control group|This Group will receive the usual care
9843035|NCT02894840|Active Comparator|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
9843036|NCT02894840|Placebo Comparator|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
9843037|NCT02895035|Active Comparator|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
9843038|NCT02895035|Active Comparator|Omidria|Omidria is the intracameral additive during cataract surgery.
9843039|NCT02895100|Experimental|PTG-100 (150 mg QD)|Low dose
9843040|NCT02895100|Experimental|PTG-100 (300 mg QD)|Medium dose
9843041|NCT02895100|Experimental|PTG-100 (900 mg QD)|High dose
9843042|NCT02895100|Placebo Comparator|Placebo group|Placebo control
9843043|NCT02895295|Active Comparator|Control|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and will be provided with a list of resources available in the community to help them choose a prescription drug plan.
9843044|NCT02895295|Experimental|Expert Recommendation|"Participants randomized to the Expert Recommendation arm will receive access to a decision support tool that provides personalized expert scores for particular plans based on individual's likely annual out-of-pocket spending, including plan premiums and spending on prescription drugs, and the Medicare star ratings (a measure of customer satisfaction)."
9843045|NCT02895295|Active Comparator|Individual Analysis|"Participants randomized to Individual Analysis arm will receive access to a decision support tool that provides individualized cost information for each plan but not the expert scores for particular plans."
10207076|NCT03089515|Active Comparator|Healthy Controls|
10207077|NCT03089515|Experimental|Survivors|
10207078|NCT03086889|Experimental|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
10207079|NCT03086889|Other|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
10207080|NCT03072043|Experimental|Phase 1b Dose Escalation|Participants will receive intravenous infusions of APR-246 as a lead-in phase on days -14 to -11 starting at Dose Level 1 prior to starting cycle #1 of combination therapy with azacitidine. Combination therapy will consist of APR-246 on days 1-4 and azacitidine on days 4-10 (or days 4-5 and 8-12) of a 28 day cycle.
10207081|NCT03072043|Experimental|Phase 2 Treatment|Participants will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing schedule as in Phase 1b.
10207082|NCT03059823|Experimental|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks.
10207083|NCT03059823|Experimental|Dose Escalation- Q3W|INCMGA00012 treatment once every 3 weeks.
10207084|NCT03059823|Experimental|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks.
9793148|NCT01466166||Pegloticase|Participants received pegloticase 8 mg by intravenous (IV) infusion every 2 weeks for up to 1 year, as prescribed by their treating physician.
9793149|NCT01466179|Experimental|Blinatumomab|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
9793150|NCT01466192|Experimental|MP-424|
9793151|NCT01466270|Experimental|Arm I|Patients receive donepezil hydrochloride PO QD.
9793152|NCT01466270|Placebo Comparator|Arm II|Patients receive placebo PO QD.
9793153|NCT01466348|Experimental|Paracetamol and Caffeine|Paracetamol and caffeine
9793154|NCT01466348|Active Comparator|Paracetamol|Paracetamol
9793155|NCT01466361|Active Comparator|Lower dose Nicotine|lower dose nicotine lozenge
9793156|NCT01466361|Active Comparator|Higher dose Nicotine|higher dose Nicotine lozenge
9793157|NCT01466361|Placebo Comparator|Placebo|Placebo
9793158|NCT01466387|Active Comparator|TF+YF|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
9793159|NCT01466387|Active Comparator|TF + YF + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
9793160|NCT01466387|Active Comparator|JE + Rabies|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
9793161|NCT01466387|Active Comparator|JE + Rab + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
9793162|NCT01466387|Active Comparator|Rabies|Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
9793163|NCT01466387|Active Comparator|MenACWY-CRM197 (Combined)|Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
9793164|NCT01466491|Placebo Comparator|4-site injection|The superior technique of Phase 1 will be compared to a 4-site technique (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
9793165|NCT01466491|Active Comparator|2-site Injection|The superior technique of Phase 1 will be compared to a 2-site technique (2 mL injected at the tenaculum site, 18 mL equally distributed between 4 and 8 o'clock) in a randomized fashion (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
9793166|NCT01466491|Placebo Comparator|4-Site PCB followed by 3-minute wait|Women will be randomized to receive a 4-site PCB followed by a 3-minute wait (PCB 20/4/3) prior to dilation
9793167|NCT01466491|Active Comparator|4-site PCB followed by no wait|Women will be randomized to receive a 4-site PCB followed by no wait (PCB 20/4/0).
9793168|NCT01466595|Experimental|Arm A: Treatment with rifaximin|Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
9793169|NCT01466595|No Intervention|Arm B: No study treatment|No study treatment for 4 weeks
9793170|NCT01466660|Experimental|afatinib|afatinib once daily.
9793171|NCT01466660|Active Comparator|gefitinib|gefitinib once daily
9793172|NCT01466673|Experimental|Ethinyl estradiol/Norgestimate (EE/NGM)|
9793173|NCT01466673|Active Comparator|Ethinyl estradiol/Desogestrel (EE/DSG)|
9793174|NCT01466751|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
9793175|NCT01466751|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
9793176|NCT01466764|Active Comparator|Anakinra|Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
9793177|NCT01466764|Placebo Comparator|Saline injection|Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
9793178|NCT01466790|Experimental|Arm 1|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
9793179|NCT01466790|Experimental|Arm 2|15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
9793180|NCT01466790|Experimental|Arm 3|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
9793181|NCT01466790|Experimental|Arm 4|15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.
9793182|NCT01466881|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
9793183|NCT01466972|Experimental|Pazopanib in combination with a NSAI|Non-randomized, open label
9793184|NCT01466985|Experimental|Panel A: Doravirine 25 mg or Placebo|Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
9793185|NCT01466985|Experimental|Panel B: Doravirine 200 mg or Placebo|Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
9793186|NCT01466985|Experimental|Panel C: Doravirine or Placebo|Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
9793187|NCT01467037||Rotavirus-negative|Patients with a negative result for rotavirus via enzyme immunoassay (EIA). No intervention done.
9793188|NCT01467037||Rotavirus-positive|Patients with a positive result for rotavirus via enzyme immunoassay (EIA). Rotavirus-positives were confirmed via real-time reverse-transcriptase polymerase chain reactions (RT-PCR). RT-PCR results were used in the event of discordant EIA results. Rotavirus genotyping was performed. No intervention done.
9793189|NCT01467063|Active Comparator|Glutamine|
9843046|NCT02895347|No Intervention|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
9843047|NCT02895347|Experimental|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
9843048|NCT02895360|Experimental|Phase 1|Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
9843049|NCT02895360|Experimental|Phase 2a|BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma
9843050|NCT02895945|Experimental|BAX 802 in Surgery|Participants who are undergoing major or minor elective surgical, dental, or other invasive procedures.
9843051|NCT02896075|Experimental|Randomized cross-over approach|"The main study was conducted using a randomized controlled cross-over approach. Participants made three visits each for the two video watching interventions. The interventions were separated by a minimum of~1week as a washout. Each intervention included one day of inducing muscle soreness in one leg through eccentric muscle contractions; a second day of testing muscle soreness and pain tolerance and watching a 30-min video (either a comedy or documentary); and a third day of testing muscle soreness and pain tolerance again to see if the effects of the video viewing persisted the next day (i.e., 24 h after the video viewing)."
9843052|NCT02896127|Experimental|Secukinumab|"Secukinumab 150 mg s.c.~Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16"
9843053|NCT02896127|Placebo Comparator|Placebo|Placebo s.c.
9843054|NCT02896296|Experimental|RBP-6000 (100/300 mg Flex)|"On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time.~For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator."
9843055|NCT02896361|Experimental|Stimulation order 1|"Stimulations delivered in following order:~Standard burst~Burst Microdosing 1~Burst Microdosing 2"
9843056|NCT02896361|Experimental|Stimulation order 2|"Stimulations delivered in following order:~Burst Microdosing 1~Burst Microdosing 2~Standard burst"
9843057|NCT02896361|Experimental|Stimulation order 3|"Stimulations delivered in following order:~Burst Microdosing 2~Standard burst~Burst Microdosing 1"
10207085|NCT03059823|Experimental|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors.
9843058|NCT02896400|Experimental|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
9843059|NCT02896400|Experimental|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
9843060|NCT02896400|Experimental|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
9843061|NCT02896400|Experimental|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
9843062|NCT02896400|Experimental|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
9843063|NCT02896400|Experimental|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
9843064|NCT02896400|Experimental|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
9843065|NCT02896400|Experimental|BNI only|Brief Negotiated Interview (BNI)
9843066|NCT02896400|Experimental|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
9843067|NCT02896400|Experimental|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
9843068|NCT02896400|Experimental|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
10207086|NCT03043794|Experimental|SBRT to the breast then surgery|Stereotactic Body Radiation of 21 gy followed by standard of care surgery
10207087|NCT03042104|Experimental|TAVR|Transcatheter aortic valve replacement (TAVR)
10207088|NCT03042104|No Intervention|CS|Clinical surveillance (CS)
10207089|NCT03016013|Placebo Comparator|Placebo plus MTX|Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
10207090|NCT03016013|Experimental|Experimental: RC18 160 mg+MTX|Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
10207091|NCT03015324|Experimental|Hydroxychloroquine|Hydroxychloroquine
10207092|NCT03011307|Experimental|Oxytocin|Oxytocin 100 micrograms administered intrathecally
10207093|NCT03011307|Placebo Comparator|Placebos|Placebo injection administered intrathecally
10207094|NCT02985138|Experimental|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
10207095|NCT02985138|Active Comparator|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
10207096|NCT02981407|Active Comparator|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
10214111|NCT01077817||Risedronate|Participants initiating treatment for osteoporosis with risedronate
10214112|NCT01077817||Raloxifene|Participants initiating treatment for osteoporosis with raloxifene
9793190|NCT01467063|Placebo Comparator|Placebo|
9793191|NCT01467076|Active Comparator|Inhaled PGE1 (150 ng/kg/min)|150 ng/kg/min Inhaled PGE1
9793192|NCT01467076|Placebo Comparator|Aerosolized Normal Saline|Eligible infants will be randomly assigned to either IPGE1 [150ng/kg/min], IPGE1 [300ng/kg/min] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
9793193|NCT01467076|Active Comparator|Inhaled PGE1 (300 ng/kg/min)|300 ng/kg/min of Inhaled PGE1
9793194|NCT01467427|Experimental|NNC-0156-000-0009|
9793195|NCT01467466|Active Comparator|Saline & oral placebo|IV isotonic saline and oral placebo drug capsule
9793196|NCT01467466|Active Comparator|Saline & oral N-acetylcysteine|IV isotonic saline and oral N-acetylcysteine drug capsule
9793197|NCT01467466|Active Comparator|Bicarbonate & oral placebo|IV isotonic bicarbonate and oral placebo drug capsule
9793198|NCT01467466|Active Comparator|Bicarbonate & oral N-acetylcysteine|IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
9793199|NCT01467479|Experimental|T/PR + HAART Regimen (ATV/r-Based)|Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
9793200|NCT01467479|Experimental|T/PR + HAART Regimen (EFV-Based)|Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
9793201|NCT01467479|Experimental|T/PR + HAART Regimen (RAL-Based)|Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
9793202|NCT01467492|Experimental|Black|Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing <75 kilograms [kg]) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
9793203|NCT01467492|Experimental|Non-Black|Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing <75 kg) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
9793204|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Tacrolimus)|Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
9793205|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Cyclosporine)|Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
9793206|NCT01467557||1-Day ACUVUE TruEye contact lens users|1-Day ACUVUE TruEye contact lens users
9793207|NCT01467557||1-Day ACUVUE MOIST contact lens users|1-Day ACUVUE MOIST contact lens users
9793208|NCT01467570|Experimental|Hipp ORS Apple 200|oral rehydration solution Hipp ORS 200 Apple
9793209|NCT01467570|Active Comparator|ESPGHAN ORS|ESPGHAN oral rehydration solution
9799796|NCT01669538|Experimental|Galantamine|"Galantamine hydrobromide-ER (extended release) is currently marketed for the treatment of Alzheimer's disease. The dosing regimen follows the FDA-approved guidelines. For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.~Galantamine will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
9843069|NCT02896400|Experimental|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
9843070|NCT02896400|Experimental|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
9843071|NCT02896400|Experimental|QL only|Referral to CT Smokers Quitline (QL)
9843072|NCT02896400|Experimental|Text only|Registration in SmokefreeText (Text)
9843073|NCT02896400|No Intervention|Control|Control arm, no intervention
9922345|NCT00838292|Active Comparator|ART: no food|ART + nutrition counseling
9793210|NCT01467583|Experimental|Renal failure on intermittent dialysis|These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
9793211|NCT01467583|Experimental|Renal failure-renal replacement therapy|These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
9793212|NCT01467583|Experimental|Renal failure, not on dialysis|These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
9793213|NCT01467661|Experimental|SPD422 (anagrelide hydrochloride)|
9793214|NCT01467700|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual (SL) [dissolved under the tongue], once daily (QD), every night at bedtime for up to 8 weeks.
9793215|NCT01467700|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
9793216|NCT01467700|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
9793217|NCT01467700|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
9793218|NCT01467713|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.
9793219|NCT01467713|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
9793220|NCT01467713|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
9793221|NCT01467713|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
9793222|NCT01467882|Experimental|Triptorelin|Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
9793223|NCT01467934||Trivalent inactivated influenza vaccine|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1
9793224|NCT01467934||TIV and PCV13 together|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
9793225|NCT01467934||13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
9793226|NCT01467947|Experimental|Berinert|
9793227|NCT01467960||Group I|Healthy Subjects aged 20-40
9793228|NCT01467960||Group II|Healthy Subjects aged 40-65
9793229|NCT01467960||Group III|Healthy Subjects aged more than 65
9793230|NCT01467960||Group A|Patients at Stage I, H&Y classification
9793231|NCT01467960||Group B|Patients at Stage II, H&Y classification
9793232|NCT01467960||Group C|Patients at Stage more than III, H&Y classification
9793233|NCT01467999|Experimental|Guanfacine|Guanfacine, 4mg given once daily
9793234|NCT01468012|Experimental|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
9793235|NCT01468012|Placebo Comparator|Placebo|placebo
9793236|NCT01468077|Experimental|Tocilizumab, Normal Administration|Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
9793237|NCT01468077|Experimental|Tocilizumab, Fast Administration|Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
9793238|NCT01468181|Experimental|LY2189265 + Sulfonylureas (SU)|"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study."
9793239|NCT01468181|Experimental|LY2189265 + Biguanides (BG)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study."
9793240|NCT01468181|Experimental|LY2189265 + alpha-glucosidase inhibitor (a-GI)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study."
9793241|NCT01468181|Experimental|LY2189265 + Thiazolidinedione (TZD)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study."
9793242|NCT01468181|Experimental|LY2189265 + Glinides|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study."
9793243|NCT01468207|Placebo Comparator|Placebo|Placebo for 12 weeks.
9793244|NCT01468207|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
9793245|NCT01468207|Experimental|Placebo/Adalimumab Every Week (EW)|Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
9793246|NCT01468207|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
9793247|NCT01468207|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
9793248|NCT01468207|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
9793249|NCT01468233|Placebo Comparator|Placebo|Placebo for 12 weeks.
9793250|NCT01468233|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
9793251|NCT01468233|Placebo Comparator|Placebo/Placebo|Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
9843074|NCT02896569|Experimental|Topical combination therapy|Application of human bone marrow stem cell derived growth factor and cytokines serum followed by a botanical lipid-based occlusive immediately post-radio-frequency treatment of the face
9843075|NCT02896569|No Intervention|Standard of care|No topical therapies for 24 hours post-radio-frequency treatment of the face
9843076|NCT02896595|Active Comparator|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
9843077|NCT02896595|Active Comparator|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
9843078|NCT02896907|Experimental|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9843079|NCT02897115|Experimental|Treat-to-Target (T2T)|Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
9843080|NCT02897115|Active Comparator|Standard of Care (SOC)|Participants received treatment as prescribed by their physician according to the local standard of care.
9843081|NCT02897141|Experimental|mVIP group|This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
9843082|NCT02897141|Placebo Comparator|Attention Control Group|This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.
9843083|NCT02897349|Experimental|linagliptin|
9843084|NCT02897349|Placebo Comparator|Placebo|
9843085|NCT02898077|Experimental|8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel|"8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
9843086|NCT02898077|Experimental|Placebo + 80 mg/m² Paclitaxel|"Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
9843087|NCT02898103|Experimental|Active Current then Sham then Active Current|Electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes; then sham/placebo for 5 minutes; and then active electrical current for the following 2-4 weeks
9843088|NCT02898103|Active Comparator|Sham then Active Current|Sham/placebo will be introduced to the insulated percutaneous lead(s) for 5 minutes; then active electrical current for the following 2-4 weeks
9843089|NCT02898116|Experimental|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for one to two 28-day cycles, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
9843090|NCT02898454|Experimental|Dupilumab 300 mg q2w|Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
9843091|NCT02898454|Experimental|Dupilumab 300 mg q2w then q4w|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.
9843092|NCT02898454|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
9843093|NCT02898597|Experimental|Video|Video-call delivered cognitive behavioral therapy
9843094|NCT02898597|Active Comparator|Voice|Voice-call delivered cognitive behavioral therapy
9843095|NCT02898662|Experimental|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
9843096|NCT02898662|Placebo Comparator|Placebo|Matching placebo
9843097|NCT02898740|Experimental|Exercise|Structured exercise
9843098|NCT02898740|Active Comparator|Health Education|Health education
9843099|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
9843100|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
9843101|NCT02899156|Active Comparator|Flumazenil Infusion|The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
9843102|NCT02899156|Placebo Comparator|Placebo Infusion|The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
9922346|NCT00838292|Active Comparator|pre-ART: food|no ART (cotrimoxazole provided) + food supplementation + nutrition counseling
9922347|NCT00838292|Active Comparator|pre-ART: no food|no ART (cotrimoxazole provided) + nutrition counseling
9922348|NCT00838305|Placebo Comparator|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
9922349|NCT00838305|Experimental|mdma|drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
9998274|NCT01516593|Experimental|intensive short term immuno-chemotherapy|Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.
9793252|NCT01468233|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
9793253|NCT01468233|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
9793254|NCT01468233|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
9793255|NCT01468311|Experimental|Yttrium-90-labeled Daclizumab + Chemotherapy|Yttrium-90-labeled Daclizumab + BCNU, etoposide, cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)
9793256|NCT01468337|Experimental|Interferon gamma-1b|"Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. A single dropperette contains 1 mL of topical interferon gamma-1b (Actimmune®) at a concentration of 200 µg/mL, which is equivalent to 28 drops. Each drop provides a dose of 7 µg of investigational product.~All participants will receive interferon gamma-1b for two weeks. Doses of interferon gamma-1b eye drops will be escalated among participants during this initial 2-week period; however, additional doses will be dispensed to participants if needed at Week 4 or after the initial 8-week study period. Participants eligible for additional doses after 8 weeks will be administered the maximum dose of 4 drops 4 times daily for a total daily dose of 112 μg."
9793257|NCT01468350|Placebo Comparator|(PART A) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive a single witnessed dose of (A) dalfampridine-ER 10 mg, and a single witnessed dose of (B) placebo, two days apart
9793258|NCT01468350|Placebo Comparator|(PART A) BA: placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive a single witnessed dose of (B) placebo, and a single witnessed dose of (A) dalfampridine-ER 10 mg, two days apart
9793259|NCT01468350|Placebo Comparator|(PART B) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive multiple doses of (A) dalfampridine-ER 10mg and multiple doses of (B) placebo
9793260|NCT01468350|Placebo Comparator|(PART B) BA: Placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive multiple doses of (B) placebo, and multiple doses of (A) dalfampridine-ER 10mg
9793261|NCT01468454|Experimental|(18F-DOPA) PET/CT imaging|Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion
9793262|NCT01468532|Experimental|Treatment (chemotherapy, receptor agonist)|Patients receive pasireotide IM, 40 mg on day 1, docetaxel 75mg/m2 IV over 1 hour, and prednisone 5mg PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9793263|NCT01468558|Other|All subjects|Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
9793264|NCT01468584|Experimental|MP-424|
9793265|NCT01468597||One group|Emergency surgery
9793266|NCT01468675|Experimental|Intervention|The intervention is completion of a validated, web-based risk assessment used to assess personalized risk and generate a risk report
9793267|NCT01468675|No Intervention|Control|Usual Care
9793268|NCT01468818|Experimental|Immunotherapy for Metastatic Melanoma|Patients will receive non-myeloablative lymphodepleting preparative regimen cons
9793269|NCT01468844|Experimental|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
9793270|NCT01468844|Placebo Comparator|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
9793271|NCT01468909|Placebo Comparator|Arm I (paclitaxel and placebo)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9793272|NCT01468909|Experimental|Arm II (paclitaxel and pazopanib hydrochloride)|Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9793273|NCT01468974|Other|ESPRIT BVS|Subjects receiving the ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries.
9793274|NCT01468987|Active Comparator|Insulin Glargine + Insulin Lispro|"Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks."
9793275|NCT01468987|Experimental|LY2605541 + Insulin Lispro|"Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks."
9793276|NCT01469000|Experimental|250 mg Gefitinib/500 mg Pemetrexed|250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.
9793277|NCT01469000|Active Comparator|250 mg Gefitinib|250 milligrams (mg) Gefitinib taken orally QD
9793278|NCT01469013|Placebo Comparator|Placebo|"2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
9793279|NCT01469013|Experimental|1-mg Baricitinib (LY3009104)|"1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
9793280|NCT01469013|Experimental|2-mg Baricitinib (LY3009104)|"2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
9793281|NCT01469013|Experimental|4-mg Baricitinib (LY3009104)|1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
9793282|NCT01469013|Experimental|8-mg Baricitinib (LY3009104)|2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
9793283|NCT01469039|Experimental|ALKS 9072|
9793284|NCT01469039|Placebo Comparator|Placebo|
9793285|NCT01469052|Experimental|Cohort 1|
9793286|NCT01469052|Experimental|Cohort 2|
9793287|NCT01469052|Experimental|Cohort 3|
9793288|NCT01469052|Experimental|Cohort 4|
9793289|NCT01469052|Experimental|Cohort 5|
9793290|NCT01469052|Experimental|Cohort 6|
9793291|NCT01469065|Experimental|PF-04991532|PF-04991532 experimental study medication
9793292|NCT01469065|Placebo Comparator|Placebo|PF-04991532 Matching Placebo
9793293|NCT01469182|Experimental|SCH 39641 12 Amb a 1-U|12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
9793294|NCT01469182|Placebo Comparator|Placebo|Matching placebo tablet, sublingual, once daily.
9793295|NCT01469221|Experimental|Apaziquone|Apaziquone (4 mg in 40 mL)
9793296|NCT01469221|Placebo Comparator|Placebo|Matching placebo (40 mL)
9793297|NCT01469234|Experimental|loratadine|Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
9793298|NCT01469234|Experimental|fexofenadine|Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
9793299|NCT01469234|Placebo Comparator|placebo|Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
9793300|NCT01469364|Experimental|Aztreonam Lysine for Inhalation (AZLI)|Patients to received Aztreonam Lysine(AZLI)
9793301|NCT01469377|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
9793302|NCT01469377|Experimental|Cariprazine 1-2 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
9793303|NCT01469377|Experimental|Cariprazine 2-4.5 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
9793304|NCT01469546|Experimental|Axitinib (AG-013736)|A prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma who have received no more than two prior lines of systemic therapy for recurrent or metastatic head and neck cancer.
9793305|NCT01469585|Active Comparator|Sub-antimicrobial doxycycline|Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.
9793306|NCT01469585|No Intervention|Continuous Oral Contraceptive Pill|Women will take only the continuous oral contraceptive.
9793307|NCT01469637|Experimental|Sulfamethoxazole + MMX placebo|
9793308|NCT01469637|Experimental|Sulfamethoxazole + MMX Mesalazine/mesalamine|
9793309|NCT01469715|Experimental|GBP-CGM|All participants will wear one active GBP-CGM and one inactive GBP-CGM
9986315|NCT01401556|Experimental|Case Manager Intervention|Osteoporosis case-managers will identify older fracture patients in Emergency Departments and Fracture Clinics; arrange bone mineral density (BMD) tests; meet with patients to counsel them and go over their results; and then offer and prescribe bisphosphonate treatment to those with low BMD.
9986316|NCT01401556|Active Comparator|Multifaceted quality improvement intervention|Active-comparator control consisting of telephone-based education for patients and treatment guidelines with reminders for family physicians
9793310|NCT01469767|Experimental|Fluocinonide cream|Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.
9793311|NCT01469819|Experimental|Lubiprostone|Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.
9793312|NCT01470001|Active Comparator|solifenacin|patients in this arm will receive drug
9793313|NCT01470001|Placebo Comparator|placebo|patients is this arm will receive placebo
9793314|NCT01470027|Active Comparator|N-acetylcysteine 1800mg|N-acetylcysteine 1800mg/day for 30 days
9793315|NCT01470027|Active Comparator|N-acetylcysteine 3600mg|N-acetylcysteine 3600mg daily for 30 days
9793316|NCT01470027|Placebo Comparator|Placebo|Placebo effervescent tablets daily for 30 days
9793317|NCT01470118|Active Comparator|LASTACAFT® (alcaftadine 0.25%)|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
9793318|NCT01470118|Active Comparator|Pataday™ (olopatadine 0.2%)|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
9793319|NCT01470118|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of placebo instilled in each eye at Day 0 and Day 14.
9793320|NCT01470144|Experimental|Treatment|Single arm, open-label
9793321|NCT01470170|Experimental|Group1|Alfentanil 2.5μg/kg before propofol
9793322|NCT01470170|Experimental|Group2|Alfentanil 5μg/kg before propofol
9793323|NCT01470170|Experimental|Group 3|Alfentanil 2.5μg/kg two minutes before propofol
9793324|NCT01470170|Experimental|Group 4|Alfentanil 5μg/kg two minutes before propofol
9793325|NCT01470170|Placebo Comparator|Group 5 Control|propofol alone
9793326|NCT01470196|Experimental|Treatment Arm|Carfilzomib, dexamethasone, rituximab
9793327|NCT01470248|Experimental|Arsenic Trioxide Treatment|This is a single arm study. All patients will be treated with the investigational agent, Arsenic Trioxide, according to the dose and schedule indicated in the protocol.
9793328|NCT01470417|Active Comparator|Chemotherapy|Individuals with low risk disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
9793329|NCT01470417|Active Comparator|Chemotherapy and ChemoRadiotherapy|Individuals with high-risk disease or borderline resectable disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
9793330|NCT01470469|Active Comparator|SPD503|
9793331|NCT01470469|Placebo Comparator|Placebo|
9793332|NCT01470599|Experimental|5mg BID|
9793333|NCT01470599|Experimental|10mg BID|
9793334|NCT01470612|Experimental|CP-690,550 5 mg BID|5 mg BID
9793335|NCT01470612|Experimental|CP-690,550 10 mg BID|10 mg BID
9793336|NCT01470651|Experimental|Armodafinil|Active medication
9793337|NCT01470651|Placebo Comparator|Sugar pill|Inactive pill, matched to look like active medication
9793338|NCT01470781|Experimental|Cognitive Remediation|This arm will receive computer-based cognitive remediation treatment 3 times per week for 24 weeks, for a total of 70 hours of treatment
9793339|NCT01470781|Placebo Comparator|Computer Control|Group will receive 70 hours of computer time playing pre-selected computer games administered in a similar format as the Cognitive Remediation condition
9793340|NCT01470859|Active Comparator|pramipexole|0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
9793341|NCT01470859|Active Comparator|Levodopa|Sinemet CR CR， Controlled Release
9793342|NCT01470989|Experimental|canakinumab|canakinumab 150 mg s.c.
9793343|NCT01471015|Active Comparator|High dose Darbepoetin alfa|10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
9793344|NCT01471015|Active Comparator|Low dose Darbepoetin alfa|2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
9793345|NCT01471015|Placebo Comparator|Placebo|Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
9793346|NCT01471028|Experimental|ELAD Treatment|This group will receive treatment with ELAD plus standard of care treatment.
9793347|NCT01471028|Other|Standard of care (Control)|This group will receive standard of care treatment as defined in the protocol.
9843103|NCT02899195|Experimental|Durvalumab|Pemetrexed/cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab every 3 weeks. The first 6 patients who are enrolled and commence treatment will be monitored for safety of the combination. Use of carboplatin in place of cisplatin will be permitted for patients who are ineligible for cisplatin due to impaired renal function at screening. For patients that receive cisplatin, carboplatin may also be substituted after Cycle 1 for cisplatin related toxicity (e.g., grade 3 ototoxicity, grade 3 nausea) at the investigator's discretion. After completion of Cycle 6 of concurrent therapy, patients with stable or responding disease per modified RECIST for malignant mesothelioma will continue on single agent durvalumab every 3 weeks until progression. Maximum duration of durvalumab treatment is 12 months starting from Cycle 1 of concurrent treatment (inclusive of any treatment delays or missed treatments).
9843104|NCT02899338|Experimental|BI695501 Autoinjector|
9843105|NCT02899338|Active Comparator|BI695501 Prefilled syringe|
9843106|NCT02899377|Experimental|Group A: Health subjects|During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)
9843107|NCT02899377|Experimental|Group B: pSS subjects|During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of <=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)
9843108|NCT02899650|Experimental|Young Fit|Young (18-39 yrs) people who have endurance training habit
9843109|NCT02899650|Experimental|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
9843110|NCT02899650|Experimental|Older Fit|Older (50-80 yrs) people who have endurance training habit
9843111|NCT02899650|Experimental|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
9843112|NCT02899689|Active Comparator|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
9843113|NCT02899689|Experimental|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
9843114|NCT02899884||Cohort 1|Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.
9843115|NCT02899962|Active Comparator|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
9843116|NCT02899962|Placebo Comparator|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
9843117|NCT02899988|Experimental|30 mg Mirikizumab|30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
9843118|NCT02899988|Experimental|100 mg Mirikizumab|100 mg Mirikizumab administered SC Q8W.
9843119|NCT02899988|Experimental|300 mg Mirikizumab|300 mg Mirikizumab administered SC Q8W.
9843120|NCT02899988|Placebo Comparator|Placebo|Placebo administered SC Q8W.
9843121|NCT02900092|Experimental|Ganaxolone|Participants received ganaxolone
9843122|NCT02900378|Experimental|LCZ696 (Sacubitril/Valsartan)|After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
9922350|NCT00838318||Arm 1 Hispanic CRC Patients|
9922351|NCT00838318||Arm 2 FDRs of Hispancic CRC Patients|First-Degree Relatives (FDRs) of Hispanic CRC Patients
9922352|NCT00838318||Arm 3 Key Informants|Key informants from Houston Hispanic Health Coalition.
9843123|NCT02900378|Active Comparator|Enalapril|After randomization, patients in this arm received Enalapril twice daily and matching placebo of LCZ696 (Sacubitril/Valsartan) depending on the patient's previous ACEI/ARB for 2 weeks. Patients could start study medication at dose level 1 or 2a or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 10 mg bid enalapril and matching placebo, provided no safety and tolerability issues arised during uptitration
9843124|NCT02901054|Experimental|open label infusion ondansetron|"A single 4-mL CSF sample per subject.~Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
9843125|NCT02901080|Experimental|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
9843126|NCT02901249|Experimental|Sertraline|"Group Started: sertraline (50mg-200mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.~Second step: Sertraline 200mg + lithium (900mg-1500mg)~Non responsive patients: 3rd step.~Third step: Nortriptyline 100mg~Non responsive patients: 4th step.~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)~Non responsive patients : 5th step~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
9843127|NCT02901275|Placebo Comparator|Placebo + Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
9843128|NCT02901275|Active Comparator|Hydromorphone (oral) 4mg + Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
9843129|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 2.5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 2.5mg. Order of dose randomized session days 2-5.
9843130|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 5.0mg. Order of dose randomized session days 2-5.
9843131|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 10mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 10mg. Order of dose randomized session days 2-5 but was never the first hydromorphone 4mg + dronabinol combination dose.
9843132|NCT02901431|Placebo Comparator|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
9843133|NCT02901431|Experimental|Balovaptan (RO5285119) 10 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
9843134|NCT02901431|Experimental|Balovaptan (RO5285119) 4 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.
9843135|NCT02901899|Experimental|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9843136|NCT02901951|Experimental|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
9843137|NCT02902081|Placebo Comparator|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
9843138|NCT02902081|Experimental|Cannabidiol|(300 mg, 600 mg, 900 mg) cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
9843139|NCT02902146|Active Comparator|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
9843140|NCT02902146|Active Comparator|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
9843141|NCT02902172|Other|Acetaminophen|Patients will be monitored for change in blood pressure
9843142|NCT02902172|Other|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
9922353|NCT00838344|No Intervention|Usual care|Usual prescription refill system and pharmacy care.
9998275|NCT01516606|Experimental|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
9843143|NCT02902237|Experimental|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
9843144|NCT02902770|Active Comparator|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
9843145|NCT02902770|Active Comparator|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
9843146|NCT02902770|Active Comparator|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
9922354|NCT00838344|Experimental|Intervention|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
9922355|NCT00838357|Experimental|Plerixafor|Plerixafor added to a G-CSF Mobilisation regimen
9922356|NCT00838370|Experimental|DPYD*2A|Patients are screened for a DPD-deficiency. Patients with a DPYD*2A mutation are eligible for intervention with capecitabine/5-FU .
9922357|NCT00838396|Experimental|XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of XP19986 10, 20, 40 or 60 mg.
9922358|NCT00838396|Placebo Comparator|Placebo for XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of placebo.
9922359|NCT00838409||1|
9922360|NCT00838422||FD-OCT, ORA, USP|
9922361|NCT00838448|Experimental|Cannabis users|Cannabis users
9922362|NCT00838448|Experimental|Cannabis no-users|Cannabis no-users
9935058|NCT04236414|Experimental|Signal identification|A secondary analysis of response in patients recruited into the signal identification phase will be conducted. Patients included in this analysis must have documented evidence of a deleterious or suspected deleterious germline or tumour HRR gene mutation. A minimum of 10 patients across age and dose cohorts with deleterious or suspected deleterious HRR mutations will be enrolled.
9935059|NCT04235777|Experimental|Arm 1|Treatment with M7824 and de-escalating doses of M9241 if appropriate
9935060|NCT04235777|Experimental|Arm 2|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with sequential SBRT
9935061|NCT04235777|Experimental|Arm 3|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with concurrent SBRT
9935062|NCT04235764||1/ Cohort 1|Bladder Cancer Patients
9935063|NCT04234360|Experimental|Eosinophil count > 2%; corticotherapy|Eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
9935064|NCT04234360|Experimental|Eosinophil count <= 2%; corticotherapy|Non-eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
9935065|NCT04234360|Placebo Comparator|Eosinophil count > 2%; placebo|Eosinophilic patients randomized to this arm will receive 5 days of placebo.
9935066|NCT04234360|Placebo Comparator|Eosinophil count <= 2%; placebo|Non-eosinophilic patients randomized to this arm will receive 5 days of placebo.
9935067|NCT04233164|Experimental|1 mg/kg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
9935068|NCT04233164|Experimental|250 mg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
9935069|NCT04232306|Experimental|Liposomal Bupivacaine + Bupivacaine HCL|Liposomal bupivacaine + bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
9935070|NCT04232306|Active Comparator|Bupivacaine HCl surgical-site incision infiltration|Bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
9935071|NCT04232228||Participants with Crohn's Disease (CD)|Adult participants with moderate to severe CD who agree to be part of the study and who fit the inclusion/exclusion criteria and use Care4Today inflammatory bowel disease (C4T IBD) alongside standard of care (SOC) at participating centers will be observed. Data available per clinical practice and via the C4T IBD application will be collected within this study. Participants will also be asked to complete questionnaires that are sent directly to the patients, which are not completed as part of clinical practice or via the application. Relevant data will be collected by prospectively following participants from the index date for 12 months, and also by retrospectively collecting data for the 6-month period prior to the index date from participant's medical records. Index is the activation date of C4T IBD application in participant's smartphone.
9986317|NCT01401569|Active Comparator|Control|All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
9843147|NCT02902809|Experimental|Open-label study to evaluate safety|A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting β2-agonist.
9843148|NCT02902913|Experimental|Oleocanthal-rich, D2i2|Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
9843149|NCT02902913|Experimental|Oleacein-rich, D2i0.5|Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
9843150|NCT02902913|Placebo Comparator|Oleocanthal and Oleacein-low, D2i0|Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
9843151|NCT02902913|Active Comparator|Ibuprofen|Ibuprofen, 400 mg
9843152|NCT02902965|Experimental|Ibrutinib+ Bortezomib+ Dexamethasone|
9843153|NCT02903030|Experimental|Visbiome, Then Placebo|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
10207097|NCT02981407|Active Comparator|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
9843154|NCT02903030|Placebo Comparator|Placebo, Then Visbiome|Placebo matched to probiotic.
9843155|NCT02903121|Experimental|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
9843156|NCT02903121|Placebo Comparator|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
9843157|NCT02903238|Experimental|Placebo|placebo capsule
9843158|NCT02903368|Experimental|Arm 1A: AAPL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 6 months~Pts x weeks to RP"
9843159|NCT02903368|Experimental|Arm 1B: APL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~APL: Abiraterone acetate (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/day orally) for 6 months"
9843160|NCT02903368|Experimental|Arm 2A: AAPL Adjuvant Therapy [Part 2]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 12 months"
9843161|NCT02903368|No Intervention|Arm 2B: Observation [Part 2]|
9843162|NCT02903394|Experimental|mLCI imaging|mLCI device images cervical epithelium
9843163|NCT02903407|Active Comparator|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
9843164|NCT02903407|Active Comparator|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
9843165|NCT02903420|Experimental|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
9843166|NCT02903446|Active Comparator|Intervention|Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
9843167|NCT02903446|No Intervention|Control|Standard urate lowering therapy
9843168|NCT02903511|Experimental|Metformin|Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
10207098|NCT02981069|Active Comparator|Byetta / Bydureon|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
10207099|NCT02981069|Active Comparator|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
10207100|NCT02981069|Active Comparator|Byetta/Bydureon plus Dapagliflozin|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS~Dapagliflozin:~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
10207101|NCT02981069|Placebo Comparator|Placebo|Placebo group (4 weeks and 12 weeks)
10207102|NCT02970981|Experimental|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
10207103|NCT02963740|Experimental|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
9843169|NCT02903511|Placebo Comparator|Placebo|Participants will receive placebo 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
9843170|NCT02903836|Experimental|Nafithromycin 800 mg 3 days|PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind
9843171|NCT02903836|Experimental|Nafithromycin 800 mg 5 days|PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind
9922363|NCT00838461|Active Comparator|1|HSD-016
9922364|NCT00838461|Placebo Comparator|2|placebo
9843172|NCT02903836|Active Comparator|Moxifloxacin 400 mg|PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind
9843173|NCT02903966|Experimental|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
9843174|NCT02903966|Placebo Comparator|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
9843175|NCT02903966|Experimental|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
9843176|NCT02904057|Experimental|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
9843177|NCT02904057|No Intervention|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
9843178|NCT02904096|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
9843179|NCT02904096|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
9843180|NCT02904200|Experimental|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
9843181|NCT02904200|Active Comparator|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
9843182|NCT02904226|Experimental|Part A (JTX-2011)|Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
9843183|NCT02904226|Experimental|Part B (JTX-2011 + nivolumab)|Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
9843184|NCT02904226|Experimental|Part C (JTX-2011)|Phase 2 expansion of JTX-2011 by IV infusion
9843185|NCT02904226|Experimental|Part D (JTX-2011 + nivolumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
9843186|NCT02904226|Experimental|Part E (JTX-2011 + ipilimumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
9843187|NCT02904226|Experimental|Part F (JTX-2011 + ipilimumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
9843188|NCT02904226|Experimental|Part G (JTX-2011 + pembrolizumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
9843189|NCT02904226|Experimental|Part H (JTX-2011 + pembrolizumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
9843190|NCT02904265|Active Comparator|Diazepam|Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
9843191|NCT02904265|Experimental|Acetazolamide|Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
9843192|NCT02904512|Active Comparator|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
9843193|NCT02904512|Placebo Comparator|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
9843194|NCT02904902|Experimental|Adalimumab|Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).
9843195|NCT02904915|Active Comparator|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
9843196|NCT02904915|Active Comparator|No analgesia|IUD placement with no analgesia.
9793348|NCT01471041|Experimental|Venous Window Needle Guide|Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula
9793349|NCT01471054|Experimental|Ozurdex|Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of best-corrected visual acuity (BCVA), complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.
9843197|NCT02904954|Experimental|Arm 1 (Durvalumab monotherapy)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
9843198|NCT02904954|Experimental|Arm 2 (Durvalumab plus SBRT)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
9843199|NCT02905006|Placebo Comparator|Placebo|
9843200|NCT02905006|Experimental|Bimekizumab dosing regimen 1|
9843201|NCT02905006|Experimental|Bimekizumab dosing regimen 2|
9843202|NCT02905006|Experimental|Bimekizumab dosing regimen 3|
9843203|NCT02905006|Experimental|Bimekizumab dosing regimen 4|
9843204|NCT02905006|Experimental|Bimekizumab dosing regimen 5|
9843205|NCT02905149|Experimental|Serrato|Standard anesthesia+serratus plane block.
9843206|NCT02905149|Placebo Comparator|Control|Standard anesthesia
9843207|NCT02905266|Experimental|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
9843208|NCT02905266|Experimental|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
9843209|NCT02905331|Experimental|Group 1 (Guselkumab: Placebo)|Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
9843210|NCT02905331|Experimental|Group 2 (Placebo: Guselkumab)|Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
9843211|NCT02905435|Experimental|Biodegradable Temporizing Matrix|Biodegradable Temporizing Matrix (BTM)
9843212|NCT02905825|Experimental|Indication for Helicobacter pylori testing|Walk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
9843213|NCT02905981|Experimental|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
9843214|NCT02905981|Experimental|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
9843215|NCT02905981|Experimental|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
9843216|NCT02906358|Active Comparator|Community-based pain self-management|Community-based pain self-management: two, one-hour meetings monthly for the first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
9843217|NCT02906358|Active Comparator|Clinic-based pain self-management|Clinic-based pain self-management: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
9843218|NCT02906566|Other|Older Group Ages 55-75|Active and Placebo. Participants received retinol lotion on one arm and placebo to match on the other arm.
9843219|NCT02906566|No Intervention|Young Group Ages 18-25|Participants in the group will give tissue sample only for comparison.
9843220|NCT02906579|Experimental|IW-1973|Placebo taken once daily Day 1-Day 3; 10 mg IW-1973 take once daily Day 4-Day 6; 20 mg IW-1973 taken once daily Day 7-Day 9; 30 mg IW-1973 taken once daily Day 10-Day 12; 40 mg IW-1973 taken once daily Day 13-Day 15; 50 mg IW-1973 taken once daily Day 16-Day 18
9843221|NCT02906644|Experimental|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
9843222|NCT02906644|Experimental|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
9843223|NCT02906670|Experimental|1 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 1 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
9843224|NCT02906670|Experimental|2 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 2 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
9843225|NCT02906670|Experimental|4 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 4 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
9843226|NCT02906670|Experimental|6 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 6 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
9843227|NCT02906670|Experimental|9 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 9 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
9843228|NCT02906670|Experimental|6 mg/kg Q2W|Phase 1a: Patients are administered a dose of 6 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
9843229|NCT02906670|Experimental|9 mg/kg Q2W|Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
9843230|NCT02906670|Experimental|9 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
9843231|NCT02906670|Experimental|12 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 12 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
9843232|NCT02906670|Experimental|15 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 15 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
9843233|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
9843234|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
9843235|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
9843236|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
9843237|NCT02906696|Experimental|Treatment (bosutinib)|Patients receive bosutinib PO daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9843238|NCT02906709|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
9843239|NCT02906709|Experimental|Placebo→Omarigliptin 25 mg|Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
9843240|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
9843241|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fat meal on Day 1 of Intervention Period 3.
9843242|NCT02906813|Experimental|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
9843243|NCT02906917|Experimental|IDegAsp|
9843244|NCT02906917|Active Comparator|IGlar + IAsp|
9843245|NCT02906930|Experimental|3 mg oral semaglutide|
9843246|NCT02906930|Experimental|7 mg oral semaglutide|
9843247|NCT02906930|Experimental|14 mg oral semaglutide|
9843248|NCT02906930|Placebo Comparator|Placebo|
9843249|NCT02907073|Experimental|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion [18F]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
9843250|NCT02907073|Experimental|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.
9843251|NCT02907073|Experimental|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
9843252|NCT02907177|Experimental|Ponesimod|Ponesimod
9843253|NCT02907177|Placebo Comparator|Placebo|Placebo
9843254|NCT02907216|Experimental|Co-administration Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
9843255|NCT02907216|Active Comparator|Staggered Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4.5, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3.5 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
9843256|NCT02907268|Active Comparator|Treatment Arm A|The first treatment group received onabotulinumtoxinA (Botox) on the right side of their face and abobotulinumtoxinA (Dysport) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
9843257|NCT02907268|Active Comparator|Treatment Arm B|The second treatment group received abobotulinumtoxinA (Dysport) on the right side of their face and onabotulinumtoxinA (Botox) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
9843258|NCT02907489|No Intervention|Control: Calcium Hydroxide|Non-setting Calcium Hydroxide
9843259|NCT02907489|Other|Test: Triple Antibiotic Paste and Anti-Inflammatory Drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
9843260|NCT02907619|Experimental|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
9843261|NCT02907814|Experimental|Uveitis and Cataract Imaging Group|Subjects will undergo up to three optical coherence tomography scans.
9843262|NCT02907814|Experimental|Control|Control subjects will undergo a brief, non-contact eye exam and then undergo up to three optical coherence tomography scans.
9843263|NCT02907892|No Intervention|Control|Standard cesarean section surgical technique per surgeon preference
9843264|NCT02907892|Experimental|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
9922365|NCT00838474|Other|music therapy|Each infant was randomized to receive music therapy or no music over 2 consecutive days
9843265|NCT02907918|Experimental|Palbociclib + letrozole + trastuzumab +/- goserelin|"Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles~Definitive surgery will be performed preferably within 6 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Letrozole will continue to be taken daily and trastuzumab will be given every 3 weeks per standard of care guidelines. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
9843266|NCT02908100|Placebo Comparator|Placebo|Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
9843267|NCT02908100|Experimental|GDC-0853 (150mg) QD|Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
9843268|NCT02908100|Experimental|GDC-0853 (200mg) BID|Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
9843269|NCT02908178||Aim 1 Cohort|"The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
9843270|NCT02908178||Aim 2 Cohort|"The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
9843271|NCT02908347|Experimental|MP1032|"Test Product:~100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days"
9843272|NCT02908347|Experimental|Placebo|"Placebo to MP1032:~2 capsules of Placebo are provided orally twice daily for 42 days"
9843273|NCT02908464|Experimental|Lumosity (CT Group)|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
9843274|NCT02908464|No Intervention|Usual Care (Control Group)|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
9843275|NCT02908490|Experimental|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
9843276|NCT02908490|Placebo Comparator|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
9843277|NCT02908529|Placebo Comparator|Placebo|Placebo 2 hours before bedtime
9843278|NCT02908529|Active Comparator|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
9843279|NCT02908620|Experimental|One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session.
9843280|NCT02908620|Experimental|2 sprays CTY-5339-A, then 1 spray CTY-5339-CB +1 spray placebo|Two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session.
9922366|NCT00838487|Active Comparator|condroflex and exercise|assent arm
9922367|NCT00838487|Placebo Comparator|sugar pill and exercise|sugar pill arm
9843281|NCT02908620|Experimental|One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
9843282|NCT02908620|Experimental|1 spray CTY-5339-CB +1 spray placebo, then 2 sprays CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
9843283|NCT02908841|Other|Control|30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.
9843284|NCT02908841|Other|Treatment|"30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least mild) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes."
9843285|NCT02908880|Experimental|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
9843286|NCT02909101|Experimental|Active Cognitive Training (ACT)|Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
9843287|NCT02909101|Sham Comparator|Control Training (CON)|Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.
9843288|NCT02909140|Experimental|Topical Mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
9843289|NCT02909140|Experimental|Intracameral Mydriasis|Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
9843290|NCT02909140|Experimental|Topical + Intracameral mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
9843291|NCT02909153|Experimental|single dose of Triferic in the peritoneal dialysis solution|The patient will receive a single dose of Triferic in the peritoneal dialysis solution (IP) during a long (12 hour) peritoneal dialysis dwell. Each Cohort will receive a different ascending IP dose ( 5 mg/L, 12.5 mg/L, 20 mg/L). Blood samples will be drawn periodically over a 12 hour period for analysis.
9843292|NCT02909153|Experimental|single IV dose of Triferic 6.6 mg over a 4 hour period|The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
9843293|NCT02909439|Active Comparator|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
9843294|NCT02909439|Active Comparator|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
9843295|NCT02909504|Other|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
9843296|NCT02909764|No Intervention|Control Group|Children will receive regularly salted cereal to consume 4 times per week over a 2-month period.
9843297|NCT02909764|Experimental|Low Sodium Group|Intervention: Children will receive low sodium cereal to consume 4 times per week over a 2-month period.
9843298|NCT02909907|Experimental|150 units of abobotulinumtoxinA|150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
9843299|NCT02909907|Experimental|75 units of abobotulinumtoxinA|75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
9843300|NCT02909959|Active Comparator|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.~The weight-based dosing schedule is as follows:~3 tablets (approx. 46.5 µmol SF) if <100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
9843301|NCT02909959|Placebo Comparator|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
9843302|NCT02910011|Experimental|Topical Administration of Study Drug|2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
9843303|NCT02910037|Experimental|patients enrolled for mNGS testing|Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
9843304|NCT02910063|Experimental|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
9843305|NCT02910089|Other|Shared Decision Making/Brief Negotiated Interviewing|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
9843306|NCT02910089|No Intervention|Control Arm|Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.
9843307|NCT02910102|Other|Sequence AB|RVT-101 35 mg in Period II and Placebo in Period IV
9843308|NCT02910102|Other|Sequence BA|Placebo in Period II and RVT-101 35 mg in Period IV
9843309|NCT02910167||Men with spasmodic syndromes|Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
9843310|NCT02910167||Women with spasmodic syndromes|Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
9843311|NCT02910362|Experimental|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
9843312|NCT02910362|Active Comparator|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
9843313|NCT02910466|Experimental|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
9843314|NCT02910674|Other|One Arm|This is a comparative diagnostic study, no interventional actions are being taken.
9843315|NCT02910713|Experimental|Intranasal Application|Intranasal Tear Neurostimulator applied intranasally device (active), intranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
9843316|NCT02910713|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device applied extranasally (control) for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
9843317|NCT02910739|Experimental|Part I: MK-8931 40 mg in Moderate HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with moderate HI in fasted state (Part I)
9843318|NCT02910739|Active Comparator|Part I: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part I)
9843319|NCT02910739|Experimental|Part II: MK-8931 40 mg in Mild HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with mild HI in fasted state (Part II)
9843320|NCT02910739|Active Comparator|Part II: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part II)
9843321|NCT02911025||Patients Treated With Clobazam|Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.
9843322|NCT02911116|Experimental|Cohort 1 (Subcutaneous Only)|Subcutaneous injections of Ustekinumab at baseline.
9922368|NCT00838500|Active Comparator|Immediate SPA treatment|Immediate spa treatment during 18 days soon after randomization (1 year)
9843323|NCT02911116|Experimental|Cohort 2 (IV and Subcutaneous)|Initial IV infusion of ustekinumab at baseline followed by one subcutaneous injection at Week 8. In participants who demonstrate an allergic reaction to the baseline IV infusion, the second dose at Week 8 can also be administered as an IV infusion instead of a subcutaneous injection.
9843324|NCT02911285|Experimental|NAC/CBT|Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.
9843325|NCT02911285|Placebo Comparator|Placebo/CBT|Participants will receive placebo pills and CBT for 8 weeks.
9843326|NCT02911324|Experimental|Nabilone|Will receive nabilone at 1 mg daily (BID) over 4 weeks.
9843327|NCT02911324|Experimental|Nabilone and EX/RP|Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks.
9843328|NCT02911519|Experimental|Brief Group Psychoeducation|It was designed after a review of the literature on the subject; content and procedures will be written in a manual. They will be five sessions of two hours once a week. Each session will be conducted by a clinical psychologist and a general practitioner trained in group management.
9843329|NCT02911519|Active Comparator|Treatment as Usual Only|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
9843330|NCT02911688|Placebo Comparator|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
9843331|NCT02911688|Active Comparator|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
9843332|NCT02911753|Experimental|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
9843333|NCT02911753|Experimental|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
9843334|NCT02911753|Placebo Comparator|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
9843335|NCT02911818|Active Comparator|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
9843336|NCT02911818|Active Comparator|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
9843337|NCT02911818|Active Comparator|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
9843338|NCT02911818|Active Comparator|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
9843339|NCT02911818|Active Comparator|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
9843340|NCT02911844|Other|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
9843341|NCT02911857|Experimental|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
9843342|NCT02911909|Active Comparator|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
9843343|NCT02911909|Experimental|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
9843344|NCT02911922|Experimental|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
9922369|NCT00838500|Sham Comparator|Late SPA treatment|Late spa treatment during 18 days soon after 12 months visit (2nd year)
9998276|NCT01516619|Experimental|romiplostim|
9998277|NCT01516645|Experimental|KHK2898|
9843345|NCT02911922|Experimental|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
9843346|NCT02911948|Experimental|Insulin degludec/liraglutide|
9843347|NCT02911948|Active Comparator|Insulin degludec|
9843348|NCT02912195|Experimental|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) in a 100 mL normal saline minibag.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
9843349|NCT02912195|Active Comparator|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
9843350|NCT02912364|Experimental|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
9843351|NCT02912364|Experimental|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
9843352|NCT02912455|Active Comparator|Study Drug (canagliflozin)|Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
9843353|NCT02912455|Placebo Comparator|Placebo|Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
9843354|NCT02912468|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
9843355|NCT02912468|Experimental|Dupilumab 300 mg|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.
9843356|NCT02912650|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
9843357|NCT02912650|Active Comparator|Ibuprofen 250 mg|2 caplets of IBU 125 mg
9843358|NCT02912650|Active Comparator|Acetaminophen 650 mg|2 tablets of APAP 325 mg
9843359|NCT02912650|Active Comparator|Placebo|2 caplets of Placebo
9843360|NCT02913105|Experimental|LMB763|Oral dose once daily for 12 weeks (84 days)
9843361|NCT02913105|Placebo Comparator|Placebo|Oral dose once daily for 12 weeks (84 days)
9843362|NCT02913326|Experimental|Dabigatran etexilate|
9843363|NCT02913326|Active Comparator|Warfarin|
9843364|NCT02913521|Experimental|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
9843365|NCT02913521|Active Comparator|Voltaren Gel|Apply 4 g of gel to the knee four times a day
9843366|NCT02913521|Placebo Comparator|Placebo|Apply 4 g of gel to the knee four times a day
10207104|NCT02957240|Active Comparator|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
10207105|NCT02957240|Experimental|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
10207106|NCT02946853|Active Comparator|CRT-D|Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).
10207107|NCT02946853|Experimental|CRT-D and AVJ Ablation|Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.
10207108|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
10207109|NCT02923570|Experimental|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
10207110|NCT02923570|Experimental|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
10207111|NCT02911935|Active Comparator|Oral azithromycin|Oral Azithromycin
10207112|NCT02911935|Placebo Comparator|Placebo|Oral Placebo
10207113|NCT02909452|Active Comparator|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
10207114|NCT02909452|Active Comparator|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
10207115|NCT02909452|Active Comparator|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
10207116|NCT02909036|Experimental|Melphalan|Test Dose CE Melphalan 10mg/m2 with PK studies Day -12 to Day-3, CE Melphalan Dose of Target AUC 13 mg/L/h infused with PK studies Day -2, 3-10 x 10^6 CD 34+ cells/kg reinfused Day 0, Pegfilgrastim 6mg injection Day +1
10207117|NCT02905032|No Intervention|Standard Care|Observations in clinical encounter via video, audio or observational notes.
10207118|NCT02905032|Active Comparator|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
10207119|NCT02898506|Active Comparator|Liraglutide|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with Victoza®
10207120|NCT02898506|Placebo Comparator|Placebo|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with placebo
10207121|NCT02895841|No Intervention|Standard of Care|Patients will continue with their normal Standard of Care for their condition
10214113|NCT01065779||FOSAMAX PLUS or FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg/2800 IU) or FOSAMAX PLUS D (70 mg/5600 IU).
10214114|NCT01056159|Experimental|Albuterol dry powder inhaler|The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler).
9843367|NCT02913924|Experimental|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
9843368|NCT02913924|Placebo Comparator|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
9922370|NCT00838552||1 Asthma subjects|Children with asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
9922371|NCT00838552||2 Non-asthma subjects|Children with other respiratory diseases than asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
9922372|NCT00838617||Participants with ALS|Participants diagnosed with ALS.
9922373|NCT00838643||Allogeneic pts|Adult allogeneic HSCT recipients
9922374|NCT00838656|Experimental|Arm I|Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9922375|NCT00838656|Experimental|Arm II|Patients receive carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours and gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9922376|NCT00838708|Placebo Comparator|Vehicle cream|
9922377|NCT00838708|Experimental|SRD174 Cream|
9922378|NCT00838734||1|Pre-LASIK
9922379|NCT00838734||2|Post-LASIK
9922380|NCT00838747||Gynaecological Cancer|Gynaecological Cancer
9922381|NCT00838773|Experimental|YMSM|Young Men Who Have Sex with Men
9922382|NCT00838773|Experimental|YHA|Young Heterosexual Adults
9922383|NCT00838773|Experimental|ROMA|Gypsies (Bulgarian)
9922384|NCT00838773|No Intervention|Control|All study participants (including those in control condition networks) receive HIV/AIDS/STD risk reduction counseling at baseline, as well as testing and treatment or treatment referral for STDs and HIV infection. STD/HIV testing and treatment or treatment referral are provided at each followup point. This constitutes the control intervention.
9922385|NCT00838812|Other|clindamicin and tretinoin gel|
9922386|NCT00838825|No Intervention|traditional|The traditional arm is composed of primary care physicians who continue the health care delivery model existing for the 5 years prior to the study. The traditional includes the physician, a pool of resources including random assignment of diabetic educators and includes the entire panel of patients assigned to the PCP.
9922387|NCT00838825|Experimental|care management|The care management group is composed of primary care physicians who have been assigned a specific physician extender, the care manager, and an additional medical assistant and form a care manager team working together with registry support, team meetings and instruction in self-management and includes the entire panel of patients assigned to the PCP.
9922388|NCT00838838||Group 1|
9922389|NCT00838851|Experimental|CCRE|
9922390|NCT00838864|Active Comparator|1|ceftrioxone 500mg q12h for 3 days
9922391|NCT00838864|Active Comparator|2|ceftrioxone 500 mg q12h for 7 days
9922392|NCT00838877|Experimental|1|
9922393|NCT00838942||1|Patients suffering from both Alzheimer's disease and low vision due to a bilateral impeding cataract.
9922394|NCT00838955|Experimental|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
9922395|NCT00838968|Active Comparator|interferon-alpha (IFN-alpha)|the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months
9922396|NCT00838968|No Intervention|control|no interventions were assigned
9922397|NCT00838994|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
9922398|NCT00838994|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Deltoideus [in the middle of the line insertion of Binao LI 14 and acromion], Forearm [1 inch laterally of the middle point between Shaohai HE3 and Shenmen HE7], Upper arm [1 inch laterally of Tianfu LU 3] and Lower leg [0.5 inch dorsally of Xuanzhong GB39]. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
9935072|NCT04230278|Experimental|START-Play Intervention|Sitting Together And Reaching to Play is an intervention designed to work on motor-based problem-solving. Thus the activities keep thinking skills at the forefront while also working on advancing motor skills. When initially developed to work with children who were emerging sitters the motor tasks focused on sitting and reaching resulting in the name.
9843369|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
9843370|NCT02914132|Other|Seraph 100 Filter|Renal replacement patient with bacteremia.
9843371|NCT02914184|Experimental|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
9843372|NCT02914184|Experimental|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
9843373|NCT02914184|Experimental|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
9843374|NCT02914184|Active Comparator|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
9843375|NCT02914210|Other|Virtual physical therapy|Virtual physical therapy rehabilitation program (VERA) used in the home with care planning and remote support and monitoring by physical therapists
9843376|NCT02914210|Other|Traditional physical therapy|No intervention. Standard home health physical therapy and/or outpatient clinic physical therapy as prescribed.
9843377|NCT02914236|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
9843378|NCT02914275|Experimental|Seqirus QIV Cohort A|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
9843379|NCT02914275|Experimental|Seqirus QIV Cohort B|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
9843380|NCT02914275|Active Comparator|Comparator QIV Cohort A|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
9843381|NCT02914275|Active Comparator|Comparator QIV Cohort B|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
9843382|NCT02914457|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
9843383|NCT02914509|Experimental|OTX-TP (sustained release travoprost) Intracanalicular Depot|OTX-TP (sustained release travoprost) Intracanalicular Depot
9843384|NCT02914509|Placebo Comparator|PV (Placebo Vehicle) Intracanalicular Depot|PV (Placebo Vehicle) Intracanalicular Depot
9843385|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 200 mg|Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.
9843386|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 100 mg|Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
9843387|NCT02914522|Placebo Comparator|Induction Study (Cohort A): Placebo|Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
9843388|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 200 mg|Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
9843389|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 100 mg|Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
9843390|NCT02914522|Placebo Comparator|Induction Study (Cohort B): Placebo|Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
9843391|NCT02914522|Experimental|Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).
9843392|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
9843393|NCT02914522|Experimental|Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).
9998278|NCT01516658|Experimental|Hydrogel coil group|use Hydrogel Coil as much as be able to use
9998279|NCT01516658|Active Comparator|Bare platinum coil group|use only bare platinum coil
9843394|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
9843395|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Placebo|Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).
9843396|NCT02914548|Experimental|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
9843397|NCT02914548|Experimental|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
9843398|NCT02914548|Placebo Comparator|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
9843399|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
9843400|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria
9843401|NCT02914834|Experimental|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
9843402|NCT02914834|Active Comparator|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
10207122|NCT02895841|Experimental|SMART app wearable device|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
10207123|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
10207124|NCT02880982|Active Comparator|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
10207125|NCT02880982|Placebo Comparator|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
10207126|NCT02880293|Experimental|Patients will undergo donor/recipient bone marrow|All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
10207127|NCT02863172||Consenting Proband Group|Questionnaires completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
10207128|NCT02863172||Family Members (MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
10207129|NCT02863172||Family Members (Not MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
9843411|NCT02915029|Experimental|Education and Lifestyle Coaching|"Education and life style coaching includes:~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
9843412|NCT02915029|No Intervention|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
9843413|NCT02915159|Experimental|Abatacept|Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
9843414|NCT02915159|Placebo Comparator|Placebo|Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
10207130|NCT02853500|Experimental|TACE Procedure With Surefire|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Surefire.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
10207131|NCT02853500|Active Comparator|TACE Procedure Traditional Delivery|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Traditional Delivery.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
10207132|NCT02842827|Experimental|Multiple ascending dose|MAD Cohorts using IMG-7289 alone
10207133|NCT02842827|Experimental|Combination Therapy|IMG-7289 in combination with all-trans retinoic acid (ATRA)
10207134|NCT02842827|Experimental|Ascending duration|Treatment duration extension Cohorts using IMG-7289 alone
10207135|NCT02837029|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10207136|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
10207137|NCT02819635|Placebo Comparator|Placebo|Administered once daily.
9843415|NCT02915705|Experimental|Burosumab|Burosumab 0.8 mg/kg starting dose, administered Q2W by SC injection during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants continued to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
9843416|NCT02915705|Active Comparator|Active Control|Multiple daily doses of oral phosphate and one or more daily doses of active vitamin D therapy, titrated and individualized by the investigator based on published recommendations during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants crossed over to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
9843417|NCT02915744|Experimental|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
10207138|NCT02819635|Experimental|Updacitinib (ABT-494) Dose A|Administered once daily.
9843418|NCT02915744|Active Comparator|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
9843419|NCT02915835|Active Comparator|riociguat|Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
9843420|NCT02915835|Placebo Comparator|Placebo|Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
9843421|NCT02915874|Active Comparator|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:~Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;~Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
9843422|NCT02915874|No Intervention|Control|Subjects randomized to not receive treatment.
9843423|NCT02915978|Experimental|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
9843424|NCT02915978|Experimental|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
9843425|NCT02915978|Placebo Comparator|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
9843426|NCT02916056|Experimental|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
9843427|NCT02916407|Active Comparator|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
10207139|NCT02819635|Experimental|Updacitinib (ABT-494) Dose B|Administered once daily.
9843428|NCT02916407|Experimental|Desflurane Group|The patients will maintained general anesthesia with desflurane.
9843429|NCT02916433|No Intervention|Usual care|This group will continue to receive treatments that have already been initiated to manage bronchial secretions.
9843430|NCT02916433|Experimental|Octreotide|This group will continue to receive treatments that have already been initiated to manage bronchial secretions. Additionally, this group will receive parenteral octreotide.
9843431|NCT02916498|Active Comparator|Bipolar then alternative field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with bipolar stimulation for 21 days, then alternative field shape stimulation for 21 days
9843432|NCT02916498|Experimental|Alternative then bipolar field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with alternative field shape stimulation for 21 days, then bipolar stimulation for 21 days
9843433|NCT02916563|Experimental|Altitude|Single arm study Blood Glucose Monitoring System Altitude Performance
9843434|NCT02916693|Experimental|Mirabegron|Participants take 25- 50mg oral Mirabegron tablets daily for 12 weeks,
9843435|NCT02916745|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
9843436|NCT02916927|Experimental|Ketamine IV infusion|Ketamine 0.3 mg/kg in 100 mL normal saline minibag infused over 15 minutes. Placebo: 10 mL normal saline in syringe pushed over 1 minute. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
9843437|NCT02916927|Active Comparator|Ketamine IV push|Ketamine 0.3 mg/kg in a syringe pushed over 1 minutes. Placebo: 100 mL normal saline minibag infused over 15 minutes. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
9843438|NCT02917031|Active Comparator|Saxagliptin|one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
10207140|NCT02819635|Experimental|Updacitinib (ABT-494) Dose C|Administered once daily.
9843439|NCT02917031|Active Comparator|Sitagliptin|one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
9843440|NCT02917031|Placebo Comparator|Placebo|one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
9843441|NCT02917122|Placebo Comparator|sertraline + sham tDCS|Patients will take sham tDCS.
9843442|NCT02917122|Active Comparator|sertraline + active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
9843443|NCT02917265|Experimental|TENS for vagus stimulation|A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
9843444|NCT02917265|Sham Comparator|TENS for sham stimulation|A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
9843445|NCT02917278|Experimental|Meals|High-protein renal-specific meals
9843446|NCT02917278|No Intervention|Control|No Meals
9843447|NCT02917447|Experimental|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
9843448|NCT02917447|Placebo Comparator|Phone Monitoring|Weekly check-in calls from a study coach.
9843449|NCT02917603|Experimental|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
9843450|NCT02917603|No Intervention|Control|These family and residents will receive usual care
9843451|NCT02917642|Experimental|Passive Ultrasonic Irrigation Protocol|ultrasonic activation of antimicrobial solutions
9843452|NCT02917642|Active Comparator|Non-Ultrasonic Irrigation Protocol|no-activation of antimicrobial solutions
9843453|NCT02917941|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.
9843454|NCT02918071|Experimental|Arm Benralizumab|Benralizumab administered subcutaneously every 4 weeks
9843455|NCT02918097|Experimental|Lithium Carbonate|"Group Started: Lithium Carbonate (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
9843456|NCT02918266|Experimental|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
9843457|NCT02918266|Experimental|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9922399|NCT00838994|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
9922400|NCT00839007|Experimental|A|Dose 1 of CD-NP
9922401|NCT00839007|Experimental|B|Dose 2 of CD-NP
9843458|NCT02918266|Experimental|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843459|NCT02918266|Experimental|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843460|NCT02918266|Experimental|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9922402|NCT00839007|Experimental|C|Dose 3 of CD-NP
9922403|NCT00839007|Experimental|D|Dose 4 of CD-NP
9922404|NCT00839007|Experimental|E|Dose 5 of CD-NP
9922405|NCT00839007|Experimental|F|Dose 6 of CD-NP
9922406|NCT00839007|Placebo Comparator|G|Placebo
9922407|NCT00839020|Active Comparator|1|Navigated total knee arthroplasty with a minimally invasive approach
9922408|NCT00839020|Active Comparator|2|Navigated total knee arthroplasty with a conventional approach
9516982|NCT03310515||HIV-1 uninfected high risk subjects|The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.
9843461|NCT02918266|Experimental|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843462|NCT02918266|Experimental|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843463|NCT02918266|Experimental|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843464|NCT02918266|Experimental|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843465|NCT02918266|Experimental|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843466|NCT02918266|Experimental|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
9843467|NCT02918279|Experimental|Liraglutide|
9843468|NCT02918279|Placebo Comparator|Placebo|
9843469|NCT02918318|Experimental|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
9843470|NCT02918318|Experimental|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
9843471|NCT02918318|Experimental|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
9843472|NCT02918318|Experimental|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
9843473|NCT02918357|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
9843474|NCT02918396|Active Comparator|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
9843475|NCT02918396|Experimental|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage <0.3 mV.
9843476|NCT02918396|Experimental|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
9843477|NCT02918552|Experimental|Treatment|20 or 40 mg sodium nitrite tid
9843478|NCT02918552|Placebo Comparator|Control|20 or 40 mg placebo tid
9843479|NCT02918617|Active Comparator|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
9843480|NCT02918617|Placebo Comparator|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
9843481|NCT02918617|Experimental|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
9843482|NCT02918617|Experimental|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
9843483|NCT02918617|Experimental|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
9843484|NCT02918617|Placebo Comparator|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
9843485|NCT02918617|Experimental|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
9843486|NCT02918617|Experimental|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
9843487|NCT02918617|Placebo Comparator|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
9922409|NCT00839033|Experimental|1|patients treated with standard treatment and a mechanical insufflation-exsufflation
10207141|NCT02819635|Experimental|Updacitinib (ABT-494) Dose D|Administered once daily.
10207142|NCT02799186|Experimental|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
10207143|NCT02794285|Experimental|Anifrolumab|Anifrolumab
10207144|NCT02794285|Placebo Comparator|Placebo|Placebo
10207145|NCT02776735|Experimental|Sarilumab|Participants will receive one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose regimen once this is identified. Sarilumab will be given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for approximately 72 patients enrolled in dose-finding and second portions and 84 weeks for approximately 28 patients enrolled in third portion)
10207146|NCT02773238|Experimental|Treatment|Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or > 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.
10207147|NCT02767518|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
10207148|NCT02767518|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
10207149|NCT02740127|Experimental|Caudal Nerve Block + General Anesthesia Group|"Participants receive a caudal nerve block (CNB) prior to surgery and receive general anesthesia during surgery.~Study staff calls participant about 3 days after surgery."
9843488|NCT02918630|Active Comparator|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
9843489|NCT02918630|Experimental|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
9843490|NCT02918656|Experimental|Infographics|Infographic presentation of health information
9843491|NCT02918656|Active Comparator|Plain Language Summary|PLS presentation of health information
9843492|NCT02918656|Active Comparator|Scientific abstract|Scientific abstract presentation of health information
9843493|NCT02918669|Experimental|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
9843494|NCT02918721|Experimental|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
9843495|NCT02918721|Active Comparator|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
9843496|NCT02918773|Experimental|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
9843497|NCT02918773|Active Comparator|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
9843498|NCT02918851|Experimental|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
9843499|NCT02918851|Experimental|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
9843500|NCT02918851|Experimental|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
9843501|NCT02918877|Experimental|Inhaled Anesthesia|Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.
9843502|NCT02918877|Active Comparator|Intravenous Anesthesia|Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.
9843503|NCT02918968|Experimental|Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT|Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
9843504|NCT02918968|Experimental|Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT|Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
9843505|NCT02919007|Experimental|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
9843506|NCT02919111|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
9922410|NCT00839033|Active Comparator|2|Patients with standard treatment and standard respiratory physiotherapy
9998280|NCT01516697|Other|Control|The patients in Group A will serve as controls and will receive standard monitoring in addition to continuous measurement of SV and CO. The physicians will not know the CO and SV and will manage the patients in a standard fashion.
9843507|NCT02919267|Other|Intra-pulmonary pressure determination|A pressure tubing catheter will be connected to the luerlock adaptor of the bronchial blocker (BB) or to the adaptor located on the side of the occluding system mounted at the extremity of the double lumen tube (DLT). The catheter will then be connected to a differential pressure transducer (AD Instruments, Colorado Springs, CO, USA), allowing direct visualisation of the bronchial pressures. Along with intra-bronchial pressure, esophageal pressure will also be measured to eliminate the pressure generated by the positive pressure of the ventilated lung (Adult esophageal balloon catheter, Cooper Surgical, Trumbull, CT, USA). Intra-bronchial pressures will be measured at end-inspiration and end-expiration.
9843508|NCT02919267|Other|Volume determination|A one-liter bag (Roxon, Etobicoke, ON, Canada) will be filled precisely with 300 mL of air with the use of a calibrated syringe of 3 liters (Hans Rudolph inc, Shawnee, Kansas, United States), through a three-way valve (Hans Rudolph inc, Shawnee, Kansas, United States). Following the filling of the bag, it will be connected to the non-ventilated lumen of the double lumen tube (DLT) or to the bronchial blocker (BB) through the three-way connector. At the end of the observation period, the collector bag will be connected to the calibrated syringe and will emptied from its residual volume.
9843509|NCT02919423|Active Comparator|10 Hz TMS|active TMS will be administered
9843510|NCT02919423|Active Comparator|1 Hz TMS|active TMS will be administered
9843511|NCT02919475|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
9843512|NCT02919475|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
9843513|NCT02919475|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
9843514|NCT02919475|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
9843515|NCT02919475|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
9843516|NCT02919657|Active Comparator|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
9843517|NCT02919657|Active Comparator|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
9843518|NCT02919696|Experimental|Abemaciclib Dose Level 1|Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
9843519|NCT02919696|Experimental|Abemaciclib Dose Level 2|Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
9843520|NCT02919761|Experimental|Part 1: All Enrolled Participants|All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
9843521|NCT02919761|Experimental|Part 2: Acthar Gel|Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
9843522|NCT02919761|Placebo Comparator|Part 2: Placebo|Participants receive Placebo 1 mL twice weekly for an additional 12 weeks
9843523|NCT02919813|Active Comparator|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
9843524|NCT02919813|Active Comparator|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
9843525|NCT02919826|Experimental|DBT Group|Adapted Dialectical Behaviour Therapy
9843526|NCT02919826|No Intervention|Control Arm|People in this group will receive treatment as usual
9843527|NCT02919995|Experimental|Higher Dose RPL554|Single dose of inhaled 6 mg RPL554
9843528|NCT02919995|Experimental|Lower dose RPL554|Single dose of inhaled 1.5 mg RPL554
9843529|NCT02919995|Placebo Comparator|Placebo|Inhaled placebo dose
9843530|NCT02920476|Experimental|Treatment arm|TAS-102
9843531|NCT02920528|Placebo Comparator|Placebo|placebo controlled arm
9516983|NCT03310489|Experimental|Digitalized cognitive-behavioral intervention|
9516984|NCT03310489|Active Comparator|Psychoeducation about anxiety|
9516985|NCT03310476|Experimental|Baked, consumed chilled potatoes|
9843532|NCT02920528|Experimental|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
9843533|NCT02920528|Experimental|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
9843534|NCT02920749|Other|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
9843535|NCT02920749|Other|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
9843536|NCT02920749|Other|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
9843537|NCT02920749|Other|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
9843538|NCT02920918|Active Comparator|Canagliflozin|Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.
9843539|NCT02920918|Active Comparator|Sitagliptin|Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.
9843540|NCT02920957|Active Comparator|comfilcon A|Participants are randomized to wear the comfilcon A lens for one month during the cross over study.
9843541|NCT02920957|Active Comparator|senofilcon C|Participants are randomized to wear the senofilcon C lens for one month during the cross over study.
9843542|NCT02920970|Active Comparator|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
9843543|NCT02920970|Active Comparator|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
9843544|NCT02920983|Active Comparator|somofilcon A|Subjects are randomized to wear somofilcon A for one week during the cross over study.
9843545|NCT02920983|Active Comparator|nelfilcon A II 2|Subjects are randomized to wear nelfilcon A II 2 for one week during the cross over study.
9843546|NCT02920983|Active Comparator|omafilcon A ll 2|Subjects are randomized to wear omafilcon A ll 2 for one week during the cross over study.
9843547|NCT02921061|Experimental|Treatment (decitabine, G-CLAM)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.~RE-INDUCTION: Patients who do not achieve MRDneg CR after first induction are eligible for re-induction. Patients receive the same treatment as during induction except that decitabine is omitted.~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction, patients are eligible to receive filgrastim, cladribine, and cytarabine as in Induction. Treatment may be repeated for up to 4 courses in the absence of disease progression or unacceptable toxicity. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks)."
9843548|NCT02921087|Other|Test followed by control|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the test daily disposable soft contact lenses at the first visit. Subjects will crossover to the control daily disposable soft contact lenses at the second visit.
9843549|NCT02921087|Other|Control followed by test|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the control daily disposable soft contact lenses at the first visit. Subjects will crossover to the test daily disposable soft contact lenses at the second visit.
9843550|NCT02921295|Active Comparator|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
9843551|NCT02921386|Other|Breakfast A - Fasting|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
9843552|NCT02921386|Other|Breakfast B - 15 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
9843553|NCT02921386|Other|Breakfast C - 30 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
9843554|NCT02921386|Other|Breakfast D - 45 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
9843555|NCT02921386|Other|Breakfast E - High Fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
9843556|NCT02921412|No Intervention|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
9843557|NCT02921412|Active Comparator|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
9843558|NCT02921425|Experimental|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.
9843559|NCT02921490|Experimental|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
9843560|NCT02921737|Experimental|Treatment Arm|TAS-102
9843561|NCT02921750|Experimental|Dressing Exufiber®Gelling Fibre Dressing|will receive dressing Exufiber®
9843562|NCT02921750|Active Comparator|Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin|Will receive Aquacel®Extra™
9843563|NCT02921841|Experimental|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
9843564|NCT02921841|Active Comparator|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
9843565|NCT02922153|Experimental|Cryoanalgesia + Standard of Care (SOC)|Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
9843566|NCT02922153|Active Comparator|Standard of Care|Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.
9843567|NCT02922582|Experimental|DepoTXA 400mg|400mg Intracapsular at the end of surgery one time
9843568|NCT02922582|Experimental|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
9843569|NCT02922582|Experimental|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
9843570|NCT02922582|Active Comparator|IV Tranexamic acid (TXA)|1 g of IV TXA at the end of surgery
9843571|NCT02922634||older surgical patients|Older surgical patients presenting for elective spine surgery
9843572|NCT02922738|Experimental|Intervention - VisualDx Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
9843573|NCT02922738|No Intervention|Control - Usual Care Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to control, did not refer to VisualDx but could refer to other information sources or none per usual care. Their patients were assigned to the control group and interviewed about the outcomes of their treatment
9843574|NCT02922868|Experimental|EndoSheath CST-5000 Scope|Cogentix Medical CST-5000 Flexible Video Cystoscope with Slide-On® EndoSheath® Technology. EndoSheath CST-5000 Scope.
9843575|NCT02922868|Active Comparator|Olympus Visera Elite OTV-S190 Scope|Olympus HD Flexible Cysto-Nephro Videoscope (CYF-VH) with Olympus Visera Elite Platform, including OTV-S190 Video Processor CLV-S190 Xenon Light Source. Olympus Visera Elite OTV-S190 Scope.
9843576|NCT02922959|Active Comparator|PTOEND|"PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.~Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment."
9843577|NCT02922959|Experimental|PTOEND+PI|"PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.~In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention."
9843578|NCT02923115|Experimental|DS-1040b|Participants who are randomized to receive DS-1040b as a single, continuous intravenous infusion (initial loading dose 3-6 mg). All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
9843579|NCT02923115|Placebo Comparator|Placebo|Participants who are randomized to receive placebo as a single, continuous intravenous infusion. All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
9843580|NCT02923167|Experimental|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
9843581|NCT02923180|Experimental|Enoblituzumab|Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.
9843582|NCT02923245|Experimental|POCUS|Patients will be given consecutive IV fluid boluses until a full bladder is visualized by the ED physician on POCUS or the patient endorses maximal bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician.
9843583|NCT02923245|No Intervention|Usual Care|Patients will be given consecutive IV fluid boluses until the patient endorses sensation of maximum bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician
9843584|NCT02923271|Experimental|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
9843585|NCT02923271|Experimental|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
9843586|NCT02923349|Experimental|INCAGN01949|
9843587|NCT02923427|Active Comparator|Laryngeal mask Supreme|"Insertion of the Laryngeal mask Supreme and evaluation of its clinical performance"
9843588|NCT02923427|Experimental|i-gel|"Insertion of the i-gel and evaluation of its clinical performance"
9843589|NCT02923895|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
9843590|NCT02923895|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
9516986|NCT03310476|Experimental|Boiled, consumed hot potatoes|
9843591|NCT02923921|Experimental|Pegilodecakin + FOLFOX|Pegilodecakin 5 microgram per kilogram (μg/kg) dosed as one of the following 2 fixed doses: 0.4 milligram (mg) for participants weighing ≤80 kg or 0.8 mg for participants weighing>80 kg on Days 1-5 and Days 8-12 subcutaneously (SC) plus FOLFOX [dl-Leucovorin (dl-LV) 400 milligram per meter square (mg/m2) and oxaliplatin 85 mg/m2 followed by bolus 5-fluorouracil (5-FU) 400 mg/m2 and a 46 to 48 hour infusion of 5- FU 2400 mg/m2] initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression. After discontinuation of FOLFOX in the absence of tumor progression [that is (i.e., completion of the planned 12 cycles or unacceptable FOLFOX related toxicity], Pegilodecakin 10µg/kg maintenance treatment administered as one of the 2 fixed doses, either 0.8 mg for participants weighing ≤80 kg or 1.6 mg for participants weighing>80 kg.
9843592|NCT02923921|Active Comparator|FOLFOX|FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression.
9843593|NCT02924051|Experimental|Motivational Interview (MI)|Intervention group participants receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families, along with monthly motivational interviewing conducted by a trained registered nurse
9843594|NCT02924051|Active Comparator|Cooking Skills/Nutritional Education|Participants in this arm receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families.
9843595|NCT02924350|Experimental|Test dentifrice containing stannous fluoride|All the participants in the test arm applied test dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using test dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
9843596|NCT02924350|Active Comparator|Control dentifrice containing sodium monofluorophosphate|All the participants in the control arm applied control dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using control dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
9843597|NCT02924428|Experimental|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
9843598|NCT02924428|Active Comparator|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
9843599|NCT02924688|Experimental|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9843600|NCT02924688|Experimental|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9843601|NCT02924688|Experimental|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9843602|NCT02924688|Experimental|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9843603|NCT02924688|Active Comparator|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9843604|NCT02924688|Active Comparator|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
9922411|NCT00839046|Active Comparator|1 Community Health Worker Intervention|This is the active control group, which all 150 participants will receive. It consists of visits from trained community health workers, who will provide asthma education, as well as provision of equipment and supplies to reduce indoor environmental exposures for asthma. These will include: vacuum cleaners, mattress and pillow covers, cleaning supplies.
9922412|NCT00839046|Experimental|2 Air Filter|The 50 families in the Air Filter Arm will receive an air filter in addition to the standard community health worker intervention. The Air Filter will be installed right after baseline measurements in the home.
9922413|NCT00839046|Experimental|3 Air Filter and Air Conditioner|"Fifty families will be assigned to the Air Filter and Air Conditioner Arm. In addition to the standard community health worker intervention, they will receive an air filter and an air conditioner (for the warmer months)."
9922414|NCT00839059|Experimental|Lenalidomide|
9922415|NCT00839085|No Intervention|1|normal procedure of CABG
9922416|NCT00839085|Active Comparator|2: GSE|100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h)
9922417|NCT00839085|Active Comparator|3: Vit C|25 mg/kg through pump
9922418|NCT00839111|Experimental|A|Sorafenib plus FOLFIRI regimen
9843605|NCT02924883|Experimental|Trastuzumab Emtansine + Atezolizumab|Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
9843606|NCT02924883|Active Comparator|Trastuzumab Emtansine + Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
9843607|NCT02925078|Other|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have <2 mm mucosa thickness.
9843608|NCT02925078|Other|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
9843609|NCT02925117|Placebo Comparator|Placebo|Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.
9843610|NCT02925117|Experimental|Upadacitinib 7.5 mg|Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.
9843611|NCT02925117|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.
9843612|NCT02925117|Experimental|Upadacitinib 30 mg|Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.
9843613|NCT02925143|Experimental|E-learning course|
9843614|NCT02925312|Experimental|Intervention|Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
9843615|NCT02925312|No Intervention|Matched controls|Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.
9843616|NCT02925403|Active Comparator|Group 1|10μg R21/Matrix-M1 on days 0, 28, and 56.
9843617|NCT02925403|Active Comparator|Group 2|50μg R21/Matrix-M1 on days 0, 28, and 56.
9843618|NCT02925403|Placebo Comparator|Group 3|Saline injection on days 0, 28, and 56.
9843619|NCT02925455|Experimental|Stimulation + Video Games|Contralaterally-controlled functional electrical stimulation (CCFES) enables patients with upper extremity hemiplegia to open their paretic hand by stimulating finger and thumb extensors with surface electrodes. CCFES is used during functional task practice and hand therapy video games to link motor intent with execution. Four intuitive and engaging games were developed to provide goal-oriented motor skill training, impairment-appropriate difficulty, and performance feedback that motivates iterative play and skill improvement.
9843620|NCT02925455|Active Comparator|Video Games (no stimulation)|Participants receive duration-matched, identical hand therapy video games and task practice therapy as the experiment arm, but do not receive CCFES to assist hand opening.
9843621|NCT02925494|Experimental|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
9843622|NCT02925494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
9843623|NCT02925611|Active Comparator|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
9843624|NCT02925611|Active Comparator|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
9843625|NCT02925741|Experimental|Silk-Like Linens|Patients in the experimental arm will be cared for on silk-like bed linens.
9516987|NCT03310463|Experimental|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
9843626|NCT02925741|No Intervention|Standard Cotton Linens|Patients in the standard of care arm will be cared for on standard cotton bed linens.
9843627|NCT02925858|Experimental|Intervention|Intraoperative infusion of ketamine
9843628|NCT02925858|Placebo Comparator|Control|Control group receiving a saline infusion
9843629|NCT02925923|Active Comparator|Ticagrelor|crushed ticagrelor (180 mg); (n=50 patients)
9843630|NCT02925923|Active Comparator|Eptifibatide bolus+clopidogrel|Eptifibatide bolus (180 mcg/kg x 2 boluses) + clopidogrel 600 mg and heparin low-dose (n=50 patients)
9843631|NCT02926027|Active Comparator|Active subjects|Vascepa (4 gm/day), oral dose
9843632|NCT02926027|Placebo Comparator|Placebo subject|oral dose of placebo
9843633|NCT02926209|Active Comparator|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
9843634|NCT02926209|Active Comparator|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
9843635|NCT02926573|Active Comparator|Gabapentin|Gabapentin liquid by mouth or Per Tube 300mg twice a day
9843636|NCT02926573|Placebo Comparator|Placebo|Placebo liquid by mouth or Per Tube twice a day
9843637|NCT02926677|Experimental|Cue-Centered Therapy (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
9843638|NCT02926677|Experimental|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
9843639|NCT02926677|Experimental|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
9843640|NCT02926937|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 400 milligrams (mg) administered as two 200 mg tablets, once daily (QD), before the first meal of the day in the double-blind treatment period for up to 26 weeks.
9843641|NCT02926937|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 Sotagliflozin tablet and 1 matching placebo tablet, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
9843642|NCT02926937|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
9843643|NCT02926950|Experimental|Sotagliflozin 400 mg + Metformin|Following a 2-week run-in period, sotagliflozin 400 mg was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
9843644|NCT02926950|Placebo Comparator|Placebo + Metformin|Following a 2-week run-in period, matching placebo was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
9843645|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) 150mg|ACE-083 150 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
9843646|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
10207150|NCT02740127|Active Comparator|General Anesthesia Alone Group|"Participants receive general anesthesia (GA) during surgery without a caudal nerve block.~Study staff calls participant about 3 days after surgery."
9843647|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA bilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
9843648|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) 150 mg|ACE-083 150 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
10207151|NCT02737553|Active Comparator|enclosed morcellation|"In this group, after extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9.~doi: 10.1097/AOG.0000000000000823.)."
9843649|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) 200 mg|ACE-083 200 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
9843650|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) 240 mg|ACE-083 240 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
9843651|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Tibialis Anterior (TA)|"Part 2, double-blind (DB) placebo-controlled (PC). Placebo TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
9843652|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
9843653|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Biceps Brachii (BB)|"Part 2, double-blind placebo-controlled. Placebo BB bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
9922419|NCT00839124|Active Comparator|Allergic asthma|subjects with allergic asthma will undergo challenge with 20,000 EU CCRE
9843654|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
9843655|NCT02927171|No Intervention|Usual Care|Skilled nursing facility rehabilitation therapists provide all patients with usual standard of care.
9843656|NCT02927171|Experimental|I-STRONGER|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER) Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities. Skilled nursing facility rehabilitation therapists will be trained in I-STRONGER intervention and will implement to all eligible patients as new standard of care.
9843657|NCT02927223|Experimental|Treadmill then Treadmill with Atropine|Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
9843658|NCT02927301|Experimental|Atezolizumab|Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.
9843659|NCT02927327|Experimental|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.~Zero Echo Time (ZTE) scan for head attenuation"
9843660|NCT02927327|Experimental|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.~PET/MR Q Static (Q. MRAC)"
9843661|NCT02927366|Experimental|QCC374|Adult patients with pulmonary arterial hypertension (PAH) on QCC374. All patients were initiated at 0.03 mg BID (Day 1-3), and were up-titrated to next higher dose 0.06 mg BID (Day 4) and increased to 0.12 mg BID (Day 7-14).
9843662|NCT02927366|Placebo Comparator|Placebo|Adult patients with pulmonary arterial hypertension (PAH) on placebo matching to QCC374 doses (0.03 mg BID (Day 1-3), 0.06 mg BID (Day 4) and 0.12 mg BID (Day 7-14)).
9843663|NCT02927431|Experimental|Danirixin 15 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
9843664|NCT02927431|Experimental|Danirixin 50 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
9843665|NCT02927431|Placebo Comparator|Placebo of danirixin IV plus 75 mg oseltamivir|Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
9843666|NCT02927457|Experimental|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
9843667|NCT02927457|Experimental|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
9843668|NCT02927457|Experimental|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
9843669|NCT02927457|Experimental|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
9843670|NCT02927457|Experimental|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F >G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
10207152|NCT02737553|Active Comparator|vaginal morcellation|In this group, after extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
10207153|NCT02737475|Experimental|Part 1: Dose Escalation|"BMS-986178 at specified doses at specified intervals~Enrollment is closed for this arm"
10207154|NCT02737475|Experimental|Part 2: Dose Escalation and Expansion|"BMS-986178 in combination with Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
10207155|NCT02737475|Experimental|Part 3: Dose Escalation and Expansion|"BMS-986178 in combination with Ipilimumab at specified doses at specified intervals~Enrollment is closed for this arm"
10207156|NCT02737475|Experimental|Part 4: Dose Schedule and Exploration|"BMS-986178/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
10207157|NCT02737475|Experimental|Part 5: Dose Schedule and Exploration|"BMS-986178/Ipilimumab at specified doses at specified intervals~Enrollment is closed for this arm"
10207158|NCT02737475|Experimental|Part 6: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
10207159|NCT02737475|Experimental|Part 7: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
10207160|NCT02737475|Experimental|Part 8: Dose Exploration|"BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval~Enrollment is closed for this arm"
9843671|NCT02927457|Experimental|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F >G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
9843672|NCT02927639|Experimental|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
9843673|NCT02927639|No Intervention|Control|This group will receive the usual standard of care for 6 months.
9843674|NCT02927795||Spiolto Respimat|QOL measurement of COPD patients taking Spiolto Respimat
9843675|NCT02927834|Active Comparator|Antibiotic only|1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.
9843676|NCT02927834|Active Comparator|Augmentin with 6 day steroid|Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)
9843677|NCT02927834|Active Comparator|Augmentin with 21 day steroid|Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )
9843678|NCT02927873|Experimental|RSV LD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV low dose (LD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
9843679|NCT02927873|Experimental|RSV MD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of the RSV middle dose (MD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
9843680|NCT02927873|Experimental|RSV HD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV high dose (HD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
9843681|NCT02927873|Placebo Comparator|Placebo LD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
9843682|NCT02927873|Placebo Comparator|Placebo MD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
9843683|NCT02927873|Placebo Comparator|Placebo HD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
9843684|NCT02927925|Experimental|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
9843685|NCT02928029|Experimental|Phase1, arm1: 33 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/ dexamethasone.
9843686|NCT02928029|Experimental|Phase1, arm2: 55 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/ dexamethasone.
9843687|NCT02928029|Placebo Comparator|Phase2, arm1: Placebo+SOC|Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.
9843688|NCT02928029|Experimental|Phase2, arm2: Radium-223 dichloride+SOC|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone
9843689|NCT02928055|Experimental|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
9843690|NCT02928055|Experimental|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
9843691|NCT02928055|Experimental|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
9843692|NCT02928380|Active Comparator|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
9843693|NCT02928380|Experimental|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
9843694|NCT02928380|No Intervention|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
9843695|NCT02928770|Experimental|Nastent|A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device.
9843696|NCT02928848|Experimental|Real tDCS|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
9843697|NCT02928848|Sham Comparator|Sham tDCS|Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS.
9843698|NCT02928952|Experimental|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
9843699|NCT02928952|No Intervention|DSME alone|Usual care control
9922420|NCT00839124|Active Comparator|healthy control|Healthy volunteers will undergo challenge with 20,000 EU CCRE
9922421|NCT00839150||1|Diabetic patients without diabetic retinopathy : No intervention
9922422|NCT00839150||2|Sex and age-matched control subjects : No intervention
9922423|NCT00839163|Experimental|Arm 1|
9843700|NCT02929329|Experimental|Omecamtiv Mecarbil|Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations < 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and < 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and < 1000 ng/mL maintained a 25 mg BID dosing regimen.
9843701|NCT02929329|Placebo Comparator|Placebo|Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.
9843702|NCT02929407|Experimental|FE 204205|
9843703|NCT02929407|Placebo Comparator|Placebo|
9843704|NCT02929498|Experimental|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
10207161|NCT02737475|Experimental|Part 9: Dose Exploration|"BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals~Enrollment is open for this arm [Tumor type triple negative breast cancer (TNBC)]"
10207162|NCT02725580|Experimental|Open Label|Subjects with diagnosis of vLINCL6 Batten disease will receive a single intrathecal injection into the lumbar spinal cord region of AT-GTX-501.
10207163|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in TN patients|Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
10207164|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in RR patients|Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
10207165|NCT02717624|Experimental|Part 2: Acalabrutinib+VR in TN patients|Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
10207166|NCT02709512|Experimental|Drug: ADI-PEG 20 plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
9843705|NCT02929498|Experimental|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
9843706|NCT02929667|Active Comparator|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
9843707|NCT02929667|Placebo Comparator|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
9843708|NCT02929823|Experimental|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
9843709|NCT02929823|Experimental|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
9843710|NCT02929823|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
9922424|NCT00839163|Experimental|Arm 2|
9922425|NCT00839163|Experimental|Arm 3|
9922426|NCT00839163|Experimental|Arm 4|
9922427|NCT00839163|Active Comparator|Arm 5|
9922428|NCT00839176|Placebo Comparator|Placebo|Placebo (w/o API)
9922429|NCT00839176|Experimental|2|5mg dose of RX-10100
9922430|NCT00839176|Experimental|3|10mg dose of RX-10100
9922431|NCT00839176|Experimental|4|15 mg dose of RX-10100
9998281|NCT01516697|Experimental|experimental|The patients in Group B will receive the same monitoring as those in Group A. But the physicians will know instantaneously the CO and SV in real time and will manage the patients accordingly.
10207167|NCT02709512|Placebo Comparator|Drug: Placebo plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
10207168|NCT02703714|Experimental|Pembrolizumab and GM-CSF|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
10207169|NCT02689440|Experimental|Treatment (dasatinib, venetoclax)|Patients receive dasatinib PO QD for 15 years in the absence of disease progression or unacceptable toxicity. After 3 months of dasatinib treatment, patients also receive venetoclax PO QD on days 1-14 of each month for 3 years in the absence of disease progression or unacceptable toxicity (patients enrolled prior to 4/1/2018 receive only dasatinib).
10207170|NCT02684006|Experimental|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
10207171|NCT02684006|Active Comparator|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
10207172|NCT02677064||patients with acute leukemia (AML or ALL)|
10207173|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
10207174|NCT02642965|Experimental|Treatment (CPX-351 and FLAG)|"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.~COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5."
9843711|NCT02929979|Experimental|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
9843712|NCT02929979|Placebo Comparator|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
9843713|NCT02930005|Experimental|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
9843714|NCT02930005|Experimental|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
9843715|NCT02930018|Placebo Comparator|Placebo|Drug vehicle only
9843716|NCT02930018|Experimental|Nerinetide (NA-1), 2.6 mg/kg|
9843717|NCT02930174|Active Comparator|Respironics V-60, then Draeger V500|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm one applies the Respironics V-60, then the Drager V-500.
9843718|NCT02930174|Active Comparator|Draeger V500, then Respironics V-60|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm two applies the Drager V-500, then the Respironics V-60.
9843719|NCT02930226|Experimental|1 unit FDP-CPD|Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD
9843720|NCT02930226|Experimental|Reinfusion 1 unit FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD
9843721|NCT02930226|Experimental|Reinfusion 2 units FDP-CPD|Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD
9843722|NCT02930226|Experimental|Reinfusion 2 units FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD
9843723|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (1st)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
10207175|NCT02641483|Experimental|Colonic Motility|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
9843724|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (2nd)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
9843725|NCT02930343|Active Comparator|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
9843726|NCT02930343|Active Comparator|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
9843727|NCT02930590|Experimental|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
9843728|NCT02930590|Experimental|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
9843729|NCT02930590|Active Comparator|Standard mattress|basic foam
9843730|NCT02930824|Experimental|Adult Genotype guided treatment|For adults randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
10207176|NCT02638090|Experimental|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
10207177|NCT02638090|Experimental|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.~Level 1: Maximum Tolerated Dose (MTD)"
10207178|NCT02638090|Active Comparator|Arm A: Pembrolizumab|"Pembrolizumab treatment only.~Level 1: Pembrolizumab 200 mg Q3 wks"
10207179|NCT02638090|Active Comparator|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.~Level 1: MTD"
10207180|NCT02632175|Experimental|Subjects receiving Adalimumab|Subjects receiving Adalimumab up to 288 weeks
10207181|NCT02629809|Experimental|Treatment (iFCG)|See Detailed Description.
10214115|NCT01056159|Active Comparator|Albuterol HFA MDI|The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler).
9843731|NCT02930824|No Intervention|Adult Conventional treatment|For adults randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
9843732|NCT02930824|Experimental|Pediatric Genotype guided treatment|For children randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
9843733|NCT02930824|No Intervention|Pediatric Conventional treatment|For children randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
9843734|NCT02930837|Experimental|alteplase|
9843735|NCT02930941|Experimental|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
9843736|NCT02930941|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
9843737|NCT02930980|Experimental|Investigational Software|Investigational Software loaded on Micra device
9843738|NCT02931045|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
9843739|NCT02931045|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
9843740|NCT02931253|Experimental|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
9843741|NCT02931253|No Intervention|Control Group|Standard of care - ablation only
9843742|NCT02931396|Experimental|FES intervention|Study participants who are randomized into the intervention group will be fitted with a portable commercially available surface FES device and instructed in its use by a study investigator. Participants will be directed to use the FES 30 minutes a day for the first week, one hour a day during the next week, 90 minutes a day during the third week, and then a minimum of 2 hours per day or 10 hours per week for the next three months at home.
9843743|NCT02931396|No Intervention|Control|Participants will be asked to continue their activities of daily living as usual.
9843744|NCT02931539|Experimental|Maribavir Treatment|Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks.
9843745|NCT02931539|Active Comparator|Investigator-Assigned Treatment|Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.
9843746|NCT02931565|Experimental|IW-1701|Single 5-mg dose of IW-1701 administered orally
9843747|NCT02931565|Placebo Comparator|Placebo|Matching placebo administered orally
9843748|NCT02931838|Experimental|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
9843749|NCT02931838|Experimental|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
9843750|NCT02931838|Experimental|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
9843751|NCT02931838|Experimental|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
9843752|NCT02931838|Experimental|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
9843753|NCT02931838|Placebo Comparator|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
9843754|NCT02932228|Experimental|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
9843755|NCT02932228|No Intervention|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
9843756|NCT02932267|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
9843757|NCT02932306|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
9843758|NCT02932306|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
9843759|NCT02932462|Experimental|DSXS 1535|DSXS 1535 topical product
9843760|NCT02932462|Placebo Comparator|Placebo|Vehicle
9843761|NCT02932787|Experimental|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
9843762|NCT02932787|No Intervention|Control|
9843763|NCT02932878|Experimental|DSXS topical|administered twice daily for 28 days
9843764|NCT02932891|Experimental|DSXS topical|active treatment
9843765|NCT02932904|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
9843766|NCT02932904|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
9843767|NCT02932904|Active Comparator|Paroxetine 20 mg|Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
9843768|NCT02932904|Placebo Comparator|Placebo|Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
9843769|NCT02932943|Experimental|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
9843770|NCT02932943|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
9843771|NCT02933034|Experimental|Coronary Disease|Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.
9843772|NCT02933060|Experimental|IV fluid bolus|Patients will receive a 1000 ml bolus of normal saline, administered over 60 minutes.
9843773|NCT02933060|Sham Comparator|Control|Patients will have an IV catheter and will be connected to an IV bag, but will receive only 10 ml of normal saline over 60 minutes.
9843774|NCT02933320|Experimental|Part A: Arm 1: BI-1206 single agent dose escalation phase|BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).
9843775|NCT02933320|Experimental|Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase|Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).
9843776|NCT02933320|Experimental|Part B: Arm1: BI-1206 single agent expansion phase|Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.
9843777|NCT02933320|Experimental|Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase|Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.
9843778|NCT02933372|Experimental|Parkinson's Disease Patients|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
9843779|NCT02933372|Experimental|Healthy Controls|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.
9843780|NCT02933450|Active Comparator|Patiromer group|Patiromer 25.2 g dose
9843781|NCT02933450|No Intervention|Standard of Care group|Standard of Care
9843782|NCT02933476|Experimental|Vibrotactile Stimulation Treatment|All patients will receive the vibrotactile stimulation treatment. No deception will be used.
9843783|NCT02933489|Experimental|Arm A (DBT, AB-MR)|Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.
9843784|NCT02933489|Experimental|Arm B (AB-MR, DBT)|Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.
9843785|NCT02933502|Experimental|DSXS topical product|treatment with DSXS once daily for 28 days
9843786|NCT02933528|Experimental|Dsxs topical product|treatment with DSXS once daily for 28 days
9843787|NCT02933866|Experimental|DSXS topical|applied once daily for 28 days
9516988|NCT03310463|Experimental|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to <90 mL/min/1.73 meters squared [m^2] calculated by the Modified Diet in Renal Disease [MDRD] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
9843788|NCT02933866|Placebo Comparator|Vehicle topical|applied once daily for 28 days
9843789|NCT02933879|Experimental|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
9843790|NCT02933879|Placebo Comparator|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
9843791|NCT02934178|Experimental|Cohort 1: WRSS1 3 x 10³ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
9843792|NCT02934178|Experimental|Cohort 2: WRSS1 3 x 10⁴ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
9843793|NCT02934178|Experimental|Cohort 3: WRSS1 3 x 10⁵ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
9843794|NCT02934178|Experimental|Cohort 4: WRSS1 3 x 10⁶ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
9843795|NCT02934178|Placebo Comparator|Cohort 1: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.
9843796|NCT02934178|Placebo Comparator|Cohort 2: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.
9843797|NCT02934178|Placebo Comparator|Cohort 3: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.
9843798|NCT02934178|Placebo Comparator|Cohort 4: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.
9843799|NCT02934191|Experimental|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
9843800|NCT02934191|Active Comparator|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
9843801|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
9843802|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
9843803|NCT02934555|Placebo Comparator|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
9843804|NCT02934555|Experimental|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
9843805|NCT02934698|Experimental|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
9843806|NCT02935036|Experimental|ADPS topical product|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
9843807|NCT02935036|Placebo Comparator|Placebo Control|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
9843808|NCT02935062|Active Comparator|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
9843809|NCT02935062|Experimental|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
9843810|NCT02935062|Placebo Comparator|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
9843811|NCT02935179|Placebo Comparator|Control Group|Normal diet with 1500~2000 kcal
9843812|NCT02935179|Experimental|Treatment Group|White sweet potato diet with 1500~2000 kcal
9843813|NCT02935192|Experimental|Vaccine Arm|Seasonal trivalent split, inactivated influenza vaccine
9843814|NCT02935192|Placebo Comparator|Placebo Arm|Phosphate buffered saline
9843815|NCT02935452|Active Comparator|Genie|This group will have the Genie social tool delivered on a one to one basis at discharge points in the study.
9843816|NCT02935452|No Intervention|Normal Care|This group will have the same questionaires at discharge, but will be offered normal care
9843817|NCT02935543|Experimental|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
9843818|NCT02935673|Experimental|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
9843819|NCT02935673|Experimental|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
9843820|NCT02935673|Experimental|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
9843821|NCT02935699|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
9843822|NCT02935699|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
9843823|NCT02935738|Experimental|Prednisolone treated men / positive SPA / IVF|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
9843824|NCT02935738|Experimental|Prednisolone treated men / negative SPA / ICSI|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
9843825|NCT02935738|No Intervention|Control men / positive SPA / IVF|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (more than five) were then admitted to in vitro fertilization (IVF) cycle.
9998282|NCT01516710|Active Comparator|Open liver resection|Patients will be operated with open liver resection
9516989|NCT03310463|Experimental|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 m^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
9843826|NCT02935738|No Intervention|Control men / negative SPA / ICSI|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were then admitted to intracytoplasmic sperm injection (ICSI) cycles.
9843827|NCT02935842|Experimental|Specific SL-therapy for PD (with and without DBS)|Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
9843828|NCT02935842|Active Comparator|rBMT for PD (with and without DBS)|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
9843829|NCT02935842|No Intervention|PD (with and without DBS); no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
9843830|NCT02935842|No Intervention|Healthy Controls; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
9843831|NCT02935894|Experimental|Single group|"All subjects will participate in 4 study day visits in the same order.~compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).~compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).~collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).~collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
9843832|NCT02936037|Placebo Comparator|GROUP 1|Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
9843833|NCT02936037|Experimental|GROUP 2|MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
9843834|NCT02936076|Active Comparator|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
9843835|NCT02936076|Placebo Comparator|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
9843836|NCT02936479|Experimental|Berinert treatment|
9922432|NCT00839202|Experimental|FVIII immuno-assay|The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
9922433|NCT00839228|Experimental|Perhexiline|perhexiline 100mg o bd for 3 months
9922434|NCT00839228|Placebo Comparator|Placebo|Placebo one tablet bd for 3 months
9922435|NCT00839267||Unstable|Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support
9922436|NCT00839267||Stable|Patients with myocardial infarction hemodynamically completely (Killip I)stable.
9922437|NCT00839280|Experimental|Arm 1|
9922438|NCT00839280|Active Comparator|Arm 2|
9922439|NCT00839293|Experimental|A|ABT -335 capsules 135mg
9922440|NCT00839293|Experimental|B|ABT-335 capsules 45mg
9922441|NCT00839358|Active Comparator|Albumin plus midodrine|Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.
9922442|NCT00839358|Placebo Comparator|salin solution plus pills|Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.
9922443|NCT00839371|Active Comparator|Midazolam|i.v. midazolam titration until adequate depth of sedation
9922444|NCT00839371|Active Comparator|Propofol|i.v. propofol titration until adequate depth of sedation
9922445|NCT00839384|Experimental|Implant Advisa IPG|Advisa IPG implant
9922446|NCT00839397|Other|Paroxetine|A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
9922447|NCT00839449|Experimental|A|Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.
9922448|NCT00839449|No Intervention|B|Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.
9922449|NCT00839462|Experimental|Arm 1|
9922450|NCT00839462|Active Comparator|Arm 2|
9922451|NCT00839488|Active Comparator|I|pantoprazole 40 mg iv qd
9843837|NCT02936635|Experimental|Delayed Start Treatment|The Delayed Start Treatment group consisted of patients who received placebo in CY 4031 and tirasemtiv in CY 4033.
9843838|NCT02936635|Experimental|Early Start Treatment|The Early Start Treatment group consisted of patients who received tirasemtiv in both CY 4031 and CY 4033.
9843839|NCT02936648|Experimental|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
9843840|NCT02936869|No Intervention|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
9843841|NCT02936869|Experimental|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
9843842|NCT02937116|Experimental|Phase 1a|"Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
9843843|NCT02937116|Experimental|Phase 1b Cohort A|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
9843844|NCT02937116|Experimental|Phase 1b Cohort B|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
10207182|NCT02629159|Placebo Comparator|Placebo followed by ABT-494|"Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).~Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2."
9843845|NCT02937116|Experimental|Phase 1b Cohort C|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
9843846|NCT02937116|Experimental|Phase 1b Cohort D|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308/Cisplatinum/Pemetrexed"
9843847|NCT02937116|Experimental|Phase 1b Cohort E|"Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\gemcitabine\cisplatin"
9843848|NCT02937116|Experimental|Phase 1b Cohort F|"Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\oxaliplatin\capecitabine"
9843849|NCT02937116|Experimental|Phase 1b Cohort G|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\etoposide\cisplatin"
9843850|NCT02937116|Experimental|Phase 1b Cohort H|"Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\irinotecan\5-FU"
9843851|NCT02937168|Experimental|Part 1: PET/CT Scan|Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
9843852|NCT02937168|Experimental|Part 2: Reslizumab|Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
9843853|NCT02937168|Placebo Comparator|Part 2: Placebo|Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
9843854|NCT02937194|Experimental|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
9843855|NCT02937194|Active Comparator|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
9843856|NCT02937350|Experimental|Study Population|D6-25-hydroxyvitamin D3
10207183|NCT02629159|Active Comparator|Adalimumab|"Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
9843857|NCT02937454|Active Comparator|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
9843858|NCT02937454|Placebo Comparator|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
9843859|NCT02937506|Experimental|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
9843860|NCT02937506|Experimental|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
9843861|NCT02937545|Experimental|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
9843862|NCT02937545|Experimental|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
9843863|NCT02937558|Experimental|CSI-Glucagon (Double-Blind Phase - 2 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
9843864|NCT02937558|Placebo Comparator|Placebo (Double-Blind Phase - 2 days)|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
9843865|NCT02937558|Experimental|CSI-Glucagon (Open-label Phase - Up to 28 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
9843866|NCT02937584|Experimental|GP MDI (PT001) 14.4 μg|Glycopyrronium
9843867|NCT02937584|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
9843868|NCT02937623|Experimental|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
9843869|NCT02937623|No Intervention|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
9843870|NCT02937636|Experimental|Test Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
9843871|NCT02937636|Active Comparator|Reference Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
9843872|NCT02937701|Experimental|ABP 710|"Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46."
9843873|NCT02937701|Active Comparator|Infliximab|"Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46."
9843874|NCT02937740|Other|Naive patients - ARM 1|"NATESTO Testosterone Nasal Gel administered intranasally to patients with no prior TRT experience. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
9843875|NCT02937740|Other|Non-naive patients - ARM 2|"NATESTO Testosterone Nasal Gel administered intranasally to patients who had prior TRT. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
9843876|NCT02937870|Experimental|Test Product 1|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
9843877|NCT02937870|Experimental|Test Product 2|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
9843878|NCT02937870|Active Comparator|Reference Product|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
9843879|NCT02937870|Other|Negative Control|
9843880|NCT02938052|Experimental|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
9843881|NCT02938169|Experimental|walking exercise group|"**walking exercise with bracing exercise~walking exercise: treadmill gait with tolerable gait speed~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
9843882|NCT02938169|Experimental|stabilization exercise group|"** stabilization exercise with bracing exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
9843883|NCT02938169|Experimental|walking and stabilization exercise group|"**walking exercise, bracing exercise with stabilization exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise:treadmill gait with tolerable gait speed"
9843884|NCT02938169|Sham Comparator|flexibility exercise group|"**Stretching exercise(control)~Only educate the flexibility exercise(stretching exercise)~Don't educate the walking exercise method and stabilization exercise method"
9843885|NCT02938494|Experimental|IDP-123 Lotion|Lotion
9843886|NCT02938494|Active Comparator|Tazorac Cream|Cream
9843887|NCT02938494|Active Comparator|Vehicle Lotion|Lotion
9843888|NCT02938494|Active Comparator|Vehicle Cream|Cream
9843889|NCT02938520|Experimental|CAB LA + RPV LA every 4 weeks|After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
9843890|NCT02938520|Active Comparator|ABC / DTG / 3TC (600 mg/50mg/300mg) once daily|After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
9843891|NCT02938585|Experimental|Prophylactic treatment|
9843892|NCT02938585|Experimental|On-demand treatment|
9843893|NCT02938949|Active Comparator|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
9843894|NCT02938949|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
9843895|NCT02939014|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
9843896|NCT02939079|Experimental|Fingolimod and Fish Oil|Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year.
9843897|NCT02939079|Active Comparator|Fingolimod and Placebo|Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year.
9843898|NCT02939105|Experimental|CoolSculpting Treatment in the Upper Arm|"Subjects in the study were treated with the CoolSculpting System with one of two vacuum applicator types for bilateral fat reduction in the upper arms. Applicators were used concurrently, with an applicator on each arm. Each subject received 1 or 2 cooling cycles on each arm for 35 minutes at protocol-defined temperatures.~The Investigator selected the applicator for each subject based on the intended fat volume of the treatment area."
9843899|NCT02939131|Experimental|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
9843900|NCT02939131|Active Comparator|Enhanced Standard of Care|Enhanced Standard of Care (ESC)
9843901|NCT02939170|Experimental|DT1 MF MM|Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
9843902|NCT02939170|Active Comparator|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
9843903|NCT02939326|Placebo Comparator|Placebo|"Intervention: Drug: Placebo~Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area."
9843904|NCT02939326|Active Comparator|EB-001 Dose 1 (1X)|"Intervention: Drug: EB-001~Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
9843905|NCT02939326|Active Comparator|EB-001 Dose 2 (3X)|"Intervention: Drug: EB-001, 3X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
9843906|NCT02939326|Active Comparator|EB-001 Dose 3 (9X)|"Intervention: Drug: EB-001, 9X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
9843907|NCT02939326|Active Comparator|EB-001 Dose 4 (12X)|"Intervention: Drug: EB-001, 12X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
9843908|NCT02939326|Active Comparator|EB-001 Dose 5 (16X)|"Intervention: Drug: EB-001, 16X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
9843909|NCT02939326|Active Comparator|EB-001 Dose 6 (21X)|Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
9843910|NCT02939326|Active Comparator|EB-001 Dose 7 (28X)|"Intervention: Drug: EB-001, 28X Dose 1~Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
9843911|NCT02939560|Experimental|rTMS|Participants will receive rTMS sessions according to the study protocol.
9843912|NCT02939599|Experimental|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg~-active patients will continue at the dose they finished on the QCC374X2201 study"
9843913|NCT02939651|Experimental|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
9843914|NCT02939716|Active Comparator|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
9843915|NCT02939716|Active Comparator|Bread|2 slices of white bread, 40g each; served with 10g butter
9843916|NCT02939716|Experimental|Lettuce|300g lettuce; served with 30g mayonnaise
9843917|NCT02939781||Febrile critically ill children|Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.
9843918|NCT02939937|Experimental|phenytoin|patients received phenytoin 100mg three time daily up to 3 months
9843919|NCT02939937|Experimental|placebo|patients received placebo 100 mg three time daily for 3 months
9843920|NCT02939950|Experimental|Bausch + Lomb Samfilcon A Soft Contact Lens|Participants will wear Bausch + Lomb samfilcon A soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
9843921|NCT02939950|Active Comparator|Bausch + Lomb Pure Vision Soft Contact Lens|Participants will wear Bausch + Lomb pure vision soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
9843922|NCT02940249|Experimental|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
9843923|NCT02940249|Experimental|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
9843924|NCT02940249|Experimental|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
9843925|NCT02940249|Placebo Comparator|Placebo|No polyphenols delivered in a low sugar drink.
9843926|NCT02940392|Experimental|Rezum Treatment|Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
9998283|NCT01516710|Active Comparator|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
9998284|NCT01516723|Experimental|Hybrid sirolimus-eluting stents|ORSIRO, Biotronik Inc.
9843929|NCT02940574|Experimental|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
9843930|NCT02940574|Placebo Comparator|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
9843931|NCT02940626|Placebo Comparator|Placebo|Placebo administered as 2 separate intravenous (IV) infusions
9843932|NCT02940626|Experimental|ASN100|ASN100 administered as 2 separate intravenous (IV) infusions
9843933|NCT02940691|Experimental|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
9843934|NCT02940730|Active Comparator|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
9843935|NCT02940730|Active Comparator|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
9843936|NCT02940860|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
9843937|NCT02940860|Active Comparator|Iron sucrose|Administered IV
9843938|NCT02940886|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
9843939|NCT02940886|Active Comparator|Iron sucrose|Administered IV
9843940|NCT02941523|Experimental|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
9843941|NCT02941523|Experimental|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
9843942|NCT02941523|Experimental|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
9843943|NCT02941614||Intervention|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
9843944|NCT02941614||Control|Newly diagnosed breast cancer patients will experience usual care.
9843945|NCT02941627|Experimental|Neuro Cochlear Implant System study group|All patients will receive a Neuro Zti implant and fitted with Neuro One sound processor
9843946|NCT02941640|Experimental|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
9843947|NCT02941640|Experimental|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
9843948|NCT02941640|Experimental|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
9843949|NCT02941640|Experimental|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
9843950|NCT02941692|Experimental|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
9843951|NCT02941692|Placebo Comparator|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
9843952|NCT02942160|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
9843953|NCT02942264|Experimental|Phase I Arm 1 Dose Dense Temozolomide plus Zotiraciclib (TG02)|dose dense (dd) Temozolomide (TMZ) 125 mg/m^2 x 7 days on / 7 days off plus Zotiraciclib (TG02) dose escalation
9843954|NCT02942264|Experimental|Phase I Arm 2 Metronomic Temozolomide Plus Zotiraciclib (TG02)|metronomic Temozolomide (TMZ) 50 mg/ m^2 daily plus Zotiraciclib (TG02) dose escalation
9843955|NCT02942264|Experimental|Phase II Arm 1 Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) Plus Temozolomide (TMZ)|"Maximum tolerated dose (MTD) of Zotiraciclib (TG02) from phase I plus and winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I"
9843956|NCT02942264|Active Comparator|Phase II Arm 2 Metronomic Temozolomide (TMZ)|"winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I alone"
9843957|NCT02942407|Experimental|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
9843958|NCT02942407|Experimental|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
9843959|NCT02942485|Experimental|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
9843960|NCT02942485|Active Comparator|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
9843961|NCT02942576|Experimental|Edoxaban-based regimen|Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
9843962|NCT02942576|Active Comparator|VKA-based regimen|VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
9843963|NCT02942654|Experimental|LY900014|Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
9843964|NCT02942654|Active Comparator|Insulin Lispro|Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.
9843965|NCT02942771|Experimental|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
9843966|NCT02942771|Experimental|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
9843967|NCT02942771|Experimental|Cohort 3- TT301/MW189|TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
9843968|NCT02942771|Experimental|Cohort 4- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
9843969|NCT02942771|Placebo Comparator|Placebo|No drug intervention.
9843970|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
9843971|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
9843972|NCT02943070|Experimental|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
9843973|NCT02943096|Active Comparator|Flavanol|Blinded treatment with either CocoaVia 500mg or placebo.
9843974|NCT02943096|Placebo Comparator|Placebo|Blinded treatment with either CocoaVia 500mg or placebo.
9843975|NCT02943213|Experimental|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
9843976|NCT02943213|Experimental|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
9843977|NCT02943226|Experimental|Becton Dickinson Nexiva Diffusics System|Intervention with the new Becton Dickinson Nexiva Diffusics System will be evaluated to see if it will improve image quality compared to the standard catheter.
9843978|NCT02943226|Active Comparator|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to novel 3 hole Becton Dickinson Nexiva Diffusics System to see which catheter provides the best image quality.
9843979|NCT02943447|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
9843980|NCT02943447|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.
9843981|NCT02943447|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
9843982|NCT02943447|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.
9843983|NCT02943460|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks
9843984|NCT02943460|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks
9843985|NCT02943460|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks
9843986|NCT02943460|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.
9843987|NCT02943473|Experimental|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
9922452|NCT00839488|Active Comparator|II|famotidine 20 mg q12h
9998285|NCT01516723|Active Comparator|Everolimus-eluting stents|XIENCE PRIME, Abbott
9843988|NCT02943499|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
9843989|NCT02943499|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
9843990|NCT02943564|Experimental|Rapastinel 225 mg|Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
9843991|NCT02943564|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
9843992|NCT02943564|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
9843993|NCT02943577|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
9843994|NCT02943577|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
9843995|NCT02943668|Experimental|Treatment (deferasirox)|Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
9843996|NCT02943941|Other|All participants|All participants enrolled in a single arm to evaluate effect of variables (posture, respiration, exertion) on pulmonary artery pressure (PAP)
9843997|NCT02944383|Experimental|Gemcabene 300 mg|Participants received 300 mg Gemcabene orally, once daily for 12 weeks.
9843998|NCT02944383|Experimental|Gemcabene 600 mg|Participants received 600 mg Gemcabene orally, once daily for 12 weeks.
9843999|NCT02944383|Placebo Comparator|Placebo|Participants received matching placebo orally, once daily for 12 weeks.
9844000|NCT02944448|Active Comparator|CR845 tablet 1 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
9844001|NCT02944448|Active Comparator|CR845 tablet 2.5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
9844002|NCT02944448|Active Comparator|CR845 tablet 5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
9844003|NCT02944448|Placebo Comparator|Placebo tablet|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
9844004|NCT02944461|Experimental|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
9844005|NCT02944565|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
9844006|NCT02944656|Experimental|Gabapentin group|This group will receive local anesthesia per clinic protocol plus Gabapentin 600mg 1-2 hours preoperatively.
9844007|NCT02944656|Placebo Comparator|Placebo group|This group will receive local anesthesia per clinic protocol plus placebo 1-2 hours preoperatively.
9844008|NCT02944968|Experimental|Treatment group|Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
9844009|NCT02945046|Placebo Comparator|Placebo|Participants will receive placebo administered via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injection at Weeks 4 and 8, respectively.
9844010|NCT02945046|Experimental|Fremanezumab 675 mg/Placebo/Placebo|Participants will receive placebo as an approximately 1-hour intravenous infusion followed by fremanezumab at 675 milligrams (mg) administered as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 and placebo administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
9844011|NCT02945046|Experimental|Fremanezumab 900/225/225 mg|Participants will receive fremanezumab at 900 mg administered via an approximately 1-hour intravenous infusion followed by 3 placebo subcutaneous injections at Week 0 and fremanezumab at 225 mg administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
9922453|NCT00839501|Experimental|1|Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.
9516990|NCT03310463|Experimental|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR <30 mL/min/1.73 m^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
9516991|NCT03310463|Experimental|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
9516992|NCT03310437||Primary PCI|In primary PCI we use arterial sheath , wires ,heparin ,intracoronary stents
9844012|NCT02945150|Experimental|Elbasvir/grazoprevir for HCV+ kidney transplant recipients|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
9844013|NCT02945254|Active Comparator|Background noise|Overnight sleep study with filtered white noise
9844014|NCT02945254|No Intervention|Silence|Overnight sleep study with normal environmental noise
9844015|NCT02945410|Experimental|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
9844016|NCT02945410|Active Comparator|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
9844017|NCT02945410|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
9844018|NCT02945553|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
9844019|NCT02945553|Active Comparator|Microstimulation|Microstimulation
9844020|NCT02945657|Experimental|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
9844021|NCT02946021|Experimental|Pneumatic Compression-1 session per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
9844022|NCT02946021|Experimental|Pneumatic Compression-2 sessions per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
9844023|NCT02946034|Experimental|Viekira Pak ± ribavirin or Mavyret|"12 week therapy with Viekira Pak ± ribavirin~8 or 12 week therapy with Mavyret"
9844024|NCT02946073|Placebo Comparator|Placebo|CAM2038 placebo injections
9844025|NCT02946073|Experimental|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
9844026|NCT02946229|Other|MHD Population Ultrasound|Eligible subjects in a convenience population at the site (Maintenance Hemodialysis, MHD) incidentally undergoingnon-invasive cardiac, pulmonary, and abdominal ultrasound scanning on the commercially available GE Vivid S70 system for use in testing feasibility of new algorithms for processing this data.
9844027|NCT02946385|Experimental|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
9844028|NCT02946385|Experimental|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
9844029|NCT02946385|Experimental|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
9844030|NCT02946385|Experimental|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
9844031|NCT02946385|Active Comparator|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study
9844032|NCT02946385|Active Comparator|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study
9844033|NCT02946463|Experimental|Ravulizumab|"Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligram (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
9844034|NCT02946463|Active Comparator|Eculizumab|"Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
9844035|NCT02946489|Experimental|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
9844036|NCT02946515|Experimental|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
9844037|NCT02946515|Experimental|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
9516993|NCT03310437||Thrombolytic|In patients recieving thrombolytics they continue on LWMH for 72h ,plus aspirin , clopedogril , BB, statins
9516994|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
9516995|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
9516996|NCT03310385|Experimental|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
9516997|NCT03310385|Experimental|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
9844038|NCT02946580|Experimental|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
9844039|NCT02946580|Placebo Comparator|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
9844040|NCT02946892|Experimental|Carvedilol|Study participants will receive carvedilol for 12 weeks
9844041|NCT02946892|Experimental|Placebo|Study participants will receive placebo (sugar pill) for 12 weeks
9844042|NCT02946918|Experimental|Tablets|Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)
9844043|NCT02946918|Experimental|Gelcaps|Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)
9844044|NCT02947984|Experimental|Standard Treatment|Standard radiation therapy: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week.
9844045|NCT02947984|Experimental|Higher Dose Treatment|63 CGE in 35 treatments of 1.8 CGE given once a day, for five days of each week.
9844046|NCT02947997||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
9844047|NCT02948426|Experimental|Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml)|Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
9844048|NCT02948426|Experimental|Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
9844049|NCT02948426|Experimental|Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
9844050|NCT02948426|Experimental|Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml)|Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
9844051|NCT02948426|Experimental|EX1 Dose Expansion Arm|10 additional patients will be treated at the maximum tolerated dose (MTD)
9844052|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
9844053|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
9844054|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
9844055|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
9844056|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
9844057|NCT02948582|Placebo Comparator|Placebo 0.5mL|Placebo 0.5mL via e-flow nebulizer, once daily
9844058|NCT02948634|Sham Comparator|Sham Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
9844059|NCT02948634|Active Comparator|Active Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
9922454|NCT00839566|Experimental|AV ablation|
9922455|NCT00839566|Active Comparator|Rate control|Rate control by drugs
9922456|NCT00839566|No Intervention|Sinus rhythm|
9922457|NCT00839579|Experimental|4x4min|4x4minutes interval group
9922458|NCT00839579|Experimental|1x4min|
9935803|NCT03198351||"Registry group (not eligible for cohorts)"|Women who contact the OTIS registry study staff and who do not meet the criteria for the prospective study, for example, at time of contacting the study, having known prenatal diagnosis of congenital defect, or gestation weeks greater than 20 following a first trimester teriflunomide exposure, etc.; these participants will not be included in the primary analysis for the cohort study.
9844060|NCT02948777|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
9844061|NCT02948829|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
9844062|NCT02949011|Experimental|Baloxavir Marboxil|Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
9844063|NCT02949011|Active Comparator|Oseltamivir|Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
9844064|NCT02949011|Placebo Comparator|Placebo|Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
9844065|NCT02949024|Experimental|TX Naïve Arm|Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
9844066|NCT02949024|Experimental|Previous TX Arm|Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
9844067|NCT02949141|Experimental|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
9844068|NCT02949219|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9844069|NCT02949271|Active Comparator|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
9844070|NCT02949271|Active Comparator|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
9844071|NCT02949362|Experimental|Standard of Care (SOC) Treatment +/- Teduglutide|TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
9844072|NCT02949518|Experimental|Enhanced Recovery Pathway for Spine|
9844073|NCT02949518|No Intervention|Usual Care|
9844074|NCT02949674|Experimental|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
9844075|NCT02949674|Experimental|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
9844076|NCT02949674|No Intervention|Control|No application of anesthetic
9844077|NCT02949908||Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)|
9844078|NCT02949921|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
9844079|NCT02949921|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
9844080|NCT02949973|Experimental|Voclosporin|Voclosporin, oral, 23.7 mg twice daily (BID)
9844081|NCT02950025|Active Comparator|Online non-adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
9844082|NCT02950025|Experimental|Arm B: Online-Adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
9844083|NCT02950467|Experimental|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.
9844084|NCT02950545|Experimental|Placebo, Spherical, then Toric Lenses|Crossover order 1
9844085|NCT02950545|Experimental|Placebo, Toric, then Spherical Lenses|Crossover order 2
9844086|NCT02950545|Experimental|Spherical, Placebo, then Toric Lenses|Crossover order 3
10207184|NCT02629159|Experimental|Upadacitinib|"Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
10207185|NCT02611232|Active Comparator|Victoza®|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
9844087|NCT02950545|Experimental|Spherical, Toric, then Placebo Lenses|Crossover order 4
9844088|NCT02950545|Experimental|Toric, Placebo, then Spherical Lenses|Crossover order 5
9844089|NCT02950545|Experimental|Toric, Spherical, then Placebo Lenses|Crossover order 6
9844090|NCT02950558|Active Comparator|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
9844091|NCT02950558|Experimental|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
9844092|NCT02950753|Experimental|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
9844093|NCT02950753|Placebo Comparator|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
9844094|NCT02950831|Experimental|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
9844095|NCT02951143|Experimental|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
9844096|NCT02951143|Experimental|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
9844097|NCT02951143|Experimental|1.3 mg/g Concentration|Participants in this arm will experience the 1.3 mg/g Concentration
9844098|NCT02951143|Experimental|2.4 mg/g Concentration|Participants in this arm will experience the 2.4 mg/g Concentration
9844099|NCT02951143|Experimental|5.2 mg/g Concentration|Participants in this arm will experience the 5.2 mg/g Concentration
9844100|NCT02951143|Experimental|15.8 mg/g Concentration|Participants in this arm will experience the 15.8 mg/g Concentration
9844101|NCT02951156|Experimental|Phase 1b Arm A|avelumab/utomilumab/rituximab
9844102|NCT02951156|Experimental|Phase 1b Arm B|avelumab/utomilumab/azacitidine
9844103|NCT02951156|Experimental|Phase 1b Arm C|avelumab/rituximab/bendamustine
9844104|NCT02951156|Experimental|Phase 3 Arm D (selected from Phase 1b)|Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
10207186|NCT02611232|Placebo Comparator|Placebo|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
10207187|NCT02604433|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Luspatercept, subcutaneous(ly) (SC) once every 21 days
9844105|NCT02951156|Active Comparator|Phase 3 Arm E|Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
9844106|NCT02951182|Placebo Comparator|Part 1: Placebo - Cohort 1A and 1B Combined|Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
9844107|NCT02951182|Experimental|Part 1 Cohort 1A: Triple Combination (TC)|Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
9844108|NCT02951182|Experimental|Part 1 Cohort 1B: TC Low Dose|Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
9844109|NCT02951182|Experimental|Part 1 Cohort 1B: TC High Dose|Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
9844110|NCT02951182|Active Comparator|Part 2: TEZ/IVA|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
9844111|NCT02951182|Experimental|Part 2: TC-2|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
9844112|NCT02951195|Placebo Comparator|Part 1: Placebo|
9844113|NCT02951195|Experimental|Part 1 Cohort 1A: TC|
9844114|NCT02951195|Experimental|Part 1 Cohort 1B: TC|
9844115|NCT02951195|Experimental|Part 1 Cohort 1C: TC|
9844116|NCT02951195|Active Comparator|Part 2 Cohort 2A: TEZ/IVA|
10207188|NCT02604433|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
9844117|NCT02951195|Experimental|Part 2 Cohort 2A: TC|
9844118|NCT02951195|Active Comparator|Part 2 Cohort 2B: TEZ/IVA|
9844119|NCT02951195|Experimental|Part 2 Cohort 2B: TC|
9844120|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
9844121|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
9844122|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
9844123|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
9844124|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
9844125|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
9844126|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
9844127|NCT02951312|Placebo Comparator|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
9844128|NCT02951351|Active Comparator|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection will then proceed.
9844129|NCT02951351|Experimental|Proparacaine + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
9844130|NCT02951429|Placebo Comparator|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
9844131|NCT02951429|Experimental|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
9844132|NCT02951533|Experimental|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
9844133|NCT02951533|Active Comparator|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
9844134|NCT02951702|No Intervention|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
9844135|NCT02951702|Experimental|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
9844136|NCT02951780|Experimental|LY3185643|LY3185643 administered subcutaneous (SC)
9844137|NCT02951780|Experimental|rGlucagon|rGlucagon administered subcutaneous (SC)
9844138|NCT02951819|Experimental|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
9844139|NCT02951884|Experimental|Aspiration|Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
9844140|NCT02951884|Experimental|Aspiration with injection|Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
9844141|NCT02951884|No Intervention|Control|Participants assigned to this arm receive no injection or aspiration therapy.
9844142|NCT02951988|Experimental|Rapastinel 450 mg Weekly|Rapastinel 450 milligrams (mg) intravenous (IV) once a week during OLTP followed by rapastinel 450 mg IV once a week during DBTP.
9844143|NCT02951988|Experimental|Rapastinel 450 mg Every 2 Weeks|Rapastinel 450 mg IV once a week during OLTP followed by rapastinel 450 mg IV once every 2 weeks during DBTP.
9844144|NCT02951988|Placebo Comparator|Placebo|Rapastinel 450 mg IV once a week during OLTP followed by placebo-matching rapastinel 450 mg IV once a week during DBTP.
9844145|NCT02952001||4 mg CLS-TA Suprachoriodal Injection|Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
9844146|NCT02952001||Sham procedure|Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
9844147|NCT02952261|Other|CT-guided localization|This group of participants received conventional CT-guided lung nodule localization.
9844148|NCT02952261|Experimental|template-guided localization|Three-dimensional printed template was customized based on participant's computed tomography information. Participants received template-guided lung nodule localization.
9844149|NCT02952313|Other|Latera Implant|All participants have unilateral or bilateral placement of LATERA Nasal Implants.
9844150|NCT02952586|Experimental|Avelumab + SOC Chemoradiation Therapy|"Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
9935804|NCT03190967|Experimental|1 / Phase I|T-DM1 + TMZ in dose escalation
9935805|NCT03190967|Active Comparator|2A / Phase II / T-DM1 alone|T-DM1
9844151|NCT02952586|Placebo Comparator|Placebo + SOC CRT|"Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
9844152|NCT02952820|Experimental|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
9844153|NCT02952820|Experimental|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
9844154|NCT02952820|Placebo Comparator|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
9844155|NCT02952872|Experimental|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
9844156|NCT02952872|Experimental|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
9844157|NCT02952872|Experimental|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
9844158|NCT02952872|Experimental|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
9844159|NCT02952872|Experimental|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
9844160|NCT02952872|Experimental|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
9844161|NCT02952872|Experimental|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
9844162|NCT02952872|Experimental|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
9844163|NCT02952872|Experimental|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
9844164|NCT02952872|Experimental|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
9844165|NCT02952872|Experimental|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
9844166|NCT02952872|Experimental|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
9844167|NCT02952872|Experimental|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
9844168|NCT02952872|Experimental|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
9844169|NCT02952872|Experimental|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
9844170|NCT02952872|Experimental|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
9844171|NCT02952898|Experimental|Test Drug|GDC 695 gel applied topically as directed.
9844172|NCT02952898|Active Comparator|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
9844173|NCT02952898|Placebo Comparator|Placebo|Vehicle gel applied topically as directed.
9844174|NCT02953262|Experimental|Encouragement Arm 1|Participants in this encouragement condition will receive a mailed brochure with basic My HealtheVet content and a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
9844175|NCT02953262|Experimental|Encouragement Arm 2|Participants in this encouragement condition will receive the same brochure and training guide as Arm 1 but will also be offered optional attendance at one of several group training sessions.
9844176|NCT02953262|Experimental|Encouragement Arm 3|Participants in this encouragement condition will receive the same as in Arm 2 (brochure, training guide, and group training offer) but will also be offered a one-on-one My HealtheVet training session.
9844177|NCT02953262|Other|Brochure Only Comparison Arm|The Comparison condition will only receive a mailed brochure with basic My HealtheVet content during the trial. (The training guide will be mailed to them after completion of the interview at the end.)
10207189|NCT02598895|Experimental|Treatment (docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
9844178|NCT02953314|Experimental|Part A|"Participants weighing <25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days.~Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days."
9844179|NCT02953314|Experimental|Part B|"Participants weighing <40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks.~Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks."
9844180|NCT02953418|Experimental|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
9844181|NCT02953548|Experimental|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
9844182|NCT02953561|Experimental|Treatment (azacitidine, avelumab)|Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9844183|NCT02953639|Placebo Comparator|Placebo|Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks.
9844184|NCT02953639|Experimental|Basmisanil 80mg BID|Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
9844185|NCT02953639|Experimental|Basmisanil 240mg BID|Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
9844186|NCT02953678|Experimental|Ruxolitinib in combination with corticosteroids|Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
9844187|NCT02953782|Experimental|Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by intravenous (IV) infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented progressive disease (PD).
9922459|NCT00839592|Experimental|Electroacupuncture|"Acupoints will be treated at bilateral Ear Shenmen, Sishencong (EX-HN1), Anmian, and unilateral Yintang (EX-HN3) and Baihui (GV20).~Acupuncture will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) will be connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
10207190|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
10207191|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.
10207192|NCT02582775|Experimental|Arm C: Re-Transplant with 300 cGy of TBI|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
10207193|NCT02582775|Experimental|Arm D: HCT with 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
9516998|NCT03310385|Placebo Comparator|Placebo control|4 tablets of the placebo, three times daily for 7 days
9844188|NCT02953782|Experimental|Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
9844189|NCT02953782|Experimental|Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
9844190|NCT02953782|Experimental|Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both were given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
9935073|NCT04230278|Active Comparator|Movement, Orientation, Repetition, and Exercise (MORE-PT) - Usual Care Physical Therapy|This intervention was based on the observations of usual care from a previous study. Key principles included the use of Movement, Orientation, Repetition, and Exercise thus the intervention name was changed to MORE-PT before enrollment started. This reduced bias as the therapists and families were not informed this was usual care which could have biased them.
10207194|NCT02582775|Experimental|Arm E: HCT plus MSC, 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)
10207195|NCT02582775|Experimental|Arm F: HCT Alone, 200 cGy BID of TBI|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
9935806|NCT03190967|Experimental|2B / Phase II / T-DM1 + TMZ|T-DM1 + TMZ at RP2D
9935807|NCT03190954|Placebo Comparator|[11C]NNC-112|[11C]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
10207196|NCT02582775|Experimental|Arm G: HCT plus MSC, 200 cGy|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
10207197|NCT02570542|Active Comparator|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
10207198|NCT02570542|Experimental|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
10207199|NCT02565199|Experimental|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
10207200|NCT02565199|Experimental|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
10213465|NCT03932461|Active Comparator|"Relaparotomy on-demand"|"The Isreaelsson principle includes a running suture of the fascia with a distance of 5 mm between the stitches of 5 mm and the distance to the facial edge of 5-10 mm. Monofilament PDS 2-0 or equivalent is used. The suturing is started cranially and caudally, and the sutures are tied with self-locking knots. Four times as much suture material as the length of the wound must be used. The peritoneal fluid must be cultured at closure.~The treating surgeon decides to perform a ROD and should be guided by the patient's general condition, gastrointestinal function, renal function, and inflammatory parameters at daily rounds."
10213466|NCT03926299|Experimental|Laser|dual Fotona laser treatment (Nd:YAG and Er:YAG)
10213467|NCT03926299|Active Comparator|Topical steroid|clobetasol propionate 0.05% cream
10213468|NCT03925324|Experimental|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.
10213469|NCT03925324|Placebo Comparator|Placebo|Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.
10207201|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
10207202|NCT02550652|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
10207203|NCT02550652|Placebo Comparator|Placebo|Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
9844191|NCT02953782|Experimental|Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
10207204|NCT02544503|Experimental|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
9844192|NCT02953782|Experimental|Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced colorectal cancer (CRC) who are KRAS wild type (KRASwt) and are refractory to anti-EGFRmAb therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
9844193|NCT02953782|Experimental|Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRAS mutation (KRASm) who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
9922460|NCT00839592|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the same acupoints as stated in the electroacupuncture group. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
9922461|NCT00839605||Dexmedetomidine|Those requiring thoracic surgery and receiving dex
9922462|NCT00839605||placebo|Group having thoracic surgery and not receiving dex drug
10207205|NCT02544503|Active Comparator|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
10207206|NCT02537418|Experimental|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
10207207|NCT02519738|Active Comparator|Silver Nitrate|Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
10213470|NCT03923374||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 200 pregnant (<16weeks) mothers who have opioid use disorder and are taking buprenorphine
10213471|NCT03923374||Pregnant Mothers|Planned recruitment of 100 pregnant (>16weeks) mothers who do not have any history of opioid use disorder.
10213472|NCT03919162|Experimental|600 mg|First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID
10213473|NCT03919162|Experimental|300 mg|First 4 weeks 150 mg BID, week 5-24 300 mg BID
9844194|NCT02953782|Experimental|Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRASm who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approx. 3 hours) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approx. 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
9844195|NCT02953821|Experimental|Acthar Gel|Participants receive Acthar Gel every other day for 4 weeks, and then twice per week for 20 weeks
9844196|NCT02953821|Placebo Comparator|Placebo Gel|Participants receive Placebo Gel every other day for 4 weeks, and then twice per week for 20 weeks
9844197|NCT02953860|Experimental|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
9844198|NCT02953873|Other|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
9844199|NCT02953886|Experimental|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
9844200|NCT02953938|Active Comparator|mono therapy|ranibizumab alone
9844201|NCT02953938|Experimental|combination therapy|ranibizumab with Grid&Direct short pulse laser photocoagulation
9844202|NCT02954172|Experimental|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
9844203|NCT02954172|Active Comparator|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
9844204|NCT02954198|Active Comparator|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
9844205|NCT02954198|Active Comparator|Envarsus + Everolimus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
9844206|NCT02954354|Experimental|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
9844207|NCT02954354|Active Comparator|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
9844208|NCT02954354|Placebo Comparator|Adults: Placebo|Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
9844209|NCT02954354|Experimental|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
9844210|NCT02954354|Placebo Comparator|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
9844211|NCT02954458|Experimental|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
9844212|NCT02954575|Experimental|All patients|All patients will receive Wilate for prophylactic treatment
9844213|NCT02954601|Active Comparator|Placebo|Placebo (fish oil)
9844214|NCT02954601|Active Comparator|Dose1|Dose 1 ORMD-0801 (qd)
9844215|NCT02954601|Active Comparator|Dose2|Dose 2 ORMD-0801 (bid)
9844216|NCT02954601|Active Comparator|Dose 3|Dose 3 ORMD-0801 (tid)
9844217|NCT02954653|Experimental|Dose Escalation|Single agent PF-06747143 dose escalation
9844218|NCT02954653|Active Comparator|Cohort 1|PF-06747143 with standard dose cytarabine and daunorubicin.
9844219|NCT02954653|Active Comparator|Cohort 2|PF-06747143 in combination with Azacitidine or Decitabine.
9844220|NCT02954653|Experimental|Cohort 3|PF-06747143 dose expansion as a single agent.
9844221|NCT02954848|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
9844222|NCT02954848|Experimental|TAK-438 10 mg|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
9844223|NCT02954887|Experimental|GWP42003-P|"Administered orally, up to the target dose recommended by the data safety monitoring committee.~Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment."
9922463|NCT00839644|Active Comparator|2|
9922464|NCT00839644|Active Comparator|3|
9844224|NCT02955069|Experimental|PDR001|Subjects with advanced or metastatic, well-differentiated, NET of pancreatic, GI, or thoracic origin or poorly-differentiated GEP-NEC, that have progressed on prior treatment were treated with 400mg PDR001 administered via intravenous infusion once every 4 weeks.
9844225|NCT02955147|Experimental|Ustekinumab plus prednisone|"Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.~Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
9844226|NCT02955186|Experimental|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
9844227|NCT02955186|Placebo Comparator|Placebo|Participants will take placebo daily for 8 days.
9844228|NCT02955212|Placebo Comparator|Placebo / Upadacitinib 15 mg|Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
9844229|NCT02955212|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
9844230|NCT02955329|Experimental|Tobacco Arm|Participants will vape tobacco leaves with nicotine out of the PAX device.
9844231|NCT02955329|Experimental|Cannabis Arm|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
9844232|NCT02955329|Experimental|Combined Cannabis and Tobacco Arm|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
9844233|NCT02956044|Active Comparator|Group 1: Bexagliflozin alone|
9844234|NCT02956044|Active Comparator|Group 1: Metformin alone|
9844235|NCT02956044|Active Comparator|Group 1: Bexagliflozin + Metformin|
9844236|NCT02956044|Active Comparator|Group 2: Bexagliflozin alone|
9844237|NCT02956044|Active Comparator|Group 2: Glimepiride alone|
9844238|NCT02956044|Active Comparator|Group 2: Bexagliflozin + Glimepiride|
9844239|NCT02956044|Active Comparator|Group 3: Bexagliflozin alone|
9844240|NCT02956044|Active Comparator|Group 3: Sitagliptin alone|
9844241|NCT02956044|Active Comparator|Group 3: Bexagliflozin + Sitagliptin|
9844242|NCT02956057|Active Comparator|PEG1D|Polyethylene glycols single dose a day before colonoscopy
9516999|NCT03310372|Experimental|ultrafractionated brain irradiation - temozolomide|
9844243|NCT02956057|Active Comparator|PEG2D|Polyethylene glycols split dose
9844244|NCT02956057|Active Comparator|SPMC1D|Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy
9844245|NCT02956057|Active Comparator|SPMC2D|Natrium picosulfate/ Magnesium citrate split dose
9844246|NCT02956057|Active Comparator|PEGA1D|Polyethylene glycol / Ascorbic acid single dose day before colonoscopy
9844247|NCT02956057|Active Comparator|PEGA2D|Polyethylene glycol / Ascorbic acid split dose
9844248|NCT02956070|Experimental|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
9844249|NCT02956070|Placebo Comparator|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
9844250|NCT02956122|Experimental|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
9844251|NCT02956122|Experimental|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
9844252|NCT02956122|Placebo Comparator|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
9844253|NCT02956278|Placebo Comparator|BCRP Q141K CC|Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.
9922465|NCT00839644|Active Comparator|1|
9844254|NCT02956278|Experimental|BCRP Q141K CA|Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.
9844255|NCT02956278|Experimental|BCRP Q141K AA|Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.
9844256|NCT02956460|Active Comparator|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
9844257|NCT02956460|Active Comparator|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
9844258|NCT02956486|Experimental|Core Study: Elenbecestat 50 mg|Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.
9844259|NCT02956486|Placebo Comparator|Core Study: Placebo|Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.
9844260|NCT02956486|Experimental|Open-label Extension Phase: Elenbecestat 50 mg|Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.
9844261|NCT02956616|Experimental|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
9844262|NCT02956616|Active Comparator|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
9844263|NCT02956629|Experimental|HCV GT1|Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
9844264|NCT02956629|Experimental|HCV GT2|Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
9844265|NCT02956629|Experimental|HCV GT3|Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
9844266|NCT02956629|Experimental|HCV GT4|Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
9844267|NCT02956629|Experimental|HCV GT5|Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
9844268|NCT02956629|Experimental|HCV GT6|Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
9844269|NCT02956746|Experimental|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
9844270|NCT02956746|Active Comparator|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
9844271|NCT02956746|Experimental|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
9844272|NCT02956746|Active Comparator|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
9844273|NCT02956837|Experimental|GSK3003891A vaccine formulation 1 Group|Subjects in this group received a single 30 micrograms (µg) dose injection of the investigational GSK3003891A vaccine at Day 0.
9844274|NCT02956837|Experimental|GSK3003891A vaccine formulation 2 Group|Subjects in this group received a single 60µg dose injection of the investigational GSK3003891A vaccine at Day 0.
9844275|NCT02956837|Experimental|GSK3003891A vaccine formulation 3 Group|Subjects in this group received a single 120µg dose injection of the investigational GSK3003891A vaccine at Day 0.
9844276|NCT02956837|Placebo Comparator|Control Group|Subjects in this group received a single placebo injection at Day 0.
9844277|NCT02956967||Patients receiving Nivestim|
9844278|NCT02957123|Experimental|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.~30 patients with organic brain syndrome will receive auto-M2-BFs with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days."
9844279|NCT02957136|Experimental|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
9844280|NCT02957136|No Intervention|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
9922466|NCT00839657|Experimental|1|Genotype-guided dosing algorithm for warfarin
9922467|NCT00839657|Active Comparator|2|Clinical-guided dosing algorithm for warfarin
9844281|NCT02957305|Active Comparator|Misoprostol 400 µg|Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
9844282|NCT02957305|Experimental|Misoprostol 200 µg|Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.
9844283|NCT02957331|Experimental|Propranolol arm|One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic <100) or bradycardia (heart rate <60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.
9844284|NCT02957331|No Intervention|Non propranolol arm|Non beta blockade arm will receive standard of care treatment and will not receive beta blockade. If a subject randomized to no Inderal develops hypertension and increased heart rate, he/she will be treated according to standard of care by the trauma team caring for the patient.
9844285|NCT02957357||National Cancer Data Base|Patients within the National Cancer Database with newly diagnosed prostate cancer between 2004 and 2010. Participating institutions each provided a random of sample of 10 patients to be included in the final cohort.
9844286|NCT02957357||NC ProCESS|The North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) is a prospective population-based cohort of >1,000 patients with newly diagnosed prostate cancer, enrolled from January 2011 through June 2013.
9844287|NCT02957682|Experimental|Group 1|Praluent Regimen - Administration through subcutaneous injection
9844288|NCT02957682|Experimental|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
9844289|NCT02957747|Experimental|Safety and Health Experiences Program|Participants in the SHE arm of the study will receive a web-based intervention utilizing motivational interviewing and education.
9844290|NCT02957747|No Intervention|Control|Participants randomized to this arm will receive referrals to VA and community resources
9844291|NCT02957942|Experimental|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
9844292|NCT02957942|Active Comparator|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
9844293|NCT02958267|Experimental|BMAC injection and PRP injection|Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.
9844294|NCT02958267|Active Comparator|Gel-One® hyaluronate injection|Gel-One® is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular).
9844295|NCT02958345|Active Comparator|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
9844296|NCT02958345|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
9844297|NCT02958527||venlafaxine|Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first
9844298|NCT02958553|Other|emPOWER Ankle (powered prosthesis)|The subject's own passive prosthesis will be used as a baseline and crossed over after the emPOWER has been worn 3-4 months. Then the passive foot will be crossed back to the emPOWER for a final series of tests.
9844299|NCT02958787|Experimental|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
9844300|NCT02958826||No Smoke Evacuation|No Smoke Evacuation Group, anonymous questionnaire administered
9844301|NCT02958826||Smoke Evacuation|Smoke Evacuation Group, anonymous questionnaire administered
9844302|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
9844303|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
9844304|NCT02958969|Experimental|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
9844305|NCT02958982|Experimental|RP3128|RP3128, A CRAC channel modulator
9844306|NCT02958982|Placebo Comparator|Placebo|Placebo
9844307|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
9844308|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
9844309|NCT02959138|Experimental|Moderate Renal Impairment (Cohort 1)|Participants with moderate renal impairment and matched healthy controls will receive a single dose of lanraplenib
9844310|NCT02959138|Experimental|Severe Renal Impairment (Adaptive Cohort 2)|Participants with severe renal impairment and matched healthy controls will receive a single dose of lanraplenib
9844311|NCT02959138|Experimental|Mild Renal Impairment (Adaptive Cohort 3)|Participants with mild renal impairment and matched healthy controls will receive a single dose of lanraplenib
9844312|NCT02959177|Experimental|120 milligrams (mg) Galcanezumab|120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
9844313|NCT02959177|Experimental|240 mg Galcanezumab|120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
9844314|NCT02959177|Placebo Comparator|Placebo|Placebo administered SC once a month for 6 months.
9844315|NCT02959190|Experimental|120mg/120mg Galcanezumab - Episodic Migraine (EM)|240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
9844316|NCT02959190|Experimental|240mg/240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
9844317|NCT02959190|Experimental|Placebo/ 120mg Galcanezumab - EM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
9844318|NCT02959190|Experimental|Placebo/ 240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
9844319|NCT02959190|Experimental|120mg Galcanezumab - CM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
9844320|NCT02959190|Experimental|240mg Galcanezumab - CM|240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.
9922468|NCT00839670|Active Comparator|Modified Therapy|
9922469|NCT00839670|Active Comparator|Standard Therapy|
9922470|NCT00839683|Active Comparator|simvastatin|
9922471|NCT00839683|Active Comparator|Dapagliflozin + simvastatin|
9922472|NCT00839683|Active Comparator|Dapagliflozin|
9922473|NCT00839683|Active Comparator|valsartan|
9922474|NCT00839683|Active Comparator|Dapagliflozin + valsartan|
9922475|NCT00839709||depletion immunosuppression|
9922476|NCT00839709||no depletion immunosuppression|
9922477|NCT00839722|Experimental|1|fertility after embolization
9922478|NCT00839735||COPD|Chronic obstructive pulmonary disease
9922479|NCT00839735||Asthma|
9922480|NCT00839735||Healthy controls|
9922481|NCT00839748||asthmatics|asthmatics registry for those interested in future asthma studies
9922482|NCT00839761|Experimental|iron fortified rice group|
9922483|NCT00839761|Placebo Comparator|iron drop group|
9922484|NCT00839774|Experimental|1|Whole yellow pea flour
9922485|NCT00839774|Experimental|2|Fractionated yellow pea flour
9922486|NCT00839774|Experimental|3|White wheat flour
9922487|NCT00839787|Experimental|Morphine|Morphine Sulfate: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given.
9922488|NCT00839787|Placebo Comparator|Placebo|Normal saline
9922489|NCT00839813|Experimental|Yoga|10 week trauma-sensitive yoga classes
9922490|NCT00839813|No Intervention|Women's Health Education|10 weeks of women's health education classes as an attentional control group
9922491|NCT00839826|Active Comparator|Arm 2|
9922492|NCT00839826|Experimental|Arm 1|
9922493|NCT00839839|Experimental|Oocyte Vitrification|
9922494|NCT00839865|Experimental|herb ointment dressing change group|This group of patients in the ointment dressing every 2 days until Wound Healing or 6 months
9922495|NCT00839865|No Intervention|Conventional dressing change group|This group of patients in the Conventional dressing every 2 days until Wound Healing or 6 months
9922496|NCT00839878||A|
9922497|NCT00839891|Placebo Comparator|3|"Group 1: 56 subjects to receive active study drug (VI-0521) at steady state, PHEN/TPM 7.5/46 (a potential therapeutic dose), escalating to PHEN/TPM 22.5/138 (a supra-therapeutic dose);~Group 2: 28 subjects to receive placebo preceded by a single oral dose of moxifloxacin on Day 2;~Group 3: 28 subjects to receive placebo followed by a single oral dose of moxifloxacin on Day 24;"
9922498|NCT00839904|Experimental|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
9922499|NCT00839904|No Intervention|control|no intervention
9922500|NCT00839943|Active Comparator|ozone|obese vs non-obese women
9922501|NCT00839943|Active Comparator|air|obese vs non obese women
9922502|NCT00839969|Sham Comparator|Cystoscopy alone|Women in this arm will undergo saline cystoscopy under general anaesthesia only.
9922503|NCT00839969|Active Comparator|Cystoscopy and urethral dilatation|Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
9922504|NCT00839995||Patients undergoing multi-level spine surgery|
9922505|NCT00840008|Experimental|Educational intervention|see protocol
9922506|NCT00840008|No Intervention|Standard care|distribution of guidelines and a published algorithm
9922507|NCT00840047|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive methionine.
9922508|NCT00840112|Experimental|LCHAD/TFP with peripheral neuropathy|Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy
9922509|NCT00840125|Experimental|1|docetaxel + erlotinib
9844321|NCT02959307|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
9844322|NCT02959307|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
9844323|NCT02959437|Experimental|Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
9844324|NCT02959437|Experimental|Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
9844325|NCT02959437|Experimental|Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
9844326|NCT02959671|Experimental|Lower Anterior EXD-952 Self-ligating Brackets|
9844327|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
9844328|NCT02959840|No Intervention|Control|No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
9844329|NCT02959840|Active Comparator|Metoclopramide, Ondansetron|10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
9844330|NCT02959840|Experimental|Acupressure Point P6 stimulator|Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
9844331|NCT02959853|Placebo Comparator|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
9844332|NCT02959853|Experimental|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
9844333|NCT02959866|Experimental|Online income tool|Patients who complete the online income tool with their health provider during the study period.
9844334|NCT02959892|Experimental|TAK-041 20 mg|[11C] PHNO 180 megabecquerel (MBq), injection, intravenously, prior to positron emission tomography (PET) scan on Day 1, followed by amphetamine (AMPH) 0.5 milligram per kilogram (mg/kg), tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 20 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
9844335|NCT02959892|Experimental|TAK-041 40 mg|[11C] PHNO 180 MBq, injection, intravenously, prior to PET scan on Day 1, followed by AMPH 0.5 mg/kg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 40 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
9844336|NCT02959970|Experimental|PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
9844337|NCT02959970|Experimental|Non-PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
9844338|NCT02959983|Active Comparator|Eluxadoline|Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
9844339|NCT02959983|Placebo Comparator|Placebo|Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
9844340|NCT02959996|Placebo Comparator|Placebo|Normal saline will be infiltrated
9844341|NCT02959996|Active Comparator|Intervention|Liposomal bupivacaine will be infiltrated
9844342|NCT02960217|Experimental|Double-Blind UX007 Followed by Placebo|"Participants will first receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks. After a washout period of 2 weeks, they will then receive placebo for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
9844343|NCT02960217|Experimental|Double Blind Placebo Followed by UX007|"Participants will first receive Placebo for 10 weeks. After a washout period of 2 weeks, they will then receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
9844344|NCT02960295|Experimental|Virtual visit|"Self-monitoring of blood glucose (four times daily).~Self-weighing (weekly).~Self-checking of blood pressure (weekly).~Checking fetal heart rate (weekly).~Visits with caregivers."
9844345|NCT02960438|Experimental|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
9922510|NCT00840138||1|Patients with common bile duct injury after open cholecystectomy
9844346|NCT02960438|Experimental|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
9844347|NCT02960438|Experimental|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
9844348|NCT02960438|Placebo Comparator|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
9844349|NCT02960490|Experimental|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
9844350|NCT02960490|Experimental|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
9844351|NCT02960490|Experimental|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
9844352|NCT02960490|Experimental|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
9844353|NCT02960854|Experimental|Nivolumab 1|Dose 1
9844354|NCT02960854|Experimental|Nivolumab 2|Dose 2
9986318|NCT01401569|Experimental|physical activity program|Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.
9986319|NCT01401608||Treatment|Ablation of VT/PVCs using a magnetic RF ablation catheter
9844357|NCT02961062|Experimental|Treatment Sequence 1|
9844358|NCT02961062|Placebo Comparator|Treatment Sequence 2|
9844359|NCT02961218|Placebo Comparator|Placebo|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
9844360|NCT02961218|Experimental|ACZ885|Monthly doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
9844361|NCT02961244|No Intervention|Control Group|Perioperative management and warming was not performed according to a standard normothermia protocol, with our clinic's traditional methods except prewarming.
9844362|NCT02961244|Active Comparator|Intervention Group|Perioperative management and warming was performed according to a standard normothermia protocol with active prewarming.
9844363|NCT02961374|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
9844364|NCT02961751|Other|Ciprofloxacin|One dose of directly-observed ciprofloxacin 500 mg administered orally. N=381
9844365|NCT02961764|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
9844366|NCT02961764|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
9844367|NCT02961790|Experimental|Group I (low-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
9844368|NCT02961790|Placebo Comparator|Group II (low-dose placebo)|Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
9844369|NCT02961790|Experimental|Group III (high-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
9844370|NCT02961790|Placebo Comparator|Group IV (high-dose placebo)|Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.
9844371|NCT02961894|Experimental|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
9844372|NCT02961920|Experimental|IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
10213474|NCT03919162|Experimental|150 mg|24 weeks on 150 mg BID
10213475|NCT03919162|Placebo Comparator|Placebo|
10213476|NCT03918798|Experimental|Chloroprocaine 1%|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
10213477|NCT03918798|Experimental|Chloroprocaine 2%|All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.
10213478|NCT03918213|Experimental|healthy subjects examined with solid-state catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
9844373|NCT02961920|Active Comparator|IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
9844374|NCT02961946|Active Comparator|Sublingual Nitroglycerin spray|Sublingual Nitroglycerin spray of 0.8 mg
10207208|NCT02519738|Active Comparator|Kenalog (Triamcinolone)|Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
10207209|NCT02519738|Active Comparator|Washcloth Abrasion|Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.
10207210|NCT02517502|Experimental|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
10207211|NCT02517502|Placebo Comparator|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
10207212|NCT02502071|Experimental|Sodium Bicarbonate|All participants will receive 2 doses of 1950mg Sodium Bicarbonate
9844375|NCT02961946|Active Comparator|Sublingual Nitroglycerin tablet|Sublingual Nitroglycerin tablet of 0.8 mg
9844376|NCT02961946|Active Comparator|Nitroglycerin skin patch|Nitroglycerin skin patch of 0.8 mg/h
9844377|NCT02962284|Experimental|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
9844378|NCT02962427|Experimental|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
9844379|NCT02962427|Active Comparator|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
9844380|NCT02962609|Experimental|Semielevated Side-Lying Position-ESL|Preterm infants feed in the ESL position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
9844381|NCT02962609|Experimental|Semielevated Supine Position-ESU|Before feeding: In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
9844382|NCT02962648|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
9844383|NCT02962674|Other|Treatment|
10207213|NCT02468752|Sham Comparator|Air|Normobaric air breathing
10207214|NCT02468752|Experimental|Oxygen|Normobaric oxygen breathing
10207215|NCT02450708||For patients with 1 HLA-compatible donor for URD HCT|For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.
10207216|NCT02450708||For patients with >1 HLA-compatible donor for URD HCT|For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.
10207217|NCT02430077|Experimental|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
9844384|NCT02962687|Experimental|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
9844385|NCT02962687|Active Comparator|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
9844386|NCT02962739|Active Comparator|33%/67% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
9844387|NCT02962739|Active Comparator|33%/100% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
9844388|NCT02962739|Active Comparator|67%/33% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
9844389|NCT02962739|Active Comparator|67%/100% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
10207218|NCT02430077|Placebo Comparator|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
9844390|NCT02962739|Active Comparator|100%/33% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
9844391|NCT02962739|Active Comparator|100%/67% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
9844392|NCT02962882|Experimental|A. Mepilex Border Sacrum (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the sacrum area at pressure points in patients in the ICU, prone to get pressure injuries (PI).
9844393|NCT02962882|Experimental|B. Mepilex Border Heel (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the heels (on both left and right heels), in patients in the ICU, prone to get pressure injuries (PI).
9844394|NCT02962908|Experimental|Group 1|(n=74): FLU-v on Day 0 and Day 21
9844395|NCT02962908|Experimental|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
9844396|NCT02962908|Placebo Comparator|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
9844397|NCT02962908|Placebo Comparator|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
9844398|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
9844399|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
9844400|NCT02962960|Experimental|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
9844401|NCT02962960|Placebo Comparator|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
9844402|NCT02962960|Experimental|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
9844403|NCT02962960|Placebo Comparator|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
9844404|NCT02963311|Experimental|ALN-PCSSC|300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by >70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
9844405|NCT02963376|Active Comparator|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
9844406|NCT02963376|Placebo Comparator|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
9844407|NCT02963376|Active Comparator|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
9844408|NCT02963376|Placebo Comparator|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
9844409|NCT02963376|Active Comparator|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
9844410|NCT02963376|Placebo Comparator|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
9844411|NCT02963506|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
9844412|NCT02963506|Experimental|Bimekizumab Dose 1|Subjects will receive for 12 Weeks Bimekizumab Dose 1 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
9844413|NCT02963506|Experimental|Bimekizumab Dose 2|Subjects will receive for 12 Weeks Bimekizumab Dose 2 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
9844414|NCT02963506|Experimental|Bimekizumab Dose 3|Subjects will receive for 48 Weeks Bimekizumab Dose 3.
9844415|NCT02963506|Experimental|Bimekizumab Dose 4|Subjects will receive for 48 Weeks Bimekizumab Dose 4.
9844416|NCT02963597|Active Comparator|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
9844417|NCT02963597|Placebo Comparator|Group B|Standard medical therapy only.
9844418|NCT02963701|Experimental|Ibuprofen+Pseudoephedrine-HCl|Fixed dose combination
9844419|NCT02963701|Active Comparator|Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)|Fixed Dose Combination
9844420|NCT02963922|Experimental|liraglutide 3.0 mg|
9844421|NCT02963922|Placebo Comparator|Placebo|
9844422|NCT02963935|Experimental|Liraglutide|
9844423|NCT02963935|Placebo Comparator|Placebo|
9844424|NCT02963974|Experimental|Cochlear Implant|Pediatric patients with single sided deafness will receive a cochlear implant in the ear of loss
9844425|NCT02963987|Experimental|100% Portion Size|100% Food and Beverage Portion Size
9844426|NCT02963987|Experimental|150% Portion Size|150% Food and Beverage Portion Size
9844427|NCT02964234|Experimental|Empowerment|Behavior: Empowerment
9844428|NCT02964234|Experimental|Education|Behavior: Education
9844429|NCT02964247|Experimental|liraglutide + SGLT2i ± metformin|
9844430|NCT02964247|Placebo Comparator|liraglutide placebo + SGLT2i ± metformin|
9844431|NCT02964312|Other|Latera Implant|Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
9844432|NCT02964325|Experimental|Mirasol platelets (MIR PLTs)|Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
9844433|NCT02964325|Active Comparator|Reference platelets (REF PLTs)|Leukoreduced, apheresis platelets stored in 100% plasma
9844434|NCT02964338|Placebo Comparator|Placebo|Participants received placebo via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injections at Weeks 4 and 8.
9844435|NCT02964338|Experimental|Fremanezumab 675/225/225 mg|Participants received placebo via an approximately 1-hour intravenous infusion and fremanezumab at 675 milligrams (mg) as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
9844436|NCT02964338|Experimental|Fremanezumab 900/225/225 mg|Participants received fremanezumab at 900 mg via an approximately 1-hour intravenous infusion and placebo administered as 3 subcutaneous injections at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
9844437|NCT02964416|Experimental|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
9844438|NCT02964416|Placebo Comparator|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
9844439|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
9844440|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
9844441|NCT02964910|Experimental|the chronic Hepatitis B patients|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
9844442|NCT02964910|Active Comparator|the healthy volunteer|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
9844443|NCT02965144||HGG patients|single-group study- long term survivors
9844444|NCT02965378|Experimental|Arm I - AZD4547|Participants receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9844445|NCT02965378|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~-closed to accrual 12/18/2015"
9844446|NCT02965378|Experimental|Arm III - AZD4547 re-registration|Participants in Arm II eligible for re-registration receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9844447|NCT02965456|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
9844448|NCT02965456|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
9844449|NCT02965534|Experimental|Night Spectacle Correction|Refraction for this glasses was obtained at low luminance.
9844450|NCT02965534|Active Comparator|Spectacle Correction for photopic light conditions|Refraction for this glasses was obtained at high luminance level.
9844451|NCT02965573|Active Comparator|ARGX-113|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113
9844452|NCT02965573|Placebo Comparator|Placebo|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive placebo
9844453|NCT02965599|Experimental|GSK3117391|Subjects will receive GSK3117391 (Dose A) for 28 days.
9844454|NCT02965599|Placebo Comparator|Placebo|Subjects will receive placebo for 28 days.
9844455|NCT02965781|Active Comparator|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
9844456|NCT02965781|Active Comparator|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
9844457|NCT02965781|Placebo Comparator|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
9844458|NCT02965820|Other|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
9844459|NCT02965820|Other|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
9844460|NCT02965833|Other|CCP, then HMPS|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
9922511|NCT00840138||2|Patients with common bile duct injury after laparoscopic cholecystectomy
9844461|NCT02965833|Other|HMPS, then CCP|Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
9844462|NCT02965924|Experimental|Phenylephrine|Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
9844463|NCT02965989|Experimental|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
9844464|NCT02965989|No Intervention|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
9844465|NCT02966002|Experimental|Intervention: aspirin|650 mg. Twice a day for 8 weeks
9844466|NCT02966015|Experimental|Testing the new Coloplast Test catheter|The subjects used the new Coloplast Test catheter for 1 week
9844467|NCT02966028|Experimental|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
9844468|NCT02966028|Experimental|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
9844469|NCT02966028|Placebo Comparator|Matching Placebo|Placebo arm: 2 vials of physiological saline
9844470|NCT02966275|Experimental|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
9844471|NCT02966275|Placebo Comparator|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
9844472|NCT02966314|Placebo Comparator|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
9844473|NCT02966314|Active Comparator|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
9844474|NCT02966340|Experimental|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
9844475|NCT02966340|Experimental|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
9844476|NCT02966353|Experimental|All Subjects|10 mg BID (2 tablets of 5mg) was self-administered as starting dose for all patients. This dose was maintained for the first 12 weeks and titrated up thereafter unless they had met criteria for dose hold or dose reduction. Dose was to have been increased or decreased per standardized dosing paradigm and not to have exceeded 25 mg bid.
9844477|NCT02966509|Experimental|A: Intervention Arm|All participants randomized to Arm A will receive the EPAC intervention as well as usual oncologic care.
9844478|NCT02966509|No Intervention|B: Control Group Arm|All participants randomized to Arm B will receive usual oncologic care.
9844479|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 8 Weeks|Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.
9844480|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 12 Weeks|Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.
9844481|NCT02966834|Placebo Comparator|Placebo|Participants will receive matching placebo
9844482|NCT02966834|Experimental|GSK2330672 20 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
10207219|NCT02425592||Men on Active Surveillance|This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) <20, clinical stage <cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
10207220|NCT02420821|Experimental|Atezolizumab + Bevacizumab|Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
9844483|NCT02966834|Experimental|GSK2330672 90 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
9844484|NCT02966834|Experimental|GSK2330672 180 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
9844485|NCT02966834|Experimental|GSK2330672 40 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
9844486|NCT02966834|Experimental|GSK2330672 90 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
9844487|NCT02967016|Experimental|normal spontaneous vaginal delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
9844488|NCT02967016|Experimental|Cesarean Delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
9844489|NCT02967354|Experimental|Healthy control|Healthy control
9844490|NCT02967354|Experimental|Obese with oral antidiabetic drugs|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
9844491|NCT02967354|Experimental|Obese, treated with oral antidiabetic drugs + insulin|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
9844492|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
9844493|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
9844494|NCT02967367|Experimental|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
9844495|NCT02967393|Active Comparator|IIV4|0.5 mL intramuscular injection
9844496|NCT02967393|Active Comparator|cc IIV4|0.5 mL intramuscular injection
9844497|NCT02967458|Experimental|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
9844498|NCT02967510|Experimental|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
9844499|NCT02967510|Experimental|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
9844500|NCT02967510|Experimental|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
9844501|NCT02967510|Placebo Comparator|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
9844502|NCT02967562|Active Comparator|Inflation Breaths|Five 'inflation breaths' lasting two - three seconds
9844503|NCT02967562|Experimental|Sustained inflation|One fifteen second 'sustained inflation'
9844504|NCT02967679|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 48 weeks
9844505|NCT02967991|Active Comparator|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
9844506|NCT02967991|Experimental|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
9844507|NCT02967991|Active Comparator|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
9844508|NCT02967991|Experimental|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
9844509|NCT02968004|Experimental|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
9844510|NCT02968004|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
9844511|NCT02968134|Other|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
9844512|NCT02968173|Experimental|Children at High Risk of severe RSV Infection|A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
9844513|NCT02968277|Experimental|Started with Forearm Support Walker (LW Upright)|Data collection began with participants using the LifeWalker Upright Walker then using the two remaining walkers in a randomized order
9844514|NCT02968277|Experimental|Standard Rollator Walker (Control)|Data collection began with participants using a conventional standard rollator (SR) walker then using the two remaining walkers in a randomized order
9844515|NCT02968277|Experimental|Predicate Device (PD)|Data collection began with participants using their own rollator walkers then using the two remaining walkers in a randomized order
9844516|NCT02968368|Experimental|Oral ferric maltol|30mg capsules BID
9844517|NCT02968368|Placebo Comparator|Oral placebo|Matching placebo capsules BID
9844518|NCT02968420|Active Comparator|Group 1|Group 1: girls who received 2 doses of Q-HPV vaccine at 0, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
9844519|NCT02968420|Active Comparator|Group 2|Group 2: girls who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
9844520|NCT02968420|Active Comparator|Group 3|Group 3: young women who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 16-26 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
9844521|NCT02968433|Experimental|Infusions of Young Plasma|"All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.~Participants will receive 1 unit of young plasma, twice a week over a four week duration.~After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used."
10207221|NCT02420821|Active Comparator|Sunitinib|Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
9844522|NCT02968576|Active Comparator|Truvada|Naked form Truvada (drug)
9844523|NCT02968576|Experimental|PSS-Truvada|Proteus Sensor System (PSS) (device) encapsulated Truvada (drug)
9844524|NCT02968758|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
9844525|NCT02968914|Active Comparator|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
9844526|NCT02968914|Other|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
9922512|NCT00840151|No Intervention|Treatment Group A|Individuals randomized to Treatment Group A will receive standard treatment for study weeks 1-6.
9922513|NCT00840151|Experimental|Treatment Group B|Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.
9922514|NCT00840151|No Intervention|Aftercare Group A|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group A will receive standard treatment for study weeks 7-12.
9922515|NCT00840151|Experimental|Aftercare Group B|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.
9922516|NCT00840190|Experimental|P1446A-05|
9922517|NCT00840229|Experimental|1 capsular & intra-articular|corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
9922518|NCT00840229|Active Comparator|2 intra-articular|corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
9922519|NCT00840229|Placebo Comparator|3 placebo|placebo injections (Lidocaine) in capsule and intra-articular
9922520|NCT00840242|Experimental|Nicotine gum|Nicotine gum
9922521|NCT00840242|Placebo Comparator|Placebo gum|Placebo gum
9922522|NCT00840242|Active Comparator|Nicotine inhaler|Nicotine inhaler
9922523|NCT00840242|Placebo Comparator|Placebo inhaler|Placebo inhaler
9922524|NCT00840255|Active Comparator|Breif Behavioral Treatment of Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
9922525|NCT00840255|Other|Information Control|This arm of the study does not receive the Brief Behavioral Treatment for Insomnia. This arm will act as the control arm.
9922526|NCT00840320|Experimental|1|Repeat doses of active at escalating doses
9922527|NCT00840320|Placebo Comparator|2|Repeat doses of placebo
9922528|NCT00840333|Experimental|1|CF PATIENTS 6-11 YEARS OF AGE
9922529|NCT00840333|Experimental|2|CF PATIENTS 12-16 YEARS OF AGE
9922530|NCT00840346|Experimental|1|The first patients enrolled in the trial will be successively distributed into three cohorts of patients for each dose level of panobinostat (20 mg, 30 mg, 40 mg) in combination with idarubicin and cytarabine, according to the classical 3+3 schedule
9922531|NCT00840359|Experimental|1 PDT|Leishmania lesion
9922532|NCT00840359|Active Comparator|Cryo|Leishmania lesion
9922533|NCT00840372||1|Chronic hemodialysis patients, native arterio-venous fistula
9922534|NCT00840372||2|Chronic hemodialysis patients, native arterio-venous fistula
9922535|NCT00840385|Experimental|A|
9922536|NCT00840398|Experimental|1|
9922537|NCT00840398|Active Comparator|2|
9935808|NCT03190954|Active Comparator|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
9844527|NCT02968992|Experimental|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
9844528|NCT02968992|Placebo Comparator|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
9844529|NCT02969018|Experimental|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
9844530|NCT02969018|Experimental|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
9844531|NCT02969018|Experimental|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
9844532|NCT02969018|Experimental|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
9844533|NCT02969018|Experimental|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
9844534|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
9844535|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
9844536|NCT02969018|Placebo Comparator|Placebo|12 weeks once daily placebo
9844537|NCT02969031|Experimental|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
9844538|NCT02969031|Active Comparator|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
9844539|NCT02969044|Experimental|PF-06651600|Study Drug
9844540|NCT02969044|Placebo Comparator|Placebo|Placebo
9844541|NCT02969187|Experimental|Experimental|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
9844542|NCT02969187|Active Comparator|Control|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.
9844543|NCT02969317|Experimental|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
9844544|NCT02969356|Experimental|Dysport|Each subject will undergo two intramuscular injection (treatment) cycles, receiving AbobotulinumtoxinA (Dysport®) 1500 U on Day 1 of each cycle; the two dosing occasions will be separated by at least 12 weeks (maximum 20 weeks). Subjects will also receive daily GSC therapy. The main focus of GSC will be on the primary treatment target (TT) limb (as determined at the Baseline Visit) and then the other limb. All muscle groups requiring active training and/or stretching should be trained. Subjects will be be given a diary to record each day whether they have performed the GSC therapy.
9844545|NCT02969382|Experimental|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
9844546|NCT02969382|Placebo Comparator|Placebo|Placebo capsule once daily
9844547|NCT02969408|Experimental|ABS eMDPI|Participants will receive 90 mcg of ABS via an eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks.
9844548|NCT02969421|Active Comparator|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
9844549|NCT02969421|Active Comparator|Cough Method|This group will have their tenaculum placed using the cough method
9844550|NCT02969525|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
9844551|NCT02969525|Experimental|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
9844552|NCT02969525|Experimental|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
9844553|NCT02969525|Experimental|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
9922538|NCT00840489|Experimental|Ribavirin|Ribavirin 1000-1200 mg qd
9844554|NCT02969525|Experimental|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
9844555|NCT02969590|No Intervention|No Intervention: Spontaneous Cycle (1 month)|In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
9844556|NCT02969590|Active Comparator|NET Arm - Norethindrone (4 months)|"This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
9844557|NCT02969590|Active Comparator|E2WD Arm - Estradiol (4 months)|"This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
9844558|NCT02969655|Experimental|Daprodustat|Subjects will receive oral daprodustat once daily and intravenous (IV) darbepoetin alfa placebo once weekly for 52 weeks
9844559|NCT02969655|Active Comparator|Darbepoetin alfa|Subjects will receive IV darbepoetin alfa once weekly and oral daprodustat placebo once daily for 52 weeks
9844560|NCT02969707|Experimental|Active rTMS|The active group will receive repetitive Transcranial Magnetic Stimulation
9844561|NCT02969707|Sham Comparator|Sham rTMS|The sham repetitive Transcranial Magnetic Stimulation group will have the stimulation blocked.
9844562|NCT02969863|Active Comparator|Usual Care Arm - Monitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
9844563|NCT02969863|Active Comparator|Usual Care Arm - Unmonitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
9844564|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Monitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
9844565|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Unmonitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
9844566|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Monitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
9844567|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Unmonitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
9844568|NCT02969876|Other|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical & Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
9844569|NCT02970006|Experimental|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
9844570|NCT02970032|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
9922539|NCT00840489|Active Comparator|Colchicine|Colchicine 0.5 mg bd
9922540|NCT00840502||Pregnant women|Pregnant women who present at the SMRU antenatal clinics on the Thai Burmese border.
9922541|NCT00840515||Emulsion|
9844571|NCT02970032|Experimental|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
9844572|NCT02970162|Experimental|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
9844573|NCT02970162|Placebo Comparator|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
9844574|NCT02970292|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
9844575|NCT02970292|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
9844576|NCT02970305|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
9844577|NCT02970305|Placebo Comparator|Placebo|Placebo, taken as two tablets + background antipsychotic, once daily by mouth
9844578|NCT02970422||Quartile 1 [Mild]|
9844579|NCT02970422||Quartile 2 [Moderate]|
9844580|NCT02970422||Quartile 3 [Severe]|
9844581|NCT02970422||Quartile 4 [Very Severe]|
9844582|NCT02970552|Active Comparator|Vaginal Progesterone|Daily self-administered vaginal progesterone
9844583|NCT02970552|Placebo Comparator|Placebo|Daily self-administered indistinguishable placebo
9844584|NCT02970669|Active Comparator|Enalapril|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of enalapril and 1 tablet of matching placebo sacubitril/valsartan twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 2.5 mg enalapril BID). Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 (i.e. 10 mg enalapril BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on enalapril Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1 of sacubitril/valsartan. Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 of sacubitril/valsartan. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
9844585|NCT02970669|Experimental|Sacubitril/Valsartan|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of sacubitril/valsartan and 1 tablet of matching placebo enalapril twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 24/26 mg sacubitril/valsartan BID). Patients may have sequentially been up-titrated to achieve desired dose of Dose Level 3 (i.e. 97/103 mg sacubitril/valsartan BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1. Patients may sequentially have been up-titrated to achieve desired dose of Dose Level 3. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
9844586|NCT02970812|Experimental|Electrical Muscle Stimulation|Electrical Muscle Stimulation (EMS) program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
9844587|NCT02970812|Placebo Comparator|Transcutaneous Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
9844588|NCT02970942|Experimental|Semaglutide 0,1 mg|
9844589|NCT02970942|Experimental|Semaglutide 0,2 mg|
9844590|NCT02970942|Experimental|Semaglutide 0,4 mg|
9844591|NCT02970942|Placebo Comparator|Placebo 1|
9844592|NCT02970942|Placebo Comparator|Placebo 2|
9844593|NCT02970942|Placebo Comparator|Placebo 3|
9844594|NCT02971007|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
9844595|NCT02971007|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
9844596|NCT02971007|Active Comparator|Fluconazole 150 mg|Fluconazole Diflucan
9922542|NCT00840528|Experimental|Ozone exposure|Exposure to ozone at 0.4ppm
9844597|NCT02971163|Experimental|SynDA|The research coordinator will print the appropriate version of the SynDA based on the patient's individualized risk score and the corresponding estimated probability of a serious medical event within 30 days.
9844598|NCT02971163|No Intervention|Control|Patients in the control arm will receive usual emergency care pertaining to syncope.
9844599|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 milliunit (mU)/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
9844600|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
9844601|NCT02971202|Other|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
9844602|NCT02971228|Experimental|Part 1, Lilly glucagon then ZP4207|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
9844603|NCT02971228|Experimental|Part 1, ZP4207 then Lilly Glucagon|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
9844604|NCT02971228|Experimental|Part 2, Lilly glucagon then ZP4207|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
9844605|NCT02971228|Experimental|Part 2, ZP4207 then Lilly Glucagon|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
9844606|NCT02971293|Experimental|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
9844607|NCT02971293|Placebo Comparator|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
9844608|NCT02971293|Experimental|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
9844609|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
9844610|NCT02971605|Experimental|Psilocybin|Participants will be administered a 25 mg/70 kg dose of psilocybin
9844611|NCT02971631|Placebo Comparator|Placebo|Infusion of 1% human albumin in normal saline.
9844612|NCT02971631|Experimental|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
9844613|NCT02971670|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
9844614|NCT02971670|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
9844615|NCT02971670|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
9844616|NCT02971670|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
9844617|NCT02971735|Experimental|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
9844618|NCT02971735|Active Comparator|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
9844619|NCT02971800|Experimental|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
9844620|NCT02972242|Active Comparator|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
9844621|NCT02972242|Placebo Comparator|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
9844622|NCT02972359|Experimental|Neridronic acid|Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
9844623|NCT02972502|Active Comparator|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
9844624|NCT02972502|Experimental|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
9844625|NCT02972515|Experimental|See Me Smoke-Free|"Participants received access to the See Me Smoke-Free mobile application (app) delivered via smart phone, and were asked to use the app most days for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques."
9844626|NCT02972554|Experimental|Propanolol Hydrochloride|This is the experimental group given the beta-blocker
9844627|NCT02972554|Placebo Comparator|Placebo|This is the control group given a placebo.
9844628|NCT02972632|Experimental|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
9844629|NCT02972658|Experimental|AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg|Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
9844630|NCT02972658|Experimental|AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg|Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
9844631|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 20 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
9844632|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 50 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
9844633|NCT02973048|Placebo Comparator|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
9844634|NCT02973048|Active Comparator|Hyperbaric prilocaine|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
9844635|NCT02973087|Experimental|All Study Participants|Participants will receive prophylaxis with rVWF in two cohorts: on-demand (OD) cohort (previously treated with OD) and pdVWF switch cohort (participants switching from prophylactic treatment with pdVWF).
9844636|NCT02973100|Experimental|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
9844637|NCT02973100|Experimental|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
9844638|NCT02973100|Active Comparator|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
9844639|NCT02973100|Placebo Comparator|Placebo|Placebo administered SC
9844640|NCT02973438|Experimental|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
9844641|NCT02973438|Experimental|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
9844642|NCT02973438|Experimental|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
9844643|NCT02973438|Experimental|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
9844644|NCT02973477|Experimental|Group A: Dapagliflozin/Glimepiride|Participants will take open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride.
9844645|NCT02973477|Experimental|Group B: Glimepiride/Dapagliflozin|Participants will take open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin.
9844646|NCT02973503|Experimental|Elbasvir/Grazoprevir|evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
9844647|NCT02973516|Experimental|P03277 triphasic imaging|P03277 will be administered in order to acquire triphasic liver imaging
9844648|NCT02973802|Experimental|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
9844649|NCT02974010|Experimental|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
9844650|NCT02974010|Active Comparator|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101
9844651|NCT02974088|Experimental|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
9844652|NCT02974088|Experimental|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
9844653|NCT02974114|Experimental|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
9844654|NCT02974114|Experimental|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
9844655|NCT02974114|Placebo Comparator|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
9844656|NCT02974140|Experimental|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
9844657|NCT02974140|Active Comparator|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
9844658|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
9844659|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 2|ALD403 (Eptinezumab) Dose Level 2 (IV)
9844660|NCT02974153|Placebo Comparator|Placebo|Placebo (IV)
9844661|NCT02974296|Experimental|new target TMS|new target transcranial magnetic stimulation guided by MRI
9844662|NCT02974296|Active Comparator|standard TMS|standard transcranial magnetic stimulation
9844663|NCT02974543|Other|Sham 1st (Auditory only) then Active (Bimodal)|"To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
9922543|NCT00840541||DR|Type-2 diabetic subjects diagnosed with diabetic retinopathy (DR).
9922544|NCT00840554|Active Comparator|Physical Therapy|
9922545|NCT00840554|Experimental|Home Exercise|
9844664|NCT02974543|Other|Active (Bimodal) then Sham (Auditory only)|"During active treatment, the device will deliver electric somatosensory and auditory stimulation.~To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab."
9844665|NCT02974634|Active Comparator|Ostomy Self management Training|Ostomy self-management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
9844666|NCT02974634|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient
9844667|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
9844668|NCT02974855|Experimental|PF-06741086 (Cohort 1)|
9844669|NCT02974855|Experimental|PF-06741086 (Cohort 2)|
9844670|NCT02974855|Experimental|PF-06741086 (Cohort 3)|
9844671|NCT02974855|Experimental|PF-06741086 (Cohort 4)|
9844672|NCT02974868|Experimental|Cohort 1|PF-06651600
9844673|NCT02974868|Experimental|Cohort 2|PF-06700841
9844674|NCT02974868|Placebo Comparator|Cohort placebo|placebo
9844675|NCT02975206|Experimental|Serlopitant High Dose|serlopitant tablets - high dose
9844676|NCT02975206|Experimental|Serlopitant Low Dose|serlopitant tablets - low dose
9844677|NCT02975206|Placebo Comparator|Placebo Oral Tablet|matching placebo tablets
9844678|NCT02975297|Experimental|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
9844679|NCT02975297|Placebo Comparator|Placebo plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
9844680|NCT02975336|Placebo Comparator|Double-Blind Placebo-Controlled (DBPC) Period: Placebo|
9844681|NCT02975336|Experimental|DBPC Period: M2951 25 mg QD|
9844682|NCT02975336|Experimental|DBPC Period: M2951 75 mg QD|
9844683|NCT02975336|Experimental|DBPC Period: M2951 50 mg BID|
9844684|NCT02975336|Experimental|Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID|
9844685|NCT02975336|Experimental|LTE Period: M2951 25 mg QD/ M2951 50 mg BID|
9844686|NCT02975336|Experimental|LTE Period: M2951 75 mg QD/ M2951 50 mg BID|
9844687|NCT02975336|Experimental|LTE Period: M2951 50 mg BID/ M2951 50 mg BID|
9844688|NCT02975349|Experimental|Placebo then Evobrutinib 25 mg QD|Participants who received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1 received Evobrutinib 25 milligram (mg) orally, once daily (QD) in blinded extension (BE) period from week 25 to week 48.
9844689|NCT02975349|Experimental|Evobrutinib 25 mg QD|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
9844690|NCT02975349|Experimental|Evobrutinib 75 mg QD|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
9844691|NCT02975349|Experimental|Evobrutinib 75 mg BID|Participants received Evobrutinib 75 mg orally, twice daily (BID) up to Week 48 in active treatment period 1 and BE period.
9844692|NCT02975349|Active Comparator|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period.
9844693|NCT02975349|Placebo Comparator|Placebo|Participants received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1.
9844694|NCT02975557|Active Comparator|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
9844695|NCT02975557|Active Comparator|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
9844696|NCT02975557|Placebo Comparator|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
9844697|NCT02975804|Experimental|Interactive computer play (ICP)|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
9844698|NCT02975804|No Intervention|Standard Therapy|Children in the control group will continue their usual therapy.
9844699|NCT02975973|Experimental|2.5mA|Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
9844700|NCT02975973|Experimental|2.0mA|Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
9844701|NCT02975973|Experimental|1.5mA|Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
9844702|NCT02975973|Sham Comparator|0mA|This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
9844703|NCT02976103|Other|Standard Care|-Standard Care pain medicine/management will be given
9922546|NCT00840567|Other|Healthy Volunteers|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
9922547|NCT00840567|Other|Patients with benign, inherited hematologic disease|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
9844704|NCT02976103|Experimental|JACKI® RECOVERY JACKET + Standard Care|"Patient will be encouraged to use the Jacki Recovery Jacket at home~Patient will be taught how to tuck the drainage tubes in the jacket pocket~Patient will be taught how to un-tuck the drainage tubes from jacket pocket~Standard care pain medicine/management will be given"
9844705|NCT02976519|Experimental|BI 443651|
9844706|NCT02976519|Placebo Comparator|Placebo|
9844707|NCT02977507|Experimental|Lytera 2.0|Lytera 2.0 applied to the affected areas (dark patches) on one side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
9844708|NCT02977507|Active Comparator|4% Hydroquinone Topical Cream|4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on the other side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
9844709|NCT02977572|Experimental|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
9844710|NCT02977572|Placebo Comparator|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
9844711|NCT02978157|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
9844712|NCT02978157|Experimental|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
9844713|NCT02978183|Active Comparator|Group 1|1X ST266 dosed 4 times a day for 8 days
9844714|NCT02978183|Placebo Comparator|Group 2|Placebo dosed 4 times a day for 8 days
9844715|NCT02978339|Experimental|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
9844716|NCT02978417|Active Comparator|Vivitrol|All drug court clients in the pilot RCT will receive standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Participants randomized to Vivitrol® will receive standard treatment along with monthly Vivitrol® injections administered by study staff at outpatient visits. Vivitrol® is naltrexone for extended-release injectable suspension. It is an injectable suspension containing 380 mg of naltrexone in a microsphere formulation and 4 mL diluent. The recommended dose of Vivitrol® is 380 mg delivered intramuscularly every 4 weeks or once a month. The injection should be administered by a healthcare provider as an intramuscular (IM) gluteal injection, alternating buttocks for each subsequent injection (see Links section of PRS for more information about Vivitrol).
9922548|NCT00840580|Experimental|Vigamox|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
9922549|NCT00840580|Active Comparator|Cravit|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
9998286|NCT01516775|Experimental|1 hour fluid fasting|allowed to drink until 1 hour before scheduled anaesthesia induction
9517000|NCT03310359|Active Comparator|Astaxanthin (12 mg)|Subjects will be given capsules containing a set oral dose of astaxanthin (12 mg) and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
9844717|NCT02978417|Active Comparator|Oral naltrexone|Subjects randomized to oral naltrexone in addition to standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Oral naltrexone is the daily tablet formulation naltrexone that carries the same risks and benefits as the long-acting injectable formulation (Vivitrol®), except it does not have any of the risks related to injection (discomfort, potential for infection). Oral naltrexone is administered and provided by FHR to interested and eligible clients as part of the range of their usual care services.
9844718|NCT02978508|Experimental|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
9844719|NCT02978508|Active Comparator|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
9844720|NCT02979054|Experimental|T4020|1 drop every other day during 5 days
9844721|NCT02979054|Placebo Comparator|Saline solution|1 drop every other day during 5 days
9844722|NCT02979197|Experimental|Amlodipine+Celecoxib|OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days
9844723|NCT02979197|Active Comparator|Amlodipine+Placebo|OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
9844724|NCT02979197|Sham Comparator|Placebo+Placebo|Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
9844725|NCT02979249|Experimental|Oral Iron|standard dose of iron pills
9844726|NCT02979262|Experimental|Fathers for Change|Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
9844727|NCT02979262|Active Comparator|Parent Education (PE)|PE is an individual intervention.PE was developed to represent parent education and support that is typically available to parents with substance use problems who are at high risk for neglecting their children. Fathers enrolled in PE will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed for work with substance abusing parents. Sample pamphlet topics include routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness.
9844728|NCT02979301|Experimental|Tamoxifen 5 mg/day|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
9844729|NCT02979301|Experimental|Tamoxifen 10 mg/day|Women with high background uptake on MBI take 10 mg tam per day for 30 days.
9844730|NCT02979431|Experimental|ALX-0171 3.0 mg/kg|Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days
9844731|NCT02979431|Experimental|ALX-0171 6.0 mg/kg|Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days
9844732|NCT02979431|Experimental|ALX-0171 Dose 9.0mg/kg|Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days
9844733|NCT02979431|Placebo Comparator|Placebo|Inhalation of Placebo once daily for 3 consecutive days
9844734|NCT02979444|Experimental|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
9844735|NCT02979444|Experimental|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
9844736|NCT02979444|No Intervention|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
9935809|NCT03190954|Placebo Comparator|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to [11C]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
9844737|NCT02979522|Experimental|Brentuximab vedotin 48 mg/m^2|Brentuximab vedotin 48 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and Dacarbazine 375 mg/m^2, intravenous infusion, once on Day 1 and 15 of each 28-day cycle for up to 6 cycles. If the first 6 participants complete the dose limiting toxicity (DLT) observation period with 0 or 1 participant experiencing a DLT, 48 mg/m^2 will be established as the recommended dose for phase 2 study. If at any time more than 1 participant out of a maximum 6 DLT-evaluable participants experiences a DLT, brentuximab vedotin dose will be reduced to 36 mg/m^2. If 0 or 1 participant experiences a DLT among the 6 participants treated at 36 mg/m^2, 36 mg/m^2 will be established as recommended dose for phase 2 study. If more than 1 participant experiences a DLT in the first 6 participants treated at 36 mg/m^2, the study will be discontinued.
9844738|NCT02979613|Experimental|TAF 25 mg|Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks. Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
9844739|NCT02979613|Active Comparator|TDF 300 mg|DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.
9844740|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:~Fever >39~Lower respiratory tract infection~Acute otitis media~Serious extra-pulmonary manifestations (myositis, encephalitis)"
9844741|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
9844742|NCT02979639|Experimental|GSK1437173A Group|Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
9844743|NCT02979899|Experimental|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
9844744|NCT02979899|Active Comparator|votrient|standard dose votrient by mouth, once daily
9844745|NCT02979925|Experimental|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
9844746|NCT02979925|Sham Comparator|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
9844747|NCT02980042|Experimental|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
9844748|NCT02980042|Active Comparator|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
9844749|NCT02980107|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
9844750|NCT02980107|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
9844751|NCT02980133|Placebo Comparator|Placebo MDPI|Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.
9844752|NCT02980133|Experimental|Fp MDPI 25 mcg BID|Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.
9844753|NCT02980133|Experimental|Fp MDPI 50 mcg BID|Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.
9844754|NCT02980133|Experimental|FS MDPI 50/12.5 mcg BID|Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.
9844755|NCT02980211|Experimental|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
9844756|NCT02980224|Experimental|OmegaD|OmegaD Softgels
9844757|NCT02980224|Placebo Comparator|Placebo|Placebo Softgels
9844758|NCT02980523|Experimental|PRO-157 BID (2 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days~instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
9844759|NCT02980523|Experimental|PRO-157 TID (3 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
9844760|NCT02980523|Experimental|PRO-157 QID (4 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
9844761|NCT02980523|Active Comparator|Moxifloxacin (Vigamox®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)"
9844762|NCT02980523|Active Comparator|Gatifloxacin (Zymar®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)"
9922550|NCT00840593|Active Comparator|1. Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
10207222|NCT02412670|Experimental|Arm A (methotrexate, vinblastine, doxorubicin, cisplatin)|Patients receive methotrexate IV over 2-3 minutes, vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1. Pegfilgrastim at 6 mg is given once 24-48 hours after completion of chemotherapy. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
9922551|NCT00840593|Active Comparator|2 Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
9922552|NCT00840606|Experimental|1|
9922553|NCT00840606|Active Comparator|2|
9922554|NCT00840645|Experimental|1. YM178|
9922555|NCT00840671|Experimental|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
9922556|NCT00840671|Placebo Comparator|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
9922557|NCT00840697|Active Comparator|Work related rehabilitation|"work related rehabilitation and exercises~The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.~Exercises comprises of treatment in groups. The treatment includes exercises, both strength and fitness, in addition to cognitive intervention of how to manage pain and work."
9922558|NCT00840697|Active Comparator|Brief intervention|1 consultation at the physiotherapist, which give advise and a summary talk with the physician
9922559|NCT00840697|Active Comparator|Multidisciplinary exercise group|10 days of exercise and cognitive treatment group
9922560|NCT00840723||Current smokers|Current cigarette smokers with no other illness
9922561|NCT00840723||Healthy controls|Healthy non smokers
9922562|NCT00840736|Active Comparator|1|Laparoscopic adjustable gastric banding
9922563|NCT00840736|Active Comparator|2|vertical banded gastroplasty
9922564|NCT00840762|Experimental|VircoType HIV-1|Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm
9922565|NCT00840762|Active Comparator|Local Expert review|Local Expert HIV genotypic review, as per Badri, S. et al CID 2003
9922566|NCT00840775|Other|Presillion™ Stent System|
10207223|NCT02412670|Experimental|Arm B (gemcitabine, carboplatin)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
9922567|NCT00840788|Experimental|Skin adhesive|perineal skin repair with octyl-2-cyanoacrylate skin adhesive
9922568|NCT00840788|Active Comparator|subcuticular suture|continuous subcuticular suture of perineal skin using rapidly absorbable polyglactin 910
9922569|NCT00840801|Experimental|1|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
9922570|NCT00840801|Experimental|2|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
9922571|NCT00840853|Experimental|Group A with disease|"CD19+ B-ALL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
9922572|NCT00840853|Experimental|Group A without disease|"CD19+ B-ALL undergoing allogeneic HSCT, without detectable disease post-HSCT.~Patients will receive CD19CAR/virus specific T cells - Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
9935810|NCT03190941|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
10207224|NCT02410343|Placebo Comparator|Placebo|Placebo was injected subcutaneously once weekly on the same day and time for 24 weeks. To maintain the blind, placebo could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 to match the effect of dose titration.
9844763|NCT02980601|Experimental|Integra and a Split Thickness Skin Graft (STSG)|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
9844764|NCT02980601|Active Comparator|Split Thickness Skin Graft (STSG)|reconstruction as dictated by the protocol. They will either receive 1) a 0
9844765|NCT02980692|Experimental|SUNPG1623 dose I|low range dose
9844766|NCT02980692|Experimental|SUNPG1623 dose II|mid range dose
9844767|NCT02980692|Experimental|SUNPG1623 dose III|mid range dose
9844768|NCT02980692|Experimental|SUNPG1623 dose IV|mid range dose to high dose
9844769|NCT02980692|Placebo Comparator|Placebo|mid range dose to high dose
9844770|NCT02980705|Experimental|SUNPG1622 I|SUNPG1622 I dose
9844771|NCT02980705|Placebo Comparator|Placebo|Placebo dose
9844772|NCT02980783|Experimental|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine was injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection was determined by the investigator. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine was injected on Day 14.
9844773|NCT02980874|Experimental|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
9844774|NCT02980874|Active Comparator|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
9844775|NCT02980978|Experimental|Intervention|Individuals assigned to the intervention group will have supplemental care provided by a registered dietitian/certified diabetes educator which includes counseling on lifestyle to improve diabetes and overall health. Additionally, individuals in this group may be started on medications (or adjustments to current medications) for blood pressure, cholesterol or blood glucose to meet diabetes care goals
9844776|NCT02980978|No Intervention|Standard of Care|Individuals will be followed by their Primary Care Provider as standard of care and per usual clinical need
9844777|NCT02981342|Experimental|Abemaciclib|Abemaciclib given orally.
9844778|NCT02981342|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
9844779|NCT02981342|Experimental|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
9844780|NCT02981368|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
9844781|NCT02981524|Experimental|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
9844782|NCT02981602|Experimental|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
9844783|NCT02981602|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
9844784|NCT02981953|Other|Cardioband Tricuspid procedure|Tricuspid valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
9844785|NCT02982018|Experimental|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
9844786|NCT02982018|Active Comparator|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
9844787|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ1|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 1 of the PQ (PQ1)
9844788|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ2|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 2 of the PQ (PQ2)
10207225|NCT02410343|Experimental|TV-1106|TV-1106 was injected subcutaneously once weekly on the same day and time for 24 weeks. A common starting dose was 5.0 mg. Doses could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
10207226|NCT02370329|Experimental|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9844789|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ2
9844790|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ1|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ1
9844791|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ3|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 3 of the PQ (PQ3)
9844792|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ4|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 4 of the PQ (PQ4)
9844793|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ4|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ4
10207227|NCT02366520|No Intervention|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
10207228|NCT02366520|Experimental|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
9844794|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ3|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ3
9844795|NCT02982213|No Intervention|No companion present|No companion is present during the placement of the epidural catheter.
9844796|NCT02982213|Active Comparator|Companion present|A companion will be present during the placement of the epidural catheter.
9844797|NCT02982239|Other|Sleep Intervention|N=20 Participants received fitness tracker, information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks
9844798|NCT02982239|Other|Sleep Intervention plus Tech|N=20 Participants received fitness tracker, LED light, Blue-blocking glasses along with information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks.
9844799|NCT02982590|Active Comparator|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
9844800|NCT02982590|Experimental|apixaban|Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
10207229|NCT02343224|Experimental|Pegylated interferon alpha-2b|Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week
10207230|NCT02339740|Experimental|Treatment (tretinoin, arsenic trioxide, chemotherapy)|See Detailed Description
9844801|NCT02982772|Experimental|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.~Doses will be tailored and adjust as need it"
9844802|NCT02982772|Active Comparator|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.~Standard Flavored gums will be used as needed for 10 weeks."
9844803|NCT02982863||All Patients|
9844804|NCT02982954|Experimental|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
9844805|NCT02982954|Experimental|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
9844806|NCT02982954|Experimental|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
9844807|NCT02982954|Experimental|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
9844808|NCT02983058|Other|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
9844809|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 1|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
9844810|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 2|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
9844811|NCT02983305|Experimental|Retinal Dystrophy|Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
9935811|NCT03190941|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
10207231|NCT02335671|Experimental|Intra-operative Magnetic Resonance Imaging (MRI)|"Preoperative diagnostic MRI~Intra-operative MRI~Standard lumpectomy and sentinel node biopsy if indicated, or standard axillary dissection if clinically indicated~Specimen to Pathology and Mass Spectrometer (Analysis of Tissue Sample)"
10207232|NCT02315885|Placebo Comparator|placebo alcohol|<0.05% alcohol
10207233|NCT02315885|Active Comparator|alcohol middle dose|alcohol dose=0.45g/kg for women and 0.5g/kg for men
10207234|NCT02315885|Active Comparator|alcohol high dose|alcohol dose=0.90g/kg for women and 1.0g/kg for men
10207235|NCT02291445|Experimental|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
10207236|NCT02291445|Active Comparator|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
10207237|NCT02276456|Experimental|early follow-up|Follow-up within 7 days after discharge from hospital after having an MI. This will be the early-follow-up or experimental arm.
10207238|NCT02276456|No Intervention|standard follow-up|Follow-up appointment within 14-18 days after discharge from hospital after having an MI
10207239|NCT02262026|Experimental|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
10207240|NCT02262026|Experimental|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
10207241|NCT02262026|Experimental|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
9844812|NCT02983305|Experimental|Healthy Age-Matched Controls|Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
9844813|NCT02983448|Placebo Comparator|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
9844814|NCT02983448|Active Comparator|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
9844815|NCT02983552|Experimental|Binocular Computer Game Treatment|Binocular computer game treatment is defined as playing a Dig Rush application on an iPad® 1 hour per day, 5 days per week for 8 weeks in addition to continued spectacle correction (if required)
9844816|NCT02983552|Active Comparator|Continued Spectacle Correction|Continued spectacle correction is defined as wearing appropriate spectacle correction (if required) for all waking hours, 7 days per week for 8 weeks.
9844817|NCT02983604|Experimental|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
9844818|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
9844819|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
9844820|NCT02983604|Active Comparator|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
9844821|NCT02983825|Experimental|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
9844822|NCT02983877|Experimental|iTAB-CV|"In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention. Stage 1 will last one month.~In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from Stage 1. Stage 2 will last one month."
9844823|NCT02983981|Experimental|open label|Topicort topical spray
9844824|NCT02984267|Experimental|Ultrasound Group|The interventional group that will have their spine evaluated by ultrasound prior to epidural placement
9844825|NCT02984267|Other|Palpation Group|The control group that will have their epidural placed in the usual fashion based on palpation
9844826|NCT02984644|Active Comparator|Dapagliflozin|32 subjects will receive dapagliflozin 10mg
9844827|NCT02984644|Placebo Comparator|Placebo|16 subjects will receive placebo
9844828|NCT02984683|Experimental|SAR566658 90 mg/m^2|Participants received SAR566658 90 milligram per square meter (mg/m^2) as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
9844829|NCT02984683|Experimental|SAR566658 120 mg/m^2|Participants received SAR566658 120 mg/m^2 as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
9844830|NCT02984709|Experimental|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
9844831|NCT02984709|Active Comparator|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
9844832|NCT02984878|Experimental|Revanesse Ultra|Revanesse Ultra open label retreatment
9844833|NCT02984943|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen
9844834|NCT02984982|Active Comparator|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level <100 milligrams per deciliter (mg/dL).
9844835|NCT02984982|Experimental|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
9844836|NCT02984995|Experimental|Initial dose 30 mg/day quizartinib|Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
9844837|NCT02984995|Experimental|Initial dose 20 mg/day quizartinib|Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.
9935812|NCT03189108||Cohort 1|Patients with a diagnosis of malignant solid tumor
9986320|NCT01401621|Experimental|Scratch-Off Test Name Condition|The name of the test the recipient needs is hidden behind a scratchoff on the reminder
9844838|NCT02985021|Experimental|Treatment (docetaxel, carboplatin)|"Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.~Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity."
9844839|NCT02985398|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
9844840|NCT02985710|Other|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
9844841|NCT02985710|Other|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
9844842|NCT02985827|Active Comparator|Rohto (r) Hydra|Menthol containing over the counter eyedrop
9844843|NCT02985827|Placebo Comparator|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
9844844|NCT02985879|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection/Solution for Infusion; intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks
9844845|NCT02985879|Experimental|ABBV-8E12 2000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
9844846|NCT02985879|Experimental|ABBV-8E12 4000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
9844847|NCT02985996|No Intervention|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
9844848|NCT02985996|Experimental|Phase II/Genvoya|Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
9844849|NCT02985996|Experimental|Phase II/Truvada|Participants will receive one dose of Truvada. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
9844850|NCT02985996|Experimental|Phase III/Genvoya|Participants will receive Genvoya once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
9844851|NCT02985996|Experimental|Phase III/Truvada|Participants will receive Truvada once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
9844852|NCT02986074|Experimental|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
9844853|NCT02986074|Experimental|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
9844854|NCT02986139|Experimental|Sequence AB|Participants received a single 50 mg subcutaneous (SC) dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 1 (Treatment A) followed by a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 8 (Treatment B).
9844855|NCT02986139|Experimental|Sequence BA|Participants received a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 1 (Treatment B) followed by a single 50 mg SC dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 8 (Treatment A).
9844856|NCT02986282|Other|Single arm|Interventions - repeated ankle - brachial index measurement before and after electrical cardioversion in patients with atrial fibrillation
9844857|NCT02986373|Experimental|Risankizumab|Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.
9844858|NCT02986711|Experimental|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
9844859|NCT02986711|Sham Comparator|Control|Text messages to ask about current smoking status.
9844860|NCT02986802||Genital herpes treated before third trimester|Women with genital herpes receiving treatment before the 3rd trimester
9844861|NCT02986802||Genital herpes treated only during third trimester|Women with genital herpes receiving treatment during the 3rd trimester
9844862|NCT02986802||Genital herpes untreated|Women with untreated genital herpes
9844863|NCT02986802||Control group|Women (controls) with neither genital herpes nor treatment
9844864|NCT02986854|Experimental|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
9844865|NCT02986854|Experimental|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
9844866|NCT02986854|Active Comparator|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
9844867|NCT02986958|Experimental|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
9844868|NCT02986958|Placebo Comparator|Usual Care|Care as usual with their primary care provider
9844869|NCT02987205|Experimental|Revanesse Ultra|Revanesse Ultra in the NLF on one side of the face
9844870|NCT02987205|Active Comparator|Restylane|Restylane injection in the NLF on the other side of the face to optimal correction
9844871|NCT02987231|Sham Comparator|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
9844872|NCT02987231|Experimental|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
9844873|NCT02987374|Other|2011-2012 Fluzone IIV3 (IM)|Seasonal trivalent flu vaccine: NDC No 49281-011-50
9844874|NCT02987621|Experimental|Sham first, wash out 7 days, then tDCS|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
9998287|NCT01516775|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction
9998288|NCT01516788|Experimental|Phototesting|
9844875|NCT02987621|Experimental|tDCS first, wash out 7 days, then Sham|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
9844876|NCT02987660|Experimental|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
9844877|NCT02987660|Active Comparator|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
9844878|NCT02987829|Experimental|Dose Level 1: TRC253 40 mg daily|40 mg of single-agent TRC253 to be administered as oral capsules once daily
9844879|NCT02987829|Experimental|Dose Level 2: TRC253 80 mg|80 mg of single-agent TRC253 to be administered as oral capsules once daily
9844880|NCT02987829|Experimental|Dose Level 3: TRC253 160 mg|160 mg of single-agent TRC253 to be administered as oral capsules once daily
9844881|NCT02987829|Experimental|Dose Level 4: TRC253 240 mg|240 mg of single-agent TRC253 to be administered as oral capsules once daily
9844882|NCT02987829|Experimental|Dose Level 5: TRC253 280 mg|280 mg of single-agent TRC253 to be administered as oral capsules once daily
9844883|NCT02987829|Experimental|Dose Level 6: TRC253 320 mg|320 mg of single-agent TRC253 to be administered as oral capsules once daily
9844884|NCT02987868|Active Comparator|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
9844885|NCT02987868|Placebo Comparator|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
9844887|NCT02987972|Experimental|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
9844888|NCT02987972|Experimental|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
9844889|NCT02987972|Active Comparator|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
9844890|NCT02988050|Other|Propofol-dexmedetomidine|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
9844891|NCT02988050|Other|Propofol-remifentanil|Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
9844892|NCT02988115|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
9844893|NCT02988115|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
9844894|NCT02988193|Experimental|optima4BP Medication Management|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:~curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;~medication treatment recommendation;~active link to access additional treatment analysis tools."
9844895|NCT02988193|No Intervention|Usual Care Medication Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
9844896|NCT02988219|Active Comparator|General anesthesia (G)|Holter ECG monitor General anesthesia Open kidney cancer surgery
9844897|NCT02988219|Experimental|Combined general/epidural (G/E)|Holter ECG monitor Epidural anesthesia General anesthesia Open kidney cancer surgery
9844898|NCT02988349|Active Comparator|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
9844899|NCT02988349|Experimental|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
9844900|NCT02988622|Other|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
9844901|NCT02988843|Experimental|Brentuximab Vedotin & Bevacizumab|"Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.~Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
9844902|NCT02988856|Experimental|Magnetic lid system|All participants will trial a commercially available device and an experimental magnetic device.
9844903|NCT02988882|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
9844904|NCT02988882|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
9844905|NCT02988986|Experimental|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
9844906|NCT02989168|Experimental|GBT440 900 mg Dose|"Part A, 900 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
9844907|NCT02989168|Experimental|GBT440 1500 mg Dose|"Part B , 1500 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
9844908|NCT02989246|Experimental|Intervention Arm|Ventilator management using the proposed protocol in both acute and weaning phases. Patients will be managed according the the Ventilator protocol using the esophageal catheter for the weaning phase
9844909|NCT02989389|Experimental|LY3323795 (Part A)|Participants received escalating doses of 0.3 mg (milligrams), 1 mg, 3 mg, 10 mg, 30 mg and 100 mg of LY3323795 orally.
9844910|NCT02989389|Placebo Comparator|Placebo (Part A)|Participants received placebo identical to LY3323795 orally.
9844911|NCT02989389|Experimental|LY3323795 (Part B)|Participants received 6 mg, 20 mg and 80 mg of LY3323795 orally.
9844912|NCT02989389|Placebo Comparator|Placebo (Part B)|Participants received placebo identical to LY3323795 orally.
9844913|NCT02989389|Experimental|LY3323795 (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
9844914|NCT02989389|Experimental|LY3323795 + Itraconazole (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
9844915|NCT02989493|Experimental|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
9844916|NCT02989493|Placebo Comparator|Placebo|Participants will receive 8 weeks of matched placebo.
9844917|NCT02989545|No Intervention|Off treatment|2 week period without intervention
9844918|NCT02989545|Experimental|Treatment period|2 week period with intervention
9844919|NCT02989610|Experimental|Omnidirectional followed by directional DBS|Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary endpoint is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.
9844920|NCT02989649||Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)|Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.
9844921|NCT02989714|Experimental|HD IL2 and Nivolumab|
9844922|NCT02989727|Experimental|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
9844923|NCT02989727|Placebo Comparator|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
9844924|NCT02989727|Experimental|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
9844925|NCT02989727|Placebo Comparator|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
9844926|NCT02989805|Active Comparator|Professional Care Manager|Each participating site will have a nurse or social worker to provide care management. Training activities will include modules for each of the key domains covered in the intervention: shared decision making, action planning; motivational interviewing; and mental health as a cornerstone of recovery, working effectively within the mental health system; and self-care and stress management.
9922573|NCT00840853|Experimental|Group B with disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
9844927|NCT02989805|Experimental|Peer Specialist Care Manager|Each participating site will have a peer specialist to provide care management. Peer specialists will have a minimum of a high school education, a history of a mental illness, be self-described as 'in recovery,' and have reliable transportation to the study site. All certified peer specialists will receive training in a curriculum that supports identifying and pursuing goals for recovery; developing and documenting recovery-focused treatment plans; and supporting linkages with community-based services. Peers learn to help other individuals with mental health conditions to facilitate mental health dialogues; explore mental health choices and options; identify and work with a clinician; and obtain access to community health supports.
9844928|NCT02990000|No Intervention|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
9844929|NCT02990000|Experimental|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
9844930|NCT02990910|Other|Individualized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
9844931|NCT02990910|Other|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
9844932|NCT02991040|Experimental|Revanesse Ultra+|Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine
9844933|NCT02991118|Experimental|bempedoic acid|bempedoic acid 180 mg/day
9844934|NCT02991118|Placebo Comparator|Placebo|Placebo control
9844935|NCT02991729|Active Comparator|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
9844936|NCT02991729|Experimental|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
9844937|NCT02991820|Experimental|Inexperienced users|Inexperienced users will include trainees (SRNAs, residents, fellows, and medical students) and nurses at NCH.
9844938|NCT02991820|Experimental|Experienced users|Experienced users will include faculty pediatric anesthesiologists CRNAs.
9844939|NCT02991859|Experimental|Arm AB - FF followed by FP|Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose [TDD] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
9844940|NCT02991859|Experimental|Arm AC - FF followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
9844941|NCT02991859|Experimental|Arm AD - FF followed by ELLIPTA Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.
9844942|NCT02991859|Experimental|Arm BA - FP followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
9922574|NCT00840853|Experimental|Group B without disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, without detectable disease post-HSCT~Patients will receive CD19CAR/virus specific T cells -~Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
9844943|NCT02991859|Experimental|Arm BC - FP followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
9844944|NCT02991859|Experimental|Arm BE - FP followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.
9844945|NCT02991859|Experimental|Arm CA - BUD followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
9844946|NCT02991859|Experimental|Arm CB - BUD followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
9844947|NCT02991859|Experimental|Arm CE - BUD followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.
9844948|NCT02991859|Experimental|Arm DA - ELLIPTA Placebo followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
9844949|NCT02991859|Experimental|Arm EB - DISKUS Placebo followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
9922575|NCT00840892|Experimental|Intercom|INTERdisciplinary COMmunity-based COPD management (INTERCOM)
9922576|NCT00840892|No Intervention|Usual Care|
9517001|NCT03310359|Placebo Comparator|Placebo|Subjects will be given capsules containing placebo and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
9922577|NCT00840905||1|HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
9922578|NCT00840905||2|A cohort of HIV seropositive women from Gabarone Botswana
9922579|NCT00840905||3|A cohort of HIV seropositive women from Rio De Janeiro Brasil
9844950|NCT02991859|Experimental|Arm DC - ELLIPTA Placebo followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
9844951|NCT02991898|Experimental|Treg Infusion|The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
9844952|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
9844953|NCT02992132|Experimental|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
9844954|NCT02992132|Experimental|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
9844955|NCT02992132|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
9844956|NCT02992197|Active Comparator|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
9844957|NCT02992197|Experimental|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
9844958|NCT02992236|Placebo Comparator|Placebo|Infusion (6 hours) of Saline
9844959|NCT02992236|Active Comparator|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
9844960|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
9844961|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
9844962|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
9844963|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
9844964|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
9844965|NCT02992288|Placebo Comparator|Placebo|Chronic heart failure with reduced ejection fraction
9844966|NCT02992691|Experimental|Test Product 1|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
9844967|NCT02992691|Experimental|Test Product 2|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
9844968|NCT02992691|Experimental|Test Product 3|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
9844969|NCT02992691|Active Comparator|Positive Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
9844970|NCT02992691|Other|Negative Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
9844971|NCT02992899|Experimental|Vagal Nerve Stimulation|Participants randomized to this arm will receive stimulation of the vagus nerve in conjunction with stress exposure.
9844972|NCT02992899|Sham Comparator|Sham Stimulation|Participants randomized to this arm will receive sham stimulation of the vagus nerve in conjunction with stress exposure.
9844973|NCT02993224|Experimental|Deferasirox DT followed by deferasirox FCT|Participants were treated with deferasirox DT followed by deferasirox FCT (core phase). Those who entered the extension phase were treated with deferasirox FCT
9844974|NCT02993250|Experimental|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
9844975|NCT02993250|Experimental|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
9844976|NCT02993302|Active Comparator|PTU-Oral 1α-D3|patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
9844977|NCT02993302|Placebo Comparator|PTU-Placebos|patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
9844978|NCT02993445|Experimental|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
9844979|NCT02993445|Experimental|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
9922580|NCT00840918|Active Comparator|1|Intravenous Lidocaine group
9998289|NCT01516801|Experimental|PSA flyer|
9998290|NCT01516801|No Intervention|Control|
9844980|NCT02993471|Experimental|Drug Cocktail|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1 (day 1).
9844981|NCT02993471|Experimental|Drug Cocktail + Ixekizumab|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.
9844982|NCT02993783|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.
9844983|NCT02993783|Experimental|Vedolizumab 600 mg|Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.
9844984|NCT02994056|Experimental|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
9844985|NCT02994108|Experimental|txt2protect|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination."
9844986|NCT02994108|Active Comparator|Sexual Health Control|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination."
9844987|NCT02994238|Experimental|Intervention|The intervention group will have the full Remote Health Management Sensor Platform. Research staff will review uploaded sensor data on a daily basis. If participants are enrolled into the control group, they will only receive Standard Asthma Education. The Standard Asthma Education follows the National Asthma Education and Prevention Program (NAEPP) guidelines for asthma management. This will include the following topics: 1. Explanation of symptoms; 2. Asthma triggers (description and how to avoid them); 3. Using medications (how to use prescribed asthma medications, the difference between controller medications and rescue inhalers, how to use a spacer, how to use a mask); and 4. Managing asthma control (purpose of asthma control test, asthma action plan, how to use a peak flow meter).
9844988|NCT02994238|No Intervention|Control|The control group will receive only standardized education.
9844989|NCT02994394|Experimental|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
9844990|NCT02994394|Experimental|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
9844991|NCT02994394|Experimental|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
9844992|NCT02994394|Experimental|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
9844993|NCT02994394|Experimental|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
9844994|NCT02994394|Experimental|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
9844995|NCT02994654|Experimental|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
9844996|NCT02994654|Experimental|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
9844997|NCT02994732|Experimental|[14C]-BVD-523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
9844998|NCT02994940|Experimental|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
9844999|NCT02994940|Experimental|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
9845000|NCT02994979|Experimental|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
9845001|NCT02994979|Sham Comparator|Usual care group|Usual care plus a sham visit from the intervention CNA
9845002|NCT02995915|Experimental|Tele-health Mobile Contingency Management Intervention|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
9922581|NCT00840918|Placebo Comparator|Placebo|Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
9517002|NCT03310333|Experimental|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
9845003|NCT02995915|Active Comparator|Tele-health for Alcohol and Smoking Cessation|This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence.
9845004|NCT02995980|Experimental|Contrast enhanced mammography vs standard digital mammogram|Contrast-enhanced spectral mammography for the detection breast cancer .
9845005|NCT02996097|Experimental|CO2 ablative laser plus intralesional triamcinolone acetonide|A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
9845006|NCT02996097|Active Comparator|Intralesional triamcinolone acetonide alone|A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
9845007|NCT02996448|Experimental|NDV 3A vaccine|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
9845008|NCT02996474|Experimental|Pembrolizumab and Decitabine for treatment of AML|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days. Decitabine will be administered at a dose of 20 mg/m2 by intravenous infusion over approximately 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7) for treatment relapsed/refractory AML.
9845009|NCT02996500|Experimental|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
9845010|NCT02996500|Experimental|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
9845011|NCT02996500|Experimental|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
9845012|NCT02996500|Experimental|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
9845013|NCT02996500|Placebo Comparator|Placebo|Placebo, 0 mg BID
9845014|NCT02996500|Active Comparator|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
9845015|NCT02996591|Active Comparator|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
9845016|NCT02996591|Active Comparator|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
9845017|NCT02996682|Experimental|SOF/VEL|SOF/VEL for 12 weeks
9845018|NCT02996682|Experimental|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
9845019|NCT02996864|Experimental|Healthy Detours App|Participants will be encouraged to use the Healthy Detours app daily to track food, physical activity, and sleep.
9845020|NCT02996864|Placebo Comparator|Fat Secret App|Participants will be encouraged to use the FatSecret application daily to track food and physical activity.
9845021|NCT02996968|Experimental|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
9845022|NCT02996968|No Intervention|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
9845023|NCT02997085|Experimental|Live-Action 360° Video Virtual Reality|
9845024|NCT02997085|Active Comparator|CGI 360° Video Virtual Reality|
9845025|NCT02997085|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
9845026|NCT02997163|Experimental|Group A (control, normal renal function)|
9845027|NCT02997163|Experimental|Group B (mild renal impairment)|
9845028|NCT02997163|Experimental|Group C (moderate renal impairment)|
9845029|NCT02997163|Experimental|Group D (severe renal impairment)|
9845030|NCT02997176|Experimental|Group A (control, normal hepatic function)|
9845031|NCT02997176|Experimental|Group B (mild hepatic dysfunction)|
9845032|NCT02997176|Experimental|Group C (moderate hepatic dysfunction)|
9845033|NCT02997176|Experimental|Group D (severe hepatic dysfunction)|
9845034|NCT02997722|Experimental|Ketamine infusion|Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.
9845035|NCT02997722|Placebo Comparator|Normal Saline infusion|Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.
9998291|NCT01516814|Experimental|Arm 1|
9845036|NCT02997735|Experimental|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
9845037|NCT02997735|Other|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
9845038|NCT02997904|Experimental|Resultz Lice and Egg Elimination Kit|Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
9845039|NCT02997904|Placebo Comparator|Placebo Lice and Egg Elimination Kit|20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour
9845040|NCT02998021|Experimental|Resistance Training - Vibrating Dumbbell|Study participants who are randomized into the vibration exercise group will complete an in-home exercise program using a vibrating dumbbell.
9845041|NCT02998021|Active Comparator|Resistance Training - Standard Dumbbell|Study participants who are randomized into the control exercise group will complete an in-home exercise program using standard dumbbells.
9845042|NCT02998151|Experimental|All Study Participants|Participants received, in random order, a single dose of placebo, acamprosate, lovastatin, minocycline, or baclofen, with a two-week washout period between doses. Midway through the study (n=16) it was determined that acamprosate was undetectable in serum and this intervention was replaced by baclofen. Remaining participants (n=13) received baclofen and 5 participants were re-enrolled to receive baclofen or a second round of placebo, so investigators and participants would remain blinded to drug status during the baclofen visit. The second round of placebo was not analyzed.
9845043|NCT02998541|Experimental|SHP640|Participants will receive one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
9845044|NCT02998541|Active Comparator|PVP-I 0.6%|Participants will receive one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
9845045|NCT02998541|Placebo Comparator|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID for 7 days.
9845046|NCT02998554|Experimental|SHP640|Participants instructed to instill 1 drop of SHP640 (Povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
9845047|NCT02998554|Placebo Comparator|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
9845048|NCT02998671|Experimental|Group 1: CJM112 high dose|CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
9845049|NCT02998671|Experimental|Group 2: CJM112 low dose|CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
9845050|NCT02998671|Placebo Comparator|Group 3: Placebo, CJM112 low dose or high dose|Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
9845051|NCT02998684|Active Comparator|Active Transcranial Direct Current Stimulation|Participants will receive active Transcranial Direct Current Stimulation
9845052|NCT02998684|Sham Comparator|Sham Transcranial Direct Current Stimulation|Participants will receive sham Transcranial Direct Current Stimulation
9845053|NCT02998996|Experimental|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
9998292|NCT01516814|Active Comparator|Arm 2|
9845054|NCT02998996|Experimental|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
9845055|NCT02998996|Experimental|Influenza antigen,|15 µg HA/strain
9845056|NCT02998996|Placebo Comparator|Saline (NaCl),|Placebo
9845057|NCT02998996|Active Comparator|i.m. comparator,|15 µg HA/strain
9845058|NCT02998996|Active Comparator|i.n. comparator|
9845059|NCT02999100|Experimental|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
9845060|NCT02999100|Experimental|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
9845061|NCT02999100|Experimental|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
9845062|NCT02999178|Experimental|Nintedanib|
9845063|NCT02999178|Placebo Comparator|Placebo|
9845064|NCT02999191|Experimental|BI 1467335 (Treatment A)|Tablet under fasted conditions
9845065|NCT02999191|Experimental|BI 1467335 (Treatment B)|Oral solution under fasted conditions
9845066|NCT02999191|Experimental|BI 1467335 (Treatment C)|Tablet under fed conditions
9845067|NCT02999672|Experimental|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
9845068|NCT02999672|Experimental|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
9845069|NCT02999763|Experimental|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
9845070|NCT03000010|Active Comparator|Incisional Wound Vac|We will attach sponges and a suction tube to the incision after surgery. We will leave it on for 72 hours. From then on, patients will get the care that patients normally get after spinal fusion surgery.
9845071|NCT03000010|Active Comparator|Normal Gauze Bandage Group|We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
9845072|NCT03000075|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9845073|NCT03000075|Experimental|Risankizumab 75 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9845074|NCT03000075|Experimental|Risankizumab 150 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
9845075|NCT03000088||60° angle group|intubate using McGrath Videolaryngoscope with 60° angled stylet
9845076|NCT03000088||90°angle group|intubate using McGrath Videolaryngoscope with 90° angled stylet
9845077|NCT03000166|Experimental|Step-Up Intervention Group|Participants assigned to the Step-up intervention group will receive a 12-week physical activity intervention which includes components of education, negotiated collaboration to set individual physical activity goals during chemotherapy cycles, and tools for self-monitoring of physical activity.
9845078|NCT03000166|No Intervention|Attention Control Group|Participants assigned to the attention control group will receive usual guidance about maintaining physical activity during chemotherapy from their oncology providers.
9845079|NCT03000283|Experimental|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
9845080|NCT03000309|Other|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
9845081|NCT03000348|Active Comparator|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
9845082|NCT03000348|Active Comparator|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
9845083|NCT03000348|Active Comparator|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
9845084|NCT03000348|Placebo Comparator|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
9845085|NCT03000348|Active Comparator|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
9845086|NCT03000348|Active Comparator|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
9845087|NCT03000452|Experimental|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks [Q2W], or every 4 weeks [Q4W] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
9845088|NCT03000608|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
9845089|NCT03000608|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
9845090|NCT03000673|Active Comparator|Dose Sequence 1|UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
9845091|NCT03000673|Active Comparator|Dose Sequence 2|BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
9845092|NCT03000673|Active Comparator|Dose Sequence 3|BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
9845093|NCT03000673|Active Comparator|Dose Sequence 4|Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
9845094|NCT03000686|Experimental|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
9845095|NCT03000686|Experimental|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
9845096|NCT03001076|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
9845097|NCT03001076|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
9845098|NCT03001219|Placebo Comparator|Part 1: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
9845099|NCT03001219|Experimental|Part 1: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
9845100|NCT03001219|Placebo Comparator|Part 2: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
9845101|NCT03001219|Experimental|Part 2: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
9845102|NCT03001219|Placebo Comparator|Part 3: Placebo|"Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
9845103|NCT03001219|Experimental|Part 3: RO7123520|"Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
9845104|NCT03001258||PO (program organizers)|"PO (program organizers): Employed by Brac as field level organizers. A two day presbyopia screening training were provided.~A total of eight POs organized eye camps in two sub districts. POs were responsible for identifying the presbyopia patients through screening and SS assisted in organizing and mobilizing the community people for the eye camps, and glass sale (on the spot). Four camps were organized per day for five days by four POs in each sub-district. Thus a total of 40 eye camps were held in two sub districts by eight POs."
9845105|NCT03001258||USS (Upgraded Shashthya Shebika)|"USS (Upgraded Shashthya Shebika): A new caddre of community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, 20 USSs were assigned in two upazillas to run the two camp-day i.e. screening patients and selling glasses during the total 40 eye camps."
9845106|NCT03001258||SS (Shashthya Shebika)|"SS: Community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, the SS, undertook the screening of potential presbyopia cases. A total of 27 SS organized 25 eye camps in eight days in two upazilas."
9998293|NCT01516814|Active Comparator|Arm 3|
9845107|NCT03001453|Active Comparator|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
9845108|NCT03001453|Active Comparator|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
9845109|NCT03001557|Experimental|Lemborexant 2.5 milligrams (mg)|Participants will take one lemborexant 2.5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
9845110|NCT03001557|Experimental|Lemborexant 5 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
9845111|NCT03001557|Experimental|Lemborexant 10 mg|Participants will take one lemborexant 10 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
9845112|NCT03001557|Experimental|Lemborexant 15 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant 10 mg tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
9845113|NCT03001557|Placebo Comparator|Lemborexant-matched placebo|Participants will take two lemborexant-matched placebo tablets orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
9845114|NCT03001674|Experimental|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
9845115|NCT03001674|Experimental|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction > 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
9845116|NCT03001778|Experimental|Usability Testing|Prototype testing
9845117|NCT03001843|Active Comparator|Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
9845118|NCT03001843|Active Comparator|Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
9845119|NCT03002012|Experimental|Sertraline|Fluconazole Standard of Care + Sertraline
9845120|NCT03002012|Placebo Comparator|Control|Fluconazole Standard of Care + Placebo Oral Tablet
9845121|NCT03002038|Experimental|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
9845122|NCT03002038|Experimental|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
9845123|NCT03002077|Experimental|Rapastinel|Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks.
9845124|NCT03002194|Experimental|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
9845125|NCT03002311|No Intervention|Control|Receiving current standard of care as designated by emergency department (ED) standard operating practice.
9845126|NCT03002311|Experimental|Epharmix/CareSignal eHealth Intervention|After randomization, participants receive text reminders to have a follow-up visit. The participant can respond to these messages via numerical or binary answers (Y/N).
9845127|NCT03002454|Experimental|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
9845128|NCT03002506|Experimental|ceftolozane/tazobactam|One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
9845129|NCT03002610|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
9845130|NCT03002610|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
9845131|NCT03002610|Active Comparator|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
9845132|NCT03002623|Experimental|Group|CUDC-907 for thyroid cancer
10207242|NCT02262026|Experimental|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
10207243|NCT02262026|Experimental|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
10207244|NCT02262026|Experimental|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
10207245|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
10207246|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
10207247|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
10207248|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
9845133|NCT03002753|Experimental|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
9845134|NCT03002753|Active Comparator|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
9845135|NCT03002753|No Intervention|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
9845136|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
9845137|NCT03002974|Experimental|Anakinra 100 mg|1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
9845138|NCT03002974|Experimental|Anakinra 200 mg|2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
9845139|NCT03002974|Active Comparator|Triamcinolone 40 mg|2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
9845140|NCT03003000|Experimental|ibuprofen + caffeine|Fixed Dose Combination
9845141|NCT03003000|Active Comparator|ibuprofen|
9845142|NCT03003000|Placebo Comparator|placebo|
9845143|NCT03003130|Experimental|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
9845144|NCT03003130|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
9845145|NCT03003390|Experimental|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
9845146|NCT03003390|No Intervention|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
9845147|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
9845148|NCT03003676|Experimental|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|"Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).~Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose)."
9845149|NCT03003793||Control group|Healthy control subjects
9845150|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis
9845151|NCT03003949|Placebo Comparator|Placebo Patch and Placebo Capsule|Placebo patches worn for 16 weeks. On the 9th week of patch, oral placebo capsule taken daily for 12 days. Following the 16 weeks of patch use oral placebo capsule taken daily for 12 days.
9845152|NCT03003949|Active Comparator|Estradiol patch and progesterone capsule|Estradiol patches worn for 16 weeks. On the 9th week of patch, oral progesterone capsule taken daily for 12 days. Following the 16 weeks of estradiol patch use oral progesterone capsule taken daily for 12 days.
9845153|NCT03004469|Experimental|P-3074 + Finasteride Placebo|Participants received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 milligram (mg) tablet orally once daily for 24 weeks.
9845154|NCT03004469|Placebo Comparator|P-3074 Vehicle + Finasteride Placebo|Participants received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.
9845155|NCT03004469|Active Comparator|Oral Finasteride + P-3074 Vehicle|Participants received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.
9845156|NCT03004534|Experimental|Presurgical Molecular Assessment|Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.
10207249|NCT02262026|Active Comparator|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
10207250|NCT02262026|Active Comparator|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
10207251|NCT02248688|Other|Embolic Agent - BeadBlock|Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
10207252|NCT02224924|Active Comparator|autologous blood patch injection (ABPI)|
10207253|NCT02224924|Experimental|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|
10207254|NCT02159989|Experimental|Treatment (sapanisertib, ziv-aflibercept)|Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10207255|NCT02124902|Experimental|Washington University: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion. A total of 6 cycles will be given.
10207256|NCT02124902|Experimental|Baylor: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
10213479|NCT03915678|Experimental|Population 1: Pancreatic cancer|Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
9845157|NCT03004638|Experimental|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
9845158|NCT03004638|Placebo Comparator|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
9845159|NCT03004638|Experimental|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
9845160|NCT03004638|Experimental|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
9845161|NCT03004638|Experimental|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
9845162|NCT03004638|Placebo Comparator|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
9845163|NCT03004846|Experimental|Part A: GSK2981278 4%|Subjects will receive topical application of GSK2981278 4% ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
9845164|NCT03004846|Experimental|Part B: GSK2981278 4% and vehicle|In Part B, subjects will receive topical application of GSK2981278 4 % ointment or vehicle ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
9845165|NCT03004911|Experimental|Mobile application|
9845166|NCT03004911|Active Comparator|Paper booklet|
9845167|NCT03004924|Experimental|SHP640|Participants will instill 1 drop of SHP640 (povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
9845168|NCT03004924|Active Comparator|PVP-I 0.6%|Participants will instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID for 7 days
9845169|NCT03004924|Placebo Comparator|Placebo|Participants will instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
9845170|NCT03005041|Experimental|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
9845171|NCT03005041|Other|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
9845172|NCT03005054|Experimental|StrataGraft skin tissue|
9845173|NCT03005067|Experimental|Carbomer 980 (1146A)|Participants will be administered test product (nasal spray) containing carbomer 980 gel. Three actuations per nostril per dose will be applied, each actuation will be 140µL (microliters) i.e. equivalent to 140mg.
9845174|NCT03005067|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980. Three actuations of placebo nasal spray per nostril per dose; each actuation will be 140µL.
9845175|NCT03005106|Experimental|StrataGraft Skin Tissue|
9845176|NCT03005288|Experimental|BYM338 10 mg/kg|Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
9845177|NCT03005288|Placebo Comparator|Placebo|Placebo, every 4 weeks until week 44 (12 doses)
9845178|NCT03006341||Dabigatran etexilate|NVAF patients initiating dabigatran etexilate
9845179|NCT03006341||Warfarin|NVAF patients initiating warfarin
9845180|NCT03006393|Experimental|Infliximab|Participants randomized to the infliximab group will receive one infusion of infliximab at 5mg/kg body weight.
9845181|NCT03006393|Placebo Comparator|Placebo|Participants randomized to the placebo group will receive one placebo infusion.
9845182|NCT03006458|Experimental|comfilcon A|"Participants were randomized to wear comfilcon A toric lenses for two weeks during the cross over study.~The final optical design of comfilcon A contact lens was optimized to improve the quality and two further studies (CV-18-10 and CV-18-11) were conducted after completion of this study to evaluate the modified optical design."
9845183|NCT03006458|Active Comparator|omafilcon B|Participants were randomized to wear omafilcon B toric lenses for two weeks during the cross over study.
9845184|NCT03006471|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
9845185|NCT03006471|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
9845186|NCT03006562|Experimental|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
9845187|NCT03006562|No Intervention|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
9845188|NCT03006848|Experimental|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.~Interventions: Avelumab and quality of life questionnaires."
9845189|NCT03006887|Experimental|lenvatinib 20 mg plus pembrolizumab 200 mg|Participants with selected tumors will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once daily in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
10213480|NCT03915678|Experimental|Population 2: Virus-associated tumors|Participants with virus-associated tumors will be treated with Atezolizumab combined with BDB001 and radiotherapy.
10213481|NCT03915678|Experimental|Population 3: anti-PD-1/L1 refractory non-small lung cancer|Participants with anti-PD-1/L1 refractory non-small lung cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
10213482|NCT03915678|Experimental|Population 4: Soft-tissue sarcoma|Participants with soft-tissue sarcoma will be treated with Atezolizumab combined with BDB001 and radiotherapy.
9845190|NCT03007225|Active Comparator|group 1 Drug eluting beads intervention|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
9845191|NCT03007225|Active Comparator|group 2 Conventional TACE intervention|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
9845192|NCT03007394|Active Comparator|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
9845193|NCT03007394|Placebo Comparator|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
9845194|NCT03007472|Experimental|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
9845195|NCT03007953|Experimental|Intervention|This is a nurse-led telephone-based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer, who will receive therapy other than solely surgical resection. The intervention lasts for the duration of patients' primary lung cancer treatment (usually 3-4 months).
9845196|NCT03007953|No Intervention|Usual Care|Subjects randomized to the usual care arm will receive medical oncology, radiation oncology, pulmonary, CT surgery, as indicated by the type and stage of cancer. At the completion of their primary lung cancer treatment, they will be disenrolled from the study.
9845197|NCT03007966|Active Comparator|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
9845198|NCT03007966|Experimental|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
9845199|NCT03008070|Experimental|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
9845200|NCT03008070|Experimental|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
9845201|NCT03008070|Placebo Comparator|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
9922582|NCT00840931|Experimental|Immunotherapy|Participants will take two 5 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Participants will receive 4 treatment cycles with 28 days in each cycle. Those participants showing a clinical response after 4 cycles of treatment may continue to receive lenalidomide as a single agent for additional cycles at the treating Physicians discretion. During each 28 day cycle participants will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
9922583|NCT00840944|Experimental|ZOMATRIP|GnRH agonist triptorelin plus somatropin
9922584|NCT00840957||A|Rhumatoid arthritis patient currently receiving infliximab
9922585|NCT00840983|No Intervention|1-Immediate Cord Clamping|infants received the routine care of immediate clamping of the umbilical cord
9922586|NCT00840983|Experimental|2-Delayed Cord Clamping|after birth, cord clamping was delayed 30 to 45 seconds while infant was held lower than the level of the placenta.
9922587|NCT00841022|Experimental|1|Information of children with comic leaflet
9922588|NCT00841022|No Intervention|2|
9922589|NCT00841048|Experimental|1|AZD4017 in ascending doses (start dose 75mg od)
10207257|NCT02113878|Experimental|BKM120|"Participants will be enrolled in cohorts of 3- 6 per dose level. Once the MTD is reached, an additional 10 patients will be treated at that dose level and an amendment will be submitted to declare the dose.~BKM120 will start 2 weeks prior to first dose of cisplatin and radiation start. During the study, BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.~Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).~Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
10207258|NCT02101970|Experimental|Weight Loss + Omega-3 FA|Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
10207259|NCT02101970|Active Comparator|Weight Loss + Placebo|Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
10207260|NCT02097680|Experimental|Letrozole|
10207261|NCT02097680|Placebo Comparator|Placebo comparator|
10207262|NCT02088554|Experimental|Model 400 aortic valve bioprosthesis|
10207263|NCT02076906|Experimental|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
10207264|NCT02045303|Experimental|Ambulatory Wound Clinic|Intervention with contact ultrasound therapy and noncontact ultrasound therapy following the study protocol on subjects receiving care at the wound clinic.
10207265|NCT02025556|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
10207266|NCT02025556|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
9845202|NCT03008174|Experimental|Intervention|"Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
9845203|NCT03008174|No Intervention|Control|"Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
9845204|NCT03008213|Experimental|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
9845205|NCT03008460|Experimental|Eziclen®/Izinova®|
9845206|NCT03008460|Active Comparator|Klean-Prep®|
9845207|NCT03008590|Other|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
9845208|NCT03008590|Other|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
9845209|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
9845210|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
9845211|NCT03008837|Experimental|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
9845212|NCT03008837|Active Comparator|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
9845213|NCT03008889|Experimental|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
9845214|NCT03008889|Placebo Comparator|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
9845215|NCT03008915|Active Comparator|Aspirin first then placebo|Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
9845216|NCT03008915|Placebo Comparator|Placebo first then aspirin|Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
9845217|NCT03009162|Experimental|Renal impaired participants|Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
9845218|NCT03009162|Experimental|Healthy participants|Participants received single 200 mg oral tablet of lasmiditan.
9845219|NCT03009396|Experimental|RHB-104 - patients on ACTIVE therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study
9845220|NCT03009396|Experimental|RHB-104 - patients on PLACEBO therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.
9845221|NCT03010137|Placebo Comparator|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
9845222|NCT03010137|Active Comparator|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
9845223|NCT03010254|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
9845224|NCT03010254|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
9845225|NCT03010462|Active Comparator|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
9845226|NCT03010462|Sham Comparator|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
9845227|NCT03010488|Experimental|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
9845228|NCT03010488|Active Comparator|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
9845229|NCT03010501|Experimental|100% Food Energy Density|Baseline Food Energy Density
9845230|NCT03010501|Experimental|80% Food Energy Density|Lower Food Energy Density
9845231|NCT03010501|Experimental|120% Food Energy Density|Higher Food Energy Density
9845232|NCT03010527|Placebo Comparator|Placebo|Subjects with a PASI90 response at Week 12 and receiving Placebo in PS0010 entering PS0011 will receive Placebo.
9845233|NCT03010527|Experimental|Bimekizumab dosing regimen 1|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 will be assigned to a higher dosing regimen."
9845234|NCT03010527|Experimental|Bimekizumab dosing regimen 2|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 will be assigned to a higher dosing regimen."
9845235|NCT03010527|Experimental|Bimekizumab dosing regimen 3|Subjects that were initially randomized to bimekizumab dosage regimen 3, 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3.
9845236|NCT03010631|Active Comparator|Cohort 1 (Treatment Sequence AB)|Cohort 1: Treatment A. Capsule Fasted (7-day Washout) then Treatment B. Sprinkle Formulation, Fasted
9845237|NCT03010631|Experimental|Cohort 1 (Treatment Sequence BA)|Cohort 1: Treatment B. Sprinkle Formulation, Fasted (7-day Washout) then Treatment A. Capsule Fasted
9845238|NCT03010631|Experimental|Cohort 2 (Treatment Sequence CD)|Cohort 2: Treatment C: Sprinkle Formulation, Fed (7-day Washout) then Treatment D: Sprinkle Formulation, Fasted
9845239|NCT03010631|Experimental|Cohort 2 (Treatment Sequence DC)|Cohort 2: Treatment D: Sprinkle Formulation, Fasted (7-day Washout) then Treatment C. Sprinkle Formulation, Fed
9845240|NCT03010683|Active Comparator|liraglutide|
9845241|NCT03010683|Active Comparator|Metformin|
9845242|NCT03010800|Experimental|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
9845243|NCT03010800|Experimental|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
9845244|NCT03011099|Experimental|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
9845245|NCT03011099|Active Comparator|Conventional Physical Therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
9845246|NCT03011333|Experimental|Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 60 mg/1.8 mg via nerve block.
9845247|NCT03011333|Experimental|Group 2: HTX-011|HTX-011(bupivacaine/meloxicam), 120 mg/3.6 mg via nerve block.
9845248|NCT03011333|Experimental|Group 3: HTX-011|HTX-011(bupivacaine/meloxicam), 240 mg/7.2 mg via nerve block.
9845249|NCT03011333|Experimental|Group 4: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via nerve block.
9845250|NCT03011333|Experimental|Group 5: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/ 12 mg via instillation.
10207267|NCT02025556|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
10207268|NCT01995708|Experimental|Arm 1 Vaccine|This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical & Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10^6 LCs per dose (i.e., combination of 3x10^6 CT7 mRNA-electroporated LCs + 3x10^6 MAGE-A3 mRNA-electroporated LCs + 3x10^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
10207269|NCT01995708|Active Comparator|Arm 2 control|Patients receive standard of care treatment after autologous stem cell transplant
9845251|NCT03011333|Active Comparator|Group 6: Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
9845252|NCT03011333|Placebo Comparator|Group 7: Saline Placebo|Saline placebo via nerve block.
9845253|NCT03011840|No Intervention|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
9845254|NCT03011840|Experimental|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
9845255|NCT03011892|Placebo Comparator|Double Blind (DB): Vehicle BID|Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
9922590|NCT00841048|Placebo Comparator|2|Placebo
10207270|NCT01995578|Experimental|low dose 5'-azacitidine|This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
10207271|NCT01986933|Experimental|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
10207272|NCT01986933|Experimental|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
10207273|NCT01986933|Experimental|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
9845256|NCT03011892|Active Comparator|DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID|Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
9845257|NCT03011892|Experimental|DB: Ruxolitinib 0.15% Once Daily (QD)|Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
9845258|NCT03011892|Experimental|DB: Ruxolitinib 0.5% QD|Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
9845259|NCT03011892|Experimental|DB: Ruxolitinib 1.5% QD|Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
9845260|NCT03011892|Experimental|DB: Ruxolitinib 1.5% BID|Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
9845261|NCT03011892|Placebo Comparator|Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
9845262|NCT03011892|Active Comparator|OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
9845263|NCT03011892|Experimental|OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
9845264|NCT03011892|Experimental|OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
9845265|NCT03011892|Experimental|OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
10207274|NCT01986933|Experimental|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
9845266|NCT03011892|Experimental|OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
9845267|NCT03012061|Placebo Comparator|Placebo|Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.
9845268|NCT03012061|Experimental|UMEC 62.5 mcg|Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
9845269|NCT03012061|Experimental|UMEC 31.25 mcg|Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
9845270|NCT03012191|Experimental|Gentamicin|Topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
9845271|NCT03012334|Experimental|Lasmiditan 50mg (milligrams)|Participants received 50mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
9845272|NCT03012334|Experimental|Lasmiditan 100mg|Participants received 100mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
9845273|NCT03012334|Experimental|Lasmiditan 200mg|Participants received 200mg of Lasmiditan tablets given as single doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
9845274|NCT03012334|Active Comparator|Alprazolam 1mg|Participants received 1mg of Alprazolam tablets as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
9845275|NCT03012334|Placebo Comparator|Placebo|Participants received placebo tablets identical to Lasmiditan, administered as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
9845276|NCT03012477|Experimental|cisplatin + AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.~AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
9845277|NCT03012594|Experimental|Lanreotide|Open label
9845278|NCT03012828|Experimental|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
9845279|NCT03012828|Experimental|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
9845280|NCT03012828|Experimental|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
10207275|NCT01986933|Experimental|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
9845281|NCT03012828|Experimental|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
9845282|NCT03012828|Experimental|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
10213483|NCT03915678|Experimental|Population 5: anti-PD-1/L1 refractory bladder cancer|Participants with anti-PD-1/L1 refractory bladder cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
10213484|NCT03915678|Experimental|Population 6: Triple negative breast cancer|Participants with triple negative breast cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
9845283|NCT03012828|Placebo Comparator|Placebo|10 subjects will receive a single oral dose of placebo
9845284|NCT03012841|Experimental|Treatment Arm|Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter
10213485|NCT03913104|Experimental|Medication Abortion Patients|Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
9922591|NCT00841061|Active Comparator|Cereal L|Rice cereal with electrolytic iron
9922592|NCT00841061|Active Comparator|Cereal M|Rice cereal with ferrous fumarate
9845285|NCT03013985|Experimental|Basal bolus insulin with glargine U300 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U300 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose described above will be given. Half of TDD will be given as glargine U300 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
9845286|NCT03013985|Active Comparator|Basal bolus insulin with glargine U100 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U100 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose as described above will be given. Half of TDD will be given as glargine U100 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
9845287|NCT03014011|Other|Hypoglycaemic clamp first, then euglyceamic clamp|First intervention with a hypoglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with an euglycaemic clamp (approximately 5 hours).
9845288|NCT03014011|Other|Euglycaemic clamp first, then hypoglycaemic clamp|First intervention with an euglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with a hypoglycaemic clamp (approximately 5 hours).
9845289|NCT03014180|Experimental|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
9845290|NCT03014479|Experimental|Trelagliptin|Trelagliptin 100 mg, orally, once weekly for up to 12 weeks. Trelagliptin 50 mg, orally, once weekly for up to 12 weeks in patients with moderate renal impairment.
9845291|NCT03014479|Active Comparator|Daily DPP-4 inhibitors|An inhibitor orally administered at the dosage and administration in the package inserts for each drug, for up to 12 weeks.
9845292|NCT03014492|Experimental|Collar Group|Soccer girls that wore the collar device
9845293|NCT03014492|No Intervention|No Collar Group|soccer girls that did not wear the collar
9845294|NCT03014674|Experimental|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
9845295|NCT03014674|Experimental|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
9845296|NCT03014674|Active Comparator|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
9845297|NCT03014700|Active Comparator|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
9845298|NCT03014700|Active Comparator|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
9845299|NCT03015116|Active Comparator|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
9845300|NCT03015116|Experimental|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
9845301|NCT03015116|Experimental|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
9845302|NCT03015181|Experimental|Group 1: 1 mg/kg IV Single Dose|Group 1 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 1 mg/kg.
9845303|NCT03015181|Experimental|Group 2: 5 mg/kg IV Single Dose|Group 2 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
9845304|NCT03015181|Experimental|Group 3: 5 mg/kg SC Single Dose|Group 3 subjects received a single SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
9845305|NCT03015181|Experimental|Group 4: 20 mg/kg IV Single Dose|Group 4 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 20 mg/kg.
9845306|NCT03015181|Experimental|Group 5: 40 mg/kg IV Single Dose|Group 5 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 40 mg/kg.
9845307|NCT03015181|Experimental|Group 6: 5 mg/kg SC Multiple Doses|Group 6 subjects received a SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 5 mg/kg.
9922593|NCT00841074|Experimental|1|Peridex mouthwash
9922594|NCT00841074|Placebo Comparator|2|Placebo mouthwash
10207276|NCT01986075|Experimental|Computer-assisted CBT plus Mixed-Amphetamine Salts- Extended Release (MAS-ER)|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
10207277|NCT01986075|Placebo Comparator|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial. Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week.
9845308|NCT03015181|Experimental|Group 7: 20 mg/kg IV Multiple Doses|Group 7 subjects received an IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 20 mg/kg.
9845309|NCT03015220|Experimental|Oral semaglutide 3 mg|
9845310|NCT03015220|Experimental|Oral semaglutide 7 mg|
9845311|NCT03015220|Experimental|Oral semaglutide 14 mg|
9845312|NCT03015220|Active Comparator|Dulaglutide 0.75 mg|
9845313|NCT03015532|Experimental|Cohort 1, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
9845314|NCT03015532|Experimental|Cohort 1, Group 2: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
9845315|NCT03015532|Placebo Comparator|Cohort 1, Group 3: Saline Placebo|Saline placebo via injection
9845316|NCT03015532|Active Comparator|Cohort 1, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
9845317|NCT03015532|Experimental|Cohort 2, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
9845318|NCT03015532|Experimental|Cohort 2, Group 2: HTX-011 + Ropivacaine|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
9845319|NCT03015532|Placebo Comparator|Cohort 2, Group 3: Saline Placebo|Saline placebo via injection
9845320|NCT03015532|Active Comparator|Cohort 2, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
9845321|NCT03015649|Experimental|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
9845322|NCT03015961|Active Comparator|EXPAREL admixed with bupivacaine HCl|EXPAREL 266 mg + bupivacaine HCl
9845323|NCT03015961|Placebo Comparator|Bupivacaine HCl|Bupivacaine HCl
9845324|NCT03016078|Other|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
9845325|NCT03016325|Experimental|Part 1 Cohort 1 HNO Donor|
9845326|NCT03016325|Placebo Comparator|Placebo Part 1 Cohort 1|
9845327|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- low dose|
9845328|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- high dose|
9845329|NCT03016325|Placebo Comparator|Placebo Part 2 Cohort 2|
9845330|NCT03016403|Experimental|Stepped-Care Intervention|Intervention strategies are grounded in evidence-based Cognitive Behavioral Therapy (CBT), that includes stress management and relaxation treatment strategies and coping skills training. Treatment strategies have been adapted from the Transactional Model of Stress and Coping (TMSC), a theoretical model that predicts that individuals who are able to cope and adapt to the stress related to cancer treatment or caregiving will report less psychological distress than those unable to cope.
9845331|NCT03016403|Active Comparator|Enhanced Usual Care|Denver Health, St. Mary's and St. Joseph's hospitals provide supportive mental health care for patients such as printed materials, support groups, crisis counseling, and specialized care (e.g., psychiatric medication). Because the amount of usual mental health care that each patient receives varies at each site, the investigators will standardize and monitor the usual care arm across the three sites with an enhanced usual care condition.
9845332|NCT03016598|Experimental|Oxytocin|Patients in methadone maintenance treatment (MMT) programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring opioid use disorder (OUD) to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
9845333|NCT03016598|Placebo Comparator|Placebo|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
9845334|NCT03017079|Experimental|semi-solidification with nutrient|"semi-solidification with nutrient:after infusion of semi-solid agent, enteral nutrition is applied less than 60 mins.~Intervention: Other: bolus Intermittent enteral feeding"
9845335|NCT03017079|Placebo Comparator|Standard enteral nutrition|"After infusion of Sterile Water for Injection,bolus Intermittent enteral feeding via the nasogastric tube is applied less than 60 mins.~Intervention: Other: Standard enteral feeding"
9845336|NCT03017235|Experimental|NaP/MC Oral Solution|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
9845337|NCT03017235|Active Comparator|PREPOPIK®|
9845338|NCT03017261|Experimental|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
9845339|NCT03017508|Experimental|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
9845340|NCT03017508|Placebo Comparator|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
9922595|NCT00841113|Experimental|1 Abarelix|Investigative drug
9845341|NCT03017612|Experimental|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
9845342|NCT03017846|Experimental|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
9845343|NCT03017924|Experimental|Q collar|Subjects that will wear the Q collar during the breacher training
9845344|NCT03017924|No Intervention|No collar|Subjects that will not wear the Q collar during the breacher training
9845345|NCT03017937|Experimental|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
9845346|NCT03018028|Experimental|Oral semaglutide 3 mg|
9845347|NCT03018028|Experimental|Oral semaglutide 7 mg|
9845348|NCT03018028|Experimental|Oral semaglutide 14 mg|
9845349|NCT03018028|Placebo Comparator|Oral placebo|
9845350|NCT03018028|Active Comparator|Liraglutide 0.9 mg|
9845351|NCT03018106|Experimental|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
9845352|NCT03018106|Active Comparator|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
9845353|NCT03018223|Experimental|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.~Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.~Peripheral blood hematopoietic cell transplantation~Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.~Growth factor support: G-CSF"
9845354|NCT03018249|Active Comparator|Arm I (medroxyprogesterone acetate, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.
9845355|NCT03018249|Experimental|Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.
9845356|NCT03018340|Experimental|Pimavanserin 34 mg + SSRI/SNRI|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
9845357|NCT03018340|Placebo Comparator|Placebo + SSRI/SNRI|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
9845358|NCT03018691|Experimental|0.3% OPA-15406 Ointments|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
9845359|NCT03018691|Experimental|1% OPA-15406 Ointments|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
9845360|NCT03018691|Placebo Comparator|Placebo Ointments|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
9845361|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
9845362|NCT03018938|Experimental|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
9845363|NCT03018938|Experimental|Basal Insulin Analog|Basal insulin analog given SC.
9845364|NCT03019055|Experimental|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
9845365|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
9845366|NCT03019055|Experimental|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
9845367|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
9845368|NCT03019107|Experimental|VentFree Stimulation|Breath synchronized abdominal NMES
9845369|NCT03019107|Sham Comparator|Sham Stimulation|Sham breath synchronized abdominal NMES
9845370|NCT03019289|Experimental|pridopidine|Pridopidine (TV-7820) capsules
9845371|NCT03019406|Experimental|Cohort 1: Avalglucosidase Alfa 20 mg/kg|Avalglucosidase alfa, 20 mg/kg intravenous (IV) infusion every other week (qow) for 25 weeks in the Primary Analysis Period (PAP), followed by same treatment from Week 26 up to Week 371 in extension treatment period (ETP).
9845372|NCT03019406|Experimental|Cohort 2: Avalglucosidase Alfa 40 mg/kg|Avalglucosidase alfa 40 mg/kg IV infusion qow for 25 weeks in the PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
9845373|NCT03019406|Experimental|Cohort 3a: Avalglucosidase Alfa 40 mg//kg|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received avalglucosidase alfa 40 mg/kg (the highest tolerated dose) IV infusion qow for 25 weeks in PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
9845374|NCT03019406|Experimental|Cohort 3b: Alglucosidase Alfa in PAP|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received alglucosidase alfa at their current stable dose (defined as dose [between 20 mg/kg qow and 40 mg/kg weekly as per physician] administered regularly for a minimum of 6 months immediately prior to entry in this study) IV infusion for 25 weeks in PAP. After PAP, participants received avalglucosidase alfa 40mg/kg IV infusion qow from Week 26 up to Week 371 in ETP.
9845375|NCT03019458|Experimental|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
9845376|NCT03019458|No Intervention|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
9845377|NCT03019549|Experimental|Rosuvastatin|Period 1: 20 mg rosuvastatin administered once orally (PO)
9845378|NCT03019549|Experimental|Lanabecestat + Rosuvastatin|Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8
9845379|NCT03019627|Experimental|rhNGF 20μg/mL|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
9845380|NCT03019627|Placebo Comparator|Vehicle|vehicle eye drops six times daily
9845381|NCT03019744|Experimental|MeCFES|25 daily sessions (45 minutes each) of MeCFES-assisted task-oriented upper limb rehabilitation
9845382|NCT03019744|Active Comparator|Control|25 daily sessions (45 minutes each) of usual care task-oriented upper limb rehabilitation
9845383|NCT03019783|Placebo Comparator|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
9845384|NCT03019783|Active Comparator|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
9845385|NCT03019796|Experimental|PLACEBO FIRST THEN MEDICATED|Subjects first receive the PLACEBO tablet during 72 hours (full withdrawal). After a week of taking again their medication (MEDICATION TRIAL), they will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
9845386|NCT03019796|Experimental|MEDICATED FIRST THEN PLACEBO|Subjects first receive their antihypertensive MEDICATION tablet (habitual dose prescribed by their primary care doctors). After a week they will take a PLACEBO tablet for 72 hours and will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
9845387|NCT03019887|Experimental|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
9845388|NCT03019939|Experimental|Prevention (isavuconazole)|Patients receive isavuconazole PO every 8 hours for 6 doses and then Once a day (QD) or IV over 1 hour every 8 hours for 6 doses and then QD for up to 4 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
9845389|NCT03019965|Active Comparator|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.
9845390|NCT03019965|Experimental|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.
9845391|NCT03019965|Active Comparator|Intermittent Imipenem|Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.
9845392|NCT03019965|Experimental|Extended Imipenem|Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.
9845393|NCT03019965|Active Comparator|Intermittent Meropenem|Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.
9922596|NCT00841113|Active Comparator|2 Goserelin plus bicalutamide|Standard therapy
9845394|NCT03019965|Experimental|Extended Meropenem|Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.
9845395|NCT03020004|Experimental|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg) for 12 weeks.
9845396|NCT03020069|Experimental|Glucose Meter|Continuing Glucose Monitoring Device
9845397|NCT03020069|Active Comparator|No Glucose Meter|Average Blood glucose measure
9845398|NCT03020082|Experimental|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
9845399|NCT03020095|Experimental|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
9845400|NCT03020407|Experimental|IVC Ultrasound-guided|The treating physician will promptly assess the IVC diameter to obtain the collapsibility index (IVCCI) (or distensibility index, IVCDI) of an eligible patient. A previous study showed that IVCCI > 40% were strongly associated with fluid responsiveness. Accordingly, the patient will be given 10 ml/kg of bolus of 0.9% normal saline solution (NSS) each time when the IVCCI > 40% is discovered and serial measurements will be done after each intravenous bolus is achieved until the IVCCI < 40 % during our protocol. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
9845401|NCT03020407|No Intervention|Usual care|Patients will be promptly and empirically treated by 30 ml/kg loading of NSS in this treatment arm. After the NSS bolus, treatment with either the additional intravenous fluid or a vasopressor is given depended on physicians' discretion during the 6-hour study period. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
9845402|NCT03020472|Experimental|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
9845403|NCT03020498|Other|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
9845404|NCT03020498|Other|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
9845405|NCT03020498|Other|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
9845406|NCT03020524|Experimental|Dose level 1:|Autologous CD4 T-Cells0.8-1x10^9 transduced CD4+T-cells administered IV as a single dose
9845407|NCT03020524|Active Comparator|Dose level 2|Autologous CD4 T-Cells 2.4-3x10^9 transduced CD4+ T-cells administered IV as a single dose
9845408|NCT03020524|Active Comparator|Dose level 3|Autologous CD4 T-Cells 0.8-1x10^10 transduced CD4+ T-cells administered IV as a single dose
9845409|NCT03020537|Other|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
9845410|NCT03020537|Other|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
9845411|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
9845412|NCT03020576|Active Comparator|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
9845413|NCT03020576|Experimental|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
9845414|NCT03020615|Active Comparator|Stable Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
9922597|NCT00841126|Experimental|Magnesium iron hydroxycarbonate|
9922598|NCT00841126|Active Comparator|Lanthanum carbonate|
9845415|NCT03020615|Experimental|Intensive Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
9845416|NCT03020641|Experimental|Low pneumoperitoneum pressure.|Pneumoperitoneum pressure at 8 mmHg or lower.
9845417|NCT03020641|Active Comparator|standard pneumoperitoneum pressure|Pneumoperitoneum pressure at 12 mmHG or higher
9845418|NCT03020719|Experimental|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
9845419|NCT03020719|Placebo Comparator|Placebo|Placebo oral powder at 65mg/kg/day
9845420|NCT03020745|Experimental|Part 1, Cohort A : GSK3389404 30 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 30 mg or matching placebo
9845421|NCT03020745|Experimental|Part 1, Cohort B: GSK3389404 60 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 60 mg or matching placebo
9845422|NCT03020745|Experimental|Part 1, Cohort C: GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
9845423|NCT03020745|Experimental|Part 1, Cohort C1 (optional): GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
9845424|NCT03020745|Experimental|Part 1, Cohort D: GSK3389404 </= 240 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 <= 240 mg or matching placebo
9845425|NCT03020745|Experimental|Part 2: GSK3389404 or placebo SC|Enrolled subjects will receive different parallel dose level and regimens of GSK3389404 or placebo SC at dose determined in part 1. The treatments for Part 2 are 60 mg GSK3389404 weekly, 120 mg bi-weekly GSK3389404, 120 mg GSK3389404 weekly or placebo.
9845426|NCT03020888|Experimental|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.~Marker located during surgery using the Sentimag system, and removed with the lesion."
9845427|NCT03020966|Experimental|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
9845428|NCT03020966|Experimental|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
9845429|NCT03020992|Experimental|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
9845430|NCT03021005|Experimental|Self Testing Kit|"This group will be provided a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the I Want The Kit website."
9845431|NCT03021005|No Intervention|No Self Testing Kit|"This group will not receive a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will not receive referral cards for their partners or peers for them to request a free HIV self-testing kit from the I Want The Kit website."
9845432|NCT03021018|Experimental|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
9845433|NCT03021018|Experimental|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
9845434|NCT03021018|Active Comparator|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
9845435|NCT03021187|Experimental|Semaglutide 3 mg|
9845436|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg|
9845437|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg + 14 mg|
9845438|NCT03021187|Placebo Comparator|Placebo|
9922599|NCT00841126|Placebo Comparator|Placebo|
9922600|NCT00841139|Experimental|Perhexiline|perhexiline 100mg bd for 1 month duration
9922601|NCT00841139|Placebo Comparator|Placebo|placebo one tablet bd for 1 month duration
9922602|NCT00841152||Hand lesions|Stratum I: comparison of three interventions (autograft, bioactive glass and beta-tricalcium phosphate)
9922603|NCT00841152||Long-bone lesions|Stratum II: comparison of three interventions (bioactive glass, beta-tricalcium phosphate, allograft)
9922604|NCT00841165|Experimental|1|Participants in this arm are treated with Continuous Positive Airway Pressure at 5cm H2O and 100% oxygen
9922605|NCT00841165|Active Comparator|2|Participants in this arm receive standard of care therapy- oxygen via a non-rebreather mask
9922606|NCT00841191|Experimental|Siltuximab 2.8 mg/kg (Cohort 1)|
9922607|NCT00841191|Experimental|Siltuximab 5.5 mg/kg (Cohort 2)|
9922608|NCT00841191|Experimental|Siltuximab 11 mg/kg (Cohort 3)|
9922609|NCT00841191|Experimental|Siltuximab 15 mg/kg (Cohort 4)|
9922610|NCT00841191|Experimental|Siltuximab 15 mg/kg (Expansion Cohort 5)|
9922611|NCT00841191|Experimental|Siltuximab 15 mg/kg (Ovarian Cancer Cohort 6)|
9922612|NCT00841191|Experimental|Siltuximab 15 mg/kg (KRAS Mutant Tumors Cohort 7)|
9922613|NCT00841217|Placebo Comparator|1|placebo group
9922614|NCT00841217|Active Comparator|2|GW501516, 2.5mg
9922615|NCT00841230|Placebo Comparator|Lactose placebo|1x/day
9922616|NCT00841230|Experimental|Deanxit|
9922617|NCT00841243|Active Comparator|nutritional advise/support|Nutritional advise and support
9845439|NCT03021265||T80/A5/H12.5 FDC|Patients with hypertension
9845440|NCT03021304|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
9845441|NCT03021343|Active Comparator|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.
9845442|NCT03021343|No Intervention|No colchicine|In this arm no active medication was administered
9845443|NCT03021499|Experimental|Voclosporin|oral, 23.7 mg twice daily (BID)
9845444|NCT03021499|Placebo Comparator|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
9845445|NCT03021538||Cardiopulmonary Bypass|There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
9845446|NCT03021538||Extracorporeal Membrane Oxygenation|There will be 40 patients placed on ECMO during lung transplantation.
9845447|NCT03021642|Experimental|First Tepotinib Test, Then Tepotinib Reference|
9845448|NCT03021642|Experimental|First Tepotinib Reference, Then Tepotinib Test|
9845449|NCT03021668|Experimental|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel & Place Dressing.
9845450|NCT03021668|Placebo Comparator|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
9845451|NCT03021759|No Intervention|Control|No intervention
9845452|NCT03021759|Experimental|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
9845453|NCT03021759|Experimental|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
9845454|NCT03022045|Experimental|Risankizumab 75 mg|Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
9845455|NCT03022045|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
9845456|NCT03022084|Experimental|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
9845457|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
9845458|NCT03022370|Experimental|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
9845459|NCT03022370|No Intervention|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
9845460|NCT03022396|Other|Group A: age 8-17 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
9845461|NCT03022396|Other|Group B: age 18-30 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
9845462|NCT03022396|Other|Group C: age 18-30 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
9845463|NCT03022396|Other|Group D: age 40 - 59 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
9845464|NCT03022396|Other|Group E: age 40 - 59 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
9845465|NCT03022396|Other|Group F: age 70 - 100 yo identical twins|Individual twins to receive Fluzone® (intramuscular) or High Dose Fluzone® (intramuscular)
9845466|NCT03022422|Other|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
9845467|NCT03022422|Other|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
9845468|NCT03022422|Other|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
9845469|NCT03022422|Other|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
9845470|NCT03022422|Other|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
9845471|NCT03022422|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
9845472|NCT03022435|Other|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
9845473|NCT03022435|Other|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
9845474|NCT03022435|Other|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
9845475|NCT03022435|Other|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
9845476|NCT03022435|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
9845477|NCT03022526|Experimental|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
9845478|NCT03022526|Active Comparator|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
9845479|NCT03022617|Experimental|Study Group|Open-label drug administration group. No comparator.
9845480|NCT03022630|Other|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
9845481|NCT03022630|Other|Usual hepatic care|Usual hepatic care
9845482|NCT03022799|Experimental|KM-819|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
9845483|NCT03022799|Placebo Comparator|Placebo|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
9845484|NCT03022916|Active Comparator|Nail Polish + Efinaconazole Solution|One big toe will receive application of Efinaconazole Solution on top of nail polish (without the presence of a top coat or base coat)
9845485|NCT03022916|Placebo Comparator|Nail Polish Only|Both big toes will use nail polish only
9845486|NCT03022916|Active Comparator|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with base coat and top coat.
9845487|NCT03022916|Active Comparator|Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with top coat.
9845488|NCT03022981|Experimental|12 to < 18 Years Old|"PK Lead-in Phase: Sofosbuvir/Velpatasvir (SOF/VEL) 400/100 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 400/100 mg once daily for 12 weeks."
9845489|NCT03022981|Experimental|6 to < 12 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks."
9845490|NCT03022981|Experimental|3 to < 6 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 7 days for participants who weigh < 17 kg. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 12 weeks for participants who weigh < 17 kg."
9845491|NCT03023137|Active Comparator|Walking & dietary modification (W&D)|W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
9845492|NCT03023137|No Intervention|Controls|No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
9845493|NCT03023176|Other|Healthy 1-8 year-old twins|Healthy 1-8 yr old identical and fraternal twin pairs given trivalent, inactivated influenza (Fluzone® standard IIV3 0.5ml or Fluzone® standard IIV3 Pediatric Dose) per participant age and standard of care.
9845494|NCT03023397|Other|Der f treated Non-smoker|
9845495|NCT03023397|Other|Der f treated Cigarette smoker|
9845496|NCT03023397|Other|Der f treated E-cig user|
9845497|NCT03023423|Experimental|Treatment Arm A: Atezolizumab|Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
9845498|NCT03023423|Experimental|Treatment Arm B: Atezolizumab and Daratumumab|Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
9922618|NCT00841243|No Intervention|control|Control
9922619|NCT00841256|Experimental|Immunotherapy|Grass pollen allergens in a water/glycerol solution
9845499|NCT03023488|Experimental|Flexible ureteroscopy arm|the findings of patients undergoing flexible ureteroscopy + laser lithotripsy for renal stones according to EAU Guidelines Doppler Ultrasound examination has been performed in the pre-operative and post-operative periods
9845500|NCT03023553|Other|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
9845501|NCT03023553|Other|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
9845502|NCT03023683|Other|Group A: 2-8 yo healthy non-twins|Participants will be given seasonal live, attenuated influenza vaccine (LAIV), FluMist® . Children with no prior influenza vaccine history will receive a second dose of LAIV at least 28 days after the first study dose.
9845503|NCT03023683|Other|Group B: 18-49 yo healthy non-twins|Participants will be given seasonal LAIV, FluMist® .
9845504|NCT03023709|Other|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
9845505|NCT03023709|Other|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
9845506|NCT03023722|Experimental|All Subjects|Patients with advanced metastatic pancreatic cancer who have measurable disease
9845507|NCT03023826|Experimental|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) capsule under fasting conditions.
9845508|NCT03023826|Experimental|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) tablet under fasting conditions.
9845509|NCT03023826|Experimental|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
9845510|NCT03023878|Experimental|Blinatumomab|"Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time.~An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days.~There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death."
9845511|NCT03023891|Experimental|Prednisone|"Each participant will received a single dose of oral 60 mg of prednisone~Visit 1: Baseline Oral Glucose Tolerance Test (OGTT) and White Blood Count (WBC) count Visit 2: Prednisone 60mg oral at 7am, OGGT and WBC count at 4 to 8 hours post drug"
9845512|NCT03024112|Experimental|Heated humidified high-flow nasal cannula (HHFNC) oxygen|The intervention group received HHFNC O2 at a set flow of 40L/min. FiO2 was titrated by respiratory therapists to maintain SpO2 ≥ 90%. The HHFNC O2 apparatus included: 1) Air-Oxygen blender - capable of delivering 21-100% FiO2 at flow rates up to 60L/min, 2) Heated Humidifier - providing active heating and humidification to the delivered air-O2 blend, 3) Nasal cannula - larger diameter, slightly elongated nasal cannula with single limb connection to humidifier
9845513|NCT03024112|Active Comparator|Standard oxygen Therapy|The standard O2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO2 ≥ 90%.
9845514|NCT03024606|Active Comparator|texting group|text messages focused on smoking cessation and pregnancy
9845515|NCT03024606|No Intervention|control group|No text messages
9845516|NCT03024970|Experimental|stenfilcon A lens with solution additive (test)|Participants were randomized to wear the stenfilcon A lens with solution additive (test) for 1 month during the cross over study.
9845517|NCT03024970|Active Comparator|stenfilcon A lens (control)|Participants were randomized to wear stenfilcon A (control) lens pair for 1 month during the cross over study.
9845518|NCT03025217|Experimental|TLC Program|The TLC Program consists of one in-person visit with a licensed dietician and biweekly phone coaching sessions. During the program, the dietician will 1) identify specific nutrition goals, 2) review and tailor the education materials to the patient's needs, and 3) set up regular telephone coaching sessions of up to two sessions per month for six months for each patient. Motivational interviewing and nutrition/health coaching will be provided.
9845519|NCT03025945|Experimental|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
9845520|NCT03025945|Placebo Comparator|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
9845521|NCT03026075|Experimental|Colonoscopy with MCS|Standard colonoscopy procedure with Motus Cleansing System
9845522|NCT03026088|Experimental|Bisoprolol|
9845523|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression."
9922620|NCT00841256|Placebo Comparator|Placebo|Water/glycerol solution with phosphate buffered saline
9922621|NCT00841282|Active Comparator|1|Water Infusion in lieu of Air Insufflation Colonoscopy
9922622|NCT00841282|Placebo Comparator|2|Air Insufflation Colonoscopy
10207278|NCT01978288||Cohort 1 Newborns with asthmatic mothers|Infants born to mothers who have diagnosis of Asthma that were enrolled in study from 5/7/14 to 6/1/16.
10207279|NCT01978288||Cohort 2 Newborns with asthmatic mothers|Infants born to mothers who have a diagnosis of Asthma with enrollment from June 2, 2016 going forward.
10207280|NCT01978288||Cohort 3 Newborns with healthy parents|Infants born to healthy parents without atopy (asthma, eczema, seasonal allergies) from June 2, 2016 going forward.
9845524|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
9845525|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
9845526|NCT03026257|Experimental|AOHG|Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
9845527|NCT03026257|Active Comparator|Habitual|Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)
9845528|NCT03026283||1: HeartFlow CT-FFR Arm|All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
9845529|NCT03026530|Experimental|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
9845530|NCT03026530|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
9845531|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
9845532|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
9845533|NCT03026777|Experimental|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
9845534|NCT03026777|No Intervention|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
9845535|NCT03026803|Experimental|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
9845536|NCT03027466|Experimental|Baseline Affirmation and Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study and will receive affirmation text messages throughout the study"
9845537|NCT03027466|Active Comparator|Baseline Affirmation and No Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study but will not receive affirmation text messages throughout the study"
9845538|NCT03027466|Active Comparator|No Baseline Affirmation and Affirmation Texts|"Participants will not be given a Baseline Affirmation Quiz but will receive affirmation text messages throughout the study"
9845539|NCT03027466|Placebo Comparator|No Baseline Affirmation and No Affirmation Texts|Participants will experience the Smoke Free United Kingdom (UK) app without any affirmation content Smoke Free UK app (no baseline affirmation quiz and no affirmation text messages)
9845540|NCT03027557|Experimental|Combined treatment.|20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
9845541|NCT03027557|Active Comparator|Monotherapy|20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
9845542|NCT03027557|Placebo Comparator|Placebo|20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
9845543|NCT03027661|Placebo Comparator|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
9845544|NCT03027661|Active Comparator|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
9845545|NCT03028012|Experimental|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
9845546|NCT03028012|Experimental|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
9845547|NCT03028012|Experimental|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
9922623|NCT00841295|Experimental|Carnitine|Intervention 'Parenteral L-carnitine supplementation' Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
9845548|NCT03028025|Active Comparator|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
9845549|NCT03028025|Experimental|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
9845550|NCT03028103|Experimental|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
9845551|NCT03028129|Experimental|Treatment|Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.
9845552|NCT03028129|Placebo Comparator|Control|Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).
9845553|NCT03028142|Experimental|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
9845554|NCT03028142|Experimental|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
9845555|NCT03028142|Placebo Comparator|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
9845556|NCT03028220|Active Comparator|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
9845557|NCT03028220|Active Comparator|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
9845558|NCT03028324|Experimental|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
9845559|NCT03028363|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
9845560|NCT03028363|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
9845561|NCT03028415|Experimental|AMPLEX|
9845562|NCT03028415|Active Comparator|Autogenous Bone Graft (ABG)|
9845563|NCT03028467|Experimental|GSK3196165 Dose 1|Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
9845564|NCT03028467|Experimental|GSK3196165 Dose 2|Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
9922624|NCT00841295|Placebo Comparator|Controle|Intervention 'Parenteral supplementation with sterile water'
9922625|NCT00841308|Active Comparator|Usual care|
9922626|NCT00841308|Active Comparator|Home blood pressure monitoring|
9922627|NCT00841334|Experimental|1|ACTION
10207281|NCT01950377||Healthy Adults|Healthy adults healthy adults - male and female
9845565|NCT03028467|Experimental|GSK3196165 Dose 3|Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
9845566|NCT03028467|Placebo Comparator|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
9845567|NCT03028870|Experimental|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
9845568|NCT03028870|Experimental|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
9845569|NCT03028870|Active Comparator|Naproxen|Naproxen 500-mg capsules taken orally twice daily
9845570|NCT03028870|Placebo Comparator|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
9845571|NCT03028974|Other|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
9845572|NCT03028974|Other|Group B: 2-4 yo LAIV4 (Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
9845573|NCT03028974|Other|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
9845574|NCT03028974|Other|Group D: 6 - 23 mos old IIV4 (Return)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
9845575|NCT03028974|Other|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
9845576|NCT03028974|Other|Group F: 9-13/18-49 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
9845577|NCT03028974|Other|Group G: 9-13/18-49 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
9845578|NCT03028987|Other|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
9845579|NCT03028987|Other|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
9845580|NCT03029091|Experimental|EoE +/- CTD|Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
9845581|NCT03029091|Experimental|EoE + CTD|Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
9845582|NCT03029091|Experimental|EoE - CTD|Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
9845583|NCT03029143|Experimental|Lead-in Period: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion once at Day 1 and at Week 2 . Participants were then assessed to estimate the vedolizumab clearance at Week 5 and response at Week 6.
9845584|NCT03029143|Experimental|Randomized Treatment Period (RTP): Standard Treatment Arm|Following Lead-in Period, participants received vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) at Weeks 6, 14 and 22 as standard treatment plus 18 weeks follow-up.
9845585|NCT03029143|Experimental|RTP: Dose Optimized Arm|Following Lead-in Period, participants received vedolizumab 600 mg, IV infusion at Week 6, followed by Regimen A: vedolizumab 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up, or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up based on drug clearance.
9845586|NCT03029208|Experimental|Daprodustat treated anemic subjects|Subjects will receive oral daprodustat once daily.
9845587|NCT03029208|Active Comparator|Darbepoetin alfa treated anemic subjects|Subjects will receive darbepoetin alfa subcutaneously or intravenously.
9845588|NCT03029247|Active Comparator|Participants receiving Epoetin alfa|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
9845589|NCT03029247|Experimental|Participants receiving Daprodustat|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
9922628|NCT00841334|Active Comparator|2|Usual care
10207282|NCT01935466||Pioglitazone|Ever users of Pioglitazone
10207283|NCT01935466||Other drugs|Never users of pioglitazone
10207284|NCT01872169|Other|Disordered eating screening questionnaire|
10207285|NCT01871727|Experimental|E7777|
9845590|NCT03029585|Experimental|NanoPac® 100 mg/m2|Intraperitoneal NanoPac® 100 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
9845591|NCT03029585|Experimental|NanoPac® 200 mg/m2|Intraperitoneal NanoPac® 200 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
9845592|NCT03029585|Experimental|NanoPac® 300 mg/m2|Intraperitoneal NanoPac® 300 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
9845593|NCT03029585|Experimental|NanoPac® 400 mg/m2|Intraperitoneal NanoPac® 400 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
9845594|NCT03029585|Active Comparator|Standard of Care Intravenous Chemotherapy|Standard of care intravenous chemotherapy (with platinum and taxane agents) administered per institutional standards.
9845595|NCT03029624|Experimental|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
9845596|NCT03029650|Active Comparator|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
9845597|NCT03029650|Experimental|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
9845598|NCT03029715|Other|Intravenous anaesthesia|Propofol Dexmedetomidine Remifentanil
9845599|NCT03029715|Other|Inhalation anaesthesia|Desflurane Remifentanil
9845600|NCT03029780|Experimental|Co-Administration|Nivolumab and Ipilimumab Co-Administration
9845601|NCT03029780|Experimental|Sequential Administration|Nivolumab and Ipilimumab Sequential Administration
9845602|NCT03029819|Active Comparator|Mindfulness-based Addiction Treatment (MBAT)|Nicotine patch; self-help guide; MBAT
9845603|NCT03029819|Experimental|iQuit Mindfully|Nicotine patch; self-help guide; MBAT; text messaging
9845604|NCT03029988|Experimental|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
9845605|NCT03029988|Experimental|Cohort 2|"Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data."
9845606|NCT03030183|Experimental|Zilucoplan (RA101495)|Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
9845607|NCT03030599|Placebo Comparator|Placebo|Placebo
9845608|NCT03030599|Experimental|JZP-258|JZP-258
9845609|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
9845610|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
9845611|NCT03030989|Active Comparator|Chlorhexidine Gluconate 2% Wipe|
9845612|NCT03030989|Placebo Comparator|Placebo wipe|
9845613|NCT03031431|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, mothers will be encouraged to provide Kangaroo Mother Care (KMC) whenever possible. If an infant's temp is not rising by ½ degree C per hour with KMC alone, the infant warmer will be offered as an addition by the study team. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the warmer. Bundling in clothes will only be used in addition to the warmer per carer preference. Temp measurement of the infant, warmer, and ambient air will be measured every 15 mins for the first hr, then hrly and as needed for the remainder of use or until warmer endpoint is reached (warmer temp below 36 degrees or phase-change material hardens [soft, semisoft, or hardened]).
9845614|NCT03031496|Experimental|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
10207286|NCT01850888|Experimental|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
9845615|NCT03031496|Experimental|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
9845616|NCT03031678|Other|Study procedures|
9845617|NCT03031795|Experimental|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
9845618|NCT03031795|Placebo Comparator|placebo|look alike placebo
9845619|NCT03031899||Rose Bengal positive lesion and biopsy|Lesions that were stained positive with rose bengal were biopsied and assessed for dysplasia
9845620|NCT03031899||Toluidine blue positive lesion and biopsy|Lesions that were stained positive with toluidine blue were biopsied and assessed for dysplasia
9845621|NCT03031938|Other|Cohort 1|Long term observational study of subjects from tanezumab parent study
9922629|NCT00841347|No Intervention|1|Study of habitual sleep length on non obese teen group
9922630|NCT00841347|Experimental|2|Study of habitual sleep length period followed by extended sleep length period on obese teen group
9845622|NCT03032263|Active Comparator|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
9845623|NCT03032263|Experimental|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
9845624|NCT03032380|Experimental|Cefiderocol|Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
10207287|NCT01841333|Experimental|PF-04449913|Beginning 80 days after allogeneic stem cell transplant, patients receive PF-04449913 (100mg) orally once daily on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9845625|NCT03032380|Active Comparator|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
9845626|NCT03032393|Experimental|Dominant|Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds.
9845627|NCT03032393|Active Comparator|Submissive|Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds.
9845628|NCT03032523|Experimental|Remote Monitoring CGM Group|Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
9845629|NCT03032523|No Intervention|Blinded CGM Group|Participants wear a blinded CGM during the study period. Values are blinded to study staff, participant, and clinical staff.
9845630|NCT03032965|Experimental|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
9845631|NCT03032965|Other|Isoproterenol|This group will not receive adenosine during the procedure.
9845632|NCT03033108|Experimental|Emixustat Dose 1|lowest dose of once-daily oral emixustat
9845633|NCT03033108|Experimental|Emixustat Dose 2|middle dose of once-daily oral emixustat
9845634|NCT03033108|Experimental|Emixustat Dose 3|highest dose of once-daily oral emixustat
9845635|NCT03033134|Experimental|BSJ003W|BSJ003W implant group
9845636|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
9845637|NCT03033511|Experimental|Rovalpituzumab tesirine/dexamethasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
9845638|NCT03033511|Experimental|Placebo|Placebo q6 wk; omitting every third cycle
9845639|NCT03033745|Experimental|IgPro20 (Pump-Assisted Volume Cohort)|Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
9845640|NCT03033745|Experimental|IgPro20 (Pump Assisted Flow Rate Cohort)|Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
9845641|NCT03033745|Experimental|IgPro20 (Manual Push Flow Rate Cohort)|Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
9845642|NCT03033784|Experimental|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
9845643|NCT03033784|Placebo Comparator|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
9845644|NCT03034057|Other|sayana press|single arm
9845645|NCT03034135|Experimental|DSF-Cu|Disulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
9845646|NCT03034460|Experimental|CD5024 1% cream|Active drug;
9845647|NCT03034460|Placebo Comparator|CD5024 cream placebo|Placebo of active drug;
9845648|NCT03034460|Other|CD0271/CD1579 gel|Positive control;
9845649|NCT03034460|Other|CD0271/CD1579 gel placebo|Placebo of positive control;
9922631|NCT00841347|Experimental|3|Study of extended sleep length period followed by habitual sleep length period on obese teen group
9922632|NCT00841360||HIV Positive|"Participant self-discloses as HIV positive.~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
9922633|NCT00841360||HIV Negative|"Participant self-discloses as HIV negative (based on receiving a negative HIV test within 12 months prior to study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
9986321|NCT01401621|Experimental|Scratch-Off Call to Action Condition|The recipient will be prompted to scratch-off the paper in order to find out how to follow the recommendation that the test be received.
10207288|NCT01823237|Active Comparator|rTMS|rTMS condition, rTMS will be applied at 0.1-0.5 Hz frequency at a subthreshold intensity
10207289|NCT01823237|Placebo Comparator|rTMS sham|Placebo condition will use a sham coil and apply a very small magnetic stimulus
10207290|NCT01822743|Experimental|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
10207291|NCT01822743|Sham Comparator|Sham comparator|sham Osteopathic pterygopalatine node compression
10207292|NCT01802788||Cohort A|Patients implanted with a Portico valve after CE mark
10207293|NCT01802788||Cohort B|Patients implanted in previous SJM-sponsored premarket studies
10207294|NCT01800669|Experimental|Intervention|Use of the complete CHICA MLP module in routine clinical care. The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
9845650|NCT03034577|Active Comparator|ModNMB|"Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more~Neostigmine"
9845651|NCT03034577|Active Comparator|DeepNB|Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex
9845652|NCT03034772|Active Comparator|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
9845653|NCT03034772|Placebo Comparator|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
10207295|NCT01800669|Active Comparator|Control|CHICA without the MLP module. This version includes a module that screens families for medical-legal issue but does not provide additional guidance or referrals to resolve them.
10207296|NCT01776034|Experimental|SystemCHANGE Group Lifestyle counseling|"The SystemCHANGE™ intervention will be delivered over a six-month period involving 12 face-to-face group sessions (1.5 to 2 hours each) held weekly for three months, followed by three monthly booster calls. Intervention groups include ~10 to 15 patients, and friends and family members are encouraged to attend. Intervention sessions consist of 30-min to 60-min of behavior change activities and 60-min focused on healthy behaviors."
9845654|NCT03034915|Experimental|UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
9845655|NCT03034915|Experimental|UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
9845656|NCT03034915|Experimental|Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA|Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
9845657|NCT03034928|Other|Test 1/Control 1, then Control 2/Test 2|Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
9845658|NCT03034928|Other|Test 2/Control 2, then Control 1/Test 1|Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
9845659|NCT03034928|Other|Control 1/Test 1, then Test 2/Control 2|Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
9845660|NCT03034928|Other|Control 2/Test 2, then Test 1/Control 1|Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
9845661|NCT03034954|Active Comparator|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
9845662|NCT03034954|Sham Comparator|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
9845663|NCT03034967|Experimental|Danirixin 5 mg|Eligible participants will receive danirixin 5 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
9845664|NCT03034967|Experimental|Danirixin 10 mg|Eligible participants will receive danirixin 10 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
9845665|NCT03034967|Experimental|Danirixin 25 mg|Eligible participants will receive danirixin 25 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
9845666|NCT03034967|Experimental|Danirixin 35 mg|Eligible participants will receive danirixin 35 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
9845667|NCT03034967|Experimental|Danirixin 50 mg|Eligible participants will receive danirixin 50 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
9845668|NCT03034967|Placebo Comparator|Placebo|Eligible participants will receive placebo tablet with food twice daily along with standard care of treatment for 24 weeks.
9845669|NCT03035032|Experimental|Leuprolide Acetate 22.5 milligrams (mg)|Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
10207297|NCT01776034|Active Comparator|Phone Lifestyle Counseling|Participants will receive pamphlets that contain information on healthy eating, physical activity, sleep, and symptom management, and will be followed-up with telephone calls.
10207298|NCT01759836|Experimental|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
9845670|NCT03035318|Active Comparator|DePuy Global® Anchor Peg Glenoid|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Glenoid Instrumentation to position the glenoid component.
9845671|NCT03035318|Experimental|DePuy Instrumentation with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Instrumentation with SmartBone™, to position the glenoid component.
10207299|NCT01759836|Placebo Comparator|Placebo|Placebo daily for 1 year
9845672|NCT03035318|Experimental|IRI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBone™, to position the glenoid component.
9845673|NCT03035318|Experimental|RTI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses Real Time Instrumentation (RTI), with a SmartBone™, to position the glenoid component.
9845674|NCT03035318|Experimental|IRI with SmartBase|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBase™, to position the glenoid component.
9845675|NCT03035487|Experimental|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:~Low resolution transrectal ultrasound examination (LR-TRUS)~Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
9845676|NCT03035708|Experimental|varenicline|1 mg BID (2 capsules BID)
9845677|NCT03035708|Placebo Comparator|Placebo|1 mg BID (2 capsules BID)
9845678|NCT03035760|Experimental|1|3 mg/kg orally once daily for 5 days (n = 8)
9845679|NCT03035760|Experimental|2|7.5 mg/kg orally once daily for 5 days (n = 8)
9845680|NCT03035760|Experimental|3|15 mg/kg orally once daily for 5 days (n = 8)
9845681|NCT03035760|Experimental|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
9845682|NCT03035864|Experimental|rhNGF 20 µg/ml|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
9845683|NCT03035864|Placebo Comparator|Vehicle|Vehicle eye drops six times daily
9845684|NCT03035916|Experimental|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
9845685|NCT03035916|Active Comparator|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
9845686|NCT03035916|Placebo Comparator|Control|The Control group receives standard IV-inhaled general anesthesia.
9845687|NCT03035929|Experimental|Healthy|"10 Healthy subjects will undergo study procedures at four study visits.~All subjects will undergo the same procedures and interventions."
9845688|NCT03035942|Experimental|D Group|Dexamethasone 8 mg
9845689|NCT03035942|Experimental|O group|Ondansetron 4 mg
9845690|NCT03035942|Placebo Comparator|S group|Normal saline (5 mL total volume)
9845691|NCT03035955|Active Comparator|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
9845692|NCT03035955|No Intervention|no treatment|no treatment on the other side of the face
9986322|NCT01401621|Experimental|Control Condition|A control condition with no scratch-off element.
9845693|NCT03036072|Active Comparator|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
9845694|NCT03036072|Experimental|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
9845695|NCT03036124|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
9845696|NCT03036124|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
9845697|NCT03036150|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
9845698|NCT03036150|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
9845699|NCT03036163|Experimental|Cohort 1|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
9845700|NCT03036163|Experimental|Cohort 2|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
9845701|NCT03036163|Experimental|Cohort 3|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
9845702|NCT03036163|Experimental|Cohort 4|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
9845703|NCT03036163|Experimental|Cohort 5|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
9845704|NCT03036163|Experimental|Cohort 6|5 male healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
9845705|NCT03036163|Experimental|Cohort 7|5 male healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
10207300|NCT01758328|Experimental|Pts with Mutiple myeloma|Patients will undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor. Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. The administration of WT1-specific cytotoxic T cells (WT1 CTLs) post transplantation is integrated to induce complete remissions in patients with residual disease and to decrease the rate of relapse following the allogeneic transplant.
10207301|NCT01746849|Experimental|palifermin with Lupron|All patients undergo total body irradiation (TBI) on days -9 to -6 & receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, & anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 & no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 & d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.
9845706|NCT03036215|No Intervention|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
9845707|NCT03036215|Experimental|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
9845708|NCT03036293|Experimental|Tenoten, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
9845709|NCT03036293|Placebo Comparator|Placebo, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
9845710|NCT03036293|Experimental|Tenoten, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
9845711|NCT03036293|Placebo Comparator|Placebo, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
9845712|NCT03036384|Experimental|Cohort 1 : HB prilocaine 2%, 45mg|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845713|NCT03036384|Experimental|Cohort 2 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9986323|NCT01401634|Other|Intravenous Fluids|Intravenous fluids for patients with hyperglycemia is part of the standard protocol in our department
9845714|NCT03036384|Experimental|Cohort 3 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845715|NCT03036384|Experimental|Cohort 4 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845716|NCT03036384|Experimental|Cohort 5 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845717|NCT03036384|Experimental|Cohort 6 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845718|NCT03036384|Experimental|Cohort 7 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845719|NCT03036384|Experimental|Cohort 8 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845720|NCT03036384|Experimental|Cohort 9 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845721|NCT03036384|Experimental|Cohort 10 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
9845722|NCT03036813|Active Comparator|Dose 1|voxelotor
9845723|NCT03036813|Active Comparator|Dose 2|voxelotor
9845724|NCT03036813|Placebo Comparator|Placebo|Placebo
9845725|NCT03036839|Experimental|LDV/SOF for 8 weeks|Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
9845726|NCT03036839|Experimental|LDV/SOF for 12 weeks|Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
9845727|NCT03036839|Experimental|LDV/SOF for 24 weeks|Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks
9845728|NCT03036852|Experimental|SOF/VEL|SOF/VEL for 12 weeks
9845729|NCT03037203|Experimental|Arm A|JZP-110 and Placebo
9845730|NCT03037203|Experimental|Arm B|JZP-110 and Placebo
9845731|NCT03037203|Placebo Comparator|Arm C|Placebo
9845732|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse >90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
9845733|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
9845734|NCT03037307|Experimental|Test product|Participants will topically apply the test product to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
9845735|NCT03037307|Active Comparator|Positive Control|Participants will topically apply the positive control to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
9845736|NCT03037307|Other|Negative Control|Participants of this group will not be assigned to any treatment.
9845737|NCT03037489|Experimental|MIV-711|MIV-711 for a total of 26 weeks
9845738|NCT03037541|Experimental|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
9845739|NCT03037541|Placebo Comparator|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
9845740|NCT03037580|Experimental|Oral treprostinil|Sustained-release oral tablets for TID administration
9845741|NCT03037580|Placebo Comparator|Placebo|Placebo (sugar pill) for TID oral administration
9845742|NCT03037619|Experimental|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months.
9845743|NCT03037619|Experimental|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
9845744|NCT03037905|Experimental|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
9845745|NCT03037905|No Intervention|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
9845746|NCT03037983|Active Comparator|Active rTMS|Subjects will receive actual rTMS treatment.
9845747|NCT03037983|Sham Comparator|Sham rTMS|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
9845748|NCT03038113|Experimental|Part 1: Single-Ascending Dose (SAD)|Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
9845749|NCT03038113|Experimental|Part 2: Multiple Ascending Dose|Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.
9845750|NCT03038126|Active Comparator|CCHT|Veterans Administration (VA) CCHT with an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
9845751|NCT03038126|Placebo Comparator|Usual care|
9845752|NCT03038308|Experimental|ROP Intervention|Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study
9845753|NCT03038399|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
9845754|NCT03038399|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
9845755|NCT03038399|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
9845756|NCT03038399|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
9845757|NCT03038620|Experimental|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug~Other Names:~Saxenda~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
9845758|NCT03038620|Placebo Comparator|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL~Other Names:~Placebo~Saline injection~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
9845759|NCT03038815|Experimental|Controll-VACOped-Ortho Tri|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the VACOped as the first intervention.
9845760|NCT03038815|Experimental|Controll-Ortho Tri-VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the Ortho Tri first intervention
9845761|NCT03038867|Experimental|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
9845762|NCT03038867|Placebo Comparator|Placebo|Placebo
9986324|NCT01401634|Experimental|Oral Fluids|
9986325|NCT01401660||Group A|Subjects who do not currently have low back pain.
9845763|NCT03038880|Experimental|6 mg Faricimab Q12W|6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).
9845764|NCT03038880|Experimental|6 mg Faricimab Q16W|6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.
9845765|NCT03038880|Active Comparator|0.5 mg Ranibizumab Q4W|0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).
9845766|NCT03039023|Experimental|Whole Hardboiled Eggs|Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
9845767|NCT03039023|Experimental|Choline Bitartrate Tablets|Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
9845768|NCT03039023|Experimental|Hardboiled Eggs + Choline Bitartrate Tablets|Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
9845769|NCT03039023|Experimental|Egg Whites + Choline Bitartrate Tablets|Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
9845770|NCT03039023|Experimental|Phosphatidylcholine Capsules|Subjects will consume six (6) 420 mg phosphatidylcholine capsules by mouth per day for 28 days.
9845771|NCT03039088||Fibromyalgia patients|
9845772|NCT03039088||Not fibromyalgia patients|
9845773|NCT03039179|Experimental|Polyurethane foam|
10207302|NCT01746849|Experimental|palifermin with Degarelix|Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
9845774|NCT03039179|No Intervention|standard care|Only application of the Walker in the immediate postoperative period.
9845775|NCT03039192|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.
9845776|NCT03039192|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.
9845777|NCT03039283||Nucleus CI532 cochlear implant|
9845778|NCT03039543|Active Comparator|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
9986326|NCT01401660||Group B|Subjects who have low back pain at the time of the study, and who are currently being treated or have been previously treated for their low back pain and do not wish to receive further treatment for their pain.
10207303|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone + stem cell|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.
10207304|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone Alone|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.
10207305|NCT01742143||ICCAN|For those randomized into the ICCAN arm, the core of the intervention will be three ICCAN Access Facilitators who will assess needs and synchronize for each patient an individualized set of transdisciplinary services.
10207306|NCT01742143||Usual and Customary Group (U&C)|Participants in this group will receive the same written materials on social and economic resources as ICCAN group.
10207307|NCT01701674|Experimental|Combination Therapy|The combination of ipilimumab followed by lymphodepletion with chemotherapy, TIL infusion, and high dose IL-2.
10207308|NCT01630421||affected, unaffected|Individuals with diagnosed ACC
10207309|NCT01618279||Tryptase|Patients with clinical manifestations have been discovered and documented symptoms of coronary heart
10207310|NCT01597388|Experimental|AZD2014 with Fulvestrant|AZD2014 with Fulvestrant
10207311|NCT01563107|Experimental|High Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
10207312|NCT01563107|Experimental|Low Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
10207313|NCT01456104|Experimental|vaccine|This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A*0201-restricted flu matrix peptide).
10207314|NCT01423630|Experimental|Probiotics and fruit fibre|Probiotics and fruit fibre
10207315|NCT01320072||Aspirin-sensitive asthmatics|asthma patients with aspirin allergy
10207316|NCT01320072||aspirin-tolerant asthmatics|asthma patients without aspirin allergy
10207317|NCT01318486|Active Comparator|Heparin free dialysis standard of care|Standard of care: can be either saline flushes or predilution (on-line or bags)
10207318|NCT01318486|Experimental|Heparin free dialysis with Evodial|
10207319|NCT01280825||Adult Patients|Adults receiving health care at the University of Chicago Medical Center.
9845779|NCT03039543|Experimental|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
9845780|NCT03039569|Experimental|Text messaging|Participants will receive 3 messages weekly consisting of nutrition education and diabetes self-management information and skills for 3 months (12 weeks).
9845781|NCT03039569|No Intervention|Control|Participants will not receive text message intervention. This is the measurement-only group
9845782|NCT03039621|Experimental|Ergoferon|Tablet for oral use, 1 tablet per intake (outside a meal/feeding). On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day (total 8 tablets). From day 2, one tablet is taken every 8 hours. The drug is administered outside a meal (in the interval between meals or 15 minutes before meal or fluid intake). Keep the tablet in the mouth, without swallowing, until completely dissolved. For young children (aged 6 months to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature. The therapy lasts for 5 days.
9845783|NCT03039621|Placebo Comparator|Placebo|Placebo using Ergoferon scheme.
9845784|NCT03039686|Experimental|RO7239361 Low Dose|Participants received low dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received low dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
9845785|NCT03039686|Experimental|RO7239361 High Dose|Participants received high dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
9845786|NCT03039686|Placebo Comparator|Placebo|Participants received matching placebo solution subcutaneously (SC) on specified days of the 48-week double-blind (DB) period. Following the DB period participants received low dose or high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
9845787|NCT03039699|Experimental|Ergoferon|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
9845788|NCT03039699|Placebo Comparator|Placebo|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
9845789|NCT03039738|Active Comparator|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
9845790|NCT03039738|Experimental|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
9845791|NCT03040011|Experimental|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
9845792|NCT03040011|Active Comparator|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
9845793|NCT03040011|Placebo Comparator|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
9845794|NCT03040024|Experimental|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
9845795|NCT03040024|Experimental|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
9845796|NCT03040024|Placebo Comparator|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
9845797|NCT03040154|Experimental|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
9845798|NCT03040154|Other|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
9845799|NCT03040336|Experimental|Prehabilitation|Standard of care + Prehabilitation
9845800|NCT03040336|No Intervention|Standard of Care|Standard of Care
9845801|NCT03040362|Experimental|[14C]-lasmiditan|[14C]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
9845802|NCT03040414|Active Comparator|PID Algorithm|Participants will receive insulin delivered by the Medtronic Minimed 670G 3.0 HCL system using a PID algorithm..
9845803|NCT03040414|Experimental|PID + Fuzzy Logic Algorithm|Participants will receive insulin delivered by the Medtronic advanced hybrid closed loop system (Minimed 670G 4.0 AHCL) with Guardian Sensor (3) continuous glucose monitoring sensor.
9845804|NCT03040427|Experimental|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
9845805|NCT03040466|Active Comparator|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
9845806|NCT03040466|Experimental|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
9845807|NCT03040479|Experimental|Mild hepatic impairment|lasmiditan 200 mg single dose
9845808|NCT03040479|Experimental|Moderate hepatic impairment|lasmiditan 200 mg single dose
9845809|NCT03040479|Experimental|Healthy participants|lasmiditan 200 mg single dose
9845810|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
9845811|NCT03040687|Experimental|Anti-CS6 group|Anti-CS6 BSIgG and challenge strain CS6-expressing ETEC (B7A)
9845812|NCT03040687|Experimental|Anti-whole cell B7A|Anti- whole cell B7A (killed) BSIgG and challenge strain CS6-expressing ETEC (B7A)
9845813|NCT03040687|Experimental|control Immunoglobulin group|Negative Control (Nonhyperimmune BSIgG placebo) and challenge strain CS6-expressing ETEC (B7A)
9845814|NCT03040713|Experimental|FTD Subjects|Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan
9845815|NCT03040804|Experimental|Low Dose Radiotherapy|Patients will receive skin-directed radiotherapy, using a total prescription dose of 7.5 gy in five fractions of 1.5 gy over one week
9845816|NCT03040986|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate by mouth (PO) twice daily (BID). Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
9845817|NCT03041025|Experimental|Cohort 1: GSK2330811 100 mg|During Cohort 1, participants will receive a single dose of GSK2330811 100 mg by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
9845818|NCT03041025|Experimental|Cohort 2: GSK2330811 300 mg|During Cohort 2, participants will receive a single dose of GSK2330811 300 mg by SC injection (3 vials of 1 mL each of GSK2330811 100 mg) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
9845819|NCT03041025|Placebo Comparator|Cohort 1: Placebo|During Cohort 1, participants will receive a single dose of placebo by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
9845820|NCT03041025|Placebo Comparator|Cohort 2: Placebo|During Cohort 2, participants will receive a single dose of placebo by SC injection (3 vials of 1 mL each) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
9845821|NCT03041038|Experimental|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
9845822|NCT03041038|Placebo Comparator|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
9986327|NCT01401660||Group C|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
9986328|NCT01401712|Experimental|Paravertebral catheter (ON-Q® Pain Relief System)|
9986329|NCT01401712|Active Comparator|Thoracic epidural catheter|
9986330|NCT01401725|Experimental|Hamilton General Hospital|
9793350|NCT01471054|Active Comparator|Bevacizumab|Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.
9793351|NCT01471093|Experimental|Solution|A single dose of OPC-12759 Ophthalmic solution for two-day treatment
9793352|NCT01471093|Active Comparator|Suspension|A single dose of OPC-12759 Ophthalmic suspension for two-day treatment
9793353|NCT01471171|Experimental|Aclidinium bromide|3-week treatment periods
9793354|NCT01471171|Experimental|Placebo|3-week treatment periods
9793355|NCT01471197|Experimental|Arm 1: Ipilimumab|
9793356|NCT01471197|Active Comparator|Arm 2: Pemetrexed|
9793357|NCT01471353|Experimental|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study.
9793358|NCT01471379|Experimental|Group A (50mg - 100mg)|Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
9793359|NCT01471379|Active Comparator|Group B (50mg x12)|Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
9793360|NCT01471379|Placebo Comparator|Group C (Placebo - 50mg)|Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II
9793361|NCT01471457|Experimental|Trimo-San group|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
9793362|NCT01471457|No Intervention|Control group|Pessary wearers are informed on standard care of pessary, which includes topical estrogen application if they are using. Pessary wearers do not use Trimo-San gel
9793363|NCT01471522|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
9793364|NCT01471522|Active Comparator|Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
9793365|NCT01471574|Experimental|Daclatsvir + Ribavirin + PEG-Interferon alfa-2a|
9793366|NCT01471626|Experimental|telematic attended polysomnography|
9793367|NCT01471639|Experimental|Intranasal ketorolac (Sprix)|FDA approved drug used in single arm study
9793368|NCT01471691|Experimental|intravitreal ranibizumab 0.5mg|
9793369|NCT01471691|Experimental|intravitreal ranibizumab 1.0mg|
9793370|NCT01471782|Experimental|Blinatumomab|Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
9793371|NCT01472185|Placebo Comparator|Placebo|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
9793372|NCT01472185|Experimental|Ranolazine|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
9793373|NCT01472289|Experimental|BMMNC treated group|Autologous bone marrow mononuclear cell concentrate (BMMNCs) prepared using the Res-Q 60 technology (a point of care system) to be injected intramuscularly into multiple sites in the ischemic muscle tissue of the affected limb at 0.5 cc/injection for a total of 15-20 cc.
9793374|NCT01472341||All Participants|Participants receiving routine care under a diabetologist.
9793375|NCT01472380|Active Comparator|Efavirenz 600mg alone|efavirenz 600mg by mouth taken on Day 1
9793376|NCT01472380|Active Comparator|Efavirenz co-administered with fenofibric acid|co-administered oral doses of efavirenz 600 mg and fenofibric acid 105 mg taken on Day 31
9845823|NCT03041090|Experimental|Static Imaging participants|"This arm of the study assessed participants' static PET/CT images. These were the standard of care images acquired after their standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (Lucerno Device Identity Document (LD ID), Lucerno Device 1 (LD1), Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
9845824|NCT03041090|Experimental|Dynamic image participants|"This arm of the study assessed participants' dynamic PET/CT images. These were the study related images of and around the injection site acquired during the participants' standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (LD ID, LD1, Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
9845825|NCT03041116|Experimental|Fosmetpantotenate|Administered as powder for reconstitution.
9845826|NCT03041116|Placebo Comparator|Placebo|Administered as powder for reconstitution.
9845827|NCT03041181|Experimental|Arm A - Single Agent Chemotherapy + Nivolumab|"Single Agent Chemotherapy of choice plus nivolumab:~Taxotere Pemetrexed Gemcitabine"
9845828|NCT03041181|Active Comparator|Arm B - Single Agent Chemotherapy|Single Agent Chemotherapy of choice Taxotere Pemetrexed Gemcitabine
9845829|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
9845830|NCT03041441|Experimental|MRICP method|MRI sequences have been developed that may be able to estimate ICP in a non-invasive fashion.6-10 The MRI-based method for measurement of ICP (MRICP method) is based on basic principles of the cranio-spinal CSF physiology: The mono-exponential relationship between intracranial volume and pressure leads to a linear relationship between elastance (i.e., the derivative of pressure with respect to volume) and pressure.
9845831|NCT03041467|Experimental|IN.PACT AV DCB|"PTA will be performed using the IN.PACT AV Access Drug Coated Balloon. IN.PACT AV Access DCB was the device name used during the clinical study. Medtronic has changed the name of the device to IN.PACT™ AV Paclitaxel-Coated Balloon Catheter (also referred as IN.PACT AV DCB). Hence, throughout posting, the study device will be referred to as the IN.PACT AV DCB."
9845832|NCT03041467|Active Comparator|Standard Balloon Angioplasty|PTA will be performed using a commercially available uncoated PTA balloon.
9845833|NCT03041636|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
9845834|NCT03041792|Experimental|Active|Liraglutide
9845835|NCT03041792|Placebo Comparator|Placebo|Placebo comparator
9845836|NCT03041896||Decompression|Standard of care decompression for spinal stenosis, 1 or 2 levels.
9845837|NCT03041896||Fusion|Standard pedical and rod fixation with standard decompression, 1 or 2 levels.
9845838|NCT03041896||coflex®|Decompression surgery with the coflex® Interlaminar Technology, 1 or 2 levels.
9845839|NCT03041896||Hybrid|coflex and fusion at adjacent levels
9845840|NCT03041909|Experimental|Single Arm|Single Arm / open label
9845841|NCT03042299|Experimental|TAK-536 Granules + TAK-536 Tablet|TAK-536 10 milligram (mg), granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
9845842|NCT03042299|Experimental|TAK-536 Tablet + TAK-536 Granules|TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
9845843|NCT03042312|Experimental|177Lu-PSMA-617 (6.0 GBq)|Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
9845844|NCT03042312|Experimental|177Lu-PSMA-617 (7.4 GBq)|Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
9845845|NCT03042559|Active Comparator|Protonics knee brace|All subjects were fitted with a regular-sized Protonics knee brace with resistive settings to resist knee flexion.
9845846|NCT03042559|Experimental|Sport cords|Resistive sports cord to resist knee flexion.
9845847|NCT03042702|Experimental|Kevetrin 250 mg/m2 IV Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
9845848|NCT03042702|Experimental|Kevetrin 350 mg/m2 IV Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
9986331|NCT01401725|Active Comparator|Juravinski Hospital|
9986332|NCT01401725|Other|St. Joseph's Hospital|
9845849|NCT03042715||Psychological Intervention refinement|"Eight weekly sessions in-person or via telephone~Qualitative interviews~Feedback from 5-10 caregivers to refine the intervention."
9845850|NCT03042767|Experimental|IMM-124E Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive 600mg of IMM-124E powder three times daily for twelve weeks.
9845851|NCT03042767|Placebo Comparator|Placebo Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive placebo powder three times daily for twelve weeks.
9845852|NCT03042910|Experimental|Patients with advanced solid tumors|Talazoparib 1 mg daily
9845853|NCT03043079|Experimental|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
9845854|NCT03043079|Other|Healthy Volunteers|Twenty-five volunteers without ventral hernia
9845855|NCT03043079|Other|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
9986333|NCT01401751|Other|Single Arm|non-randomized, uncontrolled, feasibility study
9986334|NCT01401764|Other|Platform II, PASS, ARG 100|
9986335|NCT01401777||Control, No PercuNav|Patient having procedure without PercuNav Guidance information
9845856|NCT03043105|Experimental|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
9845857|NCT03043274|Experimental|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
9845858|NCT03043274|No Intervention|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
9845859|NCT03043365|Experimental|Arm 1: Control Fish Oil first, then Saury Oil|Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm
9845860|NCT03043365|Experimental|Arm 2: Saury Oil first, then Control Fish Oil|Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm
9845861|NCT03043365|No Intervention|Washout Period|8 week washout period to occur between week 8 and week 16. No study supplement taken by subject at this time.
9845862|NCT03043534|Experimental|Gel and Brush|The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
9845863|NCT03043534|No Intervention|Control|Subjects will use their normal razors and shave products during the six week study. Subjects must shave at least 3 times weekly. No change in normal shaving is done in this group
9845864|NCT03043560|Experimental|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
9845865|NCT03043560|Placebo Comparator|Placebo|Participants will receive treatment with a matching placebo pill.
9845866|NCT03043651|Experimental|Oral treprostinil|Sustained-release tablets for TID administration
9845867|NCT03043885|Experimental|PRF|
9845868|NCT03043885|Experimental|PRF+FDBA|
9845869|NCT03043885|Active Comparator|FDBA|
9845870|NCT03043885|Active Comparator|Blood Clot|
9845871|NCT03044028|Experimental|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
9845872|NCT03044028|Experimental|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
9845873|NCT03044028|No Intervention|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
9845874|NCT03044106|Active Comparator|CLRT, Then Sham|Subjects performed the KEA, HHD, PPT functional tests on their right hamstring before and after the CLRT intervention.
9845875|NCT03044106|Sham Comparator|Sham, Then CLRT|The Sham procedure was identical to CLRT except the laser device was placed in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
9845876|NCT03044197|Experimental|MRI/ultrasound transperineal prostate biopsy|In arm A, all patients with positive mpMRI evidence of lesions suspicious for PCa, i.e. PI RADS ≥ 3 will be submitted to transperineal mpMRI-targeted prostate biopsy (arm A MRI+). The gland and the regions of interest will be contoured, and the prostate contour will be fused in real time with the TRUS image. Biopsies will be performed via a transperineal approach in the operating room. The patient will be placed in dorsal lithotomy position. mpMRI-targeted biopsies will be performed on regions of interest, and three to six cores will be obtained for biopsy from each lesion and is standard of care according to START criteria for targeted biopsy. In cases of negative mpMRI results i.e. PI RADS<3, arm A patients will undergo TRUS-guided transrectal 12-core prostate biopsy (arm A MRI-) as described in arm B.
9845877|NCT03044197|Active Comparator|transrectal ultrasound-guided prostate biopsy|TRUS-guided transrectal prostate biopsy will be performed using a disposable 18-gauge biopsy gun with a specimen size of 18-22 mm (Bard Medical, Covington, GA, USA). The 12 cores will be obtained from 12 separate anatomical regions of the prostate which is standard practice in performing TRUS-guided transrectal prostate biopsy: left medial apex, left lateral apex, left medial midgland, left lateral midgland, left medial base, left lateral base, right medial apex, right lateral apex, right medial midgland, right lateral midgland, right medial base and right lateral base.
9845878|NCT03044249|Experimental|MP-101|"Week 0:~Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps.~Week 1:~Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps.~Week 2 through Week 9:~Participants received 60 mg MP-101 orally QD (3 x 20-mg caps )."
9845879|NCT03044249|Placebo Comparator|Placebo|Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
9845880|NCT03044353|Experimental|Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants|Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR will be included. Participants will receive 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.
9845881|NCT03044353|Experimental|Group 2: Post-chemotherapy AL Amyloidosis participants|Immunoglobin light chain amyloidosis (AL) participants who attain either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.
9845882|NCT03044353|Experimental|Group 3: Newly diagnosed Mayo stage II/IIIa AL participants|Newly diagnosed Mayo stage II/IIIa AL participants who attain a free light chain CR during the first 3 cycles of first-line chemotherapy where the first cycle was cyclophosphamide, bortezomib, dexamethasone (CyBorD) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.
9922634|NCT00841360||HIV Status Unknown|"Participant self-discloses as HIV negative (no history of prior HIV testing, or HIV screening more than 12 months prior to date of study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
9922635|NCT00841360||Friendship Network Members|Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
9922636|NCT00841373|Active Comparator|1|Panretinal Photocoagulation
9922637|NCT00841373|Active Comparator|2|Ranibizumab Supplementing Panretinal Laser Photocoagulation
9922638|NCT00841386|Experimental|Cross-linking treatment|Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.
9922639|NCT00841386|Sham Comparator|Sham treatment group|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.
9922640|NCT00841399|Experimental|E75 + GM-CSF vaccine|The dose escalation scheme is for three patients to receive each of the doses, 100, 500, and 1,000 mcg of peptide + 250 mcg GM-CSF each month for 6 months until the maximum tolerated dose is determined. Patients who receive the vaccine are HLA-A2+ and/or HLA-A3+. Responses to the vaccine are measured via immunologic assays.
9922641|NCT00841399|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients do not receive the E37 + GM-CSF vaccine, but are instead enrolled to the control arm for observation.
9922642|NCT00841425||Swimmers|
9922643|NCT00841438|Active Comparator|Provisional use of Clotinab|Provisional use of clotinab
9922644|NCT00841438|Experimental|Upstream use of clotinab|early upstream use of clotinab
9922645|NCT00841477|No Intervention|A1|standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
9922646|NCT00841477|Active Comparator|A2|standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
9922647|NCT00841477|Active Comparator|B1|enhanced behavioral intervention, standard vaccine schedule
9922648|NCT00841477|Active Comparator|B2|enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
9922649|NCT00841490||1|Intellectually & Developmentally Disabled Adults
9922650|NCT00841490||2|Control Group of Adults without Intellectual & Developmental Disabilities
9922651|NCT00841503||12 healthy volunteers|Healthy volunteers are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
9922652|NCT00841503||12 Participants with Type 2 diabetes|Volunteers with type 2 diabetes are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
9922653|NCT00841516|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
9922654|NCT00841516|Experimental|80 µg rBet v1-FV Immunotherapy|All randomized patients were treated with either placebo or 80 µg rBet v1-FV (maintenance dose) for 2 years.
9922655|NCT00841581|Experimental|Lucentis|"All patients receive iL for for first 6 months of study. At 6 months - patients are classified as responders or non-responders. Responders receive iL PRN based on OCT,clinical exam etc. Non-responders are seen again at 12 months for repeat investigations."
9922656|NCT00841594|Active Comparator|1|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the hand."
9922657|NCT00841594|Active Comparator|2|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the chest."
9845883|NCT03044418||anesthesia with laser tube|The special endotracheal (ET) laser tube is tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
9845884|NCT03044431||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
9845885|NCT03044574|Experimental|Experimental group (SCD + GCS + LMWH)|"SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
9845886|NCT03044574|Active Comparator|Control group (GCS + LMWH)|"GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
9845887|NCT03044691|No Intervention|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
9845888|NCT03044691|Experimental|Intervention Clinic|Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
9845889|NCT03044730|Experimental|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9845890|NCT03044886|Experimental|2000IU/day|Subjects took 2000IU vitamin D per day
9845891|NCT03044886|Experimental|1000IU/day|Subjects took 1000IU vitamin D per day
9845892|NCT03044886|Placebo Comparator|Placebo|Subjects took placebo
9845893|NCT03045081|No Intervention|Usual care|Patients receive outcome tracking tool, PainTracker, but no additional web-based support for self-management
9845894|NCT03045081|Experimental|PainTracker Self-Manager|Patients are invited to complete the web-based PainTracker Self-Manager and interact with a nurse care manager who supports chronic pain self-management
9845895|NCT03045302|Experimental|BIM23B065|
9845896|NCT03045328|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
9845897|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
9845898|NCT03045861|Experimental|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
9845899|NCT03045861|Experimental|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
9845900|NCT03045861|Experimental|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
9986336|NCT01401777||PercuNav aided procedure|Biopsy procedure aided with use of PercuNav
9845901|NCT03045861|Experimental|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
9845902|NCT03045887|Experimental|Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
9845903|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-Placebo-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, placebo in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
9845904|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg- GSK 200 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
9845905|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-GSK 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
9845906|NCT03045887|Experimental|Part A Cohort 2: Placebo-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 µg in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
9986337|NCT01401790|Experimental|Telehomecare|3 month use of a new telehomecare program
9986338|NCT01401790|Active Comparator|Control|3 month regular education program and follow up at the Diabetes Clinic
9845907|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-Placebo- GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, placebo in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
9845908|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
9845909|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2, GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
9845910|NCT03045887|Experimental|Part B: GSK|Subjects will receive inhaled repeat dose of GSK2292767 2000 µg once daily for 14 days.
9845911|NCT03045887|Experimental|Part B: Placebo|Subjects will receive inhaled repeat dose of placebo once daily for 14 days.
9845912|NCT03045926|Experimental|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
9845913|NCT03046056|Experimental|Filgotinib 200 mg|Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.
9845914|NCT03046056|Experimental|Filgotinib 100 mg|Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.
9845915|NCT03046056|Placebo Comparator|Placebo|PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.
9845916|NCT03046212|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
9845917|NCT03046212|Active Comparator|Physical therapy|This group received only conventional physical therapy (exercises).
9845918|NCT03046225|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
9845919|NCT03046225|Active Comparator|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
9845920|NCT03046446|Experimental|FX006 32 mg|Single intra-articular injection
9845921|NCT03046472|Experimental|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.~Total duration 12 weeks/3 months"
9845922|NCT03046472|Active Comparator|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
9845923|NCT03046966|Other|Intervention Control: No Training|Does not receive hands-on intubation training in the Simulation Lab.
9845924|NCT03046966|Other|Intervention: Receives Training|Receives hands-on intubation training in the Simulation Lab.
9845925|NCT03047174|Experimental|Arm A: Treatment with Mepitel® Film|"Arm A:~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
9922658|NCT00841607|Experimental|Pancreaticojejunostomy|Pancreaticojejunostomy reconstruction used following Whipple surgery.
9922659|NCT00841607|Active Comparator|Pancreaticogastomy|Pancreaticogastomy reconstruction used following Whipple surgery.
9922660|NCT00841620|Active Comparator|1|Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids
9922661|NCT00841620|Active Comparator|2|Stapled anopexy for grade 3-4 haemorrhoids
9845926|NCT03047174|Active Comparator|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
9845927|NCT03047447|Experimental|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
9845928|NCT03047447|Active Comparator|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
9845929|NCT03047447|Active Comparator|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
9845930|NCT03047551|Active Comparator|Transabdominal Sonography|"Subjects will receive transabdominal sonography using a standard ultrasound device to determine medical abortion eligibility.~A transabdominal ultrasound is used to look at the pelvic organs. Gel is placed on your abdomen. Then a small, handheld unit called a transducer is gently moved around to view the pelvic organs. The transducer sound waves make a picture on the TV screen."
9845931|NCT03047551|Active Comparator|Transvaginal Sonography|"Subjects will receive transvaginal sonography using a standard ultrasound device to determine medical abortion eligibility.~Transvaginal ultrasound is an examination of the female pelvis and urogenital tract (kidneys and bladder). It differs from an abdominal ultrasound as it looks at the pelvic organs from inside the vagina."
9845932|NCT03047720|Other|One: Study Phases (S1 and S2)|The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
9845933|NCT03047720|Other|Two: Study Phases (S2 and S1)|The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)
9845934|NCT03047980|Experimental|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
9845935|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
9845936|NCT03048058|Experimental|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
9845937|NCT03048058|Active Comparator|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
9845938|NCT03048383|Active Comparator|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
9845939|NCT03048383|Active Comparator|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
9845940|NCT03048383|Active Comparator|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
9845941|NCT03048500|Experimental|Treatment (metformin hydrochloride, nivolumab)|Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
9845942|NCT03048747|Experimental|Tolvaptan|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
9845943|NCT03049215|Active Comparator|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
9845944|NCT03049215|Active Comparator|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
9845945|NCT03049280|Experimental|Transoral robotic surgery|
9845946|NCT03049488|Experimental|Group 1: DS-Cav1 (50 mcg)|"DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
9922662|NCT00841633|No Intervention|1|No induced hypertension (reference group)
9986339|NCT01401803|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass.
9845947|NCT03049488|Experimental|Group 2: DS-Cav1 (50 mcg) + alum|"DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
9845948|NCT03049488|Experimental|Group 3: DS-Cav1 (150 mcg)|"DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose."
9845949|NCT03049488|Experimental|Group 4: DS-Cav1 (150 mcg) + alum|"DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
9845950|NCT03049488|Experimental|Group 5: DS-Cav1 (500 mcg)|"DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
9845951|NCT03049488|Experimental|Group 6:DS-Cav1 (500 mcg) + alum|"DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
9845952|NCT03049501|Experimental|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
9845953|NCT03049501|Placebo Comparator|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition.
9845954|NCT03049748|Active Comparator|Control Group|Participants in the control group (20 LVAD patients) will receive usual care over 6 months. Usual care consists of routine clinic visits/follow-up at 1, 3, and 6 months post hospital discharge. A customary LVAD self-management/discharge education and training will be provided to patients and caregiver before hospital discharge and as need throughout the duration of the study. The control group will NOT receive the VAD Care App.
9845955|NCT03049748|Experimental|Intervention Group|Participants in the experimental group (20 LVAD patients) will receive usual care plus VAD Care App. They will implement LVAD self-management as directed by VAD Care App. The app will be used daily by patients and/or caregivers for over 6 months. Their LVAD self-management competencies will be assessed at months 1 and 5 post hospital discharge with a review of LVAD self-management skills provided by the LVAD RN Coordinator.
9845956|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Single dose|One drop in the study administered one time only for one day
9845957|NCT03049852|Placebo Comparator|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
9845958|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Multidose|One drop in the study administered three times daily (TID) for 4 weeks
9845959|NCT03049917|No Intervention|No incentive|No incentive
9845960|NCT03049917|Experimental|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
9845961|NCT03049917|Experimental|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
9845962|NCT03049917|Experimental|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
9845963|NCT03049917|Experimental|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
9845964|NCT03050203|Experimental|custom pack|
9845965|NCT03050203|Active Comparator|standard care|
9845966|NCT03050216|Experimental|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide~ALT-803 Activation of Donor NK Cells~ALT-803 to Facilitate NK Cell Survival and Expansion"
9845967|NCT03050294|Active Comparator|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
9845968|NCT03050294|Experimental|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
9845969|NCT03050294|Active Comparator|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
9845970|NCT03050294|Experimental|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
9922663|NCT00841633|Experimental|2|Induced hypertension with a MAP of 30 mmHg above the average MAP on the previous day; during 24-36 hours, until a perfusion CT scan has been performed
9922664|NCT00841646|Other|1|
9922665|NCT00841685|Experimental|1|Goldlock
9922666|NCT00841685|Active Comparator|2|Visicoil smallest size
10207320|NCT01166737|No Intervention|Control Arm - Chemotherapy only|Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice
10207321|NCT01166737|Experimental|Procedure/Surgery|Maximum effort cytoreductive surgery
10207322|NCT01116648|Experimental|Arm I (cediranib maleate and olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10207323|NCT01116648|Active Comparator|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10207324|NCT01064479|Experimental|Arm A (combination chemotherapy and erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.
10207325|NCT01064479|Active Comparator|Arm B (combination chemotherapy and placebo)|Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.
9799797|NCT01669538|Placebo Comparator|Placebo|"Participants assigned to the placebo (sugar pill) arm will take one capsule daily, preferably with food, for a total of 23 days. They will follow the same instructions and complete the same procedures as those in the active treatment.~Placebo ingredients (sucrose filler and gel capsules) will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
9799798|NCT01669577||severe trauma patients|analysis of blood samples and clinical features
9799799|NCT01669603|Experimental|Bifidobacterium animalis lactis Bl-04|Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
9799800|NCT01669603|Placebo Comparator|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
9799801|NCT01669629|Experimental|Delefilcon A/ Etafilcon A|6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
9799802|NCT01669629|Experimental|Etafilcon A / Delefilcon A|6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
9799803|NCT01669642|Experimental|Ketamine|participants who get the ketamine sedation will be enrolled. there is no control or comparison group.
9799804|NCT01669720|Experimental|Aflibercept|Patients will be randomized 2:1, to receive Aflibercept,4mg/kg IV q2weeks until progression for a maximum of 2 years
9799805|NCT01669720|No Intervention|Observation|Patients will be randomized 2:1 to receive Aflibercept. Patients who are randomized to observation will be followed per the study table, but will receive no intervention.
9845971|NCT03050307|Experimental|TAK-438 20 mg|Helicobacter Pylori positive (HP+) participants: TAK-438 20 mg tablet, twice daily (BID) along with lansoprazole placebo-matching, capsule BID in addition to bismuth-containing quadruple antibiotic therapy for the first 2 weeks. Following 2 weeks of eradication therapy participants received TAK-438 20 mg QD along with lansoprazole matching placebo 30 mg, capsule QD for up to 6 weeks. HP negative (HP-) participants: TAK-438 20 mg tablet, (QD) along with lansoprazole matching placebo, 30 mg capsule QD for up to 8 weeks.
9845972|NCT03050307|Experimental|Lansoprazole 30 mg|HP+ participants: Lansoprazole 30 mg, capsule, orally, BID and TAK-438 placebo-matching tablet, orally, BID along with bismuth-containing quadruple antibiotic therapy for first 2 weeks. Following 2 weeks participants received Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 6 weeks. HP- participants: Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 8 weeks.
9845973|NCT03050320|Experimental|Exercise|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Five class times will be offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
9845974|NCT03050320|Other|No Exercise|The participants in this arm will be asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group will be offered the same exercise program following completion of the study. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
9845975|NCT03050359|Experimental|TAK-438 20 mg|H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
9922667|NCT00841685|Active Comparator|3|Visicoil larger size
9922668|NCT00841685|Active Comparator|4|Bard goldmarker smallest size
9922669|NCT00841685|Active Comparator|5|Bard goldmarker larger size
9922670|NCT00841711|Other|Behavioral counseling|
9845976|NCT03050359|Experimental|Lansoprazole 30 mg|H. pylori negative (HP -) participants: lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, QD for up to 6 weeks. HP + participants: lansoprazole 30 mg, capsules, orally, BID and TAK-438 placebo-matching tablets, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed by lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, BID for up to 4 weeks.
9845977|NCT03050372|Experimental|Active Low Field Magnetic Stimulation|LFMS - Active
9845978|NCT03050372|Sham Comparator|Sham Low Field Magnetic Stimulation|LFMS - Sham
9845979|NCT03050450|Experimental|dose level 1|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
9845980|NCT03050450|Experimental|dose level 2|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
9845981|NCT03050450|Experimental|dose level 3|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
9845982|NCT03050450|Experimental|dose level 4|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
9845983|NCT03050450|Experimental|dose level 5|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
9845984|NCT03050541|Experimental|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
9845985|NCT03050541|Experimental|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
9845986|NCT03050541|Placebo Comparator|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
9845987|NCT03050619||New users of Empagliflozin|New users of empagliflozin
9845988|NCT03050619||New users of Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
9845989|NCT03050619||New users of Other non-insulin GLDs|New users of other non-insulin GLDs
9845990|NCT03050697|Experimental|HMTIOL|HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
9845991|NCT03050775|Experimental|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
9845992|NCT03050775|Active Comparator|Standard Ventilator Circuit|Standard ventilation and temperature management.
9845993|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 1 day|Experiment 1
10207326|NCT01042522|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
10207327|NCT01042522|Experimental|Arm II (bleomycin sulfate, etoposide phosphate, cisplatin)|Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
10207328|NCT00958737|Experimental|Arm I|"Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).~Patients receive XELOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)"
9845994|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 3 days|Experiment 1
9845995|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 4 days|Experiment 1
9845996|NCT03050801|Experimental|Experiment 2 - Parietal Cortex rTMS stimulation - 3 days|Experiment 2
9845997|NCT03050801|Experimental|Experiment 2 - Vertex rTMS stimulation - 3 days|Experiment 2
9845998|NCT03050801|Experimental|Experiment 2 - Prefrontal Cortex rTMS stimulation - 3 days|Experiment 2
10207329|NCT00958737|Experimental|Arm II|Patients receive modified FOLFOX 6 or XELOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding XELOX every 21 days for 8 courses (6 month).
9845999|NCT03050918|Active Comparator|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
9846000|NCT03050918|No Intervention|Usual Care Group (Control Arm)|Patients assigned to the control group receive standard discharge planning and follow-up per the usual care of their medical providers.
9846001|NCT03051100|Experimental|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
9846002|NCT03051100|Placebo Comparator|placebo|Matching placebos taken orally, daily.
9846003|NCT03051165|Other|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
9846004|NCT03051256|Experimental|REL-1017 25 mg|REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
9846005|NCT03051256|Experimental|REL-1017 50 mg|REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
9846006|NCT03051256|Placebo Comparator|Placebo|100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.
9846007|NCT03051607|Experimental|Tozadenant|120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.
9846008|NCT03051633|Experimental|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
9846009|NCT03051633|No Intervention|Control|Assessment only
9846010|NCT03051646|Experimental|Acetylsalicylic acid first, placebo second|Participant is administered acetylsalicylic acid one hour prior to exercise.
9846011|NCT03051646|Placebo Comparator|Placebo oral capsule first, ASA second|Participant is administered placebo one hour prior to exercise.
9846012|NCT03051672|Experimental|Pembrolizumab With Radiation|"pembrolizumab : 200 mg intravenously 2 to 7 days prior to radiotherapy (RT) and on day 1 of repeating 21-day cycles. Treatment up to 35 cycles.~Palliative radiation: a total dose of 20 Gy in 5 fractions"
9846013|NCT03052257|Experimental|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
9846014|NCT03052257|Active Comparator|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
9846015|NCT03052322|Experimental|MSB11022|
9846016|NCT03052322|Active Comparator|EU-Humira|
9846017|NCT03052426|Active Comparator|30 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 30 minutes throughout their workday.
9846018|NCT03052426|Active Comparator|60 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 60 minutes throughout their workday.
9846019|NCT03052426|Active Comparator|90 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 90 minutes throughout their workday.
9846020|NCT03052517|Experimental|QAW039 150mg|QAW039 Dose 1 once daily
9846021|NCT03052517|Experimental|QAW039 450 mg|QAW039 Dose 2 once daily
9846022|NCT03052517|Placebo Comparator|Placebo|Placebo once daily
9846023|NCT03052530|Experimental|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
9846024|NCT03052725|Experimental|reslizumab 110 mg|Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.
9846025|NCT03052751|Experimental|Dosage Regimen 1|Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
9846026|NCT03052751|Experimental|Dosage Regimen 2|Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
9846027|NCT03052764|Active Comparator|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
9846028|NCT03052764|Placebo Comparator|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
9986340|NCT01401816|Experimental|Intervention Group|Subjects in this group will receive a prescription for emergency contraception and then text-messages (on Day 1, 3 and 5 after enrollment) to their personal cell phone with a reminder to fill their prescription.
9846029|NCT03052816|Experimental|ICE T|"ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with PO Tylenol and PO toradol PRN."
9846030|NCT03052816|Active Comparator|Standard|"Motrin 600mg PO Q4h PRN pain 1-3~Percocet 1 tab PO Q4-6 hours PRN 4-6 pain~Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
9846031|NCT03052959|Experimental|Immediate Intervention|
9846032|NCT03052959|Other|Wait List Intervention|
9846033|NCT03052972|Experimental|Amyloid Positive|Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
9846034|NCT03052972|Experimental|Amyloid Negative|Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan
9846035|NCT03053050|Experimental|SEL 18 mg|"Randomized Phase: Selonsertib (SEL) 18 mg tablet + placebo to match SEL 6 mg tablet for 240 weeks~Open-Label (OL) Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
9846036|NCT03053050|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
9986341|NCT01401816|No Intervention|Control Group|Subjects in this group will receive a only a prescription for emergency contraception and no reminder text messages.
9986342|NCT01401829|Experimental|75 weekly minutes walking|12-week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week
9846037|NCT03053050|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
9846038|NCT03053063|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label (OL) Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
9846039|NCT03053063|Experimental|SEL 18 mg|"Randomized Phase: SEL 18 mg plus placebo to match SEL 6 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
9846040|NCT03053063|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
9846041|NCT03053102|Experimental|Danicopan|Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).
9846042|NCT03053180||Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir|"Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis received paritaprevir/ritonavir (r), ombitasvir and dasabuvir (3DAA ABBVIE REGIMEN) for 12 weeks.~The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer a patient the opportunity to participate in this study."
9846043|NCT03053271|Experimental|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
9846044|NCT03053271|Placebo Comparator|Placebo|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
9846045|NCT03053401|Active Comparator|Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
9846046|NCT03053401|Active Comparator|Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
9846047|NCT03053427|Placebo Comparator|Placebo|Placebo was administered orally once daily after the evening meal.
9846048|NCT03053427|Experimental|Gabapentin enacarbil|Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to < 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week followed by gabapentin enacarbil 600 mg for 11 weeks.
9846049|NCT03053492|Experimental|Duck Duck Punch|Subjects in this arm will engage in Duck Duck Punch Play, a custom designed computer game developed for stroke rehabilitation for 6 weeks.
9846050|NCT03053492|Active Comparator|Commercially Available Game|Subjects in this arm will engage in a Commercially Available Game Play off-the-shelf computer game for 6 weeks.
9846051|NCT03054051|Experimental|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
9846052|NCT03054051|No Intervention|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
9846053|NCT03054064|Experimental|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
9846054|NCT03054077|No Intervention|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
9793377|NCT01472432|Placebo Comparator|Placebo|In the placebo group, the dose of other concomitant hypoglycemic medication was changed to obtain a similar profile of metabolic parameters. All patients had diabetes and at least one full-thickness wound below the ankle for >3 months. All patients were examined weekly for the first 4 weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each visit, tracings of the wound margins were made for computer planimetry to document changes in wound size, and photographs were taken for a visual record. All patients followed the regular treatment at the multidisciplinary diabetes foot clinic, included treatment of infection, debridement, off-loading, and metabolic control according to high international standards and standard good medical practice.
9793378|NCT01472432|Experimental|Vildagliptin|The experimental arm followed the same treatment of placebo group, but received also vildagliptin 50 mg per os b.i.d. for 4 months
9793379|NCT01472445|Experimental|Non-obese (Body Mass Index ≤ 25)|Non-obese participants receive Vitamin D at 400 or 10,000 IU/day
9793380|NCT01472445|Experimental|Obese (Body Mass Index > 25)|Obese participants receive Vitamin D at 400 or 10,000 IU/day
10207330|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 1|A single 15 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
10207331|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 2|A single 18 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
10207332|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 3|A single 21 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
10207333|NCT00941915|Experimental|Stereotactic Radiotherapy|Five fractions of 7.4 Gy each
10207334|NCT00826462|Experimental|1|"Corticosteroid injection in combination with physical therapy~Injection with triamcinolone 10 mg and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn Entero 500 mg bid for 14 days"
10207335|NCT00826462|Placebo Comparator|2|"Placebo injection in combination with physical therapy~Injection with sodium chloride and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn entero 500 mg bid for 14 days"
10207336|NCT00826462|Active Comparator|3|Control group: wait-and-see treatment Naprosyn entero 500 mg bid for 14 days
10207337|NCT00710970|Experimental|Single Arm Receiving 25mg Tamoxifen|
10207338|NCT00685919|Experimental|Carbidopa then Placebo|Carbidopa 200 mg every 6 hours orally for 5 doses followed by Placebo every 6 hours for 5 doses
10207339|NCT00685919|Experimental|Placebo then Carbidopa|Placebo matching carbidopa given every 6 hours orally for 5 doses followed by Carbidopa
10207340|NCT00647036|Active Comparator|1|Dipeptiven (L-glutamine- Lalanine)
10207341|NCT00647036|Placebo Comparator|2|Isonitrogenous Vaminolact
10207342|NCT00587886||Cases|Cases will be women with newly diagnosed endometrial or ovarian cancer who are residents of six counties in New Jersey.
10207343|NCT00587886||Controls|Controls will be selected from the general population in those counties by use of random digit dialing for those under 65 years of age, from Centers for Medicare and Medicaid Services (CMS) lists for those aged 65 years and over, and from neighborhood sampling.
10207344|NCT00574496|Experimental|High-Risk or Relapsed Hodgkin Lymphoma|This is a phase 2 intention-to-treat study of salvage chemotherapy followed by allogeneic HSC transplant for the treatment of primary refractory or relapsed HL. Patients who 1) do not progress on salvage chemotherapy, and 2) have both suitable HSC donors and 3) a satisfactory pre-allograft work-up will proceed to allograft. Patients who fail any of these 3 criteria will be off-study and considered treatment failures for the purposes of the intention-to-treat study.
10207345|NCT00482794||1|Individuals with APS who also have one or more of their family members affected specifically by APS
10207346|NCT00482794||2|Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
10207347|NCT00482794||3|Individuals with APS and no family or no family affected with APS or another autoimmune disorder
10207348|NCT00394550|No Intervention|control|If laryngomalacia is found, then in the control group, no supraglottoplasty will be performed. Only the tonsils and adenoids will be removed.
10207349|NCT00394550|Experimental|Treatment|"If laryngomalacia is found, then in the Treatment group, a supraglottoplasty with laser will be performed, as well as removal of the tonsils and adenoids.~Intervention: supraglottoplasty with laser"
10207350|NCT00344487|Experimental|lopinavir/ritonavir (Kaletra)|lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.
10207351|NCT00281658|Experimental|Combination|Paclitaxel and Lapatinib (Blinded)
10207352|NCT00281658|Active Comparator|Paclitaxel|Paclitaxel and Placebo (Blinded)
10207353|NCT00281658|Other|Monotherapy Extension|Open-label monotherapy lapatinib
10207354|NCT05209698||Ethnic groups- Jews and Arabs|Data will be extracted from electronic medical records for all people with PD residing in a specific HMO district according to a record-based survey (e.g., individuals whose medical records include a diagnosis of PD). Currently, there are 2500 patients with PD in that district. In the second part of the study, a sub-sample of 100 Jewish and 100 Arab Patients with Parkinson's disease will be asked to answer standardized questionnaires.
10207355|NCT05209685|Experimental|Experimental|Resistance exercise with blood flow restriction
10207356|NCT05209685|Active Comparator|Control|Traditional resistance exercise
10207357|NCT05209659||Low Back Pain|Pragmatic Mobilization The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment)
9846055|NCT03054077|Experimental|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
9846056|NCT03054103|Placebo Comparator|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
9846057|NCT03054103|Active Comparator|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
9846058|NCT03054103|Active Comparator|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
9846059|NCT03054337|Experimental|Vadadustat, Dose 1|Daily oral dose
9846060|NCT03054337|Experimental|Vadadustat, Dose 2|Daily oral dose
9846061|NCT03054337|Experimental|Vadadustat, Dose 3|Daily oral dose
9846062|NCT03054337|Placebo Comparator|Placebo|Daily oral dose
9846063|NCT03054350|Experimental|Vadadustat, Dose 1|Daily oral dose
9846064|NCT03054350|Experimental|Vadadustat, Dose 2|Daily oral dose
9846065|NCT03054350|Experimental|Vadadustat, Dose 3|Daily oral dose
9846066|NCT03054350|Placebo Comparator|Placebo|Daily oral dose
9846067|NCT03054428|Experimental|Placebo|Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling the amount of placebo on day 1 to match the loading dose). In order to maintain blinding for the study, participants in the <60 kilogram (kg) weight stratum received, in a 1:1 ratio, either placebo matching 200 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose) or placebo matching 300 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose). In the ≥60 kg weight stratum, the participants randomized to the placebo group received placebo matching 300 mg dupilumab (including doubling the amount of placebo on day 1 to match the loading dose).
9846068|NCT03054428|Experimental|Dupilumab 300 mg Q4W|Participants received once every 4 weeks (Q4W) subcutaneous (SC) injections of 300 milligrams (mg) dupilumab following a loading dose of 600 mg on day 1. In order to maintain blinding, all participants received an injection once every 2 weeks (Q2W) from day 1 to week 14. Participants received placebo 2 milliliter (mL) injection at the weeks dupilumab was not given.
9846069|NCT03054428|Experimental|Dupilumab 200 mg or 300 mg Q2W|Participants with baseline weight <60 kg received once every 2 weeks (Q2W) subcutaneous (SC) injections of 200 milligrams (mg) dupilumab following a loading dose of 400 mg on day 1. Participants with baseline weight ≥60 kg received Q2W SC injections of 300 mg dupilumab following a loading dose of 600 mg on day 1.
9846070|NCT03054506|Experimental|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
9846071|NCT03054506|Active Comparator|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
9846072|NCT03054506|Placebo Comparator|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
9846073|NCT03054649|Experimental|Cohort 1|Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
9846074|NCT03054649|Experimental|Cohort 2|Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
9846075|NCT03054740|Active Comparator|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
9846076|NCT03054740|Placebo Comparator|Nature's Tears|Device: Sterile Water
9846077|NCT03054805|Experimental|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks.~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks."
9846078|NCT03054805|Active Comparator|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
9846079|NCT03054805|No Intervention|Healthy Children|Healthy Children
9846080|NCT03054844|Experimental|PREMED|Patients will receive 0.25 mL of IN 4% lidocaine (10 mg) in each naris (total of 0.5 mL/20 mg for both nares) preceding adminstration of IN midazolam.
9846081|NCT03054844|Experimental|PREMIX|Patients will receive midazolam mixed with 0.5 mL of 4% lidocaine (20 mg).
9846082|NCT03054857|Experimental|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
9793381|NCT01472549|Active Comparator|Iodine-alcohol|8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
9793382|NCT01472549|Experimental|Chlorhexidine-alcohol|2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)
9793383|NCT01472718|Active Comparator|standard primary coronary intervention|
9793384|NCT01472718|Experimental|coronary thrombectomy|
9793385|NCT01472757|Placebo Comparator|Placebo|
9793386|NCT01472757|Active Comparator|Dose 1|
9793387|NCT01472757|Active Comparator|Dose 2|
9793388|NCT01472757|Active Comparator|Dose 3|
9793389|NCT01472822|Experimental|Omija extract.|
9793390|NCT01472822|Placebo Comparator|Placebo|
9793391|NCT01472835|Experimental|Sedation|Pt will receive sedation with their procedure
9793392|NCT01472835|No Intervention|Control|Patient will not receive sedation during procedure
9793393|NCT01472874|Experimental|Once a day Trientine|Patients receive once a day trientine
9793394|NCT01472939|Active Comparator|SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)|
9793395|NCT01472939|Active Comparator|SSP-002358 (0.5 mg) + PPI|
9793396|NCT01472939|Active Comparator|SSP-002358 (2.0 mg) + PPI|
9793397|NCT01472939|Placebo Comparator|Placebo + PPI|
9793398|NCT01472965|Active Comparator|Treatment|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with 70% ethanol catheter lock therapy.
9793399|NCT01472965|Placebo Comparator|Control|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with heparin-saline placebo catheter lock therapy.
9793400|NCT01473160|Experimental|delefilcon A|Delefilcon A randomly assigned to one eye, with narafilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
9793401|NCT01473160|Active Comparator|narafilcon A|Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
9793402|NCT01473355|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm
9793403|NCT01473368|Active Comparator|prebiotic (Saccharomyces boulardii)|500 mg, 2 times daily for 14 days
9793404|NCT01473368|Active Comparator|antibiotic (Amoxicillin Clavulanate)|875/125 mg 2 times daily at least 1 hour before meals for 7 days
9793405|NCT01473368|Active Comparator|combination (prebiotic and antibiotic)|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
9793406|NCT01473368|No Intervention|control|
9793407|NCT01473381|Placebo Comparator|Placebo|Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
9793408|NCT01473381|Experimental|Vilazodone 20 mg/day|Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
9793409|NCT01473381|Experimental|Vilazodone 40 mg/day|Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
9793410|NCT01473381|Active Comparator|Citalopram 40 mg/day|Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.
9793411|NCT01473394|Placebo Comparator|Dose-matched placebo|Participants received dose-matched placebo orally once daily for 9 weeks.
9846083|NCT03054857|Placebo Comparator|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
9846084|NCT03054870|Other|Xe-133 Followed by Technegas|Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.
9846085|NCT03054922|Active Comparator|Normal Saline|0.9% Sodium Chloride
9846086|NCT03054922|Active Comparator|Lactated Ringers|"Each 100 mL of Lactated Ringer's Injection USP contains:~Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs"
9846087|NCT03054922|Active Comparator|Normosol-R|Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
9846088|NCT03055000|Experimental|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
9846089|NCT03055000|Experimental|AGS-v with adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
9846090|NCT03055000|Placebo Comparator|Placebo|WFI (0.5mL) on Day 0 and Day 21
9846091|NCT03055156|Experimental|Low rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
9846092|NCT03055156|Experimental|High rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
9846093|NCT03055195|Experimental|Mepolizumab|Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
9846094|NCT03055195|Placebo Comparator|Placebo|Eligible subjects will receive matching placebo subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
9846095|NCT03055221|Experimental|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
9846096|NCT03055260|Experimental|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
9846097|NCT03055260|Placebo Comparator|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
9846098|NCT03055338|Experimental|MK-8189|Participants receive MK-8189 (4 mg controlled release [CR] oral tablet[s]) in combination with placebo matching risperidone (oral capsule[s]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
9846099|NCT03055338|Active Comparator|Risperidone|Participants receive risperidone (2 mg oral capsule[s]) in combination with placebo matching MK-8189 (oral tablet[s]), QD for 4 weeks. Over the initial 7 treatment days, risperidone is titrated from 2 mg to 6 mg as follows: 2 mg (1 capsule; Day 1); 4 mg (2 capsules; Day 4); and 6 mg (3 capsules; Day 7). Placebo matching MK-8189 is also titrated as follows: 1 tablet (Day 1), 2 tablets (Day 4), and 3 tablets (Day 7). After Day 7, risperidone is maintained at 6 mg (3 capsules) in combination with placebo matching MK-8189 (3 tablets), QD for 3 weeks.
9846100|NCT03055338|Placebo Comparator|Placebo|Participants receive both placebo matching MK-8189 (oral tablet[s]) as well as placebo matching Risperidone (oral capsule[s]), QD for 4 weeks. Over the initial 7 treatment days, placebo matching both MK-8189 and risperidone are respectively titrated as follows: 1 tablet/1 capsule (Day 1); 2 tablets/2 capsules (Day 4); and 3 tablets/3 capsules (Day 7). After Day 7, placebo matching both MK-8189 and risperidone are respectively maintained at 3 tablets/3 capsules, QD for 3 weeks.
9846101|NCT03055494|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
9846102|NCT03055494|Placebo Comparator|Placebo|Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
9846103|NCT03055624|Experimental|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
9922671|NCT00841724|Active Comparator|Busilvex, Fludara, Thymoglobuline|D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion
9846104|NCT03055650|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
9846105|NCT03055806|Experimental|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
9846106|NCT03055806|Placebo Comparator|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
9846107|NCT03055806|Experimental|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
9846108|NCT03055806|Experimental|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
9846109|NCT03055832|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
9846110|NCT03055832|Active Comparator|LipiFlow Thermal Pulsation System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
9846111|NCT03055858|Experimental|PDA closure|
9846112|NCT03055897|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
9846113|NCT03055936|Experimental|A1|levodopa 50 mg, carbidopa 12.5 mg
9846114|NCT03055936|Experimental|B1|levodopa 50 mg, carbidopa 65 mg
9846115|NCT03055936|Experimental|C1|levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg
9846116|NCT03055936|Experimental|D1|levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
9846117|NCT03055936|Experimental|A2|levodopa 100 mg, carbidopa 25 mg
9846118|NCT03055936|Experimental|B2|levodopa 100 mg, carbidopa 65 mg
9846119|NCT03055936|Experimental|C2|levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg
9846120|NCT03055936|Experimental|D2|levodopa 100 mg, carbidopa 37,5 mg
9846121|NCT03055936|Experimental|A3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
9846122|NCT03055936|Experimental|B3|levodopa 150 mg, carbidopa 65 mg
9846123|NCT03055936|Experimental|C3|levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg
9846124|NCT03055936|Experimental|D3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
9846125|NCT03055936|Experimental|A4|levodopa IR 100 mg (Sinemet), carbidopa 25 mg
9846126|NCT03055936|Experimental|B4|levodopa 100 mg, carbidopa 65 mg
9846127|NCT03055936|Experimental|C4|levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg
9846128|NCT03055936|Experimental|D4|levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
9846129|NCT03055988|Experimental|Tiotropium/Olodaterol Fixed Dose Combination|
9846130|NCT03055988|Active Comparator|Fluticasone Propionate + Salmeterol Fixed Dose Combination|
9846131|NCT03056040|Experimental|Ravulizumab|"On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
9846132|NCT03056040|Active Comparator|Eculizumab|"Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
9846133|NCT03056144|Experimental|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
9846134|NCT03056300|Experimental|Powered vascular stapler|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
9846135|NCT03056352|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
9846136|NCT03056456|Experimental|LY900014|LY900014 (Treatment B) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
9846137|NCT03056456|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro (Treatment A) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
9846138|NCT03056573|Experimental|Subclavian/axillary|Subclavian/axillary access route
9846139|NCT03056573|Experimental|Transaortic|Transaortic access route
9846140|NCT03056690|Experimental|ASP0819|Participants received ASP019 15 mg capsules, orally, once daily in the morning, with or without food for 8 weeks.
9846141|NCT03056690|Placebo Comparator|Placebo|Participants received ASP019 matching placebo capsules, orally, once daily in the morning, with or without food for 8 weeks.
9846142|NCT03057132|Experimental|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
9922672|NCT00841737|Experimental|Psychoeducational group intervention|Psychoeducational group received weekly a psychoeducational intervention during a period of 12 weeks run by a nurses.
9922673|NCT00841737|Active Comparator|Control group|Individual conventional care
9922674|NCT00841750|Experimental|No chest tube|No chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
9922675|NCT00841750|Active Comparator|Chest tube|Chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
9922676|NCT00841789|Experimental|Arm 1 -Etanercept|Drug - Treatment with Etanercept as adjunct to standard treatment with IVIG and aspirin
9922677|NCT00841789|Placebo Comparator|2|Placebo
9922678|NCT00841802|Experimental|Prednisone|Steroid medication
9793412|NCT01473394|Experimental|Vilazodone|Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.
9922679|NCT00841802|No Intervention|No Intervention|No Intervention
9793413|NCT01473407|Experimental|Epoetin Hospira|Epoetin Hospira
9793414|NCT01473407|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
9793415|NCT01473420|Experimental|Epoetin Hospira|Epoetin Hospira
9793416|NCT01473420|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
9793417|NCT01473524|Experimental|DB OCA 5-10 mg|OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.
9793418|NCT01473524|Experimental|DB OCA 10 mg|OCA 10 mg for 12 months during the DB phase.
9793419|NCT01473524|Placebo Comparator|DB Placebo|Matching placebo for 12 months during the DB phase.
9793420|NCT01473524|Experimental|LTSE OCA|After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg. Participants who were previously titrated above 10 mg OCA daily were down-titrated to ≤10 mg OCA daily.
9793421|NCT01473563|Experimental|Pemetrexed|500 milligrams per square meter (mg/m^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
9793422|NCT01473589|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
9793423|NCT01473589|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
9799806|NCT01669785|Active Comparator|Group C|"NUPRO Classic Prophy Paste~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains no Novamin or Fluoride..~Leave in contact for 60 seconds, rinse with water and expectorate."
9799807|NCT01669785|Experimental|Group A|"NUPRO Sensodyne Prophy Paste w/ Novamin~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 15% Novamin. Does not contain Fluoride.~Leave in contact for 60 seconds, rinse with water and expectorate"
9799808|NCT01669785|Experimental|Group B|"NUPRO Sensodyne Prophy Paste w/ Novamin w/ Fluoride~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 1.23% fluoride ion and 15% Novamin.~Leave in contact for 60 seconds, rinse with water and expectorate."
9799809|NCT01669798|Experimental|BIBF 1120|BIBF 1120 will be administered at a daily oral dose of 200 mg BID until disease progression or adverse effects prohibit further therapy.
9799810|NCT01669811|Experimental|D961H 20mg twice daily|Double-blinded
9799811|NCT01669811|Active Comparator|D961H 20mg once daily|Double-blinded
9799812|NCT01669863|Experimental|Use of ECMO in non-intubated patients|ECMO will be used in non-intubated patients with ARDS
9799813|NCT01669902||Cohort|
9799814|NCT01669928|Active Comparator|Evening medication|Anti hypertensive medication in the evening (between 18.00 and 23.00)
9799815|NCT01669928|Active Comparator|Morning medication|Antihypertensive medication in the morning(between 06.00 and 11.00)
9799816|NCT01670019|Experimental|Asenapine 5-20 mg daily|Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability
9799817|NCT01670019|Placebo Comparator|Placebo 1-4 tablets daily|Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability
9799818|NCT01670045||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.
9799819|NCT01670097|Experimental|Dexamethasone|"Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
9799820|NCT01670097|Placebo Comparator|Placebo|"Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
9799821|NCT01670110|Active Comparator|Pasireotide LAR (SOM230)|Active Pasireotide LAR
9799822|NCT01670110|Placebo Comparator|placebo injection|
9799823|NCT01670188|Active Comparator|Pneumatic SCD|Use of pneumatic SCD (VenaFlow System - DJO Global) on upper extremity with PICC line inserted.
9799824|NCT01670188|No Intervention|Non-SCD group|Standard care
9799825|NCT01670201|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
9793424|NCT01473602|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
9793425|NCT01473602|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
9793426|NCT01473745|Active Comparator|modified alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The modified alar cinch suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
9793427|NCT01473745|Placebo Comparator|conventional alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The conventional alar base cinch suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
9793428|NCT01473758|Active Comparator|Roflumilast|added on to standard therapy for acute COPD exacerbations
9793429|NCT01473758|Placebo Comparator|Placebo|added on to standard therapy for acute COPD exacerbations
9793430|NCT01473836|Experimental|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
9793431|NCT01473940|Experimental|Treatment (monoclonal antibody, chemotherapy)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes in weeks 1, 4, 7, and 10 and gemcitabine hydrochloride IV over 30 minutes in weeks 1-7 and 9-11.~MAINTENANCE: Beginning in week 22, patients receive ipilimumab IV over 90 minutes once every 12 weeks and gemcitabine hydrochloride IV over 30 minutes once weekly for 3 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response."
9793432|NCT01473953|Experimental|Cohort 1a: Lira-depot 2.25 mg|
9793433|NCT01473953|Experimental|Cohort 2a: Lira-depot 6.75 mg|
9793434|NCT01473953|Experimental|Cohort 3a: Lira-depot 15 mg|
9793435|NCT01473953|Experimental|Cohort 4a: Lira-depot 30 mg|
9793436|NCT01473953|Placebo Comparator|Placebo|
9793437|NCT01473992|Active Comparator|Prosthetic knee 1 (Otto Bock C-Leg)|This arm included unilateral transfemoral amputees who were assessed while using their preferred knee at study start(C-Leg). The Otto Bock C-Leg is a microprocessor knee using 2 sensors (1 for kinetics and 1 for kinematics).
9793438|NCT01473992|Active Comparator|Prosthetic knee 2 (Otto Bock Genium)|This arm included unilateral transfemoral amputees who were assessed while using the experimental/study knee, the Genium. The Otto Bock Genium is a microprocessor knee using multiple sensors that hypothetically increase mobility functions (e.g. walking backwards, intuitive stance)
9793439|NCT01473992|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
9793440|NCT01474018|No Intervention|Metformin + Insulin|5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
9793441|NCT01474018|Experimental|QR-Bromocriptine +metformin+insulin|study drug add-on the usual therapy
9793442|NCT01474109|Active Comparator|macitentan 3mg|macitentan 3mg tablet once daily
9793443|NCT01474109|Active Comparator|macitentan 10mg|macitentan 10mg tablet once daily
9793444|NCT01474109|Placebo Comparator|placebo|matching placebo once daily
9793445|NCT01474122|Active Comparator|Macitentan 3 mg|Oral macitentan 3 mg, once daily
9793446|NCT01474122|Active Comparator|Macitentan 10 mg|Oral macitentan 10 mg, once daily
9793447|NCT01474122|Placebo Comparator|Placebo|Oral placebo, once daily
9793448|NCT01474200|Experimental|Aquapheresis (AQ) - isolated veno-venous ultrafiltration|Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
9793449|NCT01474200|Active Comparator|IV Loop Diuretics (LD)|Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment
9793450|NCT01474213|Active Comparator|dexmedetomidine|a loading dose (1.5mcg/kg) infused over10 min followed by a continuous infusion of 0.7 μg/kg/h
9793451|NCT01474213|Active Comparator|remifentanil|The initial target was 3.0 ng/ml and the TCI was adjusted by 0.5 ng/ml after the target concentration at the effect site had equilibrated with the plasma concentration, until the desired level of sedation was acheived.
9793452|NCT01474239|Experimental|Calibration Arm|
9793453|NCT01474239|Experimental|Investigational Arm|
9793454|NCT01474291||Tocilizumab|Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
9793455|NCT01474317|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
9793456|NCT01474434|Experimental|Pradigastat (LCQ908) followed by placebo|Pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by pradigastat 20 mg (2 x 10-mg tablets) daily for two days followed by a 30-day washout period in between followed by 5-day placebo treatment
9793457|NCT01474434|Experimental|Placebo followed by pradigastat (LCQ908)|Placebo (5-day treatment period) followed by a 30-day washout period followed by pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by p20 mg (2 x 10-mg tablets) daily for two days
9793458|NCT01474486|Experimental|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
9793459|NCT01474512|Experimental|80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)|Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 [every 2 weeks (Q2W)] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 [every 4 weeks (Q4W)] or Dosing Regimen 3 [every 12 weeks Q12W)].
9793460|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 2 (Q4W)|Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
9846143|NCT03057366|Experimental|[14C]-Pevonedistat 25 mg/m^2|[14C]-pevonedistat (containing approximately 60-98 mCi [approximately 2.22-3.626 MBq] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles. Based on investigator and sponsor discretion, participants deriving benefits will continue to receive current combination therapy or pevonedistat alone beyond 12 cycles.
9846144|NCT03057496|Experimental|Intervention|Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.
9846145|NCT03057613|Experimental|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
9846146|NCT03057704|Active Comparator|Intravenous lidocaine: flushed|Lidocaine injection flushed
9846147|NCT03057704|Experimental|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
9846148|NCT03057977|Experimental|Empagliflozin|
9846149|NCT03057977|Placebo Comparator|Placebo|
9846150|NCT03058679|Experimental|Specific Carbohydrate Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.
9846151|NCT03058679|Active Comparator|Mediterranean Style Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the MD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Meals were designed to be heated in an oven or microwave. No other preparation was required.
9846152|NCT03058692|Experimental|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
9846153|NCT03058692|Placebo Comparator|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
9846154|NCT03058991|Experimental|Distress Tolerance Intervention|For the Distress Tolerance Intervention, the investigators will use a Mindfulness Based Stress Reduction (MBSR) program that has been adapted for use with adolescents. This version of MBSR follows closely the original conceptualization developed by Kabat-Zinn. The focus is on formal and informal mindfulness practices, which encourage participants to foster intention, attention and attitude. The investigators will make slight modifications to the delivery of the MBSR intervention to take into account the developmental period of their participants (e.g., attention span) to encourage retention and increase relevancy. These changes will also allow the investigators to match the duration with their Working Memory Intervention.
9846155|NCT03058991|Experimental|Working Memory Intervention|"For the working memory training, the investigators will use the Cogmed RM program. Participants will be asked to use the program, while supervised twice a week, each time for an hour, for 8 weeks. Participants will also be asked to use the program on the other days for 25-35 minutes. The program resembles a video game, and comprises several different games that require visuo-spatial working memory (remembering the position of objects) and a combination of verbal and visual working memory (remembering phonemes, letters, and digits). The program adapts to the user's performance, such that trainees are able to perform at the limit of their ability, stimulating WM capacity adaptation."
9846156|NCT03058991|Active Comparator|Control Informational Intervention|This Control Informational Intervention has been used in the investigators' and other's previous studies. In the current application, it will match the session time of the Distress Tolerance and Working Memory interventions and will omit a focus on smoking (which is specific to the SPII intervention provided across all interventions), and will consist of discussions of a variety of healthy lifestyle topics, such as healthy eating, stress/time management, and recommended health screenings.
9846157|NCT03059810|Experimental|Participating Subjects|Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.
9846158|NCT03059901|Experimental|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
9846159|NCT03059901|Active Comparator|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
9922680|NCT00841841|Experimental|Dipyrone|"Analgesic affectiveness using Dipyrone (500mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
9793461|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 3 (Q12W)|Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
9793462|NCT01474512|Placebo Comparator|Placebo|Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
9793463|NCT01474538|Active Comparator|Insulin Lispro, then Insulin Aspart|Insulin lispro [100 units/milliliter (U/mL)] administered by continuous subcutaneous insulin infusion (CSII) pump for 16 weeks in Treatment Period 1, followed by insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
9793464|NCT01474538|Active Comparator|Insulin Aspart, then Insulin Lispro|Insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 1, followed by insulin lispro (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
9793465|NCT01474551|Experimental|vemurafenib|This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
9793466|NCT01474590|Experimental|Epiduo/Tactuo + doxycycline 200mg|
9793467|NCT01474590|Active Comparator|Isotretinoin + vehicle gel|
9793468|NCT01474681|Experimental|HSC835|HSC835 infusion
9793469|NCT01474746|Placebo Comparator|Placebo|This arm will undergo identical treatment and assessments as the experimental group, with the exception of the active agent, sertraline. This group will be placed on a placebo.
9793470|NCT01474746|Experimental|Active|This arm will undergo identical treatment and assessments as the placebo group. This group will receive the active agent, sertraline.
9793471|NCT01474772|Experimental|Pregabain|
9793472|NCT01474772|Placebo Comparator|Placebo|
9793473|NCT01474863|Active Comparator|Low Dose Citrulline|Low Dose Citrulline
9793474|NCT01474863|Placebo Comparator|Placebo|Placebo IV infusion
9793475|NCT01474863|Active Comparator|High Dose Citrulline|High Dose Citrulline
9793476|NCT01474876||Ankylosing Spondylitis|Participants with a diagnosis of ankylosing spondylitis
9793477|NCT01474876||Psoriatic Arthritis|Participants with a diagnosis of psoriatic arthritis
9793478|NCT01474915|Active Comparator|Aprepitant|"Aprepitant is given orally, along with an oral or PO placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy 40mg Aprepitant PO + IV placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
9793479|NCT01474915|Active Comparator|Ondansetron|"Ondansetron is given via IV, along with an oral or IV placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication (25mg promethazine, 10mg dexamethasone, and either 4mg ondansetron or 40mg aprepitant) plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy~4mg Ondansetron IV + PO placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
9793480|NCT01474993|Placebo Comparator|Placebo|inactive placebo.
9793481|NCT01474993|Experimental|Interventional|sulforaphane-rich Broccoli Sprout Extract.
9793482|NCT01475071|Experimental|Metvix and daylight|
9793483|NCT01475071|Active Comparator|Metvix and lamp|
9793484|NCT01475097|Active Comparator|Active Arm|
9793485|NCT01475097|Active Comparator|Comparator Arm|
9793486|NCT01475136|Experimental|LY2140023|A single oral dose of 80 milligrams (mg) LY2140023 administered on Day 1.
9793487|NCT01475162|Experimental|Tocilizumab|"Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response."
9793488|NCT01475175|Experimental|CRT pacing at rest and during exercise|Rest and sub-maximal exercise
9793489|NCT01475214|Active Comparator|potassium bicarbonate low dose|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
9793490|NCT01475214|Active Comparator|potassium bicarbonate higher dose|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
9793491|NCT01475214|Placebo Comparator|placebo|microcrystalline cellulose
9793492|NCT01475253|Experimental|Lidocaine Releasing Intravesical System|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
9793493|NCT01475253|Placebo Comparator|LiRIS containing inactive substance only|LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
9793494|NCT01475253|Sham Comparator|Cystoscopy Procedure|No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.
9793495|NCT01475305|Placebo Comparator|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
9793496|NCT01475305|Experimental|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
9793497|NCT01475331|Active Comparator|Control Group|Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
9793498|NCT01475331|Experimental|Study Group|Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
9793499|NCT01475370|Experimental|OCV-501|
9986343|NCT01401829|Experimental|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week
9793500|NCT01475461|Placebo Comparator|Placebo|
9793501|NCT01475461|Experimental|PF-04937319 - Dose 1|
9793502|NCT01475461|Experimental|PF-04937319 - Dose 2|
9793503|NCT01475461|Experimental|PF-04937319 - Dose 3|
9793504|NCT01475461|Experimental|PF-04937319 - Dose 4|
9793505|NCT01475461|Active Comparator|Sitagliptin|
9793506|NCT01475487|Active Comparator|Cricothyrotomy using Digital Palpation|Group-1 will perform Cricothyrotomy using conventional digital palpation technique
9793507|NCT01475487|Experimental|Ultrasound guided cricothyrotomy group|Group-2 Ultrasound guided cricothyrotomy
9793508|NCT01475513|Active Comparator|African-American women|African-American women
9793509|NCT01475513|Active Comparator|Caucasian women|Caucasian women
9793510|NCT01475643|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5%
9793511|NCT01475643|Active Comparator|Prednisolones acetate|Prednisolone acetate 1.0%
9793512|NCT01475721|Experimental|ADVAIR 100/50mcg|experimental drug
9793513|NCT01475721|Experimental|ADVAIR 250/50mcg|experimental drug
9793514|NCT01475721|Experimental|ADVAIR 500/50mcg|experimental drug
9793515|NCT01475721|Active Comparator|FLOVENT 100mcg|active comparator
9793516|NCT01475721|Active Comparator|FLOVENT 250mcg|active comparator
9793517|NCT01475721|Active Comparator|FLOVENT 500mcg|active comparator
9793518|NCT01475734|Active Comparator|albiglutide|single dose of albiglutide
9793519|NCT01475734|Placebo Comparator|placebo|single dose of placebo
9793520|NCT01475825|Experimental|Regimen A: Mipomersen|Subcutaneous injection of mipomersen 200 mg once weekly
9793521|NCT01475825|Placebo Comparator|Regimen A: Placebo|Placebo matching subcutaneous injection once weekly.
9793522|NCT01475825|Experimental|Regimen B: Mipomersen|Subcutaneous injection of mipomersen 70 mg thrice weekly.
9793523|NCT01475825|Placebo Comparator|Regimen B: Placebo|Placebo matching subcutaneous injection thrice weekly.
9793524|NCT01475838|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
9793525|NCT01475838|Active Comparator|PI+RTV+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of a PI boosted with RTV plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
9793526|NCT01475851|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet is administered orally once daily
9793527|NCT01475955|Experimental|Broad Area ALA 1-hour incubation|Broad Area ALA 1-hour incubation
9793528|NCT01475955|Experimental|Broad Area ALA 2-hour incubation|Broad Area ALA 2-hour incubation
9793529|NCT01475955|Experimental|Broad Area ALA 3-hour incubation|Broad Area ALA 3-hour incubation
9793530|NCT01475955|Experimental|Spot ALA 2-hour incubation|Spot ALA 2-hour incubation
9793531|NCT01475955|Placebo Comparator|Vehicle PDT|VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
9793532|NCT01476202|Experimental|Nicotine mouth strip|single dose
9793533|NCT01476202|Active Comparator|nicotine lozenge|single dose
9793534|NCT01476202|Active Comparator|nicotine gum|single dose
9793535|NCT01476267|Experimental|Single Arm|
9793536|NCT01476345|Experimental|LY2963016|A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
9793537|NCT01476345|Experimental|Lantus|A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
9793538|NCT01476449|Active Comparator|Monthly Ranibizumab|Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
9793539|NCT01476449|Experimental|Treat and Extend Ranibizumab|"Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically dry, at which point the evaluation and injection interval will be extended."
9793540|NCT01476475|Experimental|Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
9793541|NCT01476475|Active Comparator|Insulin glargine|Insulin glargine QD for 24 weeks. Dose individually adjusted.
9793542|NCT01476644|Other|Glaucoma Patients|Moderate glaucoma patients with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma were included to complete annual visits over a 4 year period. Each visit included (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measures: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (VRQoL) (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).
9793543|NCT01476696|Experimental|Part A: Prasugrel Single Dose|Prasugrel 0.03 milligrams per kilogram (mg/kg) to 0.60 mg/kg dosage to be titrated up or down based on desired platelet inhibition, administered orally [oral-disintegrating tablet (ODT)], single dose given up to 3 occasions, at different strengths, with up to 18 days between doses.
9793544|NCT01476696|Experimental|Part B: Prasugrel Once-Daily Dose|Daily prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 30% administered orally, once daily for 10-18 days and then followed by prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 50% administered orally, once daily for 10-18 days, for a total of 20-36 days.
9793545|NCT01476722|Experimental|OPTI-FREE PureMoist|OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
9793546|NCT01476748|Active Comparator|Ethicon Xcel Trocars|Ethicon Xcel trocars will be used in this arm with Laprostop device
9793547|NCT01476748|Active Comparator|Covidien Veraport Trocars|Covidien Veraport Trocars will be used in this arm with the Laprostop device
9793548|NCT01476748|Active Comparator|Storz Reusable Trocars|Storz Reusable Trocars will be used in this arm with the Laprostop device
9793549|NCT01477320|Active Comparator|Pantoprazole 40mg IV daily and tube feed|
9846160|NCT03060447|Experimental|Vesatolimod|Participants in Period 1 will receive 10 doses of vesatolimod (4 mg to 8 mg) once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and vesatolimod and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
9846161|NCT03060447|Experimental|Placebo|Participants in Period 1 will receive 10 doses of placebo matched to vesatolimod once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and placebo and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
9846162|NCT03060486|Experimental|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
9846163|NCT03060512|Active Comparator|Crossover Group 1|"Crossover Group Movantik to Polyethylene Glycol 3350~2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout."
9846164|NCT03060512|Active Comparator|Crossover Group 2|"Crossover group Polyethylene Glycol 3350 to Movantik~2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout."
9846165|NCT03060551|Experimental|SVF injection|SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles
9846166|NCT03060759|Active Comparator|Light Therapy-Spectrum 1|Light from 'active' spectrum
9846167|NCT03060759|Placebo Comparator|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
9846168|NCT03061097|Experimental|Treatment (autologous fecal microbiota preparation)|"Participants randomized into the treatment arm will receive a single dose of autologous fecal microbiota preparation (auto-FMP) via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months.~Route of Administration: Enema Dosing Regimen: 125mL x 1 dose"
9846169|NCT03061097|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive a single dose of placebo FMT via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months. The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
9846170|NCT03061175|Experimental|Arm I (Web-Based Contralateral Prophylactic Mastectomy CPM-DA)|Patients receive a website address, a secure username and password, and instructions for using the web-based Contralateral Prophylactic Mastectomy (CPM)- Decision Aid (DA).
9846171|NCT03061175|Experimental|Arm II (Usual Care)|Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.
9846172|NCT03061188|Experimental|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9846173|NCT03061214|Experimental|Semaglutide 0.5 mg OW + sitagliptin placebo OD|
9846174|NCT03061214|Experimental|Semaglutide 1 mg OW + sitagliptin placebo OD|
9846175|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 0.5 mg OW|
9846176|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 1 mg OW|
9846177|NCT03061331|Experimental|Treatment Sequence 1|LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
9846178|NCT03061331|Experimental|Treatment Sequence 2|Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
9846179|NCT03061513|Active Comparator|Ubiquinol|600mg ubiquinol daily for 24 weeks
9846180|NCT03061513|Placebo Comparator|Placebo|Placebo daily for 24 weeks
9846181|NCT03061812|Experimental|Rovalpituzumab tesirine|"Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted.~Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered."
9986344|NCT01401829|Active Comparator|Stretching and Flexibility exercise|Stretching/Flexibility exercise
9846182|NCT03061812|Active Comparator|Topotecan|Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m^2 on Days 1 to 5 of each 21-day cycle.
9986345|NCT01401855||In Vivo Probe Prediction|
9986346|NCT01401855||Cytology Results|
9986347|NCT01401868|Experimental|single arm|dose escalation
9846183|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.~No interventions will be administered."
9846184|NCT03062267|No Intervention|Treatment as Usual|Treatment as usual for 3 months.
9846185|NCT03062267|Experimental|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
9846186|NCT03062488|Active Comparator|opioid only|2 mcg/Kg of fentanyl
9846187|NCT03062488|Active Comparator|opioid plus PO analgesic|2 mcg/Kg of fentanyl plus PO acetaminophen 15 mg/Kg
9846188|NCT03062488|Active Comparator|opioid plus IV acetaminophen|2 mcg/Kg of fentanyl plus 15mg/Kg of IV acetaminophen
9846189|NCT03062605|Active Comparator|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
9846190|NCT03062605|Active Comparator|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
9846191|NCT03062891|Experimental|Online CBT for insomnia|"CBT participants will receive six weekly sessions delivered by an animated 'virtual therapist' (The Prof) via the online platform 'Sleepio'. The programme comprises a fully automated media-rich web application, driven dynamically by baseline, adherence, performance and progress data, and provides additional access to elements such as an online library with background information, a community of fellow users, and support, prompts and reminders sent by e-mail.~CBT content was consistent with the literature (4) and covered behavioral (e.g., sleep restriction, stimulus control) and cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors (sleep hygiene). The intervention was based upon a previously validated manual (4)."
9846192|NCT03062891|No Intervention|Puzzles|Each week participants will be sent a puzzle to complete online (e.g. logic puzzles, crosswords etc). The puzzles have been designed to be cognitively engaging and take a similar amount of time to one session of Sleepio (20-25 minutes).
9846193|NCT03062917|Other|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
9846194|NCT03062917|Other|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
9846195|NCT03062917|Other|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
9846196|NCT03062917|Other|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
9846197|NCT03062917|Other|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
9846198|NCT03063086|Active Comparator|Sequence 1|A-B-C
9846199|NCT03063086|Active Comparator|Sequence 2|A-C-B
9846200|NCT03063086|Active Comparator|Sequence 3|B-C-A
9846201|NCT03063086|Active Comparator|Sequence 4|B-A-C
9846202|NCT03063086|Active Comparator|Sequence 5|C-A-B
9846203|NCT03063086|Active Comparator|Sequence 6|C-B-A
9846204|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
9846205|NCT03063255|Active Comparator|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
9846206|NCT03063255|Active Comparator|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
9846207|NCT03063294|Active Comparator|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
9846208|NCT03063294|Experimental|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
9846209|NCT03063385|Experimental|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
9846210|NCT03063385|Active Comparator|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
9846211|NCT03063437|Experimental|Active: Encapsulated Fecal Microbiota Preparation|Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.
9846212|NCT03063437|Placebo Comparator|Placebo: Encapsulated Placebo|Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.
9922681|NCT00841841|Experimental|Acetaminophen|"Analgesic affectiveness using Acetaminophen (750mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
9922682|NCT00841854|Active Comparator|PBMT7|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days
9922683|NCT00841854|Active Comparator|PBMT14|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days
9922684|NCT00841867||1|Subjects 18-80 years of age who have previously undergone partial pancreatectomy due to a benign lesion
9922685|NCT00841867||2|Healthy control subjects, 18-80 years of age, who have not had partial pancreatectomy.
9793550|NCT01477320|Placebo Comparator|Placebo and tube feed.|
9793551|NCT01477333|Experimental|UT-15C SR BID|Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
9793552|NCT01477450|Active Comparator|1 L/min ; 16 mL|Cylinder oxygen delivery (1 L/min) followed by pulse-dose oxygen by concentrator (16 mL)
9793553|NCT01477450|Active Comparator|2 L/min ; 32 mL|Cylinder oxygen delivery (2 L/min) followed by pulse-dose oxygen by concentrator (32 mL)
9793554|NCT01477450|Active Comparator|3 L/min ; 48 mL|Cylinder oxygen delivery (3 L/min) followed by pulse-dose oxygen by concentrator (48 mL)
9793555|NCT01477463|Experimental|Arm A: Vitamin D|4,000 IU oral vitamin D3
9793556|NCT01477463|Experimental|Arm B: Placebo + Vitamin D|Placebo + 4000 IU oral Vitamin D3
9793557|NCT01477567|Experimental|0.3 mg LY3009385|LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
9793558|NCT01477567|Experimental|1 mg LY3009385|LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
9793559|NCT01477567|Experimental|3 mg LY3009385|LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
9793560|NCT01477567|Experimental|9 mg LY3009385|LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
9793561|NCT01477567|Experimental|22 mg LY3009385|LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
9793562|NCT01477567|Experimental|54 mg LY3009385|LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
9793563|NCT01477567|Placebo Comparator|Placebo|Placebo: saline, subcutaneous (SC) injection, single dose on Day 1
9793564|NCT01477710|Active Comparator|Hold Mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
9793565|NCT01477710|Active Comparator|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
9793566|NCT01477710|Active Comparator|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
9793567|NCT01477749|Experimental|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
9793568|NCT01477762|Active Comparator|PTSD Negative|Participants who do not have PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
9793569|NCT01477762|Experimental|PTSD Positive|Participants with PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
9793570|NCT01477853|Experimental|Sitagliptin/Sitagliptin + Atorvastatin|In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
9793571|NCT01477853|Active Comparator|Atorvastatin/Atorvastatin + Glimepiride|In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
9793572|NCT01477853|Experimental|Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin|In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
9793573|NCT01477892|Experimental|low dose remifentanil|continuous infusion of remifentanil 0.1mcg/kg/min
9793574|NCT01477892|Active Comparator|high dose remifentanil|continuous infusion of remifentanil 0.25mcg/kg/min
9793575|NCT01478009|Experimental|KRG Extract|
9793576|NCT01478009|Placebo Comparator|Placebo|
9793577|NCT01478048|Experimental|Arm A: Elotuzumab + Bortezomib + Dexamethasone|On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
9793578|NCT01478048|Active Comparator|Arm B: Bortezomib + Dexamethasone|
9793579|NCT01478087|Other|Mysorba(single-arm)|
9793580|NCT01478256|Active Comparator|Besifloxocin|Use of topical besifloxocin to treat acute blepharitis
9793581|NCT01478256|Active Comparator|Erythromycin|Topical Erythromycin ointment for treatment of acute blepharitis
9793582|NCT01478321|Experimental|Treatment (radiation, chemotherapy, monoclonal antibody)|"CONCURRENT THERAPY: Patients undergo hypofractionated radiation therapy 5 days a week beginning on day 0. Patients also receive temozolomide PO QD and bevacizumab IV over 30-90 minutes once every 2 weeks beginning on days -3 to 0. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity."
9793583|NCT01478347|Experimental|rMenB+OMV NZ|Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
9793584|NCT01478360|Experimental|AIN457|AIN457 10 mg/kg
9793585|NCT01478360|Placebo Comparator|Placebo|Placebo intravenous injection
9793586|NCT01478373|Experimental|Dovitinib (TKI258)|Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
9846213|NCT03063476|Experimental|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
9846214|NCT03064152|No Intervention|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
9846215|NCT03064152|Experimental|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
9846216|NCT03064438|Experimental|ACU-D1 Ointment|Twice-daily application of ACU-D1 ointment to the face for 12 weeks.
9846217|NCT03064438|Placebo Comparator|ACU-D1 Ointment Vehicle|Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.
9846218|NCT03064451|Experimental|Intervention|cartofinder guided ablation followed by PVI
9846219|NCT03064841||Outpatient with confirmed T2DM|subjects with confirmed T2DM
9846220|NCT03065023|Experimental|Group A: Cutaenous lesions|Participants with transdermally/transmucosally injectable tumors including cutaneous, subcutaneous or lymph node injectable tumors received escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection twice each week (Q2W) over a period of 4 weeks. Participants may have continued to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years).
9846221|NCT03065023|Experimental|Group B: Liver lesions|Participants with injectable liver tumors or liver metastases were to receive escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection once each week over a period of 4 weeks. Participants were to have been able to continue to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years). (Group B was not started. Development will continue with new protocol.)
9846222|NCT03065075|Experimental|Phenazopyridine|Participant is given Phenazopyridine 200mg on postoperative day 1
9846223|NCT03065075|No Intervention|No Phenazopyridine|Participant is not given Phenazopyridine on postoperative day 1
9846224|NCT03065179|Experimental|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
9846225|NCT03065205|Experimental|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
9846226|NCT03065283|Active Comparator|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
9846227|NCT03065283|Placebo Comparator|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
9846228|NCT03065400|Experimental|Pembolizumab|
9846229|NCT03065530|Placebo Comparator|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
9846230|NCT03065530|Experimental|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
9846231|NCT03065530|Experimental|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
9846232|NCT03065530|Experimental|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
9846233|NCT03065647|No Intervention|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
9846234|NCT03065647|Experimental|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
9846235|NCT03066193|Experimental|Dronabinol and Palmitoylethanolamide|All participants will be titrated up on Dronabinol dose during the first week of the trial (2.5mg Dronabinol for 3 days and then 5mg Dronabinol for 4 days increasing to 10mg Dronabinol for the remainder of the trial). Dronabinol will only be increased to 10mg at the week 1 assessment if the subject is tolerating the 5mg dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. All participants will receive two 400mg tablets of PEA daily for the same 12 weeks that they receive the Dronabinol.
9846236|NCT03066609|Experimental|Secukinumab 150mg|Secukinumab 150mg s.c.
9846237|NCT03066609|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c.
9846238|NCT03066609|Placebo Comparator|Placebo|Placebo to secukinumab s.c
9846239|NCT03066778|Experimental|Pembrolizumab+EP|During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
9846240|NCT03066778|Active Comparator|Placebo+EP|During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
9846241|NCT03066804|Experimental|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
9846242|NCT03066804|Active Comparator|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
9846243|NCT03066830|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received two Sotagliflozin tablets of 200 mg, orally once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
9846244|NCT03066830|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
9846245|NCT03066947|Experimental|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation
9846246|NCT03066999|Active Comparator|Cystoscopy|will have catheter placement using the cystoscopy method
9846247|NCT03066999|Active Comparator|DirectVision|will have catheter placement using DirectVision.
9846248|NCT03067129|Experimental|Cohort 1: Adult formulation GLE/PIB, participants 12 to < 18 yrs|Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to < 18 years of age
9846249|NCT03067129|Experimental|Cohort 2: Pediatric formulation GLE/PIB, participants 9 to < 12 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to < 12 years of age
9846250|NCT03067129|Experimental|Cohort 3: Pediatric formulation GLE/PIB, participants 6 to < 9 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to < 9 years of age
9846251|NCT03067129|Experimental|Cohort 4: Pediatric formulation GLE/PIB, participants 3 to < 6 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to < 6 years of age
9846252|NCT03067311|Experimental|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
9793587|NCT01478581|Experimental|Cohort 1|PCI-32765 420 mg per day
9793588|NCT01478581|Experimental|Cohort 2|PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
9793589|NCT01478581|Experimental|Cohort 3|PCI-32765 840 mg per day
9793590|NCT01478581|Experimental|Cohort 4|PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
9793591|NCT01478594|Experimental|Tivozanib + mFOLFOX6|Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
9793592|NCT01478594|Active Comparator|Bevacizumab + mFOLFOX6|Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
9793593|NCT01478620|Experimental|Canephron® N|
9793594|NCT01478828|Experimental|Lovastatin|After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.
9793595|NCT01478854|Experimental|Neural Progenitor Cell Sparing Radiation with Temozolomide|All subjects are treated with neural progenitor cell sparing radiation to 60 Gy in 2 Gy per day, 30 fractions Concurrent and adjuvant temozolomide chemotherapy
9793596|NCT01478958|Active Comparator|high saturated fat diet|
9793597|NCT01478958|Experimental|high monounsaturated fat diet|
9793598|NCT01478958|Experimental|high n-6 polyunsaturated fat diet|
9793599|NCT01478971|Experimental|peginesatide injection|In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).
9793600|NCT01479127|Experimental|Levodopa-carbidopa intestinal gel|"Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks.~The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms."
9793601|NCT01479270|Active Comparator|TAP Block|20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.
9793602|NCT01479270|No Intervention|No Block|Patients randomized to this arm have band aids applied to sites on lateral abdomen without injection.
9793603|NCT01479348|Experimental|1/Intravenous (IV) Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
9793604|NCT01479348|Experimental|2/Oral Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
9793605|NCT01479374|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop to each eye, 3 nonconsecutive days
9793606|NCT01479374|Placebo Comparator|Vehicle|AL-4943A vehicle, 1 drop to each eye, 3 nonconsecutive days
9793607|NCT01479374|Active Comparator|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop to each eye, 3 nonconsecutive days
9793608|NCT01479426|Experimental|EFLA400(960mg)|
9793609|NCT01479426|Placebo Comparator|Placebo(960mg)|
9793610|NCT01479439|Experimental|Sickle cell disease|The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
9793611|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part A)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
9793612|NCT01479465|Experimental|FOLFIRI + SIM 200 mg (Part B)|Participants will receive SIM 200 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
9793613|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part B)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
9793614|NCT01479465|Experimental|FOLFIRI + Placebo (Part B)|Participants will receive placebo to match SIM via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
9793615|NCT01479478|Active Comparator|Probiotic dietary supplement|Probiotic dietary supplement one capsule once per day until delivery.
9793616|NCT01479478|Placebo Comparator|Placebo|Placebo capsule, one daily until delivery.
9793617|NCT01479517|Experimental|Kovacaine Mist 0.1 mL x 4 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
9793618|NCT01479517|Experimental|Kovacaine Mist 0.2 mL x 2 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
9793619|NCT01479517|Experimental|Kovacaine Mist, 0.2 mL x 1 spray|Total dose: 6 mg tetracaine/0.1 mg oxymetazoline
9793620|NCT01479530|Placebo Comparator|Placebo|
9793621|NCT01479530|Experimental|Azilect®|
9793622|NCT01479543|Experimental|Group A|Volunteers received Probiotic CNCM I-4034.
9793623|NCT01479543|Experimental|Group B|Volunteers receive Probiotic CNCM I-4035.
9793624|NCT01479543|Experimental|Group C|Volunteers are given Probiotic CNCM I-4036.
9793625|NCT01479543|Experimental|Group D|Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
9793626|NCT01479543|Placebo Comparator|Group E|Volunteers receive a Placebo.
9793627|NCT01479595|Experimental|QBX258|Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
9793628|NCT01479595|Placebo Comparator|Placebo|Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.
9793629|NCT01479621|Experimental|Fp MDPI 12.5 mcg|"Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9793630|NCT01479621|Experimental|Fp MDPI 25 mcg|"Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9793631|NCT01479621|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9793632|NCT01479621|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9793633|NCT01479621|Experimental|Placebo MDPI|Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
9793634|NCT01479621|Experimental|Flovent Diskus 100mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9793635|NCT01479725|Experimental|Ulcerative IC|HBOT for ulcerative IC
9793636|NCT01479725|Experimental|Non-Ulcerative IC|HBOT for non-ulcerative IC
9793637|NCT01479764|Experimental|Sugammadex|Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
9793638|NCT01479764|Active Comparator|Neostigmine/glycopyrrolate|Participants receive neostigmine/glycopyrrolate per usual practice
9793639|NCT01479777|Experimental|FES Stepping|For the next 8 weeks, we will ask you to come to the ICSCI twice (2) time per week during which you will perform FES Stepping.
9793640|NCT01479868|Experimental|TMC435 + pegylated interferon alpha-2a + ribavirin|Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.
9799826|NCT01670279|Experimental|Cohort 1|14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
9799827|NCT01670279|Experimental|Cohort 2|14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
9799828|NCT01670279|Experimental|Cohort 3|21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
9799829|NCT01670279|Placebo Comparator|Placebo|Placebo
9799830|NCT01670292|Other|Experimental: HVLA-SM|Experimental High Velocity Low Amplitude Spinal Manipulation
9799831|NCT01670487|Active Comparator|Vapocoolant (Pain Ease Medium Stream)|Application of the stream steadily 4 to 10 seconds onto the cannulation site.
9799832|NCT01670487|Placebo Comparator|Nature's Tears|Apply sterile water (see manufacturer above) steadily 4-10 seconds onto the cannulation site.
9799833|NCT01670526|Experimental|Rivastigmine|Rivastigmine transdermal patch
9799834|NCT01670526|Placebo Comparator|Placebo|Placebo
9799835|NCT01670721|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
9799836|NCT01670760|Experimental|Zero-Heat-Flux|This is a single arm study. All patients will have deep tissue temperature monitored from the nasopharyngeal and lateral forehead sites simultaneously.
9799837|NCT01670825|Experimental|Pulsed radiofrequency + local anesthetic injection|Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve
9799838|NCT01670825|Active Comparator|Corticosteroid injection + sham pulsed radiofrequency|"Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency"
9799839|NCT01671059||Tocilizumab|Participants with rheumatoid arthritis (RA) receiving tocilizumab either as combination therapy or monotherapy through routine clinical practice.
9846253|NCT03067311|Active Comparator|Treatment as Usual|Usual treatment provided at the University of North Carolina at Chapel Hill (UNC) Outreach and Support Intervention Services (OASIS) Clinic by trained clinicians.
9846254|NCT03067441|Experimental|Open-Label bempedoic acid|bempedoic acid 180 mg tablet
9846255|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
9846256|NCT03067948|Experimental|Intervention - Positive Screen Shared|In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to the participant's next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to the next HIV primary care visit.
9846257|NCT03067987|Active Comparator|720 shockwave therapy|5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
9846258|NCT03067987|Active Comparator|600 shockwave therapy|"Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration."
9846259|NCT03068091|Other|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
9846260|NCT03068312|Experimental|Sequence 1: First Ivacaftor (IVA) Then Placebo|Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
9846261|NCT03068312|Experimental|Sequence 2: First Placebo Then IVA|Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
9846262|NCT03068455|Experimental|nivolumab + ipilimumab|Specified Dose on Specified Days
9846263|NCT03068455|Experimental|nivolumab|Specified Dose on Specified Days
9846264|NCT03068468|Experimental|BIIB092|Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
9846265|NCT03068468|Placebo Comparator|Placebo|Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
9846266|NCT03068611|Active Comparator|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
9846267|NCT03068611|Experimental|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
9846268|NCT03068715|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
9846269|NCT03068715|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
9846270|NCT03068754|Experimental|Arm A: Treatment Period Acthar|"Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39."
9846271|NCT03068754|Placebo Comparator|Arm B: Treatment Period Placebo|"Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39."
9846272|NCT03068754|Experimental|Arm C: Extension Period Acthar-Acthar|Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
9846273|NCT03068754|Experimental|Arm D: Extension Period Placebo-Acthar|Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
9846274|NCT03068767|Experimental|Vitamin D group|Patients receiving vitamin D supplement (2000 IU/day) for 2 months
9846275|NCT03068767|No Intervention|Control group|Patients without receiving vitamin D supplement
9846276|NCT03068897|Active Comparator|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
9846277|NCT03068897|Active Comparator|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
9846278|NCT03068897|Active Comparator|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
9793641|NCT01479985|Experimental|CDM Tool|participants will be randomized to completing the CDM tool
9793642|NCT01479985|No Intervention|Control|Participants will fill out a computer survey similar to CDM tool without the decisive factors and computer print out
9793643|NCT01480076|Experimental|(BIIB041) Fampridine|All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.
9793644|NCT01480089|Placebo Comparator|Atomized Intraperitoneal Saline (AIS)|Participants randomized to this arm will be given atomized intraperitoneal saline(AIS).
9793645|NCT01480089|Active Comparator|Intraperitoneal Ropivacaine(AIR)|Participants randomized to this arm will receive atomized intraperitoneal ropivacaine (AIR).
9793646|NCT01480219||Any Voriconazole|
9793647|NCT01480219||No Voriconazole|
9793648|NCT01480232|Experimental|EVP-6124 + NicoDerm (Active)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
9793649|NCT01480232|Active Comparator|Placebo + NicoDerm (Active)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
9793650|NCT01480232|Experimental|EVP-6124 + NRT Patch (Placebo)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
9793651|NCT01480232|Placebo Comparator|Placebo + NRT Patch (Placebo)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
9793652|NCT01480258|Experimental|PR5I|"Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
9793653|NCT01480258|Active Comparator|INFANRIX™ hexa|"Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
9793654|NCT01480284|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
9793655|NCT01480284|Active Comparator|ETV 0.5 mg|ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily
9793656|NCT01480297|Experimental|Salsalate|All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
9793657|NCT01480596|Experimental|Belimumab|10mg/kg
9793658|NCT01480596|Placebo Comparator|Placebo|placebo IV infusion
9793659|NCT01480674||Trastuzumab|Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
9793660|NCT01480843|Experimental|Glargine|We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
9793661|NCT01481116|Experimental|TAK-875 25 mg QD|
9793662|NCT01481116|Experimental|TAK-875 50 mg QD|
9793663|NCT01481116|Active Comparator|Glimepiride 1-2 mg QD|
9793664|NCT01481129|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9793665|NCT01481324||Functioning Pressure Sensor Group|This group will have a functioning pressure sensor placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
9793666|NCT01481324||Non-Functioning Pressure Sensor Group|This group will have a non-functioning pressure sensor (a placebo) placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
9793667|NCT01481324||No Sensor Group|This group will not have a pressure sensor placed on the foot ankle orthosis.
9793668|NCT01481545|Experimental|preoperative chemoradiotherapy|Preoperative radiation therapy and combination chemotherapy plus bevacizumab
9846279|NCT03068897|Placebo Comparator|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
9846280|NCT03068949|Active Comparator|FluBlok|FluBlok 0.5 mL given IM X1
9846281|NCT03068949|Active Comparator|Fluzone|Fluzone 0.5 mL given IM X1
9846282|NCT03068949|Active Comparator|FluCelVax|FluCelVax 0.5 mL given IM X 1
9846283|NCT03068949|Active Comparator|Fluzone HD|Fluzone HD 0.5 mL given IM X1
9846284|NCT03069313|Experimental|Arm I|Oral Vitamin B12
9846285|NCT03069352|Experimental|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
9846286|NCT03069352|Placebo Comparator|Placebo + LDAC|Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
9846287|NCT03069365|Experimental|GLE/PIB for 8 weeks|HCV genotype 1,2,4-6 non-cirrhotic, treatment-naive or treatment-experienced; genotype 3 non-cirrhotic, treatment-naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 8 weeks
9846288|NCT03069365|Experimental|GLE/PIB for 12 weeks|HCV genotype 1,2,4-6 compensated cirrhosis, treatment-naive or treatment-experienced; genotype 3 compensated cirrhosis, treatment- naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 12 weeks
9846289|NCT03069365|Experimental|GLE/PIB for 16 weeks|HCV genotype 3 non-cirrhotic or with compensated cirrhosis, treatment-experienced participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 16 weeks
9846290|NCT03069482|Experimental|Learn to Quit|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
9846291|NCT03069482|Active Comparator|NCI QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
9846292|NCT03069677|Active Comparator|Music group|research-selected music
9846293|NCT03069677|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
9846294|NCT03069716|Experimental|Smartphone Text Messaging|"Group receives personalized, health coaching via smart text messages."
9846295|NCT03069716|Other|No Smartphone Text Messaging|"Group does not receive personalized, health coaching via smart text messages."
9846296|NCT03069989|Experimental|Cohort 1 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
9846297|NCT03069989|Placebo Comparator|Cohort 1 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
9846298|NCT03069989|Experimental|Cohort 2 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
9846299|NCT03069989|Placebo Comparator|Cohort 2 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
9846300|NCT03070171|Experimental|Dabigatran Etexilate Capsule|
9846301|NCT03070171|Experimental|Dabigatran Etexilate Tablet|
9846302|NCT03070236|Experimental|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
9846303|NCT03070431|Experimental|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
9846304|NCT03070470|Active Comparator|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
9846305|NCT03070470|Active Comparator|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
9846306|NCT03070470|Active Comparator|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
9846307|NCT03070470|Active Comparator|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
9846308|NCT03070470|Placebo Comparator|Placebo|Placebo capsules
9846309|NCT03070470|Active Comparator|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
9846310|NCT03070483|Experimental|Vitamin D|Participants will all receive supplementation with cholecalciferol 5000 IU and calcium citrate 1000 mg daily for 3 months
9846311|NCT03070548|Experimental|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
9846312|NCT03070730|Other|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
9846313|NCT03070730|Other|Placebos|"In this arm subjects are randomized to placebo tid.~Placebo is used to control the administration effect."
9846314|NCT03070730|Other|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
9922686|NCT00841880|Experimental|1|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine
9922687|NCT00841880|Active Comparator|2|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg
9922688|NCT00841893|Experimental|1|Mustard
9922689|NCT00841893|Experimental|2|Placebo
9922690|NCT00841919|Active Comparator|2|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
9922691|NCT00841919|Experimental|1|"The study group will receive Insulin Glargine as basal insulin and bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff"
9922692|NCT00841932||Fractional Flow Reserve|Patients with suspected coronary artery disease undergoing FFR to assess physiological significance of stenosis
9922693|NCT00841945|Active Comparator|1|"Chemotherapy + Radiotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone~Radiotherapy 40 gray on initial nodes"
9922694|NCT00841945|Experimental|2|"Chemotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone"
9922695|NCT00841984||1|patients with complex neurological disease of unknown cause
9922696|NCT00841984||2|positive controls : patients with already known metabolic disease for whom we already have CSF or urines
9922697|NCT00841984||3|negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture
9922698|NCT00842010||HND|Patients with hyperglycemia, without previous diagnosis of diabetes
9922699|NCT00842010||DH|Patients that have previous diagnosis of Diabetes Mellitus
9922700|NCT00842010||NHND|Patient with NO previous diagnosis of diabetes, and no hyperglycemia
9922701|NCT00842036|Active Comparator|ANft|12- step Al/Nar-Anon Facilitation
9793669|NCT01481558|Sham Comparator|Sham tDCS|sham-tDCS application every 2 days for 2 weeks (total of 6 applications)
9793670|NCT01481558|Experimental|Transcranial direct current stimulation|tDCS application every 2 days for 2 weeks (total of 6 applications)
9793671|NCT01481740|Experimental|Phenylephrine bolus|
9793672|NCT01481740|Experimental|Phenylephrine infusion|
9793673|NCT01481779|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
9793674|NCT01481779|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
9793675|NCT01481896||Metal-on-Metal Total Hip Arthroplasties|Consecutive series of patients who had metal-on-metal primary total hip arthroplasty performed with DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium alloy femoral heads.
9793676|NCT01482065|Experimental|CPAP|"Patients with moderate to severe apnea will be randomized to CPAP or deferred CPAP. Those in the CPAP group will be sent home with an autoset CPAP device, which they will be instructed to utilize for 4 months. The CPAP device will be set in the auto mode so that it will automatically adjust the pressure at night to eliminate upper airway obstruction during sleep.~Criteria for OSA severity are specifically designed to target patients with nocturnal hypoxemia, which is hypothesized to contribute to NAFLD progression. According to the guidelines of the American Academy of Sleep Medicine, apnea will be defined as cessation of airflow for ≥ 10 sec. and hypopnea will be defined as decreased airflow for ≥ 10 sec. leading to oxyhemoglobin desaturation ≥ 4%. Mild, moderate and severe OSA will be diagnosed by an Apnea-Hypopnea Index (AHI) of 5-14.9, 15-29.9, and ≥ 30 events/hr, respectively."
9793677|NCT01482091|Placebo Comparator|Intranasal Saline|
9793678|NCT01482091|Experimental|Intranasal Fentnayl|
9793679|NCT01482169|Active Comparator|Adenoscan|Subjects will have the FFR Measurement with IV Adenoscan®
9793680|NCT01482169|Experimental|Regadenoson|Subjects will have the FFR Measurement with IV Regadenoson
9793681|NCT01482221|Experimental|1|
9793682|NCT01482221|Experimental|2|
9793683|NCT01482221|Placebo Comparator|3|
9793684|NCT01482312|Active Comparator|Lotrafilcon A / Comfilcon A / Glasses|Lotrafilcon A contact lenses worn first, followed by comfilcon A contact lenses, followed by habitual glasses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
9793685|NCT01482312|Active Comparator|comfilcon A / glasses / lotrafilcon A|Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
9793686|NCT01482312|Active Comparator|glasses / lotrafilcon A / comfilcon A|Glasses worn first, followed by lotrafilcon A contact lenses, followed by comfilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
9793687|NCT01482351|Experimental|MCI/OSA/CPAP Adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was equal to or greater than 4 hours per night over one year. CPAP adherence Intervention was provided by research staff.
9793688|NCT01482351|Experimental|MCI/OSA/CPAP Non-adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was less than 4 hours per night or CPAP use was withdrew for any reason over one year. Attention control intervention was provided by staff.
9793689|NCT01482429|Experimental|Protocol-directed|Discontinuation of ventilation was based in multidisciplinary protocol.
9793690|NCT01482429|No Intervention|Usual care|Discontinuation of ventilation was left entirely to the discretion of the physicians.
9793691|NCT01482715|Experimental|Part 1 (Phase 1)|Rucaparib 40, 80, 160, 300, 500 mg QD and 240, 360, 480, 600, 840 mg BID, for continuous 21-day cycles. Patients in Part 1 were initially treated in a Dose-escalation Evaluation Period (Cycle 1) and could then continue to receive treatment in an optional Treatment-extension Period (Cycle 2 and beyond).
9793692|NCT01482715|Experimental|Part 2A (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
9793693|NCT01482715|Experimental|Part 2B (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
9793694|NCT01482715|Experimental|Part 3 (Phase 2)|Rucaparib 600 mg BID for 21-day cycles. Patients also received a single administration of 600 mg rucaparib on both Day -7 and Day 1 for assessing the effect of food on PK.
9793695|NCT01482767|Experimental|HCV Treatment-Naive (Group A)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
9793696|NCT01482767|Experimental|HCV Treatment-Experienced (Group B)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
9793697|NCT01482819|Other|Sequence 1|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Spectacles~Galyfilcon A Plus~Polymacon~Galyfilcon A"
9793698|NCT01482819|Other|Sequence 2|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Galyfilcon A~Lotrafilcon A~Polymacon~Spectacles"
9846315|NCT03070782|Experimental|Cohort A: ISIS 681257: 20 mg Q4W|Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
9846316|NCT03070782|Experimental|Cohort B: ISIS 681257: 40 mg Q4W|Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
9846317|NCT03070782|Experimental|Cohort C: ISIS 681257: 60 mg Q4W|Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
9846318|NCT03070782|Experimental|Cohort D: ISIS 681257: 20 mg Q2W|Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
9846319|NCT03070782|Experimental|Cohort E: ISIS 681257: 20 mg QW|Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
9846320|NCT03070782|Placebo Comparator|Placebo|Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).
9846321|NCT03070964|Experimental|Plitidepsin|
9846322|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase I|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
9846323|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase IIa|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
9846324|NCT03071263|Experimental|Group 1 - Patiromer|spironolactone + blinded patiromer
9846325|NCT03071263|Experimental|Group 2 - Placebo|spironolactone + blinded placebo
9846326|NCT03071276|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
9846327|NCT03071744|Other|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
9846328|NCT03071887|Experimental|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
9846329|NCT03072160|Experimental|Cohort 1: Participants that had an immune stimulating cancer vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 1: cancer vaccine"
9846330|NCT03072160|Experimental|Cohort 2: Participants that have had no vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 2: had no previous vaccine"
9846331|NCT03072186|Experimental|near-infrared light nasal endoscope used with ICG|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery and tumor dissection: before intradural dissection and during tumor dissection.
9846332|NCT03072550|Experimental|Multi-center open label|Thirty Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
9846333|NCT03072602|Experimental|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
9846334|NCT03072602|Active Comparator|White|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
9846335|NCT03072719|Experimental|Dentifrice containing stannous fluoride|Toothpaste
9846336|NCT03072719|Active Comparator|Dentifrice containing Sodium Monofluorophosphate|Toothpaste
9846337|NCT03072732|Other|study arm 1 - below left axilla|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left axilla and the ZOE Fluid Status Monitor
9846338|NCT03072732|Other|study arm 2-upper left pectoral area|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper left pectoral area and the ZOE Fluid Status Monitor
9846339|NCT03072875|Experimental|CAMS-RAS|In this single-arm study design, all enrolled patient participants are asked to provide feedback on the CAMS-RAS prototype as it is developed for this study. Feedback will be gathered via survey measure and interview.
9846340|NCT03072953|Other|APD334|APD334 active treatment for 12 weeks.
9846341|NCT03073005|No Intervention|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
9846342|NCT03073005|Experimental|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
9846343|NCT03073148|Experimental|Tangible Boost|Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
9846344|NCT03073148|Placebo Comparator|Control|"Participants will treat their lenses with a placebo Tangible Boost kit containing saline after 30 days and again after 60 days."
9846345|NCT03073200|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
9846346|NCT03073200|Placebo Comparator|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
9846347|NCT03073200|Experimental|Open-Label Etanercept|Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
9846348|NCT03073213|Experimental|Ixekizumab single dose|Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
9846349|NCT03073213|Experimental|Ixekizumab Multiple Regimen 1 (80mg Q2W)|Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
9846350|NCT03073213|Experimental|Ixekizumab Multiple Regimen 2 (80mg Q4W)|Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.
9846351|NCT03073486|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
9846352|NCT03073486|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
9846353|NCT03073759|Experimental|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
9846354|NCT03073759|Sham Comparator|Sham|Patients will receive a sham.
9846355|NCT03073798|Active Comparator|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
9846356|NCT03073798|Placebo Comparator|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
9846357|NCT03073876|Experimental|Drug|Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
9846358|NCT03073876|Placebo Comparator|Placebo|"Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment."
9846359|NCT03074162|Experimental|Diclofenac Sodium (A)|
9846360|NCT03074162|Experimental|Diclofenac & Capsaicin (B)|
9846361|NCT03074162|Active Comparator|Diclofenac Sodium Topical Gel|
9846362|NCT03074331|Experimental|SOF/VEL|SOF/VEL for 12 weeks
9846363|NCT03074409|Experimental|oxytocin|intranasal administration of oxytocin
9846364|NCT03074409|Placebo Comparator|placebo|intranasal administration of the same ingredient except oxytocin
9846365|NCT03074500|Experimental|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
9846366|NCT03074500|Sham Comparator|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
9846367|NCT03074500|Other|Control|Stretching and strengthening exercises of wrist
9846368|NCT03074630|Experimental|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
9846369|NCT03074682|Experimental|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
9846370|NCT03074682|Active Comparator|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
9846371|NCT03074682|Active Comparator|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
9846372|NCT03075085|Active Comparator|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
9846373|NCT03075085|Experimental|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
9846374|NCT03075163|Experimental|Acupressure|Manual pressure will be applied on the wrists bilaterally.
9846375|NCT03075163|Active Comparator|Ondansetron|Ondansetron (Zofran) is used for the treatment of nausea and vomiting.
9846376|NCT03075267|Experimental|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
9846377|NCT03075267|Experimental|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
9846378|NCT03075267|Experimental|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
9922702|NCT00842036|Experimental|TEnT|Treatment Entry Training
9922703|NCT00842036|Experimental|CRAFT|Community Reinforcement and Family Training
9922704|NCT00842049|Experimental|Study|Insertion of lumbar drain
9922705|NCT00842049|Other|Control|Normal clinical management without lumbar drain
9846379|NCT03075410|Experimental|Cohort 1- GSK3036656 in Part A|During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
9846380|NCT03075410|Placebo Comparator|Cohort 1- Placebo in Part A|During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
9846381|NCT03075410|Experimental|Cohort 2- GSK3036656 in Part A|During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
9846382|NCT03075410|Placebo Comparator|Cohort 2- Placebo in Part A|During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
9846383|NCT03075410|Experimental|Cohort 3- GSK3036656 in Part B|During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
9846384|NCT03075410|Placebo Comparator|Cohort 3- Placebo in Part B|During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
9846385|NCT03075410|Experimental|Cohort 4- GSK3036656 in Part B|During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
9922706|NCT00842062|Experimental|MyoScience Tissue Remodeling Device|
9922707|NCT00842101||pressure monitor|Tibial Fracture
9846386|NCT03075410|Placebo Comparator|Cohort 4- Placebo in Part B|During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
9846387|NCT03075410|Experimental|Cohort 5- GSK3036656 in Part B|During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
9846388|NCT03075410|Placebo Comparator|Cohort 5- Placebo in Part B|During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
9846389|NCT03075410|Experimental|Cohort 6- GSK3036656 in Part B|During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
9846390|NCT03075410|Placebo Comparator|Cohort 6- Placebo in Part B|During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
9846391|NCT03075501|Active Comparator|Paired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in only one room.
9846392|NCT03075501|Other|Unpaired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in both rooms.
9846393|NCT03075553|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9846394|NCT03075644|Experimental|Somapacitan|
9846395|NCT03075644|Active Comparator|Norditropin|
9846396|NCT03075761|Experimental|Intervention|Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
9846397|NCT03075761|Active Comparator|Control|Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
9846398|NCT03075839|Experimental|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
9846399|NCT03075878|Experimental|Cohort 1: ALXN1830|SYNT001 Dose 1
9846400|NCT03075878|Experimental|Cohort 2: ALXN1830|SYNT001 Dose 2
9846401|NCT03075891|Experimental|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
9846402|NCT03075891|Placebo Comparator|Ivermectin 1% cream + Oral placebo capsules|
9846403|NCT03075904|Experimental|Cohort 1: ALXN1830|Participants received 5 doses of ALXN1830 10 mg/kg administered weekly.
9846404|NCT03075904|Experimental|Cohort 2: ALXN1830|Participants were to receive 3 doses of ALXN1830 30 mg/kg administered weekly (loading) followed by 5 doses of ALXN1830 10 mg/kg administered every other week or 10 weekly doses of ALXN1830 IV (maintenance).
9922708|NCT00842114|Experimental|R+CVP+IFN|8 cycles of Rituximab plus CVP chemotherapy (Bagley's et al) associated with Interferon for 12 weeks
9922709|NCT00842140|Active Comparator|1|This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate
9846405|NCT03076190|No Intervention|Active Control Group (Health Education)|"Prior to surgery:~Demographics survey~Baseline surveys~Participants receive online information regarding nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery.~Follow-up questions about the handouts (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
9846406|NCT03076190|Experimental|My Surgical Success Treatment Group|"Prior to surgery:~Demographics survey~Baseline surveys~Intervention:~90-minute psychoeducational My Surgical Success video that emphasizes catastrophizing treatment.~audio file~personalized plan that incorporates the information learned in the video.~Follow-up questions about the video (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
9846407|NCT03076333|Experimental|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
9846408|NCT03076359|Active Comparator|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
9846409|NCT03076359|Experimental|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
9846410|NCT03076515|Active Comparator|Nerivio Migra active|This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
9846411|NCT03076515|Sham Comparator|Nerivio Migra placebo|This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
9846412|NCT03076970|Experimental|Lasmiditan 200 mg|single oral tablet
9846413|NCT03076970|Active Comparator|Sumatriptan 100 mg|single oral tablet
9846414|NCT03076970|Experimental|Combination of lasmiditan and sumatriptan|single oral tablet of each
9846415|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
9846416|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
9846417|NCT03076996|Experimental|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
9846418|NCT03077165|Experimental|Group A|S42909 dose 100 mg p.o., 50 mg bid
9846419|NCT03077165|Experimental|Group B|S42909 dose 200 mg p.o., 100 mg bid
9846420|NCT03077165|Experimental|Group C|S42909 dose 400 mg p.o., 200 mg bid
9846421|NCT03077165|Experimental|Group D|S42909 dose 800 mg p.o., 400 mg bid
9846422|NCT03077165|Experimental|Group E|S42909 dose 1200 mg p.o., 600 mg bid
9846423|NCT03077165|Placebo Comparator|Group F|Placebo p.o. bid
9846424|NCT03077607|Experimental|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
9846425|NCT03077607|Experimental|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
9846426|NCT03077646|Experimental|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
9846427|NCT03077646|Experimental|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
9846428|NCT03077646|Active Comparator|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
9846429|NCT03077659|Experimental|NanoPac® 6 mg/mL|NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
9846430|NCT03077659|Experimental|NanoPac® 10 mg/mL|NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
9846431|NCT03077659|Experimental|NanoPac® 15 mg/mL|NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
9846432|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 1|Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
9846433|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 2|Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
9846434|NCT03077724|Experimental|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
9846435|NCT03077724|Placebo Comparator|Placebos|Olive oil supplements
9846436|NCT03077893|Experimental|Active Group|Treatment with active Provant Therapy System
9846437|NCT03077893|Sham Comparator|Sham Group|Treatment with Inactive (sham) Provant Therapy System
9846438|NCT03077919|Active Comparator|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
9846439|NCT03077919|Sham Comparator|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
9846440|NCT03078075|Experimental|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
9846441|NCT03078075|Placebo Comparator|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
9846442|NCT03078127|Active Comparator|Sequence A|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), Whole body vibration, High Frequency Chest Wall Oscillation (HFCWO, aka Vest or TheVest®), Oscillatory Positive Expiratory Pressure (OPEP) (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
9846443|NCT03078127|Active Comparator|Sequence B|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), HFCWO, OPEP, Whole body vibration (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
9846444|NCT03078127|Active Comparator|Sequence C|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), OPEP, Whole body vibration, HFCWO (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
9846445|NCT03078504|Experimental|Experimental arm|The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics
9846446|NCT03078556|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
9846447|NCT03078556|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
9846448|NCT03078556|Experimental|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
9846449|NCT03078556|Experimental|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
9846450|NCT03078556|Experimental|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
9846451|NCT03078556|Experimental|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
9846452|NCT03078582|Experimental|Zilucoplan (RA101495) treatment naive|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
9846453|NCT03078582|Experimental|Zilucoplan (RA101495) previously on eculizumab|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
9846454|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
9846455|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
9846456|NCT03078647|Experimental|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
9846457|NCT03078751|Experimental|Ribociclib + adjuvant endocrine therapy (ET)|"Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy.~ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted after protocol amendment 2)"
9846458|NCT03078751|Placebo Comparator|Placebo + adjuvant endocrine therapy (ET)|Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen
9846459|NCT03078816|Experimental|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:~Activa PC Primary Cell Neurostimulator - (Model 37601)~Activa RC Rechargeable Neurostimulator - (Model 37612)~Activa SC Single Cell Neurostimulator (Models 37602 and 37603)~DBS Lead - (Model 3387)~DBS Extension - (Models 37085/6)~Patient Programmer - (Model 37642)~Test Stimulator - (Model 3625)~N'Vision Clinician Programmer - (Model 8840)~N'Vision Software Application Card - (Model 8870)"
9846460|NCT03078907|Experimental|Selexipag|Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
9846461|NCT03078907|Placebo Comparator|Placebo|Regimen and titration scheme similar to those in the selexipag group
9846462|NCT03078946|Active Comparator|Dexmedetomidine Group (N=30)|
9846463|NCT03078946|Active Comparator|Morphine with Midazolam (N=30)|
9846464|NCT03079375|No Intervention|usual care|no pharmaceutical intervention.
9846465|NCT03079375|Sham Comparator|basic intervention|Medication review
9846466|NCT03079375|Sham Comparator|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
9846467|NCT03079531|Experimental|Secukinumab arm|Participants receive secukinumab (7 doses over a 16-week study period).
9846468|NCT03080142|Experimental|Group 1|Single injection of Exparel
9846469|NCT03080142|Active Comparator|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
9846470|NCT03080454|Placebo Comparator|Sham Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
9846471|NCT03080454|Active Comparator|Anodal Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
9846472|NCT03080493|Active Comparator|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
9846473|NCT03080493|Placebo Comparator|Placebo oral capsule|"Matched placebo~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
9846474|NCT03080961|Experimental|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
9846475|NCT03081117|Experimental|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
9846476|NCT03081117|Placebo Comparator|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
9846477|NCT03081884|Experimental|FACBC PET-CT Imaging|Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.
9846478|NCT03082196|Experimental|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
9846479|NCT03082196|Active Comparator|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
9846480|NCT03082261|Other|All enrolled subjects|All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite Implantable Pulse Generator (IPG).
9846481|NCT03082586|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
9846482|NCT03082586|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
9846483|NCT03082586|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
9846484|NCT03082586|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
9846485|NCT03082586|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
9846486|NCT03082586|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
9846487|NCT03082599|Active Comparator|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
9846488|NCT03082599|Experimental|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
9846489|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
9846490|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
9846491|NCT03083132|Active Comparator|Early-start|24 weeks of modafinil 50 mg oral daily
9846492|NCT03083132|Placebo Comparator|Delayed-start|12 weeks of oral placebo followed by 12 weeks of modafinil 50 mg oral daily
9846493|NCT03083379|Active Comparator|Volumetric Incentive Spirometry|Incentive Spirometry
9846494|NCT03083379|Experimental|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
9846495|NCT03083470|Experimental|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
9846496|NCT03083470|Experimental|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
9846497|NCT03083470|Experimental|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
9846498|NCT03083470|Experimental|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
9846499|NCT03083470|Sham Comparator|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
9998294|NCT01516827|Experimental|TF-CBT|"12 Sessions Trauma-focused Cognitive Behavioral Therapy including the child/adolescents and a non-abusive caregiver according to the treatment manual:~Cohen JA, Mannarino AP, and Deblinger E (2006) Treating Trauma and Traumatic Grief in Children and Adolenscents. Guilford, N.Y."
9793699|NCT01482819|Other|Sequence 3|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Polymacon~Galyfilcon A Plus~Spectacles~Lotrafilcon A"
10207358|NCT05209646|Experimental|Trial (Intervention) group|Patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation
10207359|NCT05209646|No Intervention|Control (Non-intervention) group|No honey will be given to this group
10207360|NCT05209607|Experimental|Interventional group|Participants will be given mobile medical and bundle care
10207361|NCT05209607|Other|Control group|Participants will be given mobile medical and standard of care.
10207362|NCT05209594|Experimental|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|Students in grades 9 to 12 participating in GSAs where the HRP for 2SLGBTQIA+ Youth is being implemented.
10207363|NCT05209594|Active Comparator|Regular GSA Programming|Students in grades 9 to 12 participating in regular GSA programming.
10207364|NCT05209581||Study Group|Adult refugees/immigrants living in accommodation structures
10207365|NCT05209568|Experimental|Celiac Disease|Individuals with a confirmed diagnosis of celiac disease based on serology and/or histology
9793700|NCT01482819|Other|Sequence 4|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Lotrafilcon A~Polymacon~Galyfilcon A Plus~Galyfilcon A"
9793701|NCT01482819|Other|Sequence 5|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Galyfilcon A~Spectacles~Galyfilcon A Plus~Lotrafilcon A"
9793702|NCT01482819|Other|Sequence 6|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Galyfilcon A Plus~Polymacon~Lotrafilcon A~Spectacles"
9793703|NCT01482819|Other|Sequence 7|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Spectacles~Galyfilcon A~Lotrafilcon A~Galyfilcon A Plus"
9793704|NCT01482819|Other|Sequence 8|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Lotrafilcon A~Galyfilcon A~Spectacles~Polymacon"
9793705|NCT01482819|Other|Sequence 9|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Galyfilcon A Plus~Spectacles~Galyfilcon A~Polymacon"
9793706|NCT01482819|Other|Sequence 10|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Polymacon~Lotrafilcon A~Galyfilcon A~Galyfilcon A Plus"
9793707|NCT01482884|Experimental|1|tralokinumab (CAT-354) sc injection
9793708|NCT01482884|Placebo Comparator|2|placebo sc injection
9793709|NCT01482910|Experimental|Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
9793710|NCT01482910|Active Comparator|PDT treatments|Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
9793711|NCT01482962|Experimental|Alisertib|Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
9793712|NCT01482962|Active Comparator|Pralatrexate, or Romidepsin, or Gemcitabine|Pralatrexate 30 mg/m^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
9793713|NCT01483118|Active Comparator|Cinnamon Extract Arm|PCOS patients receiving abstract of cinnamon
9793714|NCT01483118|Placebo Comparator|Placebo Arm|PCOS patients receiving placebo capsules
9793715|NCT01483144|Experimental|Eflornithine plus Sulindac|Eflornithine 750 mg and Sulindac 150 mg
9793716|NCT01483144|Active Comparator|Eflornithine plus Sulindac Placebo|Eflornithine 750 mg and Placebo
9793717|NCT01483144|Active Comparator|Sulindac plus Eflornithine Placebo|Sulindac 150 mg and Placebo
9793718|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 1: OPC-108459|To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
9793719|NCT01483183|Placebo Comparator|Persistent or Paroxysmal AF Part 1: Placebo|
9793720|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 2: OPC-108459|Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
9793721|NCT01483183|Placebo Comparator|Placebo Part 2|
9793722|NCT01483352|Experimental|Single Arm|Participants were implanted with Accu-Chek DiaPort with Infusion Set connected to an Accu-Chek Insulin Pump to perform continuous intraperitoneal insulin delivery.
9793723|NCT01483378|Other|Subjects who received the vaccine|Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
9793724|NCT01483378|No Intervention|Subjects who declined the vaccine|
9846500|NCT03083483|Experimental|Bilateral M1, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the bilateral M1 areas of the brain by measurement of 20% length of periauricular distance left and right of the vertex. The anode was placed on the left side and the cathode was placed on the right side.
9846501|NCT03083483|Experimental|SMA, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the supplementary motor area. The cathode was placed 10% of nasion-inion distance above the nasion and 15% of nasion-inion distance anterior to the vertex.
9846502|NCT03083483|Sham Comparator|sham tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants in this group were either randomized into either Bilateral or SMA configurations using the same measurements, but did not receive active stimulation. Half of these subjects will be placed in the SMA configuration and the other half in the bilateral M1 electrode configuration.
9846503|NCT03083639|Experimental|Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet|Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
9846504|NCT03083639|Experimental|Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule|Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
9846505|NCT03083769||Cohort 1|The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
9846506|NCT03083769||Cohort 2|The retrospective cohort consists of about 663 kidney transplant recipients from Guilin No. 924 Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
9846507|NCT03083847|Experimental|Pilot (1a): 1 injection of 5x10^4 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 5x10^4 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
9846508|NCT03083847|Experimental|Pilot (1b):1 injection of 1x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
9846509|NCT03083847|Experimental|Pilot (1d):1 injection of 2x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
9846510|NCT03083847|Experimental|Pilot (5a): 1 injection of 1x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
9846511|NCT03083847|Experimental|Pilot (5b): 1 injection of 2x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
9846512|NCT03083847|Experimental|Main (2a):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+NF54|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + homologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (NF54) at 12 weeks after third injection
9846513|NCT03083847|Experimental|Main (2b):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + heterologous CHMI with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
9846514|NCT03083847|Experimental|Main (3):3 doses of 2x10^5 PfSPZ Challenge+chloroquine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + weekly chloroquine (1000mg given 2 days prior to injections and 500mg given 5 days post injection and weekly thereafter until 5 days post third injection) + heterologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
9846515|NCT03083847|Experimental|Main Phase (4a) - Infectivity Control: NF54 (homologous) CHMI|Main Phase - Infectivity Control with one dose of 3.2x10^3 sporozoites of PfSPZ Challenge (NF54) (homologous) controlled human malaria infection (CHMI)
9846516|NCT03083847|Experimental|Main Phase (4b) - Infectivity Control: 7G8 (heterologous) CHMI|Main Phase - Infectivity Control with 3.2x10^3 sporozoites of PfSPZ Challenge 7G8 (heterologous) controlled human malaria infection (CHMI)
9846517|NCT03083990|Experimental|Group A|IBI 305 ,3mg/kg, infusion in 90 minutes
9998295|NCT01516827|No Intervention|Wait-list|Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
9998296|NCT01516840|Experimental|Arm 1|
9793725|NCT01483560|Experimental|Metformin|Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
9793726|NCT01483560|Placebo Comparator|Placebo|
9793727|NCT01483599|Experimental|CNTO 1959 (5 mg)|CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
9793728|NCT01483599|Experimental|CNTO 1959 (15 mg)|CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
9793729|NCT01483599|Experimental|CNTO 1959 (50 mg)|CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
9793730|NCT01483599|Experimental|CNTO 1959 (100 mg)|CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
9793731|NCT01483599|Experimental|CNTO 1959 (200 mg)|CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
10207366|NCT05209568|Experimental|Healthy Controls|Individuals without a diagnosis of celiac disease
10207367|NCT05209542|Active Comparator|Hysterosalpingo-Foam Ultrasonography|3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
9846518|NCT03083990|Active Comparator|Group B|Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes
9846519|NCT03084302||Pregnant women|Women in their first trimester of pregnancy, aged 18-45, who plan to receive their prenatal care from University of Pittsburgh Medical Center providers.
9846520|NCT03084315|Sham Comparator|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
9846521|NCT03084315|Active Comparator|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
9846522|NCT03084796|Experimental|Treatment A|CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose [TDD] of CHF 5259 12.5 μg)
9846523|NCT03084796|Experimental|Treatment B|CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
9846524|NCT03084796|Experimental|Treatment C|CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
9846525|NCT03084796|Experimental|Treatment D|CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
9846526|NCT03084796|Placebo Comparator|Treatment E|Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
9846527|NCT03084796|Active Comparator|Treatment F|Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)
9846528|NCT03085017|Active Comparator|Ostene|Application of Ostene onto cut sternal site for hemostasis.
9846529|NCT03085017|Experimental|BoneSeal|Application of BoneSeal onto cut sternal site for hemostasis.
9846530|NCT03085238|Experimental|M-Trap|
9846531|NCT03085758|Experimental|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
9846532|NCT03085758|Experimental|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
9846533|NCT03085758|Placebo Comparator|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
9846534|NCT03085797|Experimental|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
9846535|NCT03085797|Placebo Comparator|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
9846536|NCT03085836|Experimental|TAK-438 10 milligram (mg) Once Daily|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
9846537|NCT03085836|Experimental|TAK-438 20 mg Once Daily|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
9846538|NCT03085836|Experimental|TAK-438 20 mg Twice Daily|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
10207368|NCT05209542|Active Comparator|laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
10207369|NCT05209529|Experimental|Olaparib|Olaparib treatment for a total of 16 weeks
10207370|NCT05209529|Experimental|Olaparib and durvalumab|Olaparib and durvalumab treatment for a total of 16 weeks
10207371|NCT05209516|Experimental|Parkinson's disease (PD) patients Group 1|PD patients treated by Dopamine replacement therapy, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
10207372|NCT05209516|Experimental|Parkinson's disease (PD) patients Group 2|PD patients treated by Deep Brain Stimulation, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
10207373|NCT05209516|Active Comparator|Healthy individuals|Healthy participants, aged between 18 and 85, will be recruited as control subjects by means of ads posting.
9846539|NCT03085914|Experimental|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
9846540|NCT03085914|Experimental|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
9846541|NCT03085914|Experimental|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
9846542|NCT03085914|Experimental|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
9846543|NCT03085914|Experimental|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
9846544|NCT03085914|Experimental|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
9846545|NCT03085914|Experimental|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
9922710|NCT00842140|Experimental|2|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
9922711|NCT00842140|Experimental|3|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.
9922712|NCT00842179||Manual Closure|Patients who received vascular closure with manual compression after percutaneous coronary intervention (PCI)
9922713|NCT00842179||Perclose Device|Patients who received vascular closure with the Perclose VCD after percutaneous coronary intervention (PCI)
9922714|NCT00842192||A|
9846546|NCT03085927|Experimental|Arm 1-Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
9846547|NCT03085927|Experimental|Arm II- Audio-Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
9922715|NCT00842205|Active Comparator|1 HCV positive pts|"Patients with chronic HCV infection undergoing liver biopsy followed by antiviral treatment.~peg-IFN alfa 2a 180ug s.c. QW + ribavirin 1000-1200mg p.o. daily 48weeks or peg-IFN alfa 2b 1.5 ug/kg s.c. QW + ribavirin 100-1200mg p.o. daily 48 weeks"
9922716|NCT00842205|No Intervention|2 Other liver disease|pts. with NASH (or other liver disease) undergoing liver biopsy.
9935074|NCT04225221|Experimental|Sequence A: estradiol followed by progesterone|"Participants are randomly assigned to treatment Sequence A: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence A will receive estradiol addback first, followed by progesterone.~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
9935075|NCT04225221|Experimental|Sequence B: progesterone followed by estradiol|"Participants are randomly assigned to treatment Sequence B: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence B will receive progesterone first followed by estradiol.~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
9935076|NCT04225130|Experimental|Written Exposure Therapy -for Suicide|Written Exposure Therapy-for Suicide (WET-S) consists of 5 treatment sessions. Each session includes a written exposure exercise. It also includes CRP. Participants assigned to WET-S will complete the CRP prior to beginning their writing in session 1. Patient use of the CRP since the previous session will be briefly reviewed at the start of each WET-S session to manage safety and problem solve fluctuations in risk during treatment.
9935077|NCT04225130|Active Comparator|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team. TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
9935078|NCT04224870||Surgical Incision|A single cohort study, of 12 participants with a scheduled surgical procedure, of at least 4 hours, for up to six (6) timed tissue sampling at surgical incision. No investigational therapy is planned.
9935079|NCT04222413|Experimental|1/Arm 1|Escalating/de-escalation doses of metarrestin
9935080|NCT04222413|Experimental|2/Arm 2|MTD of metarrestin
9935081|NCT04216342|Experimental|1|subjects entered into the trial may go thru a 0-4 weeks screening (Screening Phase). On the Intervention phase, subjects will be followed for 7 days which includes: entry criteria assessments and settling at the inpatient unit on Day 0, a single-dose I.V. infusion with data collection on Day 1 followed by 24 hours monitoring (Day 2), a 7-day and 28-day outpatient follow-up visit (Follow-Up Phase).
9935082|NCT04216329|Experimental|1/Experimental therapy|Selinexor with temozolomide and radiation
10207374|NCT05209464|Experimental|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via a mobile application.
10207375|NCT05209412|Experimental|Drug-coated balloon|Lepu Paclitaxel coated balloon will be used
9935085|NCT04214093|Experimental|Arm A|Dose escalation for patients with solid tumors, lymphoma and multiple myeloma with low risk of TLS. Each cohort within Arm A will test a single dose level.
9935086|NCT04214093|Experimental|Arm B|Dose escalation for patients with hematologic malignancies with an intermediate to high risk of TLS. Intrapatient dose ramp-ups within each cohort will be used.
10207376|NCT05209412|Active Comparator|Drug-eluting stent|Resolute Integrity Zotarolimus eluting stents will be used
10207377|NCT05209386|Experimental|Patient Participants|"This single-group study will recruit patients through the PI's clinical practice who are undergoing invasive neurophysiological monitoring (sEEG) with clinically necessary placement of electrodes in the supratemporal plane.~All participants will complete the same behavioral response paradigms."
9935087|NCT04209946|Active Comparator|Less Invasive Surfactant Administration (LISA)|Infants that are spontaneously breathing with a normal heart rate will be randomized to receive prophylactic surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) by the LISA procedure in the first 2 hours of life, using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter. Any repeat dosing for surfactant will be based on clinical indication at the physician discretion by the conventional endotracheal approach.
9935088|NCT04209946|Active Comparator|Continuous Positive Airway Pressure (CPAP)|Infants that are spontaneously breathing with a normal heart rate will be randomized to early Continuous Positive Airway Pressure (CPAP).
9935089|NCT04209673||Transcutaneous nerve stimulation (TENS) patients|Patients who received a TENS unit after surgery
9935090|NCT04209673||No TENS|Historic controls- Patients who did not receive a TENS unit after surgery
9846548|NCT03086018|Experimental|Successor hearing aid to Juna|The intervention is the new device which is the successor to the Juna device. The participants will use their current device as a control. The will wear the intervention device for approximately two weeks.
9846549|NCT03086057|Experimental|Strength Based Case Management|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
9846550|NCT03086057|Experimental|PrEP adherence training and counseling|Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
9846551|NCT03086057|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to The Miriam Hospital PrEP Clinic.
9846552|NCT03086057|No Intervention|Standard of Care: Stage 2|Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
9846553|NCT03086135|Experimental|Bone-conduction hearing device|The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
9846554|NCT03086213|Experimental|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
9846555|NCT03086213|Active Comparator|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
9846556|NCT03086265|Experimental|THRIVE|high flow nasal oxygen
9846557|NCT03086265|Active Comparator|Endotracheal tube|tracheal intubation
9846558|NCT03086330|Experimental|Semaglutide|
9846559|NCT03086330|Placebo Comparator|Placebo|
9846560|NCT03086343|Active Comparator|Abatacept|500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
9846561|NCT03086343|Experimental|Upadacitinib 15 mg|One 15 mg tablet taken once per day by mouth for 24 weeks
9846562|NCT03086356|Experimental|All Subjects|Dabigatran etexilate alone (days 1-4) and (days 8-10) and with Idarucizumab (day 11)
9846563|NCT03086408|Experimental|THRIVE|high flow nasal oxygen
9846564|NCT03086408|Active Comparator|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
9846565|NCT03086447|Experimental|Experimental: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed the investigational contact lens to be worn from 28-36 days, to include a total of 5 visits.
9846566|NCT03086447|Active Comparator|Control: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed marketed contact lens to be worn from 28-36 days, to include a total of 5 visits.
9846567|NCT03086460|Experimental|Treatment A|"Treatment A, CHF 1531 pMDI:~CHF 1531 pMDI 6 μg total daily dose (TDD):~1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
9846568|NCT03086460|Experimental|Treatment B|"Treatment B, CHF 1531 pMDI:~CHF 1531 pMDI 12 μg TDD:~1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
9846569|NCT03086460|Experimental|Treatment C|"Treatment C, CHF 1531 pMDI:~CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID."
9846570|NCT03086460|Experimental|Treatment D|"Treatment D, CHF 1531 pMDI~CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID."
9846571|NCT03086460|Experimental|Treatment E|"Treatment E, Matched placebo~Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID."
9846572|NCT03086460|Active Comparator|Treatment F|"Treatment F, Formoterol fumarate inhalation solution (IS)~Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID."
9846573|NCT03086551|Experimental|Experimental|Application of active continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
9846574|NCT03086551|Placebo Comparator|Control|Application of sham continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
9846575|NCT03086707|Active Comparator|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
9846576|NCT03086707|No Intervention|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.~Subjects will not be allowed to smoke until discharge at Visit 3."
9846577|NCT03087019|Experimental|Pembrolizumab + Radiation|"Up to 5 metastatic lesions targeted with radiation~Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab~Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
10213486|NCT03911856|Experimental|Non-invasive assesment techniques|We hypothesize that non-invasive indices of right ventricular RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction pulmonary arterial hypertension and heart failure with preserved ejection fraction(PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
9846578|NCT03087019|Experimental|Pembrolizumab|"Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
9846579|NCT03087513|Active Comparator|Initial Arm|The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
9846580|NCT03087513|Active Comparator|Crossover Arm|The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .
9846581|NCT03087604|Active Comparator|Traditional Technique Group|In the traditional loss of resistance technique group, the epidural catheter will be placed after achieving loss of resistance to air. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.
9846582|NCT03087604|Experimental|Electric Stimulation Group|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.Thoracic epidural block with Electrical Nerve stimulation
9846583|NCT03087643|Experimental|Passive mobilization - PM|Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
9846584|NCT03087643|No Intervention|Control group - ctrl|Participants will receive ther standard therapies.
9846585|NCT03087786|Experimental|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
9846586|NCT03087786|Active Comparator|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
9846587|NCT03087851|Active Comparator|6-month group|Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.
9846588|NCT03087851|Active Comparator|9-months group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
9846589|NCT03087851|Active Comparator|Observation group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
9846590|NCT03088267|Active Comparator|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
9846591|NCT03088267|Placebo Comparator|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
9846592|NCT03088345|Experimental|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin in normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
9846593|NCT03088345|Placebo Comparator|Placebo|Patients randomized to this arm will receive a continuous normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
9846594|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior cruciate retaining total knee arthroplasty
9846595|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
9846596|NCT03088800|Active Comparator|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
9846597|NCT03088800|Active Comparator|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
9846598|NCT03088800|Active Comparator|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
9846599|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
9846600|NCT03089047|Experimental|Rejuvenated RBC Transfusion|Washed and Rejuvenated autologous blood
9998297|NCT01516840|Experimental|Arm 2|
10213487|NCT03911856|Experimental|Efficacy of acute-oxygen therapy during exercise|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing pulse volume recording PVR, increasing RV functional reserve, increasing gas diffusion).
10213488|NCT03909061|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent maintenance training materials. They will complete data collection measures embedded in the maintenance training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Assistive Technology Module Questionnaire (ATM-Q), and the Wheelchair Maintenance Training Questionnaire (WMT-Q).
9846601|NCT03089047|Sham Comparator|Standard RBC Transfusion|Washed autologous blood (so as to maintain equivalent unit volume and Hct)
9846602|NCT03089216|Experimental|Combined Bleaching(2x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
9846603|NCT03089216|Experimental|Combined Bleaching(2x20) with arginine|Combined Bleaching(2x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
9846604|NCT03089216|Experimental|Combined Bleaching(1x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
9846605|NCT03089216|Experimental|Combined Bleaching(1x20) with arginine|Combined Bleaching(1x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
9922717|NCT00842270|Experimental|2|4,5 mg/kg/day
9922718|NCT00842270|Experimental|3|6 mg/kg/day
9998298|NCT01516840|Active Comparator|Arm 3|
9998299|NCT01516840|Active Comparator|Arm 4|
9846606|NCT03089580|Experimental|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
9846607|NCT03089580|Placebo Comparator|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
9846608|NCT03089697|Experimental|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
9846609|NCT03089697|Placebo Comparator|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
9846610|NCT03089879|Experimental|Shigella Group|Healthy male and female subjects, aged 22 to 50 years, previously primed with 3 doses of the GVGH Shigella sonnei 1790GAHB vaccine in the H03_01TP parent study and who had undetectable antibody titers at baseline, received one intramuscular booster dose of the same vaccine in the current study, at Day 1.
9846611|NCT03089879|Experimental|Placebo Group|Healthy male and female subjects, aged 22 to 50 years, who previously received placebo in the H03_01TP parent study and who had undetectable antibodies at baseline, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
9846612|NCT03089879|Experimental|Naïve Group|Healthy male and female subjects, aged 22 to 50 years, who were not part of H03_01TP parent study, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
9846613|NCT03089944|Experimental|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
9846614|NCT03090100|Experimental|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
9846615|NCT03090100|Active Comparator|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
9846616|NCT03090256|Experimental|PanOptix IOL|AcrySof® IQ PanOptix™ IOL, bilateral implantation
9846617|NCT03090620|Experimental|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
9846618|NCT03090620|Experimental|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
9846619|NCT03090958|Experimental|AllyQuest Pilot|The research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.
9846620|NCT03091179|Experimental|THRIVE|high flow nasal oxygen
9846621|NCT03091179|Active Comparator|Endotracheal tube|tracheal intubation
9846622|NCT03091348|Experimental|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
9846623|NCT03091348|Experimental|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
9846624|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
9846625|NCT03091400|Experimental|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
9846626|NCT03091400|Placebo Comparator|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
9846627|NCT03091439|Experimental|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
9846628|NCT03091439|Active Comparator|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
9846629|NCT03091478|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg every 3 weeks
9846630|NCT03091673|Experimental|G-Pen (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
10207378|NCT05209373|Experimental|Group-Delivered Self-Compassion Intervention|"A 4-week intervention pairing behaviour change and self-compassion education, aimed to increase physical activity and help women cope with their risk of cardiovascular disease. Participants in the group condition will complete Sessions 2-4 with 6-9 other participants plus a facilitator. Both conditions will be exposed to identical intervention content. All intervention sessions will be hosted on an institution-sponsored Zoom videoconferencing account.~Week 1, Session 1 (60 minutes): Participants will meet in their group to discuss CVD risk factors and set physical activity goals.~Weeks 2-4, Sessions 2-4 (60 minutes each): Participants will meet in their group to receive self-compassion education to aimed at encouraging adaptive coping with cardiovascular risk and physical activity behaviour change. Brief self-compassionate writing exercises will be assigned as home practice after Sessions 2-4."
10213489|NCT03909061|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the wheelchair maintenance training. Participants may also be asked to complete a user satisfaction survey.
9846631|NCT03091673|Experimental|G-Pen (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
9846632|NCT03091738|Experimental|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
9846633|NCT03091751|Experimental|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
9846634|NCT03091777|Experimental|Test Drug|GDC-229 gel applied vaginally as directed.
9846635|NCT03091777|Active Comparator|Reference Drug|Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
9846636|NCT03091777|Placebo Comparator|Vehicle Placebo Gel|GDC-229 Vehicle
9846637|NCT03091920|Experimental|IW-1973 QD/QD|On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
9846638|NCT03091920|Experimental|IW-1973 BID (Twice Daily)/QD|On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
9846639|NCT03091920|Placebo Comparator|Placebo|On Days 1-14: Placebo taken in AM and in PM.
9846640|NCT03092024|Experimental|SPIN-HAND program|
9846641|NCT03092024|No Intervention|Not Offered the SPIN-HAND program|Treatment as usual
9846642|NCT03092089|Experimental|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
9846643|NCT03092375|Experimental|Arm A: G/P 300 mg/120 mg QD for 12 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
9846644|NCT03092375|Experimental|Arm B: G/P 300 mg/120 mg QD for 16 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
9846645|NCT03092375|Experimental|Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
9846646|NCT03092375|Experimental|Arm D: G/P 300 mg/120 mg QD for 16 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
9846647|NCT03092479|Experimental|Behavioral Intervention|4-month bi-weekly comprehensive postoperative behavioral support program addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
9846648|NCT03092479|No Intervention|Usual Care|Usual postoperative follow-up per the GHS Center for Nutrition and Weight Management guidelines.
9846649|NCT03092726|Experimental|ASP8062|Participants received 30 mg of ASP8062 orally once daily for 8 weeks.
9846650|NCT03092726|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 8 weeks.
9846651|NCT03092752||Patients with T2DM|
9846652|NCT03092791|Experimental|Adult Lead-in Cohort: sIPV High Dose|Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
9846653|NCT03092791|Placebo Comparator|Adult Lead-in Cohort: Placebo|Placebo, intramuscular injection on Day 1.
9846654|NCT03092791|Experimental|Toddler Lead-in Cohort: sIPV High Dose|sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
9846655|NCT03092791|Active Comparator|Toddler Lead-in Cohort: Reference IPV|Reference IPV, intramuscular injection on Day 1.
9846656|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Low Dose|sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
9846657|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Medium Dose|sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
9846658|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV High Dose|sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
9846659|NCT03092791|Active Comparator|Infant Dose Ranging Cohort: Reference IPV|Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
9846660|NCT03092934|Experimental|25 milligrams (mg) LY3295668 (Phase 1)|25 milligrams (mg) LY3295668 twice daily (BID) administered orally in 21-day cycles.
9846661|NCT03092934|Experimental|50 mg LY3295668 (Phase 1)|50 mg LY3295668 BID administered orally in 21-day cycles.
9846662|NCT03092934|Experimental|75 mg LY3295668 (Phase 1)|75 mg LY3295668 BID administered orally in 21-day cycles.
9846663|NCT03092934|Experimental|25 mg LY3295668 (Phase 2)|25 mg LY3295668 BID administered orally in 21-day cycles.
9846664|NCT03092960|Active Comparator|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
10207379|NCT05209373|Other|Positive control condition: Individually-Delivered Self-Compassion Intervention|"A 4-week intervention pairing behaviour change and self-compassion education, aimed to increase physical activity and help women cope with their risk of cardiovascular disease. Participants in the individual condition will complete Sessions 2-4 individually with a facilitator. Both conditions will be exposed to identical intervention content. All intervention sessions will be hosted on an institution-sponsored Zoom videoconferencing account.~Week 1, Session 1 (60 minutes): Participants will meet individually with a facilitator to discuss CVD risk factors and set physical activity goals.~Weeks 2-4, Sessions 2-4 (60 minutes each): Participants will meet individually with a facilitator to receive self-compassion education to aimed at encouraging adaptive coping with cardiovascular risk and physical activity behaviour change. Brief self-compassionate writing exercises will be assigned as home practice after Sessions 2-4."
10207380|NCT05209347|No Intervention|NoCDO|Participants will be evaluated without a CDO
10207381|NCT05209347|Experimental|CDO-A|The first study CDO will be designated CDO-A
10207382|NCT05209347|Experimental|CDO-B|The second study CDO will be designated CDO-B
9846665|NCT03092960|Experimental|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
9846666|NCT03093025|Experimental|TS-121 10mg|
9846667|NCT03093025|Experimental|TS-121 50mg|
9846668|NCT03093025|Placebo Comparator|Placebo|
9846669|NCT03093181|Placebo Comparator|No treatment and Standard cleanser|Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
9846670|NCT03093181|Experimental|Test product and Standard cleanser|Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.
9846671|NCT03093181|Active Comparator|Positive control and positive cleanser|Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
9846672|NCT03093207|Placebo Comparator|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
9846673|NCT03093207|Experimental|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
9846674|NCT03093272|Experimental|ARN-509 Combined With Docetaxel|"Apalutamide (ARN-509) will be taken orally at home daily~Docetaxel will be administered every 3 weeks intravenously~Prednisone will be taken orally twice daily~Leuprolide Acetate will be administered at the specification of the physician"
9846675|NCT03093324|Experimental|ALKS 8700|Oral capsules, administered orally twice daily.
9846676|NCT03093324|Active Comparator|Dimethyl Fumarate|Oral capsules, administered orally twice daily.
9846677|NCT03093350|Experimental|TAA-Specific CTLs|Patients receiving TAA-specific CTLs as therapy for breast cancer.
10207383|NCT05209295|Experimental|Group 1|
10207384|NCT05209295|Experimental|Group 2|
10207385|NCT05209295|Other|Group 3|Control - participants with normal hepatic function
9846678|NCT03093415|Active Comparator|Old Town Clinic, Medication Assisted Therapy group|25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
9846679|NCT03093415|Active Comparator|Outside In Clinic, Needle Exchange Program|25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
10207386|NCT05209282|Experimental|Grup I|Conventional physiotherapy program, Video-based action observation training
10207387|NCT05209282|Experimental|Grup II|Conventional physiotherapy program, Live Action Observation Training
10207388|NCT05209282|Other|Grup III|Conventional physiotherapy program
10207389|NCT05209256|Experimental|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve [AUC] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
10207390|NCT05209256|Sham Comparator|chemotherapy|arboplatin (area under the curve [AUC] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
10207391|NCT05209243|Experimental|Interventional arm|STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
9793732|NCT01483599|Active Comparator|Adalimumab (approved psoriasis dosing)|Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
9793733|NCT01483599|Placebo Comparator|Placebo to CNTO 1959 (100 mg)|Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
9793734|NCT01483625|Experimental|tiotropium 18mcg|active
9793735|NCT01483625|Placebo Comparator|Placebo|placebo
9793736|NCT01483651|Experimental|Low, Medium and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
9793737|NCT01483651|Experimental|Low, High and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
9793738|NCT01483651|Experimental|Medium, Low and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
9793739|NCT01483651|Experimental|Medium, High and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
9793740|NCT01483651|Experimental|High, Low and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
9793741|NCT01483651|Experimental|High, Medium and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
9793742|NCT01483690|Experimental|Initial Dose Level|"Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24"
9793743|NCT01483690|Experimental|Modified Dose Level|"Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21"
9793744|NCT01483807|Experimental|SPT-B then SPT-R|Participants first received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
9793745|NCT01483807|Experimental|SPT-R then SPT-B|Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
9793746|NCT01483924|Experimental|10 mg Apo805K1, or placebo|
9793747|NCT01483924|Experimental|30 mg Apo805K1, or placebo|
9793748|NCT01483924|Experimental|60 mg Apo805K1, or placebo|
9793749|NCT01483924|Experimental|100 mg Apo805K1, or placebo|
9793750|NCT01483937|Active Comparator|Usual care physical therapy only|Subjects will receive usual care physical therapy intervention provided by vestibular and balance specialists. Usual care physical therapy, in general, includes but is not limited to static and dynamic balance activities with or without head movements on firm floor or compliant surfaces.
9793751|NCT01483937|Experimental|Usual care physical therapy plus SEMD|"Subjects will receive usual care physical therapy intervention provided by vestibular balance specialists while using the Sensory Enrichment Multimodal Device (SEMD). SEMD protocols use visual, vibrotactile, and auditory cueing referenced to subject's Center of Gravity (COG) and/or Sum of Pressure (SOP) data collected from a force platform upon which the subject is placed. Static and dynamic balance activities with or without head movement are preformed while watching a computer screen; paced with an auditory metronome; and cued by touch vibration via coin tactors imbedded in a belt worn around the waist matching the COG/SOP data display."
9793752|NCT01483963|Experimental|AA4500 0.29 mg/1 mL|Up to three injections
9793753|NCT01483963|Experimental|AA4500 0.58 mg/2 mL|Up to three injections
9793754|NCT01483963|Experimental|AA4500 0.58 mg/1 mL|Up to three injections
9793755|NCT01483963|Experimental|AA4500 0.58 mg/0.5 mL|Up to three injections
9793756|NCT01483963|Other|Shoulder exercises|Home shoulder exercises for 64 days
9793757|NCT01484028|Other|EALE/1DM|etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
9793758|NCT01484028|Other|1DM/EALE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
9793759|NCT01484028|Other|EADE/1DM|etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
9793760|NCT01484028|Other|1DM/EADE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
9793761|NCT01484041|Experimental|Dovitinib plus aromatase inhibitors|Dovitinib with aromatase inhibitor
9922719|NCT00842270|Placebo Comparator|4|matching placebo for AB1010 3, 4,5 and 6 mg/kg/day
9922720|NCT00842270|Experimental|1|AB1010 3 mg/kg/day
10207392|NCT05209243|Active Comparator|Control arm|STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
10207393|NCT05209204||40 pateint glucoma suspect|ASOCT
10207394|NCT05209191|Experimental|Student Athlete Wellness Portal|Web-based intervention that illustrates opioid misuse and diversion resistance strategies.
9793762|NCT01484054|Other|EAPVPDE/EADE|etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
9793763|NCT01484054|Other|EADE/EAPVPDE|etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
9793764|NCT01484132|Experimental|Composite|
9793765|NCT01484197|Experimental|75 µg Indacaterol (LB) + Placebo (PoS)|75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
9793766|NCT01484197|Experimental|75 µg Indacaterol (PoS) + Placebo (LB)|75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
9793767|NCT01484197|Experimental|37.5 µg Indacaterol (PoS) + Placebo (LB)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
9793768|NCT01484197|Experimental|Placebo (LB) and Placebo (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
9793769|NCT01484275|Experimental|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
9793770|NCT01484275|Placebo Comparator|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
9793771|NCT01484288|Experimental|Device group|Barostim Neo system
9793772|NCT01484340|Experimental|Counseling only|Participants in this arm will receive advice to quit smoking and self-help materials from the study interventionist in a standardized fashion (intensive anti-smoking counseling).
9793773|NCT01484340|Experimental|Nicotine Replacement Therapy +counseling|Participants in this arm will receive the nicotine patch in addition to the intensive anti-smoking counseling. Participants will receive instruction on proper use of the nicotine patch (i.e., placement, use of one patch a day, importance of not smoking while using the patch, and tapering of patches).
9793774|NCT01484431|Experimental|Tadalafil|"Light Weight <25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks.~Middle Weight: 25 kg to <40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks.~Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks."
9793775|NCT01484496|Placebo Comparator|Placebo plus standard therapy|Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
9793776|NCT01484496|Experimental|Belimumab 200 mg SC plus standard therapy|Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
9793777|NCT01484561|Active Comparator|Sequence 1|
9793778|NCT01484561|Placebo Comparator|Sequence 2|
9793779|NCT01484626|Experimental|Bendamustine|Bendamustine is combined with standard chemotherapy.
9793780|NCT01484652|Experimental|COV795|
9793781|NCT01484652|Placebo Comparator|Placebo|
9793782|NCT01484834|Experimental|Exercise and Education|Company A received intervention of exercise in the workplace, posters with tips on health and quality of life computer software. The interventions with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
9793783|NCT01484834|Active Comparator|Exercise|The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
9793784|NCT01484834|Active Comparator|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
9793785|NCT01484834|Placebo Comparator|Control Company|No intervention
9793786|NCT01484873|Experimental|Exenatide|All patients received exenatide 10mcg BID x 50 weeks
9793787|NCT01484912|Experimental|STA-2|"STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
9846680|NCT03093415|Other|OHSU Hepatology Clinic, Academic center Retrospective Cohort|50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health & Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
9846681|NCT03093454|No Intervention|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
9846682|NCT03093454|Experimental|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
9846683|NCT03093662|Experimental|Ventilation with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula.
9846684|NCT03093662|Active Comparator|Ventilation without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula.
9846685|NCT03093870|Experimental|Varlitinib and Capecitabine|
9846686|NCT03093870|Placebo Comparator|Placebo and Capecitabine|
9846687|NCT03094195|Experimental|EMA401 25mg BID|Ema401 25 mg was administered orally twice a day
9846688|NCT03094195|Experimental|EMA401 100mg BID|Ema401 100 mg was administered orally twice a day
9846689|NCT03094195|Placebo Comparator|Placebo BID|Matching placebo capsules administered orally twice a day
9846690|NCT03094325|Experimental|Septal myectomy|
9846691|NCT03094611|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.
9846692|NCT03094637|Experimental|Treatment (azacitidine, pembrolizumab)|Patients receive azacitidine Intravenous (IV) over 10-40 minutes or Subcutaneous (SC) on days 1-7, and pembrolizumab IV over 30 minutes every 3 weeks. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9846693|NCT03094806|Experimental|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
9846694|NCT03094806|Placebo Comparator|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
9846695|NCT03095027|Other|FID122819, then stenfilcon A|FID122819 contact lenses worn first, followed by stenfilcon A contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
9846696|NCT03095027|Other|Stenfilcon A, then FID122819|Stenfilcon A contact lenses worn first, followed by FID122819 contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
9846697|NCT03095053|Active Comparator|PGT-A group|Next Generation sequencing preimplantation genetic testing for aneuploidy
9846698|NCT03095053|No Intervention|Morphology group|morphological assessment of blastocyst by light microscope
9846699|NCT03095118|Experimental|Daratumumab|Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
10207395|NCT05209191|Active Comparator|Student Athlete Nutritional Program|Web-based intervention that teaches about healthy eating habits for athletes.
10207396|NCT05209178|Experimental|Self-collection of specimen first|"Participants allocated to this arm will initially perform specimen collection for the antigen test independently using written instructions and access to a video.~Afterwards, a similar sample is performed by a health care personnel."
10207397|NCT05209178|Active Comparator|Healthcare-collection of specimen first|"Participants allocated to this arm will initially have specimen collection for the antigen test done by a healthcare personnel.~Afterwards, a similar sample is performed independently."
9846700|NCT03095508|Experimental|Angal S (Arm A)|Patients received Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
9846701|NCT03095508|Active Comparator|ANTI-ANGIN® FORMULA (Arm B)|"Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
9846702|NCT03095521|Experimental|Arm A|Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
9846703|NCT03095521|Active Comparator|Arm B|ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.
9846704|NCT03095599|Experimental|Vaccine|Received one dose of IVACFLU-S vaccine intramuscularly.
9846705|NCT03095599|Placebo Comparator|Placebo|Received one dose of placebo intramuscularly.
9846706|NCT03095638|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B in Part 1 and will receive A: conventional 10 mg DTG tablet (5 tablets) in Period 1 and B: conventional 50 mg DTG tablet in Period 2, administered directly to mouth.
9846707|NCT03095638|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A in Part 1 and will receive B: conventional 50 mg DTG tablet in Period 1 and A: conventional 10 mg DTG tablet (5 tablets) in Period 2, administered directly to mouth.
9846708|NCT03095638|Experimental|Treatment sequence C/D/E: Part 2|Eligible subjects will be randomized in sequence C/D/E in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
9846709|NCT03095638|Experimental|Treatment sequence D/E/C: Part 2|Eligible subjects will be randomized in sequence D/E/C in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
10207398|NCT05209152|Experimental|Part 1A - AMG 176 Monotherapy (Dose Exploration)|Two dose levels of AMG 176 will be tested in Part 1A to find the optimal biological dose/minimum safe biologically effective dose (OBD/MSBED).
10207399|NCT05209152|Experimental|Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration)|After the OBD is found in Part 1A, two dose levels of AMG 176 in combination with azacitidine will be tested in Part 1B to find the OBD/MSBED.
10207400|NCT05209152|Experimental|Part 2 - AMG 176 and Azacitidine Combination Therapy (Dose Expansion)|"After the completion of Part 1, the Part 2 dose expansion phase will begin at the OBD/MSBED identified in Part 1.~Venetoclax-naïve and venetoclax-exposed R/R HR-MDS participants after HMA failure will be enrolled along with participants with newly diagnosed HR-MDS/CMML."
10207401|NCT05209048||VTE of Derivation group|VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and developed VTE within 30 days after operation
10207402|NCT05209048||No-VTE of Derivation group|No-VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and did not develop VTE within 30 days after surgery or after 30 days
10207403|NCT05209048||VTE of Validation group|VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and developed VTE within 30 days after operation
10207404|NCT05209048||No-VTE of Validation group|No-VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and did not develop VTE within 30 days after surgery or after 30 days
10207405|NCT05209022|Experimental|Beetroot supplementation|One serving 140 mL of beetroot juice (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
9793788|NCT01484912|Placebo Comparator|Placebo|"Placebo capsule, containing non-active ingredients.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
9793789|NCT01484938|Experimental|OPTI-FREE|OPTI-FREE PureMoist multi-purpose contact lens solution used for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses, per protocol-specified regimen
9793790|NCT01484951|Experimental|AZARGA|Brinzolamide 1% and timolol 0.5% fixed combination eye drops, one drop administered to the study eye(s) twice daily (8:00 am and 8:00 pm) for up to 8 weeks.
9793791|NCT01484977|Experimental|Lacosamide|Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)
9793792|NCT01485055|Experimental|Infliximab and Basiliximab|"Other Names:~Simulect Remicade Monoclonal antibody~Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
9793793|NCT01485094|Placebo Comparator|Matching placebo|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
9793794|NCT01485094|Experimental|GRT6010|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
9793795|NCT01485094|Active Comparator|Pregabalin|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
9793796|NCT01485120|Other|Blood Pressure monitoring|Blood Pressure (BP) monitoring using invasive arterial insertion as a standard reference, and an investigational, non-invasive blood pressure (NIBP) monitoring cuff. Data obtained from the cuff used the SuperSTAT NIBP algorithm and the Classic NIBP algorithm for output.
9793797|NCT01485172|Experimental|ropinirole|ropinirole 2, 4, 8, 12, or 24 mg/day
9793798|NCT01485172|Placebo Comparator|placebo|placebo comparator 2, 4, 8, 12, or 24 mg/day
9793799|NCT01485354|Experimental|Armeo Spring training|Subjects will participate in upper extremity rehabilitation using the Armeo Spring system for a period of 6 weeks. The intervention will consist of 18 training sessions (60 minute sessions, 3 times a week).
9793800|NCT01485380|Experimental|Active study arm|Subjects recruited into this study will be required to undergo two magnetic resonance imaging- positron emission tomography (MRI-PET) scans of the brain in addition to high density electroencephalogram (EEG) acquisition. The first scan will be a baseline scan while the second scan will be performed while dexmedetomidine is being infused.
9793801|NCT01485393|Experimental|Healthy Control Subjects: Zolpidem, Then Dexmedetomidine|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Zolpidem induced-sleep and then a night of Dexmedetomidine induced-sleep.
9793802|NCT01485393|Experimental|Healthy Control Subjects: Dexmedetomidine, Then Zolpidem|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Dexmedetomidine induced-sleep and then a night of Zolpidem induced-sleep.
9793803|NCT01485536|Experimental|AUY922|AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.
9793804|NCT01485588|Experimental|hI-con1™ 60µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
9793805|NCT01485588|Experimental|hI-con1™ 150µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
9793806|NCT01485588|Experimental|hI-con1™ 300µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
9793807|NCT01485614|Experimental|Sitagliptin|Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
9799840|NCT01671085|Experimental|1.0 milligrams per kilogram (mg/kg) of LY3015014|1.0 mg/kg of LY3015014 given subcutaneously (SQ) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
9846710|NCT03095638|Experimental|Treatment sequence E/C/D: Part 2|Eligible subjects will be randomized in sequence E/C/D in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
9846711|NCT03095638|Experimental|Treatment sequence C/E/D: Part 2|Eligible subjects will be randomized in sequence C/E/D in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
9846712|NCT03095638|Experimental|Treatment sequence D/C/E: Part 2|Eligible subjects will be randomized in sequence D/C/E in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
9846713|NCT03095638|Experimental|Treatment sequence E/D/C: Part 2|Eligible subjects will be randomized in sequence E/D/C in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
9846714|NCT03095651|Experimental|T1DM MK-5160 16 nmol/kg|Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846715|NCT03095651|Experimental|T1DM MK-5160 32 nmol/kg|Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846716|NCT03095651|Experimental|T1DM MK-5160 64 nmol/kg|Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846717|NCT03095651|Active Comparator|T1DM Glargine 0.4 U/kg|Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846718|NCT03095651|Experimental|T2DM MK-5160 16 nmol/kg|Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846719|NCT03095651|Experimental|T2DM MK-5160 32 nmol/kg|Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846720|NCT03095651|Experimental|T2DM MK-5160 64 nmol/kg|Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846721|NCT03095651|Active Comparator|T2DM Glargine 0.6 U/kg|Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
9846722|NCT03095885|Other|Test Meal|controlled oxalate-rich test meal
9846723|NCT03095976|Experimental|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
9846724|NCT03096314|Active Comparator|High dose vitamin D formulation|A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
9846725|NCT03096314|Placebo Comparator|Placebo|A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
9922721|NCT00842283||dermatologic diseases|skin tissue sample
9922722|NCT00842322|Experimental|High fluid intake|fluid intake of 4 litres per day
9922723|NCT00842322|Experimental|normal fluid intake|Fluid intake of 2 litres per day
9986348|NCT01401881||Post STEMI|The study population will consist of adult patients with acute STEMI and primary PCI with clear identification of symptoms onset, willing to participate in the research protocol and not having any of the exclusion criteria. Patient screening will take place after the primary PCI in the cardiac catheterization laboratory or in the coronary care unit. Participation will be offered to all those who meet eligibility criteria.
9799841|NCT01671085|Placebo Comparator|Placebo|0.9% sodium chloride injection given SQ (to match LY3015014) on 2 dosing occasions Q4W (Days 1 and 29).
9799842|NCT01671111|Experimental|SSP-004814AQ|
9799843|NCT01671176|Other|Wide diameter bone anchored implant|Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
9799844|NCT01671280||Azithromycin IV|Subjects who are treated with Azithromycin IV
9799845|NCT01671293|Experimental|Multicomponent remote care model|A remote intervention based on counseling (telephone-based).
9799846|NCT01671293|Active Comparator|Usual care|Usual care.
9799847|NCT01671319|Experimental|dose dense TC + pegfilgrastim|Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle
9799848|NCT01671332|Active Comparator|Docetaxel|
9799849|NCT01671332|Experimental|Docetaxel plus Suramin|
9799850|NCT01671345|Active Comparator|Intervention|Patients randomized to the intervention will view the intervention video
9799851|NCT01671345|Placebo Comparator|Control|Patients randomized to control will view an informative video about nutrition and exercise of similar length
9799852|NCT01671423|Active Comparator|Prednisone|In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
9799853|NCT01671423|Placebo Comparator|Placebo|In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
9799854|NCT01671488|Experimental|Treatment|"The first dose will be given 10-14 days prior to the initiation of chemoradiation.~Patient will then receive 5-FU: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days and Mitomycin: 10 mg/m2, day 1 and 29 with IMRT radiation: 54 Gy in 30 fractions at 1.8 Gy per fraction.~The 2-4th dosages of ADXS11-001 will not be until after completion of all chemoradiation. The second dosage of ADXS11-001 will not be administered until a minimum of 10 days after completion of chemoradiation. The subsequent third and fourth treatment with of ADXS11 will be administered at 28 day intervals."
9799855|NCT01671605||CKD not on dialysis|Patients with CKD not on dialysis (CKD III-IV)
9799856|NCT01671605||Controls|Controls with normal kidney function (Control)
9799857|NCT01671748|Active Comparator|Standard Care|Standard treatment for VLUs is administered once a week, i.e. compression bandaging and non-adherent dressing, with debridement if required.
9799858|NCT01671748|Experimental|MIST and Standard Care|MIST ultrasound therapy is applied for between 3 and 12 minutes (depending on wound size) 3 times a week in combination with standard treatment for VLUs of compression bandaging and non-adherent dressing change 3 times a week, with debridement as required.
9799859|NCT01671839|Experimental|Subcutaneous tissue release|Device: Subcutaneous tissue release with the Cabochon System
9799860|NCT01672294|Experimental|treatment|three facilitator-led end-of-life preparation and completion sessions with a facilitator with both patient and caregiver
9799861|NCT01672294|Active Comparator|attention control|three facilitator led sessions of listening to a relaxation CD.
9799862|NCT01672658|Experimental|Sensory Kinectics Balance System|Subjects will be randomized in to one of two groups. The group that will receive training on the SKBS device along with traditional vestibular and balance training.
9799863|NCT01672658|Active Comparator|Traditional Vestibular Rehabilitation|Traditional vestibular rehabilitation will include VOT exercises that will work toward increasing the gain of the system as well as walking, balance re-training, and functional mobility.
9799864|NCT01672710|Experimental|regimen of niacin, exercise, sauna,|4-5 week daily sauna, exercise and niacin with other supplements
9799865|NCT01672710|Other|waitlist|4 week waitlist with treatment as usual
9799866|NCT01672723|Experimental|Naltrexone|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
9799867|NCT01672723|Placebo Comparator|Placebi|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
9799868|NCT01672736|Experimental|ASP7487, Velcade, Dexamethasone|ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg
9799869|NCT01672788|Experimental|Test 1|fixed dose combination tablet
9799870|NCT01672788|Active Comparator|Reference 1|empagliflozin tablets and metformin tablet
9799871|NCT01672788|Experimental|Test 2|fixed dose combination tablet
9799872|NCT01672788|Active Comparator|Reference 2|empagliflozin tablet and metformin tablet
9846726|NCT03096353|Experimental|Naloxone, then Placebo|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again."
9846727|NCT03096353|Experimental|Placebo, then Naloxone|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again."
9846728|NCT03096444|Experimental|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
9846729|NCT03096444|Experimental|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
9846730|NCT03096444|Experimental|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
9846731|NCT03096444|Experimental|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
9846732|NCT03096444|Placebo Comparator|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
9846733|NCT03096483|Experimental|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
9846734|NCT03096730|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
9846735|NCT03096730|Sham Comparator|Sufentanil|Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil
9846736|NCT03096730|Active Comparator|Dexmedetomidine|Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil
9846737|NCT03096730|Active Comparator|Nalmefene|Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil
9846738|NCT03096730|Active Comparator|Dexmedetomidine-Nalmefene|A dose of 0.1ug/kg nalmefene and a dose of 0.25ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil
9846739|NCT03096847|Experimental|ribociclib + letrozole cohort A|"ribociclib + letrozole cohort A - postmenopausal women, or men; naïve.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily."
9846740|NCT03096847|Experimental|ribociclib + letrozole cohort B1|"ribociclib + letrozole cohort B1 - premenopausal women or perimenopausal women; naïve~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
9846741|NCT03096847|Experimental|ribociclib + letrozole cohort B2|"ribociclib + letrozole cohort B2 - premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
9846742|NCT03096873|No Intervention|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake: 1921.7 kcal/day
9846743|NCT03096873|Experimental|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 5 times a week for 12 weeks. Caloric intake: 1921.7 kcal/day
9846744|NCT03097029|Experimental|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
9846745|NCT03097133|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
9846746|NCT03097133|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
9846747|NCT03097289|Experimental|Platelets stored in InterSol|Platelets collected on the Trima Accel system and stored in 65% InterSol/35% plasma
9846748|NCT03097315|Experimental|4 mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA
9846749|NCT03097341|Experimental|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
9846750|NCT03097341|Experimental|xisomab 3G3- Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
9846751|NCT03097341|Experimental|xisomab 3G3- Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
9846752|NCT03097341|Experimental|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
9846753|NCT03097341|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
9922724|NCT00842374||Non-STEMI ACS|
9846754|NCT03097484|Experimental|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
9846755|NCT03097484|No Intervention|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
9846756|NCT03097588|Experimental|Supportive care (NEPA)|"Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.~Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies"
9846757|NCT03097614|Experimental|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
9846758|NCT03097653|Experimental|Decision-aid|
9846759|NCT03097653|Active Comparator|Standard information|
9846760|NCT03097783|Experimental|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
9846761|NCT03097783|No Intervention|No intervention arm|No treatment
9846762|NCT03097861|Active Comparator|Lubiprostone Capsule|Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
9846763|NCT03097861|Experimental|Lubiprostone Sprinkle|Lubiprostone 24 mcg sprinkle BID for 7 days.
9846764|NCT03097861|Placebo Comparator|Placebo|Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.
9846765|NCT03098030|Experimental|Part 1: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
9846766|NCT03098030|Active Comparator|Part 2: Irinotecan|Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle.
9846767|NCT03098030|Experimental|Part 2: Dinutuximab + Irinotecan|Dinutuximab (16 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
9846768|NCT03098030|Active Comparator|Part 2: Topotecan|Topotecan (1.5 mg/m^2 IV) on Days 1 to 5 of each q21d cycle.
9846769|NCT03098173|Experimental|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
9846770|NCT03098173|Active Comparator|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
9846771|NCT03098420|Placebo Comparator|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
9846772|NCT03098420|Active Comparator|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
9846773|NCT03098420|Active Comparator|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
9922725|NCT00842387||1|Patients with symptoms suggestive of GERD, managed according to a new structured and implemented pathway
9922726|NCT00842387||2|Patients with symptoms suggestive of GERD, managed according to usual clinical practice.
9922727|NCT00842413||1|The study compares brain-damaged patients with healthy ones on two psychophysical tasks.
9922728|NCT00842413||2|The study does not intervene on the brain-damaged patients, it merely compares their behaviour with that of healthy patients on a range of psychophysical tasks.
9922729|NCT00842426|No Intervention|Usual Care|Usual Care
9922730|NCT00842426|Experimental|Self-Management Program|Online Self-Management.
9922731|NCT00842426|Experimental|Care Management Program|Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
9922732|NCT00842439|Experimental|Cognitive Behavioral Intervention (CBI)|Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.
9922733|NCT00842439|Experimental|Nutritional Supplements (NUT)|Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
9922734|NCT00842439|Experimental|CBI + NUT|Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
9922735|NCT00842439|No Intervention|No intervention|Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.
9922736|NCT00842452|Experimental|Oral Topotecan|
9922737|NCT00842465||1|benign breast diseases
9922738|NCT00842465||2|breast cancer
9922739|NCT00842465||3|control
9922740|NCT00842478|Experimental|Raspall|
9922741|NCT00842478|No Intervention|Control|
9922742|NCT00842491|Experimental|endostar+chemotherapy|
9922743|NCT00842504|Other|Micafungin|3 mg/kg given once
9922744|NCT00842517|Experimental|Extended|36-week duration contingency management program
9922745|NCT00842517|Active Comparator|Standard|12-week duration contingency management program
9922746|NCT00842556|Active Comparator|Dapagliflozin|
9922747|NCT00842556|Active Comparator|Glimepiride|
9922748|NCT00842556|Active Comparator|Dapagliflozin + Glimepiride|
9922749|NCT00842556|Active Comparator|Sitagliptin|
9922750|NCT00842556|Active Comparator|Dapagliflozin + Sitagliptin|
9922751|NCT00842569||Normal weighted|BMI<25
9846774|NCT03098433|Experimental|Liothyronine|Each participant will receive a single dose of lithyronine
9846775|NCT03098433|Active Comparator|Levothyroxine|Each participant will receive a single dose of levothyroxine
9846776|NCT03098433|Placebo Comparator|Placebo|Each participant will receive a single dose of placebo
9846777|NCT03098550|Experimental|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
9846778|NCT03098550|Experimental|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
9846779|NCT03098615|Other|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
9846780|NCT03098745|Active Comparator|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
9846781|NCT03098745|Active Comparator|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
9846782|NCT03098745|Active Comparator|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
9846783|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
9846784|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
9846785|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
9846786|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
9846787|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
9846788|NCT03098979|Placebo Comparator|Placebo|Chronic heart failure with preserved ejection fraction
9846789|NCT03099096|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
9846790|NCT03099161|Experimental|Preladenant 25 mg Twice a Day (BID)|During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
9846791|NCT03099161|Experimental|Preladenant 50 mg BID|During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
9846792|NCT03099161|Experimental|Preladenant + Pembrolizumab|During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
9846793|NCT03099187|Experimental|Pirfenidone|Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
9846794|NCT03099187|Experimental|Placebo|Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
9922752|NCT00842569||Obese|BMI>30
9922753|NCT00842582|Experimental|Single group assignment|Patients will receive Azacitidine at 20, 40, or 75 milligrams per meter squared subcutaneous once daily for 7 days.
9922754|NCT00842595|Experimental|R NIMP|(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5
9935091|NCT04209595|Experimental|1/Arm 1|Escalating doses of PLX038 and rucaparib
9846795|NCT03099369|Experimental|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.~Week 1: walk at least 3,000 steps every day.~Week 2: walk at least 3,500 steps every day.~Week 3: walk at least 4,000 steps every day.~Week 4: walk at least 4,500 steps every day.~Weeks 5-12: walk at least 5,000 steps every day."
9846796|NCT03099369|Active Comparator|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).~Walk on a flat surface at a constant speed until there is mild to moderate pain~Rest until the pain has completely ceased~Resume walking at the same speed~Increase the speed when you can walk 8 minutes without stopping for leg symptoms~Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
9846797|NCT03099538|Experimental|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
9846798|NCT03099655|Experimental|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
9846799|NCT03099694|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
9846800|NCT03099694|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
9846801|NCT03100058|Experimental|LIK066 2.5mg qd (Epoch 3)|LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.
9846802|NCT03100058|Placebo Comparator|Placebo (Epoch 3)|Matching placebo tablets for 24 weeks
9846803|NCT03100058|Experimental|LIK066 10mg qd (Epoch 3)|LIK066 10mg qd (once daily) dosing frequency for 24 weeks
9846804|NCT03100058|Experimental|LIK066 50mg qd (Epoch 3)|LIK066 50mg qd (once daily) dosing frequency for 24 weeks
9846805|NCT03100058|Experimental|LIK066 150mg qd (Epoch 3)|LIK066 150mg qd (once daily) dosing frequency for 24 weeks
9846806|NCT03100058|Experimental|LIK066 2.5mg bid (Epoch 3)|LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks
9846807|NCT03100058|Experimental|LIK066 5mg bid (Epoch 3)|LIK066 5mg bid (once daily) dosing frequency for 24 weeks
9846808|NCT03100058|Experimental|LIK066 25mg bid (Epoch 3)|LIK066 25mg bid (once daily) dosing frequency for 24 weeks
9846809|NCT03100058|Experimental|LIK066 50mg bid (Epoch 3)|LIK066 50mg bid dosing frequency for 24 weeks
9846810|NCT03100058|Experimental|LIK066 qd/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
9846811|NCT03100058|Experimental|LIK066 bid/LIK066 35mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
9846812|NCT03100058|Experimental|Placebo/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
9846813|NCT03100058|Placebo Comparator|Placebo/Placebo (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
9846814|NCT03100123|Active Comparator|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
9846815|NCT03100123|Experimental|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
9846816|NCT03100344|Experimental|Group 1|Nemolizumab (low dose)
9846817|NCT03100344|Experimental|Group 2|Nemolizumab (medium dose)
9846818|NCT03100344|Experimental|Group 3|Nemolizumab (high dose)
9846819|NCT03100344|Placebo Comparator|Group 4|Nemolizumab placebo
9846820|NCT03100500|Experimental|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
9846821|NCT03100825|Experimental|QVM149|All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
9846822|NCT03100838|Experimental|Nifedipine (Generic)|1 x 60 mg Nifedipine extended-release tablet
9846823|NCT03100838|Active Comparator|Nifedipine (Brand)|1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet
9846824|NCT03100838|Active Comparator|Nifedipine (Generic) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg Nifedipine extended-release tablet on day 7
9846825|NCT03100838|Active Comparator|Nifedipine (brand) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet on day 7
9846826|NCT03100864|Experimental|Spesolimab|
9846827|NCT03100942|Experimental|Lanraplenib|Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
9846828|NCT03100942|Experimental|Filgotinib|Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
9846829|NCT03100942|Experimental|Tirabrutinib|Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
9846830|NCT03100942|Placebo Comparator|Placebo, then active treatment|"Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48:~filgotinib + lanraplenib placebo + tirabrutinib placebo~lanraplenib + filgotinib placebo + tirabrutinib placebo~tirabrutinib + filgotinib placebo + lanraplenib placebo"
9846831|NCT03100968|Active Comparator|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
9846832|NCT03100968|Active Comparator|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
9846833|NCT03101020|Experimental|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
9846834|NCT03101020|Placebo Comparator|Control Group|The participants will receive standard care physiotherapy plus placebo visceral manipulation
9846835|NCT03101033|Experimental|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
9846836|NCT03101033|Active Comparator|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
9846837|NCT03101111|Experimental|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
9846838|NCT03101111|Active Comparator|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
9846839|NCT03101150|Active Comparator|400 IU Vitamin D3|400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
9846840|NCT03101150|Experimental|4000 IU Vitamin D3|4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
9846841|NCT03101241|Experimental|CX-8998|
9846842|NCT03101241|Placebo Comparator|Placebo|
9846843|NCT03101267|Experimental|ASP4070 4 mg|Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.
9846844|NCT03101267|Experimental|ASP4070 1 mg|Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.
9846845|NCT03101267|Placebo Comparator|Placebo|Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.
9846846|NCT03101293|Experimental|TAK-831 400 mg Fasted + TAK-831 400 mg Fed|TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
9846847|NCT03101293|Experimental|TAK-831 400 mg Fed + TAK-831 400 mg Fasted|TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.
9846848|NCT03101358|Experimental|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
9846849|NCT03101358|Experimental|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
9846850|NCT03101358|Experimental|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days or up to 56 days
9935092|NCT04209595|Experimental|2/Arm 2|MTD of PLX038 and rucaparib
9846851|NCT03101371|Active Comparator|Standard of care catheter insertion|Standard of care catheter insertion in which catheter is inserted right out of package/non-treated catheter.
9846852|NCT03101371|Experimental|Aseptic protocol for catheter insertion|Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter
9846853|NCT03101462|Active Comparator|Group 1|One dose of 0.5 mL Licensed Inactivated Influenza Vaccine (IIV) on Day 0
9846854|NCT03101462|Active Comparator|Group 2|One dose of 0.5 mL Licensed Live Attenuated Influenza Vaccine (LAIV) on Day 0
9846855|NCT03101514|Experimental|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
9846856|NCT03101592|No Intervention|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
9846857|NCT03101592|Experimental|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
9846858|NCT03101592|Experimental|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
9846859|NCT03102190|Experimental|Phase Ib|The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
9846860|NCT03102437|Experimental|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
9846861|NCT03102645|Experimental|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
9846862|NCT03102645|Experimental|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
9846863|NCT03102710|Experimental|tDCS Enhancement|In this group, the transcranial direct current stimulation (tDCS) stimulates the areas of the brain being examined in this study to increase their activity.
9846864|NCT03102710|Experimental|tDCS Inhibition|In this group, the transcranial direct current stimulation (tDCS) inhibits the areas of the brain being examined in this study to decrease their activity.
9846865|NCT03102710|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) does not provide real stimulation though you will not know this until your debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
9846866|NCT03102736|Placebo Comparator|Placebo and Ketamine|Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes
9846867|NCT03102736|Experimental|Nitroprusside and Ketamine|0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)
9517003|NCT03310333|Active Comparator|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
9846868|NCT03102762|Experimental|Botulinum Toxin Type A (BTX-A) Group|Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
9846869|NCT03102762|Placebo Comparator|Placebo Group|"Saline Group:~The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
9846870|NCT03102879|Experimental|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
9846871|NCT03102879|Active Comparator|Conventional Root Canal Treatment|Conventional endodontic procedure
9846872|NCT03102918|Active Comparator|Cannabidiol|Epidiolex
9846873|NCT03102918|Placebo Comparator|Placebo|Placebo
9846874|NCT03103061|Experimental|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
9846875|NCT03103100|Active Comparator|1% Lidocaine|Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine
9846876|NCT03103100|Active Comparator|0.25% Bupivacaine|Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine
9846877|NCT03103100|Active Comparator|Bupivacaine plus Lidocaine|Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.
9846878|NCT03103438|Experimental|Cohort 1|his cohort includes one subject who will receive the maximum safe starting dose of BCD-089 (0.06 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
9846879|NCT03103438|Experimental|Cohort 2|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.3 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no.3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3.
9846880|NCT03103438|Experimental|Cohort 3|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.625 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4.
9846881|NCT03103438|Experimental|Cohort 4|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.0 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5.
9846882|NCT03103438|Experimental|Cohort 5|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.6 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6.
9846883|NCT03103438|Experimental|Cohort 6|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7.
9846884|NCT03103438|Experimental|Cohort 7|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.9 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level.
9846885|NCT03103763||Aged 90 and older|Subjects 90 years and older with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
9846886|NCT03103763||Aged 80-89|Subjects aged 80-89 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
9517004|NCT03310320|Placebo Comparator|Placebo|Placebo for AZD0284 oral solution
9517005|NCT03310320|Experimental|AZD0284|AZD0284 oral solution 2.5 mg/mL
9846887|NCT03103763||Aged 70-79|Subjects aged 70-79 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
9846888|NCT03103906|Experimental|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
9846889|NCT03103906|Other|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
9846890|NCT03103919|Active Comparator|Rotigotine + Standard Care|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms. The optimal dose of Neupro for any given subject will be determined by standard clinical practice.
9846891|NCT03103919|Experimental|Rotigotine + Standard Care + Kinesia-360™ wearable device|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
9846892|NCT03104192|Active Comparator|Develop & Refine MOWI w/o Amulet (2A)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults without the use of Amulet technology.
9846893|NCT03104192|Experimental|MOWI Weight Loss Maintenance|Evaluate the feasibility, acceptability, and potential effectiveness of an 8-session, tri-weekly, psychosocial skills group intervention to support weight loss maintenance post-MOWI.
9846894|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit (2B)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology.
9846895|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit/Protein (2P)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology augmented by whey protein.
9846896|NCT03104322|Other|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
9846897|NCT03104647|Experimental|VRP-Clinic|VRP-Clinic software on a virtual reality platform
9846898|NCT03104725|Experimental|Healthy Volunteers|HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
9846899|NCT03104725|Experimental|PD Patients|Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).
9846900|NCT03104738|No Intervention|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
9846901|NCT03104738|Experimental|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
9846902|NCT03104816|Experimental|Acetaminophen IV Soln 10 MG/ML (A)|Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
9517006|NCT03310307|Active Comparator|vitamin D3|50,000 IU
9517007|NCT03310307|Placebo Comparator|Placebo|Similar in size, shape and color to vitamin D3
9846903|NCT03104816|Experimental|PO acetaminophen (B)|Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
9846904|NCT03104816|Active Comparator|Hydromorphone (control arm) (C)|Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.
9846905|NCT03104985|Active Comparator|Conventional treatment|"Conventional treatment only.~An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2~Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.~Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
9846906|NCT03104985|Experimental|Conventional therapy and combined LLLT|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:~- 365-405nm, power 1-2mW, exposure 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min"
9846907|NCT03105297|Experimental|All participants (Baseline phase)|All the participants were applied nasal dilator strip during the sleep laboratory night on Day 1.
9846908|NCT03105297|Experimental|All Participants (Active Phase)|All the participants wore nasal dilator strip over a 1 month in-home use period and returned for sleep laboratory nights after 7 (Day 8) and 28 days (Day 29) of treatment
9922755|NCT00842621||1|Pediatric participants with severe sickle cell disease (HbSS or Hb S/β°-thalassemia) who are not receiving treatment, e.g., hydroxyurea or chronic transfusions
9517008|NCT03310294|Placebo Comparator|placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)
9846909|NCT03105297|Experimental|All Participants (Nasal Resistance Phase)|The participants were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip' on 2 sleep laboratory nights (on Day 30 and Day 31) based on the randomization schedule
9846910|NCT03105362|Experimental|Amino Acid-ORS arm|Patients consumed an amino acid based oral rehydration solution (enterade®) as part of their oral rehydration care plan. Enterade® oral rehydration solution volumes varied from patient to patient depending on baseline clinical need.
9846911|NCT03105479|Experimental|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
9846912|NCT03105479|Experimental|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
9846913|NCT03105479|Experimental|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
9846914|NCT03105479|Experimental|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
9846915|NCT03105479|Experimental|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
9846916|NCT03105479|Experimental|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
9846917|NCT03105479|Active Comparator|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin capsule (for subjects able to swallow) or vancomycin solution (for the others) during 10 days .
9846918|NCT03105518|Experimental|Analgesia options|Protocolized analgesia based on VAS degree of discomfort and time. Analgesic options include heating pad, acetaminophen, percocet (oxycodone), fentanyl 0.5-1 mcg/kg.
9846919|NCT03106077|Experimental|Cohort A (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unaccepted toxicity.
9846920|NCT03106077|Experimental|Cohort B (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
9846921|NCT03106337|Experimental|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
9846922|NCT03106636|Active Comparator|KEEP-P|Caregivers are randomly assigned to one of two groups. The KEEP-P group completes a basic version of the curriculum. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
9846923|NCT03106636|Experimental|KEEP-P+|Caregivers are randomly assigned to one of two groups. The KEEP-P+ group completes an augmented version of the intervention with curriculum that includes the addition of information about recent findings in early brain development and a video coaching component based on the Filming Interactions to Nurture Development (FIND) program. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
9846924|NCT03106753|Active Comparator|Spinal anesthesia immediately for ECV.|The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
9846925|NCT03106753|Experimental|Spinal anesthesia if no intervention fails for ECV.|The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
9846926|NCT03106844|Experimental|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
9846927|NCT03106870|Active Comparator|oral metformin and insulin|Intervention 'Insulin Mixtard' and Intervention 'metformin' had included
9846928|NCT03106870|Active Comparator|insulin therapy only|Intervention 'Insulin Mixtard' had included
9846929|NCT03107026|Experimental|dasotraline 4mg|dasotraline 4mg once daily
9846930|NCT03107026|Experimental|dasotraline 6mg|dasotraline 6mg once daily
9846931|NCT03107026|Placebo Comparator|Placebo|Placebo, once daily
9922756|NCT00842621||2|Pediatric participants with other forms of SCD or severe sickle cell disease patients (HbSS or Hb S/β°-thalassemia) being treated with hydroxyurea or chronic transfusions
9922757|NCT00842621||3|Pediatric and adult participants with other non-sickling hematological disorders
9922758|NCT00842634|Experimental|Cohort 1|Patients who have failed two more HAART regimens
9922759|NCT00842634|Experimental|Cohort 2|Patients doing well on a stable antiretroviral medication
9517009|NCT03310294|Active Comparator|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS), 90 grams)
9922760|NCT00842634|Experimental|Cohort 3|Patients who have an undetectable viral load on HAART who have exhibited suboptimal CD4+ T cell gains during long term antiretroviral therapy. This group will not participate in the structured treatment interruption.
9922761|NCT00842660|Experimental|Gemzar,survival|
9846932|NCT03107052|Experimental|Fremanezumab 225 mg Monthly|Participants with ECH or CCH who received fremanezumab at 900 mg intravenous (IV) infusion at Week 0 and fremanezumab at 225 mg subcutaneous (SC) injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056 or TV48125-CNS-30057, and participants with CCH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab at 225 mg SC injection monthly (approximately every 4 weeks, administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 milliliter {mL}] at Week 0 and 36; and 2 placebo SC injections at Weeks 0, 12, 24, and 36 for blinding in participants rolled over from Study TV48125-CNS-30056; fremanezumab at 225 mg as a single SC injection (225 mg/1.5 mL) at Week 0, 12, 24, and 36; 2 SC injections of placebo at Week 0 for blinding in participants rolled over from Study TV48125-CNS-30057) through Week 36 in this study.
9846933|NCT03107052|Experimental|Fremanezumab 675/225 mg Monthly|Participants with CCH who received placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab 675 mg SC injection as loading dose (administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Week 0) followed by monthly (approximately every 4 weeks) fremanezumab at 225 mg SC injection (administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 12, 24, and 36) through Week 36.
9846934|NCT03107052|Experimental|Fremanezumab 675 mg Quarterly|Participants with ECH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study; or placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056; will receive fremanezumab at 675 mg SC injection quarterly (approximately every 12 weeks, administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 0 an 36; and single placebo SC injections at Weeks 4, 8, 16, 20, 28, and 32 for blinding) through Week 36.
9846935|NCT03107091|Experimental|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
9846936|NCT03107377|Active Comparator|EVO100|A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
9846937|NCT03107377|Placebo Comparator|Placebo|An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
9846938|NCT03107715|Active Comparator|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
9846939|NCT03107715|Active Comparator|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
9846940|NCT03107754|Placebo Comparator|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
9846941|NCT03107754|Experimental|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
9846942|NCT03107793|Experimental|All Participants|At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
9846943|NCT03107793|Experimental|Routine Care Arm|In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
9922762|NCT00842673|Experimental|1|30 mg ST101
9922763|NCT00842673|Experimental|2|90 mg ST101
9922764|NCT00842673|Experimental|3|180 mg ST101
9846944|NCT03107793|Experimental|Treat to Target (T2T) Arm|UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with <25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with >=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.
9846945|NCT03107793|Experimental|Exploratory Extension period: From Week 48 to Week 104|At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score <=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
9846946|NCT03108027|Experimental|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
9846947|NCT03108027|Experimental|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
9846948|NCT03108027|Experimental|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
9846949|NCT03108027|Experimental|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
9846950|NCT03108027|Experimental|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
9846951|NCT03108027|Experimental|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
9846952|NCT03108157|Experimental|GROUP A: intervention group|Patients will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before the embryo transfer and then they will follow the conventional preparation protocol to receive embryos coming from an egg donation treatment.
9846953|NCT03108157|No Intervention|GROUP B: no intervention group|Patients will receive the conventional preparation protocol to receive embryos coming from an egg donation treatment.
9846954|NCT03108469|Active Comparator|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
9846955|NCT03108469|Placebo Comparator|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
9846956|NCT03108482|Experimental|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
9846957|NCT03108482|Active Comparator|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
9846958|NCT03108482|Active Comparator|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
9846959|NCT03108482|Placebo Comparator|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
9846960|NCT03108521|Experimental|Sitagliptin group|Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.
9846961|NCT03108521|No Intervention|non-T2DM group|Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.
9846962|NCT03108924|Experimental|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
9846963|NCT03108924|Experimental|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
9846964|NCT03108924|Other|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
9846965|NCT03108924|Experimental|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixant immediately after the scheduled HD, followed in Period 2 with a single 50 mg dose of gefapixant two hours prior to HD. Between the Periods 1 and 2 MK-7264 dose administrations there was approximately a 7-day washout period with 3 dialysis sessions.
9846966|NCT03109015|Active Comparator|Schedule 4/2|
9846967|NCT03109015|Experimental|Schedule 2/1|
9846968|NCT03109184|No Intervention|Waitlist Control|Parents and teens enrolled in the study and randomized to the control condition wait until they complete their 3-month and 9-month follow-up surveys before completing the web-based program.
9846969|NCT03109184|Experimental|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
9846970|NCT03109769|Experimental|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
9846971|NCT03109769|Active Comparator|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
9846972|NCT03109951|Other|Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
9922765|NCT00842673|Placebo Comparator|4|Placebo
9846973|NCT03110003|Active Comparator|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
9846974|NCT03110003|Active Comparator|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
9846975|NCT03110029|Active Comparator|Efinaconazole 10 % and Nail Polish|Subject will have Efinaconazole 10% solution application and nail polish
9846976|NCT03110029|Placebo Comparator|Efinaconazole 10% without Nail Polish|Subject will have only Efinaconazole 10% application and no nail polish
9846977|NCT03110185|Other|delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
9846978|NCT03110185|Other|no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
9846979|NCT03110458|Experimental|SENS-111 100mg|SENS-111 100mg: 2 Oral Dispersible Tablets (1 SENS-111 100 mg and 1 placebo)
9846980|NCT03110458|Experimental|SENS-111 200mg|SENS-111 200mg: 2 Oral Dispersible Tablets (SENS-111 100 mg)
9846981|NCT03110458|Placebo Comparator|Placebo|Placebo: 2 placebo Oral Dispersible Tablets
9846982|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
9846983|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
9846984|NCT03110471||Neuadd Drymmau Care Home|As above
9846985|NCT03110471||Monkstone House,|As above
9846986|NCT03110471||Danygraig House|As above
9846987|NCT03110471||Ty Coch|As above
9846988|NCT03110471||Swn y mor|As above
9846989|NCT03110471||Hengoed court|As above
9846990|NCT03110471||Hengoed park|As above
9846991|NCT03110471||Cefn Lodge care home|As above
9846992|NCT03110562|Active Comparator|selinexor+bortezomib+dexamethasone (SVd)|Selinexor will be given on Days 1, 8, 15, 22, and 29 of each 35-day cycle. Bortezomib will be given Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
9846993|NCT03110562|Active Comparator|bortezomib+dexamethasone (Vd)|Bortezomib will be given Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, bortezomib will be given on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, dexamethasone will be given on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
9846994|NCT03110601|Active Comparator|Control - Conventional SCS|Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
9846995|NCT03110601|No Intervention|Washout Period|1 day where no stimulation is provided
9846996|NCT03110601|Experimental|Test - Stimgenics SCS|Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
9846997|NCT03110692|No Intervention|Usual practice (control)|The usual practice group will rollover to the intervention arm after 3 months.
9846998|NCT03110692|Experimental|Intervention|Default initiation: Introduce a default prescription template in the palliative setting in order to reduce unnecessary daily image guided radiation.
9846999|NCT03110770|Experimental|Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 injections|Zika virus wildtype (ZIKVwt) DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered intramuscularly (IM) by a needle-free injection device
9847000|NCT03110770|Experimental|Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
9847001|NCT03110770|Experimental|Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 8 mg of vaccine administered IM by a needle-free injection device
9847002|NCT03110770|Experimental|Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
9847003|NCT03110770|Placebo Comparator|Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 injections|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 1 mL of placebo administered IM by a needle-free injection device
9847004|NCT03111108|Experimental|Arm 1: EBR/GZR for 8 Weeks|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
9847005|NCT03111108|Experimental|Arm 2: EBR/GZR for 12 Weeks|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
9847006|NCT03111316|Other|Foley Catheter & Dinoprostone Insert|transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
9847007|NCT03111316|Other|Foley Catheter Alone|a Foley catheter alone
9847008|NCT03111381|Experimental|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
9847009|NCT03111381|No Intervention|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
9847010|NCT03111407|Other|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
9847011|NCT03111407|Other|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
9847012|NCT03111550|Other|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Tecnis Model ZHR00
9847013|NCT03111550|Other|Investigational Lens Device #2|Investigational Intraocular Lens Device #2: Tecnis Model ZQR00
9847014|NCT03111550|Other|Control Device|Control TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
9922766|NCT00842699||1|patients receiving IL-2 receptor antagonist (Simulect) as induction treatment
9922767|NCT00842699||2|patients receiving Thymoglobulin as induction treatment
9922768|NCT00842738|Active Comparator|Mindfulness meditation|Women with mild dysplasia offered mindfulness meditation
9922769|NCT00842738|Other|No meditation|Women with mild dysplasia offered health care services as usual
9922770|NCT00842738|Other|Controls|Women with normal cervical cells
9922771|NCT00842777|Experimental|Parent group treatment|Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
9922772|NCT00842777|Active Comparator|Parent self-help groups|Professionals initiate and organize the self-help groups initially. The groups will not receive any teaching or counseling concerning eating and physical activity.
9922773|NCT00842803|No Intervention|Control Group|Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
9922774|NCT00842803|Experimental|Albumin group|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
9922775|NCT00842816|Experimental|1|10 mg ST101
9922776|NCT00842816|Experimental|2|60 mg ST101
9922777|NCT00842816|Experimental|3|120 mg ST101
9922778|NCT00842816|Placebo Comparator|4|Placebo
9922779|NCT00842842|Active Comparator|1: tacks|mesh fixation with tacks
9922780|NCT00842842|Experimental|2: glue|mesh fixation with glue
9922781|NCT00842855||1|274 GERD patients, partial responders to PPI treatment
9922782|NCT00842881|No Intervention|a|healingstone
9922783|NCT00842881|No Intervention|b|stone powder
9922784|NCT00842894||Insulin detemir|
9922785|NCT00842894||Biphasic insulin aspart 30|
9922786|NCT00842907|Active Comparator|oral isotretinoin|Twelve subjects will be treated with oral isotretinoin 20.0 mg, once a day, every other day, for 24 weeks.
9922787|NCT00842907|Active Comparator|tretinoin|Twelve patients will be treated with 0,05% tretinoin cream applied on face and forearms at night and moisturizer broad-spectrum sunscreen twice a day.
9922788|NCT00842920|Placebo Comparator|Placebo|Placebo or 20 mg Simvastatin (stratified by prior use of statins)
9922789|NCT00842920|Experimental|Simvastatin 60 mg|Simvastatin 60 mg once daily
9922790|NCT00842920|Experimental|Simvastatin 20 mg|Simvastatin 20 mg once daily
9922791|NCT00842933|Experimental|Experimental group|Corticosteroids discontinued 24 hours after cessation of vasopressor therapy or 7 days, which ever comes first.
9922792|NCT00842933|Active Comparator|Standard of care group|Standard corticosteroid therapy given for 7 days as treatment for adrenal insufficiency during septic shock.
9922793|NCT00842959|Other|ZO|XL Stabi ZO or Invent ZO
9922794|NCT00842998|Experimental|1 - Trastuzumab|Day1 Week1: 8 mg/kg iv in 90 min. Following 1st week: 2 mg/kg once/weekly for 8 weeks
9922795|NCT00842998|Experimental|2 - Lapatinib|1500 mg/die orally
9922796|NCT00843011|Experimental|Arm 1|Orvepitant 60 mg
9922797|NCT00843063|Active Comparator|pantoprazole|pantoprazole 20 mg om and matching placebo nocte
9922798|NCT00843063|Active Comparator|famotidine|Famotidine 40 mg om and nocte
9922799|NCT00843089|No Intervention|1|Standard care
9922800|NCT00843089|Experimental|2|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
9922801|NCT00843128|Experimental|1: RAGT|Following randomization, 20 patients will be treated with RAGT, 12 sessions over three weeks
9922802|NCT00843128|Active Comparator|2: Control|The control group will be treated by CWT, 12 sessions in three weeks.
10207406|NCT05209022|Placebo Comparator|Placebo supplementation|One serving of beetroot juice depleted in NO3- (0.08 mmol of NO3-) as placebo (Beet It; James White Drinks Ltd, Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
9847015|NCT03111628|Other|Omalizumab|Omalizumab 300mg every month for 3 doses
9847016|NCT03111940|Experimental|PCI optimisation|Post PCI FFR below 0.9
9847017|NCT03111940|No Intervention|No PCI optimisation|Post PCI FFR 0.9 or higher
9847018|NCT03112473|Active Comparator|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
9847019|NCT03112473|Placebo Comparator|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side and sham electrical stimulation on the non-paretic side
9847020|NCT03112473|Placebo Comparator|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
9847021|NCT03112473|No Intervention|Control group|No Active intervention
9847022|NCT03112863|Experimental|Bakuchiol|Bakuchiol 0.5% applied to face twice daily
9847023|NCT03112863|Active Comparator|Retinol|0.5% retinol applied to face nightly
9847024|NCT03113656|Experimental|Weighted Blanket First|This group will receive the Weighted Blanket first and then the Non-weighted blanket
9847025|NCT03113656|Experimental|Non-weighted Blanket First|This group will receive the Non-weighted Blanket first and then the Weighted blanket
9847026|NCT03113916|Experimental|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
9847027|NCT03113916|No Intervention|Enhanced usual care|Printed materials
9847028|NCT03114124|Active Comparator|Bipolar Ablation Catheter|Subjects will be randomized by random computer programming to receive standard ablation catheter for their procedure.
9847029|NCT03114124|Experimental|MIFI Ablation Catheter|Subjects will be randomized by random computer programming to receive an ablation with MIFI technology. MIFI Catheter contains tightly spaced multielectrode pattern
9847030|NCT03114488|Experimental|Anodal Stimulation|
9847031|NCT03114488|Sham Comparator|Sham Stimulation|
9847032|NCT03114657|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
9847033|NCT03114657|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
9847034|NCT03114683|Experimental|IBI308|
9847035|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
10207407|NCT05209009|Experimental|Group A|COVAC-2 25 µg: 200 generally healthy adults > 18 years of age receive the vaccine on Day 0, followed by a second dose on Day 28.
10207408|NCT05209009|Placebo Comparator|Group B|100 generally healthy adults > 18 years of age receive a dose of normal saline (placebo) on Day 0, followed by a dose of normal saline (placebo) on Day 28.
9847036|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
9847037|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
9847038|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
9847039|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
9847040|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
9847041|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
9847042|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
9847043|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
9847044|NCT03114995|Experimental|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
9847045|NCT03114995|No Intervention|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
9847046|NCT03114995|No Intervention|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
9922803|NCT00843141|Experimental|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
10207409|NCT05208996|Experimental|siCoV/KK46|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use
10207410|NCT05208983||70 years and Older|Persons aged 70 years and over receiving a first or second dose of an approved COVID-19 vaccine and is a resident of Ontario
10207411|NCT05208983||30 - 50 years of age|Persons aged 30 - 50 years receiving a first or second dose of an approved COVID-19 vaccine and a resident of Ontario
9847047|NCT03115112|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
9847048|NCT03115112|Active Comparator|Sitagliptin|Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
9847049|NCT03115177|Active Comparator|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
9847050|NCT03115177|Active Comparator|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
9847051|NCT03115411|Experimental|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
9847052|NCT03115476|Experimental|Ingenol disoxate gel 0.018%|
9847053|NCT03115476|Experimental|Ingenol disoxate gel 0.037%|
9847054|NCT03115476|Placebo Comparator|Vehicle gel|
9847055|NCT03115580|Active Comparator|Rotational atherectomy|Rotational atherectomy (RA)
9847056|NCT03115580|Active Comparator|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
9847057|NCT03115801|Active Comparator|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64."
9847058|NCT03115801|Active Comparator|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
9847059|NCT03115827|Experimental|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
9847060|NCT03116152|Experimental|IBI308|IBI308 200mg Intravenous drip every three weeks
9847061|NCT03116152|Active Comparator|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
9847062|NCT03116230|Experimental|Experimental Treatment A then B|Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
9847063|NCT03116230|Experimental|Experimental Treatment B then A|Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.
9847064|NCT03116698|Experimental|Low dose DFD07 once daily|
9847065|NCT03116698|Experimental|High dose DFD07 once daily|
9847066|NCT03116698|Experimental|High dose DFD07 twice daily|
9847067|NCT03116698|Placebo Comparator|Placebo twice daily|
9847068|NCT03116828|Experimental|eslicarbazepine acetate (arm 1)|eslicarbazepine acetate (as first add-on)mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
9847069|NCT03116828|Experimental|eslicarbazepine acetate (arm 2)|eslicarbazepine acetate (as later add-on)
9847070|NCT03116841|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
9847071|NCT03117140|Active Comparator|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
9847072|NCT03117140|Experimental|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
9847073|NCT03117140|Experimental|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
9847074|NCT03117140|Experimental|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
9847075|NCT03117361|Experimental|Experimental|"Plitidepsin + bortezomib + dexamethasone~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
9847076|NCT03117517|Experimental|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
9847077|NCT03117517|Active Comparator|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
9847078|NCT03117569|Other|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
9847079|NCT03117569|Experimental|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
9847080|NCT03117634|Active Comparator|Fixed dosing group (2Q8)|Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.
9847081|NCT03117634|Experimental|Treat and Extend group (T&E)|Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and indocyanine green angiography (ICGA). Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.
9847082|NCT03117738|Experimental|AstroStem|
9847083|NCT03117738|Placebo Comparator|Placebo-Control|
9847084|NCT03118297|Experimental|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
9847085|NCT03118297|Placebo Comparator|Placebo|Identical placebo (capsule) daily for 7 days
9847086|NCT03118466|Experimental|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
9847087|NCT03118518|Active Comparator|Anti-arrhythmic drug|
9847088|NCT03118518|Experimental|Cryoablation|
9847089|NCT03118596|Active Comparator|I-gel|Fibreoptic guided tracheal intubation through I-gel
9847090|NCT03118596|Active Comparator|LMA Protector|Fibreoptic guided tracheal intubation through Protector
9847091|NCT03118739|Experimental|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
9847092|NCT03118739|Placebo Comparator|Placebo|Capsule administered orally, once daily for 24 weeks
9847093|NCT03118765|Experimental|Test Treatment T1: GSP304 Inhalation Solution|
9847094|NCT03118765|Experimental|Test Treatment T2: GSP304 Inhalation Solution|
9847095|NCT03118765|Experimental|Test Treatment T3: GSP304 Inhalation Solution|
9847096|NCT03118765|Placebo Comparator|Test Treatment T4: GSP304 Placebo Inhalation Solution|
9847097|NCT03118765|Active Comparator|Test Treatment T5: Spiriva® Respimat® inhalation spray|
9847098|NCT03118843|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
9847099|NCT03118934|Experimental|AOA MF|Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 10 ± 3 days
9847100|NCT03118934|Experimental|DACP MF|Nelfilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
9847101|NCT03118934|Experimental|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
9847102|NCT03118947|Experimental|Pimavanserin 20 mg OR 34 mg per day|
9847103|NCT03119025|Experimental|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
9847104|NCT03119168|Experimental|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations ( 4L Polyethyleneglycol)
9847105|NCT03119168|Active Comparator|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation (4L Polyethylenglycol)
9847106|NCT03119181|Experimental|Active Tymbion Iontophoresis|Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
9847107|NCT03119181|Sham Comparator|Sham Tymbion Iontophoresis|The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.
9847108|NCT03119389|Experimental|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
9847109|NCT03119389|No Intervention|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
9847110|NCT03119571|Experimental|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
9847111|NCT03119571|Active Comparator|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
9847112|NCT03119610|Experimental|Oxytocin nasal spray|Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
9847113|NCT03119610|Experimental|Placebo nasal spray|Placebo nasal spray, 4x a day for 8 weeks, self administered
9847114|NCT03119649|Experimental|Cohort A: GLPG2222 50 mg once daily (QD)|Participants received a single GLPG2222 50 mg tablet and two matching placebo tablets orally, QD for 29 days.
9847115|NCT03119649|Experimental|Cohort A: GLPG2222 100 mg QD|Participants received a single GLPG2222 100 mg tablet and two matching placebo tablets orally, QD for 29 days.
9847116|NCT03119649|Experimental|Cohort B: GLPG2222 200 mg QD|Participants received two GLPG2222 100 mg tablets and one matching placebo tablet orally, QD for 29 days.
9847117|NCT03119649|Experimental|Cohort B: GLPG2222 400 mg QD|Participants received two GLPG2222 150 mg tablets and one GLPG2222 100 mg tablet orally, QD for 29 days.
9847118|NCT03119649|Placebo Comparator|Cohort A Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
9847119|NCT03119649|Placebo Comparator|Cohort B Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
9847120|NCT03119688|Other|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
9847121|NCT03119688|Other|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm by topical dermal administration of towel moistened with sterile water that had been rubbed onto the 100 g bar of soap for 6 seconds to generate a lather.
9847122|NCT03119688|Other|Negative Control|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
9847123|NCT03119688|Other|No Treatment|An area of the forearm that remained unwashed and was included in the study as a reference for the treated areas.
9847124|NCT03119701|Experimental|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
9847125|NCT03119701|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
9847126|NCT03119831|Experimental|C31G (Group A)|C31G
9847127|NCT03119831|Experimental|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
9847128|NCT03119831|Experimental|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
9847129|NCT03120013|Experimental|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
9847130|NCT03120013|Sham Comparator|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
9847131|NCT03120351|Experimental|Lidocaine patch 5%|1) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
9847132|NCT03120351|Placebo Comparator|Placebo Patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
9847133|NCT03120520|Experimental|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
9847134|NCT03120520|Experimental|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
9847135|NCT03120520|Experimental|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
9847136|NCT03120520|Placebo Comparator|Matching placebo|Taken orally once daily in the morning for 8 weeks
9847137|NCT03120832|Experimental|PAN-301-1 (SNS-301) Vaccine|PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
9847138|NCT03121144|Experimental|Masimo Centroid System|Single-arm study. All subjects are enrolled into the test group wherein the noninvasive positional monitoring device will be administered.
9847139|NCT03121365|Active Comparator|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
9847140|NCT03121365|Experimental|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
9847141|NCT03121612|Experimental|Dolphin CPAP|CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. [Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement]
9847142|NCT03121612|Active Comparator|Fisher-Paykel CPAP|Fisher-Paykel (F&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.
9847143|NCT03121820|Experimental|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
9847144|NCT03121820|Active Comparator|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH & Co. KGaA, Germany - reference)
9847145|NCT03121950|Experimental|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
9847146|NCT03121950|Active Comparator|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
9847147|NCT03122145|Experimental|Healthy Volunteers - Experiment 1|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo voluntary and reflexive cough testing. The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
9986349|NCT01401920||patients undergoing open heart surgery|small infant or children patients undergoing open heart surgery
9847148|NCT03122145|Experimental|Healthy Volunteers - Experiment 2|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
9847149|NCT03122171|Experimental|Prosthesis|
9847150|NCT03122184|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
9847151|NCT03122184|Active Comparator|Motivational Interviewing Health Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week. Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
9847152|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
9847153|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
9847154|NCT03122223|Active Comparator|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
9847155|NCT03122223|Placebo Comparator|Placebo|10 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
9847156|NCT03122457|Experimental|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
9847157|NCT03122535|Active Comparator|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
9847158|NCT03122535|Active Comparator|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
9847159|NCT03122548|Experimental|CRS-207 + Pembrolizumab|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
9847160|NCT03122587|Sham Comparator|Active Sham (Session 1 and Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
9847161|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 10 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
9847162|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 40 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
9847163|NCT03122860|Experimental|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
9847164|NCT03122860|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
9847165|NCT03122860|Experimental|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
9847166|NCT03122860|Experimental|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
9847167|NCT03122860|Placebo Comparator|Placebo|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
9847168|NCT03122860|Sham Comparator|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
9847169|NCT03122886|Experimental|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
9847170|NCT03122886|Placebo Comparator|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
9847171|NCT03123055|Experimental|B-701 (vofatamab)|B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
9847172|NCT03123055|Experimental|B-701 (vofatamab) plus pembrolizumab|B-701 (vofatamab, 25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
9847173|NCT03123068|Active Comparator|Active treatment group - Group A|Participants will receive a daily oral dose of 1,000 mg cocoa flavanol (CocoaVia®) for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
9847174|NCT03123068|Placebo Comparator|Placebo treatment group - Group B|Participants will receive a daily oral dose of a placebo for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
9847175|NCT03123120|Experimental|Spesolimab|1200 milligrams (mg) of Spesolimab (BI 655130) were administered every 4 weeks (q4w) via intravenous infusion over 12 weeks of treatment (3 injections of Spesolimab 1200 mg in total during the 12 weeks: at Week 0, 4, and 8 respectively).
9847176|NCT03123120|Placebo Comparator|Placebo|Matching placebo was administered via intravenous infusion over 12 weeks of treatment.
9847177|NCT03123354|Experimental|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
9847178|NCT03123471|Experimental|Apremilast 30 mg BID|Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
9847179|NCT03123471|Placebo Comparator|Placebo|Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
9847180|NCT03123588|Experimental|Group A : Ruxolitinib and anagrelide placebo|Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.
9847181|NCT03123588|Active Comparator|Group B : Anagrelide and Ruxolitinib PLacebo|Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.
9847182|NCT03123614|Active Comparator|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
9847183|NCT03123614|Active Comparator|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
9847184|NCT03123848|Experimental|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
9847185|NCT03123861|Active Comparator|Gabapentin|Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.
9847186|NCT03123861|Placebo Comparator|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
9847187|NCT03123874|Experimental|Sterile pump set-up first|Participants will pump with sterile pump set-ups first. Approximately 3 hours later, participants will pump with their own pump set-ups.
9847188|NCT03123874|Experimental|Mother's Own pump set-up first|Participants will pump with their own pump set-ups first. Approximately 3 hours later, participants will pump with sterile pump set-ups.
9847189|NCT03123939|Experimental|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
9847190|NCT03124069|Experimental|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
9847191|NCT03124108|Placebo Comparator|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
9847192|NCT03124108|Active Comparator|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
9847193|NCT03124108|Active Comparator|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
9847194|NCT03124121|Other|Induction cohort|Golimumab induction therapy
9847195|NCT03124121|Other|Maintenance cohort|Golimumab maintenance therapy
9847196|NCT03124199|Experimental|Rifaximin|Patient with Helicobacter pylori infection with standard triple therapy prescribed by clinical practice.
9847197|NCT03124342|Experimental|VANDERBILT ICU RECOVERY PROGRAM (VIP)|Patients assigned to the Vanderbilt ICU Recovery Program (VIP) group will receive the components of the ICU Recovery Program intervention.
9847198|NCT03124342|No Intervention|Usual care|Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
9847199|NCT03124368|Experimental|Group 1: Danicopan 100 mg TID (Sentinel)|All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.
9847200|NCT03124368|Experimental|Group 2: Danicopan up to 200 mg TID|All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.
9847201|NCT03124381|Active Comparator|Acne Mask|Cleanser, Acne Mask
9847202|NCT03124381|Experimental|Gel-Cream + Acne Mask|Cleanser, Gel-Cream, Acne Mask
9847203|NCT03124407|Active Comparator|Once daily-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
9847204|NCT03124407|Placebo Comparator|Once daily-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e., with no capsaicin) to the knee
9847205|NCT03124407|Active Comparator|Twice daily-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
9847206|NCT03124407|Placebo Comparator|Twice daily-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e., with no capsaicin) to the knee
9847207|NCT03124459|Experimental|Part 1 Cohort 1|ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
9847208|NCT03124459|Experimental|Part 1 Cohort 2|ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
9847209|NCT03124459|Experimental|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
9986350|NCT01401933|Experimental|Linifanib|
9847210|NCT03124459|Experimental|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
9847211|NCT03124459|Experimental|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
9847212|NCT03124537|Experimental|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
9847213|NCT03124537|Experimental|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
9847214|NCT03124550|Experimental|Exergame Experience|Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
9847215|NCT03124563|Experimental|Control group|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
9847216|NCT03124563|Experimental|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.
9847217|NCT03124602|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
9847218|NCT03124693|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
9847219|NCT03124758|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
9847220|NCT03124771|Experimental|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
9847221|NCT03124784|Experimental|RD Disposable Sensors|All subjects are enrolled into the test group and all subjects received the RD Disposable Sensors
9847222|NCT03124797|Experimental|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
9847223|NCT03124823|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
9847224|NCT03124836|Experimental|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
9922804|NCT00843141|Active Comparator|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
9922805|NCT00843154|Experimental|Candesartan QD|
9922806|NCT00843154|Active Comparator|Standard chronic heart disease therapy|
9922807|NCT00843219||PET/CT Scan|
9922808|NCT00843232||Elderly T2DM|Elderly T2DM subjects 65 to 80 years old
9922809|NCT00843232||Middle-age T2DM|Middle-age T2DM subjects 35 to 50 years old
9922810|NCT00843245||heart failure|Heart failure attending a HF clinic with or without clinical decompensation
9922811|NCT00843258|No Intervention|Active Sonographic surveillance|Follow-up at 1.5 and 3 months (Ultrasound,Clinical examination), at 6 and 12 months (clinical examination, pelvic X-ray)
9922812|NCT00843258|Experimental|Abduction treatment|Treatment (abduction splint) from 0-6 weeks, follow-up at 1.5 and 3 months (clinical examination and ultrasound) and at 6 and 12 months (clinical examination and pelvic x-ray)
9935093|NCT04206319|Experimental|1|Participants will receive radium-223 treatment every 4 weeks for up to 6 cycles. 18F-NaF PET scans will be used to assess response in bone.
9986351|NCT01401946|Active Comparator|soy isoflavones|
10207412|NCT05208944|Experimental|Part A|"Safety lead-in, modified 3+3 design. Part A:~Cohort 1: THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2 (pending emerging data from Cohort 1): THIO total 180 mg per cycle (60 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5"
10207413|NCT05208944|Experimental|Part B|Cohort 1: THIO total 60 mg per cycle (20 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 2: THIO total 180 mg per cycle (60 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5; Cohort 3 (pending emerging data from Part A): THIO total 360 mg per cycle (120 mg on Days 1-3 Q3W) plus 350 mg cemiplimab on Day 5
9847225|NCT03124901|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
9847226|NCT03124927|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
9847227|NCT03124966|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all will receive the pulse oximeter sensor.
9847228|NCT03124979|Other|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
9847229|NCT03125005|Experimental|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
9847230|NCT03125018|Experimental|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
9847231|NCT03125031|Experimental|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
9847232|NCT03125031|Experimental|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
9847233|NCT03125200|Experimental|ADCT-502|"Part 1 (dose escalation): Participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined.~Part 2 (expansion): Participants were due to be assigned to the recommended dose level of ADCT-502 as identified in Part 1 by the Dose Escalation Steering Committee."
9847234|NCT03125226|Experimental|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
9847235|NCT03125395|Experimental|LUM/IVA|LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
9847236|NCT03125629|Experimental|18F-FDG PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 18F-FDG.
9847237|NCT03125629|Experimental|18F-FDG PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 18F-FDG.
9847238|NCT03125629|Experimental|68Ga-DOTA-TATE PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 68Ga-DOTA-TATE.
9847239|NCT03125629|Experimental|68Ga-DOTA-TATE PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 68Ga-DOTA-TATE.
9847240|NCT03125915|Active Comparator|CHTC as usual|Participants receive couples HIV testing and counseling following the CDC approved protocol.
9847241|NCT03125915|Experimental|CHTC + communication skills videos|The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
9847242|NCT03125915|Experimental|CHTC + substance use module|The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
9847243|NCT03125915|Experimental|CHTC + video + substance use module|The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.
9847244|NCT03125941|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
9847245|NCT03125941|Active Comparator|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
9847246|NCT03126227|Active Comparator|AR101 Powder Provided in Capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
9847247|NCT03126227|Placebo Comparator|Placebo powder|Placebo formulation in pull-apart capsules containing only excipients color-matched to AR101 study product.
9847248|NCT03126344|Experimental|King Vision video laryngoscope|
9847249|NCT03126344|Experimental|McGrath MAC video laryngoscope|
9847250|NCT03126344|Active Comparator|Macintosh|
9847251|NCT03126370|Experimental|TAF with a boosted PI and LDV/SOF|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for the next 12 weeks.~After taking TAF/FTC for 12 weeks, participants will then start taking ledipasvir 90mg/sofosbuvir 400mg (LDV/SOV, Harvoni) in combination with TAF/FTC and a boosted protease inhibitor for 4 weeks.~Participants will then return to taking TAF/FTC with a boosted protease inhibitor for the final 12 weeks of the study."
9847252|NCT03126448|Other|Group 1: Closed Index Fractures|Group 1 is clean, closed fractures undergoing index open reduction internal fixation (ORIF), intramedullary nailing (IMN) where the fracture site is accessible, or staged treatment of a pilon or plateau that was initially treated by joint spanning external fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
9847253|NCT03126448|Other|Group 2: Hardware Removal from Healed Fractures|Group 2 will include patients having a plate removed from a healed fracture without clinical evidence of infection and excluding history of open fracture. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
9986352|NCT01401946|Placebo Comparator|Placebo|
9998300|NCT01516853||Patient Group|Subjects with known or suspected iron overload will undergo serum iron measurements and a non-contrast MRI scan.
9847254|NCT03126448|Other|Group 3: Index Treatment of Fracture Nonunions|Group 3 will be patients that are undergoing an index procedure for fracture nonunion at a site where prior surgery has been undertaken for the fracture. Exclusions include bone grafting of 'critical' defects, active clinical infection, or < 3 months from index fracture fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
9847255|NCT03126539|Experimental|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
9847256|NCT03126539|Experimental|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
9847257|NCT03126682|Active Comparator|Wellbutrin during ECT 1|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 1
9847258|NCT03126682|Active Comparator|Wellbutrin during ECT 2|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 2.
9847259|NCT03126760|Experimental|Acthar Gel|Participants receive Acthar Gel under the skin once a day for 14 consecutive days
9847260|NCT03126760|Placebo Comparator|Placebo|Participants receive Placebo under the skin once a day for 14 consecutive days
9847261|NCT03126786|Active Comparator|Active|Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
9847262|NCT03126786|Sham Comparator|Control|Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
9847263|NCT03127228|Other|Standard mechanical debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with dental scalers.
9847264|NCT03127228|Experimental|Er:YAG laser-assisted debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with the aid of the laser treatment.
9847265|NCT03127358|Experimental|AiCure App|Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.
9847266|NCT03127358|No Intervention|Treatment As Usual|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.
9847267|NCT03127358|Active Comparator|AiCure with gamification|Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.
9847268|NCT03127384|Experimental|No-treatment control|
9847269|NCT03127384|Experimental|Treatment|Intradermal injection Restylane Lidocaine
9847270|NCT03127514|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
9847271|NCT03127514|Experimental|AMX0035|AMX0035 administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
9847272|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
9847273|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
9847274|NCT03127644|Placebo Comparator|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
9847275|NCT03127943|Active Comparator|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
9847276|NCT03127943|Active Comparator|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
9847277|NCT03127956|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face
9998301|NCT01516853||Control Group|Subjects with no known history of iron overload or liver disease will undergo a serum iron measurement and a non-contrast MRI scan.
9847278|NCT03128008|Experimental|Carboplatin/Paclitaxel with radiation therapy|Single arm, non randomized, open label study. Eligible subjects will receive standard of care Carboplatin IV once a week, Paclitaxel IV once a week given concurrently with daily hyperfractionated radiation therapy (RT). RT will be delivered as 6 fractions weekly.
9847279|NCT03128086|Experimental|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation: performing a spontaneous breathing trial through a T-tube and after that to assess the patient's capacity to maintain airway. In case of reach a score the patient will extubated.
9847280|NCT03128086|No Intervention|Conventional weaning|A control group of weaning from mechanical ventilation according to the usual procedure: performing a spontaneous breathing trial through a T-tube and then extubation if the patient success this trial.
9847281|NCT03128099|Experimental|Low dose VR social skills training|In the low dose condition, participants play the video game for one hour per session. This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
9847282|NCT03128099|Experimental|High dose Low dose VR social skills training|In the high dose condition, participants play the same video game twice per session (it takes them two hours). This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
9847283|NCT03128099|No Intervention|Healthy Control Participants|23 healthy control participants were recruited and consented to yield baseline comparison data. These participants did not undergo VR training. Only baseline comparison data were collected.
9847284|NCT03128372|Experimental|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
9847285|NCT03128723|Experimental|Acne Mask|The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
9847286|NCT03128892|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Noninvasive Oxygen Reserve Index - RD Lite Sensors
9847287|NCT03129100|Experimental|Ixekizumab (IXE) 80Q4W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
9847288|NCT03129100|Experimental|Ixekizumab (IXE) 80Q2W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
9847289|NCT03129100|Placebo Comparator|Placebo|Participants received subcutaneous dose of placebo.
9847290|NCT03129178|Experimental|Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
9847291|NCT03129178|Experimental|Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
9847292|NCT03129568|Experimental|CDC infusion|CDCs infusion by coronary intervention.
9847293|NCT03129945|Active Comparator|Nifedipine|Participants will be given this medication orally
9847294|NCT03129945|Active Comparator|Indomethacin|Participants will be given this medication orally
9847295|NCT03130257|Active Comparator|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure at their clinic once within the subsequent three weeks.
9847296|NCT03130257|Active Comparator|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over three weeks.
9847297|NCT03130257|Active Comparator|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
9847298|NCT03130738|Active Comparator|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
10207414|NCT05208944|Experimental|Optional Part C|THIO total 540 mg per cycle (180 mg on D1-3 Q3W) plus 350 mg cemiplimab on Day 5
10207415|NCT05208931||adhesion|the group in which the adhesion of neuroepithelial detachment was observed after Anti-vascular endothelial growth factor therapy
10207416|NCT05208931||no adhesion|group in which there was no adherence of neuroepithelial detachment after Anti-vascular endothelial growth factor therapy
10207417|NCT05208931||разрыв|group in which neuroepithelial detachment rupture was observed after anti-vascular endothelial growth factor therapy
10207418|NCT05208918|Active Comparator|PRF group|Pulsed radiofrequency application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
10207419|NCT05208918|Active Comparator|PRF plus steroids group|Pulsed radiofrequency plus Depo-Medrol (steroid) application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
10207420|NCT05208892|Experimental|SZMN Treatment Group|Patients randomized into the SZMN treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic per side.
10207421|NCT05208892|Experimental|SZMN+Dexmedetomidine Treatment Group|Patients randomized into the SZMN+Dexmedetomidine treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic along with 0.25 mcg/kg (max 10 mcg) Dexmedetomidine on each side (total of 0.5 mcg/kg, total max 20 mcg).
10207422|NCT05208892|No Intervention|No Intervention: Control Group|Patients in this group will receive the standard of care for T&A procedures within the pediatric population.
9847299|NCT03130738|Active Comparator|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
9847300|NCT03130738|Placebo Comparator|14-Day Placebo - Oil Vehicle|14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
9847301|NCT03131167|Experimental|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
9847302|NCT03131167|Placebo Comparator|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
9847303|NCT03131206|Experimental|Phase 1 RP2D of alectinib|"The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NSCLC, not everyone who participates in this research study will receive the same dose of the study drug. The dosage will depend on the number of participants who have been enrolled in the study and how well the dosage has been tolerated.~Alectinib~Oral, BID~A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days."
9847304|NCT03131206|Experimental|Cohort A|"Participants with RET-rearranged NSCLC with no previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
9847305|NCT03131206|Experimental|Cohort B|"Participants with RET-rearranged NSCLC with previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
9847306|NCT03131206|Experimental|Cohort C|"Participants with RET-rearranged thyroid cancer~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
9847307|NCT03131453|Experimental|CNP520 50 mg|50 mg capsule taken orally once daily
9847308|NCT03131453|Experimental|CNP520 15 mg|15 mg capsule taken orally once daily
9847309|NCT03131453|Placebo Comparator|Placebo|Matching placebo to 15 and 50 mg CNP520 taken orally once daily
9847310|NCT03131479|Experimental|Mild|Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
9847311|NCT03131479|Experimental|Moderate A|Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
9847312|NCT03131479|Experimental|Moderate B|Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
9847313|NCT03131479|Experimental|Severe|Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
9847314|NCT03131479|Experimental|Normal|Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.
9847315|NCT03131570|Experimental|Group 1|6 months of Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period.
9847316|NCT03131570|Placebo Comparator|Group 2|Placebo followed by Secukinumab. 3 months of placebo followed by 3 months of Secukinumab at a dose of 300 mg with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period.
9847317|NCT03131596|Experimental|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
9847318|NCT03131596|No Intervention|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
9847319|NCT03131648|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks."
9847320|NCT03131648|Placebo Comparator|Initial treatment period - Placebo Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks."
9847321|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks."
9847322|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks."
9847323|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo Q2W|"Week 16 to Week 52:~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks."
9847324|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52:~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks."
9847325|NCT03131648|Experimental|Open-label treatment - Tralokinumab + optional TCS|"Week 16 to Week 52:~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W.~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS* regimen Q2W.~*TCS = topical corticosteroids."
9847326|NCT03131648|Experimental|Open-label short-term- Tralokinumab + optional TCS|"Week 52 to Week 68 [Short term extension (Japan only)] :~Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy."
9847327|NCT03131687|Placebo Comparator|Placebo|Tirzepatide placebo and dulaglutide placebo administered subcutaneously (SC) once weekly.
9847328|NCT03131687|Experimental|1 mg Tirzepatide|1 milligrams (mg) tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
9847329|NCT03131687|Experimental|5 mg Tirzepatide|5 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
9847330|NCT03131687|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
9847331|NCT03131687|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
9847332|NCT03131687|Active Comparator|1.5 mg Dulaglutide|1.5 mg Dulaglutide administered SC once weekly. Tirzepatide placebo administered SC once weekly.
9847333|NCT03131713|No Intervention|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
9847334|NCT03131713|Experimental|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
9847335|NCT03131895|Experimental|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
9847336|NCT03131895|Experimental|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
9847337|NCT03131895|Experimental|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
9847338|NCT03131895|Experimental|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
9847339|NCT03131999|Experimental|Imatinib Mesylate 400mg capsule|56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.
9847340|NCT03131999|Placebo Comparator|Placebo Capsule|56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.
9847341|NCT03132220|Active Comparator|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
9847342|NCT03132220|Experimental|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
9847343|NCT03132246||Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group went on to develop an infection."
9847344|NCT03132246||Not Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group did not go on to develop an infection."
9935094|NCT04206163|Experimental|Acute myocarditis|Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.
9847345|NCT03132298|Experimental|Implicit Theories of Personality Program|"This program is self-administered, computer-based, and 30 minutes in length. Content is designed to maximize relevance for youths with internalizing distress. The program includes 5 elements: 1. An introduction the concept of neuroplasticity; 2. Testimonials from older youths describing beliefs that people's traits are malleable, given the brain's capacity for change; 3. Further vignettes by older youths describing times when they used growth mindsets to cope with peer rejection, hopelessness, and feared embarrassment; 4. A worksheet describing strategies for applying these principles to participants' lives; 5. An exercise wherein participants write notes to younger children, using newly-gleaned information about the malleability of personal traits to help them to cope with setbacks"
9847346|NCT03132298|Active Comparator|Control Program|The Control Program is a computer-based session of supportive therapy (ST), designed to encourage youths to identify and express feelings. ST does not teach specific skills or beliefs and has been shown to be less effective than cognitive-behavioral interventions in reducing youth internalizing distress. Here, ST was designed to control for nonspecific intervention elements (eg. completing an interactive computer program) and to encourage youths to share emotions with others. ST included the same number of reading/writing activities as the experimental program and took the same amount of time (30 mins.) to complete.
9847347|NCT03132571|Experimental|Naltrexone with Bupropion|Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
9847348|NCT03132571|Placebo Comparator|Placebo with Bupropion|Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
9847349|NCT03133481|Active Comparator|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
9847350|NCT03133481|Active Comparator|Femoral Nerve Block|Participants will be randomized using block randomization.
9847351|NCT03133676|Experimental|KA34 Active Drug|KA34 active drug in the dose range of 50 - 400 ug per knee
9847352|NCT03133676|Placebo Comparator|Placebo|Placebo is the formulation for KA34.
9847353|NCT03133767|Experimental|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
9847354|NCT03133767|Experimental|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
9847355|NCT03134092|No Intervention|Generalized Risk Communication (GRC)|Generalized Risk Communication (GRC): Participants in this arm will receive standard discharge instructions similar to instructions they would receive during usual care. This arm represents a standardized way of communicating post-discharge risk-benefit information about treatment options for patients with back pain and renal colic. The GRC, includes a standardized discharge information sheet about the clinical condition of interest and a written overview of population based evidence describing comparative benefits and side effects of alternative classes of medication acute pain.
9847356|NCT03134092|Active Comparator|Probabilistic Risk Communication (PRT)|Probabilistic Risk Communication (PRT): The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
9847357|NCT03134092|Active Comparator|Narrative Enhanced Risk Tool (NERT)|Narrative Enhanced Risk Tool (NERT): Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale related to prolonged opioid use. Narrative videos are developed from actual patient stories - put into a in a structured format of ~ 2-minute length and recorded.
9847358|NCT03134144|Experimental|First without exoskeleton then with exoskeleton|"Subject will perform the conditions as described under model description first without the exoskeleton and then with the exoskeleton."
9847359|NCT03134144|Experimental|First with exoskeleton then without exoskeleton|"Subject will perform the conditions as described under model description first with the exoskeleton and then without the exoskeleton."
9847360|NCT03134183|Experimental|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
9847361|NCT03134183|Experimental|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
9847362|NCT03134209|Experimental|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
9847363|NCT03134209|Active Comparator|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
9847364|NCT03134209|Active Comparator|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
9847365|NCT03134222|Experimental|Lanraplenib 30 mg|Lanraplenib + filgotinib placebo for 48 weeks
9847366|NCT03134222|Experimental|Filgotinib 200 mg|Filgotinib + lanraplenib placebo for 48 weeks
9847367|NCT03134222|Placebo Comparator|Placebo|Filgotinib placebo + lanraplenib placebo for 12 weeks
9847368|NCT03134222|Experimental|Placebo to Lanraplenib 30 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.
9847369|NCT03134222|Experimental|Placebo to Filgotinib 200 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.
9847370|NCT03134248|Experimental|MyDay Toric|Participants were randomized to wear a new pair of MyDay Toric lenses each day for one week during the cross over study
9847371|NCT03134248|Active Comparator|1-Day Acuvue Moist for Astigmatism|Participants were randomized to wear a new pair of 1-Day Acuvue Moist Toric lenses each day for one week during the cross over study
9847372|NCT03134248|Active Comparator|Dailies Aquacomfort Plus Toric|Participants were randomized to wear a new pair of Dailies Aquacomfort Plus Toric lenses each day for one week during the cross over study
9847373|NCT03134313|Experimental|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
9847374|NCT03134326|Experimental|Test group|All subjects will be enrolled in the test group and will receive both R1-25 and R2-25 Pulse Oximeter Sensors
9847375|NCT03134599|Active Comparator|etafilcon A|
9847376|NCT03134599|Active Comparator|methafilcon A - Interozzo|
9847377|NCT03134599|Active Comparator|methafilcon A - CVI|
9847378|NCT03134703|Experimental|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
9847379|NCT03134703|Active Comparator|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
9847380|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
9847381|NCT03134911||anticoagulation non controlled patients|Treated with VKA
9847382|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria~Clinical diagnosis of MCI made by a specialist* in a patient who fulfils the established clinical consensus criteria for MCI [NIA/AA 2011] specifically:~Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant~Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.~Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions~Not demented"
9847383|NCT03134963||Alzheimer disease|"NIA/AA criteria~Meets the criteria for dementia~o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains~Insidious or gradual onset~Clear history of worsening cognition by report or observation~The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:~Amnestic: impaired learning and recall of recently learned information~Non amnestic: language/visuospatial/executive dysfunction"
9847384|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:~Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.~One or more of:~Onset of dementia within 3 months of a diagnosed stroke~Abrupt deterioration in cognitive function~Fluctuating, stepwise progression of cognitive deficits"
9847385|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria~No evidence of subjective or objective memory impairment on cognitive testing~No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
9847386|NCT03134989|Other|Cochlear implant recipients|Study group is comprised of cochlear implant patients already identified as candidates and undergoing surgery.
9847387|NCT03135015|Other|Lean Participants|Participants with BMI >18.5 and <25.0kg/m²
9847388|NCT03135015|Other|Overweight/Obese Participants|Participants with BMI ≥25.0 and <35.0kg/m²
9847389|NCT03135028|Experimental|ENTO monotherapy (Group A)|Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
9847390|NCT03135028|Experimental|ENTO + cytarabine + daunorubicin (Group B)|"Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission [CR] or morphologic complete remission with incomplete blood count recovery [CRi] and do not require or cannot proceed to allogeneic stem cell transplantation [SCT] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles."
9847391|NCT03135210|Active Comparator|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
9847392|NCT03135210|Experimental|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
9847393|NCT03135379|Experimental|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
9847394|NCT03135379|Placebo Comparator|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
9847395|NCT03135431|Experimental|Salpingectomy|Bilateral salpingectomy following cesarean delivery
9847396|NCT03135431|Active Comparator|Tubal Ligation|Bilateral tubal ligation following cesarean delivery via Parkland or modified Pomeroy methods.
9847397|NCT03135522|Active Comparator|Zinc Acetate 50 mg oral capsule|50 mg zinc acetate oral capsules, over-encapsulated, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
9847398|NCT03135522|Placebo Comparator|Placebo oral capsule|Placebo matched to zinc acetate 50 mg oral capsule active arm, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
9847399|NCT03135535|Experimental|Avex Footbeat|Subjects will receive a new pair of diabetic shoes with BOA shoelace closure and a pair of AVEX Footbeat insoles, which include a micro-mobile compression pump. The entire system is named 'intervention shoes' for simplicity. They will be instructed to wear the intervention shoes on daily basis for 4 weeks for duration of at least 4 hours per day.
9847400|NCT03135548|Experimental|Spesolimab (low dose)|
9847401|NCT03135548|Experimental|Spesolimab (high dose)|
9847402|NCT03135548|Placebo Comparator|Placebo|
9847403|NCT03135899|Experimental|BI 443651|
9847404|NCT03135899|Placebo Comparator|Placebo|
9847405|NCT03136068|Experimental|Digoxin|Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance
9847406|NCT03136068|Placebo Comparator|Placebo|Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume
9847407|NCT03136107|Experimental|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
9847408|NCT03136107|Active Comparator|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
9847409|NCT03136107|No Intervention|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
9847410|NCT03136159|Experimental|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
9847411|NCT03136198|Experimental|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
9847412|NCT03136198|Placebo Comparator|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
9847413|NCT03136328|Experimental|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
9847414|NCT03136367|Experimental|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
9847415|NCT03136367|Experimental|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
9847416|NCT03136367|No Intervention|Arm 3: Usual Care|In the usual care arm, surgeons provided their standard information about breast cancer
9847417|NCT03136380|Experimental|Part 1: Group A|Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
9847418|NCT03136380|Experimental|Part 1: Group B|Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
9847419|NCT03136380|Experimental|Part 1: Group C|Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
9847420|NCT03136380|Experimental|Part 2: Group D|Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
9847421|NCT03136380|Experimental|Part 2: Group E|Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.
9847422|NCT03136484|Experimental|Semaglutide + canagliflozin placebo|
9847423|NCT03136484|Active Comparator|Canagliflozin + semaglutide placebo|
9847424|NCT03136861|Experimental|Secukinumab 150 mg (Group A)|Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
9847425|NCT03136861|Placebo Comparator|Placebo (Group B)|Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
9847426|NCT03136861|Active Comparator|Arm A1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
9847427|NCT03136861|Active Comparator|Arm A2|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
9847428|NCT03136861|Active Comparator|Arm A3|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
9847429|NCT03136861|Active Comparator|Arm B1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
9847430|NCT03136861|Active Comparator|Arm B2|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
9847431|NCT03136913|Active Comparator|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
9847432|NCT03136913|Active Comparator|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
9847433|NCT03137069|Placebo Comparator|Cohort 1: Placebo|Participants received matching placebo twice daily from Day 1 to 56.
9847434|NCT03137069|Experimental|Cohort 1: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
9847435|NCT03137069|Placebo Comparator|Cohort 2: Placebo|Participants received matching placebo up to twice daily from Day 1 to 56.
9847436|NCT03137069|Experimental|Cohort 2: GDC-0853 50mg QD|Participants received GDC-0853 50mg once daily from Day 1 to 56.
9847437|NCT03137069|Experimental|Cohort 2: GDC-0853 150mg QD|Participants received GDC-0853 150mg once daily from Day 1 to 56.
9847438|NCT03137069|Experimental|Cohort 2: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
9847439|NCT03137121|Experimental|Olanzapine|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
9847440|NCT03137121|Placebo Comparator|Placebo|Patients will receive a placebo orally for 1 to 7 days daily.
9847441|NCT03137303|Placebo Comparator|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
9847442|NCT03137303|Experimental|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Pre and post-bronchodilator using Albuterol (BD) spirometry"
9847443|NCT03137459|Experimental|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
9847444|NCT03137459|Active Comparator|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
9998193|NCT01515930|Active Comparator|Active Caregiver and Active Child|Parent & Child Computer-Delivered Motivational Intervention will be delivered to participants. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered behavior change counseling intervention for children with diabetes to improve completion of daily diabetes care.
9847446|NCT03137784|Other|1(NVA237 50 ug/NVA237 25 ug/placebo)|Treatment sequence: NVA 237 50 ug, 25 ug and placebo
9847447|NCT03137784|Other|2(NVA237 50 ug/placebo/NVA237 25 ug)|Treatment sequence: NVA 237 50 ug, placebo and 25 ug
9847448|NCT03137784|Other|3 (NVA237 25 ug/NVA237 50 ug/placebo)|Treatment sequence: NVA237 25 ug, 50 ug and placebo
9847449|NCT03137784|Other|4 (NVA237 25 ug/placebo/NVA237 50 ug)|Treatment sequence: NVA 237 25 ug, placebo and 50 ug
9847450|NCT03137784|Other|5 (placebo/NVA237 50 ug/ NVA237 25 ug)|Treatment sequence: Placebo, NVA237 50 ug and 25 ug
9847451|NCT03137784|Other|6 (placebo/ NVA237 25 ug/NVA237 50 ug)|Treatment sequence: placebo, NVA237 25 ug and 50 ug
9847452|NCT03137992|Experimental|Test Product (tiotropium bromide inhalation powder)|Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
9847453|NCT03137992|Active Comparator|Reference Product (Spiriva®)|Single dose of reference product (Spiriva®) 18 mcg
9847454|NCT03137992|Placebo Comparator|Placebo|Single dose of placebo inhalation powder
9922813|NCT00843271||MESA Lung|MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
9922814|NCT00843297|Active Comparator|CG|Coolgard: invasive Cooling
9922815|NCT00843297|Active Comparator|AS|ArcticSun: Surface-Cooling
9922816|NCT00843297|Sham Comparator|UnCOOL|No Cooling-Therapy due to non-operational cooling-devices
9922817|NCT00843336|Experimental|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that measures urinary estrogen and LH and provides users with low, high, or peak fertility readings.
9922818|NCT00843336|Active Comparator|Cervical mucus monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
9922819|NCT00843362|Experimental|1|24-hours vaginal dinoprostone pessary
9922820|NCT00843362|Active Comparator|2|Vaginal dinoprostone gel
9922821|NCT00843388|Active Comparator|1|60 days treatment with tablet hexalacton 25 mg OD.
9922822|NCT00843388|Placebo Comparator|2|Inactive drug of 25 mg OD
9922823|NCT00843427|Experimental|Aphasia - CIAT|Patients with aphasia >1 year after left MCA stroke who will be randomized to receive CIAT
9922824|NCT00843427|No Intervention|Aphasia - observation|Patients with aphasia >1 year after left MCA stroke who will be randomized to no intervention (observation)
9922825|NCT00843440|Experimental|Bevacizumab|Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
9847455|NCT03138382|Experimental|Treatment then sham|20 subjects will be randomised to first receive active vestibular nerve stimulation during indirect calorimetry. Then 2 weeks later they will return for sham stimulation during indirect calorimetry.
9847456|NCT03138382|Experimental|Sham then treatment|20 subjects will be randomised to first receive sham stimulation during indirect calorimetry. Then 2 weeks later they will return for active vestibular nerve stimulation during indirect calorimetry.
9847457|NCT03138577|Other|Dose Cohort 7|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
9847458|NCT03138577|Other|Dose Cohort 6|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
9847459|NCT03138577|Other|Dose Cohort 5|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
9847460|NCT03138577|Other|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
9847461|NCT03138577|Other|Dose Cohort 3|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
9847462|NCT03138577|Other|Dose Cohort 2|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
10207423|NCT05208879||Case group.|"Patients with genetically proven familial hypocholesterolemia, who will accept to participate in this study and have been treated for this pathology since 1990 in the Department of Gastroenterology and Paediatric Nutrition (Pr Peretti) and continue their follow-up into adulthood at the GHE (Groupement Hospitalier Est) in Lyon in the endocrinology-nutrition service (Pr Moulin).~They may be girl/woman or boy/man over 6 years of age and over 12 kg at the time of inclusion (age required for cooperation on macular pigment measurement), agreeing to participate in the study with clear and informed consent. These patients are covered by social security."
9847463|NCT03138577|Other|Dose Cohort 1|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
9847464|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 100 mg|Participants with UC having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847465|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 200 mg|Participants with UC having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847466|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 100 mg|Participants with CD having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847467|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 200 mg|Participants with CD having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847468|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 150 mg|Participants with UC having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847469|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 300 mg|Participants with UC having baseline weight of >=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847470|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 150 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847471|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 300 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
9847472|NCT03138798|Experimental|Laboraide TM dental support device|Receive Laboraide
9847473|NCT03138798|No Intervention|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
9847474|NCT03138876|Other|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
9847475|NCT03138967|Experimental|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
9847476|NCT03138967|Active Comparator|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
9847477|NCT03139032|Experimental|APD334|APD334 active treatment for 12 weeks.
9847478|NCT03139240|Experimental|Gestational age <7 weeks|Women with a gestational age <7 weeks will be randomized to oxycodone 10mg oral vs placebo
9922826|NCT00843453|Other|1|Comparison of serum vitamin and B12 concentrations of PPI and non-PPI groups
9847479|NCT03139240|Experimental|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
9847480|NCT03139279|Experimental|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
9847481|NCT03139279|Placebo Comparator|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
9847482|NCT03139448|Active Comparator|Oxygen via nasal cannula (Standard of Care)|The anesthesia provider will supply oxygen via nasal cannula at oxygen flow rates as per standard of care routine at Vanderbilt University Medical Center.
9847483|NCT03139448|Experimental|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
9847484|NCT03139552|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
9847485|NCT03139552|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
9847486|NCT03139552|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
9847487|NCT03139578|Experimental|C 8.5\C 9.0\T 8.5\T 9.0|Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
9847488|NCT03139578|Experimental|C 9.0\C 8.5\T 9.0\T 8.5|Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
9847489|NCT03139578|Experimental|T 8.5\T 9.0\C 8.5\C 9.0|Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
9847490|NCT03139578|Experimental|T 9.0\T 8.5\C 9.0\C 8.5|Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
9847491|NCT03139604|Experimental|Itacitinib|Itacitinib plus corticosteroids
9847492|NCT03139604|Placebo Comparator|Placebo|Matching placebo plus corticosteroids
9847493|NCT03140254|Active Comparator|comparator|Chlorhexidine gluconate
9847494|NCT03140254|Experimental|experimental|BDIP-0001
9847495|NCT03140254|Placebo Comparator|placebo|Vehicle
9847496|NCT03140631|No Intervention|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of <200s or return to pre-procedural baseline prior to sheath removal.
9847497|NCT03140631|Active Comparator|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of <200s or return to preprocedural baseline prior to removal of vascular sheaths.
9847498|NCT03140722|Experimental|vadadustat|Vadadustat daily oral dose, adjustable based on Hb level
9517010|NCT03310281|Active Comparator|ALK-T03|AKL-T03 is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
9847499|NCT03140722|Active Comparator|epoetin alfa|Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
9847500|NCT03141086|Experimental|Group 1|LML134, then placebo
9847501|NCT03141086|Experimental|Group 2|Placebo, then LML134
9847502|NCT03141151|Experimental|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
9847503|NCT03141151|Active Comparator|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
9847504|NCT03141242|Active Comparator|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
9847505|NCT03141242|Placebo Comparator|Mailed Resources|Participants will receive printed advance care planning resources by mail.
9847506|NCT03141281|Experimental|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
9847507|NCT03141281|Experimental|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
9847508|NCT03141281|Experimental|IADL training|Participants will be enrolled in American Association of Retired Persons' web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
9847509|NCT03141281|Active Comparator|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
9847510|NCT03141307|Active Comparator|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
9847511|NCT03141307|Placebo Comparator|Control|This group will receive the standard of care currently used (paper-based brochure)
10207424|NCT05208879||Control group.|The control group consists of children over 6 years old or adult patients, followed routinely in the ophthalmology department of the Edouard Herriot Hospital, Lyon (Pr Kodjikian) not suffering from genetic hypocholesterolemia and requiring a fundus examination as part of the usual follow-up of their ocular pathology, if this pathology does not interfere with the macular pigment density. An additional measurement of the macular pigment density will be made during this examination. The control group is only needed for the macular pigment analysis. No control group is considered for the characterization of plasma lutein and zeaxanthin deficiency and for the analysis of oxidative stress, so there will be no additional blood sampling for control patients.
10207425|NCT05208853|Experimental|Anti CD30 CAR T cells|"Patients receive anti CD30 CAR-T cells on day 0 after lymphodepleting treatment.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to anti CD30 CAR-T cells infusion."
9847512|NCT03141372|Active Comparator|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
9847513|NCT03141372|Active Comparator|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
9847514|NCT03141528|Active Comparator|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
9847515|NCT03141528|Experimental|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
9847516|NCT03141788|Other|3M Clear Aligner|Clear Aligner for Orthodontic Treatment
9847517|NCT03141905|Active Comparator|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVRSDRS weekly remote monitoring
9847518|NCT03141905|Placebo Comparator|Usual Care|Standard clinical care
10207426|NCT05208827|Experimental|Experimental group|Take two tablets once a day.Each tablet contains 800 units of vitamin D3, for a total of 1600 units taken orally daily
10207427|NCT05208827|Placebo Comparator|Control Group|The control group received the same packaged, similar-looking, similar-tasting placebo from the same manufacturer, containing starch, peanut oil (no pharmaceutical value)
10207428|NCT05208801|Sham Comparator|Control|a sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle
10207429|NCT05208801|Active Comparator|Morphine|
10207430|NCT05208801|Experimental|Morphine+bupivicaine|
10207431|NCT05208788||Renal transplant patients - group 1|Renal transplant patients with stable renal function parameters (mean SCr (or cystatin C) or mean eGFR based on creatinine and / or cystatin C defined as changes ≤ ±15 % for at least three consecutive ambulatory controls).
10207432|NCT05208788||renal transplant patients - group 2|Renal transplant recipients with stable renal function at inclusion, facing a pre-defined event during the course of the study. Pre-defined events are Acute Rejection (AR), viral transplant-associated infection (e.g. BKV), bacterial infection (febrile urinary tract infection (fUTI)), calcineurin-inhibitor (CNI) toxicity, and acute tubular necrosis (ATN).
9847519|NCT03141931|Experimental|Supplement|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
9847520|NCT03141931|Placebo Comparator|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
9847521|NCT03142438|Experimental|F&P Seal Improvement Project|participants will be placed on this arm for a total of 14 +- 4 days from visit 1. participants will be using the trial mask during this treatment arm
9847522|NCT03142451|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
9847523|NCT03142451|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
9847524|NCT03142750|Experimental|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
9847525|NCT03142932|Active Comparator|Control|A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute (NCI) 5 A's model.
9847526|NCT03142932|Experimental|COach2Quit|"A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute's 5 A's model.~Participants in the COach2Quit arm will be provided with an individualized carbon monoxide (iCO) monitor along with instructions on the use of the monitor and the COach2Quit application."
9847527|NCT03143101|Experimental|FluMist trivalent (2015-2016)|Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
9847528|NCT03143101|Experimental|FluMist Quadrivalent (2015-2016)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
9847529|NCT03143101|Experimental|FluMist Quadrivalent (2017-2018)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
9847530|NCT03143166|Experimental|All participants|Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
9847531|NCT03143569|Active Comparator|aPTT nomogram|aPTT guided heparin management
9847532|NCT03143569|Experimental|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
9847533|NCT03143855|Experimental|Lorcaserin|
9847534|NCT03143855|Placebo Comparator|Control Group|
9847535|NCT03143894|Active Comparator|Active tDCS first|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
9847536|NCT03143894|Sham Comparator|Sham tDCS first|Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.
9847537|NCT03144089|Active Comparator|Guedel oral airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Guedel oral airway first and measurements were taken during breaths 6 through 10. After its removal the Articulated Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
9847538|NCT03144089|Experimental|Articulated Oral Airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Articulated oral airway first and measurements were taken during breaths 6 through 10. After its removal the Guedel Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
9847539|NCT03144180|No Intervention|Control|The Q-cup will not be used to collect umbilical cord blood.
9847540|NCT03144180|Active Comparator|Study Group|The Q-cup will be used to collect umbilical cord blood.
9847541|NCT03144518|Experimental|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
9847542|NCT03144518|Active Comparator|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
9847543|NCT03144635|Experimental|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
9847544|NCT03144687|Experimental|Cohort A|Participants with MF who were tolerating a ruxolitinib dose of less than 20 milligrams (mg) daily with no dose increase or no dose modification in the 8 weeks before screening visit received a combination of the itacitinib at the dose of 200 mg, orally, once daily (QD) and ruxolitinib, orally, twice daily (BID) at their previous stable dose (must had been < 20 mg daily). Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
9847545|NCT03144687|Experimental|Cohort B|Participants with MF who progressed after initial reduction in spleen with ruxolitinib treatment, progressed or discontinued for hematologic toxicities received treatment with itacitinib alone at the dose of 600 mg QD. Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
9847546|NCT03144804|Experimental|Lamivudine|"Lamivudine administered orally every 4 weeks~Treatment cycles will last 28 consecutive days~The dosage will be determine by the PI"
9847547|NCT03145064|Experimental|Zanubrutinib|Participants received zanubrutinib BID.
9847548|NCT03145207|Other|name brand patch|name brand lidocaine patch
9847549|NCT03145207|Other|generic patch|generic lidocaine patch
9847550|NCT03145207|Other|name brand patch-early|name brand lidocaine patch-early
9847551|NCT03145207|Other|name brand patch-late|name brand lidocaine patch-late
9847552|NCT03145207|Other|generic patch-early|generic lidocaine patch-early
9847553|NCT03145207|Other|generic patch-late|generic lidocaine patch-late
9847554|NCT03145207|Other|both patches|brand name and generic lidocaine patch
9847555|NCT03145259|Other|Diclofenac patch|Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]
9847556|NCT03145259|Other|Diclofenac solution|Study Session 2: diclofenac sodium solution (PK) [47 h study duration]
9847557|NCT03145259|Other|Diclofenac patch and solution|Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) [51 h study duration]
9847558|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
9847559|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
9847560|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
9847561|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
9847562|NCT03146403|Experimental|GEN-003|60μg of each GEN-003 antigen with 50μg Matrix-M2 adjuvant, administered as a 0.5mL intramuscular (IM) injection
9847563|NCT03146403|Placebo Comparator|Placebo|0.9% normal saline administered as a 0.5mL intramuscular (IM) injection
9847564|NCT03146585||Patients on artificial ventilation|
9847565|NCT03146585||Patients on renal replacement therapy|
9847566|NCT03146585||Patients with targeted temperature management|
9847567|NCT03146663|Experimental|Arm A|NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
9847568|NCT03146663|Experimental|Arm B|NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
9847569|NCT03146741|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg)|
9847570|NCT03146806|Experimental|Intranasal ketamine treatment|Study participants who are receiving intranasal ketamine treatments.
9847571|NCT03147248|Active Comparator|Cohort 1: CT-P13 IV 3 mg/kg|CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
9847572|NCT03147248|Experimental|Cohort 2: CT-P13 SC 90 mg|CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
9847573|NCT03147248|Experimental|Cohort 3: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
9847574|NCT03147248|Experimental|Cohort 4: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
9847575|NCT03147248|Experimental|Arm 1: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
9847576|NCT03147248|Active Comparator|Arm 2: CT-P13 IV 3 mg/kg|CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)
9847577|NCT03147495||the study group|The participants with medial compartment knee osteoarthritis and without lateral compartment knee osteoarthritis according to the Ahlbäck classification.
9847578|NCT03147495||the control group|The healthy volunteers without knee osteoarthritis according to the American College of Rheumatology criteria for the classification and reporting of OA of the knee joint. Radiographic evidence of the knee with Ahlbäck classification grade 0.
9847579|NCT03147690|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
9922827|NCT00843453|Experimental|2|Comparison of baseline and end of treatment serum vitamin B12 and MMA concentrations.
9922828|NCT00843505|Experimental|1|Participants will take part in a telemedicine smoking cessation program.
9922829|NCT00843505|Active Comparator|2|Participants will take part in a telephone quitline smoking cessation program.
9922830|NCT00843544|Experimental|Integrative Medicine|
9922831|NCT00843544|No Intervention|Control|
9922832|NCT00843557||all ICU admissions|patients admitted to the ICU for greater then 72hrs
9922833|NCT00843570|No Intervention|1|Natural FER (frozen embryo replacement)
9922834|NCT00843570|Active Comparator|2|HRT-FER (Down regulated frozen embryo replacement)
9922835|NCT00843583||resistant hypertension subjects|subjects with resistant hypertension
9922836|NCT00843596|Experimental|vacuum device - suction cup|
9922837|NCT00843609|Experimental|Continuous glucose monitoring|Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
9922838|NCT00843609|No Intervention|Control|Using SMBG with standard routine instructions
9922839|NCT00843648||preterms|mother and preterm babies
9922840|NCT00843648||term-bfing|term breastfed babies and mothers
9922841|NCT00843648||term-PIF|term non breastfed babies and mothers
9922842|NCT00843648||c-section|c-section babies and their mothers
9922843|NCT00843661|Experimental|Ezetimibe and fenofibrate|
9922844|NCT00843661|Active Comparator|Pravastatin|
9922845|NCT00843700|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy, 16 individual sessions within 32 weeks
9922846|NCT00843700|Active Comparator|Individual Psychotherapy|Individual Psychotherapy, 16 individual sessions within 32 weeks
9922847|NCT00843739|Experimental|EMST|Four week device driven strength training program
9922848|NCT00843739|Sham Comparator|sham|Four week sham device driven training program
9922849|NCT00843739|No Intervention|Control|Four weeks of no intervention
9847580|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
9847581|NCT03148236|Active Comparator|Vitamin C|
9847582|NCT03148236|Placebo Comparator|Placebo|
9847583|NCT03148262|Experimental|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
9847584|NCT03148262|Placebo Comparator|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
9847585|NCT03148470|Experimental|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
9847586|NCT03148470|Experimental|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
9847587|NCT03148691|Placebo Comparator|Vehicle|Vehicle Topical Solution
9847588|NCT03148691|Active Comparator|A-101 Low Dose|A-101 Low Dose Topical Solution
9847589|NCT03148691|Active Comparator|A-101 High Dose|A-101 High DoseTopical Solution
9847590|NCT03149042||CCTA|Patients who are scheduled for clinically mandated elective invasive coronary angiography (ICA) at Buffalo General Hospital.
9847591|NCT03149055|Experimental|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
9847592|NCT03149172|Experimental|Equimatrix®|Equimatrix® + Mucograft or alternatives
9847593|NCT03149172|Experimental|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
9847594|NCT03149172|Experimental|Endobon®|Endobon® + Mucograft or alternatives
9847595|NCT03149328|Experimental|Northern Alberta Renal Program (NARP)|Provide in NARP (intervention group), 1) an electronic tool (ePRO) that facilitates real time PRO data collection and feedback in clinical practice, and 2) educational support to multidisciplinary home dialysis clinicians about how to use PROs routinely in their practice.
9847596|NCT03149328|No Intervention|Southern Alberta Renal Program (SARP)|In SARP (comparator group), clinicians will not receive PRO feedback or education sessions.
9847597|NCT03149848|Experimental|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
9847598|NCT03149848|Experimental|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
9847599|NCT03149887|Experimental|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
9847600|NCT03149887|Active Comparator|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
9847601|NCT03149991|Active Comparator|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
9847602|NCT03149991|Placebo Comparator|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
9847603|NCT03150043|Other|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
9847604|NCT03150056|Experimental|GSK525762 + Abiraterone (+ Prednisone) (Arm A)|
9517011|NCT03310281|Active Comparator|AKL-T09|AKL-T09 is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
9517012|NCT03310242|Experimental|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
9847605|NCT03150056|Experimental|GSK525762 + Enzalutamide (Arm B)|
9847606|NCT03150082|Experimental|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
9847607|NCT03150082|Experimental|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
9847608|NCT03150108|Experimental|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
9847609|NCT03150108|Experimental|Participants of Japanese Descent|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
9847610|NCT03150199|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
9922850|NCT00843765|Active Comparator|TCM integrated group|800 patients with acupuncture, massage and basic Chinese medicine treatment
9922851|NCT00843765|Active Comparator|Western Medicine group|400 patients with modern rehabilitation techniques and Western Medicine basic treatment
9847611|NCT03150199|Active Comparator|MI-Based Health Education Intervention|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet) and will use motivational interviewing techniques to facilitate the consideration of behavior change.
9517013|NCT03310242|Experimental|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
10207433|NCT05208788||Patients with Chronic Kidney Disease Stage IV and V (CKD IV-V) - group 3|Patients with CKD IV-V (and maintained urine output, without renal replacement therapy and without pre-defined events).
9847612|NCT03150485|Experimental|etafilcon A Toric Multifocal|
9847613|NCT03150485|Active Comparator|etafilcon A Multifocal|
9847614|NCT03150589|Experimental|SB11 (Proposed ranibizumab biosimilar)|
9847615|NCT03150589|Active Comparator|Lucentis (ranibizumab)|
9847616|NCT03150719|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
9847617|NCT03150719|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
10207434|NCT05208788||Healthy controls|Healthy children serve as control group
9847618|NCT03150758|Experimental|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
9847619|NCT03150875|Experimental|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
9847620|NCT03150875|Active Comparator|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
9847621|NCT03151148|Experimental|TMT Lotion|The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to active TMT will apply 2 grams of TMT to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
9847622|NCT03151148|Placebo Comparator|Placebo Lotion|Placebo lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to placebo will apply 2 grams of placebo to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
9847623|NCT03151265|Experimental|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
9847624|NCT03151265|Experimental|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
9847625|NCT03151395|Other|Total Group|Moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) patients with at least 1 documented moderate or severe Acute exacerbation of COPD (AECOPD) in the year before enrolment and for whom sputum and blood samples are collected during specified visits
9847626|NCT03151434|Active Comparator|Group #1|US Guided Single Shot Paravertebral Block
9847627|NCT03151434|Active Comparator|Group #2|US Guided Paravertebral Catheter
9847628|NCT03151434|Active Comparator|Group #3|Thoracic Epidural
9847629|NCT03151551|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps."
9847630|NCT03151551|Active Comparator|Adalimumab|"80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps."
9847631|NCT03152019|Active Comparator|Protopic® 0.1% (Tacrolimus) ointment|Protopic® 0.1% ointment, packed in blinded tube of 30g.
9847632|NCT03152019|Placebo Comparator|Placebo ointment|Same formulation as the Protopic® 0.1% ointment but without tacrolimus, packed in blinded tube of 30g.
9847633|NCT03152084|Experimental|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
9847634|NCT03152084|Experimental|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between >90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
10207435|NCT05208775|Experimental|PDT group|After enrollment, patients were injected with photosensitizer at a dose of 2mg/kg, and received photodynamic irradiation 48 hours later.
10207436|NCT05208775|Active Comparator|ESD group|Patients received standard ESD treatment after enrollment
10207437|NCT05208749|Active Comparator|Rotablation|Use of rotational atherectomy first-line if NC balloon does not fully open
9847635|NCT03152084|Experimental|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
9922852|NCT00843791|Placebo Comparator|Placebo|Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
10207438|NCT05208749|Active Comparator|Shockwave IVL|Use of Shockwave IVLS first-line if NC balloon does not fully open
10207439|NCT05208671|Experimental|NOURISH Food Box|12-week food assistance with low Dietary Inflammatory Index (DII) foods
10207440|NCT05208671|No Intervention|Wait-list Control|Wait-list control group eligible to receive NOURISH box after study period
9847636|NCT03152110|Experimental|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
9847637|NCT03152136|Experimental|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
9847638|NCT03152136|Sham Comparator|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
9847639|NCT03152136|No Intervention|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
9847640|NCT03152552|Experimental|LIK066 2.5mg|Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
9847641|NCT03152552|Experimental|LIK066 10mg|Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
9847642|NCT03152552|Experimental|LIK066 50mg|Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
9847643|NCT03152552|Active Comparator|Empagliflozin|Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
9847644|NCT03152552|Placebo Comparator|Placebo|Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.
9847645|NCT03152591|Experimental|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
9847646|NCT03152591|Placebo Comparator|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
9847647|NCT03153956|Experimental|Active Treatment Arm|Personally calibrated bio-mechanical device
9847648|NCT03153956|Placebo Comparator|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
9847649|NCT03154047|Experimental|Open label|Open Label Study Drug NEOD001
9847650|NCT03154086|Experimental|Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg|Subjects will receive single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847651|NCT03154086|Experimental|Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847652|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847653|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847654|NCT03154086|Experimental|Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed|Subjects will receive single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847655|NCT03154086|Experimental|Part A: Cohort 2: Placebo Fasted/Placebo Fed|Subjects will receive single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9922853|NCT00843791|Active Comparator|2|Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
9847656|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150 mg/Placebo|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847657|NCT03154086|Experimental|Part A:Cohort 3: Placebo/GSK3352589 400 mg|Subjects will receive single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847658|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
9847659|NCT03154086|Experimental|Part B: GSK3352589|Subjects will receive repeat oral doses of GSK3352589 of 5 mg, 15 mg, 50 mg, 100 mg or 200 mg twice daily administered for 14 days.
9847660|NCT03154086|Placebo Comparator|Part B: Placebo|Subjects will receive repeat oral doses of placebo twice a day tablet administered for 14 days.
9847661|NCT03154333|Experimental|diacerein 1% ointment|diacerein 1% ointment will be used for 8 weeks
9847662|NCT03154333|Placebo Comparator|vehicle ointment|vehicle ointment will be used for 8 weeks
9847663|NCT03154476|Experimental|Sildenafil|Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
9847664|NCT03154476|Placebo Comparator|Placebo|Subjects will receive placebo times per day for 12 months.
9847665|NCT03154658|Experimental|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
9847666|NCT03154658|Active Comparator|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
9847667|NCT03154710|Experimental|Web-application follow up|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
9847668|NCT03154710|No Intervention|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
9847669|NCT03155178|Experimental|3M CHG/IPA Prep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
9847670|NCT03155178|Active Comparator|ChloraPrep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
9847671|NCT03155269|Experimental|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
9847672|NCT03155269|Other|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
9847673|NCT03155724|Experimental|MultiPole Pacing|Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.
9847674|NCT03155945|Experimental|Olorinab 25 mg TID|Participants received olorinab 25 milligrams (mg) tablet by mouth, three times daily (TID) for 8 weeks
9847675|NCT03155945|Experimental|Olorinab 100 mg TID|Participants received olorinab 100 mg oral tablets TID for 8 weeks
9847676|NCT03156270|Experimental|Vivaer Stylus Treatment|Thermal treatment of the submucosal tissue including cartilage in the internal nasal valve area
9847677|NCT03156543|Experimental|Group A|This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
9847678|NCT03156543|Experimental|Group B|This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.
9847679|NCT03156621|Experimental|Alirocumab SC Q2W|"Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
10207441|NCT05208658|Experimental|Classical Vision Therapy Treatment: vision therapy exercises for fusional vergence abilities|"The Experimental Group (EG) it consist in a Classical Vision Therapy Treatment. This group will do weekly office-based therapy of 45 minutes of visual exercises during 12 weeks. The office-based done by the EG consists of a vergence therapy and its protocol will follow Scheiman's Protocol and Indications.~The exercises do not tough the eye or use drugs. They are just visual training exercises that improve fusional convergence and divergence response."
10207442|NCT05208658|Placebo Comparator|Eye Movement Therapy Treatment: vision therapy placebo exercises not improve fusional vergence|"The Control Group or Placebo Group consist in a Control: Eye Movement Therapy Treatment. This group will do weekly office-based placebo therapy of 15 minutes during 12 weeks of visual exercises. This placebo therapy will consist of smooth-pursuit and discrimination exercises that do not influence vergence response.~The exercises do not tough the eye nor use drugs. They are just visual training exercises that do not improve fusional vergence response as they improve smooth-pursuit eye movements."
10207443|NCT05208632||BLOCK SİDE|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
10207444|NCT05208632||UNBLOCK SİDE|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
9847680|NCT03156621|Experimental|Placebo SC Q2W|"Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
10207445|NCT05208606|Experimental|Wawokiya Health Advocate|Patients and caregivers allocated to the Wawokiya Health Advocate arm will receive a palliative intervention consisting of regular needs assessments and home visits. After the first 2 visits, visits will occur bi-weekly, though a WHA may increase or decrease frequency of visits pending patient and caregiver needs and cancer status. The first two study visits will follow the same broad structure-structure of follow up visits will be flexible based on patient and caregiver needs. The location of study visits will vary and may include the local IHS site, cancer centers, and the patient's home depending on health status. Patients will be randomized to either receive home visits upon enrollment or be placed on a waitlist.
10207446|NCT05208606|No Intervention|Waitlist Arm|Patients enrolled into the waitlist group will not receive any additional services beyond what is available to them in their standard course of care. Patients randomized to the waitlist group will be asked to identify a primary caregiver upon enrollment. Data collection procedures will occur as described below. While on the waitlist, any services available for patients and their families will be according to the standards of their local providers and primary cancer providers.
9922854|NCT00843869||Chronic Rhinosinusitis|Participants with chronic rhinosinusitis
9922855|NCT00843908|Active Comparator|TVT|Women in this arm will undergo the Tension Free Vaginal Tape procedure
9922856|NCT00843908|Experimental|Miniarc|Women in this group will undergo the Miniarc suburethral sling procedure
9922857|NCT00843921|Experimental|Carbaglu|Investigate whether a 3-day treatment with NCG can improve or restore urea genesis capacity in patients with NAGS, CPSI, or OTC deficiency or PA or MMA using surrogate markers: [13C] label incorporation into urea and plasma levels of ammonia, urea nitrogen (BUN) and amino acids
9922858|NCT00843934|Experimental|anti-cancer agent|
9922859|NCT00843960|Active Comparator|1|intervention group
9922860|NCT00843960|No Intervention|2|control group
9922861|NCT00843973||iliac crest bone graft|Bone graft harvested via iliac crest bone graft procedure
9922862|NCT00843973||Reamer Irrigator Aspirator|Bone graft harvested via the Reamer Irrigator Aspirator (RIA) Procedure
9922863|NCT00844012|Experimental|Experimental group|
9922864|NCT00844012|Active Comparator|Control|
9922865|NCT00844025|Experimental|Pharmacist intervention|Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions.
9922866|NCT00844025|No Intervention|Usual care|Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse.
9922867|NCT00844038||1|Sick
9922868|NCT00844064|Experimental|AP 12009|
9922869|NCT00844077||Barrett's metaplasia|Barrett's intestinal metaplasia, confirmed via pathology, undergoing standard of care endoscopic screening.
9922870|NCT00844103|Experimental|1|
9922871|NCT00844103|Placebo Comparator|2|
9922872|NCT00844116|Active Comparator|Conventional Spirometry|personal spirometry
9922873|NCT00844116|Experimental|Telematic Spirometry|"performed remotely on line"
9922874|NCT00844129||Neurofibromatosis Type 1|Children with Neurofibromatosis Type 1
9922875|NCT00844142|Other|1|etanercept 25mg twice weekly
9922876|NCT00844142|Active Comparator|2|Sulfasalazine 2000- 3000mg daily
9922877|NCT00844155|Active Comparator|A.Oseltamivir 75 mg dose|Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.
9922878|NCT00844155|Active Comparator|B. Oseltamivir 150mg|Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.
9922879|NCT00844168|Experimental|Treatment (adjuvant sorafenib tosylate after liver transplant)|Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9922880|NCT00844181||0|white women
9922881|NCT00844181||1|Black women
9935095|NCT04206163|Experimental|Cardiac sarcoidosis|Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.
9847681|NCT03157089|Experimental|All patients|
9847682|NCT03157232|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
9847683|NCT03157531|Experimental|B-Laser™ Atherectomy System|B-Laser™ Atherectomy System
9847684|NCT03157583|Active Comparator|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
9847685|NCT03157583|Experimental|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
9847686|NCT03157583|Experimental|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
9847687|NCT03157583|Experimental|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
9847688|NCT03157583|Experimental|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
9847689|NCT03157583|No Intervention|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
9847690|NCT03157583|Active Comparator|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
9847691|NCT03157583|Other|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
9847692|NCT03158012|Active Comparator|Active treatment|
9847693|NCT03158012|Placebo Comparator|Placebo treatment|
9847694|NCT03158038|Experimental|Monovalent Influenza Vaccine|Participants will receive a single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain] by intranasal spray on Day 1.
9847695|NCT03158038|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.
9847696|NCT03158116|Experimental|Treatment|All participants will be receiving the study drug
9847697|NCT03158220|Experimental|Adult Women 27- to 45-years Old|Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
9847698|NCT03158220|Active Comparator|Young Adult Women 16- to 26-years Old|Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
9847699|NCT03158272|Experimental|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
9847700|NCT03158272|Experimental|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
9847701|NCT03158311|Experimental|QVM149 150/50/80 μg|QVM149 150/50/80 μg o.d. delivered via Concept1
9847702|NCT03158311|Experimental|QVM149 150/50/160 μg|QVM149 150/50/160 μg o.d. delivered via Concept1
9847703|NCT03158311|Active Comparator|Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
9847704|NCT03158714|Experimental|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
9847705|NCT03158714|Experimental|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
9847706|NCT03158714|No Intervention|Control|No programming is offered.
9847707|NCT03159091|Experimental|Rengalin|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
9847708|NCT03159091|Placebo Comparator|Placebo|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
9847709|NCT03159143|Experimental|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m^2 as a 2 hour IV infusion.
9847710|NCT03159195||Breast Cancer Patients|HR+/HER2- advanced/metastatic breast cancer patients across multiple countries.
9847711|NCT03159260|Experimental|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
9847712|NCT03159260|Placebo Comparator|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
9847713|NCT03159299|Experimental|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
9847714|NCT03159299|No Intervention|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
9847715|NCT03159455|Experimental|BI 1467335|
9847716|NCT03159455|Placebo Comparator|Placebo|
9847717|NCT03159468|Experimental|Cognitive Restructuring & Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
9847718|NCT03159468|Experimental|Mindfulness & Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
9847719|NCT03159468|Experimental|Nutrition Information & Alcohol Condition|Participants will receive general information about nutrition. They will then consume an alcoholic beverage in the lab.
9847720|NCT03159468|Experimental|Cognitive Restructuring & No Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
9847721|NCT03159468|Experimental|Mindfulness & No Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
9847722|NCT03159468|No Intervention|Nutrition Information & No Alcohol Condition|Participants will receive general information about nutrition. They will then consume a non-alcoholic beverage in the lab.
9847723|NCT03159611|Experimental|Tenoten for children|
10207447|NCT05208593|Placebo Comparator|Negative Event Only|Participants will be asked to think of a specific example of the most (or one of the most) negative, unpleasant event with alcohol they have experienced; the event they choose must have occurred at least a year ago. Or they will be asked to think of the most significant event that has occurred in the past year. After thinking of a specific event, they will be given three minutes to write about their experience. The writing prompt will ask that they express the event information in a few sentences. This writing prompt will help participants place themselves back into that moment and access salient emotions and cognition about it. Similar negative event prompts have been used in counterfactual thinking studies (McFarland & Alvaro, 2000; White & Lehman, 2005).
10207448|NCT05208593|Active Comparator|Negative Event + Factual Thinking Task|"Participants in this group, the event plus the factual thinking task condition, will be told the following after completing the negative event writing task, After disappointing and/or negative experiences like the one you described on the previous page, people often think about the details of the situation. For example, when it happened, who was involved, and what happened right before or after the incident occurred. In the space below please provide examples of some of these details.. There will be 10 blank boxes below the instructions and participants will be asked to provide some examples of details from their traumatic event. They will be asked to only list as many as they can naturally recall without repeating any. This procedure is derived from Kray and colleague's (2010) study on counterfactual thinking and meaning in life."
9847724|NCT03159611|Placebo Comparator|Placebo|
9847725|NCT03159624|Experimental|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
9847726|NCT03159624|Active Comparator|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
9847727|NCT03160027|Experimental|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
9847728|NCT03160027|No Intervention|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
9847729|NCT03160170|Experimental|Use of Cobb device|Use of SISTER device during surgery
9847730|NCT03160170|No Intervention|Control|Standard exposure technique and instruments will be used during surgery
9847731|NCT03160287|Experimental|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
9847732|NCT03160560|Active Comparator|Test-Unflavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.
9847733|NCT03160560|Active Comparator|Test-Flavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution with mint flavoring.
9847734|NCT03160560|Placebo Comparator|Placebo|CloSYS Oral Rinse product (no chlorine dioxide)
9847735|NCT03160573|Active Comparator|Test-Unflavored Rinse then Placebo Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
9847736|NCT03160573|Active Comparator|Test-Flavored Rinse then Placebo Flavored Rinse|Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks. After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
9847737|NCT03160573|Placebo Comparator|Flavored Oral Rinse-Placebo then Test-Flavored Rinse|Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
9847738|NCT03160573|Placebo Comparator|Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
9847739|NCT03160703|Experimental|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
9847740|NCT03160703|Experimental|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
10213490|NCT03909061|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the wheelchair maintenance training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent maintenance training program.
10213491|NCT03905265|Experimental|Moxidectin 2 mg|Moxidectin 2 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
10213492|NCT03905265|Experimental|Moxidectin 8 mg|Moxidectin 8 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
9847741|NCT03160703|Other|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
9847742|NCT03160703|Active Comparator|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
9847743|NCT03160716|Other|Treatment|
9847744|NCT03160885|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks"
9847745|NCT03160885|Placebo Comparator|Initial treatment period - Placebo|"Week 0 to Week 16 (Initial treatment period):~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks"
9847746|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks"
9847747|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks"
9847748|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks"
9847749|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo (tralokinumab naive)|"Week 16 to Week 52~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks"
9847750|NCT03160885|Experimental|Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS|"Week 16 to Week 52~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W~• TCS = topical corticosteroids"
10213493|NCT03905265|Experimental|Moxidectin 20 mg|Moxidectin 20 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
9847751|NCT03160898|Experimental|Reldesemtiv 150 mg twice daily|Patients in this arm took 1 reldesemtiv 150 mg oral tablet and 2 matching placebo tablets every 12 hours for 12 weeks.
9847752|NCT03160898|Experimental|Reldesemtiv 300 mg twice daily|Patients in this arm took 2 reldesemtiv 150 mg oral tablets and 1 matching placebo tablet every 12 hours for 12 weeks.
9847753|NCT03160898|Experimental|Reldesemtiv 450 mg twice daily|Patients in this arm took 3 reldesemtiv 150 mg oral tablets every 12 hours for 12 weeks.
9847754|NCT03160898|Placebo Comparator|Placebo|Patients in this arm took 3 placebo oral tablets every 12 hours for 12 weeks.
9847755|NCT03161158|Active Comparator|Ultrafiltration Group|Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
9847756|NCT03161158|Other|Control group (Usual care IV diuretics)|Guideline-directed therapy including IV loop diuretics according to treatment algorithm.
9847757|NCT03161327|Other|ABI|ABI will be performed in patient
9847758|NCT03161405|Experimental|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
9847759|NCT03161483|Experimental|CC-220 0.45 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
9847760|NCT03161483|Experimental|C-220 0.3 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
9847761|NCT03161483|Experimental|CC-220 0.15 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
9847762|NCT03161483|Placebo Comparator|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
9847763|NCT03161938|Active Comparator|Dexamethasone 48 mg|Dexamethasone 48 mg pre-operative, single shot injection
9847764|NCT03161938|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative, single shot injection
9847765|NCT03162055|Experimental|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
9847766|NCT03162055|Active Comparator|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
9922882|NCT00844207|Experimental|Treatment A|Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base.
9922883|NCT00844207|Active Comparator|Treatment B|A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base.
9922884|NCT00844220|Experimental|CT/MR|CT/MRI-directed clinical management strategy
10213494|NCT03905265|Experimental|Moxidectin 36 mg|Moxidectin 36 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
10213495|NCT03905135|Experimental|1- Experimental Treatment: Dose Escalation|IL-15 by civ infusion at escalating doses of 1, 2, 3 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with avelumab by IV infusion at a dose of 10mg/kg on Day 8 and 22 of each cycle, to determine MTD
9847767|NCT03162328|Placebo Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers. After 2 nights in the lab in the sham condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
9847768|NCT03162328|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night. After 2 nights in the lab in the stim condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
9847769|NCT03162354|Experimental|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
9847770|NCT03162354|No Intervention|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
9847771|NCT03162458|Experimental|Anaferon for children|
9847772|NCT03162458|Placebo Comparator|Placebo|
9847773|NCT03162614|Active Comparator|AduFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
9847774|NCT03162614|Experimental|2PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
9847775|NCT03162614|Experimental|PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
9847776|NCT03162614|Experimental|Adu2Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
9847777|NCT03162614|Active Comparator|Adu1Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
9847778|NCT03162614|Other|Control Group|Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.
9847779|NCT03162796|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
9847780|NCT03162796|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
9847781|NCT03162796|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
9847782|NCT03163017|Experimental|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
9847783|NCT03163134|No Intervention|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
10213496|NCT03905135|Experimental|2- Experimental Treatment: Dose Expansion|IL-15 by civ infusion at the MTD on days 1-5 of cycles 1-6 with avelumab at 10mg/kg on Day 8 and 22 of each cycle
10213497|NCT03900689||Health Services Research - Part 1 Survey|Participants will be asked to complete a series of surveys. This will be preferentially completed on the same day of the visit but may be completed at a subsequent visit, over the telephone or taken home and sent back to the clinic.
9847784|NCT03163134|Experimental|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
9847785|NCT03163303|Experimental|Tobacco Status Project (TSP) + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
9847786|NCT03163303|Experimental|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
9847787|NCT03163342|Other|Open label|Licensed seasonal influenza vaccine, intramuscular
9847788|NCT03163446|Experimental|CF-301|Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
10213498|NCT03900689||Health Services Research - Part 2 - Focus Group|Patients identified in Part 1 will be offered participation in the focus groups in Part 2. All patients enrolled in Part 1 will be considered for participation in Part 2. Approximately 30 total patients will be invited to participate. Patients who agree to be contacted will receive a telephone call or contacted in clinic and invited to participate in the Part 2 focus group.
9847789|NCT03163446|Placebo Comparator|Placebo|Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
9847790|NCT03163472|Active Comparator|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
9847791|NCT03163472|Experimental|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
10207449|NCT05208593|Experimental|Negative Event + Counterfactual Task|"Participants will be told after completing the negative event writing task, After disappointing and/or negative experiences like the one you described, people sometimes cannot help thinking what if… or if only… and imagining how things might have gone differently. That is, if only I had done something differently, the negative drinking situation could have been avoided or turned out better. In the box below please identify things that, had they been different, would have improved the outcome of the negative drinking situation you described earlier and briefly describe how the outcome would have been better. Participants will be asked to list three counterfactuals about the event. Participants will also be asked to think of situations where these strategies could be used, to list out any obstacles that might prevent them from implementing these strategies and to indicate their intention to use each strategy over the next week."
9847792|NCT03163758|Experimental|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
9847793|NCT03163758|Sham Comparator|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
9847794|NCT03164538|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
10207450|NCT05208593|Experimental|Personalized Normative Feedback|Participants in this group, the personalized normative feedback, will be asked to rate the frequency and quantity of TAMU students that use PBS when drinking.
9847795|NCT03164538|Active Comparator|Diabetes Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet).
9847796|NCT03164551|Active Comparator|GERI+ Incubator|
9847797|NCT03164551|Other|Conventional incubator|
9847798|NCT03164629|Experimental|3D Angiogram + Emboguide|Participants will receive cone-beam CT 3D Emboguide: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
10207451|NCT05208580|Experimental|On-line education|Virtual educational activities
10207452|NCT05208580|Experimental|Contact education|Live educational classes
9847799|NCT03164629|Active Comparator|No 3D Angiogram + Emboguide|Embolization will be guided by a standard of care CT.
9847800|NCT03165045||patients treated with Spiolto® Respimat®|Patients with COPD
9847801|NCT03165058||Inflammatory Bowel Disease|Patients undergoing standard of care colonoscopy for inflammatory bowel disease (IBD) surveillance will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
9847802|NCT03165058||control|Patients undergoing standard of care colonoscopy for age appropriate screening will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
9847803|NCT03165110|Experimental|Users of the Onyx Blood Glucose Meter/ app System at home|Participants have a diagnosis of either type 1 or type 2 diabetes for at least 6 months and use insulin.
9847804|NCT03165175|Experimental|App + treatment as usual|The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
9847805|NCT03165175|No Intervention|Treatment as usual|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
9847806|NCT03165617|Experimental|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
9847807|NCT03165617|Active Comparator|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
9847808|NCT03165981|Other|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
9847809|NCT03165981|Other|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
9847810|NCT03166124|Experimental|Elderly Adults LY900014|Single, subcutaneous (SC) 15-U dose of LY900014 in the elderly adult group.
9847811|NCT03166124|Active Comparator|Elderly Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in in the elderly adult group.
9847812|NCT03166124|Experimental|Younger Adults LY900014|Single, SC 15-U dose of LY900014 in the younger adult group.
9847813|NCT03166124|Active Comparator|Younger Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in the younger adult group.
9922885|NCT00844220|Active Comparator|Catheterization|Standard clinical management
9922886|NCT00844233|Experimental|1|Irinotecan Bead
10207453|NCT05208580|No Intervention|Control group|Regular perioperative care without additional educational activities
10207454|NCT05208515|Other|stardard group|wowen who need emergency cesarean section will be send to the general operating center.
10207455|NCT05208515|Experimental|new group|women who need emergency cesarean section will be send to the obstetric operating center
10207456|NCT05208502||BIS|All inclusions will receive the general anesthesia with BIS monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the EEG monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
10207457|NCT05208502||DSA|All inclusions will receive the general anesthesia with SedLine monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the DSA monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
10207458|NCT05208450|Experimental|Intervention Group|
10207459|NCT05208450|No Intervention|Usual care (UC) Group|
9847814|NCT03166215|Placebo Comparator|Part 1: Placebo|TAK-935 matching-placebo tablets, orally or through gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) from Days 1 to 30 in dose titration period.
9847815|NCT03166215|Experimental|Part 1: TAK-935|TAK-935 100 mg, tablet, orally or through G-tube/PEG tube, BID from Days 1 to 10 followed by TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 11 to 20 followed by TAK-935 100 mg tablets x3, orally or through G-tube/PEG tube, BID from Days 21 to 30 in dose titration period. The dose of TAK-935 was escalated or de-escalated during Part 1 as per investigator's discretion.
9847816|NCT03166215|Experimental|Part 2: TAK-935|TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 31 to 40 followed by TAK-935 100 mg tablets x1, x2 or x3, orally or through G-tube/PEG tube, BID from Days 31 to Day 85 as per investigator's discretion in the maintenance period. At the end of Part 2, the dose of TAK-935 was de-escalated until discontinuation.
9847817|NCT03166735|Experimental|BI 1467335 dose 1|
9847818|NCT03166735|Experimental|BI 1467335 dose 2|
9847819|NCT03166735|Experimental|BI 1467335 dose 3|
9847820|NCT03166735|Experimental|BI 1467335 dose 4|
9847821|NCT03166735|Placebo Comparator|Placebo|
9847822|NCT03167073|Experimental|BreastFeeding Friend (BFF)|BFF is a novel android app initially created in Microsoft PowerPoint with the results of a well-validated questionnaire administered to the target patient population, in which participants identified barriers preventing them from starting or continuing breastfeeding. The app was then modified by a multidisciplinary team of neonatologists, perinatologists, and certified lactation consultants. The finalized prototype was presented to three focus groups of test users sociodemographically similar to the target population. This approach allowed BFF to be adjusted to maximize the users' experience per their opinions. Once the focus groups' feedback was consistent, the app prototype was provided to a freelance coding team at Washington University of St. Louis, which built a native android app.
9847823|NCT03167073|Placebo Comparator|dummy app|The dummy app looks identical to BFF but is limited to a few pages of information on breastfeeding that is provided in hand-out form during routine prenatal care.
9847824|NCT03167151|Experimental|Arm A Intravesical|"Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 & D64.~Dose to be decided after safety run-in."
9847825|NCT03167151|Active Comparator|Arm B Intravenous|Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64
9847826|NCT03167359|Experimental|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
9847827|NCT03167411|Experimental|Bexagliflozin alone|
9847828|NCT03167411|Active Comparator|Bexagliflozin with exenatide injection|
9847829|NCT03167541|Experimental|1|Treatment Order: Test, Reference
9847830|NCT03167541|Experimental|2|Treatment Order: Reference, Test
9847831|NCT03168022|Experimental|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
9847832|NCT03168022|Experimental|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
9847833|NCT03168295|Experimental|Placebo first and then dapagliflozin|Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo
9847834|NCT03168295|Active Comparator|Dapagliflozin first then placebo|Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin
9847835|NCT03168295|Other|Control Group|Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.
9847836|NCT03168308|Active Comparator|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
9847837|NCT03168308|Active Comparator|Sugammadex|Patients randomized to receive Sugammadex
9847838|NCT03168321|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
9847839|NCT03168321|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
9847840|NCT03168334|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
9847841|NCT03168334|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
9847842|NCT03168425|Experimental|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
9847843|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
9847844|NCT03168542|Experimental|Toric Multifocal Contact Lens|JJVC Investigational Toric Multifocal Contact Lens for Presbyopia
9847845|NCT03168542|Experimental|Multifocal Contact Lens|1-Day Acuvue® Moist Brand Multifocal Contact Lens
9847846|NCT03168711|Experimental|Inosine|Subjects will be administered oral inosine daily. The dose of inosine will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
9847847|NCT03168711|Placebo Comparator|Placebo|Subjects will be administered oral placebo daily. The dose of placebo will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
9847848|NCT03168841|Experimental|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
9847849|NCT03168919|Experimental|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
9847850|NCT03169062|Experimental|All patients|Gated Stationary Chest Tomosynthesis
10207460|NCT05208411|Experimental|ImPACT group|Group of children at elevated likelihood of ASD who will receive the ImPACT intervention
10207461|NCT05208411|No Intervention|No intervention group|Group of children at elevated likelihood of ASD who won't receive any intervention
10207462|NCT05208398|Experimental|Apixaban|Apixaban, 5 mg oral tablets, on top of updated guidelines of acute coronary syndrome management recommendations
10207463|NCT05208398|Active Comparator|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acute coronary syndrome management recommendations
10207464|NCT05208372||Laparotomy group|Patients who undergo radical laparotomy for gastric cancer.
9847851|NCT03169153|Other|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
9847852|NCT03169153|Other|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
9847853|NCT03169244|Active Comparator|Bupropion|Bupropion extended release
9847854|NCT03169244|Placebo Comparator|Placebo|Placebo oral tablet
9847855|NCT03169816|Experimental|Lorcaserin|10 mg capsule taken twice daily of lorcaserin
9847856|NCT03169816|Placebo Comparator|Placebo|a placebo comparator capsule taken twice daily
9847857|NCT03170154|Experimental|Clareon IOL|Clareon aspheric hydrophobic acrylic monofocal IOL implanted in one eye during routine small incision cataract surgery
9847858|NCT03170193|Experimental|AMG 529|Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.
9847859|NCT03170193|Placebo Comparator|Placebo|Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.
9847860|NCT03170219|Experimental|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
9847861|NCT03170219|No Intervention|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
9847862|NCT03170232|Experimental|Subjects receiving danirixin|Following screening and assessment of rescue medication use, subjects will receive one tablet of danirixin 35 mg (as hydrobromide hemihydrate salt) orally twice daily with food for 52 weeks during treatment period. Study treatment will be dispensed to subjects at the study visits.
9847863|NCT03170232|Placebo Comparator|Subjects receiving placebo|Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
9847864|NCT03170271|Experimental|Benralizumab (Medi-563)|Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
9847865|NCT03170271|Placebo Comparator|Placebo|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
9847866|NCT03170388|Experimental|IDP-126 Gel|Gel
9847867|NCT03170388|Active Comparator|IDP-126 Component A|Component A
9847868|NCT03170388|Active Comparator|IDP-126 Component B|Component B
9847869|NCT03170388|Active Comparator|IDP-126 Component C|Component C
9847870|NCT03170388|Placebo Comparator|IDP-126 Vehicle Gel|Vehicle Gel
9847871|NCT03170544|Experimental|Part 1, MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
9847872|NCT03170544|Experimental|Part 1, MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
9847873|NCT03170544|Experimental|Part 1, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
9847874|NCT03170544|Experimental|Part 1, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
9847875|NCT03170544|Experimental|Part 1, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
9847876|NCT03170544|Active Comparator|Part 1, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
9847877|NCT03170544|Experimental|Part 2, MK-1092, 8.0 nmol/kg + lispro, 1.2 nmol/kg|MK-1092, 8.0 nmol/kg dose selection based on Part 1 + lispro (Humalog®), 1.2 nmol/kg, as a single dose, in healthy participants
9847878|NCT03170544|Experimental|Part 3, MK-1092, 8.0 nmol/kg|MK-1092, (8.0 nmol/kg based on Part 1), SC, in participants with T1DM.
9847879|NCT03170544|Experimental|Part 3, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T1DM
9847880|NCT03170544|Active Comparator|Part 3, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
9847881|NCT03170544|Experimental|Part 4, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T2DM
9847882|NCT03170544|Experimental|Part 4, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose, in participants with T2DM
9517014|NCT03310242|Placebo Comparator|Placebo|Intake of placebo for 8 weeks
9517015|NCT03310216|Experimental|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
9847883|NCT03170544|Experimental|Part 4, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose, in participants with T2DM
9847884|NCT03170544|Active Comparator|Part 4, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM
9847885|NCT03170609|Experimental|Lowest dose formulation a|Multivalent group B streptococcus vaccine
9847886|NCT03170609|Experimental|Middle dose formulation a|Multivalent group B streptococcus vaccine
9847887|NCT03170609|Experimental|Highest dose formulation a|Multivalent group B streptococcus vaccine
9847888|NCT03170609|Experimental|Lowest dose formulation b|Multivalent group B streptococcus vaccine
9847889|NCT03170609|Experimental|Middle dose formulation b|Multivalent group B streptococcus vaccine
9847890|NCT03170609|Experimental|Highest dose formulation b|Multivalent group B streptococcus vaccine
9847891|NCT03170609|Placebo Comparator|Placebo|Saline control
9847892|NCT03170661|No Intervention|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
9517016|NCT03310216|Active Comparator|Order II of visual inspection|Participants in group II are provided EDTRS first and AI visual inspection system later.
9847893|NCT03170661|Experimental|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
9847894|NCT03171051|Other|Lipolysis treatment|"The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.~The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes."
9847895|NCT03171415|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):~40mg RZL-012 -administered at 8 sites~80mg RZL-012 - administered at 16 sites~120mg RZL-012 - administered at 24 sites~180mg RZL-012 - administered at 36 sited"
9847896|NCT03171415|Placebo Comparator|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-36 sites (0.1mL per site)
9847897|NCT03172130|Experimental|Straight CPAP|Patients randomized to straight CPAP will receive 10 cm of air pressure, or as determined by the results of polysomnography, for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
9847898|NCT03172130|Sham Comparator|Sham CPAP|Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
9847899|NCT03172325|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
9847900|NCT03172325|Active Comparator|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
9847901|NCT03172364|Experimental|Test product 1|All the participants in this arm will receive test product 1 (micellar cleanser) at home twice a day (morning and evening) for 21 (±2) days.
9847902|NCT03172364|Experimental|Test product 2|All the participants in this arm will receive test product 2 (micellar foaming cleanser) at home twice a day (morning and evening) for 21 (±2) days.
9847903|NCT03172481|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
9847904|NCT03172481|Placebo Comparator|Placebo Treatment|
9847905|NCT03172494|Experimental|Insulin degludec/liraglutide|
9847906|NCT03172494|Active Comparator|Insulin degludec|
9847907|NCT03172494|Active Comparator|Liraglutide|
9847908|NCT03172702|Experimental|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
9847909|NCT03172884|Experimental|BAY80-6946/Healthy subject|Healthy subjects
9847910|NCT03172884|Experimental|BAY80-6946/moderate hepatically impaired patients|Patients with Child-Pugh B (score 7-9) at the screening visit
9847911|NCT03172884|Experimental|BAY80-6946/severe renal impaired patients|Patients with eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation
9847912|NCT03172884|Experimental|BAY80-6946/severe hepatically impaired patients|Patients with Child-Pugh C (score 10-15) at the screening visit
9847913|NCT03173170|Experimental|TAK-954 0.2 mg + Itraconazole 200 mg and TAK-954 0.2mg|TAK-954 0.2 milligram (mg), infusion, intravenously, once on Day 1 of First Intervention Period, followed by a minimum of 7-day washout period, further followed by Itraconazole 200 mg, capsule, orally, once daily on Days 1 to 8 along with TAK-954 0.2 mg, infusion, intravenously on Day 4 of Second Intervention Period.
9517017|NCT03310203|Experimental|Obese women: central obesity|OGTT with iron
9847914|NCT03173313|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
9847915|NCT03173313|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
9847916|NCT03173547|Active Comparator|146-9251 cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
9847917|NCT03173547|Placebo Comparator|Vehicle cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
10207465|NCT05208372||Laparoscopy group|Patients who undergo laparoscope-assisted radical gastrectomy for gastric cancer.
10207466|NCT05208294|Experimental|High expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a sulpiride 400mg-capsule (note that the dose is presumably too high to produce antidepressant effects).
10207467|NCT05208294|Experimental|High expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a placebo capsule.
10213499|NCT03897491|Experimental|Interstitial photodynamic therapy|20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.
9847918|NCT03173560|Experimental|Lenvatinib 14 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any >= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to [=] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
9847919|NCT03173560|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length =28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
9922887|NCT00844246|Experimental|SRS|School Readiness Specialist (SRS) will administer the screening questionnaire to the subject during the intervention period, at the subject's 9, 18, 24 and 30 month visits. They will then see their PCP for a well child visit in which the results of the test will be interpreted, developmental counseling and/or anticipatory guidance provided as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
9922888|NCT00844246|Experimental|Provider|Primary Care Physician (PCP) will do the developmental screening at the subject's 9, 18, 24 and 30 month well child visits. Once the screening questionnaire is complete the PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
9922889|NCT00844246|No Intervention|Routine|Subjects randomized to routine surveillance will receive routine preventive care as well as developmental surveillance at all well child visits, including the 9, 18, 24 and 30 month visits. EI referral will be completed, at the discretion of the provider, if the PCP observes a developmental delay during surveillance or the caregivers raise a specific concern about the child's development.
9922890|NCT00844259||Research Group|15 children with Down syndrome, observed in two interaction conditions: playing with their therapist (A) and playing with their caregiver (B).
9922891|NCT00844272|Experimental|Psychoeducation|"PE group sessions lasted 60 minutes and were carried out under continuous supervision. The manualised program was especially tailored to (former) IDUs in HCV treatment, containing the following aspects:~Module 1: HCV infection and symptoms, course of illness, interaction with opioid dependence, further problems and risk factors~Module 2: HCV treatment, side effects, psychiatric and somatic comorbidities, reinfection and drug use, risk behaviour~Module 3: Coping strategies, resources and self-help, effective use of health-care support, the role of social environment, healthy living & nutrition"
9922892|NCT00844272|No Intervention|Treatment as usual|Control group did not received no intervention.
9922893|NCT00844285||Cimzia Cohort:|Patients about to receive treatment with Cimzia® as part of pre-existing management plan for Crohn's disease or has already been receiving treatment with Cimzia® for ≤12 months. Patients must also receive a Cimzia dose within 2 months following enrollment.
9922894|NCT00844285||Comparison cohort|Patient must be about to receive treatment with any other medication as part of a pre-existing management plan for Crohn's disease or has already been receiving treatment (previous Cimzia® treatment is prohibited).
9922895|NCT00844311|Active Comparator|Control arm|150 iu/day of rFSH alone
9922896|NCT00844311|Experimental|hCG low dose|150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1
9922897|NCT00844311|Experimental|hCG medium dose|150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1
9922898|NCT00844311|Experimental|hCG high dose|150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1
9922899|NCT00844324|Experimental|A|Candesartan cilexetil 1mg/mL
9922900|NCT00844324|Experimental|B|Candesartan cilexetil 1.6mg/mL
9922901|NCT00844337|Active Comparator|1|One study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
9922902|NCT00844337|Active Comparator|2|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
9922903|NCT00844337|Active Comparator|3|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
9922904|NCT00844350|No Intervention|letrozole+hCG|
9922905|NCT00844350|No Intervention|letrozole+oxytocin|
9922906|NCT00844350|No Intervention|letrozole+oxytocin+hCG|
9922907|NCT00844350|No Intervention|clomiphene citrate +oxytocin|
9922908|NCT00844350|No Intervention|clomiphene citrate +oxytocin+hCG|
9922909|NCT00844363|Other|NB-UVB|Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
9847920|NCT03174132|Experimental|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
10207468|NCT05208294|Experimental|Low expectation with sulpiride group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, while participants actually receive a sulpiride capsule (400 mg).
10207469|NCT05208294|Experimental|Low expectation with placebo group|Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, and participants actually receive a placebo capsule.
10207470|NCT05208281|Experimental|Adult: GNR-055|GNR-055: 1.0-2.0-3.0 mg/kg
9847921|NCT03174132|Active Comparator|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
9847922|NCT03174158|Active Comparator|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
9847923|NCT03174158|Experimental|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the Massachusetts General Hospital (MGH) tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
9847924|NCT03174158|Experimental|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
9847925|NCT03174158|Experimental|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
9847926|NCT03174366|Experimental|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
9847927|NCT03174925|Experimental|Tissue Stiffness by Elastography|Potentially cancerous thyroid nodules were assessed by elastrography, then a fine needle biopsy specimen or the surgically-excised nodule was assessed pathologically to determine cancer status.
9847928|NCT03175120|Experimental|Insulin degludec/liraglutide|
9847929|NCT03175120|Active Comparator|Insulin degludec|
9847930|NCT03175172|Experimental|Experimental|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
9847931|NCT03175562|Experimental|Test product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
9847932|NCT03175562|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
9847933|NCT03175731|Experimental|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
9847934|NCT03175731|Placebo Comparator|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
9847935|NCT03176238|Experimental|everolimus + exemestane|Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily
9847936|NCT03176407|Experimental|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
9922910|NCT00844389|Active Comparator|NIR light|Group of patients stimulated with near to infrared light daily stimulation
10207471|NCT05208281|Experimental|Paediatric: GNR-055 2.0 mg/kg|GNR-055 2.0 mg/kg
10207472|NCT05208281|Experimental|Paediatric: GNR-055 3.0 mg/kg|GNR-055 3.0 mg/kg
10207473|NCT05208268||Pariet|Participants with gastric and duodenal ulcer being administered with Pariet 5 mg, tablet within the scope of the approved label for Korea under the medical judgment of the investigator will be observed up to maximum of 24 weeks.
10207474|NCT05208255|Experimental|Exercise Group1|"The telerehabilitation-based neurocognitive exercise group~6 weeks, 2 sessions per week Session duration: 60 minutes"
10207475|NCT05208255|Experimental|Exercise Group2|"The telerehabilitation-based neurocognitive exercise+motor imagery training group~6 weeks, 2 sessions per week Session duration: 60 minutes (45 minutes-neurocognitive exercise; 15 minutes-motor imagery training)"
10207476|NCT05208255|Active Comparator|Control Group|"The medication group - Participants who voluntarily participated in the study but did not want to participate in exercise groups.~6 weeks of medication use"
10207477|NCT05208242|Experimental|Hyperoncotic albumin|Hyperoncotic albumin for all fluid resuscitation and also as a daily supplement, guided by daily serum albumin values, for up to 7 days.
10207478|NCT05208242|Active Comparator|Buffered crystalloids|Buffered crystalloid solutions for all fluid resuscitation and maintenance purposes. Participants in this arms will NOT receive any albumin during their participation.
10213500|NCT03897296|Experimental|healthy subjects examined with water-perfused catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
9847937|NCT03176459|Experimental|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
9847938|NCT03176459|Active Comparator|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
9847939|NCT03176654|Experimental|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
9847940|NCT03176654|Sham Comparator|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
9847941|NCT03176784|Experimental|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Nicotine Patches:~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
9847942|NCT03176784|Experimental|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
9847943|NCT03176784|Experimental|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Nicotine Patches:~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
9847944|NCT03176784|Experimental|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
9847945|NCT03177395|No Intervention|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
9847946|NCT03177395|Experimental|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes."
9847947|NCT03177512|Experimental|LYNX Mobile App|
9847948|NCT03177512|No Intervention|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
9847949|NCT03177603|Experimental|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
9847950|NCT03177603|Experimental|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
9922911|NCT00844389|Placebo Comparator|Green light|Group of patients stimulated with green light.
9922912|NCT00844402|Experimental|Atorvastatin|Atorvastatin 10 mg per day for 48 weeks
9847951|NCT03177603|Experimental|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
9847952|NCT03177603|Experimental|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
9847953|NCT03177798|Experimental|Icatibant then Placebo|"Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
9847954|NCT03177798|Experimental|Placebo then Icatibant|"Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
9847955|NCT03178266||Zip Closure Device|Patients will receive the Zip Closure Device for final skin closure after knee arthroplasty.
9847956|NCT03178266||Metal Staples|Patients will receive Metal Staples for final skin closure after knee arthroplasty.
9847957|NCT03178344|Experimental|Sham Stimulation, then Alpha Stimulation|"Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS."
9847958|NCT03178344|Experimental|Alpha Stimulation, then Sham Stimulation|"Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham."
9847959|NCT03178669|Experimental|Cobitolimod Dose 2x31 mg|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
9847960|NCT03178669|Experimental|Cobitolimod Dose 2x125 mg|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
9847961|NCT03178669|Experimental|Cobitolimod Dose 2x250 mg|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
9847962|NCT03178669|Experimental|Cobitolimod Dose 4x125 mg|Dose 125 mg of cobitolimod, at 4 occasions
9847963|NCT03178669|Placebo Comparator|Placebo|Placebo at four occasions
9847964|NCT03178773|Active Comparator|TExT-MED only|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
9847965|NCT03178773|Experimental|TExT-MED+FANS|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
9847966|NCT03178851|Experimental|Cohort A|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.
9847967|NCT03178851|Experimental|Cohort B|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.
9847968|NCT03178851|Experimental|Cohort C|Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.
9847969|NCT03178942|Active Comparator|Reference: Elimite™ Cream|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
9847970|NCT03178942|Experimental|Test: Permethrin Cream, 5%|Test: Permethrin Cream, 5% (Encube Ethicals)
9847971|NCT03179319|Experimental|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
9847972|NCT03179319|No Intervention|Standard of Care|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
9847973|NCT03179345|Active Comparator|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
9847974|NCT03179345|Active Comparator|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
9847975|NCT03179345|Active Comparator|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
9922913|NCT00844454|Experimental|QFEA|multi-pronged ethanol ablation
9922914|NCT00844454|Active Comparator|RFA|radiofrequency ablation
9847976|NCT03179345|Placebo Comparator|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
9847977|NCT03179410|Experimental|Neuroendocrine prostate cancer (NEPC)|Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
9847978|NCT03179891|Experimental|Interictal Period|All subjects received 12.5 mg DBF during the interictal state.
9847979|NCT03179891|Experimental|Ictal/Peri-ictal Period|All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
9847980|NCT03180138|No Intervention|Controls|
9847981|NCT03180138|Active Comparator|Reminders alone|
9847982|NCT03180138|Active Comparator|Reminders + compliance-linked incentives|
9847983|NCT03180385|Experimental|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
9847984|NCT03180385|Active Comparator|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
9847985|NCT03180489|Experimental|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
9847986|NCT03180489|Placebo Comparator|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
9847987|NCT03180515|Experimental|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
9847988|NCT03180528|Experimental|Treatment (remetinostat)|Patients receive topical remetinostat 1% gel applied TID directly to the lesion, for 6 weeks in the absence of disease progression or unacceptable toxicity.
9847989|NCT03180619|Experimental|Part A (Renal Impairment): Moderate or Severe Renal Impairment|Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.
9847990|NCT03180619|Experimental|Part A (Renal Impairment): End Stage Renal Disease|Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
9847991|NCT03180619|Experimental|Part B: Hepatic Impairment|Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
9847992|NCT03180645|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
9847993|NCT03180645|Other|Test product/ Positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
9847994|NCT03180645|Other|Positive control /No treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
9847995|NCT03180801|Placebo Comparator|Group 1 adjuvanted placebo|0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0
9847996|NCT03180801|Experimental|Group 2 adjuvanted FLU-v one dose|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0
9847997|NCT03180801|Experimental|Group 3 adjuvanted FLU-v two doses|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0
9847998|NCT03181009|Experimental|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
9847999|NCT03181009|Active Comparator|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
9848000|NCT03181308|Experimental|TRC105 plus Nivolumab|
9848001|NCT03181451|Active Comparator|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 & Day 10.
9848002|NCT03181451|Active Comparator|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 & Day 10.
9848003|NCT03181451|Active Comparator|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 & Day 10.
9848004|NCT03181503|Placebo Comparator|Placebo|Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) every 4 weeks (Q4W) up to Week 8.
9848005|NCT03181503|Experimental|Nemolizumab 0.5 mg/kg|Participants received 3 subcutaneous injections of nemolizumab 0.5 milligram per kilogram (mg/kg) Q4W up to Week 8.
9848006|NCT03181594|Experimental|Treatment with the ClariFix Device|Bilateral ablation of nasal tissue for treatment of chronic rhinitis
9848007|NCT03181724|Active Comparator|Decision Aid|Cohort that will receive a decision aid.
9848008|NCT03181724|No Intervention|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
9848009|NCT03181932|Experimental|Double-blind vancomycin inhalation powder|Vancomycin inhalation powder 30 mg is administered twice daily (BID) during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
9848010|NCT03181932|Placebo Comparator|Double-blind placebo inhalation powder|Matching placebo is administered BID during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
9848011|NCT03181932|Experimental|Open-label vancomycin inhalation powder|In the 24-week Period 2, all participants receive AeroVanc 30 mg BID by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
9922915|NCT00844480|Experimental|zoledronic acid|
9922916|NCT00844480|Placebo Comparator|placebo|
10207479|NCT05208229||Patients with mCRPC enrolled in the Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol|Patients with mCRPC enrolled in the IRST 185.03 Lu-PSMA study, performing baseline CT and WB-MRI examinations and at least one CT and WB-MRI re-evaluation.
10207480|NCT05208203||stroke patients|acute ischemic stroke patients including all treatments.
9848012|NCT03181958|Experimental|NHFOV|"neonates assigned to NHFOV will be started with the following boundaries:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment, similar to what is done in endotracheal high frequency oscillatory ventilation targeting a FiO2≤25-30%. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90%-95%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-12Hz). c)Inspiratory time 50% (1:1).d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2o; amplitude will be titrated according to PaCO2."
9848013|NCT03181958|Active Comparator|NCPAP|Neonates assigned to the CPAP group were initiated on a pressure of 5 cmH2O. CPAP can be raised in steps of 1 cmH2O up to 8 cmH2O. If this is not enough to maintain SpO2 between 90% and 95%, FiO2 will be added up to 0.40.
9848014|NCT03181958|Experimental|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of 15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec(according to clinicians' evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at 30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
9848015|NCT03182582|Active Comparator|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
9848016|NCT03182582|Active Comparator|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
9848017|NCT03182725|Placebo Comparator|Placebo|Patient will consume one placebo pill twice a day for one month.
9848018|NCT03182725|Experimental|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
9848019|NCT03182738|Experimental|Intervention|VIP app that delivers HIV-related symptom strategies
9848020|NCT03182738|Sham Comparator|Control|VIP app without HIV-related symptom strategies
9848021|NCT03182868|Experimental|Repeatability Group|Healthy participants perform goggle testing on two consecutive days to determine if the testing results are repeatable. Testing will be between 10 am and 2 pm and testing on the two sessions will be within 30 minutes of the same time. Sessions can be on two consecutive days or separated by up to 4 days.
9848022|NCT03182868|Experimental|Time of Day Group|Healthy participants perform goggle testing at two different times of day to determine if time of day affects goggle testing performance. One quarter of the participants in this arm will undergo one test at 8 am on the first session and 10 am on the second session. A second quarter will undergo the tests at 10 am on first session and 8 am on the second session. A third quarter will undergo one test at 3 pm on the first session and 10 am on the second session. The fourth quarter will undergo the tests at 10 am on first session and 3 pm on the second session. In all these cases the sessions can be on consecutive days or separated by up to 4 days.
9922917|NCT00844493|Experimental|H10407 challenge 1|7 or 8 logs of E. coli strain H10407 with CeraVacx buffer
10207481|NCT05208177|Experimental|SHR-1802 for injection combined with Camrelizumab for Injection and Famitinib Malate Capsules|
10207482|NCT05208138|Experimental|Intervention|Bariatric operation with the Senhance surgical system
10207483|NCT05208125|Experimental|CSSMS|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
10207484|NCT05208125|Placebo Comparator|PPPPP|Normal saline solution at weeks 0, 4, 12, 22, and 28 (PPPPP).
10207485|NCT05208086||Patients|"Cycle1 day1: collection of 24h urine and an urine sample from miction the day of the visit.~Cycle 2 day1:collection of 24h urine and an urine sample from miction the day of the visit Cycle 4 day 1: collection of 24h urine and an urine sample from miction the day of the visit."
10207486|NCT05208008||With service dog|Veterans living with a certified service dog
10207487|NCT05208008||Without service dog|Veterans living without a certified service dog
10207488|NCT05207995|Experimental|Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells|Group 1: Patients with Type 1 Diabetes Mellitus receiving standard treatment and Tolerogenic Dendritic Cells
10207489|NCT05207995|Active Comparator|Patients with Type 1 Diabetes Mellitus receiving standard treatment|Group 2: Patients with Type 1 Diabetes Mellitus receiving standard treatment
10207490|NCT05207969|No Intervention|Control Arm|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure patient will not giving instruction to urinate during the procedure.
10207491|NCT05207969|Experimental|Experimental Arm|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
9848023|NCT03182868|Experimental|Learning Affect Group|Healthy participants perform goggle testing back to back on the same day to determine if performance on second test changes from first test suggesting a learning affect.
9848024|NCT03182868|Experimental|MSQ Group|Healthy participants perform goggle testing and upon completion of each goggle testing session will complete a Motion Sickness Questionnaire (MSQ) to determine if they show any signs of motion sickness.
9848025|NCT03182868|Experimental|OKN Only Group|OKN Only Group is for exploratory aims only. Healthy participants will undergo goggle testing limited to Optokinetic Nystagmus (OKN) recordings at two stimulus speeds (20 and 60 deg/s) in both the counterclockwise and clockwise directions.
9848026|NCT03182920|Experimental|200 mg Lasmiditan (Group 1 Elderly)|200 milligrams (mg) lasmiditan on Day 1 of 1 of 2 dosing periods.
9848027|NCT03182920|Placebo Comparator|Placebo (Group 1 Elderly)|Placebo on Day 1 of 1 of 2 dosing periods.
9848028|NCT03182920|Experimental|200 mg Lasmiditan (Group 2 Young)|200 mg lasmiditan on Day 1.
9848029|NCT03182933|Experimental|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
9848030|NCT03182933|Active Comparator|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
9848031|NCT03183063|Experimental|4DCT and SPECT/CT|Anticipated 15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing. Data will be analyzed for objectives 1, 4 and 5.
9848032|NCT03183063|Experimental|4DCT with BiPAP and SPECT/CT|Anticipated 5 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. The second of the two 4DCT scans will be obtained with positive airway breathing via BiPAP. Results in these patients will be analyzed for objective 6 only.
9848033|NCT03183063|Experimental|4DCT with CTA in suspected PE|Anticipated 124 participants with CTA ordered/performed for suspected PE will be enrolled to have 4DCT. Goal for analysis is 62 with positive CTA results for PE and 62 with negative CTA results for PE. Data will be analyzed for objectives 2 and 3.
9848034|NCT03183518|Experimental|Test Product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
9848035|NCT03183518|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
9848036|NCT03183869|Active Comparator|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
9848037|NCT03183869|Active Comparator|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
9848038|NCT03183908|Active Comparator|Adjuvanted influenza vaccine (FLUAD®)|In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.
9848039|NCT03183908|Active Comparator|High-dose influenza vaccine (Fluzone® HD)|In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.
9848040|NCT03184077|Active Comparator|Polyglactin 910|
9848041|NCT03184077|Active Comparator|poliglecaprone 25|
9848042|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
9848043|NCT03184441|Experimental|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
9848044|NCT03184519|Experimental|All patients|Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.
9848045|NCT03184558|Experimental|Bemcentinib (BGB324) + pembrolizumab|Participants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3. A dose of 200 mg pembrolizumab was given by intravenous infusion over 30 minutes every 3 weeks in all participants. Dosing of both drugs commenced on Day 1. On days when both BGB324 and pembrolizumab were given, pembrolizumab was given first and participants were observed for 1 hour after the end of infusion before BGB324 was administered. From Day 4 onward, participants received a daily maintenance dose of 200 mg along with Pembrolizumab 200 mg intravenous (IV) infusion over 30 minutes every 3 weeks until disease progression, until an unacceptable toxicity occurred that required treatment withdrawal or withdrawal of consent or until 106 weeks had passed.
9848046|NCT03184701|Experimental|Experimental|Patients assigned to this arm receive the intervention in addition to routine standard of care. Telehealth based remote monitoring of symptoms and brain tests is the intervention in this study. A device with preloaded questionaires will be given to patients randomized to this group. The patients will respond on a daily basis for the 3 months of intervention phase.
9848047|NCT03184987|Experimental|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
9848048|NCT03184987|Experimental|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
9848049|NCT03185065|Experimental|Arm A|amantadine, placebo, modafinil, methylphenidate
9848050|NCT03185065|Experimental|Arm B|placebo, methylphenidate, amantadine, modafinil
10207492|NCT05207956|Experimental|Enhanced Electronic Platform|A basic electronic platform for data collection that contains additional features designed to increase motivation to collect data and ease of data collection.
10207493|NCT05207956|Active Comparator|Electronic Platform Not Enhanced|A basic electronic platform for data collection.
10207494|NCT05207943|Experimental|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and and in the popliteal fossa.
9848051|NCT03185065|Experimental|Arm C|modafinil, amantadine, methylphenidate, placebo
10207495|NCT05207943|Sham Comparator|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level and in the popliteal fossa.
10207496|NCT05207943|No Intervention|Control|Participant will maintain the conventional rehabilitation treatment
9848052|NCT03185065|Experimental|Arm D|methylphenidate, modafinil, placebo and amantadine
9848053|NCT03185182|Experimental|experimental group|"185 megabecquerel (MBq) of Ioflupane I-123 (DaTSCAN) will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.The images from the DaTSCAN investigation will be analyzed and anatomically compared to CT-scan from the same the patient. Any adverse effects during the study will be reported.~This is a exploratory open single arm trial, including a small number of patients with suspected disseminated renal cell carcinoma."
9848054|NCT03185455|No Intervention|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
9848055|NCT03185455|Experimental|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
9848056|NCT03185481|Experimental|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
9848057|NCT03185481|Experimental|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
9848058|NCT03185481|Experimental|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
9848059|NCT03185481|Experimental|15 mg QD PF-06649751|15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
9848060|NCT03185481|Experimental|1 mg to 7 mg QD PF-06649751|Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
9848061|NCT03185481|Experimental|3 mg QD to 7 mg QD PF-06649751|Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
9848062|NCT03185481|Experimental|7 mg QD to 7 mg QD PF-06649751|7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
9848063|NCT03185481|Experimental|15 mg to 7 mg QD PF-06649751|15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751
9848064|NCT03185546|Experimental|Normal Nicotine Content (NNC) cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
9848065|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
9848066|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
9848067|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
9848068|NCT03185546|Experimental|Very Low Nicotine Content (VLNC) cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
9848069|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
9848070|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
9848071|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
9848072|NCT03186261|Experimental|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
9848073|NCT03186261|Active Comparator|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
9848074|NCT03186378|Experimental|Exposure Group|This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
9922918|NCT00844493|Experimental|H10407 challenge 2|7 or 8 logs of E. coli strain H10407 with bicarbonate buffer
10207497|NCT05207930|Experimental|Intervention Group|This arm will undertake a centre-based health education on nutrition and cognitive frailty for 4 weeks, followed by an 8-week homed based gamified cognitive-nutrition training (GAHOCON).
9517018|NCT03310203|Experimental|Obese women: peripheral obesity|OGTT with iron
9517019|NCT03310203|Experimental|Lean women|OGTT with iron
9848075|NCT03186378|Experimental|Standard Group|This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
9848076|NCT03186677|Experimental|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
10207498|NCT05207930|Placebo Comparator|Control Group|This arm will undertake the same centre-based health education on nutrition and cognitive frailty for 4 weeks but will be opened to undertake a remotely supervised online open-source cognitive games, with which the contents are unrelated to nutrition, at the elderly community centre.
10207499|NCT05207917|Active Comparator|Gastric bypass|Gastric bypass
9848077|NCT03186677|Experimental|Cohort 2|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
9848078|NCT03186677|Experimental|Cohort 3|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
9848079|NCT03186677|Experimental|Cohort 4|One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
9848080|NCT03186677|Experimental|Cohort 5|One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
9848081|NCT03186781|Experimental|Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs|HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
9848082|NCT03186781|Experimental|Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
9848083|NCT03186781|Experimental|Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
9848084|NCT03186781|Experimental|Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
9848085|NCT03186781|Experimental|Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
9848086|NCT03186781|Experimental|Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)
9848087|NCT03187002|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
9848088|NCT03187002|Active Comparator|Moderate IV Sedation|Fentanyl, versed
9848089|NCT03187119|Experimental|Pictorial Asthma Action Plan|Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
9848090|NCT03187119|Active Comparator|Written Asthma Action Plan|Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.
9848091|NCT03187132|Experimental|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
9848092|NCT03187132|Active Comparator|Active Control|Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
9848093|NCT03187197||Cohort A|consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
9848094|NCT03187197||Cohort B|patients being newly diagnosed with NVAF and initiated on Pradaxa®
9998194|NCT01515930|Experimental|Active Caregiver and Child Education|Parent Computer-Delivered Motivational Intervention will be delivered to the parents only. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered informational session about diabetes related topics for their child with diabetes.
9848096|NCT03187301|Experimental|APL-130277|APL-130277 at the dose determined in the dose titration phase
10207500|NCT05207917|Active Comparator|Sleeve gastrectomy|Sleeve gastrectomy
10207501|NCT05207904|Experimental|tislelizumab plus chemotherapy|
10207502|NCT05207878|Experimental|Movement task|"All participants perform the STEGA-MRI (standardized tracing evaluation & grapheme assessment - MRI) precision drawing task during fMRI scanning.~Motor assessments outside the MRI do not qualify as interventions."
10207503|NCT05207852||0.5 h group|Blood samples were taken 0.5 h after dexamethasone administration
10207504|NCT05207852||2 h group|Blood samples were taken 2 h after dexamethasone administration
10207505|NCT05207852||4 h group|Blood samples were taken 4 h after dexamethasone administration
10207506|NCT05207852||6 h group|Blood samples were taken 6 h after dexamethasone administration
9848097|NCT03187301|Placebo Comparator|Placebo|Placebo
9848098|NCT03187301|Active Comparator|moxifloxacin|moxifloxacin at a single 400mg dose
9848099|NCT03187418|Experimental|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
9848100|NCT03187678|Experimental|Selexipag|Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.
9848101|NCT03187730|Active Comparator|Intervention Arm|
9848102|NCT03187730|Placebo Comparator|Waitlist Control|
9848103|NCT03187756|Experimental|Cyclophosphamide|
9848104|NCT03188055|Experimental|Best Case/Worst Case communication tool|The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
9848105|NCT03188055|No Intervention|Usual Care|Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.Usual care also consists of daily updates with patient and family, describing each new problem as it arises and what will be done to treat it, regardless of how this fits into the patient's overall prognosis or health trajectory.
9848106|NCT03188120||Spiriva Respimat group|
9848107|NCT03188185|Experimental|ALKS 5461|Sublingual tablets
9848108|NCT03188185|Placebo Comparator|ALKS 5461 Placebo|Sublingual tablets
9848109|NCT03188263|Experimental|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
9848110|NCT03188263|Placebo Comparator|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
9848111|NCT03188523|Experimental|MK-8504 100 mg (Panel A)|Participants receive a single oral dose of MK-8504 100 mg.
9848112|NCT03188523|Experimental|MK-8504 240 mg (Panel B)|Participants receive a single oral dose of MK-8504 240 mg.
9848113|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel C)|Participants receive a single oral dose of MK-8504 ≤240 mg.
9848114|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel D)|Participants receive a single oral dose of MK-8504 ≤240 mg.
9848115|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
9848116|NCT03188718|Other|WatchPAT Intervention|Wearing the WatchPAT device simultaneously while receiving a clinically indicated sleep study (polysomnogram).
9848117|NCT03188991|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
9848118|NCT03188991|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
9848119|NCT03188991|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
9848120|NCT03188991|Experimental|Second Phase: NanoPac® at Best Dose|Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.
9848121|NCT03189134|Experimental|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
9848122|NCT03189446|Experimental|Vaginal Cuff Brachytherapy + Chemotherapy|Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles
9848123|NCT03189524|Experimental|Part I: 160 mg BID|"Safety Evaluation: Two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily [BID]) administered in the morning and at night, or 320 mg (once daily [QD]), and a 3+3 design was adopted for Part I of the study to determine recommended Phase 2 dose (RP2D)."
9848124|NCT03189524|Experimental|Part I: 320 mg QD|"Safety Evaluation: Two regimens of zanubrutinib 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and a 3+3 design was adopted for Part I of the study to determine RP2D."
9848125|NCT03189524|Experimental|Part II: 160 mg BID|Dose Expansion: The RP2D determined in Part I was used in Part II to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL).
9848126|NCT03189589|Experimental|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
9848127|NCT03189589|Experimental|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
9848128|NCT03189745|Experimental|MenACWY-TT Booster|10 year booster dose of MenACWY
9848129|NCT03190005||group 1|placebo control without medication.
9848130|NCT03190005||group 2|hyper-reactive responser after clopidogrel.
9848131|NCT03190005||group 3|hypo-reactive responser after clopidogrel.
9848132|NCT03190005||group 4|normo-reactive responser after clopidogrel.
9848133|NCT03190005||group 5|reaction after OPC-13013
9848134|NCT03190005||group 6|reaction after AR-C
9848135|NCT03190005||group 7|reaction after simastatin
9848136|NCT03190083|Experimental|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
9848137|NCT03190213|Experimental|Pembrolizumab, all patients|
9848138|NCT03190460|Experimental|Intervention|
9848139|NCT03190460|Other|Education|
9848140|NCT03190993|Active Comparator|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
9848141|NCT03190993|Active Comparator|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: ~2.1g whey protein powder.
9848142|NCT03191396|Experimental|Semaglutide|Half the study participants are randomised to receive semaglutide
9848143|NCT03191396|Active Comparator|Liraglutide|Half the study participants are randomised to receive liraglutide
9848144|NCT03191552|Experimental|SPIO 2 hours|"All children will be hospitalized for 2 weeks and will receive conventional exercise therapy including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks 2 hours a day.~SPIO 2 hours group will receive conventional exercise therapy with the garment on for 2 hours."
9848145|NCT03191552|Experimental|SPIO 6 hours|SPIO 6 hours group will receive conventional exercise therapy with the garment on for 2 hours and worn SPIO 4 hours more in addition to 2 hour of wear during exercise therapy.
9848146|NCT03191552|Active Comparator|Control(conventional exercises)|Control group will only receive conventional exercise therapy (for two hours a day) including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks
9922919|NCT00844493|Experimental|H10407 challenge 3|6 logs of E. coli H10407 with bicarbonate buffer
9922920|NCT00844493|Experimental|H10407 challenge 4|5 logs of E. coli H10407 with bicarbonate buffer
9922921|NCT00844571||E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
9922922|NCT00844571||control group|
9922923|NCT00844584|Other|ablation|patients with atrial fibrillation underwent radiofrequency ablation with totally thoracoscope.
9922924|NCT00844636|Active Comparator|Sharp Needles|Sharp needles to close uterus, fascia and skin during cesarean section
9922925|NCT00844636|Active Comparator|Blunt Needles|Assignment to blunt needles to close uterus, fascia and skin during cesarean section
9922926|NCT00844662|Experimental|1|
9922927|NCT00844662|Active Comparator|2|
9922928|NCT00844675|Experimental|rabeprazole|rabeprazole
9922929|NCT00844675|Experimental|placebo|placebo
9922930|NCT00844688|Other|sorafenib/gemcitabine|
9922931|NCT00844701||Non-smoker|Non-smoking control
9922932|NCT00844701||Nicotine Dependent Smoking Group|current smokers
9922933|NCT00844727|Active Comparator|1|Rofexocib 25 mg OD, 1 year treatment
9922934|NCT00844727|Placebo Comparator|2|Placebo
9922935|NCT00844740|Experimental|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood and urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
9922936|NCT00844779||T|(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
9922937|NCT00844779||A|(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
9922938|NCT00844779||B|(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
9922939|NCT00844792|Experimental|1|This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy.
9922940|NCT00844792|Placebo Comparator|2|This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy.
9922941|NCT00844818|No Intervention|Control|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
9922942|NCT00844818|Experimental|Intervention Group|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
9922943|NCT00844870|Active Comparator|1|stabilization training group
9922944|NCT00844870|Experimental|2|auditory response training group
9922945|NCT00844922|Experimental|Org 34517|Org 34517 titrated to 900 mg daily for 2 weeks
9922946|NCT00844922|Placebo Comparator|Placebo|
9922947|NCT00844948||Young adults (18-25 years old)|Young adults (18-25 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
9922948|NCT00844948||Elderly (60-80 years old)|Elderly (60-80 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
10207507|NCT05207852||12 h group|Blood samples were taken 12 h after dexamethasone administration
10207508|NCT05207852||24 h group|Blood samples were taken 24 h after dexamethasone administration
9848147|NCT03191630|Experimental|Control|This arm includes participants randomized to the control group who will use activity trackers (Fitbits) only, and not receive the SystemCHANGE intervention.
9848148|NCT03191630|Experimental|Intervention|This are includes participants randomize to the intervention group who will receive the combination of the SystemCHANGE TM and activity tracker intervention
9848149|NCT03191799|Experimental|1.5 mg/kg Emicizumab QW|Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
9848150|NCT03192137|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
9848151|NCT03192137|Placebo Comparator|Vehicle|DuraSite® 2 Vehicle
9848152|NCT03192150|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
9848153|NCT03192150|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
9848154|NCT03192176|Placebo Comparator|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
9848155|NCT03192176|Experimental|Fezolinetant 15 mg|Participants received fezolinetant 15 mg capsules orally, BID for a period of 12 weeks.
9848156|NCT03192176|Experimental|Fezolinetant 30 mg|Participants received fezolinetant 30 mg capsules orally, BID for a period of 12 weeks.
9848157|NCT03192176|Experimental|Fezolinetant 60 mg|Participants received fezolinetant 60 mg capsules orally, BID for a period of 12 weeks.
9848158|NCT03192176|Experimental|Fezolinetant 90 mg|Participants received fezolinetant 90 mg capsules orally, BID for a period of 12 weeks.
9848159|NCT03192176|Experimental|Fezolinetant 30 mg + Placebo|Participants received fezolinetant 30 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
9848160|NCT03192176|Experimental|Fezolinetant 60 mg + Placebo|Participants received fezolinetant 60 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
9848161|NCT03192176|Experimental|Fezolinetant 120 mg + Placebo|Participants received fezolinetant 120 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
9848162|NCT03192306|Active Comparator|Merlin|glycolic acid and ethanol mixture
9848163|NCT03192306|Placebo Comparator|Ethanol|
9848164|NCT03192475|Active Comparator|Group Lifestyle Balance plus phone contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
9848165|NCT03192475|Placebo Comparator|Group Lifestyle Balance plus newsletter contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
9848166|NCT03192488|Experimental|Cetirizine/Hypoxia|Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
10207509|NCT05207852||36 h group|Blood samples were taken 36 h after dexamethasone administration
9848167|NCT03192488|Placebo Comparator|Placebo/Normoxia|Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
9848168|NCT03192488|Placebo Comparator|Placebo/Hypoxia|Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
9848169|NCT03192826|Active Comparator|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
10207510|NCT05207852||48 h group|Blood samples were taken 48 h after dexamethasone administration
9848170|NCT03192826|Active Comparator|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
9848171|NCT03192826|Placebo Comparator|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
9848172|NCT03192904|Experimental|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
9848173|NCT03192904|Experimental|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
9848174|NCT03193021|Experimental|Cardiva Mid-Bore VVCS|Cardiva Mid-Bore VVCS will be used to close all femoral venous access sites at the end of the case.
9848175|NCT03193021|Active Comparator|Manual Compression|Direct manual compression to the access sites will be used to close all femoral venous access sites at the end of the case.
10207511|NCT05207839|Placebo Comparator|Milk powder without GOS|
10207512|NCT05207839|Active Comparator|Milk powder with GOS|
10207513|NCT05207813||Basivertebral nerve ablation treatment|Patient-reported outcomes at two (2) follow-up visits for previously treated participants from the CLBP Single-Arm study.
10207514|NCT05207800||healthy pregnant woman|healthy pregnant woman
10207515|NCT05207800||pregnant women with TPROM|pregnant women with term premature rupture of membranes
10207516|NCT05207800||pregnant women with PPROM|pregnant women with preterm premature rupture of membranes
10207517|NCT05207787|Experimental|HS-10365|There are five escalating dose cohorts.
10207518|NCT05207774|Experimental|oxytocin|8 U/oxytocin three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks
10207519|NCT05207774|Placebo Comparator|placebo|intranasal spray containing placebo three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks
10207520|NCT05207761|Experimental|Sequence 1|"Period 1: D565 7days~Period 2: D565+D930 91days"
10207521|NCT05207761|Experimental|Sequence 2|"Period 1: D930 91days~Period 2: D565+D930 7days"
9848176|NCT03193047|Experimental|bempedoic acid|Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
9848177|NCT03193047|Placebo Comparator|placebo|Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
9848178|NCT03193398|Experimental|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
9848179|NCT03193398|Placebo Comparator|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
9848180|NCT03193593|Placebo Comparator|Placebo Injections|"Intervention: Drug: Placebo~Single Saline Injection into the Pectoralis Muscle"
9848181|NCT03193593|Active Comparator|EB-001 Dose 1|"Intervention: Drug: EB-001~1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle"
9848182|NCT03193593|Active Comparator|EB-001 Dose 2 (1.6X)|"Intervention: Drug: EB-001~2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle"
9848183|NCT03193593|Active Comparator|EB-001 Dose 3 (3.3X)|"Intervention: Drug: EB-001~3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
9848184|NCT03193593|Active Comparator|EB-001 Dose 4 (6.7X)|"Intervention: Drug: EB-001~4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle"
9848185|NCT03193593|Active Comparator|EB-001 Dose 5 (10X)|"Intervention: Drug: EB-001~5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle"
9848186|NCT03193593|Active Comparator|EB-001 Dose 6 (13.3X)|"Intervention: Drug: EB-001~6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
9848187|NCT03193736|Experimental|implant|
9848188|NCT03194217|Experimental|BEN-2001, 0.5mg|Experimental treatment
9848189|NCT03194217|Placebo Comparator|Placebo|Placebo comparator
9848190|NCT03194217|Experimental|BEN-2001, 1.0mg|Experimental treatment
9848191|NCT03194217|Experimental|BEN-2001, 3.0mg|Experimental treatment
9848192|NCT03194334|No Intervention|Control|continued their omnivorous diet throughout the entire study
9848193|NCT03194334|Experimental|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
9848194|NCT03194334|Experimental|Veg+ creatine and beta-alanine|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
9848195|NCT03194373|Experimental|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
9848196|NCT03194464|Experimental|Task-failure, Extended Session|Repeated sub-maximal gripping exercise with the less affected hand to task-failure - followed by repeated measurements (5) during recovery period
9848197|NCT03194490|Experimental|The combined intervention group|The combined intervention group will receive the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).
9848198|NCT03194490|Active Comparator|The standard intervention|The standard intervention group will receive cervical mobilization and home program (ROM exercises).
9848199|NCT03194503|Active Comparator|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
9848200|NCT03194503|No Intervention|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
9848201|NCT03194698|Experimental|MGX and Intense Pulsed Light Treatment (IPL)|Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
9848202|NCT03194698|Active Comparator|Meibomian Gland Expression (MGX)|Treatment with 4 visits and 4 treatments of MGX only
9848203|NCT03194737|Experimental|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
9848204|NCT03194737|No Intervention|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
9848205|NCT03194776|Experimental|LLG783|Patients will receive LLG783 i.v. infusion every 4 weeks for 12 weeks.
9848206|NCT03194776|Placebo Comparator|Placebo|Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
9848207|NCT03195010|Experimental|Group I (lower dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
9848208|NCT03195010|Experimental|Group II (higher dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
9848209|NCT03195517|Experimental|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Institute of Università degli Studi di Perugia. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.~Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.~This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls."
9848210|NCT03195517|No Intervention|No additional physical exercise|Usual recommendations for prevention of fractures in adults and elderly.
9848211|NCT03196076|Experimental|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
9848212|NCT03196076|Experimental|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
9848213|NCT03196076|No Intervention|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
9848214|NCT03196193|Experimental|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
9848215|NCT03196193|Active Comparator|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
9848216|NCT03196232|Experimental|Treatment (epacadostat, pembrolizumab)|Participants receive oral epacadostat BID on Days 1 to 21 and pembrolizumab IV over 30 minutes on Day 1, with cycles repeating every 21 days for up to 24 months, in the absence of disease progression or unacceptable toxicity.
9848217|NCT03196284|Experimental|Concizumab|Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes
9848218|NCT03196284|Active Comparator|Eptacog alfa and concizumab|Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase
9848219|NCT03196297|Experimental|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
9848220|NCT03196349|Active Comparator|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
9848221|NCT03196349|Active Comparator|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
9848222|NCT03196349|Active Comparator|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
9848223|NCT03196505|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
9848224|NCT03196505|Active Comparator|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
9848225|NCT03196635|Experimental|All Study Participants|All subjects will undergo their regularly scheduled full-field digital mammogram, consisting of bilateral, 2-view (craniocaudal [CC] and mediolateral oblique [MLO]) image acquisition. In addition, a study-specific, unilateral 2-view image set will obtained, utilizing the PA breast compression mode.
9848226|NCT03196791|Experimental|Deep neuromuscular block group|Sugammadex sodium 4mg/kg/IV after operation
9848227|NCT03196791|Experimental|Moderate neuromuscular group|Sugammadex sodium 2mg/kg/IV after operation
9848228|NCT03196973|Experimental|DF289 plus DF277|Otic solution
9848229|NCT03196973|Active Comparator|DF289|Otic solution
9848230|NCT03196973|Active Comparator|DF277|Otic solution
9848231|NCT03197025|Experimental|1/Arm 1 - Dose Escalation|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at escalating doses) + aldesleukin
9848232|NCT03197025|Experimental|2/Arm 2 - Maximum Tolerated Dose (MTD)|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at the MTD) + aldesleukin
9848233|NCT03197038|Experimental|Home-based walking exercise|Home-based exercise program: The exercise training group will participate in an educational session on exercise for CKD. Participants will receive a packet of information with an exercise prescription and a heart rate monitor that monitors the exercise. Participants will be asked to exercise (a brisk walk) at home, 3 times per week, for 30-60 minutes for 24 weeks. Participants will be contacted via phone biweekly or more frequently if they are behind the exercise routine, and the investigators will meet with them monthly to provide encouragement and progression of exercise, and to download the heart rate monitor.
9848234|NCT03197038|Active Comparator|Control|The control group will receive standard instructions on exercise for patients with kidney disease similar to what is commonly done in clinical practice. The control group will not receive an exercise prescription or heart rate monitor. Participants will be contacted via phone biweekly to answer any questions and ensure continued study participation. The control group will not meet with the investigators monthly.
9848235|NCT03197129|Experimental|SADE waiting room|children that will wait in the SADE waiting room
9848236|NCT03197129|No Intervention|Traditional waiting room|children that will wait in the traditional waiting room
9848237|NCT03197324|Active Comparator|Digoxin Alone first, then Digoxin With Bexagliflozin|
9848238|NCT03197324|Active Comparator|Digoxin with Bexagliflozin, then Digoxin alone|
9848239|NCT03197376|Experimental|Pneumosil Lot 1|Pneumosil Lot 1
9848240|NCT03197376|Experimental|Pneumosil Lot 2|Pneumosil Lot 2
9848241|NCT03197376|Experimental|Pneumosil Lot 3|Pneumosil Lot 3
9848242|NCT03197376|Active Comparator|Synflorix|Synflorix
9848243|NCT03197389|Other|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
9848244|NCT03197389|Other|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
9848245|NCT03197389|Other|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
9848246|NCT03197389|Other|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
9848247|NCT03197389|Other|Cohort A3|Cohort A3 will include patients with ER positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
9848248|NCT03197389|Other|Cohort B3|Cohort B3 will include patients with a ER positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
9848249|NCT03197558|Other|Tube insertion using Tube Delivery System (TDS)|Active Tymbion iontophoresis and tube insertion using the TDS
9848250|NCT03197883|Experimental|Group 1|Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
9848251|NCT03197883|Other|Group 2|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
9848252|NCT03198000|Experimental|Formula # 13418-148|
9848253|NCT03198000|Experimental|Formula # 13418-158|
9848254|NCT03198000|Active Comparator|Control Formula # PF004390|
9848255|NCT03198221|Active Comparator|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
9848256|NCT03198221|Active Comparator|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
9848257|NCT03198221|Active Comparator|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
9848258|NCT03198221|Active Comparator|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
9848259|NCT03198507|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin
9848260|NCT03198507|Active Comparator|Active Comparator|Active comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole; as well as separate Riboflavin
9517020|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
9517021|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
9848261|NCT03198520|Other|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
9848262|NCT03198715|Experimental|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
9848263|NCT03198715|Experimental|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
9848264|NCT03198715|Experimental|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
9848265|NCT03198715|Experimental|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
9848266|NCT03198715|Placebo Comparator|Placebo|Participants receive saline by intravenous infusion over six hours
9848267|NCT03198754|Experimental|PEI Experimental Light|Ambient light fixture installed in the patient's hospital room
9848268|NCT03198754|Active Comparator|Comparison Light|Ambient light fixture installed in the patient's hospital room
9848269|NCT03198767|Experimental|Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
9848270|NCT03198767|Experimental|Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
9848271|NCT03198767|Experimental|Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
9848272|NCT03198767|Experimental|Part A: LIK066 + P1: 8% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
9848273|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
9848274|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
9848275|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)
9848276|NCT03198871|Experimental|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
9848277|NCT03198871|Placebo Comparator|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
9848278|NCT03199079||Group 1: Non-pregnant women|Non-pregnant women with normal pelvic floor
9848279|NCT03199079||Group 2: Pregnant women|Pregnant women; 22-29 weeks of pregnancy
9848280|NCT03199118|Experimental|CAF+SCTG+PRF|The patients suffering from class I or II gingival recession in the intervention group will receive a subepithelial connective tissue graft (SCTG) covered by platelet rich fibrin membrane (PRF) followed by a coronally advanced flap (CAF)
9848281|NCT03199118|Active Comparator|CAF+SCTG|Control group patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG only
9848282|NCT03199872|Experimental|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
9848283|NCT03199911|Experimental|Topical Antibiotic Ointment|Intervention: 200 patients in the antibiotic arm will receive either erythromycin or bacitracin, based on allergies, surgeon preference, and antibiotic availability. If neither antibiotic is obtainable by the patient, bacitracin polymyxin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
9848284|NCT03199911|Placebo Comparator|Topical Non-Antibiotic Ointment|Intervention: 200 patients in the placebo group will receive mineral oil/petrolatum-based artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.
9848285|NCT03199963|Experimental|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
9848286|NCT03199963|Placebo Comparator|Matching Placebo Gel|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
9848287|NCT03200366|Active Comparator|Tailored DVD|Tailored digital video disc (DVD)
9848288|NCT03200366|Active Comparator|Tailored DVD + Patient Navigation|Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
9848289|NCT03200366|No Intervention|Usual Care|Care normally provided by a nurse in the endoscopy department of the healthcare system
9848290|NCT03200535|No Intervention|Usual care|Usual care
9848291|NCT03200535|Active Comparator|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
9517022|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
9848292|NCT03200535|Active Comparator|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
9848293|NCT03200535|Active Comparator|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
9848294|NCT03200860|Active Comparator|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
9848295|NCT03200860|Placebo Comparator|Placebo|Matching Placebo 10 mg daily, oral, 30 days
9848296|NCT03200912|Active Comparator|Picato|Picato® (ingenol mebutate) gel, 0.15% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
9848297|NCT03200912|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.15% [Test]
9848298|NCT03200912|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
9848299|NCT03200925|No Intervention|Group A - no video group|"Group A will be asked a short survey:~their intention to practice skin to skin at the time of delivery~if they participated in skin to skin in a previous pregnancy~if they had any formal education about skin to skin~if they did have formal education was it either~a.) Provided at a prenatal appointment,~b.) A formal class led by either a nurse or a lactation consultant.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
9848300|NCT03200925|Experimental|Group B - video group|"Group B will be asked the same short survey as group A.~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
9848301|NCT03201003|Active Comparator|AR101|AR101 powder provided in capsules & sachets
9848302|NCT03201003|Placebo Comparator|Placebo|Placebo powder provided in capsules & sachets
9848303|NCT03201211|Experimental|10-10-10-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, PE-PilA and UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
9848304|NCT03201211|Experimental|10-10-3-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
9848305|NCT03201211|Placebo Comparator|PLACEBO|Subjects who received two doses of placebo (saline solution), administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974) and were enrolled in the study.
9848306|NCT03201562|Experimental|Aceclidine+tropicamide combination|Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)
9848307|NCT03201562|Active Comparator|Aceclidine|Aceclidine single dose
10207522|NCT05207735|Experimental|GROUP 1|"Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
10207523|NCT05207683||patients with pulmonary hypertension|patients who are more than 18 years old , diagnosed with pulmonary hypertension by echocardiography
9848308|NCT03201562|Sham Comparator|Vehicle|Vehicle single dose
9848309|NCT03201809|Experimental|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
9848310|NCT03201809|Active Comparator|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
9848311|NCT03201900|Experimental|E2007|The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period [6 weeks] and the Maintenance Period [26 weeks]) and the 8 mg Treatment Phase (the Titration Period [4 weeks] and the Maintenance Period [26 weeks]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.
9935096|NCT04203199|Experimental|Real rTMS to the mPFC using H7 Coil|One session of low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
10207524|NCT05207657|Experimental|Lentiviral vector transduced CD34+ cells|The investigational product is patient-specific and corresponds to cryopreserved autologous CD34+ cells transduced ex vivo with the pCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.
10207525|NCT05207631|No Intervention|Control cohort|Participants in the control cohort received standard care.
10207526|NCT05207631|Active Comparator|Cohort with intervention|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhaler on admission to our department. Their inhalers are adapted in accordance with a prescribing guide.
10207527|NCT05207618|Experimental|IBS PATIENTS|Natural specific tannin, chestnut
10207528|NCT05207605|Experimental|Rhythmic Stabilization (RS)|The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended
10207529|NCT05207605|Experimental|McKenzie technique|McKenzie exercises will be guided to conduct four extension exercises and three flexion exercises.
10207530|NCT05207527|Experimental|Cardiovascular exercise|Cycloergometer
10207531|NCT05207527|Experimental|Muscle strength|Strength exercises will be performed during the hemodialysis session.
10207532|NCT05207527|Experimental|Mixed|Both aerobic and muscular strength exercises will be performed.
10207533|NCT05207527|No Intervention|Control|Conventional treatment or dyalisis usual care
10207534|NCT05207514|Experimental|Nanoxel M|AC(Doxorubicin, Cyclophosphamide) followed by Nanoxel M
10207535|NCT05207514|Active Comparator|Taxotere|AC(Doxorubicin, Cyclophosphamide) followed by Taxotere
10207536|NCT05207501|Active Comparator|Moderate-intensity intermittent training (MIIT)|The MIIT will be conducted on a cycle ergometer (Lode Ex. calibur Sport Ergometer, Lode B.V., the Netherlands) in normoxia (FiO2 = ~ 21%). The participants will perform the MIIT starting with the ergometer resistance set to obtain the %HRmax set (~75-80%) during 5 minutes and will rest 5 minutes after each interval of exercise. The HRmax will be considered as 200 - age.
9848312|NCT03202134||opioid free anesthesia (OFA)|The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
9848313|NCT03202134||opioid anesthesia (OA)|OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.
10207537|NCT05207501|Experimental|MIIT during intermittent hypoxic exposure (IHYP + MIIT)|A normobaric hypoxic chamber (ATS Altitude Training, Sydney, Australia) will be used for this protocol. The chamber (2.4 m x 5 m x 2.5 m) allows, via a filter and compressor system, to extract oxygen molecules and to reduce the fraction of inspired oxygen (FiO2) with no modification of the barometric pressure.
10207538|NCT05207501|Experimental|MIIT during intermittent blood flow restriction (IBFR + MIIT)|The IBFR + MIIT protocol will be performed while cycling in normoxia (FiO2 = ~ 21%). Elastic, pneumatic cuffs (BStrong, Park City, Utah, USA) will be administered as high as possible at the inguinal crease of the upper thigh and will be inflated during the cycling to the set pressure of 400 mmHg (except for the first training session, it will be of 250 mmHg to minimize soreness and to accustom patients to vascular occlusion training). The cuffs will be deflated at interval rest.
9848314|NCT03202264||TAPERMD|80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities
9848315|NCT03202472|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
9848316|NCT03202511|Active Comparator|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
9848317|NCT03202511|Experimental|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
9848318|NCT03202550|Placebo Comparator|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
9848319|NCT03202550|Active Comparator|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
9848320|NCT03203291|Experimental|Tethered Pelvic Assist Device (TPAD) Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
9848321|NCT03203447|Active Comparator|Active|Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection
9848322|NCT03203447|Sham Comparator|Control|Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure
9848323|NCT03203564|Active Comparator|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
9848324|NCT03203564|Placebo Comparator|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
9848325|NCT03203681|Other|Natesto|Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.
9848326|NCT03204279|Experimental|Netupitant 1.33 mg/kg plus Palonosetron|Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients < 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.
9848327|NCT03204279|Experimental|Netupitant 4 mg/kg plus Palonosetron|Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients < 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.
9848328|NCT03204526|Experimental|low frequency stimulation (LFS)|Low-frequency deep brain stimulation of the subthalamic nucleus
9848329|NCT03204942|Active Comparator|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
9848330|NCT03204942|Active Comparator|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
9848331|NCT03204942|Active Comparator|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
9848332|NCT03204981|Experimental|Intramural Needle Ablation|
9848333|NCT03205046|Experimental|Part 1 continuous dose for vistusertib|acalabrutinib daily + vistusertib daily
9848334|NCT03205046|Experimental|Part 1 intermittent dose for vistusertib|acalabrutinib daily + vistusertib 5 days on and 2 days off
9848335|NCT03205150|Experimental|LIK066 30 mg|Film coated tablet of LIK066 30 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
9848336|NCT03205150|Experimental|LIK066 150 mg|Film coated tablet of LIK066 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
9848337|NCT03205150|Experimental|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
9848338|NCT03205488|Active Comparator|Cohort 1|Moderate to Advanced PD Population Randomized 1:1:1
9848339|NCT03205488|Active Comparator|Cohort 2|Early/de novo Randomized 2:1
9848340|NCT03205566|Active Comparator|Arm A Raltegravir, then Raltegravir/Lamivudine|7 days Raltegravir 400mg bd followed by minimum 4 weeks wash out and then 7 days Raltegravir 400mg/lamivudine 150mg (oral tablets) bd.
9848341|NCT03205566|Active Comparator|Arm B Raltegravir/Lamivudine, then Raltegravir|Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days followed by a minimum of 4 weeks wash out and then 7 days Raltegravir 400mg bd.
9848342|NCT03206749|Experimental|VX-150|
9848343|NCT03206749|Active Comparator|Hydrocodone Bitartrate/Acetaminophen (HB/APAP)|
9848344|NCT03206749|Placebo Comparator|Placebo|
9848345|NCT03206788|Experimental|Losartan group|Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
9848346|NCT03206788|Placebo Comparator|Placebo group|Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.
9848347|NCT03206918|Experimental|Zanubrutinib|
9848348|NCT03206970|Experimental|Zanubrutinib|Zanubrutinib (160 milligrams) administered orally twice daily
9848349|NCT03207022|Active Comparator|lidocaine 2% with normal saline|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
9848350|NCT03207022|Experimental|lidocaine 2% with clonidine|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.
9848351|NCT03207035|Active Comparator|20 ml of lidocaine 2% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
9848352|NCT03207035|Experimental|40 ml 0f lidocaine 1% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)
9848353|NCT03207074|Other|All patients|Single study arm. All patients who participate in the study will receive conventional histological diagnosis and diagnosis with the new technology (iKnife)
9848354|NCT03207243|Experimental|Subjects receiving GSK3772847|Eligible subjects will receive GSK3772847 once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
9848355|NCT03207243|Placebo Comparator|Subjects receiving placebo drug|Eligible subjects will receive placebo once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
9848356|NCT03207386|Experimental|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
9848357|NCT03207399|Other|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
9848358|NCT03207438|Experimental|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
9848359|NCT03207438|Placebo Comparator|Placebo 1|Placebo OD for 6 weeks
9848360|NCT03207438|Experimental|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
9848361|NCT03207438|Placebo Comparator|Placebo 2|Placebo OD for 6 weeks
9848362|NCT03207750|Experimental|HRV PCV-free Liq Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
9848363|NCT03207750|Active Comparator|HRV Lyo Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).
9848364|NCT03207763|Experimental|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
9848365|NCT03207763|Experimental|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
9848366|NCT03208088|Experimental|Sequence 1|etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental)
9848367|NCT03208088|Experimental|Sequence 2|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator)
9848368|NCT03208088|Experimental|Sequence 3|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental)
9848369|NCT03208088|Experimental|Sequence 4|etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental)
9848370|NCT03208088|Experimental|Sequence 5|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental)
9848371|NCT03208088|Experimental|Sequence 6|etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental / etafilcon A Test Lens 1 (experimental)
9848372|NCT03208088|Experimental|Sequence 7|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental)
9848373|NCT03208088|Experimental|Sequence 8|etafilcon A Test Lens 1 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental / etafilcon A Test Lens 3 (experimental)
9848374|NCT03208088|Experimental|Sequence 9|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental / etafilcon A Control Lens (Active Comparator) /etafilcon A Test Lens 4 (experimental)
9848375|NCT03208088|Experimental|Sequence 10|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental / etafilcon A Control Lens (Active Comparator)
9848376|NCT03208166|Experimental|Ischemic Conditioning|Doctormate device is used daily.
9848377|NCT03208166|Other|Usual Care|Standard medical care.
9922949|NCT00844948||Chinese speakers|Chinese speakers (Mandarin or Cantonese). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
9922950|NCT00844961|Experimental|Internet CBT|10 weeks of internet delivered cognitive behaviour therapy
9922951|NCT00844961|No Intervention|Waiting list|Waiting list which is offered treatment after completion of post intervention assessments
9922952|NCT00844974|Other|1|
9922953|NCT00845052||First group of house staff|First group of house staff to be surveyed
9922954|NCT00845052||Second group of house staff|Second group of house staff to be surveyed
9922955|NCT00845052||Thirst group of house staff|Third group of house staff to be surveyed
9922956|NCT00845078||1|Immediate reconstruction followed by radiation therapy
9922957|NCT00845078||2|Radiation therapy followed by delayed reconstruction
9922958|NCT00845091|Experimental|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
9922959|NCT00845091|Active Comparator|Heart Healthy Education|Educational topics on heart health (e.g., nutrition, smoking, sleep)
9922960|NCT00845104|Experimental|Arm I|See Detailed Description
9517023|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
9848378|NCT03208192|Experimental|ErbeJet|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
9848379|NCT03208192|Experimental|Misonix|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)
9848380|NCT03208673|Experimental|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
9848381|NCT03208933|Experimental|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
9848382|NCT03209050|Other|Central Venous Access Placement|Central venous access placement
9848383|NCT03209362|Experimental|SI-613|
9848384|NCT03209362|Placebo Comparator|Placebo|
9848385|NCT03209492||Leuprorelin acetate|Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
9848386|NCT03209505|Other|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
9848387|NCT03209505|Other|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
9848388|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin acetate was subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants received Leuprorelin as part of routine medical care.
9848389|NCT03209570|Experimental|TENA Identifi with sensor wear data|All individuals in this arm will receive care planning using TENA Identifi sensor wear data
9848390|NCT03209570|Active Comparator|TENA Identifi without sensor wear data|All individuals in this arm will receive care planning without using TENA Identifi sensor wear data
9848391|NCT03209882|Experimental|One TILS, one sham, and then five TILS interventions|Participants first received a TILS intervention, followed by a sham session one week later. Then, participants received another five weekly TILS interventions.
9848392|NCT03209882|Experimental|One sham, then six TILS interventions|Participants first received a sham session, followed by six weekly TILS sessions.
9848393|NCT03209973|Experimental|Tislelizumab|Tislelizumab 200 mg administered intravenously (IV) every-3-weeks (Q3W)
9848394|NCT03210155|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
9848395|NCT03210155|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
9848396|NCT03210220|Experimental|pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
9848397|NCT03210220|No Intervention|control group|There is no block.
9848398|NCT03210259|Experimental|BI 695501|
9848399|NCT03210259|Active Comparator|Humira®|
9848400|NCT03210337|Experimental|Active|A-101 Topical Solution
9848401|NCT03210337|Placebo Comparator|Vehicle|Vehicle
9848402|NCT03210376|Experimental|Deep Neuromuscular Blockade (NMB) + Sugammadex|"Deep Neuromuscular Blockade (NMB) given during surgery.~Sugammadex intravenously as a single bolus injection after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
9848403|NCT03210376|Experimental|Moderate Neuromuscular Blockade (NMB) + Neostigmine|"Moderate Neuromuscular Blockade (NMB) given during surgery.~Neostigmine intravenously slowly over a period of at least 1 minute after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
9848404|NCT03210519|Experimental|Eleutherococcus senticosus|Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial
9848405|NCT03210519|Placebo Comparator|Placebo|Fructus Ziziphi Jujube concentrated juice15ml/vial
9848406|NCT03210701|Other|Patients requesting a HIV screening test|
9848407|NCT03210961|Experimental|PF-06826647 tablet|
9848408|NCT03210961|Placebo Comparator|Placebo tablet|
9848409|NCT03210961|Experimental|PF-06826647 oral suspension|
9848410|NCT03210961|Placebo Comparator|Placebo oral solution/suspension|
9922961|NCT00845117|Experimental|Limbal Stem Cell Transplant|The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.
9922962|NCT00845156|Active Comparator|Anti-Oxidant|Alpha Lipoic Acid
9922963|NCT00845156|Placebo Comparator|Placebo|Placebo
9848411|NCT03211117|Experimental|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
9848412|NCT03211117|Experimental|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
9848413|NCT03211156|Placebo Comparator|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
9848414|NCT03211156|Experimental|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
9848415|NCT03211234|Experimental|2.0 mg DE-122|2.0 mg DE-122 and Lucentis ® 0.5 mg
9848416|NCT03211234|Experimental|4.0 mg DE-122|4.0 mg DE-122 and Lucentis ® 0.5 mg
9848417|NCT03211234|Sham Comparator|Sham|Sham and Lucentis ® 0.5 mg
9848418|NCT03212261|Experimental|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
9848419|NCT03212326|Experimental|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
9848420|NCT03212365|Other|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
9848421|NCT03212365|Experimental|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
9848422|NCT03212521|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 weeks.
9848423|NCT03212638|Experimental|Baricitinib T1 (Part A)|4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)
9848424|NCT03212638|Experimental|Baricitinib T2 (Part A)|4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)
9848425|NCT03212638|Experimental|Baricitinib R (Part A)|4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)
9848426|NCT03212638|Experimental|Baricitinib TF Fasted (Part B)|4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)
9848427|NCT03212638|Experimental|Baricitinib TF Fed (Part B)|4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)
9848428|NCT03212690|Experimental|Mechanically ventilated subjects|Subjects receiving invasive mechanical ventilation (Duration of ventilation <=48 hours) will be evaluated using standard care investigations.
9848429|NCT03213210|Other|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
9848430|NCT03213366|Experimental|E-PrEP- Peer-Led Intervention about PrEP|8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm. Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms. PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues. All contents will be formatted to be both mobile device accessible.
9848431|NCT03213366|Active Comparator|BxNow - General Health Campaign|BxNow is an attention-matched control. Eight of the 16 PLs will be randomly assigned to the BxNow arm. The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm. Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups. General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
9922964|NCT00845169|Experimental|Diesel Exposure|1 hour exposure to diesel exhaust at 300 µg/m3 during intermittent exercise
9848432|NCT03213405|Active Comparator|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
9848433|NCT03213405|Experimental|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
9848434|NCT03213405|Experimental|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
9848435|NCT03213405|Experimental|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
9848436|NCT03213509||Perinatal Death With Pause Point(s) Observed, Intervention Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the intervention arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
9848437|NCT03213509||Perinatal Death With Pause Point(s) Observed, Control Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the control arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
9848438|NCT03213626|Experimental|Cabozantinib + erlotinib|
9848439|NCT03213938|Experimental|Acupuncture|The participants in the acupuncture group will receive treatment that consists of 20 acupuncture sessions over an 8-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Sanyinjiao (SP6), Zhongliao (BL33), Shenshu (BL23), and Huiyang (BL35), were selected as acupoints protocol. SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL32 is in the sacral region, in the second posterior sacral foramen; BL33 is in the third posterior sacral foramen; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
9848440|NCT03213938|Sham Comparator|Sham acupuncture|The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
9848441|NCT03214081||Vonoprazan 10 mg or 20 mg|Usually, for adults, 10 mg of vonoprazan administered orally once daily. If that dosing proved insufficient, the dosage may have been increased up to 20 mg once daily. Participants received vonoprazan as part of a routine medical care.
9848442|NCT03214094||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
9848443|NCT03214198||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
9848444|NCT03214224|Experimental|remote PFT (rPFT) validation|Subjects in this arm perform both standard and remote PFT assessments in order to validate the procedure.
9848445|NCT03214367|Experimental|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
9848446|NCT03214367|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
9848447|NCT03214367|Experimental|LY900014 Postmeal (Open Label)|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
9848448|NCT03214367|Experimental|LY900014 - Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
9848449|NCT03214367|Active Comparator|Insulin Lispro (Humalog)-MEE|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
9848450|NCT03214367|Experimental|LY900014 Postmeal (Open Label)-MEE|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
9848451|NCT03214380|Experimental|LY900014|LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
9848452|NCT03214380|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
9848453|NCT03214380|Experimental|LY900014 Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
9848454|NCT03214380|Active Comparator|Insulin Lispro (Humalog) MEE|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
9848455|NCT03214406|Experimental|Arm & Hammer Advance White Brilliant Sparkle (Test product)|2X daily brushing for 12 weeks with Arm & Hammer Advance White Brilliant Sparkle (Test product). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
9848456|NCT03214406|Active Comparator|Crest Cavity Protection Regular Toothpaste (Negative Control)|2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
9848457|NCT03214588|Placebo Comparator|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
9848458|NCT03214588|Experimental|TAK-831 75 mg|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
9848459|NCT03214588|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
9848460|NCT03214640|Active Comparator|Palpation with spinal block (Group C-P)|insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest) for placement of spinal block for cesarean delivery
9848461|NCT03214640|Active Comparator|Palpation with neuraxial block (Group L-P)|the needle insertion site for the neuraxial block will be identified with palpation for labor analgesia, using the spinous process and iliac crest for reference
9848462|NCT03214640|Experimental|Rivanna Accuro Ultrasound Device with spinal block (Group C-R)|insertion will be identified with Rivanna Accuro U/S device for placement of spinal block for cesarean delivery
9848463|NCT03214640|Experimental|Rivanna Ultrasound Device with neuraxial block (Group L-R)|insertion will be identified with Rivanna Accuro U/S device for placement of neuraxial block (combined spinal epidural) for labor analgesia
9848464|NCT03214952||Vonoprazan 20 mg|The usual adult dosage for oral use is 20 mg of vonoprazan administered orally once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use was administered for a total of 4 weeks of treatment, and if that dosing proved insufficient, the administration may have been extended, but for no longer than 8 weeks of treatment. Participants received vonoprazan as part of a routine medical care.
9848465|NCT03215667|Experimental|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
9848466|NCT03215706|Experimental|Module A|Chemotherapy/Biologics combined
9848467|NCT03215706|Active Comparator|Module B|Chemotherapy Combination
9848468|NCT03215758|Active Comparator|QAW039|QAW039 once daily
9848469|NCT03215758|Placebo Comparator|Placebo|Placebo once daily
9848470|NCT03215771|Experimental|MyoPro + Motor Learning-Based Therapy|Subjects received 9 weeks of motor learning-based therapy in combination with use of MyoPro myoelectric elbow wrist hand orthosis, followed by 9 weeks of home use with a customized exercise program.
9848471|NCT03215901|Experimental|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
9848472|NCT03215901|Sham Comparator|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
9848473|NCT03215901|No Intervention|Pure Control|Participants view no video.
9848474|NCT03216200|Experimental|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
9848475|NCT03216226|Experimental|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
9848476|NCT03216226|Experimental|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
9848477|NCT03216265|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
9922965|NCT00845169|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
9922966|NCT00845208|Active Comparator|Case Management|
9922967|NCT00845208|Experimental|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
9848478|NCT03216265|Other|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
9848479|NCT03216265|Other|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
9848480|NCT03216382|Experimental|Attention Training Technique|Participants in this arm will listen to the Attention Training Technique. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
9848481|NCT03216382|Placebo Comparator|Control Condition|Participants in this arm will listen to the control condition recording. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
9848482|NCT03216512|Experimental|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
9848483|NCT03216512|Experimental|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
9848484|NCT03216746|Experimental|Oral orientation and App for smartphone|The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
10207539|NCT05207501|Experimental|Moderate-intensity eccentric cycling (MIEC)|The MIEC will be conducted on a cycle ergometer (Excalibur, Lode, Groningen, The Nederlands) in normoxia (FiO2 = ~ 21%). The participants will be instructed to resist against the pedal movement (cadence set at 15 revolutions/min) to produce the required torque (set to obtain the 75-80%HRmax) indicated by visual feedback for 5 minutes and will rest 5 minutes after each interval of exercise. The HRmax will be considered as 200 - age. The HR responses will be monitored (Polar Electro Oy, Kempele, Finland).
10207540|NCT05207488|Experimental|Exercise + Prebiotic|The Exercise + Prebiotic intervention group will consume 10 g/d of fructo-oligosaccharides (FOS). Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
10207541|NCT05207488|Placebo Comparator|Exercise + Placebo|The Exercise + Placebo group will consume 10 g/d of a placebo (maltodextrin) powder every day. Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).
10207542|NCT05207475|Experimental|RIC group|RIC treatment and regular treatment.
10207543|NCT05207475|No Intervention|Regular treatment|Regular treatment alone.
10207544|NCT05207436|Experimental|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Oxytocin|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (B-CBCT) weekly. Prior to each session, the Veteran participant will self-administer intranasal oxytocin. The estimated length of treatment participation is 8 to 15 weeks. All procedures take place in the Veterans home via home-based clinical video teleconferencing (CVT).
10207545|NCT05207371|Experimental|GAIA-102 alone|GAIA-102: 1 vial (2 x 10^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks.
10207546|NCT05207371|Experimental|GAIA-102 with Pembrolizumab|"GAIA-102: 1 vial (2 x 10^8 cells) / dose at a fixed dose, 1 to 3 doses / week for 3 consecutive weeks.~Pembrolizumab：200 mg Administer on Day 1."
10207547|NCT05207345|Experimental|Experimental Group|"90-minute session divided into:~45 minutes of core stability treatment~45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
10207548|NCT05207345|Active Comparator|General Group|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
10207549|NCT05207332|Experimental|Vegan product|
10207550|NCT05207332|Active Comparator|Control|
10207551|NCT05207319|Experimental|the MRDI group (Moral Reasoning Development Intervention)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
10207552|NCT05207319|No Intervention|the control group|The control group is the Treatment as Usual (TAU).
10207553|NCT05207267|Experimental|testing arm|ventilated with different VT using an EIT monitor (PulmoVista® 500, Dräger, Lübeck, Germany)
10207554|NCT05207254||difficult airway|C-L≥3 grade
10207555|NCT05207254||none difficult airway|C-L<3 grade
10207556|NCT05207241||Control group|Under the professional guidance of doctors, participating women (1) breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding
10213501|NCT03896360|Experimental|Food order behavioral intervention plus standard care|Subjects will receive standard nutrition counseling and additional carbohydrate-last food order behavioral counseling.
10213502|NCT03896360|Other|Standard care|Subjects will receive standard nutrition counseling.
10213503|NCT03893903|Experimental|IDH1 peptide vaccine|IDH1R132H peptide vaccine alone
10213504|NCT03893903|Experimental|combination|IDH1R132H peptide vaccine and Avelumab
10213505|NCT03893903|Experimental|Avelumab|Avelumab alone
9848485|NCT03216746|Experimental|Oral orientation|The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases.
9848486|NCT03216746|Experimental|Video orientation and App for smartphone|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
9848487|NCT03216746|Experimental|Video orientation|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience.
9848488|NCT03216850||Patients in ICU requiring parenteral nutrition|
9848489|NCT03216902|Placebo Comparator|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
9848490|NCT03216902|Experimental|Ultra-low dose 0.0005% DE-126|
9848491|NCT03216902|Experimental|Low dose 0.001% DE-126|
9848492|NCT03216902|Experimental|Medium dose 0.002% DE-126|
9848493|NCT03216902|Experimental|High dose 0.003% DE-126|
9848494|NCT03216902|Active Comparator|0.005% Latanoprost|
9848495|NCT03216954|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules two times daily.
10207557|NCT05207228|No Intervention|Treatment as usual|After completing the inpatient care (at discharge of inpatient care), patients randomized to TAU will receive day-care / outpatient treatment.
10207558|NCT05207228|Experimental|Treatment as usual + CBT4CBT|After completing the inpatient care (at discharge), the patients randomly assigned to the experimental condition will receive the TAU + CBT4CBT a web-based treatment which has been tested on individuals with cocaine use disorder in America by the team of Dr. K.M. Carroll.
10207559|NCT05207215|Active Comparator|Group A: Video Conferencing|Video conferencing is a 2-way interactive session that is enabled using telecommunication networks and the internet. The investigators will be working with 3rd party provider to create the video conferencing platform. Subjects can login to do SAFE exercises while physiotherapists monitor remotely. Subjects will complete two sessions per week (1hour for each session) for 12 weeks.
10207560|NCT05207215|Active Comparator|Group B: Gamification|Gamification refers to exercise-driven gaming, where games are developed with specifications/parameters that incorporate exercise movements. Currently, the investigators have an ongoing pilot study on game-assisted rehabilitation at SGH Physiotherapy Outpatient clinic and the exercise games are developed by an external company. The investigators will engage an external company to develop exercise games based on the exercises used in SAFE programme. Each game will have different difficulty levels to provide progressive training for subjects
9848496|NCT03216954|Experimental|Low Dose n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine two times daily.
9848497|NCT03216954|Experimental|High Dose n-Acetylcysteine|Subjects will receive 1.2 g oral n-acetylcysteine two times daily.
9848498|NCT03217968|Experimental|Active|120 minutes of Cefaly® Abortive Program device stimulation as abortive treatment of an early stage migraine attack
9848499|NCT03218397|Active Comparator|Standard blood culture and AST|Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
9848500|NCT03218397|Active Comparator|Rapid organism identification and AST|Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.
9848501|NCT03218566|Other|Single Arm|Single Arm - Use of Indigo Aspiration System (mechanical thrombectomy) to treat pulmonary embolism
9848502|NCT03218592|Experimental|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
9848503|NCT03218592|Experimental|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
9848504|NCT03218592|Experimental|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
10207561|NCT05207215|Active Comparator|Group C: Self Guided|Subjects in the self-guided exercise programme will be instructed to do SAFE exercises at least twice a week for an hour each by themselves.
10207562|NCT05207215|Placebo Comparator|Group D: Self Guided|Subjects in the self-guided exercise programme will be instructed to do SAFE exercises at least twice a week for an hour each by themselves.
10207563|NCT05207189|Experimental|UVT|Biological sling used as a replacement of the synthetic sling.
10207564|NCT05207176|Experimental|DWP16001|Total number of subjects: 24 (8 Korean, 8 Caucasian, and 8 Hispanic)
10207565|NCT05207163|Experimental|Received CME|
10207566|NCT05207163|No Intervention|Not received CME|
10207567|NCT05207150|Active Comparator|LINQ II/Apple Watch Series 6|
10207568|NCT05207150|Active Comparator|LINQII/SkyLabs CART-I ring|
10207569|NCT05207072||Mobile Cardiac Rehabilitation (mCR) group|The mCR programme involves a home-based programme for 12 months in which patients are supplied with a smartphone/application with a data subscription from LIVA. Through this application patients are able to measure and register physical activity, heart frequency and intensity (BORG scale) and can monitor progress. A healthcare professional (coach) also has access to a portal to monitor progress of different patients, advice on rehabilitation approach and stimulate compliance. Together with their coaches every patient makes their own rehabilitation programme. Patients will be coached for 12 months starting intensively with decreasing amounts of contacts over time.
10207570|NCT05207072||Traditional Cardiac Rehabilitation (CR) group|The traditional CR programme involves standard a standard CR programme over a 6-8 weeks period. Subjects receive no advice or coaching after the end of the traditional CR program.
10207571|NCT05207033|Active Comparator|Unregulated ad condition|This arm will include exposure to unregulated e-cigarette ads or ads as they appear in modern media.
10207572|NCT05207033|Experimental|Regulated ad condition|This arm will include exposure to regulated e-cigarette ads or ads where we have taken out the appealing features.
9848505|NCT03218787|Experimental|XIENCE|Subjects will receive XIENCE family stents and if a subject was DAPT compliant and event free, then took 3 month DAPT, following with aspirin mono-therapy until 12 month
9848506|NCT03219216|Experimental|Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Arm A: Hepatitis C virus (HCV) genotype (GT) 1 to GT6 participants without cirrhosis (fibrosis stage F2 to F3) received glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
9848507|NCT03219216|Experimental|Arm B: GLE/PIB for 12 Weeks|Arm B: HCV GT1 to GT6 participants with compensated cirrhosis (F4) received GLE/PIB 300 mg/120 mg QD for 12 weeks.
9848508|NCT03219294|Active Comparator|Moderate Neuromuscular Blockade (NMB)|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.
9848509|NCT03219294|Active Comparator|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at Maine Medical Center (MMC) but is in common use since the advent of Sugammadex.
9848510|NCT03219320|Placebo Comparator|Placebo Oral Capsule|Up to 300 subjects: Placebo
9848511|NCT03219320|Experimental|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
9848512|NCT03219723||Vonoprazan 20 mg|For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.
9848513|NCT03219840|Experimental|CPC + Xylitol chewing gum, then Xylitol only chewing gum|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.
9848514|NCT03219840|Experimental|Xylitol only chewing gum, then CPC + Xylitol chewing gum|Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.
9848515|NCT03219866|Experimental|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
9848516|NCT03219866|Experimental|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
9848517|NCT03219892|Experimental|High-frequency rTMS|Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.
9848518|NCT03219892|Sham Comparator|Sham rTMS|Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
9848519|NCT03220048|Other|Cohort A: Sentinel Group|Sentinel group in which subjects received a challenge virus inoculum volume of 100uL on Day 0.
9848520|NCT03220048|Experimental|Cohort B: PrEP-001|PrEP-001 6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
9848521|NCT03220048|Experimental|Cohort B: Placebo|Nasal dose of placebo Comparator equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
9848522|NCT03220204|Experimental|PP-based health behavior intervention|Participants will undergo a 12-week, Positive Psychology (PP)-based health behavior intervention. Each weekly session will include (a) a review of the week's PP exercise, (b) a discussion of the rationale of the next week's PP exercise through a guided review of the PP manual, and (c) assignment of the next week's PP exercise. Additionally for the goal-setting portion, participants will (a) review their goals and behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week.
9848523|NCT03220204|Experimental|MI-based educational control condition|Participants will undergo 12 weekly phone sessions to learn about a different health behavior topic related to cardiac health. This Motivational Interviewing (MI)-based educational control condition will introduce these participants to motivational interviewing topics in concert with the health behavior education topics.
9848524|NCT03220204|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group will not receive any interventions between the baseline visit and follow-up visits.
9848525|NCT03220217|Experimental|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
9848526|NCT03220217|Experimental|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
9848527|NCT03220217|Experimental|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
9848528|NCT03220412|Experimental|Experimental Condition|Intervention was guns in movies. Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition Intervention is m
9848529|NCT03220412|No Intervention|Control Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
9848530|NCT03220737|Experimental|Cohort 1 (active, 12-17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.
9848531|NCT03220737|Placebo Comparator|Cohort 1 (placebo, 12 - 17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
9848532|NCT03220737|Experimental|Cohort 2 (active, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
9848533|NCT03220737|Placebo Comparator|Cohort 2 (placebo, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
9848534|NCT03220737|Experimental|Cohort 3 (active, 2 - 5 yrs)|Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
9848535|NCT03220737|Placebo Comparator|Cohort 3 (placebo, 2 - 5 yrs)|Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
9848536|NCT03220737|Other|Historical Control: Adult Bridging Population|This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
9848537|NCT03220958|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
9848538|NCT03220958|Placebo Comparator|Placebo|Normal saline, administered as an intravenous drip
9848539|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
9848540|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
9848541|NCT03221387|Other|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
9848542|NCT03221595|Experimental|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
9848543|NCT03221595|No Intervention|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
9848544|NCT03221738|Experimental|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
9848545|NCT03221764|Experimental|Amiodarone with CoSeal administered with CO2 driver|Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
9998195|NCT01515930|Active Comparator|Education Caregiver/Education Child|Participants will receive computer-delivered information. A brief computer delivered information session about diabetes related topics for both the caregiver and the child with diabetes.
10207573|NCT05206890||fluzoparib treatment|patients with Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
9848546|NCT03222037|Experimental|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
9848547|NCT03222037|Experimental|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
9848548|NCT03222141|Experimental|SAPIEN 3™ valve|
9848549|NCT03222349|Experimental|Interictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
9848550|NCT03222349|Experimental|Ictal/Peri-ictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
9848551|NCT03222414|Experimental|Arm A: Conical then Cylindrical|BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
9848552|NCT03222414|Active Comparator|Arm B: Cylindrical then Conical|BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
9848553|NCT03222427|Experimental|LY3314814|Single 50 milligram (mg) dose of LY3314814 administered orally
9848554|NCT03222427|Experimental|[13C415N3] LY3314814|Single 100 micrograms (μg) intravenous (IV) dose of [13C415N3] LY3314814 administered as an IV infusion.
9848555|NCT03222505|Experimental|Treadmill|
9848556|NCT03222505|Experimental|Overground Walking|
9848557|NCT03222583|Experimental|Glecaprevir/Pibrentasvir|"Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 or 16 weeks during the double-blind (DB) treatment period.~Participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
9848558|NCT03222583|Experimental|Placebo / Glecaprevir/Pibrentasvir|"Participants received placebo to glecaprevir/pibrentasvir for 8 or 16 weeks during the DB treatment period followed by glecaprevir/pibrentasvir (300 mg/120 mg) once daily for 8 or 16 weeks during the open-label (OL) treatment period.~In each period participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
9848559|NCT03223246|No Intervention|Usual care|
9848560|NCT03223246|Experimental|Additional teaching|
9848561|NCT03223272|Experimental|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
9848562|NCT03223337|Experimental|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
9848563|NCT03223337|Active Comparator|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
9848564|NCT03223337|Experimental|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
9848565|NCT03223337|Active Comparator|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
9848566|NCT03223649|Experimental|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
9848567|NCT03223649|Experimental|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
9848568|NCT03223909|Experimental|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
9848569|NCT03223909|Active Comparator|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.~1 drop every 4 hours for 90 days."
9848570|NCT03223909|Active Comparator|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.~1 drop every 4 hours for 90 days."
9848571|NCT03224130|Experimental|Nurse Phone Call|Families in this arm will receive a phone call within 96 hours of discharge
9848572|NCT03224130|Active Comparator|Standard of Care|This arm will receive standard of care.
9848573|NCT03224182|Experimental|Qapzola|Participants were randomized to receive a single dose of Qapzola 8 mg by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
9848574|NCT03224182|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of Qapzole-matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
9848575|NCT03224234|Experimental|Insulclock with feedback (Group A)|Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
9848576|NCT03224234|Active Comparator|Insulclock without feedback (Group B)|Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
9848577|NCT03224299|Experimental|Investigational Product #1 (IP1)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
9848578|NCT03224299|Experimental|Investigational Product #2 (IP2)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
9848579|NCT03224299|Active Comparator|Active Control|ChloraPrep® - Hi-Lite Orange® applicator
9848580|NCT03224299|Placebo Comparator|Negative Control|sterile 0.9% saline applied with single use applicator
9848581|NCT03224325|Other|Placebo (Pooled)|TAK-831 placebo-matching suspension, orally, once daily (QD) for up to Day 16.
9848582|NCT03224325|Experimental|TAK-831 100 mg|TAK-831 100 mg, tablets, orally, QD on Days 1 and 3 to 16.
9848583|NCT03224325|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, QD on Days 1 and 3 to 16.
9848584|NCT03224325|Experimental|TAK-831 600 mg|TAK-831 600 mg, tablets, orally, QD on Days 1 and 3 to 16.
9848585|NCT03224325|Experimental|TAK-831 15 mg|TAK-831 15 mg, suspension, orally, multiple doses (MD) daily, on Days 1 and 3 to 16.
9848586|NCT03224325|Experimental|TAK-831 800 mg|TAK-831 800 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
9848587|NCT03224325|Experimental|TAK-831 1200 mg|TAK-831 1200 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
9848588|NCT03224351|Placebo Comparator|Part 1: Placebo|Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
9848589|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Low Dose|Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
9848590|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Medium Dose|Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
9848591|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - High Dose|Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
9848592|NCT03224351|Active Comparator|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
9848593|NCT03224351|Experimental|Part 2: VX-659/TEZ/IVA TC|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
9848594|NCT03224351|Placebo Comparator|Part 3: Placebo|Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
9848595|NCT03224351|Experimental|Part 3: VX-659/TEZ/VX-561 TC|Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
9922968|NCT00845208|Experimental|Network Support + Contingency Mgmnt|12 weekly sessions intended to help patients change their social networks to be more supportive of abstinence. Contingency management component added to reinforce efforts to make network changes.
9922969|NCT00845221|Experimental|Imatinib|
9922970|NCT00845234|No Intervention|Standard of Care Group|Received the current standard of care as operationally defined by the investigators- Q&A session + Video
9922971|NCT00845234|Experimental|Intervention Group|Intervention group- Patients will receive the brief educational CBT intervention + video and Q&A session
9922972|NCT00845247|Placebo Comparator|Control|Control group patients will receive usual medical plus usual supportive treatment.
9922973|NCT00845247|Active Comparator|Case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
9922974|NCT00845260|Experimental|Internet CBT|Internet-based cognitive behavior therapy (CBT).
9848596|NCT03224390|Experimental|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
9848597|NCT03224390|No Intervention|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
9848598|NCT03224403|Experimental|Test acetaminophen|Test acetaminophen 1000 mg dose
9848599|NCT03224403|Active Comparator|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
9848600|NCT03224403|Active Comparator|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
9848601|NCT03224403|Placebo Comparator|Placebo|Placebo
9848602|NCT03224520|Experimental|Fully enhanced|Peer recruitment and recommender CTHC
9848603|NCT03224520|Experimental|Recommender CTHC only|Recommender CTHC and standard online recruitment
9848604|NCT03224520|Experimental|Peer recruitment only|Peer recruitment and standard CTHC
9848605|NCT03224520|Experimental|Standard|Standard online recruitment and standard CTHC
9848606|NCT03224585|Experimental|Anakinra|100 mg subcutaneous injection
9848607|NCT03224585|Placebo Comparator|Placebo|100 mg NaCl 0.9% subcutaneous injection
9848608|NCT03224598|Experimental|No medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
10207574|NCT05206539|Experimental|SAP11-4 group (Gr CR)|The Gr CR will receive treatment with Curodont RepairTM (Credentis; Windisch, Switzerland), according to the manufacturer's instructions.
9848609|NCT03224598|Experimental|Medically abrading|A-101 40% with the identified DPN lesions medically abraded prior to treatment
9848610|NCT03224598|Experimental|Initial cohort - no medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
9848611|NCT03225001|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
9848612|NCT03225313|Placebo Comparator|control group|normal saline will be injected in the rectus sheath
9848613|NCT03225313|Active Comparator|Rectus block group|bupivicaine will be injected in the rectus sheath
9848614|NCT03225313|Experimental|Field block group|bupivicaine will be injected locally in a circular fashion surrounding the site of the hernia
9848615|NCT03225599|Experimental|Procedure|
9848616|NCT03225859|Experimental|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
9848617|NCT03226223|Placebo Comparator|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
9848618|NCT03226223|Experimental|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
9848619|NCT03226249|Experimental|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
9848620|NCT03226275|Experimental|Fasting: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
9848621|NCT03226275|Experimental|Fasting: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
9848622|NCT03226275|Experimental|Fed: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
9848623|NCT03226275|Experimental|Fed: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
9848624|NCT03226353|Experimental|somofilcon A 1-day soft contact lenses|Habitual and refitted wearers of omafilcon A were refit into somofilcon A for a week
9848625|NCT03226366||Pre-implementation (intervention site)|Adult patients age ≥18 years who received usual care after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
9848626|NCT03226366||Post-implementation (intervention site)|"Adult patients age ≥18 years eligible to receive immediate evaluation by multidisciplinary team (swarming) after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017"
10207575|NCT05206539|Active Comparator|CPP-ACFP group (Gr V)|The Gr V will receive treatment with MI varnishTM (GC Corporation, Tokyo, Japan), according to the manufacturer's instructions.
10207576|NCT05206539|Active Comparator|Resin infiltration group (Gr I)|The Gr I receive treatment with Icon Vestibular (DMG, Germany), according to the manufacturer's instructions.
9848627|NCT03226366||Pre-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
9922975|NCT00845260|Experimental|Group CBT|Group cognitive behavior therapy (CBT).
9848628|NCT03226366||Post-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017
9848629|NCT03226392|Active Comparator|QAW039|QAW039 once daily
9848630|NCT03226392|Placebo Comparator|Placebo|Placebo once daily
9848631|NCT03226457|Active Comparator|Empagliflozin/Placebo|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
9848632|NCT03226457|Active Comparator|Placebo/Empagliflozin|Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
9848633|NCT03226652||Patients with clinically suspected sleep disordered breathing (SDB)|Patients referred for Sleep disordered breathing assessment.
9848634|NCT03226691|Experimental|Single Cohort - Plerixafor|Plerixafor at a single dose of 240 microgram/kg
9848635|NCT03226769|Active Comparator|Thermalon|Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
9848636|NCT03226769|Experimental|TrueTear™|Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.
9848637|NCT03226899|Active Comparator|Lesinurad + XOI|lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI
9848638|NCT03226899|Placebo Comparator|Placebo + XOI|placebo tablet QD plus a stable, medically appropriate dose of an XOI
9848639|NCT03227445|Experimental|Treatment sequence A|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
9848640|NCT03227445|Experimental|Treatment sequence B|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
9848641|NCT03227445|Experimental|Treatment sequence C|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
9848642|NCT03227445|Experimental|Treatment sequence D|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
9848643|NCT03227692|Experimental|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
9848644|NCT03227692|Active Comparator|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
9848645|NCT03227861|Experimental|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
9848646|NCT03228017|Other|Psoriatic Disease Patients|Moderate to severe psoriatic disease
9848647|NCT03228017|No Intervention|Healthy Control|
9848648|NCT03228212|Experimental|TEST/CONTROL/CONTROL|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
9848649|NCT03228212|Experimental|CONTROL/TEST/TEST|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
9848650|NCT03228420|Active Comparator|HF10 therapy plus CMM|The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
9848651|NCT03228420|Other|CMM Alone|Conventional Medical Management
9848652|NCT03228433|Experimental|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
9848653|NCT03228433|Experimental|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
9848654|NCT03228433|Experimental|Cohort 3: TAK-418 30 mg Fasted + TAK-418 30 mg Fed|TAK-418 30 mg, capsule, in fasted state, orally, once on Day 1, followed by a 28-day washout period, further followed by TAK-418 30 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
9848655|NCT03228433|Experimental|Cohort 4: TAK-418 40 mg|TAK-418 40 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
9848656|NCT03228433|Experimental|Cohort 5: TAK-418 60 mg|TAK-418 60 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
9848657|NCT03228433|Placebo Comparator|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
9848658|NCT03228836|Experimental|Sintilimab (IBI308)|
9848659|NCT03228914|Active Comparator|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
9848660|NCT03228914|Active Comparator|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
9848661|NCT03229109|Experimental|Group 1|Age 18-25, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
9848662|NCT03229109|Experimental|Group 2|Age 26-35, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
9848663|NCT03229109|Experimental|Group 3|Age 36-45, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
9848664|NCT03229109|Experimental|Group 4|Age 46-50, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
9848665|NCT03229252|Placebo Comparator|Placebo|Placebo Inhalation solution twice daily for 28 days.
9848666|NCT03229252|Experimental|SPX-101 Low Dose|Inhalation solution twice daily for 28 days.
9848667|NCT03229252|Experimental|SPX-101 High Dose|Inhalation solution twice daily for 28 days.
9848668|NCT03229486|Experimental|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
9848669|NCT03229486|Active Comparator|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine & glycopyrrolate
9848670|NCT03229759|Experimental|Investigational Product|Polyester cloth impregnated with investigational product
9848671|NCT03229759|Placebo Comparator|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
9848672|NCT03229759|Placebo Comparator|Saline Control (SC)|Saline applied wtih polyester cloth
9848673|NCT03230175|Experimental|TTAX01 plus standard care|Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. A six week course of systemic antibiotics will be used to resolve baseline infection. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary.
9848674|NCT03230864|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
9848675|NCT03230864|Experimental|Double-blind treatment (DBT) period, Lu AF35700 10 mg|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks
9848676|NCT03230864|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks. Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period
9848677|NCT03231228|Active Comparator|Cefazolin 1 g Infusion|Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.
9848678|NCT03231228|Active Comparator|Cefazolin 2 g Infusion|Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.
9848679|NCT03231345|Experimental|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
9848680|NCT03231371|Experimental|Study Arm|
9848681|NCT03231709|Experimental|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
9848682|NCT03231709|Experimental|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.
9848683|NCT03231800|Experimental|Dasotraline|Dasotraline capsule 2mg/day
9848684|NCT03231800|Placebo Comparator|Placebo|Placebo capsule
9848685|NCT03231917|Experimental|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
9848686|NCT03231917|Experimental|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
9848687|NCT03231943|Experimental|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
9848688|NCT03231943|Experimental|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
9848689|NCT03231943|Placebo Comparator|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
9848690|NCT03231969|Experimental|Bilastine 0.2%|"Bilastine Ophthalmic solution 0.2%~1 drop in each eye at 3 separate times during a 25 day period."
9848691|NCT03231969|Experimental|Bilastine 0.4%|"Bilastine Ophthalmic solution 0.4%~1 drop in each eye at 3 separate times during a 25 day period."
9848692|NCT03231969|Experimental|Bilastine 0.6%|"Bilastine Ophthalmic solution 0.6%~1 drop in each eye at 3 separate times during a 25 day period."
9848693|NCT03231969|Placebo Comparator|Bilastine 0%|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 3 separate times during a 25 day period."
9848694|NCT03232281|Experimental|Triptorelin pamoate PR 3-month|Subjects received 15 mg triptorelin pamoate per injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections, at baseline and Week 12).
9848695|NCT03232281|Active Comparator|Triptorelin acetate PR 1-month|Subjects received 3.75 mg triptorelin acetate per injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20).
9848696|NCT03232333||MIRODERM|Biologic wound graft
10207577|NCT05206539|Placebo Comparator|Control group (Gr NT)|The control group (Gr NT) receive no intervention except brushing twice daily with aminofluoride toothpaste and toothbrush provided by researcher.
9848697|NCT03232567|Experimental|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
9848698|NCT03232567|Experimental|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
9848699|NCT03232567|Experimental|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
9848700|NCT03232567|Placebo Comparator|Placebo|Normal saline administered by intranasal spray at a single dose
9848701|NCT03232580|Experimental|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
9848702|NCT03232645|Other|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
9848703|NCT03232749|Other|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
9848704|NCT03232827|Active Comparator|Flavored-sweetened|Flavored-sweetened (FS) WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
9848705|NCT03232827|Active Comparator|Unflavored-sweetened|Unflavored-sweetened (US) WP will be associated with the second longest and slightly less frequent puffing than FS resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
9848706|NCT03232827|Active Comparator|Unflavored very low sweetened|Unflavored-very low sweetened (UU) WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
9848707|NCT03232827|Active Comparator|Flavored-very low sweetened waterpipe|Flavored-very low sweetened WP will be associated with the third longest and slightly less frequent puffing than US resulting in the third greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
9848708|NCT03232983|Experimental|LY900014 (SC Abdomen)|Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
9848709|NCT03232983|Experimental|LY900014 (SC Thigh)|Single dose of 15-U of LY900014 administered SC into the thigh in one period
9848710|NCT03232983|Experimental|LY900014 (SC Arm)|Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
9848711|NCT03232983|Active Comparator|LY900014 (IV)|Single dose of 15-U of LY900014 administered intravenously (IV) in one period
9848712|NCT03233009|Experimental|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
9848713|NCT03233009|Experimental|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
9848714|NCT03233009|Experimental|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
9848715|NCT03233009|Experimental|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
9848716|NCT03233009|Sham Comparator|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
9848717|NCT03233230|Placebo Comparator|Placebo|
9848718|NCT03233230|Experimental|M2951 25 mg QD|
9848719|NCT03233230|Experimental|M2951 75 mg QD|
9848720|NCT03233230|Experimental|M2951 50 mg BID|
9848721|NCT03233308|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
9848722|NCT03233308|Placebo Comparator|Placebo Comparator|Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye
9922976|NCT00845273||Pegaptanib sodium|Patients administered Pegaptanib sodium.
10207578|NCT05198154||Advanced NSCLC patients with long-term benefit after first-line immunotherapy|For patients with advanced NSCLC who have long-term benefit (PFS 12 months) after first-line immunotherapy
10207579|NCT05192122|Other|Bone marrow MRD-negative VGPR or CR|Discontinue maintenance therapy after at least three years
10207580|NCT05192122|Other|Bone marrow MRD-positive VGPR or CR|Continue maintenance therapy as per SOC
10207581|NCT05191160|Active Comparator|2% Soy Milk|Participants will be asked to substitute their regular sugar sweetened beverage with the 2% soy milk (up to a maximum of 6 servings/day)
9848723|NCT03233438|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
9848724|NCT03233438|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
9848725|NCT03233529|Experimental|Crisaborole ointment|
9848726|NCT03233529|Placebo Comparator|Placebo ointment (vehicle)|
9848727|NCT03233737|Experimental|Stage II: One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session. Used in Stage II of the study only.
9848728|NCT03233737|Active Comparator|Stage II: One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session. Used in Stage II of the study only.
9848729|NCT03233737|Experimental|Stage I: One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
9848730|NCT03233737|Active Comparator|Stage I: One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
9848731|NCT03233737|Placebo Comparator|Stage I: One spray CTY-5339-P|Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (placebo: vehicle control). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
9848732|NCT03234036|Experimental|Treatment sequence ABC: Part 1|"A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.~Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
9848733|NCT03234036|Experimental|Treatment sequence BAC: Part 1|"A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
9848734|NCT03234036|Experimental|GSK2838232 tablet without RTV: Part 2|In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
9848735|NCT03234036|Placebo Comparator|Placebo without RTV: Part 2|In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
9848736|NCT03234374|Experimental|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
10207582|NCT05191160|Active Comparator|2% Cow's Milk|Participants will be asked to substitute their regular sugar sweetened beverage with the 2% cow's milk (up to a maximum of 6 servings/day)
10207583|NCT05191160|Active Comparator|Usual Sugar Sweetened Beverage|Participants will be asked to continue drinking their regular sugar sweetened beverage
10207584|NCT05189951|Experimental|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
10207585|NCT05189951|Experimental|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
10207586|NCT05189951|Experimental|first vertical then circular motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside. Different swabs were used in both wipes.
10207587|NCT05187338|Experimental|3 drugs|Three antibodies combination against PD1, PDL1, and CTLA4.
10207588|NCT05187273|Experimental|intervention|
10207589|NCT05187273|No Intervention|control|
10207590|NCT05187260||5q SMA type I|
10207591|NCT05187260||5q SMA type II|
10207592|NCT05187260||5q SMA type III|
10207593|NCT05187260||Non-5q SMA|
10207594|NCT05187260||Non-SMA subjects|Including asymptomatic carriers of SMA, relatives of SMA patients and carriers, and patients undergoing clinical standard lumbar puncture
10207595|NCT05187208|Experimental|Experimental|BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients (high-grade serous or high-grade endoemtrioid)
10207596|NCT05187026||EPIC-26 follow-up|All men will receive EPIC-26 in paper and also an electronic version.
10207597|NCT05186467|Active Comparator|Intraperitoneal magnesium sulfate (IP) group|They will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then an intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
10207598|NCT05186467|Active Comparator|Intravenous magnesium sulfate (IV) group|They will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
10207599|NCT05185531|Experimental|Neoadjuvant|PD-1(Tislelizumab) plus stereotactic body radiotherapy
9848737|NCT03234374|Active Comparator|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
9848738|NCT03234465|Experimental|AG013: three mouth rinses/day|Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
9848739|NCT03234465|Placebo Comparator|Placebo: three mouth rinses/day|Subjects will rinse three times per day with placebo mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
9848740|NCT03234608|Experimental|AASPIRE Healthcare Toolkit|Patients will use the AASPIRE Healthcare Toolkit and will share a copy of their Autism Healthcare Accommodations Report with their primary care provider.
9848741|NCT03234608|No Intervention|Usual Care|Patients will receive usual care.
9848742|NCT03235050|Experimental|MEDI0382 low dose + Metformin|Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
9848743|NCT03235050|Experimental|MEDI0382 mid dose + Metformin|Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
9848744|NCT03235050|Experimental|MEDI0382 high dose + Metformin|Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
9848745|NCT03235050|Placebo Comparator|Placebo + Metformin|Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
9848746|NCT03235050|Active Comparator|Liraglutide + Metformin|Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
9848747|NCT03235089|Active Comparator|Test lens|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
9848748|NCT03235089|Active Comparator|nelfilcon A lens (control)|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
9848749|NCT03235115|Active Comparator|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
9848750|NCT03235115|Active Comparator|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
9848751|NCT03235115|Active Comparator|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
9848752|NCT03235154|Other|Treatment Arm|In this open label, single arm study, all subjects will receive the intervention as prescribed by psychiatrists in the office based opiate addition treatment program.
9848753|NCT03235180|Experimental|Crohn's Disease Subjects|"Subjects will receive ultrasound exams of the bowel with 2 different machines (Ultrasound Elastography and Ultrasound Vascularity) at three time points: baseline, 4 weeks, and 6 months. The ultrasound exams will be performed at first with no contrast agent, and then ultrasound measurements will be repeated with 1-2 ml of Sulfur Hexafluoride, a contract agent.~Subjects also will receive Magnetic Resonance Enterography (MRE) exams at baseline and 6 months as part of their clinical care."
9848754|NCT03235284|Active Comparator|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
9848755|NCT03235284|Active Comparator|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
9848756|NCT03235284|Experimental|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
9848757|NCT03235349|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
9848758|NCT03235414|Experimental|Normals|Will receive an MRI and a blood draw
9848759|NCT03235479|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
9848760|NCT03235479|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
9848761|NCT03235726|Experimental|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
9848762|NCT03235726|Placebo Comparator|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
9848763|NCT03235726|Experimental|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
9848764|NCT03235726|Placebo Comparator|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
9848765|NCT03235726|No Intervention|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
10207600|NCT05185310|Experimental|CTI/AAD (control)|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 1- Cavo-tricuspid isthmus (CTI) ablation with adjustment and/or optimization of antiarrhythmic drug regimen where possible (control arm)
9848766|NCT03235726|Experimental|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
9848767|NCT03235726|Placebo Comparator|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
9848768|NCT03235726|Experimental|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
9848769|NCT03235726|Placebo Comparator|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
9848770|NCT03236168|Other|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight <15kg) Permethrin Cream and Malathion shampoo
9848771|NCT03236246|Experimental|Group 1|KRX-0502 1 tablet thrice daily (TID) with meals
9848772|NCT03236246|Experimental|Group 2|KRX-0502 2 tablets twice daily (BID) with the largest 2 daily meals
9848773|NCT03236506|Experimental|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
9848774|NCT03236506|Active Comparator|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
9848775|NCT03236506|Active Comparator|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
9848776|NCT03236779|Experimental|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
9848777|NCT03236779|Active Comparator|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
9848778|NCT03237013|No Intervention|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
9848779|NCT03237013|Experimental|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
9922977|NCT00845312||Complicated hospitalization|"Patients 60 years old or younger, who were diagnosed with community acquired pneumonia (CAP) between March 1, 2005 and December 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality.~was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. Otherwise, the hospitalization was defined uncomplicated .The Rambam hospital Institutional Review Board approved the study."
10207601|NCT05185310|Experimental|Posterior wall isolation|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 2-LA Posterior wall isolation by creation of a LA roof and floor line
10207602|NCT05185310|Experimental|Empiric Isolation of common trigger sites|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 3-empiric ablation of common sites of non-PV triggers of AF in both the right and left atria.
10207603|NCT05182892|Experimental|Part 1: All participants|All participants who will participate in part 1.
10207604|NCT05182892|No Intervention|Part 2: All participants|All participants who participated in part 1
10207605|NCT05182892|No Intervention|Part 3: All participants|All participants who will participate in part 3
10207606|NCT05182593|Experimental|Diet 1: moderate/high FODMAP diet. Diet 2: low FODMAP diet.|The subjects will follow the moderate/high FODMAP diet as the first intervention, and the low FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
9848780|NCT03237013|Placebo Comparator|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman & Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
9848781|NCT03237065|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
9848782|NCT03237065|Active Comparator|Ferric carboxymaltose|Administered IV
9848783|NCT03237156|Experimental|TAK-906 50 mg; Cohort 1|TAK-906 50 milligram (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
9848784|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
9848785|NCT03237156|Experimental|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
9848786|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
9848787|NCT03237156|Experimental|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
9848788|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
9848789|NCT03237481|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
9848790|NCT03237481|Active Comparator|Treatment Group 2: Bupivacaine HCI|Bupivacaine HCl
9848791|NCT03237481|Placebo Comparator|Treatment Group 3: Saline Placebo|Saline placebo
9848792|NCT03237845|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
9848793|NCT03237845|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
9848794|NCT03237871|Experimental|Survey and informational text messages|Text-message survey and informational text messages
9848795|NCT03238001|Experimental|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
9848796|NCT03238352|Experimental|Test Product|Participants will rinse twice daily (morning and evening) with 10 milliliters (mL) of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
9848797|NCT03238352|Other|Negative Control|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
9848798|NCT03238352|Placebo Comparator|Placebo|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
9935097|NCT04203199|Sham Comparator|Sham rTMS to the mPFC using H7 Coil|One session of sham low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (sham rTMS - 20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
9848799|NCT03238417|Experimental|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
9848800|NCT03238417|No Intervention|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
9848801|NCT03238651|Experimental|Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
9848802|NCT03238651|Experimental|Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1|TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
9848803|NCT03238651|Experimental|Expansion Part: TAK-659 MTD/RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
9848804|NCT03238781|Placebo Comparator|Placebo|Participants randomized to Placebo were administered 6 subcutaneous (SC) injections on day 1 and weeks 2, 4, 6, 8 and 10 during the 12 week double-blind treatment period.
9848805|NCT03238781|Experimental|AMG 301 210 mg Q4W|Participants randomized to AMG 301 210 mg every fourth week (Q4W) received a total of 3 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) plus 3 matching placebo injections on day 1 and weeks 4 and 8. Participants also received 6 SC placebo injections on weeks 2, 6, and 10 during the 12 week double-blind treatment period.
9986353|NCT01402024|Experimental|Aprepitant|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
10207607|NCT05182593|Experimental|Diet 1: low FODMAP diet. Diet 2: moderate/high FODMAP diet.|The subjects will follow the low FODMAP diet as the first intervention, and the moderate/high FODMAP diet as the second intervention. The subjects will follow both interventions for seven days.
9848806|NCT03238781|Experimental|AMG 301 420 mg Q2W|Participants randomized to AMG 301 420 mg every second week (Q2W) received a total of 6 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) on day 1 and weeks 2, 4, 6, 8, and 10 during the 12 week double-blind treatment period.
9848807|NCT03238911|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
9848808|NCT03238911|Active Comparator|Ferric carboxymaltose|Administered IV
9848809|NCT03238924|Experimental|Oxytocin|40 IU intranasal oxytocin spray
9848810|NCT03238924|Placebo Comparator|Placebo|Placebo is matching saline nasal spray
9848811|NCT03238963|Experimental|BI 1467335|
9848812|NCT03238963|Placebo Comparator|Placebo|
9848813|NCT03239106|Experimental|open label|All participants will receive Apremilast 30 mg BID.
9848814|NCT03239470|Experimental|Cohort 1: 1.0 x 10^8 PolyTregs|A single intravenous infusion of 1.0 x 10^8 PolyTregs will be administered.
9848815|NCT03239470|Experimental|Cohort 2: 2.5x10^8 PolyTregs|A single intravenous infusion of 2.5x10^8 PolyTregs will be administered.
9848816|NCT03239483|Experimental|Dapivirine gel|Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic.
9848817|NCT03239483|Placebo Comparator|Placebo gel|Participants will receive a single dose of placebo gel rectally, followed by 7 daily doses of placebo gel to be administered under direct observation in the clinic.
9848818|NCT03239496|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
9848819|NCT03239496|Experimental|Group B|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
9848820|NCT03239496|Experimental|Group C|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
9848821|NCT03239496|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
9848822|NCT03239522|Experimental|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of [14C]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg [14C]-GSK1278863 as an oral solution.
9848823|NCT03239574|Experimental|MightySat Test group|The subjects will be enrolled into the test group and will receive the MightySat investigational pulse oximeter.
9848824|NCT03239665|Active Comparator|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
9848825|NCT03239665|Experimental|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
9848826|NCT03239873|Experimental|VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II®|VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
9848827|NCT03239873|Active Comparator|VARIVAX® 2016 Commercial Process + M-M-R II®|VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
9848828|NCT03240081|Active Comparator|50mcg estradiol cream|Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
9848829|NCT03240081|Active Comparator|100mcg estradiol cream|Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
9848830|NCT03240133|Experimental|Part1: BCX7353 750 mg|
9848831|NCT03240133|Experimental|Part 2: BCX7353 500 mg|
9848832|NCT03240133|Experimental|Part 3: BCX7353 250 mg|
9848833|NCT03240133|Placebo Comparator|Parts 1, 2 and 3: placebo|
9922978|NCT00845325|Active Comparator|Group One|"The first group (early motion) will have a bulky dressing placed at the time of surgery. They will be instructed to remove the dressing on the first postoperative day and to place a band-aid over the incision. A set of non-weight bearing stretching exercises will be explained on the day of surgery and instructions with diagrams sent home with the patient. They will begin these exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work."
9922979|NCT00845325|Other|Behavorial Control Group Two|The second group will have wrist immobilization splints placed at the time surgery. The thumb and fingers will not have limited motion in this splint. Due to the splint placement, the patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
9922980|NCT00845338|Experimental|Arm 1|
9922981|NCT00845351|Experimental|Bexarotene|Bexarotene 300 mg/m2/day times 5 days
9922982|NCT00845364|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
9922983|NCT00845364|Placebo Comparator|Placebo|Pre-operative administration of placebo tablets according to dosing schedule
9922984|NCT00845377|Experimental|Counseling|
9922985|NCT00845455||1. Harm Avoidance|Personality type
9922986|NCT00845455||2. Reward Dependence|Personality type
9922987|NCT00845455||3. Novelty Seeking|Personality type
9922988|NCT00845468||No treatment|
9922989|NCT00845494|Other|medication history education|Four hospital unit nurses asked to participate in the study. Two nursing units will receive the cognitive behavioral intervention.
9922990|NCT00845546|Experimental|1|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets of Ranbaxy
9922991|NCT00845546|Active Comparator|2|(Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
9922992|NCT00845559|Experimental|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide.
9922993|NCT00845559|No Intervention|No Treatment|
9922994|NCT00845572|Experimental|Consta Club|
9922995|NCT00845585|Active Comparator|Owniflow II|
9922996|NCT00845585|Active Comparator|PTFE|
10207608|NCT05181553|Experimental|Canada's Food Guide principles (CFG diet)|During 28 days, participants will receive de CFG diet. The CFG diet emphasizes low intakes of red and processed meats and high intakes of minimally processed plant foods with water as the drink of choice, as per Canada's Food Guide. The number of portions of protein foods, whole-grains, fruits and vegetables to be served daily reflects the recommended ¼-¼-½ proportions. Regarding protein quality, vegetable proteins are served more often than animal proteins as stated in Canada's Food Guide. Weekly, red meat is served once, two days are meatless, and one day is free of animal products.
9922997|NCT00845598|Experimental|Azelastine Fluticasone|
10207609|NCT05181553|Experimental|Standard North American diet (NAD diet)|During 28 days, participants will receive de NAD diet. The NAD diet reflects current dietary intakes of the French-Canadian adult population in terms of foods, nutrients, and diet quality, as characterized in recent surveys conducted in an age- and a sex-representative sample of adults from the Province of Quebec. Intakes of minimally processed fruits and vegetables will be low; animal proteins, mostly red and processed meats, will be consumed more often than vegetable proteins; grains will be mostly refined; and ready-to-eat/ready-to-heat foods and sugary beverages will be served daily.
10207610|NCT05181345||Normal sleep first|"The night before the first heat exposure, the participants will have a normal night at home.~The night before the second heat exposure, the participants sleep will be restricted to 3 hours in bed."
10207611|NCT05181345||Reduced sleep first|"The night before the first heat exposure, the participants sleep will be restricted to 3 hours in bed.~The night before the second heat exposure, the participants will have a normal night at home."
10207612|NCT05171673|Experimental|Investigational|LicartTM topical system application once per day for a maximum of 14 days or until pain resolution, whichever occurs first.
10207613|NCT05171569|Experimental|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-3 intervention will take biophysical measurements with the RAM technology, complete a daily recovery survey, complete video visits with a virtual care clinical team, and take would photos during the 14 days after discharge. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician.
9848834|NCT03240575|Experimental|Tiotropium + Olodaterol fixed dose combination|
9848835|NCT03240575|Active Comparator|Fluticasone propionate + Salmeterol fixed dose combination|
9848836|NCT03241030|Experimental|Experimental Group|Subjects will receive sucralfate
9848837|NCT03241030|Placebo Comparator|Placebo Group|Subjects will receive a placebo
9848838|NCT03241342|Active Comparator|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
9848839|NCT03241342|Active Comparator|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
9848840|NCT03241342|Placebo Comparator|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
9848841|NCT03241368|Other|MRE, Patency Capsule (if needed), CE, and IC|Single-arm study, which includes MRE procedure, Patency Capsule Procedure (if needed), PillCam Crohn's Capsule Endoscopy Procedure and Ileocolonoscopy procedure.
9848842|NCT03241485|Placebo Comparator|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
9848843|NCT03241485|Active Comparator|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
9848844|NCT03241810|Experimental|Arm A|"Seribantumab~Fulvestrant"
9848845|NCT03241810|Active Comparator|Arm B|"Placebo~Fulvestrant"
9848846|NCT03241862|Experimental|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
9848847|NCT03241927|Experimental|Pembrolizumab|200 mg IV infusion every 3 weeks
9848848|NCT03241927|No Intervention|Healthy Donors|
9848849|NCT03242018|Placebo Comparator|Placebo|Following a 2-week run-in phase, participants received two placebo tablets (identical to sotagliflozin 200 milligrams [mg] in appearance) orally once daily for up to 56 weeks.
9848850|NCT03242018|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in phase, participants received two tablets, one sotagliflozin 200 mg tablet and one placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily for up to 56 weeks.
9848851|NCT03242018|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received sotagliflozin 400 mg, administered as 2 sotagliflozin 200 mg tablets, orally once daily for up to 56 weeks.
9848852|NCT03242148|Experimental|Toffee Nasal Pillows Mask|Participants will be placed on this arm for a total of 14 +- 5 days from visit 2. participants will be using the Toffee mask during this treatment arm
9848853|NCT03242252|Placebo Comparator|Placebo|Following a 2-week run-in period, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 54 weeks.
9848854|NCT03242252|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants received two tablets, 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 58 weeks.
9848855|NCT03242252|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants received sotagliflozin 400 mg, administered as two 200 mg sotagliflozin tablets, orally once daily, before the first meal of the day for up to 60 weeks.
9848856|NCT03242408|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
9848857|NCT03242434|Other|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
9848858|NCT03242434|Other|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
9922998|NCT00845598|Active Comparator|Fluticasone propionate|
9848859|NCT03242590|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
9848860|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
9848861|NCT03242863|Experimental|Control|Baseline proportions of high and low energy dense foods.
9848862|NCT03242863|Experimental|Addition|Increased portion of low energy dense foods.
9848863|NCT03242863|Experimental|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
9848864|NCT03242928|Placebo Comparator|Placebo|Matching tablet of placebo taken orally BID
9848865|NCT03242928|Experimental|AFQ056|Mavoglurant was up titrated on a bid regimen followed by fixed-dose bid regimen: 50 mg bid from Day 1 to Day 7, 100 mg bid from Day 8 to Day 14, and then fixed-dose 200 mg bid for 84 days
9848866|NCT03242941|Experimental|Persistent and Paroxtmal AF Patients|Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
9848867|NCT03242954|Active Comparator|Adolescents: Consent Condition 1|Autonomous minor consent
9848868|NCT03242954|Active Comparator|Adolescents: Consent Condition 2|Adult permission required
9848869|NCT03242954|Active Comparator|Adolescents: Consent Condition 3|Parental permission required
9848870|NCT03242954|Active Comparator|Parents: Consent Conditions 1-3|Autonomous minor consent, adult permission required, and parental permission required
9848871|NCT03243084|Sham Comparator|Sham tACS|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
9848872|NCT03243084|Active Comparator|Active 10 Hz tACS|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
9848873|NCT03243305|Experimental|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non-hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
9848874|NCT03243630|Placebo Comparator|Menthol e-liquid|Menthol Flavor + IV saline Menthol Flavor + IV nicotine (0.25mg/70kg) Menthol Flavor + IV nicotine (0.5mg/70kg)
9848875|NCT03243630|Active Comparator|green apple e-liquid|Green apple + IV saline Green apple + IV nicotine (0.25mg/70kg) Green apple + IV nicotine (0.5mg/70kg)
9848876|NCT03243630|Active Comparator|green apple and menthol e-liquid|Green apple and menthol + IV saline Green apple and menthol + IV nicotine (0.25mg/70kg) Green apple and menthol + IV nicotine (0.5mg/70kg)
9848877|NCT03243981|Experimental|Open label study-- single arm|All patients will receive Skintyte treatment as well as Skintyte plus broadband light
10207614|NCT05171569|No Intervention|Standard Care|Standard post surgical care per treating institution.
9848878|NCT03244618|Experimental|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
10207615|NCT05168488|Experimental|All participants|There is only one study arm consisting of all participants.
10207616|NCT05167487||Experimental: platinum-based neoadjuvant treatment and surgery.|Resectable stage IIIA non-small cell lung cancer patients treated with platinum-based neoadjuvant treatment and surgery.
10207617|NCT05166239|Experimental|HAIC-Cola group|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. 12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily after HAIC. 200 mg of Camrelizumab injection intravenously for 1h before 24h of HAIC every 4 week.
10207618|NCT05166239|Active Comparator|Cola group|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily. 200 mg of Camrelizumab injection intravenously for 1h every 4 week.
10207619|NCT05153707|Experimental|Clinical Pharmacist-led discharge education program|Clinical pharmacist-led services
10207620|NCT05153707|No Intervention|Control group|Usual care
10207621|NCT05151822|Experimental|Virtual reality mask|"Realization of the following examinations with virtual reality mask :~Training session~Acceptability of the device before and after surgery~Monitoring of the device during surgery"
10207622|NCT05149287|Experimental|Experimental|The experimental group will receive a single intravenous dose of 1 g of ceftriaxone immediately postoperative in the operating room.
10207623|NCT05149287|Placebo Comparator|Placebo|The placebo group will receive a single intravenous dose of 1% lidocaine and saline immediately postoperative in the operating room.
10207624|NCT05142306|Experimental|COVID-HIG Intramuscular|COVID-HIG single dose administered IM
9848879|NCT03244618|Placebo Comparator|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
9848880|NCT03244800|Placebo Comparator|Placebo Cohort 1|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
9848881|NCT03244800|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 7 days, followed by Dose 2 for 7 days, Dose 3 for 7 days, and Dose 4 for 28 days
9848882|NCT03244800|Placebo Comparator|PLacebo Cohort 2|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
9848883|NCT03244800|Experimental|MEDI0382 Cohort 2|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 14 days, followed by Dose 2 for 14 days, Dose 3 for 14 days, and Dose 4 for 7 days.
10207625|NCT05142306|Experimental|COVID-HIG Subcutaneous|COVID-HIG single dose administered SC
10207626|NCT05142306|Experimental|COVID-HIG Intravenous|COVID-HIG single dose administered IV
10207627|NCT05139680||Patients with mixed phenotype ATTRv-CM|Hereditary ATTR-CM patients presenting with mixed phenotype
10213506|NCT03883139|Active Comparator|JASPER|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing JASPER. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified JASPER for 3 hours a week (3 days, 1 hour per day)."
9848884|NCT03244865||Pregnant Females|"All patients admitted to the Labor & Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
9848885|NCT03244917|Experimental|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education.
9848886|NCT03244917|No Intervention|CONTROL|Facility randomized to the control arm will employ usual care for the management for suspected infections in advanced dementia,
9848887|NCT03245372|Active Comparator|Standard care|Basic intraoperative hemodynamic objectives
9848888|NCT03245372|Experimental|Goal directed therapy|Target value is a cardiac index equal or superior to 2.2 l/min/m2.
9848889|NCT03245398|Active Comparator|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
9848890|NCT03245398|Active Comparator|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
9848891|NCT03245463|Active Comparator|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
9848892|NCT03245463|Active Comparator|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
9848893|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.
9848894|NCT03245619|Experimental|Subjects receiving Placebo (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
9848895|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
9848896|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
9848897|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.
9848898|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
9848899|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
9848900|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.
9848901|NCT03245723|Active Comparator|Preterm|"Participants born premature either registered on the National Lung Project (currently in their late twenties) or not registered on the National Lung Project Cohort (current age ranges 18-35 years).~All the participants in this group will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging."
9848902|NCT03245723|Placebo Comparator|Term - Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
9848903|NCT03245736|Experimental|Tisotumab Vedotin|All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
9848904|NCT03245762|Active Comparator|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
9848905|NCT03245762|Placebo Comparator|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
9848906|NCT03246061|Active Comparator|BVN Ablation|BVN ablation with continued standard care
9848907|NCT03246061|Active Comparator|Standard Care Control|Continue with non-surgical standard care
9848908|NCT03246152|Experimental|Bevacizumab group|Monthly intravitreal injection of 2.5 mg of Bevacizumab for at least 3 consecutive months. This is followed by treat and extend regimen after resolution of macular edema.
9922999|NCT00845624||1|Preterm infants <1500 grams or 32 weeks gestation.
10207628|NCT05138965||using the mCP|When the secretion reducing or the wound suture being removed, two pieces of 5cm×7cm-12p sterile gauzes will be crimped by the long side as the center of the reel,and be made as cylindrical gauze rolls with about D=1.5cm. After cleaning the wound, the cylindrical gauze rolls with its surface covered by alginates dressing will be placed above the vaginal wound with the help of endoscope.Itself tension of the rolls pressuring on the wound and the deep tissue can promote the wound healing. The rolls will be placed on about 5-6 hours every time, 2 times a day, for 7 days.Then observing the wound, if necessary, the method will be executed for another 7 days.
10207629|NCT05138965||no using the mCP|When the secretion reducing or the wound suture bing removed, only alginates dressing will be placed above the vaginal wound with the help of endoscope, without any pressure, being placed about 5-6 hours every time, 2 times a day, for 7 days.
10207630|NCT05136755|Experimental|NMDAE|An NMDA enhancer
10207631|NCT05136755|Placebo Comparator|Placebo|Placebo
10207632|NCT05128539|Experimental|JS001(Toripalimab)+JS002|
9848909|NCT03246646|Experimental|Coaching + VA CRAFT|Telephone coaching along with web-based CRAFT course
9848910|NCT03246646|Other|Treatment as usual|Treatment as usual matched comparison
9848911|NCT03246672|Experimental|maintenance|behavioral intervention to increase adherence to lifestyle recommendations
9848912|NCT03246724|Experimental|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:~• Cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
9848913|NCT03246724|Experimental|Retina Procedures|"The following ocular procedures will fall under this arm of the study:~Pars plana vitrectomy~Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
9848914|NCT03246724|Experimental|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:~Descemet Stripping Endothelial Keratoplasty (DSEK)~Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)~Descemet Membrane Endothelial Keratoplasty (DMEK)~Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)~Conjunctival and/or corneal lesion excisions~Pterygium~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
9848915|NCT03246724|Experimental|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:~Ahmed valve~Ahmed valve with cataracts~Trabeculectomy~Trabeculectomy with cataracts~Baerveldt~Baerveldt with cataracts~Endocyclophotocoagulation~Endocyclophotocoagulation with cataracts~Istent~Cataracts with istent~Kahook~Cataracts with kahook~Cypass~Cypass with cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
9848916|NCT03247322|Experimental|mHealth Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
9848917|NCT03247322|No Intervention|Usual Care Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
9848918|NCT03247517|Placebo Comparator|Placebo|Placebo, qd, oral capsule
9848919|NCT03247517|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
9848920|NCT03247517|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
9848921|NCT03247530|Placebo Comparator|Placebo|Placebo, qd, oral capsule
9848922|NCT03247530|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
9848923|NCT03247530|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
9848924|NCT03247543|Placebo Comparator|Placebo|Placebo, qd, oral capsule
9848925|NCT03247543|Active Comparator|200mg SPN-812|200mg SPN-812, qd, oral capsule
9848926|NCT03247543|Active Comparator|400mg SPN-812|400mg SPN-812, qd, oral capsule
9848927|NCT03247556|Placebo Comparator|Placebo|Placebo, qd, oral capsule
9848928|NCT03247556|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
9848929|NCT03247556|Experimental|600mg SPN-812|600mg SPN-812, qd, oral capsule
9848930|NCT03247673|Experimental|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
9848931|NCT03247673|Active Comparator|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
9848932|NCT03247673|Active Comparator|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
9848933|NCT03247686|Placebo Comparator|Placebo|Placebo
9848934|NCT03247686|Active Comparator|RSLV-132|Experimental drug
9848935|NCT03247738|Experimental|Cangrelor|Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
9848936|NCT03247738|Placebo Comparator|Placebo|Normal saline bolus and infusion for 2 hours
9848937|NCT03247790|Experimental|Lasmiditan (Period 1)|200 mg Lasmiditan tablet given once orally during migraine attack.
9848938|NCT03247790|Experimental|Lasmiditan (Period 2)|200 mg Lasmiditan tablet given once orally during inter-ictal period.
9848939|NCT03247985|Active Comparator|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
9848940|NCT03247985|Active Comparator|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
9848941|NCT03248037|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
9848942|NCT03248037|Placebo Comparator|Placebo|Placebo eye drop, dosed topically once a day for 9 months
9848943|NCT03248440|Experimental|SUN-131 1.5% TDS|
9848944|NCT03248440|Placebo Comparator|Placebo TDS|
9848945|NCT03248492|Experimental|DS-8201a Low Dose|T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
9848946|NCT03248492|Experimental|DS-8201a Medium Dose|T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
9848947|NCT03248492|Experimental|DS-8201a High Dose|T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
9848948|NCT03248492|Other|Exploratory Arm|In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm
9848949|NCT03248882|Placebo Comparator|Placebo|Double-Blind, PF-05221304-matching Placebo
9848950|NCT03248882|Active Comparator|PF-05221304 - 2 mg|PF-05221304 - 2 mg, once-daily
9848951|NCT03248882|Active Comparator|PF-05221304 - 10 mg|PF-05221304 - 10 mg, once-daily
9848952|NCT03248882|Active Comparator|PF-05221304 - 25 mg|PF-05221304 - 25 mg, once-daily
9848953|NCT03248882|Active Comparator|PF-05221304 - 50 mg|PF-05221304 - 50 mg, once-daily
9848954|NCT03248947|Other|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
9848955|NCT03249116|Active Comparator|Control - interaction with a stuffed dog|Active control - interaction with a stuffed dog
9848956|NCT03249116|Experimental|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during stress task.
9848957|NCT03249116|Experimental|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during stress task.
9848958|NCT03249272|Active Comparator|Hypertrophic cardiomyopathy|
9848959|NCT03249272|Active Comparator|Non-ischemic dilated cardiomyopathy|
9848960|NCT03249272|Active Comparator|Control|
9848961|NCT03249454|Experimental|Anode, then Cathode, then Anode, then Sham, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848962|NCT03249454|Experimental|Sham, then Cathode, then Anode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848963|NCT03249454|Experimental|Anode, then Cathode, then Sham, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848964|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Anode, then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848965|NCT03249454|Experimental|Anode, then Anode, then Sham, then Cathode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9793808|NCT01485614|Placebo Comparator|Placebo/Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
9793809|NCT01485614|Active Comparator|Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
9793810|NCT01485614|Placebo Comparator|Placebo/Sitagliptin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
9793811|NCT01485627|Experimental|Intervention|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
9793812|NCT01485627|No Intervention|Control|Patients will receive usual care
9793813|NCT01485640|Experimental|Lurasidone|Lurasidone flexibly dosed
9793814|NCT01485770|Experimental|Placebo, Then ADX-N05|Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
9793815|NCT01485770|Placebo Comparator|ADX-N05, Then Placebo|Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).
9793816|NCT01485796|Experimental|Epoch 1 and Epoch 2|In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
9793817|NCT01485887|Experimental|Venlafaxine ER|
9793818|NCT01485991|Experimental|TMC435/PR|
9793819|NCT01485991|Active Comparator|TVR/PR|
9793820|NCT01486043|Experimental|Metformin and insulin therapy|Up to 30-40 patients will be in the prospectively recruited treatment group, which will receive both metformin and insulin therapy for transient hyperglycemia
9793821|NCT01486199|Experimental|CF pediatric|In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
9793822|NCT01486199|Experimental|Controls adult|In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.
9793823|NCT01486238|Experimental|IVMac q6 Arm|Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
9793824|NCT01486238|Experimental|IVMac q4 Arm|Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.
9793825|NCT01486264|Active Comparator|Xeomin® Short Flex|short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
9793826|NCT01486264|Active Comparator|Xeomin® Long Flex|long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
9793827|NCT01486316|Other|Control arm|Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
9793828|NCT01486316|Experimental|Risk Status Guided|Study doctors will have access to the experimental IDENTIFY-HF Risk Status for subjects in the Guided arm between months 6 and 18. At all times during the study, study doctors will also be able to use the standard device diagnostics in the office using the programmer, or by data transmission from the patient's home (or another remote location).
9793829|NCT01486446|Experimental|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
9793830|NCT01486446|Placebo Comparator|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
9793831|NCT01486615|Placebo Comparator|Melatonin|Premedication with 3 mg melatonin (Meloset) tablet orally 1-2 hour prior to anesthesia
9793832|NCT01486615|Placebo Comparator|melatonin and alprazolam premedication|Premedication with 3 mg melatonin and 0.5 mg alprazolam (Stresnil) tablet orally 1-2 hrs prior to anesthesia
9848966|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Cathode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848967|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Sham, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848968|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848969|NCT03249454|Experimental|Cathode, then Cathode, then Sham, then Anode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848970|NCT03249454|Experimental|Anode, Then Cathode, Then Anode, Then Cathode Then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848971|NCT03249454|Experimental|Sham, Then Anode, Then Anode, Then Cathode, Then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
9848972|NCT03249584|Other|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
9848973|NCT03249779|Experimental|Scrambler|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
9848974|NCT03249909|Other|Exufiber Ag +|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
9923000|NCT00845637|Active Comparator|Eggplant extract|
9923001|NCT00845637|Placebo Comparator|Placebo|
9793833|NCT01486615|Placebo Comparator|alprazolam premedication|Premedication with 0.5 mg alprazolam (Alprax) tablet orally 1-2 hr prior to anesthesia
9793834|NCT01486615|Active Comparator|placebo premedication|Premedication with a similar looking placebo tablet orally 1-2 hr prior to anesthesia
9793835|NCT01486758|Active Comparator|Azithromycin|Oral azithromycin
9793836|NCT01486758|Placebo Comparator|Placebo|Oral Placebo
9793837|NCT01486784|Experimental|Phase 1 DL1|26mg/m2/dose IV once per week x 3 weeks of 4 week cycle
9793838|NCT01486784|Experimental|Phase 1 DL-1|17mg/m2 IV/dose once per week x 3 weeks of 4 week cycle
9793839|NCT01486784|Experimental|Phase 1 DL-1a|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
9793840|NCT01486784|Experimental|Phase 1 DL-1b|17mg/m2/dose IV three times per week x 3 weeks of 4 week cycle
9793841|NCT01486784|Experimental|Phase 1 DL-1c|22mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
9793842|NCT01486784|Experimental|Phase 1 DL-1d|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
9793843|NCT01486810|Experimental|Lisdexamfetamine and medication management|Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
9793844|NCT01486927|Experimental|Recombinant Factor VIII (rFVIII)|
9793845|NCT01486966|Experimental|Insulin detemir / IAsp|
9793846|NCT01486966|Active Comparator|insulin NPH|
9793847|NCT01487161|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
9793848|NCT01487161|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
9793849|NCT01487161|Experimental|FX006 60 mg|Single 3mL intra-articular (IA) injection Extended-Release Formulation
9793850|NCT01487161|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide
9793851|NCT01487200|Experimental|FX006 10mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
9793852|NCT01487200|Experimental|FX006 40mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
9793853|NCT01487200|Experimental|FX006 60 mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
9793854|NCT01487200|Active Comparator|TCA IR (40 mg)|Single 1 mL intra-articular (IA) injection Immediate-release formulation
9793855|NCT01487265|Experimental|BKM120 and Erlotinib|"Cycle 1: BKM120 80 mg PO daily; Erlotinib 100mg PO daily~Cycles 2 and beyond: BKM120 100 mg PO daily; Erlotinib 100mg PO daily"
9793856|NCT01487525|Placebo Comparator|PBFR-|double leg press without application of partial blood flow restriction to the upper leg
9793857|NCT01487525|Experimental|PBFR+|double leg press with application of partial blood flow restriction to the upper leg
9793858|NCT01487577|Experimental|Mycophenolate mofetil|Pharmacokinetics-based targeting of mycophenolate mofetil
9793859|NCT01487668|No Intervention|Arm 1 - Usual Care|Usual care will include standard mental health and medical care available in the VA clinics but with no active management by the LGCC health specialist.
9793860|NCT01487668|Experimental|Arm 2 - Life Goals Collaborative Care|
9848975|NCT03249909|Other|Exufiber|Gelling fibre dressing without silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
9848976|NCT03249909|Other|Aquacel® Ag Extra|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
9848977|NCT03249935|Experimental|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
9848978|NCT03250182|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol per protocol. Administered as 2 inhalations per use as instructed in the protocol.
9848979|NCT03250234|Other|Adequate Carbohydrate|Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
9848980|NCT03250234|Other|Low Carbohydrate|Non-nutritive control beverage. Low carbohydrate diet 1.2 g/kg/d
9848981|NCT03250689|Experimental|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
9848982|NCT03250689|Experimental|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
9848983|NCT03251482|Experimental|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
9848984|NCT03251482|Experimental|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
9848985|NCT03251482|Experimental|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
9848986|NCT03251482|Experimental|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
9848987|NCT03251482|Experimental|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
9848988|NCT03251482|Experimental|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
9848989|NCT03251482|Experimental|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
9848990|NCT03251482|Experimental|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
9848991|NCT03251482|Experimental|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
9848992|NCT03251482|Experimental|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
9848993|NCT03251482|Experimental|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
9848994|NCT03251937|Experimental|Spinal Cord Stimulation|Spectra WaveWriter SCS System
10207633|NCT05125081|Experimental|LDP group|Liuwei Dihuang Pill (LDP）marketed product in China donated by pharmaceutical company.
10207634|NCT05125081|Placebo Comparator|placebo group|Same smell, color and shape as Liuwei Dihuang Pill (LDP）without herbs in capsules.
10207635|NCT05122130|Experimental|Melatonin group|Melatonin loaded Carbopol hydrogel will be synthesized as follows: 1 gm of Carbopol will be dissolved in 100 ml deionized water while stirring at 600 rpm for 25°C. Melatonin (3gm) will be dissolved in 1 ml ethanol and added to the formed gel while stirring at 600 rpm at 25 °C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed and it will be loaded on gelatin sponge and will be applied to the donor site.
10207636|NCT05122130|Placebo Comparator|Placebo group|•Topical placebo carbopol gel will be prepared as follows: 1 gm of Carbopol will be dissolved in 100ml deionized water while stirring at 600 rpm for 25°C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed
10207637|NCT05120531||Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
10207638|NCT05120531||Non-Down Syndrome patients undergoing otolaryngologic surgery with anesthesia|
10207639|NCT05119816|Experimental|music therapy group|Patients receive an individual intervention of receptive music therapy during biopsy
10207640|NCT05119816|No Intervention|Control group|Patients receive standard care
10207641|NCT05119166||Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study|The CHILD Cohort Study is a prospective longitudinal birth cohort study. It is an observational study of healthy term infants in Canada (Vancouver, Edmonton, Manitoba, Toronto). The birth years were between 2009-2012, and is currently at the 8 year postnatal follow up phase. IMiC will receive 400 breast milk samples from 400 dyads (100/site) that were taken between 3-4 months postnatal.
10213507|NCT03883139|Active Comparator|DTT|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing DTT. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified DTT for 3 hours a week (3 days, 1 hour per day)."
9848995|NCT03251963|Experimental|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
9848996|NCT03251963|Experimental|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
9848997|NCT03252015|Experimental|Probe Drug Cocktail (Cohort 1a)|Probe Drug Cocktail administered orally on Day -3.
9848998|NCT03252015|Experimental|200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1)|200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
9848999|NCT03252015|Placebo Comparator|Placebo+Probe Drug Cocktail (Cohort 1b)|Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
9849000|NCT03252015|Experimental|400 mg Lasmiditan (Cohort 2a)|400 mg lasmiditan administered orally for 7 days.
9849001|NCT03252015|Experimental|Placebo (Cohort 2b)|Placebo administered orally for 7 days.
9849002|NCT03252145|Experimental|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
9849003|NCT03252145|Active Comparator|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
9849004|NCT03252353|Active Comparator|Octreotide capsules|Octreotide capsules
9849005|NCT03252353|Placebo Comparator|Matching Placebo|Matching placebo capsules
9849006|NCT03252431|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
9849007|NCT03252431|Active Comparator|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
9849008|NCT03252964|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
9849009|NCT03253094|Active Comparator|Fluconazole|150 mg/day for 1 day
9849010|NCT03253094|Experimental|Ibrexafungerp 750mg|750mg QD for 1 day only
9849011|NCT03253094|Experimental|Ibrexafungerp 300mg|300mg BID for 1 day only
9849012|NCT03253094|Experimental|Ibrexafungerp 450mg|450mg BID for 1 day only
9849013|NCT03253094|Experimental|Ibrexafungerp 150mg|150mg BID for 3 days
9849014|NCT03253094|Experimental|Ibrexafungerp 300mg D1-D3|300mg BID for 3 days
9849015|NCT03254108|Experimental|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
9849016|NCT03254108|Experimental|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
9849017|NCT03254108|Experimental|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
9849018|NCT03254108|Experimental|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
9849019|NCT03254108|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
9849020|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
9849021|NCT03254147||patients prescribed with Oral Anti-coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
9849022|NCT03254459|Experimental|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
9849023|NCT03254459|Active Comparator|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
9849024|NCT03254602|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
9849025|NCT03254719|Other|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
9849026|NCT03255187|Experimental|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
9849027|NCT03255187|Placebo Comparator|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
9923002|NCT00845689|Placebo Comparator|1|liver resection with Pringle + placebo
9849028|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
9849029|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
9849030|NCT03255291|Experimental|Risk Display Format:Table:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
9849031|NCT03255291|Experimental|Risk Display Format:Table: Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
9849032|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
9849033|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
9849034|NCT03255382|Experimental|Risankizumab|Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
9849035|NCT03255382|Active Comparator|Fumaderm|Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.
9923003|NCT00845689|Active Comparator|2|liver resection with Pringle + adenosine preconditiong
9849036|NCT03255655|Experimental|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
9849037|NCT03255655|Placebo Comparator|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
9849038|NCT03255733|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
9849039|NCT03255824|Active Comparator|Propofol Group|Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination.
9849040|NCT03255824|Experimental|Dexmedetomidine Group|Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
9849041|NCT03255902|Experimental|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, & questionnaires
9849042|NCT03255941|Active Comparator|Clinic Provider - Urban|Urban Clinic Provider providing DMPA or Sayana Press
9849043|NCT03255941|Active Comparator|Lay Provider - Urban|Urban Lay Provider providing DMPA or Sayana Press
9849044|NCT03255941|Active Comparator|Clinic Provider- Rural|Rural Clinic Provider providing DMPA or Sayana Press
9849045|NCT03255941|Active Comparator|Lay Provider- Rural|Rural Lay Provider providing DMPA or Sayana Press
9849046|NCT03255980|Experimental|Xonrid®|Xonrid® is a medical device for radiation dermatitis
9849047|NCT03255980|Active Comparator|Standard of Care|Standard of care suggested by MASCC guidelines
9849048|NCT03256136|Experimental|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
9849049|NCT03256136|Experimental|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
9849050|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
9849051|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
9849052|NCT03256162|Experimental|Ketamine|Participants will receive four once-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
9849053|NCT03256162|Active Comparator|Midazolam|Participants will receive four once-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
9849054|NCT03256253|Experimental|pregabalin|pregabalin up to daily dose of 600 mg
9849055|NCT03256526|Placebo Comparator|Placebo|
9849056|NCT03256526|Experimental|PF-06835919 Low Dose|75 mg once daily
9849057|NCT03256526|Experimental|PF-06835919 High Dose|300 mg once daily
9849058|NCT03256552|Active Comparator|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
9849059|NCT03256552|Active Comparator|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
9849060|NCT03256552|Active Comparator|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
9849061|NCT03256552|Placebo Comparator|Placebo MDI|Placebo Inhalation Aerosol
9849062|NCT03256578|Experimental|RFM visible|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
9849063|NCT03256578|No Intervention|RFM masked|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
9849064|NCT03256695|Experimental|ABS eMDPI|Participants will receive 90 micrograms (mcg) of albuterol sulfate (ABS) via eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks. ABS eMDPI is a rescue/reliever agent that includes an eModule on top of the approved PROAIR RESPICLICK® inhaler. Participants will be allowed to continue use of other COPD and non-COPD medications as advised by their physician without changes unless deemed necessary by their physician.
9849065|NCT03256799|Experimental|Ivacaftor/Ataluren|
9849066|NCT03256851|Active Comparator|In-Person Delivered Exercise|"Participants in the in-person training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~complete one of their prescribed training sessions (lasting 1 hour total) each week with a physical therapist or trained member of the research team. Training sessions will focus on progression of aerobic and strength training exercises."
9923004|NCT00845689|Active Comparator|3|liver resection with Pringle + adenosine pre- and postconditioning
9923005|NCT00845715|Other|Early motion|
9849067|NCT03256851|Experimental|Telephone-Delivered Exercise|"Participants in the telephone-delivered training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~receive a 60-minute, 1x/week telephone call from a trained research team member. Participants will report their progress from the prior week, discuss/troubleshoot any issues or problems, and receive progressions of both aerobic and strength training exercises for the upcoming week."
9849068|NCT03256968|Experimental|ataluren administration|dose of the drug administered (mg/kg body weight)
9923006|NCT00845715|Other|Standard motion|
9923007|NCT00845754|Placebo Comparator|1|Placebo
9923008|NCT00845754|Active Comparator|2|Ketorolac
9923009|NCT00845767|Experimental|Diesel Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 with intermittent exercise
9923010|NCT00845767|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
9923011|NCT00845780|Experimental|withdrawal amiodarone|withdrawal amiodarone afer at least 6 months of sinus rhythm maintenance on amiodarone therapy
9923012|NCT00845780|Active Comparator|continuation amiodarone|continuation of amiodarone after 6 months of sinus rhythm maintenance on amiodarone therapy
9923013|NCT00845806||Arabic Speakers|All subjects must be male native arabic speakers who can read and speak english.
9923014|NCT00845819|Active Comparator|EGF|rhEGF + povidone iodine, chlorhexidine, & nystatin
9923015|NCT00845819|Placebo Comparator|Placebo|Placebo + povidone iodine, chlorhexidine, & nystatin
9923016|NCT00845884|Experimental|AVDCF|Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
9923017|NCT00845910|Experimental|1|
9923018|NCT00845936|Experimental|1|850 mg of Metformin bid
9923019|NCT00845936|Placebo Comparator|placebo|Tablets Identical to Metformin, bid
9923020|NCT00845962|Active Comparator|Chloroprocaine|
9923021|NCT00845962|Active Comparator|Bupivacaine|
9923022|NCT00845988|Active Comparator|treatment as usual|patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine
9923023|NCT00845988|Experimental|switch to aripiprazole|aripiprazole
9923024|NCT00846001|Active Comparator|CABG alone|Standard coronary artery bypass grafting according guidelines
9923025|NCT00846001|Experimental|CABG+CRT|Standard coronary artery bypass grafting according guidelines with concomitant three bipolar epicardial leads implantation for cardiac resynchronization therapy
9923026|NCT00846014|Experimental|Asthmatics|All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
9923027|NCT00846092|Experimental|Device|"The study will require 20 subjects.~Each subject will have one study eye that will be designated for treatment.~Subjects will be exposed to light emitted from Warp 10 LED's (Quantum Devices, Barneveld, WI) at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~Treatments involve application of the LED-generated light for 80 seconds, twice daily.~Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study.~• This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group."
9998196|NCT01515969|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
9923028|NCT00846105|Experimental|Rapid PCR screen|Rapid PCR screen test for detection of MRSA carriers upon hospital admission
9923029|NCT00846105|Active Comparator|Conventional culture|Conventional culture screen for detection of MRSA carriers upon hospital admission
9923030|NCT00846118|Active Comparator|Pitavastatin|Pitavastatin in addition to optimal standard care
9923031|NCT00846118|No Intervention|optimal standard care|
9923032|NCT00846131|Active Comparator|A: Y-90 alone|Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
9923033|NCT00846131|Experimental|B: Sorafenib + Y-90|Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin > 1.5 x ULN to ≤ 3 x ULN. After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
9935098|NCT04203199|Experimental|Real rTMS to the dlPFC using H1 Coil|One session of high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
9849069|NCT03257189|Other|Single Arm|"This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices.~This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention."
9849070|NCT03257202|No Intervention|Control|No topical treatment
9849071|NCT03257202|Experimental|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
9849072|NCT03257202|Experimental|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
9849073|NCT03257202|Experimental|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
9849074|NCT03257358|Other|Cohort 1|RMS patients who were newly prescribed commercially available fingolimod 0.5mg per day
9849075|NCT03257358|Other|Cohort 2|RMS patients who had been on commercially available fingolimod 0.5mg per day continuously for ≥ 2 years
9849076|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
9849077|NCT03257410|Experimental|Theranova 400|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
10207642|NCT05119166||The Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) Study|(NCT03268902). ELICIT is a randomized controlled trial (RCT) evaluating the efficacy of antimicrobials and nicotinamide in increasing growth in the setting of Rural Tanzania. It is factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis to infants. IMiC will receive 400 breast milk samples from 200 dyads, 2 samples per dyad taken at 1 & 5 months postnatal.
9849078|NCT03257410|Active Comparator|Elisio-17H|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
9849079|NCT03257631|Experimental|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
9849080|NCT03257657|Experimental|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC Registered Dietitian (RD) at the 12 week visit.
9849081|NCT03257657|Experimental|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
9849082|NCT03257813|Other|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
9849083|NCT03257813|Other|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
9849084|NCT03257865|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
9849085|NCT03257865|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind
9849086|NCT03257995|Experimental|Sequence 1|A-B-C
9849087|NCT03257995|Experimental|Sequence 2|B-C-A
9849088|NCT03257995|Experimental|Sequence 3|C-A-B
9849089|NCT03257995|Experimental|Sequence 4|A-C-B
9849090|NCT03257995|Experimental|Sequence 5|B-A-C
9849091|NCT03257995|Experimental|Sequence 6|C-B-A
9849092|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
10207643|NCT05119166||VITAL Pakistan|Two Randomized Controlled Trials: Mumta (Nutritional support for lactating women with or without azithromycin)PW - NCT04012177 and MumtaLW - NCT03564652 VITAL is a community-based, randomized control, assessor blinded trial in peri-urban settings of Karachi, Pakistan to study the impact of Lipid-based Nutritional Supplement for Pregnant and Lactating women which is balanced energy-protein (BEP) dietary supplement, a locally produced ready-to-use nutritional product for lactating women (LW) and single prophylaxis dose of Azithromycin for infants, on growth of infants over the period of six months since birth compared to current standard of care. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 2-3 months.
10207644|NCT05119166||Micronutriments pour la Santé de la Mère et de l'Enfant (MISAME)-3 study (NCT03533712)|MISAME-3 is a randomized controlled clinical trial in the setting of Rural Burkina Faso. A BEP supplement provides less than 25% of protein of the total energy content, and includes different vitamins and minerals. The first part of an exploratory study will determine which type of BEP supplement (bar, drink, biscuit, soup or paste) is most accepted by pregnant women. Subsequently, two products will be tested for longer-term acceptability and at-home use (phase 1). The effect of the most suitable supplement will be tested in a controlled clinical trial (phase 2). The intervention group will receive the dietary supplement during pregnancy and/or lactation, while the control group complies with the standard iron and folic acid tablets following the national guidelines. IMiC will receive 600 breast milk samples from 200 dyads, 3 samples per dyad taken at 0-1, 1-2 & 3-4 months.
9849093|NCT03258710|Experimental|All subjects treated with Tenofovir Disoproxil Fumarate|Subjects with on-going ETV treatment will be switched to Tenofovir Disoproxil Fumarate treatment. Subjects will start TDF on the day ETV is discontinued, without having overlapping treatment periods. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
9849094|NCT03258762|Experimental|Healthy Japanese male subjects|Healthy Japanese male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
9849095|NCT03258762|Experimental|Healthy Caucasian male subjects|Healthy Caucasian male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
10207645|NCT05119036|No Intervention|Observation|If patients have negative margins and have all negative nodes or only a single positive node, patients will be placed in the observation arm and will not receive further adjuvant treatment, only postoperative follow-up visits and a surveillance visit 3 months after surgery with a CT or PET-CT.
9849096|NCT03258814||Active Supervised Training (AST)|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
9849097|NCT03258814||Standard of Care (SOC) Physiotherapy|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
9849098|NCT03259087|Experimental|Part 1: Mild Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
9849099|NCT03259087|Experimental|Part 1: Moderate Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
9849100|NCT03259087|Experimental|Part 1: Severe Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
9849101|NCT03259087|Experimental|Part 1: Healthy Participants|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
9849102|NCT03259087|Experimental|Part 2: End-stage Renal Disease Undergoing Hemodialysis|End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
9849103|NCT03259139|Experimental|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
9849104|NCT03259139|Experimental|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
9849105|NCT03259139|Other|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
9849106|NCT03259308|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
9849107|NCT03259308|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using PFS on Week 0, Week 4 and Week 8.
9849108|NCT03259308|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab SC injection using PFS on Week 0, Week 4, and Week 8.
9849109|NCT03259334|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligrams (mg) of ontamalimab (SHP647) subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
9849110|NCT03259334|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
9849111|NCT03259334|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
9849112|NCT03259425|Experimental|Nivolumab and HF10, all participants|
9849113|NCT03259490|Experimental|Test Treatment|High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
9849114|NCT03259490|Experimental|Reference Treatment|Single tablets of empagliflozin + linagliptin + metformin XR
9849115|NCT03259555|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
9849116|NCT03259555|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind.
9849117|NCT03259789|Active Comparator|Bexagliflozin tablets, 20 mg; Double-Blind|
9849118|NCT03259789|Placebo Comparator|Bexagliflozin tablets, Placebo; Double Blind|
9849119|NCT03259789|Experimental|Bexagliflozin Tablets, 20 mg; High Glycemic Group|
9849120|NCT03260205|Placebo Comparator|Placebo|Participant will receive placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
9849121|NCT03260205|Experimental|SPD489 (Lisdexamfetamine dimesylate)|Participants will be randomized to receive SPD489 capsule in a 5:5:5:5:6 ratio to SPD489 5, 10, 20, 30 milligram (mg) orally once daily for 6 weeks. Dosing will begin with the lowest strength of SPD489 (5 mg), and will be titrated until the randomly assigned fixed-dose is reached.
9849122|NCT03260426|Experimental|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
9849123|NCT03260426|Experimental|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
9849124|NCT03260595|Experimental|Crisaborole ointment 2%|
9849125|NCT03260595|Placebo Comparator|Vehicle|
9849126|NCT03260699|No Intervention|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
9849127|NCT03260699|Experimental|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery ~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
9849128|NCT03260790|Experimental|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23
9849129|NCT03260790|Active Comparator|PPSV23|Participants randomized to receive PPSV23 alone
9849130|NCT03261037|Other|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
9849131|NCT03261167|Experimental|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
9849132|NCT03261167|Active Comparator|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
9849133|NCT03261167|Experimental|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
9849134|NCT03261336|Experimental|Calcitriol, Ketoconazole, Hydrocortisone|Patients receive calcitriol (10mcg QD X3 weekly) in addition to ketoconazole (400mg QD) and hydrocortisone (20mg AM, 10 mg PM).
9849135|NCT03261947|Experimental|Western Safety Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.
9849136|NCT03261947|Experimental|Pancreatic Cancer Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
9849137|NCT03261947|Experimental|Metastatic CRC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.
9849138|NCT03261947|Experimental|sqEC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
9849139|NCT03261947|Experimental|sqNSCLC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.
9849140|NCT03261960|Experimental|Experimental Arm|BLI4700 Bowel Preparation
9849141|NCT03261960|Active Comparator|Control Arm|FDA Approved Bowel Preparation
9849142|NCT03261973|Other|DV8 esophageal deviation tool|This is a non-randomized one arm study.
9849143|NCT03261999|Experimental|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
9849144|NCT03262012|Experimental|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
9849145|NCT03262012|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
9849146|NCT03262012|Experimental|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
9849147|NCT03262012|Active Comparator|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
10207646|NCT05119036|Experimental|Adjuvant Radiation 44 Gray|If patients have 4 or fewer positive nodes and 1 mm or less of cancer spread extending outside the lymph nodes, patients will receive 44 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
9849148|NCT03262038|Experimental|Ondansetron IV|Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
9849149|NCT03262038|Placebo Comparator|Placebo|Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)
9849150|NCT03262233|Experimental|Active Deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
9849151|NCT03262233|Experimental|Active Non-deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
9849152|NCT03262233|Active Comparator|Placebo Deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
9849153|NCT03262233|Active Comparator|Placebo Non-deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
9849154|NCT03262389|Experimental|Multiple Myeloma Patients|Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
9849155|NCT03262441|Experimental|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
9849156|NCT03263442|Experimental|Intervention|Thiamine 200 mg IV
9849157|NCT03263442|Placebo Comparator|Control|Normal saline IV
9849158|NCT03263702|Experimental|Computational Mapping Algorithm|AF mapping (utilizing CMA) will be performed and used to point the operator to regions within a heart chamber that should be interrogated further for suspicious electrogram activity, as measured by the St. Jude Ensite System, and ablated if the suspicious electrogram activity persists.
9849159|NCT03263780|Experimental|18F-Fluciclovine|10mCi +/-20% 18F-fluciclovine injection
9849160|NCT03264066|Experimental|Cohort 1 - SCCHN - Treatment Naive|In participants with recurrent or advanced / metastatic SSCHN who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
9849161|NCT03264066|Experimental|Cohort 2 - UC - Treatment Naive|In participants with advanced / metastatic UC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
9849162|NCT03264066|Experimental|Cohort 3 - RCC - Treatment Naive|In participants with metastatic RCC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 milligrams (mg) once daily (QD) for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
9849163|NCT03264066|Experimental|Cohort 4 - SCCHN - Previous Treatment Exposure|In participants with SCCHN whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
9849164|NCT03264066|Experimental|Cohort 5 - UC - Previous Treatment Exposure|In participants with UC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
9849165|NCT03264066|Experimental|Cohort 6 - RCC - Previous Treatment Exposure|In participants with RCC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
9849166|NCT03264066|Experimental|Cohort 7 - Biopsy Cohort|In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
9849167|NCT03264092|Experimental|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
9849168|NCT03264092|Experimental|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
9849169|NCT03264092|Experimental|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
9849170|NCT03264157|Experimental|BPL HRIG + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
9849171|NCT03264157|Active Comparator|Comparator HyperRab + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
9849172|NCT03264248|Experimental|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
9849173|NCT03264456|Experimental|[18F] Fluciclovine PET/MRI|[18F] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer
9849174|NCT03265119|Experimental|AEVI-001|
9849175|NCT03265119|Placebo Comparator|Placebo|
9849176|NCT03265132|Experimental|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
10207647|NCT05119036|Experimental|Adjuvant Radiation 54 Gray|If patients have 4 or fewer positive nodes with greater than 1 mm of cancer spread extending outside the lymph nodes or 5 or more positive nodes with 1 mm or less of cancer spread extending outside the lymph nodes, patients will receive 54 gray fractions (the full dose of radiation divided into smaller doses) of adjuvant radiation.
10207648|NCT05116540|Experimental|Treatment|Adipose derived Mesenchymal stem cells (Autologous)
9849177|NCT03265132|Placebo Comparator|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
9849178|NCT03265600|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
9849179|NCT03265600|Other|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
9849180|NCT03265938||Indirect laryngoscopy|Head and neck pathology patients undergoing indirect laryngoscopy. Patients with a past medical history of active or previously treated head and neck pathology.
9849181|NCT03266094|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs Radio frequency (RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
9849182|NCT03266107|Experimental|Treatment|BVN Ablation
9849183|NCT03266172|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
9849184|NCT03266172|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR
9849185|NCT03266172|Experimental|Subjects in Part C|Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)
9849186|NCT03266419|Experimental|Deep NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
9849187|NCT03266419|Active Comparator|Moderate NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
9849188|NCT03266588|Experimental|Rimegepant|
9849189|NCT03267212|Active Comparator|Non-invasive Ventilation(NIV)|Subjects will perform FES-row testing while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
9849190|NCT03267212|Sham Comparator|Sham Non-invasive ventilation(NIV)|Subjects will perform FES-row testing while receiving sham ventilation applied through a full face-mask.
9849191|NCT03267264|Experimental|Group 1|
9849192|NCT03267264|Experimental|Group 2|
9849193|NCT03267264|Experimental|Group 3|
9849194|NCT03267264|Experimental|Group 4|
9849195|NCT03267511|Experimental|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
9849196|NCT03267511|Experimental|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
9849197|NCT03267511|Active Comparator|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
9849198|NCT03267511|Active Comparator|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
9849199|NCT03267576|Experimental|Treatment Sequence AB|Participants will receive metformin monotherapy at stable doses (greater than or equal to [>=] 1500 milligram per day [mg/day]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin >=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
9849200|NCT03267576|Experimental|Treatment Sequence BA|Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
9849201|NCT03267940|Experimental|Run-in Portion: PEGCISGEM|Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m^2) of CIS plus 1000 mg/m^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
9923034|NCT00846157|No Intervention|control|Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.
9923035|NCT00846157|Active Comparator|Active|R-CHOP plus Natural Killer Cell therapy
10207649|NCT05116540|Placebo Comparator|Placebo|Normal Saline
10207650|NCT05113017||SBRT group|Patients with residual lung nodules are treated with SBRT
10207651|NCT05112848|Experimental|Group 1 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
10207652|NCT05112848|Experimental|Group 2 PLWH|Three doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0, Day 21, and Day 70.
10207653|NCT05112848|Experimental|Group 3 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
9849202|NCT03267940|Experimental|Run-in Portion: PEGCISGEMATEZO|After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
9849203|NCT03267940|Experimental|Expansion Portion: PEGCISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
9849204|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Twice Weekly|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
9849205|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly|After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
9849206|NCT03267940|Active Comparator|Expansion Portion: CISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
9849207|NCT03268343|Experimental|Schedule A: Fed Then Fasted|"Schedule A (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
10207654|NCT05112848|Experimental|Group 4 HIV-Negative Participants|"2 doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
10207655|NCT05112848|Experimental|Group 5 HIV-Negative Participants|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
9849208|NCT03268343|Experimental|Schedule B: Fasted Then Fed|"Schedule B (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
9849209|NCT03268590|Experimental|All Study Participants|Breathing 21% oxygen via non-rebreather face mask followed by breathing 100% oxygen via non-rebreather face mask
9849210|NCT03268746|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag following cataract removal. Both eyes will be implanted.
9849211|NCT03268941|Placebo Comparator|Part 1: Placebo|TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.
9849212|NCT03268941|Experimental|Part 1: TAK 906 Maleate 5 mg|TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.
9849213|NCT03268941|Experimental|Part 1: TAK 906 Maleate 25 mg|TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.
9849214|NCT03268941|Experimental|Part 1: TAK 906 Maleate 100 mg|TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.
9849215|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fed Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.
10207656|NCT05112432|No Intervention|Treatment as Usual|Participants will be treated as usual and will not complete cognitive training or use the Personalized Real-Time Motivational Enhancement App. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
10207657|NCT05112432|Experimental|Cognitive Training plus Personalized Real-Time Motivational Enhancement App (PRIME)|The Mobile Intervention. 20 hours of training consisting of 10 hours of cognitive training exercises plus 10 hours of social cognitive training exercises will be delivered over the course of 12 weeks in addition to PRIME. Participants may choose to complete study activities in person at their coordinated specialty care program or may choose to complete study activities remotely.
10207658|NCT05110976|Experimental|Part A1: SAD (AZD8630)|Healthy participants will administered single inhaled doses 1 to 5 of AZD8630.
10207659|NCT05110976|Experimental|Part A2: SAD (AZD8630)|Healthy participants of Chinese and Japanese ethnicity will administered single inhaled dose 5 of AZD8630.
10207660|NCT05110976|Experimental|Part A3: MAD (AZD8630)|Healthy participants will administered once daily inhaled doses 3, 4, and 5 of AZD8630.
10207661|NCT05110976|Experimental|Part A4: MAD (AZD8630)|Healthy participants of Chinese and Japanese ethnicity will administered once daily inhaled dose 5 of AZD8630.
9849216|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fasted Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.
9849217|NCT03268941|Active Comparator|Part 2: Metoclopramide 10 mg|Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.
9849218|NCT03269435|Experimental|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%~+ Normal saline IV"
9849219|NCT03269435|Active Comparator|Metoclopramide|"Metoclopramide 10mg IV~+ Bilateral greater occipital nerve block with normal saline"
9849220|NCT03269552|Experimental|Treatment (carfilzomib, rituximab)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.
9849221|NCT03270085|Active Comparator|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
9849222|NCT03270085|Placebo Comparator|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
9849223|NCT03270332|Experimental|Albuterol followed by placebo|Participants in this group will receive albuterol first followed by Placebo on the next visit
9849224|NCT03270332|Experimental|Placebo followed by albuterol|Participants in this group will receive placebo first followed by albuterol on the next visit
9849225|NCT03270436|Experimental|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|The Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program (WORD DPP) is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. The first 8 modules are intended to be delivered weekly. The last 8 modules are intended to be delivered every other week. Participants in the WORD DPP will be encouraged to maintain a daily weight, nutrition, physical activity and prayer log.
9849226|NCT03270436|Experimental|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|The Partnership for Improving Lifestyle Intervention Diabetes Prevention Program (PILI DPP) is a family and community based diabetes prevention curriculum that teaches participants to engage their social support (family and community) to have a healthy weight, eat healthy, and be physically active. The PILI DPP includes 14 modules that are intended to be delivered over a 24 week period and each module approximately 90 minutes in length. The first 4 modules are intended to be delivered weekly. The last 10 modules are intended to be delivered every other week. Participants will be encouraged to track their weight, physical activity, and their nutrition in a log on a daily basis.
9849227|NCT03270514|Experimental|Exparel Injectable Product|Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the liposomal bupivacaine (Exparel) group (~30).
9849228|NCT03270514|Active Comparator|Bupivacaine Hydrochloride|Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (~30).
9849229|NCT03270644|Experimental|Lasmiditan Reference|Single oral dose of lasmiditan 200 mg on Day 1 as reference treatment.
9849230|NCT03270644|Active Comparator|Propranolol Reference|Twice-daily oral doses of propranolol 80 mg on Days 4-10 as reference treatment.
9849231|NCT03270644|Experimental|Lasmiditan + Propranolol Test|Single oral dose of lasmiditan 200 mg + two oral doses of propranolol 80 mg on Day 9 as test treatment.
9849232|NCT03270657|Other|Intraoperative Recording During DBS Implant Surgery|Participants will be recruited and enrolled from individuals who have Parkinson's disease (PD) and who already are scheduled to undergo the planned deep brain electrode placement for treatment of their movement disorder. Intraoperative recordings of participants' neural signals will be made through the implanted deep brain electrode(s).
10207662|NCT05110976|Placebo Comparator|Part A: SAD (Placebo)|Healthy participants and healthy participants of Chinese and Japanese ethnicity will administered single inhaled doses of placebo.
10207663|NCT05110976|Placebo Comparator|Part A: MAD (Placebo)|Healthy participants and healthy participants of Chinese and Japanese ethnicity will administered once daily inhaled dose of placebo.
10207664|NCT05110976|Experimental|Part B (AZD8630)|Participants with asthma will be randomized to one of 3 inhaled dose levels 3, 6, and 7 of AZD8630 once daily.
10207665|NCT05110976|Placebo Comparator|Part B (Placebo)|Participants with asthma will administered once daily inhaled dose of placebo.
10207666|NCT05109156||This is an observational study|This is an observational study
10207667|NCT05089617|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
10207668|NCT05089617|Experimental|SAD Cohort 2|25 mg YG1699 or Placebo
10207669|NCT05089617|Experimental|Multiple Doses Cohort 1|20 mg YG1699 or Placebo
10207670|NCT05086250|Experimental|Arm A: Ketamine Followed by Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
10207671|NCT05086250|Experimental|Arm B: Placebo Followed by Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
9849233|NCT03270943|Experimental|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
9849234|NCT03270943|Active Comparator|Healthy Lifestyles (HLG)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
9849235|NCT03271307|No Intervention|AIm 1: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
9849236|NCT03271307|Experimental|Aim 1: Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
9849237|NCT03271307|Experimental|Aim 1: Facility HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
9849238|NCT03271307|No Intervention|Aim 2: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients. Partner referral slips will be given to HIV-positive clients to encourage partner testing.
9849239|NCT03271307|Experimental|Aim 2: Index HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
9849240|NCT03271424|No Intervention|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
9849241|NCT03271424|Active Comparator|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
9849242|NCT03271424|Active Comparator|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
9849243|NCT03271528|Experimental|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
9849244|NCT03271528|Placebo Comparator|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
9849245|NCT03272139|Experimental|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
9849246|NCT03272139|Experimental|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
9849247|NCT03273153|Experimental|Cobimetinib and Atezolizumab|Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
9849248|NCT03273153|Active Comparator|Pembrolizumab|Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
9849249|NCT03273166|Experimental|INVSENSOR00001 sensor|This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
9849250|NCT03273257|Active Comparator|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
9849251|NCT03273257|Placebo Comparator|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
9849252|NCT03273270|Experimental|Active TMS|1 Hz repetitive transcranial magnetic stimulation
9849253|NCT03273270|Placebo Comparator|Sham TMS|No active stimulation
9849254|NCT03273283|Experimental|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techniques to enhance motivation to reduce alcohol use or to initiate treatment. Patients were referred to specialized treatment when indicated.
9849255|NCT03273283|No Intervention|Control|Informative leaflets regarding alcohol use
9849256|NCT03273387|Placebo Comparator|Sugar pill|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
9849257|NCT03273387|Experimental|trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
9849258|NCT03273426|Experimental|Core needle Biopsy|Ultrasound-guided core needle biopsy (14G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
9849259|NCT03273426|Experimental|Vacuum-assisted biopsy|Vacuum-assisted biopsy (10G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
9849260|NCT03273543|Experimental|Nasal Tip Projection|
9849261|NCT03273543|Experimental|Upper Lip Position|
9923036|NCT00846170|Active Comparator|probiotics|patients with IBS that will receive investigational treatment for 4 weeks
9923037|NCT00846170|Placebo Comparator|Placebo|cross over of patients from arm 1
9923038|NCT00846183|Active Comparator|local ingury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed.
9923039|NCT00846183|No Intervention|control|in 60 patients routine IVF are performed
9923040|NCT00846196|Experimental|2|one commercial risedronate 35 mg DR tablet
9849262|NCT03273673|Experimental|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
9849263|NCT03273673|No Intervention|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
9849264|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask in clinical practice.
9849265|NCT03274076|Active Comparator|Tofacitinib|5mg Tofacitinib twice a day
9849266|NCT03274076|Placebo Comparator|Placebo|5mg Placebo twice a day
9849267|NCT03274440|Experimental|High THC/Low CBD Marijuana|This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (<1%) content.
9849268|NCT03274440|Experimental|Low THC/High CBD Marijuana|This condition involves the ingestion of marijuana with a low THC (<1%) and high CBD (>10%) content.
9849269|NCT03274440|Placebo Comparator|No THC/No CBD|This condition involves the ingestion of a placebo control with no THC and no CBD content.
9849270|NCT03274453|Active Comparator|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
9849271|NCT03274453|Placebo Comparator|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
9849272|NCT03274453|Placebo Comparator|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
9849273|NCT03274453|Experimental|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
9849274|NCT03274466|Experimental|Closed Incision Negative Pressure Therapy (ciNPT)|Prevena Peel & Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit
9849275|NCT03274466|Active Comparator|Standard of Care Dressing|Silver impregnated dressing
9849276|NCT03274518|Active Comparator|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
9849277|NCT03274518|Experimental|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
9849278|NCT03274804|Experimental|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
9849279|NCT03274856|Other|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
9849280|NCT03274856|Other|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
9849281|NCT03274986|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
9849282|NCT03274986|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
9849283|NCT03274999|Experimental|TrueTear™ Intranasal then Extranasal Application|TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
9849284|NCT03274999|Experimental|TrueTear™ Extranasal then Intranasal Application|TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.
9849285|NCT03275246|Experimental|Total knee arthroplasty|Patients undergoing total knee arthroplasty
9923041|NCT00846196|Active Comparator|1|one Phase III risedronate 35 mg DR tablet
9923042|NCT00846222|Experimental|Mild theraputic hypothermia|
9923043|NCT00846235|Experimental|Moisturising cream|
9923044|NCT00846248|Active Comparator|1|Chromium picolinate
9923045|NCT00846248|Placebo Comparator|2|2 sugar pills taken twice daily
9793861|NCT01487863|Experimental|Concurrent Arm|Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
9793862|NCT01487863|Experimental|Sequential Arm|Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
9793863|NCT01487954|Experimental|Arm I: alkaline water|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
9793864|NCT01487954|Active Comparator|Arm II: distilled water|Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy
9793865|NCT01488019|Experimental|Perforomist, nebulization, COPD|Active
9793866|NCT01488019|Placebo Comparator|Perforomist-Placebo|Placebo
9793867|NCT01488071|Experimental|Vortioxetine 10 mg or 20 mg|
9793868|NCT01488071|Active Comparator|Agomelatine 25 mg or 50 mg|
9793869|NCT01488097|Experimental|Open-Label Sebelipase Alfa|Participants were administered sebelipase alfa once weekly (qw) as an intravenous (IV) infusion at the same dose received in Study LAL-CL01 (0.35, 1, or 3 milligrams per kilogram [mg/kg]) for 4 weeks. After the initial 4 qw doses, participants transitioned to dosing every other week (qow) at either 1 mg/kg (participants who initiated treatment at 0.35 or 1 mg/kg qw) or 3 mg/kg (participants who initiated dosing at 3 mg/kg qw). Subsequent modifications to the dose and dosing frequency were permitted for individual participants based on observed safety, tolerability, and clinical response to treatment. Participants could continue to receive treatment with sebelipase alfa for up to 5 years.
9793870|NCT01488188|Active Comparator|Influenza vaccine-Nasal|Nasal administration
9793871|NCT01488188|Active Comparator|Influenza vaccine -Sublingual|Sublingual administration
9793872|NCT01488279|Active Comparator|Dexamethasone 2.5mg and Sitagliptin100mg|Participants received Dexamethasone 2.5 mg plus Sitagliptin 100 mg daily for 8 days
9793873|NCT01488279|Placebo Comparator|Dexamethasone 2.5mg and placebo tablet|Participants received Dexamethasone 2.5 mg plus Sitagliptin-matched placebo tablet daily for 8 days.
9793874|NCT01488318|Experimental|CETUXIMAB AND DASATINIB|"Cetuximab on a standard weekly schedule (see Section 6.2). Group 1 (subjects more than 2 weeks post last dose of Cetuximab): Loading dose of 400 mg/m2 on cycle 1, day 1 then 250 mg/m2 IV weekly.~Group 2 (subjects last Cetuximab treatment within 2 weeks): Cycle 1 will start at a dose of 250 mg/m2 Dasatinib 150 mg once daily without interruption. On the FIRST cycle (1 cycle is 3 weeks) dasatinib will start 3 days after the cetuximab loading dose (i.e. cycle 1, day 4) to avoid headache as shown on the previous phase I trial.~Treatment will continue until progression."
9793875|NCT01488370|Active Comparator|Glidescope|A device for endotracheal intubation.
9793876|NCT01488370|Active Comparator|Storz|A device for endotracheal intubation.
9793877|NCT01488370|Active Comparator|Standard Laryngoscope|A device for endotracheal intubation
9793878|NCT01488409|Experimental|Acipimox|Treatment with the study drug Acipimox
9793879|NCT01488409|Placebo Comparator|Placebo|Treatment with Placebo control.
9793880|NCT01488448|Experimental|Nebulized Hypertonic Saline|4mL nebulized 3% sodium chloride every 4 hours until discharge
9793881|NCT01488448|Placebo Comparator|Nebulized Normal Saline|4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
9793882|NCT01488487|Experimental|Everolimus + pasireotide|Oral Everolimus 7.5 mg administered daily for 28 days per cycle, plus pasireotide Long Acting Release (LAR) 60 mg administered by intramuscular injection once per 28 day cycle on day 1.
9793883|NCT01488578||Tolterodine tartrate.|Subjects taking Tolterodine tartrate.
9793884|NCT01488708|Experimental|LY 2127399 Q2W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
9793885|NCT01488708|Experimental|LY2127399 Q4W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
9793886|NCT01488877|Experimental|PF03882845|
9793887|NCT01488877|Active Comparator|Spironolactone|25 mg once daily
9793888|NCT01488877|Placebo Comparator|Placebo|Placebo once daily
9793889|NCT01488994|Experimental|BAX326 < 6 years of age|
9793890|NCT01488994|Experimental|BAX326 6 to <12 years of age|
9793891|NCT01489020|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
9793892|NCT01489020|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
9793893|NCT01489020|Experimental|group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
9793894|NCT01489020|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
9793895|NCT01489020|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 doses of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
9849286|NCT03275389|Experimental|D-SUIV Adjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849287|NCT03275389|Experimental|D-SUIV Adjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849288|NCT03275389|Experimental|D-SUIV Adjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849289|NCT03275389|Experimental|D-SUIV Adjuvanted Group 4|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849290|NCT03275389|Experimental|D-SUIV Adjuvanted Group 5|Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849291|NCT03275389|Experimental|D-SUIV Adjuvanted Group 6|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849292|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849293|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849294|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849295|NCT03275389|Active Comparator|IIV4 Group|Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
9849296|NCT03275623|Active Comparator|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
9849297|NCT03275623|Active Comparator|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
9923046|NCT00846261|Experimental|Ilzarov|
9923047|NCT00846274|Active Comparator|Antithrombin III|
9923048|NCT00846274|Experimental|SK Antithrombin III|
9923049|NCT00846313|Active Comparator|Dietary counseling|Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary.
9923050|NCT00846313|No Intervention|Control|
9923051|NCT00846326|Experimental|Oxymetazoline-Fluticasone Propionate|Combination nasal spray with oxymetazoline 0.05% and fluticasone propionate 0.05%
9923052|NCT00846326|Placebo Comparator|Oxymetazoline-placebo|oxymetazoline 0.05% w/v and placebo fluticasone propionate
9923053|NCT00846339|Experimental|1|DRD2 Taq1A1 allele
9923054|NCT00846339|Experimental|2|DRD Taq1 A2 homozygote2
10207672|NCT05083884||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
10207673|NCT05083884||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
9923055|NCT00846352|Active Comparator|Early Bronch|This group will receive bronchoscopy within 36 hours of enrollment into the study.
9849298|NCT03275766|Active Comparator|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
9849299|NCT03275766|Experimental|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA~should inhibit overactive premotor cortices"
9849300|NCT03275766|Experimental|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA~should facilitate neural activity within premotor cortices"
9849301|NCT03275766|Sham Comparator|sham TMS|"sham rTMS with a placebo coil over occipital cortex~should have no effect at all (no transcranial magnetic stimulation, only sound)"
9849302|NCT03275870|Experimental|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
9849303|NCT03276026|Active Comparator|Control Group/Neostigmine|The control group will be the 63 patients who receive Neostigmine in a dose of 5mg, along with the anti-cholinergic glycopyrrolate 0.6mg.
9849304|NCT03276026|Active Comparator|Study Group/Sugammadex|63 patients will be given Sugammadex in a dose of 2mg/kg if the train of four twitch count is 2 and 4mg/kg if the twitch response has reached 1-2 post-tetanic counts with no twitch response to train of four.
9849305|NCT03276078|Experimental|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
9849306|NCT03276494|Other|Intraosseous|Administration of intraosseous hypertonic saline
9849307|NCT03276637|Experimental|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
9849308|NCT03276871|Active Comparator|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
9849309|NCT03276871|Experimental|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
9849310|NCT03276975|Active Comparator|Patching of CSF Leaks with Autologous Blood and Fibrin|CT fluoroscopy-guided blood and fibrin glue patching targeted to the site of CSF leak.
9849311|NCT03276975|Placebo Comparator|Simulated Patching Procedure|Instead of injection of blood and fibrin glue patching material through the needles, an equivalent volume of preservative free sterile Elliots B solution will be injected.
9849312|NCT03277274|Experimental|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
9849313|NCT03277274|Experimental|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
9849314|NCT03277274|Experimental|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
9849315|NCT03277274|Experimental|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
9849316|NCT03277352|Experimental|INCAGN01876 + Pembrolizumab + Epacadostat|INCAGN01876 in combination with pembrolizumab and epacadostat
9849317|NCT03277378|Active Comparator|Group 1 (AB)|Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
9849318|NCT03277378|Active Comparator|Group 2 (TB)|Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
9849319|NCT03277794|Active Comparator|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
9849320|NCT03277794|Experimental|Full HOP-C Service|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
9849321|NCT03277846|Experimental|Accept ECT - TES|Accept ECT where subject is randomized to TES
9849322|NCT03277846|Placebo Comparator|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
9849323|NCT03277846|Experimental|Reject ECT - TES|Reject ECT where subject is randomized to TES
9849324|NCT03277846|Placebo Comparator|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
9849325|NCT03278028|Experimental|Active|A-101 Topical Solutions
9849326|NCT03278028|Placebo Comparator|Vehicle|Vehicle
9849327|NCT03278067||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017.
9849328|NCT03278067||Vaccinated_Non GSK Group|Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017.
9849329|NCT03278067||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or non-GSK not known) in 10 volunteer GP practices between 01 September and 30 November 2017.
9849330|NCT03278106|Experimental|Treatment (TAS-102)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9849331|NCT03278223|Active Comparator|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
9849332|NCT03278223|Active Comparator|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
9849333|NCT03278613|Experimental|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS treatment entails insertion of a 36 gauge needle electrode at a 60 degree angle 3-4 cm deep towards the tibial nerve, approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. The PTNS grounding electrode, placed near the calcaneus and the needle electrode will be connected to the ES-130 device pulse generator.
9849334|NCT03278613|Sham Comparator|Validated Sham|Sham treatment will use the Streitberger acupuncture placebo needle in the same location as the needle electrode for PTNS. The sham uses an active gel surface electrode pad placed on the bottom of the foot just below the fifth (smallest) toe. This location is not part of the acupuncture nerve pathway connected to the bladder, pelvis or any major organs. Electrical current is delivered to this pad via a TENS unit resulting in sensory stimulation.
9849335|NCT03278886|Experimental|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
9849336|NCT03278886|Experimental|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
9849337|NCT03279237|Experimental|FOLFIRINOX + pre-operative radiation|"FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle~Oxaliplatin is administered intravenously~Leucovorin is administered intravenously~Irinotecan is administered intravenously~5-Fluorouracil is administered intravenously~Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
9849338|NCT03279458|Experimental|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
9849339|NCT03279458|Active Comparator|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
9849340|NCT03279731|Active Comparator|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
9849341|NCT03279731|Placebo Comparator|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
9849342|NCT03280108|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
9849343|NCT03280108|Active Comparator|Monofocal IOL|AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
9849344|NCT03280121|Experimental|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
9849345|NCT03280264|Experimental|KHK7580|oral administration
9849346|NCT03280381|Experimental|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
9849347|NCT03280381|Experimental|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
9849348|NCT03280537|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
9849349|NCT03280537|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
9849350|NCT03280550|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
9849351|NCT03280550|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
9849352|NCT03280615|Experimental|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
9849353|NCT03280615|Placebo Comparator|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
9849354|NCT03281200||Anatomical main group:|
9849355|NCT03281200||Therapeutic subgroup|
9849356|NCT03281200||Pharmacological subgroup|
9849357|NCT03281200||Chemical subgroup|
9849358|NCT03281200||Chemical substance|
9849359|NCT03281304|Experimental|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
9849360|NCT03281304|Experimental|CP-690,550 10 mg|CP-690,550 10 mg BID
9849361|NCT03281538|Experimental|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
9849362|NCT03281577|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
9849363|NCT03281577|Experimental|TAK-954 0.1 mg|TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
9849364|NCT03281577|Experimental|TAK-954 0.3 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
9849365|NCT03281577|Experimental|TAK-954 1 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
9849366|NCT03281668|Experimental|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
9849367|NCT03281876|Experimental|GSK3277511A Group|Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.
9849368|NCT03281876|Placebo Comparator|CONTROL Group|Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.
9849369|NCT03282071|Experimental|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
9849370|NCT03282071|No Intervention|Control|No intervention will be provided to control groups during study period.
9849371|NCT03282227|Experimental|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
9849372|NCT03282357|Experimental|Radiesse|Subjects are randomized as to which of the two nasolabial folds is treated with Radiesse.
9849373|NCT03282357|Active Comparator|Restylane|Subjects are randomized as to which of the two nasolabial folds is treated with Restylane.
9849374|NCT03282591|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
9849375|NCT03282591|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
9849376|NCT03282682|Experimental|hypogonadal males without TRT|Strength training
9849377|NCT03282682|Experimental|hypogonadal males with TRT|Strength training and regular prescribed testosterone therapy given by participant urologist.
9849378|NCT03282682|Active Comparator|healthy eugonadal males|Strength training
9849379|NCT03283098|Placebo Comparator|Placebo|Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
9849380|NCT03283098|Experimental|Etelcalcetide|5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
9849381|NCT03283319|Experimental|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
9849382|NCT03283319|Experimental|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
9849383|NCT03283319|Experimental|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
9849384|NCT03283319|Experimental|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
9849385|NCT03283319|Experimental|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
9849386|NCT03283319|Experimental|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
9923056|NCT00846352|Active Comparator|Late bronch|This group will receive bronchoscopy within 5 days of enrollment.
9998302|NCT01516866||Cohort A: Microtubule directed chemotherapy treatment|Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
9849387|NCT03283436|Experimental|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
9849388|NCT03283436|No Intervention|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
9849389|NCT03283553|Experimental|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
9849390|NCT03283553|Placebo Comparator|Usual Care|Care as usual with the medical oncologist.
9849391|NCT03283696|Experimental|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab 15 milligrams per kilogram (mg/kg) on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin and ifosfamide was administered. When the safety of the 15-mg/kg dose of olaratumab was established, a 20-mg/kg loading dose cycle of olaratumab on Days 1 and 8 of a 21-day cycle in Cycle 1 only, followed by 15 mg/kg on Days 1 and 8 of subsequent cycles in combination with doxorubicin and ifosfamide plus mesna, was administered.
9849392|NCT03283787|Active Comparator|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
9849393|NCT03283787|Active Comparator|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
9849394|NCT03283787|Active Comparator|Group 3|Negative Pressure Wound Therapy
9849395|NCT03284229|Experimental|Excimer Laser Coronary Atherectomy|ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.
9849396|NCT03284359|Experimental|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
9849397|NCT03284359|No Intervention|Standard Consent|Arm 2 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
9849398|NCT03284398||Parenteral nutrition bag type|Groups with different parenteral nutrition bags (3CBs or HCBs)
9849399|NCT03284411|Experimental|Spinal Cord Stimulation|Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude
9849400|NCT03284424|Experimental|R/M cSCC cohort|Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
9849401|NCT03284424|Experimental|LA cSCC cohort|Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
9849402|NCT03284710|Active Comparator|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
9849403|NCT03284710|Active Comparator|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
9849404|NCT03284710|Active Comparator|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
9849405|NCT03284710|Active Comparator|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
9849406|NCT03285061|No Intervention|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
9849407|NCT03285061|Experimental|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
9849408|NCT03285113|Experimental|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
9849409|NCT03285295|Experimental|Screening|All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
9849410|NCT03285308|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
9849411|NCT03285308|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 μg injected subcutaneously twice daily for up to 12 weeks.
9849412|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
9849413|NCT03285477|Placebo Comparator|Placebo|Vehicle Ointment was applied topically once daily for 5 consecutive days on face or scalp
9849414|NCT03285477|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment 1% was applied topically once daily for 5 consecutive days on face or scalp
9849415|NCT03285490|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment was applied once daily for 5 consecutive days on the face or scalp.
9849416|NCT03285490|Placebo Comparator|Placebo|The Vehicle Ointment was applied once daily for 5 consecutive days on the face or scalp.
9849417|NCT03285529|Active Comparator|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
9849418|NCT03285529|Placebo Comparator|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
9849419|NCT03285542|Active Comparator|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
9849420|NCT03285542|Placebo Comparator|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
9849421|NCT03285555|Active Comparator|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
9849422|NCT03285555|Placebo Comparator|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
9849423|NCT03285594|Placebo Comparator|Placebo|Following a 4-week run-in period, participants were randomized to matching placebo to sotagliflozin 200 milligrams (mg) administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
9849424|NCT03285594|Experimental|Sotagliflozin 200 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
9998303|NCT01516866||Cohort B: AR-directed therapy|Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks. A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
9849425|NCT03285594|Experimental|Sotagliflozin 400 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
9849426|NCT03285646|Experimental|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
9849427|NCT03285646|Experimental|Placebo|SC every 4 weeks
9849428|NCT03285711|Experimental|Lanraplenib 30 mg|"Participants receive lanraplenib 30 mg tablet + filgotinib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
9849429|NCT03285711|Experimental|Filgotinib 200 mg|"Participants receive filgotinib 200 mg tablet + lanraplenib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
9849430|NCT03285711|Experimental|Lanraplenib 30 mg to Filgotinib 200 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive filgotinib 200 mg + lanraplenib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
9849431|NCT03285711|Experimental|Filgotinib 200 mg to Lanraplenib 30 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive lanraplenib 30 mg + filgotinib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
9849432|NCT03285724|Experimental|Harpoon Medical Transapical device TSD-5|This is a prospective, single arm, nonrandomized, early feasibility study to evaluate the safety and performance of the Harpoon Medical Device.
9849433|NCT03285958|Experimental|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
9849434|NCT03285958|No Intervention|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
9849435|NCT03285984|Experimental|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
9849436|NCT03285984|Experimental|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
9849437|NCT03285984|Experimental|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
9849438|NCT03285984|Experimental|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
9849439|NCT03286218|Placebo Comparator|Placebo|Placebo was administered orally in one of five treatment periods
9849440|NCT03286218|Active Comparator|Alprazolam 2 milligram (mg)|2 mg of alprazolam was administered orally in one of five treatment periods
9849441|NCT03286218|Experimental|Lasmiditan 100 mg|100 mg of lasmiditan was administered orally in one of five treatment periods
9849442|NCT03286218|Experimental|Lasmiditan 200 mg|200 mg of lasmiditan was administered orally in one of five treatment periods
9849443|NCT03286218|Experimental|Lasmiditan 400 mg|400 mg of lasmiditan was administered orally in one of five treatment periods
9849444|NCT03286283|Experimental|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
9849445|NCT03286400||CTAG Device with ACTIVE CONTROL|All consecutive patients meeting protocol selection criteria, consented, with an intention to be treated with CTAG Device with ACTIVE CONTROL.
9998304|NCT01516905||I124-NM404 brain metastases or GBM imaging|determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
9849446|NCT03286465|Experimental|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
9849447|NCT03286465|Active Comparator|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
9849448|NCT03286543|Experimental|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
9849449|NCT03286543|No Intervention|Control Group|Subjects in the control group will receive the standard of care.
9849450|NCT03286751|Experimental|LY900014|Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
9849451|NCT03286751|Active Comparator|Insulin Lispro (Humalog)|Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
9849452|NCT03286829|Experimental|"Tesomet High dose in fasted condition"|"A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (High dose)"
9849453|NCT03286829|Experimental|"Tesomet Low dose in fasted condition"|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
9849454|NCT03286829|Active Comparator|Comperator|1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
9849455|NCT03286829|Experimental|"Tesomet High dose in fed condition"|"A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
9849456|NCT03287219|Active Comparator|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
9849457|NCT03287219|Active Comparator|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
9849458|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
9849459|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
9849460|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
9849461|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
9849462|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
9849463|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
9849464|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
9849465|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
9849466|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
9849467|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
9849468|NCT03287622|Experimental|Education Intervention + Nudge|This group will receive BOTH the scenario-tailored STOMP educational feedback AND the behavioral Nudge intervention
9849469|NCT03287622|Experimental|Standard of Care + Nudge|This group will receive routine, standard of care information AND the behavioral Nudge intervention
9849470|NCT03287622|Experimental|Educational Intervention no Nudge|This group will receive scenario-tailored opioid message (STOMP) feedback and NO behavioral nudge intervention.
9849471|NCT03287622|No Intervention|Standard of Care no Nudge|This group will receive only standard of care information and NO behavioral nudge intervention.
9849472|NCT03287635|Experimental|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
9849473|NCT03287674|Experimental|Patient group|"All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks.~The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13.~Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days."
9849474|NCT03287791|Experimental|Generic Azelaic Acid Foam|A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
9849475|NCT03287791|Active Comparator|Finacea® (Azelaic Acid) Foam|A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
9849476|NCT03287791|Placebo Comparator|Vehicle Foam|A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
9849477|NCT03287804|Experimental|AUTO2|Relapsed or refractory Myeloma patients
9849478|NCT03287869|Experimental|Brexpiprazole|Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
9849479|NCT03288714|Experimental|Active sTMS|Synchronized Transcranial Magnetic Stimulation (sTMS) treatments to be administered using an active device 5 times per week for six treatment weeks.
9849480|NCT03288714|Sham Comparator|Sham Stimulation|Sham treatments to be administered using a sham device 5 times per week for six treatment weeks.
9849481|NCT03288779|Other|Theta Burst Stimulation Arm|This is a pilot open label study.
9849482|NCT03288987|Experimental|Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
9849483|NCT03288987|Active Comparator|Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.
9849484|NCT03289052|Experimental|Restylane Volyme|Single injection and optional touch up injection with Restylane Volyme in Midface
9849485|NCT03289052|No Intervention|No intervention arm|No treatment
9849486|NCT03289208|Experimental|mild renal impairment|
9849487|NCT03289208|Experimental|moderated renal impairment|
9849488|NCT03289208|Experimental|normal renal function|
9849489|NCT03289234|Experimental|mild hepatic impairment|
9849490|NCT03289234|Experimental|moderate hepatic impairment|
9849491|NCT03289234|Experimental|normal hepatic function|
9849492|NCT03289455|Experimental|AUTO3|Paediatric patients with relapse or refractory B-cell ALL
9849493|NCT03289481|Active Comparator|Active lozenge first|Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
10207674|NCT05083884||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
10207675|NCT05083884||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
10207676|NCT05082688|Experimental|1: Young adults herpes zoster vaccination|Young adults between 18 and 35 years old will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
10207677|NCT05082688|Experimental|2: Older adults herpes zoster vaccination|Adults older than 60 years of age will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
10207678|NCT05082688|Experimental|3: Young adults influenza vaccination|Young adults between 18 and 35 years old will receive the influenza vaccine (Fluarix Tetra).
10207679|NCT05082688|Experimental|4: Older adults influenza vaccination|Adults older than 60 years of age will receive the influenza vaccine (Fluarix Tetra).
10207680|NCT05082688|Placebo Comparator|5: Young adults herpes zoster vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl). 60 days later, they will receive another placebo.
10207681|NCT05082688|Placebo Comparator|6: Young adults influenza vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl).
10207682|NCT05081206|Experimental|Manually controlled|
10207683|NCT05081206|Experimental|Target controlled|
10207684|NCT05076734|Other|Analysis of blood samples from healthy pregnant women|A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.
10207685|NCT05070975||Twins|Twins identified from the birth cohort (Hospices Civils de Lyon) with at least one twin hospitalized for an acute RSV-infection
10207686|NCT05065983|Experimental|PXVX0317 (CHIKV VLP, alum-adjuvanted) vaccine|All study participants will receive the same Investigational Product (40 µg CHIKV VLP, alum-adjuvanted according to the same single dose schedule on Day 1).
10207687|NCT05063032|Experimental|High-density mapping guided ablation|High-density map and return-cycles map in order to localize the protected isthmus with precision for focal/minimal ablation.
9849494|NCT03289481|Active Comparator|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.
9849495|NCT03289533|Experimental|Experimental 1|Avelumab (MSB0010718C) in combination with axitinib (AG-013736)
9849496|NCT03289676|Experimental|Quitting Smoking Video|This arm will receive a storytelling narrative intervention by watching a video of women living with HIV taking about their success in quitting smoking.
9849497|NCT03289676|Active Comparator|HIV Infection Video|This arm will watch an attention-control storytelling narrative intervention by watching a video of women living with HIV taking about their life after the diagnosis of HIV.
9849498|NCT03289858|Experimental|Exparel (Liposomal Bupivacaine)|"Exparel (liposomal bupivacaine) is FDA approved, with a labeled indication of single-dose infiltration into the surgical site to produce postsurgical analgesia."
9849499|NCT03289858|Placebo Comparator|Saline Control|Saline Solution (Sodium Chloride)
9849500|NCT03290027|Experimental|Active|DFD-03 (0.1% tazarotene) Lotion
9849501|NCT03290027|Placebo Comparator|Vehicle|Vehicle (0% tazarotene) Lotion
9849502|NCT03290300||Long-Term Study Subjects|This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.
9849503|NCT03290378|Active Comparator|AVE-901 50 mg|
9849504|NCT03290378|Active Comparator|AVE-901 25 mg|
9849505|NCT03290378|Placebo Comparator|Placebo|
9849506|NCT03290768|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
9849507|NCT03291041|Experimental|tasimelteon|tasimelteon, administered as oral capsule(s)
9849508|NCT03291041|Placebo Comparator|Placebo|Placebo, administered as oral capsule(s)
9849509|NCT03291080|Experimental|Liquid|Oral liquid formulation of 13-Cis Retinoic Acid - test product.
9849510|NCT03291080|Experimental|Capsule|Isotretinoin capsules (13-CRA extracted per standard of care)- reference product.
9923057|NCT00846378|Experimental|Post conditioning|After 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. The balloon should be inflated to only occlude the coronary artery. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
9923058|NCT00846378|Active Comparator|Usual Care|Usual care for treatment of thrombolysis in myocardial infarction (TIMI) 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
9923059|NCT00846404||Case|Patients with Diastolic Dysfunction
9923060|NCT00846404||Control|Patients without Diastolic Dysfunction
9923061|NCT00846417||Case|Patients with ICDs who attend the ICD Support Groups.
9923062|NCT00846417||Control|Patients with ICDs who do not attend the ICD support groups.
9923063|NCT00846430|Experimental|Open-Label Intervention|This is a phase II single arm study with sequential treatments available by response where all participants begin therapy with a combination of celecoxib and interferon alpha-2b (CI, treatment-1). Response to CI therapy will be assessed at six months by clinical and radiographic evaluations. Those patients who have achieved a partial response (improvement in pain, improvement in functioning, or ≥50% reduction in tumor size) or complete response (resolution of pain, and normalization of functioning with a ≥ 90% reduction in tumor size) will continue with the same CI therapy for up-to two years on study.
9923064|NCT00846443|Experimental|1|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
9923065|NCT00846443|Experimental|2|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
9923066|NCT00846443|Experimental|3|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
9923067|NCT00846443|Experimental|4|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
9923068|NCT00846469|Experimental|chest pain|CCTA (Coronary computed tomography angiography)
9923069|NCT00846508|Experimental|ciaplantin,cancer,survival|
9923070|NCT00846534||Post operative atrial fibrillation|To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.
9923071|NCT00846560||1 ALS patients|
9923072|NCT00846560||2 Healthy subjects|
9923073|NCT00846599||1|High omega-3
9923074|NCT00846599||2|High saturated fat
9923075|NCT00846612|Experimental|Avastin-Doxil|
9923076|NCT00846625|Experimental|1|Ranibizumab (0.5 mg)
9923077|NCT00846625|Active Comparator|2|Triamcinolone (4 mg/0.1 ml)
9923078|NCT00846638|Experimental|1|Diagnostic assessment with brief intervention and 3, 6, and 12 month follow-up
9923079|NCT00846638|Active Comparator|2|Diagnostic assessment with 12 month follow-up
9923080|NCT00846664|Experimental|Group 1|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
9923081|NCT00846677|Experimental|1|Vitamin D quick dissolve strip
9923082|NCT00846677|Active Comparator|2|Vitamin D syrup
9923083|NCT00846690|Active Comparator|Benzocaine|"serves as active control"
9923084|NCT00846690|Experimental|TAC|serves as comparator
9923085|NCT00846703|Active Comparator|Protocol A (MM)|
9923086|NCT00846703|Experimental|Protocol B (MM/VD)|
9849511|NCT03291197|Experimental|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
9849512|NCT03291288|Experimental|Pexidartinib|"Part 1 (Drug-drug Interaction Phase):~On Day 1, all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg). On Day 3, pexidartinib (800 mg/d) in twice daily (400 mg BID) dosing will be initiated and continue throughout the remainder of Part 1 and into Part 2. On the first day of pexidartinib treatment (Day 3), a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning pexidartinib dose (400 mg). On Day 13, a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning dose of pexidartinib (400 mg).~Part 2 (Efficacy and Safety Phase):~All participants will continue to receive pexidartinib 400 mg BID."
9849513|NCT03291379|Experimental|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
9849514|NCT03291613|Experimental|Pinpoint App|Tablet application.
9849515|NCT03292016|Experimental|APL-130277, sublingual thin film|APL-130277, sublingual thin film, once daily
9849516|NCT03292016|Active Comparator|Subcutaneous APO-go|Subcutaneous APO-go, once daily
9849517|NCT03292016|Active Comparator|Subcutaneous APOKYN|Subcutaneous APOKYN, once daily
9849518|NCT03292406|Experimental|CD11301 Gel 0.06%|Participants applied 0.06% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
9849519|NCT03292406|Experimental|CD11301 Gel 0.03%|Participants applied 0.03% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
9849520|NCT03292406|Experimental|Placebo|Participants applied placebo gel during cycle one followed by 0.03% CD11301 gel topically during cycle two once daily, 3 to 5 times per week, for 24 weeks.
9849521|NCT03292432|Active Comparator|Standard of Care (SOC)|Standard of Care for adherence support at Site
9849522|NCT03292432|Experimental|TERA Intervention (TERA)|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
9849523|NCT03292562|Active Comparator|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
9849524|NCT03292562|Active Comparator|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
9849525|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
9849526|NCT03292640|Experimental|DFD-03 Lotion (0.1% tazarotene)|DFD-03 Lotion (0.1% tazarotene)
9849527|NCT03292640|Placebo Comparator|DFD-03 Vehicle (0% tazarotene)|DFD-03 Vehicle Lotion (0% tazarotene)
9849528|NCT03292653|Placebo Comparator|Placebo|Participants were randomized to matching placebo to sotagliflozin administered as two tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
9849529|NCT03292653|Experimental|Sotagliflozin 200 mg|Participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
9849530|NCT03292653|Experimental|Sotagliflozin 400 mg|Participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
9849531|NCT03292692|Experimental|OurRelationship|Online Intervention
9849532|NCT03292692|No Intervention|Waitlist Control|2 month waiting period before couples can receive intervention
9849533|NCT03292809|Experimental|CyclASol Ophthalmic Solution|Cylclosporine A solution in vehicle
9849534|NCT03292809|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle only
9849535|NCT03292952|Experimental|Double-blind KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
9849536|NCT03292952|Placebo Comparator|Double-blind Placebo|Placebo oral capsule
9849537|NCT03292952|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
9849538|NCT03293238|Active Comparator|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
9849539|NCT03293238|Sham Comparator|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
9849540|NCT03293238|Active Comparator|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
9849541|NCT03293238|Sham Comparator|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch without ultrasound guidance.
9849542|NCT03293394|Experimental|Real tDCS|10 days anodal bilateral motor cortex and cathodal spinal tDCS
9849543|NCT03293394|Placebo Comparator|Sham tDCS|10 days sham bilateral motor cortex and sham spinal tDCS
9849544|NCT03293485|Experimental|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
9849545|NCT03293654|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
9849546|NCT03293654|Active Comparator|US licenced Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
9849547|NCT03293654|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
9849548|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
9849549|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
9849550|NCT03294538|Experimental|Generic Estradiol Vaginal Cream USP, 0.01%|Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
9849551|NCT03294538|Active Comparator|Estrace Vaginal Cream USP, 0.01%|Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
9849552|NCT03294538|Placebo Comparator|Vehicle Vaginal Cream|Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
9849553|NCT03294629|No Intervention|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
9849554|NCT03294629|Experimental|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
9849555|NCT03294681||Cochlear Implant Recipients|
9849556|NCT03294850|Experimental|NASH group|These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.
9849557|NCT03294850|Active Comparator|Non-NASH (NAFLD or normal) group|These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.
9849558|NCT03294941|Other|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
9849559|NCT03295201|Experimental|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
9849560|NCT03295201|Active Comparator|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
9849561|NCT03295266|Experimental|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI (estimated glomerular filtration rate [eGFR] of ≤60mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
9849562|NCT03295266|Experimental|Severe Hepatic Impairment (Panel B)|Participants with severe HI (eGFR of ≤50 mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
9849563|NCT03295266|Experimental|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
9849564|NCT03295318|Experimental|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
9849565|NCT03295318|Experimental|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
9849566|NCT03295318|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
9849567|NCT03295630|Other|Actigraph GT3X accelerometer|Ward based patients recovering from critical illness will wear two accelerometers placed on the thigh and ankle of the non-dominant leg
9849568|NCT03295721|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
9849569|NCT03295721|Placebo Comparator|Treatment Group 2: Saline Placebo|Saline placebo
9849570|NCT03295721|Active Comparator|Treatment Group 3: Bupivacaine HCI|Bupivacaine HCl
9923087|NCT00846716|Experimental|Pioglitazone add on to SU or biguanide|
9849571|NCT03296072|Experimental|Test product|Participants will apply a full ribbon of the test product (1.5 grams [g]) containing 0.254% w/w sodium fluoride and 5% KNO3.
9849572|NCT03296072|Active Comparator|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
9849573|NCT03296072|Placebo Comparator|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
9849574|NCT03296163|Experimental|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
9849575|NCT03296163|Active Comparator|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
9849576|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
9849577|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
9849578|NCT03296345|Active Comparator|Intervention|"Prior to the second dose of IV opiates, the experiment was to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores were collected using the FACES scale currently in place. In consenting patients, chart review was performed with the following data collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, and whether or not the patient was discharged.~In addition, a survey, which is attached, was given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
9849579|NCT03296345|No Intervention|Historical Control|"Patient data from at least one but up three patient encounters within the prior year were compared to their visit in which they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients acted as their own controls in the above manner. Patients were allowed to re-enroll 4 weeks after presentation, which is typically considered a separate vaso-occlusive episode in the literature."
9849580|NCT03296527|Experimental|Follitropin delta|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
9849581|NCT03296527|Active Comparator|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
9849582|NCT03296566|Experimental|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
9849583|NCT03296566|No Intervention|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
9849584|NCT03296787|Experimental|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
9849585|NCT03296787|Experimental|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
9849586|NCT03296787|Experimental|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
9849587|NCT03296787|Experimental|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
9849588|NCT03296787|Experimental|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
9923088|NCT00846716|Active Comparator|SU or Biguanide|
9849589|NCT03296800|Experimental|Bexagliflozin/probenecid|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.
9849590|NCT03296800|Experimental|Bexagliflozin/rifampin|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.
9849591|NCT03296800|Experimental|Bexagliflozin/verapamil|Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.
9849592|NCT03297021|Placebo Comparator|Ondansetron 4mg Pre-emergence|
9849593|NCT03297021|Experimental|Ondansetron 8mg Pre-emergence|
9849594|NCT03297021|Experimental|Ondansetron Pre-Incision and Pre-emergence|4mg Ondansetron Pre-Incision and 4mg Ondansetron Pre-emergence
9849595|NCT03297112|Experimental|contrast-enhanced subharmonic ultrasound imaging|Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
9849596|NCT03297216|Active Comparator|250 mg 17P|weekly intramuscular injection of 250mg 17P
9849597|NCT03297216|Placebo Comparator|Placebo|weekly intramuscular injection of indistinguishable placebo
9849598|NCT03297294|Experimental|EMA401|During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
9849599|NCT03297294|Placebo Comparator|Placebo|Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
9849600|NCT03297398|Placebo Comparator|Other|Placebo Group
9849601|NCT03297398|Experimental|Drug Group 1|15mg, OPK-88004
9849602|NCT03297398|Experimental|Drug Group 2|25,mg OPK-88004
9849603|NCT03297944|Experimental|All Participants|All participants received each intervention with alprazolam, zolpidem and placebo.
9849604|NCT03298035|Active Comparator|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
9849605|NCT03298035|Experimental|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
9849606|NCT03298048|Active Comparator|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
9849607|NCT03298048|Active Comparator|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
9849608|NCT03298048|Active Comparator|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
9849609|NCT03298113|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
9849610|NCT03298113|Other|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
9849611|NCT03298412|Experimental|Blinatumomab|"After a run-in period of up to 24 months to evaluate MRD status and assess eligibility for treatment assignment, participants received blinatumomab intravenous (IV) infusion at an initial dose of 9 μg/day for the first 7 days of treatment, escalated (dose-step) to 28 μg/day starting on Day 8 (Week 2), followed by a dose-step to 112 μg/day starting on Day 15 (Week 3) and continuing until completion of therapy (Day 57 of Cycle 1).~Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval."
9849612|NCT03298880|Other|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
9849613|NCT03299101|Experimental|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
9986354|NCT01402024|Placebo Comparator|Control|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
9849614|NCT03299244|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
9849615|NCT03299244|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
9849616|NCT03299686|Experimental|CJM112|Study treatment
9849617|NCT03299686|Placebo Comparator|Placebo to CJM112|Placebo
9849618|NCT03299881|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
9849619|NCT03299881|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
9849620|NCT03300050|Experimental|Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
9849621|NCT03300050|Experimental|Group 2: cH8/1N1 LAIV and cH5/1N1 IIV|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.
9849622|NCT03300050|Placebo Comparator|Group 3: Placebo|Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.
9849623|NCT03300050|Experimental|Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
9849624|NCT03300050|Placebo Comparator|Group 5: Placebo|Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.
9849625|NCT03300466|Experimental|GP0045|Treatment with GP0045
9849626|NCT03300466|Active Comparator|Comparator|Treatment with active comparator
9849627|NCT03300570|Experimental|Arm A (dolcanatide)|Participants receive dolcanatide PO QD for 7 days.
9849628|NCT03300570|Placebo Comparator|Arm B (placebo)|Participants receive placebo PO QD for 7 days.
9849629|NCT03300674|Active Comparator|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
9849630|NCT03300674|Active Comparator|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
9849631|NCT03300752|Experimental|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
9849632|NCT03300752|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
10207688|NCT05063032|Active Comparator|Empirical linear ablation|Empirical predefined set of linear ablation.
10207689|NCT05059314|Experimental|Interventional group|"Warm up and cool down~Brisk walk (30 mintues each session per week 5 days)~Week 1 to 6"
10207690|NCT05059314|No Intervention|Control group|Routine activity
10207691|NCT05049382|Experimental|Mesioangular|Classified as mesioangular according to winter classification
10207692|NCT05049382|Experimental|Vertical|Classified as vertical according to winter classification
10207693|NCT05049382|Experimental|Distoangular|Classified as distoangular according to winter classification
10207694|NCT05049382|Experimental|Horizontal|Classified as horizontal according to winter classification
10207695|NCT05047939|Experimental|remimazolam group|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil 0.2mg, is administered at the end of surgery. In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
10207696|NCT05047939|Active Comparator|propofol group|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
10207697|NCT05047731|Experimental|Deprescribing group|The facility pharmacist will actively deprescribe antihypertensive medication of residents in this group.
10207698|NCT05047731|No Intervention|Usual care group|The facility pharmacist and the attending physician will provide usual care to residents in this group, and this includes quarterly medication reviews.
10207699|NCT05044884|Experimental|Otago exercise group|"The Otago exercise group will practice the Otago exercise protocol which includes strength and balance exercises along with pulmonary rehabilitation.~3 times per week for 8 weeks.~Each session will be of 60 minutes~Total number of sessions: 24"
10207700|NCT05044884|Active Comparator|Circuit training group|"The Circuit training group will practice balance exercises including Stance exercise, Functional strength exercise, Transition exercise and Gait training along with pulmonary rehabilitation.~3 times per week for 8 weeks.~Each session will be of 60 minutes~Total number of sessions: 24"
10207701|NCT05042687|Experimental|Tc99m sestamibi|MBI uses an injection of a small amount of radioactive material called technetium99m (Tc99m) sestamibi
9849633|NCT03300843|Experimental|Peptide loaded dendritic cell vaccine|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
9849634|NCT03301155|Experimental|Anaferon for children|"Tablet for oral use. One tablet per intake, once daily (approximately at the same time).~The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature."
9849635|NCT03301155|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Anaferon for children scheme.
9849636|NCT03301272|Experimental|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
9849637|NCT03301272|Experimental|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
9849638|NCT03301298|Experimental|SXC-2023, 50 mg|Single dose of 50 mg, given orally in capsule form.
9849639|NCT03301298|Experimental|SXC-2023, 100 mg|Single dose of 100 mg, given orally in capsule form.
9849640|NCT03301298|Experimental|SXC-2023, 200 mg|Single dose of 200mg, given orally in capsule form.
9849641|NCT03301298|Experimental|SXC-2023, 400 mg|Single dose of 400mg, given orally in capsule form.
9849642|NCT03301298|Experimental|SXC-2023, 800 mg|Single dose of 800mg, given orally in capsule form.
9849643|NCT03301298|Experimental|SXC-2023, 1600 mg|Single dose of 1600 mg, given orally in capsule form.
9849644|NCT03301298|Placebo Comparator|Placebo oral capsule|Placebo comparator, given once orally in matching capsule form.
9849645|NCT03301623|Experimental|Clinical Decision Support|Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
9849646|NCT03301623|Experimental|Patient Education and Activation Tools|Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. They will receive these materials every time they have an office visit with their PCP.
9849647|NCT03301649|Experimental|Generic Ivermectin Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
9849648|NCT03301649|Active Comparator|Sklice (Ivermectin) Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
9849649|NCT03301649|Placebo Comparator|Vehicle Lotion|Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
9849650|NCT03301714|No Intervention|Control: Standard of Care|Regular dental care under the standard clinic operation
9849651|NCT03301714|Experimental|Intervention 1: Group-based oral health education|Group based oral health education
9849652|NCT03301714|Experimental|Intervention 2: Individual-based oral health education|Individual-based motivational interviewing
9849653|NCT03301740|Experimental|UF Profiling Phase First|"First treatment phase begins with linear UF profiling during HD.~Participants randomized to starting with the experimental UF profiling phase will receive 9 HD treatments with UF profiling (1st experimental phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 conventional HD treatments (1st control phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase)."
9849654|NCT03301740|Experimental|Conventional HD Phase First|"First treatment phase begins with conventional HD.~Participants randomized to starting with the control conventional HD phase will receive 9 conventional HD treatments (1st control phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 HD treatments with UF profiling (1st experimental phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase)."
9849655|NCT03301779|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
9849656|NCT03301779|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
9849657|NCT03301831|Experimental|Resourcefulness Training Intervention|The intervention arm will receive an intervention that includes: a face-to-face session for teaching social (help-seeking) and personal (self-help) resourcefulness skills; ongoing access to video vignettes of caregivers of technology-dependent children describing resourcefulness skill application in daily life; 4 weeks of skills' reinforcement using daily journal writing; weekly phone calls for the first 4 weeks; and booster sessions at 2 and 4 months post enrollment.
9849658|NCT03301831|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post enrollment plus any usual care.
9849659|NCT03301844|Experimental|Study treatment|Blephapad Combo twice daily for one month. Blephapad is a disposable wet wipe containing Hy-Ter® solution (sodium hyaluronate acid and 4-terpineol), aloe, natural anti-inflammatories and antiseptics.
9849660|NCT03301844|Other|Standard treatment|Wet, warm gauze twice daily for one month.
9849661|NCT03302091|Experimental|BI 1467335 Normal (R)|Participants with normal renal function.
9849662|NCT03302091|Experimental|BI 1467335 Moderate (T)|Participants with moderate renal impairment.
9849663|NCT03302416|Experimental|[C-11]NOP-1A PET Scan conditions|Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition
9849664|NCT03302559|Experimental|Retinol Complex 0.5|During a 2-week washout period the participant used a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin were made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.
9849665|NCT03302741|Active Comparator|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
9849666|NCT03302741|Experimental|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
9849667|NCT03302767|Experimental|Psychological and Social Consultation|Psychological and Social Consultation
9849668|NCT03302780|Experimental|Sham tDCS and BreEStim|This arm includes a 20-min sham tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
9849669|NCT03302780|Experimental|active tDCS (M1) and BreEStim|This arm includes a 20-min active tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
9849670|NCT03302793|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
9849671|NCT03302793|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
9849672|NCT03302936|Experimental|Pyridium arm|Phenazopyridine 200mg tablet, once prior to surgery
9849673|NCT03302936|No Intervention|Control arm|No intervention in this group. Routine perioperative care.
9849674|NCT03302975|Experimental|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
9849675|NCT03303079|Experimental|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
9849676|NCT03303079|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/ placebo/placebo).
9849677|NCT03303079|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
9849678|NCT03303092|Experimental|TEV-48125 (225/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
9849679|NCT03303092|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
9849680|NCT03303092|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
9849681|NCT03303105|Experimental|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly [except for a loading dose of 675 mg in subjects with CM]).
9849682|NCT03303105|Experimental|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
9849683|NCT03303144|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
9849684|NCT03303144|Experimental|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
9849685|NCT03303144|Experimental|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
9849686|NCT03303196|Experimental|Bihormonal bionic pancreas admission|Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.
9849687|NCT03303196|No Intervention|Standard care admission|Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.
9849688|NCT03303404|Experimental|Ambulatory (24-hour) Blood Pressure|
9849689|NCT03303417|Experimental|Kiwifruit|Participants asked to consume 2 kiwifruit twice a day for 3 days before undergoing MRI Scan
9849690|NCT03303417|Placebo Comparator|Control|Participants asked to consume a calorie-matched sugar drink twice a day for 3 days before undergoing MRI Scan
9849691|NCT03303521|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
9849692|NCT03303521|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
9849693|NCT03303794|Active Comparator|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
9849694|NCT03303794|Experimental|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
9849695|NCT03303911|Experimental|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
9849696|NCT03303911|Experimental|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
9849697|NCT03303950|Experimental|Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)|Participants receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo HSCT on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
9849698|NCT03304054|Experimental|amifamapridine phosphate tablets|
9849699|NCT03304054|Placebo Comparator|placebo tablets|
9849700|NCT03304106|Experimental|Newly Implanted CI Recipients|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
9849701|NCT03304106|Experimental|Existing CI recipients|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
9849702|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
9849703|NCT03304119||Control group control|Group that has not been checked for patellar instability.
9849704|NCT03304184|Placebo Comparator|Photac-fil|Participants will have a restoration placed with photac-fil in the lesion near the gum line.
9849705|NCT03304184|Experimental|Biodentine|Participants will have a restoration placed with Biodentine in the lesion near the gum line.
9849706|NCT03304522|Experimental|VX-150|
9849707|NCT03304522|Placebo Comparator|Placebo|
9849708|NCT03304626|Experimental|Study Group|"Budesonide EC 3 mg capsule. The dose will be as follows~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1"
9849709|NCT03304626|Active Comparator|Control Group|"Standard of Care~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Prednisone 15-60 mg Days 31-45 SIS + Prednisone 10 mg Days 46-90 SIS + Prednisone 2.5 to 7.5 mg Days 90 onwards SIS"
9849710|NCT03304873|Experimental|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
9849711|NCT03304873|Placebo Comparator|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
9849712|NCT03305081|Experimental|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
9849713|NCT03305081|Active Comparator|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
9849714|NCT03305159|Active Comparator|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
9849715|NCT03305159|Experimental|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
9849716|NCT03305419|Experimental|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
9849717|NCT03305419|Experimental|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
9849718|NCT03305419|Experimental|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
9849719|NCT03305419|Experimental|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
9849720|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
9849721|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
9849722|NCT03305419|Experimental|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
9849723|NCT03305419|Experimental|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
9849724|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
9849725|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
9849726|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
9849727|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
9923089|NCT00846755|Active Comparator|Levothyroxine, Propylthiouracil|Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
9923090|NCT00846755|No Intervention|clinical checks|Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated
9923091|NCT00846794||1 Asymptomatic|students with conditions being studied
9923092|NCT00846794||2 Symptomatic|students without conditions being studied
9923093|NCT00846833|Experimental|Cyclophosphamide, high-dose interleukin-2, NK cell|
9923094|NCT00846859|Experimental|varenicline|
9923095|NCT00846859|Placebo Comparator|placebo|
9923096|NCT00846872|Active Comparator|Low dose GHRP-3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
9923097|NCT00846872|Active Comparator|High dose GHRP -3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
9923098|NCT00846872|Placebo Comparator|Saline Infusion|Subjects will receive Placebo for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
9923099|NCT00846898|Experimental|cinnamon|Subjects in this group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
9923100|NCT00846898|Placebo Comparator|Control|Subjects in this group will receive placebo capsules (starch flour) for 12 weeks period. The 2 g dose of starch capsules will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
9923101|NCT00846911||Group 1|
9923102|NCT00846924|Active Comparator|repeat 24-hour Holter monitor|
9923103|NCT00846924|Experimental|30-day ambulatory cardiac event monitor|
9923104|NCT00846950|Experimental|healthy volunteers|
9923105|NCT00846963|Experimental|Ursodiol|Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.
9923106|NCT00846963|Placebo Comparator|placebo|A placebo suspension that looks like the ursodiol suspension used.
9923107|NCT00846976|Experimental|200 mg Casodex|
9923108|NCT00847028|Experimental|1|glucose 10%
9923109|NCT00847028|Experimental|2|glucose 20%
9923110|NCT00847028|Experimental|3|glucose 30%
9923111|NCT00847028|Placebo Comparator|4|placebo: sterile water
9923112|NCT00847054|Experimental|MORAb-004|
9923113|NCT00847067|Active Comparator|Block|
9849728|NCT03305575|Experimental|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
9849729|NCT03305575|Active Comparator|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
9849730|NCT03305653|Experimental|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
9849731|NCT03305666|Active Comparator|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
9849732|NCT03305666|Active Comparator|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).
9849733|NCT03305731|Experimental|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
9849734|NCT03305770|Experimental|DD T2|Verofilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
9849735|NCT03305770|Active Comparator|DT 1|Delefilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
9849736|NCT03305809|Placebo Comparator|Placebo|Participants received placebo administered orally once a day (QD).
9849737|NCT03305809|Experimental|10 milligram (mg) LY3154207|Participants received 10 mg LY3154207 administered orally QD.
9849738|NCT03305809|Experimental|30 mg LY3154207|Participants received 30 mg LY3154207 administered orally QD.
9849739|NCT03305809|Experimental|75 mg LY3154207|Participants received 75 mg LY3154207 administered orally QD.
9849740|NCT03305822|Experimental|LY900014|Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
9849741|NCT03305822|Active Comparator|Insulin Lispro (Humalog)|Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods
9849742|NCT03305887|Experimental|Barbed suture group|"The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric Knotless Tissue suture respectively. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation."
9849743|NCT03305887|Active Comparator|Conventional suture group|VICRYL® Plus sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
9849744|NCT03306043|Experimental|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
9849745|NCT03306277|Experimental|Onasemnogene Abeparvovec-xioi|One-time Intravenous administration of onasemnogene abeparvovec-xioi at the therapeutic dose.
9849746|NCT03306420|Experimental|Part IA Dose Escalation: M4112 100 mg|Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
9923114|NCT00847067|Sham Comparator|Sham injection|Skin injections with Normal Saline
9923115|NCT00847080|Experimental|Sitagliptin|
9923116|NCT00847080|Placebo Comparator|Placebo|
9849747|NCT03306420|Experimental|Part IA Dose Escalation: M4112 200 mg|Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
9849748|NCT03306420|Experimental|Part IA Dose Escalation: M4112 400 mg|Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
9849749|NCT03306420|Experimental|Part IA Dose Escalation: M4112 600 mg|Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
9849750|NCT03306420|Experimental|Part IA Dose Escalation: M4112 800 mg|Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
9849751|NCT03306433|Experimental|UDMA-K18|UDMA-K18 smooth surface sealant
9849752|NCT03306433|Placebo Comparator|UDMA-control|UDMA smooth surface sealant without K18
9849753|NCT03306433|No Intervention|Negative control|No intervention to provide baseline
9849754|NCT03306589|Experimental|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
9849755|NCT03306589|Experimental|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
9849756|NCT03306641|Active Comparator|Test Contact Lens|Per randomized schedule, subject will wear a pair of the test lens or control lens for one week and then cross-over with the control pair for 1 week.
9849757|NCT03306641|Active Comparator|nelfilcon A lens (control)|Per randomized schedule, subject will wear a pair of the control lens for one week and then cross-over with the test pair for 1 week.
9849758|NCT03307005|Experimental|Intervention|
9849759|NCT03307005|Placebo Comparator|Control|
9849760|NCT03307174|Active Comparator|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
9849761|NCT03307174|Experimental|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
9849762|NCT03307252|Experimental|Treatment Reference 1|
9849763|NCT03307252|Experimental|Treatment Reference 2|
9849764|NCT03307252|Experimental|Treatment Reference 3|
9849765|NCT03307252|Experimental|Treatment 1|
9849766|NCT03307252|Experimental|Treatment 2|
9849767|NCT03307252|Experimental|Treatment 3|
9849768|NCT03307252|Experimental|Treatment 4|
9849769|NCT03307252|Experimental|Treatment 5|
9849770|NCT03307252|Experimental|Treatment 6|
9849771|NCT03307837|Active Comparator|CA-008 Cohort 1 0.5 mg|Intra-operative, local administration
9849772|NCT03307837|Active Comparator|CA-008 Cohort 2 1 mg|Intra-operative, local administration
9849773|NCT03307837|Active Comparator|CA-008 Cohort 3 2 mg|Intra-operative, local administration
9849774|NCT03307837|Active Comparator|CA-008 Cohort 4 3 mg|Intra-operative, local administration
9849775|NCT03307837|Active Comparator|CA-008 Cohort 5 4.2 mg|Intra-operative, local administration
9849776|NCT03307837|Placebo Comparator|Placebo|Intra-operative, local administration of saline (equivalent volume in active comparator arm)
9849777|NCT03308058|Experimental|Breastfeeding Computer education|Breastfeeding Computer education
9849778|NCT03308058|No Intervention|Printed Educational material|Printed educational material
9849779|NCT03308097|Experimental|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
9849780|NCT03308097|Active Comparator|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
9849781|NCT03308669|Experimental|Lasmiditan Alone|Lasmiditan administered orally, alone
9849782|NCT03308669|Placebo Comparator|Placebo Alone|Placebo administered orally, alone
9849783|NCT03308669|Experimental|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
9849784|NCT03308669|Experimental|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
9849785|NCT03308799|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
9849786|NCT03308799|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
9849787|NCT03308799|Placebo Comparator|Cream vehicle|One application daily for 8 weeks.
9849788|NCT03308942|Experimental|Stage 1 (Cohort 1): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/programmed death-ligand 1 (PD-L1) inhibitor treatment and whose tumors have high PD-L1 expression (tumor proportion score [TPS]: >= 50 percent [%]) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
9849789|NCT03308942|Experimental|Stage 1 (Cohort 2): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
9849790|NCT03308942|Experimental|Stage 1 (Cohort 3): Niraparib|Participants with locally advanced and metastatic squamous NSCLC who have been previously treated with both platinum and either PD-1 or PD-L1 inhibitor will receive single agent niraparib.
9849791|NCT03308942|Experimental|Stage 2 (Cohort 1A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have high PD-L1 expression (TPS: >= 50%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
9849792|NCT03308942|Experimental|Stage 2 (Cohort 2A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
9849793|NCT03308968|Placebo Comparator|Placebo|Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
9849794|NCT03308968|Experimental|Fremanezumab Quarterly|DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
9849795|NCT03308968|Experimental|Fremanezumab Monthly|DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
9849796|NCT03309020|Active Comparator|Control|Control with clinical need for cataract surgery
9849797|NCT03309020|Experimental|EVD Survivors|EVD survivors with need for cataract surgery
9849798|NCT03309202|Experimental|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
9849799|NCT03309202|Experimental|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
9849800|NCT03309202|Experimental|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
9849801|NCT03309202|Experimental|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
9849802|NCT03309449|Other|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
9849803|NCT03309449|Other|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
9849804|NCT03309449|Other|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
9849805|NCT03309605|Placebo Comparator|Placebo Comparator Arm|Placebo
9849806|NCT03309605|Experimental|ELX-02|ELX-02
9849807|NCT03309657|Experimental|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
9849808|NCT03309696|Experimental|tDCS and 1 Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC. .
9849809|NCT03309696|Experimental|tDCS and 10Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
9849810|NCT03309696|Experimental|tDCS over DLFC and 1 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
9849811|NCT03309696|Experimental|tDCS over DLFC and 10 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
9849812|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
9849813|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
9849814|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
9849815|NCT03309943|Experimental|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
9849816|NCT03309943|Placebo Comparator|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
9849817|NCT03310021|Experimental|Cohort 1|Apixaban + low dose andexanet
9849818|NCT03310021|Experimental|Cohort 2|Rivaroxaban + high dose andexanet
9849819|NCT03310021|Experimental|Cohort 3|Edoxaban + high dose andexanet
9849820|NCT03310021|Experimental|Cohort 4|Edoxaban + high dose andexanet
9849821|NCT03310021|Experimental|Cohort 5|Apixaban + low dose andexanet
9849822|NCT03310021|Experimental|Cohort 6|Apixaban + high dose andexanet
9849823|NCT03310021|Experimental|Cohort 7|Edoxaban + low dose andexanet
9849824|NCT03310021|Experimental|Cohort 8|Apixaban + low dose andexanet
9849825|NCT03310021|Experimental|Cohort 9|Rivaroxaban + low dose andexanet
9849826|NCT03310021|Experimental|Cohort 10|Edoxaban + low dose andexanet
9849827|NCT03310268|Experimental|Test Product|Participants will be instructed to self administer experimental dentifrice containing 0.454% SnF2 and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total).
9849828|NCT03310268|Active Comparator|Negative Control|Participants will be instructed to self administer negative control dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (SMFP).
9849829|NCT03310268|Active Comparator|Positive Control|Participants will be instructed to self administer positive control dentifrice containing SnCl2 and 0.15% NaF (1450 ppm fluoride in total).
9849830|NCT03310411|Experimental|Lasmiditan + Sumatriptan (A)|Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
9849831|NCT03310411|Experimental|Lasmiditan + Placebo (B)|Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
9849832|NCT03310411|Active Comparator|Sumatriptan + Placebo (C)|Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
9849833|NCT03310411|Placebo Comparator|Placebo + Placebo (D)|Oral doses of placebo tablets in one of four treatment periods.
9849834|NCT03310450||Group 140kms cycling|"Participants of Tour de Borobudur 2017 140 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
9849835|NCT03310450||Group 100kms cycling|"Participants of Tour de Borobudur 2017 100 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
9849836|NCT03310450||Group 240kms cycling|"Participants of North Coast 2017 240 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
9849837|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
9849838|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
9849839|NCT03310580|Placebo Comparator|Placebo Comparator|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
9849840|NCT03310723|Active Comparator|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
9849841|NCT03310723|Experimental|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
9849842|NCT03310775|Experimental|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
9849843|NCT03310775|Experimental|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
9849844|NCT03310970|Active Comparator|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
9849845|NCT03310970|Active Comparator|Lidoderm® 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
9849846|NCT03310970|Active Comparator|Intravenous lidocaine|A single intravenous dose of 0.5 mg/kg lidocaine hydrochloride will be administered to each subject.
9849847|NCT03311230|No Intervention|Control|Participants in this arm will receive no other interventions during the 9 month study period
9849848|NCT03311230|Experimental|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
9849849|NCT03311230|Experimental|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
9849850|NCT03311230|Experimental|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
9849851|NCT03311373|Experimental|Treatment Period 1|Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)
9849852|NCT03311373|Experimental|Treatment Period 2|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
9849853|NCT03311373|Experimental|Treatment Period 3|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
9849854|NCT03311373|Experimental|Treatment Period 4|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
9849855|NCT03311646|Experimental|Nicotine Content Manipulation|All participants receive normal nicotine content (NNC) cigarettes during Baseline and all participants receive very low nicotine content (VLNC) cigarettes during the very low nicotine content condition.
9849856|NCT03311659|Experimental|dTpa group|Healthy female and male subjects with age 4 years and above and who received a single dose of Boostrix vaccine at Day 1.
9849857|NCT03311724|Experimental|4,8,12mg Tirzepatide|Participants received Tirzepatide by subcutaneous (SC) injection in three dose escalations starting with 4 milligrams (mg) for four weeks followed by 8mg for four weeks followed by 12mg for four weeks.
9849858|NCT03311724|Experimental|2.5,5,10,15mg Tirzepatide|Participants received Tirzepatide by SC injection in four dose escalations starting with 2.5mg for two weeks followed by 5mg for two weeks followed by 10mg for four weeks followed by 15mg for four weeks.
9849859|NCT03311724|Experimental|2.5,7.5,15mg Tirzepatide|Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.
9849860|NCT03311724|Placebo Comparator|Placebo|Placebo administered by SC injection.
9849861|NCT03311841|Experimental|End Stage Renal Disease|Participants requiring hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). A washout period of at least 14 days will separate dosings.
9849862|NCT03311841|Experimental|Severe Impairment|Participants with <30 mL/min/1.73m^2 estimated glomerular filtration rate (eGFR) not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
9849863|NCT03311841|Experimental|Moderate Impairment|Participants with 30 to <60 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
9849864|NCT03311841|Experimental|Mild Impairment|Participants with 60 to <90 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
10207702|NCT05040711|Experimental|mindfulness coach|"Mindfulness coach is an app that provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. . To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
10207703|NCT05040711|Active Comparator|control - web MD|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
9849865|NCT03311841|Active Comparator|Healthy Control|Participants with ≥90 mL/min creatinine clearance. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
9849866|NCT03312023|Experimental|Group A (LDV/SOF for low replicative HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.
9849867|NCT03312023|Experimental|Group B (LDV/SOF for viral suppressed HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.
9849868|NCT03312023|Experimental|Group C (SOF for low replicative HBV)|"12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group D."
9849869|NCT03312023|Experimental|Group D (LDV for low replicative HBV)|"12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group C."
9849870|NCT03312114|Experimental|Single arm|Avelumab and SABR
9849871|NCT03312218|Experimental|Intervention|Intervention site residents will receive alerts through an app to adaptively reinforce the learning of clinical content based on cases and test questions (spaced education).
9849872|NCT03312218|No Intervention|Control|Residents in the control group will receive the same app providing identical clinical cases and test questions-on-demand, but with alerts inactivated (no spaced education).
9849873|NCT03312231|Experimental|Group 1|3.75 mcg of H7N9 vaccine with PBS diluent plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
9849874|NCT03312231|Experimental|Group 2|7.5 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
9849875|NCT03312231|Experimental|Group 3|15 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
9849876|NCT03312231|Experimental|Group 4|15 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
9849877|NCT03312231|Experimental|Group 5|45 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
9849878|NCT03312348|Experimental|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
9849879|NCT03312517|Active Comparator|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
9849880|NCT03312517|Active Comparator|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
9849881|NCT03312517|Sham Comparator|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
9849882|NCT03312543|Experimental|Active Cell: Active Mask|Cleanser, Moisturizer, Active Mask
9849883|NCT03312543|Sham Comparator|Sham Cell: Sham Mask|Cleanser, Moisturizer, Sham Mask
9849884|NCT03312595|Other|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
9849885|NCT03312933||Duration of boot >2 weeks|All patients who were placed into a CAM walker boot for >2 weeks were prospectively enrolled. Patients were placed by an orthopedic cast technician into either a tall or short CAM walker boot, based upon the appropriate boot type needed for treatment. Inclusion criteria included anticipated boot wear for at least two weeks, and weightbearing as tolerated weightbearing restrictions. Exclusion criteria included transitioning into a CAM walker boot as part of a postoperative protocol, injury requiring restricted weightbearing, or an additional acute injury to the lower back or lower extremity. Those who subsequently reported wearing the boot for less than two weeks or had a treatment plan change were removed from the study.
9849886|NCT03313037|Experimental|Multivalent|Pneumococcal conjugate vaccine
9849887|NCT03313037|Active Comparator|Control|Prevnar 13 and PPSV23
9849888|NCT03313050|Experimental|Stage 1 multivalent (ages 50-64 years)|multivalent
9849889|NCT03313050|Active Comparator|Stage 1 Tdap (ages 50-64 years)|Tdap
9849890|NCT03313050|Experimental|Stage 2 multivalent (ages 65-85 years)|multivalent
9849891|NCT03313050|Active Comparator|Stage 2 polysaccharide (ages 65-85 years)|polysaccharide
9849892|NCT03313076|Experimental|n-3 PUFA (O3FA) + Vitamin D3|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule
9849893|NCT03313076|Experimental|n-3 PUFA (O3FA) Placebo + Vitamin D3|4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule
9849894|NCT03313076|Experimental|n-3 PUFAs (O3FA) + Vitamin D3 Placebo|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule
9849895|NCT03313076|Placebo Comparator|n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo|4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule
9849896|NCT03313310|Experimental|Employment Intervention|An employment intervention (iFOUR) that has been adapted from previous piloting work of focus groups, key informant interviews and a community advisory board.
9849897|NCT03314233|Experimental|DING intervention|Delayed Cord Clamping
9849898|NCT03314519|Experimental|Ultrasonography|Patients in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering pleural cavity.
9849899|NCT03314519|Active Comparator|Fiberoptic bronchoscopy|Patients in this group receive fiberoptic bronchoscope to detect lung collapse after inserting a double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering the pleural cavity.
9849900|NCT03314662|Experimental|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
9849901|NCT03314662|Experimental|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
9849902|NCT03314662|Experimental|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
9849903|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: Arctic Front® & Arctic Front Advance® Cardiac CryoAblation Catheter System.~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
9849904|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
9849905|NCT03314857|Experimental|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
9849906|NCT03315104|Experimental|FLU-IGIV High Dose|"Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
9849907|NCT03315104|Experimental|FLU-IGIV Low Dose|"Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
9849908|NCT03315104|Placebo Comparator|FLU-IGIV Placebo|"Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~Placebo for FLU-IGIV: Single dose, normal saline solution for IV administration."
9849909|NCT03315208|Experimental|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
9849910|NCT03315208|Active Comparator|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
9849911|NCT03315286|Experimental|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
9849912|NCT03315286|Active Comparator|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
9849913|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
9849914|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
9849915|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
9849916|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
10207704|NCT05026723|Experimental|Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI)|The Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
10207705|NCT05026723|Active Comparator|Standard MTM|The Standard Medically Tailored Meal (MTM) intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian.
9849917|NCT03315689|Placebo Comparator|Vehicle|Vehicle
9849918|NCT03315689|Experimental|Active|ATI-50002 Topical Solution
9849919|NCT03315702||control／mechanical ventilation|venous blood samples collected from patients twice，relatively before mechanical ventilation and 3rd hour after mechanical ventilation
9849920|NCT03315780|Experimental|Dulaglutide, Placebo|Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
9849921|NCT03315780|Experimental|Placebo, Dulaglutide|Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
9849922|NCT03315793|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
9849923|NCT03315793|Placebo Comparator|Placebo|Placebo given orally.
9849924|NCT03315949|Experimental|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
9849925|NCT03315949|Active Comparator|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
9849926|NCT03316131|Experimental|Treatment A|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin;"
9849927|NCT03316131|Experimental|Treatment B|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin matched placebo"
9849928|NCT03316170|Experimental|Social Support + NRT Sampling|"The treatment group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,~a brief phone consult (10-15 minutes via phone) germane to smoking cessation,~a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and~a free, 2-week supply of nicotine patches and lozenges delivered via mail."
9923117|NCT00847093|Experimental|Cream|Experimental group receiving either medicated topical cream or placebo cream
10207706|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine, Arm 1|
10207707|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 2|
10207708|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3|
10207709|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 4|
10207710|NCT05021432|Experimental|Virtual Reality Group|Virtual Reality group will receive video based games training.
10207711|NCT05021432|Active Comparator|Circuit Training Group|They will receive Task-oriented Circuit training exercise program
10207712|NCT05014815|Experimental|Arm A: Ociperlimab + tislelizumab histology-based chemotherapy|
10207713|NCT05014815|Placebo Comparator|Arm B: Placebo + tislelizumab + histology-based chemotherapy|
10207714|NCT05012254|Experimental|Induction treatment + Maintenance|"Induction: 2 cycles of platinum-based chemotherapy plus (Nivolumab + Ipilimumab):~- Non-squamous NSCLC patients: Pemetrexed: 500 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6 or Cisplatin: 75 mg/m2 IV, Q3W Nivolumab: 360 mg IV Q3W Ipilimumab: 1mg/kg IV Q6W~2 cycles will be administered at 21-day intervals (Q3W) for Pemetrexed, Carboplatin/Cisplatin and Nivolumab. Ipilimumab will be administered at 42 days interval (Q6W).~- Squamous NSCLC patients: Paclitaxel: 200 mg/m2 IV, Q3W Carboplatin: AUC 5 o 6, Q3W Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W~Maintenance: following two cycles of chemo-immunotherapy the patients will receive:~Nivolumab: 360 mg IV, Q3W Ipilimumab: 1mg/kg IV, Q6W~Immunotherapy will be administered until disease progression, unacceptable toxicity, loss of clinical benefit or up to a maximum of 2 years of treatment."
10207715|NCT05011448|Other|Single arm study with two interventions|Single arm where each participant will undergo two interventions in the following order: Verbal Interaction and Music Therapeutic Interaction. Both interactions will be conducted by the same music therapist.
10207716|NCT05008822|Experimental|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
10207717|NCT05008822|Active Comparator|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
10207718|NCT05007405||Osteoarticular infections|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
10207719|NCT04999319|Active Comparator|PVB Group|Paravertebral block administered group
10207720|NCT04999319|Active Comparator|ESPB group|Erector spinae plane block administered group
10207721|NCT04993287|Experimental|Pilot|45 eligible HF patients
9793896|NCT01489020|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
9793897|NCT01489111|Experimental|Surgery|
9793898|NCT01489189|Experimental|Anti-VEGF+Deferred PRP|Anti-VEGF= Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
9793899|NCT01489189|Active Comparator|Prompt PRP|PRP= Panretinal Photocoagulation. PRP alone.
9793900|NCT01489254|Experimental|GTR|Drug
9793901|NCT01489254|Active Comparator|Copaxone®|Drug
9793902|NCT01489254|Placebo Comparator|Placebo|Drug
9793903|NCT01489358|Experimental|Group 1|Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
9793904|NCT01489358|Experimental|Group 2|Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
9793905|NCT01489358|Experimental|Group 3|Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
9793906|NCT01489527|Active Comparator|Gardasil Vaccine Administration|Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
9793907|NCT01489527|Placebo Comparator|Placebo Administration|Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
9793908|NCT01489579|Active Comparator|BST counseling group|The patients in the Brief, structured, telephone tobacco cessation, BST, counseling group, will receive tobacco cessation counseling, intervention, by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources.
9793909|NCT01489579|Placebo Comparator|Usual care group|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
9793910|NCT01489670||Lumigan® 0.01%|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
9793911|NCT01489826|Experimental|Dexanabinol 2 mg/kg|Dexanabinol 2 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793912|NCT01489826|Experimental|Dexanabinol 3 mg/kg|Dexanabinol 3 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793913|NCT01489826|Experimental|Dexanabinol 6 mg/kg|Dexanabinol 6 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793914|NCT01489826|Experimental|Dexanabinol 12 mg/kg|Dexanabinol 12 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793915|NCT01489826|Experimental|Dexanabinol 15 mg/kg|Dexanabinol 15 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793916|NCT01489826|Experimental|Dexanabinol 22 mg/kg|Dexanabinol 22 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793917|NCT01489826|Experimental|Dexanabinol 30 mg/kg|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793918|NCT01489826|Experimental|Dexanabinol 36 mg/kg|Dexanabinol 36 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793919|NCT01489826|Experimental|Dexanabinol Expansion Phase|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
9793920|NCT01489891|Active Comparator|Lidocaine group|Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
9793921|NCT01489891|Placebo Comparator|Placebo|Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
9793922|NCT01489956|Experimental|Immucothel alone (Part A)|100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
9793923|NCT01489956|Experimental|Immucothel+Montanide (Part A)|If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
9849929|NCT03316170|Active Comparator|Social Support|"The control group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,"
9849930|NCT03316378|Experimental|Group with Achilles Tendinopathy|Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
9799873|NCT01672801|Placebo Comparator|Placebo|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes
9849931|NCT03316378|No Intervention|Group without Achilles Tendinopathy|The control group did not receive an injection between test repetitions
9849932|NCT03316547|No Intervention|Control|The control group received standard hospital care.
9849933|NCT03316547|Experimental|Intervention|Parents in the sensory-based intervention group were educated to provide daily sensory-based interventions across the length of hospitalization as outlined in the manualized intervention (the SENSE Program). A sensory support team completed the doses of sensory exposures when parents were unable.
9849934|NCT03316911|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
9849935|NCT03316911|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
9849936|NCT03316976|Experimental|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
9849937|NCT03316976|Experimental|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
9849938|NCT03317002|Experimental|AZD5718 Dose A|AZD5718 Dose A once daily
9849939|NCT03317002|Experimental|AZD5718 Dose B|AZD5718 Dose B once daily
9849940|NCT03317002|Placebo Comparator|Placebo|Matching placebo once daily
9849941|NCT03317288|Other|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
9849942|NCT03317379|Experimental|Peer mentorship|Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
9849943|NCT03317379|Active Comparator|Social support mentorship|Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
9799874|NCT01672801|Active Comparator|Nimodipine|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes
9799875|NCT01672827|Experimental|[18F]Flutemetamol|
9799876|NCT01672853|Experimental|Treatment Arm A|Simtuzumab 75 mg for 96 weeks
9799877|NCT01672853|Experimental|Treatment Arm B|Simtuzumab 125 mg for 96 weeks
9799878|NCT01672853|Placebo Comparator|Treatment Arm C|Placebo for 96 weeks
9799879|NCT01672866|Experimental|SIM 75 mg|During the Randomized Double-Blind Phase, participants will receive SIM 75 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
9799880|NCT01672866|Experimental|SIM 125 mg|During the Randomized Double-Blind Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
9799881|NCT01672866|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
9799882|NCT01672879|Experimental|SIM 200 mg|During the Randomized Double-Blind Phase, participants will receive SIM 200 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
9799883|NCT01672879|Experimental|SIM 700 mg|During the Randomized Double-Blind Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
9799884|NCT01672879|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM administered via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg administered via intravenous infusion every 2 weeks for up to an additional 240 weeks.
9849944|NCT03317379|No Intervention|Wait list|Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later
9849945|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
9849946|NCT03317444|Experimental|TRC101|Administered once daily (QD) for 12 weeks
9849947|NCT03317444|Placebo Comparator|Placebo|Administered once daily (QD) for 12 weeks
9849948|NCT03318315|Experimental|Group 1|3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant and 0.5 ml dose of IIV4 vaccine, both administered intramuscularly within 15 minutes on day 1, and 3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22, n=60
9849949|NCT03318315|Experimental|Group 2|0.5 ml dose of IIV4 vaccine intramuscularly on day 1 and 3.75 mcg HA per 0.5 ml dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22 and day 43, n=60
10207722|NCT04975841|No Intervention|Standard of Care|Standard of Care (SOC) Study: The 6 subjects in the late injection group will start on Part 1. - The Part 1 study subject participation is 12 months. Two subjects will be enrolled at each of Months 0, 3 and 6. This will include an initial assessment and SOC follow-up. Subjects will continue standard of care treatment. Part 1 study duration (with staggering included) will be 18 months. After Part 1, the late injection subjects may proceed to Part 2 depending on safety data from the early injection group (see 3. below).
10207723|NCT04975841|Active Comparator|Stem Cell Injection|Stem Cell Injection: The three subjects randomized to early injections will proceed directly to Part 2 with staggered enrollment of 1 subject every 3 months. Once the safety data of the first subject at Month 3 is assessed, the second subject will be enrolled. Once the safety data of the first 2 subject (Subject 1 at Month 6 and Subject 2 at Month 3) are assessed, the third early injection subject will be enrolled in Part 2.
10207724|NCT04975217|Experimental|Treatment (FMT, FMT capsules)|Patients undergo FMT during colonoscopy. Patients also receive FMT capsules PO QW for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection of tumor(s).
9849950|NCT03318315|Active Comparator|Group 3|0.5 ml dose of IIV4 vaccine intramuscularly on day 1, n=30
9849951|NCT03318341|Other|Real then Sham|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies real stimulation in the first month. The device applies sham stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
9849952|NCT03318341|Other|Sham then Real|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies sham stimulation in the first month. The device applies real stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
9849953|NCT03318783|Active Comparator|GSK2256294|10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
9849954|NCT03318783|Placebo Comparator|Placebo|10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
9849955|NCT03318809|Experimental|Group 1: Severely Renal Impaired Participants|Participants with severely impaired renal function (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m^2) receive a single oral dose of 200 mg AMG 986.
9849956|NCT03318809|Active Comparator|Group 2: Healthy Participants|Participants with normal renal function (eGFR >= 90 mL/min/1.73 m^2 or above) receive a single oral dose of 200 mg AMG 986.
9849957|NCT03319134|Experimental|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
9849958|NCT03319134|Sham Comparator|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
9849959|NCT03319134|Experimental|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
9923118|NCT00847119|Experimental|Bevacizumab & capecitabine & radiotheraphy|"Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period."
9923119|NCT00847158|Active Comparator|1|phacoemulsification alone
9923120|NCT00847158|Active Comparator|2|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
10207725|NCT04973800|Experimental|Experimental arm: Simvastatin|Simvastatin 20mg ON PO for 28-30 days
10207726|NCT04973800|Placebo Comparator|Control arm: Placebo|Sucrose placebo ON PO for 28-30 days
10207727|NCT04962035||Alprem RTF Brain Follow-up|Neurocognitive Follow-up of children previously having participated in the Alprem RTF study
10207728|NCT04961021|Active Comparator|Medial rectus advancement with resection|Surgery will be done to strengthen the medial rectus muscle with resection and anterior displacement again to the original insertion site 5 mm from limbus
10207729|NCT04961021|Active Comparator|Medial rectus advancement with lateral rectus recession|Surgery will be done to strengthen the medial rectus muscle with anterior displacement again to the original insertion site 4- 5 mm from limbus with weakening procedure to the lateral rectus muscle at the same time
10207730|NCT04959435||Case|Behcet's disease patients
10207731|NCT04959435||Controls|Controls that matched two to two at case according to sex,social status and diet.
10207732|NCT04947059|Active Comparator|Gemcitabine|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with gemcitabine hydrochloride 2gr in 100ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
10207733|NCT04947059|Active Comparator|Epirubicin|Bladder cancer patients, who are treated with a transurethral resection of a bladder tumor, receive postoperatively, within 6 hours after the resection, an immediate single intravesical instillation with epirubicine hydrochloride 50mg in 50ml of saline for 45-60 minutes and continuous saline irrigation for 24 hours
9849960|NCT03319173|Experimental|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
9849961|NCT03319173|Active Comparator|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
9849962|NCT03319212|Other|Active Comparator|Subjects that are between the ages 18-55 and are current spherical soft contact lens wearers will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
9849963|NCT03319277|Active Comparator|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
9849964|NCT03319277|Experimental|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
9849965|NCT03319719|Experimental|Belotero® Balance with integral lidocaine|Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
9849966|NCT03319719|Active Comparator|Belotero Balance without lidocaine|Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
9849967|NCT03319810|Experimental|infusion of IVIG|
9849968|NCT03319953|Experimental|Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics|TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
9849969|NCT03319953|Experimental|Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
9849970|NCT03319953|Experimental|Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics|TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
9849971|NCT03319953|Experimental|Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
9849972|NCT03320057|Experimental|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
9849973|NCT03320057|Other|Pharmacists|Pharmacists providing services at one of the study pharmacies during the study
9849974|NCT03320096|Experimental|Microfocused ultrasound with visualization|
9849975|NCT03320369|Other|Treatment|Elemental formula Intervention: Elemental Diet Therapy
9923121|NCT00847184|Active Comparator|1. Airtraq|Intubation with the use of the Airtraq technique
9923122|NCT00847184|Active Comparator|2. MacIntosh|Intubation using the standard MacIntosh blade
9923123|NCT00847223|Experimental|ZARNESTRA (Tipifarnib)|
9923124|NCT00847236||Subjects with Polymyalgia Rheumatica|50 subjects with Polymyalgia Rheumatica, both acute and chronic
9923125|NCT00847236||Subjects w/o Polymyalgia Rheumatica|50 subjects with Rheumatic Disease other than polymyalgia Rheumatica
9923126|NCT00847236||Subjects w/o Rheumatic Disease|50-Non Rheumatic disease subjects
9923127|NCT00847249|Experimental|1|Solution for nebulisation, inhaled
9923128|NCT00847249|Placebo Comparator|2|Solution for nebulisation, inhaled
9923129|NCT00847262|Experimental|Telmisartan Group|Telmisartan intervention group
9923130|NCT00847262|Active Comparator|Amlodipine Group|Amlodipine intervention group
9923131|NCT00847275|Placebo Comparator|1|"Exclusive nephrology follow-up arm"
9923132|NCT00847275|Experimental|2|"Geriatric follow-up arm"
9923133|NCT00847314||Group 1|
9923134|NCT00847327|Experimental|Parental Support|
9923135|NCT00847327|Active Comparator|Diabetes Education|
9923136|NCT00847392|Experimental|Ultrasound|Bladder ultrasound prior to catheterization
9923137|NCT00847392|No Intervention|Standard catheterization|No ultrasound prior to bladder catheterization
9923138|NCT00847418|Experimental|Esketamine|
9923139|NCT00847431||STN DBS Group|PD patients with deep brain stimulators in the subthalamic nucleus. Subjects within this group will be placed into either a 1 contact group, or 2 contact group, depending on contact location requirements for this study.
9923140|NCT00847431||Control Group|PD patients without deep brain stimulator surgery, with similar symptoms to the study group.
9923141|NCT00847444|Active Comparator|AA|Drug intervention
9923142|NCT00847444|Active Comparator|BA|Lifestyle intervention
9923143|NCT00847444|No Intervention|BB|No individualized lifestyle intervention program.
9793924|NCT01489956|Experimental|Immucothel alone or Immucothel+Montanide (Part B)|"Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35."
9793925|NCT01489969|Active Comparator|20 mg|Neu-P11 dose of 20 mg
9793926|NCT01489969|Active Comparator|50 mg|Neu-P11 dose of 50 mg
9793927|NCT01489969|Placebo Comparator|placebo|matching placebo
9793928|NCT01490060|Experimental|Single Dose Day 1|Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
9793929|NCT01490060|Experimental|Two Doses Day 1 + Day 4|Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
9793930|NCT01490073|Active Comparator|Active nitroglycerin ointment|
9793931|NCT01490073|Placebo Comparator|Placebo ointment|
9793932|NCT01490086|Experimental|15mg RP5063 daily|
9793933|NCT01490086|Experimental|30mg RP5063 daily|
9793934|NCT01490086|Experimental|50mg RP5063 daily|
9793935|NCT01490086|Placebo Comparator|Placebo|
9793936|NCT01490086|Active Comparator|aripiprazole|aripiprazole 15 mg daily
9793937|NCT01490125|Experimental|QVA149 + placebo to tiotropium|Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
9793938|NCT01490125|Active Comparator|Tiotropium + placebo to QVA149|Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
9793939|NCT01490125|Placebo Comparator|Placebo|Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
9793940|NCT01490151|Experimental|TTR controller|The intervention will consist of using the TTR controller (Medtronic) for post-prandial glucose control following high and low glycemic meals
9793941|NCT01490294|Experimental|Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
9793942|NCT01490294|Experimental|Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.025 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.025 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
9793943|NCT01490294|Experimental|Gadobutrol 0.05 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.05 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.05 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
9793944|NCT01490294|Experimental|Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
9793945|NCT01490359|Experimental|HIV/STD risk-reduction|Men Making a Difference HIV/STD Risk Reduction Intervention was designed to reduce sexual risk behaviors that increase risk of HIV and other sexually transmitted diseases.
9793946|NCT01490359|Active Comparator|Health Promotion Control|Health Promotion Intervention was designed to increase physical activity, healthful diet, and other behaviors to reduce risk of noncommunicable diseases, including diabetes, hypertension, and cancers.
9793947|NCT01490450|Placebo Comparator|PBO: Placebo matching BMS-945429|
9793948|NCT01490450|Experimental|BMS-945429 (25mg)|
9793949|NCT01490450|Experimental|BMS-945429 (100mg)|
9793950|NCT01490450|Experimental|BMS-945429 (200mg)|
9793951|NCT01490580|Experimental|Atropine + Propofol|
9793952|NCT01490580|Active Comparator|Atropine + atracurium + sufentanil|
9793953|NCT01490632|Placebo Comparator|Placebo|Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
9793954|NCT01490632|Experimental|Baricitinib 2 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
9793955|NCT01490632|Experimental|Baricitinib 4 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
9849976|NCT03320824|Experimental|New Dermal Filler|hyaluronic acid
9849977|NCT03320824|Active Comparator|Dermal Filler|hyaluronic acid
9849978|NCT03320850|Experimental|100U cohort - BOTOX® plus Hydrogel admixture|100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849979|NCT03320850|Placebo Comparator|100U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849980|NCT03320850|Experimental|300U cohort - BOTOX® plus Hydrogel admixture|300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849981|NCT03320850|Placebo Comparator|300U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849982|NCT03320850|Experimental|400U cohort - BOTOX® plus Hydrogel admixture|400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849983|NCT03320850|Placebo Comparator|400U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849984|NCT03320850|Experimental|500U cohort - BOTOX® plus Hydrogel admixture|500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849985|NCT03320850|Placebo Comparator|500U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
9849986|NCT03320941|Experimental|LIK066 2.5 mg|Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
9849987|NCT03320941|Experimental|LIK066 10 mg|Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
9849988|NCT03320941|Experimental|LIK066 25 mg|Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
9849989|NCT03320941|Experimental|LIK066 50 mg|Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
9849990|NCT03320941|Placebo Comparator|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
9849991|NCT03321006|Active Comparator|Antidepressant (AD) + full amplification hearing aids|Participant will be randomized to active comparator and will receive escitalopram or duloxetine + active hearing aid for 12 weeks.
9849992|NCT03321006|Sham Comparator|Antidepressant (AD) + Low amplification (sham) hearing aids|Participant will be randomized to sham comparator and will receive escitalopram or duloxetine + sham hearing aid for 12 weeks.
9849993|NCT03321097|Experimental|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
9849994|NCT03321097|Experimental|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
9849995|NCT03321253|Experimental|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
9849996|NCT03321396|Experimental|Endoscopic submucosal dissection|All participants in the study received Endoscopic submucosal dissection with Sodium Alginate mixed with Calcium Lactate prior to endoscopic resection.
9849997|NCT03321721|No Intervention|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
9849998|NCT03321721|Active Comparator|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
9849999|NCT03322423|Active Comparator|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
9850000|NCT03322423|Active Comparator|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
9850001|NCT03322462|Experimental|Flortaucipir PET Scan|
9850002|NCT03322514|Experimental|experimental group|10 g of Inulin-Propionate Esters will be administered per day
9850003|NCT03322514|Active Comparator|Inulin|10 g of Inulin will be administered per day
9850004|NCT03322657|Active Comparator|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
9850005|NCT03322657|Experimental|Sugammadex|Sugammadex 4 mg/kg at the end surgery
9850006|NCT03322930||Retinitis Pigmentosa|patients with a diagnosis of retinitis pigmentosa and reduced rod function on baseline testing
9799885|NCT01672892|Experimental|Intensity-Modulated Radiation Therapy|intensity-modulated radiation therapy (IMRT) to the pelvis of either 45 Gy or 50.4 Gy
9799886|NCT01672892|Active Comparator|Standard Radiation Therapy|Standard radiation therapy (4-field) to the pelvis of either 45 Gy or 50.4 Gy
9799887|NCT01672957||Renal Transplant Participants|Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
9799888|NCT01672970||Cohort|
9799889|NCT01672983|Experimental|Arm 1|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
9799890|NCT01672983|Experimental|Arm 2|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
9799891|NCT01672983|Experimental|Arm 3|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
9799892|NCT01672983|Experimental|Arm 4|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
9799893|NCT01672983|Experimental|Arm 5|Participants with HCV GT2 received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
9799894|NCT01672983|Experimental|Arm 6|Participants with HCV GT2 received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
9799895|NCT01672996|Experimental|Arm 1 - Ioforminol 160mgI/mL|Single administration of Ioforminol 160mgI/mL given to the subject.
9799896|NCT01672996|Experimental|Arm 2 - Ioforminol 200mgI/mL|Given as a single administration to the subject
9799897|NCT01672996|Active Comparator|Arm 3 - Iopamidol 300mgI/mL|Given as a single administration to the subject
9799898|NCT01673009|Experimental|Administration of Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
9799899|NCT01673022|Experimental|IC Green Arm|One arm only: Receives IC Green for testing of study objective
9799900|NCT01673113|Experimental|Cryolipolysis|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device, which is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks. Sensory testing was done before and after the procedure.
9799901|NCT01673113|No Intervention|Control|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device. The untreated flank served as the internal control for each subject.
9799902|NCT01673126|Active Comparator|Anodal tDCS|Patients received anodal tDCS (on DLPF cortex) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised)
9799903|NCT01673126|Sham Comparator|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
9799904|NCT01673178|Placebo Comparator|Placebo Arm|
9799905|NCT01673178|Experimental|25 mg|
9799906|NCT01673178|Experimental|50 mg|
9799907|NCT01673178|Experimental|100 mg|
9799908|NCT01673178|Experimental|150 mg|
9799909|NCT01673191|Experimental|OZURDEX intraocular implant|OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
9799910|NCT01673191|Active Comparator|Steroid plus NSAID eye drop combination therapy|NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
9799911|NCT01673256||SJM Confirm ICM Observational Group|
9799912|NCT01673282||Vimpat + Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
9799913|NCT01673282||Vimpat + Non-Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.
9799914|NCT01673347|Experimental|MENISCAL ALLOGRAFT|The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe.
9799915|NCT01673373|Experimental|iCAST RX™ Stent Systen|All enrolled subjects will receive the iCAST RX™ Stent System
9799916|NCT01673386|Experimental|Tivozanib Hydrochloride|1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks.
9799917|NCT01673386|Active Comparator|Sunitinib|50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks.
9799918|NCT01673490|Experimental|Combodart/Duodart|Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
9799919|NCT01673568|Active Comparator|abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company."
9799920|NCT01673568|No Intervention|no abdominal binder|no abdominal binder
9923144|NCT00847457|Experimental|Aerobic exercise|Participants will perform aerobic exercise regularly for 12 weeks.
9799921|NCT01673594|Experimental|Naltrexone|Arm 1: Naltrexone + SODAS MPH
9799922|NCT01673594|Placebo Comparator|Placebo|Arm 2: Placebo + SODAS MPH
9799923|NCT01673646|Experimental|Pasireotide LAR 20mg|Enrolled patients were randomized to 20mg pasireotide LAR.
9799924|NCT01673646|Experimental|Pasireotide LAR 40mg|Enrolled patients were randomized to 40mg pasireotide LAR.
9799925|NCT01673646|Experimental|Pasireotide LAR 60mg|Enrolled patients were randomized to 60mg pasireotide LAR.
9799926|NCT01673698|Active Comparator|ReShape Duo Balloon|ReShape Duo Balloon
9799927|NCT01673698|Sham Comparator|Sham Comparator|Sham Comparator
9799928|NCT01673802|Experimental|CT imaging|Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
9799929|NCT01673828|Experimental|Allopregnanolone|Allopregnanolone injection (intravenous solution) continuous infusion for 5 days
9799930|NCT01673828|Placebo Comparator|Placebo|Placebo injection (intravenous solution) continuous infusion for 5 days
9799931|NCT01673854|Experimental|Vemurafenib, 960 mg + Ipilimumab, 10 mg/kg|Participants received vemurafenib, 960 mg, twice daily for 6 weeks (Vem1 Phase). After a washout period of 3-10 days, patients received ipilimumab, 10 mg/kg, every 3 weeks for a maximum of 4 doses. At Week 24, participants received ipilimumab, 10 mg/kg, every 12 weeks until disease progression or unacceptable toxicity. Patients who did not progress or have unacceptable toxicity in the Vem1 Phase were retreated with vemurafenib (Vem 2 Phase) at the last dose level identified at the end of the Vem1 Phase until disease progression or unacceptable toxicity.
9799932|NCT01673893||ST elevation myocardial infarction|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~1st Group/Cohort - ST elevation myocardial infarction"
9799933|NCT01673893||Non-ST elevation myocardial infarction/ACS/UNSTABLE ANGINA|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~2nd Group/Cohort - Non-ST elevation myocardial infarction/ACS/Unstable Angina"
9799934|NCT01673919|Experimental|RoActemra/Actemra|
9799935|NCT01673984|Experimental|Decapeptyl® SR 22.5mg (Triptorelin)|
9799936|NCT01673984|Active Comparator|Current 3-monthly LHRH agonist|One of the following: Decapeptyl® SR 11.25mg (Triptorelin), Prostap® 3 DCS 11.25mg, Zoladex® LA 10.8mg
9799937|NCT01674010|Experimental|Lamotrigine or Valproic acid + ELND005|Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
9799938|NCT01674010|Placebo Comparator|Lamotrigine or Valproic acid + placebo|Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
9799939|NCT01674062|Experimental|Pertuzumab + Trastuzumab (Cohorts 1 and 2)|Females with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer will receive dual-agent treatment with pertuzumab and trastuzumab. Trastuzumab will be administered IV as 2 milligrams per kilogram (mg/kg) once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, beginning on Day 2 of Cycle 1. Thereafter, both medications will be administered on Day 1 of each 3-week cycle. Treatment will continue for a minimum of 8 cycles and may be extended until disease progression, intolerable toxicity, or death.
9799940|NCT01674062|Experimental|Pertuzumab +/- Trastuzumab (Cohort 3)|Females with HER2-positive metastatic breast cancer will receive single-agent treatment with pertuzumab. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, administered on Day 1 of each 3-week cycle. Participants with documented disease progression may have trastuzumab added to the regimen, per the dosing schedule described for Cohorts 1 and 2, to receive dual-agent treatment until disease progression, intolerable toxicity, or death.
9799941|NCT01674478|Experimental|Microlipid with fish oil group|This group will be given early enteral lipid supplementation with Microlipid and fish oil.
9799942|NCT01674478|Active Comparator|Microlipid group|This group will be given early enteral lipid supplementation only with Microlipid.
9799943|NCT01674569|Experimental|50 mg X-82 oral alternate days|50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops
9799944|NCT01674569|Experimental|50 mg X-82 oral QD|50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops
9799945|NCT01674569|Experimental|100 mg X-82 oral alternate days|100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops
9799946|NCT01674569|Experimental|100 mg X-82 oral QD|100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
9799947|NCT01674569|Experimental|200 mg X-82 oral QD|200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
9799948|NCT01674569|Experimental|300 mg X-82 oral QD|300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.
9799949|NCT01674621|Experimental|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
9799950|NCT01674621|Experimental|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
9799951|NCT01674621|Experimental|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
9799952|NCT01674621|Active Comparator|Abaloparatide Injection (80 mcg)|Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
9799953|NCT01674621|Placebo Comparator|Abaloparatide Transdermal Placebo (0 mcg)|Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months
9799954|NCT01674634|Experimental|XIAFLEX / XIAPEX|AA4500 (collagenase clostridium histolyticum)
9850007|NCT03322930||Age-related Macular Degeneration|patients with a diagnosis of intermediate AMD and reduced rod function on baseline testing
9850008|NCT03323086|Experimental|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
9850009|NCT03323086|Other|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the Centers for Disease Control and Prevention on the study topics.
9850010|NCT03323164|Active Comparator|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
9850011|NCT03323164|Active Comparator|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
9850012|NCT03323307|Experimental|OCT imaging|OCT device images retina
9850013|NCT03323723|Other|RS-2 SUI Device|Comparing use of device to non-treatment phase
9850014|NCT03323736|Other|Pivotal Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office.
9850015|NCT03323736|Other|Office Lead-In Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office. Physician initial in-office iontophoresis and tube insertion procedures (minimum of 2 subjects per investigator).
9850016|NCT03323736|Other|OR Lead-In Cohort|Tubes insertion using the Tube Delivery System in the operating room (OR). Physician initial tube insertion procedures in the OR (minimum of 2 subjects per investigator).
9850017|NCT03323801|Experimental|13-cis retinoic acid|20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks
9850018|NCT03323853|Experimental|CARS-SA Report|Emergency care providers for subjects in this group will receive a copy of the subject's CARS-SA summary results.
9850019|NCT03323853|Other|No CARS-SA Report|Emergency care providers for subjects in this group will not receive a copy of the subject's CARS-SA summary results.
9850020|NCT03324451|Experimental|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management"
9850021|NCT03324451|Placebo Comparator|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
9850022|NCT03324581|Experimental|OPC-64005|During the titration period, participants received OPC-64005 two 10 milligram (mg) tablets, and one OPC-64005-matching placebo tablet along with two atomoxetine-matching placebo capsules, orally, once daily (QD), from Day 1 up to Day 4. During the treatment period, participants received OPC-64005 three 10 mg tablets, and two atomoxetine-matching placebo capsules, orally, QD, from Day 5 up to Day 56. The dose was reduced to 20 mg if the 30 mg dose in the treatment period was not tolerable.
9850023|NCT03324581|Active Comparator|Atomoxetine|"During the titration period, participants received atomoxetine one 40 mg capsule and one atomoxetine-matching placebo capsule along with three OPC-64005-matching placebo tablets, orally, QD, from Day 1 up to Day 4.~During the treatment period, participants received two atomoxetine 40 mg capsules and three OPC-64005-matching placebo tablets, orally, QD, from Day 5 up to Day 56. The dose was reduced to 40 mg if the 80 mg dose in the treatment period was not tolerable."
9850024|NCT03324581|Placebo Comparator|Placebo|Participants received three OPC-64005-matching placebo tablets and two atomoxetine-matching placebo capsules, orally, QD, from Day 1 up to Day 56.
9850025|NCT03324607|Experimental|single arm|glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.
9850026|NCT03325010|Placebo Comparator|Placebo|Participants received placebo (matching valbenazine) once daily for 12 weeks.
9850027|NCT03325010|Experimental|Valbenazine|Participants received valbenazine once daily for 12 weeks. The starting dose was 20 mg for participants <50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects <50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of valbenazine for each participant.
9850028|NCT03325556|Placebo Comparator|Placebo|
9850029|NCT03325556|Experimental|Drug - Pimavanserin|
9850030|NCT03325673|Experimental|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on contact lens (CL) wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
9850031|NCT03325673|Sham Comparator|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
9923145|NCT00847457|Active Comparator|Stretch|Participants will stretch regularly for 12 weeks.
9923146|NCT00847483|Active Comparator|Latanoprost|
9923147|NCT00847483|Active Comparator|Travoprost|
10207734|NCT04945967|Experimental|New Method|This intervention will be given once a day, 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 18 minutes.
10207735|NCT04945967|Active Comparator|Conventional Method|This intervention will be given once a day, 30 minutes before feeding schedule based on the neonatologist. Each session of intervention will take time about 15 minutes.
10207736|NCT04941001|Active Comparator|Healthcare professional using ReferID Tool in primary care|The asthma review will be undertaken by a healthcare professional with the use of the ReferID tool in primary care
10207737|NCT04941001|No Intervention|Usual care in primary care|A cohort of patients will be recruited who continue to receive usual care in primary care
10207738|NCT04941001|Active Comparator|Healthcare professional using ReferID Tool in secondary care|The follow up (post A&E attendance) review will be undertaken by a healthcare professional with the use of the ReferID tool in secondary care
10207739|NCT04941001|No Intervention|Usual care post A&E attendance|The usual care post A&E attendance in secondary care.
10207740|NCT04938609|Experimental|Pembrolizumab + SBRT + Surgery|Pembrolizumab administration (3 dose) every 3 weeks and 1 dose before radiation (5 days) therapy followed by an additional administration of Pembrolizumab (2 doses) prior to restaging and surgical resection followed by risk-adapted adjuvant therapy, per standard of care. Patient will then be treated with adjuvant pembrolizumab every 3 weeks for 14 additional doses (17 doses total)
9850032|NCT03325816|Experimental|Phase II - Arm 1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion."
9850033|NCT03325816|Experimental|Phase I - Dose Level -1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses."
9850034|NCT03325816|Experimental|Phase I - Dose Level 0|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses."
9850035|NCT03325816|No Intervention|Phase II - Arm 2|Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed
10207741|NCT04934657||normal steps|patients in this group have normal preoperative step counts
9850036|NCT03325881|Experimental|SHP465|Participants will be randomized to receive SHP465 capsule 6.25 milligram (mg) orally once daily for 4 weeks.
9850037|NCT03325881|Placebo Comparator|Placebo|Participant will receive placebo matching to SHP465 capsule orally once daily for 4 weeks.
10207742|NCT04934657||low steps|patients in this group have low preoperative step counts
9850038|NCT03325894|Experimental|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
9850039|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
9850040|NCT03326518|Experimental|Lumentin® 44|Contrast agent
9850041|NCT03326518|Active Comparator|Diluted Omnipaque®|Contrast agent
9850042|NCT03326518|Active Comparator|Movprep®|Contrast agent
9850043|NCT03326843|Experimental|Avatrombopag 60 mg|Open-label: oral avatrombopag
9850044|NCT03326895|Experimental|Group 1|Powered circular stapler used to complete anastomosis of colon
9850045|NCT03326986|Experimental|Panel A|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
9850046|NCT03326986|Experimental|Panel B|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
9850047|NCT03326986|Experimental|Panel C|Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
9850048|NCT03326999|Experimental|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
9850049|NCT03326999|Sham Comparator|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
9850050|NCT03327051|Active Comparator|Omeprazole and VSL #3|Participants will receive a proton pump inhibitor (Omeprazole) and VSL #3 Probiotics
9850051|NCT03327051|Placebo Comparator|Placebo and VSL #3|Participants will receive placebo and VSL #3 Probiotics
9850052|NCT03327220|Experimental|iovera° Device Treatment Group|Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
9850053|NCT03327220|No Intervention|Standard of Care Treatment Group|All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
9850054|NCT03327402|Experimental|SHP465|Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.
9923148|NCT00847483|Active Comparator|Bimatoprost|
10207743|NCT04921735||Elderly|patients aged 80 years or older
10207744|NCT04921735||young|patients aged 18-40 years
10213508|NCT03875092|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
10213509|NCT03875092|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
9850055|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
9850056|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
9850057|NCT03328182|Experimental|New oral endotracheal tube holder|Single Study Product Arm
9850058|NCT03328208|Experimental|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
9850059|NCT03328208|Active Comparator|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
9850060|NCT03328325|Experimental|Arm 1|0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240
9850061|NCT03328624|Experimental|DVT Cuff users|Current or previous DVT cuff users
9850062|NCT03328832|Active Comparator|Combined topical TXA and Floseal|Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
9850063|NCT03328832|Active Comparator|Topical TXA alone|Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
9850064|NCT03328897|Experimental|Omalizumab 300mg|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
9850065|NCT03328897|Experimental|Omalizumab 150mg|patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
9850066|NCT03328897|Placebo Comparator|Placebo|patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
9850067|NCT03328949|Experimental|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
9850068|NCT03329196|Experimental|MT-6548|
9850069|NCT03329196|Active Comparator|Darbepoetin alfa|
9850070|NCT03329209|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
9850071|NCT03329352|Experimental|F&P Full-Face Mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial full-face mask during this treatment arm. Participants on the extension will use for a further six months after Visit 3.
9850072|NCT03329573|Experimental|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
9850073|NCT03329573|Experimental|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
9850074|NCT03329573|Experimental|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
9850075|NCT03329573|Experimental|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
9850076|NCT03329846|Active Comparator|Nivolumab + Placebo|"Specified dose on specified day~Participants will no longer receive BMS-986205 Placebo"
9850077|NCT03329846|Experimental|Nivolumab + BMS-986205|"Specified dose on specified day.~Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion"
9850078|NCT03329885|Experimental|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
9850079|NCT03329885|Experimental|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
9850080|NCT03329885|Experimental|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
9850081|NCT03329911|Active Comparator|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
9850082|NCT03329911|Experimental|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
9850083|NCT03329937|Experimental|Participants with HER2-negative and BRCAmut breast cancer|Participants with HER2-negative and BRCAmut localized breast cancer (primary tumor >=1 cm) will receive niraparib (200 mg PO).
9923149|NCT00847496|Experimental|1|AWBAT
9850084|NCT03329989|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
9850085|NCT03330002||CE-marked MANTA vascular closure devices per IFU|Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.
9850086|NCT03330041|Experimental|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
9850087|NCT03330041|Experimental|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
9850088|NCT03330119|Experimental|Alternate Management|
9850089|NCT03330119|Placebo Comparator|Control|The regular Lankenau cesarean section order set.
9850090|NCT03330236|Experimental|Study arm|"All patients in the study arm will receive the anesthetic care guided by the SedLine EEG Brain Function Monitor in addition to the conventional monitors. In addition to the conventional/standard interventions of anesthetic care, an additional intervention related to this trial is the anesthetic depth management via the titration of the propofol and remifentanil infusion rates to maintain SEF and PSI in the targeted ranges based on the SedLine EEG monitoring."
9850091|NCT03330236|No Intervention|Control arm|All patients in the control arm will receive the anesthetic care guided by the conventional monitors only. Patients in the control arm will be monitored using the SedLine EEG Brain Function Monitor; however, the screen of this monitor will be covered by an opaque cloth and blinded to the anesthesia team.
9850092|NCT03330262|Experimental|BALCAP prosthesis, then Control|Participants performed exercises daily at home wearing the BALCAP prosthesis for 6 weeks. After 6 weeks, participants performed the control condition (the same exercises without the BALCAP). Tests were performed before and after each 6-week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
9850093|NCT03330262|Experimental|Control, then BALCAP prosthesis|Participants performed exercises daily at home for 6 weeks without wearing the BALCAP prosthesis (control), followed by another 6 weeks of the same exercises with the BALCAP prosthesis (intervention). Tests were performed before and after each 6 week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
9850094|NCT03330275|Experimental|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
9850095|NCT03330275|Experimental|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
9850096|NCT03330275|Experimental|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
9850097|NCT03330275|Experimental|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
9850098|NCT03330275|Experimental|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
9850099|NCT03330275|Experimental|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
9850100|NCT03330288||Participants with Stage I-III Knee osteoarthritis (KOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
9850101|NCT03330288||Participants with Stage I-III Hip osteoarthritis (HOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
9850102|NCT03330457|Experimental|Cohort 1 Bertrixaban/Andexanet|Andexanet 800 mg, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
9850103|NCT03330457|Experimental|Cohort 1 Bertrixaban/Placebo|Placebo, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
9850104|NCT03330457|Experimental|Cohort 2 Bertrixaban/Andexanet|andexanet 800 mg administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
9850105|NCT03330457|Experimental|Cohort 2 Bertrixaban/Placebo|Placebo administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
9923150|NCT00847496|Active Comparator|2|BIOBRANE(R)
9923151|NCT00847548|Experimental|combined treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
9850106|NCT03330834|Experimental|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.
9850107|NCT03331042|Experimental|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
9850108|NCT03331042|Experimental|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
9850109|NCT03331042|Experimental|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
9850110|NCT03331042|Experimental|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
9850111|NCT03331185|Active Comparator|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
9850112|NCT03331185|Experimental|L-PRF Clot|Socket filled with L-PRF Clot
9850113|NCT03331315|Active Comparator|Ketorolac|Patients receiving scheduled ketorolac postoperatively
9850114|NCT03331315|Experimental|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
9850115|NCT03331666|Active Comparator|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.
9850116|NCT03331666|Placebo Comparator|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.
9850117|NCT03331835|Experimental|Brodalumab|Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
9850118|NCT03331835|Active Comparator|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)>~> Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
9850119|NCT03331965|Experimental|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
9850120|NCT03331965|Placebo Comparator|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
9850121|NCT03332160|Active Comparator|Standard of Care|Standard home lymphedema care
9850122|NCT03332160|Experimental|Flexitouch head and neck lymphedema treatment system|Daily treatment with Flexitouch® pneumatic compression device for treatment of head and neck lymphedema and standard home lymphedema care
9850123|NCT03332212|Experimental|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
9850124|NCT03332212|Experimental|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
9850125|NCT03332459|Experimental|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
9850126|NCT03332459|Placebo Comparator|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
9923152|NCT00847548|Active Comparator|control condition|Cognitive behavioral therapy addressing partner violence
9923153|NCT00847574|Experimental|Moderate-fat|35% of calories from fat
9850127|NCT03332628|Other|Microneedle application|This is the only study arm, which all participants complete. Nine sites on the upper arm will be identified. Baseline measurements of transepidermal water loss, electrical resistance, hydration, and color will be made at each site. The 9 sites will be divided into clusters of 3 sites each. The first cluster will have small microneedle patches applied to at each site. This will only occur on the first study day. Transepidermal water loss and electrical resistance are re-measured immediately after microneedle application. The sites will be covered with a small patch secured with medical tape. The second cluster of sites will not receive microneedle application but will just be covered with patches. The last cluster of sites will not have microneedle application or patches. Electrical resistance will be re-measured at all sites for 4 days after microneedle application. Measurements from the 2nd and 3rd cluster of sites allow each subject to serve as their own control in data analysis.
9850128|NCT03332771|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
9850129|NCT03332771|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
9850130|NCT03332771|Active Comparator|Glimepiride|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
9850131|NCT03332771|Placebo Comparator|Placebo|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
9850132|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 1)|TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
9850133|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 2)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
9850134|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 3)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
9850135|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 4)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
9850136|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
9850137|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 6)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
9850138|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 1-2)|TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
9850139|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 3; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.
9850140|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 3)|TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.
9850141|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 4; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.
9850142|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 5)|TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
9850143|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 6)|TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
9850144|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 7)|TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
9850145|NCT03332784|Placebo Comparator|Part 2: Placebo (Cohort 5-7)|TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
9850146|NCT03333109|Experimental|AMG334 70 mg|AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
9850147|NCT03333109|Experimental|AMG334 140 mg|AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
9850148|NCT03333109|Placebo Comparator|Placebo|Two pre-filled syringes containing placebo identical in appearance to erenumab
9850149|NCT03333317|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
9850150|NCT03333317|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
9923154|NCT00847574|Experimental|Lower-fat|20% of calories from fat
9850151|NCT03333317|Placebo Comparator|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
9850152|NCT03333577|Experimental|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
9850153|NCT03333876|Active Comparator|Nasal Dilator|Nasal dilators have been used to treat snoring and sleep apnea. Many studies focus on external nasal dilators like Breathe Right Strips. These interventions largely were not effective in treating OSA. However, there is some evidence to suggest internal to the nose dilators (like Mute) may work to reduce snoring
9850154|NCT03333876|Active Comparator|Mandibular Advancement|Mandibular advancement devices have shown to be effective, but not necessarily acceptable to primary snorers.
9850155|NCT03333876|Active Comparator|Positional Therapy|Studies have shown mixed results for positional therapy as a whole. Braver and Block reported that foam wedges used to keep patients in a lateral position were not effective in reducing snoring in 20 individuals.
9850156|NCT03333941||RES (Regenerative Epithelial Suspension)|
9850157|NCT03334175|Experimental|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
9850158|NCT03334175|No Intervention|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
9850159|NCT03334188|Other|Control|Patients will receive care-as-usual. The only study procedures patients will be exposed to will be a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment.This arm will include 'No Intervention--Usual Care'.
9850160|NCT03334188|Active Comparator|Intervention|Patients will receive the patient engagement video and HFrEF medication checklist by email one week prior to their next clinic appointment after enrollment. Patients in the intervention arm will also receive a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment. This arm will include the 'Intervention :Behavioral: Patient engagement materials.'
9850161|NCT03334214|Experimental|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
9850162|NCT03334214|Placebo Comparator|Placebo (sterile saline 0.9)|Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks
9850163|NCT03334396|Experimental|4 milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
9850164|NCT03334396|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
9850165|NCT03334396|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
9850166|NCT03334396|Placebo Comparator|Placebo|Placebo administered orally once daily.
9850167|NCT03334396|Experimental|4 mg Baricitinib Maximum Extended Enrollment Cohort|4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
9850168|NCT03334396|Experimental|2 mg Baricitinib Maximum Extended Enrollment Cohort|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
9850169|NCT03334396|Experimental|1 mg Baricitinib Maximum Extended Enrollment Cohort|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
9850170|NCT03334396|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo administered orally once daily.
9850171|NCT03334422|Experimental|4 Milligram (mg) Baricitinib|4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
9850172|NCT03334422|Experimental|2mg Baricitinib|2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
9850173|NCT03334422|Experimental|1mg Baricitinib|1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
9850174|NCT03334422|Placebo Comparator|Placebo|Placebo administered orally once daily.
9850175|NCT03334448|Experimental|LY900014-U200|Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
9850176|NCT03334448|Experimental|LY900014-U100|Single SC dose of 15 U LY900014 U-100 in two of four study periods
9850177|NCT03334630|Experimental|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter
9850178|NCT03334630|Active Comparator|TactiCath Quartz Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter
9850179|NCT03334695|Experimental|Group 1: Ad26.RSV.preF|Participants will receive single intramuscular injection of 1*10^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.
9923155|NCT00847600|Experimental|1 Pregnenolone|50 mg/day
9850180|NCT03334695|Placebo Comparator|Group 2: Placebo|Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
9850181|NCT03334721|Experimental|Gabapentin, Then Placebo Oral Capsule|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
9850182|NCT03334721|Experimental|Placebo Oral Capsule, Then Gabapentin|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of Gabapentin medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
9850183|NCT03334734|Experimental|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
9850184|NCT03334734|Experimental|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
9850185|NCT03334734|Experimental|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
9850186|NCT03334734|Active Comparator|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
9850187|NCT03334747|Experimental|Treatment arm 1: KAE609 10 mg Single Dose (SD)|KAE609 10 mg once daily (QD) for 1 day
9850188|NCT03334747|Experimental|Treatment arm 2:KAE609 25 mg SD|KAE609 25 mg once daily (QD) for 1 day
9850189|NCT03334747|Experimental|Treatment arm 3:KAE609 10 mg 3 Days|KAE609 10 mg (QD) for 3 days
9850190|NCT03334747|Experimental|Treatment arm 4:KAE609 50 mg SD|KAE609 50 mg once daily (QD) for 1 day
9850191|NCT03334747|Experimental|Treatment arm 5:KAE609 25 mg 3 Days|KAE609 25 mg once daily (QD) for 3 days
9850192|NCT03334747|Experimental|Treatment arm 6:KAE609 75 mg SD|KAE609 75 mg once daily (QD) for 1 day
9850193|NCT03334747|Experimental|Treatment arm 7:KAE609 50 mg 3 Days|KAE609 50 mg once daily (QD) for 3 days
9850194|NCT03334747|Experimental|Treatment arm 8: KAE609 150 mg SD|KAE609 150 mg once daily (QD) for 1 day
9850195|NCT03334747|Active Comparator|Treatment arm 9: Coartem Control|Coartem® control
9850196|NCT03334812|Experimental|LNA043 20mg/ml|LNA043 20mg/ml single dose
9850197|NCT03334812|Placebo Comparator|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
9850198|NCT03334812|Experimental|LNA043 40mg/ml|LNA043 40mg/ml single dose
9850199|NCT03334812|Placebo Comparator|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
9850200|NCT03334825|Experimental|Enhanced housing placement assistance|
9850201|NCT03334825|Active Comparator|Standard housing placement assistance|
9850202|NCT03334903|No Intervention|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
9850203|NCT03334903|Experimental|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
9850204|NCT03335150|Active Comparator|Supportive Care|Support Group for PD-MCI
9850205|NCT03335150|Experimental|CogSMART-PD|Cognitive Rehabilitation for PD-MCI
9850206|NCT03335254|Experimental|Dose-Escalating Arm 1|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~Assigned Intervention: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850207|NCT03335254|Experimental|Dose-Escalating Arm 2|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 633 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850208|NCT03335254|Experimental|Dose-Escalating Arm 3|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850209|NCT03335254|Experimental|Dose-Escalating Arm 4|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9923156|NCT00847600|Placebo Comparator|2 Placebo|1 caps.
9923157|NCT00847639|Experimental|Lenalidomide|Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
9850210|NCT03335254|Experimental|Dose-Escalating Arm 5|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9517024|NCT03310151|Experimental|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
9850211|NCT03335254|Experimental|Dose-Escalating Arm 6|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850212|NCT03335254|Experimental|Dose-Escalating Arm 7|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850213|NCT03335254|Experimental|Dose-Escalating Arm 8|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850214|NCT03335254|Experimental|Dose-Escalating Arm 9|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850215|NCT03335254|Experimental|Dose-Escalating Arm 10|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 443 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850216|NCT03335254|Experimental|Dose-Escalating Arm 11|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850217|NCT03335254|Experimental|Dose-Escalating Arm 12|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850218|NCT03335254|Experimental|Dose-Escalating Arm 13|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9923158|NCT00847678|Experimental|1|Mycograb + Amphotericin B + 5 flucytosine
9923159|NCT00847678|Placebo Comparator|2|Placebo + Amphotericin B + 5 flucytosine
9923160|NCT00847678|Experimental|3|Mycograb + Amphotericin B
9923161|NCT00847691||Sarcoma|patients with biopsy or excision of sarcoma (suspected or diagnosed)
9923162|NCT00847717|Experimental|1|IIb preserving neck dissection
9923163|NCT00847717|Other|2|Conventional neck dissection
9793956|NCT01490632|Experimental|Baricitinib 8 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
9793957|NCT01490632|Experimental|Baricitinib 10 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
9517025|NCT03310151|No Intervention|control|Follows usual care
9793958|NCT01490697|Experimental|Mifepristone plus d-Cycloserine (DCS)|DCS 100 mg capsule orally followed by mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
9793959|NCT01490697|Placebo Comparator|Placebo plus Placebo|Placebo-matching DCS 100 mg capsule orally followed by placebo-matching mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
9793960|NCT01490723|Experimental|Yttrium-90 Ibritumomab + Chemo|Day -22 and -14, Rituximab 250 mg/m2 preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14, (90Y) ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.
9793961|NCT01490788|Experimental|Treatment A|1 x TNX-102 2.4 mg gelcap under fasting conditions
9793962|NCT01490788|Experimental|Treatment B|1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions
9793963|NCT01490788|Active Comparator|Treatment C|1 x TNX-102 2.4 mg gelcap under fed conditions
9793964|NCT01490814|Active Comparator|Cryoballoon ablation|
9793965|NCT01490814|Active Comparator|Radiofrequency ablation|
9793966|NCT01490840|Experimental|E-training|Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
9793967|NCT01490840|Experimental|Waiting|Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
9793968|NCT01490866|Experimental|FOLFOX/bevacizumab and Axitinib|"Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC. (FOLFOX is a combination of 5-Fluorouracil, Leucovorin and Oxaliplatin.)~All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks). After 4 cycles, maintenance axitinib will be started."
9793969|NCT01490892|Experimental|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
9793970|NCT01490918|Placebo Comparator|Acarbose placebo, Metformin, Sitagliptin|The Acarbose placebo should be changed into real Acarbose from the 16th week.
9793971|NCT01490918|Experimental|Sitagliptin, Metformin, Acarbose|Metformin, Sitagliptin, Acarbose group
9850219|NCT03335254|Experimental|Dose-Escalating Arm 14|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850220|NCT03335254|Experimental|Dose-Escalating Arm 15|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850221|NCT03335254|Experimental|Dose-Escalating Arm 16|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 253 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850222|NCT03335254|Experimental|Dose-Escalating Arm 17|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850223|NCT03335254|Experimental|Dose-Escalating Arm 18|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850224|NCT03335254|Experimental|Dose-Escalating Arm 19|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850225|NCT03335254|Experimental|Dose-Escalating Arm 20|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
9850226|NCT03335566|Experimental|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
9850227|NCT03335566|Active Comparator|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
9850228|NCT03335761|Experimental|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
9850229|NCT03335761|Experimental|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
9850230|NCT03335761|Experimental|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
9923164|NCT00847756||rAOM|Children 0-5 years of age suffering from recurrent acute otitis media and waiting for tympanostomy tube insertion.
9923165|NCT00847756||COME|Children 0-5 years of age suffering from chronic otitis media with effusion and waiting for tympanostomy tube insertion.
9923166|NCT00847756||CSOM|Children 0-5 years of age suffering from chronic suppurative otitis media and waiting for tympanostomy tube insertion. Note: Only 3 patients with CSOM were recruited and therefore not suitable for publication.
9923167|NCT00847769|Experimental|High velocity, low amplitude stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
9923168|NCT00847769|Active Comparator|Slow, mobilization stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
10207745|NCT04913116||SARS-Cov-2 positives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
9850231|NCT03335800|Experimental|Apple Heart Study App|
10207746|NCT04913116||SARS-CoV-2 negatives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
10207747|NCT04908475|Experimental|Arm 1: Risankizumab|Participants will receive risankizumab Dose A in Period A and Period B.
10207748|NCT04908475|Experimental|Arm 2a: Apremilast/Risankizumab|Participants will receive apremilast Dose A in Period A followed by risankizumab Dose A in Period B.
10207749|NCT04908475|Active Comparator|Arm 2b: Apremilast|Participants will receive apremilast Dose A in Period A and Period B. Non-responders at Week 28 and Week 40 will be offered to receive risankizumab Dose A.
10207750|NCT04908358|Sham Comparator|Sham preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
10207751|NCT04908358|Sham Comparator|Sham preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by Sham Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
10207752|NCT04908358|Experimental|Stimulation preceded by cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
10207753|NCT04908358|Experimental|Stimulation preceded by cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
9793972|NCT01490918|Other|Metformin placebo, Sitagliptin, Acarbose|The Metformin placebo should be changed into real Metformin from the 16th week.
9793973|NCT01490931|Experimental|Ketorolac nasal spray 31.5 mg|Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
9793974|NCT01491022|Experimental|Ampyra|Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
9793975|NCT01491022|Sham Comparator|Placebo|placebo 4 weeks followed by Ampyra 10 mg po BID
9793976|NCT01491035|Experimental|Cohort CC1, 6 children|
9793977|NCT01491035|Experimental|Cohort CC2, 6 children|
9793978|NCT01491035|Experimental|Cohort CC3, 6 children|
9793979|NCT01491035|Experimental|Cohort CC4, 6 children|
9793980|NCT01491035|Experimental|Cohort AC1, 6 adolescents|
9793981|NCT01491035|Experimental|Cohort AC2, 6 adolescents|
9793982|NCT01491035|Experimental|Cohort AC3, 6 adolescents|
9793983|NCT01491035|Experimental|Cohort AC4, 6 adolescents|
9793984|NCT01491113|Experimental|Group A: Normal renal function|"Subjects who have normal renal function (CLcr >80 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose"
9793985|NCT01491113|Experimental|Group B: Mild renal impairment|"Patients who have mild renal impairment (50<CLcr <80 mL/min/1.73 m^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose"
9793986|NCT01491113|Experimental|Group C: Moderate renal impairment|"Patients who have moderate renal impairment (30<CLcr < 50 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose"
9793987|NCT01491113|Experimental|Group D: Severe renal impairment|"Patients who have severe renal impairment (CLcr <30 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose"
9793988|NCT01491113|Experimental|Group E: End-stage renal disease|"Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3.~The 4-h Hemodialysis are scheduled as follows:~Dialysis: 44 h to 48 h after the first dose (Day 3)~Dialysis: 92 h to 96 h after the first dose (Day 5)~Dialysis: 140 h after the first dose (Day 7)~Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44*, 44.25*, 44.5*, 45*, 46*, 47*, 48*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing.~49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis.~*Inflow blood, outflow blood, and dialysate fluid will be collected."
9793989|NCT01491178||Patients with NVAF|
9793990|NCT01491490|Active Comparator|GWP42003 : GWP42004 (40:1)|
9793991|NCT01491490|Placebo Comparator|Placebo|
9793992|NCT01491607|Experimental|BioThrax (0.5 mL, on days 0, 14, and 28)|
9793993|NCT01491633|Experimental|Dasatinib|Dasatinib 140 mg by mouth each day
9793994|NCT01491672|Experimental|RAD001|Participants, received RAD001 10 mg orally once daily.
9850232|NCT03336450|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
9850233|NCT03336502|Experimental|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
9850234|NCT03336645|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
9850235|NCT03336853|Experimental|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
9850236|NCT03336853|Placebo Comparator|Control|5 cc of sterile saline water for 20 sec
9850237|NCT03337139|Active Comparator|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
9850238|NCT03337139|Experimental|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
9850239|NCT03337152|Other|1A: primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
9850240|NCT03337152|Other|1B: chloroquine + primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
9850241|NCT03337308|Experimental|BA 180 mg + EZE 10 mg FDC|Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
9850242|NCT03337308|Experimental|BA 180 mg|Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
9850243|NCT03337308|Active Comparator|EZE 10 mg|Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
9850244|NCT03337308|Placebo Comparator|Placebos|Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
9850245|NCT03337477|Experimental|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
9850246|NCT03337477|Placebo Comparator|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
9850247|NCT03337490|Experimental|Ivermectin 0.5% Lotion|Ivermectin 0.5% lotion, topical, 117g, single dose
9850248|NCT03337490|Active Comparator|Ivermectin 0.5% Lotion [SKLICE]|Sklice 0.5% Lotion, topical, 117g, single dose
9850249|NCT03337490|Placebo Comparator|Placebo 0% Lotion|0% lotion, 117g, single dose
9850250|NCT03337542|Other|Treatment arm description|Subjects will receive maintenance dosing with AR101. Maintenance doses are provided in sachets, where each sachet contains 300 mg of peanut protein. Subjects are to ingest 300 mg orally once a day during maintenance.
9850251|NCT03338010|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre [mmol/L]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
9850252|NCT03338010|Active Comparator|Lantus®|Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.
9850253|NCT03338023|Experimental|LY2963016 + Insulin Lispro|Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
9850254|NCT03338023|Active Comparator|Lantus® + Insulin Lispro|Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
9850255|NCT03338036|Experimental|Heart Rate Variability/Neurofeedback|Participants in this arm of the study will receive HRV biofeedback and neurofeedback. HRV biofeedback will occur twice daily, using an android device and application. Additionally, three times per week they will have one-hour long neurofeedback sessions.
9850256|NCT03338036|No Intervention|Post-Concussed Control Group|Age-matched, previously concussed individuals that have completed the same concussion rehabilitation program (Brain Ex 90) will be recruited for this arm.
9850257|NCT03338036|No Intervention|Non-Concussed Control Group|Age-matched individuals who have not been diagnosed with a concussion in the previous two years
9850258|NCT03338062|Experimental|Theragnostic SBRT Planning|The theragnostic SBRT plan using the HIDA scan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
9850259|NCT03338062|No Intervention|Standard SBRT Planning|The standard SBRT plan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
9850260|NCT03338296|Experimental|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
9850261|NCT03338296|Placebo Comparator|Placebo|Participants will receive placebo QD for up to 52 weeks.
9850262|NCT03338400|Active Comparator|Dexamethasone|Patients in the Dexamethasone arm will be administered the drug at the time of induction.
9850263|NCT03338400|Placebo Comparator|Normal Saline|The placebo arm patients will receive normal saline at the time of induction.
9850264|NCT03338556|Active Comparator|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
9850265|NCT03338556|Placebo Comparator|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
9850266|NCT03338556|Active Comparator|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
9850267|NCT03338556|Placebo Comparator|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
9850268|NCT03338569|Sham Comparator|Placebo|Placebo designed to mimic intervention
9850269|NCT03338569|Active Comparator|Intervention|6000 mg per day Vitamin C supplement
9850270|NCT03338673|Experimental|Dual Therapy First|Participants receive 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises (BrainHQ), followed by 10 hours of computerized cognitive exercises alone
9850271|NCT03338673|Experimental|Mono Therapy First|Participants complete 10 hours of computerized cognitive exercises (BrainHQ) alone, followed by 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises
9850272|NCT03338686|Active Comparator|Free Gingival Graft|Free Gingival Graft (FGG)
9850273|NCT03338686|Experimental|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft (CTG) followed by Laser Gingivoplasty
9850274|NCT03338803||Patients with a written prescription for linagliptin|
9850275|NCT03338816|Experimental|Givosiran/Givosiran|Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
9850276|NCT03338816|Placebo Comparator|Placebo/Givosiran|Matching placebo (normal saline [0.9% NaCl]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.
9850277|NCT03338855|Active Comparator|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
9850278|NCT03338855|Placebo Comparator|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
9850279|NCT03338894|Other|Yoga group|Each subject will serve as their own control
9850280|NCT03338998|Experimental|BAF312|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally
9850281|NCT03338998|Placebo Comparator|Placebo|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally - matching placebo
9850282|NCT03339206|Experimental|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
9850283|NCT03339206|Experimental|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
9850284|NCT03339206|Other|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
9850285|NCT03339219|Experimental|Cabozantinib 60 mg|Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.
9850286|NCT03339297|Experimental|Defibrotide Prophylaxis|Standard of Care Immunoprophylaxis + Defibrotide
9850287|NCT03339297|Active Comparator|Standard of Care|Standard of Care Immunoprophylaxis Alone
9850288|NCT03339453|Experimental|Nasal Glucagon|Single dose of Nasal Glucagon.
9850289|NCT03339453|Active Comparator|Intramuscular Glucagon|Single intramuscular (IM) dose of Glucagon.
9850290|NCT03339570||Orthopedic treatment|This is the prospective cohort which includes 20 patients presenting three-four proximal humeral fracture who were treated non-surgically and followed prospectively during 12 months.
9850291|NCT03339583|Experimental|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
9850292|NCT03339583|Experimental|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
9850293|NCT03339713|Experimental|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
9850294|NCT03339713|Experimental|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.
9850295|NCT03339726|Experimental|New Formulation Phenylephrine HCl|
9850296|NCT03339726|Active Comparator|Marketed Phenylephrine HCl|
9850297|NCT03339726|Placebo Comparator|Placebo|
9850298|NCT03339999|Placebo Comparator|Placebo|Placebo-matching AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
9850299|NCT03339999|Experimental|AGN-242428 Higher Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
9850300|NCT03339999|Experimental|AGN-242428 Medium Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
9850301|NCT03339999|Experimental|AGN-242428 Lower Dose|AGN-242428 capsule and placebo-matching AGN-242428 capsule, oral administration, once-daily for up to 12 weeks.
9850302|NCT03340025|Experimental|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
9850303|NCT03340025|Placebo Comparator|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
9850304|NCT03340337|Experimental|Neo-Russian Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
9850305|NCT03340337|Experimental|Aussie Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
9850306|NCT03340337|Experimental|RBS Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
9850307|NCT03340350|Experimental|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
9850308|NCT03340415|No Intervention|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
9850309|NCT03340415|Experimental|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
9850310|NCT03340428|Experimental|Transition Community Adherence Club (TCAC)|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
9850311|NCT03340428|No Intervention|Care as usual (CAU)|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
9850312|NCT03340610|Other|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
9850313|NCT03340805|Experimental|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
9850314|NCT03340805|Active Comparator|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
9850315|NCT03340883|Experimental|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
9850316|NCT03340961|Experimental|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
9850317|NCT03340961|Experimental|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
9850318|NCT03340961|Experimental|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
9850319|NCT03340961|Placebo Comparator|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
9850320|NCT03341273|Experimental|Azithromycin|500 mg of Azithromycin (2 capsules of 250 mg) administered orally as a single dose on Day 1, followed by 250 mg capsule of Azithromycin administered orally once daily for 4 days (Day 2 through Day 5). N=337
9850321|NCT03341273|Placebo Comparator|Placebo|2 capsules of Azithromycin placebo administered orally as a single dose on Day 1, followed by 1 capsule of Azithromycin placebo administered orally once daily for 4 days (Day 2 through Day 5). N=337
9850322|NCT03341299|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
9850323|NCT03341299|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
9850324|NCT03341299|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
9850325|NCT03341299|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
9850326|NCT03341312|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
9850327|NCT03341312|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
9850328|NCT03341312|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
9850329|NCT03341312|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
9850330|NCT03341507|Experimental|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a McIntosh laryngoscope will be performed.
9850331|NCT03341533|Experimental|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
9850332|NCT03341533|Active Comparator|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
9850333|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
9850334|NCT03341637|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
9850335|NCT03341637|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
9850336|NCT03341728|Experimental|Intervention, then Control|Older adults will walk during exposure to optical flow perturbations
9850337|NCT03341728|Experimental|Control, then Intervention|Older adults will walk normally (without optical flow perturbations)
9850338|NCT03341910|Experimental|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
9850339|NCT03341910|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
9850340|NCT03341910|Placebo Comparator|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
9850341|NCT03341910|Placebo Comparator|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
9850342|NCT03341923|Other|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
9850343|NCT03341923|Other|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
9850344|NCT03341975|Experimental|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
9850345|NCT03341975|No Intervention|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
9850346|NCT03342404|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days
9850347|NCT03342404|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
9850348|NCT03342469|Experimental|ADHD- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
9850349|NCT03342469|Experimental|ADHD - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
9850350|NCT03342469|Experimental|Controls- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
9850351|NCT03342469|Experimental|Controls - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
9850352|NCT03342560|Experimental|30 Patients with known liver biopsy results|Patients with chronic liver disease with known biopsy results
9850353|NCT03342690||Eplerenone|Patients with CHF receiving Selara (eplerenone)
9850354|NCT03342898|Experimental|Group 1: YF-17D + Placebo/TDV/TDV|YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
9850355|NCT03342898|Experimental|Group 2: TDV + Placebo/TDV/YF-17D|TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
9850356|NCT03342898|Experimental|Group 3: TDV + YF-17D/TDV/Placebo|TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
9850357|NCT03342963|Experimental|ASC-01 in period 1, Aripiprazole and sertraline in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting."
9850358|NCT03342963|Experimental|Aripiprazole and sertraline in period 1, ASC-01 in period 2|"At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
9850359|NCT03342963|Experimental|Fasting in period 1, After breakfast in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast."
9850360|NCT03342963|Experimental|After breakfast in period 1, Fasting in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
9850361|NCT03343067|Experimental|Arm A|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24"
9850362|NCT03343067|Experimental|Arm C|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
9850363|NCT03343067|Experimental|Arm D|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
9850364|NCT03343067|Experimental|Arm B|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24."
9850365|NCT03343080|Experimental|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the buffered lidocaine arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
9850366|NCT03343080|Placebo Comparator|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the air arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
9850367|NCT03343639|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
9850368|NCT03343639|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
9850369|NCT03343704|Experimental|Group A - patients with uncontrolled or life-threatening bleeding|
9850370|NCT03343704|Experimental|Group B - patients not bleeding but requiring emergency surgery or invasive procedure|
9850371|NCT03344172|Experimental|PGHA|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab
9850372|NCT03344172|Experimental|PGH|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
9850373|NCT03344510|Experimental|Kinetic anesthesia device, then no intervention|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device, then will receive an injection without the kinetic anesthesia device intervention
9850374|NCT03344510|Experimental|No intervention, then kinetic anesthesia device|In this arm of the crossover study, participants will receive lidocaine injection without the kinetic anesthesia device intervention, then will receive an injection in conjunction with the kinetic anesthesia device.
9850375|NCT03344640|Experimental|secukinumab|AIN457 300 mg subcutaneously (s.c.) for 12 weeks
9517026|NCT03310138|Active Comparator|Dorsolateral Prefrontal Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left dorsolateral prefrontal cortex (10Hz, 110% of resting motor threshold) using a MagVenture MagPro B60 coil."
9850376|NCT03344640|Placebo Comparator|Placebo|Placebo subcutaneously for 12 weeks
9850377|NCT03344861|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
9850378|NCT03345108|Experimental|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
9850379|NCT03345108|Experimental|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
9850380|NCT03345108|Other|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
9850381|NCT03345160|Experimental|Peanut Flour: Open label peanut OIT|This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study
9850382|NCT03345394|Active Comparator|Standard Treatment|12 weeks of standard treatment offered by Unidade Recomeço Helvétia treatment program
9850383|NCT03345394|Experimental|Contingency Management|12 weeks of standard treatment offered at Unidade Recomeço Helvétia treatment program associated with Contingency Management
9850384|NCT03345407|Placebo Comparator|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
9850385|NCT03345407|Experimental|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
9850386|NCT03345407|Experimental|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
9850387|NCT03345407|Experimental|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
9850388|NCT03345407|Experimental|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
9850389|NCT03345407|Experimental|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
9850390|NCT03345472|Experimental|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
9850391|NCT03345914|Experimental|Group 1|Participants will receive dupilumab, dosing regimen 1
9850392|NCT03345914|Experimental|Group 2|Participants will receive dupilumab, dosing regimen 2
9850393|NCT03345914|Experimental|Group 3|Participants will receive matching placebo
9850394|NCT03345979|Experimental|Treatment Group 1|Regular injections
9850395|NCT03345979|Active Comparator|Treatment Group 2|Regular injections
9850396|NCT03346057|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
9850397|NCT03346057|Experimental|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
9850398|NCT03346057|Experimental|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
9850399|NCT03346057|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
9850400|NCT03346070|Experimental|Sugammadex 2 mg/kg ABW|Following administration of NMBA, participants received a single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
9850401|NCT03346070|Experimental|Sugammadex 2 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 2 mg/kg as determined utilizing participant IBW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
9850402|NCT03346070|Experimental|Sugammadex 4 mg/kg ABW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant ABW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
9850403|NCT03346070|Experimental|Sugammadex 4 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant IBW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
9850404|NCT03346070|Active Comparator|Neostigmine/Glycopyrrolate|Following administration of NMBA, participants received a single i.v. bolus containing both Neostigmine (50 µg/kg; up to 5 mg maximum dose) and Glycopyrrolate (10 µg/kg; up to 1 mg maximum dose) as determined utilizing participant ABW. Neostigmine/Glycopyrrolate was used for reversal of moderate NMB. Active comparator treatment for reversal for deep NMB was not available.
10207754|NCT04908358|Other|cross-over Stimulation-Sham|Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham One time RAVANS versus one time Sham Two weeks wash-out
9850405|NCT03346161|Experimental|Arm 1: BREASTChoice (Decision Tool)|Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.
9850406|NCT03346161|Active Comparator|Arm 2: Enhanced Usual Care (Surgical Care Booklet)|"Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet Breast Reconstruction. They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
9850407|NCT03346759|Experimental|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
9850408|NCT03346759|Experimental|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
9850409|NCT03346850|Active Comparator|nasogastric tube (NGT) feeding|
9850410|NCT03346850|Active Comparator|nasoduodenal tube (NDT) feeding|
9850411|NCT03346902|Placebo Comparator|Placebo|"Drug: : Placebo: 0.9% Sodium Chloride Injection~Injection of Placebo into area of scarring (forehead)"
9850412|NCT03346902|Active Comparator|EB001|Drug: EB-001 Injection of EB-001 into area of scarring (forehead)
9850413|NCT03347188|Experimental|Fremanezumab|Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters [mL] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
9850414|NCT03347188|Placebo Comparator|Placebo|Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
9850415|NCT03347279|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
9850416|NCT03347279|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
10207755|NCT04908358|Other|cross-over Sham-Stimulation|Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) One time RAVANS versus one time Sham Two weeks wash-out
10207756|NCT04902898|Other|Circumcision|Adult patients treated with circumcision
10207757|NCT04902898|Active Comparator|Circumcision with device|Adult patients treated with sterile single-use circular stapling device CIRCCURERII (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
10207758|NCT04900714|Experimental|Decremental PEEP|Every participant will be exposed to a stepwise decremental PEEP.
10207759|NCT04883138|Experimental|5 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 5 mg GIGA-2050 per kg BW
10207760|NCT04883138|Experimental|15 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 15 mg GIGA-2050 per kg BW, or as determined by SRC review
10207761|NCT04883138|Experimental|50 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 50 mg GIGA-2050 per kg BW, or as determined by SRC review
10207762|NCT04879368|Experimental|RegoNivo|"Participants in the RegoNivo arm will;~self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and;~receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion.~After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days."
10207763|NCT04879368|Active Comparator|Standard of Care|"Participants in the control arm will receive investigator choice chemotherapy with any of the following agents~taxane (paclitaxel or docetaxel)~irinotecan or~oral trifluridine/tipiracil (TAS102)~All treatment groups will receive Best Supportive Care (BSC)."
10207764|NCT04867473|Experimental|Teleyoga|Lyme disease participants will attend home-based yoga sessions using HIPAA-compliant telehealth software and devices and complete pain inventory questionnaires pre and post-treatment
10207765|NCT04854746|Active Comparator|Cohort 1 Low Dose Active|VXA-GI.1-NN tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log10
10207766|NCT04854746|Active Comparator|Cohort 3 High Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 1x10Log11
10207767|NCT04854746|Placebo Comparator|Cohort 1 Low Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
10207768|NCT04854746|Placebo Comparator|Cohort 3 High Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
9850417|NCT03347695|Experimental|A new operation|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
9850418|NCT03347695|Other|A new operation (Selected pilot study)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
9850419|NCT03348683|Experimental|Propranolol|2mg of IV push
9850420|NCT03348683|Placebo Comparator|Placebo|an equivalent quantity in milliliters of normal saline
9850421|NCT03349034|Experimental|Test Group|Local Ropivicaine Infusion
9850422|NCT03349034|Placebo Comparator|Control Group|Local Saline Infusion
9850423|NCT03349060|Experimental|PF-04965842 100 mg|
9850424|NCT03349060|Experimental|PF-04965842 200 mg|
9850425|NCT03349060|Placebo Comparator|Placebo|
9850426|NCT03349099|Active Comparator|Cook Flexor|ureteral access sheath
9850427|NCT03349099|Active Comparator|Boston Scientific Navigator HD|ureteral access sheath
9850428|NCT03349333|Experimental|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
9850429|NCT03349437|Experimental|Vitabreath Device|The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
9850430|NCT03349437|Active Comparator|Pursed Lip Breathing|Pursed lip breathing is a commonly used technique by COPD patients. That involves exhaling through tightly pressed lips and inhaling through the nose with the mouth closed.
9850431|NCT03349515|Active Comparator|Group A - povidone-iodine ophthalmic solution.|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.
9850432|NCT03349515|Active Comparator|Group B - ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution, with the right eye to receive the drops first.
9850433|NCT03349567|Experimental|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
9850434|NCT03349567|No Intervention|Control|The control arm will consist of providers who do not receive the intervention.
9850435|NCT03349632|Other|DD T2/Oasys 1-Day|Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized
9850436|NCT03349632|Other|DD T2/MyDay|Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
9850437|NCT03349632|Other|DD T2/Moist|Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
9850438|NCT03349710|Experimental|Arm A|Cohort 1
9850439|NCT03349710|Experimental|Arm B|Cohort 1
9850440|NCT03349710|Experimental|Arm C|Cohort 2
9850441|NCT03349710|Experimental|Arm D|Cohort 2
9850442|NCT03349892|Experimental|Stereotactic Ablation Treatment Arm|This is a single-arm, non-blinded study.
9850443|NCT03350217|Active Comparator|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
9850444|NCT03350217|Active Comparator|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
9850445|NCT03350256|Experimental|Microdosing group|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
9850446|NCT03350542|Experimental|SYNERGY 48 mm|SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
9850447|NCT03350672|Experimental|Cohort 1a|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
9850448|NCT03350672|Experimental|Cohort 1b|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
10207769|NCT04854746|Active Comparator|Cohort 2 Medium Dose Active|VXA-GI.1 tableted vaccine group, 2 doses (Day 1 and Day 29) at 3x10Log11
10207770|NCT04854746|Placebo Comparator|Cohort 2 Medium Dose Placebo|Placebo tablets matching in number and appearance to active vaccine doses.
10207771|NCT04839978|Experimental|Preventive Intervention|Students in schools assigned to the preventive intervention study condition will take part in the Connect school-based prevention program and the community-level Communities Mobilizing for Change and Action (CMCA) intervention.
10207772|NCT04839978|No Intervention|Delayed Intervention Control Group|Students in schools assigned to the control group will not receive the Connect and CMCA interventions. Schools in the control group will receive usual school and community prevention and be offered the trial's programs after this three-year study ends.
10207773|NCT04832568||Delirium is determined by CAM or CAM-ICU score|
10207774|NCT04832568||No delirium is determined by CAM or CAM-ICU score|
10213510|NCT03872778|Experimental|Phase I Cohort I|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 50 mCi (1.85 GBq) cycle 1, 60% Estimated Cumulative Dose (ECD) for cycles 2-4, q6w"
10213511|NCT03872778|Experimental|Phase I Cohort II|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 60% ECD for 3 cycles (q6w)"
10213512|NCT03872778|Experimental|Phase I Cohort III|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 80% ECD for 3 cycles (q6w)"
9850449|NCT03350672|Active Comparator|Cohort 2|"Age 18 or older at the time of signed informed consent~Willing and able to independently provide written informed consent~Last viral load < 20 copies/mL within the last four weeks of screening~Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months~Undetectable viral load, as defined by < 50 copies/ml, for at least 6 months"
9923169|NCT00847769|Sham Comparator|Passive positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
9923170|NCT00847782|Other|Blood draw (Group 1)|"Normocholesterolemic Subjects~Normal Healthy Volunteers"
9923171|NCT00847782|Other|Blood draw (Group 2)|Hypercholesterolemic Subjects
9923172|NCT00847782|Other|Blood draw (Group 3)|Hypercholesterolemic Subjects with Statin Treatment
9923173|NCT00847795|Experimental|1|5ng Avotermin
9923174|NCT00847795|Experimental|2|50ng Avotermin
9923175|NCT00847795|Experimental|3|100ng Avotermin
9923176|NCT00847795|Placebo Comparator|4|Placebo
9923177|NCT00847795|No Intervention|5|Standard Care
9923178|NCT00847821||Bazedoxifene 10 mg/CE 0.625 mg|
9923179|NCT00847821||Bazedoxifene 20 mg/CE 0.625 mg|
9923180|NCT00847821||Bazedoxifene 40 mg/CE 0.625 mg|
9923181|NCT00847821||Bazedoxifene 10 mg/CE 0.45 mg|
9923182|NCT00847821||Bazedoxifene 20 mg/CE 0.45 mg|
9923183|NCT00847821||Bazedoxifene 40 mg/CE 0.45 mg|
9923184|NCT00847821||Raloxifene 60 mg|
9923185|NCT00847821||Placebo|
9923186|NCT00847834|Experimental|1|"4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:~If DBP<85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg~If DBP≥85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet of Irbesartan 150mg"
9923187|NCT00847834|Experimental|2|"2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:~If DBP<85mmHg: 4 weeks of of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg~If DBP≥85mmHg: 4 weeks of two tablets Irbesartan 150mg / Hydrochlorothiazide 12.5mg"
9923188|NCT00847847|Other|2|control subjects with muscle biopsy
9923189|NCT00847847|Other|1|ALS patients with muscle biopsy
9923190|NCT00847860|Experimental|1|Cilostazol
9923191|NCT00847860|Active Comparator|2|Asprin
9923192|NCT00847873|Experimental|Combined SU/IPV treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
9923193|NCT00847873|Active Comparator|control condition|Cognitive behavioral therapy addressing substance abuse
9923194|NCT00847899|Active Comparator|1|AR9281
9923195|NCT00847899|Active Comparator|2|AR9281
9923196|NCT00847899|Placebo Comparator|3|Placebo
9923197|NCT00847899|Placebo Comparator|4|Placebo
9923198|NCT00847925|Other|A|50ng Avotermin/100ul
9923199|NCT00847925|Other|B|20ng Avotermin/100ul
9923200|NCT00847925|Other|C|5ng Avotermin/100ul
9923201|NCT00847925|Other|D|100ng Avotermin/100ul
9923202|NCT00847925|Other|E|500ng Avotermin/100ul
9923203|NCT00847925|Other|F|0.25ng Avotermin/100ul
9923204|NCT00847925|Other|G|1ng Avotermin/100ul
9923205|NCT00847925|Other|H|20ng Avotermin/100ul
9923206|NCT00847925|Other|I|50ng Avotermin/100ul
9923207|NCT00847951|Other|Renal perfusion in Neonates|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys.
9923208|NCT00847964|Experimental|Algisyl-LVR implants|Algisyl-LVR implants to the left ventricular wall
9923209|NCT00847977|Active Comparator|1|Heafusine - Physiologic serum
9923210|NCT00847977|Experimental|2|Isofundine - Tetraspan
9923211|NCT00847990||Pregnant women|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will receive the fetal FISH and/or karyotype results from the procedure.
9923212|NCT00848003|Active Comparator|1. Active|"Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)~Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days"
9923213|NCT00848003|Placebo Comparator|2. Placebo|Strawberry flavored yogurt
9935099|NCT04203199|Sham Comparator|Sham rTMS to the dlPFC using H1 Coil|One session of sham high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (sham rTMS- 20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
9935100|NCT04193397|Other|Physical exercise|To study the effects of resistance training program on physical-functional fitness, muscle mass and strength, endothelial function, blood pressure, biochemical markers of cardiovascular risk and bone metabolism, density and microstructure and quality of life of post-bariatric patients (Study 1). To compare bone and muscle changes in post-bariatric patients with non-bariatric controls, as well as to correlate these health indicators with the time of surgical procedure and weight loss (Study 2)
9935101|NCT04193371|Experimental|active acupuncture + lifestyle management|Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.
9850450|NCT03350724|Experimental|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
9850451|NCT03350724|Active Comparator|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
10207775|NCT04808245|Experimental|Standard patient cohort|"All fifteen patients will receive in total 11 doses of H3K27M peptide vaccine starting with standard radiotherapy (RT) and 14 doses of the human anti-PD-L1 antibody Atezolizumab/ Tecentriq® (every three weeks, q3w) starting four weeks after completion of RT. The first 3 vaccines will be given bi-weekly (q2w) in combination with RT. One dose of vaccination will be given at the beginning of recovery (RE) period following RT. Vaccines 5-11 (q6w) will be initiated with Atezolizumab after completion of RE. The H3K27M peptide vaccine is administered in combination with topical Imiquimod that serves as an adjuvant.~For safety reasons, the first three patients will be enrolled sequentially: Each patient will receive the first vaccination at the earliest 28 days after the previous patient has received the first vaccination."
10207776|NCT04804046|Experimental|Synbiotic|Bifidobacterium longum spp. longum R0175, Bifidobacterium animalis spp. Lafti B94, Bifidobacterium bifidum R0071 at 3x10^9 CFU/d plus resistant starch type 2, arabinoxylan, and galactooligosaccharide at 24 g/d will serve as the treatment.
9850452|NCT03350919|Experimental|Training in the blind field|Training in the blind field using software
9850453|NCT03350919|Experimental|Training in the intact field|Training in the intact field using software
9850454|NCT03351101|Experimental|Senofilcon C|Senofilcon C Contact Lens
9850455|NCT03351101|Experimental|Samfilcon A|Samfilcon A Contact Lens
9850456|NCT03351114|Experimental|Crisaborole 2% ointment|Crisaborole 2% ointment applied to affected skin twice per day.
9850457|NCT03351231|Experimental|Dose Escalation|BMS-986242 administered in combination with Nivolumab
9850458|NCT03351231|Experimental|Dose Expansion|BMS-986242 administered in combination with Nivolumab
9850459|NCT03351335|Experimental|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
9850460|NCT03351335|Experimental|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
9850461|NCT03351335|Experimental|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
9850462|NCT03351478|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
9850463|NCT03351478|Active Comparator|Empagliflozin 25 mg|Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
9850464|NCT03351478|Placebo Comparator|Placebo|Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
9850465|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part A)|Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.
9850466|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part A)|Single i.v. bolus of sugammadex at 4 mg/kg.
9850467|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part B)|Single i.v. bolus of sugammadex at 2 mg/kg.
10207777|NCT04804046|Placebo Comparator|Digestible Maltodextrin|Digestible maltodextrin will serve as the placebo.
9850468|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part B)|Single i.v. bolus of sugammadex at 4 mg/kg.
9850469|NCT03351608|Active Comparator|Neostigmine (Part B)|Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
9850470|NCT03351699|Experimental|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
9850471|NCT03351699|Experimental|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
10207778|NCT04776447|Experimental|Experimental: Atezolizumab plus induction chemotherapy plus CT-radiotherapy|"Induction Treatment:~Atezolizumab: 1200mg, IV infusion Carboplatin: AUC5, IV infusion Paclitaxel: 200 mg/m2 The treatment will start within 1-5 days from enrollment. The treatment will be 3 cycles administered at 21-day intervals.~Concurrent Chemotherapy (CT)-Radiotherapy Treatment:~Chemotherapy and radiotherapy treatment will be at the discretion of the principal investigator of each site. It is recommended to use as concurrent chemotherapy treatment a platinum based doublet.~After the 3rd cycle of the induction treatment, concurrent treatment will start, 1st concurrent cycle will be administered from day 1 of cycle 3 of induction treatment.~Concurrent chest radiotherapy will be administered starting at day 1 of cycle 1 of concurrent chemo-radiotherapy.~Maintenance with Atezolizumab:~Atezolizumab: 1200mg, IV infusion After the 3rd cycle of the concurrent treatment, Atezolizumab maintenance treatment will start from day 1 of cycle 6 and will be administered for 12 months."
9850472|NCT03351699|Experimental|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
9923214|NCT00848029|Experimental|1|
9923215|NCT00848055|Experimental|arm 1|AbGn168 cohort 1
10207779|NCT04739865|Experimental|Psilocybin|25mg Psilocybin
10207780|NCT04738279|Experimental|Soft Launch|The study will conduct a soft launch on the first five HF patients enrolled to finetune process and protocol.
10207781|NCT04738279|Experimental|Calibration|After learning from the soft launch and updating the protocol, the study will continue to enroll 15 HF patients for calibration purposes
10207782|NCT04736511|Other|Healthy volunteers|Handball players
10207783|NCT04727931||Newly diagnosed epileptic patients|Newly diagnosed epileptic patients who have never be treated by antiepileptic drugs and who have no psychiatric (mental illness) and/or evolutive neurological history and for minor patients the non-opposition of the parental authority holders.
9850473|NCT03351699|Experimental|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
9850474|NCT03351699|Experimental|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
9850475|NCT03351738|Placebo Comparator|Placebo|Participants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
9850476|NCT03351738|Experimental|MEDI5884 50 mg|Participants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
9850477|NCT03351738|Experimental|MEDI5884 100 mg|Participants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
9850478|NCT03351738|Experimental|MEDI5884 200 mg|Participants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
9850479|NCT03351738|Experimental|MEDI5884 350 mg|Participants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
9850480|NCT03351738|Experimental|MEDI5884 500 mg|Participants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.
9850481|NCT03351933|Experimental|Immune Globulin (Human) GamaSTAN|The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
9850482|NCT03352245|Experimental|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
9850483|NCT03352245|No Intervention|Control Group|Usual care group will receive standard of care management from their Oncologist.
9850484|NCT03352323|Experimental|oxymetazoline cream|
9850485|NCT03352414|Experimental|Alvimopan|alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
9850486|NCT03352414|Placebo Comparator|Placebo|Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
9850487|NCT03352453|Experimental|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
9850488|NCT03352453|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections.
9850489|NCT03352609|Experimental|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
9850490|NCT03352609|Sham Comparator|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
9850491|NCT03352713|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
9850492|NCT03353220|Experimental|Arm A|Participants receive lorcaserin (Belviq) 10 mg twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive placebo twice a day for 7 days.
9850493|NCT03353220|Experimental|Arm B|Participants receive placebo twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive lorcaserin (Belviq)10 mg twice a day for 7 days.
9850494|NCT03353246|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
9850495|NCT03353740|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
9850496|NCT03353753|Active Comparator|Arm 1|150 mg QD DCC-2618
9850497|NCT03353753|Placebo Comparator|Arm 2|Placebo
9850498|NCT03354325|Active Comparator|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
9850499|NCT03354325|Experimental|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
9850500|NCT03354429|Experimental|TICAGRELOR|
9850501|NCT03354429|Placebo Comparator|TICAGRELOR PLACEBO|
9850502|NCT03354598|Experimental|Sulopenem-etzadroxil/probenecid|Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
9850503|NCT03354598|Active Comparator|Ciprofloxacin|Ciprofloxacin 250 mg PO administered twice daily for 3 days
9850504|NCT03354637|Active Comparator|ATI-50002 high dose Topical Solution|High dose active
9850505|NCT03354637|Active Comparator|ATI-50002 low dose Topical Solution|low dose active
9850506|NCT03354637|Placebo Comparator|Vehicle Topical Solution|placebo
9850507|NCT03354663|Experimental|TactiCath SE|Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
9850508|NCT03354754|Experimental|LYS228|IV infusion every 6 hours for at least 5 days
9850509|NCT03354754|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
9850510|NCT03355326|Experimental|Glycerin Suppository Group|
9850511|NCT03355326|No Intervention|Non-suppository Group|
9850512|NCT03355742|Experimental|XIENCE|XIENCE + Short duration (1 month) of DAPT
9850513|NCT03355820|Experimental|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.
9850514|NCT03356145|Experimental|12 mL arm|"Intervention:~Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
9850515|NCT03356145|Active Comparator|20 mL arm|"Intervention:~Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
9850516|NCT03356977|Experimental|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
9850517|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
9850518|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
9850519|NCT03357393|Active Comparator|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
9850520|NCT03357393|Experimental|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
9850521|NCT03357393|Experimental|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
9850522|NCT03357471|Experimental|Certolizumab Pegol Q2W injection by e-Device|Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
9850523|NCT03357471|Experimental|Certolizumab Pegol Q4W injection by e-Device|Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
9850524|NCT03357614|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
9850525|NCT03357614|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
9850526|NCT03357731|Experimental|Placebo/BMS-986231/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
9850527|NCT03357731|Experimental|Placebo/NTG/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
9850528|NCT03357731|Experimental|NTG/Placebo/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
9850529|NCT03357731|Experimental|NTG/BMS-986231/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
9850530|NCT03357731|Experimental|BMS-986231/Placebo/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
9850531|NCT03357731|Experimental|BMS-986231/NTG/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
9850532|NCT03358147|Experimental|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
9850533|NCT03358147|Experimental|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
9850534|NCT03358147|Experimental|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
9850535|NCT03358147|Placebo Comparator|Placebo MDI|Taken as 2 inhalations BID
9850536|NCT03358147|Other|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
9850537|NCT03358238|Placebo Comparator|No weekly review|Individuals will not review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
9850538|NCT03358238|Experimental|Weekly review|Individuals will review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
9850539|NCT03358251|Other|SRP+Pocket-X Gel, split-mouth|This arm is a split-mouth arm, i.e., participants will receive conventional treatment for periodontitis (scaling and root planing) for the entire mouth, and, in addition, will receive experimental treatment (Pocket-X Gel) for periodontal pockets present in one/two mouth segments (quadrants), while the contralateral quadrants will serve as control and will not undergo any further intervention.
9850540|NCT03358290|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
9850541|NCT03358290|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
9850542|NCT03358290|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
9850543|NCT03358290|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
9850544|NCT03358290|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
9850545|NCT03358329|Experimental|S8 Sinus Implant|corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)
9850546|NCT03358355|Experimental|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
9850547|NCT03358407|Experimental|Part A: Cohort 1|Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
9850548|NCT03358407|Experimental|Part A: Cohort 2 fasting|Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
9850549|NCT03358407|Experimental|Part A: Cohort 2 fed|In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
9850550|NCT03358407|Experimental|Part B|Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
9850551|NCT03358472|Experimental|Pembrolizumab + Epacadostat|
9850552|NCT03358472|Experimental|Pembrolizumab|
9850553|NCT03358472|Active Comparator|EXTREME|EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.
9850554|NCT03358576|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment
9850555|NCT03358576|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead
9850556|NCT03359395|Active Comparator|Alfentanil|
9517027|NCT03310138|Active Comparator|Motor Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left primary motor cortex (10Hz, 80% of resting motor threshold) using a MagVenture MagPro B60 coil."
9850557|NCT03359395|Placebo Comparator|placebo|
9850558|NCT03359473|Experimental|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
9850559|NCT03359473|Placebo Comparator|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
9850560|NCT03359473|Experimental|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
10207784|NCT04727931||Normal controls|Matched (on age, gender, socio-educationnal level and manual laterality) healthy controls who have no psychiatric (depression, mental illness) and/or neurological (stroke, traumatic brain injury, etc.) history and for minor patients the non-opposition of the parental authority holders.
9850561|NCT03359473|Placebo Comparator|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
10207785|NCT04722887|Experimental|Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg)|Participants will receive Alpha-1 15% 72 mg/kg, single weekly subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.
9850562|NCT03359590|Experimental|Sitagliptin arm|Sitagliptin 100 mg
9850563|NCT03359590|Placebo Comparator|Placebo arm|Placebo comparator
9850564|NCT03359850|Experimental|Normal hepatic function (Group 1):|To evaluate the pharmocokinetics and safety of niraparib
9850565|NCT03359850|Experimental|Moderate hepatic impairment (Group 2):|To evaluate the pharmocokinetics and safety of niraparib
9850566|NCT03359889||patients administered with PraxbindTM|
9850567|NCT03360071|Experimental|Allergen Immunotherapy Group|
9850568|NCT03360071|Placebo Comparator|Control Group|
9850569|NCT03360110|Active Comparator|Test lens|Subjects randomized to wear pair of test lens either first or second
9850570|NCT03360110|Active Comparator|stenfilcon A lens (control)|Subjects randomized to wear pair of control lens either first or second
9850571|NCT03360344|Experimental|Kinesio Tape|"Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.~A tape removal form will be provided should the participants want to remove it prior to the next visit."
9850572|NCT03360344|Sham Comparator|Control group|Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
9923216|NCT00848055|Experimental|arm 2|AbGn168 cohort 2
9923217|NCT00848055|Experimental|arm 3|AbGn168 cohort 3
9923218|NCT00848055|Experimental|arm 4|AbGn168 cohort 4
10213513|NCT03872778|Experimental|Phase I Cohort IV|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 3 cycles (q6w)"
10213514|NCT03872778|Experimental|Phase I Cohort V|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 3 cycles (q6w)"
9850573|NCT03360344|Active Comparator|Standard of Care|Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
9850574|NCT03360747|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received a subcutaneous (SC) injection of AKCEA-ANGPTL3-LRx, 20 milligrams (mg), weekly (QW) for 13-weeks of treatment period. Participants were followed up to Week 26.
9996908|NCT01504256|Experimental|catumaxomab|"this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm~[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))"
9850575|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Surgery Not Performed Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled but did not have surgery. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
9850576|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
9850577|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
9850578|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
9850579|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
9850580|NCT03361176|Active Comparator|Control|Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
9850581|NCT03361176|Experimental|w/ Triamcinolone|Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
9850582|NCT03361293|Active Comparator|Cognitive Training and Active tDCS|5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus active tDCS (also 5 sessions).
9850583|NCT03361293|Sham Comparator|Cognitive Training and Sham tDCS|"5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus sham tDCS (also 5 sessions) which consists of placebo stimulation with tDCS (ramp-up, but no actual stimulation)."
9850584|NCT03361423|Active Comparator|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
9850585|NCT03361423|Sham Comparator|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
9850586|NCT03361605|Experimental|Propofol Administration|
9850587|NCT03361917|No Intervention|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
9850588|NCT03361917|Experimental|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
9850589|NCT03362879||Participants with advanced Parkinson's disease|Participants with advanced Parkinson's disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
9850590|NCT03362944|Experimental|Active Music Therapy|
9850591|NCT03362944|Experimental|Passive Music Therapy|
9850592|NCT03362957|Experimental|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
9850593|NCT03362957|Sham Comparator|Sham Procedure|Patients will be randomized to a sham procedure.
9850594|NCT03362957|Experimental|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
9850595|NCT03363321|Experimental|PF-06741086 (Cohort 1)|
9850596|NCT03363321|Experimental|PF-06741086 (Cohort 2)|
9850597|NCT03363321|Experimental|PF-06741086 (Cohort 3)|
9850598|NCT03363321|Experimental|PF-06741086 (Cohort 4)|
9850599|NCT03363321|Experimental|PF-06741086 (Cohort 5)|
9850600|NCT03363321|Experimental|PF-06741086 (Cohort 6)|
9850601|NCT03363776|Experimental|Monotherapy|BMS-986277 administered alone
9850602|NCT03363776|Experimental|Combination Dose Escalation Therapy|BMS-986277 administered in combination with Nivolumab
9850603|NCT03363776|Experimental|Combination Expansion Therapy|BMS-986277 monotherapy with option for subsequent Nivolumab therapy
9850604|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
9850605|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen B."
9850606|NCT03363854|Experimental|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
9850607|NCT03363854|Experimental|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
9850608|NCT03363854|Placebo Comparator|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Placebo continuation SC injection regimen A."
9850609|NCT03363906|Experimental|Dulaglutide (Reference)|Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods
9850610|NCT03363906|Experimental|Dulaglutide (Test)|Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods
9850611|NCT03364023||Acute Ischemic Stroke Patients|Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device
9850612|NCT03364049|Experimental|MK-7162 25 mg +Pembrolizumab (Pembro)|Participants receive MK-7162 25 mg via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 25 mg orally QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks [Q3W]).
9850613|NCT03364049|Experimental|MK-7162 50 mg + Pembro|Participants receive MK-7162 50 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-71625 50 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
9850614|NCT03364049|Experimental|MK-7162 100 mg + Pembro|Participants receive MK-7162 100 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 100 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
9850615|NCT03364049|Experimental|MK-7162 200 mg + Pembro|Participants receive MK-7162 200 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 200 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
9850616|NCT03364192|Experimental|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
9850617|NCT03364309|Experimental|Ixekizumab 80mg Q4W|Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
9850618|NCT03364309|Experimental|Ixekizumab 80mg Q2W|Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
9850619|NCT03364309|Placebo Comparator|Placebo|Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.
9850620|NCT03364335|Placebo Comparator|Placebo|Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.
9850621|NCT03364335|Experimental|Leu Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
9850622|NCT03364335|Experimental|Leu Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
9850623|NCT03364335|Experimental|Leu Met Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
9850624|NCT03364335|Experimental|Leu Met Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
9923219|NCT00848055|Experimental|arm 5|AbGn168 cohort 5
9850625|NCT03364608|Experimental|• AS MDI 90 µg|(2 actuations of 45 µg/actuation)
9850626|NCT03364608|Experimental|• AS MDI 180 µg|(2 actuations of 90 µg/actuation)
9850627|NCT03364608|Placebo Comparator|• Placebo MDI|(2 actuations)
9850628|NCT03364608|Active Comparator|• Proventil 90 µg|(1 actuation of 90 µg/actuation)
9850629|NCT03364608|Active Comparator|• Proventil 180 µg|(2 actuations of 90 µg/actuation)
10207786|NCT04722887|Experimental|Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg)|Following treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation phase, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
10207787|NCT04722887|Experimental|Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg)|Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.
9850630|NCT03364673|Experimental|Fitness Tracker + Social Incentive Intervention|Participants will enroll with a teammate (i.e. family or friend) and collaborate together. Teams will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive a social incentive intervention.
9850631|NCT03364738|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (>) 2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be administered.
9850632|NCT03364751|Active Comparator|IQOS arm|~86 patients, switching from cigarette smoking to IQOS use.
9850633|NCT03364751|Active Comparator|Cigarette arm|~86 patients, continuing cigarette smoking.
9850634|NCT03365011|Placebo Comparator|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
9850635|NCT03365011|Experimental|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
9850636|NCT03365154|Experimental|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
9850637|NCT03365778|Active Comparator|Patient Educational Intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
9850638|NCT03365778|Placebo Comparator|Usual care group|Patients receive standard of care.
9850639|NCT03365778|Other|Ophthalmologist Educational Intervention group|General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database receive online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT).
9850640|NCT03365934|Experimental|ADHESIVE BANDAGE #1|bandage applied to wounded site.
9850641|NCT03365934|Experimental|ADHESIVE BANDAGE #2|bandage applied to wounded site.
9850642|NCT03365934|Experimental|ADHESIVE BANDAGE #3|bandage applied to wounded site
9850643|NCT03365934|Experimental|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
9850644|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
9850645|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded and no bandage applied, serving as a positive control site.
9850646|NCT03366207|Experimental|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
9850647|NCT03366298|Active Comparator|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
9850648|NCT03366298|Active Comparator|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
9850649|NCT03366298|Active Comparator|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
10207788|NCT04722887|Experimental|Cohort 2: Treatment Period 1 (Alpha-1 15%, 144 mg/kg)|Participants will receive Alpha-1 15% 144 mg/kg, single weekly SC infusion in treatment-period 1 (Single-Dose) at Week 1.
10207789|NCT04722887|Experimental|Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg)|Following treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation phase. During the single-dose data evaluation phase, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 20, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
10207790|NCT04722887|Experimental|Cohort 2: Treatment Period 2 (Alpha-1 15%, 144 mg/kg)|Following treatment period 1 and single-dose data evaluation phase, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 144 mg/kg, for 8 weekly SC infusions.
10207791|NCT04722185|Experimental|Evaluation of the Veriton SPECT/CT system|To determine if the Veriton system can achieve equal or better image quality than a standard SPECT/CT system.
10207792|NCT04722029|No Intervention|Donor|"Donors will be evaluated to determine suitability to undergo apheresis collection and their infectious disease status. Donor evaluation will include history and physical examination, laboratory tests, FDA- approved donor testing of communicable diseases (HIV, HVB, HCV, HTLV-I, II, WNV, T. pallidum, T. cruzi, and Zika virus), ABO and Rh typing, pregnancy tests, and donor serology for ADV.~Qualified donors will undergo leukapheresis. Collection will proceed for 2 hours or 2 blood volumes, whichever occurs first."
9850650|NCT03366298|Active Comparator|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
9850651|NCT03367793|Experimental|Clinical, then Metric #1, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
9850652|NCT03367793|Experimental|Clinical, then Metric #2, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
9850653|NCT03367793|Experimental|Metric #1, then Clinical, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
9850654|NCT03367793|Experimental|Metric #2, then Clinical, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
9850655|NCT03367793|Experimental|Metric #1, then Metric #2, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
9850656|NCT03367793|Experimental|Metric #2, then Metric #1, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.
9850657|NCT03368053|Experimental|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate in the PRO-HIV-002 study.
9850658|NCT03368235|Experimental|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
9850659|NCT03368235|Active Comparator|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
9850660|NCT03368807||Blinded CGM (Continuous Glucose Monitoring)|Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
9850661|NCT03368807||Unblinded CGM|Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
9850662|NCT03368859|Experimental|ABT-165 plus FOLFIRI|ABT-165 plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
9850663|NCT03368859|Active Comparator|Bevacizumab plus FOLFIRI|Bevacizumab plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
9850664|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
9850665|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
9850666|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
9850667|NCT03368937|Experimental|Tandem t:slim X2 with Control-IQ Technology|Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
9850668|NCT03369158|Experimental|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
9850669|NCT03369158|Active Comparator|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
9850670|NCT03369236|Active Comparator|Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Danicopan was administered at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then dosage was to be increased to 200 mg TID for the remainder of the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
9850671|NCT03369236|Placebo Comparator|Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Placebo was administered TID during the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
9850672|NCT03369340|Active Comparator|Product Sequence 1|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4"
9850673|NCT03369340|Active Comparator|Product Sequence 2|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4"
9850674|NCT03369340|Active Comparator|Product Sequence 3|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4"
9850675|NCT03369340|Active Comparator|Product Sequence 4|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4"
9850676|NCT03369340|Active Comparator|Product Sequence 5|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4"
9923220|NCT00848055|Experimental|arm 6|AbGn168 cohort 6
9923221|NCT00848055|Experimental|arm 7|AbGn168 cohort 7
9923222|NCT00848055|Experimental|arm 8|AbGn168 cohort 8
9850677|NCT03369340|Active Comparator|Product Sequence 6|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4"
9850678|NCT03369418|Active Comparator|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
9850679|NCT03369418|Sham Comparator|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
9850680|NCT03369704|Experimental|Omalizumab|Eligible patients randomized to this arm received omalizumab subcutaneously for 12 weeks
9850681|NCT03369704|Placebo Comparator|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 12 weeks
9850682|NCT03369756|Other|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
9850683|NCT03369951|Experimental|Minocin® IV|200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
9850684|NCT03370042|Active Comparator|Semilunar Coronally Positiones Flap + Free Gingival Graft|semilunar coronally positioned flap with free gingival graft for root coverage
9850685|NCT03370042|Sham Comparator|Semilunar Coronally Positioned Flap|semilunar coronally positioned flap alone without free gingival graft for root coverage
9850686|NCT03370289|Experimental|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
9923223|NCT00848068|Other|OD (Right Eye)|FID 114657 or OPTIVE
9923224|NCT00848068|Other|OS (Left eye)|FID 114657 or OPTIVE
10207793|NCT04722029|Experimental|Recipient|"Recipient will undergo a screening period that will include history and physical examination, laboratory tests, performance status, HLA typing and pregnancy test (if needed).~Qualified patients will receive ADV-VSTS infusion from haploidentical donors up to a maximum of 5.0 x 104 interferon gamma-negative cells/kg. All patients will be followed for laboratory and clinical response, safety, efficacy and tolerance."
9923225|NCT00848094|Other|arm 1|Arm I: tumor diameter more than 5 cm and less than 10 cm.
10207794|NCT04720963|Placebo Comparator|group P (Placebo group)|intranasal placebo 20-30min before anesthesia induction
9923226|NCT00848094|Other|arm 2|Arm II: tumor diameter no less than 10 cm.
9923227|NCT00848133|Active Comparator|mini-midvastus|
9923228|NCT00848133|Active Comparator|mini-subvastus|
9923229|NCT00848146|Experimental|NOTES-Assisted Lap Chole|These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
9923230|NCT00848159||1|Group 1 was composed of six women with a densitometric diagnosis of osteoporosis in column (DP =- 2.70 to -4.97), with an average weight of 57.5 (+6.9) kg, mean height of 1 , 4 (+ 0.07) my body mass index (BMI) of 26.1 (+1.8) Kg/m2
10207795|NCT04720963|Experimental|group R (remimazolam group)|intranasal remimazolam 20-30min before anesthesia induction
9923231|NCT00848159||2|Group 2 consists of six women with a densitometric diagnosis of osteopenia in column (DP =- 1.07 to -2.09), with an average weight of 62.1 (+9.9) kg, mean height of 1, 5 (+0.03) I BMI 25.3 (3.3) kg/m2, both compared with young adults
10207796|NCT04720963|Active Comparator|group D (Dexmedetomine group)|intranasal dexmedetomidine 20-30min before anesthesia induction
10207797|NCT04716803|Experimental|Bone marrow aspiration concentrate using the Angel System|"Bone marrow aspirate concentrate (BMAC) will be administered via injection to the knee of interest on day 14 of the study.~Bone marrow aspiration will be concentrated using the Angel System."
10207798|NCT04715542|Experimental|Stibium metallicum praeparatum 6x|Patients are treated with Stibium metallicum praeparatum 6x (subcutaneus injection), which is authorized in Switzerland and is listed by Swissmedic as an authorized anthroposophic medicinal product.
10207799|NCT04715542|Placebo Comparator|Saline subcutaneous injection|Placebo (a saline subcutaneous injection) is chosen as comparator to the treatment group.
9923232|NCT00848224|Experimental|2|
9923233|NCT00848263|Active Comparator|DVR|Volar plate
9923234|NCT00848263|Active Comparator|DNP|Dorsal nail plate
9923235|NCT00848276||1|Hypogonadal Men before and after starting testosterone replacement therapy
9923236|NCT00848276||2|Post-menopausal women before and after starting Estrogen Replacement Therapy
9923237|NCT00848289||Participants with Bladder Cancer|Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
9923238|NCT00848302|Experimental|L-arginine|Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography
9923239|NCT00848315|No Intervention|1|Usual Care that the Type 2 Diabetes Patients usually receive at the health centers.
9923240|NCT00848315|Experimental|2|Cognitive Behavioral Intervention
9923241|NCT00848341||Control|
9923242|NCT00848380||1|Patients with hypertension and hyperlipidemia and other CV risk factors
9923243|NCT00848406||1|30 individuals ≤ 40 years, who currently smoke ≥ 10 cigarettes/day and > 10 packyears
9923244|NCT00848406||2|30 individuals ≤ 40 years, who have not smoked during the last year, have never smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have < 0.5 packyear.
9923245|NCT00848406||3|30 individuals above 40 years, who currently smoke ≥ 10 cigarettes per day, and > 20 packyears.
9850687|NCT03370302|Experimental|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
9850688|NCT03370302|Experimental|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
9850689|NCT03370419|Experimental|The Pick Two to Stick To|Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
9850690|NCT03370419|Other|Usual Care|Participants receive usual care only.
9850691|NCT03370471|Experimental|Healthy Older Adults|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
9850692|NCT03370471|Experimental|Individuals with Aphasia|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
9850693|NCT03370770||patients with EGFR mutation-positive NSCLC|(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
9850694|NCT03371355|Placebo Comparator|Pooled Placebo|Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).
9850695|NCT03371355|Experimental|Cohort B: ISIS 703802, 40 mg Q4W|Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.
9850696|NCT03371355|Experimental|Cohort C: ISIS 703802, 80 mg Q4W|Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.
9850697|NCT03371355|Experimental|Cohort A: ISIS 703802, 20 mg QW|Participants received ISIS 703802, 20 mg once every week for 26 doses.
9850698|NCT03371381|Experimental|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
9850699|NCT03371381|Active Comparator|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
9850700|NCT03371459|Experimental|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
9850701|NCT03371459|Active Comparator|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
9850702|NCT03371732|Other|Groupe 1|G1 : Motivational Intervention group
9850703|NCT03371732|Other|Groupe 2|G2 : Educational advises group
9850704|NCT03371836|Other|Clobazam|open label (single treatment arm)
9850705|NCT03372083|Experimental|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing was based on subject's weight.
9850706|NCT03372096|Experimental|All patients|Patients will receive the Prostatic Artery Embolization procedure.
9850707|NCT03372369|Active Comparator|CDC Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
9850708|NCT03372369|Experimental|Patient-Centered Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.
9850709|NCT03372382|Active Comparator|ibuprofen plus acetaminophen|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
9850710|NCT03372382|Experimental|ibuprofen plus acetaminophen/hydrocodone|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
9850711|NCT03372434|Experimental|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Model ZFR00
9850712|NCT03372434|Experimental|Investigational Lens Device #2|Investigational Intraocular Lens Device #1: Model ZYR00
9850713|NCT03372434|Active Comparator|Control Device|Control TECNIS Multifocal Intraocular Lens Model ZLB00
9850714|NCT03372551|Experimental|somofilcon A 1 day test lens|Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
9850715|NCT03372551|Active Comparator|somofilcon A 1 day control lens|Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
9850716|NCT03372603|Experimental|Treatment Sequence AB|Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
9850717|NCT03372603|Experimental|Treatment Sequence BA|Subjects will receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days).
9850718|NCT03372928|Experimental|Standard EAA Dose|EAA dose provided at 0.10 g/kg body mass
9850719|NCT03372928|Experimental|High EAA Dose|EAA dose provided at 0.30 g/kg body mass
9850720|NCT03373006|Experimental|Men with Gleason Score 7 prostate cancer|Men seeking focal therapy for Gleason Score 7 prostate cancer will receive Axumin PET/CT imaging to detect metastasis which will result in exclusion from laser focal therapy.
9850721|NCT03373162|Experimental|MRI Scans Pre and Post-Botox Injection|Participants will receive MRI scans pre and post-Botox injection, including magnetic resonance spectroscopy, structural, and functional MRI.
9850722|NCT03373240|Experimental|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
9850723|NCT03373240|Placebo Comparator|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
9850724|NCT03373383|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
9850725|NCT03373383|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
9850726|NCT03373383|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
9850727|NCT03373383|Experimental|Padsevonil dosing regimen 4|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
9850728|NCT03373383|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.
10207800|NCT04713150||COVID-19 Positive During Pregnancy|Sixty mother-child dyads, who have or had a confirmed positive COVID-19 test during pregnancy, will be recruited and enrolled in this study. All women enrolled must be 18 years of age or older. Her child will go on to participate at 2-5 days of age, and again at 3-, 6-, 9-, 12- and 24-months of age.
10207801|NCT04713150||COVID-19 Negative During Pregnancy|Twenty-five mother-child dyads, who have a confirmed negative COVID-19 test during pregnancy will be recruited and enrolled in the study. Women without any SARS-CoV-2 positive test during pregnancy or any suspected COVID illness, even if not tested, will be enrolled. All women enrolled must be 18 years of age or older. Her child will go on to participate at 3-, 6-, 9-, 12- and 24-months of age.
10207802|NCT04699357|Active Comparator|Group 1|0.01% atropine
10207803|NCT04699357|Experimental|Group 2|0.04% atropine
10207804|NCT04699357|Experimental|Group 3|0.1% atropine
10207805|NCT04690192|Experimental|CNCT19 following ASCT|Participants will receive high-dose chemotherapy followed by stem-cell reinfusion, and a fixed dose of CNCT19 (2×10^6/kg) will be infused in a single-dose on day +2, +3 or +4.
10207806|NCT04679038|Experimental|combinational therapy part|SHR-1701 + famitinib
10207807|NCT04679038|Experimental|monotherapy part|famitinib
10207808|NCT04666311||Adult presumptive TB cases|Adult presumptive TB cases (age ≥18years) with one or more TB symptoms (WHO recommended four-symptom screening; cough, weight loss, night sweats, fever) of any duration.
10207809|NCT04661007|Experimental|Part 1 : tafasitimab monotherapy|Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 2 groups: Group 1 will evaluate weight-based doses of tafasitamab, and Group 2 will evaluate fixed doses of tafasitamab.
10213515|NCT03872778|Experimental|Phase I Cohort VI|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 2 cycles (q6w)"
9850729|NCT03373591|Experimental|Liposomal Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
10207810|NCT04661007|Experimental|Part 2 : tafasitamab combination therapy|tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.
9850730|NCT03373591|Active Comparator|Regular Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
9850731|NCT03373591|No Intervention|No TAP block|Patients will be randomized to receive no TAP block as a control group.
9850732|NCT03373890|Experimental|Short burst Interval Treadmill Training High Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
9850733|NCT03373890|Active Comparator|Short Burst Interval Treadmill Training Low Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks
9850734|NCT03374176|Active Comparator|AMX-MET|"AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules.~1 capsule tid during 7 days."
9850735|NCT03374176|Experimental|Clindamycin|"Clindamycin Clindamycin 300 mg + placebo. Capsules.~1 capsule tid during 7 days."
9850736|NCT03374189|Experimental|EZ Close arm|EZ close used for port-site closure.
9850737|NCT03374189|Active Comparator|Carter Thomason arm|Carter Thomason used for port-site closure.
9850738|NCT03374358|No Intervention|No intervention arm.|Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).
9850739|NCT03374358|Experimental|Raltegravir arm.|Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).
9850740|NCT03374488|Experimental|Pembrolizumab 200 mg + Epacadostat 100 mg BID|Pembrolizumab + epacadostat
9850741|NCT03374488|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
9850742|NCT03374683|Experimental|RR Digital Tool|Participants in the RR digital tool were provided with a link to the web-based intervention (https://outsideplay.ca) to complete within one week.
9850743|NCT03374683|Active Comparator|RR In-Person Workshop|Participants in the in-person workshop attended the 45-90 minute in-person workshop.
10207811|NCT04661007|Experimental|Part 3 : Dose Expansion of tafasitamab +parsaclisib|tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2
9850744|NCT03374683|Sham Comparator|Position Statement on Active Outdoor Play|Participants in the control condition were provided with a web link to the Position Statement on Active Outdoor Play, which includes information on research and recommendations for action.
9850745|NCT03374995|Experimental|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
9850746|NCT03374995|Active Comparator|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
9850747|NCT03375294|Experimental|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
10207812|NCT04660175|Experimental|Non-resistance therapy|From the 2nd to 5th day of hospitalization, once a day, 4 times of non-resistance therapy is administered. And non-resistance therapy group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
10207813|NCT04660175|Active Comparator|Oriental medicine integrated treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
10207814|NCT04651387|Experimental|Intervention group|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered"
10207815|NCT04651387|No Intervention|Control group|For the control group, the placebo will be not considered and they will follow the routine standard treatments for COVID-19.
10207816|NCT04643860||General population|Subjects, at low and high risk of SARS-Cov-2, who undergo the nasopharyngeal swab procedure for the diagnosis of SARS-CoV-2 infection will be consecutively recruited at the Clinic Laboratory of IRCCS Neuromed in Pozzilli and Diagnostica Medica Spa in Avellino, Italy.
9850748|NCT03376061|Active Comparator|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
9850749|NCT03376061|Active Comparator|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
9850750|NCT03376256|Experimental|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
9923246|NCT00848406||4|30 individuals above 40 years, who have not smoked during the last year, have never smoked for as long as a year, and have < 0.5 packyear.
10207817|NCT04638920||Exacerbators|Patients with COPD exacerbation
10207818|NCT04629651|Experimental|Captopril|"In phase I, Cohorts of 3 patients each will receive doses of captopril with a goal dose of 150mg total by mouth (PO) daily. Initial dose per patient will start at 12.5 mg daily, which will then be increased on weekly intervals as tolerated. To be administered per the intra-patient dose escalation scheme below~Phase I:~Day 0: 12.5mg/day Day 7: 12.5mg twice daily Day 14: 12.5mg three times daily Day 21: 25mg three times daily Day 28: 50mg three times daily~Phase II: The efficacy of captopril will be assessed in the Phase II portion. Captopril given at Maximum Tolerated Dose - bone marrow evaluation to be done at 6 months"
9850751|NCT03376256|Experimental|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
9850752|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
9850753|NCT03376321|Experimental|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
9850754|NCT03376321|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
9850755|NCT03376516|Experimental|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
9850756|NCT03377127|Active Comparator|Standard of Care (SOC)|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
9850757|NCT03377127|Experimental|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
9850758|NCT03377244|Experimental|HBHS|Participants in the Healthy Bodies Healthy Souls (HBHS) arm received the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) with the addition of church-level policy changes to support the individual behavioral intervention of the WORD DPP. The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
9850759|NCT03377244|Active Comparator|HBHS Policy|Participants in the HBHS Policy arm included members of churches enrolled in the HBHS study who did not receive the WORD DPP intervention (ie, these participants were exposed to only the church-level policy changes). Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
9850760|NCT03377244|Other|WORD DPP|Participants in the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) arm included participants enrolled in a separate DPP study without the church-level policy changes (ie, these participants received only the WORD DPP intervention). The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP-LI includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length.
9850761|NCT03377556|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9850762|NCT03377634|Experimental|Intervention|Participants receive the MORPH intervention.
9850763|NCT03377634|No Intervention|Control|The wait list control participants receive usual care and are offered intervention materials on completion of the study.
9850764|NCT03378076|Experimental|FX006 32 mg|Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
9850765|NCT03378076|Active Comparator|TAcs 40 mg|Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
9850766|NCT03378635|Experimental|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
9850767|NCT03378635|Placebo Comparator|Placebo|Single fixed dose (s.c.injection) of placebo
9850768|NCT03378635|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
9923247|NCT00848419|Active Comparator|Methadone|Epidural methadone bolus 4mg
9923248|NCT00848419|Active Comparator|Morphine|Epidural morphine 4mg bolus
9850769|NCT03378921|Experimental|donors feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
9850770|NCT03378921|Placebo Comparator|patients own feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
9850771|NCT03378973|Experimental|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
9850772|NCT03378973|Active Comparator|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
9850773|NCT03379259|Experimental|Phase 1A: BGB-A333 monotherapy dose escalation|
9850774|NCT03379259|Experimental|Phase 2A: BGB-A333 monotherapy dose expansion|
9850775|NCT03379259|Experimental|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
9850776|NCT03379259|Experimental|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
9850777|NCT03379376|Experimental|Supportive Care (eMMB)|Participants receive a self-directed 20-minute eMMB video and are instructed to practice eMMB at least once before surgery and daily for 2 weeks after surgery. Participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible.
9850778|NCT03379506|Experimental|EBR/GZR|Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.
9850779|NCT03379545|Other|3D MR and 3D CT Imaging|All shoulder arthroplasty candidates with glenohumeral osteoarthritis will be receiving both 3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR) imaging.
9850780|NCT03379662|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
9850781|NCT03379662|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
9850782|NCT03379740|Experimental|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
9850783|NCT03379740|Experimental|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
9850784|NCT03379753|Experimental|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
9850785|NCT03379753|No Intervention|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
9850786|NCT03380000|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
9850787|NCT03380000|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
9850788|NCT03380026|Experimental|Valchlor 0.016% Topical Gel|0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
9850789|NCT03380026|Active Comparator|Valchlor plus Triamcinolone|0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
9850790|NCT03380091|Experimental|Metformin|Metformin 1000 mg PO bid
9850791|NCT03380091|Experimental|Vitamin D (Cholecalciferol)|Cholecalciferol 5,000 IU PO daily
9850792|NCT03380390|Experimental|Oxymetazoline + Energy-Based Therapy|Participants will receive energy-based therapy (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.
9850793|NCT03380429|Experimental|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
9850794|NCT03380429|Experimental|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
9850795|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
9850796|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
9850797|NCT03380429|Active Comparator|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
9850798|NCT03380572|Experimental|Senhance Cholecystectomy|Cholecystectomy operation performed using Senhance robotic system
9850799|NCT03380572|Active Comparator|Laparoscopic Cholecystectomy|Cholecystectomy operation performed using standard laparoscopic instruments
9850800|NCT03380624|Experimental|Refresh Optive, then Refresh Optive MEGA-3|"Participants first utilized one drop of Refresh Optive in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements.~."
9850801|NCT03380624|Experimental|Refresh Optive MEGA-3, then Refresh Optive|Participants first utilized one drop of Refresh Optive MEGA-3 in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive before taking lipid layer thickness measurements.
9850802|NCT03380780|Experimental|Emicizumab|
9850803|NCT03380845|Active Comparator|Fraxel Restore on one side of the face|"Fraxel Restore on one side of the face~Fraxel Restore: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
9850804|NCT03380845|Active Comparator|Fractora on the other side of the face|"Fractora on the other side of the face~Fractora: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
9850805|NCT03381196|Experimental|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
9850806|NCT03381196|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
9850807|NCT03381248|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
9850808|NCT03381248|Active Comparator|Hyaluronic Acid Injection|Hyaluronic acid injections will be administered to study subjects' knees to reduce knee pain
9850809|NCT03381339|Experimental|Powered toothbrush intervention|Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
9850810|NCT03381339|No Intervention|Manual toothbrush|Subjects will be provided a manual toothbrush as the control group and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
9850811|NCT03381742|Experimental|ticagrelor 45mg bidpo.|To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
9850812|NCT03381742|Experimental|ticagrelor 90mg qdpo.|To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
9850813|NCT03381742|Active Comparator|ticagrelor 90mg bidpo.|To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
9850814|NCT03381742|Active Comparator|clopidogrel 75mg qdpo.|To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
9850815|NCT03381989|Experimental|Single arm: open-label treatment|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
9850816|NCT03382262|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
9850817|NCT03382262|Active Comparator|TAcs 40 mg|Single intra-articular (IA) injection of TAcs 40 mg
9850818|NCT03382418|Experimental|Group 1: gp145 C.6980 (high dose)|Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
9850819|NCT03382418|Experimental|Group 2: gp145 C.6980 (low dose)|Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
9850820|NCT03382418|Placebo Comparator|Group 3: Placebo|Participants will receive placebo at Day 0 and Months 2 and 6.
9850821|NCT03382509|Experimental|Single Dose Group|
9850822|NCT03382509|Experimental|Multiple Dose Group|
9850823|NCT03382821|Active Comparator|Transforaminal ESI with dexamethasone|Group 1: Transforaminal cervical ESI with dexamethasone sodium phosphate
9850824|NCT03382821|Active Comparator|Transforaminal catheter-targeted ESI with triamcinolone|Group 2: Catheter-targeted cervical ESI with triamcinolone acetonide
9850825|NCT03382847|Experimental|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
9850826|NCT03382899|Experimental|Pegilodecakin + Pembrolizumab|"Participants received pegilodecakin subcutaneously (SQ) at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Pembrolizumab administered as an intravenous (IV) infusion at 200 mg on Day 1 of a 21-day cycle."
9850827|NCT03382899|Active Comparator|Pembrolizumab|Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle.
9850828|NCT03382912|Experimental|Pegilodecakin+Nivolumab|"Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
9850829|NCT03382912|Active Comparator|Nivolumab|Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
9850830|NCT03383146|Placebo Comparator|Placebo|Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
9850831|NCT03383146|Experimental|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
9850832|NCT03383198|Active Comparator|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
9850833|NCT03383198|Active Comparator|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
9850834|NCT03383523|Experimental|Part 1a - treatment A|5 mg emodepside LSF, fasted
9850835|NCT03383523|Experimental|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
9850836|NCT03383523|Experimental|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
9850837|NCT03383523|Experimental|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
9850838|NCT03383523|Experimental|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
9850839|NCT03383523|Experimental|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
9850840|NCT03383523|Experimental|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
9850841|NCT03383588|Active Comparator|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
9850842|NCT03383588|Active Comparator|bupivacaine 0.25% + epinephrine|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
9850843|NCT03383588|Placebo Comparator|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
9850844|NCT03383614|Experimental|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
9850845|NCT03383614|Experimental|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
9850846|NCT03383614|Experimental|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
9850847|NCT03383627|Experimental|Continuous glucose monitoring|"If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.~There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.~Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
9923249|NCT00848419|Active Comparator|Fentanyl|Epidural fentanyl 200 microgram bolus
9850848|NCT03383757|Experimental|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
9850849|NCT03383783|Other|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
9850850|NCT03383783|Other|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
9850851|NCT03383783|Other|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
9850852|NCT03383783|Other|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
9850853|NCT03383887|Placebo Comparator|Placebo|Placebo capsule 30 minutes before sleep
9850854|NCT03383887|Active Comparator|DAW1033D|DAW1033D capsule 30 minutes before sleep
9850855|NCT03384173|Experimental|NIRS monitoring|These infants will be monitored with NIRS
9850856|NCT03384316|Experimental|1/Arm 1-Dose De-Escalation|Dose De-Escalation
9850857|NCT03384316|Experimental|2/Arm 2 - Dose Expansion|Dose Expansion
9850858|NCT03384329|Experimental|Resveratrol Pill|
9850859|NCT03384329|Placebo Comparator|Placebo|
9850860|NCT03384693|Experimental|Prophylactic Defibrotide|6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.
9850861|NCT03384745|Experimental|M1095 (Sonelokimab) 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
9850862|NCT03384745|Experimental|M1095 (Sonelokimab) 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
9850863|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
9850864|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
9850865|NCT03384745|Placebo Comparator|Placebo / M1095 (Sonelokimab) 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
9850866|NCT03384745|Active Comparator|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
9850867|NCT03384940|Experimental|DS-8201a Cohort A|Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
9850868|NCT03384940|Experimental|DS-8201a Cohort B|Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
9850869|NCT03384940|Experimental|DS-8201a Cohort C|Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks
9850870|NCT03384953|Experimental|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
9850871|NCT03384953|Experimental|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
10207819|NCT04626024|Experimental|All Subjects Enrolled (stop taking TKI)|Patients with a diagnosis of Philadelphia chromosome- or BCR-ABL1-positive CML (as determined by cytogenetics, FISH, or PCR), prior evidence of a quantifiable BCR-ABL1 transcript by RT-PCR, and whom have been taking TKI for > 36 months with a current status of complete molecular remission (CMR). TKI cessation begins within 7 days of study registration. Patients undergo BCR-ABL1 test every month in 24 months.
10207820|NCT04624620|Experimental|Pilot|Participants will participate in a 16 week, culinary intensive study that will consist of 2 hour virtual classes taught by a chef, a dietitian, and a health coach that focus on diet, culinary competency, daily physical activity, mindfulness and support for behavior change.
9850872|NCT03384966|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
9850873|NCT03384966|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
10207821|NCT04616963|Other|FTC 200 mg / TDF 300 mg and FTC 200 mg / TAF 25 mg|"Phase I: Participants will continue or initiate F/TDF for PrEP for a minimum 12-week lead-in period prior to switching to F/TAF.~Phase II: Participants will be switched to study-provided F/TAF for PrEP until 48 weeks after initiation. Participants will receive study treatment for the duration of the study unless they meet criteria for discontinuation."
10207822|NCT04613297|Other|COVID-19 uninfected patients|Patient with negative PCR result
10207823|NCT04613297|Other|non-hospitalized COVID-19 infected patients|Patient with positive PCR result who does not require hospitalization for COVID-19
9850874|NCT03384966|Placebo Comparator|Placebo|Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
9850875|NCT03386032|Experimental|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
9850876|NCT03386032|Sham Comparator|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
9850877|NCT03386032|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
9923250|NCT00848419|Placebo Comparator|Saline|Epidural saline bolus
9850878|NCT03386110|Experimental|Couples Health Project (CHP)|The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
9850879|NCT03386110|Active Comparator|Education|The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
9850880|NCT03386344|Placebo Comparator|Placebo|Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
9850881|NCT03386344|Experimental|Sotagliflozin 200 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
9850882|NCT03386344|Experimental|Sotagliflozin 400 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
9850883|NCT03386435|Experimental|RIPC|intervention: RIPC groups receive remote ischaemic preconditioning after anaesthesia induction and before surgery started.
9850884|NCT03386435|No Intervention|Control|In the control group, the same maneuver was applied but without cuff inflation.
9850885|NCT03386448|Placebo Comparator|control|Participants will receive placebo medication
9850886|NCT03386448|Experimental|Active|participants will receive active medications scopolamine and naltrexone
9850887|NCT03386474|Experimental|Brolucizumab|Brolucizumab 6 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8, and Week 16 or Week 20
9850888|NCT03386474|Other|Aflibercept|Aflibercept 2 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8 and Week 16 to maintain the masking of the extension trial only.
9850889|NCT03386994||Idiopathic Pulmonary Fibrosis patients|all IPF patients
9850890|NCT03387020|Experimental|Treatment (ribociclib, everolimus)|Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.
10207824|NCT04613297|Other|hospitalized COVID-19 infected patients|Patient with positive PCR who require hospitalization for COVID-19
10207825|NCT04608812|Experimental|Direct Infusion of OS2966|OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery
10207826|NCT04602559|Experimental|MOBIDERM Panty group|"MOBIDERM Panty group :~All patients will wear the Panty MOBIDERM device for 12 weeks, day and night recommended. A removable pad is also recommended to be worn additionnaly to the panty."
10207827|NCT04590781|Experimental|Part A: XmAb18087 Monotherapy|Part A, will enroll subjects with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.
10207828|NCT04590781|Experimental|Part B: XmAb18087 + pembrolizumab|Part B, will enroll subjects with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.
10207829|NCT04590781|Experimental|Part C: XmAb18087 monotherapy|Part C will enroll subjects with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.
10207830|NCT04590521|Experimental|Intervention|A standard 3-dose schedule (0, 2 and 6 months) of licensed HPV vaccine (Gardasil®, Merck) will be administered to all participants intramuscularly.
10207831|NCT04589208|Experimental|Ketamine|ketamine
10207832|NCT04577638|Experimental|Nivolumab and accelerated IMRT|
10207833|NCT04576923|Experimental|Liver Incytes|Patients with known or suspected Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) will be scanned with Liver Incytes.
10207834|NCT04576897|Experimental|Liver Incytes|Patients with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplantation will be scanned with Liver Incytes.
10207835|NCT04567082||Cancer group|
10207836|NCT04567082||Control group|
10207837|NCT04567056||Cancer group|Patients with verified head and neck squamous cell carcinomas
10207838|NCT04567056||Control group|Matched control group without active or earlier cancer and a normal ENT examination.
10207839|NCT04561557|Experimental|CAR T cells therapy，Dose level 1: 0.5 × 10^6 CAR-T cells/Kg|"The tolerability and safety of CT103A cells will be assessed in an initial dose of 0.5×10^6 CAR-T cells/Kg and three subjects will be enrolled firstly. If no dose-limiting toxicity (DLT) occurs and at least one subject benefits from the treatment, there will be two options for the investigator based on the available data: 1) three more subjects will be enrolled in the 0.5 × 10^6 CAR-T cells/Kg group and DLT will be evaluated in a total of six subjects; 2) another three subjects will be treated with 1 × 10^6 CAR-T cells/Kg instead of 0.5 × 10^6 CAR-T cells/Kg.~If DLT occurs in one of the first three subjects, three more subjects will be enrolled in this cohort to reach the total subjects of six."
10207840|NCT04561557|Experimental|CAR T cells therapy，Dose level 2: 1 × 10^6 CAR-T cells/Kg|If neither DLT nor efficacy is shown in the first three subjects, the dose of CAR-T cells will be increased to 1 × 106 CAR-T cells/kg to assess DLT.
10207841|NCT04561557|Experimental|CAR T cells therapy，Dose level 3: 0.25 × 10^6 CAR-T cells/Kg|If DLT occurs in two subjects, whether to test the safety and efficacy in 0.25 × 10^6 CAR-T cells/kg group will be determined by the investigator based on the initial data of efficacy, PK and PD.
9850891|NCT03387033|Experimental|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
9850892|NCT03387046|Experimental|D-aspartate + IFN beta-1a + Methylprednisolone|Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
9850893|NCT03387046|Placebo Comparator|Placebo + IFN beta-1a + Methylprednisolone|Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
9850894|NCT03387267|Other|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
9923251|NCT00848432|Experimental|1|Optimal therapeutic doses of risperidone continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months in clinically stable schizophrenia patients
9923252|NCT00848432|Experimental|2|Optimal therapeutic doses of risperidone continued for 26 weeks followed by a 50% dose reduction for at least another 6 months in clinically stable schizophrenia patients
9923253|NCT00848432|Experimental|3|Optimal therapeutic doses of risperidone continued for at least 1 year in clinically stable schizophrenia patients
9923254|NCT00848445|Experimental|APP and VRR on|APP and VRR turned on at 2 week visit
9923255|NCT00848445|Active Comparator|APP and VRR off|APP and VRR turned off
9923256|NCT00848458|Experimental|Azelaic Acid Iontophoresis|
9923257|NCT00848458|Active Comparator|Azelaic acid topical|
9923258|NCT00848471|Experimental|1|Quark RMR calorimeter (Cosmed)
9923259|NCT00848471|Active Comparator|2|Deltatrac II (GE health Care Clinical Systems)
9923260|NCT00848562|Experimental|Nicorandil|
9923261|NCT00848575||Group 1 - Device|The principal Investigator and sub-investigators of this study will identify potential participants that attend the gynecologic oncology or gynecology clinics of UAMS. These subjects will have been scheduled for diagnostic or therapeutic laparoscopy. Based on the Inclusion Criteria and Exclusion Criteria of this study, women who are eligible for the study will be approached to participate.
9923262|NCT00848588||1|Full and part-time 9-1-1 call takers employed at Ambulance Communication Centres in the Canadian provinces of Ontario, Nova Scotia, New Brunswick, as well as the city of Montreal, Quebec, Canada.
9923263|NCT00848627||Males|60 years of age or older Smokers or history of smoking
9923264|NCT00848640|Experimental|Sorafenib|
9923265|NCT00848666|Experimental|I|Patients with tinea pedis
9923266|NCT00848679|Active Comparator|Epidural lidocaine|30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.
9923267|NCT00848679|Placebo Comparator|Epidural saline|30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant
9923268|NCT00848692|Experimental|1|Rituximab
9923269|NCT00848692|Placebo Comparator|2|Placebo (saline)
9923270|NCT00848705|Active Comparator|Measurement Only|
9923271|NCT00848705|Experimental|Internet Intervention|
9923272|NCT00848770|Active Comparator|1, 140 to 160 mmHg|Esmolol, NPS or NOR
9923273|NCT00848770|Active Comparator|2, 161 to 180 mmHg|Esmolol, NPS or NOR
9923274|NCT00848770|Active Comparator|3, 181 to 200 mmHg|Esmolol, NPS or NOR
9923275|NCT00848796|Other|Heparin|Compare two market brands of Heparin
9923276|NCT00848809||1|Slow-low efficiency daily dialysis group
9923277|NCT00848809||2|Intermittent Hemodialysis group
9923278|NCT00848835||control|all patients in the control group
9923279|NCT00848848|Active Comparator|1|
9923280|NCT00848848|Active Comparator|2|
9923281|NCT00848848|Active Comparator|3|
9923282|NCT00848848|Active Comparator|4|
10207842|NCT04557540|Experimental|Arm I (Fasting WORD)|Participants receive the Fasting WORD intermittent fasting weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
9923283|NCT00848848|Active Comparator|5|
9923284|NCT00848848|Active Comparator|6|
9923285|NCT00848848|Active Comparator|7|
9923286|NCT00848848|Active Comparator|8|
9923287|NCT00848848|Active Comparator|9|
9923288|NCT00848848|Active Comparator|10|
9923289|NCT00848861|Active Comparator|1 propofol|
9923290|NCT00848861|Active Comparator|2 midazolam plus meperidine|
9923291|NCT00848874|Experimental|PVGS User|
10207843|NCT04557540|Experimental|Arm II (The WORD)|Participants receive The WORD CER weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
9923292|NCT00848887|Experimental|1|
9923293|NCT00848900|No Intervention|Control|
9923294|NCT00848900|Experimental|Outdoor activity|Adding 1 hour outdoor time into school curricula
9923295|NCT00848913|Active Comparator|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
9923296|NCT00848913|Experimental|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of fractured limb every day during admission.
9923297|NCT00848939|Experimental|treprostinil diethanolamine|
9923298|NCT00848978|Experimental|2|The experimental group will participate in the aerobic and strength training program.
9923299|NCT00848978|No Intervention|1|The usual care group will receive general physical activity guidelines.
9850895|NCT03387319|Experimental|Racialized Stressful Event Recall|Participants in this study are recall a stressful event related to race.
9850896|NCT03387319|Experimental|Non-racialized Stressful Event Recall|Participants in this study arm recall a stressful event unrelated to race.
9850897|NCT03387462|Experimental|DOT Diary Optimization Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
9850898|NCT03387683|Placebo Comparator|placebo|placebo tablets once daily
9850899|NCT03387683|Experimental|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
9850900|NCT03388008|Active Comparator|Standard of care|Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365
9850901|NCT03388008|Experimental|Belatacept-based immunosuppression|Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365
9850902|NCT03388164|Active Comparator|Escitalopram + RT2CK17|10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
9850903|NCT03388164|Placebo Comparator|Escitalopram + Placebo|10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.
9850904|NCT03388268|Active Comparator|Oral vancomycin|125mg of oral vancomycin four times per day
9850905|NCT03388268|Placebo Comparator|Placebo|Placebo four times per day
10207844|NCT04547816|Experimental|biofeedback and tibial neuromodulation (BFB+TNM)|
10207845|NCT04547816|Experimental|BFB+TNM + pelvic floor muscles training (PFMT)|
9850906|NCT03388294|Experimental|PC followed by SR|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention pre-linguistic (PC) domain to identify their child's pre-linguistic communication bids during daily routines and respond to those bids in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on sensory reactivity bids.
10207846|NCT04547816|Experimental|BFB+TNM+PFMT+diet modification|
9850907|NCT03388294|Experimental|SR followed by PC|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention sensory reactions (SR) domain to identify their child's sensory reactions to daily activities and respond to those reactions or modify the environment in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on pre-linguistic communication bids.
9850908|NCT03388645|Experimental|Low Dose 10^6.3 PFU of RSV A2|Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
9850909|NCT03388645|Experimental|High Dose 10^7 PFU of RSV A2|Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
9850910|NCT03389308|Experimental|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
9850911|NCT03389555|Experimental|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :~Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days~Vitamin B1 (thiamine) 100mg every 6 hours x 4-days~Hydrocortisone 50mg every 6 hours x 4-days"
9850912|NCT03389555|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
9850913|NCT03389854|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
10207847|NCT04540120|Experimental|dapansutrile capsules|Subjects will receive 4 x 250mg dapansutrile capsules BID for 14 days with an initial (first) dose of 8 x 250mg (2000 mg) administered at the study site on Day 1 (Day 1 dose may be 3000 mg).
9850914|NCT03389854|Experimental|Group 2 - PTT 1x daily x 3 months|Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
9850915|NCT03389854|Experimental|Group 3 - PTT 2x daily x 3 months|Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
9935102|NCT04193371|Sham Comparator|control acupuncture + lifestyle management|Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.
10207848|NCT04540120|Placebo Comparator|placebo capsules|Subjects will receive 4 placebo capsules BID for 14 days with an initial (first) dose of 8 capsules administered at the study site on Day 1.
10207849|NCT04536116|Experimental|MRI simulation|MRI simulation with a Virtual Reality headset
10207850|NCT04536116|No Intervention|Standard medical care|Standard medical care
10207851|NCT04534049|Experimental|Intensive strength training (IST)|
10207852|NCT04534049|Experimental|Strength Endurance training (SET)|
10207853|NCT04534049|Other|Flexibility training (FT)|
10207854|NCT04528836|Experimental|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
10207855|NCT04528836|Experimental|Dose Expansion|"Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)~Cohort A: Advanced KRAS G12C NSCLC~Cohort B: Advanced KRAS G12C non-NSCLC~Cohort C: Advanced solid tumor with NF1 loss-of-function (LOF)~Cohort D: Advanced EGFR-mutant NSCLC"
10207856|NCT04528836|Experimental|Food Effect/PK Cohort|BBP-398 Monotherapy
9850916|NCT03389854|Experimental|Group 4 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
9850917|NCT03389893|Experimental|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
9850918|NCT03389893|Placebo Comparator|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
9850919|NCT03390101|Experimental|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
9850920|NCT03390101|Experimental|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
9850921|NCT03390101|Placebo Comparator|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
9850922|NCT03390114|Experimental|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
9850923|NCT03390114|No Intervention|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
9850924|NCT03390166|Active Comparator|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
9850925|NCT03390166|Active Comparator|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
9850926|NCT03390257|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
9850927|NCT03390426|Experimental|Mepivacaine Block Group|Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
9850928|NCT03390426|Placebo Comparator|Saline Sham Group|Injection of salt water (saline) above and beside the femoral artery.
9850929|NCT03390842|Experimental|TRC101|Administered once daily (QD) for 40 weeks
9850930|NCT03390842|Placebo Comparator|Placebo|Administered once daily (QD) for 40 weeks
9850931|NCT03390907|Experimental|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
9850932|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:~Heart Failure~COPD~Cancer"
9850933|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:~Heart Failure~COPD~Cancer"
9850934|NCT03391765|Experimental|M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
9850935|NCT03391765|Experimental|M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
9850936|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
10213516|NCT03872778|Experimental|Phase I Cohort VII|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 2 cycles (q6w)"
9850937|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
9850938|NCT03391986|Active Comparator|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
9850939|NCT03391986|Placebo Comparator|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
9850940|NCT03391986|No Intervention|Routine Care|This arm will receive no intervention.
9850941|NCT03392168|Experimental|Cohort 1 - ARQ-151 cream 0.5%|Single-dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s)
9850942|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.5%|ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
9850943|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
9850944|NCT03392168|Placebo Comparator|Cohort 2 - ARQ-151 vehicle cream|Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
9850945|NCT03392194|Experimental|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
9850946|NCT03392194|Active Comparator|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
9850947|NCT03392532|Other|AOHG toric, then AO toric|Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
9850948|NCT03392532|Other|AO toric, then AOHG toric|Lotrafilcon B toric contact lenses, followed by lotrafilcon B toric contact lenses with HYDRAGLYDE, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
9850949|NCT03392935|Experimental|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
9850950|NCT03392974|Experimental|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
9850951|NCT03393000|Experimental|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
9850952|NCT03393000|Active Comparator|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
9850953|NCT03393208|Experimental|First Test GIR (Fasting), Then Reference GIR (Fasting)|Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
9850954|NCT03393208|Experimental|First Reference GIR (Fasting), Then Test GIR (Fasting)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
9850955|NCT03393208|Experimental|First Test GIR (Fed), Then Reference GIR (Fed)|Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
9850956|NCT03393208|Experimental|First Reference GIR (Fed), Then Test GIR (Fed)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
9850957|NCT03393494|Experimental|Perrigo active|Test product
9850958|NCT03393494|Active Comparator|Reference active|RLD product
9850959|NCT03393494|Placebo Comparator|Perrigo placebo|placebo product
9850960|NCT03393754|Experimental|Sci-B-Vac® Hepatitis B Vaccination|Sci-B-Vac® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.
9850961|NCT03393754|Active Comparator|Engerix-B® Hepatitis B Vaccination|Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.
9850962|NCT03393806|Experimental|Participants receiving GSK3772847|Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks
9850963|NCT03393806|Placebo Comparator|Participants receiving placebo|Participants will be randomized to receive matching placebo as IV infusion
9850964|NCT03394391|Experimental|Intervention group|Daily ART-adherence SMS reminder
9850965|NCT03394391|Active Comparator|Control group|Standard adherence counselling/Patient experience group chat
9850966|NCT03394508|Placebo Comparator|Placebo|ALK diluent 0,3% human albumin'
9850967|NCT03394508|Experimental|Active treatment|Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension
9935103|NCT04177394||MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system
9935104|NCT04170153|Experimental|Part A1: Monotherapy Dose Escalation|Participants will initially receive M1774 once daily under fasting conditions. Additional schedules may be evaluated if needed.
9850968|NCT03394768||NICOM Cheetah®|Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
9850969|NCT03394768||FloTrac®|Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).
9850970|NCT03394885|Experimental|Atezolizumab, Carboplatin, Paclitaxel (+Optional Bevacizumab)|"Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by~Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by~Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing).~(Optional, Physician choice) Bevacizumab IV maintenance administered starting at cycle 5 of chemotherapy over 30-90 minutes. For those who receive bevacizumab, it will be given for a total duration of 16 cycles"
9850971|NCT03394924|Experimental|EDP-305 1 mg|Subjects will take 2 tablets once a day orally for 12 weeks
9850972|NCT03394924|Experimental|EDP-305 2.5 mg|Subjects will take 2 tablets once a day orally for 12 weeks
9850973|NCT03394924|Placebo Comparator|Placebo|Subjects will take two tablets once a day orally for 12 weeks
9850974|NCT03395353|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
9850975|NCT03395808|Other|AVE-901 50mg|IV Tramadol
9850976|NCT03395886||remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
9850977|NCT03395886||dexmedetomidine group|Eligible patients will receive a continuous infusion of dexmiditomidine starting with 0.5 μg/kg/h. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 1 μg/kg/h.
9850978|NCT03395990|Active Comparator|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
9850979|NCT03395990|Sham Comparator|saline|15 ml of 0.9% saline via a femoral nerve block technique
9850980|NCT03396432|Active Comparator|Video Laryngoscopy for endotracheal (ET) Placement|"Device:~Storz C-MAC Video Laryngoscope"
9850981|NCT03396432|Active Comparator|Direct Laryngoscopy for ET Placement|"Device:~Miller Laryngoscope"
9850982|NCT03396835|Experimental|INVSENSOR00009 Sensor|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
9850983|NCT03396913|Experimental|IPL followed by Meibomian Gland Expression (MGX)|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
9850984|NCT03396913|Sham Comparator|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
9850985|NCT03396952|Experimental|Treatment (pembrolizumab, ipilimumab, aspirin)|Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9850986|NCT03397121|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
9850987|NCT03397121|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
9850988|NCT03397394|Experimental|Rucaparib|Oral rucaparib (monotherapy)
9850989|NCT03397771|Experimental|Litoxetine oral capsules|oral experimental study medication litoxetine
9850990|NCT03397771|Placebo Comparator|Placebo oral capsules|oral comparator
9850991|NCT03398213|Experimental|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
9850992|NCT03398213|Sham Comparator|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
9850993|NCT03398213|No Intervention|Standard care|Standard conventional care for COPD exacerbation
9850994|NCT03398265|Experimental|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
9850995|NCT03398265|Other|Control|Referrals to treatment from corrections staff.
9850996|NCT03398278|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
9850997|NCT03398278|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
9850998|NCT03398330|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
9850999|NCT03398330|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
9851000|NCT03398356|Other|group A|metformin dose 3 x 500 mg
9851001|NCT03398356|Other|group B|metformin dose 3 x 1000 mg
9851002|NCT03398356|No Intervention|group C|healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study
9851003|NCT03398421|Experimental|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
9851004|NCT03398798|Active Comparator|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
9851005|NCT03398798|Active Comparator|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
9851006|NCT03398798|Active Comparator|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
9851007|NCT03398798|Active Comparator|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
9851008|NCT03398928|Experimental|Acupuncture|Acupuncture for delirium treatment
9851009|NCT03398928|No Intervention|Standard care|Standard conventional delirium care at the discretion of the department medical staff
9851010|NCT03399370|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
9851011|NCT03399370|Placebo Comparator|Saline Solution|Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.
9851012|NCT03399786|Experimental|evinacumab|
9851013|NCT03399786|Experimental|Placebo|
9851014|NCT03400033|Experimental|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
9851015|NCT03400033|Active Comparator|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
9851016|NCT03400163|Experimental|Treatment Group D:|Administered as specified on specified days
9851017|NCT03400163|Placebo Comparator|Treatment Group E:|Administered as specified on specified days
9851018|NCT03400449|Active Comparator|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
9851019|NCT03400449|Active Comparator|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
9851020|NCT03400475|Experimental|Simvastatin group (Treatment)|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
9851021|NCT03400475|Placebo Comparator|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
9851022|NCT03400579|Experimental|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
9851023|NCT03400748|Experimental|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
9851024|NCT03400787|Sham Comparator|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
9517028|NCT03310138|Placebo Comparator|Sham stimulation|"Intervention: Sham Transcranial Magnetic Stimulation~Sham Transcranial Magnetic Stimulation will be delivered to the prefrontal cortex (10Hz, 110% of resting motor threshold) using the integrated sham system on the MagVenture MagPro B60 coil."
9851025|NCT03400787|Experimental|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
9851026|NCT03400800|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
9851027|NCT03400800|Placebo Comparator|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
9851028|NCT03400852|Experimental|Period 1: MNK-1411|Participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 1
9851029|NCT03400852|Experimental|Period 1: Placebo|Participants receive placebo at a volume appropriate to body weight during Period 1
9851030|NCT03400852|Experimental|Period 2: MNK-1411|All participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 2
9851031|NCT03400956|Experimental|Vilaprisan (A1)|Vilaprisan in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
9851032|NCT03400956|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
9851033|NCT03400956|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan in treatment period 1 for 12 weeks, and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
9851034|NCT03401229|Experimental|Benralizumab 30mg SC + MF|SC - subcutaneously MF - Mometasone Furoate
9851035|NCT03401229|Placebo Comparator|Placebo SC + MF|
9851036|NCT03401450|Active Comparator|ACB within true AC with bupivacaine|The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine
9851037|NCT03401450|Active Comparator|ACB proximal to true AC with bupivacaine|The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine
9851038|NCT03401671|Experimental|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
9851039|NCT03401671|Experimental|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
9851040|NCT03402126||TPD RAMWare Download|Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.
9851041|NCT03402243|Experimental|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
9851042|NCT03402243|Experimental|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
9851043|NCT03402243|Other|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
9851044|NCT03402386|Experimental|MT-6548|
9851045|NCT03402659|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
9851046|NCT03402659|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
9851047|NCT03402750|Experimental|Meds to Beds|Patients receive medication in-hand at discharge from the hospital
9851048|NCT03402750|Active Comparator|Standard Care|Electronic prescription with patient pickup at the pharmacy
9851049|NCT03402893|Experimental|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
9851050|NCT03402932|Experimental|Auditory Amplified-Visual|This arm is designed to test the contrast between auditory amplified and visual conditions.
9851051|NCT03402932|Experimental|Auditory Amplified-Unamplified|This arm is designed to test the contrast between auditory amplified and unamplified conditions.
9851052|NCT03402932|Experimental|Auditory Unamplified-Visual|This arm is designed to test the contrast between auditory unamplified and visual conditions.
9851053|NCT03402932|Other|Younger control group|This arm is designed to validate the visual version by comparing to the auditory version in a group of younger normal hearing controls.
9851054|NCT03403036|Experimental|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
9851055|NCT03403192|Active Comparator|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
9851056|NCT03403192|Active Comparator|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
9851057|NCT03403192|Active Comparator|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
9851058|NCT03403192|Active Comparator|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
9851059|NCT03403231|Active Comparator|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
9517029|NCT03310125|Experimental|Colchicine|Oral colchicine 0.5mg
9851060|NCT03403231|Experimental|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
9851061|NCT03403231|Experimental|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
9851062|NCT03403231|Experimental|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
9851063|NCT03403231|Experimental|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
9851064|NCT03403231|Experimental|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
9851065|NCT03403231|Experimental|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
9851066|NCT03403231|Experimental|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
9851067|NCT03403231|Experimental|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
9851068|NCT03403231|Experimental|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
9851069|NCT03403231|Experimental|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
9851070|NCT03403231|Experimental|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
9517030|NCT03310125|Placebo Comparator|Placebo|Placebo oral tablet
9517031|NCT03310112|Experimental|4-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.
9851071|NCT03403231|Experimental|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
9851072|NCT03403231|Experimental|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
9851073|NCT03403231|Experimental|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
9851074|NCT03403231|Experimental|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
9851075|NCT03403374|Experimental|Evolocumab|Evolocumab 420 mg subcutaneous (SC) once monthly (QM) or every 2 weeks (Q2W; for participants on apheresis).
9851076|NCT03403400|Experimental|VRWP Group|Vestibular Rehabilitation plus Walking with Pedometer Groupd
9851077|NCT03403400|Active Comparator|VRW Group|Vestibular Rehabilitation plus Walking without Pedometer Group
9851078|NCT03403400|No Intervention|VR Group|Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
9851079|NCT03403413|Experimental|Muscle Vibration|Test feasibility of muscle vibration of tibialis anterior, rectus femoris, short head of biceps and tensor fasciae latae bilaterally during walking for 1 hour 3 times per week for 12 weeks to improve walking speed through improved coordination of hip, knee and ankle flexion.
9851080|NCT03403426|Experimental|Wingman Crossing Catheter|Use of the device to support CTO crossing
9851081|NCT03403491|Other|Sequence 1|Usual care for 2 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
9851082|NCT03403491|Other|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks.
9851083|NCT03403504|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 10 mg
9851084|NCT03403504|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 10 mg
9851085|NCT03403517|Experimental|Methylprednisolone|10 mg/kg, single preoperative infusion
9851086|NCT03403517|Active Comparator|Dexamethasone|8 mg dexamethasone, single preoperative infusion
9851087|NCT03403712|Experimental|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
9851088|NCT03403712|Active Comparator|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
9851089|NCT03403725|Experimental|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
9851090|NCT03403751|Experimental|Reltecimod 0.5 mg/kg|Single IV infusion of Reltecimod 0.5 mg/kg
9851091|NCT03403751|Placebo Comparator|Placebo|Single IV infusion of 0.9% Sodium Chloride Injection (Normal Saline)
9851092|NCT03404167|Experimental|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
9851093|NCT03404206|Experimental|Naproxen Sodium (Aleve, BAY117031)|Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
9851094|NCT03404206|Active Comparator|Ibuprofen (Advil)|Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
9851095|NCT03404206|Placebo Comparator|Placebo|Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
9851096|NCT03404219|Experimental|Intervention|Mobile intervention (i.e., Ecological momentary intervention [EMI]) addressing social motivation and social skills. Twice daily notifications sent to deliver EMI content. Social goal reminders and steps provided to support goal attainment. Social Skills Training content delivered via brief video clips.
9851097|NCT03404375|Other|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
9851098|NCT03404401|Experimental|BLI4700 Bowel Preparation|
9851099|NCT03404401|Active Comparator|FDA Approved Bowel Preparation|
9996909|NCT01504256|Active Comparator|standard therapy|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
9851100|NCT03404609|Experimental|Accelerated course of modified continuous theta-burst stimulation (cTBSmod)|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
9851101|NCT03404648|Experimental|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
9851102|NCT03404674|Experimental|Group A1: CssBA 5 ug|Participants received an intramuscular injection of 5 ug CssBA on days 1, 22, and 43.
9851103|NCT03404674|Experimental|Group A2: DmLT 100 ng|Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.
9851104|NCT03404674|Experimental|Group B: CssBA 5 ug + DmLT 100 ng|Participants received an intramuscular injection of 5 ug CssBA + 100 ng dmLT on days 1, 22, and 43.
9851105|NCT03404674|Experimental|Group C: CssBA 5 ug + DmLT 500 ng|Participants received an intramuscular injection of 5 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
9851106|NCT03404674|Experimental|Group D: CssBA 15 ug + DmLT 500 ng|Participants received an intramuscular injection of 15 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
9851107|NCT03404674|Experimental|Group E: CssBA 45 ug + DmLT 500 ng|Participants received an intramuscular injection of 45 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
9923300|NCT00848991|Active Comparator|Precedex|In the operating room routine anesthesia monitors will be placed and vital signs will be recorded continuously using data collection software. A routine propofol anesthetic will be administered to subjects randomized to the control group or a Precedex infusion with propofol for subjects randomized to the treatment group. Precedex infusion will be started after induction of general anesthesia. Vital signs (SBP, DBP, MAP) will be recorded continuously throughout the surgery. At the end of the case subjects will be extubated and the blinded observer will assess emergence from anesthesia based on hemodynamic stability and tolerance of the endotracheal tube. Videotaping of emergence will be used to assist in the evaluation of emergence of anesthesia and extubation.
9923301|NCT00848991|Active Comparator|Propofol|Propofol for emergence from anesthesia
9923302|NCT00849004|Active Comparator|Gel vs. Sheet|One group will act to compare the effectiveness between silicone gel and silicone sheet.
9996910|NCT01504282|Active Comparator|MMC group|One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
9923303|NCT00849004|Active Comparator|sheet vs. paper tape|The second group between silicone sheet and paper tape.
9923304|NCT00849004|Active Comparator|gel vs. paper tape|One group will act to compare the effectiveness between silicone gel and paper tape.
9923305|NCT00849030|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
9923306|NCT00849030|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
9923307|NCT00849030|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
9923308|NCT00849043||Provent|Provent Professional Sleep Apnea Therapy device
9923309|NCT00849069|Experimental|Group A|
9923310|NCT00849069|Active Comparator|Group B|
9923311|NCT00849095|Experimental|as needed medication|patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
9923312|NCT00849095|Active Comparator|guideline treatment|bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
9923313|NCT00849134|Placebo Comparator|Cohort 1,2 & 3|This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing the study drug. Effects will be compared to those seen when a placebo is taken. Up to 3 groups of 8 healthy male and female volunteers may be enrolled.
9923314|NCT00849134|Active Comparator|Cohort 4|If an investigation of food effect is not possible in Cohorts 2 or 3, this Cohort will be used to check if there is a difference in the blood levels of the study drug when taken with or without a high fat meal.
9923315|NCT00849160|Experimental|Darunavir/r|
9923316|NCT00849199||High risk of breast or ovarian cancer|
9923317|NCT00849264|Experimental|A|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar
9923318|NCT00849264|Active Comparator|B|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with CBP and 5-FU
9923319|NCT00849264|Experimental|C|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar, CBP and 5-FU
9923320|NCT00849303|Experimental|earlier gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
9923321|NCT00849303|Active Comparator|later gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
9923322|NCT00849316||A|
9923323|NCT00849329|Experimental|Period 1|1250mg lapatinib once daily in the morning
9923324|NCT00849329|Experimental|Period 2|1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.
9923325|NCT00849342||A|
9923326|NCT00849355|Experimental|unique|RCOMP-14 with Rituximab
9923327|NCT00849368|Experimental|Azathioprine / Allopurinol|Single arm study: Dose escalations as described.
9923328|NCT00849394||1|Shortened infusions of bevacizumab
9923329|NCT00849407||1|melanoma patients
9923330|NCT00849407||2|controls
9923331|NCT00849433||1|30 patients with asthma
9923332|NCT00849433||2|30 patients with COPD
9923333|NCT00849446||Activity monitoring in CVA patients|
9923334|NCT00849446||Activity monitoring in healthy persons|
9996911|NCT01504282|Placebo Comparator|BSS group|One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
9996912|NCT01504295|Experimental|Metadoxine|Metadoxine 500mg tablet t.i.d.for 12 weeks
9851108|NCT03404843|Experimental|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
9851109|NCT03404843|Placebo Comparator|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
9851110|NCT03405259|Experimental|Super Seal® Desensitizer|Professionally Applied
9851111|NCT03405259|Sham Comparator|Acclean® Fluoride Varnish|Professionally Applied
9851112|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
9851113|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
9851114|NCT03405818|Experimental|Tavaborole 5% Topical Solution|All study participants apply study drug
9851115|NCT03405935|Experimental|B/F/TAF|B/F/TAF FDC for at least 96 weeks.
9851116|NCT03406260|Experimental|Lasmiditan 200 mg (milligrams)|Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
9851117|NCT03406260|Experimental|Lasmiditan 100 mg|Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
9851118|NCT03406260|Placebo Comparator|Placebo|Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
9851119|NCT03406325||urticaria|Patients with this condition
9851120|NCT03406325||asthma|Patients with this condition
9851121|NCT03406325||eczema|Patients with this condition
9851122|NCT03406325||food allergy|Patients with this condition
9851123|NCT03406325||anaphylaxis|Patients with this condition
9851124|NCT03406325||mastocytosis|Patients with this condition
9851125|NCT03406325||mast cell activating syndrome|Patients with this condition
9851126|NCT03406377|Placebo Comparator|Placebo|Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
9851127|NCT03406377|Experimental|OPK-88003|70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)
9851128|NCT03406962|Experimental|MGTA-456|MGTA-456 is an expanded CD34+ cell therapy investigational product used in replacement of single umbilical cord blood transplantation.
9851129|NCT03407053|Active Comparator|Ultra-processed diet then unprocessed diet|Participants assigned to this arm will consume ultra-processed diet for two weeks followed by unprocessed diet for two weeks
9851130|NCT03407053|Active Comparator|Unprocessed diet then ultra-processed diet|Participants assigned to this arm will consume unprocessed diet for two weeks followed by ultra-processed diet for two weeks
9851131|NCT03407118|Experimental|LY900014|Single, 15 units (U)LY900014 administered subcutaneously (SC) in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus (T1DM).
9851132|NCT03407118|Active Comparator|Insulin Lispro (Humalog)|Single, 15 U insulin lispro administered SC in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus.
9851133|NCT03407170|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
9851134|NCT03407313|Experimental|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
9851135|NCT03407430|Experimental|Pregabalin, then Placebo|"Pregabalin in cycle 1; placebo in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg twice a day (BID) for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
9851136|NCT03407430|Experimental|Placebo, then Pregabalin|"Placebo in cycle 1; pregabalin in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg BID for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
9517032|NCT03310112|Active Comparator|2-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.
9851137|NCT03407482|Experimental|GDC-0853 (200mg) BID|Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).
9851138|NCT03407612|Active Comparator|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
9851139|NCT03407612|No Intervention|No CPM|No CPM was administered to these subjects.
9851140|NCT03407625|Experimental|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
9851141|NCT03407625|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
9996913|NCT01504295|Placebo Comparator|Sugar pill|Placebo group
9996914|NCT01504308|Experimental|MR-HIFU treatment|Patients receiving MR-HIFU treatment
9996915|NCT01504308|Sham Comparator|Sham Treatment|Patients receiving sham treatment
9851142|NCT03407651|Experimental|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
9851143|NCT03407651|Experimental|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
9851144|NCT03407651|Experimental|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
9851145|NCT03408171|Active Comparator|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
9851146|NCT03408171|Active Comparator|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
9851147|NCT03408392|Experimental|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
9851148|NCT03408392|Experimental|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
9851149|NCT03408483|Experimental|quadratus lumborum block (QLB)|"Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.~After QLB is placed, patients will have THA under spinal anesthesia."
9851150|NCT03408483|Active Comparator|Standard of Care|"Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected."
9851151|NCT03408639|Experimental|CinnaPoietin®|"The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.~In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients."
9851152|NCT03408639|Active Comparator|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
9851153|NCT03408730|Experimental|Sci-B-Vac Lot A Hep B Vaccination|Sci-B-Vac Lot A Hepatitis B Vaccination
9851154|NCT03408730|Experimental|Sci-B-Vac Lot B Hep B Vaccination|Sci-B-Vac Lot B Hepatitis B Vaccination
9851155|NCT03408730|Experimental|Sci-B-Vac Lot C Hep B Vaccination|Sci-B-Vac Lot C Hepatitis B Vaccination
9851156|NCT03408730|Active Comparator|Comparator: ENGERIX-B Hep B Vaccination|Active Comparator: ENGERIX-B Hepatitis B Vaccination
9996916|NCT01504321|Active Comparator|Active|
9996917|NCT01504321|Placebo Comparator|Placebo|
9851157|NCT03408808|Active Comparator|Aspiration alone|The patients will have their dorsal wrist ganglion aspirated and then pressure dressing for 48 hours.
9851158|NCT03408808|Experimental|Aspiration plus platelet rich plasma|The patients will have their dorsal wrist ganglion aspirated, and then injected with platelet rich plasma (derived from a blood sample taken at the same visit) and then pressure dressing for 48 hours.
9851159|NCT03409107|Experimental|Daprodustat receivers|Participants will receive oral daprodustat once daily
9851160|NCT03409107|Placebo Comparator|Placebo receivers|Participants will receive oral placebo once daily
9851161|NCT03409796|Other|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
9851162|NCT03409796|Other|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
9851163|NCT03410056|Placebo Comparator|Phase 1b: Placebo|Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).
9851164|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 1|A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
9851165|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 2|A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
9851166|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 3|A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
9851167|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 4|A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
9851168|NCT03410056|Placebo Comparator|Phase 2a: Placebo|Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.
9851169|NCT03410056|Experimental|Phase 2a: Efavaleukin alfa|Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.
9851170|NCT03410628|Experimental|gammaCore Active Device|open label
9851171|NCT03410797|Other|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
9851172|NCT03410862|Experimental|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
9851173|NCT03410862|Placebo Comparator|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
9851174|NCT03410914|Experimental|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery
9851175|NCT03410953|Experimental|Fendrix|"The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
9851176|NCT03411902|Active Comparator|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
9851177|NCT03411902|Placebo Comparator|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
9851178|NCT03412019|No Intervention|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
9851179|NCT03412019|Experimental|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
9851180|NCT03412084|Experimental|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
9851181|NCT03412084|No Intervention|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
9851182|NCT03412734|Experimental|Chlorhexidine group|
9851183|NCT03412734|Active Comparator|Iodine group|
9851184|NCT03412929|Experimental|Honey Impregnated Dressing|Honey Impregnated Dressing
9851185|NCT03413618|Experimental|Experimental: Rivaroxaban + Diosmin + Stockings|treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
9851186|NCT03413618|Active Comparator|Control: Rivaroxaban + Stockings only|standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings
9851187|NCT03414047|Experimental|Prexasertib Cohort 1|Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
9851188|NCT03414047|Experimental|Prexasertib Cohort 2|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA negative and have received <3 lines of prior therapy.
9851189|NCT03414047|Experimental|Prexasertib Cohort 3|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
9851190|NCT03414047|Experimental|Prexasertib Cohort 4|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum refractory disease, BRCA positive or negative, no restriction on number of lines of prior therapy.
9851191|NCT03414359|Active Comparator|2% Lidocaine|Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts [0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl
9851192|NCT03414359|Experimental|3% Chloroprocaine|20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride
9851193|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
9851194|NCT03415178|Experimental|Auto-Injector Device (AI)|Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
9851195|NCT03415178|Experimental|New Auto-injector Device (SYDNEY)|Alirocumab 300 mg SC injection on Week 0 (Day 1), self-administered using new auto-injector device (SYDNEY), on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, same treatment (Alirocumab 300 mg) with the same device (SYDNEY) was self-administered, (unsupervised) Q4W until Week 16 in the single arm treatment period added to LMT. Duration of single arm treatment period was 12 weeks, i.e. from Week 4 to 16.
9851196|NCT03415243|Experimental|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg).
9851197|NCT03415243|Experimental|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg).
9851198|NCT03415581|Placebo Comparator|Doxazosin (Placebo First)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, followed by 4-week maintenance on active doxasozin (up to 16mg/day or the highest tolerated dose. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
9851199|NCT03415581|Active Comparator|Doxazosin (Active First)|Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
9851200|NCT03416127|Experimental|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
9851201|NCT03416127|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
9851202|NCT03416127|Placebo Comparator|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
9851203|NCT03416621|Active Comparator|Experimental: Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
9851204|NCT03416621|Placebo Comparator|Placebo Comparator: Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
9851205|NCT03416621|Experimental|Active Comparator: Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
9851206|NCT03416946|Active Comparator|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
9851207|NCT03416946|Active Comparator|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
9851208|NCT03416985|Active Comparator|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
9851209|NCT03416985|Active Comparator|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
9851210|NCT03416985|Active Comparator|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
9851211|NCT03417024||All Subjects|All subjects will undergo scanning with both Automated Breast Ultrasound and Digital Breast Tomosynthesis devices.
9851212|NCT03417141|Experimental|Valchor treatment of Lichen Planopilaris|Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
9851213|NCT03417219|Experimental|Mobile Media Education and Skill-Building Rehabilitation Int|The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
9851214|NCT03417219|Active Comparator|Usual Care|"Usual Care (plus supplemental educational materials). Participants randomized to the Usual Care (UC) group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
9851215|NCT03417466|Experimental|Study arm|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6).
9851216|NCT03417505|Experimental|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
9851217|NCT03417505|Experimental|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
9851218|NCT03417557|Experimental|Comfilcon A lens (test)|Subjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
9851219|NCT03417557|Active Comparator|Omafilcon B Lens (control)|Subjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
9851220|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
9851221|NCT03417739|Experimental|BVD-523|BVD-523 is administered at the RP2D of 600mgs taken twice daily orally for 28 consecutive days (1 cycle). Planned does may modified based on toxicity.
9851222|NCT03417752|Experimental|Exposure to firearm safety Public Service Announcement (PSA)|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
9851223|NCT03417752|Experimental|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
9851224|NCT03417752|Active Comparator|Active control|Exposure to the general health promotion video once per week for 3 weeks.
9851225|NCT03417778|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
9851226|NCT03417778|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
9851227|NCT03417778|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
9851228|NCT03417830|Experimental|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
9851229|NCT03417830|Experimental|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
9851230|NCT03418051|No Intervention|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
9851231|NCT03418051|Experimental|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
9851232|NCT03418051|Experimental|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
9851233|NCT03418064|Experimental|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
9851234|NCT03418064|Active Comparator|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
9851235|NCT03418324|Experimental|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
9851236|NCT03418324|Experimental|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
9851237|NCT03418376|Experimental|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
9851238|NCT03418376|Placebo Comparator|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
9851239|NCT03418376|Experimental|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
9851240|NCT03418376|Placebo Comparator|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
9851241|NCT03418545|Experimental|JUVÉDERM VOLBELLA® XC|JUVÉDERM® VOLBELLA™ XC injectable gel was injected into the infraorbital and adjacent area at Randomization as determined by the investigator. Participants were eligible to receive an optional touch-up treatment 1 month later and an optional repeat treatment 12 months after last treatment, if applicable. A maximum of 2.2 milliliter (mL) per side was injected for initial and touch-up treatments combined.
9851242|NCT03418545|No Intervention|No-treatment Control|Participants randomized to the No-treatment Control group completed a 3-month No-treatment Period. Participants were then eligible to receive optional treatment with JUVÉDERM® VOLBELLA™ XC injectable gel injected into the infraorbital and adjacent area followed by an optional touch-up treatment 1 month later.
9851243|NCT03418571|Experimental|ALX-0171 1.5 mg/kg|
9851244|NCT03418571|Placebo Comparator|Placebo|
9851245|NCT03418662|No Intervention|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
9851246|NCT03418662|Experimental|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
9851247|NCT03418714|Experimental|Salvinorin A administration|All volunteers will be assigned to the salvinorin A administration arm.
9851248|NCT03419403|Experimental|Standard Steroids|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days
10207857|NCT04523779|Experimental|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
9923335|NCT00849459|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
9923336|NCT00849511|Active Comparator|Placebo first|Placebo 8 weeks, 6 weeks washout, extended-release melatonin 2 mg vesper for 8 weeks
10207858|NCT04523779|No Intervention|Enhanced Usual Care|EUC participants will receive anxiety education materials, a note in their medical record indicating the presence of elevated anxiety symptoms, and 4 brief monthly check-in calls with project staff. The primary outcome, anxiety symptoms, will be evaluated at 4-, 8- and 12-month follow-ups. Due to ethical concerns of withholding needed treatment, EUC participants will NOT be restricted from receiving mental health services including psychotherapy during the study period. The investigators fully expect that EUC participants may receive anxiety treatments (e.g., antianxiety and antidepressant medications or psychotherapy).
10207859|NCT04519437|Experimental|REGN10933+REGN10987|
10207860|NCT04519437|Placebo Comparator|Placebo|
10207861|NCT04515927|Experimental|subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.|
10207862|NCT04509011|Experimental|Fluobeam® LX|Fluobeam® LX is used to detect autofluorescens and identify and evaluate parathyroid glands
10207863|NCT04509011|No Intervention|Control|In the control group, the parathyroid glands are identified and evaluated by eye (ocular examination).
10207864|NCT04503148|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
10207865|NCT04503148|Active Comparator|inhalation group|Patients receiving inhalation anesthesia using sevoflurane or desflurane
10207866|NCT04498468|Experimental|Treatment Arm|Commercially available Sustained Release Dexamethasone, 0.4 mg intracannalicular insert (DEXTENZA® - Ocular Therapeutix, Bedford, MA)
10207867|NCT04498468|Sham Comparator|Control Arm|Commercially available EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL) (Vera90™ - Elkridge, MD)
10207868|NCT04477200|Experimental|Phase 0 - Recurrent glioblastoma (GBM) / gliosarcoma (GS)|Mycophenolate mofetil
10207869|NCT04477200|Experimental|Phase 1 - Recurrent GBM / GS|Mycophenolate mofetil; radiation therapy
10207870|NCT04477200|Experimental|Phase 1 - Newly Diagnosed GBM / GS|Mycophenolate mofetil; radiation therapy; temozolomide
10207871|NCT04474223|Experimental|Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms|
10207872|NCT04473378||FreeStyle Libre sensor cohort|Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
10207873|NCT04443153|Experimental|De-escalation|Subjects randomized to this arm will proceed from DSS to PF to SAM
10207874|NCT04443153|Experimental|Escalation|Subjects randomized to this arm will proceed from SAM to PF to DSS
10207875|NCT04435964||Overall series|Patients treated with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule. No limitations to previous lines of treatment. ICI therapy may be either as single agent or in combination. Concomitant chemotherapy (CT) and radiotherapy (RT) is allowed.
10207876|NCT04433065|Experimental|Primary Cohort|Device: Intrepid TTVR System
10207877|NCT04420221|Experimental|Half dose non-adj Group 1a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1.
10207878|NCT04420221|Placebo Comparator|Placebo Group 1b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
10207879|NCT04420221|Experimental|Full dose non-adj Group 2a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1
10207880|NCT04420221|Placebo Comparator|Placebo Group 2b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
9851249|NCT03419403|Experimental|Standard Steroids + Vasoconstrictor + Cold Compress|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).
9851250|NCT03419403|Experimental|Enhanced Steroids + Vasoconstrictor + Cold Compress|Enhanced steroid eye drops: 1 drop each eye, 6 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Ophthalmic Steroid Ointment; applied to each eye once daily before sleep, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. Cold compress was to be applied in increments no longer than 30 min (could be shorter if the patient is uncomfortable).
9851251|NCT03419533||2018 school leavers|South Australian school leavers in 2018 (year 12 in 2017)
9851252|NCT03419533||2019 school leavers|South Australian school leavers in 2019 (year 12 in 2018)
9851253|NCT03419598||All study participants|All virtual participants who received a virtual opening wedge high tibial osteotomy. The baseline information was the individual CT-based geometry of tibia.
9851254|NCT03419780|Active Comparator|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
9851255|NCT03419780|Active Comparator|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
9851256|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
9851257|NCT03420300|Experimental|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
9851258|NCT03420625|Active Comparator|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
9851259|NCT03420625|Active Comparator|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
9851260|NCT03420625|Active Comparator|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
9851261|NCT03420625|Active Comparator|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
9851262|NCT03421210|Other|Nicotine Replacement Therapy|Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.
9851263|NCT03421379|Experimental|Glucagon Nasal Powder|A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
9851264|NCT03421379|Active Comparator|Glucagon Hydrochloride Solution|A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)
9851265|NCT03421431|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
9517033|NCT03310112|No Intervention|No training control (NTC)|Participants will receive no intervention but will be tested before and after a no-training interval.
9851266|NCT03421431|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
9851267|NCT03421431|Placebo Comparator|Placebo|Subjects will take 2 tablets once a day orally for 12 weeks
9851268|NCT03421730|Experimental|AB - VR647 5 breaths, then VR647 10 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851269|NCT03421730|Experimental|AC - VR647 5 breaths, then VR647 20 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851270|NCT03421730|Experimental|AD - VR647 5 breaths, then Pulmicort|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
9851271|NCT03421730|Experimental|BA - VR647 10 breaths, then VR647 5 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851272|NCT03421730|Experimental|BC - VR647 10 breaths, then VR647 20 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851273|NCT03421730|Experimental|BD - VR647 10 breaths, then Pulmicort|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
9851274|NCT03421730|Experimental|CA - VR647 20 breaths, then VR647 5 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851275|NCT03421730|Experimental|CB - VR647 20 breaths, then VR647 10 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851276|NCT03421730|Experimental|CD - VR647 20 breaths, then Pulmicort|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
9851277|NCT03421730|Experimental|DA - Pulmicort, then VR647 5 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851278|NCT03421730|Experimental|DB - Pulmicort, then VR647 10 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851279|NCT03421730|Experimental|DC - Pulmicort, then VR647 20 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
9851280|NCT03421886|Experimental|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
9851281|NCT03421886|Active Comparator|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
9851282|NCT03422159|Experimental|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
9851283|NCT03422159|Placebo Comparator|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
9851284|NCT03422172|Experimental|Subjects receiving CAB|Eligible subjects will receive oral doses of CAB 30 milligrams (mg) tablets once daily for 4 weeks followed by IM injectable suspension of CAB LA 600 mg at Week 5, Week 9, Week 17, Week 25 and Week 33. There will be an approximately 1-week washout period between the last oral dose and the first injection of CAB at Week 5.
9851285|NCT03422250|Experimental|Arm 1|Alzheimer's disease (AD): anodal tDCS of the default mode network (DMN)
9851286|NCT03422250|Experimental|Arm 2|Alzheimer's disease (AD): cathodal tDCS of the salience network (SN)
9851287|NCT03422250|Experimental|Arm 3|Behavioral-variant frontotemporal dementia (bvFTD): anodal tDCS of the salience network (SN)
9851288|NCT03422250|Experimental|Arm 4|Behavioral-variant frontotemporal dementia (bvFTD): cathodal tDCS of the default mode network (DMN)
9851289|NCT03423082|Experimental|18F fluciclovine PET scan|Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.
9851290|NCT03423173|Placebo Comparator|Placebo|TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
9851291|NCT03423173|Experimental|TDV Lot 1|Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
9851292|NCT03423173|Experimental|TDV Lot 2|Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
9851293|NCT03423173|Experimental|TDV Lot 3|Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
9851294|NCT03423186|Experimental|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
9851295|NCT03423186|Experimental|Dose group 2|SOBI003 dose 10 mg/kg once weekly for 24 weeks
9851296|NCT03423238|Active Comparator|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
9851297|NCT03423238|Experimental|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
9851298|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
9851299|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
9851300|NCT03424044|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
9851301|NCT03424044|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
9851302|NCT03424044|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
9851303|NCT03424187|Experimental|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
9851304|NCT03424187|Experimental|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
9851305|NCT03424187|Experimental|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
9851306|NCT03424239|Experimental|Drug: Zoledronic Acid, Calcium+Vitamin D|Subjects will receive a single intravenous infusion of zoledronic acid (5 mg). Supplemental calcium citrate + vitamin D (500mg+500IU) and vitamin D3 (1000 IU) will be dispensed throughout the study to fit individual needs.
9851307|NCT03424265|Experimental|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
9851308|NCT03424265|Experimental|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
9851309|NCT03424681|Experimental|Modafinil|Modafinil 300 mg by mouth each day
9851310|NCT03424681|Placebo Comparator|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
9851311|NCT03425019|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
9851312|NCT03425097|Experimental|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
9851313|NCT03425097|Experimental|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
9851314|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
9851315|NCT03425253|Experimental|BELKYRA® and Juvéderm® VOLUMA™ with Lidocaine|BELKYRA® was injected into subcutaneous preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart). When the investigator and participant agreed that no further intervention was required to achieve the desired result, participants were eligible to receive VOLUMA™ treatment. VOLUMA™ was injected along the mandibular border, with an optional touch-up visit 2 weeks later if applicable.
9851316|NCT03425396|Experimental|Omadacycline 300/300 once every 24 hours|Participants received omadacycline 300 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
9923337|NCT00849511|Active Comparator|Melatonin first|Extended-release melatonin 2 mg vesper for 8 weeks, 6 weeks washout, placebo 8 weeks
9923338|NCT00849537|Experimental|Triamcinolone|Injection of intravitreal Triamcinolone
9851317|NCT03425396|Experimental|Omadacycline 450/300 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
9851318|NCT03425396|Experimental|Omadacycline 450/450 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
9851319|NCT03425396|Experimental|Omadacycline 450/450 once every 12 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
9851320|NCT03425396|Active Comparator|Nitrofurantoin 100/100 once every 12 hours|Participants received nitrofurantoin 100 milligrams orally, once every 12 hours, fed on Day 1 and nitrofurantoin 100 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
9923339|NCT00849550|Experimental|XELOX-A-Ev|
9923340|NCT00849563|Active Comparator|SRA+genetic test|patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
9923341|NCT00849563|No Intervention|SRA only|Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
9923342|NCT00849563|No Intervention|no testing control|Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
9923343|NCT00849589|No Intervention|1|Treatment as Usual (TAU)
9923344|NCT00849589|Experimental|2|Computerized Screening and Brief Physician Advice (SBA)
9923345|NCT00849589|Experimental|3|Computerized screening and brief physician advice with technological extenders (SBA/TE)
9923346|NCT00849602|Placebo Comparator|1|
9923347|NCT00849602|Active Comparator|2|
9923348|NCT00849615|Experimental|FLOT|
9923349|NCT00849628||1|Constipation
9923350|NCT00849641||1|patients with decompensated liver cirrhosis admitted to the medical ICU
9923351|NCT00849641||2|critically ill patients without liver cirrhosis, matched to group 1
9923352|NCT00849641||3|healthy control group
9923353|NCT00849654|Experimental|PCI-32765|
9923354|NCT00849706||Study group|Medical staff personal, doctors and nurses, working night shifts.
9923355|NCT00849719|Experimental|1|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient.
9923356|NCT00849719|Active Comparator|2|Patients in this arm will be administered with only boluses of 1.5 mg/bolus of MO, by request.
9923357|NCT00849732|Experimental|1|V520 (1x10^9 vp/d)
9923358|NCT00849732|Experimental|2|V520 (1x10^10 vp/d)
9923359|NCT00849732|Placebo Comparator|3|Placebo to V520
9923360|NCT00849745|Experimental|Systemic Lupus Erythematosus|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Satisfy the American College of Rheumatology (ACR) criteria for the diagnosis of SLE~Have Lupus nephritis, refractory and severe seizures or encephalopathy, severe pulmonary involvement, transfusion-dependent cytopenias, catastrophic antiphospholipid syndrome or vasculitis and/or immune complex deposition causing end-organ signs or symptoms.~Have received a trial of corticosteroids equivalent to prednisone greater than or equal to 0.5 mg/kg/d for at least one month~Have received a trial of IV cyclophosphamide pulse greater than 500 mg/square meter at least once within the previous 6 months, unless contraindicated because of severe cytopenias or intolerance."
9923361|NCT00849745|Experimental|Systemic Sclerosis|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Have diagnosis of SSc as defined by American College of Rheumatology and at high-risk for fatal outcome.~Have (1) both a and b below and (2) at least one of c, d, or e.~Diffuse cutaneous scleroderma with skin score of >= 16~Duration of systemic sclerosis <= 3 years from the onset of first non-Raynaud's symptom.~Presence of interstitial or pulmonary vascular lung involvement (FVC or DLCO <70% of predicted) especially with evidence of alveolitis (abnormal bronchoalveolar lavage or high-resolution chest CT scan).~Presence of myocardial disease~History or presence of proteinuria > 500 mg/24 hrs or serum creatinine > the upper limit of normal."
9923362|NCT00849758||1|chemotherapy: elderly patients receiving 4x adjuvant taxotere cyclophosphamide adjuvant for breast cancer
9923363|NCT00849758||2|adjuvant hormone therapy: 40 patients receiving adjuvant aromatase inhibitor without chemotherapy
9923364|NCT00849771||1|Operative Treatment (Open Reduction Internal Fixation)
9923365|NCT00849771||2|Non-operative/Conservative Care
9923366|NCT00849823|Active Comparator|Male Sexual Health Program|
9923367|NCT00849823|Experimental|Focus on the Future Program|
9923368|NCT00849836||Acute exacerbation|
9923369|NCT00849836||Stable disease|
9923370|NCT00849836||Healthy control|
9923371|NCT00849849||Postpartum GDM OGTT|200 women with prior GDM in their index pregnancies will undergo postpartum screening assessment. This program will follow these women who are at a high risk of developing DM2 after delivery for 1 year.
9923372|NCT00849914||1|Patients with actinic keratoses of the skin
9923373|NCT00849914||2|Patients with basal cell carcinoma of the skin
9923374|NCT00849914||3|Patients with squamous cell carcinoma of the skin
9923375|NCT00849953||FinESS Treatment|Subjects undergoing treatment with the FinESS Sinus Treatment System
9923376|NCT00849966|Experimental|A|Celebrex suspension
9923377|NCT00849966|Placebo Comparator|B|Placebo
9923378|NCT00849979|Other|Questionnaire|
9923379|NCT00849979|Other|Questionnaire + Interview|
9851321|NCT03426267|Experimental|SDN-037|
9851322|NCT03426267|Placebo Comparator|vehicle|
9851323|NCT03426345|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
9851324|NCT03426345|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 12 weeks.
9851325|NCT03426436|Other|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
9851326|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
9851327|NCT03426631|Placebo Comparator|Placebo|Placebo before sleep
9851328|NCT03426631|Experimental|DAW1033B2 oral capsule|DAW1033B2 before sleep
9851329|NCT03426787|Experimental|Decision Aid|A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.
9851330|NCT03426995|Experimental|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
9851331|NCT03426995|Experimental|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
9851332|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
9851333|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
9851334|NCT03426995|Experimental|Part B, GSK3358699 under Fasted followed by Fed conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fasted condition in TP1 followed by fed condition in TP2. This cohort intended to evaluate the effect of food.
9851335|NCT03426995|Experimental|Part B, GSK3358699 under Fed followed by Fasted conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fed condition in TP1 followed by fasted condition in TP2. This cohort intended to evaluate the effect of food.
9923380|NCT00849992|Other|Imiquimod 5%|Patients randomized to this arm will receive treatment with imiquimod 5%
9923381|NCT00849992|Other|Photodynamic therapy|Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.
10213517|NCT03872778|Experimental|Phase IIa|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
10213518|NCT03869697|Experimental|SCB-313|Cohorts in SAD phase: 5 mg, 10mg, 20mg, 40mg, 80 mg. Cohort in MAD phase: biological effective dose determined from SAD phase. 1 intrapleural injection of SCB-313 on Day 1 for the SAD cohorts, and 3 intrapleural injections of SCB-313 on Days 1, 2 and 3 for the MAD cohort.
10213519|NCT03868956|Experimental|Diagnostic strategy|Colour doppler ultrasound (CDUS) with or without D-dimer test to rule-in or rule-out deep vein thrombosis recurrence
10213520|NCT03868020|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.
9517037|NCT03310073|Experimental|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.~The subject received bOPV, Pentabio and IPV according to the study schedule."
9851336|NCT03426995|Experimental|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
9851337|NCT03426995|Placebo Comparator|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
9851338|NCT03427073|Experimental|Solid tumours|"Part 1 - Dose-escalation of ALM201 in patients with advanced solid tumours~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
9851339|NCT03427073|Experimental|Ovarian cancer|"Part 2 - Dose-expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the MTD determined in Part 1"
9851340|NCT03427177|Experimental|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool.
9851341|NCT03427177|No Intervention|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
9851342|NCT03427268|Experimental|PM060184|PM060184
9851343|NCT03427619|Experimental|OK432 (Picibanil)|There is no control in this study. All participants will receive the actual drug -OK432. With each injection they may receive 0.01 to 0.05mg/mL 6-12 weeks apart up to 4 injections total.
9851344|NCT03427892|Experimental|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
9851345|NCT03427931|Experimental|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
9851346|NCT03428100|Experimental|4 mg Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
9851347|NCT03428100|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
9851348|NCT03428100|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
9851349|NCT03428100|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with topical corticosteroids.
9851350|NCT03428152||Hypo|The participants with a superior hypogastric block
9851351|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
9851352|NCT03428230|Experimental|30 mg Paracetamol 3% (1 mL)|30 mg Paracetamol 3% (1 mL), solution for injection, single dose by intrathecal injection (IT)
9851353|NCT03428230|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3% (2 mL), solution for injection, single dose by intrathecal injection (IT)
9793995|NCT01491737|Experimental|Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy|"Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
9851354|NCT03428230|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3% (3 mL), solution for injection, single dose by intrathecal injection (IT)
9851355|NCT03428230|Placebo Comparator|Placebo, 0.9% saline solution|Placebo, 0.9% saline solution (1 mL, 2 mL or 3 mL), solution for injection, single dose by intrathecal injection (IT)
10207881|NCT04420221|Experimental|Half dose adj Group 3a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1.
9851356|NCT03428360|Experimental|Subjects with Epilepsy|Male or female subjects between the ages of 2 and 65 years who had an established diagnosis of epilepsy exhibited by motor seizures with clear alteration of awareness, and while on a regimen of anti-epileptic medication(s), still experienced bouts of seizures (frequent breakthrough seizures, eg, seizure clusters) and who, in the opinion of the Investigator, could need benzodiazepine intervention for seizure control at least 1 time a month on average. Subjects must have been on at least 1 concomitant anti-epileptic drug at screening.
9851357|NCT03428750|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
9851358|NCT03428750|Placebo Comparator|Placebo|
9851359|NCT03428815|Experimental|PCM liner|Willowwood Smart Temp Liner
9851360|NCT03428815|Active Comparator|regular liner|User's regular prescribed liner
9851361|NCT03428997|Experimental|Lotion|Test sites were patched with the lotion F #13451-131.
9851362|NCT03428997|Other|Negative Control|Test sites were patched with undosed occlusive patch.
9851363|NCT03429270|Experimental|Urodynamics Arm|
9851364|NCT03429348|No Intervention|No additional rehabilitation|No additional rehabilitation will be done
9851365|NCT03429348|Other|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
9851366|NCT03429556|Placebo Comparator|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
9851367|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 1|Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
9851368|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 2|Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
9851369|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 3|Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
9851370|NCT03430050|Active Comparator|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
9851371|NCT03430050|Placebo Comparator|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
9851372|NCT03430206|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
9851373|NCT03430206|Experimental|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
9851374|NCT03430245|Experimental|VelaShape III & UltraShape Power|VelaShape III treatment with radiofrequency, infrared and massage combined with UltraShape Power treatment, using pulsed, focused ultrasound treatment.
10207882|NCT04420221|Placebo Comparator|Placebo Group 3b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
10207883|NCT04420221|Experimental|Full dose adj Group 4a|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61)
10207884|NCT04420221|Placebo Comparator|Placebo Group 4b|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
9851375|NCT03430349|Experimental|Novel OPV2 Candidate 1|Participants received one vaccination with novel OPV2 candidate 1 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
9851376|NCT03430349|Experimental|Novel OPV2 Candidate 2|Participants received one vaccination with novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
9851377|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
9851378|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
9851379|NCT03430856|Active Comparator|Insulin Aspart|Pre-filled pen: 100 U/L
9851380|NCT03430986|Experimental|JUVÉDERM® VOLUMA® with Lidocaine|Participants were treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel during the 24-week Control Period. Participants were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable. Follow-up continued in the 24-week Post-Control period.
9851381|NCT03430986|Experimental|No-treatment Control|Participants received no treatment during the 24-week Control Period. After 24 weeks, participants had the option of treatment with JUVÉDERM® VOLUMA® with Lidocaine Injectable Gel in the nose area during the 24-week Post-Control period and were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable.
9851382|NCT03431012|Experimental|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
9851383|NCT03431012|Experimental|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
9851384|NCT03431012|Experimental|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
9851385|NCT03431012|Experimental|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
10207885|NCT04420221|Experimental|Vaccine Group 5a|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61).
9851386|NCT03431337|Experimental|High dose|Amoxicillin/clavulanate 875mg/125mg & amoxicillin 875 mg twice a day x 7 days
9851387|NCT03431337|Active Comparator|Standard dose|Amoxicillin/clavulanate 875 mg/125mg & placebo (lactase) twice a day x 7 days.
9851388|NCT03431441|Experimental|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
9851389|NCT03431857||TESS V2 Prosthesis|Single study patient cohort, including 106 patients who meet the inclusion/exclusion criteria and who received the TESS V2 shoulder prosthesis.
9851390|NCT03432390|Experimental|CPAP|
9851391|NCT03432390|Active Comparator|Control|
9851392|NCT03432533|Active Comparator|Romosozumab 210 mg QM: PFS|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
9851393|NCT03432533|Active Comparator|Romosozumab 210 mg QM: AI/Pen|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
9851394|NCT03432858|Active Comparator|Vancomycin|
9851395|NCT03432858|Active Comparator|Cefazolin|
10207886|NCT04420221|Placebo Comparator|Placebo Group 5b|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
9851396|NCT03432858|Placebo Comparator|Saline|
9851397|NCT03433482|Experimental|GSK3536820A ACWY_Liq24 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.
9851398|NCT03433482|Active Comparator|ACWY_1 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.
9851399|NCT03433482|Experimental|GSK3536820A ACWY_Liq30 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.
9851400|NCT03433482|Active Comparator|ACWY_2 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.
9851401|NCT03433677|Experimental|LY900014|100 units per milliliter (U/mL) LY900014 administered by individualized, continuous, subcutaneous insulin infusion (CSII)
9851402|NCT03433677|Experimental|Insulin Lispro|100 U/mL insulin lispro (Humalog®) administered by individualized CSII
9923382|NCT00850005|Experimental|IVIG|Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous [human], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).
9923383|NCT00850005|Placebo Comparator|Placebo|The placebo treatment will be intravenous normal saline and will be infused in a similar manner.
10207887|NCT04405102|Experimental|Ozanimod + standard of care|During hospitalization, the experiment treatment of Ozanimod will be given with the standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data.).
9851403|NCT03433703|Experimental|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.
9851404|NCT03433755|Placebo Comparator|Placebo Q2W|Placebo subcutaneous (SC) Q2W for 12 weeks
9851405|NCT03433755|Placebo Comparator|Placebo QM|Placebo SC QM for 12 weeks
9851406|NCT03433755|Experimental|Evolocumab 140 mg Q2W|Evolocumab 140 mg SC Q2W for 12 weeks
9851407|NCT03433755|Experimental|Evolocumab 420 mg QM|Evolocumab 420 mg SC QM for 12 weeks
9851408|NCT03433794|Placebo Comparator|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
9851409|NCT03433794|Active Comparator|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
9851410|NCT03433794|Experimental|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
9851411|NCT03434249|Experimental|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
9851412|NCT03434249|Placebo Comparator|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
9851413|NCT03434457||Prenatal and 3 to 72 months|
9851414|NCT03434834|Experimental|OCT of esophagus|optical coherence tomography of esophagus
9851415|NCT03434977|Experimental|TAK-536 10 mg (fasted) + TAK-536 10 mg (fed)|TAK-536 10 milligram (mg) granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) in the morning under fasted condition, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) after starting breakfast.
9851416|NCT03434977|Experimental|TAK-536 10 mg (fed) + TAK-536 10 mg (fasted)|TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) after starting breakfast, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) in the morning under fasted condition.
9851417|NCT03435055|Experimental|Nitrous Oxide - inhaled|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.
9851418|NCT03435081|Experimental|2 milligram (mg) Baricitinib|2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
9851419|NCT03435081|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
9851420|NCT03435081|Placebo Comparator|Placebo|Placebo administered orally every day.
9851421|NCT03435211|Experimental|INVSENSOR00006|All subjects consented are enrolled into the test group and received the INVSENSOR00006.
9851422|NCT03435224|Experimental|INVSENSOR00012|All subjects consented are enrolled into the test group and will receive the INVSENSOR00012.
9851423|NCT03435497|Experimental|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
9923384|NCT00850018|Experimental|1|Participants will receive monthly blood transfusions.
10207888|NCT04405102|Active Comparator|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
10207889|NCT04400799|Experimental|Test Group|Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.
10207890|NCT04400799|No Intervention|Control Group|No study drug
10207891|NCT04368910|Experimental|Pyronaridine - artesunate|"Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
10213521|NCT03863704|Sham Comparator|nerve stimulation ear then leg|Subjects in this arm will be randomized to receive nerve stimulation with TENS of the ear followed by leg stimulation
10213522|NCT03863704|Sham Comparator|nerve stimulation leg then ear|Subjects in this arm will be randomized to receive leg nerve stimulation with TENS followed by ear nerve stimulation
9851424|NCT03435497|No Intervention|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
9851425|NCT03435562|Experimental|electronic cigarette vs own brand use|Participants will come in for three session. During one session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (the session will be approximately 3 hours). The order of the sessions will be determined randomly and data about session will not be recorded or used in the analysis.
9851426|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
9851427|NCT03435692|Experimental|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
9851428|NCT03435692|Active Comparator|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
9851429|NCT03435692|Active Comparator|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
9851430|NCT03435783|Experimental|Intervention|
9851431|NCT03435783|Active Comparator|Attention-matched control|
9851432|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
9851433|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
9851434|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALH)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
9851435|NCT03436147||Vaginal Hysterectomy and Vaginal vault suspension (VAH+VVS)|Patients who were performed vaginal hysterectomy and vaginal vault suspension(VAH+VVS)
9851436|NCT03436420|Experimental|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
9851437|NCT03436732|Experimental|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
9851438|NCT03436732|Experimental|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at recommended phase 2 dose (RP2D)
9851439|NCT03436810|Experimental|Experimental group|The experimental group will receive training programs of Motor imagery (MI) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration of program session will be 90 minutes. Training for 3 times a week over duration of 4 weeks.
9851440|NCT03436810|Active Comparator|Control group|The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
9851441|NCT03437031|No Intervention|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
9851442|NCT03437031|Experimental|Latent-Virtual Reality (VR)|Patients in the latent phase of labor who will receive the Virtual Reality (VR) intervention.
9851443|NCT03437044|Experimental|Ticagrelor|180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD
9851444|NCT03437044|Active Comparator|Clopidogrel|600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD
9923385|NCT00850018|Active Comparator|2|Participants will receive usual care.
10207892|NCT04368910|Active Comparator|Chloroquine|"Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
10207893|NCT04367467||Individuals with solid tumors receiving PARPi|"Kidney function will be assessed by serum creatinine, serum cystatin C, and urine creatinine clearance calculation for patients who opt-in to 24 hour urine collection.~These laboratory measures will be completed by patients at the following time points:~Timepoint A: Baseline (prior to PARP inhibitor initiation, at the time of standard of care clinical testing)~Timepoint B: On-treatment (within 3-9 weeks of PARP inhibitor initiation, at the time of standard of care clinical testing)~Timepoint C: Post-treatment (within 4 weeks of PARP inhibitor discontinuation, only for those patients with clinically significant changes in GFR based on serum creatinine, cystatin C, or 24 hour urinalysis at Timepoint B"
9851445|NCT03437265|Experimental|PLENVU powder for oral solution|"Dose 1: Oral administration of 1 sachet (115.96 g) PLENVU Dose 1, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 1.~Dose 2: Oral administration of 2 sachets (101.91 g) comprising PLENVU Dose 2, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 2.~Additional water was permitted ad libitum during and after each dose."
10207894|NCT04365985|Placebo Comparator|Placebo|Placebo by mouth 1 time per day for patients with stage I or stage 2A COVID-19
10207895|NCT04365985|Experimental|Naltrexone|Naltrexone 4.5 mg by mouth 1 time per day for patients with stage I or stage 2A COVID-19.
10207896|NCT04365985|Experimental|Ketamine|Ketamine IV infusion (0.15 mg/kg based on total body weight for maximum 20 mg every 6 hours) for patients with stage 2B or stage 3 COVID-19; may be increased to 0.3 mg/kg based on total body weight for a maximum of 30 mg every 6 hours if needed. Patients entering this arm from the placebo or naltrexone arms remain on those medications as well.
9851449|NCT03437447|Experimental|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
9851450|NCT03437447|Experimental|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
9851451|NCT03437447|Experimental|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
9851452|NCT03437512|Experimental|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
9851453|NCT03437512|Sham Comparator|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
9851454|NCT03437564|Experimental|Vortioxetine one 20 mg tablet + two 10 mg tablets|Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
9851455|NCT03437564|Experimental|Vortioxetine two 10 mg tablets + one 20 mg tablet|Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
9851456|NCT03437577|Active Comparator|immediate-release tacrolimus|This is standard of care
9851457|NCT03437577|Experimental|extended release tacrolimus|replace standard of care
9851458|NCT03437733|Experimental|Intervention|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
9851459|NCT03437863|Experimental|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
9851460|NCT03438006||Cervarix group|Healthy female Chinese subjects aged between 9 and 45 years, vaccinated according to the Prescribing Information (PI) as per routine practice.
9851461|NCT03438045|Experimental|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
9851462|NCT03438266|Experimental|JUVÉDERM VOLUMA® XC Injectable Gel with Cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
9851463|NCT03438266|Other|JUVÉDERM VOLUMA® XC Injectable Gel with Needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
9851464|NCT03438383|Sham Comparator|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O)."
9851465|NCT03438383|Active Comparator|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
9851466|NCT03438396|Experimental|Single arm|tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)
9923386|NCT00850044|Active Comparator|1|ABT-450
9923387|NCT00850044|Placebo Comparator|2|Placebo for ABT-450
10207897|NCT04336397|Active Comparator|High Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
10207898|NCT04336397|Active Comparator|Medium Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
10207899|NCT04336397|No Intervention|Usual Care|usual care (i.e., opportunistic screening recommendation at a clinic visit)
10207900|NCT04336124|Experimental|CVM-1118 ER|Dose escalation (escalation from 400, 600, 800 to 1200 mg of CVM-1118 ER Capsule)
10207901|NCT04317612|Active Comparator|Active berry product|Once daily consumption over the period of the study
9851467|NCT03438539|Sham Comparator|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
9851468|NCT03438539|Experimental|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
9851469|NCT03438539|Experimental|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
9851470|NCT03438539|No Intervention|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
9851471|NCT03438539|Experimental|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
9851472|NCT03438539|Experimental|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
9851473|NCT03438578|Experimental|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
9851474|NCT03438578|No Intervention|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
9851475|NCT03439072|Other|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
9851476|NCT03439072|Other|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
9851477|NCT03439137|Experimental|MT-6548|
9851478|NCT03439137|Active Comparator|Darbepoetin alfa|
9851479|NCT03439189|Experimental|Emricasan 5mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
9851480|NCT03439189|Experimental|Emricasan 25mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
9851481|NCT03439189|Experimental|Emricasan 50mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
9923388|NCT00850044|Active Comparator|3|ABT-450/ritonavir
9923389|NCT00850044|Placebo Comparator|4|Placebo for ABT-450/placebo for ritonavir
9517038|NCT03310060|Active Comparator|Tisseel combined Tranexamic acid|"Drug: Tisseel® Applied on potential bleeding sites. The entire content was 4 mL.~Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery"
9851482|NCT03439189|Placebo Comparator|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
9851483|NCT03440229|No Intervention|Emuslfier-free diet|This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.
9851484|NCT03440229|Experimental|Emulsifier-containing diet|This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
9851485|NCT03440320|Experimental|MY-Skills Intervention - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
9851486|NCT03440320|Active Comparator|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
9851487|NCT03440411|Active Comparator|ARM pom-dex Early (A-I)|Patients will receive treatment at biochemical relapse with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
9851488|NCT03440411|Experimental|ARM pom-cyclo-dex Early(B-I)|Patients will receive treatment at biochemical relapse with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
9851489|NCT03440411|Experimental|ARM pom-dex Late (A-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
9851490|NCT03440411|Active Comparator|ARM pom-cyclo-dex Late (B-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-cyclo-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
9851491|NCT03440424|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
9851492|NCT03440424|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
9851493|NCT03440424|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index [BMI]) will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
9851494|NCT03440619|Experimental|INVSENSOR00013 Test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00013 investigational device.
9851495|NCT03440723|Active Comparator|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
9851496|NCT03440723|Experimental|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
9851497|NCT03440918|Active Comparator|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
9851498|NCT03440918|Experimental|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
9851499|NCT03440944|Active Comparator|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
9851500|NCT03440944|Active Comparator|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
9851501|NCT03441178|Experimental|Colectomy/Gynecological/Thoracic|Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
9851502|NCT03441269|Active Comparator|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
9851503|NCT03441269|Active Comparator|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
9851504|NCT03441269|Active Comparator|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
9851505|NCT03441581|Experimental|Eluxadoline 100 mg with BAM|IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.
9851506|NCT03441581|Experimental|Eluxadoline 100 mg without BAM|IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.
9851507|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date."
9851508|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date."
9851509|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date."
9851510|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date."
9851511|NCT03441789|Experimental|Otezla plus Enstilar foam|Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
9851512|NCT03441789|Placebo Comparator|Otezla plus vehicle foam|Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
9851513|NCT03441984|Experimental|Subjects with treatment sequence ABC|The subjects in Part 1 of the study, will receive a single dose of treatment A= adult TRIUMEQ (DTG 50 mg/ABC 600 mg/3TC 300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment B=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment C=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851514|NCT03441984|Experimental|Subjects with treatment sequence BCA|The subjects in Part 1 of the study, will receive treatment B in TP1, treatment C in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9923390|NCT00850083||Children in the ED|
9923391|NCT00850122|Experimental|Cefazolin|"Dosage Number of Infants~≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6"
9851515|NCT03441984|Experimental|Subjects with treatment sequence CAB|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment A in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851516|NCT03441984|Experimental|Subjects with treatment sequence ACB|The subjects in Part 1 of the study will receive, treatment A in TP1, treatment C in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851517|NCT03441984|Experimental|Subjects with treatment sequence BAC|The subjects in Part 1 of the study will receive a single dose each of, treatment B in TP1, treatment A in TP2 and treatment C in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851518|NCT03441984|Experimental|Subjects with treatment sequence CBA|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment B in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851519|NCT03441984|Experimental|Subjects with treatment sequence DEF|The subjects in Part 2 of the study, will receive a single dose of treatment D= Adult DTG (50 mg, 1 conventional tablet) and adult 3TC (300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment E= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment F= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851520|NCT03441984|Experimental|Subjects with treatment sequence EFD|The subjects in Part 2 of the study, will receive a single dose respectively of treatment E in TP1, treatment F in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851521|NCT03441984|Experimental|Subjects with treatment sequence FDE|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment D in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851522|NCT03441984|Experimental|Subjects with treatment sequence DFE|The subjects in Part 2 of the study, will receive a single dose of treatment D in TP1, treatment F in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851523|NCT03441984|Experimental|Subjects with treatment sequence EDF|The subjects in Part 2 of the study, will receive a single dose of treatment E in TP1, treatment D in TP2 and treatment F in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851524|NCT03441984|Experimental|Subjects with treatment sequence FED|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment E in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
9851525|NCT03442036|Active Comparator|Through-the-Needle Technique|"Perineural catheters are inserted through a straight hollow-bore needle.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
9851526|NCT03442036|Experimental|Suture-Method Technique|"Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
9851527|NCT03442296|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
9851528|NCT03442296|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
9851529|NCT03442569|Experimental|Open-label, single arm, Phase II|Nivolumab and ipilimumab with panitumumab
9851530|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
9851531|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
9851532|NCT03442699|Experimental|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
9851533|NCT03442725|Experimental|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
9851534|NCT03442725|Active Comparator|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
9923392|NCT00850148|Experimental|Melles|
10207902|NCT04317612|Placebo Comparator|Reference product|Once daily consumption over the period of the study
10207903|NCT04316689|Experimental|S-588210 (S-488210 + S-488211)|Participants will receive subcutaneous injections once a week for 4 weeks and then a biweekly extension treatment for 8 weeks. Each treatment will consist of 1 subcutaneous injection of 1 mL of S- 488210 and 1 subcutaneous injection of 1 mL of S-488211 containing 1 mg each of the 5 peptides.
10207904|NCT04309266|Experimental|Robot Assisted Therapy with Metacognitive Skills Training|All participants will be enrolled in the single arm of this study, where they will receive robot assisted therapy combined with metacognitive skills training.
10207905|NCT04307407|Experimental|Aerobic Exercise|The aim is for participants to complete three weekly sessions of supervised aerobic treadmill based exercise for five months. Session duration varies from 20-60 minutes, with exercise intensity ranging from 55-95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate), will be determined by the CPET performed by certified exercise physiologists at baseline.
10207906|NCT04307407|No Intervention|Standard care|Participants in this arm will not receive any follow-up on exercise during the intervention period.
10207907|NCT04307407|Other|Reference Group|Participants in this arm are age-matched women with no history of any malignant disease, which will undergo similar assessments at baseline and post-intervention and also follow similar exercise intervention as the breast cancer survivors randomized to the Aerobic exercise arm
10207908|NCT04278209|Experimental|Breakfast 1 - Breakfast 2|Participants will receive Breakfast 1 then Breakfast 2.
10207909|NCT04278209|Experimental|Breakfast 1 - water|Participants will receive Breakfast 1, then water.
9851535|NCT03442725|Experimental|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
9851536|NCT03442725|Experimental|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
9923393|NCT00850148|Experimental|Anwar|
9923394|NCT00850161|Experimental|Nasulin™|Intranasal insulin spray
9923395|NCT00850161|Active Comparator|aspart|Subcutaneous administration
9923396|NCT00850187|Experimental|Bone marrow mesenchymal stem cells|
9923397|NCT00850213||Endeavor Resolute Stent|Patients implanted with the Medtronic Endeavor Resolute stent
9923398|NCT00850226|Experimental|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
9923399|NCT00850226|Experimental|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
9923400|NCT00850239|Experimental|1|dutogliptin/PHX1149T
9923401|NCT00850239|Placebo Comparator|2|Plabeco
9923402|NCT00850252|Experimental|Lifeline blood vessel|
9923403|NCT00850265|Experimental|Spacer|Extrafine formoterol plus beclomethasone with spacer
9923404|NCT00850265|No Intervention|No Spacer|Extrafine formoterol plus beclomethasone without spacer
9923405|NCT00850278|Experimental|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
9923406|NCT00850291||1|Electrosurgical vessel sealing device
9923407|NCT00850291||2|traditional surgical methods:stitches and ligations
9923408|NCT00850304|Experimental|Arm one|
9923409|NCT00850330||Hospitalized patients|Patients elder than 65 years old hospitalized for any reason.
9923410|NCT00850356||Bariatric Surgery Patient (Sx)|Participants who are patients in an Adult Weight Management Clinic (AWMC) and undergo bariatric surgery.
9923411|NCT00850356||Medical Treamtent (Mx)|Participants who are patients in the same AWMC as above and are currently undergoing a medical treatment program that includes intensive lifestyle counseling (diets, exercise, behavioral modification).
9923412|NCT00850356||Wait-List (Wx)|Participants who are on the Wait-List for the AWMC, and waiting to undergo medical treatment program and/or bariatric surgery.
9923413|NCT00850369|Experimental|1|All subjects wil receive monthly RBC transfusions for 6 months
9923414|NCT00850382|Experimental|Dasatinib|"Induction cycle(s):~Patients will receive in cycle 1 induction therapy with daunorubicin 60 mg/m2/day administered on days 1 through 3 and cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7). Patients will receive dasatinib 100 mg QD on days 8-21. Patients not achieving CR or CRi at the end of cycle 1 will be evaluable to receive a second induction cycle identical in schedule and dosage to the first induction cycle.~Consolidation Cycles 1, 2, 3, 4:~Patients achieving CR or CRi at the end of cycle 1 will receive consolidation therapy for 4 cy-cles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
9923415|NCT00850408|Experimental|Real rTMS|Real rTMS - subjects receiving real repetitive TMS - 1Hz over unaffected hemisphere
9851537|NCT03442777|Experimental|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand)."
9851538|NCT03442777|Experimental|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
9851539|NCT03442777|No Intervention|Study Arm 3 (standard of care)|"Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
9851540|NCT03442829|Experimental|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
9851541|NCT03442829|Active Comparator|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
9851542|NCT03442868|Experimental|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
9851543|NCT03442933|Active Comparator|Road Cycling first, then Mountain Biking|First Intervention (3 hours: Road cycling), followed by a 7 days washout, and the second Intervention (3 hours: Mountain Biking).
9851544|NCT03442933|Active Comparator|Mountain Biking first, then Road Cycling|First Intervention (3 hours: Mountain Biking), followed by a 7 days washout, and the second Intervention (3 hours: Road cycling).
9851545|NCT03443024|Experimental|125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W)|"125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.~Baseline: Loading dose 250 mg Lebrikizumab SC (two injections SC 1-milliliter (mL) of 125 mg/mL Lebrikizumab and 1-mL placebo).~Week 2: Four 1-mL SC injections placebo.~Weeks 4, 8, 12: 125 mg SC Lebrikizumab and 1-mL SC placebo.~Weeks 6, 10, 14: Two 1-mL SC placebo."
9851546|NCT03443024|Experimental|250 mg Lebrikizumab - Q4W|"250 mg Lebrikizumab administered SC once Q4W.~Baseline: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 2: Four 1-mL SC injections of placebo.~Weeks 4, 8, 12: 250 mg (two 1-mL injections of 125 mg/mL Lebrikizumab).~Weeks 6, 10, 14: Two 1-mL injections of placebo."
9851547|NCT03443024|Experimental|250 mg Lebrikizumab - Every 2 Weeks (Q2W)|"250 mg Lebrikizumab administered SC once Q2W.~Baseline and Week 2: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 4, 6, 8, 10, 12, 14: 250 mg (two 1-mL SC injections of 125 mg/mL Lebrikizumab)."
9851548|NCT03443024|Placebo Comparator|Group 4 - Placebo|"Placebo administered SC once Q2W.~Baseline and Week 2: Four 1-mL SC injections of placebo.~Week 4, 6, 8, 10, 12, 14: Two 1-mL SC injections of placebo."
9851549|NCT03443063|Experimental|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliters per minute (mL/min/1.73 square meter [m^2]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
9851550|NCT03443063|Experimental|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
9851551|NCT03443414|Experimental|0.75 mg RPL554|
9851552|NCT03443414|Experimental|1.5 mg RPL554|
9851553|NCT03443414|Experimental|3 mg RPL554|
9851554|NCT03443414|Experimental|6 mg RPL554|
9851555|NCT03443414|Placebo Comparator|Placebo|
9851556|NCT03443427|Experimental|Schedule 0-2-6 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).
9851557|NCT03443427|Experimental|Schedule 0-2-12 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).
9851558|NCT03443713|Experimental|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
9851559|NCT03443713|Experimental|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
9851560|NCT03443713|Experimental|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
9851561|NCT03444090|Experimental|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size <10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size >10 mm will be performed only during withdrawal of the scope.
9851562|NCT03444090|Active Comparator|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
9851563|NCT03444155|Active Comparator|Natural Panmol-B-Complex first, then synthetic Vitamin B-complex|Participants first received a Natural Vitamin B-complex, i.e., Panmol-B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
9851564|NCT03444155|Active Comparator|Synthetic Vitamin B-complex first, then Natural Panmol-B-Complex|Participants first received a Synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a natural Vitamin B-complex, i.e., Panmol-B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
9851565|NCT03444584|Experimental|MEDI0382|Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.
9851566|NCT03444584|Placebo Comparator|Placebo|Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period
9851567|NCT03444766|Experimental|Monotherapy|administering nivolumab only
9851568|NCT03444961|Experimental|CAREN system training|CAREN training
9851569|NCT03445065|Experimental|Cohort 1, Enabled - Eversense XL CGM System|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
9851570|NCT03445065|Active Comparator|Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
9851571|NCT03445065|Experimental|Cohort 2, Enabled - Eversense XL CGM System|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
9851572|NCT03445065|Active Comparator|Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
9851573|NCT03445156|Experimental|Pilot Study|After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
9851574|NCT03445156|Experimental|Experiment Proper|"After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed."
9851575|NCT03445195|Experimental|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
9851576|NCT03445195|Placebo Comparator|Placebo + Imipenem/Cilastatin|
9851577|NCT03445390|Experimental|Acetaminophen First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive acetaminophen first.
9851578|NCT03445390|Experimental|Placebo First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive placebo first.
9851579|NCT03446053|Experimental|N-Rephasin® SAL200|Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.
9851580|NCT03446053|Placebo Comparator|INT200-Placebo|Saline
9851581|NCT03446690|Experimental|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
9851582|NCT03446690|Other|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
9851583|NCT03446781|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
9851584|NCT03446781|Placebo Comparator|Placebo|Placebo
9851585|NCT03446846|Experimental|5.0 mg MIN-117|MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks
9851586|NCT03446846|Experimental|2.5 mg MIN-117|MIN-117 2.5 mg (consisting of one 2.5 mg capsule and one placebo capsule) orally daily for 6 weeks
9851587|NCT03446846|Placebo Comparator|Placebo|Placebo (consisting of two placebo capsules) orally daily for 6 weeks
9851588|NCT03446885|Experimental|Lab visit 1|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
9851589|NCT03446885|Experimental|Lab visit 2|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
9851590|NCT03447015|Experimental|Ambulation during labour|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
9851591|NCT03447015|No Intervention|Standard Maternity care|women will receive usual maternity care.
9851592|NCT03447249|Placebo Comparator|Placebo|Participants who received placebo matched to VX-659/TEZ/IVA for 24 weeks in the TC treatment period.
9851593|NCT03447249|Experimental|VX-659/TEZ/IVA TC|Participants who received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
9851594|NCT03447353|Experimental|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
9851595|NCT03447353|Experimental|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
9851596|NCT03447353|Experimental|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
9851597|NCT03447353|Experimental|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
9851598|NCT03447730|Experimental|Part 1: SYNB1020|Part 1 comprised a sentinel open-label cohort of subjects enrolled sequentially to receive SYNB1020, which was administered orally at a dose of 5 × 10^11 colony-forming units (CFU) 3 times daily (TID) given immediately after meals from Days 1 through 6.
9851599|NCT03447730|Experimental|Part 2: SYNB1020|Subjects randomized to receive SYNB1020 in Part 2 received SYNB1020 administered orally at a dose of 5 × 10^11 CFU TID given immediately after meals from Days 1 through 6.
9851600|NCT03447730|Placebo Comparator|Part 2: Placebo|Subjects randomized to receive control in Part 2 received matching placebo (100 mL masking solution) administered orally TID given immediately after meals from Days 1 through 6.
9851601|NCT03447821|Active Comparator|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
9851602|NCT03447821|Active Comparator|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
9851603|NCT03447821|Active Comparator|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
9851604|NCT03448068|Experimental|Ketamine Therapy|"Ketamine 0.3 mg/kg (IBW) bolus with induction.~Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion will not be titrated.~Remaining care will be identical to standard therapy group."
9923416|NCT00850408|Sham Comparator|Sham rTMS|Sham rTMS
9923417|NCT00850434|Experimental|modified autoset|the modified AutoSet responds to different breathing patterns than the standard AutoSet, to treat OSA. Participants in this arm will trial the modified AutoSet for one night, and the standard AutoSet for one night, in a randomised order
10207910|NCT04278209|Experimental|Breakfast 2 - water|Participants will receive Breakfast 2, then water.
9851605|NCT03448068|Active Comparator|Standard Therapy|"Calculation ideal body weight (IBW)~Pre-op dexamethasone~Pre-op midazolam at discretion of anesthesiologist~Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.~Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.~Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.~Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac~Other post-op care as per usual surgical routine"
9851606|NCT03448224|Experimental|Group I (web-based Indoor Tanning intervention)|Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
9851607|NCT03448224|Active Comparator|Group II (wait-list)|Participants are placed on wait-list and may receive full intervention after follow-up.
9851608|NCT03448406|Experimental|Empagliflozin|
9851609|NCT03448406|Active Comparator|Placebo|
9851610|NCT03448419|Experimental|Empagliflozin|
9851611|NCT03448419|Placebo Comparator|Placebo|
9851612|NCT03448536|Experimental|Naproxen Sodium : Acetaminophen|Subjects received one single oral dose of 440 mg naproxen sodium in treatment period 1, followed by one single oral dose of 1000 mg acetaminophen in treatment period 2
9851613|NCT03448536|Experimental|Acetaminophen : Naproxen Sodium|Subjects received one single oral dose of 1000 mg acetaminophen in treatment period 1, followed by one single oral dose of 440 mg naproxen sodium in treatment period 2
9851614|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
9851615|NCT03449030|Experimental|Part B Expansion Stage: TAK-164 Q3W|TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 RP2D dose to be decided based on safety, PK, pharmacodynamics and antitumor response data observed in Part A escalation stage.
9851616|NCT03449030|Experimental|Part C Imaging Substudy: 89Zr-TAK-164 and TAK-164|89Zr-TAK-164, intravenous infusion, followed by unlabeled TAK-164, intravenous infusion in combination with 89Zr-TAK-164, intravenous infusion, and further followed by unlabeled TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 recommended imaging dose (RID) or RP2D dose to be decided based on safety, PK, PD and antitumor response data observed in Part A escalation stage.
9851617|NCT03449134|Placebo Comparator|Placebo|Participants receive dose-matched placebo tablets twice daily (BID) during the 12-week main study period and 40-week extension period.
9851618|NCT03449134|Experimental|Gefapixant 15 mg BID|Participants receive a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 12-week main study period and 40-week extension period.
9851619|NCT03449134|Experimental|Gefapixant 45 mg BID|Participants receive a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 12-week main study period and 40-week extension period.
9851620|NCT03449147|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and the 28-week extension period.
9851621|NCT03449147|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and the 28-week extension period.
9851622|NCT03449147|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and during the 28-week extension period.
9851623|NCT03449342|Experimental|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
9851624|NCT03449433|Experimental|LY900014|T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
9851625|NCT03449433|Active Comparator|Insulin Lispro (Humalog®)|T1DM participants received a single, individualized, SC dose of insulin lispro.
9851626|NCT03449433|Active Comparator|Insulin Aspart (NovoRapid®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
9851627|NCT03449433|Active Comparator|Insulin Aspart (Fiasp®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
9851628|NCT03449433|No Intervention|Healthy Participants|Healthy participants who received no study drug.
9851629|NCT03449446|Experimental|Selonsertib (SEL)|Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
9851630|NCT03449446|Experimental|Firsocostat (FIR)|Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
9851631|NCT03449446|Experimental|Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
9851632|NCT03449446|Experimental|Selonsertib (SEL) + Firsocostat (FIR)|Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
9851633|NCT03449446|Experimental|Selonsertib (SEL) + Cilofexor (CILO)|Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
10207911|NCT04278209|Experimental|Breakfast 2 - Breakfast 1|Participants will receive 2 servings, then 1 serving of the study product.
10207912|NCT04278209|Experimental|Water - Breakfast 1|Participants will receive water, then Breakfast 1.
10207913|NCT04278209|Experimental|Water - Breakfast 2|Participants will receive water, then Breakfast 2.
10207914|NCT04276870|Experimental|Subjects with hypodiploid B-ALL|
10207915|NCT04276870|Experimental|Subjects with t(17;19) B-ALL|
10207916|NCT04276870|Experimental|Infant subjects with very high risk KMT2A B-ALL|
10207917|NCT04276870|Experimental|Subjects with central nervous system (CNS) relapse|who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT)
10207918|NCT04258722|Experimental|Trainee + Teleneonatologist|Trainee, teleneonatologist, nurse, and respiratory therapist will perform resuscitation
10207919|NCT04258722|Active Comparator|Trainee|Trainee, nurse, and respiratory therapist will perform resuscitation.
9851634|NCT03449446|Experimental|Firsocostat (FIR) + Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
9851635|NCT03449446|Experimental|Placebo|Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
9996918|NCT01504334|Experimental|Pirfenidone(200mg)|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
9851637|NCT03449979|Experimental|alpha stimulation in participants in a depressive episode|Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
9851638|NCT03449979|Placebo Comparator|sham stimulation in participants in a depressive episode|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.
9851639|NCT03449979|Experimental|alpha stimulation in healthy participants|Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
9851640|NCT03449979|Placebo Comparator|sham stimulation in healthy participants|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.
9851641|NCT03450070|Experimental|Test Panel|Light Therapy Mask Cream
9851642|NCT03450083|Active Comparator|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
9851643|NCT03450083|Placebo Comparator|Placebo group|Placebo treatment group delivered subcutaneously
9851644|NCT03450369|Experimental|NB01|"NB01 is a live probiotic containing a single strain of P. acnes, frozen, on a pad, in a single use pouch, for topical application.~Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose."
9851645|NCT03450915|Experimental|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
9851646|NCT03450915|Placebo Comparator|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
9851647|NCT03451071|Experimental|Gardasil9|
9851648|NCT03451084|Experimental|Part 1: Dose Level 1|
9851649|NCT03451084|Experimental|Part 1: Dose Level 2|
9851650|NCT03451084|Experimental|Part 1: Dose Level 3|
9851651|NCT03451084|Experimental|Part 1: Dose Level 4|
9851652|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine|
9851653|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level & Azacitidine|
9851654|NCT03451721|Experimental|ImageReady™ MR Conditional Defibrillation System|"Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology~Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
9851655|NCT03451773|Experimental|1/ Arm 1-Gemcitabine + de-escalating dose of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + de-escalating dose of M7824
9851656|NCT03451773|Experimental|2/ Arm 2-Gemcitabine + Recommended Phase 2 Dose (RP2D) of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + RP2D of M7824
9851657|NCT03452033|Placebo Comparator|H-1337 Placebo|H-1337 Placebo
9851658|NCT03452033|Experimental|H-1337 [1]|H-1337 [1]
9851659|NCT03452033|Experimental|H-1337 [2]|H-1337 [2]
9851660|NCT03452033|Experimental|H-1337 [3]|H-1337 [3]
9851661|NCT03452176|Experimental|Scrambler|This arm will receive the Scrambler intervention for 1 hour daily x10 days.
9851662|NCT03452176|Sham Comparator|Sham-Control|This arm will receive the Sham-Control intervention for 1 hour daily x10 days.
9851663|NCT03452189|Active Comparator|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
9851664|NCT03452189|Placebo Comparator|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
9851665|NCT03452371|Active Comparator|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
9851666|NCT03452371|Experimental|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to ten hours of patient navigation over three months.
9851667|NCT03452527|Experimental|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
9851668|NCT03452527|Experimental|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
9851669|NCT03452943|Experimental|TEV-50717|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 12 weeks
9851670|NCT03452943|Placebo Comparator|Placebo|Placebo matched to TEV-50717 BID for a total of 12 weeks
9851671|NCT03453060|Experimental|E-WE Thrombin Dose 1|Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
9851672|NCT03453060|Experimental|E-WE Thrombin Dose 2|Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
9996919|NCT01504334|Placebo Comparator|Placebo (without active ingredient)|
9996920|NCT01504347|Experimental|Primary vaccination in seronegative subjects|
9851673|NCT03453060|Experimental|E-WE Thrombin Dose 3|Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
9851674|NCT03453060|Experimental|E-WE Thrombin Dose 4|Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
9851675|NCT03453060|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
9851676|NCT03453151|Experimental|Regional nerve anesthesia|
9851677|NCT03453515|Experimental|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
9851678|NCT03453515|Other|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
9851679|NCT03454048|Experimental|Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 1 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg).
9851680|NCT03454048|Experimental|Group 2 (Cohort A) LD-PIP/LD-PIP2/SP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 2(LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
9851681|NCT03454048|Experimental|Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 3 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg)
9851682|NCT03454048|Experimental|Group 4 (Cohort B) LD-PIP/LD-PIP2/SP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 4 (LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
9851683|NCT03454581|Experimental|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.~18 individuals"
9851684|NCT03454581|Experimental|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.~16 individuals."
9851685|NCT03454581|Experimental|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
9851686|NCT03455218|Experimental|Nitric Oxide|20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time
9851687|NCT03455218|Placebo Comparator|Placebo|INOmax device attached to the oxygenator, but no gas is delivered through the device
9851688|NCT03455491|Experimental|XC221 100 mg|"XC221 100 mg orally.~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
9851689|NCT03455491|Experimental|XC221 200 mg|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
9851690|NCT03455491|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
9851691|NCT03455543|Experimental|Active Group|Treatment with active Provant Therapy System
9851692|NCT03455543|Sham Comparator|Sham Group|Treatment with in-active (sham) Provant Therapy System
9851693|NCT03456245||Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
9851694|NCT03456427|Other|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
9851695|NCT03456856|Experimental|Ivabradine|The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise. Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
9851696|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
9851697|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
9996921|NCT01504347|Experimental|Booster vaccination in seronegative subjects|
9996922|NCT01504347|Experimental|Primary + booster vacc. (seronegative + seropositive subjects)|
9851698|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
9851699|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
9851700|NCT03456960|Experimental|Study 2,TAK-438ASA (Fasted + Fed condition)|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
9851701|NCT03456960|Experimental|Study 2,TAK-438ASA (Fed + Fasted condition)|One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
9851702|NCT03457103|Experimental|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
9851703|NCT03457103|Active Comparator|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
9851704|NCT03457116|Active Comparator|NSAIDS|400mg of Ibuprofen
9851705|NCT03457116|Active Comparator|Opiates|Norco (hydrocodone 5mg- acetaminophen 325mg)
9851706|NCT03457636|Experimental|doxycycline anhydrous and adapalene/benzoyl peroxide|All subjects will receive at Baseline doxycycline anhydrous 40 mg (Oracea) to be taken once daily and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily for 12 weeks
9851707|NCT03457727|Experimental|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
9851708|NCT03457727|Experimental|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
9851709|NCT03457727|Experimental|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
9851710|NCT03457909|Experimental|DS-MCE|outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.
9851711|NCT03458702|Experimental|YogaFit then Quiet Rest|Participants participated in a 30 min YogaFit and then a session of 30 min of Quiet Rest on a separate day.
9851712|NCT03458702|Experimental|Quiet Rest then YogaFit|Participants participated in a 30 min Quiet Rest session and then a session of 30 min of YogaFit on a separate day.
9851713|NCT03458871|Experimental|4-week TTNS home based protocol|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 4-week protocol.
9851714|NCT03459040|Experimental|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
9851715|NCT03459131|Other|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
9851716|NCT03459131|Other|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
9851717|NCT03459196|Experimental|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
9851718|NCT03459612|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
9851719|NCT03459612|Experimental|100 milligrams (mg) Lasmiditan|100 mg lasmiditan administered orally in one of four study periods.
9851720|NCT03459612|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally in one of four study periods.
9996923|NCT01504360|Experimental|sarcoma group|patient suffering form radiation-induced sarcoma
9851721|NCT03459612|Active Comparator|Diphenhydramine|50 mg diphenhydramine administered orally in one of four study periods.
9851722|NCT03459794|Active Comparator|Ivermectin|Ivermectin will be administered once at 150mcg/kg, orally.
9851723|NCT03459794|Placebo Comparator|Control|An oral placebo will be administered once
9851724|NCT03460587|Experimental|Home-based Telerehabilitation|Home-based Telerehabilitation
9851725|NCT03460652|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
9851726|NCT03460899|Experimental|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
9851727|NCT03460990|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
9851728|NCT03460990|Experimental|VX-659/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
9851729|NCT03461146|Experimental|MT-6548|
9851730|NCT03461289|Experimental|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
9851731|NCT03461757|Experimental|Arm 1: Rimegepant 75 mg|Participants were administered a single sublingual dose of 75 mg of rimegepant ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
9851732|NCT03461757|Placebo Comparator|Arm 2: Placebo|Participants were administered a single sublingual dose of matching placebo for rimegepant (75 mg) ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
9851733|NCT03461965|Experimental|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
9851734|NCT03461965|Active Comparator|Verbal Counselling|Participants in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
9851735|NCT03462082|No Intervention|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
9851736|NCT03462082|Experimental|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
9851737|NCT03462082|Experimental|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
9851738|NCT03462576|Experimental|Emricasan 25mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
9851739|NCT03462576|Experimental|Emricasan 5mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
9851740|NCT03462576|Placebo Comparator|Placebo|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
9851741|NCT03462680|Active Comparator|niacin|Niacin 250 mg is compared to placebo tablet.
9851742|NCT03462680|Placebo Comparator|placebo|placebo
9851743|NCT03462745|Experimental|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
9851744|NCT03462745|No Intervention|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
9851745|NCT03462927|Experimental|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
9851746|NCT03462927|Active Comparator|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
9851747|NCT03463031|Experimental|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
9851748|NCT03463031|Placebo Comparator|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
9851749|NCT03463161|Experimental|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
9851750|NCT03463161|Experimental|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
9851751|NCT03463512|Experimental|Racecadotril plus standard treatment oral rehydration solution|
9851752|NCT03463512|Active Comparator|ORS (standard treatment)|
9851753|NCT03463889|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
9851754|NCT03463915|Active Comparator|Bladder instillation WITH triamcinolone acetonide|Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
9851755|NCT03463915|Placebo Comparator|Bladder instillation WITHOUT triamcinolone acetonide|Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
9851756|NCT03463941|Experimental|African American church members|
9923418|NCT00850434|Active Comparator|standard AutoSet|The standard autoset treat OSA by using pressure increases to overcome abnormal breathing patterns. Patients in this arm will use the standard AutoSet for one night and the modified AutoSet for one night, in a randomised order
9923419|NCT00850447|Experimental|Cognitive Remediation Therapy|
9923420|NCT00850447|Placebo Comparator|Videogames|
9923421|NCT00850512|Experimental|CHOP21|4 cycles CHOP21-R plus Zevalin
9923422|NCT00850551|Active Comparator|Usual Care|Usual Care
9923423|NCT00850551|Other|Intervention|Twice weekly home spirometry and symptom assessment
9851757|NCT03464383|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
9851758|NCT03464383|Active Comparator|Standard of Care|A psychiatry referral order placed by epileptologist under typical care circumstances (internal or external referral based on the participant's geographic preferences). Internal referrals will be processed by current clinic/institutional protocols. External referral orders will be printed and provided to the patient along with brief instructions on how to find a provider covered by the patient's insurance.
9851759|NCT03464383|Other|Survey Arm|This option will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are found to be ineligible for intervention arms of the study, or those who are eligible for the intervention arm but decline to participate in the intervention.
9851760|NCT03464422|Experimental|Young gay and bisexual men of color|Approximately 30 young MSM of color will take part in weekly 90-minute group treatment sessions over 10 weeks. All participants will complete outcome assessments at baseline and three months post-treatment, as well as an exit interview.
9851761|NCT03465436|Experimental|100 milligrams (mg) Lasmiditan|A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
9851762|NCT03465436|Experimental|400 mg Lasmiditan|A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
9851763|NCT03465436|Placebo Comparator|Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
9851764|NCT03465436|Active Comparator|Moxifloxacin|A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
9851765|NCT03465709|Experimental|Pegcetacoplan Study Drug|
9851766|NCT03465722|Experimental|avapritinib|300 mg PO QD
9851767|NCT03465722|Active Comparator|regorafenib|160 mg PO QD
9851768|NCT03465878|Experimental|LY900014-Part A|Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
9851769|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part A|Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
9851770|NCT03465878|Experimental|LY900014-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
9851771|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
9851772|NCT03465904|Experimental|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
9851773|NCT03465904|Sham Comparator|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
9851774|NCT03466047|Experimental|Protein stomach|Encapsulated protein released in the stomach
9851775|NCT03466047|Experimental|Protein distal small intestine|Encapsulated protein released in the distal small intestine
9851776|NCT03466047|Experimental|CHO stomach|Encapsulated CHO released in the stomach
9851777|NCT03466047|Experimental|CHO distal small intestine|Encapsulated CHO released in the distal small intestine
9851778|NCT03466047|Experimental|Fat stomach|Encapsulated Fat released in the stomach
9851779|NCT03466047|Experimental|Fat distal small intestine|Encapsulated Fat released in the distal small intestine
9851780|NCT03466060|Active Comparator|etafilcon A|Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.
9851781|NCT03466060|Active Comparator|senofilcon A|Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.
9851782|NCT03466060|Active Comparator|senofilcon C|Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.
9851783|NCT03466073|Experimental|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
9851784|NCT03466073|Experimental|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
9851785|NCT03466073|Experimental|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
9851786|NCT03466073|Experimental|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
9851787|NCT03466086|Experimental|Test/Control|Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
9851788|NCT03466086|Experimental|Control/Test|Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
9851789|NCT03466099|Experimental|KVD001 Injection (high dose)|
9851790|NCT03466099|Experimental|KVD001 Injection (low dose)|
9851791|NCT03466099|Sham Comparator|Sham Procedure|
9851792|NCT03466918|Experimental|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
9851793|NCT03467048|Experimental|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
9851794|NCT03467048|Active Comparator|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
9851795|NCT03467217|Active Comparator|Losartan potassium capsule|Dose will be one 50 mg capsule of losartan per day for one week and then increased to two capsules of 50 mg of losartan per day (100 mg total) for 23 weeks patients with baseline weight ≥ 70 kg to <150 kg.
9851796|NCT03467217|Placebo Comparator|Placebo losartan capsule|Dose will be one 50 mg capsule of placebo losartan per day for one week and then increased to two capsules of 50 mg of placebo losartan per day (100 mg total) for 23 weeks for patients with baseline weight ≥ 70 kg to <150 kg.
9851797|NCT03467412|Experimental|0.00625 μg FOL-005|50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.
9851798|NCT03467412|Experimental|0.025 μg FOL-005|50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.
9851799|NCT03467412|Experimental|0.050 μg FOL-005|50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.
9851800|NCT03467412|Experimental|0.100 μg FOL-005|50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.
9851801|NCT03467412|Placebo Comparator|Placebo|50 μl solution (placebo) injected intradermally three times per week for 12 weeks.
9851802|NCT03467425|Experimental|TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)|Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
9851803|NCT03467425|Active Comparator|Non-ELLIPTA MITT|Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
9851804|NCT03467477|Experimental|Flortaucipir PET Scan|
9851805|NCT03467685|Placebo Comparator|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
9851806|NCT03467685|Experimental|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
9851807|NCT03467763|Active Comparator|Metformin Hydrochloride Extended Release|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.
9851808|NCT03467763|Placebo Comparator|Placebo|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of placebo, followed by 500 mg placebo, 750 mg, and 1,000 mg placebo with each treatment period separated by a 2-week course of metformin XR in the same increments of dosage.
9851809|NCT03467945|Experimental|Treatment Sequence 1|Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
9851810|NCT03467945|Experimental|Treatment Sequence 2|Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
9923424|NCT00850590|Experimental|Low Dose|NRL001 at 5, 7.5, and 10 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
9851811|NCT03467945|Experimental|Treatment Sequence 3|Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
9851812|NCT03467945|Experimental|Treatment Sequence 4|Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
9851813|NCT03467971|Experimental|Metformin-Gliclazide (fasted), Then Metformin-Gliclazide (fed)|Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
9851814|NCT03467971|Experimental|Metformin-Gliclazide (fed), Then Metformin-Gliclazide (fasted)|Participants received single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 2. Each treatment period will be separated by a 14-day wash-out period.
9851815|NCT03468075|Experimental|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
9851816|NCT03468179|Experimental|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
9851817|NCT03468543|Experimental|Cohort 1|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days
9851818|NCT03468543|Experimental|Cohort 2|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days
9851819|NCT03468543|Experimental|Cohort 3|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days
9851820|NCT03468816|Experimental|A-B-A|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant A, at next dressing change they received variant B, and on the third dressing change they received variant A again. No washout periods.
9851821|NCT03468816|Experimental|B-A-B|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant B, at next dressing change they received variant A, and on the third dressing change they received variant B again. No washout periods.
9851822|NCT03468855|Experimental|ATI-50002 Topical Solution|ATI-50002 topical solution, high dose active, twice-daily, 24 weeks
9851823|NCT03468920|Experimental|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
9851824|NCT03468920|Active Comparator|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
9851825|NCT03468933|Active Comparator|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
9851826|NCT03468933|Active Comparator|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
9851827|NCT03469336|Other|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
9851828|NCT03469349|Experimental|Actovegin 1200 mg|Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
9851829|NCT03469349|Placebo Comparator|Placebo|Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
9851830|NCT03470012|Experimental|Treatment Arm|Investigational tape
9851831|NCT03470194|Active Comparator|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
9851832|NCT03470194|Active Comparator|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
9851833|NCT03470493|Experimental|Participants|ApneaLink Air
9851834|NCT03470545|Experimental|mavacamten (MYK-461)|
9851835|NCT03470545|Placebo Comparator|Placebo|
9851836|NCT03470740|Other|intervention group|An individualized rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.
9851837|NCT03470740|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
9851838|NCT03471065|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
9851839|NCT03471078|Experimental|Avatrombopag|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
9851840|NCT03471078|Placebo Comparator|Placebo|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
9851841|NCT03471832|Experimental|stenfilcon A lens|MyDay contact lens
9851842|NCT03471832|Active Comparator|narafilcon A lens|1-Day Acuvue TruEye
9851843|NCT03471871|Experimental|HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg|Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
9851844|NCT03471871|Experimental|HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo|Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
10207920|NCT04249258|Experimental|Dobutamine|Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
10207921|NCT04235608|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane, as vaporized via the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
9851845|NCT03471871|Experimental|HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg|Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
9851846|NCT03471871|Experimental|OSA Cohort, Sequence D: Placebo, Lemborexant 10mg|Eligible adult and elderly participants with mild OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
9851847|NCT03471871|Experimental|OSA Cohort, Sequence E: Lemborexant 10mg, Placebo|Eligible adult and elderly participants with mild OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
9851848|NCT03471975|Active Comparator|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
9851849|NCT03471975|Active Comparator|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.~Trainer and Trainee both see the monitor."
9851850|NCT03472014|Experimental|IMVAMUNE®|Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals
9851851|NCT03472287|Experimental|Cohort 1 (Adolescents, Adults)|Adolescent and adult subjects with EB (aged 12 years and older) received diacerein 1% ointment daily for 10 days.
9851852|NCT03472287|Experimental|Cohort 2 (Children)|Children with EB (aged 4 to 11 years, inclusive) received diacerein 1% ointment daily for 10 days.
9851853|NCT03472326|Experimental|Part 1 Sentinel Cohort 1: GS-9131 60 mg|Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.
9851854|NCT03472326|Experimental|Part 1 Sentinel Cohort 2: GS-9131 180 mg|Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.
9851855|NCT03472326|Experimental|Part 1: Randomized Cohort|Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.
9851856|NCT03472326|Experimental|Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV|Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
9996924|NCT01504360|Active Comparator|free from sarcoma group|patient without sarcoma 5 years after radiation therapy
10207922|NCT04235608|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs
10207923|NCT04231838|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
10207924|NCT04231838|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS
10207925|NCT04226742|Experimental|Treatment|Participants randomly assigned to this condition will receive the ADAPT platform (treatment) for a treatment period of 8 weeks.
10207926|NCT04226742|Active Comparator|Control|Participants randomly assigned to this condition will receive a similar self-guided platform (control) for a treatment period of 8 weeks.
10207927|NCT04224155|Experimental|enVista MX60EFH trifocal intraocular lens (IOL)|
10207928|NCT04224155|Active Comparator|enVista MX60E monofocal intraocular lens (IOL)|
10207929|NCT04222985|Experimental|Part A - Group 1|HSV 2 formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
9851857|NCT03472326|Experimental|Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF|Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
9851858|NCT03472469|Active Comparator|Original MMPR - descending dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
9851859|NCT03472469|Active Comparator|MAST MMPR - escalating dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
9851860|NCT03472521|Experimental|Gabapentin|Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
9851861|NCT03472521|Placebo Comparator|Control|Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
9851862|NCT03472534|Other|study in healthy volunteers|diacerein 1% ointment
9851863|NCT03472547|Experimental|Single cohort (Healthy Volunteers)|diacerein 1% ointment
9851864|NCT03473171|Experimental|Nasal non-invasive ventilation with RAM cannula|
9851865|NCT03473184|Experimental|Single Cohort (Healthy Volunteers)|Single cohort received diacerein 1% ointment
9851866|NCT03473197|Other|Single Cohort (Healthy Volunteers)|Diacerein 1% topical ointment Intra-subject photoallergy (photosensitization) test
9851867|NCT03473236|Experimental|Cohort 1A|Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
9851868|NCT03473236|Experimental|Cohort 2A|Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
9851869|NCT03473236|Experimental|Cohort 3A|Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
9851870|NCT03473236|Experimental|Cohort 4A|Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
9851871|NCT03473236|Experimental|Cohort 5A|Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
9851872|NCT03473236|Experimental|Cohort 1B|Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
9851873|NCT03473236|Experimental|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
9851874|NCT03473236|Experimental|Cohort 3B|Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
10207930|NCT04222985|Experimental|Part A - Group 2|HSV 2 formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207931|NCT04222985|Experimental|Part A - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207932|NCT04222985|Experimental|Part A - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
9851875|NCT03473301|Experimental|Allogeneic Umbilical Cord Blood|Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
9851876|NCT03473301|Experimental|Cord Tissue Mesenchymal Stromal Cells|Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
9851877|NCT03473301|Active Comparator|Natural History|Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.
9851878|NCT03473665|Active Comparator|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
9851879|NCT03473665|Active Comparator|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
9851880|NCT03473665|Active Comparator|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
9851881|NCT03473665|Active Comparator|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
9851882|NCT03473808|Experimental|therapy + vibration|Imperceptible vibration applied to the wrist during a standardized hand task practice therapy program.
9851883|NCT03473886|Experimental|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
9851884|NCT03474081|Experimental|Subjects receiving FF/UMEC/VI + Placebo to match tiotropium|Eligible subjects will receive FF/UMEC/VI at a dose of 100/62.5/25 microgram (mcg) administered once daily in the morning via ELLIPTA along with placebo to match tiotropium administered once daily in the morning via HANDIHALER. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via metered dose inhaler (MDI).
9851885|NCT03474081|Experimental|Subjects receiving Tiotropium + Placebo to match FF/UMEC/VI|Eligible subjects will receive Tiotropium at a dose of 18 mcg administered once daily in the morning via HANDIHALER along with placebo to match FF/UMEC/VI administered once daily in the morning via ELLIPTA. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via MDI.
9851886|NCT03474172|Experimental|Genuine Tuina|Participants will receive genuine tuina manipulated on their skin in addition to the conventional therapy given by the doctors. The whole process of the Tuina, which may last for 15 minutes, should be completed under the Cloak Shape device. After that the parents and the observers may be required to fill out corresponding questionnaires. The outcomes assessors will ask the child the sense perception of the manipulation via a questionnaire if he is equal or older than 3 years old.
9851887|NCT03474172|Sham Comparator|Sham Tuina|Except for the conventional therapy given by doctors, participants in this group will receive sham Tuina. A cloak shape device will be adopted, while inside the cover the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead of childrens' hand or childrens' body. The acupoints and the manipulation time are the same as real Tuina group. Same questionnaires as those adopted in real Tuina group are also required to be completed.
9851888|NCT03474874|Other|Collagen Dressing and Comparator|NeoMatriX Collagen Dressing and Comparators - positive control and normal saline will be applied to the absorbent pad portion of the exclusive dressing.
9851889|NCT03475056|Experimental|Group 1: cAd3-Marburg vaccine (1x10^10 PU)|cAd3-Marburg vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
9851890|NCT03475056|Experimental|Group 2: cAd3-Marburg vaccine (1x10^11 PU)|cAd3-Marburg vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
9851891|NCT03475316|Experimental|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
9851892|NCT03475316|Active Comparator|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
9851893|NCT03475875|Experimental|TEST/CONTROL/CONTROL|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
9851894|NCT03475875|Experimental|CONTROL/TEST/TEST|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
9851895|NCT03475992|Experimental|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
9851896|NCT03475992|Experimental|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.~No prior biopsy"
9851897|NCT03475992|Experimental|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
9851898|NCT03476278||regional, questionnaire|patients who underwent surgery under regional anesthesia.
9851899|NCT03476798|Experimental|Bevacizumab + Rucaparib|
9996925|NCT01504373|Other|NAVA-PSV|Subject will receive 4 hours of NAVA followed by 4 hours of PSV.
9996926|NCT01504373|Other|PSV-NAVA|Subject will receive 4 hours of PSV followed by 4 hours of NAVA.
9851900|NCT03476850|Active Comparator|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
9851901|NCT03476850|Active Comparator|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
9851902|NCT03477006|Experimental|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
9851903|NCT03477006|No Intervention|Standard Care|Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
9851904|NCT03477279|No Intervention|Individual (SOC)|HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
9851905|NCT03477279|Experimental|Couple (Intervention)|In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
9851906|NCT03477279|No Intervention|HIV-Uninfected Cohort|HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.
9851907|NCT03477838|Experimental|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
9851908|NCT03478163|No Intervention|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
9851909|NCT03478163|Experimental|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
9851910|NCT03478254||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
9851911|NCT03478371|Sham Comparator|Marketed Tampon D|Regular absorbency tampon
9851912|NCT03478371|Sham Comparator|Marketed Tampon M|Regular absorbency tampon
9851913|NCT03478371|Sham Comparator|Marketed Tampon T|Regular absorbency tampon
9851914|NCT03478371|Sham Comparator|Marketed Tampon V|Regular absorbency tampon
9851915|NCT03478644|Experimental|Experimental Denture Wipe|Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
9851916|NCT03478644|Placebo Comparator|Tap Water|Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
9851917|NCT03478657|Experimental|Subjects using placebo ELLIPTA DPI|Subjects in stratum 1 and stratum 2 will be of age group from 5 to 7 years and 8 to 11 years respectively. Subjects will take placebo ELLIPTA DPI once daily. During Visit 2 (Day 28) subjects will be randomized to receive questionnaire on ELLIPTA DPI usage either version A or B.
9851918|NCT03478683|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
9851919|NCT03478683|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
9851920|NCT03478696|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
9851921|NCT03478696|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
9851922|NCT03478787|Experimental|Risankizumab|Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
9996927|NCT01504386|Experimental|TAP block|TAP block with ropivacaine
9851923|NCT03478787|Active Comparator|Secukinumab|Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.
9851924|NCT03478891|Experimental|Group 1: 5 mg/kg IV|Group 1 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5 mg/kg.
9851925|NCT03478891|Experimental|Group 2: 25 mg/kg IV|Group 2 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25 mg/kg.
9851926|NCT03478891|Experimental|Group 3: 50 mg/kg IV|Group 3 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50 mg/kg.
9851927|NCT03478904|Experimental|4x40mg Enzalutamide Capsule Followed by 160mg Enzalutamide Liquid|Enzalutamide capsule (Treatment A) followed by enzalutamide liquid (Treatment B)
9851928|NCT03478904|Experimental|160mg Enzalutamide Liquid Followed by 4x40mg Enzalutamide Capsule|Enzalutamide liquid (Treatment B) followed by enzalutamide capsule (Treatment A)
9851929|NCT03478969|Experimental|Group A: Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
9851930|NCT03478969|Experimental|Group B: MDI, then Accu-Chek® Solo|Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
9851931|NCT03478969|Experimental|Group C: mylife™ OmniPod®, then Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
9851932|NCT03478982|Experimental|Staccato Alprazolam 1.0 mg|single dose for inhalation
9851933|NCT03478982|Experimental|Staccato Alprazolam 2.0 mg|single dose for inhalation
9851934|NCT03478982|Placebo Comparator|Placebo|single dose for inhalation
9851935|NCT03479216|Experimental|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
9851936|NCT03479216|Experimental|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
9851937|NCT03479944|Experimental|FLACS|Femtosecond laser assisted cataract surgery (FLACS) in 1 eye, with manual conventional surgery in the fellow eye, as randomized
9851938|NCT03479944|Active Comparator|Conventional|Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized
9851939|NCT03480009|Experimental|Dextromethorphan, opted for narcotic prescription|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
9851940|NCT03480009|Placebo Comparator|Placebo, opted for narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)
9851941|NCT03480009|Experimental|Dextromethorphan, declined narcotic prescription|Dextromethorphan hydrobromide and patient declines narcotic
9851942|NCT03480009|Placebo Comparator|Placebo, declined narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic
9851943|NCT03480022|Experimental|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
9851944|NCT03480022|Placebo Comparator|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
9851945|NCT03480048|Experimental|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
9851946|NCT03480048|No Intervention|Usual care|Participants receive usual care from their prenatal care provider.
9851947|NCT03480152|Experimental|1/Phase - Escalating doses of mRNA vaccine|Escalating doses of messenger ribonucleic acid (mRNA) vaccine
9851948|NCT03480152|Experimental|2/Phase II -MTD of mRNA vaccine established in Phase I|Maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I
9851949|NCT03480243|Experimental|Padsevonil and Erythromycin|"Treatment Period 1 (Day 1 to Day 11):~Padsevonil 100 mg twice daily (bid) on Day 1 to Day 4~Padsevonil 100 mg single dose on Day 5~1 week of wash-out (from evening of Day 5 to Day 11)~Treatment Period 2 (Day 12 to 22):~Padsevonil 100 mg twice daily (bid) on Day 12 to Day 15~Padsevonil 100 mg single dose on Day 16~1 week of wash-out (from evening of Day 16 to Day 22)~Treatment Period 3 (Day 23 to Day 38):~Erythromycin 500 mg twice daily (bid) on Day 23 to Day 25~Padsevonil 100 mg bid and erythromycin 500 mg bid on Day 26 to Day 32~Padsevonil 100 mg single dose on Day 33~Erythromycin 500 mg twice daily (bid) on Day 33 to Day 36~Erythromycin 500 mg single dose on Day 37"
9851950|NCT03480425|Experimental|Esophageal then tracheal intubated patient|Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to >30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to >30cm water pressure, and force of extubation recorded.
9851951|NCT03480685|Other|IVUS Imaging vs. OCT Imaging|A vessel segment will be imaged with intravascular ultrasound (IVUS). The same vessel segment will be imaged with optical coherence tomography (OCT).
9851952|NCT03480750|Experimental|trientine with chemotherapy|trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1
9851953|NCT03480763|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
9851954|NCT03480763|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
9851955|NCT03480802|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
9851956|NCT03480802|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
9851957|NCT03480841|Experimental|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
9851958|NCT03480919|Experimental|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
9851959|NCT03480919|Sham Comparator|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
9851960|NCT03480919|Placebo Comparator|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
9851961|NCT03480932|Active Comparator|SOF+DAC+PEG|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach
9851962|NCT03480932|Active Comparator|SOF+DAC, DOT|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach
9851963|NCT03480932|Active Comparator|SOF+DAC, standard|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)
9851964|NCT03481270|Placebo Comparator|Discordant|Does not receive the concordant provider.
9851965|NCT03481270|Experimental|Concordant|The intervention is that the subject receives the concordant provider.
9851966|NCT03481309|Active Comparator|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
9851967|NCT03481309|Active Comparator|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
9851968|NCT03481309|Sham Comparator|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
9851969|NCT03481595|No Intervention|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
9851970|NCT03481595|Experimental|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
9923425|NCT00850590|Experimental|High Dose|NRL001 at 10, 12.5, and 15 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
9923426|NCT00850616|Experimental|1|MRKAd6 Trigene 0.5x10^9 Ad6 vg
9923427|NCT00850616|Experimental|2|MRKAd6 Trigene 0.5x10^10 Ad6 vg
9923428|NCT00850616|Experimental|3|MRKAd6 Trigene 0.5x10^11 Ad6 vg
9923429|NCT00850616|Experimental|4|MRKAd5 Trigene 0.5x10^10 Ad5 vg
9851971|NCT03481725|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
9851972|NCT03481725|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
9851973|NCT03481816|Experimental|Arm 1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts.
9851974|NCT03481816|Experimental|Arm 2/Dose expansion|Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.
9851975|NCT03482011|Experimental|Mirikizumab|"Induction Period:~Participants received 250 milligrams (mg) mirikizumab administered subcutaneously (SC) every 4 weeks (Q4W).~Maintenance Period:~Participants received one of the four options below:~Placebo administered SC every 8 weeks (Q8W) for responders (≥PASI 90).~125 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for non-responders (<PASI 90)."
9851976|NCT03482011|Placebo Comparator|Placebo|"Induction Period: Participants received placebo administered SC Q4W.~Maintenance Period:~Participants received one of the two options below:~Placebo administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q4W during week 16 to week 32 and Q8W during week 40 and 48 for non-responders (< PASI 90)."
9851977|NCT03482453|Experimental|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
9851978|NCT03482453|Experimental|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
9851979|NCT03482453|Experimental|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
9851980|NCT03482453|Experimental|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
9851981|NCT03482453|Experimental|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
9851982|NCT03482453|Experimental|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
9851983|NCT03482453|Experimental|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
9851984|NCT03482453|Experimental|Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)|TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.
9851985|NCT03482453|Experimental|Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)|TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.
9923430|NCT00850616|Experimental|5|MRKAd5 Trivalent 1.5x10^10 Ad5 vg
9923431|NCT00850616|Experimental|6|MRKAd5+6 Trigene 1x10^9 Ad vg
9923432|NCT00850616|Experimental|7|MRKAd5+6 Trigene 1x10^10 Ad vg
9851986|NCT03482583|Other|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
9851987|NCT03482583|Other|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
9851988|NCT03482583|Other|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
9851989|NCT03482635|Experimental|Group 1- Placebo Group|
9851990|NCT03482635|Experimental|Group 2- Small Dose Group|
9851991|NCT03482635|Experimental|Group 3- Medium Dose Group|
9851992|NCT03482635|Experimental|Group 4 - High Dose Group|
9851993|NCT03482713|Experimental|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
9851994|NCT03482713|Placebo Comparator|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
9851995|NCT03482882|Experimental|Drug - pimavanserin|
9851996|NCT03482973|Experimental|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
9851997|NCT03482973|Placebo Comparator|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
9851998|NCT03483506|Experimental|All subjects|
9851999|NCT03483623|Experimental|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
9852000|NCT03483623|Experimental|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
9852001|NCT03483623|Experimental|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
9852002|NCT03483623|Experimental|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
9852003|NCT03483675|Active Comparator|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
9852004|NCT03483675|Experimental|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
9852005|NCT03483896|No Intervention|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
9923433|NCT00850616|Placebo Comparator|8|Placebo
9923434|NCT00850629|Placebo Comparator|placebo|Placebo
9923435|NCT00850629|Experimental|lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
9852006|NCT03483896|Active Comparator|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
9852007|NCT03483935|Experimental|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. The microwave dose will be between 2 Watt and 4 Watt. The treatment will consist of 3, 2 to 3 second bursts delivered to the same lesion with 5-20 seconds between bursts.
9852008|NCT03483935|No Intervention|Control|No treatment will be given.
9852009|NCT03483961|Experimental|Group 1: 20 mcg/unadjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
9852010|NCT03483961|Experimental|Group 2: 6 mcg/adjuvanted (Day 1 & 29)|6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
9852011|NCT03483961|Experimental|Group 3: 10 mcg/adjuvanted (Day 1 & 29)|10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
9852012|NCT03483961|Experimental|Group 4: 20mcg/adjuvanted (Day 1 & 29);40mcg/adjuvant (Day 547)|20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
9852013|NCT03483961|Experimental|Group 5: 6 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
9852014|NCT03483961|Experimental|Group 6: 10 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
9852015|NCT03483961|Experimental|Group 7: 20 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
9852016|NCT03483961|Experimental|Group 8: 40 mcg/adjuvanted (Day 29)|Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
9852017|NCT03483961|Experimental|Group 9: 20 mcg/adjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
9852018|NCT03483961|Experimental|Group 10: 40 mcg/adjuvanted (Day 1)|40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.
9852019|NCT03484273|Experimental|Full Compression|The LifeWrap compression garment will be fully secured with all straps.
9852020|NCT03484273|Experimental|Abdominal and Pelvic Compression|The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
9852021|NCT03484273|Experimental|Lower Limb Compression|The Lifewrap compression garment calf and ankle straps only will be secured.
9852022|NCT03484273|No Intervention|No Compression|None of the LifeWrap compression garment straps will be secured.
9852023|NCT03484429|Experimental|Group 1|Standard medical therapy and 30 to 60 days of peripheral nerve stimulation starting within 7 days after surgery
9852024|NCT03484429|Active Comparator|Group 2|Standard medical therapy only
9852025|NCT03485222|Experimental|Empagliflozin|10mg once a day
9852026|NCT03485222|Placebo Comparator|Placebos|placebo once a day
9996928|NCT01504386|Placebo Comparator|Placebo TAP block|Sham block with saline
9852027|NCT03485495|Experimental|Divaza|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
9852028|NCT03485495|Placebo Comparator|Placebo|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
9852029|NCT03485976|Experimental|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
9852030|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
9852031|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
9852032|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
9852033|NCT03486392|Placebo Comparator|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
9852034|NCT03486392|Active Comparator|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
9852035|NCT03486834|Experimental|V160 3-Dose Regimen|Participants received 3 doses of vaccine V160 (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant [MAPA], 4°C stable formulation) administered by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
9852036|NCT03486834|Experimental|V160 2-Dose Regimen|Participants received 2 doses of vaccine V160 (100 Units/0.5 mL dose with MAPA, 4°C stable formulation) administered IM on Day 1 and Month 6 and a placebo-saline solution at Month 2.
9852037|NCT03486834|Placebo Comparator|Placebo|Participants received placebo (saline solution) by IM injection on Day 1, Month 2, and Month 6.
9852038|NCT03486990|Experimental|Part A, Cohort 1: 0.1 mg/kg|TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
9852039|NCT03486990|Experimental|Part A, Cohort 2: 0.5 mg/kg|TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
9852040|NCT03486990|Experimental|Part A, Cohort 3: 1.0 mg/kg|TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
9852041|NCT03486990|Experimental|Part A, Cohort 4: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
9852042|NCT03486990|Experimental|Part A, Cohort 5: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
9852043|NCT03486990|Experimental|Part A, Cohort 6: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
9852044|NCT03486990|Experimental|Part B, Cohort 1: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
9852045|NCT03486990|Experimental|Part B, Cohort 2: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
9852046|NCT03486990|Experimental|Part B, Cohort 3: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
9852047|NCT03487276|Placebo Comparator|Cohort 1|Placebo
9852048|NCT03487276|Experimental|Cohort 2|Minimum Dose IFX-1 (400 mg Q4W)
9852049|NCT03487276|Experimental|Cohort 3|Low dose IFX-1 (800 mg Q4W)
9852050|NCT03487276|Experimental|Cohort 4|Medium Dose IFX-1 (800 mg Q2W)
9852051|NCT03487276|Experimental|Cohort 5|High Dose IFX-1 (1200 mg Q2W)
9852052|NCT03487445|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
9852053|NCT03487445|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
9852054|NCT03487549|Experimental|VP-102|Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.
9852055|NCT03487588|Experimental|A-101 Topical Solution|Open Label Arm
9852056|NCT03487718|Active Comparator|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
9852057|NCT03487718|Experimental|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
9852058|NCT03487848|Experimental|Daclatasvir with Sofosbuvir|Specified dose on specified days for specified duration
9852059|NCT03488108|Experimental|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
9852060|NCT03488108|Experimental|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
9852061|NCT03488225|Experimental|Treatment (hyper-CVAD, inotuzumab ozogamicin)|See detailed description.
9852062|NCT03488238|Experimental|ORi sensor|All subjects are enrolled in the test group and receive an ORi sensor during their scheduled, general surgery procedure
9852063|NCT03488849|Experimental|SureCRIC|SureCRIC-aided cricothyroid membrane identification
9852064|NCT03488849|Active Comparator|Freehand|Freehand cricothyroid membrane identification
9852065|NCT03488927|Experimental|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
9852066|NCT03488927|No Intervention|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
9852067|NCT03489304|Other|Zaleplon|Open-label zaleplon 5-10mg daily
9852068|NCT03489343|Experimental|Sym023 0.03 mg/kg|Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion
9852069|NCT03489343|Experimental|Sym023 0.1 mg/kg|Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion
9852070|NCT03489343|Experimental|Sym023 0.3 mg/kg|Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion
9852071|NCT03489343|Experimental|Sym023 1.0 mg/kg|Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion
9852072|NCT03489343|Experimental|Sym023 3.0 mg/kg|Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion
9852073|NCT03489343|Experimental|Sym023 10.0 mg/kg|Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion
9852074|NCT03489343|Experimental|Sym023 20.0 mg/kg|Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion
9852075|NCT03489369|Experimental|Sym022|Sym022 will be administered at up to 4 planned dose levels.
9852076|NCT03489551|Experimental|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
9852077|NCT03489720|Experimental|Arm A: Exercise intervention then usual exercise program|8 weeks of exercise intervention followed by 8 weeks of usual exercise program
9852078|NCT03489720|Active Comparator|Arm B: Usual Exercise Program then exercise intervention|8 weeks of usual exercise program followed by 8 weeks of exercise intervention
10207933|NCT04222985|Experimental|Part A - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2.
10207934|NCT04222985|Placebo Comparator|Part A - Group 6|Sodium chloride 0.9% (in both arms) at Month 0 and Month 2
9852079|NCT03489850|Active Comparator|Ibudilast|20mg BID Days 1-2 50mg BID Days 3-14
9852080|NCT03489850|Placebo Comparator|Placebo|Matched to active
9852081|NCT03489863|Active Comparator|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
9852082|NCT03489863|Active Comparator|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
9852083|NCT03489941|Experimental|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
9852084|NCT03489941|Experimental|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
9852085|NCT03489941|Experimental|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
9852086|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase I)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
9852087|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
9852088|NCT03490032|Experimental|Metastatic Prostate Cancer (mPCa) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
9852089|NCT03490110|Experimental|State regulation skill training|This arm utilizes a training system designed to strengthen goal-directed cognitive-emotional state regulation skills. The emphasis is on practice and active application of skills across a range of challenge contexts. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches guide learning for successful application of skills to challenges in personal life.
9852090|NCT03490110|Active Comparator|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA and other clinics.
9852091|NCT03490942|Experimental|CSGI high infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
9852092|NCT03490942|Experimental|CSGI low infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
9852093|NCT03490942|Placebo Comparator|Placebo high infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
9852094|NCT03490942|Placebo Comparator|Placebo low infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
9852095|NCT03490981|Other|Treatment as usual (TAU) only|Primary care treatment as usual
9852096|NCT03490981|Experimental|Treatment as usual (TAU) plus Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Primary care treatment as usual and Brief CBT-CP
9852097|NCT03491150|Placebo Comparator|Parent Placebo|Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
9852098|NCT03491150|Experimental|Parent Crenezumab|Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
9852099|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-positive CHB Participants|Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
9852100|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
9852101|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
9852102|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
9517039|NCT03310060|Placebo Comparator|Tranexamic acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery
9852103|NCT03491553|Experimental|Placebo: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
9923436|NCT00850668|Active Comparator|EMP-123|Participants who are not allergic to peanuts will receive four escalating doses of study product on a weekly basis
10207935|NCT04222985|Experimental|Part B (Stage 1) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207936|NCT04222985|Experimental|Part B (Stage 1) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
9852104|NCT03491553|Experimental|Placebo: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
9852105|NCT03491800|Other|Question/Topic Prompt List|The Question/Topic Prompt List is provided to HF Patients and their family member (if applicable) for completion prior to being seen by the doctor.
9852106|NCT03491891||derivation cohort|no interventions will be administrated
9852107|NCT03491891||validation cohort|no interventions will be administrated
9852108|NCT03491917||DBT plus S-View|Breast images utilizing DBT plus S-View
9852109|NCT03491917||FFDM alone|Breast images using FFDM alone only
9852110|NCT03492281|Experimental|Vibegron + Placebo to match Tolterodine|
9852111|NCT03492281|Placebo Comparator|Placebo to match vibegron + Placebo to match Tolterodine|
9852112|NCT03492281|Active Comparator|Tolterodine + Placebo to match vibegron|
9852113|NCT03492398|Experimental|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
9852114|NCT03492398|Experimental|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
9852115|NCT03492398|Experimental|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
9852116|NCT03492398|Experimental|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
9852117|NCT03492398|Experimental|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
9852118|NCT03492398|Experimental|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
9852119|NCT03492398|Experimental|Cohort B HY209 0.5% gel|multiple dose of HY209 0.5% gel or multiple dose of placebo
9852120|NCT03492554|Other|Atrial fibrillation (AF)|Patient with a known history of AF who are in AF at the time of study screening.
9852121|NCT03492554|Other|Normal Sinus Rhythm (SR)|Patient with no known diagnosis of AF or other arrhythmia
9852122|NCT03493386|Experimental|Treatment Group A: Part 1|Subjects will be randomized to receive single dose of two tablets of 2 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
9852123|NCT03493386|Experimental|Treatment Group B: Part 1|Subjects will be randomized to receive single dose of 4 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of two tablets of 2 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
9852124|NCT03493386|Experimental|Treatment Group C: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
9852125|NCT03493386|Experimental|Treatment Group D: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fasted state during period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fed state. There will be a wash-out period of 5 days between the Periods.
9852126|NCT03493542|Experimental|Chinese Girls Aged 9 to 19 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
9852127|NCT03493542|Active Comparator|Chinese Young Women Aged 20 to 26 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
9852128|NCT03493607|Experimental|AMO-01|Intravenous Infusion
9852129|NCT03493698|Experimental|Treatment A: Midazolam|All subjects will receive a single oral dose of 2 mg Midazolam on Day 1
9852130|NCT03493698|Experimental|Treatment B and C: Inarigivir|All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18
9852131|NCT03493698|Experimental|Treatment D: Inarigivir with Midazolam|All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19
9852132|NCT03493815|Experimental|Transabdominal Ultrasound Guided IUD Insertion|Ultrasound Guided IUD Insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
9852133|NCT03493815|Active Comparator|Traditional Blind IUD Insertion|Traditional blind IUD insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
9923437|NCT00850668|Experimental|EMP-123 in Peanut Allergics|Participants who are allergic to peanuts will receive weekly dose escalation of the study product for 10 weeks followed by administration every 2 weeks for 6 weeks
9852134|NCT03493828|Active Comparator|TAP using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
9852135|NCT03493828|Active Comparator|TAP using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
9852136|NCT03493828|Placebo Comparator|Placebo|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
9852137|NCT03494725|Active Comparator|Lpc-37|"Lacticaseibacillus paracasei Lpc-37 (Lpc-37), formerly Lactobacillus paracasei Lpc-37~1x 1 capsule in the morning for 5 weeks"
9852138|NCT03494725|Placebo Comparator|Placebo|"Placebo capsule manufactured to mimic Lpc-37 capsule~1x 1 capsule in the morning for 5 weeks"
9852139|NCT03494816|Experimental|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
9852140|NCT03494985|Experimental|OralBalance moisturizing gel|All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
9852141|NCT03494985|Experimental|Oral rinse|All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
9852142|NCT03494985|Experimental|Moisturizing mouth spray|All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
9852143|NCT03494985|Sham Comparator|Water only use|All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
9852144|NCT03495102|Active Comparator|Dulaglutide 1.5 mg|Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
9852145|NCT03495102|Experimental|Dulaglutide 3 mg|Dulaglutide 3 mg administered SC once a week.
9852146|NCT03495102|Experimental|Dulaglutide 4.5 mg|Dulaglutide 4.5 mg administered SC once a week.
9852147|NCT03495648|Experimental|Walking Group (Low Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. Low engagers are defined as those participants who walked to the market two or fewer times during the program.
9852148|NCT03495648|Experimental|Walking Group (High Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. High engagers are defined as those participants who walked to the market three or more times during the program.
9852149|NCT03495817|Experimental|ATI-50002 Topical Solution|"This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia.~Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks."
9852150|NCT03495856|Experimental|Mindfulness Training For Chronic Pain|The intervention is adapted from the mindfulness-based stress reduction program. The adapted mindfulness training program consists of four, weekly 90 minute group sessions that focus on education on chronic pain and mindfulness, instruction and in-class mindfulness skills practice, and group discussion.
9852151|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder (n=50).~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
9923438|NCT00850681|Experimental|1|PEP005 (ingenol mebutate) Gel
9996929|NCT01504399||Microscopic:|Microscopic (single nostril, direct endonasal with nasal speculum)transsphenoidal nasal surgery
9996930|NCT01504399||Endoscopic|Fully endoscopic: (bi-nostril, no nasal speculum) transsphenoidal pituitary surgery
9996931|NCT01504438|Other|Salto Talaris Total Ankle Replacement|
9852152|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder (n=200).
9852153|NCT03495869||Individuals with Marijuana Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Marijuana Use Disorder (n=50).
9852154|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls (n=100).
9852155|NCT03495908|Experimental|VGo with Regular Human Insulin|U-100 short-acting insulin, Regular, human insulin rDNA origin, including Humulin® R, Novolin® R, and ReliOn (Novolin R) delivered by V-Go
9852156|NCT03495908|Active Comparator|VGo with Rapid Acting Insulin|U-100 fast-acting insulin including Humalog® (insulin lispro, rDNA origin) or NovoLog® (insulin aspart, rDNA origin), which have both been tested by Valeritas, Inc. and found to be safe for use in the V-Go or Apidra® (insulin glulisine, rDNA origin) delivered by V-Go
9852157|NCT03496220|Experimental|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
9852158|NCT03496220|Other|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
9852159|NCT03496298|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.
9852160|NCT03496298|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide as SC injection 2 milligrams (mg) per week for 4 weeks then 4 mg per week up to end of treatment.
9852161|NCT03496298|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide as SC injection 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 6 mg per week up to end of treatment.
9852162|NCT03496324|Active Comparator|Test (fed): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fed condition~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
9852163|NCT03496324|Active Comparator|Test (fasted): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
9852164|NCT03496324|Experimental|Reference (fed): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fed condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
9852165|NCT03496324|Experimental|Reference (fasted): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
9852166|NCT03496428|Other|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
9852167|NCT03496467|Active Comparator|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
9852168|NCT03496467|Placebo Comparator|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
9923439|NCT00850694||1|Obese female adolescents
9923440|NCT00850707||1|220 hemodialysis patients with Arterovenous fistula (AVF group)
9852169|NCT03496545|Active Comparator|Acetaminophen|Standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
9852170|NCT03496545|Experimental|Bromocriptine and Acetaminophen|Bromocriptine 5mg every 4 hours PO/NG/FT for 48 hours and acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
9852171|NCT03496701|Experimental|Stenfilcon A / Test lens|All subjects will first wear stenfilcon A contact lenses for one week, then refitted with test contact lenses to wear for one week.
9852172|NCT03496974|Experimental|Group A: 200 mg cohort|The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation)
9852173|NCT03496974|Experimental|Group B: 400 mg cohort|The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection
9852174|NCT03496987|No Intervention|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
9852175|NCT03496987|Experimental|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
10207937|NCT04222985|Experimental|Part B (Stage 1) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207938|NCT04222985|Experimental|Part B (Stage 1) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
10207939|NCT04222985|Experimental|Part B (Stage 1) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
10207940|NCT04222985|Placebo Comparator|Part B (Stage 1) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
9852176|NCT03497026|Experimental|Robotic Bronchoscopy|Robotic bronchoscopy with Robotic Bronchoscopy Platform
9852177|NCT03497039|Experimental|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
9852178|NCT03497039|Placebo Comparator|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
9852179|NCT03497130|Experimental|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
9852180|NCT03497130|No Intervention|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
9852181|NCT03497429|Experimental|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
9852182|NCT03497429|Experimental|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
9852183|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
9852184|NCT03497845|Experimental|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
9852185|NCT03497845|Experimental|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
9852186|NCT03497845|Experimental|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
9852187|NCT03497845|Experimental|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
10207941|NCT04222985|Experimental|Part B (Stage 1) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207942|NCT04222985|Experimental|Part B (Stage 2) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207943|NCT04222985|Experimental|Part B (Stage 2) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207944|NCT04222985|Experimental|Part B (Stage 2) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207945|NCT04222985|Experimental|Part B (Stage 2) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
10207946|NCT04222985|Experimental|Part B (Stage 2) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
10207947|NCT04222985|Placebo Comparator|Part B (Stage 2) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
10207948|NCT04222985|Experimental|Part B (Stage 2) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
10207949|NCT04213989|Active Comparator|Conservative Care|Conservative care (may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT)
10207950|NCT04213989|Experimental|Flexitouch Plus and Conservative Care|Flexitouch Plus with conservative care
10207951|NCT04213053|Other|Concomitant strabismus patients|Horizontal strabismus surgery
9852188|NCT03497845|Experimental|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
9852189|NCT03497845|Experimental|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
9852190|NCT03497845|Experimental|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
9852191|NCT03497845|Experimental|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
9852192|NCT03497845|Experimental|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
9852193|NCT03497845|Experimental|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
9852194|NCT03497845|Experimental|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
9852195|NCT03497845|Experimental|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
9852196|NCT03498196|Experimental|Avelumab|Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
9852197|NCT03498287|Experimental|Study Device|Small, non-invasive, stiff patch for the wrist
9852198|NCT03498287|Sham Comparator|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
9852199|NCT03498300|Experimental|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
9852200|NCT03498300|No Intervention|Active comparator|dT vaccine as standard protocol
9852201|NCT03499028|No Intervention|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
9852202|NCT03499028|Experimental|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
9852203|NCT03499067|Experimental|Test lens|Subjects wearing the test contact lens either as first or second pair during the cross-over study.
9852204|NCT03499067|Active Comparator|Control lens|Subjects wearing the control contact lens either as first or second pair during the cross-over study.
9852205|NCT03499353|Experimental|TALAZOPARIB|SINGLE ARM, NON-RANDOMIZED
9852206|NCT03499873|Experimental|Nepafenac 0.3% Opthalmic Suspension|Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.
9852207|NCT03499873|Active Comparator|Ilevro 0.3% Opthalmic Suspension|Reference product manufactured by Alcon Laboratories Inc.
9852208|NCT03499873|Placebo Comparator|Placebo (vehicle) Opthalmic Suspension|Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.
9852209|NCT03500094|Experimental|migalastat HCl 150 mg|"One migalastat 123 milligrams (mg) capsule equivalent to 150 mg migalastat hydrochloride (HCl) (herein referred to as migalastat) was administered every other day for 12 months."
9852210|NCT03500198|Experimental|Investigational Device: Next Generation TECNIS IOL|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
9852211|NCT03500198|Active Comparator|Control Device: TECNIS Monofocal IOL|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
9852212|NCT03500211|Experimental|Lidoderm 5% Topical Patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
9852213|NCT03500211|Sham Comparator|Sham Topical Patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
9852214|NCT03500224|Experimental|[14C]-TAK-954 0.5 mg|[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [µCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
9852215|NCT03500289|Experimental|Ketamine|
9852216|NCT03500289|Placebo Comparator|Midazolam|
9852217|NCT03500302|Experimental|Evolocumab|All enrolled patients will receive evolocumab sq once a month for a total of two doses
9852218|NCT03500419|Active Comparator|Control|No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.
9852219|NCT03500419|Experimental|Group AB - PTT 1-2x daily x 5-7 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months.
9852220|NCT03500679|Experimental|Group 1: ExPEC4V (JNJ-63871860)|Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram [mcg]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.
9852221|NCT03500679|Placebo Comparator|Group 2: Placebo|Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.
9923441|NCT00850707||2|58 hemodialysis patients with Arterovenous graft (AVG group)
9923442|NCT00850707||3|180 hemodialysis patients with Tunneled cuffed catheters (TCC group)
9923443|NCT00850707||4|60 healthy subjects as controls
9923444|NCT00850746|Placebo Comparator|A. Placebo|
9923445|NCT00850746|Experimental|B. Ym443 Lower Dose|
9923446|NCT00850746|Experimental|C. YM443 Higher Dose|
9923447|NCT00850746|Active Comparator|D. Moxiflocxacin|
9923448|NCT00850772|Experimental|Early post-operative enteral feeding|Standard post-operative care and diet together with early post-operative enteral feeding
9923449|NCT00850772|No Intervention|Standard post-operative care and diet|Standard post-operative care and diet only
9923450|NCT00850798|Experimental|1|Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
9923451|NCT00850798|Active Comparator|2|Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
9923452|NCT00850811|Experimental|1|
9923453|NCT00850824|Experimental|Behavioral|Community Health Worker home visits
9923454|NCT00850824|Active Comparator|Usual Care|Usual Care, Wait List Control
9923455|NCT00850837|Experimental|1|Participants will apply Acidform lubricant twice daily for 14 consecutive days between menses
9923456|NCT00850837|Placebo Comparator|2|Participants will apply HEC gel twice daily for 14 consecutive days between menses
9923457|NCT00850850|Active Comparator|Physostigmine|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.
9923458|NCT00850850|Placebo Comparator|NaCl|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).
9923459|NCT00850863||A|20 healthy individuals not susceptible for COPD (age 18-40 years, 0 < pack years > 10, FEV1/FVC >70% , FEV1 >85% predicted)
9923460|NCT00850863||B|30 healthy individuals susceptible for COPD (age 40-75years, pack years >20, FEV1/FVC > 70%, FEV1 > 85% predicted)
9923461|NCT00850863||C|20 healthy individuals very susceptible for COPD (age 18-40 year, 0 < pack years > 10, FEV1/FVC > 70%, FEV1 > 85% predicted)and high prevalance of COPD in smoking family members older than 45 years
9923462|NCT00850863||D1|30 COPD patients with GOLD stage I (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 > 80% predicted)
9923463|NCT00850863||D2|30 COPD patients with GOLD stage II (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)
9923464|NCT00850863||D3|30 COPD patients with GOLD stage III (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)
9923465|NCT00850863||D4|30 COPD patients with GOLD stage IV (age 40-75 years,Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)
9923466|NCT00850863||E|20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 < Pack years > 10, FEV1/FVC >70%, FEV1 > 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
9923467|NCT00850863||F|30 COPD patients who are highly susceptible (age > 53 years with Pack years > 10 , FEV1/FVC ≤ 70% and FEV1 < 40% predicted) or (age >18 years with 0 < pack years > 5, FEV1/FVC ≤ 70% and FEV1 < 80% predicted)
9923468|NCT00850902|Active Comparator|Moderate Humidity (MH)|
9923469|NCT00850902|Experimental|High Humidity|
9923470|NCT00850915|Other|1|in this arm contacts of enrolled TB-HIV index cases were actively approached and screened for TB and offered HIV testing by CHW at their homes
9923471|NCT00850915|Other|2|no interventation was done in this group, they received the regulare care and follow up following NTP guidelines
9923472|NCT00850928||Subjects|65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.
9923473|NCT00850941||Questionnaire|Prognostic factors and outcome for patients treated with radiation with curative intent for rising Prostate Specific Antigen (PSA) post-prostatectomy.
9923474|NCT00850954|Experimental|Group I (smoking cessation)|Participants receive smoking cessation intervention materials based on TTM.
9923475|NCT00850954|Experimental|Group II (informational)|Participants receive fotonovelas and other materials on secondhand smoking and how to assist the smoker in quitting.
9923476|NCT00851019|Experimental|DDR|"Dance Dance Revolution (DDR) Exergaming"
9923477|NCT00851019|Active Comparator|Treadmill|Treadmill exercise
9923478|NCT00851032||Molecular Profiling Analyses|Participants seen in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas
9923479|NCT00851058|Experimental|Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
9923480|NCT00851058|Active Comparator|Community Counseling|Four session of group counseling and six hours of volunteering in a local not for profit community agency.
9923481|NCT00851058|Placebo Comparator|Prototypic Community Service|Four hours of education about road safety and 16 hours volunteering at a local not for profit community service.
9923482|NCT00851071|Active Comparator|Cognitive Behavioral Therapy|Three individual 45 minute cognitive behavioral therapy sessions over a 3 month period
9923483|NCT00851071|No Intervention|Usual Care Arm|The Usual Care Arm will be the control arm. These patients will not be scheduled with any CBT sessions.
9923484|NCT00851123|Experimental|1. Modified Constraint-Induced Movement therapy|Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
9923485|NCT00851123|Experimental|2.Task-specific bimanual training|Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.
9923486|NCT00851136|Experimental|1|
9923487|NCT00851149||1/10|Abdominal aortic surgery patients
9923488|NCT00851149||2/10|Total hip replacement patients
9852222|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
9852223|NCT03501043|Experimental|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
9852224|NCT03501069|Experimental|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
9852225|NCT03501069|Experimental|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
9852226|NCT03501069|Experimental|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
9852227|NCT03501069|Experimental|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
9852228|NCT03501069|Experimental|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
9852229|NCT03501069|Experimental|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
9852230|NCT03501264|Experimental|Intervention group|This group receives the game
9852231|NCT03501264|Active Comparator|Control Group|This group receives LGBTQ resources only
9852232|NCT03501277|Experimental|Sequence I: ABCD|SYR-322-4833 BL (alogliptin 25 [milligram] mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 2 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 4 (Regimen D).
9852233|NCT03501277|Experimental|Sequence II: BCDA|Alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 1 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 3 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen A).
9852234|NCT03501277|Experimental|Sequence III: CDAB|SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 2 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 4 (Regimen B).
9852235|NCT03501277|Experimental|Sequence IV: DABC|Alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 1 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 3 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen C).
9852236|NCT03501550|Experimental|CDI-31244 + SOF/VEL|CDI-31244 in combination with SOF/VEL
9852237|NCT03501693||DBT plus S-View|Breast images utilizing DBT plus S-View
9852238|NCT03501693||FFDM alone|FFDM alone images
9852239|NCT03502265|Experimental|Otteroo adjunct|A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). There is only one arm due to the study design. It is a within-subjects comparison, not a between-subjects comparison of different study arms.
9852240|NCT03502616|Experimental|Tofacitinib|
9852241|NCT03502616|Placebo Comparator|Placebo|
9852242|NCT03502681|Experimental|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
9852243|NCT03502798|Experimental|scanning a/LCI|
9852244|NCT03502915|Experimental|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
9852245|NCT03502915|Placebo Comparator|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
9852246|NCT03502941|Experimental|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in ~12 oz water.
9923489|NCT00851162|Experimental|Trinity|Trinity multipotent stem cells
9852247|NCT03502941|Experimental|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in ~12 oz water
9852248|NCT03502941|Experimental|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
9852249|NCT03503162|Experimental|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
9852250|NCT03503188|Experimental|All participants|
9852251|NCT03503292|Experimental|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
9852252|NCT03503292|Experimental|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
9852253|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
9852254|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
9852255|NCT03503578|Experimental|EEG Dynamics|EEG data will be collected on patients receiving sevoflurane, and sevoflurane and ketamine together.
9852256|NCT03504189|Experimental|PregSense™|PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
9852257|NCT03504839|Other|Intervention|S-ICD implantation.
9852258|NCT03504852|Experimental|Secukinumab 300 mg every 2 weeks (Q2W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
9852259|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks (Q4W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
9852260|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)|2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
9852261|NCT03504917|Experimental|Balovaptan|
9852262|NCT03504917|Placebo Comparator|Placebo|
9852263|NCT03505021|Experimental|Levosimendan|Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
9852264|NCT03505021|Placebo Comparator|Placebo for levosimendan|Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
9852265|NCT03505190|Experimental|RO7062931 0.3mg/kg|Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.
9852266|NCT03505190|Experimental|RO7062931 1.0mg/kg|Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.
9852267|NCT03505190|Experimental|RO7062931 2.0mg/kg|Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.
9852268|NCT03505190|Experimental|RO7062931 4.0mg/kg|Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.
10207952|NCT04207229||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
10207953|NCT04194346|Experimental|Determination of local pleural strain|The average Von Mises coefficient will be calculated for each recorded ultrasound loop using a non-invasive vascular elastography platform.
10207954|NCT04184726|Experimental|MBCT-vision|8 x once weekly group sessions, and home practice between sessions
9852269|NCT03505190|Placebo Comparator|Placebo|Participants will receive matching placebo.
9852270|NCT03505593|Experimental|EFT placement using ENVUE System|Placement of the ENvizion Medical™ Enteral Feeding Tube (EFT) in the stomach or small intestine of adult patients who require feedings via the oro/ nasoenteric route, using the ENVUE™ System.
9852271|NCT03506295|Other|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
10207955|NCT04176419|Experimental|Treatment Group|"Perioperative intervention (preoperative acetaminophen, gabapentin, and celecoxib and intraoperative ketamine and lidocaine).~The Investigational Drug Service will mix and prepare the study medications necessary for each participant. An Investigational Drug Service staff member will deliver the oral medications to the nursing team in the preoperative holding unit and the IV medications to the anesthesia team in the OR unit."
10207956|NCT04176419|Placebo Comparator|Control Group|"Perioperative placebo~Placebo oral drugs will be encapsulated versions provided by the Investigational Drug Service and will appear identical to the interventional oral drugs. Placebo IV infusions will be prepared by Investigational Drug Service as per institutional guidelines and will appear identical to the interventional IV drugs."
10213523|NCT03863704|Other|Subjects receiving Infliximab|Subjects on Infliximab as part of their clinical care will not be randomized as the study treatment for these subjects will be the same. The sham arm is not included for patients on infliximab.
10213524|NCT03861793|Experimental|ALKS 4230|Administered via SC injection once every 7 days or once every 21 days at escalating doses
10213525|NCT03861793|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via SC injection once every 7 or 21 days at escalating doses or at the recommended phase 2 dose and schedule; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label. In December 2020, an RP2D of 3 mg with an administration schedule of q7d was determined for SC ALKS 4230.
10213526|NCT03858647||Sensorineural hearing loss patients post cochlear implant|Patients who have documented sensorineural hearing loss and have received cochlear implantation (per standard of care).
9852272|NCT03506295|Experimental|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
9923490|NCT00851162|Active Comparator|Demineralized bone matrix|Demineralized bone matrix
9923491|NCT00851175|No Intervention|1|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia
9852273|NCT03506347|Active Comparator|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
10207957|NCT04174157||Prospective observational registry|This is a prospective, multi center, multinational, non-interventional observational registry.
10207958|NCT04159909|Experimental|VNS transcutaneous stimulation|"5 minutes of stimulation (VNS) twice a day for 4 days. Patients will receive transcutaneous stimulation (30 Hz, 300 msec.) on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days. Due to the theoretical risk that right vagus nerve stimulation could affect the heart, and to ensure consistency of the intervention, all subjects randomized to receive transcutaneous vagus nerve stimulation will receive stimulation of the auricular branch of the left vagus nerve. The subject will be blinded to their treatment arm.~The device to be used will include a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide stimulation to the auricular branch of the afferent vagus nerve."
10207959|NCT04159909|Sham Comparator|Sham stimulation|"5 minutes of sham stimulation (no electrical stimulation) twice a day for 4 days Patients will receive sham stimulation on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days.~The subject will be blinded to their treatment arm. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide sham stimulation (no electrical current) to the auricular branch of the afferent vagus nerve."
10207960|NCT04146324||Adjuvant nivolumab therapy|Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia
10207961|NCT04141579|Experimental|Treatment arm|Evolocumab (140mg) will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of 140 mg/mL Evolocumab.
9852274|NCT03506347|Experimental|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
9852275|NCT03506386||Multiple Myeloma Participants|Participants with multiple myeloma (MM) were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.
9852276|NCT03506425|Experimental|Group 1|Standard care for 1 month, then standard care and Triheptanoin for 5 months.
9852277|NCT03506425|Experimental|Group 2|Standard care and Triheptanoin for 6 months.
10207962|NCT04141579|Placebo Comparator|Comparator arm|Placebo will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of placebo.
9852278|NCT03506425|No Intervention|Group 3|Healthy controls for biomarkers
9852279|NCT03506477|Experimental|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
9852280|NCT03506477|Placebo Comparator|Vehicle foam|does not contain the active ingredient
9852281|NCT03506724|Other|Oral nifedipine|Oral medication 10mg and 20mg
9852282|NCT03506724|Other|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
9852283|NCT03507036|Experimental|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
9852284|NCT03507569|Experimental|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
9852285|NCT03508050|Experimental|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
9852286|NCT03508050|No Intervention|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
9852287|NCT03508609|Experimental|Autologous CD34 cells|Open label active treatment arm. Subjects receive autologous CD34 cells.
9852288|NCT03508661|Experimental|SPIN-SSLED Program|13-session SPIN-SSLED Program
9852289|NCT03508687|Experimental|Group 1: 300 mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.
9852290|NCT03508687|Experimental|Group 2: 600mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.
9852291|NCT03508830|Experimental|Liposomal Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation: 266mg (20cc) Liposomal Bupivacaine admixed with 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) and varied 0.9% normal saline volume for total volume of 60cc."
9923492|NCT00851175|Active Comparator|2|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
9852292|NCT03508830|Active Comparator|Standard Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation - 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) admixed with varied 0.9% normal saline volume for total volume of 60cc."
9852293|NCT03508843|Experimental|interactive virtual presence|install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence
9852294|NCT03509350|Experimental|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
10207963|NCT04129242|Active Comparator|"paired taVNS + Task Specific Training"|
10207964|NCT04129242|Active Comparator|"unpaired taVNS + Task Specific Training"|
10207965|NCT04125459||Individuals with Gout|This arm will be getting a biopsy as well as a blood draw
9852295|NCT03509350|Placebo Comparator|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
9852296|NCT03509675|Placebo Comparator|Placebo|Placebo suspension was compounded with the same taste as the active medication but without the active ingredient.
9852297|NCT03509675|Active Comparator|Active ingredient|The topical suspension of the topical NSAID was 100 mg per 5 ml concentration of ibuprofen, with similar ingredients as OTC children's ibuprofen and was compounded by an external drug service.
9852298|NCT03509766|Experimental|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
9852299|NCT03509883|Experimental|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets
9852300|NCT03509883|Active Comparator|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
9852301|NCT03509948|Experimental|Schedule A: Fed Then Fasted|"Schedule A (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
9852302|NCT03509948|Experimental|Schedule B: Fasted Then Fed|"Schedule B (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
9852303|NCT03509974|Experimental|Bone Anchored Hearing Device (OSIA)|All subjects will receive the Bone Anchored Hearing Device (OSIA)
9852304|NCT03510182|Experimental|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
9852305|NCT03510195|Experimental|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
9852306|NCT03510273|Other|Thermocoagulation treatment|Acceptability of Liger Medical Thermocoagulator treatment
9852307|NCT03510455|Experimental|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
9852308|NCT03510481|Experimental|Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
9923493|NCT00851175|Experimental|3|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg
9996932|NCT01504438|Other|STAR Total Ankle Replacement|
9996933|NCT01504451|Active Comparator|Biosense Webster ablation|Biosense Webster irrigated multi-electrode phased radiofrequency AF ablation
10207966|NCT04125459||Controls|These individuals will not be getting a joint biopsy and will just get a blood draw
10207967|NCT04122469|Experimental|Oligo-Progression; GU|Receiving SBRT.
10207968|NCT04122469|Experimental|Oligo-metastatic Breast Cancer|Receiving SBRT.
10207969|NCT04111757|Experimental|Technolas TENEO 317 Model 2|One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0.
10207970|NCT04094519|Experimental|digoxin plus rosuvastatin and enzalutamide|Participants will receive a single oral dose cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin on Day 1 and 64. A single oral dose of placebo to match enzalutamide will be given on Day 1 and 160 mg enzalutamide once daily on Days 8 through 71.
10207971|NCT04080531|Experimental|Arm I (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
10207972|NCT04080531|Experimental|Arm II (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
10207973|NCT04064359|Experimental|OBT076 Dose Escalation and Expansion|OBT076 administered intravenously (IV) every 3 weeks in escalating dose cohorts during Part A and OBT076 administered at or below the MTD in the Part B expansion cohort.
10207974|NCT04053075|Active Comparator|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
10207975|NCT04053075|Active Comparator|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
10207976|NCT04039191|Placebo Comparator|SMS survey|Subject to receive SMS survey.
10207977|NCT04039191|Active Comparator|SMS survey with education|Subject to receive SMS survey with education.
9852309|NCT03510481|Experimental|Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
9852310|NCT03510481|Placebo Comparator|Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks|Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
9852311|NCT03510481|Placebo Comparator|Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks|Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
9852312|NCT03510663|Experimental|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
9852313|NCT03510663|Experimental|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
9852314|NCT03510663|Active Comparator|Moxifloxacin|400mg tablet will be administrated once a week.
9852315|NCT03510663|Placebo Comparator|Placebo|Placebo will be intravenously administered once a week.
9852316|NCT03510715|Experimental|Alirocumab|"Participants with BW less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to [>=] 50 kg.~Participants with BW >=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks."
9852317|NCT03510910|Experimental|Acetaminophen along with a reduced quantity of Percocet|
9852318|NCT03510910|Experimental|Percocet only|
9852319|NCT03511001|Experimental|E-Cigarette|6 weeks of JUUL electronic cigarettes
9852320|NCT03511001|Active Comparator|Assessment Only|6 weeks of smoking as usual
9852321|NCT03511053|Experimental|All participants|Epidural Lavage followed by Lumbar Epidural Steroid Injection
9852322|NCT03511105|Experimental|Subjects receiving GSK2798745|Eligible subjects will receive two tablets of 2.4 milligrams GSK2798745 on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose of a single tablet of 2.4 milligrams of GSK2798745 will be administered 10 hours after LPS and saline challenge.
9852323|NCT03511105|Placebo Comparator|Subjects receiving matching Placebo|Eligible subjects will receive two tablets of placebo on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose placebo will be administered 10 hours after LPS and saline challenge.
9852324|NCT03511326|Experimental|Luxerm®|
9852325|NCT03511378|Experimental|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
9852326|NCT03511378|Experimental|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
9852327|NCT03511521|Experimental|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; >80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
9852328|NCT03511521|Active Comparator|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone >80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
9852329|NCT03511638|Experimental|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
9852330|NCT03511638|Active Comparator|Alcon VISCOAT®|Ophthalmic viscosurgical device
9852331|NCT03511937|Experimental|Sugar-Sweetened Beverage Health Warning Label|
9852332|NCT03511937|Other|Neutral Label|
9852333|NCT03512028|Experimental|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
9996934|NCT01504451|Active Comparator|Surgical ablation|Minimally invasive thoracoscopic surgical AF ablation
9852334|NCT03512028|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
9852335|NCT03512041|Experimental|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
9852336|NCT03512041|Experimental|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
9852337|NCT03512041|Experimental|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
9852338|NCT03512041|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
9852339|NCT03512067|Experimental|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
9852340|NCT03512288|Experimental|Multivalent|Pneumococcal conjugate vaccines
9852341|NCT03512288|Active Comparator|Control|13vPnC
9852342|NCT03512353|Experimental|Carfilzomib Plus Dexamethasone|"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.~Participants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12."
9852343|NCT03512457|Experimental|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
9852344|NCT03512457|Active Comparator|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
9852345|NCT03513588|Placebo Comparator|Placebo|
9852346|NCT03513588|Experimental|PF-06865571 100 mg|
9852347|NCT03513588|Experimental|PF-06865571 600 mg|
9852348|NCT03513757|Active Comparator|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
9852349|NCT03513757|Experimental|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
9852350|NCT03513848|Experimental|Bright Light|
9852351|NCT03513848|Placebo Comparator|Dim Light|
9852352|NCT03514277|Active Comparator|Local infiltration of EXPAREL and Bupivacaine|
9852353|NCT03514277|Active Comparator|Local infiltration of Exparel|
9852354|NCT03514277|Active Comparator|Local infiltration of Bupivacaine|
9852355|NCT03514420|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received AKCEA-ANGPTL3-LRx 20 milligrams (mg) administered every week for 26 weeks by subcutaneous (SC) injection.
9852356|NCT03514641|Other|Sequence 1|Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
9852357|NCT03514641|Other|Sequence 2|Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
9852358|NCT03514641|Other|Sequence 3|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
9852359|NCT03514641|Other|Sequence 4|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
9852360|NCT03514966|No Intervention|Conventional group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
9852361|NCT03514966|Experimental|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
9852362|NCT03515681|Experimental|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
9852363|NCT03515681|No Intervention|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
9852364|NCT03515824|Experimental|Part A: MK-1696 20 mg|Participants received 20 mg of MK-1697 by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
9852365|NCT03515824|Experimental|Part A: MK-1697 65 mg|Participants received 65 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
9852366|NCT03515824|Experimental|Part A: MK-1697 200 mg|Participants received 200 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
9852367|NCT03515824|Experimental|Part B: Expansion Cohort|Participants with select tumor types were to receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
9852368|NCT03515941|Experimental|Arm 1: Adjuvant Chemotherapy|Three cycles of chemo with CAPEOX (Oxaliplatin:130 mg/m2 by IV and Capecitabine: 625 or 1000 mg/m2 by PO (BID) on 21 day-cycle or FOLFOX (Oxaliplatin:85 mg/m2 by IV, Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 2400 mg/m2 by IV) on 14 day-cycle
9852369|NCT03515941|Experimental|Arm 2: Adjuvant Chemoradiation|Three cycles of chemo with Capecitabine: 750 mg/m2 by PO BID on days 1-14 of a 28 day-cycle or 5-fluorouracil (Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 1200 mg/m2 by IV) on days 1 and 15 of a 28 day cycle After 1st chemo cycle above, chemoradiation for 5 weeks with 45 Gy in 1.8 Gy/fraction, 5 days a week, to the entire gastric bed (including anastomosis) and draining lymph nodes, and a single agent fluoropyrimidine, either capecitabine or 5-fluorouracil After 5 weeks chemoradiation, 2 cycles of chemo as described above.
9852370|NCT03516227|Experimental|HRVBF|Heart rate variability biofeedback
9852371|NCT03516227|No Intervention|Control|Usual Care
9852372|NCT03517436|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
9852373|NCT03517566|Placebo Comparator|placebo|Placebo
9852374|NCT03517566|Experimental|ZPL389 3mg|ZPL389 3 mg oral powder
9852375|NCT03517566|Experimental|ZPL389 10 mg|ZPL389 10 mg oral powder
9852376|NCT03517566|Experimental|ZPL389 30mg|ZPL389 30 mg oral powder
9852377|NCT03517566|Experimental|ZPL389 50mg|ZPL389 50 mg oral powder
9852378|NCT03518008|Other|DD T2, then Clariti 1 Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable modality.
9852379|NCT03518008|Other|Clariti 1 Day, then DD T2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally for 1 week in a daily disposable modality.
9852380|NCT03518125|Experimental|Age ≥ 66, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
9852381|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.
9852382|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
9852383|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 29)|Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.
9852384|NCT03518125|Active Comparator|Age18-50, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
9852385|NCT03518125|Active Comparator|Age 18-50, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
9852386|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
9852387|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
9852388|NCT03518840|Other|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
10207978|NCT04034355|Experimental|PledOx (5 µmol/kg)|Calmangafodipir 5 µmol/kg
10207979|NCT04034355|Placebo Comparator|Placebo|0.9% sodium chloride in 20 mL vials
10207980|NCT04031040|Experimental|Genio(TM) system therapy|Following activation of the Genio™ system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery.
10207981|NCT03993171|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10207982|NCT03993171|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10207983|NCT03993171|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10207984|NCT03993171|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10213527|NCT03856996|Experimental|Group 1: Stable CH505TF gp120 + GLA-SE|Participants in Group 1 will receive 100 mcg of Stable CH505TF gp120 admixed with 10 mcg of GLA-SE by intramuscular (IM) injection at Months 0, 2, and 6.
9852389|NCT03519087|Experimental|Interdisciplinary Evaluation|Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
9852390|NCT03519087|No Intervention|Standard Evaluation|Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
9852391|NCT03519087|Experimental|Posture and Movement Training|Participants will receive six training sessions with a physical therapist over a 3-week period.
9852392|NCT03519087|No Intervention|3-week Wait Period|Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
9852393|NCT03519087|Other|Observational Arm|Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
9852394|NCT03519204|Experimental|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
9852395|NCT03519204|Experimental|No-treatment Control|No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.
9852396|NCT03519243|Experimental|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
9852397|NCT03519243|Experimental|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
9852398|NCT03519243|Experimental|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
9852399|NCT03519243|Active Comparator|Mircera|subcutaneously monthly
9852400|NCT03519282|Experimental|Test Multifocal Toric Lens|comfilcon A multifocal toric lens
9852401|NCT03519282|Active Comparator|omafilcon A Multifocal Toric Lens|Control multifocal toric lens
9852402|NCT03519516|Experimental|PRO-174|"Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
9852403|NCT03519516|Active Comparator|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
9852404|NCT03519854|Placebo Comparator|Arm A. Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852405|NCT03519854|Experimental|Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852406|NCT03519854|Experimental|Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852407|NCT03519854|Experimental|Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852408|NCT03519854|Experimental|Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852409|NCT03519854|Experimental|Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852410|NCT03519854|Placebo Comparator|Arm G. Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852411|NCT03519854|Experimental|Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852412|NCT03519854|Experimental|Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852413|NCT03519854|Experimental|Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852414|NCT03519854|Experimental|Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852415|NCT03519854|Experimental|Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852416|NCT03519854|Placebo Comparator|Arm M. Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852417|NCT03519854|Experimental|Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852418|NCT03519854|Experimental|Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9517040|NCT03310047|Experimental|Right-low, left-high|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.~This will be repeated after 24 hours."
9852419|NCT03519854|Experimental|Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852420|NCT03519854|Experimental|Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852421|NCT03519854|Experimental|Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
9852422|NCT03519867|Experimental|1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced neuromuscular blockade (NMB) reaches 1 to 2 PTCs.
9852423|NCT03519867|Experimental|2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852424|NCT03519867|Experimental|3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852425|NCT03519867|Experimental|4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852426|NCT03519867|Experimental|5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852427|NCT03519867|Experimental|6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852428|NCT03519867|Experimental|7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852429|NCT03519867|Experimental|8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852430|NCT03519867|Experimental|9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
9852431|NCT03519867|Experimental|10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
10207985|NCT03969511|Experimental|Direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and pre stroke mRS, and performing the blood sample, patient undergoes rotational CBCT in order to exclude intracerebral hemorrhage and cerebral angiography to confirm proximal arterial occlusion. Mechanical thrombectomy is then performed as well as intravenous thrombolysis in the absence of contraindications.
9852432|NCT03519919|Experimental|Somofilcon A multifocal lens|Habitual wearers of multifocal contact lenses will be refit to somofilcon A multifocal lens and provide a subjective assessment.
9852433|NCT03519932|Experimental|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
10207986|NCT03969511|Active Comparator|Standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy, mechanical thrombectomy or intravenous thrombolysis alone when indicated.
9852434|NCT03519932|Active Comparator|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
9852435|NCT03520283|Experimental|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
9852436|NCT03520348|Experimental|PRO-167|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom
9852437|NCT03520348|Active Comparator|Corneregel®|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom of the right eye sac.
9852438|NCT03520387|Experimental|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves
9852439|NCT03520387|Active Comparator|Simulated lumbar radiofrequency ablation (simulated LRFA)|Simulated radiofrequency ablation of the dorsal rami of the lumbar spinal nerves(simulated LRFA), with targeted steroid injections
9852440|NCT03520387|Experimental|AcTIVE-CBT|Activity-Tracker Informed Video-enabled Cognitive Behavioral Therapy (AcTIVE-CBT)
9852441|NCT03520387|Active Comparator|TBSCE|Telephone-based self-directed CBT and education (TBSCE)
9852442|NCT03520400|Experimental|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
9852443|NCT03520400|No Intervention|PCI group (usual care)|Group receives standard clinical care with no intervention
9852444|NCT03520920|Experimental|R/R Non-GCB DLBCL|Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
9852445|NCT03520920|Experimental|R/R FL or MZL|Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
9852446|NCT03520959|Placebo Comparator|Placebo|A sequential regimen of LV305-matching placebo and G305-matching placebo.
9852447|NCT03520959|Experimental|CMB305|A sequential regimen of LV305 and G305.
9852448|NCT03520998|Experimental|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
9852449|NCT03520998|Experimental|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
9923494|NCT00851175|Active Comparator|4|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
9923495|NCT00851188|Experimental|internet CBT self-help|CBT via the internet
9923496|NCT00851188|Experimental|CBT self-help booklet|
9923497|NCT00851188|Active Comparator|Waiting list|
10207987|NCT03940365|Experimental|Study Group|As detailed above, a single group will be used for the study to compare the output of the study device with the output of the standard device in each patient.
10213528|NCT03856996|Experimental|Group 2: Transient CH505TF gp120 + GLA-SE|Participants in Group 2 will receive 100 mcg of Transient CH505TF gp120 admixed with 10 mcg of GLA-SE by IM injection at Months 0, 2, and 6.
9852450|NCT03521089|Active Comparator|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
9852451|NCT03521089|Sham Comparator|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
9852452|NCT03521115|Experimental|Smart Choices 4 Teens|A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component. Numbers are provided for the number of families
9852453|NCT03521115|No Intervention|Control condition|This group was provided with websites where information was available regarding the same topics.
9852454|NCT03521141|Other|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
10207988|NCT03939962|Experimental|treatment group|"Neoadjuvant therapy:SHR1210 combined with FOLFOX repeat every 14 days for a total of 4 cycles.~Adjuvant therapy:SHR1210 combined with chemotherapy (the specific regimen will be chosen at the discretion of the investigator), every 14 days for a total of 4 cycles. After that, the patients will receive camrelizumab monotherapy for up to 1 year (from the first SHR1210 treatment)."
10207989|NCT03938584|Experimental|Vitamin C|
9852455|NCT03521141|Active Comparator|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
9852456|NCT03521141|Active Comparator|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
9852457|NCT03521193|Experimental|Migraine evaluation in PFO patients|Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Patients will undergo evaluation of platelet reactivity, serotonin and cytokines before PFO closure with a dedicated device and at 6 months follow-up and these results compared to those of a control, group of healthy subjects treated with aspirin alone
9852458|NCT03521193|No Intervention|healthy subjects on aspirin treatment|12 healthy subjects on 100 mg aspirin daily will be compared to PFO patients in terms of platelet reactivity, serotonin and cytokines
9852459|NCT03521479|Experimental|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
9852460|NCT03521479|Experimental|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
9852461|NCT03521479|Active Comparator|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
9852462|NCT03521479|Active Comparator|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
9852463|NCT03521505|Experimental|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
9852464|NCT03521505|Active Comparator|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
10207990|NCT03938584|Placebo Comparator|Placebo|
9852465|NCT03521635|Experimental|Pramipexole SR|
10207991|NCT03935100|Experimental|Treatment Group|All visible diverticula clipped during index colonoscopy
10207992|NCT03935100|Placebo Comparator|Control Group|5 clips fired at random into colon lumen. No diverticula closed.
10207993|NCT03917381|Experimental|Arm|GEN1046 Open label, single arm trial where GEN1046 will be administered as monotherapy (or in combination with docetaxel or pembrolizumab in separate expansion cohorts)
10207994|NCT03898388|Experimental|Knee Synovial Fluid collection before Regenexx-SD|Measure components of knee synovial fluid 2-4 days before the Regenexx-SD treatment.
10207995|NCT03843710|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10207996|NCT03843710|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10207997|NCT03843710|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10207998|NCT03843710|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
10207999|NCT03837873|Experimental|DLCL002 protocol|Patients will receive R-DA-EDOCH(rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide, doxorubicin) as induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP(rituximab, lenalidomide(only for patients with non-GCB DLBCL), dexamethasone, cisplatin, cytarabine). Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments.
10208000|NCT03836209|Experimental|Arm A|"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and gilteritinib."
9852466|NCT03521635|Active Comparator|Pramipexole IR|
9852467|NCT03521791|Experimental|PRO-155|Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
9852468|NCT03521791|Placebo Comparator|Placebo|Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
9852469|NCT03521817|Experimental|Alcohol|Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the ~240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila).
9852470|NCT03521817|Active Comparator|No Alcohol|No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat).
9852471|NCT03522350|Active Comparator|EmbryoScope|Standard of care embryo incubator.
9852472|NCT03522350|Experimental|EmbryoScope+|New experimental embryo incubator.
9852473|NCT03522441|Experimental|Clindamycin 1% gel (Akorn Pharmaceuticals)|
9852474|NCT03522441|Active Comparator|Clindamycin 1% gel (Greenstone LLC)|
9852475|NCT03522441|Placebo Comparator|Placebo|
9852476|NCT03522506|Experimental|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
9852477|NCT03522506|Experimental|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
9852478|NCT03522506|Experimental|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
9852479|NCT03522506|Experimental|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
9852480|NCT03522675|Other|NeoMatriX and Two Comparators|NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
9852481|NCT03522948|Experimental|Open pilot|The intervention is a brief, in-person motivational intervention followed by 4 weeks of text messaging to reduce heavy episodic drinking and sexual risk behavior (unprotected anal intercourse) among men-who-have-sex-with-men.
9852482|NCT03523715|Experimental|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
9852483|NCT03523715|Placebo Comparator|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
9852484|NCT03523871|Experimental|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
10208001|NCT03836209|Active Comparator|Arm B|"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and midostaurin."
10208002|NCT03824145|Experimental|Immediate Intervention|"The experimental arm will receive a 12-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 12-week intervention includes:~1) a curriculum binder covering 12-weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 12-weeks, with four in-person supervised exercise sessions and eight telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to three cooking classes emphasizing plant-based eating."
9852485|NCT03523988|Active Comparator|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
10208003|NCT03824145|No Intervention|Wait List Control|The Wait List Control group receives no intervention for 12-weeks. Following the 12-week waitlist period, the wait list control group participants receive the experimental intervention.
10208004|NCT03810495|Experimental|OLANI (naltrexone implant)|2 OLANI containing 60% naltrexone (1.8 g total) administered one time subcutaneously
10208005|NCT03781726|Experimental|Treatment with glecaprevir/pibrentasvir Fixed Dose Combination|8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
9852486|NCT03523988|Active Comparator|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
9852487|NCT03523988|Experimental|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
9852488|NCT03524157|Experimental|PRO-087|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
9852489|NCT03524157|Active Comparator|Xyel Ofteno|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
9852490|NCT03524157|Active Comparator|Systane ultra|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc.
9852491|NCT03524339|Placebo Comparator|Placebo|
9852492|NCT03524339|Experimental|Tamsulosin|
9852493|NCT03525119|Other|HAV Vaccine 1.0 ml + Placebo/ Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).
9852494|NCT03525119|Experimental|TDV 0.5 ml + Placebo/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
9852495|NCT03525119|Experimental|TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
9852496|NCT03525210|Other|HIV patients|All HIV patients will receive the study vaccines
9852497|NCT03525210|Other|SOT patients|All SOT patients will receive the study vaccines
9852498|NCT03525444|Placebo Comparator|Placebo|Participants who received placebo matched to VX-445/TEZ/IVA for 24 weeks in the TC treatment period.
9852499|NCT03525444|Experimental|VX-445/TEZ/IVA TC|Participants who received VX-445 200 mg/TEZ 100 mg/IVA150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
9852500|NCT03525548|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
9852501|NCT03525548|Experimental|VX-445/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
9852502|NCT03525834|Experimental|Everolimus|Participants targeted to receive Everolimus tablets 10 mg orally once daily for 48 weeks.
9852503|NCT03526055|Active Comparator|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to <500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
9852504|NCT03526055|Experimental|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to >1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
9852505|NCT03526458|Active Comparator|Holmium:YAG laser: 0.2J&15Hz|Patients are assigned to treat stones with 0.2J&15Hz of the holmium laser.
9852506|NCT03526458|Experimental|Holmium:YAG laser: 0.8J&15Hz|Patients are assigned to treat stones with 0.8J&15Hz of the holmium laser.
9852507|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen A."
9852508|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen B."
9852509|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen A."
9852510|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen B."
9852511|NCT03526861|Experimental|Placebo initial-> Placebo maintenance|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52 (maintenance period):~Placebo continuation SC injection regimen A."
9923498|NCT00851201|Active Comparator|Standard Intervention|
9923499|NCT00851201|Experimental|Intensive lifestyle|
9852512|NCT03526861|Experimental|Tralokinumab (Dose1) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
9852513|NCT03526861|Experimental|Tralokinumab (Dose2) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
9852514|NCT03526861|Experimental|Placebo initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
10208006|NCT03777306|Experimental|ARM A EARLY INTERVENTION GROUP|In Arm A, the intervention group, the participants will start on the program immediately. The participants will receive MPI educational program, implemented in parallel with standard of care treatment. The MPI is implemented at the time of enrollment x 12 weeks
9852515|NCT03527173|Experimental|S. sonnei Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
9852516|NCT03527173|Placebo Comparator|Placebo Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
10208007|NCT03777306|Experimental|ARM B DELAYED INTERVENTION GROUP|Arm B, is a wait-list control group that will serve as the control. The wait-list control group will be observed for an initial 12 week period while receiving usual care and then have the educational intervention implemented from week 12-24 in parallel with standard of care
10208008|NCT03775200|Experimental|Low dose|Low dose Psilocybin
10208009|NCT03775200|Experimental|Medium dose|Medium dose Psilocybin
9852517|NCT03527550|Experimental|Cognitive Training plus Treatment as Usual|Participants in this arm will receive daily computerized cognitive training sessions during partial hospitalization, in addition to treatment as usual. Cognitive training sessions will alternate between response inhibition training and working memory training.
9852518|NCT03527550|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment As Usual group will receive usual treatment in the partial hospitalization program.
9852519|NCT03527745|Experimental|200 mg albendazole|against T. trichiura in preschool-aged children or against hookworm infections in preschool-aged children, school-aged children and adults
9852520|NCT03527745|Experimental|400 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or against hookworm infections in preschool-aged children, school-aged children and adults
9852521|NCT03527745|Experimental|600 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
9852522|NCT03527745|Experimental|800 mg albendazole|against T. trichiura in school-aged children and adults or against hookworm infections in school-aged children and adults
9852523|NCT03527745|Placebo Comparator|Placebo|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
9852524|NCT03527966|Active Comparator|Intervention group - 5cc Vivigen and local autograft|
9852525|NCT03527966|Active Comparator|Control group - small kit rhBMP-2 with local autograft|
9852526|NCT03528174|Experimental|Single Hormone closed loop|Subjects will have glucose managed using the Artificial Pancreas Control system (APC) using insulin only. Insulin will be infused through the Pacific Diabetes Technologies CGM Insulin Infusion system.
9852527|NCT03528369|Experimental|CGS-200-1|CGS-200-1 (1% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
9852528|NCT03528369|Experimental|CGS-200-5|CGS-200-5 (5% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
9852529|NCT03528369|Sham Comparator|CGS-200 Vehicle|CGS-200 Vehicle (no Capsaicin), a topical liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
9852530|NCT03528512|Experimental|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
9852531|NCT03528512|Active Comparator|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
9852532|NCT03528551|Experimental|N8-GP, once weekly|All participants will receive turoctocog alfa pegol (N8-GP) once weekly.
9852533|NCT03528551|Experimental|N8-GP, twice weekly|All participants will receive N8-GP twice weekly.
9852534|NCT03528551|Experimental|N8-GP, three times weekly|All participants will receive N8-GP three times weekly.
10208010|NCT03775200|Experimental|High dose|High dose Psilocybin
10208011|NCT03769766|Active Comparator|Curcumin|"Other names for the supplement: BCM-95 CG (Biocurcumax),Tumeric~Manufacture- DolCas Biotech, LLC.~Classification - type of agent: Supplement~Protocol dose: 500 mg twice"
10208012|NCT03769766|Placebo Comparator|Placebo|"Drug: placebo~placebo orally twice a day Other Names: •sugar pill"
10208013|NCT03753555|Active Comparator|Routine-dose statin group|Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months
9852535|NCT03528577|Experimental|Test|Albuterol Sulfate Inhalation Aerosol, eq 90 mcg
9852536|NCT03528577|Active Comparator|Reference|PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg
9852537|NCT03528577|Placebo Comparator|Test Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
9852538|NCT03528577|Placebo Comparator|Reference Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
9923500|NCT00851214||Acute CHF/COPD|Patients presenting with shortness of breath secondary to acute exacerbation of CHF/COPD
9852539|NCT03529162|Active Comparator|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
9852540|NCT03529162|Active Comparator|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
9852541|NCT03529409|Experimental|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
9852542|NCT03529409|No Intervention|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
9852543|NCT03529461|Other|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
9852544|NCT03529461|Experimental|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
9852545|NCT03530098|No Intervention|Control (Without-AI)|This is the control arm where no intervention is provided; represents current standard of care.
9852546|NCT03530098|Experimental|Experiment (With-AI)|"This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final."
9852547|NCT03530345|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
9852548|NCT03530345|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
9852549|NCT03530631|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
9852550|NCT03530631|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
9852551|NCT03530631|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
9852552|NCT03530631|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
9986355|NCT01402037|Other|NDP 12-39 y|In newly diagnosed patients a hyperglycemic clamp tests will be performed within 4 weeks after diagnosis and 6, 12, 18 and 24 months later in 40 patients. The clamp will not be carried out in participants who became Cpeptide negative (defined as AUC C-peptide ≤ 0.03 nmol/L x min.) at a previous visit. HbA1c will be determined at the day of the clamp and glycemic variability during 5 days starting immediately after the clamp procedure. Insulin requirements and severe hypoglycemia (defined as an episode in which a patient required the assistance of another person and which was associated with a blood level of < 50 mg/dL or prompt recovery following intravenous glucose, glucagon or oral carbohydrate) will be recorded
10208014|NCT03753555|Experimental|high-dose statin or PCSK9 inhibitor group|"high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.~PCSK9 inhibitor group will receive the subcutaneous injection of Evolocumab (140mg, 2 / month) for one year."
9852553|NCT03530917|Experimental|Single Ascending Dose (SAD): Placebo|In SAD Cohorts 1-4, there will be eight participants in total receiving placebo, two in each cohort.
9852554|NCT03530917|Experimental|SAD: Cohort 1|Eight participants will be administered 40mg RO7020531 orally on Day 1.
10208015|NCT03748485|Experimental|wait and watch group|clinical local advanced colorectal cancer (cTxN1/2M0) following pre-operational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) without adjuvant chemotherapy
9852555|NCT03530917|Experimental|SAD: Cohort 2|Eight participants will be administered 100mg RO7020531 orally on Day 1.
9852556|NCT03530917|Experimental|SAD: Cohort 3|Eight participants will be administered 140mg RO7020531 orally on Day 1.
9852557|NCT03530917|Experimental|SAD: Cohort 4|Eight participants will be administered 170mg RO7020531 orally on Day 1.
9852558|NCT03530917|Experimental|Multiple Ascending Dose (MAD): Placebo|In MAD Cohorts 1-3, there will be six participants in total receiving placebo, two in each cohort.
9852559|NCT03530917|Experimental|MAD: Cohort 1|Eight participants will be administered 100mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
9852560|NCT03530917|Experimental|MAD: Cohorts 2 and 3|Sixteen participants will be administered 150mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
10208016|NCT03748485|Active Comparator|adjuvant chemotherapy group|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) with adjuvant chemotherapy
9852561|NCT03531710|Experimental|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
9923501|NCT00851214||Acute Trauma|Acute trauma patients with a trauma ISS>15
9852562|NCT03531710|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
9852563|NCT03531840|Experimental|Arm 1/Olaparib|Twice daily oral olaparib
10208017|NCT03738566|Other|Endoscopic Dilation|Patients randomized to the observation group will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses. A relapse will be considered if a patient developed solid food dysphagia at least once a week.
9852564|NCT03531905|Experimental|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
9852565|NCT03531905|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
9852566|NCT03531905|Placebo Comparator|Placebo|Placebo Oral Tablet, Placebo oral capsule
9852567|NCT03532009|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Powder for oral suspension
9852568|NCT03532009|Placebo Comparator|Placebo|Powder for oral suspension
9852569|NCT03532048|Experimental|Intervention Group|The Papás Saludables, Niños Saludables Program
9852570|NCT03532048|Other|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
9852571|NCT03532308|Experimental|Intervention|Daily Fermented Soy (two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
9852572|NCT03532308|Placebo Comparator|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
9852573|NCT03532776|Experimental|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
9852574|NCT03532776|Active Comparator|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
9852575|NCT03532776|Placebo Comparator|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
9852576|NCT03533036|Experimental|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
9852577|NCT03533036|No Intervention|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
10208018|NCT03738566|Active Comparator|Esophageal Self Dilation|Patients will be instructed to start Esophageal self dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months.
10208019|NCT03734029|Experimental|Trastuzumab deruxtecan|HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
10208020|NCT03734029|Active Comparator|Physician's Choice|"HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:~Capecitabine~Eribulin~Gemcitabine~Paclitaxel~Nab-paclitaxel"
10208021|NCT03726333|Active Comparator|Group A1 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
10208022|NCT03726333|Active Comparator|Group A2 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
10208023|NCT03726333|Experimental|Group B mild hepatic impairment|continued daily administration of lorlatinib in patients with mild hepatic imapirment
10208024|NCT03726333|Experimental|Group C moderate hepatic impairment|continued daily administration of lorlatinib in patients with moderate hepatic impairment
9852578|NCT03533114|Experimental|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
9852579|NCT03533114|Placebo Comparator|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
9852580|NCT03533244|Placebo Comparator|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
9852581|NCT03533244|Experimental|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
9852582|NCT03533244|Experimental|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
9852583|NCT03533374||Patients with epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
9852584|NCT03533374||Patients with non-epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
9852585|NCT03533608|Experimental|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
9852586|NCT03533829|Active Comparator|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
9852587|NCT03533829|Active Comparator|Music|Music will be selected and listened to as a distraction before and during vaccination.
9852588|NCT03533829|Active Comparator|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
9852589|NCT03534427|No Intervention|Control group|No exercise intervention
9852590|NCT03534427|Experimental|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
9852591|NCT03534986|Experimental|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
9852592|NCT03534986|Experimental|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
9852593|NCT03534986|Experimental|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
9852594|NCT03535194|Experimental|250mg Q4W/250mg Q8W Mirikizumab|Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
9852595|NCT03535194|Experimental|250mg Q4W/125mg Q8W Mirikizumab|Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
9852596|NCT03535194|Experimental|Placebo/250mg Mirikizumab|Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
9852597|NCT03535194|Active Comparator|300mg Secukinumab|Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period.
9852598|NCT03535194|Experimental|Japan GPP/EP|Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.
9852599|NCT03535571|Experimental|Salmon Protein Hydrolysate (CollaGo®)|Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
9852600|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 17 August 2017 and the date when at least 100 cases are collected from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
9852601|NCT03535844|Experimental|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
9852602|NCT03535844|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
9852603|NCT03535974|Active Comparator|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
9852604|NCT03535974|Placebo Comparator|Placebo|6 weeks bid Placebo
9852605|NCT03536663|Other|Optiflux/Endexo|Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
9852606|NCT03536702|Experimental|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
9852607|NCT03536702|Active Comparator|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
9852608|NCT03536819|Experimental|Treatment|Participants receive Votiva treatment
9852609|NCT03536923|Experimental|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
9852610|NCT03536949|Experimental|RVL-1201 Ophthalmic Solution, 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
9852611|NCT03536949|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
9923502|NCT00851214||Sepsis|Patients presenting with a suspicion of acute sepsis (fever, tachycardia, tachypnea)
9852612|NCT03537014|Experimental|MDMA-assisted therapy|Administration of 80 or 120 mg MDMA (with a supplemental dose offered 1.5 to 2 hours later of 40 or 60 mg MDMA respectively) in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart.
9852613|NCT03537014|Placebo Comparator|Placebo with therapy|Administration of inactive placebo in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart
9852614|NCT03537092|Experimental|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
9852615|NCT03537261|Experimental|CPI-Parent Training|Will receive one-day (6-hour) training in P-CPI including the use of nonverbal, paraverbal, verbal, and physical intervention techniques.
9852616|NCT03537261|No Intervention|Waitlist Control|"Will not receive active P-CPI training during the experimental treatment interval.~NOTE: The waitlist group will be offered the P-CPI training session after the treatment group completes their follow-up measures."
9852617|NCT03537274|Experimental|PEG-Intron, 0.5 mg/kg|PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
9852618|NCT03537274|Experimental|PEG-Intron, 1.0 mg/kg|PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
9852619|NCT03537274|Experimental|PEG-Intron, 1.5 mg/kg|PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
9852620|NCT03537274|Active Comparator|Interferon Alfa-2b|Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
9852621|NCT03537404|Active Comparator|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
9852622|NCT03537404|Active Comparator|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
9852623|NCT03537404|Active Comparator|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
9852624|NCT03537404|Experimental|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
9852625|NCT03537404|Experimental|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
9852626|NCT03537651|Experimental|TEZ/IVA|TEZ 50 mg once daily (qd)/IVA 75 mg every 12 hours (q12h) or TEZ 100 mg qd/IVA 150 mg q12h based on body weight for participants aged 6 through 11 years at enrollment and TEZ 100 mg qd/IVA 150 mg q12h for participants aged >=12 years at enrollment. Doses were adjusted upward for changes in body weight and/or age.
9852627|NCT03537664|Experimental|Total bacteria analysis after 1rst- and 2nd-visit procedures|DNA levels and activity (RNA/DNA ratio) of total bacteria after the first-visit procedures (root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation) and the second-visit protocol (intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation). Additionally, the composition of the active microbiome will be assessed by Next Generation Sequencing (NGS) analysis of the root canal samples, and the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
9852628|NCT03537664|Other|Bacterial species analysis after root canal preparation|DNA levels and activity (RNA/DNA ratio) of Bacteroidaceae sp. 272 , Cutibacterium acnes, Selenomonas spp., and Enterococcus faecalis after root canal preparation.Additionally, the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
9852629|NCT03538431|Experimental|Buspirone|These subjects will receive buspirone prior to engaging in the driving simulation.
9852630|NCT03538431|Experimental|Unmedicated|These subjects will take no medication prior to engaging in the driving simulation
9852631|NCT03538678|Experimental|Kwit app|Use of Kwit smartphone app
9852632|NCT03538678|No Intervention|Standard of care|Patient initiated follow-up post discharge
9852633|NCT03538743|Placebo Comparator|Placebo|
9852634|NCT03538743|Experimental|PF-06882961 30 mg|
9852635|NCT03538743|Experimental|PF-06882961 100 mg|
9852636|NCT03538743|Experimental|PF-06882961 300 mg|
9986356|NCT01402037|Other|NDP 5-12 y|Ten childhood-onset patients (under age 12) will be tested for 5 days with CGM (without clamp) and their glycemic variability compared with that of 10 patients aged 12-17 years at diagnosis.
9986357|NCT01402037|Other|FDR 12-39 y|In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
9793996|NCT01491737|Active Comparator|Arm B: Trastuzumab + AI +/- Chemotherapy|"Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
9793997|NCT01491802|Experimental|LAMA alone, then LAMA/LABA combination|Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product [LAMA plus long-acting beta2-agonist (LABA)] once daily for 4 weeks.
9793998|NCT01491802|Experimental|LABA/LAMA combination, then LAMA alone|Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks.
9793999|NCT01491841|Experimental|Phase 1: Pixantrone, 55mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 55mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
9794000|NCT01491841|Experimental|Phase 1: Pixantrone, 85mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 85mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
9794001|NCT01491841|Experimental|Phase 1: Pixantrone, 115mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 115mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
9794002|NCT01491854|Other|Monitoring of long-term safety|Long-term safety follow-up after the end of treatment with Omnitrope (single arm)
9794003|NCT01491919|Experimental|Low Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
9794004|NCT01491919|Experimental|Medium Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
9794005|NCT01491919|Experimental|High Dose: Lisinopril|Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.
9794006|NCT01491945|Experimental|Ventana Fenestrated Stent Graft System|Ventana Fenestrated Stent Graft System
9794007|NCT01491958|Experimental|Donor|Related donors will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines. Peripheral blood stem cells will not be manipulated or T-depleted prior to administration.
9794008|NCT01491958|Experimental|Patient|Patients will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first. Standard post transplant care will be administered.
9794009|NCT01491984|Experimental|Laryngoscopy order: 1) MAC, 2) Levitan|Levitan FPS Intubation
9794010|NCT01491984|Experimental|Laryngoscopy order: 1) Levitan, 2) MAC|Macintosh Intubation
9794011|NCT01492088|Experimental|Brentuximab vedotin: Phase 1|Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
9794012|NCT01492088|Experimental|Brentuximab vedotin: Phase 2|Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
9794013|NCT01492101|Experimental|NKTR-102|
9794014|NCT01492101|Active Comparator|Physician's Treatment of Choice|
9794015|NCT01492309|Active Comparator|Active Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive active 1 Hz right-sided dorsolateral prefrontal cortex (DLPFC) TMS.
9794016|NCT01492309|Sham Comparator|Sham Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive sham transcranial magnetic stimulation.
9794017|NCT01492400|Experimental|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
9794018|NCT01492400|Active Comparator|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
9852637|NCT03538743|Experimental|PF-06882961 600 mg|
9852638|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 5|
9852639|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 6|
10208025|NCT03726333|Experimental|Group D severe hepatic impairment|continued daily administration of lorlatinib in patients with severe hepatic impairment
9852640|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 7|
9852641|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 8|
9852642|NCT03538795|Experimental|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS&eCIMT, and then receive post-treatment testing.
9852643|NCT03538808|Active Comparator|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
9852644|NCT03538808|Placebo Comparator|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
9852645|NCT03538808|Active Comparator|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
9852646|NCT03538808|Placebo Comparator|Low Dose Placebo Deception|told low dose medication + received placebo
9852647|NCT03539211|Experimental|Rotation Exercises|8 minute program of rotation based exercises
9852648|NCT03539211|Active Comparator|Control Exercises|8 minute program of traditional exercises
9852649|NCT03539432|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily
9852650|NCT03539432|Placebo Comparator|Placebo|Microcrystalline cellulose powder packaged in capsules identical to the experimental condition
9852651|NCT03539484|Experimental|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
9852652|NCT03539484|Experimental|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
9852653|NCT03539484|Experimental|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
9852654|NCT03539549|Experimental|Abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
10208026|NCT03721276|Experimental|Therapy|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
10208027|NCT03721276|Other|Waitlist|Individuals assigned to waitlist will be put on a waitlist for 3 months after baseline assessment, after which they will also receive the same treatment as the therapy group.
9852655|NCT03540030|No Intervention|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
9852656|NCT03540030|Active Comparator|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
9852657|NCT03540134|Experimental|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
10208028|NCT03716609|Experimental|Magnesium supplement group|Subjects receive citrate acid drinks with additional magnesium citrate (300mg magnesium)
10208029|NCT03716609|Placebo Comparator|placebo group|Subjects receive citrate acid drinks without additional magnesium
10208030|NCT03712358|Experimental|Cohort 0 (PVSRIPO)|A single dose of PVSRIPO into a single lesion.
10208031|NCT03712358|Experimental|Cohort 1 (PVSRIPO)|A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
10208032|NCT03712358|Experimental|Cohort 2 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
9852658|NCT03540147|Experimental|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
9852659|NCT03540147|Experimental|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
9852660|NCT03540147|Sham Comparator|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
9852661|NCT03540147|Experimental|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
9852662|NCT03540147|Sham Comparator|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
9852663|NCT03540160|Experimental|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
10208033|NCT03712358|Experimental|Cohort 3 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
9852664|NCT03541044|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
9852665|NCT03541044|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
9852666|NCT03541356|Placebo Comparator|Placebo|
9852667|NCT03541356|Active Comparator|L-dopa 35 mg|
9852668|NCT03541356|Active Comparator|L-dopa 70 mg|
9852669|NCT03541356|Active Comparator|L-dopa 140 mg|
9852670|NCT03541356|Active Comparator|L-dopa 70 mg/carbidopa 7 mg|
9852671|NCT03541941|Experimental|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
9852672|NCT03541941|Active Comparator|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
9852673|NCT03541941|Placebo Comparator|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
9852674|NCT03541980|Active Comparator|Intervention|Patients allocated to receive IV acetaminophen
9852675|NCT03541980|Placebo Comparator|Placebo|Patients allocated to receive IV normal saline placebo
9852676|NCT03542019|Active Comparator|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
9852677|NCT03542019|Active Comparator|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
9852678|NCT03542019|Active Comparator|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
9852679|NCT03542266|Experimental|CC486 +CHOP|CC486 +CHOP
9852680|NCT03542305|Experimental|Mild|Mild renal impairment
9852681|NCT03542305|Experimental|Moderate|Moderate renal impairment
9852682|NCT03542305|Experimental|Severe|Severe renal impairment
9852683|NCT03542305|Other|Normal|Normal renal function
9852684|NCT03542474|Experimental|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
9852685|NCT03543085|Experimental|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
9852686|NCT03543137|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
10208034|NCT03712358|Experimental|Cohort 4 (PVSRIPO)|A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
10208035|NCT03709355|Active Comparator|Elpida® single dose|Single dose of Elpida® (capsule 20 mg)
10208036|NCT03709355|Experimental|Rifampin & Elpida®|Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose
10208037|NCT03709355|Experimental|Rifabutin & Elpida®|Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose
10208038|NCT03709355|Experimental|Clarithromycin & Elpida®|Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose
10208039|NCT03709355|Experimental|Omeprazole & Elpida®|Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose
10208040|NCT03709355|Experimental|Atorvastatin & Elpida®|Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose
10208041|NCT03709355|Experimental|Levonorgestrel+Ethinylestradiol & Elpida®|Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose
10208042|NCT03709355|Active Comparator|Elpida® multiple dose|Elpida® QD dosing for 14 days
10208043|NCT03700658|Experimental|TV-46046 Undiluted|Participants will receive TV-46046 undiluted (120 mg/0.3 mL of 400 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
10208044|NCT03700658|Experimental|TV-46046 Diluted|Participants will receive TV-46046 saline-diluted (60 mg/0.3 mL of 200 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
10208045|NCT03700658|Placebo Comparator|TV-46046 Placebo|Participants will receive TV-46046 placebo (0.3 mL) SC injection in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
10208046|NCT03700658|Active Comparator|Depo-subQ 104|Participants will receive Depo-subQ 104 (medroxyprogesterone acetate injectable suspension; 104 mg/0.65 mL) SC injection as a reference formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
9852687|NCT03543137|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
9852688|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
9923503|NCT00851214||Stroke|Patients presenting with symptoms and signs of acute stroke (thrombotic or hemorrhagic)
10208047|NCT03698552|Experimental|ADCT-602|Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
10208048|NCT03695484||Manual guided RF ablation|Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters
10208049|NCT03695484||Cryoballoon ablation|Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm
10208050|NCT03695484||RMN guided RF ablation - High power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.~High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference."
10208051|NCT03695484||RMN guided RF ablation - Low power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.~Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference."
10208052|NCT03691961|Experimental|Medium dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
10208053|NCT03691961|Experimental|High dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
10208054|NCT03669133|Active Comparator|Group A|Vitamin E 800 IU/daily for 24 weeks
10208055|NCT03669133|Placebo Comparator|Group B|Matching placebo for 24 weeks
10208056|NCT03637491|Experimental|Avelumab and binimetinib|Open label
10208057|NCT03637491|Experimental|Avelumab, binimetinib and talazoparib|Open label
10208058|NCT03637491|Experimental|Binimetinib and talazoparib.|Open label.
10208059|NCT03616535|Active Comparator|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
10208060|NCT03616535|Active Comparator|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
10208061|NCT03616535|Active Comparator|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
10208062|NCT03616535|No Intervention|Standard of Care|Participants in this arm will receive standard of care
10208063|NCT03610334|Experimental|SAD IFB-088 2.5mg|Cohort 1: A single daily dose of 2.5mg IFB-088 in oral capsule, is administered with 250 ml of water at room temperature, in the morning around 8:00am, in one intake
10208064|NCT03610334|Placebo Comparator|SAD Placebo 2.5mg|Cohort 1: A single daily dose of 2.5mg placebo in oral capsule, is administered with 250 ml of water at room temperature, in the morning around 8:00am, in one intake
10208065|NCT03610334|Experimental|SAD IFB-088 5.0mg|Cohort 2: A single daily dose of 5.0mg IFB-088 in oral capsule, divided in two doses of 2.5mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208066|NCT03610334|Placebo Comparator|SAD Placebo 5.0mg|Cohort 2: A single daily dose of 5.0mg placebo in oral capsule, divided in two doses of 2.5mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208067|NCT03610334|Experimental|SAD IFB-088 10.0mg|Cohort 3: A single daily dose of 10.0mg IFB-088 in oral capsule, divided in two doses of 5.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208068|NCT03610334|Placebo Comparator|SAD Placebo 10.0mg|Cohort 3: A single daily dose of 10.0mg Placebo in oral capsule, divided in two doses of 5.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208069|NCT03610334|Experimental|SAD IFB-088 20.0mg|Cohort 4: A single daily dose of 20.0mg IFB-088 in oral capsule, divided in two doses of 10.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208070|NCT03610334|Placebo Comparator|SAD Placebo 20.0mg|Cohort 4: A single daily dose of 20.0mg Placebo in oral capsule, divided in two doses of 10.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208071|NCT03610334|Experimental|SAD IFB-088 40.0mg|Cohort 5: A single daily dose of 40.0mg IFB-088 in oral capsule, divided in two doses of 20.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208072|NCT03610334|Placebo Comparator|SAD Placebo 40.0mg|Cohort 5: A single daily dose of 40.0mg Placebo in oral capsule, divided in two doses of 20.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
9923504|NCT00851227|Experimental|1. Mildly Hepatic Impaired Subjects|
9986358|NCT01402037|Other|FDR 5-12 y|"Ten high-risk first-degree relatives (see criteria) aged 5 to 12 years will also be tested for CGM and their results correlated with beta-cell function derived from a mini-clamp procedure (first 10 min. C-peptide release in hyperglycemic clamp) and results (CGM and first clamp phase) from relatives aged 12-17 years."
9986359|NCT01402076|Experimental|Steady State PK Group|
9986360|NCT01402076|Experimental|No steady state PK|
9986361|NCT01402154||All study patients|All patients included according to stated inclusion and exclusion criteria.
9986362|NCT01402167|Experimental|Kyphoplasty|Patients randomized to this arm will be treated via balloon kyphoplasty.
9794019|NCT01492426|Experimental|Daclatasvir + Peginterferon alfa-2a + Ribavirin|
9794020|NCT01492426|Experimental|Telaprevir + Peginterferon alfa-2a + Ribavirin|
9794021|NCT01492439|Experimental|Cognitive Remediation and Supported Education|Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
9794022|NCT01492439|Active Comparator|Supported Education Only|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
9794023|NCT01492582|Experimental|Prevention (vaccine therapy)|Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
9794024|NCT01492673|Experimental|Cyclophosphamide, Topotecan, and Bevacizumab (CTB)|This is a multi-center, open label phase II study evaluating the safety and efficacy of the novel combination of agents consisting of bevacizumab, cyclophosphamide, and topotecan.
9794025|NCT01492686|Experimental|Arm 1|
9794026|NCT01492686|Placebo Comparator|Arm 2|
9794027|NCT01493024|Placebo Comparator|Placebo|Placebo (silicified microcrystalline cellulose) randomized to mimic escalating doses of experimental drug administered three times daily (TID) with meals.
9794028|NCT01493024|Experimental|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated, microporous zirconium silicate, an oral sorbent) administered 3 times daily (tid) with meals.
9794029|NCT01493089|Experimental|Zegerid|Treatment of heartburn with Zegerid
9794030|NCT01493089|Active Comparator|Losec|Treatment of heartburn with Losec
9794031|NCT01493167|Other|limb casting/splinting|Patient age 0-90 years. Patient treatment requires extremity immobilization
9794032|NCT01493180|Experimental|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
9794033|NCT01493180|Active Comparator|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution
9794034|NCT01493284|Experimental|Transfemoral Access|Transfemoral Access for transcatheter aortic valve implant
9794035|NCT01493414|Experimental|INC424|5 - 25 mg twice a day (BID)
9794036|NCT01493427|Experimental|TRAVATAN® BAK-free|Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
9794037|NCT01493531|Experimental|lesinurad 200 mg + allopurinol|
9794038|NCT01493531|Experimental|lesinurad 400 mg + allopurinol|
9794039|NCT01493531|Placebo Comparator|Placebo + allopurinol|
9794040|NCT01493557|Other|Pradaxa (dabigaran etexilate)|Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
9794041|NCT01493557|Active Comparator|Pradaxa and pantoprazole|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
9794042|NCT01493557|Active Comparator|Pradaxa, 30 minutes after a meal|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
9794043|NCT01493596|Other|CPP-115 Dose 1|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
9794044|NCT01493596|Other|CPP-115 Dose 2|2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
9794045|NCT01493596|Other|CPP-115 Dose 3|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
9852689|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
9923505|NCT00851227|Experimental|2. Moderately Hepatic Impaired Subjects|
9923506|NCT00851227|Experimental|3. Subjects with Normal Hepatic Function|
9923507|NCT00851240|Experimental|BTT1023|
9923508|NCT00851240|Placebo Comparator|Placebo|
9923509|NCT00851266|Experimental|1|V512
9923510|NCT00851266|Placebo Comparator|2|Placebo to V512
9923511|NCT00851292|Active Comparator|Side-firing|prostate biopsies obtained with side-firing probe
9923512|NCT00851292|Active Comparator|End-firing|
9923513|NCT00851305|Experimental|1 confocal laser endomicroscopy|Targeted biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by confocal laser endomicroscopy.
9923514|NCT00851305|Active Comparator|2 Conventional endoscopy|Routine biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by conventional endoscopy.
9923515|NCT00851344|Active Comparator|GSK835726 (10mg)|10mg oral dose
10208073|NCT03610334|Experimental|SAD IFB-088 60.0mg|Cohort 6: A single daily dose of 60.0mg IFB-088 in oral capsule, divided in two doses of 30.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
10208074|NCT03610334|Experimental|SAD Placebo 60.0mg|Cohort 6: A single daily dose of 60.0mg Placebo in oral capsule, divided in two doses of 30.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
9923516|NCT00851344|Active Comparator|GSK835726 (50mg)|50mg oral dose
9923517|NCT00851344|Active Comparator|GSK835726 (100mg)|50mg oral dose
9923518|NCT00851344|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
9923519|NCT00851344|Placebo Comparator|placebo|placebo tablet
9923520|NCT00851370|Experimental|Omalizumab|
9923521|NCT00851370|Placebo Comparator|Placebo|
9923522|NCT00851383|Experimental|Group A|Ad35-GRIN/ENV: 2x10^9 vp
9923523|NCT00851383|Experimental|Group B|Ad35-GRIN/ENV: 2x10^10 vp
9923524|NCT00851383|Experimental|Group C|Ad35-GRIN/ENV: 2x10^11 vp
9923525|NCT00851383|Experimental|Group D|Ad35-GRIN at 1x10^10 vp
9923526|NCT00851396||Obese female adolescents|Obese adolescents will be screened for vitamin D deficiency through an existing study. Those found to be vitamin D deficient will be given standard treatment of vitamin D deficiency. In this study, patients who self report that they had taken the treatment for vitamin D will be screened for serum 25 OH D level and will undergo OGTT. The OGTT results as well as insulin resistance indices will be compared to their initial values.
9923527|NCT00851435|Experimental|KBPA-101, a monoclonal antibody|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
9923528|NCT00851448|Experimental|1|Oral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
9923529|NCT00851448|Placebo Comparator|2|isocaloric, isonitrogenous
9923530|NCT00851487|Experimental|Amoxicillin|Oral amoxicillin in the dose of 15 mg/kg/dose 8 hourly was given as an active drug
9923531|NCT00851487|Placebo Comparator|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
9923532|NCT00851500|Experimental|low dose K-604|
9923533|NCT00851500|Experimental|high dose K-604|
9923534|NCT00851500|Placebo Comparator|placebo|
9923535|NCT00851513|Experimental|Group B|local anesthetics (lidocaine) associated with local steroids (depo-medrol)
9923536|NCT00851513|Experimental|Group C|local anesthetics (lidocaine) associated with local steroids (depomedrol) and important volumes of physiological serum
9923537|NCT00851513|Active Comparator|Group A|only local anesthetic (lidocaine)
9923538|NCT00851526||Coronary bifurcation lesion|
9923539|NCT00851539|No Intervention|Control|Participants received counseling from a live counselor.
9923540|NCT00851539|Experimental|Video|Behavioral Intervention Video
9923541|NCT00851565|Active Comparator|1|Patients with Crohn's disease with secondary loss of response to infliximab.
9923542|NCT00851565|Active Comparator|2|Patients with Crohn's disease with secondary loss of response to infliximab.
9923543|NCT00851578|Experimental|WATCHMAN|non-valvular atrial fibrillation patients contraindicated to warfarin
9923544|NCT00851604||1|Patients with malignant neuroendocrine tumors
9923545|NCT00851617|Experimental|IMT Group|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
9923546|NCT00851617|No Intervention|Control Group|Patients were evaluated until weaning without interventions
9923547|NCT00851669|Experimental|IPT|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
10213529|NCT03854123||Old MS patients|"75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the Observatoire français de la sclérose en plaques (OFSEP)."
10213530|NCT03841318|Experimental|Sjogren's Syndrome|
10213531|NCT03841097|Active Comparator|Extended Release Tacrolimus Tablets|Dosed once daily in the morning and started at a dose of 0.14 mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
10213532|NCT03841097|Active Comparator|Immediate Release Tacrolimus Capsules|Dosed twice daily 12 hours apart and started at a dose of 0.1mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
10213533|NCT03837132||Advanced pancreatic cancers|Newly diagnosed patients with advanced pancreatic cancer
10213534|NCT03836079|Experimental|ADHF Patients|Treatment with preCARDIA System
10208075|NCT03610334|Experimental|MAD IFB-088 15 mg|Cohort 7: subject taking 15.0mg of IFB-088 in oral capsule divided into 2 doses of 7.5mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
10208076|NCT03610334|Placebo Comparator|MAD Placebo 15 mg|Cohort 7: subject taking 15.0mg of placebo in oral capsule divided into 2 doses of 7.5mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
10208077|NCT03610334|Experimental|MAD IFB-088 30 mg|Cohort 8: subject taking 30.0mg of IFB-088 in oral capsule divided into 2 doses of 15.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
10208078|NCT03610334|Placebo Comparator|MAD Placebo 30 mg|Cohort 8: subject taking 30.0mg of Placebo in oral capsule divided into 2 doses of 15.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
10208079|NCT03610334|Experimental|MAD IFB-088 50 mg|Cohort 9: subject taking 50.0mg of IFB-088 in oral capsule divided into 2 doses of 25.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
10208080|NCT03610334|Placebo Comparator|MAD Placebo 50 mg|Cohort 9: subject taking 50.0mg of Placebo in oral capsule divided into 2 doses of 25.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
9852690|NCT03543878|Experimental|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
9852691|NCT03543878|Active Comparator|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
9852692|NCT03544216|Experimental|Single Vision First|Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.Therefore, this group will receive both study interventions.
10208081|NCT03582618|Experimental|Sorafenib + CVM-1118|"Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)~400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.~Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)~Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
9852693|NCT03544216|Experimental|Multifocal first|Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks. Therefore, this group will receive both study interventions.
9852694|NCT03544307|Experimental|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
9852695|NCT03544307|No Intervention|Control|Sedentary control asked not to exercise
9852696|NCT03544333|Experimental|real transcranial magnetic stimulation|In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
10208082|NCT03574207|Other|Arm A: Stimulation then Sham|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm A, transcranial magnetic stimulation (TMS) will be applied in the first week of participation, and sham stimulation will be applied in the second week of participation.
9852697|NCT03544333|Placebo Comparator|sham transcranial magnetic stimulation|In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.
9852698|NCT03544879|Experimental|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
9852699|NCT03544879|Active Comparator|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
9852700|NCT03545165|Experimental|All Subjects|"177Lu-PSMA-617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~177Lu-J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~68Ga-PSMA-HBED-CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
9852701|NCT03545412|Experimental|Microfocused ultrasound with visualization|
9852702|NCT03545503|Active Comparator|Etomidate|Etomidate will be dosed once at a standard of 0.3 mg/kg via IV Push
9852703|NCT03545503|Active Comparator|Ketamine|Ketamine will be dosed once at a standard 2 mg/kg via IV Push
9852704|NCT03545893|Active Comparator|Ibuprofen|
9852705|NCT03545893|Active Comparator|Ibuprofen + Oxycodone|
9852706|NCT03545984|Experimental|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
9852707|NCT03545984|Active Comparator|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
9852708|NCT03546270|Experimental|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at ~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
9852709|NCT03546270|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
9852710|NCT03546491|Experimental|Preventive Gel|0.4% stannous fluoride
9852711|NCT03546491|Active Comparator|Marketed Control|0.243 % Sodium Fluoride
9852712|NCT03546621|Experimental|Arm A|Myrcludex B, 2 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
9852713|NCT03546621|Experimental|Arm B|Myrcludex B, 5 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
9852714|NCT03546621|Experimental|Arm C|Myrcludex B, 10 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
9852715|NCT03546621|Active Comparator|Arm D|tenofovir treatment for 48 weeks
9852716|NCT03546647|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
9852717|NCT03546647|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
9852718|NCT03546816|Experimental|5 mg Serlopitant Tablets|
9852719|NCT03546816|Placebo Comparator|Matching Placebo Tablets|
9852720|NCT03546842|Experimental|9vHPV vaccine|Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6
9852721|NCT03547154|Experimental|Pegylated interferon alfa-2b|Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
10208083|NCT03574207|Other|Arm B: Sham then Stimulation|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm B, sham stimulation will be applied in the first week of participation, and transcranial magnetic stimulation (TMS) will be applied in the second week of participation.
10208084|NCT03540069|Experimental|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
9852722|NCT03547154|Active Comparator|Interferon alfa-2b|Participants received interferon alfa-2b (Intron^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
9852723|NCT03547167|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
9852724|NCT03547167|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
9852725|NCT03547531|Active Comparator|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
9852726|NCT03547531|Experimental|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
9852727|NCT03547583|Experimental|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
10208085|NCT03540069|No Intervention|Control|No educational program is implemented for each cluster prior to crossover to intervention.
10208086|NCT03517761|Experimental|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ and upper cervical injections to C0-C3 ligaments and facets.
10208087|NCT03517761|Sham Comparator|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia as well as receive sham upper cervical injections to C0-C3 ligaments and facets.
10208088|NCT03514017|Experimental|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
9852728|NCT03547583|Experimental|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
9852729|NCT03547583|Placebo Comparator|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
9852730|NCT03547635|Experimental|AMNIOEXCEL Plus Amniotic Membrane|
9852731|NCT03547635|Active Comparator|A Marketed Comparator|
9852732|NCT03547635|Other|Standard of Care|
9923548|NCT00851669|Active Comparator|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
9923549|NCT00851695||Asthma|All 1024 participants of the Childhood Asthma Management Program, who provided blood samples.
10208089|NCT03498391|Experimental|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
10208090|NCT03498391|Experimental|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
10208091|NCT03484702|Experimental|Administration of JCAR017|
10208092|NCT03477162|Experimental|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
10208093|NCT03465618|Experimental|surgical patients|Patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans may be acquired prior to surgery. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging.
10208094|NCT03465618|Experimental|non-surgical patients|Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging
10208095|NCT03461952|Experimental|Nivolumab|240mg Q2W
10208096|NCT03461952|Experimental|Nivolumab + Ipilimumab|Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
10208097|NCT03430869|Experimental|F-18 AV-45|F-18 AV-45 imaging
10208098|NCT03430869|Experimental|F-18-THK-5351|F-18-THK-5351 imaging
10208099|NCT03425825||LD-SCLC receiving 1st line treatment|patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
10208100|NCT03425825||ED-SCLC receiving 1st line treatment|patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
10208101|NCT03425825||relapsed/refractory receiving 2nd or later-line treatment|relapsed/refractory patients receiving second- or later-line treatment
10208102|NCT03420508|Experimental|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
10208103|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
10208104|NCT03401385|Experimental|Dose Escalation - All Participants|All participants enrolled in the dose escalation part
10208105|NCT03401385|Experimental|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
10208106|NCT03400059|Experimental|Active Treatment|
10208107|NCT03400059|Sham Comparator|Sham Treatment|
10208108|NCT03390296|Experimental|Arm A (anti-OX40 antibody PF-04518600)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208109|NCT03390296|Experimental|Arm B (azacitidine, venetoclax, GO)|Patients receive azacitidine IV over 10-40 minutes or via injection SC on days 1-7 or 1-5 and 8-9. Patients also receive venetoclax PO on days 1-28 and GO IV over 2 hours on day 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208110|NCT03390296|Experimental|Arm C (azacitidine, GO, avelumab)|Patients receive azacitidine and GO as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208111|NCT03390296|Experimental|Arm D (azacitidine, venetoclax, avelumab)|Patients receive azacitidine and venetoclax as in Arm A and avelumab as in Arm C. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208112|NCT03390296|Experimental|Arm E (azacitidine, avelumab, anti-OX40 antibody PF-04518600)|Patients receive azacitidine and avelumab as in Arm C and anti-OX40 antibody PF-04518600 as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208113|NCT03390296|Experimental|Arm F (GO, glasdegib)|Patients receive GO IV over 2 hours on days 1, 4, and 7, and glasdegib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208114|NCT03372057|Experimental|Dose Optimization Phase: Cohort 1|Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
10208115|NCT03372057|Experimental|Dose Optimization Phase: Cohort 2|Duvelisib 75 mg PO BID, administered in 28-day cycles.
10208116|NCT03372057|Experimental|Expansion Phase|Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)
10208117|NCT03359993||Preterm infants intubated|All participants were preterm infants intubated in the delivery room for Infantile Respiratory Distress Syndrome (IRDS). The purpose of this research is to determine a premedication of intubation. This consists of describing a simple and effective method for premedication in the delivery room, using the umbilical vein, directly perforated through the Wharton jelly.
10208118|NCT03354143|Active Comparator|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
10208119|NCT03354143|Experimental|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
10208120|NCT03348228|Placebo Comparator|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
10208121|NCT03348228|Active Comparator|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
10208122|NCT03342664|Experimental|Artemis + Medical Management (MIS)|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
9986363|NCT01402167|Active Comparator|Vertebroplasty|Patients randomized to this arm will be treated via vertebroplasty.
10208123|NCT03342664|Active Comparator|Best Medical Management Alone (MM)|Best medical management alone per standard of care at treating institution
10208124|NCT03342014|Experimental|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
10208125|NCT03340727|Experimental|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
10208126|NCT03340727|Placebo Comparator|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
10208127|NCT03334539|Experimental|0.10% HL036 Ophthalmic Solution|Participants self-administered HL036 0.10 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.
10208128|NCT03334539|Experimental|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
10208129|NCT03334539|Placebo Comparator|Placebo|Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
10208130|NCT03324308|Experimental|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
10208131|NCT03314922|Experimental|Parsaclisib|
10208132|NCT03312920|Experimental|active anodal tDCS|active anodal tDCS with Face Name associate Memory task
10208133|NCT03312920|Sham Comparator|Sham tDCS|sham tDCS with Face Name associate Memory task
10208134|NCT03312920|Experimental|active cathodal tDCS|active cathodal tDCS with Face Name associate Memory task
10208135|NCT03311854|Experimental|Emapalumab|
10208136|NCT03269344|Placebo Comparator|Control Arm|Standard supportive care during definitive treatment plus placebo
10208137|NCT03269344|Experimental|Experimental Arm|Gabapentin plus standard supportive care
10208138|NCT03253926|Experimental|Lorcaserin + Marijuana|
10208139|NCT03253926|Placebo Comparator|Placebo + Marijuana|
10208140|NCT03238235|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
10208141|NCT03238235|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
10208142|NCT03215095|Experimental|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
10208143|NCT03201458|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208144|NCT03201458|Experimental|Arm B (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208145|NCT03192540|Experimental|Exercise|These are participants who will be undergoing exercise intervention.
10208146|NCT03191058|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
10208147|NCT03191058|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q or the MECTA Sigma devices.
10208148|NCT03151746|Placebo Comparator|Placebo|Placebo pill administered 1 hour before planned surgical procedure
10208149|NCT03151746|Experimental|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
10208150|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
10208151|NCT03079284|Experimental|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
10208152|NCT03076775|Experimental|Intervention|Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.
10208153|NCT03076775|No Intervention|Usual Care|Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.
9852733|NCT03547687|Experimental|Electrical Stimulation Treatment|Patient will receive electrical stimulation to the quadriceps muscle groups on both lower extremities simultaneously for 45 minutes at a time, for a total of 5 treatments each week (Mon-Sun), for up to 14 days or until ICU discharge, whichever comes first.
9852734|NCT03548337|Active Comparator|13vPnC with 2-PE from a MDV|Multi Dose Vial with preservative
9852735|NCT03548337|Active Comparator|13vPnC without 2-PE in a PFS|Pre Filled Syringe without preservative
9852736|NCT03548935|Experimental|Semaglutide s.c. 2.4 mg once weekly|Participants will receive semaglutide for 68 weeks.
9852737|NCT03548935|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide matching placebo for 68 weeks.
9852738|NCT03549117|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
9852739|NCT03549117|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH nasal strips placebo nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
9852740|NCT03549130|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
9852741|NCT03549130|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
9852742|NCT03549234|Experimental|Erector Spinae (single injection)|
9852743|NCT03549234|Active Comparator|Paravertebral (single injection)|
9852744|NCT03549338|Experimental|Arm A (Sym004)|"Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.~For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover."
9852745|NCT03549338|Experimental|Arm B (Futuximab)|Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
9852746|NCT03549338|Experimental|Arm C (Modotuximab)|Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.
9852747|NCT03549429|Experimental|TegadermTM on R eye, EyeGard® on L eye|Patients will get TegadermTM on Right eye, EyeGard® on Left eye
9852748|NCT03549429|Experimental|TegadermTM on L eye, EyeGard® on R eye|Patients will get TegadermTM on Left eye, EyeGard® on Right eye
9852749|NCT03549598|Experimental|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan, 18FDG PET/CT scan and 13NH3 PET/CT scan will be performed on each subject
10208154|NCT03071406|Active Comparator|Arm A: Nivolumab + Ipilimumab|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.
10208155|NCT03071406|Active Comparator|Arm B: Nivolumab + Ipilimumab + SBRT|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.
10208156|NCT03067493|Experimental|Neo-MASCT group|Patients in the treatment group will receive a total of 6 courses of Neo-MASCT treatment. The whole period of Neo-MASCT treatment for each patient will be up to 24 months.Three stratification factors are considered, i.e.tumor size (2.1-3.0cm, 3.1-5.0cm), tumor number (1, >1) and type of surgery (RFA，hepatectomy).
10208157|NCT03067493|No Intervention|Control group|Patients in the control group will be actively monitored during the trial period. Patients will receive assessment every 3 months in the first 3 years.
10208158|NCT03055884|Experimental|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
10208159|NCT03055884|Experimental|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
10208160|NCT03055884|Sham Comparator|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
10208161|NCT03055884|Sham Comparator|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
10208162|NCT03049969|Experimental|Cognitive Remediation|For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a pre/post treatment assessment measures will be completed.
10208163|NCT03047213|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208164|NCT03047083||IC eligible AML patients with FLT3 mutation|Newly diagnosed AML patients
10208165|NCT03047083||IC ineligible patients with FLT3 mutation|Newly diagnosed AML patients
10208166|NCT03047083||AML patients after R/R with FLT3 mutation|R/R are relapse/refractory patients
10208167|NCT03047083||IC eligible patients without FLT3 mutation|Newly diagnosed AML patients
10208168|NCT03047083||IC ineligible patients without FLT3 mutation|Newly diagnosed AML patients
10208169|NCT03047083||AML patients after R/R without FLT3 mutation|R/R are relapse/refractory patients
10208170|NCT03029338|Experimental|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
10213535|NCT03824366|Experimental|Volumetric MR imaging planning|"All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.~Patients will receive standard of care palliative radiation therapy"
10213536|NCT03823157|Experimental|Tai Chi|Tai Chi exercise
10208171|NCT03028857|Placebo Comparator|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
10208172|NCT03028857|Active Comparator|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
10208173|NCT03006328|Experimental|Obese Subjects + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
9794046|NCT01493596|Other|CPP-115 Dose 4|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
9794047|NCT01493596|Other|CPP-115 Dose 5|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
10208174|NCT03006328|Active Comparator|Obese Subjects + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
9794048|NCT01493596|Other|CPP-115 Dose 6|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
9794049|NCT01493687|Experimental|CD5024|CD5024 1% Cream
9794050|NCT01493687|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
9794051|NCT01493778|Experimental|turoctocog alfa|
9794052|NCT01493947|Experimental|Ivermectin 1% cream|
9794053|NCT01493947|Active Comparator|Metronidazole 0.75% cream|
9794054|NCT01493960|Experimental|Cobitolimod|2 doses 4 weeks apart
9794055|NCT01493960|Placebo Comparator|Placebo|2 doses 4 weeks apart
9794056|NCT01494038|Experimental|Arm A (Immediate INH Treatment)|Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
9794057|NCT01494038|Experimental|Arm B (Deferred INH Treatment)|Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
9794058|NCT01494051|Active Comparator|High carbohydrate diet|Diet composition of 10% long-chain fatty acids, 20% medium-chain triglycerides, 12% protein and 68% carbohydrate is the current standard of care in long-chain fatty acid oxidation disorders.
9794059|NCT01494051|Experimental|High protein diet|Diet composition of 10% long-chain fatty acids, 20% medium chain triglycerides, 25% protein and 45% carbohydrate is the comparison diet. Fat content is the same between treatments; only the carbohydrate to protein ratio varies.
9794060|NCT01494298||T2DM|African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
9794061|NCT01494298||Control|African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.
9794062|NCT01494350|Experimental|WR 279,396 topical cream|120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream
9794063|NCT01494467|Experimental|CD5024|CD5024 1% Cream
9794064|NCT01494467|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
9794065|NCT01494506|Experimental|MM-398|MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
9794066|NCT01494506|Active Comparator|5 Fluorouracil and Leucovorin IV|5 Fluorouracil and Leucovorin IV
9794067|NCT01494506|Experimental|MM-398, 5-FU and Leucovorin|MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
9794068|NCT01494532|Experimental|ropinirole|active treatment 4, 8, 12, 16, or 24mg/day
9794069|NCT01494532|Placebo Comparator|placebo|placebo comparator 4, 8, 12, 16, or 24mg/day
9794070|NCT01494545|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks. A new pair was inserted each day.
9794071|NCT01494584|Experimental|ezogabine/retigabine|ezogabine dose escalation
9794072|NCT01494610|Experimental|SERETIDE Rotacaps|Fluticasone propionate (250 micrograms [ug])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler
9794073|NCT01494610|Active Comparator|SERETIDE Diskus|Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler
9794074|NCT01494610|Placebo Comparator|Placebo Rotacaps|Placebo delivered in a capsule-based inhaler
9794075|NCT01494610|Placebo Comparator|Placebo Diskus|Placebo delivered in a multi-dose dry powder inhaler
9794076|NCT01494649|Active Comparator|Toothpaste containing 0.454% stannous fluoride|USA marketed toothpaste [test]
9794077|NCT01494649|Other|Toothpaste containing 0.76% sodium monofluorophosphate|USA marketed toothpaste [negative control]
9794078|NCT01494753|Active Comparator|Prostaglandin|One drop.
9794079|NCT01494753|Experimental|T2345|One drop
9794080|NCT01494818|Experimental|CLEAR CARE/AOSEPT Plus|Hydrogen peroxide-based contact lens care system used per manufacturer's instructions
9794081|NCT01494818|Active Comparator|ReNu MultiPlus|PHMB-containing contact lens solution used per manufacturer's instructions
10208175|NCT02971501|Experimental|Arm I (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10208176|NCT02971501|Experimental|Arm II (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10208177|NCT02970448|Experimental|LITT with Radiation and Temozolomide|Laser interstitial thermal therapy (LITT) followed by Radiation therapy, three-dimensional conformal radiotherapy (3D-CRT) or intensity modulation radiation therapy (IMRT), 60 Gy/30 fractions. Radiation given with chemotherapy Temozolomide
10208178|NCT02966093|Experimental|Lenvatinib|In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
10208179|NCT02966093|Experimental|Placebo|In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
9794082|NCT01494922|Experimental|Open Label|
9794083|NCT01494987|Experimental|Ranolazine+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24.~Participants will be required to maintain their diet and exercise regimen."
9794084|NCT01494987|Placebo Comparator|Placebo+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks.~Participants will be required to maintain their diet and exercise regimen."
9794085|NCT01495000|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
9794086|NCT01495000|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
9794087|NCT01495221|Other|Intravitreal aflibercept|All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.
9794088|NCT01495481|Experimental|Adenosine and Dexmedetomidine|Patients will receive adenosine and then dexmedetomidine for the termination of SVT
9794089|NCT01495572|Experimental|High Dose (HD) Aldesleukin|Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.
9794090|NCT01495572|Experimental|Peripheral Blood Lymphocytes (PBL)|Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10^11 IV over 20-30 minutes on day 0
9794091|NCT01495585|Placebo Comparator|Placebo|Placebo control
9794092|NCT01495585|Experimental|Group 1|lonafarnib 100mg
9794093|NCT01495585|Experimental|Group 2|lonafarnib 200mg
9794094|NCT01495689|Active Comparator|Usual Care|Usual care for smoking cessation will be delivered to the control arm which comprises of strong physician advice, brief counseling from the clinic nurse +/- a prescription for smoking cessation aid if requested and willing
9794095|NCT01495689|Experimental|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
9794096|NCT01495702|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
9794097|NCT01495702|Active Comparator|NNRTI+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of an NNRTI plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
9794098|NCT01495793|Experimental|Rotigotine|In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.
9794099|NCT01495819|Active Comparator|Nicotine|subjects will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg). At the beginning of each experimental session, subjects will first sample the assigned nicotine dose and placebo (saline) condition that are randomly labeled as A or B. which may be nicotine or saline. This procedure will allow subjects to sample the nicotine and saline that will be available during that session. In addition, subjective and physiological responses to the sample nicotine dose and saline will be assessed.
9794100|NCT01495819|Placebo Comparator|Saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
9794101|NCT01495858|Experimental|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|
9794102|NCT01495858|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
10208180|NCT02953093|Other|Acarbose first|Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
10208181|NCT02953093|Other|Placebo first|Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
10208182|NCT02940106|Placebo Comparator|closed device|Standard cryopreservation system.
10208183|NCT02940106|Active Comparator|open device|New cryopreservation system.
9852750|NCT03550066|Experimental|Values affirmation|In the values affirmation condition, the health outreach message contained a prompt asking participants to reflect on important personal values.
9852751|NCT03550066|Active Comparator|No affirmation|"In the no affirmation condition, the health outreach message appeared alone, with no values affirmation."
10208184|NCT02937948|Experimental|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
9852752|NCT03550209|Experimental|LCPUFA Oil Supplement, Low Dose|25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
9852753|NCT03550209|Experimental|LCPUFA Oil Supplement, Medium Dose|50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
9852754|NCT03550209|Experimental|LCPUFA Oil Supplement, High Dose|75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
10208185|NCT02933944|Experimental|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
10208186|NCT02933073|Experimental|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
10208187|NCT02921997|Experimental|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
10208188|NCT02921997|Experimental|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
9852755|NCT03550209|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
9852756|NCT03550313|Experimental|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
9852757|NCT03550313|Experimental|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
9852758|NCT03550313|Active Comparator|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
9852759|NCT03550378|Experimental|MEDI0382|Participants will receive subcutaneous (SC) dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
9852760|NCT03550378|Placebo Comparator|Placebo|Participants will receive SC dose of placebo matched to MEDI0382 once daily for 32 days.
9852761|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.~Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
9852762|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 cigarettes~Smokes cigarettes daily > 1/day~Uses IQOS less than daily~Uses less than 30 HeatSticks/month~Cigarette is > 95% of tobacco/nicotine product (all product use)"
9852763|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
9852764|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
9852765|NCT03551730|Experimental|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
9852766|NCT03551730|Experimental|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
9852767|NCT03551730|Experimental|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
9852768|NCT03551730|Placebo Comparator|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
9852769|NCT03551743|Experimental|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
9852770|NCT03551743|Experimental|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
9852771|NCT03551743|Experimental|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
9852772|NCT03551743|Placebo Comparator|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
9852773|NCT03551821|Experimental|ATI-50002 Topical Solution|ATI-50002 Topical Solution
9852774|NCT03552198|No Intervention|General public/usual health advice|Healthy participants with a self-reported existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
10208189|NCT02921997|Experimental|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
10208190|NCT02879162|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4
10208191|NCT02868528|Experimental|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
10208192|NCT02868528|No Intervention|control group|After blastocyst culture, blastocysts will be transferred
10208193|NCT02833935|Experimental|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
9794103|NCT01495858|Active Comparator|DPH 50 mg|
9794104|NCT01495923|Experimental|Epidural steroids|Injection of steroids into the epidural space
9794105|NCT01495923|Active Comparator|Gabapentin|Titration of gabapentin to effect
9794106|NCT01495975|No Intervention|Usual Care|Usual care for diabetes in the 1 month after discharge.
9794107|NCT01495975|Experimental|Diabetes Transitions Tool Kit|Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
9794108|NCT01496066|Experimental|LAL|LAL implanted
9794109|NCT01496066|Active Comparator|Monofocal control|Monofocal control IOL implanted
9794110|NCT01496131|Active Comparator|Standard therapy|Radiation therapy in combination with androgen deprivation therapy (ADT).
9794111|NCT01496131|Experimental|Standard therapy plus tecemotide (L-BLP25)|Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).
9794112|NCT01496157|Experimental|Patients with Primary Prostate Cancer|Patients will be imaged with 18F-DCFBC
9794113|NCT01496183|Placebo Comparator|Placebo|
9794114|NCT01496183|Experimental|Olanzapine|
9794115|NCT01496248|Experimental|Korean Red Ginseng|Extract of Korean red ginseng was administrated to subjects through capsule form.
9794116|NCT01496274|Experimental|Prophylaxis|"Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention."
9794117|NCT01496274|Experimental|On-demand|Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
9794118|NCT01496287|Experimental|Tube placement group|
9794119|NCT01496313|Active Comparator|300mg vandetanib|
9794120|NCT01496313|Active Comparator|150mg vandetanib|
9794121|NCT01496352|Experimental|DFA-02|Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
9794122|NCT01496352|Placebo Comparator|DFA-02 placebo|
9794123|NCT01496365|Experimental|DS-5565 5mg nighttime|DS-5565 5 mg/day (one 5 mg tablet at bedtime)
9794124|NCT01496365|Experimental|DS-5565 10 mg at bedtime|DS-5565 10 mg/day (one 10 mg tablet at bedtime)
9794125|NCT01496365|Experimental|DS-5565 15 mg at bedtime|DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
9794126|NCT01496365|Experimental|DS-5565 20 mg total per day|DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
9794127|NCT01496365|Experimental|DS-5565 30 mg total per day|DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
9794128|NCT01496365|Active Comparator|Pregabalin 300 mg total per day|Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)
9794129|NCT01496430|Placebo Comparator|Placebo QD|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
9794130|NCT01496430|Experimental|Azilsartan Medoxomil 40 mg QD|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
9794131|NCT01496430|Experimental|Azilsartan Medoxomil 80 mg QD|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
9794132|NCT01496456|Placebo Comparator|Preventative measures|Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
9794133|NCT01496456|Active Comparator|Lesion infiltration|Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
9794134|NCT01496469|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
9794135|NCT01496469|Placebo Comparator|Placebo QD|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
9794136|NCT01496612|Experimental|Study Phase|
9794137|NCT01496612|Placebo Comparator|Alternate Study Phase|
9794138|NCT01496807|Experimental|Yervoy with Sylatron|Participants are given Yervoy induction every 3 weeks for four doses, for 12 weeks, and all participants simultaneously receive Sylatron induction weekly, followed by Sylatron maintenance alone for up to 144 additional weeks (total 156 weeks = 3 years).
9794139|NCT01496846|Active Comparator|IANB Articaine|IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
9794140|NCT01496846|Active Comparator|SUP Articaine|SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
9794141|NCT01496846|Active Comparator|SUP Lidocaine|SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.
9794142|NCT01496885||Nonhemorrhagic Ischemic Stroke|Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke
9794143|NCT01497067|Experimental|CACHET|ACRYSOF CACHET Phakic Lens (L-series) previously implanted
9852775|NCT03552198|Experimental|General public/alternative health advice|Generally healthy participants were randomised to receive targeted health advice about the adoption of protective behaviours in an alternative format.
9852776|NCT03552198|No Intervention|At risk group/usual health advice|Participants with a self-reported pre-existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
9852777|NCT03552198|Experimental|At risk group/alternative health advice|Participants with a self-reported existing health conditions were randomised to receive targeted health advice (based on their health condition) about the adoption of protective behaviours in an alternative format.
9852778|NCT03552289|Active Comparator|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
9852779|NCT03552289|Active Comparator|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
9852780|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
9852781|NCT03552523|Experimental|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
9852782|NCT03552536|Experimental|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
9852783|NCT03552536|Experimental|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
9852784|NCT03552536|Experimental|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
9852785|NCT03552549|Experimental|PEG-Intron|Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.
9852786|NCT03552549|Experimental|INTRON A|Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units [MIU]/m^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m^2 three times per week) for 48 weeks post-surgery.
9852787|NCT03552757|Experimental|Semaglutide 1.0 mg|Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
9852788|NCT03552757|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
9852789|NCT03552757|Placebo Comparator|Semaglutide placebo I/II|Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
9852790|NCT03553758|Experimental|Ketamine|15 subjects undergoing ketamine general anesthesia.
9852791|NCT03553823|Experimental|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
9852792|NCT03553823|Active Comparator|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
9852793|NCT03553940|Experimental|Arm 1|A single dose of monovalent live attenuated influenza H3N2 M2SR vaccine (M2SR) administered intranasally on Day 1, and a single dose of licensed quadrivalent influenza vaccine (QIV) administered intramuscularly on Day 92. N=25
9852794|NCT03553940|Placebo Comparator|Arm 2|A single dose of Placebo administered intranasally on Day 1, and a single dose of licensed QIV administered intramuscularly on Day 92. N=25
10208194|NCT02833935|No Intervention|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
9852795|NCT03554005|Experimental|PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)|Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
9852796|NCT03554005|Experimental|PEG Interferon Alfa-2b 1.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
10213537|NCT03815058|Experimental|Safety Run-in Period: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of RO7198457.
10213538|NCT03815058|Active Comparator|Randomized Period: Arm A: Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with RO7198457 plus pembrolizumab (Arm B) after confirmed disease progression.
9852797|NCT03554005|Experimental|PEG Interferon Alfa-2b 3 mcg/kg OW|Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
9923550|NCT00851695||Asthma in Hispanics|All 616 subjects in the Genetic Epidemiology of Asthma in Costa Rica who have serum.
9923551|NCT00851695||Lung function and lung function decline|626 subjects from the Normative Aging Study who have serum and lung function.
9852798|NCT03554005|Experimental|PEG Interferon Alfa-2b 4.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
9852799|NCT03554005|Experimental|PEG Interferon Alfa-2b 6 mcg/kg OW|Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
9852800|NCT03554005|Experimental|PEG Interferon Alfa-2b 7.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
9852801|NCT03554018|Experimental|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
9852802|NCT03554018|Active Comparator|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
9852803|NCT03554486|Experimental|Fiasp then Novolog|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
9852804|NCT03554486|Experimental|Novolog then Fiasp|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Novolog insulin for 2 weeks, followed by Fiasp insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
9852805|NCT03554629|Other|Capnography CO2 Sampling Filterline Performance|Adult volunteer exhaled gas was sampled by 8 different CO2 cannula sampling filterline (CCSF) designs connected to a Capnostream 35 for measurement of CO2 during patient simulated scripted activities in order to assess patient interface design performance to provide a quality gas sample for CO2 partial pressure measurement.
9852806|NCT03554746|Experimental|GC group|It mainly involve core stability exercise, stretching exercise and gluteal control training. All of above will be arranged 3 times a week for a total 6 weeks.
9852807|NCT03554746|Experimental|CG group|It involve core stability exercise and stretching exercise. All of above will be arranged 3 times a week for a total 6 weeks.
9852808|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Single dose containing 62.5 mg of celecoxib in 10 ml solution
9852809|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 125 mg|Single dose containing 125 mg of celecoxib in 10 ml solution
10208195|NCT02822092||Patients with Psychotic Disorders taking Risp. or Arip.|Risperidone or aripiprazole will be administered. Subjects will start risperidone 1 mg qhs or 5mg qhs aripiprazole; on day 4 the daily dose will be increased to 2 mg risperidone or 10mg aripiprazole and to 3 mg risperidone or 15mg aripiprazole at day 7. The target dose is 3 mg risperidone or 15 mg aripiprazole daily but patients who remain psychotic can be increased to 4 mg risperidone or 20mg aripiprazole at week 4; 5 mg risperidone or 25 mg aripiprazole at week 6 and 6 mg risperidone or 30 mg aripiprazole at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
9923552|NCT00851708|Active Comparator|NAC|treatment
10208196|NCT02822092||Healthy Volunteers|Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.
9923553|NCT00851708|No Intervention|control|
10208197|NCT02804074|Active Comparator|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
10208198|NCT02804074|Experimental|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
10208199|NCT02798263|Experimental|Group I kinesiotherapy|Treated with standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes
10208200|NCT02798263|Experimental|: Group II Acupuncture|Treated with 30 minutes of classical acupuncture using predefined points
10208201|NCT02798263|Experimental|Group III Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper®
10208202|NCT02781857||100 patients with lung cancer|"Group A: 70 patients with any type of lung cancer eligible for lung cancer surgery~Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma)."
10208203|NCT02781857||60 controls|60 controls (group C) matched for age, gender, smoking history.
10208204|NCT02744651|Active Comparator|EUS-FNA|All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
10208205|NCT02744651|Active Comparator|EUS-Endodrill biopsy|All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
10208206|NCT02717416|Experimental|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
10208207|NCT02717416|Active Comparator|Hemoclip (HX-610-135, Olympus, Japan) or electrical coagulation group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip or electrical coagulation therapy.
10208208|NCT02712905|Experimental|INCB059872|
10213539|NCT03815058|Experimental|Randomized Period: Arm B: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of RO7198457.
10213540|NCT03814967|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
9852810|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 250 mg|Single dose containing 250 mg of celecoxib in 10 ml solution
9852811|NCT03554772|Placebo Comparator|Placebo|Single dose containing 0 mg of celecoxib in 10 ml solution
9794144|NCT01497197|Experimental|Gonal-f®+Luveris®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 1 until required recombinant human chorionic gonadotropin (r-hCG) level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
9852812|NCT03555266|Experimental|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
10208209|NCT02712905|Experimental|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:~Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.~Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML~Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
10208210|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
10208211|NCT02675946|Experimental|Arm 1: CGX1321 Single Agent dose escalation and dose expansion|"Arm 1: Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle~Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle."
9852813|NCT03555266|Sham Comparator|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
9852814|NCT03555305|Experimental|Insulin Glargine|Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).
9852815|NCT03555305|Active Comparator|Lantus|Participants received 0.5 U/Kg of Lantus subcutaneously.
9852816|NCT03555435|Experimental|On Your Own|Participants in this group will use the online program on their own for 6 weeks.
10208212|NCT02675946|Experimental|Arm 2: CGX1321 in combination with pembrolizumab dose escalation, dose expansion and Roll-over,|"Arm 2: Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).~Arm 2: Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
10208213|NCT02675946|Experimental|Arm 3: CGX1321 in combination with encorafenib + cetuximab, dose escalation and dose expansion|Arm 3: Phase 1b: Ascending doses of CGX1321, once daily, orally for 3 weeks (21 days) followed by a one-week (7 day) washout period in combination with enocrafenib administered orally once daily and cetuximab administered IV once weekly
10208214|NCT02660827|Experimental|Hybrid closed loop|All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
10208215|NCT02627963|Experimental|Tivozanib hydrochloride|Patients randomized to this arm will receive the study drug, tivozanib hydrochloride.
10208216|NCT02627963|Active Comparator|Sorafenib|Patients randomized to this arm will receive the comparator drug, sorafenib.
9852817|NCT03555435|Experimental|Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
10208217|NCT02619760|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
9852818|NCT03555435|Placebo Comparator|Wait|Participants in this group will wait 6 weeks.
9852819|NCT03555565||Alogliptin and Metformin hydrochloride|Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
9852820|NCT03555890|Experimental|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
9852821|NCT03555890|Experimental|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
9852822|NCT03555890|Experimental|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
9923554|NCT00851734|Experimental|LX214 0.02%|LX214 ophthalmic solution 0.02%
9923555|NCT00851734|Experimental|LX214 0.2%|
9923556|NCT00851734|Placebo Comparator|placebo|placebo
10213541|NCT03814967|Active Comparator|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
9852823|NCT03555890|Experimental|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
9852824|NCT03556579|Experimental|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
9852825|NCT03556579|Experimental|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
9852826|NCT03556761|Experimental|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
9852827|NCT03556761|Placebo Comparator|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
9852828|NCT03556891|Experimental|eCoin Tibial Nerve Stimulation|
9852829|NCT03557034|No Intervention|Standard of Care Monitoring|Standard of Care
9852830|NCT03557034|Experimental|Kardia Monitoring|Kardia Mobile/Kardia Pro
9852831|NCT03557086|Experimental|Advanced Care Planning Video Decision Support Tool|We designed a 3-minute advance care planning video to provide patients with advanced liver disease general understanding of the types of medical care patients may receive at the end of life (EOL) and a description of medical interventions such as hospitalizations, intensive care unit (ICU) admission, cardiopulmonary resuscitation (CPR), and intubation. The video begins by addressing the importance of the patient's personal goals and perspectives by asking the viewer to reflect on their concerns about getting sick and their overall goals for their EOL care. The physician narrator then introduces a framework for choices of medical care at the EOL including: 1) life-prolonging care; 2) limited medical care; and 3) comfort care followed by visual images illustrating each of these EOL care choices. All three sequences of video images accompanying the narration attempt to help the viewer imagine the experience and likely outcomes of receiving these medical interventions at the EOL.
9852832|NCT03557086|Active Comparator|Verbal Narrative Control|Immediately after completing baseline assessments and randomization, patients assigned to the verbal narrative control arm will listen to the same description of the 3 goals of care used in the video arm read out by a research assistant
9852833|NCT03557125|Active Comparator|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
9852834|NCT03557125|Placebo Comparator|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
9852835|NCT03557333|Experimental|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
9852836|NCT03557372|Experimental|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
9852837|NCT03557476|Experimental|Octacosanol|Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
9852838|NCT03557476|Placebo Comparator|Placebo|A placebo pill was taken twice daily in replacement of the octacosanol supplement
9852839|NCT03557658|Experimental|Hepatic Impaired|Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9)
9852840|NCT03557658|Experimental|Healthy Volunteer|Subjects with normal hepatic function
9852841|NCT03557775|Experimental|Inspiratory Muscle Strength Training|"The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
9923557|NCT00851760|Experimental|1 Combined Surgery|
9923558|NCT00851760|Active Comparator|2 consecutive surgery|
9923559|NCT00851773|Experimental|A|
9923560|NCT00851773|Experimental|B|
9923561|NCT00851773|Experimental|C|
9923562|NCT00851773|Experimental|D|
9923563|NCT00851773|Experimental|E|
9923564|NCT00851773|Placebo Comparator|F1|
9923565|NCT00851773|Placebo Comparator|F2|
9923566|NCT00851773|Placebo Comparator|F3|
9923567|NCT00851773|Placebo Comparator|F4|
9923568|NCT00851773|Placebo Comparator|F5|
9923569|NCT00851812|Other|Arm 1|Usual Care: Standard care monitoring
9923570|NCT00851812|Experimental|Arm 2|Progressive walking and resistance exercise treatment
9923571|NCT00851838|Experimental|PD solution|
9923572|NCT00851864|Experimental|A|Women requiring therapeutic anticoagulation, singleton pregnancy,<30weeks
9923573|NCT00851916|Other|CyberKnife Radiosurgery|Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
9935813|NCT03187262|Experimental|Daratumumab|"Daratumumab will be administered in three phases: Induction, consolidation and maintenance~During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day~During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle~During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
9935814|NCT03185819|Placebo Comparator|Oral Midazolam + Intranasal Placebo|Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
9852842|NCT03557775|Experimental|Expiratory Muscle Strength Training|"The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
9852843|NCT03557775|Active Comparator|Voice Exercises|The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.
9852844|NCT03557801|Active Comparator|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
9852845|NCT03557801|Experimental|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
9852846|NCT03557801|Experimental|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
9852847|NCT03557931|Experimental|ASP4345 50 milligram (mg)|Participants on stable doses of antipsychotic medication received ASP4345 50 mg, capsules, orally, once daily for 12 weeks.
9852848|NCT03557931|Experimental|ASP4345 150 mg|Participants on stable doses of antipsychotic medication received ASP4345 150 mg, capsules, orally, once daily for 12 weeks.
9852849|NCT03557931|Placebo Comparator|Placebo|Participants on stable doses of antipsychotic medication received ASP4345 placebo matching capsules, orally, once daily for 12 weeks.
9852850|NCT03558061|Experimental|Active|ALK4290 800 mg daily
9852851|NCT03558074|Experimental|Active|ALK4290 800 mg daily
9852852|NCT03558230|Experimental|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
9852853|NCT03558230|Placebo Comparator|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
9852854|NCT03558516|Experimental|Magnesium group|The patient will receive magnesium sulfate injection 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed
9852855|NCT03558516|Placebo Comparator|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed
9852856|NCT03558555|Active Comparator|Oral Acetaminophen|Patients who are randomized to have oral acetaminophen will take oral acetaminophen preoperatively and receive saline intraoperatively.
9852857|NCT03558555|Active Comparator|Acetaminophen IV Soln|Patients randomized to IV acetaminophen will receive IV acetaminophen after induction of general anesthesia and will take placebo pills preoperatively.
9852858|NCT03558997|Experimental|Placebo|Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
9852859|NCT03558997|Experimental|Dupilumab|Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
9923574|NCT00851929|Experimental|sarcoidosis associated pulmonary hypertension|sarcoidosis associated pulmonary hypertension
9923575|NCT00851942|Experimental|Synacthen 250 micrograms|IV injection of 250 micrograms of Synacthen in 1m
9986364|NCT01402180|Experimental|A|Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation
9852860|NCT03558997|Experimental|SCIT|Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.
9852861|NCT03558997|Experimental|Dupilumab + SCIT|Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
9852862|NCT03559062|Other|Placebo|Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
9852863|NCT03559062|Experimental|TEZ/IVA|Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
9852864|NCT03559062|Experimental|Ivacaftor|Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.
9852865|NCT03559179|Experimental|Waivered Providers Receive the Opioid Wizard|All providers who have a buprenorphine waiver will receive the OUD clinical decision support tool (Opioid Wizard).
9852866|NCT03559179|No Intervention|Does not Receive the Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid Wizard. This arm of providers will continue to treat their patients as usual.
9852867|NCT03559179|Experimental|Non-Waivered Providers who receive Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid. This arm of providers will receive the OUD clinical decision support tool (Opioid Wizard).
9852868|NCT03559205|No Intervention|MSK-Tracker (before)|Before - (Usual care in clinic consultations)
9852869|NCT03559205|Active Comparator|MSK-Tracker (after)|After - (MSK-Tracker in clinic consultations)
9852870|NCT03559218|Other|Standard of care|Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
9986365|NCT01402180|Active Comparator|B|Patients randomized in Arm B will receive chemoradiation only
9852871|NCT03559218|Experimental|KeraStat Cream|Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
9852872|NCT03559257|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
9852873|NCT03559257|Placebo Comparator|Placebo|Placebo administered SC.
9852874|NCT03559517|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
9852875|NCT03559517|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
9852876|NCT03559517|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
9852877|NCT03559530||Patients|Patients with microbiologically proven A. baumannii-related osteomyelitis
9852878|NCT03559829|Experimental|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
9852879|NCT03559933|Experimental|PEPNS System|The pdSTIM lead will be temporarily inserted near the right and left phrenic nerves and connected to the PEPNS system console in order to stimulate the phrenic nerves and activate the diaphragm on the patients until extubated/removed from mechanical ventilation or until 48 hours has elapsed, whichever comes first.
9852880|NCT03560102|Experimental|MR-HIFU treatment|Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat& resect model
9852881|NCT03560128|Experimental|Endocuff Vision Arm|Colonoscopy with Endocuff Vision device attached to the distal end of the scope.
9852882|NCT03560128|Experimental|AmplifEYE Arm|Colonoscopy with AmplifEYE device attached to the distal end of the scope.
9852883|NCT03560141|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
9986366|NCT01402193|Active Comparator|Study Arm|"Investigational treatment: Arimidex commenced before and continued during radiotherapy.~Interventions:~Drug: Pre-radiotherapy commencement of Arimidex Radiation: Radiotherapy"
9852884|NCT03560141|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
9852885|NCT03560245|Experimental|Bryostatin 20µg|20µg Bryostatin administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
9852886|NCT03560245|Placebo Comparator|Placebo|"Placebo administered IV over 45 minutes every other weekafter 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.~The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
9852887|NCT03560518|Experimental|Rapastinel 450mg|Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)
9852888|NCT03560518|Experimental|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
9852889|NCT03560518|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration)
9852890|NCT03560739|Other|OMB 20mg PFS abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on abdomen
9852891|NCT03560739|Other|OMB 20mg AI abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on abdomen
9852892|NCT03560739|Other|OMB 20mg PFS thigh|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on thigh
9852893|NCT03560739|Other|OMB 20mg AI thigh|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on thigh
9852894|NCT03560869|Experimental|Normal hydration then dehydration|Participants will consume water to maintain proper hydration for three days prior to testing (visit 1). Seven to 60 days later, participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 2).
9852895|NCT03560869|Experimental|Dehydration than normal hydration|Participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 1). Seven to 60 days later, participants will consume water to maintain proper hydration for three days prior to testing (visit 2).
9852896|NCT03560986|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
10208218|NCT02619760|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
10208219|NCT02581930|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208220|NCT02547298||All participants|All participants will be filling out questionnaires and undergoing cystoscopy with hydrodistension for evaluative reasons
10208221|NCT02543281|Active Comparator|aCRT Off|The adaptive CRT algorithm will be turned off for the CRT device implanted in the patients in this arm.
10208222|NCT02543281|Experimental|aCRT On|The adaptive CRT algorithm will be turned on for the CRT device implanted in the patients in this arm.
10208223|NCT02520063|Experimental|Phase I Cohort 1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
9852897|NCT03560986|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
9852898|NCT03561090|Experimental|1500 mg IW-3718 BID + PPI|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
9852899|NCT03561090|Placebo Comparator|Placebo + PPI|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
9852900|NCT03561883|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
9852901|NCT03561883|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
9852902|NCT03562117|Experimental|Normal Hepatic function, Part 1 (Group D)|The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
9852903|NCT03562117|Experimental|Moderate hepatic impairment, Part 1 (Group B)|The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
9852904|NCT03562117|Experimental|Mild hepatic impairment, Part 2 (Group A)|The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
9852905|NCT03562117|Experimental|Severe hepatic impairment, Part 2 (Group C)|The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
9852906|NCT03562117|Experimental|Normal Hepatic function, Part 2 (Group E)|The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
10208224|NCT02520063|Experimental|Phase I Cohort 2|Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
10208225|NCT02520063|Experimental|Phase I Cohort -1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
10208226|NCT02520063|Experimental|Phase II|Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
9852907|NCT03562377|Experimental|Tralokinumab|"Week 0 to 16:> Tralokinumab will be given as subcutaneous injections. >~> Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
9852908|NCT03562377|Placebo Comparator|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections. >~> Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
9923576|NCT00851955||1. Normal pancreas patients|Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
9923577|NCT00851955||2. Chronic pancreatitis patients|Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
9923578|NCT00851955||3. Pancreatic cancer patients|Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
9923579|NCT00851968|Active Comparator|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
9923580|NCT00851968|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy
9923581|NCT00851968|Experimental|portal vein occlusion|Patients with HCC received portal vein occlusion in hepatectomy
9923582|NCT00851981|Placebo Comparator|1|
9923583|NCT00851981|Active Comparator|SAMe|
9923584|NCT00851994||1|Patients having surgery
9923585|NCT00852007|Experimental|DC-Tn-MUC|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1. 1.2 x 10e7 dendritic cells per dose. 5 administrations (doses)may be given in total.
9923586|NCT00852020|Experimental|1|oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants
9923587|NCT00852020|Placebo Comparator|2|oral nutritional supplement (isocaloric, isonitrogenous)
9923588|NCT00852033|No Intervention|1|Assessment Group (no intervention)
9923589|NCT00852033|Active Comparator|2|Brief Motivational Intervention (BMI)
9923590|NCT00852033|Active Comparator|3|Parent Based Intervention (PBI)
9923591|NCT00852033|Active Comparator|4|BMI and TBI
9923592|NCT00852046|Experimental|1. Low dose dexmedetomidine|Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl & propofol.
9923593|NCT00852046|Experimental|2. High dose dexmedetomidine|Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl & propofol.
9923594|NCT00852046|Placebo Comparator|3. Placebo|Placebo added to fentanyl & propofol.
9923595|NCT00852059|Experimental|Immediate release|Treatment with immediate release (IR) methylphenidate (Medikinet®) in the morning and 3-4 h later (twice a day)
9923596|NCT00852059|Active Comparator|Extended release|Treatment with extended release (ER) methylphenidate (Medikinet reatard®) applied with breakfast(once daily)
9923597|NCT00852072|Active Comparator|Single-operator cholangioscopy guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
9923598|NCT00852072|Active Comparator|Balloon sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
9923599|NCT00852085|Experimental|Group MI|Four group counseling sessions and a directed observational visit to the emergency department of a busy urban hospital
9923600|NCT00852085|Active Comparator|Enhanced community service|
9923601|NCT00852098|Active Comparator|1|dividing short gastric vessels
9923602|NCT00852098|Active Comparator|2|non-dividing short gastric vessels
9923603|NCT00852163|Experimental|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
9923604|NCT00852176||On-label treatment|"Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (on-label)."
9923605|NCT00852215|Active Comparator|1|Taxus stent group
9923606|NCT00852215|Active Comparator|2|Vision stent group
9923607|NCT00852228|Experimental|chronomodulated HAI chemotherapy|
9923608|NCT00852228|Experimental|conventional HAI chemotherapy|
9923609|NCT00852267|Active Comparator|High CHO, High SatFat Diet|
9923610|NCT00852267|Experimental|Low CHO, High SatFat Diet|
9923611|NCT00852267|Experimental|Low CHO, Low SatFat Diet|
9923612|NCT00852293||study group|Patients with liver disease followed at the liver unit at Hadassah Medical Center.
9923613|NCT00852306|Experimental|slow freeze|these recipients will have their first embryo transfer with oocytes frozen via the slow freeze method.
9923614|NCT00852306|Experimental|vitrification|these recipients will have their first attempt at an embryo transfer with oocytes frozen via the vitrification method.
9923615|NCT00852319|Experimental|Central Mississippi group|Participants from central Mississippi are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
9852909|NCT03562481|Experimental|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
9852910|NCT03562481|Experimental|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
9852911|NCT03562559||TKA Patients|
9852912|NCT03562663|Experimental|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
9852913|NCT03562663|Sham Comparator|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
9852914|NCT03562988|Other|Vitamin C gummy, Then Vitamin C Caplet|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.
9852915|NCT03562988|Other|Vitamin C tablet, Then Vitamin C gummy|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.
9852916|NCT03563027|No Intervention|Control|This arm serves as control and uses a wearable device to track daily step counts
10208227|NCT02496663|Experimental|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10208228|NCT02442375|Active Comparator|standard dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
10208229|NCT02442375|Experimental|FDG-PET guided gradient dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
10208230|NCT02437370|Experimental|Arm A (pembrolizumab, docetaxel)|pembrolizumab IV over 30 minutes on day 1 and docetaxel IV over 60 minutes on day 1.
10208231|NCT02437370|Experimental|Arm B (pembrolizumab, gemcitabine hydrochloride)|pembrolizumab IV as in Arm A and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.
10208232|NCT02425644|Experimental|Ponesimod|Subjects to receive 20 mg ponesimod
10208233|NCT02425644|Active Comparator|Teriflunomide|Subjects to receive 14 mg teriflunomide
9852917|NCT03563027|Experimental|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
9852918|NCT03563027|Experimental|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
9852919|NCT03563183||Overall Group|Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
9852920|NCT03563313|Experimental|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months.
9852921|NCT03563313|Active Comparator|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
9852922|NCT03564444|Experimental|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1
9852923|NCT03564444|Placebo Comparator|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
9852924|NCT03564886|Experimental|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
10208234|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
10208235|NCT02395614|Experimental|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
10208236|NCT02395614|Active Comparator|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
10208237|NCT02381561|Experimental|Treatment (ropidoxuridine, IMRT)|Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
9852925|NCT03564886|Placebo Comparator|Normal Saline|Lactate Ringer's (LR, 273mOsm/L) is commonly used at our facility as our isotonic standard irrigation solution and will serve as the control to be evaluated against a hyperosmolar (1.9%, 600mOsm) solution.
9852926|NCT03565068|Experimental|Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg|Healthy participants will receive MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
10208238|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
10208239|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
9852927|NCT03565068|Placebo Comparator|Panel A (Healthy Participants): Placebo Monotherapy|Healthy participants will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
9852928|NCT03565068|Experimental|Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
9852929|NCT03565068|Placebo Comparator|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
9852930|NCT03565068|Experimental|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg|In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia will receive MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
9852931|NCT03565068|Placebo Comparator|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In addition to background AAP treatment, participants with Schizophrenia will receive MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
9852932|NCT03565068|Experimental|Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg, depending on safety and tolerability.
9852933|NCT03565068|Placebo Comparator|Panel D (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-15.
9852934|NCT03565211|Experimental|Progesterone vaginal ring (PVR)|Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
9852935|NCT03565315|Experimental|Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group|10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)
9852936|NCT03565315|Experimental|Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
9852937|NCT03565315|Experimental|Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group|10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)
9852938|NCT03565315|Experimental|Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
9852939|NCT03565666|Active Comparator|Adult RCT: Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy) for 7 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM) and half of all subjects also were a senseonics CGM. The usual care period was followed by the other 2 arms according to each subject's randomization schedule
9852940|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
9852941|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet using Fiasp|Participants randomized to the iLet with Fiasp first started the insulin-only iLet arm using faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm was set to the same value as is used for Humalog and Novolog (65 minutes). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
9852942|NCT03565679|Experimental|Masimo SpO2 Adhesive Sensors, Adtx (1859) & (2329)|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
9852943|NCT03565679|Sham Comparator|Covidien Nellcor SpO2 Sensor, MAX-A and MAX-N|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
9852944|NCT03565874|Experimental|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
9852945|NCT03565887|Experimental|RVL-1201 ophthalmic solution 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
9852946|NCT03565887|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
9852947|NCT03566238|Experimental|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
9852948|NCT03566238|Experimental|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
9852949|NCT03566238|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
10208240|NCT02359253|Experimental|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
10208241|NCT02359253|Experimental|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
9852950|NCT03566485|Experimental|Phase 2 (atezolizumab, cobimetinib)|Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9852951|NCT03566485|Experimental|Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO|
9852952|NCT03566550||CF|people with cystic fibrosis
9852953|NCT03566550||Control|people without cystic fibrosis
9852954|NCT03566680|Experimental|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
10208242|NCT02359253|Experimental|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
10208243|NCT02359253|Experimental|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
9852955|NCT03566810|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
9852956|NCT03566810|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
9852957|NCT03566810|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
10208244|NCT02340221|Experimental|Taselisib + Fulvestrant|Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
10208245|NCT02340221|Placebo Comparator|Placebo + Fulvestrant|Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
10208246|NCT02270957|Active Comparator|Abatacept|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
9852958|NCT03566810|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
9852959|NCT03566823|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
9852960|NCT03566823|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
9852961|NCT03566823|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
9852962|NCT03566979|Experimental|Test naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
9852963|NCT03566979|Active Comparator|Commercial naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
9852964|NCT03566979|Active Comparator|Commercial naproxen sodium liquid gels capsule|Single dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
9852965|NCT03566979|Placebo Comparator|Placebo tablet|Single dose of two Placebo tablets
9852966|NCT03567005|Other|DACP Digital then DACP|Nelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
9852967|NCT03567005|Other|DACP then DACP Digital|Nelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
9852968|NCT03567252|Experimental|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
9852969|NCT03567252|No Intervention|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
9852970|NCT03567291|Experimental|TEV-50717- Part A|All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
9852971|NCT03567291|Experimental|TEV-50717- Part B RW|TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.
9852972|NCT03567291|Placebo Comparator|Placebo- Part B RW|Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.
9852973|NCT03567382|Experimental|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load >10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
9852974|NCT03567382|Experimental|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load <10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
9852975|NCT03567616|Experimental|Part 1: Dose Escalation|Venetoclax (400 mg oral [PO], once daily [QD]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly [qw]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
9852976|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) positive|Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
9852977|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) negative|Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
9852978|NCT03567980|Experimental|topical crisaborole 2%|
9852979|NCT03568500|Experimental|Aripiprazole|Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
9852980|NCT03568500|Experimental|Olanzapine|Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
9852981|NCT03568500|Experimental|Quetiapine|Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
9852982|NCT03568500|Experimental|Risperidone|Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
9852983|NCT03568539|Experimental|IBI308|
9852984|NCT03568942|Experimental|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (>=10 WBC/mm^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
9852985|NCT03569020|Experimental|Dietitian-Directed Diet|Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
9852986|NCT03569020|No Intervention|Self-Directed Diet|Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
9852987|NCT03569033|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
9852988|NCT03569033|Placebo Comparator|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
9852989|NCT03569098|Experimental|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
9852990|NCT03569098|Experimental|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
9852991|NCT03569098|Placebo Comparator|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
9852992|NCT03569202|Experimental|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
10208247|NCT02270957|Placebo Comparator|Placebo|Patients receive placebo instead of Abatacept in a double blind fashion. Otherwise participation is the same, including that at the time of treatment failure they may elect any standard of care treatment and/or to begin taking open label abatacept but this rescue will define non-response in the primary endpoint at six months.
10208248|NCT02237183|Experimental|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
9852993|NCT03569202|Active Comparator|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
9852994|NCT03569371|Experimental|INCB054707|
9852995|NCT03569397|Experimental|Music Therapy|Administer music therapy during the operation
9852996|NCT03569397|No Intervention|Non-Music Therapy|No headphones or music therapy during the operation
9852997|NCT03569618|Active Comparator|Game 1|Tablet-based Game 1.
9852998|NCT03569618|Placebo Comparator|Game 2|Tablet-based Game 2.
9852999|NCT03569748|Experimental|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
9853000|NCT03569748|Active Comparator|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
9853001|NCT03570255|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
9853002|NCT03570476|Experimental|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
9853003|NCT03570554|Experimental|Treatment A-D-C-B|Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
9853004|NCT03570554|Experimental|Treatment B-C-D-A|Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
9853005|NCT03570554|Experimental|Treatment C-A-B-D|Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
9853006|NCT03570554|Experimental|Treatment D-B-A-C|Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
9853007|NCT03570658|Experimental|Single-Ascending Dose (SAD)|Participants will receive a single dose of RO7049389.
9853008|NCT03570658|Experimental|Multiple-Ascending Dose (MAD)|Participants will receive multiple doses of RO7049389.
9853009|NCT03570658|Placebo Comparator|Placebo|Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.
9853010|NCT03570697|Experimental|Evolocumab|Participants receive evolocumab subcutaneous injection once every month (QM) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
9853011|NCT03570697|Placebo Comparator|Placebo|Participants receive placebo subcutaneous injection QM for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
9853012|NCT03571256|Experimental|TEV-50717 High-Dose|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
9853013|NCT03571256|Experimental|TEV-50717 Low-Dose|TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
9853014|NCT03571256|Placebo Comparator|Placebo|Placebo matched to TEV-50717 for a total of 8 weeks
9853015|NCT03571516|Experimental|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
9853016|NCT03571516|Other|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
9853017|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
9853018|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
9853019|NCT03571607|Experimental|13-valent pneumococcal conjugate vaccine|
9853020|NCT03571672|Experimental|DEFINITY|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
9853021|NCT03571724|Experimental|Usual Brand (UB) non-mentholated filtered cigarettes|Usual Brand (UB) mentholated filtered cigarettes Usual Brand (UB) non-mentholated filtered cigarettes or to very low nicotine non-mentholated cigarettes
9853022|NCT03571724|Experimental|Usual Brand (UB) mentholated filtered cigarettes|Subjects will be randomized to continue to smoke Usual Brand (UB) mentholated filtered cigarettes or to very low nicotine mentholated cigarettes
9853023|NCT03572062|Experimental|Arm 1|Low dose formulation A and SIIV
9853024|NCT03572062|Experimental|Arm 2|Low dose formulation B and SIIV
9853025|NCT03572062|Experimental|Arm 3|Mid dose formulation A and SIIV
9853026|NCT03572062|Experimental|Arm 4|Mid dose formulation B and SIIV
9853027|NCT03572062|Experimental|Arm 5|High dose formulation A and SIIV
9853028|NCT03572062|Experimental|Arm 6|High dose formulation B and SIIV
10208249|NCT02237183|Placebo Comparator|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
10208250|NCT02237183|Experimental|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
9853029|NCT03572062|Experimental|Arm 7|High dose formulation C and SIIV
9853030|NCT03572062|Placebo Comparator|Arm 8|Placebo and SIIV
9853031|NCT03572062|Experimental|M0M2 Arm 1|High dose formulation B
9853032|NCT03572062|Placebo Comparator|M0M2 Arm 2|Placebo
9853033|NCT03572218|Experimental|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
9853034|NCT03572218|Active Comparator|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
9853035|NCT03572478|Experimental|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
9853036|NCT03572478|Experimental|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
9853037|NCT03572478|Experimental|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
9853038|NCT03572478|Experimental|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
9853039|NCT03572972||Patients prescribed apixaban|
9853040|NCT03572972||Patients prescribed dabigatran|
9853041|NCT03572972||Patients prescribed rivaroxaban|
9853042|NCT03572972||Patients prescribed warfarin|
9853043|NCT03572972||Patients prescribed antiplatelet|
10208251|NCT02237183|Placebo Comparator|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
9853044|NCT03573206|Experimental|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
9853045|NCT03573323|Experimental|Ixekizumab|"A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
9853046|NCT03573323|Experimental|Guselkumab|"During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
9853047|NCT03573505|Experimental|BG00011|Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
9853048|NCT03573505|Placebo Comparator|Placebo|Participants will receive placebo once weekly by (SC) injection for 52 weeks.
9853049|NCT03573804|Experimental|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
9853050|NCT03573830|Active Comparator|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
9853051|NCT03573830|Experimental|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
9853052|NCT03573908|Experimental|Linaclotide 290 µg|Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
9853053|NCT03573908|Placebo Comparator|Placebo|Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.
9853054|NCT03574441|Active Comparator|TegadermTM only|
9853055|NCT03574441|Active Comparator|Dressing with TegadermTM plus Steri-StripTM bands|
9853056|NCT03574441|Experimental|Dressing with TegadermTM plus catheter support pad.|
9853057|NCT03574753|Experimental|ABBV-399|"C-MET overexpression is seen in 30% of patients with lung squamous cell carcinoma (SCCA). ABBV-399 (Process II) is a first-in-class antibody-drug conjugate (ADC) comprised of ABT-700, an anti-c-Met monoclonal antibody linked to monomethyl auristatin E (MMAE), which is a potent microtubule inhibitor. This delivers a direct anti-mitotic effect without relying on MET pathway inhibition.~ABBV-399 will be administered intravenously on day 1 of each 21-day cycle. Treatment will continue in consenting patients until disease progression or intolerable toxicity."
9853058|NCT03574818|Experimental|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).~The regimen will be given for a total of 3 cycles.~The regimen will be given for a total of 3 cycles."
9853059|NCT03575702|Experimental|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
9853060|NCT03575702|Active Comparator|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
9853061|NCT03575754|Experimental|Interventional|This arm utilizes the investigational device, as specified in protocol.
9853062|NCT03575806|Experimental|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
9853063|NCT03575806|Active Comparator|TACE group|Active comparator: TACE to treat HCC.
9853064|NCT03575871|Experimental|PF-04965842 100 mg|
9853065|NCT03575871|Experimental|PF-04965842 200 mg|
9853066|NCT03575871|Placebo Comparator|Placebo|
9853067|NCT03575962|Experimental|GSK3640254 Bis-hydrochloride followed by GSK3640254 mesylate|The subjects in this arm will receive an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsules(reference), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1, during Period 2 of the study. The drug will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
10208252|NCT02204085|Experimental|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
9853068|NCT03575962|Experimental|GSK3640254 Mesylate followed by GSK3640254 Bis-hydrochloride|The subjects in this arm will receive an oral administration of 200 mg as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsule, 100 mg (reference), as single oral dose, on the morning of Day 1 during Period 2, of the study. The drug, will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
9853069|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
9853070|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
9853071|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
9853072|NCT03576066|Experimental|ABI-H0731 + SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
9853073|NCT03576066|Active Comparator|Placebo + SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
9853074|NCT03576118|Experimental|Deep neuromuscular block|Deep neuromuscular relaxation and low pressure pneumoperitoneum
10213542|NCT03814967|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
9853075|NCT03576118|Active Comparator|Moderate neuromuscular block|Moderate neuromuscular relaxation and standard pressure pneumoperitoneum
9853076|NCT03576183|Active Comparator|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)~The vaccine is administered orally in 2 doses about 1 week apart."
9853077|NCT03576183|Placebo Comparator|Placebo|"The buffer component of VLA1701 will be used as Placebo.~The vaccine is administered orally in 2 doses about 1 week apart."
9853078|NCT03576716|Experimental|Study Population|D6-25-hydroxyvitamin D3 with vitamin D3
9853079|NCT03576768|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
9853080|NCT03576768|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
9853081|NCT03576768|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
9853082|NCT03576768|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
9853083|NCT03577171|Experimental|ABI-H0731 + SOC ETV|Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
9853084|NCT03577171|Experimental|Placebo + SOC ETV|Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
9853085|NCT03577275|Placebo Comparator|Placebo oral capsule|Single dose of placebo to match NST-4016
9853086|NCT03577275|Active Comparator|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
9853087|NCT03577275|Experimental|NST-4016 600mg|Likely therapeutic dose of NST-4016
9853088|NCT03577275|Experimental|NST-4016 2000mg|Supratherapeutic dose of NST-4016
9853089|NCT03577730|Experimental|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
9996935|NCT01504451|Active Comparator|Medtronic ablation|Medtronic multi-electrode phased radiofrequency AF ablation
10208253|NCT02204085|Experimental|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
10208254|NCT02134925|Experimental|Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)|Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.
10208255|NCT02134925|Placebo Comparator|Arm II (saline)|Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.
9853090|NCT03577730|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
9853091|NCT03578146|Experimental|Module 2 (210 mg)|210 mg andexanet IV bolus administered over 7 minutes (~30 mg/min)
9853092|NCT03578146|Experimental|Module 2 (420 mg)|420 mg andexanet IV bolus administered over 14 minutes (~30 mg/min)
9853093|NCT03578146|Experimental|Module 2 (600 mg)|600 mg andexanet IV bolus administered over 20 minutes (~30 mg/min)
9853094|NCT03578146|Experimental|Module 2 (720 mg bolus + 240 mg infusion)|720 mg IV bolus administered over 24 minutes [~30 mg/min] followed by 240 mg continuous IV infusion [4 mg/min over 60 min)
9853095|NCT03578146|Experimental|Module 2 (800 mg bolus + 960 mg infusion)|800 mg IV bolus administered over 26.7 minutes [~30 mg/min] followed by 960 mg continuous IV infusion [8 mg/min over 120 min]
9853096|NCT03578146|Experimental|Module 2 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
9853097|NCT03578549||Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
9853098|NCT03578926|Experimental|fanfilcon A toric lens|Randomized participants will wear fanfilcon A toric contact lenses bilaterally for two weeks then switch to senofilcon A toric contact lenses for another two weeks.
9853099|NCT03578926|Active Comparator|senofilcon A toric lens|Randomized participants will wear senofilcon A toric contact lenses bilaterally for two weeks then switch to fanfilcon A toric contact lenses for another two weeks.
9853100|NCT03579290|Experimental|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
9853101|NCT03579433|Experimental|ORA with VerifEye+|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
9853102|NCT03579433|Active Comparator|Barrett Toric Calculator|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
9853103|NCT03579719|Experimental|Balovaptan + Itraconzole|Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
9853104|NCT03579940|Experimental|Lasmiditan - Japanese|Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.
9853105|NCT03579940|Placebo Comparator|Placebo - Japanese|Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.
9853106|NCT03579940|Experimental|Lasmiditan - Caucasian|Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.
9853107|NCT03579940|Placebo Comparator|Placebo - Caucasian|Single dose of Placebo administered orally in up to one of three study periods.
9853108|NCT03580343|Experimental|Tofacitinib Treatment|11mg extended-release tofacitinib, once daily, oral
9853109|NCT03581084|Experimental|N-acetylcysteine|"This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs."
9923616|NCT00852319|Experimental|Mississippi Delta group|Participants from 18 counties of the Mississippi delta are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
10208256|NCT02133573|Experimental|Progesterone|Vaginal gel, 90mg twice a day (BID)
10208257|NCT02133573|Placebo Comparator|Vaginal Lubricant|Vaginal twice a day (BID)
10208258|NCT02133183|Experimental|Arm I (sapanisertib before and after surgery)|Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208259|NCT02133183|Experimental|Arm II (sapanisertib after surgery)|Patients undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208260|NCT02054104|Experimental|1/Vaccine Plus Chemotherapy|H1299 cell lysates with iscomatrix vaccine with metronomic chemotherapy
10208261|NCT02054104|Experimental|2/Vaccine Alone|H1299 cell lysates with iscomatrix adjuvant vaccine
9853110|NCT03581097|Experimental|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
9853111|NCT03581097|No Intervention|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
9853112|NCT03581474|Other|aScope 3 Large|Bronchoscopic procedure
10208262|NCT01954979|Experimental|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
10208263|NCT01899144|Experimental|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
9853113|NCT03581825|Experimental|Test/Control|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
9853114|NCT03581825|Experimental|Control/Test|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
9853115|NCT03582215|Experimental|Part 1: Cream|"Part 1: Cream~Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule"
9853116|NCT03582215|Experimental|Part 1: Lotion|"Part 1: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
9853117|NCT03582215|Experimental|Part 1: Spray 1|"Part 1: Spray 1~Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate"
9853118|NCT03582215|Experimental|Part 1: Spray 2|"Part 1: Spray 2~Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene"
9853119|NCT03582215|Experimental|Part 2: Lotion|"Part 2: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
9853120|NCT03582215|Experimental|Part 2: Aerosol Spray|"Part 2: Aerosol Spray~Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate"
9853121|NCT03582215|Experimental|Part 2: Nonaerosol Spray|"Part 2: Nonaerosol Spray~Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
9853122|NCT03582215|Experimental|Part 2: Pump Spray|"Part 2: Pump Spray~Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
9853123|NCT03582553|Experimental|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
9853124|NCT03582553|Experimental|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
9996936|NCT01504464|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
10208264|NCT01899144|Experimental|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
10208265|NCT01899144|Active Comparator|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
10208266|NCT01899144|Active Comparator|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
10208267|NCT01899144|Placebo Comparator|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
10208268|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell ALL|"3 daily doses of cyclophosphamide together with fludarabine with be administered finishing at least 24 hours before T cell infusion.~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
9853125|NCT03582553|Experimental|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
9853126|NCT03582553|Experimental|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
9853127|NCT03582553|Placebo Comparator|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
9923617|NCT00852332|Experimental|Curcumine|With curcumin capsules
10208269|NCT01853631|Experimental|CD19 CAR T Cells for Bcell ALL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
10208270|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell NHL/CLL|"3 daily doses of cyclophosphamide together with fludarabine will be administered finishing at least 24 hours before T cell infusion.~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
9923618|NCT00852332|Active Comparator|Drug taxotere only|Without curcumin
9853128|NCT03582813|Experimental|Self-directed care|Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
9853129|NCT03582813|Active Comparator|Services as usual|Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.
9853130|NCT03582826|Experimental|MEBO/PATM cohort|"Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes.~The following subcohorts were formed for analyses of different outcomes: MEBO and PATM subcohorts, TMAU positive and negative subcohorts, Active MEBO, Active PATM, Regression and Remission; MEBO/PATM Cohort that Submitted Gut Samples, MEBO/PATM cohort that answered QoL survey, MEBO/PATM Subcohort that observed and documented both flareups and improvements."
9853131|NCT03582826|No Intervention|non-MEBO cohort|Data volunteers that never experienced episodes of uncontrollable socially debilitating metabolic body odor (MEBO) or PATM
9853132|NCT03582943|Experimental|Remote limb ischemic conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
9853133|NCT03582943|Sham Comparator|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
9853134|NCT03583372|Experimental|Vibegron + Placebo to match Tolterodine|
9853135|NCT03583372|Active Comparator|Tolterodine + Placebo to match vibegron|
9853136|NCT03583385|Experimental|First Glucophage XR (Test), Then Glucophage XR (Comparator)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
9853137|NCT03583385|Experimental|First Glucophage XR (Comparator), Then Glucophage XR (Test)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
9923619|NCT00852358|Experimental|intrathecal laronidase|The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
9923620|NCT00852358|Other|Control Group|During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
9923621|NCT00852371|Active Comparator|Combination of Amodiaquine +sulfadoxine-pyrimethamine|Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
9923622|NCT00852371|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
9923623|NCT00852371|Placebo Comparator|Placebo|Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
9923624|NCT00852371|Active Comparator|Sulfadoxine-pyrimethamine alone|sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
9923625|NCT00852410|Active Comparator|1% lidocaine with 1:100000 adrenaline|high dose adrenaline
9923626|NCT00852410|Active Comparator|1% lidocaine with 1:200,000 adrenaline|low dose
9923627|NCT00852423|Experimental|DHAPQ|Three-day treatment with dihydroartemisinin-piperaquine
9923628|NCT00852423|Experimental|MQAS|Three-day treatment with mefloquine artesunate
9923629|NCT00852423|Active Comparator|AQAS|Three-day treatment with artesunate-amodiaquine
9923630|NCT00852423|Active Comparator|AL|Three day treatment with artemether-lumefantrine (Coartem(R)
9923631|NCT00852436|Active Comparator|1|Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
9996937|NCT01504464|Experimental|placebo|The patients who are in control group and underwent placebo injection.
9853138|NCT03583450|Experimental|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app and routine anesthetic care
9853139|NCT03583450|No Intervention|Control|Routine anesthetic care
9853140|NCT03583606|Experimental|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10^11 vp) intramuscularly into the opposite arm on Day 8, n = 20
9853141|NCT03583606|Experimental|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
9853142|NCT03583606|Experimental|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
9853143|NCT03584009|Experimental|Venetoclax + Fulvestrant|Participants were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
9853144|NCT03584009|Active Comparator|Fulvestrant|Participants were administered Fulvestrant 500mg only intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
9853145|NCT03584100|Experimental|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
9853146|NCT03584100|Active Comparator|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
9853147|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
9853148|NCT03585296|Experimental|ATI-502|ATI-502 topical solution applied daily for four weeks.
9853149|NCT03585504|Experimental|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
9853150|NCT03585504|Active Comparator|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
9853151|NCT03585543|Experimental|Single group intervention arm|
9853152|NCT03585712|Other|Arm A: Delayed then Missed Pill|Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg
9853153|NCT03585712|Other|Arm B: Missed then Delayed Pill|Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg
10208271|NCT01853631|Experimental|CD19 CAR T Cells for Bcell NHL/CLL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
9853154|NCT03585790|Other|Multifocal Optics first, then Single Vision Optics|First Intervention (1 week) Second Intervention (1 week)
9853155|NCT03585790|Other|Single Vision Optics first, then Multifocal Optics|First Intervention (1 week) Second Intervention (1 week)
9853156|NCT03585959|Experimental|Fluoroscopic Navigation Arm|An Electromagnetic navigation bronchoscopy (ENB) system which provides enhanced three-dimensional fluoroscopy to improve lesion visibility and to compensate for CT-to-body divergence, with an integrated real-time local registration feature allowing the operator to update the catheter position relative to the target during the procedure.
9853157|NCT03586167|Experimental|LID014341|LID014341 contact lenses worn bilaterally (in both eyes) for 30 days on a daily wear basis
9853158|NCT03586167|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally for 30 days on a daily wear basis
9853159|NCT03586544|Experimental|Albuterol first|Order albuterol and then interval warm up (IWU)
9853160|NCT03586544|Experimental|Interval warm-up first|Order is interval warm up (IWU) and then albuterol
9853161|NCT03586583||FBP (old processing)|Filtered back projection; old processing.
9853162|NCT03586583||ISR (new processing)|Iterative super resolution; new processing.
9853163|NCT03586648|Experimental|Test/Control|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
10208272|NCT01850758|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
10208273|NCT01850758|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.
10208274|NCT01793610|Active Comparator|Comparator-dose (40 mg) MDMA and Psychotherapy|Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
10208275|NCT01793610|Experimental|Active Dose 2 (100 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
10208276|NCT01793610|Experimental|Active Dose 1 (125 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.
10208277|NCT01788683|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.
10208278|NCT01788683|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
10208279|NCT01757665|Experimental|Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M|Aortic/Mitral valve replacement therapy
10208280|NCT01730170||Pregnant Women without Epilepsy|Women in their first trimester of pregnancy who are not diagnosed with epilepsy
9853164|NCT03586648|Experimental|Control/Test|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
9853165|NCT03586726|Experimental|Balovaptan + Rifampicin|Participants received the study drugs in 2 periods. There was a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
9853166|NCT03586830|Experimental|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
9853167|NCT03586830|Experimental|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
9853168|NCT03586830|Experimental|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
9853169|NCT03586830|Placebo Comparator|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
9853170|NCT03587207|Experimental|MenABCWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
9853171|NCT03587207|Active Comparator|rMenBOMV+ACWY_S Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
9853172|NCT03587207|Active Comparator|rMenBOMV+ACWY_D Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
9853173|NCT03587207|Active Comparator|rMenBOMV Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
9853174|NCT03587207|Active Comparator|MenACWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
9853175|NCT03587428|Experimental|Zinc-A toothpaste|In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
9853176|NCT03587428|Experimental|Zinc-B toothpaste|In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
9853177|NCT03587428|Other|Mineral Water|In this arm, participants received mineral water.
9853178|NCT03587974|Experimental|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
9853179|NCT03587974|No Intervention|Enhanced control|Single session with education about nature of dementia
9853180|NCT03588572|Experimental|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
9853181|NCT03588572|No Intervention|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
9853182|NCT03588741|Experimental|Turoctocog alfa|
9853183|NCT03588806|Experimental|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
9853184|NCT03588910|Active Comparator|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
9853185|NCT03588910|Experimental|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
9853186|NCT03589469|Experimental|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
9923632|NCT00852436|Placebo Comparator|2|Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
9996938|NCT01504490|Experimental|CS-7017 and Bexarotene|Combination of CS-7017 and Bexarotene
9853187|NCT03589807|Experimental|Heterologous Arm 1|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=30
9853188|NCT03589807|Experimental|Heterologous Arm 2|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
9853189|NCT03589807|Experimental|Heterologous Arm 3|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
9853190|NCT03589807|Experimental|Homologous Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 22. PBS diluent may be used to achieve targeted dosages. N=30
9853191|NCT03589807|Experimental|Homologous Arm 2|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 121. PBS diluent may be used to achieve targeted dosages. N=30
9853192|NCT03589807|Experimental|Homologous Arm 3|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 Adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
9853193|NCT03589885|Placebo Comparator|Placebo 2 mL auto-injector|Placebo to secukinumab s.c., provided in 2 mL auto-injector form
9853194|NCT03589885|Placebo Comparator|Placebo 1 mL prefilled syringe|Placebo to secukinumab s.c., provided in 2 * 1 ml prefilled syringe form
9853195|NCT03589885|Experimental|Secukinumab 2 mL auto-injector|Secukinumab 300 mg provided in 2 mL auto-injector form
9853196|NCT03589885|Active Comparator|Secukinumab 1 mL prefilled syringe|Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
9853197|NCT03590613|Experimental|Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID|The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
9853198|NCT03590613|Experimental|Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
9853199|NCT03590613|Experimental|Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
9853200|NCT03590613|Experimental|Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
9853201|NCT03591068|Experimental|OPN-375 186 mcg BID|
9853202|NCT03591146|Experimental|TLC590 190mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
9853203|NCT03591146|Experimental|TLC590 380mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
9853204|NCT03591146|Experimental|TLC590 570mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
9853205|NCT03591146|Experimental|TLC590 475mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
9853206|NCT03591146|Active Comparator|Naropin 150mg|Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
9853207|NCT03591406|Experimental|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
9853208|NCT03591406|Active Comparator|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
9853209|NCT03592121|Experimental|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
9853210|NCT03592121|Placebo Comparator|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
9853211|NCT03592745|Experimental|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
9853212|NCT03592745|Sham Comparator|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
9853213|NCT03593200|Experimental|Experimental: Cohort 1|270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364*
9853214|NCT03593538|Experimental|Low Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 500 mg and 1 Placebo capsule per day; Days 15-23: Metformin 500 mg and 2 Placebo capsules per day
9853215|NCT03593538|Experimental|High Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 1000 mg per day; Days 15-23: Metformin 1500 mg per day
9853216|NCT03593538|Placebo Comparator|Placebo|Days 1-7: 1 Placebo capsule per day; Days 8-14: 2 Placebo capsules per day; Days 15-23: 3 Placebo capsules per day
9853217|NCT03593876|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
9853218|NCT03593902|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
9853219|NCT03594045|Experimental|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
9853220|NCT03594045|Experimental|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
9853221|NCT03594227|Active Comparator|400mg BID (Low dose)|ATI-501 low dose - oral administration
9853222|NCT03594227|Active Comparator|600mg BID (Mid dose)|ATI-501 mid dose - oral administration
9853223|NCT03594227|Active Comparator|800mg BID (High dose)|ATI-501 high dose - oral administration
9853224|NCT03594227|Placebo Comparator|Placebo|Placebo - oral administration
9853225|NCT03594500|Experimental|Intervention: PockeTalker|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
9853226|NCT03594500|Other|Control: No PockeTalker|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
9853227|NCT03595176|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
9853228|NCT03595215|Experimental|TENS Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
10208281|NCT01730170||Nonpregnant Women with Epilepsy|Women diagnosed with epilepsy and not currently pregnant.
10208282|NCT01730170||Pregnant Women with Epilepsy|Women in their first trimester of pregnancy and diagnosed with epilepsy
9853229|NCT03595280|No Intervention|Control|Participants in the control group receive no study messages
10208283|NCT01724879|Experimental|Dasatinib and chemotherapy|Dasatinib, QD p.o. administration, day 1 to EOS
10208284|NCT01658293|Experimental|thermal stimulation|The experimental group receiving heat and cold-water stimulation, 30 minutes a session, five sessions a week for six weeks.
9853230|NCT03595280|Experimental|Untailored Messages|Participants in the untailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones.
9853231|NCT03595280|Experimental|Tailored Messages|Participants in the tailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones that are personalized to their hookah tobacco use behavior and beliefs.
9853232|NCT03595449|Active Comparator|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
9853233|NCT03595449|Sham Comparator|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
9853234|NCT03595579|Experimental|AXS-05|
9853235|NCT03595579|Active Comparator|Bupropion|
9853236|NCT03595618|Experimental|GLPG1972 75 mg|Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
9853237|NCT03595618|Experimental|GLPG1972 150 mg|Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
9853238|NCT03595618|Experimental|GLPG1972 300 mg|Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.
9853239|NCT03595618|Placebo Comparator|Placebo|Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.
9853240|NCT03595904|Experimental|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
9853241|NCT03595904|Active Comparator|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
9853242|NCT03596151|Experimental|Click Device|One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.
10208285|NCT01658293|Active Comparator|control group|The control group receiving the similar intensity of ergometer exercise as the experimental group.
10208286|NCT01482195|Experimental|Subretinal Injection of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|Single arm of 6 patients undergoing subretinal injection of Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus. Each patient received the injection in one eye.
10208287|NCT01482195|No Intervention|fellow eye without intervention|fellow eye without intervention
10208288|NCT01468831|Placebo Comparator|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
10208289|NCT01468831|Experimental|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
10208290|NCT01383109|Experimental|Pyronaridine|All subjects will receive a single dose of Pyronaridine
10208291|NCT01355094|Active Comparator|"Stampede VAC"|"Calgary-home-made Stampede VAC system with only closed drain bulb suction"
10208292|NCT01355094|Experimental|KCI AbThera|commercial AbThera vacuum assisted abdominal closure at 125 mmHg suction
10208293|NCT01096602|Experimental|Group 1|DC AML Fusion Vaccine
10208294|NCT01005615|Sham Comparator|No FES Cycling|
10208295|NCT01005615|Active Comparator|FES Cycling|
10213543|NCT03814382|Experimental|Acupuncture|All subjects will receive up to 10 needles for 20 minutes for 1 treatment using acupuncture needles.
9853243|NCT03596177|Experimental|MEDI0382|Participants will receive subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
9853244|NCT03596177|Placebo Comparator|Placebo|Participants will receive SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.
9853245|NCT03596723|Experimental|KPI-121 1% BID (twice daily)|
9853246|NCT03596723|Active Comparator|Prednisolone acetate QID (four times daily)|
9853247|NCT03597009|Experimental|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
9853248|NCT03597022|Experimental|BAY1093884 100mg|Subjects received BAY1093884 100 mg once a week until premature termination of the study
9853249|NCT03597022|Experimental|BAY1093884 225mg|Subjects received BAY1093884 225 mg once a week until premature termination of the study
9853250|NCT03597022|Experimental|BAY1093884 400mg|Subjects received BAY1093884 400mg once a week until premature termination of the study
9853251|NCT03597061|Experimental|Healthy Start to Feeding Intervention|Participants and their parents will participate in a 3 session intervention targeting healthy introduction of complementary foods. Intervention sessions will occur when the infant is 4, 6, and 9 months of age.
9853252|NCT03597061|No Intervention|Control|Participants and their parents will complete pre- and post-treatment period study visits to assess study outcomes. They will receive no intervention.
9853253|NCT03597139|Experimental|Voclosporin ophthalmic solution (VOS)|0.2% VOS, Twice Daily (BID), both eyes for 28 days
9853254|NCT03597139|Active Comparator|Comparator|0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
9853255|NCT03597178|Experimental|senofilcon A|Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
9853256|NCT03597347|Experimental|Group 1|Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.
9853257|NCT03597347|Experimental|Group 2|Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.
9853258|NCT03597347|Experimental|Group 3|Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).
9853259|NCT03597529|Experimental|Low-Dose Melatonin (mg)|melatonin 2mg (equal to or over 40kg) melatonin 1mg (under 40kg) Melatonin: melatonin
9853260|NCT03597529|Experimental|High-Dose Melatonin (mg)|melatonin 8mg (equal to or over 40kg) melatonin 4mg (under 40kg) Melatonin: melatonin
9853261|NCT03597789|Other|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
9853262|NCT03598647|Active Comparator|Physical activity information - for non-exercisers only|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
9853263|NCT03598647|Experimental|Affect and physical activity - for non-exercisers only|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention focused on affective responses to exercise.
9853264|NCT03598647|No Intervention|Exercisers|Engaging in >=150 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
9853265|NCT03598647|No Intervention|Non-exercisers|Engaging in <30 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
9853266|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 0.7 mg (0.05 mg/mL concentration)|Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
9853267|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 2.1 mg (0.15 mg/mL concentration)|Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
9853268|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 4.2 mg (0.3 mg/mL concentration)|Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
9853269|NCT03599089|Placebo Comparator|Placebo|Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
9853270|NCT03599193|Experimental|DFD-03 Lotion|DFD-03 Lotion will be applied to the affected areas twice daily for 1 minute and rinsed off. 29 subjects will be enrolled into this arm.
9853271|NCT03599193|Active Comparator|Tazorac Cream|Tazorac Cream will be applied to the affected areas once daily and left on for ~12 hours. 29 subjects will be enrolled into this arm.
9853272|NCT03599271|Experimental|Drug-Coated Device|Randomized cohort: Drug-Coated Device to dilate randomized frontal sinus ostium.
9853273|NCT03599271|Active Comparator|Control Sinus Dilation Device|Randomized cohort: Control Device to dilate randomized contralateral frontal sinus ostium.
9853274|NCT03599271|Experimental|PK cohort- Drug-Coated Device|PK cohort: One Drug-Coated Device to dilate both frontal sinus ostia.
10208296|NCT00822120|Experimental|HIV Positive, PET Positive: BEACOPP standard|Etoposide 100 mg/m2 IV Days 1, 2, 3 Dox 25 mg/m2 IV Day 1 Cyclo 650mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 Q 21 Days x 6 cycles
10208297|NCT00822120|Experimental|HIV Negative, PET Positive: BEACOPP escalated|Etoposide 200 mg/m2 IV Days 1, 2, 3 Dox 35 mg/m2 IV Day 1 Cyclo 1,250 mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles
10208298|NCT00822120|Active Comparator|HIV Positive, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
9794145|NCT01497197|Experimental|Gonal-f® Followed by Luveris®|GONAL-f® 300 IU per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 6 until required r-hCG level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
9794146|NCT01497262|Experimental|Fingolimod|Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
9794147|NCT01497275|Experimental|Zevalin + Velcade|"Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi."
9794148|NCT01497366|Experimental|Sofosbuvir+RBV|Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
9794149|NCT01497366|Active Comparator|PEG+RBV|Participants were randomized to receive PEG+RBV for 24 weeks.
9794150|NCT01497496|Experimental|Immunotherapy|Combination regimen consisting of high dose methylprednisolone combined with ofatumumab, followed by consolidative therapy with lenalidomide in combination with ofatumumab.
9794151|NCT01497613|Active Comparator|PRISM B: Notebook Condition|Telephone check-in calls and a notebook containing similar categories of information as the features on the PRISM C computer system such as a resource guide; games; classroom and information, calendar.
9794152|NCT01497613|Experimental|PRISM C: Computer Condition|A computer-based system designed to support socialization and access to resources; knowledge and prospective memory. The system is placed in the homes of those randomized to the condition for 12 months.
9794153|NCT01497665|Experimental|GRN1005 alone|GRN1005 alone
9794154|NCT01497756|Experimental|CAPP application|Patients in whom device is used
9794155|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 2)|
9794156|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 3)|
9794157|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 2)|
9794158|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 3)|
9794159|NCT01497860|Experimental|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
9794160|NCT01497899|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
9794161|NCT01497899|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
9794162|NCT01497899|Experimental|E/C/F/TAF Open-Label|"Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase.~Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase."
9794163|NCT01497938|Experimental|Low Glucose Suspend feature (LGS)|According to randomization, Low Glucose Suspend (LGS) will be turned ON in the treatment arm of the study
9794164|NCT01497938|Experimental|Control Arm|The Low Glucose Suspend feature will not be available to subjects in the control arm
9794165|NCT01498068|Experimental|Treatment-naïve|Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
9794166|NCT01498068|Experimental|Treatment-experienced|Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
9794167|NCT01498120|Experimental|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)"
9794168|NCT01498185|Experimental|Arm 1: Dapagliflozin (1 mg)|
9794169|NCT01498185|Experimental|Arm 2: Dapagliflozin (2.5 mg)|
9794170|NCT01498185|Experimental|Arm 3: Dapagliflozin (5 mg)|
9794171|NCT01498185|Experimental|Arm 4: Dapagliflozin (10 mg)|
9794172|NCT01498185|Experimental|Arm 5: Placebo matching Dapagliflozin|
9794173|NCT01498289|Experimental|Arm I|FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9794174|NCT01498289|Experimental|Arm II|Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9853275|NCT03599349|Experimental|Microfocused ultrasound w/ visualization|Each subject to receive a full face and neck area treatment using a standard 800 line treatment with set energy levels (0.90 joules for the 4-4.5mm transducer, 0.30 joules for the 7-3.0mm/7-3.0N transducers and 0.75 joules for the 7-4.5mm transducer)
9853276|NCT03599362|Experimental|Multi Agent Chemotherapy Cancer Patients|Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.
9853277|NCT03600194|Active Comparator|PowerSleep Stim|In this arm soft audio tones (below 65dB) will be administered by the PowerSleep Stim Device during deep sleep as determined by the functionality of the device.
9853278|NCT03600194|Placebo Comparator|PowerSleep Sham|This PowerSleep Sham device is the same as the PowerSleep Stim device, however, it can be configured in a mode that does not play audio tones
10208299|NCT00822120|Active Comparator|HIV Negative, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
10208300|NCT00799110|Experimental|Group 2|Vaccine, GM-CSF and imiquimod,
9853279|NCT03600194|Active Comparator|Northwestern Stim|The NorthWestern Stim device is set up will function similarly to the PowerSleep prototype. Acoustic stimulation provided by headphones with an audible soft volume that do not result in arousals will be used.
9853280|NCT03600194|Placebo Comparator|Northwestern Sham|The Northwestern Sham device will be the same as the Northwestern Stim set up, however no audio tones will be played.
9853281|NCT03600376|Experimental|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
9853282|NCT03600376|Other|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
9853283|NCT03600428|Experimental|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
9853284|NCT03600428|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
9853285|NCT03601052|Experimental|Remlarsen - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
9853286|NCT03601052|Placebo Comparator|Placebo - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
9853287|NCT03601117|Experimental|Dorsolateral Prefrontal Cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC), for 10 sessions per day for up to 5 days.
9853288|NCT03601117|Experimental|Anterior Cingulate Cortex|The accelerated theta burst stimulation protocol will be applied to the left anterior cingulate cortex (ACC), for 10 sessions per day for up to 5 days.
9853289|NCT03601715|Active Comparator|Coplanar|Electrode placed side by side on the same aspect of the right tight.
9853290|NCT03601715|Active Comparator|Contraplanar|Electrode placed over opposite aspects of the right tight.
9853291|NCT03601715|Active Comparator|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
9853292|NCT03602053|Experimental|ROTAVAC 5D|Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.
9853293|NCT03602053|Experimental|ROTAVAC®|Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
9853294|NCT03602053|Active Comparator|Rotarix®|GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
9853295|NCT03602339|Experimental|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
9853296|NCT03602339|Experimental|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
9853297|NCT03602482|Experimental|Standing|Participants will complete cognitive testing while standing.
9853298|NCT03602482|Active Comparator|Supine|Participants will complete cognitive testing while supine.
9853299|NCT03603028|Experimental|Exergaming|
9853300|NCT03603106|Experimental|Part I (Phase I)|In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
9853301|NCT03603106|Experimental|Part II (Phase IIA)|In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
9923633|NCT00852449|Experimental|restrictive fluid|Restrictive fluid administration: 6 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
10208301|NCT00799110|Experimental|Group 1|Vaccination plus GM-CSF
10208302|NCT00697684|No Intervention|Cohort 1|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
10208303|NCT00697684|Experimental|Cohort 2|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
9853302|NCT03603652|Experimental|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
9853303|NCT03604263|Experimental|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
9794175|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 100 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
9853304|NCT03604341|Experimental|Gestational age up to 10w0d - Dronabinol|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
9853305|NCT03604341|Placebo Comparator|Gestational age up to 10w0d - Placebo|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
9853306|NCT03604497|Experimental|beacon alerts|active intervention - participants are receiving alerts to warn them about distracted pedestrian behavior near intersections
9853307|NCT03604497|No Intervention|no alerts baseline|baseline - participants do not receive any alerts on their mobile smartphone when near intersections
9853308|NCT03604497|Other|no alerts retention|retention phase - alerts have stopped after active intervention and behavior is monitored to test retention of learned behavior
9853309|NCT03604523|Active Comparator|Dilation by Balloon|Esophageal dilation by balloon device.
9853310|NCT03604523|Active Comparator|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
9853311|NCT03604705|Experimental|APX001 Treatment|
9853312|NCT03605212|Experimental|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
9853313|NCT03605212|Experimental|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
9853314|NCT03605212|Experimental|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
9853315|NCT03605212|Experimental|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
9853316|NCT03605212|Active Comparator|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
9853317|NCT03605693|Active Comparator|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
9853318|NCT03605693|No Intervention|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
9853319|NCT03605745|Experimental|Treatment|Prostatic Vapor Ablation with Rezum
9853320|NCT03605836|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
9853321|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
9853322|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
9853323|NCT03605836|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
9853324|NCT03605914|Experimental|NSAID|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
9794176|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
9794177|NCT01498419|Active Comparator|Drug Sensitive: Rifafour|Drug Sensitive Participants: Rifafour was administered orally once daily for 8 weeks according to weight: 30 kg to 37 kg: two tablets; 38 kg to 54 kg: three tablets; 55 kg to 70 kg: four tablets; ≥71 kg: five tablets
9853325|NCT03605914|Active Comparator|opioid|The Opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
9853326|NCT03606187|Experimental|Test Arm|Subjects randomized to this arm will receive test treatment
9853327|NCT03606187|Active Comparator|Control Arm|Subjects randomized to this arm will receive control treatment
9853328|NCT03606343|Experimental|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
9853329|NCT03606460|Experimental|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
9853330|NCT03606460|Experimental|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
9853331|NCT03607539|Experimental|Sintilimab in combination with pemetrexed and platinum|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
9853332|NCT03607539|Placebo Comparator|Sitilimab Placebo Comparator|placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
9853333|NCT03607682|Experimental|Prevention (TTF therapy, NovoTTF-200A device)|
9853334|NCT03607695|Experimental|Gait training|1 hour walking exercise on a treadmill
9853335|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement|Vitamin D replacement (50.000 IU/per week, for 8 weeks)
9853336|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement and exercise|Vitamin D replacement (50.000 IU/per week, for 8 weeks) and Core and balance exercises for 8 weeks.
9853337|NCT03608488|Experimental|Vitamin D<10 ng/ml; exercise|Core and balance exercises for 8 weeks.
9853338|NCT03608488|Active Comparator|Vitamin D>30ng/ml; exercise|Core and balance exercises for 8 weeks.
9853339|NCT03608774|Experimental|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=123
9853340|NCT03608774|Experimental|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=123
9853341|NCT03608839|Experimental|0,01ml dexamethasone solution|One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
9853342|NCT03608839|Experimental|0,03 ml dexamethasone solution|One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
9853343|NCT03608839|Experimental|0,05 ml dexamethasone solution|One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
9853344|NCT03609619|Experimental|AEVI-001|
9853345|NCT03609619|Placebo Comparator|Placebo|
9923634|NCT00852449|Experimental|liberal fluid|Liberal fluid administration: 12 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
9923635|NCT00852462|Experimental|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
9923636|NCT00852462|No Intervention|Usual Care|Symptom assessment and management follows customary procedures in each study site.
9923637|NCT00852488|Experimental|Catheter|Cohort undergoing catheter placement using the new technique being studied
9923638|NCT00852501||Non-functioning pituitary macroadenoma|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
9923639|NCT00852514|Experimental|Monthly BIA|monthly BIA to monitor fluid status
9923640|NCT00852566|Active Comparator|Imatinib|Standard treatment Imatinib 400mg OD
9923641|NCT00852566|Experimental|dasatinib|Dasatinib 100mg OD
9923642|NCT00852579|Experimental|1|Active treatment.
9923643|NCT00852579|Placebo Comparator|2|Placebo control group.
9923644|NCT00852605|No Intervention|Oxygen|Conventional Treatment including Oxygen-support
9923645|NCT00852605|Experimental|NIV|Conventional Treatment plus intermittent Non-Invasive-Ventilation
9923646|NCT00852618||A|Participants undergoing treatment with raltegravir (RAL) in the main study
9923647|NCT00852618||B|Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
9923648|NCT00852657|Active Comparator|Surgical treatment|Open or mini-open tendon repair with acromioplasty
9923649|NCT00852657|Active Comparator|Physiotherapy|Physiotherapy by exercises
9923650|NCT00852670|Experimental|A|
9853346|NCT03609658|Experimental|Nurse Navigator Pathway Group|Participants in this Nurse Navigator led ACP pathway group will participate in ACP discussions, surveys, and participant visit(s) for duration of the study (12 months)
9853347|NCT03609658|Sham Comparator|Usual Care Group|Participants in the Usual Care group will follow usual daily living activities for the duration of the study (12 months).
9853348|NCT03610048|Experimental|ALKS 5461|Sublingual tablets
9853349|NCT03610165|Placebo Comparator|Arterial line - Control|Arterial line waveform and pressure
9853350|NCT03610165|Experimental|Acumen HPI-enabled EV1000 screen|Arterial line waveform and pressure + HPI alert from EV1000 monitor
9853351|NCT03610269|Experimental|INVSENSOR00026|All enrolled subjects receive INVSENSOR00026 Pulse CO-Oximeter and sensor for the noninvasive measurement of hemoglobin (SpHb).
9853352|NCT03610399|Other|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
9853353|NCT03610399|Active Comparator|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
9853354|NCT03610399|Active Comparator|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
9853355|NCT03610464|Experimental|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
9853356|NCT03610581|Experimental|Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
9853357|NCT03610581|Experimental|Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
9853358|NCT03610581|Experimental|Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18|Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
9853359|NCT03610581|Placebo Comparator|Control: Placebo|Participants will receive matched placebo as prime and boost immunizations.
9853360|NCT03610633|Experimental|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
9853361|NCT03610633|Placebo Comparator|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
9853362|NCT03611062|Experimental|VR Executive Functions Training|Participants will receive training of executive functions in a virtual reality environment.
9853363|NCT03611062|Placebo Comparator|Control|Participants will play a virtual reality game using the same hardware and similar environments, but without the training of executive functions.
9853364|NCT03611075|Experimental|Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
9853365|NCT03611075|Experimental|High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
9853366|NCT03611075|Experimental|Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
9853367|NCT03611075|Experimental|High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
9853368|NCT03611075|Experimental|Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
9853369|NCT03611075|Experimental|High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
9853370|NCT03611075|No Intervention|Typically Developing (TD) Healthy Participant Children|Participants will be 5-12 years old
9853371|NCT03611075|No Intervention|TD Healthy Participant Adolescents|Participants will be 13-17 years old
9853372|NCT03611075|No Intervention|TD Healthy Participant Adults|Participants will be 18-45 years old
9853373|NCT03611582|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
9853374|NCT03611582|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
9853375|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
9853376|NCT03611829|Active Comparator|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
9853377|NCT03611829|Experimental|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
9853378|NCT03613129|Active Comparator|D0.20|Subcutaneous infusion of CT38 at 0.20 μg/kg/hour, for 3 hours on each of 2 days
9853379|NCT03613129|Active Comparator|D0.03|Subcutaneous infusion of CT38 at 0.03 μg/kg/hour, for 3.5 hours on each of 3 days
9923651|NCT00852670|Placebo Comparator|B|
9923652|NCT00852683|Active Comparator|A|
9853380|NCT03613129|Active Comparator|D0.06|Subcutaneous infusion of CT38 at 0.06 μg/kg/hour, for 3.5 hours on each of 3 days
9853381|NCT03613129|Active Comparator|D0.01|Subcutaneous infusion of CT38 at 0.01 μg/kg/hour, for 3.5 hours on each of 3 days
9853382|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic coils|
9853383|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic plugs|
9853384|NCT03613493|Other|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
9853385|NCT03613493|Experimental|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
9853386|NCT03613493|Experimental|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
9853387|NCT03613493|Active Comparator|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
9853388|NCT03613649|Experimental|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
9853389|NCT03613649|Experimental|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
9853390|NCT03613649|Placebo Comparator|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
9853391|NCT03613649|Active Comparator|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
9853392|NCT03613818|Experimental|eCHECKUP TO GO|Brief, web-based alcohol intervention
9853393|NCT03613818|No Intervention|Control|Assessment only
9853394|NCT03614078|Experimental|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
9853395|NCT03614078|Experimental|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
9853396|NCT03614078|Placebo Comparator|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
9853397|NCT03614130|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
9853398|NCT03614130|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
9853399|NCT03614156|Experimental|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
9853400|NCT03614156|Experimental|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
9853401|NCT03614156|Placebo Comparator|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
9853402|NCT03614416|Experimental|EOXY device and Gold standard oximter and SaO2 measures|Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
9853403|NCT03614975|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
9853404|NCT03614975|Active Comparator|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
9853405|NCT03615001|Experimental|Urodynamics Arm|
9853406|NCT03615066|Experimental|Selgantolimod 3 mg + TAF|Participants with hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
9923653|NCT00852683|Placebo Comparator|B|
9923654|NCT00852696|Placebo Comparator|Placebo Group|Placebo Orally 9 weeks once daily.
9923655|NCT00852696|Experimental|Solifenacin Group|Solifenacin Orally 9 weeks once daily.
9794178|NCT01498419|Experimental|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|Multi Drug-Resistant Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
9794179|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2|Less Intensive, Schedule A1 Dasatinib 100 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
9853407|NCT03615066|Experimental|Selgantolimod 1.5 mg + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
9794180|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2|More Intensive, Schedule A2: Dasatinib 100 mg daily by mouth ; Decitabine ose 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
9794181|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
9794182|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib 140 mg daily by mouth ; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
9794183|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth; Decitabine e 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
9794184|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib140 mg daily by mouth; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
9794185|NCT01498458|Experimental|pazopanib plus capecitabine|
9794186|NCT01498549|Active Comparator|Atomoxetine|Atomoxetine compared to the sugar pill
9794187|NCT01498549|Placebo Comparator|Sugar Pill|Sugar pill compared to atomoxetine
9794188|NCT01498575|Experimental|Teen Driving Plan|Access to web-based driving intervention
9794189|NCT01498575|No Intervention|Usual practice|Use of typical supervised practice driving resources
9794190|NCT01498588|Experimental|Eribulin+Doxorubicin+Cyclophosphamide|"Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide~Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:~Day 1: Eribulin 1.4mg/m² IV~Day 8: Eribulin 1.4mg/m² IV~Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:~Day 1: Doxorubicin 60mg/m² IV~Day 1: Cyclophosphamide 600mg/m² IV~Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy at the discretion of the investigator."
9794191|NCT01498601|Experimental|Oral care treatment group|All subjects in the prospective intervention group will receive the same enhanced oral care protocol
9794192|NCT01498601|No Intervention|Retrospective study group|For comparison purposes, a retrospective chart review of matched in-patient population will reveal pneumonia rates in the same population who did not receive the enhanced oral care protocol.
9794193|NCT01498640|Experimental|XIAFLEX/XIAPEX MP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
9794194|NCT01498640|Experimental|XIAFLEX/XIAPEX PIP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
9794195|NCT01498653|Experimental|FF/VI 200/25mcg once daily|ICS/LABA
9794196|NCT01498653|Active Comparator|Fluticasone propionate 500mcg twice daily|ICS
9794197|NCT01498679|Active Comparator|fluticasone furoate/vilanterol trifenatate|Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination
9794198|NCT01498679|Placebo Comparator|Placebo|placebo comparator
9794199|NCT01498692|Experimental|PROMUS Element|Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
9794200|NCT01498744|Experimental|5 days postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
9794201|NCT01498744|Experimental|1 day postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
9794202|NCT01498822|Experimental|Levetiracetam|Levetiracetam twice a day treatment group
9794203|NCT01498822|Active Comparator|Oxcarbazepine|Oxcarbazepine twice a day treatment group
9794204|NCT01498887|Experimental|Naive or de novo participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
9794205|NCT01498887|Experimental|Previously treated with first-line DMTs participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
9794206|NCT01498952|Experimental|Phase 1b Cohort A|Participants will receive MEDI-573 10 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
9794207|NCT01498952|Experimental|Phase 1b Cohort B|Participants will receive MEDI-573 45 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
9517041|NCT03310047|Experimental|Right-high, left-low|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.~This will be repeated after 24 hours."
9986367|NCT01402193|Active Comparator|Control Arm|"Standard Treatment: Arimidex delayed until 2 weeks after radiotherapy~Interventions:~Radiation: Radiotherapy Drug: Post radiotherapy commencement of Arimidex"
9996939|NCT01504503|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
9996940|NCT01504503|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
9517042|NCT03310034|Active Comparator|Intervention|
9517043|NCT03310034|Placebo Comparator|Control|
9794208|NCT01498952|Experimental|Phase 1b Cohort C|Participants will receive MEDI-573 30 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
9794209|NCT01498952|Experimental|Phase 2 Arm 1|Participants will receive recommended dose of MEDI-573 from Phase 1b IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
9794210|NCT01498952|Active Comparator|Phase 2 Arm 2|Participants will receive sorafenib 400 mg orally twice daily until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
9794211|NCT01498978|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression then receive maintenance ipilimumab IV once every 3 months for 4 additional doses.
9794212|NCT01499043|Experimental|PLX3397|Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.
9794213|NCT01499134|Experimental|nebivolol|nebivolol 1 to 4 capsules daily
9794214|NCT01499134|Active Comparator|metoprolol succinate|metoprolol 1 to 4 capsules daily
9794215|NCT01499147|Active Comparator|Arm 1|All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
9794216|NCT01499147|Active Comparator|Arm 2|All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
9794217|NCT01499173|Experimental|Stroke preparedness intervention|Youth and adults from predominately African American churches in Flint will be enrolled to undergo a faith-based, scientific theory-driven, peer-led behavioral intervention utilizing a pre-post test design.
9794218|NCT01499199|Experimental|Dolutegravir 50mg Once Daily|All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
9794219|NCT01499277|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
9794220|NCT01499277|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
9794221|NCT01499290|Experimental|CAZ-AVI + Metronidazole|IV treatment
9794222|NCT01499290|Active Comparator|Meropenem|IV treatment
9794223|NCT01499303|Experimental|Fostamatinib 200|200mg fostamatinib bid n=60
9794224|NCT01499355|Placebo Comparator|Placebo|Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
9794225|NCT01499355|Experimental|BIIB023 3 mg/kg|BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
9794226|NCT01499355|Experimental|BIIB023 20 mg/kg|BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
9794227|NCT01499368|Experimental|Lafutidine|Lafutidine 20mg/day
9794228|NCT01499368|Active Comparator|Famotidine|Famotidine 40mg/day
9794229|NCT01499368|Other|Omeprazole|Omeprazole 20mg/day
9794230|NCT01499498|Experimental|Sildenafil and Boceprevir|Healthy volunteers
9794231|NCT01499511||ASCOT participants amlodipine|It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
9794232|NCT01499511||ASCOT participants atenolol|It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.
9794233|NCT01499576|Experimental|Acetic acid spraying|
9794234|NCT01499654|Experimental|Half-dose radiotracer administration|For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
9853408|NCT03615066|Placebo Comparator|Placebo + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
9853409|NCT03615079|Other|Cognitive Behavioral Therapy (CBT) program|
9853410|NCT03615183|Experimental|Panel A: 10 mg MK-8527|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
9853411|NCT03615183|Experimental|Panel B: 3 mg MK-8527|Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
9853412|NCT03615183|Experimental|Panel C: 1 mg MK-8527|Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
9853413|NCT03615183|Experimental|Panel D: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
9853414|NCT03615183|Experimental|Panel E: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
9853415|NCT03615404|Experimental|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
9986368|NCT01402206|Other|Structured patient visits|Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
9986369|NCT01402206|Other|Treatment as usual|The control group receives treatment as usual by general practitioner (no intervention).
9853416|NCT03615482|Experimental|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
9853417|NCT03615482|Experimental|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
9853418|NCT03615534|Placebo Comparator|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
9853419|NCT03615534|Active Comparator|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
9853420|NCT03615534|Active Comparator|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
9853421|NCT03615534|Active Comparator|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
9853422|NCT03615807|Experimental|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
9853423|NCT03615807|Active Comparator|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
9853424|NCT03615911|Experimental|Vaccination with 10^7 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
9853425|NCT03615911|Experimental|Vaccination with 10^8 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
9853426|NCT03615924|Experimental|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~>48 kg: Ticagrelor 45 mg, twice a day."
9923656|NCT00852722|Experimental|1. Low fat study diet|The low fat study diet arm will receive low fat diet training and followed for 12 months on the diet.
9986370|NCT01402219|Active Comparator|Iopamiro-370|
9986371|NCT01402219|Active Comparator|Visipaque 320|
9986372|NCT01402232||coronary angiography|We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
9986373|NCT01402245|No Intervention|Pneumonia group|Patients with Pnc pneumonia
9986374|NCT01402245|Active Comparator|PPV Group|Volunteers immunized with Pnc polysaccharide vaccine
9853427|NCT03615924|Placebo Comparator|Placebo|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
9853428|NCT03616106|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
9853429|NCT03616171|Experimental|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:~One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
9853430|NCT03616171|Other|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
10208304|NCT00697684|Experimental|Cohort 3|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
10208305|NCT00697684|Experimental|Cohort 4|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
9853431|NCT03616600|Experimental|Treatment|Wearing the orthokeratology lenses for 3 months
9853432|NCT03616600|No Intervention|Control|Not wearing any contact lenses
9853433|NCT03616899|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
10208306|NCT00603954|Active Comparator|TBI + fludarabine|Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
10208307|NCT00603954|Active Comparator|TLI + ATG|Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.
9853434|NCT03616899|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
9853435|NCT03616977|Experimental|LY900014 U-200|Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
9853436|NCT03616977|Experimental|LY900014 U-100|Single SC dose of LY900014 U-100 in two of four study periods.
9853437|NCT03617419|Other|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System~The following post-market products will be used on label:~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
9853438|NCT03617588|Experimental|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
9853439|NCT03617770|Experimental|Sleep-Opt-In|Sleep optimization intervention
9853440|NCT03617770|Active Comparator|Healthy Living|Health education
9853441|NCT03617861|Experimental|Healthy Controls: Secretin Then Placebo|Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
9853442|NCT03617861|Experimental|Healthy Controls: Placebo Then Secretin|Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
9853443|NCT03617861|Experimental|Functional Dyspepsia: Secretin Then Placebo|Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
9853444|NCT03617861|Experimental|Functional Dyspepsia: Placebo Then Secretin|Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
9853445|NCT03617913|Experimental|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
9986375|NCT01402245|Active Comparator|PCV Group|Volunteers immunized with Pnc conjugate vaccine
10208308|NCT00392353|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC QD on days 1-7 and vorinostat PO 2-3 times daily on days 3-5, 3-9, or 3-16. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
10208309|NCT05214599|Experimental|Group 1|Low dose
10208310|NCT05214599|Experimental|Group 2|Middle dose
10208311|NCT05214599|Experimental|Group 3|High dose
9853446|NCT03618017|Experimental|CCC Website|The intervention, ConnectedCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
9853447|NCT03618017|Other|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
9853448|NCT03618030|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
9853449|NCT03618030|Placebo Comparator|Placebo Treatment|Matched placebo
9853450|NCT03618628|Experimental|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
9853451|NCT03618823|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary.
9853452|NCT03618823|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary.
9853453|NCT03619135|Experimental|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
9853454|NCT03619135|Placebo Comparator|Control|No Buzzy device was used - standard IV access for this arm.
9853455|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
9853456|NCT03619811|Experimental|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device)
9853457|NCT03619837|Experimental|Treatment Arm|"Single Arm: Sofosbuvir/Velpatasvir~Dosage: 400mg/100mg. Once daily for 12 weeks."
9853458|NCT03619889|Sham Comparator|Sham simulation group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
9853459|NCT03619889|Experimental|Pressure release technique group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
9853460|NCT03620162|Active Comparator|Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™|Participants will receive a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
9853461|NCT03620162|Experimental|Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
9853462|NCT03620162|Experimental|Group 3: Prevnar 13™-Prevnar 13™-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
9853463|NCT03620162|Experimental|Group 4: Prevnar 13™-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
9853464|NCT03620162|Experimental|Group 5: V114-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
9853465|NCT03620383|Experimental|Heat|Distal topical heat application
9853466|NCT03620383|No Intervention|No Heat|Inactive heat pack to blind the investigator.
9853467|NCT03620708|Experimental|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
9853468|NCT03620708|Active Comparator|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
9853469|NCT03620708|Other|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
10208312|NCT05214586|Experimental|Spiculotomy and application of a Gel Nail|A nail spicule removal technique will be performed of the edge or nail edges affected by ingrown toenail. After, a gel nail will be applied to remodeling the nail apparatus and avoid damage of the nail in the lateral fold.
10208313|NCT05214586|Active Comparator|Spiculotomy and Nail Re-education with Gauze Bandage|A nail spicule removal technique will be performed and a cord of gauze bandage between the nail channel and the sheet will be applied. This technique consists in the removal of the portion of the nail sheet that causes ingrown toenail in order to release the soft parts.
9853470|NCT03620890|Active Comparator|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
9853471|NCT03620890|Active Comparator|Detemir|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
9853472|NCT03621085|Experimental|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
9853473|NCT03621085|Placebo Comparator|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
9853474|NCT03621189|Active Comparator|Active-Active|"Participants received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 8 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
9853475|NCT03621189|Sham Comparator|Sham-Active|"Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the posterior superior temporal sulcus for 4 weeks (2 days/week) and then received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 4 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
9853476|NCT03621202|Experimental|Saranas Early Bird Bleed Monitoring System (EBBMS)|
9853477|NCT03621787|Experimental|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
9853478|NCT03621878|Active Comparator|Control group|Patients in this group had 6 sessions in 2 weeks of Transcutaneous Electric Nerve Stimulation (TENS).
9853479|NCT03621878|Experimental|Tensioner Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Tensioner technique).
9853480|NCT03621878|Experimental|Slider Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Slider technique).
9853481|NCT03622112|Experimental|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
10208314|NCT05214573||Aims 1, 2B, and 3 Groups|De-identified administrative claims with linked laboratory results, electronic health record (EHR), and mortality data from the OptumLabs Data Warehouse (OLDW) and Medicare fee-for-service data (Medicare parts A, B, D) will be utilized to identify adults (≥21 years) with T2D (established using validated Healthcare Effectiveness Data and Information Set criteria) who first filled any study drug GLP-1RA, SGLT2i, DPP-4i, or SU between 1/1/2014-12/31/2020.
10208315|NCT05214573||Aim 2A Group|Adults with Type 2 diabetes treated with one or more of the study medications (GLP-1RA, SGLT2i, DPP-4i, or SU) and not treated with insulin who receive medical care at Mayo Clinic Rochester, Mayo Clinic Health System in Minnesota or Wisconsin, or Emory University/Grady Hospital.
9853482|NCT03622112|Experimental|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
9853483|NCT03622112|Experimental|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
9853484|NCT03622112|Experimental|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
9986376|NCT01402258|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
10208316|NCT05214521|Experimental|"digital interactive technology Smart glove SensoRehab"|"The operation of the digital interactive complex Smart glove SensoRehab is based on the visual and kinesthetic (proprioceptive) biofeedback principle by using a set of cognitive interactive computer games controlled by finger and hand movements. The technique involves neurosensory training and retraining to improve the fine use of the hand and arm, and the patient's cognitive and emotional state."
9853485|NCT03622112|Experimental|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
10208317|NCT05214508|Active Comparator|COPD patient|COPD patients diagnosed based on spirometry, PFT and history
9853486|NCT03622112|Placebo Comparator|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
10208318|NCT05214508|No Intervention|Control|Healthy volunteers
10208319|NCT05214482|Experimental|Phase Ib|Subjects receive AK112 plus AK117 until progression
10208320|NCT05214482|Experimental|Phase II|AK112 + chemotherapy± AK117 until progression
10208321|NCT05214469||Case Group|Individuals diagnosed with knee-osteoarthritis
10208322|NCT05214469||Control Group|Individuals who do not have a chronic disease and are not diagnosed with osteoarthritis
9853487|NCT03622112|Active Comparator|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
9853488|NCT03622619|Experimental|Manuka eye drops|
9853489|NCT03622619|Active Comparator|Systane Ultra|
9853490|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
9853491|NCT03623334|Experimental|Dose Level A: IGRT 3.33Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks
9853492|NCT03623334|Experimental|Dose Level B: IGRT 3.67Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks
9853493|NCT03623334|Experimental|Dose Level C: IGRT 4.00Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 60 Gy) which is given over the course of about 3 weeks
9853494|NCT03623698||Before treatment|Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)
9853495|NCT03623698||After treatment|Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)
9853496|NCT03624192|Experimental|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
9853497|NCT03624192|Active Comparator|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
9853498|NCT03624504|Experimental|Micra Implant Group|Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)
9853499|NCT03624920|Placebo Comparator|THN102 Dosage A|THN102 Dosage A is a Placebo
9853500|NCT03624920|Experimental|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
9853501|NCT03624920|Experimental|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
9853502|NCT03624946|Experimental|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
9853503|NCT03624946|Placebo Comparator|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
9853504|NCT03624972|Active Comparator|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
9853505|NCT03624972|Experimental|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
9853506|NCT03624972|No Intervention|Clinician Arm|Clinicians were consented in order to have their clinic visits audio recorded. No outcomes data were collected from clinician participants.
9853507|NCT03626415|Experimental|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
9853508|NCT03626623|Placebo Comparator|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
9853509|NCT03626623|Active Comparator|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
9853510|NCT03626714|Experimental|Sustained Release Tacrolimus|All subjects will be treated with a single dose injection of sustained-release Tacrolimus
9853511|NCT03627065|Experimental|Parsaclisib|
9853512|NCT03627195|Experimental|DSP-1349M|Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
9853513|NCT03627195|Placebo Comparator|Placbo|placebo injection
9853514|NCT03627299|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks
9853515|NCT03627416|Experimental|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
9853516|NCT03627416|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
9853517|NCT03627494|Experimental|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
10208323|NCT05214430|Experimental|3 months exclusive enteral nutrition after surgery|3 months exclusive enteral nutrition after surgery
10208324|NCT05214430|Experimental|less than 1 months exclusive enteral nutrition after surgery|less than 1 months exclusive enteral nutrition after surgery
10208325|NCT05214391|Experimental|Intervention ( zanubrutinib)|30 enrolled patients are picked up to take zanubrutinib at the indicated dose.
10208326|NCT05214352||young population with cerebral palsy-Families-Therapist and researchers|The principal group is designed by all people who composed the research and who will work together in the intervention manual elaboration on the participation in the community.
9935815|NCT03185819|Experimental|Oral Placebo + Esketamine 84 mg|Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
10208327|NCT05214339|Experimental|TRIPLET|"Combination Product: Hepatic Arterial Infusion combined with Bevacizumab and Sintilimab Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Bevacizumab and Sintilimab for injection.~Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times. 2. Intravenous infusion of Bevacizumab 7.5mg/kg every 3 weeks on the 4th day. 3. On the 25nd day of treatment, namely the second session of HAIC, intravenous infusion of Sintilimab 200mg every 3 weeks. 4. The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
10208328|NCT05214261|Experimental|TAP block group|Patiens undergo laparoscopic-guided TAP block installation for laparoscopic clolorectal surgery
9853518|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853519|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853520|NCT03627494|Experimental|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
10208329|NCT05214261|Active Comparator|Epidural analgesia group|Patients undergo epidural catheters placement for laparoscopic colorectal surgery
10208330|NCT05214248|Experimental|multimedia admission orientation|Multimedia admission orientation for the parents of infants admitted to NICU is provided to the experimental group of the parents. The multimedia orientation based on animation and graphic figures to explain the basic information about the NICU environment and precautions and the essential tests and examination taken for their infant during the initial stage of NICU admission.
9853521|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853522|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853523|NCT03627494|Experimental|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853524|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853525|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853526|NCT03627494|Experimental|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
10208331|NCT05214235||Metformin|Patients who use metformin to control blood sugar level.
10208332|NCT05214235||Sitagliptin|Patients who use sitagliptin to control blood sugar level.
9853527|NCT03627494|Placebo Comparator|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
9986377|NCT01402271|Experimental|pazopanib in combination with paclitaxel and carboplatin|Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
10208333|NCT05214222|Experimental|group A|Penpulimab plus chemotherapy with Anlotinib
9986378|NCT01402271|Active Comparator|Paclitaxel and carboplatin only|Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
9996941|NCT01504516|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
10208334|NCT05214222|Experimental|group B|Penpulimab plus chemotherapy
10208335|NCT05214170|Experimental|Electroanatomic mapping with NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
10208336|NCT05214157|Experimental|group A|interventional group, final two operative steps applied
10208337|NCT05214157|No Intervention|group B|control group
10208338|NCT05214131|Experimental|gogoband alarm|patients will be assigned to the novel bedwetting alarm
10208339|NCT05214131|Active Comparator|standard nocturnal enuresis alarm (SNEA) group|this is the standard bedwetting alarm that is presently available through out the world
9853528|NCT03627494|Experimental|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853529|NCT03627494|Experimental|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
9853530|NCT03627767|Experimental|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
10208340|NCT05214079|Active Comparator|1 , Left paratracheal pressure|50 male
10208341|NCT05214079|Active Comparator|2, Left paratracheal pressure|50 female
9853531|NCT03627767|Experimental|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
9853532|NCT03627767|Placebo Comparator|Placebo QD|Double-blind randomized treatment following open label run-in period.
9853533|NCT03627832|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
9853534|NCT03627832|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
9853535|NCT03628417|Experimental|Calcium Electroporation|"Calcium~Calcium chloride 220 mmol/L (9 mg/ml):~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)"
9853536|NCT03628417|Experimental|Bleomycin based electrochemotherapy|"Bleomycin~Bleomycin 1000 IU/ml:~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)~Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU. Normal maximum limit for bleomycin is 15.000 IU/m² body surface area."
9853537|NCT03628456|Experimental|AffloVest Monarch Arm|Devices placed on highest intensity / highest frequency
9853538|NCT03628508|Experimental|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
9853539|NCT03628599|Experimental|TOTAL1|Delefilcon A contact lenses worn bilaterally (in both eyes) for 4 weeks in a daily disposable modality
9853540|NCT03628599|Active Comparator|1-DAY|Senofilcon A contact lenses worn bilaterally for 4 weeks in a daily disposable modality
9853541|NCT03628885|No Intervention|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
9853542|NCT03628885|Experimental|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
9853543|NCT03628885|Experimental|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
9853544|NCT03628898|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor
9853545|NCT03628924|Experimental|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
9853546|NCT03628924|Experimental|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
9853547|NCT03628924|Experimental|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
9853548|NCT03629028|Active Comparator|Single Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
9853549|NCT03629028|Active Comparator|Double Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
9853550|NCT03629041|Experimental|Treatment A - Microneedle patch|The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
9935816|NCT03185819|Experimental|Oral Placebo + Esketamine 56 mg|Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
10208342|NCT05214014|Experimental|Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells|Group 1: Patients with systemic sclerosis receiving standard treatment and autologous regulatory Т-cells
10208343|NCT05214014|Active Comparator|Patients with multiple sclerosis receiving standard treatment|Group 2: Patients with multiple sclerosis receiving standard treatment
10208344|NCT05214001|Experimental|Almotriptan|12.5 mg almotriptan taken orally once
10208345|NCT05214001|Active Comparator|Ubrogepant|50 mg ubrogepant taken orally once
9986379|NCT01402297|Experimental|COPD patients|Thirteen nonsmoking patients, suffering from GOLD II and GOLD III stage participated in the study (mean age 57 years (range 42-79), 9 men, 4 women). COPD was diagnosed based on GOLD 2009 criteria. All the participants were diagnosed at Department of Clinical Physiology, Medical university of Lodz.
9986380|NCT01402310||Women attending antenatal clinic|Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation.
9986381|NCT01402323|Other|early or late tooth extraction|
9794235|NCT01499667|Experimental|8-week washout + Fingolimod (FTY720)|8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
9794236|NCT01499667|Experimental|12-week washout + Fingolimod (FTY720)|12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
9794237|NCT01499667|Experimental|16-week washout + Fingolimod (FTY720)|16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
9794238|NCT01499810|Experimental|Renal denervation|All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.
9794239|NCT01499849|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
9794240|NCT01499849|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
9794241|NCT01499862|Experimental|Tibion Arm|Arm of the study in which enrolled post-stroke subjects undergo rehabilitative therapy with the Tibion Bionic Leg.
9794242|NCT01499940|Experimental|Vitamin D3 2000 IU/day|Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study
9794243|NCT01500031|Experimental|OffRoad Re-entry catheter|Participants treated with OffRoad Re-entry Catheter System
9794244|NCT01500057|Active Comparator|Greenlight XPS Laser|Greenlight XPS Laser of the prostate
9794245|NCT01500057|Active Comparator|BiVAP Saline Vaporization|BiVAP Saline Vaporization of the prostate
9794246|NCT01500083|Experimental|Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with CLL will receive bendamustine at a dose of 100 mg/m2 on Days 1 and 2 in treatment cycles of 28 days for up to six cycles.
9794247|NCT01500083|Experimental|Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)|Patients with iNHL will receive bendamustine at a dose of 120 mg/m2 on Days 1 and 2 in treatment cycles of 21 or 28 days for up to eight cycles.
9794248|NCT01500096|Active Comparator|American ginseng 1000 mg/day|4-week of American ginseng 1000 mg/day every morning
9794249|NCT01500096|Placebo Comparator|Placebo for American ginseng 1000 mg/day|4-week of placebo for American ginseng 1000 mg/day every morning
9794250|NCT01500096|Active Comparator|American ginseng 3000 mg/day|4-week of American ginseng 3000 mg/day every morning
9794251|NCT01500096|Placebo Comparator|Placebo for American ginseng 3000 mg/day|4-week of placebo for American ginseng 3000 mg/day every morning
9794252|NCT01500135|Experimental|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
9794253|NCT01500135|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
9794254|NCT01500187|Active Comparator|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
9794255|NCT01500187|Experimental|3M Vanish Varnish|5% sodium fluoride varnish
9794256|NCT01500200|Experimental|ALKS 5461|
9794257|NCT01500200|Placebo Comparator|Placebo|
9794258|NCT01500213|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
9794259|NCT01500213|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
9794260|NCT01500226|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
9794261|NCT01500226|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
9794262|NCT01500252|Experimental|Patellar Resurfacing|These subjects received a Profix TKR including an all polyethylene patellar implant.
9794263|NCT01500252|Active Comparator|Patellar Retention|This group received a Profix TKR, but retained their native patella
9794264|NCT01500278|Active Comparator|Certolizumab Pegol + Methotrexate (CZP + MTX)|
9794265|NCT01500278|Active Comparator|Adalimumab + Methotrexate (ADA + MTX)|
9794266|NCT01500278|Active Comparator|CZP + MTX followed by ADA + MTX|Those subjects who received Certolizumab Pegol (400 mg at Weeks 0, 2, 4 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) at Baseline and are Non-Responders at Week 12, switch to Adalimumab (40 mg) + Methotrexate (ADA + MTX) after Week 12.
9853551|NCT03629041|Sham Comparator|Treatment B - Patch with no microneedles|The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
9853552|NCT03629054|Experimental|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
9853553|NCT03629054|Experimental|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
9853554|NCT03629184|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
10208346|NCT05213988|Experimental|Low-Carbohydrate/High-Protein Diet|
9517044|NCT03310008|Experimental|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
9853555|NCT03629184|Active Comparator|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
9853556|NCT03629249|Experimental|QAW039 150 mg|QAW039 150 mg once daily orally
9853557|NCT03629249|Experimental|QAW039 450 mg|QAW039 450 mg once daily orally
9853558|NCT03629249|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
9853559|NCT03629535|Experimental|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
9853560|NCT03629886|No Intervention|Vacc-039 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received HPV vaccine in HPV-039 study (NCT00779766), underwent cervical sample collection and didn't receive any vaccine in the current study.
10208347|NCT05213988|Experimental|Fibrate|
10208348|NCT05213988|Experimental|Intermittent Fasting|
10208349|NCT05213988|No Intervention|Control|
10208350|NCT05213975|Experimental|intervention group|kinesio taping group
9853561|NCT03629886|Experimental|Vacc-092 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received placebo (control group) in HPV-039 study (NCT00779766), were intended to receive HPV vaccine in the current study and were to provide cervical samples before HPV vaccination.
9853562|NCT03629925|Experimental|Sintilimab+ gemcitabine plus platinum|Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin
9853563|NCT03629925|Placebo Comparator|Placebo+gemcitabine plus platinum|Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin
9853564|NCT03630016|Active Comparator|Reference CO-Oximetry|Reference Co-Oximetry
9853565|NCT03630016|Experimental|Owlet BabySat v1.0|Owlet BabySat v1.0
9853566|NCT03630016|Experimental|Owlet Smart Sock V2 v1.1|Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock
9853567|NCT03630185|Experimental|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
9996942|NCT01504516|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
10208351|NCT05213975|No Intervention|control group|Standard of care
10208352|NCT05213923|No Intervention|Pre-intervention|Patients presenting to the Emergency Department meeting severe sepsis criteria prior to implementation of an ED Sepsis Tracking Sheet
10208353|NCT05213923|Experimental|Post-intervention|Patients presenting to the Emergency Department meeting severe sepsis criteria following implementation of an ED Sepsis Tracking Sheet
10208354|NCT05213884|Experimental|Camrelizumab plus chemoradiotherapy|Induction camrelizumab therapy at least one cycle (every 3 weeks) followed by definitive concurrent chemoradiotherapy. After 4~6 weeks of the completion of radiotherapy, adjuvant camrelizumab therapy will begin every 3 weeks for 16 cycles (1 year) or continue until progression or unacceptable toxicity.
10208355|NCT05213832|Experimental|Inhalatory group|Patience with severe SAH (WFNS > 3) are enrolled in the study. In these patients we administered a inhalatory dose of Isofluorane
10208356|NCT05213819|Other|Carpal tunnel syndrome|Patients with carpal tunnel syndrome were treated with phonophoresis, low level laser therapy and exercise.
10208357|NCT05213793||ischemic stroke|The cohort includes patients with acute stroke who underwent CTP, multi-delay ASL, DWI, CTA or TOF-MRA scanning.All patients will be examined within 24 hours of onset. CBF, CBV, MTT and Tmax cerebral blood flow parameter images of CTP will be obtained. CBF, CBV and ATT cerebral blood flow parameter images in multi-delay ASL will be obtained by the quantitative evaluation system. The volume of reversible ischemic tissue will be calculate according to CTP and multi-delay ASL respectively.
10208358|NCT05213767|Experimental|TQB2916 injection|2.5mg/ quaque die (QD) was used as the initial dose, 21 days as a treatment cycle. The drug is administered on the first day of each cycle until the disease progresses or the investigator judges that it is not suitable for subject to continue to take medicine.
10208359|NCT05213702|Active Comparator|Traditional free hand puncture for renal calyx access|For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
10208360|NCT05213702|Active Comparator|RObotic ANT-X device puncture for renal calyx access|For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
10208361|NCT05213689|Experimental|HIV self-testing + educational comic book|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics. Participants will also receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
10208362|NCT05213689|Active Comparator|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, in addition to contact information for confirmatory testing and linkage to care at local clinics.
9853568|NCT03630185|Active Comparator|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
9853569|NCT03630198|Active Comparator|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
9853570|NCT03630198|Experimental|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
9923657|NCT00852722|No Intervention|2. Regular diet group|The regular diet arm will be a wait-listed group that will receive no training in diet and will be advised to continue their regular (usual) diet as was prior to entry into the study, for the duration of the study. They will have a similar clinic follow up schedule as the treatment group. The regular diet group will be given identical instructions to exercise regularly similar to the treatment group.
9923658|NCT00852774||1|Endometrial Cancer Patients Hysterectomy Robotic Surgery
9923659|NCT00852774||2|Endometrial Cancer Patient Hysterectomy Laparotomy Surgery
9923660|NCT00852787|Experimental|Low|0.1mg/kg
9923661|NCT00852787|Experimental|Medium|0.4mg/kg
9923662|NCT00852787|Experimental|High|1.6 mg/kg
9923663|NCT00852787|Placebo Comparator|Placebo|
9923664|NCT00852800|Active Comparator|Standard regimen|Albumin in standard regimen (1.5 g/Kg IV on day 1 and 1 g/kg IV on day 3)with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
10208363|NCT05213689|Active Comparator|Educational comic book|Participants will receive an educational comic book focused on HIV testing information and decision making that was developed with qualitative data collected from an earlier study phase. PNs will meet with small groups of participants to read through and discuss the comic book together.
10208364|NCT05213689|No Intervention|Standard of Care|PNs will provide information about HIV testing, care and support services at local clinics.
10208365|NCT05213676|Active Comparator|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
9923665|NCT00852800|Experimental|Dose reduced regimen|Albumin in dose reduced regimen (1 g/kg IV on day 1 and 0.5 g/kg IV on day 3) with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
9923666|NCT00852826|Sham Comparator|1|Standard axillary lymphadenectomy
10208366|NCT05213676|Active Comparator|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
10208367|NCT05213585|Experimental|Treated eyes|All participants will have one eye randomly selected for treatment.
9923667|NCT00852826|Experimental|2|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
9923668|NCT00852852|Experimental|Intervention|Patient participants in the intervention arm can access educational information about self-care strategies, track and share reports of their symptoms and quality of life issues over time, and receive coaching on how to discuss these issues with their care team.
10208368|NCT05213585|No Intervention|Untreated eyes|No treatment will be given to the control eye.
9923669|NCT00852852|No Intervention|Control|Participants in the control arm access the ESRA-C from home or clinic to self-assess only.
10208369|NCT05213546|Active Comparator|High intensity aerobic training group(HIT)|15 patients who received High Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months.
9923670|NCT00852865|Experimental|1|24 healthy volunteers consuming L.farciminis during three weeks
10208370|NCT05213546|Active Comparator|Moderate intensity aerobic training group(MIT)|15 patients who received moderate Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months.
10208371|NCT05213546|Active Comparator|Low intensity aerobic training group(LIT)|15 patients who received low Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months
10208372|NCT05213520|Experimental|Alternate Day Intermittent Energy Restriction|Participants assigned to this diet will be asked to alternate between full calorie (no restriction) eating days with eating 40% of their daily caloric requirement on the other day. For example, if their requirement is 2000 calories they would eat 800 calories one day and as much as you want on the other day and repeat every two days. There will be occasional exceptions allowed with maximum of two 40% days in a row (followed by two full days) based on personal schedule with prior approval. They will follow this for 4 weeks.
9923671|NCT00852865|Placebo Comparator|2|24 healthy volunteers consuming placebo during three weeks
9923672|NCT00852878|Active Comparator|Biofeedback|heart rate variability biofeedback
10208373|NCT05213520|Active Comparator|Reduced Calorie Diet|Participants assigned to this diet will be asked to restrict calorie intake by 500-1000 calories below their daily energy requirement every day. They will follow this for 4 weeks.
10208374|NCT05213494|Active Comparator|Low-dose inulin|3-5 years old: 3g of fiber/day from inulin mixed in a beverage 6-9 years old: 5g of fiber/day from inulin mixed in a beverage
10208375|NCT05213494|Experimental|Low-dose soluble corn fiber|3-5 years old: 3g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 5g of fiber/day from soluble corn fiber mixed in a beverage
10208376|NCT05213494|Active Comparator|High-dose inulin|3-5 years old: 6g of fiber/day from inulin mixed in a beverage 6-9 years old: 8g of fiber/day from inulin mixed in a beverage
10208377|NCT05213494|Experimental|High-dose soluble corn fiber|3-5 years old: 6g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 8g of fiber/day from soluble corn fiber mixed in a beverage
10208378|NCT05213494|No Intervention|Baseline|3-9 years old: pre-intervention.
9853571|NCT03630679||Preterm|born at <37 weeks of gestation
9853572|NCT03630679||Full term Term|born at >/= 37 weeks of gestation
9853573|NCT03631355|Active Comparator|ACL Reconstruction w/ BTB Autograft + IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients received two individual doses of intravenous TXA intra-operatively.
9853574|NCT03631355|No Intervention|ACL Reconstruction w/ BTB Autograft, no IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients did not receive two individual doses of intravenous TXA intra-operatively. Only the consented surgery was performed.
9853575|NCT03631433|Active Comparator|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
9853576|NCT03631433|Experimental|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
9853577|NCT03631732|Experimental|B/F/TAF|Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
9853578|NCT03631732|Active Comparator|Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF|Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
9853579|NCT03631927||Patient|Patients admitted to participating ICUs on the specified dates
10208379|NCT05213442|Other|All inpatients in Vinatier psychiatric Hospital|All hospitalized patients can potentially be recruited. They will benefit from the usual clinical and paraclinical examinations as part of their hospitalization diagnostic work-up. For the determination of biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.
10208380|NCT05213403||Patient G1|Correlation between surgery and scoring system
9853580|NCT03632083|Active Comparator|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution.
9853581|NCT03632083|Active Comparator|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution.
9853582|NCT03632109|Experimental|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
9853583|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
9853584|NCT03633084|Experimental|RBM-007 Injectable Solution - 0.2 mg|No additional information.
9853585|NCT03633084|Experimental|RBM-007 Injectable Solution - 1.0 mg|No additional information.
9853586|NCT03633084|Experimental|RBM-007 Injectable Solution - 2.0 mg|No additional information.
9853587|NCT03633331|Experimental|Treatment (palbociclib, letrozole or fulvestrant)|Patients receive palbociclib PO QD on days 1-21. Patients also receive letrozole PO QD on days 1-28 or fulvestrant IM on days 1 and 15 of course 1 and on day 1 of subsequent courses per MD discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9853588|NCT03633344|Active Comparator|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
9853589|NCT03633344|Placebo Comparator|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
9853590|NCT03633448|Experimental|Mucinex® 1 x 200 mg (10 mL)|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
9853591|NCT03633448|Experimental|Mucinex® 1 x 400 mg (20 mL)|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
10208381|NCT05213403||Patients G2|Incongruence between surgery and scoring system
10208382|NCT05213351|Experimental|Graded Motor İmagery|Graded Motor İmagery (GMI) group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, traditional exercises and home exercises.
10208383|NCT05213351|Active Comparator|Exercise|Exercise group will receive training involves mobilizations, stretching, specific exercises for the frozen shoulder.
10208384|NCT05213325||Cases|Children with acute diarrhea
10208385|NCT05213325||Control|Healthy control children
10213544|NCT03814356|Experimental|IV MPH|All patients will receive IV Methylphenidate (MPH). Patients will receive escalating daily doses of IV MPH starting at 0.5 mg/kg, increasing stepwise to 1.0mg/kg and 2.0 mg/kg unless an adverse event (AE) necessitates dose de-escalation or a serious adverse event (SAE) necessitates that the patient stop participation in the study.
10213545|NCT03814200|Experimental|Treatment period A|"Treatment A1: saline 0.9%~followed by~Treatment A2: ACT-246475"
9853592|NCT03633487|Experimental|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
9853593|NCT03633526|Experimental|VX-659/TEZ/IVA|Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.
9853594|NCT03633825|No Intervention|Control|
9853595|NCT03633825|Experimental|Intervention|
9853596|NCT03633903|Active Comparator|Mindfulness|Mindfulness: Eight sessions, twice per week over four weeks. Surveys administered prior to each session.
9853597|NCT03633903|No Intervention|Control|Treatment as usual (i.e., pharmacotherapy, psychotherapy, etc.) for the four week duration with twice weekly surveys administered.
9853598|NCT03633929||KIOS OUD|
9853599|NCT03634085|Experimental|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
9853600|NCT03634085|Experimental|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
9853601|NCT03634306|Active Comparator|ARM 1|Laparoscopic hysterectomy with use of the Ultravision System
9853602|NCT03634306|Placebo Comparator|ARM 2|Laparoscopic Hysterectomy per Standard of Care/no Ultravision System
9853603|NCT03634306|Active Comparator|ARM 3|Laparoscopic myomectomy with use of the Ultravision System.
9853604|NCT03634579|Experimental|MRI-guided focal laser ablation|Subjects will undergo MRI Guided Focal Laser Interstitial Thermal Ablation of localized low and intermediate risk prostate cancer.
9853605|NCT03634800|Experimental|nivolumab/radiotherapy|"All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy (6 Gy x 5 fractions) to a targetable lesion.~Nivolumab 240 mg IV starts with the first radiotherapy fraction 240 mg IV every 2 weeks from first radiotherapy fraction until disease prograssion or dose limiting toxicity is reached~Radiotherapy Dose of 6 Gy x 5 days will be given (patients will receive 1 fraction over 5 days for a total of 5 fractions) during the first week of starting Nivolumab"
9986382|NCT01402336|Experimental|GnRH antagonist, SD #1 starting group|Start GnRH antagonist from stimulation day 1 during ovulation induction cycles
10208386|NCT05213312|Experimental|NIT+NCT Group (Arm A)|"Neoadjuvant immunotherapy : Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;~Neoadjuvant chemotherapy (investigator's choice) : Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.~MIE : Esophagectomy plus two/three field lymphadenectomy, 4-6 weeks after neoadjuvant therapy.~Adjuvant immunotherapy : 4-6 weeks after operation, (for subjects with non-pCR) Nivolumab injection, 240mg intravenous infusion, Q2W for 16 weeks, followed by 480mg intravenous infusion, Q4W. The maximum duration of adjuvant Nivolumab therapy is one year."
9853606|NCT03634813|Experimental|High Blood Pressure Monitoring and Counseling|"Enrolled patients will be fitted with a HBPM device and instructed in its use. Patients will be asked to return the HBPM device on the morning of surgery. At the same time they receive the HBPM device, they will also be provided with the National Institutes of Health (NIH) booklet called Your guide on lowering blood pressure, which has several guidelines regarding diet, exercise and lifestyle changes that can be implemented to improve blood pressure control."
9853607|NCT03634813|Active Comparator|Usual Care|The usual care group will receive brief counseling after the PAT visit which will review their blood pressure readings taken at the clinic and how they compare with the American Heart Association (AHA) blood pressure guidelines. They will be offered the suggestion that they should follow up with their primary care doctor 2-4 weeks after their surgical episode is completed, or at their earliest convenience.
9853608|NCT03635086|Experimental|Group A: Two MV-CHIK lyophilized low dose|Participants received two vaccinations with MV-CHIK lyophilized formulation, low dose, on day 0 and day 28.
9853609|NCT03635086|Experimental|Group B: Two MV-CHIK liquid frozen low dose|Participants received two vaccinations with MV-CHIK liquid frozen low dose formulation on day 0 and day 28.
9853610|NCT03635086|Experimental|Group C: Two MV-CHIK liquid low dose stabilizing and protecting solution (SPS®)|Participants received two vaccinations with MV-CHIK liquid low dose SPS® formulation on day 0 and day 28.
9853611|NCT03635086|Experimental|Group D: Two MV-CHIK liquid frozen high dose|Participants received two vaccinations with MV-CHIK liquid frozen high dose formulation on day 0 and day 28.
9853612|NCT03635086|Experimental|Group E: One MV-CHIK liquid frozen high dose/placebo|Participants received one vaccination with MV-CHIK liquid frozen high dose formulation on day 0 and placebo on day 28.
10208387|NCT05213312|Placebo Comparator|NCT Group (Arm B)|"Placebo: NS ivgtt (dose, frequency and duration same as the Nivolumab);~Neoadjuvant chemotherapy (investigator's choice) : Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.~MIE : Esophagectomy plus two/three field lymphadenectomy, 4-6 weeks after neoadjuvant therapy.~Adjuvant immunotherapy : 4-6 weeks after operation, (for subjects with non-pCR) Nivolumab injection, 240mg intravenous infusion, Q2W for 16 weeks, followed by 480mg intravenous infusion, Q4W. The maximum duration of adjuvant Nivolumab therapy is one year."
10208388|NCT05213299|Experimental|First auricular acupuncture, then sham acupuncture in left ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the left ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
10213546|NCT03814200|Experimental|Treatment period B|"Treatment B1: rifampicin~followed by~Treatment B2: ACT-246475"
10208389|NCT05213299|Experimental|First auricular acupuncture, then sham acupuncture in right ear|Participants are experienced two phases of our study. The first phase, participants are received auricular acupuncture at TF4, AT4, LO1, LO3 points in the right ear. The second phase, participants are received sham acupuncture at the same points. The facial pain threshold will be recorded before and after performing auricular acupuncture.
10208390|NCT05213273|Experimental|Group A: Fresh/frozen fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish), excluding the consumption of canned fish.
10208391|NCT05213273|Experimental|Group B: Canned fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish where at least 1-2 servings will be in the form of canned fish). A selection of canned fish (tuna, sardine, salmon and mackerel) will be administered to each volunteer for the duration of the study.
10208392|NCT05213195|Experimental|NKG2D CAR-NK|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation
10208393|NCT05213143|Experimental|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening.
9853613|NCT03635320|Experimental|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
9853614|NCT03635320|Active Comparator|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
10208394|NCT05213117|Experimental|Co-localized Residents|Investigators plan to randomize 15 PGY-1 residents in internal medicine from the possible 74 PGY-1 incoming residents who agree to partake in the study, to one general medicine clinical floor for the academic year. These co-localized residents will complete 16-20 weeks of scheduled rotation time on White 9
9853616|NCT03635775|Experimental|Anodal ipsilesional Active tDCS|Anodal tDCS (excitatory) applied to the lesioned hemisphere. Participant must have lesioned hemisphere MEP.
9853617|NCT03635775|Experimental|Cathodal contralesional Active tDCS|Cathodal tDCS (inhibitory) applied to the non-lesioned hemisphere. Participant must have lesioned hemisphere MEP.
9853618|NCT03635775|Experimental|Anodal contralesional Active tDCS|Anodal tDCS (excitatory) applied to the non-lesioned hemisphere. Participant must not have lesioned hemisphere MEP.
9853619|NCT03635775|Sham Comparator|Sham tDCS|Sham tDCS applied in one of the above configurations
10208395|NCT05213117|No Intervention|Normally Schedule Residents|The control arm will consist of 18 PGY-1 residents who are scheduled by the residency program's algorithm in the usual fashion to complete general medicine rotations on 5 difference clinical floors. The 18 active comparator participants will be selected based on completing one of four general medicine rotation on the control floor White 8. These participants will then be followed while completing the remaining general medicine rotations on all clinical floors.
10208396|NCT05213065|Experimental|Treatment Arm|The participants randomized into this arm will receive the SPG block with 0.5% bupivacaine.
10208397|NCT05213065|Placebo Comparator|Placebo Arm|The participants randomized into this arm will receive the SPG block with saline.
10208398|NCT05213052|Experimental|Topical cream, 1 - 2 times daily|Application of a pea-sized amount of cream applied to skin over the area with chronic pain
10208399|NCT05213000|Experimental|Exercise post-immunization|After the mRNA-based COVID-19 vaccine is received (booster dose), a supervised 90 minute light to moderate exercise session will take place.
10208400|NCT05213000|No Intervention|Daily routine as usual (control)|After the mRNA-based COVID-19 vaccine is received (booster dose), participants will be asked to go about their daily routine as usual, but avoid exercise for that day.
10208401|NCT05212987|Experimental|Dose Escalation and Expansion|FCN-098 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
10208402|NCT05212974||Nurses|Adult (≥ 20 and ≤80 years) male and female participants with verification of registered nurse license.
10208403|NCT05212974||General publics|Adult (≥ 20 and ≤80 years) male and female participants with reading abilities above the intermediate level.
9853620|NCT03635957|Experimental|Pegloticase With Methotrexate (MTX)|"Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase.~Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion."
10208404|NCT05212896|Experimental|Dose Escalation: Phase Ia|Participants will receive escalating doses of BC006 at assigned dose (0.08, 0.3, 1.0, 3.0, 10, 20 mg/kg) via intravenous (IV) infusion every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
10208405|NCT05212896|Experimental|Dose Expansion: Phase Ib Cohort 1|Participants with GCTTS will receive BC006 at recommended dose for expansion (RDE) IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 24 weeks of treatment, whichever occurs first.
10208406|NCT05212896|Experimental|Dose Expansion: Phase Ib Cohort 2~4|Participants with other solid tumors will receive BC006 at RDE IV every 2 weeks until disease progression, unacceptable toxicity, withdrawal of informed consent, or up to 48 weeks of treatment, whichever occurs first.
10208407|NCT05212870||Low back and neck pain group with experience of Covid-19|
10208408|NCT05212870||Low back and neck pain group without experience of Covid-19|
10208409|NCT05212818|Experimental|Low Dose of Active Drug|80 patients will be randomly assigned to low dose, take active drug BID.
10208410|NCT05212818|Experimental|Low Dose Placebo Control|80 patients will be randomly assigned to Low dose placebo, take the placebo BID.
10208411|NCT05212818|Experimental|High Dose of Active Drug|160 patients will be randomly assigned to high dose, take the active drug BID.
10208412|NCT05212818|Experimental|High Dose Placebo Control|80 will be randomly assigned to high dose placebo, take the placebo BID.
10208413|NCT05212805|Experimental|Aerobic Exercise Promotion|This group will be submitted to an aerobic exercise program combined with upper-limb motor training.
9853621|NCT03636061|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL
10208414|NCT05212805|Active Comparator|Control|This group will be submitted to a standard motor rehabilitation. No aerobic nor sport activity will be delivered to the Control group.
9853622|NCT03636061|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL
9853623|NCT03636061|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL
9853624|NCT03636061|Placebo Comparator|Placebo|Placebo (vehicle) nasal spray
9853625|NCT03636386|Experimental|Percutaneous microelectrolysis group (MEP)|Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
9853626|NCT03636386|Active Comparator|Ultrasound therapy|Group treated with conventional ultrasound (US) on MTrP with 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
9853627|NCT03636893|Experimental|FLOT Chemotherapy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered~A cycle consists of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via an intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
9853628|NCT03636893|Active Comparator|SOX Chemotherapy regimen|"Three preoperative cycles and three postoperative cycles of SOX chemotherapy administered~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
9853629|NCT03637296|Experimental|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
9853630|NCT03637296|No Intervention|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
9853631|NCT03637348|Other|TrueTear|Use of TrueTear device to stimulate tear production
9853632|NCT03637517|Experimental|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
9853633|NCT03637517|Active Comparator|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
9853634|NCT03637517|Active Comparator|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
9853635|NCT03637699|Other|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
9853636|NCT03637699|Other|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
9853637|NCT03637842|Active Comparator|Lorcaserin XR|Lorcaserin XR 20mg daily
9853638|NCT03637842|Placebo Comparator|Placebo|Placebo Oral Capsule
9853639|NCT03638011|No Intervention|Standard of Care|These participant will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They standard neuraxial anesthesia with neuraxial Duramorph for post-operative pain.
9853640|NCT03638011|Active Comparator|Bilateral TAP Block|These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.
9853641|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
9853642|NCT03638622|Experimental|Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)|Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.
9853643|NCT03638635|Active Comparator|Standard Bupivacaine|Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
9853644|NCT03638635|Experimental|Bupivacaine Liposome|Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
10208415|NCT05212779||Females with Stage II-IV epithelial ovarian cancer|"All patients, as participation requirements in this study, are required to have blood drawn at the completion of their adjuvant treatment. Blood sample should be collected within 6 weeks of receiving the last cycle of adjuvant chemotherapy.~Other optional time points which will be encouraged but not required:~After debulking surgery~Serial draws every 3 months while on maintenance or surveillance."
10208416|NCT05212766||Vaccinated or unvaccinated uninfected South Asian ethnicity|Participants will have not experienced infection (positive test) - we will aim to recruit both vaccinated and unvaccinated individuals although the latter may be harder to recruit. They will identify as of South Asian ethnicity. Uninfected subjects, will be recruited by advertisement within KCL or social media, from non-COVID in-patients or outpatients or attending A&E at GSTT and at SARS-CoV2 antigen testing centres and vaccination centres and at PIC sites.
10213547|NCT03811847|Experimental|Methylphenidate|During this study, participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order.
9853645|NCT03638908|Other|Fluoxetine|"Dosing will be~Week 1-4: 20 mg daily~Week 5-8: 40 mg daily~Week 9-12: 60 mg daily~Week 13-24: 80 mg daily"
9853646|NCT03639675|Experimental|NVG patients|Japanese patients with neovascular glaucoma
9853647|NCT03639766|Experimental|Abobotulinum toxin A|Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.
9853648|NCT03639766|Placebo Comparator|Saline solution|Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.
9853649|NCT03639779|Experimental|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
9853650|NCT03639779|Placebo Comparator|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
9853651|NCT03639857|Experimental|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
9853652|NCT03639857|Experimental|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
9853653|NCT03639857|Active Comparator|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
9853654|NCT03639987|Experimental|Group 1|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
9853655|NCT03639987|Experimental|Group 2|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
9853656|NCT03640052|Placebo Comparator|Placebo|Placebo capsule 1 time before bedtime
9853657|NCT03640052|Active Comparator|LTM1201L|LTM1201L capsule 1 time before bedtime
9853658|NCT03640052|Active Comparator|LTM1201LN|LTM1201LN capsule 1 time before bedtime
9853659|NCT03640052|Active Comparator|LTM1201LB|LTM1201LB capsule 1 time before bedtime
9853660|NCT03640052|Active Comparator|LTM1201LD|LTM1201LD capsule 1 time before bedtime
9853661|NCT03640507|Active Comparator|Chlorhexidine-alcohol|Subjects will receive vaginal preparation with chlorhexidine-alcohol.
9853662|NCT03640507|Active Comparator|Povidine-iodine|Subjects will receive vaginal preparation with povidine-iodine.
9853663|NCT03640507|Placebo Comparator|Saline|Subjects will receive vaginal preparation with sterile saline.
9853664|NCT03640559|Placebo Comparator|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
9853665|NCT03640559|Experimental|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
9853666|NCT03640832|Experimental|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
9853667|NCT03640832|Active Comparator|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
9853668|NCT03641508|Active Comparator|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
9853669|NCT03641508|Active Comparator|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
9853670|NCT03641716|Experimental|Mealtime PREP Intervention|Parents of young children will receive 6 weekly sessions, each lasting approximately one-hour, in the home environment. An occupational therapy clinician will deliver the Mealtime PREP intervention to the family.
9853671|NCT03642262|Experimental|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
9853672|NCT03642262|Active Comparator|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
9853673|NCT03642457|Active Comparator|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
9853674|NCT03642457|Placebo Comparator|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
9853675|NCT03642717||Subjects diagnosed with type 2 diabetes mellitus|
9853676|NCT03642873|Experimental|Treatment A|Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.
9853677|NCT03642873|Experimental|Treatment B|Hydrocodone Bitartrate of 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals administered with 240 mL of room temperature water in the fasted state.
9853678|NCT03642873|Experimental|Treatment C|Hydrocodone Bitartrate 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals and guaifenesin (Humibid®) 1200 mg ER administered with 240 mL of room temperature water in the fasted state.
9853679|NCT03643432|Active Comparator|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
9853680|NCT03643432|Experimental|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
9853681|NCT03643575|Experimental|Treatment A: Vicks Cough Syrup for Chesty Coughs|Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
9853682|NCT03643575|Experimental|Treatment B: Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
9853683|NCT03643575|Experimental|Treatment C: Organ-I- NR tablet|Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
9853684|NCT03643692|Experimental|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
9986383|NCT01402336|Experimental|GnRH antagonist, SD #6 starting group|Start GnRH antagonist from stimulation day 6 during ovulation induction cycles
9853685|NCT03643952|Experimental|Daptomycin|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
9853686|NCT03644095|Experimental|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
9853687|NCT03644095|Active Comparator|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
9853688|NCT03644108|Experimental|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
9853689|NCT03644173|Experimental|Study arm - PREP Intervention|Participants receiving the coaching intervention
9853690|NCT03644212|Active Comparator|Vitamin D treatment|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
9853691|NCT03644212|No Intervention|Non treated|Sixteen vitamin D deficient women (6 with PCOS and 10 without PCOS) were not supplemented vitamin D3. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
9853692|NCT03645421|Placebo Comparator|placebo|Placebo per day,SC injection on 48 days.
9853693|NCT03645421|Experimental|MEDI0382 100μg|50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
9853694|NCT03645421|Experimental|MEDI0382 200μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
9853695|NCT03645421|Experimental|MEDI0382 300μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days
9853696|NCT03645434|Experimental|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
9853697|NCT03645434|Experimental|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
9853698|NCT03645434|Experimental|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
9853699|NCT03645434|Experimental|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
9853700|NCT03645434|Experimental|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
9853701|NCT03645434|Experimental|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
9853702|NCT03645785|Active Comparator|Normal Diet/Drinking|Baseline diet and drinking patterns for patients. This is the pre-intervention baseline for cross-over analysis
9853703|NCT03645785|Experimental|Increased fluid Intake and Citrate Supplementation|Patients will increase fluid (with goal to double their baseline) and further take a citrate supplement in the form of True Lemon (citric acid).
9853704|NCT03645811|Experimental|Implementation of music therapy|"For the music therapy, lecturers specializing in music therapy were consulted and accordingly a mahur maqam, an instrumental piece of traditional Turkish music played on the saz, was chosen. The mahur maqam has a descending scale, which has a relaxing impact as it moves along a 1-2 octave sound spectrum. It elicits feelings of joy and positivity, and immediately draws the attention of the listener, helping keep the mind clear. The mahur maqam belongs to the rast maqam family. Rast maqams are usually evocative of feelings of peacefulness, surrender, tranquility, trust, and mystical sentiments."
9853705|NCT03645811|Experimental|Implementation of EFT|"The EFT application protocol was explained to the students with the help of the image in the picture for 5 minutes. The method was applied through the investigator tapping on their bodies and the students repeating the steps for three sessions. Each of the treatment sessions was approximately three minutes, resulting in a nine-minute treatment for intervention. Each EFT session was performed by following the steps below.~The content of each EFT session was as follows:~Preparation~Tapping Series~The Nine Gamut Sequence and Eye Movements"
9517045|NCT03310008|Experimental|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
9853706|NCT03645811|No Intervention|Control|For the control group, 15 minutes of free time was given.
9853707|NCT03645954|Active Comparator|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
9923673|NCT00852878|Active Comparator|Behavioral|Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements
9986384|NCT01402336|Active Comparator|Conventional GnRH agonist long group|Conventional GnRH agonist long protocol
9853708|NCT03645954|Active Comparator|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
9853709|NCT03646305|Experimental|Verbally repeat body-related thoughts|A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
9853710|NCT03646305|Experimental|Sing negative body-related thoughts|A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
9853711|NCT03646305|No Intervention|Verbally repeat body-unrelated thoughts|"A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds."
9853712|NCT03646305|No Intervention|Sing body-unrelated thoughts|"A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds"
9853713|NCT03646656|Experimental|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
9853714|NCT03646656|Other|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
9853715|NCT03647033|No Intervention|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
9853716|NCT03647033|Experimental|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
9853717|NCT03647046|Experimental|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
9853718|NCT03647267|Active Comparator|Pneumatic Vitreolysis|Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.
9853719|NCT03647267|Placebo Comparator|Observation|Participants randomized to the observation group will receive a sham injection.
9853720|NCT03647475|Experimental|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfilled the inclusion criteria and none of the exclusion criteria were treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal was evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
10208417|NCT05212766||Asymptomatic / mild infected South Asian ethnicity|Participants will have experienced asymptomatic or mild infection (positive test). They will identify as of South Asian ethnicity. Volunteers or subjects attending SARS-CoV2 testing centres who are found to be antigen positive or In-patients who have positive Covid tests and designated as asymptomatic/mild but admitted for non-covid reasons or those attending A&E with COVID but designated as mild/asymptomatic
9853721|NCT03648853|Experimental|intervention|all participants receive the same intervention
9853722|NCT03648879|Experimental|1/Arm 1 - Upper white-light endoscopy and confocal endoscopic microscopy|Upper white-light endoscopy and confocal endoscopic microscopy
9853723|NCT03649412|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).
9853724|NCT03649412|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
9853725|NCT03649477|Placebo Comparator|Placebo|matched placebo during first 8-weeks; prospectively randomized 1:1 to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods
9853726|NCT03649477|Experimental|3.2 mg of LV-101|3.2 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
9853727|NCT03649477|Experimental|9.6 mg of LV-101|9.6 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
9853728|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
9853729|NCT03649750|Experimental|Treatment A: Mucinex® 600 mg (fast)|Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
9853730|NCT03649750|Experimental|Treatment B: Mucinex® 600 mg (fed)|Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
9853731|NCT03649815|Experimental|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
9853732|NCT03649867|Other|Semi-structured interview|Each female patient who attended the Survive & Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
9853733|NCT03649932|Experimental|L-citrulline 100 mg/kg/day|50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.
9853734|NCT03649932|Experimental|L-citrulline 200 mg/kg/day|100 mg/kg given two times a day (200 mg/kg/day) for total 7 days
9853735|NCT03649932|Experimental|L-citrulline 300 mg/kg/day|150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.
9853736|NCT03650192|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
9853737|NCT03650387|Experimental|RADIESSE® (+) Lidocaine|
9853738|NCT03650400|Experimental|Cohort A Fevipiprant 75 mg|QAW039 75 mg Chewable tablet
9853739|NCT03650400|Experimental|Cohort B Feviprant 375 mg|QAW039 375 mg Chewable tablet
9853740|NCT03650452|Placebo Comparator|Placebo|TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
9853741|NCT03650452|Experimental|TAK-935|TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing <60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
9853742|NCT03650842|Experimental|Laparoscopic pyloromyotomy|Infants undergoing laparoscopic pyloromyotomy.
9853743|NCT03651479|Experimental|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
9853744|NCT03651479|Experimental|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
9853745|NCT03651856|Experimental|Atomoxetine|Atomoxetine 40mg daily for 2 weeks uptitration Atomoxetine 40mg BID for 4 weeks Atomoxetine 40mg daily for 1 week weaning off
9853746|NCT03652610|Experimental|GSK3536820A ACWY_Liq Group|Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
9853747|NCT03652610|Active Comparator|ACWY Group|Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).
9853748|NCT03652662|Experimental|RESP-FIT Intervention|"Intervention:~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
9986385|NCT01402362||Ethiopians participating in previous study, year 2000|
9853749|NCT03652662|Active Comparator|RESP-FIT Comparator|"Active Comparator:~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
10208418|NCT05212766||Symptomatic infected South Asian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission). They will identify as of South Asian ethnicity. Patients either seen at GSTT or admitted as in-patients to GSTT or KCH and found to be SARS-CoV2 positive by RT-PCR in nasopharyngeal samples and designated as moderate/severe on the NIH/NIMR COVID severity scale.
10208419|NCT05212766||Infected recovered South Asian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission) and recovered. They will identify as of South Asian ethnicity.
10208420|NCT05212766||Vaccinated or unvaccinated uninfected Caucasian ethnicity|Participants will have not experienced infection (positive test) - we will aim to recruit both vaccinated and unvaccinated individuals although the latter may be harder to recruit. They will identify as of Caucasian ethnicity. Uninfected subjects, will be recruited by advertisement within KCL or social media, from non-COVID in-patients or outpatients or attending A&E at GSTT and at SARS-CoV2 antigen testing centres and vaccination centres and at PIC sites.
9853750|NCT03652675|Experimental|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|
9853751|NCT03652675|No Intervention|Educational control condition|Participant will spend 20 minutes at the clinic, observed by the counselor, reviewing an educational pamphlet on drinking, HIV, and HCV.
9853752|NCT03652818|Experimental|Group A|"Pre-op Placebo 1;~Post-op Placebo 1;~Post-op Placebo 2"
9853753|NCT03652818|Experimental|Group B|"Pre-op Placebo 1;~Post-op Placebo 2;~Post-op acetaminophen."
9853754|NCT03652818|Experimental|Group C|"Pre-op Placebo 1;~Post-op pregabalin;~Post-op Placebo 2."
9853755|NCT03652818|Experimental|Group D|"Pre-op Placebo 1;~Post-op pregabalin~Post-op acetaminophen."
9853756|NCT03652818|Experimental|Group E|"Pre-op pregabalin;~Post-op Placebo 1;~Post-op acetaminophen."
9853757|NCT03653208|Experimental|Group 1 (hzVSF-v13 10mg)|Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.
9853758|NCT03653208|Experimental|Group 2 (hzVSF-v13 20mg)|Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.
9853759|NCT03653208|Experimental|Group 3 (hzVSF-v13 50mg)|Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.
9853760|NCT03653208|Experimental|Group 4 (hzVSF-v13 100mg)|Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.
10208421|NCT05212766||Asymptomatic / mild infected Caucasian ethnicity|Participants will have experienced asymptomatic or mild infection (positive test). They will identify as of Caucasian ethnicity. Volunteers or subjects attending SARS-CoV2 testing centres who are found to be antigen positive or In-patients who have positive Covid tests and designated as asymptomatic/mild but admitted for non-covid reasons or those attending A&E with COVID but designated as mild/asymptomatic
10208422|NCT05212766||Symptomatic infected Caucasian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission). They will identify as of Caucasian ethnicity. Patients either seen at GSTT or admitted as in-patients to GSTT or KCH and found to be SARS-CoV2 positive by RT-PCR in nasopharyngeal samples and designated as moderate/severe on the NIH/NIMR COVID severity scale.
9853761|NCT03653208|Experimental|Group 5 (hzVSF-v13 200mg)|Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.
10208423|NCT05212766||Infected recovered Caucasian ethnicity|Participants will have experienced moderate or severe symptomatic infection (positive test, admission) and recovered. They will identify as of Caucasian ethnicity
10208424|NCT05212714|Experimental|taVNS Treatment|n = 20
10208425|NCT05212714|Sham Comparator|Sham Comparator|n = 10
10208426|NCT05212688|Active Comparator|Acupuncture|
9853762|NCT03653208|Experimental|Group 6 (hzVSF-v13 400mg)|Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.
9853763|NCT03653208|Experimental|Group 7 (hzVSF-v13 800mg)|Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.
9853764|NCT03653208|Experimental|Group 8 (hzVSF-v13 1200mg)|Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.
9853765|NCT03653208|Placebo Comparator|Placebo|Placebo group received a single placebo on Day 1.
9853766|NCT03653351|Sham Comparator|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
9853767|NCT03653351|Active Comparator|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
9853768|NCT03653416|Experimental|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
9853769|NCT03653416|Active Comparator|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
9853770|NCT03653429|Active Comparator|Tranexamic acid group|10mg/kg intravenous tranexamic
9853771|NCT03653429|Placebo Comparator|Normal Saline group|10mg/kg intravenous normal saline
9923674|NCT00852904||NCS Vanguard cohort|Women of child bearing potential, children born to women enrolled in the study, the children s biological and/or social fathers, and primary caregivers (if other than parent)
9923675|NCT00852956|Experimental|Treatment|Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
9923676|NCT00852956|Active Comparator|Control|Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
9923677|NCT00852982|Experimental|Exercise|Five hours of Nordic walking per week, during four months
9923678|NCT00852982|No Intervention|Control|Control group asked not to alter lifestyle during study
9923679|NCT00853034|Active Comparator|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
9923680|NCT00853034|Experimental|AXOS|arabinoxylan-oligosaccharides (AXOS)
9923681|NCT00853086||A|
9923682|NCT00853138|Experimental|CBT|Cognitive-behavioral therapy delivered via the internet in eight treatment modules for children (education, stress and negative emotions, deep breathing and relaxation, distraction, cognitive skills, sleep hygiene and lifestyle, staying active, relapse prevention) and eight treatment modules for parents (education, stress and negative emotions, operant strategies I, operant strategies II, modeling, sleep hygiene and lifestyle, communication, relapse prevention).
9923683|NCT00853138|No Intervention|SMC|The standard medical care wait-list control group continued with the treatment recommendations proscribed by their pain care team.
9923684|NCT00853164|Experimental|aerobic exercise|Subjects who are randomly assigned to this arm will be assigned a walking program to participate in 3 times a week for eight weeks
9923685|NCT00853164|Experimental|resistence training|Subjects who are randomly assigned to this arm will be assigned a weight training program to participate in 3 times a week for eight weeks
9923686|NCT00853164|Active Comparator|Usual Care|Subjects who are randomly assigned to this arm will not participate in any exercise program and will continue with usual care treatment
9923687|NCT00853177|Experimental|nitrous oxide|"N2O of 50% and 50% O2~MEOPA"
9923688|NCT00853177|Active Comparator|lidocaine|Injection solution 1%
9923689|NCT00853190|Experimental|A|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule
9923690|NCT00853190|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
9923691|NCT00853203||Part 1|Interviews + Questionnaire + Electronically Activated Recorder (EAR)
9923692|NCT00853203||Part 2, Expressive Disclosure Group|Group Meetings + Written Materials
9923693|NCT00853203||Part 2, Standard Care Control Group|Written Materials
9923694|NCT00853216|Experimental|A|Oxycodone hydrochloride tablet 30 mg
9923695|NCT00853216|Active Comparator|B|Roxicodone™ tablet 30 mg
9923696|NCT00853255|Experimental|1|Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
9923697|NCT00853268|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
9923698|NCT00853268|Active Comparator|B|OxyContin® 40 mg tablet
9923699|NCT00853281|Experimental|Hammocks with LLIN|Locally-made hammocks covered with long-lasting insecticidal net (LLIN)- Olyset(R), used in addition to the standard vector control measures
9923700|NCT00853281|Active Comparator|ITN|Standard vector control measures (insectice-treated net or ITN)
9923701|NCT00853294|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
9923702|NCT00853294|Experimental|A|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
9923703|NCT00853320|Experimental|A|Oxycodone hydrochloride tablet 15 mg
9923704|NCT00853320|Active Comparator|B|Roxicodone™ tablet 15 mg
9923705|NCT00853346|Experimental|1|Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
9923706|NCT00853346|Active Comparator|2|Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
9923707|NCT00853398|Experimental|Minimal Invasive Surgery,|
9923708|NCT00853398|Active Comparator|Standard Surgical Technique|
9923709|NCT00853424|Active Comparator|M|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
9923710|NCT00853424|Experimental|I|subjects receive an islet cell transplant in addition to all recommended medical treatment for diabetes and diabetic eye disease
9923711|NCT00853450|Experimental|1|AZD6482 on top of ASA
9923712|NCT00853450|Active Comparator|2|Clopidogrel on top of ASA
9923713|NCT00853463|No Intervention|No Alert|The responsible physician of a patient randomized to the control arm will not be contacted regarding the increased VTE risk of the patient.
9986386|NCT01402388|Experimental|Lifestyle intervention group.|
10208427|NCT05212688|Active Comparator|Active Control|
10208428|NCT05212675|Other|short daily dialysis|7 days 2hours dialysis
10208429|NCT05212675|No Intervention|conventional dialysis|3 times weekly 4hours dialysis
10208430|NCT05212662|Experimental|TTI-0102|Cysteamine-pantetheine disulfide (TTI-0102) is supplied in a vial as a powder to be dissolved in water and administered orally.
10208431|NCT05212662|Placebo Comparator|Placebo|Placebo is supplied in a vial as a powder to be dissolved in water and administered orally.
10208432|NCT05212649||More-GDMT|Baseline guideline-directed medications therapy (GDMT), including angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB), beta-blockers, mineralocorticoid receptor antagonist (MRA), and angiotensin receptor neprilysin inhibitor (ARNI) were documented at discharge. More-GDMT group was defined as patient population received GDMT >=2 kinds of above medications.
10208433|NCT05212649||Few-GDMT group|Baseline guideline-directed medications therapy (GDMT), including angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB), beta-blockers, mineralocorticoid receptor antagonist (MRA), and angiotensin receptor neprilysin inhibitor (ARNI) were documented at discharge. Few GDMT-group was defined as patients who received GDMT < 2 kinds of the above medications.
10208434|NCT05212636|Experimental|MDD patient with HRSD score of at least 18|MDD patients who meet the DSM-5 diagnostic criteria of MDD and their current episode show a 17-Item Hamilton Rating Scale for Depression (HRSD) score of at least 18
9853772|NCT03654326|Experimental|Gefapixant|Participants will receive a gefapixant 45 mg tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
9853773|NCT03654326|Placebo Comparator|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
9853774|NCT03654417|Active Comparator|EMLA|
10208435|NCT05212597|Active Comparator|Sacubitril-Valsartan Group|Participant start Sacubitril/Valsartan tablet 50mg twice a day and uptitrate to 100mg twice a day. Participants take the maximum dose considering blood pressure for a total of 48 weeks.
9853775|NCT03654417|Active Comparator|Lidocaine|
9853776|NCT03654560|Active Comparator|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
10208436|NCT05212597|Placebo Comparator|Amlodipine-Losartan group|Participant start amlodipine/losartan 25/2.5mg once a day and uptitrate to 5/100mg once a day. Participants take the maximum dose considering blood pressure for a total of 48 weeks.
10208437|NCT05212584|Experimental|CD7 CAR T cells|Dose escalation phase: CD7 CAR T cells will be transduced with a lentiviral vector to express a CD7 CARs. with an escalation approach, 1 e6 to 7 e6 CAR-T cells/kg
10208438|NCT05212558|Placebo Comparator|Placebo group|This group received a conventional respiratory retraining program plus unloaded (placebo) respiratory muscle training
9853777|NCT03654560|Active Comparator|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
9853778|NCT03655054|Experimental|eCoin Tibial Nerve Stimulation|
9853779|NCT03655080|Experimental|nab-Paclitaxel and Radiation Therapy|"10 fractions of 3Gy radiation therapy will be delivered.~A total of 4 chemoradiation blocks should be delivered ideally in consecutive days~On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)~On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day~There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks"
9853780|NCT03655106|Active Comparator|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
9853781|NCT03655106|Experimental|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
9853782|NCT03655301|Experimental|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
9853783|NCT03655405|Experimental|Individual Deprescribing Intervention|Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
9853784|NCT03655405|No Intervention|Control|Participants allocated to the control group will receive usual care.
9853785|NCT03655444|Experimental|Phase I: Abemaciclib + Nivolumab|"Abemaciclib (150 mg) will be administered orally twice per day (with or without food) on Days 1 through 28 of every 4-week cycle~Nivolumab 480 mg will be given intravenously (IV) over 30 minutes on Day 1 of every 4-week cycle."
9923714|NCT00853463|Other|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
10208439|NCT05212558|Active Comparator|Inspiratory muscle training group|This group received a conventional respiratory retraining program plus inspiratory muscle training only
10208440|NCT05212558|Experimental|Combined training group|This group received a conventional respiratory retraining program plus inspiratory and expiratory muscle training in the same respiratory cycle.
10208441|NCT05212532|Experimental|non-ICU hospitalized|Patients who are hospitalized at study enrollment but are not being treated in the ICU
10208442|NCT05212532|Experimental|ICU hospitalized|Patients who, at study enrollment, are being treated in the hospital ICU
10208443|NCT05212519||25-hydroxyvitamin D3≥30 ng/ml|the patients were categorized as having vitamin D sufficiency if its concentrationis ≥30 ng/m
10208444|NCT05212519||25-hydroxyvitamin D3< 30 ng/ml|insufficiency if levels are <30 but ≥20 ng/ml, deficiency when levels are <20 but ≥10 ng/ml and severe deficiency with levels <10 ng/ml
10208445|NCT05212506||vaccinated and unvaccinated|
9923715|NCT00853502|Active Comparator|testosterone cypionate|
9923716|NCT00853502|No Intervention|bone monitoring|
9923717|NCT00853515|Experimental|1|Goal-directed fluid resuscitation with lactated Ringer's solution
9923718|NCT00853515|Experimental|2|Goal-directed fluid resuscitation with normal saline
9923719|NCT00853515|No Intervention|3|Standard fluid resuscitation with lactated Ringer's solution
9923720|NCT00853515|No Intervention|4|Standard fluid resuscitation with normal saline
9923721|NCT00853528|Experimental|Single-fraction radiosurgery; 16 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 16 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
9935817|NCT03185819|Experimental|Oral Placebo + Esketamine 28 mg|Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
9853786|NCT03655444|Experimental|Phase II: Abemaciclib + Nivolumab|"Phase II Lead-in: Patients will be treated with abemaciclib monotherapy at the recommended phase II dose (150 mg) on Day -7 through Day -1 prior to starting Cycle 1 with the combination of abemaciclib and nivolumab. Patients will proceed directly from Day -1 to Cycle 1 Day 1 of combination abemaciclib + nivolumab, there is not a Day 0.~Patients will be treated with abemaciclib at the RP2D (150 mg) (Days 1 through 28) + nivolumab (480 mg, Day 1) of each 4-week cycle."
9853787|NCT03655951|Experimental|Resource 1|Web-based resource on adolescent sexual health
9853788|NCT03655951|Active Comparator|Resource 2|Alternate web-based resource on adolescent sexual health
9853789|NCT03656939||Prevenar 13 cohort|This is a non-interventional study. Children in the study receive Prevenar 13 per normal medical practice.
9853790|NCT03657095|Experimental|Esuberaprost|Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
9853791|NCT03657095|Placebo Comparator|Placebo/Esuberaprost|Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).
9853792|NCT03657134|Experimental|EP Procedure|Patient will continuously wear the CoVa-2 monitoring system until they are discharged. During this period, data from the sensor will be sent to the Gateway and Cloud-based System, and then analyzed retrospectively.
9853793|NCT03657264|Experimental|Sequence 1|"The sequence of administration is: P/ScD/PC/CD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
9853794|NCT03657264|Experimental|Sequence 2|"The sequence of administration is: CD/PC/ScD/P~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
9853795|NCT03657264|Experimental|Sequence 3|"The sequence of administration is: ScD/CD/P/PC~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
9853796|NCT03657264|Experimental|Sequence 4|"The sequence of administration is: PC/P/CD/ScD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
9853797|NCT03657277|Other|Micropatch Application|This is the only study arm, which all participants complete. Five sites each on each the upper arm, forearm, and abdomen will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, hydration, and skin color will be made. Micropatches will be applied at three sites (at each body location). This only occurs on the first study day. Trans-epidermal water loss and electrical resistance are re-measured immediately after micropatch application. The sites will be covered with a small patch secured with medical tape. One site at each location will just be covered with a patch. The last site will not have micropatch application or patches. Electrical resistance will be re-measured at all sites for 3 days. Measurements from the 4th and 5th sites allow each subject to serve as their own control in data analysis.
9853798|NCT03657407|Active Comparator|B&O|29 women randomized to Belladonna & Opium suppository
9853799|NCT03657407|Sham Comparator|Placebo|27 women randomized to Glycerin suppository
9853800|NCT03658811|Experimental|Upper eyelid meibomian gland dysfunction|Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments
9853801|NCT03658876|Active Comparator|EPO group|
9853802|NCT03658876|Active Comparator|Iron group|
9853803|NCT03658889||Patients under treatment(s) for GCA|Patients at least 50 years old with Giant Cell Arteritis (GCA) and under treatment(s) for GCA
9935818|NCT03181867|Experimental|1/Localized High Risk|18F-DCFPyL PET/CT imaging and possible prostatectomy
9853804|NCT03660787|Placebo Comparator|Placebo, 1.5 mL/kg|each subject received the placebo at the dose of 1.5 mL/kg of body weight;
9853805|NCT03660787|Placebo Comparator|Placebo, 2.4 mL/kg|each subject received the placebo at the dose of 2.4 mL/kg of body weight;
9853806|NCT03660787|Experimental|Seroguard, 1.5 mL/kg|each subject received the test drug at the dose of 1.5 mL/kg of body weight;
9853807|NCT03660787|Experimental|Seroguard, 2.4 mL/kg|each subject received the test drug at the dose of 2.4 mL/kg of body weight.
9853808|NCT03661346|Experimental|Esmolol|Patients receiving esmolol when intra-operative MAP > 80 mmHg.
9853809|NCT03661346|Active Comparator|Labetalol|Patients receiving labetalol when intra-operative MAP > 80 mmHg
9853810|NCT03661541|Experimental|Group A, 6 or more outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months.~Subjects in group A will receive 2% Squaric Acid Dibutyl Ester (SADBE) dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."
9853811|NCT03661541|No Intervention|Group B, 1 or 2 outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
9853812|NCT03661541|No Intervention|Group C, zero outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group C: 12 subjects with zero outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
9853813|NCT03661697|Experimental|Lytera Arm|4 week washout period with skin care regimen including Lytera 2.0 followed by 2 laser treatments.
9853814|NCT03661697|Active Comparator|Laser only arm|4 week washout period with a basic skin care regimen, no Lytera 2.0, followed by 2 laser treatments.
9853815|NCT03661762||Healthy Volunteers|All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
9853816|NCT03661814|Experimental|Prevena|This group will receive the negative pressure wound therapy device.
9853817|NCT03661814|No Intervention|Standard of Care|This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.
9853818|NCT03661983|Experimental|Open Label Stabilization Phase: Aripiprazole|Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.
9853819|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Full Dose|Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for <50 kg participants,and 10 mg or 20 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
9853820|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Half Dose|Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for <50 kg participants, and 5 mg or 10 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
10208446|NCT05212428|Other|Screening (biospecimen collection, genetic analysis)|Participants receive a saliva kit, register with Helix then undergo collection of saliva sample which is returned o Helix. Participants also receive an online link to complete the About Me family history. Once sequencing is completed by Helix, ancestry/trait information and genetic findings are shared with participants and their primary provider, if applicable. Participants with positive results are offered genetic counseling and are encouraged to seek clinical confirmatory testing. Following clinical confirmation, results are scanned into the electronic health record. Participants may also undergo the collection of blood, urine, and stool samples for future studies.
10208447|NCT05212415||Children with CP|Children and adolescents with spastic CP are the group of the observational study.
10208448|NCT05212363|Experimental|Calf Compression|Subjects will wear calf compression garments while video gaming for 2 hours. All subjects will undergo blood flow assessments before and after wearing lower leg graduated compression gear during their gaming session (i.e. compression during uninterrupted sitting).
10208449|NCT05212363|Experimental|6- minute Walk|Subjects will game for 2 hours sitting and take a 6 minute walking break at the one hour period before resuming game play. All subjects will undergo blood flow assessments before and after taking an active break (i.e. 6-minute walk) during their gaming session.
10208450|NCT05212363|No Intervention|Continuous video game play|Subjects will game for 2 hours sitting with no break. All subjects will undergo blood flow assessments without wearing lower leg graduated compression gear or taking an active break during their gaming session (i.e. during uninterrupted sitting).
10208451|NCT05212350|Active Comparator|Pancreatic anastomosis|"Pancreatic anastomosis (PA) will be carried out according to the techniques adopted by the participating Centre, either pancreaticojejunostomy (PJ) (i.e. dunking PJ, Cattel-Warren duct-to-mucosa PJ, Blumgart PJ) or pancreatico-gastrostomy (PG) will be considered eligible. Any mitigation strategy (i.e. ETS, use of glues/biological matrices to protect the anastomosis, surgical feeding jejunostomy, prophylactic hydrocortisone/somatostatin administration) can be used according to the Center practice. The other two anastomosis, hepaticojejunostomy and duodenojejunostomy (in case of Longmire-Traverso pancreatoduodenectomy) or gastrojejunostomy (in case of Kausch-Whipple pancreatoduodenectomy), will be carried out as usual according to each Institution's operative standards.~At least one surgical drain will be placed in the retroperitoneum in all patients."
10208452|NCT05212350|Experimental|Total pancreatectomy|Total pancreatectomy will be carried out according to each Institution's operative standards. Preservation of the spleen will be considered whenever possible according to Kimura technique. Either ligation or preservation of gastric vessels (right/left gastric artery/vein) will be allowed according to clinical necessity but will be recorded and correlated with postoperative outcomes. The reconstruction phase will be carried out according to each Institution's operative standards. One or more surgical drains can be left in place according to surgeon's preference.
10208453|NCT05212337|Active Comparator|Denosumab|Subcutaneous injection with 60 mg Denosumab once
10208454|NCT05212337|Placebo Comparator|Placebo|Subcutaneous injection with NaCl once
10208455|NCT05212324||widening|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
9853821|NCT03661983|Placebo Comparator|Double Blind Phase: Placebo|Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.
9853822|NCT03662074|Experimental|Treatment (gemcitabine, nivolumab)|Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
9853823|NCT03662139||Cerebral Palsy Group|16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
9853824|NCT03662139||Healthy Control Group|16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
10208456|NCT05212285||Early-stage NSCLC with sarcopenia|Patients diagnosed with NSCLC meeting Stage IA-IIIA as well as sarcopenia by the enrollment
10208457|NCT05212285||Early-stage NSCLC without sarcopenia|Patients diagnosed with NSCLC meeting Stage IA-IIIA but without sarcopenia by the enrollment
9853825|NCT03662282|Experimental|Drug - Omegaven®|Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.
9853826|NCT03662334|Experimental|Hylenex recombinant|Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).
9853827|NCT03662334|Sham Comparator|Sham Injection|Comparing the preadministration of a sham injection in the setting of CSII.
9853828|NCT03662360|No Intervention|GROUP A - control group|16 patients who respect the inclusion criteria, treated with psychotropic drugs Pro Re Nata.
9853829|NCT03662360|Experimental|GROUP B - aromatherapy group|16 patients included in the inclusion criteria, treated with psychotropic drugs Pro Re Nata and, in a complementary way, with diffusion aromatherapy
9853830|NCT03662750|Experimental|Acute stroke cohort|Acute stroke cohort
10208458|NCT05212246|Experimental|5% Imiquimod Cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
10208459|NCT05212246|Placebo Comparator|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
9935819|NCT03181867|Experimental|2/biochemical recurrence (bcr)|18F-DCFPyL PET/CT imaging
10208460|NCT05212129|Active Comparator|Treatment Arm A (hEDS)|(n=60) patients who meet criteria for hEDS or Hypermobile Spectrum Disorder (HSD) will receive aVNS (acoustic vagal nerve stimulation) therapy via filtered vocal music sound therapy using the Safe and Sound protocol (randomized 1:1 to active vs sham music; double blind study design)
10208461|NCT05212129|Experimental|Treatment Arm B (ANS Dysfunction)|(n=30) patients with concerns for ANS dysfunction (with or without hEDS) will receive auricular percutaneous vagal nerve stimulation (pVNS) therapy. Additional sub-study option: 15-20 subjects will undergo gastric MRI and (those who consent to it) will also participate in a biobank blood sample collection study.
10208462|NCT05212064|Sham Comparator|Nasal cannula group|Heated and humidified oxygen of 6 L/minute was supplied via an HFNC
10208463|NCT05212064|Experimental|High-flow nasal cannula (HFNC)|Heated and humidified oxygen of 40 L/minute was supplied via an HFNC
10208464|NCT05212051|Experimental|JS005 150 mg|30 patients will be enrolled in this arm.
10208465|NCT05212051|Placebo Comparator|Placebo 150 mg|10 patients will be enrolled in this arm.
10208466|NCT05212051|Experimental|JS005 300 mg|30 patients will be enrolled in this arm.
10208467|NCT05212051|Placebo Comparator|Placebo 300 mg|10 patients will be enrolled in this arm.
10208468|NCT05212051|Experimental|JS005 450 mg|30 patients will be enrolled in this arm.
10208469|NCT05212051|Placebo Comparator|Placebo 450|10 patients will be enrolled in this arm.
10208470|NCT05212038|Experimental|liopsoas plane block group|Arm Description: a iliopsoas plane block before surgery
10208471|NCT05212038|Sham Comparator|sham block group|sham block before surgery
10208472|NCT05212025|Experimental|Adavosertib and Gemcitabine|"Participants will receive:~Adavosertib 1x per day on days 2, 3, 9, 10, 16, and 17 of every 28 day study cycle.~Gemcitabineon on days 1,8, and 15 of every 28-day cycle"
10208473|NCT05211999|Experimental|Precede-Proceed Model Based Simulation Experience|
10208474|NCT05211999|No Intervention|Control Group|
10208475|NCT05211934||The group with delirium|
10208476|NCT05211934||The group without delirium|
10208477|NCT05211921|Other|Multi-Gyn ActiGel Plus|vaginal gel
10208478|NCT05211908|Experimental|D-SE|Absence of dentinal sclerosis and self-etching adhesive protocol
10208479|NCT05211908|Active Comparator|D-SELETIVE|Absence of dentinal sclerosis and selective enamel etching adhesive protocol
10208480|NCT05211908|Experimental|SD-SE|Sclerotic dentin and self-etching adhesive protocol
9853831|NCT03662789|Active Comparator|Iron isomaltoside 1000|"The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment)."
9853832|NCT03662789|Placebo Comparator|Placebo|Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%
9853833|NCT03662997|Active Comparator|Five-layer vs Hydropolymer|Bordered Five-layer Foam Dressing for 2 weeks, followed by Hydropolymer Foam Dressing for 2 weeks.
9853834|NCT03662997|Active Comparator|Hydropolymer vs Five-layer|Hydropolymer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
9853835|NCT03662997|Active Comparator|Five-layer vs Hydrocellular|Bordered Five-layer Foam Dressing for 2 weeks, followed by Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks.
9853836|NCT03662997|Active Comparator|Hydrocellular vs Five-layer|Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
9853837|NCT03663101|Experimental|Pre-Randomization, Run-In period (part A)|Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
9853838|NCT03663101|Experimental|Dysport dose 1 (part B)|Dysport dose 1 as a single-dose, intradermal injection.
9853839|NCT03663101|Experimental|Dysport dose 2 (part B)|Dysport dose 2 as a single-dose, intradermal injection.
9853840|NCT03663101|Experimental|Dysport dose 3 (part B)|Dysport dose 3 as a single-dose, intradermal injection.
9853841|NCT03663101|Placebo Comparator|Placebo (saline solution) (part B)|Placebo single-dose, intradermal injection.
9853842|NCT03663179|Experimental|Active TMS|Participants will receive 20 sessions of active TMS targeting the left DLPFC.
9853843|NCT03663179|Sham Comparator|Sham TMS|Participants will receive 20 sessions of sham TMS over the left DLPFC.
9853844|NCT03663231|Experimental|Biotene|People who present with dry mouth and will receive a single dose of Biotene.
9853845|NCT03663231|Placebo Comparator|Placebo|People who present with dry mouth and will receive a single dose of an alternative agent.
9853846|NCT03663283|Experimental|Liposomal Bupivacaine|Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
9853847|NCT03663283|Active Comparator|Plain Bupivacaine|Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
9853848|NCT03663569||subjects with COPD|
9853849|NCT03663582|Experimental|Teduglutide 0.05 mg|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
9853850|NCT03663816|Experimental|Healthy men and women|Participants will serve as their own control. Balance and gait measures will be collected during an initial visit and after one week of using the experimental foot device
9853851|NCT03664193|Other|Single Arm|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
9853852|NCT03664544|Experimental|Subjects with severe hepatic impairment|HP PK MCI-186
9853853|NCT03664544|Experimental|Subjects with normal hepatic function|NHV PK MCI-186
9853854|NCT03665155|Experimental|89Zr-daratumumab|"Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.~Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II."
9853855|NCT03666026|No Intervention|Standard of care control|Participants in this group will not receive any MyChart influenza vaccination reminders
9853856|NCT03666026|Experimental|1 MyChart R/R|Participants in this group will receive up to 1 influenza reminder recall notice via their MyChart account
9853857|NCT03666026|Experimental|2 MyChart R/R|Participants in this group will receive up to 2 influenza reminder recall notices via their MyChart account
9853858|NCT03666026|Experimental|3 MyChart R/R|Participants in this group will receive up to 3 influenza reminder recall notices via their MyChart account
9853859|NCT03666663|Experimental|Lidocaine|Participants will receive SPG blocks with lidocaine.
9853860|NCT03666663|Experimental|Bupivacaine|Participants will receive SPG blocks with bupivacaine
9853861|NCT03666663|Experimental|Ropivacaine|Participants will receive SPG blocks with ropivacaine
9853862|NCT03666663|Placebo Comparator|Placebo (saline)|Participants will receive SPG blocks with placebo (saline)
9853863|NCT03666858||Neosaldina|Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
9853864|NCT03667053|Experimental|dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
9853865|NCT03667053|Placebo Comparator|placebo|Single fixed dose (s.c.injection) of placebo
9853866|NCT03667053|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
9853867|NCT03667547|Experimental|Raltegravir|Participants will receive a single oral dose of raltegravir 1200 mg (600 mg tablet X 2) in a fasted state on Day 0 and will be followed up to 2 weeks
9853868|NCT03668600|Experimental|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
9853869|NCT03668613|Experimental|secukinumab low dose|secukinumab low dose
9853870|NCT03668613|Experimental|secukinumab high dose|secukinumab high dose
9853871|NCT03669081|Experimental|Toradol and Lyrica|Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
9853872|NCT03669081|Placebo Comparator|Placebo and Standard of Care|Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
9853873|NCT03669354||Cohort SMT|Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT
9853874|NCT03669354||Cohort OAT|Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT
9853875|NCT03669354||Cohort SMTX|Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT
9853876|NCT03669354||Cohort OATX|Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT
9853877|NCT03669549|Experimental|Nevanimibe hydrochloride|Ascending dose level of oral nevanimibe hydrochloride beginning with 500 mg BID up to 2000 mg BID
9853878|NCT03669861|Experimental|Abatacept|To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD
9853879|NCT03670017|Other|Time In Range during OptiScanner Connection|Participants will be connected to the OptiScanner 5000 for up to 72 hours.
9853880|NCT03670030|Experimental|ABI-009|In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.
9853881|NCT03670160|Active Comparator|Phenobarbital|Phenobarbital loading dose 20mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital continued throughout the infants hospitalization.
9853882|NCT03670160|Active Comparator|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be continued to achieve control of NAS symptoms. Clonidine may be weaned after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
9853883|NCT03670264|Experimental|Quitline Incentive|The incentive structure emphasizes engaging with the Quitline Delivered Treatment, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the Quitline, for maintaining involvement in the Quitline program (per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the Way to Health (WTH) platform.
9853884|NCT03670264|Experimental|Tobacco Cessation Incentive|The incentive structure emphasizes quitting regardless of engagement with the Quitline Delivered Treatment (though the Quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, compensation for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the WTH platform.
9853885|NCT03670264|Placebo Comparator|No Financial Incentive|No financial incentive to engage in Quitline Delivered Treatment or report abstinence. Study procedures and reminders are managed through the WTH platform.
9853886|NCT03670537||First trimester pregnant women|
9853887|NCT03670641|Experimental|Insulin and CGM Intervention|10 individuals with newly diagnosed type 2 diabetes will be started on basal (glargine) bolus (lispro) insulin therapy for up to 4 weeks with titrations guided by continuous glucose monitor (Dexcom G6) to achieve euglycemia and then insulin stopped after 4 weeks with hopes of diabetes remission.
9853888|NCT03670810|Experimental|100 milligram (mg) Lasmiditan|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
9853889|NCT03670810|Experimental|200 mg Lasmiditan|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
9935820|NCT03173950|Experimental|1/Experimental Therapy|Patients will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
10208481|NCT05211908|Experimental|SD-SELETIVE|Sclerotic dentin and selective enamel etching adhesive protocol
10208482|NCT05211882|Experimental|Immediate|Participants in the intervention arm will start on the ENABLE program at point of randomization.
9853890|NCT03670810|Placebo Comparator|Control 1 Sequence|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
9853891|NCT03670810|Placebo Comparator|Control 2 Sequence|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
9853892|NCT03670810|Experimental|100 mg Lasmiditan Maximum Extended Enrollment (MEE)|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
9853893|NCT03670810|Experimental|200 mg Lasmiditan MEE|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
10208483|NCT05211882|Experimental|Wait-list (delayed)|Participants on wait-list will start ENABLE 6 months after randomization.
10208484|NCT05211869|Experimental|T1DTehCHW: CHW Intervention|The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, goal-setting, peer support, and social needs management. Over the 6-month study period, session frequency will involve weekly individual sessions during Month 1 (4 sessions - month 1), bi-weekly individual sessions during Months 2-3 (4 sessions - months 2-3), individual sessions during Months 4-6 (3 sessions - months 4-6), and an optional monthly CHW-led peer group support sessions equaling a total of 11 individual CHW sessions and 6 potential group sessions. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institution COVID-19 rules.
9853894|NCT03670810|Placebo Comparator|Control 1 Sequence MEE|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
9853895|NCT03670810|Placebo Comparator|Control 2 Sequence MEE|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
9853896|NCT03672006|Experimental|alteplase|patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)
9853897|NCT03672006|Active Comparator|Heparin|patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)
9853898|NCT03672032|Active Comparator|Fork-tip Needle|
9853899|NCT03672032|Active Comparator|Franseen Needle|
9853900|NCT03672097|Experimental|Prasugrel|Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)
10208485|NCT05211869|No Intervention|Usual Care Control Condition|Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.
10208486|NCT05211843|No Intervention|No drink|Control; Participants will receive no drink
10208487|NCT05211843|Experimental|Drinking water|Intervention drink; Participants will receive 500 ml drinking water from the San Francisco tap (i.e. fluoridated tap water). 500 ml is the standard bottle size.
10208488|NCT05211843|Active Comparator|Apple juice|Intervention drink; Participants will receive 200 ml box of apple juice. 200 ml is the standard serving usually available to this study population in the school setting
10208489|NCT05211830|Experimental|SXR1096 cream|The active treatment will be the specific small molecule inhibitor of KLK5, 7 and 14 in a proprietary skin cream formulation.
10208490|NCT05211830|Placebo Comparator|Placebo cream|The placebo control will be the proprietary skin cream formulation without the active substance.
10208491|NCT05211817|Experimental|Complex Intervention with Carnosine|Obese middle aged individuals will be subjected to 3 month complex lifestyle intervention including exercise (3 times per week) nutritional (weekly consultation) and psychological (monthly) interventions combined with oral administration of carnosine in dose 2g per day.
10208492|NCT05211817|Experimental|Complex Intervention with placebo|Obese middle aged individuals will be subjected to 3 month complex lifestyle intervention including exercise (3 times per week) nutritional (weekly consultation) and psychological (monthly) interventions combined with oral administration of identically looking placebo.
9853901|NCT03672370||Alloclassic® Variall® Cup|Subjects who received the Alloclassic® Variall® Cup Ceramic Bearing System
9853902|NCT03672396|Experimental|Home-based Exercise|The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour.
9853903|NCT03673670|Experimental|1.5 mg RPL554 and tiotropium/olodaterol|1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
9853904|NCT03673670|Experimental|6 mg RPL554 and tiotropium/olodaterol|6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
9853905|NCT03673670|Experimental|Placebo and tiotropium/olodaterol|Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
9853906|NCT03674177|Experimental|RSV MAT formulation 1 Group|Subjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
9853907|NCT03674177|Experimental|RSV MAT formulation 2 Group|Subjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
9853908|NCT03674177|Experimental|RSV MAT formulation 3 Group|Subjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
9853909|NCT03674177|Placebo Comparator|Control Group|Subjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm
9853910|NCT03674281|Experimental|Sensor Augmented Pump (SAP)-Closed-Loop Control (CLC)|"SAP: Subjects will be utilizing their own insulin pumps (without automated insulin delivery) plus Dexcom G6 CGM to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period.~CLC with Control-IQ plus CGM: Following SAP, subjects will be utilizing the Tandem t:slim X2 with Control-IQ along with a Dexcom G6 continuous glucose monitor to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period."
9853911|NCT03674970|Experimental|Random Nicotine Delivery|One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.
9853912|NCT03674970|Active Comparator|Steady State Nicotine Delivery|One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
9853913|NCT03674970|Placebo Comparator|Placebo Control|One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
9853914|NCT03675451|Experimental|Interventional|"Injection of study drug followed by PET/CT imaging.~Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.~Followed by prostatectomy"
9853915|NCT03675581|Experimental|All subjects|
9853916|NCT03675685|Experimental|CCH (Collagenase clostridium histolyticum)|
9853917|NCT03675776|Experimental|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
9853918|NCT03675776|Experimental|Rapastinel 225mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
9853919|NCT03675776|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration).
9853920|NCT03676634|Experimental|Vaccine|rBV A/B
9853921|NCT03676725|Experimental|All subjects|All subjects get the lidocaine taste test
9853922|NCT03676803|Experimental|Mixed spices intervention group|healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
9853923|NCT03676803|Placebo Comparator|placebo group|healthy participants consume placebo capsule containing 5 g of maltodextrin
9853924|NCT03676972|Experimental|LithoVue ureteroscope system|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
9853925|NCT03677089|Experimental|ECHO Cohort|Sites undergo 12 ECHO Autism telehealth clinics. Clusters of two sites each will initiate intervention with 3 months between the start of each cluster.
9853926|NCT03677245|Experimental|Balance Biking|Strider Balance Bike riding for 5 days following the Strider Learn to Ride Curriculum
9853927|NCT03677375|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00026.
9853928|NCT03677401|Experimental|5 mg Serlopitant Tablets|
9853929|NCT03677401|Placebo Comparator|Matching Placebo Tablets|
9853930|NCT03677869|Experimental|Pneumatic vitreolysis (PVL)|Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.
9853931|NCT03678103|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
9853932|NCT03678285|Experimental|HIFRT Workout|Consecutive completion of; 1 mile run, 100 pull ups, 200 push-ups, 300 bodyweight squats, 1 mile run.
9853933|NCT03678311|Other|Sleep Apnea ahi > 5|If Sleep Apnea index is > 5 and diagnosed with Long QT Syndrome
9853934|NCT03678870|Experimental|Education|Opioid Education
9853935|NCT03678870|No Intervention|Control|standard discharge instructions, which lists medications prescribed at discharge
9853936|NCT03679494|Experimental|SDM intervention group|Using shared decision making support tool for intervention
9853937|NCT03679494|No Intervention|Usual care group|No intervention, just continue using usual care
9853938|NCT03679741|Experimental|TEST/CONTROL/CONTROL|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
9853939|NCT03679741|Experimental|CONTROL/TEST/TEST|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
9853940|NCT03679975|Experimental|Subjects with ALS|Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria were administered a single dose of the Riluzole Oral Soluble Film (ROSF) 50 mg.
9853941|NCT03680105|Experimental|Part 1; Cohort 1; RJX or Placebo|Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.
9853942|NCT03680105|Experimental|Part 1; Cohort 2; RJX or Placebo|Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.
9853943|NCT03680105|Experimental|Part 1; Cohort 3; RJX or Placebo|Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.
9853944|NCT03680105|Experimental|Part 1; Cohort 4; RJX or Placebo|Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.
9853945|NCT03680105|Experimental|Part 1; Cohort 5; RJX or Placebo|Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.
9853946|NCT03680105|Experimental|Part 1; Cohort 6; RJX or Placebo|Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.
9853947|NCT03680105|Experimental|Part 2; Cohort 1; RJX or Placebo|"Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.~The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile."
9853948|NCT03680105|Experimental|Part 2; Cohort 2; RJX or Placebo|Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
9853949|NCT03680105|Experimental|Part 2; Cohort 3; RJX or Placebo|Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
9853950|NCT03680521|Experimental|Sitravatinib and nivolumab|Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.
9853951|NCT03680742|Experimental|Treated|All eligible patients who underwent an attempt with the Contour device.
9853952|NCT03681093|Experimental|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily orally
9853953|NCT03681093|Experimental|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily orally
9853954|NCT03681093|Placebo Comparator|Placebo|Placebo once daily orally
9853955|NCT03681119|Experimental|Advanced Demential Patients|
9853956|NCT03681119|Experimental|Hospice IDT Members|
9853957|NCT03681353|Experimental|Reduced Use Condition|This arm includes six weeks of mobile contingency management treatment administered via a smart-phone based application (mobile CM), in which participants are provided monetary reinforcement for reducing cannabis use.
9853958|NCT03681405|Experimental|Group I (eMMB)|Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
9853959|NCT03681405|Active Comparator|Group II (AC)|Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
9853960|NCT03681808|Experimental|Test|Soft Contact Lens
9853961|NCT03681808|Active Comparator|Control|Contact lens
9853962|NCT03681886|Experimental|Primary Implantation (Cohort 1)|Primary implantation with HMIOL through Month 1 visit, followed by study exit. 1 site followed up to Month 12.
9853963|NCT03681886|Experimental|Optic Exchange (Cohort 2)|Subset of Cohort 1 with optic exchange at Month 1 post primary implantation, followed up to Month 1 post optic exchange
9853964|NCT03681951|Experimental|Part 1: Dose Escalation - GSK3145095 monotherapy|In Part 1, advanced or metastatic PDAC will be enrolled. Part 1 will be using escalating doses of GSK3145095 (total daily dose of 100 mg, 200 mg, 400 mg, 800 mg, and 1600 mg) orally as monotherapy for up to 2 years. For each dose level, subjects will receive a single dose of half the total daily dose on Day 1; and as BID (total daily dose divided in two equal doses) starting from Day 2.
9853965|NCT03681951|Experimental|Part 2: Dose Escalation - GSK3145095 + pembrolizumab|In Part 2, subjects with selected solid tumors, including but not limited to, PDAC, NSCLC, TNBC and/or melanoma will be enrolled. Part 2 will be using GSK3145095 combination escalation to start at least one dose level below the highest dose of GSK3145095 shown to be safe in Part 1, orally BID for up to 2 years along with pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) for up to 2 years.
9853966|NCT03681951|Experimental|Part 3: Dose Expansion - GSK3145095 + pembrolizumab|In Part 3, subjects with selected solid tumors will be enrolled. Part 3 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with pembrolizumab 200 mg IV Q3W for up to 2 years.
9853967|NCT03681951|Experimental|Part 4: Dose Expansion - GSK3145095 + anticancer agent|In Part 4, subjects with selected solid tumors will be enrolled. Part 4 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with combination of additional anticancer agents.
9853968|NCT03682107|Experimental|Arm 1 (2 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
9853969|NCT03682107|Experimental|Arm 2 (2 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
9853970|NCT03682107|Experimental|Arm 3 (4 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
9986387|NCT01402414|Active Comparator|NB-UVB|NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
9853971|NCT03682107|Experimental|Arm 4 (4 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
9853972|NCT03682120|Experimental|Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
9853973|NCT03682120|Experimental|Arm 2|7.5 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
9853974|NCT03682120|Experimental|Arm 3|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
9853975|NCT03682120|Experimental|Arm 4|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) unadjuvanted administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=53
9853976|NCT03682302|Experimental|Group 1: 12 to less than 17 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
9853977|NCT03682302|Active Comparator|Group 1: 12 to less than 17 years, undergoing spine surgery, bupivacine|Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.
9853978|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
9853979|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing cardiac surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.
9853980|NCT03682705|Placebo Comparator|ELS placebo/UPA placebo|Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
9853981|NCT03682705|Experimental|UPA 15 mg/ELS 60 mg|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks
9853982|NCT03682705|Experimental|ELS 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
9853983|NCT03682705|Experimental|ELS 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
9853984|NCT03682705|Experimental|ELS 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
9853985|NCT03682705|Experimental|UPA 15 mg/ELS placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks
9853986|NCT03682809|Experimental|Systane Complete|Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
9853987|NCT03682809|No Intervention|No Treatment|Subjects randomized to this group will not receive a treatment.
9853988|NCT03682965|Experimental|Intra-lymphatic allergenic extract|A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
9853989|NCT03682965|Placebo Comparator|Intra-lymphatic placebo|Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
9853990|NCT03683576|Placebo Comparator|Placebo|Placebo once per day (QD) for 24 weeks
9853991|NCT03683576|Experimental|GB001 20 mg|GB001 20 mg QD for 24 weeks
9853992|NCT03683576|Experimental|GB001 40 mg|GB001 40 mg QD for 24 weeks
9853993|NCT03683576|Experimental|GB001 60 mg|GB001 60 mg QD for 24 weeks
9853994|NCT03683719|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
10208493|NCT05211817|Experimental|Without complex intervention with carnosine|Obese middle aged individuals will be subjected to standard clinical procedure without lifestyle interventions. Oral administration of carnosine in dose 2g per day will be provided.
9853995|NCT03683719|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
9853996|NCT03683719|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
9853997|NCT03683719|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
9853998|NCT03683719|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 16 weeks.
9853999|NCT03683758|Experimental|FIFA11+ / Intervention Group|This group will complete the FIFA11+ warm-up three times per week for eight weeks.
9854000|NCT03683758|Active Comparator|Typical Warm-up / Control Group|This group will complete their usual warm-up three times per week for eight weeks
9854001|NCT03683901|Experimental|TENS/t-NMES/No stimulation|TENS stimulation parameters were of a symmetric waveform, a frequency of 100 Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #7) applied for 10 seconds. t-NMES parameters were a symmetric waveform with 2 second ramp-up and 2 second ramp-down, a frequency of 35Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #3). The t-NMES current intensity was set by adjusting the amplitude to yield the strongest contraction of the underlying muscles without initiating pain. Device and electrodes remained in place but no stimulation was delivered over the 10 second interval. Exposed to each stimulation 3 times for each shoulder ROM.
9854002|NCT03684044|Experimental|Baloxavir Marboxil|"Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
9854003|NCT03684044|Placebo Comparator|Placebo|"Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
9854004|NCT03684265|Experimental|Test to Reference|
9854005|NCT03684265|Experimental|Reference to Test|
9854006|NCT03684642|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide subcutaneous (SC) injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.
9854007|NCT03684642|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.
9854008|NCT03684642|Active Comparator|Dulaglutide 1.5 mg|Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.
10208494|NCT05211817|No Intervention|Without complex intervention with placebo|Obese middle aged individuals will be subjected to standard clinical procedure without lifestyle interventions. Oral administration of identically looking placebo will be provided.
9854009|NCT03684928|Active Comparator|Comfilcon A (test)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
9854010|NCT03684928|Active Comparator|Senofilcon C (control)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
9854011|NCT03685344|Experimental|ADCT-402|"Dose escalation phase: Ascending doses of Loncastuximab tesirine will be administered using a traditional 3+3 design. Dose level 1: 90 µg/kg, every 3 weeks (Q3W). Dose level 2: 120 µg/kg, Q3W. Dose level 3: 150 µg/kg, Q3W. Loncastuximab tesirine will be given for 2 doses, 3 weeks apart.~Dose expansion phase: Loncastuximab tesirine will be administered at the recommended dose determined in the dose escalation phase. Durvalumab will also be administered at a dose of 1500 mg once every 4 weeks (Q4W) throughout the dose escalation phase and dose expansion phase."
9854012|NCT03685396|Experimental|Test Group|In the Test Group venous blood sampling was done in order to prepare PRF membranes used to cover the donor site of the connective tissue graft.
9854013|NCT03685396|Active Comparator|Control Group|In Control Group hemostatic agents with oxidized and regenerated cellulosa were used to cover the donor site.
9854014|NCT03685643|Experimental|Intervention - Dating application topic|The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
9986388|NCT01402414|Active Comparator|Bath-PUVA|Phototherapy with UVA irradiation following bathing in psoralen water
10208495|NCT05211791|Active Comparator|Group TEA|insertion of Thoracic epidural anesthesia plus GA with lung isolation using suitable size double lumen tube at level T6
10208496|NCT05211791|Active Comparator|Group ESB|U/S guided erector spinae block anesthesia using 15 ml local anesthesia plus GA with lung isolation using a suitable size double-lumen tube
10208497|NCT05211791|Active Comparator|Group PVB|U/S guided paravertebral block anesthesia using 15 ml local anesthesia as total volume plus GA with lung isolation using suitable size double lumen tube
10208498|NCT05211778|No Intervention|Control Group|This group will continue to receive the routine standard of care during their treatment journey.
10208499|NCT05211778|Experimental|Digital Education Group|In addition to the standard of care, this group will complete an audiovisual digital education module during their postoperative stay in hospital.
9854015|NCT03685643|Placebo Comparator|Control - Health and exercise topic|The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.
9854016|NCT03685968|Experimental|Glidescope AVL|
9854017|NCT03685968|Experimental|King Vision Channeled VL|
9854018|NCT03685968|Experimental|King Vision Non-Channeled (Standard) VL|
9854019|NCT03686033|Experimental|Placebo, E2082 2.5 mg, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between all the treatment periods.
9854020|NCT03686033|Experimental|E2082 2.5 mg, E2082 25 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
9854021|NCT03686033|Experimental|E2082 25 mg, Placebo, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
9854022|NCT03686033|Experimental|Placebo, E2082 25 mg, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
9854023|NCT03686033|Experimental|E2082 2.5 mg, Placebo, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
9854024|NCT03686033|Experimental|E2082 25 mg, E2082 2.5 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
9854025|NCT03686176|Experimental|Virtual Reality Group (Study Group)|In this arm, patients will receive support from child life specialists plus may use virtual reality simulation goggles during a qualifying medical procedure.
9854026|NCT03686176|No Intervention|Active Control Group|In this arm, patients will receive standard of care with child life specialists plus distraction of the child's choosing, during a qualifying medical procedure.
9854027|NCT03686176|No Intervention|External Control (Reference Group)|No virtual reality and no child life specialists; no standardized or formal form of support.
9854028|NCT03687125|Experimental|Tinostamustine 180 mg/m^2|Participants received single dose of tinostamustine 180 milligrams per meter square (mg/m^2) intravenous (IV) injection on Day -1 followed by autologous stem cell transplantation (ASCT) on Day 1.
9854029|NCT03687125|Experimental|Tinostamustine 220 mg/m^2|Participants received single dose of tinostamustine 220 mg/m^2 IV injection on Day -1 followed by ASCT on Day 1.
9854030|NCT03687372|Experimental|A-101|topical solution
9854031|NCT03687372|Other|Vehicle|topical solution
9854032|NCT03687450|Experimental|Intervention (Yoga) Arm|Received a weekly 60-minute yoga-based class over 6 weeks with direction for a 5-10 minute daily home practice.
9854033|NCT03687450|No Intervention|No-treatment Control Arm|Waitlist control-- group received one session of yoga-based class at the completion of the study.
9854034|NCT03687684|Experimental|Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg|TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
9854035|NCT03687684|Experimental|Japanese Cohort 1-B; TAK-831 100 mg + Placebo|TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.
9854036|NCT03687684|Experimental|Japanese Cohort 1-C; Placebo + TAK-831 300 mg|TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
9854037|NCT03687684|Experimental|Japanese Cohort 2; TAK-831 300 mg|TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
9854038|NCT03687684|Experimental|Chinese Cohort 3; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
9854039|NCT03687684|Experimental|Japanese Cohort 4; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
9986389|NCT01402414|Active Comparator|NB-UVB plus salt water baths|Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths
9854040|NCT03687684|Experimental|Japanese Cohort 5; TAK-831|TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
9854041|NCT03687736|Other|AbobotulinumtoxinA|Open-label
9854042|NCT03687827|Experimental|Insulin degludec|Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
9854043|NCT03687827|Active Comparator|Insulin glargine|Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
9854044|NCT03687970|Experimental|Group A: Painful CIPN Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
9854045|NCT03687970|Active Comparator|Group B: Control Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
9854046|NCT03688282|Sham Comparator|Sham Wearable belt|Device will be worn but not turned on for 30 minutes.
9854047|NCT03688282|Experimental|Wearable vibration belt (30)|Device will be worn and turned on for 30 minute treatment.
9854048|NCT03688542|Experimental|Intervention|Nursing Homes allocated to the Intervention arm will enact the Quality Circle Deprescribing Module and create a local deprescribing consensus and implementation strategy.
9854049|NCT03688542|No Intervention|Control|Nursing Homes allocated to the Control arm will not enact the intervention.
9854050|NCT03688620|Other|Vaccinated_AlphaRix Tetra Group|Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.
9854051|NCT03688620|Other|Vaccinated_Influsplit Tetra Group|Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.
9986390|NCT01402440|Experimental|AEB071|
9986391|NCT01402453|No Intervention|Control Subjects|Receive educational materials and a home BP monitor.
9854052|NCT03688620|Other|Vaccinated_Fluarix Tetra Group|Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.
9854053|NCT03688685|Experimental|Open-label study of CAD-1883|Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET
9854054|NCT03688711|Experimental|Dasiglucagon|single fixed dose (subcutaneous injection) of dasiglucagon
9854055|NCT03688711|Placebo Comparator|Placebo|single fixed dose (subcutaneous injection) of placebo
9854056|NCT03688880|Active Comparator|Dermabond Advanced|Dermabond Advanced (a topical skin adhesive) was applied on Day 0. Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions; the wound was held for 60 seconds to allow for complete polymerization.
9854057|NCT03688880|Experimental|MAR-CUTIS|MAR-CUTIS (polyurethane-based skin adhesive) was applied on Day 0. MAR-CUTIS was applied in 1 to 2 millimeter (mm) thick layer ensuring that at least 1 cm of the glue is applied over the length of the wound on each side; the wound was held for approximately 30 seconds to allow for initial polymerization.
9854058|NCT03689452|Placebo Comparator|Control|15 participants will receive 3 mL of preservative free normal saline injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
9854059|NCT03689452|Experimental|Treatment|15 participants will receive 3-6 mL of platelet rich plasma injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
9854060|NCT03689504|Active Comparator|Standard of Care|The standard of care is an intensive individualized home-based nutrition education program, together with a home food ration and micronutrient supplement, delivered by frontline workers for 6 months.
9854061|NCT03689504|Experimental|Home Garden Intervention|This arm adds an 8 month individualized home-based family garden intervention to the existing standard of care (home-based nutrition education)
9854062|NCT03690375|Experimental|BBL Left|Left arm selected to be treated with BBL, right arm not treated
9854063|NCT03690375|Experimental|BBL Right|Right arm selected to be treated with BBL, left arm not treated
9854064|NCT03691779|Experimental|Part A: ELX/TEZ/IVA|Participants in Part A received ELX 100 milligrams (mg) once daily (qd)/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) in the treatment period for 15 days.
9854065|NCT03691779|Experimental|Part B: ELX/TEZ/IVA|Participants in Part B weighing less than (<) 30 kilograms (kg) at Day 1 received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h and participants weighing greater than equals to (>=) 30 kg at Day 1 received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
9854066|NCT03691831|Active Comparator|Active|A-101 45% (Topical solution, hydrogen peroxide 45%)
9854067|NCT03691831|Placebo Comparator|Vehicle|Topical solution, isopropyl alcohol and water
9854068|NCT03691844|Experimental|AMZ001 + Placebo|on the target knee
9854069|NCT03691844|Experimental|AMZ001|on the target knee
9854070|NCT03691844|Placebo Comparator|Placebo|on the target knee
9854071|NCT03691844|Active Comparator|Comparator|Diclofenac gel on the target knee
9854072|NCT03691948|Experimental|ROPEs|
9854073|NCT03691948|Active Comparator|Control|
9854074|NCT03692676||Subjects with Asthma|Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC
9854075|NCT03693625|Experimental|Parent Study: GDC-0853|Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
9854076|NCT03693625|Placebo Comparator|Parent Study: Placebo|Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
9854077|NCT03693742|Experimental|18F-DCFPyL PET/CT scan with MSG drink|Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
9854078|NCT03693742|Placebo Comparator|18F-DCFPyL PET/CT scan with placebo drink|Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.
9854079|NCT03693950|Experimental|BCD-066 1 µg/kg|Healthy volunteers will receive BCD-066 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
9854080|NCT03693950|Active Comparator|Aranesp 1 µg/kg|Healthy volunteers will receive Aranesp 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
9854081|NCT03693989|Experimental|PRO-145.|Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
9854082|NCT03693989|Active Comparator|Prednefrin|Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
9854083|NCT03694197|Experimental|Open label|
9854084|NCT03694210|Experimental|EndoRotor Therapy|Physicians will perform direct endoscopic necrosectomy using the EndoRotor in patients with walled off necrosis.
9854085|NCT03694275|Experimental|Soticlestat Dup 15q|Soticlestat tablets twice daily (BID) orally or via gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, BID. Participants with Dup 15q weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
9854086|NCT03694275|Experimental|Soticlestat CDD|Soticlestat tablets BID orally or via G-tube/ PEG tube, BID. Participants with CDD weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
9854087|NCT03694548|Other|Part A Survey: Group 1 Adolescent Patients with SCD|Adolescent patients with SCD and chronic pain completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
9854088|NCT03694548|Other|Part A Survey: Group 2 Parents of Adolescent Patients with SCD in Part A|Parents of adolescent patients with SCD and chronic pain from Group 1 completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
9854089|NCT03694548|Experimental|Part B Yoga Program|Participants from Part A Group 1 had the opportunity to enroll in Part B to receive eight in-person instructor-led group yoga sessions.
9854090|NCT03694613|Other|Placental/Umbilical Cord Blood sample|Placental/Umbilical Cord Blood sample will be collected after delivery from every participant.
9854091|NCT03694925||Primary total knee arthroplasty|Primary TKA patients included in the study, to provide a baseline level for calprotectin.
9854092|NCT03694925||Aseptic revision total knee arthroplasty|Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
9854093|NCT03694925||Revision septic total knee arthroplasty|Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
9854094|NCT03695094|Experimental|Cohort 1|Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
9854095|NCT03695094|Experimental|Cohort 2|Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
9854096|NCT03695367|Experimental|Cohort 1: HTX-011 + MMA Regimen|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen.
9854097|NCT03695367|Experimental|Cohort 2: HTX-011 + MMA Regimen + Ketorolac|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac.
9854098|NCT03695393|Experimental|Intervention- ACT Therapy|Participants randomized to this group will receive three ACT sessions over 1 month
9854099|NCT03695393|No Intervention|Standard of Care|Participants in the control group will receive standard care as normally provided to patients by civil society organizations.
9854100|NCT03695913|Experimental|Normal Diet + CGM then low carb + CGM|"Phase I (part 1) - regular diet:~Patients will wear a CGM sensor (with no real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings.~Phase II (part 2) - low carb diet:~Patients will wear a CGM sensor (with real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings; document their blood sugar before and two hours after eating (as well as before breakfast and before going to bed)."
9854101|NCT03696108|Experimental|Gefapixant 15 mg BID|Participants will receive gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg twice daily (BID) during the study period (52 weeks).
9854102|NCT03696108|Experimental|Gefapixant 45 mg BID|Participants will receive gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the study period (52 weeks).
9854103|NCT03696342|Experimental|PRO-157|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
9854104|NCT03696342|Active Comparator|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
9854105|NCT03696576|Active Comparator|PhoRTE|This group will undergo standard PhoRTE therapy.
9854106|NCT03696576|Experimental|PhoRTE + EMST|This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.
9854107|NCT03696758|Experimental|Sildenafil followed by Metoprolol|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
9854108|NCT03696758|Experimental|Metoprolol followed by Sildenafil|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
9854109|NCT03697083|Experimental|Reminders Through Association Arm|participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
9854110|NCT03697083|Active Comparator|Active Control Arm|Participants will be asked to think about where they will store their prescription.
9854111|NCT03697083|Active Comparator|Baseline Control Arm|Participants are thanked for enrolling in the reminder program.
9854112|NCT03697122|Experimental|HHBC and Forced Air Warming|Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
9854113|NCT03697252|Experimental|KarXT|
9854114|NCT03697252|Placebo Comparator|Placebo|
9854115|NCT03697460|Experimental|INCB018424|INCB018424 Cream
9854116|NCT03697993|Experimental|Strategy 1|Fosfomycin 3 g orally once daily for 5-7 days as initial or step-down oral therapy for complicated urinary tract infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy. N=317
9854117|NCT03697993|Experimental|Strategy 2|Levofloxacin 750 mg orally once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therap, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.y. N=317
9854118|NCT03698331|Experimental|Valbenazine|Valbenazine or placebo oral capsules administered once daily for 7 weeks.
9854119|NCT03698331|Placebo Comparator|Placebo|Placebo oral capsules administered once daily for 7 weeks.
9935821|NCT03173937|Experimental|1|Omidubicel (formerly Nicord (Registered Trademark) and Cordin (TM)) is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
9935822|NCT03173924|Experimental|1/Experimental intervention|18F-DCFPyL is administered to cohorts
10208500|NCT05211713|Experimental|Intervention group receiving Opp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
10208501|NCT05211713|No Intervention|Control group|The waiting list control group will receive the intervention after study completion.
10208502|NCT05211674||COPD patients|
10208503|NCT05211674||Healthy controls|
10208504|NCT05211661||Invasively ventilated patients (n=15)|"First measurement (comprehensive protocol) within 48 hours from initiation of MV.~Serial measurements every third day including 2 measurements after extubation."
10208505|NCT05211622|Experimental|Group I, OZOCLO|"• Group I, OZOCLO~alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks~chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks"
10208506|NCT05211622|Placebo Comparator|Group II, OBC|• Group II, OBC Sodium bicarbonate 5% solution - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 3 weeks
10208507|NCT05211622|Active Comparator|Group III, CHX|• Group III, CHX Chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks
10208508|NCT05211622|Active Comparator|Group IV, AAL-OZ|"• Group IV, AAL-OZ~alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks"
10208509|NCT05211583||subfertile women|Subfertile women with regular menses (menstrual cycle length range from 21 to 35 days) will be examined by transvaginal ultrasonography at menstruation, before the anticipated date of ovulation and after ovulation. Serum hormone levels will be measured at menstruation, before ovulation and after ovulation with a serial manner.
10208510|NCT05211557|Experimental|fhB7H3.CAR-T cells|In phase I study, 9 enrolled patients diagnosed with advanced ovarian cancer will receive one-time infusion of fhB7H3.CAR-Ts at the doses of 1×10^6/kg, 3×10^6/kg and 5×10^6/kg, 3 patients for each dose. To further confirm the therapeutic efficacy, in phase II study, 6 enrolled patients will receive an optimal dose (balancing effectiveness and toxicity) of fhB7H3.CAR-Ts. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
10208511|NCT05211544|Active Comparator|intervention group 1|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
9854120|NCT03698591|Experimental|Transcranial magnetic stimulation (TMS), then Sham TMS.|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes after stimulation, experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
9854121|NCT03698591|Sham Comparator|Sham TMS, then Transcranial magnetic stimulation (TMS)|Experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject. Experimenters have defined the target coordinates for the stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes post sham stimulation, experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates.
9854122|NCT03699124|Active Comparator|GP 1: two doses of FD MVA-BN--Lot 1|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 1
9854123|NCT03699124|Active Comparator|GP 2: two doses of FD MVA-BN--Lot 2|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 2
9854124|NCT03699124|Active Comparator|GP 3: two doses of FD MVA-BN--Lot 3|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 3
9854125|NCT03700320|Active Comparator|Oral SOC Migraine Preventive Medication|Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
9854126|NCT03700320|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet taken orally, once daily for 52 weeks.
9854127|NCT03700372|Experimental|IOWA Approach Cardiac Ablation|Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.
10208512|NCT05211544|Active Comparator|intervention group 2|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
10208513|NCT05211544|Active Comparator|control group|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
10208514|NCT05211518|Other|Tasty&Healthy|Tasty&Healthy intervention: subjects will receive dietary advice to exclude pro-inflammatory dietary components
9854128|NCT03700385|Experimental|IOWA Approach Endocardial Ablation|Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.
9854129|NCT03700671|Experimental|High intensity interval training|HIIT was set at > 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
9854130|NCT03700671|Active Comparator|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.
9854131|NCT03700736|Active Comparator|Facebook|"Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via a private (secret) Facebook group. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. A study counselor will facilitate discussions about the topics posted in the Facebook group. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to download the MyFitnessPal app to track daily diet."
9854132|NCT03700736|Active Comparator|Traditional|Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
10208515|NCT05211518|Other|Habitual diet|Habitual diet: subjects will continue their habitual diet.
10208516|NCT05211492|Other|Chronic pain|
10208517|NCT05211492|Other|Acute pain|
10208518|NCT05211492|Other|Control group|
10208519|NCT05211479|Experimental|intervention group|Tele-nursing will be applied to adolescents in this group for 24 weeks. Weekly meeting and blood glucose monitoring will be done. The HbA1c value will be checked and the scales will be filled by meeting 3 times in total with 3 months intervals.
10208520|NCT05211479|No Intervention|Control Group|This group will be given face-to-face training only in the first encounter. During the research, no interviews will be provided through tele nursing. Only at the 3rd and 6th months will be interviewed to measure the HbA1c value and to fill the scales.
9854133|NCT03700892|Experimental|Cinnamaldehyde, then PG/VG|Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
9854134|NCT03700892|Experimental|PG/VG, then Cinnamaldehyde|Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
9854135|NCT03700892|No Intervention|Healthy Controls|Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.
9854136|NCT03701061|Experimental|Participants that received AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
9854137|NCT03701061|Active Comparator|Participants that did not receive AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
9854138|NCT03701074|Experimental|ibuprofen and acetaminophen arm (intervention arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
9854139|NCT03701074|Active Comparator|ibuprofen and placebo arm (control arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.
9854140|NCT03702010|Active Comparator|CME branch|In this study, the conventional spinal cord stimulation method (control Branch-CME branch)
10208521|NCT05211466||Depressive disorder, major|Patients with major depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
9854141|NCT03702010|Experimental|EME branch|In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)
9854142|NCT03702166|Other|Interventional CPT|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) for the alleviation of PTSD and tinnitus-related distress among individuals with co-morbid PTSD and tinnitus.
9854143|NCT03702608|Other|EluNIR 38mm|
9854144|NCT03703336|Experimental|ROTAVIN Liquid Formulation|Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
9854145|NCT03703336|Active Comparator|ROTAVIN-M1 Frozen Formulation|Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
9854146|NCT03703466|Experimental|200 mg Abemaciclib With a Meal|200 mg abemaciclib given twice a day (BID) orally with a meal.
9854147|NCT03703466|Experimental|200 mg Abemaciclib Without a Meal|200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
9854148|NCT03703466|Experimental|200 mg Abemaciclib Without Regard to Food|200 mg abemaciclib given twice a day (BID) orally without regard for food.
9854149|NCT03703817||tofacitinib citrate users|patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
9854150|NCT03703817||adalimumab users|patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
9854151|NCT03704194|Experimental|Adapted LiFE|Participants in the Adapted LiFE group learns to imbed 19 exercise activities (7 balance and 12 lower extremity muscle strength activities) into daily routines. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
9854152|NCT03704194|Sham Comparator|Attention control|Participants in the attention control group will learn gentle stretch exercise. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
10208522|NCT05211466||Depressive disorder, bipolar|Patients with bipolar depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
10208523|NCT05211466||Depressive disorder, recurring|Patients with recurring depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
10208524|NCT05211466||Digital care staff|Staff working most of their time (20% or more) with the digital healthcare platform.
10208525|NCT05211466||Traditional care staff|Staff working traditionally, using the digital healthcare platform to a very little extent.
10208526|NCT05211453|Active Comparator|Right sided atrioventricular node ablation|Right sided atrioventricular node ablation
10208527|NCT05211453|Active Comparator|Left sided atrioventricular node ablation|Left sided atrioventricular node ablation
10208528|NCT05211440|Placebo Comparator|Placebo (Maltodextrin)|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days.
10208529|NCT05211440|Experimental|BC-006|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days.
10208530|NCT05211427|Experimental|Patients|Patients with oropharynx cancer
10208531|NCT05211427|Experimental|Healthy subjects|Patients with non malignant pharynx pathology
10208532|NCT05211401|Experimental|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera®) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
10208533|NCT05211401|Experimental|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera®) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera®) in 400 ml of NaCl 0.9%.
9794267|NCT01500278|Active Comparator|ADA + MTX followed by CZP + MTX|Those subjects who received Adalimumab (40 mg + Placebo at Weeks 0, 2, 4 followed by 40 mg ADA every two weeks) + Methotrexate (ADA+ MTX) at Baseline and are Non-Responders at Week 12, switch to Certolizumab Pegol (400 mg at Weeks 12, 14, 16 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) after Week 12.
9794268|NCT01500317|Active Comparator|Tapentadol|75 mg tapentadol tid
9794269|NCT01500317|Active Comparator|Oxycodone|5 mg oxycodone tid
9794270|NCT01500317|Placebo Comparator|Placebo|Placebo tid
9794271|NCT01500382|Experimental|Vibegron 100 mg + tolterodine ER 4 mg → placebo|During Treatment Period 1, participants will receive 7 days of once-daily vibegron 100 mg and tolterodine extended-release (ER) 4 mg. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER.
9794272|NCT01500382|Experimental|Placebo → vibegron 100 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 100 mg and placebo to match tolterodine ER.
9794273|NCT01500382|Active Comparator|Placebo → tolterodine ER 4 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily tolterodine 4 mg and placebo to match vibegron.
9794274|NCT01500382|Experimental|Placebo → vibegron 50 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 50 mg and placebo to match tolterodine ER.
9794275|NCT01500434|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
9794276|NCT01500525||asthmatic children|children diagnosed by a specialist as asthmatic patients
9794277|NCT01500525||non-asthmatic children|children who are healthy and who do not have respiratory syndrom
9794278|NCT01500629|Experimental|C-1266-7|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-7. After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-6 (placebo).
9794279|NCT01500629|Experimental|Placebo|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-6 (placebo). After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-7.
9800466|NCT01688609|Experimental|Treatment (lapatinib, trastuzumab, paclitaxel, surgery)|"Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.~Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30 minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy or mastectomy."
9800467|NCT01688635|Experimental|LY2963016|Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
9800468|NCT01688635|Experimental|US-approved Lantus|Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
9800469|NCT01688726|Experimental|SYSTANE BALANCE|SYSTANE® BALANCE eyedrops, 1 drop 4 times a day for a continuous period of 1 month
9800470|NCT01688726|Active Comparator|Minims Saline|Minims® Saline 0.9% eyedrops, 1 drop 4 times a day for a continuous period of 1 month
9800471|NCT01688739|Experimental|Erenumab|Participants received a single dose of erenumab by subcutaneous injection at doses of 1 mg, 7 mg, 21 mg, 70 mg, 140 mg, and 210 mg or by IV injection at a dose of 140 mg.
9800472|NCT01688739|Placebo Comparator|Placebo|Participants received a single dose of matching placebo administered by SC or IV injection.
10208534|NCT05211401|Placebo Comparator|Placebo arm|1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
9794280|NCT01500694|Experimental|Extended-release Guanfacine HCl|
9794281|NCT01500720|Experimental|Cabazitaxel|
9794282|NCT01500720|Active Comparator|Topotecan|
9794283|NCT01500746|Experimental|Lavage arm|This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
9794284|NCT01500746|Active Comparator|Moist dressings|This group will serve as the control group. They will undergo twice daily dressing changes with moist gauze dressings for a total of 4 days (8 dressing changes). Bacterial counts and gene expression analysis will be performed prior to the first dressing change and after the last dressing change.
9794285|NCT01501110|Active Comparator|n-acetylcysteine|intra-venous infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours.
9794286|NCT01501110|No Intervention|no intervention|No intervention
9794287|NCT01501162|Placebo Comparator|alcohol, hepatitis, Placebo|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
9794288|NCT01501162|Active Comparator|hepatitis, alcohol, probiotics|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
9794289|NCT01501929|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
9794290|NCT01501929|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
9794291|NCT01502033|Experimental|Transcranial Magnetic Stimulation|Open-label course of 30 daily treatments with repetitive transcranial magnetic stimulation (rTMS) at 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
9794292|NCT01502072|Experimental|Inhaled Ribavirin|Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.
9794293|NCT01502072|Experimental|Oral Ribavirin|Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.
9794294|NCT01502072|No Intervention|No Ribavirin|Group 3: No Ribavirin treatment.
9794295|NCT01502228|Experimental|62Cu-ETS PET assessment|CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
9794296|NCT01502293|Experimental|Main Study: tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 3-month intervals until disease progression or unacceptable toxicity for up to 5 cycles.
9794297|NCT01502293|Experimental|Addendum: Regimen A tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 8, and 15) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 9 cycles.
9794298|NCT01502293|Experimental|Addendum: Regimen B tavo EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 2 cycles.
9794299|NCT01502306|Experimental|Telephone counseling|One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling begins immediately after intake, if the client is available for a 30-minute session or by appointment at the clients' convenience. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls. The follow-up calls (about 10 minutes) will be scheduled as follows: a reminder call if the quit date is more than one week out for the initial counseling, on the quit date, 4-7 days after the quit date, and 10-14 days after the quit date.
9794300|NCT01502306|Experimental|Phone counseling & nicotine patches|"One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients the day after the screening intake. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day."
9800473|NCT01688830|Experimental|BI 655075|
9800474|NCT01688830|Placebo Comparator|Placebo|
9800475|NCT01688830|Experimental|BI 655075 with dabigatran|
9800476|NCT01688843|Experimental|INGEVITY lead|INGEVITY lead implant
9854153|NCT03704376|Active Comparator|Femoral Nerve Blockade|Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation.
9854154|NCT03704376|Active Comparator|Adductor Canal Blockade|Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ).
9854155|NCT03704467|Experimental|Part A: Carboplatin + M6620 + Avelumab|
9854156|NCT03705273|Experimental|Dexamethasone IV for PO|Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
9854157|NCT03705273|Active Comparator|Dexamethasone crushed tablets|Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally
10208535|NCT05211388|Experimental|arm 1: generator-controlled RFA|In up to 6 patients (arm 1: generator-controlled RFA), RFA will be performed directly following manufacturer-specified algorithms, with recording of 3D ultrasound echo decorrelation images during ablation.
10208536|NCT05211388|Experimental|arm 2: imaging-controlled RFA|In up to 6 additional patients (arm 2: imaging-controlled RFA), real-time, 3D echo decorrelation imaging during ablation will provide an additional treatment end point.
10208537|NCT05211375|Active Comparator|SG group|Patients undergoing sleeve gastrectomy
9854158|NCT03705481|Other|Remote treatment of PCI.|5 sequential subjects presenting for remote PCI who have signed informed consent.
9854159|NCT03705494|Active Comparator|Home-based peer counselling intervention|Women planning to breastfeed who meet the study's inclusion criteria
9854160|NCT03705494|No Intervention|Standard usual care|Women planning to breastfeed who meet the study's inclusion criteria
9854161|NCT03705793|Experimental|Mometasone Furoate Nasal Irrigation|The study intervention will be mometasone furoate powder (1.2 mg/capsule) and placebo nasal spray. The placebo nasal spray will contain the same inert ingredients found in MF nasal spray: glycerin, microcrystalline cellulose and carboxymethylcellulose, sodium citrate, citric acid, benzalkonium chloride, and polysorbate 80. The placebo nasal spray will be packaged identically to the mometasone nasal spray. Participants will be required to dissolve the contents of two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
10208538|NCT05211375|Experimental|DJB group|Patients undergoing duodenojejunal bypass with sleeve gastrectomy
10208539|NCT05211297||Exposed cohort:|Children whose mothers suffered a suspected preterm labour during pregnancy.
10208540|NCT05211297||Unexposed cohort|Children born at term (> 37 weeks) whose mothers did not suffer a suspected preterm labour during pregnancy.
10208541|NCT05211271|Experimental|Intervention Arm|Treatment of cervical neoplasia by thermal ablation
10208542|NCT05211258|Experimental|a novel portable upper gastrointestinal endoscopy system|
9854162|NCT03705793|Active Comparator|Mometasone Nasal Spray|The study intervention will be mometasone nasal spray (50 mcg/spray) and placebo nasal irrigation. The placebo will contain lactose monohydrate and will be supplied in capsules identical to the budesonide capsules. Participants will be required to dissolve the contents of the two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
9854163|NCT03706040|Placebo Comparator|Placebo|Participants randomized to receive placebo for 16 weeks in Period A followed by either risankizumab 150 mg or risankizumab 300 mg for 36 weeks in Period B.
9854164|NCT03706040|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg for 16 weeks in Period A followed by risankizumab 150 mg for 36 weeks in Period B.
10208543|NCT05211245|Experimental|Pulse mode|Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central & peripheral sensitization. The non-thermal effect of US can be explain by frequency resonance theory which states that the proteins in these structures absorbs mechanical energy thus altering the structure & function, finally resulting in stimulation of phagocytosis, increase number of free radicals, increase cell membrane permeability, cellular proliferation &acceleration of fibrinolysis
10208544|NCT05211245|Active Comparator|Continous mode|Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons & joint capsules, thus leading to decrease in the pain & muscle spasm, stiffness of the joint & temporary increase in the blood flow.
10208545|NCT05211219|Experimental|Probiotics|The probiotics group was advised to consume a chewable tablet once a day in 14 days.
10208546|NCT05211219|Experimental|Kefir|The kefir group was advised to consume kefir as a liquid once a day in 14 days.
10208547|NCT05211219|Other|Control|the control group was advised without additional food supplements.
10208548|NCT05211206||Aggressive hydration|Patients with greater than or equal to 2 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
10208549|NCT05211206||Conservative hydration|Patients with less than 1 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
10208550|NCT05211180|Active Comparator|Vida Sana|Vida Sana is a cultural-adaption of Group Lifestyle Balance, a 12-month intervention that targets at least 5% weight loss and at least150 minutes per week of moderate-to-vigorous physical activity. Health coaches will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
10213548|NCT03811847|Placebo Comparator|Placebo|During this study the participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order. Placebo is being used in this study to compare to see if any improvements in cognition other areas are due to the study drug or due to other reasons.
9854165|NCT03706040|Experimental|Risankizumab 300 mg|Participants randomized to receive risankizumab 300 mg for 16 weeks in Period A followed by risankizumab 300 mg for 36 weeks in Period B.
9854166|NCT03706313|Active Comparator|Genicular nerve block with bupivacaine|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
9854167|NCT03706313|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
9854168|NCT03706456|Experimental|Darvadstrocel 24 mL|Darvadstrocel (Cx601) 24 mL suspension of 120 million cells of expanded allogeneic adipose-derived stem cells (eASC) as an intralesional injection, once on Day 1.
9854169|NCT03706469|Experimental|Fasted (T2 50 mg+T3 50 mg+T3 600 mg+T2 600 mg)+Fed (T3 600 mg)|TAK-831 T2 50 milligram (mg), tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
9923722|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 21 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 21 Gray
10208551|NCT05211180|Experimental|Vida Sana y Completa|Vida Sana y Completa is an obesity intervention with integrated treatment for food insecurity. This arm includes all the activities described for the active comparator arm (Vida Sana) as well as a weekly food box delivery for the first 12 weeks of the intervention. The food box will contain approximately 40 pounds of food including proteins and dairy, whole grains, and produce. Just like the Vida Sana active comparator arm, the Vida Sana y Completa group will include health coaches who will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
10208552|NCT05211167|Active Comparator|Group A|Intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
10208553|NCT05211167|Experimental|Group B|Intravenous administration,50μg, once every two weeks, for 32 weeks
10208554|NCT05211141||Patient with knee arthroplasty|patient with HLS KneeTec Deep Dish prosthesis
10208555|NCT05211128||Radical prostatectomies|
10208556|NCT05211128||Total hysterectomies|
10208557|NCT05211128||Thoracic lobectomies|
10208558|NCT05211128||Partial nephrectomies|
10208559|NCT05211115|Experimental|Split thickness flap + Volume stable collagen matrix|A split thickness flap will be raised with a micro-blade, keeping a flap thickness >0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 6mm thick volume stable collagen matrix will be stabilised at the inner aspect of the flap.
10208560|NCT05211115|Active Comparator|Full thickness flap + Volume stable collagen matrix|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide by 6-8mm high volume stable collagen matrix will be stabilised at the inner aspect of the flap.
10208561|NCT05211115|Active Comparator|Split thickness flap + Autogenous connective tissue|A split thickness flap will be raised with a micro-blade, keeping a flap thickness >0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
10208562|NCT05211115|Active Comparator|Full thickness flap + Autogenous connective tissue|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
10208563|NCT05211076|Experimental|Music Group|"In the selection of the music to be played,Rast,Uşşak,Kürdi,Muhayyer modes were chosen by taking expert opinion.Before starting the music application,the selected music will be sent to the mothers in this group by the researcher over the internet to the mother's phone and it will be ensured that the mother listens to the music transmitting the sound from her own phone in each session.~Music practice will take place in mothers' rooms or in the NICU.~The room will be quiet and your mother will be alone.~To make the mother listen to music;The mother will be asked to sit on the bed/seat in a comfortable position.~At the same time,the mother will be asked to close her eyes and be relaxed.~Later, music will be turned on from the mother's phone, allowing the mother to listen to music for 30 minutes~While the mother listening to the music,at the 16th minute of the music,researcher will manually express each breast separately for at least 15 minutes until no milk comes out"
10213549|NCT03809624|Experimental|Single Agent Escalation|INBRX-105 will be escalated in patients with locally advanced or metastatic solid tumors.
9854170|NCT03706469|Experimental|Fasted (T3 50 mg+T2 600 mg+T2 50 mg+T3 600 mg)+Fed (T3 600 mg)|TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
9854171|NCT03706469|Experimental|Fasted (T2 600 mg+T3 600 mg+T3 50 mg+T2 50 mg)+Fed (T3 600 mg)|TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
9854172|NCT03706469|Experimental|Fasted (T3 600 mg+T2 50 mg+T2 600 mg+T3 50 mg)+Fed (T3 600 mg)|TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
9854173|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 1|Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart
9854174|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 1|Two administrations of P218 placebo (capsules p.o.), 48 hours apart
9854175|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 2|One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.
9854176|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 2|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.
9854177|NCT03707041|Experimental|P218 100 mg (Oral Capsules) - Cohort 3|One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.
9854178|NCT03707041|Active Comparator|P218 Placebo Oral Capsule - Cohort 3|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.
9854179|NCT03707522|Experimental|Growth mindset + MRF Information|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
9854180|NCT03707522|Experimental|Control + MRF information|Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes
9854181|NCT03707522|Experimental|Control + Growth mindset|Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)
9854182|NCT03707522|Placebo Comparator|Control + Control|2 doses online daily activity scheduling interactive article (control)
9854183|NCT03707587|Experimental|1200 mg intravenous (IV) of M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
9854184|NCT03707821|Experimental|senofilcon A TEST Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.
9854185|NCT03707821|Active Comparator|senofilcon A CONTROL Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.
9923723|NCT00853528|Experimental|Single-fraction radiosurgery; 18 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 18 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
9923724|NCT00853528|Experimental|Single-fraction radiosurgery; 20 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 20 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
9923725|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 24 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 24 Gray
9854186|NCT03707912|Experimental|Anaferon|"1 tablet per administration. Day 1: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals through the rest of the day.~Days 2-5: 1 tablet 3 times a day. The drug is taken out of the meal (in the interval between meals or 15-30 minutes before eating), keep the tablet in the mouth, without swallowing, until completely dissolved."
9854187|NCT03707912|Placebo Comparator|Placebo|Placebo using Anaferon regimen until the end of the study.
9854188|NCT03708211|Experimental|Part1: TAK-931 80 mg PIC + TAK-931 80 mg Tablet|TAK-931 80 milligram (mg), PIC, orally, once on Day 1 Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, tablet, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until progressive disease (PD), or unacceptable toxicity or any treatment discontinuation is determined.
9854189|NCT03708211|Experimental|Part1: TAK-931 80 mg Tablet + TAK-931 80 mg PIC|TAK-931 80 mg, tablet, orally, once on Day 1 of Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, PIC, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until PD, or unacceptable toxicity or any treatment discontinuation is determined.
9854190|NCT03708211|Experimental|Part 2: TAK-931 Fed + TAK-931 Fasted + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fed state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fasted state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
9854191|NCT03708211|Experimental|Part 2: TAK-931 Fasted + TAK-931 Fed + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fasted state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fed state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
9854192|NCT03708367|Experimental|Study Group: LipiFlow Treatment at PreOp|Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
9854193|NCT03708367|Other|Control Group|Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
9854194|NCT03708393|Active Comparator|Imagio IUS|Read 1 - Mammo (as available) + Imagio Ultrasound
9854195|NCT03708393|Experimental|Imagio (IUS+OA)|Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)
9854196|NCT03708562|Other|endoAVF|
9854197|NCT03708744|Experimental|Treatment A|Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
9854198|NCT03708744|Experimental|Treatment B|Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
9854199|NCT03708744|Experimental|Treatment C|Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
9854200|NCT03708744|Active Comparator|Treatment D|Treatment D: Intranasal zolmitriptan 2.5 mg
9854201|NCT03708770|Other|endoAVF|
9854202|NCT03709602||Adolescents ages 11 to 14 years|Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017
9854203|NCT03709602||Parent of adolescents|Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
9854204|NCT03709602||Cohort of Adolescents From Electronic Health Record (EHR)|A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.
9854205|NCT03709654|Experimental|Treatment Arm|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.
9854206|NCT03709654|Placebo Comparator|Vehicle Control|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.
9854207|NCT03709810|Experimental|Test Denture Adhesive|Test denture adhesive will be applied directly from the tubes using a continuous strip pattern to the upper and lower denture which will then be placed in mouth of the participants.
9854208|NCT03709810|Other|Control|Participants will not apply any denture adhesive in this treatment arm.
9854209|NCT03709823|Experimental|1.5 mg Cytisine, Commercial Schedule|1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
9854210|NCT03709823|Experimental|3.0 mg Cytisine, Commercial Schedule|3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
9854211|NCT03709823|Placebo Comparator|Placebo, Commercial Schedule|Placebo tablets using the commercial 25-day titration schedule + behavioral support
9854212|NCT03709823|Experimental|1.5 mg Cytisine, TID Schedule|1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
9854213|NCT03709823|Experimental|3.0 mg Cytisine, TID Schedule|3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
9854214|NCT03709823|Placebo Comparator|Placebo, TID Schedule|Placebo tablets for 25 days using a simplified TID schedule + behavioral support
9854215|NCT03710083|Experimental|Study arm|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7).
9854216|NCT03710161|Experimental|4000 IU Vitamin D|4000 IU Vitamin D taken daily for six months
9854217|NCT03710161|Active Comparator|800 IU Vitamin D|800 IU Vitamin D taken daily for six months
9854218|NCT03710187|Experimental|Combination|Hydrocortisone 50 mg IV Q6h plus Fludrocortisone 50 mcg PO/PFT Q24h
9854219|NCT03710187|Active Comparator|Hydrocortisone only|Hydrocortisone 50 mg IV Q6h
9854220|NCT03710577|Experimental|Yoga|40 minutes of Vinyasa yoga
9854221|NCT03710577|Placebo Comparator|Quiet Rest|40 minutes of quiet rest
9854222|NCT03710590|Active Comparator|Cigarette smokers|
9854223|NCT03710590|Active Comparator|Electronic cigarette users|
9854224|NCT03710889|Experimental|Abaloparatide|Participants self-administered a single daily dose of 80 micrograms (µg) of abaloparatide subcutaneously (SC) during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.
9854225|NCT03711396|Experimental|Advance Care Planning Group Visits - amnestic Mild Cognitive Impairment|Participants with amnestic Mild Cognitive Impairment will attend group visits to discuss advance care planning with their study partners. Group visits will last up to two hours and be help up to twice.
9854226|NCT03711396|Experimental|Advance Care Planning Group Visits - Care Partners|Care partners of persons with amnestic Mild Cognitive Impairment will attend group visits, with the person with Mild Cognitive Impairment, to discuss advance care planning. Group visits will last up to two hours and be help up to twice.
9854227|NCT03711578|Experimental|Tenalisib|Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
9854228|NCT03712189|No Intervention|Alaris Pump|Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.
9854229|NCT03712189|Experimental|LifeFlow|Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.
9854230|NCT03712280|Experimental|Group A: MNK6106 2 grams (tid)|Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
9854231|NCT03712280|Experimental|Group B: MNK6106 4 grams (bid)|Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
10208564|NCT05211076|Experimental|Marmet Technique Group|Marmet Technique is one of the non-pharmacological methods used to increase milk production.The Marmet Technique is a combined method that includes breast massage and manual milking.The Marmet Technique will be performed in the mothers' rooms or in the Breastfeeding Room of the Neonatal Intensive Care Unit. It will be ensured that the mother is comfortable by paying attention to her privacy. Mothers will be manually milked into the hopper in their own milking set. In addition, the reservoir will be used after washing with hot water. This technique consists of two stages, these stages are emptying the milk ducts and stimulating the milk stroke reflex (massage).
10208565|NCT05211076|Experimental|control group|On the other hand, no application will be made to the control group, and the milking process will be carried out manually by the researcher for at least 15 minutes until the milk does not come.
9854232|NCT03712280|Experimental|Group C: MNK6106 4 grams (tid)|Participants receive 4 tablets of MNK6106 tid for 5 days
10208566|NCT05211063|Experimental|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
10208567|NCT05211063|Placebo Comparator|Placebo|Daily intake of one tablet for 42 days. This tablet is organoleptically indistinguishable from the experimental tablet.
10208568|NCT05211050|Active Comparator|Levcromakalim-Sumatriptan|20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of sumatriptan.
10208569|NCT05211050|Placebo Comparator|Levcromakalim-Placebo|20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of saline.
10208570|NCT05211037|Experimental|Kidney function assessment|
10208571|NCT05211011|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
10208572|NCT05210972||Diabetes|"Patients with level of HbA1c ≥ 6.5%, or Fasting blood glucose (FBG) ≥126 mg/dL, or a random plasma glucose (RBG) ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia.~In the absence of unequivocal hyperglycemia, diagnosis will be based on two abnormal test results, for FBG or RBG and HbA1c, from the same sample or in two separate test samples."
9854233|NCT03712280|Active Comparator|Group D: Rifaximin 550 mg (bid)|Participants receive 1 tablet of rifaximin bid for 5 days
9854234|NCT03712449|Experimental|BELKYRA Treatment|"BELKYRA was injected into the subcutaneous fat for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose did not exceed 100 milligrams (mg) [10 milliliters (mL)] in a single treatment.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 9 and Month 10."
9854235|NCT03712449|Experimental|Non-BELKYRA Treatment|"Participants who did not receive BELKYRA.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 0 to Month 5.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 0 to Month 2. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 3 and Month 4."
9935823|NCT03169101||HIV+|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
9935824|NCT03169101||HIV-|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
9854236|NCT03712852|Active Comparator|PRF+CAF treated patients|The clot collected from the blood samples is pressed through a calibrated compression system into the PRF box the folded membrane is transferred on a sterile gauze. A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the PRFs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
9854237|NCT03712852|Active Comparator|SCTG+ CAF treated patients|SCTG is taken from the opposite palate area of gingival defect. The graft is collected with a single incision technique and it is measured and adjusted to 1 mm by measuring with a standard caliper.A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the SCTGs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
9854238|NCT03712852|Active Comparator|CAF treated patients|A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the flap is sutured over the enamel in a tension free position.
9854239|NCT03712917|Active Comparator|Greater Occipital Nerve Block|"The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼ (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood."
10208573|NCT05210972||Prediabetes|HbA1c 5.7-6.4% or FBG 110 mg/dL to 125 mg/dL The diagnosis will be based on two abnormal test results, for FBG or RBG and HbA1c, from the same sample or in two separate test samples.
10208574|NCT05210972||Normal glycemia|HbA1c <5.7% and FBG 110 mg/dL
10208575|NCT05210946|Experimental|Pemigatinib in Advanced Non-Small Cell Lung Cancer Patients with FGFR Gene Alterations|"This study is a prospective single-arm clinical study. Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to"
9854240|NCT03712917|Active Comparator|Topiramate|Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
9854241|NCT03712917|Active Comparator|Flunarizine|Flunarizine is introduced with a single dose of 10 mg/day.
9854242|NCT03712930|Experimental|Pamiparib|Participants will receive pamiparib for a period up to 1 year
9854243|NCT03713398|Experimental|T4C-SMI Group|Participants will receive the T4C-SMI intervention, in addition to standard prison mental health services
9854244|NCT03713398|No Intervention|Control Group|The control group receives standard prison mental health services
9854245|NCT03714022|Experimental|Treatment A|Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
9854246|NCT03714022|Active Comparator|Treatment B|Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
9854247|NCT03714256|Experimental|Children 6-17 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
9854248|NCT03714256|Experimental|Children 18 - 36 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
9854249|NCT03714659|Experimental|Intervention|Group will receive a single injection of autologous, micro-fragmented adipose tissue into the torn meniscus and knee joint. The group will then be followed for one year, filling out pain and function questionnaires.
9854250|NCT03714672|Experimental|Tramadol/Diclofenac 50/50|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
9854251|NCT03714672|Experimental|Tramadol/Diclofenac 25/25|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
9854252|NCT03714672|Active Comparator|Tramadol 50|Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
9935825|NCT03167437|Experimental|1|participants will receive Vorinostat 100mg PO BID for 12 weeks
9935826|NCT03167437|Experimental|2|participants will receive Vorinostat 100mg PO BID for 6months
10208576|NCT05210868|Experimental|CM355|"Dose Escalation Phase CM355~Dose Expansion Phase CM355"
10208577|NCT05210855|Experimental|Patients with head trauma|
10208578|NCT05210829||High Parent Anxiety|Stationary and Trait Anxiety Scale ≥ 44 points
10208579|NCT05210829||Low Parent Anxiety|Stationary and Trait Anxiety Scale < 44 points
10208580|NCT05210803||Roll over|No intervention All subjects that previously received RGX-314 in a parent study
10208581|NCT05210751||Women patients with fibromyalgia|women with fibromyalgia beween age 30-75
10208582|NCT05210751||Control group|Healthy female volunteers aged 30-75 years
10208583|NCT05210738||Single incision sling group|The patient will receive Altis mini-incision sling for treatment of occult SUI
10208584|NCT05210738||Urethral bulking group|The patient will receive Bulkamid urethral bulking agent for treatment of SUI
10208585|NCT05210686|Experimental|subgingival re-instrumentation + gel containing PDRN and HA|subgingival re-instrumentation + gel containing PDRN and HA
10208586|NCT05210686|Active Comparator|subgingival re-instrumentation|subgingival re-instrumentation
10208587|NCT05210647||conventional laparoscopy surgery|Conventional laparoscopy surgery for colon and rectal disease.
10208588|NCT05210647||robot assisted surgery|robotic assisted surgery for colon and rectal disease.
9854253|NCT03714672|Active Comparator|Diclofenac 50|Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
9854254|NCT03714919|Experimental|Non-opiod pain relief|Subjects will receive preoperative oral dextromethorphan & acetaminophen and intraoperative intravenous dexmedetomidine & ketamine.
9854255|NCT03715426|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
9854256|NCT03715426|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
9854257|NCT03715452||DyeVert Plus Contrast Reduction System|DyeVert Plus Contrast Reduction System
9854258|NCT03715530|Experimental|Pregnant subjects|These are pregnant women that are admitted to Labor &Delivery (L&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
9854259|NCT03715530|Active Comparator|Pregnant controls|These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
9854260|NCT03715530|Sham Comparator|Non pregnant controls|These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.
9854261|NCT03715803||Calistar A|Calistar A mesh to treat anterior and apical POP
10208589|NCT05210608|Experimental|Working Memory Intervention|Computerized Working Memory Intervention Participants will be scheduled for10 training sessions. For each of the 10 training sessions, participants will complete four working memory training programs. These programs have been used successfully to decrease DD (Bickel et al., 2011). These programs are: Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Words - Visual, Verbal Memory - Visual. Each session will take 30 minutes to complete.
10213550|NCT03809624|Experimental|Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
9854262|NCT03715803||Calistar S|Calistar S mesh to treat anterior and apical POP
9854263|NCT03716024|Experimental|PTK 0796|
9854264|NCT03716024|Active Comparator|Linezolid|
9854265|NCT03716050|Other|Group 1|Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No treatment, including dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.
9854266|NCT03716050|Active Comparator|Group 2|Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.
9854267|NCT03716050|Active Comparator|Group 3|Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.
9854268|NCT03716050|Active Comparator|Group 4|Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.
9854269|NCT03716050|Active Comparator|Group 5|Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.
9854270|NCT03716050|Active Comparator|Group 6|Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.
9854271|NCT03716050|Active Comparator|Group 7|Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.
9854272|NCT03716050|Active Comparator|Group 8|Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.
9854273|NCT03716076|Experimental|Participant receives 50 mcg of carbetocin post-delivery.|Participant receives 50 mcg of carbetocin post-delivery.
9854274|NCT03716076|Experimental|Participant receives 100 mcg of carbetocin post-delivery.|Participant receives 100 mcg of carbetocin post-delivery.
9854275|NCT03717012|Active Comparator|Nintedanib treatment alone|
9854276|NCT03717012|Experimental|Nintedanib with a pulmonary rehabilitation program|
9923726|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 27 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 27 Gray
9923727|NCT00853541||heart failure with renal impairment|Heart Failure patients with renal impairment
10213551|NCT03809624|Experimental|Expansion Cohort Melanoma|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
10208590|NCT05210608|Placebo Comparator|Computerized Control Condition|For the control training program, the tasks will be matched on all essential features (e.g., stimulus, response, feedback) with four exceptions: (1) correct answers are provided or indicated to participants within each trial as part of the program interface, and (2) instruction indicates how to identify and respond to the stimulus that indicates the correct response. This will ensure that the sensory/motor experience of participants in the active training vs control training conditions are as similar as possible, with the exception of the memory requirement.
9854277|NCT03717051|Experimental|Intervention|The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
9854278|NCT03717051|Active Comparator|Control|The control group subjects will receive medication counseling. They will be advised to obtain free NRT by enrolling in the smoking cessation services, but will not be given the sampling. The same one-page leaflet will be provided by the SC clinics.
9854279|NCT03717064|Experimental|Pitavastatin|"Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.~Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4."
9854280|NCT03717155|Experimental|Avelumab and Cetuximab|Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
9854281|NCT03717506|Experimental|Test product|GDC 268 Lotion applied topically as directed.
9854282|NCT03717506|Active Comparator|Reference Product|Clindamycin Phosphate Lotion, 1% applied topically as directed.
9854283|NCT03717506|Placebo Comparator|Placebo|GDC Vehicle lotion applied topically as directed.
9854284|NCT03718000|No Intervention|Control|Participants in this group received no intervention during t he holiday season
9854285|NCT03718000|Experimental|Daily Self-Weighing (DSW)|Participants in this group performed daily self-weighing using digital WiFi scales during the holiday season
10208591|NCT05210595|Experimental|Control group|Clopidogrel 75 mg/day as maintenance dose
10208592|NCT05210595|Experimental|Treatment group 1|De-escalation strategy dose receive ticagrelor 60 mg twice daily
10208593|NCT05210595|Experimental|Treatment group 2|De-escalation strategy dose receive ticagrelor 45 mg twice daily
10208594|NCT05210582|Experimental|Afamelanotide|
10208595|NCT05210569||Bilateral implantation of the Vivity IOL|Vivity intraocular lens (IOL)
10208596|NCT05210517|No Intervention|No intervention|
10208597|NCT05210517|Experimental|Empagliflozin|Empagliflozin 25 mg once daily for one week
10208598|NCT05210517|Experimental|Benzbromarone|Benzbromarone 100 mg once daily for one week
10208599|NCT05210517|Experimental|Empagliflozin-Benzbromarone|Empagliflozin 25 mg once daily for one week combined with Benzbromarone 100 mg once daily for one week
10208600|NCT05210491|Experimental|The observation of eyelid positioning and EEG pulses from the eyelid on increasing brightness|In a dimly lit room the participant will place their chin on the slit lamp We will use t he optimal background illumination used for Humphrey and Goldman visual fields which is 31.5 apostilbs (10Lux 9 They will look into the video camera placed 50cm away, which will have a dimmable remote control ring light fitted around it. The part icipant will have a reference measure taped to the headrest and three electrodes placed around the right eye. One active electrode place on the lower lid and one reference electrode towards the temporal margin and one earth electrode placed on the forehead The brightness of the ring light will be increased via the dimmer switch whilst simultaneously recording the lux with the LED light meter. The participant will be advised t o close their eyes if the brightness becomes uncomfortable and this will be repea ted three times.
10208601|NCT05210465||patients with stable angina pectoris and prior MI|
10208602|NCT05210452|Experimental|Patients with alopecia receiving standard treatment and follicular stem cells|Patients with alopecia receiving standard treatment and autologous follicular stem cells
10208603|NCT05210452|Active Comparator|Patients with alopecia receiving standard treatment|Patients with alopecia receiving standard treatment
10208604|NCT05210426|Experimental|Pilates|The Pilates Group completed a 10-week. The intervention was performed in 20 sessions. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week .
10208605|NCT05210426|No Intervention|Control|The Control Group did not perform any Pilates. The children in the CG continued their routine physical activities at school.
10208606|NCT05210387|Experimental|7-day adequate antibiotic therapy|Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
10208607|NCT05210387|Active Comparator|14-day adequate antibiotic therapy|Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
10208608|NCT05210348||HPV positive group|
10208609|NCT05210348||HPV negative group|
10208610|NCT05210348||Disease group (clinical diagnosis positive)|CIN2 and above disease cases, including HSIL or (CIN2, CIN2-3, CIN3) cervical cancer.
10208611|NCT05210348||Control group (clinical diagnosis is negative)|includes other benign lesions such as inflammation, polyps, and HPV-negative cases without pathological diagnosis and no abnormalities in TCT.
10208612|NCT05210335|No Intervention|Observational part|This part covers the list for comprehensive medication use at admission, medication reconciliation and medication review at preoperative surgical ward, postoperative intensive care, postoperative surgical ward and discharge made by clinical pharmacist. The identification and classification of drug related problems was made at each ward according to PCNE classification system. The expert panel (2 surgeon, 2 nurse, 1 pharmacist) scored all the drug related problems as a part of the risk analysis model development. Patients quality of life, nutritional status, cognitive functions and frailty status also recorder at admission, discharge and 1 month after surgery.
9854286|NCT03718871|Experimental|Healer HIV testing intervention|We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
9854287|NCT03718871|No Intervention|Healer control arm|Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.
9854288|NCT03719300|Experimental|Single Arm BC-819|inodiftagene vixteplasmid
9854289|NCT03719378|No Intervention|Traditional Fluid|"NPO Clears and Food after midnight.~2 Liters of lactated ringers administered by anesthesia intraoperatively.~Postoperatively - 2 Liters of Crystalloid while in PACU and Inpatient Room for a Total of 4 Liters of Crystalloid within 24 hours. (Patient will receive 500 milliliters while in PACU and 1500 milliliters while in their Inpatient Room, for a total of 2 Liters).~Normal diet postoperatively."
9854290|NCT03719378|Experimental|Oral Fluid|"Pre Operative Oral Fluids (Patients encouraged to drink a minimum of 60 ounces of clear liquid per day for the 3 days prior to procedure.)~NPO Food/Milk: none beginning 8 hours prior to procedure time.~Pre Operative Oral Fluids (Patients are asked to drink 10 ounces of clear liquid 4 hours prior to their scheduled procedure time.)~Preoperative holding area, IV is started in the patient with Lactated Ringers IV fluid at a rate of 75ml/hr. IV fluids will be stopped and hep-locked in the PACU when the patient is taking PO fluid; the total amount of IV fluids is not to exceed 500ml total.~PO fluid protocol: a minimum of 60 ounces of liquid per day for 3 days."
9854291|NCT03719586|Experimental|A|Remdesivir plus optimized Standard of Care (oSOC)
9854292|NCT03719586|Experimental|B|MAb114 plus optimized Standard of Care (oSOC)
9854293|NCT03719586|Experimental|C|REGN-EB3 plus optimized Standard of Care (oSOC)
9854294|NCT03719586|Experimental|Control|Zmapp plus optimized Standard of Care (oSOC)
9854295|NCT03719612|Experimental|DEFINITY®|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
9854296|NCT03719677|Experimental|Habit development intervention|Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.
9854297|NCT03719885|Experimental|Intervention|
9854298|NCT03720470|Experimental|PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg|Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20
9854299|NCT03720470|Experimental|PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg|Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20
9854300|NCT03720470|Active Comparator|Dupilumab Injection + Oral Placebo followed by Oral Placebo|Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20
9854301|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 100 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20
9854302|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 200 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20
9854303|NCT03720652|Experimental|8-Week Mindful Self-Compassion (MSC)|CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
9854304|NCT03720652|Experimental|6-Week Mindful Self Compassion (MSC)|CNAs from both nursing homes in Aim 2 will participate in the 6-week Mindful Self-Compassion course, that was shortened and customized to fit the needs of health care staff. Each 6-week session will last for 1 hour.
9923728|NCT00853554|Experimental|A|Hydromorphone Hydrochloride tablet 8 mg
9923729|NCT00853554|Active Comparator|B|Dilaudid® tablet 8 mg
9923730|NCT00853619|Experimental|Services Demo at PHS and RI|Service based CDS intervention at PHS.
9923731|NCT00853619|Active Comparator|Normal CDS interventions at PHS and RI|Normal CDS intervention at both PHS and RI hospitals
9923732|NCT00853684|Experimental|oxaliplatin, capecitabine plus endostar|
9517046|NCT03310008|Experimental|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
10208613|NCT05210335|Experimental|Interventional part|This part covers the list for comprehensive medication use at admission, medication reconciliation and medication review at preoperative surgical ward, postoperative intensive care, postoperative surgical ward and discharge made by clinical pharmacist. Clinical pharmacist made recommendation about drug related problems regarding solutions, record intervention type and problem status differently from observational part. As a component of the risk analysis model the affect of clinical pharmacist was shown clearly. Patients quality of life, nutritional status, cognitive functions and frailty status also recorder at admission, discharge and 1 month after surgery.
9854305|NCT03720847|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
9854306|NCT03720847|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
9854307|NCT03720938|No Intervention|Control Group|Physically inactive children who did not play AVGs.
9854308|NCT03720938|Experimental|Intervention Group|Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.
9854309|NCT03721172|Experimental|Placebo-controlled Phase:|Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).
9854310|NCT03721172|Experimental|Placebo-controlled Phase: Apremilast 30 mg|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).
9854311|NCT03721172|Experimental|Extension Phase: Apremilast 30 mg|Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
9854312|NCT03721549|Experimental|Moderate Dose Inoculum|Moderate dose of Norwalk GI.1 Virus, 3.6x10^5 genome copies
9854313|NCT03721549|Experimental|Higher Dose Inoculum|Higher dose of Norwalk GI.1 Virus, 1x10^6 genome copies
9854314|NCT03722030|Experimental|Strength-Training Intervention|Following baseline measures, participants will receive an initial in-person instructional session, instructional material and resistance training equipment, support and feedback via video coaching, mid-point assessment, and an in-person study visit to collect post study measures. Intervention will be 10 weeks, with a 5 week follow up period.
9854315|NCT03722030|Placebo Comparator|Waitlist Control|Following baseline measures, participants will provide mid-point measures, and in-person post-study measures with no 10-week strength training intervention.
9854316|NCT03722238|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Tablets|Ibuprofen 600 mg Immediate Release/Extended Release Tablets
9854317|NCT03722264|Experimental|OpalSeal|"OpalSeal will be applied~to the buccal surfaces of to-be-extracted teeth on one side of the mouth which will be determined randomly for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Since OpalSeal has fluoride releasing capability, this would be experimental arm"
9854318|NCT03722264|Placebo Comparator|Transbond XT|"TransbondXT will be applied~to the buccal surfaces of to-be-extracted teeth on the other side of the mouth which will be determined based on which side received OpalSeal for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Transbond XT does not have fluoride and hence would be considered as a placebo."
9854319|NCT03722446|Other|Arrow Catheter Kit.|Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
9854320|NCT03722446|Other|B.Braun Catheter Kit|Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
9854321|NCT03722524||Patients with arterial hypertension|"The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.~Presumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients."
9854322|NCT03722576|Experimental|Vidofludimus Calcium (VC)|Daily dosing of VC over 6 months
9854323|NCT03722784|Experimental|Invigor A (test)|Subjects will be randomized to wear Invigor A (test) for one month of daily wear during the study.
9854324|NCT03722784|Active Comparator|Invigor B (Control)|Subjects will be randomized to wear Invigor B (Control) for one month of daily wear during the study.
9854325|NCT03723915|Experimental|Treatment (pembrolizumab, wild-type reovirus)|See Detailed Description
9854326|NCT03724812|Experimental|Portico valve and FlexNav™ Delivery System|Portico valve implantation with the second-generation FlexNav Delivery system
9854327|NCT03725982|Experimental|With exoskeleton, then without exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) with the exoskeleton, then without the exoskeleton.
10208614|NCT05210296|Experimental|Trunk strengthening exercises|"After 5 minutes of warm-up exercises, 20 minutes of trunk strengthening exercises and 10 minutes of balance exercises will be applied to the participants, and the session will end with 5 minutes of cooling-off exercises.~In trunk strengthening exercises, trunk resistance exercises will be applied with an elastic exercise band."
9854328|NCT03725982|Experimental|Without exoskeleton, then with exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) without the exoskeleton, then with the exoskeleton.
9854329|NCT03727841|Experimental|1/Arm 1 Marizomib|Marizomib at days 1, 8, and 15 of each 28-day cycle
9854330|NCT03727841|No Intervention|P/Pregnancy Evaluation|Data collection on pregnancy, birth and Health of Child
9854331|NCT03736967|Experimental|REGN3500|
9854332|NCT03736967|Experimental|Dupilumab|
9854333|NCT03736967|Experimental|Combo|
9854334|NCT03736967|Experimental|Placebo|
9854335|NCT03739840|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
9854336|NCT03739840|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
9854337|NCT03739840|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
9854338|NCT03739840|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several placebo tablets to maintain the blinding.
9517047|NCT03310008|Experimental|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
9854339|NCT03739983|Experimental|VRP Therapy|All subjects on this study will receive the Vaginal Renewal Program intervention. Enrolled subjects will receive inperson instruction on how to perform the VRP. Subjects will be encouraged to use the device for 3-4 days per week for 5 minutes at a time.
9854340|NCT03746002|Active Comparator|Metolazone Pre-dosing|Metolazone 5 mg by mouth administered 60 minutes prior to furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
9854341|NCT03746002|Active Comparator|Metolazone Concurrent Dosing|Metolazone 5 mg by mouth administered at the same time as furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
9854342|NCT03748771|Experimental|ApneaLink Air|Half of the participants will undergo HST no greater than one week prior to their in-laboratory PSG, while the other half will undergo HST no greater than one week following their in laboratory PSG. All participants will also undergo their HST concurrent to their in-laboratory PSG. The rational for splitting participants in these two groups is to equally distribute the effects of the first night evenly, in which the sleep architecture including reduced total rapid eye movement (REM) sleep time can vary during the first ever sleep study. As the HST will be compared to the in-lab PSG, we would like to evenly distribute this effect by having two groups of ten participants.
9854343|NCT03752177|Experimental|LY3415244 Dose Escalation|Participants received 3 milligrams (mg) LY3415244 (Cohort A1), 10 mg LY3415244 (Cohort A2), 30 mg LY3415244 (Cohort A3) and 70 mg LY3415244 (Cohort A4) as an intravenous (IV) infusion on day (D)1 and D15 of each 28-day cycle every 2 weeks (Q2W).
9854344|NCT03752177|Experimental|LY3415244 Dose Expansion|Phase 1b dose expansion was planned but not initiated as dose escalation ended at cohort A4. Study did not achieve its primary objective of establishing a recommended phase 2 dose (RP2D) due to early termination of the study by Cohort A4.
9854345|NCT03753763|Experimental|Active|Safinamide methanesulfonate film-coated tablets once daily
9854346|NCT03753763|Placebo Comparator|Placebo|Safinamide Methanesulfonate matching placebo film-coated tablets once daily
9854347|NCT03756571|Experimental|Ankle Foot Orthoses-Footwear Combination|The intervention is a Ankle Foot Orthoses Footwear Combination (AFO-FC). This is some form of solid ankle AFO combined with modified footwear individually designed per algorithm.
9854348|NCT03756571|Active Comparator|Traditional Solid Ankle AFO (TSAFO)|"The intervention is a solid AFO (SAFO) aligned with the ankle at 90 degrees and worn with regular footwear. We'll refer to this as the traditional SAFO (TSAFO)..."
9854349|NCT03761537|Experimental|Tralokinumab + TCS|4 subcutaneous (SC) injections of tralokinumab 150 mg as a loading dose on Day 0, followed by 2 SC injections of tralokinumab 150 mg every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
9854350|NCT03761537|Placebo Comparator|Placebo + TCS|4 subcutaneous (SC) injections of placebo as a loading dose on Day 0, followed by 2 SC injections of placebo every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
9854351|NCT03763877|Experimental|Group 1|PXL770 Dose 1
9854352|NCT03763877|Experimental|Group 2|PXL770 Dose 2
9854353|NCT03763877|Experimental|Group 3|PXL770 Dose 3
9854354|NCT03763877|Placebo Comparator|Group 4|Placebo oral capsule
9854355|NCT03764007|Experimental|18F-Fluorocholine PET|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
9854356|NCT03772587|Placebo Comparator|Group 1|
9854357|NCT03772587|Experimental|Group 2|
9854358|NCT03772587|Experimental|Group 3|
9854359|NCT03772587|Experimental|Group 4|
9854360|NCT03772587|Experimental|Group 5|
9854361|NCT03789292|Experimental|CT-P17 Subcutaneous(SC) (adalimumab)|CT-P17 SC (adalimumab)
9854362|NCT03789292|Active Comparator|Humira SC (adalimumab)|Humira SC (adalimumab)
9935827|NCT03167437|Active Comparator|3|participants will receive ustekinumab (weight base induction dose followed by 90mg SC every 8 weeks for 24 months)
9854363|NCT03799289|Experimental|Iyengar Yoga|Participants randomized to the yoga intervention arm will receive 12 weeks of group-based yoga instruction, following a 12-week standard behavioral weight loss program. Group-based yoga instruction will occur twice per week and classes will be 60 minutes in duration. The yoga program will consist of breathing, postural, and meditation practices and home-based yoga practice will also be prescribed.
9854364|NCT03799289|Active Comparator|Cooking/dietary education|Participants randomized to the cooking/dietary education intervention arm will receive 12 weeks of group-based, cooking/dietary education instruction, following a 12-week standard behavioral weight loss program. This group-based instruction will occur twice per week and classes will be 60 minutes in duration. Classes will focus on providing basic nutrition knowledge and culinary skills, and will include cooking demonstrations.
9854365|NCT03805438|Experimental|Chloroprocaine dose|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
9854366|NCT03808948|Experimental|All Patients|VFI dose: 47 mg / 3 mL Number of doses: 2 Route of administration: intravenous
9854367|NCT03810053|Experimental|Mobile App/Online Module|Subjects will watch a short video containing information about cancers and benefits of uptake cancer prevention and early detection measures. Information regarding gender, age, smoking status, BMI and positive cancer history in family will be captured. Subjects will be provided with a list of cancer prevention and early detection measures based on the responses provided.
9854368|NCT03812224|Experimental|Erenumab|Participants were to receive erenumab 70 mg once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
9854369|NCT03812224|Placebo Comparator|Placebo|Participants were to receive placebo to erenumab once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
9854370|NCT03817528|Experimental|ITI-007|Open-Label ITI-007 40-60 mg
9854371|NCT03817580|Experimental|Project X 26ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 26ml volume. Single use.
9854372|NCT03817580|Experimental|Project X 5.1ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 5.1ml volume. Single use.
9854373|NCT03817580|Active Comparator|Prevantics Maxi Swabstick|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. 5.1ml volume. Single use.
9854374|NCT03828422||patients with essential thrombocythemia|"essential thrombocythemia with JAK2 V617F positive mutation~patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019~blood for laboratory tests~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
9854375|NCT03828422||control group|"the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives~they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~blood for laboratory tests~examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
9854376|NCT03829228|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.
9854377|NCT03829618|Active Comparator|Topical Lidocaine|16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.
9854378|NCT03829618|Active Comparator|Nebuliser Solution|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.
9854379|NCT03829618|Active Comparator|Nebuliser Suspension|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.
9854380|NCT03830333|Experimental|Ceftolozane/Tazobactam + Metronidazole|Participants receive ceftolozane/tazobactam 1500 mg (ceftolozane 1000 mg + tazobactam 500 mg) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days (per protocol, ceftolozane/tazobactam may be adjusted to 500 mg/250 mg if creatinine clearance [CrCL] is 30 to ≤50 mL/min)
9935828|NCT03157115|Experimental|HFrEF: Heart failure - reduced ejection fraction|Patients with heart failure and reduced ejection fraction (around 35%).
9854381|NCT03830333|Active Comparator|Meropenem + Placebo|Participants receive meropenem 1000 mg plus saline administered as an IV infusion every 8 hours for 4 to 14 days (per protocol, meropenem may be adjusted to every 12 hours if CrCL was 30 to ≤50 mL/min).
9854382|NCT03831880|Other|Daily to Weekly|Genotropin to somatrogon
9854383|NCT03831880|Other|Weekly to Daily|somatrogon to Genotropin
9854384|NCT03831945|Active Comparator|Single infusion of VRC01 and 10-1074|Single infusion of 40 mg/kg VRC-HIVMAB060-00-AB (VRC01) in 100 mL of saline and 30 mg/kg of 10-1074 in 250 mL of saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
9854385|NCT03831945|Placebo Comparator|Single infusion of Normal Saline|Single infusion of 100 mL and 250 mL of normal saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
9854386|NCT03835728|Active Comparator|Treatment Arm|Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
9854387|NCT03835728|Placebo Comparator|Treatment Placebo Arm|Saline will be used as the matching placebo
9854388|NCT03840174|Experimental|V160|Participants will receive V160 vaccination by IM injection on Day 1, Month 2, and Month 6.
9854389|NCT03840174|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 2, and Month 6.
9854390|NCT03848910|Experimental|Investigational device - Sound Processor|
9854391|NCT03852524|Experimental|Study Arm|The study arm will receive subcutaneous methylnaltrexone (0.15mg/kg rounded to 8 or 12 mg) before surgery and then daily, for the following three days after surgery (four doses).
9854392|NCT03852524|Placebo Comparator|Placebo Arm|The placebo arm will receive subcutaneous placebo before surgery and then daily, for the following three days after surgery (four doses).
9923733|NCT00853697|Experimental|testosterone with the 5α-reductase inhibitor dutast|This trial is a multi-center, open-label, phase II trial of the combination of exogenous testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride in patients with castration-resistant metastatic prostate cancer.
9923734|NCT00853710|Experimental|rapid PSA assay on whole blood|
9923735|NCT00853736|Experimental|A|Oxycodone hydrochloride tablet 30 mg
9923736|NCT00853736|Active Comparator|B|Roxicodone™ tablet 30 mg
9923737|NCT00853775||African American Families|Families with 2 parents and 2 children - no intervention, observational study
9923738|NCT00853775||Caucasian Families|Families with 2 parents and 2 children - no intervention, observational study
9923739|NCT00853801|Experimental|1|Lifestyle modification education and counseling for intervention patients. Diagnosis and treatment education and feedback on performance for providers of intervention patients.
9935105|NCT04170153|Experimental|Part A2 - Preliminary Food Effect Assessment|Participants in the food effect assessment will receive M1774 at the dose and schedule determined as recommended dose for expansion (RDE) in Part A1. A single dose of M1774 will be administered on Day -7 under a fed (high-fat meal) or fasted condition, followed by a 1-week washout period. After completion of the scheduled food effect assessments, participants will follow the same schedule as participants in Part A1. Participants will be administered M1774 at a dose and schedule determined as RDE in Part A1.
9935106|NCT04170153|Experimental|Part A3 - Monotherapy Expansion|Part A3 is an expansion of Part A1 where M1774 will be administered as a single agent at the RDE established in Part A1. Participants with defined loss-of-function mutation in ARIDIA, ATRX and/or DAXX, and ATM will be enrolled.
9935107|NCT04170153|Experimental|Part B1a: Combination Therapy Dose Finding|Participants with baseline body weight less than (<) 77 kilogram (kg) or platelets <150,000 cubic per millimeter (mm^3) will receive Niraparib once daily combined with different doses of M1774.
9935108|NCT04170153|Experimental|Part B1b: Combination Therapy Dose Finding|Participants with baseline body weight greater than or equal to (>=) 77 kg and or platelets >= 150,000 mm^3 will receive Niraparib once daily combined with different doses of M1774 and schedule determined as recommended dose for expansion (RDE) in Part B1a.
9935109|NCT04166383|Experimental|1/Arm 1|VB-111 and nivolumab
9935110|NCT04163016|Experimental|Pharmacokinetics Sampling|"This study will include pregnant women who have decided to continue treatment with commercial certolizumab pegol (CZP) in accordance with their treating physician prior to participating in the study. Study participants will be responsible for obtaining and administering commercially available CZP under the care of their physician and according to the locally approved product label.~From all study participants blood samples will be drawn for pharmacokinetics during the study."
9935111|NCT04159805|Experimental|TAK-079 Dose 1|TAK-079 dose 1 injection, subcutaneously, once weekly for 8 weeks.
9854393|NCT03857841|Experimental|20 pmol phospholipid/kg body weight|UNEX-42 administered at 20 pmol phospholipid/kg body weight
9854394|NCT03857841|Experimental|60 pmol phospholipid/kg body weight|UNEX-42 administered at 60 pmol phospholipid/kg body weight
9854395|NCT03857841|Experimental|200 pmol phospholipid/kg body weight|UNEX-42 administered at 200 pmol phospholipid/kg body weight
9854396|NCT03857841|Placebo Comparator|Placebo|Phosphate-buffered saline
9854397|NCT03861780|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
9854398|NCT03861780|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.
9854399|NCT03861780|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.
9854400|NCT03862625|Experimental|a modular adaptive seating system|In the first group, there is home exercises program for scoliosis and a modular adaptive seating system.
9854401|NCT03862625|Active Comparator|home exercises for scoliosis|In the second group there is only home exercise program for scoliosis.
9854402|NCT03862755|Experimental|Thromboprophylaxis|All surgical patients classified into low risk and moderate/high risk groups based on Caprini score and received different thromboprophylaxis strategies Briefly, early ambulation alone was used in patients at low risk, early ambulation plus chemoprophylaxis with Low Molecular Weight Heparin was used in patients at moderate/high risk.
9854403|NCT03869541||Intensive care patients|Adult intensive care patients receiving vasoactive drugs
9854404|NCT03869541||Intensive care unit clinicians|Clinicians for participation in a survey on the hypothetical randomization of patient participants in a future randomized controlled trial.
9854405|NCT03869541||ICU rehabilitation clinicians|Clinicians for participation in a survey on the feasibility of an ICU physical rehabilitation adverse event tool.
9854406|NCT03877224|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
9854407|NCT03877224|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
9854408|NCT03883607|Experimental|Elafibranor 80 mg|Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.
9854409|NCT03883607|Experimental|Elafibranor 120 mg|Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.
9854410|NCT03885596|Experimental|CA-008 Cohort 1|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block."
9854411|NCT03885596|Experimental|CA-008 Cohort 2|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
9854412|NCT03885596|Experimental|CA-008 Cohort 3|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
9854413|NCT03885596|Active Comparator|Exparel|"106 mg [8 mL of the 133 mg/10 mL suspension] only~All subjects received monitored anesthesia care (MAC) and a Mayo block."
9854414|NCT03885661|Experimental|Icosapent ethyl|Icosapent ethyl with a total daily dose of 4 grams, as 2 x 1 gram capsules by mouth twice daily, against a statin background
9854415|NCT03885661|No Intervention|Usual Care|Statin background
9854416|NCT03886493|Experimental|Dupixent Subcutaneous (SQ) Injection|Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.
9854417|NCT03888235|Experimental|Immediate corrective exercises|"At this visit, participants will be examined as described in the protocol and given an exercise to correct their sacroiliac malrotation. They will use this exercise as needed for pain control. They will be reassessed one month later.~At that time they will be given the pelvic support belt and the concurrent use of both treatments will be assessed at their last visit one month after that."
9854418|NCT03888235|Experimental|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their pelvis. They will use this belt for activities likely to precipitate back pain. They will be reassessed one month later.~At that time they will be given the exercises and the concurrent use of both treatments will be assessed at their last visit one month after that."
9854419|NCT03888235|Active Comparator|Delayed treatment|"These participants will continue using their current therapies to deal with their low back pain for one month prior to being scheduled for a treatment visit. At the treatment visit, one month later they will be given both the exercise and the belt.~The concurrent use of both treatments will be assessed at their last visit one month after that."
9854420|NCT03889158|Experimental|Acute Inflammation|All participants will receive the typhoid vaccination (intramuscular injection, 0.5 mL, 1 time).
9854421|NCT03889158|Experimental|Ascorbic Acid|All participants will receive ascorbic acid (Vit C) on two occasions [oral pill, 2g, 2x (baseline, during acute inflammation)].
9854422|NCT03890419|Active Comparator|Control Group|Control Group participants will be exposed to full spectrum light during the study.
9854423|NCT03890419|Experimental|Green light Group|Green light Group participants will be exposed to green light during the study.
9854424|NCT03890419|Experimental|Blue light Group|Blue light Group participants will be exposed to blue light during the study.
9854425|NCT03897348|Experimental|Crossover Sequence A: Placebo, then Lacosamide 200 mg, then Lacosamide 100 mg|Participants receive a single dose of Placebo in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
9854426|NCT03897348|Experimental|Crossover Sequence B: Lacosamide 200 mg, then Lacosamide 100 mg, then Placebo|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 100 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
9854427|NCT03897348|Experimental|Crossover Sequence C: Lacosamide 200 mg, then Placebo, then Lacosamide 100 mg|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Placebo. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
9854428|NCT03897348|Experimental|Crossover Sequence D: Lacosamide 100 mg, then Lacosamide 200 mg, then Placebo|Participants receives a single dose of Lacosamide 100 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
9854429|NCT03900416|Experimental|Mindfulness App|Guided mindfulness exercises will be delivered via mobile app for three weeks.
9854430|NCT03900416|No Intervention|Control condition|Participants will use app for assessment for three weeks, but no mindfulness exercises will be delivered.
9854431|NCT03905863|No Intervention|Standard of care arm|SOC was defined to include wound cleansing with sterile water or saline solution, and gentle irrigation of the study ulcer with warm tap water; sharp debridement using a standardised protocol based on TIME principles for wound bed preparation; offloading with a TCC twice in the first week and weekly thereafter (all exceptions had to be agreed by the lead investigator; a fixed ankle walker boot or similar device was acceptable as an alternative, but shoe inserts were not deemed to provide sufficient offloading); moisture balance was provided using a hydrofibre or alginate dressing. In addition, patients were instructed on adherence to the protocol and given instructions to call their clinic if they suspected any signs of an infection.
9923740|NCT00853814|Experimental|Reduced access to sedentary behaviors, High park access|
9923741|NCT00853814|Experimental|Usual access to sedentary behaviors, High park access|
9923742|NCT00853814|Experimental|Reduced access to sedentary behaviors, Low park access|
9923743|NCT00853814|Experimental|Usual access to sedentary behaviors, Low park access|
9935112|NCT04159805|Experimental|TAK-079 Dose 2|TAK-079 dose 2 injection, subcutaneously, once weekly for 8 weeks.
9854432|NCT03905863|Active Comparator|Intervention arm|Same protocol as SOC only but were also provided with a Natrox® Oxygen Wound Therapy System, consisting of two elements: the Natrox® OG and the Natrox® ODS. The OG is a multi-use battery powered device which generates oxygen though water electrolysis at a rate of 15mL/hr. The ODS is a sterile, single use device that allows wound exudate to pass through to the secondary dressing while allowing the diffusion of oxygen across the wound bed. It connects directly to the OG via a thin flexible fine-bore tube. While the ODS can remain in situ for 7 days, it should be changed at each dressing change, based on exudate level or clinical judgement. This is a battery-operated system with a 30-hour battery life; the kit includes two interchangeable, rechargeable batteries. Each participant was advised to charge one battery while the other was in use, as the battery required changing daily. The oxygen generator is worn in a holster so that patients can remain ambulatory.
9854433|NCT03907033|Active Comparator|Standard Bupivacaine|Patients in the control group will receive 0.25% bupivacaine hydrochloride (bupivacaine HCl). 10cc will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc of will be injected bilaterally into the deeper uterosacral ligaments.
9854434|NCT03907033|Experimental|Liposomal Bupivacaine|Patients in the study group will receive a mixture of 0.5% bupivacaine HCl and liposomal bupivacaine in 1:1 ratio. 10cc of the mixture will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc will be injected bilaterally into the deeper uterosacral ligaments
9854435|NCT03909178|Active Comparator|Hip Arthroscopy Surgery with Acetabular Labral Repair|Hip Arthroscopy Surgery with Acetabular Labral Repair
9854436|NCT03909178|Active Comparator|Physical Therapy Focused on the Hip and Hemi-pelvis|Physical Therapy focusing on the hemipelvis strengthening, including the lower back, lower abdominal core, quadriceps, hamstrings, and gluteal muscles.
9854437|NCT03909971|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
9854438|NCT03920215|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, 0.12 mg/mL
9854439|NCT03920215|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.60 mg/mL
9854440|NCT03920215|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
9854441|NCT03920215|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
9854442|NCT03921151|Other|Cocaine-dependent|Participants who use and are dependent on cocaine
9854443|NCT03921151|Other|Non-drug using Healthy Controls|Participants who are not drug users
9854444|NCT03926039|Experimental|sharing decision-making program interventions|"Description of conventional traditional treatment options and add sharing decision-making program The intervention measures in this study sharing decision-making plan mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process."
9854445|NCT03926039|No Intervention|Description of traditional treatment options|Description of conventional traditional treatment options
9854446|NCT03927911|Active Comparator|Open or mini-open surgical technique cohort|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
9854447|NCT03927911|Active Comparator|Tubular or Percutaneous cohort (Minimally Invasive Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
9854448|NCT03927911|Active Comparator|Lumbar decompression without fusion (Outpatient Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
9854449|NCT03937570|Experimental|EO GROUP|Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.
9854450|NCT03937570|No Intervention|CONTROL GROUP|Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.
9854451|NCT03938857|Placebo Comparator|Fen. SOC+saline placebo (bolus+infusion)|Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
9854452|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
9854453|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
9854454|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
9854455|NCT03941912|Experimental|Erchonia EVRL|635 nanometers (nm) and 405 nm dual-diode laser application
9854456|NCT03945981|Experimental|Participants receiving Dolutegravir + Lamivudine FDC|Participants will receive DTG 50mg and 3TC 300 mg FDC tablet orally once daily (OD) with or without food
9854457|NCT03950167||Hyperemesis gravidarum|pregnant women before 14 weeks of pregnancy diagnosed with hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
9854458|NCT03950167||Healthy pregnant women|Healthy pregnant women before 14 weeks of pregnancy without hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
9854459|NCT03954834|Experimental|5 mg Tirzepatide|Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
9854460|NCT03954834|Experimental|10 mg Tirzepatide|Participants received 10mg of tirzepatide as subcutaneous injection once a week.
9854461|NCT03954834|Experimental|15 mg Tirzepatide|Participants received 15mg of tirzepatide as subcutaneous injection once a week.
9854462|NCT03954834|Placebo Comparator|Placebo|Participants received placebo as subcutaneous injection once a week.
9854463|NCT03958071||Subjects with Idiopathic Pulmonary Fibrosis|
9854464|NCT03961529|Experimental|0.3% OPA-15406 ointment|Twice daily
9854465|NCT03961529|Experimental|1% OPA-15406 ointment|Twice daily
9854466|NCT03968159|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
9854467|NCT03968159|Placebo Comparator|Placebo|Placebo tablets
9854468|NCT03968965|Experimental|3D MvIGS|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 3D MvIGS intraoperative navigation guidance.
9854469|NCT03968965|Other|2D Fluoroscopy|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 2D fluoroscopy.
9854470|NCT03970824|Experimental|CT-P17|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
9854471|NCT03970824|Active Comparator|US-licensed Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
9854472|NCT03970824|Active Comparator|EU-approved Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
9854473|NCT03978403|Experimental|ABDC|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
9854474|NCT03978403|Experimental|BCAD|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
9854475|NCT03978403|Experimental|CDBA|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
9854476|NCT03978403|Experimental|DACB|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
9854477|NCT03979807||Subjects with Chronic obstructive pulmonary disease|
9854478|NCT03980470|Other|Normal-dose versus Low-dose|"The standard intervention consists of the routinely performed cardiac CT datasets reconstructed with a standard iterative reconstruction algorithm (ASIR-V). Median radiation dose is about 0.5 mSv, range between about 0.2 and 1.2 mSv; median contrast agent administration about 45 mL, range between 35 and 55 mL.~The experimental intervention is an additional CT scan with a lower dose (about 20 to 50% decrease) and a similar contrast agent administration that is reconstructed with a deep-learning image reconstruction immediately after the clinical CT scan. The additional time required is about 5 minutes."
9854479|NCT03982069|Active Comparator|FluMist live attenuated influenza vaccine|Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
9854480|NCT03982069|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
9854481|NCT03984812|Experimental|Part 1,Cohort 1:Subjects receiving blinded GSK3732394 10mg/PBO|GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects.
9854482|NCT03984812|Experimental|Part 1,Cohort 2:Subjects receiving blinded GSK3732394 40mg/PBO|GSK3732394 40 mg or PBO will be administered by SC injection to the subjects. This is projected dose, dose will be based on PK/PD results from preceding dosing cohorts.
9854483|NCT03984812|Experimental|Part1,Cohort 3:Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts.
9854484|NCT03984812|Experimental|Part1,Cohort 4:Subjects receiving blinded GSK3732394 350mg/PBO|GSK3732394 350 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
9854485|NCT03984812|Experimental|Part1,Cohort5: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
9854486|NCT03984812|Experimental|Part1,Cohort6: Subjects receiving blinded GSK3732394 800mg/PBO|GSK3732394 800 mg or PBO will be administered by SC injection to the subjects. This is a projected dose and will be given if necessary. The dose administered in Part 1, Cohort 6 (if necessary) will be based on PK/PD results from preceding dosing cohorts.
9854487|NCT03984812|Experimental|Part2,Cohort1: Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The dose administered in Part 2, Cohort 1 will be based on PK/PD results from preceding dosing cohorts.
9854488|NCT03984812|Experimental|Part2,Cohort2: Subjects receiving blinded GSK3732394 400mg/PBO|GSK3732394 400 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 2 will be based on PK/PD results from preceding dosing cohorts.
9854489|NCT03984812|Experimental|Part2,Cohort3: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1).
9986392|NCT01402453|Experimental|Intervention Subjects|Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
9986393|NCT01402466|Active Comparator|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
9854490|NCT03985813|Experimental|Screening Wizard|Youth and parents receiving Screening Wizard will be screened for depression and suicidal risk within their pediatric primary care provider's office. Screening will be analyzed in real-time to produce a decision support tool meant to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
9854491|NCT03998163|Experimental|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
9854492|NCT04000373|Other|gait training with exoskeleton device|uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
9854493|NCT04001517|Experimental|Neflamapimod|40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
9854494|NCT04001517|Placebo Comparator|Placebo|40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
9854495|NCT04006171|Active Comparator|women with polycystic ovary syndrome|36 patients with PCOS
9854496|NCT04006171|Active Comparator|Healthy women of reproductive age|30 patients with regular normal menstrual cycle
9854497|NCT04011436|Experimental|Core, Hip and knee.|Physical Exercises to strengthen the core, hip and knee.
9854498|NCT04011436|Sham Comparator|Hip and Knee|Physical Exercises to strengthen the hip and knee.
9854499|NCT04011592|Experimental|Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)
9854500|NCT04011592|Experimental|Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)
9854501|NCT04013529|Placebo Comparator|Control|Participate in technology-enabled care without regret lottery
9854502|NCT04013529|Experimental|Experimental|Participate in technology-enabled care with regret lottery
9854503|NCT04016324|Other|Basic evaluation|Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
9854504|NCT04018066|Experimental|GP-SPI intervention|20 g of GP-SPI taken twice per day for 10 days
9854505|NCT04018794|Experimental|Behavioral/organizational skills intervention plus mobile app|Behavioral/organizational skills intervention plus mobile application (16, 20-30 minute sessions, twice/weekly for 8 weeks)
9854506|NCT04032327|Active Comparator|Plain Bupivacaine|20 mL of 0.25% plain bupivacaine
9854507|NCT04032327|Active Comparator|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed
9854508|NCT04033640|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as finger-stick capillary blood samples.~At the clinic site, study staff performed the SD Biosensor STANDARD G6PD test and the POC HemoCue hemoglobin test on finger stick blood samples.~At the reference laboratories, G6PD activity was measured from whole blood samples using the SD Biosensor STANDARD G6PD test and the Pointe Scientific G6PD reference assay and hemoglobin was measured using the HemoCue hemoglobin test and by a complete blood count (CBC) using an automated hematology analyzer (Manaus site only)."
9854509|NCT04033640|No Intervention|Health Workers|Participants were trained on use of the SD Biosensor STANDARD G6PD test by members of the study team with extensive experience with G6PD diagnostics and the STANDARD G6PD test. Health worker participants were surveyed to assess label and packing comprehension as well as results interpretation.
9854510|NCT04036292|Active Comparator|OC-01 Low Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.6 mg/ML
9854511|NCT04036292|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/ML
9854512|NCT04036292|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
9854513|NCT04041440|Experimental|Auditory Training|Pre- and post assessments of auditory training intervention
9854514|NCT04041570|Experimental|Group 1: cAd3-EBO S vaccine (1x10^10 PU)|cAd3-EBO S vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
9854515|NCT04041570|Experimental|Group 2: cAd3-EBO S vaccine (1x10^11 PU)|cAd3-EBO S vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
9854516|NCT04043143|Placebo Comparator|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
9854517|NCT04043143|Experimental|Arm 2 Prescription Tool Intervention|At the time of writing the discharge prescription for a patient the provider will be informed by the best practice alert (BPA) Prescription Tool that a patient may be considered for a lower post-discharge opioid dose (no opioids for patients who did not take any opioids in the last 24 hours, and 10 oxycodone 5mg tablets, for patients having taken less than 22.5 MME, e.g. 1-3 oxycodone 5mg tablets in the last 24 hours). Final dosing decisions and drug choices will remain at the discretion of the treating provider and decisions will be tracked.
9854518|NCT04049123|Active Comparator|Insulin Lispro (Humalog)|15 units (U) Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.
9854519|NCT04049123|Experimental|LY900014|7 U, and 15 U LY900014 administered once, SC, in two of three study periods.
9854520|NCT04051463|Active Comparator|Netarsudil|A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
9854521|NCT04051463|Placebo Comparator|Placebo|A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.
9854522|NCT04052204|Experimental|Combination A|Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
9854523|NCT04052204|Experimental|Combination B|Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
9854524|NCT04052204|Experimental|Combination C|Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
9854525|NCT04054661|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor STANDARD point-of-care G6PD test and the point-of-care HemoCue hemoglobin test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
9854526|NCT04067011|Experimental|Group 1:Ciprofloxacin + AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 1 will concomitantly receive ciprofloxacin."
9854527|NCT04067011|Experimental|Group 2: Doxycycline +AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 2 will concomitantly receive doxycycline."
9854528|NCT04067011|Experimental|Group 3: AV7909|Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
9854529|NCT04072159|Experimental|Pharmacist-Administered HPV Vaccine Series Completion group|For the Pharmacist-Administered HPV Vaccine Series Completion group (intervention group), primary care providers will refer patients who have received the initial HPV vaccine to receive the additional doses at patients' community retail pharmacies. Patients between ages 9-14 will need to receive one additional HPV vaccine dose with their community pharmacist 6-12 months after receiving Dose 1. Patients aged 15 and older will need to receive the 2nd dose 1-2 months after receiving the first HPV vaccine dose and the 3rd dose 6-months after receiving the initial dose.
9935113|NCT04159805|Placebo Comparator|TAK-079 Placebo-matching|TAK-079 placebo-matching injection, subcutaneously, once weekly for 8 weeks.
9854530|NCT04072159|No Intervention|Primary Care Provider HPV Vaccine Series Completion|Participant in the Primary Care Provider HPV Vaccine Series Completion (control group) will receive standard care and will be scheduled to return to the clinic for the remaining HPV vaccine doses.
9854531|NCT04085341|Experimental|GB-102 Dose 1 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.
9854532|NCT04085341|Experimental|GB-102 Dose 2 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.
9854533|NCT04094870|Active Comparator|Antidepressant medication|Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table
9854534|NCT04094870|Active Comparator|Interpersonal therapy|Up to 11 planned therapy sessions over a 24-week period beginning the day of randomization
9854535|NCT04096482|Experimental|Standard 30° 4mm Endoscope Followed by Peregrine Endoscope|Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.
9854536|NCT04098172|Experimental|Pressure Guidewire test subject|Stable patients with suspected or known CAD, who are scheduled for diagnostic angiography and pressure wire assessment, and signed the informed consent, will be screened for enrollment in this study.
9854537|NCT04103515||Subjects implanted with PCR TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
9854538|NCT04103515||Subjects implanted with PS TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
9854539|NCT04111276|Experimental|Subjects diagnosed with osteoarthritis of the knee|Subjects must be diagnosed with marked unicompartimental degenerative joint space narrowing.
9854540|NCT04123405|Experimental|Group A: 600 mg acetylcysteine|one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
9854541|NCT04123405|Experimental|Group B: 1200 mg acetylcysteine|two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
9854542|NCT04123405|Experimental|Group C: 2400 mg acetylcysteine|four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)
9854543|NCT04123405|Placebo Comparator|Group D: Placebo|four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
9854544|NCT04132973|Experimental|Compassion guided self-help|Participants will engage in a six-week online compassion-based self-help programme with email guidance from the researcher.
9854545|NCT04133415|Experimental|Lattice stereotactic body radiation therapy|-Lattice SBRT prescribed to a dose of 20 Gy in 5 fractions with a simultaneous integrated boosts of 66.7 Gy in 5 fractions
9854546|NCT04138758||Patients initiating Tiotropium+Olodaterol therapy|
9854547|NCT04138758||Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy|
9854548|NCT04147715|Placebo Comparator|Part 1: Placebo|Participants received a single oral dose of matching placebo in a fasted state on Day 1.
9854549|NCT04147715|Experimental|Part 1: 10 mg S-648414|Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.
9854550|NCT04147715|Experimental|Part 1: 30 mg S-648414|Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.
9854551|NCT04147715|Experimental|Part 1: 100 mg S-648414|Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.
9854552|NCT04147715|Experimental|Part 1: 250 mg S-648414|Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.
9854553|NCT04147715|Experimental|Part 1: 500 mg S-648414|Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.
9854554|NCT04147715|Experimental|Part 1: 1000 mg S-648414|Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.
9854555|NCT04147715|Placebo Comparator|Part 2: Placebo + Midazolam|Participants received matching placebo once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.
9986394|NCT01402466|Experimental|Project Bridge|Participants randomized to this arm will be given the Project Bridge intervention
9986395|NCT01402479|Active Comparator|ramipril|open label single arm trial
9854556|NCT04147715|Experimental|Part 2: 50 mg S-648414 + Midazolam|Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
9854557|NCT04147715|Experimental|Part 2: 30 mg S-648414 + Midazolam|Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
9854558|NCT04147715|Experimental|Part 3: 100 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.
9854559|NCT04147715|Experimental|Part 3: 200 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.
9854560|NCT04150068|Experimental|Cohort 1A: Lenacapavir|"Participants with human-immunodeficiency virus-1 ribonucleic acid (HIV-1 RNA) ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at Cohort Selection visit compared with screening visit will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive subcutaneous (SC) lenacapavir 927 mg and will initiate an OBR at Day 1 SC Visit (14 days after the first dose of oral lenacapavir). Participants will receive their subsequent SC lenacapavir injection at Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
9854561|NCT04150068|Placebo Comparator|Cohort 1B: Placebo|"Participants with HIV-1 RNA ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at the Cohort Selection visit compared with screening visit will receive oral lenacapavir placebo on Days 1, 2, and 8 while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive oral lenacapavir 600 mg on Days 15 and 16 and 300 mg on Day 22, and will initiate an OBR on Day 15. At Day 1 SC (14 days after the first dose of oral lenacapavir), participants will receive SC lenacapavir 927 mg while continuing OBR. Participants will receive their next SC injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue study in the country."
9923744|NCT00853853|Active Comparator|1. EnSeal Device|The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
9935114|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 1|Participants will receive 1 dose of Dose Level 1 of mRNA-3927 by intravenous (IV) infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
9986396|NCT01402505||Transvaginal NOTES sleeve gastrectomy|Transvaginal NOTES sleeve gastrectomy
9986397|NCT01402518||Per-oral endoscopic myotomy|
9854562|NCT04150068|Experimental|Cohort 2: Lenacapavir|"Participants with a ≥ 0.5 log10 copies/mL HIV-1 RNA decline at the Cohort Selection Visit compared with the screening visit or with HIV-1 RNA < 400 copies/mL or if Cohort 1 is fully enrolled will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, and will initiate an OBR on Day 1 in Oral Lead-in Period (Baseline to Day 14); followed by Maintenance Period where participants will receive SC lenacapavir 927 mg at Day 1 SC Visit (14 days after the first dose of oral lenacapavir) while continuing their OBR. Participants will receive their subsequent SC lenacapavir injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given the option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
9854563|NCT04154605|Active Comparator|ClariFix|Cryotherapy of the nasal passages with the ClariFix device.
9854564|NCT04154605|Sham Comparator|Sham|Sham cryotherapy of the nasal passages with the ClariFix device
9854565|NCT04160091|Experimental|FX006 32mg in Glenohumeral OA Population|Single intra-articular (IA) injection
9854566|NCT04160091|Placebo Comparator|Normal Saline in Glenohumeral OA Population|Single intra-articular (IA) injection
9854567|NCT04160091|Experimental|FX006 32mg in Adhesive Capsulitis Population|Single intra-articular (IA) injection
9854568|NCT04160091|Placebo Comparator|Normal Saline in Adhesive Capsulitis Population|Single intra-articular (IA) injection
9854569|NCT04160260|Experimental|Omadacycline: Omadacycline Tablets|
9854570|NCT04164758|Experimental|Drug - pimavanserin|Pimavanserin 34 mg provided as 2 x 17 mg encapsulated tablets
9854571|NCT04164758|Placebo Comparator|Placebo|Placebo encapsulated tablet
9854572|NCT04164758|Active Comparator|Quetiapine|Immediate release Quetiapine encapsulated tablets
9854573|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A1 High Dose|Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles.
9854574|NCT04165031|Experimental|LY3499446 Phase 1 Cohort AO Mid Dose|Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles.
9854575|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A-2 Low Dose|Participants received low dose LY3499446 as oral monotherapy once daily (QD) in 21-Day cycles.
9854576|NCT04165031|Experimental|LY3499446 + Combination Drugs Phase 1|"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~This trial was terminated prior to initiation of combination therapy cohorts."
9854577|NCT04165031|Experimental|LY3499446 Monotherapy + Combination Drugs Phase 2|"LY3499446 as oral monotherapy and LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~The trial was terminated prior to initiation of Phase 2 of this study."
9854578|NCT04165031|Active Comparator|Docetaxel Phase 2|"Docetaxel IV infusion.~The trial was terminated prior to initiation of Phase 2 of this study."
9854579|NCT04166032|Experimental|ANICGM|non-invasive continuous glucose monitoring device
9854580|NCT04171414|Experimental|"CT-P17 SC AI (adalimumab)"|CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)
9854581|NCT04175808|Experimental|Part A|After an overnight fast of at least 10 hours participants received a single oral dose of 25 mg omecamtiv mecarbil on Day 1.
9854582|NCT04175808|Experimental|Part B|"Participants with a maximum observed plasma OM concentration ≤ 350 ng/mL in Part A were randomly assigned to receive a single dose of each the following 3 treatments in one of six treatment sequences:~Placebo~50 mg omecamtiv mecarbil~400 mg moxifloxacin Each treatment was separated by a washout of at least 7 days."
9986398|NCT01402557|Active Comparator|Telephone Support Only|These participants receive telephone support only during the weight maintenance phase.
9854583|NCT04178720|Experimental|LID018869|Lehfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
9854584|NCT04178720|Active Comparator|Biofinity|Comfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
9854585|NCT04184297||Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)|
9854586|NCT04184297||Subjets initiated with LABA/LAMA/ICS|Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods
9854587|NCT04189848|Experimental|Semaglutide followed by dulaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
9854588|NCT04189848|Experimental|Dulaglutide followed by semaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
9854589|NCT04210232|Experimental|TECNIS® TORIC II Intraocular Lens (IOL)|Subjects will be implanted with the TECNIS Toric II IOL in one or both eyes qualified for study inclusion
9854590|NCT04211909|Experimental|SOF/VEL|Participants with chronic HCV infection (genotype 1 or 2), who are treatment-naive or treatment-experienced with interferon (IFN)-based treatments will receive SOF/VEL for 12 weeks.
9854591|NCT04211909|Experimental|SOF/VEL/VOX|Participants with chronic HCV infection (genotype 1), who are treatment-experienced with nonstructural protein 5A (NS5A) direct-acting antiviral (DAA)-based treatments of at least 4 weeks duration will receive SOF/VEL/VOX for 12 weeks.
9854592|NCT04218110|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
9854593|NCT04218110|Experimental|Project X 10.5ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
9854594|NCT04218110|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
9854595|NCT04218110|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.
9854596|NCT04222725|Experimental|TRS01 low dose|
9854597|NCT04222725|Experimental|TRS01 medium dose|
9854598|NCT04222725|Experimental|TRS01 high dose|
9854599|NCT04222725|Placebo Comparator|Placebo|
9854600|NCT04223843|Experimental|Active Arm|Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat
9854601|NCT04223843|Placebo Comparator|Placebo Arm|Matching placebo via Respimat
9854602|NCT04229303|Experimental|Part 1 - ZP-059 5mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 1: 5mg (1 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
9854603|NCT04229303|Experimental|Part 1 - ZP-059 10mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 2: 10mg (2 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
9854604|NCT04229303|Experimental|Part 1 - ZP-059 20mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 3: 20mg (4 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
10208615|NCT05210296|Experimental|Lower extremity strengthening exercises|"After 5 minutes of warm-up exercises, lower extremity strengthening exercises and 10 minutes of balance exercises will be applied to the participants, and the session will end with 5 minutes of cool-down exercises.~In lower extremity strengthening exercises, lower extremity resistance exercises will be applied with elastic exercise band."
10208616|NCT05210296|No Intervention|Control|Participants will not be included in any exercise program. At the end of the study, the elderly will be informed about the effects of exercises and appropriate exercise program training will be given.
10208617|NCT05210257|Other|Conventional physiotherapy|Conventional physiotherapy program consists of neck isometric exercises, neck isotonic exercises, stabilization exercises, stretching exercises and posture exercises and physiotherapy agents.
9854605|NCT04229303|Experimental|Part 1 - ZP-059 40mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 4: 40mg (8 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
9854606|NCT04229303|Experimental|Part 2 - ZP-059 10mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Days 1 to 10.~Cohort 1: 10mg (2 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
9854607|NCT04229303|Experimental|Part 2 - ZP-059 20mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 2: 20mg (4 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
9854608|NCT04229303|Experimental|Part 2 - ZP-059 40mg qd|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 3: 40mg (8 x 5 mg capsule) ZP-059 once daily (qd) administered via DPI (RS01 monodose device) on Days 1 to 10."
10208618|NCT05210257|Active Comparator|Neuroscience education|Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.
10208619|NCT05210244|Experimental|BJ supplementation|
10208620|NCT05210244|Placebo Comparator|PLA supplementation|
10208621|NCT05210218|Experimental|mildly hypocaloric diet + CC 300 mg +WS 150 mg tid|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK) to be taken three times a day. All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
10208622|NCT05210218|Placebo Comparator|mildly hypocaloric diet + placebo tid|Each patient took the placebo (i.e., the same amount of cellulose). All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
10208623|NCT05210205|Experimental|EAA-enhanced food products|Consume approximately 1500 calories of EAA-enhanced food products plus ad libitum consumption of 3 combat rations each day during training.
10208624|NCT05210205|Experimental|Energy dense food products|Consume approximately 1500 calories of energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
10208625|NCT05210205|Active Comparator|Control food products|Consume approximately 1500 calories of low energy dense food products plus ad libitum consumption of 3 combat rations each day during training.
10208626|NCT05210192|Placebo Comparator|placebo arm|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. Placebo group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
10208627|NCT05210192|Active Comparator|lidocaine arm|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. Lidocaine group will be injected with 4ml of 0.1%Lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
9854609|NCT04229303|Experimental|Part 3 - ZP-059 / Oral Voriconazole|Crossover treatment period: Single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI, and a single dose of oral voriconazole (200 mg Vfend® tablet) on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
9854610|NCT04229303|Experimental|Part 3 - Oral Voriconazole / ZP-059|Crossover treatment period: Single dose of oral voriconazole (200 mg Vfend® tablet), and a single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
9854611|NCT04243421|Experimental|Group with implants|"Flap will be elevated following the crestal and releasing incisions (if necessary).~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below."
9854612|NCT04244084|Experimental|MMH-407|Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.
9854613|NCT04244084|Placebo Comparator|Placebo|According to the scheme of receiving MMN-407 until the end of the study.
9854614|NCT04256603|Other|Gabapentin early|Gabapentin prior to admission
9854615|NCT04256603|Other|Gabapentin late|Gabapentin during admission
9854616|NCT04256603|Other|No gabapentin|No gabapentin
9854617|NCT04258995|Experimental|GBS6 no aluminum phosphate (GBS6 no AlPO4)|
9854618|NCT04258995|Experimental|GBS6 with aluminum phosphate (GBS6 with AlPO4)|
9854619|NCT04280445|Experimental|Psychological therapy|All participants will receive psychological therapy. There will be no placebos or waiting list controlled participants to compare findings to.
9854620|NCT04290494||CNSR I (2007 to 2008)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
9854621|NCT04290494||CNSR II (2012 to 2013)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
9854622|NCT04290494||CNSR III (2015 to 2017)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
9854623|NCT04303156|Experimental|Severe Renal Impairment|Participants with severe renal impairment received a single oral dose of 60 mg MK-8591 (Islatravir) administered in capsule form.
9854624|NCT04303156|Experimental|Healthy|Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.
9854625|NCT04317040|Experimental|CD24Fc|Participants receive single dose of 480 mg CD24Fc, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1.
9854626|NCT04317040|Placebo Comparator|Placebo|Participants receive single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes, on Day 1.
9854627|NCT04319159|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single Photodynamic therapy (PDT)."
9854628|NCT04321239|Experimental|Intervention group|Participants will engage in a 7-week positive psychology-based chronic pain self-management program.
9854629|NCT04321239|No Intervention|Usual care control group|After completing the follow-up telephone survey, individuals in the control condition will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a one-time 2.5-hour in-person or telephone workshop that summarizes intervention content and that will be led jointly by study staff and a community health worker.
9854630|NCT04323852|Experimental|vitamin D|35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units
9854631|NCT04323852|Placebo Comparator|control group|35 patients that will receive placebo for 3 days and each day for 3 doses
9854632|NCT04327843|Experimental|CAE + LAI|Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)
9854633|NCT04331899|Experimental|Study drug Peginterferon Lambda-1a|Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
9854634|NCT04331899|Placebo Comparator|Placebo injection|Study participants will receive a placebo along with the standard of care treatment.
9854635|NCT04334148|Active Comparator|Hydroxychloroquine|Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.
9854636|NCT04334148|Placebo Comparator|Placebo|Matching placebo tablets
9854637|NCT04343287|Active Comparator|BRM421 Ophthalmic Solution|A topical solution of BRIM421 ophthalmic drops
9854638|NCT04343287|Placebo Comparator|Placebo|A vehicle ophthalmic drops
9854639|NCT04347954|Experimental|Povidone-Iodine 2%|"Participants will administer PVP-I 2% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
9854640|NCT04347954|Experimental|Povidone-Iodine 0.5%|"Participants will administer PVP-I 0.5% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5"
9854641|NCT04347954|Placebo Comparator|Isotonic saline 0.9%|"Participants will administer two sprays of isotonic saline nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
9854642|NCT04349098|Experimental|Selinexor 20 mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
9854643|NCT04349098|Placebo Comparator|Placebo|Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
9854644|NCT04353037|Experimental|Sub Study 1 Patients|Patients tested for COVID-19 who meet symptomology and age requirements for eligibility
9854645|NCT04353037|Experimental|Sub Study 2 Health Care Workers|Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months
9854646|NCT04355117|Experimental|Treatment: TEV-48125|
9854647|NCT04355767|Experimental|Convalescent Plasma|Participants receive 1 unit of convalescent plasma.
9854648|NCT04355767|Placebo Comparator|Placebo|Participants receive 1 unit of saline with multivitamin.
9854649|NCT04356573|Placebo Comparator|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects first ate 2 gold kiwifruit with midday meal for 2 weeks before crossing over to the green Hayward kiwifruit intervention
9854650|NCT04356573|Active Comparator|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects first ate 2 green Hayward kiwifruit with midday meal for 2 weeks before crossing over to the gold kiwifruit intervention
9854651|NCT04357379|Experimental|IQOS group|
9854652|NCT04358068|Experimental|Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|"Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days)."
9935115|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 2|Participants will receive 1 dose of Dose Level 2 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
9854653|NCT04358068|Placebo Comparator|Arm B: Placebo for Hydroxychloroquine and Azithromycin|"Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days)."
9854654|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 70 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
9854655|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 140 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
9854656|NCT04366349|Placebo Comparator|Participants receiving Placebo|Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).
9854657|NCT04369885|Experimental|Home Telemedicine Device|This arm will receive the intervention of the home telemedicine device for three months.
9854658|NCT04373421|Active Comparator|chlorhexidine gluconate plus benzydamine hydrochloride|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects. The most common side effect of chlorhexidine is oral discoloration, taste changes and allergic responses. Furthermore, it has been reported that chlorhexidine has cytotoxic effect on gingival fibroblasts, epithelial cells, neutrophils and red blood cells; also shows incremental trend in genotoxicity as the duration of usage is increased. Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that elicits anti-inflammatory, analgesic, anesthetic and antimicrobial effects. It is often used in addition to the topical application of chlorhexidine.. However, side effects such as urticaria, erythema, pruritus, photosensitivity, bronchospasm and renal problems can be observed associated with the use of benzydamine.
9854659|NCT04373421|Active Comparator|St. John's wort oil|St. John's Wort (Hypericum perforatum) is a European medicinal plant with a history of more than 2000 years which possessing a variety of important constituents including phloroglucinols (hyperforin and adhyperforin), naphthodianthrones (hypericin and pseudohypericin), xanthones, essential oil, biflavones (biapigenin and amentoflavone), flavonol derivatives and phenolic compounds. The important components of St. John's Wort such as hypericin and hyperforin exert anti-inflammatory, antimicrobial, anticancer effects as well as stimulating tissue growth and differentiation. Hypericin exhibits anti-inflammatory effects by inhibiting the production of interleukin-12; whereas hyperforin reveals this effect by inhibiting the mechanisms of cyclooxygenase 1, 5-lipoxygenase and prostaglandin E2. St. John's Wort oil is extracted by maceration of the hypericum herb in carrier oil, such as virgin olive oil.
9854660|NCT04373421|Active Comparator|Virgin olive oil|The olive oil, a product extracted from the fruit of Olea europaea, exerts also antioxidant and anti-inflammatory effects due to its important contents including oleic acids, phenolic acids, secoiridoids and flavonoids. The oral application of olive oil has been shown to have protective anti-inflammatory effects and accelerated epithelial healing.
9854661|NCT04381728|Experimental|Womed Leaf|"At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.~Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.~A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion."
9854662|NCT04382053|Experimental|DFV890 + SoC|DFV890 was administered for 14 days in addition to SoC.
9854663|NCT04382053|Active Comparator|Standard of Care (SoC)|SoC was used as an active comparator arm.
9854664|NCT04388826|Experimental|Veru-111 18 mg|Veru-111 18mg capsules
9854665|NCT04388826|Placebo Comparator|Placebo|Placebo capsules
9854666|NCT04394845|Experimental|[18F]GTP1|Participants will receive a single bolus injection of radioligand [18F]GTP1 intravenously (IV).
9854667|NCT04398732||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.
9854668|NCT04401293|Experimental|Full Dose LMWH anticoagulation therapy|Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and < 30ml/min) during the course of their hospitalization.
9935116|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 3|Participants will receive 1 dose of Dose Level 3 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
9854669|NCT04401293|Active Comparator|Prophylactic/Intermediate Dose LMWH or UFH therapy|Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.
9854670|NCT04411628|Experimental|LY3819253|Participants received single doses of 700 milligrams (mg), 2800 mg or 7000 mg LY3819253 administered as intravenous infusion.
9854671|NCT04411628|Placebo Comparator|Placebo|Participants received single dose of Placebo as intravenous infusion.
9854672|NCT04418947|No Intervention|No intervention|
9854673|NCT04418947|Active Comparator|MPM control letter|
9854674|NCT04418947|Experimental|MPM intervention letter|
9854675|NCT04418947|Active Comparator|Mailed control letter|
9854676|NCT04418947|Experimental|Mailed intervention letter|
9854677|NCT04420273|Experimental|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
9854678|NCT04420273|Active Comparator|Active control: Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
9854679|NCT04420572|Experimental|ozone injection group|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
9854680|NCT04420572|Experimental|steroid injection group|1ml betamethasone will be used for steroid injection.
9854681|NCT04428411||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease
9854682|NCT04435184|Experimental|Crizanlizumab|Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
9854683|NCT04435184|Active Comparator|Placebo Saline|0.9% saline 100 ml IV once.
9854684|NCT04476784|Other|LID018869, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
9854685|NCT04476784|Other|Biofinity, then LID018869|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
9854686|NCT04484207|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
9854687|NCT04484207|Experimental|vignette intervention|A brief vignette about coping with COVID-19 stress presented to the participants
9854688|NCT04484207|No Intervention|Control|Only assessment, no intervention arrm
9854689|NCT04485455|Experimental|iTBS Therapy|Teenage participants with depression will receive iTBS therapy using a Transcranial Magnetic Stimulation (TMS) protocol delivering electro-magnetic stimulation
9854690|NCT04495283|Experimental|PGB and APAP (Group A)|Group A receives PGB plus APAP prior to surgery and placebo 1 post-surgery.
9854691|NCT04495283|Experimental|APAP (Group B)|Group B receives placebo 2 prior to surgery and APAP post-surgery.
9854692|NCT04495283|Experimental|Placebo (Group C).|Group C receives placebo 1 prior to surgery and placebo 2 post-surgery.
9854693|NCT04497948|Other|Single Arm|Single Arm
9854694|NCT04501640|Experimental|Mirabegron 25 mg fed/Mirabegron 25 mg fasted|Participants received single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 25 milligram (mg) mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
9854695|NCT04501640|Experimental|Mirabegron 25 mg fasted/Mirabegron 25 mg fed|Participants received single dose of 25 mg mirabegron tablet under fasted condition orally, on day 1 of period 1 followed by single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
9854696|NCT04501640|Experimental|Mirabegron 50 mg fed/Mirabegron 50 mg fasted|Participants received single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
9854697|NCT04501640|Experimental|Mirabegron 50 mg fasted/Mirabegron 50 mg fed|Participants received single dose of 50 mg mirabegron under fasted condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
9854698|NCT04501952|Experimental|Remdesivir (RDV)|Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.
9854699|NCT04501952|Placebo Comparator|Placebo|Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.
9854700|NCT04504032|Experimental|Rivaroxaban|
9854701|NCT04504032|Placebo Comparator|Placebo|
9854702|NCT04507763||Patients with ankylosing spondylitis|Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease
9854703|NCT04507867|Sham Comparator|control group|Patients who received the standard diet
9854704|NCT04507867|Experimental|Intervention group|Patients who received the nutritional support system (NSS) and the standard diet
9854705|NCT04525079|Experimental|Cohort 1|Cohort 1 will receive a dose of CT-P59 or matching placebo
9854706|NCT04525079|Experimental|Cohort 2|Cohort 2 will receive a dose of CT-P59 or matching placebo
9854707|NCT04525079|Experimental|Cohort 3|Cohort 3 will receive a dose of CT-P59 or matching placebo
9854708|NCT04525079|Experimental|Cohort 4|Cohort 4 will receive a dose of CT-P59 or matching placebo
9854709|NCT04527978|Other|PRECISION1, then Biotrue ONEday|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9854710|NCT04527978|Other|Biotrue ONEday, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9854711|NCT04528017|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9854712|NCT04528017|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
9854713|NCT04529109|Experimental|Test/Control|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Test/Control).
9854714|NCT04529109|Experimental|Control/Test|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Control/Test).
9854715|NCT04536571|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
9854716|NCT04536571|Active Comparator|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
9854717|NCT04544787|Experimental|Group 1: One Dose of Novel OPV2 Candidate 1|Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
9854718|NCT04544787|Experimental|Group 2: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
9854719|NCT04544787|Experimental|Group 3: One Dose of Novel OPV2 Candidate 2|Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
9854720|NCT04544787|Experimental|Group 4: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
9854721|NCT04544787|Experimental|Group 5: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
9854722|NCT04544787|Experimental|Group 6: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
9854723|NCT04544787|Placebo Comparator|Group 7: Two Doses of Placebo|Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).
9854724|NCT04555031|Experimental|kalifilcon A lenses|
9854725|NCT04555031|Active Comparator|Dailies Total 1|
9854726|NCT04555031|Active Comparator|Precision 1|
9854727|NCT04555031|Active Comparator|Biotrue ONEday|
9854728|NCT04559282|Experimental|New SP followed by Baha 5 SP followed by single blinded SP|Aided hearing with new Sound Processor followed by aided hearing with the Baha 5 sound processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
9935117|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 4|Participants will receive 1 dose of Dose Level 4 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
9854729|NCT04559282|Experimental|Baha 5 SP followed by the New SP followed by single blinded SP|Aided hearing with Baha 5 sound processor followed by aided hearing with the new Sound Processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
9854730|NCT04580290||JewelACL + Autograft (Hybrid)|JewelACL + Autograft (Hybrid)
9854731|NCT04580290||JewelACL only|JewelACL only
9854732|NCT04601103|Experimental|Comparator: No SLS Toothpaste|3M Oral Rinse in combination with no SLS toothpaste (A)
9854733|NCT04601103|Experimental|Comparator: Medium SLS Toothpaste|3M Oral Rinse in combination with medium SLS toothpaste (B)
9854734|NCT04601103|Experimental|Comparator: High SLS Toothpaste|3M Oral Rinse in combination with high SLS toothpaste (C)
9854735|NCT04617574||AEON Endostapler|Stapling performed with AEON Endostapler
9854736|NCT04617574||Endo GIA Reloads with Tri-Staple Technology|Stapling performed with Endo GIA Reloads with Tri-Staple Technology
9854737|NCT04658797|Active Comparator|Single Vision Spectacle for Vision correction|Single Vision Spectacle
9854738|NCT04658797|Experimental|somofilcon A Daily disposable contact lenses|Daily disposable contact lenses
9854739|NCT04664855|Experimental|Experimental Yoga Group|35 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
9854740|NCT04664855|No Intervention|Control Group (No Yoga Intervention)|20 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
9854741|NCT04701658|Experimental|Bamlanivimab|Participants received 700 milligram single intravenous infusion of Bamlanivimab.
9854742|NCT04701658|No Intervention|Controls|"Matched controls who received standard of care.~[The study was originally designed to include a matched control arm. However, due to low enrollment, it was amended to be a single arm study with Bamlanivimab arm only. No matched controls were utilized.]"
9854743|NCT04706416|Experimental|N-Acetyl Glucosamine|All patients in the treatment arm of the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
9854744|NCT04706416|Placebo Comparator|Control|All patients in the comparator arm were admitted to the same hospital with COVID-19 but did not receive N-Acetyl Glucosamine treatment. All these patients were identified retrospectively.
9854745|NCT04709484|Experimental|USG-guided steroid injection group|In the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
9854746|NCT04709484|Experimental|Palpation-guided steroid injection group|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
9854747|NCT04727749|Experimental|Therapy Dog Team Visit|Patient interacts with the therapy dog and handler.
9854748|NCT04727749|No Intervention|No Therapy Dog Team Visit|No patient interaction with the therapy dog or handler.
9854749|NCT04777214|Active Comparator|Active TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS are delivered to a previously determined optimal response site in right frontal lobe.
9854750|NCT04777214|Sham Comparator|Sham TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz TMS are delivered, however, the coil will be rotated 90 degrees during stimulation.
9854751|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH|The ovarian stimulation (OS) protocols included monotherapy protocols with using follitropin alpha biosimilar only and antagonists/agonists of of gonadotropin-releasing hormone (GnRH): ganirelix, cetrorelix, triptorelin, buserelin.
9854752|NCT04854707||Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH|The OS protocols included: mixed protocols (recombinant with addition of urinary-derived gonadotropins) and antagonists/agonists of GnRH (ganirelix, cetrorelix, triptorelin, buserelin), where follitropin alpha biosimilar used for at least 5 days during OS.
9854753|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH|The OS protocols included: monotherapy protocols with using only follitropin alpha biosimilar and antagonists of GnRH.
9854754|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH|The OS protocol included: monotherapy protocols with using only follitropin alpha biosimilar and agonists of GnRH.
9854755|NCT04854707||The overall protocols|The OS protocols included: (1) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH, (2) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH
9854756|NCT04926233||COPD patients from US IBM Marketscan database|
9854757|NCT04926233||COPD patients from UK CPRD GOLD database|
9854758|NCT04943159|Experimental|Afamelanotide group A|
9854759|NCT04943159|Experimental|Afamelanotide group B|
9854760|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation|
9854761|NCT04947436|Active Comparator|Mechanical insufflation/ exsufflation|
9854762|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation and Mechanical insufflation/ exsufflation|
9854763|NCT05002972|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
9854764|NCT05002985|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
9935118|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 5|Participants will receive 1 dose of Dose Level 5 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
9854765|NCT04512482|Experimental|Experimental: Bromelain, Then Placebo|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the placebo rinse (powdered sugar), following the same protocol and series of intraoral photographs.
9854766|NCT04512482|Placebo Comparator|Experimental: Placebo, Then Bromelain|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of powdered sugar that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the bromelain rinse, following the same protocol and series of intraoral photographs.
9854767|NCT04499599|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
9854768|NCT04499599|Placebo Comparator|Breakfast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a breakfast bar on day 2.
9854769|NCT04499599|Experimental|Fast Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar on day 2.
9854770|NCT04525157|Experimental|Afamelanotide and NB-UVB|Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
9854771|NCT04525157|Placebo Comparator|Placebo and NB-UVB|Participants received Placebo implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
9854772|NCT04525157|Experimental|Single-Arm, Open Label Group|"The study design was modified into a single-arm, open label study with only one treatment group receiving afamelanotide implants plus NB-UVB light.~Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0)."
9854773|NCT04523831|Active Comparator|Ivermectin and Doxycycline|Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
9854774|NCT04523831|Placebo Comparator|Placebo|Standard treatment
9854775|NCT04521777|Experimental|Supportive care (exercise intervention)|Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week.
9854776|NCT04512703||Healthy Group|Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
9854777|NCT04512703||Arrhythmia Monitoring Group|Patients with a clinical indication for outpatient cardiac monitoring. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 90 days.
9854778|NCT04512703||Front Position Devices|All devices placed in the front position
9854779|NCT04512703||Side Position Devices|All devices placed in the side position
9854780|NCT04511520|Experimental|Physical training|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)
9854781|NCT04511520|Experimental|Trimetazidine|Treatment of trimetazidine in addition to standart therapy
9854782|NCT04511520|No Intervention|Control|Standard follow-up at the participating heart center
9854783|NCT04507776||Patients with spondyloarthropathies|Patients with spondyloarthrosis that received Etanercept as treatment for disease
9923745|NCT00853853|Active Comparator|2. Ferguson Hemorrhoidectomy|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced.
9923746|NCT00853866|Experimental|1|reboxetine + tDCS verum
9923747|NCT00853866|Experimental|2|reboxetine + sham tDCS
9923748|NCT00853866|Experimental|3|placebo drug + verum tDCS
9923749|NCT00853866|Experimental|4|placebo drug + sham tDCS
9923750|NCT00853879|Active Comparator|Arm 1. B6, B12, folate|Triple therapy with folate. Intervention #1.
9854784|NCT04502979|Experimental|Responsive Feeding|Intervention families will receive approximately 4 hours of ASL and development specific content related to language and feeding during home visits and phone calls. The initial in-home session with families will focus on teaching ASL signs indicative of hunger, thirst, and satiety. A video and placemat of mealtime signs will be left with families at the completion of the first visit. The remaining sessions, in-home over the next 3 months and by phone monthly thereafter for 6 months total, will focus on reinforcing ASL signing in addition to focused education on particular aspects of language development (receptive language preceding expressive language and increasing intentional communication), feeding development (such as hunger and fullness cues, fear of new foods, the importance of repeated food exposures, variations in intake from meal-to-meal, and the propensity to reject bitter tastes [many vegetables]55], and appropriate portion sizes and variety for healthy growth.
9854785|NCT04502979|No Intervention|Routine Care|No intervention is provided to the families in this group; however, portions of the intervention lessons will be made available after completion of data collection.
9854786|NCT04502056|Experimental|AMA RI - B- B - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color.
9854787|NCT04502056|Experimental|AMA RI - B - B - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
9854788|NCT04502056|Experimental|AMA RI - W - W - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
9854789|NCT04502056|Experimental|AMA RI - W - W - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
9854790|NCT04502056|Experimental|AMA DP - B- B - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color .
9854791|NCT04502056|Experimental|AMA DP - B- B - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
9854792|NCT04502056|Experimental|AMA DP - W- W - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
9854793|NCT04502056|Experimental|AMA DP - W- W - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
9854794|NCT04502056|Placebo Comparator|Control: AMA RI - B - B|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA"
9854795|NCT04502056|Placebo Comparator|Control: AMA RI - W - W|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA"
9854796|NCT04502056|Placebo Comparator|Control: AMA DP - B - B|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
9854797|NCT04502056|Placebo Comparator|Control: AMA DP - W - W|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
9854798|NCT04498403|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied twice daily (BID)
9854799|NCT04495374|Placebo Comparator|Group P(0) - Placebo|Patients were randomly allocated to Group P(0) - Placebo by a double blind randomized study. Group P(0) received two placebo tablets as medication, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
9854800|NCT04495374|Experimental|Group P(1) - Pregabalin 300mg|Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
9854801|NCT04495712|Active Comparator|Spironolactone|Patients randomized to active therapy with spironolactone
9854802|NCT04495712|Placebo Comparator|placebo|patients randomized to placebo
9854803|NCT04492397|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for one week and then switch to control lenses for one week.
9854804|NCT04492397|Active Comparator|Control Contact Lens|Subjects will be randomized to wear control lenses for one week and then switch to test lenses for one week.
9854805|NCT04491994|No Intervention|Standard of Care (SOC)|Patients selected in supportive arm will be given daily standard doses of oral Vit C (2g), Vit D (alfacalcidiol 1µg), Zinc (50mg) and paracetamol (as required).
9854806|NCT04491994|Experimental|HCQ arm|Patients selected in experimental arm will be given Tab HCQ (400mg BD on D0 followed by 200mg BD D1-D5) in addition to supportive treatment
9854807|NCT04491240|Experimental|EXO-1|Participants (n=10) in this group will receive standard therapy and exosomes of the first type.
9854808|NCT04491240|Experimental|EXO-2|Participants (n=10) in this group will receive standard therapy and exosomes of the second type.
9854809|NCT04491240|Placebo Comparator|Placebo|Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.
9854810|NCT04490863|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
9854811|NCT04490499|Experimental|HBVAXPRO™|Healthy children vaccinated approximately 8-9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™).
9854812|NCT04490239|Experimental|Experimental Arm|"Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL.~Acute phase:~On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~Chronic phase:~The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records."
9854813|NCT04486235|Experimental|Intervention|Receive experiential pamphlet
9854814|NCT04486235|No Intervention|Control|No materials, usual care
9854815|NCT04483011|Experimental|RiaGev|RiaGev, 2000mg, BID
9854816|NCT04483011|Active Comparator|Comparator|Comparator matched to RiaGev, BID
9854817|NCT04475588|Experimental|Arm A - Itolizumab + BSC|
9854818|NCT04475588|Active Comparator|Arm B - Best supportive care (BSC)|
9854819|NCT04474496||Marshallese adults in the U.S.|Marshallese persons 18 years of age or older currently residing in the United States
9854820|NCT04448210|Experimental|Educational website intervention|The intervention is an educational website designed to teach youth (12-17 years) about pediatric clinical trials.
9854821|NCT04448210|No Intervention|Wait-list control|The wait-list control group did not receive the intervention between the pre-test and post-test assessments. After completing the post-test questionnaire, youth in the wait-list control group had the option to receive access to the intervention (DigiKnowIt News).
9854822|NCT04474405|Experimental|Brain flortaucipir PET scan|Subjects receiving a brain PET scan after flortaucipir administration
9854823|NCT04474405|Experimental|Whole body flortaucipir PET scan|Subjects receiving a whole body PET scan after flortaucipir administration
9854824|NCT04474405|Other|MRI and Amyloid Extension Cohort|Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)
9854825|NCT04470375|Experimental|VR pain education|Students receiving the 45 minute pain education through Virtual Reality
9854826|NCT04468347|Experimental|Alzheimer's disease (AD)|Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
9854827|NCT04468347|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
9854828|NCT04468347|Experimental|Subjective memory complainers (SMC)|Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
9854829|NCT04468347|Experimental|Cognitively normal (CN)|Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months
9854830|NCT04467424|Experimental|Pediatric anesthesia with ketofol|ketamine, propofol
9854831|NCT04467424|Experimental|Pediatric anesthesia with ketofol plus lidocaine|ketamine, propofol, lidocaine
9854832|NCT04465422|Experimental|Intervention Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~The research at this stage is based on the theoretical framework of the MOHO model and the clinical practice of OTPF-3. Clinical experts are requested to assist in providing relevant suggestions as a reference for modifying intervention activities. Design OT@tcpc service model for occupational therapy intervention activities. The event design is based on the 4 systems of determinationl, habits, performance and environment, and 2 events are designed for each to be carried out in a group. Each activity includes 4 parts: warm-up, activity, feedback and homework. Each activity group will be explained separately so that the occupational therapist of the group can complete it under the guidance."
9854833|NCT04465422|Active Comparator|Control Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~This study was approved by the Institutional Review Board of Taipei City Hospital. After informed consent, the patients signed the consent form for this study and became the participant of this study.~Each activity group will be explained separately so that the participants of each group can complete it under the guidance. The group description includes: activity title, activity time (location), MOHO theory system, group purpose, activity content, equipment or materials, precautions, etc."
9854834|NCT04463004|Active Comparator|Intervention|Treatment infusion
9854835|NCT04463004|Placebo Comparator|Control|Placebo infusion
9854836|NCT04463069|Experimental|intervention group|Participants in the intervention group participated in the APA intervention consisting of simple and fun endurance and strength-building exercise at a frequency of two sessions per week.
9854837|NCT04463069|No Intervention|control group|Participants in the control group received no intervention in the study time period.
9923751|NCT00853879|Active Comparator|Arm 2. B6, B12, L-methylfolate|Triple therapy with L-methylfolate. Intervention #2
9923752|NCT00853879|Placebo Comparator|Arm 3. B6, B12, Placebo|Triple therapy with placebo. Intervention #3.
9923753|NCT00853892|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
9923754|NCT00853892|Active Comparator|B|OxyContin® 40 mg tablet
9923755|NCT00853918|Experimental|$20 Cash|
9923756|NCT00853918|Experimental|$50 Cash|
9923757|NCT00853918|Experimental|$50 Check|
9923758|NCT00853918|Experimental|$100 Check|
9923759|NCT00853931|Experimental|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
9923760|NCT00853944|No Intervention|P|subjects take 1 tablet of placebo daily
9923761|NCT00853944|Experimental|S|subjects take 1 tablet of sitagliptin 100 mg daily
9923762|NCT00854009|Experimental|1|BLI-489
9923763|NCT00854009|Placebo Comparator|2|Placebo
9923764|NCT00854022||Healthy|Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
9923765|NCT00854022||RCC|Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
9923766|NCT00854035|Experimental|E|
9923767|NCT00854035|Placebo Comparator|P|
9923768|NCT00854074|No Intervention|2|Subject will be observed until recovery of normal GI function
9923769|NCT00854074|Experimental|1|Spinal neurostimulation
9923770|NCT00854126|Experimental|1|
9923771|NCT00854139|Experimental|Bone marrow and renal transplant|Cyclophosphamide, anti-thymocyte globulin, thymic irradiation conditioning and kidney transplant and bone marrow transplant from a related donor for patients with multiple myeloma and end stage renal disease with cyclosporine for graft versus host disease prophylaxis
9923772|NCT00854152|Experimental|1|
9923773|NCT00854178|Experimental|2|
9923774|NCT00854191|Experimental|1|4 half-day of simulator ERCP practice and usual training
9923775|NCT00854191|Active Comparator|2|Usual training
9923776|NCT00854217|Placebo Comparator|placebo, hemodilution|
9923777|NCT00854230|Experimental|1|Naltrexone
9923778|NCT00854230|Placebo Comparator|2|
9923779|NCT00854256|Experimental|Canaloplasty|
9923780|NCT00854256|Active Comparator|Trabeculectomy with mitomycin C|
9923781|NCT00854295|Other|1|Follow-up of existing IDE study subjects
9854838|NCT04448561|Experimental|ASP8062 in combination with morphine|Participants received ASP8062 tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 dose.
9854839|NCT04448561|Placebo Comparator|Placebo in combination with morphine|Participants received ASP8062 matching placebo tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 matching placebo dose.
9854840|NCT04462731|Experimental|Obturation technique: WVT|Warm vertical compaction technique (WVT): Teeth filled with AH Plus Jet Root Canal Sealer were filled with .04 taper gutta-percha points by WVT. The sealer was introduced with the master cone. The depth of heated plugger was within 3-5 mm of WL in the WVT group, and the remaining canal space was backfilled with additional sealer and thermoplasticized gutta-percha.
9854841|NCT04462731|Active Comparator|Obturation technique: SBT|Sealer-based filling technique (SBT): Teeth filled with SBT were obturated with EndoSequence BC Sealer by injecting the sealer into the coronal third of each canal. Size 30 Lentulo spiral coated with additional sealer was introduced 3 mm short of WL depth at 300rpm. Bioceramic coated gutta-percha was dipped in BC sealer and introduced into the canal to WL. A heated plugger was used to sear the gutta-percha point at each orifice.
9854842|NCT04459585|Experimental|Dabigatran + Quizartinib|Participants who will receive a single oral dose of 150mg dabigatran etexilate on Day 1 of Period 1 and then will receive a single oral dose of 60mg quizartinib 2 hours prior to the administration of a single oral dose of 150mg dabigatran etexilate on the morning of Day 5 of Period 2.
9854843|NCT04458818|Experimental|Prolene Mesh Implant|The Group of Patients who were offered Prolene mesh Laryngeal implants for Vocal Cord Medialization.
9854844|NCT04456634|Experimental|AL&RUX|"Oral administration of:~• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
9854845|NCT04456634|Placebo Comparator|AL& Placebo|20 mg/120 mg artemether-lumefantrine (AL) + Placebo
9854846|NCT04454138||Targeted supratenon's placement of XEN 45|Placement of Xen-45 gelatin microstent in the supra-tenon's space to maximize aqueous outflow, while preventing obstruction, limiting fibrosis of the bleb, and promoting long-term patency.
9854847|NCT04454138||Non-targeted placement of XEN 45|Implantation of the XEN-45 gelatin microstent within the subconjunctival space, avoiding intra-tenon's placement.
9854848|NCT04452435|Experimental|C21 100 mg twice daily|Oral C21 treatment 100 mg twice daily for 7 days
10208628|NCT05210166|Active Comparator|Active tSCS and Lokomat|"20 sessions, 5 sessions per week of active transcutaneous spinal cord stimulation (tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes tSCS will be applied at the beginning of each session."
10208629|NCT05210166|Placebo Comparator|Sham tSCS and Lokomat|"20 sessions, 5 sessions per week of sham transcutaneous spinal cord stimulation (sham-tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes sham-tSCS will be applied at the beginning of each session."
9854849|NCT04452435|Placebo Comparator|Placebo|Oral placebo treatment 100 mg twice daily for 7 days
9854850|NCT04451707||non-cholera Vibrio infection|Patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019
10208630|NCT05210153||Standard dose|Patients are allocated to this group at visit V1 if 100 mg/day sertraline dose resulted in optimal sertraline exposure (20-40 ng/ml) as measured at VK. These patients continue to be treated with 100 mg/day during the V1-V2 period.
9854851|NCT04449263|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (test) the control Lens B for 2 weeks in this randomized, cross-over bilateral dispensing study.
9854852|NCT04449263|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) and Lens A (Test) for 2 weeks in this randomized, cross-over bilateral dispensing study.
9854853|NCT04449263|Active Comparator|Habitual Lenses|All subjects will wear their habitual lenses for two weeks prior to randomization of Test lens A and control lens B.
9854854|NCT04450381|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
9854855|NCT04449341|Experimental|Standard care venipuncture with additional of virtual reality|Patients undergoing blood draw while interacting with VR application Ocean Rift while wearing Oculus Go headset
9854856|NCT04449341|No Intervention|Standard care venipuncture without addition of virtual reality|Patients undergoing blood draw while wearing Oculus Go headset that is turned off
9854857|NCT04441255|Experimental|TAK-788 160 mg Fasted + TAK-788 160 mg Fed|TAK-788 160 milligram (mg), capsule, orally, once on Day 1 of Period 1 under fasted conditions (Treatment A), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fed conditions (Treatment B).
9854858|NCT04441255|Experimental|TAK-788 160 mg Fed + TAK-788 160 mg Fasted|TAK-788 160 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (Treatment B), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions (Treatment A).
9854859|NCT04440449|Experimental|Behavioral Lifestyle Intervention|The participants will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
9854860|NCT04440449|Other|Group B control arm|Participants use the smart-phone app to record their daily diet and physical activity, with no group sessions.
9854861|NCT04439214|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10208631|NCT05210153||Adjusted dose|Patients are allocated to this group at visit V1 if 100 mg/day sertraline dose resulted in high (>40 ng/ml) or low (<20 ng/ml) sertraline exposure, as measured at VK. These patients continue to be treated with the adjusted sertraline dose, different from 100 mg/day, during the V1-V2 period.
10208632|NCT05210140||Standard dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram treatment resulted in optimal escitalopram exposure (25-50 ng/ml) as measured at VK. These patients will continue their treatment with 10 mg/day during the V1-V2 period.
9854862|NCT04439240|Experimental|Treatment (AZD4547)|Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9854863|NCT04438785|Experimental|INTERVENTION (AirwayGym) GROUP|Patients newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the AirwayGym app for 20 min a day for 90 days.
9854864|NCT04438785|No Intervention|CONTROL GROUP|Patients newly diagnosed with severe OSAHS do no therapy for 90 days.
9854865|NCT04431908||Outpatients (Drive Thru)|Patients receiving testing through a drive thru location.
9854866|NCT04431908||High Risk Asymptomatics|Asymptomatic patients (residents) in a high risk location.
9854867|NCT04413929||Ergoferon|Oral administration in the therapeutic dosage specified in the instructions for medical use.
9854868|NCT04430634|Experimental|ABDC|Subjects use MybluTM e-cigarette product variant A (2.4 % nicotine) ad libitum for 2 days, then switch to use variant B (3.6% nicotine) for 2 days, then D (4.0% nicotine) for 2 days and then C (2.5% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
9854869|NCT04430634|Experimental|BCAD|Same as previous arm, but in a different randomization order.
9854870|NCT04430634|Experimental|CDBA|Same as previous arm, but in a different randomization order.
9854871|NCT04430634|Experimental|DACB|Same as previous arm, but in a different randomization order.
9854872|NCT04430634|Experimental|EFHG|Subjects use MybluTM e-cigarette product variant E (3.6 % nicotine) ad libitum for 2 days, then switch to use variant F (2.4% nicotine) for 2 days, then H (3.6% nicotine) for 2 days and then G (4.0% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
9854873|NCT04430634|Experimental|FGEH|Same as previous arm, but in a different randomization order.
9854874|NCT04430634|Experimental|GHFE|Same as previous arm, but in a different randomization order.
9854875|NCT04430634|Experimental|HEGF|Same as previous arm, but in a different randomization order.
9854876|NCT04429932|Experimental|Product use sequence ABDC|Subjects use MybluTM e-cigarette product variant A (2.4% nicotine) ad libitum for 2 days, then switch to use variant B (2.4% nicotine) for 2 days, then D (2.4% nicotine) for 2 days and then C (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
9854877|NCT04429932|Experimental|Product use sequence BCAD|Same as previous arm, but in a different randomization order.
9854878|NCT04429932|Experimental|Product use sequence CDBA|Same as previous arm, but in a different randomization order.
9854879|NCT04429932|Experimental|Product use sequence DACB|Same as previous arm, but in a different randomization order.
9854880|NCT04429932|Experimental|Product use sequence EFHG|Subjects use MybluTM e-cigarette product variant E (1.2% nicotine) ad libitum for 2 days, then switch to use variant F (1.2% nicotine) for 2 days, then H (2.4% nicotine) for 2 days and then G (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
9854881|NCT04429932|Experimental|Product use sequence FGEH|Same as previous arm, but in a different randomization order.
9854882|NCT04429932|Experimental|Product use sequence GHFE|Same as previous arm, but in a different randomization order.
9854883|NCT04429932|Experimental|Product use sequence HEGF|Same as previous arm, but in a different randomization order.
9854884|NCT04428502||Patients with psoriatic arthritis|Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
9854885|NCT04428424||Patients with rheumatoid arthritis|Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease
9854886|NCT04428359|Experimental|Measles, Mumps, Rubella vaccine|All Group A patients will receive intralesional MMR.
9854887|NCT04428359|Experimental|Vitamin D3|All Group B patients will receive intralesional Vitamin D3
9854888|NCT04410159|Experimental|Povidone-iodine|gargle with povidone-iodine 10mL, 30 seconds, 3 times per day, 7 days
9854889|NCT04410159|Experimental|Essential Oils|gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days
9854890|NCT04410159|Experimental|Tap water|gargle with tap water 100 mL, 30 seconds, 3 times per day, 7 days
9854891|NCT04410159|No Intervention|Control|This group will receive the standard treatment protocol without any additional intervention
9854892|NCT04425850||IVER+|Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
9854893|NCT04425850||IVER-|Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.
9854894|NCT04425863||Mild cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
9854895|NCT04425863||Moderate cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
9854896|NCT04425863||Severe cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia
9854897|NCT04425746|Experimental|Afamelanotide|Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
9854898|NCT04425746|Placebo Comparator|Placebo|Subjects visited the clinic on Day 0 (administration of placebo implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
9854899|NCT04422561|Experimental|Ivermectin group|Contacts who will receive prophylactic ivermectin
9854900|NCT04422561|No Intervention|Control group|Contacts who will be only observed without prophylaxis
9854901|NCT04421404|Experimental|COVID-19 Convalescent Plasma|Subjects in the COVID-19 convalescent plasma group will receive a single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
9854902|NCT04421404|Placebo Comparator|Placebo|Subjects in the placebo group will receive a single infusion of 250 ml of standard fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
9854903|NCT04419311|Experimental|Ultra-congruent insert group|Ultra-congruent inserts were used during total knee arthroplasty in patients randomized to this group.
9854904|NCT04419311|Experimental|Posterior cruciate ligament-stabilized insert|Posterior cruciate ligament-stabilized inserts were used during total knee arthroplasty in patients randomized to this group.
9854905|NCT04415489|Active Comparator|Office Hysteroscopy|Use of office hysteroscope with operative port to evaluate uterine cavity, and potentially treat minor abnormalities within the same procedure with hysteroscopic graspers. This involve inserting the hysteroscope through the cervix and instillation of saline for a direct look at the cavity.
9854906|NCT04415489|No Intervention|Saline Infusion Sonography (SIS)|This is our institution's current first line approach for screening evaluation of the uterine cavity. If not enrolled in the study, patients are required to do this to move forward with embryo transfer. It involves instillation of saline into the uterus via a small catheter with simultaneous imaging with pelvic ultrasound.
9854907|NCT04411667|Experimental|Group A (study drug+SOC)|Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.
9854908|NCT04411667|No Intervention|Group B (SOC)|Standard of Care
10208633|NCT05210140||Adjusted dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram dose resulted in to high (>50 ng/ml) or to low (<25 ng/ml) escitalopram exposure, as measured at VK. These patients will be treated with the adjusted escitalopram dose, different from 10 mg/day, during the V1-V2 period.
10208634|NCT05210127|Experimental|After Scarf Osteotomy Group|30 participants after surgery
10208635|NCT05210127|Experimental|Without Scarf Osteotomy Group|30 participants without surgery
10208636|NCT05210101|Other|Sotrovimab|Two intravenous (IV) doses of sotrovimab 500mg will be administered in total - the first on Treatment Day 1 and the second dose approximately 12-24 weeks after the first dose. The exact dosing interval will be determined by pharmacokinetic data collected from the first 10 patients enrolled in this study.
10208637|NCT05210075|Experimental|A wait list controlled|A wait list controlled
10208638|NCT05210049|Other|Patients undergoing routine screening via upper endoscopy (EGD)|All enrolled patients will complete upper endoscopy for screening for Barrett's esophagus and esophageal adenocarcinoma.
10208639|NCT05210036|Active Comparator|Ultrasound Therapy|"The patients in group 1 received therapeutic US with BTL-4710 ultrasound device.~The therapeutic US was administered at the frequency of 3 megahertz, intensity of 1.5 w/cm2 and an area of 25 cm2 for 5 minutes in the continue mode.~The procedure of therapeutic US was performed by a physiotherapist experienced in using the device for 15 sessions in total 5 times a week for 3 weeks."
10208640|NCT05210036|Active Comparator|High-Intensity Laser Therapy|"The patients in group 2 received HILT with BTL-6000 high-intensity laser device.~The therapy consisted of 2 stages in each session.~The first stage was performed in analgesic mode for analgesic effect at the frequency of 25 Hz, in the wavelength of 1064 nm, the power of 8 watt, the dose of 12 j/cm2, the area of 25 cm2, and 300 j in total for 2 minutes and 30 seconds.~The second stage was performed in bio-stimulating mode for biostimulation effect in the wavelength of 1064 nm, the power of 7 watt, the dose of 100 j/cm2, the area of 25 cm2, and 2500 j in total for 5 minutes and 57 seconds.~The total length of administration was approximately 8.5 minutes for each stage.~The procedure of the therapy was performed by a physiotherapist experienced in using the device for 9 sessions in total 3 times a week for 3 weeks."
10208641|NCT05210023|Experimental|Nutrigenetic Diet Group|Participants randomly included in this group will receive nutrigenetic menus, i.e., considering the genotypes of the 11 variants analyzed.
10208642|NCT05210023|Experimental|Conventional Diet Group|Participants randomly included in this group will receive menus prepared following the international conventional guidelines set out by the WHO, AHA and Official Mexican Standards (NOM) for the treatment of obesity and dyslipidemia.
10208643|NCT05210010|Other|Algorithm|All participating cardiologists.
10208644|NCT05209984|Experimental|Experimental drug (Sibutramine IR 15mg / Topiramate XR 75mg)|ADF1 Group Eurofarma drug association of sibutramine IR 15mg / topiramate XR 75mg
10208645|NCT05209984|Experimental|Experimental drug (Sibutramine IR 15mg / Topiramate XR 100mg)|ADF2 Group Eurofarma drug association of sibutramine IR 15mg (Sibus®) Topiramate XR 100mg from Eurofarma Laboratórios S.A..
9854909|NCT04409886|Experimental|HBOT (Hyperbaric Oxygen Therapy)|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
9854910|NCT04407507|Experimental|Ivermectin|Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
9854911|NCT04407507|Placebo Comparator|Placebo|Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
9854912|NCT04406194|Experimental|FAVICOVIR then AVIGAN|Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
9854913|NCT04406194|Experimental|AVIGAN then FAVICOVIR|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state.
9854914|NCT04404907||Males who never deliberately tan|Males responded to an anonymous online survey that they never deliberately tan
9854915|NCT04404907||Males who ever deliberately tan|Males responded to an anonymous online survey that they had ever deliberately tan
9854916|NCT04404010|Active Comparator|Immersive Virtual Reality|"Participants randomized to the immersive virtual reality (iVR) study arm, considered the intervention group will receive training on completion of a reverse shoulder arthroplasty using an iVR simulator (PrecisionOS Technology)."
9854917|NCT04404010|Other|Surgical Video|"Participants randomized to the standard video study arm, considered the control group will receive training on completion of reverse shoulder arthroplasty using a technical surgical instructional video."
9854918|NCT04403399|Experimental|Varenicline then Placebo|Varenicline 0.5 mg BID orally for 3 weeks, followed by a 3-week washout period, then placebo BID orally for 3 weeks
9854919|NCT04403399|Experimental|Placebo then Varenicline|Placebo BID orally for 3 weeks, followed by a 3-week washout period, then Varenicline 0.5 mg BID orally for 3 weeks
9854920|NCT04402970|Experimental|Inhaled/nebulized dornase alfa|Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
9854921|NCT04402970|No Intervention|Standard of care|Standard of care provided for ARDS.
9854922|NCT04403113|Experimental|Study Group (SG)|feeding and oral motor intervention strategies+structured neck and trunk stabilization exercises+caregiver training related to feeding (Study Group)
9854923|NCT04403113|Placebo Comparator|Control Group (CG).|feeding and oral motor intervention strategies+caregiver training related to feeding (Control Group)
9854924|NCT04401202|Experimental|NSO|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
9854925|NCT04401202|No Intervention|Control|Standard of care
9854926|NCT04400682|Experimental|FAVIRA then AVIGAN|Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
9854927|NCT04400682|Experimental|AVIGAN then FAVIRA|Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
9854928|NCT04399161|Experimental|Child Participants|Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
9854929|NCT04399161|Experimental|Elderly Participants|Elderly citizens (above 60 yrs) at high risk for caries. A total of 36 elderly will be chosen based on eligibility criteria and randomly divided into 3 groups with 12 participants per group. The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
9854930|NCT04399980|Active Comparator|Intervention|Treatment infusion
9854931|NCT04399980|Placebo Comparator|Control|Placebo infusion
9854932|NCT04399122|Active Comparator|Acetaminophen with codeine|codeine 30mg/acetaminophen 325mg Take one to two tablets every 4 to 6 hours as needed for pain for up to 4 days following surgery.
9854933|NCT04399122|Active Comparator|Acetaminophen with oxycodone|oxycodone 5mg/acetaminophen 325mg Take one tablet every 4 to 6 hours as needed for pain for up to 4 days following surgery.
9854934|NCT04397445|Experimental|Ranitidine and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of ranitidine (300 mg) plus low nitrite/NDMA meals (noncured-meats diet)
9854935|NCT04397445|Placebo Comparator|Placebo and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of placebo plus low nitrite/NDMA meals (noncured-meats diet)
9854936|NCT04397445|Experimental|Ranitidine and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of ranitidine (300 mg) plus high nitrite/NDMA meals (cured-meats diet)
9854937|NCT04397445|Placebo Comparator|Placebo and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of placebo plus high nitrite/NDMA meals (cured-meats diet)
9854938|NCT04397094|Experimental|Theracal LC|Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
9854939|NCT04397094|Active Comparator|Formocresol|Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
10208646|NCT05209984|Active Comparator|Sibus (Sibutramine 15mg)|SIB Group Sibutramine 15mg
10208647|NCT05209984|Placebo Comparator|Placebo Group|Placebo Group
10208648|NCT05209971||macular thickness and visual acuity|optical coherence tomography
10208649|NCT05209958||Group A|Patients with NLR level below 2
9854940|NCT04396639|Experimental|Treatment Arm|Fifty eligible male subjects will be enrolled in the treatment arm to receive Moroctocog alfa (AF-CC) until 24 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
9854941|NCT04396665|Experimental|Precam Group (Intervention Group)|150 Women without breast cancer, aged from 25 to 50 years old
9854942|NCT04396665|No Intervention|Control Group|150 Women without breast cancer, aged from 25 to 50 years old
9854943|NCT04393493|Experimental|GROUP A|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution~Day 2 Furosemide 200mg / day infused with 100cc of Hartmann solution~Day 3 Furosemide 300mg / day infused with 100cc of Hartmann solution~Day 4 Furosemide 400mg / day infused with 100cc of Hartmann solution"
9854944|NCT04393493|Experimental|GROUP B|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 2 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs."
9854945|NCT04392362|Active Comparator|Intervention group|Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush
9854946|NCT04392362|Active Comparator|Control group|Giving adenosine Ising the recommended AHA two syringe method
9854947|NCT04392141|Experimental|Standard Treatment|Patients diagnosed with COVID-19 which receive the standard treatment national guideline
9854948|NCT04392141|Experimental|Colchicine and Herbal Phenolic Monoterpene Fractions|Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions
9854949|NCT04392219|Experimental|EIDD-2801|EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.
9854950|NCT04392219|Placebo Comparator|Placebo|Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).
9854951|NCT04391842|Experimental|Experimental: SAM ultrasound and diclofenac patch|Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
9854952|NCT04390022|Active Comparator|Ivermectin|Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.
9854953|NCT04390022|Placebo Comparator|Placebo|Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.
9854954|NCT04386902||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
9854955|NCT04385238||Pregnant Women|Pregnant women who are 18 years of age or older.
9854956|NCT04385238||Post-partum women|Women who gave birth within the last 6 months who are 18 years of age or older.
9854957|NCT04384523|Experimental|OsrHSA 20 mg/kg IV|
9854958|NCT04384523|Experimental|OsrHSA 40 mg/kg IV|
9854959|NCT04384523|Experimental|OsrHSA 80 mg/kg IV|
9854960|NCT04384523|Experimental|OsrHSA 140 mg/kg IV|
9854961|NCT04384523|Experimental|OsrHSA 200 mg/kg IV|
9854962|NCT04383665|Sham Comparator|STN DBS off|
9854963|NCT04383665|Experimental|STN DBS 10Hz|
9854964|NCT04383665|Active Comparator|STN DBS 130Hz|
9854965|NCT04383132|Experimental|Abdominal Binder Intervention Group|Patients randomized to Abdominal Binder Intervention Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy.
10208650|NCT05209958||Group B|Patients with NLR level equal to or above 2
10208651|NCT05209945|Experimental|Vibration|Vibration (WBV, heel, and tendon vibration) was applied to participants
10208652|NCT05209919||Pulmonary arterial hypertension|All patients with pulmonary arterial hypertension and significant functional tricuspid regurgitation
10208653|NCT05209919||HFrEF|All patients with HFrEF and significant functional tricuspid regurgitation
9923782|NCT00854295|Other|2|Newly enrolled study subjects
9923783|NCT00854321||patients with active RA|drug, follow-up
10208654|NCT05209919||HFpEF|All patients with HFpEF and significant functional tricuspid regurgitation
10208655|NCT05209919||Heart Failure mildly-reduced ejection fraction|All patients with Heart Failure mildly-reduced ejection fraction and significant functional tricuspid regurgitation
10213552|NCT03809624|Experimental|Expansion Cohort PD-L1 Positive Basket|Patients with gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
9854966|NCT04383132|Sham Comparator|Sham Group|Sham Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure
9854967|NCT04382066|Experimental|Experimental 1|Plitidepsin 1.5 mg / day x 3 consecutive days
9854968|NCT04382066|Experimental|Experimental 2|Plitidepsin 2.0 mg / day x 3 consecutive days
9854969|NCT04382066|Experimental|Experimental 3|Plitidepsin 2.5 mg / day x 3 consecutive days
9854970|NCT04381481|Experimental|Control beverage, text snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
9854971|NCT04381481|Experimental|Control beverage, control snack|The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a barcode label (control label) (task 2).
9854972|NCT04381481|Experimental|Control beverage, graphic snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
9854973|NCT04381481|Experimental|Claim 1 beverage, text snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
9854974|NCT04381481|Experimental|Claim 1 beverage, control snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a barcode label (control label) (task 2)."
9854975|NCT04381481|Experimental|Claim 1 beverage, graphic snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
9854976|NCT04381481|Experimental|Claim 2 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
9854977|NCT04381481|Experimental|Claim 2 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a barcode label (control label) (task 2)."
9854978|NCT04381481|Experimental|Claim 2 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
9854979|NCT04381481|Experimental|Claim 3 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
9854980|NCT04381481|Experimental|Claim 3 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a barcode label (control label) (task 2)."
10208656|NCT05209880|Experimental|Intervention Arm|The intervention will take place in the emergency department or days after an emergency department visit at home/hospital virtually using zoom or phone by our trained clinicians. At the time of follow-up assessments, participants may also receive additional counseling by our trained clinicians as needed.
10208657|NCT05209880|No Intervention|Control Arm|No intervention will be conducted (standard of care).
9854981|NCT04381481|Experimental|Claim 3 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
10208658|NCT05209815||Group 1|continuation of NTZ throughout pregnancy and postpartum
10208659|NCT05209815||Group 2|exposure during the first trimester
9854982|NCT04380688|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
9854983|NCT04380688|No Intervention|Arm 2|Best Supportive Care
9854984|NCT04376060|Experimental|Study population|Fifteen patients (1 male, 14 females) aged between 27 and 64 years old
9854985|NCT04374500|Experimental|Leptin infusion|This applies to protocol 1 when 10 healthy men got leptin infused locally in the forearm and blood flow was measured. The other forearm was used as the control.
9854986|NCT04374500|Experimental|Leptin infusion plus vasodilator infusion|This applies to protocol 2 when 10 healthy men got either a background infusion of leptin or saline locally in the forearm when measuring vasoresponse to four vasodilatators. Each participant had two examinations with either leptin or saline and the order was randomised. The other forearm was used as the control.
9854987|NCT04374500|Experimental|Vasodilator infusion in CAD patients|This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse. The other forearm was used as the control.
9854988|NCT04372186|Placebo Comparator|Placebo|Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
9854989|NCT04372186|Experimental|Tocilizumab|Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
9923784|NCT00854334||1.|Children with both obesity and obstructive sleep apnea
10208660|NCT05209815||Group 3|exposure during the first and the second trimester
10208661|NCT05209802|Experimental|A: Exercise|High intensity interval exercise training (4 x 4 minutes of intensity above 17 on the Borg Rating of Perceived Exertion)
10208662|NCT05209802|Active Comparator|B: Exercise|Moderate intensity exercise training
10208663|NCT05209789|Experimental|HUGS therapy|A structured group intervention that aims to observe mother's behavior and responses with her baby, promote mother-baby interaction through play, and provide tools for positive interaction. This therapy involves cognitive and behavioral work. Therapists observe the mother-baby duo and share their observations from a perspective of encouragement and support. A playful and non-judgmental interaction is cultivated within the group. The main objective is to change the negative trajectory of mother-child interactions through tools from cognitive-behavioral therapies as well as using knowledge about child development.
10213553|NCT03809624|Experimental|Expansion Cohort Head and Neck Squamous Cell Carcinoma|Patients with head and neck squamous cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
9854990|NCT04371419|Experimental|Control - CDC - Mask (Control) - Concordant|Control Intro, CDC Social Distancing, Mask Control version delivered by minority doctor of same background as the recipient - other definitions are similar
9854991|NCT04371419|Experimental|Control - CDC - Mask (Control) - Discordant|Control Intro, CDC Social Distancing, Mask Control version delivered by majority doctor of different background as the recipient - other definitions are similar
9854992|NCT04371419|Experimental|Control - MGH - Mask (Control) - Concordant|Control Intro, MGH Social Distancing, Mask Control version delivered by concordant doctor
9854993|NCT04371419|Experimental|Control - MGH - Mask (Control) - Discordant|Control Intro, MGH Social Distancing, Mask Control version delivered by discordant doctor
9854994|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Concordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by concordant MD
9854995|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Discordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by discordant MD
9854996|NCT04371419|Experimental|Ack. econ. circumstance- MGH - Mask (Control ) Concordant|Intro econ. circumstance -MGH - Mask (Control ) Concordant
9854997|NCT04371419|Experimental|Ack. econ. circumstance - MGH - Mask (Control ) Discordant|
9854998|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Concordant|Control Intro - CDC - Mask (antiStigma) Concordant messenger
9854999|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Discordant|Control Intro - CDC - Mask (antiStigma) discordant messenger
10208664|NCT05209789|Active Comparator|Playtime|The participants assigned to the control group will also be in the presence of two therapists, allowing to reproduce the framework of the HUGS therapy. The difference will be the lack of direct therapeutic intervention from the therapists, but only classic psychoeducational guidance. The mothers are offered a time to play with their baby as well as the opportunity to discuss and share their experiences with other mothers, which is generally seen as supportive by them.
9855000|NCT04371419|Experimental|Control - MGH - MaskS (antiStigma) Concordant messenger|Control - MGH - MaskS (antiStigma) Concordant sender
9855001|NCT04371419|Experimental|Control- MGH-MaskS (antiStigma) Discordant messenger|Control - MGH - MaskS (antiStigma) Discordant sender
10208665|NCT05209776|Experimental|Patients|Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle
10213554|NCT03809624|Experimental|INBRX-105 Escalation in Combination with Pembrolizumab|INBRX-105 will be escalated in combination with Pembrolizumab in pateitns with locally advanced or metastatic solid tumors.
9855002|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Concordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Concordant sender
9855003|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Discordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Discordant sender
9855004|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Concordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) Concordant sender
9855005|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Discordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) discordant sender
9855006|NCT04371419|Placebo Comparator|Info later - Pure Control|This group will not receive the videos but will receive information later.
9855007|NCT04370834|Experimental|Other (tocilizumab)|Patients receive tocilizumab IV over 60 minutes. A second dose may be given if there is sustained or recurrent fever, no decrease or not more than a 1-category improvement on the 7-category ordinal scale (only stabilization or partial improvement following first dose), or a >= 1-category worsening on the 7-category ordinal scale from nadir.
9855008|NCT04370548|Experimental|Clindamycin phosphate vaginal gel, 2%|
9855009|NCT04370548|Placebo Comparator|Placebo vaginal gel (Universal HEC Placebo Gel)|
9855010|NCT04370028||Divaza|Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.
9855011|NCT04363736|Active Comparator|TCZ 8 mg/kg|Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
9855012|NCT04363736|Experimental|TCZ 4 mg/kg|Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
9855013|NCT04366583|Experimental|Argon plasma coagulation plus distilled water injection|The patients in this group received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
9855014|NCT04366583|Active Comparator|Hemoclipping plus distilled water injection|The patients in this group received hemoclipping (Olympus HX 110/610, Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
9517048|NCT03309995|Experimental|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
9855015|NCT04365699|Experimental|Interventional Patients: AT-001|AT-001 1500 mg (3 capsules) were administered by mouth twice daily for up to 14 days
9855016|NCT04365699|No Intervention|Control Match Group 1|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The first matching approach selected all subjects with diabetes mellitus and hypertension, and available data to match participants who received AT-001 for gender, age group (in bins of 5 years), weight, and C-reactive protein (CRP) value at the time of hospital admission.
9923785|NCT00854334||2|Children without the presence of both obesity and obstructive sleep apnea
9923786|NCT00854386|Active Comparator|1|liberal fluid administration group
9855017|NCT04365699|No Intervention|Control Match Group 2|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The second matching approach selected all subjects in the registry with diabetes mellitus and available data to match participants who received AT-001 for gender, age group (in bings of 5 years), and weight (+/- 0.5 kgs).
9855018|NCT04365153|Active Comparator|High Dose Intervention|600 mg of canakinumab (8 mg/kg for patients </= 40 kg)
9855019|NCT04365153|Active Comparator|Low Dose Intervention|300 mg of canakinumab (4 mg/kg for patients </= 40 kg)
9855020|NCT04365153|Placebo Comparator|Control|Placebo
9855021|NCT04363879|Active Comparator|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
9855022|NCT04363879|Experimental|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
9855023|NCT04362137|Experimental|Ruxolitinib 5 mg|Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
9855024|NCT04362137|Placebo Comparator|Placebo|Matching-image placebo for 14 days with possible extension of treatment to 28 days
9855025|NCT04359771|Active Comparator|Yellow MPL|
9855026|NCT04359771|Active Comparator|Diode MPL|
9855027|NCT04358991||invasive bacterial infections|patients who are receiving Ceftazidime-avibactam are asked to provide blood samples around a dosing of the medication for analysis of samples
9855028|NCT04358081|Experimental|Arm 1: hydroxychloroquine + aithromycin placebo|Hydroxychloroquine 600mg o.d. as loading dose (Day 1) +followed by 200mg t.i.d was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin (AZT) placebo o.d.
9855029|NCT04358081|Experimental|Arm 2: hydroxychloroquine + azithromycin|Hydroxychloroquine 600 mg o.d. as a loading dose (Day 1) followed by 200 mg t.i.d. was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5
9855030|NCT04358081|Placebo Comparator|Arm 3: hydroxychloroquine placebo + azithromycin placebo|Hydroxychloroquine placebo o.d. (day 1) followed by hydroxychloroquine placebo t.i.d Azythromycin placebo o.d.
9855031|NCT04356937|Experimental|Tocilizumab|"Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.~Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures."
9855032|NCT04356937|Placebo Comparator|Standard of care plus placebo|Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.
10208666|NCT05209776|Experimental|Control case|Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).
9855033|NCT04355663|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
9923787|NCT00854386|Experimental|2|Restrictive fluid administration group
10208667|NCT05209750|Experimental|FAPI PET/CT|"Colon cancer patients: one FAPI PET/CT scan early after standard diagnostic imaging and prior to planned surgery.~Rectal cancer patients: two FAPI PET/CT scans, one for initial staging (pre neoadjuvant therapy) and one for restaging (post neoadjuvant therapy)."
10208668|NCT05209724|Experimental|Provider Supervised|Digital monitoring system with provider supervision
10208669|NCT05209724|No Intervention|Self Supervised|Digital monitoring system without provider supervision
10208670|NCT05209217||Participant Group|Participants will all have history of good to excellent clinical response to intranasal ketamine for at least two months and on a treatment schedule varying from use every other day to every fifth day. Participants will be tested one or two days beyond their customary administration date and again 2-3 hours after their administration of ketamine.
10208671|NCT05209113|Experimental|Study Group|The self-management module, which will be applied only to the study group, includes the clinical pharmacist informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms. The first interview will end after the Patient Health Engagement-PHE-s, Multiple Sclerosis Self-Management Revised-MSSM-R, Patient Assessment of Chronic Illness Care-PACIC scales and self-management module are applied to the study group by the clinical pharmacist. When the patients come to the outpatient clinic examination 4 and 8 months after the first interview, second and third face-to-face interview will be held with the clinical pharmacist and all scales will be applied again. During the second and third interview, no written and/or verbal information will be given to the patient again.
10208672|NCT05209113|No Intervention|Control Group|Patient Health Engagement (PHE-s), Multiple Sclerosis Self-Management Revised (MSSM-R), Patient Assessment of Chronic Illness Care (PACIC) scales will be administered to the control group patients whose medications and demographic information were obtained in the first face-to-face interview. The same scales will be repeated at the 4th month and 8th month, the self-management module will not be applied to the control group, and within this scope, the patients will not be informed by the clinical pharmacist, and the patient's routine outpatient services will continue.
9855034|NCT04355663|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
9855035|NCT04355663|Experimental|Functional electric stimulation|Functional electric stimulation in the postural corrected position was developed at our workplace. Participants first underwent individual two-hour session consisting of postural correction using MPAT and the device (The WalkAide® System, Innovative Neurotronics Inc., 4999 Aircenter Circle, Suite 103 Reno, NV 89502, USA) programming (28). Patients received the device to use as much as they felt they were able to during their normal daily living activities thereafter.
9855036|NCT04354870|Experimental|HCQ Group|Approximately 300 Health Care Workers (HCW) who choose to be provided HCQ
9855037|NCT04354870|No Intervention|Control Group|approximately 50 HCW who choose not to be provided HCQ
9855038|NCT04350307|Active Comparator|22-Gauge Arm|Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle
9855039|NCT04350307|Active Comparator|25-Gauge Arm|Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle
9855040|NCT04352660|Active Comparator|Injection group|MMC delivered by preoperative subconjunctival injection
9855041|NCT04352660|Active Comparator|Sponge group|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
9855042|NCT04350788|Placebo Comparator|Survivorship Care Plan (SCP)|The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
9855043|NCT04350788|Experimental|Enhanced SCP (ESCP)|ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
9855044|NCT04349917|Placebo Comparator|Placebo, then Methylphenidate|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
9855045|NCT04349917|Experimental|Methylphenidate, then Placebo|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
9855046|NCT04348851|Experimental|4-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
9855047|NCT04348851|Experimental|8-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
9855048|NCT04348851|Active Comparator|8-Week Attention Control|The Registered Nurses (RNs) will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare provider.
9855049|NCT04348851|No Intervention|Standard Care|Caregivers receiving standard of care
9855050|NCT04348357|Active Comparator|Traditional Visit|Patients come to the office for a traditional postoperative visit
9855051|NCT04348357|Experimental|Tele-medicine|Patients receive postoperative care via telemedicine
9855052|NCT04346199|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
9855053|NCT04346199|No Intervention|Arm 2|Best Supportive Care
9855054|NCT04345653|Experimental|Study arm - Hydroxychloroquine Sulfate (HCQ)|HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth
9855055|NCT04343261|Experimental|COVID-19 patients treated with convalescent plasma|Severely ill COVID-19 patients treated with convalescent plasma
9855056|NCT04343222|Experimental|Group A: Bromfenac then Artificial Tears|Participant receives 1 drop of topical Bromfenac 0.09% 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
9855057|NCT04343222|Experimental|Group B: Artificial Tears then Bromfenac|Participant receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of topical Bromfenac 0.09% immediately after the injection and wash.
9855058|NCT04343222|Placebo Comparator|Group C: Artificial Tears then Artificial Tears|Participants receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
9855059|NCT04343092|Experimental|Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)|Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily
9855060|NCT04342663|Experimental|Fluvoxamine|Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
9923788|NCT00854425|Experimental|L-asp|
9855061|NCT04342663|Placebo Comparator|Placebo|Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.
9855062|NCT04342897|Experimental|LY3127804|Participants received 20 milligrams (mg) per kilogram (kg) of LY3127804 as an intravenous (IV) infusion on Days 1 and 15.
9855063|NCT04342897|Placebo Comparator|Placebo|Participants received 20 mg/kg of Placebo as an IV infusion on Days 1 and 15.
9855064|NCT04342130|Experimental|All Participants|People with low back pain who were given and oral dose of 30 mg morphine.
9855065|NCT04340557|Experimental|Group A (Study drug+SOC)|Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.
9855066|NCT04340557|No Intervention|Group B (SOC)|Standard of Care
9855067|NCT04339972|Experimental|Active LIFUP then Sham LIFUP|Real LIFUP is delivered to the participant for visit 1, followed by sham lifup visit 2
9855068|NCT04339972|Sham Comparator|Sham LIFUP then Active LIFUP|Sham LIFUP is delivered to the participant for visit 1, followed by real lifup visit 2
9855069|NCT04339296|Experimental|Intervention group|Intervention group included medication management with Spencer.
9855070|NCT04339296|No Intervention|Control Group|The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.
9855071|NCT04338009|Experimental|Discontinuation arm|The randomized intervention will be the discontinuation of ACEI/ARBs
9855072|NCT04338009|Experimental|Continuation arm|The randomized intervention will be the continuation of ACEI/ARBs
9923789|NCT00854438|Experimental|Active treatment arm|Reduction of anticholinergic drug effects by pharmacist review
9923790|NCT00854438|No Intervention|Control|No intervention
9923791|NCT00854451|Active Comparator|1 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk
9923792|NCT00854451|Active Comparator|2 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk
9923793|NCT00854451|Active Comparator|3 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk
9923794|NCT00854451|Active Comparator|4 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk
9923795|NCT00854503|Active Comparator|Simvastatin|Simvastatin 20 mg/day
9923796|NCT00854503|Active Comparator|Rosuvastatin|Rosuvastatin 20 mg/day
9923797|NCT00854529|Experimental|1|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery
9923798|NCT00854529|Active Comparator|2|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery
9923799|NCT00854529|No Intervention|3|20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.
9923800|NCT00854542|Active Comparator|TCSCT|
9517049|NCT03309995|Placebo Comparator|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
9923801|NCT00854542|Placebo Comparator|Usual Care|
9923802|NCT00854555|Experimental|robot|30 persons with incomplete SCI who live within driving distance to Oslo and who meet the inclusion/exclusion criteria will be selected for randomization to robotic assisted training or control (conventional treatment). Intervention consists of locomotor training with robot for 60 days during 6 months period in an out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
9923803|NCT00854555|Experimental|manual assistance|30 persons with incomplete SCI who live outside driving distance to Oslo and who meet inclusion/exclusion criteria will be selected for manually assisted training in Tromsø or control (conventional treatment). Intervention consists of 60 days locomotor training with manual assistance during 6 months period in an in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
9923804|NCT00854568|Experimental|CEOP regimen|CEOP regimen
9923805|NCT00854568|Active Comparator|CHOP regimen|CHOP regimen
9923806|NCT00854633|Experimental|1|Talactoferrin
9923807|NCT00854633|Placebo Comparator|2|Placebo
9923808|NCT00854646|Experimental|ON 01910.Na|The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.
9923809|NCT00854659|Active Comparator|1|ABT-102 Tablets, 4 mg BID
9923810|NCT00854659|Active Comparator|2|ABT-102 Tablets BID, escalating dose
9923811|NCT00854659|Active Comparator|3|ABT-102 Tablets BID, escalating dose
9923812|NCT00854659|Placebo Comparator|4|Placebo Tablets, BID
9923813|NCT00854672||sarcoidosis patients|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
9923814|NCT00854685|Experimental|1|
9923815|NCT00854685|Experimental|2|
9923816|NCT00854685|Experimental|3|
9923817|NCT00854685|Experimental|4|
9923818|NCT00854685|Placebo Comparator|5|
9923819|NCT00854685|Placebo Comparator|6|
9923820|NCT00854698|Experimental|Group with MVA|
9923821|NCT00854698|Other|group without MVA|
9923822|NCT00854711|Experimental|nitric oxide|inhaled nitric oxide 80 ppm and oxygen
9923823|NCT00854711|Placebo Comparator|standart of care|no intervention
9923824|NCT00854737|Active Comparator|1|Omega-3 fatty acid and cytidine supplementation
9923825|NCT00854737|Active Comparator|2|omega-3 fatty acid supplementation
9923826|NCT00854737|Placebo Comparator|placebo|placeno or sugar pill
9923827|NCT00854750|Experimental|ACTHAR- placebo first|Placebo, 20 mg, 40 mg, 80 mg
9855073|NCT04338074|Experimental|Tranexamic Acid Treatment|
9855074|NCT04338074|Placebo Comparator|Placebo Treatment|
9855075|NCT04336475|Experimental|Group 1|exercise regimen and oral hygiene care advices
9855076|NCT04336475|Active Comparator|Group 2|oral hygiene care advices
9855077|NCT04335929|Experimental|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
10208673|NCT05206513|Placebo Comparator|Placebo|Placebo dosed for 14 weeks followed by open label valbenazine treatment for 32 weeks
10208674|NCT05206513|Experimental|Valbenazine|Valbenazine dosed for 14 weeks followed by open label valbenazine treatment for 32 weeks
9855078|NCT04335812|Experimental|R-ICBT|The intervention offered is a guided relaxation-based CBT offered via the Internet. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules provided will focus on applied relaxation only.
9855079|NCT04335812|Active Comparator|F-ICBT|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules are a mixture of applied relaxation, Cognitive Behavioral Therapy and advice addressing common problems
9855080|NCT04335136|Active Comparator|Group A (active) APN01|Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01
9855081|NCT04335136|Placebo Comparator|Group B (placebo control)|
9855082|NCT04335552|Active Comparator|Standard of care|
9855083|NCT04335552|Experimental|Standard of care plus hydroxychloroquine|Standard of care plus hydroxychloroquine for 5 days
9855084|NCT04335552|Experimental|Standard of care plus azithromycin|Standard of care plus azithromycin for 5 days
9855085|NCT04335552|Experimental|Standard of care plus hydroxychloroquine plus azithromycin|Standard of care plus hydroxychloroquine plus azithromycin for 5 days
9855086|NCT04334876|Other|High Risk Healthcare Workers|At home, finger prick, antibody test.
10208675|NCT05205538|Experimental|Females|Female participant group
10208676|NCT05205538|Experimental|Males|Male participant group
10208677|NCT05204459||RRMS, SPMS, PPMS, CIS or RIS|Multiple Sclerosis (relapsing-remitting, primary or secondary progressive forms), clinically isolated syndrome, or radiologically isolated syndrome
10208678|NCT05204459||NMOSD|Neuromyelitis optica spectrum disorders
10208679|NCT05204459||MOGAD|Myelin oligodendrocyte glycoprotein antibody disorders
9855087|NCT04334681||UC Group|Patients operated on the un-roofing curettage method in the treatment of pilonidal disease will be analyzed in this group.
9855088|NCT04334681||LF Group|Patients who have been operated with the modified Limberg flap method after rhomboid excision in the treatment of pilonidal disease will be analyzed in this group.
9855089|NCT04333225|Experimental|Hydroxychloroquine|Subjects who chose to enter the HCQ arm received a loading dose of 800 mg HCQ on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks
9855090|NCT04333225|No Intervention|Control|Subjects who declined taking HCQ were considered as controls
9855091|NCT04333199|No Intervention|Control|Patients do not receive an email
9855092|NCT04333199|Experimental|Timely nudge - view results|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page."
9855093|NCT04333199|Experimental|Timely nudge - get started|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results."
9855094|NCT04332991|Active Comparator|Hydroxychlorquine|Participants assigned to the hydroxychloroquine arm will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
9855095|NCT04332991|Placebo Comparator|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
9855096|NCT04332614||Control|A standard marketing message encouraging activation and describing the benefits of myGeisinger
10208680|NCT05204459||Neurological disorder other than MSRD|Neurological disorders due to neurodegenerative, vascular, or headache conditions that are not related to multiple sclerosis or related disorders.
10208681|NCT05204459||Healthy controls|Healthy controls with no known neurological conditions
10208682|NCT05204212|Experimental|Experimental intervention|Percutaneous closure of the LAA by use of the CE-mark approved LAA exclusion device Amplatzer Cardiac Plug or Amulet followed by dual antiplatelet therapy with aspirin 100mg od and clopidogrel 75 mg od for 3 months. In patients with excessive bleeding risk DAPT duration can be shortened according to the physicians' discretion to a minimum of 6 weeks. Oral anticoagulants are not prescribed in this group.
10208683|NCT05204212|No Intervention|Control intervention|No catheter-based LAA closure. Treatment with best medical care (warfarin or NOAC therapy or other best medical care if (N)OAC therapy is contraindicated).
10208684|NCT05202704|Experimental|Experimental: Hidden conditioning procedure + Positive Expectation|Patients with chronic low back pain will receive verbal delivered positive instructions regarding manipulative therapy. Then, after the manipulative therapy they will be submitted to a hidden conditioning procedure in which the pain threshold will be surreptitiously downgrade to conditioning pain decrease to manipulative therapy (G1).
10208685|NCT05202704|Active Comparator|Active Comparator: Positive expectations|Patients with chronic low back pain will receive verbal delivered positive instructions regarding manipulative therapy (G2) before the administration of a manipulative therapy approach.
9855097|NCT04332614||Focused on provider communication|A simple message focused on one benefit of myGeisinger: communicating easily with providers
9855098|NCT04332614||Focused on scheduling|A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
9855099|NCT04332614||Focused on medical information access|A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
9855100|NCT04332614||Social proof|A message similar to control, but including information about how many other patients are using myGeisinger
9855101|NCT04332614||Endowment / decision staging|"A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.~Endowment: Give patients the impression they already have the account, so they value it more.~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete"
9855102|NCT04322968|Experimental|Chronic pain with PTSD+IV ketamine infusion|
9855103|NCT04322968|Active Comparator|Chronic pain with PTSD+IV ketorolac infusion|
9855104|NCT04322968|Experimental|Chronic pain without PTSD+IV ketamine infusion|
9855105|NCT04322968|Active Comparator|Chronic pain without PTSD+IV ketorolac infusion|
9855106|NCT04332419|Experimental|PET/CT & PET/MR|One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
9855107|NCT04332081|Experimental|Hyperbaric oxygen therapy (HBOT)|
9855108|NCT04332081|No Intervention|Standard of Care|
9855109|NCT04332107|Experimental|Azithromycin|1.2g of oral azithromycin
9855110|NCT04332107|Placebo Comparator|Placebo|Matching placebo
9855111|NCT04323592||Exposed to Methylprednisolone|Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
9855112|NCT04323592||Non-exposed to Methylprednisolone|Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.
9855113|NCT04326842||Carotid artery stenosis|Patients with carotid artery stenosis. Procedure: Carotid artery revascularization procedure
9855114|NCT04326842||Control|Patients without carotid artery stenosis
9855115|NCT04325542|Other|HBSAG positive with rapid test|Newborns from woman who are positive with HBSAG rapid test got WHO recommended HBV vaccination at birth to avoid HBV transmission
9855116|NCT04329923|Active Comparator|Cohort 1 HCQ|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with hydroxychloroquine 400 mg twice a day for up to 14 days
9855117|NCT04329923|Placebo Comparator|Cohort 1 Placebo|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with placebo twice a day for up to 14 days. Crossover is allowed if symptoms worsen after 7 days of treatment.
9855118|NCT04329923|Experimental|Cohort 2 HCQ high dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg twice a day for up to 14 days
9855119|NCT04329923|Active Comparator|Cohort 2 HCQ low dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for up to 7 days
9855120|NCT04329923|Experimental|Cohort 3 HCQ|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for 2 months
9855121|NCT04329923|Placebo Comparator|Cohort 3 Placebo|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with placebo for 2 month. Crossover is allowed if subject becomes SARS-CoV2 positive.
9855122|NCT04328467|Experimental|Intervention Once Weekly|400 mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg weekly for the duration of follow up, up to 12 weeks
9855123|NCT04328467|Experimental|Intervention Twice Weekly|400mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg twice weekly for the duration of follow up, up to 12 weeks
9855124|NCT04328467|Placebo Comparator|Control Group|Placebo 2 tabs once, followed by 2 tabs 6 to 8 hours later, thereafter two tabs weekly or twice weekly for the duration of follow up, up to 12 weeks
9855125|NCT04322526|Experimental|Naltrexone, then placebo|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.
9855126|NCT04322526|Placebo Comparator|Placebo, then naltrexone|In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.
9855127|NCT04322500|Other|Group A: conservative|conservative treatment
9855128|NCT04322500|Experimental|Group B: probiotics|in addition to the conservative treatment they receive a probiotics mixture (Streptococcus thermophilus ST10, Lactococcus lactis LLCO2 and Lactobacillus delbrueckii subsp. bulgaricus LDB01)
9855129|NCT04322682|Active Comparator|Colchicine|Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
9855130|NCT04322682|Placebo Comparator|Placebo|Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
9855131|NCT04321980|Experimental|Cohort 1|Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a subcutaneous (SC) injection.
9855132|NCT04321980|Experimental|Cohort 2|Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.
9855133|NCT04322396|Placebo Comparator|Control|"This arm will receive standard care and placebo in 15 days.~Azithromycin placebo:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine placebo:~Day 1-15: 200 mg x 2"
9855134|NCT04322396|Active Comparator|Intervention|"This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.~Azithromycin:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine:~Day 1-15: 200 mg x 2"
9855135|NCT04320823|Experimental|Experimental Group|Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.
9855136|NCT04320823|Active Comparator|Control Group|Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.
9855137|NCT04320615|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
9855138|NCT04320615|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
9855139|NCT04318535|Experimental|Participants receiving T1T2R|Participants will receive a single oral dose of Griseofulvin T1: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
9855140|NCT04318535|Experimental|Participants receiving T2RT1|Participants will receive a single oral dose of Griseofulvin T2: 1 x 250 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
9855141|NCT04318535|Experimental|Participants receiving RT1T2|Participants will receive a single oral dose of Griseofulvin R: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
9855142|NCT04316260|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
9855143|NCT04316260|Active Comparator|Treatment As Usual|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
9855144|NCT04314037|Experimental|Sequence 1 (T1-R1-T2-R2)|Participants will receive first dose of Cesol on Day 1 in treatment period 1 followed by first dose of Biltricide on Day 8 in treatment period 2 followed by second dose of Cesol on Day 15 in treatment period 3 followed by second dose of Biltricide on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
9855145|NCT04314037|Experimental|Sequence 2 (R1-T1-R2-T2)|Participants will receive first dose of Biltricide on Day 1 in treatment period 1 followed by first dose of Cesol on Day 8 in treatment period 2 followed by second dose of Biltricide on Day 15 in treatment period 3 followed by second dose of Cesol on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
9855146|NCT04315298|Experimental|Sarilumab 200mg IV (P2)|Phase 2
9855147|NCT04315298|Experimental|Sarilumab 200mg IV (P3:C1)|Phase 3: Cohort 1
9855148|NCT04315298|Experimental|Sarilumab 400mg IV (P2)|Phase 2
9855149|NCT04315298|Experimental|Sarilumab 400mg IV (P3:C1)|Phase 3: Cohort 1
9855150|NCT04315298|Experimental|Sarilumab 800mg IV (P3:C2)|Phase 3: Cohort 2
9855151|NCT04315298|Experimental|Sarilumab 800mg IV (P3: C3)|Phase 3: Cohort 3
9855152|NCT04313647|Experimental|1X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
9855153|NCT04313647|Experimental|2X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
9855154|NCT04313647|Experimental|4X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
9855155|NCT04313647|Experimental|6X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
9855156|NCT04313647|Experimental|8X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
9855157|NCT04310085|Experimental|PfSPZ-DVI challenge and artemether lumefantrine|"16 healthy, malaria-naïve males and females, aged 18-55 years, were enrolled in 2 cohorts (8 participants/cohort; a participant may be enrolled in one cohort only). There were two target levels of parasitaemia previously achieved in healthy participants in malaria VIS at other study sites, i.e., 5000 parasites/mL blood in Cohort 1 and 10000 parasites/mL blood in Cohort 2. (Based on observed levels of parasitaemia in Cohort 1, the target threshold for treatment in Cohort 2 was maintained at 5,000 p/mL).~qPCR was performed, malaria clinical score assessed twice daily and participants were administered registered antimalarial therapy, i.e., Riamet®, when the following criteria were met:~Cohort 1: ≥5000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion.~Cohort 2: ≥10000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion."
9855158|NCT04309617||patients with Renal Cell Carcinoma(RCC)|Patients diagnosed with RCC who received a nephrectomy between 01Apr2014 and 31Mar2019
9855159|NCT04308239|Experimental|Reactive balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~Reactive balance training involved both slip and trip training.~Slip training involved repeatedly stepping onto a low-friction interface (nylon fabric placed over a 0.9 × 0.9 meter polycarbonate sheet) while practicing controlling/decelerating the slipping foot and properly positioning the non-slipping foot under the pelvis.~Trip training involved repeatedly practicing recovery from simulated trips on a modified treadmill. While standing on a modified treadmill, the treadmill belt was quickly accelerated posteriorly to elicit a forward loss of balance that mimicked a trip while walking. Participants attempted to step to avert a fall, and to establish a stable gait on the treadmill, after which the treadmill speed was slowed to zero to complete the trial."
9855160|NCT04308239|Active Comparator|Control balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~The control intervention involved general balance exercises adapted from the Otago Exercise program. Briefly, all four sessions involved balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support)."
9855161|NCT04308668|Experimental|Treatment|Participants in this arm will receive the study drug.
9855162|NCT04308668|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
9855163|NCT04307940|Experimental|Naproxen sodium|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
9855164|NCT04307940|Active Comparator|Hydrocodone/Acetaminophen|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
9855165|NCT04307940|Placebo Comparator|Placebo|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
9855166|NCT04302545|Experimental|Cystoinflation group|Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
9855167|NCT04302545|No Intervention|Control group|Pelvic adhesiolysis will be performed without bladder retrofill.
9855168|NCT04297631|Experimental|Vancomycin Powder|All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.
9855169|NCT04297631|Experimental|Tobramycin Powder|All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.
9855170|NCT04297241|Experimental|Isosorbide Dinitrate|Each enrolled participant will be on a titrated dosage of isosorbide dinitrate to determine effectiveness on both primary and secondary outcome measures.
9855171|NCT04296448|No Intervention|Traditional Otoscope|Pediatric trainees use a traditional otoscope to evaluate pediatric patient ears. Trainees' supervisors will also evaluate patients with the traditional otoscope. The study evaluates concordance of the exams.
9855172|NCT04296448|Experimental|Cellscope|Pediatric trainees use a cellphone otoscope (Cellscope) to evaluate pediatric patient ears. Trainees' supervisors will evaluate patients remotely with the video on the cellphone otoscope. The study evaluates concordance of the exams.
9855173|NCT04296227|Experimental|ISO 81060-2:2018.|The intended purpose of the test is to evaluate the Vital Detect blood pressure monitor to ISO 81060-2:2018. The intended use for these products are manual and automatic Non-Invasive Blood Pressure monitoring on adults age 18 and older.
10208686|NCT05202704|Active Comparator|Active Comparator: Neutral Expectations|Patients with chronic low back pain will receive verbal delivered neutral instructions regarding manipulative therapy (G3) before the administration of a manipulative therapy approach.
9517050|NCT03309982|Experimental|Plant polyphenol blend|The study product (4 g) consists of 3 g of a mix a maltodextrins, and 1 g of anthocyanin-rich plant polyphenol blend containing: 1) 100 mg bilberry extract; 2) 300 mg black currant extract; and 3) 600 mg black rice extract.
9855174|NCT04295356|Active Comparator|Auto injector|a single dose (40 mg) of CT-P17 via AI
9855175|NCT04295356|Active Comparator|Pre-filled syringe|a single dose (40 mg) of CT-P17 via PFS
9855176|NCT04292639|Experimental|Respiratory Rate|The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Vital USA Vital Detect to an FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda). This report documents exclusively the results of the Respiratory Rate accuracy performance for the Vital USA Vital Detect.
9855177|NCT04292535|Active Comparator|Passive Control|20 minute sedentary control period during which participants watched an emotionally neutral video.
9855178|NCT04292535|Experimental|Acute Exercise|20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.
10208687|NCT05200923|Experimental|Pelvic health Electrically Evoked Recording (PEER) 2 Study|Collect physiological signals
10208688|NCT05197049|Experimental|Group 1: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.
10208689|NCT05197049|Experimental|Group 2: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.
10208690|NCT05197049|Placebo Comparator|Group 3: Placebo|Participants will receive placebo injection subcutaneously.
10208691|NCT05196958|Experimental|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
10208692|NCT05193474|No Intervention|Refuse to integrate palliative care into usual care.|Usual ESRD care team
10208693|NCT05193474|Experimental|Agree to integrate palliative care into usual care.|Usual ESRD care + combined palliative care team
10208694|NCT05192954|Experimental|Vessel sealing device|Vessel sealing device to be utilized for vaginal hysterectomy
9855179|NCT04292171|Active Comparator|Gabapentin Arm|Gabapentin 600 mg given 1-2 hours prior to surgical abortion
9855180|NCT04292171|Placebo Comparator|Placebo Arm|Placebo (vit C) given 1-2 hours prior to surgical abortion
9517051|NCT03309982|Placebo Comparator|Placebo|The placebo (4 g) consists of a mix of maltodextrins (3.85 g) and Red Dye No. 40 (0.125 g) and Blue Dye No. 1 (0.025 g).
9855181|NCT04292899|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
9855182|NCT04292899|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
9855183|NCT04292899|Experimental|Part B: Remdesivir, 10 Days (Extension)|Part B (Extension) will enroll participants after enrollment to Part A is complete. Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10.
9855184|NCT04292899|Experimental|Part B: Remdesivir 10 days (Mechanically Ventilated)|Participants on mechanical ventilation will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10
9855185|NCT04292730|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
9855186|NCT04292730|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
9855187|NCT04292730|Active Comparator|Part A: SOC Therapy|Participants will receive continued standard of care therapy.
9855188|NCT04292730|Experimental|Part B: Extension Treatment, Remdesivir 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
9855189|NCT04290676||DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
9855190|NCT04290039|Active Comparator|Low Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
9855191|NCT04290039|Active Comparator|High Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
9923828|NCT00854750|Experimental|ACTHAR- placebo second|20mg, Placebo, 40 mg, 80mg
9923829|NCT00854750|Experimental|ACTHAR- placebo third|20 mg, 40 mg, Placebo, 80 mg
9923830|NCT00854750|Experimental|ACTHAR- placebo fourth|20 mg, 40 mg, 80 mg, Placebo
9923831|NCT00854763||Hypertension|
10208695|NCT05192954|No Intervention|Conventional clamping and suturing method|Vaginal hysterectomy will be performed utilizing conventional Heaney clamps, scissors, and suturing material.
9923832|NCT00854776|Active Comparator|1|Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
10208696|NCT05192499|Other|Case|"Patients aged to 1 to 3 years with severe asthma (i.e. resistant to inhaled corticosteroid doses less than or equal to 200μg fluticasone equivalent).~Severe asthma patients (cases) are defined by poor asthma control under doses of inhaled corticosteroids ≤200μg fluticasone equivalent."
10208697|NCT05192499|Other|Control|"Patients aged to 1 to 3 years with low or moderate asthma (controlled with mild to moderate doses of inhaled corticosteroids less than or equal to 200μg of fluticasone equivalent).~Mild to moderate asthma patients (controls) are defined by disease control by first-line treatment in asthma, i.e. corticosteroids inhaled at mild to moderate doses of ≤200 micrograms/day of fluticasone equivalent."
10208698|NCT05192421|Active Comparator|Level 1|Wellness Education
10208699|NCT05192421|Experimental|Level 2|Wellness Education + Pre-recorded Exercise Videos
10208700|NCT05192421|Experimental|Level 3|Wellness Education + Livestream Exercise Classes
10208701|NCT05191953|Active Comparator|Group ESPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
10208702|NCT05191953|Active Comparator|Group ESPB+Superficial PIPB|A bilateral ESPB (40 ml, %0.25 bupivacaine, totally) and a bilateral superficial PIPB (20 ml, %0.25 bupivacaine, totally) + IV morphine-PCA
10208703|NCT05191368||Normal group|Healthy people who received two doses of COVID-19 vaccine
10208704|NCT05191368||RA Patients injected with 2 doses of vaccine|RA Patients who received two doses of COVID-19 vaccine
10208705|NCT05191368||Unvaccinated RA patients|RA Patients who received zero doses of COVID-19 vaccine
9986399|NCT01402557|Experimental|Telehealth|These participants receive telehealth support (with Internet-enabled digital video recorders) during the weight maintenance phase. These participants also receive telephone support monthly.
9855192|NCT04290039|Active Comparator|Intravenous (IV)|"Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.~Atropine sulfate injection, USP,8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).~Atropine sulfate injection will be supplied in multidose vials containing 20 mL.~Each vial will only be used to administer a single dose, to a single subject."
9855193|NCT04289623||Standard email|This email mentions the cost-saving benefits of enrollment by participants who met their 2018 goals. It also includes the message that registration can be completed quickly (in less than five minutes). Finally, it also includes reward incentive information, wherein registering by a March deadline provides qualified recipients with the potential to win prizes. This information is contained in all other emails.
9855194|NCT04289623||Loss frame email|"In addition to the content of the generic email, the subject line and content of the loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. This email further frames the reward as something recipients will miss out on if they do not sign up.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
9855195|NCT04289623||Testimonial (medical expert) email|"In addition to the content of the generic email, the testimonial (medical expert) email includes a testimonial from a doctor, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a presumed authority figure. Recipients may be more likely to enroll for this program if they see a physician - who would be seen as an authority on health and wellness - talking about the medical benefits of the program. It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
9855196|NCT04289623||Testimonial (rank-and-file) email|"In addition to the content of the generic email, the testimonial (rank-and-file) email includes a testimonial from a customer care specialist, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a peer (relative to most Geisinger employees). Recipients may be more likely to enroll for this program if they see a rank-and-file employee talking about the program as this person would be more relatable (relative to a doctor). It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
9986400|NCT01402583||PEG IFN/Ribavirin|Subjects with Hepatitis C undergoing PEG IFN/Ribavirin treatment
9986401|NCT01402596|Active Comparator|Chloral hydrate|Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
9986402|NCT01402596|Active Comparator|Midazolam|Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
9855197|NCT04289623||Social norms (percentage) email|"In addition to the content of the generic email, the social norms (percentage) email will include communication about the percentage of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a majority of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. The use of percentages makes it clear that this behavior is indeed being done by most people in the group. It is unclear in the current context and population if a message using percentages or numbers would be more effective."
9855198|NCT04289623||Social norms (number) email|"In addition to the content of the generic email, the social norms (number) email will include communication about the number of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a large number of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. While the use of numbers does not indicate that this behavior is being done by a majority, using a large number can be more convincing just in showing sheer quantity."
9855199|NCT04276207|Experimental|100 U/mL LY900014|100 units per milliliter (U/mL) LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
10208706|NCT05191303|Experimental|Intervention group|In addition to standard usual care of breastfeeding counseling, the intervention group will have an opportunity to access the mobile application breastfeeding counseling from weeks 18 of pregnancy, continuing for up to 6 months after childbirth.
10208707|NCT05191303|No Intervention|Control group|"The control group receives the standard usual care of breastfeeding counseling in maternity care and in hospital from weeks 18 of pregnancy, continuing for up to 6 months after childbirth.~The standard usual care of breastfeeding follows the 10 steps of the Baby Friendly Hospital Initiative programme and Finnish Institute for Health and Welfare recommendation."
10213555|NCT03809624|Experimental|Combination Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with INBRX-105 in combination with Pembrolizumab.
9855200|NCT04276207|Active Comparator|100 U/mL Insulin Lispro (Humalog)|100 U/mL Insulin Lispro (Humalog) administered by CSII in one of two study periods.
9855201|NCT04289714|Experimental|R-DOT|Remote Directly Observed Therapy
9855202|NCT04289714|Experimental|Haillie|Smartinhaler Haillie
9855203|NCT04289714|Experimental|Rafi-tone/INCA|Rafi-tone with Flo-tone /INCA
9855204|NCT04288752|Experimental|VR101 Lubricating Intravaginal Ring|VR101 is a clear, flexible, torus-shaped lubricating intravaginal ring (IVR) manufactured from hollow tubing formed from Excipient Grade Thermoplastic Urethane Pathway® Polymer PY-PT42DE35 by hot-melt extrusion. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
9855205|NCT04288752|Sham Comparator|Sham Ring|"Performance of VR101 will be compared to that of an inactive ring. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.~Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added."
9855206|NCT04287517|Active Comparator|Capacitive-Resistive Therapy Group|This group was treated with capacitive resistive diathermy and exercise
9855207|NCT04287517|Sham Comparator|Sham Group|This group was treated with sham capacitive-resistive diathermy and exercise
9855208|NCT04287036|Experimental|Test/Control|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Test/Control
9855209|NCT04287036|Experimental|Control/Test|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Control/Test.
9855210|NCT04286412|Experimental|Treatment Arm|At least twenty five eligible male subjects will be enrolled in the treatment arm to receive Nonacog alfa until 16 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
9855211|NCT04285411|Experimental|ARMS SpO2 70-100%|Comparison to Reference CO-Oximetry
9855212|NCT04284930|Experimental|Depobupivacaine|Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.
9855213|NCT04284930|Active Comparator|OnQ Pump|Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.
9855214|NCT04284930|Active Comparator|bupivacaine|Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.
9855215|NCT04283773||Malignant ovarian germ cell tumors ( MOGCTs).|22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
9855216|NCT04283773||Mature cystic teratomas.|20 cases of mature teratomas will be treated by anti P16 antibody .
10213556|NCT03809624|Experimental|Combination Expansion Cohort Melanoma|Patients will be treated with INBRX-105 in combination with Pembrolizumab.
10213557|NCT03809624|Experimental|Combination Expansion Cohort Cohort PD-L1 Positive Basket|Patients with head and neck squamous cell carcinoma, gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-105 in combination with Pembrolizumab.
9855217|NCT04283773||Normally apparent ovaries.|20 cases of normally apparent ovaries will be treated by anti P16 antibody .
9855218|NCT04281901|Experimental|PVRP treated participants|Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
9855219|NCT04281901|Active Comparator|Standardly treated participants|Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).
9855220|NCT04280653|Experimental|NDE L68 StableFit® punctal plug|Each study subject that qualifies at the baseline visit will receive an NDE L68 StableFit® punctal plug in the lower punctum in one of their eyes. All study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion
9855221|NCT04277936|Experimental|Levetiracetam (LEV) 500 mg|Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
9855222|NCT04275336|Experimental|EMLA group|The specialist nurse who is to perform IV cannulation determine the puncture site. A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse performed IV cannulation for them.
9855223|NCT04275336|Experimental|Distraction group|The multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They are also taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
9855224|NCT04275336|Experimental|Combined group|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
9855225|NCT04272775|Experimental|Cohort 1: Ixazomib 4.0 mg|Ixazomib 4.0 milligram (mg), capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
9855226|NCT04272775|Experimental|Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone|Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 milligram per day (mg/day), capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 62.
9855227|NCT04272775|Experimental|Cohort 3: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
9855228|NCT04272775|Experimental|Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 87.
9855229|NCT04271020|Experimental|UroLift|
9855230|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, B, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, B, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
9855231|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, C, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, C, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
9855232|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, A, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, A, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
9855233|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, C, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, C, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
9855234|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, A, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, A, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
9855235|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, B, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, B, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
9855236|NCT04271605|Experimental|behavior intervention and pharmacological therapy|"For participants with abnormal biochemical markers, pharmacological therapy and diet modification are applied.~Dietary education on phosphorus additives is applied specifically for retention of phosphorus or high serum phosphorus level.~Exercise for bone and cardiovascular health.~Osteoporosis medications are initiated according to the reimbursed criteria of National Health Insurance, otherwise medications are used with non-insurance payment."
9855237|NCT04271761||Current adult recipients of Cochlear Carina System|Adults who are current recipients of the Cochlear Carina System. Participants will attend one scheduled visit where several acoustic measurements will be taken that do not require active participation by the participant.
9855238|NCT04268316|Experimental|Virtual Reality Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in virtual reality. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable activities to enjoy in virtual reality.
10208708|NCT05191264||percutaneous osteosynthesis and cementoplasty procedure|"Patient with percutaneous osteosynthesis and cementoplasty procedure will be included.~Patients have assessed for pain and quality of life during consultations as part of an interventional radiology procedure (pre-procedure consultation, and follow-up consultations at 1, 3, 6 and 12 months after the procedure."
10208709|NCT05190627|Experimental|Loratadine treatment on rapamycin|Loratadine (oral administration, daily dose 10mg) in LAM patients that are treated with rapamycin
10208710|NCT05190627|Placebo Comparator|Placebo treatment on rapamycin|Placebo (oral administration, daily dose 10 mg) in LAM patients that are treated with rapamycin
10208711|NCT05190406|Experimental|Pulpotomy|complete pulpotomy will be done till the level of root canal orifice.
10208712|NCT05190406|Active Comparator|Root canal treatment|Single visit root canal treatment will be done according to standard protocol.
10208713|NCT05190016||Cases (Current/fresh)|Cases (current/fresh) are defined as those samples which has been tested positive by RT-PCR at IEDCR as a regular screening program and have not been stored in the freezer.
10208714|NCT05190016||Cases(stored)|Cases (stored) are defined as those samples which has been tested positive by RT-PCR at IEDCR as a regular screening program and have been stored in the -80°C freezer at IEDCR.
9855239|NCT04268316|Active Comparator|Behavioral Activation in real-life|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life.
9855240|NCT04268316|No Intervention|Waitlist Control|Participants randomized to this arm will not receive any type of intervention and will be asked to complete the PHQ-9 once a week for three weeks (4 sessions) to track symptoms. Participants will be offered to engage in behavioral activation in real life or with virtual reality when the four weeks are complete. Their data will only be used from the time they were on the waitlist.
9855241|NCT04269629||patients with a history of an anaphylactic sting reaction|At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.
9855242|NCT04267575|Experimental|Primary Arm|After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
9855243|NCT04267770|Experimental|circadian insulin infusion rates|Initial variable basal rates aim to replicate circadian changes in insulin requirements and are derived from total basal insulin in adults over 24 years old, and from weight in adults aged 18 to 24 years.
9855244|NCT04267770|Active Comparator|flat rates|flat basal rate
9855245|NCT04266925|Experimental|3 referees|Three referees were present on the field during these youth soccer matches.
9855246|NCT04266925|Active Comparator|1 referee|One referee was present on the field during these youth soccer matches.
9855247|NCT04263142|Experimental|Part 1: Treatment AB|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855248|NCT04263142|Experimental|Part 1: Treatment BA|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855249|NCT04263142|Experimental|Part 2: Treatment CDE|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855250|NCT04263142|Experimental|Part 2: Treatment DEC|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855251|NCT04263142|Experimental|Part 2: Treatment ECD|Participants will receive a single dose of GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855252|NCT04256785|Experimental|VSL#3|probiotic VSL#3, 2 sachets b.i.d for 3 months
9855253|NCT04256785|Placebo Comparator|placebo|matched placebo, 2 sachets b.i.d for 3 months
9855254|NCT04252092|Experimental|Sensory Group|15 patients who will be applied 15 sessions of sensory training
9855255|NCT04252092|Experimental|Electrical Stimulation Group|15 patients who will be applied 15 sessions of electrical stimulation
9855256|NCT04250987|Experimental|IC connected to a sensor|Single use of a IC connected to a sensor
10208715|NCT05190016||Control (Current/fresh)|Control (Current/fresh) are defined as those samples which has been tested negative by RT-PCR at IEDCR as a regular screening program and have not been stored in the freezer.
10208716|NCT05190016||Control (stored)|Control (stored) are defined as those samples which has been tested negative by RT-PCR at IEDCR as a regular screening program and have been stored in the -80°C freezer at IEDCR
10208717|NCT05189522|Experimental|Innova Breeze®-based roadmap|"An Innova Breeze® bolus chase acquisition is realized prior to the revascularization to assess the lesions of the entire target limb. Guidance to the different lesions is done using a 2D roadmap based on the Innova Breeze® bolus acquisition frames if the patient position has not moved on the table.~An Innova Breeze® bolus chase acquisition is realized to assess the final result of the revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm. Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. Innova Breeze® bolus chase acquisitions are performed with the injector set at 4mL/s and the volume at 24mL (pressure limit 1000psi). An injector with iodinated contrast (50% of dilution) will be used."
10213558|NCT03809624|Experimental|Combination Expansion Cohort Treatment Naive Non-small Cell Lung Cancer|Treatment naive patients (PD-L1 IHC between 1 and 49%) will be treated with INBRX-105 in combination with Pembrolizumab.
9855257|NCT04249336|Experimental|BioMin F Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
9855258|NCT04249336|Active Comparator|Colgate Sensitive Pro relief Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
9855259|NCT04249336|Active Comparator|Sensodyne Rapid Action Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
9855260|NCT04249336|Placebo Comparator|Colgate Total Trade Mark|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
9855261|NCT04249310||Tiotropium/Olodaterol|Combination of Tiotropium and Olodaterol
9855262|NCT04249310||Tiotropium|
9855263|NCT04247581|Other|Cohort 1|This will include subjects with no known history of AF and are in normal sinus rhythm at time of screening
9855264|NCT04247581|Other|Cohort 2|This will include subjects with known persistent or permanent AF who are in AF at the time of screening
9855265|NCT04247061|Experimental|Smoking Cessation intervention|At a dental cleaning visit, participants will watch a brief educational video that provides guidance and advice on smoking cessation. Participants will then interact with a text program for a month to motivate them to use smoking cessation resources. Participants will also be required to make contact with the resources in order to demonstrate feasibility of study flow.
9855266|NCT04245202|Active Comparator|Active Comparator: HFNCOT|Set between 2 to 25 l/min, adjusted to obtain peripheral oxygen saturation >92%.
9855267|NCT04245202|Active Comparator|Active Comparator: St-FMOT|To obtain oxygen saturation >92%
9855268|NCT04243369|Other|Experimental - Collaboration Live software|
9855269|NCT04241146|Active Comparator|Standard Blind Technique of Tube placement|FDA approved technique of enteral nutrition tube placement
9855270|NCT04241146|Active Comparator|CORTRAK enteral access system (CEAS) placement|An electromagnetic device used to enable enteral nutrition tube placement
9855271|NCT04240678|Experimental|HBV Alert Group|
9855272|NCT04240678|No Intervention|Control Group|
9855273|NCT04238650|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
9855274|NCT04238650|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
9855275|NCT04238663|Experimental|MB02 (Bevacizumab Biosimilar)|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
9855276|NCT04238663|Active Comparator|EU approved Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
10208718|NCT05189522|Other|control group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
10208719|NCT05189119||LVFgroup|patients with AECOPD and left ventricular failure
9855277|NCT04238663|Active Comparator|US licenced Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
9855278|NCT04235582|Experimental|Outcomes Group|"During the intervention period, the Outcomes group will receive incentives for abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care and a similar mobile app and debit card as the Inputs group. However, the app will prompt patients in this group to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). Patients will receive immediate financial rewards in exchange for submitting drug-negative samples. Saliva tests typically have a window of detection between 24-48 hr after drug use."
9855279|NCT04235582|Experimental|Inputs Group|"Will receive incentives for behaviors that are inputs to abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care. Additionally, patients will be registered for a mobile phone app provided by DynamiCare Health and provided with a linked debit card. The app will prompt patients to complete actions that are inputs to abstinence an average of three times per week. These actions will be tailored to the patient's individual needs, and may include:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions"
9855280|NCT04235582|Experimental|Combination Group|"Will receive interventions from both Inputs and Outputs groups, as well as standard of care therapy services and urine drug tests an average of three times per week, total. Interventions include incentives for:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions~Random saliva tests"
9855281|NCT04203225|Active Comparator|Single LET|One (single) application of LET topical gel [Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%)] applied for 30 minutes
9855282|NCT04203225|Experimental|Triple LET|Three applications of LET topical gel, one applied every 10 minutes
9855283|NCT04234672|Experimental|TAK-831 500 mg + [14C]TAK-831 50 μg + [14C]TAK-831 500 mg|TAK-831 500 mg, tablet, orally, once on Day 1, followed by [14C]TAK-831 50 micrograms (μg) [approximately 1 microcurie (μCi)], infusion, intravenously (IV), once on Day 1 of Treatment Period 1, followed by a washout period of 8 days, further followed by [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, once under fasted state on Day 1 of Treatment Period 2.
9855284|NCT04223635|Experimental|Hepatic impaired|Participants with moderate hepatic impairment who will receive a single oral dose of pexidartinib.
10208720|NCT05189119||non LVF group|patients with AECOPD and whithout left ventricular failure
9855285|NCT04223635|Experimental|Healthy controls|Sex-, age-, and weight-matched healthy participants who will receive a single oral dose of pexidartinib.
9855286|NCT04214951||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
9855287|NCT04214951||Eltrombopag group|Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10^9/L.The efficacy, safety, and patient/physician preference will be assessed.
9855288|NCT04234425|Experimental|Experimental Group|18 high school students in a weight training class will be assigned to this experimental group and will receive the one-hour intervention twice weekly for 8 weeks.
9855289|NCT04232137|Experimental|Coffee ceremony|Antenatal care patients will be told on their first antenatal care visit that a postpartum coffee ceremony will be organized for them and up to 4 relatives
9855290|NCT04232137|No Intervention|NO Coffee ceremony|Antenatal care patients will be told that they will NOT receive a postpartum coffee ceremony, as is the current status quo
9855291|NCT04222699|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
9855292|NCT04208698|Experimental|CIN-102 Tablets Dose 1|CIN-102 tablets by mouth twice daily for 14 days
9855293|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 1|Placebo tablets by mouth twice daily for 14 days
9855294|NCT04208698|Experimental|CIN-102 Dose 2|CIN-102 tablets by mouth twice daily for 14 days
9855295|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 2|Placebo tablets by mouth twice daily for 14 days
9855296|NCT04206293|Experimental|Juvéderm® VOLITE|Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.
9923833|NCT00854776|Placebo Comparator|2|Upper GI tract symptoms are evaluated at each visit. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. An ulcer is defined as a circumscribed mucosal break at least 3 mm in diameter. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
9923834|NCT00854789|Experimental|Vaccine|HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
9923835|NCT00854789|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.
9923836|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
9923837|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
9923838|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
9923839|NCT00854802|Placebo Comparator|Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
9923840|NCT00854815|Active Comparator|Irrigation|Irrigation of the area with at least 500ml normal saline using the power suction/irrigator
9923841|NCT00854815|Active Comparator|No Irrigation|Only suction with the power suction/irrigator without saline attached
9923842|NCT00854854|No Intervention|Control|"Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16~LV infusions (200 mg/m2) on days 1, 2, 15 and 16"
9923843|NCT00854854|Active Comparator|Active|"Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times~and chemotherapy schedule"
9923844|NCT00854867|Experimental|Whole brain radiotherapy (WBRT) with concomitant Depocyte|Subjects will receive a total of 38.4 Gray (Gy) WBRT given over 4 weeks. Subjects will receive 3 GyWBRT on Days 1 and 2 and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 3 (or Day 4 or 5) of Week 1, i.e. the third day of radiotherapy treatment when the dosage is reduced to 1.8 Gy. The second dose will be administered on Day 17(+2 days); the third dose will be administered on Day 31 (+2 days); the fourth dose will be administered on Day 45 (+2 days) to complete the induction phase of the protocol. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
9855297|NCT04228302|Experimental|EC5026|Single Ascending Doses of oral EC5026
9855298|NCT04228302|Placebo Comparator|Placebo|Single doses of matching oral placebo
9855299|NCT04227119|Experimental|Irrigated ablation catheter and 5F balloon tipped PA catheter|Participants undergoing cardiac ablation will have cardiac pressures measured with an irrigated ablation catheter (standard protocol for this procedure) and a 5F balloon tipped pulmonary artery (PA) catheter (for study purposes only).
9855300|NCT04224753|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
9855301|NCT04218799|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|
9855302|NCT04204057|Experimental|Tenalisib|Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles
9855303|NCT04195594|Experimental|Nic's Keto Diet|
9855304|NCT04223687|Experimental|Sugar-Sweetened Beverage Warning Label|
9855305|NCT04223687|Other|Neutral label|
9855306|NCT04223232|Experimental|MD1003|radiolabeled 14C MD1003 (High Dose Biotin) 100mg
9855307|NCT04189224|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Test/Control.
9855308|NCT04189224|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Control/Test.
9855309|NCT04214600|Experimental|Cognitive Behavioral Therapy|This group will receive four CBT sessions twice a month for two months
9855310|NCT04214600|No Intervention|Control|This group will be scheduled the same number of visits as a follow up for diabetes
9855311|NCT04202497|Experimental|TAK-418 1.5 mg|TAK-418 1.5 milligram (mg), orally, once on Day 1. Participants will also receive 10 millicurie (mCi) of [18F]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3. Dose levels for subsequent participants may vary based on available review of imaging and pharmacokinetics (PK) data.
9855312|NCT04214080|Experimental|Study Group (SG)|"In addition to feeding and oral motor intervention strategies, intensive neck and trunk stabilization exercises based on Neurodevelopmental treatment-Bobath (NDT-B) concept principles were applied to this group.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
9855313|NCT04214080|Placebo Comparator|Control Group (CG).|"(NDT-B) concept approaches and feeding and oral motor intervention strategies were applied to this group in routine treatment.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
9855314|NCT04209530|Experimental|Buttock & Posterolateral Thigh|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
9855315|NCT04209335|Other|healthy working age population|isometric core muscle endurance tests (McGill V-sit, Biering-Sorensen and sideplank)
9855316|NCT04207333|Experimental|Prolonged Sitting + Mental Stress, Then Brief Sitting + Mental Stress|Participants will sit for 120 min prior to being exposed to mental stress Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 120 minutes while watching a documentary. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (brief sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Following the 10 minutes quiet rest in the seated position, participants will be subjected to a 5 minute mental arithmetic test.
9855317|NCT04207333|Experimental|Brief Sitting + Mental Stress, Then Prolonged Sitting + Mental Stress|Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 10 minutes. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (prolonged sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Participants will sit quietly for 120 min while watching a documentary, following which the participants will be subjected to a 5 minute mental arithmetic test.
9855318|NCT04207840|Experimental|Primatene Mist, E004|Participants who dosed with Primatene Mist.
9855319|NCT04207840|Active Comparator|Epinephrine Injection Auto-Injector (Generic of EpiPen)|Participants who were dosed with an Epinephrine Injection Auto-Injector.
9855320|NCT04207840|Active Comparator|Albuterol HFA|Participants who dosed with Albuterol HFA.
9855321|NCT04206800|No Intervention|Routine care|Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
9517052|NCT03309969||observation group|Subjects with suspicious iliac vein compression syndrome were included in the observation group.
9855322|NCT04206800|Experimental|Ejaculatory abstinence less than 24 hours|Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.
9855323|NCT04205669|Active Comparator|Individual Treatment|
9855324|NCT04205669|Active Comparator|Household Treatment|
9855325|NCT04198948|Experimental|Omeprazole, Then Placebo|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.
9855326|NCT04198948|Experimental|Placebo, Then Omeprazole|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.
9855327|NCT04206384|Experimental|Treatment group|Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.
9855328|NCT04204200|Active Comparator|Allocated to conventional vitamin C (n= 22)|"Received allocated conventional vitamin C (n= 22)~Did not receive allocated conventional vitamin C (n= 0)"
9855329|NCT04204200|Active Comparator|Allocated to liposomal vitamin C (n= 22)|"Received allocated liposomal vitamin C (n= 22)~Did not receive allocated liposomal vitamin C (n= 0)"
9855330|NCT04204200|Placebo Comparator|Allocated to placebo (n= 22)|"Received allocated intervention (n= 22)~Did not receive allocated intervention (n= 0)"
9855331|NCT04196907|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse Oximeter and DCI Mini sensor for measurement of hemoglobin.
9855332|NCT04195893|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to etafilcon A daily disposable lenses for one week.
9855333|NCT04195893|Active Comparator|etafilcon A|Subjects will be randomized to wear etafilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
9855334|NCT04195880|Experimental|Experimental VA Community Living Centers|Eight VA CLCs selected to receive the INTERACT intervention
9855335|NCT04195880|No Intervention|Control VA Community Living Centers|Eight CLCs, matched to experiment CLCs, based on size, location to VAMC, and hospitalization rates, did not receive the intervention and continued care as usual
9855336|NCT04195581|Experimental|comfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
9855337|NCT04195581|Experimental|comfilcon A with All in One Light Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
9855338|NCT04195581|Experimental|comfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
9855339|NCT04195581|Active Comparator|fanfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
9855340|NCT04195581|Active Comparator|fanfilcon A with All in One Light multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
9855341|NCT04195581|Active Comparator|fanfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
9855342|NCT04194151|Active Comparator|2 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol
9855343|NCT04194151|Active Comparator|2 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol
9855344|NCT04194151|Active Comparator|2 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol
9855345|NCT04194151|Active Comparator|1 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol
9855346|NCT04194151|Active Comparator|1 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol
9855347|NCT04194151|Active Comparator|1 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol
9855348|NCT04194008|Experimental|Nerivio device treatment|Treatment with active Nerivio device
9855349|NCT04191668|Other|PSG and NightOwl|Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
9855350|NCT04189081|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
9855351|NCT04189081|Sham Comparator|Water Control|Water will be used as a mouth rinse and can be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using water, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
9855352|NCT04189081|Active Comparator|Positive Control|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
9855353|NCT04186780|Experimental|Intervention group|Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
9855354|NCT04186780|Placebo Comparator|Placebo group|Patients with borderline cholesterol consumed two placebo cereal bars for 66 days.
9855355|NCT04186806|Experimental|3M Dry Mouth Moisturizing Spray|Dry mouth agent
9855356|NCT04186806|Active Comparator|Biotene Moisturizing Mouth Spray|Dry mouth agent
9855357|NCT04186481||Minitac Ti 2.0 suture anchor|Subjects who have undergone extremities repair using the Minitac Ti 2.0 Suture anchor
9855358|NCT04184999|Experimental|Intracameral dexamethasone 9% + postoperative topical prednisolone acetate|dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively
9855359|NCT04184999|Active Comparator|postoperative topical prednisolone acetate|topical ophthalmic prednisolone acetate for 3 weeks post-operatively
9855360|NCT04184271|Experimental|38% silver diamine fluoride|38% silver diamine fluoride, topical, 1 drop, single application
9855361|NCT04183231|Experimental|Anti-caries varnish|topical dental varnish, 10% PVP-I, 2.5% NaF, topical application to teeth, 0.4 ml, single application
9855362|NCT04182958|Experimental|(14C)-OPC-61815|
9855363|NCT04179838|Experimental|Sleep-Deprived first, then Non-Sleep Deprived|Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
9855364|NCT04179838|Experimental|Non-Sleep Deprived first, then Sleep-deprived|Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).
9855365|NCT04179461|Experimental|Personalized Treatment|"Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention."
9855366|NCT04179474|Experimental|Part 1 (Intervention A then B then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
9855367|NCT04179474|Experimental|Part 2 (Intervention A then C then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
9855368|NCT04178590|Experimental|SRP + Injectable Platelet-Rich Fibrin|Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
9855369|NCT04178590|Placebo Comparator|SRP + placebo|Scaling and root planing in conjunction with saline
9855370|NCT04177862|Experimental|Sublingual Sufentanil|Single dose of sublingual sufentanil for acute pain.
9855371|NCT04177862|Active Comparator|IV Fentanyl|single dose of IV fentanyl for acute pain.
9855372|NCT04176406|Active Comparator|rTMS over a node within the fronto-parietal network|excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.
9855373|NCT04176406|Sham Comparator|Sham rTMS over a node within the fronto-parietal network|electrical sham coil applied over a node within the fronto-parietal network.
9855374|NCT04176406|Active Comparator|rTMS over the DLPFC|excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.
9855375|NCT04176406|Sham Comparator|Sham rTMS over the DLPFC|electrical sham coil applied over the DLPFC.
9855376|NCT04175262||Patients with mRCC|Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
9855377|NCT04171102|Active Comparator|Short term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-5 weeks post implantation
9855378|NCT04171102|Active Comparator|Mid term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-4 months post implantation
9855379|NCT04171102|Active Comparator|Long term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 6-8 months post implantation
9855380|NCT04174638|Experimental|"Intervention Group"|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring.
9855381|NCT04174638|No Intervention|"Control Group"|The control group received routine hemodialysis treatment and nursing care in the hemodialysis unit.
9855382|NCT04174313||VILI VORTEX and No VILI VORTEX|Measurement of pulmonary pressures and volumes in the same patient
9855383|NCT04173429|Experimental|nadroparin calcium-warfarin sequential therapy group|nadroparin calcium every 12 hours for 1 month followed by an oral administration of warfarin for 5 months
9855384|NCT04173429|No Intervention|Control group|No anticoagulation therapy.
9855385|NCT04173741||Leg Rise Position - 3 Minutes|Patients who stayed in passive leg rise position for 3 minutes
9855386|NCT04173741||Leg Rise Position - 1 Minute|Patients who stayed in passive leg rise position for 1 minute
9855387|NCT04169061|Experimental|All participants|"Participants receive:~a shot of Acthar (80 units) under the skin twice a week for 12 weeks~a shot of Acthar (40 units) twice a week for 2 weeks~a shot of Acthar (40 units) once a week for 2 more weeks~At each visit they will have medical tests and answer questions about their symptoms."
9855388|NCT04157738|Experimental|Fixed Group|Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
9855389|NCT04157738|Active Comparator|Insulin to carbohydrate ratio (ICR) Group|Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
9855390|NCT04156646|Experimental|Treatment sequence ABC|In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
9855391|NCT04156646|Experimental|Treatment sequence BAC|In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
9855392|NCT04170686|Experimental|Immediate Treatment|Participants will have immediate access to the self-help app. They will take 8 weeks to work through the content at their own pace.
9855393|NCT04170686|No Intervention|Waitlist Control|"Participants in the waitlist will receive no intervention for 8 weeks, other than a few check in emails from study personnel. At the end of 8 weeks, they will be crossed over to the active treatment group and will be given access to the app."
9855394|NCT04169113|Active Comparator|Group 1 - Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
9855395|NCT04169113|Active Comparator|Group 2 - Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
9855396|NCT04160975|Experimental|Black R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
9855397|NCT04160975|Experimental|Black R/Race C/Layperson/Standard Script|Video which contains a racially concordant actor playing a layperson and reading a standard script. The receiver of the message will be Black.
9855398|NCT04160975|Experimental|Black R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
9855399|NCT04160975|Experimental|Black R/Race D/Doctor/Acknowledgement Script|Video which contains a racially discordant actor playing a doctor and reading an acknowledgement script. The receiver of the message will be Black.
9855400|NCT04160975|Experimental|White R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
9855401|NCT04160975|Experimental|White R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
9855402|NCT04153409|Experimental|Active|Subjects will be given two 30 mg capsules of the investigational medicinal product (LAT8881), and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
9855403|NCT04153409|Placebo Comparator|Placebo|Subjects will be given two capsules of placebo, and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
9855404|NCT04167189|Other|Observational study of prevalence in hard-to-treat ADHD|Subjects will be tested with lidocaine gel.
9855405|NCT04162795|Experimental|Loratadine chewable tablet|Participants received one dose of loratadine chewable tablet to chew completely before swallowing.
9855406|NCT04161807|Experimental|Nerivio device treatment|participant will receive the Nerivio device for treating their migraine attacks. Treatment will be perform as soon as the participant feel that the migraine attack started
9855407|NCT04161144|Active Comparator|Rapamycin 15mg (sirolimus)|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
9855408|NCT04161144|Placebo Comparator|Placebo|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
9855409|NCT04161131|Experimental|ONBOARD Intervention|ONBOARD consists of four 60-minute sessions over 3 months. Each session will target a key barrier to CGM use: physical, data, social, and trust. Sessions will be delivered individually to participants by a doctoral level psychologist with diabetes expertise. Each session will include relevant first-person digital stories told adults to with T1D, recounting how they managed relevant CGM barriers.
9855410|NCT04161079||MAR population|Subjects, who underwent MV repair operation with successful MAR implantation in clinical investigation 2010-040
9855411|NCT04158466|Experimental|Kalifilcon A Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
9855412|NCT04158466|Active Comparator|Biotrue ONEday Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
9855413|NCT04152083|Experimental|Eptinezumab|Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.
9855414|NCT04152083|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.
9855415|NCT04155567|Experimental|TAK-123|TAK-123 as 3.75 gram per square meter (g/m^2) of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 90 minutes, followed by TAK-123 as 3.75 g/m^2 of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 24 hours.
9855416|NCT04155047|Active Comparator|Glycopyrrolate Inhalation Solution|Glycopyrrolate Inhalation Solution 25mcg administered by Magnair
9855417|NCT04155047|Placebo Comparator|Placebo|Placebo Inhalation Solution administered by Magair
9855418|NCT04152642|Active Comparator|Marketed Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
9855419|NCT04152642|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
9855420|NCT04152642|Sham Comparator|Water/Negative Control|subjects will swallow 15 ml of water (on-site). Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after water intake (on-site) on Day 1 and Day 4.
9855421|NCT04150861|Experimental|Follitropin delta 12 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
9855422|NCT04150861|Experimental|Follitropin delta 18 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
9855423|NCT04150861|Experimental|Follitropin delta 24 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
9855424|NCT04150250|Experimental|iOWH032|On Day 1, participants were challenged with 10^6 colony-forming units (CFU) of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral iOWH032 500 mg tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
9855425|NCT04150250|Placebo Comparator|Placebo|On Day 1, participants were challenged with 10^6 CFU of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral matching iOWH032 placebo tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
9855426|NCT04149925||AEON Endostapler|Stapling performed by AEON Endostapler
9855427|NCT04149925||Echelon Flex Powered Stapler|Stapling performed by Echelon Flex Powered Stapler
9855428|NCT04150224|Experimental|Cohort 1 (C1A), PBTZ169|Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
9855429|NCT04150224|Experimental|Cohort 1 (C1B), PBTZ169|Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
9855430|NCT04150224|Experimental|Cohort 2 (C2), PBTZ169|Single dose of PBTZ169: 960 mg fasted
9855431|NCT04150224|Experimental|Cohort 3 (C3), PBTZ169|Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
9855432|NCT04150224|Experimental|Cohort 4 (C4), PBTZ169|Single dose of PBTZ169: 1280 mg fasted
9855433|NCT04150224|Experimental|Cohort 5 (C5), PBTZ169|Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
9855434|NCT04149405|Active Comparator|Group A|"Subjects with chronic periodontitis and osteoporosis.~Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
9855435|NCT04149405|Active Comparator|Group B|"Subjects with chronic periodontitis and systemically healthy.~Phase 1 periodontal theraphy was administered to the subjects."
9855436|NCT04149405|Active Comparator|Group C|"Subjects with periodontally healthy and osteoporosis.~Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
9855437|NCT04149405|No Intervention|Group D|"Systemically and periodontally healthy controls~No intervention has been made."
9855438|NCT04144088|Active Comparator|Wu Ling San|"Drug : Wu Ling San Extract Granules Sun-Ten"
9855439|NCT04144088|Active Comparator|Yin-Chen Wu Ling San|"Drug : Yin-Chen-Wu-Ling-San Extract Power SUN-TEN"
9855440|NCT04144088|Placebo Comparator|Placebo|Drug : 1/10 Wu Ling San
9855441|NCT04149353|Experimental|PET/MR|Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.
9855442|NCT04137783||homozygous or compound heterozygous ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated homozgyous or compound heterozygous ABCA3 mutations.
9855443|NCT04137783||single ABCA3 mutation|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated single mutations.
9855444|NCT04137783||no ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which exclude all gene mutations involving in the respiratory disease.
9855445|NCT04136444|Experimental|Healthy participants|Participants will receive assigned single and multiple doses of padsevonil.
9855446|NCT04136444|Experimental|Hepatically impaired participants|Participants will receive assigned single and multiple doses of padsevonil.
9855447|NCT04124536|Experimental|Intervention|In addition to standard partner notification services, the intervention arm will receive HIV self-test kits and structured counseling about HIVST, regardless of HIV status.
9855448|NCT04124536|No Intervention|Control|Standard partner notification services, regardless of HIV status.
9855449|NCT04147611|Experimental|Remote Microphone (RM) Technology Group|"The RM technology group will limited to the pediatrics participants.~Participants will be tested separately on the three following conditions:~Bone Conduction Device (BAHA) only~BAHA + Wireless Audio-Streaming Accessory~BAHA + Digital Adaptive RM System"
9855450|NCT04147611|Active Comparator|Normal Hearing Controls|"The normal hearing controls will be limited to 15 adults.~Participants will be tested separately on the six following conditions:~Unaided~Unilateral hearing aid with contralateral plug.~Unilateral hearing aid + Digital Adaptive RM System (using Roger™, Sonova)~Bone Conduction Device (BAHA) only~BAHA + Wireless Audio-Streaming Accessory~BAHA + Digital Adaptive RM System"
9855451|NCT04147442|Experimental|Music program fine-tuned and standard|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
9855452|NCT04147455|Experimental|RealConsent|Participants randomized to this study arm will receive an adapted program of RealConsent.
9855453|NCT04147455|Active Comparator|Health Education Control Condition|Participants in the control arm will receive a web-based health promotion program.
9855454|NCT04146272|Active Comparator|Moderate Hearing loss current Mermaid first, then new|Participants were randomized to wear the current Mermaid hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new Mermaid Hearing aid for another 10 days.
9855455|NCT04146272|Active Comparator|Moderate Hearing loss new Mermaid first, then current|Participants were randomized to wear the new Mermaid hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current Mermaid Hearing aid for another 10 days.
9855456|NCT04146272|Active Comparator|Severe hearing loss current Power first, then new|Participants were randomized to wear the current power hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new power Hearing aid for another 10 days.
9855457|NCT04146272|Active Comparator|Severe hearing loss new Power first, then current|Participants were randomized to wear the new power hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current power Hearing aid for another 10 days.
9855458|NCT04143945|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
9855459|NCT04143945|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
9855460|NCT04143373|Experimental|Warm saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 37 ± 1 ° C as for the experimental side.
9855461|NCT04143373|No Intervention|Room temperature saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C as for the control side.
9855462|NCT04142216|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum for three months.
9855463|NCT04142216|No Intervention|Control group|The patients will not chewing gum during three months.
9855464|NCT04141930|Other|Study Drug Eligible|Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant
9935119|NCT04159103|Experimental|Dose Expansion Stage|Participant will receive the optimal dose of mRNA-3927 identified during the Dose Optimization Stage at 1 dose on Day 1 of each 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
9855465|NCT04142450|Experimental|CoolSculpting® System|Participants underwent a single CoolSculpting® treatment session on Day 1 that was comprised of timed segments of cooling followed by 2 minutes of manual massage. Each treated arm had up to two timed segments (or cycles) in the treatment session, each treated thigh had one timed segment (or cycle) in the treatment session.
9855466|NCT04142242|Experimental|Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MEQ00066).
9855467|NCT04142242|Experimental|Group 2: MenACYW Conjugate Vaccine (MET49 - MenACYW Conjugate Vaccine-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single IM dose of MenACYW Conjugate vaccine at Day 0 in the present study (MEQ00066).
9855468|NCT04142242|Experimental|Group 3: MenACYW Conjugate Vaccine (MET49: Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
9855469|NCT04142242|Experimental|Group 4: MenACYW Conjugate Vaccine (MET49: MenACYW-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
9855470|NCT04142242|Other|Group 5: Menomune-primed Participants (MET44)|Participants who received a single dose of Menomune vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
9935120|NCT04158427|Experimental|Fecal transplant|A single dose fecal transplant is given (via colonoscopy) from a healthy donor
9517053|NCT03309956|Other|Holter Monitor and Zio Patch|All subjects will wear the Holter monitor and Zio patch for a total of 48 hours.
9855471|NCT04142242|Other|Group 6: MenACYW Conjugate Vaccine-primed Participants (MET44)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
9855472|NCT04140890|Experimental|Treatment|Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
9855473|NCT04140890|Placebo Comparator|Control|Participants in the control group will receive newsletters focused on general healthy aging topics over 12 weeks. With the exception of two, 1-page handouts covering PA and dietary recommendations, the weekly content will not overlap with the treatment content. Within 4 days of mailing the newsletter, a trained research assistant (RA) will call the participant, verify receipt of the newsletter, and ask them if they have any questions about the materials. The phone call will last ~15 minutes. Control condition participants receive no further intervention.
9855474|NCT04139018|Experimental|Timolol Gel Arm|Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
9855475|NCT04139018|Placebo Comparator|Placebo Gel Arm|Participants in the placebo gel arm will receive the gel itself with no active medication.
9855476|NCT04138810|Experimental|post-op VCE|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The VCE group will conduct their encounter via the videoconference section of the MyChart mobile applications. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
9855477|NCT04138810|Active Comparator|Office post-operative visits|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
9855478|NCT04131556|Experimental|Part 1: Sequence ABC|Participants will receive 200 milligram (mg) of maribavir tablet orally (Sequence A) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
9855479|NCT04131556|Experimental|Part 1: Sequence BCA|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
9855480|NCT04131556|Experimental|Part 1: Sequence CAB|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
9855481|NCT04131556|Experimental|Part 1: Sequence CBA|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
9855482|NCT04131556|Experimental|Part 1: Sequence ACB|Participants will receive 200 mg of maribavir tablet orally (Sequence A) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
9855483|NCT04131556|Experimental|Part 1: Sequence BAC|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 and with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
9855484|NCT04131556|Experimental|Part 2: Sequence DEGF|Participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 1 followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 4 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 7 and then followed by participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
9935121|NCT04158427|Placebo Comparator|Placebo|A single dose patient's own feces is given (via colonoscopy)
9935122|NCT04154956|Experimental|SAR408701 (tusamitamab ravtansine)|Administered intravenously once every 2 weeks
9935123|NCT04154956|Active Comparator|Docetaxel|Administered intravenously once every 3 weeks
9855485|NCT04131556|Experimental|Part 2: Sequence EFDG|Participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 1 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 4 followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 7 and then followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
9855486|NCT04131556|Experimental|Part 2: Sequence FGED|Participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 1 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 4 followed by participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 7 and then followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
9855487|NCT04131556|Experimental|Part 2: Sequence GDFE|Participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 1 followed by participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 4 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 7 and then followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
9855488|NCT04126174|Active Comparator|Femtosecond limbal relaxing incision (LRI)|Eyes will be treated with arcuate incisions from a femtosecond laser system.
9855489|NCT04126174|Active Comparator|Manual LRI|Eyes will be treated with arcuate incisions completed manually with a blade.
9855490|NCT04134429||Everion®|The Everion® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
10208721|NCT05189080|Experimental|Open Trial|Patients within the Wake Forest Baptist Health system who no-showed for scheduled well child visits at Pediatrics-Downtown Health Plaza, Family Medicine-Piedmont Plaza, Pediatrics-Winston East, Family Medicine-Peace Haven, and Pediatrics-Clemmons.
10208722|NCT05188820|Active Comparator|Corticosteroid group|Patients will receive intra-articular z-joint injection of cortisone
10208723|NCT05188820|Experimental|PRP group|Patients will receive intra-articular z-joint injection of PRP
10208724|NCT05188417|Experimental|Tirofiban 0.25μg/kg/min(0.005ml/kg/min) group|The tirofiban hydrochloride sodium chloride injection is pumped intravenously at a constant rate of 0.25μg/kg/min (0.005 ml/kg/min) for 30 minutes, and then pumped intravenously at a constant rate of 0.1 μg/kg/min (0.002 ml/kg/min) for 24 hours.
10208725|NCT05188417|Experimental|Tirofiban 0.4μg/kg/min(0.008ml/kg/min) group|The tirofiban hydrochloride sodium chloride injection is pumped intravenously at a constant rate of 0.4 μg/kg/min (0.008 ml/kg/min) for 30 minutes, and then pumped intravenously at a constant rate of 0.1 μg/kg/min (0.002 ml/kg/min) for 24 hours.
10208726|NCT05188417|Placebo Comparator|0.9% sodium chloride solution|The placebo is pumped intravenously at a constant rate of 0.008 ml/kg/min for 30 minutes, and then pumped intravenously at a constant rate of 0.002 ml/kg/min for 24 hours.
10208727|NCT05188365|Active Comparator|group A|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
10208728|NCT05188365|Sham Comparator|Group B|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days.
10208729|NCT05188326|Experimental|Azacitidine|Vidaza consists of 50 mg/ m2 s.c or i.v for 7 days (5 + weekend off + 2) every 28 days and increase after 1st cycle, if well tolerated, to 75 mg/m2 s.c or i.v. for 7 days (5 + weekend off + 2) every 28 days for further 5 cycles followed by cycles every 56 days for 4 years and six months
10208730|NCT05188326|Placebo Comparator|Best supportive care|No drug administration
10208731|NCT05188261|Experimental|Cohort 1: 100μg IW-3300|Dose 1: within the cohort, 6 participants receive active drug (IW-3300)
10208732|NCT05188261|Placebo Comparator|Cohort 1: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
10208733|NCT05188261|Experimental|Cohort 2: Dose 2|Dose 2: within the cohort, 6 participants receive active drug (IW-3300)
10208734|NCT05188261|Placebo Comparator|Cohort 2: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
10208735|NCT05188261|Experimental|Cohort 3: Dose 3|Dose 3: within the cohort, 6 participants receive active drug (IW-3300)
10208736|NCT05188261|Placebo Comparator|Cohort 3: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
10208737|NCT05188261|Experimental|Cohort 4: Dose 4|Dose 4: within the cohort, 6 participants receive active drug (IW-3300)
10208738|NCT05188261|Placebo Comparator|Cohort 4: Placebo|Within the cohort, 2 participants will receive the matching placebo dose
10208739|NCT05188261|Experimental|Cohort 5 (optional): ≤2500μg IW-3300|Dose 5: within the cohort, 6 participants receive active drug (IW-3300)
10208740|NCT05188261|Placebo Comparator|Cohort 5 (optional): placebo|Within the cohort, 2 participants will receive the matching placebo dose
10208741|NCT05187923||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
9855491|NCT04130425|Experimental|Healthy Individuals|Subject will be measured for forearm rotation while wearing the custom orthoses Hely & Weber MTC Fracture Brace, thermoplastic orthosis, and delta cast orthosis.
9855492|NCT04138498|Experimental|Sequence 1 (ADBC)|Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.
9855493|NCT04138498|Experimental|Sequence 2 (BACD)|Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.
9855494|NCT04138498|Experimental|Sequence 3 (CBDA)|Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.
9855495|NCT04138498|Experimental|Sequence 4 (DCAB)|Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.
9855496|NCT04138043|Experimental|GSK2330811 450 mg|Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter [mg/mL]).
9855497|NCT04138043|Placebo Comparator|Placebo|Participants will receive GSK2330811 matching placebo administered as three separate SC injections.
9855498|NCT04137627|Experimental|Melatonin|The group received standard treatment with the oral administration of Melatonin
9855499|NCT04137627|Placebo Comparator|Placebo|The group received standard treatment with the oral administration of Placebo
9855500|NCT04136145|Experimental|Belimumab SC|Subjects will be administered a single dose of belimumab 200 mg via the SC route. The dose will be administered in the front of the thigh via auto-injector device.
9855501|NCT04136145|Experimental|Belimumab IV|Subjects will be administered a single dose of belimumab 200 mg via the IV route administered over approximately 1 hour.
9855502|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 1|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/medium low dose) after extraction of third molars
9855503|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 2|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/low dose) after extraction of third molars
9855504|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 3|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ medium low dose) plus one tablet of placebo after extraction of third molars
9855505|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 4|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ low dose) plus one tablet of placebo after extraction of third molars
9855506|NCT04132336|Active Comparator|Naproxen sodium|Participants received a single dose of one tablet of naproxen sodium (low dose) plus one tablet of placebo after extraction of third molars
9855507|NCT04132336|Active Comparator|Caffeine|Participants received a single dose of two tablets of caffeine (medium low dose) after extraction of third molars
9855508|NCT04132336|Placebo Comparator|Placebo|Participants received a single dose of two tablets of matching placebo after extraction of third molars
9855509|NCT04131517|Experimental|Oral contraceptive|Participants will receive oral contraceptive in Period 2 of Sequence A and Period 1 of Sequence B of Part 1 and Part 2.
9855510|NCT04131517|Experimental|Oral contraceptive + padsevonil|Participants will receive padsevonil + oral contraceptive in Period 1 of Sequence A and Period 2 of Sequence B of Part 1 and Part 2.
9935124|NCT04145141||1/ Cohort 1|Subjects with a diagnosis or suspicion of PLC
9935829|NCT03157115|Active Comparator|Control|Patients with a cardiac condition but a normal ejection fraction (>45%), without heart failure. The patients from the HFrEF group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
9935830|NCT03152773|Experimental|1|Open label
10208742|NCT05187923||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
10208743|NCT05187247|Experimental|VR group|"Women assigned to the VR group will use the virtual reality technology throughout the insertion procedure"
10208744|NCT05187247|No Intervention|control group|control group for the intervention group
10208745|NCT05187221||Control Group|The participants will respond to CVS-F4 questionnaire online via SurveyMonkey to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. This group will contains participants with no CVS complains.
10208746|NCT05187195|Experimental|Telerehabilitation-video group|This group will perform their exercises with prepared personalized exercise videos through the telerehabilitation system 3 days a week for 8 weeks.
10208747|NCT05187195|Experimental|Telerehabilitation-brochure group|This group will perform exercises with personalized exercise brochures defined through the telerehabilitation system 3 days a week for 8 weeks.
10208748|NCT05186454|Active Comparator|Morphine|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 200 µg of morphine intrathecally.
10208749|NCT05186454|Active Comparator|Multimodal|Patients will receive 10-12.5 mg bupivacaine and 1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam intrathecally
10208750|NCT05185817||Hematopoietic Stem Cell Transplantation (HSCT)|Patients who are a candidate for HSCT within the the Hematology, Oncology, and Stem Cell Transplantation Research Center of Shariaty Hospital, and agree to be vaccinated with an approved vaccine against the COVID-19 virus.
10208751|NCT05185050||adolescent idiopathic scoliosis|the participants who has Cobb angle above 10 degrees.
10208752|NCT05178433|Experimental|Experimental group|Use baby moisturizers in addition to basic skin care and protection during phototherapy.
10208753|NCT05178433|No Intervention|control group|Only basic skin care and protection during phototherapy.
10208754|NCT05177640|Experimental|99mTC-duramycin|single dose of 99mTc-duramycin in healthy volunteers who will undergo SPECT-CT scanning at different time points
9855511|NCT04128293|Experimental|Sequence 1 - Treatment ABCD|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855512|NCT04128293|Experimental|Sequence 2 - Treatment BADC|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855513|NCT04128293|Experimental|Sequence 3 - Treatment CDAB|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9855514|NCT04128293|Experimental|Sequence 4 - Treatment DCBA|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
9923845|NCT00854867|Active Comparator|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|Subjects will receive a total of 38.4 Gy WBRT given over 4 weeks. Subjects will receive 3 Gy (WBRT on Day 1 and Day 2) and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 29 (+2 days); the second dose will be administered on Day 43(+2 days); the third dose will be administered on Day 57 (+2 days); the fourth dose will be administered on Day 71 (+2 days) to complete the induction phase of the protocol. DepoCyte should never be administered more frequently than every 14th day. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
9923846|NCT00854893|Experimental|anodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
9923847|NCT00854893|Experimental|cathodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, cathodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
9923848|NCT00854893|Experimental|sham (placebo)|sham stimulation (placebo condition): 30 seconds during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
9923849|NCT00854919|Experimental|CBT|All subjects received cognitive-behavioral therapy (CBT) during the study period.
9923850|NCT00854919|Experimental|1|Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
9923851|NCT00854919|Active Comparator|2|Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
9923852|NCT00854932|Experimental|PCT group|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.
9935831|NCT03152760||Abstinent Group (AB)|Current AUD diagnosis, currently abstaining from alcohol
9935832|NCT03152760||Current Drinking Group (CD)|Current AUD diagnosis, not seeking AUD treatment
9935833|NCT03152760||Healthy Control Group (HC)|NO current or past AUD diagnosis
10208755|NCT05176743|Other|Usual Care|"Referral to services~Nutrition pamphlets~One-time payment of $300 paid 4 months after baseline"
10208756|NCT05176743|Experimental|Unconditional Cash Transfer Intervention|"Three monthly payments of $100~Referral to services~Nutrition pamphlets"
10208757|NCT05176457|No Intervention|BEFORE PICT'REA introduction|Patients will have the usual communication tools (pen and paper, hands gestures...)
10208758|NCT05176457|Experimental|AFTER PICT'REA introduction|Patients will be given a tablet to communicate with the caregivers whenever needed
10208759|NCT05176080|Experimental|Treatment group|Famitinib Plus SHR6390 and Endocrine therapy
10208760|NCT05175755|Experimental|Patients|The procedure involves taking a total of 12 ml of blood.
10208761|NCT05173428|Experimental|Interventional Gruop|Online motivational interviews based on the transtheoretic model with the intervention group will be held via zoom. Data collection forms will be applied to the intervention group at the first interview, at the 3rd month as an interim monitoring, and at the 6th month as the final monitoring.
10208762|NCT05173428|No Intervention|Control Gruop|No intervention will be made to the control group, and data collection forms will be applied at the first interview and 6 months after the first interview.
10208763|NCT05172687||Patients of treated study prescribers|Patients attributed to physicians who received overprescribing letters in the primary study.
9855515|NCT04126343|Experimental|Padsevonil|Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.
9855516|NCT04126343|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.
9855517|NCT04126343|Active Comparator|Moxifloxacin|Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.
10208764|NCT05172687||Patients of control study prescribers|Patients attributed to physicians who received placebo letters in the primary study.
9855518|NCT04126187||Panoptix|Bilateral implantation of the Panoptix trifocal IOL
9855519|NCT04124952||Panoptix|Patients bilaterally implanted with the Panoptix intraocular lens.
9855520|NCT04123665|Experimental|Experimental Test Dentifrice|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
10208765|NCT05166629|Other|Usual Care|Usual care in the POWER Kids weight management program includes a nutrition assessment and education by a registered dietician nutritionist (RD). This includes taking a detailed dietary history, and providing individualized counseling, motivational interviewing, and nutrition education handouts/ web-based resources.
9855521|NCT04123665|Placebo Comparator|Control Dentifrice|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as sodium monofluorophosphate [SMFP] to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
10208766|NCT05166629|Experimental|Eatable Alphabet|The intervention group will receive usual care, as described above, plus a set of Eatable Alphabet cards, which will be utilized during the visit for counseling and education, and given to the family to take home and use as they wish.
9855522|NCT04122534|Experimental|Treatment Group|Treatment groups receives the intervention training.
10208767|NCT05164393|Experimental|AVX001 1%|Application of AVX001 1% gel to treatment field once daily
10208768|NCT05164393|Experimental|AVX001 3%|Application of AVX001 3% gel to treatment field once daily.
9855523|NCT04121078|Experimental|Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg|TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
10208769|NCT05164393|Placebo Comparator|AVX001 Vehicle|Application of AVX001 vehicle gel to treatment field once daily
10208770|NCT05163821||Participants|Somali migrants in UK, aged over 50.
10208771|NCT05162898|Experimental|GROUP 1|
10208772|NCT05161819|Experimental|High-frequency rTMS at left DLPFC|Receive an rTMS course with high-frequency stimulation at left DLPFC
10208773|NCT05161819|Sham Comparator|High-frequency sham stimulation at left DLPFC|Receive an sham rTMS course with high-frequency stimulation at left DLPFC with the sham coil
10208774|NCT05161676|Experimental|Ketone monoester (3-OHB)|
10208775|NCT05161676|Experimental|Placebo Treatment|
10208776|NCT05161650|Experimental|Ketone monoester (3-OHB)|
10208777|NCT05161650|Experimental|Isocaloric placebo|
10208778|NCT05160467||Deresuscitation cohort|"Patients with fluid overload (defined by a cumulative fluid balance > 5%), stable hemodynamic (defined by Norepinephrine equivalent < 0.5µg/kg/min and nor clinical nor biological sign of hypoperfusion) and continuous renal replacement therapy. All these patients benefit in our service from a protocol directed, perfusion based deresuscitation strategy with a 2mL/kg/h net ultra filtration to induce negative fluid balance and correct fluid overload. If hypoperfusion occurs, the net ultra filtration is stopped; if pulmonary oedema or right ventricular dysfunction occurs, the net ultra filtration is set to 3mL/kg/h.~We carried out at day 0, 1,3 and 5 bio electrical impedance analysis with an eight polar multifrequency bio impedance monitor (InBody S10), and monitor cumulative fluid balance with our prescription software and daily weight assessment."
10208779|NCT05160389|Experimental|Fasted|Study drug will be administered with water, after an overnight fast.
10208780|NCT05160389|Experimental|Low-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard low-fat breakfast will be given.
10208781|NCT05160389|Experimental|High-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard high-fat breakfast will be given.
10208782|NCT05159492|Experimental|PEF Arm|PEF is a non-thermal ablation modality using extremely short high voltage pulses to induce cell death, with tissue selectivity, cardiomyocytes being much more sensitive to this energy than Phrenic nerve or Esophageal cells. Energy (2000 V) will be delivered 8 times per vein with 2 different catheter configurations and rotations
10208783|NCT05159492|Active Comparator|Pulmonary vein isolation using Contact Force RF|The PVI strategy using RF is very standard. The CARTO© platform will be used, with a contact force catheter (SmartTouch), aiming at an ablation index value of 300 to 400 on the posterior wall, and at least 500 on the anterior wall. Power will be limited to 35/45 W, with a distance between consecutive deliveries of 6 mm or less (CLOSE protocol).
10208784|NCT05159102|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)-[Parents and Children-Workshop Group]. These workshops will be offered in person. In addition to the workshops, this group and the home-based group will receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment.
10208785|NCT05159102|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops (face to face), but they will receive the same information remotely (workshop content) and will have access to the activity booklets (via the App) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
9855524|NCT04121078|Experimental|Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg|Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.
9855525|NCT04117607|Experimental|BA1|100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
9855526|NCT04117607|Experimental|BA2|100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
9855527|NCT04117607|Experimental|MAD1|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
9855528|NCT04117607|Experimental|MAD2|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
9855529|NCT04117607|Experimental|MAD3|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
9855530|NCT04117607|Experimental|MAD4|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
9855531|NCT04117607|Experimental|SAD1|1 mg (1 injection of 0.1 ml diluted 1:10 in 5% Dextrose Injection, USP) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=3 (no sentinel dosing), or matching placebo, n=1 (no sentinel dosing), on Day 1 in a double-blind manner.
9855532|NCT04117607|Experimental|SAD2|10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
9855533|NCT04117607|Experimental|SAD3|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
9855534|NCT04117607|Experimental|SAD4|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
9855535|NCT04117607|Experimental|SAD5|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
9855536|NCT04117607|Experimental|SAD6|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
9855537|NCT04116684|Experimental|Intervention Group (digital BP monitoring)|This group will receive a Withings digital BP monitor to transmit recordings to the study team who will make medication adjustments.
9855538|NCT04116684|No Intervention|Standard of care BP monitoring|This group will use a standard BP cuff and record and transmit data to their medical team as instructed by their providers or if they are concerned.
9855539|NCT04096365|Experimental|Subcostal temporary extracardiac pacing lead|All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.
9855540|NCT04080297|Experimental|100 mg Q-122|10 patients treated with Q-122, 100 mg. Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.
9855541|NCT04080297|Experimental|200 mg Q-122|11 patients treated with Q-122, 200 mg. Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.
9855542|NCT04115358|Experimental|Hyaluronic acid|Gengigel teething (%0,54 hyaluronic acid), 0,1ml to the orifice of the root canals of the primary molar.
9855543|NCT04115358|Active Comparator|Formocresol|0,1 ml to the orifice of the root canals of the primary molar.
9855544|NCT04115358|Active Comparator|Ferric sulfate|0,1 ml to the orifice of the root canals of the primary molar.
9855545|NCT04114058|Active Comparator|Liposomal Bupivicaine|Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control
9855546|NCT04114058|Active Comparator|fascia iliaca blockade|Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control
9855547|NCT04113785||Klassic TKA|Subjects implanted with a Klassic TKA. Subjects will undergo flouoroscopic evaluation during a deep knee bend evaluation and the postoperative kinematics will be reported.
9855548|NCT04113694|Experimental|Extended Wear Infusion Set|Each subject is given 12 Extended Wear Infusion Sets to wear.
9855549|NCT04112160|Placebo Comparator|control|normal saline 0.9%
9855550|NCT04112160|Active Comparator|Ketorolac|30 mg of Ketorolac
9855551|NCT04112069|Active Comparator|Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with continuous subcutaneous insulin infusion (pump therapy) for approximately 5 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM). If randomized to the usual care arm first, subjects crossed over to the bionic pancreas arm following a 2-day washout period.
9855552|NCT04112069|Experimental|iLet Bionic Pancreas with Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
9855553|NCT04109703|Active Comparator|High level pulsed heat|Subjects randomized to this arm received a generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered as waves peaking at 45° C.
9855554|NCT04109703|Placebo Comparator|Low level steady heat|Subjects randomized to this arm received an identical generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered in a steady manner at 37° C.
9855555|NCT04109443|Experimental|Young Men & Media Program group|Participants randomized to the Young Men and Media Program group will have access to the online sexual health media literacy materials. They will also complete three assessments at baseline, post-intervention, and a 3 month follow-up.
9855556|NCT04109443|Active Comparator|Control group|Participants randomized to the control group will have access to available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections including HIV. They will complete three assessments at baseline, post-intervention, and a 3 month follow-up.
9855557|NCT04107493|Active Comparator|Portable oxygen cylinder|Continuous flow oxygen cylinders will be used as a comparison.
9855558|NCT04107493|Experimental|Mobi™ Portable Oxygen Concentrator|Mobi™ is indicated for patients who require supplemental oxygen, including COPD patients. It provides supplemental, high oxygen concentration to these patients. It is available via prescription only and may be used in the home, institution, and hospital settings, as well as travel environments
9855559|NCT04106817|Experimental|Cohort 1|1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 10^6TCID50/dose)
9855560|NCT04106817|Experimental|Cohort 2|1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
9855561|NCT04106817|Experimental|Cohort 3|1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
9855562|NCT04105972|Active Comparator|TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.
9855563|NCT04105972|Experimental|ELX/TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
9935834|NCT03141684|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9855564|NCT04105218|Experimental|Evening Exercise|Participants will arrive in the Clinical and Translation Research Center (CTRC) and enter the whole room calorimeter approximately 1 hour after arrival. During the evening exercise condition, participants will perform 45-minutes of moderate intensity continuous exercise on a treadmill 12 hours after habitual wake time in the evening. Participants will begin with a warm-up for 5 minutes at 2.0-2.5 mph. Heart rate will be monitored continuously with a heart rate monitor. Participants will maintain heart rate at 65% of age-predicted maximum heart rate. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
9855565|NCT04105218|Placebo Comparator|Control|Participants will arrive in the Clinical and Translation Research Center (CTRC) in the morning within 2 hours of their habitual wake time. Participants will enter the whole room calorimeter approximately 1 hour after arriving at the CTRC. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
9855566|NCT04102956|Experimental|Kallikrein+Standard treatment group|The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
9855567|NCT04102956|No Intervention|Standard treatment group|The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
9855568|NCT04102540|Experimental|Infographic intervention group|Participants in the infographic intervention group will receive health education using infographics during a study visit scheduled immediately following their regularly scheduled clinic visits.
9855569|NCT04102345|Experimental|Lavender|1-2 drops of Lavender (essential oil) in approximately 120 ml of distilled water is added to a diffuser 10 minutes before light out. The diffuser runs for approximately 2 hours before automatically being shut off. A low mist option is used on the diffuser.
9855570|NCT04102345|Active Comparator|Zolpidem|Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.
9855571|NCT04092907|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
9855572|NCT04092907|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
9855573|NCT04089982|Active Comparator|Varenicline|Varenicline BID
9855574|NCT04089982|Placebo Comparator|Placebo|
9855575|NCT04086433||Arm A - Echelon Stapler|"Excised gastric tissue specimens will be resected with the Echelon Stapler (Ethicon, size: 60mm, Echelon) and evaluated for burst pressure and staple malformation"
9986403|NCT01402609|Placebo Comparator|Control group, usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
9800477|NCT01688856|Experimental|Arm+Hand CCFES|Uses an electrical stimulator that opens the paretic hand and extends the paretic elbow in response to and with an intensity proportional to movement of the contralateral arm and hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
9800478|NCT01688856|Experimental|Hand CCFES|Uses an electrical stimulator that opens the paretic hand in response to and with an intensity proportional to movement of the contralateral hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
9800479|NCT01688856|Active Comparator|Arm+Hand Cyclic NMES|Uses an electrical stimulator that delivers stimulation to open the hand and extend the elbow repeatedly with preprogrammed timing and intensity. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
9800480|NCT01688882|Experimental|QGE031|QGE031 240 mg Q2W s.c.
9800481|NCT01688882|Placebo Comparator|Placebo|Placebo to Match Q2W s.c.
9800482|NCT01688882|Experimental|Open Label QGE031|Open Label QGE031 Q2W s.c.
9800483|NCT01688895||Participants with Protoporphyrias|Individuals with a documented diagnosis of Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
9800484|NCT01688921|Experimental|STRATIS Needle-Free|Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
9800485|NCT01688921|Active Comparator|Needle-Syringe|Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
9800486|NCT01688973|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28.
9800487|NCT01688973|Experimental|Arm II (tivantinib and erlotinib hydrochloride)|Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
9800488|NCT01688999|Experimental|Cabozantinib|Administered orally at a dose of 60 mg once daily on each day of a 28-day cycle.
9800489|NCT01689155||Study Group|Participants must have received Menactra Vaccine according to routine clinical practice.
9800490|NCT01689207|Experimental|Drug: A|Avibactam (AVI)
9800491|NCT01689207|Experimental|Drug: B|Aztreonam (ATM)
9800492|NCT01689207|Experimental|Drug: C|combination of Aztreonam-Avibactam (ATM-AVI)
9800493|NCT01689207|Placebo Comparator|Drug: D|Matching Placebo
9800494|NCT01689324|Experimental|Study Group|Participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0.
9800495|NCT01689337|Experimental|Sprifermin (AS902330), 30 mcg|
9800496|NCT01689337|Experimental|Sprifermin (AS902330), 100 mcg|
9800497|NCT01689337|Placebo Comparator|Placebo|
9800498|NCT01689350|No Intervention|Control Group|The cases in control group received traditional therapy that the initial dose of cyclophosphamide (CPA) was 0.2-0.6g/week injection according to clinical experience.
9800499|NCT01689350|Experimental|Experimental Group|Genetic: Genotype Detection To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM),with initial dose of CPA as 0.2g, 0.4g and 0.6g per week by injection, respectively.
9800500|NCT01689363|Experimental|Arm H|Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
9800501|NCT01689363|Active Comparator|Arm P|Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
9800502|NCT01689363|Placebo Comparator|Arm N|Intradermal injection of saline (0.02 mL)
9800503|NCT01689441|Experimental|Calcitriol|Calcitriol 2mcg IV x 1
9800504|NCT01689441|Placebo Comparator|Placebo|Normal saline 2cc IV x 1
9800505|NCT01689519|Active Comparator|Placebo + Vemurafenib|Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
9800506|NCT01689519|Experimental|Cobimetinib + Vemurafenib|Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
9800507|NCT01689532|Experimental|Sirukumab 100 mg|
9800508|NCT01689532|Experimental|Sirukumab 50 mg and Placebo|
9800509|NCT01689649|Experimental|Topiramate|For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
9800510|NCT01689701|Experimental|Hizikia Fusiformis extract|
9800511|NCT01689701|Placebo Comparator|Placebo|
9800512|NCT01689779|Active Comparator|Cholecalciferol|A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
9800513|NCT01689779|Placebo Comparator|Placebo|A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
9800514|NCT01689857|Experimental|Scarclinic™ Thin|Scarclinic™ Thin
9800515|NCT01689857|Active Comparator|Scarclinic™ Normal|Scarclinic™ Normal
9800516|NCT01690000|Active Comparator|Melatonin1|1 mg melatonin nightly
9855576|NCT04086433||Arm B - Titan Stapler|"Excised gastric tissue specimens will be resected with the Titan SGS Stapler (Standard Bariatrics, Titan) and evaluated for burst pressure and staple malformation"
9855577|NCT04086407|Experimental|Forehead sensor recording precision head pitch and roll angle|During an overnight polysomnography, participants were coached by sleep research technologists to sleep with their head in positions hypothesized to minimize apnea severity ≤20⁰ or ≥160⁰, and those hypothesized to maximize apnea severity between 30⁰ and 150⁰. Head roll angles were measured and recorded by the participant's forehead sensor attached with adhesive and tape. Extreme head positions were attempted with the torso in both supine and non-supine positions so show insensitivity to torso position. A custom interface was developed to maintain compatibility with specific bedside polysomnography recorder auxiliary inputs. Sleep epochs were considered those where the subject slept for at least 10 minutes. Each head position epoch was analyzed for apnea hypopnea index and oxygen desaturation.
9855578|NCT04099277|Experimental|Part A: 10 milligrams (mg) LY3435151|Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
9855579|NCT04099277|Experimental|Part B: LY3435151 + Pembrolizumab Dose Escalation|Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
9855580|NCT04099277|Experimental|Part C: LY3435151 Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
9855581|NCT04099277|Experimental|Part D: LY3435151 + Pembrolizumab Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
9855582|NCT04098809|Active Comparator|Catheter 16 French|16 French urinary catheter
9855583|NCT04098809|Active Comparator|Catheter 20 French|20 French urinary catheter
9855584|NCT04098575||Patients receiving Empagliflozin until mid Sep 2015|Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
9855585|NCT04098575||Patients receiving Empagliflozin until CV Label Change time|Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
9855586|NCT04098575||Patients receiving Empagliflozin until last available data cut|Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3
9855587|NCT04098458|Experimental|NDURE|NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels.
9855588|NCT04095286|Experimental|AMB dispersed in water/AMB oral tablet/reference AMB|Eligible participants will receive a single oral dose of 5 milligram (mg) AMB tablet dispersed in water during treatment period 1 followed by a single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive a single oral dose of reference 5 mg AMB tablet. There will be a washout period of 7 days between doses in each treatment period.
9855589|NCT04095286|Experimental|AMB oral tablet/reference AMB/AMB dispersed in water|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive single dose of 5 mg AMB tablet dispersed in water. There will be a washout period of 7 days between doses in each treatment period.
9855590|NCT04095286|Experimental|Reference AMB/AMB dispersed in water/AMB oral tablet|Eligible participants will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
9855591|NCT04095286|Experimental|AMB dispersed in water/reference AMB/AMB oral tablet|Eligible participants will receive single dose of 5 mg AMB tablet dispersed in water during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
9855592|NCT04095286|Experimental|AMB oral tablet/AMB dispersed in water/reference AMB|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of reference 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
9855593|NCT04095286|Experimental|Reference AMB/AMB oral/AMB dispersed in water|Eligible participants in this arm will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB tablet dispersed in water There will be a washout period of 7 days between doses in each treatment period.
9855594|NCT04094883|Experimental|4CMenB Vaccine|Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.
9855595|NCT04091659|Active Comparator|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
9855596|NCT04091659|Experimental|Virtual Reality|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
9855597|NCT04091061|Experimental|PF-06865571 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
9855598|NCT04091061|Experimental|PF-06865571 Severe Hepatic Impairment|This arm includes participants with severe hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
9855599|NCT04091061|Experimental|PF-06865571 Mild Hepatic Impairment|This arm includes participants with mild hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
9855600|NCT04091061|Experimental|PF-06865571 Healthy Participants|This arm includes healthy participants who will receive an oral dose of PF-06865571 100 mg on Day 1
9855601|NCT04090242|Active Comparator|App plus Nano|Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin
9855602|NCT04090242|No Intervention|Standard Care|Standard of Care/Subject is to continue on their current diabetes management regime
9855603|NCT04089761|Experimental|Active Device|Treatment of acute migraine with an active form of Nerivio device
9855604|NCT04079803|Placebo Comparator|Placebo Cohort|Subjects administered placebo oral tablets twice daily (BID)
9855605|NCT04079803|Experimental|Simufilam (PTI-125) 100 mg tablets Cohort|Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)
9855606|NCT04079803|Experimental|Simufilam (PTI-125) 50 mg tablets Cohort|Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)
9855607|NCT04087343|Experimental|Meals plus exercise|
9855608|NCT04087343|Active Comparator|Meals only|
9855609|NCT04087122|Experimental|Esophageal warming|Patients receive the Attune Medical Esophageal Heat Transfer Device
9855610|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 1|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
9855611|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 2|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: BACtrack Vio, Drinkmate, and Floome which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
9855612|NCT04086641|Experimental|Foot 1: Crossover Foot, Foot 2: Energy Storing Foot|Participant randomized to crossover foot as first condition, energy storing foot as second condition
9855613|NCT04086641|Experimental|Foot 1: Energy Storing Foot, Foot 2: Crossover Foot|Participant randomized to energy storing foot as first condition, crossover foot as second condition
9855614|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 1|AbobotulinumtoxinA dose 1 injected into platysma bands
9855615|NCT04080882|Placebo Comparator|placebo|placebo injected into platysma bands
9855616|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 2|AbobotulinumtoxinA dose 2 injected into platysma bands
10208786|NCT05159102|Other|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks after the completion of the 12-week period. Immediately following the follow-up test, participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
10208787|NCT05156645|Experimental|SCTA01 and SCTA01C+SOC|
10208788|NCT05156645|Placebo Comparator|Placebo+SOC|
9855617|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 3|AbobotulinumtoxinA dose 3 injected into platysma bands
9855618|NCT04086472|Experimental|MK-1654 100 mg|Participants receive a single IV infusion of MK-1654 100 mg on Day 1.
9855619|NCT04086472|Experimental|MK-1654 200 mg|Participants receive a single IV infusion of MK-1654 200 mg on Day 1.
9855620|NCT04086472|Experimental|MK-1654 300 mg|Participants receive a single IV infusion of MK-1654 300 mg on Day 1.
9855621|NCT04086472|Experimental|MK-1654 900 mg|Participants receive a single IV infusion of MK-1654 900 mg on Day 1.
9855622|NCT04086472|Placebo Comparator|Placebo|Participants receive a single IV infusion of placebo on Day 1.
9855623|NCT04085289|Experimental|Galcanezumab|Participants received single subcutaneous (SC) doses of 120 milligram (mg) or 240 mg Galcanezumab.
9855624|NCT04085289|Placebo Comparator|Placebo|Participants received a single SC dose of Placebo.
9855625|NCT04084015|Experimental|Early axillary Impella®|Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO
9855626|NCT04082663|Experimental|Dental Mouthpiece|Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans.
9855627|NCT04084028|Experimental|Active Cooking +meal kits and recipes|"Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal.~Following 6 weeks of cooking classes, participants will receive 6 weeks of home-delivered meal kits. Following 6 weeks of meal kits, participants will received 6 weeks of recipes. Both the meal kits and recipes will accommodate major dietary needs (vegan, gluten-free, etc.)"
9923853|NCT00854932|No Intervention|Standard group|The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.
10208789|NCT05155137|Experimental|Riskometer + Polypill|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
10208790|NCT05155137|Placebo Comparator|Riskometer + Placebo|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use placebo polypill
10208791|NCT05155137|Experimental|No Riskometer + Polypill|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
10208792|NCT05155137|No Intervention|No Riskometer + Placebo (Usual Care)|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the placebo polypill = usual care
10208793|NCT05153525|Experimental|Intermittent boluses group|Thirty children with ARDS will be managed with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
10208794|NCT05153525|Experimental|Intravenous infusion for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
10208795|NCT05152394|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
10208796|NCT05150925|Experimental|Immediate mobilization after distal radius fracture treated with volar locking plate|
10208797|NCT05150925|Active Comparator|2 weeks cast immobilization after distal radius fracture treated with volar locking plate|
10208798|NCT05144997|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
9855628|NCT04084028|Active Comparator|Active cooking only|Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal. Unlike the previous arm, no further instruction will be given once cooking classes end.
9855629|NCT04084028|Active Comparator|Meal Kits only|Participants will receive weekly meal kit deliveries for 6 weeks. Following 6 weeks of meal kit deliveries, students will receive emails at the beginning of each week providing them with 5 healthy recipes.
9855630|NCT04084028|No Intervention|Control|Participants will receive no interventions.
9855631|NCT04082819|Other|Low Blood Pressure|Low blood pressure (systolic: 0-129, diastolic: 0-79)
9855632|NCT04082819|Other|Medium Blood Pressure|Medium blood pressure (systolic: 130-160, diastolic: 80-100)
9855633|NCT04082819|Other|High Blood Pressure|High blood pressure (systolic: 161 or higher, diastolic: 101 or higher)
9855634|NCT04081961||Asymptomatic current smokers|No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
9855635|NCT04081961||"Grey zone current smokers"|Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
9855636|NCT04081961||Current smokers with COPD|Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)
9855637|NCT04081610|Experimental|Lagricel® Ofteno Multidose|Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
9855638|NCT04081610|Active Comparator|Lagricel® Ofteno Single dose|Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
9855639|NCT04081324|Placebo Comparator|Placebo|Participants received placebo administered orally on Day 1 and repeated doses on Days 4 to 10 (7 days of dosing).
9855640|NCT04081324|Experimental|50 milligram (mg) Lasmiditan|Participants received 50 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 50 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
9855641|NCT04081324|Experimental|100 mg Lasmiditan|Participants received 100 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 100 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
9855642|NCT04081324|Experimental|200 mg Lasmiditan|Participants received 200 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 200 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
9800517|NCT01690000|Active Comparator|Melatonin3|3 mg melatonin given nightly
9800518|NCT01690000|Active Comparator|Placebo|Identical placebo given nightly
9986404|NCT01402609|Experimental|electronic discharge communication tool|Patients allocated to the experimental arm will receive a copy of the discharge summary that is generated by the electronic discharge communication tool. The same copy is shared with their healthcare providers using an electronic, web-based, communication platform that allows communication between acute-care and community -care physicians. The electronic discharge communication tool allows physicians to start generating the discharge summary from time of admission to hospital.
9855643|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 1|Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
9855644|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 1|Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
9800519|NCT01690052|Active Comparator|Cevimeline|Cevimeline vs Pilocarpine
9800520|NCT01690052|Active Comparator|Pilocarpine|Pilocarpine vs. Cevimeline
9986405|NCT01402622|Active Comparator|Control group|balanced anaesthesia with antiemetic prophylaxis
9986406|NCT01402622|Active Comparator|TIVA group|TIVA without antiemetic prophylaxis
9986407|NCT01402622|Active Comparator|TIVA-P group|TIVA with antiemetic prophylaxis
9986408|NCT01402635|Experimental|POCT lab|The patient group whose laboratory test perform by POCT chemistry analyzer.
9986409|NCT01402635|Active Comparator|central laboratory group(CLT)|The patients group whose laboratory test perform by central laboratory.
9986410|NCT01402648|Placebo Comparator|Dietary supplement|900 mg Maltodextrins
10208799|NCT05144295|Experimental|Investigational Arm|"Patients will receive lubiprostone capsules (Amiprostone 8 and 24 mcg, or Lubicont 8 mcg)~Patients weighing <50 kg will be given lubiprostone at doses of 8 mcg/8 hours.~Patients weighing ≥ 50 kg will be given lubiprostone at doses of 24 mcg BID.~Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and a large volume of fluid."
10208800|NCT05144295|Active Comparator|Control Arm|"Subjects will receive the conventional therapy (one or a combination of the following):~Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day),~Bisacodyl tablets  Bisacodyl 5 mg/tablet in a dose of 2 tab/day for < 12 years or 3 tab/day for > 12 years, or~Sodium Picosulfate 0.75% drops (Picolax drops) in a daily dose of 2.5-20 mg/day."
10208801|NCT05143697|Other|Wellness Coaching for Families and Kids|For clinics assigned to mBMI2Kids intervention, Pediatricians will be trained in Motivational Interviewing (MI) and behavioral intervention. Pediatricians will conduct up to 3 sessions with each parent (3 x 10 min) and refer patients electronically to experienced MI-trained lifestyle coaches. With full access to the electronic medical record coaches will call referred families (child's BMI-for-age ≥85th percentile) and deliver a telephonic MI counseling over two years (6 x 45 min) simultaneous with pediatricians. 36 clinics will be selected with 18 participating in the intervention and 18 providing patients with usual care.
10208802|NCT05142358|Active Comparator|left-sided breast cancer|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
10208803|NCT05142358|Active Comparator|Lung SBRT|Participants will come in for their regularly scheduled radiation planning and treatment. Participants will undergo three scans (with and without DIBH (i.e., free-breathing), with CPAP). Participants will also use the CPAP device before the CT scan, for which they will be educated and trained.
10208804|NCT05140980||"women aged 18 to 25 group"|"women aged 18 to 25 group: women aged 18 to 25 with or without sexual activity"
10208805|NCT05135676|Active Comparator|Standard Target Group|Standard therapy with glucose target 140-180 mg/dL (ADA guidelines) and masked CGM
10208806|NCT05135676|Experimental|Intensive Target Group|Intensive therapy with glucose target 90-130 mg/dL with real-time CGM
10208807|NCT05135546|Experimental|Experimental|Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.
10208808|NCT05135546|Placebo Comparator|Placebo control|Placebo
10208809|NCT05134857|Experimental|ZON+ST|Zonisamide (ZON) plus standard treatment (ST)
10208810|NCT05134857|Placebo Comparator|PLO+ST|Placebo (PLO) plus standard treatment (ST)
9800521|NCT01690117|Experimental|GE-REACH-program|GE-REACH-program
9800522|NCT01690117|No Intervention|control group|usual care
9800523|NCT01690130|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual.The brain stimulation techniques could theoretically improve the efficacy of smoking cessation. Treatment was standardized at 100% magnetic field intensity relative to the participant's resting MT, at 10 pulses per second (10 Hz) for 5 seconds, with an intertrain interval of 10 seconds. Treatment session lasted for 15 minutes with 3000 pulses.
9800524|NCT01690130|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rMT determination and DLPFC cortex localization, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes were connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device (Empi; St. Paul, MN, USA)
9800525|NCT01690143|Experimental|Carfilzomib + high dose melphalan|Single arm.
9800526|NCT01690273|No Intervention|ankylosing spondylitis control|control group
9800527|NCT01690273|Experimental|mobility exercise|mobility exercises
9800528|NCT01690273|Experimental|mobility and elastic resistance exercise|AS patients was submitted to a program mobility exercise plus elastic resistance exercises
10208811|NCT05132907|Experimental|Cohort 1 (previously vaccinated, two dose recipients)|Cohort 1 will include individuals with vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
9855645|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 2|Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
9855646|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 2|Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
10208812|NCT05132907|Experimental|Cohort 2 (previously vaccinated, single dose recipients)|Cohort 2 will include individuals with vaccination against COVID-19 who will receive a one-dose schedule of HDT-301. Dose will be escalated from low to mid to high according to predefined safety parameters.
10208813|NCT05132907|Experimental|Cohort 3 (previously unvaccinated)|Cohort 3 will include 21 individuals with no history of vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
10208814|NCT05130671|Active Comparator|Standard of care|This arm will receive the standard of care as per the hospital guidelines.
10208815|NCT05130671|Experimental|Investigational treatment|This arm will receive combination of nutritional supplements quercetin and curcumin as add-on to the standard of care.
9855647|NCT04079127||Patients suffering from severe hip pain and disability|Patients in need of a total hip arthroplasty.
9855648|NCT04076787||Favorable IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
9855649|NCT04076787||Intermediate IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
9855650|NCT04076787||Poor IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
9855651|NCT04075812|Experimental|Neuromuscular Stimulator|Neuromuscular Stimulator is setup and calibrated, various spatial and temporal stimulation patterns will be tested to evoke wrist/hand movements in various sequences of individual and combined movements.
9855652|NCT04075409|Experimental|Extensive metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
9855653|NCT04075409|Experimental|Intermediate metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
9855654|NCT04075409|Experimental|Poor metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
9855655|NCT04074941|Experimental|Low sodium diet|This group will get a low sodium diet (<0.9 mg per kcal of energy intake).
9855656|NCT04074941|Active Comparator|Usual sodium diet|This group will get a usual sodium diet (~2 mg per kcal of energy intake).
9855657|NCT04073823|Active Comparator|Flexitouch Plus|
9855658|NCT04073823|Experimental|Flexitouch Plus with SW|
10208816|NCT05128513|Experimental|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
10208817|NCT05128513|No Intervention|control group|
10208818|NCT05127421|Experimental|Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID|Participants will be treated with ruxolitinib cream 1.5% or vehicle cream twice a day (BID) in a double-blind fashion.
10208819|NCT05127421|Experimental|Open Label Extension: Ruxolitiib cream 1.5%|Patients will be treated with Ruxoltinib cream 1.5% twice per day (BID) during the open label extension period. Participants who complete the double-blind period will continue into this open-label extension period for an additional 4 weeks of treatment.
10208820|NCT05125939||Screening indication|Screening indication includes asymptomatic patients aged ≥50 years with no prior colonoscopy and at average risk of CRC. Screening indication also includes asymptomatic patients with negative prior colonoscopy.
10208821|NCT05125939||Surveillance indication|Surveillance indication includes patients with prior colon neoplasms, including conventional adenomas and clinically significant serrated polyps.
9855659|NCT04073407|Active Comparator|AXA1957|AXA1957 20.4g
9855660|NCT04073407|Placebo Comparator|Placebo|Placebo 24g
9855661|NCT04073368|Active Comparator|AXA1957 high dose|AXA1957 20.3g
9855662|NCT04073368|Active Comparator|AXA1957 low dose|AXA1957 13.5g
9855663|NCT04073368|Active Comparator|AXA1125|AXA1125 24g
9855664|NCT04073368|Placebo Comparator|Placebo|Placebo 24g
10208822|NCT05125939||Diagnostic indication|Diagnostic indication includes patients who report symptoms (e.g., abdominal pain, a change in bowel habits, or rectal bleeding) before their first screening examination and undergo evaluation of an abnormality on other image study, unexplained anemia and/or unexplained weight loss.
10208823|NCT05125939||Positive fecal immunochemical test|FIT+ indication includes patients who undergo colonoscopy for positive FIT results in screen-eligible individuals. FIT+ indication also applies to those with a positive FIT result and a recent colonoscopy.
10208824|NCT05125809|Placebo Comparator|Placebo -> Placebo -> Open Label (OL) Setrusumab|Double-blind placebo during phase 2 followed by double-blind placebo in phase 3 followed by open-label setrusumab
10208825|NCT05125809|Experimental|Low Dose Setrusumab -> Setrusumab Selected Dose -> OL Setrusumab|Double-blind setrusumab low dose during phase 2 followed by double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab
10208826|NCT05125809|Experimental|High Dose Setrusumab -> Setrusumab Selected Dose -> OL Setrusumab|Double-blind setrusumab high dose during phase 2 followed by double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab
10208827|NCT05125809|Experimental|Setrusumab Selected Dose -> OL Setrusumab|Double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab
10208828|NCT05124769|Experimental|Pain Allow|Pain is allowed up to 5/10 during exercises, monitored by NPRS. Depending on tissue irritability and other factors such as ROM, the exercises may be performed in an isometric way, or dynamic.
9855665|NCT04073186|Experimental|ACUVUE® OASYS with Transitions™|Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.
9855666|NCT04072237|Experimental|Study Population|MarzAA (Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)
9855667|NCT04063371||Control Group 1|At least one location will serve as the control office and will continue to conduct their visits including screening for cognitive impairment as they normally do using their usual method based on the primary care provider's normal practice.
9855668|NCT04063371||Intervention Group|At least one different location will serve as the intervention office where all the providers, as their standard of care, use a standardized method for screening for cognitive impairment consisting of using the SAGE or eSAGE test and having a conversation with an individual who knows the patient well (if possible) to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
9855669|NCT04063371||Control Group 2|Control group 2 consists of patients handled by the intervention office who did not complete the SAGE or eSAGE.
9855670|NCT04042324|Experimental|Triferic post-dialyzer; UFH via continuous infusion|Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.
9855671|NCT04042324|Experimental|UFH and Triferic admixture|"Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer heparin line. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis."
9855672|NCT04042324|Experimental|UFH via continuous infusion pre-dialyzer|Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis
9855673|NCT04071392||Post-Essure Group|"Healthy women with history of Essure hysteroscopic permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
9855674|NCT04071392||Control Group|"Healthy women with no history of permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
9855675|NCT04071301|Experimental|Investigational Device|TENA SmartCare Change Indicator
9855676|NCT04071158|Experimental|Lower RSV vaccine dose and Tdap|Lower RSV vaccine dose and Tdap
9855677|NCT04071158|Experimental|Lower RSV vaccine dose and Placebo|Lower RSV vaccine dose and Placebo
9855678|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
9855679|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
9855680|NCT04071158|Placebo Comparator|Placebo and Tdap|Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
9855681|NCT04070287|Active Comparator|SMART Pack|"This involves using SMART Pack a HIV self-testing kit to promote uptake of HIV self-testing among young people at community centers."
9855682|NCT04070287|Active Comparator|Luv Box|"The intervention involves using Luv Box a box that include personal hygiene products and HIV self-testing kit as strategy to promote uptake of HIV testing among young people."
9855683|NCT04070287|Active Comparator|Bili Vibes|"The intervention involves using a program program called Bili that leverages community youth events such as football matches as a strategy to promote the uptake of HIV self-testing among young people."
10208829|NCT05124769|Active Comparator|Pain Avoid|Pain is not allowed during the exercises, and should be <2/10, monitored by NPRS.
10208830|NCT05120765|Experimental|Intervention|"Intervention to be administered is The CONNECT Program. This is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT)."
10208831|NCT05120765|No Intervention|Waitlist|Waitlist intervention requires participants to wait 6 weeks. This waitlist group will receive the intervention after this 6 week waiting period, due to the exploratory nature of this Pilot Randomized Controlled Trial (RCT).
10208832|NCT05119231|Experimental|Pulmonary Vein Isolation|"Pulmonary Vein Isolation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standards:~Trial participants will assigned to the PVI-arm will undergo catheter ablation within 48 hours after baseline evaluation, with the aim to achieve isolation of all pulmonary veins and restore sinus rhythm.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
10213559|NCT03805022|Experimental|Arm A|"Control-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 3 cycles in neoadjuvant setting.~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
9855684|NCT04070287|Active Comparator|BeterDoc|"This intervention involve using BeterDoc Safety kits that includes HIV self-testing kit, location and phone number to the health centers in the community as a strategy to promote update of HIV self-testing among young people."
9855685|NCT04070287|Active Comparator|IUNGO|This intervention involves using a program utilizes community vocational skills training centers to promote uptake of HIV self-testing among young people.
9855686|NCT04069715|Experimental|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng)|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
9855687|NCT04069715|Placebo Comparator|Placebo|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
9855688|NCT04050722|Experimental|Test Product|Participants with no visible plaque will be instructed to apply full ribbon of the test product (containing 0.454 percent [%] of stannous fluoride] on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
9855689|NCT04050722|Other|Negative Control Dentifrice|Participants with no visible plaque will be instructed to apply full ribbon of the negative control dentifrice (containing sodium fluoride) on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
9855690|NCT04069221|Experimental|Part 1, single arm|"This was an open-label study in 8 healthy subjects to determine the absolute bioavailability of OZ439 following a single oral dose of OZ439 and co-administration of a single iv infusion of a [14C]-OZ439 radiolabeled microdose at the anticipated Tmax of the oral dose. Subjects received the following treatment:~Treatment A: A single oral dose of 800 mg OZ439 simple granules administered as a 100-mL dispersion followed by a 15-minute 10-mL iv infusion of 100 μg [14C]-OZ439 (47 kBq [1.27 μCi]) beginning 3 hours after the oral dose administration."
9855691|NCT04069221|Experimental|Part 2, Treatment B: single oral dose of 800 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
9855692|NCT04069221|Experimental|Part 2, Treatment C: single oral dose of 400 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
9855693|NCT04069221|Experimental|Part 2, Treatment D:single oral dose 400 mg OZ439+cobicistat|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
9855694|NCT04067141|Experimental|somofilcon A, then nelfilcon A|Subjects will bilaterally wear the somofilcon A lenses, then crossover to nelfilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
9855695|NCT04067141|Experimental|nelfilcon A, then somofilcon A|Subjects will bilaterally wear the nelfilcon A lenses, then crossover to somofilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
9855696|NCT04049578|Experimental|Balovaptan|
9855697|NCT04067401|Experimental|Wingman Connect|Wingman-Connect total training time is 5 hours, typically spread over three consecutive training 'blocks'(or days), plus 1-hour of booster training (one month later).
9855698|NCT04067401|Active Comparator|Stress Management|The control training condition will consist of a 2 hr. informational training that provides an overview of the human stress response system and strategies to manage stress. The training will be delivered through lecture format using PowerPoint, supplemented by brief videos and interactive discussion.
10208833|NCT05119231|Sham Comparator|Sham Control Arm|"Sham Pulmonary Vein Isolation~Trial participants will assigned to the SHAM-arm will undergo their procedure within 48 hours after baseline evaluation. The Sham procedure will include deep sedation according to the respective PVI protocol for at least one hour, femoral vein/artery puncture with introduction of sheaths and an electrical cardioversion in presence of persistent atrial fibrillation.~Dependent of the local standards an echocardiography or cardiac MRI will be performed prior to the procedure. If necessary, a transesophageal echocardiography must be performed to exclude presence of atrial thrombus.~Anticoagulation will be initiated/continued for at least 3 months after the procedure."
10208834|NCT05116618||Cohort 1|10 evaluable enrollments to Cohort 1 with EGFR-mutant NSCLC
10208835|NCT05116618||Cohort 2|10 evaluable enrollments to Cohort 2 with ALK-rearranged NSCLC
10208836|NCT05116618||Cohort 3|10 evaluable enrollments to Cohort 3 with ROS1-rearranged NSCLC
10208837|NCT05116046|Experimental|Low Dose|Low Dose
10208838|NCT05116046|Experimental|Medium Dose|Medium Dose
10208839|NCT05116046|Experimental|High Dose|High Dose
9855699|NCT04067050|Experimental|comfilcon A asphere|Subjects will wear their comfilcon A asphere contact lenses for two months. Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
9855700|NCT04067050|Active Comparator|Habitual Spectacles|Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
9855701|NCT04066647|Experimental|Dexamthesone|Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.
9855702|NCT04066426|Experimental|naproxen sodium+codeine phosphate|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Codeine phosphate is an opioid analgesic which has similar applications to those of morphine. However, it is significantly less potent as an analgesic and has only mild sedative effects. The drug's principal site of action is at the µ-opioid receptors (MOR) which are distributed in the central nervous system. Peak effect is reached within 2 hours and analgesic action continues for approximately 4 hours. Naproxen sodium (550 mg)+codeine phosphate (30 mg) was used twice daily in this study.
10208840|NCT05113290|Experimental|H101+Sorafenib|H101 combined with Sorafenib
9855703|NCT04066426|Experimental|naproxen sodium+dexamethasone|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily + dexamethasone (8 mg) was used once daily in this study.
9855704|NCT04066426|Experimental|naproxen sodium|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily in this study.
9855705|NCT04066426|Active Comparator|paracetamol|Paracetamol is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea.
9855706|NCT04061694|Experimental|Digital Immediate loading|Single dental implant installed with the assistance of fully guided-surgery, submitted to immediate loading with restorations fabricated with the help of intraoral scanning and 3D printing
9855707|NCT04061694|Other|Immediate loading|Historic cohort subjected to immediate loading
9855708|NCT04060654|Experimental|SUBLOCADE|All subjects will receive SUBLOCADE 300mg on Day 1, followed by injections every 4 weeks at a dose determined by the Investigator (either 100 mg or 300 mg) for up to 5 total injections
10208841|NCT05113290|Active Comparator|Sorafenib|Patients take Sorafenib only
10208842|NCT05112419|Experimental|Cohort 1: Participants with moderate hepatic impairment and moderate renal impairment|Participants will receive a single oral dose of zibotentan under fasted conditions.
10208843|NCT05112419|Experimental|Cohort 2: Healthy participants|Participants will receive a single oral dose of zibotentan under fasted conditions.
10208844|NCT05112185|Experimental|Healthy Beverage Access and Promotion|Intervention group will receive BPA-free self-serve pitchers and cups for serving water at mealtimes, individualized education to help families set healthy drinks goals for their family, and a curricula focused on increasing intake of water and healthy beverages.
10208845|NCT05112185|No Intervention|Control|Usual care.
10208846|NCT05110131|Active Comparator|Needle-centered|Participants affiliated to this arm will undergo ENB-guided biopsy with needle aspiration first, followed by forceps biopsy
10208847|NCT05110131|Active Comparator|Forceps-centered|Participants affiliated to this arm will undergo ENB-guided biopsy with forceps first, followed by needle aspiration.
10208848|NCT05109351|Experimental|Participating to Boost Meal Participation|Intervention group will receive marketing and communication strategies developed by researchers, community organizations, parents, school nutrition directors, and other school stakeholders.
10208849|NCT05109351|No Intervention|Control|Usual care.
10208850|NCT05108987|Experimental|Noom+Exercise and Diet Standard of Care|If subjects are randomly assigned to this group, they will participate in exercise training and receive a Noom mobile app. Subjects will be asked to attend 2 regularly supervised and scheduled training sessions per week. For 3 days of the week, they will be instructed to exercise on their own for half the time they do in the supervised training sessions. Additionally, they will be provided standard of care diet advice that matches the American Diabetes Association recommendations.
10208851|NCT05108987|Active Comparator|Exercise and Diet Standard of Care|If subjects are assigned to this group, they will participate in the same exercise program and receive the same diet advice. Subjects will also be asked to exercise either in the morning or afternoon. They will not use Noom during the intervention.
10208852|NCT05107778|Experimental|Queue ASC42 10mg|ASC42 10mg, ih PEG-IFN α-2a and ETV for 12 weeks.
10208853|NCT05107778|Experimental|Queue ASC42 15mg|ASC42 15mg , ih PEG-IFN α-2a and ETV for 12 weeks.
10208854|NCT05107778|Placebo Comparator|Queue Placebo|Placebo, ih PEG-IFN α-2a and ETV for 12 weeks.
10208855|NCT05107492|Experimental|Cohort 1|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 450mg and placebo arms.
10208856|NCT05107492|Experimental|Cohort 2|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 150mg and placebo arms.
10208857|NCT05104125|Experimental|Experimental group 1|ASC40 25mg for 12 weeks
10208858|NCT05104125|Experimental|Experimental group 2|ASC40 50mg for 12 weeks
10208859|NCT05104125|Experimental|Experimental group 3|ASC40 75mg for 12 weeks
10208860|NCT05104125|Placebo Comparator|Placebo group|Placebo for 12 weeks
9855709|NCT04059250|Experimental|Nobio flange|On the Nobio flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it the Nobio composite.
9855710|NCT04059250|Placebo Comparator|Traditional composite flange|On the traditional composite flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it a traditional composite.
9855711|NCT04058353|Active Comparator|Control: IVA or TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants either received IVA 150 milligrams (mg) every 12 hours (q12h) or TEZ 100 mg once daily (qd)/IVA 150 mg q12h in the treatment period for 8 weeks.
9855712|NCT04058353|Experimental|TC: ELX/TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 8 weeks.
9855713|NCT04057248|Experimental|Digital platform and CDE coaching intervention for patients with type 2 Diabetes|"Patients provided with digital platform and connected devices. They undergo digital and human (CDE) intervention based on patient captured clinical data.~Clinical parameters (HbA1C, weight, lipids profile, etc.) before and after intervention is assessed."
9855714|NCT04055519|Other|LID017569, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
9855715|NCT04055519|Other|Biofinity, then LID017569|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
9855716|NCT04055675||Asymptomatic Male Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are male.
9855717|NCT04055675||Asymptomatic Female Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are female.
9855718|NCT04054765|Experimental|Teens in the Invite Only VR videogame|155 adolescents playing the Invite Only VR intervention
9855719|NCT04054765|Other|Teens receive treatment as usual|132 adolescents receive treatment as usual, which includes regular instruction in health class regarding the dangers of e-cigarettes
9855720|NCT04054011|Experimental|deoxycholic acid|Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)
9855721|NCT04059094|Placebo Comparator|Placebo|2 puffs ofmatching placebowere inhaledorally via theRespimat®inhaler twice dailyfor a treatmentperiod of 4 weeksin patients withcystic fibrosis.
9855722|NCT04059094|Experimental|BI 1265162 50 μg b.i.d.|2 puffs of 25micrograms (μg)BI 1265162(Total: 50μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:100μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
9855723|NCT04059094|Experimental|BI 1265162 100 μg b.i.d.|2 puffs of 50micrograms (μg)BI 1265162(Total: 100μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:200μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
9855724|NCT04059094|Experimental|BI 1265162 200 μg b.i.d.|2 puffs of 100micrograms (μg)BI 1265162(Total: 200μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:400μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
9855725|NCT04059094|Experimental|BI 1265162 20 μg b.i.d.|2 puffs of 10micrograms (μg)BI 1265162(Total: 20μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:40μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
9855726|NCT04051684|Experimental|TAP, Bupivacaine|This group will receive general anesthesia and at the end of the operation, but still in the operating room, a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
9855727|NCT04051684|No Intervention|No intervention|General anesthesia
9855728|NCT04046341|Experimental|Behavioral Sleep Intervention|Parents attend 1-3 one-hour sessions at their primary care office or via telemedicine, where they receive sleep education and work with interventionists to develop strategies to help their child at bedtime.
9855729|NCT04045964|Experimental|Motivational advice and free NRT|
9855730|NCT04045964|Active Comparator|Quitline referral|
9923854|NCT00854971|No Intervention|control|Oxaliplatin infusion (85mg/m2) on days 1 and 15 (every 2 weeks) 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16 LV infusions (200 mg/m2) on days 1, 2, 15 and 16
9923855|NCT00854971|Active Comparator|Active|FOLFOX-4 regimen + Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times
9855731|NCT04043416|Experimental|System + Fall Prevention First, then Fall Prevention|"Participants in this arm will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the first 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program. Following the 6 week washout period, the participants in this arm will just participate in the Fall Prevention program alone.~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
9855732|NCT04043416|Experimental|Fall Prevention first, then System +Fall Prevention|"Participants in this arm will participate in the Fall Prevention program alone during the first 6 week campaign. Following the 6 week washout period the participants will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the second 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
9855733|NCT04057768|Other|Intervention|Device: Venus Viva
9855734|NCT04052542|Active Comparator|Traditional online continuing education|
9855735|NCT04052542|Active Comparator|Interprofessional education|
9855736|NCT04052542|Active Comparator|Just-in-time education|
9855737|NCT04054193|Experimental|Fosaprepitant Treatment|Participants received fosaprepitant dimeglumine once daily (QD) for 3 days and were followed for 14 days during the 17-day Cycle 1. Participants also optionally received dexamethasone as background therapy, and a serotonin (5-hydroxytryptamine [5-HT3]) receptor antagonist on Day 1 and optionally on Days 2-3 as background therapy. After completing Cycle 1, participants had the option to continue for up to 2 additional 17-day cycles of the same treatment regimen.
9855738|NCT04050618|Experimental|ocufilcon D control lens, then fanfilcon A test lens|Participants will wear the ocufilcon D control lens for 4 weeks, then crossover to fanfilcon A test lens for 4 weeks of daily wear.
9855739|NCT04050618|Experimental|etafilcon A controls, then fanfilcon A test lens|Participants will wear the etafilcon D control lens for 2 weeks, then crossover to fanfilcon A test lens for 2 weeks of daily wear.
9855740|NCT04053465|Experimental|Exercise in heat group|Exercise in a hot environment
9855741|NCT04053465|Placebo Comparator|Exercise in cool group|Exercise in a cool environment
9855742|NCT04053270|Experimental|Group A|Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300
9855743|NCT04053270|Placebo Comparator|Group B|Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
9923856|NCT00854984|Experimental|Self-help CBT|A nurse supported self-help CBT intervention in addition to usual care.
9923857|NCT00854984|No Intervention|Usual care|
9923858|NCT00854997||1|AMI with OSA
9923859|NCT00854997||2|AMI without OSA
9923860|NCT00855023||Asymptomatic Volunteers|healthy volunteer athletes and excluded those who had any of the following criteria: 1) counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical hardware [plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.]); (2) relevant medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the knee that required medical attention; (5) previous surgery on the knee; or (6) current pain in the knee.
9923861|NCT00855049|Experimental|1|Intranasal acetaminophen administration
9923862|NCT00855049|Active Comparator|2|Oral acetaminophen administration
9923863|NCT00855075||Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
9923864|NCT00855088|Experimental|Darunavir, ritonavir, etravirine|Single arm trial looking at the pharmacokinetics of darunavir, ritonavir, etravirine in healthy volunteers.
9923865|NCT00855101|Experimental|voriconazole|
9923866|NCT00855114|Experimental|Patients Treated with Everolimus|Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.
9855744|NCT04049552|Experimental|RAPA intervention|Rapamycin ointment will be applied to one keloid on the subject
9855745|NCT04049552|Placebo Comparator|Placebo|Placebo will be applied as a control on one keloid on the subject
9855746|NCT04053023|Experimental|Participants receiving obeticholic acid and linerixibat|In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
9855747|NCT04051710|Experimental|Group-I (Test)|One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.
9855748|NCT04051710|Active Comparator|Group-II (Reference)|One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.
9855749|NCT04051710|Placebo Comparator|Group-III (Placebo)|One inhalation of Placebo Inhalation Aerosol twice daily.
9855750|NCT04050865|Experimental|OTX-DP|
9855751|NCT04050865|Placebo Comparator|Placebo|
9855752|NCT04050605|Experimental|somofilcon A toric (habitual), then fanfilcon toric (test)|Participants are habitual wearers of somofilcon A toric lens and refitted with fanfilcon A toric lens.
9855753|NCT04050371|Experimental|TRUVADA DOT|one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days
9855754|NCT04048460|Experimental|eAudiology|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
9855755|NCT04048681|Experimental|Diet Soda|12oz can of Diet Coke
9855756|NCT04048681|Active Comparator|Soda|12oz can of Coke
9855757|NCT04048681|Placebo Comparator|Carbonated Water|12oz can of carbonated (unflavored) water
9855758|NCT04046250|Experimental|TK112690|TK112690 treatment
9855759|NCT04046250|Placebo Comparator|Placebo|TK112690 formulation
9855760|NCT04047342||Standard welcome email|The standard welcome email mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
9855761|NCT04047342||Loss frame email|"The loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
9855762|NCT04044352|Experimental|Group 1|2 mL (approximately 5x10^6/mL tissue culture infective dose (TCID50)) of influenza A/Bethesda/MM2/H1N1challenge virus administered intranasally via a sprayer on Day 1. N=80.
9923867|NCT00855127||Liver transplant recipients|
9855763|NCT04043728|Experimental|Mindfulness|This module introduces mindfulness training skills, with the goal of cultivating nonjudgmental, present-focused experience of emotions, thoughts, and physical sensations related to cigarette smoking. By progressing though a series of experiential exercises (e.g., awareness of the breath, anchoring in the present), this module seeks to reduce maladaptive attempts to control negative emotions and facilitate tolerance of the physical and emotional symptoms of nicotine withdrawal.
9855764|NCT04043728|Experimental|Interoceptive Exposure (Practice Quitting)|This module introduces interoceptive exposure, a technique in which participants purposefully and systematically complete exercises to evoke physical sensations typically associated with anxiety and distress, in order to reduce fear and avoidance of these sensations. Interoceptive exercises will focus on a gradual exposure to nicotine withdrawal symptoms, through a series of 'practice quit attempts' (i.e., brief periods of smoking abstinence without intention to permanently quit).
9855765|NCT04043728|Experimental|Behavioral Activation (Countering Emotional Behaviors)|This module introduces behavioral activation, which seeks to increase positive emotions by systematically introducing greater engagement with natural rewards. Treatment sessions focus on the identification of avoidance strategies, including cigarette smoking as a coping strategy for negative emotions. The goal of this treatment module is to replace smoking with adaptive coping strategies to facilitate contact with and enjoyment of reinforcing activities that are incompatible with smoking.
9855766|NCT04041453|Active Comparator|Albendazole 400mg|Albendazole 400mg in single dose
9855767|NCT04041453|Experimental|Albendazole/Ivermectin|Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
9855768|NCT04041453|Experimental|Albendazole 400mg x 3|Albendazole 400mg/day for 3 consecutive days
10208861|NCT05102643|Experimental|Test Product|SARS-CoV-2 DNA Vaccine at 1mg and 2mg, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
10208862|NCT05102643|Placebo Comparator|Reference Product|Matching placebo, 2 doses 3 weeks apart, intramuscular injection followed by electroporation
9855769|NCT04041453|Experimental|Albendazole/Ivermectin x 3|Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days
9855770|NCT04041414|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
9855771|NCT04041414|Active Comparator|Control schools|Students in control schools will receive no intervention
9855772|NCT04041219|Experimental|Allogeneic blood or marrow transplantation|Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota
9855773|NCT04041700|Experimental|Osia 2 system|
9855774|NCT04040933|Active Comparator|Marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
9855775|NCT04040933|Active Comparator|Marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed only on Days 3, 5, 7, 9, 11, 13, 15, and 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
9923868|NCT00855140|Placebo Comparator|Sham acupuncture|Sham acupuncture at non-active acupuncture points, using the Park Sham Device
10208863|NCT05102409|Experimental|Reproxalap Ophthalmic Solution (0.25%)|Single dose
10208864|NCT05102409|Active Comparator|Xiidra® (5% lifitegrast ophthalmic solution)|Single dose
10208865|NCT05101824|Other|Single arm|All recruited patients are treated with SABR.
10208866|NCT05100706|Experimental|Continuous adductor canal block (CACB)|Will receive an infusion of 0.2% ropivacaine 5mL/h through adductor canal catheter.
10208867|NCT05100706|Placebo Comparator|Sham continuous adductor canal block (ShACB).|Will receive an infusion of NaCl 0.9% 5mL/h through adductor canal catheter.
10208868|NCT05099549|Experimental|Phase 1, Dose Escalation|"It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants.~SNK01 (fixed dose) will be administered weekly by IV infusion."
10208869|NCT05099549|Experimental|Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
10208870|NCT05099549|Experimental|Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)|SNK01 (fixed dose) will be administered weekly by IV infusion.
10208871|NCT05099549|Experimental|Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)|SNK01 (fixed dose) will be administered weekly by IV infusion.
10208872|NCT05098015|Experimental|Intervention|8-session group intervention to train participants to engage in HIV prevention advocacy.
10208873|NCT05098015|No Intervention|Usual care control|Participants will receive HIV usual care, and no added intervention.
10208874|NCT05097716|Experimental|Ritlecitinib and tolbutamide|In Period 1, participants will be dosed with a single administration of tolbutamide 500 mg tablet on Day 1. Period 1 will be immediately followed by Period 2 with no washout. In Period 2, participants will be dosed with oral 200 mg ritlecitinib QD for 10 days followed by administration of a single dose of 500 mg tolbutamide oral tablet within approximately 5 minutes after administration of a 200 mg dose of ritlecitinib on the morning of Day 10.
10208875|NCT05096286|Experimental|Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy|"A diagnostic MRI-only, simulation-free plan will be generated from diagnostic brain MRI imaging, using a semi-automated, AI-assisted plan template within the Ethos Therapy system.~The radiation prescription dose twill be 3.0 Gy daily over approximately 2 weeks for a total of 30.0 Gy (10 fractions)."
10208876|NCT05095857|Active Comparator|S-ketamine|S-ketamine is given as a continuous infusion started at a dose of 2.0 mg/kg/hour. The infusion rate will be re-evaluated after 24 hours, where (1) the infusion will be stopped if 24 hours ensue without SDs, (2) maintained at 2.0 mg/kg/hour if the 24-hour incidence of SDs decreases below the rate of the previous 24 hours but SD is not totally abolished, or (3) increased to 3.0 mg/kg/hour if the incidence of SD is at or above the rate of the previous 24 hours. If the infusion rate has been increased to 3.0 mg/kg/hour, the rate will be returned to 2.0 mg/kg/hour if 24 consecutive hours of ECoG show no SD.
9855776|NCT04040933|Active Comparator|Non-marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
9855777|NCT04040933|Experimental|Non-marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
9855778|NCT04040933|Experimental|Non-marketed Adhesive Bandage #3|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
9855779|NCT04040933|Experimental|Non-marketed Adhesive Bandage #4|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
9855780|NCT04040933|Experimental|Non-marketed Adhesive Bandage #5|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
9855781|NCT04040933|No Intervention|No Treatment (Uncovered, Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as negative control.
9855782|NCT04039867|Experimental|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
9855783|NCT04039412|Active Comparator|(1) Hybrid regimen|omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
9855784|NCT04039412|Active Comparator|(2) Reverse hybrid regimen|clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
9855785|NCT04039412|Active Comparator|(3) Levofloxacin quadruple regimen|levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
9855786|NCT04035161|Experimental|Investigational Product|Skin will be prepared with investigational product
9855787|NCT04035161|Other|Reference Standard|Skin will be prepared with reference standard
9855788|NCT04035161|Active Comparator|Active Control|Skin will be prepared with active comparator
9855789|NCT04035161|Other|Negative Control|Skin will be prepared with negative control
9855790|NCT04029519|Experimental|PN40082|All subjects in this study will receive one open-label treatment with PN40082.
9855791|NCT04039919|Experimental|Part A: Padsevonil and Ethanol|Subjects will be randomized to receive Padsevonil and Ethanol.
9855792|NCT04039919|Placebo Comparator|Part A: Padsevonil and Ethanol-Placebo|Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
9855793|NCT04039919|No Intervention|Part A: Ethanol and Ethanol-Placebo|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
9855794|NCT04039919|No Intervention|Part A: Ethanol-Placebo and Ethanol|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
9855795|NCT04039919|Experimental|Part B: Padsevonil and Cannabidiol|Subjects will be randomized to receive Padsevonil and Cannabidiol.
10208877|NCT05095857|Placebo Comparator|Isotonic saline|Isotonic saline is given as placebo. It will be given as a continuous infusion started at a dose corresponding to a dose of S-ketamine of 2.0 mg/kg/hour, and follow the criteria for increasing/decreasing infusion rates as S-ketamine. The infusion rate is read from a table listing different infusion rates (ml/hour) based on participant weight and if the treatment tier corresponds to a S-ketamine dose of 2 or 3 mg/kg/hour.
10208878|NCT05095805|Experimental|Test group|additional weight-bearing exercise
9855796|NCT04039919|Placebo Comparator|Part B: Padsevonil-Placebo and Cannabidiol|Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.
9855797|NCT04037969|Experimental|Nesofilcon A/Delefilcon A|Nesofilcon A was worn in right eye and delefilcon A worn in the left eye.
9855798|NCT04037969|Experimental|Delefilcon A/Nesofilcon A|Delefilcon A was worn in right eye and Nesofilcon A worn in the left eye.
9855799|NCT04037865|Experimental|PF-06651600 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
9855800|NCT04037865|Experimental|PF-06651600 Normal Renal Function|This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
9855801|NCT04037865|Experimental|PF-06651600 Moderate Renal Impairment|This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
9855802|NCT04037865|Experimental|PF-06651600 Mild Renal Impairment|This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
9855803|NCT04037748|Experimental|First Puran T4®, then Eutirox®|Participants received single oral dose of Puran T4® 600 micrograms (mcg) (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
10208879|NCT05095805|Active Comparator|Control group|standard weight-bearing exercise
9855804|NCT04037748|Experimental|First Eutirox®, then Puran T4®|Participants received single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Puran T4® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
9855805|NCT04036838|Experimental|Indication for H.pylori testing|Walk in basis: Symptomatic patients of H.pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test in addition to at least 2 other diagnostic tools from one obtained biopsy as comparison.
9855806|NCT04034121|Other|DESolve Cx|DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
9855807|NCT04027686|Experimental|SRP + Adjunctive Laser Therapy|Laser therapy used as an adjunct to scaling and root planing
9855808|NCT04027686|Active Comparator|SRP alone|Scaling and root planing used as conventional non-surgical periodontal therapy
9855809|NCT04022694|Active Comparator|Calorie/Control Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. It will simply state that those beverages are sold in the school store.
9855810|NCT04022694|Experimental|SSB Warning and Non-SSB Promotion Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. In addition, the message will state that SSBs are high in sugar and should be avoided, while low or no sugar beverages are healthier options and should be chosen.
9855811|NCT04022694|No Intervention|Baseline for Calorie/Control Poster|We will collect baseline data from a group of students before posting the Calorie/Control Poster in the control school.
9855812|NCT04022694|No Intervention|Baseline for SSB Warning and Non-SSB Promotion Poster|We will collect baseline data from a group of students before posting the SSB Warning and Non-SSB Promotion Poster in the intervention school.
9855813|NCT04036110|Experimental|Intervention 1|Vitamin C 500 mg taken daily for 3 months
10208880|NCT05095779|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
9855814|NCT04036110|Experimental|Intervention 2|Vitamin C 1000 mg taken daily for 3 months
9855815|NCT04036110|Placebo Comparator|Control|Placebo tablets taken daily for 3 months
9855816|NCT04035694|Experimental|Intervention|Participants will receive access to Media Aware.
9855817|NCT04035694|No Intervention|Delayed-Intervention Control|Participants will receive their regular health education programming not related to sexual health education or media literacy education.
9855818|NCT04035577|Experimental|Extended usability of a mobile self-help intervention|Participants will have open access to the Intellicare Hub app for 8-weeks and be surveyed at Baseline, 4-weeks, and 8-weeks
9855819|NCT04035564|Active Comparator|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life one
9855820|NCT04035564|Experimental|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life one
9855821|NCT04032977|Experimental|PN40082|Test device: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w
9855822|NCT04032977|Active Comparator|Restylane Silk|Restylane Silk (manufactured by Q-Med AB for Medicis - A Division of Valeant Pharmaceuticals Corporation North America, LLC ) is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
9855823|NCT04032652|Active Comparator|1200 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 1200 mg asacol
9855824|NCT04032652|Active Comparator|2400 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 2400 mg asacol
9855825|NCT04024501|Experimental|Treatment 1|During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.
9855826|NCT04024501|Experimental|Treatment 2|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.
9855827|NCT04024501|Experimental|Treatment 3|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.
9855828|NCT04024501|Experimental|Treatment 4|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.
10208881|NCT05095779|Experimental|Standard Care + Financial Incentives|Financial Incentives participants will receive standard care for completing counseling calls and for biochemically-verified smoking abstinence.
10208882|NCT05090852|Experimental|Hi-VNI as primary or adjunct oxygenation technique|Hi-VNI used as a primary or adjunct oxygenation technique during upper airway surgery
9855829|NCT04024501|Experimental|Treatment 5|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.
9855830|NCT04032613|Experimental|Vascular access quality improvement program participants|All participants enrolled in the study who are involved in the Vascular Access Navigation and Education Quality Improvement Program.
9855831|NCT04032171|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
9855832|NCT04032171|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
9855833|NCT04032158|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
9855834|NCT04032158|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
9855835|NCT04031404|Experimental|Glucose drink followed by placebo|Participants will consume the glucose drink at session 1, then they will consume the placebo (water) at session 2.
9855836|NCT04031404|Experimental|Placebo followed by glucose drink|Participants will consume the placebo (water) at session 1, then they will consume the glucose drink at session 2.
9855837|NCT04031885|Experimental|Abemaciclib + Fulvestrant|150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
9855838|NCT04031885|Active Comparator|Standard Chemotherapy|Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.
9855839|NCT04018924|Experimental|T - Treated|After standard cleansing or debridement of all wounds, on wound or portion of wound selected for treatment is treated with EmoLED device. Then covered with hydro fibre medication and dressing or compressive dressing when needed on the whole wound (SOC). Treatment is repeated once a week.
9855840|NCT04015440|Experimental|HBMT|
9855841|NCT04015440|Placebo Comparator|Placebo|
9855842|NCT04030104|Active Comparator|Imagio IUS|Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
9855843|NCT04030104|Experimental|Imagio (IUS+OA)|Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.
9855844|NCT04029961|Active Comparator|Video Education|Participants will receive video education on radiation therapy.
9855845|NCT04029961|Experimental|VR-based Education|Participants will receive VR-based education on radiation therapy.
9855846|NCT04025684|Other|Test toothbrush 1|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 1 after applying a strip of standard fluoride (1450 parts per million [ppm] fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
9923869|NCT00855140|Experimental|Verum Acupuncture|Acupuncture following a specific TCM-based protocol
9923870|NCT00855153|Experimental|treatment|Subjects receive 50mg DCS prior to 90 min session with graded VRE treatment
9923871|NCT00855192|Experimental|mindfulness-based therapy|mindfulness-based meditation
10208883|NCT05088616|Experimental|Virtual Diabetes Wellness Classes and Medically Tailored Meals|"All participants will receive the same intervention: four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals. Additionally, participants will be paired with one to two buddies to provide support to each other, although participants can opt out of having a buddy and still participate in the rest of the study."
10208884|NCT05087524|Experimental|BinaxNOW Surveillance|Participants will agree to the performance of nasal swabs samples to be used for diagnosis or screening. Samples will be obtained by research staff in the school setting. Madison Metropolitan School District (MMSD) has obtained a Clinical Laboratory Improvement Amendments (CLIA) waiver for collection of samples. When there is a positive test, a saliva sample will be collected for testing with a standard polymerase chain reaction (PCR) method. The standard PCR samples will be processed at University of Wisconsin (UW) Clinical Laboratory.
10208885|NCT05083741||Chitogel|Chitodex gel plus Kenalog inserted into the middle meatus
9855847|NCT04025684|Other|Test toothbrush 2|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 2 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
9855848|NCT04025684|Other|Test toothbrush 3|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 3 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
10208886|NCT05083741||Nexfoam|NexFoam plus Kenalog inserted into the middle meatus
10208887|NCT05080595|Experimental|Transportation assistance, reports unreliable transportation|Lyft rides provided to transplant-related appointments
9855849|NCT04025684|Other|Test toothbrush 4|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 4 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
9855850|NCT04019054|Experimental|Active iTBS, Ventromedial Prefrontal Cortex (vmPFC)|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vmPFC, as determined by position Fpz of the international 10-20 EEG electrode system."
9855851|NCT04019054|Placebo Comparator|Control iTBS, vertex|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vertex, as determined by position Cz of the international 10-20 EEG electrode system."
9855852|NCT04029545|Experimental|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. The study device will be provided by the Sponsor.
9855853|NCT04029545|Active Comparator|RV001 with lidocaine cream|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used with LMX4, a topical lidocaine. The study device will be provided by the Sponsor. LMX4 will be provided in commercial stock packaging by the Sponsor
9855854|NCT04029545|Experimental|RV001|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used alone. The study device will be provided by the Sponsor.
9923872|NCT00855192|Experimental|interpersonal therapy|psycho-educational
9923873|NCT00855205|Experimental|Treatment|Treatment with rituximab
9923874|NCT00855244|Other|BMT survivors|Diagnostic exams
9923875|NCT00855257|Experimental|1|treatment by acid nicotinique
9923876|NCT00855257|Placebo Comparator|2|Treatment by placebo
10208888|NCT05080595|No Intervention|No transportation assistance, reports unreliable transportation|No intervention, standard-of-care
10208889|NCT05080595|No Intervention|Transportation assistance, control|No intervention, standard-of-care
9923877|NCT00855270|Placebo Comparator|saline|An IV injection of saline will be administered to the control group in a double blind, randomized manner.
10208890|NCT05076877|Experimental|Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin|Participants will receive a single oral dose of probe substrates of midazolam, rosuvastatin, and metformin on Day 1 under fasted conditions followed by a single oral dose of lazertinib under fed conditions from Day 5 to Day 14 except Day 13 which is under fasted conditions and co-administered with probe substrates under fasted conditions on Day 13.
10208891|NCT05076838|Experimental|Valtoco In Pediatric Subjects with Epilepsy|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
10208892|NCT05071846|Experimental|MVX-ONCO-2|
10208893|NCT05070702|Experimental|CT-1500 Active (SAD)|6 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of CT-1500 between 5 mg and 120 mg
10208894|NCT05070702|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of matching placebo
10208895|NCT05070702|Experimental|CT-1500 Active (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of CT-1500 between 5 and 45 mg
10208896|NCT05070702|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of matching placebo
10208897|NCT05070039|Other|patients with invasive and non invasive urothelial carcinoma|patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.
10208898|NCT05062746|Experimental|MRT group|One session Matrix-Rhythm Therapy
10208899|NCT05062746|Other|Control group|One session routine, conventional physiotherapy and rehabilitation
10213560|NCT03805022|Experimental|Arm B|"Experimental-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 6 cycles in neoadjuvant setting.~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
10213561|NCT03805022|Experimental|Prospective cohort|Patients will be treated at the discretion of the investigator
10213562|NCT03802240|Experimental|Sintilimab +IBI305+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: IBI305 15mg/kg IV Q3W~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W"
10213563|NCT03802240|Experimental|Sintilimab +Placebo2+Pemetrexed+Cisplatin|"Drug: Sintilimab 200mg IV Q3W Other Name: IBI308~Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
10208900|NCT05058872|Experimental|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg - once a day for 21 days
10208901|NCT05058872|Placebo Comparator|Placebo|Placebo once a day for 21 days
9855855|NCT04029584|Experimental|Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg|"The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule first. Separated by one day of washout, they then receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.~Before starting hepatic induced period, subjects will have a washout for greater than one week.~To induce hepatic enzyme and transporter, Subjects will be pretreated with 5 days with 600mg oral rifampin. Subjects will be then randomized first to receive a single dose of fluvastatin 20mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg."
9855856|NCT04029584|Experimental|Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone|"The effect of rifampin on the disposition of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to first receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.Separated by one day of washout, subjects will be then receive a single dose of fluvastatin (Lescol®) 20mg capsule.~Before starting induction periods, subjects will have a washout greater than one week.~To induce hepatic enzyme and transporter, subjects will be pretreated with 5 days with 600mg oral rifampin. subjects will be randomized to receive first one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg."
9855857|NCT04029311|Experimental|Combination Therapy with Preferred Mask|Preferred Mask refers to a type of existing medical mask used for PAP therapy.
9855858|NCT04029311|Experimental|Combination Therapy with Custom Mask|Custom Mask refers to a mask which is supported by an interface which attaches directly to the patient's oral appliance.
9855859|NCT04028960|Placebo Comparator|Placebo|No active drug
9855860|NCT04028960|Experimental|Humulin-R|Insulin
9855861|NCT04026399|Experimental|stimulation + therapy|The participant receives stimulation and home therapy.
9855862|NCT04026399|Sham Comparator|no stimulation + therapy|The participant receives no stimulation and receives home therapy.
9855863|NCT04023578|Experimental|Rheo Knee XC|Amputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
9855864|NCT04023695|Active Comparator|Corticosteroid with lidocaine with epinephrine|This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
9855865|NCT04023695|Experimental|Corticosteroid with normal saline|This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
9855866|NCT04018664|Placebo Comparator|Placebo|"Placebo~150 mL flavored beverage"
9855867|NCT04018664|Experimental|90 mg nalbuphine HCl solution|"90 mg nalbuphine HCl solution~9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage"
9855868|NCT04018664|Experimental|120 mg nalbuphine HCl solution|"120 mg nalbuphine HCl solution~12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage"
9855869|NCT04018664|Experimental|150 mg nalbuphine HCl solution|"150 mg nalbuphine HCl solution~15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage"
9855870|NCT04018664|Experimental|180 mg nalbuphine HCl solution|"180 mg nalbuphine HCl solution~18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage"
9855871|NCT04018664|Experimental|270 mg nalbuphine HCl solution|"270 mg nalbuphine HCl solution~27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage"
9855872|NCT04018664|Experimental|Up to 405 mg nalbuphine HCl solution|"Up to 405 mg nalbuphine HCl solution~Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage"
9855873|NCT04018664|Experimental|Up to 540 mg nalbuphine HCl solution|"Up to 540 mg nalbuphine HCl solution~Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage"
9855874|NCT04016259|Experimental|Self-CES|
9855875|NCT04016259|Placebo Comparator|Sham-CES|
9855876|NCT04016077|Experimental|PF-06651600 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
10208902|NCT05057741|Experimental|Experimental|Multimodal prehabilitation: exercise, nutrition and relaxation
10208903|NCT05057741|No Intervention|No intervention|Usual care group: advice of surgeons about self care
10208904|NCT05050591|Experimental|Single-Arm Study|This is a prospective trial of the clinical utility of a patient-specific silicone stent implant for patients with complex airway disease, requiring an airway stent. The aim of this study is to observe the outcomes associated with the implants. Current stents have been suboptimal for treating benign stenosis of the airway and we are seeking to create a better treatment option. We hypothesize, based on the previous compassionate-use cases, that placing a patient-specific silicone stent will effectively alleviate symptoms associated with stenosis of the airway. The main measure of effectiveness will be patient-reported outcomes.
10208905|NCT05044104|Experimental|Wearable technology in endoscopic gastrointestinal procedures with sedation|Subjects undergoing a endoscopic gastrointestinal procedure with sedation as part of standard of care will wear a consumer-facing wearable smart watch for the duration of the procedure.
10208906|NCT05044052|Experimental|Intervention Group - Viral prescription pad + emphasis|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. As part of the intervention, these physicians will also receive additional emphasis on the viral prescription pad by 1) encouraging it in the dissemination email of the MyPractice feedback report, and (2) mailing a paper version of the viral prescription pad with instructions on embedding the viral prescription pad into the recipient's EMR.
9855877|NCT04016077|Experimental|PF-06651600 Healthy participants|This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
9855878|NCT04016077|Experimental|PF-06651600 Mild Hepatic Impairment|"This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.~The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10."
10208907|NCT05044052|No Intervention|Control group|Physicians in this group will receive their usual MyPractice: Primary Care report from Ontario Health. This report will include antibiotic prescribing indicators as well as a link to the viral prescription pad. This group will not receive any additional emphasis on the viral prescription pad and will not receive a paper copy in the mail.
10208908|NCT05041075|Active Comparator|WB:UC|Weighted Blanket 2nd infusion Usual Care 3rd infusion
9855879|NCT04027803|Experimental|BCD-148|39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min
9855880|NCT04027803|Active Comparator|Soliris|39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min
9855881|NCT04016311|Experimental|Mindful Drinking/Eating Group|Behavioral: Mindful Drinking/Eating Intervention Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
9855882|NCT04016311|No Intervention|Wait list control|Usual care. Offered intervention after post-test data collected.
9855883|NCT04027439|Active Comparator|Part A: RPL554|Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
9855884|NCT04027439|Active Comparator|Part B: RPL554|Double-blind, placebo-controlled, complete block cross-over
9855885|NCT04027218|Active Comparator|Current clinical practice-Dry heat|"The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice)."
9855886|NCT04027218|Active Comparator|Current clinical practice- Hihg pressure|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice)."
9855887|NCT04027218|Active Comparator|Current clinical practice-Combination|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice)."
9855888|NCT04026750|Experimental|Pitolisant|
9855889|NCT04026750|Placebo Comparator|Matching placebo|
9855890|NCT04026308|No Intervention|Written Safety Plan|Participants will complete a traditional written suicide safety plan.
9855891|NCT04026308|Experimental|Electronic Safety Plan|Participants will complete a suicide safety plan in the Safety Net app using a tablet.
9855892|NCT04023682|Other|Anesthesia Provider hands|"Each provider will serve as their own control.~Control phase is at baseline using standard hygiene practices.~Intervention phase will include the addition of Provodine hand sanitizer"
9855893|NCT04021771|Other|Group A (Intervention Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
10208909|NCT05041075|Active Comparator|UC:WB|Usual Care 2nd infusion Weighted Blanket 3rd infusion
10208910|NCT05039671|Experimental|Measurement-based care|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
10208911|NCT05035095|Experimental|Oral semaglutide|Participants will receive once daily semaglutide tables in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68)
10208912|NCT05035095|Placebo Comparator|Oral semaglutide placebo|All participants are given once daily dose for 68 weeks
10208913|NCT05033223|Other|Follow-up|
10208914|NCT05032144|Experimental|Cohort 1:2mg/kg|All participants (fasted) received either 2mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10208915|NCT05032144|Experimental|Cohort 2:5mg/kg|All participants (fasted) received either 5mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10208916|NCT05032144|Experimental|Cohort 3:10mg/kg|All participants (fasted) received either 10mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10208917|NCT05032144|Experimental|Cohort 4:20mg/kg|All participants (fasted) received either 20mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10208918|NCT05032144|Experimental|Cohort 5:30mg/kg|All participants (fasted) received either 30mg/kg of STSA-1002 as a single dose or dose-matched placebo.
10208919|NCT05029882|Experimental|Part 1 (Monotherapy Dose Escalation)|Participants with advanced solid tumors will receive escalating doses of ABBV-400.
10208920|NCT05029882|Experimental|Part 2a (wtEGFR Non-Small Cell Lung Cancer [NSCLC])|Participants with c-Met intermediate/high advanced non-squamous wtEGFR NSCLC will receive ABBV-400 at the Recommended Phase 2 dose (RP2D).
10208921|NCT05029882|Experimental|Part 2b (mutEGFR NSCLC)|Participants with c-Met intermediate/High advanced non-Squamous mutEGFR NSCLC will receive ABBV-400 at RP2D.
10208922|NCT05029882|Experimental|Part 2c (wtEGFR NSCLC)|Participants with c-Met low non-squamous wtEGFR NSCLC will receive ABBV-400 at RP2D.
9855894|NCT04021771|Other|Group B (Control Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP; following this session, participants in Group B will be introduced to the intervention. Group B will return for a third visit (T3) to provide information on how the curriculum impacts their score.
9855895|NCT04019626|Active Comparator|Continue-smoking|The subject's usual brand of combustible cigarette
9855896|NCT04019626|Experimental|myblu Tobacco 2.5%|myblu e-cigarette system with Tobacco flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
9855897|NCT04019626|Experimental|myblu Tobacco 4.0%|myblu e-cigarette system with Tobacco flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
9855898|NCT04019626|Experimental|myblu Honeymoon 2.5%|myblu e-cigarette system with Honeymoon flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
9855899|NCT04019626|Experimental|myblu Honeymoon 4.0%|myblu e-cigarette system with Honeymoon flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
9855900|NCT04019626|Active Comparator|JUUL 5%|JUUL® system with Virginia Tobacco Flavor JUULpod, 5.0% nicotine. This arm is only included in the PK sub-study.
9855901|NCT04023994|Placebo Comparator|Placebo|In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.
9855902|NCT04023994|Experimental|RO7126209 (0.1 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).
9855903|NCT04023994|Experimental|RO7126209 (0.4 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).
10208923|NCT05029882|Experimental|Part 2d (Squamous NSCLC)|Participants with squamous NSCLC will receive ABBV-400 at RP2D.
10208924|NCT05029882|Experimental|Part 3 (Gastric/Gastroesophageal Junction Adenocarcinoma)|Participants with c-Met overexpressing Gastroesophageal adenocarcinoma will receive ABBV-400 at the RP2D.
9855904|NCT04023994|Experimental|RO7126209 (1.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).
9855905|NCT04023994|Experimental|RO7126209 (3.6 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).
9855906|NCT04023994|Experimental|RO7126209 (7.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).
9855907|NCT04022668||STEMI|Current international ECG criteria (New ST-segment elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV millivolts (mV) in all leads other than leads V2-V3; for leads V2-V3: ≥2 mm in men ≥40 years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age) with troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia.
9855908|NCT04022668||NSTEMI|Troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia without abovementioned criteria.
9855909|NCT04022668||Normal|Emergency department admission with a clinical picture compatible with acute coronary syndrome, but no change in serial ECGs and no rise in cardiac biomarkers
9855910|NCT04020822|Experimental|Subjects Wearing Guardian Sensor (3)s|Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear.
9923878|NCT00855270|Experimental|Hydrocortisone|IV hydrocortisone will be given in a double blind random manner as the active treatment group
9923879|NCT00855283|Experimental|Arm 1|SCI
9923880|NCT00855322|Experimental|1|Gym group exercise intervention
10208925|NCT05029349|Other|VOC analysis|VOC analysis in exhaled air in patients hospitalised for stable severe COPD
10208926|NCT05028816|Other|Group 1|"Side 1: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)~Side 2: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)"
10208927|NCT05028816|Other|Group 2|"Side 1: Final layer closure with force modulating tissue bridges (FMTB) (Brijjit BP100-6, Brijjit Medical Inc., Marietta, GA)~Side 2: Final layer dermal closure with poliglecaprone 25 suture (Monocryl ®, Ethicon, Inc. Bridgewater, NJ)"
9923881|NCT00855322|Experimental|2|Hydrotherapy group exercise intervention
10208928|NCT05027685||Renal Denervation Treatment|Patients candidate for treatment or already treated within 6 months prior to consent, as per the sites normal practice with the commercially available Paradise Ultrasound Renal Denervation System, will be enrolled in this single arm registry.
10208929|NCT05023733||1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1|One to two contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1 whose condition requires the use of interbody fusion.
10208930|NCT05023148|Active Comparator|Electroacupuncture with dietary intervention|"Acupoints stimulation with an electric stimulator on CV12 Zhongwan, CV9 Shuifen, CV6 Qihai, CV4 Guanyuan, ST25 Tianshu bilateral, SP15 Daheng bilateral, ST40 Fenglong bilateral using continuous 2 Hz for 30 minutes. Therapy sessions are three times a week for four weeks (total 12 times).~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
10208931|NCT05023148|Active Comparator|Thread embedded acupuncture with dietary intervention|"Acupoints stimulation by embedding PDO thread in CV12 Zhongwan penetrating to CV9 Shuifen using 27G x 60 mm, CV4 Guanyuan penetrating to CV6 Qihai using 27G x 40 mm, ST25 Tianshu penetrating to SP15 Daheng using 27G x 40 mm, and perpendicular in ST40 Fenglong bilateral using 31G x 25 mm. Therapy will be done only once.~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
9855911|NCT04019990|Other|Wheelchair basketball and ambulant basketball players|13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.
9855912|NCT04017611|Experimental|INVSENSOR00038|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00038 sensor.
9855913|NCT04015232|Experimental|INTP5 biosimilar product|INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
9855914|NCT04015232|Active Comparator|US Neulasta reference product|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
9855915|NCT04016623|Experimental|1-day toric test contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
9855916|NCT04016623|Active Comparator|1-day toric control contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
9855917|NCT04013737||Patients and Public|Exploration of patient and public engagement with antibiotic decision making in secondary care. Prospective evaluation of a co-designed intervention to support enhanced knowledge and understanding of infections and their management.
9855918|NCT04013737||Prescribers|Quantitative evaluation of the impact of using a clinical decision support system to support antibiotic decision making.
9855919|NCT04014062|Experimental|INTP5 Period I Crossover|"Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta."
9855920|NCT04014062|Active Comparator|US Neulasta Period I Crossover|"Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5."
9855921|NCT04013789|Other|DACP FreshTech, then DACP|DACP FreshTech contact lenses worn first, followed by DACP contact lenses, as randomized. Each product was worn in both eyes for approximately 8 hours per day for 1 week with a new pair of lenses worn each day.
9855922|NCT04013789|Other|DACP, then DACP FreshTech|DACP contact lenses worn first, followed by DACP FreshTech contact lenses, as randomized.. Each product was worn in both eyes for approximately 8 hours per day, for 1 week with a new pair of lenses worn each day.
9855923|NCT04012970|Experimental|A - Intervention then control|Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
9855924|NCT04012970|Experimental|B - Control then intervention|Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.
9855925|NCT04013191|Experimental|Adult study participants|Participants will receive assigned single and multiple doses of padsevonil.
9855926|NCT04013191|Experimental|Elderly study participants|Participants will receive assigned single and multiple doses of padsevonil.
9855927|NCT04011631|Experimental|Patients with cardiac surgery|All patients undergoing cardiac surgery at the Ziekenhuis Oost-Limburg, meeting all inclusion and no exclusion criteria, are asked to participate in the investigation.
9855928|NCT04011735||Respimat SMI-experienced: Switching to re-usable Respimat|patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry.
9855929|NCT04011735||Respimat SMI-naïve|patients who have not previously used a Respimat SMI product and receive their first prescription at study entry
9855930|NCT04011735||Respimat SMI-experienced: Maintenance treatment|patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry.
9855931|NCT04010695|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor point-of-care G6PD test and the point-of-care HemoCue Hb test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
9855932|NCT04009577|Experimental|Cohort 1 (LEM 5 mg)|"Participants who were taking zolpidem tartrate (ZOL) at least 3 but fewer than 5 nights per week, for each of at least 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.~Participants who meet both criteria for intermittent (Cohort 1) and frequent ZOL use (Cohort 2A and 2B) for 1 week each of the last 2 weeks of the 3-week Screening Period will be assigned to Cohort 1 and also will receive LEM 5mg."
9855933|NCT04009577|Experimental|Cohort 2A (LEM 5 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
9855934|NCT04009577|Experimental|Cohort 2B (LEM 10 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 10 mg administered as a tablet, orally for up to 2 weeks.
9855935|NCT04007159|Experimental|Developmental Serum|The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square [mL/cm^2] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
9923882|NCT00855322|No Intervention|3|Control group
9855936|NCT04007159|Experimental|Developmental Lotion|The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
9855937|NCT04007159|Experimental|Developmental Cream|The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
9855938|NCT04007159|Placebo Comparator|Negative Control|The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
9855939|NCT04007107|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
9855940|NCT04007107|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
9855941|NCT04006795|Experimental|Developmental Serum|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square[mL/cm^2] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
10208932|NCT05022485||Investigational group|Subjects that will be implanted with the ZNN Bactiguard tibia device.
10208933|NCT05022485||Control group|Subjects that have received an uncoated titanium-alloy tibia nail in the past (data collection is retrospective; patients will not have to undergo any study-related procedure).
9855942|NCT04006795|Experimental|Developmental Lotion|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
9855943|NCT04006795|Experimental|Developmental Cream|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
9923883|NCT00855348||Adults > 50 Years Scheduled for Colonscopy|Average to increased risk adults older than 50 years without symptoms indicative of CRC and designated for colonoscopy.
9923884|NCT00855361|Experimental|Rabeprazole sodium|
10208934|NCT05022251||Lumbar radiculopathy|Lumbar radiculopathy patients (n=122), classified as ASA I to II without any symptoms of spinal cord compression (i.e. bilateral leg pain), who are scheduled for a first-time, single-level, unilateral lumbar discectomy.
10208935|NCT05022251||Healthy controls|Sex, age, and BMI-matched healthy, pain-free control subjects (n=122) will be recruited for study participation.
10208936|NCT05020145||Immunocompromised|Vaccinated Subject with 1 or >1 immunocompromising conditions.
9923885|NCT00855387||Costs|Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections).
9923886|NCT00855400|Experimental|Transplant|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
9923887|NCT00855478|Experimental|1|Cypher drug-eluting stent
9923888|NCT00855491|Experimental|1. MYOPIA|axial length > 26.00 mm
10208937|NCT05020145||Non-Immunocompromised|Vaccinated subjects without evidence of immunocompromising condition.
10208938|NCT05020145||Total Population (immunocompromised and non)|Vaccinated Subjects with or without 1 or >1 immunocompromising conditions.
10208939|NCT05015569|Active Comparator|Patient Gown + COVR garment|Patients will receive the standard of care patient gown and a COVR garment. Patients undergoing unilateral lower extremity surgery will receive a half short. Patients undergoing upper extremity or spine surgery will receive the brief (bilateral) style COVR garment.
10208940|NCT05015569|Active Comparator|Patient Gown|Patient will receive the standard of care patient gown only without undergarments.
10208941|NCT05013333|Other|AED 3 with Uni-padz|
10208942|NCT05012605||SLEEPR cohort|Individuals within first 3 months following stroke who did not have obstructive sleep apnea within the first 15 days following stroke
10208943|NCT05009875|Experimental|SBD111|
10208944|NCT05009875|Placebo Comparator|Placebo|
10208945|NCT05007964|Experimental|Spatz4 subjects|Subjects will be studied in an open label multi-center center study which will examine the usability of the adjustment process and success of the process. .
10208946|NCT05005975|Experimental|Dersimelagon 100mg|
9855944|NCT04006795|Placebo Comparator|Negative Control|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
9855945|NCT04005885|Experimental|somofilcon A then stenfilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear somofilcon A daily disposable test lens for 1 week of daily wear and stenfilcon A daily disposable test lens for 1 week of daily wear.
9855946|NCT04005885|Experimental|stenfilcon A then somofilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear stenfilcon A daily disposable test lens for 1 week of daily wear and somofilcon A daily disposable test lens for 1 week of daily wear.
9855947|NCT04000815|Active Comparator|Reproductive age women|The healthy women between 18-40 years old.
9855948|NCT04000815|Active Comparator|Perimenopausal women|The healthy women between 40-49 years old.
9855949|NCT04000815|Active Comparator|Postmenopausal women|The healthy women that has been in to menopause more than a year
9855950|NCT03999944|Other|Sequence 1|"FRESCA Airbox Flow Generator set to fixed pressure first, then FRESCA Airbox Generator set to auto-adjusting pressure.~Second intervention within 1 - 10 days of first intervention."
9855951|NCT03999944|Other|Sequence 2|"FRESCA Airbox Flow Generator set to auto-adjusting pressure first, then FRESCA Airbox Generator set to fixed pressure.~Second intervention within 1 - 10 days of first intervention."
9855952|NCT03995680|Experimental|Chewable tablet of mebendazole|"3-5 year olds allocated to the swallowable tablet arm will be given the crushed tablet on a spoon mixed with a small amount of clean water;~6-12 year olds allocated to the swallowable tablet arm will be given the whole tablet to swallow with a glass of clean water;"
9855953|NCT03995680|Active Comparator|Swallowable tablet of mebendazole|"3-5 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and swallow it without water; if they cannot chew it then a small amount of water will be added to the tablet in a spoon;~6-12 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and then swallow it without water."
9855954|NCT04006366|Other|Intervention|To test the effects of a 10-hour time restricted eating intervention before and after the 12 weeks of treatment on weight (primary), caloric and macronutrient intake, and a variety of psychosocial measures, including sleep, physical activity, blood pressure and eating behaviors (all secondary).
9855955|NCT04006145|Experimental|Elobixibat|Elobixibat 5 mg once daily
9855956|NCT04006145|Placebo Comparator|Placebo|Placebo
9855957|NCT04005755|Experimental|Maxigesic® IV|Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
10208947|NCT05004662|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with Florida Quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
9855958|NCT04005586|Experimental|Light Delivery Device (LDD)|Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.
10208948|NCT05004662|Experimental|Automated Treatment|Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
10208949|NCT05002777|Experimental|Rilzabrutinib|Oral rilzabrutinib 400 mg BID
9855959|NCT04005404|Experimental|intertrochanteric femoral fractures|geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
9855960|NCT04005404|Experimental|neck femur fractures|geriatric patients with neck of femur fracture who have consented to the study intervention
9855961|NCT04005404|Experimental|subtrochanteric femoral fractures|geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
9855962|NCT03993288|Experimental|Ferrum Lek|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
9855963|NCT03993288|Active Comparator|MALTOFER|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
9855964|NCT03990298|Other|All subjects|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages.
9855965|NCT03988647|Experimental|Pembrolizumab + Palliative Radiation Therapy|Pembrolizumab will be administered at 200 mg IV every 3 weeks as standard of care. Palliative radiation therapy will be given between the first and second cycles of immunotherapy
9855966|NCT03979872|Active Comparator|Arm 1: Skin Cancer Education Only|Participants will be randomized to receive education only.
10208950|NCT04997265|Experimental|Low Intensity Anticoagulation|For patients assigned to the low intensity anticoagulation strategy, clinical teams will be instructed to initiate low intensity anticoagulation at doses and frequencies commonly used for deep vein thrombosis (DVT) prophylaxis. The choice of anticoagulant, dose, and frequency of administration will be deferred to treating clinicians.
10213564|NCT03802240|Active Comparator|Placebo1+Placebo2+Pemetrexed+Cisplatin|"Drug: Pemetrexed 500mg/m2 IV Q3W~Drug: Cisplatin 75mg/m2 IV Q3W~Drug: Placebo1 Placebo1 IV Q3W~Drug: Placebo2 Placebo2 IV Q3W"
10208951|NCT04997265|Active Comparator|Moderate Intensity Anticoagulation|For patients assigned to the moderate intensity anticoagulation group, clinical teams will be instructed to initiate a continuous infusion of moderate intensity anticoagulation targeting either a partial thromboplastin time (PTT) of 40-60 seconds or an Anti-Xa level of 0.2 to 0.3 IU/mL. The choice of anticoagulant and approach to dosing will be deferred to treating clinicians.
10208952|NCT04995406||Active TB ATB|Participants with active tuberculosis with diagnosis confirmed by GeneXpert and/or culture positivity
10208953|NCT04995406||Latent Tuberculosis Infections LTBI|Participants with presumed latent TB infection
9855967|NCT03979872|Experimental|Arm 2: Skin Cancer Education + UV Photo|Participants randomized to receive education + UV photo will have a UV light photo taken of their face to show UV damage in the skin that is invisible to the naked eye in addition to receiving skin cancer education.
9855968|NCT03979872|Experimental|Arm 3: Skin Cancer Education + MC1R Testing|Participants randomized to receive education + genetic testing will be asked to provide a saliva sample for MC1R testing in addition to receiving skin cancer education.
9855969|NCT03979872|Experimental|Arm 4: Skin Cancer Education + UV Photo + MC1R Testing|Participants randomized to receive education + UV photo + genetic testing will have a UV light photo taken of their face, Submit a saliva sample for MC1R testing, and receive skin cancer education.
9855970|NCT03978832|Experimental|Oral Risperidone followed by PERSERIS|All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.
9855971|NCT04005391|Experimental|Postpartum Contraceptives offered to Intervention Clusters|"Women will have postpartum contraceptive options (condoms vive amor, birth control pills segura plus, injectable cyclofem, contraceptive implant jadelle) offered to them at their routine forty day postpartum visit after routine care is provided, first."
9855972|NCT04005391|No Intervention|Routine Care offered to Control Clusters|Women will receive routine postpartum care
9923889|NCT00855491|Active Comparator|2. Emmetropia|emmetropic eyes- eyes with an axial length of 21.00 to 23.99 mm
9923890|NCT00855504||Subjects|All the consecutive primigravidae who register in the antenatal clinic before 20 weeks of gestation
10208954|NCT04995406||Healthy controls HC|Participants who do not have Active or Latent tuberculosis or other pathologies investigated in this study
10208955|NCT04995406||Non-tuberculous symptomatic participants|This cohort refers to participants who are known with chronic respiratory conditions and present with one or more signs and symptoms suggestive of TB, but in whom microbiological testing is negative.
9923891|NCT00855517|Experimental|Punctal Plug|
9935125|NCT04142814|Experimental|T-PEP|"Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound.~T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation."
9935126|NCT04142814|Active Comparator|IPV|"Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound.~IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation."
9935127|NCT04141696|Experimental|Ketamine|Given intravenously over 40 minutes
9935128|NCT04141696|Active Comparator|Midazolam (Placebo)|Given intravenously over 40 minutes
9935129|NCT04141150|Experimental|[18F]APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
9935130|NCT04140305|Experimental|Administration of RPC-1063|Patients with relapsing MS will receive RPC-1063 orally:
9935131|NCT04138953|Experimental|TMS over premotor cortex|Noninvasive brain stimulation in the premotor cortex
9935132|NCT04138953|Experimental|TMS over primary motor cortex|Noninvasive brain stimulation in the motor cortex
9935133|NCT04138953|Sham Comparator|Sham TMS over premotor cortex|Sham brain stimulation in the premotor cortex
9935134|NCT04137068|Other|Sedentary to Active|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their normal level of physical activity. After the baseline visit, participants will reduce their step count by more than half for two weeks, and then maintain baseline activity level for two weeks. The fifth week will be maintaining baseline activity level. Participants will visit the laboratory once every week during these 5 weeks.
9935835|NCT03141684|Experimental|Arm II (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10208956|NCT04990687|Experimental|Intervention Group|Treatment effects will be measured using standard rating scales including the HDRS-17, MADRS, SF-36, CSSR-S, CGI-I, CGI-S, which will be completed at each visit. The following scales will be completed at every other visit following the screening visit: Social Anhedonia Scale, the Motivation and Energy Inventory and the Physical Anhedonia Scale. At each study visit safety assessments including vital sign assessment and adverse event assessment will be completed. Subjects will also undergo physical examination and an ECG for safety during screening, after 8 weeks of treatment and at the end of 12 weeks of treatment.
10208957|NCT04988906|No Intervention|Before Arm|The before arm of the study prehospital providers will provide resuscitation as per standard practice. The providers will utilize the Zoll Accuvent device without activation of the real-time dashboard. This will allow us to collect baseline ventilation data.
9855973|NCT04004481||Adult patients undergoing major open abdominal surgery|Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.
9855974|NCT04004260|Experimental|Experimental group|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
9855975|NCT04004260|Other|Weekly check-in control group|The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.
9855976|NCT03997851|Experimental|Topical 5% acetaminophen gel|Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
9855977|NCT03997851|Experimental|Topical 2.5% acetaminophen gel|Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
9855978|NCT03997851|Experimental|Topical 1% acetaminophen gel|Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
9855979|NCT03997851|Placebo Comparator|Topical vehicle gel|Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
10208958|NCT04988906|Active Comparator|After Arm|The after arm of the study the prehospital providers will provide resuscitation as per standard practice. The real-time ventilation dashboard will be activated and the providers will use real-time feedback to monitor ventilation quality during the resuscitation.
10208959|NCT04984655|Other|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|
9855980|NCT03991715|Experimental|Activity Tracker|Participants provided an activity tracker to wear and weekly reports
9855981|NCT03990415|Experimental|Stay Strong, Stay Healthy Group|The Stay Strong, Stay Healthy strength training group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured program to learn and progress through strength training exercises designed to increase overall fitness, flexibility, and balance.
9855982|NCT03990415|Active Comparator|Walking Group|The walking group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured walking program to help delineate the effects of the strength training program and exercise in general.
9855983|NCT03990415|No Intervention|Delayed Start Group|The delayed start group will not make any changes to their sedentary lifestyle and will be encouraged to not begin any exercise programs throughout the duration of the study.
9855984|NCT04002960|Experimental|INVSENSOR00036|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00036 sensor
9855985|NCT04002973|Experimental|INVSENSOR00037|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.
9855986|NCT04002648||MT-Right|
9855987|NCT04002648||Sternotomy|
9855988|NCT03993210|Experimental|GYN Cancer Cases|"Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
9855989|NCT03993210|Active Comparator|GYN Benign Controls|"Benign gynecological (GYN) fibroids.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
9855990|NCT03992014|Experimental|Linerixibat + [14C]-linerixibat|Subjects will receive a single oral dose of linerixibat 90 milligram (mg) (2*45 mg) tablets concomitantly with [14C]-linerixibat 100 microgram (approximately 9.25 kilobecquerel; 250 nano curie) IV infusion for 3 hours, after an overnight fast that continues for 2 hours after the oral dose/start of IV infusion, small standard high-fat meal will be given on Day 1 in treatment Period 1; followed by a single oral dose of [14C]-linerixibat 90 mg (approximately 4.96 megabecquerel; 134.1 micro curie) solution on Day 1 in treatment Period 2. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
9923892|NCT00855530|Experimental|1|
9923893|NCT00855569||1|Each donor site will act as it own control - both dressings will be applied to the donor site and assessments will be made
10208960|NCT04983420|Experimental|non-alcoholic Pilsner|1 L non-alcoholic Pilsner per day for 2 weeks
10208961|NCT04983420|Experimental|non-alcoholic wheat beer|1 L non-alcoholic wheat beer per day for 2 weeks
10208962|NCT04983420|Active Comparator|apple spritzer|1 L apple spritzer per day for 2 weeks
9855991|NCT03990649|Placebo Comparator|Double-Blind Treatment Period - Part A: Placebo|Soticlestat matching placebo tablets, orally, twice daily (BID) for Weeks 1, 2 and 3 in Double blind Titration Period. Soticlestat matching placebo tablets, orally BID for 12 weeks in Double blind Maintenance Period. Taper period (if participant did not continue to Part B): Dose of soticlestat matching placebo tablets was reduced to next lower dose every 3 days (maximum 6 days) until discontinuation.
9855992|NCT03990649|Experimental|Double-Blind Treatment Period - Part A: Soticlestat|Soticlestat, tablet, orally, 100 mg BID for Week 1, followed by 2×100 mg tablets, soticlestat, orally BID for Week 2, further followed by 3×100 mg tablets, soticlestat, orally BID for Week 3. Dose was uptitrated every week based on safety and tolerability. Part A (Double blind Maintenance Period): 3×100 mg tablets, soticlestat, orally BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period (if participant did not continue to Part B): Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
9855993|NCT03990649|Experimental|Open-Label Extension Period - Part B: Soticlestat|Soticlestat, 2×100 mg tablets, orally, BID for Week 1, followed by 3×100 mg tablets, soticlestat, orally, BID for Week 2. Dose was uptitrated every week based on safety and tolerability. Part B (Open label extension: Maintenance Period): 3×100 mg tablets, soticlestat, orally, BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period: Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
9855994|NCT04002791|Placebo Comparator|Group 1: TR Band Arm|"Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using Patent hemostasis protocol to achieve full hemostasis."
9855995|NCT04002791|Active Comparator|Group 2: Vaso-band Arm|Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.
9855996|NCT04000581|Active Comparator|Arm I (usual care)|Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
9855997|NCT04000581|Experimental|Arm II (additional mobility)|Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
9855998|NCT03996694|Experimental|Treatment A: Belbuca 300 µg and oral placebo|Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
9855999|NCT03996694|Experimental|Treatment B: Belbuca 600 µg and oral placebo|Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
9856000|NCT03996694|Experimental|Treatment C: Belbuca 900 µg and oral placebo|Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
9856001|NCT03996694|Active Comparator|Treatment D: Oxycodone 30 mg and buccal placebo|Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
9856002|NCT03996694|Active Comparator|Treatment E: Oxycodone 60 mg and buccal placebo|Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
9856003|NCT03996694|Placebo Comparator|Treatment F: Oral Placebo and buccal placebo|Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
9856004|NCT03988907|Experimental|Part 1|Participants will receive a dose of 5 milligram (mg) risdiplam once daily (QD) for 14 consecutive days
9856005|NCT03988907|Experimental|Part 2|All study participants will receive a single oral dose of 2 mg midazolam on Day 1. On Day 3, the 14-day QD treatment period with risdiplam will begin. The precise dose will be based on the results of Part 1, with single dose administration of 2 mg midazolam again on Day 15 (1 hour after the thirteenth dose of risdiplam)
9856006|NCT03988088|Experimental|Lasmiditan|Participants with lower body weight (15 to ≤40 kilograms (kg)) received single oral dose of 100 milligrams (mg) Lasmiditan in Cohort 1 and higher body weight (>40 to ≤55 kg) participants received single oral dose of 200 mg Lasmiditan in Cohort 2.
9856007|NCT03980522|Experimental|KPL-914: Part 1 Participants|Part 1 enrolls symptomatic participants with recurrent idiopathic pericarditis (RIP) with an elevated marker of systemic inflammation (C-reactive protein [CRP] > 1mg/dL).
9856008|NCT03980522|Experimental|KPL-914: Part 2 Participants|Part 2 enrolls symptomatic participants with RIP with CRP ≤1 mg/dL which, in the opinion of the Investigator, can be attributed to concomitant medications (e.g., corticosteroids) and with pericardial inflammation present on cardiac magnetic resonance imaging (MRI) confirmed by the imaging core lab.
9856009|NCT03980522|Experimental|KPL-914: Part 3 Participants|Part 3 enrolls participants with corticosteroid-dependent RIP not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
9856010|NCT03980522|Experimental|KPL-914: Part 4 Participants|Part 4 enrolls symptomatic participants with recurrent post pericardiotomy syndrome (PPS) with an elevated marker of systemic inflammation (CRP > 1mg/dL).
9856011|NCT03980522|Experimental|KPL-914: Part 5 Participants|Part 5 enrolls participants with corticosteroid-dependent recurrent PPS not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
9856012|NCT03999684|Experimental|Tretinoin|-Participants will receive Tretinoin orally divided over two daily doses for days 1 through 14 of a 28-day cycle
9856013|NCT03995784|Experimental|Intravenous Dose|Coagulation Factor IX variant, 50 IU/kg by intravenous route
9856014|NCT03995784|Experimental|Subcutaneous Dosing|Coagulation Factor IX variant, 100 IU/kg by subcutaneous route
9856015|NCT03993392|Experimental|TM buprenorphine followed by SUBLOCADE 300 mg|Participants with a diagnosis of OUD stopped use of their current opioid prior to coming to the clinic to be assessed for withdrawal symptoms. If confirmed to be in withdrawal, participants were administered 4 mg transmucosal (TM) buprenorphine. If tolerated without sensitivity, clinical signs of sedation, or precipitated withdrawal, 300 mg SUBLOCADE was administered. Following SUBLOCADE administration, participants remained in the clinic for approximately 48 hours and were assessed for safety and tolerability, as well as for any signs of precipitated withdrawal. Participants returned to the clinic weekly, until the end-of-treatment (EOT) visit (28 days after SUBLOCADE administration).
9856016|NCT03989427|Experimental|Brushing First and Flossing Later (BF)|The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
10208963|NCT04983420|Placebo Comparator|lemonade|1 L lemonade per day for 2 weeks
10208964|NCT04982003|Experimental|Single Group|A single group of subjects with pretest, posttest, and one-month follow-up testing relative to 10-week drumming exercise classes
9856017|NCT03989427|Experimental|Flossing First and Brushing Later (FB)|The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.
9856018|NCT03981822|Active Comparator|Part A: VP-102 2 hour-Active|For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.
9856019|NCT03981822|Active Comparator|Part A: VP-102 6-hour Active|For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
9856020|NCT03981822|Active Comparator|Part A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
9856021|NCT03981822|Placebo Comparator|Part A: Placebo|For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments.
9856022|NCT03981822|Active Comparator|Part B & A: VP-102 6 hour-Active|Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
9856023|NCT03981822|Placebo Comparator|Part B & A: 6-hour-Placebo|Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
9856024|NCT03981822|Active Comparator|Part B & A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
9856025|NCT03981822|Placebo Comparator|Part B & A: 24-hour-Placebo|Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
9856026|NCT03992482|Experimental|IVIG-Eye Drop|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
9856027|NCT03992482|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl)
9856028|NCT03993119||patients with NVAF|
9856029|NCT03991494|Experimental|Pamiparib|
9856030|NCT03989570|Experimental|Group I (A group)|31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
9856031|NCT03989570|Active Comparator|Group II (B group)|31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
9856032|NCT03989570|Placebo Comparator|Group III (C group)|31 patients anesthetized with the protocol followed by Minia University Hospital
9856033|NCT03988803|Experimental|All subjects|
9856034|NCT03987932|Experimental|NEAT!2|Participants will be asked to use the NEAT!2 app for 3 months after randomization. App use between 4-6 months is optional.
9856035|NCT03987932|Experimental|NEAT!2+Calls|Participants will be asked to use the NEAT!2 app for 3 months after randomization. In addition, participants will receive bi-weekly coaching calls over 3 months. App use between 4-6 months is optional.
9856036|NCT03987932|Other|Delayed NEAT!2|Participants will receive the NEAT!2 app to use between 3 and 6 months.
10208965|NCT04981626||Control|"Females~Age : matched for the AN group~No present or past eating disorders~No past or current psychotic disorders~No current substance abuse or dependence.~No current psychiatric medication"
10208966|NCT04981626||AN group|"Females~16 years ≤ Age ≤ 25 years~Diagnostic of AN according to DSM-5 criteria~No past or current psychotic disorders~No current substance abuse or dependence (excluding tobacco).~No current psychiatric medication"
10208967|NCT04978376|Experimental|Time restricted eating|ad-libitum eating between 12:00-20:00
10208968|NCT04978376|Experimental|TRE with endurance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised endurance exercise per week
10208969|NCT04978376|Experimental|TRE with resistance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised resistance training per week
10208970|NCT04978376|No Intervention|Control|no change in diet or physical activity
9856037|NCT03987191|Active Comparator|Standard of Care Transition|Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections
9856038|NCT03987191|Experimental|Inverstigational Transition|Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition
9856039|NCT03988842|Experimental|Alteplase & Unfractionated Heparin & Apixaban|Alteplase 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
9856040|NCT03988842|Active Comparator|Placebo & Unfractionated Heparin & Apixaban|Alteplase placebo solution 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
9856041|NCT03981861|Experimental|Overall Study|Treatment with Metformin and Spironolactone
9856042|NCT03974334|Experimental|OWL-Hypertension 8 Wk Trial|Two groups of thirteen participants will use the Our Whole Lives - Hypertension eHealth online tool for 8 weeks each, with baseline, midline, and follow-up data collected to determine any change due to the intervention.
9856043|NCT03988426|Experimental|Octanorm|Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center [during first training sessions and then for every 4th administration] or at home by the patient or caregiver). The initial weekly dose was determined based on subjects' previous IVIG treatment.
9856044|NCT03988374|Active Comparator|0% Baking Soda Dentifrice|
9856045|NCT03988374|Active Comparator|20% Baking Soda Dentifrice|
9856046|NCT03988374|Active Comparator|35% Baking Soda Dentifrice|
9856047|NCT03987074|Experimental|Semaglutide|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
9856048|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
9856049|NCT03987074|Experimental|Semaglutide + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
9856050|NCT03987074|Experimental|Semaglutide + Cilofexor 100 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
9856051|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
9856052|NCT03977935|No Intervention|The first-generation MCCG group|"The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the 360-degree automatic scanning mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the small-bowel mode. The magnetic steering time for passing through the pylorus was not allowed more than 15 min."
9856053|NCT03977935|Experimental|The second-generation MCCG group|All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.
9856054|NCT03988049|Active Comparator|1,550 laser|This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.
9856055|NCT03988049|Active Comparator|755 laser|This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.
9856056|NCT03979820|Experimental|10 mg BI 1467335/10 mg BI 1467335 + Tyramine|
9856057|NCT03979820|Experimental|15 mg BI 1467335/15 mg BI 1467335 + Tyramine|
9856058|NCT03979820|Active Comparator|Phenelzine/Phenelzine + Tyramine|
9856059|NCT03979820|Placebo Comparator|Placebo/Placebo + Tyramine|
9856060|NCT03972137|Experimental|Heart Rate Variability Biofeedback-Smoking Cessation Therapy|All participants in this open trial received individualized cognitive-behavioral smoking cessation treatment (SCT), up to 8 weeks of the transdermal nicotine patch (NRT) and individualized heart rate variability biofeedback (HRVB).
10208971|NCT04976049||Orthopedic infection|Subjects who have undergone previous trauma surgeries and have developed an infection will be assessed for protocol inclusion criteria. Patients will be administered a single, oral, 20mg/kg dose of 5-Aminolevulinic Acid (ALA) by a qualified member of their care team. This dose will be administered ideally 3 hours prior to surgery. Fluorescent imaging will be obtained pre and post irrigation and debridement.
10208972|NCT04975646|Experimental|Test group|Prescribed exercise program
10208973|NCT04975646|No Intervention|Control group|Exercising at patient's own discretion
10208974|NCT04972604||Duchenne and Becker muscular dystrophy|Individuals with Duchenne muscular dystrophy and Becker muscular dystrophy
10208975|NCT04972604||Carriers|Carriers of Duchenne muscular dystrophy and Becker muscular dystrophy
10208976|NCT04970199|Active Comparator|group 1|thirty lupus women received laser acupuncture (active) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was applied for 1 min on every acupiont).
10208977|NCT04970199|Sham Comparator|group 2|thirty lupus women received laser acupuncture (sham) for one month (3 days) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser was be applied for 1 min on every acupiont).
9856061|NCT03970395|Experimental|Osteopathic manipulative therapy|"Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits."
9856062|NCT03970395|Sham Comparator|Light Touch Therapy|"Repositioning Therapy plus Light Touch Therapy (LTT)~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group."
9856063|NCT03987620|Experimental|Ibrexafungerp (SCY-078)|300 mg BID for one day
9856064|NCT03987620|Placebo Comparator|Placebo|Matching Placebo
9856065|NCT03983317|No Intervention|Baseline|For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
9856066|NCT03983317|Experimental|Active treatment|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
9856067|NCT03985657|Active Comparator|Baseline Sleep Study|Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.
9856068|NCT03985657|Experimental|CPAP Sleep Study|Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.
9856069|NCT03981939||CD Participants with CPAF - The Ottawa Hospital (TOH)|Participants diagnosed with Complex Perianal Fistula (CPAF) from the Ottawa Hospital (TOH) were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
9856070|NCT03981939||CD Participants without CPAF (ICES database)|Participants diagnosed with CD and without CPAF from Institute for Clinical Evaluative Sciences (ICES) database who did not meet the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
9856071|NCT03981939||CD Participants with CPAF (ICES database)|Participants with CD and CPAF from ICES database who met the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
9856072|NCT03973905||Pertussis Case Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
9856073|NCT03973905||Control Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
9856074|NCT03984838|Experimental|Subjects receiving Dolutegravir and Rilpivirine FDC|Subjects will receive Dolutegravir/Rilpivirine 50mg/25mg fixed dose combination (FDC) tablet as a single oral dose in a fed state.
9856075|NCT03983941|Active Comparator|FNB-AC + Sciatic nerve block|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.
9856076|NCT03983941|Experimental|FNB-AC + IPACK|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)
10208978|NCT04969770|Experimental|Neuromuscular scoliosis|Minor patients with neuromuscular scoliosis and followed at Necker Hospital
10208979|NCT04969770|Other|Neuromuscular pathologies without instrumented scoliosis|Minor patients with neuromuscular pathology without instrumented scoliosis and followed at Necker Hospital
10208980|NCT04969770|Other|Controls|Minor patients without neuromuscular pathology or scoliosis and followed at Necker Hospital
9856077|NCT03976752|No Intervention|Pre-drug|Participants enrolled in the pre-drug arm will not receive any drug. At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
9856078|NCT03976752|Experimental|Genvoya - 2 and 48 hours specimen collection|Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
10208981|NCT04968366|Experimental|DC vaccine group|Subjects will receive five to eight doses of the DC vaccine through i.d. injection into regions near to the groin and axillary during they receive TMZ adjuvant chemotherapy
10208982|NCT04964128|Experimental|meal gesture dosing for unannounced meals within the AHCL System|
10208983|NCT04957524|Active Comparator|Set Amplitude|This arm is to test a specific amplitude. Participants will be instructed to set the amplitude to 20 mA, frequency to 20 Hz, and pulse duration to 5 mS. The parameters will stay the same for the entire session. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
9856079|NCT03976752|Experimental|Genvoya - 4 and 72 hours specimen collection|Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
9856080|NCT03976752|Experimental|Genvoya - 24 and 96 hours specimen collection|Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96 hours after taking the medication in the clinic (visit 5).
9856081|NCT03976752|Experimental|Genvoya - Single time point specimen collection|Specimen collection 8 hours after taking the medication in the clinic (visit 4).
9856082|NCT03984825|Experimental|Portia followed by Portia co-administered with GSK3640254|Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.
9856083|NCT03971721|Experimental|Wave Mattress Support|The mattress support will be delivered at the subject's home by professional staff of the sponsor (Hill-Rom) in the presence of the research coordinator or investigator. The subject will sleep on mattress support for the duration of study participation.
9856084|NCT03982433|Experimental|Intervention|participants all receive the intervention
9856085|NCT03979677|Experimental|Intervention Group|All participants will be provided written and verbal instructions regarding the lifestyle modification intervention.
9856086|NCT03976466|Experimental|Calcium sulfate Group|Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
9856087|NCT03976466|Active Comparator|Control Group|Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
9856088|NCT03979638|Experimental|BLU-5937 oral tablet BID|Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
9856089|NCT03979638|Placebo Comparator|Placebo oral tablet BID|Randomized crossover design of matching placebo tablets to be administered orally BID
9856090|NCT03979274|Experimental|Reference Eutirox®, then Test Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (mcg) (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
9856091|NCT03979274|Experimental|Test Eutirox®, then Reference Eutirox®|Participants received single oral dose of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Reference Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
9856092|NCT03979066|Active Comparator|Atezolizumab|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
9856093|NCT03979066|Experimental|Atezolizumab in combination with PEGPH20|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery in combination with PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
9856094|NCT03977727|Experimental|Fiasp/Novolog|7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
9856095|NCT03977727|Experimental|Novolog/Fiasp|7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
9856096|NCT03977155|Experimental|High dose of BOS-589|Participants will receive a high dose of BOS-589 orally twice a day (BID).
9856097|NCT03977155|Experimental|Low dose of BOS-589|Participants will receive a low dose of BOS-589 orally BID.
9856098|NCT03977155|Placebo Comparator|Placebo|Participants will receive matching placebo orally BID.
9856099|NCT03974802|Experimental|somofilcon A (habitual) lens, then fanfilcon A (test) lens|Participants are habitual wearers of somofilcon A lens and refitted with fanfilcon A lens.
9856100|NCT03970733|Experimental|VLA15 with Alum lower dose|Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued
9856101|NCT03970733|Experimental|VLA15 with Alum higher dose|Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo
9856102|NCT03970733|Placebo Comparator|Placebo|Main Study Phase: placebo - Booster Phase: arm discontinued
9856103|NCT03968978|Experimental|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
9856104|NCT03968978|Experimental|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
9856105|NCT03968848|Experimental|Subjects with Severe Hepatic Impairment|Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.
9856106|NCT03968848|Experimental|Matched-Control Subjects|Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.
9856107|NCT03967444|Other|Restylane Kysse|Hyaluronic acid
9856108|NCT03967444|Other|Restylane Kysse with other HA|Hyaluronic acid
9856109|NCT03966924|Experimental|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
9856110|NCT03966911|Other|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.
9856111|NCT03966365|Experimental|PRO-122|- Dosage: 1 drop every 12 hours, in both eyes
9856112|NCT03966365|Active Comparator|Krytantek Ofteno®|- Dosage: 1 drop every 12 hours, in both eyes
9923894|NCT00855608|Experimental|adalimumab arm|intravitreal mode of delivery
9923895|NCT00855621|Active Comparator|Single microelectrode|Surgical procedure performed using single microelectrode recording guidance intraoperatively
9856113|NCT03965403|Experimental|Arm motor function retraining with BURT|All participants will receive 1 hour sessions, 2-3x/week for 6 weeks (total 18 sessions). Sessions will be organized with 30 minutes of robotic-assisted training and 30 minutes of hands-on training with a research therapist to work on the baseline goals of the subject. Hands-on training will be done with routinely employed techniques in therapy to transfer the skills gained with the robotic device in everyday life activities.
9856114|NCT03965754||No email|No email will be sent out to this subset of GHP members during the week that the other emails are sent.
9856115|NCT03965754||Standard email reminder|The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
9856116|NCT03965754||Social norms email|The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
9856117|NCT03965754||Loss framing|"The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action."
9856118|NCT03965533|Placebo Comparator|Part A: Placebo IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of 0.9% weight by volume (w/v) saline placebo.
9856119|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of GSK2831781 at a dose of 450 milligram (mg), diluted in 0.9% w/v saline.
9856120|NCT03965533|Placebo Comparator|Part A: Placebo IV- Japanese Participants|Japanese male participants were administered a single IV infusion of 0.9% w/v saline placebo.
9856121|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Japanese Participants|Japanese male participants were administered a single IV infusion of GSK2831781 at a dose of 450 mg, diluted in 0.9% w/v saline.
9856122|NCT03965533|Placebo Comparator|Part B: Placebo SC|Caucasian male participants were administered three SC injections of 0.9% w/v saline placebo.
9856123|NCT03965533|Experimental|Part B: GSK2831781 150 mg SC|Caucasian male participants were administered a single SC injection of a unit dose strength of 150 mg per milliliter (mL) of GSK2831781, diluted in 0.9% w/v saline. Participants also received 2 dummy injections of 0.9% w/v saline placebo SC to maintain the blinding.
9856124|NCT03965533|Experimental|Part B: GSK2831781 450 mg SC|Caucasian male participants were administered three SC injections of a unit dose strength of 150 mg per mL of GSK2831781 to achieve a dose of 450 mg.
9856125|NCT03965351|Experimental|Probenecid|the study medication (probenecid) as well as a placebo.
9856126|NCT03965351|Placebo Comparator|Placebo|placebo compared to probenecid
9856127|NCT03964220||Patients with Asthma|
9856128|NCT03958955|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 6 weeks
9856129|NCT03958955|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 6 weeks
9856130|NCT03965052|Experimental|PRO-179|Dosage: 1 drop every 24 hours, at night, in both eyes.
9856131|NCT03965052|Active Comparator|Travatan®|Dosage: 1 drop every 24 hours, at night, in both eyes.
9856132|NCT03965039|Active Comparator|Marketed stannous fluoride toothpaste|Brush twice daily
9856133|NCT03965039|Active Comparator|Marketed potassium nitrate toothpaste|Brush Twice Daily
9856134|NCT03965039|Placebo Comparator|Marketed sodium monofluorophosphate toothpaste|Brush Twice Daily
9856135|NCT03965039|Experimental|Experimental dipotassium oxalate toothpaste|Brush Twice Daily
9856136|NCT03963401|Experimental|PF-06700841 60 mg once daily|PF-06700841 60 mg once daily for 52 weeks
9856137|NCT03963401|Experimental|PF-06700841 30 mg once daily|PF-06700841 30 mg once daily for 52 weeks
9856138|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 60 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
9856139|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 30 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
9856140|NCT03963401|Placebo Comparator|Placebo once daily followed by 60 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
9856141|NCT03963401|Placebo Comparator|Placebo once daily followed by 30 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
9856142|NCT03962634|Experimental|Kovanaze Nasal Spray (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
9856143|NCT03962634|Active Comparator|Articaine Injections (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth
9856144|NCT03962790|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
9856145|NCT03962790|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
9856146|NCT03956225|Experimental|iLux|Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes will be treated.
9856147|NCT03956225|Active Comparator|LipiFlow|Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes will be treated.
9856148|NCT03951610|Experimental|Test lens|Subjects wearing the test lens for one week, either randomized as the first or second pair.
10208984|NCT04957524|Experimental|Customizable Amplitude|In this arm, the participant will set the frequency to 12 Hz and pulse duration to 1 millisecond. The participant will be instructed to increase the amplitude gradually and set it at the maximal tolerable amplitude. This stimulation will last 15 minutes and patients will be instructed to perform the at-home therapy once per day.
9856149|NCT03951610|Active Comparator|Control lens|Subjects wearing the control lens for one week, either randomized as the first or second pair.
9856150|NCT03958149|Other|Spinal collar|Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.
9856151|NCT03953183|Other|P3P-1mg|Subjects randomized to exclusive use of P3P-1mg
9856152|NCT03953183|Other|P3P-2mg|Subjects randomized to exclusive use of P3P-2mg
9856153|NCT03949335|Experimental|Investigational|Bilateral implantation with investigational IOL Model ZFR00V
9856154|NCT03949335|Active Comparator|Control|Bilateral implantation with control IOL Model ZCB00
9856155|NCT03962738|Experimental|50 milligram (mg) Lasmiditan|50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
9856156|NCT03962738|Experimental|100 mg Lasmiditan|100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
9856157|NCT03962738|Experimental|200 mg Lasmiditan|200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
9856158|NCT03962738|Placebo Comparator|Placebo|Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
9856159|NCT03962101|Experimental|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
9856160|NCT03959137||Primary study group|Stage IV untreated NSCLC
9856161|NCT03946124|Other|Fesoterodine|Subjects (irrespective of preference) will receive a 90-day supply of open label fesoterodine 4 mg per day. Medication will start 1 week after the baseline visit. After 2 weeks of treatment, dose may be increased to 8 mg over the telephone based on symptom report. This dosing regimen is direct alignment with clinical care. Change of prescription to another anti-cholinergic may occur during the study period, if determined necessary by the physician.
9856162|NCT03961308|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
9856163|NCT03961308|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
9856164|NCT03961295|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
9856165|NCT03961295|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
9856166|NCT03960957|Experimental|Experimental|AbobotulinumtoxinA
9856167|NCT03960957|Placebo Comparator|Placebo|
10208985|NCT04957394|Experimental|Experimental (Family Partner)|The treatment group will receive six hours follow-up and support weekly. The service will be provided by a dedicated Family Partner.
10208986|NCT04957394|No Intervention|Control group|"The control group will receive defult support from the child welfare services. The service will be business as usual, provided by the local staff at the child welfare services."
10208987|NCT04952493|Experimental|anlotinib + RAI|Patients in this arm will receive anlotinib 6 cycles around RAI treatment ( 4 cycles before and 2 cycles after RAI)
10208988|NCT04952493|Other|RAI only|Patients in this arm will receive RAI treatment as scheduled.
10208989|NCT04952493|Experimental|Penpulimab + RAI|Patients in this arm will receive Penpulimab from one week prior to RAI treatment until the disease progressed or intolerable.
10208990|NCT04951245|Experimental|UC group|Ultrasound-assisted CNSs guided SLN mapping
10208991|NCT04951245|Active Comparator|GC group|CNSs plus ICG dual-tracer-guided SLN mapping
10208992|NCT04947293|Experimental|Yoga Exercise|Subjects in the experimental group will be invited to participate in 60-minute yoga sessions twice a week for 12 weeks. Each session will include postural (asanas), breathing (pranayama), and meditative exercises. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, blankets, blocks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support.
9856168|NCT03956862|Experimental|GB001|GB001 40 mg once per day (QD) for 16 weeks
9856169|NCT03956862|Placebo Comparator|Placebo|Placebo QD for 16 weeks
9856170|NCT03954444|Active Comparator|Oxymetazoline hydrochloride Cream, 1%|Oxymetazoline hydrochloride cream, 1%
9856171|NCT03954444|Active Comparator|RHOFADE Cream, 1%|RHOFADE Cream, 1%
9856172|NCT03954444|Placebo Comparator|Vehicle Cream|Vehicle cream
9856173|NCT03953820|Experimental|Diazepam Buccal Film, Then Diastat Rectal Gel|Participants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
9856174|NCT03953820|Experimental|Diastat Rectal Gel, Then Diazepam Buccal Film|Participants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
9856175|NCT03953820|Experimental|Diazepam Buccal Film following a High-Fat Meal|Participants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.
9856176|NCT03951766|Other|Smiling Instead of Smoking App|This is a pilot study; all participants will use the app in the same manner/time period.
9923896|NCT00855621|Active Comparator|Multiple microelectrode|Surgical procedure performed using multiple microelectrode recording guidance intraoperatively
9856177|NCT03961100|Experimental|Part 1|Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
9856178|NCT03961100|Experimental|Part 2|Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.
9856179|NCT03950856|Experimental|V114 Lot 1|Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)
10208993|NCT04947293|Active Comparator|Fitness and mobility exercise|Subjects in the control group will be invited to participate in more conventional exercise sessions, based on a fitness and mobility exercise (FAME) program, 60-minute per sessions twice a week for 12 weeks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support. The effectiveness of this program has already been demonstrated in previous studies.
10208994|NCT04945746|Experimental|Software VX1 + Stability|Utilization of the software VX1 + Stability
10208995|NCT04942457|Experimental|Fasting|Participants will be councelled and accompanied to follow a prolonged fasting regime of 7-10 days in an outpatient setting under medical supervision.
9856180|NCT03950856|Experimental|V114 Lot 2|Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)
9856181|NCT03950856|Experimental|V114 Lot 3|Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)
9856182|NCT03950856|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
9856183|NCT03947983|Experimental|Intervention Group|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
9856184|NCT03947983|Active Comparator|Control group|The control group will receive only the weight monitoring and physical activity sensors
9856185|NCT03960658|Experimental|Ketamine and PE|ketamine treatment followed by a standardized prolonged exposure session for the first 3 weeks; then, weekly prolonged exposure as usual.
9856186|NCT03959332|Experimental|Baloxavir Marboxil 40 mg|
9856187|NCT03959332|Experimental|Baloxavir Marboxil 80 mg|
9856188|NCT03959189|Experimental|ERX-963 then placebo|Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.
9856189|NCT03959189|Experimental|Placebo then ERX-963|Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.
9856190|NCT03956550|Experimental|REGN5069 Low Dose|Randomized in a 1:1:1 ratio
9856191|NCT03956550|Experimental|REGN5069 High Dose|Randomized in a 1:1:1 ratio
9856192|NCT03956550|Experimental|Matching Placebo|Randomized in a 1:1:1 ratio
9923897|NCT00855634|Active Comparator|1|"COHORT 1 (minimal metastatic disease):~Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases~Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy"
9923898|NCT00855634|Active Comparator|2|"COHORT 2 (venous infiltration):~Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)~Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection"
9923899|NCT00855660|Active Comparator|Riociguat|Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
9923900|NCT00855660|Placebo Comparator|Placebo|Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
9923901|NCT00855673|Experimental|Active|Active group receiving intermittent compression
9923902|NCT00855673|Active Comparator|Control|Standard Medical Treatment
9923903|NCT00855686|Experimental|Memantine|
9923904|NCT00855686|Placebo Comparator|Placebo|
9923905|NCT00855777|Experimental|Etoricoxib|Etoricoxib 120 mg/day x 3 days
9923906|NCT00855777|Active Comparator|Ibuprofen|Ibuprofen 1800 mg/day x 3 days
9923907|NCT00855790|Active Comparator|RJ3 Biopsy Forcep|use of RJ3 Biopsy forcep for the polypectomy
9923908|NCT00855790|Active Comparator|RJ4 Biopsey Forcep|Use of RJ$ biopsy forcep for polypectomy
9923909|NCT00855829|Active Comparator|Miniature Actilady device active|one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
9923910|NCT00855829|Sham Comparator|Miniature Actilady device not active|Sham Comparator: one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
10208996|NCT04942457|No Intervention|Control group|waiting list, usual diet should be maintained
10208997|NCT04935489|Experimental|Patients receiving accelerated rTMS|
10208998|NCT04935047|Experimental|Experimental (Multilingual Support)|The treatment group will receive seven hours multilingual support weekly.
10208999|NCT04935047|No Intervention|Control group|The control group will receive the same amount of support as the experimental group, but from a person without multilingual qualifications.
10209000|NCT04933773|Experimental|Set averaging times: 2-4 seconds and 8 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 2-4 seconds, the second pulse oximeter is set to an averaging time of 8 seconds.
9923911|NCT00855881|Experimental|Treatment arm|Treated with tegafur-uracil for 1 year
9856193|NCT03954158|Experimental|Crisaborole ointment 2% once daily (QD) vs vehicle QD|intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
9856194|NCT03954158|Experimental|Crisaborole ointment 2% twice daily (BID) vs vehicle BID|Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
9856195|NCT03958656|Experimental|1/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Dose Escalation|Patients will receive escalating doses (up to 4 planned) of Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)-CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^22 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
10209001|NCT04933773|Experimental|Set averaging times: 8 seconds and 16 seconds|SpO2 is measured by two pulse oximeters on one participant's hand (on the index finger and middle finger). One pulse oximeter is set to an averaging time of 8 seconds, the second pulse oximeter is set to an averaging time of 16 seconds.
10209002|NCT04924881|Experimental|Active Arm|COVID Rehab Formula granules once daily for 8 weeks
9856196|NCT03958656|Experimental|2/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Expansion Phase|Maximum tolerated dose (MTD) dose of Anti-Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)- CAR T Cells + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
9856197|NCT03955133|Experimental|intervention|This is a single arm before and after study with data collection at 4 time points.
9856198|NCT03954626|Experimental|RTH258|Intravitreal injection
9856199|NCT03951805|Experimental|Insulin 287 algorithm A|Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
9856200|NCT03951805|Experimental|Insulin 287 algorithm B|Controlled on metformin with or without DPP4i and with or without SGLT2i.
9856201|NCT03951805|Experimental|Insulin 287 algorithm C|Controlled on metformin with or without DPP4i and with or without SGLT2i.
9856202|NCT03951805|Active Comparator|Insulin Glargine algorithm D|Controlled on metformin with or without DPP4i and with or without SGLT2i.
9856203|NCT03944785||Parkinson's Disease Patients|PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert
9856204|NCT03950622|Experimental|V114|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
9856205|NCT03950622|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
9856206|NCT03949621|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
9856207|NCT03949621|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
9856208|NCT03949244|Active Comparator|Latanoprost 0.005%|Latanoprost 0.005% drops to the nailfold.
9856209|NCT03949244|Experimental|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% drops to the nailfold.
9856210|NCT03949244|Placebo Comparator|Normal saline 0.9%|Normal saline 0.9% to the nailfold.
9856211|NCT03948581|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
9856212|NCT03948581|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
9856213|NCT03948386|Active Comparator|isobaric bupivacaine|"Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for > 74 height"
9856214|NCT03948386|Active Comparator|hyperbaric bupivacaine|"hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for > 74 height"
9856215|NCT03948386|Active Comparator|isobaric mepivacaine|"isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for > 74 height"
10209003|NCT04924881|Placebo Comparator|Placebo Arm|Placebo granules once daily for 8 weeks
10209004|NCT04924387|Experimental|Experimental Group (EXP group)|The experimental group (EXP Group) is going to follow a programme of stabilisation through specific therapeutic exercises of the lumbopelvic centre. Two weekly sessions will be programmed for 12 weeks, making a total of 24 sessions. Each sesión will have a duration of 60 minutes, the first 5 minutes for a warm-up and the last 10 for a cool-down phase of active stretching. All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercices will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercies of 2-3 minutes.
10209005|NCT04924387|Active Comparator|Experimental Group and Manual Therapy (MT Group)|Additionally to the core exercises previously exposed in Group EXP, Group MT will lay on the stretcher first, where the physiotherapist will work on a manual therapy thrust. The patient will receive an impulse technique in lateral decubitus position, with high velocity and low range on both sides.
10209006|NCT04924387|Active Comparator|Experimental Group and Kinesio Tape (KT Group)|"The experimental group plus kinesio tape (KT Group) will go previously through physiotherapy, where a kinesio tape band will be applied (kinesio tape Nondolens 5cm x 5cm black color), in Y technique, by applying the KT base in neutral position of the lumbar spine without any tension on the tape."
10209007|NCT04923958|Experimental|Evaluation of various novel TB triage and diagnostic tests.|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 1500 patients, including 300 people living with HIV and 300 people with diabetes, for evaluation of various novel TB triage and diagnostic tests.
10209008|NCT04923958|Experimental|Evaluation of novel rDST assays|Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 200 patients for evaluation of novel rDST assays.
9856216|NCT03948334|Experimental|ZPL389 30mg|30mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
9856217|NCT03948334|Experimental|ZPL389 50mg|50mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
9856218|NCT03946059|Experimental|iTBS then cTBS|"Participants in this arm first receive the iTBS brain stimulation in week 1, then have a one-week washout period and then receive cTBS brain stimulation in week 2.~intermittent Theta-Burst-Stimulation (iTBS) entails a 2 second train of stimuli (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). Each 2 second train is followed by an 8 second pause, followed by another 2 second train. In total, 20 trains will be delivered, for a total of 200 bursts and 600 total pulses.~continuous Theta-Burst-Stimulation (cTBS) consists of a continuous stimulus train (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). In total, 200 bursts and 600 total pulses will be delivered."
9856219|NCT03946059|Experimental|cTBS then iTBS|Participants in this arm first receive the cTBS brain stimulation in week 1, then have a one-week washout period and then receive iTBS brain stimulation in week 2.
9856220|NCT03944707|Experimental|LOU064|LOU064 100 mg once daily orally
9856221|NCT03944707|Placebo Comparator|Placebo|Placebo once daily orally
9856222|NCT03944668|Experimental|Intervention|Exercise intervention
9856223|NCT03943095|Experimental|Test Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 5 % weight by weight (w/w) potassium nitrate and 0.454% w/w stannous fluoride (1100 parts per million [ppm] fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
9856224|NCT03943095|Active Comparator|Control Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
9856225|NCT03943290|Experimental|Part 1 Cohort 1a|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for FSHD patients
9856226|NCT03943290|Experimental|Part 1 Cohort 1b|ACE-083 240 mg/muscle administered bilaterally by injection into the BB muscle every 4 weeks for up to 6 doses for FSHD patients
9856227|NCT03943290|Experimental|Part 1 Cohort 1c|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for CMT patients
9856228|NCT03943290|Experimental|Part 2 Cohort 2a|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for FSHD patients
9856229|NCT03943290|Experimental|Part 2 Cohort 2b|ACE-083 Administered into the BB muscle q4w for up to 24 months (24 doses) for FSHD patients
9856230|NCT03943290|Experimental|Part 2 Cohort 2c|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for CMT patients
9856231|NCT03943290|Experimental|Part 2 Cohort 3a|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for FSHD patients
9856232|NCT03943290|Experimental|Part 2 Cohort 3b|ACE-083 Administered into the BB muscle q8w for up to 24 months (12 doses) for FSHD patients
9856233|NCT03943290|Experimental|Part 2 Cohort 3c|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for CMT patients
9856234|NCT03942042|Experimental|Ixekizumab|"Induction Dosing Period:~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.~Maintenance Dosing Period:~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1."
9856235|NCT03938337|Experimental|Cohort 1 Not Previously Treated|Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
9856236|NCT03938337|Experimental|Cohort 2 Treated Previously|Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
9856237|NCT03923530|Experimental|Eplerenone|Eplerenone 50 mg daily, administered orally for 8 weeks.
9856238|NCT03914417|Experimental|Imiquimod 3.75% cream|applied topically
9856239|NCT03913377|Experimental|Observational|Eligible subjects that are habitual spectacle wearers will use their habitual optical correction and undergo ocular evaluations and questionnaires at the baseline and 1-week visit.
9856240|NCT03913377|Experimental|Interventional|Eligible subjects that are habitual contact lens wearers who own spectacles will be randomized into 1 of 2 sequences (Spectacle/ACUVUE OASYS 1-Day or ACUVUE OASYS 1-Day/Spectacle)
9856241|NCT03937791|Experimental|Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells|1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.
9856242|NCT03937778|Experimental|Tourniquet block to left upper arm|Participants underwent ~10 minutes of baseline testing followed by a tourniquet placement to left upper arm and inflated to 80-100 mmHG above systolic blood pressure. Participants repeatedly rated a variety of sensory stimuli after tourniquet was placed. Participants rated intensity and pleasantness of slow brushing and deep pressure on both hands/forearms at baseline and after loss of A-beta sensation.
9856243|NCT03937479|Experimental|RPL554 0.375 mg twice daily|RPL554 0.375 mg twice daily
9856244|NCT03937479|Experimental|RPL554 0.75 mg twice daily|RPL554 0.75 mg twice daily
9856245|NCT03937479|Experimental|RPL554 1.5 mg twice daily|RPL554 1.5 mg twice daily
9856246|NCT03937479|Experimental|RPL554 3.0 mg twice daily|RPL554 3.0 mg twice daily
9856247|NCT03937479|Placebo Comparator|Placebo twice daily|Placebo twice daily
9856248|NCT03936387|Experimental|Bilateral erector spinae blocks|Bilateral erector spinae block catheters are placed at end of the sternotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. Patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH.
9856249|NCT03935399|Other|Oxytocin first, then saline placebo|Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day
9856250|NCT03935399|Placebo Comparator|Saline placebo first, then oxytocin|Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day
9856251|NCT03936608|Experimental|Individualized RV-LV Pacing Offset|
9856252|NCT03936608|Active Comparator|No RV-LV Pacing Offset|
10209009|NCT04923555|Experimental|Group/Cohort1|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in cysteine, leucine and arginine (VP, vegetable proteins) only once during the visit
10209010|NCT04923555|Experimental|Group/Cohort2|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt rich in animal proteins (AP) only once during the visit
9856253|NCT03936244|Active Comparator|M-TURP|The M-TURP procedure requires the use of a resectoscope (Olympus or Storz, 26Ch), camera system and irrigation fluid (Glycine 1.5%, Baxter). The system consists of a generator unit (ForceTriadTM, Medtronic) and a stainless steel loop with an electrical current running through the loop used to cut (120W) prostate tissue and cauterize (80W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
9856254|NCT03936244|Experimental|PK-TURP|The PK-TURP procedure requires the use of a resectoscope (Storz, 26Ch), camera system and irrigation fluid (NaCl 0.9%, Baxter). The system consists of a generator unit (PlasmaKineticTM Superpulse de Gyrus, ACMI) and a platinum-iridium superloop with an electrical current running through the loop used to cut (180W) prostate tissue and cauterize (100W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
9856255|NCT03935126||All patients|
9856256|NCT03928327|Experimental|Part 1, Treatment Sequence AB|TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments.
9856257|NCT03928327|Experimental|Part 2, Treatment Sequence CD|TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
9856258|NCT03933462|Experimental|InnoSpire Go|The InnoSpire Go is a handheld, single patient use, vibrating mesh nebulizer system designed to aerosolize liquid medications for respiratory disease. The device operates continuously once initiated and automatically switches off once the medication has been delivered. The device may be used in pediatric and adult populations, as permitted by the prescribed medication, and is suitable for use in home environments or hospital/clinic settings.
9856259|NCT03933462|Active Comparator|Jet Nebulizer|Jet Nebulizers are the standard delivery system for aerosolized medications. A nebulizer breaks up medical solutions into small droplets suspended in air (aerosol) so that they may be delivered to the patient's airways for respiratory therapy.
9856260|NCT03933774|Experimental|Tretinoin 0.05% cream group|Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
9856261|NCT03933774|Placebo Comparator|Placebo|PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night
9856262|NCT03931330|Experimental|Percutaneous neurostimulation|Subjects will have 4 weeks of active therapy.
9856263|NCT03918811|Experimental|Positive Pressure Extubation Technique|ETT is removed in PSV 15/10 mode and without endotracheal suction.
9856264|NCT03918811|Active Comparator|Traditional Extubation Technique|ETT is removed with continuous endotracheal suction
9856265|NCT03933618|Other|anastrazole-clomiphene-placebo|anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks
9856266|NCT03933618|Other|anastrazole-placebo-clomiphene|anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks
9856267|NCT03933618|Other|clomiphene-anastrazole-placebo|clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks
10209011|NCT04923555|Placebo Comparator|Group/Cohort3|33 subjects aged 65 years old with predisposition to cardiometabolic syndrome will consume 400ml of yogurt without any proteins (T) only once during the visit
10209012|NCT04917315|Experimental|JLP-2002|Drug: JLP-2002
10209013|NCT04917315|Placebo Comparator|Placebo|Drug: Placebo
10209014|NCT04916340|Experimental|Muscular Strength|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular strength
10209015|NCT04916340|Experimental|Muscular fitness|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular fitness
10209016|NCT04908436|Experimental|Normal renal function|Healthy participants with creatinine clearance (CLCR) >80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
10209017|NCT04908436|Experimental|Mild renal impairment|Participants with CLCR 50-80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
10209018|NCT04908436|Experimental|Moderate renal impairment|Participants with CLCR 30-<50 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
10209019|NCT04908436|Experimental|Severe renal impairment|Participants with CLCR <30 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
10209020|NCT04906330||PPHM-0000-21|50-70 year old female patients, without a personal history of oncological pathology, who attend for gynecological and mammographic control.
10209021|NCT04903015|Experimental|professional Soccer players|
10209022|NCT04903015|Active Comparator|athletes not exposed to head injuries.|
10209023|NCT04901715|Active Comparator|Genotypes associated mild phenotype|Subjects with 2 confirmed mutations in RSPH1, Radial Spoke Head Component 9 (RSPH9), Radial Spoke Head Component 4A (RSPH4a), or Dynein Axonemal Heavy Chain 11 (DNAH11). This group may also include subjects with mutations in newly identified genes that are associated with a milder clinical phenotype.
9856268|NCT03933618|Other|clomiphene-placebo-anastrazole|clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks
9856269|NCT03933618|Other|placebo-clomiphene-anastrazole|placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks
9856270|NCT03933618|Other|placebo-anastrazole-clomiphene|placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks
9856271|NCT03931785|Experimental|MD-7246 300 μg|1 MD-7246 300-μg oral tablet and 3 matching placebo oral tablets
9856272|NCT03931785|Experimental|MD-7246 600 μg|2 MD-7246 300-μg oral tablets and 2 matching placebo oral tablets
9856273|NCT03931785|Experimental|MD-7246 1200 μg|4 MD-7246 300-μg oral tablets
9856274|NCT03931785|Placebo Comparator|Placebo|4 matching placebo oral tablets
9856275|NCT03930641|Experimental|RTH258|brolucizumab 6 mg in a prefilled syringe
9856276|NCT03927846|Active Comparator|Telephone Contact (Nurse)|6 regular telephone contacts by nurses who will use a motivational interviewing technique
9856277|NCT03927846|Active Comparator|E-mail contact|6 computer generated email reminders (control arm) over an 8-week period.
9856278|NCT03927105|Experimental|Nivolumab + Cabiralizumab|Nivolumab 240mg IV + Cabiralizumab 4mg/kg on day 1 of every 14 day cycle.
9856279|NCT03923933|Placebo Comparator|Placebo|This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
9856280|NCT03923933|Experimental|Treatment grup|This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.
10209024|NCT04901715|Active Comparator|Genotypes associated with severe phenotype|Subjects with 2 confirmed mutations in DNAH5, Dynein Axonemal Intermediate Chain 1 (DNAI1), Coiled-Coil Domain Containing 39 (CCDC39), or Coiled-Coil Domain Containing 40 (CCDC40). This group may also include subjects with mutations in newly identified genes that are associated with a more severe clinical phenotype.
10209025|NCT04888767|No Intervention|Control group|Patients benefiting from the usual re-training sessions
10209026|NCT04888767|Experimental|ITHI Group|Patients benefiting from ITHI re-training sessions
10209027|NCT04887597|Experimental|Secukinumab Treatment|all patients receive Secukinumab as well as a biopsy before and after treatment
10209028|NCT04887415|Experimental|Respiratory strength training|Enrolled cardiac surgical patients will undergo 4 weeks of preoperative respiratory strength training using two respiratory strength training devices.
9856281|NCT03909295|Experimental|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
9856282|NCT03908970|Experimental|1% OPA-15406|Twice daily
9856283|NCT03908970|Placebo Comparator|Placebo|Twice daily
9856284|NCT03897179|Experimental|INVSENSOR00032 and INVSENSOR00033 test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00032 and/or INVSENSOR00033 device.
10209029|NCT04885829|Experimental|DRL_TC|Subcutaneous injection of DRL's Tocilizumab
9856285|NCT03930264|Active Comparator|Imurek®,|Generic name : Azathioprine Trade name : Imurek® 50mg tablet Dosage form : Tablet containing 50 mg azathioprine Dose : 1 x Imurek 50mg Tablet per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Aspen Pharma Trading Limited, Dublin, Ireland Country of origin : Ireland
9856286|NCT03930264|Experimental|Jayempi™|"Generic name : Azathioprine~Trade name : (Jayempi™) 10 mg/ mL Oral solution Dosage form : Oral suspension containing 10 mg/mL Azathioprine Dose : 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Nova Laboratories Ltd. Country of origin : Leicester, UK"
9856287|NCT03929367|Other|Oxytocin (Pitocin®), 10 IU|Oxytocin 10 IU administered once per intravenous injection
9856288|NCT03928522|Active Comparator|Pre-mixed tobramycin|patients will receive pre-mixed tobramycin cement
9856289|NCT03928522|Active Comparator|hand mixed tobramycin|patients will receive hand mixed tobramycin cement
10209030|NCT04885829|Active Comparator|RP and RMP|Subcutaneous injection of Actemra and RoActemra (Commercially available Tocilizumab)
10209031|NCT04885322|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
10209032|NCT04885322|Experimental|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
10209033|NCT04885322|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
10209034|NCT04884308|Experimental|Cystic Fibrosis|Participants with Cystic Fibrosis.
10209035|NCT04884308|Experimental|Non Cystic Fibrosis Bronchiectasis|Participants with Non Cystic Fibrosis Bronchiectasis.
10209036|NCT04884308|Active Comparator|Healthy Volunteer|Participants with no condition (healthy volunteers).
10209037|NCT04882631|Experimental|Cumulative Irritation Test|Participants will receive topical applications of three concentrations of PBI-100 Topical Cream, one application of vehicle, one application of sodium lauryl sulfate as a positive control and one application of a plain patch as a negative control daily (excluding weekends) for 21 days or 15 applications.
10209038|NCT04882150|Experimental|Part A: SAD|SAD = single ascending dose. Each participant will receive a single dose of BMS-986196 or placebo.
9856290|NCT03928522|Active Comparator|hand mixed vancomycin|patients will receive hand mixed vancomycin cement
9856291|NCT03928522|Experimental|hand-mixed vancomycin and tobramycin|patients will receive hand mixed vancomycin and tobramycin
9856292|NCT03910439|Experimental|1/Avelumab 800 mg intravenous (IV) every two weeks in combination with radiation therapy|Avelumab 800 mg IV every two weeks in combination with radiation therapy
9856293|NCT03907241|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
9856294|NCT03927950|Experimental|Escitalopram bupropion open-label|No comparator
9856295|NCT03927781|Experimental|Pregabalin 300mg|300mg pregabalin, PO, once, 1 hr before surgery
9856296|NCT03927209|Experimental|BI 1467335 (low dose)|
9856297|NCT03927209|Experimental|BI 1467335 (high dose)|
9856298|NCT03920670|Experimental|Tetragraph (TG)|TetraGraph placed on dominant hand, ToFscan placed on non-dominant hand
9856299|NCT03920670|Active Comparator|ToFscan (TS)|ToFscan placed on dominant hand, TetraGraph (TG) placed on non-dominant hand
9856300|NCT03919422|Active Comparator|IC group|Interscalene brachial plexus-Cervical plexus
9856301|NCT03919422|Experimental|ICTP group|Interscalene brachial plexus-Cervical plexus combined with T2 Paravertebral blockade
9856302|NCT03907579|Experimental|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.
9856303|NCT03905811|Experimental|Active|Terazosin administered 5 mg once daily p.o. for 12 weeks
9856304|NCT03905811|Placebo Comparator|Placebo|Placebo administered once daily p.o. for 12 weeks
9856305|NCT03898063|Active Comparator|Control|participants will receive a standard-of-care brochure detailing HIV status disclosure.
9856306|NCT03898063|Experimental|intervention: 90 DAYS film|participants will watch the film, 90 DAYS
9856307|NCT03895307|Experimental|kinesio taping|two 15 cm I type kinesio tape applied longitudinally
9856308|NCT03895307|Placebo Comparator|sham kinesio taping|two 15 cm I type kinesio tape applied longitudinally but without stretching
9856309|NCT03895307|Experimental|local anesthetic|18-20 cc %0.5 lidocaine subcutaneous injection
9856310|NCT03895307|Placebo Comparator|local serum physiologic|18-20 cc % 0.09 NaCl subcutaneous injection
9856311|NCT03926208|Active Comparator|Control|Subjects in this group will receive the standard chlorhexadine prep of the foot (standard of care) prior to surgery, and a cotton swab will be collected from the hallux nail fold.
9856312|NCT03926208|Experimental|Soak and Scrub|In addition to the standard chlorhexadine prep of the foot prior to surgery, subjects in this group will also receive a betadine soak and scrub of the foot, and a cotton swab will be collected from the hallux nail fold.
9856313|NCT03926065|Experimental|Standard Palatability and Standard Portion Size|Vegetables with Standard Palatability and Standard Portion Size
9856314|NCT03926065|Experimental|Standard Palatability and Larger Portion Size|Vegetables with Standard Palatability and Larger Portion Size
9856315|NCT03926065|Experimental|Enhanced Palatability and Standard Portion Size|Vegetables with Enhanced Palatability and Standard Portion Size
9856316|NCT03926065|Experimental|Enhanced Palatability and Larger Portion Size|Vegetables with Enhanced Palatability and Larger Portion Size
9856317|NCT03909100|Experimental|CoolSculpting® System|Participants received up to two CoolSculpting® treatment sessions for the abdomen, flanks or both 8 weeks apart. A treatment session was comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage. Up to 12 cycles per treatment session were performed at the investigator's discretion.
9856318|NCT03905642|Experimental|560 mg Arikayce™|Subjects in this cohort will receive 560 mg of Arikayce™
9856319|NCT03892889|Experimental|Abilify MyCite®|Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.
9856320|NCT03921723|Experimental|Subject receiving Dolutegravir 10 mg|Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of >= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
9856321|NCT03921190|Active Comparator|Open-mouth|Patients receiving maxillary buccal infiltration anesthesia (MBIA) with their mouth wide open
9856322|NCT03921190|Experimental|Closed-mouth|Patients receiving MBIA using a closed-mouth technique
9856323|NCT03920865|Experimental|Part 1|Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
9856324|NCT03920865|Experimental|Part 2|Participants with moderate hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
9856325|NCT03918239|Experimental|SHP643 Prefilled Syringe (PFS)|Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
9856326|NCT03918239|Experimental|SHP643 Autoinjector (AI)|Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
9856327|NCT03917823|Experimental|Cryoneurolysis (active)|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
10209039|NCT04882150|Experimental|Part B: MAD|MAD = multiple ascending dose. Each participant will receive multiple doses of BMS-986196 or placebo.
10209040|NCT04882150|Experimental|Part C: FE/Formul.|FE/Formul. = food and formulation effects and relative absorption. Participants will receive two formulations of BMS-986196 (solution and suspension), each formulation with and without food.
10209041|NCT04880707|Active Comparator|Twin Block with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
9856328|NCT03917823|Sham Comparator|Sham|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
9856329|NCT03911752||People with Acquired Brain Injury|People with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=8).
9856330|NCT03911752||Partners of people with Acquired Brain Injury|Partners of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
9856331|NCT03911752||Relatives of people with Acquired Brain Injury|Relatives of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
9856332|NCT03902613|Experimental|Lurasidone|Open-label treatment with lurasidone within the dose range of 20-60 mg daily
9856333|NCT03902574|Experimental|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
9856334|NCT03902574|Experimental|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
9856335|NCT03902574|Experimental|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
9856336|NCT03914950|Other|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen (in case of already performed diagnostic CT of the abdomen < 2 weeks ago) with 2 phases, 1 - 4 mSv, ca. 20 sec., 1 x~Contrast medium (Iodixanol 550 mg/ml) 1 x 1.4 ml/kg body weight i.v. for 40 sec, 1 x if creatinine, GFR, and TSH levels are within the normal range~1 x 500 ml water oral, 1 x~Biopsy or FNA (fine-needle aspiration) or operation of the pancreas"
9856337|NCT03911843|Experimental|CASES|Of eligible subjects, 26/64 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months
9856338|NCT03911843|Active Comparator|CONTROLS|Others 38/64 subjects joined to the study as data contributors, and were entered as controls (CONTR).
9856339|NCT03896633|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
9856340|NCT03896633|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
9856341|NCT03894813|Experimental|Probiotics and Metronidazole|Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
9856342|NCT03894813|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories(1 suppositories,qd,7 days )
9856343|NCT03911960|Experimental|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of Acceptance and Commitment Therapy for tobacco cessation plus up to 8 weeks of nicotine patch.
9856344|NCT03911960|Active Comparator|Enhanced Usual Care|2 in-person sessions of tobacco cessation counseling, electronic referral to state quitline, up to 8 weeks of nicotine patch
9856345|NCT03907072|Experimental|WVE-210201 (3 mg/kg)|Weekly IV administrations of WVE-210210 at 3 mg/kg
9856346|NCT03907072|Experimental|WVE-210201 (4.5 mg/kg)|Weekly IV administrations of WVE-210210 at 4.5 mg/kg
9856347|NCT03907072|Placebo Comparator|Placebo|Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021
9856348|NCT03906448|Experimental|Astrocytoma Patients|Patients newly diagnosed with Grade II and III astrocytoma.
9856349|NCT03906448|No Intervention|Control Arm|Data collection from medical record only
9856350|NCT03911401|Experimental|0.3% OPA-15406|Twice daily
9856351|NCT03911401|Experimental|1% OPA-15406|Twice daily
9856352|NCT03911401|Placebo Comparator|Placebo|Twice daily
9856353|NCT03909763|Experimental|Berberine plus danazol|Berberine plus danazol group
9856354|NCT03909009|Active Comparator|Active rTMS|Group 1 will receive high frequency repetitive transcranial magnetic stimulation (10hz-HF-rTMS) A total 14 sessions of HF-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
9923912|NCT00855907||cases|IBD patients above the age of 18 years old, suffering from the disease for at least one year.
9856355|NCT03909009|Sham Comparator|Sham rTMS|Group 2 will receive sham stimulation. A total 14 sessions of sham-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
9856356|NCT03906968|Experimental|SinuSonic Device|SinuSonic Device used twice a day for four to six weeks.
9856357|NCT03904420|Experimental|Group A - New Model|Standardized programming and testing method
9856358|NCT03904420|Active Comparator|Group B - Traditional Model|Traditional clinical model which is not standardized across clinical sites
9856359|NCT03903822|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
9856360|NCT03903822|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
9856361|NCT03903822|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
9856362|NCT03903822|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
9856363|NCT03903822|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
9856364|NCT03903822|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
9856365|NCT03903822|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
9856366|NCT03903822|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
9856367|NCT03905096|Experimental|Part 1|
9856368|NCT03905096|Experimental|Part 2|
9856369|NCT03899064|Experimental|Induction:MC2-01 Cream, irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
9856370|NCT03899064|Experimental|Induction: MC2-01 Cream, no irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
9856371|NCT03899064|Experimental|Induction: MC2-01 vehicle, irradiation|Applications with MC2-01 vehicle, followed by irradiation
9856372|NCT03899064|Experimental|Induction: MC2-01 vehicle, no irradiation|Applications with MC2-01 vehicle, no irradiation
9856373|NCT03899064|Experimental|Challenge: MC2-01 Cream, irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
9856374|NCT03899064|Experimental|Challenge: MC2-01 Cream, No irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
9856375|NCT03899064|Experimental|Challenge: MC2-01 vehicle, irradiation|Application with MC2-01 vehicle, followed by irradiation
9856376|NCT03899064|Experimental|Challenge: MC2-01 vehicle, no irradiation|Application with MC2-01 vehicle, no irradiation
9856377|NCT03899064|Experimental|Challenge: Control, irradiation|No application, but irradiation
9856378|NCT03894969|Experimental|Sh_NTHi-Mcat_1 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
9856379|NCT03894969|Experimental|Sh_NTHi-Mcat_3 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.
9856380|NCT03894969|Experimental|Sh_NTHi-Mcat_6 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.
9856381|NCT03894969|Active Comparator|NTHi-Mcat Group|Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
9856382|NCT03894969|Experimental|Shingrix-Only Group|Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.
9856383|NCT03903159|Other|Treatment Group|Positive Peer Journaling (PPJ)
9856384|NCT03902392|Active Comparator|NATUR-OX Group (A)|Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
9856385|NCT03902392|Placebo Comparator|Placebo Group (B)|Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
9856386|NCT03901105|Experimental|Flortaucipir PET Scan|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.
9856387|NCT03895853|Active Comparator|Group I (standard of care)|Patients receive standard of care for septic shock.
9856388|NCT03895853|Experimental|Group II (early metabolic resuscitation)|Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.
9856389|NCT03901313|Experimental|Sequence ABC|Healthy volunteers will receive Treatments A, then B, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
9856390|NCT03901313|Experimental|Sequence ACB|Healthy volunteers will receive Treatments A, then C, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
9856391|NCT03901313|Experimental|Sequence BAC|Healthy volunteers will receive Treatments B, then A, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
9856392|NCT03901313|Experimental|Sequence BCA|Healthy volunteers will receive Treatments B, then C, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
10209042|NCT04880707|Placebo Comparator|Twin Block with sterile normal saline|Following lower third molar extraction under intravenous sedation, the patient randomized to this arm with receive the Twin block using sterile normal saline, on the day after extraction, if the patient has pain greater than or equal to 5 on 10 in their jaw-closer muscles (Numerical Pain rating scale).
10209043|NCT04877392|No Intervention|Control (usual measures to control pain)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure.
10209044|NCT04877392|Experimental|Case (usual measures to control pain plus inhaled lavender essential oil)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure. The neonate also had a 7 x 7 cm gauze pad with 1 drop (43.75 mg) of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under their nose for 2 minutes prior to starting the frenotomy and for the duration of the procedure.
9856393|NCT03901313|Experimental|Sequence CAB|Healthy volunteers will receive Treatments C, then A, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
9856394|NCT03901313|Experimental|Sequence CBA|Healthy volunteers will receive Treatments C, then B, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
9856395|NCT03901092|Experimental|Flortaucipir PET Scan|Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
9856396|NCT03895034|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
9856397|NCT03900728|Active Comparator|Auriculotherapy with needles (acupuncture) + usual care|A designated trained therapist will perform auriculotherapy with 1mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place until removal at the 1-week follow-up visit
9856398|NCT03900728|Active Comparator|Auriculotherapy with gold beads (acupressure) + usual care|A designated trained therapist will perform auriculotherapy with beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place until removal at the 1-week follow-up visit.
9856399|NCT03900728|Sham Comparator|Placebo group + usual care|A designated trained therapist will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place until removal at the 1-week follow-up visit.
9856400|NCT03900299|Other|oncoplastic breast surgery|
9856401|NCT03898349|No Intervention|Non-Texters|"Patients did not receive the automated text messaging system Annie"
9856402|NCT03898349|Active Comparator|Texters|Patients received the Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
9856403|NCT03897634|Experimental|Experiences Hearing Aid user|Single arm study, all participants in this arm. Participants will be experienced hearing aid users.
9856404|NCT03895372|Experimental|PF-06826647 Drug Dose Level 1|Delivered orally for 16 weeks during the Investigational Treatment Period
9856405|NCT03895372|Experimental|PF-06826647 Placebo|Delivered orally for 16 weeks during the Investigational Treatment Period
9856406|NCT03895372|Experimental|PF-06826647 Drug Dose Level 2|Delivered orally for 16 weeks during the Investigational Treatment Period
10209045|NCT04876599|Experimental|Intervention (IN FOCUS)|Participants will be randomly assigned and participate in approximately eight weekly virtual group sessions to learn mind-body, cognitive behavioral, and positive psychology skills.
10209046|NCT04876599|Active Comparator|Usual Care|Participants will be randomly assigned and receive usual care, which is a referral for virtual group supportive services for cancer survivors provided in the community.
9856407|NCT03895372|Experimental|PF-06826647 Drug Dose Level 3|Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
9856408|NCT03895372|Experimental|PF-06826647 Drug Dose Level 4|Delivered orally for 16 weeks then for 24 weeks in Extension Period.
9923913|NCT00855985|Active Comparator|1|Pancreaticojejunostomy for reconstruction after pancreaticoduodenectomy
9923914|NCT00855985|Active Comparator|2|Pancreaticogastrostomy for reconstruction after pancreaticoduodenectomy
9923915|NCT00855998||1|With BRCA1 or BRCA2 mutations
9923916|NCT00855998||2|Without BRCA1 or BRCA2 mutations
9923917|NCT00856011||1|Diabetic patients with carpal tunnel syndrome
10209047|NCT04876105||Acute-subacute group|According to the duration of low back pain, it is classified as acute pain if it lasts less than a month, subacute pain if it lasts for 1-3 months.
10209048|NCT04876105||Chronic group|According to the duration of low back pain, it is classified as chronic pain if it lasts for more than 3 months.
10209049|NCT04874545|Experimental|Propofol group|Maintenance of anaesthesia will be done using Propofol total intravenous anesthesia (TIVA) 6-12 mg/ kg/h by syringe pump, 100 % O2.
9856409|NCT03896022|Active Comparator|Auriculotherapy - Acupressure with Gold Beads|A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
9856410|NCT03896022|Active Comparator|Auriculotherapy - Acupuncture with Pyonex Needles|A designated trained auriculotherapy provider will place 1.2mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
9856411|NCT03896022|Sham Comparator|Placebo Group|A designated trained auriculotherapy provider will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
9856412|NCT03891862|Experimental|Open-label Valbenazine|Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.
9856413|NCT03891862|Placebo Comparator|Placebo-controlled Placebo|Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
9856414|NCT03891862|Experimental|Placebo-controlled Valbenazine|Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
9856415|NCT03894449|Placebo Comparator|Placebo only|
9856416|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt FeSO4|
9856417|NCT03894449|Experimental|Prebiotic GOS & Iron Salt FeSO4|
9856418|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt NaFeEDTA|
9856419|NCT03894449|Experimental|Prebiotic GOS & Iron Salt NaFeEDTA|
9856420|NCT03892564|Experimental|MC2-01 Cream, irradiation|One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation
9856421|NCT03892564|Experimental|MC2-01 Cream, no irradiation|One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
9856422|NCT03892564|Experimental|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
9856423|NCT03892564|Experimental|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
9856424|NCT03892564|Experimental|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
9856425|NCT03892707||NSAIDs group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
9856426|NCT03892707||NSAIDs+Milgamma+Milgamma compositum group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum
9856427|NCT03892460|Experimental|Treatment|Neuromuscular electrical stimulation
9856428|NCT03892460|No Intervention|Control|No treatment control
9856429|NCT03891641|Experimental|Treadling Group|Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks.
9856430|NCT03891641|No Intervention|Control Group|Control Subjects continue their normal daily activities.
9856431|NCT03889704|Experimental|Neuromuscular electrical stimulation|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
9856432|NCT03889444||OZURDEX®|Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.
9856433|NCT03888755|Experimental|Icatibant|Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.
9856434|NCT03888391|Experimental|Active TNS|Participants will receive trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for up to 12 months of this open-extension trial.
9856435|NCT03888482|Other|DDT2, then Clariti|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
9856436|NCT03888482|Other|Clariti, then DDT2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
9856437|NCT03888274|Experimental|Active|
9856438|NCT03888365||Cohort A: Treprostinil|Participants who are currently prescribed and using inhaled treprostinil for the treatment of PAH.
9856439|NCT03888365||Cohort B: Non-Treprostinil PAH Medications|Participants who are taking other PAH medications (instead of inhaled treprostinil).
9856440|NCT03888469|Other|DDT2, then 1DAVM|Verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
9856441|NCT03888469|Other|1DAVM, then DDT2|Etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
9856442|NCT03887442|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
9856443|NCT03887442|Experimental|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
9856444|NCT03887286|Experimental|treatment group|All participants to receive standard transthoracic echocardiogram and hand held echocardiogram
9856445|NCT03881007|Experimental|LCM, then placebo|Mouthwash with LCM for 3 months followed by mouthwash with placebo for 3 months.
9856446|NCT03881007|Experimental|Placebo, then LCM|Mouthwash with placebo for 3 months followed by mouthwash with LCM for 3 months
9856447|NCT03878602|Active Comparator|Control Group|Newborns will be subjected to umbilical cord immediate clamping
9856448|NCT03878602|Experimental|Study Group|Newborns will be subjected to umbilical cord delayed clamping
9856449|NCT03875118|Experimental|The intervention group|Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
9856450|NCT03875118|Active Comparator|The control group|Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
9856451|NCT03873987|Active Comparator|Current Formulation of Oritavancin|Three single-use vials, each containing 400 mg (1200 mg total) of oritavancin diphosphate (as the free base) and the inactive component mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted in D5W for a total volume of 1000 mL and infused intravenously over 3 hours.
9856452|NCT03873987|Experimental|Kimyrsa|A single vial containing 1200 mg of oritavancin, HPβCD, and mannitol. Kimyrsa vials will be reconstituted with SWFI and further diluted with 0.9% sodium chloride for a total volume of 250 mL and infused intravenously over 1 hour.
9856453|NCT03870893|Experimental|Intervention group|Intervention is administered to patients in this Arm.
9856454|NCT03870893|No Intervention|control group|No intervention
9856455|NCT03887299|Placebo Comparator|Standard Wound Care|Wound dressing and care as per our current practice. Compression dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively. Dressing will be removed after 24 hours from surgery completion and subjects will have an absorption pad with overlying garments for the remaining postoperative days until standard postoperative visit for wound check.
9856456|NCT03887299|Active Comparator|CHG Wound Care|ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's instructions intraoperatively. The dressing will be in place until the postoperative clinic visit on postoperative day 7.
9856457|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 33G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2
9856458|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 34G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2
9856459|NCT03878758|Experimental|BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™|Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2
9856460|NCT03849300|No Intervention|Control Group|No exercise intervention
9856461|NCT03849300|Experimental|Aquatic walking exercise group 1|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
9856462|NCT03849300|Experimental|Aquatic walking exercise group 2|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
9923918|NCT00856011||2|Non-diabetic patients with carpal tunnel syndrome
9856463|NCT03849300|Active Comparator|Land-based walking exercise group|"The land-based walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of low-intensity forward, backward, and lateral side-stepping movements on flat group. The remaining 30 minutes included treadmill walking exercise.~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
9856464|NCT03887429|Experimental|SXC-2023 200 mg followed by placebo|SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
9856465|NCT03887429|Experimental|Placebo followed by SXC-2023 200 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
9856466|NCT03887429|Experimental|SXC-2023 800 mg followed by placebo|SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
9856467|NCT03887429|Experimental|Placebo followed by SXC-2023 800 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
9856468|NCT03886701|Experimental|Experimental|Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)
9856469|NCT03883113|Experimental|MVA-NP+M1 & H3N2 Challenge Virus|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
9856470|NCT03883113|Placebo Comparator|Saline Placebo & H3N2 Challenge Virus|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
9856471|NCT03880227|Experimental|Anodal followed by sham stimulation tDCS to rTPJ|cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.
9856472|NCT03880227|Active Comparator|Anodal followed by sham stimulation tDCS to dmPFC|cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.
9856473|NCT03880227|Experimental|Sham followed by anodal stimulation tDCS to rTPJ|cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.
9856474|NCT03880227|Active Comparator|Sham followed by anodal stimulation tDCS to dmPFC|cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.
9856475|NCT03876743|Experimental|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
9856476|NCT03876743|Experimental|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
9856477|NCT03876743|Experimental|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
9856478|NCT03876743|Experimental|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
9856479|NCT03885934|Experimental|V114, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL intramuscular (IM) injection for 7 to 11 months of age (Pneumococcal conjugate vaccine [PCV]-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
9856480|NCT03885934|Active Comparator|Prevnar 13®, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL IM injection for 7 to 11 months of age (PCV-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
9856481|NCT03885934|Experimental|V114, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
9856482|NCT03885934|Active Comparator|Prevnar 13®, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
9856483|NCT03885934|Experimental|V114, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced) (1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
9856484|NCT03885934|Active Comparator|Prevnar 13®, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced)(1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
9856485|NCT03885726|Active Comparator|Treatment as Usual|
9856486|NCT03885726|Experimental|High Velocity Nasal Insufflation|
9856487|NCT03885154|Active Comparator|Valproic Acid|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
9856488|NCT03885154|Active Comparator|Dihydroergotamine|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
10209050|NCT04874545|Active Comparator|sevoflurane group|Maintenance of anaesthesia will be done using sevoflorane1.5-2%, 100 % O2.
9856489|NCT03885154|Active Comparator|Cross-Over to Dihydroergotamine|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
9856490|NCT03885154|Active Comparator|Cross-Over to Valproic Acid|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
9856491|NCT03883386|Experimental|Loratadine first|Take treatment daily for 7 days.
9856492|NCT03883386|Placebo Comparator|Placebo first|Take placebo daily for 7 days.
9856493|NCT03882528|Experimental|Infective controls|Controlled Human Malaria Infection (CHMI) will consist of exposure to Plasmodium falciparum sporozoites through the bites of infected mosquitoes. Beginning 5 days after the challenge, subjects will be evaluated daily for the development of malaria infection using a blood smear.
9856494|NCT03882801|Experimental|Sequence 1: Placebo -> Gefapixant|In Period 1, participants receive a single oral dose of placebo matching gefapixant (MK-7264) every night at bedtime (QHS), for 7 days. In Period 2, participants receive a single oral dose of gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
9856495|NCT03882801|Experimental|Sequence 2: Gefapixant -> Placebo|In Period 1, participants receive a single oral dose of gefapixant (MK-7264) QHS for 7 days. In Period 2, participants receive a single oral dose of placebo matching gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
9856496|NCT03882424|Experimental|TRS003|Proposed biosimilar of bevacizumab，Intravenous administration
9856497|NCT03882424|Active Comparator|China-approved Bevacizumab|Intravenous administration
9856498|NCT03882424|Active Comparator|US-licensed Avastin|Intravenous administration
9856499|NCT03881163|Experimental|Single dose regime of N-acetylcysteine (NAC)|On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.
9856500|NCT03881163|Experimental|Multiple dose regime of N-acetylcysteine (NAC)|On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.
10209051|NCT04874441|No Intervention|blood culture-based diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy
10209052|NCT04874441|Experimental|C. glabrata / krusei PCR diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata / krusei PCR
10209053|NCT04870281||CRT-DX System|
10209054|NCT04864678||Young people who are experiencing or at risk of homelessness|Young people aged 15-24 years who have accessed a homeless youth service, refuge, or flexible learning center in Melbourne, Australia.
10209055|NCT04854993|Experimental|Increased dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
10209056|NCT04854993|Active Comparator|Standard dose of sugammadex|A dose of 6 mg/kg of sugammadex will be given intravenously for deep neuromuscular block reversal at the end of surgery
10209057|NCT04854941|Experimental|Probiotics group (PRO)|99 patients with COVID-19 infection who have been supplemented with a Lactobacillus and Bifidobacterium containing probiotic in addition to standard regimen (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
10209058|NCT04854941|No Intervention|Control group (CON)|101 patients with COVID-19 infection who have been treated with standard regimen only (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
10209059|NCT04853641||Living Donor Liver Transplant Recipient|Patients who have received a living donor liver transplant.
10209060|NCT04853641||Deceased Donor Liver Transplant Recipient|Patients who have received either a Deceased by Circulatory Death or Deceased by Brain Death Liver Transplant
10209061|NCT04852029|Active Comparator|Control Group|to remain on current dose of low dose hCG
9856501|NCT03881670|Placebo Comparator|Lotrafilcon B|
9856502|NCT03881670|Active Comparator|Lotrafilcon B Hydraluxe|
9856503|NCT03880266|Active Comparator|Group 1 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
10209062|NCT04852029|Experimental|Intervention Group|increased dose of low dose hCG prescribed
10209063|NCT04851834|Experimental|NTX-301 Monotherapy Dose Escalation|NTX-301 monotherapy dose escalation in patients with advanced solid tumours
10209064|NCT04851834|Experimental|NTX-301 platinum-based doublet therapy Dose Escalation|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian & bladder cancer
10209065|NCT04851834|Experimental|NTX-301 platinum-based doublet therapy Dose Expansion|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian & bladder cancer
10209066|NCT04851834|Experimental|NTX-301 Temozolomide doublet therapy Dose Escalation|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
9856504|NCT03880266|Placebo Comparator|Group 1 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
9856505|NCT03880266|Active Comparator|Group 2 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
9856506|NCT03880266|Placebo Comparator|Group 2 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
9856507|NCT03880266|Active Comparator|Group 3 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes
9856508|NCT03880266|Placebo Comparator|Group 3 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes
9856509|NCT03880266|Active Comparator|Group 4 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes
9856510|NCT03880266|Placebo Comparator|Group 4 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes
9856511|NCT03856320|No Intervention|Usual Care|Patient attends a MOVE! visit (weight management visit).
9856512|NCT03856320|Experimental|Intervention|Patient attends a MOVE! visit (weight management visit) and watches an educational video describing obesity treatment options available in the VA.
10209067|NCT04851834|Experimental|NTX-301 Temozolomide doublet therapy Dose Expansion|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
9856513|NCT03848871|Experimental|Enstilar foam|Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
9856514|NCT03880474|Experimental|MVA-NP+M1|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.)
9856515|NCT03880474|Placebo Comparator|Saline Placebo|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)
9856516|NCT03878160|Other|Women and Men, <2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS within the past 2 years and have elevated depression symptoms.
9856517|NCT03878160|Other|Women and Men, >2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS greater than 2 years ago and have elevated depression symptoms.
9856518|NCT03878160|Other|Women and Men, Lifetime History of ACS, Individual Interview|Individual interviews for women and men who have experienced an ACS at some point in their life and do not have elevated depression symptoms.
9856519|NCT03864627|Placebo Comparator|Placebo|Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1, 15, 29 and 43 given concomitantly with a medium potency TCS once daily until Day 57.
9856520|NCT03864627|Experimental|MOR106 320 mg|Participants will receive MOR106 320 milligrams (mg) via s.c. injection every other week on Day 15, 29 and 43 given concomitantly with a medium potency topical TCS once daily until Day 57. A loading dose of MOR106 2 x 320 mg via s.c. injection will be administered on Day 1.
10209068|NCT04848870||Sjögren patients|Patients in specialized consultations for Sjögren's patients in the oral medicine department of the Charles Foix Hospital AP-HP France
9856521|NCT03861000|Experimental|Whole body PET Scan with intravenous 11C-T-1650|10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.
9856522|NCT03861000|Experimental|Brain PET scan with 11C-T-1650 and blocking with BPN14770|Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.
9856523|NCT03848403|Experimental|Ixekizumab (Reference)|Reference formulation 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection in a prefilled syringe in one of three study periods.
9856524|NCT03848403|Experimental|Ixekizumab (Test 1)|Test 1 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
9856525|NCT03848403|Experimental|Ixekizumab (Test 2)|Test 2 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
9856526|NCT03847233|Experimental|Jetstream Atherectomy System|
9856527|NCT03879603|Experimental|Group 1: 6 mcg WEVEE vaccine|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
9856528|NCT03879603|Experimental|Group 2: 6 mcg WEVEE vaccine + alum|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
9856529|NCT03879603|Experimental|Group 3: 30 mcg WEVEE vaccine|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
9856530|NCT03879603|Experimental|Group 4: 30 mcg WEVEE vaccine + alum|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
9856531|NCT03879603|Experimental|Group 5: 60 mcg WEVEE vaccine|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
9856532|NCT03879603|Experimental|Group 6: 60 mcg WEVEE vaccine + alum|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
9856533|NCT03878745|Experimental|BD Nano™ PRO 32G pen needle|Participants are to perform 6 pairs of injections.
9856534|NCT03878745|Active Comparator|Terumo Nanopass® 34G pen needle|Participants are to perform 6 pairs of injections.
9856535|NCT03848221|Experimental|Systane Complete|Subjects in this group will use Systane Complete before, during, and after contact lens use.
9856536|NCT03848221|Active Comparator|Sensitive Eyes Rewetting Drops|Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
9856537|NCT03848221|No Intervention|No Treatment|Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
9856538|NCT03878108|Active Comparator|LCHF diet then LFHC diet|Low carbohydrate, high fat (LCHF) diet then low fat, high carbohydrate diet (LFHC) diet
9856539|NCT03878108|Active Comparator|LFHC diet then LCHF diet|Low fat, high carbohydrate diet (LFHC) diet then low carbohydrate, high fat (LCHF) diet
9856540|NCT03877432|Experimental|Dermatome stimulation|Check the effect of improving the function of bladder storage and bladder capacity before and after dermatome stimulation.
9856541|NCT03877237|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
9856542|NCT03877237|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
9856543|NCT03866434|Experimental|SPD422 + Omeprazole|Participants will receive 1 milligram (mg) of SPD422 (Anagrelide hydrochloride) (2*0.5 mg) capsule orally on Day 1 in fasted state (10 hours prior to and until 4 hours following administration of anagrelide), followed by 40 mg of Omeprazole capsule orally once daily (prior to breakfast) on Days 2 to Day 7, followed by 1 mg of Anagrelide in fasted state in combination with Omeprazole 40 mg on Day 8.
9856544|NCT03863210|Experimental|Participants who received informations about lifestyle change|
9856545|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.2 mg/kg|Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.
9856546|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.5 mg/kg|Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.
9856547|NCT03859323|Experimental|Single Ascending Dose (SAD): 1 mg/kg|Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.
9856548|NCT03859323|Experimental|Single Ascending Dose (SAD): 2 mg/kg|Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.
9856549|NCT03859323|Experimental|Single Ascending Dose (SAD): 4 mg/kg|Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.
9856550|NCT03859323|Placebo Comparator|Single Ascending Dose (SAD): Placebo|Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.
9856551|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.2 mg/kg|Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
9856552|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.5 mg/kg|Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
9856553|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 1 mg/kg|Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
9856554|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 2 mg/kg|Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
9856555|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 4 mg/kg|Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
9856556|NCT03859323|Placebo Comparator|Multiple Ascending Dose (MAD): Placebo|Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.
9856557|NCT03867838|Experimental|Stroke survivors|Stroke survivors with upper extremity motor impairments
9856558|NCT03855059|Placebo Comparator|Placebos|Depending on the randomization, this group will receive a saline solution either in the IV catheter or the saline solution will be given perineural with the Mepivicaine nerve block solution.
9856559|NCT03855059|Active Comparator|Dexamethasone Sodium Phosphate|Depending on the randomization, this group will receive dexamethasone 0.1 - 0.15 mg/kg, either in the IV catheter or the dexamethasone, 0.1 - 0.15 mg/kg will be given perineural with the Mepivicaine nerve block solution.
9856560|NCT03852537|Active Comparator|Usual Care|Usual care as determined by the patient's primary team.
9856561|NCT03852537|Experimental|Biomarker-adjusted Steroid Dosing|Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP < 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level > 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).
9856562|NCT03875859|Experimental|Remetinostat|Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.
9856563|NCT03875508|Experimental|Risankizumab|Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28
9856564|NCT03869333|Experimental|Invaplex[AR-Detox] 2.5 μg|Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
9856565|NCT03869333|Experimental|Invaplex[AR-Detox] 10 μg|Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
9856566|NCT03869333|Experimental|Invaplex[AR-Detox] 25 μg|Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
9856567|NCT03869333|Placebo Comparator|Placebo|Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.
9856568|NCT03864900|Experimental|The intervention group|The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
9856569|NCT03864900|No Intervention|The control group|Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
9856570|NCT03863795||Observational (survey)|Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
9856571|NCT03875482|Experimental|Risankizumab|Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
9856572|NCT03875482|Placebo Comparator|Placebo|Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16
9856573|NCT03874377|Experimental|Mindfulness|The mindfulness intervention consists of 6 weekly sessions, blending material from the evidence-based Learning to BREATHE and Mindfulness-Based Eating Awareness Training manualized interventions. Sessions will focus on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.Participants in this arm will also receive the usual care provided by the weight management clinic.
9856574|NCT03863496|Other|Neuromuscular scoliosis|Efficacy of Surgical Treatment by Different Pedicle Screw Systems in Pediatric Neuromuscular Spinal Deformity
9856575|NCT03874013|Experimental|MOD-4023 Treatment Arm|MOD-4023 (investigational treatment): weekly MOD-4023 SC injections for 12 months; initially over the first 6 weeks, MOD-4023 will be administered in 3 stepwise escalating doses (0.25 mg/kg/week, 0.48 mg/kg/week and 0.66 mg/kg/week), each for two weeks sequentially. For the remaining 46 weeks, patients will continue to receive MOD-4023 at a dose of 0.66 mg/kg/week.
10209069|NCT04846036|Experimental|Sonlicromanol|Paediatric-equivalent dose (as determined by Physiologically Based Pharmacokinetics (PBPK) modelling and the results of the Adaptive PK study) of sonlicromanol twice daily administered as an oral liquid for 26 weeks
10209070|NCT04846036|Placebo Comparator|Placebo|Matching placebo twice daily orally for 26 weeks
9856576|NCT03874013|Active Comparator|Genotropin Treatment Arm|Genotropin® (reference treatment): daily Genotropin® (0.025 mg/kg/day).
9856577|NCT03873116|Experimental|BCX7353 110mg once daily|BCX7353 capsules administered orally once daily
9856578|NCT03873116|Experimental|BCX7353 150mg once daily|BCX7353 capsules administered orally once daily
9856579|NCT03873116|Placebo Comparator|Placebo|Matching placebo oral capsules administered orally once daily
9856580|NCT03872843|Active Comparator|Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.
9856581|NCT03872843|Active Comparator|Non-Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.
9856582|NCT03870997|Experimental|Diabetes Digital Intervention|
9856583|NCT03870997|Experimental|Generic Digital Intervention|
9856584|NCT03870997|No Intervention|No Influenza Vaccination Intervention|
9856585|NCT03869684|Experimental|MT-0814 High dose|
9856586|NCT03869684|Experimental|MT-0814 Low dose|MT-0814 plus placebo
9856587|NCT03869684|Placebo Comparator|Placebo|
9856588|NCT03861338|Experimental|sublocade|Sublocade buprenorphine extended-release (BXR) injection, 300 mg and 100 mg
10209071|NCT04842630|Experimental|SHR-1916|
10209072|NCT04835415|Active Comparator|group T|Group (T) (n=26): will receive ultrasound guided thoracic epidural analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
10209073|NCT04835415|Active Comparator|group R|Group (R) (n=26): will receive bilateral ultrasound guided retrolaminar block analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
10209074|NCT04830488|Experimental|Body Image after Head and Neck Cancer Treatment|
10209075|NCT04829461|Experimental|Ambu® aScope™ 4 Cysto|Ureteral stent removal procedure performed with Ambu® aScope™ 4 Cysto (single-use cystoscope).
10209076|NCT04829461|Active Comparator|Standard of Care (SOC)|Ureteral stent removal procedure performed with standard of care (reusable cystoscope).
10209077|NCT04827979|Experimental|Cohort 1 (N=5 Subjects)|"Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:~Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.~Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%."
10209078|NCT04827979|Experimental|Cohort 2 (N=10 Subjects)|"The enrollment of ten additional subjects is dependent on the results in Cohort 1.~Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:°~Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.~Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%.~May be modified based on the safety and efficacy analysis of Cohort 1."
10209079|NCT04824092|Experimental|Tafasitamab plus lenalidomide in addition to R-CHOP|"Patients will receive tafasitamab plus lenalidomide in addition to R-CHOP for six 21-day cycles:~Tafasitamab dose: 12 mg/kg body weight. Each 21-day cycle (cycles 1-6) will comprise of a tafasitamab IV infusion on Day 1, Day 8 and Day 15.~Lenalidomide dose: 25 mg as a starting dose per os (orally) once per day on Days 1-10 of each 21-day cycle~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
10213565|NCT03798678|Experimental|Treatment (CB-839 HCI, dexamethasone, carfilzomib)|Patients receive glutaminase inhibitor CB-839 Patients receive glutaminase inhibitor CB-839 hydrochloride PO every 12 hours on days 1-28, dexamethasone PO on days 1, 2, 8, 9, 15, 16, and 23, and carfilzomib IV over 10 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
10213566|NCT03795246|Experimental|Study Process|Consultation, Biological Test, Pelvic Ultrasound
9856589|NCT03858335|Experimental|Constraint-induced movement therapy|Children in constraint-induced movement therapy (CIMT) group will wear forearm splint on the unaffected arm 24 hours for 3 weeks, and receive 15 mCIMT sessions(30-hour dosage)
9856590|NCT03858335|No Intervention|Control|Children in control group will receive only traditional rehab therapies without wearing splint
9856591|NCT03857243|Experimental|dTDCS plus physical therapy|active dual transcranial direct current stimulation (TDCS) arm (M1-M1)
9856592|NCT03857243|Placebo Comparator|Sham dTDCS plus physical therapy|Non-effective dose dual TDCS stimulation arm, identical with intervention arm except for the stimulation intensity/duration used.
9856593|NCT03851744|Active Comparator|Sea Level|Carbohydrate metabolism measured at SL
9856594|NCT03851744|Experimental|High Altitude|Carbohydrate metabolism measured at HA
9856595|NCT03849937|Experimental|Intervention|Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
9856596|NCT03849937|Active Comparator|Waitlist Control|After the intervention group takes the training, the waitlist control group will crossover and take the training.
9856597|NCT03848416|Experimental|Ixekizumab (Reference)|Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.
9856598|NCT03848416|Experimental|Ixekizumab (Test 1)|Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
9856599|NCT03848416|Experimental|Ixekizumab (Test 2)|Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
9856600|NCT03847987|Experimental|Part 1|Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses.
9856601|NCT03847987|Experimental|Part 2|Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses.
9856602|NCT03854253|Experimental|Long introducer 6Fr-25cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using long introducer sheath 6Fr-25cm
9856603|NCT03854253|Active Comparator|Short introducer 6Fr-10cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using short introducer sheath 6Fr-10cm
9856604|NCT03870737|Experimental|Active TNS|Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.
9856605|NCT03860181|Active Comparator|Traditional Dermabond + subcuticular sutures - Surgeon 1|Subcuticular sutures with traditional Dermabond applied to incision.
9856606|NCT03860181|Active Comparator|Metal staples - Surgeon 2|Metal staples
9856607|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 1|Dermabond PRINEO System
9856608|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 2|Dermabond PRINEO System
9856609|NCT03856944|Experimental|ReSTOR Toric|Patients will be bilaterally implanted, with the Toric ReSTOR +2.5D model implanted in the dominant eye and the Toric ReSTOR +3.0D model implanted in the non-dominant eye. Patients will self-select for multifocal implantation.
9856610|NCT03853551|Experimental|Single|Single arm
9856611|NCT03870555|Experimental|Sequence 1|"Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
9856612|NCT03870555|Experimental|Sequence 2|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
9856613|NCT03870555|Experimental|Sequence 3|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period."
9856614|NCT03861845|Active Comparator|Standard off-the-shelf pillbox|Participants will engage in reflection on medication routines. Then they will receive a standard off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
9856615|NCT03861845|Experimental|Custom off-the-shelf|Participants will engage in reflection on medication routines. Then they will receive a custom off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
9856616|NCT03861845|Experimental|Custom designed and manufactured|Participants will engage in reflection on medication routines. Then they will receive a custom designed and manufactured pillbox. Finally, the participants will receive education & training on how to use the pillbox.
9856617|NCT03851094|No Intervention|Standard of Care (Group A)|Standard of care is dictated by the HME normal practices for new CPAP patients.
9856618|NCT03851094|Experimental|Wellth App (Group B)|Intervention is use of the Wellth app during the initial compliance period.
9856619|NCT03869450|Experimental|Restylane Volyme|According to the treatment algorithm, treated with Restylane Volyme
9856620|NCT03869450|Experimental|Restylane Defyne|According to the treatment algorithm, treated with Restylane Defyne
9856621|NCT03869450|Experimental|Restylane Lyft Lidocaine|According to the treatment algorithm, treated with Restylane Lyft Lidocaine
9856622|NCT03868631|Active Comparator|Soy protein group|
9856623|NCT03868631|Active Comparator|Whey protein group|
9856624|NCT03865953|Active Comparator|LAT8881|1 x 30 mg capsule of LAT8881 taken by mouth, twice daily (morning and evening) during the four-week treatment period.
9856625|NCT03865953|Placebo Comparator|Placebo|1 x 30 mg capsule of placebo, taken by mouth, twice daily (morning and evening) during the four-week treatment period.
9856626|NCT03865381|Other|Virtual Diabetes Clinic|The Onduo Virtual Diabetes Clinic (VDC) is the suite of diabetes management services including remote monitoring, diet/lifestyle coaching, medication management accessed via Onduo App and partner apps. Subjects will engage with a Care Lead through the App and will have a medical consultation via telemedicine with an Onduo VDC Physician.
9856627|NCT03865446|Experimental|Cohort 1 (Dacomitinib)|severe hepatic impairment group
9856628|NCT03865446|Experimental|Cohort 2 (Dacomitinib)|normal hepatic function
9856629|NCT03862027|Experimental|Esophageal Balloon catheter|All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed > 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
9856630|NCT03868059|Experimental|LPCN 1021|LPCN 1021 at a 225 mg dose taken twice daily (total daily dose of 450 mg taken as 225 mg in the morning and 225 mg in the evening),
9856631|NCT03868254||Implant|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
9856632|NCT03868254||Implant + Phaco|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
9856633|NCT03865407|Active Comparator|Allopurinol|Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
9856634|NCT03865407|No Intervention|Standard of Care Control|The treatment arm will be compared to a standard of care arm.
9856635|NCT03857230|Experimental|Sequence A: Primapur - Gonal-F|Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
9856636|NCT03857230|Active Comparator|Sequence B: Gonal-F - Primapur|Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
9856637|NCT03865329|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants will be offered a Home-based pulmonary rehabilitation program with health coaching.
9923919|NCT00856037|Experimental|Treatment (doxorubicin hydrochloride, topotecan hydrochloride)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 6 of course 1 and on days 6, 13, and 20 of courses 2-5. Patients also receive topotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
9923920|NCT00856076||VTE case group 1/2|Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.
9923921|NCT00856076||VTE control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
9923922|NCT00856076||VTE control group 2|Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.
9923923|NCT00856076||VTE case group 3|Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
9856638|NCT03864653|Other|MoodGym|"Non-randomized single-arm intervention; eligible persons are newly enrolled methamphetamine use treatment service program (i.e., Getting Off) participants who will be invited to participate in the study during their enrollment, and can enroll in the study at any time during their first two weeks of program participation. Participants who enroll will take the preexisting, low-intensity MoodGym intervention."
9856639|NCT03862482|Active Comparator|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at one site
9856640|NCT03862482|Experimental|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Device placement: B (Brånemark® dental implant) placed at one site, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at two sites
9856641|NCT03862482|Experimental|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at one site, SC (Screw-Vent® dental implant) placed at two sites
9856642|NCT03853213|Experimental|Cognitive Bias Modification Training|"Participants in this intervention group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is Cognitive Bias Modification Training for Attention. It is designed to reinforce attention away from ACS threat-related stimuli (e.g., death, chest pain) and toward neutral stimuli (e.g., curve, barn doors). The second task is Cognitive Bias Modification Training for Interpretation. It is designed to train participants to appraise ambiguous information that is potentially related to ACS threat as benign."
9856643|NCT03853213|Sham Comparator|Attention Control Training|Participants in this placebo control group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is the placebo version of Cognitive Bias Modification Training for Attention. It is designed NOT to train attention toward or away from threatening or neutral information. The second task is the placebo version of Cognitive Bias Modification Training for Interpretation. It is designed NOT to train the interpretation of information as either threatening or benign.
9856644|NCT03847610|Experimental|Healthy volunteer|
9856645|NCT03850093|Active Comparator|gabapentin|gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative
9856646|NCT03850093|Active Comparator|bisoprolol|bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative
9856647|NCT03850093|Placebo Comparator|control|placebo was given to patients of control group 2 hours preoperative
9856648|NCT03848208|Experimental|Cohort 1: Cytisine 6.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856649|NCT03848208|Placebo Comparator|Cohort 1: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856650|NCT03848208|Experimental|Cohort 2: Cytisine 9.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856651|NCT03848208|Placebo Comparator|Cohort 2: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856652|NCT03848208|Experimental|Cohort 3: Cytisine 12.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856653|NCT03848208|Placebo Comparator|Cohort 3: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856654|NCT03848208|Experimental|Cohort 4: Cytisine 15.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856655|NCT03848208|Placebo Comparator|Cohort 4: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856656|NCT03848208|Experimental|Cohort 5: Cytisine 18.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856657|NCT03848208|Placebo Comparator|Cohort 5: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856658|NCT03848208|Experimental|Cohort 6: Cytisine 21.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856659|NCT03848208|Placebo Comparator|Cohort 6: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856660|NCT03848208|Experimental|Cohort 7: Cytisine 24.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856661|NCT03848208|Placebo Comparator|Cohort 7: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
10209080|NCT04824092|Placebo Comparator|Tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP|"Patients will receive tafasitamab placebo plus lenalidomide placebo in addition to R-CHOP for six 21-day cycles:~Tafasitamab placebo: 0.9% saline solution Days 1, 8 and 15 of each 21-day cycle~Lenalidomide placebo: Days 1-10 of each 21-day cycle~R-CHOP dose: Rituximab (or locally approved biosimilar) 375 mg/m2, IV Day 1 of every 21-day cycle; Cyclophosphamide 750 mg/m2, IV Day 1 of 21-day cycle; Doxorubicin 50 mg/m2, IV Day 1 of 21-day cycle; Vincristine 1.4 mg/m2 (max 2 mg) IV Day 1 of 21-day cycle; Prednisone/prednisolone 100 mg/day, per os, Day 1-5 of every 21-day cycle"
9856662|NCT03848208|Experimental|Cohort 8: Cytisine 27.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856663|NCT03848208|Placebo Comparator|Cohort 8: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856664|NCT03848208|Experimental|Cohort 9: Cytisine 30.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856665|NCT03848208|Placebo Comparator|Cohort 9: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
9856666|NCT03847389|Other|clobetasol propionate topical oil|clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
9856667|NCT03862040|Experimental|Cefiderocol|All participants were receiving standard of care (SOC) antibiotic treatment for pneumonia. Forty hours after the start of SOC treatment, participants will be administered 2 g doses of cefiderocol (or renally adjusted doses) infused intravenously over 3 hours, every 8 hours (or every 6 hours for participants with augmented renal function), for an expected minimum of 3 doses and up to a total of 6 doses in participants with normal renal function and participants with mild or moderate renal impairment, and for an expected minimum of 6 doses and up to a total of 9 doses in participants with severe renal impairment.
9856668|NCT03861936|Experimental|BOTOX® 72U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 72 units (U) total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
10209081|NCT04822480||DPP Patients|UMMC Patients with prediabetes or risk for diabetes based on risk parameters referred to and enrolled in the DPP.
10209082|NCT04822480||Non-DPP Patients|Control matched UMMC patients with prediabetes or risk for diabetes based on risk parameters not enrolled in the DPP.
9856669|NCT03861936|Experimental|BOTOX® 48U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
9856670|NCT03861936|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1.
9856671|NCT03859739|Experimental|Panel A. MK-8558 400 mg|Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.
9856672|NCT03859739|Experimental|Panel B. MK-8558 at dose level 2|Single oral dose of MK-8558 administered at dose level 2 following a 10-hour fast. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
9856673|NCT03859739|Experimental|Panel C. MK-8558 at dose level 3|Single oral dose of MK-8558 administered at dose level 3 following a 10-hour fast. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
9856674|NCT03859739|Experimental|Panel D. MK-8558 at dose level 4|Single oral dose of MK-8558 administered at dose level 4 following a low-fat breakfast. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
9856675|NCT03857750||Elderly (>80 years)|Patients planned for elective surgery above 80 years
9856676|NCT03857750||Younger (18-40 years)|Patients planned for elective surgery between 18-40 years
9856677|NCT03856255|Experimental|Micro-Tech Endoscopic Gauge|Use of the device during screening or surveillance colonoscopy
10213567|NCT03795038|Other|Lipoprotein Apheresis MONET and DALI|"Patients routinely treated with MONET:~The first subgroup will be treated first with the MONET adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber System.~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the MONET adsorber system"
10213568|NCT03795038|Other|Lipoprotein Apheresis DIAMED and DALI|"Patients routinely treated with DIAMED:~The first subgroup will be treated first with the DIAMED adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber system.~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DIAMED adsorber System."
10213569|NCT03794986|Experimental|Motivational Interviewing|Sexual and gender minority males who are sexual abuse survivors.
10213570|NCT03794986|Active Comparator|MI with trauma-informed SGM affirmative care|MI w/trauma-informed SGM affirmative care
10213571|NCT03784716|Experimental|Ketogenic Diet|Ketogenic Diet for 28 Days
10213572|NCT03784716|Active Comparator|Standard Weight Loss Diet|Standard Weight Loss Diet for 28 Days
10213573|NCT03784066|Active Comparator|A|Durvalumab
10213574|NCT03784066|Active Comparator|B|Durvalumab + Tremelimumab
10213575|NCT03773978|Experimental|Baricitinib Open-Label|Baricitinib given orally.
10213576|NCT03773978|Experimental|Baricitinib Double Blind|Baricitinib given orally.
10213577|NCT03773978|Placebo Comparator|Placebo Double Blind|Placebo given orally.
10213578|NCT03768648|Experimental|patient|RRMS diagnosis according to McDonald criteria (Polman et al.,2005);
10213579|NCT03768648|Active Comparator|Control|40 Healthy controls (HC)
10213580|NCT03766672||Intervention Arm|Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .
10213581|NCT03761069|Experimental|PTC299|PTC299 will be administered orally once daily (QD) for each 28-day cycle.
10213582|NCT03760471|Experimental|Collaborative palliative and oncology care|
10213583|NCT03749278|Experimental|ALMA Intervention Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention after baseline assessment.
9856678|NCT03850509|Experimental|OPS-2071 150 mg BID|Participants were to receive OPS-2071 150 mg, tablets, orally, twice daily (BID) in the morning and evening (8 to 12 hours apart) with 240 milliliters (mL) of water for up to 12 weeks.
9856679|NCT03850509|Experimental|OPS-2071 300 mg BID|Participants received OPS-2071 300 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 6 weeks.
9856680|NCT03850509|Experimental|OPS-2071 600 mg BID|Participants were to receive OPS-2071 600 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 12 weeks.
9856681|NCT03850509|Placebo Comparator|Placebo|Participants received OPS-2071-matched placebo, tablets, orally, BID in morning and evening (8 to 12 hours apart) with 240 mL of water for up to 4 weeks.
9856682|NCT03860753|Experimental|Pioglitazone|
9856683|NCT03860753|Placebo Comparator|Placebo|
9856684|NCT03848455||Parkinson's disease group|"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;~Newly diagnosed primary PD patients, diagnosed within 3-6 months;~informed consent to the study;~age > 18 older."
9856685|NCT03848455||Non-parkinson group|Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.
9856686|NCT03858894|Experimental|Drug Arm: DE-117 QD|DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
9856687|NCT03858894|Experimental|Test Arm: DE-117 BID|DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)
9856688|NCT03856164|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
9856689|NCT03856164|Placebo Comparator|Placebo|Normal saline for intravenous administration.
9856690|NCT03850275|Experimental|Experimental: Placebo, then caffeinated placebo, then e+shots|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
9856691|NCT03850275|Experimental|Experimental: Caffeinated placebo, then placebo, then e+shots|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
9856692|NCT03850275|Experimental|Experimental: placebo, then e+shots, then caffeinated placebo|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received e+shots and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
9856693|NCT03850275|Experimental|Experimental: caffeinated placebo, then e+shots, then placebo|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the e+shots and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
9856694|NCT03850275|Experimental|Experimental: e+shots, then caffeinated placebo, then placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
9856695|NCT03850275|Experimental|Experimental: e+shots, then placebo, then caffeinated placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
9856696|NCT03851016|Experimental|Life Story Book Intervention First, Then Usual Care|Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
9856697|NCT03851016|Experimental|Usual Care First, Then Life Story Book Intervention|Participants first received the Usual Care Intervention for 3 weeks. After a washout period of 1 week, they then received the Life Story Book Intervention once a week for 3 weeks. Posttests were then conducted for 1 week.
9856698|NCT03850496|No Intervention|Group A|No device utilised for 6 weeks.
9856699|NCT03850496|Experimental|Group B|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
9856700|NCT03850496|Experimental|Group C|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
9856701|NCT03848949|Experimental|Orthotic Group|Subjects enrolled in the orthotic group receive the orthotic (Evenup) meant to increase the effective leg length of the uninjured limb.
9856702|NCT03848949|No Intervention|Control|Subjects enrolled in the control group receive the standard treatment associated with their injury (no orthotic)
9923924|NCT00856076||VTE control group 3|Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
9923925|NCT00856076||IUFD group 1|Women who have experienced IUFD - data verified from medical records.
9856703|NCT03849690|Experimental|TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.
9856704|NCT03845933|Active Comparator|Water exchange (WE) colonoscopy|Water exchange will be used during colonoscopy insertion. Upon arriving at the cecum, CO2 will be opened. The scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The scope will be reinserted into the cecum by the first endoscopist. A tandem inspection of right colon will be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
9856705|NCT03845933|Active Comparator|CO2 insufflation colonoscopy|The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
9856706|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.01%|1 drop daily into each eye in the evening for 28 days
9856707|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop daily into each eye in the evening for 28 days
9856708|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.04%|1 drop daily into each eye in the evening for 28 days
9856709|NCT03844945|Placebo Comparator|Netarsudil Ophthalmic Solution Placebo|1 drop daily into each eye in the evening for 28 days
9856710|NCT03844321|Experimental|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
9856711|NCT03844321|Experimental|Brief Mindfulness|3 sessions of online mindfulness therapy
9856712|NCT03843632|Experimental|VARIVAX™|All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.
10209083|NCT04816812|Other|Exercise|In the intervention arm, a 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level.
10209084|NCT04816812|Other|Comparison|Comparison
10209085|NCT04814355|Experimental|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
9856713|NCT03840811|Experimental|Group 1|Subjects (n = up to 8) will receive a bacterial inoculum containing only the isogenic mutant N. gonorrhoeae strain
9856714|NCT03840811|Experimental|Group 2|Subjects (n = up to 8) will receive a bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain.
9856715|NCT03840811|Experimental|Group 3|Subjects (n= up to 16) will receive a bacterial inoculum containing a mixture of equivalent numbers the isogenic mutant and WT strain
9856716|NCT03837028||HPV 16/18 (+), cytology normal|"Women who have HPV 16/18 positivity and normal cytology results in their cervical cancer screening test (co-test) results.~The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later."
9923926|NCT00856076||IUFD group 2|Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
10209086|NCT04812106||Participants with LC-FAOD|
10209087|NCT04805983|Experimental|10 mg BMS-984923|
10209088|NCT04805983|Experimental|40 mg BMS-984923|
10209089|NCT04805983|Experimental|70 mg BMS-984923|
10209090|NCT04805983|Experimental|100 mg BMS-984923|
10209091|NCT04804579|Experimental|Fall Prevention Intervention|"The Intervention involves 3 primary components: virtual group sessions, at-home exercises, and weekly phone check-ins.~Virtual Group Session will be held via phone/video call for approximately 30 minutes per week for 10 weeks.~At-Home Exercises will be assigned by a registered occupational therapist member of the study team, and participants will be instructed to complete them independently at home 3 times per week. Participants will record the exercises that they complete.~Weekly Phone Check-Ins will occur once per week. These check-ins will be used to provide support and problem solving as needed, and individualized reminder systems will be set up to prompt the participant to engage in their weekly exercises (e.g., set up alarm on phone, notifications through calendar app)."
10209092|NCT04804579|No Intervention|Control Group|Participants will be provided with an educational pamphlet that includes resources related to falls and alcohol use.
10209093|NCT04801576|Placebo Comparator|Placebo mouthrinse|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse without flouride for 28 days; toothpaste with 1050 ppm F and mouthrinse without flouride for 28 days; toothpaste with 1450 ppm F and mouthrinse without flouride for 28 days.
10209094|NCT04801576|Experimental|Fluoride in mouthrinses|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse with 450 ppm F for 28 days; toothpaste with 1050 ppm F and mouthrinse with 450 ppm F for 28 days; toothpaste with 1450 ppm F and mouthrinse with 450 ppm F for 28 days.
10209095|NCT04801173|Experimental|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
10209096|NCT04801173|Active Comparator|Low calorie diet|Control treatment with a low calorie standard diet
10209097|NCT04800835|Active Comparator|Group 1- Spatz3 adjustable balloon 12-month implantation;|A 12 month adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
10209098|NCT04800835|Active Comparator|Group 2- 6-month non adjustable balloon implantation with additional 6 months follow-up|A 6-month non adjustable intragastric balloon for weight loss
10209099|NCT04798339|Experimental|Phase 1b: Dose Level 1|Patients will be treated at dose level 1: Canakinumab 150 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
9856717|NCT03837028||HPV 16/18 (+), cytology abnormal|Women who have HPV 16/18 positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
9856718|NCT03837028||non-16/18 HPV (+), cytology abnormal|Women who have non- 16/18 high-risk HPV positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
9856719|NCT03837028||non-16/18 HPV (+), cytology normal|Women who have non- 16/18 high-risk HPV positivity and normal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
9856720|NCT03825939|Experimental|Intravenous Tranexamic Acid|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery"
9856721|NCT03825939|Placebo Comparator|Intravenous Placebo|- IV 0.9% sterile saline
9856722|NCT03825939|Active Comparator|Intravenous Tranexamic Acid followed by Intravenous Placebo|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery~IV 0.9% sterile saline"
9856723|NCT03817775|No Intervention|Control|The control group will undergo coronary angiography without music intervention.
9856724|NCT03817775|Experimental|Music therapy|The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.
9856725|NCT03843372|Experimental|First night HFNC group|The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
9856726|NCT03843372|Active Comparator|First night CPAP group|In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.
9856727|NCT03841331|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
9856728|NCT03841331|Placebo Comparator|5 mg Placebo Tablets|Placebo Tablets
9856729|NCT03840278|Experimental|Bihormonal iLet first, then Insulin-Only iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the bihormonal iLet bionic pancreas for 1 week. They then used the insulin-only iLet bionic pancreas for 1 week."
9856730|NCT03840278|Experimental|Insulin-Only iLet first, then Bihormonal iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the insulin-only iLet bionic pancreas for 1 week. They then used the bihormonal iLet bionic pancreas for 1 week."
9856731|NCT03840135|Experimental|Polyoxidonium 6 mg/ml|Polyoxidonium 6 mg/ml nasal and sublingual spray - 0,15 mg/kg daily - 7 days.
9856732|NCT03840135|Placebo Comparator|Placebo|Placebo, nasal and sublingual spray - 7 days.
9856733|NCT03839641|Experimental|High Fat Meal First|Arm 1 participants randomized to receive high fat meal first, and low fat meal second
9517054|NCT03309930|Experimental|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
9856734|NCT03839641|Experimental|High Fat Meal Second|Arm 2 participants randomized to receive low fat meal first, and high fat meal second
9856735|NCT03839212|Experimental|Happy Older Latinos are Active (HOLA)|A 16-week multi-component, health promotion intervention
9856736|NCT03839355|Active Comparator|Eliquis|
9856737|NCT03839355|Active Comparator|Warfarin|
9856738|NCT03838874|Active Comparator|Low-Dose Bupivacaine|Subjects in this group will be given 10mg of Low-Dose Bupivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
9856739|NCT03838874|Active Comparator|Mepivacaine|Subjects in this group will be given 70mg of Mepivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
9856740|NCT03838731|Experimental|REGN1908-1909|
9856741|NCT03838731|Placebo Comparator|Placebo|
9856742|NCT03838198|Other|Safety plan + booster text messages + booster call (Group A)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group A: Participants will receive the in-person MI-enhanced safety plan (individual meeting with the adolescent and a family meeting) during hospitalization -- focused on developing a personalized list of coping strategies and enhancing adolescents' motivation and self-efficacy to utilize these strategies-- which will be followed by 4 weeks of daily post-discharge booster text messages and a phone booster call.
9856743|NCT03838198|Other|Safety plan + booster text messages (Group B)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group B: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by 4 weeks of daily booster text messages post discharge.
10209100|NCT04798339|Experimental|Phase 1b: Dose Level 2|Patients will be treated at dose level 2: Canakinumab 300 mg by subcutaneous injection on day 1 of each 28 day cycle. Darbepoetin alfa will be administered subcutaneously at a dose of 300mg on days 1 and 15 of each cycle.
10209101|NCT04798339|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Patients will be treated with Darbepoetin alfa subcutaneously at a dose of 300 mg on days 1 and 15 of each cycle plus the maximum tolerated dose of Canakinumab.
9856744|NCT03838198|Other|Safety plan + booster call (Group C)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group C: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by a post-discharge booster call.
9856745|NCT03838198|Other|Safety plan (Group D)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group D: Participants will receive the in-person MI-enhanced safety plan during hospitalization.
9856746|NCT03831451|Experimental|Stroke Preparedness Intervention|The stroke preparedness educational intervention was designed with input from the community where it is being tested. It will be delivered in-person by a research team member. The intervention focuses on recognizing stroke symptoms and the importance of calling 911.
9856747|NCT03831451|Active Comparator|Healthy lifestyle intervention|The Healthy lifestyle stroke risk reduction educational intervention is based on patient materials from the American Heart Association. It will be delivered in-person by a research team member. The intervention focuses on stroke risk reduction.
9856748|NCT03822078|Placebo Comparator|Placebo|Participants received a single subcutaneous injection of placebo to denosumab on day 1.
9856749|NCT03822078|Experimental|Denosumab|Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
9856750|NCT03815240|Other|no dressing (A)|No dressing will be applied at sacrum before 3.5 hours loading period in supine position
9856751|NCT03815240|Active Comparator|Mepilex (B)|'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
9856752|NCT03815240|Active Comparator|Allevyn (C)|'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
9856753|NCT03815240|Active Comparator|Optifaom (D)|'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position
9856754|NCT03836859|Experimental|rhNGF 20μg/mL|rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
9856755|NCT03836859|Placebo Comparator|Placebo|Vehicle: formulation containing L-methionine as excipient.
9856756|NCT03835078|Experimental|methalfilcon A contact lenses / fanfilcon A contact lenses|All subjects will first wear methafilcon A contact lenses for four (4) weeks of daily wear, then be refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
9856757|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 1.
9856758|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 2.
9856759|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 3.
9856760|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 1.
10209102|NCT04795908|Experimental|Active rTMS Group|Patients will be seated in a comfortable reclined chair. The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% resting motor threshold (RMT). The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10 minute break in between each session.
10209103|NCT04795362||patients with Delayed cerebral ischemia|50 adult patients hospitalized in neurological intensive care unit for subarachnoid hemorrhage, in whom the onset of delayed cerebral ischemia is suspected will be included.
10209104|NCT04795232|No Intervention|Control|Participants in this arm will receive no intervention
10209105|NCT04795232|Experimental|COD45|Participants in this arm will participate in a COD training session consisted of 45 degrees changes of direction
10209106|NCT04795232|Experimental|COD90|Participants in this arm will participate in a COD training session consisted of 90 degrees changes of direction
10209107|NCT04791137|No Intervention|Monitoring|Participants complete weekly questionnaires (QIDS-SR, PMH, GAD-7) on a weekly basis but receive no intervention.
9856761|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 2.
9856762|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 3.
9856763|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 1.
9856764|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 2.
9856765|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 3.
9856766|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 1.
9856767|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 2.
9856768|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 3.
9856769|NCT03836677|Experimental|BGF-GFF|Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
9856770|NCT03836677|Experimental|GFF-BGF|Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
9856771|NCT03836989|Experimental|High-volt electrical stimulation|"Plan to use a monophasic waveform having 100µmsec pulse duration, at 35 Hz using tolerated voltage to generate a contraction a total of 20 minutes.~The stimulation will have 10 seconds on time, 30 seconds off time and 2 second ramp up and down. Electrical stimulation will be produced with the Orthostim 3 device (VQ Ortho Care). The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral mastoid region.~Four facial muscles will be stimulated: 1)frontalis, 2) orbicularis oculi, 3) zygomaticus major, and 4) orbicularis oris.~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated. Ten contractions in each muscle group will be performed or 5 minutes per muscle if no contraction is achieved."
9856772|NCT03836989|Placebo Comparator|Subsensory electrical stimulation|"Plan to use the same device and settings to provide placebo treatment by delivering minimal electricity. The settings will be the same as the intervention except the voltage will be subsensory. ie. below the minimum at which patients feels any effect of the current.~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting."
9856773|NCT03827564|Experimental|ITN [TrueTear®] - Intranasal Application|Intranasal application of the ITN. Single application at application visit.
9856774|NCT03827564|Experimental|ITN [TrueTear®] - Extranasal Application|Extranasal application of the ITN. Single application at application visit.
9923927|NCT00856076||IUFD control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
9856775|NCT03824236|Experimental|P-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
9856776|NCT03824236|Experimental|NP-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and not protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
9856777|NCT03824236|No Intervention|InfectivityCtrl group|Healthy subjects, between and including 18 and 55 years of age, who did not receive, in the current study, any immunization but underwent sporozoite challenge.
9856778|NCT03811951|Experimental|Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
9856779|NCT03811951|Experimental|Non-Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
9856780|NCT03810235|Active Comparator|Transdermal Lidocaine Patch|Drug: Including placebo The intervention is the post-operative application of a 5% lidocaine transdermal patch for women who have undergone Cesarean delivery.
9856781|NCT03810235|Placebo Comparator|Transdermal Hydrocolloid Placebo Patch|Drug: Including placebo The intervention is the post-operative application of a hydrocolloid transdermal patch for women who have undergone Cesarean delivery.
9856782|NCT03806556|Experimental|Tranexamic Acid|Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).
9856783|NCT03806556|Placebo Comparator|Placebo|Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.
9856784|NCT03836664|Experimental|Group 1: Timolol|Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
9856785|NCT03836664|Placebo Comparator|Group 2: Placebo|Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
9856786|NCT03832738|Experimental|JTE-451 Dose 1|JTE-451 Tablets Dose 1 daily for 16 weeks.
9856787|NCT03832738|Experimental|JTE-451 Dose 2|JTE-451 Tablets Dose 2 daily for 16 weeks.
9856788|NCT03832738|Placebo Comparator|Placebo|Placebo Tablets daily for 16 weeks.
9856789|NCT03823391|Experimental|ABBV-3373 Followed by Placebo|Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
10209108|NCT04791137|Experimental|Standard imagery cognitive bias modification|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention derived from that implemented in previous studies.
9856790|NCT03823391|Experimental|Adalimumab|Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.
9856791|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 8 Weeks|Direct-acting antiviral (DAA)-naive participants without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 8 weeks.
9856792|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 12 weeks.
9856793|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
9856794|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
9856795|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 3 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
9856796|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 3 (3 to < 6 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
9856797|NCT03819491|Experimental|Group A|100 mg OD
9856798|NCT03819491|Experimental|Group B|100 mg BID
9856799|NCT03808298|Experimental|Treatment Sequence 1: A, B, C|
10209109|NCT04791137|Experimental|Standard imagery cognitive bias modification plus additional rationale and transfer instructions|Participants are scheduled to complete a first introductory session then 12 further training sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, but in addition are first presented with a more extended rationale for completing the training, and during each training session are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions.
9856800|NCT03808298|Experimental|Treatment Sequence 2: A, C, B|
9856801|NCT03808298|Experimental|Treatment Sequence 3: B, A, C|
9856802|NCT03808298|Experimental|Treatment Sequence 4: B, C, A|
9856803|NCT03808298|Experimental|Treatment Sequence 5: C, A, B|
9856804|NCT03808298|Experimental|Treatment Sequence 6: C, B, A|
9856805|NCT03808298|Experimental|Treatment Sequence 7: A, B, D|
9856806|NCT03808298|Experimental|Treatment Sequence 8: A, D, B|
9856807|NCT03808298|Experimental|Treatment Sequence 9: B, A, D|
9856808|NCT03808298|Experimental|Treatment Sequence 10: B, D, A|
9856809|NCT03808298|Experimental|Treatment Sequence 11: D, A, B|
9856810|NCT03808298|Experimental|Treatment Sequence 12: D, B, A|
9856811|NCT03836729|Experimental|TAF/FTC followed by TAF/FTC + GSK3640254|Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
9856812|NCT03835975|Active Comparator|13vPnC|Pneumococcal conjugate vaccine
9856813|NCT03835975|Active Comparator|PPSV23|Pneumococcal polysaccharide vaccine
9856814|NCT03835975|Experimental|20vPnC|Pneumococcal conjugate vaccine
9856815|NCT03821259||Older adults with mental health history|Eligible participants, aged 65 and over, will be established in treatment for PTSD, anxiety or depression in the Older Adult Psychological Therapies service.
9856816|NCT03803085|Experimental|Control Condition|Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
9856817|NCT03803085|Experimental|Treatment condition|Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.
9856818|NCT03801473|Experimental|robot assisted training (RAT)|RoboGait which is an automated locomotor therapy system was used for treating RAT group. The system composed of a robotic lower extremity orthosis, adjustable dynamic gait support, synchronized treadmill and biofeedback utilities
9856819|NCT03801473|Active Comparator|conventional training (CT)|Participants in CT group had physiotherapist assisted walking exercises on the parallel bars and on the ground with aids/cane, tripod or walker.
9856820|NCT03834168|Other|Study Individuals|Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).
9856821|NCT03828149|Active Comparator|Drug: OP0201|20 mg dose one time, followed by a washout and then a 0 mg dose one time, cross over design
10209110|NCT04791137|Experimental|Standard imagery cognitive bias modification with frequent brief sessions|"Participants are scheduled to complete a first introductory session then 40 brief (~5 min) sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 2 per day five days per week for each of the four training weeks. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 30.05.21."
9856822|NCT03828149|Placebo Comparator|Drug: Placebo|0 mg dose one time, followed by a washout and then a 20 mg dose one time, cross over design
9856823|NCT03835221|Experimental|methafilcon A toric / fanfilcon A toric contact lenses|All subjects will first wear methafilcon A toric contact lenses for four (4) weeks of daily wear, then refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
9856824|NCT03819634|Experimental|Lantern infusion set|Multi-slitted lantern infusion set
9856825|NCT03812679|Experimental|AMIA APD Solution Generation System|A simulated treatment will take place before the patient receives study treatment, during week 1 and after 4, 8 and 12 weeks of study treatment period. The dialysis solution generated by the simulated treatment will be collected from the system in the heater bag and used to evaluate the chemical composition of the final dialysis solution produced by patients using the AMIA APD Solution Generation System. Also, product water from the Water Device (pre-sterilizing filters) will be collected and tested at each visit.
10209111|NCT04791137|Experimental|Standard imagery cognitive bias modification with a less intensive schedule|"Participants are scheduled to complete a first introductory session then 11 further sessions of a 'standard' imagery cognitive bias modification (CBM) intervention, with 3 sessions scheduled for each of the four training weeks. Sessions have fewer training scenarios than the Standard imagery cognitive bias modification condition and more varied task instructions. In addition, as with the arm Standard imagery cognitive bias modification plus additional rationale and transfer instructions, participants are first presented with a more extended rationale for completing the training, and during many of the training sessions are provided with instructions to practice retrieval and rehearsal of the training contents in between sessions. This arm was added into the ongoing trial on 09.06.21."
10209112|NCT04789304|Experimental|BI 1595043|
10209113|NCT04789304|Placebo Comparator|Placebo|
10209114|NCT04787549|Experimental|Virtual reality exergames|Cognitively challenging exergames using fully immersive virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
10209115|NCT04784637|Experimental|Group 1|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) for 6 weeks
10209116|NCT04784637|Experimental|Group 2|AID + Auto Titration Module (ATM) and Web Simulation Tool (WST) +Behavioral Adaptation Module (BAM) for 6 weeks
10209117|NCT04780724|Experimental|Hypoxic|Participants inhale ambient air, the hypoxic gas mixture, and ambient air.
10209118|NCT04780724|Experimental|Hypercapnic|Participants inhale ambient air, the hypercapnic and hypoxic gas mixture, and the ambient air.
10209119|NCT04780477|Experimental|High Fiber Diet (HFD)|High Fiber Diet (HFD) will add approximately 25-30 grams of dietary fiber/d from legume dishes.
9856826|NCT03809052|Experimental|A1 - 5 mg GB1211 single dose and Placebo|6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
9856827|NCT03809052|Experimental|A2 - 20 mg GB1211 single dose and Placebo|6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
9856828|NCT03809052|Experimental|A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo|6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.
9856829|NCT03809052|Experimental|A4 - 100 mg GB1211 single dose and Placebo|6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
9856830|NCT03809052|Experimental|A5 - 200 mg GB1211 single dose and Placebo|6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
9856831|NCT03809052|Experimental|B1 - GB1211 multiple ascending doses, 50mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.
9856832|NCT03809052|Experimental|B2 - GB1211 multiple ascending doses, 100mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..
9856833|NCT03809052|Experimental|A6 - 50mg GB1211 single dose and Placebo|8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
9856834|NCT03809052|Experimental|A7 - 400 mg GB1211 single dose and Placebo|8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
9856835|NCT03809052|Experimental|Part A - Placebo for GB1211|In Part A - 2 subjects from each arm (A1-A5) will receive placebo.
9856836|NCT03809052|Experimental|Part B - Placebo for GB1211 (BID)|Part B - 3 subjects from each arm B1 and B2 will receive placebo.
9856837|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TOB) + Dexlansoprazole 30mg (TPC)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
9856838|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TPC) + Dexlansoprazole 30mg (TOB)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
9856839|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TOB) + Dexlansoprazole 60mg (TPC)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
9856840|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TPC) + Dexlansoprazole 60mg (TOB)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
9856841|NCT03832907|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|"The Dexcom G6 CGM is a commercially available factory-calibrated sensor system. The system measures interstitial glucose every 5-15 minutes, providing real-time and more complete glycemic profile during 24-hours compared to standard POC glucose testing, and replaces the need for finger sticking. Potential limitations include the need for removing the sensor before MRI or diathermy treatment, and the potential interference in patients with severe dehydration.~In parallel, same participants will be monitored by the standard of care point-of-care (POC) capillary glucose tests. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital."
10209120|NCT04780477|Active Comparator|Healthy American Diet|Healthy American Diet pre-portioned meal replacement entrées with legumes replaced by lean chicken/meat.
9856842|NCT03832322||Water exchange colonoscopy|During the insertion phase of the first-pass colonoscopy, water exchange (WE) method was used. WE entailed the infusion of water to open the lumen and sequentially suction of water. When the cecum was reached and after most of the water was suctioned to collapse the cecal lumen, CO2 was opened during the withdrawal phase of the first-pass colonoscopy. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
9856843|NCT03832322||CO2 insufflation colonoscopy|During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
9856844|NCT03832387|Experimental|Non-invasive mechanical ventilation|"Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.~The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
9856845|NCT03832387|Active Comparator|Venturi mask|"For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.~The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
9856846|NCT03831971|Experimental|ANS-6637 & Midazolam|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
9856847|NCT03831854|Active Comparator|lamotrigine|Patient will receive 300 mg of oral lamotrigine with small sips of water to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
9856848|NCT03831854|Placebo Comparator|Placebo|Patient will receive oral Placebo with small sips of water, to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
9856849|NCT03807739|Experimental|Part I: GDC-0134 F16 vs F09 Capsule Formulation|In Part 1 participants will receive single doses of either GDC-0134 F16 capsules (prototype) or GDC-0134 F09 capsules (reference) after having consumed a standard meal.
9856850|NCT03807739|Experimental|Part II: GDC-0134 F15 vs F09 Capsule Formulation|In Part 2, participants will receive a single dose of either GDC-0134 F15 capsules (prototype) or GDC-0134 F09 capsules (reference) after an overnight fast.
9856851|NCT03831282|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
9856852|NCT03824912|Experimental|Test: Ketoconazole Cream 2%|Test: Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd)
9856853|NCT03824912|Active Comparator|Reference: Ketoconazole Cream 2%|Ketoconazole Cream 2% (G&W Laboratories Inc.; Registrant: Teva Pharmaceuticals USA Inc.)
9856854|NCT03824912|Placebo Comparator|Placebo: Cream (Test vehicle)|Placebo Cream (Test vehicle) (Encube Ethicals Pvt Ltd)
9856855|NCT03822884|Experimental|Hemax® PFS 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
9856856|NCT03822884|Experimental|Hemax® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
9856857|NCT03822884|Active Comparator|Erypo ® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
9856858|NCT03816709|Other|Therapeutic ultrasound treatment|All subjects received a therapeutic ultrasound treatment with the Chattanooga Intelect Legend XT machine with the following parameters: 3 MHz, 1.0 W/cm2, 15 minute treatment time.
9856859|NCT03810014|Experimental|Arm 1|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
9856860|NCT03810014|Experimental|Arm 2|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
9856861|NCT03810014|Experimental|Arm 3|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
9856862|NCT03810014|Experimental|Arm 4|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
9856863|NCT03806270||Midazolam|"Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
9923928|NCT00856076||IUFD control group 2|Subjects from VTE control group 1/2 with validated data from medical records.
9856864|NCT03806270||Midazolam&Hydroxyzine dihydrochloride1/2|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
9856865|NCT03806270||Midazolam&Hydroxyzine dihydrochloride|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
9856866|NCT03830892|Active Comparator|E-cigarette User (Exclusive)|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette
9856867|NCT03830892|Active Comparator|Dual User|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette/Cigarette
9856868|NCT03830307|Experimental|Intervention Group|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
9856869|NCT03825042|Experimental|Food supplement|A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
9856870|NCT03825042|Placebo Comparator|Placebo|Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
9856871|NCT03823378|Experimental|ABBV-599 in M16-063/ABBV-599 in M16-763|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
9856872|NCT03823378|Experimental|ABBV-105 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
9856873|NCT03823378|Experimental|ABBV-105 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
9856874|NCT03823378|Experimental|ABBV-105 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
9856875|NCT03823378|Experimental|UPA 15 mg/ABBV-105 placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
9856876|NCT03823378|Experimental|Placebo in M16-063/ABBV-599 in M16-763|Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
9856877|NCT03831191|Experimental|50 mg LY3375880|"Induction Period:~Participants received 50 mg LY3375880 administered SC Q4W."
9856878|NCT03831191|Experimental|150 mg LY3375880|"Induction Period:~Participants received 150 mg LY3375880 administered SC Q4W."
9856879|NCT03831191|Experimental|600 mg LY3375880|"Induction Period:~Participants received 600 mg LY3375880 administered SC Q4W."
9856880|NCT03831191|Placebo Comparator|Placebo|"Induction Period:~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W)."
9856881|NCT03830281|Active Comparator|Insulin Lispro (Humalog)|Participants received individual dose of 100 U/mL insulin lispro (Humalog) by CSII; where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
9856882|NCT03830281|Experimental|Ultra-Rapid Lispro|Participants received individual dose of 100 units per milliliter (U/mL) ultra rapid lispro by continuous subcutaneous insulin infusion (CSII); where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
9856883|NCT03828734|Experimental|TMS to frontal cortex followed by TMS to parietal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
9856884|NCT03828734|Experimental|TMS to parietal cortex followed by TMS to frontal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
9856885|NCT03827395|Experimental|HEV-239|0.5 mL of HEV-239 administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=20
9856886|NCT03827395|Placebo Comparator|Placebo|0.5 mL of HEV-239 placebo administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=5
9856887|NCT03819218|Experimental|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
9856888|NCT03818815|Active Comparator|Drug: OP0201 + Antibiotics|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
9856889|NCT03818815|Placebo Comparator|Placebo Comparator: Placebo +Antibiotics|Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
9856890|NCT03828487|Experimental|Neonatal Test group|Subjects will receive a Masimo O3 Neonatal sensors as well as a 510(k) cleared sensor.
9856891|NCT03828617|Experimental|20vPnC Lot 1|20vPnC Lot 1
9856892|NCT03828617|Experimental|20vPnC Lot 2|20vPnC Lot 2
9856893|NCT03828617|Experimental|20vPnC Lot 3|20vPnC Lot 3
9856894|NCT03828617|Active Comparator|13vPnC|13vPnC
9856895|NCT03828539|Experimental|Erenumab|70 mg and 140 mg Erenumab
9856896|NCT03828539|Active Comparator|Topiramate|Topiramate in the highest tolerated dose (50 - 100 mg/day)
9856897|NCT03824704|Experimental|Cohort A: Ovarian Cancer Cohort|"Oral rucaparib and Intravenous (IV) nivolumab (combination therapy)~Cohort A1~Cohort A2"
9856898|NCT03823937||Fibromyalgia|Diagnosed with ACR 2016 criteria
9856899|NCT03823937||Control|18-70 years healthy subjects
9856900|NCT03817879|Experimental|VivaSight double-lumen tube|
10209121|NCT04779437|Experimental|Imagery Cognitive Bias Modification First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of imagery cognitive bias modification followed by two weeks of cognitive control training. Daily QIDS will be completed throughout the intervention phases.
9856901|NCT03817879|Active Comparator|Conventional double-lumen tube|
9856902|NCT03811834|Experimental|Mobocertinib 160 mg and [14C]-Mobocertinib 50 mcg + [14C]-Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once under fasted state, followed by [14C]-mobocertinib 50 mcg (approximately 2 microcurie [mcCi]), infusion, intravenously, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by [14C]-mobocertinib 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.
9923929|NCT00856076||IUFD control group 3|Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.
10209122|NCT04779437|Experimental|Cognitive Control Training First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of cognitive control training followed by two weeks of imagery cognitive bias modification. Daily QIDS will be completed throughout the intervention phases.
10209123|NCT04776278|Experimental|Brief Alcohol Intervention (BAI) + Substance Free Activity Session (SFAS)|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the Substance-free activity session (SFAS), a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
10213584|NCT03749278|Active Comparator|ALMA Delayed Intervention Control Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention six months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
9923930|NCT00856089|Experimental|Retapamulin|
9923931|NCT00856102|Experimental|Exercise|
9923932|NCT00856102|No Intervention|Control|
9923933|NCT00856115||African American Female|
9923934|NCT00856115||African American Male|
10213585|NCT03749148|Active Comparator|Dupilumab|Dupilumab, s.c. administration 2 injections (600mg) as loading dose, 1 injection (300mg) every 14 days for a total of 16 weeks
10213586|NCT03749148|Placebo Comparator|Placebo|matching Placebo, s.c. administration 2 injections as loading dose, 1 injection every 14 days for a total of 16 weeks
9923935|NCT00856115||Caucasian Female|
9923936|NCT00856115||Caucasian Male|
9923937|NCT00856141|Experimental|1. High fluidic parameters|Bottle height varied from 90-110cms, fixed aspiration flow rate 40cc/min, vacuum upto 650mmHg depending on the grade of cataract
9923938|NCT00856141|Active Comparator|2. Low fluidic parameters|Bottle height varied from 70-90cms, fixed aspiration flow rate of 25cc/min, vacuum upto 400mmHg, depending on the grade of cataract
9923939|NCT00856167|Active Comparator|TCM|Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
9923940|NCT00856167|Active Comparator|Self-care|Self-care for TMD developed by Dworkin, LeResche et al.
9923941|NCT00856219|Active Comparator|Enteral Continuous|Continuous tube feeding for 72 hours.
9923942|NCT00856219|Active Comparator|Enteral Intermittent|Intermittent tube feedings for 72 hours
9923943|NCT00856219|Active Comparator|Parenteral|Parenteral continuously for 72 hours
9923944|NCT00856258|Placebo Comparator|Cohort 1|Cohort 1 completed.
9923945|NCT00856258|Placebo Comparator|Cohort 2|Cohort 2 not studied
9923946|NCT00856258|Placebo Comparator|Cohort 3|Cohort 3 not studied
9923947|NCT00856258|Placebo Comparator|Cohort 4|Cohort 4 not studied
9923948|NCT00856271|Experimental|1|olmesartan medoxomil
9923949|NCT00856271|Active Comparator|2|losartan potassium
9923950|NCT00856310|Active Comparator|Cohort 1|Dose 1 REGN475
9923951|NCT00856310|Active Comparator|Cohort 2|Dose 2 of REGN475
9923952|NCT00856310|Active Comparator|Cohort 3|Dose 2 of REGN475
9923953|NCT00856310|Active Comparator|Cohort 4|Dose 1 of REGN475
9923954|NCT00856310|Active Comparator|Cohort 5|Dose 2 of REGN475
9923955|NCT00856310|Active Comparator|Cohort 6|Dose 1 REGN475 subcutaneous administration
9923956|NCT00856310|Active Comparator|Cohort 7|Dose 2 REGN475 subcutaneous administration
9923957|NCT00856362|Experimental|1|
10213587|NCT03749135|Active Comparator|Dupilumab|Dupilumab (anti-IL4Ra), s.c. administration
10213588|NCT03749135|Placebo Comparator|Placebo Comparator|matching Placebo, s.c. administration
9856903|NCT03806127|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 12 weeks.
10209124|NCT04776278|Experimental|Relaxation Training (RT) + Substance Free Activity Session (SFAS)|Participants will complete a relaxation training session that will include a clinician leading them through a diaphragmatic breathing exercise, a progressive muscle relaxation protocol, and then a brief breath-counting (mindfulness) exercise. A week later, the participant will receive the SFAS, a 50-minute counseling session designed to increase the salience of the individual's goals, to highlight the connection between their current patterns of behavior (including drinking and substance-free activities) and the attainment of these goals, and to increase future orientation and engagement in enjoyable and goal-directed activities that are inconsistent with substance use (even if the participant has no desire to change their use).
10209125|NCT04776278|Active Comparator|Education Control|This minimal contact control condition will include a brief (2-3 minute) discussion where the research assistant (RA) who completed the assessment session will describe the educational handout. This condition is meant to approximate a public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or motivational interviewing. Participants will receive information on risks associated with alcohol/drug misuse, strategies for reducing alcohol problems, managing stress, and goal-setting. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact
9856904|NCT03806127|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 12 weeks.
9856905|NCT03827473|Experimental|Arm A (ADT, docetaxel)|Participants receive androgen deprivation therapy (ADT) per standard of care and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9856906|NCT03827473|Experimental|Arm B (ADT, abiraterone acetate, prednisone)|Participants receive androgen deprivation therapy (ADT) per standard of care, abiraterone acetate PO daily, and prednisone PO twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
9856907|NCT03826914|Experimental|Experimental group|Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
9856908|NCT03826914|Placebo Comparator|Control Group|Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.
9856909|NCT03812328|Experimental|SelK2 and Enoxaparin|I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)
9856910|NCT03812328|Active Comparator|Enoxaparin|SC, QD for up to 10 ± 2 days
9856911|NCT03812328|Experimental|SelK2|I.V., single-dose
9856912|NCT03808688|Other|Netarsudil Ophthalmic Solution 0.02%|
9856913|NCT03811093|Experimental|Care as Usual Group|A randomly selected group of 20 participants who received treatment per the prescribed trial protocol using a fully functional invisa-RED Technology Elite device. Treatment protocol was as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular LLLT protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
9856914|NCT03811093|Placebo Comparator|Sham Group|A randomly selected group of 20 participants who will receive treatment per the prescribed trial protocol using a non functional invisa-RED Technology Elite device. (The sham device will be disabled and will deliver no low laser light energy during therapy.) Treatment protocol is as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
9856915|NCT03822182|Other|Control/Bupivicaine +DMSO|Group 1 will serve as the control and receive the standard injection consisting 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone.
9856916|NCT03822182|Active Comparator|Liposomal bupivicaine|Group 2 will receive a block with 15ml 0.5% bupivacaine and 10ml (133mg) of liposomal bupivicaine (Exparel) and 5.4ml of Normal Saline
9856917|NCT03822182|Active Comparator|Liposomal Bupivicaine +DMSO|Group 3 will receive 15ml of 0.5% bupivicaine and 10ml (133mg) of Liposomal Bupivicaine (Exparel) and 0.4ml (4mg) dexamethasone and 5ml normal saline
9856918|NCT03822416|Experimental|Intervention|Intervention group will receive counseling and nicotine replacement therapy including the nicotine patch and/or nicotine lozenges.
9856919|NCT03822416|Other|Control|Control group will receive information about mental illness and smoking cessation and a listing of community resources available for assistance with smoking cessation.
9856920|NCT03809104|Experimental|elderly with sarcopenia|Virtual reality-based rehabilitation programs
9856921|NCT03807089|Experimental|Short-Turn Radius Colonoscope|Colonoscopy performed with Short-Turn Radius Colonoscope. The colonoscope will provide a forward-facing view of the colon during advancement to the cecum (standard of care). The scope will then be withdrawn all the way to the rectum and the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and be withdrawn using the retrograde view.
9856922|NCT03807089|Active Comparator|Conventional Pediatric Colonoscope|Colonoscopy will be performed with a conventional pediatric colonoscope. During withdrawal, the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and again withdrawn using the forward-facing view.
10209126|NCT04774965|Experimental|Slumber Curve Group|Patients receiving Slumber Curve sleep aid for management of pain and sleep quality following rotator cuff repair.
10209127|NCT04774965|No Intervention|Normal Sleep Routine Group|Patients not receiving sleep aid.
10209128|NCT04769531|Experimental|Hip Joint Mobilizations|Hip joint mobilizations Hip strength training Knee exercises
10209129|NCT04769531|Experimental|Hip & Knee Muscles strength training|Hip strength training Knee exercises
10209130|NCT04769531|Active Comparator|Knee Muscles strength training|Knee exercises
10209131|NCT04768478|Active Comparator|Cannabidiol (CBD)|
10209132|NCT04768478|Placebo Comparator|Control|
9856923|NCT03806231|Experimental|Outpatient Cervical Ripening|Patients randomized to the outpatient cervical ripening arm will come in for a scheduled visit in Labor and Delivery prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be monitored for 2 hours and sent home after a the following are present: (1) reactive non-stress test (NST) (2) category 1 tracing x 2 hours (3) no vaginal bleeding (4) normal maternal vital signes (5) intact bag of water (BOW) and (6) less than 1 contraction every 10 minutes at the time of discharge. The patient will remove the insert the following morning prior to her scheduled induction.
9856924|NCT03806231|Active Comparator|Inpatient Cervical Ripening|The patient will be admitted into the Labor and Delivery unit prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be watched with continuous fetal monitoring for 2 hours. The patient remains hospitalized and the following morning the induction will be started per Intermountain Healthcare protocol.
9856925|NCT03804710|Experimental|Test Product 1|Participants will apply 2 pumps of the test product (approximately 0.3ml x 2= 0.6ml) to the randomly assigned side of the face, including forehead and chin, and 6 pumps of test product (approximately 0.3 ml x 6 = 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) topically twice-daily (in the morning and evening) after cleansing.
9856926|NCT03804710|Experimental|Test Product 2|Participants will apply pea-sized amount of the test product (approximately 0.6ml) to the randomly assigned side of the face, including forehead and chin, and walnut-sized amount of the test product (approximately 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) twice-daily (in the morning and evening) after cleansing.
9856927|NCT03804710|Placebo Comparator|Standard soap cleanser|Participants will use wet soap with warm water and form lather. Participants will cleanse their entire face and both lower legs (between the knees and ankles) twice daily (morning and evening).
9856928|NCT03822377|Experimental|Ticagrelor orodispersible tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets."
9856929|NCT03822377|Active Comparator|Ticagrelor standard tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills."
9856930|NCT03820388|Experimental|Propofol Group|Propofol 2 mg/kg
9856931|NCT03820388|Experimental|Etomidate Group|Etomidate 0.3 mg/kg
9856932|NCT03820388|Experimental|Propofol plus Etomidate Group|Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
9856933|NCT03816696|Experimental|DTG followed by GSK3640254 followed by DTG+GSK3640254|Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
9856934|NCT03821064|Experimental|Patient Navigation|45 patients (15 African American, 30 white) will interact with a patient navigator three times over three months to identify and address barriers before they cause breakdowns in care delivery, employing resources, education, and care coordination from the day of surgery until post-operative radiation treatment begins.
9856935|NCT03820544|Experimental|SEMS|Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
9856936|NCT03820544|Active Comparator|Standard of care surgical resection|Patients undergo standard of care surgical resection.
10209133|NCT04765449|Experimental|ARM A: Covid-19 Patients Receiving CTLs|Patients who have an HLA antigen in common with COVID-19 fighting T cells will be admitted to the hospital and receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. The patients will be monitored for side effects for at least 4 days prior to discharge. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated.
9856937|NCT03820024|Experimental|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
10209134|NCT04765449|No Intervention|ARM B: Covid-19 Patients Not Receiving CTLs|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.
10209135|NCT04758104|Experimental|Yttrium90|Intracystic application of yttrium90
10209136|NCT04750889||RFID tags localization|
10209137|NCT04750889||Wire localization|
10209138|NCT04744207|Experimental|GS-248|GS-248, capsule, 120 mg, once daily for 4 weeks
10209139|NCT04744207|Placebo Comparator|Placebo|placebo, capsule, once daily for 4 weeks
10209140|NCT04742959|Experimental|Monotherapy Cohorts|TT-00420 tablets will be administered once daily in 28-day cycles.
10209141|NCT04742959|Experimental|Dose Escalation Cohorts (Combination Therapy)|TT-00420 tablets will be administered once daily in 28-day cycles. Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Day 1, 8, and 15 of each 28-day cycle. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
10209142|NCT04739839||Inception cohort, former pupils in different schools in Western Zealand|1327 former Western Zealand pupils (originally 1389). Aged 14-15 in 1997. This is the first follow up on this cohort.
10209143|NCT04739293|Experimental|ON 123300|ON 123300 capsules at increasing doses per cohort, starting at 40 mg
9856938|NCT03820024|No Intervention|No Messages|No feedback messages
10209144|NCT04737954|Experimental|Suspected VTE patients|Venous blood draw of up to 20ML and up to 6 fingerstick capillary draws
10209145|NCT04735835|Experimental|Dietary Intervention|Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.
9856939|NCT03807544|Experimental|TENS treatment arm|This study is a usability study, where all subjects will receive the same experimental treatment for their single visit.
9856940|NCT03809182|Experimental|Dexmedetomidine|After anesthesia induction, patients who were randomized to the Dexmedetomidine group received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
9856941|NCT03809182|Placebo Comparator|0.9% Sodium-chloride|After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
9856942|NCT03816761|Experimental|Fast-acting insulin aspart, default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
9856943|NCT03816761|Experimental|Fast-acting insulin aspart, non-default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
9856944|NCT03801044||PD patients|All PD patients treated in out unit were enrolled.
9856945|NCT03805672|Active Comparator|Low Dose Enoxaparin|Subjects are randomized to receive or begin prophylactic dosing (30 mg BID) of enoxaparin for 6 weeks or until DVT resolution.
9856946|NCT03805672|Active Comparator|High Dose Enoxaparin|Subjects are randomized to begin therapeutic dosing (1 mg/kg body weight BID) of enoxaparin for 6 weeks or until DVT resolution.
10209146|NCT04733950|Experimental|Patients with cochlear implant|Patients with cochlear implant for 6 months and more
9856947|NCT03808493|Experimental|Study 1, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
9856948|NCT03808493|Experimental|Study 1, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
10209147|NCT04733950|Active Comparator|Healthy volunteers (normal hearing)|Healthy volunteers with a normal tonal audiometry for age
9856949|NCT03808493|Experimental|Study 2, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
9856950|NCT03808493|Experimental|Study 2, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
9856951|NCT03815292|Experimental|MMH-MAP|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatment will be 24 weeks.
9856952|NCT03815292|Placebo Comparator|Placebo|Placebo for 24 weeks, according to the MMH-MAP dosing regimen.
9856953|NCT03812510|Experimental|A-101|Topical Solution
10209148|NCT04721106||Vizimpro treatment group|This group is included the patients that Vizimpro are prescribed and administrated according to local label in the routine clinical practice
10209149|NCT04720209|Experimental|Circuit-style aerobic and resistance Exercise(CARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months.~-16 weeks of circuit-style aerobic and resistance exercise"
9856954|NCT03802994|Experimental|1.Aging RT|Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
9856955|NCT03802994|Active Comparator|2.Young RT|Renal transplant recipients between 35-45 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
9856956|NCT03802994|Active Comparator|3.Healthy elderly|Healthy persons between the ages 65-75 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
9923958|NCT00856401|Experimental|PTH1-84 in parent study|In the RELAY, RACE, and HEXT study participants utilize PTH1-84. In the REPLACE Study participants utilize PTH1-84 or placebo of PTH1-84.
10209150|NCT04720209|Experimental|Traditional Aerobic Resistance Exercise (TARE)|"This research study involves exercise. Participants in this study will be assigned to one of 2 exercise groups, undergo three (voluntary) biopsies of fat tissue, and participate in 7 testing visits and 48 exercise training visits. Participation is expected to last 12 months~- 16 weeks of traditional aerobic and resistance exercise"
10209151|NCT04720209|Active Comparator|Home-Based Stretching|"Attention Control for 16 weeks home-based stretching~-structured home-based stretching program, participants will be asked to maintain their current activity level for the 4-month study duration, and will be offered the CARE program upon study completion"
10209152|NCT04717726|Experimental|MT|Participants in the MT group will be supplemented with Milk Thistle extract for 12 weeks
10209153|NCT04717726|Experimental|LAC|Participants in the LAC group will be supplemented with Lactobacillus Gassri for 12 weeks
10209154|NCT04717726|Experimental|EX|Participants in the EX group will perform aerobic exercise, 5 days per week for 12 weeks
9856957|NCT03802994|Active Comparator|4.Elderly DMII or HTN and normal renal function|Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
9856958|NCT03802994|Experimental|5.Healthy young|Healthy persons between the ages 35-45 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.
9856959|NCT03810183|Experimental|QAW039 450 mg|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet.
9856960|NCT03810183|Placebo Comparator|Placebo|Placebo once daily for 6 weeks administered orally as a tablet.
10209155|NCT04717726|Experimental|MT + EX|Participants in the MT + EX group will be supplemented with Milk Thistle extract and exercise for 12 weeks
10209156|NCT04717726|Experimental|LAC + EX|Participants in the LAC + EX group will be supplemented with Lactobacillus Gassri and exercise for 12 weeks
9856961|NCT03809910|Experimental|Prototype PTB (Gum line mode)|Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste
9856962|NCT03809910|Experimental|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste. Following this, participants will brush their teeth with prototype power toothbrush in 'Interdental' mode with a fluoride toothpaste."
9856963|NCT03809910|Sham Comparator|Reference MTB|Participants will brush their teeth with manual toothbrush and fluoride toothpaste.
9856964|NCT03809910|Active Comparator|Reference PTB|Participants will brush their teeth with reference power toothbrush and fluoride toothpaste.
9856965|NCT03806790|Experimental|LEO 90100 foam|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
9856966|NCT03806790|Active Comparator|Dovobet® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
9856967|NCT03809611|Experimental|UNR844-Cl Ophthalmic Solution|1.5% UNR844-Cl ophthalmic solution for twice-daily dosing
9856968|NCT03809611|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution for twice-daily dosing
9856969|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart
9856970|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 25|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
9856971|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 50|Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart
9856972|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 50|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
9856973|NCT03805971||patient aged more than 18 years admitted for thoracoscopy|Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies
9856974|NCT03802916|Experimental|Low dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
9856975|NCT03802916|Experimental|High dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
9856976|NCT03809039|Experimental|Single Ascending Dose: MT-6345 & Placebo|
9856977|NCT03809039|Experimental|Multiple Ascending Dose: MT-6345 & Placebo|
9856978|NCT03807700|Experimental|Experimental denture adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
9856979|NCT03807700|No Intervention|No adhesive|In this arm, participants will not use any denture adhesive.
9856980|NCT03804918|Experimental|Interventional group: All participants|Given access to a selected breaking bad news mobile learning resource (VitalTips application).
9856981|NCT03805386|Active Comparator|Standard of Care|Subjects will be prescribed the standard amount of opioids that are typically prescribed by our practice after surgery. Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
9856982|NCT03805386|Experimental|Patient Directed Care|Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
9856983|NCT03803475|Experimental|Ga-68 labeled PSMA-11 PET PSMA|The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 millicurie (mCi) +/- 10% of 68Ga-PSMA-11.
9856984|NCT03802227|Experimental|Group 1|NKTR-181 400 mg and oxycodone IR placebo
9856985|NCT03802227|Experimental|Group 2|Oxycodone IR 40 mg and NKTR-181 placebo
9856986|NCT03802864|Experimental|Liposomal Bupivacaine|Participants in this arm will have a single injection of liposomal bupivacaine admixed with standard bupivacaine (266mg liposomal bupivacaine mixed with 50mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
10209157|NCT04717726|Placebo Comparator|CON|Participants in the CON group will be supplemented with maltodextrin pills made to look like the pills received by the MT and LAC groups for 12 weeks
10209158|NCT04715399||Cross-sectional|
10209159|NCT04715399||Longitudinal|
10213589|NCT03747835|Active Comparator|Exposure and Response Prevention|Inpatients will be provided three 90-minute sessions of Exposure and Response Prevention therapy each week.
10213590|NCT03747835|Active Comparator|Motivational Interviewing|Inpatients will be provided two 60-minute sessions of Motivational Interviewing each week.
10213591|NCT03740009|Experimental|Perimenopausal women, depressed|Participants will take Bazedoxifene/Conjugated Estrogen orally for 3 weeks
10213592|NCT03738852|Experimental|Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months|Continuous Glucose Monitor for 3 months duration
10213593|NCT03738852|Experimental|Aim 1: Impact of hypoglycemia on brain connectivity Type 1|Healthy controls, T1 aware, and T1 unawares
9856987|NCT03802864|Active Comparator|Standard Bupivacaine|Participants in this arm will have a single injection of standard bupivacaine (100mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
9856988|NCT03801265|Active Comparator|Lumbar Plexus block|0.5% ropivacaine 100 mg (20 ml) will be injected
9856989|NCT03801265|Experimental|Quadratus Lumborum type 3 block|0.5% ropivacaine 100 mg (20 ml) will be injected
9856990|NCT03802344|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
9856991|NCT03802344|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
9856992|NCT03802344|Placebo Comparator|Vehicle|One application daily for 8 weeks
9856993|NCT03801928||Ulcerative Colitis|Group treated with Inflectra for Ulcerative Colitis
9856994|NCT03801928||Crohn's Disease|Group treated with Inflectra for Crohn's Disease
9856995|NCT03800173|Experimental|Galidesivir|Galidesivir IV infusion
9856996|NCT03800173|Placebo Comparator|placebo|Placebo IV infusion
9856997|NCT03799783|Experimental|Dexmedetomidine|2 mcg/Kg iv dexmedetomidine (this dose may be repeated up to 2 times) followed by 1-2 mcg/Kg/hour iv continuous infusion
9856998|NCT03800030|Experimental|Theta-gamma, Delta-beta, Sham|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS"
9856999|NCT03800030|Experimental|Theta-gamma, Sham, Delta-beta|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS"
9857000|NCT03800030|Experimental|Delta-beta, Theta-gamma, Sham tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS"
9857001|NCT03800030|Experimental|Delta-beta, Sham, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS"
9857002|NCT03800030|Experimental|Sham, Delta-beta, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS"
9857003|NCT03800030|Experimental|Sham, Theta-gamma, Delta-beta tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS"
9857004|NCT03799211|Experimental|Motivational Interviewing|
9857005|NCT03799211|Active Comparator|Usual Care|
9857006|NCT03798717|No Intervention|Control|Participants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.
9857007|NCT03798717|Experimental|Pre OGTT|Condition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.
9857008|NCT03798717|Experimental|Post OGTT|Condition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.
9857009|NCT03798483|Experimental|Individualized exercise|Participants after a lateral kneecap dislocation will be enrolled into an individualized exercise intervention supervised by a physiotherapist
9857010|NCT03798366|Experimental|GLPG1690 600 mg|Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks.
9857011|NCT03798366|Placebo Comparator|Placebo|Participants received GLPG1690 matching placebo, orally once daily for 24 weeks.
9857012|NCT03799952|Experimental|Intervention|Participants are offered to attend a 12-week exercise program, classes offered twice a week, each class 60 minutes in length.
9857013|NCT03799952|No Intervention|Control|"Participants are instructed to continue with their daily activities and their normal physical activity levels for 12-weeks."
9923959|NCT00856427|Experimental|Diagnostic|Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
9923960|NCT00856440||1|SCI
9857014|NCT03797872|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice. Commonly Initial therapy will be with methotrexate alone unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (sulfasalazine or leflunomide). In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
9857015|NCT03797872|Experimental|Local/IM steroid injections|Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local injections of methylprednisolone or triamcinolone to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication. All active joints will be treated with injections. Injections can be either be given as an intra-articular injection or as an intra-muscular injection. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy).
9857016|NCT03799614|Experimental|Lower dose vibration|RMBand lower dose vibration
9857017|NCT03799614|Experimental|Higher dose vibration|RMBand higher dose vibration
9857018|NCT03799484|Other|Topical Anesthesia|2.5% Lidocaine/2.5% Prilocaine Cream will be applied to one side of the forehead and Petrolatum Ointment to the other prior to administration of Botulinum Toxin Type A Injection
9857019|NCT03799484|Other|Petrolatum|Petrolatum Ointment will be applied to one side of the forehead and 2.5% Lidocaine/2.5% Prilocaine Cream to the other side prior to administration of Botulinum Toxin Type A Injection
9857020|NCT03796728|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Initial treatment with Juvéderm® VOLIFT™ with Lidocaine injectable gel to augment the lips on Day 1, with an optional touch-up treatment 14 days later, if applicable. Volume was determined by the Investigator not to exceed 3.0 milliliters (mL).
9857021|NCT03797144|Experimental|Fenestrated Screw System|
9857022|NCT03782571|Experimental|Test1/Test2/Control/Test3|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
9857023|NCT03782571|Experimental|Test2/Test3/Test1/Control|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
9857024|NCT03782571|Experimental|Test3/Control/Test2/Test1|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
9857025|NCT03782571|Experimental|Control/Test1/Test3/Test2|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
9857026|NCT03796260|Experimental|F1 to F06 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F1 (test formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F06 (reference formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
9857027|NCT03796260|Experimental|F06 to F1 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F06 (reference formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F1 (test formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
9857028|NCT03796039|Experimental|Standing and Social Intervention|Participants be exposed to an additional 100 minutes of standing per week. Participants will do this by standing for 20 minutes Monday through Friday.
9857029|NCT03796039|No Intervention|Control Group|Control group will receive social visits, but no exposure to standing
9857030|NCT03783780|Experimental|INVSENSOR00031|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00031 sensor during motion and non-motion.
9857031|NCT03780959|Placebo Comparator|Etanercept/Placebo|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to receive placebo subcutaneous injection twice weekly for up to 4 months.
9857032|NCT03780959|Experimental|Etanercept/Etanercept|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to continue receiving etanercept twice weekly for up to 4 additional months.
9857033|NCT03796182|Experimental|Sequence 1|Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
9923961|NCT00856440||2|Able-bodied
9923962|NCT00856453|Experimental|Yoga classes plus home yoga practic|
10209160|NCT04715074|No Intervention|Identify EOCRC Hotspots in Utah|"Linking incidence and mortality data (years 2000-2020) from the Utah Cancer Registry (UCR) and the Utah Population Database (UPDB), we will derive county-level estimates of hotspots for EOCRC incidence and mortality among Utahns aged 18-49; we will obtain county-level estimates using our geospatial methods.39 Counties with high EOCRC incidence and/or mortality rates will be identified as hotspots.~Using UCR-UPBD linked data, we will determine independent contributions of (1) geographical, (2) personal, and (3) county-level factors on EOCRC incidence/survival. We will perform hierarchical Cox regression models and implement a generalized R-square analysis to determine the variance explained by each factor.~Central hypotheses: (1) Patients residing in hotspots will have significantly worse EOCRC survival compared with those residing in other Utah areas. (2) Rurality and county-level access to healthcare will contribute to an explanation of EOCRC incidence/survival."
9857034|NCT03796182|Experimental|Sequence 2|Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
9857035|NCT03796013|Experimental|Form A to Form C Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
9857036|NCT03796013|Experimental|Form C to Form A Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
9857037|NCT03795753|Experimental|F2S Communicator|The F2S Communication System is a communication aid for use with a noninvasive ventilation (NIV) mask covering at least the mouth. It is a two-component system consisting of (1) a disposable, single patient use patch and signal cable and (2) a reusable communicator with power cable.The non-invasive aid for patients receiving BPAP/CPAP therapy delivers communication between the patient and medical personnel.
9857038|NCT03795753|Sham Comparator|Non-functioning Communicator|Non-functioning study communication device is used.
9857039|NCT03792477|Experimental|Part 1: Treatment A|Single 200mg IM testosterone cypionate solution (Test formulation)
9857040|NCT03792477|Active Comparator|Part 1: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
9857041|NCT03792477|Experimental|Part 2: Treatment A|Single 200 mg IM testosterone cypionate solution (Test formulation)
9857042|NCT03792477|Active Comparator|Part 2: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
9857043|NCT03783962|Experimental|Active Intervention - Cooking|Twelve cooking classes will be run every other week after the in-person weight loss meetings. These lessons will be patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for individuals specifically interested in weight loss. Classes will begin with a brief lecture on the day's topic, followed by a laboratory session. Participants work in teams of two in the Nutrition and Food Sciences (NFS) foods lab to actively practice skills and cook a meal. Subjects will receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. Classes will be taught by a chef trained in the pedagogy by Dr. Trubek and participants will have the opportunity to sample the food they prepared at the end of class.
9857044|NCT03783962|Active Comparator|Demonstrations - Cooking|"The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All participants will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."
9857045|NCT03782272|Experimental|AA-ORS|Those receiving enterade oral re-hydration solution with amino acids
9857046|NCT03782272|Placebo Comparator|Placebo|Those receiving placebo solution without amino acids or rehydration salts
9857047|NCT03779724|Experimental|isokinetic exercise|The isokinetic dynamometer (Biodex Multijoint Pro 3) was used for isokinetic exercises. The isokinetic exercise program was implemented over eight weeks, twice a week on non-consecutive days under the supervision of a doctor. The number of repetitions undertaken by the patients over the program were as follows: first week 5 at 60°/s and 10 at 180°/s, second week 10 at 60°/s and 15 at 180°/s, third week 15 at 60°/s and 20 at 180°/s, fourth week 20 at 60°/s and 30 at 180°/s, and in the last four weeks 20 at 60°/s and 40 at 180°/s angular velocities. Each block of 10 repetitions were performed as a set.
9923963|NCT00856453|Experimental|home yoga practice alone|
9923964|NCT00856479|Active Comparator|1 Infuse|The patient will receive BMP 2 with allograft
9857048|NCT03779724|Active Comparator|home exercise|The patients undertook lower extremity strengthening and balance exercises three times a week for eight weeks without supervision. They started with three repetitions, which was gradually increased to 10-15. The patients were called two times a week to inquire about exercise continuity and encouraged to undertake the recommended exercises.
9857049|NCT03775915|Experimental|Real Neurofeedback|3 sessions of Real Neurofeedback over 1 week
9857050|NCT03775915|Sham Comparator|Sham Neurofeedback|3 sessions of Sham Neurofeedback over 1 week
9857051|NCT03794752|Other|Vision Aided by a Head Mounted Device|A Head-Mounted Visual Enhancement Device developed by Evergaze Technology LLC has designed an electronic visual enhancement device that is compact and similar to glasses. It will be powered by a battery pack connected to the device. The electronic display will be affixed over only one of the user's eyes. The vision through the unobstructed eye will aid with the subject's balance and spatial orientation.
9857052|NCT03794024||Dorsal Column Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
9857053|NCT03794024||Dorsal Root Ganglion Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Axium Neurostimulator System
9857054|NCT03793751|Experimental|DEX Group|Receiving Dexmedetomidine injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
9857055|NCT03793751|Placebo Comparator|CONTROL Group|The Control Group will receive an equal volume placebo infusion of normal saline.
10209161|NCT04715074|Experimental|Ascertain Psychosocial and Lifestyle Challenges|Drawing on factors associated with hotspots identified in Aim 1 and our team's prior research,39-44 we will develop an interview guide with five EOCRC advocate-survivors and conduct one-on-one interviews with 20 individuals first diagnosed with CRC at 18-49 years of age. Interviews will be recorded, transcribed, and analyzed using Hatch's methods previously utilized by our team.45-47
9857056|NCT03793556|Experimental|GERDOFF® + omeprazole|"GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).~Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days)."
9857057|NCT03793556|Active Comparator|Omeprazole|Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
9857058|NCT03785548||Mirror group|This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room.
9857059|NCT03785548||No mirror group|This group of patients decline a mirror, and they will undergo the standard pelvic examination.
9857060|NCT03782701|Active Comparator|Lumify Eye Drop|Participants will be randomized to receive a single drop of Lumify to either the left or right eye.
9857061|NCT03782701|Active Comparator|Saline Solution Eye Drop|Participants will be randomized to receive a single drop of sterile balanced saline solution to either the left or right eye.
9857062|NCT03773133|Experimental|Treatment|i.v. administrations of up to three radioactivity levels of Satoreotide tetraxetan.
9857063|NCT03792672|Experimental|TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
9857064|NCT03792672|Experimental|TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
9857065|NCT03792672|Experimental|TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
9857066|NCT03792672|Experimental|TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
9857067|NCT03792672|Experimental|Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
9923965|NCT00856479|Active Comparator|2 Iliac crest autograft|Autograft from Patients Iliac Crest and allograft
9923966|NCT00856505|Experimental|Everolimus and mycophenolate sodium|Combination of experimental immunosuppressants for GvHD prophylaxis
9923967|NCT00856531||1|
9923968|NCT00856531||2|
9923969|NCT00856531||3|
10213594|NCT03738852|Experimental|Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1|Healthy controls, T1 aware, and T1 unawares
10213595|NCT03738397|Experimental|Upadacitinib 30 mg QD|Participants will receive 30 mg upadacitinib orally once a day (QD) up to Week 24 and placebo to dupilumab by subcutaneous injection every other week from Baseline to Week 22.
10213596|NCT03738397|Experimental|Dupilumab 300 mg EOW|Participants will receive a loading dose of 600 mg dupilumab by subcutaneous (SC) injection on Day 1 followed by 300 mg dupilumab SC every other week (EOW) until Week 22 and placebo to upadacitinib orally QD up to Week 24.
9857068|NCT03792672|Experimental|Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
9857069|NCT03786744|Experimental|ASD CB-MNC injection.|ASD CB-MNC injection from different donors and standard therapy.
9857070|NCT03786744|Other|Standard therapy.|Patients with standard therapy as control group.
9857071|NCT03782181|Active Comparator|Whole body vibration plat|An arm type in which a group of patients with fibromyalgia receives an intervention based on the use of a whole body vibration platform, considered to be effective by clinical evidence.
9857072|NCT03782181|No Intervention|Control group|No intervention arm
9857073|NCT03792191|Experimental|Ultrasonography|Preprocedural lumbar spinal ultrasonography and skin marking. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
9857074|NCT03792191|Active Comparator|Palpation|Sham ultrasound procedure. Conventional landmark palpation and skin marking.Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
9857075|NCT03791489|Experimental|Active Treatment|Cryotherapy of the posterior nasal nerve using the ClariFix device
9857076|NCT03790865|Experimental|Low-Dose Livoletide|Daily subcutaneous injection of ~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
9857077|NCT03790865|Experimental|High-Dose Livoletide|Daily subcutaneous injection of ~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
9857078|NCT03790865|Placebo Comparator|Placebo|Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
9857079|NCT03784300|Active Comparator|50 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.
9857080|NCT03784300|Placebo Comparator|50 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.
9857081|NCT03784300|Active Comparator|100 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.
9857082|NCT03784300|Placebo Comparator|100 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.
9857083|NCT03784300|Active Comparator|200 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.
9857084|NCT03784300|Placebo Comparator|200 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.
9857085|NCT03790878|Experimental|Mindful Breathing|Participants receive training in a mindful breathing skill to regulate their emotional distress during a stressor task. They will then receive one week of reminders to use this skill, delivered through their mobile phones.
9857086|NCT03790878|Active Comparator|Habituation|Participants receive an exposure/habituation intervention to regulate their emotional distress during a stressor task. They will then receive one week of reminders, delivered through their mobile phones.
9857087|NCT03790878|Placebo Comparator|Control|Participants complete the stressor task with no emotion regulation training. Similar to the other conditions, they will then receive one week of reminders, delivered through their mobile phones to test for placebo effects.
9857088|NCT03789474|No Intervention|Group A|No intervention was done ,served as a control group.
9857089|NCT03789474|Experimental|Group B|Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.
9857090|NCT03789175|Other|Nicotinamide riboside (NR) in Li-Fraumeni syndrome|Nicotinamide riboside (NR) to be initiated at week 0 at dose of 250 mg twice a day. At Week 1, NR will be titrated to 500 mg twice a day. At Week 6, NR will be titrated to 750 mg twice a day. At Week 7, NR will be titrated to 1000 mg twice a day or as tolerated until end of week 12. At week 12, if participant responds to primary endpoint, participant will washout of NR at week 18 then restart NR at week 24 until week 30. If there is not response to NR treatment at week 12, the participant may continue taking NR at a tolerated dose until week 24 and the primary endpoint will be re-measured. If participant has a positive response to NR treatment at week 24, then the participant will washout of NR until week 30, at which time the primary endpoint will be re-measured to ensure return to baseline. If there is no response to continued NR treatment at week 24, the study will be ended.
9857091|NCT03787615|Other|The sipIT tools|The wrist-worn sensors used to detect a drinking event (FitBit Versa with custom algorithm), an H2OPal connected water bottle and fluid consumption monitoring mobile applications.
9857092|NCT03786718|Experimental|Intervention|Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.
9857093|NCT03784963|Experimental|Primary Prevention Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
9857094|NCT03784963|Placebo Comparator|Primary Prevention Non-Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
9923970|NCT00856531||4|
9923971|NCT00856531||5|
9857095|NCT03784963|Experimental|Secondary Prevention Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
9857096|NCT03784963|Placebo Comparator|Secondary Prevention Non-Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
9857097|NCT03771274|Experimental|Tecnis ZLB00 & Symfony IOL|The Tecnis multifocal ZLB00 and the Symfony IOLs are presbyopia correcting lenses designed to improve the vision at distance, intermediate and near reducing the need for glasses in patients undergoing cataract surgery.
9857098|NCT03787472|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
9857099|NCT03787472|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
9857100|NCT03787212|Experimental|MiBo ThermoFlo / Bruder mask|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
9857101|NCT03787212|Experimental|Bruder Mask / MiBo ThermoFlo|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
9857102|NCT03784001|Active Comparator|Gratitude + No Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks.
9857103|NCT03784001|Experimental|Gratitude + Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks. They will also be told a benefit of gratitude each time they write an online gratitude list.
9857104|NCT03784001|Active Comparator|Events Control|Participants will type online lists of up to five events from their day, every two day for two weeks.
9857105|NCT03783702|Experimental|Experimental group|Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.
9857106|NCT03783702|Active Comparator|Control group|Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).
9857107|NCT03781479|Experimental|Amifampridine Phosphate - Placebo|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
9857108|NCT03781479|Experimental|Placebo - Amifampridine Phosphate|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
9857109|NCT03781037|Experimental|GIVE module|The GIVE module consists of one 50-minute treatment session and a second partial session (15-20 minutes) embedded within a larger cognitive behavioral treatment (CBT) protocol for anxiety or depression. The GIVE module uses cognitive behavioral principles to target youth's beliefs that they are a burden or drain on others.
9857110|NCT03784079|Experimental|Part 1: GSK3640254 10 mg|Participants will receive GSK3640254 10 milligram (mg), capsules, orally for 10 days.
9857111|NCT03784079|Experimental|Part 1: GSK3640254 200 mg|Participants will receive GSK3640254 200 mg, capsules, orally for 10 days.
9857112|NCT03784079|Placebo Comparator|Part 1: Placebo|Participants will receive placebo capsules, orally for 10 days.
9857113|NCT03784079|Experimental|Part 2: GSK3640254 40 mg|Participants will receive GSK3640254 40 mg, capsules, orally for 7 days.
9857114|NCT03784079|Experimental|Part 2: GSK3640254 80 mg|Participants will receive GSK3640254 80 mg, capsules, orally for 7 days.
9857115|NCT03784079|Experimental|Part 2: GSK3640254 140 mg|Participants will receive GSK3640254 140 mg, capsules, orally for 7 days.
9857116|NCT03784079|Placebo Comparator|Part 2: Placebo|Participants will receive placebo capsules, orally for 7 days.
9857117|NCT03783039|Experimental|SURGICEL Powder|SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
9857118|NCT03783039|Active Comparator|SURGICEL Original|SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form
9857119|NCT03783130|Experimental|Group 1: Trimer 4571 (100 mcg) IM with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
9857120|NCT03783130|Experimental|Group 2: Trimer 4571 (100 mcg) SC with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
9857121|NCT03783130|Experimental|Group 3: Trimer 4571 (500 mcg) IM with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
9857122|NCT03783130|Experimental|Group 4: Trimer 4571 (500 mcg) SC with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
9923972|NCT00856531||6|
10209162|NCT04715074|Experimental|Develop and Pilot iBeat CRC|"Intervention development will be informed by (1) integrating Aims 1 and 2 findings, (2) Community Action Board [CAB] input, and (3) the Behaviour Change Wheel,48 a step-by-step intervention development approach that identifies and addresses barriers using theory and evidence-based methods.~The intervention pilot may be based on a multicomponent media campaign, as endorsed by the Community Preventive Services Taskforce for promoting CRC screening among individuals ≥ age 50.49,50 iBeat CRC may entail both outdoor mass media and online social media. iBeat CRC will target Utah hotspots and non-hotspots for comparison, with pre-post-assessment among 17 individuals in each group."
9923973|NCT00856531||7|
9923974|NCT00856531||8|
9923975|NCT00856531||9|
9923976|NCT00856531||10|
9923977|NCT00856531||11|
9923978|NCT00856531||12|
9923979|NCT00856531||13|
9923980|NCT00856531||14|
9923981|NCT00856531||15|
9923982|NCT00856596|Other|Males and females with athlete's foot|Male and female subjects with athlete's foot inbetween their toes without nail involvement
10209163|NCT04709432||ECMO group|children supported by ECMO in the past 10 years
10209164|NCT04708158|Experimental|Active|Inhaled Novaferon, given 20 ug BID, daily for 7 days
10209165|NCT04708158|Placebo Comparator|Placebo|Inhaled saline (placebo), given BID, daily for 7 days
9857123|NCT03776175|Placebo Comparator|Placebo|Placebo (PF 05221304) BID Placebo (PF 06865571) BID
9857124|NCT03776175|Experimental|PF-05221304 Monotherapy|15 mg PF-05221304 BID Placebo (PF-06865571) BID
10209166|NCT04706208|Other|One time testing - able-bodied healthy adults|"Participants in this arm will be able-bodied healthy adults who will not receive an intervention.~This is just a one time testing of clinical assessments (over zoom), one MRI scan, and an optional blood draw test."
10209167|NCT04706208|Experimental|Usual Care, then Cognitive Multisensory Therapy - adults with spinal cord injury + neuropathic pain.|This is a cross-over study for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive usual care and then switch over to the experimental cognitive multisensory therapy training.
10209168|NCT04706208|Experimental|Cognitive Multisensory Therapy, then Usual Care - adults with spinal cord injury + neuropathic pain.|This is a cross-over study for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive the experimental cognitive multisensory therapy training and then switch over to usual care.
10209169|NCT04704830|Experimental|Standard Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 months olds
10209170|NCT04704830|Placebo Comparator|Standard Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 months olds
9857125|NCT03776175|Experimental|PF-06865571 Monotherapy|Placebo (PF-05221304) BID 300 mg PF-06865571 BID
9857126|NCT03776175|Experimental|PF-05221304 and PF-06865571 Combination|15 mg PF-05221304 BID 300 mg PF-06865571 BID
9857127|NCT03771963|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously (SC), once on Day 1 (first dose) and Day 90 (second dose).
9857128|NCT03771352|Other|RxSight RxLAL IOL|Eligible patients will be implanted with the RxSight RxLAL intraocular lens (IOL)
10209171|NCT04704830|Experimental|Seasonal Regime - Malaria vaccine|R21/Matrix-M x 3, n = 1600, 5-36 month olds
10209172|NCT04704830|Placebo Comparator|Seasonal Regime - Rabies vaccine|Rabies vaccine x 3, n = 800, 5-36 month olds
10209173|NCT04703790||Adults from the United States|Adult participants 18 years of age or older who are panelists recruited and maintained by Ipsos (KnoweledgePanel). All participants live within the United States.
10209174|NCT04702763||Multiple Sclerosis (Eye-Tracker®T2 + e-VOG)|Multiple Sclerosis subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
10209175|NCT04702763||Multiple Sclerosis (e-VOG + Eye-Tracker®T2)|Multiple Sclerosis subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
10209176|NCT04700800|Experimental|Exercise, Infusion of Amino Acids|Exercise followed by infusion of amino acids, or infusion of amino acids alone.
10209177|NCT04700800|Active Comparator|Exercise|Exercise with no infusion of amino acids
10209178|NCT04700007|Experimental|Study group|
10209179|NCT04699253||Consenting participants|Patients meeting the eligibility criteria and are using the SanaCoach heart failure during the study period.
10209180|NCT04699253||Consenting non-participants|Patients meeting the eligibility criteria but do not wish to use the SanaCoach heart failure and only fill-in an anonymized questionnaire once, without any follow-up.
10209181|NCT04697381|Experimental|somatropin - GH naïve pediatric cohort|All participants will receive somatropin.
10209182|NCT04697381|Experimental|somatropin - GH treated pediatric cohort|All participants will receive somatropin
10209183|NCT04697381|Experimental|somatropin - adult cohort|All participants will receive somatropin
10209184|NCT04691154|Experimental|L606|
10209185|NCT04684901|No Intervention|Standard of Care Group|Standard of Care - No AlloWrap used during surgery
10209186|NCT04684901|Experimental|AlloWrap Group|AlloWrap used in surgery
10209187|NCT04681079||Crossover Sequence 1|Subjects randomized to receive commercially available albuterol sulfate via MDI with spacer first, followed by albuterol sulfate via nebulizer with filtered mouthpiece.
10209188|NCT04681079||Crossover Sequence 2|Subjects randomized to receive commercially available albuterol sulfate via nebulizer with filtered mouthpiece first, followed by albuterol sulfate via MDI with spacer.
10209189|NCT04680481|Experimental|Stimulation Theta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 4 Hz (theta condition).
10209190|NCT04680481|Experimental|Stimulation Beta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 23 Hz (beta condition).
10209191|NCT04674228||Observational (medical record review)|Patients who participated in MAY2016-07-01 undergo review of medical records.
10209192|NCT04672382|Experimental|Morphine|"During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), while two areas will be treated with injections of isotonic saline (0.05 ml, 0.9%) as vehicle. Fifteen minutes after the injections, the measurement of FLPI and wheal size will be conducted in one morphine and one saline treated area.~This measurement will be followed by application of histamine and cowhage in the four areas (two pre-treated with morphine and two pre-treated with vehicle)"
10209193|NCT04668586|Experimental|Holmium:YAG laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Holmium:YAG laser machine.
10209194|NCT04668586|Experimental|Thulium Fiber laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Thulium Fiber laser machine.
10209195|NCT04663282|Experimental|INS068|Intervention: Drug: INS068 injection
10209196|NCT04663282|Active Comparator|IDeg|Intervention: Drug: insulin Degludec
10213597|NCT03731260|Experimental|(Part 1) Avapritinib Dose 1 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
10213598|NCT03731260|Experimental|(Part 1) Avapritinib Dose 2 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
9857129|NCT03773796|Other|Treatment Group|Assessment of long-term efficacy and safety of nabilone 0.25 mg - 2 mg
9857130|NCT03782233|Experimental|deep neuromuscular blockade group (Group D)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive deep neuromuscular blockade (post-tetanic count = 1-2) using high dose rocuronium.
9857131|NCT03782233|Other|moderate neuromuscular blockade group (Group M)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive moderate neuromuscular blockade (train-of-four count = 1-2) using moderate dose rocuronium.
9857132|NCT03781375|Placebo Comparator|Methotrexate + Placebo|Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
9857133|NCT03781375|Experimental|Methotrexate + Etanercept|Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
9857134|NCT03781336|Experimental|Mindfulness-based self-care|Mindfulness-based self-care (5 weeks)
9857135|NCT03781336|No Intervention|Life as usual control|Life as usual control (5 weeks)
9857136|NCT03780400|Experimental|Osteoarthritis Physical Activity Care Pathway|4 month physical activity (PA) counseling intervention
9857137|NCT03779997|Experimental|Video-based DOT Application|
9857138|NCT03779997|No Intervention|Treatment as Usual (TAU)|
9857139|NCT03779503|Active Comparator|midafilcon A|Subjects will be randomized to wear midafilcon A 1 day for one week of daily wear during the study.
9857140|NCT03779503|Active Comparator|somofilcon A|Subjects will be randomized to wear somofilcon A 1 day for one week of daily wear during the study.
9857141|NCT03780010|Experimental|TRC105 + B + P + C|TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
9857142|NCT03778190|Experimental|Magnet|The physician will attempt to remove the corneal foreign body using an eye magnet for these patients.
9857143|NCT03777059|Placebo Comparator|Placebo|Placebo-matching atogepant tablets orally once daily for 12 weeks.
9857144|NCT03777059|Experimental|Atogepant 10 mg|Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
9857145|NCT03777059|Experimental|Atogepant 30 mg|Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
9857146|NCT03777059|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
9857147|NCT03772522|Experimental|Immediate dk Leadership Intervention|"Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.~After the delayed intervention group takes the intervention, the two groups are joined into a single arm."
9857148|NCT03772522|Placebo Comparator|Delayed dk Leadership Intervention|"Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses."
9857149|NCT03772327|Experimental|Routine counseling + AdhereTech bottle|"Participants will receive routine medication adherence counseling and be given the AdhereTech smart bottle with reminders."
9857150|NCT03772327|Active Comparator|Routine counseling|Participants will receive routine medication adherence counseling.
9857151|NCT03777865|Experimental|13vPnC provided as a 0.5-mL dose in a prefilled syringe|All subjects receive a single dose (0.5mL) of 13vPnC
9857152|NCT03774576|Experimental|RO7017773|Single dose of RO7017773
9857153|NCT03774576|Experimental|RO7017773 and Itraconazole|Single dose of RO7017773 and multiple doses of itraconazole
9857154|NCT03776539|Experimental|ELX-02|Drug: ELX-02
9857155|NCT03772041|Experimental|OPC-61815 injection 16 mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
9857156|NCT03772041|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
9857157|NCT03775681|Experimental|Device feasibility (Laryngeal Mask Airway, ERCP)|Patients wear Laryngeal Mask Airway after receiving general anesthesia and falling asleep. Patients then undergo standard of care endoscopic retrograde cholangiopancreatography. Patients also complete a 5-minute interview following ERCP procedure.
9857158|NCT03774823|Experimental|Freeze Plus|Subjects in this arm will receive treatment using RF and PEMF
9857159|NCT03774823|Experimental|Ultrasound|Subjects in this arm will receive treatment using ultrasound
9857160|NCT03774745|Experimental|Progesterone|"Micronized progesterone 200mg oral capsules starting 24 hours after mifepristone 200mg ingestion (day 1).~Progesterone treatment days 2-4: two capsules twice daily orally. Progesterone treatment days 5-15, 16 or 17: two capsules once daily orally."
9857161|NCT03774745|Placebo Comparator|Placebo oral capsule|Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
9857162|NCT03774433|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
9857163|NCT03771560|Experimental|Open-label|In this open-label trial, all subjects will receive the twice daily dose of folinic acid. Folinic acid will be delivered in pill form at a weight-based dose.
9857164|NCT03770091|Experimental|Foam and Compression Wrap|Patients will use Theraworx foam and a compression wrap
9857165|NCT03770091|Placebo Comparator|Placebo Foam and Compression Wrap|Patients will use placebo foam and a compression wrap
9857166|NCT03770091|Experimental|Foam alone|Patients will use Theraworx foam without compression wrap
9857167|NCT03769896|Active Comparator|Treatment Group|Nabilone 0.25 mg
9857168|NCT03769896|Placebo Comparator|Placebo Group|Placebo (corn starch)
9857169|NCT03769649|Experimental|Treatment arm|Subjects receive CelluTite treatment followed by Morpheus8 treatment
9857170|NCT03769207|Other|Ambulatory ECG|
9857171|NCT03768856|Experimental|Temporally Feathered Radiation Therapy (TFRT)|"Temporally feathered radiation therapy is designed for targets within close proximity to multiple organs at risk. The foundation of this planning technique is the rotation of radiation dose to the nearby organs at risk on a daily basis, and hence the term feathering."
9857172|NCT03768726|Experimental|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
9857173|NCT03768206|Experimental|PATH|PATH participants will receive Standard Outpatient Physical Therapy. In addition, physical therapist discuss physical activity & assist with goal setting during therapy sessions.
9857174|NCT03768206|Active Comparator|PATH-12|PATH-12 participants will receive Standard Outpatient Physical Therapy. In addition, PATH-12 participants will receive a Physical activity session (1-hour) focusing on physical activity and goal setting at 12 weeks after surgery.
9857175|NCT03767894|Experimental|MyHand orthosis|Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.
9857176|NCT03767738|Experimental|Intravitreal Aflibercept Injection (IAI)|Cohort 1 - Initial patients Cohort 2 - Additional patients
9857177|NCT03767153|Experimental|80 pin applicator|
9857178|NCT03767153|Active Comparator|160 pin applicator|
9857179|NCT03767062|Active Comparator|Topiramate|Topiramate will be introduced 25 mg/day b.i.d. for the first week and increased to 100 mg/day b.i.d. for the second week.
9857180|NCT03767062|Active Comparator|Greater Occipital +Supratrochlear Nerve Block|"Greater occipital nerve block (GONB) will be applied to medial of the occipital artery which localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg) and 1 ml 0,9% sodium chloride (NaCl). The injection is performed using a 22 gauge (G) × 1¼ (0.7 × 40mm) injector when the patient is lying prone on the table. The scalp is cleaned with iodine before procedure and injections are performed bilaterally with a volume of 2 mL after negative aspiration for blood. Supratrochlear nerve block (STNB) is applied 1 cm medial to superior orbital fissure using a mixture of 8 mg bupivacaine and 1.4 ml 0,9% NaCl. STNB is performed bilaterally with a volume of 1.5 mL after negative aspiration for blood."
9857181|NCT03766646|Experimental|Speech|Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
9857182|NCT03766646|Active Comparator|Non-speech|Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
9857183|NCT03766373|Active Comparator|Drug: OP0201|
10209197|NCT04659746|No Intervention|Control|Participants allocated to the control group will receive the routine care and follow-up for chronic patients in Pandemic situation at Hospital Regional de Encarnación (Encarnación, Paraguay), according to epidemiological surveillance and preventive isolation management protocol released by the Ministry of Health of Paraguay (URL: https://www.mspbs.gov.py/dependencias/portal/adjunto/c1c79a-ProtocoloVigilanciaEpidemiolgica.pdf)
9857184|NCT03766373|Placebo Comparator|Drug: Placebo|
9857185|NCT03766165|Experimental|Intervention|Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
9857186|NCT03766165|Other|Control|Job announcements only
9857187|NCT03765996|Active Comparator|Decongestive Physiotherapy|This group received Complex Decongestive Physiotherapy.
10209198|NCT04659746|Experimental|Intervention|"Participants allocated to the intervention group will follow the same routine care as the control group. Additionally, they will receive access to the MejoraCare app.~The MejoraCare app delivers the following functionalities:~Remote symptoms monitoring through an electronic Patient Reported Outcome (ePRO)~Patient empowerment through personalized educational resources promoting healthy lifestyles"
9857188|NCT03765996|Experimental|Decongestive Physiotherapy plus taping|This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.
9857189|NCT03765762|Experimental|GRF6019|Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
9857190|NCT03765762|Placebo Comparator|Placebo|Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
9857191|NCT03765502|Experimental|Nasal Glucagon Device (NG)|Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
9923983|NCT00856622|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
10209199|NCT04656899|Active Comparator|Pillsy arm|Participants in the Pillsy arm will receive a prescription for buprenorphine-naloxone with an ''active'' Pillsy smart cap that will continuously collect data on pill bottle openings, missed doses, text messages sent, automated phone calls made. A participant who misses an entire day of buprenorphine-naloxone will automatically receive a survey about cravings and risk of relapse.
10209200|NCT04656899|No Intervention|Service as usual arm|Participants in the Service As Usual arm will receive a prescription for buprenorphine-naloxone with an ''inactive'' Pillsy smart cap that will track openings but will not provide reminders or any other messaging. They will receive a basic application that can deploy patient satisfaction surveys.
10209201|NCT04656080||transplant recipients <1year without AMR|20 recent transplant recipients (<1 year) without antibody-mediated rejection (AMR);
10209202|NCT04656080||3 months post-heart transplant with AMR|• 7 transplant recipients, at least 3 months post-transplant, with antibody-mediated rejection
10209203|NCT04655079|Experimental|Real tDCS group|Participants receive anodal tDCS on the left dlPFC for 5 days/week for 2 weeks
10209204|NCT04655079|Sham Comparator|Sham group|Participants receive sham stimulation on the left dlPFC for 5 days/week for 2 weeks
10209205|NCT04654689|Experimental|Intervention group|30 patients will be given the combination of resveratrol and curcumin liposomed with G04CB02, in a single daily dose for 4 months.
10209206|NCT04654689|Placebo Comparator|Control group|30 patients, who will receive a placebo with the same dosage pattern and for the same period of time. The placebo will consist of water with sucrose replacing the liposomal polyphenols, and a soft capsule of microcrystalline methylcellulose instead of G04CB02. Both the packaging and the capsule format will be identical to those of the treatment administered in the intervention group
10209207|NCT04654533|Experimental|COSC|"Eight weekly manualized sessions of Circle of Security Classroom (COSC), delivered in groups, two hours per session, 5-10 childcare providers per group.~COSC is facilitated by a psychologist who is a registered COSP facilitator and who has completed the an additional COSC online training."
10213599|NCT03731260|Experimental|(Part 1) Avapritinib Dose 3 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
9857192|NCT03765502|Active Comparator|Glucagon Emergency Kit (GEK)|Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
9857193|NCT03765164|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
9857194|NCT03765164|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to GlycoMark 1,5-AG test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
9857195|NCT03765138|Experimental|PE/Pramipexole|Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
9857196|NCT03764449|Experimental|Cohort 1|Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
9857197|NCT03764449|Experimental|Cohort 2|Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
9857198|NCT03763929|Experimental|Trans Sodium Crocetinate|Trans sodium crocetinate (TSC) will be administered intravenously as a bolus to subjects randomized to experimental drug. The bolus dose will consist of 0.25 mg/kg of TSC based on the estimated subject weight.
9857199|NCT03763929|Placebo Comparator|Placebo|The placebo consists of commercially available sterile saline. Placebo will be administered intravenously as a bolus to subjects randomized to placebo. The volume of sterile saline will be based on the estimated subject weight.
9857200|NCT03763747|Experimental|Scoreflex NC Scoring PTCA Catheter|Single arm with investigational Scoreflex NC Scoring PTCA catheters
9857201|NCT03763175|Active Comparator|SYN-010 21 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (21 mg PO QD). Study activities will be the same across all three arms.
9857202|NCT03763175|Active Comparator|SYN-010 42 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (42 mg PO QD). Study activities will be the same across all three arms.
9857203|NCT03763175|Placebo Comparator|Placebo|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of placebo. Study activities will be the same across all three arms.
9857204|NCT03763058|Other|Music intervention|The music intervention is administered via a smartphone- (and computer-) based application called Music Care.
9857205|NCT03762993|Experimental|Healthy Adults|Participants will complete vocal rest and controlled phonation
9857206|NCT03762993|Experimental|Healthy Adults reporting Vocal Fatigue|Participants will complete vocal rest and controlled phonation
9857207|NCT03762681|Experimental|Part 1: Single Ascending Dose, HV|Healthy volunteers will be administered a single dose of RO7239958 or placebo subcutaneously (SC).
9857208|NCT03762681|Experimental|Part 2a: Multi-dose, CHB|Participants with chronic hepatitis B will be administered different dose levels of RO7239958 or placebo SC. Dosages will be determined from data collected from Part 1.
9857209|NCT03762681|Experimental|Part 2b: Multi-dose, CHB (Optional)|Additional study arm to open based on data collected from Part 2a. Participants with chronic hepatitis B will be administered different doses and frequencies of RO7239958 or placebo SC.
9857210|NCT03762668|Other|MDACL, then DACL|Modified delefilcon A contact lenses (MDACL) worn first, followed by delefilcon A contact lenses (DACL), as randomized. Each product worn bilaterally (in both eyes) for approximately 1 week in a daily disposable modality.
9857211|NCT03762668|Other|DACL, then MDACL|DACL worn first, followed by MDACL, as randomized. Each product worn bilaterally for approximately 1 week in a daily disposable modality.
9857212|NCT03762616|Experimental|Micro-Ultrasound Biopsy|
9857213|NCT03762616|Experimental|MRI Targeted Biopsy|
9923984|NCT00856622|Active Comparator|timolol 0.5% ophthalmic solution|one drop in the morning and evening
9923985|NCT00856622|Active Comparator|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
9923986|NCT00856648||Group 1|SCI
9857214|NCT03762213|Experimental|Oculus GO VR HMD, application Happy Place (© Mimerse)|"Oculus GO is a stand-alone, consumer-grade, virtual reality head-mounted display (HMD). The HMD is placed on the head of the user blocking off the surrounding environment. The visuals and audio are relayed through the HMD in a virtual space.Happy Place (© Mimerse) is a publicly available application with an explicit intent to be used for chronic pain patients. It has the critical elements of VR, namely immersion and interactivity.~Immersion: The scene is a serene lakeside campground with guided relaxation and soothing music. The application intends to promote positive effects such as calmness and feeling of wonder.~Interactivity: Happy Place uses an innovative 'gaze-based interaction' with the virtual world. Around 50 'gaze objects' are placed around the scene and gazing at them would trigger an event.~The entire duration of the experience will be kept at 10 minutes."
9857215|NCT03762213|Placebo Comparator|iPad, application Happy Place (© Mimerse)|An iPad with earphones (Apple Inc. Cupertino CA) will be used for controls. The participants in control group will watch the same content for the same duration on an iPad screen (flat version of Happy Place). This experience will be different from the intervention group in two ways: first, lack of an immersive environment, and second, lack of interactivity with the environment.
9857216|NCT03762200|Other|SURGICEL Powder - Single arm|Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
9857217|NCT03761368|Experimental|RIPC group|The RIPC group underwent Remote Ischemic Preconditioning.
9857218|NCT03761368|Sham Comparator|Control group|Patients from control group had sham Remote Ischemic Preconditioning.
9857219|NCT03761147|Experimental|Paula Method|
9857220|NCT03761147|No Intervention|Standard of Care|
9857221|NCT03760913|Experimental|OLP-1002: Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 μg, 3 μg, 6 μg, 12 μg, 20 μg, 40 μg, 80 μg, 160 μg
9857222|NCT03760913|Experimental|OLP-1002: Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
9857223|NCT03760913|Placebo Comparator|Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
9857224|NCT03760913|Placebo Comparator|Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
9857225|NCT03760796|Experimental|Corrie Health Digital Platform group|Receives the Corrie Health intervention plus the standard of care
9857226|NCT03760640|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) of LY900014 administered via continuous subcutaneous insulin infusion (CSII) by the Medtronic MiniMed 670G insulin pump.
9857227|NCT03760640|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL of Insulin lispro (Humalog) administered via CSII by the Medtronic MiniMed 670G insulin pump.
9857228|NCT03760510|Experimental|Adhesive Tape|Patients in adhesive tape arm had endotracheal tube secured with adhesive tape
9857229|NCT03760510|Experimental|Tube Fastener|Patients in the tube fastener arm had endotrachel tube secured with tube fastener
9857230|NCT03760250|Experimental|Imiquimod|5% Imiquimod cream once daily to keloid area 5-times a week for 6 weeks, starting 1-week prior to keloid excision
9857231|NCT03759600|Experimental|Niraparib 300 mg|Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 - 28 of each 28-day treatment cycle up to 6 cycles till data cut-off: 01 July 2019.
9857232|NCT03759340|Experimental|ATI 502 0.46% Topical Solution|Subjects will apply ATI-502 Topical Solution, 0.46% twice-daily for 24 weeks followed by a 4-week post-treatment follow up period.
9857233|NCT03758716|Experimental|FB825|Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.
9857234|NCT03758365|Experimental|MC2-01 Cream|Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
9857235|NCT03758365|Active Comparator|Clobetasol propionate 0.05% lotion|Single application of Clobetasol propionate 0.05%,
9857236|NCT03758365|Active Comparator|Betamethasone dipropionate 0.05% cream|Single application of Betamethasone dipropionate 0.05%,
9857237|NCT03758365|Active Comparator|Triamcinolone acetonide 0.1% cream|Single application of Triamcinolone acetonide 0.1%,
9857238|NCT03758365|Active Comparator|Hydrocortisone Butyrate 0.1% cream|Single application of Hydrocortisone Butyrate 0.1% Cream
9857239|NCT03758365|Active Comparator|Desonide 0.05% cream|Single application of Desonide 0.05%
9857240|NCT03758365|Placebo Comparator|Vehicle cream|Single application of Vehicle
9857241|NCT03758157||Temperature Measurement|Each subject will have his or her temperature measured by both the welloStationX Automated Non-Contact Thermometer and the Welch Allyn SureTemp Oral Thermometer.
9857242|NCT03757988|Experimental|Single Arm Experimental Walking Group|This is a pilot project with one single group that will be evaluated on the adherence to a walking protocol (Exercise Intervention- PACE-Life). Subjects will be walking two times a week under the supervision of the psychiatric clinic. In addition, subjects will be encouraged to add walking on their own on the days when subjects are not exercising under the supervision of the clinic. This pilot will be used to inform the final design of the subsequent randomized clinical trial that will be implemented following this pilot.
9857243|NCT03757312|Experimental|Fontan|Patients undergoing Fontan procedure to redirect blood flow from the lower body to the lungs.
9857244|NCT03757312|Active Comparator|Non-Fontan|Patients undergoing other cardiac surgeries requiring cardiopulmonary bypass.
9857245|NCT03757234|Experimental|Omadacycline 200 iv/200 iv|On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
9923987|NCT00856648||Group 2|Able-bodied
9923988|NCT00856687|Experimental|PF-03893787|
9923989|NCT00856687|Placebo Comparator|Placebo|
9857246|NCT03757234|Experimental|Omadacycline 200 iv/100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
9857247|NCT03757234|Experimental|Omadacycline 200 iv/300 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
9857248|NCT03757234|Experimental|Omadacycline 200 iv/450 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
9857249|NCT03757234|Active Comparator|Levofloxacin 750 iv/750 po or iv|On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
9857250|NCT03757039|Experimental|Multifocal Contact Lenses|Multifocal soft contact lenses according to the subject's prescription and fitted using the Alcon multifocal fitting guide. Lenses were worn bilaterally (in both eyes) for up to 3 hours, 1 day only.
9857251|NCT03757039|Active Comparator|PAL Spectacles|Progressive addition lens spectacles according to the subject's habitual prescription, with testing up to 3 hours, 1 day only.
9857252|NCT03756883|Experimental|Test|Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg
9857253|NCT03756883|Active Comparator|Reference|ADVAIR DISKUS® 100/50 (fluticasone propionate and salmeterol) Inhalation Powder
9857254|NCT03756883|Placebo Comparator|Placebo|Placebo
9857255|NCT03756506|Active Comparator|Novel Microbicidal Liquid Polymer|"All pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge,tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris. Step 3: Apply product with Q-tip on clean dry wound around (extending approximately one inch around pin site) and on the pin. The Polymer will be applied daily while in the hospital and then at a minimum of at least three times a week until pin removal."
9857256|NCT03756506|No Intervention|Control group: no Novel Microbicidal Liquid Polymer|"The usual care of pin track sites will be followed as outlined belowAll pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.~Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge, tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Research participants will be instructed that the approach to pin care should occur in a step-wise fashion. Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris."
9857257|NCT03756285|Experimental|AZD4831|AZD4831 tablets taken orally for for 90 days.
9857258|NCT03756285|Placebo Comparator|Placebo|Placebo tablets taken orally for 90 days.
9857259|NCT03756129|Experimental|MIJ821 low dose weekly|Infusion. MIJ821 low dose weekly - 0.16 mg/kg
9857260|NCT03756129|Experimental|MIJ821 low dose bi-weekly|Infusion. MIJ821 low dose bi-weekly - 0.16 mg/kg
9857261|NCT03756129|Experimental|MIJ821 high dose weekly|Infusion. MIJ821 high dose weekly - 0.32 mg/kg
9923990|NCT00856687|Active Comparator|Montelukast|
9857262|NCT03756129|Experimental|MIJ821 high dose bi-weekly|Infusion. MIJ821 high dose bi-weekly - 0.32 mg/kg
9857263|NCT03756129|Placebo Comparator|Placebo weekly|Infusion. Placebo weekly
9857264|NCT03756129|Active Comparator|Ketamine 0.5 mg/kg weekly|Infusion. Ketamine 0.5 mg/kg weekly
9857265|NCT03756038|Experimental|Drug: Oral Lorazepam (1mg)|Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
9857266|NCT03756038|Placebo Comparator|Drug: Oral Placebo|
9794301|NCT01502306|Experimental|Phone counseling, NRT and incentives|"One-on-one, proactive telephone counseling to quit smoking; The counseling addresses behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day.~Gift cards (to one of 4 major chains) are $20 for the first counseling session and $10 for each additional one (up to five sessions total)."
9794302|NCT01502332|Experimental|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways.
9794303|NCT01502332|Active Comparator|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways.
9794304|NCT01502410|Experimental|Group 1 Relapsed/Refractory Rhabdomyosarcoma|"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
9794305|NCT01502410|Experimental|Group 2 Relapsed/Refractory Wilms tumor|"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
9794306|NCT01502410|Experimental|Group 3 Relapsed/Refractory hepatocellular carcinoma|"Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
9794307|NCT01502410|Experimental|Group 4 Papillary thyroid carcinoma|"Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
9794308|NCT01502423|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
9794309|NCT01502423|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
9794310|NCT01502631|Active Comparator|SUN13837|
9794311|NCT01502631|Placebo Comparator|Placebo|
9794312|NCT01502644|Active Comparator|Low Negative Affect (NA)|Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
9794313|NCT01502644|Active Comparator|Moderate NA|Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
9794314|NCT01502644|Active Comparator|High NA|Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
9794315|NCT01502709|Experimental|Caloric Vestibular Neurostimulation|Subjects received caloric vestibular neurostimulation
9794316|NCT01502709|Placebo Comparator|Placebo Arm|Subjects received placebo
9794317|NCT01502761|Experimental|Regional Intra-arterial Magnesium 0.75g|Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
9794318|NCT01502761|Experimental|Regional Intra-arterial magnesium 1.5g|Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
9794319|NCT01502761|Experimental|Regional/ Distal (75/25%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
9794320|NCT01502761|Experimental|Regional/ Distal (50/50%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
9857267|NCT03756012|Active Comparator|Low Pulse Width (<500 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths <500 μsec.
9857268|NCT03756012|Active Comparator|High Pulse Width (>1000 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths >1000 μsec
9857269|NCT03755882|Experimental|TEST/CONTROL|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
9857270|NCT03755882|Experimental|CONTROL/TEST|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
9857271|NCT03755661|Experimental|Intervention|This intervention arm is a combined in-person text messaging intervention
9857272|NCT03755661|No Intervention|Assessment Only Control|The is the assessment only comparison condition
9857273|NCT03754582|Experimental|Perampanel|Participants with POS with or without secondarily generalized seizures or PGTC seizures will receive perampanel 8 to 12 milligram (mg), tablets, orally, once daily for 28 days (Day -28 to Day -1) in Pretreatment Phase and followed by 8 to 12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4 in Treatment Phase, and then again 8 to 12 mg, tablets, orally, once daily from Day 5 to Day 11 in Follow-up Phase as an adjunctive therapy, along with 1 to a maximum of 3 marketed concomitant antiepileptic drugs (AEDs).
9857274|NCT03754556||Women with IUD|Women with an intrauterine device (IUD) and electronic health records in the Kaiser Permanente Northern California (KPNC), Kaiser Permanente Southern California (KPSC), Kaiser Permanente Washington (KPWA) and the Regenstrief Institute (RI) databases.
9857275|NCT03753113|Experimental|Treatment group|The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
9857276|NCT03753113|Active Comparator|Control group|The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
9857277|NCT03752567||Group study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, fundus oculi, ankle arm index) and self analysis (glycated hemoglobin, lipid profile, uric acid microalbuminuria).
9857278|NCT03752528||Part A Cohort|Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
9857279|NCT03752528||Part B Cohort|Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.
9857280|NCT03752151|Experimental|MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode|Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.
9857281|NCT03751657|Experimental|Insulin 287|Participants will receive once weekly insulin 287 and once daily placebo in combination with metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i) during 26 weeks of treatment period.
9857282|NCT03751657|Active Comparator|Insulin glargine|Participants will receive once daily insulin glargine and once weekly placebo in combination with metformin with or without DPP4i during 26 weeks of treatment period.
9857283|NCT03751280|Experimental|PEAR-004|Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
9857284|NCT03751280|Sham Comparator|Sham|Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.
9857285|NCT03751020|Experimental|Expressive Writing (EW)|Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
9857286|NCT03751020|Experimental|Self-Affirmation (SA)|Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
9857287|NCT03751020|Placebo Comparator|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.
9857288|NCT03750955|Experimental|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where plaque induced gingivitis results from a cessation of oral hygiene in a sextant using a stent-induced biofilm overgrowth model.
9857289|NCT03750955|Active Comparator|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene (tooth brushing with fluoride toothpaste and flossing twice daily) is maintained.
9857290|NCT03750695|Experimental|Acute Resistance Exercise|One acute exercise session of 40 minutes of resistance exercise
9857291|NCT03750695|Experimental|Acute Aerobic Exercise|One acute session of 40 minutes of aerobic exercise
9857292|NCT03750695|Placebo Comparator|Acute Resting Session|One session of 40 minutes of quiet rest
9857293|NCT03748992|Experimental|gNO|Subjects will be receiving nitric oxide every week day for 3 weeks.
9857294|NCT03748979|Experimental|Cohort A1; TAK-925 (Dose Level A1)|TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
9857295|NCT03748979|Experimental|Cohort A2; TAK-925 (Dose Level A2)|TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857296|NCT03748979|Experimental|Cohort A3; TAK-925 (Dose Level A3)|TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857297|NCT03748979|Experimental|Cohort A4; TAK-925 (Dose Level A4)|TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857298|NCT03748979|Experimental|Cohort A5; TAK-925 (Dose Level A5)|TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857299|NCT03748979|Experimental|Cohort A6; TAK-925 (Dose Level A6)|TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857300|NCT03748979|Placebo Comparator|Part A (Cohorts A1-A6); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in healthy participants.
9857301|NCT03748979|Experimental|Cohort B1; TAK-925 (Dose Level B1)|TAK-925, Dose Level B1, once daily for up to 7 days in participants with narcolepsy.
9857302|NCT03748979|Experimental|Cohort B2; TAK-925 (Dose Level B2)|TAK-925, Dose Level B2, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857303|NCT03748979|Experimental|Cohort B3; TAK-925 (Dose Level B3)|TAK-925, Dose Level B3, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857304|NCT03748979|Experimental|Cohort B4; TAK-925 (Dose Level B4)|TAK-925, Dose Level B4, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857305|NCT03748979|Placebo Comparator|Part B (Cohorts B1-B4); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
9857306|NCT03748979|Experimental|Cohort C1; TAK-925 (Dose Level C1)|TAK-925, Dose Level C1, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857307|NCT03748979|Experimental|Cohort C2; TAK-925 (Dose Level C2)|TAK-925, Dose Level C2, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857308|NCT03748979|Placebo Comparator|Part C (Cohorts C1-C2); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
9857309|NCT03748979|Experimental|Cohort A'1; TAK-925 (Dose Level A'1)|TAK-925, Dose Level A'1, single dose in healthy participants.
9857310|NCT03748979|Experimental|Cohort A'2; TAK-925 (Dose Level A'2)|TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
9857311|NCT03748758|Active Comparator|Drug: OP0201 (30 mg)|Cohort A- 30 mg per day X 14 days
9857312|NCT03748758|Placebo Comparator|Drug: Placebo|Cohort A- 0 mg per day X 14 days Cohort B- 0 mg per day X 14 days
9857313|NCT03748758|Active Comparator|Drug: OP0201 (60 mg)|Cohort B-60 mg per day X 14 days
9857314|NCT03748706|Experimental|Simufilam (PTI-125)|Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)
9923991|NCT00856700|Experimental|GLP-1 infusion|Patients with metabolic syndrome
9923992|NCT00856713|Experimental|1 YM|Healthy young males
10209208|NCT04654533|No Intervention|Control|"Usual care control condition, i.e., standard practice in the participating childcare centers.~Teams of childcare providers are allocated to either COSC or waitlist in clusters, and baseline and follow-up measures are collected parallel in both groups. Childcare providers allocated to the waitlist will receive COSC after the follow-up data have been collected."
9857315|NCT03748264|Active Comparator|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant. Therapy information is available continuously to site staff personnel in the standard care arm.
9857316|NCT03748264|Experimental|DreamMapper Application|The DreamMapper Application group will receive the site's therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. Participants in this group will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously as well
9857317|NCT03748264|Experimental|DreamMapper Application with Therapist Assist|The DreamMapper Application wit Therapist Assist group will not receive the site's therapy initiation standard of care but will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, and their Philips Respironics mask. and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously as well
9857318|NCT03747497|Experimental|contezolid acefosamil|contezolid acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV q12h for at least 3 total IV doses, followed by 1300 mg PO q12h for 10 to 14 days
9857319|NCT03747497|Active Comparator|linezolid|linezolid 600 mg IV q12h for at least 3 total IV doses, followed by 600 mg PO q12h for 10 to 14 days
9857320|NCT03746405|Active Comparator|Repetitive TMS (rTMS)|excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)
9857321|NCT03746405|Sham Comparator|Sham repetitive TMS (rTMS)|electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)
9857322|NCT03745937|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous (SC) dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week treatment extension period (TEP).
9857323|NCT03745937|Placebo Comparator|Placebo Cohort 1|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the uptitration period and thereafter once daily through 3 week TEP.
9857324|NCT03745937|Experimental|MEDI0382 Cohort 2|Participants will receive SC dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week TEP.
9857325|NCT03745937|Placebo Comparator|Placebo Cohort 2|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
9857326|NCT03745222|Experimental|Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy|Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide
9857327|NCT03745222|Experimental|Arm 2: Placebo + cCRT followed by tislelizumab monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
9923993|NCT00856713|Experimental|2 EM|Healthy elderly males
9923994|NCT00856713|Experimental|3 YF|Healthy young females
9923995|NCT00856713|Experimental|4 EF|Healthy elderly females
10209209|NCT04651634|Experimental|20 mg|MIT-001 20 mg
10209210|NCT04651634|Experimental|40 mg|MIT-001 40 mg
10209211|NCT04651634|Experimental|60 mg|MIT-001 60 mg
10209212|NCT04651634|Placebo Comparator|Placebo|Matching placebo
10209213|NCT04651192||Soldiers|50 Israeli Defense Forces (IDF) infantry soldiers, all male, aged 18 years, with Hebrew as the dominant language and no condition excluding an MRI scan.
10209214|NCT04651192||Students|50 Reserve Officer Training Corps (ROTC) undergraduate students at Tel-Aviv University, all male, aged 18-19, with Hebrew as the dominant language and no condition excluding an MRI scan.
10209215|NCT04649866|Experimental|Test group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
10209216|NCT04649866|Active Comparator|Control group|Endothelial dysfunction will be tested using Strain-gauge plethysmography to measure forearm blood flow during infusions of acetylcholine [ACh] and sodium nitroprusside [SNP]
10209217|NCT04647656|Active Comparator|HBOT treatment group|40 daily hyperbaric oxygen treatment sessions will be administered 5 days per week
10209218|NCT04647656|Sham Comparator|HBOT sham group|40 daily Sham non-hyperbaric oxygen treatment will be administered 5 days per week
10209219|NCT04643405|Experimental|APG1387 in combination with Gemcitabine and Nab-Paclitaxel|
10209220|NCT04640155|Other|Regular Diet|
10209221|NCT04640155|Experimental|Low FODMAP|
10209222|NCT04640038|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
9857328|NCT03745222|Placebo Comparator|Arm 3: Placebo + cCRT followed by placebo monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
9857329|NCT03745092|Experimental|NBO group|Between the two time 30min-EEG recordings, the patients in the NBO group would receive NBO (8L/min, via face mask) for 45min.
9857330|NCT03745092|Placebo Comparator|Control group|Between the two time 30min-EEG recordings, the patients in the control group would have a rest (lying, sitting or walking) for 45min.
9857331|NCT03744780|Experimental|ACT Workshop for Emotional Eating|All participants will be assigned to a one-day intervention using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
9923996|NCT00856713|Experimental|5 CTP-A|Patients with hepatic cirrhosis CTP-class A
9923997|NCT00856713|Experimental|6 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
9923998|NCT00856752|Experimental|T1|Pre-treatment with rifampicin
9923999|NCT00856752|Experimental|T2|Pre-treatment with cyclosporin
9924000|NCT00856752|Experimental|Reference|Administration of NRL001 alone: no pre-treatment
9924001|NCT00856765|Experimental|1|Drug eluting balloon followed immediately by implantation of bare metal stent
9924002|NCT00856765|Active Comparator|2|Drug eluting stent
9924003|NCT00856765|Active Comparator|3|Bare metal stent
9924004|NCT00856804|Experimental|1|thalidomide added to peg-interferon + ribavirina
9924005|NCT00856817|Experimental|1|L-arginine treatment first, heme arginate treatment second
9924006|NCT00856817|Experimental|2|Heme arginate treatment first, L-arginine treatment second
9924007|NCT00856869|Experimental|1 YM|Healthy young males
9924008|NCT00856869|Experimental|2 EM|Healthy elderly males
9924009|NCT00856869|Experimental|3 YF|Healthy young females
9924010|NCT00856869|Experimental|4 EF|Healthy elderly females
9924011|NCT00856869|Experimental|5 NASH|Patients with presumed NASH
9924012|NCT00856869|Experimental|6 CTP-A|Patients with hepatic cirrhosis CTP-class A
9924013|NCT00856869|Experimental|7 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
9924014|NCT00856882|Experimental|soy protein and isoflavones|
9924015|NCT00856882|Experimental|milk protein and isoflavones|
9924016|NCT00856882|Placebo Comparator|milk protein only|
9924017|NCT00856895||Hispanic|
9924018|NCT00856895||Non-Hispanic|
9924019|NCT00856960|Active Comparator|1|Aliskiren 600 mg
9924020|NCT00856960|Active Comparator|2|Aliskiren 150 mg
9924021|NCT00856960|Active Comparator|3|Losartan 100 mg
9924022|NCT00856960|Placebo Comparator|4|Placebo
9924023|NCT00857012||All patients|treated with Anastrozole as per SPC
9924024|NCT00857025|Experimental|Treatment (beta-glucan MM-10-001)|Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9924025|NCT00857038|Experimental|1|Doxycycline 100mg daily
9924026|NCT00857038|Placebo Comparator|2|Placebo
9924027|NCT00857051|Experimental|1|A 22 minute DVD that discusses common stressor in the early postpartum.
9924028|NCT00857051|Experimental|2|A 24 hour hotline available for the first 3 months postpartum.
9924029|NCT00857051|Experimental|3|Both the film and the hotline will be given to this arm.
9924030|NCT00857051|No Intervention|4|A CD of children's music will be given to mothers in this arm.
9924031|NCT00857077|Placebo Comparator|1 Placebo|
9924032|NCT00857077|Active Comparator|2 Sulfadoxine-pyrimethamine (SP)|
9924033|NCT00857103|No Intervention|1|Standard care
9924034|NCT00857103|Experimental|2|Use of Choice intervention to support consultations
9924035|NCT00857116|Active Comparator|Albendazole|Albendazole 400mg per os once daily for three consecutive days
9924036|NCT00857116|Placebo Comparator|Placebo|Placebo 400mg per os for three consecutive days
9924037|NCT00857129|No Intervention|1|Low risk women with expected normal birth are being Randomized to The Midwife-led Unit, with low amount of intervention, No epidural is offered, no medical augmentation available, unless for the active phase of the second stage. If extended surveillance is necessary or if the birth no longer is considered to be normal and needs to be taken over by a doctor, the woman will be transferred to either the Normal Unit or the Special Unit
9924038|NCT00857129|Experimental|2|Low-risk women are randomised to this Low-risk maternal unit, The Normal Unit.The unit is organised for low-risk women with expected normal birth. The unit has access to extended surveillance, epidural and operative vaginal deliveries. If extended surveillance is necessary for a woman randomised to this unit, she does not have to be transferred to a higher level of care. Instrumental vaginal deliveries can be carried out at this unit.
9924039|NCT00857129|Experimental|3|Women with expected normal births are being randomised to this Special birth unit designed to take care of women before, under and after birth. The Special Unit cares for women with extended need for surveillance, but does also handle low-risk women.
9924040|NCT00857142|Experimental|1|Oxymorphone hydrochloride 40 mg extended release tablets (Sandoz)
9924041|NCT00857142|Active Comparator|2|Opana 40 mg extended release tablets
9924042|NCT00857155|No Intervention|Aspirin only|Continue aspirin until surgery
9924043|NCT00857155|Other|Clopidogrel and Aspirin|
9924044|NCT00857168|Active Comparator|Group 1|
9924045|NCT00857168|Active Comparator|Group 2|
9924046|NCT00857168|Active Comparator|Group 3|
9924047|NCT00857168|Active Comparator|Group 4|
9924048|NCT00857168|Active Comparator|Group 5|
9924049|NCT00857168|Active Comparator|Group 6|
9924050|NCT00857181||Liver Cirrhosis|Single cohort of patients with liver cirrhosis to be investigated in the study. Two-monthly measurements of serum cytokines.
9924051|NCT00857194||Group 2|Chronic, stable spinal cord injury
9857332|NCT03743311||Surgical treatment of Hemmorhoid|Patients after surgical treatment (Instrumental Invasive Surgical Procedures or Thrombectomy, Hemorrhoidectomy etc.)
9857333|NCT03743311||Conservative treatment of Hemmorhoid|Patients taken conservative treatment (Detralex)
9857334|NCT03743311||Combined treatment of Hemmorhoid|Combined treatment patients (surgery and conservative treatment)
9857335|NCT03743038|Experimental|FMX101 vehicle|FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)
9857336|NCT03743038|Experimental|Hydro-alcohol solution base|Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)
9857337|NCT03742973|Experimental|Baricitinib Cohort A|Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
9857338|NCT03742973|Placebo Comparator|Placebo Cohort A|Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
9857339|NCT03742973|Experimental|Baricitinib Cohort B|Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.
9857340|NCT03742973|Placebo Comparator|Placebo Cohort B|Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.
9857341|NCT03742440|Other|GrafixPL PRIME|Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
9857342|NCT03742427|Experimental|effect of c-collar in optic nerve sheath diameter|Comparing the effect of c-collar in minor head trauma patients by using optic nerve sheath diameter ultrasonography
9857343|NCT03742271|Experimental|senofilcon A|Subjects that are habitual spectacle wearers that have never worn contact lenses and have had an eye exam and an updated spectacle prescription in the last 6 months will be enrolled and fitted into the senofilcon A TEST Lens for a total period of 4 weeks.
9857344|NCT03742154|Experimental|Varenicline Group|50 participants will be enrolled in this group. They will receive a sample of varenicline to use for up to 4-weeks. They are receiving 40 - 0.5mg pills of varenicline, with instructions for titration.
9857345|NCT03742154|No Intervention|Control Group|49 participants will be enrolled in this group.
9857346|NCT03741725|Experimental|Pay-it-forward|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
9857347|NCT03741725|Experimental|Pay-what-you-want|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
9857348|NCT03741725|No Intervention|Standard of care|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing at the standard patient price.
9857349|NCT03741088|Experimental|VORTX Rx treatment|Focused ultrasound ablation of liver tumors.
9857350|NCT03741062|Experimental|J. Morita AdvErl Evo Er:YAG laser|Immediately following completion of the surgical procedure, this group will receive photobiomodulation treatment of the palatal tissue donor site with Er:YAG laser according to the parameters recommended by experts in this field and which have shown to induce maximal proliferation of human gingival fibroblasts (Energy Setting: 80 mJ, Pulse Rate: 25 Hz, Duration: 30 s).
9857351|NCT03741062|Sham Comparator|Control|This group will receive sham treatment of the palatal tissue donor site. The laser unit will be turned off. The clinician will simulate usage of the Er:YAG laser in a manner that is indistinguishable to the patient from the experimental group.
9857352|NCT03740659|Experimental|Levofloxacin + Dexamethasone|"Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
9857353|NCT03740659|Active Comparator|Levofloxacin|"Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
9857354|NCT03740659|Active Comparator|Dexamethasone|"Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
9857355|NCT03740152|Experimental|Transcranial Light Therapy|All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.
9857356|NCT03739866|Experimental|Part A: Lenacapavir 20 mg|Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
9857357|NCT03739866|Experimental|Part A: Lenacapavir 50 mg|Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
9857358|NCT03739866|Experimental|Part A: Lenacapavir 150 mg|Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
9857359|NCT03739866|Experimental|Part A: Lenacapavir 450 mg|Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
9857360|NCT03739866|Experimental|Part A: Lenacapavir 750 mg|Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
9857361|NCT03739866|Placebo Comparator|Part A: Placebo|Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
10209223|NCT04639388|Experimental|22q11.2DS|Children aged from 4 to 13 years old with 22q11.2 deletion syndrome
9857362|NCT03739866|Experimental|Part B: TAF 200 mg|Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
9857363|NCT03739866|Experimental|Part B: TAF 600 mg|Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
9857364|NCT03739684|Experimental|18F-DCFPyL Injection|9 mCi (333 MBq) IV injection of 18F-DCFPyL
9857365|NCT03739528|Experimental|Levofloxacin + Dexamethasone followed by dexamethasone|Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
9857366|NCT03739528|Active Comparator|Tobramycin + dexamethasone|Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
9857367|NCT03739242|Experimental|Nutraceutical combination|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
9857368|NCT03739242|Placebo Comparator|Placebo|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
9857369|NCT03738865|Experimental|G-Pen followed by Novo Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit
9857370|NCT03738865|Active Comparator|Novo Glucagon followed by G-Pen|1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
10209224|NCT04639388|Active Comparator|Control Group (Non22q11.2DS)|Children aged from 4 to 13 years old without developmental disease
9857371|NCT03738826|Experimental|Intervention arm|Lupus clinic providers will use Surescripts refill information to assess adherence level and address adherence barriers. We will assess the feasibility and acceptability of the intervention.
9857372|NCT03738475|Experimental|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
9857373|NCT03738475|Placebo Comparator|Placebo|Normal saline administered intravenously on days 1 and 8.
9857374|NCT03738241|Experimental|Arm 1|Participants will have prior administration of 2013 A/H7N9 IIV with MF59. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
9857375|NCT03738241|Experimental|Arm 2|Participants will have prior administration of 2013 A/H7N9 IIV with AS03. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
9857376|NCT03738241|Experimental|Arm 3|Participants will have prior administration of 2013 A/H7N9 IIV 15 mcg or 45 mcg unadjuvanted. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
9857377|NCT03738241|Experimental|Arm 4|Participants will have prior administration of 2013 A/H7N9 IIV + MF59 or AS03 (1st) then 2013 A/H7N9 IIV 15 mcg (2nd). Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
9857378|NCT03738241|Experimental|Arm 5|Participants who are A/H7 IIV-Naïve. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
9857379|NCT03738163|Other|Epaderm Cream|This is an open, non randomised single arm study.
9857380|NCT03738020|Experimental|HA IDF|
9857381|NCT03738020|Active Comparator|Restylane|
9857382|NCT03736928|Placebo Comparator|Placebo|Intramuscular single treatment
9857383|NCT03736928|Experimental|AbobotulinumtoxinA dose level 1 or 2|Intramuscular single treatment
9857384|NCT03736928|Experimental|AbobotulinumtoxinA dose level 3|Intramuscular single treatment
10209225|NCT04633759|Experimental|Blood Flow Restriction Exercise|Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
9857385|NCT03736928|Experimental|AbobotulinumtoxinA dose level 4|Intramuscular single treatment
9857386|NCT03736785|Experimental|LY3209590 Algorithm 1|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of <140 milligram per deciliter (mg/dL).
9857387|NCT03736785|Experimental|LY3209590 Algorithm 2|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous injection. Dose titration was done to maintain fasting blood glucose of <120 mg/dL.
9857388|NCT03736785|Active Comparator|Insulin Degludec|Participants received same dose of Degludec as the total basal insulin dose already administered prior to randomization. Dose was titrated to maintain fasting blood glucose of ≤100 mg/dL to achieve glycemic goal of HbA1C <7%.
9924052|NCT00857298|Active Comparator|HIV-MS|HIV-positive obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
9924053|NCT00857298|Active Comparator|MS only|HIV-negative obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
9924054|NCT00857324|Experimental|ZMP|Combination with Vorinostat, Melphalan and Prednisone
9924055|NCT00857350||HIV+, opiod dependent|
10213600|NCT03731260|Placebo Comparator|(Part 1) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
10213601|NCT03731260|Experimental|(Part 2) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
10213602|NCT03731260|Placebo Comparator|(Part 2) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
10209226|NCT04630054|Experimental|Mask Intervention|"Communities and individuals randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use.~In the community experiment, every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people.~In the individual experiment, individuals randomized to the intervention arm will not be asked to recommend masks to others, but will also not be discouraged from recommending mask use to others."
9857389|NCT03736031|Experimental|Intervention (Promotora)|The intervention group will have three face-to-face meetings with the promotora. Participant will continue to receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
9857390|NCT03736031|No Intervention|Self-Education (Control)|Participant will receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
9857391|NCT03735862||Observations Group|Patients who have undergone a hiatal hernia repair with MIROMESH.
9857392|NCT03734991|Experimental|Ibrexafungerp (SCY-078)|300 mg orally every 12 hrs for 1 day (2 doses in 1 day)
9857393|NCT03734991|Placebo Comparator|Placebo|Matching Placebo
9857394|NCT03734822|Other|CF|Cystic fibrosis patients undergoing general anesthesia.
9857395|NCT03734601|Experimental|TBI+TLI|TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)
9857396|NCT03733899|Experimental|Upper lid margin/Lower lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences of an ocular surface region. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
9857397|NCT03733899|Experimental|Lower lid margin/Cornea/ Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
9857398|NCT03733899|Experimental|Cornea/Upper lid margin/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
9857399|NCT03733899|Experimental|Cornea/Lower lid margin/Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
9857400|NCT03733899|Experimental|Upper lid margin/Cornea/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
9857401|NCT03733899|Experimental|Lower lid margin/Upper lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
9857402|NCT03733483|Experimental|Sleep Deprivation|
9857403|NCT03733470|Experimental|Nonsusceptible Smokers (NS)|8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
9857404|NCT03733470|Experimental|Susceptible Smokers (SS)|11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume. For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
9857405|NCT03733301|Experimental|4 Milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.
9857406|NCT03733301|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.
9857407|NCT03733301|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with TCS.
9857408|NCT03732638|Experimental|Rimegepant|Rimegepant - Randomization Phase: Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks.
9857409|NCT03732638|Placebo Comparator|Placebo|Placebo - Randomization Phase: Participants received a single oral dose of matching placebo tablet every other day (EOD) for 12 weeks.
9857410|NCT03732248|Active Comparator|Rapamycin (sirolimus) 15mg|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
9857411|NCT03732248|Placebo Comparator|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
10209227|NCT04630054|No Intervention|Control|Control individuals will receive no masks or behavior change communication.
10213603|NCT03731260|Experimental|(Part 3) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
9857412|NCT03731182|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.
9924056|NCT00857363||Constipated|Adult subjects with functional constipation as define by Rome II criteria
9857413|NCT03731182|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1.
9857414|NCT03730961|Experimental|Placebo+Diuretic to BMS-986231+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
9857415|NCT03730961|Experimental|BMS-986231+Diuretic to Placebo+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
9857416|NCT03730116||the patients with HT and concomitant stable CAD|
9857417|NCT03730103|No Intervention|Historical control group|The investigators will use data from a historical control group discharged on POD 1 after minimally invasive sacrocolpopexy to examine Aim 1 and Aim 2. This is a cohort of 60 women matching our eligibility criteria from a prospective randomized trial of two different types of lightweight polypropylene mesh (IRB #14-354). This study completed recruitment 2017. It consists of a group of women who underwent minimally invasive sacrocolpopexy using the same surgical approaches, at the same institutions
9857418|NCT03730103|Experimental|Same day discharge group|47 women will be recruited for same day discharge after laparoscopic sacrocolpopexy. We will compare aim 1 and 2 (serious adverse events and procedure-related costs) between the two groups
9857419|NCT03729960|Other|LENA|Lena device with Fitbit and Cocooncam being optional
9857420|NCT03729024|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
9857421|NCT03728790|No Intervention|Usual Care|Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
9857422|NCT03728790|Experimental|Remote Patient Monitoring|Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
9857423|NCT03728348||Subject aged 45-49 with Average CRC Risk|Subject aged 45-49 with average risk for development of CRC.
9857424|NCT03728140|Experimental|Self-spent Culture Medium|Changing embryo transfer solution with self-spent culture medium
9857425|NCT03728140|No Intervention|New Culture Medium|embryo transfer with new culture medium in IVF-ET
9857426|NCT03727854|Experimental|Premeal protein group|Premeal protein enriched bar with dietary modification
9857427|NCT03727854|Other|Dietary modofication only group|Dietary modification only
9857428|NCT03727425|Experimental|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
9857429|NCT03727347|Experimental|InSeca Stylus Treatment Group|Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)
9857430|NCT03726996|Experimental|Children with INAD|Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
9857431|NCT03726164|Active Comparator|Remote Conditioning group|Patients will receive a standard remote ischaemia preconditioning protocol comprising a blood pressure cuff placed on arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle repeated three times, prior to the PCI procedure.
9857432|NCT03726164|Placebo Comparator|Control Group|Patients will receive a standard sham remote ischaemia preconditioning protocol with an un-inflated cuff be placed on the arm in this group of patients for 30 minutes. This is the sham intervention for this group.
9857433|NCT03725852|Experimental|GLPG1205 100 mg|Participants will receive GLPG1205 100 milligrams (mg) (2 capsules x 50 mg), orally once daily for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
9857434|NCT03725852|Placebo Comparator|Placebo|Participants will receive GLPG1205 matching placebo, orally once daily (as 2 capsules) for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
9857435|NCT03725722|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 8 weeks
9857436|NCT03725722|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 8 weeks
9857437|NCT03725722|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 8 weeks
9857438|NCT03725722|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 8 weeks
9857439|NCT03725722|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 8 weeks
9857440|NCT03725098|Experimental|HEMOBLAST Bellows (Hemostatic Device)|Bleeding sites will be treated with HEMOBLAST Bellows per its approved Indications for Use
9857441|NCT03725098|Active Comparator|FLOSEAL (Hemostatic Device)|Bleeding sites will be treated with FLOSEAL per its approved Indications for Use
9857442|NCT03725085|Experimental|Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)|"2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days.~GGE = Guaifenesin~BID = Twice in a day"
9857443|NCT03725033|Experimental|Subetta|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
9857444|NCT03725033|Placebo Comparator|Placebo|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
9857445|NCT03724981|Experimental|Dulaglutide Pen|Injection of commercial dulaglutide pen on a practice pad.
9857446|NCT03724981|Experimental|Semaglutide Pen|Injection of commercial semaglutide pen on a practice pad.
9857447|NCT03724968|Experimental|Arm A|Nivolumab and Relatlimab
9857448|NCT03724968|Experimental|Arm B|Nivolumab and Ipilimumab
9857449|NCT03724877||Subjects with Chronic obstructive pulmonary disease (COPD)|
9857450|NCT03724253|Experimental|Phase II dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
9857451|NCT03724253|Experimental|Phase II non-dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
9857452|NCT03723980|Active Comparator|Control Group or Group I or Calcium hydroxide Group|
9857453|NCT03723980|Experimental|Experimental Group or Group II or Propolis Group|
9857454|NCT03723603|Experimental|Fibrillar Collagen Powder Dressing|
9857455|NCT03723447|Active Comparator|Bupivacaine/epinephrine/dexamethasone TAP block|For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
9857456|NCT03723447|Active Comparator|Liposomal bupivacaine TAP block|For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.
9857457|NCT03723070|Experimental|PV Cryoablation|Ablation of the ostium of the pulmonary veins (PV) as a means to electrically isolate the veins in the treatment of atrial fibrillation. A cryoablation balloon will be inserted into the left atrium and cryo applications will be administered to create an endocardial thermal injury by using the Cryterion Cardiac Cryoablation System
10209228|NCT04627714|Experimental|Early Fencing|"patients of the Early Fencing arm will start adapted fencing practice (1h30/week) within 4 weeks after the breast surgery and for a duration of 3 months"
9857458|NCT03720210|Experimental|RFA group|RFA
9857459|NCT03718455|Experimental|Axillary Magseed|Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.
9857460|NCT03718143|Experimental|Arm A: Elderly Newly diagnosed AML|"Combination AZD1775 with AraC~Elderly, newly diagnosed AML"
9857461|NCT03718143|Experimental|Arm B:Relapsed AML and MDS|"Combination AZD1775 with AraC~Relapsed/Refractory AML & HMA failure AML/ MDS"
9857462|NCT03718143|Active Comparator|Arm C: Relapsed AML, MDS and MF|"AZD1775 only~Relapsed/Refractory AML & HMA failure AML/ MDS and Relapsed/Refractory Primary & Secondary MF"
9857463|NCT03709576|Experimental|Pevonedistat and Azacitidine|The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.
9857464|NCT03704636|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.
9857465|NCT03703791|Active Comparator|Group 1 (AR101 Treatment + standard of care)|Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.
9857466|NCT03703791|No Intervention|Group 2 (Standard of Care Treatment)|Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.
9857467|NCT03701295|Experimental|Treatment (pinometostat, azacitidine)|Patients receive pinometostat IV continuously on days 1-28 and azacitidine IV over 10-40 minutes or SC for 7 of the first 10 days of the cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
9857468|NCT03697551|Experimental|68Ga-OPS202|A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.
10209229|NCT04627714|Experimental|Delayed Fencing|"patients of the Delayed Fencing arm will start adapted fencing practice (1h30/week) 3 months after the breast surgery and for a duration of 3 months"
9857469|NCT03694821|Experimental|Ketorolac|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
9857470|NCT03694821|Active Comparator|Corticosteroid|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
9857471|NCT03694821|Active Comparator|Hyaluronic Acid|One knee injection of Hylan G-F 20 (Synvisc-One)
9857472|NCT03686969|Experimental|Octanorm|0.5g/kg/week octanorm 16.5%
9857473|NCT03686969|Placebo Comparator|Placebo|Placebo
9857474|NCT03682367|Placebo Comparator|Control|Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
9857475|NCT03682367|Experimental|Intervention|Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.
9924057|NCT00857376|Placebo Comparator|placebo|Placebo 2 tabs three times daily
10209230|NCT04625803|Experimental|chemotherapy, PD-1 inhibitor and Apatinib|Participants received 5 preoperative cycles of PD-1 inhibitor and chemotherapy (mFOLFOX6), 2 months of apatinib, followed by surgery. Apatinib,PD-1 inhibitor and chemotherapy needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of mFOLFOX6 combined with PD-1 monoclonal antibody were performed as adjuvant therapy.
10209231|NCT04623567|Experimental|Jiangtang Tiaozhi Recipe Group|Jiangtang Tiaozhi formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.
9857476|NCT03680911|Experimental|NAC Group|NAC group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
9857477|NCT03680911|Placebo Comparator|Placebo Group|Placebo group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
9857478|NCT03656692|Other|Acthar Gel|Participants received Acthar 1 mL (80 units [U]) subcutaneously (SC) 2 times per week for 36 weeks followed by a taper to Acthar 1 mL (80 U) SC once a week for 2 weeks, then 0.5 mL (40 U) SC once a week for 2 weeks.
9857479|NCT03648983|Active Comparator|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
9857480|NCT03648983|Experimental|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
9857481|NCT03643159|Experimental|Abilify MyCite|Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
9857482|NCT03643159|Active Comparator|Virtual Matched Controls|Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.
9857483|NCT03632655|Active Comparator|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
10209232|NCT04623567|Active Comparator|Metformin Group|500mg metformin tablet per time, 3 times a day, take it with meals.
10209233|NCT04622267|Active Comparator|Standard suture|Standard antimicrobial suture (vicryl) - control arm
10209234|NCT04622267|Experimental|Barbed suture|Barbed suture type is STRATAFIX Symmetric PDS Plus Knotless Tissue
10209235|NCT04621279||Mild Hypoxic Ischemic Encephaolpathy|"Infant ≥ 360/7 weeks with evidence of BOTH 1) perinatal event fetal acidosis and 2) encephalopathy on exam.~Perinatal depression as defined by NICHD based on at least one of the following; pH <7.00 in a cord gas or Base deficit ≥15 mmol/L in a gas (arterial or venous) obtained at <60 min of age, Apgar score <5 at 10 minutes, or Need for resuscitation at 10 minutes (i.e., chest compressions, or positive pressure respiratory support including endotracheal, mask ventilation, or CPAP).~Mild encephalopathy, as defined by PRIME-study 1-6 hours after birth. At least 1 of 6 Sarnat criteria is scored as a mild, moderate, or severe abnormality, and Fewer than 3 of 6 Sarnat criteria are scored as a moderate or severe abnormality"
10209236|NCT04620681|Experimental|Phase 1 Dose Level 1|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 1: 1X10^6 CD4 T Cells/kg
10209237|NCT04620681|Experimental|Phase 1 Dose Level 2|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 2: 1X10^7 CD4 T Cells/kg
9857484|NCT03632655|Active Comparator|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
9857485|NCT03630120|Active Comparator|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
9857486|NCT03630120|Experimental|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with >=50% drop: Lenvatinib + Sorafenib.
9857487|NCT03630120|Active Comparator|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
9857488|NCT03630120|Experimental|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with >=50% drop: Cabozantinib + Vandetanib.
9857489|NCT03621657|Experimental|Low dose FMT Capsule DE|FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic
9857490|NCT03621657|Active Comparator|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
9857491|NCT03621657|Placebo Comparator|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
9857492|NCT03615144|Active Comparator|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
10209238|NCT04620681|Experimental|Phase 1 Dose Level 3|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 3: 5 X10^7 CD4 T Cells/kg
10209239|NCT04620681|Experimental|Phase 2 -Treatment at Maximum Tolerated Dose (MTD)|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at MTD.
10209240|NCT04618770|Other|Triathlon PSR Tibial Insert|Cases receiving a Triathlon Total Knee with the Triathlon PSR Tibial Insert
10209241|NCT04617977|Experimental|Parent-child I-BMS intervention group|Children with eczema and their parent caregivers will attend the six sessions simultaneously in a parallel group format. Parent caregivers will attend the parents group in the first 2.5 hours; while children will attend the children group in the first 2.5 hours. Both parents and children will later reunite in the joint group in the final 0.5 hours.
10209242|NCT04617977|Experimental|Parent only I-BMS intervention group|Only parent caregivers of children with eczema will attend the six sessions. The content of the 2.5-hour parents group will be the same as the one in Arm 1 (Parent-child I-BMS intervention group), with an additional 0.5 hour of reflective discussion among group members. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
9857493|NCT03615144|Active Comparator|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
9857494|NCT03605303|Active Comparator|CONTROL- etafilcon A current molding|1-Day ACUVUE® MOIST
9857495|NCT03605303|Experimental|TEST- etafilcon A novel molding|Investigational Contact Lens
9857496|NCT03600740|Experimental|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
9857497|NCT03598140|Placebo Comparator|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
9857498|NCT03598140|Active Comparator|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
9857499|NCT03598036|Experimental|Voclosporin|"Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1."
10209243|NCT04617977|Active Comparator|Parent only health education active control group|Only parent caregivers of children with eczema will attend the six sessions. Each session consists of teaching in the first 2.5 hours and Q&A in the final 0.5 hour. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
10209244|NCT04617821|Experimental|albumin bound paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine were given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles.
9857500|NCT03591458|Experimental|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
9857501|NCT03591458|Placebo Comparator|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
9857502|NCT03590743|Active Comparator|Apixaban|Apixaban 5mg (10 mg twice daily for 7 days followed by 5 mg twice daily for 3 months).
9857503|NCT03590743|Placebo Comparator|Placebo|Patients will receive matching placebo.
9857504|NCT03580382|Experimental|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
9857505|NCT03580382|Experimental|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
9857506|NCT03571646|Other|Capnostream 20|Continuous monitoring of CO2
9857507|NCT03571646|Other|PM1000N-RR|Continuous monitoring of SpO2
9857508|NCT03565328|Experimental|Nicotinamide Riboside in patients with stable heart failure|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) then increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000 mg PO BID (2000 mg/day) in patients with stable, systolic heart failure.
9857509|NCT03544242|Active Comparator|Control group|
9857510|NCT03544242|Experimental|Pre-Isolation Infusion|
9857511|NCT03544242|Experimental|Post-Isolation Infusion|
10209245|NCT04617821|Active Comparator|mFOFLIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
9857512|NCT03543358|Experimental|Arm A: Post-Treatment Follow-Up/Optional Retreatment|Arm A includes participants who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone per participant per retreatment period.
9857513|NCT03543358|Experimental|Arm B: Continued Treatment|Arm B includes participants who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
9857514|NCT03538015|Experimental|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
9857515|NCT03538015|Experimental|Carvedilol 2.5 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
9857516|NCT03538015|Placebo Comparator|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
9857517|NCT03534362|Active Comparator|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
9924058|NCT00857376|Experimental|Alpha lipoic acid 1|Alpha lipoic acid 600 mg daily
9857518|NCT03534362|Active Comparator|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
9857519|NCT03509207|Experimental|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
9857520|NCT03505372|Experimental|Contrast enhanced mammography|"The CESM images will be performed according to clinical protocol~Images will be acquired within approximately 2-12 minutes of contrast injection~A total of four images per breast will be acquired with low and high energy~Two radiologists will prospectively review the CESM, and will use a third as tie-breaker~The CESM will be evaluated for the biopsy site and up to two additional findings in either breast~The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement"
9857521|NCT03500406|Sham Comparator|Group 1 - Control|No treatment will be administered and men will not have to delay their IPP procedure
9857522|NCT03500406|Experimental|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
9857523|NCT03500341|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00014 sensor
9857524|NCT03500159|Experimental|AQX-1125|AQX-1125 200 mg
9857525|NCT03500159|Placebo Comparator|Placebo|Matching placebo
9857526|NCT03490916|Experimental|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
9857527|NCT03490916|Placebo Comparator|Placebo|One (1) dose of placebo
9924059|NCT00857376|Experimental|Alpha lipoic acid 2|Alpha Lipoic acid 1200 mg daily
9924060|NCT00857376|Experimental|Alpha lipoic acid 3|Alpha lipoic acid 1800 mg daily
9924061|NCT00857402|Active Comparator|Peanuts|
9924062|NCT00857402|Active Comparator|Daboqolo|
9924063|NCT00857428|Experimental|1|Oxymorphone ER 40 mg tablets Sandoz
9924064|NCT00857428|Active Comparator|2|Opana ER 40 mg tablets Eon Pharmaceuticals
9924065|NCT00857441|Experimental|1|Use of Dior balloon and implant of Liberté Bare Metal Stent
9924066|NCT00857441|Active Comparator|2|Use of standard balloon and implant of Liberté Bare Metal Stent
9924067|NCT00857441|Active Comparator|3|Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
9924068|NCT00857467|Experimental|1 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository
9924069|NCT00857467|Experimental|2 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.
9924070|NCT00857480|Experimental|Reference|No pre-treatment
9924071|NCT00857480|Experimental|T1|Cloxacillin pre- and co-treatment
9924072|NCT00857480|Experimental|T2|UDCA pre-treatment
9924073|NCT00857519|Experimental|Chemotherapy|Chemotherapy using Melphalan, Carboplatin.
9924074|NCT00857558|Experimental|1|OPC-262 1mg
9924075|NCT00857558|Experimental|2|OPC-262 2.5mg
9924076|NCT00857558|Experimental|3|OPC-262 5mg
9924077|NCT00857558|Placebo Comparator|4|
9924078|NCT00857571|Experimental|Suspension|PF-02413873 suspension
9924079|NCT00857571|Experimental|Tablet|PF-02413873 Phase 2 Tablets
9924080|NCT00857597|Experimental|EsophyX|
9924081|NCT00857597|Active Comparator|Proton Pump Inhibitors|
9924082|NCT00857610||1|Subjects using 0.1% retinol one day per week
9924083|NCT00857610||2|Subjects using 0.1% retinol three days per week
9924084|NCT00857610||3|Subjects using 0.1% retinol seven days per week
9924085|NCT00857610||4|Subjects using 0.5% retinol one day per week
9924086|NCT00857610||5|Subjects using 0.5% retinol three days per week
9924087|NCT00857610||6|Subjects using 0.5% retinol seven times per week
9924088|NCT00857636|Experimental|Health Literacy|
9924089|NCT00857662|Experimental|Onyx|
9924090|NCT00857662|Active Comparator|TRUFILL|
9924091|NCT00857675|Experimental|Adefovir Dipivoxil|ADV 10mg tablets once daily
9924092|NCT00857675|Placebo Comparator|Adefovir Dipivoxil matched placebo|Adefovir Dipivoxil matched placebo one tablet once daily
9924093|NCT00857688|Experimental|1 - Test|Patients will recieve the association.
9924094|NCT00857688|Placebo Comparator|2|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
9924095|NCT00857701|No Intervention|1|Patient will receive post-surgical standard of care treatment with standard Physical therapy and NSAIDs.
9924096|NCT00857701|Experimental|2|Patients will be treated with the Standard of Care physical therapy and NSAIDs as well as a Knee Extension Dynasplint that includes tension chambers.
9924097|NCT00857753|Experimental|1|Fentanyl patch 25 ug/hr Sandoz
9924098|NCT00857753|Active Comparator|2|Duragesic Patch 25 ug/hr
9924099|NCT00857779|Active Comparator|subcutaneous immunotherapy|subcutaneous immunotherapy using a slow updosing schedule
9924100|NCT00857779|Active Comparator|subcutaneous injections|subcutaneous immunotherapy using a fast updosing schedule
9924101|NCT00857805|Active Comparator|Transarterial Chemoembolization|Transarterial Chemoembolization
9924102|NCT00857805|Active Comparator|Proton Beam Radiotherapy|Proton Beam Radiotherapy
9935135|NCT04137068|Other|Active to Sedentary|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their normal level of physical activity. After the baseline visit, participants will maintain their baseline level of physical activity for one week, and then reduce their step count for two weeks. The fifth week will be maintaining baseline activity level. Participants will visit the laboratory once every week during these 5 weeks.
9935136|NCT04136353|Experimental|Darolutamide|"Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
9935137|NCT04136353|Placebo Comparator|Placebo|"Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
9857528|NCT03483051|Experimental|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
9857529|NCT03483051|Sham Comparator|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
9857530|NCT03477903|Experimental|Group A: TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
10209246|NCT04612478|Other|Clinic-Based Physical Therapy|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
10213604|NCT03729115|Other|Screening Arm|Enrolled patients will undergo Magnetic Resonance Imaging (MRI) every 6 months (2x/year) in addition to an annual screening mammogram.
9857531|NCT03477903|Experimental|Group B: TAK-954 0.3 mg|TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
10213605|NCT03727061|Active Comparator|Arm A (standard of care chemotherapy at doctor's discretion)|Patients receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion
9857532|NCT03477903|Experimental|Group C: TAK-954 1.0 mg|TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
9857533|NCT03477903|Active Comparator|Group D: Metoclopramide 10 mg|Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.
9857534|NCT03469258|Experimental|Zenpep|"Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.~Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
9857535|NCT03466658|Experimental|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
9857536|NCT03466658|No Intervention|Control group|This group will have no intervention pre-operatively. Intervention: none
9857537|NCT03465891|Experimental|atezolizumab|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
9857538|NCT03465891|Experimental|atezolizumab plus low-dose, local radiotherapy|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year). 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
9857539|NCT03465735|Other|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
9857540|NCT03465735|Other|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
9857541|NCT03461705|Experimental|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
9857542|NCT03457818|Experimental|Treatment Group|Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.
9857543|NCT03457818|Placebo Comparator|Control Group|Placebo SC at Baseline and 6 months.
9857544|NCT03455556|Experimental|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9857545|NCT03447639|Experimental|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
9857546|NCT03447639|No Intervention|Standard of Care|Catheter removal with no bladder irrigation
9857547|NCT03429712|Experimental|Dose Split CT|
9857548|NCT03426137|Active Comparator|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
9857549|NCT03426137|Placebo Comparator|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
9857550|NCT03426137|Placebo Comparator|C (Control)|Participants in this group will receive NSAIDs and placebo pills
9857551|NCT03425799|Placebo Comparator|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
9857552|NCT03425799|Experimental|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
9857553|NCT03423654|Experimental|Training Group|Spatial training
9857554|NCT03423654|Other|Control Group|Letter number matching
9857555|NCT03387059|Experimental|Forielle Endometrial Washing|
9857556|NCT03387059|No Intervention|No Endometrial Washing|
9857557|NCT03382925|Active Comparator|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
9857558|NCT03382925|Active Comparator|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
9857559|NCT03379233|Active Comparator|Usual Care|Concept2 inhaler
9857560|NCT03379233|Experimental|Telehealth|Concept2 inhaler with patient application
9857561|NCT03370536|Experimental|Patients with AF|Patients with AF and planned to undergo first catheter procedure
9857562|NCT03363633|No Intervention|Observation|
9857563|NCT03363633|Experimental|Injection + Compression|
9857564|NCT03363633|Active Comparator|Compression|
9857565|NCT03361228|Experimental|INCB001158 + Epacadostat + Pembrolizumab|
9857566|NCT03361228|Experimental|INCB001158 + Epacadostat|
9857567|NCT03360903|Experimental|Placebo then Caffeine|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control) followed by a washout period and then anesthetized again and allowed to wake after injection of caffeine (15 mg/ kg).
9857568|NCT03360903|Experimental|Caffeine then Placebo|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg) followed by a washout period and then anesthetized again and allowed to wake after injection of saline (placebo control).
9857569|NCT03359174|Experimental|All-trans retinoic acid (ATRA) therapy|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
9857570|NCT03352882|Other|Open Label|All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.
9857571|NCT03348904|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum doublet
9857572|NCT03348904|Active Comparator|Arm B|Platinum doublet chemotherapy
9857573|NCT03348904|Experimental|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
9857574|NCT03345901|Experimental|Pemafibrate|.2 mg pemafibrate orally BID
9857575|NCT03345901|Placebo Comparator|Placebo|Placebo pill orally BID
9857576|NCT03344562|Experimental|CES Active|Active cranial electrical stimulation device
9857577|NCT03344562|Sham Comparator|CES Sham|Inactive device identical to the active device.
9857578|NCT03342638|Experimental|Control Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
9857579|NCT03342638|Experimental|IVIg Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.
9857580|NCT03342157|Experimental|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
9857581|NCT03342157|Experimental|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
9857582|NCT03339401|Experimental|Brincidofovir|"Brincidofovir (BCV) for the treatment of adenovirs (AdV) infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Brincidofovir (BCV) treatment began no later than 100 days post-transplant and was to continue for a maximum of 16 weeks. Brincidofovir (BCV) was discontinued once AdV viremia was confirmed undetectable.~Subjects who did NOT receive concurrent cyclosporine on Day 1:~If ≥48kg body weight, one 100mg oral tablet BIW (or 10mL of 10mg/mL oral suspension if unable to take tablets).~If <48kg body weight, 2mg/kg oral volume of 10mg/mL oral suspension BIW.~Subjects who received cyclosporine on Day 1 (or initiated cyclosporine at any time):~1.4mg/kg (maximum of 70mg) oral volume of 10mg/mL oral suspension BIW.~2mg/kg (maximum of 100mg) oral volume of 10mg/mL oral suspension BIW if discontinued cyclosporine."
9857583|NCT03339401|Other|Standard of Care|"Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Management of these subjects was prescribed by the investigator as being in the best interests of the subject and may have included a watch-and-wait approach, with or without decreased immunosuppression (ergo, no treatment), or treatment administration with other available antivirals, most commonly cidofovir intravenously.~Decisions regarding SoC, including administration of therapy, dose and regimen of therapy, modification of immunosuppression, and monitoring was the responsibility of the clinical team caring for the subject, according to institutional guidelines, local practices, and applicable guidelines for the management of AdV infection."
9857584|NCT03339245|Experimental|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
9857585|NCT03339245|Experimental|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
9924103|NCT00857831|Experimental|Arm 1|Vitamin D & Calcium supplementation in FES
9924104|NCT00857844||Group 1|Normal GFR (>90ml/min/1.73m2). Stage I CKD
9857586|NCT03333746|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9857587|NCT03329404|Experimental|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1-6°C
9857588|NCT03329404|Active Comparator|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
9857589|NCT03326869|Experimental|Delayed|"Intervention: Raindrop Near Vision Inlay~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
9857590|NCT03326869|Active Comparator|Non-Delayed|"Intervention: Raindrop Near Vision Inlay~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
9857591|NCT03325114|Other|Chlorthalidone|Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks
9857592|NCT03319407|Other|Observation|All participants will be monitored with EPAD system
9857593|NCT03316105|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
9857594|NCT03316105|Sham Comparator|No TENS stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
9857595|NCT03305055|Experimental|Fentanyl Plus Ketamine|"Study drug group~Ketamine Loading Dose (Low Dose, Slow Infusion) =~• 0.3 mg/kg; Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, … Then,~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg. This is given to participants in both Group 1 and Group 2 initiated < 1 minute prior to wound care.~Ketamine (Study Drug, Infusion) = • 2.5 mcg/kg/min, Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~Fentanyl PRN dose* = 1 mcg / kg. Provided when participant requires additional pain medication."
9857596|NCT03305055|Active Comparator|Fentanyl Plus Saline|"Usual care group~Saline Loading Dose (Low Dose, Slow Infusion) =~• An identical volume of saline as that in 0.3 mg/kg of ketamine. Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, (i.e., same time/rate as STUDY DRUG GROUP receives ketamine loading dose), … Then, ...~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg: This is given to participants in both Group 1 and Group 2 initiated <1 minute prior to wound care.~Saline (Placebo, Infusion) = • Identical volume of fluid as that in 2.5 mcg/kg/min of ketamine; Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~FENTANYL PRN DOSE = 1 mcg / kg. Provided when participant requires additional pain medication."
9857597|NCT03303469|Experimental|FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT)|FMISO imaging at baseline, post-TACE and post-SBRT
9857598|NCT03302247|Experimental|Nivolumab+Gemcitabine|Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle
9924105|NCT00857844||Group 2|GFR between 30-59ml/min/1.73m2. Stage III CKD
9857599|NCT03300024|Active Comparator|Expanded polytetrafluoroethylene (ePTFE)|The ePTFE grafts used are the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used is at the surgeons' discretion. The graft it is offered in both large and small diameters, as well as thin-wall and rapidly-tapering designs for cases where arterial steal syndrome is a potential complication. A 6 mm graft featuring external supporting rings in 5 cm centered or 7 cm offset sections enables tight loop configurations and crossing the cubitus. A 4-7 mm tapered graft with 10 or 15 cm of removable rings allows for tailoring or exact placement of the ringed section.
9857600|NCT03300024|Experimental|Bovine carotid Artery Graft|The bovine carotid artery biological grafts (Artegraft®; Artegraft, Inc., North Brunswick, NJ) consist of a biological fibrous matrix processed to enhance long-term patency and provide a tightly woven, cross-linked conduit that is flexible and compliant.
9857601|NCT03283709|Experimental|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
9857602|NCT03283709|Other|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
9857603|NCT03277183|Placebo Comparator|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
9857604|NCT03277183|Experimental|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
9857605|NCT03269968|Experimental|Negative pressure wound therapy (NPWT)|Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
9857606|NCT03269968|Placebo Comparator|Standard dressing|Standard dressing
9857607|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
9857608|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
9857609|NCT03263806|Active Comparator|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
9857610|NCT03263806|Experimental|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
9857611|NCT03261531|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
9857612|NCT03251326|Experimental|Nabilone|Nabilone capsules (4 mg)
9857613|NCT03251326|Active Comparator|Propranolol|Propranolol capsules (40mg)
9857614|NCT03251326|Experimental|Smoked cannabis|(0.0 and 5.6% THC)
9857615|NCT03251326|Placebo Comparator|Placebo|Placebo capsules
9857616|NCT03219372|Experimental|Pravastatin Pill|Daily pravastatin (40mg)
9857617|NCT03219372|Placebo Comparator|Placebo Oral Tablet|Placebo
9857618|NCT03217175|Active Comparator|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
9857619|NCT03217175|Placebo Comparator|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
9857620|NCT03231397|Other|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
9857621|NCT03231397|Other|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
9924106|NCT00857844||Group 3|GFR between 15-29ml/min/1.72m2. Stage IV CKD
9924107|NCT00857870|Active Comparator|Metformin|
9924108|NCT00857870|Active Comparator|Insulin glargine|
9857622|NCT03231397|Other|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (>0.5cm over 6 months and/or >1.0cm over 12 months).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
9857623|NCT03231397|Other|AAA's undergoing treatment|"Six subjects (three males, AAA >5.5cm and three females, AAA >5.0cm) with AAAs that are indicated for treatment.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
9857624|NCT03232892|Experimental|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
9857625|NCT03223662|Other|Neoadjuvant Chemoradiotherapy and esophagectomy|Standard of care neoadjuvant chemoradiotherapy (nCRT) and esophagectomy
9857626|NCT03212144|Experimental|High Intensity Interval Training then Peanut Consumption|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
9857627|NCT03212144|Experimental|Peanut Consumption then High Intensity Interval Training|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
9857628|NCT03218163|Experimental|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
9857629|NCT03172520|Experimental|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the automatic periodic stimulating(APS) electrode during parotidectomy surgery.
9857630|NCT03204539|Experimental|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
9857631|NCT03204539|Other|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
9857632|NCT03206216|Experimental|Group A - Painful CIPN|Participants with painful chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
9857633|NCT03206216|Active Comparator|Group B - Painless CIPN|Participants with painless chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
9857634|NCT03195660|Experimental|ASV Therapy|ASV Therapy
9857635|NCT03195465|Experimental|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
9857636|NCT03166618|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
9857637|NCT03166618|No Intervention|Control_No Treatment|No treatment is administered.
9857638|NCT03169530|Active Comparator|Alcohol|One standard serving of alcohol (~15 gm) daily
9857639|NCT03169530|No Intervention|Abstention|Abstention from alcohol
9857640|NCT03189433|Active Comparator|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures [ice packs, evaporative cooling(application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
9857641|NCT03189433|No Intervention|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities].
9857642|NCT03151226|Other|capnography monitoring|single arm, all subjects receiving duramorph will receive capnography monitoring
9857643|NCT03165747|Experimental|VSL#3|VSL#3 two active sachets [containing 450x109 colony-forming units (CFU)/sachet], taken daily in a single administration.
9857644|NCT03165747|Placebo Comparator|Control|Placebo, no supplemental probiotics.
9857645|NCT03168906|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
9857646|NCT03168906|Placebo Comparator|Placebo|Placebo
9857647|NCT03178201|Experimental|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
9857648|NCT03172026|Experimental|Maraviroc + Augmented Rehabilitation|Participants will take Maraviroc 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
9857649|NCT03172026|Placebo Comparator|Placebo + Augmented Rehabilitation|Participants will take placebo 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
9857650|NCT03152526|Other|Single-arm trial|Multi-center, open-label, single-arm, phase I/II clinical trial
9857651|NCT03161964|Experimental|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
9857652|NCT03161964|Experimental|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
9857653|NCT03150160|Experimental|Simbrinza + Travatan|Brinzolamide 1%/brimonidine 0.2% fixed combination + travoprost 0.004% ophthalmic solution
9857654|NCT03150160|Placebo Comparator|Placebo + Travatan|Placebo + travoprost 0.004% ophthalmic solution
9857655|NCT03137225|Experimental|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
9857656|NCT03137225|Experimental|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
9857657|NCT03123393|Experimental|Cohort A: TAK-659 100 mg|TAK-659 100 mg tablet, orally, once daily (QD), during each 28-days cycle (median exposure was 41 days).
9857658|NCT03123393|Experimental|Cohort B: TAK-659 Ramp-up Dosing|TAK-659 60-100 mg tablet, orally, QD, dose based on safety and tolerability during each 28-days cycle (median exposure was 28 days).
9857659|NCT03123328|Experimental|Test Subjects|Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU.
9857660|NCT03119662|Experimental|Visipaque™: Contrast-Enhanced Computed Tomography (CECT)|Participants received 1 intravenous injection of Visipaque™ 320 mg I/ml injection (100 mL iodixanol) and underwent computed tomography (CT) examination.
9857661|NCT03119662|Placebo Comparator|Saline: Non-Enhanced Computed Tomography (NECT)|Participants received 1 intravenous injection of saline placebo (matched to Visipaque™ 320 mg I/ml injection) and underwent computed tomography (CT) examination and supplemental non-contrast duplex ultrasonography imaging examination.
9857662|NCT03109418|Placebo Comparator|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
9857663|NCT03109418|Active Comparator|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
9857664|NCT03120676|Experimental|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
9857665|NCT03109873|Experimental|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
9857666|NCT03109873|Placebo Comparator|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
9857667|NCT03100617|Experimental|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
9857668|NCT03115853|Experimental|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.~Then HCTZ 25 mg po plus Placebo"
9857669|NCT03115853|Experimental|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
9857670|NCT03113071|Experimental|Newly diagnosed AML/MDS|For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
9857671|NCT03113071|Experimental|Refractory or relapsed AML/MDS|or Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
9857672|NCT03110900|Active Comparator|haloperidol + lorazepam|IM haloperidol 5mg + IM lorazepam 2mg + placebo inhaler
9857673|NCT03110900|Experimental|loxapine|Inhaled loxapine 10mg + IM normal saline
9857674|NCT03078868|Experimental|Single-point intervention|magnetic resonance scanner
9857675|NCT03078270|Other|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
9857676|NCT03078270|Placebo Comparator|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
9857677|NCT03065933|Experimental|clonidine as an antimanic agent|Subjects with Bipolar Disorder, Mania receive an extended-release form of clonidine on the second day of this 3-day study. Rating scales, record of sleep, and a questionnaire of adverse effects is recorded on each of the three days.
9857678|NCT03070002|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
9857679|NCT03058705|Experimental|Hexaminolevinulate HCL with Near Infrared Fluorescence (NIRF)|During the transurethral resection of the bladder procedure, the bladder will initially be examined in a systematic meridian fashion. Suspicious tumors identified by white light only, NIRF only, and both will be identified. If intense fluorescence is observed in the initial patient(s) at 10 min, dwell duration will be reduced to 5 min for the next patient(s); if abundant fluorescence is detected there as well, dwell duration will be shortened again to 2.5 min. At least three patients will be studied at each duration to document intense fluorescence before proceeding to shorter instillation durations in subsequent patients.
9857680|NCT03061279|Experimental|Fixation by Acutrak headless screw|
9935138|NCT04128371|Experimental|1|Subjects will receive mepolizumab 700 mg IV x 3 doses at approximately one month intervals, at predicted eosinophil nadir (2-3 weeks after peak), at study visits 4, 6, and 7.
9857681|NCT03061279|Active Comparator|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
9857682|NCT03040323|Experimental|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
9857683|NCT03040323|Placebo Comparator|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
9857684|NCT03053518|Active Comparator|Life Style|
9857685|NCT03053518|Experimental|Life Style + Metformin|
9857686|NCT03050398|Experimental|ribociclib + letrozole|ribociclib with letrozole per the core study
10209247|NCT04612478|Other|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program. The SDEP manual will provide detailed instructions on exercises, such as repetitions, frequency, and required equipment, which can be implemented in the home environment. The basis for the exercise regimen is derived from the American Academy of Orthopaedic Surgeons (AAOS) sample home based exercise program available in handout form. The program provides instructions on exercises, repetitions or duration, frequency, and required equipment which can be implemented in the home environment.
9857687|NCT03042780|Experimental|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m^2 of oxaliplatin, 400 mg/m^2 of leucovorin over the first 2 hours, 165 mg/m^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
9857688|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
9857689|NCT03036735|Experimental|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
9857690|NCT03029832|Experimental|MOXR0916 plus Atezolizumab|
9857691|NCT03029832|Active Comparator|Atezolizumab|
9857692|NCT03020446|Experimental|Sorbion dressing to venous leg ulcer|any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed
9857693|NCT03031340|Placebo Comparator|Placebo|
9857694|NCT03031340|Experimental|Pregabalin|
9857695|NCT03017040|Experimental|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
9857696|NCT03017040|Active Comparator|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
9857697|NCT03007719|Experimental|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
9857698|NCT03007719|Experimental|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
10209248|NCT04612478|No Intervention|Observational|Patients who are unwilling to be randomized will be enrolled in an observational arm of the study. They will be asked to complete all baseline and follow-up assessments, and participation in formal PT or SDEP will be documented.
9857699|NCT03010423|Experimental|Nicorandil|
9857700|NCT02985801|Experimental|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
9857701|NCT02985801|Experimental|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
9924109|NCT00857883|Placebo Comparator|Part A|Part A: This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing doses of the study drug. Effects will be compared to those seen when a placebo is taken. Up to 4 groups of 6-9 healthy male or female volunteers will be enrolled.
9924110|NCT00857883|Active Comparator|Part B|Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
9924111|NCT00857883|Placebo Comparator|Part C|Part C: A well tolerated dose selected from Parts A & B will be used to test whether the drug has an effect on individual preferences for sugary and high fat food, when compared to placebo. Up to 32 healthy overweight male volunteers will be enrolled.
9924112|NCT00857909|Active Comparator|Randomisation 1|Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
9857702|NCT02991430|Active Comparator|active|active neuromodulation
9857703|NCT02991430|Placebo Comparator|placebo|placebo neuromodulation
9857704|NCT02995967|Active Comparator|Botulinum toxin A alone group|Just the intradetrusor injection of 100 units of botulinum toxin A alone
9857705|NCT02995967|Experimental|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
9857706|NCT02994251|Experimental|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
9857707|NCT02978885|Other|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
9857708|NCT02978885|Other|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
9857709|NCT02978833|Experimental|PRP|
9857710|NCT02978833|Active Comparator|Whole Blood|
9857711|NCT02971839|Experimental|VX-561 20 mg|
9857712|NCT02971839|Experimental|VX-561 100 mg|
9857713|NCT02971839|Experimental|VX-561 150 mg|
9857714|NCT02971839|Active Comparator|Ivacaftor|
9857715|NCT02971839|Placebo Comparator|Placebo|
9857716|NCT02985840|Active Comparator|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
9857717|NCT02985840|Experimental|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
9857718|NCT02966223|Experimental|MRI and HIDA scan|
9857719|NCT02965846|Experimental|AGN-195263|
9857720|NCT02965846|Placebo Comparator|Vehicle|
9857721|NCT02974803|Experimental|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
9857722|NCT02974686|Active Comparator|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
9857723|NCT02974686|Active Comparator|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
9857724|NCT02956005|Other|Envarsus|Open Label; Envarsus XR started at the time of transplant. Initial dosing of 0.17mg/kg. Target trough level of 8-10 ng/mL
9857725|NCT02966184|No Intervention|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
9857726|NCT02966184|Experimental|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
9857727|NCT02940223|Experimental|Group I (ethyl icosapentate, physical activity)|Patients receive ethyl icosapentate PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally continue to receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks.
9857728|NCT02940223|Experimental|Group II (placebo, physical activity)|Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
9857729|NCT02940223|Experimental|Group III (placebo, stretching exercises)|Patients receive placebo PO BID for 8 weeks. Patients meet with an exercise specialist during the first week to learn different stretching exercises and complete the stretching exercises 3 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
9857730|NCT02954159|Active Comparator|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
9857731|NCT02954159|Placebo Comparator|Placebo Arm|vedolizumab at standard regimen with placebo.
9857732|NCT02954952|Other|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
9857733|NCT02954952|Experimental|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
9857734|NCT02954952|Experimental|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
9857735|NCT02950896||intraoperative FHR monitoring|Intraoperative fetal heart rate (FHR) monitoring
9857736|NCT02947022|Experimental|Calcium DTPA followed by Zinc DTPA|Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.
9857737|NCT02936999|Experimental|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
9857738|NCT02950480|Experimental|Zafirlukast|Zafirlukast
9857739|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
9857740|NCT02949947|Experimental|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
9857741|NCT02949947|Active Comparator|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
9857742|NCT02947100|Experimental|SCD-Omegatex™|single arm
9857743|NCT02936206|Experimental|Fulvestrant|750 mg injection in 3 divided doses
9857744|NCT02936206|Active Comparator|Tamoxifen|20mg orally
9857745|NCT02934932|Experimental|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
9857746|NCT02934932|Experimental|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
9857747|NCT02934932|Placebo Comparator|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
9857748|NCT02908516|Experimental|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
9857749|NCT02908516|Placebo Comparator|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
9857750|NCT02923830|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
9857751|NCT02923830|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
9857752|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])|
9857753|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])|
9857754|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])|
9857755|NCT02920450|Experimental|Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)|
9857756|NCT02920177|Experimental|platelet-rich plasma|platelet-rich plasma injection into the head-neck junction of the hip joint
9857757|NCT02920177|Active Comparator|Kenalog 10 mg/mL Injectable Suspension|corticosteroid injection into the head-neck junction of the hip joint
9857758|NCT02926638|Experimental|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
9857759|NCT02926638|Active Comparator|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
10209249|NCT04611880|Other|Single Arm Study|Single arm study: crizanlizumab will be supplied in single use vials containing 10 mL at a concentration of 10 mg/mL for administration by IV infusion. Each patient will receive one dose of crizanlizumab on day 1 of Week 1, day 1 of Week 3, day 1 of Week 7, and then day 1 of every 4-week cycle. On infusion day, the pharmacist or designated personnel will prepare individual doses of crizanlizumab for subjects on a milligram per kilogram basis (5 mg/kg) in a 100 mL infusion bag in accordance with the Pharmacy Manual. Crizanlizumab will be administered over 30 minutes by IV infusion
10209250|NCT04610658|Experimental|Phase 1 Dose Level 1: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 1: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 1.5 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 1 every 3 weeks.
9857760|NCT02920242|Experimental|Rifaximin|Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
9857761|NCT02920242|Active Comparator|Xifaxan|Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
9857762|NCT02920242|Placebo Comparator|Placebo|Patients received placebo tablet 3 times per day for 3 days.
9857763|NCT02900781|Active Comparator|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
9857764|NCT02900781|Placebo Comparator|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
9857765|NCT02892500|Experimental|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
9924113|NCT00857909|Active Comparator|Randomisation 2|Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
9924114|NCT00857909|Placebo Comparator|Placebo|calcium tablet
9857766|NCT02892500|Active Comparator|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
9857767|NCT02904356|Experimental|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
9857768|NCT02899728|Experimental|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
9857769|NCT02899728|Experimental|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
9857770|NCT02875067|Experimental|Pembrolizumab and Lenalidomide|"An intravenous infusion of 200 mg of pembrolizumab (MK3475) once every 3 weeks for a total of 4 infusions~Lenalidomide at either 15 mg, 10 mg or 20 mg (depending on which cohort patients are enrolled in) days 1-14 every 21 days"
9857771|NCT02877732|Experimental|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
9857772|NCT02877732|Active Comparator|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
9857773|NCT02860169|Experimental|Participants with cold and flu|Eligible participants with cold and flu were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
9857774|NCT02860169|Placebo Comparator|Healthy participants|Eligible healthy participants were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
9857775|NCT02865395|Experimental|Pre-operative Suppository|A B&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
9857776|NCT02865395|Active Comparator|Post-operative Suppository|A B&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
9857777|NCT02865395|Placebo Comparator|Rectal Exam|Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.
9857778|NCT02868892|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
9857779|NCT02865083|Active Comparator|Treatment|Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
9857780|NCT02865083|No Intervention|Standard|Patients will receive use of the standard of care option which is the montgomery straps
9857781|NCT02865122|Experimental|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
9857782|NCT02865122|Experimental|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
9857783|NCT02865122|Placebo Comparator|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
9857784|NCT02865915|Placebo Comparator|Placebo|Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
9857785|NCT02865915|Experimental|MLE4901|Plain, round, biconvex, white film-coated tablets administered twice per day
9857786|NCT02855411|Experimental|0.15 mg PF-04958242|Participants received 0.15 mg oral capsule, twice daily (BID) for 12 weeks
9857787|NCT02855411|Experimental|0.5 mg PF-04958242|Participants received 0.5 mg oral capsule, twice daily (BID) for 12 weeks
9857788|NCT02855411|Placebo Comparator|Placebo|Participants received matching placebo oral capsule, twice daily (BID) for 12 weeks
9857789|NCT02828124|Experimental|Dose Escalation Monotherapy|
9857790|NCT02828124|Experimental|Dose Expansion Monotherapy|
9857791|NCT02828124|Experimental|Dose Escalation Combination Therapy|
9857792|NCT02828124|Experimental|Dose Expansion Combination Therapy|
9857793|NCT02826551|Placebo Comparator|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
9857794|NCT02826551|Experimental|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
9857795|NCT02825043|Experimental|High Flow Nasal Cannula Participants|High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
9857796|NCT02819804|Experimental|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9857797|NCT02809118|Placebo Comparator|Placebo|Placebo gel for intratympanic use
9857798|NCT02809118|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
9857799|NCT02809118|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
9857800|NCT02818946|Other|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
9857801|NCT02819908|Active Comparator|Imprimis Dropless|TriMoxiVanc 0.2cc intravitreal one time
9857802|NCT02819908|Active Comparator|Imprimis Less Drops|Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
9857803|NCT02808390|Experimental|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
9857804|NCT02808390|Experimental|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
9857805|NCT02808390|Experimental|Placebo|Placebo BID for 8 Weeks
9857806|NCT02806960|Experimental|Treatment 1|Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg).
9857807|NCT02806960|Experimental|Treatment 2|Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.
9857808|NCT02806960|Experimental|Treatment 3|Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.
9857809|NCT02806960|Experimental|Treatment 4|Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.
9857810|NCT02815397|Experimental|Single arm, open label|Metformin added to standard of care treatment for all patients
9857811|NCT02802592|Active Comparator|Epogen|1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
9857812|NCT02802592|Placebo Comparator|Normal Saline|250 ml normal saline infused over 1 hr
9857813|NCT02774148|Active Comparator|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
9857814|NCT02774148|Experimental|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
9857815|NCT02773576|Experimental|2x360 mg risperidone implant|2, 360 mg risperidone implants
9857816|NCT02773576|Experimental|3x300 mg risperidone implant|3, 300 mg risperidone implants
9857817|NCT02730793|Active Comparator|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
9857818|NCT02730793|Experimental|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
9857819|NCT02744352|Active Comparator|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
9857820|NCT02744352|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
9857821|NCT02760602|Experimental|Solanezumab|Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
9857822|NCT02760602|Experimental|Placebo|Placebo given IV once every 4 weeks for up to 2 years.
9857823|NCT02757521|Placebo Comparator|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
9857824|NCT02757521|Experimental|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
9857825|NCT02758132|Active Comparator|Alliance A031201|Denosumab plus enzalutamide, abiraterone and prednisone
9857826|NCT02758132|Active Comparator|Standard of Care|Denosumab plus enzalutamide alone
9857827|NCT02757547|Placebo Comparator|Transcranial magnetic stimulation - Placebo Arm|A placebo TMS coil is used.
9857828|NCT02757547|Active Comparator|Transcranial magnetic stimulation - Active Arm|An active TMS coil is used.
9857829|NCT02757053|Experimental|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
9857830|NCT02757053|No Intervention|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
9857831|NCT02734940|Active Comparator|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
9857832|NCT02734940|Experimental|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to <250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
9857833|NCT02749617|Experimental|apixaban|apixaban 2.5 mg PO BID
9857834|NCT02749227|Experimental|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
9857835|NCT02745210|Experimental|Experimental|13C Magnetic resonance (MR) spectroscopy.
9857836|NCT02725671|Other|Cardiogoniometry and ECG Assessment|The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG
9857837|NCT02746263|Experimental|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
9857838|NCT02746263|Active Comparator|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
9857839|NCT02721277|Experimental|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
9857840|NCT02732327|Experimental|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
9857841|NCT02732327|Active Comparator|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
9857842|NCT02726399|Experimental|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
9857843|NCT02720510|Active Comparator|Arm 1 - RVD + Pan|Revlimid, Velcade, dexamethasone and Farydak
9857844|NCT02720510|Active Comparator|Arm 2 - RVD|Revlimid, Velcade and Dexamethasone
9857845|NCT02715765|Sham Comparator|Sham|The sham procedure involves only 40 sec direct current stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec.
9857846|NCT02715765|Experimental|Active tDCS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). The current is held constant for 20 min. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
9857847|NCT02715765|Experimental|Active tRNS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). Once at 2mA, an alternating current of 2mA with a 0mA offset is applied at random frequencies over a range of 0.1 to 100 Hz. This is performed for 20 minutes. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
9857848|NCT02717949|Experimental|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
9857849|NCT02717949|Experimental|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those >75 kg and 1000 mg for those <75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
9857850|NCT02717130|Experimental|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
9857851|NCT02685202|Experimental|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
9857852|NCT02709083|Experimental|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
9857853|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
9857854|NCT02696226|Experimental|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
9857855|NCT02696226|Experimental|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
9857856|NCT02696226|Experimental|SAVR Aspirin Arm|Aspirin arm (81mg/day)
9857857|NCT02696226|Experimental|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
9857858|NCT02693743|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
9857859|NCT02693743|Sham Comparator|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
9857860|NCT02706691|Experimental|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
9857861|NCT02708849|Experimental|Ketamine plus lamotrigine|
9857862|NCT02708849|Placebo Comparator|ketamine plus placebo|
9857863|NCT02693717|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9857864|NCT02694757|Experimental|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
9857865|NCT02693002|Active Comparator|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
9857866|NCT02693002|Placebo Comparator|Placebo|Inert ingredients by mouth oral daily for 12 weeks
9857867|NCT02689518|Other|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
9857868|NCT02687165|Active Comparator|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
9857869|NCT02687165|Placebo Comparator|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
9857870|NCT02679560|Active Comparator|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
9857871|NCT02679560|Placebo Comparator|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
9857872|NCT02679066|Active Comparator|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
9857873|NCT02679066|Active Comparator|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
9857874|NCT02673684|Sham Comparator|Sham Neurostim System (Sham NSS)|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
9857875|NCT02673684|Experimental|Working Neurostim System (Working NSS)|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
9857876|NCT02674204|Experimental|Study Agent|One atorvastatin 20 mg oral capsule per day
9857877|NCT02674204|Placebo Comparator|Control|One matching placebo daily
9857878|NCT02665221|Placebo Comparator|Control group|
9857879|NCT02665221|Experimental|Treatment group|
9857880|NCT02672033|Experimental|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
9857881|NCT02671461|Experimental|BMS-986141 0.8mg|BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)
9857882|NCT02671461|Experimental|BMS-986141 4.8mg|BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)
9857883|NCT02671461|Placebo Comparator|Placebo|Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)
9857884|NCT02671136|Other|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
9857885|NCT02671136|Other|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
9857886|NCT02663752|Other|Deferasirox|All patients are already on commercial deferasirox before entering the study.
9857887|NCT02658357|Experimental|600 mg|Two, 300 mg Risperidone Implants
9857888|NCT02658357|Experimental|900 mg|Three, 300 mg Risperidone Implants
9857889|NCT02665988|Experimental|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
9857890|NCT02665988|Placebo Comparator|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
9857891|NCT02660528|Experimental|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
9924115|NCT00857922||Neurosurgical patient|Neurosurgical patient of the Mischer Neuroscience Institute, 18 years and over
9924116|NCT00857922||Family members|Family members of specific vascular, trauma, brain tumor and functional disorder cohorts
9924117|NCT00857935|Experimental|1|NatrOVA Creme Rinse - 1%
9924118|NCT00857935|Active Comparator|2|NIX Creme Rinse
9924119|NCT00857974|No Intervention|Usual Care|No physical activity intervention will be prescribed for the Usual Care Arm.
9924120|NCT00857974|Active Comparator|Physical Activity|
9924121|NCT00857987|Experimental|1|Guaifenesin, doxylamine succinate and hydrochloride etafedrine syrup
9924122|NCT00857987|Placebo Comparator|2|Vehicle
9924123|NCT00858000||Group A|No intervention
9924124|NCT00858026|Other|1|Breastfed babies
9924125|NCT00858026|Active Comparator|2|Weaning with the standard milk
9924126|NCT00858026|Experimental|3|Weaning with the fermented milk
9924127|NCT00858039||Her-2 positive ESBC|
9924128|NCT00858065|Active Comparator|RCT FM|Random control trial- Family Matters. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Family Matters program.
9924129|NCT00858065|Active Comparator|Choice SFP|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Strengthening Families Program (SFP).
9924130|NCT00858065|Active Comparator|RCT SFP|Random control trial- Strengthening Families Program. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Strengthening Families Program.
9924131|NCT00858065|No Intervention|RCT Control|Random control trial- Control Group. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to the control group and received no prevention program. However, this group and all groups received an informational pamphlet about youth alcohol and other drug use.
9924132|NCT00858065|Active Comparator|Choice FM|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Family Matters (FM) program.
9924133|NCT00858104|Active Comparator|1|Laser thermal ablation
9924134|NCT00858104|No Intervention|2|Follow-up
9924135|NCT00858182|Experimental|Group A|
9924136|NCT00858182|Experimental|Group B|
9924137|NCT00858195|Experimental|1|Indomethacin 75mg ER Capsules
9924138|NCT00858195|Active Comparator|2|Indocin 75mg SR Capsules
9924139|NCT00858260||hemodialysis patients|Adult patients undergoing maintenance dialysis since at leat three months
9924140|NCT00858273|Active Comparator|Antioxidant Supplement|Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
9924141|NCT00858273|Placebo Comparator|Placebo|
9924142|NCT00858286|Experimental|Stable dosing with SERETIDE, short acting B-2agonist as needed|Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
9924143|NCT00858286|Experimental|Maintenance treatment with SYMBICORT and SYMBICORT as needed|Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
9924144|NCT00858299|Experimental|valsartan|
9924145|NCT00858312|Experimental|1|Diet with 3-4 servings of dairy-rich foods/day
9924146|NCT00858312|Placebo Comparator|2|Low Dairy < 1 serving of dairy food/day
9924147|NCT00858351|Experimental|Thermal Biofeedback Assisted Relaxation|
9924148|NCT00858351|Active Comparator|Discussion|
9857892|NCT02658877|Experimental|Omalizumab|
9857893|NCT02658877|Placebo Comparator|Placebo|
9857894|NCT02654782|Active Comparator|Lactated Ringer's|Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
9857895|NCT02654782|Active Comparator|5% Human Albumin|Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
9857896|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
9857897|NCT02654639|Experimental|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
9857898|NCT02653495|Experimental|Influenza vaccine in metabolic syndrome|Influenza vaccine
9857899|NCT02653495|Experimental|Influenza vaccine in healthy controls|Influenza vaccine
9857900|NCT02640573|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
9857901|NCT02639390|Experimental|Robotic|The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
9857902|NCT02639390|Active Comparator|Conventional|Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).
9857903|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
9857904|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
9857905|NCT02634606|Placebo Comparator|Sugar Pill|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
9857906|NCT02634827|Experimental|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
9857907|NCT02636283|Active Comparator|Entresto|oral route
9857908|NCT02636283|Placebo Comparator|Placebo group|Oral placebo
9857909|NCT02638129|Other|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
9857910|NCT02638129|Other|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
9857911|NCT02638129|Active Comparator|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
9857912|NCT02638129|Placebo Comparator|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
9857913|NCT02615990|Experimental|Erigo Pro plus standard Physical Therapy|The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
9857914|NCT02615990|Active Comparator|Standard Physical Therapy|Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
9857915|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the United States (U.S) who received at least 1 dose of 4CMenB vaccine within 30 days prior to Last Menstrual Period (LMP) or at any time during pregnancy
9857916|NCT02633540|Experimental|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
9857917|NCT02623959|Experimental|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status."
9857918|NCT02623959|Active Comparator|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status"
9857919|NCT02631148|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 6 weeks
9857920|NCT02631148|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 6 weeks
9857921|NCT02630472|Experimental|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
9924149|NCT00858377|Experimental|Arm 1- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
9924150|NCT00858377|Experimental|Arm 1- Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD) of AMG 900 and if necessary, the MTD with prophylactic GCSF support (MTD-G).
9924151|NCT00858416|Experimental|AB|First active then Sham
9924152|NCT00858416|Sham Comparator|BA|First sham then active
9924153|NCT00858429|Experimental|Cohort 1 (capecitabine, Y90)|2,000mg/m2 capecitabine +110 Y90
9924154|NCT00858429|Experimental|Cohort 2 (capecitabine , Y90)|2,000mg/m2 capecitabine + 130 Y90
9924155|NCT00858429|Experimental|Cohort 3 (capecitabine, Y90)|2,000mg/m2 Capecitabine + 150 Y90
9924156|NCT00858429|Experimental|Cohort 4 (capecitabine, Y90)|2,000 mg/m2 capecitabine = 170 Y90
9924157|NCT00858455|Experimental|Healthy Volunteers|4 period cross over
9924158|NCT00858481|Placebo Comparator|1|Vehicle control
9924159|NCT00858481|Active Comparator|2|0.5% Spinosad creme rinse
9924160|NCT00858481|Active Comparator|3|1.0% Spinosad Creme Rinse
9924161|NCT00858481|Active Comparator|4|2.0% Spinosad Creme Rinse
9924162|NCT00858520||Smoking controls|Smokers without lung cancer and without COPD
9924163|NCT00858520||COPD patients|Smokers with COPD but without lung cancer
9924164|NCT00858520||Lung cancer patients|smokers - never smokers with lung cancer
9924165|NCT00858533|Other|workplace health advice|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances.
9857922|NCT02630472|Placebo Comparator|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
9857923|NCT02626520|Experimental|Resectable, Low Risk|Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
9857924|NCT02626520|Experimental|Locally Advanced|Systemic chemotherapy followed by chemoradiation, followed by definitive surgery
9857925|NCT02614898||Eculizumab|The targeted population consists of pediatric and adult participants with aHUS who received eculizumab at the discretion of the treating physician.
9857926|NCT02622828|Other|Behavioural|Participant-identified community based activity
9857927|NCT02624739|Experimental|Intervention|Reassure Non-Contact Respiration Monitor: Respiration parameters transmitted by the Reassure device will be evaluated daily by the study team and participants will be contacted for further evaluation if a change in respiration patterns is noted. Participants will continue with standard of care heart failure treatment.
9857928|NCT02624739|Active Comparator|Control|Reassure Non-Contact Respiration Monitor: Respiration parameters will be transmitted and stored, but there will be no active evaluation of respiration patterns. Participants will continue with standard of care heart failure treatment.
9857929|NCT02608905|Experimental|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
9857930|NCT02608905|Placebo Comparator|Placebo|Placebo tablets by mouth daily for 12 weeks
9857931|NCT02619812|Active Comparator|Group A: SBI + Placebo|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
9857932|NCT02619812|Active Comparator|Group B: Colesevelam + Placebo|Colesevelam 1.875 g + Placebo twice per day
9857933|NCT02619812|Active Comparator|Group C: Colesevelam + SBI|Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
9857934|NCT02619812|Placebo Comparator|Group D: Double Placebo|Double placebo twice per day
9857935|NCT02612285|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
9857936|NCT02614586|Experimental|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
9857937|NCT02614586|Experimental|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
9857938|NCT02614586|Experimental|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
9857939|NCT02614586|Experimental|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
9857940|NCT02614586|Experimental|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
9857941|NCT02614586|Experimental|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
9857942|NCT02606279|Placebo Comparator|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
9857943|NCT02606279|Experimental|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
9857944|NCT02605824|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
9857945|NCT02605824|Placebo Comparator|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
9857946|NCT02598622|Experimental|Acetyl-L-Carnitine only|The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
9857947|NCT02598622|Experimental|Acetyl-L-Carnitine or Placebo|Subjects 16-30 will be randomized to receive drug or placebo.
9857948|NCT02589145|Experimental|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.~Melphalan administered at 60 mg/m2 on days -3 and -2.~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
9857949|NCT02582749|Active Comparator|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
9857950|NCT02582749|Experimental|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
9857951|NCT02590068|Experimental|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
9857952|NCT02590068|Active Comparator|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
9857953|NCT02593682|Experimental|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
9857954|NCT02593682|Placebo Comparator|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
9857955|NCT02587650|Experimental|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
9857956|NCT02587650|Experimental|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
9857957|NCT02587650|Experimental|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
9857958|NCT02587650|Experimental|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
9857959|NCT02569957|Active Comparator|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9924166|NCT00858533|No Intervention|GP sickness absence consultation|Routine general practitioner care for workplace sickness absence.
9924167|NCT00858546|Experimental|Active repetitive transcranial Stimulation|Active repetitive transcranial Stimulation
9924168|NCT00858559|Experimental|1|Home Monitoring
9794321|NCT01502787|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
9794322|NCT01502787|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
9794323|NCT01502813|Experimental|Citicoline, Creatine, and Omega-3 Arm|Each participant will be given a supplement log at the end of visit 1. They will be asked to complete the log during the 28 days to indicate that the daily dose of supplements were taken according to instructions. The study coordinator will check the log on the second and third visits as well as count the remaining supplement pills. If participants do not comply with the daily supplement schedule, then the PI will determine if the participant should be withdrawn from the study.
9794324|NCT01502956|Active Comparator|InterStim® device|The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/>50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
9794325|NCT01502956|Active Comparator|Botox® injection|Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
9794326|NCT01503021|Other|SFP/Placebo|Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
9794327|NCT01503021|Other|Placebo/SFP|Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
9794328|NCT01503164|Active Comparator|Positive pressure therapy (PAP)|Positive airway pressure(PAP) therapy is the standard of care for patients with obstructive sleep apnea. During sleep, a mask is worn over the nose and connected to the PAP machine.
9794329|NCT01503164|Sham Comparator|Lifestyle counseling|
9794330|NCT01503229|Experimental|Treatment (abiraterone acetate and prednisone)|Patients receive abiraterone acetate orally once daily and prednisone orally twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9794331|NCT01503333|No Intervention|Control|The control condition will complete data collection activities and receive their usual school offerings.
9794332|NCT01503333|Experimental|Physical activity intervention|Receiving Physical activity intervention which includes individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
9794333|NCT01503749|No Intervention|Control|Three patients with liver cirrhosis of this arm will not receive any intervention regarding to peripheral blood mononucleated cells.
9794334|NCT01503749|Active Comparator|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm.
9794335|NCT01503749|Experimental|Infusion of the mobilized monocyte cells|"G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells~. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance."
9794336|NCT01504204|Experimental|Medication with sample and demonstration|Subjects will receive a sample tube of the Adapalene + benzoyl peroxide samples with demonstration of how to use it at the first visit.
9794337|NCT01504204|Active Comparator|Medication without samples|Subjects will receive the Adapalene + benzoyl peroxide from standard tube without a sample or demonstration of proper use of the medication.
9794338|NCT01504412|Experimental|DS-5565 Low Dose|DS-5565 10mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
9794339|NCT01504412|Experimental|DS-5565 Middle Dose|DS-5565 20mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
9794340|NCT01504412|Experimental|DS-5565 High Dose|DS-5565 30mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
9794341|NCT01504412|Placebo Comparator|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
9794342|NCT01504412|Active Comparator|Pregabalin|Pregabalin capsules 300mg/day administered in 2 doses
9794343|NCT01504477|Experimental|Combination of Panitumumab and Bortezomib|IV panitumumab and bortezomib
9794344|NCT01504672|Experimental|Medication review|
9794345|NCT01504672|No Intervention|Usual care|
9794346|NCT01504711|Experimental|Treatment (nausea and vomiting prophylaxis)|Receive fosaprepitant dimeglumine IV 30 mins. prior to FOLFIRINOX chemotherapy.
9794347|NCT01504841|Experimental|Cohort I: Treatment experienced, 2 to 6 years of age|Children in this arm were at least 2 but younger than 6 years of age; they received the study drug etravirine (ETR) together with an optimized background regimen (OBR) consisting of one active boosted protease inhibitor (PI) and at least one other active antiretroviral (ARV) drug.
9794348|NCT01504841|Experimental|Cohort II: Treatment experienced, 1 to 2 years of age|Children in this arm were at least 1 but younger than 2 years of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
9794349|NCT01504841|Experimental|Cohort III: Treatment experienced, 2 months to 1 year of age|Children in this arm were at least 2 months but younger than 1 year of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
9794350|NCT01504854|Experimental|Resveratrol|Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
9794351|NCT01504854|Placebo Comparator|Placebo|Subjects will receive a matching placebo to be taken with or without food.
9794352|NCT01504867|Experimental|Aspirin|This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
9794353|NCT01504867|Placebo Comparator|Placebo|This group received matching lactose powder filled capsules on days 1-7.
9794354|NCT01504958|Active Comparator|Active rTMS with real cognitive training|High frequency rTMS stimulation to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
9794355|NCT01504958|Sham Comparator|Sham rTMS with real cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
9794356|NCT01504958|Sham Comparator|Sham rTMS with sham cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent sham cognitive training.
9794357|NCT01504971||Gastroesophageal reflux disease (GERD)|
9794358|NCT01504997|Experimental|Robot assisted distal gastrectomy|patients who received robot assisted distal gastrectomy
9794359|NCT01505010|Other|Control group|Standard antihypertensive drug treatment
9794360|NCT01505010|Experimental|Intervention group|Renal denervation plus standard antihypertensive drug treatment
9924169|NCT00858559|Active Comparator|2|Home Monitoring not used
9924170|NCT00858572|Experimental|Cohort|
9986411|NCT01402648|Active Comparator|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside) + 750 mg non starch, insoluble and indigestible fiber (6% in lignin).
9986412|NCT01402661||Rheumatoid Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible.
9986413|NCT01402674|Active Comparator|LPT|Subjects treated with phentermine for 2 years or more.
9986414|NCT01402674|No Intervention|APT|Patients treated with phentermine for 7 to 14 days.
9794366|NCT01505114|Experimental|Arm 1|MVC 300 mg plus FTC placebo and TDF placebo orally once daily
9794367|NCT01505114|Experimental|Arm 2|MVC 300 mg plus FTC 200 mg and TDF placebo orally once daily
9794368|NCT01505114|Experimental|Arm 3|MVC 300 mg plus FTC placebo and TDF 300 mg orally once daily
9794369|NCT01505114|Experimental|Arm 4|MVC placebo plus FTC 200 mg and TDF 300 mg orally once daily
9794370|NCT01505166|Experimental|Vigil™|Patients will receive 1 x 10^7 cells (Group A) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses (vaccine) starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
9794371|NCT01505166|Placebo Comparator|Placebo|Patients will receive placebo (Group B) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
9794372|NCT01505166|Experimental|Vigil™ Vaccine (6 patient run-in)|Six patients will be enrolled into the Part 1 of the study to receive intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations).
9794373|NCT01505179|Active Comparator|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
9794374|NCT01505179|Placebo Comparator|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
9794375|NCT01505374|Experimental|Study Technique Left Leg, Control Technique Right Leg|
9794376|NCT01505374|Experimental|Study Technique Right Leg, Control Technique Left Leg|
9794377|NCT01505387|Placebo Comparator|Placebo|Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
9794378|NCT01505387|Experimental|Litramine|Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
9794379|NCT01505465|Experimental|Study: Melatonin|
9794380|NCT01505465|Placebo Comparator|Control: Placebo|
9794381|NCT01505491|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
9794382|NCT01505491|Active Comparator|adalimumab - US|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
9794383|NCT01505491|Active Comparator|adalimumab - EU|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
9794384|NCT01505530|Experimental|300 mg LY2495655 + chemotherapy|300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
9794385|NCT01505530|Experimental|100 mg LY2495655 + chemotherapy|100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
9794386|NCT01505530|Placebo Comparator|Placebo + chemotherapy|Placebo in combination with standard of care chemotherapy (investigator's choice)
9794387|NCT01505634|Experimental|Relebactam 250 mg with imipenem/cilastatin|Relebactam 250 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
9794388|NCT01505634|Experimental|Relebactam 125 mg with imipenem/cilastatin|Relebactam 125 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
9794389|NCT01505634|Placebo Comparator|Relebactam placebo with imipenem/cilastatin|Matching placebo for relebactam (0.9% normal saline) IV co-administered with 500 mg dose of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
9794390|NCT01505647|Experimental|ZOSTAVAX™ (AMP)|ZOSTAVAX™ manufactured with an alternative process
9794391|NCT01505647|Active Comparator|ZOSTAVAX™|ZOSTAVAX™ manufactured with the current process
9794392|NCT01505673|Active Comparator|Liraglutide|
9794393|NCT01505673|Placebo Comparator|Saline injection|
9794394|NCT01505764|Experimental|Arm 1 (Anamorelin HCl)|Anamorelin HCl
9794395|NCT01505764|Placebo Comparator|Arm 2 (Placebo)|Placebo
9794396|NCT01505868|Experimental|Arm I (cabazitaxel)|Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
9794397|NCT01505868|Experimental|Arm II (cabazitaxel and carboplatin)|Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
9794398|NCT01505881|Experimental|Dabigatran etexilate|Patient dose determined by dose allocated in 1160.113 and CrCl levels
9794399|NCT01505881|Active Comparator|warfarin|warfarin doses to maintain INR levels
9794400|NCT01505933|Active Comparator|dexmedetomidine|
9794401|NCT01505933|Active Comparator|propofol|
9857960|NCT02569957|Experimental|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9857961|NCT02568007|No Intervention|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
9857962|NCT02568007|Experimental|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
9857963|NCT02568007|Experimental|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
9857964|NCT02575365|Experimental|Fingolimod arm|0.5 mg p.o fingolimod daily
9857965|NCT02549755|Other|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
9857966|NCT02547129|Active Comparator|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
9857967|NCT02547129|Active Comparator|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
9857968|NCT02528097|Placebo Comparator|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
9857969|NCT02528097|Experimental|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr > 1.0 or BUN or Cr are above baseline.
9857970|NCT02549716|Experimental|IV acetaminophen + oral placebo|Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
9857971|NCT02549716|Experimental|Oral acetaminophen + IV placebo|Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.
9857972|NCT02540434|Active Comparator|RiaSTAP Arm|Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
9857973|NCT02540434|Active Comparator|Cryopreciptiate Arm|Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
9924171|NCT00858598||Pro Osteon|All patients in this pilot study will receive pro osteon as a bone void filler and will be enrolled according to the same inclusion / exclusion criteria.
9924172|NCT00858624|Active Comparator|Chronic Cough Patients|
9924173|NCT00858624|Active Comparator|Healthy Volunteers|
9857974|NCT02531308|Experimental|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
9857975|NCT02533531|Experimental|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
10209251|NCT04610658|Experimental|Phase 1 Dose Level 2: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 2: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 2.6 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 2 every 3 weeks.
9857976|NCT02534038|Placebo Comparator|Placebo|Placebo drug to be taken twice a day for 6 weeks
9857977|NCT02534038|Active Comparator|AVP-786|Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
9857978|NCT02520726|Experimental|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age >65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
9857979|NCT02520726|Placebo Comparator|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
9857980|NCT02520297|Experimental|TRV130|Drug: TRV130
9857981|NCT02519712|Experimental|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
9857982|NCT02518750|Experimental|Study Participants|"Participants with ALL will receive the following interventions in three treatment blocks:~Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.~Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.~Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide."
9857983|NCT02516228|Experimental|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
9857984|NCT02515851|Active Comparator|Active Group|Group that receives actual liposomal bupivacaine injections
9857985|NCT02515851|Placebo Comparator|Placebo Group|Group that receives placebo injections
9857986|NCT02506985|Experimental|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
9857987|NCT02506985|Experimental|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is >= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
9857988|NCT02514252|Experimental|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
9857989|NCT02501759|Experimental|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
9857990|NCT02487277|Experimental|Combination therapy with 1 week Run-In|"PEGPH20: 3ug/kg on Days 1 and 4~1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
9857991|NCT02487277|Experimental|Combination therapy alone|"1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
9986415|NCT01402687||Mucositis Positive|Participants who developed severe mucositis
10213606|NCT03727061|Experimental|Arm B(porfimer sodium, I-PDT, SoC chemotherapy)|Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later. Patients also receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion at either 7 days, 14 days, or 28 days later.
9857992|NCT02506101|Experimental|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC & SP Phototherapy Cabinet for treatment of vitiligo.
9857993|NCT02506101|No Intervention|no intervention|untreated
9857994|NCT02499887|Active Comparator|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
9986416|NCT01402687||Mucositis Negative|Participants who did not develop severe mucositis
9857995|NCT02499887|Experimental|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
9857996|NCT02504099|Experimental|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
9857997|NCT02500901|Experimental|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
9857998|NCT02483533|Experimental|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
9857999|NCT02483533|Placebo Comparator|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
9858000|NCT02496039|Other|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
9858001|NCT02492295|Experimental|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
9858002|NCT02494206|Experimental|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
9858003|NCT02473445|Experimental|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
9858004|NCT02491411|Experimental|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
9858005|NCT02476994|Experimental|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
9858006|NCT02476994|Active Comparator|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
9858007|NCT02473523|Experimental|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
9858008|NCT02468583|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
9858009|NCT02468583|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
9858010|NCT02450591|Experimental|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression [partial response (PR) or stable disease (SD)] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
9858011|NCT02472639|Experimental|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
9858012|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
9858013|NCT02469415|Experimental|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
9858014|NCT02461550|Experimental|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
9858015|NCT02461355|Experimental|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
9858016|NCT02461355|Sham Comparator|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
9858017|NCT02452359|Experimental|Treatment Group|Group receiving treatment with Venus Versa IPL energy
9858018|NCT02434146|Experimental|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
9858019|NCT02452398|Experimental|Treatment Group|Hair removal treatment using Venus Versa IPL energy
9858020|NCT02452398|Placebo Comparator|No intervention|Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
9858021|NCT02447887|Experimental|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
9858022|NCT02431494|Active Comparator|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
9858023|NCT02431494|Active Comparator|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
9858024|NCT02431494|Active Comparator|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
9858025|NCT02439970|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; 1 tablet) administered orally twice weekly, plus valganciclovir (vGCV) placebo (2 tablets) administered orally once daily.
9858026|NCT02439970|Active Comparator|Treatment 2|900 mg valganciclovir (vGCV; two 450 mg tablets) administered orally once daily, plus brincidofovir (BCV) placebo (1 tablet) administered orally twice weekly.
9858027|NCT02439957|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
9858028|NCT02439957|Active Comparator|Treatment 2|900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
9858029|NCT02441036|Active Comparator|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
9858030|NCT02441036|Active Comparator|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
9858031|NCT02441036|Active Comparator|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
9858032|NCT02441036|Active Comparator|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
9858033|NCT02441036|Active Comparator|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
9858034|NCT02436265|Sham Comparator|Group 1 Ropivacaine|Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
9858035|NCT02436265|Active Comparator|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
9858036|NCT02429583|Active Comparator|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
9858037|NCT02429583|Active Comparator|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
9858038|NCT02417870|Experimental|aldesleukin|
9858039|NCT02430532|Experimental|Dimethyl fumarate|BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
9924174|NCT00858650||Standard of Care|Hypogonadal males treated by standard of care, with or without testosterone replacement therapy
9858040|NCT02430532|Experimental|Placebo|BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
9858041|NCT02428231|Active Comparator|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
9858042|NCT02428231|Experimental|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
9858043|NCT02424565|Experimental|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
9858044|NCT02424565|Placebo Comparator|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
9858045|NCT02413047|Experimental|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
9858046|NCT02414698|Active Comparator|Percutaneous Hydrodiscectomy|Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System
9858047|NCT02414698|Active Comparator|TESI|Transforaminal Epidural Steroid Injections
9858048|NCT02422303|Active Comparator|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
9858049|NCT02422303|No Intervention|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
9858050|NCT02415166|Experimental|VACCINE MDD|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
9858051|NCT02415166|Placebo Comparator|PLACEBO MDD|SALINE (0.5ML) DELIVERED I.M.
9858052|NCT02415166|Experimental|VACCINE HC|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
9858053|NCT02415166|Placebo Comparator|PLACEBO HC|SALINE (0.5ML) DELIVERED I.M.
9858054|NCT02414152|Experimental|anakinra|100mg of Anakinra administered as a daily subcutaneous injection
9858055|NCT02410551|Experimental|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
9858056|NCT02411643|Other|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
9858057|NCT02410954|Experimental|tDCS electrode configuration|Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)
9858058|NCT02410954|Placebo Comparator|Using tDCS to reduce acute fear|Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.
9858059|NCT02410577|Experimental|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
9858060|NCT02409355|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
9858061|NCT02409355|Active Comparator|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
9858062|NCT02403154|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be internal fixator.
9858063|NCT02403154|Experimental|Randomized to External Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be external fixator.
9858064|NCT02403154|Other|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the internal fixator intervention based on their preference for the specific case or the patient chose the internal fixator.
9858065|NCT02403154|Other|Observational - External Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the external fixator intervention based on their preference for the specific case or the patient chose the external fixator.
9858066|NCT02404545|No Intervention|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
9858067|NCT02404545|Active Comparator|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
9924175|NCT00858663|Experimental|Chemoradiation|"IMRT, 1 fraction/day, over approximately 33 treatment days~RAD001 per oral or PEG, per dose escalation scheme (Days 1 - 42)~Cisplatin IV weekly, per dose escalation scheme (Days 1, 8, 15, 22, 29, 36)"
9924176|NCT00858676|Active Comparator|Acarbose|
9924177|NCT00858715|Active Comparator|1|75 mg clopidogrel + 100 mg aspirin
9924178|NCT00858715|Active Comparator|2|150 mg clopidogrel + 100 mg aspirin
9924179|NCT00858741|Experimental|8 Gy arm|8.0 Gy in 1 fraction to 8.0 Gy total dose.
9858068|NCT02392377|Experimental|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
9858069|NCT02392377|Experimental|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
9858070|NCT02399111|No Intervention|Not obese:BMI<30; Standard Care|Standard Wound Care
9858071|NCT02399111|No Intervention|Obese:BMI≥30; Standard Care|Standard Wound Care
9858072|NCT02399111|Other|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
9858073|NCT02399111|Other|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
9924180|NCT00858741|Active Comparator|30 Gy arm|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
9924181|NCT00858754|Experimental|Group 1 Active Drug|Methylnaltrexone
9924182|NCT00858754|Placebo Comparator|Group 2 Non-Active Drug|Placebo
9924183|NCT00858767|Active Comparator|1|2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
9924184|NCT00858767|Active Comparator|2|2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
9924185|NCT00858767|Active Comparator|3|2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
9924186|NCT00858793|Experimental|A|
9924187|NCT00858806|Experimental|Intermittent Imatinib|"Imatinib will be given with the following schedule:~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
9924188|NCT00858819||AS|Patients with AS attending three different rheumatology clinics in Western Sweden have been invited to participate.
9924189|NCT00858884|No Intervention|No intevention|No intervention
9924190|NCT00858897|Experimental|1|Normoglycemia (80-140 mg/dL)
9924191|NCT00858897|Experimental|2|Hyperglycemia (200-250 mg/dL)
9924192|NCT00858910|Experimental|EG1: embedded MI|"Experimental group 1:~Participants receive motor imagery (MI) training included in 45min physiotherapy, 3 times per week for 2 weeks."
9924193|NCT00858910|Experimental|EG2: added MI|"Experimental group 2:~Participants receive a 15 minutes motor imagery (MI) training added to a 30 min physiotherapy session, 3 times a week for two weeks."
9924194|NCT00858910|Placebo Comparator|CG|"Control group:~Participants receive a 15 min control intervention added to their 30 min physiotherapy session, 3 times a week for two weeks."
9924195|NCT00858936|Experimental|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
9924196|NCT00858936|Placebo Comparator|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
9924197|NCT00858949||Post surgery monitored group|Outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids
9924198|NCT00858975|Experimental|Cryotherapy|The patients who receive cryotherapy for their renal tumors
9924199|NCT00859001|Experimental|FM+R|4 cycles of FM+R plus Zevalin
9924200|NCT00859066||Control Group|"First year University of Michigan Radiology residents will take call as scheduled without a buddy call experience.~(Enrollment completed for the control group)"
9986417|NCT01402713|Experimental|GC1107-T5.0|Dosage: 0.5ml
10209252|NCT04610658|Experimental|Phase 1 Dose Level 3: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 3: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 3.2 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 3 every 3 weeks.
9858074|NCT02402036|Experimental|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
9858075|NCT02394665|Experimental|Group 1: SIB + IMRT|"Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
9858076|NCT02394665|Experimental|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) <= 4cm; or multiple HTVs <= 3 cm:~Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
9858077|NCT02389712|Active Comparator|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
9858078|NCT02389712|Active Comparator|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
9858079|NCT02390362|Experimental|Rituximab|Rituximab 375 mg/m2 will be administered intravenously on Study weeks 1 & 3.
9858080|NCT02390362|Active Comparator|Mycophenolate Mofetil (MMF)|Mycophenolate Mofetil will be continued in the patients in the MMF arm at a standard oral dose of 600 mg/m2 PO, BID starting on Study week 1 and continuing for 12 months
9858081|NCT02388776|Experimental|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
9858082|NCT02383433|Experimental|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9858083|NCT02382588|Experimental|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
9858084|NCT02382588|Placebo Comparator|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
9858085|NCT02381626|Experimental|Intervention Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
9858086|NCT02381626|Experimental|Wait-list Control Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. The Wait-list Control Group drivers will not receive a HEPA air purifier at this time, but will also have the air monitoring and biological parameters repeated for another 2 weeks. At the end of the 1 month period of measurements for both groups of drivers, the Wait-list drivers will then receive a HEPA air purifier, so that they may also potentially benefit from the intervention being tested in this study, but no further measurements will be taken.
9858087|NCT02379390|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
9858088|NCT02379390|Active Comparator|Abiraterone acetate or Enzalutamide|Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
9858089|NCT02373865|Experimental|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
9858090|NCT02373865|Active Comparator|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
9858091|NCT02365688|Other|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
9858092|NCT02361580|Experimental|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
9858093|NCT02361580|No Intervention|No Diary|Control Group
9858094|NCT02369744|Active Comparator|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
9858095|NCT02369744|Active Comparator|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
9858096|NCT02379585|Active Comparator|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
9858097|NCT02379585|Active Comparator|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
9986418|NCT01402713|Experimental|GC1107-T7.5|Dosage: 0.5ml
9858098|NCT02370888|Experimental|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.~The dose levels of lenalidomide will be as follows:~Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
9858099|NCT02367170|Experimental|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
9858100|NCT02367170|Sham Comparator|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
9858101|NCT02376933|Experimental|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
9858102|NCT02365233|Active Comparator|Thiazolidinedione|(Pioglitazone, 15 mg/day)
9858103|NCT02365233|Active Comparator|Lantus Insulin|0.35 U per kg body weight once daily
9858104|NCT02365233|Active Comparator|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
9858105|NCT02365207|Experimental|BCG treatment of invasive bladder cancer|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
9858106|NCT02360111|Experimental|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
9858107|NCT02353468|Experimental|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
9858108|NCT02360059|Experimental|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
9858109|NCT02360059|Placebo Comparator|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
9858110|NCT02350777|Experimental|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
9858111|NCT02350777|Experimental|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
9858112|NCT02345460|Experimental|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9858113|NCT02346877|No Intervention|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
9924201|NCT00859066||Experimental Group|2009 class of first year Radiology residents who will be assigned two 5 hour shifts working side by side with a more senior resident (who has experience taking call).
9924202|NCT00859079|Active Comparator|GLP-1|Intravenously administered GLP-1
9858114|NCT02346877|Other|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
9858115|NCT02351063|Experimental|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
9858116|NCT02345772|Experimental|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
9858117|NCT02340728|Experimental|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
9858118|NCT02340728|Active Comparator|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
9858119|NCT02353572|Experimental|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
9858120|NCT02345369|Active Comparator|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
9858121|NCT02345369|Active Comparator|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
9858122|NCT02343263|No Intervention|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
9858123|NCT02343263|Active Comparator|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
9924203|NCT00859079|Active Comparator|Insulin intravenously|Insulin intravenously according to the Munich registry
9924204|NCT00859092|Experimental|Thickening of feeds|
9924205|NCT00859092|No Intervention|Removal of thickener|
9924206|NCT00859105|Experimental|Imiquimod 5%|Manufactured by Apotex
10209253|NCT04610658|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Participants will be treated with nivolumab 1mg/kg, ipilimumab 3mg/kg plus maximum tolerated dose of lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at MTD every 3 weeks.
10209254|NCT04607980|Experimental|Treatment Group A (ABP 654)|Participants will receive subcutaneous (SC) injection of ABP 654, 45 mg (baseline BW less than equal to [<=] 100 kg) or 90 mg (baseline BW greater than [>] 100 kg) at weeks 0, 4, and 16. Further from week 28 participants will receive ABP 654 (same dose) every 12 weeks (Q12W) at weeks 28 and 40 or may receive dose intensification Q8W at weeks 28, 36, and 44, depending on PASI score.
10209255|NCT04607980|Experimental|Treatment Group B (Ustekinumab - ABP 654)|Participants will receive SC injection of ustekinumab,45 mg (baseline BW <= 100 kg) or 90 mg (baseline BW > 100 kg) at weeks 0, 4, and 16. At week 28, participants will be re-randomized to continue on ustekinumab (Treatment group B1), or to receive ABP 654 (Treatment group B2) on weeks 28 and 40. Depending on PASI score, some participants may not be re-randomized and may receive dose intensification with ustekinumab Q8W at weeks 28, 36, and 44.
10209256|NCT04607746|Experimental|Capsule|Participants will swallow the capsule for imaging prior to completing colonoscopy. Capsule swallow may be 1 day prior or 3-6 weeks prior to colonoscopy.
10209257|NCT04605874|Experimental|2 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 2 cigarillos per pack.
10209258|NCT04605874|Experimental|4 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 4 cigarillos per pack.
9858124|NCT02343263|Experimental|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
9858125|NCT02343159|Experimental|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
9858126|NCT02343159|Experimental|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
9858127|NCT02343159|Experimental|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
9858128|NCT02341495|Experimental|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
9858129|NCT02336425|Experimental|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
9858130|NCT02336425|Experimental|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
10209259|NCT04604652|Experimental|Open-label|HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.
9858131|NCT02336425|Experimental|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
9858132|NCT02336425|Placebo Comparator|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
9858133|NCT02336763|Experimental|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
9858134|NCT02320825|Experimental|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
9858135|NCT02320825|Experimental|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
9858136|NCT02319005|Active Comparator|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
9858137|NCT02319005|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
9858138|NCT02318901|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
9858139|NCT02318901|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
9858140|NCT02318901|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
9858141|NCT02317276|Experimental|Treatment|Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
9858142|NCT02307188|Experimental|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
9858143|NCT02308475|Experimental|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
9858144|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
9858145|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
9858146|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
10209260|NCT04601350|Experimental|Remimazolam 1|
10209261|NCT04601350|Experimental|Remimazolam 2|
10209262|NCT04601350|Experimental|Remimazolam 3|
10209263|NCT04601350|Experimental|Remimazolam 4|
10209264|NCT04596475|Experimental|Treatment Arm|
10209265|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator, we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
10209266|NCT04594200|Experimental|Intervention Group: Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on both lack of benefit and potential harms caused by unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
10213607|NCT03717597|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
9858147|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
9858148|NCT02299206|Experimental|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
9858149|NCT02299206|Experimental|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
9858150|NCT02302859|Experimental|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.~Participants complete saliva cotinine test 3 months after intervention."
9858151|NCT02302859|Experimental|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.~Participants complete saliva cotinine test 3 months after intervention."
9858152|NCT02299934|Other|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
9858153|NCT02297230|Experimental|Arm 1 Capecitabine and RT|Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
9858154|NCT02297230|Experimental|Arm 2 Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
9858155|NCT02297230|Experimental|Arm 3: Paclitaxel and RT|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
9858156|NCT02297230|Experimental|Arm 4: Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
9858157|NCT02294981|Active Comparator|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
9858158|NCT02294981|Experimental|Plaque based dosing|Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
9858159|NCT02284906|Experimental|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
9858160|NCT02284906|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
9858161|NCT02287025|Experimental|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
9858162|NCT02287025|Active Comparator|Standard of Care|Investigators were supported with standard prescribing information.
9858163|NCT02282332|Experimental|Patiens Discharged on Ticagrelor|Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
9858164|NCT02287636|Experimental|Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)|Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
9858165|NCT02276560|Experimental|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
9858166|NCT02276560|Experimental|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
9858167|NCT02276560|Other|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
9858168|NCT02280252|Experimental|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:~Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule~Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
9858169|NCT02284373|Other|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
9858170|NCT02284373|Other|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
9858171|NCT02284373|Other|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
9858172|NCT02285270|Other|Single group assignment|Diagnostic test/procedure - FDG PET/CT
9858173|NCT02275481|Experimental|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
9858174|NCT02275481|Active Comparator|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
9858175|NCT02266914|Experimental|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
9858176|NCT02273752|Experimental|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
9858177|NCT02270684|Experimental|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
9858178|NCT02270684|No Intervention|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
9858179|NCT02262000|Experimental|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
9858180|NCT02262000|Experimental|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
9858181|NCT02271594|Active Comparator|Intervention|Intensive education on injection technique
9858182|NCT02271594|Placebo Comparator|Control|Standard education on injection technique
9858183|NCT02263365|No Intervention|Control|
9858184|NCT02263365|Experimental|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
9858185|NCT02266797|Active Comparator|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
9858186|NCT02266797|Placebo Comparator|Saline|Subject will receive doses of intravenous physiological saline solution.
9858187|NCT02249377|Experimental|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
9858188|NCT02249377|Active Comparator|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
9858189|NCT02253394|Active Comparator|AMB + Spiro, Cardiopulmonary fitness|Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
9858190|NCT02253394|Placebo Comparator|Placebo Cardiopulmonary fitness|Placebo mimics spironolactone 50 mg and will be taken QD
9858191|NCT02241551|Experimental|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
9858192|NCT02241551|Experimental|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
9858193|NCT02246114|Experimental|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
9858194|NCT02246114|Experimental|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
9924207|NCT00859105|Active Comparator|Adara 5 % Cream US|Manufactured by 3M, US.
9924208|NCT00859105|Active Comparator|Adara 5% Cream Canada|Manufactured by 3M, Canada
9924209|NCT00859105|Placebo Comparator|Vehicle|Manufactured by Apotex
10213608|NCT03712813|Experimental|Macrodyne LivMD plate|
10213609|NCT03712813|No Intervention|Wait-Listed Control|
10213610|NCT03710525|Experimental|Own-Price Elasticity|"The price of vegetables will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
10213611|NCT03710525|Experimental|Cross-Price Elasticity|"The price of vegetables will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
10213612|NCT03705845|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
10213613|NCT03705845|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
9858195|NCT02232880|Active Comparator|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those >100 kg will receive 1000 mg abatacept by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
9858196|NCT02232880|Placebo Comparator|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
9858197|NCT02248740|Active Comparator|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
9858198|NCT02248740|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
9858199|NCT02239627|Active Comparator|Steroid|Epidural steroid injection
9858200|NCT02239627|Experimental|Clonidine|Epidural clonidine injection
10209267|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Simple Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a simple comparator to represent a target or benchmark for antibiotic prescribing. For the simple comparator we will rank the antibiotic prescribing outcomes for all Ontario family physicians and use the lowest quartile as the benchmark. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month post initial dissemination.
10209268|NCT04594200|Experimental|Intervention Group: No Harms Emphasis - Complex Comparator|Physicians in this group will receive a personalized antibiotic prescribing feedback letter which contains a complex (adjusted) comparator to represent a target or benchmark for antibiotic prescribing. For the complex comparator, recipients will be compared only to top-performing 'like-peers' - the group of physicians with similar complexity and numbers of patients. We will adjust the prescribing indicators for patient sex, number of patients >85 years, rurality, continuity of care score, proportion of emergency room practice, proportion nursing home practice, neighborhood income quintile of patients, and rates of common patient comorbidities. The letter will also include information on lack of benefit of unnecessary use of antibiotics. Physicians will also receive a paper-copy viral prescription pad and will receive the intervention letter again 1-month later.
9858201|NCT02244944|Experimental|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
9858202|NCT02241187|Experimental|PEGPH20 And Cetuximab|5 participants will undergo DW- & DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) & (DCE)-MRI for repeatability investigation & T1 mapping. Optional DW- & DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- & DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- & DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
9858203|NCT02239926|Active Comparator|Ranolazine|tablet, 1000 mg twice daily for four weeks
9858204|NCT02239926|Placebo Comparator|Placebo|Placebo
9858205|NCT02231892|Experimental|Real TMS|rTMS (frequency and intensity)
9858206|NCT02231892|Sham Comparator|Sham TMS|Sham setting on coil
9858207|NCT02241343|Other|Trial cohort|Measurements taken before and after venous occlusion applied
9858208|NCT02242578|Experimental|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
10209269|NCT04594200|No Intervention|Control Group|Participants in this group will not receive a personalized antibiotic prescribing feedback letter and they will not receive a viral prescription pad.
10209270|NCT04592250||Observational (survey)|Participants will complete a survey packet that is estimated to take about 30 minutes. The survey packet will be collected at baseline and at 6 months.
9858209|NCT02242578|Experimental|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
9858210|NCT02234011|Experimental|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
9858211|NCT02234011|Experimental|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
9858212|NCT02236546|Experimental|FDG-PET/CT|Patients undergo [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). Molecular assays on biopsied tissue obtained from a subset of patients will also undergo molecular assays, the results from which will be correlated with FDG-PET/CT data.
10213614|NCT03696433|Experimental|Low- then high-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
9858213|NCT02234687|Placebo Comparator|Placebo|Placebo, one dose
9858214|NCT02234687|Experimental|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
9858215|NCT02234687|Experimental|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
9858216|NCT02224599|Experimental|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
9858217|NCT02201472|Experimental|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
9858218|NCT02202044|Experimental|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
9858219|NCT02192775|Experimental|MV-NIS + Cyclophosphamide|
10209271|NCT04585178|Experimental|Biobeat patch|Patients will be asked to keep Biobeat patch during 72 hours after their surgery.
10209272|NCT04583514|Experimental|Control|The control group will be expected to maintain their weight within 1 kg of baseline weight throughout the duration of the study.
9858220|NCT02200328|Experimental|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
9858221|NCT02200328|Placebo Comparator|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
9858222|NCT02200042|Experimental|Radiation therapy|Liver-directed radiation therapy
9986419|NCT01402713|Active Comparator|TD_PUR INJ /SK Td vaccine|The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml
9858223|NCT02200042|No Intervention|Observation|No radiation therapy
9858224|NCT02181790|Experimental|First Group|excimer laser treatment to one palm and/or one sole
9858225|NCT02181790|Experimental|Second Group|excimer laser treatment to both palms and/or soles
9858226|NCT02198833|Experimental|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
9858227|NCT02198833|Active Comparator|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
9858228|NCT02175628|Experimental|Acoustic Angiography|All breast patients will be included in the experimental group.
9858229|NCT02175628|Experimental|Healthy Volunteers|A volunteer group was added to the study to perfect the image acquisition techniques.
9858230|NCT02177266|Placebo Comparator|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
9858231|NCT02177266|Experimental|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
9858232|NCT02184520|Active Comparator|TRANSITION|Stabilization System
9858233|NCT02184520|Active Comparator|REVERE|Stabilization System
9858234|NCT02170298|Placebo Comparator|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.~Drug: Placebo"
9858235|NCT02170298|Experimental|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.~Drug: Lisdexamfetamine"
9858236|NCT02177773|Experimental|Ga-68 DOTA-TOC PET/CT|Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.
9858237|NCT02162979|Experimental|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
9858238|NCT02162979|Placebo Comparator|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
9858239|NCT02169830|Active Comparator|nortriptyline|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
9858240|NCT02169830|Active Comparator|topiramate|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
9858241|NCT02169830|Other|diet modification|Participants will begin with diet modification for four (4) weeks.
9858242|NCT02163187|Experimental|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
9858243|NCT02163187|Experimental|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
9858244|NCT02161016|Other|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
9858245|NCT02159040|Active Comparator|Azacitidine|75mg/m2 7days/28 day cycle
9858246|NCT02159040|Experimental|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
9858247|NCT02168270|Experimental|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9858248|NCT02157116|Experimental|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
9924210|NCT00859118|Experimental|Schedule A Cohort 1|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
9935139|NCT04119843|Experimental|Mangoral|All participants will receive a single dose of Mangoral (equivalent to 800 mg Manganese (II) chloride tetrahydrate [MnCl2 4H2O]).
9858249|NCT02154087|Experimental|HP802-247|
9858250|NCT02152670|Experimental|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
9858251|NCT02152670|Experimental|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
9858252|NCT02152670|Experimental|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
9858253|NCT02152566|Experimental|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
9858254|NCT02137096|Experimental|High Dose Conditioning|Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
9858255|NCT02147834|Active Comparator|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
9858256|NCT02147834|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
9858257|NCT02145390|Experimental|TURBT, NAC and Chemoradiation|"Transurethral Resection of the Bladder Tumor & Cystoscopy (TURBT);~Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;~For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;~For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;~Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);~International Prostate Symptom Score (IPSS)."
9858258|NCT02132884|Active Comparator|Arm A (standard of care treatment)|Patients receive standard of care treatment based on the discretion of the treating physician.
10209273|NCT04583514|Experimental|Overfeeding|The overfeeding group will be subjected to a similar relative change in energy intake, in which their dietary intake will be 30% more kcal/d than needed for weight maintenance.
9858259|NCT02132884|Experimental|Arm B (genetic sequencing and targeted therapy)|Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing.
9858260|NCT02144155|Experimental|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
9858261|NCT02144155|Sham Comparator|Vehicle placebo|Placebo for 3 weeks
9858262|NCT02140788|Active Comparator|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
9858263|NCT02140788|Active Comparator|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
9858264|NCT02140788|Active Comparator|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
9858265|NCT02140788|No Intervention|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
9858266|NCT02150863|Active Comparator|Ultrapulse laser alone|
9858267|NCT02150863|Active Comparator|Ultrapulse laser plus Cellutome Harvesting system|
9858268|NCT02150863|No Intervention|Control|
10209274|NCT04581148||M6|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M6) with residual blood samples.
10209275|NCT04581148||M12|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M12) with residual blood samples.
9858269|NCT02145169|Experimental|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
9858270|NCT02130622|Experimental|Promethazine|Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
10209276|NCT04581148||M15|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M15) with residual blood samples.
10209277|NCT04581148||M19|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M19) with residual blood samples.
10209278|NCT04581148||M21|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M21) with residual blood samples.
10209279|NCT04581148||M22|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M22) with residual blood samples.
10209280|NCT04581148||M23|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M23) with residual blood samples.
10209281|NCT04581148||M24|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M24) with residual blood samples.
10209282|NCT04581148||M25|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M25) with residual blood samples.
10209283|NCT04581148||M26|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M26) with residual blood samples.
9858271|NCT02130622|Placebo Comparator|Sugar Pill|Placebo P.O. t.i.d. for 4 weeks
9858272|NCT02133534|Experimental|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
9858273|NCT02134912|Experimental|Arm I (crizotinib, pemetrexed disodium)|Patients receive crizotinib PO BID on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.
9858274|NCT02134912|Experimental|Arm II (pemetrexed disodium)|ARM II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Upon disease progression or symptomatic deterioration, patients may crossover to Arm I.
9858275|NCT02131155|Experimental|Afatinib (BIBW2992)|Once daily
9858276|NCT02131155|Placebo Comparator|Placebo|Once daily
9858277|NCT02117050|Experimental|Rebif® via Rebidose® auto-injector|
9858278|NCT02110069|Active Comparator|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
9858279|NCT02110069|Experimental|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.~Sirolimus trough levels will be maintained between 10-15 ng/ml."
9858280|NCT02110277|Experimental|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
9858281|NCT02109809|Experimental|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
9858282|NCT02105116|Experimental|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
9858283|NCT02099318|Active Comparator|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
9986420|NCT01402726|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with heart failure.
9986421|NCT01402726|No Intervention|Absolute medicine therapy|Maintenance of anti-heart failure medications only
9986422|NCT01402739|Experimental|PoC algorithm guided transfusions|experimental arm
9986423|NCT01402739|Active Comparator|standard of care transfusions|control arm
9986424|NCT01402752|Experimental|All patients|All patients included in this study according to stated inclusion and exclusion criteria.
9986425|NCT01402765|Active Comparator|Group 1 (Summit first)|In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
9986426|NCT01402765|Active Comparator|Group 2 (Nimbus 3 first)|In Group 2 pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
9986427|NCT01402778||Cather fixation by tunneling and suture|
10209284|NCT04579367||Bempedoic acid and/or fixed-dose combination with ezetimibe|Participants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe.
9986428|NCT01402778||Catheter fixation by adhesive tape|
9986429|NCT01402791||The study population|All patients included according to state inclusion and exclusion criteria.
9986430|NCT01402804||Stable CAD, ASA, NSAID|
9986431|NCT01402804||Stable CAD, ASA|
10209285|NCT04574232|Other|athletic subjects|athletic subjects who may need intra-articular knee infiltration
10209286|NCT04568382|Experimental|Intervention|Enhanced PVP
10209287|NCT04568382|Active Comparator|Standard|Standard PVP
10209288|NCT04565379|Active Comparator|NuSepin® 0.1 mg|NuSepin® 0.1 mg/kg in 100 ml normal saline infusion
10209289|NCT04565379|Active Comparator|NuSepin® 0.2 mg|NuSepin® 0.2 mg/kg in 100 ml normal saline infusion
10209290|NCT04565379|Placebo Comparator|Placebo|100 ml normal saline infusion
10209291|NCT04565119||Severe traumatic brain injury (TBI)|This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.
10209292|NCT04563195|Other|open label|open label study; all subjects will receive the same drug at the same dose
10213615|NCT03696433|Experimental|High- then low-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
10209293|NCT04561115|Active Comparator|Gamunex-C|Participants will receive Gamunex-C by means of an infusion pump at an individualized dose (based on historical IVIG treatment dose) between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. The subject's usual mg/kg dose (given on either a 3 or 4 week repeating schedule) will be the same mg/kg dose and schedule that the subject was receiving prior to entering screening. This mg/kg dose and schedule will be used throughout the study duration. Note that the weight of the subject will be measured at each visit and if the subject's weight changes, the actual weight at each visit will be used to calculate amount of drug (mg) to be administered. Gamunex-C will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
9794402|NCT01506193|Active Comparator|Group A|Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
9794403|NCT01506193|Experimental|Group B|Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
9794404|NCT01506193|Active Comparator|Group C|Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).
9794405|NCT01506271|Experimental|Relebactam 250 mg with imipenem/cilastatin|Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
9794406|NCT01506271|Experimental|Relebactam 125 mg with imipenem/cilastatin|Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
9794407|NCT01506271|Placebo Comparator|Placebo to relebactam with imipenem/cilastatin|Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
9794408|NCT01506323|Experimental|Mantram Repetition Program (MRP)|"A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma."
9794409|NCT01506323|Active Comparator|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
9794410|NCT01506362|Experimental|A synthetic oligonucleotide for treatment of IBD.|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
9794411|NCT01506453|Active Comparator|Gabapentin|Active treatment arm.
9794412|NCT01506453|Placebo Comparator|Placebo|Placebo arm.
9794413|NCT01506479|Sham Comparator|Control Group|Wait listed to moderate or vigorous exercise after 6 months of no exercise.
9794414|NCT01506479|Experimental|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
9794415|NCT01506479|Experimental|Moderate Exercise|Endurance exercise at 60-65% HR max, 4x/wk for 6 months.
9794416|NCT01506596|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
9794417|NCT01506609|Experimental|Veliparib with Temozolomide|Veliparib 40 mg twice daily (BID) Days 1 through 7 plus TMZ 150 to 200 mg/m^2 QD Days 1 through 5 in each 28-day cycle.
9794418|NCT01506609|Placebo Comparator|Placebo with Carboplatin and Paclitaxel|Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
9794419|NCT01506609|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
9794420|NCT01506726|Experimental|Active drug - oral salsalate|Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.
9794421|NCT01506726|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.
9858284|NCT02099318|Placebo Comparator|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
9858285|NCT02099344|Active Comparator|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
9858286|NCT02099344|Active Comparator|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
9858287|NCT02094352|Experimental|Ketamine Infusion + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of KETAMINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three ketamine booster infusions over the course of three months."
9858288|NCT02094352|Placebo Comparator|Control Group + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of SALINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three saline booster infusions over the course of three months."
9858289|NCT02096042|Experimental|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
9858290|NCT02096042|Experimental|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
9858291|NCT02088957|Experimental|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
9858292|NCT02088957|Active Comparator|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
9858293|NCT02093689|Experimental|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
9858294|NCT02093689|Experimental|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
9858295|NCT02093689|Placebo Comparator|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
9858296|NCT02091752|Experimental|Ruxolitinib|All participants received ruxolitinib.
9858297|NCT02068547|Active Comparator|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
9858298|NCT02068547|Experimental|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
10209294|NCT04561115|Experimental|IVIG-PEG|Following treatment with Gamunex-C, participants will receive IVIG-PEG by means of an infusion pump at an equivalent dose between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. IVIG-PEG will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
10209295|NCT04558840|Active Comparator|Enhanced Recovery After Surgery (ERAS) Arm|"ERAS Arm will undergo multimodal regiment:~Before Surgery- gabepentin 300mg and celecoxib 400mg once the day before surgery and again 3 hours prior to surgery.~During surgery- subjects will receive ketorolac 30mg IV ketorolac once (15mg for patients age 64 years and above).~Post-operatively- Gabapentin 100mg three times daily for POD0-7, ketorolac 10mg four times daily for POD1-5 days, and ondansetron 4mg as needed for nausea; patients will also have a prescription for hydrocodone-acetaminophen 5/325mg tabs that they may fill if needed for emergency/breakthrough pain."
9858299|NCT02075411|Active Comparator|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
9858300|NCT02075411|Active Comparator|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
9858301|NCT02075411|Active Comparator|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
9858302|NCT02075411|Active Comparator|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
9858303|NCT02074904|Experimental|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
9858304|NCT02074904|Placebo Comparator|Placebo|placebo
9858305|NCT02084147|Experimental|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
9858306|NCT02081183|Experimental|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
9858307|NCT02081183|Active Comparator|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
9858308|NCT02067611|Experimental|X0002|low dose, BID;middle dose, BID, or high dose, BID.
9858309|NCT02067611|Placebo Comparator|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
9858310|NCT02067104|Placebo Comparator|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
9858311|NCT02067104|Experimental|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
9858312|NCT02075021|Experimental|lenalidomide and nab-paclitaxel|100 mg/m^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
9858313|NCT02057874|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
9858314|NCT02057237|Experimental|single arm|Mitotane will be administered on an outpatient or inpatient basis.
9858315|NCT02047747|Experimental|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
9858316|NCT02058537|Experimental|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
9858317|NCT02057276|Active Comparator|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
9858318|NCT02057276|Sham Comparator|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
9858319|NCT02038153|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
9858320|NCT02054910|Experimental|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
9858321|NCT02054910|Sham Comparator|Sham|A celiac plexus block will not be administered for pain management
9858322|NCT02044302|Active Comparator|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
9986432|NCT01402830||001|Visual analogue scales (EVAs) This scale measures the pain intensity.
9986433|NCT01402843|Experimental|pitavastatin + valsartan|
9858323|NCT02044302|Experimental|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
9858324|NCT02044302|Experimental|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
9858325|NCT02044302|Experimental|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
9858326|NCT02046226|Experimental|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
9858327|NCT02046226|No Intervention|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
9858328|NCT02044848|Experimental|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
9858329|NCT02044848|Placebo Comparator|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
9858330|NCT02042950|Experimental|Carfilzomib|Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
9858331|NCT02048904|Active Comparator|Sitagliptin|100 mg/day for 3 months
9858332|NCT02048904|Placebo Comparator|Placebo|1 pill/day for 3 months
9858333|NCT02044822|Experimental|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
9858334|NCT02042924|Experimental|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
9858335|NCT02043860|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
9858336|NCT02017522|Experimental|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
9858337|NCT02030015|Experimental|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
9858338|NCT02015663|Experimental|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
9858339|NCT02015663|Active Comparator|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
9858340|NCT02029846|Active Comparator|Standard Treatment|A regimen with traditional drugs only
9858341|NCT02029846|Experimental|Incretin-based Treatment|A regimen including incretin-based drugs
9858342|NCT02027272|Active Comparator|Dexamethasone|Dexamethasone 12 mg, 2 doses, 12 hours apart.
9858343|NCT02027272|Placebo Comparator|Placebo|Placebo, 2 doses, 12 hours apart
9858344|NCT02012608|Active Comparator|Glutamine|Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day
9858345|NCT02012608|Placebo Comparator|Placebo|Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day
9858346|NCT02017379|Experimental|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
9858347|NCT02017379|Experimental|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
9858348|NCT02017379|No Intervention|Control|no medications will be given prior to endoscopy
9858349|NCT02011542|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
9858350|NCT02011542|Active Comparator|VSL #3|VSL #3 (probiotic mixture) is given to this group
9858351|NCT02008370|Experimental|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
9858352|NCT02009982|Experimental|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
9858353|NCT02009982|No Intervention|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
9858354|NCT02013414|Experimental|3D ultrasound-guided biopsy|Participants will have a 3D ultrasound-guided biopsy of the prostate rather than the standard of care 2D ultrasound-guided biopsy.
9858355|NCT02005445|Experimental|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure
9858356|NCT02005445|Sham Comparator|Healthy Lifestyle and Sleep Education (HLSE)|Healthy living and sleep education
10209296|NCT04558840|Active Comparator|Current Practice Arm|The current practice arm will include: post-operatively, hydrocodone-acetaminophen 5/325mg tabs and ibuprofen 800mg, as needed for pain. Additionally, acetaminophen may be used in conjunction with the above regiment. Ibuprofen and acetaminophen can be taken as needed or alternating every 6 hours, scheduled.
10209297|NCT04554888|Experimental|Doxepin Application|During the session each forearm of the subject will be divided into four squared areas (2.5x2.5 cm), see Figure 4. Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours 48. At the end of the pre-treatment period, the patches will be removed and the skin will be cleaned with alcohol.
10209298|NCT04554888|Experimental|Itch Induction|After Doxepin removal, Then tests with papain, cowhage, histamine or vehicle will be conducted. Each substance will be randomly applied in two areas, one pretreated with doxepin and one with no pre-treatment.
10209299|NCT04554316|Active Comparator|Parallel placement|Steri-strips will be placed in-line (parallel) with the surgical incision.
9858357|NCT02020837|Experimental|Lymphaticovenous Micro-Anastomosis|
9858358|NCT02015910|Experimental|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
9858359|NCT02015910|Placebo Comparator|Placebo|Placebo
9858360|NCT02006927|Experimental|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
9858361|NCT01996982|Experimental|Device|CCS Device application
9858362|NCT02006407|Other|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
9858363|NCT01986751|Experimental|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
9858364|NCT01986751|Active Comparator|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
9858365|NCT01996410|Active Comparator|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
9858366|NCT01996410|Active Comparator|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
9986434|NCT01402843|Placebo Comparator|pitavastatin + placebo|
10209300|NCT04554316|Active Comparator|Perpendicular placement|Steri-strips will be placed perpendicular to the surgical incision.
10209301|NCT04553848|Experimental|Augmented Reality+ Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) incorporating augmented feedback games chosen to address clinically perceived deficits using the C-Mill training system.
10209302|NCT04553848|Active Comparator|Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) using the C-Mill training system.
9986435|NCT01402843|Placebo Comparator|valsartan + placebo|
9986436|NCT01402843|Placebo Comparator|placebo|
10209303|NCT04553848|Active Comparator|Over ground training/standard of care|Participants allocated to this group will receive over ground balance and mobility training that would be considered standard of care in outpatient rehabilitation.
9858367|NCT01996410|Active Comparator|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
9858368|NCT01996410|Active Comparator|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
9858369|NCT01996410|No Intervention|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
9858370|NCT01996410|No Intervention|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
9858371|NCT01996410|No Intervention|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
9858372|NCT01996410|No Intervention|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
9858373|NCT01996852|Active Comparator|Standard ED Care|Standard medical treatment of erectile dysfunction (ED) including administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)
9986437|NCT01402856||Southern Lehigh HS, PA School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
10209304|NCT04551599|Experimental|Part 1: Sequence 1|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fed conditions.~Period 2: Danicopan administered under fasted conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
10209305|NCT04551599|Experimental|Part 1: Sequence 2|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fasted conditions.~Period 2: Danicopan administered under fed conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
9858374|NCT01996852|Experimental|Standard ED Care + Cognitive-Behavioral Intervention|standard medical treatment of ED (administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)) in addition to cognitive-behavioral meetings
9858375|NCT01996852|No Intervention|Usual Care (UC)|Study participants will not receive any study intervention, but will continue with standard care.
9858376|NCT01997567|Active Comparator|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
9858377|NCT01997567|Placebo Comparator|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
9924211|NCT00859118|Experimental|Schedule A: Cohort 2|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
9924212|NCT00859144|Experimental|BART|Participants will complete the Becoming a Responsible Teen (BART) program.
9924213|NCT00859144|Experimental|Reducing the Risk|Participants will complete the Reducing the Risk program.
9924214|NCT00859144|Active Comparator|Be Proud Be Responsible|Participants will complete the Be Proud! Be Responsible! program.
9924215|NCT00859157||Group 1|Patients undergo standard mastectomy.
9924216|NCT00859157||Group 2|Patients undergo tumescent mastectomy.
9924217|NCT00859170|Experimental|Accordion use|Use of an Accordion device during the lithotripsy.
9924218|NCT00859170|No Intervention|Control Group|Patients who will not have an Accordion device used during lithotripsy.
9858378|NCT01977729|Experimental|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
9858379|NCT01977729|Experimental|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for ~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
9858380|NCT01973062|Experimental|rituximab and yttrium Y 90 ibritumomab tiuxetan|Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
9858381|NCT01982253|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
9858382|NCT01982253|Experimental|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
9858383|NCT01982253|Experimental|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
9858384|NCT01984268|Experimental|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
9858385|NCT01984268|Experimental|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
9858386|NCT01974284|Experimental|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
9858387|NCT01971853|Placebo Comparator|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
9858388|NCT01971853|Active Comparator|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
9858389|NCT01980875|Experimental|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
9858390|NCT01980875|Experimental|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
9858391|NCT01980875|Active Comparator|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
9858392|NCT01982383|Experimental|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
9924219|NCT00859183|Active Comparator|1|cumulative loading dose of 8 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
10209306|NCT04551599|Experimental|Part 2|Healthy, elderly, male participants will receive a single dose of danicopan under fed conditions.
10209307|NCT04548973|Experimental|Esketamine Group|At the beginning of the operation, 0.25mg/kg ketamine was administered intravenously, and normal saline was diluted to 2mL to assist sedation and analgesia
10209308|NCT04548973|Placebo Comparator|Control Group|At the beginning of the operation, 2ml normal saline was given intravenously
10209309|NCT04547985|Placebo Comparator|Placebo|24 randomized patients will take placebo daily for 8 weeks.
10209310|NCT04547985|Active Comparator|Naltrexone|24 randomized patients will take naltrexone daily for 8 weeks
10209311|NCT04547673||NPC group|Patients pathologically diagnosed as NPC by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
10209312|NCT04547673||Non-NPC group|Patients pathologically diagnosed as non-NPC (including inflammatory hyperplasia, Atypical hyperplasia, Papilloma etc.) by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
10209313|NCT04547192|No Intervention|Pre TIF introduction|Emergency Health Service prior to introduction of TIF.
10209314|NCT04547192|Experimental|Post introduction of TIF|Emergency Health Service after introduction of TIF.
10209315|NCT04544189|Experimental|Alpelisib+Fulvestrant (randomized cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
10209316|NCT04544189|Placebo Comparator|Placebo+Fulvestrant (randomized cohort)|Placebo (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
10209317|NCT04544189|Experimental|PK cohort (open label cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
10209318|NCT04542291|Experimental|Dapagliflozin|"Dapagliflozin is an oral drug which will be administered on an outpatient basis. Dosing will start at 5 mg daily and will increase to 10 mg daily after 2 weeks (after consulation with a study endrocrinologist) if the patient is tolerating the 5 mg dose. Dapagliflozin will be given for a total of 8 weeks (2 weeks at 5 mg and 6 weeks at 10 mg)~Treatment with dapagliflozin will be initiated on Cycle 1 Day 1 of standard of care chemotherapy.~Participants will use the BIOSENSE meter once daily"
9858393|NCT01982383|Placebo Comparator|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
9858394|NCT01980342|Experimental|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
9858395|NCT01978535|Experimental|Iron infusion|Iron Sucrose (Venofer (R))
10209319|NCT04539548|Experimental|Dextenza|1 dosing group - Approximately 30 subjects treated with Dextenza
10209320|NCT04539548|Active Comparator|Prednisolone|1 dosing group - Approximately 30 subjects treated with Prednisolone
10209321|NCT04538040|Experimental|Biktarvy + Doravirine Switch|bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets + doravirine 100mg tablets taken orally once per day
10209322|NCT04534673|Experimental|Intervention group|Pegylated interferon lambda + Standard of care treatment
10209323|NCT04534673|No Intervention|Control group|Standard of care treatment
10209324|NCT04532294|Experimental|BGB-DXP593: Dose Level A|Participants will receive BGB-DXP593 10 mg/kg on Day 1
10209325|NCT04532294|Experimental|BGB-DXP593: Dose Level B|Participants will receive BGB-DXP593 30 mg/kg on Day 1
9858396|NCT01978535|Placebo Comparator|Normal saline infusion|Equal volume to intervention of normal saline
9858397|NCT01974635|Experimental|AMES Therapy and Diagnostic|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.
9858398|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
9858399|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
9858400|NCT01970462|Experimental|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
9858401|NCT01970462|Placebo Comparator|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
9858402|NCT01969565|Experimental|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
9858403|NCT01968226|Experimental|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of [F-18]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
9858404|NCT01965782|Experimental|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
9858405|NCT01962675|Experimental|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
9858406|NCT01962675|Sham Comparator|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
9858407|NCT01962974|Experimental|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
9858408|NCT01954160|Other|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
9858409|NCT01954160|Other|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
9858410|NCT01951378|Active Comparator|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
9858411|NCT01951378|Active Comparator|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
9858412|NCT01941615|Experimental|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
9858413|NCT01946542|Placebo Comparator|placebo|placebo drink, single dose, taste and color-matched to experimental drink
9858414|NCT01946542|Experimental|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
9858415|NCT01937507|Experimental|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
10209326|NCT04532294|Experimental|Placebo|Placebo to match (PTM) BGB-DXP593 on Day 1
10209327|NCT04530643|Experimental|HY209 0.3%|multiple dose of HY209 0.3% gel
10209328|NCT04530643|Experimental|HY209 0.5%|multiple dose of HY209 0.5% gel
10209329|NCT04530643|Placebo Comparator|Placebo|multiple dose of Placebo
10209330|NCT04527510||double reading|Each patient will have the following: Screening whole breast ultrasound.
10209331|NCT04527510||second-reading|Each patient will have the following: Screening whole breast ultrasound.
9858416|NCT01944059|Active Comparator|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
10209332|NCT04527510||concurrent-reading|Each patient will have the following: Screening whole breast ultrasound.
9858417|NCT01944059|Placebo Comparator|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
9858418|NCT01935947|Experimental|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9858419|NCT01935947|Experimental|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
9858420|NCT01935947|Active Comparator|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
9858421|NCT01939223|Experimental|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
9858422|NCT01939223|Placebo Comparator|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
9858423|NCT01938716|Experimental|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
9858424|NCT01936974|Experimental|Platinum, Gemcitabine and Bevacizumab|"Platinum:~Carboplatin* on day 1~*If a patient is allergic to carboplatin, then give~Cisplatin** on day 1~**If a patient is allergic to cisplatin and carboplatin, then give~Oxaliplatin on day 1~Gemcitabine on day 1 only~Bevacizumab on day 1"
9858425|NCT01936974|Active Comparator|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8~Bevacizumab on day 1"
9858426|NCT01938833|Experimental|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9924220|NCT00859183|Active Comparator|2|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
9924221|NCT00859183|Placebo Comparator|3|oral placebo
9924222|NCT00859196|Experimental|Arm 1|
9924223|NCT00859196|Placebo Comparator|Arm 2|
9924224|NCT00859235|Active Comparator|1|
9924225|NCT00859235|Placebo Comparator|2. Plain water|
9924226|NCT00859261|Experimental|Breast imaging using Ultrasound and Photoacoustic|Evaluating 3D ultrasound for breast abnormalities/masses/cysts. This includes ultrasound imaging and possibly photoacoustic imaging.
9924227|NCT00859274|Experimental|Budesonide|All patients receive this treatment to induce a change in asthma control
9924228|NCT00859300||1|500 patients with ventricular fibrillation at the acute phase of myocardial infarct
9924229|NCT00859300||2|500 patients without ventricular fibrillation at the acute phase of myocardial infarct.
9924230|NCT00859352|Experimental|1|AZD1981 100mg and Midazolam
9924231|NCT00859352|Experimental|2|AZD1981 500mg and Midazolam
9924232|NCT00859365|Experimental|Acupuncture|Real Acupuncture
9924233|NCT00859365|Placebo Comparator|2 Placebo acupuncture|
9924234|NCT00859365|No Intervention|3 No treatment|No treatment performed
9924235|NCT00859378|Active Comparator|1 - cemented|Patients are treated with a cemented semiendoprosthesis
9924236|NCT00859378|Active Comparator|2 - non-cemented|Patients are treated with a non-cemented semiendoprosthesis
9924237|NCT00859391||1 - Active|This group received gluten pre-treated with ALV003
9924238|NCT00859391||2 - Placebo|This group received Gluten pre-treated with placebo.
9924239|NCT00859404|Experimental|1. oglemilast|
9924240|NCT00859404|Experimental|2. oglemilast|
10209333|NCT04527146|Experimental|IMAGINE-PD/Virtual|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via virtual visit with a genetic counselor.
10209334|NCT04527146|Experimental|IMAGINE-PD/Telephone|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via telephone with a genetic counselor.
10209335|NCT04527146|Experimental|Virtual/Telephone|Pre-test genetic counseling virtual visit with a genetic counselor. Genetic results disclosure via telephone with a genetic counselor.
10209336|NCT04527146|Active Comparator|Virtual/Virtual|Pre-test genetic counseling and genetic results disclosure via virtual visit with a genetic counselor.
9924241|NCT00859404|Experimental|3. oglemilast|
10209337|NCT04524533|Experimental|Intervention group|Participants randomized into the intervention arm will watch smoking cessation videos (ready to quit or not ready to quit) during a dental cleaning clinic visit, receive a brochure about EBTs, and participate in a 4-week text message program which consists of automated and tailored text messages to motivate EBT utilization. After the 4-week program, the intervention group will receive monthly assessment text messages.
9858427|NCT01934647|Experimental|1 mg MK-8892|Participants will receive a single oral dose of 1 mg MK-8892.
9858428|NCT01934647|Experimental|4 mg MK-8892|Participants will receive a single oral dose of 4 mg MK-8892.
9858429|NCT01934647|Experimental|8 mg MK-8892|Participants will receive a single oral dose of 8 mg MK-8892.
9858430|NCT01934504||Tolerant AAV|Tolerant participants with AAV
9858431|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
9858432|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
9858433|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
9858434|NCT01928082|Experimental|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
9858435|NCT01928615|Experimental|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
9858436|NCT01928615|Experimental|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
9858437|NCT01911793|Experimental|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
9858438|NCT01911793|No Intervention|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
9858439|NCT01912404|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
9858440|NCT01912404|Placebo Comparator|Placebo|Placebo capsules BID
9858441|NCT01910389|Active Comparator|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
9858442|NCT01910389|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
9858443|NCT01921114|Active Comparator|BioFlo™ PICC|BioFlo™ Peripherally Inserted Central Catheter (PICC)
9858444|NCT01921114|Active Comparator|Bard® PowerPICC SOLO2®|Bard® Dual-Lumen PowerPICC SOLO2®
9858445|NCT01916590|Active Comparator|Bupivacaine|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
9858446|NCT01916590|Placebo Comparator|Placebo|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.
9858447|NCT01913327|Experimental|aripiprazole|aripiprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
9858448|NCT01913327|Active Comparator|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
9858449|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
9858450|NCT01901224|Experimental|Metformin 1000 mg|metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
9858451|NCT01901224|Placebo Comparator|Control|placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
9858452|NCT01910441|Experimental|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
10209338|NCT04524533|Active Comparator|Control group|Participants randomized into the control arm will watch a control video during a dental hygiene visit and receive a brochure about EBTs, and a 4-week assessment-only text message program.
10209339|NCT04522804|Experimental|Treatment: all patients|"Subjects will participate in a total of seven group sessions. There will be 4 or 6 subjects per group and one therapist will be assigned to each subject for a total of 4 or 6 therapists. In addition, there will be one Group Leader that will facilitate the group sessions. Group sessions will occur once per week for approximately five weeks. The first three sessions are Preparatory sessions followed by three Integration sessions. During the week following the third Preparatory session and prior to the first Integration session, participants will participate in a psilocybin session."
9858453|NCT01910441|Active Comparator|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
9858454|NCT01902966|Experimental|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
9858455|NCT01901679|Experimental|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
9858456|NCT01900730|Placebo Comparator|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
9858457|NCT01900730|Experimental|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
9858458|NCT01877564|Experimental|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
9858459|NCT01877564|No Intervention|Group 2 - No treatment|
9858460|NCT01890694|Placebo Comparator|Placebo|"Subjects will receive placebo once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
9858461|NCT01890694|Experimental|Tolvaptan|"Subjects will receive Tolvaptan once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
9858462|NCT01900626|Active Comparator|single epidural catheter|
9858463|NCT01900626|Active Comparator|double epidural catheter|
9858464|NCT01890577||Study population|Single cohort of dialysis patients
9858465|NCT01895959|Other|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
9858466|NCT01889420|Experimental|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg >75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
9858467|NCT01884077|Active Comparator|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
9858468|NCT01884077|Active Comparator|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
9858469|NCT01881984|Experimental|Ravicti|Open Label Study
9924242|NCT00859404|Placebo Comparator|4. placebo|
9858470|NCT01893359|Experimental|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
9858471|NCT01893359|Experimental|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
9858472|NCT01893359|Placebo Comparator|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
9858473|NCT01883908|Experimental|Acupuncture with Seirin® needles|Participants will be randomized to receive acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
9858474|NCT01883908|Active Comparator|Usual medical care|Participants will be randomized to receive usual medical care for 8 weeks coinciding with their chemoradiation treatments. Patients will receive usual medical care such as viscous Lidocaine for relief of pain.
9858475|NCT01887288|Experimental|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle~(1 cycle - 4 weeks)"
9858476|NCT01881932|No Intervention|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
9858477|NCT01881932|Experimental|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
9858478|NCT01881932|Active Comparator|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
9858479|NCT01878786|Experimental|ERL & TAC|Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw
9858480|NCT01878786|Experimental|ERL & TAC --> MMF/MPA|Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
9858481|NCT01878786|Experimental|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
9858482|NCT01877343|Experimental|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
9858483|NCT01861717|Experimental|Somatuline Depot Subcutaneous (SC)|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
9858484|NCT01866709|Active Comparator|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
9858485|NCT01866709|Placebo Comparator|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
9858486|NCT01860040|Experimental|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
9858487|NCT01860040|Experimental|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
9858488|NCT01869478|Active Comparator|Intravenous Thrombolysis|0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
9858489|NCT01869478|Active Comparator|Endovascular Arterial Reperfusion|Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.
9858490|NCT01851174|Experimental|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days~nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days"
9858491|NCT01846182|Active Comparator|Group 1|60 mg of duloxetine in the AM for 20 weeks and placebo in PM
9858492|NCT01846182|Active Comparator|Group 2|300 mg of pregabalin in the PM for 20 weeks and placebo in AM
9858493|NCT01846182|Placebo Comparator|Group 3|placebo in the AM & PM for 20 weeks
9858494|NCT01844206|Active Comparator|Epidural Morphine|Group receiving 3mg epidural morphine, 24 hours after the initial dose
9858495|NCT01844206|Placebo Comparator|Epidural Saline|Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.
9858496|NCT01856322|Active Comparator|Sulindac|one tablet twice daily
9858497|NCT01856322|Placebo Comparator|Placebo|one tablet twice daily
9858498|NCT01856322|Other|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
9858499|NCT01853176|Experimental|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
9858500|NCT01853176|Active Comparator|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
9858501|NCT01857271|Experimental|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
9858502|NCT01856361|Experimental|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
9858503|NCT01856361|Sham Comparator|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
9858504|NCT01853982|Experimental|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
9858505|NCT01853982|Active Comparator|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
9858506|NCT01836809|Experimental|Total Artificial Heart|Nesiritide
9858507|NCT01836809|Placebo Comparator|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
9858508|NCT01836809|Active Comparator|LVAD: Nesiritide|Active arm of the LVAD group
9858509|NCT01836809|Placebo Comparator|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
9858510|NCT01831596|Experimental|ciSNaP|
9858511|NCT01834144|Active Comparator|Moderate intensity exercise|150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
9858512|NCT01834144|Active Comparator|Moderate + Vigorous Intensity Exercise|150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
9858513|NCT01821963|Experimental|Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir|Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.
9858514|NCT01821898|Active Comparator|Positive for food allergy: Group A|Oral Budesonide
9858515|NCT01821898|Active Comparator|Positive for food allergy: Group B|Elimination diet
9858516|NCT01814722||Raltegravir + 2 NRTIs|Raltegravir is an integrase inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
9858517|NCT01814722||NNRTI + 2 NRTIs|Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs.
9858518|NCT01814722||PI + 2 NRTIs|Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs.
9858519|NCT01830790|Active Comparator|Healthy Controls|Healthy individuals >65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
9858520|NCT01830790|Experimental|AMD patients|Age-related macular degeneration (AMD) patients >65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
9858521|NCT01829477|Experimental|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
9858522|NCT01829477|Placebo Comparator|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
9858523|NCT01803711|Experimental|Desvenlafaxine + Omega 3 FA supplement|Desvenlafaxine 50mg/day & Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
9858524|NCT01803711|Active Comparator|Desvenlafaxine + Placebo (for Omega 3 FA supplement)|Desvenlafaxine 50mg/day & Placebo (for Omega 3 FA supplement) over a 12 week period
9858525|NCT01821859|Experimental|Abraxane/Bevacizumab|"Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.~Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion."
9858526|NCT01808950|Experimental|0.06% Resiquimod Gel - A|"60 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
9858527|NCT01808950|Experimental|0.06% Resiquimod Gel - B|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
9858528|NCT01808950|Experimental|0.06% Resiquimod Gel - C|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation~The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed"
9858529|NCT01806051|Experimental|PKU Participants (Arm 1)|"Subjects will be administered Kuvan once daily.~They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6)."
9858530|NCT01806051|No Intervention|Control Group (Arm 2)|"Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2)."
9858531|NCT01808794|Active Comparator|Mucograft|Placement of randomized membrane on half of subjects Mucograft
9858532|NCT01808794|Active Comparator|Dynamatrix|Placement of randomized membrane on half of subjects Dynamatrix Membrane Placement
9858533|NCT01809899|Experimental|Enhanced Consent Procedure|Participants in this group will receive an enhanced consent that will be an hour longer than usual.
9858534|NCT01809899|Active Comparator|Consent as Usual Procedure|Participants in this group will receive a normal consent procedure to the study
9858535|NCT01810302|Experimental|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
9858536|NCT01810302|Placebo Comparator|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
9858537|NCT01806961||clearance at end of trial SP848-AK-1101|no trial medication during this follow-up trial
9858538|NCT01804166|Other|IBD patients with HSTCL|Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
9858539|NCT01783015|Experimental|Group A|Subjects who are mAb ADA positive
9858540|NCT01783015|Experimental|Group B|Subjects who are mAb ADA negative
9858541|NCT01783015|Placebo Comparator|Group C|Subjects who are mAb ADA positive
9858542|NCT01783015|Placebo Comparator|Group D|Subjects who are mAb ADA negative
9858543|NCT01800162|Active Comparator|Uterine evacuation, then MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
9858544|NCT01800162|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
9858545|NCT01800162|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
9858546|NCT01794936|Experimental|VTI Probe|During robotic-assisted laparoscopic prostatectomy, the VTI Doppler probe (test) will utilized to measure blood blow within the neurovascular bundles. This is to be completed after the bladder neck and seminal vesicles are identified and dissected. To use the probe, the assistant surgeon will place the Doppler probe within the abdomen and systematically move it cephalad along the lateral prostate pedicles to identify NVB vessels. The Doppler flow in these regions will be quantified as arterial (strong) flow, venous (minimal) flow or no flow. The procedures will proceed by dissecting the lateral margin of prostate step by step up to the gland's apex. Blood loss and the time required to identify and dissect the NVB will be recorded.
9858547|NCT01794936|No Intervention|Non-Probe|Patients randomized to not receive probe evaluation.
9858548|NCT01797380|Placebo Comparator|Sugar Pill|Placebo
9858549|NCT01797380|Active Comparator|Active Drug|Escitalopram tablet, 10mg, daily, 9 weeks.
9858550|NCT01781026|Experimental|Vemurafenib Administration|Vemurafenib 960 mg orally, twice per day
9858551|NCT01788475|Active Comparator|Dexamethasone implant up to every 3 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
9924243|NCT00859417|Active Comparator|1|Traditional surgical method without prosthesis
9924244|NCT00859417|Experimental|2|Surgical method with Perigee prosthesis
9986438|NCT01402856||Bethlehem HS, PA Area School District|Freedom & Liberty HS's in Bethlehem, PA will serve as the study's control group.
9858552|NCT01788475|Active Comparator|Dexamethasone implant up to every 6 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
9858553|NCT01788475|Sham Comparator|Sham Implant|"Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.~Sham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
9858554|NCT01784991|Active Comparator|1mg + 1mg Hydromorphone|Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
9858555|NCT01784991|Active Comparator|Usual Care Group|"Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion."
9858556|NCT01777854|Active Comparator|Omeprazole|"Yes. Omeprazole (generic) will be used. Children >20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain."
9858557|NCT01777854|Placebo Comparator|Sugar pill|The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.
9858558|NCT01760993|Experimental|SPD489|
9858559|NCT01772719|Experimental|Study Arm|Study Arm
9858560|NCT01764997|Experimental|Adalimumab Open Label run-in|Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
9858561|NCT01764997|Active Comparator|Etanercept + MTX (Randomized)|Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
9858562|NCT01764997|Experimental|Sarilumab 150 mg + MTX (Randomized)|Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
9858563|NCT01764997|Experimental|Sarilumab 200 mg + MTX (Randomized)|Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
9858564|NCT01764997|Experimental|Sarilumab 150 mg + MTX Open Label Sub-study|Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
9858565|NCT01760941|Experimental|Treatment (radiation therapy)|"This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment."
9858566|NCT01769443|No Intervention|No Desensitization Therapy|Subject(s) randomized to no desensitization therapy pre-transplant.
9858567|NCT01769443|Experimental|Desensitization Therapy|"Subject(s) randomized to desensitization therapy pre-transplant.~Desensitization therapy regimen pre-transplant: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib."
9858568|NCT01760889|Experimental|SPD489 Low Dose Range|
9858569|NCT01760889|Experimental|SPD489 High Dose Range|
9858570|NCT01760889|Placebo Comparator|Placebo|
9858571|NCT01749826|Experimental|Chronic Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
9858572|NCT01749826|Experimental|Acute Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
9858573|NCT01756586|Active Comparator|Control|Plain bupivacaine
9794422|NCT01506882|Experimental|Levetiracetam 1000 mg/day to 2000 mg/day group|"Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
9794423|NCT01506882|Experimental|Levetiracetam 3000 mg/day group|"Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period.~They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
9794424|NCT01506908|Active Comparator|Nicotine Polacrilex mint mini lozenge|
9794425|NCT01506908|Placebo Comparator|placebo|mint mini lozenge with no active
9794426|NCT01506947|Experimental|Paricalcitol|"Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.~Participants may have also received routine darbepoetin alfa to treat anemia."
9794427|NCT01506960|Experimental|Coronary stenting with OCT, NIRS/IVUS|All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.
9794428|NCT01507051|Experimental|Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939)|Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
9794429|NCT01507051|Placebo Comparator|Warfarin followed by Placebo|Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
9794430|NCT01507051|Active Comparator|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
9794431|NCT01507090||Normal Children|Otherwise healthy children 2 months to 16 years of age.
9794432|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)+CPA|
9794433|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)|
9794434|NCT01507103|Active Comparator|Chemoradiotherapy|
9794435|NCT01507155|Experimental|Patient-Reported Measures|Patients age 18 and older with a diagnosis of Major Depressive Disorder or Generalized Anxiety disorder who received genetic testing using the Genecept Assay and completed patient scales.
9794436|NCT01507155|Experimental|Clinician-Reported Outcomes|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
9794437|NCT01507181|Experimental|Ketamine|single dose IV ketamine, .5mg/kg
9794438|NCT01507181|Placebo Comparator|Midazolam|single dose IV midazolam, .45mg/kg
9794439|NCT01507220|Active Comparator|Morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
9794440|NCT01507220|Experimental|EXPAREL|EXPAREL (bupivacaine liposome extended-release injectable suspension)
9794441|NCT01507246|Active Comparator|IV morphine sulfate|Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
9794442|NCT01507246|Experimental|EXPAREL (bupivacaine liposome injectable suspension)|EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.
9794443|NCT01507298||Capsule endoscopy|
9794444|NCT01507298||24 hour oesophageal pH study|
9794445|NCT01507350||Obesity Surgery|Patients having gastric band, sleeve gastrectomy, and gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
9794446|NCT01507493||mutant alleles|grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
9794447|NCT01507493||wild-type alleles|grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
9794448|NCT01507662|Experimental|BMD Result Letter and Brochure|Patients who receive the intervention - BMD result letter with brochure.
9794449|NCT01507662|No Intervention|Control|Those who received usual care
9794450|NCT01507688|Experimental|Arm 1 SSM Intervention|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
9794451|NCT01507688|No Intervention|Arm 2 Usual Care|Usual care
9794452|NCT01507779|Experimental|Influenza vaccine|Received 0.50 mL of inactivated monovalent influenza vaccine (IVACFLU), administered intramuscularly, on days 0 and 21
9794453|NCT01507779|Placebo Comparator|Placebo|Received placebo, administered intramuscularly, on days 0 and 21
9794454|NCT01507831|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
9794455|NCT01507831|Experimental|Alirocumab|Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
9794456|NCT01507896|Experimental|BAX326 in Surgery|BAX 326 (recombinant factor IX) in Surgery
9794457|NCT01507987||Patients with SJM leads implanted|Patient has at least one market released Riata, Riata ST, QuickSite/QuickFlex, or Durata lead implanted
9794458|NCT01508013|Experimental|Appearance-Focused Website Intervention|This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
9794459|NCT01508013|Active Comparator|Control Website|Control participants viewed an Internet site designed to provide drug and alcohol education for teens.
9794460|NCT01508052|Active Comparator|sequential compression device|Apply sequential compression device during the thyroidectomy
9794461|NCT01508052|Experimental|elastic stockings|Apply elastic stockings during the thyroidectomy
9794462|NCT01508117|Experimental|Axitinib + Radiation Therapy|Axitinib 5mg twice daily for 28 days followed by concurrent axitinib plus hypofractionated radiation therapy (45 Gy in 15 fractions) followed by maintenance axitinib 5mg twice daily until progression or unacceptable toxicity
9794463|NCT01508130||Cohort|
9794464|NCT01508169|Experimental|Foot orthosis|Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
9794465|NCT01508169|No Intervention|Control Group|Forty-seven elderly women with osteoporosis (in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas- UNICAMP) were assigned, at random, to enter the control group with no foot intervention. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
9794466|NCT01508325|Experimental|Bisoprolol|
9794467|NCT01508325|Active Comparator|Metoprolol|
9794468|NCT01508455|Experimental|Dexmedetomidine|Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
9794469|NCT01508650|Active Comparator|No intervention|Usual care control group
9794470|NCT01508650|Active Comparator|Active Comparator|Multi domain rehabilitation intervention
9794471|NCT01508676|Active Comparator|Pennsaid Phase I|Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
9794472|NCT01508676|Placebo Comparator|Placebo Phase I|Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
9794473|NCT01508702|Experimental|lesinurad 400 mg|
9794474|NCT01508702|Placebo Comparator|placebo|
9794475|NCT01508832|Active Comparator|Lidocaine|Lidocaine 1% Digital Nerve Block (2 cc)
9794476|NCT01508832|Active Comparator|Bupivacaine|Bupivacaine 0.25% Digital Block (2 cc)
9794477|NCT01508910|Experimental|Treatment Arm|Targeted intramyocardial delivery of 1 x 10^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis
9794478|NCT01508910|Placebo Comparator|Active Control Arm|Targeted intramyocardial delivery of placebo after G-CSF mobilization and apheresis
9794479|NCT01508910|Other|Unblinded Standard of Care (SOC) Arm|No study-related procedures will be performed.
9794480|NCT01508936|Placebo Comparator|Placebo|Placebo intravenous injection every 4 weeks for a total of 4 doses.
9794481|NCT01508936|Experimental|Reslizumab 3.0 mg/kg|Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.
9794482|NCT01509040|Active Comparator|Control|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
9858574|NCT01756586|Experimental|Experimental|Bupivacaine with Dexamethasone
9858575|NCT01754987|Experimental|Ascorbic Acid + Sorafenib|"Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate~Dosage:~Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
9858576|NCT01754987|Other|Sorafenib alone|Sorafenib: taken daily (oral)
9858577|NCT01756560|Active Comparator|control|in this group, plain bupivacaine will be used to block femoral and sciatic nerve
9858578|NCT01756560|Experimental|Dexamethasone|Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve
9858579|NCT01756573|Active Comparator|Bupivacaine|Control
9858580|NCT01756573|Experimental|Bupivacaine with Dexamethasone|Dexamethasone will be mixed with bupivacaine
9858581|NCT01756573|Active Comparator|Intravenous Dexamethasone|Dexamethasone will be given intravenously
9858582|NCT01745913|Experimental|Haplo-Cord SCT|The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
9858583|NCT01745913|Active Comparator|UCB SCT|For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
9858584|NCT01752023|Experimental|Cisplatin + Gemcitabine with SUBATM-itraconazole|SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.
9858585|NCT01752023|Active Comparator|Cisplatin + Gemcitabine|Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
9858586|NCT01740154|Experimental|Supportive care (sunitinib malate, neuromuscular testing)|Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
9858587|NCT01748890|Experimental|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
9858588|NCT01748162|Experimental|Inhaled steroids|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
9858589|NCT01748162|Active Comparator|Oral control|Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.
9858590|NCT01738698|Experimental|SPD489 40mg|
10209340|NCT04519645|Experimental|Lacosamide|Study participants randomized to this arm will receive lacosamide (LCM) as an intravenous infusion in the Treatment Period and may continue to receive lacosamide in the Extension Period. Participants should be switched to oral dosing of LCM as soon as medically possible during the Extension Period.
10209341|NCT04519645|Active Comparator|Active Comparator|Study participants randomized to this arm will receive Active Comparator chosen based on standard of care (StOC) in the Clinical Practice in the Treatment Period and may continue to receive in the Extension Period.
9858591|NCT01738698|Experimental|SPD489 100mg|
9858592|NCT01738698|Experimental|SPD489 160mg|
9858593|NCT01738698|Placebo Comparator|Placebo|
9858594|NCT01732926|Experimental|Rituximab + Bendamustine + Idelalisib|Participants will receive rituximab + bendamustine + idelalisib.
10209342|NCT04517643|Experimental|Therasphere Therapy|All participants will receive the Therasphere Therapy.
9858595|NCT01732926|Experimental|Rituximab + Bendamustine + Placebo|Participants will receive rituximab + bendamustine + placebo.
9858596|NCT01727167|Placebo Comparator|Control Group|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
9858597|NCT01727167|Experimental|CO group|This group will breath 200 ppm of CO for one hour per day over the course of the three days immediately prior to surgery.
9858598|NCT01732913|Experimental|Rituximab + idelalisib|Participants will receive rituximab + idelalisib.
9858599|NCT01732913|Placebo Comparator|Rituximab + Placebo|Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
9858600|NCT01732211|Experimental|PD 0360324|
9858601|NCT01732211|Placebo Comparator|Placebo|
9858602|NCT01716052|Active Comparator|Ibuprofen|Pfizer 200 mg caplets (Advil)
9858603|NCT01716052|Placebo Comparator|Placebo|Lactulose
9858604|NCT01718444|Experimental|Group A (No PIES)|"Subjects randomized to this group will receive clomiphene citrate (CC) without using progestin throughout their treatment course.~CC 50 mg oral for 5 days (Days 3-7)~If no ovulation, CC 100 mg for 5 days (Days 12-16)~If no ovulation, CC 150 mg for 5 days (Day 21-25)~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
9858605|NCT01718444|Active Comparator|Group B (PIES Group)|"Women randomized to this group will receive progestin to induce endometrial shedding before starting any doses of clomiphene citrate (CC)~Progestin 10 mg oral for 10 days to induce endometrial shedding (PIES)~CC 50 mg oral for 5 days (Day 3-7)~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding (starting on CD28) and CC 100 mg x 5 days, starting on day 3 of induced menses~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding, and CC 150 mg for 5 days~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
9858606|NCT01712854|Experimental|Symbicort|A combination of budesonide + long acting beta agonist (Symbicort): Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
9858607|NCT01712854|Placebo Comparator|Budesonide only|Budesonide 80 mcg (Entocort EC) only
9858608|NCT01717482|Active Comparator|Metformin|Metformin 850mg twice a day
9858609|NCT01717482|Placebo Comparator|Observation|Standard of Care Observation
10209343|NCT04514991|Experimental|Foundation|Subjects assigned to this group will receive Foundation in the bone defect before suturing the surgical site.
9858610|NCT01702896|Experimental|Interleukin-2|Interleukin-2 will be used in this group
9858611|NCT01709136|Experimental|Sirolimus|
9858612|NCT01708057|Experimental|1|Single dose of AZD8683 50 µg
9858613|NCT01708057|Experimental|2|Single dose of AZD8683 150 µg
9858614|NCT01708057|Experimental|3|Single dose of AZD8683 300 µg
9858615|NCT01708057|Experimental|4|Single dose of AZD8683 900 µg
9858616|NCT01708057|Placebo Comparator|5|Single dose of placebo
9858617|NCT01708057|Active Comparator|6|Single dose of tiotropium 18 µg
9858618|NCT01697332|Experimental|Subjects with and without COPD|All subjects will inhale hyperpolarized 129Xe gas and then have a MRI scan performed to measure lung function.
9858619|NCT01693367|Active Comparator|DLS 5.0 (Dynamic Locking Screws)|ORIF with DLS 5.0 (Dynamic Locking Screws)
9858620|NCT01693367|Active Comparator|SLS (Standard locking screw)|ORIF with SLS (Standard locking screw)
9858621|NCT01705106|Experimental|Treatment (capecitabine, celecoxib)|Patients receive celecoxib PO BID for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9858622|NCT01702909|Experimental|Interleukin-2|Interleukin-2
9924245|NCT00859599|Active Comparator|1|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
9924246|NCT00859599|Placebo Comparator|2|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
9924247|NCT00859625|Experimental|1|Nurse participation during colonoscope withdrawal
9924248|NCT00859625|No Intervention|2|usual colonoscopy practice
9924249|NCT00859664||Neuroleptics|Children with autistic spectrum disorder, treated with neuroleptics
10209344|NCT04514991|No Intervention|Control|
10209345|NCT04512261|Experimental|Tucatinib + Pembrolizumab + Trastuzumab|Patients will receive a combination therapy of tucatinib with pembrolizumab and trastuzumab during the treatment period until progression, treatment intolerance, or patient withdrawal from study. Tucatinib and pembrolizumab are administered as experimental use while trastuzumab is administered per standard use. Patients are expected to be on treatment for at least 12 weeks.
10209346|NCT04510779|Experimental|Heart Failure Patients|This will be a single arm study of heart failure patients with acute decompensation
10209347|NCT04509765|Experimental|Patients with Hematologic Malgnancies|
10209348|NCT04489420|Experimental|Intravenous IV ( Recurrent and Surgical ) GBM|Cohort 1A ( recurrent GBM) will receive CYNK-001 at a dose of 1.2 x 10^9 cells intravenous ( IV) on Days 0, 7, and 14 and will include up to 6 subjects. The subjects will be followed for a 42 day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose). No other treatment interventions are planned between the last day of CYNK-001. In the event of DLTs, Cohort 1C ( recurrent GBM dose-De escalation) will receive CYNK-001 at a dose of 600 x 10^6 cells (IV) on Days 0, 7, 14, and will include up to 6 subjects who will be followed for a 42-day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose. Cohort 1B (surgical cohort) will receive CYNK-001 at the maximum safe dose (MSD) (either 1.2x10^9 cells or 600x10^6 cells) (IV) at Days 0, 7, 14, and will include up to 6 subjects. The tumor resection surgery will be performed after the last CYNK-001 infusion during the DLT period.
10213616|NCT03689244|Experimental|Selexipag DB|During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
9924250|NCT00859677||1|HIV-positive and MRSA negative
9924251|NCT00859677||2|HIV-positive and MRSA infected (skin/soft tissue)
9924252|NCT00859677||3|HIV-positive and MRSA colonized
9924253|NCT00859677||4|HIV-negative and MRSA negative
9924254|NCT00859677||5|HIV-negative and MRSA infected (skin/soft tissue)
9924255|NCT00859677||6|HIV-negative and MRSA colonized
9924256|NCT00859690||Sleep Disorder - Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have Obstructive Sleep Apnea (OSA).
9924257|NCT00859690||Sleep Disorder - Not Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have a sleep disorder other than Obstructive Sleep Apnea (OSA).
9924258|NCT00859703|Placebo Comparator|2|"Patients receive placebo 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
9986439|NCT01402856||Phillipsburg HS, NJ Area School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
9986440|NCT01402882|Experimental|Tranexamic acid|
9858623|NCT01701622|Experimental|Allopurinol, febuxostat|Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.
9858624|NCT01697800|Placebo Comparator|Placebo|Patients received placebo capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
9858625|NCT01697800|Active Comparator|Tadalafil|Patients received 20 mg tadalafil capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
9858626|NCT01700348|Experimental|Airflosser|Use of Airflosser
9858627|NCT01700348|Active Comparator|Manual Floss|Normal Routine
9858628|NCT01693484|Experimental|ICG administered|The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
9858629|NCT01693653|Active Comparator|Tocilizumab|tocilizumab infusion every 4 weeks over 3 months
9858630|NCT01693653|Placebo Comparator|Placebo|placebo infusion 0.9% sodium chloride every 4 weeks over 3 months
9858631|NCT01692691|Experimental|Dacarbazine, carmustine, neulasta|Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3
9858632|NCT01691079|Placebo Comparator|placebo|placebo 2 puffs prior to exercise challenge
9858633|NCT01691079|Active Comparator|ipratropium bromide|ipratropium bromide HFA 2 puffs prior to exercise challenge
9858634|NCT01690910|Active Comparator|Front Wheeled Walker|The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
9858635|NCT01690910|Active Comparator|Rifton Gait Trainer|The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.
9858636|NCT01689974|Other|Arm A: Ipilimumab|Ipilimumab administered alone Day 4, 25, 46, and 67
9858637|NCT01689974|Other|Arm B: Ipilimumab and Radiation|Radiation Therapy and Ipilimumab. Radiation treatment is administered for 5 fractions (sessions) over 1 week. On Day 4 treatment with Ipilimumab begins and continues on Days 25, 46, and 67.
9858638|NCT01676961|Experimental|Supportive care (romiplostim)|Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count > 50 x 10^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen..
9858639|NCT01681589|Sham Comparator|Control Group|The control group will receive sham-tDCS and computerized cognitive training also twice a week for 20 minutes for 6 weeks (12 training sessions).
9858640|NCT01681589|Experimental|Transcranial Direct Current Stimulator (TDCS)|The experimental group will receive active tDCS for 20 minutes and computerized cognitive training twice a week for 30 minutes for 6 weeks.
9858641|NCT01681589|Other|Healthy Control Group|Fifteen (15) healthy control subjects will participate.
9858642|NCT01681745|Experimental|Cryo-Touch Treatment|Initial treatment with Cryo-Touch III and three optional re-treatments (up to 4 treatments) performed 68 days to 1 day prior to abdominoplasty.
9858643|NCT01682928|Active Comparator|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
9858644|NCT01682928|Active Comparator|Hydrotherapy Group|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
9858645|NCT01668940|Experimental|Lillipops Iced Soothies (4 flavours)|"Initially, women will be given 1 multiflavour box of Lillipop samples minus the ginger flavour (4 flavours). Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
9924259|NCT00859703|Active Comparator|1|"Patients receive risedronate 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
9924260|NCT00859716|Experimental|1|vaccination with ACE393 followed by challenge with campylobacter jejuni
9924261|NCT00859716|Placebo Comparator|2|Placebo vaccination followed by challenge with campylobacter jejuni
9924262|NCT00859729|Experimental|Cohort I|50 µg DNA/dose, 3 patients
9924263|NCT00859729|Experimental|Cohort II|150 µg DNA/dose, 3 patients
9858646|NCT01668940|Experimental|Lillipop Iced Soothies (Ginger flavour)|Initially, women will be given 1 Ginger flavor box of Lillipop samples. Each box contains 24 freezies (20 mL each). Each 20ml contains 80mg of dried ginger root. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 a day and to not have any other popsicles, freezies or other ginger products throughout the duration of the study (7 days). Due ginger's antiemetic property, a maximum daily dose is up to 1000mg/day of dried ginger root powder in pregnancy.They can request an additional box of freezies at each follow-up, as needed.All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol.
9858647|NCT01668940|Active Comparator|Mr. Freeze Freezies (4 flavours)|"Initially, women will be given 1 multiflavour box of Mr. Freeze samples. Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
9858648|NCT01668940|No Intervention|Natural Course Group|"Women will not receive any freezies and will be asked to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days).~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
9858649|NCT01663285|Experimental|Neoadjuvant Gemcitabine and Cisplatin|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
9858650|NCT01683864|Experimental|positive cytology with HIPEC|gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
9858651|NCT01683864|No Intervention|positive cytology without HIPEC|gastric cancer cytology positive without HIPEC
9858652|NCT01683864|No Intervention|negative cytology without HIPEC|gastric cancer with negative cytology
9858653|NCT01675011|Experimental|Embozene® Microspheres|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
9858654|NCT01675011|Active Comparator|Embosphere®|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
9858655|NCT01673425|Experimental|Live Attenuated Influenza Vaccine|Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.
9858656|NCT01673061|Active Comparator|Lidocaine|Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
9858657|NCT01673061|Active Comparator|Vapocoolant|Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.
9858658|NCT01675960|Experimental|Gabapentin, then placebo|Participants first receive gabapentin 3 times per day, with varying dosing based on the protocol. After 34-38 days, a washout period of 3 days occurs, before then receiving the placebo dose for 32 days.
9858659|NCT01675960|Experimental|Placebo, then Gabapentin|Participants first receive placebo 3 times per day. After 34-38 days, a washout period of 3 days occurs, before then receiving Gabapentin, with varying dosing based on the protocol, for 32 days.
9858660|NCT01668147|Experimental|Control|Session 1: Control (no pretreatment) - IV 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging
9858661|NCT01668147|Active Comparator|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
9858662|NCT01668147|Active Comparator|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
9858663|NCT01676701|Experimental|Tabalumab Auto-Injector|Tabalumab 180 milligram (mg) loading dose administered using auto-injectors at Week 0 as 2 subcutaneous (SC) injections (90 mg each), followed by a 90 mg SC injection every 2 weeks (Q2W) up to Week 12.
9858664|NCT01676701|Experimental|Tabalumab Prefilled Syringe|Tabalumab 180 mg loading dose administered using prefilled syringes at Week 0 as 2 SC injections (90 mg each), followed by a 90 mg SC injection Q2W up to Week 12.
9858665|NCT01669148|Active Comparator|Conventional + Tomosynthesis|conventional (2D) imaging plus tomosynthesis (3D) imaging first then tomosynthesis alone 1 month later.
9924264|NCT00859729|Experimental|Cohort III|400 µg DNA/dose, 3 patients
9858666|NCT01669148|Active Comparator|Tomosynthesis alone|tomosynthesis (3D) imaging alone first then conventional (2D) imaging plus tomosyntheis 1 month later.
9858667|NCT01662102|Experimental|Zevalin Regimen Consolidation (Group A)|"90Y-Ibritumomab tiuxetan administered 8 to 12 weeks after the last chemotherapy infusion. Each participant randomized to this treatment group was to receive a therapeutic dose of 14.8 MBq/kg (0.4 mCi/kg of total body weight) of 90Y ibritumomab tiuxetan (maximum 1,184 MBq or 32 mCi). Participants with a pre-treatment platelet count between 100 and 149 x10^9/L were to receive 0.3 mCi/Kg 90Y-ibritumomab tiuxetan. (Body weight ≤80 kg: 14.8 MBq [0.4 mCi] yttrium-90/kg and Body weight >80 kg: 1,184 MBq [32 mCi] maximum dose).~The 90Y ibritumomab tiuxetan regimen is as follows: Day 1 rituximab (250 mg/m^2); Day 7,8, or 9 rituximab (250 mg/m^2) followed by 90Y ibritumomab tiuxetan within 4 hours of the end of the rituximab infusion. (Maximum duration of study was up to approximately 2.7 months)."
9858668|NCT01662102|Active Comparator|Rituximab Maintenance (Group B)|Participants were to receive 375 mg/m^2 of rituximab, administered by intravenous (I.V.) infusion every 8 weeks, starting 8 to 12 weeks after the last R-chemotherapy cycle. (Maximum duration of study was up to approximately 2.7 months).
9858669|NCT01659554|Experimental|Out-Patient Intraperitoneal Chemotherapy|Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
9858670|NCT01658813|Experimental|5-Fluorouracil and Interferon|"5-Fluorouracil~Interferon-alfa-2b"
9858671|NCT01648296|Experimental|Dosimetry Group|A total of 12 subjects will receive a single intravenous injection of[18F]FluorbetaOx followed by PET-CT imaging. Four normal healthy volunteer subjects and 8 subjects with or without Type 2 Diabetes Mellitus with Chronic Dilated Cardiomyopathy.
9858672|NCT01648296|Experimental|Kinetic Dynamic Group|A total of 38 subjects will receive a single intravenous injection of [18F]FluorbetaOx, [11C]Palmitate, and [15O]Water followed by PET-CT imaging. Ten normal healthy volunteer subjects and 28 subjects with or without Type 2 Diabetes Mellitus of which 18 subjects will have Chronic Dilated Cardiomyopathy and 10 obese subjects with a Body Mass Index of ≥ 30kg/m2.
9858673|NCT01649505|Experimental|Arm I (fibrin sealant)|Patients undergo sharp dissection technique with fibrin sealant closure.
9858674|NCT01649505|Active Comparator|Arm II (standard electrocoagulation)|Patients undergo standard electrocoagulation dissection technique.
9858675|NCT01642732|Experimental|Everolimus with combined hormonal and radiation therapy|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 10 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
9858676|NCT01645709|Experimental|Verapamil|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
9858677|NCT01645709|Placebo Comparator|Placebo|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
9858678|NCT01648270|Experimental|Study Arm|"Subjects will be studied on four occasions. Sessions and drugs are:~Intravenous buprenorphine~Sublingual buprenorphine~Cyclosporine plus intravenous buprenorphine~Cyclosporine plus sublingual buprenorphine"
9858679|NCT01643525|Other|Nautilus NeuroWave Recording Arm|Nautilus NeuroWaveTM System
9858680|NCT01641601|No Intervention|Usual Management|Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
9858681|NCT01641601|Experimental|Outpatient transcervical Foley balloon|Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
9858682|NCT01633814|Experimental|Transdermal estradiol|Transdermal estradiol, delivery rate 100 µg day-1
9858683|NCT01633814|Placebo Comparator|Placebo|placebo patch.
9858684|NCT01636466|Experimental|Everolimus conversion|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to take everolimus 0.75 mg twice daily after discontinuing current calcineurin inhibitor. Subjects will be weaned off of all other immunosuppression medicines when dialysis starts.
9924265|NCT00859729|Experimental|Cohort IV|1000 µg DNA/dose, 3 patients
9924266|NCT00859729|Experimental|Cohort V|Optimal dose to be determined, 6 patients
9924267|NCT00859742|Experimental|EBUS-TBNA|
9858685|NCT01636466|No Intervention|Control|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to continue on current immunosuppressive regimen. Subjects will be weaned off of all immunosuppression medicines when dialysis starts.
9858686|NCT01629329|Active Comparator|Aspirin, Acetaminophen, Caffeine pills|Patients receiving AAC(acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet)will receive 2 pills with active compound and placebo syringe with 2 ml of saline.
9858687|NCT01629329|Active Comparator|Prochlorperazine 10mg|Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills
9858688|NCT01627899|Other|VerioIQ|Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
9858689|NCT01632020|Placebo Comparator|Placebo|Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
9858690|NCT01632020|Active Comparator|Metformin|Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
9858691|NCT01602471|Experimental|[F-18]RDG-K5|[F-18]RDG-K5 was administred and PET scan performed
9858692|NCT01619800|Experimental|Blended Sensor Optimization (BSO)|Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
9858693|NCT01619800|Sham Comparator|Accelerometer Alone (AA)|Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active
9858694|NCT01608906|Experimental|continuous low dose intravenous heparin infusion|titrated to a PTT of 40-45
9858695|NCT01608906|Active Comparator|subcutanous heparin 5000 units 3 times/day|standard of care
9858696|NCT01621737|Experimental|Oxytocin: Low Dose|42 IU BID for the six weeks
9858697|NCT01621737|Experimental|Oxytocin: High Dose|84 IU BID for six weeks
9858698|NCT01621737|Placebo Comparator|Placebo|
9858699|NCT01614067|Experimental|Delayed Start|Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.
9858700|NCT01614067|Active Comparator|Conventional Start|Ovarian stimulation with standard antagonist protocols (no delay).
9858701|NCT01607320|Experimental|Raloxifene|3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
10209349|NCT04489420|Experimental|Intratumoral IT ( Recurrent and Surgical ) GBM)|The cohort 2A or cohort 2C (recurrent GBM) IT route of administration can be started only after the safety results were acceptable from the completion of cohort 1A or Cohort 1C (IV route of administration). The Treatment Period for the IT cohorts will begin with having the Ommaya catheter placement per institutional policy, which is planned to occur within one week prior to the CYNK-001 administration on Day 0. Cohort 2A will be treated with CYNK-001 IT at 200 x 10^6 ± 50 x 10^6 cells IT on Day 0, 7 and 14 includes up to 6 recurrent GBM subjects Cohort 2C ( dose de-escalation) will be treated with CYNK-001 200 x 106 ± 50 x 106 cells IT on Day 0, and Day 7 ( only two days dosing) and include up to 6 recurrent GBM subjects. Cohort 2B ( the surgical IT cohort) will be treated with CYNK-001 at the maximum safe dose ( MSD) (either 200 x 10^6 ± 50 x 10^6 cells on Days 0, 7 and 14 or at 200 x 10^6 ±50x10^6 cells on Days 0 and 7) and include up to 6 surgical GBM subjects
10209350|NCT04488497|Experimental|Peer coach guided online learning program|
9858702|NCT01607320|Active Comparator|Clomiphene|3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7
9858703|NCT01605019|Experimental|CoSeal Arm|patient randomized to received Coseal during LVAD implantation
9858704|NCT01605019|Placebo Comparator|BioGlue® Surgical Adhesive|BioGlue® Surgical Adhesive or use of no sealant application
9858705|NCT01609231|Experimental|Arm A: Dalotuzumab + Irinotecan|Participants receive irinotecan intravenously (IV), 180 mg/m^2 once every two weeks + dalotuzumab IV, 10 mg/kg once weekly, during ≥1 42-day treatment cycle(s).
9858706|NCT01609231|Active Comparator|Arm B: Cetuximab + Irinotecan|Participants receive cetuximab IV, initial dose of 400 mg/m^2 and then 250 mg/m^2 IV weekly + irinotecan IV, 180 mg/m^2 once every two weeks, during ≥1 42-day treatment cycle(s).
9858707|NCT01602198|Active Comparator|Exelon transdermal patch|Exelon [rivastigmine] transdermal patch
9858708|NCT01602198|Placebo Comparator|Placebo transdermal patch|Placebo transdermal patch
9858709|NCT01606150|Active Comparator|Subcutaneous Lidocaine|0.1 ml/kg of 1% Lidocaine
9858710|NCT01606150|Active Comparator|Topical Lidocaine|LMX-4, 1 gram placed over lumbar puncture needle insertion site 30 minutes prior to the procedure
10209351|NCT04488497|Placebo Comparator|Self-administered online learning program|
9858711|NCT01603043|Experimental|AL-78898A|1 intravitreal injection per month for up to 12 months
9858712|NCT01603043|Sham Comparator|Sham Injection|1 mock injection per month for 12 months
10209352|NCT04481945|Active Comparator|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
10209353|NCT04481945|Experimental|bioceramic sealer and silver nanoparticles|silver nanoparticles are antibacterial ions that can interact with multiple targets in the bacterial cell
10209354|NCT04481945|Experimental|bioceramic sealer and chitosan|chitosan has an excellent antibacterial, antiviral and antifungal properties, as an antibacterial, it works better on gram negative than gram positive
10213617|NCT03689244|Placebo Comparator|Placebo DB|During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
9858713|NCT01605370|Experimental|Nebivolol|Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
9858714|NCT01605370|Other|Metoprolol succinate|Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
9858715|NCT01605617|Active Comparator|PTNS + fesoterodine fumarate first, then PTNS + placebo|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
9924268|NCT00859755|Experimental|ARRY-403|
9924269|NCT00859755|Placebo Comparator|Placebo|
9986441|NCT01402882|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
9858716|NCT01605617|Placebo Comparator|PTNS + placebo first, then PTNS + fesoterodine fumarate|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate
9858717|NCT01606709|Experimental|GnRH agonist trigger|Induction of oocyte maturation with GnRH agonist
9858718|NCT01606709|Active Comparator|hCG trigger|Induction of oocyte maturation with hCG
9858719|NCT01603121|Experimental|Lisofylline subcutaneous|Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
9858720|NCT01603121|Experimental|Lisofylline intravenous|Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
9858721|NCT01602016|No Intervention|Phase I|Baseline Visit Phase 1: The screening portion of the CELF will be administered to the child to screen for language impairment. If a child is determined to be pre-verbal they will automatically qualify,If there is no language impairment, the subject will not be eligible. If language impairment is confirmed, the participant will immediately go on to the baseline visit of Phase 2.
9858722|NCT01602016|Other|Phase II: 12 week Folinic Acid or Placebo intervention|The child will be consented for Phase 2 (the RCT) and undergo a blood draw (up to 20mL) for metabolic and autoantibody testing. the child will undergo language and behavioral assessment while the parent will be interviewed for the Vineland and other questionnaires (ASQ, RBS-R, SRS, and ABC). Demographic information including; age, race, gender, and ethnicity will be collected. The research pharmacist will randomize the participant to either Intervention A or B (only the research pharmacist will know which intervention has the folinic acid). The research pharmacist will distribute the drug or placebo to the parent and instruct the parent of the proper administration of the intervention. This will be considered the 12 week randomly controlled clinical trial that is investigating the safety and efficacy of folinic acis interventions in ASD and will last for approximately 12 weeks. At the end of 12 weeks, the same assessments that were conducted at baseline will be readministered
9858723|NCT01602016|Experimental|Phase III: Open Label Extension of Folinic Acid|If consent for Phase 3 is signed by parents with children who qualify for Phase 3, the research pharmacist will provide a 12 week supply of folinic acid to the parent. This arm will be offered to all clients that completed phase 2 of the trial. After consenting and 12 weeks of folinic acid dosing, the client will come back and complete the same protocol and be tested on the same measures used in phase II of the study. This will be a rolling stopping point so that new therapies can be started, if the parent/caregiver is so inclined
9858724|NCT01603394|Experimental|Pregabalin (300-600 mg/day; 150 mg/day starting dose)|
9858725|NCT01592383|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9858726|NCT01598025|Experimental|REGIMEN 1|"REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
9858727|NCT01598025|Experimental|Regimen 2|"To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
9858728|NCT01587963|Active Comparator|Ascorbic Acid|Ascorbic Acid
9858729|NCT01587963|Placebo Comparator|Ringers Lactate or Normal Saline|Ringers Lactate or Normal Saline
9858730|NCT01591096|Experimental|Tissue plasminogen activator|All patients will receive study drug.
9858731|NCT01591954|Experimental|Video Augmentation|Qualitative assessment of the value of video-based navigation system
9858732|NCT01589926|Experimental|Bi-level Positive Airway Pressure Device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
9858733|NCT01589926|Sham Comparator|Sham CPAP|Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.
10209355|NCT04479332|Experimental|Resuscitation Area|Critical patient is assigned to the resuscitation area for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1-2 licensed physicians, 2-3 nurses (1 for preparing intubation materials and acts as the assist, 1-2 for administering medications and documentation); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside resuscitation area, 1 at nurses' station), 4 nurses (2 inside resuscitation area, 2 at the sterile area)
10209356|NCT04479332|Experimental|Negative Pressure Isolation Room|Critical patient is assigned to the negative pressure isolation room for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1 licensed physician, 2 nurses (1 for preparing intubation materials, acts as the assist, and for administering medications; 1 for documentation at the anteroom); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside negative pressure isolation room, 1 at nurses' station), 5 nurses (2 inside negative pressure isolation room, 1 at the anteroom, 2 at the sterile area)
9935140|NCT04119024|Experimental|Treatment (chemotherapy, IL13Ralpha2, Il-2)|Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 15-30 minutes on days -4 to -1. Patients then receive IL13Ralpha2 CAR T cell IV on day 0. Patients may also receive recombinant interleukin-2 SC BID on days 1-7.
10209357|NCT04478812|Experimental|Single Group Assignment|
10209358|NCT04477265|Experimental|combination of drug and exercise|Participant will be prescribed with oral medication in combination with biofeedback-assisted pelvic floor muscle training (PFMT) during the first month, participant will continue to have biofeedback assisted PFMT for another 2 months
10209359|NCT04477265|Active Comparator|drug only|Participant will be prescribed with oral medication for 3 months
10209360|NCT04477265|Active Comparator|exercise only|Participant will be doing biofeedback-assisted pelvic floor muscle training for 3 months
10209361|NCT04474847|Experimental|Blinded Abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
9858734|NCT01576575|Experimental|Healthy males and non-pregnant females|"Subjects will be studied during a maximum of seven occasions.~Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.~Sessions 1&2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)~Sessions 3&4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine~Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine~Sessions 6&7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine"
9858735|NCT01590394|Experimental|Pancreatic Cancer Patients|A large plastic biliary stent was placed in the bile duct.
9858736|NCT01577628|Other|Group 1: Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
9858737|NCT01577628|No Intervention|Group 2: No intervention control group|Subjects may use a moisturizer if they wish to but no instruction or product is provided
9858738|NCT01582100|Experimental|GERD subjects with nausea|subjects with GERD and nausea will receive treatment with Reletex
9858739|NCT01583647|Experimental|MK-0524A 1 g/20 mg (Panel A)|Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
9858740|NCT01583647|Experimental|MK-0524A 2 g/40 mg (Panel B)|Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
9858741|NCT01575028|Active Comparator|Local anesthetic infiltration injection|Patients will receive local anesthetic infiltration injected at the surgical site by the surgeon at the end of surgery.
9858742|NCT01575028|Experimental|Transversus abdominis plane (TAP) block|Patients will receive a transversus abdominis plane (TAP) block.
9858743|NCT01578785|Experimental|Glatiramer Acetate|Glatiramer acetate (GA) 20 mg/0.5 ml solution in prefilled syringe for subcutaneous injection once daily.
9858744|NCT01578785|Placebo Comparator|Placebo|Placebo solution in prefilled syringe for subcutaneous injection once daily.
10209362|NCT04474847|Placebo Comparator|Blinded Placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
10209363|NCT04467554|Experimental|Measurements and T-chair training|This group will receive three measurements sessions and training with a new developed device (15 therapy sessions in total).
9858745|NCT01576549|Experimental|LY2127399|LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.
9858746|NCT01570634|Experimental|Open Label CASAD|Treatment with CASAD for 14 days
9858747|NCT01566370|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind
9858748|NCT01566370|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group
9858749|NCT01561989|Experimental|Arm I (400 IU cholecalciferol and vaccine therapy)|Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
9858750|NCT01561989|Experimental|Arm II (4,000 IU cholecalciferol and vaccine therapy)|Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
9858751|NCT01564732|Active Comparator|Standard-LAGB|Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
9858752|NCT01564732|Experimental|Plicated-LAGB|"Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to anchor the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months."
9858753|NCT01560507|Active Comparator|varenicline (Chantix)|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
9858754|NCT01560507|Active Comparator|nicotine patches|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
9858755|NCT01560507|Active Comparator|bupropion (Zyban) and nicotine patches|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.
9858756|NCT01557881|Experimental|Diagnostic (PET/MRI)|After undergoing standard PET/CT, patients undergo PET/MRI.
9858757|NCT01555489|Experimental|Ascorbic Acid, Gemcitabine & Erlotinib|Ascorbic Acid (50-100g, 3x weekly) Standard Chemotherapy of Gemcitabine and Erlotinib for Pancreatic Cancer
9858758|NCT01549977|Experimental|Febuxostat 80 mg|Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
9858759|NCT01549977|Placebo Comparator|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
9858760|NCT01558492|Experimental|All subjects|Carboplatin and Paclitaxel
9858761|NCT01550562|Placebo Comparator|Sham Stimulation|Sham subthreshold spinal cord stimulation therapy
9858762|NCT01550562|Active Comparator|Treatment 1|subthreshold spinal cord stimulation therapy
9858763|NCT01550562|Experimental|Treatment 2|subthreshold spinal cord stimulation therapy
10209364|NCT04467554|No Intervention|Measurements|This group will receive three measurements sessions.
10209365|NCT04464954|Experimental|Auricular semi-permanent (ASP gold) needles|
10209366|NCT04464954|Experimental|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|
10209367|NCT04464954|Experimental|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|
9858764|NCT01561495|Experimental|All Participants|Proton Radiotherapy
9858765|NCT01555073|Active Comparator|Pregabalin/celecoxib group|pregabalin/celecoxib twice a day for 13 days.
9858766|NCT01555073|Active Comparator|Pregabalin/placebo group|pregabalin/placebo twice a day for 13 days.
9858767|NCT01555073|Active Comparator|Celecoxib/placebo group|celecoxib/placebo twice a day for 13 days.
10209368|NCT04464070|Experimental|niacin|"Blood (10 ml) will be drawn from the subject. Immediately before or after the blood draw the subject will collect a urine (3-10 ml) sample. After the baseline blood draw and the urine sample is collected the subject will take 500 mg of niacin. The niacin will not be an extended release formulation. Subjects will be encouraged to drink plenty of water during the study. Subjects are instructed to collect urine 1, 2, 4, 6, 8, and 10 hours after niacin administration. Subjects will collect their urine in separate plastic tubes that will be provided to them.~Approximately 1-2 h after niacin administration a second blood sample (10 ml) will be drawn from the subject."
10209369|NCT04464070|Experimental|niacin + low-dose aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of low-dose aspirin (81 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
10209370|NCT04464070|Experimental|niacin + regular-strength aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of regular-strength aspirin (325 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
10213618|NCT03689244|Experimental|Selexipag OL|All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
9858768|NCT01555073|Placebo Comparator|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
9858769|NCT01551082||Outpatient chest tubes|All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device.
9858770|NCT01556009|Active Comparator|Drug (Vismodegib)|Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
9858771|NCT01556009|Active Comparator|Aminolevulinic acid %20 topical solution|Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
9858772|NCT01550510|Experimental|Ascorbic Acid + Irinotecan|Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks
9858773|NCT01550510|Active Comparator|Standard of Care (irinotecan alone)|350mg/m2 irinotecan once a week every 3 weeks
9858774|NCT01541397|No Intervention|Non-Kuvan treated|Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.
9858775|NCT01541397|Experimental|Kuvan treated|Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
9858776|NCT01546207|Other|catheter-based ablation|catheter ablation - a medical procedure used to treat some types of arrhythmia
9858777|NCT01553240|Experimental|TMS and fMRI|"functional MRI~single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)"
9858778|NCT01547728|Experimental|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
9858779|NCT01548651|Placebo Comparator|Placebo|Placebo 5 mg orally daily for 6 months
9858780|NCT01548651|Experimental|Saxagliptin|Saxagliptin 5 mg orally daily for 6 months
9858781|NCT01545648|Experimental|denosumab|"Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
9858782|NCT01546883|Experimental|Dabigatran|Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
9858783|NCT01545518|Experimental|all subjects|IVIG
9858784|NCT01536015|Experimental|Rotigotine|Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
9858785|NCT01536015|Placebo Comparator|Placebo|Placebo patch.
9858786|NCT01539590|Experimental|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
9858787|NCT01539590|Placebo Comparator|Normal Saline|Daily intravenous administration for four (4) days
9858788|NCT01539811|Active Comparator|Short course antibiotics|Surgical intervention followed by short course of antibiotics (<2 weeks)
9858789|NCT01539811|Active Comparator|Long course antibiotics|Surgical intervention followed by a long course of antibiotics (>2 weeks)
9858790|NCT01534676|Active Comparator|Transfusion of Fresh blood|The recipient will receive one or two units of fresh blood <14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
9858791|NCT01534676|Experimental|Transfusion of Stored blood|The recipient will receive one or two units of old blood >28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
9858792|NCT01534676|Active Comparator|Transfusion of Cryopreserved Blood|The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
9858793|NCT01534676|Active Comparator|Transfusion of Washed Blood|The recipient will receive one or two units of washed (fresh/old) stored blood >28 days old, as per their chronic transfusion schedule - off chelation therapy.
9858794|NCT01533753|Experimental|Arm A: Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
9858795|NCT01533753|Experimental|Arm B: Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
9858796|NCT01534143|Experimental|Treatment (chemotherapy, enzyme inhibitor)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.~GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0."
9858797|NCT01530880|Experimental|Intravenous Ibuprofen|Patients assigned to the ibuprofen treatment group will receive a 400 mg IV ibuprofen bolus over 30 minutes followed by an infusion of ibuprofen at 85 mg/hr.
9858798|NCT01530880|Other|Standard of Care|Patients assigned to the standard of care group will be given 650 mg of oral acetaminophen and continue to receive 650 mg of oral acetaminophen every 6 hours as needed to maintain temperature < 38.3 C (100.9 F).
9858799|NCT01530087|Experimental|Treatment|CASTLE Barrier
9924270|NCT00859768|Experimental|Intervention group 1|Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
9986442|NCT01402895|Active Comparator|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
9858800|NCT01527942|Experimental|Arm 1 - Active Drug|Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
9858801|NCT01527942|Placebo Comparator|Arm 2 - Placebo|Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
9858802|NCT01521143|Experimental|Part A - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
9858803|NCT01521143|Placebo Comparator|Part A - Placebo|Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
9858804|NCT01521143|Experimental|Part B - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
10209371|NCT04464070|Experimental|deuterated PGD2|"Volunteers will come to the clinical research center. Volunteers will provide a urine sample. The volunteers will be fitted to record an electrocardiogram (ECG) and blood pressure. ECG will be recorded continuously. Blood pressure will be taken at baseline and every 10 minutes thereafter for one hour. The solution with deuterated PGD2 (10 microgram) will be infused over the course of 30 min. Volunteers will be monitored for 1 h after the end of the infusion, and volunteers will start collecting urine in intervals up to 10 h.~Infusion of the deuterated PGD2 solution will be performed in the presence of a physician. The injection solution will be prepared by Vanderbilt University Medical Center (VUMC) Investigational Drug Services. The solution will be sterile and pyrogen free."
10209372|NCT04463667|Experimental|The effects of exercise intervention on fatty liver|The effects of exercise intervention on fatty liver and the improvement of the above-mentioned various metabolic indicators, including improvement of sleep patterns and changes of intestinal microflora.
10209373|NCT04456517|Experimental|Ranolazine, Then Placebo|- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
9858805|NCT01521143|No Intervention|Part B - Observational standard of care|Participants in this group did not receive any treatment during the study.
9858806|NCT01532635|Experimental|Allogeneic HSCT Using Two Related Donors|"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28."
9858807|NCT01531387|No Intervention|Standard Therapy: Observation|Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
9858808|NCT01531387|Experimental|Hydroxyurea|Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
9858809|NCT01532362|Experimental|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
9858810|NCT01532362|Other|No drug intervention|
9858811|NCT01527292|Active Comparator|Control Group|Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
9858812|NCT01527292|Experimental|Treatment Group|SRT with Vertebral Augmentation Procedure Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure
9858813|NCT01525745|Active Comparator|Radiosurgery/SBRT|Radiosurgery/SBRT
9858814|NCT01525745|Active Comparator|External Beam Radiation Therapy|External Beam Radiation Therapy
9858815|NCT01528696|Placebo Comparator|Standard Dressing|Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
9858816|NCT01528696|Experimental|Silverlon|Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing
9858817|NCT01526408|Placebo Comparator|Placebo Arm|Treatment with 3 months of placebo
9858818|NCT01526408|Active Comparator|Active Arm|Treatment with 3 months of active drug
9858819|NCT01528293|Active Comparator|ActiVAC System+ Compression therapy|ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
9858820|NCT01528293|Other|Compression therapy only|Standard of Care compression therapy only
9858821|NCT01525927|Active Comparator|Chemotherapy non-responders|Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
9858822|NCT01525927|Experimental|Chemotherapy responders|Patients who respond to chemotherapy are treated with reduced dose radiotherapy.
9858823|NCT01520714|Experimental|Medtronic passive fixation LV lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
9858824|NCT01520714|Experimental|Medtronic 4195 Active Fixation LV Lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
9858825|NCT01507233|Active Comparator|IV morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
9858826|NCT01507233|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
9858827|NCT01516034|Experimental|Treatment|Cupola Tattoo Removal Device
9858828|NCT01500772|Experimental|Alisporivir|ALV 400 mg twice daily (BID), plus PEG and RBV for 48 weeks
9858829|NCT01517763|Placebo Comparator|Conventional CPAP|Fisher & Paykel HC244™
9858830|NCT01517763|Active Comparator|CPAP without Humidification|Fixed pressure ICON™ without ThermoSmart™
9858831|NCT01517763|Experimental|APAP with all technologies|Auto ICON™ with SensAwake™ and ThermoSmart™
9858832|NCT01507584|Active Comparator|Prostaglandin Analogue|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (PGA + BB)
9858833|NCT01507584|Active Comparator|Carbonic Anhydrase Inhibitor|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (CAI+ BB)
9858834|NCT01510756|Experimental|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
9858835|NCT01511081|Experimental|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
9858836|NCT01511081|Experimental|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
9858837|NCT01500109|Experimental|Ofirmev®|Oral inert cherry syrup will be administered preoperatively as placebo for oral acetaminophen. Ofirmev® will be administered in the operating room once intravenous access is established. Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon before surgical incision as well as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patients will receive Ofirmev® every 6 hours as well as placebo oral cherry elixir every 6 hours and morphine as needed for 24 hours.
9858838|NCT01500109|Active Comparator|Oral acetaminophen|Patients will receive oral acetaminophen cherry elixir preoperatively. After intravenous access is obtained intraoperatively patients will receive placebo for Ofirmev® (saline). Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to surgical incision as wel as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patient will receive oral acetaminophen every six hours and intravenous placebo (normal saline) for intravenous acetaminophen. Intravenous morphine will be administered as needed for 24 hours.
9858839|NCT01500109|Placebo Comparator|Opioid only|This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
9858840|NCT01509053|Experimental|Aripiprazole IM depot injection|Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
9858841|NCT01495988|Active Comparator|Vemurafenib/Cobimetinib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
9858842|NCT01495988|Experimental|Vemurafenib/Cobimetinib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Bevacizumab will be administered at the MTD (determined by phase Ib safety lead-in), intravenously, every 2 weeks. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
9858843|NCT01495988|Active Comparator|Vemurafenib|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
9858844|NCT01495988|Experimental|Vemurafenib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients assigned to the combination arm will also receive bevacizumab 15 mg/kg every IV every 3 weeks. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
9858845|NCT01498991|Experimental|AMES Treatment|The subject will receive 30 treatment sessions, conducted 3-4 times per week on the AMES device. Each session will consist of testing followed by 40 minutes of treatment time (20 minutes per each leg) using the AMES device.
9858846|NCT01497171|Active Comparator|Elevate Mesh|Elevate transvaginal mesh - surgical repair of prolapse
9858847|NCT01497171|Active Comparator|Anterior Colporrhaphy|Anterior colporrhaphy - surgical repair of prolapse
9858848|NCT01483872|Experimental|NAC/Tigecycline/Heparin combination lock solution|A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
9858849|NCT01483872|Placebo Comparator|Standard anticoagulant (heparin or citrate)|Standard anticoagulant (heparin or citrate)
9858850|NCT01487499|Experimental|patients with limited stage SCLC|Subjects with limited stage SCLC treated sequentially with cisplatin.
9858851|NCT01487499|No Intervention|Historical Controls|No intervention
9858852|NCT01478113|Active Comparator|WBT + amphetamine/dextroamphetamine|In the active group, participants will receive treatment with Well-being therapy and amphetamine-dextroamphetamine.
9858853|NCT01478113|Placebo Comparator|WBT + placebo|In the placebo group, participants will receive treatment with Well-being therapy and pill placebo.
9858854|NCT01483209|Experimental|Botox injection|Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia
9858855|NCT01484314|Experimental|Migration Arm|Administration of eltrombopag to support platelets during chemotherapy
9858856|NCT01482598|Active Comparator|Optimal Remote Care|Patient follow up is performed through remote care, remote alerts on CRT-D device data are transmitted daily to the hospital, remote follow up is scheduled every 6 months, hospital in clinic follow up is scheduled at 12 months after implant.
9858857|NCT01482598|No Intervention|Optimal Standard Care|Patient standard in clinic visits are performed every 6 months.
9858858|NCT01479010|Experimental|Anakinra|
9858859|NCT01482325|Experimental|Subjects requiring blood pressure monitoring|Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring
9858860|NCT01477177|Experimental|Polar Wand Treatment|Cryotherapy device utilizing carbon dioxide (room temperature gas) for treatment of GI neoplasia
9858861|NCT01473732|Experimental|Everolimus (Zortress)|
9858862|NCT01473732|Active Comparator|Reduced dose Tacrolimus (Prograf)|
9858863|NCT01472692|Active Comparator|Febuxostat|
9858864|NCT01472692|Placebo Comparator|Placebo|
9858865|NCT01465230|Experimental|lenalidomide|Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
9858866|NCT01464723|Experimental|Lucentis|Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
9858867|NCT01446250|Experimental|Alisporivir|At the time of partial clinical hold, participants randomized to original treatment arms A and B (Alisporivir triple therapy arms with Peginterferon alfa-2a and Ribavirin) discontinued alisporivir treatment immediately while continuing their treatments with the other two therapies. These participants were combined into the same arm because they received the same dose of alisporivir 400 mg twice per day (BID) for the same duration. Amendment 1 offered them the opportunity to continue in the study receiving boceprevir triple therapy.
9858868|NCT01446250|Active Comparator|Boceprevir|Participants randomized to boceprevir triple therapy with Peginterferon alfa-2a and Ribavirin (the original treatment arm C).
9858869|NCT01463293|Experimental|High-dose probiotic|Capsule containing 10 billion cfu B. lactis HN019
9858870|NCT01463293|Experimental|Low dose probiotic|Capsule containing 1 billion cfu B. lactis HN019
9858871|NCT01463293|Placebo Comparator|Placebo|Placebo capsule
9858872|NCT01457053|Active Comparator|Ultrafiltration|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
9858873|NCT01457053|Active Comparator|Diuretic Therapy|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.
9858874|NCT01451723|Experimental|Polyphenon E 400mg twice a day|Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
9858875|NCT01451723|Placebo Comparator|Placebo|Matching placebo capsules.
9858876|NCT01452854||Cancer|The study cohort will include adult women of childbearing potential with a diagnosis of low grade glioma (WHO grade II) who are being treated with low doses of Temozolomide (Temodar).
9858877|NCT01440517|Experimental|Tc99m-Maraciclatide|
9858878|NCT01440595|Experimental|Grazoprevir 200 mg + Peg-IFN + RBV|Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
9858879|NCT01440595|Experimental|Grazoprevir 400 mg + Peg-IFN + RBV|Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
9858880|NCT01440595|Placebo Comparator|Placebo + Peg-IFN + RBV|Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
9858881|NCT01440595|Experimental|Grazoprevir 800 mg + Peg-IFN + RBV|Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.
9858882|NCT01446796|Placebo Comparator|Native Conduction|Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
9858883|NCT01446796|Experimental|Continuous RV Pacing|Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (>80%) of paced right ventricular beats
9858884|NCT01443923|Active Comparator|1-HCV|Hepatitis C Mono-infected
9858885|NCT01443923|Active Comparator|2 HCV/HIV|Hepatitis C and HIV co-Infected
9858886|NCT01439347|Experimental|Vincristine Sulfate Injection (VSI)|VSI dosed at 1.4 mg/m^2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes.
9858887|NCT01439347|Experimental|Marqibo|Marqibo dosed at 2.25 mg/m^2 (without any dose cap) as an IV infusion over 60 minutes.
9858888|NCT01440452|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
9858889|NCT01440452|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
9858890|NCT01440452|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
9858891|NCT01440452|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
9858892|NCT01433471|Experimental|Trichuris suis ova followed by placebo|Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
9858893|NCT01433471|Active Comparator|Placebo followed by Trichuris Suis Ova|Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
9858894|NCT01436084|Experimental|SB1518|400 mg orally a day for 28 day cycle.
9858895|NCT01434511|Experimental|OBI-1|
9858896|NCT01426555|Active Comparator|FES Rowing|Group 1 - FES-Rowing Exercise for entire study period
9858897|NCT01426555|Experimental|FES Rowing + Zoledronic acid|Group 2 - FES-Rowing Exercise for entire study period plus Zoledronic Acid 5mg administered by i.v. infusion one-time at the end of observation period
9858898|NCT01434745|Placebo Comparator|Placebo|placebo
9858899|NCT01434745|Experimental|Simvastatin|0.5 mg/kg body weight/day
9858900|NCT01415986|Experimental|Subjects receiving Temoporfin|
9858901|NCT01410799|Experimental|Growth Hormone Releasing Hormone (GHRH)|Drug: GHRH
9858902|NCT01426113|Experimental|bimatoprost ophthalmic solution formulation A and vehicle|1 drop bimatoprost vehicle in the affected eye(s) in the morning and 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning and 1 drop bimatoprost vehicle in the affected eye(s) in the evening for 6 additional weeks.
9858903|NCT01426113|Active Comparator|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
9858904|NCT01426516|No Intervention|Treatment as usual (TAU)|Subjects will give DNA sample for genetic testing but will not receive genetic results and will therefore receive treatment as usual.
9858905|NCT01426516|Experimental|Genecept Assay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account.
9858906|NCT01420965|Active Comparator|Arm A|Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)
9858907|NCT01420965|Experimental|Arm B|Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
9858908|NCT01420965|Experimental|Arm C|Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
9858909|NCT01417377||Cohort|Mircera
9858910|NCT01416272|Experimental|KeraSoft IC Soft Contact Lenses|KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
9858911|NCT01414166|Experimental|ERN/LRPT group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive ERN/LRPT for 16 weeks.
9858912|NCT01414166|Placebo Comparator|Placebo group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive placebo for 16 weeks.
9858913|NCT01406860|Experimental|Droperidol|
9858914|NCT01406860|Active Comparator|Metoclopramide + Diphenhydramine|
9858915|NCT01401049|Experimental|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
9858916|NCT01401049|Active Comparator|Propofol/Lidocaine|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (a lipid based medication); Lusedra (a water based medication); and the drug combination of propofol with lidocaine (a local anesthetic commonly used with propofol injection).
9858917|NCT01409031|Experimental|Intravenous Sildenafil|
9858918|NCT01409031|Placebo Comparator|Placebo|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
9858919|NCT01402531|Experimental|Submucosal Bevacizumab|200mg Bevacizumab, submucosal injection
9858920|NCT01394926|Experimental|Arm Number 1|
10209374|NCT04456517|Experimental|Placebo, Then Ranolazine|- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
9858921|NCT01383681||All Participants|This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
9858922|NCT01403194|Experimental|CPAP/Bi-PAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
9858923|NCT01397552|Active Comparator|Dexamethasone|Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
10209375|NCT04454242|Experimental|L-EMST|"At 30% of the maximum expiratory pressure (MEP), 25 breaths, 7 days / week, a total of 8 weeks will be trained once a day with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 30% of the new measurement."
9858924|NCT01397552|Active Comparator|methylprednisolone acetate|Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded
9858925|NCT01392170|Experimental|PEG-IFNá-2a|PEG-IFNá-2a (Pegasys) 45 mcg subcutaneously as single weekly dose.
10209376|NCT04454242|Active Comparator|H-EMST|"In 60% of the maximum expiratory pressure (MEP), 25 breaths a day, 7 days / week, a total of 8 weeks will be trained with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 60% of the new measurement."
10209377|NCT04447768|Experimental|Venetoclax and Obinutuzumab|All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
9858926|NCT01389817|Experimental|Symptomatic LHON patients.|Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
9858927|NCT01389817|No Intervention|Asymptomatic LHON mutation carriers|Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
10209378|NCT04442022|Experimental|Phase 2: Selinexor 40 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1, and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
10209379|NCT04442022|Experimental|Phase 2: Selinexor 60 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
10209380|NCT04442022|Active Comparator|Phase 2: R-GDP|Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
10209381|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
9858928|NCT01397695|Experimental|bevacizumab|
9858929|NCT01390181|Experimental|Losartan|
9858930|NCT01385033|Experimental|Part I, Healthy Elderly (HE) and AD Participants|HE and AD participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
9858931|NCT01385033|Experimental|Part II, Healthy Young, HE and AD Participants|Healthy Young, HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
9858932|NCT01385033|Experimental|Part III, Participants with aMCI|Participants with aMCI will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
9858933|NCT01394211|Experimental|Neoadjuvant enzyme inhibitor therapy|"Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.~NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery."
9858934|NCT01377441|Experimental|Ibuprofen|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo.
9858935|NCT01377441|Placebo Comparator|Placebo/Saline solution|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo
9794483|NCT01509040|Experimental|Low Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/h, ultrafiltration 45 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
9794484|NCT01509040|Experimental|High Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/kg/h, ultrafiltration 90 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
10209382|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
9794485|NCT01509079|Experimental|Vitamin D3 4000 IU|
9794486|NCT01509079|Active Comparator|Vitamin D3 600 IU|
9794487|NCT01509105||Group1|
9799955|NCT01674647|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
9799956|NCT01674647|Active Comparator|Vitamin K antagonist (VKA)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
9799957|NCT01674712|Experimental|Fenofibrate/simvastatin 145/20 mg|
9799958|NCT01674712|Active Comparator|Simvastatin 20 mg|
9799959|NCT01674712|Active Comparator|Fenofibrate 145 mg|
9799960|NCT01674712|Experimental|Fenofibrate/simvastatin 145/40 mg|
9799961|NCT01674712|Active Comparator|Simvastatin 40 mg|
9799962|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
9799963|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks
9799964|NCT01675050|Experimental|Cyproheptadine first then Placebo|4 weeks of cyproheptadine or placebo with crossover to the other
9799965|NCT01675050|Experimental|Sugar Pill first then Cyprotheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
9799966|NCT01675063|Other|Retia Non-Invasive Sensors|Sensors will be placed on the patient and connected to an amplifier that produces a waveform for 8 hours post cardiac surgery.
9799967|NCT01675128|Experimental|Phase I Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 started 800 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
9799968|NCT01675128|Experimental|Phase I Dose Level II|Irinotecan 180 mg/m^2 every other week; ISIS 183750 1000 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
10209383|NCT04442022|Placebo Comparator|Phase 3: Placebo + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
10209384|NCT04439994|Active Comparator|Hypertonic saline|Each participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
10209385|NCT04439994|Placebo Comparator|Isotonic Saline|Each participant will be given i.d. in 0.1 mL volumes of a isotonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
10209386|NCT04436757|Experimental|IPS (Self-image and body-representation program)|"The IPS program (Self-image and body representation) was designed by Dr PLAZAT and coll. for specific use with patients with severe mental disorders suffering of low self- and body-esteem and aiming at  reinsert themselves in the society."
10209387|NCT04436757|Active Comparator|TAU|Treatment As Usual : the usual care proposed by the health service (SUR/CL3R).
10209388|NCT04433299||low back pain patients|no intervention
10209389|NCT04433299||controls|no intervention
10209390|NCT04426981|Experimental|Intervention arm|Consenting patients will be enrolled into a Behavioral Activation treatment arm. Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities.
10209391|NCT04423471||Group 1|Psoriasis patients who will receive systemic treatment (mainly methotrexate)
10209392|NCT04423471||Group 2|Psoriasis patients who will receive a biological treatment
10209393|NCT04423471||Group 3|Patients with major depression who will receive an antidepressant treatment
9794488|NCT01509183|Active Comparator|Intervention Group|Intervention group (IG) participants received access to and feedback from the Propeller Health System (formerly Asthmapolis System).
9794489|NCT01509183|No Intervention|Control Group|Control group (CG) participants were outfitted with sensors from the Propeller Health System, but did not receive feedback.
10209394|NCT04423393|Experimental|VIR-3434|
10209395|NCT04423393|Placebo Comparator|Placebo|
10209396|NCT04418115|Experimental|Acupuncture + usual care|Participants randomized to acupuncture treatment will receive 12 acupuncture treatments during 8-12 weeks.
10209397|NCT04418115|No Intervention|Usual care|"Our control group will receive business as usual. Hence, they will continue with their usual care for their CRF. By inclusion in the study and by the end of it, the participants in the control group will fill in the requested and similar instruments as the participants in the acupuncture group. Further, we will document any medical care they have received during the study period. This includes also life styles advice, and to which point they have followed such advices."
10209398|NCT04416412||Open Fracture Cohort|"Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion.~Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.~Will have all planned fracture care surgeries performed by a participating surgeon or delegate.~Provision of informed consent."
10209399|NCT04414917|Experimental|Twin Block local anesthetic|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s
10209400|NCT04414917|Sham Comparator|Control|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block injection but with no medication administered/dispensed from the syringe, on the side/s of their extraction/s
10209401|NCT04414033|Experimental|research group|
10209402|NCT04406545||healthy volunteers|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
10209403|NCT04406545||cardiovascular disease and COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
9794490|NCT01509404|Active Comparator|Valcyte|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
9794491|NCT01509404|Active Comparator|Valcyte then Cytogam|valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
9794492|NCT01509547|Experimental|varenicline|Participants >55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
9794493|NCT01509547|Placebo Comparator|placebo|Participants >55 kg will take placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
9794494|NCT01509586|Experimental|PREP (Potentially Reduced Exposure Product) Group|
9794495|NCT01509586|No Intervention|cigarette group|
9794496|NCT01509612|Active Comparator|Additive homeopathy in cancer patients|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
9794497|NCT01509612|Placebo Comparator|Additive homeopathic placebo globules|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
9794498|NCT01509612|No Intervention|No intervention|No intervention
9794499|NCT01509638|Active Comparator|Group 1 Standard of Care|IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
9794500|NCT01509638|Active Comparator|Group 2 EXPAREL|bupivacaine liposome injectable suspension.
9794501|NCT01509664|Experimental|Discount intervention|Receives 50% discount intervention on selected fruits and vegetables at participating supermarket.
9794502|NCT01509664|No Intervention|Control|Received no discount at the participating supermarket.
9794503|NCT01509677|Active Comparator|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
9794504|NCT01509677|Placebo Comparator|Placebo|tablet, once daily, oral administration in the morning after breakfast
9794505|NCT01509807|Active Comparator|Group 1|IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
9794506|NCT01509807|Experimental|Group 2|EXPAREL (bupivacaine liposome injectable suspension)
9794507|NCT01509846|Experimental|Cohort 1|Received one oral dose of 2.6±0.8 x 10^8 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
9794508|NCT01509846|Experimental|Cohort 2|Received three oral doses of 2.6±0.8 x 10^9 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
9794509|NCT01509846|Experimental|Cohort 3|Received three oral doses of 2.6±0.8 x 10^10 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
9794510|NCT01509846|Experimental|Cohort 4|Received three oral doses of 2.6±0.8 x 10^11 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
9794511|NCT01509846|Placebo Comparator|Placebo|Received oral dose of placebo concurrent with Cohort 1 (one dose), 2, 3, or 4 (3 doses).
9794512|NCT01509872|Experimental|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behaviour Therapy (Cohen, Mannarino, Deblinger, 2006; Smith and Saunders, 2005) is a child-friendly, manualised psychological intervention for children who experience nightmares, flashbacks, anxiety, anger, social isolation, poor concentration or self-blame after experiencing or witnessing a violent and terrifying life event (e.g. rape, murder, abduction etc). This intervention was culturally modified for use with war-affected children.
9794513|NCT01509872|Active Comparator|A Child Friendly Space|A Child Friendly Space is a psychosocial intervention combining creative (e.g. art), imaginative (e.g. drama), physical (e.g. football), communicative (e.g. group discussions) and manipulative activities (e.g. story telling). It aids children's natural development by providing a safe place for children to learn, express themselves, grow and develop, supported by trained animators and peer educators.
9858936|NCT01383447|Experimental|Treatment (entinostat and imatinib mesylate)|Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9858937|NCT01372618|Experimental|SOM 230/Pasireotide|Treatment with SOM230 600mcg twice daily for 20 days.
9858938|NCT01385280|Experimental|Arm I|Patients receive oral therapeutic estradiol once daily on days 1-3, twice daily on days 4-7, and thrice daily on days 8-90. Beginning on day 98, patients receive oral exemestane once daily in the absence of disease progression or unacceptable toxicity. Also laboratory biomarker analysis and enzyme-linked immunosorbent assay will be taken for correlative studies.
9858939|NCT01379274|Experimental|lenalidomide and azacitidine combination|Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
9858940|NCT01379469|Active Comparator|Drug-Carbamazepine (Tegretol XR)|One arm receives Drug-Carbamazepine (Tegretol XR).All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
9858941|NCT01379469|Placebo Comparator|Drug-Carbamazepine (Tegretol XR) Placebo|One arm receives Carbamazepine (Tegretol-XR) placebo.All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
9858942|NCT01369641|Experimental|Experimental Ear - Sodium Thiosulfate (STS)|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
9858943|NCT01369641|Placebo Comparator|Comparator Ear - Placebo|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
9858944|NCT01365156|Experimental|EPLND + Chemoradiation|Group 1: Extraperitoneal laparoscopic lymphadenectomy followed by chemoradiation therapy
9858945|NCT01365156|Active Comparator|Chemoradiation|Group 2: standard-of-care chemoradiation therapy only
9858946|NCT01359254|Experimental|Conditioning Regimen I|Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
9858947|NCT01359254|Experimental|Conditioning Regimen II|Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
9858948|NCT01347632|Other|BV pre treatment|Open Label Study. All participants had BV and took metronidazole 500 mg po BID for 7 days.
9858949|NCT01356667|Active Comparator|Treatment-As-Usual|Substance Abuse treatment typically received
9858950|NCT01356667|Experimental|DARTNA|12-week DARTNA program
9858951|NCT01354951|Experimental|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.
9858952|NCT01350232|Experimental|HSCT|"Subjects receive the preparative regimen in 2 steps. The first step will be with fludarabine and cytarabine and a low dose of total body irradiation. This will be followed by the first step of the transplant graft - the donor lymphocytes. The second step of the chemotherapy will be two doses of cyclophosphamide. This will then be followed by the second step of the transplant graft - the stem cells.~Only subjects with prior alloimmunization against donor will receive desensitization. Subjects who demonstrate alloimmunization against the HLA of the donor will receive bortezomib and rituximab in combination with plasmapheresis prior to the admission for transplant."
9858953|NCT01350583|Experimental|Sodium Bicarbonate Therapy|Dose Escalation
9858954|NCT01352416|Active Comparator|CABG surgery with Ranolazine|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
9858955|NCT01352416|Placebo Comparator|CABG surgery with placebo|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
9858956|NCT01352416|Active Comparator|Heart Valve surgery with Ranolazine|Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
9858957|NCT01352416|Placebo Comparator|Heart Valve surgery with placebo|Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.
9858958|NCT01350258|Experimental|Transplant Treatment Group|All patients treated on this research study.
9858959|NCT01349595|Experimental|Bortezomib|Bortezomib is a type of targeted chemotherapy
9858960|NCT01349595|No Intervention|Standard Post-transplant Treatment|Mayo Clinic standard post kidney transplant follow-up.
9858961|NCT01337609|Experimental|GanedenBC30|Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
9858962|NCT01337609|Placebo Comparator|Sugar pill|Arm 2 will take placebo (sugar pill) for 60 days.
9794514|NCT01509950|Active Comparator|Staples|Use of staples for skin closure at cesarean section
9794515|NCT01509950|Active Comparator|Prolene non-absorbable sutures|Use of Prolene non-absorbable sutures for skin closure at cesarean section
9794516|NCT01509950|Active Comparator|Absorbable sutures|Use of absorbable sutures for skin closure at cesarean section; monocryl or vicryl.
9794517|NCT01510028|Experimental|Cohort 1 (10 mg)|6 patients treated with HGT-1110 10 mg EOW by IT injection
9794518|NCT01510028|Experimental|Cohort 2 (30 mg)|6 patients treated with HGT-1110 30 mg EOW by IT injection
9794519|NCT01510028|Experimental|Cohort 3 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
9794520|NCT01510028|Experimental|Cohort 4 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
9794521|NCT01510145|Experimental|TRAVATAN® BAK-free|Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.
9794522|NCT01510158|Experimental|lesinurad 200 mg + allopurinol|
9794523|NCT01510158|Experimental|lesinurad 400 mg + allopurinol|
9794524|NCT01510158|Placebo Comparator|Placebo + allopurinol|
9794525|NCT01510327|Experimental|PROMUS Element|Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.
9794526|NCT01510379|Active Comparator|Reletex|Reletex plus scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
9794527|NCT01510379|Other|Control|Scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
9794528|NCT01510457|Placebo Comparator|Sugar Pill|BID placebo
9794529|NCT01510457|Experimental|Milnacipran|Uptitration from 10mg to 50mg BID Milnacipran
9794530|NCT01510652|Active Comparator|Quad Group|Patients in the Quad group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
9794531|NCT01510652|Active Comparator|BiP Group|Patients in the BiP Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
9794532|NCT01510704|Placebo Comparator|Placebo|
9794533|NCT01510704|Experimental|Low dose APD421|1mg dose level
9794534|NCT01510704|Experimental|Mid Dose APD421|5mg dose level
9794535|NCT01510704|Experimental|High Dose APD421|20mg dose level
9794536|NCT01510717|Experimental|Multifocal IOL|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
9794537|NCT01510717|Active Comparator|Monofocal IOL|AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation
9794538|NCT01510769|Experimental|lesinurad 400 mg + febuxostat 80 mg|
9794539|NCT01510769|Experimental|lesinurad 200 mg + febuxostat 80 mg|
9794540|NCT01510769|Placebo Comparator|placebo + febuxostat 80 mg|
9794541|NCT01510834|Experimental|All STR2IVE Participants|All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.
9794542|NCT01510912|Experimental|Diclofenac Capsules 35 mg bid or tid|
9794543|NCT01511016|Experimental|human recombinant leptin (metreleptin)|Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months.
9794544|NCT01511016|Placebo Comparator|Placebo injection|Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg for two more months.
9794545|NCT01511055|Experimental|Folate-FITC|
9794546|NCT01511068|Experimental|Inhaled Leukine (rhGM-CSF)|Inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
9794547|NCT01511107|Active Comparator|Amoxicillin-Clavulanate, 10 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
9794548|NCT01511107|Other|Amoxicillin-Clavulanate, 5 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days
9794549|NCT01511250|Experimental|Part I: TDV 21 to 45 Years (yrs)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
9794550|NCT01511250|Placebo Comparator|Part I: Placebo 21 to 45 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
9794551|NCT01511250|Experimental|Part I: TDV 12 to 20 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
9794552|NCT01511250|Placebo Comparator|Part I: Placebo 12 to 20 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
9794553|NCT01511250|Experimental|Part I: TDV 6 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
10209404|NCT04406545||cardiovascular disease without COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
10209405|NCT04403204||Established SSI Fracture Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
10209406|NCT04403204||Established SSI Fracture Cohort Subset (DCE-MRI)|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
9794554|NCT01511250|Placebo Comparator|Part I: Placebo 6 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
9794555|NCT01511250|Experimental|Part I: TDV 1.5 to 5 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
9794556|NCT01511250|Placebo Comparator|Part I: Placebo 1.5 to 5 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
9794557|NCT01511250|Experimental|Part II: TDV 1.5 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
9794558|NCT01511250|Placebo Comparator|Part II: Placebo 1.5 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
9794559|NCT01511315|Experimental|Ustekinumab|
9794560|NCT01511419|Experimental|LAIV H7N3|"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.~Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.~Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.~Route of administration: Intranasal aerosol.~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28."
9794561|NCT01511419|Placebo Comparator|Placebo|"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.~Dose: 0.5 ml; 0.25 ml/nare~Route of administration: Intranasal aerosol~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28"
9794562|NCT01511445|Active Comparator|ACDF with PEEK interbody cage|Anterior cervical discectomy and fusion (ACDF) with an interbody spacer made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is to be filled with local autologous bone harvested during the decompression phase of the procedure.
9794563|NCT01511445|Experimental|ACDF with Valeo CSC Ceramic Cage|ACDF with the Valeo CSC cage, a silicon nitride ceramic interbody cage. The center area of the cage is filled with porous silicon nitride. No autologous bone is used; the cage is soaked in patient blood.
9794564|NCT01511536|Experimental|Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
9794565|NCT01511536|Experimental|Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
9794566|NCT01511536|Experimental|Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
9794567|NCT01511640|Experimental|Pregabalin 1|Dose 1
9794568|NCT01511640|Placebo Comparator|Placebo 1|Placebo 1
9794569|NCT01511640|Experimental|Pregabalin 2|Dose 2
9794570|NCT01511640|Placebo Comparator|Placebo 2|Placebo 2
9794571|NCT01511809|Experimental|Atazanavir/ritonavir monotherapy|Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
9794572|NCT01511809|No Intervention|Atazanavir/ritonavir triple therapy|Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone
9794573|NCT01511939|Other|Pennsaid, warfarin|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months
9794574|NCT01511939|Other|Pennsaid, dabigatran|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months
9794575|NCT01511939|Other|Pennsaid, aspirin and/or clopidogrel|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months
9794576|NCT01511978|Active Comparator|Continuous 3,4-DAP|Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
9858963|NCT01337609|Other|Ganeden BC30, Sugar pill|Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
9858964|NCT01347840||All Subjects|This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.
9858965|NCT01340573||Genotype 1 CHC Participants|
9858966|NCT01340573||Non-genotype 1 CHC participants|
9794577|NCT01511978|Placebo Comparator|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
9794578|NCT01512108|Experimental|Liraglutide + an OAD therapy|
9794579|NCT01512108|Active Comparator|Two OADs combination therapy|
9794580|NCT01512160|Experimental|PF-04531083 2000 mg|
9794581|NCT01512160|Experimental|PF-04531083 1000 mg|
9794582|NCT01512160|Active Comparator|Ibuprofen 400 mg|
9794583|NCT01512160|Placebo Comparator|Placebo|
9794584|NCT01512225|Experimental|Domperidone for days 1 to 28|Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
9794585|NCT01512225|Placebo Comparator|Placebo for days 1 to 14 and domperidone for day 15-28|Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28
9794586|NCT01512251|Other|No Previous Treatment|150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.
9794587|NCT01512264|Experimental|rTMS|3 weeks of nerTMS
9794588|NCT01512264|Sham Comparator|1 week of Sham Treatment + 2 weeks of nerTMS|1 week of Sham Treatment + 2 weeks of nerTMS
9794589|NCT01512264|Sham Comparator|2 weeks of Sham Treatment +1 week of nerTMS|2 weeks of Sham Treatment +1 week of nerTMS
9794590|NCT01512264|Placebo Comparator|Control Group|3 weeks of Sham Treatment
9794591|NCT01512368|Experimental|Supervised exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.
9794592|NCT01512446|Active Comparator|Alendronate|
9794593|NCT01512446|Placebo Comparator|Placebo|
9794594|NCT01512667|Experimental|Severe Renal Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency.
9794595|NCT01512667|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
9794596|NCT01512693|Experimental|Moderate Hepatic Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with moderate hepatic insufficiency.
9794597|NCT01512693|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
9794598|NCT01512745|Experimental|apatinib|
9794599|NCT01512745|Placebo Comparator|placebo|
9794600|NCT01512758|Experimental|Alisertib 30 mg|Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
9794601|NCT01512758|Experimental|Alisertib 40 mg|Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
9794602|NCT01512797|Active Comparator|Sitagliptin phosphate|100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
9794603|NCT01512797|Placebo Comparator|Placebo|1 Placebo pill / day PO once a day for 4-5 weeks
9794604|NCT01512849|Experimental|TA-7284 Low|
9794605|NCT01512849|Experimental|TA-7284 High|
9794606|NCT01512979|Experimental|linagliptin|patients receive linagliptin tablet once daily
9794607|NCT01512979|Experimental|linagliptin plus metformin|patients receive linagliptin tablet once daily and metformin tablets twice daily
9794608|NCT01513122|Active Comparator|Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
9794609|NCT01513122|Active Comparator|Arm 2. Lopinavir /ritonavir + raltegravir|
9794610|NCT01513148|Experimental|Superluminous Light Diode Irradiation|Application of super luminous diodes light irradiation over the superficial radial nerve
9794611|NCT01513148|Placebo Comparator|Sham Superluminous Light Diode Irradiation|Sham Superluminous Light Diode Irradiation over the Superficial Radial Nerve for the same time period as the intervention group
9794612|NCT01513239|Experimental|MK-6072 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI
9794613|NCT01513239|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI
9794614|NCT01513239|Placebo Comparator|Placebo + SOC|Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI
9794615|NCT01513291|Experimental|MK-6096|Participants were randomized to receive double-blind MK-6096, two 5 mg tablets (10 mg dose), orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period were randomized 1:1 to receive double-blind MK-6096 or placebo once daily in the 2-week Run-out Period.
9986443|NCT01402895|Active Comparator|Exercise|The physiotherapist will teach the participant how to tighten the transversus abdominus muscle. The participant will be asked to do a series of these exercises.
9799969|NCT01675128|Experimental|Phase II Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.
9799970|NCT01675141|Experimental|Lenalidomide Maintenance Therapy for Multiple Myeloma|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
9799971|NCT01675154|Placebo Comparator|SLx-4090 placebo/Orlistat Placebo|"Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.~Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.~This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment."
9799972|NCT01675154|Experimental|Orlistat/placebo|Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
9799973|NCT01675154|Experimental|Orlistat placebo /SLx-4090|Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
9799974|NCT01675154|Experimental|Orlistat/SLx-4090|Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
9799975|NCT01675167|Placebo Comparator|Placebo Buccal Film|Twice Daily Dosing
9799976|NCT01675167|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
9799977|NCT01675297|Experimental|Risendronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months
9799978|NCT01675297|Active Comparator|Risedronate|Sedron tablet: one tablet once a week for 12months
9799979|NCT01675427|Experimental|Chronic hepatitis C patients|
9799980|NCT01675453|Active Comparator|7.2% NaCl /hydroxyethyl starch 200/0.5|On-pump CABG. 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5 solution (HyperHAES) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
9799981|NCT01675453|Placebo Comparator|0.9% NaCl|On-pump CABG. 0.9% NaCl (isotonic saline) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
9799982|NCT01675492|Experimental|wave-front guided LASIK|
9799983|NCT01675531|Experimental|Targin|Targin
9799984|NCT01675544||Heart Failure Admission|Patients admitted for acute decompensated heart failure
9799985|NCT01675596|Experimental|Test|SAPIEN XT™ valve with the NovaFlex and NovaFlex+ delivery systems.
9799986|NCT01675622|Experimental|Oxycodone Capsules for cancer pain|
9799987|NCT01675622|Active Comparator|Morphine tablets for cancer pain|
9799988|NCT01675635|Experimental|OxyNorm Capsules|To determine the efficacy and safety of OxyNorm Capsules.
9799989|NCT01675635|Active Comparator|Morphine tablet|To determine the efficacy and safety of Morphine tablet.
9799990|NCT01675661|Active Comparator|NAC plus CM|N-acetylcysteine (NAC) plus Contingency Management (CM)
9799991|NCT01675661|Placebo Comparator|Placebo plus CM|Placebo plus Contingency Management (CM)
9799992|NCT01675765|Experimental|Immunotherapy plus chemotherapy|"Weeks 1 and 3: CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: CRS-207~Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression"
9799993|NCT01675765|Experimental|Immunotherapy with cyclophosphamide plus chemotherapy|"Weeks 1 and 3: cyclophosphamide (200 mg/m^2), CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: cyclophosphamide one day before CRS-207~Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression"
9799994|NCT01675778|Other|Hydromorphone|Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
9799995|NCT01675830|Experimental|Head Retention Head Wrap device|All subjects recieved the experimental intervention with the Heat Retention Head Wrap device for during the rewarming phase of cardiopulmonary bypass surgery.
9799996|NCT01675882|Experimental|Viaskin Peanut 50 mcg|
9799997|NCT01675882|Experimental|Viaskin Peanut 100 mcg|
9799998|NCT01675882|Experimental|Viaskin Peanut 250 mcg|
9799999|NCT01675882|Placebo Comparator|Viaskin Placebo|
10209407|NCT04398862||Children with Down syndrome and aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
10209408|NCT04398862||Children with Down syndrome without aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
10209409|NCT04397614|Experimental|No Elevated Risk for COVID-19 Detected|Continue daily mHealth assessments
9794616|NCT01513291|Placebo Comparator|Placebo|Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
9794617|NCT01513317|Experimental|Siltuximab|15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
9794618|NCT01513317|Experimental|Placebo|Placebo administered as a 1-hour infusion every 4 weeks + BSC
10209410|NCT04397614|Experimental|Elevated Risk for COVID-19 Detected|Daily mHealth assessments and telemedicine/nurse triage. If non-emergent intervention, enhanced symptom monitoring will occur.
10209411|NCT04382755|Active Comparator|Group A (active)|Standard of Care (SoC) + subcutaneous Zilucoplan® + prophylactic antibiotics until 14 days after last Zilucoplan®
10209412|NCT04382755|Placebo Comparator|Group B (control)|Standard of Care (SoC) + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
10209413|NCT04379154|Experimental|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air in patients hospitalised for COVID-19 infection
10209414|NCT04377334|Experimental|MSC Treatment|
10209415|NCT04377334|No Intervention|control|
10209416|NCT04373226|Experimental|22q11.2DS|Children aged from 4 to 11 years old with 22q11.2 deletion syndrome
9794619|NCT01513330|Experimental|First Standard Care, then SenSura Mio|Subjects first test Standard Care (Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima) and after cross-over SenSura Mio
9794620|NCT01513330|Experimental|First SenSura Mio, then Standard Care|Subjects first test SenSura Mio and after cross-over Standard Care(Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima)
9794621|NCT01513447|Active Comparator|Sterile Water Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
9794622|NCT01513447|Placebo Comparator|Normal Saline Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
9794623|NCT01513460|Experimental|NVA237 + Fluticasone/Salmeterol (Flu/Sal)|NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
9794624|NCT01513460|Active Comparator|Tiotropium + Flu/Sal|Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
9794625|NCT01513460|Placebo Comparator|Flu/Sal|Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
9794626|NCT01513473|Experimental|Insulin Degludec + Insulin Aspart|
9794627|NCT01513473|Experimental|Insulin Detemir +Insulin Aspart|
9794628|NCT01513538||TherapyGuide|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function
9794629|NCT01513551|Experimental|V114|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
9794630|NCT01513551|Active Comparator|PNEUMOVAX® 23|Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
9794631|NCT01513551|Active Comparator|PREVNAR 13®|Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.
9794632|NCT01513590|Experimental|IDegAsp BID|
9794633|NCT01513590|Active Comparator|BIAsp 30 BID|
9794634|NCT01513759|Experimental|EkoSonic® Endovascular System|Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
9794635|NCT01513902|Experimental|Cohort 1|Ages 12 to less than 18
9794636|NCT01513902|Experimental|Cohort 2|Ages 6 to less than 12
9794637|NCT01513902|Experimental|Corhort 3|Ages 2 to less than 6
9794638|NCT01513967|Experimental|Part A, SAD Treatment 1|RPh201 single dose (SAD Low Dose )
9794639|NCT01513967|Placebo Comparator|Part A, SAD Placebo 1|Placebo single dose (SAD Low Dose )
9794640|NCT01513967|Experimental|Part A, SAD Treatment 2|RPh201 single dose (SAD Mid Dose )
9794641|NCT01513967|Placebo Comparator|Part A, SAD Placebo 2|Placebo single dose (SAD Mid Dose )
9794642|NCT01513967|Experimental|Part A, SAD Treatment 3|RPh201 single dose (SAD High Dose )
9794643|NCT01513967|Placebo Comparator|Part A, SAD Placebo 3|Placebo single dose (SAD High Dose )
9794644|NCT01513967|Experimental|Part B, MAD Treatment 1|RPh201 multiple dose (MAD Low Dose )
9794645|NCT01513967|Placebo Comparator|Part B, MAD Placebo 1|Placebo multiple dose (MAD Low Dose )
9794646|NCT01513967|Experimental|Part B, MAD Treatment 2|RPh201 multiple dose (MAD Mid Dose )
9794647|NCT01513967|Placebo Comparator|Part B, MAD Placebo 2|Placebo multiple dose (MAD Mid Dose )
9794648|NCT01513967|Experimental|Part B, MAD Treatment 3|RPh201 multiple dose (MAD High Dose )
9794649|NCT01513967|Placebo Comparator|Part B, MAD Placebo 3|Placebo multiple dose (MAD High Dose )
9794650|NCT01514136|Experimental|One arm|The arm consists of two periods: in period one, products are tested in the order A, B, C, D, and in period two, products are tested in the order A*, B*, C*, D*.
9794651|NCT01514149|Experimental|Arm 1 - Weekly CJC-1134-PC|
9794652|NCT01514149|Experimental|Arm 2 - Weekly CJC-1134-PC|
9794653|NCT01514149|Experimental|Arm 3 - Weekly CJC-1134-PC|
9794654|NCT01514149|Experimental|Arm 4 - Weekly CJC-1134-PC|
9794655|NCT01514149|Placebo Comparator|Arm 5 - Weekly Placebo|
9794656|NCT01514162|Experimental|Trifecta Valve Group|Subjects implanted with a Trifecta valve.
9794657|NCT01514201|Experimental|Treatment (veliparib, temozolomide, 3D-CRT, IMRT)|"DOSE-ESCALATION: Patients receive veliparib PO BID 5 days a week for 6-7 weeks. Patients also undergo concurrent 3D-CRT or IMRT QD 5 days a week for 6-7 weeks.~MAINTENANCE THERAPY: Beginning 3-4 weeks later, patients receive veliparib PO BID on days 1-5 and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
9794658|NCT01514240|Experimental|D9421-C|D9421-C 9 mg once daily
9794659|NCT01514240|Active Comparator|Mesalazine|Mesalazine 1 g three times a day
9794660|NCT01514279|Experimental|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
9794661|NCT01514279|Experimental|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines
9794662|NCT01514279|No Intervention|Tools4CHANGE|In contrast to the behavioral arms, youths with their parent(s)/guardian randomized to this group will have one 60-minute face-to-face meeting at initiation of the study with a dietitian who is also trained in recommendations for exercise and sedentary behavior.
9794663|NCT01514292|Experimental|Real Time Continuous Glucose Monitoring System|7 day use of real time continuous glucose monitoring system
9794664|NCT01514318||Revelation|Subjects who received the Revelation Hip Stem prior to 2002 and have agreed to come into the office for a single visit.
9794665|NCT01514357|Other|Nesiritide (BNP)|Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.
9794666|NCT01514357|Placebo Comparator|Placebo|Subjects will receive SQ placebo bid for seven consecutive days.
9794667|NCT01514370|Experimental|IFN beta 1a 44 mcg TIW + curcumin (BCM95)|
9794668|NCT01514370|Placebo Comparator|IFN beta 1a 44 mcg TIW + placebo|
9794669|NCT01514383|Experimental|Surgical Adhesive|The surgical adhesive (cyanoacrylate) will be used once to close the topical skin surgical incision created during surgical procedures.
9794670|NCT01514396|Experimental|Surgical Glue|Surgiseal
9794671|NCT01514422|Experimental|Minocycline|All subjects will be given minocycline over 8 weeks
9794672|NCT01514448|Experimental|Everolimus|Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
9794673|NCT01514461|Experimental|LCQ908 20 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
9794674|NCT01514461|Experimental|LCQ908 40 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
9794675|NCT01514461|Placebo Comparator|Placebo|"In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
9794676|NCT01514513|Experimental|Licefreee Spray|
9794677|NCT01514513|Active Comparator|Nix Creme Rinse, 1% Permethrin|
9794678|NCT01514630|Experimental|Creatine monohydrate|14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.
9986444|NCT01402921|Experimental|Elastic Medical Compressive Therapy|"V0322BC verum medical compressive therapy is a progressive compressive sock with:~ankle pressure: 10 mmHg~calf pressure : 23 mmHg"
9986445|NCT01402921|Placebo Comparator|Placebo|"V0322BC placebo medical compressive therapy is a progressive compressive sock with:~ankle pressure: <5 mmHg~calf pressure : <7 mmHg"
9794679|NCT01514734|Experimental|AZARGA|Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks
9794680|NCT01514760|Experimental|Mobile-based Asthma Action Plan|The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts.
9794681|NCT01514786|No Intervention|Control|Same information is presented in the control website as is found in the intervention website, but no interactive component: preferences and risk assessment.
9794682|NCT01514786|Active Comparator|Intervention with Colorectal Website|Intervention website includes an interactive component including preferences and risk assessment.
9794683|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)|Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
9794684|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With DDR2 Mutation)|Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
9794685|NCT01515046|Experimental|Gemcitabine with escalating IV ascorbate|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle."
9794686|NCT01515072|No Intervention|No Remote Ischemic Preconditioning|The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
9794687|NCT01515072|Experimental|Remote Ischemic Preconditioning|The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
9794688|NCT01515176|Experimental|Treatment (ofatumumab, dinaciclib)|Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
9794689|NCT01515189|Experimental|Arm 1: Ipilimumab (3 mg/kg)|Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
9794690|NCT01515189|Experimental|Arm 2: Ipilimumab (10 mg/kg)|Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
9794691|NCT01515319|Experimental|2mg Y242 (Part A)|Y242 single dose, subcutaneous
9794692|NCT01515319|Experimental|7.5mg Y242 (Part A)|Y242 single dose, subcutaneous
9794693|NCT01515319|Experimental|15mg Y242 (Part A)|Y242 single dose, subcutaneous
9794694|NCT01515319|Experimental|30mg Y242 (Part A)|Y242 single dose, subcutaneous
9794695|NCT01515319|Experimental|60mg Y242 (Part A)|Y242 single dose, subcutaneous
9794696|NCT01515319|Experimental|90mg Y242 (Part A)|Y242 single dose, subcutaneous
9794697|NCT01515319|Placebo Comparator|Placebo - Part A|0.9% saline
9794698|NCT01515319|Experimental|60mg Y242 (Part B1)|Y242 single subcutaneous dose, administered once a week for 5 weeks
9794699|NCT01515319|Experimental|90mg Y242 (Part B2-B4)|Y242 single subcutaneous dose, administered once a week for 5 weeks
9794700|NCT01515319|Placebo Comparator|Placebo - Part B|0.9% saline
9794701|NCT01515345|Active Comparator|standard therapy|standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
9794702|NCT01515345|Experimental|individualized therapy|dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer
9794703|NCT01515410|Experimental|DM-1992|DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
9794704|NCT01515410|Active Comparator|Sinemet IR|An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
9794705|NCT01515423|Experimental|Paliperidone palmitate 3-month (PP3M)|A formulation of paliperidone palmitate with a 3-month injection interval
9794706|NCT01515423|Active Comparator|Paliperidone palmitate 1-month (PP1M)|A formulation of paliperidone palmitate with a 1-month injection interval
9794707|NCT01515475|Active Comparator|Glasses|Glasses are prescribed at enrollment and worn per protocol throughout the duration of the study.
9794708|NCT01515475|Placebo Comparator|Observation|Glasses will not be prescribed unless the patient has confirmation of one or more deterioration criteria as described in the protocol.
9794709|NCT01515488|Experimental|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
9794710|NCT01515488|Experimental|Nurse-initiated triage|Nurse-initiated triage for obtaining medical history and presenting problem(s)
9794711|NCT01515540|Active Comparator|lidocaine|5% lidoderm patch
9794712|NCT01515540|Placebo Comparator|control|placebo patch
9794713|NCT01515566|Experimental|Fentanyl|Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
9858967|NCT01335997|Experimental|ERN/LRPT/SIM → ERN/LRPT+SIM|Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.
9858968|NCT01335997|Active Comparator|ERN/LRPT+SIM → ERN/LRPT/SIM|Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.
9858969|NCT01340885|Active Comparator|atomoxetine|Strattera 10-30 mg b.i.d.
9858970|NCT01340885|Active Comparator|rivastigimine|Exelon 1.5-4.5 mg b.i.d.
9858971|NCT01340885|Placebo Comparator|Placebo|sugar pill
9858972|NCT01341587|No Intervention|Control|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
9858973|NCT01341587|Active Comparator|Intervention|"Home diabetes monitoring by patient using cellular enabled glucometer to communicate information and receive feedback.~Care provider can access raw and analyzed patient data; Physician receives report summary."
9858974|NCT01326923|Other|Single arm|Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
9858975|NCT01332799|Active Comparator|Allopurinol|
9858976|NCT01332799|Placebo Comparator|Placebo (sugar pill)|
9924271|NCT00859768|Experimental|Intervention group 2|No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
9924272|NCT00859768|No Intervention|Control group 1|Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
9924273|NCT00859768|No Intervention|Control group 2|No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
9924274|NCT00859807|Experimental|Sequence 1 (19 subjects)|"Period 1: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment.~Period 2: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis); reference treatment)."
9924275|NCT00859807|Experimental|Sequence 2 (19 subjects)|Period 1: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis Period 2: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment
10209417|NCT04373226|Active Comparator|NON22q11.2DS|Children aged from 4 to 11 years old without developmental disease
10209418|NCT04370054|Experimental|PF-07055480 (giroctocogene fitelparvovec)|Single administration of PF-07055480
9924276|NCT00859846|Experimental|Long Axis arterial line placement|Twenty four patients will undergo arterial line placements using long axis arterial line placement under ultrasound.
9924277|NCT00859846|Experimental|Short Axis arterial line placement|Twenty four patients will undergo arterial line placements using short axis arterial line placement under ultrasound.
9924278|NCT00859846|Active Comparator|Palpation arterial line placement|Twenty four patients will undergo arterial line placements using Traditional palpation arterial line placement.
9935141|NCT04113382|Experimental|Participants aged 2 to <4 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (½ bottle [approximately 80 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL."
9935142|NCT04113382|Active Comparator|Participants aged 2 to <4 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 4 ounce (oz) for every 30 minutes, one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
9986446|NCT01402934|Experimental|fluid infusion|
9986447|NCT01402960|Experimental|Active Anodal HD-tDCS|Subject will receive one 20-minute session of active anodal HD-tDCS.
9986448|NCT01402960|Experimental|Active Cathodal HD-tDCS|Subject will receive one 20-minute session of active cathodal HD-tDCS.
9986449|NCT01402960|Sham Comparator|Sham HD-tDCS|Subject will receive one sham session of HD-tDCS
9986450|NCT01402973|Experimental|High-AGE Diet|The high-AGE diet will be approximately four times higher in AGEs than the low-AGE diet.
9986451|NCT01402973|Experimental|Low-AGE Diet|The low-AGE diet will be approximately four times lower in AGEs than the high-AGE diet.
9996943|NCT01504529||Neupro Treatment|Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
9996944|NCT01504542|Experimental|Low-dose HS-110|2,000,000 cells/0.5mls + erlotinib 150mg orally once daily
10209419|NCT04369755|Other|MRI|A MRI on PTX mode will be done on healthy subjects (approx. 90 min of sequences)
10209420|NCT04365114||Single reading|Only one clinician examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
10209421|NCT04365114||Double reading|Two clinicians examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
10209422|NCT04360980|Active Comparator|Intervention|40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment
10209423|NCT04360980|No Intervention|Standard treatment|40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days
9858977|NCT01329549|Experimental|BIBF 1120 (low) + Carboplatin + PLD|BIBF 1120 (low dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
9858978|NCT01329549|Experimental|BIBF 1120 (medium) + Carboplatin + PLD|BIBF 1120 (medium dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
9858979|NCT01329549|Experimental|BIBF 1120 (high) + Carboplatin + PLD|BIBF 1120 (high dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
9858980|NCT01326845|Experimental|Deferasirox am|Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
9858981|NCT01326845|Experimental|Deferasirox pm|Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal
9858982|NCT01329341|Experimental|Arm 1|Service Dogs
9858983|NCT01319760|Sham Comparator|Standard of care|Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
9858984|NCT01319760|Experimental|Impella 2.5|24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
9858985|NCT01320683|Experimental|Treatment (combination chemotherapy and radioimmunotherapy)|FOLFOX* + BEVACIZUMAB CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 12 courses in the absence of disease progression or unacceptable toxicity. RIT: Within 4-12 weeks after completion of post-hepatic resection therapy chemotherapy, patients receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes. Treatment repeats every 6-10 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. NOTE:*Patients previously failing oxaliplatin regimen receive FOLIFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, leucovorin calcium over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9858986|NCT01313273|Other|Arm A|
9858987|NCT01313273|Experimental|Arm B|
9858988|NCT01321008|Experimental|Radiation + Chemotherapy|Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.
9858989|NCT01310803|Experimental|Maintenance therapy|Chemotherapeutic: EN3329-301 (VALSTAR)
9858990|NCT01310803|Other|No Maintenance (Standard of care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
9858991|NCT01309581|Experimental|Ketamine|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
9858992|NCT01309581|Active Comparator|Methohexital|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
9858993|NCT01315873|Experimental|Bortezomib and Bendamustine|
9858994|NCT01313923|Experimental|Sirolimus (formerly known as Rapamycin)|Subjects with stable pemphigus vulgaris already on treatment with prednisone will be enrolled. Subjects will start taking oral sirolimus and have it up-titrated while decreasing the prednisone dosage. Their disease state will be monitored during this time.
9858995|NCT01321697||Vulvar Cancer|
9858996|NCT01312428|Other|Pelvic Alignment Level (PAL)|Pelvic Alignment Level Instrument Used
9858997|NCT01312428|Other|No Pelvic Alignment Level (PAL)|No Pelvic Alignment Level Instrument Used
9858998|NCT01313416|Experimental|Single arm|Combination CT-011 and Gemcitabine
9858999|NCT01303003|Experimental|Treatment Arm 1|Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
9986452|NCT01403025||Liraglutide|
9859000|NCT01303003|Active Comparator|Treatment Arm 2|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
9859001|NCT01302444|Active Comparator|Tadalafil|first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
9859002|NCT01302444|Placebo Comparator|Placebo|first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks
9859003|NCT01301963|Active Comparator|Arm I|Patients receive G-CSF SC QD on days 1-4.
9859004|NCT01301963|Experimental|Arm II|Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
9859005|NCT01298921|Active Comparator|Continous Flow Oxygen|
9859006|NCT01298921|Experimental|Oxygen Demand Valve|
9859007|NCT01292070|Experimental|Control-Experimental arm|Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).
9859008|NCT01292265|Experimental|CZP 200 mg|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
9859009|NCT01290822|Experimental|BiVP Pacing|BIVP optimize AVD, VVD, and LVPS parameters and assess the effect on cardiac output.
9859010|NCT01290822|Active Comparator|AAI Pacing|Traditional atrial (AAI) pacing
9859011|NCT01290718|Experimental|Single Arm|
9859012|NCT01293123|Experimental|Raltegravir|
9859013|NCT01293123|Active Comparator|Efavirenz|
9859014|NCT01294046|Experimental|Deep brain stimulation of SPG for migraine|Electrical SPG for Treatment of Migraine
9924279|NCT00859872|Experimental|oral group|risperidone oral solution combination clonazepam oral
9859015|NCT01280643|Experimental|Arm A|Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
9859016|NCT01280643|Experimental|Arm B|Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
9859017|NCT01280643|Experimental|Arm C|Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.
9859018|NCT01280643|Experimental|Arm D|Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.
9859019|NCT01280643|Experimental|Arm E|Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
9859020|NCT01280643|Experimental|Arm F|Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
9859021|NCT01280643|Experimental|ARM G|Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.
9859022|NCT01280643|Experimental|Arm H|Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.
9859023|NCT01280643|Experimental|Arm I|Patients receive treatment as in Arm D.
9859024|NCT01281124|Experimental|Treatment (azacitidine)|Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9859025|NCT01272141|Experimental|Arm A: Lapatinib plus Everolimus|
9859026|NCT01282216|Active Comparator|Donor PCV13|Donors receive PCV13 prior to bone marrow donation.
9859027|NCT01282216|Active Comparator|Donor Havrix|Donors receive Havrix prior to bone marrow donation.
9859028|NCT01282216|Active Comparator|Recipient vaccine|Recipients receive Havrix and PCV13 post bone marrow transplant.
9859029|NCT01284491|Active Comparator|Standard of Care (SOC)|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
9859030|NCT01284491|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
9859031|NCT01284504|Experimental|Celecoxib|Celecoxib, 200 mg tab
9859032|NCT01284504|Placebo Comparator|Placebo|placebo, tab
9859033|NCT01269034|Experimental|Part A|Exenatide and long acting insulin before the boost.
9859034|NCT01269034|Active Comparator|Part B|Rapid and long acting insulin before the boost
9859035|NCT01269034|Active Comparator|Part C|long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost
9859036|NCT01269034|No Intervention|Healthy controls|healthy controls without any medication before the boost.
9859037|NCT01274533|Experimental|Lenalidomide|Oral lenalidomide is initiated on Day 1 of Cycle 1 and continues once daily days 1-21 of a 28 day cycle. Subjects may continue participation in the Treatment Phase of the study for 24 months unless disease progression or drug is discontinued for safety reasons.
9859038|NCT01279616|Experimental|Hematopoietic Stem Cell Transplant|Stem cell infusion on Day 0.
9859039|NCT01276054|Experimental|SNB plus ARM or ALND (+/- SNB) plus ARM|Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
9859040|NCT01276054|Active Comparator|SNB or ALND (+/- SNB)|Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
9859041|NCT01264965|Active Comparator|Acetaminophen|
9859042|NCT01264965|Active Comparator|Long Acting Oxycodone|
9859043|NCT01266824|Experimental|Proparacaine|Infants in this group will receive 1 drop of Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) into each eye prior to receiving mydriatic eye drops
9924280|NCT00859872|Active Comparator|IM group|haloperidol IM injection
9859044|NCT01266824|No Intervention|Standard of Care|Infants in this arm will not receive Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) prior to mydriatic eye drops.
9859045|NCT01274429|Experimental|Open label peanut flour|Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.
9859046|NCT01273064|Experimental|CTS-1027 60 mg + ribavirin + peglyated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
9859047|NCT01273064|Experimental|CTS-1027 30 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
9859048|NCT01273064|Experimental|CTS-1027 15 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
9859049|NCT01273064|Active Comparator|placebo + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.
9859050|NCT01274559|Experimental|Extended-release niacin/laropiprant|ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
9859051|NCT01274559|Placebo Comparator|Placebo|Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
9859052|NCT01270581|Experimental|High Flow Nasal Cannula|Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
9859053|NCT01270581|Active Comparator|Control Group- Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
9859054|NCT01269749|Other|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
9859055|NCT01269749|Other|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
9859056|NCT01270919|Other|BioDuct Meniscal Repair Device|BioDuct Meniscal Repair Device
9859057|NCT01262339|Active Comparator|Comparator of Hand A intervention vs Hand B|Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
9859058|NCT01267825|Experimental|CT-guided intervention|CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
9859059|NCT01267825|Active Comparator|Standard medical care|
9986453|NCT01403038|Experimental|Elagolix Dose Regimen 1|Elagolix Dose regimen 1 for 84 days
9859061|NCT01259284|Experimental|Atorvastatin|1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
9859062|NCT01259284|Experimental|Fish Oil Supplement|3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
10209424|NCT04358900||Mood disorder group|Participants must meet criteria for one of the following disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 criteria (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, cyclothymia. Multiple mood disorders are employed, in line with the Research Domain Criteria (RDoC; (53)) framework and the relative imprecision of current symptom diagnostic clusters for tracking treatment responses and course of disease. To ensure adequate representation across diagnostic categories (including controls), the investigators will cap enrollment of major mood disorders (MDD, BD type I/II) to 50%, PDD and cyclothymia to 25% and recruit a healthy comparison group to comprise the remaining 25% of the sample.
9859063|NCT01259284|Placebo Comparator|Placebo|4 capsules orally every morning and 3 every evening for 5 days pre-surgery.
9924281|NCT00859885||1|Patients who receive antithrombotic treatment only
9924282|NCT00859885||2|Patients who undergo percutaneous device closure
9986454|NCT01403038|Experimental|Elagolix Dose Regimen 2|Elagolix Dose Regimen 2 for 84 days
9986455|NCT01403038|Experimental|Elagolix Dose Regimen 3|Elagolix Dose Regimen 3 for 84 days
9986456|NCT01403038|Experimental|Elagolix Dose Regimen 4|"Elagolix Dose Regimen 4 for 84 days~Additional Dose Regimens may be added and will be administered for 84 days."
9859064|NCT01249157|Experimental|MRI and PEM scans|All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
9859065|NCT01263028|Experimental|Ergocalciferol supplementation|
9859066|NCT01256281|Experimental|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
9859067|NCT01253668|Experimental|Arm 1|Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity.
9859068|NCT01259024|Experimental|doxorubicin-eluting LC Bead|transarterial chemoembolization using doxorubicin-eluting LC Beads
9859069|NCT01251952|Experimental|Denileukin Diftitox (Ontak)|Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
9859070|NCT01251120|Experimental|1|
9859071|NCT01251120|Active Comparator|2|
9859072|NCT01248130|Active Comparator|Omega-3 Fatty Acid Treatment|
9859073|NCT01248130|Placebo Comparator|Placebo (Sugar Pill)|
9859074|NCT01243892||Cohort 1: IGHD participants|Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid [DNA] origin) (recombinant human growth hormone [rhGH]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
9859075|NCT01243892||Cohort 2: ISS participants|Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
9859076|NCT01246011|Experimental|Heparin PF4 antibody positive -Drug (argatroban and warfarin)|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
9859077|NCT01246011|No Intervention|Heparin PF4 antibody positive no drug|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
9986457|NCT01403038|Experimental|Elagolix Dose Regimen 5|Elagolix Dose Regimen 5 for 84 days
10209425|NCT04358900||Control group|Participants who do not meet the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, or cyclothymia.
9859078|NCT01246011|No Intervention|Heparin PF4 antibody negative|Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication
9859079|NCT01242020|Other|Lean Healthy Subjects|"Lean defined as (BMI ≥18 and ≤25)"
9859080|NCT01242020|Other|Obese Healthy Subjects|Obese grade I-II defined as (BMI>30 and ≤35)
9859081|NCT01244620|Experimental|Treatment A|sitaxsentan 100 mg QD for 6 days (Treatment A)
9859082|NCT01244620|Experimental|Treatment B|tadalafil 40 mg QD for 6 days
9859083|NCT01244620|Experimental|Treatment C|sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
9859084|NCT01244620|Experimental|Treatment D|sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
9859085|NCT01240304|Experimental|Gemcitabine, radiation therapy, surgery|
9859086|NCT01241279|Experimental|Crystalens AO|A silicone multi-piece accommodating intraocular lens
9859087|NCT01241279|Active Comparator|SoftPort LI61AO|A silicone multi-piece foldable aspheric intraocular lens
9859088|NCT01230788|Experimental|rituximab|study drug given
9859089|NCT01239680|Placebo Comparator|Ringer's Lactate and Placebo for Glutamine|Ringer's Lactate 1 liter once over 6 hours
9859090|NCT01239680|Experimental|Ringer's Lactate with 25 grams Glutamine|Ringer's Lactate with 25 grams Glutamine (1 liter) once over 6 hours
9859091|NCT01237613|Experimental|Artelon|This is an open, prospective study with an anticipated enrollment of 10 patients with chronic or repeat Achilles tendon rupture undergoing surgical repair augmented with Artelon® Tissue Reinforcement.
9859092|NCT01234103|Experimental|Preventing sexual health risks|The over goal is to prevent STIs, unintended pregnancies, and related behaviors including sexual risk, alcohol and other substance misuse
10209426|NCT04356404||Prospective group|Patients will be followed up until development of hepatitis flare or at 2 years after study recruitment. We plan to recruit 150 patients for the prospective cohort.
10209427|NCT04335214|Other|Interview|One to one interview with older people from moroccon origin in Belgium
10209428|NCT04334811|Other|Arm|No arm
10209429|NCT04333732|Experimental|M-M-R II ®|Education and surveillance plus M-M-R II ®
10209430|NCT04333732|Placebo Comparator|Placebo|Education and surveillance plus placebo
10209431|NCT04332588|Experimental|Herceptin monotherapy cohort|Herceptin monotherapy cohort. Locally advanced HER2+ breast cancer patients receiving neoadjuvant Herceptin monotherapy prior to combination therapy will undergo three contrast-enhanced [18F]FMISO PET/MRI scans. Each imaging session will be identical. Imaging session one will be after diagnosis and before beginning monotherapy. Imaging session two will be within 10 days prior to beginning combination therapy with targeted HER2 agents. Imaging session three will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
10209432|NCT04332588|Experimental|Combination therapy cohort|Locally advanced HER2+ breast cancer patients that receiving neoadjuvant combination therapy including Herceptin will undergo two contrast-enhanced [18F]FMISO PET/MRI imaging. Imaging session one will be after diagnosis and before beginning combination therapy. Imaging session two will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
10209433|NCT04331704|Experimental|Personalized Information|Participants randomized to this condition will complete a web-based questionnaire and then receive personalized information regarding their alcohol use and sexual health behavior. They will complete daily, phone-based IVR monitoring for assessment purposes and receive further personalized information based on their responses.
9794714|NCT01515566|Active Comparator|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
9800000|NCT01676012||five types of bronchoscopy|"Bronchoscopy will be performed in a standardized order using five different imaging modes.~Standard white light videobronchoscopy (WLB)~High Definition -Bronchoscopy~HD-bronchoscopy + surface enhancement (iScan-surface)~HD-bronchoscopy + tone enhancement (iScan-tone)~Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode"
9800001|NCT01676116|Experimental|Insulin degludec/liraglutide + OADs|
9800002|NCT01676116|Active Comparator|Liraglutide or exenatide + OADs|
10209434|NCT04331704|Active Comparator|Educational Information|Participants randomized to this condition will complete a web-based questionnaire and then receive educational material regarding their alcohol use and sexual health behavior. They will complete daily phone-based IVR monitoring for assessment purposes.
10209435|NCT04324437|Other|eRAPID online symptom monitoring in lung cancer|Two groups of patients with differing internet access: access from home or access in clinic only
10209436|NCT04323124|Experimental|Treatment|PF-07059013 assignment
10209437|NCT04323124|Placebo Comparator|Placebo|Placebo assignment
10209438|NCT04312178|Other|return vaginal self-swab by mail|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail
10209439|NCT04312178|Other|financial incentive mail-back vaginal self-swab|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail to obtain a cash incentive
10209440|NCT04312178|Other|handing over the vaginal swab to a professional|Socially disadvantaged women who have received a vaginal self-swab and need to report it to a health professional
9800003|NCT01676220|Experimental|HOE901-U300|
9800004|NCT01676220|Active Comparator|Lantus|
9800005|NCT01676311|Experimental|Huperzine A|Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
9924283|NCT00859911|Active Comparator|2|Thiamine Mononitrate 5mg, Riboflavin 2 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg
10209441|NCT04312178|Other|financial incentive the vaginal self-swab to a pro|Socially disadvantaged women who have received a vaginal self-swab and have to report it to a health professional to obtain a cash incentive
10209442|NCT04311034|Experimental|RC48|
10209443|NCT04306523||Observational Cohort|One group of 100 sets of twin infants, observed from 4 months of age until 2years of age.
10209444|NCT04305795|Other|Cohort 1L- HNSCC|Recurrent locally advanced and/or metastatic head and neck squamous cell carcinoma
10209445|NCT04305795|Other|Cohort 2- 1LcuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
10209446|NCT04305795|Other|Cohort 3- 2L CuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
10209447|NCT04305756|Experimental|Weight-based LMWH|"Participants will receive a weight-based dose of prophylactic enoxaparin.~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours"
10209448|NCT04305756|Active Comparator|Fixed LMWH|"Participants will receive a fixed dose of prophylactic enoxaparin.~For BMI <40: 40mg injected subcutaneously every 24 hours~For BMI > or = to 40: 40mg injected subcutaneously every 12 hours"
10209449|NCT04301934|Active Comparator|Vaginal Estrogen Therapy Group|Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
10209450|NCT04301934|Experimental|Laser Therapy Group|Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.
10209451|NCT04301258||Articular Cartilage Defect of the Knee|Patients, who undergo an articular cartilage repair of the knee using ProChondrix CR.
10209452|NCT04301258||Articular Cartilage Defect of the Ankle|Patients, who undergo an articular cartilage repair of the ankle using ProChondrix CR.
10209453|NCT04301258||Articular Cartilage Defect of the Foot|Patients, who undergo an articular cartilage repair of the foot using ProChondrix CR.
10209454|NCT04301258||Articular Cartilage Defect of the Hip|Patients, who undergo an articular cartilage repair of the hip using ProChondrix CR.
10209455|NCT04299776|Experimental|IPR therapy|Intrathoracic pressure regulation (IPR) therapy level of -10 cmH2O (-7 cmH2O for run-in) provided by the CirQPOD device during shoulder surgery in the sitting position
10209456|NCT04299776|Active Comparator|Standard airway|Standard airway pressure (PEEP of +5 cmH2O) during shoulder surgery in the sitting position
9800006|NCT01676311|Placebo Comparator|Placebo|Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
9800007|NCT01676415|Active Comparator|Prednisone|Oral steroid medication
9800008|NCT01676415|Active Comparator|Topical Mometasone|Topical steroid medication
9800009|NCT01676532||Students attending SBHC|Students who attend the SBHC from either Sprucecourt Public School or any other participating schools.
9800010|NCT01676714|Experimental|Dovitinib|500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.
9800011|NCT01676727||CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
9800012|NCT01676831|Experimental|topical resiquimod 0.06%|Topical resiquimod 0.06% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will be 3 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
9859093|NCT01234103|Other|Improving nutrition, fitness and injury prevention|The goals are: (1) maintain and improve nutrition and physical fitness through healthier lifestyle and food choices; (2) reduce the risk of sports or physical training injuries and learning how to treat injuries; and (3) Learn to recognize stress and the steps you can take to reduce stress
9859094|NCT01231750|Active Comparator|0.1% Capsaicin Cream|0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise
9859095|NCT01231750|Placebo Comparator|Placebo Cream|Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise
9859096|NCT01230307|Active Comparator|Vitamin D|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
10209457|NCT04296305|Experimental|Group A (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes."
10209458|NCT04296305|Experimental|Group B (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes."
9859097|NCT01230307|Placebo Comparator|Placebo|A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
10213619|NCT03682094|Experimental|Probiotic|The treatment will consist of VSL#3, 3 grams (g), taken orally once a day for 4 weeks. The VSL#3 will be delivered in the form of a sachet of freeze-dried powder. Participants will be instructed to mix the sachets with water to consume. Those participants taking thickened liquids will mix the sachet with liquids thickened to the level (nectar versus honey) prescribed by their clinician. In order to facilitate delivery of the probiotic solution throughout the oral cavity, participants will be instructed to swish the solution in the mouth for up to 10 seconds (as tolerated) prior to each swallow.
10213620|NCT03676218||Elderly cancer patients|
9859098|NCT01230489|No Intervention|Standard Care|This group will undergo the current standard of care for post operative exit sites at the involved institutions. This group will act as the control or the group to which the interventional group will be compared too.
9859099|NCT01230489|Experimental|MediHoney|This study group will have the dry 2 x 2 dressing replaced with a honey 2 x 2 dressing. Additionally all indentations in the exit site wound will be filled with honey ointment prior to the application of the dressing.
9859100|NCT01222871|Experimental|Triamcinolone|Triamcinolone soaked nasopore dressing
9859101|NCT01222871|Placebo Comparator|Control Group|Saline soaked sponge
9859102|NCT01219673|Placebo Comparator|Placebo|Placebo by mouth 2 times every day.
9859103|NCT01219673|Experimental|Armodafinil|Armodafinil 150 mg by mouth once a day.
9859104|NCT01219673|Experimental|Minocycline|Minocycline 100 mg by muth two times a day.
9859105|NCT01219673|Experimental|Bupropion|Bupropion 100 mg by mouth two times a day.
9859106|NCT01219673|Experimental|Armodafinil + Minocycline|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by mouth two times a day."
9859107|NCT01219673|Experimental|Armodafinil + Bupropion|"Armodafinil 150 mg by mouth once a day.~Bupropion 100 mg by mouth two times a day."
9859108|NCT01219673|Experimental|Minocycline + Bupropion|"Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
9859109|NCT01219673|Experimental|Armodafinil + Minocycline + Bupropion|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
9859110|NCT01223001|Active Comparator|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
9859111|NCT01223001|Placebo Comparator|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
10213621|NCT03674320|Placebo Comparator|Placebo|Placebo (saline) injections will be given via intramuscular injection at study weeks 2,3, 6, 7, 10, and 11.
9859112|NCT01217060|Experimental|Docetaxel + 5-FU + Radiation + Surgery|Docetaxel 20 mg/m2 given by vein (IV) once a week up to 5 1/2 weeks. Dexamethasone 10 mg IV 30 minutes prior to weekly Docetaxel. 5-FU 300 mg/m2 IV, continuously for 96 hours 5 days a week for about 5 1/2 weeks. Radiation 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks. Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
9859113|NCT01217047|Experimental|Group A|For 3 weeks, you will need to come to the ICSCI one (1) time per week during which you will perform FES cycling for 1 hour each.
9859114|NCT01217047|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
9859115|NCT01217047|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
9859116|NCT01217047|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
9859117|NCT01206101|Experimental|Liraglutide|
9859118|NCT01206101|Placebo Comparator|Liraglutide placebo|
9859119|NCT01216631|Active Comparator|IA steroid|Intra-articular injection of steroid (80mg depomedrone)
9859120|NCT01216631|Experimental|IA infliximab|intra-articular injection of 100mg infliximab
9859121|NCT01216631|Experimental|IV infliximab|intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
9859122|NCT01211756|Experimental|Oxytocin|20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.
9859123|NCT01211756|Placebo Comparator|Placebo|Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.
9859124|NCT01209520|Experimental|Adjuvant Chemotherapy + Vidaza|
9859125|NCT01207726|Experimental|Arm I (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-5 and 8-10 and entinostat PO QD on days 3 and 10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9859126|NCT01207726|No Intervention|Arm II (standard of care)|Patients receive standard of care.
9859127|NCT01206296|Experimental|Intraperitoneal Gemcitabine|Intraperitoneal Gemcitabine
9859128|NCT01207102|Experimental|Abraxane, Carboplatin|Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
9859129|NCT01213329|Experimental|Phase I: Alemtuzumab|During Phase I Portion: Each kidney transplant recipient received one 30mg dose (IV push)of Alemtuzmab in the operating room per Standard of Care.
9859130|NCT01202110|Experimental|Propranolol|Propranolol 1mg iv
9859131|NCT01202110|No Intervention|Control|Routine care
9859132|NCT01206439|Experimental|Nebivolol 5 or 10 mg, oral, daily|Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
9859133|NCT01204788|Experimental|Arm 1 (Prophylactic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
9859134|NCT01204788|Experimental|Arm 2 (Therapeutic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
9859135|NCT01200602|Experimental|Arm A|Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
9859136|NCT01200602|Active Comparator|Arm B|Patients have clinical observation for weight loss and gain for 4 weeks.
9859137|NCT01198548|Experimental|Treatment (FOLXFOX, bevacizumab, cholecalciferol)|Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
9859138|NCT01194908|Experimental|Arm A|Patients treated with decitabine and LBH589
9859139|NCT01194856|Active Comparator|Efavirenz 600 mg|Serving as the Control Arm - patients will maintain EFV-containing antiretroviral regimen
9859140|NCT01194856|Experimental|Arm B - Atazanavir/Ritonavir|Atazanavir 300 mg orally with Ritonavir 100 mg orally once daily for 96 wks
9859141|NCT01194427|Experimental|Vorinostat and Tamoxifen|Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.
9859142|NCT01193556|Active Comparator|Standard of Care|Traditional electrosurgery will be used for the tonsillectomy.
9859143|NCT01193556|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the tonsillectomy.
9859144|NCT01189435|Experimental|erlotinib|This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.
9859145|NCT01193530|Experimental|Bright Light Therapy|Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
9859146|NCT01193530|Placebo Comparator|Dim Red Light Therapy|Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.
9859147|NCT01182610|Experimental|Treatment group|"Panitumumab 9mg/kg on Days 1, 22, and 43~Paclitaxel 200mg/m2 on Days 1 and 22~Carboplatin AUC=6 on Days 1 and 22~5FU 225mg/m2/day on Days 1-15 and 22-36"
9859148|NCT01189071|Active Comparator|Darifenacin|3 days of preoperative darifenacin anticholinergic medication
9859149|NCT01189071|No Intervention|no pill|The control group will have the standard of care which is no preoperative anticholinegic medication.
9859150|NCT01183416|Experimental|3F8 monoclonal antibody and 13-cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. The patients are post-transplant and in 1st complete/very good partial remission (CR/VGPR),89 with no evidence of NB by standard studies, but are at high risk for relapse.
9859151|NCT01184456|Experimental|GanedenBC30, GBI-30, PTA-6086|
9859152|NCT01184456|Placebo Comparator|Placebo|
9859153|NCT01183221|Experimental|Syntocinon then Placebo|24IU intranasal oxytocin, minimum of 3 weeks off, then placebo
9859154|NCT01183221|Placebo Comparator|Placebo then Syntocinon|Placebo, minimum of 3 weeks off, then 24IU intranasal oxytocin or placebo
9859155|NCT01189227|Experimental|Arm 1: Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
9859156|NCT01189227|Experimental|Arm 2: Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
9859157|NCT01190306|Experimental|CXL Treatment|Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.
9859158|NCT01190306|Active Comparator|Sham Control|Eyes in the control group will be treated with riboflavin only.
9859159|NCT01179737|Experimental|Nilotinib|Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days
9859160|NCT01179737|Placebo Comparator|Placebo|Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
9924284|NCT00859911|Experimental|1|Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocobalamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
9924285|NCT00860002||1|Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)
9924286|NCT00860002||2|Laparoscopically aided myomectomy (LAM) versus LM
9924287|NCT00860002||3|LAM versus UMLT-M
9924288|NCT00860002||4|Mini laparotomy myomectomy (ML-M) versus UMLT-M
9924289|NCT00860002||5|Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)
9924290|NCT00860002||6|LUVO+LAM versus LUAO+LAM
9924291|NCT00860002||7|LUVO+LM versus LUAO+LM
9924292|NCT00860002||8|LUVO+UMLT-M versus LUAO+UMLT-M
9924293|NCT00860002||9|LUVO versus UMLT-UVO
9924294|NCT00860002||10|UMLT-UVO versus UMLT-UAO
9924295|NCT00860002||11|LUAO versus UMLT-UAO
9924296|NCT00860002||12|UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M
9924297|NCT00860002||13|LUVO versus LM
9924298|NCT00860002||14|LUVO versus LAM
9924299|NCT00860002||15|LUVO versus LUAO+LM
9924300|NCT00860002||16|LUVO versus LUAO+UMLT-M
9924301|NCT00860002||17|LUVO versus LUAO+LAM
9924302|NCT00860041||Group I|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
9924303|NCT00860041||Group II|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
9924304|NCT00860041||Group III|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
9924305|NCT00860041||Group IV|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
9924306|NCT00860054|Experimental|Medium Phytosterols|Diets with daily 400 mg of phytosterols
9924307|NCT00860054|Experimental|High Phytosterols Diet|Diet with 2000 mg of daily phytosterols
9924308|NCT00860054|Placebo Comparator|Low Phyto Diet|Diet with less than 100 mg of daily phytosterols
9924309|NCT00860080|Experimental|PXL01|Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
9924310|NCT00860080|Placebo Comparator|Placebo|One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
9924311|NCT00860093|Experimental|1|MPC-5971
9924312|NCT00860093|Placebo Comparator|2|placebo identical in appearance to study drug
9924313|NCT00860106|Other|Follow up|"ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).~Phone follow up for 2 years."
9924314|NCT00860119|Experimental|Sublingual tablet|Test treatment
9924315|NCT00860119|Experimental|Oral tablet|Reference treatment
9924316|NCT00860132||2|a group of consecutive hip fracture patients admitted to a dedicated comprehensive orthogeriatric ward and a group of similar patients admitted to an orthopedic ward and later on transferred to geriatric rehab center
9924317|NCT00860145|Experimental|radiosurgery|Radiosurgical treatment of the medial temporal lobe
9924318|NCT00860145|Active Comparator|temporal lobectomy|Resection of medial temporal lobe
9924319|NCT00860184||50-79% stenosis|Subjects with 50-79% stenosis of the carotid artery Absence of prior ischemic neurological symptoms Age 18 or older
9924320|NCT00860197|No Intervention|Control|No coffee
9924321|NCT00860197|Experimental|Group 1|Fully torrefied coffee
9924322|NCT00860197|Experimental|Group 2|Partially torrefied coffee
9924323|NCT00860223|Experimental|1|Digoxin alone
9924324|NCT00860223|Experimental|2|Digoxin plus neratinib
9924325|NCT00860236|Active Comparator|Psycoeducation/counseling|
9924326|NCT00860236|Active Comparator|Cognitive behavioural therapy|
9924327|NCT00860275|Active Comparator|BMS-708163 / Ketoconazole|
9924328|NCT00860275|Active Comparator|BMS-708163 / Fluconazole|
9924329|NCT00860301|Experimental|Acupuncture group|
9924330|NCT00860301|No Intervention|Control group|Infants come to the clinic six times, are left alone for five minutes with the acupuncture nurse who hold its hand and talks to it.
9924331|NCT00860327||Newborns|Newborns with hypoplastic left heart syndrome who are receiving a right ventricle to pulmonary artery shunt as first stage palliation.
9924332|NCT00860327||Infants|Infants who are undergoing complete repair for tetralogy of Fallot or similar pathology.
9924333|NCT00860340|Experimental|1|Study patient will take 100mg tablet of Spironolactone
9924334|NCT00860353|Experimental|1|
9924335|NCT00860353|Placebo Comparator|2|
9859161|NCT01183468|Experimental|Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs|Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
9859162|NCT01183468|Experimental|Part 1a (Aralast NP)-Subjects 8-15 Yrs|Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
9859163|NCT01183468|Experimental|Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
9859164|NCT01183468|Experimental|Part 1b (Aralast NP)-Subjects 8-17 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
9859165|NCT01181921|Experimental|Galantamine|
9859166|NCT01188798|Experimental|Transplant recipients receiving Methotrexate|Participants will be biologically stratified according to disease, donor, and KIR match. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
9859167|NCT01188798|Experimental|Transplant recipients receiving Pentostatin|Participants will be biologically stratified according to disease, donor, and KIR match.between donor and host.In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
9859168|NCT01174368|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
9859169|NCT01183897|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II study of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response in of primary refractory neuroblastoma in bone marrow (i.e., incomplete response to standard treatment).
9859170|NCT01183884|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.
9859171|NCT01183429|Experimental|3F8 and 13-cis-retinoic acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(8), patients no longer receive high dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles.
9859172|NCT01166178|Experimental|Zoledronic Acid|Participants received zoledronic acid infusion in addition to calcium and vitamin D
9859173|NCT01166178|Placebo Comparator|Placebo|Participants received placebo to zoledronic acid infusion in addition to calcium and vitamin D
9859174|NCT01176513|Experimental|GE 148-002|
9859175|NCT01165450|Active Comparator|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
9859176|NCT01165450|Placebo Comparator|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
9859177|NCT01179399|Experimental|TAK-960|
9859178|NCT01169753|Placebo Comparator|Placebo|Patients randomized to nonintervention will take a placebo every morning for 2 weeks.
9859179|NCT01169753|Experimental|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
9859180|NCT01171534|Active Comparator|Vessel Loop fasciotomy closure|Fasciotomy closure using vessel loops and staples.
9859181|NCT01171534|Experimental|DermaClose fasciotomy closure|Fasciotomy closure via DermaClose device
9859182|NCT01169610|Experimental|Varenicline|
9986458|NCT01403038|Experimental|Elagolix Dose Regimen 6|Elagolix Dose Regimen 6 for 84 days
9986459|NCT01403038|Experimental|Elagolix Dose Regimen 7|Elagolix Dose Regimen 7 for 84 days
9859185|NCT01163084|Experimental|Arm I (leuprolide acetate, goserelin acetate, vismodegib)|Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
9986460|NCT01403077|Experimental|Scaffold Treatment|
9986461|NCT01403103|Experimental|Treatment (chemoprevention)|Patients receive cholecalciferol orally (PO) 7 days prior to scheduled surgery or endorectal ultrasound. Patients with sigmoid colon cancer or clinical stage I rectal cancer would proceed with surgical resection without preceding chemoradiation and will have a portion of normal colorectal mucosa and tumor tissue obtained for research purposes.
9986462|NCT01403129||Keratoconus-Suspect|A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
9859186|NCT01163084|Active Comparator|Arm II (leuprolide acetate, goserelin acetate)|Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
9859187|NCT01166724|Active Comparator|Sirolimus|patients will be switched from Tacrolimus to Sirolimus
9859188|NCT01166724|No Intervention|Tacrolimus|Patient will stay on Tacrolimus
9859189|NCT01162382|Experimental|Transcranial Magnetic Stimulation|Open-label transcranial magnetic stimulation
9859190|NCT01157533|Experimental|Vancomycin Loading|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
9859191|NCT01162304|Active Comparator|ER Oxycodone vs IR Oxycodone|"Extended release Oxycodone to assess pain relief adverse effects, treatment satisfaction and impact of treatment on health related quality of life.~IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every four hours"
9859192|NCT01151904|Experimental|COMBIGAN® with Latanoprost|Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.
9859193|NCT01155518|Experimental|testosterone|intramuscular injections every 2 weeks
9859194|NCT01155518|Experimental|clomiphene|oral drug thrice a week
9859195|NCT01155518|Placebo Comparator|placebo for testosterone|placebo for testosterone arm
9859196|NCT01155518|Placebo Comparator|placebo for clomiphene|oral placebo for clomiphene arm
10209459|NCT04293094|Experimental|Dose Exploration Phase|Participants will receive AMG 650 in 1 of 3 alternative schedules. The maximum tolerated dose (MTD) of each schedule will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.
10209460|NCT04293094|Experimental|Dose Expansion Phase Group 1: TNBC|Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
9859197|NCT01155518|No Intervention|eugonadal obese|obese men with normal testosterone level
9859198|NCT01155518|No Intervention|lean|healthy lean men (control)
9859199|NCT01150409|Experimental|hydrocortisone|Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
9859200|NCT01150409|Placebo Comparator|Normal Saline (placebo)|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
9859201|NCT01151553|Other|Patients with CHF with CRT Therapy|Patients with CHF with CRT Therapy
9859202|NCT01148056|Experimental|Short course IMRT|Patients will receive short course IMRT (Intensity Modulated Radiation Therapy) prior to surgery. Dose will be 5 Gy x 5, followed by surgery the week after
9859203|NCT01147393|Experimental|All subjects|two weekly infusions of 90Y-epratuzumab tetraxetan in combination with four weekly infusions of 200 mg/m2 veltuzumab.
9859204|NCT01147042|Active Comparator|gp91 CGD with relatively high baseline superoxide|"Patients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production.~IFN-gamma was the administered intervention."
9859205|NCT01147042|Active Comparator|Autosomal Recessive CGD with p47|Patients with Autosomal Recessive Chronic Granulomatous Disease (CGD) with p47 phox mutation. IFN-gamma was the administered intervention.
9859206|NCT01147536|Experimental|HSPPC-96 Vaccine|Participants will receive up to 8 administrations of HSPPC-96 25 µg intradermally over 3 months (4 weekly doses, followed by 4 bi-weekly doses [at Weeks 14, 15, 16, 17 19, 21, 23, and 25 in Part 1a and at Weeks 1-4, 6, 8, 10, 12 in Part 1b). Participants will remain untreated with HSPPC-96 for the initial 3-month period in Part 1a for immune monitoring blood draw.
9859207|NCT01139996|Experimental|Transdermal Clonidine/Oral Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
10209461|NCT04293094|Experimental|Dose Expansion Phase Group 2: HGSOC|Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
10209462|NCT04288947|Other|Usual Care|Training of midwives on 4 respectful maternal care modules.
10209463|NCT04285892|Experimental|CAPA IVM|CAPA IVM is a 2-step In vitro Maturation system in which an additional culture step, in which the oocytes are kept in meiotic arrest by the presence of the C-type Natriuretic peptide (CNP) for 22-24 hours, is preceding the in vitro maturation step in which maturation medium is supplemented with amphiregulin (AREG). The 'IVM System' of Medicult-Origio is used as a base medium.
9859208|NCT01139996|Placebo Comparator|Comparator|Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet
9859209|NCT01142128|Active Comparator|Nexium alone|Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
9859210|NCT01142128|Placebo Comparator|Placebo to Nexium, alone|Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
10209464|NCT04285892|No Intervention|Standard IVM|The IVM is performed as a single step protocol in which oocytes are immediately exposed to in vitro maturation medium for 30 hours. This is the current standard procedure in the clinical practice using the commercially available 'IVM System' of Medicult-Origio. Standard IVM medium: 10% HSA + 75mIU/ml FSH + 100mIU/ml hCG
10209465|NCT04280549||Healthy Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
10209466|NCT04280549||Type 2 Diabetic Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
10213622|NCT03674320|Active Comparator|Testosterone Enanthate|Testosterone Enanthate (100mg men, 25mg women) will be given via intramuscular injection at study weeks 2, 3, 6, 7, 10 and 11.
9859211|NCT01142128|Active Comparator|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
9859212|NCT01142128|Placebo Comparator|Viokase 16 + placebo to Nexium|Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone
9859213|NCT01131884|Active Comparator|Fosamax|Fosamax at 70 mgs q weekly by mouth for the duration of the study.
9859214|NCT01131884|Placebo Comparator|Placebo Sugar Pill|Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
9859215|NCT01128114|Experimental|Quetiapine XR|Quetiapine fumarate (Seroquel XR)
9859216|NCT01126879|Experimental|Arm I|Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
9859217|NCT01126879|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
9859218|NCT01136811|Experimental|Computer assisted surgery|
9859219|NCT01139294|No Intervention|standard IV therapy|control arm of the study
9859220|NCT01139294|Experimental|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours
9859221|NCT01139125|Experimental|Cystagon, Cysteamine Bitartrate|We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.
9859222|NCT01136668|Experimental|Treatment group|Bupivacine-TAP block
9859223|NCT01136668|Active Comparator|Control Group|Bupivacaine- wound infiltration
9859224|NCT01133639|Placebo Comparator|Placebo|Placebo plus standard of care
9859225|NCT01133639|Experimental|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
9859226|NCT01131455|Active Comparator|Fusion+ACP+Autograft|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus, external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with dissection through the capsule and penetration to the joint. Standard debridement of the gutters, tibia osteophyte, tibia-talor joint resection and autograft preparation will be performed in the joint. Depending on randomization of the subject, (Autologous concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and reduced.
9859227|NCT01131455|Active Comparator|Fusion + ACP +DBM|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). Depending on the randomization of the subject, (Autologous Concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
9859228|NCT01131455|No Intervention|Standard-Fusion +Autograft only|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with blunt dissection through the capsule and penetration to the joint. Depending on the randomization of the subject, ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
9859229|NCT01126801|Experimental|Estradiol|
9859230|NCT01126801|Placebo Comparator|Placebo control|
9859231|NCT01123850|Active Comparator|Single ARM - Copios Bone Filler|All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.
9859232|NCT01126957|Experimental|Ketamine|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
9859233|NCT01126957|Placebo Comparator|Placebo|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
9859234|NCT01127503|Experimental|Metyrosine|
9859235|NCT01127503|Placebo Comparator|Placebo|
9859236|NCT01122511|Experimental|700 ug dexamethasone and ranibizumab|Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
9859237|NCT01122511|Active Comparator|ranibizumab and sham|Intravitreal injection of ranibizumab and Sham into study eye
9859238|NCT01118013|Experimental|Treatment|"Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60.~Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover.~Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.~Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies.~After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years."
9859239|NCT01122381|Experimental|Arm 1-ethosuximide|"ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
9859240|NCT01122381|Placebo Comparator|Arm 2-placebo comparator|"placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
9859241|NCT01116232|Experimental|anti-thymocyte globulin, rituximab, sirolimus, tacrolimus,|"anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter~Rituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;~For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).~Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose."
9666948|NCT04102371|Active Comparator|"0.9% Normal Saline Fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
9859242|NCT01110174|Experimental|HD PET/CT|utilization of PET/CT for diagnostic of breast cancer progression.
9859243|NCT01115699|Experimental|Repetitive Transcranial Magnetic Stimulation|All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.
9859244|NCT01108666|Experimental|Proton RT and Nelfinavir|
9859245|NCT01115244|Experimental|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
9859246|NCT01115244|No Intervention|Not treated|One arm of the patient will be left untreated.
9859247|NCT01108523|Experimental|HP828-101|HP828-101 Experimental Formulation
9859248|NCT01106534|Placebo Comparator|12 month DAPT arm|placebo + aspirin
9859249|NCT01106534|Active Comparator|30 month DAPT arm|clopidogrel + aspirin OR prasugrel + aspirin
9859250|NCT01104116|Experimental|PET/CT imaging|Surgical patients will undergo [18F]-FDG PET/CT imaging
9859251|NCT01100658|Active Comparator|Methylphenidate|Administered 1 capsule each day for 1 week, .3 mg/kg dose.
9859252|NCT01100658|Placebo Comparator|Placebo|Administered 1 capsule each day for 1 week.
9859253|NCT01103180|Experimental|Escitalopram|10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
9859254|NCT01103180|Placebo Comparator|Placebo|Inert placebo (sugar pill) taken daily for eight weeks
9859255|NCT01090141|Active Comparator|Subjects recieving 100 mg of Micafungin|
9859256|NCT01090141|Active Comparator|Subjects recieving 300 mg of Micafungin|
9859257|NCT01102140|Active Comparator|POMx|15 subjects will received 1000 mg of oral POMx for 12 weeks.
9859258|NCT01102140|Placebo Comparator|Control- sugar Pill|15 subjects will receive a matching sugar pill for 12 weeks.
9859259|NCT01095250|Experimental|AIN457 300mg s.c every 2 weeks|AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks.
9859260|NCT01095250|Experimental|AIN457 300mg s.c. every 4 weeks|AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks.
9859261|NCT01095250|Experimental|AIN457 150mg s.c every 4 weeks|AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks
9859262|NCT01095250|Placebo Comparator|Placebo s.c every 2 weeks|Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks
9859263|NCT01094561|Experimental|Synthetic Human Secretin|Single arm (open label).
9859264|NCT01093846|Experimental|AIN457 300 mg every 2 weeks|
9859265|NCT01093846|Experimental|AIN457 300 mg monthly|
9859266|NCT01093846|Placebo Comparator|Placebo|
9859267|NCT01078844|Placebo Comparator|Placebo|Treatment as usual plus placebo
9859268|NCT01078844|Active Comparator|memantine|Treatment as usual plus memantine
9859269|NCT01081886|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
9859270|NCT01081886|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
9859271|NCT01085643|Active Comparator|Lubiprostone|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
9859272|NCT01085643|Placebo Comparator|Placebo|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
9859273|NCT01083472|Active Comparator|Strattice(TM) TM repair|Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
9859274|NCT01083472|Active Comparator|Standard of Care repair|Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh
9859275|NCT01080768|Experimental|Aliskiren/amlodipine + Placebo to amlodipine|"During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
9859276|NCT01080768|Active Comparator|Amlodipine + Placebo to aliskiren/amlodipine|"During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
9859277|NCT01079598|Other|Treatment|RF ablation with ClosureRFS Stylet
9859278|NCT01074502|Experimental|apremilast|apremilast 20 mgs twice a day for 12 weeks
9859279|NCT01074437|Other|Group A: Corticosteroid with Placebo|Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
9859280|NCT01074437|Other|Group B: Corticosteroid with Propranolol|Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.
9859281|NCT01069861|Experimental|one|
9859282|NCT01072526|Active Comparator|Intervention|Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) .
9859283|NCT01072526|Placebo Comparator|Control|Subjects will receive placebo in combination with cyclosporin solution (Restasis) .
9859284|NCT01071993|Active Comparator|atorvastatin|
9859285|NCT01071993|Placebo Comparator|placebo|
9859286|NCT01065051|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received a single oral dose of 1 mg riociguat.
9859287|NCT01065051|Placebo Comparator|Placebo|Participants received a single oral dose of 1 mg placebo.
9859288|NCT01069120|Active Comparator|50 mg Proellex®|2, 25 mg capsules
9859289|NCT01069120|Active Comparator|25 mg Proellex®|1, 25 mg capsule
9924336|NCT00860366|Experimental|Uric Acid|Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).
9924337|NCT00860366|Placebo Comparator|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
9859290|NCT01066637|Experimental|Dosimetry Group|To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.
9859291|NCT01066637|Experimental|Kinetic Analysis Group|Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
9859292|NCT01058642|Experimental|ADL5747|ADL5747 150 milligrams (mg) administered orally as 1 ADL5747 150-mg capsule and 1 placebo capsule twice daily (BID) for 14 days during 1 of 2 Treatment Periods.
9859293|NCT01058642|Placebo Comparator|Placebo|"Placebo: two placebo capsules administered orally BID for 14 days during 1 of 2 Treatment Periods.~Participants were also administered placebo orally BID during a 14-day washout period that took place between Treatment Period 1 and Treatment Period 2."
9859294|NCT01058642|Active Comparator|Pregabalin|Pregabalin administered orally as a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for the first 3 days, increased to a dose of 1 pregabalin 150-mg capsule and 1 placebo capsule BID for the last 11 days of 1 of 2 fourteen-day Treatment Periods, followed by a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for 3 days as a taper period.
9859295|NCT01065818|Experimental|Fluoro-L-Thymidine|Injection pre-Neoadjuvant Therapy (CRT, CT, or RT) and post-3 weeks Neoadjuvant Therapy (CRT, CT, RT)(3 weeks from the start of Neoadjuvant Therapy) prior to surgery.
9859296|NCT01051921|Experimental|CTS-1027, Peg IFN, Ribavirin|"Study drug (CTS-1027) plus Standard of Care treatment (pegylated interferon and ribavirin).~CTS-1027, 15 mg taken twice daily. Pegylated interferon, 180 μg injected once a week. Ribavirin, 1000 mg or 1200 mg daily (depending on patient weight), taken in two divided doses."
9859297|NCT01048125|Experimental|Study group|Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
9859298|NCT01048125|Active Comparator|Control|Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
9859299|NCT01056315|Experimental|A GRT3983Y|Participants randomly assigned to receive GRT3983Y.
9859300|NCT01056315|Placebo Comparator|B Placebo|Participants randomly assigned to placebo.
9859301|NCT01058369|Experimental|Deferasirox|
9859302|NCT01048723|Experimental|RAD001 Administration|RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.
9859303|NCT01053221|Experimental|MPA monotherapy|Subjects will discontinue calcineurin inhibitor (cyclosporine or tacrolimus) and remain on MPA (mycophenolate mofetil or mycophenolate sodium) monotherapy
9859304|NCT01053221|Active Comparator|Control: MPA and CNI|Subjects will continue with their current immunosuppressive regimen of MPA (mycophenolate mofetil or mycophenolate sodium) and calcineurin inhibitor (cyclosporine or tacrolimus)
9859305|NCT01038752|Experimental|Suramin|This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.
9859306|NCT01038752|Placebo Comparator|Standard of care|This group will receive placebo with docetaxel and carboplatin.
9859307|NCT01050218|Other|DVS SR Open Label|Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level.
9859308|NCT01045694|Experimental|Botulinum Toxin Type A|Arm investigates the efficacy of Botulinum Toxin A injection for the treatment of basal thumb joint arthritis
9859309|NCT01045694|Active Comparator|Steroid - Triamcinolone Acetonide|Arm uses the standard of care - Steroid injection - as an active comparator to the experimental injection of Botulinum Toxin A for the treatment of basal thumb joint arthritis
9859310|NCT01045694|Placebo Comparator|Lidocaine|Arm uses plain lidocaine injection to serve as a baseline for evaluating the efficacy of Botulinum toxin as compared to steroid injection for the treatment of basal thumb joint arthritis.
9859311|NCT01035944|Experimental|HemCon Operating Room|The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
9859312|NCT01035944|Active Comparator|Control Operating Room|The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
9859313|NCT01035944|Experimental|HemCon Bedside|The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
9859314|NCT01035944|Active Comparator|Control Bedside.|The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
9924338|NCT00860392|Experimental|1|Biomarker evaluation
9859315|NCT01031628|Active Comparator|Arm A|Patients with blood level less than 1100 will continue imatinib 400 mg daily
9859316|NCT01031628|Active Comparator|Arm B|Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
9859317|NCT01031628|Active Comparator|Arm C|Patients with blood level ≥1100 will continue imatinib 400 mg daily
9859318|NCT01031628|Active Comparator|Arm D|Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily
9859319|NCT01030757|Experimental|Tomotherapy|Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.
9859320|NCT01035073|Experimental|Duloxetine|
9859321|NCT01031550|Active Comparator|standard anesthetic management|standard anesthetic management with propofol 100-150mcg/kg/min
9859322|NCT01031550|Experimental|preconditioning with 2 MAC isoflurane group|After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).
9859323|NCT01030198|Experimental|Fresh surgical scars|Treatment of scars
9859324|NCT01030198|Experimental|Mature scars|Treatment of scars
9859325|NCT01028300|Other|ProDisc L|
9859326|NCT01025271|Other|open label|patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin
9859327|NCT01022398|Experimental|Vitamin D|Subjects will receive Vitamin D supplementation 10,000 international units of cholecalciferol (vitamin D3) by mouth weekly
9859328|NCT01022398|Placebo Comparator|Placebo|Subjects will receive placebo (an exact replica of the vitamin D capsule that does not contain any medically active substance) by mouth weekly
9859329|NCT01019980|Experimental|Diclofenac potassium|
9859330|NCT01019980|Active Comparator|Acetaminophen|
9859331|NCT01025492|Active Comparator|Trilipix|Trilipix (fenofibric acid) 135 mg tablet orally, once daily for 12 weeks
9859332|NCT01025492|Placebo Comparator|Placebo|Matching placebo tablet orally, once daily for 12 weeks
9859333|NCT01017263|Active Comparator|Open label Vyvanse|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
9924339|NCT00860418|Active Comparator|1|Standard asthma education delivered during 2 home visits by a nurse.
9924340|NCT00860418|Experimental|2 PAAL|PAAL
9924341|NCT00860431|No Intervention|1|Standard-of-care (conservative treatment)
9666949|NCT04101331|Experimental|Cohort A|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥10%
9924342|NCT00860431|Experimental|2|AST-120 6g/day (3 times a day)
9924343|NCT00860444|Active Comparator|1|Participants will take part in the basic educational and counseling program through their community health care center.
9924344|NCT00860444|Experimental|2|Participants will take part in the comprehensive educational and counseling program through their community health care center.
9924345|NCT00860483|No Intervention|observational|This is an observational study. no intervention occurs in subjects. their performance in a laparoscopic trainer is observed and correlated with brain activity
9924346|NCT00860496|Other|1|Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
9924347|NCT00860496|Other|2|Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.
9924348|NCT00860509|Placebo Comparator|Low Phytosterol Diet|Diet with 100 mg of daily phytosterols
9924349|NCT00860509|Active Comparator|High Phytosterol Diet|Diet with 600 mg of daily phytosterols
9859334|NCT01020903|Active Comparator|Aprepitant|
9859335|NCT01020903|Placebo Comparator|Placebo|
9859336|NCT01023620|Experimental|Pioglitazone|10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
9859337|NCT01023620|Sham Comparator|Observation/Comparison|10 male patients with lipodystrophy not taking daily Pioglitazone
9859338|NCT01018810|Experimental|180 mg LY2525623|
9859339|NCT01018810|Placebo Comparator|Intravenous Placebo|
9859340|NCT01018810|Placebo Comparator|Subcutaneous Placebo|
9859341|NCT01018810|Experimental|3 mg LY2525623|
9859342|NCT01018810|Experimental|10 mg LY2525623|
9859343|NCT01018810|Experimental|30 mg LY2525623|
9859344|NCT01018810|Experimental|90 mg LY2525623|
9859345|NCT01016561|Experimental|Arm I|Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
9859346|NCT01016847|Active Comparator|leukotriene receptor antagonist (LTRA) montelukast|Montelukast (LTRA) administered with moderate dose of inhaled steroid
9859347|NCT01016847|Placebo Comparator|Sugar Pill|High dose of inhaled steroid administered with sugar pill
9859348|NCT01014767|Experimental|Standard Arm (1)|Alternating chemotherapy cycles with etoposide 100 mg/m2 over 1 hour on days 1-5, carboplatin 350 mg/m2 over 2 hours on day 2 and 3, vincristine 1.5 mg/m2 on day 5 alternating with: etoposide 100 mg/m2 over 1 hour on days 1-5, cyclophosphamide 1 g/m2 over 1 hour on day 2 and 3, vincristine 1.5 mg/m2 on day 5. Six blocks are given in 4 week intervals (day1 to day1). Radiation is given between the second and the third cycle only to a small subgroup of patients defined by age histology staging and response to the first to cycles of chemotherapy.
9859349|NCT01014767|Experimental|Doxorubicin/cisplatin arm (2)|Doxorubicin 25 mg/m²/day over 12 hrs on days 1-3, Dactinomycin 45 µg/kg/day (max. 2 mg), i.v. on day 1, and Cisplatin 70 mg/m²/d over 6 hrs on day 4, and Vincristine 1.5 mg/m²/day (max. 2 mg), i.v. on days 8, 15. An identical second cycle is started on day 28 if the side effects allow it. The further treatment is identical to the standard arm with four more cycles of chemotherapy following radiation in some of the patients in all treatment arms.
9859350|NCT01014767|Experimental|Methotrexate Arm (3)|Methotrexate 5g/m^2 over 24 hours with leucovorin rescue at hour 42 given three times on days 1 15 and 29. The further treatment is identical in all four treatment arms.
9859351|NCT01014767|Experimental|Temozolomide Irinotecan arm (4)|Temozolomide is given at 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day x 5 days as one hour infusions. Two of these cycles are followed by the common radiation - four cycle chemotherapy protocol.
9859352|NCT01013701|Active Comparator|Fluticasone Furoate|nasal steroid
9859353|NCT01013701|Placebo Comparator|Placebo|nasal spray vehicle without drug
9859354|NCT01012414|Experimental|oral paricalcitol 2 mcg daily|oral paricalcitol 2 mcg daily
9859355|NCT01012414|Placebo Comparator|Placebo|one oral placebo drug daily
9859356|NCT01011634|Active Comparator|Moderate sedation|
9859357|NCT01011634|Active Comparator|Oral medication|
9859358|NCT01009931|Experimental|TPA + Dexamethasone and CMT|12-O-tetradecanoylphorbol-13-acetate (TPA) plus Dexamethasone & Choline magnesium trisalicylate (Trilisate)
9859359|NCT01001390|Other|Group One|Group one will take a six minute walk test with AFO device, and after a rest of fifteen minutes, they will take another six minute walk test without AFO, with similar speed to the previous test.
9859360|NCT01001390|Other|Group Two|Group two will take a six minute walk test without AFO device, and after a rest of fifteen minutes, they will take another six minute walk test with AFO, with similar speed to the previous test.
9859361|NCT01006018|Experimental|Sitagliptin + Pioglitazone PLACEBO|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone PLACEBO daily by mouth"
9859362|NCT01006018|Experimental|Sitagliptin + Pioglitazone|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone (TZD) 15 mg daily by mouth"
9859363|NCT01006018|Placebo Comparator|PLACEBO|"Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth~+ pioglitazone (TZD) PLACEBO daily by mouth"
9859364|NCT01004510|Experimental|Zoledronic Acid|Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.
9859365|NCT01005914|Experimental|Group 1|"Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3~Drug:cytarabine Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4~Drug:dexamethasone Day 1-4; 11-14: 40 mg daily~Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours~Drug:imatinib mesylate 600 mg/day~Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion~Drug: methylprednisolone Day 1-3: 50mg IV BID~Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV~Drug: vincristine sulfate Day 4 & 11: 2 mg IV"
9859366|NCT00996333|Experimental|Gemzar, Taxotere, Xeloda|"Gemcitabine, Docetaxel, Capecitabine:~Gemzar intravenously on Day 4 and 11 Taxotere intravenously on Day 4 and 11 Xeloda tablet taken orally every day for 14 days"
9859367|NCT00998738|Experimental|Arm I (calcium gluconate, magnesium sulfate)|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after each ixabepilone administration.
9859368|NCT00998738|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 30 minutes immediately before and after each ixabepilone administration.
9859369|NCT00996502|Experimental|Combination regimen|"Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation)~Phase I:~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid"
9859370|NCT00997386|Experimental|busulfan, and melphalan, and alemtuzumab|Three drug regimen using busulfan, and melphalan, and alemtuzumab.
9859371|NCT00985738|Experimental|Dutasteride|The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
9859372|NCT00985738|Placebo Comparator|Placebo|The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
9859373|NCT00986999|Experimental|rosuvastatin|rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
9859374|NCT00989937|Experimental|Group 1|20 IU BID for the first week, 40 IU BID for the following two weeks, one week washout, 3 week placebo trial
9859375|NCT00989937|Placebo Comparator|Group 2|Three week placebo trial, one week washout, 20 IU BID for the fifth week, 40 IU BID for the following two weeks
9859376|NCT00986947|Experimental|IvIg with Rituximab|
9859377|NCT00982995|Experimental|Palonosetron|Palonosetron 0.25 mg I.V. bolus
9859378|NCT00984490|Experimental|Metformin|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
9859379|NCT00986310|Active Comparator|fluoxetine|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
9859380|NCT00986310|Placebo Comparator|Placebo|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
9859381|NCT00978874|Experimental|All subjects|
9859382|NCT00983645|Active Comparator|Neoral|Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
9859383|NCT00983645|Active Comparator|Prograf|Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
9859384|NCT00979147|Experimental|Modular Metal Tibial Baseplate|Patients who were randomized to receive the modular polished tibial baseplate/XLK TKA
9859385|NCT00979147|Active Comparator|All Polyethylene Tibial Baseplate|Patients who were randomized to receive the nonmodular APT/GVF TKA design.
9859386|NCT00970606|Placebo Comparator|Placebo tablet|Placebo
9859387|NCT00970606|Experimental|Rosuvastatin (crestor)|Experimental arm
9859388|NCT00979550|Experimental|Aldara cream|Imiquimod (Aldara cream) will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
9859389|NCT00979550|Placebo Comparator|non-medicated petroleum cream|Non-medicated petroleum cream will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
9859390|NCT00966992|No Intervention|Arm 1 (No Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
9859391|NCT00966992|Experimental|Arm 2 (Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.
9859392|NCT00981370|Other|Single Arm study|Single Arm study, all subjects to receive study medication, deferasirox (Exjade).
9859393|NCT00975611|Active Comparator|Amantadine 100mg BID|Subjects take amantadine 100mg tablets twice per day (BID)
9859394|NCT00975611|Active Comparator|Amantadine, 200mg BID|Subjects take amantadine 200mg tablets twice per day (BID)
9859395|NCT00975611|Placebo Comparator|Amantadine, placebo BID|Subjects take placebo tablets twice per day (BID)
9859396|NCT00978419|Active Comparator|Rosuvastatin|Rosuvastatin
9859397|NCT00978419|Placebo Comparator|Placebo|Placebo
9859398|NCT00973856|Experimental|PURELL Left Hand/ Placebo Right Hand|"One product will be assigned to each hand to minimize treatment confusion for the participants.~PURELL VF481 Left Hand/ Placebo Right Hand"
9859399|NCT00973856|Placebo Comparator|Placebo Solution Left Hand/ PURELL Right hand|"One (1) product will be assigned to each hand to minimize treatment confusion for the participants PURELL VF481 Right Hand/ Placebo Left Hand~One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed"
9859400|NCT00979810|Experimental|18F-FLT PET scan|This is a pilot study intended to collect preliminary data on 15 patients diagnosed with untreated high-grade glioma who are scheduled to undergo surgical resection.
9859401|NCT00974922|Active Comparator|Phase I: Aliskiren|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Aliskiren 150 mg to 300 mg once daily for 6 weeks
9859402|NCT00974922|Active Comparator|Phase I: Cholecalciferol|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Cholecalciferol (3000 I.U.) once daily for 6 weeks
9859403|NCT00974922|Active Comparator|Phase II: Aliskiren and Vitamin D3|Aliskiren 150-300 mg orally once daily and Cholecalciferol 3000 I.U. in combination once daily for 6 weeks
9859404|NCT00976339|Experimental|Cholecalciferol 20,000 IU|Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.
9859405|NCT00976339|Experimental|Cholecalciferol 30,000 IU|Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.
9859406|NCT00965146|Experimental|Scorpio® CR Total Knee System|Scorpio® CR Total Knee System Study Device
9924350|NCT00860522|Experimental|Phase I|Three patients will be enrolled at dose Level 1. If the patient does not completed the three infusion of JVRS-100 during cycle 1 for reason other than toxicity, another patient will be accrued at the same dose level.
9859407|NCT00972023|Experimental|DHEA, surgical resection|Day-14 (approx. 2 wks prior to surgery): begin a 2 week course of DHEA; Day-7 (approx. 1 wk after starting treatment): answer question about pill diary; Day 0 (approx. 2 wks after starting treatment, within 48 hours prior to surgery;
9859408|NCT00970736||1|20 healthy participants between 60 and 80 years of age. Ten men and 10 women.
9859409|NCT00957827|Experimental|keflex|keflex 500mg twice a day for five days
9859410|NCT00957827|Placebo Comparator|placebo|placebo 500mg twice a day for five days
9859411|NCT00953329|Experimental|Alefacept 15 mg IM qweek|Alefacept will be given to subjects with plaque psoriasis who have failed treatment with Fnbrel.
9859412|NCT00965055|Placebo Comparator|Atorvastatin|
9859413|NCT00965055|Experimental|Atorvastatin/Ezetimibe|
9859414|NCT00962429|Active Comparator|Lipoic acid|alpha lipoic acid
9859415|NCT00962429|Placebo Comparator|Placebo|sugar pill
10209467|NCT04280523|Experimental|ESR-specific PET Scan|"Specific Aim: To test the hypothesis that among PAH patients, higher lung ESR density associates with a more severe hemodynamic profile and worse 1 year outcomes.~Study Design: Enroll 20 randomly selected subjects from each group (PAH vs. control)"
10209468|NCT04279548|Active Comparator|On DBS|Patients in the on mode DBS
9859416|NCT00958893|Experimental|25 mg Proellex|25 mg Proellex daily
9859417|NCT00966654|Placebo Comparator|Saline|Saline
9859418|NCT00966654|Active Comparator|GLP-1|GLP-1 (7-36) amide
9859419|NCT00960154|Experimental|PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
9859420|NCT00960154|Active Comparator|SOC|The SOC consists of scalpel for the skin incision and traditional electrosurgery for the entirety of the subcutaneous dissection.
9859421|NCT00960752|Active Comparator|Group 1: gp100 and MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
9859422|NCT00960752|Active Comparator|Group 2: gp100 and MAGE-3|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
9859423|NCT00960752|Active Comparator|Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
9859424|NCT00958347|Other|Omnifit HA Hip Stem|Participants underwent total hip replacement surgery using the Omnifit HA Hip Stem.
9859425|NCT00954187|Experimental|Gabapentin|Neurontin
9859426|NCT00954187|Experimental|Pregabalin|Lyrica
9859427|NCT00953615|Experimental|Thalidomide|Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.
9859428|NCT00947284|Experimental|Women|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm.
9859429|NCT00947284|Experimental|Men|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm
9859430|NCT00957034|Placebo Comparator|placebo|placebo patch
9859431|NCT00957034|Experimental|300 µg/day testosterone|300 micrograms/day transdermal testosterone patch
9859432|NCT00957034|Experimental|450 µg/day testosterone|450 micrograms/day transdermal testosterone patch
9859433|NCT00949988|Active Comparator|Dasatinib - 100 mg (Phase I)|Dasatinib - 100 mg (Phase I)
9859434|NCT00949988|Active Comparator|Dasatinib - 70 mg (Phase I)|Dasatinib - 70 mg (Phase I)
9859435|NCT00948194|No Intervention|No nitric oxide|This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
9859436|NCT00948194|Experimental|Nitric Oxide|Will receive Nitric oxide and other standard inhaled anesthetics
10209469|NCT04279548|Sham Comparator|Off DBS|Patients in the off mode DBS
10209470|NCT04278144|Experimental|Single agent BDC-1001|Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
10209471|NCT04278144|Experimental|Combination BDC-1001 plus nivolumab|Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
10209472|NCT04277273|Other|Patients treated in the MaxilloFacial Prosthesis consultation|Patients treated in the MaxilloFacial Prosthesis consultation (Dental Department, Pitié-Salpêtrière Hospital Group)
10209473|NCT04273867||Chronic Hypersensitivity Pneumonitis Patients|
10209474|NCT04270032||malignant group|women with malignant lesions confirmed by pathology
10209475|NCT04270032||benign group|women with benign lesions confirmed by pathology or stable in follow-up > 2 years
10209476|NCT04270032||normal group|women have normal images with follow up > 2 years
10209477|NCT04261777|Experimental|SPL-01-001|
10209478|NCT04250571|Experimental|No treatment group|Participants will receive no pills and will be told that they are in the no treatment group
10209479|NCT04250571|Experimental|Imaginary pill (IP) group|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence)
10209480|NCT04250571|Experimental|Open label placebo group|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo)"
9986463|NCT01403129||Keratoconus-Related|A person who is genetically related to someone with keratoconus. Will have either or both Artemis-2 exam and OCT exam.
9996945|NCT01504542|Experimental|High dose HS110|10,000,000 HS110 cells/0.5ml + erlotinib 150mg orally once daily.
9794715|NCT01515657|Experimental|PL2200 Aspirin Capsules|Investigational drug arm; crossover design
9794716|NCT01515657|Active Comparator|Immediate-Release Aspirin Tablets|Active comparator; crossover design
9794717|NCT01515657|Active Comparator|Enteric-coated aspirin caplets|Active comparator; crossover design
9794718|NCT01515696|Active Comparator|Gastrografin|infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
9794719|NCT01515696|Placebo Comparator|Sterile water|infants receive 9ml/kg sterile water
9794720|NCT01515865|Experimental|Midodrine HCl|
9794721|NCT01515865|Placebo Comparator|Placebo|
9794722|NCT01515891|Experimental|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
9794723|NCT01515943|Active Comparator|Computer-based therapy (CBT)|The CBT group will be assigned active home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
9794724|NCT01515943|Active Comparator|Near target push-up (NTP)|The NTP group will be assigned placebo home-based computer vergence/accommodative therapy (5 minutes/day) plus near target push-ups (15 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
9794725|NCT01515943|Placebo Comparator|Placebo|The placebo group will be assigned placebo home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
9794726|NCT01515956|Experimental|BMN 110 Weekly|
9794727|NCT01515995|Experimental|Magnesium sulfate group|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
9794728|NCT01515995|Active Comparator|Normal Saline group|15 mg albuterol in 22 ml of normal saline solution via nebulizer over one hour
9794729|NCT01516008|Experimental|Tapentadol IR 50 mg|
9794730|NCT01516008|Experimental|Tapentadol IR 75 mg|
9794731|NCT01516008|Placebo Comparator|Placebo|
9794732|NCT01516268|Active Comparator|Sufentanyl group|IN case group we add 1cc sufentanyl to 20 cc bupivacain in TAP block
9794733|NCT01516268|Placebo Comparator|Control group|In control group we add 1cc salin to 20cc bupivacain in TAP block
9794734|NCT01516424|Experimental|Blonanserin|Antipsychotics
9794735|NCT01516424|Active Comparator|Risperidone|Antipsychotics
9794736|NCT01516437|Experimental|HNS Group|Healthy non-smokers aged between 45-75 years
9794737|NCT01516437|Experimental|HS Group|Healthy smokers aged between 45-75 years
9794738|NCT01516437|Experimental|FeCOPD Group|COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years
9794739|NCT01516437|Experimental|NFeCOPD Group|COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years
9794740|NCT01516632|Experimental|SMS USA|The 6-week smoking cessation intervention
9794741|NCT01516632|No Intervention|Attention matched control|Messages aimed at improving one's sleep and increasing one's fitness, along with general messages about the most well known health dangers of smoking. Messages sent on the same schedule as the intervention group.
9794742|NCT01516684|Experimental|Arm I (EMLA)|Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
9794743|NCT01516684|Active Comparator|Arm II (placebo)|Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
9794744|NCT01516736|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
9794745|NCT01516736|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
9794746|NCT01516749|Experimental|Anakinra|All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
9794747|NCT01516879|Experimental|Evolocumab|Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
9794748|NCT01516879|Placebo Comparator|Placebo|Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
9794749|NCT01516892|Experimental|BOTOX®|Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
9794750|NCT01516957|Experimental|AMG 827 140|140 mg AMG 827
9794751|NCT01516957|Placebo Comparator|Placebo SC|Placebo
9794752|NCT01516957|Experimental|AMG 827 280|280 mg AMG 827
9794753|NCT01516957|Experimental|AMG 827 210|AMG 827 SC 210 mg
9666950|NCT04101331|Experimental|Cohort B|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥1% to <10%
9859437|NCT00946985|Experimental|001|paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years
10209481|NCT04250077|Experimental|CRAFT-A|"Participants assigned to the CRAFT-A will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1)Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.~CRAFT-A participants also attend a weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations."
9859438|NCT00946985|Active Comparator|002|oral risperidone 2 4 6 or 8 mg tabs once daily for two years
9859439|NCT00950183|Other|Foot and Ankle Surgery|Please note that the study was terminated prior to randomization of patients.
9859440|NCT00950690||Study Drug - Xalatan 0.005% eye drops|
9859441|NCT00944229|Active Comparator|1 Drug Treatment - LOVAZA|Drug Treatment - LOVAZA 4 gm q24 for 8 weeks
9859442|NCT00944229|Placebo Comparator|2 placebo|Placebo 4 capsules q24 for 8 weeks
9859443|NCT00941928|Experimental|Haploidentical NK cells + Epratuzumab|Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
9859444|NCT00949403|Experimental|Obese Females (pre-bariatric surgery)|Twenty obese females (18-45 years of age, BMI > or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.
9859445|NCT00947791|Experimental|Ketamine/Midazolam|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
9859446|NCT00947791|Experimental|Midazolam/Ketamine|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
9859447|NCT00947011|Placebo Comparator|Placebo|
9859448|NCT00947011|Active Comparator|Januvia|
9859449|NCT00943605|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
9859450|NCT00943605|Experimental|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
9859451|NCT00942409|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
9859452|NCT00936585|Other|Immunologic Monitoring|Blood draws and colonoscopy performed on patients enrolled in both intervention arms of the main study
9859453|NCT00936598|Experimental|zolpidem|Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women > or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
9859454|NCT00936598|Placebo Comparator|sugar pill|Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
9859455|NCT00920309|Experimental|Rapamycin|"Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml."
9859456|NCT00920309|Placebo Comparator|Standard of Care-Placebo|Standard of Care
9859457|NCT00935649|Experimental|Randomized great toe|Subjects with both great toes infected. Right/left randomized to treatment / no treatment
9859458|NCT00935649|No Intervention|Untreated Toe|
9859459|NCT00934791|Active Comparator|Control Group|Tacrolimus, mycophenolate mofetil, and prednisone
9859460|NCT00934791|Active Comparator|Sirolimus Group|Sirolimus, mycophenolate mofetil, and prednisone
9859461|NCT00932152|Active Comparator|Arm B, Group 1|Best supportive care only: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support PRN
9859462|NCT00932152|Active Comparator|Arm B, Group 2|Best supportive care and Bevacizumab 15mg/kg every 21 days
9859463|NCT00932152|Experimental|Arm A, Group 1|Fulvestrant and anastrozole only
9859464|NCT00932152|Experimental|Arm A, Group 2|Fulvestrant, anastrozole and Bevacizumab
9859465|NCT00928499|Other|Interstim - continuous|Continuous stimulation
9859466|NCT00928499|Other|Interstim - cyclic|Cyclic stimulation
9859467|NCT00924807|Experimental|Androgen Depr, Radiotherapy, Sorafenib|Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
9859468|NCT00930787|Experimental|Strattice Reconstructive Tissue Matrix|Use of Strattice Reconstructive Tissue Matrix to support hernia repair
9859469|NCT00930787|Active Comparator|Proceed Surgical Mesh|Use of Proceed Surgical Mesh to support hernia repair
9859470|NCT00929474|Experimental|QuickOpt|
9859471|NCT00929474|Active Comparator|Control|
9859472|NCT00925548|Experimental|Investigational Arm|"Investigational Arm:~Pretreatment (Single Dose): 300 milligrams per square meter (mg/m^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide~tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)"
9859473|NCT00925548|Active Comparator|Control Arm|"Control Arm:~Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion~Placebo plus Hormonal Therapy (Standard Dose)"
9859474|NCT00926575|Experimental|orBec®|Investigational drug
9859475|NCT00926575|Placebo Comparator|Placebo|Control
9859476|NCT00911053|No Intervention|Baseline|
9859477|NCT00911053|Experimental|Melatonin|Subjects will be administered melatonin.
9859478|NCT00911053|Experimental|Light|
9859479|NCT00911053|Experimental|Regular Sleep Schedule|
9859480|NCT00911053|No Intervention|Longitudinal Monitoring|Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
9859481|NCT00918463|Experimental|all patients|
9859482|NCT00918645|Experimental|41 Ca|
9859483|NCT00907218|Experimental|1|Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.
9859484|NCT00895284|Experimental|Robot|Robotic hysterectomy
9859485|NCT00895284|Active Comparator|Standard|Standard hysterectomy
9859486|NCT00901303|Other|Early Stage Disease|Group A
9859487|NCT00901303|Other|Advance Stage Disease|Group B
9859488|NCT00906035|Active Comparator|Dipyridamole 200mg and Aspirin 25mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
9859489|NCT00906035|Active Comparator|Dipyridamole 200 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
9859490|NCT00906035|Active Comparator|Aspirin 25 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.
9666951|NCT04101331|Experimental|Cohort C|TMF (transformed mycosis fungoides) patients with CD30 expression ≥1%
9666952|NCT04095598||Syndesmotic injured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
9859491|NCT00904423|Experimental|Vitamin D|
9859492|NCT00903396|Experimental|Arm I|Patients receive palonosetron hydrochloride IV on day 1.
9859493|NCT00903396|Experimental|Arm II|Patients receive palonosetron hydrochloride IV on days 1 and 4.
9859494|NCT00903396|Placebo Comparator|Arm III|Patients receive placebo IV on day 1.
9859495|NCT00903396|Placebo Comparator|Arm IV|Patients receive placebo IV on days 1 and 4.
9859496|NCT00894790|Experimental|1|
9859497|NCT00894790|Active Comparator|2|
9859498|NCT00902668|Experimental|Supportive care (lovastatin)|Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
9859499|NCT00881205|Experimental|Rivastigmine|Rivastigmine patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
9859500|NCT00881205|Placebo Comparator|Placebo|Placebo patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
9859501|NCT00896025|Active Comparator|N-acetycylcysteine|Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous N-acetylcysteine infusion for a total of 72 hours.
9859502|NCT00896025|No Intervention|Standard of care|Each eligible Acute Liver Failure patient for whom the investigator chooses not to utilize N-acetylcysteine may serve as a control and receives standard of care.
9794754|NCT01516970|Experimental|DRV/r with 2 NRTIs|DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
9986464|NCT01403129||Age-Matched Normal|"A person who is approximately the same age as subjects who have been enrolled in the study.~Will have either or both Artemis-2 exam and OCT exam."
9986465|NCT01403155|Experimental|All subjects|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3.
9794755|NCT01516970|Active Comparator|Comparator standard of care HIV PEP|Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
9794756|NCT01517074|Experimental|Sirolimus|Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).
10209482|NCT04250077|Experimental|CRAFT-C|"Participants assigned to the CRAFT-C groups will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.~CRAFT-C participants attend a weekly 60-minute individualized on-on-one coaching session with a CRAFT certified coach. During weekly individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations. One-on-one sessions involve role-plays that are tailored to the participants' specific circumstances"
10209483|NCT04250077|Active Comparator|PEER|"Participants assigned to the PEER group will participate in an online peer support forum with other CSOs.~Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully. This individual also will report any adverse or severe adverse events that members mention online."
9794757|NCT01517178|Active Comparator|Standard Care base plate|Standard care are the participants own product and can have several manufacture and brand names
9794758|NCT01517178|Experimental|New ostomy base plate (SS)|SS = New ostomy base plate. Due to company confidentiality the product is called SS and this is not short for any name
10209484|NCT04243343|Experimental|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program.
10209485|NCT04243343|Active Comparator|Standard of care|Standard of care prescribed home exercise program.
9794759|NCT01517282|Experimental|MOR103 0.5 mg/kg|6 doses of MOR103 0.5 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
9794760|NCT01517282|Experimental|MOR103 1.0 mg/kg|6 doses of MOR103 1.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
9794761|NCT01517282|Experimental|MOR103 2.0 mg/kg|6 doses of MOR103 2.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
9986466|NCT01403168|Experimental|osteopathy + conventional analgesic treatments|
9986467|NCT01403168|Placebo Comparator|conventional analgesic treatments|
10213623|NCT03673007|Experimental|Treatment Group|Women in this arm of the study receive a voucher which can be used to buy contraception and related services at Planned Parenthood
9794762|NCT01517282|Placebo Comparator|Placebo|6 doses of placebo administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
9794763|NCT01517295|Experimental|Group 1|Blood will be drawn at 0, 1, 3, and 5 hours after taking one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 3.
9794764|NCT01517295|Experimental|Group 2|Blood will be drawn at 0, 2, 4, and 6 hours after one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 4.
9794765|NCT01517373|Placebo Comparator|Placebo|Placebo to match PF-04937319 and glimepiride
9794766|NCT01517373|Experimental|PF-04937319 10 mg|
9794767|NCT01517373|Experimental|PF-04937319 50 mg|
9794768|NCT01517373|Experimental|PF-04937319 100 mg|
9794769|NCT01517373|Active Comparator|Glimepiride|
9794770|NCT01517412|Experimental|Lixisenatide Main Meal|"Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
9794771|NCT01517412|Active Comparator|Lixisenatide Breakfast|"Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
9794772|NCT01517529||10 Hepatitis C infected subjects|10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.
9794773|NCT01517750|Experimental|APAP with humidification|ICON Auto CPAP™ with Thermosmart heated tube
9794774|NCT01517750|Active Comparator|APAP without humidification|ICON Auto CPAP™ without Thermosmart heated tube
9794775|NCT01517867|Experimental|Intervention Chicago Parent Program arm|The Chicago Parent Program is a 12-session group-based parenting skills training program
9859503|NCT00903006|Active Comparator|Group 1: Fulvestrant|Group 1 will receive Fulvestrant only.
9859504|NCT00903006|Active Comparator|Group 2: Fulvestrant + Dasatinib|Group 2 will receive Fulvestrant and Dasatinib.
9859505|NCT00903006|Active Comparator|Group 3: Fulvestrant + MK-0646|Group 3 will receive Fulvestrant and MK-0646.
9859506|NCT00903006|Active Comparator|Group 4: Fulvestrant, MK-0646 + Dasatinib|Group 4 will receive Fulvestrant, MK-0646, and Dasatinib.
9859507|NCT00904189|No Intervention|Standard of care radiation therapy|Standard of care given for treatment of cancer. Subjects receiving incidental radiation dose to fingernails.
9859508|NCT00887315|Active Comparator|Group 1|Chemotherapy only
9859509|NCT00887315|Active Comparator|2|Chemotherapy and hypofractionated image guided radiotherapy
9859510|NCT00891904|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5
9859511|NCT00881608|Placebo Comparator|Placebo|Initiation-Placebo Cycle-Five (5) placebo capsules will be dispensed to subjects to self-administer for five days starting on cycle day 18.
9859512|NCT00881608|Experimental|3 mg Proellex|First Cycle (3 mg)- Five (5) 3 mg capsules of Proellex will be dispensed to subjects to self-administer for five days starting on cycle day 18.
9859513|NCT00881608|Experimental|6 mg Proellex|Second Cycle (6 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed ten (10) 3 mg capsules of Proellex to self-administer 2, 3 mg capsules each day for five days starting on cycle day 18.
9859514|NCT00881608|Experimental|12 mg Proellex|Third Cycle (12 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed twenty (20) 3 mg capsules of Proellex to self-administer 4, 3 mg capsules for five days starting on cycle day 18.
9859515|NCT00881608|Experimental|25 mg Proellex|Fourth Cycle (25 mg)-Subjects, who have not experienced menses, will be dispensed five (5) 25 mg capsules of Proellex to self-administer for five days starting on cycle day 18.
9859516|NCT00889421|Experimental|Treatment|Patients receiving apremilast.
9924351|NCT00860522|Experimental|Phase II|3 patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity, an additional 3 patients will be enrolled at the given dose level. If the 1st 2 subjects enrolled and treated at a given dose experience dose limiting toxicities, no additional subjects will be enrolled at that dose. Dose escalation may proceed if < 2/6 patients at a given dose level experience a LDT. If ≥ 2/6 patients experience a DLT at a given dose level, the next lower dose level will be considered the RP2D. If a patient does not complete the 3 infusions of JVRS-100 during Cycle 1 for reasons other than toxicity, another patient will be accrued at the same dose level. Once the RP2D is established, the cohort will be expanded to a total of 12 patients.
9924352|NCT00860561||1|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options.
9924353|NCT00860600|Experimental|1. PG2 Treatment: 5 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
9924354|NCT00860600|Experimental|2. PG2 Treatment: 3 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
9924355|NCT00860613|Experimental|1|women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. They received a specific diet using carbohydrate counting (40-45% of carbohydrates)and a moderate energy restriction. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
9924356|NCT00860613|Experimental|2|Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
9924357|NCT00860613|No Intervention|3|women in this group received the current hospital treatment. They did not receive any intervention except for the self glucose monitoring that they did every two weeks. Weight gain and the results of the self glucose monitoring, were evaluated every two weeks.
9924358|NCT00860626|Experimental|1|At the twelfth week of interferon α treatment, HBV DNA is detectable(>1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.
9924359|NCT00860626|Active Comparator|2|At the twelfth week of interferon α treatment, HBV DNA is detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
9924360|NCT00860626|Active Comparator|3|At the twelfth week of interferon α treatment, HBV DNA is undetectable (<1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.
9924361|NCT00860639|Active Comparator|gemtuzumab ozogamycin|Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
9924362|NCT00860639|No Intervention|without Mylotarg|
9924363|NCT00860652|Experimental|Adjuvant Radiotherapy (RT)|Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)
9924364|NCT00860652|Experimental|Active Surveillance with Early SalvageRT|Active Surveillance with Early Salvage Radiotherapy
9924365|NCT00860665||1|Observational study on consecutive persons over the age of 55 years presenting for screening colonoscopy
9924366|NCT00860678|Active Comparator|A|Training group
9924367|NCT00860678|Other|B|Controls
9924368|NCT00860691|Active Comparator|ARM I - Open colorectal surgery|Open colorectal surgery
9924369|NCT00860691|Experimental|ARM II - Laparoscopic colorectal surgery|Laparoscopic colorectal surgery
9935143|NCT04113382|Experimental|Participants aged 4 to <9 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (1 bottle [approximately 160 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum."
9986468|NCT01403181||Chronic hepatitis C|"10 naïve genotype 1 chronic hepatitis C patients treated with PEG plus RBV (control arm)~20 naïve genotype 1 chronic hepatitis C patients treated with a response guided therapy consisting of Boceprevir in combination with PEG plus RBV (experimental arm)"
10209486|NCT04242524|Experimental|Circadian Clock Alignment - High BMI|Subjects will come to the Sleep Lab three nights before their bariatric surgery procedure for an intervention that will align their central circadian clock. The intervention includes eating meals and snacks at fixed times and having lights off at a specific time at night and lights on at a specific time in the morning.
9794776|NCT01517867|Active Comparator|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually tailored treatment for parents and children with behavior problems
9794777|NCT01517893|Experimental|Intervention arm|Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
9794778|NCT01517893|Placebo Comparator|Placebo Arm|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
9794779|NCT01517984|Experimental|Tacrolimus (CNI) Withdrawal|"Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal."
9794780|NCT01517984|Active Comparator|Standard Immunosuppressive Therapy|"Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur."
9996946|NCT01504542|Placebo Comparator|Placebo vaccine + erlotinib 150mg orally once daily|Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
10209487|NCT04242524|Active Comparator|Circadian Clock Control - High BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
10209488|NCT04242524|Active Comparator|Circadian Clock Control - Low BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
10209489|NCT04240483|Experimental|Intracutaneous sterile water injections (ISWI) group|
10209490|NCT04240483|Sham Comparator|Intracutaneous dry injections (IDI) group|
10213624|NCT03673007|No Intervention|Control Group|Women in this arm of the study DO NOT receive a voucher for contraceptives. Women in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
9794781|NCT01518153|Experimental|Low Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
9794782|NCT01518153|Experimental|High Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. High Dose Donor T-Cells Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
9794783|NCT01518192|Active Comparator|1Doxycycline|
9794784|NCT01518192|Active Comparator|2 Cefuroxime axetil|
9794785|NCT01518244|Experimental|AZARGA®|Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks
9794786|NCT01518257|Experimental|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
9794787|NCT01518257|Placebo Comparator|Placebo|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
9794788|NCT01518270||Healthy Females|Healthy Females
9794789|NCT01518309|Experimental|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
9794790|NCT01518322||FeNO|All subjects will have their Fractional Exhaled Nitric Oxide (FeNO) measured with the NIOX MINO® device according to instructions for NO measurements.
9794791|NCT01518374|Experimental|Florbetapir-PET Scans|
9794792|NCT01518530|Experimental|Passive Mobilization Cervical Spine|Patients with chronic neck pain according to the International Association of the Study of Pain criteria of the following types: facet joint disorder, post-whiplash injury, myofascial pain syndrome.
9794793|NCT01518699|Experimental|HA44 Abametapir Lotion|Study drug plus positive-control placebo.
9794794|NCT01518699|Placebo Comparator|Placebo|Placebo plus positive-control placebo.
9794795|NCT01518699|Active Comparator|Moxifloxacin|Placebo plus positive control
9794796|NCT01518868|Experimental|Investigational contact lens|multifocal high add soft contact lens
9794797|NCT01518868|Active Comparator|PureVision contact lens|Multi-focal contact lens
9794798|NCT01518946|Active Comparator|Midodrine HCl|
9794799|NCT01518946|Placebo Comparator|Placebo|
9794800|NCT01518972|Experimental|Prazosin|Prazosin medication
9794801|NCT01518972|Placebo Comparator|Placebo|Placebo medication
9859517|NCT00875394|Experimental|1|sitagliptin + metformin
9859518|NCT00875394|Active Comparator|2|metformin + any other oral antidiabetic drug
9859519|NCT00875394|Active Comparator|3|metformin
9859520|NCT00882310|Experimental|Gemcitabine, Docetaxel, Capecitabine GTX|GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.
9859521|NCT00880542|Experimental|Sorafenib + Ifosfamide|"* Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.~NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.~Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.~Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy."
9859522|NCT00879619|Experimental|Chemotherapy and enzyme inhibitor|Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9859523|NCT00874939|Experimental|PBO→MK-7.5→DON→MK-25|Treatment by single oral dose with Placebo (PBO) in the first crossover period; MK-0249 7.5 mg (MK-7.5) in the second crossover period; Donepezil 5 mg (DON) in the third crossover period; and MK-0249 25 mg (MK-25) in the fourth crossover period.
9859524|NCT00874939|Experimental|MK-7.5→PBO→MK-25→DON|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 25 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
9859525|NCT00874939|Experimental|DON→MK-25→PBO→MK-7.5|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
9859526|NCT00874939|Experimental|MK-25→DON→MK-7.5→PBO|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Placebo in the fourth crossover period.
9859527|NCT00874939|Experimental|PBO→MK-25→MK-7.5→DON|Treatment by single oral dose with Placebo in the first crossover period; MK-0249 25 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
9859528|NCT00874939|Experimental|MK-7.5→DON→PBO→MK-25|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Donepezil 5 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
9859529|NCT00874939|Experimental|DON→MK-7.5→MK-25→PBO|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and Placebo in the fourth crossover period.
10213625|NCT03666624|Experimental|Personalized care network|9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
10213626|NCT03666624|No Intervention|Routine medical care|No intervention
9859530|NCT00874939|Experimental|MK-25→PBO→DON→MK-7.5|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Placebo in the second crossover period; Donepezil 5 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
9859531|NCT00874939|Experimental|PBO→DON→MK-25→MK-7.5|Treatment by single oral dose with Placebo in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
9859532|NCT00874939|Experimental|MK-7.5→MK-25→DON→PBO|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Donepezil 5 mg in the third crossover period; and Placebo in the fourth crossover period.
9859533|NCT00874939|Experimental|DON→PBO→MK-7.5→MK-25|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 7.5 mg in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
9859534|NCT00874939|Experimental|MK-25→MK-7.5→PBO→DON|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; Placebo in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
9859535|NCT00878605|Experimental|Cyclo-Z (minimally effective)|3mg CHP plus 20mg zinc containing gel capsule;
9859536|NCT00878605|Experimental|Cyclo-Z (maximally effective)|9mg CHP plus 20mg zinc containing gel capsule;
9859537|NCT00878605|Experimental|Cyclo-Z (not additionally effective)|15mg CHP plus 20mg zinc containing gel capsule
9859538|NCT00878605|Placebo Comparator|Placebo (for CHP)|Placebo capsules containing no zinc or CHP
9859539|NCT00877071|Experimental|LC Drug Eluting Bead, Regional Chemoembolization|Use of LC Drug-Eluting Beads for chemoembolization will provide a method for downstaging patients with hepatocellular carcinoma which is not amenable to surgical resection or local ablative therapy to liver transplant eligibility
9859540|NCT00878969|Active Comparator|Valsartan|80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
9859541|NCT00878969|Active Comparator|Ramipril|2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
10213627|NCT03650894|Experimental|Nivolumab, Ipilimumab, and bicalutamide|Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
9859542|NCT00878969|Placebo Comparator|Placebo|matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months
9859543|NCT00865514|Experimental|Haplotypes and DCA metabolism|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
9859544|NCT00869414|Active Comparator|insulin glargine only in morning|Morning only administration of insulin glargine
9859545|NCT00869414|Active Comparator|insulin glargine only at evening|Evening only administration of insulin glargine
9859546|NCT00869414|Active Comparator|split dose insulin glargine|Split dose administration of insulin glargine, half dose in morning, half dose in evening
9859547|NCT00863512|Experimental|Arm I|Patients receive cisplatin IV on day 1 and vinorelbine ditartrate IV on days 1 and 8 OR docetaxel IV and cytarabine IV on day 1 OR gemcitabine hydrochloride IV on days 1 and 8 and cytarabine IV on day 1 OR pemetrexed disodium IV and cisplatin IV on day 1.. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9859548|NCT00863512|Experimental|Arm II|Patients receive standard care (observation).
9859549|NCT00868998|Experimental|Treatment|Gemcitabine, docetaxel, and capecitabine
9859550|NCT00869258|Experimental|GTX and Radiation Therapy with Gemzar|"Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine:~A cycle of chemotherapy is made up of 21 days. During each cycle patients will take Xeloda® twice a day for 14 days followed by a rest period of 7 days. On day 4 and 11 (+/- 2 days) of each 21-day cycle patients will also receive Gemzar and Taxotere.~Weekly Radiation Therapy with Low-Dose Gemzar Chemotherapy:~After completing a total of 3 cycles of GTX chemotherapy each patient will receive 5 weeks of standard radiation therapy in combination with low-dose Gemzar chemotherapy."
9859551|NCT00863330|Experimental|Determine toxicity of treatment regimen.|
9859552|NCT00853229|Experimental|pregabalin/placebo|pregabalin and placebo given using a cross-over design
9859553|NCT00853229|Experimental|placebo/pregabalin|placebo and pregabalin given using a cross-over design
9859554|NCT00860249|No Intervention|Usual Care|Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
9859555|NCT00860249|Experimental|Behavioral: Letter Only|Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
10209491|NCT04235374|Experimental|FFC-AC-EIT|The stakeholder team will meet with the research nurse facilitator to review the details of the 12 month intervention and identify unit goals. The research nurse facilitator will then work with the identified champion for 10 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to implement Steps 1 to 4 of FFC-AC-EIT [(1) Environment and Policy Assessments; (2) Education; (3) Establishing Patient Goals; and (4) Mentoring and Motivating of Staff, Patients and Families]. The stakeholder team will meet with the Research Nurse Facilitator monthly to review progress. In addition to monthly visits, weekly emails containing motivational Tidbits will be sent to all stakeholder team members within the cohort. The Tidbits include such things as updates about benefits of engaging patients with ADRD in physical activity while hospitalized.
9859556|NCT00860249|Experimental|Behavioral: Letter and Educational DVD|Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
9859557|NCT00860158|Experimental|Single Arm Assignment|Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
9859558|NCT00853567|Active Comparator|25 g Proellex|25 mg oral daily dose of Proellex
9859559|NCT00853567|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
9859560|NCT00853567|Placebo Comparator|Placebo|Placebo treatment
9859561|NCT00849524|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
9859562|NCT00843986|Placebo Comparator|Placebo|Matching loading dose and continuous intravenous infusion for 48 hours
9859563|NCT00843986|Experimental|Conivaptan|20mg loading dose followed by a 20mg/ day continuous intravenous infusion for 48 hours
9859564|NCT00851682|Other|Radical prostatectomy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo radical prostatectomy and have not received any preoperative treatment for prostate cancer.
9859565|NCT00851682|Other|Brachytherapy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo brachytherapy and have not received any preoperative treatment for prostate cancer.
9859566|NCT00852124|Placebo Comparator|Placebo|Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
9859567|NCT00852124|Active Comparator|VSL#3|Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
9859568|NCT00850421|Other|Botulinum Toxin Type A|
9859569|NCT00851747|Experimental|C Phosphatidylcholine Deoxycholate|Phosphatidylcholine Deoxycholate Injections. Group C will receive only study drug injections
9859570|NCT00851747|Placebo Comparator|A Saline|Group A will serve as a control and will receive only injections of saline as a placebo.
9859571|NCT00851747|Active Comparator|B PhosphatidylcholineDeoxycholate/Saline|Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side.
9859572|NCT00852241|Experimental|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
9859573|NCT00850720||Cardiac Surgery|Infants with congenital defects.
9859574|NCT00845845|Active Comparator|Omega-3-acid ethyl esters (Lovaza)|Participants receive 4 milligrams (mg) daily of omega-3-acid ethyl esters (Lovaza) and dietary counseling for 24 weeks
9859575|NCT00845845|Placebo Comparator|Placebo|Participants receive daily placebo and dietary counseling for 24 weeks
9859576|NCT00851591|Experimental|Fenugreek category 1|receive fenugreek
9859577|NCT00851591|Placebo Comparator|Placebo Category 2|receive placebo
9859578|NCT00847509|Experimental|FLT PET scan|Open label, nonrandomized, uncontrolled, single group assignment, multi-center clinical trial to evaluate [F-18] FLT as a PET imaging tool in cancer patients clinically scheduled for treatment with radiation or radiation - chemotherapy. Standard [F-18] FDG PET will be the active comparator.
9859579|NCT00843310|Experimental|ReMeDex|"Treatment phase (28 days/cycle x 6 cycles):~Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.~Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):~lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles."
9859580|NCT00847002|Active Comparator|Standard Wound Care|Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
9859581|NCT00847002|Active Comparator|Flexitouch system with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
9859582|NCT00845702|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2 ml/kg.
9859583|NCT00845702|Other|Time Of Flight Magnetic Resonance Angiography|Each subject undergo a TOF MRA
9859584|NCT00843830|Experimental|Treatment Arm|Participants will receive tumoral irradiation and dendritic cell vaccination.
9859585|NCT00835679|Experimental|Cohort A (no systemic neoadjuvant therapy)|Patients receive no systemic neoadjuvant therapy between enrollment and the time of definitive surgical resection of liver metastases. Liver biopsies were performed at surgery since this cohort received no systemic therapy.
9859586|NCT00835679|Experimental|Cohort B (cetuximab)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8. Definitive surgical resection of liver metastases will take place on day 15.
9859587|NCT00835679|Experimental|Cohort C (dasatinib)|Patients receive dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
9859588|NCT00835679|Experimental|Cohort D (cetuximab, dasatinib)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8 AND dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
9859589|NCT00841035|Experimental|Eroltinib added to standard of care|150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles
9859590|NCT00832520|Experimental|Remeron (Mirtazapine)|Mirtazapine 15 mg orally at bed time for 8 weeks
9859591|NCT00833859|Experimental|Chemotherapy followed by Radiation Treatment|GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)
9859592|NCT00843050|Experimental|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
9859593|NCT00840827|Experimental|all patients|Lenalidomide 10mg po daily/ CSA 250mg orally twice daily
9859594|NCT00835328|Experimental|Exendin (9-39) 0.02 mg/kg/hr|Cohort 1: Participants will be administered 0.02 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
9859595|NCT00835328|Experimental|Exendin (9-39) 0.04 mg/kg/hr|Cohort 2: Participants will be administered 0.04 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
9859596|NCT00835328|Experimental|Exendin (9-39) 0.10 mg/kg/hr|Cohort 3: Participants will be administered 0.10 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 6 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
9517055|NCT03309917|Experimental|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:~MAP set at 80-85 mmHg for 5 min.~MAP set at 70-75 mmHg for 5 min.~MAP set at 60-65 mmHg for 5 min.~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
9859597|NCT00835328|Experimental|Exendin (9-39) 0.20 mg/kg/hr|Cohort 4: Participants will be administered 0.20 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
9859598|NCT00832572|Experimental|Placebo-Ranolazine|Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
10209492|NCT04235374|Placebo Comparator|Education Only|Education Only (EO) Control Intervention: Hospitals randomized to EO will be provided with an in-service for nursing staff on function focused care in patients with ADRD by an EO Research Nurse Facilitator using our developed PowerPoint presentations in 30-minute sessions as is currently done in usual practice.
10209493|NCT04233840|Experimental|Sequential administration of P1101 and anti-PD1|"Phase I of Study : To determine the safety, tolerability, DLT, and potential phase 2 dose of sequential administration of P1101 and anti-PD1~:Sequential administration 6 doses (450mcg) of P1101 and 3 doses of anti-PD1 (Escalating from 0.3, 0.75, 1.5, 3 mg/kg) for Phase I Study"
9859599|NCT00832572|Experimental|Ranolazine-Placebo|Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
9859600|NCT00832624|Experimental|1|sitagliptin
10209494|NCT04233840|Active Comparator|anti-PD1|Phase II Study Group I: anti-PD1 arm 3mg/kg 3 doses
10209495|NCT04233840|Active Comparator|P1101 monotherapy|Phase II Study Group II: P1101 arm 450mcg 12 doses
9859601|NCT00832299|Experimental|6 cycles of FOLFOX pre and post TME|
9859602|NCT00836355|Experimental|Enoxaparin|
9859603|NCT00836355|Experimental|Minocycline|Minocycline 200 mg orally once daily for 5 days
9859604|NCT00836355|Experimental|Enoxaparin and minocycline|
9859605|NCT00836355|No Intervention|Control|
9859606|NCT00832598|Experimental|PET imaging|We will perform [18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc.
9859607|NCT00816777|Experimental|Chemoembolization|Chemoembolization with Irinotecan Bead in combination with Intravenous Chemotherapy Group (test arm)
9859608|NCT00816777|Active Comparator|Chemotherapy|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
9859609|NCT00823095|Experimental|Topically applied Nitric Oxide|Topically applied Nitric Oxide for 8 hours daily for 2 weeks.
9859610|NCT00827567|Experimental|RAD 001|RAD001-10 mg by mouth once everyday
9859611|NCT00815633|Experimental|Alefacept|Treatment Group (only one group)
9859612|NCT00814983|Experimental|Naive T-cell Depleted Stem Cell Transplant|Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.
9859613|NCT00814983|Active Comparator|Stem Cell Transplant No Manipulation|Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation
9859614|NCT00825227|Active Comparator|Patient responses to 150 mg/day armodafinil|"150 mg/day armodafinil~taxane chemotherapy treatment alone or in combination with other agents"
9859615|NCT00825227|Placebo Comparator|Patient responses to placebo|"placebo~taxane chemotherapy treatment alone or in combination with other agents"
9859616|NCT00819832|Experimental|Phase 1 Group 1 Vertebroplasty|Vertebroplasty
9859617|NCT00819832|Experimental|Phase 1 Group 2 Kyphoplasty|Kyphoplasty
9859618|NCT00819832|Active Comparator|Phase 2 Group 1 Vertebroplasty|Vertebroplasty
9859619|NCT00819832|Active Comparator|Phase 2 Group 2 Vertebroplasty + Cavity SpineWand|Vertebroplasty with Cavity SpineWand
9859620|NCT00819832|Active Comparator|Phase 2 Group 3 Kyphoplasty|Kyphoplasty
10209496|NCT04233840|Experimental|sequential administration of P1101 and anti-PD1|Phase II Study GroupIII:Sequential administration of 6 doses of 450mcg P1101 and followed by 3 doses of anti-PD1 dosage (base on Phase I study result)
10209497|NCT04229290|Experimental|Dolutegravir|Participants in this arm will have a switch from a protease inhibitor based second line regimen to Dolutegravir maintaining the same NRTI backbone
10209498|NCT04229290|Active Comparator|Protease Inhibitor|Participants in this arm will be maintained on their protease inhibitor based second line regimen
10209499|NCT04225442|Other|Fatty meal|To study how a fatty meal modifies the physiological chronobiome in young and old, an isocaloric controlled liquid high fat meal (ICLHFM) will be consumed within 5 min. The ICLHFM contains an equivalent to 35% of the estimated total daily energy requirements (TDE), 60% of kcal delivered from fat while 13% come from protein and 27 % from carbohydrate.
9859621|NCT00819832|Active Comparator|Phase 2 Group 4 Kyphoplasty + Cavity SpineWand|Kyphoplasty with Cavity SpineWand
9859622|NCT00822679|Experimental|1: Eszopiclone|Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
9859623|NCT00822679|Placebo Comparator|2: Placebo|Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
9859624|NCT00814892|Experimental|DC-APCC|Patients undergo standard leukapheresis to harvest peripheral blood mononuclear cells for dendritic cell vaccine preparation. Patients receive the APCC vaccine and autologous dendritic cells derived from CD14-positive myeloid peripheral blood cells ID on days 0, 14, and 28 and then every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
9859625|NCT00809458|Experimental|Arm 1 (Vitamin E)|Vitamin E
9859626|NCT00809458|Placebo Comparator|Arm 2|Placebo (same vehicle as used for vitamin E)
9859627|NCT00802659|Experimental|Group -1|1000 cGY radiation
9859628|NCT00802659|Experimental|Group 1|1200 cGY radiation
9859629|NCT00802659|Experimental|Group 2|1400 cGY radiation
10213628|NCT03650491|Experimental|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
10209500|NCT04223661|Experimental|Frailty score 1|"Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
9859630|NCT00802659|Experimental|Group 3|1600 cGY radiation
9859631|NCT00807365|Experimental|GHRH|Growth Hormone-Releasing Hormone
9859632|NCT00814333|Experimental|1|Thrombin-JMI
9859633|NCT00814333|Active Comparator|2|Merocel pack
9859634|NCT00808080|Experimental|Biologic|AML_CTL cells
9859635|NCT00802893|Experimental|Experimental Drug|
9859636|NCT00802893|Placebo Comparator|Placebo Comparator|
9859637|NCT00809341|Active Comparator|PET Negative|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a negative PET scan will complete their chemotherapy regimen as prescribed by their oncologist.
9859638|NCT00809341|Active Comparator|PET Positive|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).
9859639|NCT00804349|No Intervention|Control|Patients will receive standard medical therapy for heart failure only and will not receive Autotitrating Positive Airway Pressure therapy.
9859640|NCT00804349|Active Comparator|Autotitrating Positive Airway Pressure|Patients will receive Autotitrating Positive Airway Pressure therapy in addition to standard medical care for heart failure.
9859641|NCT00803283|Experimental|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
9859642|NCT00803283|Active Comparator|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
9859643|NCT00811590|Experimental|All patients|All participants enrolled.
9859644|NCT00808899|Experimental|1|Fixed doses of IV temsirolimus concomitantly with two courses of fixed dosages of irinotecan, 2 days off, repeated daily 5 times.If initial dosages are not tolerable, subsequent patients will be given a reduced dosage of temsirolimus with irinotecan.If this dosage combination is not tolerable,irinotecan dosage will be decreased.If this dosage combination is not tolerable.Further enrollment to initial six week treatment will be terminated.Second course of irinotecan will begin on day 22, response will be determined after six weeks. Resection of primary tumor will be attempted after initial therapy.Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide,doxorubicin,etoposide,topotecan, and cisplatin.First cohort of 17 patients will receive Block 2 with temsirolimus for all three courses, weekly 2 times.If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus.
9859645|NCT00808769|Active Comparator|1|Zegerid®
9859646|NCT00808769|Experimental|2|Prilosec OTC®
9859647|NCT00803179|Experimental|Growth Hormone Therapy|"Nutropin Aqueous (AQ):~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d"
9859648|NCT00801931|Experimental|A: Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1.The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/mycophenolate mofetil (MMF).
9935144|NCT04113382|Active Comparator|Participants aged 4 to <9 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 8 oz for every 30 minutes one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
10209501|NCT04223661|Experimental|Frailty Score 2 or above|"Starting dose of lenalidomide in frail subjects (frailty score of 2 or higher) will be 5 mg day 1-21 of 28 day cycle, and escalate to 10 mg.~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
10209502|NCT04218240|Experimental|PGB/LFX;|0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5
10209503|NCT04218240|Active Comparator|Lofexidine and PLACEBO|0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5
10209504|NCT04208126|Active Comparator|Early ECMO|ECMO is placed immediately after admission to the intensive care unit
10209505|NCT04208126|No Intervention|Control|Conservative therapy unless failure of therapy.
10209506|NCT04207931|Active Comparator|Topical steroid plus oral antibiotic group|Participants in this group receive topical steroid (class I-II applied once daily) plus oral antibiotic group (doxycyline 100 mg twice daily for 6 months), and then topical minoxidil (5% solution or foam) after 8 months of treatment.
10209507|NCT04207931|Active Comparator|Topical steroid plus intralesional steroid injection group|Participants in this group receive topical steroid (class I-II applied once daily) plus intralesional steroid group (7.5mg/cc of kenaolog, max dose of 3 cc), and then topical minoxidil (5% solution or foam) after 8 months of treatment
10209508|NCT04205370|Active Comparator|Deactivated device|Wear deactivated pregnancy coach device for the remainder of pregnancy.
10209509|NCT04205370|Experimental|Active device|Wear active device for remainder of pregnancy (including 3 day run-in period)
10209510|NCT04199793|Active Comparator|Lavare Cycle On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
9794802|NCT01519063|Experimental|Naltrexone and memantine|Treatment with Naltrexone and memantine first
9794803|NCT01519063|Placebo Comparator|Naltrexone and Placebo|Treatment with naltrexone and placebo first
9794804|NCT01519089|Experimental|CP-690,550 10 mg BID|
9794805|NCT01519089|Experimental|CP690,550 5 mg BID|
9794806|NCT01519167|Experimental|Dexmedetomidine|
9794807|NCT01519206|Experimental|Ultherapy treatment|Ulthera System Treatment
9794808|NCT01519245|Experimental|Trial Drug|Solution containing 2 grams tranexamic acid + normal saline
9794809|NCT01519245|Placebo Comparator|Placebo|Normal saline
9794810|NCT01519271|Placebo Comparator|Placebo Patch|
9794811|NCT01519271|Active Comparator|Exelon Patch (rivastigmine transdermal system)|
9794812|NCT01519284|Placebo Comparator|Group 1|Placebo at all the dosing times
9794813|NCT01519284|Experimental|Group 2|"Day 1 to 7:~BIA 9-1067 5 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 5 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
9794814|NCT01519284|Experimental|Group 3|"Day 1 to 7:~BIA 9-1067 15 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 15 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
9794815|NCT01519284|Experimental|Group 4|"Day 1 to 7:~BIA 9-1067 30 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 30 mg: 7 AM dose Placebo + levodopa/carbidopa 100/25 mg: 8 AM dose"
9794816|NCT01519284|Experimental|Group 5|"Day 1 to 7:~Placebo: 7 AM dose; Entacapone 200 mg: 8 AM; 4 PM; 12 PM dose~Day 8:~Placebo: 7 AM dose Entacapone 200 mg + levodopa/carbidopa 100/25 mg: 8 AM dose"
9794817|NCT01519323|Experimental|Vemurafenib|Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (>=)45 kilogram (kg) and other weighing less than (<)45 kg. The starting dose for participants (>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing <45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.
9794818|NCT01519414|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9794819|NCT01519414|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
9794820|NCT01519427|Experimental|Treatment (selumetinib and Akt inhibitor MK2206)|Patients receive selumetinib PO BID on days 1-21 and Akt inhibitor MK2206 PO once weekly.
9794821|NCT01519453|Experimental|Home Based Asthma Education|Families will receive 4 home based and 3 phone based asthma education sessions with a community asthma outreach worker
9794822|NCT01519453|No Intervention|Control|There is no control arm specific intervention
9794823|NCT01519466|Other|Intervention|Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
9794824|NCT01519466|Other|Control|Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
9794825|NCT01519518|Active Comparator|Unfractionated heparin|70 units/kg body weight intravenous
9794826|NCT01519518|Active Comparator|bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
9794827|NCT01519570|Experimental|An informational packet regarding shingles and the HZV|
9794828|NCT01519570|No Intervention|Standard medical care from their primary care physician|
9794829|NCT01519635|Active Comparator|Aliskiren|Aliskiren 150 to 300 mg once a Week for 8 weeks
9794830|NCT01519635|Active Comparator|Hydrochlorothiazide|HCTZ 12.5 - 25 mg/d once a day for 8 weeks
9794831|NCT01519648||Acute leukemia patients|Patients with de novo or relapsed acute myeloid and lymphoid leukemia
9794832|NCT01519648||Allo- or auto- transplant recipients|
9794833|NCT01519661|Experimental|Tobramycin Inhalation Powder (TIP)|Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
9794834|NCT01519674|Active Comparator|BIAsp 30 BID + sitagliptin + metformin|
9794835|NCT01519674|Active Comparator|BIAsp 30 BID + metformin|
9794836|NCT01519674|Active Comparator|BIAsp 30 OD + sitagliptin + metformin|
9794837|NCT01519700|Experimental|EP2006|Eligible patients will be teated with EP2006
9794838|NCT01519700|Active Comparator|Filgrastim|Eligible patients will be teated with Filgrastim
9794839|NCT01519713|Experimental|Adults Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
9794840|NCT01519713|Experimental|Adolescents Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
9794841|NCT01519713|Experimental|Children Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
9794842|NCT01519765|Experimental|Buccal misoprostol+placebo vaginal pill|
9794843|NCT01519765|Active Comparator|Vaginal Misoprostol+placebo buccal pill|
9794844|NCT01519778|Experimental|TR-701 FA|
9794845|NCT01519791|Experimental|Certolizumab Pegol + Methotrexate|
9794846|NCT01519791|Placebo Comparator|Placebo + Methotrexate|
9794847|NCT01519817|Experimental|Yeast-Brachyury vaccine|Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
9794848|NCT01519869|Experimental|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
9794849|NCT01519882|Placebo Comparator|Placebo|Placebo Transdermal Patches
9794850|NCT01519882|Experimental|Rotigotine|Rotigotine Transdermal Patches
9859649|NCT00801931|Experimental|B: Full intensity without TBI|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
9859650|NCT00801931|Experimental|C: Moderate Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
9859651|NCT00801931|Experimental|D: Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
9859652|NCT00801931|Experimental|E: Fanconi's Anemia|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and horse antithymocyte globulin on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
9859653|NCT00801931|Experimental|F: Regimen for non-malignant diseases|Patients will begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
9859654|NCT00793520|Experimental|1|Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
9859655|NCT00793520|Experimental|2|Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
9859656|NCT00795236|No Intervention|Observational|Observe to determine free-running versus entrained status.
9859657|NCT00795236|Experimental|Melatonin|Subjects with free-running rhythms will take melatonin.
9859658|NCT00799773|Experimental|1|Participants will receive rituximab in addition to plasma exchange and corticosteroids.
9859659|NCT00799773|Active Comparator|2|Participants will receive plasma exchange and corticosteroids.
9859660|NCT00790452|Active Comparator|Group 1 (Aspirin)|Aspirin 325 mg/day orally
9859661|NCT00790452|Placebo Comparator|Group 2 (Placebo)|Tablet/day orally
9859662|NCT00795665|Experimental|Bevacizumab and Carmustine|
9859663|NCT00787917|Experimental|Omalizumab|"Eligible participants received a maximum dose of 600 mg omalizumab via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. A maximum 600 mg dose required 4 injections. All participants who entered the study received itraconazole twice daily, while receiving oral corticosteroids, with a maximum daily dose of 400 mg.~Participants who completed double-blinded phase, entered open-label treatment period of 6 months and continued the same regimen of omalizumab of double-blinded phase."
9859664|NCT00787917|Placebo Comparator|Placebo|Eligible participants received placebo comparator via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. All participants who entered the study received itraconazole twice daily, while on oral corticosteroids, with a maximum daily dose of 400 mg.
9859665|NCT00798590|Experimental|GLP-1|
9859666|NCT00798590|Placebo Comparator|Saline|
9859667|NCT00796510|Experimental|Sitaxsentan|Monotherapy arm
9859668|NCT00796510|Experimental|Sitaxsentan and Sildenafil|Combination treatment
9859669|NCT00796861|Experimental|Single Arm|Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx
9859670|NCT00791076|Placebo Comparator|Saline Placebo|Saline
9859671|NCT00791076|Active Comparator|Pancreatic Polypeptide|Pancreatic Polypeptide
9859672|NCT00790478|Placebo Comparator|Placebo|Placebo -- lactose pill.
9859673|NCT00790478|Active Comparator|Melatonin|Melatonin
9859674|NCT00796107|Experimental|R1507 in Combination With Letrozole|Participants received a full daily dose of 2.5 mg of orally administered Letrozole along with 16 mg/kg of intravenous R1507 administered q3w, and observed for dose limiting toxicity for the first 2 cycles of treatment.
9859675|NCT00791336|Experimental|Nelfinavir|
9859676|NCT00786682|Experimental|Docetaxel and Hydroxychloroquine|"Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle~Drug: hydroxychloroquine 200 mg twice daily~A cycle is defined as an interval of 21 days."
9859677|NCT00787124||1|< 28 weeks gestation, < 30 days of age, < 3 previous transfusions
9859678|NCT00787124||2|< 28 weeks gestation, >=30 days of age, >= 3 previous transfusions
10209511|NCT04199793|Active Comparator|Lavare Cycle Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
10209512|NCT04199468|Experimental|Active Delta-9-THC and Placebo Ketamine|Active IV Delta-9-THC and Placebo Ketamine
9859679|NCT00785356|Experimental|25 mg Proellex|Proellex 25 mg
9859680|NCT00785356|Experimental|Proellex 50 mg|Proellex 50 mg
9859681|NCT00785356|Placebo Comparator|Placebo|Placebo
9859682|NCT00791843|Experimental|GHRH and placebo|Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
9859683|NCT00784043|Experimental|Bilateral|Bilaterally implanted simultaneously
9859684|NCT00784043|Experimental|Unilateral|Unilaterally implanted
9859685|NCT00787618|Active Comparator|50 mg Proellex Mild impairment|50 mg Proellex single dose Female subjects with mild renal impairment function.
9859686|NCT00787618|Active Comparator|50 mg Proellex Moderate|50 mg Proellex, Female subjects with moderate renal impairment function.
9859687|NCT00787618|Active Comparator|50 mg Proellex, Normal|50 mg Proellex, Female subjects with normal renal function.
10209513|NCT04199468|Experimental|Active Delta-9-THC and Active Ketamine|Active IV Delta-9-THC and Active Ketamine
10209514|NCT04199468|Experimental|Placebo Delta-9-THC and Placebo Ketamine|IV Placebo Delta-9-THC and Placebo Ketamine
10209515|NCT04199468|Experimental|Placebo Delta-9-THC and Active Ketamine|IV Placebo Delta-9-THC and Active Ketamine
9859688|NCT00774306|Active Comparator|1|Participants randomized to Group 1 will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
9859689|NCT00774306|Active Comparator|2|Participants randomized to Group 2 will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses or in a once-daily extended release formulation.
9859690|NCT00774306|Active Comparator|3|Participants randomized to Group 3 will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
9859691|NCT00774306|No Intervention|4|Participants randomized to Group 4 will receive no drug intervention.
10209516|NCT04197869|Experimental|Experimental|The experimental group will take a pre-operative course of polyethylene glycol daily for seven days prior to procedure date.
10209517|NCT04197869|No Intervention|Control|The control group will not be given any intervention preoperatively.
10209518|NCT04196023|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
10209519|NCT04196023|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
10209520|NCT04196023|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
10209521|NCT04196023|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
10209522|NCT04191187|Experimental|Conditioning Regimen + Transplant|All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)
10209523|NCT04182919|Experimental|Arm 1|Phlai 2 capsules (compound D 8 mg) od evening after meal x 4 weeks
10209524|NCT04182919|Experimental|Arm 2|Phlai 1 capsules (compound D 4 mg) and placebo 1 capsule od evening after meal x 4 weeks
10209525|NCT04182919|Placebo Comparator|Arm 3|Placebo 2 capsules od evening after meal x 4 weeks
9859692|NCT00771602|Experimental|Rituximab|Group 1: 375 mg/m^2 IV Rituximab Alone
9859693|NCT00771602|Experimental|Alemtuzumab|Group 2: 30 mg SQ Alemtuzumab Alone
9859694|NCT00771602|Experimental|Rituximab + Alemtuzumab|Group 3: 375 mg/m^2 Rituximab + 30 mg SQ Alemtuzumab
9859695|NCT00779038|Experimental|Fentanyl ITS|40 microgram (mcg) per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an Iontophoretic Transdermal System (ITS). Total duration of treatment will be 72 hours.
9859696|NCT00780455|Experimental|Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) within 15 days after randomization
9859697|NCT00780455|Experimental|Interferon beta-1b, FRP about 6 weeks after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) about 6 weeks after randomization
10209526|NCT04181476|Other|Topical products and Untreated areas|The subject will serve as their own control. Four different products will be tested.
10209527|NCT04180059|Experimental|CTL 19 : T cell therapy|Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg.
10209528|NCT04162015|Experimental|nivolumab with pemetrexed and cisplatin or carboplatin|Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.
10209529|NCT04156438|Active Comparator|Low tidal volume ventilation|Conventional low tidal volume ventilation
10209530|NCT04156438|Experimental|Airway pressure release ventilation|Early use of airway pressure release ventilation
9859698|NCT00776100|Other|Arm I|Patients undergo observation for 6 weeks.
9859699|NCT00776100|Experimental|Arm II|Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.
9859700|NCT00771316|Experimental|Group 1|MK0826 (ertapenem)
9859701|NCT00771316|Active Comparator|Group 2|meropenem
9859702|NCT00780481|Experimental|Bradykinin|Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.
9859703|NCT00769652|Experimental|Medical nutrition therapy|Medical nutrition therapy
9859704|NCT00769652|Active Comparator|Standard care|Standard care
9859705|NCT00768040|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily for 12 weeks
9859706|NCT00768040|Placebo Comparator|Placebo|Matching placebo once daily for 12 weeks
9859707|NCT00776555|Experimental|Vyvanse™|50mg capsule that has been emptied and made into solution
9859708|NCT00776555|Experimental|ADDERALL XR®|20mg capsule that has been emptied, crushed, and made into solution
9859709|NCT00775190|Active Comparator|Ortho tricyclen™|Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily
9859710|NCT00775190|Active Comparator|Trinessa™|Participant Randomized to Trinessa 1 tablet by mouth Daily
9924370|NCT00860691|Other|Control - reference value|Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum. Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay. Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay. Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. . Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube. burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
9924371|NCT00860704|Active Comparator|Ringerlactate lean|fluidtherapy with crystalloids in lean patients
9924372|NCT00860704|Active Comparator|Ringerlactate overweight|fluidtherapy with crystalloids in overweight patients
9924373|NCT00860704|Active Comparator|Ringerlactate obese|fluidtherapy with crystalloids in obese patients
9924374|NCT00860717|Active Comparator|1|Subjects from the arm number 1 received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
9924375|NCT00860717|Experimental|2|Subjects from the arm number 2 received low level laser therapy 3 times per week for 12 weeks, in addition to the same treatment as patients from the arm number 1.
9924376|NCT00860730|Experimental|Perceval S|
9924377|NCT00860756|Experimental|1|Intervention Group
9924378|NCT00860769|Experimental|ASHA Life|6-session educational group discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills.
9924379|NCT00860769|Active Comparator|Usual Care|3-session educational group focusing on HIV prevention, anti-retroviral therapy (ART) and parenting.
9924380|NCT00860782|Experimental|Annual Parent Intervention (API) Group|Participants in this group will receive the parent educational support intervention once a year for 2 years.
9924381|NCT00860782|Experimental|Quarterly Parent Intervention (QPI) Group|Participants in this group will receive the parent educational support intervention quarterly (4 times a year) for 2 years.
9924382|NCT00860808|Experimental|1 AM-101|low dose
9924383|NCT00860808|Experimental|2 AM-101|high dose
9924384|NCT00860808|Placebo Comparator|3 Placebo|
9924385|NCT00860821|Experimental|1|AZD8309
9924386|NCT00860821|Placebo Comparator|2|Placebo
9859711|NCT00755261|Experimental|Avastin and Doxorubicin|Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
9859712|NCT00762723|Experimental|Group 1|Trinica Anterior Lumbar Plate System with fixed screws only
9859713|NCT00762723|Experimental|Group 2|Trinica Anterior Lumbar Plate System with variable screws only
9859714|NCT00762723|Experimental|Group 3|Trinica Anterior Lumbar Plate with hybrid screw configuration (2 fixed-angle screws with 2 variable-angle screws).
9859715|NCT00770965|Experimental|AIN457 0.3 mg/kg|Participants received AIN457 0.3 mg/kg IV on Day 1.
9859716|NCT00770965|Experimental|AIN457 1.0 mg/kg|Participants received AIN457 1.0 mg/kg IV on Day 1.
9859717|NCT00770965|Experimental|AIN457 3.0 mg/kg|Participants received AIN457 3.0 mg/kg IV on Day 1.
9859718|NCT00770965|Placebo Comparator|Placebo|Participants received placebo to AIN457A IV on day 1.
9859719|NCT00769002|Active Comparator|Natural Infection|previously naturally infected
9859720|NCT00769002|Active Comparator|FluShield - influenza positivity|prior FluShield ipsilateral vaccinated
9859721|NCT00769002|Active Comparator|FluShield - influenza positivity2|prior FluShield contralateral vaccinated
9859722|NCT00769002|Active Comparator|FluMist|prior FluMist vaccinated.
9859723|NCT00766636|Experimental|Gemcitabine + Erlotinib Without Radiation|"Gemcitabine + Erlotinib without radiation - Arm A: Gemcitabine 1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42.~Surgical removal of the pancreas and duodenum."
9859724|NCT00766636|Experimental|Gemcitabine + Erlotinib With Radiation|Gemcitabine + Erlotinib with radiation - Arm B: Gemcitabine 400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42. Radiation therapy 1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy. Surgical removal of the pancreas and duodenum.
9859725|NCT00768248|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
9859726|NCT00768248|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
9859727|NCT00765765|Experimental|Ixabepilone and hydroxychloroquine|
9859728|NCT00764699|Experimental|rhIGF|Treatment with rhIGF (Increlex)
9859729|NCT00759577|Other|Home titration|Patients were given drug to self titrate
9859730|NCT00763009|Other|All subjects receive dipyridamole|Compare to baseline
9859731|NCT00761176|No Intervention|Standard of Care|Standard of Care will be utilized without the device.
9859732|NCT00761176|Other|The Provant Therapy System|Thirty minutes, twice daily treatment
9859733|NCT00749476|Experimental|1|
9859734|NCT00760461|Other|Domperidone|
9859735|NCT00749658|Active Comparator|Bupropion + Placebo Varenicline|Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline
9859736|NCT00749658|Active Comparator|upropion + Varenicline|Bupropion + Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Varenicline
9859737|NCT00754793|Active Comparator|1|escitalopram 10mg - 30mg daily
9859738|NCT00754793|Placebo Comparator|2|
9859739|NCT00754052|Active Comparator|1|
9859740|NCT00754052|Active Comparator|2|
9859741|NCT00754052|Placebo Comparator|3|
9859742|NCT00750555|Other|1|
9859743|NCT00754767|Experimental|Arm I|Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
9859744|NCT00754767|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
9859745|NCT00750204|Experimental|APRV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
9859746|NCT00750204|Active Comparator|Conventional MV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
9859747|NCT00748579|Experimental|Cohort 1|0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
9859748|NCT00748579|Experimental|Cohort 2|≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
9859749|NCT00748085|Experimental|Cryospray Ablation|Cryospray Ablation 4, 5-second spray cycles
9859750|NCT00752986|Experimental|Vandetanib at the dose of 100 mg|vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
9859751|NCT00752986|Experimental|Vandetanib at the dose of 300 mg|vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
9859752|NCT00752986|Placebo Comparator|Placebo to match vandetanib 100 mg and 300 mg|placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3).
9859753|NCT00751335|Experimental|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
9859754|NCT00751335|Experimental|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
9859755|NCT00746239|Active Comparator|1|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
9666953|NCT04095598||Syndesmotic uninjured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
9859756|NCT00746239|Placebo Comparator|2|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
9859757|NCT00754013|Active Comparator|Donepezil|
9859758|NCT00754013|Placebo Comparator|Placebo|
9859759|NCT00735553|Active Comparator|25 mg Proellex|25 mg oral daily dose of Proellex
9859760|NCT00735553|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
9859761|NCT00735553|Placebo Comparator|placebo|oral daily dose of placebo
9859762|NCT00751933|Experimental|2|Vaccination with Vivotif and Dukoral
9859763|NCT00751933|Experimental|3|Dietary supplement with oats
9859764|NCT00751933|Placebo Comparator|4|Placebo instead of vaccines No dietary supplement
9859765|NCT00751933|Experimental|1|Vaccination with Vivotif and Dukoral + dietary supplement with oats.
9859766|NCT00747916|Experimental|CryoSpray Ablation (TM) System|subjects will receive cryotherapy using the CryoSpray Ablation (TM) System DOSE: up to 3 cycles of 10-40 second sprays
9859767|NCT00745030|Experimental|1|Ramelteon (TAK-375) 8mg tablets
9859768|NCT00745030|Placebo Comparator|2|Placebo 8 mg tablets
9859769|NCT00747461|Experimental|Cryospray Ablation|Experimental CSA (Cryospray Ablation)
9859770|NCT00746018|Experimental|1|The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
9859771|NCT00746603|Experimental|A Intervention Arm|Escalating dose of simvastatin in subjects who are survivors of Hodgkin Lymphoma
9859772|NCT00736385|Active Comparator|Metformin|Metformin XR (extended-release) 2000 mg daily
9859773|NCT00736385|Placebo Comparator|Placebo|Placebo capsule
9859774|NCT00738972|Active Comparator|Valsartan 80 mg + Paravastin 40 mg|Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
9859775|NCT00738972|Active Comparator|Valsartan 80 mg + Simvastatin 40 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
9859776|NCT00738972|Experimental|Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
9859777|NCT00738972|Active Comparator|Valsartan 80 mg|Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
9859778|NCT00739063|Experimental|Tarceva daily|Tarceva oral 150 mg daily.
9859779|NCT00740597|Experimental|Arm 1|pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.
9859780|NCT00737594|Placebo Comparator|Placebo TID|Participants receive matching placebo capsules three times daily (TID)
9859781|NCT00737594|Experimental|12 mcg TID|Participants receive 12 mcg Cobiprostone TID
9859782|NCT00737594|Experimental|18 mcg TID|Participants receive 18 mcg Cobiprostone TID
9859783|NCT00737282|Active Comparator|25 mg Proellex|Proellex 25 mg once daily
9859784|NCT00737282|Active Comparator|Proellex 50 mg|Proellex 50 mg once daily
9859785|NCT00739882|Active Comparator|Efalizumab|
10209531|NCT04151251|Active Comparator|Sleep Kit Alone|Patients who are not randomized into the I-SLEEP intervention will receive a sleep kit that includes an eye mask, earplugs, and headphones.They will still receive the usual standard of care provided by clinicians which includes measures to reduce unnecessary nighttime disruptions and limiting excessive noise within the hospital setting.
10209532|NCT04151251|Experimental|Sleep Kit + Empowerment|"A short video will be shown on iPads and a brochure will be given that both describe the importance of good sleep and how to facilitate it with good sleep hygiene.~The video will show a few reasons why someone might not get optimal sleep while in a hospital, and offer advice to address this from a doctor. The brochure will be kept to no higher than a 6th grade reading level, considered optimal for health education materials. Text will be kept brief and to the point. To account for vision problems, we will use >12-point font & leave a large portion of each page empty. Visual Aids & graphics will be employed when possible.~All of this is given in addition to the usual standard of care provided by clinicians."
10209533|NCT04147988|Other|DONALD T list|adults on the DONALD T list seeking diagnostic advice on autism spectrum disorder or asperger's syndrome
10209534|NCT04146545|Experimental|Cases|Community Rx-Caregiver Resources
10209535|NCT04146545|No Intervention|Control|Usual Standard Care
9859786|NCT00739882|Placebo Comparator|Placebo|
9859787|NCT00739024|Active Comparator|Active Treatment|Ramelteon once daily (double-blind assignment)
9859788|NCT00739024|Placebo Comparator|Placebo|Placebo tablet, once daily (double-blind assignment)
9859789|NCT00731770|Placebo Comparator|Placebo, then Advair 250- matched|1 puff bid Placebo for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Advair 250- matched 1 puff bid for two weeks.
9859790|NCT00731770|Active Comparator|Advair 250, then Placebo- matched|1 puff bid Advair 250 for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Placebo- matched 1 puff bid for two weeks.
9859791|NCT00735254|Active Comparator|Pulsed dye laser|PDL Patient will be have scar treated with pulsed dye laser.
9859792|NCT00735254|Active Comparator|Affirm laser|Patient will be have scar treated with Affirm Laser
9859793|NCT00735254|Active Comparator|combined PDL and Affirm Lasers|Patient will be have scar treated with combined Affirm + PDL
9859794|NCT00735254|Placebo Comparator|Placebo|Patient will be have scar treated with Placebo
9859795|NCT00729365|Placebo Comparator|Dippers - Placebo Treated|Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
9859796|NCT00729365|Placebo Comparator|NonDippers - Placebo Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
9859797|NCT00729365|Active Comparator|NonDippers - Ramipril Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).
9859798|NCT00732680|Experimental|Botulinum Toxin Type A|Treatment will be in the form of 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
9859799|NCT00726180|Experimental|Treatment arm|
9859800|NCT00724282|Other|Eszopiclone or Placebo|Subjects receive either eszopiclone or placebo for 9 days, followed by 3 week washout, then crossover to opposite treatment. Treatment is double-blinded.
9859801|NCT00730886|Experimental|1|Non-invasive procedure for fertility enhancement (i.e., ExAblate treatment)
9859802|NCT00730886|Active Comparator|2|Invasive surgical procedure for fertility enhancement (i.e., myomectomy)
9859803|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel, Bevacizumab|Cohort 1: Bevacizumab Eligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
9859804|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel|Cohort 2: Bevacizumab Ineligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
9859805|NCT00726830|Experimental|Arm I: Opioid rotation to oral methadone|Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
9859806|NCT00726830|Experimental|Arm II: Opioid rotation to another long-acting strong opioid|Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.
9859807|NCT00726037|Experimental|1|Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
9859808|NCT00729560|Experimental|1|Flutamide
9859809|NCT00729560|Placebo Comparator|2|control to arm 1
9859810|NCT00716807|Experimental|TMD 1|
10209536|NCT04144894|Other|Healthy Controls|
9859811|NCT00716807|Placebo Comparator|TMD 2|
9859812|NCT00716807|Experimental|BMS 1|
9859813|NCT00716807|Placebo Comparator|BMS 2|
9859814|NCT00714948|Experimental|1|This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.
9666954|NCT04094103|Experimental|Active strawberry powder|Participants will consume a 39g freeze-dried active strawberry powder beverage once per day for 4-weeks.
9859815|NCT00720343|Experimental|Choline|Oral choline
9859816|NCT00720343|Placebo Comparator|Placebo|Gelatin Capsule
9859817|NCT00719914|Active Comparator|1|Intracoronary injection of eptifibatide
9859818|NCT00719914|Placebo Comparator|2|Intra-coronary injection of normal saline.
9859819|NCT00718640|Experimental|Bortezomib and Dexamethasone|Bortezomib 1.3 milligram (mg) per meter^2 (m^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
9859820|NCT00720083|Active Comparator|RT + Cisplatin|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
9859821|NCT00720083|Experimental|RT + Cisplatin + Vandetanib|Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
9859822|NCT00717275|Experimental|Temozolomide|
9859823|NCT00708734|Experimental|Arm 1|functional exercise training
9859824|NCT00711087|Placebo Comparator|ARM 2|Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
9859825|NCT00711087|Active Comparator|ARM 1|Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
9859826|NCT00706797|Active Comparator|Usual care|Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold).
9859827|NCT00706797|Active Comparator|ETN + MTX|Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-filled syringe) plus continuation of current dose of Methotrexate (MTX) either oral (PO), SC, or intramuscular (IM).
9859828|NCT00713596|Sham Comparator|Control group|Septorhinoplasty with postoperative application of nasal taping and an external nasal cast. The tape and cast will be left in place for one week. No tissue glue will be used during the operation, although the nurse and surgical assistant will simulate the preparation and insertion of tissue glue using a syringe containing saline.
9859829|NCT00713596|Experimental|Fibrinogen, tape, and cast|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, fibrin sealant will be applied by the surgical assistant to the surgical site. Approximately 0.5 cc to 2 cc of tissue sealant will be applied. After closure, tape and cast will be applied and left in place for one week.
9859830|NCT00713596|Experimental|Fibrinogen and tape|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, 0.5 cc to 2 cc of tissue sealant will be applied. Nasal tape will be applied after closure.
9859831|NCT00703885|Active Comparator|1|"0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
9859832|NCT00703885|Active Comparator|2|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
9924387|NCT00860834|Experimental|1|Pediatricians and parents of children with asthma will participate in the asthma coaching program.
10209537|NCT04144894|Other|Vascular Surgery Subjects|
10209538|NCT04129723|Experimental|Perianal Crohn's patient|Stopping biological therapy
10209539|NCT04121455|Experimental|Cohort 1: 200 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
10209540|NCT04121455|Experimental|Cohort 2: 400 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
10209541|NCT04121455|Experimental|Cohort 3: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
9859833|NCT00703885|Placebo Comparator|Placebo|"Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
9859834|NCT00703092|Experimental|Fiber-Stat|2 tablespoons daily
9859835|NCT00713258|Active Comparator|PTH (1-84)|PTH (1-84) + placebo alendronate
9859836|NCT00713258|Active Comparator|Alendronate|PTH (1-84) placebo + alendronate
9859837|NCT00706329|Experimental|Deflux|Treatment with Deflux.
9859838|NCT00707434|Experimental|Glucose Monitoring Device|Continuous glucose monitoring in critically ill patients.
9859839|NCT00707161|Experimental|All participants|
9859840|NCT00704496|Placebo Comparator|Placebo|Placebo
9859841|NCT00704496|Active Comparator|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
9859842|NCT00708916|Experimental|Apremilast|CC-10004 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
9859843|NCT00700778|Experimental|Recombinant human chorionic gonadotropin|Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.
9859844|NCT00699842|Experimental|Lenalidomide|Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.
9859845|NCT00702962|Experimental|Phase I: Vorinostat 200 mg|"Vorinostat 200 mg PO QD D1-14; Administer with Carbo 6 (AUC) D3; Etoposide 100 mg/m2 D1,2,3 Vorinostat, Carboplatin, Etoposide"
9859846|NCT00703534|Experimental|AZD3355|
9859847|NCT00703534|Placebo Comparator|Placebo|
9859848|NCT00698009|Experimental|Fludarabine + Cyclophosphamide + NK Cell Infusion|Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.
9859849|NCT00691444|Experimental|1|Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
9859850|NCT00691444|Experimental|2|Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
9859851|NCT00691444|Experimental|3|Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
9859852|NCT00702702|Experimental|A 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
9859853|NCT00702702|Experimental|B 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
9859854|NCT00702702|Placebo Comparator|C Placebo|Placebo, 2 capsules daily for 3 months
9859855|NCT00693628|Active Comparator|Shrinker|Patients receive 20-30 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
9859856|NCT00693628|No Intervention|No Shrinker|Control group - participants will not receive an intervention (compression shrinker).
9859857|NCT00693628|Active Comparator|Shrinker 2|Patients receive 30-40 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
9859858|NCT00699413|Active Comparator|1 - nutrition education plus active supplement|nutrition education plus active supplement
9859859|NCT00699413|Placebo Comparator|2 - nutrition education plus inactive supplement|nutrition education plus inactive supplement
9924388|NCT00860834|Active Comparator|2|Children of parents enrolled in the study will receive usual asthma care from their pediatrician.
9924389|NCT00860873|Experimental|Test 1|Oral Powder EMS
9859860|NCT00691652|Experimental|Oral Clofarabine + Rituximab in Relapsed B Cell NHL|"Phase I: Oral Clofarabine x 14 days for up to 8 cycles at assigned dose level below (1 cycle equals 14 days on drug, 14 days off).~Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV~Dose Level 1: 2 mg Dose Level 2: 4 mg Dose Level 3: 6 mg~Phase II:~Oral Clofarabine x 14 days for up to 8 cycles (Dose determined from phase I) AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV"
9859861|NCT00686972|Experimental|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
9859862|NCT00693017|Active Comparator|Zonisamide|
9859863|NCT00693017|Placebo Comparator|Placebo|
9859864|NCT00691574|Active Comparator|2|Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
9859865|NCT00691574|Experimental|1|Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.
9859866|NCT00692094|Experimental|1|Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
9859867|NCT00692094|Experimental|2|Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
9859868|NCT00692094|Experimental|3|Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
9859869|NCT00692094|Experimental|4|Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
9859870|NCT00689884|Experimental|Group A|All eligible patients will receive chemotherapy and one dose of Pegfilgrastim
9859871|NCT00692003|Active Comparator|Zonisamide|
9859872|NCT00692003|Placebo Comparator|Placebo|
9859873|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously.
9859874|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
9859875|NCT00676026|Experimental|Zolpidem 1|Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
9859876|NCT00676026|Experimental|Progesterone 2|Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
9859877|NCT00676026|Experimental|Fluoxetine 3|Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
9859878|NCT00689052|Experimental|Pramipexole ER|0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
9859879|NCT00689052|Placebo Comparator|Placebo|Placebo tablets, once daily in the evening
9859880|NCT00678574|Experimental|Premenstrual Dysphoric Disorder (PMDD) group|PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months
9859881|NCT00678574|No Intervention|Healthy controls|
9859882|NCT00683917|Experimental|Proellex 25 mg|Proellex 25 mg
9859883|NCT00683917|Experimental|Proellex 50 mg|Proellex 50 mg
9859884|NCT00683917|Active Comparator|Lupron|Lupron Depot
9859885|NCT00688935|Experimental|Melatonin|Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
9859886|NCT00685880|Experimental|Prolotherapy group|Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
9859887|NCT00685880|Active Comparator|Corticosteroid Group|Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
9859888|NCT00686036|Experimental|vandetanib|300 mg orally, once daily for up to 18 months
9859889|NCT00686036|Placebo Comparator|Placebo|orally, once daily for up to 18 months
9859890|NCT00681044|Experimental|SCT with melphalan conditioning|Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion
9859891|NCT00684255|Experimental|Reduced Intensity Regimen for Refractory SLE|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
9859892|NCT00684255|Experimental|Reduced Intensity Regimen for SSc|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).
9924390|NCT00860873|Experimental|Test 2|Hard Capsules EMS
9859893|NCT00683787|Active Comparator|Arm I|Patients receive docetaxel IV once every 3 weeks.
9859894|NCT00683787|Experimental|Arm II|Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
9859895|NCT00683787|Experimental|Arm III|Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.
9859896|NCT00679926|Experimental|Once daily|Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.
9924391|NCT00860873|Active Comparator|Comparator 1|Oral Powder Zodiac
9924392|NCT00860873|Active Comparator|Comparator 2|Hard capsules - Zodiac
9924393|NCT00860886||1|Mongolian Women
9924394|NCT00860886||2|Women in other parts of the world other than Mongolia.
9924395|NCT00860899|Active Comparator|clonidine|Clonidine is an alpha2-adrenergic agonist with sedative, analgesic and hemodynamic properties. It inhibits transmission of nociceptive stimuli in the dorsal horn of the spinal cord, acting on the inhibitory descending pathways.
9924396|NCT00860899|Active Comparator|levobupivacaine|Levobupivacaine is long-acting local anesthetic, S-enantiomer of bupivacaine, with identical anesthetic potency.
9924397|NCT00860912|Experimental|Intervention: Collagen matrix|Cystocele repair: Veritas reinforcing material implanted for reinforcement of cystocele repair with collagen matrix
9924398|NCT00860912|Other|Native tissue repair|Intervention: Cystocele repair performed: No reinforcing material used and routine performance of a cystocele repair using native tissues.
9924399|NCT00860925|Experimental|active clonidine and active ASA|
9924400|NCT00860925|Experimental|active clonidine and ASA placebo|
9924401|NCT00860925|Experimental|Clonidine placebo and active ASA|
9924402|NCT00860925|Placebo Comparator|Clonidine placebo and ASA placebo|
9924403|NCT00860964|Placebo Comparator|Placebo|
9924404|NCT00860964|Experimental|estradiol valerate|
9924405|NCT00860977|Placebo Comparator|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
9924406|NCT00860977|Experimental|Valacyclovir|oral valacyclovir 500mg twice daily
9924407|NCT00860990||1|SCI or disabled
9924408|NCT00860990||2|Able-bodied
9924409|NCT00861003||Schizophrenia, antipsychotics|Stable outpatient status of schizophrenia or schizoaffective disorder currently taking a single oral antipsychotic
9924410|NCT00861016|Experimental|1|The patients with mild to moderate essential hypertension
9924411|NCT00861029|Experimental|Pazopanib|Subjects will receive pazopanib during study
9924412|NCT00861029|Other|Placebo|Placebo as a comparator to pazopanib
9924413|NCT00861042|Experimental|1|
9924414|NCT00861055||Infants|Infants less than 7 days of age with clinical signs of sepsis
9666955|NCT04094103|Placebo Comparator|Placebo strawberry powder|Participants will consume a 39g freeze-dried strawberry powder placebo beverage once per day for 4-weeks.
9666956|NCT04094103|Active Comparator|Mixed active/placebo strawberry powder|Participants will consume a 39g mixed active/placebo strawberry powder beverage once per day for 4-weeks.
9924415|NCT00861055||Mothers|Mothers following antenatal care at SMRU antenatal clinic, Maela camp who are 28 - 30 weeks gestation
9924416|NCT00861068|Experimental|1|
9924417|NCT00861068|Placebo Comparator|2|
9924418|NCT00861081|Experimental|1: Care management|
9924419|NCT00861081|Active Comparator|2: Written Materials|
9924420|NCT00861094|Experimental|FOLFOX and radiotherapy|Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
9924421|NCT00861094|Experimental|5-FU / cisplatin and radiotherapy|5-FU (100mg/m2); Cisplatin (75mg/m2)
9924422|NCT00861159||1|
9924423|NCT00861172|Experimental|1|
9924424|NCT00861224||Observed Subjects|Subjects that submitted bone marrow biopsy and aspirates.
9924425|NCT00861237|Placebo Comparator|Placebo globules group|Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
9924426|NCT00861237|Active Comparator|Nux vomica group|Patients receive Nux vomica globules made out of sugar sublingually before surgery.
9924427|NCT00861250|Experimental|Vel/Dex|
9924428|NCT00861276|Experimental|1|Arm instructed to use spray at least once an hour when awake.
9924429|NCT00861276|Active Comparator|2|Ad libitum: patients were instructed to use NNS when craving appears.
9924430|NCT00861302|Experimental|Treatment group|This is the only group in the study. It consists of patients with chronic musculoskeletal pain who are receiving the treatment program
9924431|NCT00861315|Experimental|Nebulized amikacin|Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely
9924432|NCT00861315|Active Comparator|Intravenous amikacin|
9924433|NCT00861328|Experimental|A|Treatment of escalating doses of ON 01910.Na in combination with irinotecan
9924434|NCT00861328|Experimental|B|Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin
9924435|NCT00861367|Active Comparator|1|aspirin 100mg
9859897|NCT00678041|Experimental|Arm 1: Nitrofurantoin Group|extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
9859898|NCT00678041|Placebo Comparator|Arm 2: Placebo Group|identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
9859899|NCT00680316|Experimental|Dornase alfa|
9859900|NCT00680316|Placebo Comparator|Placebo|
9859901|NCT00681629|Experimental|Quetiapine XR Alone|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
9859902|NCT00681629|Experimental|Quetiapine XR With Integrated Care Program (ICP)|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
9859903|NCT00669461|Experimental|Patients|
9859904|NCT00671606|Experimental|Intraoperative Lymphatic Mapping|Intraoperative sentinel lymph node identification (lymphatic mapping)
9859905|NCT00673309|Experimental|Growth Hormone|Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
9859906|NCT00673309|Experimental|Insulin High Dose|Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
9859907|NCT00673309|Experimental|Oxandrolone|Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
9859908|NCT00673309|Experimental|Propranolol|Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
9859909|NCT00673309|Experimental|IGF-1/IGFBP-3|IGF-1/IGFBP-3 will be administered until 95% wound healing
9859910|NCT00673309|Experimental|Insulin Low Dose|Insulin Low Dose will be administered until 95% wound healing.
9859911|NCT00673309|Experimental|Itraconazole|Itraconazole will be administered until 95% wound healing.
9859912|NCT00673309|Experimental|Growth Hormone and Propranolol|Growth Hormone and Propranolol will be administered until 95% wound healing.
9859913|NCT00673309|Experimental|Oxandrolone and Propranolol|Oxandrolone and Propranolol will be administered until 95% wound healing
9859914|NCT00673309|Placebo Comparator|Control/Placebo|Placebo or Control will be administered until 95% wound healing
9859915|NCT00673595|Active Comparator|Varenicline|Participants on this arm will receive varenicline tablets for 15 days.
9859916|NCT00673595|Placebo Comparator|Placebo|Participants on this arm will receive placebo tablets for 15 days.
9859917|NCT00673361|Experimental|"Chemo-Switch Regimen"|
9859918|NCT00670631|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
9859919|NCT00668785|Experimental|Ranibizumab|Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
9859920|NCT00673179|Experimental|Outpatient Chemotherapy|Pre-Surgery, Regimen 1: Doxorubicin intravenous (IV) 90 mg daily, Cisplatin 60 mg/m^2/day for 2 days, Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Surgery; Post-Surgery, Regimen 1: Methotrexate 12 gm/m^2, Doxorubicin IV 90 mg, Cisplatin 60 mg/ m^2 twice daily, Leucovorin Rescue.
9859921|NCT00673179|Experimental|Additional Risk-Adapted Outpatient Chemotherapy|Pre-Surgery, Regimen 2: Dexrazoxane 900 mg/m^2 intravenous (IV) then Doxorubicin IV 90 mg daily, Cisplatin 120 mg/m^2 (intra-arterial); Surgery; Post-Surgery, Regimen 2: Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Ifosfamide 2.8 grams m^2/day and Mesna 2.8 gm/m^2/day continuous IV over 6 days; Lung-Directed Chemotherapy, Regimen 2: Gemcitabine, Sargramostim Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg).
9859922|NCT00668265|Experimental|Seroquel|
9859923|NCT00660348|Active Comparator|morphine|morphine given traditionally (IV, pill, patch). This is standard of care dosing.
9859924|NCT00660348|Active Comparator|Intrathecal pump|Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
9859925|NCT00667017|Experimental|IMTOX25 at 2mg/m²/dose|Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.
9859926|NCT00665444|Experimental|A|Aripiprazole
9859927|NCT00656916|Experimental|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
9859928|NCT00656916|No Intervention|Observational Group|Comparator group, no intervention.
9859929|NCT00660595|Experimental|1|Oral
9859930|NCT00660595|Active Comparator|2|Oral
9859931|NCT00661466|Experimental|1|Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
9859932|NCT00661466|Placebo Comparator|2|Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
9859933|NCT00646282|Experimental|Doxercalciferol|Stable kidney transplant recipients will receive Doxercalciferol
9859934|NCT00646282|No Intervention|Control|Stable kidney transplant recipients will not receive any drug
9859935|NCT00657553|Active Comparator|Bortezomib/Treatment Arm|Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
9859936|NCT00657553|No Intervention|Observation Arm (watchful waiting)|monitor myeloma parameters every 3-6 months
9859937|NCT00655057|Active Comparator|1|Healthy participants will undergo TRODAT-1 SPECT imaging.
9859938|NCT00655057|Experimental|2|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with s-citalopram.
9859939|NCT00655057|Active Comparator|3|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with cognitive behavioral therapy.
9859940|NCT00648895|Active Comparator|1|Nebivolol
9859941|NCT00648895|Active Comparator|2|Metoprolol ER (TM)
9859942|NCT00647426|Experimental|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
9859943|NCT00645567||Unassisted manual transfer|this group will use no additional aid in transfer.
9859944|NCT00645567||Standard sliding board transfer|The standard transfer board is a flat surface board designed to bridge the gap that exists with transfers from wheelchair to vehicle and/or other horizontally displaced seating surfaces.
9859945|NCT00645567||Glide n' Go Lift|The Glide n' Go lift is a flip down power list seat that enables the person to enter and exit the vehicle by lifting them from their wheelchair up tot eh vehicle seat that they can make an easy transfer into the vehicle. Trunk stability may be required to successfully use the device.
9859946|NCT00645567||Easy Reach lift|The Easy Reach lift seat allows the vehicles original seat to swivel out of the vehicle and lower to wheelchair height. the chair extends far from the vehicle to provide access for a safe, easy transfer.
9859947|NCT00645567||Ryno lift|The Ryno lift is an under-vehicle list (UVL) system. Using this lift, the wheelchair user is raised into the vehicle cab using independent controls and can then maneuver into a convenient position in the cab. The wheelchair is locked down and the lift stored beneath the vehicle chassis. This technology eliminated the need to store and retrieve a wheelchair during transit.
9859948|NCT00637806|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
9859949|NCT00637806|Active Comparator|2|Megestrol acetate concentrated suspension 60 mg/mL
9859950|NCT00637806|Placebo Comparator|3|
9859951|NCT00652457|Experimental|Memantine|Memantine 10 mg BID for three months
9859952|NCT00652457|Placebo Comparator|Placebo|Placebo 10 mg BID for three months
9859953|NCT00642603|Experimental|XELOX + bevacizumab (Q2W)|
9859954|NCT00642603|Experimental|XELIRI + bevacizumab (Q2W)|
9859955|NCT00629798|Experimental|1|This is a single arm phase II trial to assess the efficacy (decrease the transplant related mortality) and safety of peri-transplant Palifermin in combination with a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with advanced MDS and AML evolved from MDS. The addition of Palifermin is to decrease the toxicity and the infection rate associated with this regimen and transplant type and to foster earlier immune reconstitution.
9859956|NCT00645359||Diffusion MRI|Patients will undergo a Diffusion MRI (dMRI) at baseline and 7 days.
9859957|NCT00637728|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
9859958|NCT00637728|Placebo Comparator|2|Placebo suspension
9859959|NCT00639626|Experimental|Levemir|
9859960|NCT00641108|Experimental|ADAM SPECT|Participants with depression will undergo ADAM SPECT scans and cognitive behavioral therapy.
9859961|NCT00641108|Active Comparator|Control|Healthy subjects without depression will undergo ADAM SPECT scans.
9859962|NCT00642382|Active Comparator|Active|Agilus (Hyaluronic Acid)
9859963|NCT00642382|Placebo Comparator|Control|Normal Saline
9859964|NCT00637416|Active Comparator|Lansoprazole and dietary control|Lansoprazole and dietary control
9859965|NCT00637416|Placebo Comparator|Placebo and dietary control|Dietary control and placebo
9859966|NCT00635167|Experimental|Contrast Enhanced Transrectal Ultrasound (TRUS)|
9859967|NCT00637312|Experimental|Advent™ Cervical Disc|Cervical artificial disc replacement: Advent™ Cervical Disc
9924436|NCT00861367|Placebo Comparator|2|empty capsule
9859968|NCT00637312|Active Comparator|Standard care - Control|Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System
9859969|NCT00638222|Active Comparator|All Study Participants|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
9859970|NCT00634322|Experimental|A|HDMTX-LV with glucarpidase
9859971|NCT00634322|Active Comparator|B|HDMTX-LV with placebo
9859972|NCT00634322|Experimental|C|compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment
9859973|NCT00633087|Experimental|2-deoxyglucose|
9859974|NCT00631137|Placebo Comparator|Arm 1: Control Group|whey protein powder
9859975|NCT00631137|Active Comparator|ARM 2 : Treatment Group|Testosterone Gel (10g pouch/day) applied to skin
9859976|NCT00634972|Experimental|1|
9859977|NCT00634972|Placebo Comparator|2|
9859978|NCT00633061|Experimental|A-randomized to treatment|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
9859979|NCT00633061|No Intervention|B-randomized to close|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks
9859980|NCT00626444|Experimental|1|Intravenous vitamin C
9859981|NCT00630292|Experimental|1|
9859982|NCT00634010|Active Comparator|Morphine Capsule|Morphine 15 mg slow release orally every 12 hours + additional doses as needed
9859983|NCT00634010|Active Comparator|Methadone Capsule|Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day
9859984|NCT00630487|Placebo Comparator|Placebo|
9859985|NCT00630487|Active Comparator|Verum|
9859986|NCT00629850|Experimental|Powerlung Performer|The arm will receive the lung trainer device to use for 10 weeks
9859987|NCT00629850|No Intervention|Control|Control. This arm will not receive any device
9859988|NCT00623974|Experimental|Calcium + Calcitriol|1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
9859989|NCT00623974|Experimental|Teriparatide 20 mcg|Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
9859990|NCT00623974|Experimental|Teriparatide 40 mcg|Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
9859991|NCT00623974|Experimental|Teriparatide 60 mcg|Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
9859992|NCT00624650|Active Comparator|Modified FACTT (control)|The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
9859993|NCT00624650|Experimental|EVLW|"When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW > 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement.~Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome."
9859994|NCT00626561|Experimental|Bevacizumab + Paclitaxel|Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.
9924437|NCT00861393|Other|CBT|
9924438|NCT00861393|Other|Waitlist|
9924439|NCT00861406|Experimental|Group 1|Pegylated Interferon alfa-2b (Once week x 4 weeks) + GP-100 Peptide
9924440|NCT00861406|Experimental|Group 2|Pegylated Interferon alfa-2b (Once week x 8 weeks) + GP-100 Peptide
9859995|NCT00613730|Experimental|Gemcitabine + panitumumab|Panitumumab 6 mg/kg was administered intravenously (IV) before gemcitabine on Day 1 of Weeks 1, 3, 5, and 7, and then every 2 weeks (day 1 and 15) of each subsequent 4-week chemotherapy cycle. Gemcitabine 1000 mg/m^2 was administered IV once weekly (on Day 1) for 7 weeks, followed by a 1-week rest period. In subsequent cycles, gemcitabine was given once weekly (on Day 1) for 3 consecutive weeks followed by 1 week of rest. Panitumumab and gemcitabine treatment continued until disease progression, unacceptable adverse events, death, or study withdrawal occurred.
9859996|NCT00625586|Experimental|RAV12 plus gemcitabine|
9859997|NCT00625703|Experimental|A|
9859998|NCT00625742|Experimental|Multimodal Treatment Strategy|Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.
9859999|NCT00619242|Experimental|sorafenib|sorafenib 2 tablets by mouth
9860000|NCT00619151|Active Comparator|1|CarboMedics Supra-annular Top Hat Valve
9860001|NCT00619151|Active Comparator|2|St. Jude Medical Regent Valve
9860002|NCT00622167|Other|1|All patients will receive integrated backscatter IVUS and dual source CT.
9860003|NCT00616577|Experimental|Group CB|Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
9860004|NCT00616577|Active Comparator|Group CA|Group CA (Caudal After-control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
9860005|NCT00616577|Active Comparator|Group LIA|Group LIA (Local Infiltration After-control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
9860006|NCT00616759|Active Comparator|1|ECT as usual
9860007|NCT00616759|Experimental|2|ECT-induced seizures terminated with propofol
9860008|NCT00616642|Experimental|Group 1 (ACTH-secreting adenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.
9860009|NCT00616642|Experimental|Group 2 (non-secreting macroadenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.
9860010|NCT00619515|Experimental|CyberKnife® stereotactic radiosurgery|
9860011|NCT00616343|Active Comparator|Zonisamide|
9860012|NCT00612677|Experimental|Premetrexed and Oxaliplatin|Patients will be treated with oxaliplatin 120 mg/m^2 i.v. over 2 hours and pemetrexed 500 mg/m^2 i.v. over 10 minutes on Day 1 of a 21day cycle. Cycles of treatment will be repeated every 3 weeks. Folic acid and B12 supplementation is obligatory.
9860013|NCT00616603|Other|Group A|This is the control arm and subjects in Group A will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV of normal saline.
9860014|NCT00616603|Experimental|Group B|Subjects in Group B will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 8mg Dexamethasone + 2ml IV of normal saline.
9860015|NCT00616603|Active Comparator|Group C|Subjects in Group C will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV (8mg)of Dexamethasone.
9924441|NCT00861406|Experimental|Group 3|Pegylated Interferon alfa-2b (Once week x 12 weeks) + GP-100 Peptide
9924442|NCT00861419|Experimental|D|3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)
9860016|NCT00613886|Experimental|Comparison for patients of lumbar drain and shunt surgery|"Subjective comparisons made for patients - before and after external lumbar drain, before and after shunt surgery.~Device: Programmable Shunt Insertion (Codman Medtronic)~Behavioral: Assessments in physical therapy, occupational therapy, and speech therapy~Follow-up testing to be administered by trained physician assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, mini-mental status exam, 9-hole grooved pegboard, motor visual perception test (MVPT), modified rankin score (MRS)"
9860017|NCT00610467|Experimental|Disease Group|Patients with suspicious breast diseases
9860018|NCT00610467|Experimental|Control Group|Healthy volunteers for system testing
9860019|NCT00610558|Experimental|Arm 1: Juvenile Myoclonic Epilepsy|Juvenile Myoclonic Epilepsy group of subjects will participate for imaging assessment
9860020|NCT00610558|Experimental|Arm 2: Frontal Lobe Epilepsy|Frontal Lobe Epilepsy group of subjects will participate for imaging assessment
9860021|NCT00610558|Experimental|Arm 3: Normal Controls|Normal Controls, eligible subjects don't have Juvenile Myoclonic Epilepsy or Frontal Lobe Epilepsy will be placed in this group
9860022|NCT00610532|Experimental|A|intravenous phenytoin alone
9860023|NCT00610532|Experimental|B|intravenous phenytoin plus probenecid
9860024|NCT00609765|Experimental|Protocol Specified Chemotherapy|"Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.~Premedications: Dexamethasone, Ondansetron"
9860025|NCT00608465|Active Comparator|Treatment A|Eplerenone (study drug)
9860026|NCT00608465|Active Comparator|Treatment B|Ramipril
9860027|NCT00601848|Experimental|Photodynamic Therapy|PDT
9860028|NCT00607477|Active Comparator|1|Minoxidil
9860029|NCT00607477|Active Comparator|2|Hydralazine
9860030|NCT00595920|Experimental|Tovaxin, open-label|Tovaxin; 30-45 million autologous myelin reactive T cells
9860031|NCT00596947|Experimental|Prednisone Withdrawal|Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
9860032|NCT00596947|Active Comparator|Prednisone Maintenance|Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.
9860033|NCT00584012|Experimental|Dose Esclation|Determine the maximum tolerated dose (MTD) of escalating doses of lovastatin in combination with docetaxel in patients with any type of solid tumor.
9860034|NCT00599131|Experimental|Chemotherapy/Radiation/Surgery|"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.~On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.~Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
9860035|NCT00597909|Experimental|Arm 1|
9860036|NCT00597909|Experimental|Arm 2|
9860037|NCT00597909|Placebo Comparator|Arm 3|
9860038|NCT00593320|Active Comparator|1|Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
9860039|NCT00593320|Active Comparator|2|High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy
9860040|NCT00589550|Experimental|Peginterferon alfa-2b|Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
9860041|NCT00577772|Active Comparator|Healthy Participants|Healthy Participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
9860042|NCT00577772|Active Comparator|Symptomatic Participants|"Subjects with symptoms suggestive of small bowel bacterial overgrowth (SBBO) (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months will be divided into 2 groups based on the results of their previous testing for SBBO (5 SBBO positive patients, 5 SBBO negative patients).~The symptomatic participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.~After the capsule has been demonstrated to be passed from the subject, the subjects with SBBO present will then enter into an open-label treatment using Rifaximin (400 mg PO TID) for 7 days."
9860043|NCT00592007|Experimental|A|Single-arm study
9860044|NCT00595582|Other|single arm|Curcumin + Bioperine
9860045|NCT00588146|Experimental|Pegylated Interferon Alpha2b, then Standard Care|Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months, then standard care for 6 months.
9860046|NCT00588146|Experimental|Standard Care, then Pegylated Interferon Alpha2b|Standard care for 6 months, then weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months.
9860047|NCT00586209|Experimental|L-glutamine|"L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
9860048|NCT00586209|Placebo Comparator|Placebo|"Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
9860049|NCT00590538|Active Comparator|Phenylbutyrate|"The standard oral adult dose is 20 g/day for 4 days.~Every participant will receive Genistein during the NPD."
9860050|NCT00590538|Placebo Comparator|Placebo|The placebo is given to match the active comparator for 4 days. Every participant will receive Genistein.
9860051|NCT00583115|Experimental|Gleevec|Drug taken orally 260mg/M2/day once per day
9860052|NCT00582712|Experimental|Lithium Capsules|Lithium carbonate
9860053|NCT00586716|Other|Group 1 intravenous immune globulin|Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
9860054|NCT00586716|Other|Group 2 intravenous immune globulin|Intravenous immune globulin for patients who have living donors with positive crossmatch results.
9860055|NCT00583466|Active Comparator|1 Normal saline arm|Polypectomy with normal saline injected for submucosal cushion creation
9860056|NCT00583466|Active Comparator|2 HPMC arm|Polypectomy after injection of hydroxypropyl methylcellulose (HPMC) to create submucosal cushion
9860057|NCT00583466|Experimental|3 Blood arm|Polypectomy after injection of autologous blood
9860058|NCT00588471|Active Comparator|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
9860059|NCT00588471|Placebo Comparator|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
9860060|NCT00587795|Active Comparator|StabilAir Wrist Brace|One study group will consist of patients treated with the StabilAir Wrist Brace.
9860061|NCT00587795|Placebo Comparator|Control|Study arm will consist of patients that are treated with placement of sugar tong splint or plaster cast.
9860062|NCT00590135|Experimental|AORTIC STENOSIS PATIENTS|Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis
9860063|NCT00582036|Active Comparator|Arm 1|Regular Sliding Scale Insulin administration for hyperglycemia
9860064|NCT00582036|Experimental|Arm 2|MiniMed Paradigm monitoring device for hyperglycemia
9860065|NCT00585585|Experimental|Arm 1: Betahistine dihydrochloride|Oral betahistine dihydrochloride; daily dose 50-300 mg
9860066|NCT00585221|Experimental|All patients|All participants enrolled in the study.
9860067|NCT00581113|Active Comparator|1|Standard Whole Brain Radiotherapy
9860068|NCT00581113|Experimental|2|Neural Stem Cell-Preserving Whole Brain Radiotherapy
9924443|NCT00861419|Experimental|A|3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
9924444|NCT00861419|Experimental|B|3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)
9924445|NCT00861419|Experimental|E|3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
9924446|NCT00861419|Experimental|H|10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
9794851|NCT01519921|Experimental|PEG-IFN alfa-2a (Treatment naïve)|Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
9794852|NCT01519921|Experimental|PEG-IFN alfa-2a (YMDD mutant)|Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
9794853|NCT01519934||Ulthera-treated subjects|All enrolled subjects will have received an Ulthera treatment prior to enrollment.
9794854|NCT01519947|Active Comparator|Pre-dialysis, sea level|Participants received 50-250 mcg SC according to local label.
9794855|NCT01519947|Active Comparator|Dialysis, sea level|Participants received 50-250 mcg SC according to local label.
9794856|NCT01519947|Experimental|Pre-dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
9794857|NCT01519947|Experimental|Dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
9794858|NCT01520207|Placebo Comparator|Placebo group: (0.9% normal saline)|0.9% saline will be administered (IV) during the hemodialysis session at 1.25mL/kg/hour (max 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
9794859|NCT01520207|Active Comparator|Intervention: intravenous mannitol (20%)|Mannitol will be administered (IV) during the hemodialysis session at a maximum rate of 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
9794860|NCT01520324|Experimental|Patients with UC undergoing colonoscopy|
9794861|NCT01520363|Active Comparator|Study drug-dextromethorphan (DM)|MECP2 mutation positive subjects randomized to receive DM
9794862|NCT01520363|Placebo Comparator|Placebo group|MECP2 positive subjects randomized to the placebo compound
9794863|NCT01520402|Experimental|Warfarin|Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.
9794864|NCT01520454|Placebo Comparator|Placebo|IV saline with heparin, oral water
9794865|NCT01520454|Experimental|High dose fat solution|Intralipid at high dose, with heparin and PO water
9794866|NCT01520454|Experimental|Low dose fat solution|Low dose IV Intralipid with heparin and PO water
9794867|NCT01520454|Experimental|Oral fat|Oral fat load with IV saline
9794868|NCT01520506|Experimental|Rapid Renal Denervation|
9794869|NCT01520519|Experimental|Rituximab + PCI-32765|Rituximab (375 mg/m2) given intravenously (IV) on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6. PCI-32765 started on Day 2 of cycle 1 at a dose of 420 mg (3 * 140-mg capsules) orally daily and will be continued daily.
9794870|NCT01520532|Other|Ablation|
9794871|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 1|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10^5 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
9794872|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 2|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
9794873|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 3|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
9794874|NCT01520688|Experimental|1 Treatment Sequence, FPQ|Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
9794875|NCT01520688|Experimental|2 Treatment Sequence, FQP|Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
9794876|NCT01520688|Experimental|3 Treatment Sequence, PFQ|Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
9794877|NCT01520688|Experimental|4-Treatment Sequence, PQF|Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
9794878|NCT01520688|Experimental|5 Treatment Sequence, QFP|Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
9794879|NCT01520688|Experimental|6 Treatment Sequence, QPF|Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
9794880|NCT01520727|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (Opicapone, OPC) - 10 mg
9794881|NCT01520727|Experimental|BIA 9-1067 25 mg|BIA 9-1067 (Opicapone, OPC) - 25 mg
9794882|NCT01520727|Experimental|BIA 9-1067 50 mg|BIA 9-1067 (Opicapone, OPC) - 50 mg
9794883|NCT01520727|Experimental|BIA 9-1067 100 mg|BIA 9-1067 (Opicapone, OPC) - 100 mg
9794884|NCT01520727|Experimental|BIA 9-1067 200 mg|BIA 9-1067 (Opicapone, OPC) - 200 mg
9794885|NCT01520727|Experimental|BIA 9-1067 400 mg|BIA 9-1067 (Opicapone, OPC) - 400 mg
9794886|NCT01520727|Experimental|BIA 9-1067 800 mg|BIA 9-1067 (Opicapone, OPC) - 800 mg
9794887|NCT01520727|Experimental|BIA 9-1067 1200 mg|BIA 9-1067 (Opicapone, OPC) - 1200 mg
9794888|NCT01520727|Placebo Comparator|Placebo|Placebo (PLC): single-dose
9794889|NCT01520870|Experimental|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end. Patients at first recurrence will be enrolled onto 1 of 2 cohorts that will be recruited and analysed independently. Cohort A will include patients who have EGFRvIII mutations. Cohort B will include patients who have EGFR gene amplification but no EGFRvIII mutations.
9794890|NCT01520909|Experimental|Eltrombopag plus standard of care|Part 1, double-blind treatment group
9860069|NCT00587223|Experimental|1|Apligraf (a living bilayered cell therapy product)
9860070|NCT00587223|Active Comparator|2|Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.
9860071|NCT00585611|Experimental|Atorvastatin|Heart failure patients assigned to atorvastatin
9860072|NCT00585611|Placebo Comparator|2|
9860073|NCT00572260|Experimental|A|Daptomycin as a single preoperative dose within 30 minutes prior to surgery Dosage: if creatinine clearance ≥ 30 ml/min: 6 mg/kg IV
9860074|NCT00571194|Other|peritoneal dialysis (CCPD)|PK profile of pravastatin
9860075|NCT00584935|Experimental|Rituximab|The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15).
9860076|NCT00577395|Experimental|2|one 150 mg risedronate once a month, orally
9860077|NCT00577395|Placebo Comparator|1|Placebo tablet once a month, orally
9860078|NCT00573391|Experimental|VTD = Velcade, Thal, and Dex|VTD = Velcade, Thalidomide, and Dexamethasone
9860079|NCT00573391|Experimental|VMD = velcade, melphalan, and dex|VMD = velcade, melphalan, and dexamethasone
9860080|NCT00570258|Placebo Comparator|2|"Fulvestrant: 250 mg IM Q 4 weeks~Placebo: 150 mg PO QD"
9860081|NCT00570258|Active Comparator|1|"Fulvestrant: 250 mg IM Q 4 weeks~Erlotinib: 150 mg PO QD"
9860082|NCT00568802|Experimental|Hydroxyurea|
9860083|NCT00568802|Placebo Comparator|Placebo|
9860084|NCT00576524|Experimental|Sham Device first, ITD next|Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.
9860085|NCT00576524|Experimental|ITD first, sham device next|Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.
9860086|NCT00568698|Experimental|Hydroxyurea|
9860087|NCT00568698|Placebo Comparator|Placebo|
9860088|NCT00574080|Experimental|Arm A|DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
9860089|NCT00574080|Experimental|Arm B|DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
9860090|NCT00558558|Other|Fermented Soy Supplement|4 oz Haelan orally twice daily for 8 weeks
9860091|NCT00573937|Active Comparator|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
9860092|NCT00573937|Active Comparator|Morphine|Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.
9860093|NCT00577317|Experimental|Arm 1|Patients receive standard home maintenance therapy and perform self-manual lymphatic drainage once daily for 60 minutes for 24 weeks.
9860094|NCT00577317|Experimental|Arm II|Patients receive Flexitouch® home maintenance therapy once daily for 60 minutes for 24 weeks
9860095|NCT00571922|Active Comparator|Acamprosate|
9860096|NCT00571922|Placebo Comparator|Placebo|
9860097|NCT00569868|Experimental|Velcade|"Treatment on this study will last 2 cycles. Each cycle consists of 3 weeks, or 21 days. After you have gone off study, you will be followed every three months for approximately 2 years.~Each cycle will consist of 3 weeks (21 days) according to the schedule below.~DRUG ROUTE DOSE DAYS Velcade IV 1.3 mg/m2 1,4,8, and 11 This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a two cycles."
9860098|NCT00573157|Experimental|Atacicept Plus Mycophenolate mofetil Plus Corticosteroids|
9860099|NCT00573157|Placebo Comparator|Placebo Plus Mycophenolate mofetil Plus Corticosteroids|
9860100|NCT00570531|Experimental|Bevacizumab|
9860101|NCT00566462|Experimental|perampanel|
9860102|NCT00566462|Placebo Comparator|1|
9860103|NCT00561912|Experimental|Decitabine + Interferon Alfa-2b|Decitabine 15 mg/m^2 intravenous (IV) daily over one hour for 5 days + Interferon Alfa-2b 0.5 million Units Subcutaneously Twice Daily Continuously, as of Cycle 3, Day 1.
9860104|NCT00561795|Experimental|Arm A|Oral Pazopanib 800 mg once a day+ carboplatin area under the concentration-time curve (AUC) 5 intravenous (IV) over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
9860105|NCT00561795|Experimental|Arm B|Oral Pazopanib 800 mg once a day+ carboplatin AUC 6 IV over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
9860106|NCT00564876|Experimental|Treatment|Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.
9860107|NCT00558870|Active Comparator|Morphine Only|"Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
9860108|NCT00558870|Active Comparator|Morphine + Methadone|"Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)"
9794891|NCT01520909|Placebo Comparator|Placebo plus standard of care|Part 1, double-blind treatment group
9794892|NCT01520909|Experimental|Eltrombopag plus standard of care (Part 2 open-label)|Part 2, open-label
9794893|NCT01520922|Experimental|Ofatumumab plus bendamustine|In this single arm, Phase II study, each patient who is willing to participate and is found eligible according to the inclusion and exclusion criteria will enter the treatment phase. Eligible subjects will be allocated to receive the following study treatments depending upon their previous CLL treatment status: Subjects with Untreated CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (90 mg/m2, Days 1 and 2; every 28 Days). Subjects with Relapsed CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (70 mg/m2, Days 1 and 2; every 28 Days).
9794894|NCT01520987|Experimental|Caucasian 5 mg OPC|OPC, opicapone, BIA 9-1067
9794895|NCT01520987|Experimental|Caucasian 25 mg OPC|OPC, opicapone, BIA 9-1067
10209542|NCT04121455|Experimental|Expansion group, Arm A: 600 mg Olaptesed pegol + Radiotherapy + 10 mg/kg Bevacizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, bevacizumab every two weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely or not resected patients
9794896|NCT01520987|Experimental|Caucasian 50 mg OPC|OPC, opicapone, BIA 9-1067
9794897|NCT01520987|Placebo Comparator|Caucasian Placebo|Placebo, PLC
9924447|NCT00861419|Experimental|G|3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
9924448|NCT00861419|Experimental|C|10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
9924449|NCT00861419|Experimental|F|10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
10209543|NCT04121455|Experimental|Expansion group, Arm B: 600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6, completely resected patients
10209544|NCT04121455|Experimental|Expansion group, Arm C: 600 mg Olaptesed pegol + Radiotherapy + 200 mg Pembrolizumab|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion, pembrolizumab every three weeks for 26 weeks plus radiotherapy during weeks 1-6, incompletely resected patients
10209545|NCT04114110||Admitted inpatients|no intervention
10209546|NCT04114110||Staff with RTLS badges|no intervention
10209547|NCT04111978|Experimental|Letrozole (aromatase inhibitor)|Letrozole, 2.5 mg Femara tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease
10209548|NCT04111978|Placebo Comparator|Placebo|Placebo tablet of Femara (without aromatase inhibitor), 0 mg Femara tablet, administered once daily for 5 years or progression of underlying disease
10209549|NCT04107662||Traumatic Brain Injury|
9794898|NCT01520987|Experimental|Japanese 5 mg OPC|OPC, opicapone, BIA 9-1067
9794899|NCT01520987|Experimental|Japanese 25 mg OPC|OPC, opicapone, BIA 9-1067
9794900|NCT01520987|Experimental|Japanese 50 mg OPC|OPC, opicapone, BIA 9-1067
9794901|NCT01520987|Placebo Comparator|Japanese Placebo|Placebo, PLC
9794902|NCT01521026|Experimental|Cognitive Training|Cognitive training group
9794903|NCT01521026|No Intervention|Standard Pharmacotherapy|
9794904|NCT01521117|Experimental|Donepezil, Then Placebo|Donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6. After a washout period of 4 weeks, placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.
9794905|NCT01521117|Experimental|Placebo, Then Donepezil|"Placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.~After a washout period of 4 weeks, donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6."
9794906|NCT01521260|Placebo Comparator|Placebo group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
9794907|NCT01521260|Active Comparator|Chlorhexidine group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
9794908|NCT01521364|Other|0mg, 250mg, and 500mg claritromycin|"Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.~After this, there is a wash-out period of one week during which no claritromycine is administered."
9794909|NCT01521494|Experimental|PA21 750 mg/day|
9794910|NCT01521494|Experimental|PA21 1500 mg/day|
9794911|NCT01521494|Experimental|PA21 2250 mg/day|
9794912|NCT01521494|Experimental|PA21 3000 mg/day|
9794913|NCT01521494|Placebo Comparator|Placebo|
9794914|NCT01521507|Experimental|LipiFlow System|Treatment with LipiFlow System at randomization in Stage 1 of study
9794915|NCT01521507|Active Comparator|Warm Compress and Lid Hygiene|Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study
9794916|NCT01521546|Active Comparator|eplerenone|active study drug
9794917|NCT01521546|Placebo Comparator|sugar pill|placebo
10209550|NCT04105010|Experimental|AZD4205 Group A|Group A: Open label AZD4205 at dose A, once daily (Phase 1)
10209551|NCT04105010|Experimental|AZD4205 Group B|Group B: Open label AZD4205 at dose B, once daily (Phase 1)
10209552|NCT04105010|Experimental|AZD4205 Group C|Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
10209553|NCT04105010|Experimental|AZD4205 Group D|Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)
10209554|NCT04103333|Experimental|Angelman Syndrome: Group 1|Participants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
10209555|NCT04103333|Experimental|Angelman Syndrome: Group 2|Participants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
9860109|NCT00559897|Experimental|3'-deoxy-3'-[18F]FLT PET & zoledronic acid|"Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-[18F]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid."
9860110|NCT00556400|Active Comparator|Lo-ovral|1 tablet of lo-ovral is administered twice a day
9860111|NCT00556400|Placebo Comparator|sugar pill|Sugar pill was provided as a placebo
10209556|NCT04103333|Experimental|Angelman Syndrome: Group 3|Participants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
10209557|NCT04103333|Experimental|Angelman Syndrome: Group 4|Participants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
10209558|NCT04103333|Experimental|Dup15q Syndrome: Group 1|Participants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
9860112|NCT00556075|Placebo Comparator|Placebo|Placebo once daily
9860113|NCT00556075|Experimental|25 mg|Proellex 25 mg once daily
9860114|NCT00556075|Experimental|50 mg|Proellex 50 mg once daily
9860115|NCT00556166|Experimental|Enterra Therapy|The Enterra Therapy Gastric Stimulator will be used on subjects who have failed all other medical options to treat gastroparesis and all have a gastric stimulator implanted.
9860116|NCT00521924|Experimental|Infliximab + basic treatment|3 mg/kg infliximab plus basic treatment
9860117|NCT00521924|Active Comparator|Basic treatment (DMARDs)|Rheumatoid Arthritis basic therapy (disease modifying anti-rheumatic drugs [DMARDs])
10209559|NCT04103333|Experimental|Dup15q Syndrome: Group 2|Participants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
10209560|NCT04103333|Experimental|Dup15q Syndrome: Group 3|Participants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
10209561|NCT04103333|Experimental|Dup15q Syndrome: Group 4|Participants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
10209562|NCT04100096|Experimental|Intervention|2-3 mg/day tablet
10209563|NCT04100096|Placebo Comparator|Placebo|Placebo tablet
10209564|NCT04099108|Experimental|Intervention|Combined cycle ergometry and bolus amino acid supplementation, along with standard of care
10209565|NCT04099108|No Intervention|Control|Standard of care only
10209566|NCT04092257|Experimental|VIA and thermocoagulation|Participants will undergo same day VIA and thermocoagulation
10209567|NCT04086589||Young|Observational study without intervention
10209568|NCT04086589||Elderly|Observational study without intervention
10209569|NCT04079868|Experimental|Bone Health Service arm|Interventional arm
10209570|NCT04079868|No Intervention|Usual care (control) arm|"This arm represents a no practice management support control group."
10209571|NCT04078373||Without urinary disorders|Subacute stroke patients without urinary disorders
10209572|NCT04078373||With urinary disorders|Subacute stroke patients with urinary disorders
10209573|NCT04068142|No Intervention|Clinical Personnel Safety Planning|Patients will complete a traditional written suicide safety plan with clinical personnel.
10209574|NCT04068142|Experimental|Peer Supporter Safety Planning|Patients will complete a traditional written suicide safety plan with peer supporters.
10209575|NCT04066751|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
10209576|NCT04066751|Placebo Comparator|Placebo|Placebo, 150 mg PO every 12 hrs for 84 days
10209577|NCT04065789|Experimental|Carfilzomib,Daratumumab,revlimid and dexamethasone|Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
10209578|NCT04058652|Experimental|TENS therapy|the first step would be to administer the biologic medication in one thigh without the use of TENS therapy. Biologic medications are administered in two doses, with one in each thigh. Administering the first biologic medication injection is done to establish a control, or baseline, for how painful the injection experience is. The second step would be a study team member applying two to four TENS unit pads (made of adhesive gel) to the skin of subject's other thigh approximately two centimeters from the site where injection of the biological medication takes place. There will be no extra injection of biologic medication during this procedure. The prescribed dose will be used one time, split into two legs (which is the standard protocol for administration). The device will be turned on during the injection of the medication. Immediately after both steps, the subject will be given a brief survey to determine your pain level. The subject's involvement would last roughly 10-15 minutes.
10209579|NCT04049994|Experimental|Immunomodulation|Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).
10209580|NCT04049994|Placebo Comparator|Placebo|Oral placebo tablet once daily for 90 days.
10209581|NCT04049695|Experimental|Exercise Intervention|This arm will receive a 12-month individually tailored phone and email-based exercise program.
10209582|NCT04049695|Active Comparator|Health & Wellness Intervention|This arm will receive a 12-month health and wellness program.
10209583|NCT04047953|Experimental|Conversion Therapy|Paclitaxel (albumin-bound) +S-1+Oxaliplatin
9860118|NCT00548886|Experimental|Epinephrine|Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.
9860119|NCT00547456|Other|Decrease in oxygen level when sleeping|Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
9860120|NCT00539838|Experimental|Ocrelizumab 1000 mg|Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks
9860121|NCT00539838|Experimental|Ocrelizumab 400 mg|Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks
9860122|NCT00539838|Placebo Comparator|Placebo|Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks
9860123|NCT00549328|Experimental|Pazopanib Open-label|Single-arm, non-randomised, single-stage pazopanib monotherapy.
9860124|NCT00548327|Active Comparator|Atomoxetine|"Atomoxetine 80 mg final dose. Arm lasts 14 days.~Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopathology ratings"
9860125|NCT00548327|Placebo Comparator|Placebo|"Placebo administered for 14 days. Schedule Atomoxetine 25 mg Placebo Day 1 (or Day 22), Atomoxetine 40 mg Placebo Day 2-3 (or Days 23-24), Atomoxetine 60 mg Placebo Days 4-5 (or Days 25-26), Atomoxetine 80 mg Placebo Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging and neuropsychological testing in addition to psychopathology ratings"
9860126|NCT00542542|Active Comparator|Paravertebral Block + General Anesthesia|Group 1: Paravertebral Block + General Anesthesia (Ropivacaine)
9860127|NCT00542542|Active Comparator|General Anesthesia Alone|Group 2: General Anesthesia Alone (Propofol, Midazolam, Fentanyl)
9860128|NCT00545506|Active Comparator|conventional bandage|conventional bandage on sternal wound after skin closure after cardiac surgery. conventional gauze covered with elastic adhesive (Medipore™ Dress-it) The designated bandage will be positioned in the operating room by the surgeons after the skin will be closed. The conventional elastic bandage consists of several layers of gauze covered with a special adhesive bandage
9860129|NCT00545506|Active Comparator|warming bandage|The Warm-Up bandage consists of an adhesive shell and a foam frame that supports a clear window about one cm above the surface of the wound. A battery-powered heating card can then be inserted into the window to provide gentle warming of the wound. The surface temperature of heating card is fixed at 38°C, and heat is usually provided for two hours at a time. That is, the experimental bandage will be continuously applied to the wound and heated to 38°C using a two-hour on/off cycle.
9860130|NCT00547300|Experimental|Nebivolol|Nebivolol 5 mg, 10 mg or 20 mg
9860131|NCT00547300|Active Comparator|Metoprolol ER|Metoprolol ER 50 mg, 100 mg or 200 mg
9860132|NCT00539617|Experimental|Tarceva and FOLFOX|"COMBINATION THERAPY PHASE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-56. Patients also receive FOLFOX6 therapy comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1, 15, 29, and 43. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or no evidence of disease after course 2 or subsequent courses continue on to maintenance phase.~MAINTENANCE PHASE: Patients receive erlotinib hydrochloride PO QD on days 1-42. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity."
9860133|NCT00546455|Experimental|A|Subjects in this cohort will be given Fenretinide
9860134|NCT00546455|Placebo Comparator|B|Subjects in this cohort will be given placebo.
9860135|NCT00538980|Experimental|All patients|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
9860136|NCT00540969|Experimental|Arm I (percutaneous cryoablation)|Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
9860137|NCT00540969|Active Comparator|Arm II (external-beam radiotherapy)|Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.
9860138|NCT00535262|Experimental|EmSam|EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
9860139|NCT00529464|Experimental|Colposcopy|Colposcopy - a direct magnified inspection of cervix
9860140|NCT00529464|Experimental|Colposcopy + Fluorescence Spectroscopy|Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
9860141|NCT00529464|Experimental|Colposcopy + LEEP Procedure|Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.
9860142|NCT00537199|Other|OraTest + Visual Exam|OraTest dye
9860143|NCT00537446|Active Comparator|High-level ventilation|Each subject will spend 2 hours receiving high-level noninvasive ventilation.
9860144|NCT00537446|Active Comparator|Low-level ventilation|Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.
9924450|NCT00861432|Active Comparator|additive homeopathic treatment|These patients receive additive homeopathic treatment during conventional cancer treatment.
9924451|NCT00861432|No Intervention|no additive homeopathic treatment|These patients do not receive additive homeopathic treatment during conventional cancer treatment.
9924452|NCT00861445|Experimental|1|
9924453|NCT00861445|Placebo Comparator|2|
9924454|NCT00861458|Experimental|PF-00868554|
9860145|NCT00536978|Experimental|NK Cell/T-Cell Infusion|Possible Cell Adback - infusion NK cells or T-cells from donor given after blood stem cell transplantation for either Reduced intensity chemotherapy of campath, modified BEAM regimen of Campath-IH 15 mg intravenous (IV) Daily for 3 Days + BEAM Daily for 4 days (BCNU 300 mg/m^2 IV, Etoposide 100 mg/m^2 IV, Ara-C 100 mg/m^2 IV Daily for 4 days and Melphalan 100 mg/m^2 IV Over 30 Minutes for 1 Day) + Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks]; or Non-myeloablative Preparative Regimen [Fludarabine 30 mg/m^2 IV Daily Over 1 Hour for 3 Days; Cyclophosphamide 1000 mg/m^2 IV Daily Over 1 Hour for 3 Days; Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks; Campath-IH 15 mg IV Daily Over 30 Minutes for 3 Days; plus Total Body radiation (TBI)].
9860146|NCT00524485|Experimental|Arm 1 - ALA|Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
9860147|NCT00524485|Experimental|Arm 2|Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
9860148|NCT00524485|Experimental|Arm 3|Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
9860149|NCT00524485|Experimental|Arm 4|Vbeam laser pulse (photodynamic therapy) is applied to the subunit
9860150|NCT00524485|Experimental|Arm 5|Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart
9860151|NCT00533351|Experimental|AGN201781|AGN201781 50 mg capsules three-time daily for 2 weeks
9860152|NCT00533351|Placebo Comparator|Placebo|placebo 50 mg capsules three-times daily for 2 weeks
9860153|NCT00529282|Experimental|001|Ceftobiprole Medocaril 500 mg every 8 hours 120-minute infusion [250 mL]
9860154|NCT00529282|Active Comparator|002|Cefepime with or without vancomycin 2 g every 8 hrs-30 min infusion vancomycin 1 000mg every 12 hrs-60 min infusion
9860155|NCT00524134|Experimental|1|Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.
9860156|NCT00527748|No Intervention|Standard of care|Patient ankle range of motion will be assessed at clinic visit. No stretching exercises with the device, but will be provided standard care through physiotherapist in acute cases, and no stretching exercises for chronic patients. Reassessment will be done at six weeks and 10 weeks.
9860157|NCT00527748|Experimental|Non-Measuring Ankle Exerciser|Subjects will train using only one combination of movement, dorsiflexion with inversion. This is done by manipulating the ring so that the medial and anterior ropes are taut. Subject will start with 3 minute warm-up. Subject will then manipulate the ring so that the foot moves into dorsiflexion with inversion until a point of tolerable discomfort is felt; subject will hold this position for 30 seconds. Stretch will be repeated 10 times, each day, for six weeks. Reassessment will be done at six weeks and 10 weeks.
9860158|NCT00517699|Experimental|1|
9860159|NCT00528775|Experimental|HPPH|Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.
9860160|NCT00528437|Other|Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.|
9860161|NCT00524511|Experimental|1|Women receiving Dermabond for skin closure
9860162|NCT00524511|Active Comparator|2|Women receiving standard surgical skin staples
9860163|NCT00517075|Experimental|A|high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
9860164|NCT00517075|Active Comparator|B|Active high frequency rTMS to the left dorsolateral prefrontal cortex
9860165|NCT00517075|Sham Comparator|C|Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
9860166|NCT00517075|Experimental|Open cross over high frequency rTMS|Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --> open phase DLPFC and vice versa)
9860167|NCT00527982|Experimental|Celecoxib treatment|600 mg orally (PO) daily
9860168|NCT00527982|No Intervention|No treatment|
9860169|NCT00517361|Experimental|Carboplatin + Avastin|
9860170|NCT00523939|Experimental|Lymphomatous|Subjects with Lymphomatous Meningitis
9860171|NCT00523939|Experimental|Leukemic|Subjects with Leukemic Meningitis
9860172|NCT00526331|Experimental|Study Group|FloTrac Sensor + Vigileo Monitor used to decide how much fluid to give during surgery.
9860173|NCT00526331|Experimental|Control Group|FloTrac Sensor + Vigileo Monitor only used for data collection during surgery; Standard of Care to decide fluid amount.
9860174|NCT00519090|Experimental|Nilotinib (AMN107)|
9860175|NCT00519090|Active Comparator|Imatinib|
9860176|NCT00523809|Experimental|Bevacizumab + Fludarabine + Melphalan|Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.
9860177|NCT00522301|Experimental|Oral Sorafenib (BAY43-9006)|Sorafenib is supplied as 200-mg tablets. Sorafenib will be administered as 400 mg orally daily x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating). In the absence of intolerable toxicity, a patient may continue to receive treatment with sorafenib until disease progression, or until 24 months have elapsed.
9860178|NCT00504985||Fatigue in Emergency Center Patients|
9924455|NCT00861484|Experimental|GSK958108 3 mg|Experimental
9924456|NCT00861484|Placebo Comparator|Placebo of GSK958108|Placebo
9924457|NCT00861497|Experimental|Bifeprunox|
9924458|NCT00861523|Active Comparator|1. thiamine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive thiamine IV
9860179|NCT00503581|Experimental|Regimen 1 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily every day for 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after completing the megestrol treatment.
9860180|NCT00503581|Experimental|Regimen 2 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily for two weeks continuously followed by no treatment for two weeks. This course is repeated for a total of 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after the megestrol treatment.
9860181|NCT00503581|Active Comparator|Regimen 3 (surgery/biopsy)|(Closed as of 6/3/2010) Patients do not receive megestrol. At the discretion of the managing physician, patients undergo the re-evaluation biopsy and hysterectomy anytime between 2-20 weeks after enrollment and randomization.
9860182|NCT00509600|Experimental|Etanercept|0.8 mg/kg subcutaneously weekly for 90 days
9860183|NCT00515112|Experimental|A|Twenty subjects will receive testosterone gel
9860184|NCT00515112|Placebo Comparator|B|Twenty subjects will receive the placebo
9860185|NCT00508872|Experimental|FOLFOX-B|FOLFOX-B: 5-Fluorouracil 400 mg/m^2 IV + Bevacizumab 5 mg/kg IV + Leucovorin 400 mg/m^2 IV + Oxaliplatin 85 mg/m^2 IV
9860186|NCT00514813|Experimental|Dynepo (Epoetin delta)|Subjects received Dynepo (Epoetin delta) either twice weekly (BIW), once weekly (QW), once every 2 weeks (Q2W) or once every 4 weeks (Q4W) based on what is appropriate for the subject
9860187|NCT00506064|Experimental|Melatonin|0.15 mg/kg capsules by mouth daily
9860188|NCT00506064|Placebo Comparator|Placebo|Starch capsules by mouth daily
9860189|NCT00503880|Experimental|Treatment|G-CSF 300 μg subcutaneously to begin one day prior to treatment and continued until ANC greater than 1.0 or recovers back to the patients baseline ANC for 3 days in a row subsequent to completion of chemotherapy (SOC) Low-dose Cytarabine 10 mg/m2 subcutaneously daily starting on day 1 for the first 5 consecutive days of the treatment course 2-4 hours following the end of the clofarabine infusion. (SOC) Clofarabine starting at dose level 0. Dose-10 mg/m2 IV over 1 hour daily starting on day 1 for the first 5 consecutive days of the treatment course The G-CSF and cytarabine doses are fixed. The dose of clofarabine is initially fixed. For the subsequent cohort, the dose of clofarabine will be advanced to the next dose level.
9860190|NCT00511329|Experimental|Somatropin|
9860191|NCT00501228|Experimental|Filgrastim Injections|
9860192|NCT00496782|Other|Single|
9860193|NCT00506909|Experimental|Group 1|Group 1: 20 IU BID for the first week, 40IU BID for the following two weeks, 1 week washout, 3 week placebo trial.
9860194|NCT00506909|Experimental|Group 2|Group 2: 3 week placebo trial, 1 week washout, 20 IU BID for the first week, 40IU BID for the following two weeks.
9860195|NCT00487578|Active Comparator|A|Naratriptan 2.5 mg tablet bid x 30 days
9860196|NCT00487578|Placebo Comparator|B|placebo matching naratriptan 2.5 mg tablet
9860197|NCT00503009|Active Comparator|Arm 1|
9860198|NCT00503009|Active Comparator|Arm 2|
9860199|NCT00503009|Placebo Comparator|Arm 3|
9860200|NCT00500045|Experimental|Treatment|Oral niacin
9860201|NCT00499590|Active Comparator|A|Lucentis® (0.5mg) every 4 weeks.
9860202|NCT00499590|Experimental|B|Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
9860203|NCT00499590|Experimental|C|Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
9860204|NCT00501345|Experimental|Aspirin|
9860205|NCT00496756|Other|Sorafenib|"The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the table below, providing no dose limiting toxicity (Grade 3 or 4) is observed. If grade 3 or 4 toxicity is observed, delay and dose modification will occur as defined in protocol. Once dose level 3 is reached, the patient will remain at that dose as defined in following section.~Dose Level 1 Day 1-28 400 mg b.i.d. Dose Level 2 Day 29-56 600 mg b.i.d. Dose Level 3 Day 57- 800 mg b.i.d.~A treatment cycle will be 4 weeks.~Two 4-week cycles will be administered. At the completion of two cycles (week 8), restaging will occur. Patients will continue on therapy per study protocol."
9860206|NCT00495716|Active Comparator|Episodic Treatment Arm|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
9860207|NCT00495716|Active Comparator|Suppressive Therapy Arm|400 mg acyclovir orally twice daily for 1 year
9860208|NCT00500890|Experimental|Carboplatin + Etoposide + Vincristine|Carboplatin 350 mg/m^2 by vein, Over 2 Hours x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
9860209|NCT00500890|Experimental|Cyclophosphamide + Etoposide + Vincristine|Cyclophosphamide 1 g/m^2 by vein, Over 1 Hour x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
9860210|NCT00503841|Experimental|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
9860211|NCT00493025|Experimental|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
9860212|NCT00491400|Active Comparator|Fenofibrate First|Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
9860213|NCT00491400|Active Comparator|Atorvastatin First|Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second
9860214|NCT00490776|Experimental|Panobinostat 20 mg|Participants received panobinostat, 20 milligrams (mg), capsules, orally, thrice weekly on alternate Days 1, 3, and 5 per week of a 28-day treatment cycle until unacceptable toxicity, disease progression, and/or physician's discretion to discontinue the treatment.
9860215|NCT00487162|Experimental|intensive glycemic control|In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
9860216|NCT00487162|Active Comparator|conventional glycemic control|In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL
9860217|NCT00487981|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
9860218|NCT00491387|Experimental|metoprolol succinate|Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
9860219|NCT00483119|Active Comparator|Group A|IVIg alone (intravenous immunoglobulin)
9860220|NCT00483119|Experimental|Group B|IVIg with cyclophosphamide
9860221|NCT00487461|Placebo Comparator|Control Group|Placebo tablet
9860222|NCT00487461|Experimental|Study Group #1|Simvastatin 40 mg
9860223|NCT00487461|Experimental|Study Group #2|Simvastatin 80 mg
9860224|NCT00484718|Active Comparator|A|
9860225|NCT00484718|Active Comparator|B|
9860226|NCT00484718|Placebo Comparator|C|
9924459|NCT00861523|Active Comparator|2. promethazine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive promethazine IV
9924460|NCT00861536|Experimental|ATG Fresenius|
9924461|NCT00861536|Active Comparator|Thymoglobuline Genzyme|
9924462|NCT00861549|Experimental|cohort 1|1mg / 0.5 tablet
9924463|NCT00861549|Experimental|cohort 2|2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China
9924464|NCT00861549|Experimental|cohort 3|4mg / 2 tablets
9924465|NCT00861562|Active Comparator|Imescard pills/Placebo crossover|Patients received Imescard water smartweed composed pills during the first intervention period and placebo during the second, after a 10-day washout period.
9924466|NCT00861562|Active Comparator|Placebo/Imescard pills crossover|Patients received placebo during the first intervention period and Imescard water smartweed composed pills during the second, after a 10-day washout period.
9924467|NCT00861588|Experimental|isoflavones|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
9924468|NCT00861588|Placebo Comparator|starch|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
9935145|NCT04112953||Upcoming cardiac surgery|Subjects in this group will have an upcoming cardiac surgery with the use of cardiopulmonary bypass and no pre-existing renal insufficiency or failure
9935146|NCT04105855||Older Infants|Infants age 6-12 months presenting for routine healthy visits
9935147|NCT04105855||Pregnant Women|Women 18 years and older (and emancipated minors) presenting for routine antenatal visits
9935148|NCT04102436|Experimental|1/Sleeping Beauty|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Sleeping Beauty Transposed PBL + high- or low-dose aldesleukin.
9935149|NCT04102423||CCUS|All participants meeting the criteria for CCUS
9935150|NCT04102423||CHIP|Subjects will be split into five cohorts depending on specific mutations
9935151|NCT04102098|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.
9935152|NCT04102098|No Intervention|Arm B (active surveillance)|Active surveillance of participants.
9935153|NCT04097821|Experimental|Part 1 Arm 1: Ruxolitinib + Siremadlin|Dose escalation of siremadlin added to existing stable dose of ruxolitinib
9860227|NCT00477230|Experimental|1|Single ablation procedure with Endoscopic Ablation System
9860228|NCT00477230|Active Comparator|2|Medication
9860229|NCT00470067|Experimental|Doxorubicin and carboplatin|Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1
9860230|NCT00476827|Active Comparator|Bevacizumab / Capecitabine|Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
9860231|NCT00476827|Active Comparator|Bevacizumab / Docetaxel|Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
9860232|NCT00476827|Active Comparator|Bevacizumab /Irinotecan (Camptosar®, CPT-11)|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
9860233|NCT00476827|Active Comparator|Bevacizumab / Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
9860234|NCT00476827|Active Comparator|Bevacizumab /Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
9860235|NCT00476827|Active Comparator|Bevacizumab / Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.
9860236|NCT00475657|Experimental|A|
9860237|NCT00472082|Experimental|1|The study drug Efalizumab will be given as part of a triple drug regimen including mycophenolate mofetil and prednisone. A test dose of Efalizumab 0.7mg/kg will be given at the enrollment visit. Beginning with study visit 2, Efalizumab 1mg/kg will be administered subcutaneously by injection on a weekly basis for 1 year. Mycophenolate mofetil will be given at a dose of 2gm/day which is the same as the standard of care dose. If patient experiences drug toxicity with mycophenolate mofetil they may be reduced and resume a minimum of at least 1gram daily to continue in the study. Patients will be maintained at 10mg of prednisone daily, same as standard of care.
9860238|NCT00478062|Experimental|Cell vaccine after initial therapy for Hodgkin lymphoma|Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
9860239|NCT00470574|Experimental|Vaccine Therapy and QS21|"Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.~Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.~After completion of study treatment, patients are followed every 3 months"
9860240|NCT00467753|Experimental|Oxcarbazepine|Oxcarbazepine is the active drug to be given to subjects in the experimental arm
9860241|NCT00467753|Placebo Comparator|Sugar Pill|Patients are given either active or inactive intervention.
9860242|NCT00456612|Other|Cyberknife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
9860243|NCT00469612|Experimental|A|NeuroVision's NVC treatment for low myopia
9860244|NCT00469612|No Intervention|B|The subjects in this group will serve as controls and will be the no intervention group.
9860245|NCT00461812|Experimental|Mometasone|
9860246|NCT00461812|Experimental|Advair|
9860247|NCT00459121|Experimental|Zactima, Paclitaxel, Carboplatin|"Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.~Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
9860248|NCT00462904|Experimental|BPI infusion group|BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours
9860249|NCT00450333|Active Comparator|1|Erythropoietin(EPO)-naive BIW
9860250|NCT00450333|Active Comparator|2|EPO-naive QW
9860251|NCT00450333|Active Comparator|3|EPO QW
9860252|NCT00450333|Active Comparator|4|EPO Q2W
9860253|NCT00455143|Experimental|Dexmedetomidine|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
9860254|NCT00455143|Placebo Comparator|Placebo|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.
9860255|NCT00456989|Experimental|Taxotere and Doxil|Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively. Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
9860256|NCT00448682|Experimental|FUdR + Leucovorin + Oxaliplatin + Docetaxel (Taxotere)|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:~Day 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.~Day 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).~There will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles."
9860257|NCT00454571|Experimental|Pazopanib|Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9860258|NCT00454571|Active Comparator|Observation|Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
9860259|NCT00452361|Experimental|1|Sirolimus therapy
9794918|NCT01521559|Sham Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
9794919|NCT01521559|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
9794920|NCT01521780|Experimental|Imaging|Magnetic resonance imaging (MRI) of HCC tumor.
9794921|NCT01521780|Experimental|Pathology|Pathology samples from surgical resection of HCC tumor and adjacent liver.
9794922|NCT01521780|Experimental|Imaging/Pathology|MRI of HCC tumor, followed by pathology samples from surgical resection of HCC tumor and adjacent liver.
9794923|NCT01521845|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
9794924|NCT01521845|No Intervention|control|This group is without omega 3 : just receives standard treatment
9794925|NCT01521871|Experimental|Tissue glue wound closure|Skin wound closure by tissue glue
9794926|NCT01521871|Active Comparator|Conventional suture + dressing|Skin wound closure by conventional suture + dressing
9794927|NCT01521884||RA Patients treated with SC anti-TNF|
9800013|NCT01676831|Experimental|topical resiquimod 0.03%|Topical resiquimod 0.03% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will begin 5 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
9800014|NCT01676896|Experimental|Asthma in-school class|Provided in 16 15-minute sessions (4 hours total didactic time); scheduled 3 sessions/week. The content is provided by trained asthma educators. The Asthma Plan for Kids (AP-K) is a 7-step curriculum for children to use when responding to asthma symptoms. Skills practice with placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters with PEF score interpretation. Topics include (a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner.
9800015|NCT01676896|Experimental|Asthma Day Camp|The asthma day camp is provided in a single day session (5.5 hours total) by trained camp staff. The same skills (i.e., placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters) and topics [a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner] are covered as those in the asthma in-school classes.
9800016|NCT01676896|Sham Comparator|Health Promotion in-school class|The mock comparison follows the in-school format of 16 15-minute sessions; scheduled 3 sessions/week. The content is provided by trained health educators and includes skills practice (i.e., handwashing and brushing teeth) and health promotion topics of nutrition, healthy snacks, preventing colds, and safe exercise.
9860260|NCT00452361|Active Comparator|2|Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
9860261|NCT00443040|Placebo Comparator|Placebo|
9860262|NCT00443040|Active Comparator|Asimadoline 1.0 mg|Asimadoline 1.0 mg b.i.d.
9860263|NCT00443040|Active Comparator|Asimadoline 3.0 mg|Asimadoline 3.0 mg b.i.d.
9860264|NCT00447421|Experimental|A|
9860265|NCT00437398|Experimental|Islet Transplant|Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.
9860266|NCT00440271|Other|Standard of Care (SoC)|Standard of Care (SOC) Arm = Tipranavir/ritonavir (TPV/r) capsules taken orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR). No TPV/r dose changes were permitted.
9860267|NCT00440271|Other|Therapeutic Drug Monitoring (TDM)|Therapeutic Drug Monitoring (TDM) Arm = Patients began by receiving standard of care (SOC) tipranavir/ritonavir (TPV/r) capsules orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR) followed, if needed, by TPV or ritonavir (RTV) dose adjustments at Week 4, 6, 10, 14, 18, 22, 26 and 30 based on viral response, phenotypic inhibitory quotient (IQ), and TPV trough concentrations.
9860268|NCT00442260|Experimental|Abraxane dose escalation + fixed dose DOXIL|Limited dose-escalation study of Abraxane and fixed dose of DOXIL in order to identify correct dose and side effect profile of the combination.
9860269|NCT00429026|Experimental|Fludarabine + Cyclophosphamide with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
9860270|NCT00429026|Experimental|Fludarabine + Melphalan with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
9860271|NCT00428207|Active Comparator|Insulin Aspart Versus Insulin Lispro|Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
9860272|NCT00428207|Active Comparator|Insulin Lispro Versus Insulin Aspart|Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).
9860273|NCT00439569|Experimental|Single Arm|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
9860274|NCT00422669|Active Comparator|RV Mid-Septal Pacing|Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
9860275|NCT00422669|Active Comparator|RV Apical Pacing|Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex
9860276|NCT00432445|Experimental|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
9666957|NCT04093869|Experimental|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX intervention will consist of 12, 30 minute weekly sessions conducted by a respiratory therapist knowledgeable about lung transplantation and trained in motivational interviewing, Cognitive Behavioral Therapy (CBT), and exercise therapy.
9860277|NCT00434590|Experimental|Full Dose Myfortic® and Reduced Dose Neoral®|The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
9860278|NCT00434590|Active Comparator|Standard Dose of Myfortic® and Standard Dose of CsA-ME|Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.
9860279|NCT00424645|Experimental|Voraxaze|Voraxaze administered 50 units/kg intravenously (IV) repeated a maximum of 2 times in a given cycle of chemotherapy.
9860280|NCT00424645|Placebo Comparator|Placebo|Placebo administered IV following Voraxaze arm.
9794928|NCT01521897||7-valent vaccine injection|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
9794929|NCT01521923|Experimental|CZP 200 mg Q2W + Methotrexate|
9794930|NCT01521923|Experimental|CZP 200 mg Q4W + Methotrexate|
9794931|NCT01521923|Placebo Comparator|Placebo + Methotrexate|
9794932|NCT01521949|Experimental|Acai Juice|2 ounces of Acai Juice Product by mouth twice daily.
9794933|NCT01522131|Other|Bioresorbable membrane will be used as the control|Bioresorbable membrane alone (control)
9794934|NCT01522131|Experimental|laser with bioresorabable membrane (test)|
9794935|NCT01522235|Active Comparator|IVIg group|Double blinded IVIg and single blinded IVIg
9794936|NCT01522235|Other|Placebo Group|Double blinded Placebo and single blinded IVIg
9794937|NCT01522248|Active Comparator|Cohort 1|receives vaccine in morning. Blood drawn at 3, 7, 24, and 48 hours and 14 days after vaccination.
9794938|NCT01522248|Active Comparator|Cohort 2|receives vaccine in evening, Blood drawn 16, 40 hours and 14 days after vaccination.
9794939|NCT01522339|Experimental|Safety of a Customized NICU MRI System|Device: GE OPTIMA MR430s with HDX/GE Electronics
9794940|NCT01522391|Placebo Comparator|Placebo for DPK-060 ointment|
9794941|NCT01522391|Experimental|DPK-060 1% ointment|
9794942|NCT01522404|Experimental|Atomoxetine / Inactive Compound|Participants in this arm received atomoxetine, starting with 10 mg po daily and increasing weekly by increments to a maximum of 100 mg po daily or the maximum tolerated dose for up to weeks 29 and are then crossed over to Inactive compound group
9794943|NCT01522404|Placebo Comparator|Inactive compound / Atomoxetine|Subjects in this arm received a matching placebo that have inactive compound for up to weeks 29 and then are crossed over to receive active treatment of Atomoxetine
9794944|NCT01522417|Experimental|Short Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
9794945|NCT01522417|Active Comparator|Eptifibatide (Integrilin)|"Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.~Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
9794946|NCT01522417|Experimental|Long Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
9794947|NCT01522443|Experimental|Cabozantinib|"Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.~There will be a maximum of 10 infusions for mitoxantrone placebo."
9794948|NCT01522443|Active Comparator|Mitoxantrone/prednisone|"Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.~There will be a maximum of 10 infusions for mitoxantrone."
9794949|NCT01522456|Active Comparator|Epiduo Gel|Adapalene 0.1% and benzoyl peroxide 2.5% gel
9794950|NCT01522456|Active Comparator|Retin-A Micro Microsphere 0.1%|Tretinoin gel, 0.1%
9794951|NCT01522651|Placebo Comparator|Placebo|Ranolazine placebo plus dronedarone placebo for 12 weeks.
9794952|NCT01522651|Experimental|Ranolazine 750 mg|Ranolazine 750 mg plus dronedarone placebo for 12 weeks.
9794953|NCT01522651|Experimental|Dronedarone 225 mg|Ranolazine placebo plus dronedarone 225 mg for 12 weeks.
9794954|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 225 mg|Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.
9794955|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 150 mg|Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.
9794956|NCT01522703|Experimental|Broccoli Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 3 consecutive days
9794957|NCT01522703|Placebo Comparator|Alfalfa Sprouts|Alfalfa Sprouts will be eaten daily in a sandwich form for 3 consecutive days
9794958|NCT01522755||Patients implanted with the CapsureFix MRI pacing lead|Patients implanted with the CapsureFix MRI pacing lead model 5086
9794959|NCT01522924|Experimental|Counseling practice sessions|Dental students will be administered the first questionnaire before receiving a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients, and debriefing session.
9794960|NCT01522924|No Intervention|Lecture only|Students will receive the first questionnaire before the lecture and the second questionnaire after the lecture
9794961|NCT01522937|Experimental|Liver cancer patients|The aim of this study is to determine the safety and effectiveness of individualized Stereotactic Body Radiation Therapy (SBRT) in patients who either (1) have had previous liver treatments, and/or (2) have primary hepatocellular carcinoma (HCC).
9794962|NCT01522950|Active Comparator|Nebivolol|5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
9794963|NCT01522950|Active Comparator|Atenolol|25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
9794964|NCT01522950|Placebo Comparator|Placebo|"Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur."
9794965|NCT01522963|Experimental|Nicotine Lozenge Immediately Prior to Stress task|Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
9860281|NCT00430027|Experimental|Capecitabine, oxaliplatin, cetuximab, and radiation therapy|Patients enrolled on the trial will receive neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This will be followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab
9860282|NCT00429858|Experimental|Targeted therapy group|Gemcitabine monotherapy until disease progression, followed by gemcitabine + S-1
9860283|NCT00425438|Experimental|Mycophenolate Mofetil|Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
9860284|NCT00425438|Active Comparator|Cyclophosphamide/Azathioprine|Participants received cyclophosphamide 0.75 grams per square meter (g/m^2), intravenously (IV), every 4 weeks from Weeks 1 through 4, and 0.5 to (-) 1.0 g/m^2, IV, to maintain a minimum white blood cell (WBC) count of greater than or equal to (≥) 2500 per cubic millimeter (mm^3) every 4 weeks from Weeks 5 through 24. Participants also received azathioprine 100 mg, PO, daily for participants with a body weight of 50 to 70 kg and 150 mg, PO, daily for subjects with a body weight of more than 70 kg from Weeks 25 through 48. Participants also received prednisolone 0.75 to 1.0 mg/kg, PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
9860285|NCT00421954|Experimental|Ziprasidone|
9860286|NCT00422942|Experimental|1|
9860287|NCT00409344|Placebo Comparator|1|Normal Saline
9860288|NCT00409344|Active Comparator|Dexmedetomidine|Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.
9860289|NCT00414453|Active Comparator|Lidocaine 5% + placebo patch, ER and placebo pills|5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period
9860290|NCT00417248|Experimental|Investigational Treatment|Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
9860291|NCT00418145|Experimental|megadose oral methylprednisolone|1400 mg qd/5 days
9860292|NCT00418145|Experimental|IV methylprednisolone|1000 mg/qd/5 days
9860293|NCT00409331|Experimental|IMRT + Amifostine|Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.
9860294|NCT00392860|Experimental|PalmRim Experimental|Participants will have PalmRim installed on their wheelchair.
9860295|NCT00392860|Experimental|Natural-Fix Experiment|Participants will have a Natural-Fit installed on their wheelchair.
9860296|NCT00392860|Placebo Comparator|Handrim Control|Participants in this arm had a new standard handrim installed on their wheelchair as a control.
9860297|NCT00391430|No Intervention|Control|Participants assigned to the control condition will receive no treatment
9860298|NCT00391430|Active Comparator|Sertraline|Participants will receive treatment with sertraline
9860299|NCT00391430|Active Comparator|CBT|Participants will receive cognitive behavioral therapy
9860300|NCT00399841|Active Comparator|1|Stimulation will occur at the T7 followed by T8 during the trial implant period
9860301|NCT00399841|Active Comparator|2|Stimulation will occur at the T8 followed by T7 during the trial implant period
9860302|NCT00387673|Experimental|Arm 1|6 weeks of upper extremity training for 3 sessions/week, as follows: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session);
9860303|NCT00387673|Active Comparator|Arm 2|a 6-week period of 2 hours somatosensory stimulation of the hand, without training
9860304|NCT00387673|Placebo Comparator|Arm 3|a 6-week period of 2 hours sham somatosensory stimulation of the hand, followed by 1 hour of activity-based training
9860305|NCT00386724|Experimental|Precision Spinal Cord Stimulation|Single arm Precision Spinal Cord Stimulation System with Artisan Surgical Lead
9860306|NCT00387244|Experimental|Precision for Spinal Cord Stimulation|Single arm Precision for Spinal Cord Stimulation
9860307|NCT00384293|Experimental|1|MK0524A
9860308|NCT00384293|Placebo Comparator|2|placebo
9860309|NCT00383630|Experimental|Group 1|Intramyocardial injection of bone marrow mononuclear cells + LVAD
9924469|NCT00861640|Experimental|Intravenous Omeprazole|100 cases of Intravenous Omeprazole
9794966|NCT01522963|Experimental|Nicotine lozenge 10 Minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
9794967|NCT01522963|Experimental|Nicotine lozenge 20 minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
9794968|NCT01522963|Experimental|Nicotine Lozenge 30 minutes prior to stress taks|Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session
9794969|NCT01523275|Experimental|Mitomycin-C|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
9794970|NCT01523275|Placebo Comparator|Saline|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.
9794971|NCT01523301|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
9794972|NCT01523301|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
9794973|NCT01523366|Experimental|Ticagrelor|
9794974|NCT01523366|Active Comparator|Clopidogrel|
9794975|NCT01523392|Experimental|Ticagrelor|
9794976|NCT01523392|Active Comparator|Clopidogrel|
9794977|NCT01523457|Experimental|MPC modified FOLFIRINOX|Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
9794978|NCT01523457|Experimental|LAPC modified FOLFIRINOX|Patients with locally advanced pancreatic cancer (LAPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
9794979|NCT01523496|Active Comparator|HIV + Young Adults|All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
9794980|NCT01523496|Active Comparator|HIV - Controls|HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)
9794981|NCT01523587|Experimental|Afatinib|Patients receive afatinib tablets once daily
9794982|NCT01523587|Active Comparator|Erlotinib|Patients receive erlotinib tablets once daily
9794983|NCT01523613|Active Comparator|ROCK - Single Restorations|ChemFil Rock glassionomer restoration
9794984|NCT01523613|Active Comparator|Fuji IX GP - Single Restorations|Fuji IX GP Extra glassionomer restoration
9794985|NCT01523613|Active Comparator|Rock AND Fuji - Paired Restorations|"ChemFil Rock glassionomer restoration AND Fuji IX GP Extra glassionomer restoration.~While this is not truly a separate arm for outcome analysis, this arm represents those individuals who had paired restorations, one of each: 1 ChemFil Rock restoration and 1 Fuji IX GP restoration."
9794986|NCT01523704|Experimental|Home Monitoring(HM)|Patients assigned to HM Group(HM follow-up ONLY) will have Home Monitoring programmed ON. They will be seen in the office for device interrogations at the 3-month follow-up, and at 27 month follow-up. In the meanwhile the device status will be evaluated using HM only for the 9, 15 and 21 month scheduled follow-up. Patients will visit the hospital for device interrogation on 27 month final follow-up.
9794987|NCT01523704|Active Comparator|Control|Patients assigned to Control Group (HM + Conventional In-office follow-up - Control group) will have HM programmed ON. In addition to HM, these patients will visit the hospital for device interrogation at 3, 9, 15, 21 and 27 month follow-ups.
9794988|NCT01523743|Experimental|Compact catheter|Compact intermittent catheter
9794989|NCT01523743|Active Comparator|Standard Care|Standard Care: Coated intermittent catheter normally used by subject
9794990|NCT01523756|Experimental|test product 1 first|"own product (baseline) - test product 1 - test product 2~test product 1 = New ostomy base plate. Due to company confidentiality the product is just called test product 1"
9794991|NCT01523756|Experimental|test product 2 first|"own product (baseline) - test product 2 - test product 1~test product 2 = New ostomy base plate. Due to company confidentiality the product is just called test product 2"
9794992|NCT01523782|Experimental|GRASPA 50 IU/kg|Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
9794993|NCT01523782|Experimental|GRASPA 100 IU/kg|Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
9794994|NCT01523782|Experimental|GRASPA 150 IU/kg|Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
9794995|NCT01523808|Experimental|GRASPA 25|
9794996|NCT01523808|Experimental|GRASPA 50|
9860310|NCT00383630|Experimental|Group 2|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
9666958|NCT04093869|Experimental|Standard of Care plus Education (SOC-ED)|The SOC-ED intervention will consist of 12, 30 minute weekly sessions conducted by a health educator knowledgeable about transplantation and skilled in educational instruction.
9794997|NCT01523808|Experimental|GRASPA 100|
9794998|NCT01523808|Experimental|GRASPA 150|
9794999|NCT01523821|Other|Cohort 1 (30 mg/kg)|Alpha 1 anti-trypsin (AAT) will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 30mg/kg (maintenance dose) every other day (QOD) on days 3, 5, 7, 9, 11, 13 & 15.
9795000|NCT01523821|Other|Cohort 2 (60 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 60 mg/kg (maintenance dose) QOD on days 3, 5, 7, 9, 11, 13 & 15.
9795001|NCT01523821|Other|Cohort 3 (90 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg on days 1, 3, 5, 7, 9, 11, 13 & 15.
9795002|NCT01523834|Experimental|Panobinosat|"The treatment is divided in three phases: induction phase (course 1 to 6), consolidation phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for any reason). The duration of a treatment course will be 28 days. The first dose of panobinostat in course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 days later.~Treatment:~Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week (QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), as part of a 4 week (28 days) treatment cycle."
9795003|NCT01523886|Active Comparator|Deep neuromuscular blockade|
9795004|NCT01523886|Placebo Comparator|Moderate neuromuscular blockade|
9795005|NCT01523899|Experimental|Xpert MRSA/SA SSTI|use of the Xpert MRSA/SSTI diagnostic assay
9795006|NCT01523899|Active Comparator|Standard culture|performance of standard bacterial culture of abscess material
9795007|NCT01523964|Other|DMD subject ages 3-7 inclusive|Young DMD Testing with EIM
9795008|NCT01523964|Other|DMD subject ages 8-12 inclusive|Older DMD Testing with EIM
9795009|NCT01523964|Other|Healthy Control ages 3-7 inclusive|Young Healthy Testing with EIM
9795010|NCT01523964|Other|Healthy Control ages 8-12 inclusive|Older Healthy Testing with EIM
9795011|NCT01524133|Active Comparator|Sertraline + enhanced medication management (SERT/EMM)|24 weeks of sertraline + enhanced medication management
9795012|NCT01524133|Active Comparator|Prolonged Exposure + sertraline (PE/SERT)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
9795013|NCT01524133|Active Comparator|Prolonged Exposure + placebo (PE/PLB)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
9795014|NCT01524198|Placebo Comparator|Normal Saline|Subjects who are receiving normal saline (NS) in addition to Albuterol 2.5 mg if < 20 kg or 5 mg if >= 20 kg body weight and ipratropium bromide (IB) 250 mcg; 3 nebulizations back to back
9860311|NCT00383630|Other|Group 3|LVAD alone
9860312|NCT00374543|Experimental|Ziprasidone|Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
9860313|NCT00374543|Placebo Comparator|Placebo Capsules|Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.
9860314|NCT00377455|Experimental|Bosentan|
9860315|NCT00377455|Placebo Comparator|Placebo|
9860316|NCT00371462|Active Comparator|Arm 1|MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care);
9860317|NCT00371462|Experimental|Arm 2|MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment)
9860318|NCT00369265|Experimental|Lansoprazole|Lansoprazole 30 mg Twice Daily
9860319|NCT00369265|Placebo Comparator|Sugar pill|placebo
9860320|NCT00370695|Experimental|Precision Spinal Cord Stimulation System|Single arm Precision Spinal Cord Stimulation System.
9860321|NCT00364689|Experimental|lactulose given with a placebo (sugar pill)|
9860322|NCT00364689|Experimental|lactulose given with rifaximin|
9860323|NCT00364689|Active Comparator|rifaximin given alone|
9860324|NCT00352118|Experimental|Chemotherapy + Low Dose Radiation|Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.
9860325|NCT00368654|Active Comparator|A|Monotherapy with Raptiva alone
9860326|NCT00368654|Experimental|B|Combination therapy with both Raptiva and Methotrexate
9860327|NCT00368654|Experimental|C|Continue Raptiva, discontinue methotrexate
9860328|NCT00368654|Experimental|D|Continue combination therapy with both Raptiva and Methotrexate
9860329|NCT00356421|Active Comparator|Control|
9860330|NCT00356421|Experimental|Experimental|
9860331|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
9860332|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
9860333|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
9860334|NCT00356187|Experimental|Propranol Treatment|
9860335|NCT00356187|No Intervention|Standard of Care|
9860336|NCT00353275|Other|1|Strict glycemic control with a blood glucose target range of 80-110 mg/dL
9860337|NCT00353275|Other|2|Conventional glycemic control with blood glucose target range of 110-140 mg/dL
9860338|NCT00350844|Experimental|Hydroxyurea|
9860339|NCT00348556|Experimental|Nesiritide|Subjects received an intrarenal infusion of nesiritide at 0.005 microgram/kg/min for 6 hours, 0.01 microgram/kg/min for 6 hours, 0.02 microgram/kg/min for 6 hours, and 0.03 microgram/kg/min for 6 hours.
9860340|NCT00319839|Experimental|Abraxane plus Cetuximab|Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
9860341|NCT00344019|Active Comparator|atorvastatin 80 mg|80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
9860342|NCT00344019|Placebo Comparator|placebo oral tablet|placebo on average of 2-4 hours pre angio/PCI for ACS
9860343|NCT00344019|No Intervention|Screening|Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
9860344|NCT00338455|Experimental|001|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
9860345|NCT00338455|Placebo Comparator|002|Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
9860346|NCT00329108|Experimental|A|
9860347|NCT00329108|Active Comparator|B|
9860348|NCT00325572|Active Comparator|Oral zinc and vitamin C supplementation|Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
9860349|NCT00325572|Placebo Comparator|Oral Placebo|Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.
9860350|NCT00333762|Experimental|SPAM and SWCS|Smart Power Assistance Module (SPAM) Smart Wheelchair Component System (SWCS)
9860351|NCT00333229|Experimental|Zoledronic Acid|Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
9860352|NCT00333229|Placebo Comparator|Placebo|Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
9860353|NCT00322855||Chart Review|patients diagnosed with soft tissue sarcoma
9860354|NCT00323635|Experimental|Tolterodine|Tolterodine 4 mg q.d. X 8 weeks
9860355|NCT00323635|Placebo Comparator|Placebo|A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
9860356|NCT00329732|Active Comparator|Lidocaine/Bupivicaine|
9860357|NCT00329732|Placebo Comparator|saline|matching volume of saline injected
9860358|NCT00320931|Experimental|Hybrid PET/CT|
9860359|NCT00314353|Experimental|1|
9860360|NCT00314353|Experimental|2|
9860361|NCT00314327|Experimental|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
9860362|NCT00308113|Active Comparator|1|CoenzymeQ10 taken once a day each morning by mouth.
10209584|NCT04040426|Experimental|Human split thickness skin allograft (Theraskin™)|Theraskin™ is an all-human split thickness skin allograft with a native extracellular matrix that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing. Theraskin™ is an allograft tissue and will be used in compliance with homologous use by the FDA under section 361 of the PHS Act and 21 CFR Part 1271
9860363|NCT00308113|Active Comparator|2|Prednisone taken once a day each morning by mouth
9860364|NCT00308113|Active Comparator|3|CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
9860365|NCT00308113|No Intervention|4|Enhanced standard of care.
9860366|NCT00305643|Experimental|Arm I: Celecoxib + Capecitabine|Celecoxib 200 mg given orally twice/day along with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day).
9860367|NCT00305643|Placebo Comparator|Arm II: Placebo + Capecitabine|Placebo with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day)
9860368|NCT00298740|Experimental|Aventis U-400 Insulin|
9860369|NCT00301080|Placebo Comparator|Placebo (original version)|Placebo administered orally twice per day for 4 weeks.
9860370|NCT00301080|Active Comparator|D-cycloserine 200mg|D-cycloserine administered orally at a dose of 200 mg twice per day for 12 weeks.
9860371|NCT00301080|Active Comparator|D-cycloserine 50 mg|D-cycloserine administered orally at a dose of 50 mg twice per day for 12 weeks.
10209585|NCT04040426|Active Comparator|Fibracol wound dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
10209586|NCT04033692||JuggerKnot Mini Soft Anchors|Patients who have been implanted with the JuggerKnot Mini Soft Anchor who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc
10209587|NCT04031599|Active Comparator|Carbohydrate counting|Rapid acting insulin analogue with carbohydrate counting
10209588|NCT04031599|Active Comparator|Simplified qualitative meal size estimation|Rapid acting insulin analogue with simplified qualitative meal size estimation
10209589|NCT04030559|Experimental|Treatment (niraparib)|Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
10209590|NCT04025658|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10209591|NCT04025658|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10209592|NCT04025658|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10209593|NCT04025658|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9860372|NCT00301080|Active Comparator|D-cycloserine 250mg|This was the original active comparator arm (before the design was changed): D-cycloserine administered orally at a dose of 250 mg twice per day for 4 weeks.
9860373|NCT00301080|Placebo Comparator|Placebo (revised version)|Placebo administered orally twice per day for 12 weeks.
9860374|NCT00299195|Experimental|1|sulindac
9860375|NCT00299195|Placebo Comparator|2|placebo
9860376|NCT00295490|Experimental|240mg Devil claw|Sub clinical dose if the 3 doses employed
9860377|NCT00295490|Experimental|960mg Devil Claw|Active dose
9860378|NCT00295490|Experimental|1920 mg Devil claw|Active dose
9860379|NCT00295490|Placebo Comparator|Placebo|Comparator for all active intervention arms
9860380|NCT00268463|Active Comparator|Arm 1: Capecitabine + Oxaliplatin|Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
9860381|NCT00268463|Experimental|Arm 2: Floxuridine + Oxaliplatin + Capecitabine|Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
9860382|NCT00271102|Active Comparator|Anterior colporrhaphy|Anterior vaginal wall colporrhaphy (repair) for cystocele (dropped bladder)
9860383|NCT00271102|Active Comparator|Paravaginal defect repair|Abdominal paravaginal defect repair cystocele (dropped bladder)
9860384|NCT00276419|Experimental|Placebo First, then Diclofenac (Arm A)|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks, then compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks.
9924470|NCT00861640|Experimental|Oral Rabeprazole|100 cases of oral rabeprazole
10209594|NCT04025658|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10209595|NCT04025658|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
10209596|NCT04025398|Experimental|REHABILITUS|Réhabilitus is a cognitive remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among adults with intellectual disabilities.
10209597|NCT04025398|Active Comparator|CONTROL GROUP|The control group involves manual activities and research computer information.
10209598|NCT04019821|Active Comparator|Normal Bolus|Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).
10209599|NCT04019821|Experimental|Super Bolus|Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.
10209600|NCT04013139||CKD Stage 3|CKD patients with GFR between 30-60cc/min
10209601|NCT04013139||CKD Stage 4|CKD Patients with GFR 15-30 cc/min
10209602|NCT04008069|Experimental|Study drug|sarilumab 200 mg subcutaneously every two weeks
10209603|NCT04008069|Placebo Comparator|placebo|placebo subcutaneously every two weeks
10209604|NCT04006288|Active Comparator|Aspirin and clopidogrel|aspirin 81 mg/qd plus clopidogrel 75mg/qd for 30 days
10209605|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and clopidogrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
10209606|NCT04006288|Active Comparator|Aspirin and prasugrel|aspirin 81 mg/qd plus prasugrel 10mg/qd for 30 days
10209607|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and prasugrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
10209608|NCT04006288|Active Comparator|Aspirin and ticagrelor|aspirin 81 mg/qd plus ticagrelor 60mg/bid for 30 days
10209609|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and ticagrelor|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
10209610|NCT04005638||Autoimmune Cytopenia|
10209611|NCT03995121||Schizophrenia and other psychotic disorders|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
10209612|NCT03995121||Cannabis Use Disorder|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
10209613|NCT03995121||Healthy Control|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
10209614|NCT03990012|Experimental|Patients referred for breast biopsy|Patients with Breast Imaging-Reporting and Data System (BI-RADS) 4C or 5 diagnosis who have been referred for breast biopsy based on the results of their standard diagnostic breast exam will undergo IR and 3D imaging of the breasts.
10209615|NCT03988829|Active Comparator|Low-C|In an experimenter-designed simulation game, participants will be trained on predictable low attentional control shifts during working memory.
10209616|NCT03988829|Experimental|High-C|In an experimenter-designed simulation game, participants will be trained on unpredictable high attentional control shifts during working memory.
10209617|NCT03988829|Experimental|High-C+|In this commercially-available video game, in addition to unpredictable shifts of attentional control in working memory, task switching and resource planning will be trained.
10209618|NCT03988192|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients treated by immunotherapy for lung cancer.
10209619|NCT03973853|Experimental|Active group with virtual reality stimulation|The subjects in this arm will undertake 14 sessions of virtual reality stimulation. The program will be delivered by a nurse, trained to the use of such a tool, and familiar with cognitive remediation techniques. Before and after these 14 sessions, social autonomy, daily life skills, cognitive domains and self-esteem will be measured
9795015|NCT01524198|Active Comparator|Budesonide|Subjects with acute asthma exacerbation who receive Budesonide 500 mcg, in addition to Albuterol 2.5 mg if < 20 kg body weight or 5 mg if >= 20 kg body weight and Ipratropium Bromine (IB) 250 mcg; 3 nebulization doses back to back
9795016|NCT01524224|Experimental|LY2495655|"Administered intravenously (IV) every 2 weeks (14 days) for four (4) 14 day cycles. Participants receiving clinical benefit may continue to receive treatment until one or more of the discontinuation criteria are met.~Starting dose in Part 1 (dose escalation) will be 2 mg. The dose will be subsequently increased to 7 mg, 21 mg, 70 mg, 210 mg, and 700 mg. The dose administered in Part 2 (dose confirmation) will be determined from Part 1."
9795017|NCT01524289|Experimental|Anacetrapib|Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period.
9795018|NCT01524289|Placebo Comparator|Placebo|Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.
9795019|NCT01524302|Active Comparator|Levofloxacin|Pharmacodynamics
9795020|NCT01524302|Active Comparator|Ceftaroline|Pharmacodynamics
9795021|NCT01524627|Placebo Comparator|Control Group|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
10209620|NCT03973853|Placebo Comparator|Treatment as Usual group (TAU)|Patients in this group will carry on benefiting from their usual care with no additional program. They will be assessed before and after a 3 month period for social autonomy, daily life skills, cognitive domains and self-esteem.
10209621|NCT03968991|Active Comparator|Healthy volunteer group|male or female healthy volunteers
9795022|NCT01524627|Active Comparator|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
9795023|NCT01524679|Experimental|Treatment group|pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
9795024|NCT01524679|No Intervention|Control group|ongoing nucleos(t)ide based treatment alone
9795025|NCT01524692|Experimental|Single ARM Dovitinib treatment|Single ARM Dovitinib treatment
9795026|NCT01524770|Active Comparator|Manual syringe|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by manual syringe in one of two study periods separated by a 28-day minimum washout period.
9795027|NCT01524770|Experimental|Auto-injector|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by auto-injector in one of two study periods separated by a minimum 28-day washout period
9795028|NCT01524783|Experimental|Everolimus + BSC|Participants received everolimus 10 mg once daily plus best supportive care (BSC) throughout the study
9795029|NCT01524783|Placebo Comparator|Placebo + BSC|Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.
9795030|NCT01524796||Patients with peripheral neuropathic pain treated with Lyrica|
9795031|NCT01524887|Experimental|IGIV, 10% at high dose (0.4 g/kg)|
9795032|NCT01524887|Experimental|IGIV, 10% at low dose (0.2 g/kg)|
9795033|NCT01524887|Placebo Comparator|Placebo control|
10209622|NCT03968991|Experimental|Subjects with acquired visual impairment|visual acquired disability
10209623|NCT03968991|Experimental|Subjects with congenital visual impairment|Visual congenital disability
10209624|NCT03964506|Experimental|Cohort 1- AML or MDS|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
10209625|NCT03964506|Experimental|Cohort 2- CMML, aCML, CML, CNL, MDS/MPN|Patients with will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
10209626|NCT03962959|Experimental|Excitatory TBS|Excitatory TBS
10209627|NCT03962959|Experimental|Inhibitory TBS|Inhibitory TBS
10209628|NCT03962959|Placebo Comparator|Sham TBS|Sham TBS
10209629|NCT03961009|Experimental|Kedrion IVIG 10%|Participants received intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligrams per kilogram (mg/kg) body weight on every 21 or 28 days for period of 48 weeks.
10209630|NCT03957434|Experimental|Physiotherapy|12-weekly physiotherapy treatment sessions.
10209631|NCT03957434|No Intervention|Standard usual care|Participants will be asked to continue the usual care established during the regular follow-up with their medical doctor for 12 weeks.
10209632|NCT03956784|Experimental|E-assessed follow up|Patients undergoing colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric, for whom an early discharge has been programmed, and followed by a connected application and a nursing logistics platform at home.
10209633|NCT03956784|Other|Standard home follow-up care|Patients undergoing surgery for colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric surgery, for whom an early discharge has been programmed, and followed by usual way.
10209634|NCT03949881|Experimental|FEMJA transplatation|"FEMJA epithelium is obtained by culturing oral mucosal epithelial cells without any need of support substrates, or carriers, and the transparent fabricated sheets show strong, rapid adhesion on corneal stroma in vivo, without any need for suturing.~The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation."
10209635|NCT03946631||Blood Glucose Test - 2hour GTT|Only one arm: intervention group. The intervention is fasting 2 hour glucose tolerance test in the immediate postpartum period. The screening test consists of fingerstick blood glucose testing after a glucose drink. First, a fasting blood glucose finger stick will be performed. Second, the glucose drink is orally ingested containing 75g glucose. The drink is to be orally ingested over 60 seconds. Lastly, fingerstick blood glucose testing is completed at 1 hour post drink and 2 hours post drink.
10209636|NCT03945760|Experimental|Subjects Taking Baricitinib 2 mg|Subjects will be taking Baricitinib 2mg
10209637|NCT03945760|Placebo Comparator|Subjects Taking Placebo|Subjects will be taking placebo
9795034|NCT01524900||nevirapine extended release|
9795035|NCT01524913|Experimental|Hyaluronic acid|
9795036|NCT01524913|Active Comparator|Corticosteroid|
9795037|NCT01524913|Placebo Comparator|Saline|
9795038|NCT01524978|Experimental|Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib|Participants with NSCLC will be treated with vemurafenib monotherapy.
9795039|NCT01524978|Experimental|Cohort 2: Ovarian Cancer - vemurafenib|Participants with ovarian cancer will be treated with vemurafenib monotherapy.
9795040|NCT01524978|Experimental|Cohort 3a: Colorectal Cancer - vemurafenib|Participants with colorectal cancer will be treated with vemurafenib monotherapy.
9795041|NCT01524978|Experimental|Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab|Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
9795042|NCT01524978|Experimental|Cohort 4: Cholangiocarcinoma - vemurafenib|Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
9795043|NCT01524978|Experimental|Cohort 6: Multiple Myeloma - vemurafenib|Participants with multiple myeloma will be treated with vemurafenib monotherapy.
9795044|NCT01524978|Experimental|Cohort 7: Other Solid Tumors - vemurafenib|Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.
9795045|NCT01524991|Experimental|Treatment|Gemcitabine 1000 mg/m2 Days 1 & 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 (start cycle 3)
9795046|NCT01525082|Experimental|Bevacizumab + Capecitabine + Temozolomide|Cycles repeat every 28 days until disease progression, unacceptable toxicity, or withdrawal.
9795047|NCT01525173|Active Comparator|ALPHAGAN® P and LUMIGAN®|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
10209638|NCT03943667|Experimental|GEMPAX|Gemcitabine + Paclitaxel until progression
10209639|NCT03943667|Active Comparator|Control|Gemcitabine alone until progression
10209640|NCT03941444|Experimental|Active arm|ANAVEX2-73 liquid oral solution
10209641|NCT03941444|Placebo Comparator|Placebo arm|Placebo liquid oral solution
9795048|NCT01525173|Active Comparator|LUMIGAN® Alone|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
9795049|NCT01525225|Experimental|Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC|
9795050|NCT01525238|Experimental|Dapagliflozin 2.5 mg|
9795051|NCT01525238|Experimental|Dapagliflozin 5 mg|
9795052|NCT01525238|Experimental|Dapagliflozin 10 mg|
9795053|NCT01525407|Experimental|Supportive care (donor statin treatment)|Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
9795054|NCT01525420|Experimental|ACT|ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.
9795055|NCT01525420|Active Comparator|CBT|CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.
9795056|NCT01525550|Experimental|sunitinib|
9795057|NCT01525563||Subjects with irregular Menstrual cycle|Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled.
9795058|NCT01525589|Experimental|PM01183|
9795059|NCT01525602|Experimental|Part 1|"Open-label, sequential PLX3397 single-agent dose escalation in combination with paclitaxel in approximately 30 patients with advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
9795060|NCT01525602|Experimental|Part 2|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients in advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
9795061|NCT01525602|Experimental|Part 3|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients with advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.~(Closed to recruitment)"
9795062|NCT01525615|Experimental|tiotropium+olodaterol low dose|once daily 2 puffs, fixed dose combination (FDC) solution for inhalation Respimat
9795063|NCT01525615|Experimental|tiotropium+olodaterol high dose|once daily 2 puffs, FDC solution for inhalation Respimat
9795064|NCT01525615|Placebo Comparator|placebo|once daily 2 puffs, solution for inhalation Respimat
9795065|NCT01525628|Experimental|Group A|Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
9860385|NCT00276419|Experimental|Diclofenac First, then Placebo (Arm B)|Compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks, then placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks.
9860386|NCT00279409|Active Comparator|aripiprazole|"This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripiprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial."
9860387|NCT00279409|Placebo Comparator|Sugar pill|"This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis."
9860388|NCT00281879|Active Comparator|Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)|
9860389|NCT00281879|Active Comparator|Busulfan and Cyclophosphamide (Cytoxan)|
9860390|NCT00281879|Active Comparator|BEAM Regimen|On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
9860391|NCT00281879|Active Comparator|Low-Dose Fludarabine and TBI(for second stem cell donation)|A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
9860392|NCT00281879|Active Comparator|Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)|On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
9860393|NCT00281879|Active Comparator|ATG For Cord Blood Transplants|If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
9924471|NCT00861666|Other|Forgiveness-based Writing|
9924472|NCT00861679|Other|HSCT from matched family or unrelated donors(MD)|HSCT from matched family or unrelated donors(MD) to matched related donors.
9924473|NCT00861718|Experimental|AZD7268|
9924474|NCT00861718|Placebo Comparator|Placebo|
9924475|NCT00861731|Active Comparator|1|hypolipidemic treatment
9795066|NCT01525628|Experimental|Group B|Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
9795067|NCT01525628|Experimental|Group C|Effect of Dual oral DAAs on tenofovir
9795068|NCT01525628|Experimental|Group D|Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
9795069|NCT01525628|Experimental|Group E|Effect of BI 201335 and BI 207127 on raltegravir
9795070|NCT01525641||Patient with Parkinson's Disease|
9795071|NCT01525667|Experimental|150M PLX-PAD|Single course, multiple IM injections
9795072|NCT01525667|Experimental|300M PLX-PAD|Single course, multiple IM injections
9795073|NCT01525667|Placebo Comparator|Placebo|Single course, multiple IM injections
9795074|NCT01525849|Active Comparator|Balloon Sinus Dilation|XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
9795075|NCT01525849|Active Comparator|Functional Endoscopic Sinus Surgery|Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.
9795076|NCT01525862|Experimental|Balloon sinus dilation|Balloon dilation of the maxillary sinus using a transnasal approach.
9795077|NCT01525875|Active Comparator|Magnesium oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
9795078|NCT01525875|Placebo Comparator|Placebo|Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
9795079|NCT01526057|Experimental|A - PF-05280586|
9795080|NCT01526057|Active Comparator|B - Rituximab EU|
9795081|NCT01526057|Active Comparator|C- Rituximab-US|
9795082|NCT01526148|Active Comparator|Lithium|
9795083|NCT01526148|Active Comparator|Quetiapine|
9795084|NCT01526213|Other|Sequence 1: Water, GFJ, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
9795085|NCT01526213|Other|Sequence 2: Water, FC-free GFJ, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
9795086|NCT01526213|Other|Sequence 3: GFJ, FC-free GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
9795087|NCT01526213|Other|Sequence 4: GFJ, Water, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
9795088|NCT01526213|Other|Sequence 5: FC-free GFJ, GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
9795089|NCT01526213|Other|Sequence 6: FC-free GFJ, Water, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
9795090|NCT01526343|Experimental|Reveal XT|
9795091|NCT01526356|Placebo Comparator|Placebo|Cream only
9795092|NCT01526356|Active Comparator|0.1 % Rapamycin|0.1% Rapamycin cream
9795093|NCT01526356|Active Comparator|1% Rapamycin|1% Rapamycin cream
9795094|NCT01526538|Experimental|50 mg d-cycloserine|active drug condition
9795095|NCT01526538|Placebo Comparator|Sugar pill|Inactive placebo
9795096|NCT01526551|Experimental|Intervention Schools|High school students attending Wayne County and Monticello Ind. schools will be given opportunity to receive HPV Vaccine and HPV-related Health Education and Reduction of barriers to being vaccinated.
9795097|NCT01526577|Experimental|LC23-1306|experimental drug
9795098|NCT01526577|Placebo Comparator|placebo|LC23-1306 placebo
9795099|NCT01526577|Active Comparator|Ticagrelor|active comparator
9795100|NCT01526629||ICD patients with remote follow-up|Patients implanted with a fully automatic ICD and remotely followed-up.
9795101|NCT01526733|Sham Comparator|Insulin (Aspart or Lispro)-Sham|"In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16.~Each Phase was separated by a washout period of 5 to 21 days."
9924476|NCT00861731|Sham Comparator|2|hypolipidemic treatment
9924477|NCT00861731|Sham Comparator|3|hypolipidemic treatment
10209642|NCT03936933|Experimental|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
9860394|NCT00281879|Active Comparator|DLI (Donor Leukocyte Infusion)|Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
9860395|NCT00281879|Active Comparator|Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)|On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
9860396|NCT00271947|Experimental|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after the conditioning regimen
9860397|NCT00271011|Experimental|Mitomycin C, Irinotecan and Cetuximab|"Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.~Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.~Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2."
9860398|NCT00253981|Experimental|Infrared Light Therapy|Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
9860399|NCT00253981|Placebo Comparator|Standard of Care|Standard of care was characterized by the use of standard medical treatment to include medication.
9860400|NCT00252174|Experimental|Stage 1 Active methylenedioxymethamphetamine & psychotherapy|8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
9860401|NCT00252174|Active Comparator|Stage 1 low dose methylenedioxymethamphetamine & Psychotherapy|4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
9860402|NCT00252174|Experimental|Stage 2 Active methylenedioxymethamphetamine & Psychotherapy|The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
9860403|NCT00256295|Experimental|Gemcitabine plus Oxaliplatin|Gemcitabine given 1000 mg/m2 IV over 100 minutes Every 21 days. Oxaliplatin given 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days.
10209643|NCT03936933|Active Comparator|ZOLADEX® 3.6mg Injection.|3.6 mg, Subcutaneously at every 28 days
10209644|NCT03936218|Experimental|Inj. Goserelin (Test) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
10209645|NCT03936218|Active Comparator|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
10209646|NCT03935698|Experimental|Physiotherapy|12 weekly 60-minute individual sessions of multimodal physiotherapy including education, stretching techniques, pelvic floor muscle biofeedback as well as home exercises.
10209647|NCT03934658|Experimental|Active Treatment Arm|Intervention with the NightWare Therapeutic System every night.
10209648|NCT03934658|Sham Comparator|Sham Arm|NightWare Therapeutic System every night with interventions not-enabled.
10209649|NCT03927521|Experimental|Focal HIFU guided by PET-MRI/68Ga-PSMA imaging|Patient with local/focal prostate cancer recurrence after radiotherapy and no distant metastasis (negative PET-Choline imaging confirmed by PET-MRI/68Ga-PSMA) will be treated by Focal-HIFU
10209650|NCT03923699|No Intervention|Standard of care arm|Operating rooms in the standard of care group will be monitored but, the ACT clinicians will not contact the operating room unless it is clinically necessary for patient safety purposes.
10209651|NCT03923699|Experimental|Anesthesia Control Tower monitoring|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room using AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes.
10209652|NCT03923452|Experimental|MBSR: Mindfulness-based stress reduction|Participants will be exposed to the 9-week MBSR program, facilitated by a trained MBSR facilitator. Due to COVID-19, the program will be held virtually.
10209653|NCT03923452|No Intervention|WLC: Wait list Control|Participants will be asked to log their self-care activities every week.
10209654|NCT03915548|Experimental|The Behavioral Activation/ Problem Solving Intervention|BA/PS teaches survivors to a) systematically examine the reasons an activity is challenging, b) set achievable short-term goals that have the potential to improve participation, c) brainstorm solutions including activity adaptations and environmental modifications, d) construct and implement a detailed action plan, and e) evaluate the results and level of goal attainment. The structured process gives participants repeated practice in goal reengagement that leads them progressively closer to their long-term functional goals. The BA/PS framework integrates the cognitive-behavioral therapies of Behavioral Activation and Problem-solving Treatment and incorporates concepts from an occupational therapy theory called the Person-Environment-Occupational Performance Model.
10209655|NCT03915548|Active Comparator|Attention Control Condition|"Investigators provide education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts. The control condition will match the intervention in terms of the number of sessions, the delivery by telephone, use of an occupational therapist, and the use of homework between sessions (i.e., reading the education materials for the control condition versus executing the action plan for the BA/PS condition)."
10213629|NCT03650491|Experimental|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
9860404|NCT00268450|Experimental|study intervention|Neo-adjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy. Patients without residual disease will enter follow up after surgery. Patients with residual disease will receive adjuvant therapy with bevacizumab and ciaplatin.
9860405|NCT00239720|Experimental|hOKT3gamma1 (Ala-Ala)|Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
9860406|NCT00239720|Placebo Comparator|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
9860407|NCT00250718|Experimental|Arm 1 Combination Treatment|"Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient"
9924478|NCT00861770|Other|1 - Control|All subjects will receive blood volume measurement immediately before and 30 minutes after ultrafiltration is completed. In the control group, the treating physician will not see the blood volume measurement results and treat according to standard of care.
9924479|NCT00861770|Experimental|2 - BVM|Ultrafiltration will be guided by blood volume measurement results.
9924480|NCT00861783|Experimental|Group A - irinotecan|"Note: As of Amendment 2 (March 2009), treatment in the irinotecan arm of the study (Group A) is closed to enrollment.~Treatment with escalating doses of ON 01910.Na in combination with irinotecan."
9924481|NCT00861783|Experimental|Group B - oxaliplatin|Treatment with escalating doses of ON 01910.Na in combination with oxaliplatin.
9924482|NCT00861796|Experimental|1|
9924483|NCT00861796|Placebo Comparator|2|
9924484|NCT00861822|Active Comparator|RBC|Advance RBC transfusion' (ART) group
9924485|NCT00861822|Other|Standard Care|Standard-of-care RBC transfusion (SRT) group
9924486|NCT00861835|Experimental|ROSE for TBNA|
9924487|NCT00861835|No Intervention|NR|no on-site cytopathology assessment (NR)
9924488|NCT00861848||12-50 with heart disease|12-50 with heart disease
9924489|NCT00861848||12-50 normal controls|12-50 normal controls
10209656|NCT03913078|Active Comparator|Group Fitness|Subjects will be offered several sessions per week of a traditional group fitness program led by a trained group leader.
9924490|NCT00861861|Active Comparator|1|pitavastatin group
10209657|NCT03913078|Active Comparator|PlayFit|Subjects will be offered several sessions per week of a modified sports fitness program, led by a trained group leader.
9924491|NCT00861861|Active Comparator|2|atorvastatin group
10209658|NCT03911661|Active Comparator|Standard Management|The standard management phase will be historical and consist of warfarin management during the 12-months prior to signing informed consent.
10209659|NCT03911661|Experimental|Fearon Algorithm (FA) Anticoagulation Management Service|Once study patients have received an approved FA report, the FA AMS phase of the study will commence. An investigator will communicate the new warfarin tablet size, if necessary, and use the FA report to determine warfarin doses for the patient.
10209660|NCT03911661|Experimental|Fearon Algorithm (FA) Patient Self Management|At the conclusion of the six-month FA anticoagulation management service phase, patients will be trained to use the FA for patient self management (PSM) and after successfully demonstrating the ability to engage in PSM the FA PSM phase of the study will commence.
10209661|NCT03908255|Placebo Comparator|Control Group|The control group will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic), consume a maltodextrin placebo supplement beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
10209662|NCT03908255|Experimental|Intervention Group|In the intervention group, patients will receive current standard of care (locoregional therapy of the liver, serial bloodwork and imaging, serial assessments in clinic) and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
10209663|NCT03907878|Experimental|Ligelizumab|Ligelizumab q4w
10209664|NCT03904862|Experimental|Phase I - Skeletally-immature|Skeletally-immature children with refractory or recurrent medulloblastoma of the SHH group
10209665|NCT03904862|Experimental|Phase II - Skeletally-mature|Skeletally-mature subjects with refractory or recurrent medulloblastoma of the SHH group
10209666|NCT03904862|Experimental|Surgical|Subjects who are eligible for the Phase I or Phase II arm of the trial and are candidates for surgery, may be enrolled in the surgical arm prior to initiation of the Phase I or Phase II treatment.
10209667|NCT03901755||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
10209668|NCT03901755||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
10209669|NCT03900754|Experimental|Intranasal Oxytocin|Dosages of oxytocin: 20IU or 40IU.
10209670|NCT03900754|Placebo Comparator|Placebo|Saline
10209671|NCT03897244|Experimental|High-dose dual therapy|group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
10209672|NCT03897244|Experimental|Bismuth High-dose dual therapy|group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
10209673|NCT03897244|Active Comparator|Amoxicillin-Metronidazole Bismuth quadruple therapy|group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
10209674|NCT03891784|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10209675|NCT03890432|Experimental|GLUCOSAFE 2|Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
10209676|NCT03890432|Active Comparator|Local protocol control group|Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
10209677|NCT03890432|Other|Historical control group|"Retrospective data with standard care before the beginning of the pilot study in order to minimize the cross-over effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time."
9795102|NCT01526733|Experimental|Insulin (Aspart or Lispro)-rHuPH20|"In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20).~Each Phase was separated by a washout period of 5 to 21 days."
9795103|NCT01526785|Experimental|Alglucosidase alfa|Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.
9795104|NCT01526889|Experimental|LFG316 -Intravitreal Injection|
9795105|NCT01526889|Active Comparator|Conventional Therapy|
9795106|NCT01526902|Active Comparator|omafilcon A / PC 1-D MF|"omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
9795107|NCT01526902|Active Comparator|lotrafilcon B / Air Optix MF|"lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
9795108|NCT01526928|Experimental|Rociletinib <900 mg BID FB formulation|Rociletinib free base (FB) dose <900 mg twice a day (BID)
9795109|NCT01526928|Experimental|Rociletinib 900 mg BID FB formulation|Rociletinib free base (FB) dose 900 mg twice a day (BID)
9795110|NCT01526928|Experimental|Rociletinib 500 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)
10209678|NCT03888066|Experimental|Group 1: Patiromer|Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.
10209679|NCT03888066|Placebo Comparator|Group 2: Placebo|Subjects will be randomized to receive a daily dose of placebo with possible dose adjustments based on subsequent local serum potassium levels.
10209680|NCT03887520|Other|Cardiovascular disease|Patients with established Cardiovascular disease
10209681|NCT03883217|Experimental|Vibration first then no vibration|A session with PDVibe2 vibration turned on first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned off.
10209682|NCT03883217|Experimental|No vibration first then vibration|A session with PDVibe2 vibration turned off first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned on.
10209683|NCT03878316|Active Comparator|Intranasal Oxytocin|Oxytocin, 40 U per dose, intranasally twice-daily. One dose is defined as intranasal administration of 0.05 mL per each nostril for a total dose of 0.1 mL. The total daily dose of oxytocin will be 80 U or 0.2 mL.
10209684|NCT03878316|Placebo Comparator|Instrasal Placebo|Identically matched placebo administered intranasally twice-daily. One dose is defined as intranasal administration of 0.05 mL per each nostril for a total single dose of 0.1 mL or 0.2 mL total per day.
10209685|NCT03875495|Experimental|Temferon|"Autologous CD34+-enriched hematopoietic progenitor cells exposed ex vivo to a specific lentiviral vector encoding for the human IFN-ɑ2 gene.~Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of IFN-ɑ2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny."
10209686|NCT03875365||POPE Patients|Patients who underwent POPE for end-stage achalasia, a sigmoid esophagus, or a redundant conduit that has been used to replace the esophagus.
10209687|NCT03872102||Aim 1: Develop a biomarker of PD disease progression rate|"For Aim 1, we will enroll PD subjects spanning a range of progression rates that have been tracked at UT Southwestern Medical Center.~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data and known data on clinical progression using statistical techniques to determine a biomarker that associates with progression rate."
9795111|NCT01526928|Experimental|Rociletinib 625 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)
9795112|NCT01526928|Experimental|Rociletinib 750 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)
9795113|NCT01526928|Experimental|Rociletinib 1000 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)
9795114|NCT01527006|Experimental|perampanel|Age Cohort 1 ( greater than or equal to 7 to less than 12 years of age at time of consent/assent) and age Cohort 2 ( greater than or equal to 2 to less than 7 years of age).
9795115|NCT01527045|Experimental|Prevention (donor statin treatment)|See Detailed Description
9795116|NCT01527110|Experimental|Intravenous (IV) zanamivir 600mg twice daily|600mg of IV zanamivir infusion twice daily
9795117|NCT01527162|Experimental|SAFO worn|Child wears their prescribed SAFO for 14 days
9795118|NCT01527162|No Intervention|SAFO not worn|Child does not wear the prescribed SAFO for 14 days
9795119|NCT01527357|Experimental|Fibrocaps + Gelatin Sponge|Single application of Fibrocaps plus gelatin sponge.
9795120|NCT01527357|Active Comparator|Gelatin Sponge|Single application of gelatin sponge alone.
9795121|NCT01527370|Experimental|Zoster Vaccine Live|
9795122|NCT01527383|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9795123|NCT01527383|Placebo Comparator|Placebo|Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
9795124|NCT01527487|Experimental|Eribulin+Cyclophosphamide (ErC)|"Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
9795125|NCT01527487|Experimental|Docetaxel+Cyclophosphamide (TC)|"Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
9666959|NCT04093739||G7 Freedom Constrained Liners|Patients that have been implanted with a G7 Freedom Constrained liner to repair hip malfunction or disease.
9860408|NCT00244010|Other|1|
9860409|NCT00218036|Experimental|1|Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
9860410|NCT00218036|Experimental|2|Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
9860411|NCT00218036|Experimental|3|Citalopram 20/ Methadone Maintenance 1.2mg/kg
9860412|NCT00218036|Experimental|4|Citalopram 40/ Methadone Maintenance 1.2 mg/kg
9860413|NCT00218036|Placebo Comparator|5|Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
9860414|NCT00240227|Other|Placebo|Placebo no active medication
9860415|NCT00240227|Active Comparator|prazosin|Prazosin flexible dose titration up to 12 mg per day.
9860416|NCT00206375|No Intervention|1|Group 1 will be treated only with Synthroid.
9860417|NCT00206375|Experimental|2|Group 2 will be treated with Growth hormone, synthroid, and lupron.
9860418|NCT00206375|No Intervention|3|Group 3 will have acute hypothyroidism and will serve as controls.
9860419|NCT00229931|Active Comparator|Laser therapy|If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
9860420|NCT00229931|Active Comparator|Triamcinolone therapy|"At time of cataract surgery, will have IVTA injection. If macular edema does not show improvement at 1 month, then can have repeat IVTA injection. If the macular edema is stil not improved after 2nd injection, participant will be considered treatment failure and will be given the option to have laser therapy."
9860421|NCT00209131|Experimental|Flomax|Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
9860422|NCT00209131|Placebo Comparator|Sugar pill|Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.
9860423|NCT00233090|Experimental|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
9860424|NCT00233090|Placebo Comparator|Placebo|
9860425|NCT00214149|Experimental|1|breast brachytherapy to a dose of 34 Gy
9860426|NCT00205049|Experimental|Pentoxifylline/Placebo|All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
9860427|NCT00209027|Experimental|schizophrenia subjects|Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
9860428|NCT00182637|Experimental|bortezomib|
9860429|NCT00176488|Experimental|Sequential epirubicin/vinorelbine|For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.
9860430|NCT00179127|Experimental|Glargine|0.3u/kg of glargine, subcutaneously, once
9860431|NCT00179127|Placebo Comparator|Placebo|0.3u/kg of saline, subcutaneously, once
9860432|NCT00183963|No Intervention|1|
9860433|NCT00183963|Active Comparator|2|Tamoxifen 20 mg
9860434|NCT00183963|Active Comparator|3|Fulvestrant 250mg
9860435|NCT00183963|Active Comparator|4|Fulvestrant 500mg IM
9860436|NCT00178477|Experimental|Breath-holding|MRI with breath-holding
9860437|NCT00162773|Placebo Comparator|Placebo|water injection
9860438|NCT00162773|Experimental|Omalizumab|"Other Names:~Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE."
9860439|NCT00176631|Experimental|licorice root extract and docetaxel|
9860440|NCT00176501|Experimental|Irradiated allogeneic lymphocytes|
9860441|NCT00177970|Active Comparator|IVIG|
9860442|NCT00177970|Placebo Comparator|Placebo|
9860443|NCT00177866|Active Comparator|A Placebo or Celebrex|either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
9860444|NCT00177866|Placebo Comparator|B Placebo or Celebrex|either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
9860445|NCT00147238|Experimental|Ferumoxtran-10 MRI|MR lymphangiography using Ferumoxtran-10 contrast agent.
9860446|NCT00147238|Active Comparator|MRI|MR lymphangiography before injecting Ferumoxtran-10 contrast agent.
9860447|NCT00165503|Experimental|Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT|Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.
9860448|NCT00160563|Experimental|LCTZ-LCTZ|Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
9860449|NCT00160563|Placebo Comparator|LCTZ-PLC|Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
9860450|NCT00160563|Placebo Comparator|PLC-PLC|Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)
10209688|NCT03872102||Aim 2: Develop a biomarker to distinguish between PD, PSP, MSA|"For Aim 2, we will recruit subjects with PD, MSA, and PSP. We will also recruit healthy age/sex-matched controls. All subjects will complete a series of clinical assessments at three different time points, roughly 6-8 months apart:~Levodopa Equivalent Daily Dose~Parkinson disease questionnaire~Schwab and England ADL Scale~MDS-UPDRS (PD and healthy controls only)~UMSARS (MSA subjects only)~PSPRS (PSP subjects only)~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data from the participants along with prospectively collected information on clinical progression using statistical techniques to determine a biomarker that associates with the differentiation of PD, MSA, and PSP."
10209689|NCT03869034|Experimental|A, Combination group (HAIC+PD-1)|HAIC+PD-1
10209690|NCT03869034|Experimental|B, HAIC group (HAIC only)|HAIC
10209691|NCT03855046|Experimental|Xeomin|Complex treatment of chronic anal fissure with drug-induced relaxation of the internal sphincter with Botulinum Toxin Type A. (IncobotulinumtoxinA 50 U Intramuscular Powder for Solution).
9795126|NCT01527500|Experimental|LFG316 higher dose|LFG316 10 mg/100 μL
9795127|NCT01527500|Sham Comparator|Sham|Sham injection
9795128|NCT01527500|Experimental|LFG316 lower dose|LFG316 5 mg/ 50 μL
9795129|NCT01527513|Experimental|Eslicarbazepine acetate (BIA 2-093)|
9795130|NCT01527513|Placebo Comparator|Placebo|
9795131|NCT01527682|Other|Latanoprost, Dorzolamide|According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.
9795132|NCT01528033|Experimental|Vacuum Assisted Closure®|Negative pressure wound therapy
9795133|NCT01528033|Active Comparator|Standard conventional wound therapy|According to institutional clinical standards
9795134|NCT01528072|Experimental|Dynesys System|All patients will receive the Dynesys System and all patients will be compared to historical literature control. Dynesys Spinal System will be used for all subjects.
9795135|NCT01528124|Placebo Comparator|Placebo|0.9% sodium chloride given as a single subcutaneous injection
9795136|NCT01528124|Experimental|LY3025876|Single escalating doses of LY3025876 given as subcutaneous injections
9795137|NCT01528150||Accent MRI System|Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
10209692|NCT03855046|Active Comparator|Xeomin control|Complex treatment of chronic anal fissure with lateral subcutaneous sphincterotomy.
10209693|NCT03854110|Experimental|GP-2250 Monotherapy|GP-2250 in doses of 250 mg up to 30 grams intravenously on Days -7, 1, 8, 15 of a 28 day cycle with gemcitabine 1000 mg/m2 on Days 1, 8, 15 days of the cycle.
10209694|NCT03851081|Experimental|Treatment (inotuzumab ozogamicin, liposomal vincristine)|See Detailed Description.
10209695|NCT03833427|Experimental|Selumetinib at Dose Level 1 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; every three weeks [Q3W]) in combination with selumetinib at dose level 1 (dosed orally; twice daily [BID]) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
10209696|NCT03833427|Experimental|Selumetinib at Dose Level 2 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 2 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
10209697|NCT03833427|Experimental|Selumetinib at Dose Level 3 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 3 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
10209698|NCT03833427|Experimental|Selumetinib at Dose Level 4 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 4 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
10209699|NCT03833427|Experimental|Selumetinib at Dose Level 5 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 5 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
10209700|NCT03833427|Experimental|Selumetinib at Dose Level 6 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 6 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
10209701|NCT03833427|Experimental|Selumetinib at Dose Level 7 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 7 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
10209702|NCT03829254|Experimental|NUC-7738|NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
10209703|NCT03822468|Experimental|Ribociclib 400 mg|Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)
9860451|NCT00142519|Active Comparator|1|methadone
9860452|NCT00142519|Experimental|2|methadone and morphine
9860453|NCT00145704|Active Comparator|Growth Hormone only|No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
9860454|NCT00145704|Experimental|Growth Hormone & Bisphosphonate Therapy|Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
9860455|NCT00138073|Experimental|Web-based waveform interpretation guide|The arm has access to the Web-based waveform interpretation guide.
9860456|NCT00113386|Other|Induction chemotherapy, surgery, consolidation chemotherapy|Induction/surgery/consolidation
9860457|NCT00113386|Other|Chemotherapy and radiation, surgery, consolidation ch|Induction/radiation/surgery/cosolidation
9860458|NCT00138151|Experimental|Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b|"Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days"
9860459|NCT00126659|Experimental|Group I (cytoreductive nephrectomy and sorafenib tosylate)|"Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral sorafenib twice daily on days 15-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
9860460|NCT00126659|Experimental|Group II (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-7. Patients undergo cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days 22-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
9924492|NCT00861874|Experimental|Treatment|
10209704|NCT03822468|Active Comparator|Ribociclib 600 mg|Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)
10209705|NCT03822104|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
10209706|NCT03822104|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
10209707|NCT03819465|Experimental|A1|Durvalumab
10209708|NCT03819465|Experimental|A2|Durvalumab + danvatirsen
10209709|NCT03819465|Experimental|A3|Durvalumab + oleclumab
10209710|NCT03819465|Experimental|A4|MEDI5752
10209711|NCT03819465|Experimental|B1|Durvalumab + Investigator's choice of chemotherapy
10209712|NCT03819465|Experimental|B2|Durvalumab + Investigator's choice of chemotherapy + danvatirsen
10209713|NCT03819465|Experimental|B3|Durvalumab + investigator's choice of chemotherapy + oleclumab
10209714|NCT03819465|Experimental|B4|MEDI5752
10209715|NCT03819153|Experimental|Semaglutide|Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
10209716|NCT03819153|Placebo Comparator|Placebo|Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
10209717|NCT03814187|Experimental|Inclisiran|"Inclisiran sodium 300 milligrams (mg) will be administered as a single SC injection on Day 1*, 90, then every 180 days to Day 990.~*Subjects who received blinded placebo in the feeder study will receive blinded inclisiran and subjects who received blinded inclisiran in the feeder study will receive blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study will not receive any injection of study drug on Day 1. Their first dose of study medication will be at day 90"
10209718|NCT03797183||Premature Infants|Premature infants >1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
10209719|NCT03797183||Chronic Respiratory Disease|Participants ages >1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
10209720|NCT03797183||Neuromuscular Disease|Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
10209721|NCT03797183||Healthy Controls|Age and height matched healthy controls
10209722|NCT03797183||V/Q Scan validation|Adults or children who are having or have recently had a V/Q scan
10209723|NCT03797014|Experimental|B/F/TAF|Treatment group (1-arm study)
10209724|NCT03787628|Active Comparator|Cannabidiol (CBD) 600 mg|Twenty participants who meet all eligibility criteria will be randomized to receive CBD (ATL5; Ananda Scientific) at a dose of 600 mg. The active comparator cohorts will be studied sequentially according to ascending dose in order to ensure safety.
10209725|NCT03787628|Active Comparator|CBD 1200 mg|Twenty participants who meet all eligibility criteria will be randomized to receive CBD (ATL5; Ananda Scientific) at a dose of 1200 mg. The active comparator cohorts will be studied sequentially according to ascending dose in order to ensure safety.
10209726|NCT03787628|Placebo Comparator|Placebo|Twenty participants who meet all eligibility criteria will be randomized to receive placebo.
10209727|NCT03786016|Experimental|8-Days in an Isolation, Confinement Unit|Subjects will spend 7-night/8-day in an isolated and confined unit with up to 3 other subjects.
10209728|NCT03785600|Experimental|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
10209729|NCT03785600|Sham Comparator|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
9860461|NCT00126659|Experimental|Group III (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-28. Patients undergo cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days 43-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
9860462|NCT00133679|Experimental|1|Sildenafil x 45 days
9860463|NCT00133679|Placebo Comparator|2|Placebo x 45 d
9860464|NCT00125268|Active Comparator|MIRE|Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
9860465|NCT00125268|Sham Comparator|Sham|Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.
9860466|NCT00113399|Other|Radiotherapy and chemotherapy|Radiotherapy/paclitaxel/cisplatin/filgrastim
9860467|NCT00113399|Other|Chemotherapy|Cisplatin/fluorouracil/paclitaxel/docetaxel
9860468|NCT00118053|Experimental|Docetaxel, Carboplatin and Trastuzumab|"A total of six cycles of TCH [(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.~Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.~If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
9860469|NCT00107614|Experimental|DT PACE/auto transplant/maint therapy|
9860470|NCT00107315|Experimental|Arm 1|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine twice daily on days 1-7
9860471|NCT00113919|Experimental|Busulfan|study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days
9860472|NCT00108342|Active Comparator|Nicotine Replacement Treatment (NRT) Sampling|"Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device)."
9860473|NCT00108342|Sham Comparator|NRT Computer Learning|Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only
9860474|NCT00100828|Experimental|Irinotecan|
9860475|NCT00104728|Experimental|Neoadjuvant ZD1839 Preoperative Therapy|"The ZD1839 250-mg tablet will be taken once a day, every day about the same time. It can be taken with or without food.~At the time of surgery, investigators will collect tissue from the participant's tumor once it has been removed. This tissue will be used to study the effect of ZD1839 on tumor growth."
9860476|NCT00089414|Experimental|1|Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
9860477|NCT00089414|Active Comparator|2|Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
9860478|NCT00089414|Active Comparator|3|Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
9860479|NCT00083915|Active Comparator|Auto Transplant w/ High Dose Melphalan|Autologous transplant with High Dose Melphalan alone
10209730|NCT03778658|Experimental|Outpatient Physical Activity Program|The intervention will investigate a multi modal outpatient physical activity program incorporating both strength training utilizing resistance bands, as well as an aerobic activity based on hip-hop dancing.
10209731|NCT03777020|Experimental|Service Dog Training Program (SDTP)|Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
10209732|NCT03777020|Other|Dog Training Education|Veterans randomized to Dog Training Education will participate in one hour online SD training modules (https://e-trainingfordogs.com) scheduled once a week for 8 weeks. The online training modules are delivered by experienced SD trainers and will employ parallel content to the WCC SDTP. Participants will come to the WCC site for all the weekly online training modules. Members of the WLCI group will have education about dog training, but NO interaction with a SD. The online training modules for the DTE group are intended to keep the veterans who are not immediately assigned to the SDTP engaged in the study. They will participate in the SDTP after conclusion of participation in the 8 week study.
10209733|NCT03775473|Other|progastrin|anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
10209734|NCT03773120|Experimental|Using Neuromonitoring to find EBSLN|With Neuromonitoring of the EBSLN using nerve monitoring system
10209735|NCT03773120|No Intervention|No Using Neuromonitoring to find EBSLN|Without Neuromonitoring of the EBSLN using nerve monitoring system
9860480|NCT00083915|Active Comparator|Auto Transplant w/ Melphalan + DT Pace|Melphalan plus Dexamethasone, Thalidomide, CisPlatinum, Adriamycin, Cyclophosphamide, and Etoposide
9860481|NCT00090870|Experimental|PEG-Intron, BM-CSF and thalidomide|
9860482|NCT00088972|Experimental|Arm I - Celecoxib|Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
9517056|NCT03309904|Experimental|Knee Control training program|The Knee Control program is a neuromuscular training program that consists of 6 different exercises, with 4 levels of progression and one pair-exercise, for each exercise. The Knee Control program takes about 10 minute to complete after familiarization. In addition, a 5-minute running warm-up is instructed to coaches. Coaches are to perform the Knee Control program + the 5 minute warm-up at all training sessions during the season, and the 5 minute warm-up before all matches.
9860483|NCT00088972|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
9860484|NCT00088829|Experimental|Paclitaxel|Paclitaxel given before surgery
9860485|NCT00089128|Experimental|Gemcitabine and Irnotecan|
9860486|NCT00075608|Experimental|2nd Stem Cell Transplant|Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion
9860487|NCT00074724|Active Comparator|Medical Therapy|All medical interventions know to improve outcomes in patients with ischemic left ventricular dysfunction.
9860488|NCT00074724|Active Comparator|CABG|Surgical revascularization in conjunction with optimal medical therapy.
9860489|NCT00085631|Experimental|Arm I|Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
9860490|NCT00085631|Active Comparator|Arm II|Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.
9860491|NCT00062751|Experimental|A|
9860492|NCT00062751|Experimental|B|
9860493|NCT00062751|Active Comparator|C|
9860494|NCT00066807|Experimental|OFS plus T or E|Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
10209736|NCT03766126|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
10209737|NCT03759392|Experimental|Omecamtiv Mecarbil|
9860495|NCT00066807|Experimental|Chemotherapy plus OFS plus T or E|Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
9860496|NCT00058188|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.
9860497|NCT00058188|Active Comparator|Arm II|Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.
9860498|NCT00014560|Experimental|Single arm|Antibody
9860499|NCT00038142|Experimental|Arm A: VACdxr With ImmTher|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days. Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
9924493|NCT00861887|Active Comparator|Vancomycin|Vancomycin 125 mg every 6 hours x 4 weeks
10209738|NCT03759392|Placebo Comparator|Placebo|
10209739|NCT03758781|Experimental|IRX-2 Regimen combined with Nivolumab|IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
10209740|NCT03750877|Active Comparator|median approach|Spinal anesthesia will be performed with a conventional median approach
10209741|NCT03750877|Active Comparator|paramedian approach|Spinal anesthesia will be applied with a paramedian approach.
10209742|NCT03747848|Experimental|CBT group|Subjects will participate in group treatment sessions (once a week for six weeks).
10209743|NCT03747757|Experimental|Supportive Care (CBT)|Patients undergo CBT consisting of 7 counseling sessions, up to 45 minutes each over the phone.
10209744|NCT03742349|Experimental|1: spartalizumab + LAG525 + NIR178|phase Ib (escalation and expansion)
10209745|NCT03742349|Experimental|2: spartalizumab +LAG525 +capmatinib|phase Ib (escalation and expansion)
10209746|NCT03742349|Experimental|3: spartalizumab + LAG525 + MCS110|phase Ib (escalation and expansion)
10209747|NCT03742349|Experimental|4: spartalizumab +LAG525 +canakinumab|phase Ib (escalation and expansion)
10209748|NCT03737136|No Intervention|Plasmapheresis|5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session
10209749|NCT03737136|Active Comparator|Plasmapheresis plus Bortezomib|Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11
10209750|NCT03736265|Experimental|Carvedilol+ Nucleos(t)ide Analogues|Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
10209751|NCT03736265|No Intervention|Nucleos(t)ide Analogues|Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
10209752|NCT03734497|Active Comparator|Group Control|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
10209753|NCT03734497|Experimental|Group Preloading|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
10209754|NCT03734497|Experimental|Group Carotis FTc|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
10209755|NCT03725592|Active Comparator|Standard Treatment|Receives arsenic removal device and written instructions and phone calls on how to use the device (Arsenic Removal Device)
10209756|NCT03725592|Experimental|Intensive Education|Receives the Standard Treatment plus in-person visits and phone calls for follow-up (Community Participatory Arsenic Mitigation)
10209757|NCT03713463||Oral Nutritional Supplement (ONS)|2 servings per day ONS
10209758|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group A (18 years and above)|Patients will receive the adult cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
10209759|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group P (under 18 years)|Patients will receive the paediatric cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
10209760|NCT03704350|Active Comparator|20-24.9 BMI|Participants with a BMI that falls between 20 and 24.9 who will receive the controlled diet
10209761|NCT03704350|Active Comparator|25-29.9 BMI|Participants with a BMI that falls between 25 and 29.9 who will receive the controlled diet
10209762|NCT03704350|Active Comparator|30-34.9 BMI|Participants with a BMI that falls between 30 and 34.9 who will receive the controlled diet
10209763|NCT03704350|Active Comparator|35-39.9 BMI|Participants with a BMI that falls between 35 and 39.9 who will receive the controlled diet
10209764|NCT03704350|Active Comparator|40-44.9 BMI|Participants with a BMI that falls between 40 and 44.9 who will receive the controlled diet
10209765|NCT03704350|Active Comparator|45-50 BMI|Participants with a BMI that falls between 45 and 50 who will receive the controlled diet.
10209766|NCT03687190|Experimental|Tai chi|participants in this group accepted Tai chi exercise and conventional medicine.
9860500|NCT00038142|Active Comparator|Arm B: VACdxr|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days, Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin).
9860501|NCT00020722|Experimental|therapeutic autologous lymphocytes|
9860502|NCT00002975|Experimental|PDT|4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
9860503|NCT00019747|Experimental|Arm 1 - Thalidomide once daily|Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
9860504|NCT00019747|Placebo Comparator|Arm 2 - Placebo once daily|Patients receive oral placebo once daily.
9860505|NCT00006916|Experimental|Radiation therapy followed by bleomycin via Ommaya reservoir|60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.
9860506|NCT00003726|Experimental|Lepirudin|Dose level 1: 10 mg once daily -> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -> (total dose, 50 mg/d)
9860507|NCT04051996|Experimental|DAC5|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
9860508|NCT04051996|Experimental|DAC10|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
9860509|NCT02970799|Experimental|Intranasal then Extranasal Application|Intranasal Neurostimulator applied intranasally (active) followed by extranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence for Days 15 and 29.
9860510|NCT02970799|Experimental|Extranasal then Intranasal Application|Intranasal Neurostimulator applied extranasally (control) followed by intranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence at Days 15 and 29.
9860511|NCT02385292|Experimental|Intranasal then Extranasal Application|Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
9860512|NCT02385292|Active Comparator|Extranasal then Intranasal Application|Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
9517057|NCT03309904|No Intervention|Control group - usual training|The control group teams receive no intervention, and coaches are instructed to carry out their normal training and warm-up practice throughout the season.
9517058|NCT03309891|Experimental|Cohort 1|GX-H9 subcutaneous injections (weekly)
9517059|NCT03309891|Experimental|Cohort 2|GX-H9 subcutaneous injections (weekly)
9860513|NCT02126878|Active Comparator|Kenalog 20mg|20mg/ 2ml and local anesthetic
10209767|NCT03687190|Active Comparator|controlled group|participants were not received Tai chi exercise, but only routine conventional medicine
10209768|NCT03677284|Experimental|Intervention group|"Information brochure about daily time management, frequent problems, and suggested strategies to manage them.~Time assistive product. Time assistive products for time perception are products making the passage of time visible and understandable, to know for how long to perform an activity or how long to wait until the next activity starts e.g a time log.~Time assistive products for time orientation includes the use of schedules, calendars and other visual aids to promote orientation to the time of the day, week, or year.~Time assistive products for time management would compensate for deficits in time management and focus on self-scheduling skills."
9517060|NCT03309891|Experimental|Cohort 3|GX-H9 subcutaneous injections (twice-monthly)
9517061|NCT03309891|Active Comparator|Cohort 4|Genotropin subcutaneous injections (daily)
9795138|NCT01528215|Experimental|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
9795139|NCT01528215|Active Comparator|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
9795140|NCT01528228|Active Comparator|Structured TENS Therapy|This group will be given an active TENS unit to use.
9795141|NCT01528228|Sham Comparator|Sham TENS Therapy|This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
10209769|NCT03677284|Active Comparator|Control group|Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
9795142|NCT01528254|Active Comparator|Vilda 50mg bid + metformin|Metformin + vildagliptin
10209770|NCT03675282|Experimental|Parkinson Disease - Stage 1|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
10209771|NCT03675282|Experimental|Parkinson Disease - Stage 2|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
10209772|NCT03675282|Experimental|Parkinson Disease - Stage 3|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
10209773|NCT03675282|Experimental|Parkinson Disease - Stage 4|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
10209774|NCT03675282|Experimental|REM Sleep Behavior Disorder|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
10209775|NCT03675282|Experimental|Healthy Controls|MRI Brain at Baseline and 24 Months PE2i PET Scan or DaT Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
10209776|NCT03667716|Experimental|P1a Arm A (Monotherapy Dose Escalation).|COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
10209777|NCT03667716|Experimental|P1a Arm B (Combination Dose Escalation).|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
10209778|NCT03667716|Experimental|P1a Arm A (Monotherapy Expansion).|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
10209779|NCT03667716|Experimental|P1b (Combination Cohort Dose Expansion).|COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer).
9795143|NCT01528254|Experimental|Placebo + metformin|Metformin + Placebo of vildagliptin
9795144|NCT01528319|Experimental|MG-1|Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1
9795145|NCT01528332|Experimental|Pain Relief Patch|Pain Relief Patch: Light wavelength 453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm², 30 minutes
9795146|NCT01528332|Active Comparator|Control PRP device|Control PRP device: Light wavelength 531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm², light on for 5 seconds, device worn for 30 minutes
9795147|NCT01528345|Experimental|Fulvestrant + Dovitinib active|Fulvestrant in combination with the study drug Dovitinib.
9795148|NCT01528345|Placebo Comparator|Fulvestrant + Dovitinib placebo|Fulvestrant in combination with a placebo matching Dovitinib.
9795149|NCT01528592|Experimental|On / Off medication|Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
9795150|NCT01528605|Placebo Comparator|Placebo|starch in hard shell gelatine capsules
9795151|NCT01528605|Experimental|Low lutein|low lutein group
9795152|NCT01528605|Experimental|High lutein|high lutein group
10209780|NCT03665129|Experimental|Dose escalation|IPH5401 at different doses and schedule + Durvalumab
10209781|NCT03665129|Experimental|Cohort expansion NSCLC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients
10209782|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 naive|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients
10209783|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients
10209784|NCT03657576|Experimental|C134 Treatment|All patients who enroll will receive C134 inoculation into their tumor (one time procedure with 1-5 inoculation sites)
10209785|NCT03648021|Active Comparator|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
10209786|NCT03648021|Placebo Comparator|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
10209787|NCT03647306|Active Comparator|Extended Overnight Fast|The extended overnight fast group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session. Subjects will consume approximately 33% of their daily calories at breakfast, lunch and dinner, respectively. This is a model for fasting dietary chronotype.
9860514|NCT02126878|Active Comparator|Kenalog 40mg|40mg/ 2ml with local anesthetic
9860515|NCT02126878|Active Comparator|Kenalog 80mg|80mg/ 2ml and local anesthetic
9860516|NCT02221817|Active Comparator|Blind|Trochanter injection
9517062|NCT03309865|Experimental|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
9517063|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
9517064|NCT03309826|Experimental|PAP Treatment Arm|Automated positive airway pressure titration then treatment with fixed PAP.
9860517|NCT02221817|Experimental|Ultrasound|Trochanter injection
9860518|NCT02595996|Experimental|Treatment|Patients will be given propranolol in escalating doses
9924494|NCT00861887|Placebo Comparator|Placebo|Vancomycin 125 mg every 6 hours x 2 weeks, followed by placebo every 6 hours x 2 weeks
9860519|NCT03879044|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes before their scheduled work hours at least 3x/week for two consecutive weeks.
9860520|NCT03198156|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes daily for 4 sessions
9860521|NCT03198156|Sham Comparator|Sham stimulation|Sham stimulation sessions will be for 30 minutes daily for each of the 4 sessions; however, active stimulation for this arm of the study is only for 30 seconds; yet, will be applied at the same intensity as the Active arm of the study, albeit for only 30 seconds.
10209788|NCT03647306|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
10209789|NCT03647306|Experimental|Late Total Caloric Intake|The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
10209790|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose A|"1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
9860522|NCT02009384|Experimental|Ipilimumab|IV ipilimumab
9860523|NCT04558125|Experimental|Low-dose TNKase and Standard of Care Anticoagulation|"TNKase (0.25 mg/kg) bolus Other names: Tenecteplase, TNK~Standard of care anticoagulation (heparin or enoxaparin)"
10209791|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose B|"1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks."
10209792|NCT03635112|Placebo Comparator|Placebo|"1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD.~Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
10209793|NCT03617731|Active Comparator|IA|Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
10209794|NCT03617731|Experimental|IB|Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
10209795|NCT03617731|Active Comparator|IIA|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
10209796|NCT03617731|Experimental|IIB|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
10209797|NCT03614949|Experimental|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
10209798|NCT03610256|Experimental|SADI-S|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic SADI-S (laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy).~SADI-S will be performed as a primary procedure or after failure of sleeve gastrectomy, defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
10209799|NCT03610256|Active Comparator|RYGB|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic RYGB (laparoscopic Roux-en-Y Gastric ByPass).~Similarly to the experimental group, RYGB will be performed as a primary procedure or after failure of sleeve gastrectomy, which is defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
10209800|NCT03596164|Experimental|Teduglutide 0.05 mg|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
10209801|NCT03594773|Experimental|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
9860524|NCT04558125|Active Comparator|Placebo and and Standard of Care Anticoagulation|"Placebo bolus (intravenous syringe identical to that of TNK )~Standard of care anticoagulation (heparin or enoxaparin)"
10209802|NCT03594773|Experimental|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
9517065|NCT03309826|Active Comparator|Nasal Dilator Strip|Nightly use of nasal dilator strip
9517066|NCT03309813|Experimental|Transcranial ExAblate|ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
9517067|NCT03309813|Sham Comparator|Sham Transcranial ExAblate|ExAblate MRgFUS Sham Procedure
9517068|NCT03309800|Experimental|Experimental|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
9860525|NCT02401308|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation"
10209803|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
10209804|NCT03590821|Experimental|Aspirin 81 mg/Placebo|Participants will receive aspirin in Phase 1 followed by matched placebo in Phase 2, or vice versa, over 14 days. The order will be randomized and aspirin/placebo will be double-blinded.
10209805|NCT03590821|Experimental|Celecoxib 200mg capsule|Participants will receive celecoxib in Phase 1 and Phase 2 over 7 days. This is open, meaning participant and investigator will recognize celecoxib capsules.
10209806|NCT03583931|Active Comparator|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
10209807|NCT03583931|Active Comparator|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
10209808|NCT03582514|Experimental|Dose or volume radiation escalation|"Patients with a new radiological diagnosis of GBM (judged by the neuro-oncology multidisciplinary team) are to be considered for this study.~This study arm will use 5 radiotherapy doses (6 Gy, 8 Gy, 10 Gy, 12 Gy and 14 Gy) and three treatment volumes (<30 cm3, 30-60 cm3 and >60 cm3). The study will use 6 dosing levels based on a combination of radiotherapy dose and treatment volume. The stepwise inclusion process allows for variation in tumour volume and location. The study will commence with dosing level 1: 8 Gy to <30 cm3 and 6 Gy to 30-60 cm3. In collaboration with the Clinical Trials Unit, the Trial Management Group will enter outcome data for patients at a given dose level into the CRM model. The model output will then guide dose escalation to determine the next dose level. After the single fraction of radiotherapy, patients will receive the standard treatment."
10209809|NCT03576612|Experimental|Cohort 1: MGMT Unmethylated Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
10209810|NCT03576612|Experimental|Cohort 2: MGMT Methylated & undetermined Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
10209811|NCT03569956|Active Comparator|Razor Group|Subject will use the 556 razor with regular shaving products, and shave at least 5 or more times per week
10209812|NCT03569956|Experimental|Regimen|Subject will use the 556 razor with the Pre-shave Gel, Cleaning Brush, and Shaving Gel and shave at least 5 or more times per week.
10209813|NCT03557307|Experimental|Benralizumab|Benralizumab subcutaneous injection
10209814|NCT03554720|Active Comparator|Standard implants|ATTUNE PS Knee
10209815|NCT03554720|Active Comparator|Enhanced-Fixation|ATTUNE S+ PS Knee
10209816|NCT03547843|Experimental|Educational intervention|Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.
10209817|NCT03547843|Active Comparator|Waiting list|Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
10209818|NCT03543189|Experimental|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
10209819|NCT03542383|Active Comparator|Active HD tDCS|Administer 10 20-minute sessions of 1 mA anodal High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
10209820|NCT03542383|Sham Comparator|Sham HD tDCS|Administer 10 20-minute sessions of sham High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
10209821|NCT03529981|Active Comparator|Stress incidents without TVS|a fraction of physiological detected stress incidents will not trigger TVS
10209822|NCT03529981|Experimental|TVS in response to participant initiation or stress detection|The majority of detected stress incidents will trigger TVS. Participants can also trigger TVS voluntarily
10209823|NCT03523416|Experimental|Edwards Transcatheter Atrial Shunt System|
10209824|NCT03512184|Other|YMCA Class|This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.
10209825|NCT03505710|Experimental|Cohort 1: HER2 Overexpressing|Cohort 1 will enroll participants with HER2-overexpressing(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
9860526|NCT02401308|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.
9860527|NCT04381988|Experimental|Hydroxychloroquine|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of hydroxychloroquine 400mg daily.
9860528|NCT04381988|Placebo Comparator|Placebo|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of placebo 400mg daily.
9860529|NCT00521885|Active Comparator|Arixtra (Fondaparinox) 2.5 mg SC Daily|Arixtra (Fondaparinox) 2.5 mg SC Daily
9860530|NCT00521885|Active Comparator|Lovenox 40mg SC Daily|Lovenox 40mg SC Daily
9860531|NCT02376946|Active Comparator|Actipatch|The study group will be comprised of subjects that will receive PEMF ActiPatchTM treatment for postoperative management of pain and edema.
9860532|NCT02376946|Placebo Comparator|Placebo|The control group will be comprised of the subjects that will receive a placebo patch as treatment for postoperative management of pain and edema.
9860533|NCT01780636|Experimental|Botulinum toxin (Botox) injection|All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.
9860534|NCT00479167|Experimental|Bortezomib and Tositumomab I-131|
9860535|NCT03998189|Experimental|Female Participants|45 female patients will be screened to participate.
9860536|NCT03998189|Experimental|Male Participants|45 male patients will be screened to participate
9860537|NCT02212574|Other|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
9860538|NCT04422210|Experimental|Dose Escalation (Arm A1) (Maintenance only)|Cohort A1: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
9860539|NCT04422210|Experimental|Dose Escalation (Arm A2) (Maintenance only)|Cohort A2: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
9860540|NCT04422210|Experimental|Dose Escalation (Arm A3) (Maintenance only)|Cohort A3: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.
9860541|NCT04422210|Experimental|Dose Escalation (Arm B1) (Induction + Maintenance)|Cohort B1: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
9860542|NCT04422210|Experimental|Dose Escalation (Arm B2) (Induction + Maintenance)|Cohort B2: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
9924495|NCT00861926|Experimental|Beclometasone/formoterol (100/6 µg)|Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
9924496|NCT00861926|Active Comparator|salbutamol|Ventolin : salbutamol sulphate 100 µg per metered dose
9924497|NCT00861939|Experimental|1|Bupropion HCl 300mg Extended Release Tablet
9924498|NCT00861939|Active Comparator|2|WELLBUTRIN XL 300mg Tablets
9860543|NCT04422210|Experimental|Dose Escalation (Arm B3) (Induction + Maintenance)|Cohort B3: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
9860544|NCT04422210|Experimental|Dose Escalation (Arm B4) (Induction + Maintenance)|Cohort B4: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
9860545|NCT04422210|Experimental|Dose Expansion|If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort would continue to test venetoclax in both induction and maintenance. Participants would be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction precluded identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax would only be investigated in dose-expansion in the maintenance setting. Participants would be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
9860546|NCT04298918|Experimental|Dose Escalation Phase|Participants received venetoclax in combination with a fixed dose of trastuzumab emtansine.
9860547|NCT04298918|Experimental|Dose Expansion Phase|Participants were to receive venetoclax at the Phase II Recommended Dose (RP2D) in combination with trastuzumab emtansine.
9860548|NCT04298918|Experimental|Randomized Phase II Arm 1|Participants were to receive trastuzumab emtansine + placebo.
9860549|NCT04298918|Experimental|Randomized Phase II Arm 2|Participants were to receive trastuzumab emtansine + venetoclax.
10209826|NCT03505710|Experimental|Cohort 1a: HER2 Overexpressing|Cohort 1a will enroll participants with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
10209827|NCT03505710|Experimental|Cohort 2: HER2 Mutated|Cohort 2 will enroll participants with HER2-mutated, unresectable and/or metastatic NSCLC to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
10209828|NCT03496168|Experimental|mavacamten (MYK-461)|
10209829|NCT03486938|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
9860550|NCT01996371|Other|Group 1|Unilateral pedicle screws
9860551|NCT01996371|Other|Group 2|Ipsilateral pedicle screws, contralateral facet screw
9860552|NCT01996371|Other|Group 3|Bilateral pedicle screws
9860553|NCT01561378|Experimental|Insulin|Aspart Insulin 40 IU intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
9860554|NCT01561378|Placebo Comparator|Normal saline|Normal saline (0.9% sodium chloride solution) intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
10209830|NCT03486938|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
9860555|NCT00955929|Experimental|PRN Sildenafil|Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
9860556|NCT00955929|Experimental|Nightly Sildenafil Arm|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
9860557|NCT00955929|Experimental|Combination Therapy Arm|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).
9924499|NCT00861952|Experimental|Neuragen|Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
9924500|NCT00861952|Sham Comparator|Mineral oil|Mineral oil, scent and color matched to intervention
9924501|NCT00861965|Experimental|Treatment|AlloStim-8
9924502|NCT00861978|Placebo Comparator|1|
9924503|NCT00861978|Experimental|2|
9924504|NCT00861991|Experimental|Perspective taking intervention|Students were given an instruction to take the perspectives of their standardized patients
10209831|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
10209832|NCT03482479|Experimental|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
10209833|NCT03482479|Placebo Comparator|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
10209834|NCT03467191|Experimental|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
10209835|NCT03467191|Placebo Comparator|Placebo Beverage|
10209836|NCT03455829|Experimental|Part 1: G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
9795153|NCT01528605|Experimental|Low lutein zeaxanthin|lutein plus zeaxanthin group
9795154|NCT01528605|Experimental|High zeaxanthin|zeaxanthin group
9795155|NCT01528605|Experimental|high lutein zeaxanthin|Zeaxanthin plus lutein group
10209837|NCT03455829|Experimental|Part 2: G1T38 + Osimertinib|Patients will be randomized to receive G1T38 at the dose determined in Part 1 in combination with osimertinib 80 mg, each administered once-daily.
10209838|NCT03455829|Active Comparator|Part 2: Osimertinib|"Patients will be randomized to receive osimertinib 80 mg once-daily.~At the time of disease progression per RECIST v1.1, patients who were initially randomized to receive osimertinib alone may crossover to receive G1T38 + osimertinib."
10209839|NCT03453216|Experimental|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
9795156|NCT01528709|Experimental|High-dose statin therapy|Atorvastatin 80 mg daily
9795157|NCT01528709|Active Comparator|Moderate-dose statin therapy|Atorvastatin 10 mg daily
9795158|NCT01528735|Experimental|BI 207127 NA, BI 201335 NA(high dose), R|Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
9795159|NCT01528735|Experimental|BI 207127 NA,BI 201335 NA(low dose),RBV|Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
9795160|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
9795161|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
9795162|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.04%|1 drop to study eye once daily
9795163|NCT01528787|Placebo Comparator|AR-13324 Ophthalmic Solution Vehicle|1 drop to study eye once daily
9795164|NCT01528878|Experimental|Good liver function.|Patients with good liver function as defined by no more than Child-Pugh Class A.
9795165|NCT01528878|Experimental|Compromised liver function.|Patients with compromised liver function as defined by patients with Child-Pugh Class B.
9795166|NCT01528891|Active Comparator|Dexmedetomidine|Dexmedetomidine
10209840|NCT03446157|Experimental|Open-label, single arm, Phase II|Cetuximab and palbociclib
9795167|NCT01528891|Placebo Comparator|placebo|Normal saline
9795168|NCT01528969|Experimental|Xylitol|A half of the subjects will be randomly allocated into xylitol group.
9795169|NCT01528969|Active Comparator|Sorbitol|About 40 randomly allocated subjects will chew sorbitol chewing gum (1,5, g/pellet) three times a day
9795170|NCT01529034|Experimental|USL261|Intranasal midazolam 5 mg
9795171|NCT01529060|Active Comparator|Phenylbutyrate|Study Drug
10209841|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) fortnightly|Arm 1a: NUC-3373 administered IV followed by a 2-week washout period. The next dose of NUC-3373 administered in combination with LV at 400 mg/m2. All subsequent doses of NUC-3373 administered in combination with LV every 2 weeks in 28-day cycles.
9795172|NCT01529060|Placebo Comparator|Inactive Powder|Placebo powder
9795173|NCT01529112|Experimental|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)
9795174|NCT01529112|Placebo Comparator|Lenvatinib matched placebo|Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC
10209842|NCT03428958|Experimental|NUC-3373 fortnightly|Arm 1b: LV 400 mg/m2 administered IV over 2 hours prior to NUC-3373 infusion followed by a 2-week washout period. Then, NUC-3373 administered IV every 2 weeks without LV in 28-day cycles.
10209843|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) weekly|Arm 1c: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV weekly on Days 1, 8, 15 and 22 of 28-day cycles.
9795175|NCT01529203|Other|Azzalure and Restylane|All subjects will be injected with Azzalure and Restylane
9795176|NCT01529268|Active Comparator|DR cysteamine bitartrate capsule|Active DR cysteamine bitartrate capsule
9795177|NCT01529268|Placebo Comparator|DR cysteamine bitartrate placebo|Placebo DR cysteamine bitartrate capsule
10209844|NCT03428958|Experimental|NUC-3373 + leucovorin (LV); combination chemotherapy ineligible|Arm 1d: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV on Days 1, 8, 15 and 22 of 28-day cycles.
10209845|NCT03428958|Experimental|NUC-3373 + oxaliplatin weekly|Arm 2a: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
10209846|NCT03428958|Experimental|NUC-3373 + irinotecan weekly|Arm 2b: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
9795178|NCT01529346|Experimental|PF-05089771 1600 mg|
9795179|NCT01529346|Experimental|PF-05089771 450 mg|
9795180|NCT01529346|Experimental|PF-05089771 150 mg|
9795181|NCT01529346|Active Comparator|Ibuprofen 400 mg|
9795182|NCT01529346|Placebo Comparator|Placebo|
9795183|NCT01529385|Experimental|Mild Compression Diabetic Sock|Diabetic socks that provide 18-25mm Hg of pressure to the lower extremities.
9795184|NCT01529385|Other|Standard Diabetic Sock|A standard diabetic sock that is designed to limit foot ulcer formation, but does not provide compression to the leg.
9795185|NCT01529450|Active Comparator|Refractory Group|Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
9795186|NCT01529450|Active Comparator|Resistance Developed Group|Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
9795187|NCT01529502|Experimental|Fresh blood|
9795188|NCT01529502|Experimental|Old blood|
9795189|NCT01529502|Experimental|Old blood + inhaled Nitric Oxide|
9795190|NCT01529515|Experimental|Paliperidone palmitate 3-month (PP3M)|
9795191|NCT01529515|Placebo Comparator|Placebo|
9795192|NCT01529606|Active Comparator|Standard care|Fifty patients will be recruited into standard treatment group and they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline.
10209847|NCT03428958|Experimental|NUC-3373 + oxaliplatin (NUFOX) expansion|Arm 2c: At the completion of Arm 2a, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
10209848|NCT03428958|Experimental|NUC-3373 + irinotecan (NUFIRI) expansion|Arm 2d: At the completion of Arm 2b, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
9517069|NCT03309800|Placebo Comparator|Placebo comparator|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
9860558|NCT00402883|Experimental|Intervention|Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy.
9860559|NCT03482505|Experimental|INVSENSOR00004|All enrolled subjects will receive the INVSENSOR00004 sensor. The INVSENSOR00004 rainbow acoustic monitoring (RAM) acoustic respiration sensor is designed to noninvasively convert acoustical airflow patterns into respiratory rate (RRa).
9860560|NCT02934503|Experimental|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m^2) + carboplatin (AUC 6) + etoposide (100mg/m^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
9860561|NCT02137252|Experimental|Naltrexone|The treatment schedule includes a daily dose of naltrexone for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
9860562|NCT02137252|Placebo Comparator|Sugar Pill|The treatment schedule includes a daily dose of equivalent placebo for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
9860563|NCT03863522|Other|Fine Needle Aspiration|Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).
9860564|NCT01294670|Experimental|Vorinostat and Etoposide|This is a multi-center, open label, phase I/II trial of escalating doses of vorinostat in combination with etoposide.
9860565|NCT03095287|Experimental|Alphanate|Participants were to receive alphanate 100 International Units (IU/kg/day) for up to 33 months in Immune tolerance induction (ITI) Treatment Phase. The dose could be increased up to 200 IU/kg/day based on Investigator's discretion. Following ITI Treatment Phase, participants were to enter the Prophylactic Phase where alphanate dose was to be tapered down in a step wise manner to reach a final prophylactic dose of 50 IU/kg every other day or 3 times per week, at the investigator's discretion.
10209849|NCT03428958|Experimental|NUFOX + bevacizumab weekly|Arm 3a: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c will be combined with bevacizumab. NUC-3373+LV will be administered weekly, oxaliplatin will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
10209850|NCT03428958|Experimental|NUFOX + bevacizumab fortnightly|Arm 3b: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c will be combined with bevacizumab. NUC-3373+LV+oxaliplatin will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
10209851|NCT03428958|Experimental|NUFIRI + bevacizumab weekly|Arm 3c: NUC-3373, LV and irinotecan at dose levels used in Arm 2d will be combined with bevacizumab. NUC-3373+LV will be administered weekly, irinotecan will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
10209852|NCT03428958|Experimental|NUFIRI + bevacizumab fortnightly|Arm 3d: NUC-3373, LV and irinotecan at dose levels used in Arm 2d will be combined with bevacizumab. NUC-3373+LV+irinotecan will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
10209853|NCT03428958|Experimental|NUC-3373 + LV + bevacizumab; maintenance patients|Arm 3e: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with bevacizumab and bevacizumab will be administered in accordance with standard local practice.
10209854|NCT03428958|Experimental|NUFOX + cetuximab|Arm 3f: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or fortnightly, oxaliplatin will be administered fortnightly and cetuximab will be administered in accordance with standard local practice.
10209855|NCT03428958|Experimental|NUFIRI + cetuximab|Arm 3g: NUC-3373, LV and irinotecan at dose levels used in Arm 2d may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or fortnightly, irinotecan will be administered fortnightly and cetuximab will be administered in accordance with standard local practice.
9860566|NCT03236662|Experimental|Treatment|(-)-epicatechin 50mg twice per day (100mg per day total dose)
9795193|NCT01529606|Experimental|Plasma treatment|Fifty patients will be recruited into plasma treatment group and they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth.
9795194|NCT01529632|Experimental|QVA149|QVA149 plus placebo once daily for 28 days.
9795195|NCT01529632|Active Comparator|QAB149 + NVA237|Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.
9795196|NCT01529645|Experimental|Group 1: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
9795197|NCT01529645|Experimental|Group 2: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
9795198|NCT01529645|Experimental|Group 3: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
9795199|NCT01529645|Experimental|Group 4: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
9795200|NCT01529645|Experimental|Group 5: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9795201|NCT01529645|Experimental|Group 6: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9795202|NCT01529645|Experimental|Group 7: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9795203|NCT01529645|Experimental|Group 8: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9795204|NCT01529645|Experimental|Group 9: TDaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
9795205|NCT01529645|Active Comparator|Group 10: Licensed TdaP booster|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.
9795206|NCT01529749|Active Comparator|EFV/FTC/TDF|
9795207|NCT01529749|Experimental|EFV/FTC/TDF + Losartan|
9795208|NCT01529749|Experimental|FTC/TDF + MK-0518|
9795209|NCT01529749|Experimental|FTC/TDF+MK-0518+Losartan|
9795210|NCT01529827|Experimental|Treatment (reduced intensity allogeneic PBSCT)|PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.
9795211|NCT01530178|Active Comparator|Part A|Sitagliptin 25mg
9795212|NCT01530178|Active Comparator|Part B|Sitagliptin 50mg
9795213|NCT01530178|Active Comparator|Part C|Sitagliptin 100mg
9795214|NCT01530178|Placebo Comparator|Part D|Placebo oral tablet
9795215|NCT01530243|Placebo Comparator|Placebo|
9795216|NCT01530243|Active Comparator|Terazosin|
9795217|NCT01530243|Active Comparator|Tolterodine|
9795218|NCT01530243|Active Comparator|Tolterodine + Terazosin|
9795219|NCT01530256|Experimental|ALD518|
9795220|NCT01530334|Experimental|open label single arm with Gefitinib 250MG once daily|Gefitinib 250 mg/day open label until progression disease / toxicity / consent withdrawal
9795221|NCT01530399|Experimental|MDCO 1|MDCO-2010: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
9795222|NCT01530399|Experimental|MDCO 2|MDCO-2010: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
9795223|NCT01530399|Experimental|MDCO 3|MDCO-2010: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
9795224|NCT01530399|Experimental|MDCO 4|MDCO-2010: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
9795225|NCT01530399|Placebo Comparator|Saline|Commercially available saline (0.9% NaCl solution)
9795226|NCT01530399|Active Comparator|Tranexamic acid|Tranexamic acid: 12 mg/kg loading dose; 5 mg/kg/h infusion; 0.556 mg/mL CPB priming
9795227|NCT01530464|Active Comparator|Aminophylline|
9795228|NCT01530464|Active Comparator|Ambrisentan|
9795229|NCT01530464|Experimental|Aminophylline and ambrisentan|Treatment 3: Aminophylline, 500 mg plus Ambrisentan, 5 mg
9860567|NCT02930122|Experimental|Anakinra|Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury
9860568|NCT02930122|Placebo Comparator|Placebo Control|Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury
9860569|NCT01444209|Experimental|Radiation Therapy|Interstitial Radioactive Iodine Implants
9860570|NCT04267380||Corrona US RA Registry 11 mg|patients with RA who have been exposed to tofacitinib 11 mg QD tablet
9860571|NCT04267380||Corrona US RA Registry 5 mg|patients with RA who have been exposed to tofacitinib 5 mg BID tablet
9860572|NCT04090164||Study group|The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
9860573|NCT04090164||Control group|A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.
9860574|NCT04047121||Truven Health MarketScan|The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.
9860575|NCT04036799||Hypertrophic Cardiomyopathy|
9924505|NCT00861991|Active Comparator|Control|Students given standard instructions
9924506|NCT00862017|Experimental|MSG|Subjects receive a 6-d supplementation of MSG and are studied on the 7th day in the postprandial period following a standard meal ingestion with 2g MSG
9924507|NCT00862017|Placebo Comparator|Control|
9924508|NCT00862030||1|Study Cohort
10209856|NCT03393611|Experimental|CPX-351 Salvage Therapy and Transplant|Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.
9924509|NCT00862043|Experimental|Sildenafil Citrate|Sildenafil Citrate 40 mg t.i.d. oral
9924510|NCT00862043|Placebo Comparator|Placebo|Sildenafil-matched oral placebo 40 mg t.i.d
10209857|NCT03385408|Experimental|HILT group|High-intensity laser therapy application through HIRO 3.0 device
10209858|NCT03385408|Sham Comparator|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
9924511|NCT00862056||Cardiac CT|All participants will undergo a coronary artery CT angiogram
9924512|NCT00862095|Placebo Comparator|Placebo|Placebo group
9924513|NCT00862095|Experimental|Propranolol|Propranolol (target dose 80 mg a day)
9924514|NCT00862095|Experimental|Topiramate|Topiramate (target dose 100 mg a day)
9924515|NCT00862095|Experimental|Amitriptyline|Amitriptyline (target dose 50 mg a day)
9924516|NCT00862108|Experimental|Methylphenidate|
10213630|NCT03649217|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
10213631|NCT03639610|Experimental|Single arm|"Cohort 1A Melphalan flufenamide 40 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.~Cohort 1B Melphalan flufenamide 30 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.~Cohort 2A Melphalan flufenamide 20 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.~Cohort 2B Melphalan flufenamide 30 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg."
10213632|NCT03637725||Coronary Artery Disease|Suspected or known coronary artery disease
9924517|NCT00862147|Experimental|ICDP|International Child Development Program
9924518|NCT00862147|Active Comparator|Treatment as usual|Treatment as usual
9924519|NCT00862160|Active Comparator|1|using minimized cardiopulmonary bypass circuit ROCsafeTM
9924520|NCT00862160|No Intervention|2|using standard cardiopulmonary bypass circuit
9924521|NCT00862173||Patients with NSCLC with CNS Metastasis|Patients who developed CNS metastasis of NSCLC during the treatment.
9924522|NCT00862173||Patients with NSCLC without CNS Metastasis|Patients with NSCLC that does not develop CNS metastasis during the treatment.
9924523|NCT00862212|Experimental|Brief Alcohol Intervention|Half of the subjects will be randomly assigned to receive a brief physician-delivered alcohol intervention designed by the NIAAA to be delivered by primary care and mental health providers.
9924524|NCT00862212|No Intervention|Control Group|
9924525|NCT00862225|Placebo Comparator|1|
9924526|NCT00862225|Active Comparator|2|
9924527|NCT00862225|Experimental|3|
9924528|NCT00862238|Experimental|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
9924529|NCT00862238|Other|Health Promotion|4-session education offering basic information about the prevention of hepatitis A, B & C
9924530|NCT00862264|Experimental|CHF 1535 pMDI|CHF 1535 HFA pMDI aerosol (100 µg/unit dose of beclomethasone dipropionate plus 6 µg of formoterol/unit dose
9924531|NCT00862264|Active Comparator|BDP pMDI|Beclomethasone dipropionate-CFC pMDI, 250 µg/unit dose
9924532|NCT00862290||sepsis group|Patients who develop sepsis in the ICU
9924533|NCT00862290||SIRS group|Patients who develop SIRS after cardiac surgery with cardiopulmonary bypass
9924534|NCT00862290||control group|normal healthy volunteers
9924535|NCT00862303|Placebo Comparator|IL-2/IFN-α|
9924536|NCT00862303|Experimental|DC-CIK|
9924537|NCT00862316|Experimental|Computer Navigational Unit Assistance|Oxford Unicompartmental Knee arthroplasty will be performed with the assistance of a computer navigational unit.
9924538|NCT00862316|Active Comparator|Non- Computer Navigational Unit Assisted|Oxford Unicompartmental Knee arthroplasty will be performed traditionally (without the assistance of a computer navigational unit).
9924539|NCT00862329|Experimental|Casein|
9924540|NCT00862329|Experimental|MSP|
9924541|NCT00862329|Experimental|Casein/MSP|
9860576|NCT04018001||Truven Health MarketScan Research Database|individuals who are privately insured and with Medicare Supplemental insurance
9860577|NCT04017754||Study sample|"In total, 267 women with unexplained recurrent pregnancy loss was included.~Only patients with a history of 3 or more consecutive spontaneous pregnancy losses are included. Both biochemical and clinical losses documented in hospital records are accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social reasons are not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (<22 and >35 days interval), and/or no MBL measurement."
9860578|NCT04017754||Reference Group|The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information. After informed approval, all controls had an extra blood sample taken, which was analysed for p-MBL.
9860579|NCT04010370||Healthy individuals|Cross-Sectional. No intervention. Patients of both sexes who are not sedentary or who participate in heavy physical activities and residents of the metropolitan area of Guadalajara
9860580|NCT03975790||Truven Health MarketScan Research Database|Compare treatment patterns including dosing, concomitant medication use, adherence, persistence, and switching among tofacitinb+MTX patients who withdraw MTX vs. persist with MTX or experience interrupted MTX
9860581|NCT00000105||Arm A: Intracel KLH|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
9860582|NCT00000105||Arm B: Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
9860583|NCT00000105||Arm C: Biosyn KLH with Montanide ISA51|Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
9860584|NCT00000113|Experimental|Progressive Addition Lenses (PALs)|
9860585|NCT00000113|Active Comparator|Single Vision Lenses|
9860586|NCT00000145|Experimental|1|Antioxidants
9860587|NCT00000145|Experimental|2|Zinc
9860588|NCT00000145|Experimental|3|Antioxidants and zinc
9860589|NCT00000145|No Intervention|4|
9860590|NCT00000167|Experimental|1|Laser treatment
9860591|NCT00000170|Active Comparator|Patching|
9860592|NCT00000170|Active Comparator|Atropine|Atropine
9924542|NCT00862329|Experimental|Soy protein|
9924543|NCT00862342|Experimental|Bevacizumab|Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
9924544|NCT00862355|Experimental|1|SPARC147609
9924545|NCT00862355|Active Comparator|2|Reference147609
9924546|NCT00862368|Experimental|PAM -Enhanced/Asthma|The PAM-Enhanced/Asthma group: 2 in-home visits that included asthma education consistent with NIH recommendations (NIH, NAEPP, 1997) and smoking cessation counseling. Consistent with Motivational Interviewing (MI), smoking was broached in a non-judgmental manner and as another trigger for asthma. Feedback was given on expired air Carbon Monoxide (CO) levels of the smoker (to increase personal perception of risk) and the amount of smoke exposure to the child (to increase risk perception to the child). 6 phone calls were then provided over the next 4 months that focused on asthma education, a second round of feedback on the child's ETS exposure, and smoking cessation counseling. MI was used at all contacts. Free nicotine patch tx was given if they were ready to quit within 30 days.
9924547|NCT00862368|Active Comparator|PAM-Asthma|The PAM-Asthma arm received the same in-home counseling visits as PAM-Enhanced/Asthma. The 6 counseling phone calls were different from those received by PAM-Enhanced/Asthma, and included only an asthma follow-up and discussion of a child wellness topic. Smoking cessation was not discussed and additional feedback on ETS samplers was not provided. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
9935154|NCT04097821|Experimental|Part 1 Arm 2: Ruxolitinib + Crizanlizumab|Safety run-in of crizanlizumab added to existing stable dose of ruxolitinib
9860593|NCT00000249|No Intervention|Control|Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes
9860594|NCT00000249|Active Comparator|20% N2O|Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 & 30 minutes
9860595|NCT00000249|Active Comparator|30% N2O|Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes
9860596|NCT00000249|Active Comparator|40% N2O|Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes
9860597|NCT00000250|Active Comparator|Lukewarm water|Subjects will immerse forearm in lukewarm water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
9860598|NCT00000250|Active Comparator|Ice cold water|Subjects will immerse forearm in ice cold water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
9860599|NCT00000251|Placebo Comparator|Placebo|Subjects inhale 100% oxygen
9860600|NCT00000251|Active Comparator|30% N2O|Subjects inhale 30% N2O
9860601|NCT00000251|Active Comparator|0.2% isoflurane|Subjects inhale 0.2% isoflurane
9860602|NCT00000251|Active Comparator|0.4% isoflurane|Subjects inhale 0.4% isoflurane
9860603|NCT00000251|Active Comparator|0.2% isoflurane + 30% N2O|Subjects will inhale a combination of 0.2% isoflurane and 30% N2O
9860604|NCT00000251|Active Comparator|0.4% isoflurane + 30% N2O|Subjects will inhale a combination of 0.4% isoflurane and 30% N2O
9860605|NCT00000252|Sham Comparator|0% N2O|Subjects will inhale 0% N2O
9860606|NCT00000252|Active Comparator|10% N2O|Subjects will inhale 10% N2O
9860607|NCT00000252|Active Comparator|20% N2O|Subjects will inhale 20% N2O
9860608|NCT00000252|Active Comparator|30% N2O|Subjects will inhale 30% N2O
9860609|NCT00000252|Active Comparator|40% N2O|Subjects will inhale 40% N2O
9860610|NCT00000253|Active Comparator|Placebo + 10% N2O|0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
9860611|NCT00000253|Active Comparator|Placebo + 20% N2O|Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
9860612|NCT00000253|Active Comparator|Placebo + 30% N2O|Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
9860613|NCT00000253|Active Comparator|Placebo + 40% N2O|Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
9860614|NCT00000254|Sham Comparator|0% isoflurane|
9860615|NCT00000254|Active Comparator|0.2% isoflurane|
9860616|NCT00000254|Active Comparator|0.4% isoflurane|
9860617|NCT00000254|Active Comparator|0.6% isoflurane|
9860618|NCT00000255|Placebo Comparator|0% Nitrous oxide|
9860619|NCT00000255|Active Comparator|10% nitrous oxide|
9860620|NCT00000255|Active Comparator|20% nitrous oxide|
9860621|NCT00000255|Active Comparator|30% nitrous oxide|
9860622|NCT00000255|Active Comparator|40% nitrous oxide|
9860623|NCT00000256|Active Comparator|Placebo + 20% N2O|0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
9860624|NCT00000256|Active Comparator|Placebo + 40% N2O|0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
9860625|NCT00000256|Active Comparator|Placebo + 60% N2O|0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
9860626|NCT00000256|Active Comparator|Placebo + 80% N2O|0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
9860627|NCT00000257|Active Comparator|Light drinkers|
9860628|NCT00000257|Active Comparator|Moderate drinkers|
9860629|NCT00000258|Active Comparator|Informed group|Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation.
9860630|NCT00000258|Active Comparator|Non-informed Group|Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice.
9860631|NCT00000259|Placebo Comparator|Placebo|Subject inhales no drug (100% oxygen)
9860632|NCT00000259|Active Comparator|0.3% sevoflurane|
9860633|NCT00000259|Active Comparator|0.6% sevoflurane|
9860634|NCT00000259|Active Comparator|15% Nitrous oxide|
9860635|NCT00000259|Active Comparator|30% Nitrous oxide|
9860636|NCT00000261|Experimental|Moderate drinking adults|
9860637|NCT00000262|Placebo Comparator|Placebo +/- 30% Nitrous oxide|
9860638|NCT00000262|Active Comparator|Sevoflurane 0.2% +/- 30% Nitrous oxide|
9860639|NCT00000262|Active Comparator|Sevoflurane 0.4% +/- 30% Nitrous oxide|
9860640|NCT00000263|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
9860641|NCT00000263|Active Comparator|0.25 g/Kg ethanol +/- 30% nitrous oxide|
9860642|NCT00000263|Active Comparator|0.5 g/Kg ethanol +/- 30% nitrous oxide|
9860643|NCT00000264|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
9860644|NCT00000264|Active Comparator|0.35 g/Kg ethanol +/- 30% nitrous oxide|
9860645|NCT00000264|Active Comparator|0.7 g/Kg ethanol +/- 30% nitrous oxide|
9860646|NCT00000265||Low anxiety|
9860647|NCT00000265||Moderate anxiety|
9860648|NCT00000265||High anxiety|
9860649|NCT00000271|Experimental|Desipramine|Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
9860650|NCT00000271|Placebo Comparator|Placebo|Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.
9860651|NCT00000273|Experimental|Opiates|Opiate-dependent individuals who were currently not seeking treatment for their drug use, completed the 6-week protocol.
9860652|NCT00000299|Active Comparator|buprenorphine|depot buprenorphine
9860653|NCT00000299|Experimental|buprenorphine and ultra-low dose naloxone|depot buprenorphine and naloxone
9860654|NCT00000304|Experimental|1|15/30 mg d-amphetamine
9860655|NCT00000304|Experimental|2|30/60 mg d-amphetamine
9860656|NCT00000304|Experimental|3|placebo
9860657|NCT00000308|Experimental|1|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
9860658|NCT00000308|Experimental|2|30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
9860659|NCT00000308|Experimental|3|placebo
9860660|NCT00000311|Experimental|1|Methadone + CM (contingency management)
9860661|NCT00000311|Experimental|2|methadone + VC (voucher control)
9860662|NCT00000311|Experimental|3|Buprenorphine + CM
9860663|NCT00000311|Experimental|4|Buprenorphine + VC
9924548|NCT00862368|Active Comparator|PAM-Healthy|The PAM-Healthy arm received the same in-home counseling visits as PAM and PAM Enhanced but asthma information was replaced with child wellness topics. The 6 counseling phone calls were the same timing and duration as the other two groups (six, 15 minutes calls, over four months) focused on a child wellness topic. Smoking cessation or sampler feedback was not discussed. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
9924549|NCT00862381|Experimental|1|Hydrocortisone
9924550|NCT00862381|Placebo Comparator|2|Placebo
9924551|NCT00862394|Experimental|1|CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg
9924552|NCT00862394|Active Comparator|2|CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg
9924553|NCT00862394|Experimental|3|CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg
9924554|NCT00862394|Active Comparator|4|CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg
9924555|NCT00862407||1|Non-pulsatile Group (conventional)
9924556|NCT00862407||2|Pulsatile group (Alternate)
9924557|NCT00862420|Experimental|Clopidogrel|75 mg clopidogrel once daily from Day 1 to Week 12
9924558|NCT00862420|Active Comparator|Ticlopidine|200 mg ticlopidine once daily from Day 1 to Week 12
9924559|NCT00862472|Experimental|DuoTrav APS|DuoTrav APS QD AM
9924560|NCT00862472|Active Comparator|DuoTrav|DuoTrav QD AM
9924561|NCT00862485||StudyGroup|
9924562|NCT00862498|Experimental|Group 1 Treatment in Clinic|Participants will complete the written disclosure treatment in a clinic setting.
9924563|NCT00862498|Experimental|Group 2 Treatment via telephone|Participants will complete the written disclosure treatment in their homes via telephone.
9924564|NCT00862498|No Intervention|Group 3 Waitlist|Individuals will be placed on a waitlist for a period of 4 months, during which they will receive a phone call every other week to assess their suicidal ideation and post-traumatic stress disorder symptom severity.
9924565|NCT00862511|Experimental|Coated Total Knee Arthroplasty|allergy coated TKA
9517070|NCT03309774|Experimental|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
9517071|NCT03309761||Patients aged 55-60|
9924566|NCT00862511|Active Comparator|Standard Total Knee Arthroplasty|normal TKA
9924567|NCT00862550|Experimental|Group 1|Acupuncture (Areas known to help dry mouth)
9924568|NCT00862550|Experimental|Group 2|Acupuncture (Areas not known to help dry mouth)
9924569|NCT00862576||1|Burning Mouth Syndrome Group
9924570|NCT00862576||2|Control Group
9924571|NCT00862602|Experimental|1|Stepping Up to Health
9924572|NCT00862602|No Intervention|2|Usual care group
9924573|NCT00862628|Experimental|Rebamipide|
9924574|NCT00862667|Experimental|Treatment A|PF-00241939 300ug using Inhaler A
9924575|NCT00862667|Active Comparator|Treatment B|PF-00241939 300ug using Inhaler B
9924576|NCT00862667|Active Comparator|Treatment C|PF-00241939 300ug using Inhaler C
9924577|NCT00862680||Diagnostic (4D PET/CT)|Participants undergo 4D PET/CT scan over up to 12 minutes.
9924578|NCT00862693|Experimental|1 calcitriol|calcitriol 0.5ug/BIW for 12 months
9924579|NCT00862693|No Intervention|2|no intervention
9924580|NCT00862706|Experimental|A|
9924581|NCT00862732|Active Comparator|1 Cognitive Behavioural Therapy|Intervention group will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
9935155|NCT04097821|Experimental|Part 1 Arm 3: Ruxolitinib + Sabatolimab|Safety run-in of Sabatolimab added to existing stable dose of ruxolitinib
9860664|NCT00000317|Placebo Comparator|PLacebo|Placebo plus relapse prevention counseling
9860665|NCT00000317|Experimental|Risperidone|Risperidone (4mg/day) plus relapse prevention counseling
9860666|NCT00000318|Experimental|1|Maintenance treatment with daily medication
9860667|NCT00000318|Experimental|2|Maintenance treatment with thrice-weekly medication
9860668|NCT00000320|Active Comparator|1; liquid formulation|liquid formulation
9860669|NCT00000320|Active Comparator|2; tablet formulation|tablet formulation
9860670|NCT00000331|Experimental|Test Drug|Test drug to prevent heroine withdrawal
9860671|NCT00000331|Placebo Comparator|Placebo Pill|Placebo drug
9860672|NCT00000359|Experimental|Canalith repositioning maneuver|Repositioning treatment for posterior canal BPPV
9860673|NCT00000359|Experimental|Modified Epley maneuver|
9860674|NCT00000359|Sham Comparator|Sham|The subject sat in a chair; the head was passively tilted downward, turned away from the involved side, turned back to center, upward, away from the involved side, twice, slowly.
9860675|NCT00000359|Active Comparator|Liberatory maneuver|The standard liberatory maneuver (also known as the Semont maneuver) was used.
9860676|NCT00000359|Active Comparator|Brandt Daroff exercise|Modified Brandt Daroff exercise performed as a self-liberatory exercise.
9860677|NCT00000372|Experimental|Glycine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
9860678|NCT00000372|Placebo Comparator|Placebo|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
9860679|NCT00000372|Experimental|D-Cycloserine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.
9860680|NCT00000373|Active Comparator|olanzapine + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
9860681|NCT00000373|Placebo Comparator|placebo + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
9860682|NCT00000380|Experimental|GHRH|Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone.
9860683|NCT00000380|Placebo Comparator|Placebo|Placebo
9860684|NCT00000383|Experimental|Trauma-Focused CBT|Trauma -Focused CBT provides 12 sessions (45 minutes child, 45 minutes parent) of CBT treatment. This includes therapist-directed trauma-focused skills training, exposure, parenting, conjoint parent-child sessions, and safety component provided to child and parent.
9860685|NCT00000383|Active Comparator|Child Centered Therapy|Child Centered Therapy provides 12 sessions (45 minutes child, 45 minutes parent) of supportive interventions. This includes client-directed activities focused on the needs and interests of the child or parent, respectively.
9860686|NCT00000385|Experimental|1|Lithium 600 mg to 2700 mg per day
9860687|NCT00000385|Placebo Comparator|2|Matching placebo
9517072|NCT03309748|Active Comparator|Dental Prophylaxis|Standard dental prophylaxis
9517073|NCT03309748|Active Comparator|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis + aPDT
9860688|NCT00000387|Experimental|A,1,III|Behavioral intervention - Self management therapy
9860689|NCT00000387|Active Comparator|A,2,III|Regular treatment
9860690|NCT00000395|Experimental|Group 1 - Folinic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folinic acid daily for 1 week.
9860691|NCT00000395|Experimental|Group 2: Folic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folic acid daily for 1 week.
9860692|NCT00000396|Experimental|1|Education in Arthritis Self-Help Course
9860693|NCT00000400|Experimental|PTH|Human parathyroid hormone [hPTH-(1-34)]
9860694|NCT00000400|Active Comparator|ALN|Alendronate
9860695|NCT00000400|Experimental|PTH+ALN|Human parathyroid hormone [hPTH-(1-34)] plus alendronate
9860696|NCT00000401|Experimental|1|The low dose group will receive CII 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks.
9860697|NCT00000401|Experimental|2|The high dose group will receive CII 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks.
9860698|NCT00000407|Active Comparator|Enrollment Intervention|The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the vocational rehabilitation (VR) program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively.
9860699|NCT00000407|Placebo Comparator|Usual Care|
9860700|NCT00000408|Experimental|email discussion group|
9860701|NCT00000408|No Intervention|rancomized control group|usual care
9860702|NCT00000409|Active Comparator|Surgery|Decompressive Laminectomy Fusion-Instrumented Fusion-Non-instrumented
9860703|NCT00000409|Active Comparator|Non-surgical intervention|Other. Non-surgical treatments
10209859|NCT03382301|Experimental|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
10209860|NCT03382301|Placebo Comparator|NaCl preconditioning|
9860704|NCT00000410|Active Comparator|Surgery|Diskectomy
9860705|NCT00000410|Active Comparator|Non-surgical intervention|Non-surgical treatments
9860706|NCT00000411|Active Comparator|Surgery|Decompressive laminectomy
9860707|NCT00000411|Active Comparator|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
9860708|NCT00000412|Active Comparator|Group A|Group A active alendronate (10 mg/day) and placebo calcitriol.
9860709|NCT00000412|Placebo Comparator|Group B|We will give Group B placebo alendronate and active calcitriol (0.25 micrograms BID).
9860710|NCT00000414|Experimental|Arthritis Self-Management Program|small group self-management program
9860711|NCT00000414|Experimental|SMART Program|Self-Managed Arthritis Relief Therapy: mailed self management material
9860712|NCT00000416|Experimental|Rehabilitation counseling|"Rehabilitation counseling~Experimental~Rehabilitation counseling was provided by rehabilitation counselors. They administered the Work Experience Survey; provided and discussed disability rights and responsibilities and provided career counseling they as needed."
9860713|NCT00000416|Active Comparator|printed information|"Active comparator~Control group participants received relevant printed information in the mail only; no rehabilitation counseling"
9860714|NCT00000421|Active Comparator|Prednisone arm|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
9860715|NCT00000421|Placebo Comparator|Placebo|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
9924582|NCT00862732|Active Comparator|2 Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
9924583|NCT00862797||endotracheal tube|Patients intubated with cuffed endotracheal tubes
9924584|NCT00862875|Experimental|1:Insulin detemir|Insulin detemir (Levemir® - Novolin® 4 pen)
9924585|NCT00862875|Active Comparator|2:Insulin Glargin|Insulin glargine (Lantus® - Solostar®)
9924586|NCT00862888|Placebo Comparator|Cohort 1; Study Period 1, 2, 3 or 4|Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design)
9924587|NCT00862888|Placebo Comparator|Cohort 2; study periods 1, 2, 3 or 4|Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design).
9924588|NCT00862901|Experimental|1|100 J / cm2 over 24 hours
9924589|NCT00862901|Experimental|2|200 J / cm2 over 24 hours
9924590|NCT00862901|Experimental|3|400 J / cm2 over 24 hours
10209861|NCT03368079|Experimental|Negative Pressure Suction Device|
10209862|NCT03361982|No Intervention|Fresh surgical testicular sperm|Fresh, surgically obtained testicular sperm
10209863|NCT03361982|Experimental|Frozen surgical testicular sperm|Surgically obtained testicular sperm that will undergo slow freezing and thawing
10209864|NCT03360539|Experimental|Treatment-NFP|NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.
9924591|NCT00862901|Experimental|4|800 J / cm2 over 24 hours
9924592|NCT00862914||1|benign melanocytic naevi
9924593|NCT00862914||2|dysplastic melanocytic naevi
9924594|NCT00862914||3|cutaneous malignant melanoma
9924595|NCT00862927||Cue reactivity in virtual reality|Breath Scan + Saliva Sample + Questionnaires + View Virtual Reality Scenes
9924596|NCT00862953|Active Comparator|Normal protein normal carbohydrate|Normal protein normal carbohydrate calory restricted nutrition
9924597|NCT00862953|Experimental|Normal protein low carbohydrates|Normal protein low carbohydrate energy-restricted diet
9924598|NCT00862953|Experimental|High protein normal carbohydrates|High protein normal carbohydrates
9924599|NCT00862953|Experimental|High protein low carbohydrate|High protein low carbohydrate nutrition
9924600|NCT00862966|Experimental|citrate|
9924601|NCT00862966|Active Comparator|heparin|
9924602|NCT00863005|Experimental|1. K201|
9924603|NCT00863005|Active Comparator|2.|
9924604|NCT00863018||Control|Eyes with glaucoma and on anti-glaucoma medication but without glaucoma surgery
9924605|NCT00863018||Implant surgery|Eyes underwent Ahmed glaucoma valve implantation
9924606|NCT00863018||Trabeculectomy|Eyes underwent conventional trabeculectomy with mitomycin-C
9924607|NCT00863031|Experimental|problem-solving therapy|Three sessions of brief problem-solving counselling at week 1, 3 and 5 by a family doctor.
9924608|NCT00863031|Placebo Comparator|viewing video|Three sessions of health education viewing video in groups of 3 to 5 people
9924609|NCT00863044|Active Comparator|High frequency ventilation|high frequency ventilation
9924610|NCT00863044|Placebo Comparator|Apnea|lung ventilation will be stopped during distal anastomosis as is commonly done
10209865|NCT03360539|No Intervention|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
9860716|NCT00000428|Experimental|1|Patients received each intervention multiple times in random-order crossover design.
9860717|NCT00000431|Experimental|1|Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
9860718|NCT00000434|Experimental|1|Fit and Strong! is a multi-component exercise and health education program that incorporates flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
9860719|NCT00000435|Placebo Comparator|A|Subjects randomized to arm A received 25mg/day po of placebo
9860720|NCT00000435|Active Comparator|B|Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
9860721|NCT00000437|Experimental|Naltrexone Tablet and Nicotine Patch|
9860722|NCT00000437|Active Comparator|Naltrexone Tablet and Placebo Patch|
9860723|NCT00000437|Active Comparator|Placebo Tablet and Nicotine Patch|
9860724|NCT00000437|Placebo Comparator|Placebo Tablet and Placebo Patch|
9860725|NCT00000439|Active Comparator|sodium valproate|sodium valproate was added on treatment as usual and dose monitored by blood level measurements
9860726|NCT00000439|Placebo Comparator|placebo|Placebo comparator was added on treatment as usual and dose monitored by blood level measurements
10209866|NCT03359096|Experimental|Therapeutic HGNS|Therapeutic Hypoglossal Nerve Stimulation (HGNS). Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
9860727|NCT00000448|Placebo Comparator|Placebo|Subjects were given an inert placebo for 2 days, followed by daily doses of matching placebo for a total of 12 weeks.
9860728|NCT00000448|Experimental|Naltrexone|Subjects were prescribed 25 mg naltrexone for 2 days, followed by daily doses of 50 mg of naltrexone for a total of 12 weeks.
9860729|NCT00000450|Active Comparator|Naltrexone Tablet|
9860730|NCT00000450|Placebo Comparator|Matched Placebo Tablet|
9860731|NCT00000451|Experimental|1|Naltrexone plus Sertraline
9860732|NCT00000451|Experimental|2|Naltrexone alone
9860733|NCT00000457|Placebo Comparator|Placebo|Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
9860734|NCT00000457|Active Comparator|Bupropion|Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
9860735|NCT00000460||Low intensity exercise|
9860736|NCT00000460||High intensity exercise|
9860737|NCT00000511|Placebo Comparator|Potassium, Magnesium, Calcium, The 3 together, Placebo|Parallel study design, 4 treatment groups
9860738|NCT00000512|Experimental|Niacin-Colestipol Group|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation. Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
9860739|NCT00000512|Experimental|Lovastatin-Colestipol Group|Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
9860740|NCT00000512|Placebo Comparator|Conventional-Therapy Group|Patients assigned to conventional therapy (the control regimen) received placebos for colestipol and for lovastatin, given as described above, unless their base-line LDL cholesterol level exceeded the 90th percentile for age. We felt obliged to provide such patients (43 percent of the group) with colestipol instead of its placebo. For purposes of blinding, the lovastatin placebo dose for a patient assigned to conventional therapy was doubled each time the lovastatin dose was doubled for a patient assigned to receive lovastatin and colestipol.
9924611|NCT00863070||Bladder Exstrophy Patients|Patients who receive follow-up care at Connecticut CMC urology clinic for bladder exstrophy.
9924612|NCT00863083|Active Comparator|1|Multifamily group weight management intervention plus rewards for program attendance
9924613|NCT00863083|Active Comparator|2|Multifamily group weight management intervention plus rewards for attendance and goal attainment
9924614|NCT00863096||Gardasil|
9924615|NCT00863135|Experimental|Continuous Positive Airway Pressure|nocturnal continuous positive airways pressure
9924616|NCT00863135|Other|Control|Waiting list,3 months without any change in their treatment, come into the CPAP procedure after that time
9924617|NCT00863161|Experimental|1|AZD3355 65 + 65 mg capsule
9924618|NCT00863174|Experimental|1|SPARC147709
9924619|NCT00863174|Active Comparator|2|Reference147709
9924620|NCT00863187|Experimental|rituximab|b cell depletion drug
9924621|NCT00863200||Telephone Intervention Group|
9924622|NCT00863200||Standard Care Group|
9924623|NCT00863213|Experimental|Atrial Fibrillation Ablation|
9924624|NCT00863213|Active Comparator|Drug therapy|
9924625|NCT00863239|Experimental|1|Locteron™ (controlled-release interferon alpha 2b) 320 µg as biweekly subcutaneous injection
9924626|NCT00863239|Experimental|2|Locteron™ (controlled-release interferon alpha 2b) 480 µg as biweekly subcutaneous injection
9924627|NCT00863239|Experimental|3|Locteron™ (controlled-release interferon alpha 2b) 640 µg as biweekly subcutaneous injection
9924628|NCT00863239|Active Comparator|4|PEG-Intron™ (12 kDalton pegylated interferon alpha 2b) 1.5 µg/kg body weight weekly subcutaneous injection
9924629|NCT00863252|Experimental|1|MMF
9924630|NCT00863252|Active Comparator|2|Control
9935156|NCT04097821|Experimental|Part 2 Arm 1: Ruxolitinib + Siremadlin|Siremadlin added to existing stable dose of ruxolitinib
9935157|NCT04097821|Experimental|Part 2 Arm 2: Ruxolitinib + Crizanlizumab|Crizanlizumab added to existing stable dose of ruxolitinib
10209867|NCT03359096|Sham Comparator|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds."
9795230|NCT01530477|Experimental|Skeletal|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)],(total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
9795231|NCT01530477|Experimental|Body Composition|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], (total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
9795232|NCT01530477|Experimental|Skeletal & Body Composition|"Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort."
9795233|NCT01531153|Active Comparator|Sugar Pill|Sugar Pill will be compared with the active medication Galantamine
9795234|NCT01531153|Active Comparator|Galantamine|Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
9795235|NCT01531205|Experimental|Drug and Hormonal Therapy with Salvage Surgery|Androgen Ablation (hormonal therapy before surgery), Cabazitaxel (chemotherapy before surgery), Salvage Surgery (radical prostatectomy), Post-operative Hormonal Therapy, Post-operative Follow-up
9795236|NCT01531335|Active Comparator|Standard care|Patients will receive normal nutritional regime of around 25 kcal per kg.
9795237|NCT01531335|Experimental|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg
10209868|NCT03357562|Experimental|lung MRI|lung MRI without contrast injection
10209869|NCT03348995|Experimental|Bridge-Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing an absorbable implant (the BEAR Implant) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into
10209870|NCT03340506|Experimental|dabrafenib monotherapy|"Patients in this study may receive:~- monotherapy of dabrafenib"
10209871|NCT03340506|Experimental|trametinib monotherapy|"Patients in this study may receive:~- monotherapy of trametinib"
10209872|NCT03340506|Experimental|Combination therapy (dabrafenib & trametinib)|"Patients in this study may receive:~- the combination of dabrafenib and trametinib"
10209873|NCT03331198|Experimental|Phase 1 JCAR017 monotherapy|Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
9795241|NCT01531439|Active Comparator|Naloxone infusion 0.5 mcg/kg/hr|
9795242|NCT01531439|Experimental|Naloxone 2.5 mcg/kg/hr|Naloxone infusion 2.5 mcg/kg/hr
9795243|NCT01531673|Placebo Comparator|Group 1-6d Combined: Placebo|All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
9795244|NCT01531673|Experimental|Group 1: VX-661 10 mg qd|All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
9795245|NCT01531673|Experimental|Group 2a: VX-661 30 mg qd|All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
9795246|NCT01531673|Experimental|Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h|All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
9795247|NCT01531673|Experimental|Group 3a: VX-661 100 mg qd|All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
10209874|NCT03331198|Experimental|Phase 1 JCAR017 + ibrutinib|Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose + ibrutinib
10209875|NCT03331198|Experimental|Phase 2 JCAR017 monotherapy|Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
10209876|NCT03331198|Experimental|Phase 1 JCAR017 + venetoclax|Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.
10209877|NCT03328702|Experimental|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
10209878|NCT03320122|Experimental|Telemedicine|Medical Direction will be provided by pediatric physiatrists using telemedicine.
10209879|NCT03320122|Active Comparator|In-Person Pediatric Physiatrist|Medical Direction will be provided by pediatric physiatrists in-person.
10209880|NCT03320122|Active Comparator|In-Person Non-Pediatric Physiatrist|Medical Direction will be provided by contracted physicians (i.e., non-pediatric physiatrists) in-person care.
10209881|NCT03318692|Experimental|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
10209882|NCT03318692|Active Comparator|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
10209883|NCT03309033||Observational (questionnaire, biospecimen collection)|Patients complete a short questionnaire regarding risk factors for HPV infection and undergo collection of blood samples for testing HPV16 and HPV18 levels at years 13 and 15 after receiving initial vaccination.
9860741|NCT00000569|Active Comparator|Triamcinolone|1200 micrograms of triamcinolone in daily divided doses
9860742|NCT00000569|Placebo Comparator|Placebo|Placebo
9860743|NCT00000572|Experimental|Extracorporeal membrane oxygenation (CO2 removal)|Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
9860744|NCT00000572|Active Comparator|Protocol Controlled positive-pressure vent|Detailed Electronic Protocol Controlled positive-pressure ventilation
9860745|NCT00000607|Experimental|Left ventricular assist device|Subjects received Thermo Cardiosystems, Inc. (TCI) vented electric (VE) left ventricular assist device (LVAD) and were followed for at least two years
9860746|NCT00000607|Active Comparator|Optimal medical therapy|Subjects received optimal medical therapy (OMM) and were followed for at least two years
9924631|NCT00863278|Active Comparator|Arm A|"All patients will be treated by stabilized Kligman's trio with daily application during 4 months.~After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks).~Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio.~All the patients will used a sunscreen indication 50 + for the duration of the entire study.~The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser."
9924632|NCT00863278|Active Comparator|Arm B|"All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months.~After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each.~Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio~All patients will be used a sunscreen indication 50 + for the duration of study.~The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser."
9924633|NCT00863291|Active Comparator|1|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
9924634|NCT00863291|Placebo Comparator|2|Placebo given in a manner similar to he active comparator
9924635|NCT00863382|Active Comparator|1|Standard Event Monitor
9924636|NCT00863382|Active Comparator|2|Sleuth recorder
9924637|NCT00863395|Experimental|Skin Biopsy|
9924638|NCT00863460|Active Comparator|A|MTX-based chemotherapy followed by WBRT
9924639|NCT00863460|Experimental|B|MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue
9924640|NCT00863473|No Intervention|Conservative /Physiotherapy|Active training protocol with instructed physiotherapy and self excercises
9924641|NCT00863473|Active Comparator|Surgery with LCP T plate|Surgical treatment with interlocking plate
10209884|NCT03296553|Experimental|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
10209885|NCT03296553|Active Comparator|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
10209886|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
10209887|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
9924642|NCT00863499|Active Comparator|A|Short Acting methylphenidate
9924643|NCT00863499|Active Comparator|B|Long Acting Methylphenidate
9924644|NCT00863499|No Intervention|C|Healthy Controls
9935158|NCT04097821|Experimental|Part 2 Arm 3: Ruxolitinib + Sabatolimab|Sabatolimab added to existing stable dose of ruxolitinib
9935159|NCT04097821|Active Comparator|Part 2 Arm 6: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 2
9935160|NCT04097821|Experimental|Part 3 Arm 1: Ruxolitinib + Compound X|Compound from Part 2 (to be confirmed) added to existing stable dose of ruxolitinib
9935161|NCT04097821|Experimental|Part 3 Arm 2: Ruxolitinib cessation|Compound from Part 2 added to existing stable dose of ruxolitinib for 3 cycles followed by compound monotherapy
9935162|NCT04097821|Active Comparator|Part 3 Arm 3: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 3
9935163|NCT04097821|Experimental|Part 1 Arm 4: Ruxolitinib + LTT462|Dose escalation of LTT462 added to existing stable dose of ruxolitinib
9935164|NCT04097821|Experimental|Part 1 Arm 5: Ruxolitinib + NIS793|Safety run-in of NIS793 added to existing stable dose of ruxolitinib
9935165|NCT04097821|Experimental|Part 2 Arm 4: Ruxolitinib + LTT462|LTT462 added to existing stable dose of ruxolitinib
9935166|NCT04097821|Experimental|Part 2 Arm 5: Ruxolitinib + NIS793|NIS793 added to existing stable dose of ruxolitinib
9935167|NCT04097561|Experimental|Single arm, open-label|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
9935168|NCT04095026||Patients|Patients age >18 years and <= 65 years enrolled in 11-N-0051 Epilepsy Surgery
10209888|NCT03287596|Experimental|HEALTHY VOLUNTEERS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium"
10209889|NCT03287596|Experimental|SPA + NON-SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
10209890|NCT03287596|Experimental|SPA + SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
10209891|NCT03287596|Experimental|MECHANIC TENDINOPATHY|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
10209892|NCT03287583|Experimental|SBIRT|SBIRT intervention for Gambling
9935169|NCT04088630|Experimental|Fingolimod Group|In addition to Standard of care treatment, those participants randomized to the fingolimod group will receive a single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset.
9935170|NCT04088630|Placebo Comparator|Control Group|In addition to Standard of care treatment, those participants randomized to the control group will receive a single dose placebo pill within 24 hours of symptom onset
9517074|NCT03309735||1|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
9860747|NCT00000774|Experimental|1|Patients who will receive rgp120/HIV-1MN
9860748|NCT00000774|Experimental|2|Patients who will receive rgp120/HIV-1SF2
9860749|NCT00000774|Placebo Comparator|3|Patients who will receive the placebo counterpart of 120/HIV-1MN
9860750|NCT00000774|Placebo Comparator|4|Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
9860751|NCT00000783||1|Sexually active HIV-infected concordant couples
9860752|NCT00000783||2|Sexually active HIV-infected discordant couples
9860753|NCT00000784||A|Consenting patients newly enrolled in either CPCRA 007 or CPCRA 006
9860754|NCT00000785||A|All eligible CPCRA subjects
9860755|NCT00000815|Experimental|1|Participants who receive vaccination at 6 and 12 months of age
9860756|NCT00000815|Experimental|2|Participants who receive vaccination only at 12 months of age
9860757|NCT00000817|Experimental|1|Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
9860758|NCT00000829|Experimental|1|Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine
9860759|NCT00000829|Placebo Comparator|2|Patients receiving placebo vaccine
9924645|NCT00863525|Experimental|1|Odanacatib
9924646|NCT00863525|Placebo Comparator|2|Placebo
9924647|NCT00863538|Experimental|1|
9924648|NCT00863564|Active Comparator|Whey Isolate|
9924649|NCT00863564|Active Comparator|Caseine|
9924650|NCT00863564|Active Comparator|Cod|
9924651|NCT00863564|Active Comparator|Gluten|
9924652|NCT00863590|Experimental|A|Panel A
9924653|NCT00863590|Experimental|B|Panel B
9924654|NCT00863590|Experimental|C|Panel C
9517075|NCT03309735||2|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
9795248|NCT01531673|Experimental|Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h|All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
9795249|NCT01531673|Experimental|Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h|All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
9795250|NCT01531673|Experimental|Group 5a: VX-661 150 mg qd|All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
9795251|NCT01531673|Experimental|Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h|All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
9924655|NCT00863590|Experimental|D|Panel D
9924656|NCT00863603|No Intervention|1|No exposure to supplemental oxygen
9924657|NCT00863603|Other|Oxygen, treatment, supplement|6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement
9924658|NCT00863616|Experimental|HFCWO|HFCWO twice a day delivered by SmartVest device at 13Hz FOR 20min x2. Duration 4 weeks in each phase with a 2week washout.
9924659|NCT00863616|No Intervention|Placebo/Control|Self-administered breathing exercises
9924660|NCT00863629|No Intervention|1|25 normoglycemic patients as control group
9924661|NCT00863629|Active Comparator|2|20 hyperglycemic patients (glucose >140 mg/dl) randomized to conventional glycemic control by insulin (CGC group; glucose goal 180-200 mg/dl)
9924662|NCT00863629|Experimental|3|20 hyperglycemic patients (glucose >140 mg/dl) were randomized to intensive glycemic control by insunin (IGC group; glucose goal 80-140 mg/dl)
9924663|NCT00863642|Experimental|Early|In patients who present with mild to moderate gallstone pancreatitis, those randomized to the early arm will undergo laparoscopic cholecystectomy within 48 hours of admission, regardless of laboratory values normalization and resolution of abdominal pain.
9924664|NCT00863642|Other|Control|In patients in the control arm, laparoscopic cholecystectomy is delayed until laboratory values normalize and abdominal pain resolves.
9924665|NCT00863668|Active Comparator|Efavirenz|
9924666|NCT00863668|Experimental|Raltegravir|
9924667|NCT00863759|Active Comparator|1|Patients will receive an aspheric intraocular lenses (IOL) Akreos AO in the right eye and an spheric IOL Akreos Fit in the left eye, during cataract surgery.
9924668|NCT00863759|Active Comparator|2|Patients will receive an spheric intraocular lens (IOL) Akreos Fit in the right eye and an aspheric IOL Akreos AO in the left eye, during cataract surgery.
9924669|NCT00863785|Experimental|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
9924670|NCT00863811||2|POAG patients with IOP under control by prostaglandins eye drops treatment and assuming two tablets per day of the food supplement KRONEK
9924671|NCT00863811||1|POAG patients compensated by the treatment of betablockers eye drops and taking two tablets per day of KRONEK
9924672|NCT00863837|Active Comparator|Arm A|add pantoloc to reduce ulcer bleeding after banding ligation
9924673|NCT00863837|Placebo Comparator|Arm B: ligation + terlipressin 1mg q6h|Arm B, intervention: ligation + terlipressin 1mg q6h
9924674|NCT00863850|Experimental|1|
9924675|NCT00863863|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
9924676|NCT00863863|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
9924677|NCT00863876||1|non-operated healthy eyes
9924678|NCT00863876||2|eyes 1 months following LASIK
10209893|NCT03287583|Other|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
10209894|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
10209895|NCT03253796|Experimental|GLM SC QM (Full Treatment Regimen)|Period 1: participants are treated with open-label (OL) GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded SC GLM QM for up to 12 months
10209896|NCT03253796|Experimental|GLM SC Q2M (Reduced Treatment Regimen)|Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded GLM SC every other month alternating with matching placebo to GLM every other month for up to 12 months
10209897|NCT03253796|Placebo Comparator|Placebo (Treatment Withdrawal Regimen)|Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded placebo for up to 12 months
9795252|NCT01531673|Experimental|Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h|All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
9795253|NCT01531673|Experimental|Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h|All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
9795254|NCT01531673|Placebo Comparator|Group 7: Placebo|All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
9795255|NCT01531673|Experimental|Group 7: VX-661 100 mg qd|All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
9795256|NCT01531725|Experimental|BMS implantation|Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.
9795257|NCT01531738||Control|Normal weight healthy volunteers
9795258|NCT01531738||Bariatric Surgery|obese patients due to undergo gastric bypass or gastric banding
9795259|NCT01531803|Experimental|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g/L human albumin, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin). The duration of treatment is based on the subject's response to treatment until hemodynamic stability is achieved. If hemodynamic stability is not achieved within 72 hours of starting the study treatment, the subject will be withdrawn from the study and will be treated according to standard practice and data collected during the study period will be used for the safety evaluation."
9795260|NCT01531803|Placebo Comparator|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
9795261|NCT01531894|Experimental|GSK2110183 (afuresertib)|All patients received the GSK2110183 (afuresertib) treatment
9795262|NCT01531959|Active Comparator|Midodrine|
9795263|NCT01531959|Placebo Comparator|Placebo|
9795264|NCT01531998|Experimental|Siltuximab + Bortezomib + Lenalidomide|"Induction: Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1.~If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR (minimum of 4 cycles of therapy and a maximum of 8 cycles of therapy) and then transition to maintenance regimen described below.~Maintenance therapy: Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.~Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly."
9795265|NCT01532089|Active Comparator|Arm A (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
9795266|NCT01532089|Experimental|Arm B (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride as in Arm A and bevacizumab IV over 30-90 minutes on day 1. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
9795267|NCT01532128|Experimental|Group 1|Period 1: rasagiline 1 mg Period 2: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 3: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg
9795268|NCT01532128|Experimental|Group 2|Period 1: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 2: rasagiline 1 mg Period 3: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg
9795269|NCT01532128|Experimental|Group 3|Period 1: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 2: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 3: rasagiline 1 mg
9795270|NCT01532141|Experimental|Group 1|Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
9795271|NCT01532141|Experimental|Group 2|Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
9795272|NCT01532141|Experimental|Group 3|Period 1: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone
9795273|NCT01532349|Active Comparator|400 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
9860760|NCT00000874||1|Participants who are failing a regimen of ZDV, 3TC, and IDV
9860761|NCT00000874||2|Participants who are failing a regimen of ZDV, 3TC, and SRQ
9860762|NCT00000874||3|Participants who are failing a regimen of ZDV, 3TC, and RTV
9860763|NCT00000874||4|Participants who are failing a regimen of d4T, 3TC, and IDV
9860764|NCT00000884|Experimental|1|Participants will undergo treatment intramuscularly
9860765|NCT00000884|Experimental|2|Participants will undergo treatment orally
9860766|NCT00000884|Experimental|3|Participants will undergo treatment intranasally
9860767|NCT00000884|Experimental|4|Participants will undergo treatment intrarectally
9860768|NCT00000884|Experimental|5|Participants will undergo treatment intravaginally
9860769|NCT00000884|Experimental|6|Participants will undergo treatment intranasally and intramuscularly
9860770|NCT00000884|Experimental|7|Participants will undergo treatment intrarectally and intramuscularly
9860771|NCT00000928|Experimental|A|All study participants
9860772|NCT00000930||A|HIV-infected individuals enrolled in HIVNET D01
9860773|NCT00000930||B|Individuals with newly acquired HIV infection
9924679|NCT00863876||3|eyes 3-6 months following LASIK
9924680|NCT00863876||4|eyes with spherical monofocal IOLs more than 3 months postop
9924681|NCT00863876||5|eyes with aspherical monofocal IOLs more than 3 months postop
9924682|NCT00863876||6|eyes with toric monofocal IOLs more than 3 months postop
9924683|NCT00863876||7|eyes with diffractive multifocal IOLs more than 3 months postop
9924684|NCT00863876||8|eyes with phakic IOLs more than 3 months postop
9924685|NCT00863876||9|eyes with keratoconus
9924686|NCT00863889|Experimental|1|1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
9924687|NCT00863889|Placebo Comparator|2|4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
9924688|NCT00863902|Experimental|Cetirizine Hydrochloride|Cetirizine Hydrochloride 10 mg tablets, single dose
9924689|NCT00863902|Active Comparator|Zyrtec|Zyrtec® 10 mg tablets, single dose
9924690|NCT00863915|Experimental|A|Ramipril10 mg Capsules, single dose
9924691|NCT00863915|Active Comparator|B|Atlace® 10 mg capsules, single dose
9924692|NCT00863941|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
9924693|NCT00863941|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
9924694|NCT00863954|Active Comparator|Output A|
9924695|NCT00863954|Active Comparator|Output B|
9924696|NCT00863954|Active Comparator|Output C|
9924697|NCT00863954|Active Comparator|Output D|
10209898|NCT03253796|Experimental|OL GLM Retreatment|Participants who experience a disease flare during double-blinded treatment in Period 2 will discontinue blinded treatment and receive OL GLM SC QM.
9924698|NCT00863954|Active Comparator|Output E|
9924699|NCT00863954|Active Comparator|Output F|
9924700|NCT00863967||1|no cardiovascular events
9924701|NCT00863967||2|proven cardiovascular events
9924702|NCT00863967||3|possible cardiovascular events
9924703|NCT00863980|Experimental|Telmisartan|Treatment with Telmisartan
9924704|NCT00863980|Active Comparator|Candesartan|Treatment with Candesartan
9924705|NCT00864006|Experimental|1|Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
9924706|NCT00864006|Active Comparator|2|Depakote 125 MG DR Tablets Abbott Laboratories USA
9924707|NCT00864019|Experimental|A|Sertraline HCl 100 mg tablets, single dose
9924708|NCT00864019|Active Comparator|B|Zoloft® 100 mg tablets, single dose
9924709|NCT00864045|Experimental|Sertindole|
9924710|NCT00864045|Active Comparator|Olanzapine|
9924711|NCT00864058|Experimental|A|Gabapentin 400 mg capsules
9924712|NCT00864058|Active Comparator|B|Neurontin 400 mg capsules
9924713|NCT00864071|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
9924714|NCT00864071|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
9924715|NCT00864110|Experimental|99mTc EC-DG|99mTc-EC-DG with SPECT/CT imaging
9924716|NCT00864110|Active Comparator|18F FDG|18F FDG with PET/CT imaging
9924717|NCT00864136||Group 1|
9924718|NCT00864136||Group 2|
9924719|NCT00864136||Group 3|
9924720|NCT00864149|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
9924721|NCT00864149|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
9924722|NCT00864162|Experimental|A|Ramipril10 mg Capsules, single dose
9924723|NCT00864162|Active Comparator|B|Atlace® 10 mg capsules, single dose
9924724|NCT00864188|Placebo Comparator|1|Glucono-Delta-Lactone acidified milk containing no bacterial strains
9924725|NCT00864188|Experimental|2|Glucono-Delta-Lactone acidified milk containing one probiotic strain called Lactobacillus paracasei NCC2461.
9924726|NCT00864188|Placebo Comparator|3|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii subsp.bulgaricus.
9924727|NCT00864188|Experimental|4|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii and one probiotic strain called Lactobacillus paracasei NCC2461.
9924728|NCT00864188|Experimental|5|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii, one probiotic strain called Lactobacillus paracasei NCC2461 and Vitamin B2,B3, C and E, Beta Carotene and an Oil.
9924729|NCT00864201|Experimental|bosentan|
9924730|NCT00864214|Experimental|1|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
9924731|NCT00864214|Experimental|2|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
9924732|NCT00864214|Experimental|3|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
9924733|NCT00864214|Experimental|4|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
9924734|NCT00864240|Experimental|A|Clobex TM 0.05% Lotion, single exposure
9860774|NCT00000932||A|Participants currently enrolled in or currently being followed in an ongoing qualifying study. Qualifying studies can be found in the protocol.
9860775|NCT00000932||B|Participants previously enrolled in but not currently being followed in a qualifying study. Qualifying studies can be found in the protocol.
9860776|NCT00000932||C|Antiretroviral-naive participants not enrolling in a qualifying study (i.e., patients starting treatment outside the first study or patients deferring treatment)
9860777|NCT00000935|Experimental|Intravenous Immune Globulin (Human)|
9860778|NCT00000935|Placebo Comparator|Intravenous Immune Globulin (Human) Placebo|
9860779|NCT00000936|Experimental|Induction|subjects receiving hOKT3 induction therapy
9860780|NCT00000936|Active Comparator|Induction Free Therapy|Patients not receiving induction therapy
9860781|NCT00000948|Experimental|1|Participants will be broken into 3 groups. Each group will receive ART and escalating doses of aldesleukin. All participants will then receive that maximum tolerated dose of aldesleukin.
9860782|NCT00000948|Active Comparator|2|All participants will receive ART
9860783|NCT00000955|Other|A|All eligible study participants
9924735|NCT00864266|Experimental|1|After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website www.elcwp.org)
9924736|NCT00864279|Experimental|A|Cetirizine Hydrochloride 10 mg tablets, single dose
9924737|NCT00864279|Active Comparator|B|Zyrtec® 10 mg tablets, single dose
9924738|NCT00864292||HIV-infected, no dementia|Patients with HIV-infection but no dementia
9924739|NCT00864292||HIV-infected, dementia|Patients with HIV-infection and dementia
9924740|NCT00864305|Experimental|A|Gabapentin 400 mg capsules
9924741|NCT00864305|Active Comparator|B|Neurontin 400 mg capsules
9924742|NCT00864331|Active Comparator|Radiotherapy|For patients in Group A (Stage IIIA or IIIB), EBRT 39 Gy in 13 daily fractions over, with no chemotherapy.
9924743|NCT00864331|Experimental|Chemotherapy and radiotherapy|For patients in Group A (either stage IIIA or IIIB) receive a course of up to 3 cycles of chemotherapy followed by EBRT of 10 Gy in a single fraction or 16 Gy in 2 fractions 1 week apart.
9924744|NCT00864331|Active Comparator|Chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive up to 3 cycles of chemotherapy, and no radiotherapy.
9924745|NCT00864331|Experimental|Palliative radiotherapy and chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive EBRT of 10 Gy in a single fraction or 16 Gy in two fractions 1 week apart, followed by up to 3 cycles of chemotherapy.
9924746|NCT00864344|Experimental|A|Sertraline HCl 100 mg tablets, single dose
9924747|NCT00864344|Active Comparator|B|Zoloft® 100 mg tablets, single dose
9924748|NCT00864357|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
9924749|NCT00864357|Active Comparator|B|COMBONOX® tablets, single dose
9924750|NCT00864396|Experimental|Prevacid|
9924751|NCT00864409|Active Comparator|Hip 1|high volume local anesthetic infiltration
9924752|NCT00864409|Placebo Comparator|Hip 2|
9924753|NCT00864422|Experimental|1|
10209899|NCT03248258||Metastatic Breast Interview Participants - Shared Decision Making|Metastatic Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
9924754|NCT00864422|Active Comparator|2|
9924755|NCT00864435|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
9924756|NCT00864435|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
10209900|NCT03248258||Early Stage Breast Interview Participants - Shared Decision Making|Early Stage Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
10209901|NCT03248258||Provider Focus Group -Shared Decision Making|Clinic Provider Participants will participate in a focus group on the topic of Shared Decision Making. This will be a one time, focus group interview with a trained moderator.
10209902|NCT03248258||Non-UAB Provider Shared Decision Making|Non-UAB Provider Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
10209903|NCT03248258||Early Stage de-escalation Interview Participants|Early Stage Breast Patient Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
10209904|NCT03248258||Patient Advocate de-escalation Interview Participants|Patient Advocate Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
10213633|NCT03635892|Experimental|Cohort 1: Unclassified, papillary, and HL RCC|Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
9924757|NCT00864448|Experimental|A|Ramipril10 mg Capsules, single dose
9924758|NCT00864448|Active Comparator|B|Atlace® 10 mg capsules, single dose
9924759|NCT00864461||Case|Patients with clinical and cytogenetics diagnosis of Down syndrome, between 7 - 24 years old.
9924760|NCT00864461||Control|Siblings of the same gender of the case, between 7-24 years old.
9924761|NCT00864474||Maraviroc Tablets|Patients administered.
9924762|NCT00864487|Experimental|1|Neratinib alone
9924763|NCT00864487|Experimental|2|Neratinib plus rifampin
9924764|NCT00864500|Experimental|A|Clobetasol Propionate 0.05% lotion, single exposure
9924765|NCT00864500|Active Comparator|B|Clobex TM 0.05% Lotion, single exposure
9924766|NCT00864526|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
9924767|NCT00864526|Active Comparator|B|COMBONOX® tablets, single dose
9924768|NCT00864552||Group 1|
9924769|NCT00864565|Experimental|A|Fentanyl 25 μg/h transdermal system, single application
9924770|NCT00864565|Active Comparator|B|Duragesic 25 μg/h transdermal system single application
9935171|NCT04086485|Experimental|1/Lu-177-DOTATATE + Olaparib escalation|Lu-177-DOTATATE and escalating doses of olaparib to determine the maximum-tolerated dose (MTD)
9935172|NCT04086485|Experimental|2/Lu-177-DOTATATE + Olaparib fixed dose|Lu-177-DOTATATE and olaparib at the MTD
9860784|NCT00001077||1|Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
9860785|NCT00001077||2|Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
9860786|NCT00001077||3|Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
9517076|NCT03309735||3|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
9517077|NCT03309722||early stage|
9517078|NCT03309722||advanced|
9517079|NCT03309709|No Intervention|watch-and-wait patients|patients who receive a watch-and-wait approach
9860787|NCT00001082|Experimental|1|Participants will receive adefovir dipivoxil and L-carnitine
9860788|NCT00001082|Experimental|2|Participants will receive adefovir dipivoxil placebo and L-carnitine.
9860789|NCT00001131|Experimental|A|Patients will recieve a daily, self-administered subcutaneous injection of IL-2 while continuing treatment with their current oral anti-HIV medications
9860790|NCT00001131|Active Comparator|B|Patients will only follow their current oral anti-HIV medication regimen. No additional IL-2 injection will be given.
9924771|NCT00864591||SPECT and stress CMR patients|"patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.~The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.~Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study."
9924772|NCT00864604|Experimental|A|Nabumetone 750 mg tablets, single dose
9924773|NCT00864604|Active Comparator|B|Nabumetone 750 mg tablets, single dose
9924774|NCT00864617|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
9924775|NCT00864617|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
9924776|NCT00864630|No Intervention|Wait list|
9924777|NCT00864630|Experimental|Computer-based problem solving therapy|
9924778|NCT00864643|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin QD|
9924779|NCT00864643|Active Comparator|Atorvastatin QD|
9924780|NCT00864656||1|Patients submitted to application of 1 drop of 10% phenylephrine
9924781|NCT00864656||2|Patients submitted to application of 2 drops of 10% phenylephrine
9924782|NCT00864656||3|Patients submitted to application of 4 drops of 10% phenylephrine
9924783|NCT00864669|Experimental|A|Metformin HCl 500 mg tablets, single dose
9924784|NCT00864669|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
9517080|NCT03309709|Experimental|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
9924785|NCT00864695||Surgical patients|Individuals who were hospitalized in the Botucatu Medical School Hospital to undergo surgery under anesthesia administered by the Anesthesiology Service of BMS Department of Anesthesiology.
9924786|NCT00864734|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
9924787|NCT00864734|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
9924788|NCT00864747|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
9924789|NCT00864747|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
9924790|NCT00864760|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
9924791|NCT00864760|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
9924792|NCT00864786|Experimental|Cohort 1|200 mcg
9924793|NCT00864786|Experimental|Cohort 2|600 mcg
9924794|NCT00864786|Experimental|Cohort 3|1000 mcg
9924795|NCT00864786|Experimental|Cohort 4|Dose to be decided
9924796|NCT00864786|Experimental|Cohort 5|Dose to be decided
9924797|NCT00864799|Active Comparator|Vaginal misoprostol|"Women allocated to the vaginal misoprostol management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 4 hours by 400 mcg vaginal misoprostol, the latter repeated every 4 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
9924798|NCT00864799|Active Comparator|Oral misoprostol|"Women allocated to the standard management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg misoprostol orally, the latter repeated every 3-hours to a maximum of 4 oral doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
9860791|NCT00001214||Group 1|Patients with pancytopenia
9860792|NCT00001219||Patients undergoing MRI in the Clinical Center|All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.
9860793|NCT00001259|Experimental|Group 1|Group I will receive 0.1 mg/day of estradiol via skin patch (Estraderm) for a period of five weeks. During the fifth week, progesterone suppositories (200 mgs twice daily) will be added
9860794|NCT00001259|Experimental|Group II|progesterone suppositories (200 mg BID) will be administered for the first five weeks, followed by a two week washout, and then estradiol 0.1 mg /day for five weeks, with the addition of progesterone during the fifth week of estrogen treatment.
9860795|NCT00001259|Experimental|Leuprolide|3.75 mg of Leuprolide via intramuscular injection on a monthly basis in our clinic for a maximum of twenty-four weeks
9924799|NCT00864799|Active Comparator|Sublingual misoprostol|"Women allocated to the sublingual misoprostol protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg sublingual misoprostol, the latter repeated every 3 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
9924800|NCT00864812|Experimental|1|tiotropium with fluticasone propionate/salmeterol (FSC)
9924801|NCT00864812|Active Comparator|2|tiotropium
9924802|NCT00864825|Experimental|Allopurinol|
9924803|NCT00864825|Placebo Comparator|Placebo|
9924804|NCT00864838|No Intervention|1|Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
9924805|NCT00864838|Experimental|2|Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
9924806|NCT00864838|Experimental|3|topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
9924807|NCT00864838|Experimental|4|anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
9924808|NCT00864864|Experimental|Sunitinib|
9924809|NCT00864890|Experimental|A|Citalopram HBr 40 mg tablets, single dose
9924810|NCT00864890|Active Comparator|B|CelexaTM 40 mg tablets, single dose
9924811|NCT00864903||pediatric ER|any child undergoing a spinal tap due to suspected meningitis
9517081|NCT03309683|Experimental|Clip group|Olympus Quick Clip Pro - Single Use Repositionable Clips will be used for Prophylactic clipping after EMR
9924812|NCT00864929||1|Appropriate antimicrobial treatment
9924813|NCT00864929||2|Inappropriate antimicrobial treatment
9924814|NCT00864942|Experimental|BL-NHL|Bendamustine and lenalidomide for NHL
9924815|NCT00864942|Experimental|BLR-CLL|Bendamustine, lenalidomide, rituximab for CLL
9924816|NCT00864942|Experimental|BLR-NHL|Bendamustine, lenalidomide, and rituximab for NHL
9924817|NCT00864942|Experimental|BL-CLL|bendamustine and lenalidomide in patients with CLL
9924818|NCT00864955|Experimental|phototype 2|Volunteers with cutaneous phototype 2
9924819|NCT00864955|Experimental|phototype 4|Volunteers with cutaneous phototype 4
9924820|NCT00864968|Experimental|A|Nabumetone 750 mg tablets, single dose
9924821|NCT00864968|Active Comparator|B|Nabumetone 750 mg tablets, single dose
9924822|NCT00864981|Experimental|1|Bupropion HCI ER Tablets, 150 mg
9924823|NCT00864981|Active Comparator|2|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
9924824|NCT00864994||1|• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
9924825|NCT00864994||2|• 30 COPD patients with GOLD stage II (age 40-75 years)
9924826|NCT00865007|Experimental|Monotherapy group|Lopinavir/ritonavir (LPV/r).
9924827|NCT00865007|Active Comparator|Triple arm|Lopinavir/ritonavir (LPV/r)+ ABC/3TC
9924828|NCT00865033|Experimental|1|Metformin HCL Tablets, 1000 mg
9924829|NCT00865033|Active Comparator|2|Glucophage 1000 mg Tablets
9924830|NCT00865059|Experimental|A|Gabapentin 800 mg Tablets, single dose
9924831|NCT00865059|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
9924832|NCT00865072|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
9924833|NCT00865072|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
9924834|NCT00865085|Experimental|A|Citalopram HBr 40 mg tablets, single dose
9924835|NCT00865085|Active Comparator|B|CelexaTM 40 mg tablets, single dose
9924836|NCT00865111|Experimental|A|Bupropion 150 mg Extended-Released Tablet, single dose
9924837|NCT00865111|Active Comparator|B|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
9924838|NCT00865137|Experimental|1 FK506E|
9795274|NCT01532349|Active Comparator|4000 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 4000 IU/day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
9795275|NCT01532388|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use.
9795276|NCT01532388|No Intervention|Control group|Untreated control group
9795277|NCT01532414|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
9795278|NCT01532414|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
9795279|NCT01532414|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
9795280|NCT01532453|Active Comparator|Standard Sun Protection Measures|Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
9795281|NCT01532453|Experimental|MD-3511356|Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
9795282|NCT01532570|Experimental|TA-650|
9795283|NCT01532648|Experimental|Budesonide MMX|Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
9795284|NCT01532648|Placebo Comparator|Placebo|Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
9795285|NCT01532687|Experimental|Arm I (gemcitabine hydrochloride and pazopanib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9795286|NCT01532687|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9795287|NCT01532700|Experimental|Ofatumumab with GSK2110183|
9795288|NCT01532817|Experimental|alphacore|noninvasive neurostimulation of the vagus nerve
9795289|NCT01532830|Experimental|Active|n-VNS active therapy
9795290|NCT01532869|Placebo Comparator|Placebo|
9795291|NCT01532869|Experimental|Tocilizumab|
9795292|NCT01532908|Experimental|Part 1: MBL-HCV1 and Telaprevir|
9795293|NCT01532908|Experimental|Part 2: MBL-HCV1 and Sofosbuvir|
9795294|NCT01532921||Subjects with Tricuspid Valve Repair|All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
9795295|NCT01532934|Experimental|brief therapy|motivational enhancement therapy for substance use
9795296|NCT01532934|Placebo Comparator|Standard Care|standard care
9795297|NCT01532973|Experimental|GT1 HCV 10-mg Elbasvir (Panel A)|Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
9795298|NCT01532973|Experimental|GTI HCV 50-g Elbasvir (Panel B)|Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
9795299|NCT01532973|Experimental|GT1 HCV 5-mg Elbavir (Panel C)|Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
9795300|NCT01532973|Experimental|GT1 HCV 200-mg Elbasvir (Panel D)|Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
9795301|NCT01532973|Experimental|GT3 HCV 10-mg Elbasvir (Panel E)|Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
9795302|NCT01532973|Experimental|GT3 HCV 50-mg Elbasvir (Panel F)|Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
9795303|NCT01532973|Experimental|GT3 HCV 100-mg Elbasvir (Panel G)|Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
9795304|NCT01532973|Experimental|GT3 HCV 200-mg Elbasvir (Panel H)|Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
9795305|NCT01532973|Experimental|GT1a HCV 10-mg Elbasvir (Panel I)|Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
9795306|NCT01532973|Experimental|GT1a HCV 50-mg Elbasvir (Panel J)|Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
9795307|NCT01532986|Other|Usual Care (Arm 1)|"Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
10209905|NCT03248258||Physician de-escalation Interview Participants|Physician Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
9517082|NCT03309683|No Intervention|Control group|Standard treatment after EMR (as described in the detailed study description above)
10209906|NCT03248258||Early Stage Feedback Interview Participants|Early Stage Breast Patient Participants will be interviewed to provide feedback on a decision making tool (video). This will be a one time, one-on-one interview with a trained interviewer.
10209907|NCT03244696|Experimental|Step Tracking|Participants will track their physical activity in steps using an accelerometer for a period of 6 months. Participants will monitor their overall step-count using the accelerometer, and daily and weekly summaries of their progress provided by the experimenters.
9795308|NCT01532986|Experimental|Intervention (Arm 2)|"A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's Disease (PD) by collaborating with these Veterans and their families, providers, and community partners.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
9795309|NCT01532999|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
9795310|NCT01532999|Sham Comparator|Present Centered Group Therapy|Present Centered Group Therapy (PCGT) serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
9795311|NCT01533038|Active Comparator|UroLift System|UroLift System procedure
9795312|NCT01533038|Active Comparator|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate surgery
9795313|NCT01533077|Experimental|Group 1|Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
9795314|NCT01533077|Experimental|Group 2|Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
9795315|NCT01533077|Experimental|Group 3|Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
9795316|NCT01533077|Experimental|Group 4|Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
9795317|NCT01533116|Experimental|5 mg BIA 9-1067|5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
9795318|NCT01533116|Experimental|Placebo|Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
9795319|NCT01533116|Experimental|15 mg BIA 9-1067|15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
9795320|NCT01533116|Experimental|30 mg BIA 9-1067|30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
9795321|NCT01533181|Experimental|Arm I: OS-906 (linsitinib)|OS-906 daily, continuously, every 3 weeks.
9795322|NCT01533181|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes or PO QD on days 1-5. Patients may crossover to Arm I at the time of progressive disease.
9795323|NCT01533207|Experimental|Arm I (chemotherapy)|Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
9795324|NCT01533207|Other|Arm II (no treatment)|Patients undergo clinical observation.
9795325|NCT01533246|Experimental|Treatment (linsitinib)|Patients receive linsitinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo serum and plasma sample collection at baseline, on day 1 of courses 2 and 4, and after completion of study treatment for correlative studies.
9795326|NCT01533259|Experimental|Stribild|Participants will switch to Stribild for 48 weeks.
9795327|NCT01533428|Experimental|Capsaicin 8%|Capsaicin 8% patch was applied for 30 minutes to the painful area(s) on Day 1
9795328|NCT01533428|Placebo Comparator|Placebo|Placebo patch was applied for 30 minutes to the painful area(s) on Day 1
9795329|NCT01533493|Placebo Comparator|Placebo|Subjects randomized to receive memantine-matched placebo in addition to open-label OROS-Methylphenidate
9795330|NCT01533493|Active Comparator|Memantine|Subjects randomized to receive memantine in addition to open-label OROS-Methylphenidate
9795331|NCT01533597|Active Comparator|Solifenacin|
9795332|NCT01533597|Experimental|Solifenacin plus Tamsulosin|
9795333|NCT01533688|Active Comparator|Golytely + placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely)+ placebo pill
9795334|NCT01533688|Placebo Comparator|Golytely Split + placebo|split dose(2 L day before procedure and 2 L day of procedure) of 4 liters of Golytely + placebo pill
9795335|NCT01533688|Experimental|Golytely Split + Bisacodyl|split dose (2 L day prior to procedure and 2 L day of procedure) of 4 liters of Golytely + bisacodyl 10 mg
9795336|NCT01533922|Experimental|Tiotropium + olodaterol High dose QD|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
9795337|NCT01533922|Experimental|Tiotropium + olodaterol Low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
9924839|NCT00865176|Experimental|1|Eplerenone 50mg Tablets
9996947|NCT01504555||Patients under investigation for hypercortisolism|Patients undergoing routine evaluation for hypercortisolism at Haukeland University Hospital, Bergen, Norway, will be asked to participate.
9795338|NCT01533922|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
9795339|NCT01533922|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
9517083|NCT03309670||Formers young patients|all patients hospitalized between 2006 and 2010 in the Pass'Aje unit
9517084|NCT03309644||Peripheral nerve block|Peripheral nerve block
9795340|NCT01533922|Placebo Comparator|Placebo QD|
9795341|NCT01533935|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
9795342|NCT01533935|Placebo Comparator|Placebo QD|placebo comparator for tiotropium + olodaterol
9795343|NCT01533935|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
9795344|NCT01533935|Experimental|Tiotropium + olodaterol low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily
9795345|NCT01533935|Experimental|Tiotropium + olodaterol high dose|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily
9795346|NCT01533948|Experimental|Treatment (axitinib)|Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9795347|NCT01533974|Experimental|ACT|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
9795348|NCT01533974|Active Comparator|CBT|
9795349|NCT01534013|Experimental|Closed-loop insulin delivery|The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
9795350|NCT01534013|Active Comparator|Open-loop (Control visit)|Subcutaneous glucose monitor and pump will be applied to participants with type 1 diabetes
9795351|NCT01534052|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
9795352|NCT01534078|Experimental|Treatment Arm|Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine
9795353|NCT01534182|Experimental|Fingolimod|Participants received 0.5 mg orally once a day.
9795354|NCT01534182|Active Comparator|Standard Disease Modifying Therapy (DMT)|Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
9795355|NCT01534195|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
9795356|NCT01534195|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
9795357|NCT01534208|Experimental|Androxal 12.5 mg|Androxal 12.5 mg daily
9795358|NCT01534208|Experimental|Androxal 25 mg|Androxal 25 mg daily
9795359|NCT01534260|Experimental|sorafenib, vorinostat and bortezomib|Escalating cohorts of sorafenib, vorinostat and bortezomib
9795360|NCT01534273|Placebo Comparator|Placebo|Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days
9795361|NCT01534273|Experimental|35 mg LY2886721|QD oral dosing for 14 consecutive days
9795362|NCT01534273|Experimental|70 mg LY2886721|Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days
9795363|NCT01534273|Experimental|140 mg LY2886721|Single oral dose
9795364|NCT01534351|Experimental|Finasteride|Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
9795365|NCT01534351|Active Comparator|Tamsulosin|Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
9795366|NCT01534351|Experimental|Finasteride and Tamsulosin|Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
9795367|NCT01534416|Experimental|Bupivacaine|Subjects receive paracervical block with bupivacaine-epinephrine
9795368|NCT01534416|Placebo Comparator|Saline|Subjects receive paracervical injection of normal saline
9795369|NCT01534520|Experimental|Group 1: Intravaginal 2% lidocaine gel|Intravaginal insertion of 4mL of 2% lidocaine gel
9795370|NCT01534520|Placebo Comparator|Group 2: Intravaginal placebo gel|Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
9795371|NCT01534533|Placebo Comparator|Placebo|early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
9795372|NCT01534533|Experimental|Lutein group|early atherosclerosis cases, received 20mg lutein, once a day
9795373|NCT01534533|Experimental|Combination group|early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
9795374|NCT01534533|Experimental|Normal lutein control group|20mg lutein for subjects free from atherosclerosis, once a day
9860796|NCT00001397||1|treated according to the guidelines of standard medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
9924840|NCT00865176|Active Comparator|2|INSPRA 50mg Tablets
9935173|NCT04085276|Experimental|JS001 Plus Nab-Paclitaxel|Patients will receive both JS001 and Nab-Paclitaxel.
9935174|NCT04085276|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Patients will receive both placebo and Nab-Paclitaxel.
9935175|NCT04083885|Experimental|Virtual Reality|Participants receive 8 weeks of home-based or facility-based virtual reality training, supervised remotely and asynchronously, in addition to their Extra-Mural (homecare) rehabilitation.
9935176|NCT04083885|No Intervention|Usual Care|Participants receive their usual Extra-Mural (homecare) rehabilitation or usual activities.
9935177|NCT04079452|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) coformulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 4 weeks
9935178|NCT04074629|Experimental|Skin related VOCs collected by Polydimethylsiloxane patch|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\or GC-MS analysis"
9935179|NCT04074135|Experimental|1/ Arm 1|Study natural history of VHL pancreatic neuroendocrine tumors with yearly 68-Gallium DOTATATE PET/CT research scans.
9935180|NCT04074135|No Intervention|2/ Arm 2|Study natural history of VHL pancreatic neuroendocrine tumors without research scans.
9935181|NCT04072575|Experimental|Paliperidone Palmitate 6 month(PP6M)|"Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level (moderate or higher) that the participant received during previous study. Participants in the moderate dose level will receive PP6M Dose 1 and higher dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months."
9935182|NCT04071223|Experimental|Arm A (radium Ra 223 dichloride, cabozantinib s-malate)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1 of cycles 1-6 and cabozantinib S-malate PO QD on days 1-28 of every cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9935183|NCT04071223|Active Comparator|Arm B (cabozantinib s-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9935184|NCT04068311|No Intervention|Pre Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
9935185|NCT04068311|Active Comparator|Post Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
9935186|NCT04066218||age 15-19|The investigators plan to complete 24 interviews with 12 in the age 15-19 cohort.The investigators will also ensure that at least 8 people from each sex are included in this study.
9935187|NCT04066218||age 20-24|The investigators plan to complete 24 interviews with 12 in the age 20-24 cohort. The investigators will also ensure that at least 8 people from each sex are included in this study.
10209908|NCT03244696|Active Comparator|Water Tracking|Participants will track their water-intake using a smart water bottle for a period of 6 months. Participants will monitor their overall water consumption using a smart water bottle, and daily and weekly summaries of their progress provided by the experimenters.
10209909|NCT03231150|Active Comparator|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
9935188|NCT04065841|Experimental|Arm A: combination therapy|tropifexor + licogliflozin
9935189|NCT04065841|Experimental|Arm B: tropifexor monotherapy|tropifexor (+ licogliflozin placebo)
9935190|NCT04065841|Experimental|Arm C: licogliflozin monotherapy|licogliflozin (+ tropifexor placebo)
9935191|NCT04065841|Placebo Comparator|Arm D: Placebo|licogliflozin placebo + tropifexor placebo
9935192|NCT04063709|Experimental|Symptomatic with 50-69% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
9935193|NCT04063709|Experimental|Symptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
9935194|NCT04063709|Experimental|Asymptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
9935195|NCT04063709|Experimental|Asymptomatic with 50-69% stenosis|Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
9935196|NCT04054752|Experimental|1/Arm 1|NT-I7 administered at 720 and 960g/kg to select the OBD of NT-I7
9996948|NCT01504568|Other|Prophylactic Antibotics|Amoxicillin/clavulanic acid
10213634|NCT03635892|Experimental|Cohort 2: Chromophobe RCC|Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
9860797|NCT00001458||Cardiovascular|subjects with cardiovascular symptoms or known disease.
9860798|NCT00001464||Group 1|Smokers exposed to oxygen
9860799|NCT00001469||Specimens|Specimens
9924841|NCT00865215|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
9924842|NCT00865215|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
9924843|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (morning)|
9924844|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (evening)|
9924845|NCT00865228|Experimental|Lapaquistat Acetate 50 mg BID|
9924846|NCT00865228|Placebo Comparator|Placebo BID|
9924847|NCT00865241|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
9924848|NCT00865241|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
9924849|NCT00865254|Experimental|Traditional Contingency Management|Standard treatment plus prize based contingency management.
9924850|NCT00865254|Experimental|Early Enhanced Contingency Management|Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
9924851|NCT00865254|Active Comparator|Standard Treatment|Counseling and monitoring of smoking cessation.
9924852|NCT00865267|Experimental|A|Ultravate® 0.05% ointment, single exposure
9924853|NCT00865293||Obesity|Subjects with obesity, defined as BMI > 30, aged 25-60
9924854|NCT00865293||Control|Subjects with a BMI 18,5-25, aged 25-60
9924855|NCT00865319|Experimental|99 m Tc-EC-DG|99m Tc-Ec-DG injection followed by SPECT/CT imaging (range 20-30 mCi) 1mg EC-DG
9924856|NCT00865319|Active Comparator|18F-FDG|18 F FDG injection followed by PET/CT imaging
9924857|NCT00865358|Experimental|Yoga Group|A standardized hatha yoga protocol delivered in 12 weekly classes.
9924858|NCT00865358|No Intervention|Usual care|Participants continue to receive their usual medical care for their back pain
9924859|NCT00865371|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
9924860|NCT00865371|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
9924861|NCT00865384|Experimental|A|Mirtazapine 15 mg tablets, single dose
9924862|NCT00865384|Active Comparator|B|REMERON® 15 mg tablets, single dose
9924863|NCT00865397||A|
9924864|NCT00865410|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
9924865|NCT00865410|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
9924866|NCT00865423|Experimental|A|Gabapentin 800 mg Tablets, single dose
9924867|NCT00865423|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
9924868|NCT00865436|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
9924869|NCT00865436|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
9924870|NCT00865449|Active Comparator|1|Peritoneal Dialysis patients on aldactone for 6 months
9924871|NCT00865449|Placebo Comparator|2|Peritoneal dialysis Patients on the placebo arm for 6 months
9924872|NCT00865462|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
9924873|NCT00865462|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
9924874|NCT00865475|No Intervention|TZV (Trizivir)|Keeping on TZV in patients with viral suppression
9924875|NCT00865475|Experimental|2|Switching to LPV/r monotherapy
9924876|NCT00865488|No Intervention|1|patients who will be treated in accordance with standard of care
9924877|NCT00865488|Experimental|2|patients for which Adhexil will be applied to prevent/reduce adhesions
9924878|NCT00865501|Experimental|1|spironolactone
9924879|NCT00865501|Placebo Comparator|2|placebo
9924880|NCT00865527|Active Comparator|Fecal Occult Blood Test|fecal occult blood test
9924881|NCT00865527|Active Comparator|Virtual Colonoscopy|virtual colonoscopy
9924882|NCT00865527|Active Comparator|Optical Colonoscopy|optical (conventional / endoscopic) colonoscopy
9924883|NCT00865540|Experimental|prednisolone acetate 1%|one drop every 8h two days before surgery
9924884|NCT00865540|Experimental|ketorolac tromethamine 0.4%|one drop every 8h two days before surgery
9924885|NCT00865540|Experimental|nepafenac 0.1%|one drop every 8h two days before surgery
9924886|NCT00865540|Placebo Comparator|placebo|one drop every 8h two days before surgery
9924887|NCT00865579|Experimental|1|All subjects to receive first 50mg/d Safinamide with an increase of target dose of 100mg/d after 14 days of taper period until end of treatment visit. In case of any intolerance the daily dose of 100mg might be decreased to 50mg/d. Patients permanently discontinuing treatment will enter a 7day taper phase before treatment discontinuation at a dose of 50mg/day. Subjects already taking 50mg/d may stop Safinamide immediately.
9924888|NCT00865605|Experimental|A|Halobetasol Propionate 0.05% Ointment, single exposure
9860800|NCT00001621||1|Pulmonary Patients
9860801|NCT00001626|Experimental|A|D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months
9860802|NCT00001626|Experimental|B|ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months
9860803|NCT00001627||Group 1|Normal Volunteers and patients.
9860804|NCT00001651|Experimental|HIV-infected subjects|HIV-infected adults
9860805|NCT00001651|Experimental|HIV-negative subjects|HIV-negative adults
9860806|NCT00001686||Cohort A|Children and adults with cancer (or a pre-cancer syndrome or rare disease), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
9924889|NCT00865605|Active Comparator|B|Ultravate® 0.05% ointment, single exposure
9924890|NCT00865618|Experimental|1|Eplerenone 50mg Tablets
9924891|NCT00865618|Active Comparator|2|INSPRA 50mg Tablets
10209910|NCT03231150|Experimental|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
10209911|NCT03229863|Experimental|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
10209912|NCT03229863|Experimental|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
9924892|NCT00865631|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
9924893|NCT00865631|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
9924894|NCT00865644|Experimental|Imiquimod|
9924895|NCT00865657|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
9924896|NCT00865657|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
9924897|NCT00865670|Experimental|1|Azithromycin Monohydrate 600mg Tablets
9924898|NCT00865670|Active Comparator|2|Zithromax (azithromycin dihydrate)600mg Tablets
9924899|NCT00865683|Active Comparator|1|Participants will receive DHA supplements.
9924900|NCT00865683|Placebo Comparator|2|Participants will receive placebo capsules of corn oil.
9924901|NCT00865696|Experimental|A|Mirtazapine 15 mg tablets, single dose
9924902|NCT00865696|Active Comparator|B|REMERON® 15 mg tablets, single dose
9924903|NCT00865722|Active Comparator|RemotePostConditioning|Patients will receive pPCI and treatments according to guidelines for STEMI PLUS extrinsic cuff compression to the lower limb for 5 ' followed by 5' reperfusion for three cycles (30' in total) starting with myocardial reperfusion
9924904|NCT00865722|Sham Comparator|Controls|pPCI and treatments according to guidelines for STEMI
9924905|NCT00865748|Experimental|A|Metformin HCl 500 mg tablets, single dose
9924906|NCT00865748|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
9924907|NCT00865761|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
9924908|NCT00865761|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
9924909|NCT00865774|Experimental|1|Arm number 1 focuses on the traditional quantity frequency model.
9924910|NCT00865774|Experimental|2|Arm number 2 targets subjective drunkenness.
9924911|NCT00865787||Olive Oil A|
10209913|NCT03205423|Placebo Comparator|Gabapentin 0 mg|once daily at 8am
10209914|NCT03205423|Active Comparator|Gabapentin 1800 mg|once daily at 8am
10209915|NCT03187379|Experimental|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
10209916|NCT03187379|Active Comparator|Control|Subjects in this arm will receive 0.25% bupivacaine alone
10209917|NCT03181971|Experimental|Water Access and Promotion|Intervention group will receive installation of water stations in high traffic areas, schoolwide promotion, and 4th graders will receive a curricula focused on increasing intake of water.
10209918|NCT03181971|No Intervention|Control|Usual care.
9924912|NCT00865787||Olive Oil B|
9924913|NCT00865813|Experimental|Punch Biopsy|
9924914|NCT00865826||1|HIV-infected males and females who are not currently receiving ART
9924915|NCT00865839|Experimental|A|Metformin HCl 500 mg tablets, single dose
9924916|NCT00865839|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
9924917|NCT00865852|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
9924918|NCT00865852|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
9924919|NCT00865865|Other|1|Conventional total knee arthroplasty
9924920|NCT00865865|Active Comparator|2|Computer aided total knee arthroplasty
9924921|NCT00865878|Active Comparator|1|Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
9924922|NCT00865878|Placebo Comparator|2|Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
9924923|NCT00865891|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
9924924|NCT00865891|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
9924925|NCT00865917|Active Comparator|1|beta-blocker
9924926|NCT00865917|Experimental|2|I(f)-blocker
9924927|NCT00865917|Placebo Comparator|3|Placebo
10209919|NCT03163992|Experimental|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
9860807|NCT00001788||1|patients with primary immunodeficiency disorders
9860808|NCT00001806|Experimental|Group|Group education and counseling
9860809|NCT00001806|Active Comparator|Individual|Individual education and counseling
9924928|NCT00865943|Experimental|A|Citalopram HBr eq. 10 mg tablets, single dose
9924929|NCT00865943|Active Comparator|B|CELEXATM 10 mg tablets, single dose
9924930|NCT00865956|Experimental|Care Management|Care Management plus voucher incentives for adherence to primary care appointments.
9924931|NCT00865956|No Intervention|Usual care|Usual care
9924932|NCT00865995||1|patients undergoing elective procedures with intubation and no known respiratory pathology
9924933|NCT00865995||2|patients with tracheostomy
9924934|NCT00865995||3|patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy
9924935|NCT00866008|Experimental|1|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
9924936|NCT00866008|Experimental|2|Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
9924937|NCT00866021|Experimental|1|Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
9924938|NCT00866021|Active Comparator|2|Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
9924939|NCT00866060|Active Comparator|1|"10mg donepezil plus 20mg memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards"
9924940|NCT00866060|Placebo Comparator|2|"Placebo donepezil plus 20mg memantine~Participants in this arm will immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards. Donepezil dose will be reduced to 5mg daily in weeks 1 to 4 and replaced with placebo donepezil in week 5."
9924941|NCT00866060|Placebo Comparator|3|"10mg donepezil plus placebo memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence placebo memantine."
9924942|NCT00866060|Placebo Comparator|4|"Placebo donepezil plus placebo memantine~Participants in this arm will immediately commence placebo memantine dose escalation and will switch to donepezil 5mg daily in weeks 1 to 4, and replaced with placebo donepezil in week 5."
9924943|NCT00866073|Experimental|A|Decitabine 15 mg/m2 i.v. - single arm
9924944|NCT00866099|No Intervention|"Normal Care"|Primary care practices randomly allocated will be given a summary of the NICE/SCIE dementia guidelines (2006) and offered workshop training and software at the end of the study.
9924945|NCT00866099|Experimental|Training|Practices randomly allocated to the intervention arm will be asked to participate in tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
9924946|NCT00866112|Experimental|1|Intervention group to promote physical activity
9924947|NCT00866112|Other|2|Minimal contact control group
9924948|NCT00866138|Experimental|1|masitinib (AB1010)
9924949|NCT00866151||1|"Previously enrolled subjects in the Benefits and Risks of Alternative Weight Loss Strategies - a Clinical Trial, which was run at Stanford 2003-2005. (A to Z Study)"
9924950|NCT00866190|Experimental|Cohort 1|SQ109 dose 75 mg or placebo once daily for 14 days.
9924951|NCT00866190|Experimental|Cohort 3|SQ109 dose 150 mg or placebo once daily for 14 days.
9924952|NCT00866190|Experimental|Cohort 2|SQ109 dose 150 mg or placebo once daily on Days 1-5, 9, and 14.
9924953|NCT00866203|Experimental|HDS|modified high dose sequential therapy
9924954|NCT00866203|Active Comparator|ProMECE/CytaBOM|four additional courses of standard ProMECE/CytaBOM
9924955|NCT00866216|Experimental|1|Azithromycin Monohydrate 600mg Tablets
9924956|NCT00866216|Active Comparator|2|Zithromax (Azithromycin Dihydrate) 600mg Tablets
10209920|NCT03150914|Placebo Comparator|Placebo|Overencapsulated matrix
10209921|NCT03150914|Active Comparator|Treatment|Over-encapsulated 1 mg sirolimus tablet
9924957|NCT00866268|Experimental|Low suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter.
9924958|NCT00866268|Active Comparator|High suction drainage|The standard DRENOFAST® system was used in the control group, and the initial negative pressure was 700 mmHg.
9924959|NCT00866346|Experimental|PR1-CTL|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
9924960|NCT00866398||1 DES|Patients receiving drug-eluting stent
9924961|NCT00866398||2 BMS|Patients receiving bare metal stent
9924962|NCT00866424|Experimental|A,2, II|
9924963|NCT00866437|Experimental|Healthy Control group|
9924964|NCT00866437|Experimental|PMS|
9924965|NCT00866450|Active Comparator|Western style diet|high-fat, low-calcium diet
9924966|NCT00866450|Active Comparator|Prudent diet|low-fat, calcium-sufficient diet
9924967|NCT00866463|Active Comparator|Conventional Oral Tablet With Water|
9924968|NCT00866463|Experimental|Experimental Tablet With Water|
10209922|NCT03148795|Experimental|Talazoparib|Talazoparib 1 mg daily
10209923|NCT03143842|Other|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
10209924|NCT03111290|Sham Comparator|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
9860810|NCT00001964|Experimental|single arm|ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months
9860811|NCT00001964|Experimental|single arm 2|ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF
9860812|NCT00001978||Study Cohort|Selected patients with proteinuria
9860813|NCT00001981||Patients with acromegaly|Patients with acromegaly
9924969|NCT00866463|Experimental|Experimental Tablet Without Water|
9924970|NCT00866489|No Intervention|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
9924971|NCT00866489|Experimental|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
10209925|NCT03111290|Active Comparator|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
9924972|NCT00866502|Experimental|sNN0031|Continuous ICV infusion for two weeks at one of three dose levels
9924973|NCT00866502|Placebo Comparator|Placebo|Continuous ICV infusion
9517085|NCT03309644||No peripheral nerve block|No peripheral nerve block
9924974|NCT00866515|Experimental|Active|Ketoconazole 400mg OD days 1-6
9924975|NCT00866515|Placebo Comparator|Placebo|Placebo OD for 1 to 6 days
9924976|NCT00866528|Experimental|Phase I|oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
9924977|NCT00866541|Experimental|volunteers|artificial increased respiratory resistance
9924978|NCT00866554|Active Comparator|LHRH agonist|Administration of a 3-month treatment with an LHRH agonist (chosen by the treating radiation oncologist) and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
9924979|NCT00866554|Experimental|Dutasteride, Bicalutamide, Tamoxifen|"Administration of Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
9924980|NCT00866567||1|Premature infants of less than 28 weeks of gestational age
9924981|NCT00866567||2|Premature infants of more than 28 weeks and less than 32 weeks of gestational age
9924982|NCT00866567||3|Term newborns
9924983|NCT00866567||4|Adults
9924984|NCT00866580|Experimental|Group A|
9924985|NCT00866580|Experimental|Group B|
9924986|NCT00866593|Experimental|1|Generic Escitalopram Oxalate Tablets
9924987|NCT00866593|Active Comparator|2|Innovator Escitalopram(Lexapro®)
9924988|NCT00866632|Experimental|Group Cognitive Behavioural Therapy|
9924989|NCT00866632|Experimental|Telephone Cognitive Behavioural Therapy|
9924990|NCT00866632|No Intervention|Group Education|
9924991|NCT00866632|No Intervention|Telephone Education|
9924992|NCT00866645|Experimental|1|Intramuscular Levosulpiride
9924993|NCT00866645|Active Comparator|2|Intramuscular Haloperidol
9924994|NCT00866671||Nelarabine|nelarabine 650mg/m2 IV daily for 5 days. repeat every 21 days.
9924995|NCT00866684|Experimental|1|Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
9924996|NCT00866684|Active Comparator|2|Patients will stay on their previous immunosuppressive regimen.
9924997|NCT00866736|Experimental|dasatinib|
9924998|NCT00866762|Experimental|1|Treatment with study drug approximately 6 months and follow-up for 3 months
10209926|NCT03098485|Experimental|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
10209927|NCT03098485|Experimental|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
10209928|NCT03098485|Experimental|Cefpodoxime|200mg tab by mouth twice per day for 5 days
10209929|NCT03098485|Experimental|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
10209930|NCT03086486|Experimental|1200mg L x 26 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
10209931|NCT03086486|Experimental|1200 mg L x 9 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
10213635|NCT03635892|Experimental|Cohort 3: Unclassified, papillary, and HL RCC|Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
10213636|NCT03635892|Experimental|Cohort 4: Unclassified, papillary, and HL RCC|Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
9860814|NCT00002463|Experimental|Combination Chemotherapy|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
9860815|NCT00002484|Experimental|external beam radiotherapy|Patients undergo 3-dimensional conformal external beam radiotherapy 5 days a week for 8-10 weeks.
9860816|NCT00002485||Stratum 1|Not Enrolled / No IRB Applied
9860817|NCT00002485||Stratum 2|Not Enrolled / IRB Approved
10209932|NCT03086486|Experimental|600 mg L x 26 weeks + Pa + B|"1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
9860818|NCT00002494|Experimental|Combination therapy|Patients receive combination therapy as described in the study description. All patients must complete at least the first 3 courses of chemotherapy. Courses 2 and 3 each repeat 3 times in the absence of disease progression or unacceptable toxicity. On days 134-139, patients who have had prior bone marrow involvement receive cranial radiation therapy. Patients who achieve less than a complete response and who have an HLA-matched sibling should undergo allogeneic bone marrow transplant on protocol CLB-9113. Patients are followed monthly for 6 months, every 2 months for 18 months, every 6 months for 2 years, and thereafter for survival.
9860819|NCT00002495|Experimental|Nodal RT|subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
9860820|NCT00002495|Experimental|Chemotherapy + Nodal RT|3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m^2 on days 1 and 15, vinblastine 6 mg/m^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.
9860821|NCT00002501|Experimental|cyclophosphamide + filgrastim|Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.
9860822|NCT00002514|Experimental|Transplant|Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
9860823|NCT00002514|Active Comparator|Conventional Consolidation/Maintenance|Consolidation/Maintenance Therapy
9860824|NCT00002520|Experimental|Quit Smoking Intervention|Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.
9860825|NCT00002520|Active Comparator|Usual Care|"No special intervention after randomization. Usual care may or may not include advice or assistance to stop smoking. Physicians were reassured that usual care did not preclude quit smoking counseling."
9860826|NCT00002524|Experimental|Regimen A|Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.
9860827|NCT00002524|Experimental|Regimen B|Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy
9860828|NCT00002524|Experimental|Regimen C|Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation followed, as indicated, by Radiotherapy.
9860829|NCT00002527|Experimental|Aspirin|325 mg/day PO
9860830|NCT00002527|Placebo Comparator|Placebo|
9860831|NCT00002528|Experimental|Surgery w/ axillary clearance, tamox|Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
9860832|NCT00002528|Experimental|Surgery w/o axillary clearance, tamox|Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
10209933|NCT03086486|Experimental|600 mg L x 9 weeks + Pa + B|"1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
10209934|NCT03077425|Experimental|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
10213637|NCT03632889|No Intervention|Control Arm|Subjects randomized to the control group will receive a sleep hygiene handout .
10213638|NCT03632889|Other|Computerized Group|Subjects randomized to GoToSleep program will receive a sleep hygiene handout and a unique code for home access to the GoToSleep program.
10213639|NCT03631706|Experimental|M7824|
10213640|NCT03631706|Active Comparator|Pembrolizumab|
9860833|NCT00002529|Experimental|AC with concurrent tamoxifen|AC for 4 cycles with concurrent tamoxifen for 5 years
9860834|NCT00002529|Experimental|AC followed by tamoxifen|AC for 4 cycles followed by tamoxifen to 5 years from randomization.
9860835|NCT00002529|Experimental|Tamoxifen alone|Tamoxifen alone for 5 years.
9860836|NCT00002529|Experimental|AC with concurrent toremifene|AC for 4 cycles with concurrent toremifene for 5 years.
9860837|NCT00002529|Experimental|AC followed by toremifene|AC for 4 cycles followed by toremifene to 5 years from randomization.
9860838|NCT00002529|Experimental|Toremifene alone|Toremifene alone for 5 years.
9860839|NCT00002537|Experimental|Arm I|Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
9924999|NCT00866801||Healthy|Healthy subjects scheduled for general anesthesia
9925000|NCT00866801||Healthy with thoracic epidural anelgesia|Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
9925001|NCT00866801||Diabetes|Subjects with diabetes scheduled for general anesthesia
9925002|NCT00866801||Diabetes with autonomic neuropathy|Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia
9925003|NCT00866840|Experimental|Riluzole|100 mg orally twice daily
9925004|NCT00866866|Experimental|N-Acetyl Cysteine|
9925005|NCT00866866|Placebo Comparator|Placebo|
9925006|NCT00866892|Active Comparator|irrigation|
10209935|NCT03077425|Placebo Comparator|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
10209936|NCT03077243|Experimental|≤ 10 pack years smoking history|
9925007|NCT00866892|Experimental|no irrigation|
9925008|NCT00866944|Experimental|1|Adecatumumab alone
9925009|NCT00866944|Experimental|2|FOLFOX 4 followed by Adecatumumab
9925010|NCT00866944|Active Comparator|3|FOLFOX 4 alone
9935197|NCT04054752|Active Comparator|2/Arm 2a|Administration of 4 vaccines according to Sequence 1 + NT-I7 administration at OBD to assess vaccine response
9935198|NCT04054752|Active Comparator|3/Arm 2b|Administration of 5 vaccines according to Sequence 2 + NT-I7 administration at OBD to assess vaccine response
9935199|NCT04052022||1|Patients with TB who have already initiated treatment and are suspected to have paradoxical reactions, as well as patients taking TB treatment without signs of paradoxical reactions.
9935200|NCT04049604||1/Cohort 1|Women with prenatal testing results that suggest an incidental detection of maternal neoplasia
9935201|NCT04049604||2/Cohort 2|Women undergoing active treatment or surveillance for known malignancy
9935202|NCT04045795|Experimental|Dose regimen 1|Isatuximab SC administration dose level 1 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
10209937|NCT03077243|Experimental|> 10 py smoking history, no p53 mutation|
10209938|NCT03077243|Active Comparator|> 10 py smoking history, p53 mutation|
10209939|NCT03049449|Experimental|1|All patients will be receiving starting dose: 0.3x106 CAR+ T cells/kg (weight based dosing)(up to a maximum dose of 18x106 CAR+ T cells /kg)infuse on day 0 and Cyclophosphamide: 300 or 500 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamid on days -5, -4,and -3
10209940|NCT03031964||revision multihole acetabular cup|Revision total hip arthroplasty using multihole revision acetabular cup
10209941|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
9935203|NCT04045795|Experimental|Dose regimen 2|Isatuximab SC administration dose level 2 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
9935204|NCT04045795|Experimental|Dose regimen 3|Isatuximab SC administration dose level 3 using the investigational injector device once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
9935205|NCT04045795|Experimental|Dose regimen 4|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
10209942|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
9935206|NCT04045795|Experimental|Dose regimen 5|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
9935207|NCT04044365||1/Project 1 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=20 child/parent dyads
9935208|NCT04044365||2/Project 1 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=20 child/parent pairs
9935209|NCT04044365||3/Project 1 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=20 child/parent pairs
9935210|NCT04044365||4/Project 2 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=40 child/parent pairs
9935211|NCT04044365||5/Project 2 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=40 child/parent pairs
9935212|NCT04044365||6/Project 2 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=40 child/parent pairs
9935213|NCT04041050|Experimental|Part 1: Navitoclax Monotherapy|Participants will receive various doses of navitoclax once daily (QD).
9996949|NCT01504568|No Intervention|Non Treatment|Subjects will be followed without the use of antibiotics.
9996950|NCT01504581|Experimental|HM10660A|
9795375|NCT01534637|Experimental|Treatment (antiemetic, chemotherapy, and radiation therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy once daily on days 1-5 for 5.5 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes once weekly and either fluorouracil IV continuously or capecitabine PO twice daily on days 1-5.~PROPHYLACTIC THERAPY: Beginning 1 hour before chemoradiotherapy, patients receive aprepitant PO on days 1-3. Treatment repeats every 7 days for 5.5 weeks in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION CHEMOTHERAPY: Two to four weeks after completion of chemoradiotherapy and prophylactic therapy, patients without disease progression or a declining performance status receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
9795376|NCT01534663|Placebo Comparator|Placebo|The placebo for fish oil will be safflower oil. For glutamine, soy powder will serve as the placebo.
9795377|NCT01534663|Active Comparator|Glutamine/Fishoil|3.285 g of EPA and 3.285 g of Docosahexaenoic acid (DHA) and L-alanyl-glutamine (8g/d).
9795378|NCT01534689|Experimental|Erchonia FX-405™ Laser|The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
9795379|NCT01534897|Experimental|GSK2118436|Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
9795380|NCT01534910|Placebo Comparator|Sugar pill|placebo
9795381|NCT01534910|Active Comparator|Aged Garlic Extract|2400 mg of aged garlic extract
9800017|NCT01676909|Experimental|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. After completing the 12 weekly groups, participants will return to complete once monthly booster group sessions for the next three months.
9800018|NCT01676909|Active Comparator|Medical Illness Education & Support Group|We selected a comparison condition that would provide parallel focus (i.e. medical illness) but not include use of the core ingredients undergirding the Living Well intervention including behavioral action planning, problem solving, in-session and between session practice using specific disease self-management techniques and involvement of peer co-facilitators to enhance modeling and improve self-efficacy and activation. As with Living Well, the content of the intervention will have broad applicability across diverse chronic disease conditions. The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition.
9800019|NCT01677182|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
9800020|NCT01677182|Experimental|Ramelteon (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
9800021|NCT01677182|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 6 weeks.
9800022|NCT01677195|Active Comparator|ACCS100 High Dose|Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.
9800023|NCT01677195|Active Comparator|ACCS100 Low Dose|Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.
9925011|NCT00866957||Patients with liver cancer|Patients diagnosed with liver cancer
9860840|NCT00002548|Active Comparator|HDCTX and PBSC|"High dose chemotherapy with peripheral blood stem cells~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7"
9860841|NCT00002548|Experimental|HDCTX with PBSC and Autologous BMT|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Auto Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0"
9860842|NCT00002548|Experimental|HDCTX with PBSC and interferon|"High dose chemotherapy with peripheral blood stem cells and interferon~Experimental: HDCTX with PBSC and interferon High dose chemotherapy with peripheral blood stem cells and interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7~IFN: IFN 3 million units/m2 MWF SQ"
9860843|NCT00002548|Experimental|HDCTX with PBSC and transplant plus IFN|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~Experimental: HDCTX with PBSC and transplant plus IFN High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0~IFN: 3 million units/m2 MWF SQ"
9860844|NCT00002550|Experimental|RT + chemotherapy followed by surgery + chemotherapy|Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
9860845|NCT00002550|Active Comparator|RT + chemotherapy followed by chemotherapy + RT|Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
9860846|NCT00002551|Experimental|Bolus 5-FU, Pelvic XRT + PVI 5-FU, Bolus 5-FU|Bolus 5-FU (fluorouracil) (500mg/m2/day on days 1-5, 29-33), Pelvic XRT + PVI 5-FU, Bolus 5-FU (450mg/m2/day for 5 days beginning 28 days after RT, for 2 cycles on days 1-5 of a 28 days cycle).
9860847|NCT00002551|Experimental|PVI 5-FU+Pelvic XRT+PVI 5-FU+PVI 5-FU|5-FU (fluorouracil) 300mg/m2/day for 42 days followed by 2 week interruption, Day 57 through XRT will receive 225mg/m2/day of 5-FU followed by 1 month interruption, 4 weeks after completion of XRT 1 8wk cycle of 5-FU 300mg/m2/day.
9860848|NCT00002551|Experimental|Bol 5-FU+LV+LEV+Pel XRT+Bol 5-FU+LV Bol 5-FU + LV + LEV|5-FU (fluorouracil) 425/mg/m2/day Days 1-5,29-33; LV (leucovorin calcium) 20mg/m2/day Days 1-5,29-33; LEV (levamisole hydrochloride) 150mg/day (50mg TID) for 3 days every 14 days starting after each course of 5-FU. During RT: 5-FU and LV 4 days on wk 1 and wk 5 of RT. LV 20 mg/m2/day IV bolus within 2hrs after completion of that day's radiation therapy, for four days in each cycle. Followed immediately by 5- FU 400 mg/m2/day IV bolus. Treatment will be given on days 57 - 60 and 85 - 88.Treatment post-RT-chemotherapy 28 days after completion of RT consist of 5 days of chemotherapy in 28 day cycles. 5-FU, 380 mg/m2/day on days 1 - 5 and LV given at a dose of 20 mg/m2/day on days 1 - 5 with the 5-FU given immediately after the LV. For 2 post-radiation cycles on days 1 - 5 of a 28 day cycle. Levamisole will be given orally at a dose of 150 mg/day (50 mg tid) for 3 days every 14 days during the 1st 3 days of each cycle of 5-FU, and again 14 days after starting each course of 5-FU.
9860849|NCT00002556|Active Comparator|ARM A (VBMCP)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive VBMCP as in the induction phase. Courses repeat every 35 days in the absence of disease progression or unacceptable toxicity."
9925012|NCT00866970|Experimental|1|ALD518
9925013|NCT00866970|Experimental|2|ALD518
10209943|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
10209944|NCT03000803|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
10209945|NCT03000803|Active Comparator|Late Total Caloric Intake|The Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
10209946|NCT03000569|Experimental|Part A: Antiparkinsonian Agent(s) Followed by SAGE-217|Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.
10209947|NCT03000569|Experimental|Part B: Antiparkinsonian Agent(s) + SAGE-217|Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.
10209948|NCT03000530|Experimental|Part A: SAGE-217|Participants received SAGE-217, 30 milligrams (mg), oral solution, once daily for 14 days, as tolerated.
10209949|NCT03000530|Placebo Comparator|Part B: Placebo|Eligible participants received matching placebo capsules once daily for 14 days.
10209950|NCT03000530|Experimental|Part B: SAGE-217|Eligible participants received SAGE-217, 30 mg, oral capsules, once daily for 14 days.
10209951|NCT02994784|Experimental|Evomela|Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation
9925014|NCT00866970|Experimental|3|ALD518
9925015|NCT00866970|Placebo Comparator|4|No ALD518
9517086|NCT03309618|Experimental|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
9517087|NCT03309618|Placebo Comparator|Control group|16 participants received placebo per orally once daily for 30 days.
9795382|NCT01534962|Experimental|Ranolazine low dose|Ranolazine, low dose, oral, BID
9795383|NCT01534962|Experimental|Ranolazine intermediate dose|Ranolazine, intermediate dose, oral, BID
9795384|NCT01534962|Experimental|Ranolazin high dose|Ranolazine, high dose, oral, BID
9795385|NCT01534962|Placebo Comparator|Placebo|Placebo (sugar pill), oral, BID.
9795386|NCT01534975|Active Comparator|Iodixanol 320|"group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
9795387|NCT01534975|Active Comparator|iohexol 350|"group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
9795388|NCT01534975|Active Comparator|iopamidol 370|"group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
9795389|NCT01534975|Active Comparator|iodixanol 270|"group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
9795390|NCT01535001|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
9795391|NCT01535001|Active Comparator|Standard treatment|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
9795392|NCT01535014|Experimental|Dietressa (2 tablets 3 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.
9795393|NCT01535014|Experimental|Dietressa (1 tablet 6 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.
9795394|NCT01535014|Placebo Comparator|Placebo (2 tablets 3 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.
9795395|NCT01535014|Placebo Comparator|Placebo (1 tablet 6 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.
9795396|NCT01535040|Active Comparator|Arm I - Memantine|Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.
9795397|NCT01535040|Placebo Comparator|Arm II - Placebo|Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.
9795398|NCT01535053|Experimental|Arm I (dactinomcin)|Patients receive dactinomycin IV over 15 minutes on day 1.
9795399|NCT01535053|Active Comparator|Arm II (leucovorin calcium and methotrexate)|Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
9795400|NCT01535118||Adults and Children with Allergic Rhinoconjunctivitis (ARC)|Adults and children with ARC who complete the survey
9795401|NCT01535222|Experimental|Cohort 1|3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
9795402|NCT01535222|Experimental|Cohort 2|3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
9795403|NCT01535222|Experimental|Cohort 3|6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
9795404|NCT01535222|Experimental|Cohort 4|6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
9795405|NCT01535222|Experimental|Cohort 5|6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
9795406|NCT01535222|Placebo Comparator|Placebo|8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
9795407|NCT01535235|Active Comparator|ACE Inhibitor|Active group
9795408|NCT01535235|Placebo Comparator|Placebo|Placebo group
9795409|NCT01535261|Experimental|Ranibizumab arm|Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
9795410|NCT01535287|Active Comparator|Dexmedetomidine|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
9795411|NCT01535287|Placebo Comparator|Placebo|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
9795412|NCT01535326|Placebo Comparator|air insufflation|Use air insufflation during colonoscopy
9795413|NCT01535326|Active Comparator|water immersion|infuse water during insertion, remove water during withdrawal of colonoscopy
9925016|NCT00867022||1|Women with gestational diabetes
10209952|NCT02994160|Experimental|FastLIFE electrodes|Implant temporary FastLIFE electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
10209953|NCT02978781|Experimental|Part A: SAGE-217 Oral Solution|Participants received SAGE-217 10 mg oral solution on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7 with food in the morning.
10209954|NCT02978781|Experimental|Part A: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7, orally, with food in the morning.
10209955|NCT02978781|Placebo Comparator|Part B: Placebo|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 matching placebo for 7 days beginning on Day 8 with food in the morning.
9795414|NCT01535326|Active Comparator|water exchange|infuse and remove water during insertion phase of colonoscopy
9795415|NCT01535365|Active Comparator|Heat|Application of Heat pad to site of muscle sprain.
9795416|NCT01535365|Active Comparator|Cold|Application of ice pack to muscle sprain.
9795417|NCT01535443|Experimental|Bromfenac|Drug: Bromfenac ophthalmic solution 1 drop 4 times per day
9795418|NCT01535560|Experimental|AL-60371|AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
9795419|NCT01535560|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days
9795420|NCT01535573|Active Comparator|Citalopram low dose|Citalopram 20 mg
9795421|NCT01535573|Active Comparator|Citalopram high dose|Citalopram 40 mg
9795422|NCT01535573|Placebo Comparator|Placebo|Placebo
9795423|NCT01535599|Experimental|AL-60371|AL-60371, 0.3% Otic Suspension, 4 drops to the affected ear(s) twice daily for 7 days
9795424|NCT01535599|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops to the affected ear(s) twice daily for 7 days
9795425|NCT01535638|Active Comparator|BI 207127 NA TFII medium dose|Film-coated tablet for oral administration
9795426|NCT01535638|Active Comparator|BI 207127 NA FF medium dose|Film-coated tablet for oral administration
9795427|NCT01535638|Active Comparator|BI 207127 NA FF modified medium dose|Film-coated tablet for oral administration
9795428|NCT01535664||dalfampridine-ER 10mg|Subjects with MS taking dalfampridine-ER 10mg and considered to be responders
9795429|NCT01535729||Cohort|
9795430|NCT01535924|Experimental|Treatment (combination chemotherapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1 and 2. Treatment repeats every 21-28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9795431|NCT01535937|Experimental|Ketamine|0.5 mg/kg of ketamine IV over 40 minutes
9795432|NCT01535937|Active Comparator|midazolam|0.025 mg/kg IV over 40 minutes
9795433|NCT01535976|Placebo Comparator|Placebo|.9 normal saline infusion
9795434|NCT01535976|Active Comparator|Ketamine|Infusion of ketamine
9795435|NCT01536067|Experimental|Treatment (monoclonal antibody therapy)|"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
9795436|NCT01536093|Experimental|Colostrum|oropharyngeal administration of own mother's colostrum
9795437|NCT01536093|Placebo Comparator|Placebo|oropharyngeal administration of sterile water
9795438|NCT01536119|Experimental|Coparenting Breastfeeding Support Intervention|The intervention group will receive a in-hospital discussion, a video, a workbook,a breastfeeding booklet, access to a secure study website, two follow-up emails, and one telephone call.
9795439|NCT01536119|No Intervention|Usual Care Group|The usual care group will receive standard postpartum care in the hospital and in the community
9795440|NCT01536145|Experimental|Single agent CP-751,871|dose escalation design
9795441|NCT01536171||Shod versus Barefoot Running|two running conditions, with normal running shoes and barefoot
9795442|NCT01536184|Experimental|Receives COS Intervention|Circle of Security (COS) Family Intervention (B. Marvin model) is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour. The protocol itself involves a series of activities and repeated videotaped interactions between the child and their caregiver which are reviewed by the therapist who has established themselves with the caregiver as a secure base from which the attachment relationship may be explored.
9795443|NCT01536184|No Intervention|Control Group-Regular FASD Services|Regular FASD Services include general information on Fetal Alcohol Spectrum Disorder (FASD) with general behavioural management strategies and parental supports.
9795444|NCT01536197||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
9795445|NCT01536197||Gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
9795446|NCT01536197||Sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy surgery
9795447|NCT01536262|Other|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
9795448|NCT01536262|Other|Olodaterol|Olodaterol solution for inhalation - RESPIMAT
9795449|NCT01536262|Other|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
9795450|NCT01536366|Experimental|Group 1|Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide
9795451|NCT01536366|Experimental|Group 2|Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide
9860850|NCT00002556|Experimental|Arm B (VBMCP, high dose cyclophosphamide, r alpha 2b IFN)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive vincristine sulfate, carmustine, and melphalan as in the induction phase, high-dose cyclophosphamide IV on days 1-4 and prednisone PO on days 1-4 during courses 3 and 5. Patients receive VBMCP as in the induction phase during even numbered courses. Patients receive recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22 during odd courses beginning course 7. Treatment repeats every 35 days for courses 3-5, every 21 days for even courses beginning course 6, and every 22 days for odd courses beginning course 7 in the absence of disease progression or unacceptable toxicity."
9800024|NCT01677195|Placebo Comparator|Placebo|Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.
9800025|NCT01677286|Experimental|doxycycline 100 mg po bid x 12 months|Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
9800026|NCT01677299|Active Comparator|1000 mg EFB0026 (metformin immediate-release)|BID
9800027|NCT01677299|Experimental|1000 mg EFB0027 (metformin delayed-release)|BID
9800028|NCT01677299|Experimental|500 mg EFB0027 (metformin delayed-release)|BID
9800029|NCT01677299|Experimental|500 mg EFB0026 + 1000 mg EFB0027|BID
10209956|NCT02978781|Experimental|Part B: SAGE-217 Capsules|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 for 7 days beginning on Day 8 with food in the morning.
10209957|NCT02978781|Experimental|Part C: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2, 30 mg on Day 3, orally, with food in the evening. Beginning on Day 4 through Day 14, participants received a 40-mg total daily dose (administered as 10 mg with food in the morning and 30 mg with food in the evening).
9860851|NCT00002561|Active Comparator|Radiotherapy or ABVD + Radiotherapy|Radiotherapy
9860852|NCT00002561|Active Comparator|ABVD Alone|ABVD Alone
9860853|NCT00002565|Experimental|Arm I|"Sequential 4-, 5-, and 3-Drug Combination Chemotherapy. IdSHAP: IDA/CDDP/ARA-C/MePRDL; followed by BIdCOS: BLEO/IDA/CTX/VCR/MePRDL; followed by MINE: Mesna/IFF/DHAD/VP-16.~Alternating triple therapy (ATT) of IdSHAP (idarubicin, cisplatin, cytarabine, methylprednisolone), BIdCOS (idarubicin, vincristine, bleomycin, cyclophosphamide, methylprednisolone), and MINE (mesna, ifosfamide, mitoxantrone, etoposide)."
9860854|NCT00002565|Experimental|Arm II|4-Drug Combination Chemotherapy. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): CTX/DOX/VCR/PRED.
9860855|NCT00002569|Active Comparator|Radiation therapy (RT) alone|Radiation therapy (RT) alone - External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume.
9860856|NCT00002569|Experimental|Intensive pre-treatment chemotherapy and radiation therapy|Intensive pre-treatment chemotherapy (Day 1 CCNU 130 mg/m2 p.o., Day 8 - Vincristine 1.4 mg/m2 i.v., Days 8-21 - Procarbazine 75 mg/m2 p.o., Day 29 - Vincristine 1.4 mg/m2 i.v.) followed by radiation therapy (External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume).
9860857|NCT00002570|Active Comparator|Fluorouracil and folinic acid|
9860858|NCT00002570|No Intervention|Observation|
9860859|NCT00002571|Experimental|ProMACE-CytaBOM + G-CSF|6 cycles of 21 days each of ProMACE-CytaBOM (cyclophosphamide 490 mg/m^2 on day 1, doxorubicin 19 mg/m^2 on day 1, etoposide 90 mg/m^2 on day 1, cytarabine 225 mg/m^2 on day 8, bleomycin 5 u/m^2 on day 8, methotrexate 90 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, vincristine 1.4 mg/m^2 on day 8, prednisone 60 mg/m^2 on days 1-14, allopurinol 300 mg on days 1-21 of cycle 1 and days 1-8 of cycle 2 only) plus 1 double strength tablet TMP/SMX 3 days a week plus G-CSF 5 ug/kg on days 9-20. Patients also receive intrathecal cytarabine 30 mg/m^2 (BM positive: 5 doses spaced evenly during 1st 2 cycles, then on day 1 of cycles 3-6; CSF cytology positive: 5 doses spaced evenly during 1st cycle, then on day 1 of cycles 2-6; BM and CSF negative: 5 doses spaced evenly within 1 month of completion of cycle 6). All patients with CR or PR after systemic therapy and IT cytarabine receive 2400 cGy RT to the whole brain in 12 fractions.
9925017|NCT00867022||2|Pregnant women without gestational daibetes
9925018|NCT00867022||3|Women with gestational diabetes and hypertension
10209958|NCT02976701|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
10209959|NCT02976701|Placebo Comparator|Placebo|Placebo is administered two tablets three times daily, everyday for four weeks of study period
10209960|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase I)|
10209961|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase II)|
10209962|NCT02964507|Placebo Comparator|Placebo + Fulvestrant (Phase II)|
10209963|NCT02964078|Experimental|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
10209964|NCT02955394|Placebo Comparator|Fulvestrant Without Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
10209965|NCT02955394|Experimental|Fulvestrant With Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.
9800030|NCT01677312|Active Comparator|19G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
9800031|NCT01677312|Active Comparator|25G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
9800032|NCT01677377|Experimental|Cohort 1, RBP-7000 60 mg|Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87.
9800033|NCT01677377|Experimental|Cohort 2, RBP-7000 90 mg|Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87.
9860860|NCT00002574|Experimental|Arm I|Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
9860861|NCT00002575|Experimental|Conventional surgery|"Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
10209966|NCT02953301|Experimental|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
9860862|NCT00002575|Experimental|Laparoscopic-assisted colectomy|"Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
9860863|NCT00002583|No Intervention|Observation|Observation only
9860864|NCT00002583|Active Comparator|Chemotherapy|Cisplatin and Vinorelbine
9860865|NCT00002586|Experimental|13-cis retinoic acid|13-cis retinoic acid 50 mg/d
9860866|NCT00002586|Experimental|13-Cis Retinoic Acid and Tocopherol|13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
9860867|NCT00002586|No Intervention|Observation|Observation
9860868|NCT00002587|Experimental|Arm I|"Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
9860869|NCT00002590|Experimental|Regimen A|See detailed description.
9860870|NCT00002593|Active Comparator|5-FU/Leucovorin/Levamisole|levamisole hydrochloride: 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; leucovorin calcium: 20 mg/m^2/day, IV, Days 1-5 of each cycle; 5-fluorouracil: 425 mg/m^2/day, IV, Days 1-5 of each cycle;
9860871|NCT00002593|Active Comparator|Infusional 5-FU + Levamisole|levamisole hydrochloride : 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; 5-fluorouracil: 250 mg/m^2/day, continuous infusion, daily for 56 days x 3 cycles of 8 weeks.
10209967|NCT02953301|Placebo Comparator|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
10209968|NCT02949479|Other|Dissociation Investigation in Sex Offenders|The study will be proposed to the subjects after their usual clinical evaluation in the center for sexual offence, and to extend this evaluation by a specific focus on childhood abuse and neglect, trauma and dissociative history
10209969|NCT02942277|Experimental|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168
9860872|NCT00002594|Experimental|Ablative chemo followed by autologous bone marrow (ABM) rescue|Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.
9860873|NCT00002602|Experimental|Group 1|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6] x 10) is ≤ 15. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
9860874|NCT00002602|Experimental|Group 2|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6]x10)>15. Any clinical T2c with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
10209970|NCT02942277|Experimental|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168
9860875|NCT00002602|Experimental|Group 3|Clinical stage T3 with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
9860876|NCT00002610|Experimental|STRATUM A|Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
9860877|NCT00002610|Experimental|Stratum B|All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
9860878|NCT00002610|Experimental|STRATUM C|All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
10209971|NCT02942277|Experimental|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
10209972|NCT02942277|Experimental|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
10209973|NCT02942277|Experimental|2c|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 on D0, D28, D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
10209974|NCT02942277|Experimental|2d|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 (500 (Micro)L TBV + AS01) on D0, D28, then 8 micro liters Pfs230D1M- EPA/AS01 (100 (Micro)L TBV + AS01;fractional dose) on D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
9860879|NCT00002610|Experimental|STRATUM D|Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.
9860880|NCT00002611|Active Comparator|Stratum 1|Stage I favorable histology (FH) Wilms' tumor, under 24 months of age, and tumor weight less than 550 g: After conventional surgery (nephrectomy), patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
9860881|NCT00002611|Active Comparator|Stratum 2|Stage I FH Wilms' tumor and age 24 months and over or tumor weight at least 550 g; stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
9860882|NCT00002611|Active Comparator|Stratum 3|Stage II FH Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
9860883|NCT00002611|Active Comparator|Stratum 4|Stage III FH Wilms' tumor; stage II or III FA Wilms' tumor: After conventional surgery (nephrectomy), patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy.
9860884|NCT00002611|Active Comparator|Stratum 5|Stage IV FH or FA Wilms' tumor: patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy, and whole lung radiation therapy (at the discretion of the investigator).
9860885|NCT00002611|Active Comparator|Stratum 6|Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
9860886|NCT00002611|Active Comparator|Stratum 7|Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
9860887|NCT00002611|Active Comparator|Stratum 8|Stages II-IV DA Wilms' tumor: After conventional surgery (nephrectomy), Patients receive treatment as in stratum 7 (patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
9860888|NCT00002611|Active Comparator|Stratum 9|Stages I-IV rhabdoid tumor: After conventional surgery (nephrectomy), patients receive carboplatin IV on days 1-2 and VP-16 IV over 1 hour (beginning after carboplatin infusion) on days 1-3 of weeks 0, 3, 9, 12, 18, and 21 and CTX IV over 1 hour on days 1-5 of weeks 6, 15, and 24. Filgrastim G-CSF is administered as on stratum 7. Patients also undergo radiation therapy. After completion of chemotherapy, patients undergo second-look conventional surgery (laparotomy) and conventional surgery (partial nephrectomy or wedge excision if feasible). After conventional surgery (second-look surgery), patients without persistent or residual disease resume chemotherapy.
9860889|NCT00002618|Active Comparator|Regimen A|Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.
9860890|NCT00002618|Active Comparator|Regimen B|Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.
9860891|NCT00002621|Experimental|Alpha interferon (aIFN) treatment|See detailed description.
9925019|NCT00867022||4|Non pregnant women
10209975|NCT02942277|Experimental|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
10209976|NCT02942277|Experimental|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
10209977|NCT02942277|Active Comparator|4a|(n=10), to receive ENGERIX-B on D0, D28, and D168
10209978|NCT02942277|Active Comparator|4b|(n=10), to receive ENGERIX-B on DO, D28, and Dl68
10209979|NCT02942277|Active Comparator|4c|(n=120), to receive ENGERIX-B on D0, D28, and D168 (start study with Arm 2c and 2d); all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); vaccination with Menactra on D476
10209980|NCT02942017|Placebo Comparator|Placebo|Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
10209981|NCT02942017|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
10209982|NCT02942004|Placebo Comparator|Placebo|Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
9860892|NCT00002622|Active Comparator|Talc slurry via chest tube|talc slurry via chest tube
10209983|NCT02942004|Experimental|SAGE-547 60 μg/kg/h|Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
9860893|NCT00002622|Active Comparator|Talc via insufflation|4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time
9860894|NCT00002624|Experimental|Radiotherapy + surgery|"Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.~Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
9860895|NCT00002625|Experimental|Arm I|Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).
9860896|NCT00002633|Active Comparator|Total Androgen Blockade|
9860897|NCT00002633|Active Comparator|Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation|
9860898|NCT00002642|Experimental|chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery and post-surgery boost chemotherapy
9860899|NCT00002643|Experimental|Arm I|See detailed description.
9860900|NCT00002644|Experimental|Tamoxifen citrate|Tamoxifen citrate 20 mg/day for 5 years
9860901|NCT00002644|Placebo Comparator|Placebo|Placebo 20 mg/day for 5 years
9860902|NCT00002649|Experimental|Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide)|"Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21.~Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.~Patients receive interleukin-2 IV continuously on days 1-4 and 9-18."
9860903|NCT00002649|No Intervention|Arm II (observation only)|Patients undergo observation only.
9860904|NCT00002656|Experimental|Pyrazoloacridine|Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
9860905|NCT00002657|Experimental|Immumosuppression, IFN-a, ProMACE-CytaBOM|Doses and schedules of immunosuppressive drugs (cyclosporin (or FK506), prednisone, and acyclovir) will depend on whether patients are judged to have clinically urgent disease or not. Patients who do not have a CR after initial immunosuppression will receive 3 cycles (28 days each) Interferon alpha 2b at 3.0 x 10^6 IU/m^2 on days 1-28. Patients who have a CR will then receive 6 additional cycles with 3 doses per week, then go onto observation. Patients who do not have a CR will then receive a maximum of 6 21-day cycles of chemotherapy, consisting of: cyclophosphamide 650 mg/m^2 on day 1, adriamycin 25 mg/m^2 on day 1, etoposide 120 mg/m^2 on day 1, prednisone 60 mg/m^2 on days 1-14, cytosine arabinoside 300 mg/m^2 on day 8, bleomycin 5 mg/m^2 on day 8, vincristine 1.4 mg/m^2 on day 8, methotrexate 120 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, G-CSF 5 ug/kg/day on days 2-14, and one double strength tablet trimethoprim-sulfamethoxazole 3 times per week.
10209984|NCT02942004|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
10209985|NCT02939573|Experimental|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
10209986|NCT02939573|Experimental|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
10209987|NCT02938403|Experimental|In vivo group|Those who receive in vivo counseling and Nicotine Replacement Therapy (NRT)
10209988|NCT02938403|Active Comparator|Controls|Standard smoking cessation counseling and Nicotine Replacement Therapy (NRT)
10209989|NCT02929589|Experimental|Opioid naïve patients-Group A|"Group A: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.~."
10209990|NCT02929589|Experimental|Non-Opioid naïve patients-Group C|Group C: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, in addition to their preferred opioid medication prescription.
10209991|NCT02929589|Placebo Comparator|Opioid naïve patients-Group B|Group B:Subjects will be prescribed 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
10209992|NCT02929589|Experimental|Non-Opioid naïve patients-Group D|Group D: Subjects will be prescribed or advised to continue to take only their preferred current oral opioid prescription (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, or transdermal fentanyl).
10209993|NCT02912208|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
10209994|NCT02912208|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
10209995|NCT02910635|Experimental|Volanesorsen, Intravenous (IV)|300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose
10209996|NCT02910635|Experimental|Volanesorsen, Subcutaneous (SQ)|300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose
10209997|NCT02910635|Active Comparator|Moxifloxacin Hydrochloride|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
9860906|NCT00002664|Experimental|Treatment|
9860907|NCT00002668|Active Comparator|Observation|Standard pain management interventions usually given by hospital staff
9860908|NCT00002668|Experimental|Educational Intervention and Behavioral Skills Training|Patients participated in a program including video presentations, written materials, and coaching in behavioral skills to improve pain control (not to reduce analgesic use).
9935214|NCT04041050|Experimental|Part 2: Navitoclax + Ruxolitinib Combination Therapy|Participants will receive various doses of navitoclax once daily (QD) in combination with ruxolitinib twice daily (BID).
9935215|NCT04041050|Experimental|Part 3: Navitoclax Monotherapy|Participants will receive navitoclax once daily (QD).
9860909|NCT00002670|Active Comparator|Radiation therapy|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
9860910|NCT00002670|Experimental|Radiation therapy plus cisplatin|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
9860911|NCT00002676|Experimental|CHOD + BVAM + WBRT|Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions.
9860912|NCT00002677|Experimental|Arm I|Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
9860913|NCT00002678|Active Comparator|Melphan plus prednisone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.
9860914|NCT00002678|Active Comparator|Melphan, prednisone pluse dexamethasone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression
9860915|NCT00002682|Experimental|Antibiotic Treatment|
9860916|NCT00002704|Experimental|Arm I|Single Agent Chemotherapy. TSPA or DTC101. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 2-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. ARA-C/ASP; plus TIT. 4-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. CTX/MP/MTX/VP-16; with CF; plus TIT. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 6-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. ARA-C/ASP/CTX/MP/MTX/VP-16; with CF; plus TIT. Radiotherapy plus 3-Drug Combination Chemotherapy. Craniospinal irradiation using x-rays with energies of 4-6 MV (electrons acceptable for spinal cord irradiation); plus ASP/DM/VCR. 2-Drug Combination Chemotherapy Alternating with 2-Drug Combination Chemotherapy. MP/MTX; alternating with CTX/VCR.
9860917|NCT00002705|Experimental|Arm I|Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
9860918|NCT00002706|Experimental|Arm I|Patients undergo vaginal hysterectomy and BSO via laparoscopy.
9860919|NCT00002706|Active Comparator|Arm II|Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
10209998|NCT02910635|Placebo Comparator|Placebo Intravenous (IV) single dose|Administered as normal saline (0.9% Sodium Chloride)
9860920|NCT00002707|Experimental|Group 2|doxorubicin and cyclophosphamide plus Taxotere prior to surgery plus tamoxifen
9860921|NCT00002707|Experimental|Group 3|doxorubicin and cyclophosphamide followed by surgery followed by taxotere plus tamoxifen
9860922|NCT00002707|Active Comparator|Group 1|doxorubicin and cyclophosphamide plus tamoxifen
9860923|NCT00002708|Experimental|Arm 1|Whole brain radiation therapy (WBRT) to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week followed by radiosurgery to all metastases
10209999|NCT02910635|Placebo Comparator|Placebo Subcutaneous (SC) single dose|Administered as normal saline (0.9% Sodium Chloride)
10210000|NCT02861300|Experimental|CB-839 + capecitabine|Patients will receive CB-839 orally twice daily for 21 days (continuous administration) and capecitabine orally twice daily for 14/21 days. In the phase I portion of the study, patients will receive escalating doses of CB-839 and capecitabine and will have day 15 blood samples drawn and archived for as needed assessment of CB-839 pharmacokinetics. In the phase II portion of the study, patients will receiving 800mg CB-839 and 1000mg/m^2 capecitabine as were determined to be safe doses during the phase I portion of the study. They will also undergo pre-treatment and post-treatment blood samples and tissue biopsies for evaluation of pharmacodynamic biomarkers.
10210001|NCT02861014|Experimental|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
10210002|NCT02850900|Experimental|Internet Survey|Subject will receive an electronic survey weekly to complete
9860924|NCT00002708|Active Comparator|Arm 2|WBRT to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week
9860925|NCT00002715|Experimental|Combination Chemotherapy (Stanford V)|A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule
9860926|NCT00002716|Experimental|Arm I - laparotomy + conventional surgery + chemotherapy|"Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
10210003|NCT02850900|No Intervention|No Survey|No intervention
10210004|NCT02840227|Experimental|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
10210005|NCT02840227|Experimental|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous PCA opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
9860927|NCT00002716|Experimental|Arm II - conventional surgery + chemotherapy|"Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy.~Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
10210006|NCT02821299|Experimental|Laryngeal transplantation|Laryngeal transplantation
10210007|NCT02821143|Experimental|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
9860928|NCT00002718|Experimental|Candidates for transplant|Pts stratified by number of HLA-incompatible alleles(1 vs 2 or 3). Harvest:Begin 6-10 d before transplant,allogeneic BM is harvest & tx in vitro. Begin 5-6 d before transplant,G-CSF-stimulated,PBSC harvest,selected for CD34+ cells,& treatment in vitro. If doable,ABM harvest in event of allogeneic graft failure. Myeloablation:Pts u/g TBI 3x d days -9 to -6, thiotepa IV over 4hrs days -5 & -4, & cyclophosphamide IV days -3 & -2. Transplant:CD34+, E-rosette & T-cell-depleted PBSC infuse over 15mins & T-cell-depleted bone marrow infused over 1-5mins day 0. Pts get G-CSF IV over 30 min begin day 1 & continue til blood counts recover & tapering. Pts get anti-thymocyte globulin IV over 4-6hrs days 8,10,12,&14 & oral methylprednisolone days 8-14 followed by tapered doses days 15-17. See detailed description for more details.
9860929|NCT00002721|Experimental|Prostate cancer patients|Prostate cancer patients that have not responded to hormon therapy
9860930|NCT00002723|Experimental|Low dose suramin|Low dose suramin
9860931|NCT00002723|Experimental|Intermediate dose suramin|Intermediate dose suramin
9860932|NCT00002723|Experimental|High dose suramin|High dose suramin
9860933|NCT00002725|Experimental|Arm I|Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
9860934|NCT00002727|Active Comparator|Radiation therapy - conventional fractionation|Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
9860935|NCT00002727|Experimental|Radiation therapy - hyperfractionation|Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
9860936|NCT00002734|Experimental|Arm I|Patients receive interferon alfa subcutaneously on days 1, 3, 5, and 7; paclitaxel intraperitoneally (IP) on day 4 or topotecan IP on day 6; and 177Lu-CC49 IP on day 6. Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity. Once the MTD of paclitaxel is determined, the dose of 177Lu-CC49 is escalated. Once the MTD of 177Lu-CC49 is determined, 90Y-CC49 is substituted. The MTD of 90Y-CC49 is then determined when administered with paclitaxel. Topotecan is then substituted for paclitaxel (administered with the MTD of 177Lu-CC49 and interferon alfa only) and escalated until the MTD is determined.
9860937|NCT00002735|Experimental|Treatment arm|induction chemotherapy followed by chemoradiation
9860938|NCT00002740|Experimental|Treatment - Carboplatin Chemotherapy|See detailed description.
9860939|NCT00002744|Experimental|Arm I|Therapy defined in description.
9860940|NCT00002744|Experimental|Arm 2|Therapy defined in description.
9860941|NCT00002744|Experimental|Arm 3|Therapy defined in description.
9860942|NCT00002744|Experimental|Arm 4|Therapy defined in description.
9860943|NCT00002745|Experimental|aminocamptothecin|aminocamptothecin
9860944|NCT00002756|Experimental|Chemo (Reduced Induction) No BMT (Open February 2004)|
9860945|NCT00002757|Active Comparator|Group A|All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
9860946|NCT00002757|Active Comparator|Group B|Non resected stage I & II, stage III & st IV (CNS - ve, BM < 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
9860947|NCT00002757|Active Comparator|Group C|Bone marrow > 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
9860948|NCT00002759|Experimental|Arm I|See detailed description.
9860949|NCT00002760|Other|Antiandrogen withdrawal|"antiandrogen therapy withdrawn; patient who progress will be crossed over to Arm 1A: 400 mg ketoconazole PO tid and hydrocortisone 30 mgs PO q am and 10 mgs PO qhs until treatment is no longer effective"
9860950|NCT00002760|Active Comparator|Antiandrogen withdrawal + therapy|Ketoconazole and hydrocortisone
9795452|NCT01536379|Experimental|Belimumab 10 mg|Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
9795453|NCT01536379|Placebo Comparator|Placebo|Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
10210008|NCT02821143|Other|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
9795454|NCT01536392|Experimental|Granisetron|Group A: 34.3 mg of granisetron formulated in transdermal patch replaced every 7 days. Transdermal patch placed/replaced prior to the intravenous (IV) infusion of cisplatin. At cycle 1, participants receive IV granisetron prior to IV cisplatin and prior to administration of transdermal patch.
9795455|NCT01536392|Experimental|Ondansetron|Group B: 8 mg of ondansetron orally thrice daily starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
10210009|NCT02820857|Experimental|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
10210010|NCT02820857|Active Comparator|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
10210011|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
10210012|NCT02811250|Experimental|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
10210013|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
10210014|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
9795456|NCT01536405|Experimental|MMRV (AMP)|Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
9795457|NCT01536405|Active Comparator|MMRV (2006 process)|Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process
9795458|NCT01536418|Experimental|GSK1605786A, 500 milligrams, once daily|500 milligrams once daily, orally administered for 12 weeks
10210015|NCT02797457|Other|Allograft|Bilateral allograft of the hands and forearms.
10210016|NCT02797457|Other|Prostheses|Prosthetic forehands
9795459|NCT01536418|Experimental|GSK1605786A, 500 milligrams twice daily|500 milligrams twice daily, orally administered for 12 weeks
9795460|NCT01536496|Active Comparator|Control (INR, PTT, fibrinogen, D-dimer)|Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
9795461|NCT01536496|Active Comparator|Test (r-TEG)|Patients randomized to the r-TEG guided haemostatic resuscitation group (Test Group) will receive blood component therapy per usual clinical practice. The test arm involves the use of rapid-TEG to diagnose and describe post-injury coagulopathy and to guide blood product replacement per institutional algorithm. In the Test Group, blood for r-TEG will be collected on admission, or upon entering the operating room, depending on the acuity of the injury (Baseline), and this will be followed by two additional r-TEG analyses during the first six hours at the discretion of the treating team (attending surgeon, anesthesiologist) and then two further r-TEG analyses at 12 hours and at 24 hours post-injury respectively. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
9795462|NCT01536535|Experimental|Mild UC|"Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) < 45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-Tumour Necrosis Factor alpha (TNFα) therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-MP at 1-1.5 mg/kg/day Colectomy"
9795463|NCT01536535|Experimental|Moderate to Severe UC|"Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-TNFα therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-Mercaptopurine (MP) at 1-1.5 mg/kg/day Colectomy"
9800034|NCT01677377|Experimental|Cohort 3, RBP-7000 120 mg|Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87.
9800035|NCT01677507|Experimental|timolol|To compare the variation in response to timolol between individuals
10210017|NCT02796391|Experimental|Study 1: Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mb nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction.~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
10210018|NCT02796391|Experimental|Study 1: Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
10210019|NCT02796391|Experimental|Study 2: Targeted/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
9860951|NCT00002762||Patient interviewing + blood sampling|"Patients were interviewed at the time of the primary cancer surgery to determine the menstrual history. Blood sampling occurred within 1 day of surgery, and serum samples were shipped frozen to a central laboratory (Mayo Medical Laboratory, Rochester, MN) for E2, Pg, and LH determinations. Serum hormone levels, menstrual cycle length, and day of last menses were used to determine the menstrual phase at which surgery occurred.~Patients were observed every 6 months for the first year postregistration and annually for the next 2 to 10 years postregistration for adjuvant therapy information, disease recurrence, and death."
9860952|NCT00002768|Experimental|Autologous stem cell transplantation|Patients receive consolidation chemotherapy followed by autologous stem cell transplantation
9860953|NCT00002772|Experimental|High dose chemo|sequential high dose chemotherapy with doxorubicin, paclitaxel and cyclophosphamide with filgrastim support
9860954|NCT00002772|Experimental|chemo with autologous stem cell support|conventional chemotherapy with doxorubicin and cyclophosphamide followed by autologous stem cell support
9860955|NCT00002774|Experimental|Tirapazamine + cisplatin + 5-FU|2 cycles of induction chemotherapy (tirapazamine, cisplatin, and 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (tirapazamine, cisplatin, and 5-FU)
9860956|NCT00002774|Active Comparator|Cisplatin + 5-FU|2 cycles of induction chemotherapy (cisplatin + 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (cisplatin + 5-FU)
9860957|NCT00002779|Experimental|fludarabine + octreotide|Patients receive fludarabine IV over 10-30 minutes on days 1-5. Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. Treatment repeats every 28 days for 4-6 courses. Patients then receive octreotide alone for 6-8 courses. Some patients may then receive another 12 courses of octreotide alone, for a total of 2 years of treatment. Patients are followed every 3 months for 5 years or until disease progression.
9860958|NCT00002784|Active Comparator|Standard chemotherapy|EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.
9860959|NCT00002784|Experimental|Dose-intensive EC|High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.
10210020|NCT02796391|Experimental|Study 2: Targeted/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
10210021|NCT02796391|Experimental|Study 2: Generic/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
9860960|NCT00002787|Experimental|Treatment (vaccine therapy)|Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
9860961|NCT00002796|Experimental|Treatment (fluorouracil, phenylbutyrate, indomethacin, IFN-G|"Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4, and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients experience dose-limiting toxicity (DLT).~Phase II: Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in phase I at the MTD."
9860962|NCT00002798|Experimental|Arm I (combination chemotherapy)|"Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.~See Detailed Description"
9860963|NCT00002798|Experimental|Arm II (combination chemotherapy)|"Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.~Intensification: See Detailed Description"
9860964|NCT00002798|Experimental|Arm III (combination chemotherapy, aldesleukin)|Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.
9800036|NCT01677507|Active Comparator|latanoprost|To compare the variation in response to latanoprost between individuals
9800037|NCT01677624|Experimental|E7040|
9860965|NCT00002798|Active Comparator|Arm IV (combination chemotherapy)|No further treatment
9860966|NCT00002798|Experimental|Arm V (combination chemotherapy, radiotherapy)|Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.
9925020|NCT00867152|Experimental|Cohort 2|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
9925021|NCT00867152|Experimental|Cohort 1|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
9925022|NCT00867204||Short-wire device|The Fusion Short-wire ERCP device was used
9925023|NCT00867204||Long-wire device|The traditional Long-wire ERCP device was used
9925024|NCT00867230|Experimental|FTS (S-trans, trans-farnesylthiosalicylic acid)|
9925025|NCT00867243||Group 1: HCV Positive|50 patients whom are HCV positive
9925026|NCT00867243||Group 2: HCV Negative|50 patients whom are HCV negative.
9925027|NCT00867256|Experimental|Large Diameter Metal on Metal|
9925028|NCT00867282|Experimental|Treatment A|
9925029|NCT00867282|Active Comparator|Treatment B|
9925030|NCT00867295|Placebo Comparator|placebo|no antibiotic is used
9925031|NCT00867295|Active Comparator|drug|cefazolin Sodium 1g i.v. before the operation
9925032|NCT00867347|Active Comparator|Arm I|"Patients undergo a radical cystectomy, including pelvic lymphadenectomy,~between 4 and 6 weeks after initiating course 4 of chemotherapy."
9925033|NCT00867347|Experimental|Arm II|Patients with no visible residual tumor (cT0 or pT0) or residual but superficial tumor (pTa, pT1) undergo radiotherapy beginning within 4-6 weeks of day 1 of course 4 and continuing for 6.5 weeks.
9925034|NCT00867373|Experimental|Education Intervention|"The intervention used in the randomized controlled trial consists of 1) measuring the parents' height and weight and 2) providing the parents with feedback on their calculated BMI on an educational handout (included in Appendix V). The purpose of the handout is to convey the following 5 messages:~Definition of BMI~How BMI is calculated~What the parent's BMI is based on the measurements taken~What weight category the parent is in (underweight, normal weight, overweight, or obese)~Children with overweight or obese parents are at higher risk of becoming overweight themselves.~The Research Assistant will verbally review the educational handout with the parent. The handout will be available in both English and Spanish."
9925035|NCT00867373|No Intervention|Control Group|Parents assigned to the control group will proceed to their child's well child visit after their baseline data are collected.
9925036|NCT00867399|Active Comparator|20mg of ABT-126 QD|20 mg of ABT-126 QD for 10 days
9925037|NCT00867399|Active Comparator|30mg and 45mg ABT-126 QD|30 mg and 45mg of ABT-126 QD for 21 days
9925038|NCT00867412||Conventional staging|Staging with CT, mediastinoscopy and bronchoscopy
9925039|NCT00867412||Conventional staging and PET/CT|Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy
9925040|NCT00867425|Experimental|Intervention|
9925041|NCT00867438|Placebo Comparator|1|
9925042|NCT00867438|Experimental|2|
9925043|NCT00867477|Experimental|Cohort 1: Esophagus Cancer|Breathing Test + Respiratory Symptoms Questionnaire
9925044|NCT00867477|Experimental|Cohort 2: Lung Cancer|Breathing Test + Respiratory Symptoms Questionnaire
9925045|NCT00867516|Experimental|1|ALD518 80 mg
9925046|NCT00867516|Experimental|2|ALD518 160 mg
9925047|NCT00867516|Experimental|3|ALD518 320 mg
9925048|NCT00867516|Placebo Comparator|4|No ALD518
9925049|NCT00867542||past IUGR|3-4 y old children with past IUGR
9925050|NCT00867542||control|3-4 y old healthy children
9925051|NCT00867555|Experimental|EGCG|"Double blind randomized, placebo-controlled cross-over design with two arms:~the green tea extract TEAVIGO, high in EGCG and~placebo"
9925052|NCT00867555|Placebo Comparator|placebo|
10210022|NCT02796391|Experimental|Study 2: Generic/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
10210023|NCT02793258|Placebo Comparator|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
9925053|NCT00867581||1|chronic-stage patients after infarction in the territory of unilateral middle cerebral artery
9925054|NCT00867581||2|age, sex and risk factor matched volunteers without ischemic stroke
9925055|NCT00867607|Experimental|MRX-6 (2%)|
9925056|NCT00867607|Experimental|MRX-6 (1%)|
9925057|NCT00867607|Experimental|MRX-6 (0.2%)|
10210024|NCT02793258|Experimental|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
9860967|NCT00002804|Experimental|Chemotherapy Regimen|Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
9860968|NCT00002805|Experimental|Treatment|Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.
9860969|NCT00002806|Experimental|procarbazine + lomustine + vincristine + radiation|PCV followed by external-beam cranial irradiation using at least 6 MV photons.
9860970|NCT00002807|No Intervention|Observation|
9860971|NCT00002807|Experimental|Radiation|Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)
9860972|NCT00002812|Experimental|Arm A - Standard BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
9860973|NCT00002812|Experimental|Arm B - Standard BFM with Double Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (5 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
9860974|NCT00002812|Experimental|Arm C - Augumented BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
9860975|NCT00002812|Experimental|Arm D - Augmented BFM with Dbl Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
9860976|NCT00002816|Experimental|EARLY # CNS RELAPSE with BM DONOR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.
9860977|NCT00002816|Experimental|LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.
9860978|NCT00002825|Experimental|Arm I|All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
9860979|NCT00002827|Experimental|Treatment #1 (Without Zinecard)|"All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( < 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days)."
9860980|NCT00002827|Experimental|Treatment #2 (with Zinecard)|Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15
9860981|NCT00002829|Experimental|Bone Marrow Transplantation|
10210025|NCT02786186||Secikinumab|Patients treated with secukinumab
10210026|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
10210027|NCT02775435|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
10210028|NCT02775435|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
9860982|NCT00002831|Experimental|Deoxyazacytidine + Busulfan + Cyclophosphamide|Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation
9860983|NCT00002832|Experimental|Decitabine + Stem Cell Transplantation|
9860984|NCT00002833|Experimental|Group 1A|"Group 1A - With or Without Remission + Failing Fludarabine therapy:~Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
9860985|NCT00002833|Experimental|Group 1B|"Group 1B: With or Without Remission, No previous Fludara Therapy~Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
9860986|NCT00002835|Experimental|Arm I|"3 courses of early intensification:~First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.~Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.~Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity."
9860987|NCT00002835|Experimental|Arm II|IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.
9860988|NCT00002836|Experimental|Filgrastim + Chemotherapy|
10210029|NCT02767531|Experimental|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
10210030|NCT02767531|No Intervention|Off drug|Standard therapy will be given for three months
9860989|NCT00002836|Experimental|Filgrastim|
9860990|NCT00002837|Experimental|Doxorubicin, Paclitaxel + Cyclophosphamide with PBPC|
10210031|NCT02757898|Experimental|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
9860991|NCT00002838|Experimental|Combination Chemotherapy + PSCT|PSCT = Peripheral Stem Cell Transplantation
9860992|NCT00002844|Experimental|Cyclophosphamide + TBI + BMT|TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)
9860993|NCT00002849|Experimental|induction and maintenance|dexamethasone induction followed by alpha interferon maintenance
9860994|NCT00002852|Active Comparator|Arm I (surgery, observation)|Patients receive no further therapy.
9860995|NCT00002852|Experimental|Arm II (surgery, chemotherapy)|Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
9860996|NCT00002854|Experimental|Sequential high dose chemotherapy|
9860997|NCT00002855|Experimental|Arm I|Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.
9860998|NCT00002855|Experimental|Arm II|Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.
9860999|NCT00002860|Other|surgery|
9861000|NCT00002862|Experimental|Arm I|Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined. Treatment at the assigned dose continues until disease progression or unacceptable toxicity intervenes. Patients with stable disease after 8 weeks of treatment are removed from study.
9861001|NCT00002864|Active Comparator|Octreotide|
9861002|NCT00002864|Active Comparator|Tamoxifen|
9861003|NCT00002875|Experimental|Regimen A|Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
9861004|NCT00002875|Experimental|Regimen B|Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
9925058|NCT00867607|Active Comparator|Steroid|
9925059|NCT00867620||1|case group: patients with urothelial carcinoma
9861005|NCT00002879|Experimental|cladribine|Patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) daily for 5 days every 4 weeks for a maximum of 6 courses; response is assessed after every 2 courses. Patients in complete remission or with stable disease discontinue treatment and are followed; those with disease progression at any time are removed from study. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and annually for 2 years.
9861006|NCT00002880|Experimental|Etoposide|Oral etoposide for relapsed or refractory non-Hodgkin's lymphoma
9861007|NCT00002882|Experimental|IFN-A Therapy Schedule A|Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
9861008|NCT00002882|Experimental|IFN-A Therapy Schedule B|Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.
9861009|NCT00002882|Experimental|Adjuvant Biochemotherapy|Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.
9861010|NCT00002909|Experimental|Arm I|All patients receive oral phenylbutyrate three times daily. Groups of 4 or more patients receive escalating doses of phenylbutyrate until the maximum tolerated dose (MTD) is determined. Treatment continues until disease progression or unacceptable toxicity intervenes.
9861011|NCT00002912|Experimental|Arm I|Patients undergo induction therapy consisting of etoposide IV and mitoxantrone IV on days 1-5. Patients then receive PSC-833 IV over 124 hours beginning on day 2. A second course is administered no sooner than 21 days from the start of the first course if the marrow is hypocellular after the first course. Patients with persistent disease after 2 induction courses are removed from the study. Patients receive a total of 3 courses of etoposide/mitoxantrone. Patients who achieve complete remission after 1 induction course receive 2 courses of etoposide/mitoxantrone with PSC-833 as consolidation, beginning within 4 weeks of attainment of complete remission. Patients who achieve complete remission after 2 induction courses receive 1 course of etoposide/mitoxantrone with PSC-833 as consolidation. Cohorts of 3-6 patients receive escalating doses of PSC-833 until the maximum tolerated dose is determined. Patients are followed every 6 months.
9861012|NCT00002913|Experimental|Treatment (paclitaxel, cisplatin, topotecan hydrochloride)|"Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities."
9861013|NCT00002920|Active Comparator|Tamoxifen alone|Tamoxifen alone x 5 years
9861014|NCT00002920|Experimental|Tamoxifen plus MPA|Tamoxifen Plus Medroxyprogesterone Acetate (MPA) x 5 years
9861015|NCT00002921|Experimental|Suramin|
9861016|NCT00002923|Experimental|KRN5500|
9861017|NCT00002924||Source of patient samples|The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
9925060|NCT00867620||2|control group: those without previous history of any malignancy
9925061|NCT00867633||Urothelial carcinoma|The DNA samples extracted from the urothelial carcinoma tissue
9925062|NCT00867633||RCC|the DNA sample extracted from RCC
9925063|NCT00867633||Non-cancer|The DNA sample extracted from the non-cancerous kidney tissue
9925064|NCT00867672|Experimental|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
9925065|NCT00867672|Experimental|Decitabine+VPA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
9925066|NCT00867672|Experimental|Decitabine+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
9925067|NCT00867672|Experimental|Decitabine+VPA+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle
9925068|NCT00867685|Experimental|Treatment A|Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state.
9925069|NCT00867685|Experimental|Treatment B|Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state.
9925070|NCT00867685|Experimental|Treatment C|Single oral dose of 40 mg (2x20mg tablets) in a fed state.
9925071|NCT00867724|Experimental|Aer-O-Scope Colonoscopy|Screening Colonoscopy
9925072|NCT00867737|Experimental|Advair 115/21 MDI|Advair HFA 115/21 MDI Intervention = initiate intervention after screening
9925073|NCT00867737|Active Comparator|2 = Symbicort 160/4.5|Symbicort initiated after screening
9925074|NCT00867750|Experimental|RE|Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
9925075|NCT00867750|Active Comparator|TACE|Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
9925076|NCT00867763|Experimental|IVM|Early egg retrieval, in vitro maturation, then IVF
9925077|NCT00867763|Active Comparator|Mild IVF|Mild gonadotropin and conventional IVF
9925078|NCT00867776|Experimental|AAHC Excercise Program Support Group|Participants taking part in the AAHC Exercise Program Support Group (the intervention).
9861018|NCT00002925|Active Comparator|ADE|
9861019|NCT00002925|Experimental|ADEP|
9861020|NCT00002934|No Intervention|Pathology Review, Observation and Follow-up|Pathology review, observation and follow-up
9861021|NCT00002938|Other|Surgery|Salvage prostatectomy
9861022|NCT00002939|Experimental|Paclitaxel in combination with Irinotecan|The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
9861023|NCT00002941|Experimental|Reinduction Therapy|Two courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. If marrow involvement is still present at harvest, then 2 additional courses of induction chemotherapy are given. The PBSC transplantation preparative regimen should begin within 2 weeks of completing reinduction therapy course, consisting of the following: Carmustine IV over 3 hours on days -8, -7, and -6, Etoposide continuous IV over days -8, -7, and -6, Cyclophosphamide IV over 1 hour daily on days -5, -4, -3, and -2, Mesna as a 15 min infusion before each dose of cyclophosphamide then at 3, 6, 9, and 12 hours after initiation of each cyclophosphamide dose Methylprednisolone IV is given to protect lungs from the toxic effects of carmustine.
9861024|NCT00002942|Active Comparator|Peripheral Blood Progenitor Cells|
9861025|NCT00002942|Experimental|Autologous Bone Marrow Collection|
9861026|NCT00002944|Experimental|Regimen A (CV Chemotherapy)|Induction will consist of 10 weeks of therapy (carboplatin, vincristine sulfate),followed by 2 weeks without chemotherapy. Induction should only be interrupted in the event of grade 3 neurotoxicity, grade 2 renal toxicity, grade 4 hematologic toxicity, or tumor progression. Maintenance-Four Courses (2 cycles/course) commences on Day 84 (week 12) of Induction or when peripheral counts recover with ANC >1,000/$L and platelet count >100,000/$L. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine sulfate (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
9861027|NCT00002944|Experimental|Regimen B (TPCV Chemotherapy)|Each cycle of chemotherapy consists of 4 days of oral chemotherapy (Thioguanine, procarbazine hydrochloride, Lomustine and Vincristine sulfate beginning Day 0, followed by vincristine sulfate IV on Days 14 and 28. The cycle is repeated every 6 weeks (42 days). A total of 8 cycles will be given.
9861028|NCT00002946|Experimental|Arm I|atients enrolled on the bioavailability portion of this study receive one dose of IV penclomedine over 1 hour followed by 2 weeks of rest. At the end of two weeks, they receive oral penclomedine for 5 days every 28 days. The starting dose is determined by a single primary patient who has been administered oral penclomedine and observed for dose limiting toxicity (DLT). [Bioavailability portion completed as of 3/98.] Those not on the bioavailability portion of study start on a standard design dose escalating schedule in which patients enroll in cohorts of 3. Patients are administered oral penclomedine daily for 5 days. This treatment repeats every 4 weeks. The MTD is defined as the dose immediately below that at which 2 patients experience DLT. Treatment repeats for 6 courses or until severe toxicity or tumor progression is observed.
9861029|NCT00002949|Experimental|Arm A|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
9861030|NCT00002951|Experimental|Arm A (Hyper-FHX)|Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)
9861031|NCT00002952|Experimental|Arm A|Melan-A peptide loaded PBMCs (sc, q3wk x 3), rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
9861032|NCT00002956|Experimental|infusions of EBV specific cytotoxic T lymphocytes|Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression
9861033|NCT00002961|Active Comparator|Total body irradiation|Total body irradiation 1200 centigray
9861034|NCT00002961|Active Comparator|Busulfan|Busulfan 16 doses
9861035|NCT00002965|Experimental|Arm 1: Benign Meningiomas|INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
9861036|NCT00002965|Experimental|Arm 2: Other Pathologies|INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
9861037|NCT00002968|Experimental|Arm I (edrecolomab)|Patients receive adjuvant edrecolomab IV over 2 hours on day 1. Treatment repeats every 28 days for 5 courses. Patients must begin therapy no earlier than 7 days and no later than 42 days postsurgical resection. Patients also undergo observation at 3 and 6 months postrandomization.
9861038|NCT00002968|No Intervention|Arm II (no treatment)|Patients undergo observation at 3 and 6 months postrandomization. .
9861039|NCT00002970|Experimental|Arm I|"GROUP 1: Patients receive a 1 hour infusion of compound 506U78 daily for 5 days in the absence of neurologic toxicity. The course repeats every 21 days. If a first relapse T-cell ALL study of higher priority is not open, then the patient may continue to receive the drug every 21 days for a maximum of 2 years provided that the patient has achieved a second complete response.~GROUPS 2 and 4: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. After 3 courses a patient may be given CNS prophylaxis with triple intrathecal therapy (TIT), consisting of methotrexate, cytarabine and hydrocortisone after consultation with study coordinator. TIT should be given every 12 weeks.~GROUP 3: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. TIT will be given on day 1 of weeks 1-4, 6, 9 and every 6 weeks for 12 weeks, and then every 9 weeks thereafter. This stratum is open."
9795464|NCT01536561|Experimental|open-label, dose escalation|"Each subject will undergo two phases of study. The first phase, termed tracer Study, involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radio-immunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three subjects per dose level."
9795465|NCT01536574|Experimental|Requip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
9986469|NCT01403207||knee osteoarthritis|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
9996951|NCT01504581|Active Comparator|Pegasys|
9996952|NCT01504581|Placebo Comparator|HM10660A Placebo|
9795466|NCT01536587|Other|Single Arm|Inhalation of salmeterol 50 µg twice daily over 4 weeks
9795467|NCT01536704|Experimental|Test nicotine lozenge (2 mg)|2 mg test nicotine lozenge to be chewed.
9795468|NCT01536704|Experimental|Test nicotine lozenge (4 mg)|4 mg test nicotine lozenge to be chewed.
9795469|NCT01536704|Active Comparator|Reference nicotine lozenge (2 mg)|2 mg reference nicotine lozenge to be chewed.
9795470|NCT01536704|Active Comparator|Reference nicotine lozenge (4 mg)|4 mg reference nicotine lozenge to be chewed.
9795471|NCT01536795|Experimental|WR279,396 with Tegaderm dressing|24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing
9795472|NCT01536795|Experimental|WR279,396 with Gauze and Tape Dressing|24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).
9795473|NCT01536860|Placebo Comparator|Control Test Drink|control drink
9795474|NCT01536860|Experimental|Experimental Test Drink 1|control drink containing ingredient 1
9795475|NCT01536860|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
9795476|NCT01536886|Placebo Comparator|LEO 90100 vehicle|Aerosol foam with no active ingredient
9795477|NCT01536886|Active Comparator|Betamethasone plus calcipotriol|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
9795478|NCT01536886|Experimental|LEO 90100|LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
9795479|NCT01536886|Placebo Comparator|Ointment vehicle|Ointment with no active ingredients
9795480|NCT01536938|Active Comparator|Calcipotriol|"Calcipotriol aerosol foam: calcipotriol 50 mcg/g.~Applied once daily for up to 4 weeks"
9795481|NCT01536938|Active Comparator|Betamethasone|"Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
9795482|NCT01536938|Experimental|LEO 90100|"LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
9795483|NCT01536951|Placebo Comparator|Placebo|Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
9795484|NCT01536951|Experimental|LY3009104|"Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose.~Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period."
9795485|NCT01536951|Active Comparator|400 mg moxifloxacin|Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
9795486|NCT01537029|Experimental|Doxorubicin and cyclophosphamide|
9795487|NCT01537042|Experimental|Rotigotine|"Rotigotine Transdermal Patch~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h."
9795488|NCT01537042|Placebo Comparator|Placebo|Transdermal patch matched according to patch size and appearance.
9795489|NCT01537068|Experimental|Desvenlafaxine|Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
9795490|NCT01537068|Placebo Comparator|Placebo|Placebo treatment
9795491|NCT01537081|Experimental|Mucinex 2400 mg/day|The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
9795492|NCT01537081|Active Comparator|Immediate-release Guaifenesin 800 mg/Day|The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
9795493|NCT01537081|Placebo Comparator|Placebo|Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
9795494|NCT01537120|Experimental|Placebo → Vildagliptin|Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily
9795495|NCT01537133|Experimental|Inhaled corticosteroid|Fluticasone (250 mcg/puff, one puff, twice a day)
9861040|NCT00002981|Experimental|PET Scan|Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.
9861041|NCT00002994|Experimental|Monoclonal antibody + interleukin 2|"Cycle 1: low dose IL2 days 1-7; MoAb day 7; intermediate dose IL-2 days 8-10; Low dose IL2 days 11-20.~Cycle 2 & all subsequent cycles: MoAb day 1; intermediate dose IL2 days 1-3; low dose IL2 days 4-14"
9861042|NCT00002998|Experimental|gemcitabine + cisplatin|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, and 15 every 28 days. Patients with complete response may receive an additional 2 courses after attainment of complete response status. Treatment continues in the absence of disease progression or unacceptable toxicities for a maximum of 8 courses. Patients are followed every 3 months for 2 years and then at 3 years after treatment.
9861043|NCT00003005|Experimental|deoxycoformycin and cordycepin|Dose escalation for deoxycoformycin and cordycepin
9861044|NCT00003006||Group 1|At the time of thoracotomy and pulmonary resection, patients have samples of bone marrow, primary tumor, and intrathoracic lymph nodes harvested. The presence of occult metastases in bone marrow and lymph nodes is assessed using immunohistochemistry or reverse transcriptase-polymerase chain reaction.
9861045|NCT00003011|Active Comparator|Marmistat|10 mg PO BID
10210032|NCT02742246|No Intervention|Standard treatment as usual (TAU)|This is the regular treatment a participant would normally receive at the clinic and generally includes individual and/or group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as teaching about the treatment program, teaching important ideas about recovery, increasing knowledge about specific problems participants may have with addiction and/or demonstrating new ways of coping with skills designed to fit their lifestyle. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
9861046|NCT00003011|Placebo Comparator|Placebo|10 mg PO BID
9861047|NCT00003018|Experimental|Chemotherapy|dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
9861048|NCT00003019|Experimental|Chemotherapy Treatment|Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
9861049|NCT00003034|Experimental|Arm I|Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.
9861050|NCT00003034|Experimental|Arm II|Patients receive doxorubicin as in arm I for up to 6 courses.
9861051|NCT00003039|Experimental|Arm I|Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs.
9861052|NCT00003040|Experimental|Transoral CO2 laser laryngectomy and RT|Transoral CO2 laser supraglottic laryngectomy and irradiation
9861053|NCT00003045|Experimental|Hyperthermia|XRT and Hyperthermia Post-therapy evaluation PSA, Clinical Exam, and Prostate Biopsy ( @ 12 Months)
9925079|NCT00867828|Experimental|1|Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
9925080|NCT00867828|Active Comparator|2|Fish oil softgels (1g QD). Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
9925081|NCT00867828|Placebo Comparator|3|Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
9925082|NCT00867841||Pneumonia|Children diagnosed with community-acquired pneumonia by the emergency department physician
9925083|NCT00867854||Experimental|25 evaluable subjects from the experimental arm of ATN 061 who undergo de-intensification to boosted atazanavir (ATV) with VL suppression of < 100 copies/ml and CD4+ T cells > 350 cells/mm3 at week 48 and maintain VL suppression to < 400 copies/ml with stable CD4+ T cell counts after week 48.
9925084|NCT00867854||Control|25 evaluable subjects from ATN 071 will also be enrolled. These subjects will have initiated HAART according to current DHHS guidelines (CD4+ T cells < 350 cells/mm3), had viral load suppression to < 100 copies/ml at 24 through 48 weeks on HAART and maintained suppression to < 400 copies/ml through week 80.
9925085|NCT00867867|Active Comparator|1|Ferrous Fumarate with Ferrous Sulphate
9925086|NCT00867867|Active Comparator|2|Ferric pyrophosphate with ferrous sulphate
10210033|NCT02742246|Active Comparator|Individual clinician-provided CBT|This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
10210034|NCT02742246|Experimental|CBT4CBT|In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on. The CBT4CBT program will cover the same skills as the individual clinician-provided CBT, only here it will be done by a computer. Participants will be taught how to use the computer program by a staff member and will be asked to spend about 8 hours using the program (approximately one hour per week) at the clinic.Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
9861054|NCT00003046|Experimental|Interleukin-12|
9861055|NCT00003048|Experimental|Amifostine|Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle)
9861056|NCT00003056|Active Comparator|Unselected peripheral blood haemopoietic stem cells (PBSC)|Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control
9861057|NCT00003056|Experimental|CD34+ cells isolated from PBSC|CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine
9925087|NCT00867867|Placebo Comparator|3|Ferrous sulphate
9925088|NCT00867880|Experimental|1|
9795496|NCT01537133|Placebo Comparator|Placebo|Placebo fluticasone (one puff, twice a day)
9795497|NCT01537133|No Intervention|Healthy Control|
9795498|NCT01537133|No Intervention|Atopic Non-asthmatics|
9795499|NCT01537185|Experimental|Cohort 1 SPWCV+Alum 100 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
9795500|NCT01537185|Experimental|Cohort 2 SPWCV+Alum 300 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
9795501|NCT01537185|Experimental|Cohort 3 SPWCV+Alum 600 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
9795502|NCT01537185|Placebo Comparator|Normal Saline Injection|"placebo group within each cohort receive 3 injections of normal saline 28 days apart~normal saline injection: 3 cohorts of normal saline injection"
9795503|NCT01537198||Pediatric Participants at High Risk of RSV|Pediatric participants at high risk of respiratory syncytial virus (RSV) in need of the prevention of serious lower respiratory tract disease caused by RSV were prescribed Synagis prophylaxis in usual practice according to the approved Korean product label. The decision to prescribe or not to prescribe Synagis was taken prior to a participant's enrollment in the study.
9795504|NCT01537211|Experimental|Microprocessor knee then Mechanical knee|
9795505|NCT01537211|Experimental|Mechanical Knee then Microprocessor knee|
9795506|NCT01537302|Experimental|Ocelot System|CTO crossing in femoropopliteal arteries using the Ocelot System
9795507|NCT01537315|Placebo Comparator|Matching Placebo|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
9795508|NCT01537315|Experimental|Hydroxychloroquine|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
9795509|NCT01537367|Experimental|Enhanced contact only|"Patients allocated to the Enhanced contact only arm will receive:~HIV information and education~Specific to importance of coming to care regularly~Generic and tailored components~Approximately 10 minutes in length~Enhanced contact over time~Collect locator information~Follow-up contact after medical visit (face-to-face or phone)~Appointment reminders (telephone, e-mail, text message)~Periodic telephone contact across time (support, update locator info, refer any unmet needs to Case Manager)~Attempt to make immediate contact following a missed visit and re-schedule appointment (use locator contact info)"
9795510|NCT01537367|Experimental|Enhanced contact plus behavioral skills|Enhanced contact plus behavioral skills is the longer experimental intervention arm.
9795511|NCT01537367|Active Comparator|Standard of Care|Patients assigned to control arm will receive the standard services offered to all patients at the clinic.
9795512|NCT01537393|Other|0-7d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 0 to 7 days prior to transplant.
9795513|NCT01537393|Other|8-14d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 8 to 14 days prior to transplant.
9795514|NCT01537419|Active Comparator|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
9795515|NCT01537419|Experimental|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
9795516|NCT01537432|Placebo Comparator|placebo|placebo
9795517|NCT01537432|Experimental|secukinumab|secukinumab
9795518|NCT01537549|Experimental|Juvenon|
9795519|NCT01537666|Experimental|Aerovanc 16 mg in healthy volunteers|
9795520|NCT01537666|Experimental|AeroVanc 32 mg in healthy volunteers|
9795521|NCT01537666|Experimental|AeroVanc 80 mg in healthy volunteers|
9795522|NCT01537666|Active Comparator|IV vancomycin in healthy volunteers|
9795523|NCT01537666|Experimental|AeroVanc 32 mg in CF patients|
9795524|NCT01537666|Experimental|AeroVanc 80 mg in CF patients|
9795525|NCT01537783|Experimental|Intervention group|In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
9795526|NCT01537783|No Intervention|Standard of Care|In this arm, patients receive routine care of their abscess, which may or may not include either topical or oral antibiotics, at the discretion of the treating clinician.
9795527|NCT01537835|No Intervention|Standard Scrubs|Participants will be randomized to one of three types of uniforms. This arm is the standard scrub arm. The participants will wear new standard scrubs.
9795528|NCT01537835|Experimental|Antimicrobial Scrubs 1|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
9861058|NCT00003058|Experimental|Troglitazone|Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.
9861059|NCT00003070|Experimental|Stratum 1 < 350/mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
9861060|NCT00003070|Experimental|Stratum 2 < 350mg/m2 anthracycline dose|< 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
9861061|NCT00003070|Experimental|Stratum 3 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
9861062|NCT00003070|Experimental|Stratum 4 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
9861063|NCT00003070|Experimental|Stratum 5 >= 350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
9861064|NCT00003070|Experimental|Stratum 6 >=350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
9861065|NCT00003070|Experimental|Stratum 7 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
9861066|NCT00003070|Experimental|Stratum 8 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
9861067|NCT00003075|Experimental|Fenretinide|
9861068|NCT00003075|Placebo Comparator|Placebo|
9861069|NCT00003077|Experimental|Omega-3 fatty acid|"Patients receive omega-3 fatty acids orally in two equal doses with/after breakfast and lunch for 4 months or until weight loss is observed.~Dose is escalated in cohorts of two patients, although dose escalation is allowed in individual patients. Patients are evaluated for cachexia response every 2 weeks, and tumor response every 4 weeks for a maximum of 4 months. If no response of cachexia or tumor after a 2 month period, patients will be discontinued from study. Patients will be followed for survival post-treatment."
9861070|NCT00003084|Experimental|Arm I (Estramustine + Etoposide)|Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.
9861071|NCT00003084|Experimental|Arm II (Chemotherapy + Ketoconazole)|Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.
10210035|NCT02737306|Experimental|PRO 140|up to 60 subjects will be enrolled. PRO 140 will be administered as a 525 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the day of stem cell infusion (Day 0), and then weekly for up to 100±7 days. Subjects will return to the clinic for three Follow-up visits at 2 weeks after the last treatment visit, 30 days after the last treatment visit and one year after the first treatment visit.
10210036|NCT02728648|Other|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
9861072|NCT00003088|Experimental|Sequential chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles followed by cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles.
9861073|NCT00003088|Experimental|Concurrent chemotherapy 14 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 2 weeks for four cycles with filgrastim days 3 to 10 of each cycle at 5 µg/kg rounded to either 300 or 480 µg total dose.
9925089|NCT00867880|Active Comparator|2|
9925090|NCT00867893||DA group|RLS patients started treatment on dopamine agonists within the past year
10210037|NCT02726880|Active Comparator|Referral for care|
10210038|NCT02726880|Experimental|Behavioral therapy|
9925091|NCT00867893||NonDA|RLS patients started treatment on medication other than dopamine agonists within the past year
9925092|NCT00867906|Other|Cohort 1|Asthmatics using salbutamol only, subjects to receive either Cat-PAD or placebo comparator
10210039|NCT02724228|Experimental|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study, initially up to 30 μg/kg. BMN 111 will be administered in the daily dosing regimen: 15 μg/kg per day.
10210040|NCT02717728|Active Comparator|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
10210041|NCT02717728|Sham Comparator|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
10210042|NCT02687464|Experimental|Non-operative treatment group|IV fluids, minimum 12 hrs IV antibiotics, minimum 12 hrs clear PO fluids only, regular clinical review. Discharge within 24 hrs after randomization, if study criteria met. If stable but not adequate improvement for discharge, non-operative management continues. If not improved by 48 hrs, appendectomy will be done. Discharge home once vital signs are within normal limits, light oral diet tolerated, adequate oral pain relief and mobile. Total 10 days of antibiotics (IV and oral) following randomization will be given. Antibiotics used vary between centers and will be current standard of care in that center; improving study feasibility and increased generalization of results.
10210043|NCT02687464|Active Comparator|Appendectomy group|Laproscopic appendectomy within 18 hrs of randomization. IV antibiotics given from time of randomization and continued post-operatively per the standardized treatment regimen: children with visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue IV antibiotics for a minimum of 3 days and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group.
10210044|NCT02679170||Routine clinical practice group (NSCLC ALK+, ROS1)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1
9861074|NCT00003088|Experimental|Sequential chemotherapy 14 days|Patients received doxorubicin 60 mg/m2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m2 every 2 weeks for four cycles followed by cyclophosphamide 600 mg/m2 every 2 weeks for four cycles, with filgrastim days 3 to 10 of each cycle (a total of seven doses) at 5 µg/kg, which could be rounded to either 300 or 480 µg total dose.
9861075|NCT00003088|Experimental|Concurrent chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles.
9861076|NCT00003092|Experimental|Paclitaxel|"Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.~Patients are followed for second malignancies, disease progression, and survival."
9861077|NCT00003093|Experimental|Treatment|See detailed description.
9861078|NCT00003095||bone marrow transplant|bone marrow transplant
9861079|NCT00003095||standard chemotherapy|standard chemotherapy
9861080|NCT00003098|Experimental|fat reduction increased fiber|Patients are randomized to dietary fat reduction with increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
9861081|NCT00003098|Experimental|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
9861082|NCT00003099|Active Comparator|Arm 1 Tamoxifen + Fenretinide|Tamoxifen + Fenretinide daily for 14-28 days
9861083|NCT00003099|Placebo Comparator|Arm 2 Placebo|Placebo daily for 14-28 days
9861084|NCT00003117|Experimental|Paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of each course. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
10210045|NCT02664701|Active Comparator|Individual supportive therapy|"Patients randomized to this arm will have individual supportive therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Individual supportive therapy~Intervention: Evaluations with a psychiatrist"
10210046|NCT02664701|Experimental|Cognitive behavioural group therapy|"Patients randomized to this arm will have cognitive behavioural therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Cognitive behavioural group therapy~Intervention: Evaluations with a psychiatrist"
10210047|NCT02660775|Experimental|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
9861085|NCT00003117|Experimental|Paclitaxel + Carboplatin|Patients receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
9861086|NCT00003118|Experimental|Chemotherapy + Radiation + Surgery|
9861087|NCT00003118|Active Comparator|Surgery|
9861088|NCT00003119|Experimental|Treatment 1 - Asymptomatic - no immediate chemotherapy|
9861089|NCT00003119|Experimental|Symptomatic - immediate chemotherapy|
9861090|NCT00003120|Active Comparator|paclitaxel 3 cycles|paclitaxel given for 3 cycles
9861091|NCT00003120|Experimental|paclitaxel for 12 cycles|paclitaxel given for 12 cycles
9861092|NCT00003126|Experimental|Interleukin-2 (IL-2)|Patients randomized to this arm will receive one course of IL-2 [600,000 U/kg every 8 hours on post-operative days 1 to 5 and days 15 to 19 (maximum 28 doses)].
9861093|NCT00003126|No Intervention|Observation|Patients randomized to this arm will receive their normal medical care
9861094|NCT00003127|Experimental|carbo, taxol, amifostine|carbo, taxol, amifostine
9861095|NCT00003130|Experimental|paclitaxel|Patients receive single fixed dose intravenous paclitaxel over 3 hours on day 1. Blood samples must be drawn prior to the first paclitaxel infusion and then at 1, 6, and 24 hours after the start of the infusion during course 1 only. Treatment courses of intravenous paclitaxel are repeated every 3 weeks at the discretion of the treating physician. Patients are evaluated for response after the second course. Patients are followed at the discretion of the physician.
9861096|NCT00003134|Experimental|Arm I: irinotecan|"Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. This is followed by a 2 week rest and continues for a maximum of 6 courses. Patients who received prior nitrosoureas, also receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
9925093|NCT00867906|Other|Cohort 2|Asthmatics using inhaled corticosteroid, subjects to receive either Cat-PAD or placebo comparator
9925094|NCT00867906|Other|Cohort 3|Asthmatics using inhaled corticosteroid and LABA, subjects to receive either Cat-PAD or placebo comparator
9861097|NCT00003134|Experimental|Arm II: irinotecan|"Patients receive irinotecan on day 1 every 3 weeks for up to 12 courses. Patients who received prior nitrosoureas receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
9861098|NCT00003136|Experimental|Arm A|Cyclophosphamide (40mg/kg/day on days -6, -5 and -4), Carboplatin (1600, 1700 or 1800 mg/m2 on days -6, -5, -4 and -3), Amifostine (910 mg/m2 on days -6, -5, -4 and -3), Peripheral blood stem cell transplantation (day 0), G-CSF (beginning day 4)
9861099|NCT00003137|Experimental|irinotecan|"Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks. Dosage modifications are made based on toxicity. Retreatment may be delayed another 3 weeks (for a total of 6 weeks) to allow for recovery from toxic effects. Patient is taken off study if they do not recover from toxic effects, unless cause is documented to be unrelated to CPT-11. Patients with stable disease or partial response continue on treatment until disease progression or intolerable toxicity. Patients with complete response continue on treatment for another 2 courses and then are observed.~Patients are followed every 3 months for 3 years or until disease progression."
9861100|NCT00003139|Experimental|Pilocarpine hydrocloride|5mg pilocarpine hydrochloride tablets commencing 3 days prior to irradiation
9861101|NCT00003139|Placebo Comparator|Placebo|Placebo tablets commencing 3 days prior to irradiation
9861102|NCT00003140|Experimental|Arm I|Patients receive oral letrozole once daily.
9861103|NCT00003140|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
9861104|NCT00003141|Experimental|Treatment (combination chemotherapy, PBSC transplant)|Pts undergo conventional surgery for diagnosis & max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
9861105|NCT00003143|Experimental|DHAP + amifostine|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
9861106|NCT00003143|Other|DHAP|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
9861107|NCT00003145|Experimental|Treatment (chemotherapy, TBI, PBSCT, DLI)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.~DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD."
9861108|NCT00003147|Experimental|Arm I|Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
9861109|NCT00003157|Experimental|radiation + gemcitabine + cisplatin|Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
9925095|NCT00867919|Experimental|1|Participants will receive a cognitive behavioral family therapy for adolescent depression to be developed in this study.
9925096|NCT00867919|Active Comparator|2|Participants will receive treatment as usual 1 year prior to the experimental treatment group.
9925097|NCT00867945||1. Pregnant Women|
9925098|NCT00867945||2. Non-Pregnant Controls|
9925099|NCT00867945||3. IVF controls|
9925100|NCT00867971||RGH treated|
9925101|NCT00867971||Starting treatment with RGH|
9925102|NCT00867984|Experimental|1|Torsion-guided VV optimization plus AV optimization.
9925103|NCT00867984|Active Comparator|2|AV optimization only.
9925104|NCT00867997|Active Comparator|Dentifrice|Chemoactive (remineralizing, neuroactive) dentifrice treatment
9925105|NCT00867997|Active Comparator|Sealant|DBA/sealant application
9925106|NCT00867997|Active Comparator|Resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
9925107|NCT00868010|Experimental|1: donepezil|Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
9925108|NCT00868010|Placebo Comparator|2. placebo|Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
9925109|NCT00868023|Experimental|1|CHF 1535 DPI : BDP/Formo 400/24 µg
9925110|NCT00868023|Active Comparator|2|CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
9925111|NCT00868023|Experimental|3|CHF 1535 DPI : BDP/Formo 100/6 µg
9861110|NCT00003162|Active Comparator|3.0 Gy x 10 fractions in two weeks|3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
10210048|NCT02660775|Experimental|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
10210049|NCT02660775|Placebo Comparator|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
10210050|NCT02654223|Experimental|MG56 Mannosylated 500 subcutaneous|500 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
9861111|NCT00003162|Experimental|8.0 Gy x 1 fraction|8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
9861112|NCT00003166|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3 weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or 3-week treatment course at the discretion of the principal investigator.~Cohorts of 3 patients receive escalating doses of bryostatin 1 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 1 of 3 patients experience dose-limiting toxicity."
9861113|NCT00003167|Experimental|Treatment (adenovirus p53)|"Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade 3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences grade 3 toxicity, an additional 3 patients are treated at that dose level and dose escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients receive Ad-p53 at the MTD on days 1-4 and 8-11."
9861114|NCT00003170|Experimental|glutamine|Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
9861115|NCT00003170|Placebo Comparator|placebo|Beginning the first or second day of radiotherapy, patients receive placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
9861116|NCT00003178|Experimental|1st Untreated Relapse for AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
10210051|NCT02654223|Experimental|MG56 Mannosylated 1000 subcutaneous|1000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
10210052|NCT02654223|Experimental|MG56 Mannosylated 3000 subcutaneous|3000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
10210053|NCT02654223|Experimental|MG56 Mannosylated 5000 subcutaneous|5000 mTU/mL of subcutaneous immunotherapy and sublingual placebo.
10210054|NCT02654223|Experimental|MG56 Mannosylated 500 sublingual|500 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
9861117|NCT00003178|Experimental|Primary Refractory AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
9861118|NCT00003178|Experimental|MDS|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
9861119|NCT00003190|Experimental|Arm I (cytarabine, daunorubicin, etoposide)|Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus followed by etoposide IV over 2 hours on days 1-3.
9925112|NCT00868023|Active Comparator|4|CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
10210055|NCT02654223|Experimental|MG56 Mannosylated 1000 sublingual|1000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
10210056|NCT02654223|Experimental|MG56 Mannosylated 3000 sublingual|3000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
10210057|NCT02654223|Experimental|MG56 Mannosylated 5000 sublingual|5000 mTU/mL of sublingual immunotherapy and subcutaneous placebo.
10210058|NCT02654223|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
10210059|NCT02622542|Active Comparator|BMT Alone|Patients in this group will be managed with the best medical therapy (BMT) alone
10210060|NCT02622542|Experimental|BMT+TEVAR|Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
9861120|NCT00003190|Experimental|Arm II (valspodar, daunorubicin, etoposide, cytarabine)|"Patients receive treatment as in arm I with the addition of PSC 833 induction. A loading dose of PSC 833 IV is given over 2 hours, followed by a 74-hour continuous infusion of PSC 833 beginning 2 hours before daunorubicin and etoposide. Patients may receive a second induction course if residual leukemia is present in the bone marrow. Patients who experience a CR and meet certain other criteria receive postremission chemotherapy consisting of cytarabine IV continuously over 5 days plus daunorubicin IV followed by etoposide IV over 2 hours on days 1 and 2. Patients who are randomized to receive PSC 833 during induction chemotherapy receive a loading dose of PSC 833 before beginning a 48-hour continuous infusion of PSC 833 concurrently with cytarabine/daunorubicin/etoposide postremission chemotherapy.~After completing postremission chemotherapy, patients are randomized to a no further treatment group or IL-2 immunotherapy."
9861121|NCT00003191|Experimental|Arm I|Patients receive oral fenretinide 3 times a day on days 1-7. Treatment repeats every 3 weeks for up to 8 courses. Patients may receive an additional 22 courses of therapy in the presence of stable or responding residual tumor. Patients with recurrent neuroblastoma, after prior myeloablative therapy with no measurable disease, will stop treatment after 8 courses. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
9861122|NCT00003192|Experimental|Arm A|9-aminocamptothecin (25 mcg/m2/hr x 120hrs, days 1-5 and 8-12 of each 3 week cycle)
9861123|NCT00003193|Experimental|Paclitaxel, amifostine, RT|Dose-escalation arm for paclitaxel with amifostine and RT.
9861124|NCT00003196|Experimental|Treatment (irradiation, transplant, immunosuppression, DLI)|"CYTOREDUCTION: If necessary, patients with advanced malignancies undergo cytoreductive chemotherapy to reduce tumor size at discretion of primary physician and study investigators.~CONDITIONING REGIMEN: Patients undergo low-dose total-body irradiation followed by allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 to 0 and then PO BID on days 1-35 with taper to day 56. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST-TRANSPLANT DLI: Patients with mixed chimerism on day 56 and no evidence of GVHD undergo DLI over 30 minutes on day 65 and may receive up to 3 additional infusions in the absence of GVHD and disease progression or persistence. Patients who have not achieved mixed chimerism at day 56 undergo DLI if complete response is not obtained after a 2 month monitoring period."
9861125|NCT00003200|Experimental|Taxotere|"After the screening procedures confirm participation in the research study:~Taxotere-Administered weekly for 1 hour (6 doses)~Radiation Therapy (XRT) -5 days a week for 6 weeks~Exam under anesthesia~Neck Dissection (if indicated)"
9861126|NCT00003203|Experimental|Newly diagnosed cerebral PNET with histologic verification|Begin therapy within 31 days of surgery. Radiation therapy will be given in standard fractions along with filgrastim. The craniospinal axis will be treated first. Patients will receive carboplatin at 35 mg/m2/day IV over 15-20 minutes Monday through Friday, 1-4 hours prior to radiation for 6 weeks (total of 30 doses). Vincristine sulfate 1.5 mg/m2 IV will be given weekly x 6. Following radiation, patients will receive Maintenance chemotherapy. Patients enrolled prior to Amendment #5 will receive six cycles of cyclophosphamide and vincristine (Regimen A). Patients enrolled after Amendment #5 will receive six cycles of cyclophosphamide, vincristine sulfate and cisplatin (Regimen B).
9861127|NCT00003204|Experimental|Arm I (cyclophosphamide, fludarabine)|Patients receive cyclophosphamide IV over 30-45 minutes on day 1 and fludarabine IV over 10-20 minutes on days 1-5. Treatment repeats every 28 days in the absence of disease progression for a minimum of 4 courses and a maximum of 6 courses.
9861128|NCT00003204|Experimental|Arm II (cyclophosphamide, vincristine, prednisone)|Patients receive cyclophosphamide IV over 30-45 minutes and vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of disease progression for a minimum of 6 courses and a maximum of 8 courses.
9861129|NCT00003204|Experimental|Arm III (rituximab)|Patients receive maintenance therapy with rituximab (IDEC-C2B8 monoclonal antibody) IV weekly for 4 weeks. Courses repeat every 6 months for 2 years. Maintenance therapy begins 4 weeks after the last chemotherapy.
9861130|NCT00003204|No Intervention|Arm IV (no intervention)|Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.
9925113|NCT00868023|Placebo Comparator|5|Placebo
9925114|NCT00868036||Patch testing|Patch testing on patients with chronic idiopathic dermatitis.
9925115|NCT00868049||1|Obese subjects
9925116|NCT00868049||2|Normal-weight subjects
9925117|NCT00868062|Experimental|1|
9925118|NCT00868075|Experimental|Chest Physiotherapy|Twice daily chest physiotherapy
9925119|NCT00868075|Experimental|Chest Physiotherapy + Exercise Program|Chest Physiotherapy + Exercise Program
9861131|NCT00003207|Experimental|Phase 1 (Doxil & PSC 833)|Patients will receive Doxil at the standard dose of 20 mg/m2 IV for the 1st cycle. On the 2nd cycle of Doxil, the first patient will receive Doxil at 40% of standard dose or 8 mg/m2 (dose level 1) IV over one hr. 15 mn after the 2nd and subsequent cycles of Doxil, PSC 833 will be given at 2 mg/kg for 2 hrs. Simultaneously, a 72 hour CIVI of PSC 833 will be started with the loading dose. If no DLT occurs, then a double dose escalation of Doxil (dose levels 3, 5, 7 ) will be given to the same patient in the subsequent cycles until DLT occurs. On the 2nd cycle, Doxil will be given at the next dose level above the starting dose tolerated by the first patient. If no DLT occurs, a double dose escalation will also be done for the subsequent cycles (dose levels 5, 7, 9). The single-patient-cohort will terminate when a patient experiences DLT or when two episodes of grade 2 toxicity occur. At that point patients will be enrolled into cohorts of 3 patients to determine the MTD.
9861132|NCT00003210|Experimental|Treatment (interleukin-12)|Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
9861133|NCT00003211|Experimental|Average-risk|"Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
10210061|NCT02618252|Experimental|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
9861134|NCT00003211|Experimental|High-risk|"Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
9861135|NCT00003213|Experimental|Oral Granisetron + Dexamethasone|"1 mg Granisetron in the morning~1 Metoclopramide placebo in the afternoon~1 mg Granisetron in the evening 4 mg Dexamethasone in the morning"
9861136|NCT00003213|Experimental|Metoclopramide + Dexamethasone|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning
9861137|NCT00003217|Experimental|Treatment|See detailed description.
9861138|NCT00003223|Experimental|treatment|Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.
9861139|NCT00003225|Experimental|Ethyol plus Irinotecan|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
9861140|NCT00003234|Experimental|Stratum 1 - Soft Tissue Sarcoma|See detailed description.
9861141|NCT00003234|Experimental|Stratum 2 - CNS Tumors|See detailed description.
9861142|NCT00003234|Experimental|Stratum 3 - Neuroblastoma|See detailed description.
9861143|NCT00003239|Experimental|Chemotherapy with Cytarabine + Homoharringtonine|Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.
9925120|NCT00868088|Active Comparator|ALA + PDT|Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
9925121|NCT00868088|Placebo Comparator|placebo + PDT|Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
9925122|NCT00868114|Experimental|1|3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine
9925123|NCT00868114|Experimental|2|Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine
10210062|NCT02618252|Experimental|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
10210063|NCT02614547|Placebo Comparator|Placebo|Participants received infusion rates of placebo matched to SAGE-547.
10210064|NCT02614547|Experimental|SAGE-547|Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).
10210065|NCT02599454|Experimental|atezolizumab + SBRT|"DOSE ESCALATION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3.~EXPANSION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3."
10210066|NCT02595905|Active Comparator|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10210067|NCT02595905|Experimental|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10210068|NCT02592551|Experimental|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
10210069|NCT02592551|Active Comparator|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
10210070|NCT02592551|Placebo Comparator|Untreated arm (control)|4 patients will not receive MEDI4736 or Tremelimumab.
10210071|NCT02589691|Experimental|Rocuronium|Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium
10210072|NCT02589691|Placebo Comparator|Placebo|Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%
10210073|NCT02588209|Experimental|SMART Training|This group will receive the Strategic Memory Advanced Reasoning Training (SMART) program, twice a week for four weeks.
10210074|NCT02588209|Active Comparator|Health|This group will receive the Brain Health Workshop educational program, twice a week for four weeks.
10210075|NCT02583048|Experimental|Arm 1: Bedaquiline|"Participants received 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
10210076|NCT02583048|Experimental|Arm 2: Delamanid|"Participants received 100 mg of delamanid twice a day for 24 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
9795529|NCT01537835|Experimental|Antimicrobial Scrubs 2|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
9795530|NCT01537887|Placebo Comparator|Placebo|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
9795531|NCT01537887|Experimental|1200 milligrams (mg) LY2484595|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
9795532|NCT01537887|Active Comparator|400 mg Moxifloxacin|Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14-day washout period.
9795533|NCT01537900|Experimental|Grazoprevir 100 mg|Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.
9795534|NCT01537926|Experimental|N-acetylcysteine (NAC)|N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days
9795535|NCT01537926|Placebo Comparator|Placebo|Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.
10210077|NCT02583048|Experimental|Arm 3: Bedaquiline and Delamanid|"Participants received 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They then received 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
10210078|NCT02566772|Experimental|TAS3681|All participants will receive TAS3681 in 28-day cycles. The Escalation phase includes participants who have progressed after abiraterone, enzalutamide and chemotherapy. Eleven dose escalation cohorts are planned, one of which includes a preliminary assessment of food effect. The MTD/recommended dose for further development will be used for participants in the Expansion Phase. The Expansion Phase will enroll participants who have progressed after abiraterone or enzalutamide with chemotherapy consisting of no more than 2 prior taxane-based therapies (Group A) or without any chemotherapy (Group B). Participants receive TAS3681 until discontinuation criteria are met.
10213641|NCT03629951||Participants with Schizophrenia|Participants will not receive any intervention as a part of this study. Participants with a diagnosis of schizophrenia or schizoaffective disorder receiving oral antipsychotics (OAP) for example, risperidone (1 to 6 milligram [mg] once daily [OD] to twice a day [BID]), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to thrice a day [TID]) etc, per their treating physician/clinician instruction will be observed. The primary data source for this study will be the clinical assessments by the treating physician of each participant conducted as a part of routine clinical practice.
10213642|NCT03622385||Patients diagnosed with Serous Epithelial Ovarian Cancer|"Discovery Cohort: patients who were diagnosed with serous epithelial ovarian cancer whose tissue specimens were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to be cancerous."
10213643|NCT03622385||Normal patients|"Discovery Cohort: patients who were determined to have normal ovarian tissue specimens that were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to not be cancerous."
10213644|NCT03612596|Experimental|Narrative visualization|Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)
10213645|NCT03612596|Active Comparator|Standard self-regulation|Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)
10213646|NCT03607526||Barriers to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying barriers to meeting the DGA recommendation for vegetable consumption.
10213647|NCT03607526||Facilitators to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying facilitators to meeting the DGA recommendation for vegetable consumption.
10213648|NCT03598114|Experimental|Program Sustainability Training|"Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.~The intervention group will receive a follow-up survey inviting them to evaluate the training and their progress on executing their sustainability plan. The intervention group will also receive a follow-up survey inviting them to evaluate the technical assistance they have received from the research team. Responses on neither follow-up survey impact participants standing in the study"
10213649|NCT03598114|No Intervention|Control Condition|"In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training~The control group will receive a follow-up survey inviting them to evaluate their progress on creating their sustainability plan. Responses on the follow-up survey do not impact participants' standing in the study"
10213650|NCT03592641|Experimental|Treatment (savolitinib)|Patients receive savolitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10213651|NCT03589729|Experimental|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
9861144|NCT00003248|Experimental|Arm I|"Patients receive fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction. Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks.~Patients are followed every 3 months for 1 year, and then every 6 months thereafter."
9861145|NCT00003248|Experimental|Arm II|Patients receive fludarabine induction. Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.
9861146|NCT00003249|Experimental|Arm I|Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.
9861147|NCT00003254|Experimental|776C85 + 5-FU|776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
9861148|NCT00003255|Experimental|topotecan + carboplatin|Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.
9861149|NCT00003256|Experimental|Arm I|Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
9861150|NCT00003276|Experimental|irinotecan|Patients receive a 90 minute continuous infusion of irinotecan on days 1, 8, 15, and 22 for 4 weeks, followed by a 2 week rest period. Courses of treatment are repeated every 42 days. Patients continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for the next 4 years.
9861151|NCT00003278|Experimental|radiation + dexamethasone|"Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
9861152|NCT00003281|Experimental|topotecan + paclitaxel + radiotherapy|"Patients receive topotecan IV over 30 minutes on days 1-3 and paclitaxel IV over 3 hours on day 3. Courses repeat every 4 weeks.~Patients who achieve partial response or stable disease continue treatment in the absence of complete response or disease progression. Patients who develop disease progression in the CNS only should receive whole brain radiotherapy and then continue treatment. Patients who achieve complete remission receive a maximum of 6 courses of treatment. Patients may then undergo prophylactic cranial irradiation and/or thoracic radiotherapy at the discretion at the attending physician.~Patients are followed every 3 months for 2 years and then at 3 years after study."
9861153|NCT00003282|Experimental|Diagnostic (EF5)|Patients receive etanidazole derivative EF5 IV over 1-2 hours beginning approximately 24 hours prior to surgery. Tumors are then resected or biopsied after Eppendorf needle electrode measurements.
9861154|NCT00003288|Experimental|Arm I|See arm description.
9925124|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD|
9925125|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD + Added Therapy|
9925126|NCT00868153||Group 1|
9925127|NCT00868179|Experimental|Pradax|This is the only arm in the study and all will follow the same protocol for the study which is taking the pradax after total knee replacement
9925128|NCT00868205|Experimental|low coffee dose|3 cups of coffee daily for 8 weeks
9925129|NCT00868205|Experimental|high coffee dose|5 cups of coffee daily for eight weeks
9925130|NCT00868205|No Intervention|Control|Consumption of water instead of coffee daily for eight weeks
9861155|NCT00003292|Experimental|ifosfamide|ifosfamide
9861156|NCT00003299|Active Comparator|Cisplatin + Etoposide|
9861157|NCT00003299|Experimental|Cisplatin + Etoposide + Paclitaxel|
9861158|NCT00003311|Experimental|Regimen A|Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
9861159|NCT00003311|Experimental|Regimen B|Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.
9861160|NCT00003313|Experimental|Arm 1|Radiation therapy and chemotherapy + Amifostine
9861161|NCT00003313|Active Comparator|Arm 2|Radiation therapy and chemotherapy alone
9861162|NCT00003317|Active Comparator|Surgery + paclitaxel + carboplatin|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
9861163|NCT00003317|Experimental|Surgery + paclitaxel + carboplatin + radiotherapy|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients receive radiotherapy 5 days a week for 5 weeks to the mediastinum, beginning 2.5 to 4 weeks after completion of chemotherapy. Patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
9861164|NCT00003323|Experimental|Hormone Therapy|Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
9861165|NCT00003325|Other|Sentinenal lymph node mapping|Sentinenal lymph node mapping
9861166|NCT00003330|Experimental|Arm I|See detailed description.
9861167|NCT00003350|Experimental|Arm I (paclitaxel)|"Patients receive paclitaxel over 3 hours by intravenous infusion. Treatment course repeats every 2 weeks. Patients are evaluated every third course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
9861168|NCT00003350|Experimental|Arm II (pegylated liposomal doxorubicin hydrochloride)|"Patients receive doxorubicin HCL liposome over 30-60 minutes by intravenous infusion. Treatment course is repeated every 3 weeks. Patients are evaluated before every odd course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
9861169|NCT00003351|Experimental|Arm I: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every week for 4 weeks followed by a 2 week rest period. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
9861170|NCT00003351|Experimental|Arm II: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every 3 weeks for 6 weeks. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
9861171|NCT00003369|Experimental|tirapazamine/cisplatin|tirapazamine and cisplatin given Day 1 of each 21-day treatment cycle
9861172|NCT00003370|Experimental|Arm I|"If the dose limiting toxicity is myelosuppression in stratum 1, then stratum 1 is closed and stratum 2 opens.~Stratum 2 consists of the following: patients receiving no more than 2 prior chemotherapy regimens; patients who have not received prior central axis radiation or bone marrow transplantation; and patients with no known bone marrow involvement. Patients receive intravenous 6-hydroxymethylacylfulvene over 10 minutes daily for 5 days. The course is repeated every 28 days unless disease progression or unacceptable toxic effects are observed. Patients with stable or responding disease may receive up to 1 year of therapy. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose. Dose escalation will not occur until all patients within a cohort have been observed for 28 days from day 1 of therapy. Patients are followed until death."
9861173|NCT00003375|No Intervention|Observation|Observation only.
9861174|NCT00003375|Experimental|Radiation therapy|Radiation therapy only.
9861175|NCT00003375|Experimental|Radiation plus PCV chemotherapy|Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy
9861176|NCT00003384|Experimental|Diagnostic|"Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression.~Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks."
9861177|NCT00003387|Experimental|Chemo + radiation|
9861178|NCT00003387|Experimental|Induction chemo + chemo & radiation|
9861179|NCT00003416|Experimental|treatment|"Ind:~dexamethasone 40 mg/d PO D1-4,9-12,17-20 q35 days x 3 cycles~SC Collection:~cyclophosphamide 1.5gm/m2 IV q3 hrs x 2 mesna 3 gm/m2 conIV start with cyclo GCSF 5mcg/kg/d SQ start 1 day after cyclo until WBC > 50,000/mcg~Trans (x2):~melphalan 100 mg/m2/d IV D-1,-2 PBSC infusion D0~Maint:~interferon 3 million units/m2 SQ 3x/wk"
9861180|NCT00003425|Experimental|Amifostine trihydrate|
9861181|NCT00003432|Experimental|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed DC cancer vaccine
9861182|NCT00003439|Experimental|Arm I|Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
9861183|NCT00003440|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks.
9861184|NCT00003440|Active Comparator|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour weekly.
9861185|NCT00003440|Experimental|Arm C (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm I. Patients also receive trastuzumab IV weekly.
9861186|NCT00003440|Active Comparator|Arm D (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm II and trastuzumab as in Arm III.
9861187|NCT00003440|Experimental|Am E (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm C.
9861188|NCT00003440|Active Comparator|Arm F (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm D.
9861189|NCT00003441|Experimental|Irofulven|6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days every 28 day cycle.
9861190|NCT00003451|Experimental|Arm I|Cohorts of 3 patients receive interleukin-12 IV push on day 1, followed by escalating doses of interferon alfa by subcutaneous injection at 24, 48, 72, 96 and 120 hours. Courses repeat every 2 weeks for 6 months (12 courses total) in the absence of unacceptable toxicity and disease progression. Patients achieving partial response or stable disease at the completion of 6 months of therapy may receive additional courses of therapy for up to 24 months. Dose escalation of interferon alfa continues in subsequent cohorts in the absence of dose limiting toxicity (DLT). If 1 of 3 patients experiences DLT at a dose level, then 3 additional patients are entered at that dose level. If 2 of 6 patients experience DLT, then dose escalation stops. The maximum tolerated dose is defined as 1 level below that dose at which 2 or more of 6 patients experience DLT. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
9861191|NCT00003452|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861192|NCT00003454|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861193|NCT00003485|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861194|NCT00003489|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861195|NCT00003491|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861196|NCT00003494|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861197|NCT00003495|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861198|NCT00003496|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
10210079|NCT02546986|Experimental|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
10210080|NCT02546986|Experimental|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
10210081|NCT02539160|Active Comparator|CKD - Ticagrelor 90|Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
10210082|NCT02539160|Experimental|CKD - Ticagrelor 60|Patients with chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
10210083|NCT02539160|Active Comparator|Non-CKD - Ticagrelor 90|Patients without chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
10210084|NCT02539160|Experimental|Non-CKD - Ticagrelor 60|Patients without chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
10210085|NCT02536300|Experimental|Idelalisib 150 mg Continuously|"Participants will receive idelalisib 150 mg twice daily continuously.~For participants enrolled prior to protocol amendment 5: Based on the independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily."
9861199|NCT00003497|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
9861200|NCT00003500|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861201|NCT00003501|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861202|NCT00003512|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861203|NCT00003513|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861204|NCT00003515|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861205|NCT00003516|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
9861206|NCT00003520|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861207|NCT00003521|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861208|NCT00003522|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861209|NCT00003524|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861210|NCT00003525|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861211|NCT00003528|Experimental|Arm I|Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.
9861212|NCT00003530|Experimental|Antineoplaston Therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861213|NCT00003532|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861214|NCT00003533|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861215|NCT00003534|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
9861216|NCT00003545|Experimental|Arm I|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
9925131|NCT00868257||CHARTA study cohort|Primarily 5- to 10-year-old Ugandan children with HIV or AIDS who are taking ART, with some 1- to 4-year-olds included because of recent trends in treating younger children
9925132|NCT00868270||Children with UTIs|
9925133|NCT00868283|Experimental|Cerebrolysin|
9925134|NCT00868283|Placebo Comparator|0.9% Saline Solution|
9925135|NCT00868335|Active Comparator|1|Anterior cervical discectomy, no disc prosthesis
9861217|NCT00003546|Experimental|gemcitabine + radiation|Patients receive radiation therapy 5 days per week for 5 1/2 weeks and gemcitabine IV over 30 minutes not greater than 2 hours prior to radiation therapy twice weekly. This combination radiation therapy and chemotherapy is followed by 2 weeks of rest. Patients with stable or responding disease receive a higher dose of gemcitabine IV over 30 minutes weekly for 3 weeks followed by 1 week of rest. This 4 week course is repeated 3 more times for a total of 16 weeks of gemcitabine therapy alone. Patients are followed every 2 months for the first year and then every 3 months for the next 2 years or until disease progression. Upon documentation of disease progression, patients are followed every 3 months for survival and secondary malignancy.
9861218|NCT00003553|Experimental|1|The target for progenitor cell is >=5 x 106 CD 34/kg.
9861219|NCT00003556|Experimental|Arm I|Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.
9861220|NCT00003557|Experimental|Arm A|Dolastatin-10 (400 mcg/m2 IV every 3 weeks)
9925136|NCT00868335|Experimental|2|Anterior cervical discectomy, with disc prosthesis
9925137|NCT00868361|Experimental|Slow and rapid N-acetyl transferase genotypes|
9925138|NCT00868387|Experimental|energy-restricted, CHO-restricted diet|Interventions: carbohydrate restriction of diet: 40% Frequency: daily Duration: 12 months
9925139|NCT00868387|Active Comparator|energy-restricted, CHO-rich diet|Comparator: carbohydrate content of diet: > 55% Frequency: daily Duration: 12 months
9925140|NCT00868400|Experimental|1|High-carbohydrate
9925141|NCT00868400|Placebo Comparator|2|Placebo
9925142|NCT00868400|No Intervention|3|Control
9925143|NCT00868413|Active Comparator|A|FCR+ABT-263
9925144|NCT00868413|Active Comparator|B|BR+ABT-263
9925145|NCT00868426|Experimental|1|Budesonide/Formoterol Batch 1
9925146|NCT00868426|Experimental|2|Budesonide/Formoterol Batch 2
9925147|NCT00868426|Experimental|3|Budesonide/Formoterol Batch 1 and charcoal
9925148|NCT00868465|Active Comparator|1|Artemether-lumefantrine; currently the first line treatment in Tanzania
9925149|NCT00868465|Experimental|2|Dihydroartemisinin-piperaquine, alternative ACT
9925150|NCT00868504||examined by endoscopy|Patients, examined by endoscopy, being screened for GI tract tumors
9925151|NCT00868543|Active Comparator|Long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with long (150 cm) alimentary Roux limb
9925152|NCT00868543|Active Comparator|Very long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with very long (250 cm) alimentary Roux limb
9925153|NCT00868556||1 episodic migraine sufferers|
9925154|NCT00868556||2 chronic migraine sufferers|
9925155|NCT00868556||3 non migraine sufferers (controls)|
9925156|NCT00868569|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.
9925157|NCT00868569|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
9925158|NCT00868582||FDG-PET|F-18 fluorodeoxyglucose (FDG-PET)
9925159|NCT00868582||NaF-18 PET|F-18 sodum-fluoride (NaF-18 PET)
9925160|NCT00868595|Experimental|Dose escalation|"Cohort 1: BPX-101, 4 x 10*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10*6 cells administered every 4 weeks for 3 cycles~At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours."
9925161|NCT00868621||1|Control
9925162|NCT00868621||2|Overactive Bladder Patients
9925163|NCT00868621||3|Urinary Tract Infection
9925164|NCT00868634|Active Comparator|A|Capecitabine / Bevacizumab
9925165|NCT00868634|Experimental|B|Capecitabine / Bevacizumab / Vinorelbine
9925166|NCT00868647|Other|Radiofrequency Ablation|
9925167|NCT00868660|Experimental|ZP1848|Healthy Subjects or Crohn's Disease patients
9925168|NCT00868660|Placebo Comparator|Placebo|Healthy subjects or Crohn's Disease patients
9925169|NCT00868673|Active Comparator|Low fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities, defined as: Diabetes (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~They will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and rest energy (without exercise).~This group will be assigned to a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of less than 20 grams/day fructose diet levels.~Total Time of intervention 6 weeks for each patient"
9861221|NCT00003563|Experimental|WBRT|3 Gy of WBRT daily for a total of 10 days
9861222|NCT00003563|Experimental|MGd|IV does of 5.0 mg/kg MGd plus WBRT
9861223|NCT00003564|Experimental|Arm I (Procarbazine + Isotretinoin)|Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.
9861224|NCT00003564|Experimental|Arm II (Procarbazine Alone)|Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.
9861225|NCT00003565|Experimental|docetaxel|OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
9861226|NCT00003566|Experimental|video-thorascopy + surgery|Patients will undergo ipsilateral video-thorascopic evaluation. Patients may undergo surgery at the discretion of the surgeon and treating physicians.
9861227|NCT00003571||Samples of tumor and normal tissue|Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
9861228|NCT00003573|Experimental|Treatment 1, Etoposide, 50mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
9861229|NCT00003573|Experimental|Treatment 2, Etoposide, 35mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
9861230|NCT00003575|Experimental|Arm I|All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.
9861231|NCT00003587|Experimental|carboplatin/gemcitabine/paclitaxel|IV carboplatin AUC=5.5 day 1 every 21 days X 3 IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3 IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
9861232|NCT00003587|Experimental|cisplatin/vinorelbine/docetaxel|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3 IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3 IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
9861233|NCT00003588|Experimental|Arm I|Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.
9861234|NCT00003591|Experimental|Pacilitaxel + External Beam Radiation Therapy (PXRT)|Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.
9861235|NCT00003593|Experimental|Arm A: TMD patients only|Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
9861236|NCT00003593|Experimental|Arm B: AML/MDS patients only|(closed to accrual as of 6/24/04 except for patients first enrolled in group I): Patients receive induction therapy comprising cytarabine IV continuously, daunorubicin hydrochloride IV continuously, and oral thioguanine twice daily on days 0-3. Treatment repeats every 28 days for 4 courses. Patients with no CNS disease at diagnosis receive cytarabine intrathecally (IT) on day 0. Patients with CNS disease at diagnosis receive cytarabine IT on days 0, 5, and 7. If CNS disease persists on day 7, patients receive up to 6 courses of cytarabine IT, therapeutic hydrocortisone IT, and methotrexate IT, twice weekly beginning on day 10. Asparaginase during Intensification 1 day 1 hour 18.
9861237|NCT00003594|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
9861238|NCT00003594|Experimental|oxaliplatin + leucovorin + fluorouracil|"Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
9861239|NCT00003594|Experimental|oxaliplatin + irinotecan|"Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
9861240|NCT00003595|Experimental|Arm I|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 3 and oral prednisone on days 3-7. Patients receive rituximab on day 1. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response in the absence of disease progression or unacceptable toxicity. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy with rituximab followed by radiotherapy beginning 3 weeks after completion of the third course. Patients who achieve partial response for a minimum of 28 days or complete response receive maintenance rituximab IV beginning on day 28 of the final course of chemotherapy. Maintenance rituximab treatment repeats every 4 weeks for 3 courses.
9861241|NCT00003595|Active Comparator|Arm II|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy. Patients receive radiotherapy beginning 3 weeks after completion of the third course of chemotherapy.
9861242|NCT00003597|Experimental|Cohort 1|Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
9935216|NCT04041050|Experimental|Part 4: Navitoclax + Celecoxib|Participants will receive navitoclax once daily (QD) starting on Day 3. Participants will also receive celecoxib single dose on Day 1 and Day 7.
9935217|NCT04034264||Afebrile close contact|Lived in the same household or worked in the same enclosed workspace daily with a febrile enrollee at the time they got sick with a known red or yellow flag transmissible pathogen.
9861243|NCT00003597|Experimental|Cohort 2|"Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 μg/kg/dose and subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 μg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to~≥ 1,000/μL and the platelet count to ≥ 100,000/μL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6."
10210086|NCT02536300|Experimental|Idelalisib 100 mg|"Participants will receive idelalisib 100 mg twice daily continuously. Based on the IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily.~As of protocol amendment 5, enrollment to this arm has been closed."
9861244|NCT00003599|Experimental|Arm I|Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)
9861245|NCT00003599|Experimental|Arm II|Isotretinoin orally plus AT placebo orally daily (arm II).
9861246|NCT00003600|Experimental|epoetin alfa|Patients receiving chemotherapy are randomized to receive epoetin alfa subcutaneously once a week for a maximum of 16 weeks Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
9861247|NCT00003600|Placebo Comparator|placebo|Patients receiving chemotherapy are randomized to receive placebo subcutaneously once a week for a maximum of 16 weeks. Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
9861248|NCT00003610|Experimental|capsaicin + radiation therapy|Patients receive one lozenge orally of capsaicin four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
9861249|NCT00003610|Placebo Comparator|placebo + radiation therapy|Patients receive one lozenge orally of placebo four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
9861250|NCT00003611|Experimental|acitretin|"Patients receive oral acitretin daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
9861251|NCT00003611|Placebo Comparator|placebo|"Patients receive placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
9861252|NCT00003612|Experimental|Schedule A: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
9861253|NCT00003612|Experimental|Schedule B: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
9861254|NCT00003613|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9935218|NCT04034264||Febrile patient|Patients between 2 months and 65 years old who present with fever.
9935219|NCT04034251|Experimental|1/ Arm1|IP and IV paclitaxel administration with concomitant oral capecitabine
10210087|NCT02536300|Experimental|Idelalisib 150 mg 28-Day Cycles|Participants will receive idelalisib 150 mg twice daily in 28-day cycles with 21 days on-treatment and 7 days off-treatment.
10210088|NCT02530112||Phase 1|First round of survey respondents.
10210089|NCT02530112||Phase 2|Second round of survey respondents.
10210090|NCT02530112||Phase 3|Third round of survey respondents.
10210091|NCT02521103|Other|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
10210092|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Neoadjuvant Chemo (NAC) Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 6 time points.
10210093|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Non-NAC Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 1 time point.
10210094|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
10210095|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
10210096|NCT02478983|Experimental|LMA Supreme|1 arm will receive LMA supreme for airway management
10210097|NCT02478983|Active Comparator|LMA Proseal|1 arm will receive LMA Proseal for airway management
10210098|NCT02477696|Experimental|ACP-196|acalabrutinib 100 mg BID (Arm A; N=250)
10210099|NCT02477696|Active Comparator|ibrutinib|ibrutinib 420 mg QD (Arm B; N=250)
10210100|NCT02477618|Active Comparator|SAGE-547|Intravenous
10210101|NCT02477618|Placebo Comparator|Placebo|Intravenous
10210102|NCT02447653|Experimental|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
10210103|NCT02447653|Active Comparator|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
10213652|NCT03588754|Experimental|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
9861255|NCT00003620|Experimental|Treatment (flavopiridol)|"Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.~Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
9861256|NCT00003621|Experimental|carmustine + etoposide + cisplatin + radiation therapy|Patients receive carmustine IV over 1 hour on days 1-3, oral etoposide on days 1-21 and 29-49, and cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 3 courses. Patients receive radiotherapy concurrently with the third course of chemotherapy. Quality of life is assessed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 3 months for 5 years and then annually thereafter.
9861257|NCT00003622|Experimental|paclitaxel + vinorelbine|
9861258|NCT00003623|Experimental|Multivitamin|Patients receive multivitamins orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
9861259|NCT00003623|Placebo Comparator|Placebo|Patients receive placebo orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
9861260|NCT00003625|Experimental|Stratum 1|Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
9861261|NCT00003648||Group 1|Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
9861262|NCT00003653|Active Comparator|Intermittent Androgen Suppression|
9861263|NCT00003653|Active Comparator|Continuous Androgen Suppression|
9861264|NCT00003657|Experimental|High Dose ICF with Amifostine|"Patients undergo peripheral blood stem cell transplantation (PBSC) harvest on day -8,~ifosfamide IV, carboplatin IV etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4.~Patients receive amifostine IV twice a day on days -7 to -3.~PBSCs are reinfused on day 0.~Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.~Patients are followed monthly for the first 2 months and then for survival."
9861265|NCT00003665|Experimental|Arm I|Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
9861266|NCT00003665|Experimental|Arm II|Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
10210104|NCT02444741|Experimental|Group I, Phase I (pembrolizumab + SBRT)|Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
10210105|NCT02444741|Experimental|Group I, Phase II (pembrolizumab + SBRT)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT, PBT, or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
10210106|NCT02444741|Experimental|Group II, Phase I (pembrolizumab + IMRT, PBRT or 3D-CRT)|Patients who exhibit a lung lesion of size or location not amenable to SBRT, but amenable to WFRT receive pembrolizumab as in Group I and either IMRT, PBRT, or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration.
10210107|NCT02444741|Experimental|Group II, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks), patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe, then the patient will be salvaged with IMRT, PBRT, or 3D-CRT and analyzed as part of the fourth treatment group.
10210108|NCT02444741|Experimental|Group III, Phase II (pembrolizumab + IMRT, PBRT, or 3D-CRT)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT, PBRT, or 3D-CRT on days 43-61.
10213653|NCT03588754|Placebo Comparator|Placebo|Administered orally once daily at 10:00PM
10213654|NCT03588130|Active Comparator|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
10213655|NCT03588130|Placebo Comparator|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
10213656|NCT03588130|Active Comparator|Non-surgical standard of care (NSSOC)|Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved
9861267|NCT00003665|Experimental|Arm III|Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
9861268|NCT00003666|Experimental|HMAF|treatment of refractory or relapsed NSCLC with HMAF
9861269|NCT00003671|Experimental|Chemotherapy Treatment|See detailed description.
9861270|NCT00003674|Experimental|dalteparin + standard therapy|Patients receive dalteparin by subcutaneous injection once daily plus standard therapy. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
10210109|NCT02444741|Experimental|Group IV, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab, while patients with SD or PR will not start XRT and will continue to be followed. These patients will then have follow up CT scans 5 weeks after course 3 and then approximately every 3 months for the remainder of the trial; any patient at this point with PD will then have XRT delivered with the sixth dose of pembrolizumab.
9861271|NCT00003674|Active Comparator|standard therapy|Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
9861272|NCT00003675|Experimental|Oral Topotecan 5 days|Patients receive intervention twice daily for 5 days
9861273|NCT00003675|Experimental|Oral Topotecan 10 days|Patients receive intervention once daily for 10 days
9861274|NCT00003677|Experimental|Dolastatin 10|Dolastatin 10 IV bolus once every 21 days.
9925170|NCT00868673|Active Comparator|Normal fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities; defined as: Diabetes Mellitus (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet (of 15% proteins, 30% lipids and 55% carbohydrates); calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise).~This group will receive a controlled fructose diet between 50 and 70 grams/day of fructose intake.~Total time of intervention:6 weeks for each patient"
9925171|NCT00868686|Active Comparator|Volar aluminum splint|
9925172|NCT00868686|Active Comparator|Dorsal aluminum splint|
9925173|NCT00868686|Active Comparator|Custom thermoplastic|
9925174|NCT00868725||possible oral cancer|Patients reporting for oral cavity examination with the possibility or certainty of oral lesions
9925175|NCT00868738|Active Comparator|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
9925176|NCT00868738|Placebo Comparator|Placebo|Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
9925177|NCT00868764|Experimental|Sancuso® patch|Subjects receiving 1 Sancuso® patch worn for 7 days
9925178|NCT00868777|Experimental|Sinus grafting using allogenic bone|
9925179|NCT00868816|Experimental|1|12 cycles of oxaliplatine based adjuvant chemotherapy
9925180|NCT00868816|Active Comparator|2|8 cycles of oxaliplatine based adjuvant chemotherapy
9925181|NCT00868829|Experimental|Firebird2|
9925182|NCT00868855|Experimental|1|Bradykinin
9925183|NCT00868881||1|Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
10210110|NCT02444741|Experimental|Group V, Phase II (low dose radiation therapy)|Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT, PBRT, or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47.
10210111|NCT02444429|Experimental|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
9925184|NCT00868881||2|Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
9925185|NCT00868881||3|Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
9925186|NCT00868881||4|Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
9925187|NCT00868881||5|Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
9925188|NCT00868881||6|Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
9925189|NCT00868894|Experimental|1|
9925190|NCT00868894|Experimental|2|
9925191|NCT00868894|Placebo Comparator|3|
9925192|NCT00868894|Active Comparator|4|
9935220|NCT04029883|No Intervention|Control Group|The Control group will receive care as usual, as well as a MEMS-cap and a leaflet explaining the importance of pill-taking routines and how to establish them. The study coordinator will spend approximately ten minutes with them to go over the leaflet and answer questions. Control group participants also spend time with the study coordinator at each clinic visit where contact information is updated, and any MEMS-cap problems are resolved. These procedures, which we successfully applied in previous studies, minimize the possibility that results are confounded by differences in attention or other non-specific effects between groups.
9861275|NCT00003686|Active Comparator|Pilocarpine|
9861276|NCT00003686|Placebo Comparator|Placebo|
9861277|NCT00003692|Experimental|video-assisted surgery|Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
9861278|NCT00003693|Experimental|MTD Group|
9861279|NCT00003694|Experimental|Treatment (omacetaxine mepesuccinate, cytarabine)|Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days. Courses repeat every 28 days. Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity. Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon. Minor cytogenetic responders are switched to interferon, and nonresponders are removed from therapy and given the option to switch to interferon.
9861280|NCT00003700|Experimental|Daunorubicin, ara-C, & MTX Therapy|daunorubicin during induction, increasing doses of cytarabine during consolidation followed by methotrexate in place of cranial irradiation for treatment of ALL
9861281|NCT00003704|Experimental|capecitabine + radiation|This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
9861282|NCT00003714|Experimental|Pyrazoloacridine|
9861283|NCT00003723|Experimental|Gemcitabine/Cisplatin|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days) cisplatin 30 mg/m^2 days 1, 8, 15 (q 28 days)
9861284|NCT00003724|Experimental|surgery|"Patients undergo open resection (thoracotomy, median sternotomy, or bilateral sternothoracotomy).~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
9861285|NCT00003724|Experimental|video-assisted surgery|"After spiral CT showing pulmonary nodules are amenable to video-assisted thoracic surgery (VATS) resection with curative intent, patients undergo minimally-invasive video-assisted resection.~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
9861286|NCT00003735|Experimental|Stratum 1 - Stage 1|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
9861287|NCT00003735|Experimental|Stratum 2 - Stage 2|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
9861288|NCT00003744|Experimental|Intercalcated Duct|"The first group, referred to as intercalated duct will include Aadenoid cystic carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade adenocarcinoma, undifferentiated carcinoma, and adenocarcinoma.~- Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~-- Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
9861289|NCT00003744|Experimental|Excreatory Duct|"The second group, referred to as excretory duct, will include: squamous cell carcinoma and mucoepidermoid carcinoma.~Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
9861290|NCT00003745|Experimental|Arm I|Patients receive topotecan IV continuously on days 1-21. Treatment continues at least every 4 weeks in the absence of unacceptable toxicity or disease progression.
9861291|NCT00003746|Active Comparator|CDA day|CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
9861292|NCT00003746|Active Comparator|CDA week|CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
9861293|NCT00003748|Experimental|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
9861294|NCT00003750|Experimental|DG2 positive relapsed or refractory solid tumors|The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
9795536|NCT01538199|Experimental|TLT Treatment Group 1|The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
9795537|NCT01538199|Sham Comparator|TLT Treatment Group 2|The sham group will receive 2 treatments of the sham device per week for 8 weeks
9795538|NCT01538472|Experimental|Y Zevalin + BEAM|"Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.~G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 * 109/L."
9517088|NCT03309592|Other|Combination Therapy|Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
9517089|NCT03309579|Experimental|Liberal RBC Transfusion Strategy|Hemoglobin value of ≤100g/L
9795539|NCT01538615|Experimental|HOME Plus Intervention|described below
9795540|NCT01538615|No Intervention|Control|Control participants receive a monthly newsletter for the 10 months of the study with tips on healthy eating. The topics do not overlap the intervention content.
9795541|NCT01538628|Experimental|SpaceOAR|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
9795542|NCT01538628|No Intervention|Control|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.
9795543|NCT01538719|Placebo Comparator|Placebo|2:1 randomization
9795544|NCT01538719|Active Comparator|Rilonacept|2:1 randomization
9795545|NCT01538745|Experimental|Ketamine|0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.
9795546|NCT01538745|Active Comparator|Morphine|0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.
9795547|NCT01538862|Experimental|Granulocyte Colony Stimulating Factor (GCSF)|GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days
9795548|NCT01539070|Experimental|Eating and physical activity counseling|Participants randomized to intervention received a 6 week curriculum focused on obesity awareness and prevention. A trained nutritionist led diet, healthy growth and physical activity workshops, while a health educator led workshops on instilling healthy habits and routines in childhood. The nurse provided child care and developed relevant games and activities for children while parents attended the workshops.
9795549|NCT01539070|No Intervention|Usual care|According to the existing clinical practice guide within IMSS, obese children may be referred to a nutritionist if the physician considers it necessary, given general dietary advice by the attending physician, or, if necessary, sent for laboratory analyses of blood lipids and glucose. We gave the parents the height and weight results from the measurement of their child and recommended they share results with their physician in their next medical consultation.
9795550|NCT01539083|Experimental|Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]|Bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
9795551|NCT01539083|Experimental|Thalidomide + Prednisolone [TP Consolidation]|Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
9795552|NCT01539083|Experimental|Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]|Bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
9795553|NCT01539135|Active Comparator|Hi-Lo endotracheal tube|Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
9795554|NCT01539135|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
9795555|NCT01539239|Experimental|Hydrus Aqueous Implant (Treatment)|Cataract surgery plus Hydrus Aqueous Implant
9795556|NCT01539239|Active Comparator|Cataract Surgery (Control)|Cataract surgery only
9861295|NCT00003761|Experimental|rV-DF3/MUC1|"rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.~Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months"
9861296|NCT00003762|Experimental|Arm I: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
9861297|NCT00003762|Experimental|Arm II: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
9861298|NCT00003762|Experimental|Arm III: docetaxel + gemcitabine|"Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
9861299|NCT00003765|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose level at which fewer than 2 of 6 patients experience dose limiting toxicity (DLT). If myelosuppression is the DLT, stratum 1 is closed and patients are accrued to stratum 2. If neutropenia is the DLT in stratum 2, patients receive filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until blood counts recover.
9861300|NCT00003766|Experimental|Arm A|06-benzylguanine (100mg/m2 16 hrs before anticipated tumor tissue removal)
9861301|NCT00003778|Experimental|Arm I|Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9861302|NCT00003779|Active Comparator|BCG-Connaught|
9861303|NCT00003779|Active Comparator|BCG Onko-Tice|
9861304|NCT00003783|Experimental|Complete Response and no CNS 3|See detailed description.
10210112|NCT02444429|Active Comparator|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
10210113|NCT02444429|Experimental|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
9861305|NCT00003783|Experimental|Complete Response and CNS 3|See detailed description.
9861306|NCT00003786|Experimental|Arm A|MGI-114 (11mg/m2/day x 5 days every 28 days)
9861307|NCT00003787||Intervention|high fiber, high vegetable, low-fat diet
9861308|NCT00003787||Control|NCI-recommended diet
9861309|NCT00003789|Experimental|Arm I|Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.
9861310|NCT00003789|Experimental|Arm II|Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.
9861311|NCT00003793||Identification of Genetical suceptibility prior to therapy|"Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a mutator phenotype as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML."
9861312|NCT00003793||Increased Risk Of T-MDS/AML before/after Therapy|Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.
9925193|NCT00868907|Experimental|Treatment A|35 mg risedronate DR tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
9925194|NCT00868907|Experimental|Treatment B|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
10210114|NCT02444429|Active Comparator|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
10210115|NCT02424851|Active Comparator|Arm A (BBD)|Bortezomib, Bendamustine and Dexamethasone
10210116|NCT02424851|Active Comparator|Arm B (BTD)|Thalidomide, Bendamustine and Dexamethasone
10213657|NCT03576976|Active Comparator|Clinic-based Cognitive Remediation|Clinic-based cognitive remediation is the current standard of care in NY State outpatient programs. It consists of twice weekly group-based and clinician-led sessions.
9517090|NCT03309579|Active Comparator|Restrictive RBC Transfusion Strategy|Hemoglobin value of ≤80g/L
9986470|NCT01403220|Active Comparator|Group 1 (hemodiafiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
9986471|NCT01403220|Active Comparator|Group 2 (hemofiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
9986472|NCT01403233|Experimental|cogniVida™ 50 mg/day|
9986473|NCT01403233|Experimental|cogniVida™ 100 mg/day|
9986474|NCT01403233|Active Comparator|Rebaudioside-A 303.7 mg/day|
9795557|NCT01539291|Experimental|High-dose Idelalisib|Participants will receive idelalisib 300 mg twice daily (600 mg per day).
9795558|NCT01539291|Experimental|Standard-dose Idelalisib|Participants will receive idelalisib 150 mg twice daily (300 mg per day)
9795559|NCT01539317|Active Comparator|Topical liquid lidocaine|
9795560|NCT01539317|Placebo Comparator|Topical Saline|
9795561|NCT01539512|Active Comparator|Idelalisib + rituximab|Participants will receive idelalisib plus rituximab
9795562|NCT01539512|Placebo Comparator|Placebo + rituximab|Participants will receive placebo to match idelalisib plus rituximab
9795563|NCT01539525|Experimental|Motivational Interview|Motivational interview provided by a clinical research nurse or physician.
9795564|NCT01539525|Active Comparator|Motivational Interview-Electronic|Motivational Interview provided by an interactive computer program.
9795565|NCT01539525|Placebo Comparator|Treatment as Usual|No intervention- resource list provided.
9795566|NCT01539538|Experimental|Sufentanil NanoTab PCA System/15 mcg|
9795567|NCT01539538|Active Comparator|morphine IV PCA|
9795568|NCT01539642|Experimental|Sufentanil NanoTab PCA System/15 mcg|
9795569|NCT01539642|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
9795570|NCT01539694|Experimental|LD118033 contact lens|Investigational LD118033 multifocal low add soft contact lenses, to be worn on a daily wear basis.
9795571|NCT01539694|Active Comparator|PureVision multifocal contact lens|PureVision multifocal low add soft contact lens, to be worn on a daily wear basis.
9795572|NCT01539759|No Intervention|Interval IUD Placement|Women randomized to this arm will be scheduled for their IUD placement 4-8 weeks after their cesarean delivery
9795573|NCT01539759|Experimental|Immediate Postplacental IUD placement|Women randomized to this arm will receive on IUD at time of cesarean delivery, immediately after the delivery of the placenta
9795574|NCT01539837|Placebo Comparator|Placebo|Drug excipient
9795575|NCT01539837|Active Comparator|Deferiprone 20mg|20mg/kg/day deferiprone
9795576|NCT01539837|Active Comparator|Deferiprone 30mg|30mg/kg/day Deferiprone
9795579|NCT01539980|Experimental|Sericin scaffold|
9795580|NCT01540045||BASELINE|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study
9795581|NCT01540071|Experimental|NRX 194204|This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.
9795582|NCT01540162||Group I|Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.
9795583|NCT01540162||Group II|Patients of group II remain unexposed to the probiotic Mutaflor.
9795584|NCT01540266|Experimental|first year psychology_structured|First year psychology students who watched the video where the physician gives structured information to the patient
9795585|NCT01540266|Active Comparator|First year psychology_non-structured|First year psychology students who watched the video where the physician gives non-structured information to the patient
9795586|NCT01540266|Experimental|First year medical_structured|First year medical students who watched the video where the physician gives structured information to the patient
9795587|NCT01540266|Active Comparator|First year mediclal_non-structured|First year medical students who watched the video where the physician gives non-structured information to the patient
9795588|NCT01540266|Experimental|Third year medical_structured|Third year medical students who watched the video where the physician gives structured information to the patient
9795589|NCT01540266|Active Comparator|Third year medical_non-structured|Third year medical students who watched the video where the physician gives non-structured information to the patient
9795590|NCT01540370||Patients with OAG and/or OHT|Patients with OAG and/or OHT
9795591|NCT01540409|Experimental|AVI-4658 (Eteplirsen)|Multiple-Dose Extension Study
9795592|NCT01540474|Experimental|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion. This is a first-in-human study of FMP012. 30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine. Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
9795593|NCT01540474|Experimental|Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
9795594|NCT01540474|Experimental|Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
9795595|NCT01540474|Other|Control group-Challenged Only|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
9861313|NCT00003796|Experimental|Arm I|Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
9861314|NCT00003799|Experimental|Treatment (chemotherapy, radiotherapy, surgery)|"Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks. Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.~Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and radiotherapy. The surgical procedure is determined by the extent of the tumor before preoperative therapy. The type of operative procedure may be abdominoperineal resection, low anterior resection (LAR), or LAR/coloanal anastomosis.~Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses."
9861315|NCT00003800|No Intervention|Laboratory/CT evaluation|Observation following orchiectomy
9861316|NCT00003812|Experimental|chemotherapy + radiation therapy|Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.
9861317|NCT00003819|Experimental|vaccine|This is a dose escalation study. Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19. Cohorts of 5 patients each receive escalating doses of TF(c)-KLH vaccine until the optimal dose, based on antibody response, is reached. Patients are followed monthly for 6 months, then every 3 months for 1 year.
9861318|NCT00003824|Experimental|cipro|ciprofloxacin
9861319|NCT00003824|Experimental|ceph|cephalexin
9861320|NCT00003828|Experimental|vinorelbine|vinorelbine 30 mg/m2/week IV bolus over approximately 6-10 minutes
10210117|NCT02423876|Experimental|Arm I (epidural placement, ERP)|Patients undergo epidural placement in the First Day Surgery pre-operative area or similar areas suitable for insertion of epidural catheters. In the post-operative anesthesia care unit, patients may receive medication via the epidural on an as needed basis, as determined by the anesthesia team. Dosing and rate of standardized medication will be managed by the anesthesia team until the epidural is removed. Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
10210118|NCT02423876|Active Comparator|Arm II (ERP)|Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
9861321|NCT00003829|Experimental|fludarabine + cyclophosphamide|Patients receive alternating courses of fludarabine and cyclophosphamide. Fludarabine is administered IV over 10-30 minutes on days 1-5 of courses 1, 3, and 5. Cyclophosphamide is administered IV over 30-60 minutes on day 1 of courses 2, 4, and 6. Treatment repeats every 4 weeks. Patients achieving clinical complete remission (CCR) after 6 courses of chemotherapy receive 2 additional courses (one course of each drug). Patients achieving partial remission after 6 courses of chemotherapy also receive 2 additional courses. If these patients then achieve CCR, they receive another 2 courses. Patients are followed every 3 months.
9861322|NCT00003831|Experimental|Lymph node sampling|Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
9861323|NCT00003831|Active Comparator|Lymph node dissection|Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
9861324|NCT00003832|Experimental|Treatment (bromodeoxyuridine)|Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate.Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.
10210119|NCT02422355||Femoral Neck Fractures AO/OTA 31-B1:3|Fixation using the implant FNS.
9861325|NCT00003833||Normal and tumor tissue pairs|Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
9861326|NCT00003834|Experimental|oxaliplatin + leucovorin + fluorouracil|Patients receive oxaliplatin IV over 2 hours on day 1, then leucovorin calcium IV over 2 hours with fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Patients with stable disease continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable. Patients who achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates continue treatment in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a response are treated until best response or until disease is deemed resectable. Patients who achieve a CR or PR and are resected may receive 2 to 4 additional courses of therapy at the discretion of the investigator. Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
10210120|NCT02400814|Experimental|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
10210121|NCT02400814|Experimental|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
9861327|NCT00003835|Experimental|Arm I (leucovorin calcium and fluorouracil)|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
9861328|NCT00003835|Experimental|Arm II (leucovorin calcium, fluorouracil, irinotrcan)|Patients receive irinotecan IV over 90 minutes, followed by leucovorin calcium IV, then followed by fluorouracil IV weekly for 4 weeks. Treatment is repeated every 6 weeks for 5 courses
9861329|NCT00003846|Experimental|Treatment|See detailed description.
9861330|NCT00003847|Experimental|Treatment|
9861331|NCT00003849|Experimental|rituximab|Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
9861332|NCT00003850|Experimental|Arm I|Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
10210122|NCT02400814|Experimental|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
10210123|NCT02384551|Active Comparator|HTHS|High total carbohydrate with high total simple carbohydrate diet
10210124|NCT02384551|Experimental|HTLS|High total carbohydrate with low total simple carbohydrate diet
9861333|NCT00003851|Active Comparator|Nutritional Arm|Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
9861334|NCT00003851|Active Comparator|Chemotherapy Arm|Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy. Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
9861335|NCT00003854|Experimental|Surgery + radiotherapy + adjuvant therapy|"Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.~Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.~All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.~Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery."
9861336|NCT00003855|Experimental|Surgery + radiotherapy|"Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes, followed by whole-breast radiotherapy (exclusive of a third supraclavicular field) 5 days a week for a maximum of 7 weeks. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
9861337|NCT00003855|Active Comparator|Radiotherapy|"Patients undergo breast radiotherapy only. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
9861338|NCT00003857|Active Comparator|Observation +/- tamoxifen for 5 years|Observation +/- tamoxifen 20 mg per day for 5 years
9861339|NCT00003857|Experimental|Radiation therapy +/- tamoxifen for 5 years|Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years
9861340|NCT00003858|Experimental|Mitoxantrone|Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 3 years, and then every 6 months for the next 3 years or until disease progression.
9861341|NCT00003861||Ancillary-Correlative (molecular genetic features)|Previously collected blood and tissue samples are analyzed via RT-PCR and flow cytometry.
9861342|NCT00003863||Group 1|"Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission.~Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells.~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
9861343|NCT00003865|Experimental|Toremifene|All enrolled patients
9861344|NCT00003873|Experimental|Arm I|Patients receive fluorouracil IV as a continuous infusion for 28 days.
9861345|NCT00003873|Experimental|Arm II|Patients receive eniluracil/fluorouracil orally twice a day for 28 days.
9861346|NCT00003892|Experimental|ISIS 5132|ISIS 5132 x 21 days IV infusion
10210125|NCT02384551|Experimental|LTHS|Low total carbohydrate with low total simple carbohydrate diet
10210126|NCT02384551|Experimental|LTLS|Low total carbohydrate with low total simple carbohydrate diet
10210127|NCT02358928|Other|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
10210128|NCT02358928|Other|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
9861347|NCT00003900|Experimental|irinotecan + docetaxel|Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
9861348|NCT00003906|Active Comparator|Group 1|Tamoxifen and placebo
9861349|NCT00003906|Experimental|Group 2|Raloxifene and Placebo
9861350|NCT00003909|Experimental|Arm I|Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.
9861351|NCT00003926|Experimental|Solid/brain tumor patients (1-18 years)|Patients with solid tumor or brain tumor in the 1-18 years old stratum.
9861352|NCT00003926|Experimental|Solid/brain tumor patients (19-45 years)|Patients with solid tumor or brain tumor in the 19-45 years old stratum.
9861353|NCT00003930|Experimental|Arm 1|Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.
9861354|NCT00003931||blood or bone marrow samples|"All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769.~Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1."
9925195|NCT00868907|Active Comparator|Treatment C|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
9925196|NCT00868920|Experimental|1|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached, the button will be transferred to the patient for Patient C0ntrolled Sedation."
9925197|NCT00868920|Experimental|2|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached,the anesthesiologist will control the sedation."
9925198|NCT00868933|Active Comparator|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
9925199|NCT00868933|Placebo Comparator|Simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
9925200|NCT00868946|Experimental|Treatment with IND Ribavirin|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with IND Virazole (Ribavirin) for 7 days with multiple dosing regime based on weight and dosage day.
9925201|NCT00868972|Active Comparator|Embolic protection|Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
9925202|NCT00868972|Sham Comparator|No embolic protection|Percutaneous renal stenting intervention without embolic protection
9925203|NCT00868985|Experimental|PEG 3350 plus electrolytes|Patients were dosed with PEG 3350 with electrolytes
9925204|NCT00868985|Experimental|PEG 3350 without electrolytes|Patients were dosed with PEG 3350 without electrolytes
9925205|NCT00869011|Experimental|1|Exercise
9925206|NCT00869011|No Intervention|2|No structured exercise program
9925207|NCT00869037|Active Comparator|Periarticluar Multimodal Technique|
9925208|NCT00869037|Active Comparator|CFNB plus Posterior Capsular Injection|
9925209|NCT00869063|Experimental|Diclofenac Sodium Patch|
9925210|NCT00869063|Placebo Comparator|Placebo Patch|
9925211|NCT00869076|Experimental|Pharmacist Management|In this arm the Pharmacist managed the Diabetes in collaboration with the primary care physician
9925212|NCT00869076|Active Comparator|Usual Care|The patient was managed by the primary care physician
9925213|NCT00869102|Experimental|GLP-1|
9925214|NCT00869115|Experimental|1|TREATMENT 0.5 μg/kg/min
9925215|NCT00869115|Experimental|2|TREATMENT 1.0 μg/kg/min
9925216|NCT00869115|Experimental|3|TREATMENT 1.5 μg/kg/min
9925217|NCT00869115|Placebo Comparator|4|PLACEBO
9925218|NCT00869154|Active Comparator|Primary care follow up|Multidisciplinary examination and follow up by the family doctor.
9861355|NCT00003934|Experimental|Arm I|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin every 12 hours on days 1-7 and daunorubicin IV on days 1-2 or days 1-3, depending on age. Patients may receive an additional course. Treatment begins no earlier than 2 weeks and no later than 4 weeks after hematopoietic recovery."
9861356|NCT00003934|Experimental|Arm II|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin as in arm I above. Patients also receive oral mercaptopurine once a day and oral methotrexate once weekly for up to 1 year."
9861357|NCT00003935|Experimental|Treatment|Induction: Patients receive oral etoposide daily on days 1-21 and vincristine sulfate IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiation therapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine sulfate IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter
9861358|NCT00003937|Experimental|Pilot 1 - Doxorubicin Intensification without Ifosfamide|Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.
9861359|NCT00003937|Experimental|Pilot 2 - Doxorubicin Intensification with Ifosfamide|Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29
9861360|NCT00003937|Experimental|Pilot 3 - Ifosfamide/Etoposide Intensification|Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33
9861361|NCT00003950|Experimental|CPT-11 with Cyclosporine|Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
9861362|NCT00003953|Experimental|Doxorubicin and Docetaxel|
9861363|NCT00003954|Experimental|Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)|"CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
9861364|NCT00003958|Experimental|Arm I|Vincristine sulfate IV once a wk on wks 0-12, 15, 18-24, 27, 30-36, and 39. Dactinomycin IV once a wk on wks 0, 3, 6, 9, 12, 21, 24, 27, 30, 33, 36, and 39. Cyclophosphamide IV once a wk on wks 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, and 39. After 12 weeks of chemotherapy, depending on tumor shrinkage, pts may undergo surgery. After recovery from therapeutic conventional surgery, patients receive radiation therapy once a day, 5 days a wk, during wks 12-18. For pt receiving radiotherapy during wks 0-6, dactinomycin is omitted during wks 3 and 6 and during wks 15 and 18. For patients receiving radiotherapy during wks 12-18, dactinomycin is omitted during wks 15 and 18. Patients with adequate response at wk 24 continue chemotherapy during wks 24-39. All pts receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery.
9861365|NCT00003958|Experimental|Arm II|"Patients receive treatment as in arm I, except dactinomycin is replaced with topotecan hydrochloride IV over 15-30 minutes daily for 5 days during weeks 3, 9, 21, 27, 33, and 39.~All patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery."
9925219|NCT00869154|Experimental|Multidisciplinary follow up|Multidisciplinary examination and follow up by a multidisciplinary outpatient team.
9861366|NCT00003963|Experimental|Vinorelbine and Rituxan|"Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Rituxan given every 2 weeks. Vinorelbine given weekly x3, with one week off.~Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
9861367|NCT00003966|Experimental|Arm A Lower dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
9861368|NCT00003966|Experimental|Arm B Higher Dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
9861369|NCT00003968|Experimental|Arm I|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
9861370|NCT00003970|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 90 minutes once every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.
9861371|NCT00003992|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
9861372|NCT00003992|Experimental|Arm II|Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9861373|NCT00003994|Experimental|Arm I (cisplatin, vincristine sulfate, fluorouracil)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive cisplatin IV over 4 hours on day 1, vincristine sulfate IV on days 3, 10, and 17, and fluorouracil on day 3.
9861374|NCT00003994|Experimental|Arm II (cisplatin, vincristine, fluorouracil, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm I with the addition of amifostine trihydrate IV over 15 minutes prior to cisplatin on day 1.
9861375|NCT00003994|Experimental|Arm III (carboplatin, cisplatin)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive carboplatin IV over 1 hour on day 1 and cisplatin IV over 4 hours on day 15.
9861376|NCT00003994|Experimental|Arm IV (carboplain, cisplatin, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm III with the addition of amifostine trihydrate IV over 15 minutes prior to carboplatin on day 1.
9861377|NCT00003995|Experimental|Arm I|Patients receive a loading dose of trastuzumab IV over 90 minutes on week 1, and over 30-90 minutes weekly thereafter. Patients receive irinotecan IV over 90 minutes following trastuzumab weekly for 4 weeks. Courses are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
9861378|NCT00003996|Experimental|chemotherapy + carmustine + etoposide + cisplatin + radiation|Patients receive pre-irradiation chemotherapy consisting of carmustine IV over 1 hour on days 1-3 and oral etoposide on days 1-21 and 29-49 immediately followed by cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 2 courses. Patients receive concurrent cranial radiotherapy daily over 8 weeks during course 2. Patients then receive carmustine IV over 1-2 hours every 8 weeks for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before the study, prior to each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 4 months for 1 year, every 6 months for 4 years, annually for 5 years, and then for survival.
9861379|NCT00003997|Experimental|Arm I|Patients receive 6-hydroxymethylacylfulvene (HMAF) IV over 5 minutes on days 1-5. Treatment repeats every 3-4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of HMAF. The maximum tolerated dose is defined as the dose at which dose limiting toxicity occurs in at least 40% of patients.
9861380|NCT00004001|Experimental|Docetaxel and Estramustine|Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
9861381|NCT00004001|Active Comparator|Mitoxantrone and Prednisone|Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days
9861382|NCT00004010|Experimental|BEACOPP therapy|"Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment."
9861383|NCT00004011|Experimental|preooperative chemo followed by surgery|carboplatin paclitaxel conventional surgery
9861384|NCT00004011|Active Comparator|Surgery alone|conventional surgery
9925220|NCT00869180|Experimental|Diclofenac Sodium Patch|
9925221|NCT00869180|Placebo Comparator|Topical Placebo Patch|
9925222|NCT00869193|Active Comparator|Grape seed|Grape seed extract
9861385|NCT00004029|Experimental|Arm I|atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
9861386|NCT00004032|Experimental|Treatment (ALVAC-hB7.1, recombinant interferon gamma)|Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.
9861387|NCT00004038|Experimental|Arm I|Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
9861388|NCT00004050|Experimental|Leuvectin|2 intratumoral injections of 1000 ug of Leuvectin
9861389|NCT00004055|Experimental|topotecan + paclitaxel + filgrastim|Patients receive oral topotecan on days 1-5 followed by paclitaxel IV over 3 hours on day 5. Beginning 24-48 hours after chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily for up to 10 days until blood counts recover. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression. Patients who develop CNS progressive disease only should receive whole brain radiotherapy before continuing study treatment.
9861390|NCT00004056|Experimental|Chemo + STEM cell|See detailed description.
9925223|NCT00869193|Placebo Comparator|Placebo|Microcrystalline cellulose
9925224|NCT00869219|Active Comparator|Nevanac|
9925225|NCT00869219|Active Comparator|Acular LS|
9925226|NCT00869232|Experimental|MEL--VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide and Etoposide
9925227|NCT00869245|Experimental|1|Cardiac MRI Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
9517091|NCT03309566|Experimental|Test - Reference|A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
9925228|NCT00869245|Experimental|2|Conventional care cardiac testing. Patients will be transferred to the observation unit and undergo cardiac testing as determined by their treating physician.
9925229|NCT00869271|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
9925230|NCT00869271|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle.
9925231|NCT00869297|Active Comparator|Control|
9925232|NCT00869297|Experimental|Intervention|These patients receive fluid boluses based on measurements from the FloTrac
9925233|NCT00869310|Experimental|1|Dexamethasone plus Aprepitant
9925234|NCT00869310|Active Comparator|2|dexamethasone plus metoclopramide
9925235|NCT00869388|Experimental|Arm 1|rBBX-01 1.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
9925236|NCT00869388|Experimental|Arm 2|rBBX-01 2.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
9925237|NCT00869388|Experimental|Arm 3|rBBX-01 4.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
9925238|NCT00869388|Experimental|Arm 4 (optional)|rBBX-01 8.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
9925239|NCT00869427|Active Comparator|1 vitamin C|Vitamin C 1g bid
9925240|NCT00869427|No Intervention|2|Usual Care
9925241|NCT00869453||1|Healthy volunteers
9925242|NCT00869479||1|subjects with a histologically-proven diagnosis of NSF
9925243|NCT00869479||2|subjects with other fibrosing skin diseases
9925244|NCT00869479||3|subjects with non-fibrosing skin diseases
9925245|NCT00869479||4|subjects without skin diseases
9925246|NCT00869492|Other|A|instructed nadifloxacine 1% cream twice dailly, and placebo for benzoyl peroxide 5% solution once dailly
9925247|NCT00869492|Other|B|instructed nadifloxacine 1% cream twice dailly, and active benzoyl peroxide 5% solution once dailly
9925248|NCT00869505||Case Group|Intensive Residential Treatment with memantine augmentation
9925249|NCT00869505||Control Group|Intensive Residential Treatment without memantine augmentation
9925250|NCT00869531|Experimental|WW|wholegrain wheat
9925251|NCT00869531|Active Comparator|RW|refined wheat
9925252|NCT00869544||HIV|Those positive for HIV and those negative but at high risk for HIV. Both positive and negative for HIV who smoke and those who do not smoke. Both HIV positive and negative with and without asthma and/or COPD
9517092|NCT03309566|Experimental|Reference - Test|A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).
9861391|NCT00004067|Active Comparator|Arm 1: adriamycin + cyclophosphamide then taxol|
9861392|NCT00004067|Experimental|Arm 2: adriamycin + cyclophosphamide then taxol + herceptin|
9861393|NCT00004070|Experimental|IL-12 Injection 3mg/ml [Phase I]|The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
9861394|NCT00004070|Experimental|IL-12 Injection 6mg/ml [Phase I]|The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
9861395|NCT00004070|Experimental|IL-12 Injection MTD [Phase II]|The dosing schedule will consist of eight injections over a seven week period of formulated plasmid at the MTD established in the phase I portion.
9861396|NCT00004074|Experimental|Treatment (IL12 and trastuzumab)|Patients receive an initial loading dose of trastuzumab IV over 90 minutes on day 1 of the first week and a maintenance dose of trastuzumab IV over 30-90 minutes on day 1 of each subsequent week. Patients receive IL-12 IV on days 2 and 5 beginning on week 3. Treatment with maintenance trastuzumab and IL-12 repeats weekly for 14 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease continue treatment for up to 38 additional weeks.
9861397|NCT00004078|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 4 years and then annually thereafter until death or until patient enters another POG study.
9861398|NCT00004079|Experimental|Treatment (SarCNU)|"Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SarCNU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9861399|NCT00004095|Experimental|Irinotecan Plus Gemcitabine|
9861400|NCT00004101|Experimental|Arm I|Patients receive monoclonal antibody Hu1D10 IV over 2-4 hours on days 1, 8, 15, and 22. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of monoclonal antibody Hu1D10 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose limiting toxicity. Once the MTD is determined, an additional cohort of 3-6 patients receive Hu1D10 IV over 2-4 hours on days 1-5.
9861401|NCT00004109|Experimental|Doxorubicin + External-Beam RT|
9861402|NCT00004123|Experimental|RT + DOX + IORT|Preoperative external beam radiotherapy (RT) combined with doxorubicin (DOX) and followed by intraoperative radiotherapy (IORT); dose-escalation study of external beam radiotherapy.
9861403|NCT00004126|Experimental|Arm A|Paclitaxel 175 mg/m2 : administered by 1-hour constant rate IV infusion through a pump on day 1 of each cycle. Oxaliplatin 130 mg/m2 : On Day 1 of each 21-day treatment cycle, patients receive oxaliplatin diluted in 250-500 mL Dextrose 5% in Water infused intravenously over 2 hours.
9861404|NCT00004127|Experimental|Arm A|Oxaliplatin (85 mg/m2, day 1 of every 14 day cycle), Leucovorin (500 mg/m2, day 1 and 2 of every 14 day cycle), Fluorouracil (Bolus of 400 mg/m2 followed by 22 hr continuous infusion of 600 mg/m2 on days 1 and 2 of every 14 day cycle)
9861405|NCT00004135|Experimental|Arm A|Fludarabine 30 mg/m2/d x S days IVPB in 100 cc NS over 30 minutes on day -8, -7, -6, -S, and -4. Cyclophosphamide 2 gm/m2/d x 2 days IVPB in SOO cc DS W over I hour on day -3 and day-2. G-CSF (Neupogen®) administration 480 f!gld subcutaneously starting on day +5 (or first day of neutropenia if earlier)and continued until an ANC of 0.5 x 109/L is maintained for 3 consecutive days.
9861406|NCT00004136|Experimental|Heat Therapy|
9861407|NCT00004138|Experimental|FDG-PET scan + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy, fine needle aspiration, or other imaging studies are then conducted to confirm the PET findings.~Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation.~Patients are followed at 5-6 months after surgery."
9861408|NCT00004139|Experimental|Gemcitabine + Irinotecan|
9861409|NCT00004139|Experimental|Gemcitabine + Docetaxel|
9861410|NCT00004141|Experimental|Arm A|CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.
9861411|NCT00004142|Experimental|Radiofrequency Ablation + HAI of Floxuridine/5-FU|Radiofrequency Ablation Combined With Post-Ablation Hepatic Arterial Infusion (HAI) of Floxuridine Alternating With 5-Fluorouracil (5-FU)
9861412|NCT00004144|Experimental|bryostatin 1 & gemcitabine hydrochloride|
9861413|NCT00004145|Experimental|Arm A|Fludarabine (30mg/m2/day x 5 days on days -9 to -5), cyclophosphamide (2gm/m2/day on day -5), antithymocyte globulin (10mg/kg/day x 4 days on days -5 to -2), tacrolimus (.03 mg/kg/day IVPB continuous infusion), mycophenolate mofetil (1mg PO BID, days +1 to +60), allogenic peripheral blood stem cells
9986475|NCT01403259|Experimental|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles
9986476|NCT01403272|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
9861414|NCT00004148|Experimental|Arm I|Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
9861415|NCT00004154|Experimental|Fenretinide|Fenretinide (4-HPR) 200 mg orally every day for 12 months taken 25 out of every 28 days.
9861416|NCT00004154|Placebo Comparator|Placebo|Placebo orally every day for 12 months, taken 25 out of every 28 days.
9861417|NCT00004156|Experimental|Vaccine: MUC1-KLH vaccine/QS21|Patients receive glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, and 19 for a total of 5 vaccinations. Patients are followed every 3 months.
9861418|NCT00004160|Experimental|Dose 1 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
9861419|NCT00004160|Experimental|Dose 2 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
9861420|NCT00004160|Experimental|Dose 3 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
9861421|NCT00004160|Experimental|Dose 4 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
9861422|NCT00004160|Experimental|Dose 5 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
9861423|NCT00004161|Experimental|Arm I|Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
9861424|NCT00004161|Experimental|Arm II|Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
9861425|NCT00004162|Experimental|Dose group 1 - dose 1 of Doxorubicin HCL Liposome|Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9861426|NCT00004162|Experimental|Dose group 2 - dose 2 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9861427|NCT00004162|Experimental|Dose Group 3 - dose 3 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9861428|NCT00004162|Experimental|Dose group 4 - dose 4 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9935836|NCT03137693|Other|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
9935837|NCT03129126|Experimental|LP-10 2mg|LP-10 (intravesical tacrolimus), 2mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
9517093|NCT03309553|Active Comparator|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
9861429|NCT00004162|Experimental|Dose group 5 - dose 5 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9861430|NCT00004162|Experimental|Dose group 6 - dose 6 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9861431|NCT00004162|Experimental|Dose group 7 - dose 7 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9861432|NCT00004162|Experimental|MTD group|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
9861433|NCT00004163|Experimental|Trastuzumab|"Trastuzumab is administered intravenously weekly~CAT or MRI scans will be performed every 2 cycles"
9861434|NCT00004180|Experimental|Well-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
9861435|NCT00004180|Experimental|De-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
9861436|NCT00004180|Experimental|Myxoid/ round-cell liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
9861437|NCT00004180|Experimental|Pleomorphic liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
9861438|NCT00004183|Experimental|capecitabine|Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
9861439|NCT00004184|Experimental|Arm I|Patients receive human anti-idiotypic monoclonal antibody vaccine (4B5) in sargramostim (GM-CSF) subcutaneously (SQ) on days 0, 14, 28, and 42. Patients receive GM-CSF alone SQ at vaccination site on days 2, 3, and 4 following immunization.
9861440|NCT00004184|Experimental|Arm II|Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
9861441|NCT00004188|Experimental|Arm I (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
9925253|NCT00869570|Experimental|Arm A: Sorafenib & Capecitabine & RT|"Sorafenib: day 1 to 33 (5 weeks, including Saturday and Sunday) every 24 hours, immediately or within two hours after RT according to the dose escalation table during phase I, and the recommended dose during phase IIa. The intake stops at the last day of RT. On nonradiotherapy days (e.g. Saturday, Sunday), the tablets have to be taken at the same time as during the week.~Capecitabine: day 1 to 33 (5 weeks, including Saturday and Sunday) according to dose escalation table during phase I, and at the recommended dose during phase IIa. The intake stops in the evening of the last day of RT.~External beam RT: Monday through Friday for 5 weeks starting on day 1 (daily fraction 1.8 Gy, final dose 45 Gy) each day at the same time (e.g. 11:00 a.m. daily).~Surgery: 6 weeks (± 1 week) after radiochemotherapy (RCT) has been completed"
9861442|NCT00004188|Experimental|Arm II (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
9861443|NCT00004189|Experimental|Arm I|See detailed description.
9861444|NCT00004190|Experimental|gemcitabine + oxaliplatin|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.
9861445|NCT00004193|Experimental|ISIS 2503|patients who have metastatic and/or locally recurrent colorectal cancer
9861446|NCT00004195|Active Comparator|Oral eniluracil 20 mg twice daily|20 mg of eniluracil given twice daily for duration of the study. This subject may have surgery IF tumor is amenable to resection
9861447|NCT00004195|Placebo Comparator|Placebo|20 mg placebo that will be given for the duration of the study. This subject may have surgery IF tumor is amenable to resection
9861448|NCT00004196|Experimental|AI|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Patients receive adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks, then subcutaneously 3 times a week for 48 weeks
9861449|NCT00004196|Experimental|Arm AII|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Observational arm: Patients with metastases in more than one sentinel node with evidence of extracapsular extension or metastasis in any nonsentinel node receive adjuvant high-dose interferon alfa-2b as in arm AI.
9861450|NCT00004196|Experimental|Arm BI|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
9861451|NCT00004196|Experimental|Arm B II|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
9861452|NCT00004196|Experimental|Arm BIII|"Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection followed by adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks.~Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
9925254|NCT00869583|Experimental|1|Participants will immediately take part in the physical activity program.
9925255|NCT00869583|No Intervention|2|
9925256|NCT00869596|Placebo Comparator|1|Placebo
9925257|NCT00869596|Active Comparator|2|Fluticasone 440 mcg
9925258|NCT00869596|Active Comparator|3|Fluticasone 1980 mcg
9925259|NCT00869635|Experimental|1|"Treatment by combination of photodynamic therapy and S-1~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment"
9925260|NCT00869635|Active Comparator|2|"Treatment by photodynamic therapy only~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~Other managements except systemic chemotherapy were added freely."
9925261|NCT00869635|Other|3|Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label
9925262|NCT00869648|Active Comparator|Neutralposition|Head placed in neutral position
9925263|NCT00869648|Active Comparator|Extension|Head placed in extension
9925264|NCT00869648|Active Comparator|Anaesthesiologist's position|Head placed in position deemed optimal by an anaesthesiologist
9925265|NCT00869674|No Intervention|Routine pathologic method|Half of each sentinal lymph node will have rountine pathologic examination as normal practice.
9925266|NCT00869674|Experimental|GeneSearch BLN Assay|Half of each sentinal lymph node will have GeneSearch BLN testing.
9925267|NCT00869687|Other|Poly-L-Lactic Acid Injection|
9925268|NCT00869752|Experimental|Arm 1|MK-0646, a monoclonial antibody in combination with etoposide and cisplatin.
9925269|NCT00869765|Experimental|tDCS and D-CYC|Major Depression tDCS and D-cyc
9861453|NCT00004203|Experimental|Arm A|On Day 1 of each 21-day treatment cycle, patients receive 130 mg/m2 oxaliplatin diluted in 250 to 500 mL Dextrose 5% in Water infused intravenously over 2 hours through a peripheral or central vein
9861454|NCT00004205|Experimental|Tamoxifen|Tamoxifen for 5 years after randomization.
9861455|NCT00004205|Experimental|Letrozole|Letrozole for 5 years after randomization.
9861456|NCT00004205|Experimental|Tamoxifen, then letrozole|Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
9861457|NCT00004205|Experimental|Letrozole, then tamoxifen|Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.
9861458|NCT00004208|Active Comparator|Arm A: ATG + CSA|"Treatment consists of 15 mg/kg ATG (Mérieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.~Cyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
9861459|NCT00004208|Other|Arm B: Supportive care|Patients randomized to this arm will be treated as outpatients.
9861460|NCT00004221|Experimental|Treatment (Combination chemotherapy, PBSC)|See detailed description.
9861461|NCT00004227|Placebo Comparator|Arm I|"Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
9861462|NCT00004227|Active Comparator|Arm II|"Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy.~Radiotherapy groups remain the same as in Arm I:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
9861463|NCT00004229|Experimental|Arm I|Patients undergo a biopsy during prestudy and after the second course of treatment. Patients receive endostatin IV daily for 4 weeks. Patients on dose level 1-6 receive endostatin over 20 minutes. Patients on dose level 7 receive endostatin over 40 minutes, with no treatment on day 2 of the first course only. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of endostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
9861464|NCT00004233|Experimental|5-FU, Leucovorin and PN-401|PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
9861465|NCT00004235|Experimental|irinotecan + docetaxel|"Patients receive irinotecan IV over 90 minutes followed by docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.~Patients achieving a complete response (CR) receive 2 additional courses after CR. Patients experiencing disease progression after a CR and 2 additional courses may be retreated with irinotecan and docetaxel. Dysphagia, anorexia, and swallowing ability are assessed before the first course of treatment and then at each tumor assessment.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
9861466|NCT00004239|Experimental|Compound 506U78|Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.
9861467|NCT00004241|Experimental|Schedule B (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9861468|NCT00004241|Experimental|Schedule C (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9861469|NCT00004242|Experimental|Arm I|See detailed description.
9925270|NCT00869804|Experimental|Exercise|combination aerobic (walking) and resistance (strength training) exercise
9925271|NCT00869804|Sham Comparator|attention control|attention control with daily journal and cancer-related education
9925272|NCT00869830|Experimental|biofeedback|
9925273|NCT00869843|Other|Single group|
9925274|NCT00869856|Experimental|1|HX575, EPO Hexal
9861470|NCT00004244|Experimental|Arm I|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
9861471|NCT00004244|Experimental|Arm II|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
9861472|NCT00004244|Experimental|Arm III|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above."
9861473|NCT00004246|Experimental|RT + Fludarabine|Radiotherapy (RT) on Days 1-5 for 7 weeks + Fludarabine IV, 3-4 hours prior to daily RT, Days 1-5 of weeks 6 and 7 of RT
9861474|NCT00004251|Experimental|Letrozole|Letrozole 2.5 mg po daily
9861475|NCT00004262|Experimental|Treatment (motexafin gadolinium, radiotherapy, radiosurgery)|Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
9861476|NCT00004263|Experimental|Cytarabine + UCN-01|
9861477|NCT00004266|Experimental|Nifedipine|Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
9861478|NCT00004266|Experimental|Lisinopril|Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
9861479|NCT00004266|Experimental|Nifedipine and simvastatin|Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.
9861480|NCT00004266|Experimental|Lisinopril and simvastatin|Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.
9861481|NCT00004285|Active Comparator|Standard dose, low flux hemodialysis|
9861482|NCT00004285|Experimental|Standard dose, high flux hemodialysis|
9861483|NCT00004285|Experimental|High dose, low flux hemodialysis|
9861484|NCT00004285|Experimental|High dose, high flux hemodialysis|
9861485|NCT00004317|Experimental|1|This group of infants is treated with a loading dose of oral pyrimethamine followed by a higher dose for the first two months then a lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are also given orally for 12 months. The pyrimethamine loading dose is omitted if prior prenatal therapy was given.
9861486|NCT00004317|Experimental|2|This group of infants is treated with a higher dose of oral pyrimethamine for the first 6 months and then the lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are administered concurrently.
9925275|NCT00869869|Experimental|melatonin|melatonin
9925276|NCT00869869|Placebo Comparator|placebo|placebo
9925277|NCT00869882|Experimental|1|Posterolateral fusion with instrumentation combined to transforaminal lumbar interbody fusion
9925278|NCT00869882|Active Comparator|2|Posterolateral fusion with instrumentation
9925279|NCT00869895|Experimental|1|
9925280|NCT00869908||A|
9925281|NCT00869934|Active Comparator|1. Cognitive-Behavior Therapy|
9925282|NCT00869934|Experimental|2. Behavior Therapy|
9925283|NCT00869934|Experimental|3. Cognitive Therapy|
9925284|NCT00869973|Experimental|1|Aprepitant
9925285|NCT00869973|Active Comparator|2|dexamethasone
9925286|NCT00870012|Active Comparator|Lepicol probiotic & prebiotic formula+simple lifestyle advice|
9925287|NCT00870012|Placebo Comparator|Simple lifestyle advice alone|
9925288|NCT00870025|Active Comparator|hCG|200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH
9925289|NCT00870025|Placebo Comparator|placebo|similar injection at same time points with similar diluent but no hCG
9925290|NCT00870038|Experimental|1|Paclitaxel eluting balloon (Elutax) + Genous stent
9925291|NCT00870038|Experimental|2|Uncoated balloon + Genous stent
9925292|NCT00870038|Active Comparator|3|Drug eluting stent (Taxus stent)
9861487|NCT00004342||Adult Neutropenic Subject|Adult subjects with diagnosis of severe chronic neutropenia
9861488|NCT00004342||Minor Neutropenic Subject|Children under 18 years of age who are diagnosed with severe chronic neutropenia
9861489|NCT00004342||Parent of Minor Neutropenic Subjects|Parent of minor subjects (i.e., children under 18 years of age) who are diagnosed with severe chronic neutropenia
9861490|NCT00004465|Experimental|SYNSORB Pk|Oral Shiga toxin-binding agent (500 mg/kg/day)
9861491|NCT00004465|Placebo Comparator|Placebo|Cornmeal placebo
9861492|NCT00004466|Experimental|Atorvastatin|
9861493|NCT00004466|Placebo Comparator|Placebo|
9861494|NCT00004467|Placebo Comparator|Placebo|
9861495|NCT00004467|Experimental|N-acetylcysteine (NAC)|
9861496|NCT00004474|Experimental|1|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
9861497|NCT00004474|Experimental|2|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
9925293|NCT00870064|Other|Formal Operative Treatment|Children randomized to the formal operative management arm will be taken to the Operating Room within 24 hours for irrigation and debridement and appropriate bone management.
9925294|NCT00870064|Other|Emergency Department Treatment|Children in the Emergency Department Treatment arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
9925295|NCT00870077|Experimental|1|
9925296|NCT00870116|Other|1 - SBRT using cyberknife|SBRT using cyberknife: treatment = 2x15 Gy during 2 weeks
9925297|NCT00870116|Other|2 - SBRT using linear accelerator|SBRT using linear accelerator: treatment = 2x15 Gy during 2 weeks
9925298|NCT00870116|Other|3 - Conformational radiotherapy|Conformational radiotherapy: treatment = 5x2 Gy during 7 weeks
9925299|NCT00870129|Experimental|MRI|The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
9925300|NCT00870142|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
9925301|NCT00870142|Active Comparator|B|Norvasc® 10 mg Tablets, single dose
9925302|NCT00870181|Experimental|ADV-TK/GCV|ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
9925303|NCT00870181|Active Comparator|Control group|Patients received surgery or systemic chemotherapy or palliative care.
9925304|NCT00870207|Other|Immediate Intervention Group|The immediate intervention group will receive the TSSC pilot worksite intervention in the initial 12 week period from the pre-test/enrollment visit.
9925305|NCT00870207|Other|Delayed Intervention Group|The delayed intervention group will receive the TSSC pilot worksite intervention beginning in month 6 of the study (6 months from the enrollment/pre-test visit).
9925306|NCT00870220|Experimental|GH alone, Low dose E2 patch, Very Low-dose E2 patch|"Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months."
9925307|NCT00870246||1|High mobility
9925308|NCT00870246||2|Lower mobility
9925309|NCT00870272|Active Comparator|1|400mcg sublingual misoprostol
9925310|NCT00870272|Active Comparator|2|400mcg buccal misoprostol
9925311|NCT00870298|Experimental|computerized alert|An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
9925312|NCT00870298|Other|2 Current practice|Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders
9925313|NCT00870311|Experimental|Blinded Lithium|Bipolar Disorder patients
9925314|NCT00870324||1. Control|Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant
9925315|NCT00870324||2. Experimental|Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant
9925316|NCT00870337|Experimental|Single arm|
9925317|NCT00870350|Active Comparator|Td5ap|Group 1 receiving Td5ap as a single intramuscular injection.
9925318|NCT00870350|Active Comparator|Td1aP|Group 2 receiving Td1aP as a single intramuscular injection
9925319|NCT00870376||urodynamic studies|
9925320|NCT00870402|Experimental|1|
9925321|NCT00870402|Placebo Comparator|2|
9861498|NCT00004554|Experimental|Sertraline|sertraline
9861499|NCT00004554|Experimental|Naltrexone|naltrexone
9861500|NCT00004554|Experimental|Nal/Sert|naltrexone/sertraline
9861501|NCT00004554|Placebo Comparator|Placebo|Placebo
9861502|NCT00004578|Active Comparator|1|Group 1, n=32 initiated with ABT-378 & ritonavir; after 3 wks stavudine and lamivudine was added.
9861503|NCT00004578|Active Comparator|2|Group II patients (n=68) to be randomized after all Group I patients are enrolled and safety analysis is completed.
9861504|NCT00004604|Experimental|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
9861505|NCT00004660|Experimental|Radiotherapy|
9861506|NCT00004660|Sham Comparator|Sham treatment|
9925322|NCT00870415|Experimental|Surgerie|
9925323|NCT00870428||Preeclampsia Evaluation|Patients who are admitted for the evaluation of preeclampsia
9925324|NCT00870441|Experimental|1. ASP2151|
9925325|NCT00870441|Active Comparator|2. Valacyclovir|
9925326|NCT00870441|Placebo Comparator|3. Placebo|
9925327|NCT00870480|Experimental|A|Finasteride 5 mg single dose tablet, single dose
9925328|NCT00870480|Active Comparator|B|Proscar® 5 mg Tablet, single dose
9925329|NCT00870493|Experimental|I|each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
9925330|NCT00870493|Active Comparator|II|each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks
9925331|NCT00870506|No Intervention|2|No intervention (control)
9925332|NCT00870506|Experimental|1|5-minute video on donation and transplantation
9925333|NCT00870519|Experimental|I 123-MNI-168|
9925334|NCT00870519|Experimental|I123 MNI168|brain imaging using I123MNI168
9925335|NCT00870532|Experimental|1|60 mg/week of vinorelbine + sorafenib
9925336|NCT00870532|Experimental|2|90 mg/week of vinorelbine + sorafenib
9925337|NCT00870532|Experimental|3|120 mg/week of vinorelbine + sorafenib
9925338|NCT00870558|Experimental|Arm I|Patients receive an intra-arterial infusion of iodine I 131 ethiodized oil.
9925339|NCT00870558|Placebo Comparator|Arm II|Patients receive an intra-arterial infusion of unlabeled ethiodized oil.
9925340|NCT00870571|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
9925341|NCT00870571|Active Comparator|B|NorvasC® 10 mg Tablets, single dose
9925342|NCT00870597|Experimental|1|Multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
9925343|NCT00870597|Experimental|2|Multifocal IOL implantation without transconjunctival vitrectomy
9925344|NCT00870649|Experimental|Bilhvax vaccine (Sh28GST)|Arm 1 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of candidate vaccine at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
9925345|NCT00870649|Placebo Comparator|Placebo|Arm 2 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of placebo at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
9925346|NCT00870662|Experimental|Automatic Fluid Shunt|
9925347|NCT00870675||ventriculomegaly|Pregnant women carrying a fetus with the ultrasound finding of enlarged ventricles (ventriculomegaly).
9925348|NCT00870701|Experimental|Absence of Radiotherapy|No Radiotherapy; Simple monitoring without active treatment
9925349|NCT00870701|Active Comparator|Radiotherapy|Radiotherapy
9925350|NCT00870714|Experimental|A|Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
9925351|NCT00870753|Experimental|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
9925352|NCT00870753|No Intervention|Controls|Control group are offered the yoga intervention after finishing the study
9925353|NCT00870766|Active Comparator|CT|All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER.
9925354|NCT00870766|No Intervention|Current practice|The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only.
9925355|NCT00870779|Experimental|5-aminolevulinic acid|
9925356|NCT00870792|Active Comparator|Received report|
9925357|NCT00870792|Placebo Comparator|Routine care|Patients receive usual, routine, care.
9925358|NCT00870805|Experimental|bilateral-ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 3-4 times seizure threshold.
9925359|NCT00870805|Active Comparator|bilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a bilateral placement at 1.5 times seizure threshold.
9861507|NCT00004769||Myotonic dystrophy|Subjects with myotonic dystrophy
9861508|NCT00004769||Healthy controls|Healthy subjects
9861509|NCT00004769||Disease controls 1|Subjects with FSHD
9861510|NCT00004769||Disease controls 2|Subjects with CMT
9861511|NCT00004842|Experimental|Budesonide|Oral budesonide
9861512|NCT00004843|Experimental|Parathyroidectomy|
9861513|NCT00004843|Active Comparator|Observation|
9861514|NCT00004853|Experimental|1|single dose of intervention after each cycle of Standard 5 drug dose-intensive chemotherapy
9861515|NCT00004853|Experimental|2|single dose of interventionafter each cycle of Standard 5 drug dose-intensive chemotherapy
9861516|NCT00004856|Experimental|Treatment: Herceptin|Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
9861517|NCT00004857|Experimental|Fludarabine + Campath-1H|Standard of care induction with fludarabine followed by consolidation antibody therapy
9861518|NCT00004862|Experimental|Arm I|Patients receive augmerosen IV continuously on days 1-10 and filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover. Patients receive fludarabine IV over 30 minutes followed 3.5 hours later by cytarabine IV over 4 hours on days 6-10. Patients who achieve complete response (CR) receive a second course beginning 4 weeks after completion of the first course. Patients who achieve CR and have a matched sibling or unrelated bone marrow donor may undergo allogeneic bone marrow transplantation. Cohorts of 3-6 patients receive escalating doses of fludarabine and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
9861519|NCT00004867|Experimental|FDG-PET scan +/- neoadjuvant chemotherapy + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation.~Patients are followed within 6 months after surgery."
9861520|NCT00004875||Standard Heparin|
9861521|NCT00004875||Enoxaprin|
9861522|NCT00004883|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.
9861523|NCT00004889|Experimental|Rituxan|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
9925360|NCT00870805|Experimental|right-unilateral ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a right unilateral placement at 8 times seizure threshold.
9925361|NCT00870805|Active Comparator|right-unilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a right unilateral placement at 5 times seizure threshold.
9935221|NCT04029883|Active Comparator|Message Group|The Message group will receive the same brief information session as the Control group but also receive daily text messages reinforcing the information provided for 3 months. A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time. To keep the importance of routinizing pill- taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform. These messages will reinforce the information provided at recruitment, and remind participants of their personalized routinization strategy. Messages will be tailored and refreshed based on patient-specific factors including BP control, prior adherence, and current medication regimen.
9861524|NCT00004891|Experimental|primary resectable rectal cancer|
9861525|NCT00004893|Experimental|IL12 Therapy|Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
9861526|NCT00004893|No Intervention|Observation|Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
9861527|NCT00004909||Oral chemotherapy|
9861528|NCT00004909||Parenteral chemotherapy|
9861529|NCT00004918|Experimental|Arm I (dose level 1 PR1 leukemia peptide vaccine)|Patients receive dose level 1 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
9861530|NCT00004918|Experimental|Arm II (dose level 2 PR1 leukemia peptide vaccine)|Patients receive dose level 2 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
9861531|NCT00004918|Experimental|Arm III (dose level 3 PR1 leukemia peptide vaccine)|Patients receive dose level 3 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
9861532|NCT00004919|Experimental|Treatment (cisplatin, irinotecan, amifostine)|"Treatment A: Patients receive cisplatin IV over 1 hour followed immediately by irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 6 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.~Treatment B: Patients receive therapy as in treatment A. In addition, amifostine IV is administered over 15 minutes immediately before cisplatin."
9861533|NCT00004929|Experimental|Vaccine|Patients receive vaccination with glycosylated MUC-2 antigen with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, 15, and 27 for a total of 6 vaccinations. Patients are followed every 3 months for 1 year or until disease progression.
9861534|NCT00004931|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV (administered after 1 hour of leucovorin calcium) weekly for 6 weeks.
9861535|NCT00004931|Experimental|Arm II|Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and leucovorin calcium and fluorouracil as in arm I.
9861536|NCT00004932|Experimental|260 mg/m2 imatinib mesylate (ST571)|
9861537|NCT00004932|Experimental|340 mg/m2 imatinib mesylate (ST571)|
9861538|NCT00004932|Experimental|440 mg/m2 imatinib mesylate (ST571)|
9861539|NCT00004932|Experimental|570 mg/m2 imatinib mesylate (ST571)|
9861540|NCT00004933|Experimental|Homoharringtonine|
9861541|NCT00004933|Active Comparator|Hydroxyurea|
9861542|NCT00004984|Experimental|Parenteral Insulin|High risk participants randomized to intervention
9861543|NCT00004984|Active Comparator|Close Observation|High risk participants randomized to observation
9861544|NCT00004984|Experimental|Oral Insulin|Intermediate risk participants randomized to intervention
9861545|NCT00004984|Placebo Comparator|Placebo|Intermediate risk participants randomized to placebo
9861546|NCT00004992|Placebo Comparator|Placebo|
9861547|NCT00004992|Active Comparator|Metformin|
9861548|NCT00004992|Active Comparator|Intensive Lifestyle|
9861549|NCT00005005|Experimental|1|Participants will receive PTH for 1 year followed by alendronate for 1 year.
9861550|NCT00005005|Experimental|2|Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
9861551|NCT00005005|Experimental|3|Participants will receive alendronate for 2 years.
9861552|NCT00005005|Active Comparator|4|Participants will receive PTH for 1 year followed by placebo for 1 year.
9861553|NCT00005006|Active Comparator|1|Alendronate alone
9861554|NCT00005006|Active Comparator|2|Teriparatide daily plus alendronate
9861555|NCT00005006|Active Comparator|3|Teriparatide cyclically plus alendronate
9861556|NCT00005009|Experimental|Varivax®|0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).
9861557|NCT00005022|Experimental|Arm 1|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
9861558|NCT00005022|Experimental|Arm 2|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/BID x last 5 days.
9861559|NCT00005022|Experimental|Arm 3|Large field radiation therapy 32.4 Gy, 1.8 Gy/fx/D/5 days x 18 fx, boost just in pm @ 1.8 Gy/fx on days 19 & 20, then boost 1.8 Gy BID x last 5 days.
9861560|NCT00005022|Experimental|Arm 4|Large field radiation therapy 28.8 Gy, 1.8 Gy/fx/5 days x 16 fx, boost just in pm @ 1.8 Gy/fx on days 17-20, then boost 1.8 Gy BID x last 5 days.
9861561|NCT00005022|Experimental|Arm 5|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D 5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
9861562|NCT00005022|Experimental|Arm 6|Large field radiation therapy 25.2 Gy, 1.8 Gy/fx/5 days x 14 fx, boost just in pm @ 1.8 Gy/fx on days 15-20, then boost 1.8 Gy BID x last 5 days.
9861563|NCT00005028|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
9861564|NCT00005030|Experimental|SCH 66336|Starting dose of preoperative oral SCH 66336 100 mg twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases with surgery between days 8-15.
9861565|NCT00005030|No Intervention|No Treatment|Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization.
9861566|NCT00005032|Experimental|Arm A|G3139 (3 mg/kg/day continuous IV infusion over 7 days every 21 days), Paclitaxel (150 mg/m2, 3 hr IV infusion on Day 6 of every 21 day cycle)
9861567|NCT00005036|Experimental|Arm I (irinotecan)|Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
9861568|NCT00005036|Experimental|Arm II (oxalipatin, fluorouracil, leucovorin calcium)|Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
9861569|NCT00005037|Experimental|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
9861570|NCT00005039|Experimental|Arm I|Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.
9861571|NCT00005039|Experimental|Arm II|Patients receive the same vaccines as in arm I but in reverse order.
9925362|NCT00870831||Islet Recipient|Subjects that have successfully received and maintained an Islet transplant at Washington University Center for Islet Transplantation
9925363|NCT00870831||Control|subjects that were similar in height, weight and age that did NOT have diabetes to act as the comparative group
9925364|NCT00870844|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
9925365|NCT00870844|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
9925366|NCT00870844|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
9925367|NCT00870844|Placebo Comparator|Placebo|
9925368|NCT00870857||1|Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling stratified by age and smoking history. Subjects will be recruited from the University of Pittsburgh and the University of Washington (UW) MACS sites. The University of California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort
9925369|NCT00870883|Experimental|N-acetylcysteine plus deferoxamine|
9925370|NCT00870909|Active Comparator|active tDCS|"tDCS active; - Intensity = 2 milliamps (mA) during 20 minutes. ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC combined with cathodal tDCS applied over the left temporoparietal junction (TPJ).~10 sessions, 2 per day"
9925371|NCT00870909|Placebo Comparator|sham tDCS|tDCS placebo same electrode montage than in the active group. 30 sec of active tDCS in the beginning of the stimulation sessions; ramp up/ramp down 30 sec
9925372|NCT00870922|Experimental|TMD group|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
9925373|NCT00870935|Active Comparator|Balloon catheter|Hysterosalpingography using intrauterine Balloon catheter
9925374|NCT00870935|Active Comparator|Cervical vacuum cup|Hysterosalpingography using cervical vacuum cup
9925375|NCT00870935|Experimental|Operator choice|Hysterosalpingography is performed using either balloon catheter or cervical vacuum cup on the basis of the operator's choice
9925376|NCT00870948|Experimental|Regimen A|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
9861572|NCT00005059|Experimental|carboplatin + paclitaxel|"Following completion of the Lubben Social Network Scale and Frailty Questionnaire, patients receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15.~Treatment repeats every 28 days for 2 courses. Patients with complete response receive 2 additional courses of therapy. Patients with partial response or stable disease may receive additional courses of therapy at investigator's discretion. Patients are followed every 3 months for 5 years or until disease progression."
9861573|NCT00005060|Active Comparator|Taxotere-Cisplatin-5FU preoperatively|TCF preoperatively
9861574|NCT00005060|Active Comparator|Immediate surgery followed by TCF|Surgery followed by Taxotere-Cisplatin-5FU
9861575|NCT00005064|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV bolus twice weekly for 4 weeks followed by 2 weeks of rest. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
9861576|NCT00005065|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours every 3 weeks for 3 courses. Three weeks after completion of induction chemotherapy, patients receive Gd-Tex IV over 30 minutes twice weekly for 10 doses during preoperative radiotherapy. Radiotherapy is administered daily 5 days a week for 5 weeks. Approximately 3.5 weeks after completion of preoperative radiotherapy, patients undergo complete surgical resection. Three hours prior to surgery, patients receive an eleventh dose of Gd-Tex if they do not develop grade 3 or 4 toxicity with the tenth dose. Patients also receive a MRI without contrast prior to surgery. If the tumor is found to be unresectable, patients may receive additional radiation and/or chemotherapy.
9861577|NCT00005066|Experimental|Arm A|O6-BG as an intravenous infusion (through your vein) over 1 hour followed 1 hour later by BCNU intravenously over 15 minutes. chemotherapy every 6 weeks.
9861578|NCT00005067|Experimental|Treatment (motexafin lutetium, PDT)|Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
9861579|NCT00005072|Experimental|Leuvectin|Leuvectin
9861580|NCT00005076|Experimental|EgFR antibody|
9861581|NCT00005080|Experimental|Nelarabine|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
9861582|NCT00005085|Experimental|Arm I|Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
9861583|NCT00005086|Experimental|Arm A|Methotrexate will be given as a short infusion (introduced into a vein) for approximately 5 minutes on the first day (day 1). ). A week later (day 8), both methotrexate and docetaxel will be given the same way, but this will take about 1 hour. The first course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks. X-rays or scans will then be performed to determine if your tumor is shrinking. You will then start treatment with gemcitabine and cisplatin. On the first day (day 1), you will receive both cisplatin and gemcitabine into your vein. A week later (day 8), you will receive only gemcitabine as an infusion into your vein over 100 minutes and no additional intravenous fluid will be required on that day. This second course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks.
9861584|NCT00005087|Experimental|Radiation (BID) and chemotherapy|Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.
9925377|NCT00870948|Experimental|Regimen B|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein
10210129|NCT02324764|Experimental|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
10210130|NCT02324764|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
10210131|NCT02319837|Experimental|Enzalutamide plus leuprolide|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as as a single intramuscular or subcutaneous injection once every 12 weeks
10210132|NCT02319837|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
10210133|NCT02319837|Active Comparator|Placebo plus leuprolide|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks
10210134|NCT02298504|Experimental|Indirect pulp cap|IDP will be performed for this group
10210135|NCT02298504|Experimental|MTA pulpotomy|MTA pulpotomy will be performed for this group
10210136|NCT02298504|Experimental|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
10210137|NCT02285504|Experimental|SAGE-547|Participants received SAGE-547 intravenous injection over 60 hours (including 12-hour titration infusion of 21.5 micrograms per kilogram per hour [mcg/kg/hr] [4 hrs], 43 mcg/kg/hr [4 hrs] and 64.5 mcg/kg/hr [4 hrs] on Day 1, followed by 13 to 48 hrs [36 hrs] maintenance infusion of 86 mcg/kg/hr from Day 1 to 3, followed by a 12-hr taper infusion of 64.5 mcg/kg/hr [49 - 52 hrs], 43 mcg/kg/hr [53 - 56 hrs] and 21.5 mcg/kg/hr [57 - 60 hrs] on Day 3).
10210138|NCT02264899|Experimental|Alzheimer's disease and related disorders|
10210139|NCT02257528|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
10213658|NCT03576976|Experimental|Hybrid Cognitive Remediation|Hybrid cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
10213659|NCT03575156|Experimental|Systemic lupus erythematosus (SLE)|
10213660|NCT03575156|Experimental|systemic scleroderma (SSc)|
10213661|NCT03575143||PLWH+OSA|Subjects diagnosed with both Human Immunodeficiency Virus and Obstructive Sleep Apnea
9861585|NCT00005089|Experimental|CHOP + Rituximab + RT|3 21-day cycles of CHOP (cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
9861586|NCT00005090|Active Comparator|ABVD x 5 + ABVD x 3|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
9861587|NCT00005090|Experimental|ABVD x 5 + ABVD x 1 + HDT + PBSCT|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
9861588|NCT00005092|Experimental|Chemo, RT + PSCT|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation
9861589|NCT00005094|Experimental|Arm I (celecoxib)|Patients receive celecoxib twice a day for 3 years.
9861590|NCT00005094|Placebo Comparator|Arm II (placebo)|Patients receive placebo twice a day for 3 years.
9861591|NCT00005095||High Risk for Ovarian Cancer|Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
9861592|NCT00005096|Experimental|Docetaxel|Docetaxel given via iv at determined dose once a week for 4 weeks
9861593|NCT00005097|Experimental|Polyphenon E & Placebo|"Each subject will receive both the Polyphenon E and placebo, one on each arm.~One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks."
9861594|NCT00005113|Experimental|1|Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
9861595|NCT00005113|Experimental|2|Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
9861596|NCT00005145||Observational, no interventions|
9925378|NCT00870948|Experimental|Regimen C|One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
9925379|NCT00870948|Experimental|Regimen D|One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
9925380|NCT00870948|Experimental|Regimen E|700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein
9925381|NCT00870961|Experimental|Arm I|Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
9925382|NCT00870961|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
9925383|NCT00870974|Experimental|Assess [18F]FPEB and PET imaging|To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.
9925384|NCT00870987|Experimental|1|DNA vaccine prime Given at 0, 4, and 8 weeks
9925385|NCT00870987|Experimental|2|adenovirus type 5 vaccine boost Given at 24 weeks
9925386|NCT00871026|Experimental|1|CAD/CAM group, customized archwires
9925387|NCT00871026|Active Comparator|2|prefabricated archwires (superelastic)
9925388|NCT00871039|Experimental|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
9925389|NCT00871039|Experimental|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
9925390|NCT00871065|Experimental|A|Trial Arm (single arm study)
9925391|NCT00871078||A|HIV-positive patients with CD4 cell counts below 100 cells/mm³ at some point of time in their medical history lasting for at least 6 months
10213662|NCT03575143||PLWH-OSA|Subjects diagnosed with both Human Immunodeficiency Virus without Obstructive Sleep Apnea
10213663|NCT03569293|Placebo Comparator|Placebo / Upadacitinib|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
10213664|NCT03569293|Experimental|Upadacitinib 15 mg QD|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
9861597|NCT00005219||Exercise Study Participants|Data from the San Diego Health and Exercise Baseline survey conducted in 1986 were used to contact participants for the follow-up
9925392|NCT00871078||B|HIV-positive patients with CD4 cell counts never below 100 cells/mm³ in their medical records
9925393|NCT00871078||C|HIV-negative patients (control group)
9925394|NCT00871091|Experimental|1|CAD/CAM group, customized archwires
9925395|NCT00871091|Active Comparator|2|prefabricated archwires (superelastic)
9925396|NCT00871091|Active Comparator|3|prefabricated archwires with manual adjustments
9925397|NCT00871104|Experimental|1|IV fosfomycin and imipenem adjusted to renal function
9925398|NCT00871104|Active Comparator|2|IV Vancomycin twice a day with valley leves higher than 15 mcg/kg
9925399|NCT00871156|Active Comparator|Part 1|Tafenoquine + Chloroquine vs. Chloroquine alone
9925400|NCT00871156|Placebo Comparator|Part 2|Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
9925401|NCT00871208|Experimental|1|Altabax (R) and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
9925402|NCT00871208|Active Comparator|2|Vehicle and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
9925403|NCT00871247|Experimental|A|Finasteride 5 mg single dose tablet, single dose
9925404|NCT00871247|Active Comparator|B|Proscar® 5 mg Tablet, single dose
9925405|NCT00871299|Experimental|1|Mindfulness Based Cognitive Therapy (MBCT) + medication management
9925406|NCT00871299|Active Comparator|2|The Health Enhancement Program (HEP) + medication management
9925407|NCT00871312|Active Comparator|Topical Wound Oxygen Therapy|Subjects will receive four 90 minute treatments of two2 therapy per week
9925408|NCT00871312|Placebo Comparator|Placebo Therapy|Subjects will receive four 90 minute treatments of Placebo two2 therapy per week
9925409|NCT00871364|Experimental|A|VENLAFAXINE TABLETS 50 mg, single dose
9925410|NCT00871364|Active Comparator|B|Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose
9925411|NCT00871442|Active Comparator|No Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)"
9925412|NCT00871442|Active Comparator|Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 2: Basal Infusion: 10 ml/hr; Bolus 5 ml q 30min prn (5ml demand dose with 30min lockout)"
9925413|NCT00871455|Experimental|1|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
9925414|NCT00871468|Active Comparator|superior plate|Clavicle plate on the superior surface of the bone
9925415|NCT00871468|Experimental|anterior inferior plate|plate placed on anterior inferior surface of bone
9925416|NCT00871507|Experimental|001|
9925417|NCT00871507|Experimental|002|
9925418|NCT00871507|Placebo Comparator|003|
9925419|NCT00871507|Active Comparator|004|
9925420|NCT00871520||Palliative Therapy|Patients referred to the oncology / radiation oncology departments for palliative therapy.
9925421|NCT00871533|Experimental|1|"REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at MAINTENANCE dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study."
9925422|NCT00871533|Experimental|2|No intervention / no injection control.
9925423|NCT00871533|Experimental|3|"PEG IFN INDUCTION: System PEG IFN-a2b given subcutaneously at INDUCTION dose level"
10213665|NCT03569293|Experimental|Upadacitinib 30 mg QD|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
9925424|NCT00871533|Experimental|4|"REGIONAL HDI MAINTENANCE: Regional HDI given subcutaneously at MAINTENANCE dose level per standard HDI regimen"
9925425|NCT00871533|No Intervention|5|"HDI Induction: Systemic HDI given intravenously at INDUCTION dose level per the standard HDI regimen."
9925426|NCT00871546|Experimental|Participants with MCL randomized to SCH 727965|
9925427|NCT00871546|Active Comparator|Participants with MCL randomized to bortezomib|
9925428|NCT00871546|Experimental|MCL treated w/SCH 727965 after progression on bortezomib|
9925429|NCT00871546|Experimental|Participants with B-CLL randomized to SCH 727965|
9925430|NCT00871546|Active Comparator|Participants with B-CLL randomized to alemtuzumab|
9925431|NCT00871546|Experimental|B-CLL treated w/ SCH 727965 after progression on alemtuzumab|
9925432|NCT00871559|Experimental|Q2W|REGN421 (SAR153192) taken once every two weeks (Q2W)
9925433|NCT00871598|Placebo Comparator|Placebo|
9925434|NCT00871598|Experimental|Single 0.3|
9925435|NCT00871598|Experimental|Repeat 1.0|
9925436|NCT00871598|Experimental|Repeat 2.0|
9925437|NCT00871598|Experimental|Repeat 4.0|
9925438|NCT00871598|Experimental|Repeat 8.0|
9925439|NCT00871637||Group One|Healthy non-smoking controls
9925440|NCT00871637||Group Two|Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
9925441|NCT00871637||Group Three|Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
9925442|NCT00871650||Combat Veterans with PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with Combat Exposure Scale score > 17, who are not on medication and do not have trauma history before age 18.
9925443|NCT00871650||Combat Veterans without PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with combat experience, who are not suffering from PTSD, and who are not on medication.
9925444|NCT00871663|Experimental|Advanced solid tumors|Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
9861598|NCT00005289||1988-1991|
9861599|NCT00005289||2003-2004|
9861600|NCT00005305||Hemophilic individuals|Subjects receiving multiple blood products for treatment of hemophilia
9925445|NCT00871663|Experimental|Non-Hodgkin's lymphoma and multiple myeloma|Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
9925446|NCT00871663|Experimental|B cell chronic lymphocytic leukemia|Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts
9925447|NCT00871676|Active Comparator|1|Overweight/obese individuals being treated with lifestyle modification to facilitate weight loss.
9925448|NCT00871676|Experimental|2|Lifestyle modification plus use of chewing gum to facilitate weight loss in overweight/obese persons.
9925449|NCT00871702|Experimental|Donor lymphocyte infusion|CD34-TK75 transduced T lymphocytes from donors matched at a 5/6 or 6/6 antigen level at a dose of 1.0 x 105 cells/kg recipient weight.
9925450|NCT00871767|Experimental|1|40 or 100mg AZD5672, Reference formulation
9925451|NCT00871767|Experimental|2|40 or 100mg AZD5672, Test formulation
9925452|NCT00871793|Active Comparator|1|Occupational therapy
9925453|NCT00871793|No Intervention|2|watchful waiting
9925454|NCT00871806|Active Comparator|Eletriptan commercial tablet with water|Eletriptan commercial tablet given with water
9925455|NCT00871806|Experimental|Eletriptan oral disintegrating tablet (ODT) #1 without water|Oral disintegrating tablet formulation #1 without water
9925456|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 without water|Oral disintegrating tablet formulation #2 without water
9925457|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #1 with water|Oral disintegrating tablet formulation (ODT) #1 with water
9925458|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 with water|Oral disintegrating tablet formulation (ODT) #2 with water
9925459|NCT00871884|Active Comparator|Treatment As Usual|
9925460|NCT00871884|Experimental|Experimental|
9925461|NCT00871897||Cardiac Rehabilitation|People with heart failure who elect to participate in cardiac rehabilitation.
9925462|NCT00871897||No Cardiac Rehabiliation|People with heart failure who elect NOT to participate in cardiac rehabilitation.
9925463|NCT00871910|Experimental|2 Hour SCH 727965 infusion|Participants treated with 2 hour SCH 727965 IV infusion
9925464|NCT00871910|Experimental|8 Hour SCH 727965 infusion|Participants treated with 8 hour SCH 727965 IV infusion.
9925465|NCT00871910|Experimental|24 Hour SCH 727965 infusion|Participants treated with 24 hour SCH 727965 IV infusion.
9925466|NCT00871910|Experimental|2 Hour SCH 727965 infusions plus aprepitant in Cycle 1|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.
9925467|NCT00871910|Experimental|2 Hour SCH 727965 infusion plus aprepitant in Cycle 2|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.
9925468|NCT00871949|Experimental|Cohort 1, Sequence 1|Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
9925469|NCT00871949|Experimental|Cohort 1, Sequence 2|Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
9925470|NCT00871949|Experimental|Cohort 1, Sequence 3|Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
9925471|NCT00871949|Experimental|Cohort 2, Sequence 1|Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
9925472|NCT00871949|Experimental|Cohort 2, Sequence 2|Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
9925473|NCT00871949|Experimental|Cohort 2, Sequence 3|Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
9925474|NCT00871962||1|COPD patients on necessity of long-term oxygen therapy
9925475|NCT00872040||Nuliparous women and their husbands|Women in their first pregnancy with their husbands
9925476|NCT00872053|Experimental|Arm 1|Focused Ankle Training
9925477|NCT00872053|Experimental|Arm 2|Combination Therapy
9925478|NCT00872066|Active Comparator|1) SmartSet® HV Bone Cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
9925479|NCT00872066|Active Comparator|2) SmartSet® GHV Bone Cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
9925480|NCT00872092||Breath test|Subjects with suspected SBBO
9925481|NCT00872105|Other|Non-operative treatment|The first treatment strategy will involve conservative (nonoperative) management of the clavicle fracture.
9925482|NCT00872105|Active Comparator|Operative treatment|The second treatment strategy will involve operative fixation (i.e. ORIF) of the fracture with a plate and screws.
9925483|NCT00872118|Experimental|1|Brief Intervention for Socially Anxious Drinkers
9861601|NCT00005379||IV drug users and their sexual contacts|This group will be made up of an already-recruited cohort
9861602|NCT00005379||Children who receive primary care at Bellevue Hospital|
9861603|NCT00005379||Bellevue Hospital inpatients/outpatients|Inpatients being treated for TB and outpatients receiving prophylactic treatment
9861604|NCT00005446||Postmenopausal women with coronary heart disease|
9861605|NCT00005446||Postmenopausal women without coronary heart disease|Matched in age to the women with heart disease
9925484|NCT00872118|Active Comparator|2|Enhanced Alcohol Skills and Education Program
9925485|NCT00872131||Generalized social anxiety disorder participants|Participants with generalized social anxiety disorder will undergo MRI scanning and sertraline treatment.
9925486|NCT00872131||Healthy control participants|Healthy control participants will undergo MRI scanning.
9925487|NCT00872144|Active Comparator|Sativex|
9925488|NCT00872157|Experimental|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
9925489|NCT00872209|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
9925490|NCT00872209|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
9925491|NCT00872222|Other|Ceramic-on-Ceramic|Pinnacle™ Acetabular System with ceramic liner
9925492|NCT00872235|Experimental|1|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
9925493|NCT00872235|Active Comparator|2|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
9925494|NCT00872235|Experimental|3|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
9925495|NCT00872235|Active Comparator|4|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
9925496|NCT00872248|Experimental|1|Parturients received spinal anesthesia
9925497|NCT00872248|Active Comparator|2|Parturients received epidural anesthesia
9925498|NCT00872261||Proxy microbicide product|Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
9925499|NCT00872274|Experimental|1|sumatriptan succinate tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan) manufactured by OHM Laboratories In
9925500|NCT00872274|Active Comparator|2|IMITREX® 100 mg tablets (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
10210140|NCT02227394|Experimental|Z7200 - Symbicort® Turbohaler|"The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the test product (Z7200) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the second dosing day (Period 2, Visit 3).~Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.~Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.~Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided."
9925501|NCT00872287|Active Comparator|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
10213666|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:~New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%*, fasting blood glucose >126mg/dL confirmed on a subsequent day or as diagnosed by a physician~High-risk pre-diabetes: Hemoglobin A1c >6.3% or A1c >6.0% with fasting blood glucose >110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin <3 years are eligible"
9925502|NCT00872287|Active Comparator|SILS|Single transumbilical incision laparoscopic cholecystectomy
9925503|NCT00872313||1|Psychoses within the first 3 months postpartum
9925504|NCT00872313||2|Psychoses > 3 months to 6 months postpartum
9925505|NCT00872326|Experimental|Autologous Bone Marrow Mononuclear Cells|Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells
9925506|NCT00872365|Other|1|Regular aerobic physical exercise + placebo
9925507|NCT00872365|Other|2|Activities of daily living + Micronutrients
9925508|NCT00872365|Other|3|Regular aerobic exercise + micronutrients
9925509|NCT00872365|Placebo Comparator|4|Activities of daily living + placebo
9925510|NCT00872378|Active Comparator|Exenatide|Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
9925511|NCT00872378|Placebo Comparator|Placebo|Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
9925512|NCT00872391|Experimental|Hypofractionated LINAC radiotherapy|
9925513|NCT00872404|Experimental|1|CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion
9925514|NCT00872417|Experimental|Treatment-naive|To explore the efficiency and safety of generic antiretroviral drugs for 520 treatment-naive HIV/AIDS patients
9925515|NCT00872417|No Intervention|TREATMENT-EXPERIENCED|To explore the long term ARV of treatment-experienced patients who have no sign of drug resistance; to explore the long term efficiency and safety and drug sife effects of ARV in HIV/AIDS patients. These patients have taken ARV for approximately 3 years already.
9925516|NCT00872417|Experimental|drug resistance|To explore the second line drugs for those drug resistance patients
9925517|NCT00872443||FOP|Patients who already have an occlusion of POF secondary to a cryptogenic CVA and younger than 55 years old and without characterized thromboembolic events.
9925518|NCT00872469|Active Comparator|Tranexamic acid|
9925519|NCT00872469|Placebo Comparator|placebo|
9861606|NCT00005502||Residents of Olmsted County, MN with elevated Troponins|Anyone admitted to St Marys or Rochester Methodist Hospitals who have an elevated troponin during their hospitalization and are residents of Olmsted County, MN
9861607|NCT00005520||African American hydrochlorothiazide|300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.
9861608|NCT00005520||European American hydrochlorothiazide|300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks
9861609|NCT00005520||African American candesartan|300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
9861610|NCT00005520||European American candesartan|300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
9861611|NCT00005533||Coronary Heart Disease Patients|
9925520|NCT00872482|Experimental|1|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
9925521|NCT00872482|Placebo Comparator|2|"A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day."
10210141|NCT02227394|Experimental|Symbicort® Turbohaler - Z7200|"The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the test product (Z7200) on the second dosing day (Period 2, Visit 3).~Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.~Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg)."
10210142|NCT02204098|Active Comparator|Cohort 1:Neoadjuvant endocrine therapy alone|"Will be treated with standard of care adjuvant endocrine therapy as determined by their treating physician~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy"
10210143|NCT02204098|Experimental|Cohort 2:Neoadjuvant endocrine + mammaglobin-A DNA vaccine|"Will be treated with standard of care adjuvant endocrine therapy~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~All study injections will be administered using a TriGrid electroporation device"
10210144|NCT02204098|Active Comparator|Cohort 3: Neoadjuvant chemotherapy alone|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in cohort 3"
10213667|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:~Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended~Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
9925522|NCT00872495||1|"Bladder Cancer Group:~Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.~Two urine samples collected at the time of the scheduled procedure:~One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection."
9925523|NCT00872495||2|Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
9925524|NCT00872547|Active Comparator|1|Resurfacing system
9925525|NCT00872547|Active Comparator|2|Large Metal-on-Metal Total Hip Replacement
9925526|NCT00872573|Other|C-Stem™ AMT Femoral Component|
9925527|NCT00872586|Experimental|1|Olmesartan medoxomil and hydrochlorothiazide
9925528|NCT00872586|Active Comparator|2|olmesartan medoxomil
9925529|NCT00872612|Experimental|A|Endosonography arm
9925530|NCT00872612|Active Comparator|B|Conventional bronchoscopy arm
9925531|NCT00872625|Experimental|Cyberknife|
9925532|NCT00872638|Active Comparator|1|
9925533|NCT00872638|Active Comparator|2|
9925534|NCT00872651|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
9925535|NCT00872651|Active Comparator|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
9925536|NCT00872664|Active Comparator|formula with added carotenoids|Both arms are double-blinded. Infant will be assigned to receive preterm formula with added carotenoids. If infant is receiving human milk then the study formula will only be used as a supplement.
9925537|NCT00872664|Active Comparator|formula without added carotenoids|Both arms are double-blinded. This arm will use preterm formula as it is currently available, which is without any carotenoids. If the infant is receiving human milk, then the formula will be used as a supplement as needed.
9925538|NCT00872677||Dietitian-led counseling and Weight Watchers|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
9925539|NCT00872677||Dietitian & Weight Watchers + Spirituality Counseling|Dietitian wkly for the 1st-3 months, every other week for the next 3 months and monthly thereafter; Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
9925540|NCT00872690||Group 1|OEF/OIF veterans with polytrauma who have been referred by the Tampa VA Polytrauma Rehabilitation Center (PRC) to the VA VR&E Regional Office in St. Petersburg, Florida for Chapter 31 (IL) services.
9925541|NCT00872690||Group 2|Caregivers of the veterans who enroll in the study
9925542|NCT00872703||1|
9925543|NCT00872703||2|
9925544|NCT00872716|Experimental|Quetiapine XR|100 mg single-dose Quetiapine XR
9925545|NCT00872716|Placebo Comparator|Placebo|
9861612|NCT00005576|Experimental|Treatment (monoclonal antibody Ch14.18, aldesleukin)|Patients receive MOAB IV over 5 hours on days 7-10 during courses 2 and 4 and on days 3-6 during courses 1, 3, and 5; sargramostim (GM-CSF) IV over 2 hours or subcutaneously daily on days 0-13 during courses 1, 3, and 5; interleukin-2 IV continuously on days 0-3 and 7-10 during courses 2 and 4; and oral isotretinoin twice daily on days 14-27 during courses 2 and 4 and on days 10-23 during courses 3 and 5. Treatment repeats every 24-32 days for 5 courses in the absence of unacceptable toxicity.
9861613|NCT00005577|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
9861614|NCT00005578|Experimental|Arm 1|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
9861615|NCT00005578|Experimental|Arm 2|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7
9861616|NCT00005585|Experimental|Arm I: (combination chemotherapy)|CONSOLIDATION: Pts receive Methotrexate(MTX) IV over 24 hrs on day 1 and oral leucovorin calcium (CF) every 6 hrs for 3 doses at 42 hours after initiation of MTX infusion during weeks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine(6-MP) daily wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM twice a day on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
9861617|NCT00005585|Experimental|Arm II (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV over 4 hrs on day 1 and oral leucovorin calcium (CF) during wks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine (6-MP) daily on wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM 2x on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX weekly on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
9861618|NCT00005585|Experimental|Arm III (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV and leucovorin calcium (CF) as in arm I on wks 7, 10, 13, 24, 27, and 30. Pts also receive oral mercaptopurine (6-MP) daily on wks 5-13 and then on wk 24 and continuing until the end of consolidation; MTX IT on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone (DM) twice daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase intramuscularly on wk 16; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV on day 1 of wk 20; cytarabine IV or subcutaneously on days 2-5 of wks 20 and 21; and oral thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive oral 6-MP daily on wks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during wks 41, 57, 73, 89, and 105; oral MTX weekly on wks 33-130 (except during wks of IT MTX); and MTX IT on wks 37, 49, 61, 73, 85, 97, and 109.
9925546|NCT00872742|Experimental|1|Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
9925547|NCT00872742|Active Comparator|2|Participants will receive psychoeducation and supportive therapy (PST) for TTM.
9925548|NCT00872755|Active Comparator|Nissen|Laparoscopic Nissen Fundoplication
9925549|NCT00872755|Active Comparator|Gastropexy|Procedure/Surgery Laparoscopic Nissen Fundoplication combined with posterior gastropexy
9925550|NCT00872781|Experimental|1|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc (a subsidiary of Ranbaxy pharmaceuticals Inc)
9925551|NCT00872781|Active Comparator|2|ACCURETICTM tablets (containing fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg)
9935838|NCT03129126|Experimental|LP-10 4mg|LP-10 (intravesical tacrolimus), 4mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
9935839|NCT03129126|Experimental|LP-10 8mg|LP-10 (intravesical tacrolimus), 8mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
9935840|NCT03111745||1|Retrospective chart review of patients who have underwent hematopoietic stem celltransplantation (HSCT)
9935841|NCT03109288|Experimental|Combination Therapy|Any two-drug combination of study interventions
9935842|NCT03109288|Experimental|Monotherapy|Any of the study Interventions
9935843|NCT03098862||1|Direct EBOV exposure risk controls
9935844|NCT03098862||2|EVD fatal cases
9935845|NCT03098862||3|EVD survivor cases
9935846|NCT03098862||4|No known EBOV exposure population controls
9935847|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
9861619|NCT00005585|Experimental|.Arm IV (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) and leucovorin calcium (CF) on wks 7, 10, 13, 24, 27, and 30. Pts receive mercaptopurine(6-MP) daily weeks 5-13 then beginning wk 24 and continuing until end of consolidation; MTX on wks 7, 10, 13, 16, 20, 21, and 30; dexamethasone (DM) 2x daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase on wk 16; daunorubicin hydrochloride on day 1 of wks 16-18; cyclophosphamide on day 1 of wk 20; cytarabine on days 2-5 of wks 20 and 21; thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive mercaptopurine(6-MP) daily on weeks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during weeks 41, 57, 73, 89, and 105; oral MTX weekly on weeks 33-130 (except during weeks of IV MTX); and IV MTX on weeks 37, 49, 61, 73, 85, 97, and 109.
9861620|NCT00005592|Experimental|Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8|For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
9861621|NCT00005594|Experimental|ISIS 2503|All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
9861622|NCT00005596|Experimental|Arm I|Patients receive IT methotrexate on day 1 followed by methotrexate IV over 20 minutes followed by methotrexate continuously over 23.6 hrs on wks 7, 10, 13, 16,19, and 22. At 42 hrs after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium every 6 hrs for a total of 3 doses. Patients also receive oral mercaptopurine daily beginning on wk 5 and continuing until the completion of consolidation therapy; oral dexamethasone twice daily on days 1-7 of wks 8 and 17; and vincristine sulfate IV on day 1 of wks 8, 9, 17, and 18.
9861623|NCT00005596|Experimental|Arm II|Patients receive methotrexate IV over 4 hours on weeks 7, 10, 13, 16, 19, and 22. At 42 hours after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium as in arm I. Patients also receive mercaptopurine, dexamethasone, vincristine sulfate, and IT methotrexate as in arm I.
9861624|NCT00005596|Experimental|Arm III|Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
9861625|NCT00005596|Experimental|Arm IV|Patients receive methotrexate IV as in arm II on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; and pegaspargase, mercaptopurine, IT methotrexate, dexamethasone, vincristine sulfate, daunorubicin hydrochloride, cyclophosphamide, cytarabine, and thioguanine as in arm III.
9861626|NCT00005597|Experimental|Temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
9861627|NCT00005601|Experimental|rituximab+dexamethasone+cisplatin+cytarabine+sargramostim|"Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
9861628|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days|
9861629|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days|
9861630|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days|
9861631|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days|
9861632|NCT00005604|Experimental|Treatment (rhIl-12, IL-2)|Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
9861633|NCT00005605||Tamoxifen group|
9861634|NCT00005605||Chemotherapy group|
9861635|NCT00005610|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) over 10-15 minutes twice daily for 7 days. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and prior to course 5.~Patients are followed every 2 months for at least 1.5 years."
9861636|NCT00005613|Experimental|Autologous Transplant|autologous hematopoietic progenitor cell transplant
9861637|NCT00005613|Experimental|Allogeneic Transplant|allogeneic hematopoietic progenitor cell trasnplant
9861638|NCT00005614|Experimental|Gemcitabine Treatment|Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
9861639|NCT00005615|Experimental|Interferon Alfa Plus Radiation|"Combined Therapy: interferon alfa plus radiation therapy.~Patients receive interferon alfa IV over 20 minutes daily for 5 consecutive days a week for 4 weeks. Patients then receive radiotherapy on days 2 and 4 and interferon alfa subcutaneously (SQ) on days 1, 3, and 5 for 2.5 weeks. Interferon alfa SQ continues 3 times a week for 10 months in the absence of disease progression or unacceptable toxicity. Patients are followed every month for 3 months, then every 3 months for 2 years, then every six months until year 5, and then annually thereafter."
9861640|NCT00005617|Experimental|Group A|No. DC: 10^5 Route of Immunization: ID
9861641|NCT00005617|Experimental|Group B|No. DC: 10^5 Route of Immunization: IV
9861642|NCT00005617|Experimental|Group C|No. DC: 10^6 Route of Immunization: ID
9861643|NCT00005617|Experimental|Group D|No. DC: 10^6 Route of Immunization: IV
9861644|NCT00005617|Experimental|Group E|No. DC: 10^7 Route of Immunization: ID
9861645|NCT00005617|Experimental|Group F|No. DC: 10^7 Route of Immunization: IV
9861646|NCT00005622|Other|Cy/TBI|cyclophosphamide and total body irradiation (TBI)
9861647|NCT00005624|Experimental|CI-994 Treatment|Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
9861648|NCT00005626|Experimental|Irinotecan Treatment|Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
9861649|NCT00005629|Experimental|Group A - first dosing group|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.
9861650|NCT00005629|Experimental|Arm B - dosing group 2|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.
9861651|NCT00005629|Experimental|Group 3 - dosing level 3|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.
9861652|NCT00005632|Experimental|Vaccine|Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.
9861653|NCT00005639|Experimental|Regimen A: 14-day 5-AC with intermittent phenylbutyrate|"Participants receive low-dose regimen of 5-AC with intermittent phenylbutyrate 400 mg/m2/day by continuous intravenous (CIV) over 24 hours on Days 6 and 13. Each cycle lasts 35 days.~Cohort A1: 25 mg/m2/day subcutaneous (SC) Cohort A-1: 18.75 mg/m2/day SC Cohort A-2: 15 mg/m2/day SC Cohort A-3: 10 mg/m2/day SC"
9861654|NCT00005639|Experimental|Regimen B: 7-day 5-AC with sequential phenylbutyrate|"Participants receive 5-AC 75mg/m2/day SC for 7 days, followed sequentially by two different doses of phenylbutyrate CIV starting on Day 8 and continuing for 7 days. Each cycle lasts 35 days~Cohort B1: Phenylbutyrate 200 mg/m2/day CIV Cohort B2: Phenylbutyrate 400 mg/m2/day CIV"
9861655|NCT00005639|Experimental|Regimen C: 21-day 5-AC with weekly phenylbutyrate|"Participants receive two different daily doses of 5-AC SC for 21 days and phenylbutyrate 400 mg/m2/day CIV over 24 hours once-per-week. Each cycle lasts 42 days.~Cohort C1: 5-AC 10mg/m2/day SC Cohort C2: 5-AC 12.5mg/m2/day SC"
9861656|NCT00005640|Experimental|Mapping and Biopsy|Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor.
9861657|NCT00005646|Experimental|Paclitaxel|Patients receive paclitaxel for up to 4 cycles. One cycle = weekly drug for 6 weeks and 2 weeks rest
9861658|NCT00005648|Experimental|001|Gemcitabine with R115777 R115777 200 mg oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
9861659|NCT00005648|Placebo Comparator|002|Gemcitabine with Placebo Placebo oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
9861660|NCT00005655|Experimental|1|rhIL-12 in combination with rhIL-2
9861661|NCT00005675|Experimental|1|Participants will receive oral bovine type I collagen (CI) daily for 15 months
9861662|NCT00005675|Placebo Comparator|2|Participants will receive placebo daily for 15 months.
9861663|NCT00005676||VA-HIT and FOS|VA-HIT cohort: men with established CHD and low HDL-C FOS cohort: men without CHD
9925552|NCT00872794|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
9925553|NCT00872807|Experimental|Group intervention|Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
9925554|NCT00872807|Active Comparator|Individual intervention|Lifestyle counseling for each separate family practiced by single health professionals both in hospital and municipality. A more conventional model.
9925555|NCT00872820|Active Comparator|1|Participants will receive standard cognitive behavioral therapy.
9925556|NCT00872820|Experimental|2|Participants will receive acceptance- and commitment-based behavioral therapy.
9925557|NCT00872820|No Intervention|3|Participants will be placed on a waitlist for 3 months before being offered treatment.
9925558|NCT00872859|Experimental|1|Dermamatrix with radiation
9925559|NCT00872859|Experimental|2|Dermamatrix without radiation
9925560|NCT00872859|Experimental|3|Alloderm with radiation
9925561|NCT00872859|Experimental|4|Alloderm without radiation
9925562|NCT00872872|Active Comparator|AZT/3TC 1 week after delivery|AZT/3TC 1week after delivery
9861664|NCT00005699||Hypertensive|described as hypertensive according to AHA guidelines at time of trial
9861665|NCT00005699||Controls|described as non-hypertensive according to AHA guidelines at time of trial
9861666|NCT00005711|No Intervention|Usual care|Control group children received routine medical care by their primary care providers as well as study visits every 6 months. At each study visit, following assessment of technique for using peak flow and metered dose inhalers, errors were corrected and children/families were coached on correct technique.
9861667|NCT00005711|Experimental|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
9861668|NCT00005713||Continuing, preventative care for asthma|Low-income children with asthma will receive continuing, preventive care for asthma with trained staff in New York City Bureau of Child Health clinics
9861669|NCT00005724|Other|Minimal Intervention Group|Pamphlets on healthy eating mailed to participants.
9861670|NCT00005724|Experimental|Health Counselor Intervention Group|Food for Heart program, a structured diet treatment program for low-income patients with high cholesterol, given by health counselor at 4 treatment visits.
9861671|NCT00005724|Experimental|Computer Program Intervention Group|User-friendly interactive computer program providing dietary counseling tailored to the needs of the participant.
9861672|NCT00005727|Experimental|Intervention|Specially-designed nutrition education curriculum designed to lower dietary fat intake in people with low literacy skills.
9861673|NCT00005727|Active Comparator|Control|General nutrition education curriculum.
9861674|NCT00005739||Community-based therapy (case)|Community-based directly observed therapy (DOT) - A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
9861675|NCT00005739||Self-administered treatment (control)|Clinic directly observed therapy (DOT) - Traditional self-administered preventive treatment
9861676|NCT00005772|Experimental|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
9861677|NCT00005772|Placebo Comparator|Normothermic|Placebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
9861678|NCT00005773|Experimental|Early iNO Management|Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
9861679|NCT00005773|Active Comparator|Standard iNO management|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
9861680|NCT00005774|Experimental|Early surfactant group|
9861681|NCT00005774|Active Comparator|Standard Practice group|
9861682|NCT00005775|Experimental|Glutamine|TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids) with L-glutamine added (20% of the total amount of amino acids)
9861683|NCT00005775|Placebo Comparator|Placebo|Standard TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids)
9861684|NCT00005776|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO)
9861685|NCT00005776|Placebo Comparator|Oxygen|100% oxygen
9861686|NCT00005777|Experimental|Minimal ventilation with Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
9861687|NCT00005777|Experimental|Minimal Ventilation without Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
9861688|NCT00005777|Active Comparator|Routine ventilation with Dexamethasone|
9861689|NCT00005777|Active Comparator|Routine ventilation without Dexamethasone|
9925563|NCT00872872|Experimental|AZT/3TC 2 weeks after delivery|AZT/3TC 2 weeks after delivery
9925564|NCT00872911|Experimental|Nutritional supplement|
9861690|NCT00005786|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Treatment repeats every 21 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding or stable disease may receive 6 additional courses.
9925565|NCT00872911|Experimental|Placebo + Exercise|
9925566|NCT00872911|Experimental|Nutritional Supplement + Exercise|
9925567|NCT00872911|No Intervention|Placebo|
9925568|NCT00872924|Experimental|1|sumatriptan succinate 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan) of OHM laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA).
9925569|NCT00872924|Active Comparator|2|IMITREX® 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan)
9925570|NCT00872963||RABIES VACCINE|Those subjects who received the active comparator
9925571|NCT00872963||RTS,S/AS01E|The subjects who received investigational product
9925572|NCT00872976|Experimental|Cohort #1|
9925573|NCT00872976|Experimental|Cohort #2|
9925574|NCT00873002|Active Comparator|LBH589|This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.
9925575|NCT00873028|Experimental|1|
9925576|NCT00873028|No Intervention|2|Those patients assigned to Control were followed by their own physicians, received routine nursing assistance, were visited daily by the one of the investigators (CPM), but were not exposed to any specific respiratory or motor physical intervention.
9925577|NCT00873054||1 ESWL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next the patient will be transferred to a separate room and sound waves will be aimed at the center of the stone until the stone is broken into pieces.
9925578|NCT00873054||2 PCNL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next, a small (1cm) cut will be made in the back and a tube will be placed into the kidney. Through this tube a small camera will be placed inside the kidney and break the stone into many pieces and remove them through the same tube. All fragments that can be seen will be removed. A different plastic tube (drain) will be placed through the cut and into the kidney and left in place for 5-7 days.
9925579|NCT00873067|Active Comparator|ACVP plus roof line|Standard procedure for atrial fibrillation ablation, including pulmonary vein isolation plus roof line ablation. All ablation lines will be tested.
9925580|NCT00873067|Active Comparator|Additional CFAEs ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
9925581|NCT00873132||Data Collection|Collect data both retrospectively and prospectively on subjects seen at the Preston Robert Tisch Brain Tumor Center
9925582|NCT00873145||1|Patients with major bone defects around the elbow.
9925583|NCT00873158|No Intervention|Physical Therapy Group|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
9925584|NCT00873158|Experimental|Dynasplint Group|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
9925585|NCT00873171||1. OMT|This procedure consist of Sacral rocking is performed by placing the heel of the practitioner's hand over the sacrum and by using the palpatory skills of an osteopathic physician; rock the sacrum into a position with no restriction. Myofascial release will utilize various physical motions to place the patients lumbosacral region in a position of maximal comfort and tissue release.
9925586|NCT00873171||2. Attention control OMT|The procedure consist of light pressure applied to certain painful areas of the body and back to decrease pain and help patient relax. The physician will look for areas of the body that hurt, lay his/her hands on the those places, and apply light pressure.
9925587|NCT00873171||3. Standard of Care|This procedure consists of various conservative treatments that can help reduce stress. Those include dietary modifications, pharmaceuticals, bladder training, and neuromodulation. If these treatments are not successful, minimally invasive surgical procedures is performed.
9925588|NCT00873184|Other|1|A prospective, single-arm intervention study, potential participants will be identified and screened for eligibility via medical record review of patient scheduled for their post surgical primary adjuvant treatment consultation at DUMC.
9925589|NCT00873197|Experimental|Sancuso® patch/IV granisetron|Subjects will receive 1 Sancuso® patch worn for 7 days (168 hours). Immediately after the patch has been applied on Day 1, IV granisetron will be administered over 30 seconds. Following patch removal at 168 hours, a new patch will be immediately applied to the opposite arm and will remain in place for a further 7 days (168 to 336 hours).
9925590|NCT00873210||Patients treated with Sutent|125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
9925591|NCT00873223|Experimental|A|
9925592|NCT00873236|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.
9925593|NCT00873236|Experimental|Arm II|Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.
9925594|NCT00873236|Experimental|Arm III|Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.
9925595|NCT00873262|Active Comparator|Hormones|
9861691|NCT00005792|Experimental|MTV|Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant
9861692|NCT00005793|Experimental|Combination Chemotherapy|Patients receive induction chemotherapy with daunorubicin IV over 10-15 minutes on days 1-3, cytarabine IV continuously on days 1-5, topotecan IV continuously on days 6-8, and etoposide IV over 60 minutes on days 9 and 10. Within 4 weeks of hematologic recovery, patients achieving remission after induction receive consolidation chemotherapy with cytarabine IV over 1 hour every 12 hours on days 1, 3, and 5. Subsequent courses of consolidation chemotherapy begin within 2 weeks of documentation of hematologic recovery from the prior consolidation course. Consolidation chemotherapy continues for 4 courses in the absence of unacceptable toxicity or disease progression.
9861693|NCT00005796|Experimental|Single arm|PCV therapy
9861694|NCT00005797|Other|BuCy2|Busulfan & Cyclophosphamide
9861695|NCT00005797|Other|VP16/TBI|Fractionated Total Body Irradiation + VP-16
9861696|NCT00005798|Other|CTC Conditioning Regimen|Cyclophosphamide Thiotepa Carboplatin
9861697|NCT00005799|Experimental|Treatment (chemotherapy, TBI, HSCT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO BID on days 0-40 with taper to day 96. Patients with mixed chimerism, persistent or progressive disease, and no evidence of graft-versus-host disease and who have been off immunosuppression for at least 2 weeks undergo DLI over 30 minutes. DLI may be repeated every 65 days for up to 3 doses."
9861698|NCT00005800|Experimental|Dose-Dense Chemotherapy|Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
9861699|NCT00005807|Experimental|Treated Participants|dose escalation treatment
9861700|NCT00005808|Experimental|Part 1 (lutetium texaphyrin, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. Patients undergo in vivo tissue assessment by spectrometer at 0, 1, 3, 5, 12, and 24 hours and loop electrical excision procedure (LEEP) at 24 hours after lutetium texaphyrin infusion.
9861701|NCT00005808|Experimental|Part 2 (lutetium texaphyrin, laser therapy, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
9861702|NCT00005810|Experimental|Estramustine + docetaxel + carboplatin+ filgrastim|Patients receive oral estramustine 3 times daily on days 1-5. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF) SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for a maximum of 2 years.
9861703|NCT00005811|Experimental|Treatment (topotecan hydrochloride)|"INDUCTION: Patients receive topotecan hydrochloride IT over 5 minutes twice weekly for 6 weeks.~CONSOLIDATION: Beginning 1 week after completion of induction, patients receive topotecan hydrochloride IT over 5 minutes weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 2 weeks after completion of consolidation, patients receive topotecan hydrochloride IT over 5 minutes twice monthly for 4 months and then monthly through year 1."
9861704|NCT00005812|Experimental|Temozolomide|"Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:~disease progression~intolerable toxicity~complete response - 2 full additional cycles~if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response."
9861705|NCT00005817|Experimental|Arm I (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on day 1.
9861706|NCT00005817|Experimental|Arm II (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on days 1-5.
9861707|NCT00005818|Experimental|Treatment (irinotecan hydrochloride, semaxanib)|Patients receive irinotecan IV over 90 minutes on day 1 of weeks 1-4 and SU5416 IV over 60 minutes on days 1 and 4 of weeks 1-6. Treatment continues every 6 weeks in the absence of unacceptable toxicity or disease progression.
9925596|NCT00873262|Placebo Comparator|Solvent|
9935848|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
9935849|NCT03092518|Experimental|1/Arm 1|HIPEC with gastrectomy
9861708|NCT00005820|Experimental|nitrocamptothecin|"Patients receive nitrocamptothecin orally daily for 5 consecutive days each week for 3 consecutive weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until evidence of progression or relapse for a maximum of 2 years from the date of registration."
9861709|NCT00005828|Experimental|green tea extract|Patients receive oral green tea extract six times daily for 4 months. Patients with a 50% decline in PSA, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 4 months receive no further treatment. Patients are followed every 3 months for 5 years or until disease progression. If disease progression, patients are followed every 6 months for 5 years.
9861710|NCT00005829|Experimental|gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
9861711|NCT00005830|Experimental|Treatment (doxorubicin, cisplatin, radiation therapy)|Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
9861712|NCT00005831|Experimental|Treatment (trastuzumab, combination chemotherapy)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1; and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks. Patients achieving a complete response (CR) receive 3 courses past CR. Patients achieving a partial response or stable disease continue on therapy until CR or disease progression or unacceptable toxicity.
9861713|NCT00005832|Experimental|R115777|300mg/dose BID, PO, Days 1-21, q 28days
9861714|NCT00005833|Experimental|R115777|R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
9861715|NCT00005834|Experimental|chemo with thalidomide|chemo with thalidomide
9861716|NCT00005834|Active Comparator|chemo without thalidomide|chemo without thalidomide
9861717|NCT00005838|Experimental|Arm I (shark cartilage extract AE-941)|"Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
9861718|NCT00005838|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
9861719|NCT00005840|Experimental|Treatment (paclitaxel, cisplatin, abdominal radiotherapy)|"Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.~Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level."
9935850|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
9861720|NCT00005842|Experimental|Arm I|Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
9861721|NCT00005843|Experimental|Arm I|Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
9861722|NCT00005845|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9861723|NCT00005849|Experimental|Arm A|Paclitaxel (90 mg/m2, days 1, 8 and 15 of every 28 day cycle), Bryostatin-1 (50 mcg/m2, days 2, 9 and 16 of every 28 day cycle)
9861724|NCT00005850|Experimental|gemcitabine + cisplatin + fluoxetine|Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.
9861725|NCT00005851|Experimental|Treatment (nonmyeloablative donor PBSC transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.~DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD."
9861726|NCT00005856|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.
9861727|NCT00005858|Experimental|Arm I|"Patients receive LMB-9 immunotoxin IV continuously for 10 days. Treatment continues every 30 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9861728|NCT00005862|Experimental|Arm I|atients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
9861729|NCT00005866|Experimental|treatment|
9861730|NCT00005881||Quality of life forms|Completion of the development of an instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
9925597|NCT00873275|Experimental|Treatment (ursodiol, combination chemotherapy, bevacizumab)|Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9925598|NCT00873301|Experimental|vulvodynia|
9925599|NCT00873314|Experimental|Bed rest|
9925600|NCT00873314|Placebo Comparator|Activity restriction|
9925601|NCT00873340||Group 1|
9925602|NCT00873353|Experimental|Unique arm|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
9925603|NCT00873379|Active Comparator|melatonin|.5 mg (one half of a 1 mg tablet of GNC rapid dissolving Melatonin, natural product number (NPN) 80001380)
9925604|NCT00873379|Placebo Comparator|placebo|half a white placebo tablet
9925605|NCT00873392|Experimental|1|Experimental drug
9925606|NCT00873392|Active Comparator|2|Usual treatment
9925607|NCT00873405|Active Comparator|SRSG|Silastic® ring sleeve gastrectomy (SRSG).
9925608|NCT00873405|Other|SRGB|Silastic® ring gastric bypass.
9925609|NCT00873418|Experimental|Coping Skills Training|16 week telephone intervention using coping skills training to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
9925610|NCT00873418|Active Comparator|Educational Control|16 weekly telephone calls for extended (standardized) care on heart failure education.
9925611|NCT00873431|Experimental|IC47 30 mcg|30 mcg with Alum
9925612|NCT00873431|Experimental|IC47 30 mcg w/o|30 mcg without Alum
9925613|NCT00873431|Experimental|IC47 150 mcg|150 mcg with Alum
9925614|NCT00873431|Experimental|IC47 150 mcg w/o|150 mcg without Alum
9925615|NCT00873444|Active Comparator|1) Ceramic-on-Metal Bearing|A cementless acetabular cup with ceramic liner for use in total hip replacement
9925616|NCT00873444|Active Comparator|2) Metal-on-Metal Bearing|A cementless acetabular cup with metal liner for use in total hip replacement
9925617|NCT00873470|Experimental|Stimulation|All patients included have the stimulation
9861731|NCT00005914||Probands and family members|Individuals with major depressive disorder who meet study criteria, and members of their families. No intervention. This is a genetic study only.
9861732|NCT00005922|Experimental|A|Participants will receive 100% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
9861733|NCT00005922|Experimental|B|Participants will receive 100% of the dose of the medication on a partial reinforcement schedule (25% or 50%) as received during the baseline (maintenance) period
9861734|NCT00005922|Experimental|C|Participants will receive 25% or 50% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
9861735|NCT00005940|Experimental|Treatment (radiolabeled BC8, chemotherapy, PBSCT)|"RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.~CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.~GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
9861736|NCT00005942|Experimental|Treatment (liposomal danorubicin citrate, semaxanib)|Patients receive daunorubicin liposomal IV over 6 hours on days 1-3 and SU5416 IV twice a week for 2 months. The second course is administered for 1 month, then treatment continues every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
9861737|NCT00005945|Experimental|Induction Not Randomized|Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
9861738|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification CNS|Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
9861739|NCT00005945|Experimental|Induction and Augmented regimen (IV MTX, Double DI)|Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
9861740|NCT00005945|Experimental|Induction and Oral MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
9861741|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
9861742|NCT00005945|Experimental|Induction and IV MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
9861743|NCT00005945|Experimental|Induction and IV MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
9861744|NCT00005949|Experimental|Treatment (gp100:209-217, aldesleukin )|Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
9861745|NCT00005950|Experimental|Treatment|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9861746|NCT00005961|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by carmustine IV over 1 hour on day 1. Treatment continues every 6 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
9861747|NCT00005963|Experimental|docetaxel + carboplatin|This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
9925618|NCT00873483|Experimental|Arm 1|
9925619|NCT00873496||Sjögren|Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
9925620|NCT00873509|Experimental|1|Buspirone 2.5 mg
9925621|NCT00873509|Experimental|2|Buspirone 5.0 mg
9925622|NCT00873509|Placebo Comparator|3|Placebo match
9861748|NCT00005964|Experimental|Chemotherapy + prednisone + filgrastim|Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
9861749|NCT00005967|Experimental|Arm I|Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
9861750|NCT00005969|Experimental|Liposomal Tretinoin|Liposome by vein (IV) over 30 minutes every other day for 28 days and Chemotherapy.
9861751|NCT00005970|Experimental|Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor)|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
9861752|NCT00005970|Experimental|Arm II (AC, paclitaxel, trastuzumab, tamoxifen)|Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
9861753|NCT00005970|Experimental|Arm III (AC, paclitaxel, trastuzumab, tamoxifen)|"Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy."
9861754|NCT00005972|Experimental|gemcitabine + irinotecan|Patients are stratified according to prior response duration (progression 90 days or more after initial therapy vs progression less than 90 days after initial therapy or no response to initial therapy). Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually for 3 years.
9861755|NCT00005973|Experimental|Treatment|Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
9861756|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 20 mg/day|Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
9861757|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 40 mg/day|Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
9925623|NCT00873522||Community acquired pneumonia|
9925624|NCT00873522||Health-Care-Associated pneumonia|
9935851|NCT03092492||Participants with bilateral early AMD|Participants with bilateral early AMD
9861758|NCT00005976|Experimental|Arm I|"Patients receive carboplatin IV over 30 minutes and pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of carboplatin and pyrazoloacridine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
9861759|NCT00005976|Experimental|Arm II|Patients receive the same treatment as given in study 1. Dose escalation is performed as in study 1 to determine the MTD in patients not receiving concurrent anticonvulsants.
9861760|NCT00005976|Experimental|Arm III|Patients receive the same treatment as given in studies 1 and 2 without dose escalation.
9861761|NCT00005977|Experimental|STAGE III NHL (Trt 1)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABA"
9861762|NCT00005977|Experimental|STAGE IV NHL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
9861763|NCT00005977|Experimental|STAGE IV, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
9861764|NCT00005977|Experimental|B-ALL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
9861765|NCT00005977|Experimental|B-ALL, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
10210145|NCT02204098|Experimental|Cohort 4: Neoadjuvant chemotherapy + mammoglobin-A DNA vaccine|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~All study injections will be administered using a TriGrid electroporation device~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in either cohort 4"
9861766|NCT00005982|Experimental|Treatment (nelarabine)|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9861767|NCT00005983|Active Comparator|surgery|surgery followed by observation
9861768|NCT00005983|Experimental|surgery followed by RT|Surgery followed by radiation therapy
9861769|NCT00005984|Experimental|Patients with CML|Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)
9861770|NCT00005988|Experimental|in vitro-treated bone marrow transplantation|"Donor bone marrow will be harvested on Day -2~Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.~Bone marrow will be infused intravenously~Cyclophosphamide will be administered IV once daily~Total Body Irradiation (TBI) will be delivered per institutional practice~Methylprednisolone will be administered IV as 4 doses separated by 12 hours,"
9861771|NCT00006001|Experimental|Arm I|Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
9861772|NCT00006002|Experimental|Arm B|dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.
9861773|NCT00006002|Experimental|Arm A|SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment
9861774|NCT00006003|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
9861775|NCT00006006|Experimental|Arm I|Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.
9861776|NCT00006007|Experimental|gemcitabine + pemetrexed|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.~Patients are followed every 3 months for 5 years."
9861777|NCT00006010|Experimental|docetaxel + gemcitabine|"Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
9925625|NCT00873535|Active Comparator|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
9935852|NCT03092492||Participants with large RPD|Participants with large RPD
10210146|NCT02193503|Experimental|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
10210147|NCT02184741|Placebo Comparator|Placebo|Infusion of normal saline
10210148|NCT02184741|Experimental|GB-0998|Infusion of GB-0998 (Immunoglobulin)
10210149|NCT02176863|Experimental|Stage 1 Arm 1: 2 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 2 g/kg of body weight administered via intravenous infusion over 2 consecutive days (Flebogamma 5% DIF 1 g/kg infused on Day 1 and Flebogamma 5% DIF 1 g/kg infused on Day 2) every 4 weeks for 52 weeks.
9861778|NCT00006012|Experimental|topotecan + paclitaxel + filgrastim + TRT + radiation|"Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.~After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.~At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
9861779|NCT00006014|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
9861780|NCT00006015|Experimental|Combination Chemotx|Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy
9861781|NCT00006016|Experimental|Treatment (thalidomide, chemoembolization)|Patients receive oral thalidomide daily beginning 4 weeks before the first planned chemoembolization procedure. Thalidomide administration is stopped 24 hours before each chemoembolization procedure, and then restarted at 24 hours after completion of each procedure OR when blood counts and levels of bilirubin and transaminases recover, whichever occurs later. Thalidomide treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo placement of a visceral arterial catheter. Patients receive doxorubicin as a chemoemulsion via the arterial catheter into 1 hepatic lobe only under angiographic guidance. Immediately after delivery of the chemoemulsion, patients undergo particulate embolization. The opposite lobe, if involved, is treated within 3-5 weeks of treatment of the initial lobe. Patients are reevaluated for repeat chemoembolization within 8-12 weeks of the last chemoembolization.
9861782|NCT00006017|Active Comparator|Rebeccamycin 1 day|Patients receive rebeccamycin analogue IV over 1 hour on day 1.
9861783|NCT00006017|Active Comparator|Rebeccamycin 5 day|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.
9925626|NCT00873535|Placebo Comparator|Placebo|This group (N=40) will receive placebo in the same dosing regimen as for Varenicline. The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
9925627|NCT00873548||PFNA_Asia treated|
9925628|NCT00873561|Active Comparator|1 Experimental|NBI-6024 0.1 mg
9925629|NCT00873561|Active Comparator|2 Experimental|NBI-6024 0.5 mg
9925630|NCT00873561|Active Comparator|3 Experimental|NBI-6024 1 mg
9925631|NCT00873561|No Intervention|4 placebo|Placebo injection
9925632|NCT00873574||1|2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
9925633|NCT00873574||2|1 control for each family
9925634|NCT00873587|Other|Inspiration|
9925635|NCT00873587|Other|Expiration|
9925636|NCT00873613|No Intervention|Direct ophthalmoscopy|
9925637|NCT00873613|Experimental|Non-dilated retinal photography|
9925638|NCT00873626|Active Comparator|1|fluoroquinolones 5 days
9925639|NCT00873626|Active Comparator|2|fluoroquinolones 10 days
9925640|NCT00873639||A|
9925641|NCT00873665|Experimental|Aerobic exercise|"To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.~The test of the arm effect of incidence of ED will be made with the Wald chi-square test from the logistic regression model. A dichotomous variable indicating whether the patient received PDE-5 inhibitor therapy will be used as a covariate in the model. The arm effect will be summarized by giving arm-specific covariate-adjusted proportions and their 80% confidence intervals, and the p-value."
9925642|NCT00873665|Other|Wait-list control|"To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.~For the analyses of arm differences in erectile dysfunction (IIEF) score, sexual functioning, urinary incontinence, and QOL, the primary endpoints will be the change across time in these continuous variables. Specifically, change across time for LTF patients will be imputed to be zero for all these analyses."
9925643|NCT00873678||1|Children or adult patients affected with JS/CORS
9925644|NCT00873691||1|ICD shocks programmed to Tuned Waveform
9925645|NCT00873691||2|ICD shocks programmed to 50% Tilt waveform
9861784|NCT00006024|Experimental|Pre and Post radiation Chemotherapy|
9861785|NCT00006029|Active Comparator|vinorelbine + gemcitabine + doxorubicin - higher doses|"Patients who have not undergone prior transplantation receive vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
9861786|NCT00006029|Experimental|vinorelbine + gemcitabine + doxorubicin - lower doses|"Patients who have undergone prior transplantation receive lower doses of vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
9861787|NCT00006031|Active Comparator|I: Radioactive Seed Localized Breast Biopsy|Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
9861788|NCT00006031|Active Comparator|Arm II: Needle Localized Breast Biopsy|Arm II: Patients undergo a needle localized breast biopsy with a specimen x-ray.
9861789|NCT00006034|Experimental|Arm I|Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.
9861790|NCT00006034|Active Comparator|Arm II|Patients receive doxorubicin IV once weekly in weeks 1-6.
9861791|NCT00006047|Experimental|Combination Therapy|Combination Therapy with Oral 9-Nitrocamptothecin & Oral Etoposide. Patients receive oral nitrocamptothecin on days 1-3 and oral etoposide on days 4-5 each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
9861792|NCT00006079|Experimental|Arm I|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
9861793|NCT00006079|Experimental|Arm II|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
9861794|NCT00006079|Placebo Comparator|Arm III|Arm III: Patients receive oral placebo daily. Treatment continues for 28 days.
9861795|NCT00006081|Experimental|Bryostatin-1 + Taxol|
9861796|NCT00006083|Experimental|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
9861797|NCT00006083|Placebo Comparator|placebo|placebo injected subcutaneously daily
9861798|NCT00006089|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9861799|NCT00006092|Experimental|Arsenic Trioxide Treatment|Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.
9861800|NCT00006094|Experimental|Treatment (oxaliplatin, fluorouracil, EBRT)|Patients receive oxaliplatin IV over 1 hour on day 1, fluorouracil IV continuously on days 1-7, and radiotherapy on days 1-5. Treatment repeats weekly for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
9861801|NCT00006095|Experimental|Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan|
9861802|NCT00006095|Experimental|Vincristine sulfate 2.0 mg/m2/wk and Irinotecan|
9861803|NCT00006102|Experimental|Arm I|"Patients with solid tumors are stratified according to tumor histology (neuroblastoma vs Ewing's sarcoma [closed to accrual as of 5/19/03]/peripheral primative neuroectodermal tumor [PNET] vs osteosarcoma [closed to accrual as of 5/19/03] vs rhabdomyosarcoma vs non-Hodgkin's lymphoma vs other solid tumors). Patients with CNS tumors are stratified according to tumor histology (medulloblastoma/PNET vs ependymoma vs brainstem glioma vs other CNS tumors).~Patients receive rebeccamycin analogue IV over 1 hour on day 1. Treatment continues every 21 days for a total of 16 courses in the absence of disease progression or unacceptable toxicity."
9861804|NCT00006103|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
9861805|NCT00006105|Experimental|Administration of Cisplatin, Gemcitabine, and Amifostine|Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
9861806|NCT00006107|Experimental|Taxotere|"Taxotere: (1 hour infusion once a week for four weeks)~Radiation Therapy (5 days/week for 6-7 weeks)~Surgery (if required) 14 -12 weeks after radiotherapy~Follow-up"
9861807|NCT00006111|Experimental|resectable disease|
9861808|NCT00006111|Experimental|unresectable disease|
9861809|NCT00006124|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily.
9861810|NCT00006124|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily.
9861811|NCT00006125|Experimental|Doxorubicin + topotecan|"Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.~Patients are followed every 6 months for 2 years and annually for the next 3 years."
9861812|NCT00006154|Experimental|A|Patients will receive combination antiretroviral therapy with a protease inhibitor
9861813|NCT00006154|Active Comparator|B|Patients will receive combination antiretroviral therapy without a protease inhibitor
9861814|NCT00006172|Active Comparator|bright light box|60 min light therapy shortly after awakening
9861815|NCT00006172|Active Comparator|high-output negative ion generator|60 min high-density exposure shortly after awakening
9861816|NCT00006172|Placebo Comparator|low-output negative ion generator|60 min low-density exposure shortly after awakening
9861817|NCT00006205|Experimental|Ondansetron|Ondansetron + cognitive behavioral therapy
9861818|NCT00006205|Experimental|Topiramate|Topiramate + cognitive behavioral therapy
9861819|NCT00006205|Placebo Comparator|Placebo|Placebo + cognitive behavioral therapy
9861820|NCT00006205|Experimental|Ondansetron + Topiramate|Ondansetron + Topiramate + cognitive behavioral therapy
9861821|NCT00006213|Experimental|Treatment (BMS-214662)|Patients receive BMS-214662 IV over 1 hour weekly for 4 weeks. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
9861822|NCT00006214|Experimental|flutamide|"Patients receive oral flutamide once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
9861823|NCT00006214|Other|placebo|"Patients receive an oral placebo once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
9861824|NCT00006220|Experimental|Phase I|Starting dose of arsenic trioxide of 0.15 mg/kg/day
9861825|NCT00006220|Experimental|Phase II|MTD of arsenic trioxide
9861826|NCT00006220|Experimental|Treatment Failure|Arsenic trioxide and tretinoin
9861827|NCT00006221|Experimental|Arm I|"Patients receive BMS-247550 IV over 1 hour once weekly on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients treated at the MTD receive treatment once weekly on weeks 1-3 of each 4-week course."
9861828|NCT00006222|Experimental|Arm I|Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
9861829|NCT00006226|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
9861830|NCT00006228|Experimental|Treatment (trastuzumab and aldesleukin)|Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
9861831|NCT00006229|Experimental|BMS-275291|
9861832|NCT00006229|Placebo Comparator|Placebo|
9861833|NCT00006242|Experimental|Treatment (BMS-214662)|"Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.~Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.~Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD."
9861834|NCT00006243|Experimental|Arm I (vaccine therapy)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
9861835|NCT00006243|Experimental|Arm II (vaccine therapy and lower-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
9861836|NCT00006243|Experimental|Arm III (vaccine therapy and higher-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
9861837|NCT00006249|No Intervention|observation|5 years observation + 5 years follow up
9861838|NCT00006249|Experimental|pegylated interferon alfa|5 years pegylated interferon alfa + 5 years follow up
9861839|NCT00006251|Experimental|Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)|"CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)~PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart."
9861840|NCT00006252|Experimental|Allogeneic Stem Cell Tx|minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy
9925646|NCT00873704|Active Comparator|1|recieves supplemental oxygen postoperatively
9925647|NCT00873704|No Intervention|2|treated as usual without supplemental oxygen
9861841|NCT00006253|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
9861842|NCT00006253|Experimental|Non-nurse coach|Receives symptom management assistance from a non-nurse coach via telephone
9861843|NCT00006265|Experimental|Cohort I|Immunotherapy with gemtuzumab
9861844|NCT00006265|Experimental|Cohort II|Gemtuzumab + ara-C
9861845|NCT00006265|Experimental|Cohort IA|Gemtuzumab + ara C
9861846|NCT00006265|Experimental|Cohort IV|Gemtuzumab + ara-C
9861847|NCT00006294||Chlorthalidone|Participants will take chlorthalidone at recommended doses to control hypertension
9861848|NCT00006294||Amlodipine|Participants will take Amlodipine at recommended doses to control hypertension
9861849|NCT00006294||Lisinopril|Participants will take Lisinopril at recommended doses to control hypertension
9861850|NCT00006294||Doxazosin|Participants will take Doxazosin at recommended doses to control hypertension
9861851|NCT00006295||Pedigree 1|
9861852|NCT00006295||Pedigree 2|
9861853|NCT00006295||Pedigree 3|
9861854|NCT00006295||Pedigree 4|
9861855|NCT00006295||Pedigree 5|
9861856|NCT00006295||Pedigree 6|
9861857|NCT00006295||Pedigree 7|
9861858|NCT00006295||Pedigree 8|
9861859|NCT00006295||Pedigree 9|
9861860|NCT00006295||Pedigree 10|
9861861|NCT00006295||Pedigree 11|
9861862|NCT00006295||Pedigree 12|
9861863|NCT00006333||Subjects with known or suspected arthritis|Subjects with known or suspected arthritis will be evaluated longitudinally
9861864|NCT00006341|Experimental|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
9861865|NCT00006348|Experimental|Arm 1: ondansetron + placebo|Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.
9861866|NCT00006348|Experimental|Arm 2: ondansetron + placebo|Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.
9861867|NCT00006349|Experimental|donepezil + vitamin E|"Patients receive oral donepezil daily and vitamin E twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
9861868|NCT00006349|Placebo Comparator|placebo|"Patients receive oral placebo twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
9861869|NCT00006359|Experimental|Androgen suppression + EBRT + Brachytherapy|Androgen suppression with external beam radiation therapy followed by brachytherapy boost
9925648|NCT00873717|Experimental|Dentary|Intervention: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
9925649|NCT00873717|Experimental|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
9795596|NCT01540487|Experimental|linagliptin/metformin(high dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
9795597|NCT01540487|Experimental|linagliptin/metformin(low dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
9861870|NCT00006363|Experimental|Induction Arm I|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1-3. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of cytarabine IV continuously on days 1-5 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1 and 2.
9861871|NCT00006363|Experimental|Induction Arm II|Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
9861872|NCT00006363|Experimental|Intensification Favorable|Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
9861873|NCT00006363|Experimental|Intensification Unfavorable PBSCT Group|Patients receive etoposide IV continuously and HiDAC IV over 2 hours every 12 hours on days 1-4. Patients also receive G-CSF SC daily beginning on day 14 and continuing until PBSC collection is completed. Patients who are not able to undergo PBSCT after HiDAC/etoposide continue treatment in the non-PBSCT group. At least 4 weeks after HiDAC/etoposide recovery, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3 prior to PBSCT. Patients receive autologous PBSC infusion on day 0. Patients also receive G-CSF SC beginning on day 0 and continuing until hematopoietic recovery.
9861874|NCT00006363|Experimental|Intensification Unfavorable Non-PBSCT Group|Patients receive etoposide, HiDAC, and G-CSF as in the PBSCT group. After hematopoietic recovery, patients then receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more course.
9861875|NCT00006363|Experimental|Immunotherapy Arm I|Patients begin therapy no later than 120 days after the first day of the last course of HiDAC treatment OR day 0 of PBSCT. Patients receive low-dose IL-2 SC on days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90. In addition, patients receive high-dose IL-2 SC on days 15-17, 29-31, 43-45, 57-59, and 71-73.
9861876|NCT00006363|Active Comparator|Immunotherapy Arm II|Patients are observed and receive no further therapy.
9861877|NCT00006364|Experimental|Treatment (omacetaxine mepesuccinate)|"Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.~Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity."
9861878|NCT00006365|Experimental|EBRT to the prostate followed by brachytherapy|Patients received 45 Gy of external beam radiation therapy (EBRT)to the prostate followed (within 2 to 6 weeks) by permanent iodine (I-125) brachytherapy 108 Gy.
9925650|NCT00873717|Experimental|Dentary + nutrition|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed) associated with control of the administration of dietary prescriptions, incitement to eat.
9925651|NCT00873717|No Intervention|Control|usual care
9925652|NCT00873743||1|60 women after elective cesarian section
9925653|NCT00873743||2|60 women after elective cesarian section
9925654|NCT00873756|Experimental|A|
9925655|NCT00873769|Experimental|Healthy smokers|Healthy smokers, male and female
9925656|NCT00873769|Experimental|Healthy nonsmokers|Healthy nonsmokers, Healthy smokers, male and female
9925657|NCT00873795|Experimental|aripiprazole and sertraline|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
9925658|NCT00873795|Placebo Comparator|sertraline and placebo|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
9925659|NCT00873834|Experimental|Fluoxetine arm|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
9925660|NCT00873834|Placebo Comparator|placebo arm|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
9925661|NCT00873886|Experimental|Oseltamivir (Tamiflu)|
9795598|NCT01540513|Experimental|I124-NM404 brain metastases or GBM imaging|injection of I-124NM404 for imaging
9861879|NCT00006371|Active Comparator|Hydrocortisone with Ketoconazole|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
9861880|NCT00006371|Active Comparator|Hydrocortisone with Aminoglutethimide|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
9861881|NCT00006373|Experimental|TIME|Topotecan, Ifosfamide, Mesna and Etoposide
9861882|NCT00006386|Experimental|External beam radiotherapy with stereotactic boost|External beam radiotherapy (EBXRT): 50 Gy in 25 daily fractions of 2 Gy. Stereotactic radiotherapy (SRT) boost: 4 treatments of 5 or 7 Gy, once per week during weeks 3-6. Patients will not receive EBXRT on the SRT treatment days.
9861883|NCT00006388|Experimental|Radiation plus Tamoxifen|
9861884|NCT00006398|Experimental|Timolol Maleate|Dose titrated from 5 mg per day to up to 80 mg per day depending on heart rate
9861885|NCT00006398|Placebo Comparator|Placebo|Timelol placebo
9861886|NCT00006401|Experimental|Inhaled Nitric Oxide (iNO)|Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
9861887|NCT00006401|Placebo Comparator|Placebo|
9861888|NCT00006420||Observational, no interventions|
9861889|NCT00006425||1|25 women undergoing ductal lavage
9861890|NCT00006441|Experimental|A|Patients beginning IL-2 treatment regimens after 4 weeks of study
9861891|NCT00006441|Active Comparator|B|Patients beginning IL-2 treatment after some delay based on specified criteria
9861892|NCT00006461|Other|Chemotherapy, surgery, radiation therapy|Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.
9861893|NCT00006462|Experimental|Relapsed acute lymphoblastic and acute Myelogenous leukemia|Gemcitabine hydrochloride will be given as 10 mg/m2/min x 360 minutes weekly for three weeks. After a one-week rest period it may be repeated in patients without progressive disease or limiting toxicity.
9861894|NCT00006463|Experimental|Therapy ECTEINASCIDIN 743 (1100 ug/m2 )|
9861895|NCT00006463|Experimental|ECTEINASCIDIN 743 (1300 ug/m2)|
9861896|NCT00006467|Experimental|gemcitabine + ISIS 2503|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
9861897|NCT00006469|Other|Single arm study|Concurrent Paclitaxel, Carboplatin, and External-Beam Radiation Followed by Surgical Resection in Locally Advanced Non-Small-Cell Lung Cancer
9861898|NCT00006471|Experimental|Fenretinide|
9861899|NCT00006472|Other|Single arm study|Taxol® (Paclitaxel), Carboplatin and 5-Fluorouracil with Simultaneous Radiotherapy Followed by Surgical Resection
9861900|NCT00006473|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
9925662|NCT00873886|Other|Esterase|
9925663|NCT00873899||Remote Arm|The patients in Remote arm will receive a Medtronic CareLink Monitor to perform remote interrogation and transmission of ICD data. The remote arm ICD will be programmed to transmit over the CareLink Network.
9925664|NCT00873899||Implantable defibrillator patients|Heart failure patients implanted with a wireless-transmission-enabled ICD.
9925665|NCT00873925|Experimental|Autologous UCB Plus Vit D Omega 3 FA|A single autologous (self) intravenous umbilical cord blood infusion followed by 1 year of daily Vitamin D and Omega 3 Fatty Acid supplementation give as liquid drops and gel capsules that can be swallowed or added to food
9935853|NCT03092492||Participants with small or medium-sized drusen|Participants with small or medium-sized reticular pseudodrusen (RPD)
9861901|NCT00006483|Experimental|aerosolized sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.~Patients are followed for disease progression and then every 3 months thereafter."
9861902|NCT00006486|Experimental|Arm I (carboxyaminoimidazole)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive oral CAI as above."
9861903|NCT00006486|Experimental|Arm II (carboxyamidotriazole, placebo)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive a placebo."
9861904|NCT00006487|Active Comparator|chemo/RT with tirapazamine|induction and consolidation: cisplatin, etoposide, tirapazamine, radiation therapy
9861905|NCT00006501||ECG recording|After the tests are completed, people who enroll in this study are followed by telephone, 1, 4, 8, 12 16, 20 and 24 months. During these follow-up telephone calls a research coordinator asks about the participant's health condition and about cardiovascular medications that are being taken.
9861906|NCT00006505|Experimental|Transplant|Islet cell transplantation
9861907|NCT00006517|Active Comparator|bright light box|30 min exposure shortly after wake-up
9861908|NCT00006517|Active Comparator|high-output negative ion generator|90 min exposure prior to wake-up
9861909|NCT00006517|Placebo Comparator|low-output negative ion generator|90 min exposure prior to wake-up
9861910|NCT00006517|Active Comparator|dawn simulator|naturalistic incremental light exposure 90 min prior to wake-up
9861911|NCT00006517|Experimental|dawn light pulse|rectangular pulse light exposure 13 min before wake-up, matched for total illuminance with dawn signal
9861912|NCT00006565|Experimental|1|HEPA Air Cleaners
9861913|NCT00006565|Placebo Comparator|2|Inactive (placebo) filtration unit
9861914|NCT00006695|Experimental|Arm I|Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)
9861915|NCT00006708|Active Comparator|ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
9861916|NCT00006708|Experimental|Rituximab-ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3
9861917|NCT00006734|Experimental|Regimen A|Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
9861918|NCT00006734|Experimental|Regimen B|Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.
9925666|NCT00873925|No Intervention|Control|Subjects randomized to be controls will continue to use intensive insulin therapy in order to compare c-peptide production at 1 year in those receiving combination therapy vs those who do not
9861919|NCT00006747|Experimental|chemotherapy + stem cell transplantation|"Patients receive carmustine, etoposide, cytarabine and melphalan on day -1. Patients undergo allogeneic peripheral blood stem cell (PBSC) transplantation on day 0. Patients also receive tacrolimus on day -2 and then orally twice daily until day 120 and methotrexate on days 1, 3, and 6 as graft-versus-host disease (GVHD) prophylaxis. Patients receive sargramostim daily beginning on day 7 and continuing until blood counts recover.~Patients with no active GVHD who have persistent disease on day 150 or progressive disease at any time after PBSC transplantation receive donor lymphocytes IV over 2 hours. Patients may receive additional donor lymphocytes at least 8 weeks later if disease persists.~Patients are followed at 6 and 12 months post-transplantation and then annually for 4 years."
9861920|NCT00006760|Experimental|Treatment (ifosfamide, vinorelbine, filgrastim)|Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5. Patients also receive filgrastim (G-CSF) subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover. Treatment repeats at least every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive a third course of therapy at the discretion of the investigator. Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. Patients with sufficient PBSCs collected may undergo PBSC transplantation on protocol COG-AHOD0121.
9861921|NCT00006773|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9861922|NCT00006890|Experimental|Prednisone plus Thalidomide|After Autologous Stem Cell Infusion
9861923|NCT00006929|Experimental|Treatment (suramin, paclitaxel, carboplatin)|Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9861924|NCT00006942|Experimental|Treatment (bryostatin 1, cisplatin)|Patients receive bryostatin 1 IV continuously over 72 hours immediately followed by cisplatin IV over 1 hour. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression.
9861925|NCT00006994|Active Comparator|L-glutamine in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
9861926|NCT00006994|Placebo Comparator|Placebo in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
9861927|NCT00007007|Experimental|Whole brain radiation therapy + neurocognitive assessments|Whole brain radiation therapy (WBRT) with neurocognitive assessments done pre and post WBRT.
9861928|NCT00007267|Experimental|1|Participants will receive individual cognitive behavioral therapy
9861929|NCT00007267|Experimental|2|Participants will receive self-help cognitive behavioral intervention facilitated by a psychologist
9861930|NCT00007267|Active Comparator|3|Participants will receive a disease/health education intervention
9861931|NCT00007358|Experimental|1|Depending on patient and physician decision, a steroid may be administered during pregnancy.
9861932|NCT00007501|Experimental|Arm 1|varicella-zoster vaccine
9861933|NCT00007501|Placebo Comparator|Arm 2|vaccine placebo
9925667|NCT00873938||1-supervised|
9925668|NCT00873938||2 -unsupervised|
9925669|NCT00873951|Experimental|Intact casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled intact casein
9925670|NCT00873951|Experimental|Hydrolyzed casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
9925671|NCT00873951|Experimental|AA|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
9925672|NCT00873977|Active Comparator|C-flex|
9925673|NCT00873977|Active Comparator|A-flex|
9925674|NCT00873977|No Intervention|Auto-CPAP|
9925675|NCT00873990|Active Comparator|1|application of total etch bonding agent ( 5th generation) for placement of resing based pit and fissure sealants.
9925676|NCT00873990|Experimental|2|Self etch bonding agent (7th generation) application for placement of resin based pit and fissure sealant
9925677|NCT00874003|Experimental|mirtazapine, tablet, 30 mg|n=29
9925678|NCT00874003|Placebo Comparator|sugar pill|n=30
9925679|NCT00874016|Active Comparator|Airtraq|Intubation with the use of the Airtraq
9925680|NCT00874016|Active Comparator|Direct Laryngoscopy|Intubation using direct laryngoscopy
9925681|NCT00874042|Experimental|ARQ 197 in combination with gemcitabine|
9925682|NCT00874068|Active Comparator|Standard vegetable oil formula|
9925683|NCT00874068|Active Comparator|InFat|
9925684|NCT00874068|No Intervention|Breast-fed|
9925685|NCT00874107|Experimental|1|Imprime PGG + bevacizumab + paclitaxel/carboplatin
9861934|NCT00007579||1|
9861935|NCT00007605|Active Comparator|1|Amiodarone or Sotalol
9861936|NCT00007605|Active Comparator|2|Sotalol
9861937|NCT00007618||1|
9861938|NCT00007631|Active Comparator|1|Topical Tretinoin
9861939|NCT00007631|Placebo Comparator|2|Placebo
9861940|NCT00007657|Experimental|1|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
9861941|NCT00007657|Active Comparator|2|Intensive medical therapy
9861942|NCT00007683|Active Comparator|1|Warfarin Titrated to an INR of 2.5-3.0
9861943|NCT00007683|Active Comparator|2|Aspirin 182 mg
9861944|NCT00007683|Active Comparator|3|Clopidogrel 75 mg
9861945|NCT00007696||1|
9861946|NCT00007709||1|
9861947|NCT00007722||1|
9861948|NCT00007761|Experimental|1|Bipolar Disorder Program
9861949|NCT00007761|Active Comparator|2|Usual (psychiatric) Care
9861950|NCT00007774|Experimental|1|Olanzapine
9861951|NCT00007774|Active Comparator|2|Haloperidol
9861952|NCT00007787|Experimental|Antibody plus delayed cyclosporine therapy|Anti-human thymocyte globulin (rabbit) (Thymoglobulin®) is admistred at the time of transplant followed delayed clyclosporine A therapy post tranplant.
9861953|NCT00007787|Active Comparator|Standard cyclosporine A therapy|Cyclosporine A therapy (either Cyclosporine or Tacrolimus) will be initiated pre-transplantations
9861954|NCT00007813|Experimental|Arm 1|
9861955|NCT00007852|Experimental|Arm I|Rituxan and BEAM with autologous stem cell transplant
9861956|NCT00007878|Experimental|Treatment (bortezomib, fluorouracil, leucovorin calcium)|Patients receive bortezomib IV on days 1 and 4 and fluorouracil IV and leucovorin calcium IV on day 1 weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
9861957|NCT00007904|Experimental|Arm A: Combination Chemotherapy|Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.
9861958|NCT00007917|Experimental|Arm I|"Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9861959|NCT00008177|Experimental|Treatment ( I 131 BC8, chemotherapy, TBI, PBSCT, CSP, MMF)|"CONDITIONING REGIMEN: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV BID on days -3 to 56 with taper to day 80 (for patients with a related donor) OR days -3 to 100 with taper to day 177 (for patients with an unrelated donor) in the absence of GVHD. Patients also receive mycophenolate mofetil PO or IV TID on days 0 to 27 (for patients with a related donor) OR on days 0 to 40 with taper to day 96 (for patients with an unrelated donor) in the absence of GVHD."
9861960|NCT00008216||alloSCT group|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).
9861961|NCT00008320|Experimental|ceramide cream|Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
9861962|NCT00008333|Experimental|vinorelbine|Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
9861963|NCT00008346|Other|SFM then FFDM|Screen Film Mammography (SFM) followed by Full Field Digital Mammography (FFDM)
9861964|NCT00008346|Other|FFDM then SFM|Full Field Digital Mammography (FFDM) followed by Screen Film Mammography (SFM)
9861965|NCT00008411|Experimental|Docetaxel Weekly|Arm I: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days.
9861966|NCT00008411|Experimental|Docetaxel Every 3 Weeks|Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
9861967|NCT00008450|Experimental|Treatment (cyclosporine, mycophenolate mofetil, transplant)|Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.
9861968|NCT00008502||18 years of age or older|without keloids
9861969|NCT00008502||family members over 12 years of age|who have either classic or non-classic keloids
9861970|NCT00008502||Probands|original participants who have had a classic (butterfly-shaped or wound-overflowing) keloidfor at least one year
9861971|NCT00008697|Experimental|Phase 1|"Cohort 1 Arsenic trioxide = 0.1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 2 Arsenic trioxide = 0.15 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 3 Arsenic trioxide = 0.20 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 4 Arsenic trioxide = 0.25 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 5 Arsenic trioxide = 0.30 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)"
9861972|NCT00008697|Experimental|Phase 2|Arsenic trioxide = MTD found in Phase 1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
9861973|NCT00009217|Active Comparator|Haloperidol-Haloperidol|Haloperidol for 20 weeks followed by haloperidol for 24 weeks
9861974|NCT00009217|Placebo Comparator|Haloperidol-Placebo|Haloperidol for 20 weeks followed by placebo for 24 weeks
9925686|NCT00874107|Other|2|bevacizumab + paclitaxel/carboplatin
9925687|NCT00874133|Active Comparator|Motillium|20 mg motilium thrice daily for 12 weeks.
9925688|NCT00874133|Active Comparator|Acupuncture|Acupuncture treatment.
9925689|NCT00874146||1|HER2-positive advanced breast cancer
9925690|NCT00874159||A|
9925691|NCT00874172|Active Comparator|2|Combination of acetaminophen, morphine
9925692|NCT00874172|Experimental|1|Combination of acetaminophen, nitrous oxide, nefopam, morphine
9925693|NCT00874185||Questionnaire|filling in questionnaires
9925694|NCT00874211||Observation|Patients will be observed and will undergo assessment of therapy complications.
9925695|NCT00874224|Active Comparator|1|patients undergoing open left lateral hepatic sectionectomy
9925696|NCT00874224|Active Comparator|2|patients undergoing a laparoscopic left lateral hepatic sectionectomy
9925697|NCT00874224|Active Comparator|3|Prospective registry of patients that cannot be randomized (both open and laparoscopic left lateral hepatic sectionectomy)
9925698|NCT00874289||Acute heart failure patients|
9925699|NCT00874289||Chronic heart failure patients|
9925700|NCT00874302|Experimental|25 mg|25 mg Proellex
9925701|NCT00874302|Experimental|50 mg|50 mg Proellex
9925702|NCT00874328|Experimental|study arm|Irinotecan /IV D1 Cisplatin 60mg/m2 iv D1 S-1 bid, P.o. D1 ~ 14 q 3 weeks until maximum 6 cycles
9925703|NCT00874341|No Intervention|1|
9925704|NCT00874341|Active Comparator|2|4 portions fruit and vegetables daily for 12 weeks
9925705|NCT00874341|Active Comparator|3|7 portions of fruit and vegetables daily for 12 weeks
9925706|NCT00874354|Experimental|Autologous bone marrow stem cells|Patients within 3 to 14 days from percutaneous coronary intervention (PCI) and stent implantation for Acute Myocardial Infarction (AMI) will receive either 50 cc's or 100 cc's of autologous bone marrow mononuclear cells through an intracoronary tranplantation of stem cells into the infarct-related coronary artery.
9925707|NCT00874380||1|First describe the diet of a cohort of dialysis patients with focus on fiber content.
9925708|NCT00874393|Active Comparator|Dopamine and hydrocortisone|Dopamine AND hydrocortisone
9925709|NCT00874393|Active Comparator|Dopamine and placebo|Dopamine AND normal saline placebo
9925710|NCT00874393|Active Comparator|Placebo and hydrocortisone|Dextrose (D5W) placebo AND hydrocortisone
9925711|NCT00874393|Placebo Comparator|Placebo and Placebo|Dextrose (D5W) placebo AND normal saline placebo
9935854|NCT03092492||Unaffected Age-matched controls|Healthy age-matched controls
9935855|NCT03077542|Experimental|recipient|recipient
9935856|NCT03076554|Experimental|Arm 1 Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
9861975|NCT00009620|Experimental|Phenobarbital|
9861976|NCT00009620|Placebo Comparator|Placebo|
9861977|NCT00009646|Experimental|Indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.
9861978|NCT00009646|Placebo Comparator|Placebo|Saline solution
9861979|NCT00009698|Experimental|All patients|Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.
9861980|NCT00009789|Experimental|Radiotherapy|"Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.~Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.~Patients are followed at 3 weeks, 6 weeks, 3 months, every 3 months for 2 years, and then every 6 months for 3 years."
9861981|NCT00009867|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
9861982|NCT00009893|Experimental|gemcitabine + leucovorin + fluorouracil|Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
9861983|NCT00009906|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate once daily.
9861984|NCT00009906|Experimental|Arm II (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily.
9861985|NCT00009919|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.
9861986|NCT00009958|Experimental|Stage I|Patients receive fCEA-TRI vaccine SC once daily on days 1, 29, 57, and 85.
9861987|NCT00009958|Experimental|Stage II|Patients receive vCEA-TRI vaccine intradermally once on day 1 and fCEA-TRI vaccine SC at the MTD determined in stage I once daily on days 29, 57, and 85.
9861988|NCT00009958|Experimental|Stage III|A single cohort of 6-10 patients receive both vaccines as in stage II, at the MTDs determined in stages I and II, and sargramostim (GM-CSF) SC once daily on days 1-4, 29-32, 57-60, and 85-88.
9861989|NCT00009971|Experimental|Arm I|Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
9861990|NCT00009984|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
9861991|NCT00009984|Experimental|Arm II (thalidomide, fludarabine phosphate)|Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
9861992|NCT00010114||Newly diagnosed embryonal tumors|The participants in this study are infants (< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
9861993|NCT00010192|Experimental|Treatment (rituximab and aldesleukin)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.
9925712|NCT00874406|Experimental|1|transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
9861994|NCT00010205|Experimental|Treatment (benzoylphenylurea)|Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
9861995|NCT00010218|Experimental|karenitecin|"Patients receive karenitecin IV over 60 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 6 courses may receive 2 additional courses beyond best response.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
9861996|NCT00010335|Experimental|1|Participants will receive a stem cell transplant.
9861997|NCT00010608|Experimental|Transcendental Meditation program|A mental technique for stress reduction which is natural, easy and effortless and is practiced sitting in a chair with eyes closed for 20 minutes twice a day.
9861998|NCT00010608|Active Comparator|Health Education|A lifestyle modification program for improving diet, exercise, salt intake and substance use.
9861999|NCT00011037|Experimental|1|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 and Months 3 and 6
9862000|NCT00011037|Experimental|2|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
9862001|NCT00011037|Placebo Comparator|3|Participants will receive ALVAC-HIV vCP1452 placebo at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
9925713|NCT00874406|Active Comparator|2|Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
9925714|NCT00874419|Experimental|erlotinib|Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
9925715|NCT00874419|Active Comparator|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
9925716|NCT00874445||ICD shocks programmed to Tuned Waveform|ICD shocks programmed to Tuned Waveform
9925717|NCT00874445||ICD shocks programmed to Fixed Tilt Waveform|ICD shocks programmed to Fixed Tilt Waveform
9925718|NCT00874458|Experimental|MRI|
9925719|NCT00874471||sarcoidosis|
9925720|NCT00874471||ankylosing spondylitis|
9925721|NCT00874471||Behcet's disease|
9925722|NCT00874471||toxoplasmosis|
9925723|NCT00874471||herpetic acute retinal necrosis|
9925724|NCT00874471||idiopathic uveitis|
9925725|NCT00874471||ankylosing spondylitis (no uveitis)|
9925726|NCT00874471||sarcoidosis (no uveitis)|
9925727|NCT00874471||Behcet's disease (no uveitis)|
9925728|NCT00874471||normal control|
9925729|NCT00874484|Experimental|1|
9925730|NCT00874484|Placebo Comparator|2|
9925731|NCT00874523|Active Comparator|Arm A|
9925732|NCT00874523|Active Comparator|Arm B|
9925733|NCT00874536|Experimental|ALA|This group will receive the ALA supplement
9925734|NCT00874536|Placebo Comparator|Placebo|This group will receive the placebo supplement
9925735|NCT00874562|Active Comparator|Steroid Only|Corticosteroid Alone
9925736|NCT00874562|Active Comparator|Steroid plus Rapamycin|Corticosteroid plus Rapamycin
9925737|NCT00874575|Placebo Comparator|1|Control
9925738|NCT00874575|Experimental|2|Beta-hydroxy-Beta-methylbutyrate, 3 g/d
9925739|NCT00874575|Experimental|3|Vitamin D, 2000 IU/d
9925740|NCT00874575|Experimental|4|Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
9925741|NCT00874588|Experimental|Phase I study|
9925742|NCT00874601|Experimental|valsartan group|The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
9935857|NCT03071757|Experimental|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
9862002|NCT00011180||Incident Cohort with VTE|Olmsted County, Minnesota residents with with a first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year period, 1996-2000.
9862003|NCT00011180||Controls without VTE|Two Olmsted County, Minnesota residents without venous thromboembolism (VTE) were matched by age and gender to each definite or probable case of VTE within the 1996-2000 cohort.
9862004|NCT00011193||Non-Exercise Control Group|We randomly assigned 102 women in the non-exercise control group and were asked to maintain their level of activity for the 6-month study period.
9862005|NCT00011193||4-kcal/kg Energy Expenditure per week|We randomly assigned 155 women to the 4-kcal/kg per week group for 6 months.
9862006|NCT00011193||8-kcal/kg Energy Expenditure per week|We randomly assigned 104 women to the 8-kcal/kg per week group for 6 months.
9862007|NCT00011193||12-kcal/kg Energy Expenditure per week|We randomly assigned 103 women to the 12-kcal/kg per week group for 6 months.
9862008|NCT00011349||Group 1|
9862009|NCT00011362|Active Comparator|Dexamethasone|Dexamethasone
9862010|NCT00011362|Placebo Comparator|Placebo|Saline
9862011|NCT00011414|Experimental|1|Intervention given with dose escalation of tariquidar
9862012|NCT00011492||1/All Patients|All eligible patients
9862013|NCT00011531|Other|1|
9862014|NCT00011570|Other|1|
9862015|NCT00011583|Experimental|1|1 hour/day of mechanically-assisted upper limb therapy
9862016|NCT00011583|Active Comparator|2|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
9862017|NCT00011713||Infertility patients|Patients undergoing infertility treatment at Massachusetts General Hospital Infertility Clinic.
9862018|NCT00011999|Experimental|Surgery, chemotherapy and radiation therapy|Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.
9862019|NCT00012025|Experimental|fulvestrant|"Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years."
9862020|NCT00012064|Experimental|Biological/Vaccine|"Biological/Vaccine: therapeutic autologous dendritic cells.~Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product."
9862021|NCT00012116|Experimental|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
9862022|NCT00012181|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9862023|NCT00012194|Experimental|Treatment (7-hydroxystaurosporine, cisplatin)|Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9862024|NCT00012220|Active Comparator|Gemcitabine|Standard treatment
9862025|NCT00012220|Experimental|Gemcitabine + cisplastin|Addition of cisplastin to gemcitabine
9862026|NCT00012220|Experimental|Gemcitabine + docetaxel|Addition of docetaxel to gemcitabine
9862027|NCT00012220|Experimental|Gemcitabine + Irinotecan|Addition of irinotecan to gemcitabine
9862028|NCT00012259|Experimental|troxacitabine|
9862029|NCT00012350|Experimental|Oral FTI (R115777) Treatment|"Patients will be administered oral FTI (R115777) at a dose of 300-mg by mouth (PO) twice a day (BID). Drug will be taken without regard to meals.~The study regimen will consist of 3 weeks of treatment followed by one week off for a total cycle duration of 4 weeks."
9862030|NCT00012363|Experimental|Gemcitabine + Irinotecan|Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days
9862031|NCT00012376|Experimental|Treatment (bryostatin 1 and sargramostim)|Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
9862032|NCT00012597|Other|Arm 1|
9862033|NCT00012610|Other|Arm 1|
9862034|NCT00012623||Group 1|
9862035|NCT00012636|Other|Arm 1|
9862036|NCT00012649||Group 1|
9862037|NCT00012662|Other|Arm 1|
9862038|NCT00012675||Group 1|
9862039|NCT00012688|Other|Arm 1|
9925743|NCT00874601|No Intervention|control group|Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
9925744|NCT00874627|Experimental|Experimental|Administration of Milk
9925745|NCT00874627|Placebo Comparator|Placebo|meals without milk
9925746|NCT00874640||Group 1|
9925747|NCT00874653||Group 1|
9925748|NCT00874666|Active Comparator|1|Positive control with 100% allicin bioavailability
9925749|NCT00874666|Experimental|2|garlic powder tablet
9925750|NCT00874679||Group 1|
9925751|NCT00874692|Experimental|BMS and sterilisation|BMS and sterilisation programme will be delivered
9925752|NCT00874692|No Intervention|BMS standard water heating|
9925753|NCT00874718|Active Comparator|Action group|
9862040|NCT00012701||Group 1|
9862041|NCT00012714|Other|Arm 1|
9862042|NCT00012727|Other|Arm 1|
9862043|NCT00012740|Other|Arm 1|
9862044|NCT00012753|Other|Arm 1|
9862045|NCT00012766|Other|Arm 1|
9862046|NCT00012779|Other|Arm 1|
9862047|NCT00012792|Other|Arm 1|
9862048|NCT00012805|Other|Arm 1|
9862049|NCT00012818|Other|Arm 1|
9862050|NCT00012831||Group 1|
9862051|NCT00012844|Other|Arm 1|
9862052|NCT00012857|Other|Arm 1|
9862053|NCT00012870|Other|Arm 1|
9862054|NCT00012883|Other|Arm 1|Homewalking Exercise Program
9862055|NCT00012896|Other|Arm 1|
9862056|NCT00012909|Other|Arm 1|
9862057|NCT00012922|Other|Arm 1|
9862058|NCT00012935|Other|Arm 1|
9862059|NCT00012948|Other|Arm 1|
9862060|NCT00012961||Group 1|
9862061|NCT00012974|Other|Arm 1|
9862062|NCT00012987|Other|Arm 1|
9862063|NCT00013000|Other|Arm 1|
9862064|NCT00013013|Other|Arm 1|
9862065|NCT00013026|Other|Arm 1|
9862066|NCT00013039|Other|Arm 1|
9862067|NCT00013052|Other|Arm 1|
9862068|NCT00013065||Group 1|
9862069|NCT00013078|Other|Arm 1|
9862070|NCT00013091|Other|Arm 1|
9862071|NCT00013104||Group 1|
9862072|NCT00013117|Other|Arm 1|
9862073|NCT00013130|Other|Arm 1|
9862074|NCT00013143|Other|Arm 1|
9862075|NCT00013156|Other|Arm 1|
9862076|NCT00013169|Other|Arm 1|
9862077|NCT00013182|Other|Arm 1|
9862078|NCT00013195|Other|Arm 1|
9862079|NCT00013208|Other|Arm 1|
9862080|NCT00013221|Other|Arm 1|
9862081|NCT00013234|Other|Arm 1|
9862082|NCT00013247|Other|Arm 1|
9862083|NCT00013260|Other|Arm 1|
9862084|NCT00013390|Active Comparator|1|Tinnitus Masking
9862085|NCT00013390|Other|2|Tinnitus Retraining Therapy
9862086|NCT00013481|Other|1|
9862087|NCT00013533|Experimental|1|Transplant with Induction Therapy
9925754|NCT00874718|Other|Control group|Non-specific educational program for general health.
9925755|NCT00874744|Experimental|bevacizumab|
9925756|NCT00874744|Experimental|Triamcinolone|
9925757|NCT00874809|Other|Insulin Treatment|There is only one arm for this study using lispro insulin administered by insulin pump.
9925758|NCT00874861|Experimental|Vaccine + Poly-ICLC|Peptide Vaccine + Poly-ICLC
9925759|NCT00874900|Experimental|Game|
9925760|NCT00874900|Experimental|Game + Activation|
9925761|NCT00874900|No Intervention|Booklet|
9925762|NCT00874900|Experimental|Booklet + Activation|
9925763|NCT00874913|Experimental|Laser Doppler Flowmetry|
9925764|NCT00874926||Group 1|
9925765|NCT00874965|Active Comparator|ES|Electrostimulation
9925766|NCT00874965|Placebo Comparator|Sham ES|Sham stimulation
9925767|NCT00874978|Experimental|lenalidomide|
9925768|NCT00875030|Experimental|1.0|
9925769|NCT00875030|Active Comparator|2.0|
9925770|NCT00875043||1. flat Jackson table|All measurements previously described will be done with the patient in the prone postion and Jackson table flat.
9925771|NCT00875043||2. Elevated Jackson tablet|All measurements previously described will be performed with subjects placed prone on the elevated Jackson table.
9925772|NCT00875069|Experimental|ethanol|
9925773|NCT00875069|Placebo Comparator|placebo|
9925774|NCT00875082|Active Comparator|Montelukast|Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
9925775|NCT00875082|Placebo Comparator|placebo|placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed
9925776|NCT00875095||IUI patients|Patients undergoing routine semen analysis as part of their infertility treatment pertaining to success or failure with intrauterine insemination, based upon their sperm DNA integrity
9925777|NCT00875095||IVF patients|Couples undergoing routine screening prior to IVF retrievals to assess their reproductive treatment outcomes as compared to the sperm DNA integrity
9862088|NCT00014079||Group 1|"DNA is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). Immunohistochemistry is used to test for the presence or absence of the genes involved in DNA mismatch repair (hMLH1 and hMSH2).~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
9862089|NCT00014131|Experimental|Biological/Vaccine|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
9862090|NCT00014144|Experimental|ZD 1839|
9862091|NCT00014170|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9862092|NCT00014196|Experimental|chemo/RT followed by consolidation chemo|cisplatin docetaxel radiation therapy
9862093|NCT00014235|Experimental|Arm I (indolent disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27."
9862094|NCT00014235|Experimental|Arm II (aggressive disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I."
9862095|NCT00014378|Experimental|Chinese Herb Huanglian (Coptis chinesis)|
9862096|NCT00014534|Active Comparator|Gemcitabine + cisplatin|
9862097|NCT00014534|Active Comparator|Gemcitabine + Doxorubicin + Pegfilgrastim|
9862098|NCT00014612|Active Comparator|axillary lymph node dissection|complete axillary lymph node dissection
9862099|NCT00014612|Experimental|axillary radiotherapy|axillary radiotherapy, daily for 5 days a week, for 5 weeks
9862100|NCT00014820||Patients with a diagnosis of asthma (new) (Cases)|Patients with a physician diagnosis of asthma during the 7.5 years being studied who were working at the time of diagnosis, as determined by patient interviews.
9862101|NCT00014820||Patients with a diagnosis other than asthma (Controls)|Patients (age-matched to a case patient) with a physician diagnosis other than asthma who were working at the time of diagnosis.
9862102|NCT00014820||Patients with a diagnosis of asthma (previous)|Patients with a physician diagnosis of asthma prior to the 7.5 years being studied
9862103|NCT00014859||Population-based cohort|Descriptive cohort of population-based DNA samples from the newborn screening program in Missouri with vital statistics based, linked phenotype data
9862104|NCT00014859||Trio sequencing cohort|Affected infant/child (term or near term infant with progressive respiratory distress or other rare pulmonary phenotype or older child with interstitial lung disease or other rare pulmonary phenotype) and parents
9862105|NCT00015210|Active Comparator|Nefazodone|Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
9862106|NCT00015210|Placebo Comparator|Matched Placebo Tablet|Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks.
9862107|NCT00015340|Experimental|Buprenorphine/Naloxone|
9925778|NCT00875134|Experimental|Verbal prompt, cutaneous stimulation|Patient receives either or both a verbal stimulus or cutaneous stimulus
9925779|NCT00875147||with bevacizumab|Neoadjuvant chemotherapy with bevacizumab
9925780|NCT00875147||without Bevacizumab|Neoadjuvant chemotherapy without Bevacizumab
9925781|NCT00875173|Experimental|Selenium|Sodium selenite 100 micrograms in capsugel by mouth diary for 365 consecutive days
9925782|NCT00875173|Active Comparator|Placebo|Capsugel for placebo (selenium 100 micrograms capsugel) by mouth diary for 365 consecutive days
9925783|NCT00875186||multiple-exercise group (ME)|participants exercised 2 times weekly for 1 hour (aerobic endurance training)
9925784|NCT00875186||Low-exercise group (LE)|participants exercises 1 time weekly for 1 hour (aerobic endurance training)
9925785|NCT00875199|Active Comparator|A|Participants assigned to Group A will receive the DPP manual (Wing & Gillis, 1996), a behavioral weight-loss program with demonstrated efficacy in facilitating weight loss. Participants in Group A will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
9925786|NCT00875199|Experimental|B|Participants assigned to Group B will receive the DPP manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
9925787|NCT00875225|Active Comparator|Control DVD|Control DVD with usual care information
9925788|NCT00875225|Active Comparator|Intervention DVD|Intervention group will receive DVD with patient stories and information from health care professionals
9925789|NCT00875251||term infants body composition|Term infants from 2 days of life to 7 days of life without IUGR
9925790|NCT00875251||preterm infants body composition|very low birth weight infants before discharge
9862108|NCT00015821|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
9862109|NCT00015834|Experimental|Treatment (imatinib mesylate, cytarabine)|Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.
9862110|NCT00015873|No Intervention|A no VIMARAM|No VIMARAM preceding maintenance treatment
9862111|NCT00015873|Experimental|B - VIMARAM|VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days
9862112|NCT00015912|Experimental|Treatment (interferon-alpha, thalidomide)|Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.
9862113|NCT00015938|Experimental|treatment|docetaxel and vinorelbine with filgrastim support
9862114|NCT00015964|Experimental|Daily administration of ZD1839|
9862115|NCT00015977|Experimental|PSMA peptide vaccine|Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
9862116|NCT00015990|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.
9862117|NCT00016016|Experimental|Treatment (flavopiridol, cytarabine, mitoxantrone)|Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
9862118|NCT00016094|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.
9862119|NCT00016107|Experimental|Treatment (chemotherapy, bevacizumab)|Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour followed by bevacizumab IV over 30-90 minutes on day 2. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9862120|NCT00016146|Experimental|vaccine|"This is a dose-escalation study of GPI-0100.~Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.~Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.~Patients are followed every 3 months."
9925791|NCT00875264|Experimental|1|At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
9925792|NCT00875290|No Intervention|Control|Observational arm
9925793|NCT00875290|Experimental|Real-time glucose sensor|Subjects wear real-time glucose sensor
9925794|NCT00875303|Placebo Comparator|Control|Routine primary care.
9925795|NCT00875303|Experimental|Multimedia intervention|
9925796|NCT00875316|Experimental|Cohort A|
9925797|NCT00875316|Experimental|Cohort B|
9925798|NCT00875316|Experimental|Cohort C|
9795599|NCT01540565|Experimental|Treatment (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9795600|NCT01540773|Active Comparator|amino acid supplement|supplements with the proprietary amino acid derivative blend.
9986477|NCT01403298|Active Comparator|Adolescent Only Health Promotion|An individual adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
9986478|NCT01403298|Experimental|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
9795601|NCT01540773|Placebo Comparator|Placebo|Non-Active
9795602|NCT01540825|Experimental|BI 113608 high dose 1|Powder for oral solution
9795603|NCT01540825|Experimental|BI 113608 low dose 1|Powder for oral solution
9795604|NCT01540825|Experimental|BI 113608 low dose 2|Powder for oral solution
9795605|NCT01540825|Experimental|BI 113608 low dose 4|Powder for oral solution
9795606|NCT01540825|Experimental|BI 113608 low dose 5|Powder for oral solution
9795607|NCT01540825|Experimental|BI 113608 medium dose 1|Powder for oral solution
9795608|NCT01540825|Experimental|BI 113608 medium dose 2|Powder for oral solution
9795609|NCT01540825|Experimental|BI 113608 medium dose 3|Powder for oral solution
9795610|NCT01540825|Experimental|BI 113608 high dose 2|Powder for oral solution
9795611|NCT01540825|Experimental|BI 113608 high dose 3|Powder for oral solution
9795612|NCT01540825|Placebo Comparator|Placebo|Powder for oral solution
9795613|NCT01540838|Experimental|Infusion with paracetamol|Cefotaxime is administered as 12 hourly infusions, together with high dose paracetamol (acetaminophen)
9795614|NCT01540838|Active Comparator|Bolus with placebo|Cefotaxime is administered as bolus q.i.d. with a placebo of paracetamol
9795615|NCT01540851|Active Comparator|Care Navigator Intervention Group|Subjects randomized to the Care Navigator Intervention group will receive up to 10 telephone calls from a care navigator for 5 months post-operatively
9795616|NCT01540851|Active Comparator|Usual Care Group|Subjects in the Usual Care group receive the current standard post-operative TKA care
9795617|NCT01540981|Active Comparator|SOC - Standard of Care|Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
9795618|NCT01540981|Active Comparator|MIST Therapy with SOC|Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
9795619|NCT01541215|Experimental|Lira + Met|
9795620|NCT01541215|Placebo Comparator|Placebo + Met|
9795621|NCT01541254|Other|Single Arm|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
9795622|NCT01541358|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET/CT)|Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
9795623|NCT01541371|Experimental|Paliperidone ER|
9795624|NCT01541384|Experimental|Medication Dosage Reminders|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email).
9795625|NCT01541384|Experimental|Medicaiton Dosage Reminders + Coordinator Support|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
9795626|NCT01541384|Other|Usual Care with GlowCap|Subject will receive electronic pill bottle that will track adherence but all reminders will be deactivated.
9795627|NCT01541553|Active Comparator|PEP005 Gel, 0.015%|Cryotherapy followed by PEP005 Gel, 0.015%
9795628|NCT01541553|Placebo Comparator|Vehicle gel|Cryotherapy followed by vehicle gel
9795629|NCT01541644|Experimental|Acupuncture|All participants will receive acupuncture treatments over a total of 10 weeks.
9795630|NCT01541735|Placebo Comparator|Placebo|Placebo of calcined magnesia, capsules
9795631|NCT01541735|Experimental|Pantoprazole|The pantoprazole will be administered in 40mg capsules
9795632|NCT01541748||AXIS Allograft Dermis|Participants receiving AXIS Allograft Dermis for anterior, posterior or combined (anterior and posterior) female pelvic floor repair.
9795633|NCT01541826|Placebo Comparator|Color-matched rice powder pill|Color-matched rice powder pill
9795634|NCT01541826|Active Comparator|Chokeberry extract capsule|Chokeberry extract capsule
9795635|NCT01541826|Experimental|Chokeberry extract capsule (acute)|Chokeberry extract capsule pharmacokinetics
9795636|NCT01541865|Other|Renal Denvervation|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.
9795637|NCT01541891|Experimental|PRO-148 Ophthalmic Solution|Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
9795638|NCT01541891|Active Comparator|Arm B. SYSTANE® Ophthalmic Solution|Drug: SYSTANE® Intervention name: SYSTANE® applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
9795639|NCT01541917|Experimental|Web-based coping skills training|Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
9795640|NCT01541917|Active Comparator|Online disease education|Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.
9795641|NCT01541930|Experimental|GK567|GK567: Metronidazole Gel 0.75% Once or twice daily, for 14 days, up to 30g
9862121|NCT00016276|Experimental|Arm I (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes, and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery, modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5 weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks. Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning on week 36 (day 254).
9862122|NCT00016276|Experimental|Arm II (chemoprotection, radiotherapy, surgery, trastuzumab)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
9862123|NCT00016276|Experimental|Arm III (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of radiotherapy.
9862124|NCT00016276|Experimental|Arm IV (chemoprotection, paclitaxel, surgery, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
9862125|NCT00016276|Experimental|Arm V (combination chemo, radiotherapy, long term trastuzumab)|Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
9862126|NCT00016276|Experimental|Arm VI (combination chemo, paclitaxel, surgery, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
9862127|NCT00016276|Experimental|Arm VII (combination chemo, monoclonal antibody, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
9925799|NCT00875316|Experimental|Cohort D (Optional)|
9925800|NCT00875355|Experimental|Arm I|Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
9925801|NCT00875355|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
9925802|NCT00875368|Active Comparator|Maraviroc|
9925803|NCT00875368|Placebo Comparator|Placebo|Placebo drug
9986479|NCT01403311|Experimental|ALA|5-Aminolevuline Acid (ALA)
9986480|NCT01403324|Other|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
9862128|NCT00016276|Experimental|Arm VIII (combination chemotherapy, paclitaxel, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
9862129|NCT00016289|Experimental|Treatment (recombinant interleukin-12)|Patients receive interleukin-12 intraperitoneally once weekly. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease receive 2 additional courses.
9862130|NCT00016302|Experimental|Regimen A|See detailed description.
9862131|NCT00016302|Experimental|Regimen B|"Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.~Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses."
9862132|NCT00016302|Experimental|Regimen C|"Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.~If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.~Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.~Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B."
9862133|NCT00016302|Experimental|Regimen D|See detailed description.
9862134|NCT00016302|Experimental|Regimen E|Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
9862135|NCT00016302|Experimental|Regimen F|Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
9862136|NCT00016315|Experimental|Arm 1|Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
9862137|NCT00016315|Experimental|Arm 2|Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
9862138|NCT00016315|Experimental|Arm 3|Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
9862139|NCT00016315|Experimental|Arm 4|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
9862140|NCT00016315|Experimental|Arm 6|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
9862141|NCT00016315|Experimental|Arm 8|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
9862142|NCT00016315|Experimental|Arm 10|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
9862143|NCT00016315|Experimental|Arm 12|Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
9862144|NCT00016315|Experimental|Arm 14|Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
9862145|NCT00016315|Experimental|Arm 5|Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
9862146|NCT00016315|Experimental|Arm 7|Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
9862147|NCT00016315|Experimental|Arm 9|Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
9862148|NCT00016315|Experimental|Arm 11|Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT
9862149|NCT00016328|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9862150|NCT00016367|Experimental|Regimen A|Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.
9862151|NCT00016367|Experimental|Regimen B|Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.
9862152|NCT00016406|Active Comparator|AC followed by P|doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery
9862153|NCT00016406|Experimental|AC+G followed by P|weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery
9862154|NCT00016432|Experimental|Group 1|Exemestane
9862155|NCT00016432|Placebo Comparator|Group 2|Placebo
9862156|NCT00016523|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
9862157|NCT00016523|Active Comparator|Placebo|Inhaled Oxygen
9862158|NCT00016744|Active Comparator|1|"Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days~Every participant will receive Genistein during the NPD."
9862159|NCT00016744|Placebo Comparator|2|
9862160|NCT00016835|Active Comparator|Supra-gingival scaling and placebo|"This group receives a placebo (instead of systemic antibiotic), supra-gingival oral prophylaxis, and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, this group will receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
9925804|NCT00875446|Experimental|Subjects receiving GSK1223249|"Eligible subjects will receive sequential dose of intravenous infusion of GSK1223249 with a starting dose of 0.01 milligram per kilogram followed by 0.1, 0.5,~1, 2.5, 5, 7.5, and 15 milligrams per kilograms."
9862161|NCT00016835|Experimental|Subgingival scaling and metronidazole|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and metronidazole as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
9862162|NCT00016835|Experimental|Subgingival scaling and doxycycline|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and doxycycline as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
9862163|NCT00016952|Experimental|irinotecan|"Prior oxaliplatin-based chemotherapy: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
9862164|NCT00016952|Experimental|leucovorin + fluorouracil|"Prior to irinotecan and oxaliplatin combination chemotherapy: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2. Treatment repeats every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
9862165|NCT00016978|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium and fluorouracil IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a confirmed complete response for 2 consecutive courses may discontinue study treatment at the investigators discretion. Quality of life is assessed at baseline, approximately every 6-8 weeks during treatment, and then after the last course of treatment.
9862166|NCT00017004|Experimental|Arm I|Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
9862167|NCT00017004|Experimental|Arm II|Patients undergo radiotherapy and chemotherapy as in arm I. Additionally, patients receive epoetin alfa subcutaneously once weekly concurrently with radiotherapy and chemotherapy.
9862168|NCT00017095|Active Comparator|non taxane based chemotherapy|either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
9862169|NCT00017095|Experimental|taxane based chemotherapy|Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles
9862170|NCT00017121|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).~After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years."
9862171|NCT00017147|Experimental|O6-BG + BCNU + Radiation Therapy|O6-BG: 120 mg/m^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
9862172|NCT00017147|Active Comparator|BCNU + Radiation Therapy|BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
9862173|NCT00017173|Experimental|surgery with INGN 201 followed by chemo/RT|intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy
9862174|NCT00017186|Experimental|gemcitabine + epirubicin|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and epirubicin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.~Quality of life is assessed at baseline, prior to course 3, at 3 months, and then at 1 year.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
9862175|NCT00017238|Experimental|Treatment (KRN5500)|"Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose."
9862176|NCT00017251|Experimental|Treatment (oblimersen sodium, carboplatin, etoposide)|Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
9925805|NCT00875446|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive intravenous infusion of placebo.
9925806|NCT00875498|Active Comparator|active iTBS|iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
9925807|NCT00875498|Placebo Comparator|sham iTBS|iTBS placebo (placebo coil)with same parameters than active
9925808|NCT00875537|Active Comparator|Capsaicin oral gel 0.01%|
9925809|NCT00875537|Active Comparator|Capsaicin oral gel 0.025%|
9925810|NCT00875602|No Intervention|control|before-after (retrospective) and concurrent controls as comparators with a prospective intervention group
9862177|NCT00017316|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
10210150|NCT02176863|Experimental|Stage 1 Arm 2: 1 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 1 g/kg of body weight administered via intravenous infusion on Day 1 and 20 mL/kg of body weight of normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will also be administered on a separate day, for a total dosing period of 2 consecutive days. every 4 weeks for 52 weeks. The order of 1 g/kg of body weight of Flebogamma® 5% DIF or 20 mL/kg of body weight normal saline solution infused on 2 consecutive days will be randomly determined for each participant by the Interactive Web Response System (IWRS), which will remain the same for the participant for all infusion visits during the treatment period.
9862178|NCT00017368|Experimental|All Patients|
9862179|NCT00017381|Experimental|Treatment|"PART I: Patients receive rituximab IV on days 1, 8, 15, and 22 and cyclophosphamide IV over 1 hour on day 25. G-CSF is administered SC daily beginning on day 26 and continuing until autologous PBSC are harvested.~PART II: Beginning 4-6 weeks after completion of the fourth rituximab infusion, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 followed by dosimetry imaging on days 1, 2, 4, and 7. Patients then receive IDEC-Y2B8 IV over 10 minutes once between days 8-15.~PART III: All patients undergo PBSCT beginning after residual bone marrow radioactivity resolves. G-CSF is administered SC beginning 1 day after PBSCT and continuing until blood counts recover."
9862180|NCT00017394|Experimental|Treatment (bevacizumab, vinorelbine tartrate)|Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.
9862181|NCT00017472|Experimental|Arm I|Patients receive apolizumab IV over at least 2 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a complete or partial response who relapse after 2 months may receive an additional course of therapy provided they still express the 1D10 antigen.
9862182|NCT00017537|Experimental|Dose #1|dose #1 administered
9862183|NCT00017537|Experimental|Dose #2|dose #2 administered
9862184|NCT00017537|Experimental|Dose #3|Dose #3 administered
10210151|NCT02176863|Placebo Comparator|Stage 1 Arm 3: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight Normal Saline Solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight. Normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
9862185|NCT00017537|Experimental|Dose #4|Dose #4 administered
9862186|NCT00017537|Experimental|Dose #5|Administered dose #5
9862187|NCT00017693|Experimental|0.75mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
9862188|NCT00017693|Experimental|1.5mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
10210152|NCT02176863|Experimental|Stage 2 Arm 1: Flebogamma 5% DIF|The dose of Flebogamma® 5% DIF selected from Stage 1 will be administered over 2 consecutive days every 4 weeks for 52 weeks.
10210153|NCT02176863|Placebo Comparator|Stage 2 Arm 1: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
10210154|NCT02162615||Restorelle Direct Fix A|Anterior/Apical prolapse repair with Restorelle Direct Fix A
9862189|NCT00017693|Experimental|3.0mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
9862190|NCT00017693|Placebo Comparator|Placebo for rsIL-4R|The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.
9862191|NCT00017810|Experimental|Condition 1: Dietary Intervention|Patients will receive behavioral dietary intervention using normal foods.
9862192|NCT00017810|Active Comparator|Condition 2 (Control): HIV Self-Care|Patients will receive HIV self-care information, and be given the dietary intervention at the completion of the last study session (post study).
9862193|NCT00018096|Experimental|bronchoscopy|2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
9862194|NCT00018148|Experimental|1|Transdermal nicotine plus nortriptyline
9862195|NCT00018148|Active Comparator|2|Transdermal nicotine plus placebo
9862196|NCT00018174|Experimental|1|
9862197|NCT00018174|Placebo Comparator|2|
9862198|NCT00018200|Experimental|Arm 1|Desipramine, low, middle or high exposure
9862199|NCT00018200|Experimental|Arm 2|Fluoxetine, low, middle, or high exposure
10210155|NCT02162615||Native Tissue Repair Anterior|Anterior/Apical prolapse repair with native tissue only
9862200|NCT00018200|Placebo Comparator|Arm 3|Benztropine .125-.5mg daily
9862201|NCT00018356|Other|1|
9862202|NCT00018434||Group 1|
9862203|NCT00018616|Other|1|
9862204|NCT00018655|Experimental|Arm 1|Twelve Step Facilitation
9862205|NCT00018655|Experimental|Arm 2|Integrated Cognitive Behavioral Treatment
9862206|NCT00018694|Other|Arm 1|
9925811|NCT00875602|Active Comparator|Study unit|Hospitalized patients in the study group will be continously monitored / supervised by the contact-free device
9925812|NCT00875628|Other|Cohort 1|PF-00868554 100 mg or placebo
9925813|NCT00875628|Other|Cohort 2|PF-00868554 300 mg or placebo
9925814|NCT00875628|Other|Cohort 3|PF-00868554 600 mg or placebo
9925815|NCT00875654|No Intervention|1|Control group without intervention nor placebo
9925816|NCT00875654|Experimental|2|First dose of stem cells
9925817|NCT00875654|Experimental|3|Second dose of stem cells
9925818|NCT00875680|Experimental|autoPPC|
9925819|NCT00875693|Experimental|Arm A dose of CPX - 351|Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
9925820|NCT00875693|Experimental|Arm B dose of CPX-351|Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
9925821|NCT00875719|Active Comparator|continuous v intermittent Oxygen therapy|intermittent oxygen compared to constant flow oxygen as regards walking distance
9925822|NCT00875732|Experimental|1|Biventricular Pacing
9925823|NCT00875732|Active Comparator|2|Right Ventricular Pacing
9925824|NCT00875745|Experimental|Sorafenib-Vorinostat|This is a single-arm, non-randomized feasibility and safety Phase I trial of a combination of Sorafenib and Vorinostat, both administered orally.
9925825|NCT00875758|Active Comparator|Standard threshold|
9925826|NCT00875758|Experimental|Low-threshold|
9925827|NCT00875771|Experimental|1|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks"
9925828|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (4mg)|TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®
9925829|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (6mg)|TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®
9925830|NCT00875784|Active Comparator|IMITREX tablet (100mg)|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
9925831|NCT00875823||PH Patients|"Patients with:~Primary Hyperoxaluria Type I Primary Hyperoxaluria Type II Primary Hyperoxaluria NonI-NonII"
9925832|NCT00875849|Experimental|Cetuximab|
9925833|NCT00875862|Active Comparator|1. 0.2% Ropivicaine perinueral infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
9925834|NCT00875862|Placebo Comparator|2. Normal Saline perineural infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
9925835|NCT00875875|Active Comparator|1|This is the approved treatment regimen for travelers' diarrhea (600 mg)
9925836|NCT00875875|Active Comparator|2|This is the same dose as the standard dose, given once daily (200 mg)
10210156|NCT02162615||Restorelle Direct Fix P|Posterior/Apical prolapse repair with Restorelle Direct Fix P
9925837|NCT00875888|Experimental|HCO|High cut-off filters HCO1100
9925838|NCT00875888|Active Comparator|control|conventional high-flux filters
9925839|NCT00875914|Experimental|Manually guided|Treatment with manually guided RF-catheter
9925840|NCT00875914|Experimental|Magnetically navigated|Treatment with magnetically navigated RF-catheter.
9925841|NCT00875927|Active Comparator|1 - control|candy not including scraping microcapsules
9925842|NCT00875927|Active Comparator|2 - Scraping|candy including scraping TCP microcapsules
9925843|NCT00875927|Active Comparator|3 - Scraping plus Propolis|candy including scraping Propolis microcapsules
9925844|NCT00875927|Active Comparator|4 - Scraping plus Zinc|candy including scraping Zinc microcapsules
9925845|NCT00875927|Active Comparator|5 - Scraping plus Propolis and Zinc|candy including scraping Propolis and Zinc microcapsules
9925846|NCT00875940||Group 1|Patients having both Tc-99m perfusion scan and echocardiogram.
9925847|NCT00875953|Active Comparator|Standard dissection|standard neck dissection technique: scalpel and cautery.
9925848|NCT00875953|Experimental|Harmonic Scalpel|Harmonic scalpel used in neck dissection.
9925849|NCT00875966|Experimental|1|Azithromycin for oral suspension 200mg/5mL
9925850|NCT00875966|Active Comparator|2|Zithromax (azithromycin for oral suspension) 200mg/5mL
9925851|NCT00875992|Experimental|ETN with ASLS|Angle stable locking of the Expert Tibial Nail using ASLS
9925852|NCT00875992|Active Comparator|ETN with conventional locking|Conventional locking of the Expert Tibial Nail using conventional locking bolts
9925853|NCT00876005|Active Comparator|1|80% oxygen during cesarean section
9925854|NCT00876005|Active Comparator|2|30% oxygen during cesarean section
9925855|NCT00876044|Experimental|1|4 mg/kg every 2 weeks
9925856|NCT00876044|Placebo Comparator|2|matching placebo
9925857|NCT00876057|Active Comparator|TH|Total hysterectomy
9925858|NCT00876057|Active Comparator|SH|Subtotal hysterectomy
9925859|NCT00876083||Group 1|
9862207|NCT00018798||Bi-weekly telephone calls|34 participants received bi-weekly telephone calls in addition to the annual reviews
9862208|NCT00018798||Annual review only|23 participants received annual reviews only
9862209|NCT00018824|Experimental|1|Naltrexone
9862210|NCT00018824|Placebo Comparator|2|Placebo
9862211|NCT00018902|Experimental|1|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI.
9862212|NCT00018902|Experimental|2|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant.
9862213|NCT00018902|Experimental|3|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI and receive cognitive behavioral therapy (CBT).
9862214|NCT00018902|Experimental|4|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant and receive CBT.
9862215|NCT00019708|Experimental|Treatment (tanespimycin)|Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
9862216|NCT00020566|Experimental|Group 1|Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
9862217|NCT00020566|Experimental|Group 2, arm I|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
9862218|NCT00020566|Experimental|Group 2, arm II|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
9925860|NCT00876096|Other|1|precocious diagnosis and taken care therapeutics of the systematic athlete's feet
9925861|NCT00876109|Experimental|Group A: GDC-0941 QD Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally QD at a starting dose of 15 milligrams (mg).
9925862|NCT00876109|Experimental|Group B: GDC-0941 BID Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally BID at a starting dose determined from Group A assessments.
9925863|NCT00876109|Experimental|Group C: GDC-0941 QD or BID Expansion|Participants will receive GDC-0941 for up to 1 year, administered orally QD or BID. The dose/regimen will be determined on the basis of data from Groups A and B.
9925864|NCT00876122|Experimental|1|
9925865|NCT00876135|Placebo Comparator|Inhaled Bronchodilator|
9925866|NCT00876161|Experimental|DAS181|
9925867|NCT00876161|Placebo Comparator|Lactose|
9925868|NCT00876174||Patients|20 patients with genotype 1, chronic hepatitis C who are to undergo standard antiviral therapy
9925869|NCT00876174||control|Group 2, (control): 10 healthy family members or significant others of patients who are to undergo standard antiviral therapy
9925870|NCT00876252|Active Comparator|IC43 100 mcg|IC43 100 mcg with Aluminum hydroxide
9925871|NCT00876252|Active Comparator|IC43 200 mcg|IC43 200 mcg with Aluminum hydroxide
9925872|NCT00876252|Active Comparator|IC43 100 mcg w/o|IC43 100 mcg without Aluminum hydroxide
9925873|NCT00876252|Placebo Comparator|Placebo|phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant
9925874|NCT00876278|Other|*AT.Smart 46LC|The *AT.Smart 46LC is indicated for primary implantation for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
9862219|NCT00020670|Experimental|CD40 Cell Vaccination|Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination. Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine. Patients receive either 1 x 10^7 or 1 x 10^8 CD40 cells/vaccination depending on the number of tumor cells obtained. Vaccinations are administered every two weeks as outpatient therapy. Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6. Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
9862220|NCT00020683|Experimental|Arm I (low dose incyclinide)|"Patients receive low-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
9862221|NCT00020683|Experimental|Arm II (high dose incyclinide)|"Patients receive high-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
9862222|NCT00020709|Experimental|Arm I (gefitinib, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral gefitinib daily."
9862223|NCT00020709|Experimental|Arm II (placebo, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral placebo daily. In both arms, maintenance therapy continues for a maximum of 5 years in the absence of disease progression or unacceptable toxicity."
9862224|NCT00020735|Experimental|oral toremifene|
9862225|NCT00020735|Other|observation|
9862226|NCT00020761|Experimental|Gastro Esophogeal cohort|"Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
9862227|NCT00020761|Experimental|Distal Stomach cohort|"Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
9862228|NCT00020787|Experimental|Treatment|See intervention description.
9862229|NCT00020826||gastric adenocarcinoma|No protocol specific interventions. Both palliative or curative treatment allowed.
9862230|NCT00020878|Experimental|Study|See intervention description.
9862231|NCT00020943|Experimental|Chemo/immuno/autolog transplant|Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma
9862232|NCT00021060|Experimental|Arm I (paclitaxel and carboplatin)|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
10210157|NCT02162615||Native Tissue Repair Posterior|Posterior/Apical prolapse repair with native tissue only
10210158|NCT02161211|Experimental|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
10210159|NCT02161211|Experimental|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
10210160|NCT02161211|Experimental|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
10210161|NCT02133521|Placebo Comparator|Placebo|Placebo 3 x 1 tablet, given everyday for 28 days of study period
10210162|NCT02133521|Experimental|DLBS1033|DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
10210163|NCT02081768|Experimental|90yttrium colloid|90 Yttrium colloid will be inserted into the cystic cavity. Based on clinical expertise, the treating neurosurgeon will determine the appropriate surgical procedure for each patient on an individual basis which will be reflected in the surgical consent the patient is presented and signs.
10210164|NCT02073968|Experimental|Treatment (PET-adjusted IMRT, carboplatin, paclitaxel)|"RADIOTHERAPY: Patients undergo PET-adjusted IMRT or proton beam radiation therapy five days a week for 5 weeks.~CONCURRENT CHEMOTHERAPY: Patients receive carboplatin IV over 3 hours and paclitaxel IV over 1 hour once weekly for 6 weeks beginning week 1 of thoracic radiotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning approximately 4-6 weeks after the completion of all radiation therapy and when esophagitis and chemotherapy-induced neuropathy are grade 1 or less, ANC > 1500, and platelet count > 100,000, patients may receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment may repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity at the discretion of the treating physicians."
10210165|NCT02062827|Experimental|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
10210166|NCT02035566|Experimental|Telehome Care Monitoring + Usual Care|
10210167|NCT02035566|No Intervention|Usual Care|
10210168|NCT02032524|Experimental|Avalglucosidase alfa|administered intravenously every 2 weeks
9862233|NCT00021060|Experimental|Arm II (paclitaxel, carboplatin, and bevacizumab)|"Patients receive paclitaxel and carboplatin as in arm I followed by bevacizumab IV over 30-90 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~After completion of 6 courses, patients in arm II with stable or responding disease continue to receive bevacizumab only. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
9862234|NCT00021073|Experimental|Treatment (alvocidib, combination chemotherapy)|"Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.~Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I."
9862235|NCT00021099|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9862236|NCT00021151|Experimental|Alemtuzumab|
9862237|NCT00021216|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9862238|NCT00021242|Experimental|Relapsed or Refractory ALL, AML|Docetaxel 60 mg/m^2 per dose weekly (Days 1,8,15) for 3 weeks followed by 1 week of rest.
9862239|NCT00021398|Experimental|Radiation Therapy, Chemotherapy and Surgery|
9862240|NCT00021814|Placebo Comparator|Placebo|Doxazosin and Finasteride placebos
9862241|NCT00021814|Experimental|Doxazosin|Doxazosin and Finasteride placebo
9862242|NCT00021814|Experimental|Finasteride|Doxazosin placebo and Finasteride
9862243|NCT00021814|Experimental|Combination|Doxazosin and Finasteride
9862244|NCT00021840||Homogen Hispanic pop/Cent Valley CRA|Homogeneous Hispanic population from the Central Valley of Costa Rica
9862245|NCT00021866||Carbamazepine|Children and their mothers exposed to Carbamazepine monotherapy in utero
9862246|NCT00021866||Phenytoin|Children and their mothers exposed to phenytoin in utero
9862247|NCT00021866||Lamotrigine|Children and their mothers exposed to Lamotrigine in utero
9862248|NCT00021866||Valproate|Children and their mothers exposed to Valproate in utero
9862249|NCT00022087|Experimental|Zoledronic acid initial tx|Zoledronic acid + calcium + Vit D for 2 years, followed by Calcium + vit D for 1 year
9862250|NCT00022087|Experimental|Calcium + Vit D initial Tx|Calcium + vitamin D for 1 year followed by zoledronic acid + calcium + vit D for 2 years
9862251|NCT00022113|Experimental|Treatment (cilengitide)|Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9862252|NCT00022126|Experimental|Modified Augmented BFM Therapy|
9862253|NCT00022139|Experimental|carboplatin + paclitaxel + fluorouracil + radiation + surgery|"Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.~Patients are followed every 3 months for 4 years."
9925875|NCT00876291|Placebo Comparator|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
9925876|NCT00876291|Active Comparator|Probiotic|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
9935222|NCT04029883|Experimental|Incentive Group|The Incentive group will receive the same information and text messages, but in addition have a chance of winning small, intermittent rewards for taking their medication at the time coinciding with their anchoring strategy. In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits. When the participants return for their monthly visit, the study coordinator will download their MEMS-cap data and check whether this eligibility criteria was satisfied. MEMS software can be easily customized to display this information. If the patient qualifies, s/he is invited to draw one of three laminated cards with numbers 0, 25, and 50 out of a bag. The client receives the corresponding amount in USD in the form of a gift card immediately after the drawing.
9935223|NCT04027946|Experimental|1|LMB-100 + Pembrolizumab
9862254|NCT00022152|Experimental|vinorelbine|"Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and then after completion of the second course.~Patients are followed every 3 months for 5 years."
9862255|NCT00022165|Placebo Comparator|Placebo|Selenium yeast
9862256|NCT00022165|Experimental|Selenium yeast 100 micrograms per day|100 micrograms per day
9862257|NCT00022165|Experimental|Selenium yeast 200 micrograms per day|200 micrograms per day
9862258|NCT00022165|Experimental|Selenium yeast 300 micrograms per day|300 micrograms per day
9862259|NCT00022334|Experimental|Treatment|See intervention description.
9862260|NCT00022399|Experimental|Celecoxib|Participants receive celecoxib 400mg by mouth twice daily for 4 to 6 weeks prior to standard-of-care prostatectomy.
9862261|NCT00022399|Placebo Comparator|Placebo-control|Participants receive placebo for 4 to 6 weeks prior to standard-of-care prostatectomy.
9862262|NCT00022412|Placebo Comparator|Observation, then prostatectomy|Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
9862263|NCT00022412|Active Comparator|Doxercalciferol once daily for 28 days|Dietary supplement once daily to treat prostate cancer for 28 days
9862264|NCT00022477|Experimental|BMS-247550|IV administration of BMS-247550 once every 21 days
9862265|NCT00022529|Experimental|Treatment (BMS-214662, trastuzumab)|Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9862266|NCT00022542|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 2 additional courses.
9862267|NCT00022555|Experimental|Treatment (bryostatin 1, vincristine sulfate)|Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
9862268|NCT00022581|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
9862269|NCT00022646|Experimental|Arm I: pemetrexed + gemcitabine|Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
9862270|NCT00022646|Experimental|Arm II: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
9862271|NCT00022646|Experimental|Arm III: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.
9862272|NCT00022711|Experimental|Temozolomide|Temozolomide 150mg/m2/day daily. Repeat cycles every 28days for maximum of six months
9862273|NCT00022737|Experimental|Arm I|See Design Details.
9862274|NCT00022776|Experimental|1|Participants will undergo surgery for spinal stenosis. Participants in this group will undergo surgical decompression as described by Rothman and Simeone.
9862275|NCT00022776|Experimental|2|Participants will undergo physical therapy for spinal stenosis. These participants will undergo a physical therapy program emphasizing lumbar flexion exercises, general conditioning exercises, and patient education for six weeks, with a frequency of 1-2 visits per week. Each patient will receive instruction in a home exercise program.
9862276|NCT00022854|Placebo Comparator|1|
9862277|NCT00022854|Experimental|2|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
9862278|NCT00022854|Experimental|3|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
9862279|NCT00022971|Experimental|1|Apolizumab followed by rituixmab every 4 weeks
9862280|NCT00023205|Experimental|Individualized education|Individualized education with materials written in plain language. Follow-up sessions/ phone contact as requested by the subject.
9862281|NCT00023205|Active Comparator|Standard care|1 session of education with provision of standard Arthritis Foundation materials.
9862282|NCT00023231|Experimental|1|Participants will receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus prior to transplantation. Bactrim and ganciclovir will be taken for infection prophylaxis. If the participant has consistent high levels of fasting cholesterol, treatment with lipitor may be given.
9862283|NCT00023244|Experimental|Corticosteroid (steroid) withdrawal|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
9862284|NCT00023244|Active Comparator|Control Treatment|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.
9862285|NCT00023283|Experimental|1|Standard Medical Management with once-weekly medication dispensing
9862286|NCT00023283|Experimental|2|Standard Medical Management with thrice-weekly medication dispensing
9862287|NCT00023283|Experimental|3|Enhanced Medical Management with thrice-weekly medication dispensing
9862288|NCT00023374|Experimental|Rifampin+PZA+Ethambutol|6 mos of intermittent (2 or 3 times weekly) therapy with REZ
9862289|NCT00023504|Active Comparator|Pneumococcal Vaccine|To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
9862290|NCT00023504|Active Comparator|Rabies Vaccine|To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.
9862291|NCT00023543|Experimental|1|Participants will reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight.
9862292|NCT00023634|Experimental|EGFR vaccine with GMCSF|EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
9862293|NCT00023634|Experimental|EGFR vaccine with KLH|EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m
9862294|NCT00023647|Experimental|Synchrotope TA2M, 800 micrograms|Tyrosinase peptides, 800 micrograms
9862295|NCT00023647|Experimental|Synchrotope TA2M, 200 micrograms|Tyrosinase peptides, 200 micrograms
9862296|NCT00023647|Experimental|Synchrotope TA2M, 400 micrograms|Tyrosinase peptides, 400 micrograms
9862297|NCT00023686|Experimental|surgery|"Patients undergo radical prostatectomy.~Patients are followed every 6 months for 5 years and then annually thereafter."
9862298|NCT00023686|Experimental|radiation|"Patients undergo brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.~Patients are followed every 6 months for 5 years and then annually thereafter."
9862299|NCT00023751|Experimental|surgery + leucovorin + fluorouracil + radiation|"Patients with T3 disease or positive surgical margins after surgery are removed from study. Patients with T1 disease and negative surgical margins after surgery are observed. Patients with T2 disease and negative surgical margins after surgery receive adjuvant therapy.~Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks. Beginning 2 weeks after the completion of chemotherapy, patients receive chemoradiotherapy comprising radiotherapy once daily 5 times a week for 5 weeks and 5-FU IV continuously while receiving radiotherapy. Beginning 2 weeks after the completion of chemoradiotherapy, patients again receive CF IV over 2 hours with 5-FU IV bolus 1 hour into the infusion once weekly for 6 weeks. Chemotherapy repeats after 2 weeks rest for a total of 2 courses.~Patients are followed every 3 months for 2 years and then every 6 months for 5 years."
9925877|NCT00876304|Experimental|PF-04802540|
9925878|NCT00876304|Placebo Comparator|Placebo|
9925879|NCT00876317|Active Comparator|1|Etoricoxib 60 mg per oz for 14 days
9925880|NCT00876317|Active Comparator|2|Etoricoxib 90 mg per oz for 14 days
9925881|NCT00876330|Experimental|1|Receives Hypertension and Hyperlipidemia Intervention using Clinical Decision Support.
9925882|NCT00876330|Experimental|2|Receives Hypertension and Hyperlipidemia Intervention with automated telephone outreach.
9925883|NCT00876356|Active Comparator|1|Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
9925884|NCT00876356|Placebo Comparator|2|Olive oil 4.5g/day x 12 weeks.
9925885|NCT00876369||Urticaria/Angioedema|Subjects with chronic urticaria and/or angioedema
9925886|NCT00876369||allergy control|Subjects with physician diagnosed allergic rhinitis
9925887|NCT00876421|Placebo Comparator|P|
9925888|NCT00876421|Active Comparator|A|
9925889|NCT00876421|Experimental|E1|
9925890|NCT00876421|Experimental|E2|
9925891|NCT00876421|Experimental|E3|
9925892|NCT00876473||1|Acute Respiratory Failure patients
9925893|NCT00876486|Experimental|Genexol®-PM|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
9925894|NCT00876486|Active Comparator|Genexol®|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
9925895|NCT00876499||Questionnaire|
9925896|NCT00876525|Experimental|Freedom SOLO stentless valve|
9925897|NCT00876538|Experimental|TRO19622|2 capsules of TRO19622 (330mg) once day with the noon meal
9925898|NCT00876538|Placebo Comparator|Control|2 capsules of placebo once day with the noon meal
9925899|NCT00876551|Experimental|E-V.A.C.|Patients that are treated with E-V.A.C.
9925900|NCT00876564|Other|Trauma patients|Included in trauma registry
9925901|NCT00876577||Group 1|
9925902|NCT00876603||1|
9925903|NCT00876603||2|
9925904|NCT00876603||CSM - ACDF|Cervical spondylotic myelopathy treated with anterior cervical decompression and fusion
9925905|NCT00876603||CSM - Cervical laminoplasty|Cervical spondylotic myelopathy treated with cervical laminoplasty
9925906|NCT00876616|Experimental|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d+MMF 1.0g/d
9925907|NCT00876616|Active Comparator|Cyclophosphamide|CTX iv 0.75 g/m2 body surface area (BSA)
9862300|NCT00023829|Experimental|LH-RH agonist plus radiation therapy|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy
9862301|NCT00023829|Active Comparator|Radiation therapy alone|Radiation therapy alone to 63.0 - 66.6 Gy
9862302|NCT00023829|Active Comparator|LH-RH agonist alone|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years
9862303|NCT00023920|Experimental|Treatment (bevacizumab, idarubicin, cytarabine)|Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
9862304|NCT00023933|Experimental|Treatment (monoclonal antibody)|"Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.~Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
9862305|NCT00023946|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
9862306|NCT00023959|Experimental|Treatment (hydroxyurea, fluorouracil, bevacizumab, radiation)|Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
9862307|NCT00023998|Experimental|Treatment (combination chemotherapy)|See detailed description.
9862308|NCT00024011|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9862309|NCT00024024|Experimental|Arm I|Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.
9862310|NCT00024089|Experimental|Arm I|Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9862311|NCT00024154|Experimental|Treatment (trastuzumab, gefitinib)|"Phase I (completed): Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1.~Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.~Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity."
9862312|NCT00024206|Experimental|Treatment (orantinib)|"Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more.~Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9925908|NCT00876642|Experimental|1|
9925909|NCT00876642|No Intervention|2|
9862313|NCT00024466|Experimental|Vaccine|Participants are vaccinated with GVAX one month or more after finishing induction therapy (which is given as per standard of care). Two weeks later, participants go through leukapheresis on protocol, then receive autologous transplant as per standard of care. GVAX is administered eight subsequent times after the autologous transplant.
9862314|NCT00024518|Placebo Comparator|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
9862315|NCT00024518|Experimental|5,000 Units hrIFN-alpha|hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
9862316|NCT00024518|Experimental|30,000 hrIFN-alpha|30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
9862317|NCT00024596||Caucasian Families|Largest 3-generational Caucasian Families from Family Heart Study (Classic) with average family size of 10 N=2767 Subjects from 512 families. Approximately half are random sample families from FamHS-Classic, and half are high-familial CHD risk families from FamHS-Classic. 4 Field sites were Raleigh-Durham North Carolina; Minneapolis, MN; Framingham MA; and Salt Lake City, UT.
9862318|NCT00024596||African-American Families|622 subjects from 2-3 generational 212 African-American families originally recruited from the HyperGEN study in Birmingham AL. These are hypertension enriched families.
9862319|NCT00025025||Arm I|"Participants eat no red meat and take no nonsteroidal anti-inflammatory drugs (NSAIDs) and no vitamin C or multivitamins for 3 days prior to and during stool sample collection. Participants collect stool samples 3 different times and perform fecal occult blood (FOB) test smears from each stool. After each collection, participants ship the whole stool and FOB test smear to their participating center for blinded multitarget DNA-based assay panel (MTAP) testing.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
9862320|NCT00025025||Arm II|"Participants take no vitamin C or multivitamins for 3 days before and during stool sample collection. Participants collect stool samples and FOB test smears and samples are tested as in arm I.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
9862321|NCT00025038|Experimental|Treatment (tipifarnib, bone marrow/umbilical cord transplant)|See detailed description.
9862322|NCT00025207|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9862323|NCT00025220|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9862324|NCT00025246|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.
9862325|NCT00025337|Experimental|Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)|Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
9862326|NCT00025337|Experimental|Arm II (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
9862327|NCT00025337|Experimental|Arm III (bevacizumab)|Patients receive bevacizumab as in arm I.
9862328|NCT00025363|Experimental|Arm I|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
9862329|NCT00025363|Experimental|Arm II|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
9862330|NCT00025376|Experimental|Pre-Treatment biopsy followed by PS-341 administration|Pre-treatment tumor biopsy followed by 3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects can continue to receive another 3 cycles of the study drug if their disease has not worsened.
9862331|NCT00025376|Experimental|PS-341 administration followed by biopsy|3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects will have a tumor biopsy and can continue to receive another 3 cycles of the study drug if their disease has not worsened.
9862332|NCT00025389|Experimental|Arm A|Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab
9925910|NCT00876655|Experimental|free acid|TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700)
9925911|NCT00876655|Experimental|di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
9925912|NCT00876681|Active Comparator|1. Ultrasound|Ultrasound method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement and then again the first day after surgery. Time of placement is also measured and begins when the ultrasound probe first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
9935224|NCT04025580|Experimental|Flucelvax, Fluvirin, or Fluzone High Dose|Healthy Volunteer between ages 18-65 receiving Flucelvax
9935225|NCT04025554|Experimental|1/Active treatment|Patients with MS will be assigned to the same intervention
9935226|NCT04014348||Female|Diagnostic
9986481|NCT01403337|Placebo Comparator|Control|Blood pressure cuff inflated in the right or left arm to 40-50 mmHg
9862333|NCT00025415|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
9862334|NCT00025467|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862335|NCT00025493|Experimental|docetaxel|docetaxel
9862336|NCT00025584|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9862337|NCT00025675|Active Comparator|p450|p450 inhibitor
9862338|NCT00025675|Active Comparator|nonp450|not on p450 inhibitor
9862339|NCT00025766|Experimental|1|PCI with stenting of the occluded culprit infarct-related artery plus optimal medical therapy
10210169|NCT02021695||Group I: Non-diabetic controls|"Group I: Non-diabetic controls Good overall health without history of Type II diabetes. Normal fasting glucose level (<100 mg/dL) and HbA1C < 5.7%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
10210170|NCT02021695||Group II: Diabetic with HbA1C<7%|"Group II:~HbA1C<7%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
9862340|NCT00025766|Active Comparator|2|Optimal medical therapy alone without PCI of the occluded culprit artery
9862341|NCT00026091|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9862342|NCT00026104|Experimental|Arm I (radiation therapy, paclitaxel, gemcitabine)|Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
9862343|NCT00026104|Experimental|Arm II (radiation therapy, tipifarnib)|Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.
9862344|NCT00026117|Experimental|BeneFin|"Patients receive oral shark cartilage (BeneFin™) 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
9862345|NCT00026117|Other|placebo|"Patients receive oral placebo 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
9862346|NCT00026130|Experimental|Gemcitabine + 5FU + XRT|Chemo and radiation therapy in the treatment of non-metastatic pancreatic cancer
9862347|NCT00026143|Experimental|Arm I|Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
9862348|NCT00026169|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily on days 1 and 4-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients in each stratum receive escalating doses of imatinib mesylate until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9862349|NCT00026182|Experimental|Arm I (rituximab and recombinant interleukin-12)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
9862350|NCT00026182|Experimental|Arm II (rituximab and recombinant interleukin-12)|Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
9862351|NCT00026195|Experimental|irinotecan|"Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed for survival."
9862352|NCT00026234|Experimental|Treatment (chemotherapy)|Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
9862353|NCT00026247|Experimental|RFA as pain therapy|Changes in the severity of pain as measured using using the Memorial Pain Assessment Cards (MPAC) before and after RadioFrequency Ablation (RFA) will be statistically analyzed
9862354|NCT00026299|Experimental|Phase 2: Oxaliplatin plus ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
9862355|NCT00026299|Experimental|Phase 2: Oxaliplatin alone|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.
10210171|NCT02021695||Group III: Good controlled diabetics with 7 % <HbA1C < 10%|"Group III Good controlled diabetics with 7 % <HbA1C < 10%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
10210172|NCT02021695||Group IV: Poorly controlled diabetics with HbA1C > 10%.|"Group IV:~Poorly controlled diabetics with HbA1C > 10%.~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
10210173|NCT02003924|Sham Comparator|Placebo|Sugar pill manufactured to mimic enzalutamide 40 mg capsule
9862356|NCT00026299|Experimental|Phase I: Oxaliplatin with ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.
9862357|NCT00026338|Active Comparator|OSI-774 plus Gemcitabine|
9862358|NCT00026338|Active Comparator|Placebo plus gemcitabine|
9862359|NCT00026364|Experimental|Arm I|"Patients receive oral ZD 1839 daily. Beginning on day 15, patients receive irinotecan IV over 90 minutes, leucovorin calcium IV over 15 minutes, and fluorouracil IV weekly on weeks 1-2. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of ZD 1839 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are accrued to receive treatment at the MTD."
9862360|NCT00026377|Experimental|SU5416 in combination with hormone and radiation therapy|Subjects receive 5 months of hormone suppression therapy consisting of 1 month of Bicalutamide or Flutamide followed by 4 months of leuprolide or goserlin injections. After completion of at least 12 weeks of hormone therapy, subjects will receive 7 1/2 weeks of radiation therapy. SU5416 will be given by IV infusion starting 4 weeks before beginning radiation treatment and continuing until 4 weeks after completion of radiation. Multiple doses of SU5416 will be studied.
9862361|NCT00026403|Experimental|radiotherapy + gemcitabine + cisplatin|"Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy.~Patients are followed every 3 months for 2 years and then every 6 months for 1 year."
9862362|NCT00026637|Active Comparator|Sertraline|
9862363|NCT00026637|Active Comparator|CBT|
9862364|NCT00026689||1/Cohort 1|Patients suspected of having, or with biopsy proven malignant disease or patients with a benign condition for whom radiotherapy is a potential treatment
9862365|NCT00026780||Cohort 1|Children and young adults who are being evaluated for protocols within the Pediatric Oncology Branch.
9925913|NCT00876681|Active Comparator|2. Electrical Stimulation|Electrical stimulation (nerve stimulation) method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement, and then again the first day after surgery. Time of placement is also measured and begins when the nerve stimulation needle first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
9925914|NCT00876707|Active Comparator|Tecnis|
10210174|NCT02003924|Experimental|Enzalutamide|160 mg by mouth once daily
10210175|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
10210176|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
10210177|NCT01969409|Placebo Comparator|Placebo|These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.
10210178|NCT01969409|Experimental|Rituximab|Rituximab i.v. given on two occasions, with 14 days between doses.
10210179|NCT01965249|Active Comparator|Long stitch group|Long stitch suture technique Stitch interval = 10 mm; Lateral = 10 mm
10210180|NCT01965249|Experimental|Short stitch group|Short stitch technique for AWC stitch interval = 5 mm; Lateral 5 - 8 mm
10210181|NCT01965184|Experimental|Cognitive-Behavioral Therapy for Anger and Aggressive Behavior|CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
9925915|NCT00876707|Active Comparator|ReSTOR|
9925916|NCT00876707|Active Comparator|ReZoom|
9925917|NCT00876720|Experimental|1|Combined frontal and temporal transcranial magnetic stimulation
9925918|NCT00876720|Experimental|2|Temporal transcranial magnetic stimulation
9862366|NCT00027053|Experimental|Trazodone|
9862367|NCT00027053|Placebo Comparator|Placebo|
9862368|NCT00027066|Active Comparator|Active Warfarin and Aspirin Placebo|One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.
9862369|NCT00027066|Active Comparator|Active Aspirin and Warfarin Placebo|One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.
9862370|NCT00027170||Participants with cardiovascular diseases|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
9862371|NCT00027170||Healthy Participants|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
9862372|NCT00027300|Experimental|Group 1|Natalizumab 300 mg, IV
9862373|NCT00027300|Placebo Comparator|Group 2|Placebo IV infusion
9862374|NCT00027417|Active Comparator|Liothyronine Sodium/Triiodothyronine|bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function.
9862375|NCT00027417|Placebo Comparator|Placebo|bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses
9862376|NCT00027534|Experimental|TRICOM-CEA(6D)|Subjects receiving TRICOM-CEA(6D)
9862377|NCT00027573|Experimental|Chemotherapy + stem cell transplantation|"Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over 1-2 hours on days -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 5 and continuing until blood counts recover.~Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral tacrolimus twice daily on days -1 to 90 and methotrexate IV on days 1, 3, and 6.~After day 120, patients with persistent disease and no signs of active GVHD may receive donor lymphocyte infusion (DLI). DLI may be repeated every 8 weeks for a total of 2 infusions.~Patients are followed every 2 months for 1 year and then every 6 months for 4 years OR every 2 months for 6 months and then every 6 months for 4.5 years if patient receives DLI."
9862378|NCT00027586|Experimental|Imatinib Mesylate|400 mg twice a day orally
9862379|NCT00027599|Experimental|Arm I|Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.
9862380|NCT00027612|Experimental|irinotecan + carmustine and radiation|"Phase II (patients receiving concurrent EIACs or non-EIACs open to accrual as of 3/5/2005): Patients receive irinotecan at the recommended dose, carmustine, and cranial irradiation as in phase I.~Patients with disease progression are followed every 3 months for 5 years and then annually for up to 10 years.~Patients taken off study for reasons other than disease progression are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
9862381|NCT00027690|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862382|NCT00027703|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
9862383|NCT00027703|Experimental|Arm II|Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
9925919|NCT00876746|Active Comparator|1. Supraclavicular|Patients will be randomized to placement of a nerve block in the supraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
9862384|NCT00027807|Experimental|Aldesleukin, Sargramostim & therapeutic autologous lymphocytes|Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
9862385|NCT00027820|Experimental|Treatment (PBSCT)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -4, -3, and -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO every 8 hours on days 0-40 with taper to day 96."
9862386|NCT00027872|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.
9862387|NCT00027885|Active Comparator|Docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
9862388|NCT00027885|Experimental|Combine bevacizumab and docetaxel.|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
9862389|NCT00027898|Experimental|Treatment (bortezomib, carboplatin, and etoposide)|Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
9862390|NCT00027963|Experimental|gabapentin|"Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
9862391|NCT00027963|Placebo Comparator|placebo|"Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
9862392|NCT00027976|Experimental|Group 1 active arm|receipt of active drug
9862393|NCT00027976|Experimental|Group 2 active arm|receipt of active drug
9862394|NCT00027976|Experimental|group 2 placebo arm|receipt of placebo
9862395|NCT00028028|Experimental|Arm I|Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
9862396|NCT00028028|Experimental|Arm II|Patients receive high-dose CCI-779 as in arm I.
9862397|NCT00028119||Cohort 1|HIV-uninfected non-sex worker women
9862398|NCT00028119||Cohort 2|HIV-discordant heterosexual couples attending STD clinics
9862399|NCT00028145||1|Pregnant, HIV-infected women
9862400|NCT00028496|Experimental|Treatment (vaccine therapy, sargramostim, vaccine adjuvant)|"The first three cohorts of 3-12 patients receive escalating doses of recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated dose (MTD) is determined. fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then every 2 months thereafter (beginning on day 56) in the absence of disease progression or unacceptable toxicity.~The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily beginning on the day of each vaccination and continuing for a total of 4 days.~The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of recombinant fowlpox-GM-CSF (rF-GM-CSF)."
9862401|NCT00028522|Experimental|Treatment (chemotherapy)|"SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).~SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A."
9862402|NCT00028535|Experimental|Arm I|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
10210182|NCT01965184|Active Comparator|Supportive Psychotherapy (SPT)|SPT consists of 12 sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
9862403|NCT00028548|Experimental|XK469|
9862404|NCT00028561|Experimental|Treatment (ixabepilone, carboplatin)|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
9862405|NCT00028574|Active Comparator|Gabapentin (28 days)|Oral Gabapentin 300 mg days 1-28
9862406|NCT00028574|Active Comparator|Gabapentin (7, 21)|Oral Gabapentin 300 mg once daily on days 1-7 days and twice daily days 8-28
9862407|NCT00028574|Active Comparator|Gabapentin (7, 7, 14)|Oral Gabapentin 300 mg once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28
9862408|NCT00028574|Placebo Comparator|Placebo|"Oral Placebo 300 mg on one of the following schedules:~once daily on days 1-28~once daily on days 1-7, twice daily on days 8-28~once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28"
9862409|NCT00028587|Experimental|Group I (paclitaxel, carboplatin, bortezomib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and bortezomib IV over 3-5 seconds on days 2, 5, and 8.
9862410|NCT00028587|Experimental|Group II (bortezomib, paclitaxel, carboplatin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2
9862411|NCT00028600|Experimental|Autologous + Allogeneic Transplant|autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma
9862412|NCT00028665|Experimental|Arm I: with rituximab IV|
9862413|NCT00028665|Active Comparator|Arm II: without rituximab IV|
9925920|NCT00876746|Active Comparator|2. Infraclavicular|Patients will be randomized to placement of a nerve block in the infraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
9925921|NCT00876759|Active Comparator|WBRT|standard WBRT to a total dose of 30 Gy in 10 fractions
9925922|NCT00876759|Experimental|WBRT with simulatneous boost|The experimental group will be treated with helical tomotherapy giving 3 Gy per fraction to the whole brain up to a total dose of 30 Gy in 10 fractions and raising the prescribed dose to the brain metastases to 5 Gy per fraction. The dose fall off to the normal brain should be as steep as possible around each brain metastasis. The optic chiasm and the optic nerves should not receive more than 3.5 Gy per fraction.
9925923|NCT00876785|Active Comparator|1|Reference wheat bread breakfast
9925924|NCT00876785|Experimental|2|Rye bread breakfast
9925925|NCT00876811|Experimental|one-cup|
9925926|NCT00876811|Experimental|two-cups|
9925927|NCT00876811|Experimental|four-cups|
9925928|NCT00876824|Experimental|Amphotericin B lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
9925929|NCT00876824|Active Comparator|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
9925930|NCT00876837||Adults with pediatric-onset SCI|
9925931|NCT00876850|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
9925932|NCT00876850|Active Comparator|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
9925933|NCT00876876|Placebo Comparator|Placebo QD or BID|Placebo QD or BID
10210183|NCT01942122|Experimental|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
10210184|NCT01942122|Experimental|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
10210185|NCT01942122|Active Comparator|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
10210186|NCT01940094|Experimental|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
10210187|NCT01940094|Experimental|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
10210188|NCT01909895|Experimental|Anger induction|The participant will be asked to undergo a validated anger induction task.
10210189|NCT01909895|Experimental|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
10210190|NCT01909895|Experimental|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
10210191|NCT01909895|Other|Neutral emotion task|The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).
10210192|NCT01882933|Experimental|Curative Gastrectomy + HIPEC|Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
9862414|NCT00028730|Experimental|Pts < than or = 18 years with lymphohematopoietic disorders|This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.
9862415|NCT00028743|Active Comparator|Cisplatin, Topotecan, Paclitaxel plus Carboplatin|Arm 1
9862416|NCT00028743|Active Comparator|Paclitaxel plus Carboplatin|Arm 2
9862417|NCT00028756|Active Comparator|Arm I (immediate chemotherapy)|Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.
9862418|NCT00028756|Experimental|Arm II (deferred chemotherapy)|Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.
9862419|NCT00028782|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
9862420|NCT00028795|Experimental|Chemoradiotherapy|
9862421|NCT00028821|Experimental|Treatment (2-methoxyestradiol)|Patients receive oral 2-methoxyestradiol (2-ME) once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862422|NCT00028834|Experimental|Treatment (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9862423|NCT00028925|Experimental|Regimen A|"Patients receive oral topotecan once daily on days 1-5, carboplatin IV over 30 minutes on day 5, and filgrastim (G-CSF) subcutaneously once daily beginning on day 6 or 7 and continuing for up to 10 days or until blood counts recover.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
9862424|NCT00028925|Experimental|Regimen B|"Patients receive topotecan and carboplatin as in regimen A. Patients are evaluated after the first 3-week course of chemotherapy. If no patient experiences unacceptable toxicity or febrile neutropenia, the next 33 patients receive treatment as in regimen B; otherwise, patients receive treatment as in regimen A.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
9862425|NCT00028990|Active Comparator|Paclitaxel + Bevacizumab|
10210193|NCT01882933|Other|Curative Gastrectomy|Curative gastrectomy with D1-D2 lymph node dissection
9862426|NCT00028990|Active Comparator|Paclitaxel|
9862427|NCT00029003|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
9862428|NCT00029159|Active Comparator|1|
9862429|NCT00029159|Placebo Comparator|2|
9862430|NCT00029198|Experimental|1|15 minute massage tid
9862431|NCT00029198|Sham Comparator|2|non-massage touch
9862432|NCT00029913||1|Observation of participants includes a physical exam and collection of fluids. Study visits occur at Days 0, 7, 14, 28 and at Months 2, 3, 6 and every 6 months thereafter.
9862433|NCT00030225|Experimental|ELAD|Treatment with ELAD, extracorporeal liver assist system and standard of care
10210194|NCT01869829||Pediatric Invasive Candidiasis|Pediatric patients (age > 120 days and < 18 years) with documented proven or probable invasive candidiasis
9862434|NCT00030225|Other|Standard of care (Control)|Standard of care for patients with fulminant hepatic (liver) failure
9862435|NCT00030238|Other|Active Treatment|Subjects take calcium twice daily with meals
9862436|NCT00030238|Other|Control|Subjects take placebo twice daily with meals.
9862437|NCT00030303|Experimental|vaccine|recombinant 70-kD heat-shock protein
9925934|NCT00876876|Experimental|Lixivaptan QD or BID|Lixivaptan QD or BID
9925935|NCT00876902|Experimental|1|Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
9925936|NCT00876902|Placebo Comparator|2|Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
9925937|NCT00876941|Experimental|Standard Brief Intervention|
9925938|NCT00876941|Experimental|Enhanced Brief Intervention|
9925939|NCT00876941|Active Comparator|Control|
9925940|NCT00876954|Placebo Comparator|Placebo|Warming without increase in core temperature
9925941|NCT00876954|Active Comparator|Hyperthermia|Hyperthermia for 2,5 hours (39 °C core temperature)
9925942|NCT00876967|Experimental|1|metallic single use blade
10210195|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
9862438|NCT00030368|Experimental|Treatment (bortezomib, paclitaxel)|Patients receive bortezomib IV on days 2 and 9 and paclitaxel IV over 1 hour on days 1 and 8. For the first course only, patients do not receive paclitaxel on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9862439|NCT00030381|Experimental|Treatment (iododoxorubicin)|Patients receive iododoxorubicin IV over 15 minutes on days 1, 8, 15, and 22. Treatment repeats every 12 weeks for a total of 4 courses or a cumulative dose of 400 mg/m^2 in the absence of disease progression or unacceptable toxicity.
9862440|NCT00030394|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
9862441|NCT00030407|Experimental|Celecoxib & Docetaxel|"Celecoxib: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals~Docetaxel: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days."
9862442|NCT00030420|Experimental|Celecoxib & Docetaxel|"Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.~Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days"
9862443|NCT00030498|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
9862444|NCT00030576|Experimental|OSI-774 and cisplatin|HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days
9862445|NCT00030615|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9862446|NCT00030628|Experimental|radiosurgery|"Patients undergo radiosurgery.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years."
9862447|NCT00030628|Experimental|radiosurgery + WBRT|"Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.~Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
9862448|NCT00030654|Experimental|Androgen blockade + immediate chemotherapy|Androgen blockade with immediate chemotherapy
9862449|NCT00030654|Experimental|Androgen blockade + delayed chemotherapy|Androgen blockade with delayed chemotherapy
9862450|NCT00030667|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9862451|NCT00030693|Experimental|Arm I (recombinant fowlpox-B7.1 vaccine)|Patients receive rF-B7.1 vaccine intratumorally on day 1.
9862452|NCT00030693|Experimental|Arm II (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.
9862453|NCT00030732|Active Comparator|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
9862454|NCT00030732|Active Comparator|Gemcitabine alone|Gemcitabine alone
9862455|NCT00030771|Active Comparator|Arm A|Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery
9862456|NCT00030771|Active Comparator|Arm B|Neoadjuvant Chemotherapy + Surgery
9862457|NCT00030797|Active Comparator|Arm A|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
9862458|NCT00030797|Active Comparator|Arm B|Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
9862459|NCT00030914|Experimental|Arm I: venlafaxine|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
9862460|NCT00030914|Experimental|Arm II: medroxyprogesterone - long term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
9925943|NCT00876967|Experimental|2|plastic single use blade
9925944|NCT00876967|Active Comparator|3|metallic reusable blade
9925945|NCT00876980|Active Comparator|1|nasal Continuous Positive Airway Pressure treatment for 3 months
9862461|NCT00030914|Experimental|Arm III: medroxyprogesterone - short term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
9862462|NCT00030966|Experimental|Group 1|Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
9862463|NCT00030966|Placebo Comparator|Group 2|Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
9862464|NCT00031096|Experimental|Arm 1|
9862465|NCT00031096|Placebo Comparator|Arm 2|
9862466|NCT00031122||SBRR|Families with a child/pregnancy affected with spina bifida or anencephaly
10210196|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
9862467|NCT00031174||1|Blood components collected using apheresis from normal volunteers.
9862468|NCT00031174||2|Blood components collected using apheresis from patients with rheumatic or kidney diseases.
9862469|NCT00031278|Experimental|Cohort 1|0.01 mg/kg CPG 7909 plus Herceptin®
9862470|NCT00031278|Experimental|Cohort 2|0.04 mg/kg CPG 7909 plus Herceptin®
9862471|NCT00031278|Experimental|Cohort 3|0.16 mg/kg CPG 7909 plus Herceptin®
9862472|NCT00031278|Experimental|Cohort 4|0.32 mg/kg CPG 7909 plus Herceptin®
9862473|NCT00031395|Active Comparator|1|
9862474|NCT00031395|Active Comparator|2|
9862475|NCT00031395|Active Comparator|3|
9862476|NCT00031395|Placebo Comparator|4|
9862477|NCT00031421||1|16 received ganciclovir at 8 mg/kg/day in the previous study.
9862478|NCT00031421||2|31 received ganciclovir at 12 mg/kg/day in the previous study.
9862479|NCT00031434|Experimental|1|All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
9862480|NCT00031499|Experimental|Azithromycin|Azithromycin 2.0 gram single oral dose.
9862481|NCT00031499|Active Comparator|Benzathine Penicillin|Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.
9862482|NCT00031564|Experimental|Vaccine Therapy With Interleukin-2|At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.
9862483|NCT00031629|Experimental|Treatment (gemcitabine, docetaxel, G-CSF, pegfilgrastim)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8, docetaxel IV over 1 hour on day 8, and G-CSF SC on days 9-15 or pegfilgrastim SC on day 9 only. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9862484|NCT00031655|Experimental|Treatment (nonmyeloablative allogeneic PBSCT)|"NONMYELOALATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. Patients with minimal residual disease may receive donor lymphocyte infusion IV.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO very 8 hours on days 0 to 40 with taper to day 96."
10210197|NCT01860937|Experimental|Cohort 1 (MRD)|Patients with no morphologic evidence of disease at the time of T cell infusion, (<5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Cohort 1 patients will receive conditioning chemotherapy followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of End of Production (EOP) T cells, under or over estimation of CAR modified T-cells may occur. Patients may receive an altered fractionation of the total doses (e.g. ½ on Day 0 and ½ on Day +1) or up to 35% over total cell dose with approval by the participating site PI. In both cohorts, patients will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion and did not experience any non-hematologic grade 4 toxicities.
9862485|NCT00031681|Experimental|Treatment (combination chemotherapy)|"PART I: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, and 22 and 7-hydroxystaurosporine IV over 3 hours on days 2 and 23. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride and 7-hydroxystaurosporine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples are collected periodically during study treatment.~PART II: (treatment of triple negative recurrent breast cancer): Patients receive irinotecan hydrochloride IV and 7-hydroxystaurosporine IV as in part I at the MTD and undergo blood sample collection."
9862486|NCT00031707|Active Comparator|megestrol + placebo|"Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
9862487|NCT00031707|Active Comparator|eicosapentaenoic acid + placebo|"Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
9862488|NCT00031707|Experimental|megestrol + eicosapentaenoic acid|"Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
9862489|NCT00031720|Experimental|Arm I|All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
9862490|NCT00031720|Placebo Comparator|Arm II|All patients receive placebo for a 7 day run in period. Patients being treated with tamoxifen randomized to Arm II received placebo daily for 12 weeks.
9862491|NCT00031746|Active Comparator|soy protein + isoflavones|
9862492|NCT00031746|Active Comparator|casein proteins|
9862493|NCT00031759|Other|Ablative or excisional therapy|"Patients undergo ablative or excisional therapy.~Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
9862494|NCT00031759|Experimental|Ablative or excisional therapy + imiquimod|"Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
9862495|NCT00031772|No Intervention|Control|Standard level of support after recurrence diagnosis
9862496|NCT00031772|Experimental|Intervention|Phone intervention for patients experiencing first recurrence with quality of life questionnaires, psychosocial assessment and care.
9862497|NCT00031837|Experimental|Dalteparin|5,000 anti-Xa units of dalteparin subcutaneously once daily for six months in addition to gemcitabine at 1,000 mg/m2 as a 30-minute infusion weekly for 7 weeks followed by a week of rest for the first cycle and weekly for three weeks followed by a week of rest for each subsequent cycle.
9925946|NCT00876980|No Intervention|2|controls have no treatment, being observed for 3 months
9925947|NCT00877084|Experimental|1|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
9925948|NCT00877084|Placebo Comparator|2|Usual care according to clinical pathway for COPD exacerbations + NO training
9925949|NCT00877097|Experimental|1|Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
9925950|NCT00877097|Placebo Comparator|2|Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
9925951|NCT00877097|Active Comparator|3|Clodronate 800 mg / day for five years.
9925952|NCT00877110|Experimental|chemotherapy, allogeneic NK cells, 3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.
9925953|NCT00877123|Experimental|Vitamin D|Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
9925954|NCT00877123|Placebo Comparator|Placebo|
9925955|NCT00877149|Experimental|A|
9925956|NCT00877162|Experimental|1|Providing parents with a group teaching intervention (2 hours long). The teaching session is followed by 2 weeks of phone calls twice a week to offer parents support for their use of the strategies described in the teaching session and to clarify any questions about the teaching session content. The arm will have baseline data collected one week prior to the teaching session. Follow-up data will be collected at 6 and 24 weeks post intervention. A pamphlet on infant safety will be distributed to the intervention arm following the 6 week data collection point. A pamphlet on managing behavioural sleep problems will distributed to the control group following the 6 week data collection point.
9925957|NCT00877175|Experimental|1|Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
9925958|NCT00877175|Active Comparator|2|Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
9925959|NCT00877188|Experimental|exercise|supervised combined aerobic and resistance training for 12 weeks
9925960|NCT00877188|No Intervention|control|waist list control with usual care
9925961|NCT00877214|Experimental|Rituximab|Follicular Lymphomas: Rituximab 375 mg/m² for additional 2 years after 2 years of standard maintainance All other lymphomas: Rituximab 375 mg/m² for 2 years as maintainance. From 2014 only Morbus Waldenstroem: Rituximab 1.400 mg absolute s. c. injection
9925962|NCT00877214|Active Comparator|Standard|Rituximab / Observation
9862498|NCT00031889|Active Comparator|Arm I|Patients receive oral exemestane once daily
9862499|NCT00031889|Active Comparator|Arm II|Patients receive exemestane as in arm I and oral bicalutamide once daily
9862500|NCT00031980|Experimental|cyclosporine|"Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 4 months for 1 year and then every 6 months for 9 years."
9862501|NCT00031993|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9862502|NCT00032006|Experimental|brachytherapy + radiation|"Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.~Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
9862503|NCT00032019|Experimental|EPOCH-Rituximab|Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL
9862504|NCT00032032|Experimental|radiotherapy + paclitaxel + carboplatin|"Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.~Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years."
9862505|NCT00032084|Placebo Comparator|Behavioral Intervention + Placebo|Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
9862506|NCT00032084|Active Comparator|Behavioral Intervention + Bupropion|Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .
9862507|NCT00032110|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.
9862508|NCT00032162|Experimental|PLD|dose finding study of PLD in combination with Carboplatin
9862509|NCT00032188|Experimental|Arm I (aldesleukin and lowest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive lowest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
9862510|NCT00032188|Experimental|Arm II (aldesleukin and middle dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive middle dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
9862511|NCT00032188|Experimental|Arm III (aldesleukin and highest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive highest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
9862512|NCT00032227|Experimental|1|Surgical release of CTS
9862513|NCT00032227|Active Comparator|2|Non-surgical treatment for CTS (splint, physical therapy, ultrasound)
9862514|NCT00032344|Other|1|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
9862515|NCT00032357|Other|Arm 1|Usual care plus Ferritin reduction to a calculated nadir of 25 ng/mL by phlebotomy
9862516|NCT00032357|No Intervention|Arm 2|Usual care only; no intervention control
9862517|NCT00032370|Other|1|Elective vascular surgery
9862518|NCT00032370|Other|2|Cardiac revascularization prior to vascular surgery.
9862519|NCT00032435|Experimental|1|PAL-40 Active
9862520|NCT00032435|Placebo Comparator|2|PAL-40 Placebo
9862521|NCT00032448|Other|1|Open and laparoscopic herniorrhaphy
9862522|NCT00032539||1|
9862523|NCT00032552||1|
9862524|NCT00032565||1|No intervention. Telephone interview.
9862525|NCT00032617|Active Comparator|1|Prolonged Exposure
9862526|NCT00032617|Active Comparator|2|Present Centered Therapy
9862527|NCT00032643|Other|Arm 1|
9862528|NCT00033111|Active Comparator|Cabergoline|Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
9862529|NCT00033111|Placebo Comparator|Placebo|Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
9862530|NCT00033228|Experimental|Cohort 1|The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
9862531|NCT00033228|Experimental|Cohort 2|The second cohort of 6 patients received 1000 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
9862532|NCT00033228|Experimental|Cohort 3|The third cohort of 6 patients received 1500 ug of Synchrovax SEM plasmid DNA vaccine. The maximum tolerated dose (MTD) was to be determined by the observation of DLT at each dose group.
9862533|NCT00033254|Active Comparator|Arm I (radiation therapy)|Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
9862534|NCT00033254|Experimental|Arm II (radiation therapy, thalidomide)|Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
9862535|NCT00033267|Experimental|Treatment|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
9862536|NCT00033280|Experimental|Pre-RT temozolomide, RT plus temozolomide|Pre-radiation therapy (RT) temozolomide, RT plus temozolomide
9862537|NCT00033306|Experimental|BMS-247550|
9925963|NCT00877227|Experimental|folinic acid|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
9925964|NCT00877227|No Intervention|2|control subjects admitted at the Neonatal Intensive Care Unit (NICU)
9925965|NCT00877240|Other|Lifestyle counseling|
9925966|NCT00877253|Experimental|Dose Level One|
9925967|NCT00877253|Experimental|Dose Level Two|
9925968|NCT00877253|Experimental|Dose Level Three|
9925969|NCT00877266|Active Comparator|1. Ultrasound|Ultrasound is randomly chosen by use of a computer program. The time for catheter placement will begin with the ultrasound probe touches the patient. Patients will be asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and will be called the next day by the research staff.
9925970|NCT00877266|Active Comparator|2. Electrical Stimulation|Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
9925971|NCT00877292||Down syndrome|Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.
9925972|NCT00877305|Active Comparator|RIPC|Remote Ischemic Preconditioning
9925973|NCT00877305|Placebo Comparator|CONTROL|Control
9925974|NCT00877318|No Intervention|Control|Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
9925975|NCT00877318|Experimental|telemedicine|Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months
9925976|NCT00877331|Experimental|1|Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
9925977|NCT00877331|No Intervention|2|Enhanced care as usual.
9925978|NCT00877344|Experimental|1|Immediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
9925979|NCT00877344|Experimental|2|Interval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
9925980|NCT00877357|Experimental|Shan 5 Lot No 1|
9925981|NCT00877357|Experimental|Shan 5 Lot No 2|
9925982|NCT00877357|Experimental|Shan 5 Lot No 3|
9925983|NCT00877396|Experimental|Influenza|Inactivated Influenza vaccination
9925984|NCT00877396|Placebo Comparator|Control|Hepatitis A vaccine
9925985|NCT00877409|Active Comparator|Acnase|
9925986|NCT00877409|Placebo Comparator|Vehicle|
9925987|NCT00877422|No Intervention|Group A|Group A is identified as serum vitamin D level more than 16 ng/dl.
9925988|NCT00877422|Active Comparator|Group B|Group B is identified as serum vitamin D level less than 16 ng/dl and is supplemented with vitamin D3.
9925989|NCT00877422|No Intervention|Group C|Group C is identified as serum vitamin D less than 16 ng/dl and is not supplemented with vitamin D3.
9925990|NCT00877435|Experimental|1|Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
9925991|NCT00877435|Active Comparator|2|Cognitive behavioral therapy (CBT)
9862538|NCT00033345|Experimental|High-Risk Breast Cancer|All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
9862539|NCT00033358|Experimental|Arm I (medroxyprogesterone)|Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
9862540|NCT00033358|Experimental|Arm II (ethinyl estradiol, norgestrel)|Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
9862541|NCT00033397||Arm A|"Patients receive an injection of gadopentetate dimeglumine and undergo magnetic resonance imaging (MRI) of the breast before initiation, 1-3 days after initiation, and then after completion of neoadjuvant anthracycline-based chemotherapy and prior to surgery. Patients who previously received a taxane also undergo an additional contrast-enhanced MRI scan.~Mammograms and possibly ultrasounds are performed prior to and after chemotherapy (before surgery).~Patients are followed every 6 months for 5 years and then annually for up to 10 years."
9862542|NCT00033423|Experimental|Cohort 1|First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
9862543|NCT00033423|Experimental|Cohort II|Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
9862544|NCT00033423|Experimental|Cohort III|Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
9862545|NCT00033423|Experimental|Cohort IV|Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
9862546|NCT00033423|Experimental|Cohort V|MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
9862547|NCT00033449|Experimental|Treatment (gefitinib, radiation therapy, cisplatin)|See detailed description.
9862548|NCT00033462|Experimental|Arm I|Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
9862549|NCT00033553|Experimental|Paclitaxel + Carboplatin|Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
9862550|NCT00033553|Experimental|Gemcitabine + Carboplatin|Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
9862551|NCT00033592|Experimental|Arm I: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX."
9862552|NCT00033592|Experimental|Arm II: bupropion|"Participants receive oral bupropion 1-2 times daily.~Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI."
9862553|NCT00033592|Experimental|Arm III: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV."
9862554|NCT00033592|Experimental|Arm IV: bupropion|"Participants receive oral bupropion 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
9862555|NCT00033592|Placebo Comparator|Arm V: placebo|"Participants receive oral placebo 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
9862556|NCT00033592|Experimental|Arm VI: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
9862557|NCT00033592|Placebo Comparator|Arm VII: placebo inhaler|"Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
9862558|NCT00033592|Experimental|Arm VIII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
9862559|NCT00033592|Placebo Comparator|Arm IX: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
9862560|NCT00033592|Experimental|Arm X: bupropion|"Participants receive oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
9862561|NCT00033592|Placebo Comparator|Arm XI: placebo|"Participants receive oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
9862562|NCT00033592|Experimental|Arm XII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
9862563|NCT00033592|Placebo Comparator|Arm XIII: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
9925992|NCT00877474|Experimental|Arm 1|PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.
9862564|NCT00033592|Experimental|Arm XIV: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
9862565|NCT00033592|Placebo Comparator|Arm XV: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
9862566|NCT00033605|Experimental|octreotide + radiation|"Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.~Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
9862567|NCT00033605|Active Comparator|placebo + radiation|"Patients receive placebo SC on day 1 and IM on days 2 and 29. Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
10210198|NCT01860937|Experimental|Cohort 2 (Morphologic Disease)|Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion & did not experience any non-hematologic grade 4 toxicities.
9862568|NCT00033618|Experimental|Arm I (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9862569|NCT00033618|Experimental|Arm II (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862570|NCT00033696|Experimental|chemotherapy + radiation therapy|"Induction therapy: Patients receive paclitaxel IV over 3 hours on days 1 and 22, oral topotecan on days 2-4 and 23-25, and oral etoposide on days 5-7 and 26-28. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on days 8 and 29 and continuing until blood counts recover.~Consolidation therapy: Patients receive carboplatin IV over 1 hour on days 43, 64, and 85 and etoposide IV over 1 hour on days 43-45, 64-66, and 85-87. Patients undergo radiotherapy daily 5 days per week beginning on day 43 and continuing for 6-7 weeks.~Patients with rapid disease progression discontinue study therapy.~Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years."
9862571|NCT00033735|Experimental|fluorouracil|
10210199|NCT01817504|Active Comparator|Study group|The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,
10210200|NCT01817504|Other|Control group|The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis
10210201|NCT01816932|Experimental|Home Visit|20 participants will be randomized to receive a home visit for the insertion of their implantable birth control rather than the standard office visit.
10210202|NCT01816932|Placebo Comparator|Office Visit|20 participants will be randomized to receive an office visit (standard of care).
9862572|NCT00033735|Experimental|Irofulven|
9862573|NCT00033748|Experimental|Combined Monoclonal Antibody Therapy|Patients with minimal metastatic colorectal cancer are treated with 2 anti-idiotype monoclonal antibodies
10210203|NCT01783704|Experimental|PUSH and Nutrition|PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
10210204|NCT01783704|Experimental|PULSE and Nutrition|PULSE is a non-specific multi-component intervention in which participants will receive flexibility exercises, active range of motion (AROM) for the upper and lower extremities, breathing exercises, and transcutaneous electrical nerve stimulation (TENS). Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits will take place in the participant's place of residence. Participants will also receive the nutritional intervention for the duration of the 16-week study.
9862574|NCT00033865|Experimental|1|Yoga treatment for 8 weeks
9862575|NCT00033865|No Intervention|2|Sleep hygiene instructions only
9862576|NCT00034281|Experimental|TAK-165 QD|
9862577|NCT00034528|Experimental|Allogeneic stem cell transplantation|Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
9925993|NCT00877513|Experimental|Smokers|Cigarette smokers wishing to quit
9925994|NCT00877526||A|
9925995|NCT00877539|Experimental|PF-03526299|
9925996|NCT00877539|Placebo Comparator|Placebo|
9925997|NCT00877539|Active Comparator|Fluticasone propionate|
9862578|NCT00034541|Experimental|1|An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
9862579|NCT00034554|Experimental|1|0.1mg
9862580|NCT00034554|Experimental|2|0.5mg
9862581|NCT00034554|Experimental|3|2.0mg
9862582|NCT00034554|Experimental|4|4.0mg
9862583|NCT00034554|Experimental|5|8.0mg
9862584|NCT00034814|Placebo Comparator|1|Enzyme-inducing placebo TID
9862585|NCT00034814|Experimental|2|Enzyme-inducing Talampanel 35 mg TID
9862586|NCT00034814|Experimental|3|Enzyme-inducing TLP 50mg TID
9862587|NCT00034814|Placebo Comparator|4|Non-enzyme-inducing placebo TID
9862588|NCT00034814|Experimental|5|Non-enzyme-inducing TLP 25mg TID
9862589|NCT00034814|Experimental|6|Non-enzyme-inducing TLP 35mg TID
9925998|NCT00877552||Control|Typically developing
9925999|NCT00877552||Mild ventriculomegaly (MVM)|Fetal isolated mild ventriculomegaly
9926000|NCT00877552||Schizophrenia High Risk|Offspring of mothers with schizophrenia
9926001|NCT00877552||Bipolar High Risk|Offspring of mothers with schizophrenia
9926002|NCT00877578|Experimental|1|Nutri-Energie ®, a cake of high caloric density and palatability, twice a day for 4 weeks, in addition to an enriched diet.
9926003|NCT00877578|Active Comparator|2|Clinutren 1.5 ® standard isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet.
9926004|NCT00877591|Experimental|1|Buprenorphine + Fosamprenavir/Ritonavir
9926005|NCT00877591|Active Comparator|2|Control Fosamprenavir/Ritonavir
9926006|NCT00877591|Experimental|3|Buprenorphine + Darunavir/Ritonavir
9926007|NCT00877591|Active Comparator|4|Control Darunavir/Ritonavir
9926008|NCT00877591|Experimental|5|Buprenorphine + Rifampin
9926009|NCT00877591|Experimental|6|Buprenorphine + Rifabutin
9926010|NCT00877617||QOL Questionnaire|
9926011|NCT00877630||1:endoscopic group|patients underwent endoscopic thyroidectomy
9926012|NCT00877630||2:conventional group|patients underwent open thyroidectomy
9926013|NCT00877643|Experimental|Upstream rhythm control|
9926014|NCT00877643|Active Comparator|Conventional rhythm control|
9926015|NCT00877656|Experimental|CD4|Open label treatment arm
9926016|NCT00877669|Active Comparator|Transurethral resection of the prostate|TURP group
9926017|NCT00877669|Experimental|Holmium Laser Enucleation of Prostate|HoLEP group
9926018|NCT00877682|Experimental|Cryotherapy|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
9926019|NCT00877695|Experimental|Motive8 2 Change FtF|This arm of the motivational enhancement intervention (MEI) will be delivered face to face (FtF) using a real-time, dynamic implementation approach. The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
9862590|NCT00035100|Experimental|EPO906|
9862591|NCT00035126|Experimental|EPO906|
9862592|NCT00035165|Experimental|EPO906|
9862593|NCT00035243|Experimental|EPO906|
9862594|NCT00035347|Experimental|Azithromycin plus ceftriaxone group (AZY+CEF group)|IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
9862595|NCT00035347|Experimental|Levofloxacin group (LEV group)|IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.
9862596|NCT00035425|Experimental|A.|Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
9862597|NCT00035425|Experimental|B.|
9862598|NCT00035451|Placebo Comparator|1|placebo tablets
9862599|NCT00035451|Active Comparator|2|Sotalol
9862600|NCT00035451|Experimental|3|azimilide
9862601|NCT00035464|Placebo Comparator|1|Placebo tablets
9862602|NCT00035464|Experimental|2|125 mg azimilide tablets
9862603|NCT00035477|Placebo Comparator|1|placebo tablets in hospital and placebo tablets outpatient
9862604|NCT00035477|Experimental|2|Azimilide tablets in hospital and azimilide tablets outpatient
9862605|NCT00035490|Placebo Comparator|1|Placebo tablets
9862606|NCT00035490|Experimental|2|75 mg azimilide
9862607|NCT00035490|Experimental|3|125 mg azimilide
9862608|NCT00035581|Experimental|Ampligen|Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks
9862609|NCT00035581|No Intervention|No Ampligen|No Ampligen administered for first 24 weeks
9862610|NCT00035594|Placebo Comparator|Placebo|Breast cancer patients receiving docetaxel chemotherapy and placebo.
9862611|NCT00035594|Experimental|Pegfilgrastim|Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
9862612|NCT00035607|Active Comparator|Darbepoetin alfa SC|
9862613|NCT00035607|Experimental|Darbepoetin alfa IV|
9862614|NCT00035620|Active Comparator|Filgrastim|Filgrastim
9862615|NCT00035620|Experimental|Pegfilgrastim|Pegfilgrastim
9862616|NCT00035802|Experimental|001|"Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
9862617|NCT00035802|Placebo Comparator|002|Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
9862618|NCT00035893|Experimental|Ampligen|Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
9862619|NCT00035893|No Intervention|No Ampligen|No Ampligen administered for first 64 weeks
9862620|NCT00035984|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
9862621|NCT00035984|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
9862622|NCT00035984|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
9862623|NCT00035984|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
9862624|NCT00036296|Experimental|1|75mg per day (in 3 doses) Talampanel for 22 days
9862625|NCT00036296|Placebo Comparator|2|3 doses a day for 22 days
9926020|NCT00877695|Experimental|Motive8 2Change -Internet|This arm of the motivational enhancement intervention (MEI) will be delivered via the Internet face to face (FtF) using a real-time, dynamic implementation approach.The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
9926021|NCT00877695|No Intervention|delayed|
9926022|NCT00877695|Active Comparator|Motiv8 2Change Careers|Comparable in number of sessions and duration to the experimental arms, but focused on resume development and interviewing skills. This arm consisted of 2 sessions. In the first session participants reviewed different career choices and created a winning resume. The second session focused on job interviewing skills. It included role plays with feedback. It also contains ethically mandated information regarding HIV prevention. It was delivered on line by a trained facilitator.
9926023|NCT00877721|Experimental|balance treatment|
9926024|NCT00877734|Experimental|1|Baclofen
9926025|NCT00877734|Placebo Comparator|2|Placebo
9926026|NCT00877747||PET2 negative|Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD
9926027|NCT00877747||PET2 positive|Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP
9926028|NCT00877760|Experimental|ETV + pegIFN|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
9926029|NCT00877760|Active Comparator|ETV|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
9862626|NCT00036491|Experimental|rituximab|375 mg/m^2 administered intravenously
9862627|NCT00036634|Active Comparator|Tenofovir DF|Participants received tenofovir DF 300 mg for 14 days
9862628|NCT00036634|Experimental|Tenofovir alafenamide 50 mg|Participants received tenofovir alafenamide 50 mg for 14 days
9862629|NCT00036634|Experimental|Tenofovir alafenamide 150 mg|Participants received tenofovir alafenamide 150 mg for 14 days
9862630|NCT00036686|Experimental|Soy protein isolate|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
9862631|NCT00036686|Placebo Comparator|Placebo|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral placebo twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
9862632|NCT00036751|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
9862633|NCT00036764|Experimental|Treatment|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862634|NCT00036777|Experimental|Treatment (carboplatin, 7-hydroxystaurosporine)|"Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9862635|NCT00036855|Experimental|Group A (no planned PBSC support)|"Patients receive rituximab IV over 4-6 hours followed by IDEC-In2B8 IV over 10 minutes on day 0 and undergo whole body imaging. Patients may then receive rituximab IV over 4-6 hours followed by IDEC-Y2B8 IV over 10 minutes on day 7.~Some patients receive autologous PBSC IV over 30-60 minutes on day 35."
9862636|NCT00036855|Experimental|Group B (planned PBSC support)|Patients receive rituximab, IDEC-In2B8, and IDEC-Y2B8 as in group A. Patients also receive autologous PBSC IV over 30-60 minutes on day 21 and G-CSF subcutaneously beginning on day 22 and continuing until blood counts recover or day 35.
9862637|NCT00036868|Experimental|CMF + Herceptin|
9862638|NCT00036881|Experimental|zinc sulfate|"Patients receive oral zinc sulfate 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
9862639|NCT00036881|Placebo Comparator|placebo|"Patients receive oral placebo 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
9862640|NCT00036933|Experimental|vaccine|"Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50.~Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression."
9862641|NCT00037440||BHS Whites|Whites from Bogalusa, Louisiana; initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
9862642|NCT00037440||BHS African Americans|African Americans from Bogalusa, Louisiana, initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
9862643|NCT00037609|Experimental|Capecitabine + Exisulind|Capecitabine 1000 mg/m^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
9862644|NCT00037635|Experimental|AMG 073|
9862645|NCT00037635|Placebo Comparator|placebo|
9862646|NCT00037648|Placebo Comparator|placebo|
9862647|NCT00037648|Experimental|anakinra|
9862648|NCT00037713|No Intervention|1|Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease.
9862649|NCT00037713|Experimental|2|"Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur:~intolerable toxicity precluding further treatment progression of disease~patient refusal~occurrence of pregnancy"
9862650|NCT00037752|Active Comparator|1|Sibutramine plus a behavioral smoking cessation program
9926030|NCT00877786|Active Comparator|Face-to-face group therapy|
9862651|NCT00037752|Active Comparator|2|Placebo sibutramine plus a behavioral smoking cessation program
9926031|NCT00877786|Active Comparator|Online chat group therapy|
9926032|NCT00877812|Experimental|Arm 1 glycine and leucine infusion|Determine in healthy, adequately pyridoxine nourished humans using a protocol based on amino acid glycine tracer methods: (a) the postprandial rates of in vivo glycine turnover, glycine-based generation of one-carbon units, thymidylate and purine synthesis, and the impact of vitamin B6 deficiency on the rates of these processes and (b) the effect of vitamin B6 deficiency on the postprandial rate of glutathione synthesis. 14 subjects will be chosen after screening is complete and will begin a B6 deficient diet for 30 days. At the beginning and end of the 30 days they will receive an infusion of leucine and glycine then they will begin the four week diet. At the end of four weeks the infusion will be repeated.
9926033|NCT00877812|Experimental|Arm 2 Intervention of Serine and methionine infusion|This arm will allow investigation of total Hcy remethylation and remethylation from serine-derived 1C units, kinetics of serine and the methionine cycle and kinetics of transsulfuration reactions. 14 healthy subjects will be selected and screened. Prior to starting a B6 deficient diet for four weeks an infusion of serine and methionine will commence. Following the first infusion the diet will begin and after four weeks another infusion will be done.
9926034|NCT00877851|Experimental|1 CD-ROM|Use of CD-ROM for 12 weeks
9926035|NCT00877851|No Intervention|2 Control|Usual care and list of useful websites
9926036|NCT00877864|Active Comparator|High volume combined aerobic/resistance exercise|
9926037|NCT00877864|Active Comparator|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
9926038|NCT00877864|Active Comparator|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
9926039|NCT00877864|Active Comparator|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
9926040|NCT00877864|Active Comparator|Printed PA information, pedometers and step log group|Printed physical activity information, pedometers and step log group
9926041|NCT00877864|Placebo Comparator|Control|
9926042|NCT00877942||1|Typically developing children drawn from the general population
9926043|NCT00877942||2|Children with Turner Syndrome
9926044|NCT00877955|Active Comparator|alprazolam sublingual tablet reference|
9926045|NCT00877955|Experimental|alprazolam sublingual tablet test|
9935227|NCT04012164|Experimental|Microbiological, anthropological and historical study|"30 adult participants will be recruited to self-report daily activities and contacts with domesticated and wild animals for a five month period. Following the five months of data collection, we will collect 5ml blood and 2g stool from each participant.~From the fifth month of investigation, an additional 30 adult participants will participate in oral anthropological, historical interviews to develop the socio-historical context of their changing activities and relations with selected domesticated and wild animals. No other intervention will be performed."
9935228|NCT04009824|Placebo Comparator|Group 1: Saline Placebo|Participants received placebo on days 1 and 22 by subcutaneous injection
9935229|NCT04009824|Experimental|Group 2: AGS-v PLUS Non-Adjuvanted|Participants received 1012 µg of unadjuvanted AGS-v PLUS vaccine on days 1 and 22 by subcutaneous injection
9935230|NCT04009824|Experimental|Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo|Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection
9935231|NCT04009824|Experimental|Group 4: AGS-v PLUS + Montanide ISA-51|Participants received 1012 µg of AGS-v PLUS + Montanide ISA-51 on days 1 and 22 by subcutaneous injection
9862652|NCT00037817|Experimental|1|Dose escalation cohort
9862653|NCT00037817|Experimental|2|Molecular response cohort
9862654|NCT00037817|Experimental|3|Celecoxib combination cohort at MTD
9862655|NCT00037869|Experimental|MIBG|High Dose I-131 Metaiodobenzylguanidine
10210205|NCT01754779|Placebo Comparator|Calcium Phosphate stone formers without hypercalciuria|Each subject will undergo 3 phases, the order of which will be randomized by a simple randomization scheme. The 3 phases will be Placebo, Citric Acid, and Potassium Citrate. Each phase will be 1 week in duration, during which subjects will take assigned study medications. A 1-week washout period is imposed between phases.
9862656|NCT00037882|Experimental|SCH 54031|Peg Interferon Alpha-2B/PEG-Intron
9862657|NCT00037921|Other|1|
9862658|NCT00037934|Experimental|1|Robot exercise group
9862659|NCT00037934|Active Comparator|2|Traditional exercise group
9862660|NCT00037973|Experimental|1|Ventilation-feedback plus exercise
9862661|NCT00037973|Active Comparator|2|Exercise
9862662|NCT00037973|Active Comparator|3|ventilation feedback only
9862663|NCT00037986|Other|1|
9862664|NCT00038012|Experimental|rhTPO-Derived Autologous Platelets Transfusion|
9862665|NCT00038025|Experimental|Deoxycoformycin (DCF)/Pentostatin|
10210206|NCT01754779|Placebo Comparator|Calcium Phosphate stone formers with hypercalciuria|Each hypercalciuric CaP stone former will undergo 3 phases, the order of which will be randomized by a simple randomization scheme.
10210207|NCT01754610||Families participating in SFCR|Families who have experienced multiple traumas and high stress related to poverty
10210208|NCT01752491|Experimental|15g Ascorbate|"During radiation therapy:~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.~Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
9862666|NCT00038038|Experimental|PET + 18F-fluoromisonidazole|
9862667|NCT00038051|Experimental|HuM195/rGel|HuM195/rGel starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
9862668|NCT00038064|Active Comparator|rHuEPO|
9862669|NCT00038064|Experimental|Darbepoetin alfa|
9862670|NCT00038090|Experimental|Thalidomide + Dexamethasone|
9862671|NCT00038116|Active Comparator|embryonic dopamine cell implant surgery|embryonic dopamine cell implant surgery
9862672|NCT00038116|Placebo Comparator|sham surgery|sham surgery (placebo)
9862673|NCT00038129|Experimental|1|Participants will receive reaming of the intramedullary canal prior to insertion of an intramedullary nail.
9862674|NCT00038129|Experimental|2|Participants will receive insertion of an intramedullary nail without prior reaming of the intramedullary canal.
9862675|NCT00038155|Other|1|
9862676|NCT00038168|Experimental|Estramustine + Taxol|
9862677|NCT00038194|Experimental|Imatinib + Docetaxel|
9862678|NCT00038207|Experimental|Liposomal Vincristine|
9862679|NCT00038233|Experimental|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
9862680|NCT00038246|Experimental|Thalidomide, Taxol, Estramustine|Thalidomide starting dose 200 mg by mouth every day once a week; Taxol 100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10; Estramustine 140 mg by mouth three times a day on Days 1-5, 8-12.
10210209|NCT01752491|Experimental|25g Ascorbate|"If the 15g arm is tolerated, the study opens the 25g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
10210210|NCT01752491|Experimental|50g arm|"If the 25g arm is tolerated, the study opens the 50g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
9862681|NCT00038298|Experimental|50 mg|50 mg 3 times weekly
9862682|NCT00038298|Experimental|400 mg|400 mg 3 times weekly
9862683|NCT00038298|Experimental|200 mg|200 mg 3 times weekly
9862684|NCT00038298|Placebo Comparator|Placebo|Placebo comparator associated with each active arm. (3:1 active vs placebo)
9862685|NCT00038350|Experimental|1|8 week lingual strengthening exercise protocol
9862686|NCT00038376|Experimental|1|Alpha-interferon + Isotretinoin
9862687|NCT00038389|Experimental|Vioxx MTD|
9926046|NCT00877968|Placebo Comparator|Whole wheat banana bread|Banana bread made with whole wheat flour
9926047|NCT00877968|Active Comparator|Whole pea flour banana bread|Banana bread made with whole pea flour
9926048|NCT00877968|Placebo Comparator|Whole wheat biscotti|Biscotti made with whole wheat flour
9862688|NCT00038402|Experimental|Herceptin + Taxol Followed by FEC|Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m^2 IV on Day 1; Epirubicin 75 mg/m^2 IV on Day 1. Four 21-day cycles.
9862689|NCT00038415|Experimental|Vaccine|
9862690|NCT00038441|Experimental|DTI-015|
9862691|NCT00038558|Experimental|Filgrastim + ABVD Chemotherapy|
9862692|NCT00038571|Experimental|Arm A (mantle-cell lymphoma)|
9862693|NCT00038571|Experimental|Arm B (other B-cell lymphomas)|
9862694|NCT00038623|Experimental|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion (250 mg/m^2 intravenous) on Day 1, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
9862695|NCT00038701|Experimental|Gemzar Chemoradiation + TNP-470|
9862696|NCT00038766|Experimental|Semapimod 60 mg|Semapimod 60 mg IV x 5 days
9862697|NCT00038766|Experimental|Semapimod IV 30 mg|Semapimod IV 30 mg x 5 days
9862698|NCT00038766|Placebo Comparator|Placebo|Placebo IV x 3 or 5 days
9862699|NCT00038779|Experimental|Megadose T cell depleted|
9862700|NCT00038792|Experimental|aGvHD|
9862701|NCT00038805|Experimental|Mylotarg|
9862702|NCT00038818|Experimental|CD8 DLI|CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)
9862703|NCT00038831|Experimental|Chemotherapy + ATG + Stem Cell Infusion|
9862704|NCT00038844|Experimental|Campath in Nonmyeloablative Transplantation|Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.
9862705|NCT00038870|Experimental|Dendritic Cell Activated Lymphocytes|
9862706|NCT00038883|Experimental|Campath-1H|10 mg/day x 5
9862707|NCT00038961|Placebo Comparator|Placebo + intermittent pneumatic compression (IPC)|
9862708|NCT00038961|Experimental|fondaparinux + intermittent pneumatic compression (IPC)|
9862709|NCT00038974|Experimental|Interferon and rivavirin|All patients received peginterferon alfa-2a in a dose of 180 μg weekly and ribavirin in a dose of 1000 (for patients with a body weight of ⩽75 kg) or 1200 mg (for those with a body weight of >75 kg) daily.
9862710|NCT00039013|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
9862711|NCT00039013|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
9862712|NCT00039013|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
9862713|NCT00039013|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
9862714|NCT00039026|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
9862715|NCT00039026|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
9862716|NCT00039026|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
9862717|NCT00039026|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL
9862718|NCT00039091|Experimental|Treatment (ipilimumab)|Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.
9862719|NCT00039104|Experimental|Arm I (rebimastat, zoledronic acid)|Patients receive zoledronate IV over at least 15 minutes on day 1 and oral BMS-275291 daily on days 1-28.
9862720|NCT00039104|Experimental|Arm II (zoledronic acid)|Patients receive zoledronate as in Arm I.
9862721|NCT00039117|Experimental|Arm I|"INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.~Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course."
9862722|NCT00039182|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862723|NCT00039286|Experimental|Positron Emission Tomography|Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
9862724|NCT00039325|Experimental|Group A - first dose for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
9862725|NCT00039325|Experimental|Arm B - dose increase for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
10210211|NCT01752491|Experimental|62.5g|"If the 50g arm is tolerated, the study opens the 62.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
9862726|NCT00039325|Experimental|Arm C - A*0201+/DR*04+ subjects - Phase II|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
9862727|NCT00039325|Experimental|Arm D - A*0201+/DR*04- - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
9862728|NCT00039325|Experimental|Arm E - A*0201-/DR*04+ - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
9862729|NCT00039338|Experimental|Chemotherapy followed by surgery|neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)
9862730|NCT00039338|Active Comparator|Radio-chemotherapy|Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)
9926049|NCT00877968|Active Comparator|Whole pea biscotti|Biscotti made with whole pea flour
9926050|NCT00877968|Placebo Comparator|Whole wheat pasta|Pasta made with whole wheat durum
9926051|NCT00877968|Active Comparator|Whole pea flour|Pasta made with 30% whole pea flour and 70% white wheat durum
9926052|NCT00877968|Placebo Comparator|White bread|
9926053|NCT00877968|Placebo Comparator|Boiled yellow peas|
9926054|NCT00877981|Active Comparator|Videoassited surgery|"In patients randomized to a video-assisted approach, the surgeon has the option to choose either the lateral- (VAPLA) or medial (MIVAP) techniques, both initiated with a 15 mm transverse skin incision. The lateral approach is performed as described by Henry.~The medial approach is performed using the gasless procedure developed by Miccoli."
9926055|NCT00877981|Active Comparator|Open surgery|Open surgery, a 15 mm transverse skin incision is made close to the site of the parathyroid adenoma indicated by sestamibi scintigraphy.
9926056|NCT00877994|Active Comparator|Immediate|This group will receive the nurture group therapy immediately after enrolling in the study.
9926057|NCT00877994|Active Comparator|Delayed|This group will receive the nurture group therapy 16 weeks after enrolling in the study.
9926058|NCT00878007|Experimental|1|"Intermittent screening and treatment (IST) for malaria.~This intervention is a change from a previous intervention based on intermittent preventive treatment for malaria owning to the withdrawal of amodiaquine (one of the previous IPT drugs) in Kenya in 2009."
9926059|NCT00878007|Experimental|2|Enhanced teacher training on literacy instruction.
9926060|NCT00878007|Experimental|3|Intermittent screening and treatment (IST) for malaria and enhanced teacher training on literacy instruction
9926061|NCT00878007|No Intervention|4|
9926062|NCT00878020|Active Comparator|Arm 1|BMS-830216 (10 mg)
9926063|NCT00878020|Active Comparator|Arm 2|BMS-830216 (30 mg)
9926064|NCT00878020|Active Comparator|Arm 3|BMS-830216 (100 mg)
9926065|NCT00878020|Active Comparator|Arm 4|BMS-830216 (300 mg)
9926066|NCT00878020|Active Comparator|Arm 5|BMS-830216 (600 mg)
9926067|NCT00878020|Active Comparator|Arm 6|BMS-830216 (1200 mg)
9926068|NCT00878033||1|Diabetic Dialysis Patients
9926069|NCT00878033||2|Non-Diabetic Dialysis Patients
9926070|NCT00878033||3|Healthy Controls
9926071|NCT00878046|Experimental|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
9926072|NCT00878059||Proxies|A family member-caregiver (the medical decision-maker) for someone with Alzheimer's Disease. Must be the person who would be able to make decisions for someone with Alzheimer's disease about being in medical research.
9926073|NCT00878085|Experimental|1|Robot Therapy with activities of daily living (ADLs)
9926074|NCT00878085|Active Comparator|2|Standard Occupational Therapy
9926075|NCT00878111|Experimental|A: escalating dose levels of NGR-hTNF|NGR-hTNF administered at high doses
9926076|NCT00878124|Experimental|CoQ10|Coenzyme Q10 co-treatment
9926077|NCT00878124|Placebo Comparator|Placebo control|Placebo Co-treatment
9926078|NCT00878137||APLA|Patients with antiphospholipid antibody syndrome.
9926079|NCT00878137||Control|Patients on warfarin therapy but without antiphosphilipid antibody syndrome.
9926080|NCT00878150|Experimental|Telephone-based CBT|- 12 counseling sessions over 16 weeks over the telephone
9926081|NCT00878150|Experimental|In-person CBT|- 12 counseling sessions over 16 weeks at either Harborview Medical Center or the University of Washington Medical Center in Seattle, WA
9926082|NCT00878150|No Intervention|3: Usual care|- No counseling sessions as part of this study, however you are free to pursue regular medical care and counseling outside of this study
9926083|NCT00878176|Experimental|1|(Crossover study)
9926084|NCT00878202|No Intervention|Control|Optimal medical treatment of Heart failure and therapeutic education
9926085|NCT00878202|Experimental|Telemedicine|Optimal medical treatment of heart failure disease and therapeutic education
9926086|NCT00878254|Experimental|R-MACLO/IVAM|"Four 21-day cycles, followed by Maintenance Therapy as follows:~Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol.~Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol.~Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol."
9926087|NCT00878267||Interview|
9926088|NCT00878280||1|1:control(healthy subjects)
9926089|NCT00878280||2|2:case(dementia patients)
9926090|NCT00878293|Experimental|A|Dose 1, 40 µg
9926091|NCT00878293|Experimental|B|Dose 2, 120 µg
9926092|NCT00878293|Experimental|C|Dose 3
9926093|NCT00878293|Experimental|D|Dose 4
9926094|NCT00878293|Experimental|E|Dose 5
9926095|NCT00878293|Experimental|F|Dose 6
9862731|NCT00039390|Experimental|Treatment (capecitabine, gefitinib)|Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
9862732|NCT00039403|Experimental|Treatment (UCN-01, gemcitabine hydrochloride)|"Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose."
9862733|NCT00039416|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
9862734|NCT00039442|Experimental|Treatment|Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9862735|NCT00039455|Experimental|Treatment (trastuzumab and alvocidib)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9862736|NCT00039481|Experimental|Treatment (Oblimersen sodium, cytotoxic chemotherapy)|See detailed description.
9862737|NCT00039494|Experimental|Treatment (erlotinib hydrochloride, radiation, temozolomide)|Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9862738|NCT00039559|Other|Early detection|
9862739|NCT00039624|Experimental|Brachy|brachytherapy
9862740|NCT00039780|Active Comparator|1|Tavocept (BNP7787)
9862741|NCT00039780|Placebo Comparator|2|0.9% Sodium Chloride Soln.
9862742|NCT00039832|Experimental|1|CT
9862743|NCT00039832|Experimental|2|MRI
9862744|NCT00039988|Experimental|1|Participants will receive Copaxone and albuterol placebo
9862745|NCT00039988|Experimental|2|Participants will receive Copaxone and albuterol
9862746|NCT00040105|Experimental|Zarnestra + Gleevec|
9862747|NCT00040326|Active Comparator|1|anteromesial temporal resection
9862748|NCT00040326|Active Comparator|2|antiepileptic drugs
9862749|NCT00040378||Combination therapy|vitamin E (alphatocopherol) and selenium
9862750|NCT00040378||Vitamin E only|vitamine E (alphatocopherol) and placebo
9862751|NCT00040378||Selenium only|selenium and placebo (Placebo replacement for vitamin E)
9862752|NCT00040378||Placebo|placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
9862753|NCT00040456|Placebo Comparator|Placebo|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
9862754|NCT00040456|Active Comparator|MG Pidolate Administration|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
9862755|NCT00040755|Experimental|Arm I (rebimastat once daily)|Patients receive oral BMS-275291 once daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
9862756|NCT00040755|Experimental|Arm II (rebimastat twice daily)|Patients receive oral BMS-275291 twice daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
9862757|NCT00040768|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who received prior bortezomib and achieved at least a partial response of at least 6 months duration may also receive therapy as above.
9862758|NCT00040781|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
9862759|NCT00040794|Experimental|Stratum I (gefitinib, radiotherapy)|"Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
9862760|NCT00040794|Experimental|Stratum II (gefitinib, radiotherapy, chemotherapy)|"Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
9862761|NCT00040859|Experimental|oxaliplatin + capecitabine|"Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).~Patients are followed every 3 months for 1 year and then every 6 months for 2 years."
9862762|NCT00040885|Experimental|infliximab + docetaxel|"Patients receive infliximab IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses and docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
9862763|NCT00040885|Active Comparator|placebo + docetaxel|"Patients receive docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course. Patients receive placebo IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
9862764|NCT00040911|Experimental|Arm I (alternative medicine procedure)|Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
9862765|NCT00040911|Sham Comparator|Arm II (alternative medicine procedure)|Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I.
9862766|NCT00041015|Active Comparator|oral topotecan plus cisplatin IV|oral topotecan once daily on days 1-5 and cisplatin IV on day 5
9862767|NCT00041015|Experimental|Cisplatin IV plus etoposide IV|Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
9862768|NCT00041041|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9926096|NCT00878293|Experimental|G|Dose 7
9926097|NCT00878293|Active Comparator|H|Morphin
9926098|NCT00878293|Placebo Comparator|I|Placebo
9926099|NCT00878306|Active Comparator|Disulfiram|Disulfiram
9926100|NCT00878306|Experimental|Disulfiram + Efavirenz|Efavirenz alone, then in addition with Disulfiram
9926101|NCT00878306|Experimental|Disulfiram + Atazanavir|Atazanavir alone, then in addition with Disulfiram
9926102|NCT00878306|Experimental|Disulfiram + Ritonavir|Ritonavir alone, then in addition with Disulfiram
9926103|NCT00878319|Active Comparator|Surgical|Surgical intervention: open reduction and internal fixation (ORIF)
9926104|NCT00878319|Active Comparator|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
9926105|NCT00878332||partially edentulous patients|"Adult (post growth period) patients who are interested in fixed dental rehabilitation (non- removable denture) by dental implants.~Partially edentulous patients with insufficient bone height for dental implant insertion."
9926106|NCT00878345|Active Comparator|1|Dexmedetomidine sedation protocol
9862769|NCT00041054|Experimental|carboplatin + etoposide + exisulind|"Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 30-60 minutes on days 1-3. Patients also receive oral exisulind twice daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year and then every 4 months for 2 years."
9862770|NCT00041093|Experimental|Treatment (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9862771|NCT00041106|Experimental|Treatment (gemcitabine, cisplatin, and gefitinib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Patients also receive gefitinib PO QD beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete remission, partial remission, or maintain stable disease continue gefitinib PO QD for 5 years or until disease progression or unacceptable toxicity occurs.
9862772|NCT00041171|Experimental|Arm 1: placebo + docetaxel|"Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
9862773|NCT00041171|Experimental|Arm 2: Hypericum perforatum + docetaxel|"Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
9862774|NCT00041171|Experimental|Arm 3: Hypericum perforatum + docetaxel|"Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
9862775|NCT00041197|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
9862776|NCT00041197|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
9862777|NCT00041301||QoL in prostate cancer|The study sample will be composed of a consecutive series of prostate cancer patients, stratified by stage of disease, local and locally advanced versus advanced (metastatic) disease, and undergoing active anti-tumor therapy. In order to increase sample homogeneity, and to facilitate evaluation of the responsiveness of the quality of life instruments to changes in patients' health status and symptoms experience over time, the subsample of patients with local or locally advanced disease will be restricted to those undergoing surgery (radical prostatectomy) or radiation therapy, and the subsample of metastatic disease patients will be limited to those receiving hormonal therapy.
9862778|NCT00041340|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better continue therapy until disease progression or 1 year after complete response.
9862779|NCT00041457||Physicians' Health Study I|
9862780|NCT00041457||Physicians' Health Study II|
9862781|NCT00041457||Women's Health Study|
9862782|NCT00041457||Women's Antioxidant Cardiovascular Health Study|
9862783|NCT00041483|Active Comparator|Anecortave and Sham PDT|
9862784|NCT00041483|Active Comparator|PDT and Sham Anecortave Acetate|
9862785|NCT00041496|Experimental|Arm 1|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo
9862786|NCT00041496|Placebo Comparator|Arm 2|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo
9862787|NCT00041509|Experimental|SB424323, 500 mg BID|
9862788|NCT00041509|Experimental|SB424323, 125 mg BID|
9862789|NCT00041509|Placebo Comparator|Placebo|
9862790|NCT00041548|Experimental|1|Nitric Oxide for Inhalation
9862791|NCT00041548|Placebo Comparator|2|oxygen
9862792|NCT00041561|Placebo Comparator|2|Nitrogen gas
9862793|NCT00041561|Experimental|1|Inhaled Nitric Oxide
10210212|NCT01752491|Experimental|75g Ascorbate|"If the 62.5g arm is tolerated, the study opens the 75g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
10210213|NCT01752491|Experimental|87.5g Ascorbate|"If the 75g arm is tolerated, the study opens the 87.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
10210214|NCT01736059|Experimental|Stem cell treated|
10210215|NCT01735955|Experimental|AMN107 (nilotinib)|AMN107
9862794|NCT00041574|Experimental|1|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
9862795|NCT00041782|Experimental|Dalteparin|
9862796|NCT00041951||CAE participants|Both parents and a child with CAE of families without other affected members (trios) or whole families with many members affected with epilepsy.
9862797|NCT00041951||Controls|Healthy individuals without epilepsy and no family history of epilepsy.
9862798|NCT00042185|Experimental|Dissonance intervention|
9862799|NCT00042185|Active Comparator|Healthy Weight Intervention|
9862800|NCT00042185|Active Comparator|Expressive writing control intervention|
9862801|NCT00042185|No Intervention|Assessment-only control condition|
9862802|NCT00042198|Experimental|1|Cognitive Behavior Therapy. The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist. Treatment consisted of up to 12 weekly, hour-long sessions.
9862803|NCT00042198|Active Comparator|2|Supportive Stress Management. The treatment modality was individual, face-to-face therapy with an experienced psychotherapist. Treatment consisted of up to 12 weekly, hour-long sessions.
9862804|NCT00042198|No Intervention|3|Usual Care, minimally enhanced. Participants in all three arms were given information about depression. There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed. Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
9862805|NCT00042211|Experimental|1|Problem Solving Treatment
9862806|NCT00042211|Active Comparator|2|Control
9862807|NCT00042289||Women taking ARVs without TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving one or more of the following ARV drugs/drug combinations but not receiving TB treatment: atazanavir/cobicistat, darunavir/ritonavir, darunavir/cobicistat, etravirine, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF/cobicistat, TAF/ritonavir, efavirenz, or lopinavir/ritonavir.~Note: As of February 2016, the study will no longer enroll women receiving etravirine or increased dose lopinavir/ritonavir."
9862808|NCT00042289||Women taking ARVs with TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving efavirenz, lopinavir/ritonavir, or nevirapine and TB treatment with at least one of the following TB drugs at study entry: rifampicin, ethambutol, isoniazid, or pyrazinamide.~Note: As of February 2016, the study will no longer enroll women receiving nevirapine."
9862809|NCT00042289||Women taking no ARVs with TB treatment|HIV-uninfected pregnant women will be assigned to this arm if receiving at least two of the following first-line TB drugs at study entry: ethambutol, isoniazid, pyrazinamide, or rifampicin.
9862810|NCT00042289||Women with/without ARVs w/TB treatment for drug-resistant TB|HIV-infected and HIV-uninfected pregnant women with or without ARVs will be assigned to this arm if receiving at least two of the following second-line TB drugs at study entry: kanamycin, amikacin, capreomycin, moxifloxacin, levofloxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose isoniazid (INH), bedaquiline, clofazamine, delamanid, linezolid, or pretomanid.
9862811|NCT00042289||Women taking ARVs with postpartum hormonal contraceptives|"HIV-infected women 2-12 weeks postpartum will be assigned to this arm if receiving one of the following ARV drug combinations and starting postpartum contraceptives: atazanavir/ritonavir/tenofovir, darunavir/cobicistat, atazanavir/cobicistat, or efavirenz AND starting combined oral contraceptives formulated with ethinyl estradiol; or atazanavir/ritonavir/tenofovir, efavirenz, atazanavir/cobicistat, or darunavir/cobicistat AND starting etonogestrel implant.~Note: As of February 2016, the study will no longer enroll women receiving atazanavir/ritonavir/tenofovir or efavirenz AND starting etonogestrel implant."
9862812|NCT00042406|Placebo Comparator|Placebo|
9862813|NCT00042406|Experimental|HuMax-CD4 80 mg|80 mg
9862814|NCT00042406|Experimental|HuMax-CD4 160 mg|160 mg
9862815|NCT00042458|Placebo Comparator|Placebo|Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
9862816|NCT00042458|Active Comparator|Pramlintide Acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
9862817|NCT00042471|Experimental|Pramlintide acetate (AC137) injection|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
9862818|NCT00042510|Experimental|Treatment Group|500µg G17DT administered on Weeks 1, 5 and 9 and an additional treatment at Week 25. Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m^2. 5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m^2/d.
9926107|NCT00878345|Active Comparator|2|Pentobarbital sedation protocol
9926108|NCT00878358|Active Comparator|Physiotherapy|
9926109|NCT00878358|Experimental|Hydrotherapy|
9926110|NCT00878371|Other|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
9926111|NCT00878384|Active Comparator|Rate control|Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
9926112|NCT00878384|Active Comparator|Catheter Ablation|Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.
9926113|NCT00878397|Experimental|1|Free distribution of long lasting insecticide nets to school children and their younger siblings
9862819|NCT00042601|Placebo Comparator|Placebo|A clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted.
9862820|NCT00042601|Active Comparator|Pramlintide|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. It consists of pramlintide (AC137) 0.6 mg/mL in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative.
9862821|NCT00042653|Experimental|AMG 073|AMG 073
9862822|NCT00042653|Placebo Comparator|Placebo|Placebo
9862823|NCT00042731|Active Comparator|Oral isoflavones with multivitamin|Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
9862824|NCT00042731|Active Comparator|Oral lycopene with multivitamin|Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
9862825|NCT00042731|Active Comparator|Multiple vitamin alone|Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
9862826|NCT00042770|Active Comparator|Arm I|Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed.
10210216|NCT01712659|Experimental|1- CLOSED|Ruxolitinib 20mg orally twice daily for 28 days. Patient may continue to receive treatment until PD.
10210217|NCT01712659|Experimental|2- Dose Escalation|Ruxolitinib 30-50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Patients may continue to receive treatment until PD or unacceptable toxicity.
10210218|NCT01712659|Experimental|3- Dose Expansion|Ruxolitinib at the MTD orally twice daily for 28 days. Patients may continue to receive treatment until PD or unacceptable toxicity.
10210219|NCT01665144|Experimental|Siponimod (BAF312)|Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.
9862827|NCT00042770|Experimental|Arm II|Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed.
10210220|NCT01665144|Placebo Comparator|Placebo|Matching placebo to BAF312 was administered orally during the Core Part of the trial. Following the Core Part, eligible participants enter the Extension Part during which all receive open-label BAF312.
10210221|NCT01578954|Experimental|Drug|Lenalidomide (25, 35, or 50 mg induction/10mg maintenance)
10210222|NCT01558544|Other|Use of high dose chemotherapy|Use of chemotherapy without removal of the disease ovary.
9862828|NCT00042796|Experimental|Treatment (decitabine)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
9862829|NCT00042809|Experimental|Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)|See detailed description.
9926114|NCT00878397|Experimental|2|No school-based delivery of long lasting insecticide nets in the first year, followed by free delivery in the second year
9926115|NCT00878449|Experimental|ABT-263 + etoposide/cisplatin|
10210223|NCT01511328|Experimental|HPV testing|Women randomised to this arm get primary HPV testing
10210224|NCT01511328|No Intervention|cytology|women included follow the standard procedure with primary cytology
10210225|NCT01459497|Active Comparator|Radiation Therapy|Arm A:Image-Guided Radiation Therapy (IGRT), 60 Gy in 15 fractions in 3 weeks
10210226|NCT01459497|Active Comparator|Conventional Radiation|Arm B: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
10210227|NCT01307787|Experimental|fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
10210228|NCT01307787|Other|waiting list control group|The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.
10210229|NCT01250912|Experimental|Imaging Tracer|No arms, the Radio tracer will be used in all subjects imaging tests.
10210230|NCT01218555|Experimental|Lenalidomide combination with everolimus|Non-randomized study of escalating doses of daily, orally administered lenalidomide in combination with standard doses of everolimus, an orally available mammalian target of rapamycin (mTOR) inhibitor.
10210231|NCT01161394|Experimental|Pioglitazone 15mg|8 patient will receive this drug
10210232|NCT01161394|Experimental|pioglitazone 30mg|8 patients will get this drug
10210233|NCT01161394|Placebo Comparator|Placebo|8 patient will get this drug
10210234|NCT01141712|Other|Autologous transplant|Patients will receive BCNU 300 mg/m^2 Day -6, Etoposide 100 mg/m^2 BID Days -5 to -2, Cytarabine 100 mg/m^2 BID Days -5 to -2, and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
10210235|NCT01111305|Active Comparator|Reslizumab + DEC|Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
10210236|NCT01111305|Placebo Comparator|Placebo + DEC|Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
10210237|NCT00921856|No Intervention|CAD|Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.
10210238|NCT00921856|Experimental|No-CAD|Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.
10210239|NCT00867464||Observational (long term follow-up)|Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
10210240|NCT00798265|Experimental|1|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
9862830|NCT00042835|Experimental|Group I (cisplatin, etoposide, erlotinib, and docetaxel)|Patients receive cisplatin IV over 2 hours on days 1, 8, 29, and 36; etoposide IV over 1 hour on days 1-5 and 29-33; and oral erlotinib once daily on days 1-49. Patients undergo concurrent radiotherapy 5 days a week for 7 weeks beginning on day 1. Patients receive consolidation therapy comprising docetaxel IV over 1 hour on days 50, 71, and 92. Some patients may also receive oral erlotinib once daily on days 50-112.
9862831|NCT00042835|Experimental|Group II (paclitaxel, carboplatin, and erlotinib|Patients receive induction chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1 and 21. Patients receive consolidation therapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 43, 50, 57, 64, 71, 78, and 85 and oral erlotinib once daily on days 43-91. Patients undergo radiotherapy concurrently with consolidation therapy 5 days a week for 7 weeks beginning on day 43.
9862832|NCT00042874|Experimental|Treatment (combination chemotherapy)|Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
9862833|NCT00042926|Experimental|Radiolymphoscintigraphy + surgery|"Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H&E) staining. If negative by H&E, lymph nodes are further analyzed by immunohistochemistry.~Patients are followed at 30 days."
9862834|NCT00042952|Experimental|Treatment (imatinib mesylate and surgical resection)|Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.
9862835|NCT00042965|Experimental|Gemcitabine + capecitabine|"Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
9862836|NCT00042978|Experimental|Arm I (oblimersen sodium, carboplatin, and etoposide)|Patients receive oblimersen sodium IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 60 minutes on days 6-8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9862837|NCT00042978|Active Comparator|Arm II (carboplatin and etoposide)|Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9862838|NCT00043017|Experimental|MRI/MRS|MRI and MRS examinations with standard imaging, with contrast enhancement using an agent (gadopentetate dimeglumine).
9862839|NCT00043069|Active Comparator|Arm I: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
9862840|NCT00043069|Experimental|Arm II: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
9862841|NCT00043069|Placebo Comparator|Arm III: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
9862842|NCT00043069|Experimental|Arm IV: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
9862843|NCT00043082|Experimental|carboplatin and doxorubicin|carboplatin and liposomal doxorubicin given q 4 weeks
9862844|NCT00043082|Active Comparator|carboplatin|carboplatin alone
10210241|NCT00798265|Experimental|2|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
10210242|NCT00798265|Active Comparator|3|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
10210243|NCT00792831|Experimental|ITF2357|ITF2357 was supplied as hard gelatine capsules for oral administration at the strength of 100 or 50 mg. Patients had to receive ITF2357 100 mg x 2/die at 12-hour intervals, in fed conditions, for three consecutive months.
10210244|NCT00710177||PPHN|Infants born at >= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
10210245|NCT00710177||Control|Randomly selected, normal healthy infants born at >= 34 weeks gestational age and do not have PPHN
10210246|NCT00710112||VLBW|infants less than 1500 grams at birth
10210247|NCT00659646|Experimental|A|Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
9862845|NCT00043121|Experimental|Treatment (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV on days 1 and 15. Patients also receive oral capecitabine every 8 hours on days 1-2 and 15-16. Leucovorin calcium and fluorouracil administration is held at dose level 4 and above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862846|NCT00043225||Cystic Fibrosis|Cystic Fibrosis patients
9862847|NCT00043368|Experimental|1|Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
9862848|NCT00043394|Experimental|Cohort 1|0.04 mg/kg CpG 7909
9862849|NCT00043394|Experimental|Cohort 2|0.08 mg/kg CpG 7909
9862850|NCT00043394|Experimental|Cohort 3|0.12 mg/kg CpG 7909 Injection once weekly
9862851|NCT00043394|Experimental|Cohort 4|0.16 mg/kg CpG 7909
9862852|NCT00043407|Experimental|CPG 7909 Injection|
9862853|NCT00043420|Experimental|Phase I: 0.08 mg/kg|Escalating dose groups: 0.08 mg/kg PF-3512676 Injection
9862854|NCT00043420|Experimental|Phase I: 0.16 mg/kg|Escalating dose groups: 0.16 mg/kg PF-3512676 Injection
9862855|NCT00043420|Experimental|Phase I: 0.24 mg/kg|Escalating dose groups: 0.24 mg/kg PF-3512676 Injection
9862856|NCT00043420|Experimental|Phase I: 0.28 mg/kg|Escalating dose groups: 0.28 mg/kg PF-3512676 Injection
9862857|NCT00043420|Experimental|Phase I: 0.32 mg/kg|Escalating dose groups: 0.32 mg/kg PF-3512676 Injection
9862858|NCT00043420|Experimental|Phase I: 0.36 mg/kg|Escalating dose groups: 0.36 mg/kg PF-3512676 Injection
9862859|NCT00043420|Experimental|Phase II: 10 mg|Phase II: 10 mg flat dose (random assignment in Phase II)
9862860|NCT00043420|Experimental|Phase II: 25 mg|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
9862861|NCT00043537|Experimental|Social Effectiveness Therapy for Children|Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
9862862|NCT00043537|Experimental|Fluoxetine|Fluoxetine given in 10mg doses, up to 40 mg as tolerated
9862863|NCT00043537|Placebo Comparator|Pill placebo|"Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg."
9862864|NCT00043602|Experimental|1|Participants will receive clinician-managed interpersonal psychotherapy
9862865|NCT00043602|Active Comparator|2|Participants will receive standard interpersonal psychotherapy
9862866|NCT00043693|Experimental|1|Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
9862867|NCT00043693|Active Comparator|2|Participants will be placed in a family psychoeducation program.
9862868|NCT00043745|Experimental|1|Participants will receive moderate dose soy isoflavone (80 mg/day) tablets, extracted from soy protein
9862869|NCT00043745|Experimental|2|Participants will receive high dose soy isoflavone (120 mg/day) tablets, extracted from soy protein
9862870|NCT00043745|Placebo Comparator|3|Participants will receive soy extract devoid of isoflavones to serve as placebo
9862871|NCT00043810|Experimental|Gelonin Purging of ASCT|Gelonin Purging of Autologous Stem Cells for Transplantation (ASCT) + Fludara/Busulfan
9862872|NCT00043823|Experimental|Avastin + Tarceva|Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
9862873|NCT00044031|Placebo Comparator|B|Placebo (immunogen vehicle) combined with gemcitabine.
9862874|NCT00044031|Experimental|A|500 µg G17DT immunogen combined with gemcitabine.
9926116|NCT00878475||Group with obstructive causes of dyspnea|Criteria for clinical assessment of severe asthma (diffuse polyphonic bilateral and particular expiratory wheezes, chest tightness, shortness of breath, using accessory muscles of breathing, signs of hyperinflation, atopic condition, personal or family history of asthma, tachypnea, previous asthma and asthma medications, and the value of modified Boston criteria for HF ≤ 5) and criteria for chronic obstructive pulmonary disease (COPD) exacerbation (history of COPD, COPD medications, cough, worsening dyspnea, increased sputum production and volume, increased sputum purulence, rhonchi and rales, modified Boston criteria for HF ≤ 5)
9926117|NCT00878475||Heart failure group|The investigators protocol for clinical assessment of HF-related acute dyspnea (the prehospital clinical assessment for HF) was designed based on Boston (13) and Framingham criteria for HF (14) (Table 1). The investigators did not use certain criteria from the original protocols, which were not available in the prehospital setting (e.g., chest radiography).
9926118|NCT00878514|Experimental|Alprazolam|Alprazolam 1 mg tablet
9926119|NCT00878514|Active Comparator|Xanax|Xanax 1 mg tablet
9926120|NCT00878527|Experimental|Treatment with the pump|Treatment with the CircuLite Synergy Pocket Circulatory Assist Device
9926121|NCT00878540|Experimental|mirtazapine|
9926122|NCT00878566|Active Comparator|Usual Care|
9926123|NCT00878566|Experimental|Enhanced pharmacist care|
9926124|NCT00878579|Experimental|PDS System|
9926125|NCT00878579|Active Comparator|Fusion|
9926126|NCT00878592|No Intervention|Control group|The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education.
9862875|NCT00044291|Experimental|Atamestane + toremifene|
9862876|NCT00044291|Active Comparator|Letrozole + placebo|
9862877|NCT00044525|Experimental|Arm 1|
9862878|NCT00044538|Experimental|Arm 1|
9862879|NCT00044551|Experimental|Arm 1|
9862880|NCT00044564|Experimental|Arm 1|
9862881|NCT00044590||Cases|Patients with Parkinson's Disease
9862882|NCT00044590||Controls|Controls, subjects without Parkinson's Disease
9862883|NCT00044629|Experimental|Cognitive Behavioral Therapy and Ambien|Cognitive Behavioral Therapy and Ambien
9862884|NCT00044629|Placebo Comparator|Cognitive Behavioral Therapy and Placebo|Cognitive Behavioral Therapy and Placebo
9862885|NCT00044629|Active Comparator|Cognitive Behavioral Therapy alone (no drug)|Cognitive Behavioral Therapy alone (no drug)
9862886|NCT00044668|Experimental|AC2993|5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period
9862887|NCT00044694|Placebo Comparator|Placebo 0.01 mL|2 week placebo lead-in followed by Placebo 0.01 mL
9862888|NCT00044694|Placebo Comparator|Placebo 0.02 mL|2 week placebo lead-in followed by Placebo 0.02 mL
9862889|NCT00044694|Placebo Comparator|Placebo 0.03 mL|2 week placebo lead-in followed by Placebo 0.03 mL
9862890|NCT00044694|Placebo Comparator|Placebo 0.04 mL|2 week placebo lead-in followed by Placebo 0.04 mL
9862891|NCT00044694|Experimental|AC2993 2.5 mcg|2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
9862892|NCT00044694|Experimental|AC2993 5.0 mcg|2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
9862893|NCT00044694|Experimental|AC2993 7.5 mcg|2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
9862894|NCT00044694|Experimental|AC2993 10.0 mcg|2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL
9862895|NCT00044707|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
9862896|NCT00044707|Placebo Comparator|Placebo|Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted
9862897|NCT00044798|Experimental|1|Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
9862898|NCT00044798|Active Comparator|2|Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
9862899|NCT00044863|Experimental|1|Patients with metastatic EGFR-positive colorectal carcinoma
9862900|NCT00044915|Active Comparator|Arm 1|
9862901|NCT00044915|Placebo Comparator|Arm 2|
9862902|NCT00044967||Group 1|"Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline.~The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance.~Patients may be referred for genetic counseling."
9862903|NCT00045019||discharged cancer patients|patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
9862904|NCT00045175|Experimental|UCN-01 in combination with topotecan|
9862905|NCT00045188|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.
9862906|NCT00045396|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
9862907|NCT00045526|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9862908|NCT00045565|Experimental|Group A|Patients receive arsenic trioxide IV over 2 hours once weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
9862909|NCT00045565|Experimental|Group B|Patients receive arsenic trioxide at a lower dose IV over 2 hours twice weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
9862910|NCT00045591|Experimental|Celecoxib 100 mg|
9862911|NCT00045591|Experimental|Celecoxib 400 mg|
9862912|NCT00045617|Experimental|cisplatin and etoposide followed by vaccine|standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine
9862913|NCT00045669|Experimental|Imatinib Mesylate|Adult patients with unresectable or metastatic adenoid cystic carcinoma measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks
9862914|NCT00045682|Experimental|Treatment (polyglutamate paclitaxel)|Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9862915|NCT00045773||1|
9862916|NCT00045786|Experimental|400 mg CC-1088|
9862917|NCT00045786|Experimental|800 mg CC-1088|
9862918|NCT00045786|Experimental|1200 mg CC-1088|
9862919|NCT00045786|Experimental|1500 mg CC-1088|
9862920|NCT00045799|Experimental|Omeprazole sodium bicarbonate immediate release PWD/FS|
9862921|NCT00045799|Active Comparator|Cimetidine IV|
9862922|NCT00045903|Experimental|Exposure and Ritual Prevention|Exposure and Ritual Prevention Therapy
9862923|NCT00045903|Active Comparator|Stress Management|Stress Management Therapy
9862924|NCT00045916|Experimental|High dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
9862925|NCT00045916|Experimental|High dosage ECT + venlafaxine|Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
9862926|NCT00045916|Placebo Comparator|High dosage ECT + placebo|Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
9862927|NCT00045916|Experimental|Low dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
9862928|NCT00045916|Experimental|Low dosage ECT + venlafaxine|Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
9862929|NCT00045916|Experimental|Low dosage ECT + placebo|Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
9862930|NCT00045968|Active Comparator|treatment cohort|
9862931|NCT00045968|Placebo Comparator|Placebo Chohort|Autologous PBMC
9926127|NCT00878592|Experimental|Dietary and Lifestyle counseling|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
9926128|NCT00878618|Experimental|HAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with heavy breakfast
9926129|NCT00878618|Experimental|HBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with heavy breakfast
9926130|NCT00878618|Experimental|LAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with light breakfast
9926131|NCT00878618|Experimental|LBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with light breakfast
9926132|NCT00878631|Active Comparator|1 Normal Saline|infusion of 250 ccs of Normal Saline within 4 hours of the accident
9926133|NCT00878631|Experimental|2 - hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
9926134|NCT00878657|Experimental|Radiotherapy plus gemcitabine|"Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy"
9926135|NCT00878683|Experimental|1|Device and standard catheter
9926136|NCT00878683|No Intervention|2|Standard catheter
9926137|NCT00878696||Tinnitus|Tinnitus patients
9926138|NCT00878735|Experimental|1|Zen meditation
9926139|NCT00878735|No Intervention|2|No meditation (no intervention; keep regular activities) or a resting group (this group stays at the same place of the retreat group, but only to rest)
9926140|NCT00878748|Experimental|A|Effexor XR
9926141|NCT00878748|Other|B|Effexor XR discontinue
9926142|NCT00878761|Experimental|STX-100 (0.03mg/kg)|8 patients (6 active and 2 placebo)
9926143|NCT00878761|Experimental|STX-100 (0.1mg/kg)|8 patients (6 active and 2 placebo)
9926144|NCT00878761|Experimental|STX-100 (0.3mg/kg)|16 patients (12 active and 4 placebo)
9926145|NCT00878761|Experimental|STX-100 (1mg/kg)|16 patients (12 active and 4 placebo)
9926146|NCT00878774|Experimental|Cohort 1|ToleroMune Ragweed, subjects to receive either active or placebo comparator
9926147|NCT00878774|Experimental|Cohort 2|ToleroMune Ragweed or placebo comparator
9795642|NCT01541969|Experimental|CR Neuromodulation|Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device. Participants receive the intervention according to the manufacturer/funder training given to the study team.
9862932|NCT00046085|Active Comparator|Patient customary care|12 months of patient customary care
9862933|NCT00046085|Experimental|Online family education|12 months of patient customary care and relative access to online education and support program
9862934|NCT00046111|Experimental|Primary Group|40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
9862935|NCT00046631||Adolescent girls|Chosen from 6 schools in 6 cities
9862936|NCT00046735|Experimental|1|
9862937|NCT00046865|Experimental|Acupressure|Arm I: Patients receive active acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied to a specific site each morning and again whenever nausea is experienced for 3-6 minutes.
9862938|NCT00046865|Placebo Comparator|Placebo Acupressure|Arm II: Patients receive placebo acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied as in arm I except at a non-specific site.
9862939|NCT00046865|Sham Comparator|Usual Care|Arm III: Patients receive usual nausea care during the second or third course of chemotherapy.
9862940|NCT00046917|Experimental|Treatment (chemotherapy)|Patients are stratified according to the number of prior treatment regimens (0 or 1 vs more than 1). Patients receive irinotecan hydrochloride IV over 30 minutes followed immediately by cisplatin IV over 30 minutes followed 7 hours later by alvocidib IV over 1-4.5 hours weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9862941|NCT00047034|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV over 1-2 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity.
9862942|NCT00047047|Experimental|Treatment (tanespimycin, gemcitabine hydrochloride, cisplatin)|"Cohort A (closed to accrual as of 3/2/04)*: Patients receive escalating doses of gemcitabine hydrochloride intravenously (IV) over 30 minutes, tanespimycin IV over 1 hour, and cisplatin IV over 2 hours on days 1 and 8. NOTE: *The maximum tolerated dose (MTD) of this 3-drug combination has been determined as of 3/2/04.~Cohort B (closed to accrual as of 3/2/05): Patients receive gemcitabine hydrochloride** IV over 30 minutes, tanespimycin IV over 1 hour, and cisplatin** IV over 2 hours on days 1 and 8.~Cohort C: Patients receive gemcitabine hydrochloride** IV over 30 minutes and tanespimycin IV over 1-2 hours on days 2 and 9.~Cohort D: Patients receive cisplatin** IV over 2 hours and tanespimycin IV over 1-2 hours on days 1 and 8.~Cohort E: Patients receive gemcitabine hydrochloride***, tanespimycin***, and cisplatin*** as in cohort B.~Continued (see detailed description)"
9862943|NCT00047073|Experimental|Phase 1|See intervention description.
9862944|NCT00047073|Experimental|Phase 2|See intervention description.
9862945|NCT00047112|Experimental|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE
9862946|NCT00047112|Active Comparator|CHIRURGIE SEULE|CHIRURGIE SEULE
9862947|NCT00047125|Experimental|Selective irradiation|Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks).
9862948|NCT00047125|Active Comparator|Extensive irradiation + ipsilaterals levels|Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks).
9862949|NCT00047190|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9862950|NCT00047203|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
9862951|NCT00047229|Experimental|G3139 in combination with Doxorubicin|
9862952|NCT00047255|Experimental|Herceptin plus docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
9926148|NCT00878774|Experimental|Cohort 3|ToleroMune Ragweed or placebo comparator
9926149|NCT00878774|Experimental|Cohort 4|ToleroMune Ragweed or placebo comparator
9926150|NCT00878774|Experimental|Cohort 5|ToleroMune Ragweed or placebo comparator
9926151|NCT00878787|Experimental|Theta-burst Trancranial Magnetic Stim|
9926152|NCT00878813||1|All consecutive stroke patients undergoing acute intra-arterial revascularisation therapy
9926153|NCT00878813||2|All consecutive stroke patients undergoing acute intra-venous revascularisation therapy
9926154|NCT00878813||3|All consecutive stroke patients treated conservatively
9862953|NCT00047255|Experimental|Docetaxel, Carboplatin, and Herceptin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
9862954|NCT00047307|Experimental|Treatment (alvocidib, gemcitabine hydrochloride, 3DRT)|"Patients receive flavopiridol IV over 1 hour twice weekly (on days 1 and 4 or days 2 and 5) for 6 weeks. Concurrently, patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Four weeks after the completion of radiotherapy, patients are re-evaluated*. Beginning within 4-7 weeks after the completion of chemotherapy and radiotherapy, patients receive gemcitabine hydrochloride alone or in combination with another cytotoxic agent or gemcitabine hydrochloride combined with a targeted drug (e.g., erlotinib or bevacizumab) at the discretion of the oncologist. NOTE: *Patients whose imaging studies suggest potential curative resection are referred for a surgical evaluation before initiating gemcitabine hydrochloride therapy. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. Continued (see detailed description)"
9862955|NCT00047333|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9862956|NCT00047346|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9862957|NCT00047411|Active Comparator|1|Intervention: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines.
9862958|NCT00047411|Experimental|2|Use of the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
9862959|NCT00047437|Active Comparator|2|
9862960|NCT00047437|No Intervention|1|
9862961|NCT00047450|Placebo Comparator|1|Participants will take placebo
9862962|NCT00047450|Active Comparator|2|Participants will take citalopram (Celexa)
9862963|NCT00047502|Experimental|Gleevec + SCH 66336|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day, and SCH66336 100 mg by mouth twice a day."
9862964|NCT00047554||TRAVATAN|Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years
9926155|NCT00878813||4|All consecutive TIA patients
9926156|NCT00878839|Other|Toric|AcrySof Toric IOL to assess corneal aberration
9926157|NCT00878852|Active Comparator|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
9926158|NCT00878852|Experimental|Experimental|Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
9926159|NCT00878865|Experimental|Alprazolam 1 mg tablet|Alprazolam 1 mg tablet
9926160|NCT00878865|Active Comparator|Xanax 1 mg tablet|Xanax 1 mg tablet
9926161|NCT00878891|Active Comparator|1. Conventional glucose monitoring|Discontinuous glucose monitoring - GlucoDay Device with Continue record blinded
9926162|NCT00878891|Experimental|2. Conventional glucose monitoring + Glucoday|Continuous glucose monitoring - GlucoDay device with Continue record displayed
9926163|NCT00878904|Experimental|treatment with Panobinostat and Epirubicin|
9926164|NCT00878917|Experimental|Dorzolamide|
9926165|NCT00878956|Active Comparator|1|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
9926166|NCT00878956|Placebo Comparator|2|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
9926167|NCT00879008||Group 1|
9926168|NCT00879021|Placebo Comparator|Pregabalin, (other name) Lyrica|Study subjects wil be randomized to either the Pregabalin or Placebo group. There is a 5o ,50 chance of being in either group.
9926169|NCT00879021|Placebo Comparator|pregabalin, drug|study subjects that are randomized to the placebo group will receive matching placebo
9926170|NCT00879047|Experimental|HIV+, Ritonavir-regimen|10 subjects will be HIV+ and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
9926171|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Ritonavir-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
9926172|NCT00879047|Experimental|HIV+, Efavirenz-regimen|10 subjects will be HIV+ and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
9862965|NCT00047671|Active Comparator|Citalopram|All subjects receive an FDA approved dose of Citalopram
9862966|NCT00047710|Experimental|Bevacizumab|Radiation, Bevacizumab, and Capecitabine
9862967|NCT00047827|Experimental|1|
9862968|NCT00047983|No Intervention|Control|Controls and will receive no dietary supplements
9862969|NCT00047983|Experimental|Arginine and Canola Oil|Daily nutritional supplements of arginine and canola oil
9862970|NCT00047983|Experimental|Arginine and Coromega|Daily nutritional supplements of arginine and Coromega
9862971|NCT00048087|Experimental|Iressa + Docetaxel|
9862972|NCT00048100|Experimental|Apheresis + Transplant|Skin biopsy & either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.
9862973|NCT00048126|Experimental|1|
9862974|NCT00048139|Experimental|1|
9862975|NCT00048152|Experimental|1|
9862976|NCT00048152|Experimental|2|
9862977|NCT00048152|Experimental|3|
9862978|NCT00048555|Experimental|1|
9862979|NCT00048633|Experimental|Tariquidar|
9862980|NCT00048646|Placebo Comparator|placebo|placebo
9862981|NCT00048646|Experimental|IV progesterone|IV progesterone
9862982|NCT00048672|Experimental|Gleevec|Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.
9862983|NCT00048750|Experimental|1|
9862984|NCT00048750|Placebo Comparator|2|
9862985|NCT00048828|Active Comparator|1|
9862986|NCT00048828|Active Comparator|2|
9862987|NCT00048854|Active Comparator|1|Participants will receive treatment as usual
9862988|NCT00048854|Experimental|2|Participants will take sertraline
9862989|NCT00048958||No treatment|Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.
9862990|NCT00048971||Group 1|Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.
9862991|NCT00048984||Basic science (biomarker analysis)|Patients undergo various specimen collections, including bone marrow aspirate, paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens. These specimens are collected before, during, and after any chemotherapy regimens, during follow-up, and at time of recurrence. Translocation studies are performed on specimens to identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined. Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase chain reaction.
9862992|NCT00049010|Experimental|Group 1|"Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.~Patients are followed every 4 months for 3.5 years."
9862993|NCT00049023|Experimental|90Y-DOTA-tyr3-OCTREOTIDE|Dose escalation will proceed so that the single-cycle and three-cycle maximum tolerated doses of 90Y-DOTA-tyr3-Octreotide can be determined. The initial dose of 90Y-DOTA-tyr3-Octreotide to be administered is 30 mCi/m2 in each of three cycles. Dose escalation will proceed in 10 mCi/m2 intervals and will be permitted for the next cohort of subjects pending completion of Cycle 3 by 2 members of the previous cohort with no DLTs. A DLT is defined as a Grade 3 renal toxicity, Grade 4 bone marrow toxicity, or any other Grade 3 toxicity whether or not related to study drug and regardless of duration. Lymphopenia will not be used to define a DLT.
9862994|NCT00049088|Experimental|Treatment (docetaxel, bevacizumab)|For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
9862995|NCT00049114|Experimental|Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)|"PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection."
9862996|NCT00049140|Experimental|EF5|This is a non randomised single arm pilot study.
9862997|NCT00049166|Experimental|Regimen A (erlotinib hydrochloride, IMRT)|"Patients receive oral erlotinib once daily. Beginning on day 15, patients also undergo IMRT once daily 5 days a week for 7 weeks.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9862998|NCT00049166|Experimental|Regimen B (erlotinib hydrochloride, cisplatin, IMRT)|"Patients receive oral erlotinib and undergo IMRT as in regimen A. Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9862999|NCT00049192|Experimental|Treatment (oblimersen sodium, imatinib mesylate)|"Patients receive oblimersen IV continuously on days 1-10 and oral imatinib mesylate once or twice daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without a hematologic response after 2 courses go off study. Patients with complete or partial response after 4 courses may continue to receive oral imatinib mesylate daily.~Patients in cohort 2 receive an escalated dose of oblimersen; if well tolerated, subsequent cohorts receive oblimersen at the higher dose with the original dose of imatinib mesylate. If oblimersen is not well tolerated in cohort 2, subsequent cohorts receive the original dose of oblimersen with an escalated dose of imatinib mesylate. The first 6 patients accrued continue to receive the original dose (dose taken prior to study) of imatinib mesylate throughout the study."
9863000|NCT00049218|Experimental|Vaccine Administration|"• Phase I: Beginning 9 weeks after completion of chemotherapy, patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC) on days 1, 14, and 28. Patients without PD may undergo repeat leukapheresis on day 49. Patients receive vaccine SC again on days 56, 84, and 112 in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of autologous dendritic cell-adenovirus p53 vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~• Phase II: Patients receive autologous dendritic cell-adenovirus p53 vaccine at the MTD determined in phase I."
9863001|NCT00049283|Experimental|Treatment (erlotinib hydrochloride, docetaxel, and radiation)|Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
9863002|NCT00049309|No Intervention|Control|Usual diet
9863003|NCT00049309|Experimental|Flaxseed diet|30 gram flaxseed dietary modification
9863004|NCT00049309|Experimental|Low fat diet|Low fat dietary modification
9863005|NCT00049309|Experimental|Low fat + Flaxseed diet|Low fat and 30 gram flaxseed dietary modification
9863006|NCT00049335|Experimental|Capecitabine|Capecitabine 1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, Days 1-14 of 21 day cycle.
9926173|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Efavirenz-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
9926174|NCT00879047|Experimental|Maraviroc in Healthy Subjects|10 healthy subjects will begin receiving maraviroc, and their PK interactions with alcohol/placebo will be evaluated.
9926175|NCT00879073|Experimental|A - Cohort 1 Treatment|Cohort 1: Bendamustine 60 mg/m² x 4 weeks
9926176|NCT00879073|Experimental|B - Cohort 2 Treatment|Cohort 2: Bendamustine 80 mg/m² x 4 weeks
9926177|NCT00879073|Experimental|C - Cohort 3 Treatment|Cohort 3: Bendamustine 100 mg/m² x 4 weeks
9926178|NCT00879099|Active Comparator|Paroxetine|
9926179|NCT00879099|Placebo Comparator|Gelatine capsule|
9926180|NCT00879099|Experimental|Timolol 0.5 % eye drops|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
9926181|NCT00879099|Experimental|Timosan 0.1% eye gel|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
9926182|NCT00879112|Experimental|1|MB07811 Cohort 1
9926183|NCT00879112|Experimental|2|MB07811 Cohort 2
9926184|NCT00879112|Experimental|3|MB07811 Cohort 3
9926185|NCT00879112|Placebo Comparator|4|Cohort 4
9926186|NCT00879151|Experimental|Psychotherapy|Patients are randomized to one of three different types of psychotherapy: Cognitive-Behavioral Therapy for adolescents, Family-Based Therapy for Bulimia Nervosa, and Supportive Psychotherapy. All treatments consist of 18 sessions over a period of approximately 6 months.
9926187|NCT00879177|Active Comparator|Group A|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
9926188|NCT00879177|Experimental|Group B|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
9926189|NCT00879203||Type 1 Diabetes (T1DM)|Youth and young adults with T1DM
9926190|NCT00879203||Non diabetic siblings|Non diabetic, young siblings of T1DM participants
9926191|NCT00879216|Placebo Comparator|Sugar pill|
9926192|NCT00879216|Experimental|VA106483|
9926193|NCT00879242|Experimental|Deferasirox|30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.
9926194|NCT00879281|No Intervention|1 Care as usual|Regular care
9926195|NCT00879281|Experimental|2 Intervention|"Regular Care + individualized written action plan to enhance self-mananagement and early detection/treatment of an exacerbation."
9926196|NCT00879294|Sham Comparator|1 Wristband|Some patients will be randomized to wear a motion sickness wristband which does not have any drug effect.
9926197|NCT00879294|Experimental|Chewing Gum|Patients will be randomized to use chewing gum after surgery.
9926198|NCT00879294|No Intervention|Control|Usual post-operative care.
9926199|NCT00879307|Experimental|1|Use of quetiapine
9926200|NCT00879320||1|Adults with ADHD
9926201|NCT00879320||2|Healthy adults without ADHD
9926202|NCT00879346|Experimental|1|160mg oral dose of AZD8931
9926203|NCT00879372|Placebo Comparator|1|Placebo
9926204|NCT00879372|Active Comparator|2|Tianeptine
9926205|NCT00879385|Experimental|All patients|All participants enrolled.
9926206|NCT00879424|Experimental|1|
9926207|NCT00879424|Placebo Comparator|2|
9926208|NCT00879450|Experimental|1 Booklet|
9926209|NCT00879450|Active Comparator|2 standard|
9926210|NCT00879463|Active Comparator|GROUP A|Brain tissue oxygen saturation monitoring
9926211|NCT00879463|Active Comparator|GROUP B|CONTROL GROUP
9926212|NCT00879476|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
9926213|NCT00879476|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
9926214|NCT00879502||1|Men with the fragile X premutation
9926215|NCT00879502||2|Healthy men
9926216|NCT00879502||3|Brothers of men with the fragile X premutation
9926217|NCT00879515||1|Males and females with fragile X syndrome, ages 5 to 25 years old
9926218|NCT00879515||2|Males and females with the FMR1 premutation, ages 5 to 25 year old
9926219|NCT00879515||3|Males and females with Down syndrome, ages 5 to 25 years old
9863007|NCT00049387|Experimental|Treatment (tipifarnib, temozolomide, radiation therapy)|See Detailed Description
9863008|NCT00049400|Experimental|treatment|Single-arm, dose-escalation of BMS-247550
9863009|NCT00049569|Experimental|Arm I|See detailed description.
9863010|NCT00049569|Experimental|Arm II|See detailed description.
9863011|NCT00049582|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 3 hours twice daily OR IV over 1 hour once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
9863012|NCT00049595|Active Comparator|ABVD|8 cycles of ABVD
9863013|NCT00049595|Experimental|BEACOPP|4 cycles of BEACOPP Escalated + 4 cycles of BEACOPP Baseline
9863014|NCT00049764|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
9863015|NCT00049764|Placebo Comparator|2|0.9% sodium chloride
9863016|NCT00049816|No Intervention|1|Participants will receive no intervention and will act as the control group.
9863017|NCT00049816|Experimental|2|Participants will partake in a walking exercise program.
9863018|NCT00049816|Experimental|3|Participants will partake in a cycling exercise program.
9863019|NCT00050037|Experimental|CD-ROM based CBT|Group is given a copy of the CD-ROM program to complete at home over 10 weeks. At the end of each week, these patients upload and transmit their encrypted tracking data to the research coordinator. At the end of the treatment, participants who have not improved are offered a course of traditional manual-based group therapy, follow-up in an ongoing maintenance group in an eating disorders program, or an alternative treatment.
9863020|NCT00050037|Active Comparator|Standard Group CBT|"Group undergoes standard group CBT. Therapy is administered over 10 weeks in five 90-minute sessions. The key topics are similar to those covered in the CD-ROM group: psychoeducation, developing a personal profile, standardizing meal times, recognizing emotional eating, increasing daily activity, learning the language of CBT, identifying automatic thoughts, restructuring thoughts, identifying cues and consequences, chaining, surfing the urge, and preventing relapses. Therapy sessions include a didactic section followed by group interaction and discussion. All group sessions are audiotaped and monitored."
9863021|NCT00050037|No Intervention|Waiting List|Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
9863022|NCT00050076|Experimental|MCC-135 50 mg BID|
9863023|NCT00050076|Experimental|MCC-135 100 mg QD|
9863024|NCT00050076|Experimental|MCC-135 200 mg QD|
9863025|NCT00050076|Placebo Comparator|Placebo|
9863026|NCT00050115||Hepatitis A + AA cohort|Subjects seen either at Clinical center or by outside physician
9863027|NCT00050349|Experimental|EPO906|
9863028|NCT00050414|Experimental|Trabectedin|Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
9863029|NCT00050427|Experimental|001|ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
9863030|NCT00050427|Experimental|002|ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
9863031|NCT00050440|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.
9863032|NCT00050505|Experimental|Cohort C|N=100 to 110 subjects receives 1:10 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
9863033|NCT00050505|Experimental|Cohort B|N=571 to 581 subjects receives 1:5 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
9863034|NCT00050505|Experimental|Cohort A|N=226 to 236 subjects receives undiluted dose Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
9863035|NCT00050531|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
9926220|NCT00879515||4|Males and females with normal development, ages 5 to 25 years old
9863036|NCT00050531|Experimental|Gleevec + Peg-Intron + GM-CSF|Gleevec 400 mg orally twice daily. Peg-Intron 0.5 mcg/kg each week subcutaneously. GM-CSF 125 mcg/m^2 three times per week subcutaneously.
9863037|NCT00050557|Experimental|1|Participants will receive immediate Multi-Family Psychoeducation Group treatment and ongoing treatment as usual
9863038|NCT00050557|Active Comparator|2|Participants will receive treatment as usual and waitlist Multi-Family Psychoeducation Group treatment
9863039|NCT00050570|Experimental|Intervention|An 8-week, Internet- based, structured cognitive- behavioral program combined with an online, asynchronous, moderated discussion group.
9863040|NCT00050570|No Intervention|Control|The waitlist control group was only contacted at the time of assessments and was offered the intervention at the end of the study, after the 2-year follow-up assessment was completed.
9863041|NCT00050583|Experimental|1|10 Session modified CBT (including a relaxation component) administered by trained mental health clinicians at the primary care setting
9863042|NCT00050583|No Intervention|2|"Treatment as Usual, defined as the use of a consultation letter and traditional primary care management."
9863043|NCT00050609|Placebo Comparator|1|
9863044|NCT00050609|Active Comparator|2|5 mg tadalafil
9863045|NCT00050609|Active Comparator|3|20 mg tadalafil
9863046|NCT00050648|Active Comparator|cyclosporine|oral medication 2mg/kg/day orally from Day 0 until Day 90
9863047|NCT00050648|Active Comparator|anti-TAC|1mg/kg/dose medication every other week on the odd week (week 1-13)
9863048|NCT00050648|Experimental|Cyclosporine and anti-TAC|DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
9863049|NCT00050661|Active Comparator|Narrow Band Ultraviolet B|312nm
9863050|NCT00050661|Experimental|anti-TAC or placebo|
9863051|NCT00050674|Experimental|Filgrastim-SD/01|6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
9863052|NCT00050791|Experimental|VLCD and leptin|Very low calorie diet formula providing 800 calories per day and leptin treatment.
9863053|NCT00050791|Active Comparator|placebo|Very low calorie diet and placebo treatment
9926221|NCT00879541|Other|PK Biostate® [SP]|"Part 1: PK subjects are randomized to receive Biostate® [SP] either on Day 1 or Day 8.~Part 3: All PK subjects receive Biostate® [SP] on Day 180."
9926222|NCT00879541|Other|PK Biostate® [RP]|Part 1: PK subjects are randomized to receive Biostate® [RP] either on Day 1 or Day 8.
9926223|NCT00879541|Experimental|Efficacy|Part 2: This arm includes all subjects during the efficacy component of the study.
9926224|NCT00879554|Experimental|1|
9926225|NCT00879580||Non-ruptured aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have one or more non-ruptured or late ruptured (>30days), intracranial aneurysm.
9926226|NCT00879580||Acute ruptured Aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have a on or more acute ruptured (<30Days) aneurysms
9926227|NCT00879593|Experimental|PtcCO2|
9926228|NCT00879632||1|TREATMENT AS USUAL
9926229|NCT00879632||2|CONTROLS
9926230|NCT00879671|Active Comparator|1|Lutamax
9926231|NCT00879671|Placebo Comparator|2|Placebo
9926232|NCT00879723|Experimental|Vitamin and mineral supplementation|Intravenous micronutrient solution or an oral micronutrient supplementation twice per day for 14 days. Treatment is determined by percent total body surface area burned.
9926233|NCT00879723|No Intervention|Control|current vitamin regimen as listed on the Memorial medical Center Order Set for burn unit admission.
9926234|NCT00879736|Active Comparator|THT PACE eLearning module|The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
9926235|NCT00879736|Active Comparator|THT PACE eLearning module & nurse-led workshop training|THT PACE eLearning and then nurse-led workshop for training on PACE methodology
9926236|NCT00879736|Placebo Comparator|Usual care|Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
9926237|NCT00879749|Placebo Comparator|Saline|
9926238|NCT00879749|Experimental|Nexvax2|
9926239|NCT00879788|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
9926240|NCT00879788|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
9926241|NCT00879801||Subjects with IGR|Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
9935232|NCT04009824|Experimental|Group 5: AGS-v PLUS + Alhydrogel® Adjuvant|Participants received 1012 µg of AGS-v PLUS and Alhydrogel® on days 1 and 22 by subcutaneous injection
9935233|NCT04008368|Other|1|patients with HLA-matched sibling donors
9935234|NCT04008368|Other|2|patients with haploidentical donors
9935235|NCT04007029|Experimental|Treatment (fludarabine, cyclophosphamide, CD19/CD20 T-cells)|"CONDITIONING CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60 minutes 5, 4, and 3 days before cell infusion.~T-CELL INFUSION: Patients receive CD19/CD20 CAR-T cells IV on day 0. Patients with cytokine release syndrome may also receive tocilizumab IV on day 2 at the discretion of the clinical investigator."
9935236|NCT04002947|Experimental|1|Acalabrutinib 100 mg orally twice a day for 14 days; Following window: patients with > or = to 25% tumor reduction, treat with DA-EPOCH-R or R-CHOP + acalabrutinib 100mg orally twice a day for the first 10 days, for 6 cycles; whereas, patients with <25% tumor reduction, treat with DA-EPOCH-R or R-CHOP alone for 6 cycles
9863054|NCT00051090|Experimental|A|All eligible study participants
9863055|NCT00051246|Active Comparator|1 M-ITG|Mother-infant group psychotherapy
9863056|NCT00051246|Active Comparator|2 - IPT|Individual interpersonal psychotherapy
9863057|NCT00051285|Experimental|Enoximone|
9863058|NCT00051285|Placebo Comparator|Placebo|
9863059|NCT00051350|Placebo Comparator|CARB|Diet rich in carbohydrate
9863060|NCT00051350|Active Comparator|UNSAT|Diet rich in unsaturated fat
9863061|NCT00051350|Active Comparator|PROTEIN|Diet rich in protein
9863062|NCT00051714|Experimental|Early Primary Prevention|
9863063|NCT00051740|Active Comparator|Cognitive Adaptation Therapy|Subjects receive Cognitive adaptation therapy as part of treatment for schizophrenia
9863064|NCT00051740|Active Comparator|Minimal Environmental Support|Subjects receive minimal environmental support in schizophrenia treatment
9863065|NCT00051831|Experimental|1|
9863066|NCT00051922|Experimental|1|Participants will receive vaccine and will be followed for 1 year
9863067|NCT00051935|Experimental|1|
9863068|NCT00052013|Experimental|PTK787/ZK 222584|
9863069|NCT00052026|Placebo Comparator|1|Placebo
9863070|NCT00052026|Experimental|2|Low-dose carvedilol
9863071|NCT00052026|Experimental|3|high-dose carvedilol
9863072|NCT00052091|Experimental|1 Problem Solving Therapy|12 weekly sessions of problem solving therapy (PST)
9863073|NCT00052091|Experimental|2 Brief Supportive Therapy|12 weekly sessions of brief supportive therapy (BST)
9863074|NCT00052182|Experimental|1|Immunization on Day 0 and Weeks 4, 8, and 16
9863075|NCT00052195|Placebo Comparator|B|
9863076|NCT00052195|Experimental|A|
9863077|NCT00052208|Experimental|Treatment (gefitinib, radiation therapy)|Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
9863078|NCT00052221|Experimental|Arm I: Epoetin Alfa|Epoetin alfa subcutaneously (SC) once weekly for 6 weeks
9863079|NCT00052221|Placebo Comparator|Arm II: Placebo|Placebo subcutaneously (SC) once weekly for 6 weeks
9863080|NCT00052286|Experimental|drug dosage 1|- Arm I: Patients receive oral high-dose modafinil twice daily.
9863081|NCT00052286|Experimental|drug dosage 2|- Arm II: Patients receive oral low-dose modafinil twice daily.
9863082|NCT00052299|Experimental|ARM A|GO + MICE for remission induction followed by GO + mini-ICE for consolidation
9863083|NCT00052299|Active Comparator|ARM B|MICE for remission induction followed by mini-ICE for consolidation
9863084|NCT00052338|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, followed 1 hour later by bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a clinical or radiographic response may continue receiving bortezomib beyond 6 courses.
9863085|NCT00052364|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863086|NCT00052377|Experimental|Treatment (aldesleukin, recombinant interleukin-12)|"Patients receive IL-12 SC twice weekly for 24 weeks.~Disease is assessed at 13 weeks. Patients who do not have progressive disease also receive IL-2 SC 3 consecutive days a week during weeks 13-24. Patients with progressive disease at week 13 receive IL-2 SC at a fixed dose during weeks 13-24.~Patients with responding disease after week 24 may continue to receive IL-2 and IL-12 for another 12 weeks.~Cohorts of 3-6 patients receive escalating doses of IL-2 until the MTD is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RD is the dose preceding the MTD. Additional patients are treated at the RD."
9863087|NCT00052468|Experimental|TCG|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses
9863088|NCT00052468|Active Comparator|TC|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses
9863089|NCT00052481||Quality of life questionnaire|"Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy).~Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071."
9863090|NCT00052494|Experimental|STI-571 with cisplatin and irinotecan|
9863091|NCT00052559|Experimental|Treatment (bevacizumab, fluorouracil, radiation therapy)|"Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery 7 weeks after completion of chemoradiotherapy.~Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD."
9863092|NCT00052585|Experimental|Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)|Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9926242|NCT00879827|Experimental|Single Group|
9926243|NCT00879840||Females|With endometrial cancer, ovarian cancer, and women undergoing hysterectomy for benign reasons.
9926244|NCT00879853|Experimental|Interpersonal Therapy|
9926245|NCT00879853|No Intervention|Wait List Control|
9926246|NCT00879866|Experimental|1|
9926247|NCT00879892|Active Comparator|Hypothermia and xenon|
9926248|NCT00879892|Active Comparator|Hypothermia|
9926249|NCT00879905|Experimental|once weekly dosing schedule|
9926250|NCT00879905|Experimental|twice weekly dosing schedule|
9926251|NCT00879918|Experimental|Nicotine pharmacokinetics|circadian smoking protocol and IV pharmacokinetic protocol
9926252|NCT00879931|Experimental|1|methylprednisolone
9926253|NCT00879931|Placebo Comparator|2|Placebo (NaCl 0.9%)
9926254|NCT00879944||Psoriasis|Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
9926255|NCT00879944||Atopic Dermatitis Controls|Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
9926256|NCT00879944||Healthy Controls|"Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.~Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm"
9926257|NCT00879957|Active Comparator|Heparin group|The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
9926258|NCT00879957|Experimental|No heparin group|This group will only receive the prescribed fluids to infuse through their PICCs. No heparin will be added to the intravenous infusions.
9926259|NCT00879983|Other|Group 1|Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
9926260|NCT00879983|Other|Group 2|Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
9926261|NCT00880035|Experimental|Group A|Group A: day 1 = music, day 2 = washout, day 3 = headphone without music
9926262|NCT00880035|Experimental|Group B|Group B: day 1 = headphone without music, day 2 = washout, day 3 = music
9926263|NCT00880074|Experimental|FLT-PET Scan|FLT solution is administered through a peripheral intravenous catheter approximately 60 minutes before the PET scan. 3 Positron Emission Tomography (PET) scans performed 60-90 minutes after intravenous injection of FLT: 1) within 2 weeks before day 1 of chemotherapy treatment; 2) day 6-7 of chemotherapy treatment; and,3) at end of chemotherapy treatment, day 19-20.
9926264|NCT00880113||Acute stroke|Patients over 18 years of age with acute stroke symptoms of less then 9 hours duration and no hemorrhage on non-contrast CT.
9926265|NCT00880126|Experimental|CDT|Community Development Teams bring together counties who are implementing a new practice
9926266|NCT00880152|Experimental|MBSR|An 8-week course in mindfulness-based stress reduction (MBSR)
9926267|NCT00880152|No Intervention|2|Treatment as usual
9926268|NCT00880178||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
9926269|NCT00880178||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
9926270|NCT00880204|Experimental|Trained doctors|ESS-EMCH Training will be provided to doctors working in general emergency, pediatrics and obstetrics department in district hospitals.
9926271|NCT00880204|No Intervention|No Training|No training will be given to doctors (act as controls)
9863093|NCT00052611|Experimental|Celecoxib|Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
9863094|NCT00052689|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
9863095|NCT00052689|Experimental|Arm II|Patients receive bortezomib as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.
9863096|NCT00052780|Experimental|Treatment (temozolomide, O6-benzylguanine)|See Detailed Description
9863097|NCT00052845|Experimental|Combined chemotherapy|combination of 3 chemotherapy agents for hormone refractory prostate cancer
9863098|NCT00052884|Experimental|Amifostine, Melphalan, and Stem Cell Reconstitution|Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2
9863099|NCT00052897|Experimental|Arm I|"Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity."
9863100|NCT00052936|Experimental|S6|6x CHOP-14
9863101|NCT00052936|Experimental|R6|6x CHOP-14 + 8x Rituximab
9863102|NCT00052936|Experimental|S8|8x CHOP-14
9863103|NCT00052936|Experimental|R8|8x CHOP-14 + 8x Rituximab
9863104|NCT00052949|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
9863105|NCT00053027|Experimental|rituximab + cladribine|"Patients receive rituximab IV over 4-8 hours on day 1 and cladribine IV over 2 hours on days 4-8. If 2 or more patients experience unacceptable toxicity during the first course, the study is discontinued; otherwise, the study is opened for enrollment at all NCCTG sites.~Treatment repeats every 28 days for a total of 2-6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years."
9863106|NCT00053040|Experimental|Surgery for tumor resection + IL13-PE38QQR infusion|
9863107|NCT00053053|Experimental|Juven supplement|Juven nutritional supplement given twice a day for 8 weeks
9863108|NCT00053053|Active Comparator|Non-Juven supplement|Non-Juven nutritional supplement given twice a day for 8 weeks
9863109|NCT00053196|Experimental|Non myeloblative allogeneic transplant|Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
9863110|NCT00053209|Experimental|Pemetrexed Disodium and Gemcitabine|Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles
9863111|NCT00053222|Experimental|Arm A|Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)
9863112|NCT00053235||Ancillary-Correlative|Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
9863113|NCT00053326|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide 3 times daily (or 2 times daily if over 18 years of age) on days 1-7. Treatment repeats every 3 weeks for up to 30 courses in the absence of disease progression or unacceptable toxicity.
9863114|NCT00053339|Experimental|trastuzumab|"Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
9863115|NCT00053339|Experimental|trastuzumab + tamoxifen|"Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.~In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
9863116|NCT00053430|Experimental|1|Participants will receive low dose thalidomide for 28 days
9863117|NCT00053430|Placebo Comparator|2|Participants will receive low dose thalidomide placebo for 28 days
9863118|NCT00053508|Experimental|Group 1|ACAM1000
9863119|NCT00053508|Experimental|Group 2|ACAM1000
9863120|NCT00053508|Experimental|Group 3|ACAM1000
9863121|NCT00053508|Active Comparator|Group 4|Dryvax
9863122|NCT00053573|Experimental|1|
9863123|NCT00053625|Active Comparator|SA #1 Arm 1: Unilateral DBS in GPi|
9863124|NCT00053625|Active Comparator|SA #1 Arm 2: Unilateral DBS in STN|
9863125|NCT00053625|Active Comparator|SA #2 Arm 1: Bilateral DBS in GPi|Patients with GPi bilateral DBS (previously had unilateral DBS in the GPi, now have bilateral DBS in GPi)
9863126|NCT00053625|Active Comparator|SA #2 Arm 2: Bilateral DBS in STN|Patients with STN bilateral DBS (previously had unilateral DBS in the STN, now have bilateral DBS in STN)
9863127|NCT00053768|Active Comparator|CHOEP-21|"CHOEP-21-Schema:~Cyclophosphamid (750 mg/m2 i.v. d1), Doxorubicin (50 mg/m2 i.v. d1), Vincristin (2 mg i.v. d1), Etoposid (100 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
9863128|NCT00053768|Experimental|high CHOEP-21|"High-CHOEP-21-Schema:~Cyclophosphamid (1400 mg/m2 i.v. d1), Doxorubicin (32,5 mg/m2 i.v. d1+2), Vincristin (2 mg i.v. d1), Etoposid (175 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
9863129|NCT00053833|Experimental|irinotecan|irinotecan
9863130|NCT00053885|Experimental|PTK787/ZK 222584|"Patients receive oral PTK787/ZK 222584 daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year."
9863131|NCT00053950|Experimental|Cohort I|Groups of 3-6 patients receive escalating doses of PZA at a fixed infusion time until the MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
9863132|NCT00053950|Experimental|Cohort II|Groups of 3-6 patients receive PZA at the dose/hour established in cohort I at escalating infusion times until another MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
9863133|NCT00053963|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863134|NCT00053976|Experimental|Daclizumab|"Patients are randomized to 1 of 2 treatment arms.~Arm I:~Patients receive methylprednisolone or equivalent corticosteroid IV or orally~Daclizumab IV on days 0, 3, 7, 14, and then weekly as indicated until day 100.~Arm II: Patients receive methylprednisolone or equivalent corticosteroid as in arm I and placebo.~Patients are followed at 1 year and then annually thereafter."
9863135|NCT00053976|Placebo Comparator|Placebo|"Patients are randomized to 1 of 2 treatment arms.~Patients receive methylprednisolone or equivalent corticosteroid as in Daclizumab arm~Placebo IV on days 0, 3, 7, 14, and then weekly as indicated until day 100."
9863136|NCT00054041|Experimental|Arm I (HspE7)|Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
9863137|NCT00054041|Experimental|Arm II (control)|Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
9863138|NCT00054119|Experimental|Treatment|Patients receive karenitecin IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863139|NCT00054184|Experimental|Study drug|
9863140|NCT00054236|Experimental|non-myeloablative conditioning regimen|
9863141|NCT00054405|Experimental|Treatment (IL-12, aldesleukin)|"Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.~Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.~Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.~Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD."
9863142|NCT00054418|Experimental|calcium carbonate, vitamin D and risedronate|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and risedronate 35 mg weekly.
9863143|NCT00054418|Placebo Comparator|calcium carbonate, vitamin D and placebo|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and placebo weekly.
9863144|NCT00054431|Experimental|Treatment (imatinib mesylate, decitabine)|Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
9935237|NCT04002310|Experimental|BI 754132|Single Rising Dose (SRD) part followed by a Multiple Dosing (MD) part
9863145|NCT00054444|Experimental|Treatment (topotecan hydrochloride, radiation, cisplatin)|Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive cisplatin IV and topotecan IV over 30 minutes once weekly for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
9863146|NCT00054457|Experimental|docetaxel + capecitabine|"Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration."
9863147|NCT00054483|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9926272|NCT00880243|Experimental|EMA+GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.~GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10."
9926273|NCT00880243|Active Comparator|EMA without GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10."
9926274|NCT00880243|Experimental|HD AraC+ GM-CSF|"AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5~GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5"
9926275|NCT00880243|Active Comparator|HD-AraC without GM-CSF|- AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5
9926276|NCT00880282|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
9926277|NCT00880295|Active Comparator|endoscopic surgery|
9926278|NCT00880295|Active Comparator|open surgery|
9926279|NCT00880308|Experimental|LDE225|
9926280|NCT00880321|Experimental|Part 1|Part 1 will identify the recommended Part 2 dose using a dose-escalation procedure. Escalation may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached. Subjects may dose up to three times a day.
9926281|NCT00880321|Experimental|Part 2|Part 2 will explore further the safety, tolerability, and clinical activity of GSK2118436 in subjects with BRAF mutation-positive tumors using the recommended part 2 dose identified during Part 1. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
9926282|NCT00880347|Other|Alzheimer's Disease|Group of patients clinically diagnosed with probable AD
9926283|NCT00880347|Other|Non-AD dementia|Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
9926284|NCT00880347|Other|control subjects|Group of control subjects without any clinical cognitive impairment.
9926285|NCT00880373|Active Comparator|1|Diamorphine or Morphine by PCA and oral ibuprofen
9926286|NCT00880373|Placebo Comparator|2|Diamorphine or Morphine by PCA and oral placebo
9926287|NCT00880386|Experimental|Losartan Group|50 mg Losartan tablet taken daily for 24 weeks
9926288|NCT00880412|Experimental|EHT 0202 40 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
9926289|NCT00880412|Experimental|EHT 0202 80 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
9926290|NCT00880412|Placebo Comparator|placebo bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
9926291|NCT00880477|Experimental|Group A|
9926292|NCT00880477|Experimental|Group B|
9926293|NCT00880516||control|Adults with normal sinuses
9926294|NCT00880516||case|Adults with chronic sinusitis and positive findings on imaging.
9926295|NCT00880529|Experimental|ON-Q|Subcutaneous bupivicaine administration and IV opioid medication if necessary
9926296|NCT00880529|Active Comparator|IV opioids alone|Standard therapy with IV opioid administration
9926297|NCT00880594|Experimental|Open label desipramine|
9926298|NCT00880646|Experimental|1|
9926299|NCT00880646|Placebo Comparator|2|
9926300|NCT00880659|Experimental|1|Promotion of handwashing with soap and maintenance of a fully stocked handwashing station.
9926301|NCT00880659|No Intervention|2|Practice of routine handwashing among the household members
9926302|NCT00880672|Active Comparator|dutasteride|oral, 5mg, once per day, 2 weeks
9926303|NCT00880672|Placebo Comparator|placebo|oral, 5mg, once per day, 2 weeks
9926304|NCT00880711||1|Patient with advanced BC, already receiving Faslodex therapy
9926305|NCT00880724|No Intervention|Medical management|
9926306|NCT00880737||Stable PE patients|Hemodynamically stable patients with acute symptomatic pulmonary embolism
9926307|NCT00880789|Experimental|Dose Level One: 5x10^6/m2|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
9935238|NCT03996824||AAV viral transduction|Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
9935239|NCT03995173|Active Comparator|active|active rTMS
9863148|NCT00054548|Experimental|Treatment (oblimersen sodium, paclitaxel)|"Patients receive oblimersen IV continuously on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~An additional cohort of 12-15 patients receives treatment as above with oblimersen at the MTD."
9863149|NCT00054587|Active Comparator|6 FEC|Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
9863150|NCT00054587|Experimental|6 DE|Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I
9863151|NCT00054821|Experimental|Group A|Group A participants will be treated with mechanical distraction with motion
9863152|NCT00054821|Active Comparator|Group B|Group B participants will be treated with mechanical distraction without motion
9863153|NCT00054925|Active Comparator|Personal contact (PC)|The Personal Contact (PC) intervention offers one-on-one guidance and support in maintaining weight loss.
9863154|NCT00054925|Active Comparator|Interactive technology (IT)|Utilizes internet and automated phone technology to enhance the frequency and timeliness of feedback.
9863155|NCT00055302|Experimental|1|
9863156|NCT00055315|Active Comparator|STEPPS|Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes
9863157|NCT00055315|Placebo Comparator|Treatment as Usual|"Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes.~TAU for this BPD population includes medical management, group and individual therapy."
9863158|NCT00055393|Active Comparator|Subjects receivng Bupropion|The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
9863159|NCT00055393|Placebo Comparator|Subjects receiving Placebo|The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
9863160|NCT00055419|Experimental|400 mg/m2|
9863161|NCT00055679|Active Comparator|6 FEC|6 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
9863162|NCT00055679|Experimental|4 FEC|4 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
9863163|NCT00055757|Experimental|Treatment (tipifarnib, gemcitabine, cisplatin)|"Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
9863164|NCT00055770|Experimental|Arm I|"PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.~PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I."
9863165|NCT00055809|Experimental|Arm I (bevacizumab)|Patients receive bevacizumab IV on day 1.
9863166|NCT00055809|Experimental|Arm II (PEG-interferon alfa-2b)|Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
9935240|NCT03995173|Placebo Comparator|placebo|placebo rTMS
9863167|NCT00055848||Group 1|"Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.~A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.~Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment."
9863168|NCT00055861|Experimental|Treatment (bevacizumab, docetaxel)|Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
9863169|NCT00055913|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863170|NCT00055913|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863171|NCT00055978|Experimental|Arm I|Patients receive oral placebo twice daily for 6 months.
9863172|NCT00055978|Experimental|Arm II|Patients receive oral celecoxib twice daily for 6 months.
9863173|NCT00055991|Experimental|Bexarotene|Bexarotene / Targretin
9863174|NCT00055991|Placebo Comparator|Sugar Pill|Sugar pill / placebo
9863175|NCT00056030|Experimental|cetuximab + oxaliplatin + leucovorin + fluorouracil|"Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1 and 8. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity, for a minimum of 12 courses or until deemed to have resectable disease.~Quality of life is assessed at baseline and prior to each treatment course.~Patients are followed every 3 months for 1 year and then every 6 months for 3 years."
9863176|NCT00056056|Experimental|Bexarotene and PUVA|
9863177|NCT00056056|Active Comparator|PUVA|
9863178|NCT00056069|Experimental|Observational|Questionnaire Administration: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
9863179|NCT00056082|Experimental|Celecoxib 400 mg bid|Celecoxib 400 mg bid
9863180|NCT00056095|Experimental|Allograft (compatible family member)|
9863181|NCT00056095|Other|Allograft (compatible non-family member)|
9926308|NCT00880815|Experimental|Treatment (chemotherapy, stem cell transplant, rituximab)|Participants receive rituximab IV over 5-7 hours on days -13 and -6, fludarabine IV over 1 hour and bendamustine IV over 1 hour on days -5 to -3, and tacrolimus IV starting on day -2 and PO after hospital discharge for 6 to 8 months. Participants with MUD receive thymoglobulin on days -2 and -1. Participants undergo allogenic stem cell transplant over 30-45 minutes on day 0. Participants receive rituximab IV over 5-7 hours on days 1 and 8 and methotrexate IV over 30 minutes on days 1, 3, and 6. Participants with MUD also receive methotrexate IV on day 11. Participants receive G-CSF SC once daily starting on day 7 until white blood cell counts recover.
9926309|NCT00880828|Experimental|A|FIR cervical collar plus Acetaminophen
9926310|NCT00880828|Active Comparator|B|Conservative cervical collar plus Acetaminophen
9926311|NCT00880828|Placebo Comparator|C|Acetaminophen only
9926312|NCT00880841||no treatment|phase 1a study for healthy normals
9926313|NCT00880854|Experimental|1|BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 in combination with CP-675,206 I.V. week 3, week 1
9926314|NCT00880867|Experimental|Poly-ICLC|Poly-ICLC plus low dose local radiation.
9926315|NCT00880880|Experimental|pre-visit e-PAQ-PF|Participants assigned to fill out the e-PAQ-PF prior to their clinic visit. Participants will arrive early to clinic appointment and fill out e-PAQ-PF. Results will be given to clinician and participant. After their visit they will complete the post visit questionnaire.
9926316|NCT00880880|No Intervention|post-visit e-PAQ-PF|Participants assigned to complete the e-PAQ-PF after their clinic visit. Pre-visit participants will sign consent form - but otherwise will receive no study interventions. Post-visit they will fill out e-PAQ-PF and post visit questionnaire.
9926317|NCT00880932|Experimental|customized electronic alert|"This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a reason for override whenever the combination drugs of warfarin and NSAID were ordered together."
9926318|NCT00880932|No Intervention|Standard practice|The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
9926319|NCT00880945||36-40 patients|patients with small peripheral lesions who need bronchoscopy for diagnostic purposes
9926320|NCT00880958|Experimental|1|
9926321|NCT00880958|Placebo Comparator|2|
9926322|NCT00880971|Experimental|PORT|Patients undergo thoracic radiotherapy using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after postoperative chemotherapy.
9926323|NCT00880971|No Intervention|Non-PORT|Patients undergo postoperative chemotherapy.
9926324|NCT00881010||Telephone Intervention|
9926325|NCT00881010||Usual Care|
9863182|NCT00056277|Other|Arm 1|
9863183|NCT00056290|Active Comparator|1|VEGF
9863184|NCT00056290|Placebo Comparator|2|Placebo
9863185|NCT00056303|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up targets nurturance, synchrony, and non-frightening behavior, as well as providing caregivers with help calming toddlers.
9863186|NCT00056303|Active Comparator|Developmental Education for Families|Developmental Education for Families targets providing cognitive stimulation to their children.
9863187|NCT00056329|Experimental|1|vitamin E plus multivitamin
9863188|NCT00056329|Placebo Comparator|2|placebo with multivitamin
9863189|NCT00056394|Experimental|1|Participants will receive comprehensive pain coping skills.
9863190|NCT00056394|Active Comparator|2|Participants will receive arthritis education.
9863191|NCT00056394|Active Comparator|3|Participants will receive standard care.
9863192|NCT00056446|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
9863193|NCT00056446|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
9863194|NCT00056459|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
9863195|NCT00056459|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
9863196|NCT00056537|Experimental|1|
9863197|NCT00056589|Experimental|rFXIII|
9863198|NCT00056654|Experimental|1|
9863199|NCT00056667|Experimental|CBT plus relaxation response|Participants will receive cognitive behavioral therapy plus relaxation response training
9863200|NCT00056667|Active Comparator|Relaxation Response|Participants will receive relaxation response training
9863201|NCT00056667|Placebo Comparator|Education|Participants will receive rheumatoid arthritis education
9863202|NCT00056693|Experimental|A|
9863203|NCT00056966|Experimental|1|recipients of HLA matched sibling transplants
9863204|NCT00056966|Experimental|2|recipients of unrelated or mismatched family donor transplants
9926326|NCT00881062|Experimental|25 mg Proellex|25 mg (100 µCi) [14C]-Proellex
9926327|NCT00881075|Experimental|SeeMore(TM)|intravenous imaging agent for enhanced magnetic resonance imaging.
9926328|NCT00881088|No Intervention|1|Patients randomized to the no intervention group
9926329|NCT00881088|Experimental|Nadroparin|Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
9863205|NCT00056979|Experimental|Fludarabine, CAMPATH-1H , Anti-CD45, FK506|Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. To help prevent body from rejecting the transplant, the drug FK506 will be given, starting two days before the transplant and continuing for three months.
9863206|NCT00057005|Experimental|1|
9863207|NCT00057044|Other|Arm 1|
9863208|NCT00057057|Other|Arm 1|
9863209|NCT00057070|Other|Arm 1|
9863210|NCT00057083|Other|Arm 1|
9863211|NCT00057096|Other|Arm 1|
9863212|NCT00057109||Group 1|
9863213|NCT00057122|Active Comparator|1|
9863214|NCT00057122|Active Comparator|2|
9863215|NCT00057122|Active Comparator|3|
9863216|NCT00057122|Active Comparator|4|
9863217|NCT00057135|Other|Arm 1|
9863218|NCT00057148|Other|Arm 1|
9863219|NCT00057161|Other|Arm 1|
9863220|NCT00057174|Other|Arm 1|
9863221|NCT00057187|Other|Arm 1|
9863222|NCT00057200|Other|Arm 1|
9863223|NCT00057252||1|Patients with medical imaging records
9863224|NCT00057291|Experimental|caregiving intervention|One group received caregiving intervention, another received only training, and a third was business as usual. These were the interventions.
9863225|NCT00057356|Placebo Comparator|1|
9863226|NCT00057356|Experimental|2|Low dose
9863227|NCT00057356|Experimental|3|Middle dose
9863228|NCT00057356|Experimental|4|High dose
9863229|NCT00057408|Experimental|1|Treatment with olanzapine
9863230|NCT00057408|Placebo Comparator|2|Matching placebo treatment
9863231|NCT00057499|Experimental|IBC-VS01 vaccine|IBC-VS01 vaccine is administered twice.
9863232|NCT00057499|Placebo Comparator|Control Group|IBC-VS01 placebo is administered twice
9863233|NCT00057512|Experimental|Intratumoral M4N|The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.
9863234|NCT00057525|Experimental|Anthrax vaccine with or without PBS|Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
9863235|NCT00057525|Placebo Comparator|Placebo|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
9863236|NCT00057564|Experimental|A (Thalidomide & Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
9863237|NCT00057564|Placebo Comparator|B (Dexamethasone and placebo)|Dexamethasone and placebo
9863238|NCT00057603|Experimental|Deep Brain Stimulation|Participants receive deep brain stimulation treatment for 30 months.
9863239|NCT00057629|Active Comparator|1 Prolonged Exposure|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
9863240|NCT00057629|Active Comparator|2 Individual and group therapy|"TUGT (Treatment as usual group therapy - used in Study 1), delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is no formal, structured format for these groups; counselors are sensitive to the participants' needs and follow their lead re content covered in discussions and exercises.~Supportive counseling (SC - study 2): individual therapy delivered in 10 weekly, 90 minute sessions. Therapist helps patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these."
9863241|NCT00057642|Other|Sertraline, venlafaxine, bupropion|This is an open trial so there is only one arm using standard antidepressant medications.
9926330|NCT00881088|Experimental|Fondaparinux|Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
9926331|NCT00881101|Experimental|1|Liposomal paclitaxel
9926332|NCT00881114|Experimental|Cetuximab|patients with 2 or fewer genetic variants will receive cetuximab
9926333|NCT00881114|Experimental|Cisplatin|Subjects with 3 to 8 genetic variants will receive cisplatin
9926334|NCT00881127|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
9926335|NCT00881127|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
9926336|NCT00881140|Experimental|antiprogestin|Daily use of 10 mg administrated per vagina
9926337|NCT00881153|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
9926338|NCT00881153|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
9926339|NCT00881166|Experimental|1|oral MP-470 + paclitaxel/carboplatin
9926340|NCT00881166|Experimental|2|oral MP-470 + carboplatin/etoposide
9863242|NCT00057759|Experimental|Sildenafil citrate|Sildenafil with dose escalation as needed from 50 mg to 100 mg/day prn for 12 weeks.
9863243|NCT00057759|Placebo Comparator|Placebo|"Placebo with similar dose escalation opportunity for 12 weeks."
9863244|NCT00057850|Experimental|Arm I|"Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.~Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550."
9863245|NCT00057915|Experimental|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
9863246|NCT00057967|Experimental|Treatment arm|alemtuzumab
9863247|NCT00058084|Experimental|Arm I|Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
9863248|NCT00058084|Experimental|Arm II|Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863249|NCT00058097|Experimental|Treatment (tipifarnib)|"INDUCTION THERAPY: Patients receive oral tipifarnib twice daily for 3 weeks. Treatment repeats every 4 weeks for up to 3 courses.~RADIOTHERAPY: Within 14 days after the completion of induction therapy, patients undergo radiotherapy daily, 5 days a week, for 6 weeks.~MAINTENANCE THERAPY: Two weeks after the completion of radiotherapy, patients receive additional tipifarnib as in induction therapy.~Treatment continues in the absence of disease progression or unacceptable toxicity."
9863250|NCT00058201|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
9863251|NCT00058201|Experimental|Arm II|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
9863252|NCT00058201|No Intervention|Arm III|Patients undergo observation.
9863253|NCT00058227|Experimental|Treatment (alvocidib, fludarabine phosphate, rituximab)|Patients receive fludarabine phosphate IV over 15-30 minutes on days 1-5 and rituximab IV over 3-4 hours on day 1. Alvocidib is administered IV over 60 minutes on day 1 in cohort 1; on days 1 and 2 in cohort 2; and on days 1, 2, and 3 in cohort 3. In cohorts 4 and 5, patients receive fludarabine phosphate and rituximab as above and alvocidib IV over 30 minutes and then IV over 4 hours on day 1 of courses 2-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9863254|NCT00058253|Experimental|Group I|Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863255|NCT00058253|Experimental|Group II|Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863256|NCT00058292|Experimental|Treatment Arm|
9863257|NCT00058305|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours on days 1 and 15 and vincristine IV on days 2 and 16. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients without disease progression after 6 courses may continue therapy with bryostatin 1 IV over 24 hours on days 1 and 22 and vincristine IV on days 2 and 23. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity."
9863258|NCT00058318|Experimental|Treatment|Gemcitabine + Capecitabine
9863259|NCT00058331|Experimental|epoetin alfa - long term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Then patients receive EPO SC once weekly for 18 weeks. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
9863260|NCT00058331|Experimental|epoetin alfa - short term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Patients receive EPO SC on day 1 of weeks 4, 7, 10, 13, 16, and 19. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
9863261|NCT00058357|Active Comparator|Lidocaine patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
9863262|NCT00058357|Placebo Comparator|Placebo patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
9926341|NCT00881166|Experimental|3|oral MP-470 + topotecan
9926342|NCT00881166|Experimental|4|oral MP-470 + docetaxel
9863263|NCT00058461|Experimental|Treatment (chemotherapy, rituximab)|Patients receive ifosfamide IV over 2 hours and etoposide IV over 1 hour on days 3-5, rituximab IV on days 1 and 3, and carboplatin IV over 1 hour on day 3. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Patients also receive intrathecal (IT) chemotherapy comprising methotrexate and cytarabine. Patients with B-cell large cell lymphoma and negative CSF cytology receive IT chemotherapy on day 3 of the first course only. Patients with small non-cleaved cell lymphoma or B-cell acute lymphoblastic leukemia and negative CSF cytology receive IT chemotherapy on day 3. All patients with positive CSF cytology receive IT chemotherapy on days 3, 10, and 17 of the first and second courses. Treatment repeats every 23 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9863264|NCT00058474|Active Comparator|Arm 1: 5-FU + RT|Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
9863265|NCT00058474|Experimental|Arm 2: 5-FU + RT + Oxaliplatin|Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
9863266|NCT00058474|Experimental|Arm 3: Capecitabine + RT|Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
9863267|NCT00058474|Experimental|Arm 4: Capecitabine + RT + Oxaliplatin|Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
9863268|NCT00058526|Experimental|Cohort 1|Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
9863269|NCT00058526|Experimental|Cohort 2|Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
9863270|NCT00058526|Experimental|Cohort 3|Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
9863271|NCT00058526|Experimental|Cohort 4|Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
9863272|NCT00058591|Experimental|Treatment|Treatment dose levels 1, 2 and 3
9863273|NCT00058604|Experimental|Treatment|Each patient will receive a Biological/Vaccine Intravenous injection of EBV specific CTLs
9863274|NCT00058617|Experimental|Injection of EBV Specific CTLs|Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.
9863275|NCT00058773|Experimental|CTL Administration|Infusion of EBV Specific Cytotoxic T-Lymphocytes
9863276|NCT00058799|Experimental|Dose Level 1|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
9863277|NCT00058799|Experimental|Dose Level 2|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
9863278|NCT00058799|Experimental|Dose Level 3|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
9863279|NCT00058812|Experimental|EBV specific T cells|EBV specific T cells
9863280|NCT00058890|Experimental|Gabapentin|
9863281|NCT00058890|Placebo Comparator|Placebo|
9863282|NCT00058955|Experimental|1|Sodium oxybate
9863283|NCT00058955|Active Comparator|2|triazolam
9863284|NCT00058955|Active Comparator|3|pentobarbital
9863285|NCT00058955|Placebo Comparator|4|Placebo
9863286|NCT00059254|Experimental|Oleic acid (OA)|
9863287|NCT00059254|Experimental|Palmitic acid (PA)|
9863288|NCT00059280|Experimental|1|
9863289|NCT00059306|Active Comparator|Antiplatelet|Participants receive aspirin + placebo OR aspirin + clopidogrel
9863290|NCT00059306|Active Comparator|Blood pressure|The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
9863291|NCT00059345|Experimental|Arm 1: Acupuncture|Participants will receive acupuncture
9863292|NCT00059345|Placebo Comparator|Arm 2: Shallow needling|Participants will receive shallow needling on non-mederian points
9863293|NCT00059345|Other|Arm 3: No Acupuncture or Placebo Treatment|Participants will receive usual care, no acupuncture or placebo acupuncture treatment.
9863294|NCT00059358|Experimental|1|Participants will begin receive either Rebetron or PEG-Intron plus ribavirin therapy from Weeks 2 through 48
9863295|NCT00059371|Active Comparator|Circumcised immediately|
9863296|NCT00059371|Placebo Comparator|Delayed Circumcision|Men who were randomized to delayed circumcision were scheduled to be offered male circumcision 2 years after their randomization.
9863297|NCT00059423||1|Individuals of African descent with benign ethnic neutropenia (BEN) at baseline
9863298|NCT00059423||2|Individuals of African descent without benign ethnic neutropenia (BEN) at baseline
9863299|NCT00059462|Experimental|Arm 1|
9863300|NCT00059462|Active Comparator|Arm 2|
9863301|NCT00059592|Experimental|Valacyclovir|oral Valacyclovir three times a day for 5 to 10 days.
9863302|NCT00059605|Experimental|DOTAP:Chol-fus1|Infusion intravenous once every 3 weeks
9863303|NCT00059618|Experimental|Bortezomib|PS-341 (Bortezomib) 0.8-1.5 mg/m^2 IV push + Carboplatin (AUC 5) IV on Day 1 of each cycle, then Bortezomib alone on Days 4, 8 and 11 in each 28 day cycle.
9863304|NCT00059631|Experimental|Bortezomib + Mitoxantrone|"Bortezomib starting dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.~Mitoxantrone starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles."
9863305|NCT00059683|Experimental|Cervical Cerclage Group|Women randomized to receive cerclage should receive cervical cerclage
9863306|NCT00059683|No Intervention|Control Group|Women randomized to not receive cerclage represent the control arm
9926343|NCT00881166|Experimental|5|oral MP-470 + Erlotinib
9926344|NCT00881179|Experimental|1|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
9926345|NCT00881179|Active Comparator|2|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
9926346|NCT00881192|No Intervention|Control|No preoperative IABP; if needed, postoperative IABP placement
9926347|NCT00881192|Active Comparator|IABP|Preoperative IABP placement
9926348|NCT00881218|Experimental|Regadenoson CMR|Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.
9863307|NCT00059761|Experimental|Sequence A: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
9863308|NCT00059761|Experimental|Sequence B: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
9863309|NCT00059761|Experimental|Sequence A: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
9863310|NCT00059761|Experimental|Sequence B: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
9863311|NCT00059761|Experimental|Sequence A: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
9863312|NCT00059761|Experimental|Sequence B: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
9863313|NCT00059813|Experimental|Treatment (recombinant interferon alfa, oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
9863314|NCT00059826|Experimental|Interferon-based chemoradiation therapy|"Cycle 1: Chemoradiotherapy (CRT)~5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs~cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)~IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks~XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks~Cycles 2 and 3: Post-CRT Chemotherapy~Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).~-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest"
9863315|NCT00059852|Experimental|gemcitabine + erlotinib|"Patients receive gemcitabine IV on days 1 and 8 and oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients achieving a complete response are followed every 6 weeks for up to 5 years or until disease progression (PD). Patients discontinuing study therapy for any other reason are followed every 3 months until PD and then every 6 months for up to 5 years."
9863316|NCT00059865|Experimental|pemetrexed + gemcitabine|"Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
9863317|NCT00059891|Experimental|Anal Sphincter Prosthesis|All patients will follow a common treatment algorithm. Anorectal reconstruction with the ABS neosphincter device will be a staged surgical approach. Routine postoperative testing will then be performed at 6 months (+/- 8 weeks) and 12 months (+/- 8 weeks), following ileostomy reversal which we have designated as time zero. Postoperative testing will include completion of a series of questionnaires.
9863318|NCT00059930|Experimental|Adjuvant Hepatic Arterial Infusion & Combination Chemotherapy|This is a Phase I study with the primary objective of defining the maximum tolerated dose of hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump in combination with intravenous oxaliplatin plus systemic fluorouracil (5FU)/leucovorin (LV) in the adjuvant setting after resection of hepatic metastases from colorectal cancer. A total of eleven dose levels will be considered.
9863319|NCT00060086|Experimental|Pomegranate Juice|Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
9863320|NCT00060112|Experimental|Treatment (oblimersen sodium and gemcitabine hydrochloride)|Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
9863321|NCT00060125|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
9863322|NCT00060203|Experimental|Brostallicin|
9863323|NCT00060307|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863324|NCT00060320|Experimental|black cohost|"Patients receive oral black cohosh twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
9863325|NCT00060320|Placebo Comparator|placebo|"Patients receive oral placebo twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
9863326|NCT00060359|Experimental|Treatment (paclitaxel poliglumex, carboplatin)|"DOSE-ESCALATION PHASE: Patients receive CT-2103 IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of CT-2103 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of treatment.~FEASIBILITY PHASE: Once the MTD of CT-2103 is determined, an additional 20-40 patients receive treatment at that dose level combined with carboplatin as above."
9863327|NCT00060372|Experimental|Treatment (ipilmumab and donor lymphocyte infusion)|Patients receive ipilimumab IV over 90 minutes. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients with persistent or progressive disease at 60 days after ipilimumab administration and no evidence of graft-versus-host disease receive donor lymphocyte infusions every 60 days for a total of 3 infusions.
9863328|NCT00060411|Experimental|Treatment (combination chemotherapy)|Patients receive oral elotinib alone once daily for 1 week before the beginning of course 1. Patients then receive oral erlotinib once daily on days 1-28; oxaliplatin IV over 2 hours on day 1; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Patients also receive bevacizumab IV over 30-90 minutes on day 15 of course 1 and on days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863329|NCT00060450|Experimental|1|Inhaled Nitric Oxide
9863330|NCT00060450|Placebo Comparator|2|Placebo gas
9863331|NCT00060567|Other|1|Active combination of E7070 and irinotecan.
9863332|NCT00060567|Other|2|Active combination of E7070 and irinotecan.
9863333|NCT00060567|Other|3|Active combination of E7070 and irinotecan.
9863334|NCT00060632|Experimental|Cohort 1: Ridaforolimus 6.25 mg|
9863335|NCT00060632|Experimental|Cohort 2: Ridaforolimus 12.5 mg|
9863336|NCT00060632|Experimental|Cohort 3: Ridaforolimus 25 mg|
9863337|NCT00060632|Experimental|Cohort 4: Ridaforolimus 50 mg|
9863338|NCT00060632|Experimental|Cohort 5: Ridaforolimus 100 mg|
9863339|NCT00060632|Experimental|Cohort 6: Ridaforolimus 75 mg|
9863340|NCT00060645|Experimental|1|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
9863341|NCT00060723||Adenotonsillectomy group|Children ages 5-12 who are scheduled for adenotonsillectomy for obstructive sleep apnea
9863342|NCT00060723||Comparison group|Children ages 5-12, scheduled for hernia repairs, other procedures not involving the head, chest or neck, or no procedures. Additional exclusions include children with a history of recurrent throat infections, large tonsils, history of or plans for adenoidectomy and/or tonsillectomy or who have been previously diagnosed with sleep-disordered breathing.
9863343|NCT00060762|Experimental|Interpersonal Therapy|Interpersonal Therapy is a psychotherapy aimed at resolving interpersonal difficulties
9863344|NCT00060762|Active Comparator|Behavioral Weight Loss Treatment|Behavioral Weight Loss Treatment is aimed solely at weight loss, however it has been shown to decrease binge eating
9863345|NCT00060762|Active Comparator|Guided Self Help|Guided Self-Help is a brief psychotherapy based on cognitive-behavioral treatment
9863346|NCT00060814|Experimental|Combined Pharmacotherapy and Counseling|300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
9863347|NCT00060892|Active Comparator|1|0.4 mg AMG0001 on days 0, 14, and 28
9863348|NCT00060892|Active Comparator|2|4.0 mg AMG0001 on days 0, 14, and 28
9863349|NCT00060892|Active Comparator|3|4.0 mg AMG0001 on days 0 and 28; placebo on day 14
9863350|NCT00060892|Placebo Comparator|4|Placebo (saline) on days 0, 14, and 28
9863351|NCT00061087|Active Comparator|METHYLPHENIDATE|Methylphenidate
9863352|NCT00061087|Active Comparator|BUPROPION|Bupropion
9863353|NCT00061087|Placebo Comparator|PLACEBO|Placebo
9863354|NCT00061100|Experimental|RISE intervention|Targeted RISE intervention- Behavior therapy Rise
9863355|NCT00061100|Active Comparator|Standard Education|Education intervention. Standard prevention education
9863356|NCT00061113|Active Comparator|1|fluoxetine + CBT
9863357|NCT00061113|Placebo Comparator|2|placebo + CBT
9863358|NCT00061243|Experimental|1|Participants will receive different doses of the vaccine to determine the optimal dose
9863359|NCT00061243|Experimental|2|Participants will receive different doses of the vaccine to determine the optimal dose
9863360|NCT00061243|Experimental|3|Participants will receive different doses of the vaccine to determine the optimal dose
9863361|NCT00061243|Experimental|4|Participants will receive the vaccine through either intradermal or intramuscular administration
9863362|NCT00061243|Experimental|5|Participants will receive the vaccine through either intradermal or intramuscular administration
9863363|NCT00061269|Experimental|VARD|Videoscopic-Assisted Retroperitoneal Debridement (VARD)
9863364|NCT00061282|Placebo Comparator|1|
9863365|NCT00061282|Active Comparator|2|Clotrimazole Therapy
9863366|NCT00061282|Active Comparator|3|Clotrimazole Therapy
9863367|NCT00061321|Active Comparator|1|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum
9863368|NCT00061321|Experimental|2|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day)by mouth, from week 1 through week 6 post-partum Infants: Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
9863369|NCT00061347|Experimental|1|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
9863370|NCT00061360|Experimental|ATG+CsA|ATG+CsA for 6 months followed by a slow CsA taper in the subsequent 18 months
9863371|NCT00061360|Experimental|ATG+CsA+RA|ATG+CsA+RAPA for 6 months
9926349|NCT00881231|Experimental|1|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
9926350|NCT00881231|Active Comparator|2|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
9926351|NCT00881244|Experimental|1|AS1411
9926352|NCT00881257|Experimental|1|GRST Peripheral Catheter System
9926353|NCT00881270|Experimental|Dermacyd infantile (Lactic Acid)|treatment duration 21 consecutive days
9926354|NCT00881283||cured Cushing's disease|
9926355|NCT00881296|Experimental|1|"Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks"
9926356|NCT00881296|Active Comparator|2|Gemcitabine 1000mg/m2 Day 1, 8, 15
9926357|NCT00881309|Experimental|immunosuppressor|
9926358|NCT00881322|Experimental|BC-130|Active Arm
9926359|NCT00881322|Placebo Comparator|Sugar Pill|Placebo
9926360|NCT00881348|Experimental|Dermacyd infantile (Lactic Acid)|5 weeks treatment
9926361|NCT00881374|Experimental|Dermacyd Infantile (Lactic Acid)|six weeks treatment
9926362|NCT00881387|Experimental|Group 1 (eligible for SCT)|Patients receive rituximab IV, vinorelbine ditartrate IV over 6-10 minutes, and gemcitabine hydrochloride IV over 30 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) or partial response (PR) undergo SCT.
9926363|NCT00881387|Experimental|Group 2 (ineligible for SCT)|Patients receive rituximab, vinorelbine ditartrate, gemcitabine hydrochloride, and pegfilgrastim as in group 1. Patients with CR, PR, or stable disease after 3 courses continue to receive therapy in the absence of disease progression or unacceptable toxicity.
9926364|NCT00881400|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
9926365|NCT00881400|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
9926366|NCT00881413|Experimental|Esomeprazole|High-dose esomeprazole
9926367|NCT00881413|Active Comparator|Pantoprazole|High-dose pantoprazole
9926368|NCT00881426|Experimental|1|Cefprozil 500 mg Tablets (Sandoz GmbH)
9926369|NCT00881426|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
9926370|NCT00881439|Placebo Comparator|Placebo|
9926371|NCT00881439|Active Comparator|Aliskiren|
9926372|NCT00881478|Active Comparator|Nutrition counselling alone|Nutrition counseling session with registered dietician
9863372|NCT00061490|Experimental|1|16 weekly educational meetings
9863373|NCT00061490|No Intervention|2|Wait list control
9863374|NCT00061516|Experimental|Brinzolamide suspension, 1%|Dosed twice daily for 12 weeks
9863375|NCT00061516|Experimental|Levobetaxolol suspension, 0.5%|Dosed twice daily for 12 weeks
9863376|NCT00061542|Experimental|Betaxolol|Two doses daily for 12 weeks
9863377|NCT00061542|Experimental|TGFS 0.25%|Two doses daily for 12 weeks
9863378|NCT00061542|Experimental|TGFS 0.5%|Two doses daily for 12 weeks
9863379|NCT00061620|Experimental|Tezacitabine|Tezacitabine as a bolus infusion daily x 5
9863380|NCT00061698|Active Comparator|Cognitive Behavior Therapy Child Only|Participants completed 20 sessions of CBT
9863381|NCT00061698|Active Comparator|CBT plus Parent training|Child participants completed 20 sessions of CBT and parents completed 8 sessions of parent training
9863382|NCT00061698|No Intervention|Minimal Contact Control|Participants waited 12 weeks for treatment but their safety and well-being were monitored during this time
9863383|NCT00061750|Experimental|ICL670|
9863384|NCT00061750|Active Comparator|Deferoxamine|
9863385|NCT00061815|Experimental|Cetuximab+FOLFOX4|"Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes"
9863386|NCT00061815|Active Comparator|FOLFOX4.|"Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion.~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion."
9863387|NCT00061919|Experimental|Active arm (thalidomide)|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
9863388|NCT00061919|Placebo Comparator|Placebo arm|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
9863389|NCT00061958|Experimental|Treatment (arsenic trioxide)|Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
9863390|NCT00062023|Active Comparator|Arm I Sulindac|Oral sulindac twice daily.
9863391|NCT00062023|Active Comparator|Arm II Aspirin|Oral aspirin once daily.
9863392|NCT00062023|Active Comparator|Arm III Ursodiol|Oral ursodiol three times daily.
9863393|NCT00062023|Placebo Comparator|Arm IV: Sulindac Placebo|Oral sulindac placebo twice daily.
9863394|NCT00062062|Experimental|gefitinib|"Patients receive oral gefitinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
9863395|NCT00062062|Experimental|paclitaxel + carboplatin + gefitinib|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy and in the absence of disease progression, patients receive oral gefitinib as in group I.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
9863396|NCT00062075|Experimental|Treatment|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863397|NCT00062101|Experimental|Group I (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib once daily and oral celecoxib twice daily.
9863398|NCT00062101|Experimental|Group II (erlotinib hydrochloride)|Patients receive erlotinib as in group 1.
9863399|NCT00062114|Experimental|rituximab + yttrium Y 90 ibritumomab tiuxetan|"Patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV (for imaging) over 10 minutes on day 1. Patients undergo 1 (or 2 if needed) imaging scan between days 2-5. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
9863400|NCT00062127|Experimental|Arm I (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863401|NCT00062127|Experimental|Arm II (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863402|NCT00062179|Experimental|paclitaxel/carboplatin/celecoxib|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy
9863403|NCT00062179|Placebo Comparator|paclitaxel/Carboplatin/Placebo|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy
9863404|NCT00062244|Experimental|Arm I|"Phase I: Patients receive oblimersen IV continuously on days 1-7. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment as in phase I at the MTD of oblimersen. Patients are followed every 3 months for 2 years."
9863405|NCT00062309|Active Comparator|CIMRT|76 Gy in 38 fractions
9863406|NCT00062309|Experimental|HIMRT|70.2 Gy in 26 fractions
9863407|NCT00062387|Experimental|Arm I|Patients receive oral perifosine 4 times daily on days 1 and 2 and once daily on days 3-28 during course 1. Patients receive oral perifosine once daily on days 1-28 for all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863408|NCT00062452||A-1,2,3|The cohort (A) comprised of high risk infants. There were 3 sub groups studied within this cohort: (1) premature infants, (2) Infants with congenital gut anomalies, and (3) perinatal asphyxia.
9863409|NCT00062478|Experimental|1|Karenitecin for intravenous use
9863410|NCT00062491|Experimental|1|Karenitecin (BNP1350)
9863411|NCT00062504|Experimental|1|Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
9863412|NCT00062504|Experimental|2|Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
9863413|NCT00062504|Experimental|3|Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
9863414|NCT00062530|Experimental|1|All participants will receive oral vaccine at study entry, although dosage will vary
9863415|NCT00062543|Experimental|Hepatic Artery Infusion|Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 * 106 CD34+ cells/kg. Next 3 patients receive 2.5 * 106 CD34+cells/kg. Next 3 patients receive 5 * 106 CD34+ cells/kg. Less than 1 * 105 T cells/kg administered.
9863416|NCT00062569|Experimental|1|
9863417|NCT00062569|Experimental|2|
9863418|NCT00062829|Other|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
9863419|NCT00062842|Experimental|Irinotecan weekly|Irinotecan was administered over 90 min weekly 4x, every 6 weeks.
9863420|NCT00062855|Experimental|Gene Modified Neuroblastoma Cells|Gene modified neuroblastoma cells given as 4 subcutaneous injections over 5 weeks
9863421|NCT00062985|No Intervention|Control|
9863422|NCT00062985|Experimental|Mail-based weight loss intervention|
9863423|NCT00062985|Experimental|Telephone-based weight loss intervention|
9926373|NCT00881478|Experimental|Nutrition counselling + portion control|Nutrition counseling with registered dietician in addition to teaching about use of a portion control tool
9926374|NCT00881491|Experimental|Group A|Group A - Double antibiotic paste: intracanal medicament consisting of ciprofloxacin and metronidazole
9926375|NCT00881491|Experimental|Group B|Group B - Triple Antibiotic Paste: intracanal medicament consisting of ciprofloxacin, metronidazole, minocycline
9926376|NCT00881491|Active Comparator|Group C|Group C - Mineral trioxide aggregate: used as an apical barrier
9926377|NCT00881517|Experimental|Cytotect|
9926378|NCT00881517|Placebo Comparator|placebo|
9926379|NCT00881543|Placebo Comparator|1|This arm will begin taking the placebo by a month, after a month will be tested the diets (the same caloric amount with different composition on fat, protein and carbohydrates)making curves of insulin, glucagon, C peptide and glp 1 and lipid when diets are tested (three acute tests with diets). After that, the patient will begin the drug by month (Januvia, 100 mg a day)and repeat all the three curves using the prepared diets to compare with the first month.
9926380|NCT00881543|Active Comparator|2|Since the beginning they will use the drug. Then will make the three tests and after will stop the drug by 1 month and come back to do the tests. We objective to demonstrate the washout of the drug clinically.
9926381|NCT00881556|Experimental|RIC Group|"Reduced Intensity Transplant Conditioning (RIC):~Palifermin (Kepivance®) 60 mcg/kg/day for 6 days Fludarabine 30 mg/m2 IV x 1 for 6 days Busulfan 4 mg/kg/day IV divided BID for 4 days Lorazepam 0.02-0.05 mg/kg for 5 days Alemtuzumab 20 mg/m2 IV for 5 days Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days"
9926382|NCT00881582|Experimental|Pegylated interferon alfa-2a plus ribavarin|Pegylated interferon alfa-2a plus ribavarin for 48 weeks
9926383|NCT00881595|Other|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
9863424|NCT00063076|Experimental|Targretin®|Targretin® (bexarotene) Gel 1%, treat half head
9863425|NCT00063076|No Intervention|Control|Half head untreated as control
9863426|NCT00063089|Experimental|altastaph|S. aureus Immune Globulin Intravenous (Human) 5%
9863427|NCT00063089|Placebo Comparator|Placebo|0.45% Normal Saline
9863428|NCT00063128|Experimental|A|
9863429|NCT00063128|Active Comparator|B|
9863430|NCT00063141|Experimental|Arm A|
9863431|NCT00063141|Active Comparator|Arm B|
9863432|NCT00063323|Active Comparator|Bupropion|Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
9863433|NCT00063323|Active Comparator|Nicotine gum|Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
9863434|NCT00063323|Active Comparator|Bupropion+Nicotine Gum|Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
9863435|NCT00063323|Placebo Comparator|Double placebo|Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.
9863436|NCT00063336|Experimental|1|Participants will receive cognitive remediation treatment.
9863437|NCT00063336|Experimental|2|Participants will receive computer-skills training.
9863438|NCT00063388|Experimental|1|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
9863439|NCT00063401|Experimental|1|Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
9863440|NCT00063453|Experimental|Vitamin E and selenium placebo|Vitamin E alone
9863441|NCT00063453|Experimental|Selenium and vitamin E placebo|Selenium alone
9863442|NCT00063453|Experimental|Vitamin E and selenium|Vitamin E and selenium combined
9863443|NCT00063453|Placebo Comparator|vitamin E Placebo and Selenium placebo|Double placebo
9863444|NCT00063531||GeneSTAR participant meeting entry criteria|Healthy siblings of patients with early onset CAD (<60 years old) and the adult offspring of the siblings or probands
9863445|NCT00063583|Placebo Comparator|Placebo|Placebo
9863446|NCT00063583|Experimental|Pirfenidone 1200 mg/day|Pirfenidone will be administered at a dose of 1200 mg/day
9863447|NCT00063583|Experimental|Pirfenidone 2400 mg/day|Pirfenidone will be administered at 2400 mg/day
9863448|NCT00063778|Experimental|1 x 10^4 IU dose|Vaccine dose of 1 x 10^4 IU per injection
9863449|NCT00063778|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
9863450|NCT00063778|Placebo Comparator|Placebo|
9863451|NCT00063804|Experimental|1|escalating single doses of AMD070 ranging from 1/4 to 1 times the maximum tolerated dose (MTD)
9863452|NCT00063804|Experimental|2|single dose of 200 mg AMD070 after eating a standardized meal
9863453|NCT00063804|Experimental|3|single dose of 200 mg AMD070 on Days 1, 3, and 17 and single dose of 100 mg ritonavir on Days 3 through 18
9863454|NCT00063817|Experimental|Conditioning Regimen|"Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days."
9863455|NCT00063895|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863456|NCT00063947|Experimental|Treatment (radiotherapy, gemcitabine, erlotinib hydrochloride)|Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
9863457|NCT00063960|Experimental|floxuridine + irinotecan|"Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.~Patients are followed every 3 months for 2 years."
9935241|NCT03989102|Experimental|Arm 1|Arm 1: (n= 100) will receive 3 doses of PfSPZ Vaccine (9 x10(5)) via direct venous inoculation (DVI) at 1, 8, 29 days.
9863458|NCT00063973|Experimental|Treatment (cilengitide)|"Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of cilengitide until the MTD is determined. The MTD is defined as the dose at which 25% of patients are expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are accrued and treated at that dose level for a total of 12 patients at the MTD."
9863459|NCT00064012|Active Comparator|Velcade Alone|Velcade
9863460|NCT00064012|Experimental|Velcade plus Docetaxel|Velcade plus Docetaxel
9863461|NCT00064103|Experimental|Treatment (Ad5CMV-p53 gene)|"Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD."
9863462|NCT00064116|Active Comparator|Arm A: CHOP-21|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
9863463|NCT00064116|Active Comparator|Arm B: CHOP-21 + Rituximab|Rituximab 375 mg/m² i.v. day 1* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
9863464|NCT00064129|Experimental|Treatment (monoclonal antibody, colony-stimulating factors)|Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
9863465|NCT00064142|Experimental|Arm I (halofuginone hydrobromide)|Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.
9863466|NCT00064142|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.
9863467|NCT00064246|Experimental|Treatment (rituximab, yttrium Y 90 ibritumomab tiuxetan)|"Phase I: Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo 2 (or 3 if needed) imaging scans between days 1-6. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by IDEC-Y2B8 IV over 10 minutes on day 8.~Phase II: Patients receive treatment as in phase I at the MTD of IDEC-Y2B8. Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
9863468|NCT00064272|Experimental|Arm I|Patients receive lower-dose oral ginger twice daily.
9863469|NCT00064272|Experimental|Arm II|Patients receive higher-dose oral ginger twice daily.
9863470|NCT00064272|Placebo Comparator|Arm III|Patients receive oral placebo twice daily.
9863471|NCT00064324|Experimental|Arm I|Patients receive a loading dose of oral perifosine every 6 hours for a total of 4 doses on day 1 and once daily on days 2-28 of course 1 only. For all subsequent courses, patients receive oral perifosine once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9863472|NCT00064389|Experimental|1|levalbuterol 90 mcg MDI QID
9863473|NCT00064389|Active Comparator|2|racemic albuterol HFA MDI 180 mcg QID
9863474|NCT00064402|Experimental|1|Arformoterol 50 mcg QD and placebo MDI
9863475|NCT00064402|Experimental|2|Arformoterol 25 mcg BID and Placebo MDI
9863476|NCT00064402|Experimental|3|Arformoterol 15 mcg BID and placebo MDI
9863477|NCT00064402|Active Comparator|4|Salmeterol MDI 42 mcg BID and placebo inhalation solution
9863478|NCT00064402|Placebo Comparator|5|Placebo MDI and placebo inhalation solution
9863479|NCT00064415|Experimental|1|Arformoterol tartrate 50 mcg QD
9863480|NCT00064415|Active Comparator|2|Salmeterol 42 mcg BID
9863481|NCT00064428|Experimental|Fondaparinux - UFH not indicated|Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
9863482|NCT00064428|Placebo Comparator|Control - UFH not indicated|Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
9863483|NCT00064428|Experimental|Fondaparinux - UFH indicated|Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
9863484|NCT00064428|Active Comparator|Control - unfractionated heparin|Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
9863485|NCT00064519||Families with MI|"In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P < 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.~No drugs are to be administre"
9863486|NCT00064649|Active Comparator|2|Transurethral Needle Ablation (TUNA)
9863487|NCT00064649|Active Comparator|3|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
9863488|NCT00064649|Active Comparator|1|Transurethral Microwave Thermotherapy (TUMT)
9926384|NCT00881595|Active Comparator|Chemoradiotherapy Temozolomide|Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
9926385|NCT00881595|Active Comparator|Proton Therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
9926386|NCT00881634|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
9926387|NCT00881634|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
9926388|NCT00881673|Experimental|1|
9926389|NCT00881673|Active Comparator|2|
9926390|NCT00881673|Placebo Comparator|3|
9926391|NCT00881686|Experimental|adenosine|Adenosine will be administered intravenously before surgery
9926392|NCT00881699|Experimental|1|Participants will complete HIV risk reduction group meetings.
9926393|NCT00881699|Active Comparator|2|Participants will complete health promotion group meetings.
9926394|NCT00881725|Experimental|Metformin|500mg t.i.d. for 4-12 weeks prior to Radical Prostatectomy
9926395|NCT00881738|Experimental|1|Clarithromycin 250 mg Tablets (Geneva, USA)
9926396|NCT00881738|Active Comparator|2|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
9926397|NCT00881764||Exposed Cohort|Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
9926398|NCT00881764||Unexposed Cohort|Children who are siblings of the exposed children (inguinal hernia surgery and general anesthesia) and differ in age from the exposed children by less than 36 months and have no history of surgery or exposure to volatile and intravenous anesthetics or sedatives including barbiturates, benzodiazepines and chloral hydrate less than 36 months of age. These children should also be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
9926399|NCT00881777|Experimental|RF Heating + CABG|Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
9926400|NCT00881777|Active Comparator|CABG Alone|Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
9935242|NCT03989102|Experimental|Arm 2|Arm 2: (n= 100) will receive 3 doses of PfSPZ Vaccine (1.8 x10(6)) via DVI at 1, 8, 29 days.
9863489|NCT00064883||Patients|Pediatric cancer patients referred to the ROB who have received or require radiation therapy
9863490|NCT00064974|Experimental|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
9863491|NCT00065208|Experimental|Reiki|Energy therapy
9863492|NCT00065208|Sham Comparator|Pretend Reiki|
9863493|NCT00065208|Other|Rest / Guided Imagery|Rest for pre-surgery outcomes Guided Imagery for post-surgery outcomes
9863494|NCT00065325|Active Comparator|1|Exemestane
9863495|NCT00065325|Experimental|2|Fulvestrant
9863496|NCT00065351|Experimental|1|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
9863497|NCT00065546|Active Comparator|1|Post-menopausal women randomized to receive estrogen replacement therapy.
9863498|NCT00065546|Placebo Comparator|2|Post-menopausal women randomized to receive a placebo.
9863499|NCT00065546|Experimental|3|Pre-menopausal women with specific genetic variants.
9863500|NCT00065585|No Intervention|Usual care|
9863501|NCT00065585|Placebo Comparator|non needle control|
9863502|NCT00065585|Sham Comparator|Acupuncture - Standardized Points|
9863503|NCT00065585|Experimental|Accupunture - Experimental Points|
9863504|NCT00065637|Experimental|1|Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks
9863505|NCT00065637|Placebo Comparator|2|Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks
9863506|NCT00065715|No Intervention|A|No pills
9863507|NCT00065715|Placebo Comparator|B|Blinded placebo
9863508|NCT00065715|Experimental|C|Echinacea - Blinded
9863509|NCT00065715|Experimental|D|Echinacea - Unblinded, Open Label
9863510|NCT00065845|No Intervention|Abdominal Sacral Colpopexy with no Burch colposuspension|Abdominal sacral colpopexy is performed through a laparotomy approach.
9863511|NCT00065845|Experimental|Abdominal Sacral Colpopexy with Burch Colposuspension|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
9863512|NCT00066001|Placebo Comparator|1, 2, 3, 4|The 4 arms of the study are based on the treatment groups: 1. scaling and root planing alone (SRP); 2. SRP plus repeated professional supragingival plaque removal; 3. SRP + systemically administered metronidazole; 4. SRP + repeated professional supragingival plaque removal + systemically administered metronidazole.
9863513|NCT00066014|Active Comparator|treatment modalities changed for comparison|All subjects experienced all treatment modalities being studied.
9863514|NCT00066027|Experimental|low-dose doxycycline|low-dose doxycycline (20 mg doxycycline hyclate)
9863515|NCT00066027|Placebo Comparator|Placebo|Placebo
9863516|NCT00066053|Experimental|Periodontal Treatment: SRP|Comprehensive scaling & root planing and subgingival tissue removal; fluorides applied as appropriate; oral hygiene instructions.
9863517|NCT00066053|Active Comparator|Community Comparator|Referral to community dentist with copy of x-rays and letter with diagnosis and recomendations for treatment.
9863518|NCT00066092|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
9863519|NCT00066092|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
9863520|NCT00066092|Active Comparator|filgrastim|Filgrastim given daily for PBPC mobilization
9863521|NCT00066131|Active Comparator|Scaling and root planing|Scaling and root planing delivered prior to 21 weeks of gestation.
9926401|NCT00881790||Fluoride application|
9863522|NCT00066131|No Intervention|Placebo|Delayed treatment group. Controls monitored clinically from baseline to 29-32 weeks of gestation. Scaling and root planing provided after delivery.
9863523|NCT00066157|Experimental|1|estradiol patch and medroxyprogesterone
9863524|NCT00066157|Active Comparator|2|estradiol patch and placebo pill
9863525|NCT00066157|Active Comparator|3|placebo patch and medroxyprogesterone
9863526|NCT00066157|Placebo Comparator|4|placebo patch and placebo pill
9863527|NCT00066196|Other|2|Integrin + Dacarbazine
9863528|NCT00066196|Active Comparator|1|MEDI-522
9863529|NCT00066248|Experimental|Subjects that respond to Periactin|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
9863530|NCT00066248|Experimental|Non-responders to Periactin- Megace Arm|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
9863531|NCT00066378|Experimental|Arimidex + Iressa® 250 mg|Arimidex + Iressa® 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
9863532|NCT00066378|Active Comparator|Arimidex + Placebo|Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
9863533|NCT00066430|Experimental|Infrared coagulator|
9863534|NCT00066443|Experimental|Pegfilgrastim, docetaxel and epirubicin|
9863535|NCT00066456|Experimental|Treatment (chemosensitization, radiation, docetaxel)|Patients receive docetaxel IV over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. Within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. Treatment continues in the absence of unacceptable toxicity.
9926402|NCT00881803||Group 1|Ascorbic Acid Supplementation Only
9926403|NCT00881803||Group 2|Iron Supplementation Only
9926404|NCT00881803||Group 3|Concurrent Ascorbic Acid & Iron Supplementation
9926405|NCT00881816|Experimental|Liposomal paclitaxel plus capecitabine|
9926406|NCT00881829||Healthy volunteer|Smoker or non-smoker
9926407|NCT00881842|Experimental|1|
9926408|NCT00881855|Experimental|1|Cefprozil 500 mg Tablets (Sandoz, GmbH)
9926409|NCT00881855|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
9863536|NCT00066482|Experimental|combination chemotherapy|"Induction therapy: bleomycin sulfate IV over 10-20 minutes on day 1, etoposide IV over 1 hour and cisplatin IV over 4 hours on days 1-5, and cyclophosphamide IV over 1 hour on day 1. MESNA & Filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. 6 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined.~Evaluated after 4 courses of therapy. Partial response or stable disease undergo second-look conventional surgery & receive 2 more courses of induction therapy then re-evaluated. Those who do not achieve complete response (CR) after a total of 6 courses may undergo a third conventional surgery. Tumor that cannot be removed are removed from study therapy. Achievement of a CR at anytime are followed monthly for 1 year, every 6 months for 1 year, and then annually for 3 years."
9926410|NCT00881881||1|Patients with early RA
9926411|NCT00881907|Experimental|Group A|Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
9926412|NCT00881907|Experimental|Group B|Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
9926413|NCT00881907|Experimental|Group C|Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
9926414|NCT00881933|Experimental|Fludarabine|
9926415|NCT00881946|Experimental|GSK2119183|
9926416|NCT00881972|Experimental|exercise|
9926417|NCT00881985|Active Comparator|continuous positive airway pressure|
9926418|NCT00881985|No Intervention|observation|
9926419|NCT00881998|Active Comparator|1|Minimally invasive total hip arthroplasty
9926420|NCT00881998|Active Comparator|2|
9926421|NCT00882011||Arm 1|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant.
9926422|NCT00882024|Experimental|1 Tranilast|Tranilast, 300 mg/day
9926423|NCT00882024|Experimental|2 Tranilast|Tranilast, 150 mg/day
9926424|NCT00882024|Placebo Comparator|3|Placebo
9926425|NCT00882037||Meth Dependence|Methamphetamine Dependence in residential Substance Abuse Treatment Program
9926426|NCT00882063|Experimental|P276-00|Starting dose level of P276-00 is 50 mg/m2/day. The drug will be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min. Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.
9926427|NCT00882076|Experimental|Treatment Cohort 1|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6) 20 mg/m2
9926428|NCT00882076|Experimental|Treatment Cohort 2|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 25 mg/m2
9926429|NCT00882076|Experimental|Treatment Cohort 3|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
9926430|NCT00882076|Experimental|Treatment Cohort 4|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-5) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
9926431|NCT00882076|Experimental|Treatment Cohort 0|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 10 mg/m2 (In the event of a DLT in Treatment Cohort 1)
9926432|NCT00882089|Experimental|1|A Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial irradiation begins.
9926433|NCT00882128||1|
9926434|NCT00882141|Experimental|1|Weight loss
9926435|NCT00882141|Experimental|2|Exercise plus weight loss
9926436|NCT00882154|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
9926437|NCT00882154|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
9926438|NCT00882167||1|Patients with laparotomy in history
9926439|NCT00882219|Experimental|Xience V®|
9926440|NCT00882232|Experimental|1|Cross-linked hyaluronan gel and radiotherapy. Cross-linked hyaluronan gel is injected under anesthesia between the prostate and rectum prior to the start of radiotherapy. The gel pushes the prostate away from the rectum over several months, thereby reducing the dose of radiation delivered to the rectum. Hyaluronic acid is a naturally-occurring substance that is gradually absorbed by the body.
9926441|NCT00882245|Placebo Comparator|Vehicle ointment|
9926442|NCT00882245|Experimental|SRD441 Ointment|
9926443|NCT00882258|Experimental|12.5 mg Proellex|Proellex 12.5 mg daily
9926444|NCT00882258|Experimental|25 mg Proellex daily|Proellex 25 mg
9926445|NCT00882258|Placebo Comparator|Placebo|Placebo daily
9926446|NCT00882271|Experimental|1|Traditional Chinese Acupuncture
9926447|NCT00882271|Placebo Comparator|2|Placebo Acupuncture
9926448|NCT00882297|Active Comparator|1|Transversal approach guided placement
9926449|NCT00882297|Active Comparator|2|Longitudinal approach guided placement
9926450|NCT00882323|Experimental|Fludarabine|
9863537|NCT00066586|Active Comparator|Exemestane|
9863538|NCT00066586|Placebo Comparator|Placebo|
9863539|NCT00066612|Experimental|Treatment|Irinotecan
9863540|NCT00066625|Experimental|Treatment (oxaliplatin, bortezomib)|"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the MTDs are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9863541|NCT00066638|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
9863542|NCT00066768|Experimental|Arm I|Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.
9863543|NCT00066768|Experimental|Arm II|Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.
9863544|NCT00066859|Active Comparator|Arm 1: Sertraline (Zoloft) 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
9863545|NCT00066859|Active Comparator|Arm 2 - St. John's Wort 600mg|St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.
9863546|NCT00067015|Experimental|IMRT alone to 86.4 Gy|External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
9863547|NCT00067015|Experimental|IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation|Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
9863548|NCT00067080|Experimental|ICL670 + deferoxamine|
9863549|NCT00067106||1: Women failing therapy|Participants will have study visits at study entry, 2 weeks after changing medications, then every 4 weeks until the amount of HIV in the blood and genital tract are undetectable. Drug levels in the blood and genital tract will also be measured at the first visit and after changing medications. Once the level of HIV is undetectable, women will be seen every 3 months for 36 months. Participants in Group 1 will be followed no more than 42 months.
9863550|NCT00067106||2: Women suppressed on therapy|Participants will have study visits for blood and genital tract collections at study entry and then every 4 weeks for 12 months
9863551|NCT00067119|Experimental|Aggrenox|
9863552|NCT00067119|Placebo Comparator|Placebo|
9863553|NCT00067340|Experimental|Intervention group|Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
9863554|NCT00067340|Placebo Comparator|Control|Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse
9863555|NCT00067366|Experimental|Coping Skills Training|manualized coping skills training delivered along with conservative care
9863556|NCT00067366|Active Comparator|Standard Care|Attention and life counseling added to Standard conservative care
9863557|NCT00067379|Active Comparator|1|Medicaid patients with medically necessary malocclusions treated during the mixed dentition with limited goals followed by observation
9863558|NCT00067587||HIV Negative|HIV negative subjects
9863559|NCT00067587||HIV Positive - NEVER had ARV therapy.|HIV Positive - NEVER had ARV therapy.
9863560|NCT00067587||HIV positive, on a NNRTI, non-PI regimen|HIV positive, currently on a NNRTI, non-PI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI-containing regimen and at least ONE year must have passed since receipt of last PI-containing regimen.
9863561|NCT00067587||HIV positive, on a PI, non-NNRTI regimen|HIV positive, currently on a PI, non-NNRTI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of NNRTI-containing regimen and at least ONE year must have passed since receipt of last NNRTIcontaining regimen.
9863562|NCT00067587||HIV positive, on a non-PI, non-NNRTI|HIV positive, currently on a non-PI, non-NNRTI containing regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI- and/or NNRTI- containing regimen and at least ONE year must have passed since receipt of last PI- and/or NNRTI-containing regimen.
9863563|NCT00067613|Active Comparator|Intervention|Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.
9863564|NCT00067613|Placebo Comparator|Control|Clinical sites randomized to Control will continue with their normal management practices for BPD.
9863565|NCT00067626|Experimental|1|500/1000 mcg oral chromium taken daily or placebo (crossover)
9863566|NCT00067626|Experimental|2|500/1000 mcg oral chromium taken daily or placebo (crossover)
9863567|NCT00067639|Experimental|Pegfilgrastim + Apheresis|12 mg Pegfilgrastim as subcutaneous injection on day 1 + Apheresis daily till target stem cell dose reached.
9863568|NCT00067665|No Intervention|1|Control group of 50 patients where dry weight is not changed.
9863569|NCT00067665|Experimental|2|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
9863570|NCT00067704|Experimental|Trauma writing|Four sessions of writing about traumatic experiences.
9863571|NCT00067704|Sham Comparator|Writing about daily events|Four sessions of writing about their daily experiences.
9863572|NCT00067717|Experimental|Distant Healing|This group received distant healing but was blinded to the condition.
9863573|NCT00067717|Placebo Comparator|Non-blinded Distant Healing|This group received the distant healing intervention and was called every day they were receiving to be told they were receiving it, therefore enhancing expectancy.
9863574|NCT00067717|No Intervention|Blinded Control|This group was blinded to the intervention condition and did not receive any distant healing.
9863575|NCT00067730|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
9863576|NCT00067743|Other|1|Open Label trial
9863577|NCT00067756|Experimental|4-PBA|The study will involve a 4-PBA dose escalation and pharmacokinetics component The study group will be comprised of a total of at least 10 AAT-deficient,(phenotype ZZ referred to as PiZZ) patients. These patients will be divided into two groups: with and without clinical evidence of mild to moderate hepatocellular injury.
9863578|NCT00067769|Active Comparator|TAU|Patients received treatment as usual (TAU) as defined as continued clinical care.
9863579|NCT00067769|Experimental|TAU+UCanPoopToo|Patients received treatment as usual (TAU) plus the Internet intervention (UCanPoopToo.)
9863580|NCT00067873|Active Comparator|Diet only|
9863581|NCT00067873|Experimental|Diet plus aerobic exercise|
9863582|NCT00067873|Experimental|Diet plus resistance exercise|
9863583|NCT00067938|Other|Arm 1|Open label single arm study
9863584|NCT00068055|Experimental|1|60 subjects to receive Omr-IgG-am.
9863585|NCT00068055|Active Comparator|2|20 subjects to receive Polygam® S/D (IVIG).
9863586|NCT00068055|Placebo Comparator|3|20 subjects to receive normal saline.
9926451|NCT00882336||1|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
9926452|NCT00882375|Experimental|Nicotine|Nicotine
9926453|NCT00882375|Placebo Comparator|Placebo|Placebo
9926454|NCT00882388|Active Comparator|ASA|aspirin only
9926455|NCT00882388|Active Comparator|Cele|
9926456|NCT00882388|Experimental|ASA + Cele|
9926457|NCT00882388|Active Comparator|ASA + Clo|
9926458|NCT00882388|Experimental|ASA + Clo + Cele|
9926459|NCT00882401|Active Comparator|Ergocalciferol (oral)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
9926460|NCT00882401|Placebo Comparator|Placebo|Matching placebo at same dose schedule as ergocalciferol
9926461|NCT00882414|Placebo Comparator|ThromboVIT Placebo|Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.
9935243|NCT03989102|Placebo Comparator|Arm 3|Arm 3: (n=100): will receive 3 doses of normal saline (placebo) injection via DVI at 1, 8, 29 days.
9935244|NCT03986034|Experimental|Relapsed/Refractory CLL pts|Ages 18 and older
9935245|NCT03986021||At-risk girls|Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-<15
10210248|NCT00659646|Active Comparator|B|Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
9863587|NCT00068224||Ciliopathy|Children and adults who carry a clinical diagnosis of a known ciliopathy and those patients who have typical features suggestive of a cliopathy but not fulfilling the diagnostic criteria.
9863588|NCT00068302|Experimental|Sirolimus|This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose
9863589|NCT00068315|Experimental|Treatment (bortezomib, fludarabine, rituximab)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9863590|NCT00068328||Group 1|"Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.~Patients are followed annually for at least 5 years."
9863591|NCT00068432|Experimental|Gemcitabine + Celecoxib|Oral celecoxib twice daily on days 1-28. Gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
9863592|NCT00068458|Active Comparator|Arm 1: calcium diet|Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
9863593|NCT00068458|Active Comparator|Arm 2: Exercise + Calcium-Rich Diet|Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
9863594|NCT00068458|Active Comparator|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|Dietary counseling + materials promoting strength training and aerobic activity + a diet that has < 20% of energy coming from fat and intakes of fruits and vegetables of > 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
9863595|NCT00068484|Experimental|Treatment (topotecan hydrochloride, bortezomib)|Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9863596|NCT00068497|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
9863597|NCT00068510|Experimental|autologous tumor lysate-pulsed DC|
9863598|NCT00068549|Experimental|Treatment|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.
9863599|NCT00068653|Experimental|Celecoxib & ZD1839|"Celecoxib: 400mg orally two times a day, taken with meals.~ZD1839: 250 mg po every day, taken with or without food."
9863600|NCT00068666|Experimental|radiation + temozolomide|"Patients receive concurrent chemoradiotherapy comprising whole brain radiotherapy daily on days 1-5, 8-13, and 16-21 and oral temozolomide daily on days 1-5. Subsequent treatment with temozolomide repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months."
9863601|NCT00068731|Experimental|lycopene|"Patients receive oral lycopene twice daily on days 1-28. Courses repeat every 28 days for at least 4 months in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
9863602|NCT00068783|Experimental|Treatment|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
9863603|NCT00068809|Experimental|Short-cycle therapy (SCT)|At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
9863604|NCT00068874|Active Comparator|1|Educational comparison group
9863605|NCT00068874|Experimental|2|Group receiving coping intervention designed to enhance coping and psychological adjustment
9863606|NCT00068874|No Intervention|3|Comparison control group with no active intervention
9863607|NCT00068991|Experimental|1|Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session. After training, participants complete a post-training evaluation of the training sessions. Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
9863608|NCT00068991|Experimental|2|Participants will be villagers considered influential members of their community. In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Participants will also attend additional support meetings monthly, from Months 2 to 15. They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
9863609|NCT00068991|Experimental|3|Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
9863610|NCT00069017|Active Comparator|1|MEDI-522 - 4 mg/kg of MEDI-522 (N=200)
9863611|NCT00069017|Placebo Comparator|2|Placebo (N=100)
10210249|NCT00567580|Active Comparator|PBRT Alone|Prostate bed radiotherapy (PBRT) begins within 6 weeks (+/- 2 weeks) after registration.
9863612|NCT00069069|Experimental|1|single center, Phase 1, open label, dose escalation trial assessing safety profile of four doses of intranasal recombinant human E-selectin
9863613|NCT00069082|Active Comparator|Civamide|Nasal Solution 0.01%
9863614|NCT00069082|Placebo Comparator|Placebo|Placebo nasal solution with sodium chloride 10%
9863615|NCT00069134|Experimental|Sulfur Amino Acids|12 children with edematous severe malnutrition will be assigned to receive 0.65 mmol/kg/d of sulfur amino acids. Supplements will be added to the children's daily diets.
9863616|NCT00069134|Placebo Comparator|Alanine|12 children with edematous severe malnutrition are assigned to receive 0.65 mmol/kg/d of alanine as placebo. Supplements will be added to the children's daily diets.
9863617|NCT00069381|Experimental|study arm|
9863618|NCT00069407|Active Comparator|RUL|Right unilateral electroconvulsive therapy
9863619|NCT00069407|Active Comparator|BL|Bilateral electroconvulsive therapy
9863620|NCT00069407|Active Comparator|BF|Bifrontal electroconvulsive therapy
9863621|NCT00069459|Other|Extended-release Bupropion Hydrochloride|Extended-release Bupropion Hydrochloride
9863622|NCT00069706|Experimental|AL-12182 0.003%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
9863623|NCT00069706|Placebo Comparator|AL-12182 Solution Vehicle|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
9863624|NCT00069706|Active Comparator|Latanoprost|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
9863625|NCT00069706|Experimental|AL-12182 0.01%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
9863626|NCT00069706|Experimental|AL-12182 0.03%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
9863627|NCT00069836|Experimental|Arm 1|
9863628|NCT00069927|Experimental|Arm 1- Adderall- XR®|Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
9863629|NCT00069927|Experimental|Arm II Concerta®|Concerta ® 18 mg/day for 3-12 weeks depending on subject's response
9863630|NCT00069992|Experimental|Submyeloablative Allogeneic Stem Cell Transplant|Total Body Irradiation Fludarabine Campath 1H
9863631|NCT00070057|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily for 1-3 weeks (according to the duration between biopsy and surgery) in the absence of unacceptable toxicity.
9863632|NCT00070057|Experimental|Arm II (high-dose celecoxib)|Patients receive a higher dose of oral celecoxib as in arm I.
9863633|NCT00070057|Active Comparator|Arm III (surgery)|Patients do not receive treatment. All patients undergo surgery.
9863634|NCT00070122|Experimental|Arm I (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
9863635|NCT00070122|Experimental|Arm II (oxaliplatin, capecitabine)|Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
9863636|NCT00070148|Active Comparator|Arm 1 Oxandrolone 20 mg daily|Oxandrolone 20 mg (10 mg BID) for 12 weeks. 4 additional weeks of follow-up.
9863637|NCT00070148|Active Comparator|Megace 800 mg|Megestrol acetate 800 mg daily for 12 weeks. 4 additional weeks of follow-up.
9926462|NCT00882414|Experimental|ThromboVIT 1000|ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.
9926463|NCT00882414|Experimental|ThromboVIT 1500|Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).
9926464|NCT00882414|Experimental|ThromboVIT 500|ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.
9926465|NCT00882427|Experimental|eMPC|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
9926466|NCT00882453||Group 1|
9926467|NCT00882466|No Intervention|PCI only|primary PCI only
9926468|NCT00882466|Experimental|EPO|
9926469|NCT00882492|Active Comparator|1|This active arm is a continuous infusion of GLP-1 during cardiac surgery
9926470|NCT00882492|Placebo Comparator|2|This is a continuous infusion of normal saline solution infusion as placebo at (1.5 pmol/kg/min)
9926471|NCT00882531|Experimental|Isotretinoin|
9926472|NCT00882531|Placebo Comparator|placebo|
9926473|NCT00882544||Diagnosed Pediatric Hydronephrosis|Children diagnosed with hydronephrosis who are to receive robotic pyeloplasty surgery
9926474|NCT00882570|Experimental|1|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
9926475|NCT00882570|Active Comparator|2|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
9926476|NCT00882596|Experimental|1|Contura accelerated partial breast irradiation. Following a lumpectomy, a Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial breast irradiation begins.
9926477|NCT00882609|Active Comparator|TC-MDP Bone Scan|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
9935246|NCT03986021||Healthy control women|Women age >18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days
9935247|NCT03986021||post-menarche girls|Healthy, early post-menarchal girls age 8-<15
9863638|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover.~IMMUNOTHERAPY: Cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of recombinant interferon gamma and interleukin-2. When sufficiently recovered, Aldesleukin once daily for 18 days."
9863639|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-no immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover."
9863640|NCT00070200|Experimental|All patients|Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (> 12 kg 400 mg/m2/day, < 12 kg 13.3 mg/kg/day, < 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (> 12 kg 1.2 mg/m2/day, < 12 kg 0.04 mg/kg/day, < 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (> 12 kg 5 micrograms/kg, < 12 kg 5 micrograms /kg, < 2 years old 5 micrograms /kg.
9863641|NCT00070213|Active Comparator|MdG (modified de Gramont)|2 weekly 5FU/FA schedule
9863642|NCT00070213|Experimental|OxMdG (80%) for 12 weeks|MdG + oxaliplatin
9863643|NCT00070213|Experimental|Capcitabine|
9863644|NCT00070213|Experimental|OxCap|
9863645|NCT00070239|Experimental|Treatment|"PART 1 (closed to accrual as of 8/2005): Patients receive alvocidib IV over 1 hour on days 1, 8, and 15.~Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD* is determined.~PART 2: Patients receive alvocidib IV over 1 hour at or below the MTD determined in part 1 and then receive a maintenance dose of alvocidib IV over 1-6 hours on days 1, 8, and 15. Cohorts of 3-6 patients receive escalating durations of the maintenance dose of alvocidib until the MTD* is determined. An additional cohort of 10-20 patients receives alvocidib over 1 hour on days 1 and 15 at the MTD.~NOTE: *The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both parts, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9863646|NCT00070252|Experimental|Treatment (tipifarnib, capecitabine, docetaxel)|"Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine."
9863647|NCT00070265|Experimental|Treatment (oxaliplatin, capecitabine, and surgery)|"Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.~Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery."
9863648|NCT00070304|Experimental|Treatment|Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing for at least 7 days and until blood counts recover. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 2 courses may proceed directly to stem cell transplantation off study OR receive 2 additional courses. Patients with stable disease after 2 courses receive at least 2 additional courses. Patients with continued stable or responding disease (with no disease progression) after 4 courses may continue to receive study treatment for up to 1 year or discontinue study for alternative therapy at the discretion of the treating physician.
9863649|NCT00070382|Experimental|Darbepoetin alfa|darbepoetin alfa administered once every two weeks at a dose of 200 ug over a 16 week treatment period.
9863650|NCT00070382|Active Comparator|Epoetin alfa|epoetin alfa administered at 40,000 unites, once per week over a 16-week treatment period.
9863651|NCT00070434|Experimental|Irinotecan + 5-FU + Leucovorin|Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.
9863652|NCT00070434|Experimental|Irinotecan + Oxaliplatin|Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles
9863653|NCT00070434|Experimental|Oxaliplatin + 5-FU + Leucovorin|Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.
9863654|NCT00070486|Experimental|Gem + Carboplatin + Zileuton|
9863655|NCT00070486|Experimental|Gem + Carboplatin + celecoxib|
9863656|NCT00070486|Experimental|Gem + carboplatin + zilueton + celecoxib|
9863657|NCT00070525|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9863658|NCT00070551|Experimental|Stratum I (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 2 hours twice daily on days 2, 4, and 6.
9863659|NCT00070551|Experimental|Stratum II (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 4 hours once daily on days 2-6. In both strata, treatment continues in the absence of unacceptable toxicity.
9863660|NCT00070616|Experimental|Palifermin 6 x 60 μg/kg/day|The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).
9863661|NCT00070616|Experimental|Palifermin 2 x 180 μg/kg/day|The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion
9863662|NCT00070629|Experimental|1|Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection
9863663|NCT00070629|Active Comparator|2|Chemotherapy (a taxane and a platinum compound)
9863664|NCT00070642|Experimental|CPG 7909 Injection plus chemotherapy|CPG 7909 Injection plus DTIC
9863665|NCT00070642|Active Comparator|Chemotherapy alone|dacarbazine
9863666|NCT00070642|Experimental|CPG 7909 Injection 10 mg|
9863667|NCT00070642|Experimental|CPG 7909 Injection 40 mg|
9863668|NCT00070811||Revision|Patients with repaired cleft lip who receive lip revision surgery
9863669|NCT00070811||Non-Revision|Patients with repaired cleft lip who do not have lip revision surgery
9863670|NCT00070811||Non-cleft|Non-cleft 'control' subjects.
9863671|NCT00070824|Experimental|B|Patients with osteoarthritis pain at rest
9863672|NCT00070824|Experimental|A|Normal Subjects without pain
9863673|NCT00070954|Placebo Comparator|2|look-alike placebo
9863674|NCT00070954|Active Comparator|Ginkgo Biloba|Compared to placebo
9863675|NCT00071071|Experimental|280 mg and 560 mg|
9863676|NCT00071084|Experimental|280 mg and 980 mg|
9863677|NCT00071097|Experimental|001|TMC114/rtv 400mg TMC114/100mg rtv once daily
9863678|NCT00071097|No Intervention|005|Control Group Control Group, no intervention
9863679|NCT00071097|Experimental|004|TMC114/rtv 600mg TMC114/100mg rtv twice daily
9863680|NCT00071097|Experimental|003|TMC114/rtv 400mg TMC114/100mg rtv both twice daily
9863681|NCT00071097|Experimental|002|TMC114/rtv 800mg TMC114/100mg rtv once daily
9863682|NCT00071240|Experimental|Growth Hormone Arm|Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
9863683|NCT00071240|Active Comparator|2|Observation only in the 1st year, GH receipt in the second year
9863684|NCT00071409|Placebo Comparator|placebo|1.5 mL SC injection
9863685|NCT00071409|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
9863686|NCT00071409|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
9863687|NCT00071422|Placebo Comparator|placebo|1.5 mL SC injection, once daily for 90 days
9863688|NCT00071422|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
9863689|NCT00071422|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
9863690|NCT00071500|Experimental|1|Participants will use MedSignals with all of its features
9863691|NCT00071500|Experimental|2|Participants will use MedSignals with only alarm features
9863692|NCT00071500|No Intervention|3|Participants will not use any device
9863693|NCT00071539|Experimental|TP38 50 ng/mL|
9863694|NCT00071539|Experimental|TP38 100 ng/mL|
9863695|NCT00071565||1|475 families with multiple affected family members (phase I) 200 families with multiple affected family members (phase II) 1800 subjects with sporadic intracranial aneurysms
9863696|NCT00071578|Experimental|1|Group therapy Negative Emotion Focus
9863697|NCT00071578|Placebo Comparator|2|Group Psychotherapy- Self Esteem Focus
9863698|NCT00071617|Experimental|Youth-Nominated Support Team|Adolescents nominate up to 4 caring adults from family, school, community settings. These adults participate in psychoeducation sessions regarding adolescent's treatment plan and support needs. They maintain regular, supportive contact with the adolescent for 3 months -- with ongoing consultation and support check-ins from study clinical staff.
10210250|NCT00567580|Experimental|PBRT + STAD|Prostate bed radiotherapy (PBRT) and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before radiotherapy (RT), and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
10210251|NCT00567580|Experimental|PLNRT + PBRT + STADT|Pelvic lymph node radiotherapy (PLNRT), prostate bed radiotherapy (PBRT), and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before RT, and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
10210252|NCT00496431|Experimental|ITF2357|Patients were provided with the appropriate number of 50 mg hard gelatine capsules for oral administration for 7 days treatment, i.e. at the daily dose of 100 mg, 14 capsules 50 mg each, plus 2 spare capsules suitable in case of accidental loss.
9863699|NCT00071617|No Intervention|Enhanced Treatment as Usual|Adolescents in this condition receive study assessments and risk management services (at time of assessments) only
9863700|NCT00071643|Experimental|1 Problem Solving Therapy|Participants will receive problem solving therapy.
9863701|NCT00071643|Experimental|2. Escitalopram|Participants will receive escitalopram.
9863702|NCT00071643|Placebo Comparator|3 Placebo|Participants will receive placebo.
9863703|NCT00071773|Active Comparator|Modified Early Treatment Diabetic Retinopathy Study (ETDRS)|modified-ETDRS
9863704|NCT00071773|Active Comparator|Mild Macular Grid (MMG)|MMG technique
9863705|NCT00071916||African American|Adult African American participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
10210253|NCT00477412|Experimental|Treatment (combination chemotherapy)|"Participants receive Drug Combination I during courses 1, 3, 5, and 7 (if needed) and Drug Combination II during courses 2, 4, 6, and 8 (if needed) in the absence of disease progression or unacceptable toxicity.~Drug Combination I: Participants receive rituximab IV over 6 hours on day 1, cyclophosphamide IV over 3 hours BID on days 2-4, doxorubicin IV over 15-30 minutes on day 5, vincristine IV over 15-30 minutes on days 5 and 12, dexamethasone PO or IV on days 2-5 and 12-15, and bortezomib IV over a few seconds after the first dose of cyclophosphamide and immediately after vincristine and doxorubicin have been given on day 5.~Drug Combination II: Participants receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours every 12 hours on days 3-4."
9863706|NCT00071916||Caucasian|Caucasian participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
9863707|NCT00071942|Experimental|Treatment (vaccine therapy)|Patients receive vaccination comprising recombinant vaccinia-MUC-1 and recombinant vaccinia-TRICOM vaccine intradermally on days 1 and 29 (for a total of 2 doses) in the absence of disease progression or unacceptable toxicity.
9863708|NCT00071994|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9926478|NCT00882609|Experimental|F18-Fluoride PET/CT|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
9926479|NCT00882622|Active Comparator|RIPC|
9926480|NCT00882622|Sham Comparator|CONTROL|
9926481|NCT00882635|Experimental|Enoxaparin|
9926482|NCT00882635|Active Comparator|Unfractionated heparin|
9926483|NCT00882648||Drug dependent women|All drug dependent women enrolled in comprehensive substance abuse treatment at the Center for Addiction and Pregnancy of Johns Hopkins University between 2004 and 2009; retrospective chart review.
9926484|NCT00882674|Experimental|1|
9926485|NCT00882700|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
9926486|NCT00882700|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
9926487|NCT00882726|Experimental|CNTO 3649 IV (Healthy participants)|
9926488|NCT00882726|Experimental|CNTO 3649 SC (Healthy participants)|
9926489|NCT00882726|Experimental|CNTO 3649 SC (Diabetic patients)|
9926490|NCT00882739|Other|no pre-treatment|No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
9926491|NCT00882739|Experimental|600 mg loading dose|600 mg clopidogrel loading dose at first medical contact
9926492|NCT00882739|Experimental|900 mg loading dose|900 mg clopidogrel loading dose at first medical contact
9926493|NCT00882752||Ulcerative colitius|The method used to identify the microbes in the sample was chosen because it had the potential to provide more exhaustive identification of the bacteria present in the sample as compared to culturing methodology.
9926494|NCT00882765|Experimental|Arm I|Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity.
9926495|NCT00882765|No Intervention|No intervention|Patients receive no specific neoadjuvant therapy.
9926496|NCT00882804|Experimental|Hemin|
9926497|NCT00882804|Placebo Comparator|placebo|
9926498|NCT00882817|Active Comparator|1|Pulmonary Rehabilitation
9926499|NCT00882817|No Intervention|2|
9926500|NCT00882830|Experimental|EMS group|
9926501|NCT00882830|No Intervention|control group|
9926502|NCT00882843||Group 1|Healthy Able bodied Control
9926503|NCT00882843||Group 2|Spinal Cord Injury
9926504|NCT00882856|Active Comparator|Bisoprolol-washout -placebo|Bisoprolol - wash out - placebo
9926505|NCT00882856|Active Comparator|Placebo - wash out - bisoprolol|Placebo - wash out - bisoprolol
10210254|NCT00390741|Active Comparator|1|Home-based exercise program
10210255|NCT00390741|No Intervention|2|Usual care
10210256|NCT00369317|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity."
10210257|NCT00261807|Other|Single ARM Study|It was a single arm study with higher dose of daptomycin used for patients with severe skin and soft tissue infections.
10210258|NCT05216731|Experimental|Bypass group|Under general anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
10210259|NCT05216731|Active Comparator|Endovascular procedure group|Under local or general anesthesia: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
10210260|NCT05216718|Experimental|Conventional flap|BABA robotic-thyroidectomy that using conventional flap
9926506|NCT00882882|Experimental|1|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
9926507|NCT00882882|Experimental|2|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
9926508|NCT00882882|Active Comparator|3|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
9926509|NCT00882882|Active Comparator|4|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
9926510|NCT00882934|Experimental|A1|Arm 1 received an informative letter explaining that they were allocated to receive a substance for Erectile Dysfunction treatment.
9926511|NCT00882934|Placebo Comparator|A2|Arm 2 (A2) was written informed that they could or could not receive an active drug for ED treatment.
9926512|NCT00882934|Experimental|A3|Arm 3 (A3) was properly written informed to be using no effective drug for ED treatment.
9926513|NCT00882947||Group 1|
9863709|NCT00072033|Active Comparator|Arm A|Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery
9863710|NCT00072046|Experimental|Interferon|Treatment with interferon alfa 2b
9863711|NCT00072046|Experimental|Interferon + bevacizumab|Addition of bevacizumab to interferon alfa 2b treatment
9863712|NCT00072098|Experimental|Experimental Group|Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene
9863713|NCT00072137|Experimental|Arm A (rf-GM-CSF, closed to accrual 10/2004)|Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
9863714|NCT00072137|Experimental|Arm B (rf-TRICOM, closed to accrual 10/2004)|Patients receive recombinant fowlpox-TRICOM vaccine intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
9863715|NCT00072137|Experimental|Arm C (rfTRICOM and rf-GM-CSF)|Patients receive recombinant fowlpox-TRICOM vaccine combined with recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
9863716|NCT00072150|Experimental|Treatment (bortezomib)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients with a solitary site of disease (i.e., lung or nodal metastases) and who have a partial response (PR) may be considered for surgical resection. Patients with a PR with residual disease after salvage surgery are eligible to continue study therapy. Patients who achieve a complete response, either through resection or bortezomib therapy, receive 2 additional courses of study therapy."
9863717|NCT00072163|Experimental|Treatment (temozolomide, thalidomide)|Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
9863718|NCT00072215|Experimental|Regimen A: TIP|
9863719|NCT00072215|Experimental|Regimen B: VeIP|
9863720|NCT00072358|Experimental|patients have refractory bone marrow disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
9863721|NCT00072358|Experimental|patients have no evidence of disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
9863722|NCT00072436|Experimental|Treatment|"Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose."
9863723|NCT00072462|Active Comparator|Anastrozole|
9863724|NCT00072462|Active Comparator|Tamoxifen|
9863725|NCT00072527|Experimental|Induction and consolidation chemotherapy|"Induction chemotherapy (Cycles 1 and 2): Patients receive cisplatin 30 mg/m^2 on days 1, 8, 22 and 29 and irinotecan 65 mg/m^2 on days 1, 8, 22 and 29 for cycles 1 and 2.~Consolidation chemotherapy (Cycles 3, 4 and 5 beginning on day 43, week 7): Patients receive carboplatin on days 43, 64 and 85, etoposide 100 mg/m^2 IV on days 43-45, 64-66 and 85-87 and XRT 5 fractions/week starting on day 43"
9863726|NCT00072631|Experimental|1 erlotinib|
9863727|NCT00072657|Experimental|1|Participants will partake in cognitive behavioral therapy for 12 weeks.
9863728|NCT00072657|Experimental|2|Participants will partake in tai chi chih for 12 weeks.
9863729|NCT00072657|Active Comparator|3|Participants will act as a control and attend educational sessions for 12 weeks.
9863730|NCT00072670|Experimental|Trabectedin 0.58 milligram per square meter (mg/m^2)|Trabectedin will be administered as 3-hour intravenous infusion at dose of 0.58 mg/m^2 weekly on Day 1, 8 and 15 in 28-day cycle and will be continued until disease progression or unacceptable toxicity.
9863731|NCT00072670|Experimental|Trabectedin 1.5 mg/m^2|Trabectedin will be administered at dose of 1.5 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
9863732|NCT00072670|Experimental|Trabectedin 1.2 mg/m^2|Trabectedin will be administered at dose of 1.2 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
9863733|NCT00072839|Placebo Comparator|Placebo|placebo solution injected subcutaneously daily into either thigh or abdomen.
9863734|NCT00072839|Experimental|teduglutide 0.05|teduglutide 0.05 mg/kg/d injected subcutaneously daily.
9863735|NCT00072839|Experimental|teduglutide 0.1|0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
9863736|NCT00072839|Experimental|teduglutide|0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
9863737|NCT00072904|Placebo Comparator|III|Placebo take half tab with meals tid
9863738|NCT00072930|Active Comparator|1|MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55)
9863739|NCT00072930|Other|2|Docetaxel + Prednisone + Zoledronic Acid (N=55)
9863740|NCT00072982|Active Comparator|1|Fish Oil
9863741|NCT00072982|Active Comparator|2|Borage Oil
9863742|NCT00072982|Active Comparator|3|Fish Oil and Borage Oil
9863743|NCT00073242|Experimental|leptin repletion|Repletion of leptin following weight loss induced by dietary modification.
9863744|NCT00073242|Experimental|T3 repletion|Repletion of T3 following weight loss induced by dietary modification.
9863745|NCT00073346|Experimental|cognitive behavior therapy for hoarding disorder|Cognitive behavior therapy included 26 sessions of motivational enhancements; skills training for sorting, organizing and problem solving; direct practice not acquiring new items and discarding possessions to remove clutter and organize possessions; cognitive therapy to evaluate beliefs about possessions; and relapse prevention skills.
9863746|NCT00073346|No Intervention|Wait list control|Participants waited to receive treatment for 12 weeks
9863747|NCT00073593|Experimental|bivalirudin|250mg vial given as 0.75mg/kg intravenous (IV) bolus and 1.75 mg/kg/hr IV infusion for the duration of the procedure with the option to increase or decrease the infusion in 0.25 mg/kg/hr increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an ACT>300 seconds.
9863748|NCT00073593|Active Comparator|heparin/protamine|1.5-3.5 mg/kg (200-400 U/kg) intravenous (IV) bolus to target an ACT >300 seconds followed by weight-adjusted boluses as needed during the procedure to achieve/maintain the target ACT. Protamine as needed
9863749|NCT00073619|Experimental|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
9863750|NCT00073619|No Intervention|Non-intervention Comparison|Provide no active intervention to the comparison group, although assess the children at the same assessment points as the experimental group. Participants in the control arm were told they were FRIENDS Program participants.They received rewards for participating in the assessments.
9863751|NCT00073645|Experimental|1|Family/Parents CBT (FCBT) for 14 to 16 weekly sessions
9863752|NCT00073645|Active Comparator|2|Peer/Group CBT (GCBT) for 14 to 16 weekly sessions
9863753|NCT00073684|Experimental|1|Participants will receive 8 sessions of TF-CBT with narrative.
9863754|NCT00073684|Experimental|2|Participants will receive 8 sessions of TF-CBT without narrative.
9863755|NCT00073684|Experimental|3|Participants will receive 16 sessions of TF-CBT with narrative.
9863756|NCT00073684|Experimental|4|Participants will receive 16 sessions of TF-CBT without narrative.
9926514|NCT00882960|Active Comparator|1|patients who are randomized to receive intravenous fentanyl for control of their pain
9926515|NCT00882960|Active Comparator|2|patients who are randomized to receive intra-nasal fentanyl for control of their pain
9926516|NCT00882973|Experimental|Cohort 1|Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
9926517|NCT00882973|Experimental|Cohort 2|Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
9926518|NCT00882973|Experimental|Cohort 3|Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
9926519|NCT00882986||1|Men with high fitness (above VO2max of 60)
9926520|NCT00882986||2|Men with average fitness (below VO2max of 50)
9926521|NCT00883012|Experimental|Influenza vaccine|Two doses of trivalent sub-unit influenza vaccine (2009) to be administered one month apart
9926522|NCT00883012|Placebo Comparator|Placebo|Two doses of saline administered one month apart
9926523|NCT00883025||1|OSAS patients
9926524|NCT00883025||2|no OSAS Patient
9926525|NCT00883038|Active Comparator|Active Comparator|Diabetic diet following the DNSG guidelines
9926526|NCT00883038|Experimental|Experimental|Low-fat vegetarian diet
9926527|NCT00883064|Experimental|1|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
9926528|NCT00883064|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
9926529|NCT00883077||Inflammation|Patients with long standing history or short onset of ulcerative colitis.
9863757|NCT00073697|Experimental|1|Interpersonal Psychotherapy
9863758|NCT00073697|Experimental|2|Escitalopram
9863759|NCT00073697|Experimental|3|Escitalopram plus IPT
9863760|NCT00073736|Experimental|MB07133 Dose Level 1|7-day continuous infusion in 28-day cycles
9863761|NCT00073736|Experimental|MB07133 Dose Level 2|7-day continuous infusion in 28-day cycles
9863762|NCT00073736|Experimental|MB07133 Dose Level 3|7-day continuous infusion in 28-day cycles
9863763|NCT00073736|Experimental|MB07133 Dose Level 4|7-day continuous infusion in 28-day cycles
9863764|NCT00073736|Experimental|MB07133 Dose Level 5|7-day continuous infusion in 28-day cycles
9863765|NCT00073788||Subjects with PTSD|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Study group subjects will be PTSD positive. Overt CVD is exclusionary.
9863766|NCT00073788||Control Group|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Control subjects will be PTSD negative. For both groups: overt CVD is exclusionary.
9863767|NCT00073814|Experimental|1|levalbuterol MDI 90 mcg QID
9863768|NCT00073814|Active Comparator|2|racemic albuterol MDI 190 mcg QID
9863769|NCT00073814|Placebo Comparator|3|Placebo MDI QID
9863770|NCT00073827|Experimental|1|levalbuterol MDI 90 mcg QID
9863771|NCT00073827|Active Comparator|2|racemic albuterol MDI 180 mcg QID
9863772|NCT00073827|Placebo Comparator|3|Placebo MDI QID
9863773|NCT00073840|Active Comparator|I|Levalbuterol 90 ųg QID (manufacturing site A or B)
9863774|NCT00073840|Active Comparator|II|Racemic Albuterol 180 ųg QID
9863775|NCT00073840|Placebo Comparator|III|Placebo QID
9863776|NCT00073892|Experimental|PI-88|Patients receive four consecutive days treatment each week in a 4-week cycle.
9863777|NCT00073905|Active Comparator|Arm A|Capecitabine plus Gemcitabine
9863778|NCT00074022|Experimental|Treatment (GTI-2040, docetaxel)|"Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.~Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I."
9863779|NCT00074048|Experimental|1|BL22 immunotoxin
9863780|NCT00074087|Experimental|Caelyx|doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.
9863781|NCT00074204|Experimental|Immediate Docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
9863782|NCT00074204|Active Comparator|Delayed Docetaxel|Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
9863783|NCT00074295|Experimental|treatment|GVAX lung cancer vaccine
9863784|NCT00074321|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9863785|NCT00074373||human beings|human beings of all sexes, ages, and health statuses
9863786|NCT00074399|Experimental|1|Participants will receive nevirapine for 6 weeks
9863787|NCT00074399|Placebo Comparator|2|Participants will receive nevirapine placebo for 6 weeks
9863788|NCT00074438|Experimental|1|
9863789|NCT00074438|Experimental|2|
9863790|NCT00074438|Experimental|3|
9863791|NCT00074438|Experimental|4|
9863792|NCT00074438|Experimental|5|
9863793|NCT00074438|Experimental|6|
9863794|NCT00074438|Placebo Comparator|7|
9863795|NCT00074438|Placebo Comparator|8|
9863796|NCT00074438|Placebo Comparator|9|
9863797|NCT00074568||1|Patients with scleroderma and their family members (parents, brothers, and sisters)
9863798|NCT00074568||2|Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
9863799|NCT00074607|Experimental|Intrathecal gemcitabine administration|"Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.~Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.~Dose Levels and Dose Escalation:~Dose Level 1a: 5 mg~Dose Level 1b: 5 mg~Dose Level 2: 10 mg~Dose Level 3: 20 mg~Dose Level 4: 30 mg~Dose Level 5: 40 mg~Dose Level 6: 50 mg"
9863800|NCT00074737|Active Comparator|cenersen, idarubicin|cenersen, idarubicin, no cytarabine
9863801|NCT00074737|Active Comparator|cenersen, idarubicin, cytarabine|cenersen, idarubicin, standard dose cytarabine
9863802|NCT00074737|Active Comparator|cenersen, idarubicin, HDAC|cenersen, idarubicin, HDAC (high dose cytarabine)
9926530|NCT00883077||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
10210261|NCT05216718|Active Comparator|Mini-flap|BABA robotic-thyroidectomy that using Mini-flap
10210262|NCT05216679|Experimental|Main study|This is the only arm of the study. It is a 6 week period where the participants will either be using night splints or the TESS device to treat their plantar fasciitis symptoms.
9863803|NCT00074750|Experimental|DTGM|Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion, three times /week (M,W,F) for two consecutive weeks. In absence of defined grade 3/4 nonhematological toxicities in the first 0/3 or 1/6 patients, the dose will be escalated by 1 mcg/kg/day for the next patient cohort.
9863804|NCT00074763|Experimental|Platelet Transfusion|ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.
9863805|NCT00074776|Experimental|1 Lithium|
9863806|NCT00074776|Experimental|2 Lamotrigine|
9863807|NCT00074789|Experimental|1|Participants will receive home-based interpersonal depression treatment for 26 weeks
9863808|NCT00074789|Active Comparator|2|Participants will receive attention control/usual care for 26 weeks
9863809|NCT00074828|Experimental|A|
9863810|NCT00074828|Active Comparator|B|
9863811|NCT00074932|Other|1|
9863812|NCT00075010|Experimental|Decitabine + Valproic acid|Decitabine 15 mg/m^2 by vein over 1 hour times 10 days
9863813|NCT00075101|Experimental|Study Cycle|
9863814|NCT00075114|Other|1 Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
9863815|NCT00075114|No Intervention|2 Control Group|Participants randomized to this arm did not receive any interventions.
9863816|NCT00075140||1|All Participants hav a family member with Huntington Disease
9863817|NCT00075179|Experimental|Nesiritide|Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
9863818|NCT00075374|Experimental|Docetaxel|
9863819|NCT00075387|Experimental|Arm I (combination chemotherapy)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9863820|NCT00075387|Experimental|Arm II (combination chemotherapy, sodium thiosulfate)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
9863821|NCT00075439|Experimental|Arm I|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863822|NCT00075491|Experimental|Arm I (fenretinide, surgery)|Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
9863823|NCT00075491|Active Comparator|Arm II (surgery)|Patients undergo surgical resection.
9863824|NCT00075569|Active Comparator|1 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
9863825|NCT00075569|Active Comparator|2 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy
9926531|NCT00883077||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting ROME III criteria of irritable bowel syndrome.
9926532|NCT00883142||Group 1|
9926533|NCT00883155|Experimental|1|Bupropion HCl 100 mg Tablets (Invamed Inc.)
9926534|NCT00883155|Active Comparator|2|Wellbutrin 100 mg Tablets (Glaxo Wellcome)
9926535|NCT00883194|Experimental|1|PRF-108 Gel, 4% ropivacaine
9926536|NCT00883194|Placebo Comparator|2|PRF-108 Gel, Vehicle
9926537|NCT00883194|Active Comparator|3|Ropivacaine Solution 0.5%
9926538|NCT00883194|Experimental|PRF-110, 4%|PRF-110, 4% ropivacaine
9926539|NCT00883220|Experimental|Self-management of urinary catheter|Intervention: Self-management group--teaching behavioral approaches(awareness, self-monitoring, and self-management) to prevent or minimize urinary catheter complications.
9926540|NCT00883220|No Intervention|Usual care 2|Usual care for urinary catheter. Home care and/or clinic care is the usual care for people with long-term urinary catheters.
9926541|NCT00883259|Experimental|Experimental|Metformin treatment
9926542|NCT00883259|Placebo Comparator|Placebo|Placebo tablets
9926543|NCT00883272||Normal Controls|25 women with CADP-CT > 66 seconds were treated with Femarelle
9926544|NCT00883272||Thrombophilic|Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT < 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
9926545|NCT00883285||1|conventional aortic valve replacement
9926546|NCT00883285||2|transfemoral aortic valve replacement
9926547|NCT00883285||3|transapical aortic valve replacement
9926548|NCT00883298|Experimental|Open Label|temozolomide plus bevacizumab administered as open label single arm treatment
9926549|NCT00883324||1|fetal fibronectin specimens collected with a speculum
9926550|NCT00883324||2|fetal fibronectin specimens collected without a speculum
9926551|NCT00883350|Experimental|RIDE|Participants randomized to utilize the RIDE e-health application for the duration of the 12 week intervention.
9935248|NCT03986021||Women with PCOS|Women diagnosed with PCOS >18-34 at least 3-years post-menarchal with irregular menstrual cycles
9935249|NCT03983863||IRB|Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
9935250|NCT03983850|No Intervention|Donor Arm|Collection of bone marrow and/or PBSC (Up to 40 donors)
9863826|NCT00075621|Other|tandem transplant|"Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection~Drug: melphalan 200 mg/kg over 2 days~Procedure/Surgery: autologous peripheral blood stem cell transplantation~autologous peripheral blood stem cell transplantation"
9863827|NCT00075634|Experimental|Arm I|"PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD."
9863828|NCT00075647|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9863829|NCT00075686|Experimental|gemcitabine hydrochloride + IMC-C225|Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
9863830|NCT00075686|Experimental|gemcitabine hydrochloride alone|gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
9863831|NCT00075751|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone on the above schedule for up to 1 year at the discretion of the treating physician.
9863832|NCT00075842|Experimental|Arm I|Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.
9863833|NCT00075842|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 8 weeks.
9863834|NCT00075855|Experimental|testosterone|"Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
9863835|NCT00075855|Other|placebo|"Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
9863836|NCT00075868|Experimental|Sandostatin LAR® Depot|Sandostatin LAR® Depot Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
9863837|NCT00075868|Placebo Comparator|Placebo|Placebo Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
9863838|NCT00076063|Experimental|A|Participants in Groups A will receive four injections over 6 months of either LIPO-5 or a placebo.
9863839|NCT00076063|Experimental|B|Participants in Group B will receive four injections over 6 months of either the ALVAC-HIV (vCP1452) or a placebo.
9935251|NCT03983850|Experimental|Phase 1 duration de-escalation of MMF|MMF at de-escalating duration (days +5 to +18 only, no MMF))
9863840|NCT00076063|Experimental|C|Participants in Groups C will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
9863841|NCT00076063|Experimental|D|Participants in Group D will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
9863842|NCT00076063|Experimental|E|Participants in Group E will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
9863843|NCT00076141||Older, Racially Diverse Males|Racially Divers Males over 50, expected to live more than 5 years
9863844|NCT00076154||Group 1|
9863845|NCT00076180|Experimental|1|One dose of Hu-MiK Beta-1
9863846|NCT00076206|Experimental|A|CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
9863847|NCT00076206|Experimental|B|CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
9863848|NCT00076206|Experimental|C|CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
10210263|NCT05216653|Experimental|Preoperative Short-course Radiation followed by Envafolimab plus CAPEOX|"The enrolled patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery).~Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~After radiotherapy, PD-L1 antibody (150mg/week, subcutaneous injection × 6 weeks) immunotherapy combined with two courses of CAPEOX chemotherapy was performed.~Two weeks after the end of the combined treatment plan in step 2), TME surgery is performed."
10210264|NCT05216640|Active Comparator|High Flow Nasal Cannula|Standard operating procedures represented by high flow nasal cannula oxygen therapy
10210265|NCT05216640|Active Comparator|High Velocity Nasal Insufflation|Standard operating procedures represented by high velocity nasal insufflation therapy
10210266|NCT05216588||EVUSHELD (tixagévimab/cilgavimab)|"Patients who may be included in this group are patients eligible for prophylaxis treatments for COVID-19, under a cohort Temporary Authorization for Use (ATUc) of EVUSHELD. Patient are treated and monitored according to the Therapeutic Use Protocols specific for EVUSHELD defined by the ANSM.~In addition to their follow-up planned for usual care (including protocol for ATU), they are invited to participate in the research."
10213668|NCT03568630||Inherited Risk|"Must meet one of the following criteria:~Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)~One 1st degree relative with PDAC diagnosed before age 60~Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR~Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
10213669|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
10213670|NCT03566615|Active Comparator|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
10213671|NCT03566615|Experimental|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
10213672|NCT03566615|Experimental|CAP-daisy|A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
10213673|NCT03564678|Experimental|Treatment (levocarnitine, vitamin B complex)|Patients receive levocarnitine IV over 2-3 minutes every 6 hours up to 4 times a day (inpatient) or PO TID (outpatient). Patients also receive vitamin B complex PO BID. Treatment continues for up to 30 days after the last dose of either PEG-asparaginase or inotuzumab, or until Tbili of ≤ 1.5 x ULN or at least a 50% reduction in peak Tbili is achieved.
9863849|NCT00076206|Placebo Comparator|D|Placebo dose to be taken orally daily up to 12 weeks.
9863850|NCT00076232|Experimental|1|Participants will receive acyclovir for the duration of the study
9863851|NCT00076232|Placebo Comparator|2|Participants will receive acyclovir placebo for the duration of the trial
9863852|NCT00076310|Experimental|Cisplatin + Docetaxel + OSI-774|"Cisplatin 75 mg/m^2 IV every 21 days.~Docetaxel 60 mg/m^2 IV repeated every 21 days.~OSI-774 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached."
9863853|NCT00076349|Experimental|1|open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab
9863854|NCT00076453|Experimental|1|Participants will wear lateral wedge orthotic inserts.
9863855|NCT00076453|Active Comparator|2|Participants will wear standard orthotic inserts.
9863856|NCT00076791|Active Comparator|1|Each participant in Cohort 1 received a single 600 mg oral dose of TDF at the start of active labor or 4 hours prior to C-section, with concurrent administration of standard intravenous zidovudine (ZDV) prophylaxis and/or other antiretrovirals prescribed by her physician. The infants from Cohort 1 received only the standard 6 weeks of oral ZDV prophylaxis postpartum.
10213674|NCT03564353|Experimental|memory task with tDCS location 1|memory task paired with tDCS targeting C2 nerve (anode left c2; cathode right C2)
9863857|NCT00076791|Active Comparator|2|Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
9863858|NCT00076817|Experimental|1|Participants will receive vaccine injections in the groin area or the upper arm
9863859|NCT00076817|Placebo Comparator|2|Participants will receive vaccine placebo injections in the groin area or the upper arm
9863860|NCT00076934|Experimental|1|Participants receive Regimen 1 for 4 months
9863861|NCT00076934|Experimental|2|Participants receive Regimen 2 for 4 months
9863862|NCT00076934|Experimental|3|Participants receive Regimen 3 for 4 months
9863863|NCT00076934|Experimental|4|Participants receive Regimen 4 for 4 months
9863864|NCT00077025|Active Comparator|Anastrozole-placebo|Anastrozole (ZD1033, Arimidex)-Placebo
9863865|NCT00077025|Active Comparator|Anastrozole-ZD1839|Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
9863866|NCT00077051|Experimental|Single Arm|
9863867|NCT00077142|Experimental|TAC-101|Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
9863868|NCT00077155|Experimental|Treatment (cilengitide)|Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
9863869|NCT00077181|Experimental|Treatment (cytarabine and triapine)|Patients receive high-dose cytarabine IV over 2 hours on days 1-5 and triapine IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9863870|NCT00077194|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
9863871|NCT00077233|Active Comparator|Arm A: FOLFIRI|Patients receive irinotecan 180 mg/m^2 over 90 minutes on day 1, then leucovorin 400 mg/m^2 over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. One cycle of therapy is 8 weeks.
9863872|NCT00077233|Experimental|Arm B: FOLFIRI + C225|Patients receive irinotecan 180 mg/m^2 over 90 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
9863873|NCT00077233|Active Comparator|Arm C: FOLFOX|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks.
9863874|NCT00077233|Experimental|Arm D: FOLFOX + C225|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
9863875|NCT00077298|Experimental|Arm A (cetuximab, bevacizumab, irinotecan)I|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
9863876|NCT00077298|Experimental|Arm B (cetuximab and bevacizumab)|"Patients receive cetuximab as in Arm A and bevacizumab IV over 30-90 minutes on days 1*, 15, and 29.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
9863877|NCT00077311|Experimental|Chemotherapy without BNP7787|Chemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
9863878|NCT00077311|Experimental|Chemotherapy + BNP7787|Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
9863879|NCT00077324||Surgery + blood and serum collection|"Patients undergo lung resection. Patients also undergo preoperative and postoperative collection of whole blood and serum for proteomic profiling using surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue biopsy taken at surgery is also analyzed.~Patients are followed at 60-90 days and then annually for 2-5 years."
9863880|NCT00077350|Experimental|Treatment (triapine and gemcitabine hydrochloride)|Patients receive 3-AP (Triapine^®) IV over 2 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9863881|NCT00077363|Experimental|Treatment (tipifarnib, capecitabine)|Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 4 additional courses beyond documentation of CR.
9926552|NCT00883350|No Intervention|Control|Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. [6-9]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., [6].
9926553|NCT00883363|Experimental|Precondition|Induction of precondition at start of operation on a arm
9926554|NCT00883363|No Intervention|Control|No precondition
9926555|NCT00883376||1|OSAS patients
9926556|NCT00883376||2|no OSAS patients
9926557|NCT00883402|Active Comparator|CEA|Carotid endarterectomy
9926558|NCT00883402|Active Comparator|CAS|Carotid Artery Stenting
9926559|NCT00883428||Pergnant women|Pregnant women, of 28 weeks or more of gestation, who are seen in the Health Centers participating in the study.
9926560|NCT00883441|Experimental|VM|implementation of new vector control tools (insecticide treated curtains and jar covers) through the existing routine vector control programme
9926561|NCT00883441|Experimental|PM|implementation of new vector control tools (insecticide treated covers and curtains) through partnerships
9926562|NCT00883467|Other|1|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes
9926563|NCT00883467|Other|2|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes with additional 5 minutes of cuff stenosis directly after cuff release
9926564|NCT00883467|Other|3|short time preconditioning, other details according arm 2
9926565|NCT00883467|Other|4|long time preconditioning, other details according arm 2
9926566|NCT00883480|Experimental|2|The rest of the patients who do not carry the Factor Receptor mutation of Epidermal Growth will receive chemotherapy treatment individualized based on BRCA 1 m RNA levels. Function of these levels, three different subgroups of treatment: Subgroup A with low BRCA1 mRNA levels will receive treatment with gemcitabine / cisplatin Subgroup B with intermediate levels of BRCA1 mRNA: will receive treatment with docetaxel / cisplatin Subgroup C with high levels of BRCA1 mRNA: will receive treatment with docetaxel
9926567|NCT00883480|Experimental|1|The group of patients carrying EGFR mutation will receive treatment with Erlotinib, a selective oral Receptor tyrosine kinase inhibitor Epidermal Growth Factor
9926568|NCT00883506|Experimental|1|Lisinopril 40 mg Tablet under fed conditions.
9667021|NCT04053907|Experimental|CCM plus weekly fever screening and treatment|CCM plus active case detection (ACD) by fever screening and treatment if positive. Trained village health workers (VHW) recruited for this study will carry out weekly visits of all residents and screen for fever using research-grade thermometers. A standard RDT will be performed in all individuals with a body temperature ≥37.5°C or with reported fever in the last 24 hours. RDT positive individuals will be treated with AL according to national guidelines.
9863882|NCT00077428|Experimental|Treatment (bortezomib, doxorubicin hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
9863883|NCT00077441|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863884|NCT00077454|Experimental|Treatment (erlotinib hydrochloride, temozolomide)|Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
9863885|NCT00077467|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863886|NCT00077493|Active Comparator|1|BL22 immunotoxin
9863887|NCT00077493|Active Comparator|2|antibody therapy
9863888|NCT00077493|Active Comparator|3|immunotoxin therapy
9863889|NCT00077493|Active Comparator|4|monoclonal antibody therapy
9863890|NCT00077545|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9863891|NCT00077584|Experimental|Bosentan|The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
9863892|NCT00077584|Placebo Comparator|Placebo|The patients received the matching placebo for 24 weeks
9863893|NCT00077597|Experimental|1|
9863894|NCT00077597|Active Comparator|2|
9863895|NCT00077948|Experimental|active enoximone plus active ER metoprolol|
9863896|NCT00077948|Active Comparator|placebo enoximone plus active ER metoprolol|
9863897|NCT00077948|Placebo Comparator|placebo enoximone plus placebo ER metoprolol|
9863898|NCT00078195|Experimental|Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT|Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
9863899|NCT00078195|Experimental|Omalizumab pre-treatment, omalizumab|Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
9863900|NCT00078195|Active Comparator|Ragweed RIT, ragweed IT|Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
9863901|NCT00078195|Placebo Comparator|Placebo|Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
9863902|NCT00078247|Experimental|1|Participants will receive 6 months of ARV therapy and treatment for TB
9863903|NCT00078247|Experimental|2|Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
9863904|NCT00078260|Experimental|A|
9863905|NCT00078260|Experimental|B|
9863906|NCT00078273|No Intervention|Assessment Only Control|Completed Baseline and 6 month follow-up surveys only.
9863907|NCT00078273|Experimental|Personalized Feedback Intervention|See Intervention Description
10213675|NCT03564353|Experimental|memory task with tDCS location 2|memory task paired with tDCS targeting C2 nerve (anode right c2; cathode left C2)
9863908|NCT00078273|Experimental|Cognitive Behavioral Intervention|See Intervention Description
9863909|NCT00078390|Experimental|S-3304 plus chemo-irradiation|The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy
9863910|NCT00078390|Active Comparator|Chemo-irradiation|The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered
9863911|NCT00078442|Experimental|1|Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.
10213676|NCT03564353|Experimental|memory task with tDCS location 3|memory task paired with tDCS targeting C5/6 nerve
10213677|NCT03564353|Experimental|memory task with tDCS location 4|memory task paired with tDCS targeting trigeminal nerve dermatomes (left and right temple/jaw)
9863912|NCT00078507|Active Comparator|Opening Exercises Only|Standard of care opening exercises following BSSO surgery to regain mouth opening
9863913|NCT00078507|Experimental|Sensory Retraining Exercises|3 sets of facial exercises performed with soft cosmetic brush 1 wk - 4 wks after surgery; 4wks to 3 mos after surgery; 3 mos to 6 mos after surgery.
9863914|NCT00078520|Experimental|Dose Level 1|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
9863915|NCT00078520|Experimental|Dose Level 2|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
9926569|NCT00883506|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril)
9863916|NCT00078520|Experimental|Dose Level- Fixed Dose|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
9863917|NCT00078533|Experimental|CMV CTL infusion|Subjects are assigned a dose level at the time of enrollment.
9863918|NCT00078572|Active Comparator|capecitabine alone|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2. Randomization is 1:1.
9863919|NCT00078572|Experimental|Combination|Lapatinib 1250 mg once daily plus capecitbine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the combination arm was 2000 mg/m2.
9863920|NCT00078624|Experimental|1|Traditional exercise program supplemented with knee stability training activities
9863921|NCT00078624|Active Comparator|2|Traditional exercise program
9863922|NCT00078793||Methotrexate group|Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
9863923|NCT00078806|Experimental|Part 1: Etanercept|"Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months."
9863924|NCT00078806|Placebo Comparator|Part 2: Placebo|Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
9863925|NCT00078806|Experimental|Part 2: Etanercept|Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
9863926|NCT00078806|Experimental|Part 3:|Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.
9863927|NCT00078832|Experimental|anastrozole|anastrozole 1mg
9863928|NCT00078832|Placebo Comparator|placebo|anastrozole 1mg PLACEBO
9863929|NCT00078845|Experimental|Amifostine|500 mg subcutaneous three times a week on Monday, Wednesday and Friday for 4 weeks.
9863930|NCT00078858|Experimental|Treatment (prolonged MMF and truncated CSP)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 150 and mycophenolate mofetil PO or IV TID on days 0-30, BID on days 31-150, and then taper to day 180. Treatment continues in the absence of unacceptable toxicity."
9863931|NCT00078923|Experimental|Placebo|Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.
9863932|NCT00078923|Experimental|Soy isoflavones and placebo|Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.
9863933|NCT00078923|Experimental|Soy Isoflavones/Placebo|Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.
9863934|NCT00078923|Experimental|Soy Isoflavones|Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.
9926570|NCT00883506|Experimental|3|Lisinopril 40 mg Tablet under fasting conditions.
9926571|NCT00883519|Active Comparator|IPT-A|
9926572|NCT00883519|Active Comparator|IPT-AP|
9667022|NCT04053907|Experimental|CCM plus MSAT|CCM plus monthly screening for malaria infection and treatment of positive individuals, regardless of symptoms. Screening will be performed by research staff and timed to ensure a gap of 25-35 days between screening rounds; Positive individuals will be treated with AL, according to national guidelines.
9926573|NCT00883532|Experimental|budesonide|The treatment group will receive surfactant and budesonide.
9926574|NCT00883532|Placebo Comparator|surfactant and air|The placebo group will receive surfactant and air as control.
9926575|NCT00883545|Experimental|Woman endoscopist|
9926576|NCT00883545|Active Comparator|Usual care|
9863935|NCT00078962|Experimental|Treatment (GTI-2040, gemcitabine hydrochloride)|"Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
9863936|NCT00078975|Experimental|Triapine in combination with Gemcitabine|
9863937|NCT00078988|Experimental|Arm I (high-dose chemotherapy and ASCR)|Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
9863938|NCT00078988|Experimental|Arm II (intermediate-dose chemotherapy and ASCR)|Patients receive intermediate-dose chemotherapy comprising carboplatin IV over 4 hours and thiotepa IV over 3 hours on days 1-2 and G-CSF IV or SC once daily beginning on day 4 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 3. Treatment repeats every 28 days for a total of 3 courses.
9863939|NCT00078988|Experimental|Arm III (isotretinoin)|Patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for a total of 6 courses.
9863940|NCT00078988|No Intervention|Arm IV (no isotretinoin)|Patients do not receive maintenance therapy.
9863941|NCT00079014|Experimental|Treatment (triapine, doxorubicin hydrochloride)|"Patients receive doxorubicin IV over 15 minutes on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level."
9863942|NCT00079105|Active Comparator|Treatment|Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
9863943|NCT00079105|No Intervention|Registration|Registration, without treatment
9863944|NCT00079118|Experimental|docetaxel + irinotecan|"Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.~Patients are followed every 2 months until disease progression and then every 6 months thereafter."
9863945|NCT00079131|Experimental|Treatment (oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9863946|NCT00079235|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.
9926577|NCT00883571|Active Comparator|house advancement flap|house advancement flap
9926578|NCT00883571|Active Comparator|Rhomboid flap|rhomboid flapa was incised in the ischiorectal fossa. Without undermining of its fatty base, the flap was then mobilized into the anal canal so that the tip could be sutured to the top of the strictured area using Vicryl 3/0 sutures
9926579|NCT00883571|Active Comparator|Y-V anoplasty|Y-V anoplasty
9926580|NCT00883584|Active Comparator|1|IMD-1041
9926581|NCT00883584|Placebo Comparator|2|
9935252|NCT03983850|Experimental|Phase I Dose De-escalation|PTCy at de-escalating doses (25 mg/kg/day on days +3 and +4, and PTCy 25 mg/kg on day +4) to assess for safety and determine Phase II dose (up to 12 evaluable patients)
9935253|NCT03983850|Experimental|Phase I Pilot for Comparative Data|Standard PTCy 50 mg/kg/day on days +3 and +4, in a small pilot (up to 5 evaluable patients) for comparative data
9935254|NCT03983850|Experimental|Phase II Efficacy|PTCy at shortest duration, safe dose (from Phase I) to assess efficacy at providing adequate protection from grade 3-4 acute GVHD (up to 14 additional patients)
9935255|NCT03983850|Experimental|Phase II efficacy of reduced duration MMF|MMF at duration identified from de-escalation evaluation.
9935256|NCT03983837|Experimental|1|Participants will be on this diet for 4 weeks. The amount per serving will be determined on the basis of the participant s weight and caloric needs, as determined by a staff dietician.
9935257|NCT03981744|Experimental|Group 1: Ustekinumab + Placebo|Participants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
9935258|NCT03981744|Placebo Comparator|Group 2: Placebo + Ustekinumab|Participants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
9863947|NCT00079352|Experimental|Treatment (gemcitabine, irinotecan, alvocidib)|Patients receive gemcitabine IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 15. Patients also receive flavopiridol IV over 60 minutes on days 2 and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10210267|NCT05216549|Experimental|Water-based exercise|The water-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
9863948|NCT00079378|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days.~Cohorts of 6 patients receive escalating doses of decitabine until the MEPD is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences DLT.~Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.~Cohorts of 3-6 patients receive escalating doses of valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity."
9863949|NCT00079404|Experimental|Arm I|Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
9863950|NCT00079430|Experimental|Treatment (adjuvant, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9863951|NCT00079443|Experimental|Treatment|"PHASE II: Patients receive FR901228 IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients who achieve a complete or partial remission receive 2 additional courses (for a total of 6 courses). Patients with stable disease after 4 courses or progressive disease at any time after 2 courses proceed to the phase I portion of the study.~PHASE I: Patients receive rituximab IV over approximately 4-8 hours on day 1; fludarabine IV over 10-30 minutes on days 2-4; and FR901228 IV over 4 hours on days 2, 9, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
9863952|NCT00079456|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9863953|NCT00079547|Active Comparator|1|Low-calorie diet
10210268|NCT05216549|Experimental|Land-based exercise|The land-based exercise group will be held twice a week, 45 min per session for 8 weeks. Supervised exercise will be led by the experienced physiotherapist and water-based exercise by physiotherapist with aquatic exercise expertise.Each session will consist of warm up (10 min), main part (30 min) and cool-down (5 min). During warm up children will perform lower and upper limbs aerobics and breathing exercises. The main part will consist of endurance exercises of upper and lower limbs with focus on breathing pattern. During cool-down focus will be on upper limb and thoracic cage stretches and breathing control.
9863954|NCT00079547|Experimental|2|Low-carbohydrate diet
9863955|NCT00079586|Active Comparator|Heparin|unfractionated heparin will be administered as per institutional practice
9863956|NCT00079586|Experimental|Angiomax|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
9863957|NCT00079599|Experimental|1|
9863958|NCT00079599|Placebo Comparator|2|
9863959|NCT00079612|Experimental|Arm 1|
9863960|NCT00079612|Placebo Comparator|Arm 2|
9863961|NCT00079716|Experimental|1|
9863962|NCT00079820|Experimental|A|MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112
9863963|NCT00079820|Experimental|B|MVA3000 Smallpox vaccine (1x10-8) with no Challenge
9863964|NCT00079820|Placebo Comparator|C|Placebo
9863965|NCT00079820|Experimental|D|MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112
9863966|NCT00079820|Experimental|E|MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112
9863967|NCT00079911|Experimental|Suppressive + Episodic Therapy|Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
9863968|NCT00079911|Placebo Comparator|Episodic Therapy|Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
9863969|NCT00079963|Experimental|X|Vitamin C
9863970|NCT00079963|Experimental|Y|Vitamin E
9863971|NCT00079963|Placebo Comparator|Z|Placebo
9863972|NCT00080093|Experimental|1|Participants will receive individual feedback and specially-tailored manuals at study entry and at Months 2 and 4
9863973|NCT00080093|Experimental|2|Participants will receive general HIV information feedback and the best-available informational manual at study entry and at Months 2 and 4
9863974|NCT00080145|Active Comparator|risperidone plus parent management training|
9863975|NCT00080145|Active Comparator|risperidone only|
9863976|NCT00080236|Placebo Comparator|Donor organ placebo and Recipient placebo|
9863977|NCT00080236|Active Comparator|Donor organ: IDN-6556 (15μg/ml), Recipient: Placebo|
9863978|NCT00080236|Active Comparator|Donor organ: IDN-6556 (5 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
9863979|NCT00080236|Active Comparator|Donor organ: IDN-6556(15 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
9863980|NCT00080262|Experimental|1|
9863981|NCT00080314|Active Comparator|A1|
9863982|NCT00080314|Placebo Comparator|A2|
9863983|NCT00080327|Active Comparator|1|
9863984|NCT00080327|Active Comparator|2|
9863985|NCT00080327|Active Comparator|3|
9863986|NCT00080327|Placebo Comparator|4|
9863987|NCT00080444|Experimental|Part 1: Aprepitant|Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
9863988|NCT00080444|Active Comparator|Part 1: Standard Therapy|Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
9863989|NCT00080444|Active Comparator|Part 2: Aprepitant|Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
9863990|NCT00080626|Experimental|Docetaxel|Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.
9926582|NCT00883623|Experimental|Treatment Arm|Treatment Arm
9926583|NCT00883636||Focal Segmental Glomerulosclerosis|
10210269|NCT05216549|No Intervention|Control|The control group will be asked not to change their physical activity for 8 weeks. After that period and post-test the control group will receive the exercise.
10210270|NCT05216523||Cases|Admitted Covid-19 cases who developed Barotrauma
10210271|NCT05216523||Controls|Admitted Covid-19 cases who did not develop Barotrauma, matched with Cases with respect to age and sex.
10210272|NCT05216510|Experimental|Cohort 1|Healthy uninfected/unexposed subjects to SARS-CoV-2
10210273|NCT05216510|Active Comparator|Cohort 2|Subjects who have recovered from SARS-CoV-2 infection
10210274|NCT05216510|Sham Comparator|Cohort 3|Subjects who have received a complete SARS-CoV-2 vaccine course
10210275|NCT05216484|Experimental|two doses CoronaVac group|the third does was given 6 months after two doses CoronaVac group
10210276|NCT05216484|Experimental|two doses BBIBP-CorV|the third does was given 6 months after two doses BBIBP-CorV
10210277|NCT05216484|Experimental|first does CoronaVac and second does BBIBP-CorV|the third does was given 6 months after first does CoronaVac and second does BBIBP-CorV
10210278|NCT05216484|Experimental|first does BBIBP-CorV and second does CoronaVac|the third does was given 6 months after first does BBIBP-CorV and second does CoronaVac
10210279|NCT05216471||Mild illness|individuals who have any of the various signs and symptoms of covid-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging findings .
10210280|NCT05216471||Moderate illness|individuals who show evidence of lower respiratory tract disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) ≥94% on room air .
10210281|NCT05216471||Severe illness|individuals who have spO2<94% on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2)<300 mm hg, respiratory frequency>30 breaths/min, or lung infiltrate >50%.
10210282|NCT05216458|Experimental|Control|Households in the control group did not receive any messages during the intervention period from June 2021 to August 2021
10210283|NCT05216458|Experimental|Generic Outreach|"Households in the generic outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees, which explain that nearly all Covered California members get subsidies to pay for health insurance and encourage them to explore their plan options using an online Shop & Compare tool.~For the generic arm, the outreach materials described new financial assistance under the American Rescue Plan and noted the availability of plans as low as $1/month."
10210284|NCT05216458|Experimental|Personalized Outreach|"Households in the personalized outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees.~For the personalized arm, the outreach explicitly informed the household that they were eligible for a $1/month CSR Silver 94 plan and described the benefits this plan confers. The outreach materials for the personalized group were not only designed to increase enrollment, but also to simplify the search process by providing households with a clear recommendation to pick a CSR Silver plan; this included highlighting the low out-of-pocket costs these plans provide when accessing care, a screenshot of what the plan would look like when they entered the shopping portal and peer comparison language that noted 9 out of 10 consumers like them choose CSR Silver plans"
10210285|NCT05216419|Experimental|case group|"One dose of 30,000 IU of D-mac is taken once 15 days prior to surgery."
10210286|NCT05216419|No Intervention|control group|"There is no 30,000 IU of D-mac to be taken."
10210287|NCT05216406|Experimental|5-HTP|The dietary supplement (100 mg of 5-hydroxytryptophan; CLEANMOOD™) was provided by NURA™ (Irvine, California USA). Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
10210288|NCT05216406|Placebo Comparator|Control|The placebo consisted of maltodextrin. Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
10210289|NCT05216393|Experimental|intervention|The intervention group will be mailed a Fitbit device and provided access to the RecTech Match website. Intervention participants will receive weekly calls for the first 6 weeks, and a call every other week for the following 6 weeks (9 in total) from a health coach to discuss progress, facilitate setting physical activity goals, and help mitigate obstacles to participate in physical activity in the community. Participants will be free to access the features and resources of the website. The Fitbit data will be collected on an ongoing basis and the participants will receive daily texts asking them to rate the amount of physical activity for the day.
9863991|NCT00080665|Experimental|Imatinib mesylate and docetaxel|Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
9863992|NCT00080678|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel 30 mg/m^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.
9863993|NCT00080678|Placebo Comparator|Docetaxel + Placebo|Docetaxel 30 mg/m^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.
9863994|NCT00080743|Active Comparator|Tamoxifen|Tamoxifen 20 mg po once daily
9863995|NCT00080743|Placebo Comparator|Placebo|Placebo comparator one tablet po once daily
9863996|NCT00080782|Experimental|Arm I: Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
9863997|NCT00080782|Experimental|Arm II: No Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.
9863998|NCT00080808|Active Comparator|Arm I|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
9863999|NCT00080808|Active Comparator|Arm II (No sural nerve grafting)|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.
9864000|NCT00080847|Experimental|Arm I (closed to accrual as of 9/21/04)|Patients receive rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1 and oral prednisone on days 1-5.
9864001|NCT00080847|Experimental|Arm II|Patients receive oblimersen IV continuously on days 1-7; rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 5; and oral prednisone on days 5-10.
9864002|NCT00080873|Experimental|Receive Traumeel S|
9864003|NCT00080873|Placebo Comparator|Receive placebo|
9864004|NCT00080886|Other|Arm 1|
9864005|NCT00080951|Experimental|irinotecan + oxaliplatin + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV and fluorouracil IV over 90 minutes on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before each chemotherapy course, and at the end of treatment.~Patients are followed every 3 months until 5 years after registration."
9926584|NCT00883636||Non-Focal Segmental Glomerulosclerosis|
9926585|NCT00883649|Placebo Comparator|1|
9926586|NCT00883649|Active Comparator|2|
9926587|NCT00883662||Group 1|
9926588|NCT00883701||COPD patients|COPD patients who undergo exacerbation
9926589|NCT00883701||Non COPD patients (controls)|Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
9926590|NCT00883714|Experimental|Supervised exercise|
9926591|NCT00883714|Active Comparator|Control group|
9926592|NCT00883727|Experimental|stem cells|
9926593|NCT00883727|Placebo Comparator|Placebo|
9926594|NCT00883766|Active Comparator|Long agonist protocol|
9926595|NCT00883766|Experimental|Antagonist protocol|
9926596|NCT00883792|Experimental|Colonoscopy screening|One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
9926597|NCT00883792|No Intervention|Control|"The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs.~All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable."
10210290|NCT05216393|No Intervention|Control|The control participants will not have access to the RecTech Match website; however, control participants will be directed to generic information available on the NCHPAD website, which includes the same information but is not delivered through RecTechMatch.com.
10210291|NCT05216380|Experimental|ActivityLink|ActivityLink will be a clinic implementation program delivered to clinic staff.
10210292|NCT05216289|Active Comparator|probiac + topical fixed combination|
10210293|NCT05216289|Placebo Comparator|placebo + topical fixed combination|
10210294|NCT05216276|Active Comparator|TEP|Patient with uni- or bilateral inguinal hernia receiving a laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair.
9926598|NCT00883805||Metal-on-Metal Articulations|Subjects will be people who have had metal-on-metal total hip arthroplasties
9926599|NCT00883805||Ceramic-on-Metal Articulations|Subjects will be people who have had ceramic-on-metal total hip arthroplasties
9926600|NCT00883818|Experimental|Antibiotics therapy|
9926601|NCT00883831|Experimental|Individualized manual acupuncture|
9926602|NCT00883844|Experimental|1|Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
9926603|NCT00883844|Active Comparator|2|Continuation of Nucleos(t)ide analogue mono-therapy
9926604|NCT00883870|Experimental|mesenchymal stem cells|Intramuscular injection
9926605|NCT00883870|Experimental|Placebo|Intramuscular injection
9926606|NCT00883883|Experimental|1|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
9926607|NCT00883883|Active Comparator|2|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
9926608|NCT00883909||observational|A follow-up study in adult male subjects who have received investigational
9935259|NCT03976843|Experimental|1/18F-DCFPyL PET/CT + radical prostatectomy|18F-DCFPyL PET/CT with radical prostatectomy and lymphadenectomy
10210295|NCT05216276|Experimental|rTAPP|Patient with uni- or bilateral inguinal hernia receiving a robotic transabdominal preperitoneal (TAPP) inguinal hernia repair.
10210296|NCT05216237|Experimental|Treatment of HER-2 Negative MSS Advanced Gastric|Sintilimab Plus Apatinib and Chemotherapy in Patients with Previously Untreated HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer
9864006|NCT00080990|Experimental|Treatment (alvocidib with oxaliplatin, 5-FU, leucovorin)|"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose."
9864007|NCT00081094|Other|PET scan (FDG-PET & 11C-acetate-PET)|Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
9864008|NCT00081211|Experimental|Treatment (PV701)|Patients receive intratumoral PV701 once weekly for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PV701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 evaluable patients are treated at that dose.
9864009|NCT00081224|Experimental|celecoxib + capecitabine + radiation + surgery|"Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.~Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.~Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
9864010|NCT00081250|Experimental|Arm I|Patients receive oral creatine daily.
9864011|NCT00081250|Placebo Comparator|Arm II|Patients receive oral placebo daily.
9864012|NCT00081276|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864013|NCT00081354||Barrett's esophagus|Barrett's esophagus
9864014|NCT00081354||Controls negative for Barrett's esophagus|Controls negative for Barrett's esophagus
9864015|NCT00081367|Experimental|Cognitive behavioral therapy (CBT) + standard care|Participants will receive ten weekly sessions of treatment plus standard care for suicide prevention.
9864016|NCT00081367|Active Comparator|Standard care alone|Participants will receive standard care for suicide prevention.
9864017|NCT00081471|Experimental|1|
9864018|NCT00081471|Active Comparator|2|
9864019|NCT00081484|Experimental|1|
9864020|NCT00081484|Active Comparator|2|
9864021|NCT00081588|Experimental|001|TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
9864022|NCT00081822|Other|Clofarabine + Ara-C|An initial dose escalation of clofarabine with a fixed standard dose of Ara-C in phase I will be used to determine an optimal phase II dose.
9864023|NCT00081874|Experimental|RAD001|"Phase I: Participants initially treated with 5 mg RAD001 by mouth daily for 28 days.~Phase II: The MTD (either 5mg or 10mg) administered daily until intolerance or failure or lack of response after 4 cycles of therapy. For assessment purposes, each cycle will comprise a 28-day period."
9864024|NCT00081887|Experimental|Weekly Clofarabine|
9864025|NCT00081900|Experimental|DENSPM|
9864026|NCT00082043|Experimental|1|Dutasteride 2.5 mg by mouth daily for one month
9864027|NCT00082043|Placebo Comparator|2|Placebo oral capsule for two months
9864028|NCT00082095|Experimental|Group 1 (doxorubicin)|Pegylated liposomal doxorubicin 40 mg/m2 administered intravenously on Day 1 of each cycle. Cycle is repeated every 28 days, up to one year.
9864029|NCT00082095|Active Comparator|Group 2 (capecitabine )|Capecitabine administered orally at a dosage of 2000 mg/m2/day (1000 mg/m2 BID) for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
9864030|NCT00082147|Experimental|Biopsy|Biopsy
9864031|NCT00082186|Experimental|1|Oral bosentan tablets
9864032|NCT00082199|Active Comparator|A1|
9864033|NCT00082199|Placebo Comparator|A2|
9864034|NCT00082212|Experimental|1|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
9864035|NCT00082225|Experimental|EBV specific T cells|"Patients receiving CTLs as therapy for relapsed Lymphoma or who are at high risk for relapse or patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.~A fixed dose of CD45 MAb (400ug/kg over 4 hours daily times 4 given over 2 daily IV infusions) will be used."
9864036|NCT00082238|Experimental|Cystic fibrosis (CF)|
9864037|NCT00082238|Active Comparator|Healthy volunteers|
9864038|NCT00082277|Experimental|1|High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
9864039|NCT00082277|Experimental|2|Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
9864040|NCT00082277|Experimental|3|Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
9864041|NCT00082290|Experimental|a massage|About 45 minute massage
9864042|NCT00082290|Experimental|visit with a volunteer|45 minute visit
9864043|NCT00082290|Experimental|period of quiet time|45 minutes of quiet time
9864044|NCT00082446|Experimental|E|Subject will receive an SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.
9864045|NCT00082446|Active Comparator|D|Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
9864046|NCT00082446|Experimental|C|Subject will receive a SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
9864047|NCT00082446|Experimental|B|Subjects will receive a SC dose of MVA 5x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
9864048|NCT00082446|Experimental|A|Subjects will receive a SC dose of MVA 2x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
9864049|NCT00082446|Experimental|F|Subject will receive an IM dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
9864050|NCT00082485|Active Comparator|1|
9864051|NCT00082485|Placebo Comparator|2|
9864052|NCT00082498|Placebo Comparator|1|Group 1 will receive placebo
9864053|NCT00082498|Experimental|2|Group 2 will receive 5 mg vicriviroc daily
9864054|NCT00082498|Experimental|3|Group 3 will receive 10 mg vicriviroc daily
9864055|NCT00082498|Experimental|4|Group 4 will receive 15 mg vicriviroc daily
9996953|NCT01504594|Experimental|Patients|Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.
9864057|NCT00082719|Experimental|Arm I|Low-dose interferon alfa subcutaneously (SC) twice daily.
9864058|NCT00082719|Experimental|Arm II|Interferon alfa as in arm I at a higher dose.
9864059|NCT00082719|Experimental|Arm III|Interferon alfa SC once daily.
9864060|NCT00082719|Experimental|Arm IV|Interferon alfa as in arm III at a higher dose.
9864061|NCT00082732|Experimental|Arm I: Dietary Intervention|Nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52.
9864062|NCT00082732|No Intervention|Arm II: Observation|Observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.
9864063|NCT00082745||Observational (genetic analysis)|DNA from peripheral blood or saliva sample of patients is analyzed for the presence of polymorphisms in genes associated with an increased risk of late-occurring complications.
9864064|NCT00082784|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9926609|NCT00883935|Experimental|Sequence 2|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV 400mg q24h (treatment C) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
9926610|NCT00883935|Experimental|Sequence 1|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV/RTV 300/100mg q24h (treatment B) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
9926611|NCT00883948|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding.
9926612|NCT00883948|Experimental|2|Participants will receive initial full-calorie enteral feeding.
9926613|NCT00883961|Experimental|Supervised exercise|
9926614|NCT00883961|No Intervention|Control group|The patients will not carry out a structured exercise program.
9926615|NCT00883974|Experimental|1|
9795643|NCT01541969|Active Comparator|Tinnitus masking|Participants will receive the same Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device, but it will NOT be programmed according to the therapeutic algorithm (0-12 weeks).
9795644|NCT01542034|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9795645|NCT01542034|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9795646|NCT01542125|Experimental|Liposomal Lidocaine group|Patients in this groups received 4% Liposomal Lidocaine that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing
9795647|NCT01542125|Placebo Comparator|Placebo Group|This group received a placebo that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing.
9795648|NCT01542229|Experimental|Arm 1: PE + TAU|Prolonged Exposure Therapy +Treatment As Usual
9795649|NCT01542229|Active Comparator|Arm 2: Usual Treatment|Treatment As Usual
9795650|NCT01542255|Experimental|Combined Low Dose Treatment|"A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv"
9795651|NCT01542307|Experimental|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
9795652|NCT01542307|Placebo Comparator|Room Air|Medical air inhaled for 30 minutes during migraine attack
9795653|NCT01542372|Active Comparator|Medication augmentation|In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
9795654|NCT01542372|Active Comparator|CBT augmentation|In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.
9795655|NCT01542398|Experimental|Family-Focused Psychosocial Intervention|Intervention Group
9795656|NCT01542398|No Intervention|Waiting List Control|
9795657|NCT01542502|Experimental|Anakinra|Treatment with daily subcutaneous injections of Anakinra 100 mg
9795658|NCT01542502|Placebo Comparator|Placebo|Treatment with daily subcutaneous injection of placebo
9795659|NCT01542528|Experimental|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
9795660|NCT01542528|No Intervention|Treatment as Usual (TAU)|Whatever care arrangement the parents have arranged for their child during the same two hour period over the same 15 week period.
9795661|NCT01542541|Experimental|Rifaximin|
9864065|NCT00082875|Experimental|Arm I|"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *For the first course only, treatment is omitted on day 11"
9667023|NCT04053907|Experimental|CCM plus dry season MDA|CCM plus plus 3 monthly rounds of MDA with a long-acting ACT (dihydroartemisinin-piperaquine, DP) starting in the dry season (April, May, June) (tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight).
9864066|NCT00082875|Experimental|Arm II|Patients receive cilengitide as in arm I at a higher dose.
9864067|NCT00082966|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
9864068|NCT00083031|Experimental|Arm A-Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose~Bevacizumab- Via IV on predetermined days per cycle"
9864069|NCT00083031|Experimental|Arm B- Without Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose"
9864070|NCT00083070|Experimental|Temozolomide Therapy|
9864071|NCT00083109|Experimental|Treatment (suramin and fluorouracil)|"PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.~PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.~In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
9864072|NCT00083161|Experimental|Oral cyclophosphamide plus standard cisplatin with etoposide|"Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3~Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles~Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle"
9864073|NCT00083304|Experimental|Efaproxiral + WBRT + Supplemental Oxygen|
9864074|NCT00083304|Active Comparator|WBRT + Supplemental Oxygen|
9864075|NCT00083460|Active Comparator|1|
9864076|NCT00083460|Active Comparator|2|
9864077|NCT00083499||Group 1|Index cases
9864078|NCT00083499||Group 2|Relatives of Index Cases
9864079|NCT00083499||Group 3|Fetal tissue
9864080|NCT00083603|Experimental|1|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
9864081|NCT00083603|Placebo Comparator|2|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
9864082|NCT00083603|Experimental|3|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
9864083|NCT00083603|Placebo Comparator|4|Empty TBC-MVA vector administered in each deltoid on Days 0, 28; empty TBC-FPV vector administered in each deltoid on Days 84, 140, and 196
9864084|NCT00083603|Experimental|5|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
9864085|NCT00083603|Placebo Comparator|6|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
9864086|NCT00083603|Experimental|7|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
9864087|NCT00083603|Placebo Comparator|8|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
9864088|NCT00083603|Experimental|9|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
9864089|NCT00083603|Placebo Comparator|10|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
9864090|NCT00083603|Experimental|11|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
9926616|NCT00883974|No Intervention|2|Standard Neonatal Intensive Care Unit (NICU) procedures for the care of pre-term infants
9864091|NCT00083603|Placebo Comparator|12|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
9864092|NCT00083603|Experimental|13|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
9864093|NCT00083603|Placebo Comparator|14|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
9864094|NCT00083603|Experimental|15|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
9864095|NCT00083603|Placebo Comparator|16|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
9864096|NCT00083772|Experimental|1|Nesiritide
9864097|NCT00083824|Placebo Comparator|Sugar Pill|Placebo
9864098|NCT00083824|Experimental|Estrogens, Conjugated (USP)|Conjugated Equine Estrogen 0.625 mg/day for 3 years, drug
9864099|NCT00083824|Experimental|Medroxyprogesterone 17-acetate|Conjugated Equine Estrogen 0.625 mg/day plus Medroxyprogesterone Acetate 2.5 mg/day
9864100|NCT00083863||Framingham Heart Study Offspring|
9864101|NCT00083863||FHS Gen 3|
9864102|NCT00083980|Active Comparator|active antidepressant drug comparator|Venlafaxine ER
9864103|NCT00083980|Placebo Comparator|Sugar pill|Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
9864104|NCT00083980|Experimental|Herbal treatment kava|Kava
9864105|NCT00084032|Experimental|1|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.
9864106|NCT00084032|Experimental|2|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
9864107|NCT00084123|Experimental|Healing Touch|Healing Touch Therapy
9864108|NCT00084123|Active Comparator|Relaxation Therapy|Relaxation Therapy
9864109|NCT00084123|Placebo Comparator|Standard Care|Standard Care
9864110|NCT00084370|Experimental|Group 1|Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.
9864111|NCT00084370|Experimental|Group II|Group II: Patients undergo immediate prophylactic oophorectomy.
9864112|NCT00084396|Experimental|Letrozole/Surgery|
9864113|NCT00084435|Experimental|chemoRT after surgery|chemoRT with cisplatin and docetaxel after surgery
9864114|NCT00084461|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
9864115|NCT00084539|Experimental|Radiation therapy|"Radiation Therapy~Daily 5 days per week for 4 weeks~45 Gy in 20 fractions whole breast~56 Gy in 20 fractions to boost volume"
9864116|NCT00084604|Experimental|Treatment (bevacizumab, cisplatin, irinotecan)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864117|NCT00084630|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with documented tumor progression and no serious side effects may continue therapy at a higher dose for another 6 courses.
9926617|NCT00883987||Back Pain|"Patients with chronic mechanical low back pain (Chronic low back pain is defined as having pain between the lower ribs and gluteal folds, with minimal radiation to the thigh and never below the knee, present for a minimum of seven weeks)"
9926618|NCT00884000|Active Comparator|1|
9926619|NCT00884000|Experimental|2|
9926620|NCT00884013||1|Quality Payment and all clinical reminders turned on
9926621|NCT00884013||2|Quality Payment and ABCS measures reminders turned on
9926622|NCT00884013||3|Quality Payment and non-ABCS measures reminders turned on
9864118|NCT00084643|Experimental|Treatment (GTI-2040, capecitabine, oxaliplatin)|Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
9864119|NCT00084695|Experimental|Regimen A|Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.
9864120|NCT00084695|Experimental|Regimen B (patients who do not receive TBI)|Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.
9864121|NCT00084695|Experimental|Regimen C (patients with Fanconi's anemia/related disorders)|Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
9864122|NCT00084695|Experimental|Regimen D|Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
9864123|NCT00084773|Experimental|Cetuximab, Fluorouracil, and Pelvic Irradiation|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 and fluorouracil IV continuously on days 1-42. Patients undergo whole-pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Treatment continues in the absence of disease progression or unacceptable toxicity.~Approximately 1-3 weeks after completion of study treatment, patients undergo surgical resection followed by adjuvant chemotherapy off-study.~Patients are followed for up to 5 years."
9864124|NCT00084812|Experimental|Safingol and Cisplatin|"Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.~Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level."
9864125|NCT00084825|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.
9864126|NCT00084877|Experimental|Treatment (triapine, irinotecan hydrochloride)|"Patients receive irinotecan IV over 1 hour on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of irinotecan and 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are treated at that dose."
9864127|NCT00084903|Experimental|Fluorescence Spectroscopy|
9864128|NCT00084916|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864129|NCT00084981|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose."
9926623|NCT00884013||4|Quality Reporting and Recognition with all clinical reminders turned on
9864130|NCT00085111|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9864131|NCT00085124|Experimental|Arm I|"Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy."
9864132|NCT00085124|Experimental|Arm II|"Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1 and 2.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5. Patients with a continuing CR receive a second course of consolidation therapy."
9864133|NCT00085189|Experimental|Cohort I (melanoma peptide vaccine, Montanide ISA-51)|Patients receive multi-epitope peptide melanoma peptide vaccine with incomplete Freund's adjuvant and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
9864134|NCT00085189|Experimental|Cohort II (melanoma peptide vaccine, Montanide ISA 51 VG)|Patients receive multi-epitope peptide melanoma peptide vaccine with Montanide ISA 51 VG and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
9864135|NCT00085280|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment."
9864136|NCT00085306|Experimental|Recombinant interferon beta|
9926624|NCT00884013||5|Quality Reporting and Recognition with ABCS measures reminders turned on
9926625|NCT00884013||6|Quality Reporting and Recognition with non-ABCS measures reminders turned on
9926626|NCT00884026|Active Comparator|1|Subjects that experience hypotension after spinal anesthesia.
9926627|NCT00884026|Active Comparator|2|Subjects that do not experience hypotension after spinal anesthesia.
9935260|NCT03975231|Experimental|Treatment (dabrafenib, trametinib, IMRT)|See Detailed Description
9864137|NCT00085358|Experimental|Treatment (carboplatin, paclitaxel, docetaxel, bevacizumab)|"Patients receive IP carboplatin on day 1, and paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B) on day 1, and IP paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive IP carboplatin on day 1, paclitaxel IV on day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase. Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
9864138|NCT00085371|Experimental|Treatment (triapene)|Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864139|NCT00085384|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
9864140|NCT00085384|Experimental|Arm II|Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
9864141|NCT00085384|Experimental|Arm III|Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
9864142|NCT00085397|Experimental|Arm I|Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
9864143|NCT00085397|Experimental|Arm II|Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
9864144|NCT00085449|Experimental|Regimen A + B|"Conditioning regimen A: Patients receive alemtuzumab IV over 2 hours on days -14 to -12; fludarabine IV over 30 minutes on days -7 to -3; and melphalan IV over 20-30 minutes on day -2.~Conditioning regimen B: Patients receive oral or IV cyclosporine twice daily and oral or IV mycophenolate mofetil twice daily on days -15 to 0. Patients also receive alemtuzumab, fludarabine, and melphalan as in conditioning regimen A. Patients undergo low-dose total body irradiation twice daily on days -2 and -1.~All patients undergo allogeneic, T-cell-depleted, CD34-positive peripheral blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.~Patients are followed every 3 months for 1 year and then every 6 months for 5 years."
9864145|NCT00085501|Active Comparator|1|
9864146|NCT00085501|Active Comparator|2|
9864147|NCT00085527|Experimental|depsipeptide|Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.
9864148|NCT00085553|Experimental|Treatment (erlotinib hydrochloride, tipifarnib)|Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
9864149|NCT00085670||Group 1|Bone marrow failure subjects
9864150|NCT00085722|Experimental|Dextrose|Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
9864151|NCT00085722|Placebo Comparator|Normal saline|Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
9864152|NCT00085722|Other|Exercise|At-home physical therapy exercises as a non-injection control
9864153|NCT00085787|Experimental|ARRY-142886|
9864154|NCT00085852|Experimental|Single|Treatment with BLVR
9864155|NCT00085969|Placebo Comparator|A1 - Placebo 0.04 mL twice daily|
9864156|NCT00085969|Placebo Comparator|A2 - Placebo 0.04 mL once daily|
9864157|NCT00085969|Placebo Comparator|A3 - Placebo 0.08 mL once daily|
9864158|NCT00085969|Experimental|B - Exenatide 10 mcg twice daily|
9667024|NCT04053790|Placebo Comparator|placebo group|Patients in this group will receive placebo 1 tablet every 12 hours, during 4 weeks.
9864159|NCT00085969|Experimental|C - Exenatide 10 mcg once daily|
9864160|NCT00085969|Experimental|D - Exenatide 20 mcg once daily|
9864161|NCT00086060|Experimental|1 - Relaxation Training|Participants will receive relaxation training and standard care for FM
9864162|NCT00086060|Experimental|2 Exercise Regimen|Participants will receive an exercise regimen and standard care for FM
9864163|NCT00086060|Active Comparator|3 Standard Care|Participants will receive standard of care for FM
9864164|NCT00086060|No Intervention|4 Health Controls|Health participants will act as a control
9864165|NCT00086099|Experimental|1|Idarubicin plus amifostine
9864166|NCT00086099|Experimental|2|Idarubincin
9864167|NCT00086125|Experimental|1|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
9864168|NCT00086177|Active Comparator|1|Progesterone 8% vaginal gel
9864169|NCT00086177|Placebo Comparator|2|Placebo Vaginal Gel
9864170|NCT00086242|Experimental|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, ~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
9864171|NCT00086242|No Intervention|Usual Care|Eligible patients are randomized to receive either psychosocial telephone counseling (PTC) or usual care. The usual care are were only contacted by the study team to collect data in an identical frame to subjects receiving PTC.
9864172|NCT00086268|Experimental|Zometa®|4mg monthly for 12 months from date of first chemotherapy dose
9864173|NCT00086268|No Intervention|no further treatment|Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
9864174|NCT00086359|Experimental|A|One pill of abacavir/lamivudine/zidovudine twice daily
9864175|NCT00086359|Experimental|B|One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.
9864176|NCT00086489|Experimental|10 mg/kg|pts treated at 10 mg/kg dose level on a monthly regimen
9864177|NCT00086489|Experimental|15 mg/kg|pts treated at 15 mg/kg dose level on a quarterly regimen
9864178|NCT00086645|Experimental|citalopram hydrobromide|citalopram hydrobromide, up to 20 mg daily
9864179|NCT00086645|Placebo Comparator|placebo|placebo, up to equivalent of 20 mg of active comparator daily
9864180|NCT00086736|Experimental|Arm I|Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
9864181|NCT00086736|Experimental|Arm II|Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
9864182|NCT00086736|Experimental|Arm III|Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
9864183|NCT00086736|Experimental|Arm IV|Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
9864184|NCT00086749||Tamoxifen group|
9864185|NCT00086762|Experimental|MR Therapy|Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. A CD with the mindfulness relaxation technique recorded on it will be given to participant. Participant to listen to the recording for about 30 minutes before receiving chemotherapy and during the time they are receiving chemotherapy. In addition to the mindfulness relaxation technique, they will also receive general information about how to manage symptoms that develop due to the chemotherapy they are receiving.
9864186|NCT00086762|Experimental|Relaxing Music (RM) Therapy|Arm II: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment.
9864187|NCT00086762|Active Comparator|Standard Symptom Management|Arm III: Participants receive standard symptom management education.
9926628|NCT00884078|Experimental|1|C-MAPS (Culturally adapted manualized problem solving training) will be a brief problem focused therapy comprising of 8 sessions within three months after a self-harm episode. We will have two engagement sessions before the actual therapy. The adapted therapy/training will be delivered by therapists/trained counselors in the patient's home/GP practice depending upon patient's choice. Sessions will be offered weekly in the first month and than fortnightly and will last 50 minutes.
9935261|NCT03973268|Experimental|1|Individuals in Arm 1 will receive double-blinded perampanel and open-label ketamine on the first day, then double-blinded perampanel on the second day.
9935262|NCT03973268|Experimental|2|Individuals in Arm 2 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded perampanel on the second day.
9935263|NCT03973268|Experimental|3|Individuals in Arm 3 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded placebo on the second day.
9935264|NCT03973177|Experimental|Treatment Group: Phenol injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target sites
9864188|NCT00086801|Experimental|doxorubicin + vinblastine + gemcitabine|"Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed.~Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years."
9864189|NCT00086827|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have continuing tumor response or stable disease after 6 courses receive 2 additional courses beyond best response.
9864190|NCT00086840|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.
9864191|NCT00086944|Experimental|Treatment (genase, combination chemotherapy)|See detailed description.
9864192|NCT00086970|Experimental|Arm I (ifosfamide)|Patients receive high-dose ifosfamide IV continuously over 72 hours on days 1-3.
9864193|NCT00086970|Experimental|Arm II (O6-benzylguanine, ifosfamide)|Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1 followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on days 1-3.
9864194|NCT00086983|Experimental|Treatment (becatacarin, oxaliplatin)|"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5 and oxaliplatin IV over 2 hours on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
9864195|NCT00087009|Experimental|Group I|Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
9864196|NCT00087009|Experimental|Group II|Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.
9864197|NCT00087035|Experimental|Taxotere plus Tarceva|"Patients receive Tarceva 150 mg daily for 21 consecutive days (one treatment cycle). In addition, all patients will receive single agent Taxotere 60 mg/m2 IV over 1 hour infusion every 21 ± 2 days and have it administered on day 1.~Taxotere + Tarceva to be taken for three cycles past maximal response or until one of the following occurs: 1) a drug-related toxicity requiring discontinuation, 2) disease progression, or 3) for a maximum of 9 cycles.~Upon completion of 9 cycles of Taxotere plus Tarceva, patients showing evidence of objective response (CR, PR or stable disease) may continue in the extension phase of the study and receive treatment with Tarceva alone. Treatment response evaluated after four cycles of Tarceva treatment(immediately prior to cycle 14). Patients with progression of disease will be taken off study. Responding and stable disease patients will remain on study for up to 8 extension-phase cycles for a total of 17 cycles."
9864198|NCT00087074|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
9864199|NCT00087178|Active Comparator|Arm 1: adriamycin + cyclophosphamide|Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
9864200|NCT00087178|Experimental|Arm 2: fluorouracil + epirubicin + cyclophosphamide|Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
9864201|NCT00087191|Experimental|Diagnostic (EF5, motexafin lutetium)|Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.
9864202|NCT00087204|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue (XL119) IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 1 additional course beyond CR. Patients achieving a PR or HI receive 2 additional courses beyond PR or HI. Cohorts of 3-6 patients receive escalating doses of XL119 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
9864203|NCT00087217|Experimental|Treatment (tanespimycin, paclitaxel)|Patients receive 17-AAG IV over 1 hour on days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9864204|NCT00087256|Placebo Comparator|Arm 1: placebo|one placebo capsule taken orally twice a day for 3 years
9864205|NCT00087256|Experimental|Arm 2: celecoxib|one 400 mg capsule taken orally twice a day for 3 years
9864206|NCT00087269|Experimental|Treatment (erlotinib)|Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
9864207|NCT00087295|Experimental|Treatment|Depsipeptide
9864208|NCT00087373|Experimental|Treatment (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM intratumorally on day 1 of weeks 1, 4, and 7 (maximum of 3 injections for a single lesion) (course 1). After 3 injections (course 1), patients with stable or responding disease receive additional injections into new lesions following the same schedule as above. Treatment repeats every 9 weeks for a maximum total of 9 injections (3 injections total into a maximum of 3 different tumors) (total of 3 courses) in the absence of disease progression or unacceptable toxicity
9864209|NCT00087386|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
9864210|NCT00087399|Experimental|gabapentin + antidepressant|"Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.~Patients complete a hot flash diary at baseline and then daily during study treatment."
9864211|NCT00087399|Experimental|gabapentin|"Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.~Patients complete a hot flash diary at baseline and then daily during study treatment."
9864212|NCT00087412|Experimental|Treatment|Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864213|NCT00087581|Experimental|Group A: Monitored MMF + Reduced CNI|Group A will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or intravenous (IV) form. The initial dose will be at least 1 gram twice a day (BID) in adults and 600 milligrams per meter-squared (mg/m^2) in pediatrics. Subsequent doses will be adjusted to maintain blood mycophenolic acid (MPA) levels greater than or equal to (≥) 1.3 micrograms per milliliter (μg/mL) with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain reduced blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 nanograms per milliliter (ng/mL); Days 30-90, 125-165 ng/mL; Days 90 through end of study, 95-145 ng/mL. Tacrolimus target concentrations areas follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL; Days 90 through end of study, 3-5 ng/mL.
9864214|NCT00087581|Experimental|Group B: Monitored MMF + Full CNI|Group B will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
9864215|NCT00087581|Experimental|Group C: Fixed MMF + Full CNI|Group C will receive fixed-dose MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses are not to be adjusted, except in the case of unacceptable toxicity. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
9864216|NCT00087711|Experimental|A|
9864217|NCT00087711|Active Comparator|B|
9864218|NCT00087802|Active Comparator|Stratum 1|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally
9864219|NCT00087802|Active Comparator|Stratum 2|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).
9864220|NCT00087867|Experimental|001|SCIO-469 two 30-mg capsules three times daily
9864221|NCT00087867|Other|002|SCIO-469 and bortezomib In addition to SCIO-469 patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1 4 8 and 11 of a 21-day cycle followed by a 10-day rest period
9864222|NCT00087880|Active Comparator|Brief Treatment|Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
9864223|NCT00087880|Active Comparator|Extended Bupropion/Low Contact|Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
9864224|NCT00087880|Placebo Comparator|Extended Placebo/Low Contact|Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
9864225|NCT00087880|Active Comparator|Extended Bupropion/High Contact|Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
9864226|NCT00087880|Placebo Comparator|Extended Placebo/High Contact|Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
9864227|NCT00088140|Placebo Comparator|Placebo|
9864228|NCT00088140|Active Comparator|IDN-6556 5 mg twice a day (BID)|
9864229|NCT00088140|Active Comparator|IDN-6556 25mg twice a day (BID)|
9864230|NCT00088140|Active Comparator|IDN-6556 50 mg twice a day (BID)|
9864231|NCT00088231|Experimental|PTK 787 + Imatinib|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
9864232|NCT00088231|Experimental|PTK 787 (vatalanib) Alone|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. PTK 787 250 mg by mouth for Days 1 - 7.
9864233|NCT00088257||Mother-child pairs|Subset of mother-child pairs enrolled in Project Viva, a cohort study of pregnant women and their offspring. 411 mother-child pairs with measures of lymphocyte proliferation in their cord blood samples make up the subset for this study.
9864234|NCT00088426||Control|Control group of Williams-Beuren (also known as Williams) syndrome
9864235|NCT00088426||Family|Direct blood relatives (typically parents, and occasionally siblings of affected individuals) ofpatients with HPE are also eligible to participate.
9864236|NCT00088426||HPE|Patients with HPE
9864237|NCT00088543|Experimental|1 Low dose|total dose 4.5 mg/kg Thymoglobulin
9864238|NCT00088543|Experimental|2 High dose|total dose 8.5 mg/kg Thymoglobulin
9864239|NCT00088556|Experimental|Triplet Combination of TLK286 Carboplatin & Paclitaxel|Experimental
9864240|NCT00088582|Experimental|Sandostatin s.c. (Octreotide)|
9864241|NCT00088582|Experimental|Pasireotide (SOM230)|
9926629|NCT00884078|No Intervention|2 Control group|"Patients who will be randomized to the treatment as usual arm will receive routine care. In most cases this consists of an assessment by a casualty doctor or a junior psychiatrist in the emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the remainder are advised to consult their own general practitioner (Kapur 1998) this is particularly so in case of Asian females (Cooper et al, 2006). No patients are routinely referred to psychotherapy or psychology services. Participants will receive an initial assessment along with treatment as usual (TAU) as ascertained by the general practitioner or mental health professional any type of treatment apart from C-MAPS will be permitted. We will record the degree of patient adherence to standard care."
9926630|NCT00884091||Healthy Adults|"Chinese in origin~Healthy~No medication at least two weeks before the study"
9926631|NCT00884104|Experimental|1.tamsulosin + solifenacin|
9926632|NCT00884130||Laparoscopic|Patients having a laparoscopic colorectal resection
9926633|NCT00884130||Open|Patients having an open colorectal resection
9926634|NCT00884182|Experimental|Group 1|Participants on vaccination schedule 1 (Day 0 and Day 21)
9926635|NCT00884182|Experimental|Group 2|Participants on vaccination schedule 2 (Day 0 and Day 14)
9926636|NCT00884182|Experimental|Group 3|Participants on vaccination schedule 3 (Day 0 and Day 42)
9926637|NCT00884195|Experimental|1|Gratitude Journaling
9926638|NCT00884195|Placebo Comparator|2|Neutral Journaling
9864242|NCT00088764|Experimental|1|Education: Either coping skills training or arthritis education interventions
9864243|NCT00088764|Experimental|2|Writing: Either emotional disclosure writing or health behavior writing
9864244|NCT00088777|Experimental|MET|
9864245|NCT00088777|Experimental|CSE|
9864246|NCT00088855|Experimental|Treatment (bortezomib and pegylated liposomal doxorubicin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 4. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9864247|NCT00088894|Experimental|Arm I (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15.
9864248|NCT00088894|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine IV as in arm I and placebo IV over 30-90 minutes on days 1 and 15.
9864249|NCT00088933|Experimental|Arm I|Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.
9864250|NCT00088933|Experimental|Arm II|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.
9864251|NCT00088933|Experimental|Arm III|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.
9864252|NCT00088933|Experimental|Arm IV|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.
9864253|NCT00088933|Experimental|Arm V|Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.
9864254|NCT00088933|Experimental|Arm VI|Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.
9864255|NCT00088946|Experimental|Arm 1|Polyphenon E plus erlotinib placebo daily for 12 months.
9864256|NCT00088946|Experimental|Arm 2|Erlotinib and Polyphenon E placebo daily for 12 months.
9864257|NCT00088946|Placebo Comparator|Arm 3|Erlotinib placebo and Polyphenon E placebo daily for 12 months.
9864258|NCT00088959|Experimental|Treatment (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
9864259|NCT00088998|Experimental|docetaxel + bevacizumab + capecitabine|"Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years."
9864260|NCT00089063|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG SC on day 1 of weeks 0, 26, 52, 78, and 104 (total of 5 vaccinations).
9864261|NCT00089063|Experimental|Arm II (vaccine therapy, sargramostim)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG as in arm I. Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.
9864262|NCT00089089|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 1 hour on days 1-5 or on days 1-5 and 8-12. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
9864263|NCT00089154|Experimental|Treatment (apolizumab)|Patients receive apolizumab IV over 2-4 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity.
9864264|NCT00089180|Experimental|Arm I (liposomal T4N5 lotion)|Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
9864265|NCT00089180|Placebo Comparator|Arm II (placebo)|Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
9864266|NCT00089219|Experimental|Arm A. 6MHP vaccine 200 mcg|vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
9864267|NCT00089219|Experimental|Arm B. 6MHP vaccine 400 mcg|vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
9864268|NCT00089219|Experimental|Arm C. 6MHP vaccine 800 mcg|vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
9864269|NCT00089271|Experimental|Treatment (alvespimycin hydrochloride)|Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864270|NCT00089310|Experimental|Sentinal node mapping|
9864271|NCT00089323|Other|1: Bone Marrow Aspiration|
9864272|NCT00089349|Experimental|Arm I|"Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.~Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.~CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.~NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3."
9864273|NCT00089362|Experimental|Treatment (alvespimycin hydrochloride)|"Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose."
9864274|NCT00089388|Experimental|Arm I (low dose cilengitide)|Patients receive cilengitide IV at a lower dose over 1 hour twice weekly for 4 weeks.
9864275|NCT00089388|Experimental|Arm II (higher dose cilengitide)|Patients receive cilengitide IV at a higher dose over 1 hour twice weekly for 4 weeks.
9864276|NCT00089492|Experimental|1|
9864277|NCT00089492|Active Comparator|2|
9864278|NCT00089570|Experimental|Terlipressin|Terlipressin
9864279|NCT00089570|Placebo Comparator|Placebo|Placebo
9864280|NCT00089804|Active Comparator|1|300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
9864281|NCT00089804|Active Comparator|2|900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
9864282|NCT00089804|Placebo Comparator|3|A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
9864283|NCT00089856|Other|2|Standard of care - chemotherapy
9864284|NCT00089856|Experimental|1|Immunotherapy
9864285|NCT00089908|Experimental|1|One subcutaneous vaccination with rDEN1delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
9864286|NCT00089908|Experimental|2|One subcutaneous vaccination with rDEN1delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
9864287|NCT00089908|Placebo Comparator|3|One subcutaneous vaccination with placebo into the deltoid region of either arm.
9864288|NCT00089921|Experimental|001|SCIO-469 30 mg capsule three times daily for 12 weeks
9864289|NCT00089921|Experimental|002|SCIO-469 60 mg capsule three times daily for 12 weeks
9864290|NCT00089921|Experimental|003|SCIO-469 100 mg tablet once daily for 12 weeks
9864291|NCT00089921|Placebo Comparator|004|Placebo 2 capsules three times daily and one tablet daily
9864292|NCT00089960|Other|Arm|AMG 125 mg daily continuously
9864293|NCT00090025|Experimental|becatecarin|becatecarin
9864294|NCT00090025|Active Comparator|5-FU Plus Leucovorin (LV)|5-Fluorouracil (5-FU) Plus Leucovorin (LV)
9864295|NCT00090038|Experimental|1|Rituximab
9864296|NCT00090038|No Intervention|2|No drug
9864297|NCT00090129|Experimental|Onercept|
9864298|NCT00090129|Placebo Comparator|Placebo|
9864299|NCT00090194|Experimental|Low Dose|0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant
9864300|NCT00090194|Experimental|Middle Dose|1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
9864301|NCT00090194|Experimental|High Dose|2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
9864302|NCT00090337|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks.
9864303|NCT00090337|Active Comparator|Arm II|Patients undergo standard of care for 4 weeks.
9864304|NCT00090415|Experimental|1|Child participants with autism will undergo intensive behavioral therapy.
9864305|NCT00090415|No Intervention|2|Child participants without autism will receive no treatment and will undergo assessments to determine brain functioning only.
9864306|NCT00090428|Experimental|1|Participants will follow a gluten-free and casein-free diet for 18 weeks. The compliance with the diet was monitored with 24 hour dietary recall and nutritional sufficiency with diet diary analysis.
9864307|NCT00090428|Active Comparator|2|After established on a gluten free and casein free diet for at least 6 weeks, participants received double blind, placebo controlled challenges containing gluten, casein, gluten+casein, or placebo in a random order. Data was collected on behavioral and physiologic responses relative to the challenges. Children remained on the gluten free and casein free diet throughout this period.
9864308|NCT00090480|Experimental|Vaccine group|
9864309|NCT00090571||Sib Pairs|Two or more biological siblings affected with JIA.
9864310|NCT00090740||Asthmatics|People who have asthma
9864311|NCT00090740||Controls|People who do not have asthma
9864312|NCT00090896|Experimental|CTLA4-Blocking Monoclonal Antibody|
9864313|NCT00090961|Experimental|12-week exercise program + education|A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
9864314|NCT00090961|Other|Education|At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
9926639|NCT00884208||Group 1|Recommend assistive device
9926640|NCT00884208||Group 2|Consultation for PT assessment
9926641|NCT00884260|Experimental|Arm 1|
9926642|NCT00884299|No Intervention|1|Free diet
9926643|NCT00884299|Experimental|Diet rich in antioxidants|Diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients in this arm will be seen regularly in the outpatient clinic where there will be informed for the potential beneficial effects of fruits and vegetables in health status by two members of the study team (attending physician and specialist nurse). At baseline and at each visit it is clearly explained to them that the dietary goal is to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the 3-year study period.
9926644|NCT00884338|Experimental|Exercise|
9667025|NCT04053790|Active Comparator|LB 10000|Patients in this group will receive placebo 1 tablet containing 5,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
9667026|NCT04053790|Active Comparator|LB 20000|Patients in this group will receive placebo 1 tablet containing 10,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
9864315|NCT00091078|Experimental|Treatment (oblimersen sodium and imatinib mesylate)|Patients receive oblimersen IV continuously on days 1-14. Patients also receive oral imatinib mesylate on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864316|NCT00091091||All patients|Self report/Medical record review/ clinical eval
9864317|NCT00091117|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864318|NCT00091130|Experimental|Arm I (SGN-00101)|Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
9864319|NCT00091130|Placebo Comparator|Arm II (placebo)|Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
9864320|NCT00091182|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
9864321|NCT00091195|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864322|NCT00091247|Experimental|tetracycline|"Patients receive oral tetracycline twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
9864323|NCT00091247|Placebo Comparator|placebo|"Patients receive oral placebo twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
9864324|NCT00091286|Experimental|Peptide Vaccine + Montanide + GM-CSF|Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant
9864325|NCT00091299|Experimental|warfarin|
9864326|NCT00091351|Experimental|surgery|"Patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
9864327|NCT00091351|Experimental|radiation + surgery|"Patients undergo preoperative radiotherapy once daily, 5 days a week, for 5.5 weeks. Within 28-63 days after the completion of radiotherapy, patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
9864328|NCT00091377|Experimental|Arm A|Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles
9864329|NCT00091377|Experimental|Arm B|Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles
9864330|NCT00091468|Placebo Comparator|Placebo Group|Placebo for first six months of study; moved to open-label active nicotine for second six months
9864331|NCT00091468|Experimental|Active Nicotine Group|Blinded active nicotine for first six months of study; open-label active nicotine for second six months
9864332|NCT00091637|Placebo Comparator|1|Placebo infusion
9864333|NCT00091637|Experimental|2|Pexelizumab infusion
9864334|NCT00091676|Experimental|ID-KLH + GM-CSF|
9864335|NCT00091676|Active Comparator|KLH + GM-CSF|
9864336|NCT00091715|Experimental|1|62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
9864337|NCT00091715|Placebo Comparator|2|placebo for 6 months followed by an open label period
9864338|NCT00091806|Experimental|Cohort 1|6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug
9864339|NCT00091806|Experimental|Cohort 2|Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.
9864340|NCT00091858|Experimental|Darbepoetin alfa 6.75 mcg/kg Q4W|
9864341|NCT00091858|Placebo Comparator|Placebo Q4W|
9864342|NCT00091897|Experimental|Rituximab or placebo|Rituximab or placebo is administered through intravenous access on day 1 and again on day 15 (+/- 2 days)
9864343|NCT00091988|Experimental|Lifestyle & Behavioral Change Program|
9864344|NCT00091988|Active Comparator|Structured Education Program|
9864345|NCT00092001|Experimental|1|
9864346|NCT00092391|Active Comparator|Control Group|M-M-R(TM) II at current release potency
9864347|NCT00092391|Experimental|Mumps Expiry Group 1|M-M-R(TM) II at intermediate expiry potency
9864348|NCT00092391|Experimental|Mumps Expiry Group 2|M-M-R(TM) II at expiry potency
9864349|NCT00093002|Experimental|1|250 mg fulvestrant
9864350|NCT00093002|Experimental|2|500 mg fulvestrant
9864351|NCT00093080|Experimental|Ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
9864352|NCT00093197|Experimental|A1: KAI-9803|
9864353|NCT00093197|Experimental|A2: KAI-9803|
9864354|NCT00093197|Experimental|A3: KAI-9803|
9864355|NCT00093197|Experimental|A4: KAI-9803|
9864356|NCT00093197|Placebo Comparator|A5: Placebo|
9864357|NCT00093223|Experimental|1|35mg/m^2 infusion time is 3.5 minutes
9864358|NCT00093223|Experimental|2|2 doses of 35mg.m^2 with the second dose given 2 months later
9864359|NCT00093236|Experimental|Early Periodontal Treatment|Subjects will receive scaling, root planing and if needed periodontal surgery
9864360|NCT00093236|Active Comparator|Usual Dental Hygiene|Subjects will receive routine oral hygiene
9864361|NCT00093249|Experimental|clevidipine|Clevidipine was administered in a blinded fashion by intravenous (IV) infusion, starting at a rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr) and titrating upward, as tolerated, in doubling increments approximately every 90 seconds to achieve the desired blood pressure-lowering effect. Up-titration to 3.2 μg/kg/min (16 mg/hr) was allowed. Infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing in serial increments of 1.5 μg/kg/min up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
9864362|NCT00093249|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
9864363|NCT00093262|Experimental|clevidipine|Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
9864364|NCT00093262|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
9926645|NCT00884338|Active Comparator|Control group|
9926646|NCT00884364|Active Comparator|Control|
9926647|NCT00884364|Experimental|Exercise|
9926648|NCT00884416|Experimental|Sorafenib dose titration|
9926649|NCT00884429|Active Comparator|1- Conventional Chest Physiotherapy|Percussion , thorax compression and Postural Drainage/suction if necessary
9926650|NCT00884429|Active Comparator|2- Chest physiotherapy- Actual techniques|slow prolonged expiration and clearance rhinopharynx and suction if necessary
9926651|NCT00884429|Active Comparator|3- Airway Suction|Suction superior airways. Only in admission.
9926652|NCT00884442|Active Comparator|1|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state
9926653|NCT00884442|Active Comparator|2|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state
9926654|NCT00884442|Active Comparator|3|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state
9926655|NCT00884442|Active Comparator|4|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state
9926656|NCT00884468||1|Patients with PsA that fulfill the eligibility criteria of the study
9926657|NCT00884481||Natalizumab|Participants with MS treated with Tysabri over 12 months
9926658|NCT00884494|Experimental|Roux-en-Y gastric bypass|
9926659|NCT00884494|Experimental|Lean|
9926660|NCT00884520|Experimental|VM4-037|Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head & neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
9926661|NCT00884533|Experimental|Group 1|Group 1 - placebo on Day -1, rosi XR 8mg from Days 1-20, rosi XR 20mg on Day 21
9926662|NCT00884533|Placebo Comparator|Group 3|Placebo on Day -1, Days 1-20 and Day 21
9926663|NCT00884533|Active Comparator|Group 2|Placebo for Day -1, placebo on Days 1-20 and moxifloxacin active comparator 400 mg on Day 21
9926664|NCT00884546|Experimental|Arm 1|BMS-833923 (Starting dose is a loading dose of 60 mg for 7 days with a 30 mg daily dose thereafter)
9926665|NCT00884546|Active Comparator|Arm 2|"BMS-833923 (MTD or below)~Lenalidomide (at or below the recommended prescribing dose)~Dexamethasone (40 mg)"
9926666|NCT00884546|Active Comparator|Arm 3|"BMS-833923 (MTD or below)~Bortezomib (at or below the recommended prescribing dose)"
9926667|NCT00884559|Active Comparator|Technical|Technical Instructions
9926668|NCT00884559|Experimental|Leadership|Leadership-Instructions
9926669|NCT00884624||A|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
9926670|NCT00884637||CNV subjects|
9926671|NCT00884663|Experimental|1 Candesartan|
9926672|NCT00884663|Active Comparator|2 propranolol|
9926673|NCT00884663|Placebo Comparator|3 Placebo|
9926674|NCT00884676|Experimental|Schedule A|Schedule A: Ixabepilone - Weekly for 3 weeks each cycle (Days 1, 8 and 15) For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1
9926675|NCT00884676|Experimental|Schedule B|Ixabepilone - Day 1 of each 3-week cycle For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1.
9926676|NCT00884689||1|Asthma patient with specific treatment
9926677|NCT00884689||2|Asthma patient on different specific treatment compared to the other group
9926678|NCT00884728||Indigenous children aged <15 years|Indigenous children aged <15 years within participating communities of the Northern Territory
9864365|NCT00093418|Experimental|Arm I|Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
9864366|NCT00093418|Experimental|Arm II|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
9864367|NCT00093418|Experimental|Arm III|Patients receive tipifarnib as in arm I, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
9864368|NCT00093418|Experimental|Arm IV|Patients receive tipifarnib as in arm II, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
9864369|NCT00093509|Experimental|Magnetic Resonance Based Thermometry|"Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90. Interstitial temperature measurements will be taken by placing a single (less than or equal to) 15 gauge thermometry catheter into the tumor.~In addition to hyperthermia treatment and radiation therapy all patients will receive conventional surgery for the removal of their tumors. Some patients will also receive chemotherapy if their treating physician thinks it is the their best interested (including the possibility of doxorubicin hydrochloride or ifosfamide and mesna)."
9864370|NCT00093600|Experimental|PKC412 administered sequentially|twice daily oral dosing of PKC412 administered sequentially
9864371|NCT00093600|Experimental|PKC412 administered concomitantly|PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
9864372|NCT00093613|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity."
9864373|NCT00093626|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864374|NCT00093704|Experimental|Bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
9864375|NCT00093730|Experimental|BMS-59926|
9864376|NCT00093743|Experimental|Treatment (allogeneic bone marrow or PBSC transplantation)|"NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, cyclosporine IV every 8-12 hours on days -3 to 0, and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic bone marrow or PBSC transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 8-12 hours on days 1-100 with taper to day 177, and mycophenolate mofetil PO or IV every 8 hours on days 0-40 with taper to day 96."
9926679|NCT00884780||Pediatric Pain|Children between the ages of 8 and 17 experiencing pain.
9926680|NCT00884819|Experimental|1|fenofibrate 200mg/daily for 6 months
9926681|NCT00884819|Placebo Comparator|2|Placebo match for 6 months
10210297|NCT05216198||TIA patients|Diagnostic of TIA by the exams performed in the emergencies of CHUGA.
10210298|NCT05216068|Other|donated abandonment embryos|Embryos biopsies for PGT-A (by use of NGS platforms from our institute) will be used for the validation of our Lab QC.
10210299|NCT05216042|Experimental|Experimental: Low NP Genotype Group|150 Healthy self-identified African-American and Caucasian adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
10210300|NCT05216042|Experimental|Active Comparator: High NP Genotype Group|50 Healthy self-identified African-American and Caucasian adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
10210301|NCT05216029|Experimental|Group I (oncology dashboard)|Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.
10210302|NCT05216029|Experimental|Group II (standard of care)|Patients receive standard of care.
10210303|NCT05215977|Experimental|MW031|MW031 injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial, according to the investigator's assessment.
10210304|NCT05215977|Placebo Comparator|placebo|Placebo was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
10210305|NCT05215964||TAE arm|Patients will receive TAE
10210306|NCT05215925|Experimental|A|
10210307|NCT05215925|Experimental|B|
10210308|NCT05215925|Experimental|C|
10210309|NCT05215912|Experimental|Single Ascending Dose (SAD -Arm A)|Up to 5 cohorts of subjects receiving sequentially ascending dose of TNB-738 or placebo are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified
10210310|NCT05215912|Experimental|Multiple Ascending Dose (MAD- Arm B)|An expansion cohort (upto 4 cohorts) will be enrolled after maximum tolerated dose or recommended phase 2 dose is established.
10210311|NCT05215899|Experimental|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION|MINDFULNESS-BASED YOGA AND MEDITATION INTERVENTION
10210312|NCT05215899|Experimental|Comparison group|Patients in the comparison group will not be subjected to any intervention other than the tests specified in the method. Comparison group patients will continue their standard treatment and care. Questionnaires and scales will be applied to this group again before the application starts and after the application is finished.
9667027|NCT04051866|Other|Control|Usual care (provided in Primary Health Care Centres) Oral hygiene instructions
9795662|NCT01542541|No Intervention|Control|Randomly-selected matched PET-CT scans performed on same day as intervention group.
9795663|NCT01542632|Experimental|Group 1|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
9795664|NCT01542632|Experimental|Group 2|TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.
9795665|NCT01542632|Experimental|Group 3|TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
9795666|NCT01542632|Experimental|Group 4|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
9795667|NCT01542632|Experimental|Group 5|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
9795668|NCT01542632|Experimental|Group 6|1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.
9795669|NCT01542645|Experimental|Methadone|Long-acting opioid
9795670|NCT01542645|Active Comparator|Fentanyl|Shorter-acting opioid
9795671|NCT01542684|Experimental|Azacytidine + GM-CSF|"Azacytidine administered intravenously (IV) or subcutaneously (SQ) at starting dose of 40 mg/m^2, daily for 4 days.~GM-CSF administered IV or subcutaneously at 250 mcg/m^2 one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.~Each treatment cycle will last at least 4 weeks"
9795672|NCT01542788|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 12 weeks.
9795673|NCT01542788|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.
9795674|NCT01542957|Experimental|Cognitive Behavioral + Dilemma Therapy|Combines Group Cognitive Behavioral Therapy with a Individual Dilemma-Focused Intervention
9795675|NCT01542957|Active Comparator|Cognitive Behavioral Therapy|Combined Group and Individual Cognitive Behavioral Therapy
9795676|NCT01543074|Placebo Comparator|BSE placebo & garlic oil placebo|Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
9795677|NCT01543074|Active Comparator|garlic oil plus BSE placebo|one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
9795678|NCT01543074|Active Comparator|BSE plus garlic oil placebo|two BSE capsules plus one garlic oil placebo capsule per day for seven days
9795679|NCT01543074|Active Comparator|BSE & Garlic Oil|two BSE and one garlic oil capsule per day for seven days
9795680|NCT01543087|Other|One group of subjects|
9795681|NCT01543152|Experimental|Cohort 1 - IV cyclophosphamide 200 mg|
9795682|NCT01543152|Experimental|Cohort 2 - IV cyclophosphamide 0.5 g/m2|
9795683|NCT01543152|Experimental|Cohort 3 - IV cyclophosphamide 1.0 g/m2|
9795684|NCT01543152|Experimental|Cohort 4 - IV cyclophosphamide 2.0 g/m2|
9795685|NCT01543152|Experimental|Cohort 5 - IV cyclophosphamide 1.5 g/m2|
9667028|NCT04051866|Experimental|Intervention|Usual care (provided in Primary Health Care Centres) Non-surgical periodontal treatment: Scaling and root planing (SRP) Oral hygiene instructions
9864377|NCT00093769|Experimental|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
9864378|NCT00093821|Experimental|Treatment (tanespimycin)|"Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD."
9864379|NCT00093873|Experimental|AMG 706|AMG 706 QD
9864380|NCT00093886|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
9864381|NCT00093886|Active Comparator|nitroglycerin|Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
9864382|NCT00093912|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
9864383|NCT00093912|Active Comparator|sodium nitroprusside|Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
9864384|NCT00093925|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
9864385|NCT00093925|Active Comparator|nicardipine|Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
9864386|NCT00093977|Experimental|darbepoetin alfa SF|
9864387|NCT00094185||General|No intervention
9864388|NCT00094276|Experimental|1|Breathmobile intervention combined with a Facilitated Asthma Communication intervention (FACI)
9864389|NCT00094276|Active Comparator|2|FACI intervention
9864390|NCT00094276|Active Comparator|3|Breathmobile intervention
9864391|NCT00094276|No Intervention|4|Control group
9864392|NCT00094354||1|HIV-infected FPDs
9864393|NCT00094354||2|Family members of HIV-infected FPDs
9864394|NCT00094354||3|Local healthcare workers
9864395|NCT00094354||4|Villagers not related to an HIV-infected individual
9864396|NCT00094380|Experimental|Dose-escalation portion: Low dose CTLA4-IgG4m (RG2077)|Three patients will receive a single intravenous infusion of 0.2 mg/kg CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities (CTC grade 3 or higher adverse event in the first 28 days after CTLA4-IgG4m administration that is possibly, probably, or definitely related to CTLA4-IgG4m (RG2077)). are observed, enrollment in the trial will be suspended pending DSMB review. If no dose-limiting toxicity is observed in the 0.2mg/kg dose, three patients will receive a single intravenous infusion of 2 mg/kg of CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities are observed, enrollment will be suspended pending review by the Data Safety and Monitoring Board (DSMB).If no dose-limiting toxicity is observed in the 2 mg/kg dose, treatment of patients with 10 mg/kg of CTLA4-IgG4m in combination with cyclophosphamide will proceed.
9864397|NCT00094380|Experimental|Part IIA: CTLA4-IgG4m|Participants randomized to the CTLA4-IgG4m Arm will receive a single intravenous infusion of 10 mg/kg CTLA4-IgG4m (RG2077) following the scheduled cyclophosphamide infusion on the same day
9864398|NCT00094380|Experimental|Part IIA: Control Group|Participants randomized to the control group will not receive treatment with CTLA4-IgG4m (RG2077); these participants will undergo all study evaluations with the exception of the CTLA4-IgG4m (RG2077) pharmacokinetic evaluations and immunogenicity evaluations.
9864399|NCT00094432|Active Comparator|A1|
9864400|NCT00094432|Placebo Comparator|A2|
9864401|NCT00094523|Experimental|Treatment Arm A|Subjects switched their baseline PI for fosamprenavir (± ritonavir) while maintaining their baseline regimen of two nucleoside or nucleotide reverse transcriptase inhibitors for 48 weeks.
9864402|NCT00094523|Experimental|Treatment Arm B|Subjects continued baseline regimen for first 24 weeks with the option of switching their initial PI for fosamprenavir (± ritonavir) while maintaining their baseline nucleoside or nucleotide reverse transcriptase inhibitor regimen for another 24 weeks
9864403|NCT00094679|Active Comparator|2hrs daily patching|2 hours patching per day to cover the sound eye
9864404|NCT00094679|Active Comparator|6hrs daily patching|6 hours per day patching to cover the sound eye
9864405|NCT00094705|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
9864406|NCT00094705|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
9864407|NCT00094705|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm.
9864408|NCT00094718|Experimental|1|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
9864409|NCT00094718|Experimental|2|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.
9864410|NCT00094718|Experimental|3|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.
9864411|NCT00094718|Placebo Comparator|4|One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.
9864412|NCT00094744|Active Comparator|6hrs daily patching|6 hours per day of patching in the sound eye
9864413|NCT00094744|Active Comparator|Full-time daily patching|Patching of the sound eye all but one waking hour
9864414|NCT00094822||Pegfilgrastim|
9864415|NCT00094822||PLACEBO|
9864416|NCT00094926|Experimental|001|
9864417|NCT00094926|Placebo Comparator|002|
9864418|NCT00094965|Experimental|1|
9864419|NCT00095251|Active Comparator|Dexmedetomidine group|Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
9864420|NCT00095251|Active Comparator|Lorazepam group|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
9864421|NCT00095316|Placebo Comparator|Placebo|Subjects receive placebo intravenously daily for 28 days
9864422|NCT00095316|Experimental|Caspofungin|Subjects receive 50mg/day caspofungin intravenously (IV) for 28 days
9926682|NCT00884845|Experimental|Arm 1|Administration of i.v. infusions of PM02734 (on Days 1, 8 and 15) every three weeks and a daily oral dose of erlotinib
9926683|NCT00884858|Experimental|Maraviroc|Subjects in this group will add Maraviroc to their current HAART.
9926684|NCT00884858|No Intervention|2|Subjects in this group will continue their current HAART without adding Maraviroc.
9926685|NCT00884871||Laparoscopic adjustable gastric banding|100 obese women undergoing laparoscopic adjustable gastric banding
9926686|NCT00884884|Placebo Comparator|Double Placebo|Placebo, Placebo
9926687|NCT00884884|Experimental|Aripiprazole 15, Placebo|15 mg Aripiprazole, Placebo
9667029|NCT04048421|Experimental|hvNOTES group|Participants will undergo hvNOTES radical colectomy.
9926688|NCT00884884|Experimental|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
9926689|NCT00884884|Experimental|Topiramate 100mg, Placebo|Topiramate 100 mg daily plus Placebo daily
9926690|NCT00884884|Experimental|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
9926691|NCT00884884|Experimental|Topiramate 100, Aripiprazole 5|Topiramate 100 daily plus, Aripiprazole 5mg daily
9926692|NCT00884884|Experimental|Topiramate 200, Aripiprazole 15|Topiramate 200 mg daily plus Aripiprazole 15mg daily
9864423|NCT00095329|Experimental|sirolimus|
9864424|NCT00095537|Experimental|Phase 1 MTD Study|
9864425|NCT00095667|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
9864426|NCT00095680|Experimental|001|SCIO-469 two 30-mg capsules three times daily
9864427|NCT00095680|Active Comparator|002|SCIO-469 and bortezomib The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
9864428|NCT00095693|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.
9864429|NCT00095719|Active Comparator|A1|
9864430|NCT00095719|Placebo Comparator|B1|
9864431|NCT00095732|Experimental|Low Liprotamase Dose|Liprotamase in a fixed combination of lipase (5,000 units), protease (5,000 units) and amylase (750 units) administered orally (one Size 5 capsule of liprotamase and five Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
9864432|NCT00095732|Experimental|Mid Liprotamase Dose|Liprotamase in a fixed combination of lipase (25,000 units), protease (25,000 units) and amylase (3,750 units) administered orally (one Size 5 capsule of liprotamase, one Size 2 capsule of liprotamase, and four Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
9864433|NCT00095732|Experimental|High Liprotamase Dose|Liprotamase in a fixed combination of lipase (100,000 units), protease (100,000 units) and amylase (15,000 units) administered orally (one Size 5 capsule of placebo and five Size 2 capsules of liprotamase) with each of three meals and two snacks daily for 28 days
9864434|NCT00095745|No Intervention|Antidepressant + Aripiprazole|
9864435|NCT00095758|Placebo Comparator|A1|
9864436|NCT00095758|Active Comparator|A2|
9864437|NCT00095797|Experimental|Treatment (XK469R)|Patients receive XK469R IV over 30-60 minutes on days 1, 3, and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864438|NCT00095810|Experimental|A|
9864439|NCT00095823|Placebo Comparator|A1|
9864440|NCT00095823|Active Comparator|A2|
9864441|NCT00095823|No Intervention|A3|
9864442|NCT00095888|Experimental|Treatment (triapine, gemcitabine hydrochloride)|Patients receive 3-AP (Triapine®) IV over 2 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864443|NCT00095901|Experimental|Capecitabine|Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
9864444|NCT00095927|Active Comparator|Arm A Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;~4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).~Subcutaneous daily amifostine at a dose of 500 mg"
9864445|NCT00095927|Experimental|Arm B No-Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN~- 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system)."
9864446|NCT00095966|Experimental|Treatment (sorafenib tosylate and gemcitabine hydrochloride)|Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864447|NCT00096005|Experimental|Treatment (chemotherapy and enzyme inhibitor therapy)|"Patients receive tanespimycin IV over 1-2 hours and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 12 additional patients are treated as above* at the MTD.~NOTE: *Bortezomib is not administered on day 1 of course 1 only. Patients are followed at 3 months."
9864448|NCT00096070|Experimental|Arm I|Patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and fluorouracil IV continuously for 5.5 weeks. Beginning 4-6 weeks after the completion of chemoradiotherapy, patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment with gemcitabine repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9864449|NCT00096083|Active Comparator|Melphalan Administration PHP|
9864450|NCT00096148|Experimental|Arm I (idarubicin, cytarabine)|"Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
9926693|NCT00884884|Experimental|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
9926694|NCT00884884|Experimental|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
9926695|NCT00884936||Group 1|Young age: 20 to 30 years old
9864451|NCT00096148|Experimental|Arm II (idarubicin, cytarabine, bevacizumab)|"Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days* later. Patients who do not achieve CR after 2 courses are removed from the study.~NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
9864452|NCT00096213|Other|surgery|intralesional resection
9864453|NCT00096291|Active Comparator|Sequence Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
9864454|NCT00096291|Other|Sequence of neoadjuvant CT: Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
9864455|NCT00096343|Experimental|Paclitaxel IV followed by Carboplatin IV|paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9864456|NCT00096395|Experimental|Treatment (sorafenib tosylate, gemcitabine hydrochloride)|"Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.~Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9864457|NCT00096408|Active Comparator|1|Total Abdominal Hysterectomy
9864458|NCT00096408|Experimental|2|Total Laparoscopic Hysterectomy
9864459|NCT00096434|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864460|NCT00096499|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864461|NCT00096512|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864462|NCT00096629|Experimental|human PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
9864463|NCT00096629|Experimental|mouse PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
9864464|NCT00096668|Experimental|TOCOSOL Paclitaxel|TOCOSOL Paclitaxel administered weekly at 120mg/mm2
9864465|NCT00096733||Donors|Living liver donors. This label may also refer to those evaluated for liver donation who did not go on to donate, i.e., potential living liver donors.
9864466|NCT00096733||Recipients|Liver transplant recipients (either living or deceased donor). This label may also refer to those who were evaluated for liver transplantation, but never received a transplant, i.e., potential recipients.
9864467|NCT00096746||A1|HIV infected individuals on first line ATV based HAART with presence of I50L mutation.
9864468|NCT00096746||A2|HIV infected PI naïve on failed NNRTI based regimen.
9864469|NCT00096824||1|Participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of ACTG A5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue ACTG A5175. Physicians will make targeted diagnoses at each study visit.
9864470|NCT00096850|Experimental|1|From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
9864471|NCT00096863|Placebo Comparator|A - placebo|per oral pill
9864472|NCT00096863|Active Comparator|B|Ziprasidone
9864473|NCT00096863|Active Comparator|C|Haloperidol
9864474|NCT00096915|Experimental|darbepoetin alfa|
9864475|NCT00097058||1|Continue current hormone therapy
9864476|NCT00097058||2|Taper off hormone therapy
9926696|NCT00884936||Group 2|Middle Age: 38 to 48 years old (pre-menopausal only)
9926697|NCT00884936||Group 3|Elderly Age: 60 to 75 years old (Post-menopausal only)
9926698|NCT00884962|Experimental|PLVR|
9926699|NCT00884988|Active Comparator|Lymphomyosot|homeopathic remedy
9926700|NCT00884988|Placebo Comparator|Placebo remedy|identical in color, constituency and taste to true remedy
9926701|NCT00885001|Experimental|Short Arc Banding Group|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
9926702|NCT00885014|Experimental|CBT|Telephone cognitive-behavioral therapy
9926703|NCT00885014|Active Comparator|TAU|Treatment as usual through the Employees Assistance Program
9926704|NCT00885053|Experimental|Fish oil|
9926705|NCT00885053|Placebo Comparator|Olive oil|
9926706|NCT00885066|Experimental|gemcitabine, capecitabine, erlotinib|
9926707|NCT00885157|Experimental|Group A|Will receive fractional doses of IPV Intradermally
9926708|NCT00885157|Active Comparator|Group B|Will receive full doses of IPV Intramuscularly
9926709|NCT00885183|Experimental|acupuncture therapy|Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy
9864477|NCT00097214|Experimental|1|"Cetuximab 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8. Carboplatin AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.~Therapy will continue for four cycles (12 weeks)for combination therapy"
9864478|NCT00097227|Active Comparator|Arm A (3-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks."
9864479|NCT00097227|Active Comparator|Arm B (4-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks."
9864480|NCT00097266|Placebo Comparator|A|
9864481|NCT00097266|Experimental|B|
9864482|NCT00097266|Active Comparator|C|
9864483|NCT00097604|Experimental|Valerian|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
9864484|NCT00097604|Placebo Comparator|Placebo|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
9864485|NCT00097656|Experimental|Periodontal Treatment|maternal periodontal therapy
9864486|NCT00097747|Placebo Comparator|Placebo|Single injection administered intravenously
9864487|NCT00097747|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
9864488|NCT00097747|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
9864489|NCT00097747|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
9864490|NCT00097760|Experimental|Group 1|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
9864491|NCT00097760|Placebo Comparator|Group 2|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
9864492|NCT00097838|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
9864493|NCT00097838|Experimental|1 x 10^6 IU dose|Vaccine dose of 1 x 10^6 IU per injection
9864494|NCT00097838|Experimental|1 x 10^7 IU dose|Vaccine dose of 1 x 10^7 IU per injection
9864495|NCT00097838|Experimental|1 x 10^8 IU dose|Vaccine dose of 1 x 10^8 IU per injection
9864496|NCT00097838|Placebo Comparator|Placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
9864497|NCT00097903|Experimental|1|Karenitecin IV/ Karenitecin tablet
9864498|NCT00098111|Active Comparator|Azathioprine 0.5 mg/kg body weight|
9864499|NCT00098111|Active Comparator|Azathioprine 2.5 mg/kg body weight|
9864500|NCT00098111|Active Comparator|Azathioprine 3.5 mg/kg body weight|
9864501|NCT00098137|Experimental|Olmesartan|Olmesartan tablet, 1 in the morning
9864502|NCT00098137|Placebo Comparator|Placebo|Placebo tablets, 1 in the morning
9864503|NCT00098163|Experimental|1|
9864504|NCT00098163|Placebo Comparator|2|
9864505|NCT00098397|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864506|NCT00098423|Experimental|Treatment (chemotherapy)|"Patients receive induction therapy comprising cytarabine IV continuously on days 1-5 and tanespimycin IV over 1 hour on days 3 and 6.~Patients achieving a morphologic complete response with CRi or partial response may be eligible to receive a second induction course of therapy after day 21 at the discretion of the principal investigator. Patients achieving a CR receive up to 4 courses of consolidation therapy with cytarabine and tanespimycin. Consolidation therapy repeats approximately every 60 days in the absence of disease progression or unacceptable toxicity. Patients who achieve CR and remain in remission for â¥ 6 months may be retreated with cytarabine and tanespimycin (at the current dose level or the MTD) at the time of relapse. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months."
9864507|NCT00098488|Experimental|Treatment (17-AGG and rituximab)|Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
9864508|NCT00098501|Experimental|Arm I|Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.
9864509|NCT00098514|Experimental|Dose Level 1a|10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
9864510|NCT00098514|Experimental|Dose Level 1b|5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
9864511|NCT00098514|Experimental|Dose Level 1c|3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
9996954|NCT01504607||Congenital cataract surgery with IOL implantation|Congenital cataract surgery was performed with or without anterior vitrectomy, followed by in the bag IOL implantation
9864512|NCT00098514|Experimental|Dose Level 2|5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
9864513|NCT00098514|Experimental|Dose Level 3|7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
9864514|NCT00098514|Experimental|Dose Level 4|11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
9864515|NCT00098514|Experimental|Dose Level 5|17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
9864516|NCT00098527|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864517|NCT00098540|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864518|NCT00098553|Experimental|everolimus|"Patients receive oral everolimus once daily for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months until disease progression and then every 4 months for up to 5 years after registration."
9864519|NCT00098579|Experimental|Treatment (chemotherapy)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
9864520|NCT00098605|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864521|NCT00098618|Experimental|Treatment (sorafenib tosylate and recombinant interferon alfa)|Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
9864522|NCT00098631|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864523|NCT00098826|Experimental|Treatment (ispinesib)|"Induction chemotherapy: Patients receive SB-715992 IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Consolidation chemotherapy: Patients achieving CR, PR, or SD after induction chemotherapy receive up to 4 additional courses of SB-715992 beyond CR, PR, or SD.~Cohorts of 3-6 patients receive SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 9 patients are treated at the MTD."
9864524|NCT00098891|Experimental|Treatment (entinostat, isotretinoin)|Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
9864525|NCT00099008|Experimental|Arm I|Genistein
9864526|NCT00099008|Placebo Comparator|Arm II|Placebo
9864527|NCT00099125|Experimental|RT with chemotherapy + post-radiation chemotherapy|Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy
9926710|NCT00885183|Other|Usual care|Control group (usual care) receives standard chemotherapy alone
9926711|NCT00885209||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
9926712|NCT00885222|Active Comparator|1|PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
9926713|NCT00885222|Active Comparator|2|PD patients with depression that are candidates for STN DBS (n=5).
9926714|NCT00885222|Active Comparator|3|PD patients without depression that are candidates for STN DBS (n=10).
9926715|NCT00885235||A|Subjects that are indicated for colonoscopy who are suspected or known to suffer from large bowel diseases.
9926716|NCT00885274|Experimental|Split Dose|Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
9926717|NCT00885274|Active Comparator|Traditional Dose|Both doses of Pico-Salax taken the evening prior to colonoscopy.
9926718|NCT00885287|Active Comparator|HIV-positives on ARVs receiving AL for malaria|HIV-positive patients on first-line ARVs receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
9926719|NCT00885287|Active Comparator|HIV-positives receiving AL for malaria|HIV-positive patients not receiving antiretrovirals but receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
9926720|NCT00885287|Active Comparator|HIV-negatives receiving AL for malaria|HIV-negative patients receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
9926721|NCT00885300|Experimental|1|cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
9926722|NCT00885300|Active Comparator|2|heparin 1000iu/ml as catheter lock at the end of hemodialysis
9926723|NCT00885313|Experimental|DHA250|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
9864528|NCT00099177|Experimental|1|
9864529|NCT00099177|Active Comparator|2|
9864530|NCT00099203|Experimental|1|
9864531|NCT00099203|Active Comparator|2|
9864532|NCT00099320|Experimental|Exenatide|After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
9864533|NCT00099320|Placebo Comparator|Placebo|After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
9864534|NCT00099333|Experimental|Exenatide|The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
9864535|NCT00099333|Active Comparator|Insulin|The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
9864536|NCT00099502|Experimental|Arm 1|
9864537|NCT00099502|Experimental|Arm 2|
9864538|NCT00099502|Active Comparator|Arm 3|
9864539|NCT00099515|Experimental|A|
9864540|NCT00099515|Experimental|B|
9864541|NCT00099580|Experimental|1|
9864542|NCT00099580|Placebo Comparator|2|
9864543|NCT00099606|Experimental|A1|
9864544|NCT00099619|Experimental|exenatide/insulin glargine|Arm that first receives exenatide, then crosses over to insulin glargine
9864545|NCT00099619|Experimental|Insulin glargine/exenatide|Arm that first receives insulin glargine, then crosses over to exenatide
9864546|NCT00099658|Experimental|1|HIV-uninfected infants born to HIV-uninfected mothers
9864547|NCT00099658|Experimental|2|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2
9864548|NCT00099658|Experimental|3|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2
9864549|NCT00099658|Experimental|4|HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2
9864550|NCT00099658|Experimental|5|HIV-uninfected infants born to HIV infected mothers
9864551|NCT00099736|Experimental|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids,|
9864552|NCT00099736|Experimental|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|
9864553|NCT00099736|Experimental|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|
9864554|NCT00099788|Experimental|1|Ranolazine
9864555|NCT00099788|Placebo Comparator|2|Placebo
9864556|NCT00099866|Experimental|Vildagliptin|
9864557|NCT00099866|Active Comparator|Metformin|
9864558|NCT00099944|Experimental|LAF237 50 mg qd + glimepiride 4 mg qd|LAF237 50 mg qd + glimepiride 4 mg qd
9864559|NCT00099944|Experimental|LAF237 50 mg bid + glimepiride 4 mg qd|LAF237 50 mg bid + glimepiride 4 mg qd
9864560|NCT00099944|Placebo Comparator|LAF237 placebo + glimepiride 4 mg qd|LAF237 placebo + glimepiride 4 mg qd
9864561|NCT00100061|Active Comparator|Cranberry Juice|Cranberry Juice provided by Ocean Spray
9864562|NCT00100061|Placebo Comparator|Placebo cranberry juice|Taken orally
9864563|NCT00100256|Experimental|Arm 1|
9864564|NCT00100295|Experimental|A|Herbal treatment
9864565|NCT00100295|Placebo Comparator|B|
9864566|NCT00100308|Experimental|1|Standard treatment plus unfractioned heparin low-dose continuous infusion
9864567|NCT00100308|Placebo Comparator|2|Standard treatment plus placebo
9864568|NCT00100477|Other|Arm 1|
9864569|NCT00100542||1|All HIV infected and uninfected participants and their caregivers.
9864570|NCT00100568|Experimental|1|All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.
9926724|NCT00885313|Experimental|DHA500|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
9864571|NCT00100646|Experimental|1|Highly active antiretroviral therapy (HAART) consisting of lamivudine, lopinavir/ritonovir, and stavudine for 16 weeks with three structured treatment interruptions for 2, 4, and 8 weeks each; rabies vaccine at Weeks 16, 17, 22 and 92.
9864572|NCT00100646|Active Comparator|2|Continuous HAART consisting of lamivudine, lopinavir/ritonovir, and stavudine throughout the study; rabies vaccine at Weeks 16, 17, 22 and 92.
9864573|NCT00100685|Experimental|Arm 1|Volociximab administered intravenously at a dose of 10 mg/kg qowk
9864574|NCT00100685|Experimental|Arm 2|Volociximab administered intravenously at a dose of 15 mg/kg qwk
9864575|NCT00100750|Experimental|Treatment (gemcitabine hydrochloride, tipifarnib)|Patients receive tipifarnib PO BID on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864576|NCT00100854|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.
9864577|NCT00100854|Experimental|Arm II|Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.
9864578|NCT00100880|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 2-3 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which an estimated 25% of patients experience dose-limiting toxicity."
9864579|NCT00100893|Experimental|Dietary Supplement: grape seed proanthocyanidin extract|Administered orally.
9864580|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level A|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
9864581|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level B|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
9926725|NCT00885313|Placebo Comparator|PLA|placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
9926726|NCT00885326|Other|Treatment|"Bevacizumab: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.~Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).~Zoledronic acid will be administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first."
9864582|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Level C|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
9864583|NCT00100945|Experimental|gefitinib|"Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease recurrence or unacceptable toxicity.~Quality of life is assessed at baseline, 4 weeks, every 12 weeks during study treatment, and then at the end of study treatment.~Patients are followed every 3 months for up to 5 years."
9864584|NCT00101075|Experimental|XELOX|"Oxaliplatin 130 mg/m2 day 1 every 3 weeks~Capecitabine 1700 mg/m2/day days 1-14 every 3 weeks. -- Patients will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
9864585|NCT00101088|Experimental|Treatment (imatinib mesylate, temsirolimus)|Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
9864586|NCT00101114|Experimental|Treatment (sorafenib tosylate, interferon alpha-2b)|Patients receive oral sorafenib twice daily on days 1-28 and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864587|NCT00101153|Experimental|Tipifarnib with conventional induction and consolidation|
9864588|NCT00101179|Experimental|Arm I|"Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD."
9864589|NCT00101205|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9864590|NCT00101231|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
9864591|NCT00101244|Experimental|Treatment (ispinesib)|"Patients receive SB-715992 IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the MTD."
9864592|NCT00101270|Experimental|Treatment (irinotecan hydrochloride, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
9864593|NCT00101296|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
9926727|NCT00885339||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
9926728|NCT00885404|Other|Intravenous fluids|
9926729|NCT00885417|Experimental|Cravit-based sequential therapy|Cravit-based sequential therapy Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
9926730|NCT00885430|Experimental|Pico-Salax|
9926731|NCT00885443|Active Comparator|1|
9926732|NCT00885443|Active Comparator|2|
10210313|NCT05215873|Active Comparator|misoprostol group|25µg misoprostol oral tablet every 4 hours with maximum200 µg
10210314|NCT05215873|Active Comparator|oxytocin group|"oxytocin infusion according to ASUMH local protocol: Put 3IU oxytocin (3000mIU) +50ml of normal saline in syringe pump= (60mIU/ml). Commence at 1ml/hour (1mIU/min) for 1/2 hour.~If contractions inadequate +fetal monitor healthy 2 ml/hour for 1/2 hour.~If contractions inadequate +fetal monitor healthy 4 ml/hour for 1/2 hour.~If contractions inadequate +fetal monitor healthy 6 ml/hour for 1/2 hour.~If contractions inadequate +fetal monitor healthy increase by 2ml/hr. for max. 27ml/hour.~At any point there's fetal or maternal distress (e.g. pathological FHR pattern, antepartum hemorrhage, etc.) the study intervention will be stopped, and the maternal/fetal condition will be managed by cesarean section."
9864594|NCT00101348|Experimental|Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)|"Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.~Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression."
9864595|NCT00101387|Experimental|Lumbar PENS + exercise|Lumbar PENS twice a week for six weeks combined with general conditioning and aerobic exercise
9667030|NCT04047602|Experimental|Reduced Dose Stereotactic Radiosurgery|Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment
9864596|NCT00101387|Active Comparator|Lumbar PENS|Lumbar PENS twice a week for 6 weeks
9864597|NCT00101387|Placebo Comparator|Control PENS|Control lumbar PENS twice a week for 6 weeks
9864598|NCT00101387|Active Comparator|Control PENS + exercise|Control PENS twice a week for 6 weeks along with general conditioning and aerobic exercise
9864599|NCT00101491|Experimental|1|
9864600|NCT00101491|Other|2|Attention Control Comparator
9864601|NCT00101569|Experimental|A1|
9864602|NCT00101569|Experimental|A2|
9864603|NCT00101712|Experimental|Vildagliptin|
9864604|NCT00101712|Placebo Comparator|Placebo|
9864605|NCT00101725|Experimental|125 mg crofelemer|
9864606|NCT00101725|Experimental|250 mg crofelemer|
9864607|NCT00101725|Experimental|500 mg crofelemer|
9864608|NCT00101725|Placebo Comparator|placebo|
9864609|NCT00101790|Active Comparator|1|
9864610|NCT00101829|Experimental|Rituximab Treatment|Participants will receive rituximab at study entry and at Week 2
9864611|NCT00101881|Active Comparator|Monophasic Shock|Administration of monophasic waveform defibrillation
9864612|NCT00101881|Active Comparator|Biphasic Shock|Administration of biphasic waveform defibrillation
9864613|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFOX-4|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFOX-4
9864614|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFOX-4|125 mg QD AMG 706 + FOLFOX-4
9864615|NCT00101894|Experimental|50 mg QD AMG706 + panitumumab + FOLFIRI|50 mg QD AMG706 + panitumumab + FOLFIRI
9864616|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFIRI|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFIRI
9864617|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFIRI|100 mg AMG 706 + FOLFIRI
9864618|NCT00101894|Experimental|75 mg QD AMG 706 + panitumumab + FOLFOX-4|75 mg QD AMG 706 + panitumumab + FOLFOX-4
9864619|NCT00101894|Experimental|75 mg BID AMG 706 + panitumumab + FOLFIRI|75 mg BID AMG 706 + panitumumab + FOLFIRI
9864620|NCT00101894|Experimental|125 mg QD AMG 706 + panitumumab + FOLFIRI|125 mg QD AMG 706 + panitumumab + FOLFIRI
9864621|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFIRI|125 mg QD AMG 706 + FOLFIRI
10210315|NCT05215821||group1|subjects with evidence of insulin resistance estimated by high HOMA level
10210316|NCT05215821||group 2|subjects without insulin resistance estimated by normal HOMA level
10210317|NCT05215743|Experimental|Combined antioxidant therapy (CAT)|Intravenous administration of deferoxamine, n-acetylcysteine, and ascorbate over 90 minutes.
10210318|NCT05215743|Placebo Comparator|Placebo|Intravenous administration of dextrose 5% over 90 minutes
10210319|NCT05215730|Active Comparator|Copper oxide dressings (COD)|"MedCu wound dressings with copper oxide (COD) (Copper Arm)."
10210320|NCT05215730|Active Comparator|"Vacuum-assisted closure (VAC) treatment (VAC Arm)"|"Negative Pressure Wound Therapy (NPWT) known also as Vacuum-assisted closure (VAC) treatment (VAC Arm)."
10210321|NCT05215665|Experimental|group 1|Lenvatinib+Toripalimab
10210322|NCT05215665|Experimental|group 2|GEMOX+Lenvatinib+Toripalimab
10210323|NCT05215665|Experimental|group 3|Lenvatinib+Toripalimab (failure of GEMOX treatment)
10210324|NCT05215665|Experimental|group 4|GEMOX+Toripalimab
10210325|NCT05215626||Patients implanted with the Zimmer Reconstruction System|
10210326|NCT05215613||Patients implanted with the ZPS system|
10210327|NCT05215600||Anaverse Shoulder System subjects|Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed.
10210328|NCT05215522|Experimental|The BCI-FES Intervention|The BCI-FES device will be used by all participants.
10210329|NCT05215496|Experimental|[18F]fluoro-PEG-folate PET/CT scan|Patients with FIGO stage IIIB/IIIC epithelial ovarian cancer, 185 MBq of [18F]fluoro-PEG-folate.
10210330|NCT05215483|Experimental|Customised advice + LFT available at home|"Respondents will see an altered testing advice in text and picture in which they are allowed to use LFT with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
10213678|NCT03543124|Active Comparator|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
9864622|NCT00101894|Experimental|100 mg QD AMG 706 + panitumumab + FOLFIRI|100 mg QD AMG 706 + panitumumab + FOLFIRI
9864623|NCT00101894|Experimental|75 mg QD AMG 706 + FOLFOX-4|75 mg QD AMG 706 + FOLFOX-4
9864624|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFOX-4|100 mg QD AMG 706 + FOLFOX-4
9864625|NCT00101894|Experimental|50 mg QD AMG 706 + panitumumab + FOLFOX-4|50 mg QD AMG 706 + panitumumab + FOLFOX-4
9864626|NCT00101894|Experimental|75 mg QD AMG706 + panitumumab + FOLFIRI|75 mg QD AMG706 + panitumumab + FOLFIRI
9864627|NCT00101920|Experimental|ABX-EGF|Open-label, single arm panitumamab monotherapy
9864628|NCT00101998|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.
9864629|NCT00101998|Experimental|Alvimopan 1 mg Once Daily (QD)|"0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.~A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment."
9864630|NCT00101998|Experimental|Alvimopan 1 mg Twice Daily (BID)|0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.
9864631|NCT00101998|Placebo Comparator|Placebo|Placebo was administered orally BID for 3 weeks.
9864632|NCT00102011|Experimental|Study I- Arm I|Participants undergo baseline screening colonoscopy
9864633|NCT00102011|Other|Study I- Arm II|Participants receive standard care
9864634|NCT00102011|Experimental|Study II- Arm I|Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.
9864635|NCT00102011|Active Comparator|Study II- Arm II|Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
9864636|NCT00102141|Experimental|Arm 1|
9864637|NCT00102141|Experimental|Arm 3|
9864638|NCT00102141|Experimental|Arm 4|
9864639|NCT00102141|Placebo Comparator|Arm 5|
9864640|NCT00102141|Experimental|Arm 2|
9864641|NCT00102323|Placebo Comparator|Placebo|
9864642|NCT00102323|Experimental|AMG 531|Active Investigational Product
9864643|NCT00102336|Experimental|AMG 531|Active investigational product
9864644|NCT00102336|Placebo Comparator|Placebo|
9864645|NCT00102388|Experimental|vildagliptin|
9864646|NCT00102388|Active Comparator|Gliclazide|
9926733|NCT00885456|Experimental|PREVENT program|12-week program of exercise and education to induce physiological and behavioral changes needed to reduce vascular risk factors.
9926734|NCT00885456|Active Comparator|Usual Care|Average of three visits to the Neurovascular Clinic for a neurological and health assessment, counseling regarding stroke/TIA and diagnostic test results, and assessment, modification and education of secondary prevention factors
9926735|NCT00885469||1|Patients with known Barrett's Esophagus or chronic GERD
9926736|NCT00885508|Experimental|Aracytidine, Daunaurubicine, Lenalidomide|
9667031|NCT04044495|Experimental|Sample of 100 persons included in AMI / AMImage 2|Sample of 100 persons included in AMI / AMImage 2
9935265|NCT03973177|Other|Control Group: Methylprednisolone injection|Methylprednisolone acetate 10 mg with 2 mL preservative free saline and 0.5 mL iopamidol 300 will be injected at each of the target site
9935266|NCT03969914||Critically ill ventilated patients|Patients admitted to ICU with expected mechanical ventilation >48h
9935267|NCT03964090|Experimental|1|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
9864647|NCT00102453|Experimental|Solution|All enrolled participants were give pentoxifylline in this pilot protocol.
9864648|NCT00102609|Experimental|Trabectedin and doxorubicin|Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
9517855|NCT03302260|Experimental|CardioPrevent® Program|In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
9864649|NCT00102622|Experimental|Arm 1: Paclitaxel + tgDCC-E1A|80 mg/m^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m^2 weekly for six treatments every 7 days.
9864650|NCT00102622|Active Comparator|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m^2 for six treatments every 7 days.
9864651|NCT00102635|Experimental|4-HPR + FTI|SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.
9864652|NCT00102661|Experimental|CAMPATH-1H|15 mg infused daily for continuous infusion x 7 days; starting day 10, CAMPATH-1H 30 mg subcutaneously three times weekly for 11 additional weeks.
9864653|NCT00102726|Active Comparator|Arm 1|SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.
9864654|NCT00102726|Active Comparator|Arm 2|SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.
9864655|NCT00102726|Active Comparator|Arm 3|SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.
9864656|NCT00102726|Placebo Comparator|Placebo Arm|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
9864657|NCT00102908|Experimental|1|Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
9864658|NCT00102908|Placebo Comparator|2|Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
9864659|NCT00102934|Experimental|1|Participants will receive enfuvirtide for 6 months
9864660|NCT00102973|Experimental|TLK286 in Combination with Carboplatin|
9864661|NCT00102973|Active Comparator|Doxorubisin HCl Liposome Injection|
9864662|NCT00103038|Experimental|Diagnostic (ferumoxytol, gadolinium, DCE-MRI, DSC-MRI)|Patients receive ferumoxytol non-stoichiometric magnetite IV beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients also undergo MRI without contrast at baseline and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.
9864663|NCT00103168|Experimental|Imatinib mesylate|400 mg/day for 2 years
9864664|NCT00103168|No Intervention|Control|
9864665|NCT00103220|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864666|NCT00103246|Experimental|Topical silicon phthalocyanine 4 (Pc 4) + photodynamic therapy|Topical silicon phthalocyanine 4 (Pc 4) followed by photodynamic therapy.
9864667|NCT00103272|Experimental|Treatment (17-AAG and bortezomib)|"Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.~Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation."
9864668|NCT00103324|Experimental|Treatment|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864669|NCT00103337|Experimental|Arm I (500 mg cilengitide)|Patients receive lower dose cilengitide IV over 1 hour twice a week for 6 weeks.
9864670|NCT00103337|Experimental|Arm II (2000 mg cilengitide)|Patients receive higher dose cilengitide IV over 1 hour twice a week for 6 weeks.
9864671|NCT00103389|Active Comparator|docetaxel|treated with docetaxel alone
9864672|NCT00103389|Experimental|PI-88+docetaxel|treated with docetaxel and PI-88
9864673|NCT00103454|Experimental|Arm 1|
9864674|NCT00103519|Experimental|DITPA 180 mg/day|DITPA 180 mg/day BID
9864675|NCT00103519|Experimental|DITPA 360 mg/day|DITPA 360 mg/day BID
9864676|NCT00103519|Placebo Comparator|Placebo|Placebo BID
9864677|NCT00103532|Experimental|Healthy Choices - Motivational Enhancement Intervention|Motivational enhancement intervention
9864678|NCT00103532|Active Comparator|Standard Care|Standard care/individualized referrals
9864679|NCT00103701|Experimental|1|
9864680|NCT00103727|Experimental|talnetant|200mg, 400mg, 600mg) twice a day
9864681|NCT00103727|Placebo Comparator|placebo|placebo
9864682|NCT00103727|Active Comparator|risperidone|3mg twice a day
9864683|NCT00103779|Experimental|1|
9864684|NCT00103792|Experimental|1|mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
9864685|NCT00103792|Active Comparator|2|cyclophosphamide
9864686|NCT00103883||HIV Infected Teens -ATN Clinical Sites|HIV infected teens who are referred to or engaged in care at any of the 15 ATN clinical sites during the course of the study.
9864687|NCT00103883||HIV Positive - ATN Clinical Sites|Youth who test HIV positive at ATN-managed or ATN-affiliated HIV Counseling and Testing Sites (CTS) during the course of the study.
9864688|NCT00103883||HIV Positive - BCHD STD Clinic|Youth who test HIV positive at the BCHD STD Clinic during the course of the study.
9864689|NCT00103896||HIV Infected Youth in Treatment/Care|HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
9864690|NCT00103896||BVI Individuals|Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
9864691|NCT00103896||HIV Serosurvey Individuals|HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
9864692|NCT00103922|Experimental|Arm 1|
9864693|NCT00103935|Placebo Comparator|Group A1|Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
9864694|NCT00103935|Placebo Comparator|Group A2|Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
9864695|NCT00103935|Experimental|Group B|Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
9864696|NCT00103935|Experimental|Group C|Exenatide lead-in followed by exenatide LAR 2.0 mg weekly
9864697|NCT00103961||1|Treatment-naive and treatment-experienced HIV-infected adults
9864698|NCT00104091|Experimental|1|40 mL of TP-38 at a 100 nanograms/mL concentration
9926737|NCT00885521|Experimental|Exercise|8 week, twice weekly exercise program with both endurance and upper and lower limb strength training
9926738|NCT00885521|No Intervention|2|No exercise, twice weekly phone calls
9926739|NCT00885547|Experimental|immunosuppressor|
9926740|NCT00885573|Other|Sleep apnea subjects|"Patients with suspected sleep apnea syndrome will have nocturnal polysomnography. According to the number of respiratory events per hour of sleep, patients will be classified as sleep apnea or controls. All the patients will be blindly assessed for pharyngeal sensitivity the morning following the nocturnal recording."
9926741|NCT00885586|Sham Comparator|Sham-laser acupuncture|Sham laser acupuncture (c) is applied at equivalent points as needle acupuncture. Laser irradiation is faked.
9926742|NCT00885586|Active Comparator|gabapentine|standard analgesic treatment
9926743|NCT00885586|Active Comparator|Acupuncture|Acupuncture treatment is semi-standardized, i.e. beside a scheme of basic points, individual points can be chosen according to the TCM diagnostic pattern.
9926744|NCT00885599|Experimental|PERIORINSE|naturopathic remedy
9926745|NCT00885599|Active Comparator|CPC|Cepacol, standard anti-bacterial mouthwash
9926746|NCT00885599|Active Comparator|Listerine|standard anti-bacterial mouthwash
9926747|NCT00885599|Placebo Comparator|placebo|colored water
9926748|NCT00885651|Experimental|1|Metoprolol for 10 days followed by placebo for 7 days.
9926749|NCT00885651|Placebo Comparator|2|Placebo for 7 days followed by Metoprolol for 10 days
9926750|NCT00885664|Active Comparator|Truvada|
9517856|NCT03302221|Other|Group control|In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
9926751|NCT00885664|Active Comparator|Kaletra|
9926752|NCT00885690|Active Comparator|Sertindole|Sertindole 16-24 mg
9926753|NCT00885690|Active Comparator|Olanzapine|Olanzapine 10-20 mg
9926754|NCT00885716|Experimental|communication skills training|group training in shared decision making.
9926755|NCT00885716|Active Comparator|cognitive training|standard group training of cognitive skills (Konzentrationstraining)
9926756|NCT00885729|Experimental|Stem cells|Cartilage defect are treated surgical either with chondrocytes or stem cells
9926757|NCT00885729|Active Comparator|Rehabilitation|Active rehabilitation program
9926758|NCT00885781|Experimental|SMOFlipid|
9926759|NCT00885781|Active Comparator|Lipovenoes MCT|
9926760|NCT00885794|Experimental|0.5 mg Ranibizumab|3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
9926761|NCT00885794|Experimental|1.0 mg of Ranibizumab|3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
9926762|NCT00885820|Experimental|1|Protocol biopsies at 1, 2 and 3 months
9926763|NCT00885820|Active Comparator|2|No protocol biopsies
9926764|NCT00885833|Experimental|Fludarabine|
9926765|NCT00885859||1|responders: patients who have a pain reduction of 30% or more after two weeks TENS-treatment
9926766|NCT00885859||2|non-responders: patient who have a pain reduction smaller than 15% after two weeks TENS-treatment
9926767|NCT00885872|Experimental|Treat|At visit 2 each eligible subject will be allocated to rosuvastatin. Subjects who reach the criteria at visit 3, dosage of rosuvastatin will be titrated. The subjects will be encouraged to take the study drug at the same time each day for 104 weeks.
9926768|NCT00885885|Experimental|1|Panitumumab+FOLFOX 4
9926769|NCT00885885|Experimental|2|Panitumumab+FOLFIRI
9926770|NCT00885898|Active Comparator|1|"Non-invasive ventilation"
9926771|NCT00885898|Active Comparator|2|"Conventional"
9926772|NCT00885911||Extraglottic device|The laryngeal mask airway (LMA) used during pediatric anesthesia for routine and difficult airway management.
9926773|NCT00885924|Active Comparator|Active treatment|Desmopressin 0.3 microgram/kg
9926774|NCT00885924|Placebo Comparator|Placebo|NaCl 0.9%
9926775|NCT00885937|Experimental|Arm 1|
9926776|NCT00885937|Active Comparator|Arm 2|
9926777|NCT00885937|Placebo Comparator|Arm 3|
9926778|NCT00885950||Colorectal liver metastases|Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
9926779|NCT00885989|Experimental|1|
9926780|NCT00885989|Placebo Comparator|2|
9926781|NCT00886028|Experimental|Liposomal doxorubicin|Thirty patients with MPM who received liposomal doxorubicin 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
9864699|NCT00104312||1|Participants with symptomatic knee osteoarthritis
9864700|NCT00104312||2|Participants without symptomatic knee osteoarthritis, age-matched as controls
9864701|NCT00104494|Experimental|1|CF, Zinc acetate
9864702|NCT00104494|Experimental|2|CF, Placebo
9864703|NCT00104494|No Intervention|3|Controls
9864704|NCT00104559|Experimental|1|Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT
9864705|NCT00104559|Experimental|2|Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT
9864706|NCT00104559|Experimental|3|Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT
9864707|NCT00104559|Experimental|4|Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT
9864708|NCT00104585||1|People with young onset Parkinson's disease and their family members
9864709|NCT00104598|Active Comparator|Gain Framed Absitnence Program|Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
9864710|NCT00104598|Active Comparator|Loss Framed Abstinence Program|Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
9864711|NCT00104611|Active Comparator|TMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks
9864712|NCT00104611|Placebo Comparator|Placebo|Treatment 5 days/week for up to 6 weeks
9864713|NCT00104689|Experimental|Capecitabine + Oxaliplatin|Patients receive oral capecitabine once daily on days 1-14 and oxaliplatin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
9864714|NCT00104702|Experimental|Concentrated and Focalized Radiotherapy|
9864715|NCT00104715|Experimental|Hormonotherapy + chemotherapy|
9864716|NCT00104715|Active Comparator|Hormonotherapy alone|
9864717|NCT00104741|Active Comparator|radiotherapy alone|
9864718|NCT00104741|Experimental|Radiotherapy + androgene deprivation|
9864719|NCT00104754|Experimental|liposomal SN-38|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response or patients with stable disease (SD) who were previously treated before study enrollment receive up to 4 additional courses of treatment. Patients with CNS-only disease progression receive whole brain radiotherapy (WBRT). After completion of WBRT, these patients also receive up to 4 additional courses of treatment. Patients with disease progression to sites other than the CNS or patients with SD who were previously untreated before study enrollment are removed from the study.~Quality of life is assessed at baseline, before each treatment course, and then annually for 3 years.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years."
9864720|NCT00104767|Experimental|celecoxib|
9864721|NCT00104845|Experimental|human gp100 DNA vaccine|Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.
9864722|NCT00104845|Experimental|mouse gp100 DNA vaccine|Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16
9864723|NCT00104910|Experimental|Treatment (brachytherapy, radiation, cetuximab, cisplatin)|Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
9864724|NCT00104962|Experimental|Treatment (lenalidomide)|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9864725|NCT00104988|Experimental|Thalidomide and Temozolomide|Patients receive oral thalidomide once daily on days 1-56 and temozolomide once daily on days 1-42. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
9864726|NCT00105040|Experimental|Levetiracetam (LEV)|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
9864727|NCT00105040|Placebo Comparator|Matching Placebo (PBO)|Oral tablets and oral solution.
9864728|NCT00105053|Experimental|vaccine group|
9864729|NCT00105144|Experimental|1|lower dose
9864730|NCT00105144|Experimental|2|higher dose
9864731|NCT00105144|Active Comparator|3|
9864732|NCT00105339||Illustration Style Preference Group|Ten participants at each site will be invited to attend a focus group to determine their comfort with and preference for one of four styles of illustration. The same two concepts will be presented in each of the four styles and ratings will be obtained from all participants. Detailed information on why participants rated each of the styles the way they did will also be obtained by reviewing comments on the rating sheets and audiotapes of the groups. Groups will be run by the study coordinator at the Florida and New York sites, and by Dannie Hoffman, protocol coordinator, in Los Angeles, using a focus group script developed by Dr. Murphy.
9926782|NCT00886041|Other|laparoscopy group|laparoscopy
9926783|NCT00886041|Active Comparator|ovarian stimulation group|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
9864733|NCT00105339||Review of Draft Focus Group|Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
9864734|NCT00105339||Comprehension/Recall Assessment|The assessment will be read to the participants to preclude reading problems. Responses will be recorded by the interviewer on the assessment instrument.
9864735|NCT00105365|Placebo Comparator|walking shoes|walking shoes
9864736|NCT00105365|Experimental|walking shoes + shoe insert|walking shoes + shoe insert
9667032|NCT04042584|Experimental|Visio conference device evaluation|Neurological tele-evaluation by a neurologist
9864737|NCT00105547|Experimental|1|800 mg BID
9864738|NCT00105547|Placebo Comparator|2|BID dosing
9864739|NCT00105573|Experimental|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy for depression.
9864740|NCT00105573|Experimental|Interpersonal psychotherapy/child-parent psychotherapy|Participants will receive interpersonal psychotherapy for depression plus 1 year of in-home, child-parent psychotherapy.
9864741|NCT00105573|Active Comparator|Enhanced community standard|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
9864742|NCT00105599|Other|Arm 1|
9864743|NCT00105625||Group 1|
9864744|NCT00105638|Other|Arm 1|
9864745|NCT00105651|Other|Arm 1|
9864746|NCT00105664|Other|Arm 1|
9864747|NCT00105677||Group 1|
9864748|NCT00105690|Other|Arm 1|
9864749|NCT00105703|Other|Arm 1|
9864750|NCT00105716|Other|Arm 1|
9864751|NCT00105729|Other|Arm 1|
9864752|NCT00105742|Other|Arm 1|
9864753|NCT00105755|Other|Arm 1|
9864754|NCT00105768|Other|Arm 1|
9864755|NCT00105781|Other|Arm 1|
9864756|NCT00105794|Other|Arm 1|
9864757|NCT00105807|Other|Arm 1|
9864758|NCT00105820|Other|Arm 1|
9864759|NCT00105833|Experimental|Arm 1|Multifaceted collaborative intervention for depression based in primary care
9864760|NCT00105833|No Intervention|Arm 2|Treatment as usual
9864761|NCT00105846|Other|Arm 1|
9864762|NCT00105859|Other|1|
9864763|NCT00105872|Other|Arm 1|
9864764|NCT00105885|Experimental|Arm 1|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
9864765|NCT00105885|No Intervention|Arm 2|Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval.
9864766|NCT00105898|Experimental|Arm 1|Intervention group
9864767|NCT00105898|Active Comparator|Arm 2|Comparator
9864768|NCT00105898|Sham Comparator|Arm 3|Comparator
9864769|NCT00105911|Other|Arm 1|
9864770|NCT00105950|Experimental|Lapatinib|Single arm study of lapatinib with no comparator arm.
9864771|NCT00106041|Other|Arm 1|Palliative Care Nurse Case Management
9926784|NCT00886054||Neurocritical patients|Neurocritical patients including those sustaining head injury, cerebrovascular events (such as intracerebral hemorrhage, subarachnoid hemorrhage, etc.), brain tumor, or hydrocephalus.
9926785|NCT00886067|Experimental|2-[18F]-F-A85380|Single microdose
9926786|NCT00886067|Experimental|AZD1446|Single oral administration
9926787|NCT00886080|Experimental|Add-on arrhythmia surgery|"Adjuvant anti-arrhythmic surgery consists of a beating heart epicardial box isolation of all pulmonary veins using microwave energy (Flex 4 or Flex 10 ablation probes and Microwave generator by Guidant/Afix, Fremont, CA, USA). The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. In addition excision or exclusion of the left atrial appendage is performed in both the treated as the control group."
9926788|NCT00886093|Experimental|Sequence 1|
9926789|NCT00886093|Experimental|Sequence 2|
9926790|NCT00886106|Experimental|1|Remifentanil
9926791|NCT00886106|Active Comparator|2|Midazolam
9926792|NCT00886132|Experimental|Sunitinib|Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
9926793|NCT00886158||Solid Organ Transplant Recipients|Solid organ transplant recipients receiving their care at Seattle Children's Hospital
9926794|NCT00886171|Experimental|Social Skills Training|
9926795|NCT00886171|Experimental|Physical Activity Training|
9926796|NCT00886184|Experimental|1|Induction of pre hospital early hypothermia in patients having a cardiac .
9926797|NCT00886184|Active Comparator|2|Induction of hypothermia only at hospital arrival.
9926798|NCT00886197||GERD|"Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years old.~Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least 3 times per week in recent 4 months."
9926799|NCT00886210|Active Comparator|1LC with drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
9926800|NCT00886210|Active Comparator|2LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. no drain at the end of operation.
9926801|NCT00886223|Experimental|1|
9926802|NCT00886275|Experimental|Dexmedetomidine|
9926803|NCT00886275|Active Comparator|Midazolam|
9926804|NCT00886275|Experimental|Dexmedetomidine, Midazolam|Combination
9864772|NCT00106067|Experimental|Arm 1|In the intervention arm, Patients and their family caregivers have access to a coping and communication support practitioner (CCSP) (see intervention description) in addition to receiving the usual care in the site.
9864773|NCT00106067|No Intervention|Arm 2|In the control arm, Patients are receiving the usual care in the site.
9864774|NCT00106145|Experimental|Part I - Arm 1|
9864775|NCT00106145|Experimental|Part II - Arm 1|
9864776|NCT00106145|Experimental|Part III - Arm 1|
9864777|NCT00106145|Experimental|Part IV - Arm 1|
9864778|NCT00106145|Experimental|Part V - Arm 1|
9864779|NCT00106171|Experimental|1|Participants will receive HAART for 1 year
9864780|NCT00106171|No Intervention|2|Participants will receive no treatment
9864781|NCT00106197|Experimental|1|Participants will receive bupropion in the sleep study
9864782|NCT00106210|Experimental|1|Behavioral Intervention (experimental)
9864783|NCT00106210|Active Comparator|2|Behavioral Intervention 2
9864784|NCT00106223|Experimental|1|Group receiving immediate treatment with cognitive behavioral therapy
9864785|NCT00106223|Active Comparator|2|Waitlist control group to begin CBT 3 months after other CBT group begins treatment
9864786|NCT00106288|Experimental|1|
9864787|NCT00106288|Active Comparator|2|
9864788|NCT00106301|Experimental|FK228 (romidepsin)|romidepsin
9864789|NCT00106327|Experimental|1|6-month supervised treadmill exercise program
9864790|NCT00106327|Experimental|2|6-month supervised lower extremity progressive resistance training program
9864791|NCT00106327|Active Comparator|3|Diet/nutrition control group
9864792|NCT00106418|Experimental|Romidepsin|13 mg/m^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
9864793|NCT00106483||Coronary Artery Risk Development in Young Adults|There were no interventions.
9864794|NCT00106496|Experimental|1A|
9864795|NCT00106496|Active Comparator|1B|
9864796|NCT00106496|Experimental|2|Open label
9864797|NCT00106496|Experimental|3A|
9864798|NCT00106496|Placebo Comparator|3B|
9864799|NCT00106496|Experimental|4|Open label
9864800|NCT00106522|Experimental|1|
9864801|NCT00106522|Experimental|2|
9864802|NCT00106522|Placebo Comparator|3|
9864803|NCT00106548|Experimental|1|
9864804|NCT00106548|Experimental|2|
9864805|NCT00106548|Placebo Comparator|3|
9864806|NCT00106574|Experimental|1|
9864807|NCT00106574|Placebo Comparator|2|
9864808|NCT00106613|Experimental|FK228 (romidepsin)|13 mg/m2 of romidepsin
9864809|NCT00106678||Infected through risk behaviors|
9864810|NCT00106678||Infected perinatally or through blood/blood products.|
9864811|NCT00106691|Experimental|toremifene 20mg|
9864812|NCT00106691|Placebo Comparator|Placebo|
9864813|NCT00106782|Other|1|Real TEP
9864814|NCT00106782|Other|2|Sham Stimulation
9864815|NCT00106899||1|Mild Cognitive Impairment (MCI); scans performed at screening/baseline, 6, 12, 18, 24, and 36 months
9864816|NCT00106899||2|Early Alzheimer's disease (AD); scans performed at screening/baseline, 6, 12, and 24 months
9864817|NCT00106899||3|Unaffected/normal controls; scans performed at baseline/screening, 6, 12, 24, and 36 months
9864818|NCT00106977||Family|Family members (typically parents or siblings) of probands with Muenke syndrome are alsoeligible to participate.
9864819|NCT00106977||Patient|Subjects who have had confirmation of a p. Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory.
9864820|NCT00107016|Experimental|RAD001 + letrozole 2.5mg|
9864821|NCT00107016|Active Comparator|Letrozole 2.5mg|
9864822|NCT00107081|Active Comparator|Standard|Continued inpatient i.v. antibiotics
9864823|NCT00107081|Experimental|Experimental|Switch to outpatient p.o. antibiotics
9864824|NCT00107107|Active Comparator|Pramlintide Acetate|Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
9864825|NCT00107185|Experimental|Vaccine|
9864826|NCT00107237|Experimental|AEE788 200 mg + RAD001 5 mg|AEE788 200 mg qd, RAD001 5 mg qd
10210331|NCT05215483|Experimental|Customised advice + No LFT available at home|"Respondents will see an altered testing advice in text and picture in which they are allowed to use LFT with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
10210332|NCT05215483|Experimental|Regular advice + LFT available at home|"Respondents will see the regular testing advice in text and picture with the current governmental advice to visit a test facility with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
10210333|NCT05215483|Active Comparator|Regular advice + No LFT available at home|"Respondents will see the regular testing advice in text and picture with the current governmental advice to visit a test facility with corona related symptoms.~Respondents will informed in writing that they don't currently have any LFT available at home."
10210334|NCT05215457||development set|50 cases are the development set, which is used to develop the prediction model of diquat acute poisoning. These patients are all from the First Affiliated Hospital of Nanjing Medical University.
10210335|NCT05215457||validation set|50 patients are the validation set, from more than ten tertiary a-level hospitals in the surrounding area, to verify the prediction model.
10210336|NCT05215444||survivors|
10210337|NCT05215444||non survivors|
10210338|NCT05215379|Other|neoadjuvant chemoradiation therapy|neoadjuvant chemoradiation therapy
10210339|NCT05215379|Experimental|neoadjuvant chemoradiation therapy +immunotherapy|neoadjuvant chemoradiation therapy +immunotherapy
10210340|NCT05215366||children with febrile seizures|
10210341|NCT05215366||febrile children without seizures|
10210342|NCT05215366||healthy control children|
10210343|NCT05215301||Occupational Voice Users|Workers who uses voice extensively during work falls under occupational voice users (e.g. singers, actors, radio announcer, teacher, translator, lawyer). The grouping were made based on references from The Union of the European Phoniatricians
10210344|NCT05215301||Non-occupational Voice Users|Those who didn't use voice extensively during work falls under non-occupational voice users (motorcycle drivers, daily labor, administrative workers)
10210345|NCT05215249|No Intervention|Standard of Care|Patient will receive conventional tubeless anesthesia
10210346|NCT05215249|Experimental|High Flow Oxygen Delivery|Patient will receive Transnasal humidified high-flow oxygen delivery (Optiflow)
10210347|NCT05215197|Experimental|intracochlear prf administration group|intracochlear prf administration group
10210348|NCT05215171||World Trade Center - Airway Hyperreactivity (WTC-AHR)|WTC-AHR cases are defined as having either a positive MCT (PC20<16) and/or positive BDR (by ATS/ERS guidelines with improvement of FEV1 by 12% and at least 200mL) post-9/11.
10210349|NCT05215171||Control Group|Cohort Controls will be randomly selected 10% of the baseline cohort
10210350|NCT05215145|Active Comparator|Baby Navigator Bundle|Parent and child measures, including a home observation video, will be collected at baseline, after which study staff will use Motivational Interviewing techniques to engage families to access resources and support (Baby Navigator Bundle) when they first learn their child has social communication/language delay. Families may use the Baby Navigator Bundle as little or as much as they like. The Baby Navigator Bundle includes: Social Communication Growth Charts and the Baby Navigator webinar series.
10210351|NCT05215145|Active Comparator|Baby Navigator Bundle + Individual-ESI|At 18-21months of age, slow responders (communication delay still below the 10th percentile) will be randomized to continue the Baby Navigator Bundle with or without Individual-ESI, and responders (communication above the 10th percentile) will continue with Baby Navigator Bundle. For Individual ESI, trained coaches or family navigators will coach families using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. Family navigators will also engage the family in the How-to Guide for Families online course. The family navigator will use zoom or other telehealth platform to meet with parents 1 time per week for 30-60 minutes per session for 6 months.
10210352|NCT05215132|Other|Patient w/ Contrast|Patients will add 15 minutes to their SOC MRI for research purposes
10210353|NCT05215132|Other|Patient no contrast|Patients will add 15 minutes to their SOC MRI for research purposes
10210354|NCT05215132|Other|Volunteer w/ contrast|Volunteers undergo 1 research MRI for research purposes
10210355|NCT05215132|Other|Volunteer no contrast|Volunteers undergo 1 research MRI for research purposes
10210356|NCT05215106|Experimental|Preoperative durvalumab|All patients enrolled in the study will receive IV durvalumab 10mg/kg monotherapy every 2 weeks for a total of 6 weeks (3 injections) before the surgical procedures.
10210357|NCT05215080|Experimental|Treatment group|Group of infants aged 6-7 months that given organic formula milk three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
10210358|NCT05215054|Experimental|Gana V versus Sculptra|Participants will receive both Gana V and Sculptra: one in each nasolabial folds
10210359|NCT05215028||users|users of the web-application MALO
10210360|NCT05215015|Experimental|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10^9 cells.
10210361|NCT05214989|Experimental|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
10210362|NCT05214950|Experimental|ORI monitoring|SpO2, ECG, NIBP, and oxygen reserve index monitoring
10210363|NCT05214950|No Intervention|Standard monitoring|SpO2, ECG, NIBP monitoring
10210364|NCT05214924|Experimental|Injectable platelet-rich fibrin injection|Each of the participants from iPRF injection group will receive two injections of iPRF with an interval of 30 days.
10210365|NCT05214924|Active Comparator|Dextrose injection|Each of the participants from dextrose injection group will receive two injections of 10% dextrose with an interval of 30 days.
10210366|NCT05214911|Experimental|Experimental drug (Desloratadine 0.5 mg/mL/Prednisolone 4 mg/mL)|ADF Group 1 - Eurofarma drug association of Desloratadine 0.5 mg/mL / Prednisolone 4 mg/mL
9864827|NCT00107237|Experimental|AEE788 150 mg + RAD001 5mg|AEE788 150 mg qd, RAD001 5 mg qod
9864828|NCT00107263|Experimental|Arm I: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
9864829|NCT00107263|Experimental|Arm II: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
9864830|NCT00107341|Experimental|bortezomib + paclitaxel + carboplatin|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years."
9864831|NCT00107419|Experimental|pemetrexed|pemetrexed
9864832|NCT00107432|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9864833|NCT00107445|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
9864834|NCT00107458|Experimental|Treatment 1|VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
9864835|NCT00107458|Experimental|Treatment 10|VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
9864836|NCT00107458|Experimental|Treatment 20|VPA Target Trough Concentration 150-200 mcg/mL
9864837|NCT00107471|Experimental|Dose Level I (0.5 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
9864838|NCT00107471|Experimental|Dose Level 2 (0.6 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)
9864839|NCT00107497|Active Comparator|Control|50Gy in 25 fractions of radiation therapy over 5 weeks
9864840|NCT00107497|Active Comparator|Test group 1|30Gy in 5 fractions of radiation therapy over 5 weeks
9864841|NCT00107497|Active Comparator|Test group 2|28.5Gy in 5 fractions of radiation therapy over 5 weeks
9864842|NCT00107510|Experimental|docetaxel + carboplatin + pegfilgrastim + surgery|"Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.~After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years."
9864843|NCT00107549|Experimental|1|All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine
9864844|NCT00107562|Experimental|Intervention|The cohort will be comprised of up to 4 index participants and from 1-4 of their network members for a possible range of 8-16 subjects in each cohort (average of 12 per cohort). The vast majority of the intervention will be delivered to both females and males together, but it would be beneficial, and appropriate for this adolescent population, to deliver certain exercises with the two genders separated.
9864845|NCT00107588|Experimental|Reinforcement for homework completion|
9864846|NCT00107588|Active Comparator|Reinforcement for Abstinence|
9864847|NCT00107588|Active Comparator|Case Management|
9864848|NCT00107627|Active Comparator|1|Skin staples;
9864849|NCT00107627|Active Comparator|2|Monocryl subcuticular sutures.
9864850|NCT00107627|Active Comparator|3|Caprosyn subcuticular sutures.
9864851|NCT00107640|No Intervention|Usual care|Patients not assigned to the experimental condition received usual care, which may or may not have included alcohol education.
9864852|NCT00107640|Experimental|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
9864853|NCT00107770|Other|1|ALS patient
9864854|NCT00107835|Experimental|S-Caine Peel|
9864855|NCT00107887|No Intervention|1|Subjects in clinics that have not received the intervention
9864856|NCT00107887|Experimental|2|Subjects at clinics that have received the intervention
9926805|NCT00886301|Other|1|obese or overweight patients with fatty liver or ectopic fat
9864857|NCT00107926|Experimental|licarbazepine|
9864858|NCT00107926|Placebo Comparator|Placebo|
9864859|NCT00107965|Experimental|1|
9864860|NCT00107965|Experimental|2|
9864861|NCT00107965|Experimental|3|
9864862|NCT00107965|Placebo Comparator|4|
9864863|NCT00107965|Experimental|5|
9864864|NCT00107965|Experimental|6|
9864865|NCT00107965|Experimental|7|
9864866|NCT00107965|Placebo Comparator|8|
9864867|NCT00108004|Experimental|Pramlintide|"Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative"
9864868|NCT00108108|Experimental|HCD122|
9864869|NCT00108147|Experimental|1|Circuit Training
9864870|NCT00108147|Active Comparator|2|Cardiac Rehabilitation
9864871|NCT00108147|Active Comparator|3|Flexibility and toning
9864872|NCT00108173|Other|Arm 1|
9864873|NCT00108186|Other|Arm 1|Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
9864874|NCT00108225|Active Comparator|Arm 1|30% carbohydrate, 30% protein, 40% fat
9864875|NCT00108225|Placebo Comparator|Arm 2|55% carbohydrate, 15% protein, 30% fat
9864876|NCT00108251|Placebo Comparator|1|placebo tablet
9864877|NCT00108251|Experimental|2|eplerenone tablets
9864878|NCT00108316|Other|Arm 1|
9864879|NCT00108381|Experimental|Arm 1|Standard and Tailored Conditions
9864880|NCT00108407|Experimental|1|Integrated Cognitive Behavioral Therapy
9864881|NCT00108407|Experimental|2|Twelve Step Facilitation Therapy
9864882|NCT00108576|Placebo Comparator|Arm 1|Look-a-like placebo
9864883|NCT00108576|Experimental|Arm 2|Divalproex
9864884|NCT00108602|Other|1|
9864885|NCT00108615|Experimental|1|pioglitazone
9864886|NCT00108615|Active Comparator|2|metformin
9864887|NCT00108771|Experimental|ZR-02-01 matrix fentanyl Patch|ZR-02-01 matrix fentanyl patch
9864888|NCT00108771|Placebo Comparator|Placebo Patch|
9864889|NCT00108901|No Intervention|Control|Children were not provided with an after-school exercise intervention. They were free to do their usual activities. Families were offered a monthly healthy lifestyle class.
9864890|NCT00108901|Experimental|Low Dose|This group was assigned to receive a 20 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
9864891|NCT00108901|Experimental|High dose|This group was assigned to receive a 40 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
9864892|NCT00109213|Active Comparator|1|Lumbar Laminectomy without Fusion
9864893|NCT00109213|Active Comparator|2|Lumbar Laminectomy with Pedicle Screw Instrumented Fusion
9864894|NCT00109291|Placebo Comparator|Placebo|Single injection of placebo administered intravenously
9864895|NCT00109291|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
9864896|NCT00109291|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
9864897|NCT00109291|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
9864898|NCT00109369|Experimental|Active|Provider and patient receive Diabetes Information System services
10210367|NCT05214911|Active Comparator|Active Comparator: Leg® (Desloratadine 0.5 mg/mL)|Leg® Group 2 - Eurofarma drug Desloratadine 0.5 mg/mL
10213679|NCT03543124|Experimental|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
10213680|NCT03541499|Experimental|Group 1|800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15
10213681|NCT03541499|Experimental|Group 2|800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15
9864899|NCT00109369|No Intervention|Control|Usual Care
9864900|NCT00109395|Active Comparator|Lorazepam Intermittent bolus|lorazepam administered by intermittent bolus
9864901|NCT00109395|Active Comparator|lorazepam continuous infusion|lorazepam administered by continuous infusion
9864902|NCT00109395|Active Comparator|midazolam continous infusion|midazolam administered by continous infusion
9864903|NCT00109408|Experimental|1|
9864904|NCT00109408|Active Comparator|2|
9864905|NCT00109421|Experimental|Experimental arm|In the experimental condition, the intervention group will receive the half-day Project ÒRÉ intervention. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires. A subset of groups will participate in a process evaluation focus group immediately following the program.
9864906|NCT00109421|No Intervention|Attention control group|The attention control group will receive a standard health promotion control program which has been used previously with similar populations. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires.
9864907|NCT00109486|Experimental|Arm 1|
9864908|NCT00109512|Placebo Comparator|placebo|
9864909|NCT00109512|Experimental|NBI-56418 75 mg|
9864910|NCT00109512|Experimental|NBI-56418 150 mg|
9864911|NCT00109655|Experimental|1|
9864912|NCT00109720|Experimental|1|Patients in the experimental group received the services of a Diabetes Self-Management Consultant (DSC)
9864913|NCT00109720|Active Comparator|2|This Arm was a Enhanced Usual Care Control group who continued with their usual care but also they and their physicians received the results of all metabolic assessments obtained during the study.
9926806|NCT00886314|Active Comparator|midazolam|
9926807|NCT00886314|Active Comparator|clown doctor|
9926808|NCT00886327||Postoperative patients|Patients with CD who recently underwent bowel resection
9926809|NCT00886353|Active Comparator|APN01|Healthy volunteers will receive APN01
9926810|NCT00886353|Placebo Comparator|Placebo|Physiological saline administrated i.v.
9926811|NCT00886366|Experimental|1|AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)
9864914|NCT00109746|Active Comparator|Chromium Picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
9864915|NCT00109746|No Intervention|Placebo|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
9864916|NCT00109759|Experimental|RagweedMATAMPL|
9864917|NCT00109759|Placebo Comparator|Placebo|
9864918|NCT00109785|Experimental|PET Scans|The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
9864919|NCT00109798|Experimental|Temozolomide, Topotecan|Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
9864920|NCT00109811|Experimental|Treatment|Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.
9864921|NCT00109824|Experimental|Arm I|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9864922|NCT00109824|Experimental|Arm II|Patients receive decitabine as in stage 1 and valproic acid PO TID on days 5-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9864923|NCT00109863|Experimental|Hu14.18-IL2 Treatment|Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
9864924|NCT00109889|Other|MRI and PET|Magnetic resonance imaging and positron emission tomography
9864925|NCT00109941|Experimental|metenkephalin, OGF-opioid growth factor|DRUG All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly over 45 minutes
9864926|NCT00110032|Experimental|Group 1 (fluorine F 18 EF5, PET)|Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
9864927|NCT00110032|Experimental|Group 2 (EF5, PET)|Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
9864928|NCT00110032|Experimental|Group 3 (EF5, PET)|Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.
9864929|NCT00110071|Experimental|Treatment (chemoradioimmunotherapy)|Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.
9864930|NCT00110110|Experimental|CEV Chemo + Cyclosporine & Focal Therapy|Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.
9864931|NCT00110188|Experimental|Ridaforolimus|50 mg of ridaforolimis intravenously over 30 minutes, weekly
9864932|NCT00110227|Experimental|Tai Chi|12-week tai chi program
9864933|NCT00110227|Active Comparator|Heart Health Education|12-week attention control
9864934|NCT00110253|Experimental|S-Caine Peel|
9864935|NCT00110279|Experimental|1|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
9864936|NCT00110279|Experimental|2|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
9864937|NCT00110344|Experimental|Arm 1|
9864938|NCT00110344|Placebo Comparator|Arm 2|
9864939|NCT00110383|Experimental|1|Supervised therapy
9864940|NCT00110383|No Intervention|2|Inhaled steroid use as usual care
9864941|NCT00110409|Experimental|1|Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
9864942|NCT00110409|Active Comparator|2|Participants in the control group will receive standard emergency room education about asthma.
9864943|NCT00110448|Active Comparator|1|Aspirin use
9864944|NCT00110448|Active Comparator|2|No aspirin use
9864945|NCT00110526|Experimental|Ad.hIL-12|
9864946|NCT00110552|Experimental|1|Sage capsules taken by mouth
9864947|NCT00110552|No Intervention|2|No intervention, no-pill as control
9864948|NCT00110591|Placebo Comparator|Placebo|Intravenous placebo for PRO 140
9864949|NCT00110591|Experimental|PRO 140 dose 1|0.1 mg/kg PRO 140 by intravenous infusion
9864950|NCT00110591|Experimental|PRO 140 dose 2|0.5 mg/kg PRO 140 by intravenous infusion
9864951|NCT00110591|Experimental|PRO 140 dose 3|2.0 mg/kg PRO 140 by intravenous infusion
9864952|NCT00110591|Experimental|PRO 140 dose 4|5.0 mg/kg PRO 140 by intravenous infusion
9864953|NCT00110656||Kidney Transplant|All patients entered into the study will have received a kidney transplant.
9926812|NCT00886366|Experimental|2|2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food
9864954|NCT00110669|Active Comparator|High Dose Prednisone|"Subjects who are randomized to the high-dose prednisone arm of the study will receive the following starting dose:~•Prednisone at 10.0 mg/kg/wk (divided into two doses given on Saturday and Sunday)"
9864955|NCT00110669|Active Comparator|Daily Prednisone|"Subjects who are randomized to the daily prednisone arm of the study will receive the following starting dose:~•Prednisone at 0.75 mg/kg/d"
9864956|NCT00110695|Experimental|A|
9864957|NCT00110747|Experimental|S-Caine Peel|
9864958|NCT00110747|Placebo Comparator|Placebo Peel|
9864959|NCT00110760|Experimental|S-Caine Peel|
9864960|NCT00110760|Placebo Comparator|Placebo Peel|
9864961|NCT00110773|Experimental|S-Caine Peel|
9864962|NCT00110773|Placebo Comparator|Placebo Peel|
9864963|NCT00110799|Active Comparator|Arm B|SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
9864964|NCT00110799|Active Comparator|Arm C|SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
9864965|NCT00110799|Active Comparator|Arm D|SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
9864966|NCT00110799|Placebo Comparator|Arm A|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
9864967|NCT00110877|Experimental|002|LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
9864968|NCT00110877|Experimental|001|TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
9864969|NCT00110916|Experimental|Anakinra|anakinra
9864970|NCT00110916|Placebo Comparator|placebo|placebo
9864971|NCT00110942|Active Comparator|Minor sub-study AMG 108|N = 15
9864972|NCT00110942|Placebo Comparator|Minor sub-study placebo|N = 15
9864973|NCT00110942|Active Comparator|Main sub-study AMG 108|N = 73
9864974|NCT00110942|Placebo Comparator|Main sub-study placebo|N = 73
9864975|NCT00110955|Experimental|Darbepoetin alfa - Group A|
9864976|NCT00110955|Placebo Comparator|Placebo- Group B|
9864977|NCT00110981|Experimental|Single-arm|
9864978|NCT00111020|Experimental|Arm 1|
9864979|NCT00111085|Experimental|Clazosentan 1 mg/h|intravenous clazosentan at 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
9864980|NCT00111085|Experimental|Clazosentan 5 mg/h|intravenous clazosentan at 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
9864981|NCT00111085|Experimental|Clazosentan 15 mg/h|intravenous clazosentan at of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
9864982|NCT00111085|Placebo Comparator|Placebo|intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
9864983|NCT00111098|Experimental|darbepoetin alfa|
9864984|NCT00111137|Active Comparator|rHuEPO|
9864985|NCT00111137|Experimental|Darbepoetin alfa|
9864986|NCT00111176|Other|1|Endovascular Repair
9864987|NCT00111176|Other|2|Surgical
9864988|NCT00111189|Experimental|001|Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
9864989|NCT00111189|Placebo Comparator|002|Placebo Placebo every 4 wk up to 24 mo
9864990|NCT00111254|Experimental|1|In group I, acute effect group, each subject will undergo microdermabrasion of the hip/buttock. Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device). 4mm punch biopsies will be performed in the treated area at 4hrs, 8hrs, and 24hrs post-treatment. In addition, one 4mm punch biopsy will be obtained from adjacent untreated skin.
9864991|NCT00111254|Experimental|2|In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
9864992|NCT00111345|Experimental|1|Daunoxome, standard risk
9864993|NCT00111345|Active Comparator|2|Idarubicin, standard risk
9864994|NCT00111345|Experimental|3|Daunoxome, high-risk, 2-CDA
9864995|NCT00111345|Active Comparator|4|Idarubicin, high-risk, nothing
9864996|NCT00111358|Active Comparator|Lifestyle Modification|Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: <35% calories from fat, < 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, >10,000 steps in daily activity, measured by pedometer. The curriculum is modeled after the Diabetes Prevention Program. Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
9864997|NCT00111358|Placebo Comparator|Control|
9864998|NCT00111436|Experimental|50 mg|50 mg once weekly
9864999|NCT00111436|Experimental|100 mg|50 mg twice weekly
9926813|NCT00886366|Experimental|3|Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.
9926814|NCT00886392||diabetic macular edema|Type 2 diabetes patients who had clinically significant macular edema by the criterion of the ETDRS
9926815|NCT00886405|Experimental|Nytroglicerin|
9996955|NCT01504620|Other|Sugar infusion|Diagnostic assessment of blood glucose by means of different devices
9865000|NCT00111501|Experimental|Targeted Internet Intervention|Web-based self help intervention developed to include specific cultural tailoring relevant to the LGBT community
9865001|NCT00111501|Active Comparator|Standard Intervention|Standard self-help internet-based intervention with no LGBT relevant information included
9865002|NCT00111527|Active Comparator|1|Normal RV pacing
9865003|NCT00111527|Experimental|2|Echo-guided optimization of pacing
9865004|NCT00111540|Experimental|Exenatide|Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
9865005|NCT00111566|Active Comparator|18 Hour infusion|
9865006|NCT00111566|Experimental|4 hour infusion|
9865007|NCT00111579|Active Comparator|1|CAIV-T
9865008|NCT00111579|Other|2|TIV
9865009|NCT00111592|Active Comparator|1|current usual care
9865010|NCT00111592|Experimental|2|treatment protocol with clear indications for therapy
9865011|NCT00111605|Experimental|1|HIV gag DNA vaccine or placebo on Days 0, 28, and 84
9865012|NCT00111605|Experimental|2|HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84
9865013|NCT00111605|Experimental|3|HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84
9865014|NCT00111605|Experimental|4|HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84
9865015|NCT00111605|Experimental|5|HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273
9865016|NCT00111605|Experimental|6|HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273
9865017|NCT00111605|Experimental|7|HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84
9865018|NCT00111631|Experimental|1|
9865019|NCT00111631|Experimental|2|
9865020|NCT00111631|Experimental|3|
9865021|NCT00111631|Placebo Comparator|4|
9865022|NCT00111644|Experimental|1|
9865023|NCT00111644|Experimental|2|
9865024|NCT00111644|Active Comparator|3|
9865025|NCT00111670|Experimental|1|
9865026|NCT00111670|Experimental|2|
9865027|NCT00111670|Experimental|3|
9865028|NCT00111670|Experimental|4|
9865029|NCT00111670|Placebo Comparator|5|
9865030|NCT00111683|Experimental|MK-0457|Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration
9865031|NCT00111696|Experimental|MEDI-522|Drug
9865032|NCT00111748|Active Comparator|1|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:VTD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg Days 1-14 Every 21 days"
9865033|NCT00111748|Active Comparator|2|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:~VATD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Adriamycin 2.5 mg/m2 Days 1-4 & Days 9-12 Lovenox 40 mg Days 1-14 Every 21 days"
9865034|NCT00111787|Experimental|Overall study|A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
9865035|NCT00111852|Experimental|Desmoteplase, low dose|Desmoteplase 90 mcg/kg, intravenous administration.
9865036|NCT00111852|Experimental|Desmoteplase, high dose|Desmoteplase 125 mcg/kg, intravenous administration.
9865037|NCT00111852|Placebo Comparator|Placebo|Dose-Match Placebo, intravenous administration.
9865038|NCT00111865|Experimental|Exercise|Aerobic Exercise Training
9865039|NCT00111865|No Intervention|Usual Care|
9865040|NCT00111956|Experimental|Etanercept|
9865041|NCT00111956|Placebo Comparator|Placebo|
9865042|NCT00111982|Experimental|Liatermin|Bilateral continuous infusion of liatermin for up to 24 months.
9865043|NCT00112008|Experimental|darbepoetin alfa|
9865044|NCT00112021|Experimental|Pramlintide Acetate|
9865045|NCT00112021|Placebo Comparator|Placebo|
9865046|NCT00112099|Active Comparator|1|Procedure/Surgery: Surgery: Splenectomy
9865047|NCT00112099|Experimental|2|Procedure/Surgery: Surgery: Spleen-preservation
9865048|NCT00112229|Experimental|group 1|Melan-A analog peptide + CpG + Montanide
9865049|NCT00112229|Experimental|group 2|Melan-A natural peptide + CpG + Montanide
9865050|NCT00112229|Experimental|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
9865051|NCT00112229|Experimental|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
9865052|NCT00112320|Active Comparator|1|Standard PVR
9865053|NCT00112320|Experimental|2|PVR plus RV remodeling
9865054|NCT00112346|Active Comparator|A|
9865055|NCT00112346|Active Comparator|B|
9865056|NCT00112372|Experimental|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
9865057|NCT00112398|Active Comparator|Standard (paramedic) prehospital care|
9865058|NCT00112398|Experimental|Physician prehospital care|
9865059|NCT00112476|Experimental|Treatment (bryostatin, temsirolimus)|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9865060|NCT00112528|Experimental|gemcitabine + bevacizumab + oxaliplatin|"Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR.~After completion of study treatment, patients are followed every 3-6 months for up to 5 years."
9865061|NCT00112554|Experimental|Induction therapy arm I|Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
9996956|NCT01504620|Experimental|insulin infusion|infusion of insulin to achieve low glucose levels
9865062|NCT00112554|Active Comparator|Induction therapy arm II|Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
9865063|NCT00112658|Experimental|Folfirinox|
9865064|NCT00112658|Active Comparator|Gemcitabine|
9865065|NCT00112684|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9865066|NCT00112697|Experimental|Arm 1|
9865067|NCT00112697|Experimental|Arm 2|
9865068|NCT00112749|Experimental|Study Arm|Please see intervention description
9865069|NCT00112853|Experimental|Treatment (tipifarnib, etoposide)|"Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD."
9865070|NCT00112931|Active Comparator|Watch and Wait|Watch and Wait - no treatment
9865071|NCT00112931|Experimental|Arm C Rituximab 4 and Rixuximab Maintenance|4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks
9865072|NCT00112996|Experimental|Arm I: Alpha-Lipoic Acid|Oral alpha-lipoic acid three times daily for at least 24 weeks in the absence of unacceptable toxicity.
9865073|NCT00112996|Placebo Comparator|Arm II: Placebo|Oral placebo three times daily for at least 24 weeks in the absence of unacceptable toxicity.
9865074|NCT00113035||Patients with late onset Pompe Disease|
9865075|NCT00113074|Active Comparator|1|Weight management and BP control program
9865076|NCT00113074|Active Comparator|2|Self-help materials targeting lifestyle modification
9865077|NCT00113139|Experimental|Telephone-based coping skills|Telephone-based coping skills intervention
9865078|NCT00113139|Active Comparator|Usual Care|
9865079|NCT00113347|Experimental|Erlotinib + Docetaxel|Erlotinib 100, 125, or 150 mg orally daily except days receive Docetaxel 15 mg/m^2 or 20 mg/m^2 intravenously with Concomitant Boost Radiation to Head/Neck
9865080|NCT00113503|Active Comparator|Azathioprine weight-based dose|
9865081|NCT00113503|Experimental|Azathioprine individualised dose|
9926816|NCT00886418|Active Comparator|1|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. A muscle relaxant is used to facilitate tracheal intubation; its administration is continued throughout anesthesia.
9926817|NCT00886418|Experimental|2|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. No muscle relaxant is used and a placebo is infused throughout anesthesia.
9926818|NCT00886431|Experimental|Vitrification|The embryos of patients allocated to this arm will be cryopreserved by vitrification.
9926819|NCT00886431|No Intervention|Slow cooling|The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)
9926820|NCT00886444|Experimental|Ferucarbotran|
9926821|NCT00886457|Experimental|Decitabine plus PEG Interferon-alfa 2B|3.7 mg/m**2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
9926822|NCT00886509|Experimental|Collateral promotion; PCI after 6 months|First pegGCSF or placebo; PCI after 6 months
9926823|NCT00886509|Experimental|Collateral promotion after PCI at baseline|Collateral promotion with pegGCSF after PCI at baseline
9926824|NCT00886522|Experimental|Intrabone cord blood infusion|All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
9926825|NCT00886561|Experimental|HIV risk reduction intervention|Behavioral intervention designed to reduce HIV risk behaviors and enhance enhance HIV-preventive behaviors among female sex workers (FSWs) in Armenia
9926826|NCT00886561|Active Comparator|Wait list control|Will receive behavioral intervention after completion of study upon request.
9926827|NCT00886574|Active Comparator|Aspirin|Aspirin 100 mg once a day
9926828|NCT00886574|Active Comparator|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
9935268|NCT03964090|Experimental|2|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib Days 1-10 (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
9935269|NCT03961724||ESRD group|
9935270|NCT03961724||Control group|
9865082|NCT00113633|No Intervention|Control Subjects|These subjects will receive standard discharge instructions that recommend follow-up with a PCP within 3-5 days.
9865083|NCT00113633|Experimental|Intervention Subjects|As part of the intervention, the family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups. For children reporting persistent asthma symptoms, a letter will be given to the family to bring to their PCP stating that screening revealed symptoms that may require further treatment with controller medications. A mailed reminder to schedule a follow-up appointment will be sent to the family.
9865084|NCT00113659|Active Comparator|1|Participants in this arm will receive Lactobacillus GG.
9865085|NCT00113659|Placebo Comparator|2|Participants in this arm will receive a placebo.
9865086|NCT00113672|Experimental|A|Increase healthy eating and increase healthy activity
9865087|NCT00113672|Experimental|B|Increase healthy eating and decrease unhealthy activity
9865088|NCT00113672|Experimental|C|Decrease unhealthy eating and increase healthy activity
9865089|NCT00113672|Experimental|D|Decrease unhealthy activity and decrease unhealthy eating
9865090|NCT00113698|Placebo Comparator|1|
9865091|NCT00113698|Active Comparator|2|Ace inhibition (enalapril)
9865092|NCT00113789|Active Comparator|Pegfilgrastim|
9865093|NCT00113789|Placebo Comparator|Placebo|
9865094|NCT00113815|Experimental|003|topiramate 25 mg/kg/day
9865095|NCT00113815|Experimental|002|topiramate 15 mg/kg/day
9865096|NCT00113815|Experimental|001|topiramate 5 mg/kg/day
9865097|NCT00113815|Experimental|004|placebo placebo
9865098|NCT00113828|Experimental|Transplantation|T-cell depleted HLA-matched peripheral blood stem cell transplantation
9865099|NCT00114075|Experimental|Gait analysis|Gait analysis report is available for treatment planning
9865100|NCT00114075|Active Comparator|Control|Subject has gait analysis test, but report is not available for treatment planning
9865101|NCT00114179|Experimental|Treatment (capecitabine, radiation, bevacizumab, gemcitabine)|"Chemoradiotherapy and bevacizumab: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Patients undergo reevaluation 3-4 weeks after completion of chemoradiotherapy and bevacizumab.~Patients with no evidence of disease progression proceed to maintenance therapy. Patients with a marked response may undergo surgery at the discretion of the attending surgeon and then proceed to maintenance therapy approximately 4-8 weeks later.~Maintenance therapy: Beginning within 4-7 weeks after completion of chemoradiotherapy and bevacizumab, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30 minutes on days 1 and 15 provided that blood counts have returned to normal. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9865102|NCT00114257|Experimental|Arm I|"Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.~Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
9865103|NCT00114283|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9865104|NCT00114309|Experimental|1|3 Dose Regimen
9865105|NCT00114309|Experimental|2|6 Dose Regimen
9865106|NCT00114348|Active Comparator|R-Blöcke|Blocktherapie
9865107|NCT00114348|Experimental|Prot-II-Ida|a
9865108|NCT00114361|Active Comparator|1|Ribavirin + Peg IFN
9865109|NCT00114361|Active Comparator|2|Peg IFN + Placebo
9865110|NCT00114413|Active Comparator|Reference Strategy|Participants in the reference strategy group will undergo the eNO procedure but will follow NAEPP guidelines alone for asthma treatment without eNO measurements for the rest of the study.
9865111|NCT00114413|Experimental|Biomarker Strategy|Participants in the biomarker strategy group will follow NAEPP treatment guidelines, as well as eNO measurements, to determine asthma treatment at each study visit.
9865112|NCT00114452|Active Comparator|Provacel: Cohort 1|ex vivo cultured adult mesenchymal stem cells
9865113|NCT00114452|Active Comparator|Provacel: Cohort 2|ex vivo cultured adult mesenchymal stem cells
9865114|NCT00114452|Active Comparator|Provacel: Cohort 3|ex vivo cultured adult mesenchymal stem cells
9865115|NCT00114452|Active Comparator|Provacel: Cohort 4|ex vivo cultured adult mesenchymal stem cells
9865116|NCT00114452|Placebo Comparator|Placebo|ex vivo cultured adult mesenchymal stem cells
9865117|NCT00114465|Experimental|VSL#3|Probiotic
9865118|NCT00114465|Placebo Comparator|Placebo|Placebo
9865119|NCT00114543|Active Comparator|Aggressive ELBW|In Aggressive group 1, infants with birth weights 501-750g.
9865120|NCT00114543|Active Comparator|Aggressive VLBW|In the Aggressive group 2, infants with birth weights 751-1000g.
9865121|NCT00114543|Active Comparator|Conservative ELBW|In the Conservative group 1, infants with birth weights 501-750g.
9865122|NCT00114543|Active Comparator|Conservative VLBW|In the Conservative group 2, infants with birth weights 751-1000g.
9865123|NCT00114608|Experimental|1|Electrical foot stimulation
9865124|NCT00114764|Experimental|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
9865125|NCT00114764|Active Comparator|filgrastim|Filgrastim given daily after induction chemotherapy
9865126|NCT00114790|Experimental|BNCT.|Boronophenylalanine-based BNCT.
9865127|NCT00114868|Active Comparator|Vitamin A|48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
9865128|NCT00114868|Placebo Comparator|Placebo|placebo
9865129|NCT00114881||Inner-city children with asthma|Children at high risk for developing allergic diseases and asthma, on the basis of a parental history of asthma, allergic rhinitis or atopic dermatitis, and residence in the inner city
9865130|NCT00114894|Experimental|Safe Sea|
9865131|NCT00114894|Sham Comparator|Placebo|Coppertone® SPF15 (Schering-Plough)
9865132|NCT00115128||Filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
9865133|NCT00115167|Experimental|Darbepoetin alfa|
9865134|NCT00115167|Placebo Comparator|Placebo|
9865135|NCT00115180||Hispanic|Hispanic patients with long bone fractures no intervention
9865136|NCT00115180||White|White patients with long bone fractures no intervention
9865137|NCT00115180||African-American|African-American patients with long bone fracture no intervention
9865138|NCT00115193|Active Comparator|Arm A|Pegfilgrastim
9865139|NCT00115193|Active Comparator|Arm B|Pegfilgrastim
9926829|NCT00886652|Experimental|Exercise|"The patients of the Exercise group were submitted to a four-month physiotherapy protocol, with three weekly sessions of 60 minutes each, accompanied by a physiotherapist, and consisting of warm-up, aerobic exercise on an electric treadmill, and then winding down and relaxation.~Each patient in this group was therefore submitted to an average of 48 sessions of exercises, always carried out at the same physiotherapy center."
9926830|NCT00886652|No Intervention|2|The patients of the control group were not submitted to any type of physical exercises. Like the patients submitted to the protocol, they were evaluated at the beginning, and again after four months.
9926831|NCT00886665|Placebo Comparator|Placebo|
9926832|NCT00886665|Experimental|JWHGWT|
9926833|NCT00886678|Experimental|1|patients receiving pemetrexed, carboplatin and radiation therapy.
9926834|NCT00886730|Experimental|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
9926835|NCT00886730|Experimental|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
9926836|NCT00886730|Experimental|Physicians endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
9926837|NCT00886756|Experimental|1|
9926838|NCT00886756|Placebo Comparator|2|
9926839|NCT00886808|Experimental|1|110 microgram dose of iCo-007 Intravitreal Injection
9865140|NCT00115232||1|Children without family history of early atherosclerosis
9865141|NCT00115232||2|Children with family history of early atherosclerosis.
9865142|NCT00115232||3|Parents of children without family history of early atherosclerosis
9865143|NCT00115232||4|Parents of children with family history of early atherosclerosis
9865144|NCT00115258|Experimental|parenteral nutrition titrated to measured REE|parenteral nutrition titrated to measured REE
9865145|NCT00115258|No Intervention|standard of care|
9865146|NCT00115323|Active Comparator|1|Problem solving intervention
9865147|NCT00115323|Active Comparator|2|Attention control intervention
9865148|NCT00115388|Other|Deferred screening control group|Samples from women in the control group were stored and tested at the end of the trial
9865149|NCT00115440|Experimental|A|Active treatment arm.
9865150|NCT00115453|Experimental|A|Active treatment arm.
9865151|NCT00115505||Ancillary-Correlative (QOL, employment, informal care cost)|Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form; Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30, EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48, and 60 months.
9865152|NCT00115531|Experimental|Arm 1|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
9865153|NCT00115531|Experimental|Arm 2|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
9865154|NCT00115544|Experimental|1|stannsoporfin 0.75mg/kg
9865155|NCT00115544|Experimental|2|stannsoporfin 1.5mg/kg
9865156|NCT00115544|Placebo Comparator|3|saline injection
9667033|NCT04042571|Experimental|Cerebral oxymetry monitoring (NIRS)|Cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools
9865157|NCT00115557|Experimental|1|Performance feedback, academic detailing, practice facilitation, IT support
9865158|NCT00115557|Active Comparator|2|Performance feedback only
9865159|NCT00115570|Experimental|Insulin Glulisine|Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
9865160|NCT00115570|Active Comparator|Insulin Lispro|Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
9865161|NCT00115596|Experimental|Intervention Arm|"'Formal Curriculum; Low-Fidelity Simulation'~Residents randomized to the intervention arm will receive the study skills training curriculum (the intervention)."
9865162|NCT00115596|No Intervention|Control|Residents randomized to the control arm will receive standard pediatric training.
9865163|NCT00115648|Active Comparator|A|Single dose NVP + ZDV daily for the first week.
9865164|NCT00115648|Experimental|C|Arm A plus NVP + ZDV daily to age 14 weeks.
9865165|NCT00115648|Experimental|B|Arm A plus oral NVP daily to age 14 weeks.
9865166|NCT00115687|Placebo Comparator|A|placebo
9865167|NCT00115687|Experimental|B|2 mg nicotine gum
9865168|NCT00115700|Experimental|Radiotherapy+ Chemotherapy|Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
9865169|NCT00115700|Active Comparator|Radiotherapy alone|Involved field Radiotherapy (30-36 GY) alone
9865170|NCT00115726|Experimental|1|furosemide
9865171|NCT00115726|Placebo Comparator|2|placebo
9865172|NCT00115791|Experimental|1|
9865173|NCT00115791|Placebo Comparator|2|
9865174|NCT00115856|No Intervention|Subjects studied|Single arm exploratory feasibility safety and efficacy study of MRI to image atherosclerosis in arteries
9865175|NCT00115882|Experimental|1|proactive smoking-cessation telephone counseling
9865176|NCT00115882|No Intervention|2|no-intervention control
9865177|NCT00115895|Experimental|Radioactive iodine 1,1 GBq|Low activity of radioiodine, 1,1 GBq
9865178|NCT00115895|Other|Radioactive iodine 3,7 GBq|Routine activity of radioiodine, 3,7 GBq
9865179|NCT00115960|Experimental|1|Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.
9865180|NCT00115960|Experimental|2|Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
9865181|NCT00115960|Experimental|3|Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
9865182|NCT00115960|Experimental|4|Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
9865183|NCT00115960|Experimental|5|In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
9865184|NCT00115960|Experimental|7|In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.
9865185|NCT00116129|Placebo Comparator|Placebo|Placebo
9865186|NCT00116181|Experimental|continuous therapy|Subjects will receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24.
9865187|NCT00116181|Active Comparator|intermittent therapy|Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
9865188|NCT00116350|Experimental|Misoprostol|800 mcg sublingual misoprostol
9865189|NCT00116350|Active Comparator|Oxytocin|40 IU Oxytocin IV
9865190|NCT00116376|Experimental|AEE788 + non EIACD|
9865191|NCT00116376|Experimental|AEE788 + EIACD|
9865192|NCT00116402|Active Comparator|1|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
9865193|NCT00116402|Active Comparator|2|salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID
9865194|NCT00116454|Experimental|lipiocis group|intra-arterial hepatic administration, one 2200 MBQ dose, duration of treatment 1 week
9865195|NCT00116454|No Intervention|control group|group untreated
9865196|NCT00116480|Experimental|Misoprostol|three tablets of active misoprostol (600 mcg) given sublingually
9865197|NCT00116480|Placebo Comparator|Placebo|three tablets resembling misoprostol given sublingually
9865198|NCT00116493|Other|1|Standard of care (Iron-folic acid + Deworming)
9865199|NCT00116493|Experimental|2|
9865200|NCT00116493|Experimental|3|
9865201|NCT00116493|Experimental|4|
9865202|NCT00116714||Observation|
9865203|NCT00116727||Drug|etanercept 50 mg/wk SC
9865204|NCT00116818|Experimental|Arm 1|
9865205|NCT00116883|Experimental|Arm 1|
9926840|NCT00886808|Experimental|2|350microgram dose of iCo-007 Intravitreal Injection
9926841|NCT00886808|Experimental|3|700microgram dose of iCo-007 Intravitreal Injection
9926842|NCT00886808|Experimental|4|1,000microgram dose of iCo-007 Intravitreal Injection
9926843|NCT00886847|Experimental|EBUS FNA vs FNC|
9926844|NCT00886860|Active Comparator|conventional oral misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 centimeters
9996957|NCT01504633|Experimental|DHA+EPA Group|DHA/EPA capsule (100mg DHA + 20mg) and placebo syrup per day
9865206|NCT00116922|Active Comparator|A|Avandamet [ Rosuglitazone 2 and Metformin 500]
9865207|NCT00116935|Active Comparator|1|1 year of adjuvant imatinib mesylate 400 mg/day orally
9865208|NCT00116935|Experimental|2|3 years of adjuvant imatinib mesylate 400 mg/day orally
9865209|NCT00116974|Experimental|1|
9865210|NCT00116974|Placebo Comparator|2|
9865211|NCT00116987|Other|1|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
9865212|NCT00116987|Other|2|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
9865213|NCT00117026|Experimental|Benfotiamine|Benfotiamine 300mg/day
9865214|NCT00117026|Placebo Comparator|Placebo|Placebo for benfotiamine
9865215|NCT00117052|Active Comparator|During dialysis visit|Cinacalcet is given during the dialysis visit
9865216|NCT00117052|Active Comparator|Post-dialysis meal|Cinacalcet is administered with a post-dialysis meal
9865217|NCT00117195||PD/PS|
9865218|NCT00117208|Experimental|1|
9865219|NCT00117208|Active Comparator|2|DNase daily for 12 weeks
9865220|NCT00117208|Other|3|combination
9865221|NCT00117273|Experimental|1|
9865222|NCT00117273|Active Comparator|2|
9865223|NCT00117273|Active Comparator|3|
9865224|NCT00117299|Experimental|A|PTK/ZK o.d. 1250 mg p.o.
9865225|NCT00117377|Experimental|1|Pimecrolimus
9865226|NCT00117377|Placebo Comparator|2|Placebo control twice daily application
9865227|NCT00117403|Experimental|1|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals
9865228|NCT00117403|Experimental|2|CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals
9865229|NCT00117403|Placebo Comparator|3|two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals
9865230|NCT00117442|Experimental|Pegfilgrastim 18 mg|Pegfilgrastim 18 mg given once for mobilization
9865231|NCT00117442|Active Comparator|Filgrastim|Filgrastim given daily for mobilization
9865232|NCT00117442|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for mobilization
9865233|NCT00117442|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for mobilization
9865234|NCT00117468|Experimental|1|
9865235|NCT00117468|Active Comparator|2|
9865236|NCT00117481|Experimental|1|
9865237|NCT00117481|Experimental|2|
9865238|NCT00117481|Placebo Comparator|3|
9865239|NCT00117611|Active Comparator|1|Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
9865240|NCT00117611|Placebo Comparator|2|placebo administered subcutaneously once or twice monthly
9865241|NCT00117689|Experimental|1|Standard (tacrolimus based standard therapy without induction)
9865242|NCT00117689|Active Comparator|2 Standard of Care|Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy
9865243|NCT00117741|Experimental|Dialectical Behavior Therapy|Participants receive standard dialectical behavior therapy and suboxone
9865244|NCT00117741|Active Comparator|Drug Counseling|Participants receive standard individual and group counseling and suboxone.
9865245|NCT00117767|Experimental|1|Terbinafine
9865246|NCT00117767|Active Comparator|2|Griseofulvin
9865247|NCT00117936|Experimental|1|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - high dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
9865248|NCT00117936|Experimental|2|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
9865249|NCT00117936|Placebo Comparator|3|Placebo solution void (not containing) Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141), given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
9865250|NCT00118066|Experimental|Arm I|Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
9865251|NCT00118066|Other|Arm II|Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
9865252|NCT00118105|Experimental|Chemotherapy + Surgery + Chemotherapy|"Preoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4~Conventional surgery: After 4 cycles of chemotherapy~Postoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4"
9865253|NCT00118170|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib once on day 1 and then once daily, twice daily, or every other day beginning on day 8 and continuing for 3 months. Patients are re-evaluated at 3 months. Patients with responding disease may continue study treatment in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients (per treatment cohort) receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
9865254|NCT00118183|Experimental|Arm I|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
9865255|NCT00118183|Experimental|Arm II|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
9865256|NCT00118222|Active Comparator|Low light dose during surgery|Arm I: During surgery, patients receive low light dose photodynamic therapy.
9865257|NCT00118222|Active Comparator|High light dose during surgery|Arm II: During surgery, patients receive high light dose photodynamic therapy.
9865258|NCT00118235|Experimental|Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)|Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9865259|NCT00118261|Experimental|Erlotinib, modified FOLFOX6, and bevacizumab|
9865260|NCT00118456|Experimental|1|Continuous daily dosing
9865261|NCT00118456|Experimental|2|Monday, Wednesday, Friday Dosing
9865262|NCT00118508|Placebo Comparator|A|Group A will receive active study drug
9865263|NCT00118547|Other|1|
9865264|NCT00118560|Experimental|1|treadmill walking and calf exercise
9865265|NCT00118573|Experimental|EVAR|AAA repair with endografting
9865266|NCT00118573|Active Comparator|Surveillance|Not AAA repair; surveillance
9865267|NCT00118612|Experimental|Therapeutic Regimen|
9865268|NCT00118612|Experimental|Intermediate dose|
9865269|NCT00118612|Experimental|Low dose|
9865270|NCT00118612|Placebo Comparator|Placebo|
9865271|NCT00118638|Experimental|Darbepoetin alfa 500 mcg - Group A|
9865272|NCT00118638|Active Comparator|Darbepoetin alfa 2.25 mcg/kg - Group B|
9865273|NCT00118651||Positive cases|"Positive radiographic findings were defined as the presence of a new air space opacities in the setting of acute respiratory symptoms. Patients with equivocal radiographic findings interpreted as possible pneumonia were considered positive cases"
9865274|NCT00118651||Control|Acute respiratory symptoms, negative chest radiographs, and a date of birth within five years of that of the positive case
9865275|NCT00118729|Experimental|Arm 1|
9926845|NCT00886860|Experimental|titrated oral misoprostol|misoprostol 20 micrograms oral every hour until cervical dilatation 3 centimeters
9926846|NCT00886873|Experimental|Group 1|Oral administration of mifepristone 5 mg daily for six months.
9926847|NCT00886873|Experimental|Group 2|Oral administration of mifepristone 10 mg daily for six months.
9926848|NCT00886886|Other|Reboxetine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9926849|NCT00886912|Active Comparator|Hypoxia|training in simulated altitude
9926850|NCT00886912|Placebo Comparator|Normoxia|training under normoxic conditions
9926851|NCT00886925|Active Comparator|Albumin|
9926852|NCT00886925|Placebo Comparator|Saline|
9926853|NCT00886951|Experimental|Access I123MNI388/I123MNI390 and brain imaging|
9926854|NCT00886964|Active Comparator|1|HBV ID
9926855|NCT00886964|Active Comparator|2|HBV IM
9926856|NCT00886990||1|Receiving a single PI boosted by low dose ritonavir
9926857|NCT00886990||2|Receiving two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
9926858|NCT00887003|Experimental|LV/LD 1|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
9926859|NCT00887003|Experimental|LV/HD 2|Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
9926860|NCT00887003|Experimental|HV/LD 3|High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
9926861|NCT00887003|Experimental|HV/HD 4|High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
9926862|NCT00887029|Active Comparator|DuoTrav|
9926863|NCT00887029|Active Comparator|Xalacom|
9926864|NCT00887042|Experimental|Fludarabine|
9926865|NCT00887081|Experimental|Interferon and Ribavirin|Patients with hemoglobinopathy will receive Interferon and Ribavirin
9926866|NCT00887094|Experimental|Aerobic exercise|One bout of aerobic physical training will be performed on a cycle ergometer for 50 min
9926867|NCT00887094|Experimental|Aerobic-resistance exercise|One bout of aerobic-resistance physical training will be performed on a cycle ergometer added by a strenght training for 50 min (total)
9926868|NCT00887107|Experimental|sorafenib|30 patients with non-radioiodine avid differentiated thyroid carcinoma
9926869|NCT00887120|Active Comparator|1|Lopinavir/ritonavir standard dose + zidovudine and lamivudine
9926870|NCT00887120|Active Comparator|2|Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine
9926871|NCT00887133||1|Patients consulting Western Medicine outpatient clinics for a new episode of illness
9926872|NCT00887172|Experimental|1|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took treatment of Jing Fang Bai Du san.
9865276|NCT00118846|Experimental|1|25 gm soy protein administered twice daily in equivalent dosages (12.5 gm)
9865277|NCT00118846|Placebo Comparator|2|Matching placebo
9865278|NCT00118872|Active Comparator|LGG yogurt|Lactobacillus (LGG) containing yogurt
9865279|NCT00118872|Placebo Comparator|Placebo yogurt|Regular yogurt, NOT containing LGG
9865280|NCT00118924|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination.
9865281|NCT00118924|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
9865282|NCT00118924|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm. A second placebo vaccination will be given 6 months after the first vaccination.
9865283|NCT00118937|Placebo Comparator|1|Single-blind placebo run-in period. Duration one month.
9865284|NCT00118937|Active Comparator|2|Metformin 2000 mg, double-masked randomized during 12 months.
9865285|NCT00118937|Placebo Comparator|3|Placebo, double-masked randomized during 12 months.
9865286|NCT00118950|Active Comparator|4|Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.
9865287|NCT00118950|Active Comparator|2|Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.
9865288|NCT00118950|Other|1|Run-in period: Treatment: Diet-only. Duration: One month.
9865289|NCT00118950|Other|3|Wash-out period: Treatment: Diet-only: Duration: One month.
9865290|NCT00118963|Active Comparator|3|BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
9865291|NCT00118963|Active Comparator|2|BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.
9865292|NCT00118963|Other|1|Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.
9865293|NCT00118989|Placebo Comparator|PLACEBO|placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
9865294|NCT00118989|Experimental|Curcuminoids C3 Complex® to be taken orally via caps|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
9865295|NCT00119002|Active Comparator|Dexamethasone|1mg of Dexamethasone/kg
9865296|NCT00119002|Placebo Comparator|Placebo|1mg/kg placebo
9865297|NCT00119028|Other|Arm 1|Non-experimental QI intervention - No comparator
9865298|NCT00119054|Other|Arm 1|
9865299|NCT00119067|Active Comparator|AVA 8-SQ|receive 8 injections of AVA SQ
9865300|NCT00119067|Experimental|AVA 8-IM|receive 8 injections of AVA IM
9865301|NCT00119067|Experimental|AVA 7-IM|receive 7 injections of AVA IM
9865302|NCT00119067|Experimental|AVA 5-IM|receive 5 injections of AVA IM
9865303|NCT00119067|Experimental|AVA 4-IM|receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42
9865304|NCT00119067|Placebo Comparator|Saline placebo IM or SQ|
9865305|NCT00119184|Experimental|External cephalic version with spinal anesthesia|External cephalic version with spinal anesthesia
9865306|NCT00119184|Active Comparator|External cephalic version without spinal anesthesia|External cephalic version without spinal anesthesia
9865307|NCT00119197|Experimental|1|Killed Whole Cell Oral Cholera Vaccine
9865308|NCT00119197|Placebo Comparator|2|Heat-killed E. coli
9865309|NCT00119210|Placebo Comparator|Placebo|Sugar pill
9865310|NCT00119210|Experimental|Bupropion SR|
9865311|NCT00119236|Experimental|Arm I|Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.
9865312|NCT00119249|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9865313|NCT00119444|Other|periacetabular osteotomy|
9865314|NCT00119496|Active Comparator|Group 1|Inhaled beclomethasone (400mcg/day)
9865315|NCT00119496|Active Comparator|Arm 2|Rosiglitazone
9865316|NCT00119496|Active Comparator|Arm3|Oral theophylline
9865317|NCT00119496|Active Comparator|Arm 4|Oral theophylline and inhaled beclomethasone
9865318|NCT00119522||Group 1|cohort is of individuals with a spinal cord injury who use a wheelchair as their primary means of mobility
9865319|NCT00119535|Other|Arm 1|
9865320|NCT00119548|Other|Arm 1|Randomized, controlled trial with three intervention models: Model A (traditional counseling/testing);
9865321|NCT00119548|Other|Arm 2|Model B (nurse-initiated screening, traditional counseling/testing);
9865322|NCT00119548|Other|Arm 3|Model C (nurse-initiated screening, streamlined counseling/rapid testing).
9865323|NCT00119561|Experimental|Arm 1|Telephone support groups
9865324|NCT00119561|No Intervention|Arm 2|Usual VA care
9865325|NCT00119574|Other|Arm 1|
9865326|NCT00119613|Experimental|Group 1 - darbepoetin alfa|Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
9865327|NCT00119613|Placebo Comparator|Group 2 - Placebo|Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
9865328|NCT00119639|Experimental|Arm 1|
9865329|NCT00119691|Experimental|Nesiritide + standard of care|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
9865330|NCT00119691|Active Comparator|Standard of care|Standard of care until adequate diuresis achieved
9865331|NCT00119717|Experimental|1|
9865332|NCT00119717|Active Comparator|2|
9865333|NCT00119730|Experimental|Fludarabine, Mitoxantrone, Rituximab, Zevalin|Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression.
9865334|NCT00119769|Placebo Comparator|1|
9865335|NCT00119769|Active Comparator|2|
9865336|NCT00119782|Experimental|1|Comprehensive worksite intervention
9865337|NCT00119782|Experimental|2|Delayed intervention control group
9865338|NCT00119795|Active Comparator|Health education control|This is an education program for older adults entitles, successful aging.
9865339|NCT00119795|Experimental|Exercise Only|Structured exercise 150 min/wk
9865340|NCT00119795|Experimental|Weight Loss|Behavioral weight loss; goal of 7%
9865341|NCT00119821|Experimental|I|Behavioral Weight Reduction
9865342|NCT00119821|Other|II|Exercise
9865343|NCT00119821|Other|III|Smoking Cessation
9865344|NCT00119925|Active Comparator|minimal intervention|professional audit and feedback on current practice
9865345|NCT00119925|Active Comparator|maximal intervention|multi-faceted intervention consisting of professional and patient elements
9865346|NCT00119977|Active Comparator|1|
9865347|NCT00120003|Experimental|Candesartan Cilexetil|Candesartan Cilexetil
9865348|NCT00120003|Placebo Comparator|Placebo|Placebo
9865349|NCT00120016|Experimental|1|Mediterranean diet
9865350|NCT00120016|No Intervention|2|non-intervention diet
9865351|NCT00120068|Other|Arm 1|
9865352|NCT00120081|Experimental|Low dose|10 mcg Na-ASP-2/Alhydrogel
9865353|NCT00120081|Experimental|Medium dose|50 mcg Na-ASP-2/Alhydrogel
9865354|NCT00120081|Experimental|High dose|100 mcg Na-ASP-2/Alhydrogel
9865355|NCT00120081|Placebo Comparator|Saline placebo|Saline placebo
9865356|NCT00120120|Experimental|1|
9865357|NCT00120120|Experimental|2|
9865358|NCT00120211|Experimental|Radiotherapy: 6 Fractions|
9865359|NCT00120211|Active Comparator|Radiotherapy: 5 fractions|
9865360|NCT00120302|Experimental|1|Pimecrolimus
9865361|NCT00120302|Placebo Comparator|2|Vehicle
9865362|NCT00120315|No Intervention|esomeprazole|Long-term users continue antisecretory medication
9865363|NCT00120315|Placebo Comparator|placebo drug|Long-term users are treated with placebo
9865364|NCT00120380|Active Comparator|Aerosolized Iloprost|
9865365|NCT00120380|Placebo Comparator|Bosentan monotherapy|
9865366|NCT00120432|Active Comparator|A|single dose vs three doses of 1%tropicamide and 10%phenylephrine
9865367|NCT00120445|Active Comparator|2|air vs perfluoropropane gas in pneumatic retinopexy
9865368|NCT00120458|Experimental|1|Anxiolytic Therapy
9865369|NCT00120458|Placebo Comparator|2|Anxiolytic Therapy
9865370|NCT00120471|Experimental|1|Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.
9996958|NCT01504633|Experimental|Fe Group|Placebo capsule and Fe syrup (16mg elemental iron) per day
9517857|NCT03302221|Experimental|Paravertebral Block Group|In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.
9865371|NCT00120471|Experimental|2|Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
9865372|NCT00120471|Experimental|3|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
9865373|NCT00120471|Experimental|4|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
9926873|NCT00887172|Placebo Comparator|2|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took placebo of Jing Fang Bai Du san.
9926874|NCT00887172|Experimental|3|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took treatment of Ying Qiao san.
9926875|NCT00887172|Placebo Comparator|4|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took placebo of Ying Qiao san.
9926876|NCT00887185|Active Comparator|1 - Traditional training|Temporal bone dissection training in cadaveric laboratory. Subjects are provided 2 cadaveric temporal bones and asked to spend 2 weeks practicing the surgical technique of complete mastoidectomy with facial recess approach.
9926877|NCT00887185|Experimental|2 Simulator training|Subjects perform temporal bone surgical dissection training on a simulator.
9926878|NCT00887211|Active Comparator|ProStent|implant ProStent drug-eluting stents
9926879|NCT00887211|Active Comparator|Firebird|implant Firebird drug-eluting stents
9926880|NCT00887237|Experimental|TRIV|Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)
9926881|NCT00887237|Active Comparator|BIV|Conventional cardiac resynchronization
9926882|NCT00887263|Experimental|A|
9926883|NCT00887263|Placebo Comparator|B|
9926884|NCT00887276|Active Comparator|Moxifloxacin|
9926885|NCT00887276|Active Comparator|Ampicillin; Amoxicillin|
9926886|NCT00887302||1|Gastric Band
9926887|NCT00887302||2|Gastric Sleeve
9926888|NCT00887302||3|Gastric Bypass with PEG tube
9926889|NCT00887328|Experimental|IV tPA|intravenous tissue plasminogen activator
9926890|NCT00887328|Placebo Comparator|Placebo|
9926891|NCT00887367|Placebo Comparator|Placebo to match GSK598809|Placebo to match GSK598809.
9926892|NCT00887367|Placebo Comparator|Placebo to match ethanol infusion|Glucose solution to be given in the same way as ethanol.
9926893|NCT00887380|Active Comparator|Arm A: Concurrent|Investigational treatment: Anastrozole commenced before (Pre-radiotherapy commencement of anastrozole) and continued during radiotherapy.
9926894|NCT00887380|Active Comparator|Arm B: Sequential|Standard Treatment: Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (Post radiotherapy commencement of anastrozole)
9926895|NCT00887393|Other|Low carbohydrate|Low carbohydrate pre-bariatric surgery diet
9926896|NCT00887393|Other|Low fat|Low fat pre-bariatric surgery diet
9926897|NCT00887406|Experimental|Cohort 1, Period 2|GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
9926898|NCT00887406|Experimental|Cohort 1, period 1|Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
9926899|NCT00887406|Experimental|Cohort 1, period 3|GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
9926900|NCT00887406|Experimental|Cohort 1, period 4|GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
9926901|NCT00887406|Experimental|Cohort 2, period 1|Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
9926902|NCT00887406|Experimental|Cohort 2, period 2|GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
9926903|NCT00887406|Experimental|Cohort 2, period 3|GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
9926904|NCT00887406|Experimental|Cohort 2, period 4|GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
9926905|NCT00887406|Experimental|Cohort 3|GSK961081 100mcg or Placebo
9926906|NCT00887406|Experimental|Cohort 4|GSK961081 300mcg or Placebo
9935271|NCT03958643||1|In a population of adult patients with SCD we will comprehensively evaluate renal function.
9935272|NCT03958630|Experimental|PET scan|Healthy and Patients
9935273|NCT03956043||Patients with suspected sepsis in Emergency Department|Patients with suspected sepsis treated by the sepsis emergency team or the medical emergency team in the Emergency Department of Oslo University Hospital Oslo are included prospectively.
9935274|NCT03955068|Other|Strict Classic Ketogenic Diet Arm|The classic ketogenic diet is individually calculated for each patient based on age, weight, and nutritional needs. The diet is typically administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates. The basis of calculations is first on the amount of required protein needed to meet RDA to insure adequate growth. Fine tuning of ketogenic diet therapy is based on serum beta-hydroxybutyrate levels (target levels of 3.5-6.5 mmol/L), tolerance of the diet, and response to treatment.
9935275|NCT03952637|Experimental|1|In Stage 1, up to 5 Type II subjects will receive 1.5E13 vg /kg of the gene transfer agent, and asentinel Type II subject will receive 4.5E13 vg/kg of the gene transfer agent. In Stage 1, up to 3 Type I subjects will receive 1.5E13 of the gene transferagent (Cohort 1) and then up to 3 subjects will receive 4.5E13 of the gene transfer agent (Cohort 2).
9996959|NCT01504633|Experimental|DHA/EPA+Fe Group|DHA/EPA capsule (100mg DHA + 20mg) and Fe syrup (16mg elemental iron) per day
9865374|NCT00120510|Experimental|A|Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
9865375|NCT00120510|Active Comparator|B|Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3
9865376|NCT00120796|Active Comparator|1|Lamivudine alone
9865377|NCT00120796|Experimental|2|Lamivudine + Vaccine
9865378|NCT00120965|Experimental|1|Autopulse device
9865379|NCT00120965|Active Comparator|2|Manual CPR
9865380|NCT00121095|Other|1|
9865381|NCT00121212|Active Comparator|Surgery - Negative PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
9865382|NCT00121212|Experimental|Surgery - Positive PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
9865383|NCT00121212|Active Comparator|Radiation therapy Negative or Positive PET scan|If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
9865384|NCT00121264|Experimental|Treatment (sorafenib tosylate, tanespimycin)|Patients receive oral sorafenib twice daily on days -14 to 28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive 17-AAG IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9865385|NCT00121277|Experimental|SAHA (Suberoylanilide Acid) with Capecitabine|
9865386|NCT00121290|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9865387|NCT00121303|Active Comparator|Arm A low dose Dauno|Induction 45 mg Dauno
9865388|NCT00121303|Experimental|ARM B high dose Dauno|Induction 90 mg Dauno
9865389|NCT00121303|No Intervention|Arm 1 no further treatment|
9865390|NCT00121303|Experimental|Arm 2 Mylotarg|Post induction treatment with Mylotarg
9865391|NCT00121316|Experimental|1|Pimecrolimus
9865392|NCT00121316|Placebo Comparator|2|Matching vehicle cream (placebo)
9865393|NCT00121381|Experimental|1|Pimecrolimus 1 % cream plus topical corticosteroid (TCS)
9865394|NCT00121381|Placebo Comparator|2|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
9865395|NCT00121394|Experimental|Chlorhexidine|
9865396|NCT00121524|Experimental|IV yes|Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
9865397|NCT00121524|No Intervention|IV no|The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.
9865398|NCT00121550|Experimental|Clarithromycin|Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
9865399|NCT00121550|Placebo Comparator|Placebo|Placebo comparator
9865400|NCT00121602|Active Comparator|Roller bottle|
9865401|NCT00121602|Experimental|Serum free|
9865402|NCT00121654|Active Comparator|1|paresthesic SCS
9865403|NCT00121654|Active Comparator|2|subliminal SCS (75-80% of paresthesic threshold)
9865404|NCT00121654|Sham Comparator|3|low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)
9865405|NCT00121680|Experimental|1|
9865406|NCT00121693|Experimental|Music Listening 1|Intervention: Listen to Music type 1
9865407|NCT00121693|Experimental|Music Listening 2|Intervention: Listen to Music type 2
9865408|NCT00121693|Experimental|Music LIstening 3|Intervention: Listen to Music type 3
9865409|NCT00121693|No Intervention|Control|Intervention: Listen to White noise
9865410|NCT00121732|Experimental|A|
9865411|NCT00121732|Experimental|B|
9865412|NCT00121745|Experimental|1|
9865413|NCT00121745|Experimental|2|
9865414|NCT00121745|Experimental|3|
9865415|NCT00121745|Experimental|4|
9865416|NCT00121784|Experimental|1|1
9865417|NCT00121875||Turner syndrome|Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
9865418|NCT00121875||Control / idiopathic short stature|Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy
9865419|NCT00121940|Experimental|Guided Care|
9865420|NCT00121940|No Intervention|Usual Care|
9865421|NCT00122018|Experimental|NAC|N-acetylcysteine started day prior to surgery, continued through night of surgery
9865422|NCT00122018|Experimental|fenoldopam|fenoldopam started at surgery continued for 24 hours
9865423|NCT00122018|Experimental|NAC and fenoldopam|Both N-acetylcysteine and fenoldopam as above
9865424|NCT00122018|Placebo Comparator|Control|Placebo
9865425|NCT00122031|Experimental|DBS|
9865426|NCT00122070|Experimental|A|Quetiapine at dosage of 50 to 150 mg
9926907|NCT00887419|Experimental|Coping Skills Training|Coping Skills Training in pain management
9926908|NCT00887419|Active Comparator|Education|Chronic Pain Education
9926909|NCT00887419|No Intervention|Usual Care|Patients receive no study intervention, continue with usual medical care.
9926910|NCT00887445|Experimental|A|
9926911|NCT00887445|Placebo Comparator|B|
9926912|NCT00887497|Experimental|Catheterization|Patients receive angioembolization prior to surgery
9926913|NCT00887523|Experimental|1|prone intensity-modulated radiotherapy
9926914|NCT00887523|Active Comparator|2|supine intensity-modulated radiotherapy
9926915|NCT00887601|Experimental|Part I|Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.
9926916|NCT00887601|Experimental|Part II|Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
9926917|NCT00887614|Experimental|MBSR|Participation will involve online completion of a questionnaire survey before and after the Mindfulness-Based Stress Reduction (MBSR) intervention. Specifically, research study participants will complete validated self-report measures to assess mindfulness, cognitive-emotional processes, sleep quality, symptoms of stress, sense of spirituality, and quality of life before and after the MBSR intervention.
9926918|NCT00887627|Experimental|1. Mild Renal Function Impaired Subjects|
9926919|NCT00887627|Experimental|2. Moderate Renal Function Impaired Subjects|
9926920|NCT00887627|Experimental|3. Subjects with Normal Renal Function|
9926921|NCT00887705|No Intervention|1: Standard rehabilitation programme|
9926922|NCT00887705|Experimental|2. Additional ADL training|
9926923|NCT00887718|Experimental|PET scan for lymphoma assessment|
9926924|NCT00887731||Part 1 group|Observational study with a convenience sample of ten (10) patients. PART 1 will end when at least 3 of 4 consecutive patients achieve the goal of less than six (6) operator required interruptions per hour for oxygen saturation deviations from study guidelines, or at ten (10) patients.
9926925|NCT00887731||Part 2 group|(After successful completion of PART 1) Within patient cross-over study with a randomized cross-over sequence. Sequential data analysis methods will be used to help minimize the patient sample size which will be no more than twenty (20) patients plus up to a maximum of seven (7) who might be eligible from PART 1.
9926926|NCT00887731||Part 3 Group|(After successful completion of PART 2) Within patient cross-over study with a randomized cross-over sequence. Studies will last 4 to 12 hours divided in two (2) equal time blocks with one cross-over to either automatic or manual control modes.
9926927|NCT00887757|Experimental|gemcitabine +ABT-263|
9926928|NCT00887770|Experimental|A|600mg AZD5672 + Moxifloxacin placebo
9926929|NCT00887770|Experimental|B|100mg AZD5672 + Moxifloxacin placebo
9517858|NCT03302221|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
9517859|NCT03302208|Active Comparator|pregabalin group|
9926930|NCT00887770|Active Comparator|C|AZD5672 placebo + Moxifloxacin 400mg
9926931|NCT00887770|Placebo Comparator|D|AZD5672 placebo + Moxifloxacin placebo
9926932|NCT00887835|Experimental|PERPOS™ PLS|Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
9926933|NCT00887848|Experimental|Lokomat training|Lokomat training
9926934|NCT00887848|Other|Waiting list|Lokomat training after waiting phase of 5 weeks
9926935|NCT00887861|Experimental|BGG492|
9865427|NCT00122122|Other|Arm 1|
9865428|NCT00122148|Other|1|
9865429|NCT00122161|Other|Arm 1|
9865430|NCT00122174|Other|Arm 1|
9865431|NCT00122343|Experimental|1|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
9865432|NCT00122356|Other|Anastrozole and alendronate|Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
9865433|NCT00122408|Active Comparator|1|
9865434|NCT00122408|Placebo Comparator|2|
9865435|NCT00122421|Active Comparator|pharmacist recommendation|recommendations based on chart review by pharmacist, given to pcp at time of visit
9865436|NCT00122421|No Intervention|usual care|usual care
9865437|NCT00122603|Experimental|Group 1|Atazanavir + Fosamprenavir + ritonavir
9865438|NCT00122603|Experimental|group 2|Atazanavir + saquinavir + ritonavir
9865439|NCT00122616|Active Comparator|Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy|Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
9865440|NCT00122616|Placebo Comparator|HIV antiretroviral therapy|Day0 to week 96: HIV antiretroviral therapy
9865441|NCT00122642|Experimental|1|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes for patients not in the hospital.
9865442|NCT00122642|Placebo Comparator|2|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
9865443|NCT00122746|Active Comparator|Radiotherapy alone|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
9865444|NCT00122746|Experimental|Radiotherapy plus Chemotherapy|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
9865445|NCT00122772|Experimental|EBR plus 2 HDBT fractions|External Beam Radiotherapy High Dose Brachytherapy (2 fractions of 9Gy)
9865446|NCT00122772|Active Comparator|EBR plus 4 fractions HDBT|External Beam Radiotherapy High Dose Brachytherapy (4 fractions of 7Gy)
9865447|NCT00122772|Experimental|EBR/2 HDBT fractions/Chemotherapy|"External Beam Radiation~High Dose Brachytherapy (2 fractions of 9Gy)~Cisplatin"
9865448|NCT00122772|Experimental|EBR/4 fractions HDBT/chemotherapy|"External Beam Radiation~High Dose Brachytherapy (4 fractions of 7Gy)~Cisplatin"
9865449|NCT00122928|Experimental|High intensity environmental intervention|Intense intervention
9865450|NCT00122928|Experimental|Moderate intensity environmental intervention|Moderate intervention
9865451|NCT00122928|No Intervention|Individual intervention only|Control
9517860|NCT03302208|Placebo Comparator|placebo group|
9865452|NCT00122993|Experimental|1|Multi-component environmental intervention to prevent excess weight gain among bus drivers
9865453|NCT00122993|No Intervention|2|Control group
9865454|NCT00123006|Active Comparator|1|Dietary Approaches to Stop Hypertension (DASH)
9865455|NCT00123006|Placebo Comparator|2|Control diet
9865456|NCT00123019|Active Comparator|1|Minimal intervention; annual weight/waist assessment, questionnaire, and advice
9865457|NCT00123019|Experimental|2|Intensive intervention. All arm 1 activities plus ongoing environmental and group interventions in worksite for two years.
9865458|NCT00123032|Experimental|1|This group will focus on improving their diet and increasing physical activity at home and at school.
9865459|NCT00123032|No Intervention|2|A control group will not receive any intervention.
9865460|NCT00123058|Experimental|Nurse administered|"Nurse Administered Intervention:~Subject received nurse administered behavioral intervention every 8 weeks via telephone for 24 months."
9865461|NCT00123058|Experimental|Nurse & BP monitor|Subjects received both a nurse administered behavioral intervention via telephone every 8 weeks for 24 months and a study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
9865462|NCT00123058|No Intervention|Usual Care|Subjects received neither home BP monitor nor nurse phone intervention.
9865463|NCT00123058|Experimental|Home BP Monitor|Subject received study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
9865464|NCT00123084|Experimental|Voice/Respiratory Treatment|4 Days a week for 4 weeks with focus on high intensity voice exercises
9865465|NCT00123084|Experimental|Articulation Treatment|4 days a week for 4 weeks with focus on high intensity articulation tasks
9865466|NCT00123084|No Intervention|Subjects with PD in a no treatment group|Subjects do not receive therapy during experimental phases, and will be offered therapy at the end of the study enrollment period.
9865467|NCT00123084|No Intervention|Healthy Control Subjects|Subjects are without Parkinson disease and will not receive therapy.
9865468|NCT00123097|Experimental|Chlorinated polyethylene elastomer first|Patient receives prosthetic made from CPE then the SOC, silicon.
9865469|NCT00123097|Active Comparator|Silicon first|Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.
9865470|NCT00123188|Experimental|Ultrasound and Biopsy|Transvaginal Ultrasound and Endometrial Biopsy
9865471|NCT00123240|Active Comparator|High Fat/Protein Diet|
9865472|NCT00123240|Active Comparator|High Carbohydrate Diet|
9865473|NCT00123266|Experimental|Active|
9865474|NCT00123279|Experimental|1|
9865475|NCT00123279|Experimental|2|
9865476|NCT00123279|Experimental|3|
9865477|NCT00123279|Experimental|4|
9865478|NCT00123279|Experimental|5|
9865479|NCT00123279|Experimental|6|
9865480|NCT00123292|Experimental|1|
9865481|NCT00123292|Experimental|2|
9865482|NCT00123292|Experimental|3|
9865483|NCT00123292|Experimental|4a|
9865484|NCT00123292|Experimental|4b|
9865485|NCT00123305|Experimental|1|
9865486|NCT00123305|Experimental|2|
9865487|NCT00123305|Experimental|3|
9865488|NCT00123305|Placebo Comparator|4|
9865489|NCT00123318|Experimental|1|Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)
9865490|NCT00123357||Group 1|
9865491|NCT00123396|Experimental|Arm 1|Test the effectiveness of the BioCASES teaching modules by way of a randomized controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for increasing and sustaining VA clinician knowledge, skills, and ability to respond to bioterrorism events.
9865492|NCT00123435|Active Comparator|Arm 1|5-session nutritional counseling program
9865493|NCT00123435|Experimental|Arm 2|5-session nutritional counseling program + simple pedometer feedback
9865494|NCT00123435|Experimental|Arm 3|5-session nutritional counseling program + simple pedometer feedback + enhanced pedometer feedback web-based feedback
9865495|NCT00123500|Active Comparator|1|Worksite Intervention
9865496|NCT00123500|Placebo Comparator|2|Control Group
9865497|NCT00123513|Experimental|1|Worksite intervention for obesity prevention
9865498|NCT00123513|No Intervention|2|Control group
9865499|NCT00123526|Experimental|1|Worksite intervention
9865500|NCT00123526|No Intervention|2|Receive no intervention
9865501|NCT00123552|Experimental|1|
9865502|NCT00123552|Experimental|2|
9865503|NCT00123552|Experimental|3|
9865504|NCT00123578|Experimental|Lorazepam|Lorazepam for the treatment of mild GHB withdrawal.
9865505|NCT00123578|Active Comparator|Pentobarbital|Pentobarbital for the treatment of mild GHB withdrawal.
9865506|NCT00123617|Experimental|Phase III cardiac rehabilitation|Phase III group-based cardiac rehabilitation classes, weekly
9865507|NCT00123617|No Intervention|Monitoring|Normal daily living, no extra visits to study centre
9865508|NCT00123656|Active Comparator|1|fluticasone
9865509|NCT00123656|Active Comparator|2|esomeprazole
9865510|NCT00123669|No Intervention|Control|Patient will not receive Inj Progesterone 500 mg
9865511|NCT00123669|Experimental|Treatment|An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.
9926936|NCT00887861|Placebo Comparator|Placebo|
9926937|NCT00887874||A|
9926938|NCT00887887||liver surgery|patients with benign or malignant hepatobiliary disease requiring partial hepatic resection
9926939|NCT00887900|Experimental|1|Submitted to deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
9926940|NCT00887900|Active Comparator|2|Submitted to regular penetrating keratoplasty
9926941|NCT00887952|Experimental|1|Partial removal of carious dentine. Carious dentine partial removal plus restoration in one session. The group is divided according to the filling material: amalgam or resin.
9926942|NCT00887952|Active Comparator|2|Stepwise excavation: Carious dentine removal performed in 2 steps: partial removal of carious dentine, indirect pulp capping (calcium hydroxide cement); temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling (amalgam or resin).
9926943|NCT00887991||Electric Pump 1 (ISIS Duo iQ Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
9926944|NCT00887991||Electric Pump 2 (Medela Symphony Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
9926945|NCT00888004|Experimental|Active|
9926946|NCT00888004|Placebo Comparator|Placebo|
9926947|NCT00888017||PPI group|This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
9926948|NCT00888017||non-PPI group|These infants did not receive PPIs during their hospital stay.
9926949|NCT00888030||2|CKD patients with normal p-cresol
9926950|NCT00888030||3|CKD patient with normal indoxyl sulfate
9926951|NCT00888030||4|CKD patients with high indoxyl sulfate
9865512|NCT00123838|Experimental|Single Group Assignment|Calypso® 4D Localization System
9865513|NCT00123916|Experimental|Benznidazole|40 - 80 days (according to body weight) treatment with benznidazol
9865514|NCT00123916|Placebo Comparator|Placebo|40 - 80 days (according to body weight) treatment with matching placebo
10210368|NCT05214898||Immediate Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
10213682|NCT03541499|Placebo Comparator|Group 3|800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15
9865515|NCT00123929|Active Comparator|1|doxorubicin
9865516|NCT00123929|Other|2|docetaxel
9865517|NCT00123981|Active Comparator|CCABG|Coronary artery bypass surgery using cardiopulmonary bypass
9865518|NCT00123981|Experimental|OPCAB|Coronary artery bypass surgery NOT using cardiopulmonary bypass
9865519|NCT00124046|Active Comparator|Surgical|
9865520|NCT00124046|Active Comparator|Medical Treatment|
9865521|NCT00124059|Experimental|Type A SERO|
9865522|NCT00124059|Experimental|Type B SERO|
9865523|NCT00124059|Placebo Comparator|Type A PLA|
9865524|NCT00124059|Placebo Comparator|Type B PLA|
9865525|NCT00124124|Experimental|1|KLH and peptide pulsed DCs
9865526|NCT00124124|Experimental|2|KLH, peptides plus Montanide
9865527|NCT00124150|Experimental|M|Intravenous magnesium sulfate infusion for 14 days.
9865528|NCT00124150|No Intervention|S|Saline infusion without additional magnesium sulfate.
9865529|NCT00124189|Other|open label|Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
9865530|NCT00124202|Placebo Comparator|a fatty meal vs normal saline|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
9865531|NCT00124228|No Intervention|1|Antibiotic following hospital Protocols according the cause of the infection .
9865532|NCT00124228|Active Comparator|2|Antibiotic following hospital Protocols according the cause of infection plus albumin
9865533|NCT00124254|Experimental|1|Surgical group undergoing SMPA
9865534|NCT00124254|Active Comparator|2|Nosurgical group
9865535|NCT00124280|Experimental|previously treated with chemotherapy only|patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI
9865536|NCT00124280|Experimental|previously treated with chemotherapy + small|patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
9865537|NCT00124293||Factor VII|
9865538|NCT00124306|Active Comparator|1|Amitryptiline
9865539|NCT00124306|Placebo Comparator|2|Placebo will be dosed exactly as active arm.
9865540|NCT00124319||1|Incoming cadets at the U.S. Naval, Air Force, or Military Academies
9865541|NCT00124345|Experimental|1|
9865542|NCT00124501|Active Comparator|SMT|Standard Medication Treatment
10213683|NCT03541499|Experimental|Group 4|800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5
9865543|NCT00124501|Experimental|BART|Biofeedback-assisted Relaxation Training plus SMT
9865544|NCT00124540|Placebo Comparator|1|placebo resembling misoprostol
9865545|NCT00124540|Experimental|2|misoprostol
9865546|NCT00124566|Experimental|1|Irofulven + prednisone
9865547|NCT00124566|Experimental|2|Irofulven + capecitabine + prednisone
9865548|NCT00124566|Active Comparator|3|Mitoxantrone + prednisone
9865549|NCT00124605|Experimental|Treatment (pamidronate disodium and arsenic trioxide)|Patients receive pamidronate IV and over 2 hours on days 1 and 15 and arsenic trioxide IV over 2 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9865550|NCT00124683|Experimental|1|Nicotine Patch + Bupropion
9865551|NCT00124683|Placebo Comparator|2|Nicotine patch + placebo
9865552|NCT00124722|Experimental|0.45 mg/kg Zemuron|0.45 mg/kg Zemuron
9865553|NCT00124722|Active Comparator|0.6 mg/kg Zemuron|0.6 mg/kg Zemuron
9865554|NCT00124722|Experimental|1.0 mg/kg Zemuron|1.0 mg/kg Zemuron
9865555|NCT00124761|Other|Surgery + Whole Brain Radiotherapy|
9865556|NCT00124761|Experimental|RadioSurgery + Whole Brain Radiotherapy|
9865557|NCT00124787|Experimental|Dimenhydrinate|dimenhydrinate PO x 4 doses
9865558|NCT00124787|Placebo Comparator|Placebo|placebo PO x 4 doses
9865559|NCT00124839|Other|1|Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
9865560|NCT00124839|Other|2|Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
9865561|NCT00124839|Other|3|Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
9865562|NCT00124839|Other|4|Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)
9865563|NCT00124852|Placebo Comparator|High Oleic Sunflower Oil|
9865564|NCT00124852|Active Comparator|400 mg EPA+DHA/day|low dose fish oil
9865565|NCT00124852|Active Comparator|1800 mg EPA+DHA/day|high dose fish oil
9865566|NCT00124878|Active Comparator|Arm 1 Male circumcision|Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
9865567|NCT00124878|No Intervention|Arm 2|Men wait for two years of follow up before being offered male circumcision
9865568|NCT00124969|Active Comparator|1|Amlodipine
9865569|NCT00124969|Placebo Comparator|2|Placebo
9996960|NCT01504633|Experimental|Placebo Group|Placebo capsule and placebo syrup
9865570|NCT00125008|Experimental|1|Typhoid Vi vaccine
9865571|NCT00125008|Active Comparator|2|Hepatitis A vaccine
9865572|NCT00125047|Experimental|1|Typhoid Vi polysaccharide vaccine
9865573|NCT00125047|Active Comparator|2|Inactivated Hepatitis A vaccine
9865574|NCT00125216|Other|Arm 1|Single subject design - participant receives three administrations of the same treatment
9865575|NCT00125255|Experimental|S-Caine Peel|
9865576|NCT00125255|Placebo Comparator|Placebo Peel|
9865577|NCT00125385|Experimental|Cohort 1|Dose group
9865578|NCT00125385|Experimental|Cohort 2|Dose Group
9865579|NCT00125385|Experimental|Cohort 3|Dose Group
9865580|NCT00125385|Experimental|Cohort 4|Dose Group
9865581|NCT00125385|Experimental|Cohort 5|Dose Group
9926952|NCT00888030||1|CKD patients with high p cresol
9926953|NCT00888043|Other|I|CNTO 95 and avastin
9926954|NCT00888056|Experimental|ARM A|Bilateral chronic electrical stimulation of the hypothalamus/fornix
9926955|NCT00888069|Experimental|Low Dose CTAP101 Capsules|CTAP101 Capsules, 450 mcg dose
9926956|NCT00888069|Experimental|High Dose CTAP101 Capsules|CTAP101 Capsules, 900 mcg dose
9926957|NCT00888069|Experimental|CTAP101 Injection|IV injection, 448 mcg dose
9926958|NCT00888082|No Intervention|A|Patients receiving only adjuvant chemotherapy
9926959|NCT00888082|Experimental|B|Patient receiving goserelin acetate along with adjuvant chemotherapy
9926960|NCT00888095|Experimental|1|caudal Zona incerta (cZI)
9926961|NCT00888095|Experimental|2|Nucleus subthalamicus (STN)
9926962|NCT00888108|Experimental|docetaxel +ABT-263|
9926963|NCT00888147||Fiber formula|This group will receive tube feeding formula that contains fiber.
9926964|NCT00888186|Active Comparator|1. Duodopa optimal dose|
9926965|NCT00888186|Experimental|2. Duodopa 20% too high dose|
9926966|NCT00888186|Experimental|3. Duodopa 10% too low dose|
9926967|NCT00888186|Experimental|4. Duodopa 20% too low dose|
9926968|NCT00888186|Experimental|5. Duodopa 10% too high dose|
9926969|NCT00888199|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
9926970|NCT00888199|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
10210369|NCT05214898||Delayed-Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
10210370|NCT05214872||PREDIALYSIS GROUP|(n = 48) - patients in the pre-dialysis period (stages G3b-G4 of chronic kidey disease (CKD)) with moderate or severe decrease in estimated glomerular filtration rate (eGFR) (eGFR 44-29 ml/min/1.73 m^2)
10210371|NCT05214872||END-STAGE RENAL DISEASE (ESRD) GROUP|"Patients with ESRD (n=106) - (eGFR <15 ml/min /1.73 m^2) undergoing renal replacement therapy have formed this group.~Depending on the method of renal replacement therapy used, two subgroups have been distinguished: (1) peritoneal dialysis (PD) subgroup (n=35) including patients treated by peritoneal dialysis. In this subgroup, due to the treatment technique, two groups have been distinguished, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique and a group (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), (2) hemodialysis (HD) subgroup (n = 71) including patients treated with repeated hemodialysis. The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers. The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min."
9926971|NCT00888212|Experimental|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
9926972|NCT00888225|Experimental|Eccentric exercise|Group exposed to eccentric exercise treatment
9926973|NCT00888225|Active Comparator|Concentric exercise|Group exposed to concentric exercise treatment
9926974|NCT00888251||Comprehensive weight management program|
9926975|NCT00888290|Experimental|Single arm|Crossover design. Participants will be getting either placebo or different doses of sodium bicarbonate during the study.
9926976|NCT00888303|Active Comparator|A (dexamethasone)|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
9926977|NCT00888303|Placebo Comparator|B (Control)|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
9926978|NCT00888316||Without Iron Overload|Patients entering study without pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
9926979|NCT00888316||With Iron-Overload|Patients entering study with pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
9926980|NCT00888342|Active Comparator|1 supplementary oxygen|participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night
9926981|NCT00888342|Active Comparator|2 Zopiclone|participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night
9926982|NCT00888342|Active Comparator|3 Alcohol|participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night
9865582|NCT00125450|Experimental|A|Chest Physiotherapy with Forced Expiratory Technique
9865583|NCT00125450|Active Comparator|B|Aspiration
9865584|NCT00125502|Experimental|I|n=200; 20 micrograms gB with MF59
9865585|NCT00125502|Placebo Comparator|II|n=200; placebo (normal saline)
9865586|NCT00125567|Experimental|1|Stalevo (levodopa/carbidopa/entacapone)
9865587|NCT00125567|Active Comparator|2|Levodopa/carbidopa
9865588|NCT00125606|Active Comparator|conditioning therapy with 12 Gy TBI / cyclophosphamide 120|
9865589|NCT00125606|Experimental|conditioning therapy with 8 Gy TBI / fludarabine 120|
9865590|NCT00125645|Experimental|Irbesartan|Tablet Irbesartan 150 mg once daily
9865591|NCT00125723|No Intervention|No Intervention|
9865592|NCT00125723|Other|Intervention|PI Discretion
9865593|NCT00125736|Experimental|E0671 combination group|
9865594|NCT00125736|Placebo Comparator|placebo combination group|
9865595|NCT00125775|Active Comparator|1|Engerix-B 40 mcg dose
9865596|NCT00125775|Active Comparator|2|Engerix-B 80 mcg dose
9865597|NCT00125827|Experimental|1|Single-arm, dose escalation
9865598|NCT00125879|Experimental|1|
9865599|NCT00125918|Placebo Comparator|1|Placebo
9865600|NCT00125918|Active Comparator|2|2.5 mg tadalafil
9865601|NCT00125918|Active Comparator|3|10 mg tadalafil
9865602|NCT00125918|Active Comparator|4|20 mg tadalafil
9865603|NCT00125918|Active Comparator|5|40 mg tadalafil
9667034|NCT04042298||5-FU Chemotherapy (Experimental)|Comprised of newly diagnosed cancer patients 21 years or older who have received 5-FU chemotherapy within the past 30 days or are scheduled to receive 5-FU chemotherapy.
9865604|NCT00126048|Active Comparator|1|Oral atorvastatin 40mg
9865605|NCT00126048|Placebo Comparator|2|Placebo
9865606|NCT00126100|Experimental|1|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
9865607|NCT00126100|Placebo Comparator|2|Patients were randomly assigned to receive subcutaneously a daily dose of placebo for 5 days.
9865608|NCT00126217|Experimental|1|
9865609|NCT00126217|No Intervention|2|
9865610|NCT00126308|Experimental|Immediate|poly-L-lactic acid injections
9865611|NCT00126308|Active Comparator|Delayed|poly-L-lactic acid injections
9865612|NCT00126334|Active Comparator|1|Liberal transfusion threshold
9865613|NCT00126334|Experimental|2|Conservative transfusion threshold
9865614|NCT00126373|Placebo Comparator|Sugar pill|Placebo (sugar) pill with identical look to bupropion
9865615|NCT00126373|Experimental|buproprion|bupropion pill
9865616|NCT00126412|Experimental|123I-mIBG (Meta-iobenzylguanidine)|"All subjects received 123I-mIBG injection over at least 1 to 2 minutes through a cannula (or indwelling catheter in the vein). After the injection of 123I-mIBG was complete, the cannula was flushed with at least 5 mL of 0.9% sodium chloride solution over a maximum of 10 seconds.~All subjects ≥18 years of age and children with a weight of ≥70 kg were to receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq [9.0 to 11 mCi] of 123I-mIBG). Doses of 123I-mIBG for children <18 years of age (with a weight of 8-70 kg) were to be calculated on the basis of a reference activity for an adult scaled to body weight according to the schedule proposed by the European Association of Nuclear Medicine (EANM) Paediatric Task Group; for children <8 kg, a scaled activity or a fixed minimum activity of 80 ±10% MBq (72 to 88 MBq [1.9 to 2.2 mCi]) was permissible."
9865617|NCT00126516|Active Comparator|1|Angiotensin II Receptor Antagonists group
9865618|NCT00126516|Active Comparator|2|Angiotensin-converting Enzyme Inhibitors group
9865619|NCT00126542|Experimental|Treatment (bevacizumab, erlotinib hydrochloride)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to 1 of the study drugs may continue treatment with the remaining study drug alone in the absence of disease progression or unacceptable toxicity.
9865620|NCT00126607|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9865621|NCT00126620|Experimental|OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)|Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
9865622|NCT00126724|Active Comparator|1|1x10^11 DRP/mL tgAAC94
9865623|NCT00126724|Active Comparator|2|1x10^12 DRP/mL tgAAC94
9865624|NCT00126724|Active Comparator|3|1x10^13 DRP/mL tgAAC94
9865625|NCT00126724|Placebo Comparator|4|
9865626|NCT00126763|Experimental|Matrix Transdermal Fentanyl Patch|
9865627|NCT00126789|Experimental|ZR-02-01|ZR-02-01 matrix transdermal fentanyl patch
9865628|NCT00126880|Experimental|600mg BID ATC|600mg BID ATC
9865629|NCT00126880|Experimental|800mg BID ATC|800mg BID ATC
9865630|NCT00126880|Active Comparator|150mg BID 3TC|150mg BID 3TC
9865631|NCT00127075|Experimental|NOMA + estradiol|Oral NOMA (LUTENYL® 10 mg/day) combined with transdermal Estradiol (DERMESTRIL SEPTEM® 75 mcg, once a week),
9865632|NCT00127075|Placebo Comparator|placebo|Matching placebo treatments
9865633|NCT00127114|Experimental|Amantadine|
9865634|NCT00127114|Placebo Comparator|Placebo|
9926983|NCT00888368|Experimental|Transpatellar Approach|
9926984|NCT00888368|Active Comparator|Suprapatellar Approach|
9926985|NCT00888394|Experimental|1|
9926986|NCT00888394|Experimental|2|
9926987|NCT00888394|Experimental|3|
9926988|NCT00888394|Experimental|4|
9926989|NCT00888407|Experimental|HBV Screening|Small group educational session with HBV screening resources provided.
9926990|NCT00888407|Sham Comparator|Nutrition|Small group educational discussion, diet & nutrition resources provided.
9865635|NCT00127127|Experimental|1|1. level 1: 100 mg BID 14-day, level 2: 200 mg BID 14-day, level 3: 400 mg QD 14 day, level 5: 500 mg QD 14-day
9865636|NCT00127140|Experimental|Vorinostat|Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
9865637|NCT00127270|Experimental|1|Darifenacin
9865638|NCT00127270|Other|2|Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
9865639|NCT00127335|Placebo Comparator|1|
9865640|NCT00127335|Active Comparator|2|statin administration
9865641|NCT00127452|Experimental|EPA + DHA|Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
9865642|NCT00127452|Experimental|ALA|Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
9865643|NCT00127452|Experimental|EPA + DHA plus ALA|Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
9865644|NCT00127452|Placebo Comparator|Placebo|Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
9865645|NCT00127491|Experimental|EPVent|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The intervention group will undergo transpulmonary pressure-directed controlled mechanical ventilation using parameters directed by the initial balloon measurements. Driving pressures will be adjusted to maintain a transpulmonary plateau pressure of less then 30. The PEEP setting will be set to achieve a transpulmonary end expiratory pressure of 0. Repeat PES measurements will be done at 24, 48 and 72 hours following the initial measurements. Additional measurements will be taken as clinically indicated. Ventilator management by PES measurements will continue for a period of 72 hours.
9865646|NCT00127491|Active Comparator|Control|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The control group will be managed using the low tidal volume strategy laid out by the NIHBLI ARDSnet study. These recommendations include a set tidal volume of 6 ml/ kg. Respiratory rate and PEEP are set to maintain adequate ventilation and oxygenation. These settings will be continued for a period of 72 hours.
9865647|NCT00127673|Active Comparator|1|Participants will receive no choice cognitive behavioral therapy
9865648|NCT00127673|Active Comparator|2|Participants will receive choice cognitive behavioral therapy
9865649|NCT00127673|Active Comparator|3|Participants will receive no choice sertraline
9865650|NCT00127673|Active Comparator|4|Participants will receive choice sertraline
9865651|NCT00127829|Experimental|1|Gefitinib (IRESSA®)
9865652|NCT00127868|Active Comparator|1|oral griseofulvin and selenium sulfide shampoo 1%
9865653|NCT00127868|Active Comparator|2|oral griseofulvin and ciclopirox shampoo
9865654|NCT00127868|Active Comparator|3|oral griseofulvin and ketoconazole shampoo 2%
9865655|NCT00127868|Placebo Comparator|4|oral griseofulvin and baby shampoo
9865656|NCT00127881|Experimental|Zanolimumab|
9865657|NCT00127920|Experimental|Single Arm|Paclitaxel, Carboplatin and Avastin on day1 every 21 days
9865658|NCT00127946|Active Comparator|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
9865659|NCT00127946|No Intervention|placebo|This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
9865660|NCT00127985|Experimental|Active|IV 6-methyl-prednisolone
10210372|NCT05214872||CARDIOLOGY (CARD) GROUP|"CARD group (n = 37) - patients with at least one history of a cardiovascular event, admitted to hospital for elective angiography, without any signs of impaired kidney function.~The studies in this group were conducted to check the changes that occur as a result of cardiovascular disease (CVD) but without kidney disease."
9865661|NCT00127985|Placebo Comparator|Comparator|IV Placebo
9865662|NCT00128024|Active Comparator|Statins|
9865663|NCT00128024|No Intervention|No statins|
9865664|NCT00128050|Active Comparator|1|Patients treated with recombinant FVIIa
9865665|NCT00128050|Placebo Comparator|2|Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo
9865666|NCT00128076|Active Comparator|1|All-arthroscopic repair
9865667|NCT00128076|Active Comparator|2|Mini-open repair
9865668|NCT00128141|No Intervention|1|
9865669|NCT00128141|Experimental|2|tactile stimulus
9865670|NCT00128245|Experimental|Pimecrolimus 0.3%|ASM981 0.3%
9865671|NCT00128245|Experimental|Pimecrolimus 1%|ASM981 1%
9865672|NCT00128245|Placebo Comparator|Vehicle with carbopol|
9865673|NCT00128245|Placebo Comparator|Vehicle without carbopol|
9865674|NCT00128258|Experimental|open|open treatment
9865675|NCT00128284||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
9865676|NCT00128284||Gastroparesis|Subjects with documented gastroparesis
9865677|NCT00128297|Active Comparator|Arm A: continuous administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 18 months
9865678|NCT00128297|Experimental|Arm B: alternate administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 6 months, followed by a 6 month rest, and a new 6 months treatment period.
9865679|NCT00128310|Active Comparator|Arm A: Vinorelbine|Arm A: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8.
9865680|NCT00128310|Experimental|Arm B: Vinorelbine and Gemcitabine|Arm B: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8. Gemcitabine will be administered following vinorelbine at a dose of 1200 mg/m2 as an intravenous infusion over 30 minutes.
9865681|NCT00128336|Active Comparator|Nurse support|
9865682|NCT00128336|Experimental|Intensive support|
9865683|NCT00128336|Active Comparator|High carbohydrate diet|
9865684|NCT00128336|Experimental|High mono-unsaturated fat diet|
9865685|NCT00128362|Experimental|Radio guided Sentinle node biopsy|The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
9865686|NCT00128388|Experimental|1 PFPP|Panic Focused Psychodynamic Psychotherapy
9865687|NCT00128388|Active Comparator|2 ART|Applied Relaxation Training
9865688|NCT00128414|Placebo Comparator|Placebo|Placebo Comparator
9865689|NCT00128414|Experimental|Colchicine|Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
9865690|NCT00128453|Placebo Comparator|Placebo|Conventional therapy plus placebo
9865691|NCT00128453|Active Comparator|Colchicine|Conventional therapy plus colchicine
9865692|NCT00128479|Experimental|mifepristone 300 mg|
9865693|NCT00128479|Placebo Comparator|placebo|
9865694|NCT00128479|Experimental|mifepristone 600 mg|
9865695|NCT00128479|Experimental|mifepristone 1200 mg|
9865696|NCT00128505|Experimental|mifepristone|
9865697|NCT00128518|Experimental|Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
9865698|NCT00128518|Experimental|Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
9865699|NCT00128518|Experimental|Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
9865700|NCT00128518|Experimental|Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
9865701|NCT00128622|Experimental|Denileukin Diftitox plus vaccine|This is a single arm Phase I safety study.
9865702|NCT00128687|Experimental|Immediate Intervention|Participants in both arms continue to receive usual medical care throughout the study period. In addition, participants randomized to Immediate Intervention receive intensive case management for Coronary heart disease (CHD) risk reduction for 15 months and then a maintenance program for a minimum of 12 months to assess the durability of initial intervention changes.
9865703|NCT00128687|Placebo Comparator|Delayed Intervention|Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
9865704|NCT00128765|Active Comparator|usual care|usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
9865705|NCT00128765|Experimental|monitoring controls|regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
10210373|NCT05214872||Chronic kidney disease (CKD) 1-2 GROUP|"CKD1-2 (n=29) (stage G1-G2 CKD) with mild decrease in eGFR (eGFR >90-60 ml/min/1.73 m^2)~The studies in this group were performed to disclose the changes that occur as a consequence of the beginning of kidney function deterioration."
10210374|NCT05214872||Healthy volunteers (HV)|HV (n = 32) - this group was composed of healthy people, with no evidence of impairment in renal function and cardiovascular disorders in the history and at the time of enrollment in the study.
10210375|NCT05214820|Experimental|Single arm with 68Ga-PSMA|All participants will undergo a PET scan with 68Ga-PSMA
9865706|NCT00128765|Experimental|self-management|disease specific self-management program 'Living Well with COPD'
9865707|NCT00128778|Experimental|Arm A: PLD|Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
10210376|NCT05214729|Experimental|Fast to Slow Group|The Fast to Slow Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the fast UF challenge immediately after inclusion, followed by the slow UF challenge after a washout period of 24 hours.
9865708|NCT00128778|No Intervention|Arm B: Observation|Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.
9865709|NCT00128817|Experimental|1|Concurrent Chemoradiation
9865710|NCT00128817|Active Comparator|2|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
9865711|NCT00128843|Experimental|Exemestane|25mg/day per VO until progression disease, after this progression the patient could receive the another drug (comparator arm) ie Anastrozole by investigator decision
9865712|NCT00128843|Active Comparator|Anastrozole|1mg/day per VO until progression disease, after this progression the patient could receive the another drug (experimental arm) ie Exemestane by investigator decision
9865713|NCT00128856|Experimental|Gemcitabine + Adriamycine + Paclitaxel|Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.
9926991|NCT00888420||Medical Management|Patient satisfaction under current operational conditions
9926992|NCT00888420||Interventional Management|Patient satisfaction under the PSDA (Plan, do, study, act) performance improvement measures
9926993|NCT00888446|Experimental|Group A|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0 + 6"
9926994|NCT00888446|Experimental|Group B|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0+12"
9926995|NCT00888446|Experimental|Group C|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+6"
9926996|NCT00888446|Experimental|Group D|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+12"
9926997|NCT00888446|Experimental|Group E|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+6"
9926998|NCT00888446|Experimental|Group F|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+12"
9926999|NCT00888446|Experimental|Group G|"Number of Vaccine Recipients: 10~Preselected for baseline AAV neutralization titers of <1/8~Dosage level 3 x 10^12 DRP~Month 0+6"
10210377|NCT05214729|Experimental|Slow to Fast Group|The Slow to Fast Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the slow UF challenge immediately after inclusion, followed by the fast UF challenge after a washout period of 24 hours.
10210378|NCT05214716|Active Comparator|Intervention|Respiratory specimens from the subjects are tested by the FilmArray Pneumonia panel and the results are reported via an electronic health record system. Treating physicians may adjust empirical antibiotic regimens with assistance from the guidelines formulated by the study investigators. Other microbiologic tests, including cultures, are performed as per routine practice.
10210379|NCT05214716|No Intervention|Control|Microbiologic tests, including cultures, are performed as per routine practice. No intervention is made on the antimicrobial treatment in the control arm.
10210380|NCT05214703|Experimental|cold therapy|Pain scores were measured with a visual analog scale (VAS) before the port catheter was removed from the patients in the experimental group. Before the port catheters were removed, cold application with an ice pack was applied to the patients whose first visual analog scale measurement was made by the researchers. The cold application was terminated an average of 15 minutes after the body temperature decreased by 1 °C.
9927000|NCT00888446|Placebo Comparator|Placebo|3 volunteers will receive placebo matched to each experimental group.
9927001|NCT00888472|Experimental|1|
9927002|NCT00888485|Experimental|Behavioral intervention|Group exposed to behavioral intervention program
9927003|NCT00888485|Active Comparator|Standard treatment|
9927004|NCT00888498|Placebo Comparator|Hands-On Control|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the experimental groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
9927005|NCT00888498|Experimental|Fast Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
9927006|NCT00888498|Experimental|Slow Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
9927007|NCT00888524|Experimental|General Practice (GP) in Physio plus Deep water running|A supplementation of Deep Water running exercises of 20 minutes in high intensity around aerobic thresholds estimated in individual land and water test
9865714|NCT00128895|Active Comparator|azathioprine, standard|standard azathioprine maintenance upto one year after diagnosis, subsequently tapering of azathioprine with 25 mg per 3 months
9865715|NCT00128895|Experimental|azathioprine, longterm|longterm maintenance with azathioprine upto four years after diagnosis, subsequently azathioprine will be tapered with 25 mg per 3 months
10210381|NCT05214703|No Intervention|no intervention|The patients in the control group did not receive any intervention before and after port catheter removal.
10210382|NCT05214690|Experimental|Sequence A|cross-over
10210383|NCT05214690|Experimental|Sequence B|cross-over
9865716|NCT00128908|Active Comparator|Continuous triple-class therapy|Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
9865717|NCT00128908|Experimental|Alternating therapy|Patients will be assigned to weekly alternating dual-class regimen
9865718|NCT00129090|Experimental|R-CHOEP14 with 12x Rituximab|8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )
9865719|NCT00129233|Active Comparator|Valsartan|Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.
9865720|NCT00129233|Active Comparator|Amlodipine|Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.
9865721|NCT00129298|Experimental|1|Tiagabine
9865722|NCT00129298|Placebo Comparator|2|Matching placebo
9865723|NCT00129324|Other|Lead Reduction Arm|random assignment to receive lead hazard control intervention. Assessing lead hazards in the home. Reducing lead hazards by cleaning, painting, covering, and/or replacing/repairing interior and exterior components of the home.
9865724|NCT00129324|Other|Injury Reduction Arm|random assignment to receive injury hazard control intervention. Assessing home for potential injury hazards. Controlling hazards by 1) installing safety equipment such as stairway gates, cabinet locks, smoke & CO detectors, etc. 2) removing the hazards from the reach of a child and/or 3) restricting access to the hazards.
9865725|NCT00129337|Experimental|1|0.1 mg/kg
9865726|NCT00129337|Experimental|2|0.3 mg/kg
9865727|NCT00129337|Experimental|3|1 mg/kg
9865728|NCT00129337|Experimental|4|3 mg/kg
9865729|NCT00129415|Experimental|UVA1 Irradiation|UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
9865730|NCT00129415|Experimental|UVB Irridiation|UVB Irradiation maximum dose of 4000 mJ/cm2
9865731|NCT00129428|Experimental|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
9865732|NCT00129454|Experimental|Telemedicine treatment|Psychotherapy delivered by telephone
9865733|NCT00129454|Active Comparator|In-Person treatment|Psychotherapy delivered in-person
9865734|NCT00129454|No Intervention|Assessment only|No intervention
9865735|NCT00129493|Other|Arm 1|
9865736|NCT00129519|Active Comparator|Imiquimod cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
9865737|NCT00129636|Other|Patient attending hospital clinic|patients were sent a letter especially dictated for them and a copy of the letter written by the hospital consultant to their GP to review
9865738|NCT00129662|Experimental|Intervention arm|Pictorial action plan
10210384|NCT05214677|Experimental|Sequence A|cross-over
10210385|NCT05214677|Experimental|Sequence B|cross-over
10210386|NCT05214651|Experimental|novel double row group|This is the experimental group, and 26 participants will be enrolled, a novel double row technique will be using to repair the large - massive rotator cuff tears in in this group.
10210387|NCT05214651|Active Comparator|suture bridge double row group|This is the control group, and 26 participants will be enrolled, a suture bridge double row technique will be using to repair the large - massive rotator cuff tears in in this group in routine.
10210388|NCT05214638||Assessed with the paper version of Longshi Scale first and then with electronic version|
10210389|NCT05214638||Assessed with the electronic version of Longshi Scale first and then with the paper version|
10210390|NCT05201170|Experimental|PL9643 Opthalmic Solution|PL9643 ophthalmic solution bilaterally three times a day.
10210391|NCT05201170|Active Comparator|Vehicle Opthalmic Solution|Vehicle opthalmic solution bilaterally three times a day.
9865739|NCT00129714|No Intervention|wait and see|
9865740|NCT00129714|Experimental|collar|
9865741|NCT00129714|Experimental|physiotherapy|
9865742|NCT00129753|Experimental|Alemtuzumab|
9865743|NCT00129792|Experimental|1|Has 100% expectation of receiving supplement
9865744|NCT00129792|Sham Comparator|2|Has 50% expectation of receiving supplement
9865745|NCT00129792|Other|3|Has 0% expectation of receiving supplement.
9865746|NCT00129805|Experimental|MCI-9042|
9865747|NCT00129805|Active Comparator|Aspirin|
9865748|NCT00129896|Experimental|Myocet+Taxotere+Herceptin|Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg
9865749|NCT00129922|Active Comparator|Fluorouracil+Epirubicin+Cyclophosphamide|5-FU+4-Epirubicin+Cyclophosphamide
9865750|NCT00129922|Experimental|FEC followed by Paclitaxel|5-FU+4-Epirubicin+Cyclophosphamide
9865751|NCT00130026|Placebo Comparator|I|Saline placebo
9865752|NCT00130091|Experimental|Clonidine|administer with local anesthetic
9865753|NCT00130091|Placebo Comparator|Local anesthetic|Local anesthetic without clonidine
9865754|NCT00130104|Experimental|MCB|randomized to receive the metacarpal block for anesthesia
9865755|NCT00130156|Experimental|1|
9865756|NCT00130156|Experimental|2|
9865757|NCT00130169|Experimental|1|
9865758|NCT00130195|Experimental|A|
9865759|NCT00130260|Experimental|vaccine, schedule 1|3rd and 4th dose of vaccine, on original schedule
9865760|NCT00130260|Experimental|vaccine, schedule 2|3rd and 4th dose of vaccine on modified schedule
10210392|NCT05194748||camptocormia group|Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
9865761|NCT00130260|Placebo Comparator|placebo, schedule 1|3rd and 4th dose of placebo, on original schedule
9865762|NCT00130260|Placebo Comparator|placebo, schedule 2|3rd and 4th dose of placebo on modified schedule
9865763|NCT00130273|Experimental|1|Participants will receive managed problem solving for 12 months
9865764|NCT00130273|Active Comparator|2|Participants will receive standard of care for 12 months
9865765|NCT00130325|Active Comparator|A|Isoniazid arm
9865766|NCT00130325|Placebo Comparator|B|Placebo of Isoniazid tablet 300mg
9865767|NCT00130364|Experimental|1|Pimecrolimus
9865768|NCT00130364|Placebo Comparator|2|Pimecrolimus vehicle cream
9865769|NCT00130377|Experimental|cell therapy|Patient receiving active biologic
9865770|NCT00130377|Placebo Comparator|control|Patient receiving placebo or standard of care
9865771|NCT00130390|Experimental|1|One nitazoxanide 500 mg tablet twice daily for 28 days
9865772|NCT00130390|Placebo Comparator|2|One placebo tablet twice daily for 28 days
9865773|NCT00130494|Experimental|Arm A: Zoledronic acid 4 mg|Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
9865774|NCT00130494|No Intervention|Arm B: Observation|Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).
9865775|NCT00130507|Active Comparator|Arm A: VX|Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
9865776|NCT00130507|Experimental|Arm B: VXH|Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
9865777|NCT00130546|Active Comparator|1|Cypher Stent
9865778|NCT00130546|Active Comparator|2|Taxus Stent
9865779|NCT00130598|Active Comparator|1|control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
9865780|NCT00130598|Active Comparator|2|7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
9865781|NCT00130598|Active Comparator|3|short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.
9865782|NCT00130611|Placebo Comparator|BNP blinded therapy|Clinical treatment without knowledge of BNP levels
9865783|NCT00130611|Experimental|BNP guided therapy|Clinical treatment based on clinical examination and BNP-levels
9865784|NCT00130676|Experimental|mifepristone 600 mg|
9865785|NCT00130676|Placebo Comparator|matching placebo|
9865786|NCT00130702|Experimental|Gefitinib (Iressa)|All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.
9865787|NCT00130754|Experimental|1|Thymo
9865788|NCT00130754|No Intervention|2|
9865789|NCT00130819|Experimental|1|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
9865790|NCT00130819|Active Comparator|2|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
9865791|NCT00130845|Experimental|Octreotide Acetate in Microspheres|
9865792|NCT00130845|Placebo Comparator|Placebo|
9865793|NCT00130910|Experimental|1|Albendazole
9865794|NCT00130910|Placebo Comparator|2|
9865795|NCT00131014||Next of Kin of deceased subj by lymphoma|Next of Kin of deceased subject by lymphoma
9865796|NCT00131014||Subject unaffected by lymphoma|Subject unaffected by lymphoma
9865797|NCT00131014||Subject affected by lymphoma|Subject affected by lymphoma
9865798|NCT00131027|Experimental|A|HD-MTX
9865799|NCT00131027|Active Comparator|B|ID-MTX
9865800|NCT00131053|Experimental|A|
9865801|NCT00131079|Experimental|PEPAF|General Practitioner's assessment of physical activity level and minimal advice in routine clinical practice supplemented by physical activity prescription to those who accepted an additional 15 minutes appointment.
9865802|NCT00131079|Active Comparator|Control|
9865803|NCT00131131|Experimental|Exercise|The intervention was an exercise program of moderate to vigorous intensity. The intervention started with 30-minute sessions three times per week, with the ultimate goal to have participants exercise four to five times per week for 45 to 60 minutes per session.
9865804|NCT00131131|No Intervention|Control|Women in the control group did not attend instructional sessions with the exercise interventionist and did not receive the motivational mailings
9865805|NCT00131144|Experimental|Octreotide Acetate in Microspheres 20 mg|20 mg will be administered im once every 4 weeks
9865806|NCT00131144|Experimental|Octreotide Acetate in Microspheres 30 mg|30 mg will be administered im once every 4 weeks
9865807|NCT00131144|Placebo Comparator|Placebo|
9865808|NCT00131235|Placebo Comparator|Control|Standard antenatal care as described in intervention
9865809|NCT00131235|Experimental|Monthly SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine, as described in intervention
9865810|NCT00131235|Experimental|AZI-SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine + two presumptive treatments of sexually transmitted infections and malaria with azithromycin, as described in intervention
9865811|NCT00131391|Placebo Comparator|Phase A/B; Arm 1|Phase A: Arm 1: MK0364 Pbo capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.
9865812|NCT00131391|Experimental|Phase A/B: Arm 2|Phase A: Arm 2: MK0364 4 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 2: MK0364 4 mg capsule once daily.
9865813|NCT00131391|Experimental|Phase A/B: Arm 3|Phase A: Arm 3: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 3: MK0364 Pbo capsule once daily.
9865814|NCT00131391|Experimental|Phase A/B: Arm 4|Phase A: Arm 4: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 4: MK0364 2 mg capsule once daily.
9865815|NCT00131391|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 5: MK0364 4 mg capsule once daily.
9865816|NCT00131391|Experimental|Phase A/B: Arm 6|Phase A: Arm 6: MK0364 6 mg once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 6: MK0364 6 mg capsule once daily.
9865817|NCT00131404|Placebo Comparator|Phase A/B: Arm 1|"Phase A: Arm 1: MK0364 Pbo capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily."
9865818|NCT00131404|Experimental|Phase A/B: Arm 2|"Phase A: Arm 2: MK0364 2 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily."
9865819|NCT00131404|Experimental|Phase A/B: Arm 3|"Phase A: Arm 3: MK0364 4 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:~MK0364 4 mg capsule once daily."
9865820|NCT00131404|Experimental|Phase A/B: Arm 4|"Phase A: Arm 4: MK0364 6 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:~MK0364 6 mg capsule once daily."
9865821|NCT00131404|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.
9865822|NCT00131482|Experimental|10 micrograms|
9865823|NCT00131482|Experimental|30 micrograms|
9865824|NCT00131482|Placebo Comparator|Placebo|
9865825|NCT00131482|Experimental|3 micrograms|
9865826|NCT00131482|Experimental|1 microgram|
9865827|NCT00131495|Placebo Comparator|1|Placebo patch
9865828|NCT00131495|Experimental|2|Testosterone patch (300mcg/day, changed twice a week for one year
9865829|NCT00131547|No Intervention|1|Usual Clinical Care
9865830|NCT00131547|Experimental|2|Behavioral (e.g., Counseling)
9865831|NCT00131560|Other|A|
9865832|NCT00131638|Experimental|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
9865833|NCT00131638|Placebo Comparator|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
9865834|NCT00131846|Active Comparator|1|Diuretics use
9865835|NCT00131846|Active Comparator|2|No diuretics use
9865836|NCT00131963||Regimen 1|Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
9865837|NCT00131963||Regimen 2|Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients then receive paclitaxel IV over 1 hour once weekly for 12 weeks.
9865838|NCT00131989|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-14 or 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR may be considered for retreatment with sorafenib for up to an additional 6 courses upon disease recurrence provided the duration of CR is longer than 1 month.
9865839|NCT00132067|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9865840|NCT00132080|Placebo Comparator|1|Patients with acute Kawasaki disease
9865841|NCT00132119|Experimental|1|Nalmefene HCl 20 mg
9865842|NCT00132119|Experimental|2|Nalmefene HCl 40 mg
9865843|NCT00132119|Placebo Comparator|3|Placebo
9865844|NCT00132145|Other|Intervention|Behavioural
9865845|NCT00132158|Other|1|
9865846|NCT00132249||Head Injured|The Vietnam Head Injured Subjects
9865847|NCT00132249||Head Uninjured|Uninjured Vietnam Veteran Control Subjects
9865848|NCT00132262|Experimental|1|Patients randomized to this arm received an intervention based in the motivational interviewing style
9865849|NCT00132262|Active Comparator|2|Patients randomized to this arm received standard hospital care
9865850|NCT00132353||Healthy volunteers|For normative data
9865851|NCT00132353||Patients with neurological disorders|For teaching fellows electrodiagnostic techniques
9927008|NCT00888524|Experimental|General Practice in Physio|A procedure of evidence-based physiotherapy is usual care in pragmatic trial
9927009|NCT00888537|Experimental|Decision Aid|Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid.
9927010|NCT00888537|Active Comparator|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
9927011|NCT00888550|Experimental|1. Splinting|
9927012|NCT00888550|Active Comparator|2. No Splinting|
9927013|NCT00888576||1|Non-intervention
9927014|NCT00888602|Experimental|MM1 - Meal|3.4g psyllium served with a meal
9927015|NCT00888602|Experimental|MM2 - Meal|6.8 g psyllium served with a meal
9927016|NCT00888602|Experimental|MM2 (no Meal)|6.8 g psyllium consumed with no meal
9927017|NCT00888602|Sham Comparator|Meal Only|meal only
9927018|NCT00888641|No Intervention|Normothermia|After arterial clamping, no ice slush will be used
9927019|NCT00888641|Experimental|Hypothermia|After arterial clamping, the kidney will be surrounded in ice slush for 10 minutes
9927020|NCT00888667||ICD patient with frequent PVCs|
9927021|NCT00888693|Experimental|1|ABT-288 vs placebo capsules administered orally once daily for 14 days
9927022|NCT00888693|Experimental|2|ABT-288 vs placebo capsules administered orally once daily for 14 days
9927023|NCT00888693|Experimental|3|ABT-288 vs placebo capsules administered orally once daily for 14 days
9927024|NCT00888693|Experimental|4|ABT288 vs placebo administered orally once daily for 14 days
9927025|NCT00888693|Experimental|5|ABT-288 vs placebo administered orally once daily for 14 days
9927026|NCT00888693|Experimental|6|ABT-288 vs placebo administered orally once daily for 14 days
9927027|NCT00888693|Experimental|7|ABT-288 vs placebo administered orally once daily for 14 days
9927028|NCT00888693|Experimental|8|ABT-288 vs placebo administered orally once daily for 14 days
9927029|NCT00888693|Experimental|9|ABT-288 vs placebo administered orally once daily for 14 days
9927030|NCT00888706|Active Comparator|1|
9927031|NCT00888706|Active Comparator|2|
9927032|NCT00888706|Active Comparator|3|
9927033|NCT00888706|Experimental|4|
9927034|NCT00888719|Experimental|CWP-0403 50mg|
9927035|NCT00888719|Experimental|CWP-0403 100mg|
9927036|NCT00888719|Placebo Comparator|placebo|
9927037|NCT00888732|Experimental|Insulin therapy|Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin
9927038|NCT00888745|Experimental|1|
9927039|NCT00888745|Placebo Comparator|2|
9927040|NCT00888758|Experimental|1|
9927041|NCT00888758|Active Comparator|2|
9927042|NCT00888771||1|
9927043|NCT00888771||2|
9927044|NCT00888771||3|
9927045|NCT00888771||4|
10210393|NCT05194748||no camptocormia group|Diaphragmatic thickness will be measured by ultrasonography. Respiratory function will be evaluated by spirometric measurements. Postural deviations of the spine, knees, and hips will be recorded through photographs taken from the side and back
10210394|NCT05194696||Caffeine questionnaire|A questionnaire concerning caffeine habits will be handed out to the patients
9865852|NCT00132379|Experimental|1|
9865853|NCT00132418|Placebo Comparator|Placebo|placebo
9865854|NCT00132418|Experimental|Enbrel|Enbrel
9865855|NCT00132444|Active Comparator|1|0.25% gel
9865856|NCT00132444|Active Comparator|2|0.1% gel
9865857|NCT00132444|Placebo Comparator|3|
9865858|NCT00132483|Experimental|Intervention arm|
9865859|NCT00132483|No Intervention|Control|
9865860|NCT00132509|Experimental|DFIL|
9865861|NCT00132509|Active Comparator|NINDS|
9865862|NCT00132522|Experimental|Arm 1|
9865863|NCT00132613|Active Comparator|1|Procedure/Surgery: Observation alone after pericardial drainage
9865864|NCT00132613|Experimental|2|Drug: Pericardial instillation of bleomycin after drainage
9865865|NCT00132639|Experimental|1|Preoperative docetaxel-cisplatin combination chemotherapy
9865866|NCT00132639|Active Comparator|2|Preoperative docetaxel monotherapy
9865867|NCT00132665|Active Comparator|1|Procedure/Surgery: A: Radiotherapy alone
9865868|NCT00132665|Experimental|2|Drug: B: CBDCA and Radiotherapy
9865869|NCT00132704||A|The experiments in Group A will be conducted in order to determine if human tumor microvascular endothelium displays similar dose parameters as mouse tumor endothelium, and if the microvascular endothelium of tumors of different types behaves in a similar fashion in its response to IR.
9865870|NCT00132704||B|The experiments in Group B will be conducted in order to determine if tumor endothelium isolated to near homogeneity demonstrates dose parameters similar to those used in single dose radiotherapy of brain tumors.
9865871|NCT00132743|Active Comparator|1|Optimal Medical Care
9865872|NCT00132743|Active Comparator|2|Optimal Medical Care and Supervised Exercise
9865873|NCT00132743|Active Comparator|3|Optimal Medical Care and Stent
9865874|NCT00132795|Experimental|1 Therapeutic Phone System|patients assigned to this condition will have unlimited access to the therapeutic telephone system for 4 months.
9865875|NCT00132795|Active Comparator|2 Standard care|Standard post-CBT care (i.e., no formal relapse prevention or professional treatment).
9865876|NCT00132821|Active Comparator|A|Bupropion
9865877|NCT00132821|Active Comparator|B|Transdermal nicotine patch
9865878|NCT00132821|Placebo Comparator|C|
9865879|NCT00132821|Placebo Comparator|D|
9865880|NCT00132834||Asthma/no ICS|Asthmatic children who are not currently taking ICS
9865881|NCT00132834||Asthma/ICS|Asthmatic children on ICS
9865882|NCT00132834||Non-asthmatic children|Children without asthma
9865883|NCT00132899|Active Comparator|Methotrexate|Methotrexate and infliximab combination
9865884|NCT00132899|Placebo Comparator|Placebo|Placebo plus infliximab combination
9865885|NCT00133003|Active Comparator|1|
9865886|NCT00133003|Placebo Comparator|2|
9865887|NCT00133055|Experimental|Treatment booklet and telephone coaching|
9865888|NCT00133055|Other|Usual Care|
9865889|NCT00133068|Other|1|Control
9865890|NCT00133068|Experimental|2|Reduction of financial barrier
9865891|NCT00133068|Experimental|3|Computer Intervention
9865892|NCT00133068|Experimental|4|Reduction of financial barrier and Computer Intervention
10210395|NCT05194644|Experimental|Routine physical therapy + Sensorimotor stimulation|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min In Sensory Stimulation Gustatory, Tactile, Olfactory, Visual, Auditory Stimulation will be applied alternatively Time duration will be 4 min In motor stimulation first warm up session for 5-10 min, strengthening exercise, PNF techniques for upper and lower limb, abdominal curls and then different Balance exercises for 6 min 5 times a week
9865893|NCT00133094|Other|Arm 1|
9865894|NCT00133146|Experimental|Grass MATA MPL|"300 SU/0.5 mL Grass MATA MPL (Visit 2);~800 SU/0.5 mL Grass MATA MPL (Visit 4);~2000 SU/0.5 mL Grass MATA MPL (Visit 6)"
9865895|NCT00133146|Active Comparator|Grass MATA|"300 SU/0.5 mL Grass MATA (Visit 2);~800 SU/0.5 mL Grass MATA (Visit 4);~2000 SU/0.5 mL Grass MATA (Visit 6);"
9865896|NCT00133172|Experimental|1|Steroid rapid 5-day withdrawal
9865897|NCT00133172|Active Comparator|2|Standard steroid maintenance
9865898|NCT00133211|Active Comparator|1|Antiarrythmic drug treatment
9865899|NCT00133211|Experimental|2|
9865900|NCT00133224|Experimental|1|
9865901|NCT00133224|Other|2|
9865902|NCT00133237|Active Comparator|A|Sirolimus-eluting stent (Cypher)
9865903|NCT00133237|Active Comparator|B|Paclitaxel-eluting stent (Taxus)
9865904|NCT00133250|Experimental|A|Abciximab
9865905|NCT00133250|Placebo Comparator|B|Heparin Sodium
9865906|NCT00133263|Experimental|1|
9865907|NCT00133263|Active Comparator|2|
9865908|NCT00133276|Active Comparator|1|
9865909|NCT00133276|Placebo Comparator|2|
9865910|NCT00133354|Active Comparator|Arimidex and Growth Hormone|
9865911|NCT00133354|Placebo Comparator|Placebo and Growth Hormone|
9865912|NCT00133406|Experimental|a|oral glutamine with juice for 10 days
9865913|NCT00133406|Experimental|b|PO vit A q 4 mo for 1 year plus zinc placebo
9865914|NCT00133406|Active Comparator|c|Zinc 40 mg twice weekly Plus Vitamin A Placebo for one year
9865915|NCT00133406|Placebo Comparator|d|oral glycine with juice daily for 10 days
9865916|NCT00133406|Placebo Comparator|e|Vitamin A Placebo plus Zinc Placebo for one year
9865917|NCT00133406|Experimental|f|Vitamin A q 4 months and PO Zinc for 1 year
9865918|NCT00133445|Experimental|Group A|Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
9927046|NCT00888784|Active Comparator|1. Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in the gastric varix
9865919|NCT00133445|Active Comparator|Group B|Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
9865920|NCT00133471|Experimental|Group 1A: 3.75 mcg A/H9N2 no adjuvant|12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.
9865921|NCT00133471|Experimental|Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.
9865922|NCT00133471|Experimental|Group 3A: 15 mcg A/H9N2 no adjuvant|12 subjects to receive 15 mcg A/H9N2 with no adjuvant.
9865923|NCT00133471|Experimental|Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.
9865924|NCT00133471|Experimental|Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.
9865925|NCT00133471|Experimental|Group 4A: 30 mcg A/H9N2 no adjuvant|12 subjects to receive 30 mcg A/H9N2 with no adjuvant.
9865926|NCT00133471|Experimental|Group 2A: 7.5 mcg A/H9N2 no adjuvant|12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.
9865927|NCT00133471|Experimental|Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.
9865928|NCT00133523|Placebo Comparator|Group 4: Placebo: Intramuscular|N=165 subjects administered placebo intramuscularly.
9865929|NCT00133523|Placebo Comparator|Group 3: Placebo: Nasal|N=165 subjects administered placebo intranasally.
9865930|NCT00133523|Experimental|Group 1: FluMist™|N=825 subjects administered live attenuated vaccine intranasally.
9865931|NCT00133523|Experimental|Group 2: Fluzone®/Fluvirin|N=825 subjects administered inactivated vaccine intramuscularly.
9865932|NCT00133536|Experimental|1|100 subjects 45 mcg of influenza A/H5N1.
9865933|NCT00133536|Placebo Comparator|2|20 subjects saline placebo.
9865934|NCT00133549|Experimental|2|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): CRM-PS; Vaccine dose 3 (month 8): PS.
9865935|NCT00133549|Experimental|1|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): PS.
9865936|NCT00133549|Active Comparator|3|Vaccine dose 1: PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): saline placebo.
9865937|NCT00133601|Experimental|1|CBT-1
9865938|NCT00133601|No Intervention|2|Control Group
9865939|NCT00133666|Experimental|1|
9865940|NCT00133666|Active Comparator|2|
9865941|NCT00133718|Other|Structured multi intervention|Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
9865942|NCT00133718|Other|Standard of care|Standard care with or without structured care according to national guidelines
9865943|NCT00133744|Active Comparator|A, 1|
9865944|NCT00133744|Experimental|A, 2|
9865945|NCT00133744|Experimental|A, 3|Multiple micronutrient supplement
9865946|NCT00133770|Experimental|IV pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
9865947|NCT00133796|Experimental|Heceptin|Herceptin administered to enrolled subjects
9927047|NCT00888784|Placebo Comparator|2. Beta-blocker|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
9927048|NCT00888797|Active Comparator|1|Perioperative Propranolol and Etodolac
9927049|NCT00888797|Placebo Comparator|2|Placebo
9927050|NCT00888836|Active Comparator|GBP|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo gastric bypass
9927051|NCT00888836|Active Comparator|BPD 2|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo bilio-pancreatic diversion
9927052|NCT00888836|Active Comparator|Med Ter3|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 yearsundergo medical therapy
9927053|NCT00888862|Experimental|A|Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
9927054|NCT00888875|Experimental|1|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
9927055|NCT00888875|Active Comparator|2|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
9927056|NCT00888888||Cohort: Patients with colonic resections|Colonic resections in patients submitted to appendicectomy for suspected acute appendicitis
9927057|NCT00888901|Experimental|1|Patients on eltrombopag
9927058|NCT00888901|Active Comparator|2|Patients on corticosteroids
9927059|NCT00888901|No Intervention|3|Untreated patients
9927060|NCT00888953|Experimental|Intervention|Residents living in nursing homes allocated to intervention group. Assessment of risk factors. Implementation of a multifactorial tailored program to prevent falls.
9927061|NCT00888953|Other|Control|Residents living in nursing homes allocated to control group. Assessment of risk factors. Receive the usual attention.
9927062|NCT00888966||Out of hospital cardiac arrest|Out of hospital cardiac patients successfully resuscitated and admitted to ICU
9927063|NCT00888992|No Intervention|Group A|Receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls.
9927064|NCT00888992|Experimental|Group B|
9927065|NCT00888992|Experimental|Group C|
9927066|NCT00889018|Active Comparator|group 1|chemotherapy using carboplatin 560mg/m2
9927067|NCT00889018|Experimental|group 2|chemotherapy using 750mg/m2 carboplatin
9927068|NCT00889031||No Treatment|
9927069|NCT00889044|Experimental|clopidogrel by chewing|
9927070|NCT00889044|Placebo Comparator|Placebo|
9927071|NCT00889057|Experimental|sorafenib|
9927072|NCT00889070||1|Stage 1 (Pilot Study) All infants enrolled in the pilot stage and completing baseline screening will be evaluated as the analyzable set.
10210396|NCT05194644|Placebo Comparator|Routine physical therapy|Active and passive Range of motion exercise on upper and lower limb, Transfers from bed to chair, Sit to stand exercise Time duration will be 20 min, Rest period 5 min
10210397|NCT05194605||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
9865948|NCT00133887|Experimental|1|patients receiving Rapamycin
9865949|NCT00133887|Active Comparator|2|patients receiving anticalcineurin treatment
9865950|NCT00133900||Cohort|Metastatic Hormone Refractory Prostate Cancer Patients
9865951|NCT00133913||Cohort|Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy.
9865952|NCT00133965||1|Dignity Psychotherapy
9865953|NCT00133965||2|Supportive Psychotherapy
9865954|NCT00133965||3|Standard Palliative Care
9865955|NCT00134030|Active Comparator|Maintenance therapy group 1 arm I|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 17, 22, and 26 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 17. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 16, 20, 21, 24, 25, 28, and 29.
9865956|NCT00134030|Experimental|Maintenance therapy group 1 arm II|Patients receive doxorubicin, cisplatin, and high-dose MTX as in arm I. Patients than receive PEG-interferon alfa-2b subcutaneously once daily on day 1 in weeks 30-104.
9865957|NCT00134030|Active Comparator|Maintenance therapy group 2 arm I|Patients receive doxorubicin, cisplatin, and high-dose MTX as in group 1 arm I.
9865958|NCT00134030|Experimental|Maintenance therapy group 2 arm II|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 20, 28, and 36 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 28. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 19, 23, 27, 31, 35, 39, and 40. Patients receive ifosfamide IV over 4 hours on days 1-5 in weeks 16, 24, and 32 and on days 1-3 in weeks 20 and 36 and etoposide IV over 1 hour on days 1-5 in weeks 16, 24, and 32.
9865959|NCT00134069|Experimental|Treatment (sorafenib, irinotecan, cetuximab)|Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.
9865960|NCT00134160|Active Comparator|1|High-dose ARB monotherapy
9865961|NCT00134160|Active Comparator|2|Combination therapy of ARB with Calcium Channel Blocker
9865962|NCT00134277|Active Comparator|Infragenual dilatation with stenting|
9865963|NCT00134277|Active Comparator|Infragenual dilatation with cutting balloon|
9865964|NCT00134277|Active Comparator|Laser therapy|
9865965|NCT00134277|Placebo Comparator|Infragenual dilatation|
9865966|NCT00134303|Experimental|NASH|
9865967|NCT00134355|Experimental|PTK787|"PTK787:~250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily"
10210398|NCT05194605||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
10210399|NCT05194319||1/Children with diparetic cerebral palsy|Children with diparetic cerebral palsy
10210400|NCT05194319||2/Healty control|Children with healty peer ages of cerebral palsy children.
10210401|NCT05194098|Experimental|Major Depression Disorder Group: iTBS-EEG|Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: intermittent theta stimulation (iTBS): the investigators will stimulate a dorsomedial prefrontal cortex target at the scalp location (0x 60y 60z). Standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes, per session; total session length, including setup is 10-15 min.
9865968|NCT00134420|Active Comparator|Growth Hormone Treatment|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
9865969|NCT00134420|Other|GH treatment delayed by one year|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
9865970|NCT00134537|Experimental|1|Interspinous process and dynamic stabilization
9865971|NCT00134537|Active Comparator|2|Conservative Care
9865972|NCT00134615|Experimental|RQP-MH|These participants receive the RQP-MH intervention
9865973|NCT00134628|Active Comparator|A|Hyperbaric Oxygen Therapy
9865974|NCT00134628|Sham Comparator|B|Normal Air
9865975|NCT00134654|Active Comparator|Group A|Premarin once a day
9865976|NCT00134654|Active Comparator|Group B|Premarin 3 times a day
9865977|NCT00134680|Experimental|Letrozole & Trastuzumab|Letrozole 2.5 mg tablets daily and Trastuzumab 2 mg/kg by IV weekly
9865978|NCT00134745|Active Comparator|4 mg estradiol|
9865979|NCT00134745|Placebo Comparator|2 mg estradiol|
9865980|NCT00134758|Experimental|1|"Ursodeoxycholic acid during 2 years :~between 40 and 50 kg : 500 mg/day~between 51 and 75 kg : 750 mg/day~between 76 and 100 kg : 1000 mg/day"
9865981|NCT00134758|Placebo Comparator|2|
9865982|NCT00134823|Experimental|dosing decision support|weight based dosing decision support
9865983|NCT00134823|No Intervention|no decision support|no weight based dosing decision support
9865984|NCT00134966|Experimental|1|
9865985|NCT00134966|Active Comparator|2|
9865986|NCT00135005|Experimental|AMN107 + STI571|
9865987|NCT00135083|Experimental|1|"Once daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch"
9927073|NCT00889083||Control|Non septic patients needing hepatic surgery
9927074|NCT00889083||Sepsis|Septic patients needing surgery for peritonitis
9865988|NCT00135083|Experimental|2|"Twice daily:~Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper~Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime"
9865989|NCT00135083|Experimental|3|"Twice daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch"
9865990|NCT00135096|Experimental|1|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
9865991|NCT00135096|Experimental|2|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
9865992|NCT00135122|Placebo Comparator|2|Placebo in six days
9865993|NCT00135135|Other|1|
9865994|NCT00135161|Experimental|Intensity modulated radiation therapy (IMRT).|
9865995|NCT00135278|Other|CSF Drainage|
9865996|NCT00135278|Other|No CSF Drainage|
9865997|NCT00135304|Experimental|Cinacalcet and low-dose Vitamin D|Cinacalcet and low-dose IV Vitamin D
9865998|NCT00135304|Active Comparator|Vitamin D alone|Escalating doses of IV Vitamin D alone
9865999|NCT00135408|Active Comparator|A1|
9866000|NCT00135408|Active Comparator|A2|
9866001|NCT00135447||A|
9866002|NCT00135499|Experimental|R-ACVBP|Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
9866003|NCT00135499|Active Comparator|R-CHOP|Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
9866004|NCT00135525|Experimental|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
9866005|NCT00135525|Placebo Comparator|Placebo|
9927075|NCT00889096|Active Comparator|study day 1 propanolol|Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
9927076|NCT00889096|Placebo Comparator|study day 1 placebo|Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
9927077|NCT00889109||1|Open Capsular Shift
9927078|NCT00889109||2|Arthroscopic Bankart Repair
9927079|NCT00889109||3|Healthy controls
9927080|NCT00889122|Experimental|Lifestyle Counseling|
9927081|NCT00889148|Experimental|Gabapentin|600mg of gabapentin will be given orally two hours preoperatively and 200mg for 3 times a day after surgery for three days.
9927082|NCT00889148|Placebo Comparator|Placebo|
9927083|NCT00889213|Experimental|Patch and glue arm|Randomized patients to the patch and glue arm will undergo placement of a falciform ligament tissue patch and fibrin glue to the resection margin of the remnant pancreas following distal pancreatectomy
9927084|NCT00889213|Active Comparator|stapled /sutured pancreatic closure|
9927085|NCT00889239|Experimental|A|ceramic crown
9927086|NCT00889304||A|HTO cohort
9927087|NCT00889317||healthy adults|
9927088|NCT00889343|Experimental|1|
9927089|NCT00889343|Placebo Comparator|2|
9935276|NCT03952637|Experimental|2|Following the last Stage 1 subject s 6 months visit, data will be reviewed, and Stage 2 dosing andassessments will be determined. If Stage 2 dosing is toproceed, it will be reflected in a protocol amendment.
9935277|NCT03952624||Control|FNS <= 3
9935278|NCT03952624||Fatigued|FNS >= 4
9866006|NCT00135551|Active Comparator|angiotensin receptor blockers|benidipine+angiotensin receptor blockers, titlation scheme
10210402|NCT05194098|Sham Comparator|Major Depression Disorder Group: SHAM-EEG|"Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: sham stimulation (SHAM): Sham stimulation will entail the same procedures for the active stimulation day, but with the sham side of the DB-80 A/P placed exactly on the same anatomical target in the same position and duration, but without any active stimulation.~*Note, iTBS and SHAM stimulation sessions will occur on separate days scheduled one week apart (counterbalanced, across subjects). The two stimulation visits follow identical procedures (with the sole difference being active vs. sham rTMS stimulation), with each followed directly by post-stimulation EEG assessment with SLOT and MID tasks."
9866007|NCT00135551|Active Comparator|β-blockers|benidipie+β-blockers, titlation scheme
9866008|NCT00135551|Active Comparator|thiazide diuretics|benidipine+thiazide diuretics, titlation scheme
9866009|NCT00135577|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
9866010|NCT00135577|Experimental|Alvimopan 1 mg Once Daily (QD)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks."
9866011|NCT00135577|Experimental|Alvimopan 1 mg Twice Daily (BID)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening."
9866012|NCT00135577|Placebo Comparator|Placebo|Placebo was administered orally once in the morning and once in evening.
9866013|NCT00135590|Experimental|1|Protein pulse-feeding
9866014|NCT00135590|Active Comparator|2|Spread diet
9866015|NCT00135603|Active Comparator|A|appendectomy, actual usual treatment
9866016|NCT00135603|Active Comparator|B|antibiotic therapy
9866017|NCT00135668|Active Comparator|1|Nitroprusside infusion 0.3 mcg/kg/min
9866018|NCT00135668|Active Comparator|2|nitroprusside infusion 1 mcg/kg/min
9866019|NCT00135668|Active Comparator|3|nitroprusside infusion 2 mcg/kg/min
9866020|NCT00135668|Active Comparator|4|nitroprusside 3 mcg/kg/min
9866021|NCT00135733|Active Comparator|A|Amevive
9866022|NCT00135733|Placebo Comparator|B|Placebo
9866023|NCT00135759|Placebo Comparator|Group 1|Drug
9866024|NCT00135759|Experimental|2|experimental
9866025|NCT00135759|Experimental|3|experimental
9866026|NCT00135785|Active Comparator|1|Bupropion
9866027|NCT00135785|Placebo Comparator|2|Placebo
10210403|NCT05194098|No Intervention|Baseline Evaluation (Major Depressive Disorder and Healthy Control Groups)|"HC and MDD participants will have visits for clinical assessment and a baseline EEG session to complete reward processing tasks (SLOT AND MID). The SLOT task is a 288-trial EEG task developed in our laboratory. Design features mimic structural characteristics common to real-word slot machines, including sound effects and visualizations, and the display consists of 3 sequentially populated slot reels. Participants initiate each trial via button press, after which timing of the slot reels is automated, such that reward outcome is independent of task performance.~The MID task is a 130-trial EEG task designed to model anticipatory and consummatory sub-stages of reward processing in the context of participants being rewarded based on their response times to a cued target detection task."
10210404|NCT05193695|No Intervention|Control|Patients remained in the supine position for 20 minutes lying on a stretcher after dry needling.
10210405|NCT05193695|Experimental|Treadmill|The patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002).
10210406|NCT05193487|Active Comparator|inferior alveolar nerve block|Conventional inferior alvoelar nerve block anaesthesia will be given using a traditional metal syringe
10210407|NCT05193487|Experimental|intra-osseous mandibular anaesthesia|Computerized intraosseous anesthesia administration using the Quick Sleeper 5TM system (Dental Hi TecTM, Cholet, France)
10210408|NCT05192915|Other|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
10210409|NCT05189145|Active Comparator|Group I (control)|All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.
10210410|NCT05189145|Experimental|group II (experimental)|"All patients given 8 mg estradiol valerate orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle. Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation. In all Patients progesterone supplements in form of two vaginal prontogest suppositories 400 mg each. Transfer of frozen embryo will be done on day 5 after progesterone supplementation.~progesterone (P4) and estradiol assessed and Progesterone supplement adjustments based on serum level of P4 on day of embryo transfer dividing Group II (Cases) into 3 groups:~Group II A: If P4 levels < 5ng/dl, one progesterone supplement in form of 100 mg intramuscular injection daily added~Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added~Group II C: If P4 levels >10ng, continue on 400 mg prontogest suppositories twice daily"
10210411|NCT05188963|Active Comparator|Women with postvoid residual volume cut-off at 150 ml|
10210412|NCT05188963|Experimental|Women with postvoid residual volume cut-off at 250 ml|
10210413|NCT05187091|No Intervention|Standard IMRT|Standard IMRT with radical CRT/RT
9795686|NCT01543178|Experimental|Rifaximin open-label|"Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo."
9795687|NCT01543178|Experimental|Double-blind rifaximin (retreatment)|Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
9866028|NCT00135811|Active Comparator|1|Cyclosporin
9866029|NCT00135811|Active Comparator|2|MMF and Dexamethasone
10210414|NCT05187091|Experimental|Swallowing Sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures & submandibular gland sparing by SWOAR-IMRT
9866030|NCT00135902|Active Comparator|17P plus Omega-3 Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus Omega 3 supplements, 4 capsules per day for up to 5 weeks. Each capsule contained 200 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA).
9866031|NCT00135902|Placebo Comparator|17P plus Placebo Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus placebo capsules, 4 capsules per day for up to 5 weeks
9866032|NCT00135941|Experimental|1|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
9866033|NCT00135941|Experimental|2|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
9866034|NCT00135954|Other|late intervention|cyclophosphamide and steroids started at time of renal insufficiency
9866035|NCT00135954|Experimental|early intervention|immediate start of cyclophosphamide and steroids
9866036|NCT00136032|Active Comparator|1|
9866037|NCT00136032|Placebo Comparator|2|
9866038|NCT00136123|Experimental|Implants|
9866039|NCT00136136||Normal healthy term newborn|Normal healthy term newborns
9866040|NCT00136136||Ill term newly born without brain damage|Ill term newly borns without brain damage
9866041|NCT00136136||Preterm newly born without brain damage|Preterm newly borns without brain damage
9866042|NCT00136149|Experimental|Immediate implants|
9866043|NCT00136175|Experimental|Arm I|Patients with clinical stage T2 with hydronephrosis or T3 bladder cancer will receive 3 cycles of chemotherapy (200mg/m^2 paclitaxel on day 1, carboplatin on day 1, and 800 mg/m^2 gemcitabine on days 1 and 8 of each 21 day cycle).
9866044|NCT00136175|Experimental|Arm II|Patients with T4 or lymph node positive disease will receive up to 6 cycles of paclitaxel, carboplatin, and gemcitabine.
9866045|NCT00136201|Experimental|1|armDesc1
9866046|NCT00136227|Experimental|Lifestyle counseling|Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
9866047|NCT00136279|Experimental|School plus parent|Adolescents receive school-based curriculum (either Project TNT or Making a Difference) and mothers receive the Linking Lives curriculum
9866048|NCT00136279|Active Comparator|School-only|Adolescents receive school-based curriculum and parents received a control curriculum on helping their child choose a high school
9866049|NCT00136279|Experimental|Parent-Only|In the sex risk reduction portion of the study only, a second experimental group consisted of parents receiving the Linking Lives intervention and adolescents receiving no in-school intervention
9866050|NCT00136305|Experimental|Pictorial Asthma Action Plan|
9866051|NCT00136305|Active Comparator|Written Asthma Action Plan|
9866052|NCT00136370|Experimental|1|Chlorhexidine Vaginal Wipe
9866053|NCT00136370|Placebo Comparator|2|Sterile water external genital wipe
9866054|NCT00136409|Experimental|Mono-Therapy Gleevec|Gleevec administered orally at a pre-determined dose once daily.
9866055|NCT00136435|Other|Only Arm for this study|Only Arm for this study
9866056|NCT00136474|Active Comparator|Group 1|Amifostine plus radiation therapy
10210415|NCT05187065|Experimental|Mobile-based education and exercise program|Mobile-based education and progressive relaxation and knee exercise program will be applied to the patients in the experimental group.
10210416|NCT05187065|No Intervention|Standard of care|Mobile-based education and progressive relaxation and knee exercise program will not be applied to the patients in the control group, and the clinical routine will be maintained.
10210417|NCT05186155||premature baby without ROP (Group 0)|ROP: retinopathy of prematurity
9866057|NCT00136474|Active Comparator|Group 2|Radiation therapy alone
9866058|NCT00136565|Experimental|Experimental|Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
9866059|NCT00136578|Experimental|Subjects receiving carboplatin and SB-715992|Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.
9866060|NCT00136591|Active Comparator|A|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
9866061|NCT00136591|Experimental|B|
10210418|NCT05186155||ROP without treatment (Group 1)|ROP: retinopathy of prematurity
10210419|NCT05186155||ROP with laser photocoagulation treatment (Group 2)|ROP: retinopathy of prematurity
10210420|NCT05186155||ROP with anti-VEGF treatment (Group 3)|ROP: retinopathy of prematurity anti-VEGF: anti-Vascular Endothelial Growth Factor
10210421|NCT05186155||ROP with laser photocoagulation + anti-VEGF treatment (Group 4)|ROP: retinopathy of prematurity anti-VEGF: anti-Vascular Endothelial Growth Factor
10210422|NCT05186155||Fullterm baby (Group 5)|Fullterm baby
10210423|NCT05184881|Active Comparator|Group medial branch block|cervical medial branch block will done at the affected dermatomal level using 1 mL of a mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml).
10210424|NCT05184881|Active Comparator|Group retrolaminar block|cervical retrolaminar block was done using 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) for each affected dermatomal level.
9927090|NCT00889356|Experimental|Clindamycin 100mg and Ketoconazole 400mg|
9795688|NCT01543178|Placebo Comparator|Double-blind placebo (retreatment)|Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
10210425|NCT05184751||50 years and over|patients who underwent colonoscopic examination aged 50 years and over
10210426|NCT05184751||under 50 years|patients who underwent colonoscopic examination aged under 50 years
10210427|NCT05183854|Experimental|Arm I (PCV13, PPSV23)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 and pneumococcal polyvalent vaccine IM on day 60 in the absence of disease progression or unacceptable toxicity.
10210428|NCT05183854|Experimental|Arm II (PCV13, PPPSV23)|Patients who have received or are receiving venetoclax therapy, receive pneumococcal 13-valent conjugate vaccine IM on day 1 and pneumococcal polyvalent vaccine IM on day 60 in the absence of disease progression or unacceptable toxicity.
9795689|NCT01543204|Experimental|Etanercept 50 mg|Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
9795690|NCT01543490|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
9795691|NCT01543490|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
9795692|NCT01543503||Cohort|
9795693|NCT01543568|Other|2.0 mg intravitreal Aflibercept|open label, Subjects seen monthly & given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)
9795694|NCT01543581|Active Comparator|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
9795695|NCT01543581|Placebo Comparator|Inactive placebo|Those to whom the inactive placebo is given.
9795696|NCT01543607|Experimental|Treatment|Radiofrequency ablation catheter
9795697|NCT01543685|Experimental|Indomethacin 40 mg TID|
9795698|NCT01543685|Experimental|Indomethacin 40 mg BID|
9795699|NCT01543685|Experimental|Indomethacin 20 mg TID|
9795700|NCT01543685|Active Comparator|Celecoxib 200 mg|
9795701|NCT01543685|Placebo Comparator|Placebo|
9795702|NCT01543776|Active Comparator|Arm I (fasting)|Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
9795703|NCT01543776|Experimental|Arm II (fed)|Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
9795704|NCT01543828|Experimental|indacaterol then placebo|In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication.
9795705|NCT01543828|Placebo Comparator|placebo then indacaterol|In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.
9795706|NCT01543958|Experimental|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
9795707|NCT01544023||Breast Reconstruction with TilOOP|
9795708|NCT01544062|Experimental|IV acetaminophen|Study subjects receiving IV acetaminophen
9795709|NCT01544062|Placebo Comparator|Normal saline|Study subjects receiving placebo
9795710|NCT01544088|Experimental|Arm 1: GCBT|Group Cognitive Behavioral treatment (GCBT)
9795711|NCT01544088|Active Comparator|Arm 2: Group Treatment|Present Centered Group Treatment
9795712|NCT01544114|Experimental|VIMOVO|"Three VIMOVO strengths will be used in this study: 250 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 250/20), 375 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 375/20), and 500 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 500/20). The VIMOVO strength allocated to each participant will be determined by the participant's weight at baseline and based on investigator's discretion.~The target dose of the naproxen component will be within the range of 10-20 mg/kg/day divided twice daily (BID) with a maximum daily dose of 1000 mg."
9795713|NCT01544153|Other|WEB only|Control group receiving no additional intervention
9795714|NCT01544153|Experimental|WEB+SN|WEB plus social network intervention.
9795715|NCT01544153|Experimental|WEB+NRT|WEB plus nicotine replacement therapy product.
9795716|NCT01544153|Experimental|WEB+SN+NRT|WEB plus social network intervention and nicotine replacement therapy product.
9795717|NCT01544166|Experimental|Overall study|
9795718|NCT01544179|Experimental|Gefitinib|Gefitinib and cisplatin plus pemetrexed combination chemotherapy
9795719|NCT01544179|Placebo Comparator|Placebo|Placebo and cisplatin plus pemetrexed combination chemotherapy.
9795720|NCT01544309|Experimental|Atorvastatin administration group|
9795721|NCT01544309|Experimental|Rosuvastatin administration group|
9795722|NCT01544335||BIS|Subjects evaluated using Bioimpedance Spectroscopy
9795723|NCT01544348|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
9795724|NCT01544348|Active Comparator|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
9795725|NCT01544348|Experimental|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
9795726|NCT01544348|Experimental|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
9795727|NCT01544348|Experimental|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
9795728|NCT01544348|Experimental|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
10210429|NCT05178654|Experimental|[14C]PF-07321332|Single oral dose of 300 mg [14C]PF-07321332 containing approximately 100 µCi [14C]PF-07321332 coadministered with 100 mg ritonavir.
9866062|NCT00136656|Active Comparator|1|cefixime antibiotic treatment by oral route
9866063|NCT00136656|Sham Comparator|2|ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days
9866064|NCT00136682|Active Comparator|(PCEA)|patient-controlled epidural analgesia PCEA involves having an epidural catheter placed before surgery.The epidural catheter will be used during surgery to give drugs, such as morphine and a local anesthetic bupivacaine, which will help control pain. After surgery, a constant flow of pain-reducing medicine, such as morphine, will be given through the catheter. This is controlled by the patient.
9866065|NCT00136682|Active Comparator|PCA|patient-controlled intravenous analgesia (PCA) PCA involves placing a tube into the patient's vein after surgery. The tube is connected to a pump that is controlled by the patient. The pump holds a medicine, such as morphine, that eases pain.
9866066|NCT00136708|Experimental|NRP Training (Intervention)|Training in AAP neonatal resuscitation training program
9866067|NCT00136708|Other|Control|
9866068|NCT00136734|Experimental|1|methylphenidate
9866069|NCT00136734|Placebo Comparator|2|placebo
9866070|NCT00136747|Experimental|BUPROPION|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
9866071|NCT00136747|Experimental|placebo|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
9866072|NCT00136747|Experimental|memantine|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
9866073|NCT00136786|Placebo Comparator|Intervention 1|"Each participant receives three consecutive interventions.~Placebo~Bupropion~Memantine"
9866074|NCT00136786|Placebo Comparator|Intervention 2|"Bupropion~Memantine~Placebo"
9866075|NCT00136786|Placebo Comparator|Intervention 3|"Memantine~Placebo~Bupropion"
9866076|NCT00136825|Placebo Comparator|2|Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
9866077|NCT00136825|Experimental|1|N-Acetylcysteine
9866078|NCT00136864|Experimental|1|PET Imaging
9866079|NCT00136864|No Intervention|2|Standard Imaging
9866080|NCT00136890|No Intervention|1|Conventional Staging
9866081|NCT00136890|Experimental|2|PET Imaging
9927091|NCT00889356|Active Comparator|Tetracycline 100mg and Amphotericin B 50mg|
9927092|NCT00889369|Experimental|A|Use of duloxetine, flexible dose (60-120mg/day) for 8 weeks, following a 2-week placebo lead-in phase
9927093|NCT00889395|No Intervention|Home visit|Patients will have monthly home visits during which health educational talks will be given
9927094|NCT00889408|Experimental|Treatment|DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8
9927095|NCT00889434|Active Comparator|EGCG|Two cycles comprising 28 days of continuous daily treatment with EGCGgiven 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
9927096|NCT00889434|Active Comparator|Tocotrienol|
9927097|NCT00889434|Other|EGCG + Tocotrienol|Combination of both arms
9927098|NCT00889460|Placebo Comparator|1|Placebo group
9927099|NCT00889460|Experimental|2|rBet v 1 tablets
9927100|NCT00889499|Placebo Comparator|Crossover study|Crossover study
9927101|NCT00889499|Placebo Comparator|2|Crossover Study
9927102|NCT00889499|Placebo Comparator|3|Crossover Study
9927103|NCT00889525|Experimental|Cabergoline|
9927104|NCT00889538|Placebo Comparator|Placebo|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
9927105|NCT00889538|Active Comparator|Glutathione|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
9927106|NCT00889538|Active Comparator|Glutathione, Vit C and NAC|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
9927107|NCT00889590|Experimental|Zoledronic acid|Adjuvant zoledronic acid
10210430|NCT05173064|Experimental|Exercise training system|Participants randomized to the intervention group will come to the lab to use the video-based exercise training system to perform exercises.
9927108|NCT00889590|No Intervention|Control|Standard care
9927109|NCT00889629|Experimental|Doxercalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Active group receives doxercalciferol (Hectorol) 1mcgwith active titration based on intact PTH plus 25-OH Vitamin D3 (cholecalciferol) 400 IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol if target PTH value is not achieved by the predetermined midpoint.
9996961|NCT01504646|Placebo Comparator|Olive Oil Capsule|Ten subjects will take eight placebo olive oil capsules per day for three weeks.
10210431|NCT05173064|Sham Comparator|Sham system|Participants randomized to the control group will come to the lab to use the sham system to read text-and-image-based exercise instructions.
10210432|NCT05168371|Experimental|CBT-O|Women randomized to this arm will receive access to the eight modules of Cognitive-Behavioural Therapy-Online (CBT-O). Participants will meet weekly via Zoom with treatment navigators during the 8-12 weeks that it takes to complete the program.
10210433|NCT05168371|Experimental|MBT-O|Women randomized to this arm will receive access to the eight modules of Mindfulness-Based Therapy-Online (MBT-O). Participants will meet weekly via Zoom with treatment navigators during the 8-12 weeks that it takes to complete the program.
10210434|NCT05168371|No Intervention|Wait-List Control|Participants who are randomized to the wait-list group will complete two baseline online questionnaire/assessment batteries before being randomized to one of the active treatment groups. Participants will be randomized into one of the active treatment groups after a 10 week waiting period.
9866082|NCT00137176|Experimental|Rebif + Lipitor|
10210435|NCT05166967|Experimental|Individual dose of ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg), and the active ATG concentration ranges from 110 to 148.5UE/ml.
10210436|NCT05166967|Active Comparator|Fixed dose of ATG|A total amount of 10mg/kg ATG was divided into 4 days (from day -5 to day -2). The specific usage: 1.5mg/kg for day -5, 2.5mg/kg for day -4 and day -3, 3.5 mg/kg for day -2.
9866083|NCT00137189|Experimental|Music therapy|See published study protocol
9866084|NCT00137189|Other|Standard care|See published study protocol
9866085|NCT00137202|Active Comparator|2|
9866086|NCT00137215|Active Comparator|A|
9866087|NCT00137241||Group 1|
9866088|NCT00137254|Active Comparator|A|
9866089|NCT00137306|Other|Arm 1|
9866090|NCT00137501|Other|A|High dose Nifedpine arm
9866091|NCT00137501|Other|B|Low dose Nifedipine arm
9866092|NCT00137566|Experimental|1 Paracetamol|Paracetamol as per protocol
9866093|NCT00137566|Placebo Comparator|2 Placebo|Inactive placebo as per protocol.
9866094|NCT00137592|Experimental|Lifestyle counseling|Behavioral: small media, group education (multicomponent)
10210437|NCT05165758||Diabetic subjects without foot ulcer|27 diabetic subjects without foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
10210438|NCT05165758||Diabetic subjects with foot ulcer|54 diabetic subjects presenting foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
9866095|NCT00137605|Experimental|Pneumovax/immediate|
9866096|NCT00137605|Experimental|Pneumovax/delayed|
9866097|NCT00137605|Experimental|Prevnar/immediate|
9866098|NCT00137605|Experimental|Prevnar/delayed|
9866099|NCT00137735|Active Comparator|1|Gabapentin
9866100|NCT00137735|Placebo Comparator|2|Placebo
9866101|NCT00137787|Experimental|1|
9866102|NCT00137787|Active Comparator|2|
9866103|NCT00137800|Experimental|Tarceva|Chemotherapy Single Agent Systemic
9866104|NCT00137852|Experimental|Cisplatin/CPT-11/Celecoxib/XRT/Surgery|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
9866105|NCT00137865|Experimental|EGEN-001|
9866106|NCT00137995|Experimental|R-ICE|R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
9866107|NCT00137995|Experimental|R-DHAP|R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
9866108|NCT00138008|Active Comparator|1|Drug: endocrine therapy
9866109|NCT00138008|Experimental|2|Procedure/Surgery: radiotherapy
9866110|NCT00138177|Experimental|Treatment (vorinostat, mFOLFOX)|"Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD."
10210439|NCT05160922|Other|crizotinib|crizotinib oral treatment
10210440|NCT05157659|Experimental|[18F]F-AraG PET procedures|Within one week prior to resection two [18F]F-AraG PET-scans will be performed.
10210441|NCT05157139|No Intervention|Control|Patients receiving only standard care
10210442|NCT05157139|Active Comparator|Intervention (low dose)|Two capsules twice daily for 3 days then one capsule twice daily for 2 days
10210443|NCT05157139|Active Comparator|Intervention (high dose)|two capsules three times daily for 3 days, followed by one capsule three times daily for 4 days
10210444|NCT05154994|Experimental|Treatment (durvalumab, tremelimumab, belinostat)|Patients receive durvalumab IV over 30 minutes on day 1. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycle 1. Beginning cycle 2, patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
10210445|NCT05147402|Active Comparator|Fasted Treatments with 100 mg of MDMA|Following an overnight fast of at least 10 hours, participants will be administered 100 mg MDMA (equivalent to 120 mg MDMA HCl) with 240 mL of water. No food should be allowed for at least 4 hours post-dose.
9866111|NCT00138216|Experimental|Oral Irinotecan, temozolomide and vincristine sulfate|see detailed description
9866112|NCT00138437||Leprosy Patients (Group 1)|All leprosy patients
9866113|NCT00138437||Household Contacts (Group 2)|Household contacts with known contact with leprosy patients
9866114|NCT00138437||Healthy Individuals (Group 3)|Healthy persons with no known contact with leprosy patients
9866115|NCT00138463||West Nile Virus (WNV) Neuroinvasive Disease Cohort|Fever (temperature > 38 C) documented by a health care provider AND: at least one of the following, as documented by a health care provider and in the absence of a more likely clinical explanation: acutely altered mental status; other acute signs of central or peripheral neurologic dysfunction; or cerebrospinal fluid (CSF) pleocytosis associated with illness clinically compatible with meningitis.
9866116|NCT00138463||West Nile Virus Fever Cohort|Temperature > 38 C as documented by a health care provider.
9866117|NCT00138476|Experimental|Group 4: 0.48 RT-PCR units or Placebo|Group 4: dosage group of 10 subjects will receive 0.48 RT-PCR units of Lot 42399 NV or placebo control (8 subjects will receive NV and 2 subjects will receive placebo control).
9996962|NCT01504646|Experimental|Lyprinol|Ten subjects will take eight Lyprinol capsules per day for three weeks.
9866118|NCT00138476|Experimental|Group 3: 4.8 RT-PCR units or Placebo|Group 3: dosage group of 12 subjects will receive 4.8 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
9866119|NCT00138476|Experimental|Group 2: 48 RT-PCR units or Placebo|Group 2: dosage group of 12 subjects will receive 48 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
9866120|NCT00138476|Experimental|Group 1: 4800 RT-PCR units or Placebo|Group 1: dosage group of 11 subjects will receive 4800 reverse transcription polymerase chain reaction (RT-PCR) units of Lot 42399 Norwalk Virus (NV) or placebo control (9 subjects will receive NV and 2 subjects will receive placebo control).
9866121|NCT00138476|Experimental|Validation Group: 4.8 and 0.48 RT-PCR units|Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
9866122|NCT00138554|Experimental|vildagliptin 50 mg qd + pioglitazone 45 mg qd|vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks
9866123|NCT00138554|Experimental|vildagliptin 50 mg bd+ pioglitazone 45 mg qd|vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks
9927110|NCT00889629|Placebo Comparator|Cholecalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol) plus 25-OH Vitamin D3 (cholecalciferol) 400IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol placebo if target PTH value is not achieved by the predetermined midpoint.
9927111|NCT00889642|Active Comparator|Active|Contains Lidocaine and Epinephrine
9927112|NCT00889642|Placebo Comparator|Placebo|Contains Epinephrine
9927113|NCT00889655|Active Comparator|Golytely|216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy
9927114|NCT00889655|Experimental|MiraLax|216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser
9927115|NCT00889668|Experimental|Experimental|subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.
9927116|NCT00889785|Active Comparator|1 (Usual Care)|Patients will continue to review usual care in the diabetes clinic. Patients will receive monthly phone calls as an active control condition.
9927117|NCT00889785|Experimental|Intervention|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
9927118|NCT00889837|Experimental|Inhaled Loxapine|Staccato Loxapine, 10 mg doses x 2, 10 hours apart
9927119|NCT00889837|Placebo Comparator|Inhaled Placebo|Staccato Placebo,inhalations x 2, 10 hours apart
9927120|NCT00889850|Active Comparator|1|Oral fasted administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
9927121|NCT00889850|Active Comparator|2|Oral fasted administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
9927122|NCT00889850|Active Comparator|3|Oral fed administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
9927123|NCT00889850|Active Comparator|4|Oral fed administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
9927124|NCT00889876|Experimental|Metformin|
9927125|NCT00889876|Experimental|Exercise|
9927126|NCT00889941|Active Comparator|small|
9927127|NCT00889941|Active Comparator|medium|
9927128|NCT00889941|Active Comparator|large|
9927129|NCT00889954|Experimental|TGFBeta resistant HER2/EBV-CTLs|"The following dose levels will be evaluated:~Dose Level 1: 1 x 10^4 cells/m^2~Dose Level 2: 3 x 10^4 cells/m^2~Dose Level 5: 1 x 10^6 cells/m^2~Dose Level 6: 3 x 10^6 cells/m^2~Dose Level 7: 1 x 10^7 cells/m^2~Dose Level 8: 3 x 10^7 cells/m^2~Dose Level 9:1 x 10^8 cells/m^2"
9927130|NCT00889980||Melanoma|Patients with primary melanoma
9927131|NCT00890006|Experimental|MRI + CBCT in prostate cancer|
10210446|NCT05147402|Active Comparator|Fed Treatments with 100 mg of MDMA|A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal will be used as a test meal for food-effect evaluation. Following an overnight fast of at least 10 hours, participants will start the recommended meal 30 minutes prior to administration of the drug product. Participants will eat this entire meal in 30 minutes or less. 100 mg MDMA (equivalent to 120 mg MDMA HCl) will be administered 30 minutes after start of the meal with 240 mL of water.
9866124|NCT00138632|Experimental|1|
9866125|NCT00138632|Experimental|2|
9866126|NCT00138632|Placebo Comparator|3|
9866127|NCT00138684|Experimental|Venesection therapy|
9866128|NCT00138684|No Intervention|no venesection therapy|
9866129|NCT00138736|Experimental|A|MBL until the patient's absolute neutrophil count (ANC) is above 500/microL blood.
9866130|NCT00138853|Active Comparator|Tantalum knee|Tantalum Tibial component, uncemented
9866131|NCT00138853|Active Comparator|Titanium Knee|Titanium Tibial Component, screw fixed
9866132|NCT00138944|Placebo Comparator|1|Placebo
9866133|NCT00138944|Active Comparator|2|Eplerenone
9866134|NCT00139074|Active Comparator|1|quetiapine fumarate monotherapy
9866135|NCT00139074|Experimental|2|Quetiapine + sodium valproate
9866136|NCT00139113|Experimental|HAVRIX 6 and 12 mos; mother antibody pos|HAVRIX administered to infants born to anti-HAV positive mothers at ages 6 and 12 months
9866137|NCT00139113|Active Comparator|HAVRIX age 6, 12 mos; mom antibody neg|HAVRIX administered to infants born to anti-HAV negative mothers at ages 6 and 12 months
9866138|NCT00139113|Experimental|HAVRIX ages 12, 15 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 12 and 15 months
9866139|NCT00139113|Active Comparator|HAVRIX ages 12, 15 mos; mom antibody-|HAVRIX administered to infants born to anti-HAV negative mothers at ages 12 and 15 months
9866140|NCT00139113|Experimental|HAVRIX ages 15,21 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 15 and 21 months
9866141|NCT00139113|Active Comparator|HAVRIX ages 15,21 mos; mom antibody -|HAVRIX administered to infants born to anti-HAV negative mothers at ages 15 and 21 months
9866142|NCT00139152|Placebo Comparator|Placebo|Saline placebo
9866143|NCT00139152|Experimental|Xolair|Xolair treatment
9866144|NCT00139256|Experimental|Betamethasone|Betamethasone injection
9866145|NCT00139256|Placebo Comparator|Placebo|Placebo injection
9866146|NCT00139360|Experimental|1|Active drug
9866147|NCT00139386|Active Comparator|Candesratan|
9866148|NCT00139386|No Intervention|Non-candesartan|
9866149|NCT00139451|Active Comparator|Nutrition and Growth Hormone|
9866150|NCT00139451|Active Comparator|Observation and Growth Hormone|
9866151|NCT00139490|Experimental|A|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
9866152|NCT00139490|Active Comparator|B|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
9866153|NCT00139490|Placebo Comparator|C|Usual Care group
9866154|NCT00139529|Experimental|1|Participants will receive an educational intervention during pregnancy combined with a motivational interviewing program using telephone counseling to prevent postpartum relapse to tobacco use.
9866155|NCT00139529|Active Comparator|2|Participants will receive an educational intervention during pregnancy.
9866156|NCT00139542|Active Comparator|CONTROL|AED Treatment protocol following AHA Guidelines 2000 recommendations for cardiac arrest resuscitation.
9866157|NCT00139542|Experimental|STUDY|AED treatment protocol with prolonged CPR intervals, single shocks, fewer rhythm analysis and pulse checks.
9866158|NCT00139581|Experimental|1|Pimecrolimus b.i.d.
9866159|NCT00139581|Experimental|2|Pimecrolimus o.d. and placebo o.d.
9866160|NCT00139594|Experimental|licarbazepine|
9866161|NCT00139815|Active Comparator|Enoxaparin|
9866162|NCT00139815|Experimental|Fondaparinux|
9866163|NCT00139828|Other|A|The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
9866164|NCT00139841|Experimental|1|bendamustine
9866165|NCT00139958||1|
9866166|NCT00139958||2|
9866167|NCT00140010|Experimental|A|30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient
9866168|NCT00140075|Experimental|B|"ET (8 cycles)~T = docetaxel or paclitaxel"
9866169|NCT00140075|Experimental|A|"EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles~T = docetaxel or paclitaxel"
9927132|NCT00890019|Experimental|1A, 2A, 3A, 4A, 5A, 6A, 7A|AdCh63 ME-TRAP
9927133|NCT00890019|Experimental|1B, 2B, 3B, 4B, 6B, 7B, 7C|AdCh63 ME-TRAP; MVA ME-TRAP
9927134|NCT00890032|Experimental|BTSC mRNA-loaded DCs|BTSC mRNA-loaded DCs administered intradermally weekly for first 3 vaccines, then monthly until progression or withdrawal.
9927135|NCT00890058||Cases|Postmenopausal breast cancer patients with hand pain receiving aromatase inhibitors
9927136|NCT00890058||Controls|Postmenopausal breast cancer patients with hand pain not receiving aromatase inhibitors
9927137|NCT00890071||Acute circulatory failure|Patients for whom the decision to give fluids was taken because the presence of one or more clinical signs of acute circulatory failure.
9927138|NCT00890110|Experimental|Autologus vaccination with suntinib|Combination of autologous dnp irradiated modified cells with sunitinib treatments
9866170|NCT00140101|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
9866171|NCT00140101|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
9866172|NCT00140114|Other|A|A: Vaginal misoprostol (cytotec)
9866173|NCT00140114|Other|B|Sublingual misoprostol (Cytotec)
9866174|NCT00140465|Active Comparator|1|75 mg Clopidogrel Maintenance Doses
9866175|NCT00140465|Active Comparator|2|150 mg Clopidogrel Maintenance Doses
9866176|NCT00140504|Experimental|MedCheck|Electronic medication safety queries via PatientSite portal
9866177|NCT00140504|No Intervention|Usual care|No electronic medication safety messages via PatientSite portal
9866178|NCT00140530|Experimental|1|Due to randomisation patients got a Paclitaxel-eluting stent
9866179|NCT00140530|Experimental|2|Due to randomization patients got a Rapamycin-eluting stent.
9866180|NCT00140582|Experimental|A : rituximab maintenance|Maintenance with rituximab for 2 years
9866181|NCT00140582|No Intervention|B : no maintenance|No further treatment
9866182|NCT00140660|Experimental|R-ACVBP|addition of rituximab to standard ACVBP chemotherapy
9866183|NCT00140660|No Intervention|ACVBP|standard ACVBP chemotherapy
9866184|NCT00140712|Experimental|Ropinirole|single dose .25mg of IR formulation, .05mg of RLS controlled release
9866185|NCT00140738|Experimental|Group A|"Patients receive study vaccinations in 3 consecutive cycles:~In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.~In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.~In Cycle 3, subjects will patients six vaccinations at three-week intervals."
9866186|NCT00140738|Experimental|Group B|Patients receive study vaccinations as second-line therapy
9866187|NCT00140751|Experimental|Simplification|The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks
9866188|NCT00140751|No Intervention|Continued|The patients included in this arm continue their treatment without any changes
9866189|NCT00140790|Active Comparator|Valsartan 40mg|Standard Dose valsartan
9866190|NCT00140790|Active Comparator|Valsartan 160mg|High Dose valsartan
9866191|NCT00141011|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
9866192|NCT00141011|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
9866193|NCT00141024|Experimental|1|Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
9866194|NCT00141024|Experimental|2|Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
9866195|NCT00141024|Experimental|3|In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
9866196|NCT00141024|Experimental|4|In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.
9866197|NCT00141024|Experimental|5|In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
9866198|NCT00141193|Placebo Comparator|A|
9866199|NCT00141440|Experimental|1|COPD patients
9866200|NCT00141531|Active Comparator|Apaziquone|
9866201|NCT00141544|Experimental|1|
9866202|NCT00141544|Active Comparator|2|
9866203|NCT00141557|Experimental|1|
9866204|NCT00141557|Active Comparator|2|
9866205|NCT00141648|Experimental|1|Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
9866206|NCT00141661|Experimental|Low Dose Arm|
9866207|NCT00141661|Experimental|High Dose Arm|
9866208|NCT00141661|Placebo Comparator|Placebo Control|
9866209|NCT00141687|Experimental|Early External Cephalic Version Group|Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation
9866210|NCT00141687|Active Comparator|Delayed External Cephalic Version Group|Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation
9866211|NCT00141713|Experimental|1|etanercept treatment for GVHD
9927139|NCT00890123|Active Comparator|Omegaven|Patients in this arm will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively.
9927140|NCT00890123|No Intervention|Without Omegaven|Patients will not receive IV Omega 3 fatty acids
9927141|NCT00890175|Experimental|Inhaled loxapine @ 0 & 10 h|Inhalation of 10 mg of loxapine at 0 and 10 hours
9927142|NCT00890175|Placebo Comparator|Inhaled placebo @ 2 & 10 hours|Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
9927143|NCT00890188|Experimental|THALIDOMIDE and UFUR|
9927144|NCT00890214|Active Comparator|1 prostacyclin group|prostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
9927145|NCT00890214|Active Comparator|2 heparin group|unfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
9927146|NCT00890227|Active Comparator|Traditional technique|All level open instrumented posterior spinal fusions
9927147|NCT00890227|Active Comparator|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
9927148|NCT00890253|Experimental|CNI-free Immunosuppression|Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.
9927149|NCT00890279|Experimental|Cilnidipine|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
9866212|NCT00141856|Other|1|
9866213|NCT00141895|Active Comparator|A|Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
9866214|NCT00141895|Active Comparator|B|Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
9866215|NCT00141908|Placebo Comparator|Placebo progesterone injection|Placebo IM injections
9866216|NCT00141908|Active Comparator|Progesterone injections|17-hydroxyprogesterone caproate weekly injections
9866217|NCT00141986|Experimental|Vitamin D-higher dose|Vitamin D 2000 IU per os once daily
9866218|NCT00141986|Active Comparator|Vitamin D-lower dose|Vitamin D 400 IU per os once daily
9866219|NCT00142051|Experimental|1|inhaled NO
9795729|NCT01544348|Experimental|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
9795730|NCT01544348|Experimental|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
9795731|NCT01544361|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
9795732|NCT01544361|Experimental|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 milligram per kilogram (mg/kg) intravenous infusion over at least 60 minutes on Day 1.
9795733|NCT01544361|Experimental|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
9795734|NCT01544361|Experimental|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
9795735|NCT01544361|Experimental|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
9795736|NCT01544478|Experimental|V501|Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6
9795737|NCT01544491|Experimental|Investigational arm|Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
9795738|NCT01544491|Active Comparator|Control arm|MMF continuation (in combination with tacrolimus and standard dose steroids)
9795739|NCT01544582||Boceprevir + PR|CHC genotype-1 participants included in study and prescribed boceprevir plus PR as routine clinical management.
9795740|NCT01544582||Telaprevir + PR|CHC genotype-1 participants included in study and prescribed telaprevir plus PR as routine clinical management.
9795741|NCT01544582||PR Alone|CHC genotype-1 participants included in study and prescribed PR alone as routine clinical management.
9795742|NCT01544595|Placebo Comparator|PASI 75 Responders|"PASI 75 responders participated in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen."
9795743|NCT01544595|Experimental|Partial responders|Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.
9795744|NCT01544920|Active Comparator|Arm 1: peg-IFN + RBV|Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].
9795745|NCT01544920|Experimental|Arm 2: BOC + peg-IFN + RBV|Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].
9795746|NCT01544998|Experimental|Tadalafil plus Placebo, then Tadalafil plus Nesiritide|First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
9866220|NCT00142051|Placebo Comparator|2|room air inhalation
9866221|NCT00142090|Experimental|2|3% Hypertonic saline
9866222|NCT00142090|Placebo Comparator|1|Normal saline
9866223|NCT00142103|Experimental|CPG10101|
9866224|NCT00142103|Experimental|CPG10101 + pegylated interferon|
9866225|NCT00142103|Experimental|CPG10101 + ribavirin|
9866226|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin|
9866227|NCT00142103|Active Comparator|Pegylated inteferon + ribavirin|
9866228|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
9866229|NCT00142181|Experimental|Campath-1H|30 mg IV three times a week, 6-12 weeks.
9866230|NCT00142207|Active Comparator|1|Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine
9866231|NCT00142207|Active Comparator|2|Device: Insecticide-treated mosquito bed net
9866232|NCT00142207|Active Comparator|3|"Combination of Drug + Device:~Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine Device: Insecticide-treated mosquito bed net"
9866233|NCT00142233|Experimental|ANTOX (vers.)1.2|"Adults and children aged 10+ will take two ANTOX (vers)1.2 tablets three times per day. (Antioxidant treatment: daily: 300 μg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine) plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one ANTOX (vers)1.2 tablet three times daily (Antioxidant treatment: daily: 150 μg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine) plus one placebo Magnesiocard (2.5 mmol) tablet three times a day."
9866234|NCT00142233|Experimental|Magnesium|"Adults and children aged 10+ will take two Magnesiocard (2.5 mmol) tablets three times per day (total dose: 15 mmol = 365 mg per day) plus two placebo ANTOX (vers)1.2 tablets three times a day.~Children aged five to nine years of age will take one Magnesiocard (2.5 mmol) tablet three times a day (total dose: 7.5 mmol = 182 mg per day) plus one placebo ANTOX (vers)1.2 tablet three times a day."
9866235|NCT00142233|Placebo Comparator|Placebo|"Adults and children aged 10+ will take two placebo ANTOX (vers)1.2 tablets three times a day, plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one placebo ANTOX (vers)1.2 tablet three times a day, plus one placebo Magnesiocard (2.5 mmol) tablet three times per day."
9866236|NCT00142246|Experimental|1|Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
9866237|NCT00142246|Placebo Comparator|2|Dual placebo comparator
9866238|NCT00142428|Experimental|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
9866239|NCT00142467|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
9866240|NCT00142480|Experimental|Capecitabine, Oxaliplatin, Bevacizumab|There are two phases of study treatment. Phase I includes all patients and will last 6 weeks. During this phase, oxaliplatin will be given intravenously (IV) on days 1, 8, 22, and 29; bevacizumab will be given IV on days 1, 15, and 29; capecitabine will be administered orally on days 1-14 and 22-35. Radiation therapy will be given once daily for 5 days (Monday-Friday) per week for a total of 28 treatments. Phase II has two groups: 1) patients who had tumors removed prior to entering study and 2) patients who entered the study with advanced disease. Patients who had their tumors removed prior to entering the study will be treated with the above 6-week regimen twice for a total of 12 weeks of treatment. Patients who were unresectable prior to entering the study but then were deemed resectable after treatment on trial will undergo resection. Following surgical recovery (8-10 weeks) they will be treated again with the above 6-week regimen twice for a total of 12 weeks of treatment.
9866241|NCT00142493|Experimental|1|
9866242|NCT00142493|Experimental|2|
9866243|NCT00142493|Experimental|3|
9866244|NCT00142493|Experimental|4|
9866245|NCT00142493|Placebo Comparator|5|
9866246|NCT00142532|Experimental|1|At the time of pre-op preparation, 18 semi-permanent intradermal acupuncture studs will be placed at acupuncture points in the back, two will be placed in the legs and two in the ear. All studs will be replaced when the epidural is removed or, for patients without epidurals, shortly before discharge. The new leg and auricular studs will then be removed at eleven days; the new back studs will be removed at the three week post-discharge consult.
9927150|NCT00890279|Active Comparator|Imidapril|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
9996963|NCT01504659|Active Comparator|Bipolar-Ketalar|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of intranasal ketalar
9866247|NCT00142532|Placebo Comparator|2|"The treatment is the same as for the true acupuncture group, with the following exceptions. The studs in the back will be dummy studs have no needle and that have been used in previous research at MSKCC. The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.~Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
9866248|NCT00142610|Experimental|vitamin|500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks
9866249|NCT00142610|Placebo Comparator|Placebo|
9866250|NCT00142623|Experimental|1|"Use of five tailored take-home DVDs aimed at reducing exposure to ETS"
9866251|NCT00142623|No Intervention|2|Usual care
9866252|NCT00142688|Experimental|1|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
9866253|NCT00142688|Active Comparator|2|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
9866254|NCT00142740||1 - HIV Positive|Participant in parent study ATN 024, aged 12-24 years, testing HIV positive. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 024.
9866255|NCT00142740||2 - HIV Negative|Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
9866256|NCT00142753|Active Comparator|A1: ATN 024 Energix-B Standard Adult Dose|
9866257|NCT00142753|Experimental|A2: ATN 024 Engerix-B Increased Adult Dose|
9866258|NCT00142753|Active Comparator|A3: ATN 024 Twinrix Standard Adult Dose|
9866259|NCT00142753|Experimental|B1: ATN 025 Recombivax|
9866260|NCT00142753|Experimental|B2: ATN 025 Twinrix|
9866261|NCT00142805|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
9866262|NCT00142805|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
9866263|NCT00142831|Experimental|1|Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks
9866264|NCT00142831|Placebo Comparator|2|Identical Placebo
9866265|NCT00142844|Experimental|Naltrexone|Naltrexone
9866266|NCT00142844|Experimental|Disulfiram|Disulfiram
9866267|NCT00142844|Experimental|Naltrexone and Disulfiram|Naltrexone and Disulfiram
9866268|NCT00142844|Placebo Comparator|Placebo|Placebo
9866269|NCT00142870|Placebo Comparator|A|
9866270|NCT00142883|Active Comparator|pregabalin|pregabalin compared to placebo
9866271|NCT00142883|Placebo Comparator|Placebo|Placebo compared to pregabalin
9866272|NCT00142922|Experimental|1|Attended Breaking Down Barriers program
9866273|NCT00142922|Active Comparator|2|Attention control group
9866274|NCT00142922|Active Comparator|3|Indivdual attention control group
9866275|NCT00142948|Experimental|Naltrexone|Naltrexone Oral 50 mgs daily
9866276|NCT00142948|Placebo Comparator|Placebo|1 to 1 comparison of Naltrexone to placebo
9866277|NCT00142961|Experimental|1|Atomoxetine prescribed daily
9866278|NCT00142961|Placebo Comparator|2|placebo controlled arm
9866279|NCT00143039||NIH/SSIUGR fetuses|Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
9866280|NCT00143039||Control-Normal fetus|Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.
9866281|NCT00143130|Experimental|Single Arm|
9866282|NCT00143273|Experimental|Lasofoxifene Dose 1|0.05 mg
9866283|NCT00143273|Experimental|Lasofoxifene Dose 2|0.25 mg
9866284|NCT00143273|Experimental|Lasofoxifene Dose 3|0.5 mg
9866285|NCT00143273|Placebo Comparator|Placebo|0 mg
9927151|NCT00890318|Other|1|Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole
9927152|NCT00890318|Other|2|Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.
9927153|NCT00890318|Other|3|Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.
9927154|NCT00890331|Active Comparator|Diabetes Education|
9927155|NCT00890331|Experimental|TeamWork CS Sessions|
9927156|NCT00890357||Triptan User|
9927157|NCT00890357||Triptan Discontinued|
9927158|NCT00890370|Other|1|Active cycle of breathing techniques
9927159|NCT00890370|Other|2|Autogenic drainage
9927160|NCT00890370|Other|3|R-C Cornet
9927161|NCT00890370|Other|4|Flutter
9927162|NCT00890370|Other|5|PEP
9927163|NCT00890383|No Intervention|Crystalloid only|patients will receive crystalloid fluids only for volume therapy of severe trauma
9927164|NCT00890383|Active Comparator|Colloid + Crystalloid arm|Goal directed volume therapy for severe trauma resuscitation
9927165|NCT00890422|Experimental|1FSME vaccination|2 vaccination on day 0
9927166|NCT00890422|Experimental|2 FSME vaccination|1 vaccination on day 0 and one vaccination on day 4
9927167|NCT00890422|Experimental|3 FSME vaccination|2 vaccinations on day 0 and 1 vaccination on day 4
9927168|NCT00890448||Lapaquistat acetate participants|
9927169|NCT00890461||Defibrillator|The subject population will be obtained by approaching the Principal and Co- Investigators' patients who have been referred for ICD implantation or who already have an ICD. This population ranges in age from 18 years on, and includes both males and females. A maximum of 50 subjects will be enrolled in this study.
9927170|NCT00890474|Experimental|Moxibustion|
9866286|NCT00143468|Experimental|1|ALI/ARDS patients and healthy subjects
9866287|NCT00143494|Experimental|1|Critically hill, mechanically ventilated patients
9866288|NCT00143533|Other|1|
9866289|NCT00143559|Other|1|
9866290|NCT00143572|Other|1|
9866291|NCT00143611|Experimental|Resatorvid 1.2 mg/kg/day|
9866292|NCT00143611|Experimental|Resatorvid 2.4 mg/kg/day|
9866293|NCT00143611|Placebo Comparator|Placebo|
9866294|NCT00143624|Experimental|1|The first group will receive 8 mg of the study drug (rosiglitazone).
9866295|NCT00143624|Placebo Comparator|2|The second group will be given a placebo.
9866296|NCT00143637|Experimental|2|Office dust with added glucan
9866297|NCT00143637|Experimental|1|Clean air exposures in climate chamber
9866298|NCT00143663|Experimental|Lapaquistat Acetate 100 mg QD|
9866299|NCT00143663|Placebo Comparator|Placebo QD|
9866300|NCT00143676|Experimental|Lapaquistat Acetate 50 mg QD + Atorvastatin|
9866301|NCT00143676|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin|
9866302|NCT00143676|Active Comparator|Atorvastatin|
9866303|NCT00143689|Experimental|Lopinavir/ritonavir, Zidovudine, Lamivudine|"Participants will be randomly assigned to receive one of the following drug combinations:~lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;~Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;~Combivir and lopinavir/ritonavir twice a day."
9866304|NCT00143715|Experimental|1|Low dose oral vitamin K + warfarin cessation
9866305|NCT00143715|Placebo Comparator|2|
9866306|NCT00143741|Other|Lipitor|
9866307|NCT00143910||Renal transplant recipient|Recipients of successful renal transplant
9866308|NCT00143936|Active Comparator|Low Carb|Low Cabohydrate Diet: 20 week of weekly group behavior modification, 20 weekly bi-weekly, bi-monthly to finish
9866309|NCT00143936|Active Comparator|Low Calorie|Low Calorie Diet: 20 weeks of weekly behavior modification, 20 weekly of bi-weekly, bimonthly to finish 2 years
9866310|NCT00143988||Treadmill Test exertion females|
9866311|NCT00143988||Treadmill test exertion males|
9866312|NCT00143988||Sexual activity exertion females|
9866313|NCT00143988||Sexual activity exertion males|
9866314|NCT00144001||Group 1|
9866315|NCT00144040|Other|Arm 1|
9866316|NCT00144417|Active Comparator|HRZE|isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
9866317|NCT00144417|Experimental|MRZE|moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
9866318|NCT00144456|Experimental|1|
9866319|NCT00144456|Active Comparator|2|
9866320|NCT00144482|Experimental|1|
9866321|NCT00144482|Placebo Comparator|2|
9866322|NCT00144495|Experimental|1|patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
9866323|NCT00144495|Experimental|2|patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
9866324|NCT00144508|Experimental|1|
9866325|NCT00144508|Other|2|continue current treatment
9866326|NCT00144521|Experimental|1|
9866327|NCT00144521|Active Comparator|2|
9866328|NCT00144534|Experimental|1|
9866329|NCT00144547|Experimental|1|
9866330|NCT00144586|Experimental|1|
9866331|NCT00144599|Experimental|1|
9866332|NCT00144599|Placebo Comparator|2|
9866333|NCT00144612|Experimental|1|
9866334|NCT00144625|Experimental|1|
9866335|NCT00144651|Experimental|1|
9866336|NCT00144664|Experimental|1|MRA(Tocilizumab)
9866337|NCT00144755|Active Comparator|R-CHOP21|8 cycles of R-CHOP21
9866338|NCT00144755|Experimental|R-CHOP21, Darbepoetin alfa|8 cycles of R-CHOP21 + prophylactic darbepoetin alfa
9866339|NCT00144755|Experimental|R-CHOP14|8 cycles of R-CHOP14
9866340|NCT00144755|Experimental|R-CHOP14, Darbepoetin alfa|8 cycles of R-CHOP14 + prophylactic darbepoetin alfa
9866341|NCT00144807|Experimental|R-AC|rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation
9866342|NCT00144846|Other|Arm 1|
9866343|NCT00144872|Experimental|Subjects receiving lamotrigine|Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.
9866344|NCT00144885|No Intervention|1|
9866345|NCT00144898|Experimental|Sentinel Node Resection|Sentinel Node Resection
9866346|NCT00144898|Other|Conventional Axillary Dissection|Conventional Axillary Dissection
9866347|NCT00144911|Experimental|Arm 1|
9927171|NCT00890474|No Intervention|Control|
9927172|NCT00890487|Other|hyaluroni acid pill|
9927173|NCT00890500|Active Comparator|Group 1|2 umbilical cord units: Second cord blood unit modulated with ProHema
9927174|NCT00890500|Active Comparator|Group 2|2 umbilical cord units: First cord blood unit modulated with ProHema
9866348|NCT00144989|Active Comparator|1|Etoposide and cisplatin after chemoradiotherapy
9866349|NCT00144989|Experimental|2|Irinotecan and cisplatin after chemoradiotherapy
9866350|NCT00145184|Placebo Comparator|Placebo|Placebo
9866351|NCT00145184|Experimental|Multivitamins|Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E
9866352|NCT00145197|Experimental|Improving the Delivery of Effective Care to Minorities|
9866353|NCT00145314|Active Comparator|A|FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
9866354|NCT00145314|Experimental|B|FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
9866355|NCT00145314|Experimental|C|FLOX given intermittently and maintenance cetuximab
9866356|NCT00145379|Experimental|Metformin|
9866357|NCT00145379|Placebo Comparator|Placebo comparator|
9866358|NCT00145522|Experimental|1|
9866359|NCT00145522|Active Comparator|2|
9866360|NCT00145535|Experimental|1|Titanium sapphire laser treatment
9866361|NCT00145535|Active Comparator|2|Argon laser treatment
9866362|NCT00145613|Other|1|
9866363|NCT00145639|Other|1|
9866364|NCT00145678|Experimental|dynamic deconstructive psychotherapy|weekly individual psychotherapy of 50 minute duration lasting 12-18 months
9866365|NCT00145678|Active Comparator|optimized community care|eclectic weekly individual and group psychotherapy, as well as drug and alcohol rehabilitation
9866366|NCT00145743|Experimental|1|Patient's reported questionaire, profile in 10 dimensions (EORTC) and referees' report with treatment recommendations
9866367|NCT00145743|Experimental|2|Patient's reported questionaire; no recommendations given
9866368|NCT00145769|Active Comparator|Short Course Radiotherapy|Short Course (SC) pre-operative radiotherapy, followed by surgery and adjuvant chemotherapy
9866369|NCT00145769|Active Comparator|Long Course Radiotherapy|Long Course (LC) radiotherapy delivered with concurrent chemotherapy, followed by surgery and adjuvant chemotherapy
9866370|NCT00145769|Active Comparator|Surgery|Patients will receive initial surgery followed by post-operative management according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Adjuvant therapy for rectal cancer.
9866371|NCT00145847|Active Comparator|Naltrexone|Naltrexone 50 mg per day, directly administered as 100 mg on Mondays, 100 mg on Wednesdays and 150 mg on Fridays
9866372|NCT00145847|Placebo Comparator|Lactose pill|
9866373|NCT00145886|Experimental|rhPTH|Subjects will be treated rhPTH for 12 months
9866374|NCT00145912|Experimental|Intrinsic Motivation|PCP motivational interview + Internet program
9866375|NCT00145912|Active Comparator|Extrinsic Motivation|PCP breif advice + Internet Program
9866376|NCT00145925|Placebo Comparator|Blood pressure|Perindopril indapamide vs placebo
9866377|NCT00145925|Other|Glucose control|Standard versus intensive glucose control
9866378|NCT00145951||1|
9866379|NCT00145951||2|
9866380|NCT00145951||3|
9866381|NCT00146081|Experimental|A|Family Program: Participants who have identified at least 1 family member or friend to enroll in SHARE with them, who are randomly assigned to program A, are invited to bring their enrolled family member or friend (co-participant) with them to the study intervention group sessions as their supportive team member.
9866382|NCT00146081|Active Comparator|B|Coach Program: Participants who identify 1 or 2 family members or friends to enroll in SHARE with them, who are randomly assigned to program B, are invited to attend the study intervention group sessions without their enrolled family or friend (co-participants). The co-participants receive the same written materials, but act as supportive team members outside of the group sessions only. They are invited to attend special field workshops and personal counseling sessions with their co-participants.
9866383|NCT00146081|Experimental|C|Team Program: Participants who do not identify 1 or 2 family or friend co-participants, and are randomly assigned to program C, are paired with other unrelated enrollees in their group sessions as supportive team members.
9866384|NCT00146081|Active Comparator|D|Individual Program: Participants who do not identify 1 or 2 family members or friends to enroll in SHARE with them, and are randomly assigned to program D, attend group sessions as individuals.
9866385|NCT00146107|No Intervention|1|
9866386|NCT00146107|Experimental|2|Weight loss
9866387|NCT00146107|Experimental|3|Exercise
9866388|NCT00146107|Experimental|4|Weight loss and exercise
9866389|NCT00146159|Experimental|1|1st group: 12 mg Mitoxantrone/m²
9866390|NCT00146159|Experimental|2|2nd group: 9mg Mitoxantrone/m²
9866391|NCT00146159|Experimental|3|3rd group: 5mg Mitoxantrone/m²
9866392|NCT00146224|Active Comparator|Epoetin alfa RB|
9866393|NCT00146224|Experimental|Epoetin alfa DT|
9866394|NCT00146250|Experimental|Nitrous oxide|Nitrous oxide 70% as balance gas in inspired mixture
9866395|NCT00146250|Experimental|Nitrogen|Nitrogen instead of nitrous oxide 70% as balance gas in inspired mixture
9866396|NCT00146263|Active Comparator|Savyon|Computerized cognitive training using the Savyon software
9866397|NCT00146263|Placebo Comparator|Control|Usual activity
9866398|NCT00146315|Active Comparator|Control|Secondary prevention program for coronary heart disease
9866399|NCT00146315|Experimental|Supervised exercise|
9866400|NCT00146471|Active Comparator|2|
9866401|NCT00146471|Placebo Comparator|1: Diazepam plus Placebo|
9866402|NCT00146523|Experimental|mifepristone 600 mg|
9866403|NCT00146523|Placebo Comparator|matching placebo|
9927175|NCT00890526|Experimental|1|Full treatment = Counseling + sound therapy.
9927176|NCT00890526|Experimental|2|Counseling + placebo sound therapy.
9927177|NCT00890526|Experimental|3|No Counseling + Sound Therapy
9927178|NCT00890526|Placebo Comparator|4|No counseling + Placebo sound therapy.
9927179|NCT00890539|Experimental|Quadrupling|methacholine challenge using quadrupling concentrations
9927180|NCT00890539|Active Comparator|doubling|doubling concentrations of methacholine
9927181|NCT00890565|Experimental|Treatment A: Sancuso® patch|Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)
9927182|NCT00890565|Experimental|Treatment B: IV Granisetron 10 mcg/kg|Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)
9927183|NCT00890565|Placebo Comparator|Treatment C: Matching placebo patch|Treatment C: placebo patch (Day 1) and placebo IV (Day 3)
9927184|NCT00890565|Active Comparator|Treatment D: Oral Moxifloxacin 400 mg|Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).
9927185|NCT00890578||1-abdominal|half abdominal surgeries (20 patients out of 40)
9927186|NCT00890578||2-breast|half breast surgeries (20 out of 40)
9927187|NCT00890604|Other|1|Usual Care
9927188|NCT00890604|Experimental|2|Normothermia Protocol
9927189|NCT00890630|Active Comparator|Oxytocin|Induction of Labour with Oxytocin Alone
9927190|NCT00890630|Experimental|Intracervical Catheter|Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.
9927191|NCT00890643|Experimental|Arm 1|Persons with PTSD
9927192|NCT00890643|Placebo Comparator|Arm 2|Persons with PTSD
9927193|NCT00890669|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
9927194|NCT00890708|No Intervention|non-TDM of voriconazole|conventional dose
9927195|NCT00890708|Experimental|TDM of voriconazole|
9927196|NCT00890734|Experimental|1|
9927197|NCT00890734|Placebo Comparator|2|
9927198|NCT00890747|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9927199|NCT00890760|Experimental|Group 1|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
9927200|NCT00890760|Experimental|Group 2|AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
9866404|NCT00146575|Experimental|1|randomized patients get sirolimus stent
9866405|NCT00146575|Experimental|2|randomized patients get paclitaxel stent
9866406|NCT00146653||Xa|An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .
9866407|NCT00146679|Placebo Comparator|Usual Care (UC)|Usual Care provided by providers
9866408|NCT00146679|Active Comparator|Psychoeducational Telephone CounselingTC|Education and Counseling for ICD patients provided through Telephone Contact
9866409|NCT00146679|Active Comparator|Psychoeducation through Groups (SG)|Education and Counseling for ICD patients provided in a group setting with other ICD Patients
9866410|NCT00146835||Cohort A|The primary study cohort includes all infants from SCKP who have begun their primary course of vaccine with PEDIARIX co-administered with Prevnar and for whom at least one dose of PEDIARIX was administered prior to the infant's 9-month birthday and safety follow-up information is available.
9866411|NCT00146835||Cohort B|This Historical cohort includes age-, gender- and area-matched infants who received at least one dose of DTaP vaccine co-administered with 7Pn between 1 January 2002 and 29 April 2003.
9866412|NCT00146835||Cohort C|"This delayed Pediarix use clinics cohort includes all infants who, during the enrollment period for Cohort A, begin their primary course of vaccination with a DTaP vaccine co-administered with 7Pn. It is age-, gender-, and area-matched in a similar manner to Cohort B."
9866413|NCT00146900|Experimental|Prolonged Exposure (CBT)|Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
9866414|NCT00146900|Active Comparator|Cognitive Therapy|Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
9866415|NCT00146900|Experimental|SSRI (escitalopram)|Twenty milligrams daily of escitalopram (blinded capsules)
9866416|NCT00146900|Placebo Comparator|Placebo|Two concealed placebo pills resembling 10mg escitalopram tablets
9866417|NCT00146900|No Intervention|Waiting List|Twelve weeks of waiting list no intervention group
9866418|NCT00147004|Experimental|1|hydrocortisone sodium succinate
9866419|NCT00147004|Placebo Comparator|2|Placebo
9866420|NCT00147056|Experimental|ExAblate transcranial system|MR Guided Focused Ultrasound
9866421|NCT00147095||HEALTHY NON-SMOKER|Healthy non-smoker participants
9866422|NCT00147095||HEALTHY SMOKER|Healthy smoker participants
9866423|NCT00147095||COPD and smoking|Smoking participants with COPD
9866424|NCT00147121|Active Comparator|1|Rituximab+Standard CHOP
9866425|NCT00147121|Experimental|2|Rituximab+bi-Weekly CHOP
9866426|NCT00147134|Active Comparator|1|Procedure/Surgery: open colectomy
9866427|NCT00147134|Experimental|2|Procedure/Surgery: laparoscopic colectomy
9866428|NCT00147303|Experimental|group L|25mg sarpogrelate
9866429|NCT00147303|Experimental|group M|50mg sarpogrelate
9866430|NCT00147303|Experimental|group H|100mg sarpogrelate
9866431|NCT00147355|Other|A|Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
9866432|NCT00147355|Other|B|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
9866433|NCT00147355|Other|D|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
9866434|NCT00147355|Other|C|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
9866435|NCT00147381|Experimental|Campath-1H 20 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 20 mg IV infusion over 3-6 hours.~Day 1: Same protocol of Campath-1H and methylprednisolone as on Day 0.~Day 2: No treatment~Day 3: Initial dose of Tacrolimus 0,1 mg/kg/d (0,05 mg/kg/bid)~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
9866436|NCT00147381|Active Comparator|Tacrolimus|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
9866437|NCT00147381|Experimental|Campath-1H 30 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment.~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
9866438|NCT00147459|Active Comparator|booster|no antibody and boosted
9866439|NCT00147472|Other|PET|All patients receive PET scan and conventional CT imaging.
9866440|NCT00147485|Experimental|1|
9866441|NCT00147550|Experimental|1|
9866442|NCT00147732|Active Comparator|1|Accelerated radiotherapy
9866443|NCT00147732|Experimental|2|ARCON
9866444|NCT00147771|Experimental|1|
9866445|NCT00147797||Pravastatin group|Patients in the pravastatin group were consecutively recruited in four department of infectious diseases if they fulfilled the following criteria : (1) HIV-infected treated with HAART for > 12 months 2) with dyslipidemia, defined as fasting serum LDL cholesterol > 160 mg/dL before initiation of pravastatin, (3) treated with pravastatin > 12 months and one more coronary risk factor.
9866446|NCT00147797||COotrol group|The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART > 12 months 2) fasting serum LDL cholesterol > 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
9866447|NCT00147836|Active Comparator|CSII|Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
9866448|NCT00147836|Active Comparator|MDI|Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
9866449|NCT00147836|Active Comparator|OHA|In oral hpoglycemic agents group, the patients with 20 kg/m2<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization
9866450|NCT00147901|Experimental|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
9866451|NCT00147914|Active Comparator|1|cefdinir
9866452|NCT00147914|Active Comparator|2|amoxicillin/clavulanate
9866453|NCT00147979|Experimental|1|PTFE with bounded heparin
9866454|NCT00147979|Active Comparator|2|PTFE without bounded heparin
9866455|NCT00147992|Experimental|implants|
9866456|NCT00148031|Experimental|1|On-site (MMT Clinic) HCV evaluation and treatment
9866457|NCT00148031|Active Comparator|2|Off-site (GI Clinic) HCV evaluation and treatment
9866458|NCT00148096|Placebo Comparator|1|Mechanical heat recovery ventilation units installed but not fully functional
9866459|NCT00148096|Active Comparator|2|Mechanical heat recovery ventilation unit installed and active
9866460|NCT00148174|Experimental|Phone calling|Phone calling to encourage improved adherence
9866461|NCT00148239|Experimental|Caregiver Only|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
9866462|NCT00148239|Experimental|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
9866463|NCT00148239|Active Comparator|Control|Participants are provided with written materials at beginning of study; nothing thereafter
9927201|NCT00890760|Experimental|Group 3|Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
9927202|NCT00890760|Experimental|Group 4|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
9927203|NCT00890760|Experimental|Group 5|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
9927204|NCT00890760|Experimental|Group 6|Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
9927205|NCT00890760|Experimental|Group 7|Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
9927206|NCT00890760|Experimental|Group 8|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
9927207|NCT00890760|Experimental|Group 9|2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
9927208|NCT00890760|Experimental|Group 10|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
9927209|NCT00890786|Experimental|HGG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the intervention section.
9927210|NCT00890786|Experimental|DIPG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the interventions section.
9927211|NCT00890799|Experimental|occluders|Shanghai pmVSD occluder (LEPU Medical Tech-nology Co, Ltd, Beijing, China) was used in this study.
9927212|NCT00890812||Factors VIII, IX and XI levels measured|Case group
9927213|NCT00890812||Non Stroke patients|This is the control group. This group represents patients who were initially evaluated for stroke.
9927214|NCT00890838|Active Comparator|Omegaven|will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively
9927215|NCT00890838|No Intervention|Without Omegaven|will not receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperativel
9927216|NCT00890851|Other|Procedure TUNA|
9927217|NCT00890864|Active Comparator|1|Women aged 47-49 invited for breast screening
9866464|NCT00148278|Experimental|1|norepinephrine plus dobutamine
9866465|NCT00148278|Active Comparator|2|epinephrine
9866466|NCT00148304||Group 1|
9866467|NCT00148356|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
9866468|NCT00148356|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
9866469|NCT00148369||Observational Group|Subjects previously administered GDNF and have discontinued the drug.
9866470|NCT00148525|Experimental|social cognitive theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory and delivered by an automated telephone system.
9866471|NCT00148525|Experimental|Goal Systems Theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory.
9866472|NCT00148525|No Intervention|Comparison group|comparison group
9866473|NCT00148538|Active Comparator|1|resistance exercise
9866474|NCT00148538|Active Comparator|2|Aerobic and Resistance exercise
9866475|NCT00148564|Active Comparator|Olanzapine|
9866476|NCT00148564|Active Comparator|Zpirasidone|
9866477|NCT00148590|Active Comparator|Memantine plus Risperidone|6 weeks 20 mg Memantine as add-on treatment to Risperidone
9866478|NCT00148590|Placebo Comparator|Placebo plus Risperidone|6 weeks 20 mg Placebo as add-on treatment to Risperidone
9866479|NCT00148616|Active Comparator|Memantine plus Risperidone|24 weeks memantine add on treatment to risperidone
9866480|NCT00148616|Placebo Comparator|Placebo plus Risperidone|24 weeks placebo add on treatment to risperidone
9866481|NCT00148642|Experimental|1|silver salts coated endotracheal tube
9866482|NCT00148642|Placebo Comparator|2|uncoated endotracheal tube
9866483|NCT00148681|Experimental|Lower Risk Regimen|
9866484|NCT00148681|Experimental|Higher Risk Regimen|
9866485|NCT00148694|Experimental|Intervention single arm|Cisplatin 75mg/m2 q21 days x 4 pre-surgery
9866486|NCT00148876|Active Comparator|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
9866487|NCT00148876|Experimental|Capecitabine and Trastuzumab|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
9866488|NCT00148889|Sham Comparator|2|Sham-stimulation
9866489|NCT00148889|Active Comparator|1|Active GPI-DBS
9866490|NCT00148902|Experimental|All treated subjects|All subjects received Lapatinib in Combination with Docetaxel (Taxotere)
9866491|NCT00148915|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) ibandronate tablet orally once monthly for one year.
9866492|NCT00148915|Placebo Comparator|Placebo|Participants will receive ibandronate matched placebo tablet orally once monthly for one year.
9866493|NCT00149071|Active Comparator|A|rTMS
9866494|NCT00149071|Sham Comparator|B|sham rTMS
9866495|NCT00149110|Experimental|A|Sleep deprivation in combination with light and duloxetine
9866496|NCT00149110|Active Comparator|B|Exercise and duloxetine
9866497|NCT00149162|Active Comparator|1|Patients treated by Proleukin
9866498|NCT00149162|No Intervention|2|Without Proleukin
9866499|NCT00149175||Neurodegenerative disorders with cognitive impairment|
9866500|NCT00149175||Control|
9866501|NCT00149175||At risk reactive|
9866502|NCT00149292|Experimental|LY2140023|40 mg LY2140023 BID for 28 days
9866503|NCT00149292|Active Comparator|Olanzapine|15 mg Olanzapine once daily (QD) for 28 days
9866504|NCT00149292|Placebo Comparator|Placebo|placebo for 28 days
9866505|NCT00149305||Patients with gouthy diathesis|
9866506|NCT00149305||Healthy subjects|
9866507|NCT00149318||Patients with Fabry disease|
9866508|NCT00149357||1, 2 ,3|Group 1 Women with unprovoked VTE and No Known Thrombophilia Group 2 Women who are investigated for VTE and are negative (Control) Group 3 Women with unprovoked VTE who have Thrombophilia
9866509|NCT00149383|Placebo Comparator|2|
9866510|NCT00149383|Experimental|1|
9866511|NCT00149409|Placebo Comparator|Placebo|4 gelatine capsules/d
9866512|NCT00149409|Active Comparator|1g/d Omacor|
9866513|NCT00149409|Active Comparator|4g/d Omacor|
9866514|NCT00149422|Active Comparator|NT-proBNP guided treatment group|In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
9866515|NCT00149422|Placebo Comparator|Clinically guided arm|Heart failure treatment guided by clinical assessment.
9866516|NCT00149461|Experimental|Written Asthma Action Plan Group|Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
9866517|NCT00149461|No Intervention|No Written Instructions Group|Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
9866518|NCT00149500|Experimental|Coaching group for lifestyle changes|Patients received monthly phone calls with coaching for lifestyle changes over 2 years.
9866519|NCT00149500|No Intervention|Routine pediatric care|This group receives routine care with their pediatrician.
9866520|NCT00149513|Experimental|1|Targeted nurse case management
9866521|NCT00149513|Active Comparator|2|Usual Care
9866522|NCT00149552|Active Comparator|Zinc gluconate|Zinc supplementation
9866523|NCT00149552|Placebo Comparator|Placebo|Placebo
9866524|NCT00149656|Placebo Comparator|1|
9866525|NCT00149656|Experimental|2|Multivitamins
9866526|NCT00149656|Experimental|3|Multivitamins with Selenium
9866527|NCT00149656|Experimental|4|Selenium
9866528|NCT00149760|Active Comparator|Augmented Standard Medical Care|Participants will receive standard medical care augmented by a psychiatric consultation letter sent to the participants' primary care physician.
9866529|NCT00149760|Experimental|Cognitive-Affective Behavior Therapy|Participants will receive individually administered cognitive-affective behavior therapy as well as augmented standard medical care.
9866530|NCT00149773|Experimental|Cognitive Therapy + Enriched Usual Care|"The cognitive therapy intervention consists of approximately 12 (1-hour) sessions over the course of a 4-month period. The main therapy components include:~Using problem-solving and cognitive restructuring techniques to target hopelessness, reasons for living and dying, coping with loss, and perceived medical comorbidity that lead to suicidal ideation.~Improving social resources.~Improving adherence to medical regimen.~Targeting Suicidal Cognitions."
9866531|NCT00149773|No Intervention|EnrichedUsual Care Condition|"The Enriched Care (EC) condition will be used as the treatment comparison for this study. EC consists of usual care patients may obtain in the community as well as the assessment and referral services provided by the study case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health treatment in the community.~The primary role of the study case manager is to establish a strong relationship with patients in order to retain the patients in the study for the duration of the study period."
9927218|NCT00890864|Active Comparator|2|Women aged 71-73 invited for breast screening
9927219|NCT00890877|Experimental|1|
9927220|NCT00890877|Experimental|2|
9927221|NCT00890877|Experimental|3|
9927222|NCT00890877|Experimental|4|
9927223|NCT00890903||NSCLC|Patients with advanced non-small cell lung cancer
9927224|NCT00890903||MBC|Female patients with metastatic, Anthracycline-resistent breast cancer
9927225|NCT00890942|Experimental|naloxone|
9927226|NCT00890942|Placebo Comparator|normal saline|
9927227|NCT00890955|Experimental|1|"Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:~Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2~Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2~Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2~Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2~Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2"
9927228|NCT00890994||Suspected breast cancer|
9927229|NCT00891007|Experimental|Group 1|
9927230|NCT00891007|Experimental|Group 2|
9927231|NCT00891007|Active Comparator|Group 3|
9927232|NCT00891033|Experimental|Cohort 1|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 5 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
9927233|NCT00891033|Experimental|Cohort 2|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 10 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
9927234|NCT00891033|Experimental|Cohort 3|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 15 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
9927235|NCT00891033|Experimental|Cohort 4|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 20 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
9927236|NCT00891059||Placebo Diskus Inhaler|
9927237|NCT00891072|Experimental|Treatment|Patients receive oral R-(-)-gossypol acetic acid twice daily on days 1-3. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9927238|NCT00891085||Open Lung Ventilation|within 24 hours of arrival trauma patients with ISS >25 will be randomized to BiVent (APRV)
9927239|NCT00891085||SIMV|within 24 hours of arrival trauma patients with ISS >25 will be randomized to either SIMV or BiVent
9927240|NCT00891098|Active Comparator|Imaginal exposure|
9927241|NCT00891098|Experimental|Imagery rescripting|
9927242|NCT00891111|Experimental|Direct Payment|Direct Payment: Employees receive a $25 gift card upon completion of a Health Risk Assessment
9927243|NCT00891111|Experimental|Regret Lottery|Regret Lottery: Employees are divided into work units of about 5 employees. Employees in the lottery-linked incentive condition will be eligible for a weekly lottery drawing only if they have already completed their health risk assessment. The lotteries will work as follows. Participants will be assigned to work units of about 10 people. Each week, one work group is drawn at random. If a participants group was drawn and that participant already completed the health risk assessment, then that person will win a $100 cash prize. If all of the members of his or her work group also filled out the health risk assessment, then the prize will be boosted.
9927244|NCT00891124||1|Type II DM and Hypertension and/or Hyperlipidemia
9927245|NCT00891137|Experimental|Group A|Low dose, single donor CLT-008 (human myeloid progenitor cells)
9927246|NCT00891137|Experimental|Group B|Low dose, multiple donor CLT-008 (human myeloid progenitor cells)
9927247|NCT00891137|Experimental|Group C|Intermediate dose, multiple donor CLT-008 (human myeloid progenitor cells)
9927248|NCT00891137|Experimental|Group D|High dose, multiple donor CLT-008 (human myeloid progenitor cells)
9927249|NCT00891150|Active Comparator|oxytocin|group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
9927250|NCT00891150|Active Comparator|oxytocin2|group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
9927251|NCT00891150|Active Comparator|oxytocin3|group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
9927252|NCT00891163|Experimental|Synera|
9927253|NCT00891163|Placebo Comparator|Placebo|
9927254|NCT00891189||1 Control|Healthy participants without asthma
9927255|NCT00891189||2 Non-nocturnal asthma|Participants with non-nocturnal asthma
9927256|NCT00891189||3 Nocturnal asthma|Participants with nocturnal asthma
9866532|NCT00149786|Experimental|1|Those adolescents receiving family based therapy
9866533|NCT00149786|Active Comparator|2|Those adolescents receiving individual therapy
9866534|NCT00149812|Experimental|Intervention|"Intervention: Keeping Families Strong Cognitive Behavioral and Communication intervention with mothers recovering from depression and their children, 9 years and older."
9866535|NCT00149916|Experimental|Mycophenolate sodium (enteric coated)|
9866536|NCT00149968|Experimental|Myfortic|
9866537|NCT00150072|Experimental|imatinib|
9866538|NCT00150098|Experimental|lifestyle counselling|Education
9866539|NCT00150124|Experimental|block-replacement therapy|BRT regimen until 3 months after 131I therapy
9866540|NCT00150124|Active Comparator|methimazole|methimazole stopped 8 days before 131I therapy
9866541|NCT00150488|Experimental|1|Uracyst®
9866542|NCT00150631|Placebo Comparator|active (candesartan)|12 mo treatment with candesartan
9866543|NCT00150631|Placebo Comparator|placebo|12 mo placebo treatment
9866544|NCT00150644|Experimental|1|
9866545|NCT00150644|Experimental|2|
9866546|NCT00150644|Placebo Comparator|3|
9866547|NCT00150670|Experimental|1|TS-1 and cisplatin
9866548|NCT00150670|Active Comparator|2|TS-1
9866549|NCT00150748|Experimental|Levetiracetam|Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
9866550|NCT00150826|Active Comparator|Quinapril|This arm will receive quinapril which will be started at 40mg daily and titrated to 80mg daily by the end of the first week. After treatment on the maximum tolerated dose for 16 weeks, patients will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
9866551|NCT00150826|Placebo Comparator|Placebo|This arm will receive placebo for 16 weeks and will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
9866552|NCT00150839|Active Comparator|1|Probands receive mirtazapine and venlafaxine
9866553|NCT00150839|Placebo Comparator|2|Patients receive mirtazapine and placebo
9866554|NCT00150878|Other|12 Gy/Cyclophosphamide|Standard intensity conditioning
9866555|NCT00150878|Experimental|8 Gy /Fludarabine|Reduced-intensity conditioning
9866556|NCT00150995|Experimental|Tetrathiomolybdate|Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
9866557|NCT00151034|Experimental|Herceptin|"Herceptin - 4mg/kg day 1 of cycle 1; 2mg/kg day 8 and 15 of cycle 1 and subsequent cycles.~Paclitaxel - 200mg/m^2 on day 1 Carboplatin - AUC 5 on day 1 Gemcitabine - 800 mg/m^2 on day 1 and 8"
9866558|NCT00151047|Experimental|Docetaxel and Capecitabine|
9866559|NCT00151060|Experimental|Estramustine, Etoposide and Paclitaxel|
9866560|NCT00151073|Experimental|Zoledronate Alone|Zoledronate is given alone for the first cycle. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
9866561|NCT00151073|Experimental|Docetaxel and Estramustine|Docetaxel and Estramustine are given for the first cycle of therapy. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
9866562|NCT00151086|Experimental|Estramustine and Vinorelbine|Treatment will consist of 28-day cycles with estramustine at a dose of 140mg orally 3 times per day on days 1-3 and 8-10 and vinorelbine orally on days 2 and 9 beginning at dose 50mg/m^2.
9866563|NCT00151112|Experimental|1|combination of lateral position and 20° Trendelenburg Position
9866564|NCT00151112|Active Comparator|2|standard positioning
9866565|NCT00151125|Experimental|A|rhIL-11 (Interleukin-11, Neumega) 25 mcg/kg subcutaneously daily for 7 days
9866566|NCT00151125|Experimental|B|rhIL-11 (interleukin-11, Neumega) 50 mcg/kg subcutaneously daily for 7 days
9866567|NCT00151125|Experimental|C|rhIL-11 (Interleukin-11, Neumega) 10 mg/kg subcutaneously daily for 7 days
9866568|NCT00151177|Experimental|A|treatment with three nights of CPAP ventilation starting the first night of admission
9866569|NCT00151177|No Intervention|B|usual Stroke Unit care
9866570|NCT00151216|Experimental|Group A-Severe Stages of LINCL|"Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
9866571|NCT00151216|Experimental|Group B-Moderate Stages of LINCL|"Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
9866572|NCT00151229|Active Comparator|strict control|systolic blood pressure control: less than 140 mm Hg
9866573|NCT00151229|Active Comparator|moderate control|systolic blood pressure control: 140 mm Hg to 149 mm Hg
9866574|NCT00151242|Active Comparator|1|
9866575|NCT00151242|Experimental|2|
9927257|NCT00891241|Experimental|Cohort 1|Healthy Population
9927258|NCT00891241|Experimental|Cohort 2|Heart Failure Subjects with a documented ejection fraction of 35% or less, and a diagnosis of NYHA Class II-III heart failure, history of ventricular arrhythmia and ICD placement
9927259|NCT00891254|Active Comparator|1. Intraperitoneal repair|Patients with incisional hernia, 5 cm in diameter or with an area of 25 cm2, submitted to elective surgery
9927260|NCT00891254|Active Comparator|2. On-Lay repair|Patients with incisional hernia, with a diameter of 5 cm or an area of 25 cm2, submitted to elective surgery
9927261|NCT00891267|Experimental|Olmesartan medoxomil low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
9927262|NCT00891267|Experimental|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
9927263|NCT00891267|Active Comparator|Amlodipine|Amlodipine taken once daily for 6 weeks
9927264|NCT00891306|Experimental|Treatment arm|Gene Therapy
9927265|NCT00891332|Experimental|1|S-1 plus LV
9927266|NCT00891358|Experimental|Focus Group|Participants in focus groups will meet and discuss their intervention needs.
9927267|NCT00891384|Experimental|1|25 mg lenalidomide
9927268|NCT00891384|Experimental|2|5 mg lenalidomide
9927269|NCT00891397|Experimental|1|Pregabalin group is made up of 20 patients. Patients will receive 150mg/day in two divided does. The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain. The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain. This is also the maximum permissible does that will be given to the patient. If patient reports any side effects then the dose can be decreased once. The time period of 2 to 5 weeks will be the dose adjustment period. After which the drug maintenance period extends from week 5 to 12. All doses will be given in two divided doses/day.
9927270|NCT00891397|Placebo Comparator|2|Ten patients will be be in the placebo group.
9927271|NCT00891423|Active Comparator|Meropenem short infusion|"Meropenem 1g infused over 30 minutes~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
9927272|NCT00891423|Experimental|Meropenem extended infusion|"Meropenem 500mg infused over 3 hours~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
9927273|NCT00891475|Experimental|Arm 1|38 patients
9927274|NCT00891475|Experimental|Arm 2|38 patients
9927275|NCT00891475|Experimental|Arm 3|38 patients
9927276|NCT00891488||Fit|
9927277|NCT00891488||Unfit|
9927278|NCT00891501|Experimental|Single|Clinical case series
9927279|NCT00891514|Experimental|Aerobic Exercise|Treadmill training
9927280|NCT00891514|Active Comparator|Stretch Control|Stretching exercises
9927281|NCT00891540|Active Comparator|1|Local infiltration with Ropivacaine
9927282|NCT00891540|Active Comparator|2|Local infiltration with Ropivacaine
9927283|NCT00891540|Placebo Comparator|3|Local infiltration with NaCl
9927284|NCT00891553||Ronacaleret|Subjects receiving ronacaleret (200mg,300mg or 400mg) in study CR9108963 will be enrolled into this study.
9927285|NCT00891553||Placebo|Subjects receiving placebo in study CR9108963 will be enrolled into this study.
9927286|NCT00891579|Active Comparator|Alimta|Treatment of Alimta
9927287|NCT00891579|Active Comparator|IRESSA|Treatment of IRESSA
9866576|NCT00151346|Active Comparator|CSE|"Subjects assigned to this group will receive combined spinal-epidural (CSE) to relieve pain during labor. For CSE, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer directly into the spinal canal (a smaller amount than is given for traditional epidural), followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. CSE is not experimental."
9866577|NCT00151346|Active Comparator|Traditional Epidural|"Subjects assigned to this group will receive traditional epidural to relieve pain during labor. For the traditional epidural, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer into the epidural space, followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. The traditional epidural is not experimental."
9866578|NCT00151515|Experimental|1|Topical 5% minoxidil foam formulation used twice daily
9866579|NCT00151554|No Intervention|Control group|
9866580|NCT00151554|Experimental|Intervention group|
9866581|NCT00151567|Experimental|1|Tamsulosin
9866582|NCT00151567|Placebo Comparator|2|Placebo
9866583|NCT00151580|Experimental|1|Ribavirin maintenance treatment
9866584|NCT00151580|Placebo Comparator|2|
9866585|NCT00151593|Experimental|1|Celsior preservation solution
9866586|NCT00151632|Experimental|MMF+FK|Low doses of tacrolimus in association with mycophenolate mofetil
9866587|NCT00151632|Active Comparator|FK|Full recommended doses of tacrolimus
9866588|NCT00151671|Experimental|1|Perioperative Oral Nutritional Supplementation
9866589|NCT00151671|Placebo Comparator|2|Placebo of Perioperative Oral Nutritional Supplementation
9866590|NCT00151736|Experimental|Chlorambucil|Regime A
9866591|NCT00151736|Experimental|R-etodolac with chlorambucil|Regime B
9866592|NCT00151827|Experimental|Olmesartan medoxomil|Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
9866593|NCT00151827|Experimental|Losartan|Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
9866594|NCT00151957|Experimental|Methylphenidate transdermal system|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
9866595|NCT00151970|Active Comparator|Methylphenidate Transdermal System|The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
9866596|NCT00151970|Placebo Comparator|Placebo|The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
9866597|NCT00151970|Active Comparator|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
9866598|NCT00151983|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
9866599|NCT00151983|Placebo Comparator|Placebo patch|Placebo patch applied daily for 8 weeks
9866600|NCT00152113|Other|1|
9866601|NCT00152126|Other|1|
9866602|NCT00152139|Other|1|
9866603|NCT00152178|Experimental|1|UFT (uracil, tegafur) and tamoxifen
9866604|NCT00152178|Active Comparator|2|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
9866605|NCT00152191|Experimental|1|UFT (uracil, tegafur)
9866606|NCT00152191|Active Comparator|2|CMF(cyclophosphamide, methotrexate, and fluorouracil)
9866607|NCT00152204|Experimental|1|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
10210447|NCT05142917|Experimental|fNIRS based hand motor area real stimulation|Real stimulation is applied to functional brain image-based hand function area (20 minutes) and then hand motor task (20 minutes).
10210448|NCT05142917|Active Comparator|Traditional hand motor area real stimulation|Real stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
9866608|NCT00152204|No Intervention|2|
9866609|NCT00152217|Experimental|1|TS-1 (S-1)
9866610|NCT00152217|Other|2|Surgery alone
9866611|NCT00152230|Experimental|1|UFT (uracil, tegafur)
9866612|NCT00152230|Other|2|Surgery alone
10210449|NCT05142917|Sham Comparator|Traditional hand motor area sham stimulation|Sham stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (20 minutes).
10210450|NCT05136937|Experimental|Oncolytic virus injection(RT-01) for patients with advanced solid tumors|"Intratumoral administration of RT-01 as single agent for patients with advanced solid tumors.The injection dose of RT-01 was determined by the lesion size:~mL for lesion length <1.5 cm;~mL for lesion length between 1.5 cm and 2.5 cm;~mL for lesion length between 2.5 cm and 5.0 cm;~mL for lesion length between >5 cm"
9866613|NCT00152243|Experimental|1|UFT (uracil, tegafur)
9866614|NCT00152243|Other|2|Surgery alone
9866615|NCT00152256|Experimental|1|
9866616|NCT00152256|Experimental|2|
9866617|NCT00152256|Placebo Comparator|3|
9866618|NCT00152269|Experimental|1|
9866619|NCT00152269|Experimental|2|
9866620|NCT00152269|Placebo Comparator|3|
9866621|NCT00152282|Experimental|1|
9866622|NCT00152282|Experimental|2|
9866623|NCT00152282|Experimental|3|
9866624|NCT00152282|Placebo Comparator|4|
9866625|NCT00152295|Experimental|1|
9866626|NCT00152321|Experimental|A|Multifaceted intervention
9866627|NCT00152321|Active Comparator|B|Usual Care
9866628|NCT00152360|Experimental|Xenical (Orlistat)|Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
9866629|NCT00152438|Experimental|1|Oral micronized progesterone
9866630|NCT00152438|Placebo Comparator|2|Placebo
9866631|NCT00152542|Experimental|Inhaled nitric oxide|
9866632|NCT00152542|Placebo Comparator|Placebo|
9866633|NCT00152568|Experimental|Child Passenger Safety Technician services|
9866634|NCT00152633|Active Comparator|Losartan|Treatment with Losartan.
9866635|NCT00152633|Active Comparator|Betablocker|Treatment with Metoprolol.
9866636|NCT00152698|Active Comparator|Irbesartan|
9866637|NCT00152698|Placebo Comparator|Placebo|
10210451|NCT05130788|Experimental|Intervention Group|
9866638|NCT00152776|Placebo Comparator|Group I|ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks
9866639|NCT00152776|Placebo Comparator|Group II|Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks
9866640|NCT00152776|Placebo Comparator|Group III|ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks
9927288|NCT00891592|Experimental|Dose Escalation Arm|Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.
9927289|NCT00891592|Active Comparator|Observation Arm|Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.
9927290|NCT00891605|Experimental|Paclitaxel and ABT-263|
9927291|NCT00891631|Experimental|iSBIRT|Participants will complete the iSBIRT system.
9927292|NCT00891631|Experimental|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system and technological extenders
9927293|NCT00891631|No Intervention|TAU|Participants will receive Treatment as Usual from their primary care provider.
9927294|NCT00891644||1|HIV positive adolescents who never initiated care within 6 months of receipt of HIV positive results.
9927295|NCT00891644||2|HIV positive adolescents who initiated care, but did not follow up with care within 12 months of the initial care visit. Also included in this group are those who initiated and followed-up with care, but have dropped out of care for 12 or more months.
9927296|NCT00891644||3|HIV positive adolescents who initiated care and maintained care. These youth are currently in care.
9927297|NCT00891670|Active Comparator|triple group|received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
9927298|NCT00891670|Active Comparator|high maintenance dose group|received clopidogrel 150 mg/day with aspirin 100mg once daily
9927299|NCT00891683|Placebo Comparator|Placebo|4 Capsules of Placebo
9927300|NCT00891683|Active Comparator|100 mg|One 100 mg capsule and 3 placebo capsules of AEG33773
9927301|NCT00891683|Active Comparator|200 mg|Two 100 mg capsules and two placebo capsules
9927302|NCT00891683|Active Comparator|400 mg|Four 100 mg AEG33773 capsules
9927303|NCT00891696|Active Comparator|Exp 1: AA + Rap|Participants will receive amino acid supplementation and rapamycin.
9927304|NCT00891696|Placebo Comparator|Exp 1: AA|Participants will receive amino acid supplementation and placebo rapamycin.
9927305|NCT00891696|Active Comparator|Exp 1: HEx + Rap|Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
9927306|NCT00891696|Placebo Comparator|Exp 1: HEx|Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
10210452|NCT05130788|Active Comparator|Control Group|
9927307|NCT00891696|Active Comparator|Exp 1: HEx + AA + Rap|Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
9927308|NCT00891696|Placebo Comparator|Exp 1: HEx + AA|Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
9927309|NCT00891696|Active Comparator|Exp 2: LExFR + Rap|Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
9927310|NCT00891696|Placebo Comparator|Exp 2 and 3: LExFR|Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
9927311|NCT00891696|Active Comparator|Exp 2: SNP|Participants will receive sodium nitroprusside in a resting state.
9927312|NCT00891696|Active Comparator|Exp 2: FR|Participants will undergo blood flow restriction in a resting state.
9927313|NCT00891696|Active Comparator|Exp 2: LEx + SNP|Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
9927314|NCT00891696|Placebo Comparator|Exp 3: LEx|Participants will undergo low-intensity resistance exercise.
9927315|NCT00891696|Active Comparator|Exp 3: HEx|Participants will undergo high-intensity resistance exercise.
9927316|NCT00891696|Active Comparator|Exp 3: HEx + AA|Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
9927317|NCT00891709|Experimental|1|LEO 29102 2.5 mg/g cream
9927318|NCT00891709|Placebo Comparator|2|LEO 29102 cream vehicle
9927319|NCT00891748|Experimental|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
9927320|NCT00891761|Active Comparator|Active Comparator|Patients receive IV casopitant (active), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
9927321|NCT00891761|Placebo Comparator|Placebo Comparator|Patients receive IV casopitant (placebo), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
9927322|NCT00891800|Experimental|1|All patients will be treated with SIR-Sphere therapy.
9927323|NCT00891826|Placebo Comparator|Corn oil|
9927324|NCT00891826|Experimental|Omega-3 fatty acids|
9927325|NCT00891865||Pediatric lung transplantation|
9927326|NCT00891917|Placebo Comparator|Syrup|identical placebo formulation to be administered twice a day.
9927327|NCT00891917|Active Comparator|Ubiquinol-10 Syrup|CoQ (LiQ-NOL®) 10.0 mg/kg/d to be administered twice a day
9927328|NCT00891943|Other|Structured lifestyle support|Intervention group-structured lifestyle support.
10210453|NCT05128929|Experimental|Experimental Treatment Oral Hymecromone (H01)|Treatment will be initiated. Participants will be administered 800 mg of oral H01 two times a day (total dose: 1600 mg/day). Participants will continue to be on treatment for 24 weeks and will be monitored with assessments.
10210454|NCT05128929|Placebo Comparator|Placebo|Participants randomized to placebo will receive oral tablet placebo (inactive ingredients) four times a day. Participants will continue to be on placebo for 24 weeks and will be monitored with assessments.
9866641|NCT00152815|Experimental|Vitamin E|alpha-tocoperol, capsules, 2 per day
9866642|NCT00152828|Experimental|Celecoxib|Celecoxib
9866643|NCT00152854|Active Comparator|A, 1, acetaminophen|acetaminophen
9866644|NCT00152854|Placebo Comparator|B placebo|placebo PO qid
9866645|NCT00152867|Active Comparator|1|Dexamethasone
9866646|NCT00152867|Placebo Comparator|2|Placebo
9866647|NCT00152893|Experimental|Chromium|400 μg (200 μg pills, twice per day) of Cr-nicotinate
9866648|NCT00152893|Placebo Comparator|Placebo|Identical looking placebo (di-calcium phosphate)
9866649|NCT00152906|Experimental|Stereotactic RT or highly conformal RT|
9866650|NCT00153205|Placebo Comparator|Introduction of A Clinical Pharmacist|
9866651|NCT00153205|Experimental|Technological|
9866652|NCT00153231|Experimental|Infracoccygeal sacropexy|Intervention: IVS
9866653|NCT00153231|Active Comparator|Sacrospinofixation|Intervention: Sacrospinofixation
9866654|NCT00153257|Other|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
9866655|NCT00153257|No Intervention|No device|standard anterior colporrhaphy
9866656|NCT00153426|Experimental|lifestyle counseling|Women assigned to lifestyle change intervention arm for nutrition and physical activity with print-based tailored health communications and a computer-based interactive nutrition program targeting health behaviors of diet and physical activity. Women in a control group did not receive the intervention.
9866657|NCT00153504|Experimental|Housing and Health Study housing rental assistance|
9866658|NCT00153504|Active Comparator|Standard local practice housing assistance|
10210455|NCT05125601||Patients with bilateral deafness|Patients aged 2 to 10 years with bilateral deafness, wearing an amplifier device and / or a cochlear implant.
10210456|NCT05121441|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
10210457|NCT05121441|Placebo Comparator|Placebo Comparator|Placebo arm matching active arm ARD-101, 200 mg BID
9866659|NCT00153530|Active Comparator|1|1 chemotherapy with radiotherapy
9866660|NCT00153530|Experimental|2|chemotherapy without radiotherapy
9866661|NCT00153634|Experimental|1|Antibiotic regimen assignment based on biofilm susceptibility test results
9866662|NCT00153634|Active Comparator|2|Antibiotic regimen assignment based on conventional susceptibility test results
9866663|NCT00153647|Active Comparator|1|Cap-assisted Colonoscopy
9866664|NCT00153647|Placebo Comparator|2|Regular Colonoscopy
9866665|NCT00153660|Active Comparator|NSAID #1|Celecoxib and Naproxen Placebo
9866666|NCT00153660|Active Comparator|NSAID #2|Naproxen and Celecoxib Placebo
9866667|NCT00153673|Active Comparator|1|Celecoxib + Famotidine
9866668|NCT00153673|Active Comparator|2|Dologesics + Famotidine
9866669|NCT00153686|Experimental|Capsule Endoscopy|Capsule Endoscopy examination of small intestine
9866670|NCT00153686|Other|Mesenteric Angiogram|Mesenteric Angiogram of the small intestine
9866671|NCT00153712||Non NSAID non-Hp|Patient of history of peptic ulcer bleeding with Hp-ve and without prior history of taking NSAID or Aspirin within 30 days
9866672|NCT00153712||Helicobacter pylori +ve|Patient with Hp+ve at peptic ulcer bleeding
9866673|NCT00153751|Experimental|Traditional Chinese Medicine|They are Common peony root, other herbs.
9866674|NCT00153751|Active Comparator|Holopon|Holopon
9866675|NCT00153751|Placebo Comparator|placebo|Placebo
9866676|NCT00153764|Placebo Comparator|multivitamin|1 tablet morning and evening
9866677|NCT00153868|Active Comparator|1|Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
9866678|NCT00153868|Active Comparator|2|darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
9866679|NCT00153881|Experimental|1|Docetaxel/Carboplatin every 3 weeks for 2 cycles then concommitant chemotherapy and radiation Docetaxel weekly for 5 doses without premedication, then Capecitabine will be given orally, one dose prior to each fraction or irradiation (28 cycles).
9866680|NCT00153894|Active Comparator|Group A|Immediate Exercise
9866681|NCT00153894|Active Comparator|Group B|Delayed Exercise (delay by 16 weeks)
9866682|NCT00153933|Experimental|CC-5013 in combination with bortezomib|Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
9866683|NCT00153946|Active Comparator|A|The patients who are allocated to Argatroban monotherapy
9866684|NCT00153946|Active Comparator|B|The patients who are allocated to Edaravone-Argatroban combination therapy
9866685|NCT00153972|Active Comparator|Levodopa|Levodopa 300 mg per day orally.
9866686|NCT00153972|Active Comparator|Cabergoline|Cabergoline 3 mg per day orally.
9866687|NCT00153998|Active Comparator|1|Cetuximab and FOLFIRI
9866688|NCT00153998|Active Comparator|2|Cetuximab and FOLFOX
9866689|NCT00154076|Experimental|1|
9866690|NCT00154076|Active Comparator|2|
9866691|NCT00154089|Experimental|EM-1421|"Administration of EM-1421 intravaginally once per week for 3 weeks~Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)"
9866692|NCT00154115|Experimental|1|Levosimendan
9866693|NCT00154115|Placebo Comparator|2|
9866694|NCT00154154|Active Comparator|A|General Psychiatric Management
9866695|NCT00154154|Experimental|2|Dialectal Behaviour Therapy
9866696|NCT00154180|Active Comparator|Arm 1|CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg
9866697|NCT00154180|Placebo Comparator|Arm 2|Placebo patch, placebo CEE, placebo Prometrium
9866698|NCT00154193|Active Comparator|Cyclosporine|
10210458|NCT05114915|Experimental|Docetaxel for Injection-qw 3/4 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week in the first three weeks (Day 1, 8 and 15) in every 28-day cycle, starting at a dose of 30 mg/m^2.
10210459|NCT05114915|Experimental|Docetaxel for Injection-q2w 2/4 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week every other week (Day 1 and 15) in every 28-day cycle, starting at a dose of 50 mg/m^2.
9866699|NCT00154258|Experimental|1|
9866700|NCT00154336|Active Comparator|Imatinib 400mmg OD +MTX|
9866701|NCT00154336|Placebo Comparator|Imatinib Placebo + MTX|
9866702|NCT00154349|Experimental|imatinib mesylate|
9866703|NCT00154622|No Intervention|pain/ disability survey|
9866704|NCT00154687|Experimental|A|
9866705|NCT00154778|Experimental|A|
9866706|NCT00154804|Experimental|A|
9866707|NCT00154843|Experimental|A|Lycopene 15 mg/day
9866708|NCT00154843|Experimental|B|Lycopene 30 mg/day
9866709|NCT00154882|Experimental|A|
9866710|NCT00155259|Experimental|A|
9866711|NCT00155311|Experimental|days after treatment|different days after orthodontic treament, samples will be taken.
9866712|NCT00155389|Active Comparator|H pylori eradication|All enrolled subjects received chemoprevention with Helicobacter pylori eradication
9866713|NCT00155402|Experimental|1|Use of fibrin glue after corneal surgery or transplantation
9866714|NCT00155454|Experimental|Study group|Group 1 had intravitreal long acting gas (10% C3F8) injection in the vitreous cavity at the end of surgery
9866715|NCT00155454|Sham Comparator|Control group|Group 2 did not receive intravitreal long acting gas (10% C3F8)
9866716|NCT00155545|No Intervention|Metformin|
9866717|NCT00155558|Experimental|A|
9927329|NCT00891943|No Intervention|Usual care for weight management|"This is the control group, and they will receive usual care for weight management at their GP practice."
9927330|NCT00892021|Experimental|NSA-789|Active study drug
9927331|NCT00892021|Placebo Comparator|Placebo|Inactive study drug
9927332|NCT00892073|Experimental|Diazoxide and Metformin Therapy|
9927333|NCT00892112|Active Comparator|intravenous immunoglobulins|IV, 40 ml/kg over 4 days
9927334|NCT00892112|Placebo Comparator|plasma volume expander Albuman|IV, 40 ml/kg over 4 days
9927335|NCT00892138|Experimental|Mindfulness training|Mindfulness training
9927336|NCT00892138|No Intervention|Control|Study program as usual
9927337|NCT00892164|Active Comparator|FOCUS (Group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
9927338|NCT00892164|Active Comparator|LIGASURE (Group Β)|Patients submitted to total thyroidectomy with the use of the electrothermal bipolar vessel sealing device
9927339|NCT00892190|Experimental|dasatinib (SPRYCEL) and all trans retinoic acid (VESANOID)|"Dasatinib DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours~ATRA 22.5mg/m2 every 12 hours"
9927340|NCT00892216|Experimental|Acupressure Band|A band with bead attachment will be used to produce Acupressure and applied to the P6 (three fingers breath from the wrist crease on th ventral surface of the upper limb). The application will be done 20 minutes prior to anesthesia and explanation as to usage after surgery will be given. The patient of caregiver will apply pressure on the bead for three minutes and repeat this four times a day for the next five days. None of the protocol for prevention of PONV in this group of patients will be changed. The postoperative therapy for nausea and vomiting will be on a PRN (as required) basis. Nausea and vomiting scores and VAS scores for pain estimation will be carried out according to hospital protocol in the PACU amd twice a day thereafter for their period of stay in the hospital. The amount of analgesics and antiemetics used and the number of days spent in the hospital will be registered.
9927341|NCT00892216|Sham Comparator|Sham Acupressure|The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
9927342|NCT00892229|Active Comparator|Buccal Misoprostol|Group one: 50 patients with first trimester missed abortion received buccal misoprostol
9927343|NCT00892229|Active Comparator|Vaginal Misoprostol|Group two: 5 patients received vaginal misoprostol
9927344|NCT00892229|Active Comparator|Buccal and Vaginal Misoprostol|"50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.~Each group was randomly allocated (1,3,5,... for the buccal group & 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol."
9927345|NCT00892242|Experimental|Neoadjuvant Zoledronic Acid|"Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)~Pancreatic resection~Zoledronic acid 4 mg IV monthly for two additional doses"
9996964|NCT01504659|Placebo Comparator|Bipolar-Placebo|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of placebo
9866718|NCT00156026|Experimental|1|Immediate Treatment - LEEP - Loop electrosurgical excision procedure
9866719|NCT00156026|No Intervention|2|Colposcopic Follow-up
9866720|NCT00156052|Experimental|Hypofractionated whole breast radiation|Subjects treated with 4250 cGY in 16 fractions
9866721|NCT00156052|Active Comparator|Conventional whole breast radiation|Subjects treated with 5000 cGY in 25 fractions
9866722|NCT00156130||1|Accelerated whole breast irradiation
10210460|NCT05114915|Experimental|Docetaxel for Injection-qw 2/3 regimen|Docetaxel for Injection (Albumin-bound) will be administrated once every week in the first two weeks (Day 1 and 8) in every 21-day cycle, starting at a dose of 30 mg/m^2.
10210461|NCT05110352|Experimental|Obstructive Sleep Apnea Syndrome patients with polysomnography planned|Apnea-Hypopnea Index (AHI) > 15
9866723|NCT00156130||2|Conventional whole breast irradiation
9866724|NCT00156156|Experimental|1|
9866725|NCT00156156|Experimental|2|
9866726|NCT00156182|Experimental|1|
9866727|NCT00156195|Experimental|1|
9866728|NCT00156195|Experimental|2|
9866729|NCT00156208|Experimental|1|
9866730|NCT00156208|Experimental|2|
9866731|NCT00156299|Experimental|Dexamethasone plus Choline Magnesium Trisalicylate|Dexamethasone plus Choline Magnesium Trisalicylate
9866732|NCT00156299|Experimental|Choline Magnesium Trisalicylate|Choline Magnesium Trisalicylate
9866733|NCT00156338|Experimental|1|volume and sodium restriction
9866734|NCT00156338|Active Comparator|2|volume restriction
9866735|NCT00156338|Active Comparator|3|liberal fluid management
9866736|NCT00156416|Experimental|Meditation group|Participants received 8 weeks of mindfulness meditation instruction and support
9866737|NCT00156416|Active Comparator|Education group|Participants received 8 weeks of healthy living instruction
9866738|NCT00156507|Experimental|1|Parents of children in the experimental group receive asthma education prior to NICU discharge.
9866739|NCT00156637|Other|Arm 1|
9866740|NCT00156637|Active Comparator|Arm 2|Dosing & Side Effect Monitoring
10210462|NCT05103683|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-1-23
10210463|NCT05103683|Experimental|Expansion as Monotherapy - Part 2|TORL-1-23
10210464|NCT05102656||Group A (video call)|Patients receive standard of care via video call with treating physician.
10210465|NCT05102656||Group B (in-person)|Patients receive standard of care in-person physician visits.
10210466|NCT05100537|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
10210467|NCT05100537|Active Comparator|CONTROL GROUP|no intervention
10210468|NCT05089435|Other|14-day EZYPRO and 24-hr Holter|Patients wear simultaneously 14- day continuous ECG moniter (EZYPRO) and 24-hr Holter monitor.
10210469|NCT05080439|Experimental|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis in the teres major muscle
10210470|NCT05080439|Experimental|Dry needling|Dry needling based on fast-in fast-out technique in the teres major muscle
10210471|NCT05070624|Experimental|Intervention|"After informed consent, we will assign participants in a 1:1 ratio to the intervention or control group using Randomize.net.~Participants randomized to intervention group will get access to the Virtual Peer Support Program."
10210472|NCT05070624|No Intervention|Control|Control group: Those randomized to the waitlist control will be given access to the peer support intervention on completion of the first 12-week program. A waitlist control group is an ethical alternative to no-treatment control groups when studying psychological and behavioral interventions 21. will have access to informational resources via the aTouchAway™ App and will also receive the intervention at the end of the trial.
10210473|NCT05064943||Total Knee Replacement|Patients who have undergone total knee replacement
10210474|NCT05064280|Experimental|Pembrolizumab|Pembrolizumab is FDA approved and commercially available for the treatment of many types of cancer, but it may not be approved for the type of cancer that you have.
10210475|NCT05064280|Experimental|Lenvatinib|Lenvatinib in combination with pembrolizumab is FDA approved for the treatment of patients with certain types of endometrial cancer.
10210476|NCT05048849|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
9866741|NCT00156650|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (Depo-Medroxyprogesterone) (injected into muscle Day 0 & at Month 3)
9866742|NCT00156650|Active Comparator|2|T gel for 6 months + DMPA (Day 0 & Month 3) + Acyline 300 mcg/kg twice monthly for 12 weeks
9866743|NCT00156663|Other|Arm 1|
9866744|NCT00156676|Experimental|Arm 1|Cross over from body-weight support treadmill to Lokomat
9866745|NCT00156676|Experimental|Arm 2|Cross over from Lokomat to body-weight support treadmill
9866746|NCT00156702|Active Comparator|1|
9866747|NCT00156702|No Intervention|2|
9866748|NCT00156949|Experimental|Epoetin alfa DT|
9866749|NCT00156962|Active Comparator|Epoetin alfa RB|
9866750|NCT00156962|Experimental|Epoetin alfa DT|
9866751|NCT00157027|Active Comparator|1|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
9927346|NCT00892268|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
9996965|NCT01504685|Active Comparator|Unbanded laparoscopic gastric bypass|Laparoscopic Roux- en-Y gastric bypass without any band around de gastric reservoir
9866752|NCT00157131|Experimental|FS 4IU VH S/D|"FS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a painting motion from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2."
9866753|NCT00157131|Active Comparator|Staples|Staples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
9927347|NCT00892268|Active Comparator|Arm II|Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.
9927348|NCT00892346|Experimental|Single ASCT with Thalidomide maintenance|"Single ASCT followed by Thalidomide maintenance:~patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy~CTX+G-SCF mobilization to collecetd PBSC~Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance"
9927349|NCT00892359|Experimental|Anidulafungin|
9927350|NCT00892372||1 (type 2 diabetes, body weight, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
9927351|NCT00892372||2 (type 2 diabetes, pioglitazone, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
9927352|NCT00892385|Experimental|Non-CNS Disease|A traditional 3 + 3 dose escalation design will be implemented. Successive cohorts of participants (3 participants/cohort) will be entered sequentially to each dose level. If 0/3 participants at a dose level experience dose limiting toxicity (DLT) new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 2 or more experience DLT in the first cycle, no further participants are started at that dose and the MTD is the highest dose level in which <2 (of 6) participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if a DLT has not been observed.
9927353|NCT00892385|Experimental|CNS Disease|A traditional 3 + 3 dose escalation design with successive cohorts of 3 participants will be entered sequentially to each dose level. If 0/3 participants experience DLT, new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 1/3 participants experience a non-CNS DLT in Cohort B dose level 6, dose escalation will continue to dose level 7, as 3 subjects have already been treated in Cohort A dose level 6 and 7 subjects in Cohort A dose level 7, none of whom experienced non-CNS toxicities. If 2 or more experience DLT in cycle 1, no more participants are started at that dose and the MTD is the highest dose where <2/6 participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if no DLT has been observed.
9927354|NCT00892398|Experimental|ranibizumab|Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively
9927355|NCT00892398|Active Comparator|standard care|Trabeculectomy with mitomycin C and standard post-operative care
9927356|NCT00892411||All study participants|Patients With Acute Low Back Pain
9927357|NCT00892424|Experimental|Sorafenib + RT|
9927358|NCT00892450|Experimental|Arm 1|crossover design
9927359|NCT00892476|Experimental|1|Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
9927360|NCT00892476|Active Comparator|2|Infants will receive fortified breast milk or 24 cal/oz formula
9927361|NCT00892502|Active Comparator|1|Bismuth tablets
9927362|NCT00892502|Placebo Comparator|2|Placebo tablets, containing no active substance
9927363|NCT00892515|Experimental|exercise|
9927364|NCT00892554|Experimental|DHA supplementation|
9927365|NCT00892554|Placebo Comparator|corn/soy capsule, no DHA|
9927366|NCT00892567|Experimental|9 Peptide Vaccine|
9927367|NCT00892593|Experimental|1 Fecal Immunochemical Testing-Surveillance|Fecal Immunochemical Testing performed at yearly intervals.
10210477|NCT05047640|Experimental|BNT162b2 vaccine|Participants in this arm will receive one booster dose of the BNT162b2.
10210478|NCT05047640|Experimental|JNJ-78436735 vaccine|Participants in this arm will receive one booster dose of the JNJ-78436735
10210479|NCT05045872|Experimental|EMRA|Patients will receive contrast-enhanced renal artery magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography.
10210480|NCT05044676||patients with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
10210481|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Xalatan|Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan
10210482|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Monoprost|Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost
10210483|NCT05039684||Primary open angle glaucoma / ocular hypertension - Treatment with Saflutan|Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan
10210484|NCT05039684||Ocular hypertension - No treatment|Patients ocular hypertension untreated
10210485|NCT05038618|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
9866754|NCT00157300|Experimental|Epoetin beta|
9866755|NCT00157612|Other|Intervention|use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, re-hydration and close monitoring by a research nurse
9866756|NCT00157612|No Intervention|Comparator|usual care
9866757|NCT00157651|Active Comparator|1|Receiving warfarin
9866758|NCT00157651|Placebo Comparator|2|Receiving matching placebo
9866759|NCT00157677|Experimental|1|Selective D-Dimer use
9866760|NCT00157677|Active Comparator|2|Uniform D-Dimer use
9866761|NCT00157690|Active Comparator|1|Alendronate
9866762|NCT00157690|Placebo Comparator|2|Placebo
9866763|NCT00157807|No Intervention|No Ablation|
9866764|NCT00157807|Other|bipolar radiofrequency ablation of persistent and permanent AF|intra operative bipolar RF ablation of persistent and permanent AF
10210486|NCT05037071|Experimental|Upper body compression|An arm compression sleeve with a graduated compression between 18-25 mmHg will be worn on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy.
9866765|NCT00157846|Experimental|BiV Pacing|Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
9866766|NCT00157846|Active Comparator|RV Stimulation|Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months
9866767|NCT00158028|Experimental|Risperidone|starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
9866768|NCT00158028|Placebo Comparator|Placebo|placebo match in identical tablets
10210487|NCT05037071|No Intervention|No compression|Muscle oxygen saturation of the extensor radialis muscle will be measured using near infrared spectroscopy on the dominant gaming arm while performing intense gridlock training using an AIM trainer lab. .
10210488|NCT05032937|Experimental|ECMR|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.
9866769|NCT00158132|Experimental|Propranolol|Propranolol 100mg/day in 3 divided doses
9866770|NCT00158132|Experimental|Amantadine|Amantadine 100mg three times daily
9866771|NCT00158132|Experimental|Propranolol and Amantadine|Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
9866772|NCT00158132|Placebo Comparator|Placebo|Identical Placebo pills
9866773|NCT00158158|Placebo Comparator|1|Usual care
9866774|NCT00158158|Experimental|2|Reduction in smoking
9866775|NCT00158171|Experimental|1|Nicotine patch
9866776|NCT00158171|Experimental|2|Nicotine gum
9866777|NCT00158171|Placebo Comparator|3|Folic acid
9866778|NCT00158275|Experimental|Integrated Intervention|Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
9866779|NCT00158275|No Intervention|Standard of Care|Participants will receive care as usual from their health care provider.
9866780|NCT00158301|Experimental|1|Continuation phase cognitive behavioral therapy and drug therapy for 6 more months following acute treatment response
9866781|NCT00158301|Active Comparator|2|Continuation phase drug therapy only for 6 more months following acute treatment response
9866782|NCT00158327|Experimental|1|Participants will receive telephone-based collaborative care
9866783|NCT00158327|Active Comparator|2|Participants will receive usual care
9866784|NCT00158340|Experimental|1|Participants will receive guided self-help cognitive behavioral therapy
9866785|NCT00158340|Active Comparator|2|Participants will receive treatment as usual
9866786|NCT00158353|Experimental|1|GirlPOWER! mentoring program
9866787|NCT00158353|Active Comparator|2|Big Brothers Big Sisters community-based mentoring program
9866788|NCT00158366|Experimental|1|Phase 1 participants who will receive behavioral training for 14 weeks
9866789|NCT00158366|Active Comparator|2|Phase 1 participants who will receive social skills training for 14 weeks
9866790|NCT00158366|Experimental|3|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training alone for 24 months in Phase 2
9866791|NCT00158366|Experimental|4|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training plus biweekly booster treatments for 24 months in Phase 2
9866792|NCT00158431|Active Comparator|Arthroscopy plus Medical Management|Arthroscopic Surgery of the Knee plus the optimized medical management including physiotherapy, education, medication, etc
9866793|NCT00158431|No Intervention|Medical Management|Optimized Medical management including physiotherapy, education, medication, etc
9866794|NCT00158522|Experimental|1|
9866795|NCT00158574|Placebo Comparator|Placebo|IPTi placebo
9866796|NCT00158574|Experimental|Sulphadoxine-pyrimethamine|IPTi SP
9866797|NCT00158574|Experimental|Mefloquine|
10210489|NCT05024058|Experimental|Ligelizumab low dose, symptomatic dermographism group|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
10210490|NCT05024058|Experimental|Ligelizumab high dose, symptomatic dermographism|Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
9866798|NCT00158574|Experimental|Chlorproguanil dapsone|
9866799|NCT00158652|Active Comparator|1|
9866800|NCT00158652|Experimental|2|
9866801|NCT00158652|Experimental|3|
9866802|NCT00158665|Experimental|Subjects receiving vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
9866803|NCT00158678|Active Comparator|1|Conventional RT 70Gy + concomitant cisplatin
9866804|NCT00158678|Experimental|2|IMRT 75Gy + concomitant cisplatin
9866805|NCT00158769|Experimental|Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment as defined by a Child-Pugh score of 7-9 will be included. Subjects will be given GR270773 as a loading infusion of 25 milligram per kilogram per hour (mg/kg/hr) for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours.
9866806|NCT00158769|Experimental|Healthy subjects|Subjects will be matched as closely as possible to the group of moderate hepatic subjects for gender, age and body mass index (BMI). Subjects will be administered 25 mg/kg/hr GR270773 as a loading dose for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours. Following a washout period of 21 days, the subjects will then receive a loading dose of 75 mg/kg/hr for 2 hours followed by a maintenance dose of 12.5 mg/kg/hr of GR270773 for 70 hours.
9866807|NCT00158782|Experimental|Cohort 1|Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.
9866808|NCT00158782|Experimental|Cohort 2|Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.
9866809|NCT00158782|Experimental|Cohort 3|Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.
9866810|NCT00158782|Experimental|Cohort 4|Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.
9866811|NCT00158782|Experimental|Cohort 5|Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.
9866812|NCT00158782|Experimental|Cohort 6|Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.
9866813|NCT00158782|Experimental|Cohort 7|Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.
9866814|NCT00158782|Experimental|Cohort 8|Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.
9866815|NCT00158782|Experimental|Cohort 9|Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.
9866816|NCT00158782|Experimental|Cohort 10|Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.
9866817|NCT00158886|Experimental|Subjects with rectal cancer|Subjects will be administered topotecan along with concomitant radiation for five days per week for five weeks. Topotecan doses will start at 0.25 milligrams per square meter (mg/m˄2) and will be escalated 0.15 mg/m˄2 for subsequent cohorts. To advance to the next dose level of topotecan, at least two subjects will have to complete therapy with oral topotecan without experiencing grade 3 or 4 toxicity for three weeks after the oral topotecan treatment.
9927368|NCT00892593|No Intervention|2 Usual Care - Surveillance|
9927369|NCT00892593|No Intervention|3 Usual Care - Screening|
9927370|NCT00892593|Experimental|4 Fecal Immunochemical Testing-Screening|Fecal Immunochemical Testing yearly, beginning at year 6.
9927371|NCT00892619|Experimental|ILM forceps|Using ILM forceps to initiate and complete peel
9927372|NCT00892619|Active Comparator|Other|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
9927373|NCT00892632|Experimental|1|1. To compare confocal image characteristics of benign vs. malignant biliary strictures
9927374|NCT00892658|Experimental|Sorafenib + RT|
9927375|NCT00892671||medical students|
9927376|NCT00892736|Experimental|Treatment (veliparib)|"Patients receive veliparib PO BID* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive veliparib once on day 1 of course 1 for pharmacokinetic and pharmacodynamic studies."
9927377|NCT00892749|Experimental|1. ASP1585|
9927378|NCT00892788|Active Comparator|A|Participants assigned to Group A will receive the LEARN (Lifestyle, Exercise, Attitudes, Relationships, Nutrition) Program weight loss manual and will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
9927379|NCT00892788|Experimental|B|Participants assigned to Group B will receive the LEARN manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
9927380|NCT00892801|Experimental|Treatment|RAD001 + radiation therapy
9927381|NCT00892814|Experimental|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
9927382|NCT00892814|Active Comparator|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
9927383|NCT00892827|Experimental|Single Arm Study|Rituximab
9927384|NCT00892840|Experimental|Panels 1 to 7 (BMS-820836 or Placebo)|
9927385|NCT00892853|Other|Bone Density Scanning|To acquire high resolution images of the bones and aid in determining bone density.
9927386|NCT00892866||Ancillary-Correlative (biomarkers in cervical cancer)|Patients undergo liquid-based cytology specimen sample collection for analysis of CA-IX, p16, Ki-67, and MCM2 expression via IHC and for the presence of high risk HPV DNA and HPV genotyping.
9927387|NCT00892879|Experimental|1|Single port laparoscopic device
9927388|NCT00892879|Active Comparator|2|Four-port laparoscopic device
10210491|NCT05024058|Placebo Comparator|Placebo SC q4W, symptomatic dermographism|Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism
10210492|NCT05024058|Experimental|Ligelizumab low dose, cold urticaria|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria
10210493|NCT05024058|Experimental|Ligelizumab high dose, cold urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria
10210494|NCT05024058|Placebo Comparator|Placebo SC q4w, cold urticaria|Placebo subcutaneous injection every 4 weeks in participants with cold urticaria
10210495|NCT05024058|Experimental|Ligelizumab high dose, cholinergic urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria
10210496|NCT05024058|Placebo Comparator|Placebo SC q4w, cholinergic urticaria|Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria
10210497|NCT05000320||Vigabatrin-naive|Adults 18 - 80 years of age suffering from post anoxic status epilepticus (PASE) who have not received vigabatrin.
10210498|NCT04992013|Experimental|Niraparib|Participants will receive niraparib 1x daily for each 28 day study treatment cycle up to 2 years or until disease worsens or unacceptable side effects occur.
10210499|NCT04989582|Experimental|Nursing intervention|Nurses randomly assigned by applying a random selection method
10210500|NCT04989582|No Intervention|No intervention|Nurses randomly assigned by applying a random selection method
10210501|NCT04983342|Experimental|Apollo Armband|Armband that can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain.
10210502|NCT04970654|Experimental|Somapacitan weekly|participants will receive once-weekly somapacitan for 52 weeks
10210503|NCT04970654|Active Comparator|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks
10210504|NCT04967274|Experimental|Spinal cord injured subjects|
10210505|NCT04967079|Experimental|Anlotinib + Trametinib|Anlotinib given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus trametinib 2 milligrams (mg) given orally, once daily.
10210506|NCT04964193|Experimental|Elzsa film-coated tablet|Participants received Elzsa film-coated tablet (2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
9866818|NCT00159081|Experimental|1|Maintenance antipsychotic treatment with risperidone
9866819|NCT00159081|Active Comparator|2|Maintenance antipsychotic treatment with haloperidol in low-dose
9866820|NCT00159107|Experimental|2|Placebo +Integrative behavior therapy
9866821|NCT00159107|Experimental|3|Acamprosate + treatment as usual
9866822|NCT00159107|Experimental|1|Acamprosate + Integrative behavior therapy
9866823|NCT00159120|Active Comparator|1|further maintenance antipsychotic treatment and prodrome-based early intervention
9866824|NCT00159120|Experimental|2|stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
9866825|NCT00159133|Experimental|1|Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
9866826|NCT00159133|Active Comparator|2|Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
9866827|NCT00159146|Active Comparator|A|Venlafaxine and pindolol
9866828|NCT00159146|Placebo Comparator|B|Venlafaxin and placebo
9866829|NCT00159198||1|Patients with frontotemporal dementia and amyotrophic lateral sclerosis
9866830|NCT00159198||2|Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis
9866831|NCT00159211|Active Comparator|1|UMULINE NPH at bed time
9866832|NCT00159211|Experimental|2|pioglitazone 30 mg
9866833|NCT00159224|Experimental|Lopinavir/ritonavir monotherapy|Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
9866834|NCT00159224|Active Comparator|Lopinavir/Ritonavir plus 2 NRTIs|Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
9866835|NCT00159289|Experimental|1|Inhalation of LPS
9866836|NCT00159289|Placebo Comparator|2|PLacebo
9866837|NCT00159380|Experimental|Healthy volunteers|8 non smokers non asthmatic
9866838|NCT00159380|Experimental|Asthma volunteers|8 asthmatic mild
9866839|NCT00159406||cohort|Registry and Database
9866840|NCT00159484|Experimental|A|EPO906, celecoxib
9866841|NCT00159497|Active Comparator|1|Standard porouscoated Trilogy Cup
9866842|NCT00159497|Experimental|2|HA coated Trilogy cup
9866843|NCT00159510|No Intervention|Control|The control group with neither nitric oxide nor methylene blue used
9866844|NCT00159510|Active Comparator|MB alone|Single methylene blue used
9866845|NCT00159510|Active Comparator|NO alone|Nitric oxide alone used
9866846|NCT00159510|Active Comparator|MB+NO|Both nitric oxide and methylene blue used
9866847|NCT00159523|Experimental|probiotic|
9866848|NCT00159523|Placebo Comparator|placebo|
9866849|NCT00159536|Experimental|Metformin|Metformin 1000mg x 2 daily
9866850|NCT00159536|Placebo Comparator|placebo|Placebo x 2 daily
9866851|NCT00159562|Experimental|group education|Bipolar 1 and 2 patients in a stable euthymic phase will receive group education in 10 weekly sessions and then a session every third month for two years. Symptoms, admittances to hospital and function will be followed for two years.
9866852|NCT00159562|Active Comparator|individual education|Bipolar 1 and 2 patients in a stable euthymic phase will receive three individual sessions of education.
9866853|NCT00159575|Experimental|M: Metformin P: Placebo|
9866854|NCT00159601||outpatients in Child and Adolescent Mental Health Service|
9866855|NCT00159601||youth from general population|
9866856|NCT00159926|Experimental|1|With cell saver
9866857|NCT00159926|Active Comparator|2|Without cell saver
9866858|NCT00159939|Active Comparator|prone position|prone positioning
9866859|NCT00159939|No Intervention|supine position|
9866860|NCT00159952|Active Comparator|1|
9866861|NCT00159991|Experimental|A|Total arterial revascularization
9866862|NCT00159991|Active Comparator|B|Conventional revascularization
9866863|NCT00160017||Collaborative group|Participants (i.e. profesionals) participate in a Breakthrough Collaborative intervention to improve diabetes care so that patients are provided more often with diabetes care as described in guidelines
9866864|NCT00160017||usual care group|Participants are offered no intervention and care is provided as usual
9866865|NCT00160030|Experimental|1|
9866866|NCT00160030|Active Comparator|2|
9866867|NCT00160043|Experimental|Arm 1|
9866868|NCT00160043|Experimental|Arm 2|
9866869|NCT00160056|Other|Hypoglycemia|Intrerfvention is a hypoglycemic stimulus
9866870|NCT00160069|Experimental|Arm 1|
9866871|NCT00160069|Experimental|Arm 2|
9866872|NCT00160069|Experimental|Arm 3|
9866873|NCT00160186|Experimental|1|
9866874|NCT00160186|Placebo Comparator|2|
9866875|NCT00160290|Experimental|A|Lactulose Group
9866876|NCT00160290|Active Comparator|B|Plantago Group
9866877|NCT00160316|Experimental|1|
9866878|NCT00160342|Active Comparator|1|
9866879|NCT00160342|Experimental|2|
9866880|NCT00160342|Experimental|3|
9866881|NCT00160342|Active Comparator|4|
9866882|NCT00160342|Experimental|5|
9866883|NCT00160342|Experimental|6|
9866884|NCT00160342|Active Comparator|7|
9866885|NCT00160342|Active Comparator|8|
9866886|NCT00160342|Placebo Comparator|9|
9866887|NCT00160355|Other|1|
9866888|NCT00160381|Experimental|1|
9866889|NCT00160381|Experimental|2|
9866890|NCT00160381|Placebo Comparator|3|
9866891|NCT00160420|Experimental|1|
9866892|NCT00160433|Experimental|1|
9866893|NCT00160433|Experimental|2|
9866894|NCT00160433|Experimental|3|
9866895|NCT00160433|Placebo Comparator|4|
9866896|NCT00160446|Experimental|1|
9866897|NCT00160446|Experimental|2|
9866898|NCT00160446|Experimental|3|
9866899|NCT00160446|Placebo Comparator|4|
9927389|NCT00892892|Experimental|Arm 1|Rilmenidine as a sympatholytic agent for three months
9927390|NCT00892892|Active Comparator|Arm 2|Nitrendipine as a non-sympatholytic agent for three months
9927391|NCT00892905||POC INR and APTT Hemochron|Adult patients undergoing elective on pump coronary artery bypass grafting surgery who have not received anticoagulants or clopidogrel within 5 days preoperatively.
9927392|NCT00892918|Active Comparator|Moxifloxacin|About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
9927393|NCT00892918|Active Comparator|Gatifloxacin|About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
9927394|NCT00892944|Experimental|1|AZD2516
9927395|NCT00892983|No Intervention|Standard well child care|Standard Well Child Care (SWCC) - 8 Core visits at 2-4 weeks, 6 weeks, 3, 5, 8-10 and 15 months, 2 and 3 years.
9927396|NCT00892983|Experimental|Food Activity Breast feeding support|FAB (Food Activity Breast feeding support) 8 extra parent contacts for augmented education and support around breast feeding, food and activity
9927397|NCT00892983|Experimental|Sleep|Prevention of sleep problems in first 6 months and then active early intervention for sleep problems from 6 months to 24 months
9927398|NCT00892983|Experimental|FAB + Sleep|combination of interventions used in arms 2 and 3
9927399|NCT00892996|No Intervention|1|Metoclopramide 10 mg intravenous
9927400|NCT00892996|No Intervention|2|Ondansetron 8 mg intravenous
9927401|NCT00892996|Active Comparator|3|dexamethasone 5 mg and metoclopramide 10 mg
9927402|NCT00892996|Active Comparator|4|dexamethasone 5 mg and ondansetron 8 mg IV
9927403|NCT00893009|Placebo Comparator|Placebo|
9927404|NCT00893009|Active Comparator|Theophylline|100 twice a day
9927405|NCT00893048|Experimental|Prednisone|Use of prednisone to decrease LOS and overall treatment time of cellulitis
9927406|NCT00893048|Experimental|Placebo|
9927407|NCT00893061|Experimental|Arm I|Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.
10210507|NCT04964193|Active Comparator|Diane-35 Sugar-coated tablet|Participants received Diane-35 Sugar-coated tablet ( 2 mg cyproterone acetate + 0.035 mg ethinylestradiol) with 240 mL of water
9927408|NCT00893061|Experimental|Arm II|Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.
10210508|NCT04963413|Experimental|Autologous DCs derived from PBMC loaded with RNA|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
10210509|NCT04958876|Experimental|SP-104 crossover to naltrexone immediate release|SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration
10210510|NCT04958876|Experimental|Naltrexone immediate release crossover to SP-104|Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration
10210511|NCT04954820|Experimental|Experimental arm|2 additional infusions of Lutathera® according to the marketing authorization schema
10210512|NCT04954820|No Intervention|Control arm|No treatment with active monitoring (clinical, biological and radiological follow-up) every 2 months.
10210513|NCT04952532|Other|Cognitive Remediation+Bridging Intervention|This is a pilot study to collect feasibility data on this novel cognitive remediation intervention for Veterans at high risk for suicide. All patients will receive the active intervention.
10210514|NCT04928040|Experimental|Fluid challenge|Fluid challenge effects on optic nerve sheath diameter
10210515|NCT04926285|Experimental|Cohort 1|Omacetaxine 0.625 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
10210516|NCT04926285|Experimental|Cohort 2|Omacetaxine 1.25 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
10210517|NCT04926285|Experimental|Cohort 3|Omacetaxine 2.0 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
10210518|NCT04926285|Experimental|Cohort 4|Omacetaxine 2.5 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
10210519|NCT04920916|Experimental|Dupilimab|Active Dupilimab: 600 mg, given as two 300 mg subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
9927409|NCT00893087|Active Comparator|1|Flow triggering
9927410|NCT00893087|Active Comparator|2|Pressure triggering
9927411|NCT00893087|Active Comparator|3|NAVA triggering
10210520|NCT04920916|Placebo Comparator|Placebo|Dupilimab Placebo: placebo (normal saline) will be given as two one mL subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (1 mL) will be given on days 14 and 28.
9935282|NCT03951493|Experimental|RSHF + zoledronic acid|Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).
9935283|NCT03951493|Active Comparator|RSHF|Patients receive only RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction.
9935284|NCT03949647||1|Healthy males and females aged 18 years and older
10210521|NCT04918654||Study Subjects|
10210522|NCT04918225||Progressive Multiple Sclerosis patients|Progressive Multiple Sclerosis patients
10210523|NCT04918225||Healthy Volunteers|Healthy Volunteers
9866900|NCT00160459|Experimental|1|
9866901|NCT00160459|Experimental|2|
9866902|NCT00160459|Experimental|3|
9866903|NCT00160459|Placebo Comparator|4|
9866904|NCT00160485|Experimental|1|Glyburide,gestational diabetes, maternal complications, neonatal complications
9866905|NCT00160485|Active Comparator|2|Insulin, gestational diabetes, maternal complications, neonatal outcomes
9866906|NCT00160732|Experimental|Transplant|
9866907|NCT00160784|Active Comparator|Arthroscopic Manipulation|Manipulation of Shoulder performed during arthroscopy
9866908|NCT00160784|Active Comparator|Home exercise program|Shoulder exercise program performed at home to increase shoulder function
9866909|NCT00160875|Experimental|Cisplatin, Irinotecan|
9866910|NCT00160966|Active Comparator|1|Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
9866911|NCT00160966|Active Comparator|2|Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
9866912|NCT00160966|Active Comparator|3|Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing
9866913|NCT00160979|Experimental|hypoxia and RT in prostate cancer|
9866914|NCT00161187|Experimental|Treatment|Biological/Vaccine: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
9866915|NCT00161265||1|women with breast cancer
9866916|NCT00161304|Active Comparator|Testosterone Enanthate|Testosterone
9866917|NCT00161304|Placebo Comparator|Placebo|Placebo
9866918|NCT00161343|Experimental|1|Small interactive groups on preventing HIV infections using an Information-Behavioral Skills-Motivational model
9866919|NCT00161343|Placebo Comparator|2|Small interactive groups on general health-promotion topics using an Information-Behavioral Skills-Motivational model
9866920|NCT00161395|Active Comparator|1|Preconception advice.
9866921|NCT00161395|Experimental|2|Instruction in the Creighton Model Fertility Care System.
10210524|NCT04916730|Placebo Comparator|Standard of Care (SOC)|Participants will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
10210525|NCT04916730|Experimental|TRE + SOC|Participants in this arm will receive standard of care nutritional behavioral counseling and will implement a daily, self-selected, 10-hour window within which they must consume all calories. They will also be required to log their caloric intake through the use of a smartphone app
10210526|NCT04914728|Experimental|mini-invasive lumbar arthrodesis|"The patient will be admitted to the hospital on the morning of the surgery, operated on the same morning by either the posterior or anterior mini-invasive approach.~The choice of the approach depends on the specificity of the pathology leading to the arthrodesis procedure and the surgeon's experience. It is the surgeon who decides this in agreement with the patient. The patient will be discharged in the evening after agreement of the anaesthetist and the surgeon."
10210527|NCT04907292||Planned Cesarean delivery|Patients who have an elective Cesarean delivery at Mount Sinai Hospital
10210528|NCT04907292||Unplanned Cesarean delivery|Patients who have an unplanned Cesarean delivery at Mount Sinai Hospital
9866922|NCT00161421|Experimental|1|Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, & 10.
9866923|NCT00161434|Experimental|1|
9866924|NCT00161434|Placebo Comparator|2|
9866925|NCT00161447|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
9866926|NCT00161447|Active Comparator|2|Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 & at month 3) + Acyline (SQ) every two weeks for the first 12 weeks
9866927|NCT00161460|Active Comparator|1|Study nurse contacts subjects who enroll in the intervention to provide detailed education about screening tests, to assess their risk for colorectal cancer, and to facilitate screening.
9866928|NCT00161460|No Intervention|2|Patients who do not enroll receive usual care from their primary care providers.
9866929|NCT00161486|Placebo Comparator|1|Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks
9866930|NCT00161486|Active Comparator|2|Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks
9866931|NCT00161486|Active Comparator|3|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks
9866932|NCT00161577|Other|A|Group A = Ketorolac
9866933|NCT00161577|Placebo Comparator|B|
9866934|NCT00161720||All participants|Participants with severe congenital protein C deficiency who were treated under an emergency use IND.
9927412|NCT00893100|Experimental|Diltiazem|
9927413|NCT00893126||Subjects with severe psoriasis|Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
9935285|NCT03940729|Other|PWID colonized with S aureus|Repeated chlorhexidin showers for PWID colonized with S aureus
9866935|NCT00162110|Active Comparator|1|
9866936|NCT00162149|No Intervention|A1|
9866937|NCT00162149|Experimental|A2|
9866938|NCT00162149|Experimental|A3|
9866939|NCT00162149|No Intervention|B1|
9866940|NCT00162201|Experimental|1|
9866941|NCT00162214|Active Comparator|1|
9866942|NCT00162305|Active Comparator|1|
9866943|NCT00162305|Active Comparator|2|
9866944|NCT00162305|Active Comparator|3|
9866945|NCT00162305|Placebo Comparator|4|
9866946|NCT00162318|Experimental|A|
9866947|NCT00162370|Experimental|Definity|All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
9866948|NCT00162383|Experimental|Cocktail|
9866949|NCT00162435|Experimental|Genetic|
9866950|NCT00162435|Experimental|Control|
9866951|NCT00162448|Experimental|A1|
9866952|NCT00162448|Placebo Comparator|A2|
9866953|NCT00162461|Experimental|Phenytoin|
9866954|NCT00162474|Experimental|Warfarin|
9866955|NCT00162552|Active Comparator|1|Patients with severe cirrhosis treated with Pentoxifylline
9866956|NCT00162552|Placebo Comparator|2|Patients with severe cirrhosis treated with a placebo
9866957|NCT00162565|Experimental|1|bbloquant treatment
9866958|NCT00162656|Active Comparator|Standard LMB B|
9866959|NCT00162656|Experimental|LMB B without COPADM3|
9866960|NCT00162656|Experimental|LMB B with half cyclophosphamide|
9866961|NCT00162656|Experimental|LMB B without COPADM3 and with half cyclophosphamide|
9866962|NCT00162656|Active Comparator|LMB C standard|
9866963|NCT00162656|Experimental|LMB C with mini CYVE and without 3 maintenance courses|
9866964|NCT00162682|Active Comparator|1|* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
9866965|NCT00162682|Experimental|2|CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
9866966|NCT00162890||Patient with degenerative cervical disease|
9866967|NCT00162916|Placebo Comparator|1|
9866968|NCT00162916|Experimental|2|
9866969|NCT00162955|Experimental|ARB administration|80mg/day from the day of the start of 1st CHOP until the completion of all the evaluations
9866970|NCT00162955|No Intervention|non-administration|ARB non-administration group
9866971|NCT00163046|Experimental|Gabapentin|
9866972|NCT00163046|Placebo Comparator|Placebo|
9866973|NCT00163137|Experimental|Lasofoxifene 0.25 mg|lasofoxifene 0.25 mg/day
9866974|NCT00163137|Active Comparator|raloxifene|raloxifene 60 mg/day
9866975|NCT00163137|Placebo Comparator|Placebo|Placebo
9866976|NCT00163267|Placebo Comparator|ASS + Placebo|control arm
9866977|NCT00163267|Active Comparator|ASS + Plavix|active drug
9866978|NCT00163280|Experimental|1|ATL-104 50mg
9866979|NCT00163280|Experimental|2|ATL-104 100mg
9866980|NCT00163280|Experimental|3|ATL-104 150mg
9866981|NCT00163280|Placebo Comparator|4|Placebo
9866982|NCT00163449|Active Comparator|1|Ciclesonide 40 µg
9866983|NCT00163449|Active Comparator|2|Ciclesonide 80 µg
9866984|NCT00163449|Active Comparator|3|Ciclesonide 160 µg
9866985|NCT00163449|Placebo Comparator|4|Placebo
9927414|NCT00893126||Subjects without psoriasis|Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan.
9927415|NCT00893165||hemodialysis patients|chronic hemodialysis patients with elevated inflammation markers
9866986|NCT00163553|Experimental|P|Epidural pethidine group
9866987|NCT00163553|Placebo Comparator|N|placebo group
9866988|NCT00163566|Placebo Comparator|Placebo gel|Placebo gel twice per day
9866989|NCT00163566|Active Comparator|0.7% DHT gel, Dose 1|0.7% DHT gel twice per day, 35 mg/day
9866990|NCT00163566|Active Comparator|0.7% DHT gel, Dose 2|0.7% DHT gel twice per day, 70 mg/day
9866991|NCT00163579|Experimental|Bryophyllum|
9866992|NCT00163579|Placebo Comparator|Placebo|
9866993|NCT00163644|Active Comparator|Aerobic exercise plus resistance|Aerobic exercise plus resistance exercise for 6 weeks
9866994|NCT00163644|Active Comparator|Aerobic exercise|Aerobic exercise for 6 weeks
9866995|NCT00163644|Other|Control|No formal exercise and weekly phone calls
9866996|NCT00163670||Motor vehicle accident|
9866997|NCT00163670||Control|
9866998|NCT00163722|Active Comparator|Standard diagnostic strategy of culture and histology|The standard-diagnostic strategy was designed to be consistent with the 2002 guidelines for antimicrobial use in neutropenic patients with cancer. When an invasive fungal infection was suspected (e.g. persistent fevers) cultures of blood, urine, sputum (if available) and faeces (if clinically indicated), and HRCT scans of chest were performed. Bronchoscopy and biopsies were performed according to institutional protocols. Empiric antifungal therapy was recommended whilst undergoing these investigations and was continued, de-escalated to prophylaxis, or changed to treatment of invasive aspergillosis or other IFD according to test results.
9866999|NCT00163722|Experimental|Aspergillus galactomannan and PCR directed|Results of once to twice weekly testing with Aspergillus galactomannan and PCR directed the timing of CT scan performance and whether antifungal therapy was given
9867000|NCT00163761|Active Comparator|Commence VGF treatment|Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
9867001|NCT00163761|Active Comparator|Commence F-GIV treatment|Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle
9867002|NCT00163826||Trauma Patients|Major trauma patients
9867003|NCT00163865||Clinical Group|clinical adolescent group
9867004|NCT00163865||Community Group|community adolescent group
9867005|NCT00164021||Cystic Fibrosis|Patients with cystic fibrosis
9867006|NCT00164021||Control|
9867007|NCT00164138|Experimental|Pelvic Floor Training Group|Pelvic floor training, biofeedback.
9867008|NCT00164203|Experimental|Cognitive Behavioral Therapy|School-based, 12-session protocol, weekly
9867009|NCT00164203|Active Comparator|activity control condition|Structured games and activities, weekly for 12 weeks
9867010|NCT00164281|Experimental|Continuous vs limited isoniazid|The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).
9867011|NCT00164463|Experimental|Moxifloxacin|Moxifloxacin 400 mg po qd given 5 of 7 days per week
9867012|NCT00164463|Active Comparator|Isoniazid|Isoniazid 300 mg po qd given 5/7 days per week
9867013|NCT00164515|No Intervention|Arm 1: Physical activity awareness|The awareness group received a physician-recommendation to exercise an informational brochure, and pedometer.
9867014|NCT00164515|Experimental|Arm 2: Lower Support|The lower support group received arm 1 plus monthly newsletter, weekly personalized exercise support via telephone.
9867015|NCT00164515|Experimental|Arm 3: Higher support|The higher support group received arm 1 plus arm 2 plus a face-to-face monthly exercise support group.
9867016|NCT00164619|Experimental|1|Standard STD clinic services and the VOICES/VOCES intervention
9867017|NCT00164619|Active Comparator|2|Standard STD clinic services
9867018|NCT00164697|Experimental|1|Parenting group
9867019|NCT00164697|No Intervention|2|"Families in this usual care comparison group were not prevented from utilizing any service that would otherwise be available to them, even if the service was similar to the services received in the intervention arm of the study."
9867020|NCT00164723|Other|NSAID|patients taking NSAID will undergo capsule endoscopy
9867021|NCT00164723|Other|Aspirin|patients taking Aspirin will undergo capsule endoscopy
9867022|NCT00164723|Other|Non-user|patients didn't take NSAID or ASA will undergo capsule endoscopy
9927416|NCT00893191||Sildenafil|Treated with 50 mg of Sildenafil at night
9867023|NCT00164736|Active Comparator|Maternal ARVs & Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & daily nutritional supplement given to the mother
9867024|NCT00164736|Active Comparator|Infant NVP & Nutrition Supplement|Extended infant nevirapine for prophylaxis & daily nutritional supplment given to the mother
9867025|NCT00164736|Active Comparator|Maternal ARVs & No Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & no nutritional supplement given to the mother
9867026|NCT00164736|Active Comparator|Infant NVP & No Nutrition Supplement|Extended infant nevirapine for prophylaxis & no nutritional supplment given to the mother
9867027|NCT00164736|Active Comparator|No Drugs & Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & daily nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
9867028|NCT00164736|No Intervention|No Drugs & No Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & no nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
9867029|NCT00164749|Placebo Comparator|Placebo|Color-matched placebo
9867030|NCT00164749|Experimental|1 gram|1 g/day curcumin
9867031|NCT00164749|Experimental|4 gram|4 g/day curcumin
9867032|NCT00164775|Active Comparator|Imipramine|Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
9867033|NCT00164775|Placebo Comparator|Placebo|Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
9867034|NCT00164788|Active Comparator|IV Nexium|Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
9867035|NCT00164788|Active Comparator|Oral Nexium|Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours
9927417|NCT00893191||Placebo|Treated with placebo at night
9927418|NCT00893217|Active Comparator|Arm 1|
9927419|NCT00893217|Experimental|Arm 2|
9927420|NCT00893230|Experimental|Lactobacillus sakei KCTC 10755BP|
9927421|NCT00893230|Placebo Comparator|microcrystalline cellulose|
9927422|NCT00893243||1Tears Again/Control|
9927423|NCT00893243||2Opticol/Control|
9927424|NCT00893243||3Optive/Control|
9927425|NCT00893243||4Tears Again/Opticol|
9927426|NCT00893243||5Tears Again/Optive|
9927427|NCT00893243||6Opticol/Optive|
9927428|NCT00893256|Experimental|Risperidone and citalopram|24 patients were randomized to receive add-on citalopram (20 mg/day) in a double-blind fashion to open-label risperidone (4-8 mg/day)
9927429|NCT00893256|Placebo Comparator|Risperidone and placebo|24 patients were randomized to receive add-on placebo in a double-blind fashion to open-label treatment with risperidone (4-8 mg/day)
9927430|NCT00893269|Experimental|Active Medication|Participants receive active hypnotic medication prior to sleep
9927431|NCT00893269|Placebo Comparator|Placebo|Participants receive placebo prior to sleep
9927432|NCT00893282|Experimental|BackStop|Intracorporeal lithotripsy with the use of an anti-retropulsion device.
9927433|NCT00893282|Active Comparator|Control|No anti-retropulsion device will be used during lithotripsy.
9927434|NCT00893321|Other|Inferior Oblique Muscle Recession and Myectomy|
9927435|NCT00893334||BMD:|Patients diagnosed with Becker Muscular Dystrophy
9927436|NCT00893334||LGMD2A|patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
9927437|NCT00893334||LGMD2B|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
9927438|NCT00893334||LGMD2I|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
9927439|NCT00893334||Control|Healthy Controls
9927440|NCT00893347|Active Comparator|I|Treatment as usual
9927441|NCT00893347|Experimental|II|Treatment as usual + cognitive-behavioural therapy
9927442|NCT00893360|Experimental|Cardiac Stem Cell Treatment - Group 1|Autologous stem cell infusion of 12.5 MIL CDCs via intracoronary infusion.
9927443|NCT00893360|Experimental|Cardiac Stem Cell Treatment -Group 2|Autologous stem cell infusion of 25 MIL CDCs via intracoronary infusion.
10210529|NCT04899986|Experimental|Trial Group|Patients from this group will use chlorhexidine Biorepair gel and toothpaste for home oral care.
10210530|NCT04899986|Active Comparator|Control Group|Patients from this group will not use chlorhexidine and Biorepair gels and toothpastes, but will perform home oral care with standard toothpastes.
9867036|NCT00164853|Active Comparator|Standard sphincterotomy (ES)|After deep cannulation, a pull-type sphincterotomy will be performed with a 25mm sphincterotome (eg clever cut, Olympus, Tokyo, Japan) with division of sphincter up to the duodenal wall. A complete sphincterotomy is defined by the free passage of a fully bowed sphincterotome with a 25m wire and spontaneous bile drainage.
9867037|NCT00164853|Active Comparator|Sphincterotomy plus balloon dilation (ESBD)|After complete sphincterotomy, a 3-cm long 15mm diameter CRE balloon is passed over a guidewire across the lower end of common bile duct. The contrast filled balloon is inflated to the size of the bile duct for around 30 seconds until waisting is abolished.
9867038|NCT00164905|Active Comparator|Doppler ultrasound|
9867039|NCT00164905|No Intervention|No Doppler ultrasound|
9867040|NCT00164944||FDR of CRC patient|First degree relatives of patients having CRC
9867041|NCT00164944||FDR of normal colonoscopy|First degree relatives of patients having normal colonoscopy
9867042|NCT00165009|No Intervention|DUAL THERAPY|DUAL THERAPY
9867043|NCT00165009|Experimental|'Resolution clip|'Resolution clip
9867044|NCT00165035|Experimental|1|CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
9867045|NCT00165035|Active Comparator|2|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
9867046|NCT00165152|Active Comparator|Genetic Counseling|
9867047|NCT00165152|Active Comparator|Informed Consent Counseling|
9867048|NCT00165178|Experimental|Individualized ASP dose|
9867049|NCT00165178|Active Comparator|Fixed dose ASP|
9867050|NCT00165178|Experimental|Dexamethasone|
9867051|NCT00165178|Active Comparator|Prednisone|
9867052|NCT00165282|No Intervention|Usual Care|Normal standard of care
9867053|NCT00165282|Active Comparator|Nurse education|Meets with oncology nurse
9867054|NCT00165282|Experimental|Mindfulness training|Taught Mindfulness meditation
9867055|NCT00165308|Experimental|Tamoxifen|Single arm: Tamoxifen 20mg daily
9867056|NCT00165542||All patients|A PROTEIN levels in all patients and with all tumor types.
9867057|NCT00165633|Experimental|1|
9867058|NCT00165633|Experimental|2|
9867059|NCT00165633|Placebo Comparator|3|
9867060|NCT00165750|Experimental|1|
9867061|NCT00165763|Experimental|1|
9867062|NCT00165802|Experimental|1|
9867063|NCT00165828|Experimental|1|
9867064|NCT00165828|Experimental|2|
9867065|NCT00165919||HCV+|No group or cohort; not a clinical trial
9867066|NCT00166010|Experimental|Nesiritide|
9867067|NCT00166049|Placebo Comparator|Usual Care Attention Control|Usual care with provision of supplemental printed educational material on HF self care
9867068|NCT00166049|Experimental|Group 2 Patient Family Education PFE|Patient Family Education PFE Heart Failure Patients and family member dyads were provided with an educational and counseling session, and attended a 2 hour patient-family education session on heart failure self management with emphasis on dietary sodium and medication taking behaviors.
9867069|NCT00166049|Experimental|Group 3 Family Partnership Intervention|Patient and family member received one individual dyadic education/counseling session, and two group sessions focused on developing family approaches to HF self management. the emphasis of the two group sessions was on developing autonomy supportive approaches to family support.
9927444|NCT00893360|No Intervention|Observation (Control Group)|Observation of myocardial recovery after usual medical management.
10210531|NCT04897412|Experimental|CBL-514 Injection|Participant will receive CBL-514 2 mg/cm² administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
10210532|NCT04897412|Placebo Comparator|Placebo: 0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
10210533|NCT04896320|Experimental|Gemcitabine + Tucatinib + Trastuzumab|Gemcitabine (1000 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
10210534|NCT04896320|Experimental|Vinorelbine + Tucatinib + Trastuzumab|Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
10210535|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 1|In year 1, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
10210536|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 2|In year 2, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
10210537|NCT04887155|Experimental|Cognitive behavioral therapy (CBT)|
10210538|NCT04877197|Experimental|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
10210539|NCT04877197|Active Comparator|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
9867070|NCT00166075||Female ED patients|All eligible African American female patients were approached in the ED waiting room during study periods. Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
9867071|NCT00166088|Experimental|Mediterranean Diet Arm|
9867072|NCT00166088|Active Comparator|Mediterranean Dietary Supplement Arm|
9867073|NCT00166088|No Intervention|Control Arm|
9867074|NCT00166192|Active Comparator|Chemical Peel|Split face treatment paradigm
9867075|NCT00166231||Chest pain patients|
9867076|NCT00166231||Murmur group|
9867077|NCT00166244|Active Comparator|Fixed Dose|1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.
9867078|NCT00166244|Active Comparator|Concentration Controlled|1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.
9867079|NCT00166257|Active Comparator|Medical antitrhombotic treatment|
9867080|NCT00166257|Experimental|Device Implant|Percutaneous closure of patent foramen ovale
9867081|NCT00166270|Experimental|1|
9867082|NCT00166283|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
9867083|NCT00166283|Placebo Comparator|placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
9867084|NCT00166387||Phase I, II, III|Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
9867085|NCT00166413|Experimental|CC5013|Assess the proportion of confirmed hematologic responses (HCR, HPR) resulting from treatment with CC5013 after 3 months in patients with primary systemic amyloidosis.
10210540|NCT04867694|No Intervention|Control|The control group receiving the standards of care and the usual activities of the partners without additional support from the IRAM project for the implementation of the PASIM. This includes the usual Community Management of Acute Malnutrition (CMAM) program. This group will also continue to benefit from the BCC and screening services already existing in their areas.
9927445|NCT00893373|Experimental|Sorafenib|Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d
9927446|NCT00893373|Placebo Comparator|Placebo|Induction, Consolidation and Maintenance plus Placebo
9927447|NCT00893386||Non-4195 Lead, 181 days|Patients with a Medtronic LV Lead, other than Model 4195, implanted at least 181 days
9927448|NCT00893386||4195 Lead, 181 days|Patients with a Medtronic Model 4195 LV Lead implanted at least 181 days
9927449|NCT00893386||4195 Lead, 90-180 days|Patients with Medtronic Model 4195 LV Lead implanted for 90-180 days
9927450|NCT00893399|Experimental|1|chemotherapy in combination with ATRA with gemtuzumab ozogamicin
9927451|NCT00893399|Active Comparator|2|chemotherapy in combination with ATRA without gemtuzumab ozogamicin
9927452|NCT00893412|Active Comparator|Tramadol + Metal cannula|Fast-release Orodispersible Tramadol Tablet + Metal cannula
9927453|NCT00893412|Placebo Comparator|Placebo + Metal cannula|Placebo + Metal cannula
9927454|NCT00893412|Active Comparator|Tramadol + Balloon|Fast-release Orodispersible Tramadol Tablet + balloon catheter
9927455|NCT00893412|Placebo Comparator|Placebo + Balloon|Placebo + balloon catheter
9927456|NCT00893438|Experimental|FitNet treatment|FitNet treatment: web-based cognitive behaviour therapy
9927457|NCT00893438|Active Comparator|Usual care|waiting list for FitNet intervention (usual care allowed)
9927458|NCT00893451|Active Comparator|A|Vitamin D3 1600 IU orally twice daily
9927459|NCT00893451|Placebo Comparator|B|Placebo orally twice daily
9927460|NCT00893490|Experimental|Ahmed Glaucoma Valve (AGV) alone|
9927461|NCT00893490|Experimental|AGV plus MMC|
9927462|NCT00893490|Experimental|AGV plus amniotic membrane coverage|
9927463|NCT00893529|Experimental|dietary intervention 1|
9927464|NCT00893529|Experimental|dietary intervention 2|
9927465|NCT00893555|Active Comparator|control|Voriconazole dosing based on SPC
9927466|NCT00893555|Experimental|TDM|Voriconazole serum concentration based dosing
9927467|NCT00893568|Active Comparator|Healthy volunteers|Healthy volunteers without treatment
9927468|NCT00893568|Experimental|CBT|Psychotraumatized patients treated by Cognitive and Behavioral Therapies (CBT)
9927469|NCT00893568|Experimental|EMDR|Psychotraumatized patients treated by Eye Movement Desensitization and Reprocessing (EMDR)
9927470|NCT00893581|Active Comparator|1--Quetiapine & Placebo|Quetiapine & Placebo in the place of Lithium
9927471|NCT00893581|Active Comparator|2-- Lithium & Placebo|Lithium & Placebo in the place of Quetiapine
9927472|NCT00893581|Placebo Comparator|Placebo|Sugar Pill (Placebo) given to mimic drug
9927473|NCT00893594|Placebo Comparator|1|Placebo taken at onset of aura associated with migraine.
9927474|NCT00893594|Active Comparator|2|Sumatriptan with naprosyn taken at onset of aura associated with migraine.
9927475|NCT00893607|Experimental|Intra-anal|The first 12 subjects were administered 10mg NRL001 as a slow release suppository into the anal canal.
9927476|NCT00893607|Experimental|Rectal|The second 12 subjects were administered 10mg NRL001 as a slow release rectal suppository.
9927477|NCT00893620|Other|1|Treatment
9927478|NCT00893646|Experimental|weight loss counseling|individual monthly counseling on diet, physical activity and sleep
9927479|NCT00893646|No Intervention|control|no lifestyle advice, yearly assessments
9927480|NCT00893659|Experimental|wheat bread with beta-glucan supplementation|
9867086|NCT00166699|No Intervention|Palpation|Use of palpation to guide the the insertion site of combined spinal epidural needle in obese parturients
9867087|NCT00166699|Experimental|ultrasound|The use of ultrasound to guide the insertion of a combined spinal epidural needle
9867088|NCT00166868|Experimental|Neomycin prescribed|Interventions: 10 cases received Neomycin for 6 months
9867089|NCT00166868|Experimental|Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed|Interventions: 10 cases received Probiotics for 6 months
9867090|NCT00166868|No Intervention|control|10 cases without intervention were historical control.
9867091|NCT00166881|Experimental|A, 2, III|Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL
9867092|NCT00167141|Experimental|testosterone injections|injections of testosterone to normal men (arm 1) and two men with subnormal semen parameters (arm 2)
9867093|NCT00167154|Experimental|risperidone|risperidone
9867094|NCT00167154|Placebo Comparator|placebo|placebo comparator
9867095|NCT00167167|Experimental|BMT patients|All patients treated.
9867096|NCT00167232|Active Comparator|Naltrexone 150mg/day|
9867097|NCT00167232|Placebo Comparator|Placebo Sugar Pill|
9867098|NCT00167271|Experimental|Experimental|Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
9867099|NCT00167271|Active Comparator|Control|Subjects given pamphlets from the Arthritis Foundation
9867100|NCT00167297|Experimental|Atomoxetine|Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.
9867101|NCT00167362|Experimental|1|Participants will receive cognitive enhancement therapy
9867102|NCT00167362|Placebo Comparator|2|Participants will receive enriched supportive therapy
9867103|NCT00167466|Experimental|A|4 week brushing with experimental Soladey-3 toothbrush followed by 4 week washout period followed by 4 week brushing with placebo Soladey-3 toothbrush
9867104|NCT00167466|Placebo Comparator|B|subjects to brush with Placebo Soladey-3 toothbrush for 4 weeks followed by a 4 week washout followed by 4 week brushing with experimental Soladey-3 toothbrush
9867105|NCT00167505|Experimental|Risk Avoidance|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
9867106|NCT00167505|Experimental|Risk Reduction|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
9867107|NCT00167531|Experimental|Treadmill walking|30 minutes per day of treadmill walking with body weight support and assistance from one therapist
9867108|NCT00167531|Active Comparator|Overground walking|30 minutes per day of overground walking with assistance from one therapist
9867109|NCT00167557|Experimental|Single Arm Study|
9867110|NCT00167583|Active Comparator|A Cyclosporin A|Cyclosporin A
9867111|NCT00167583|Active Comparator|B Interferon alpha|Interferon-alpha2a
9867112|NCT00167596|Experimental|1|Early goal directed therapy based on StO2 evaluation
9867113|NCT00167596|Active Comparator|2|Early goal directed therapy
9867114|NCT00167622|Active Comparator|1|Physiotherapy, oxygen as needed
9867115|NCT00167622|Experimental|2|Mechanical ventilation
9867116|NCT00167635|Experimental|1|Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
9867117|NCT00167635|Experimental|2|Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
9867118|NCT00167635|No Intervention|3|Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
9867119|NCT00167648|Active Comparator|A|Leuprolide 7.5 mg or Goserelin 3.6 mg
9867120|NCT00167648|Experimental|B|Transdermal estradiol 0.6 mg q 3 days
9867121|NCT00167674|Active Comparator|B|Combined short-course Zidovudine/Nevirapine
9867122|NCT00167674|Experimental|A|HAART during pregnancy and 6 months postpartum
9867123|NCT00167687|Placebo Comparator|2|
9867124|NCT00167700|Experimental|Probiotics|
9867125|NCT00167700|Experimental|Probiotics + Dietary counseling|
9867126|NCT00167700|Experimental|Dietary counseling + placebo|
9867127|NCT00167700|Experimental|Prebiotics|
9867128|NCT00167700|Placebo Comparator|Placebo|
9867129|NCT00167700|No Intervention|Control|
9867130|NCT00167804|Other|1|Present Centered Therapy focuses on the veterans problems in the here and now. It uses a problem solving approach and avoids discussion of war related traumatic events.
9867131|NCT00167830|Experimental|Lifestyle Intervention|Dietary modification and exercise.
9867132|NCT00167856|Experimental|1|Venlafaxine HCL (extended release)
9867133|NCT00167856|Active Comparator|2|Benztropine Mesylate
9867134|NCT00167947|Active Comparator|A|
9867135|NCT00167947|Experimental|B|
9927481|NCT00893659|Placebo Comparator|wheat bread without beta-glucan|
9927482|NCT00893672||1|Routine strategy of chest radiograph prescription
9927483|NCT00893672||2|On-demand strategy of chest radiograph prescription
9927484|NCT00893685|Experimental|Home telemonitoring|
9927485|NCT00893685|No Intervention|Usual care (control group)|
9927486|NCT00893711|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.
9927487|NCT00893711|Placebo Comparator|Placebo|Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
9927488|NCT00893711|Active Comparator|L.reuteri + vit D|L. reuteri DSM 17938 (10^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months
9927489|NCT00893711|Placebo Comparator|Vit D Placebo|vitamin D3 (400 UI) five drops/day for 3 months
10210541|NCT04867694|Experimental|Intervention|"The PASIM is delivered by the care groups. Each beneficiary is visited at home at least once a month (up to once a week if possible).~The package of activities includes :~Behavior change communication (all children in care groups)~Monthly delivery of a nutritional supplement: limited to [6-11] months old children diagnosed as non-wasted (green MUAC) or for [6-59] months old for 6 months after discharge from the national CMAM program.~Monthly delivery of a water purification input: limited to households with [6-11] months old children or with [6-59] months old children under CMAM treatment and for 6 months after discharge.~Delivery of micronutrient powders to [12-23] months old children.~Screening and referral for [6-59] months old children, formative supervision of MUAC measurement in families."
10210542|NCT04866758||Cancer Survivors|Ambulatory cancer population already seeking psychosocial support.
10210543|NCT04865796|Experimental|Group 1|Patients will use products based on lactoferrin.
10210544|NCT04865796|Experimental|Probiotics|Patients will use products based on probiotics for home oral care.
10210545|NCT04865796|Active Comparator|Standard therapy|Patients will use standard toothpastes for home oral care.
10210546|NCT04858269|Experimental|Combination of Chemotherapy and Immunotherapy|The intervention will be administered on an outpatient basis. The treatment regimen will consist of combination chemotherapy and immunotherapy administered as: Pembrolizumab PLUS Carboplatin PLUS Paclitaxel.
10213684|NCT03529695|Active Comparator|Standard HVP Curriculum|"Participants will receive the standard Healthy Families America (HFA) home visitation curriculum delivered by trained home visitors. The HFA model meets the Department of Health and Human Services criteria for an evidence-based early childhood home visiting service delivery model. HFA services begin prenatally and continue until children are 2-5yo. The curriculum focuses on strengthening parent-child relationships and family functioning, promoting positive child development, and linkage to community resources. Accredited home visitors are matched to families on cultural background and language, to provide culturally sensitive services. Home visitors receive weekly supervision, ongoing developmental training, and have limited caseloads (10-15 families) to meet their families' needs."
9927490|NCT00893724|Placebo Comparator|P (Placebo)|
9927491|NCT00893724|Active Comparator|S (Supplement)|
9927492|NCT00893724|Active Comparator|SM (Supplement with Minocycline)|
9927493|NCT00893750|Experimental|NET Truth Education|
9927494|NCT00893750|Experimental|Conflict Resolution Trainings|
9927495|NCT00893750|Experimental|Traditional Methods|
9927496|NCT00893776|Active Comparator|1 Unilateral Group|This group will wear the SaeboFlex orthosis on their affected extremity and do exercises with that extremity only. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
9927497|NCT00893776|Experimental|2 Bilateral training|Members of this group will wear the SaeboFlex orthosis on the affected extremity and do exercises with the affected extremity and the non-affected extremity at the same time. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
9927498|NCT00893802|Experimental|Periodontal treatment|Scaling and root planning
9927499|NCT00893802|No Intervention|Control|
9927500|NCT00893815||1|HIV-Positive and Early HIV infection
9927501|NCT00893815||2|HIV-Positive and Late HIV-infection
9927502|NCT00893815||3|HIV-negative
9927503|NCT00893841|Placebo Comparator|1|Quetiapine XR 300mg + Placebo
9927504|NCT00893841|Experimental|2|Quetiapine XR 300mg + Pramipexole 0.25mg
9927505|NCT00893841|Experimental|3|Quetiapine XR 300mg + Pramipexole 0.50mg
9927506|NCT00893854|Experimental|Diclophenac|
9927507|NCT00893854|Experimental|Triamcinolone|
9927508|NCT00893867|Experimental|DP-b99|
9927509|NCT00893867|Placebo Comparator|Mannitol|
9927510|NCT00893880|Experimental|1|(1) 30min treatment
9927511|NCT00893880|Experimental|2|(1) 60min treatment
9927512|NCT00893880|Experimental|3|(2) 30min treatments over two consecutive days.
9927513|NCT00893880|Experimental|4|(2) 60min treatments over two consecutive days.
9927514|NCT00893893||1|Lean premenopausal women
9927515|NCT00893893||2|Visceral obese premenopausal women
9927516|NCT00893906|Experimental|TIV|Children living in villages randomized to influenza vaccine
9927517|NCT00893906|Experimental|IPV|Children living in villages randomized to polio vaccine
9927518|NCT00893932||SIRS|
9935286|NCT03938909||Patients with Multiple Sclerosis|200 patients and 200 control
9935287|NCT03938909||Patients with dementia|100 patients and 100 control
9867136|NCT00168025|Experimental|IgPro10|
9867137|NCT00168220||Drug hypersensitive group|HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz
9867138|NCT00168220||Drug tolerant group|HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.
9867139|NCT00168233||1|No antiretroviral therapy for 12 months
9867140|NCT00168233||2|Initiating ARV therapy with an NNRTI based regimen
9867141|NCT00168233||3|Initiating ARV therapy with a PI based regimen
9867142|NCT00168415|Experimental|1|Botulinum Toxin Type A
9867143|NCT00168480|Experimental|1|Botulinum Toxin Type A
9867144|NCT00168493|Active Comparator|intervention|there is no sham or placebo control arm It is a single arm study
9867145|NCT00168519|Active Comparator|1|
9867146|NCT00168558|Active Comparator|1|Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
9867147|NCT00168558|Active Comparator|2|Standard titre Schwarz measles vaccine at 9 months of age
9867148|NCT00168558|Active Comparator|3|Standard titre Edmonston-Zagreb measles vaccine at 9 months of age
9867149|NCT00168688|Active Comparator|FeFol|Iron (60 mg) and folic acid (400 ug), standard of care
9867150|NCT00168688|Experimental|MN1|"1 RDA of 15 micronutrients, including iron (30 mg) and folic acid (400 ug)~Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg"
9867151|NCT00168688|Experimental|MN2|"2 RDA of 14 micronutrients including iron (30 mg) and folic acid (800 ug)~Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg"
9867152|NCT00168714||Pregnant participants|Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy
9867153|NCT00168753|Experimental|1|
9867154|NCT00168766|Experimental|1|interferon-beta-1a in combination with methylprednisolone
9867155|NCT00168766|Placebo Comparator|2|interferon-beta-1a in combination with placebo
9867156|NCT00168909|Experimental|1|alfacalcidol 1µg/d
9867157|NCT00168909|Placebo Comparator|2|placebo
9867158|NCT00169000|Experimental|Capecitabine and Docetaxel|Escalating doses of capecitabine days 1-14 with a fixed dose of docetaxel on Day 8 of a 21 day cycle
9867159|NCT00169065|Active Comparator|Clozapine|Clozapine or olanzapine in treatment resistant schizophrenia
9867160|NCT00169065|Active Comparator|olanzapine|clozapine or olanzapine in treatment resistant schizophrenia
9867161|NCT00169091|Experimental|Clozapine|Clozapine 12.5-300 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
9867162|NCT00169091|Active Comparator|Haloperidol|Haloperidol 2-12 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
9867163|NCT00169117|Experimental|1|Behavioural intervention: Songs/posters aimed at behaviour change to increase repair and maintenance of mosquito nets
9867164|NCT00169156|Experimental|Rituximab + CHOP|Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
9867165|NCT00169182|Experimental|TPF|Docetaxel, Cisplatine, 5-FU
9867166|NCT00169182|Active Comparator|PF|Cisplatine, 5-FU
9867167|NCT00169195|Experimental|R-GEMOX|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
9867168|NCT00169208|Experimental|Experimental|4 cycles of rituximab + fludarabine + mitoxantrone
9867169|NCT00169221|Active Comparator|postop chemoradio with cisplatin|postoperative chemoradiotherapy with cisplatin
9867170|NCT00169221|Experimental|postop chemoradio (cisplatin)+gefitinib|postoperative chemoradiotherapy with cisplatin + gefitinib
9867171|NCT00169234|Experimental|0.1mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
9867172|NCT00169234|Experimental|0.5mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
9867173|NCT00169234|Experimental|1.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
9867174|NCT00169234|Experimental|2.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
9867175|NCT00169234|Experimental|0.5mL Pneumococcal Polysacc Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
9867176|NCT00169260|Experimental|1|Intervention
9867177|NCT00169260|Placebo Comparator|2|Control
9867178|NCT00169273|Active Comparator|Weight loss only intervention|Structured group weight loss intervention
9867179|NCT00169273|Experimental|Combined intervention|Structured group program for weight loss and depression
9867180|NCT00169338|Experimental|deep brain stimulation|Paladin deep brain stimulation
9867181|NCT00169338|Placebo Comparator|sham deep brain stimulation|no stimulation
9867182|NCT00169377|Active Comparator|Group A|Deep brain stimulation on followed by off
9867183|NCT00169377|Sham Comparator|Group B|No stimulation, deep brain stimulation off followed by on
9867184|NCT00169390||pregnant smokers|
9867185|NCT00169390||pregnant non smokers|
9927519|NCT00893945|Experimental|DC/AAT vaccine|Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.
9927520|NCT00894023|Experimental|Abciximab|IC bolus of abciximab
9927521|NCT00894023|Active Comparator|IV Abciximab|IV abciximab + infusion
9927522|NCT00894049|Experimental|Flu-Bu-ATG|Fludarabine (30mg/m²/5 days) Oral Busulfan (8 mg/kg over 2 days) Thymoglobuline (2.5 mg/m²/1day).
9927523|NCT00894049|Experimental|Fluda-TBI|Fludarabine (25mg/m²/ 3 days) 2 Gy TBI
9927524|NCT00894062|Active Comparator|1|ZES resolute (Endeavor® resolute)
9927525|NCT00894062|Active Comparator|2|EES (Xience®)
9927526|NCT00894101|Experimental|[F-18] FLT and FDG|
9927527|NCT00894114|Other|Stratum 1|Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
9927528|NCT00894114|Experimental|Stratum 2|Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
9927529|NCT00894114|Experimental|Stratum 3|Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
9927530|NCT00894114|Experimental|Stratum 4|High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
9927531|NCT00894140|Other|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
9927532|NCT00894153|Experimental|chemo plus p53|chemotherapy plus p53
9927533|NCT00894153|Active Comparator|chemo only|chemotherapy group
9927534|NCT00894153|Active Comparator|radio|radiotherapy
9927535|NCT00894192|Active Comparator|Wavefront guided lenses|
9927536|NCT00894192|Placebo Comparator|Conventional lenses|
9927537|NCT00894205|Experimental|strengthening exercise|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises."
9927538|NCT00894218|Active Comparator|Conventional arthroplasty|Total hip or knee conventional arthroplasty
9927539|NCT00894218|Experimental|Mini-invasive arthroplasty|Total hip or knee mini-invasive arthroplasty
9927540|NCT00894218|Experimental|Mini-invasive and computer-assisted arthroplasty|Mini-invasive and computer-assisted total hip or knee arthroplasty
9927541|NCT00894231|Placebo Comparator|placebo|Sugar tablet
9927542|NCT00894231|Active Comparator|Xyzal|
9927543|NCT00894257||HCV/HIV infected pregnant women|
9927544|NCT00894283|Active Comparator|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
9927545|NCT00894283|Active Comparator|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
9927546|NCT00894296||1|schizophrenia patients
9927547|NCT00894296||2|healthy control
9927548|NCT00894335||1|Pheochromocytoma
9927549|NCT00894335||2|Conn-Syndrome
9927550|NCT00894335||3|Cushing disease
9927551|NCT00894335||4|Metastasis
9927552|NCT00894335||5|Non-functional tumor
9927553|NCT00894374|Experimental|Artesunate (Pfizer)|
9927554|NCT00894374|Active Comparator|Artesunate (Arsuamoon® Tablets Guilin-China)|
9927555|NCT00894400|Experimental|Targeting of most fractionated electrograms first|During catheter ablation of AF patients will have fractionated electrograms targeted. In the experimental group the fractionated electrograms believed to be most critical will be targeted first.
9927556|NCT00894400|Active Comparator|Targeting least fractionated electrograms first|During catheter ablation of AF fractionated electrograms are targeted. In this arm the least fractionated electrograms will be targeted first.
9927557|NCT00894426||1|Morning Symptoms (+)
9927558|NCT00894426||2|Morning Symptoms (-)
9927559|NCT00894439|Experimental|1|
9867186|NCT00169533|Experimental|Arm 1|Lapatinib either 750, 1000, 1250 or 1500 mgs
9867187|NCT00169546|Experimental|Arm 1|
9867188|NCT00169559|Placebo Comparator|Arm 1|Placebo
9867189|NCT00169559|Active Comparator|Arm 2|Fenofibrate
9867190|NCT00169650||1|Registry and database of subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction
9867191|NCT00169676||cohort|Registry and Database
9867192|NCT00169689|Sham Comparator|rTMS|sham coil system versus verum rTMS stimulation
9867193|NCT00169702|Other|Standard|standard information
9867194|NCT00169702|Active Comparator|Intervention|weight management program, 12 sessions, 2 weekly, psychoeducational program, interactive topics like healthy food, diet behavior, physical activity, stress reduction.
9867195|NCT00169715|Other|A|
9867196|NCT00169741|Other|cohort|
9867197|NCT00169754|Other|cohort|mapping and data collection
9867198|NCT00169767||A|Comparison study between KTP and HoLAP procedures for BPH
9867199|NCT00169780||cohort|patients who require a CT scan prior to kidney stone surgery for diagnostic purposes
9867200|NCT00169793|Other|A|
9867201|NCT00169832|Experimental|Rosiglitazone (Avandia)|
9867202|NCT00169832|Placebo Comparator|Placebo|
9867203|NCT00169845|Experimental|Alpha-Tocopherol and Beta-Carotene|Patients received a daily supplementation of alpha-tocopherol (one capsule of 400 IU dl-alpha-tocopherol) and beta-carotene (one capsule of 30 mg) for 3 years after the end of radiation therapy. Due to ethical concerns, the beta-carotene supplementation was stopped during the trial (after the randomization of 156 patients). See details in JNCI, 2005: 97 (7), 481-8.
9867204|NCT00169845|Placebo Comparator|Placebo|Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
9867205|NCT00169897|Experimental|Hospital-based|This group has to go at the hospital 3 times per week to do the exercise program.
9867206|NCT00169897|Active Comparator|Home-Based|The group had to do the exercise program at home with indirect supervision (Polar watches and a phone call per week).
9867207|NCT00169910|Active Comparator|1|AUC monitored withdrawal of MMF
9867208|NCT00169910|Active Comparator|2|AUC monitored withdrawal of CNI
9867209|NCT00170001|Placebo Comparator|Sugar pill|
9867210|NCT00170001|Active Comparator|Active Comparator|
9867211|NCT00170079|Experimental|Step care vs. regular care|Participants were randomized either to (1) Step care intervention, where smokers who failed to quit or who relapsed received increasingly intensive smoking cessation interventions; vs. (2) Regular care, where smokers who failed to quit or who relapsed received repeated intervention.
9867212|NCT00170209|Active Comparator|Isoniazid|The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
9867213|NCT00170209|Active Comparator|Rifampin|The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).
9867214|NCT00170235|Experimental|1|Prehabilitation (exercises pre surgery)
9867215|NCT00170235|Active Comparator|2|Usual care as provided by the institution
9867216|NCT00170248|No Intervention|1|Physicians in this arm will be using the standard MOXXI electronic health record.
9867217|NCT00170248|Experimental|2|In addition to the standard MOXXI electronic health record, physicians in this arm will be using the computer-based decision support for asthma management
9867218|NCT00170274|No Intervention|Control Arm|Algorithms for prevention and termination of AF not activated
9867219|NCT00170274|Active Comparator|Prevention and Therapy Algorithms on|Activation of preventive and therapeutic algorithms
9867220|NCT00170287|Experimental|1|ICD Therapy plus VT-Ablation
9867221|NCT00170287|Active Comparator|2|ICD Therapy only
9867222|NCT00170313|Experimental|Conducted AF-Response Algorithm (CAFR) On|"CAFR: On~Level medium~Max. Rate: 110ppm VSR: Off"
9867223|NCT00170313|Active Comparator|Conducted AF-Response Algorithm (CAFR) Off|CAFR: Off VSR: Off
9867224|NCT00170326|Active Comparator|Dual Chamber pacing|conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex
9867225|NCT00170326|Experimental|Biventricular pacing|Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle
9867226|NCT00170456|Active Comparator|1|Low dose rPA vaccine regime 1
9867227|NCT00170456|Active Comparator|2|Low dose rPA vaccine regime 2
9867228|NCT00170456|Active Comparator|3|High dose rPA vaccine regime 1
9867229|NCT00170456|Active Comparator|4|High dose rPA vaccine regime 2
9867230|NCT00170469|Experimental|1|Low dose rPA vaccine
9867231|NCT00170469|Experimental|2|High dose rPA vaccine
9867232|NCT00170469|Active Comparator|3|Active vaccine control
9867233|NCT00170495||observation|male and female adults age 65 and older with acute respiratory illness (common colds, flu, bronchitis, pneumonia)
9867234|NCT00170547|Experimental|Group 3|382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
9867235|NCT00170547|Experimental|Group 4|382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
9867236|NCT00170547|Experimental|Group 1|382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
9867237|NCT00170547|Experimental|Group 2|382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
9867238|NCT00170573|Experimental|Caelyx|
9867239|NCT00170612|Experimental|A|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
9867240|NCT00170612|Experimental|B|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
9867241|NCT00170612|Experimental|C|PCV at 6 weeks and 14 weeks; PPS at 18 months
9867242|NCT00170612|Experimental|D|PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
9867243|NCT00170612|Experimental|E|PCV at 14 weeks; PPS at 18 months
9867244|NCT00170612|Experimental|F|PCV at 14 weeks; PPS at 12 months and 18 months
9867245|NCT00170612|Experimental|G|No PCV; PPS at 12 months and 18 months
9867246|NCT00170612|Active Comparator|H|No PCV; PPS at 18 months
9867247|NCT00170664|Experimental|Paclitaxel, Carboplatin|
9867248|NCT00170677|Active Comparator|A|
9867249|NCT00170677|Experimental|B|
9867250|NCT00170690|Experimental|1|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
9867251|NCT00170690|Experimental|2|Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
9867252|NCT00170716|Active Comparator|Control|
9867253|NCT00170716|Experimental|Investigational|
9867254|NCT00170755|Experimental|1|Darifenacin
9867255|NCT00170768|Experimental|1|Darifenacin
9867256|NCT00170768|Active Comparator|2|Oxybutynin
9867257|NCT00170768|Placebo Comparator|3|Placebo
9927560|NCT00894478||1|12 children with MRI-negative partial epilepsy who are being worked-up for epilepsy surgery
9927561|NCT00894478||2|12 children with MRI-visible FCD who are being worked-up for epilepsy surgery
9927562|NCT00894478||3|Control Group- Healthy Volunteers
9927563|NCT00894569|Active Comparator|A|6 cycles of carboplatin/paclitaxel
9927564|NCT00894569|Experimental|B|carboplatin/paclitaxel plus cetuximab until disease progression
9927565|NCT00894595|Experimental|Intervention group|The clubs in the intervention group are instructed to perform a warm-up program at two training sessions per week throughout the entire 2009 competitive season.
9927566|NCT00894595|Active Comparator|Control group|The clubs in the control group are instructed to train and play as usual throughout the 2009 season
9927567|NCT00894608|Experimental|letrozole protocol|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
9927568|NCT00894608|Experimental|long GnRHa protocol|patients in long GnRHa protocol for ovarian stimulation with Gnrha and gonadotropins
9927569|NCT00894621|Experimental|Norepinephrine|
9927570|NCT00894621|Placebo Comparator|Placebo|
9927571|NCT00894634|Experimental|Brompheniramine maleate|Brompheniramine maleate oral solution 1 mg/5 mL, single dose
9927572|NCT00894660|Experimental|Amodiaquine (Pfizer)|
9927573|NCT00894660|Active Comparator|Amodiaquine tablets (Arsuamoon-Guilin China)|
9927574|NCT00894673|Experimental|1|Heparin sodium Hipolabor
9927575|NCT00894673|Active Comparator|2|Heparim Sodium APP 5.000 USP
9927576|NCT00894725|Experimental|LPS|laparoscopic left colonic resection
9927577|NCT00894725|Active Comparator|Open|open left colonic resection
9927578|NCT00894751|Active Comparator|dexmedetomidine|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
9927579|NCT00894751|Active Comparator|propofol|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
9927580|NCT00894764||Routine Follow Up|Monthly nasopharyngeal swab for infant. Seen during acute illness.
9927581|NCT00894764||Immunology|Monthly nasopharyngeal swab for mother and infant. Serum sample taken from Infant. Seen during acute illness.
9927582|NCT00894777||1|Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
9935288|NCT03938909||Patients with Parkinson's disease|50 patients and 50 control
9935289|NCT03937830|Experimental|1/Arm 1|Durvalumab, bevacizumab and tremelimumab
9935290|NCT03937830|Experimental|2/Arm 2|Durvalumab, bevacizumab, tremelimumab and TACE
9935291|NCT03937817||1|Healthy volunteers/ patients with hematologic/ hemolytic diseases, including globin variants such as alpha and beta thalassemia variants, sickle cell disease, malaria, or other diseases involving inflammation or endothelial dysfunction.
9935292|NCT03937804||asthmatics|persons with asthma
9935293|NCT03937804||control|persons without asthma
9935294|NCT03929913|Experimental|Study arm #1|The Transcatheter Mitral Cerclage Annuloplasty implant is attached to a guidewire and pulled through the internal jugular sheath, along the coronary sinus, through the basal septum, through the tricuspidvalve, and back out of the internal jugular sheath. The position of the TMCA implant is adjusted so that the coronary protection element lies directly over any underlying branc of the left coronary artery.
9935295|NCT03928639||Cohort 1|All patients undergoing consultation for structural and valve interventional procedures are invited to participate in this registry protocol.
9935296|NCT03927612|Experimental|Alternate Perspective|After experiencing VR scenarios, participants will experience the interactions again from the virtual counterpart's perspective within the VR system.
9935297|NCT03927612|Placebo Comparator|Control Perspective|After experiencing VR scenarios, participants will experience the interactions again from the same perspective in the VR system.
9935298|NCT03922724|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
9935299|NCT03922724|Experimental|2/IOC Arm|Immunosuppression Only Conditioning, plus allogeneic HCT with GVHD prophylaxis
9935300|NCT03922724|No Intervention|3/Donor Arm|Donors for Recipients in Arm 1, Arm 2, Arm 4, or Arm 5
9935301|NCT03922724|Experimental|4/mRIC Arm|modified Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
9935302|NCT03922724|Experimental|5/ATL-RIC Arm|modified Reduced Intensity Conditioning Arm for ATL patients, plus allogeneic HCT with GVHD prophylaxis
9935303|NCT03921515|Other|1|Blister Induction
9935304|NCT03921515|Other|2|Skin Biopsies
9935305|NCT03916003|Experimental|PQ7|high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
9935306|NCT03916003|No Intervention|standard care|As per national guidelines for P. falciparum treatment
9867258|NCT00171145|Experimental|1|Darifenacin
9867259|NCT00171145|Placebo Comparator|2|Placebo
9867260|NCT00171171|Experimental|Deferasirox|
9867261|NCT00171184|Experimental|1|Darifenacin
9867262|NCT00171184|Placebo Comparator|2|Placebo
9867263|NCT00171496|Experimental|Cyclosporine microemulsion|
9867264|NCT00171496|Active Comparator|Tacrolimus|
9867265|NCT00171509|Active Comparator|BID cyclosporine|control group continuing with a BID administration of cyclosporine and C2 monitoring.
9867266|NCT00171509|Experimental|OAD cyclosporine|conversion to OAD administration of cyclosporine with the same daily dose as received prior to conversion
9867267|NCT00171509|Experimental|OAD cyclosporine reduced|OAD administration of cyclosporine with a daily dose adjusted to a reduced C2
9867268|NCT00171808|Experimental|Letrozole|
9867269|NCT00171821|Experimental|ICL670 (Deferasirox)|
9867270|NCT00171847|Experimental|A - HER-2 +ve patients with Femara alone|
9867271|NCT00171847|Experimental|B - HER-2 +ve patients with Femara + Herceptin|
9867272|NCT00171847|Experimental|C - HER-2 -ve patients with Femara alone|
9867273|NCT00171860|Experimental|STI571|
9867274|NCT00171886|Experimental|octrotide|
9867275|NCT00171899|Experimental|STI571|
9867276|NCT00171912|Experimental|imatinib mesylate (STI571)|
9867277|NCT00171964|Experimental|zoledronic acid + radiotherapy|zoledronic acid every 4 weeks in combination with radiotherapy
9867278|NCT00171977|Experimental|Imatinib Mesylate|400 mg once per day
9867279|NCT00172003|Experimental|Zoledronic acid|Zoledronic acid, dosage according to calculated creatinine clearance, administered as a 15 minute infusion every 3 weeks for 12 months. Study infusion visits should occur not earlier than the scheduled visit and no later than 3 days after the scheduled visit. The dose of zoledronic acid in patients with baseline creatinine clearance > 60 mL/min was recommended to be 4 mg infused over no less than 15 minutes.
9867280|NCT00172016|Experimental|ZOL446 (zoledronic acid)|
9867281|NCT00172029|Experimental|ZOL446 Standard radiotherapy dosage|
9867282|NCT00172029|Experimental|ZOL446 Low radiotherapy dosage|
9867283|NCT00172055|Experimental|ZOL446 (zoledronic acid)|
9867284|NCT00172068|Experimental|Treatment Group|
9867285|NCT00172068|Active Comparator|Control Group|
9867286|NCT00172081|Placebo Comparator|placebo|Daily subcutaneous injection into thigh or abdomen with 700 mg Calcium and 400 IU Vitamin D daily
9867287|NCT00172081|Experimental|PTH(1-84) 100 mcg|Subcutaneous injection of PTH(1-84) with 700 mg Calcium and 400 IU Vitamin D daily
9867288|NCT00172094|Placebo Comparator|1|PLACEBO
9867289|NCT00172094|Experimental|2|400 mg 1776 powder
9867290|NCT00172094|Experimental|3|1776 (800 mg)
9867291|NCT00172107|Placebo Comparator|1|Placebo drug injectable subcutaneously
9867292|NCT00172107|Experimental|2|50 mcg PTH(1-84)
9867293|NCT00172107|Experimental|3|75mcg PTH(1-84)
9867294|NCT00172107|Experimental|4|100 mcg PTH(1-84)
9867295|NCT00172133|Experimental|1|All patients entering the study will receive 100mcg daily for up to 6 months, making their total exposure 24 months
9867296|NCT00172172|Experimental|1|PTH 100 mcg and 700 mg calcium
9867297|NCT00172172|Experimental|2|PTH 100 mcg and placebo
9867298|NCT00172172|Placebo Comparator|3|Placebo and 700 mg calcium
9867299|NCT00172224||osteoporosis|
9867300|NCT00172380|Experimental|docetaxel and cisplatin|docetaxel 36mg/m2 and cisplatin 75mg/m2
9867301|NCT00172419|Experimental|Atorvastatin|
9927583|NCT00894816|Active Comparator|1|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19) 10E8 CFU per serving
9927584|NCT00894816|Placebo Comparator|2|Placebo (infant cereals without any additions)
9927585|NCT00894829|Experimental|1|Heparin sodium - Eurofarma
9927586|NCT00894829|Active Comparator|2|Heparin APP
9927587|NCT00894842|Active Comparator|Pregnenolone|
9927588|NCT00894842|Placebo Comparator|Sugar pill|
9927589|NCT00894855|Active Comparator|education only|This comprehensive education program included a health educator visit, on the education van, who gave education about sun safety.
9935307|NCT03915184|Experimental|CAR-BCMA T Cells|Phase 1b will include a dose escalation followed by an expansion cohort to determine the recommended dose for the expansion part. After recommended Phase 2 is determined, patients in Phase 2 will be treated.
9867302|NCT00172536|Other|Control|Received oral general education about proper diet, regular physcial activity and other medical care if necessary
9867303|NCT00172536|Experimental|Exercise training|Received a supervised structure treadmill training
9867304|NCT00172809|Active Comparator|1|Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks
9867305|NCT00172809|Active Comparator|2|Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks
9867306|NCT00173108|No Intervention|Term group|
9867307|NCT00173108|No Intervention|Usual care program group|
9867308|NCT00173108|Experimental|Clinic-based interveniton program group|
9867309|NCT00173108|Experimental|Home-based interveniton program group|
9867310|NCT00173433||Culture-confirmed relapse of TB|Patients who have a recurrent episode of culture-confirmed TB after completion of treatment for the first episode of culture-confirmed TB
9867311|NCT00173537|Other|other|
9927590|NCT00894855|Experimental|education plus dermatologist skin exam|"In addition to the education program, participants received free skin exams by board certified dermatologists from Brigham and Women's Hospital. The van was equipped with a private clinical setting conducive to carry out such examinations. Based on the recommendations of the American Academy of Dermatology (AAD), a visual full body exam was provided to participants. At the end of each skin exam the dermatologist provided a presumptive diagnosis to the participant, and made appropriate recommendations and referrals for follow up with the participants' physician/dermatologist (if and when necessary). All participants undergoing the skin exam were required to complete an AAD Skin Cancer Screening Registration and Report form."
9927591|NCT00894855|Experimental|educ, biometric fb, and derm skin exam|Participants received the active components of the other three conditions.
9927592|NCT00894855|Experimental|education plus biometric feedback|In addition to the educational program, participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
9927593|NCT00894881||1 group|patients before colonoscopy
9927594|NCT00894907|Experimental|PiCCO-group|Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids according to PiCCO-parameter-guided algorithm
9927595|NCT00894907|Other|2|Control: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
9927596|NCT00894920|Placebo Comparator|placebo|
9517861|NCT03302195|Active Comparator|Control group|"Heparin dose and cardiopulmonary bypass pump flow rate are calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
9927597|NCT00894920|Active Comparator|biotin|
9927598|NCT00894946|Experimental|Recurrent IVF implantation failure|
9927599|NCT00894946|Experimental|Endometriosis|
9927600|NCT00894959|Experimental|1|Heparin Sodium Blausiegel 1
9927601|NCT00894959|Experimental|Active Comparator|heparin sodium - APP 5.000 USP
9927602|NCT00894972|Active Comparator|1|General exercise. Participants in this group will perform aerobic exercise, range of motion exercise and general strengthening exercise.
9927603|NCT00894972|Experimental|2|Specific exercise. Participants in this group will perform aerobic exercise, range of motion exercise, and specific motor control exercises.
9927604|NCT00894985|Experimental|1|Heparin 5.000UI
9927605|NCT00894985|Active Comparator|2|Heparin 5.000USP - APP
9927606|NCT00894998|Experimental|1|Heparin sodium 5.000 UI - Cristália
9927607|NCT00894998|Active Comparator|2|Heparin Sodium 5.000 USP - APP
9927608|NCT00895024||Caregivers|
9927609|NCT00895050||1|Patients diagnosed with RA
9927610|NCT00895063|Experimental|Vocal Exercise|Subject will speak continually for one hour following injection of botulinum toxin.
9927611|NCT00895063|Placebo Comparator|Silence|Subject will remain silent for one hour following injection of botulinum toxin.
9927612|NCT00895076|Experimental|1|dexamethasone iontophoretic patch
9927613|NCT00895076|Active Comparator|2|dexamethasone intramuscular injection
9867312|NCT00173862|Experimental|A|
9867313|NCT00173875|Experimental|A|Iressa
9867314|NCT00173888|Experimental|A|
9867315|NCT00173888|Active Comparator|B|
9867316|NCT00174369|Experimental|PD0325901|15 mg BID
9867317|NCT00174434|Experimental|A|
9867318|NCT00174499|Experimental|1|2 mg nicotine gum
9867319|NCT00174499|Experimental|2|4 mg nicotine gum
9867320|NCT00174616|Experimental|Single arm|
9867321|NCT00174629|Experimental|1|
9867322|NCT00174629|Active Comparator|2|
9867323|NCT00174642|Experimental|1|Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin
9867324|NCT00174642|Experimental|2|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin
9867325|NCT00174642|Experimental|3|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue
9867326|NCT00174655|Active Comparator|A1|
9867327|NCT00174655|Active Comparator|A2|
9867328|NCT00174655|Experimental|B|
9867329|NCT00174655|Experimental|C|
9867330|NCT00174668|Experimental|1|Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously
9867331|NCT00174668|Active Comparator|2|Two daily injection conventional insulin therapy
9867332|NCT00174707|Active Comparator|A|Sequential Epidoxorubicin followed by CMF: ciclophosphamide/Methotrexate/fluorouracile (±TAM: tamoxifen)
9867333|NCT00174707|Experimental|B|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
9867334|NCT00174707|Experimental|C|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
9867335|NCT00174772|Experimental|B|Concurrent chemoradiotherapy followed by consolidation chemotherapy
9867336|NCT00174772|Experimental|A|Induction chemotherapy followed by concurrent chemoradiotherapy
9867337|NCT00174798|Placebo Comparator|Placebo|
9867338|NCT00174798|Experimental|SSR240600C|
9867339|NCT00174798|Active Comparator|Tolterodine|
9867340|NCT00174928|Experimental|Lansoprazole 0.5 mg/kg QD|
9867341|NCT00174928|Experimental|Lansoprazole 1.0 mg/kg QD|
9867342|NCT00174993|Experimental|Pioglitazone QD|
9867343|NCT00174993|Placebo Comparator|Placebo QD|
9867344|NCT00175032|Experimental|Lansoprazole 30 mg QD + Naproxen 500 mg BID|(and added aspirin)
9867345|NCT00175032|Active Comparator|Celecoxib 200 mg QD|(and added aspirin)
9867346|NCT00175045|Experimental|Lansoprazole IV 30 mg QD|
9867347|NCT00175045|Active Comparator|Lansoprazole Capsule 30 mg QD|
9867348|NCT00175058|No Intervention|1|Control - Patients with acute anterior myocardial infarction revascularized by means of PCI with stenting within 6 hours of onset of symptoms, no experimental intervention
9867349|NCT00175058|Experimental|2|AO Therapy group - anterior acute myocardial infarction patients revascularized by means of PCI with stenting within 6 hours of symptom onset, receiving adjunctive infusion of hyperoxemic blood into target coronary artery for 90 minutes post-PCI.
9867350|NCT00175071|Experimental|Comparison of cooking oils|Postmenopausal women (50-85 y) with LDL cholesterol 120 mg/dL.
9867351|NCT00175097|Other|soybeans and products made thereof|Diet: soybeans and products made thereof (soynuts, soynut butter, soy flakes & grits)
9867352|NCT00175097|Other|soybean flour and products made thereof|Diet: soybean flour and products made thereof (textured soybean)
9867353|NCT00175097|Other|soybean milk|Diet: soybean milk (tofu, soybean yogurt, cheese, etc.)
9867354|NCT00175097|Other|animal protein based diet|Diet: animal protein based diet
9867355|NCT00175136|Active Comparator|I-beam|I-beam stem design of tibial component for Total Knee Arthroplasty.
9867356|NCT00175136|Active Comparator|wedge|Wedge stem design of tibial component for Total Knee Arthroplasty.
9867357|NCT00175149|Active Comparator|1|Given alfacalcidiol. Dose adjusted after PTH level
9867358|NCT00175149|No Intervention|2|The untreated arm
9867359|NCT00175162|Active Comparator|Osteopal G bone cement|
9867360|NCT00175162|Active Comparator|Refobacin-Palacos R bone cement|
9867361|NCT00175188|Active Comparator|Cemented PIP implant|Avanta PIP
9867362|NCT00175188|Active Comparator|Uncemented PIP implant|Avanta PIP
9867363|NCT00175227|Experimental|Intervention|Saline hydration + mannitol + furosemide
9517862|NCT03302195|Experimental|Intervention group A|"Heparin dose is adjusted for lean body weight and cardiopulmonary bypass pump flow rate is calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
9867364|NCT00175227|Placebo Comparator|Controls|Saline hydration without mannitol or furosemide
9927614|NCT00895089|Experimental|A: Moxifloxacin|Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.
9927615|NCT00895089|Active Comparator|B: Ceftriaxone|Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.
9927616|NCT00895102|Active Comparator|1. ABT-333 Capsule vs ABT-333 Tablet|400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose
9927617|NCT00895102|Active Comparator|2. ABT-333 Tablet|ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)
9927618|NCT00895102|Placebo Comparator|3. Placebo|Placebo tablets, QD, single ascending doses
9927619|NCT00895115|Sham Comparator|Arm I|Patients receive no supplementation.
9927620|NCT00895115|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 1 week.
9927621|NCT00895115|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 2 weeks.
9927622|NCT00895128|Experimental|Erlotinib + Dasatinib|Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
9927623|NCT00895141|Experimental|Low saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 8%E saturated fat
9927624|NCT00895141|Experimental|High saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
9927625|NCT00895167|Experimental|curcumin|every subject receives 12 g of oral curcumin
9927626|NCT00895206|Experimental|1|individual adapted immunosuppression
9927627|NCT00895206|Active Comparator|2|golden standard therapy
9927628|NCT00895219|Active Comparator|1|Breathing re-training
9927629|NCT00895219|Active Comparator|2|Breathing re-training and musculoskeletal physiotherapy techniques
9927630|NCT00895258|Experimental|IPS-CT|Participants will receive individual placement and support (IPS) plus cognitive training (CT).
9927631|NCT00895258|Active Comparator|IPS-ES|Participants will receive individual placement and support (IPS) plus enhanced support (ES).
9927632|NCT00895349|Experimental|1|CT Abdomen and Pelvis + whole body PET-CT
9927633|NCT00895349|Active Comparator|2|CT Abdomen and Pelvis
9517863|NCT03302195|Experimental|Intervention group B|"Heparin dose is calculated using total body weight and cardiopulmonary bypass pump flow rate is adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
9867365|NCT00175344|Experimental|A|Arm A: Self-administered massage of the postoperative scar after breast cancer surgery.
9867366|NCT00175357|Active Comparator|1|Oral methadone
9867367|NCT00175357|Experimental|2|Injected diacetylmorphine
9867368|NCT00175383|Experimental|Leuprolide preparations|One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program
9867369|NCT00175396|Active Comparator|1|
9867370|NCT00175396|Experimental|2|
9867371|NCT00175409|Active Comparator|1|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
9867372|NCT00175409|Active Comparator|2|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
9867373|NCT00175435|Experimental|1|2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
9867374|NCT00175435|Active Comparator|2|3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
9867375|NCT00175435|Active Comparator|3|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
9867376|NCT00175812|Experimental|ATRA plus valproic acid plus theophyllin|ATRA for 14 days, continuous treatment with valproic acid and theophyllin
9867377|NCT00175838|Active Comparator|Intermediate risk group|Intermediate risk patients are randomised to a either a group receiving Aspirin only, or a group receiving both Hydroxyurea and Aspirin.
9867378|NCT00175838|Active Comparator|Low risk group|Patients are given Aspirin only with observation.
9867379|NCT00175890|Placebo Comparator|Placebo|Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
9867380|NCT00175890|Experimental|Levetiractem|10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
9867381|NCT00175903|Experimental|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
9867382|NCT00175903|Active Comparator|Older Antepileptic Drugs|Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
9867383|NCT00175929|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day
9867384|NCT00175929|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
9867385|NCT00175929|Experimental|Brivaracetam 150 mg/day|Brivaracetam 150 mg/day, 75 mg administered twice a day
9867386|NCT00176046|Experimental|viscum album pini|immediate start of treatment with Iscador P s.c.
9867387|NCT00176046|Active Comparator|waiting group|identical treatment with Iscador P s.c. after waiting period of 3 months
9867388|NCT00176085||healthy|healthy volunteers
9867389|NCT00176124|No Intervention|1|storage and transfusion of autologous whole blood without leukocyte depletion : Control group
9867390|NCT00176124|Experimental|2|storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
9867391|NCT00176241|Experimental|1|
9867392|NCT00176267|Experimental|1|
9867393|NCT00176293|Experimental|1|dexamethasone
9867394|NCT00176293|No Intervention|2|
9867395|NCT00176449|Active Comparator|Bupropion SR|
9867396|NCT00176449|Placebo Comparator|Placebo|
9867397|NCT00176475|Experimental|Therapeutic allogeneic lymphocytes with rituximab|
9867398|NCT00176683||All comers|capnography used for all consenting subjects
9867399|NCT00176722||surgical|males & females undergoing spine surgery in the prone position
9867400|NCT00176748|Experimental|1|
9927634|NCT00895362|Experimental|Erlotinib + Cetuximab|Erlotinib in Combination with Cetuximab
9927635|NCT00895375||Psoriasis patients|40 subjects (male or female) age 18 or older with psoriasis covering >10% BSA and without a diagnosis of depression.
9927636|NCT00895375||Patients without psoriasis|40 subjects without psoriasis matched for age, sex and BMI, as a control population.
9927637|NCT00895388|Other|Structured Rehabilitation program|
9927638|NCT00895388|No Intervention|Controls|
9927639|NCT00895401|Active Comparator|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
9667035|NCT04042298||Non-5-FU Chemotherapy (Sub-Control)|Comprised of newly diagnosed cancer patients 21 years or older who have received chemotherapy other than 5-FU within the past 30 days or are scheduled to receive chemotherapy other than 5-FU.
9867401|NCT00177086|Experimental|Alfuzosin|
9867402|NCT00177086|Placebo Comparator|Placebo|
9867403|NCT00177138|Active Comparator|Group 2|Tacrolimus/MMF/TMG
9867404|NCT00177138|Experimental|Group 1|Campath/MMF/TMG
9867405|NCT00177177|Experimental|1|L Carnosine
9867406|NCT00177177|Placebo Comparator|2|Placebo
9867407|NCT00177229|No Intervention|A|Enhanced usual care: 2 free, individual consultations with a nutritionist over first 6 months. Medical monitoring throughout study period.
9867408|NCT00177229|Experimental|B|
9867409|NCT00177346|Experimental|CAS with cerebral protection|
9867410|NCT00177346|Active Comparator|CAS without cerebral protection|
9867411|NCT00177372|Experimental|1|Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
9867412|NCT00177411|Experimental|PTHrP group|Subjects receiving PTHrP in varying doses.
9867413|NCT00177424|Active Comparator|1|Sertraline
9867414|NCT00177424|Placebo Comparator|2|matching placebo
9867415|NCT00177463|Experimental|L- Carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
9867416|NCT00177463|Placebo Comparator|Placebo|Placebo
9867417|NCT00177489|Experimental|Treatment|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
9867418|NCT00177489|Other|Control|"Caregivers in the control group received 2 brief check-in telphone calls during the 6 month intervention."
9867419|NCT00177515|Experimental|1|Computerized counseling about Emergency Contraception
9867420|NCT00177515|Active Comparator|2|Computerized counseling about peri-conception folate
9867421|NCT00177541|Experimental|Biofeedback|Biofeedback assisted pelvic floor muscle therapy (3 visits)
9867422|NCT00177645|Experimental|sodium bicarbonate|inhaled sodium bicarbonate
9867423|NCT00177840|Experimental|1|True acupuncture using true needles
9867424|NCT00177840|Sham Comparator|2|sham acupuncture using sham needles
9867425|NCT00177853|Experimental|1|Celecoxib, Irinotecan and Concurrent Radiotherapy
9867426|NCT00177892|Experimental|1|non-OSAH/overweight individuals with the Metabolic Syndrome
9867427|NCT00177892|Experimental|2|non-OSAH/overweight individuals without Metabolic Syndrome
9867428|NCT00177892|Active Comparator|3|non-OSAH/normal weight without Metabolic Syndrome
9867429|NCT00177892|Experimental|4|OSAH patients with chronic positive airway pressure therapy
9867430|NCT00177892|Experimental|5|OSAH patients without chronic positive airway pressure therapy
9867431|NCT00177918||lung transplant patients|
9867432|NCT00177931||liver transplant patients in ICU|
9867433|NCT00177944||patients with funal infections|
9867434|NCT00177996|Active Comparator|Sertaline high dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline high dose titration) are consistent with recommended FDA guidelines.
9867435|NCT00177996|Active Comparator|Sertaline low dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline low dose titration) are consistent with recommended FDA guidelines.
9867436|NCT00178217|Experimental|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
9867437|NCT00178217|No Intervention|Standard Care Control|Subjects will receive standard care at control condition sessions, which includes the use of television, books, CD's, a child life specialist (when available) or other activities to help cope with the procedure.
9867438|NCT00178360|Experimental|Music Therapy|Subject will participate in one, individual, half-hour long music therapy session every other week and one hour-long group music therapy session each month, for a period of three months.
9867439|NCT00178360|No Intervention|Standard Care|During the Standard Care time period, participants will continue to receive all of the medical care that they would normally receive for the treatment of Huntington's Disease, without the addition of music therapy services.
9867440|NCT00178373|Experimental|Modafinil|Modafinil 200 mg taken by mouth once a day. Subjects will take 2 100 mg tablets each morning.
9867441|NCT00178373|Placebo Comparator|placebo|Inactive sugar pill, 2 are taken once a day in the morning
9867442|NCT00178412|Experimental|1|Treatment group
9867443|NCT00178412|Active Comparator|2|Comparison Group
9867444|NCT00178490|Experimental|1|Children with high blood pressure who will receive treatment for high blood pressure
9867445|NCT00178490|No Intervention|2|Children with normal blood pressure who will undergo no treatment
9867446|NCT00178620|Active Comparator|I|Retavase 10 U IV Bolus
9867447|NCT00178620|Other|II|
9867448|NCT00178659||1 healthy volunteers|Healthy volunteers to act as controls - Recruitment is complete for this cohort
9867449|NCT00178659||2 head trauma|Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort
9867450|NCT00178659||3 orthopedic injury|"The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:~Fracture confirmed radiographically~No head trauma~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
9867451|NCT00178659||4 Mild TBI|"The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort~Non-penetrating head trauma manifesting one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Altered mental status~Focal neurologic deficits, seizure~GCS> 12~No abnormalities on CT other than contusion~No operative Lesions~Length of hospital stay < 48 hrs~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
9867452|NCT00178698|Other|1|Thermochemotherapy
9867453|NCT00178724||No Treatment Given|Any male or female 18 years or older admitted to a NACTN hospital, at the time of injury, with an initial (first time) spinal cord injury caused by trauma and has paralysis (muscle weakness) or loss of sensation (touch). The patient has not received medical or surgical care for this injury prior to admission to a NACTN hospital. Patient or family member must give consent to participate.
9867454|NCT00178763|Experimental|1|All protocol subjects are treated with fever-range whole-body thermal therapy combined in an optimized schedule with cisplatin + gemcitabine + metronomic low-dose interferon-alpha
9867455|NCT00178776|Experimental|Transtheoretical Model Group|
10210547|NCT04849793|Experimental|Experimental|Before the intervention, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. After rubbing, each individual's pain threshold level will be taken as a basis in order not to cause tissue damage. The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes. In the study group, an average of 13 minutes will be applied to HT7, LI4 and EX-HN3 points (five points in total) for two minutes each. The nursing students participating in the research will be given a total of 12 acupressure intervention remotely, three days a week, for four weeks, at least two hours after dinner and when they are calmest.
10210548|NCT04849793|No Intervention|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
9867456|NCT00178776|Active Comparator|Education / Advice|
9867457|NCT00178802|Other|1|thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
9867458|NCT00178880||Healthy volunteers|
9867459|NCT00178880||Depressed patients|
9867460|NCT00178971|Active Comparator|1|buspirone 15-30 mg qd
9867461|NCT00178971|Placebo Comparator|2|placebo
9867462|NCT00178984||poor blood flow|Group with partial ischemia to the small intestine
9867463|NCT00178984||Good blood flow|Group with normal blood flow, given different conditions to effect electrical currents in normal smooth muscle
9867464|NCT00178997||Good blood flow|Group without ischemia to the small intestine
9867465|NCT00178997||Poor blood flow|Groups that have partial ischemia to their small intestine
9867466|NCT00179023|Other|Part 1|Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
10210549|NCT04848961|Experimental|Women who have had a mammogram|Participants will consist of eligible women who have had a mammogram
10210550|NCT04844528|Experimental|Treatment: all patients|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
10213685|NCT03529695|Experimental|Obesity Prevention|Participants will receive the standard Healthy Families America home visitation curriculum with the obesity prevention enhancement module, delivered by trained home visitors. Families are matched to home visitors based on their ethnicity/race and language preferences. The obesity prevention program targets 4 key behaviors (physical activity, fruit and vegetable consumption, sugary beverages, fried foods) aimed at reducing obesity risks in mothers and their children. Participants will also be provided opportunities to meet in groups with other participating mothers/infants to enhance social networks that support healthy eating and physical activity.
9867467|NCT00179023|Other|Part 2 (closed)|Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
9867468|NCT00179023|Other|Part 3|Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
9867469|NCT00179023|Other|Part 4a (closed)|Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
9867470|NCT00179023|Other|Part 4b (closed)|Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
9867471|NCT00179036||Good blood flow|Group without any ischemia to the small intestine
9867472|NCT00179036||Poor blood flow|Group with partial ischemia to the small intestine
9867473|NCT00179062|Active Comparator|1|
9867474|NCT00179062|Active Comparator|2|
9867475|NCT00179140|No Intervention|1|control period
9867476|NCT00179140|Active Comparator|2|protein supplementation plus resistance exercise
9867477|NCT00179140|Active Comparator|3|protein supplementation only
9867478|NCT00179153|Active Comparator|1|
9867479|NCT00179166|Active Comparator|1|supplement contains protein content of 1.4 g/kg/day
10210551|NCT04844528|Placebo Comparator|Arm 2: Placebo|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
10210552|NCT04837677|Experimental|PRT1419|PRT1419 will be administered by intravenous infusion
9867480|NCT00179166|Active Comparator|2|supplement contains protein content of 2.0 g/kg/day
9867481|NCT00179179|Active Comparator|1|nutritional supplement plus resistance exercise
9867482|NCT00179179|Active Comparator|2|nutritional supplement only (resistance exercise will not be performed)
9867483|NCT00179192|No Intervention|1|control group
9867484|NCT00179192|Active Comparator|2|angioplasty intervention
9867485|NCT00179192|Active Comparator|3|surgery intervention
9867486|NCT00179205|Active Comparator|1|
9867487|NCT00179205|Placebo Comparator|2|
9867488|NCT00179218|Active Comparator|1|only protein supplementation
10210553|NCT04828265|Experimental|Aldafermin 0.3mg|Subcutaneous injection of a single dose of aldafermin 0.3mg in healthy adult male Japanese or non-Japanese subjects
9867489|NCT00179218|Active Comparator|2|protein supplementation plus exercise
10210554|NCT04828265|Experimental|Aldafermin 1mg|Subcutaneous injection of a single dose of aldafermin 1mg in healthy adult male Japanese or non-Japanese subjects
10210555|NCT04828265|Experimental|Aldafermin 3mg|Subcutaneous injection of a single dose of aldafermin 3mg in healthy adult male Japanese or non-Japanese subjects
10210556|NCT04826731||Incentive Spirometer Group|"Patients who would use an incentive spirometer, in addition to standard care provided to COVID-19 patients, will be categorized under Incentive Spirometer Group."
9867490|NCT00179348|Experimental|Group I (yoga-based rehabilitation program)|Participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks.
9867491|NCT00179348|Active Comparator|Group II (standard care/control)|After a 3 month wait period, participants undergo a yoga-based rehabilitation program as in Group I.
9867492|NCT00179374|Experimental|1|Tailored telephone intervention plus mailed print educational materials
9867493|NCT00179374|Active Comparator|2|print intervention with no telephone component
9867494|NCT00179387|Active Comparator|1|Psycho-educational / Stress Management group
9867495|NCT00179387|Active Comparator|2|Spiritual-Existential Support Group
9867496|NCT00179452|Experimental|Intervention|Subjects invited to participate in yoga practice.
9867497|NCT00179465|Active Comparator|Antipsychotic plus study drug|Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
9867498|NCT00179465|Placebo Comparator|Antipsychotics plus placebo|Half of the subjects will receive placebo in addition to their antipsychotic regimen.
9867499|NCT00179491|Active Comparator|Group 1|604 patients received intercessory prayer after being informed they may or may not receive prayers (Group 1)
9867500|NCT00179491|No Intervention|2|597 patients did not receive prayer after being informed they may or may not receive prayer (Group 2)
9867501|NCT00179491|Experimental|Group 3|601 patients received intercessory prayer after being informed they would receive it (Group 3).
9867502|NCT00179634|No Intervention|1|Usual Care
9867503|NCT00179634|Experimental|2|Usual care and exposure to a visually enriched milieu (landscape photograph)
9867504|NCT00179634|Experimental|3|Usual care, exposure to a visually enriched milieu and audio taped guided visualization with healing suggestions.
9867505|NCT00179764|Other|Reduced Intensity Conditioning Regimen|
10210557|NCT04826731||Standard Care Group|"Patients who did not use an incentive spirometer despite being suggested to do so will be categorized under Standard Care Group."
10210558|NCT04818086|Active Comparator|Lemborexant Arm|Study Drug Dosage: 5 mg of lemborexant, and 10 mg of lemborexant, all subjects will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
10210559|NCT04818086|Placebo Comparator|Placebo Arm|Comparative placebo, all subjects will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
9867506|NCT00179803|Experimental|high dose chemotherapy|
9867507|NCT00179894|Experimental|1 Physician training|Physician participants will receive training in guidelines and medication monitoring
9867508|NCT00179894|No Intervention|2|Physician participants will provide usual care and no special intervention
9867509|NCT00179985||Training|Behavioral: Newborn Individualized Care and Assessment Program (NIDCAP)
9867510|NCT00180011|Experimental|omaluzimab|
9927640|NCT00895401|Experimental|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available nutritional supplement designed to meet the nutritional needs of malnourished hemodialysis patients. The serving size is 8 oz which provides 425 kcal and 19 g protein
9927641|NCT00895427||1|Male ages 45-54, without diabetes, CAC score from 0 to >1000
9927642|NCT00895427||2|Male ages 55-64, without diabetes, CAC score from 0 to >1000
9927643|NCT00895427||3|Male ages 65+, without diabetes, CAC score from 0 to >1000
9927644|NCT00895427||4|Male ages 45-54, with diabetes and CAC score from 0 to >1000
9927645|NCT00895427||5|Male ages 55-64, with diabetes, CAC score from 0 to >1000
9927646|NCT00895427||6|Male ages 65+, with diabetes, CAC score from 0 to >1000
10213686|NCT03520491|Experimental|Cohort 1|Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.
9867511|NCT00180167|Active Comparator|Daunorubicin + Ara-C|
9867512|NCT00180167|Experimental|Mitoxantrone + Ara-C|
9867513|NCT00180219||1|20 to 22 years
9867514|NCT00180219||2|30 to 32 years
9867515|NCT00180219||3|40 to 42 years
9867516|NCT00180232||1|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
9867517|NCT00180310|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
9867518|NCT00180310|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
9867519|NCT00180388|Experimental|Endoscopic vein harvesting|Harvesting of vein for coronary artery bypass grafting using endoscopy to visualize the vein
9867520|NCT00180388|Active Comparator|Open Vein harvesting|Harvesting of vein for coronary artery bypass grafting without endoscopy
9867521|NCT00180401||QRS 120-150 ms|Subjects with a QRS width between 120-150 ms
9867522|NCT00180401||QRS >150 ms|Subjects with a QRS width >150 ms
9867523|NCT00180453|Experimental|1|Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
9867524|NCT00180453|Active Comparator|2|Abbott Vascular MULTI-LINK VISION® BMS
9867525|NCT00180505|Other|1|The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
9867526|NCT00180518|Experimental|1|"To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) To evaluate the efficacy of the OTW ACCUNET System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA).~To demonstrate equivalence in the safety and performance of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System and the corresponding OTW devices."
9867527|NCT00180544|Other|1|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
9867528|NCT00180557|Experimental|Active fixation lead|Active fixation lead was implanted
9867529|NCT00180557|Active Comparator|Passive fixation lead|Passive fixation lead was implanted
9867530|NCT00180583|Experimental|1|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
9867531|NCT00180635|Experimental|Healthy volunteers non smoker|Control group
9867532|NCT00180635|Experimental|Healthy volunteers smoker|More than 10 pack-years
9867533|NCT00180635|Experimental|Chronic Obstructive Pulmonary Disease COPD|COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
9867534|NCT00180700|Experimental|Self-hypnosis|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 13 participants with diagnosed HIV
9867535|NCT00180700|Experimental|Johrei healing method|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 9 participants with diagnosed HIV
9867536|NCT00180843|Placebo Comparator|saline control|nebulized saline
9867537|NCT00180843|Active Comparator|salbutamol and ipratropium bromide nebules|salbutamol 2.5 mg and ipratropium bromide 0.5 mg
9867538|NCT00181181|Active Comparator|Atorvastatin|Atorvastatin for 3 months
9867539|NCT00181181|Placebo Comparator|Placebo|
9867540|NCT00181298|Active Comparator|1|
9867541|NCT00181298|Placebo Comparator|2|
9867542|NCT00181571|Active Comparator|1|Concerta
9867543|NCT00181571|Placebo Comparator|2|Placebo
9867544|NCT00181584|Active Comparator|Group 1|
9867545|NCT00181584|Placebo Comparator|Group 2|
9867546|NCT00181649|Experimental|Recombinant human prolactin|
9867547|NCT00181753|Experimental|1|Burn Patients receiving at least 3 days of parenteral feeding on routine formula
9867548|NCT00181753|Experimental|2|Burn patients receiving at least 3 days on parenteral feeding on glutamine enriched formula.
9667036|NCT04042298||Age/Sex matched Control (Control)|Age, biological sex, and prior health history (excluding cancer diagnosis) matched control for cancer patients
9867549|NCT00181753|Experimental|3|Burn patients receiving at least 3 days of enteral feeding on routine formula.
9867550|NCT00181753|Experimental|4|Burn patients receiving at least 3 days of enteral feeding on glutamine-enriched formula.
9867551|NCT00181805||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
9867552|NCT00181805||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
9867553|NCT00181857||1|Children of Adults with ADHD NOS
9927647|NCT00895427||7|Female ages 50-59, without diabetes, CAC score from 0 to >1000
9927648|NCT00895427||8|Females ages 60-69, without diabetes and CAC score from 0 to >1000
9927649|NCT00895427||9|Females ages 70 +, without diabetes, CAC score from 0 to >1000
9927650|NCT00895427||10|Female ages 50- 59, with diabetes, CAC score from 0 to >1000
9927651|NCT00895427||11|Female ages 60-69, with diabetes, CAC score from 0 to >1000
9927652|NCT00895427||12|Female age 70+, with diabetes, CAC score from 0 to >1000
9927653|NCT00895440||1|Diabetic patients without neuropathy
9927654|NCT00895440||2|Diabetic patients with painless neuropathy
9927655|NCT00895440||3|Diabetic patients with painful neuropathy
9927656|NCT00895440||4|Diabetic patients with Charcot neuroarthropathy
9927657|NCT00895440||5|Control non-diabetic subjects
9927658|NCT00895479|Experimental|Trinam|Graft placement plus Trinam therapy
9927659|NCT00895479|No Intervention|Control|Graft placement surgery alone
9927660|NCT00895492||Sotero del Rio|Emergency Room and Hospital based surveillance
9927661|NCT00895492||Van Buren|Emergency Room and Hospital based surveillance
9927662|NCT00895505|Active Comparator|oral anticoagulants|Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.
9927663|NCT00895505|No Intervention|2|Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.
9927664|NCT00895518|No Intervention|1|Participants will receive assessments only.
9927665|NCT00895518|Experimental|2|Participants will receive prolonged exposure therapy.
9927666|NCT00895544|Experimental|1|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
9927667|NCT00895544|Experimental|2|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
9927668|NCT00895557|Active Comparator|chantix|
10210560|NCT04816773||Newly or previously implanted patients|Multicenter, non-interventional prospective follow-up of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 14 months of the study index surgery. Single study group with either newly or previously implanted patients with all EVOLUTION® NitrX™ components: Non-Porous Keeled Tibia, CS/CR Non-Porous Femur component, and EVOLUTION® MP CS tibial insert
10210561|NCT04814199||Patients using epidural management algorithm|Patients will be educated and given an algorithm to follow while in labour and after having an epidural catheter placed.
10210562|NCT04811118|Experimental|Albumin-bound docetaxel|Subjects will receive albumin-bound docetaxel via intravenous infusion (IV) once every three weeks (a cycle), at the dose of 75mg/m2
10210563|NCT04811118|Experimental|Taxotere|Subjects will receive Taxotere via intravenous infusion once every three weeks (a cycle), at the dose of 75mg/m2.
10210564|NCT04800939|Experimental|Acupressure Group|The experimental group will be given acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
9927669|NCT00895570|Experimental|Modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
9927670|NCT00895570|Placebo Comparator|Placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
9927671|NCT00895596|Experimental|LB80380 30mg|LB80380 30mg
9927672|NCT00895596|Experimental|LB80380 60mg|LB80380 60mg
9927673|NCT00895596|Experimental|LB80380 90mg,|LB80380 90mg
9927674|NCT00895596|Experimental|LB80380 150mg|LB80380 150mg
9927675|NCT00895596|Experimental|LB80380 240mg|LB80380 240mg
9927676|NCT00895609|Experimental|Sugammadex|Sugammadex in doses: 0 (placebo), 0.0625, 0.125, 0.25, 0.5 and 1 mg/kg
9927677|NCT00895609|Active Comparator|Neostigmine|Neostigmine in doses: 0 (placebo), 5, 8, 15, 25, 40 mg/kg
9927678|NCT00895635|Experimental|Treadmill Exercise Training|Participants will take part in a 12-week supervised treadmill exercise training program.
9927679|NCT00895635|Experimental|Arm Ergometry Exercise Training|Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
9927680|NCT00895635|Active Comparator|Usual Care Control Group|Participants will receive usual care for PAD from their doctor.
9927681|NCT00895648|Experimental|Alimta plus Cisplatin|
9927682|NCT00895674||Group 1|
9927683|NCT00895687|Experimental|Erlotinib + Bortezomib|Up to 4 dose levels of study drug combination tested with 3-6 participants enrolled at each dose level. Erlotinib beginning dose of 150 mg taken by mouth daily for 21-day cycle. Bortezomib beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
9927684|NCT00895700|Experimental|Web-based behavioral intervention|
9927685|NCT00895700|No Intervention|Usual care|
9927686|NCT00895713|Experimental|im HBIG Grifols|
9927687|NCT00895726|Experimental|APD209|
9927688|NCT00895778|Experimental|NMB|muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
9867554|NCT00182039|Experimental|A|metoprolol
9867555|NCT00182039|Placebo Comparator|B|placebo
9867556|NCT00182052|Active Comparator|Group 1|
9867557|NCT00182052|Placebo Comparator|Group 2|
9867558|NCT00182143|Active Comparator|LMWH (Fragmin, dalteparin)|Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose
9867559|NCT00182143|Active Comparator|2|Unfractionated Heparin 5000IU BID
9867560|NCT00182156||1|conventional HD
9867561|NCT00182156||2|short daily HD
9867562|NCT00182156||3|PD
9867563|NCT00182260|Active Comparator|Proton Pump Inhibitor|Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
9867564|NCT00182260|Active Comparator|Laparoscopic Nissen Fundoplication|Surgical patients underwent LNF using previously published technique.
9867565|NCT00182338||Peritoneal Dialysis Patients|
9867566|NCT00182455|Experimental|1|Topiramate 25 - 400 mg/day x 12 weeks
9867567|NCT00182455|Placebo Comparator|2|Placebo
9867568|NCT00182468|Experimental|1|Women are screened for intimate partner violence prior to seeing a health care provider.
9867569|NCT00182468|No Intervention|2|Women see their health care provider without being asked about intimate partner violence.
9867570|NCT00182520|Experimental|1|Topiramate
9867571|NCT00182520|Placebo Comparator|2|placebo
9867572|NCT00182533|Experimental|1|Sertraline
9867573|NCT00182533|Placebo Comparator|2|Placebo
9867574|NCT00182559|Active Comparator|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
9867575|NCT00182559|Active Comparator|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
9867576|NCT00182663|Experimental|Treatment (immunomodulator, antiangiogenesis, steroid therapy)|Patients receive thalidomide PO QD dexamethasone PO once weekly, and clarithromycin PO BID. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity.
9867577|NCT00182702|Experimental|Treatment|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9867578|NCT00182780|Experimental|Arm I - American ginseng (low dose)|"Patients receive oral American ginseng twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study.~Quality of life is assessed at baseline, every 2 weeks during treatment, and at the end of treatment.~PROJECTED ACCRUAL: A total of 280 patients (70 per treatment arm) will be accrued for this study within 35 months."
9867579|NCT00182780|Experimental|Arm II - American ginseng (mid-dose)|"Patients receive oral American ginseng at the mid-dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
9867580|NCT00182780|Experimental|Arm III - American ginseng (high-dose)|"Patients receive oral American ginseng at the high dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
9867581|NCT00182780|Other|Arm IV - Placebo|"Patients receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
9867582|NCT00182819|Other|radiotherapy|Radiotherapy (control arm), 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
9867583|NCT00182819|Experimental|Temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles (experimental arm)
9867584|NCT00182832|Experimental|1|
9867585|NCT00182832|Active Comparator|2|
9867586|NCT00183014|Experimental|1|discussion session and exercise class
9867587|NCT00183014|Active Comparator|2|exercise class only
9867588|NCT00183079|Active Comparator|1|Brief, motivationally-focused alcohol intervention
9867589|NCT00183157|Active Comparator|1|Patients will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call.
9867590|NCT00183157|Active Comparator|2|Patients will receive an assessment and a list of community resources
9867591|NCT00183157|Active Comparator|3|Patients will receive only the list of resources.
9867592|NCT00183209|Experimental|14 session behavioral intervention|7 sessions addressing problem alcohol and drug use and 7 session addressing parenting challenges (monitoring, negotiation, etc) based on based on Social Action Theory (Ewart, 1991) and Motivational Interviewing
9867593|NCT00183209|Active Comparator|Brief Video Intervention|Single session brief video intervention to build motivation to reduce or eliminate problem drinking/drug use
9867594|NCT00183261|Experimental|1|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
9867595|NCT00183261|Placebo Comparator|2|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
9867596|NCT00183313|Experimental|1|Participants will receive nurse case management intervention
9867597|NCT00183313|Active Comparator|2|Participants will receive usual care
9867598|NCT00183326|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy
9867599|NCT00183326|Active Comparator|2|Participants will receive child-centered supportive therapy
9867600|NCT00183352||1|Women with bipolar disorder
9867601|NCT00183352||2|Women who are healthy controls
9867602|NCT00183365|Experimental|1|Participants will receive the Protecting Families Program with individual parent training
9867603|NCT00183365|Active Comparator|2|Participants will receive parent training alone
9867604|NCT00183378|Active Comparator|1|Routine medical care with education: therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support.
9867605|NCT00183378|Active Comparator|2|Walking: the therapist introduces a walking program and assists the caregiver in establishing a daily walking routine of 30 minutes for the study participant.
9867606|NCT00183378|Active Comparator|3|Light exposure: the therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
9867607|NCT00183378|Active Comparator|4|Combination: the therapist provides education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
9867608|NCT00183404|Experimental|Olanzapine|Participants will take open olanzapine for up to 20 additional weeks after phase 1.
9867609|NCT00183417|Experimental|1|Participants will receive cognitive behavioral therapy
9867610|NCT00183417|Active Comparator|2|Participants will receive supportive/expressive therapy
9867611|NCT00183417|Active Comparator|3|Participants will receive bibliotherapy
9867612|NCT00183417|No Intervention|4|Participants in the control condition will receive no treatment
9867613|NCT00183508|Experimental|1 Cognitive behavioral therapy|
9867614|NCT00183508|Experimental|2 Psychoeducation|
9867615|NCT00183521|Experimental|1|Participants will receive raise-CO2 breathing regulation training
9867616|NCT00183521|Experimental|2|Participants will receive lower-CO2 breathing regulation training
9867617|NCT00183521|Active Comparator|3|Participants will receive no breathing regulation training
9927689|NCT00895778|Placebo Comparator|no NMB|no muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
9927690|NCT00895791|Active Comparator|1|AXXESS Biolimus A9-eluting bifurcation stent
9927691|NCT00895791|Active Comparator|2|culotte stenting with use of 2 drug eluting stents
9927692|NCT00895804|Other|Pindolol, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9927693|NCT00895804|Other|MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9927694|NCT00895856||Old-aged people|
9927695|NCT00895882|Experimental|1|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
9927696|NCT00895882|Experimental|2|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks
9927697|NCT00895882|Experimental|3|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
9927698|NCT00895882|Experimental|4|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks
9927699|NCT00895882|Experimental|5|vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks
9927700|NCT00895882|Placebo Comparator|6|Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks
9927701|NCT00895908|Experimental|Friendship Group Intervention|"Participants will receive the Friendship Groups intervention."
9795747|NCT01544998|Experimental|Tadalafil plus Nesiritide, then Tadalafil plus Placebo|First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
9795748|NCT01545076|Experimental|IgPro20 low dose|
9795749|NCT01545076|Experimental|IgPro20 high dose|
9795750|NCT01545076|Placebo Comparator|Placebo|
9795751|NCT01545141|No Intervention|Surgery only|Surgical resection only, performed as standard of care for the disease
9795752|NCT01545141|Experimental|Chemokin Modulatory Regimen (5 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
9795753|NCT01545141|Experimental|Chemokin Modulatory Regimen (10 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 10 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
9795754|NCT01545141|Experimental|Chemokin Modulatory Regimen (20 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
9795755|NCT01545193||Age 18-50|This is a younger study cohort who is anticipated to have a lower incidence of residual neuromuscular blockade
9795756|NCT01545193||Age 70-90|This is a older study cohort who is anticipated to have a higher incidence of residual neuromuscular blockade
9795757|NCT01545232|Active Comparator|1:1:1 Blood Transfusion Ratio|
9795758|NCT01545232|Active Comparator|1:1:2 Blood Transfusion Ratio|
9795759|NCT01545336|Experimental|Anastrozole|1 mg tablet by mouth once daily for 3 months
9795760|NCT01545336|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 3 months
9795761|NCT01545375|Experimental|dPly-PhtD Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the dPly-PhtD vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the dPly-PhtD vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
9795762|NCT01545375|Placebo Comparator|Control Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
9795763|NCT01545388|Experimental|Metformin 500 mg q.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
9795764|NCT01545388|Experimental|Metformin 250 mg b.i.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
9795765|NCT01545388|Placebo Comparator|Placebo|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
9795766|NCT01545583|Placebo Comparator|Placebo intravenous|Placebo administered once intravenously
9795767|NCT01545583|Experimental|0.1 milligram (mg) LY3016859 intravenous|0.1 mg LY3016859 administered once intravenously
9795768|NCT01545583|Experimental|1 mg LY3016859 intravenous|1 mg LY3016859 administered once intravenously
9795769|NCT01545583|Experimental|10 mg LY3016859 intravenous|10 mg LY3016859 administered once intravenously
9795770|NCT01545583|Experimental|50 mg LY3016859 intravenous|50 mg LY3016859 administered once intravenously
9795771|NCT01545583|Experimental|250 mg LY3016859 intravenous|250 mg LY3016859 administered once intravenously
9795772|NCT01545583|Experimental|750 mg LY3016859 intravenous|750 mg LY3016859 administered once intravenously
9795773|NCT01545583|Placebo Comparator|Placebo subcutaneous|Placebo administered once subcutaneously
9795774|NCT01545583|Experimental|50 mg LY3016859 subcutaneous|50 mg LY3016859 administered once subcutaneously
9667037|NCT04042298||5-FU Chemotherapy Cancer Survivor (Survivor)|Cancer survivors who have not received cancer therapy during the past year but previously received 5-Fluorouracil chemotherapy.
9667038|NCT04039347|Experimental|L-CsA 5 mg plus Standard of Care|L-CsA 5 mg twice daily plus Standard of Care for up to 144 weeks for patients post Single Lung Transplant
9667039|NCT04039347|Experimental|L-CsA 10 mg plus Standard of Care|L-CsA 10 mg twice daily plus Standard of Care for up to 144 weeks for patients post Double Lung Transplant
9667040|NCT04038593|No Intervention|Non interventional arm|Standard conditions of complex dressing cares, without experimental intervention. It will be a control intervention
9667041|NCT04038593|Active Comparator|Comparative arm with relaxation music from Youtube©|Standard conditions of complex dressing cares + use of non standardized music relaxation during complex dressing cares
9667042|NCT04038593|Experimental|Interventional arm with MUSIC CARE©|Standard conditions of complex dressing cares + administration of a specific music therapy program (U method) delivered through headphones from a tablet, under the direction of trained nurses.
9667043|NCT04037956|Experimental|Tubeless NOSES|Patients receive Tubeless NOSES.
9795775|NCT01545700|Placebo Comparator|Control, saline 0-4 hours|2 cc of saline
9795776|NCT01545700|Active Comparator|Dexamethasone 4 mg, 0-4 hours|Dexamethasone 4 mg administered intraoperatively
9795777|NCT01545700|Active Comparator|Dexamethasone 8 mg, 0-4 hours|Dexamethasone 8 mg administered intraoperatively
9667044|NCT04037956|Active Comparator|traditional laparoscopic|Patients receive traditional laparoscopic radical resection.
9667045|NCT04034212|Experimental|Singing for Lung Health group|Once weekly attendance at a Singing for Lung Health group for 12 weeks.
9667046|NCT04034212|No Intervention|Usual Care group|Usual care group, participants given advice on physical activity while continuing with usual care.
9667047|NCT04032093|Experimental|RSV dose with aluminum hydroxide|RSV vaccine with aluminum hydroxide
9667048|NCT04032093|Experimental|RSV dose without aluminum hydroxide|RSV vaccine without aluminum hydroxide
9667049|NCT04032093|Experimental|Higher RSV dose with aluminum hydroxide|Higher dose level RSV vaccine with aluminum hydroxide
9667050|NCT04032093|Experimental|Higher RSV dose without aluminum hydroxide|Higher dose level RSV vaccine without aluminum hydroxide
9667051|NCT04032093|Placebo Comparator|Placebo dose|Normal saline solution for injection (0.9% sodium chloride injection)
9667052|NCT04031105|Experimental|Condition 1|Priming sham TBS, followed by iTBS after an inter-stimulation-interval (ISI) of 0 minutes
9795778|NCT01545700|Placebo Comparator|Placebo Comparator saline 8-24 hours|placebo, 2 cc saline
9795779|NCT01545700|Active Comparator|Dexamethasone 4 mg, 8-24 hours|Dexamethasone 4 mg administered intraoperatively
9795780|NCT01545700|Active Comparator|Dexamethasone 8 mg, 8-24 hours|Dexamethasone 8 mg administered intraoperatively
9795781|NCT01545765|Experimental|lidocaine 7% and tetracaine 7%|
9667053|NCT04031105|Experimental|Condition 2|Priming cTBS, followed by iTBS after an ISI of 0 minutes
9667054|NCT04031105|Experimental|Condition 3|Priming cTBS, followed by iTBS after an ISI of 10 minutes
9667055|NCT04031105|Experimental|Condition 4|Priming cTBS, followed by iTBS after an ISI of 20 minutes
9667056|NCT04012151||Pregnant cohort|Parturients of gestational age >= 32 weeks will have measurements of arm length, MAC, proximal arm circumference, distal arm circumference, finger circumference to generate the conicity index.
9667057|NCT04009837|Experimental|Hip-focused|Hip-focused rehabilitation intervention
9667058|NCT04009837|Active Comparator|Spine-focused|Spine-focused rehabilitation intervention
9667059|NCT04006015||Main study group|31 people with COPD and 31 controls in the main study group.
9667060|NCT04006015||six-minute walk substudy|We will aim to have 40 participants participating in the 6 minute walk sub-study.
9667061|NCT04006015||Qualitative dance substudy|We will aim for 20 participants.
9667062|NCT04001504|Experimental|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV during index ACS hospitalization
9667063|NCT04001504|Active Comparator|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV 30 days after randomization
9667064|NCT04000269|Experimental|Treatment Group|Treatment with 'Soterix MxN Neuromodulation device (high definition transcranial direct current stimulator) using HD-Targets for optimal neural targeting will be provided to participants and will include 20 minutes of stimulation coupled with conventional OT treatment during and after the intervention. There will be a total of 10 sessions over about a 2 week period.
9667065|NCT04000269|Sham Comparator|Sham group|Sham stimulation will consist of using the devices auto-sham feature. The exact same setup/device will be used during both groups. This is considered a control for the experiment. Both groups will receive similar physical occupational and speech therapy
9867618|NCT00183547|Experimental|1|"Living in Harmony depression prevention program"
9867619|NCT00183547|Active Comparator|2|Depression-prevention education and support
9795782|NCT01545817|Experimental|Pazopanib followed by everolimus|First line pazopanib, followed by second line everolimus
9795783|NCT01545843|Active Comparator|No sleep deprivation|Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks
9795784|NCT01545843|Experimental|Late bedtime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
9795785|NCT01545843|Experimental|Early risetime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.
9795786|NCT01545934|No Intervention|Standard Care|
9795787|NCT01545934|Experimental|Lifestyle intervention|
9795788|NCT01546038|Experimental|Arm A (Phase 1B)|PF-04449913 in combination with low dose ARA-C (LDAC)
9795789|NCT01546038|Experimental|Arm B (Phase 1B)|PF-04449913 in combination with Decitabine
9795790|NCT01546038|Experimental|Arm C (Phase 1B)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
9795791|NCT01546038|Experimental|P2 Fit (Phase 2 Single Arm)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
9795792|NCT01546038|Other|P2 Unfit (Phase 2 Randomized)|Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).
9795793|NCT01546142|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9795794|NCT01546142|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
9795795|NCT01546155|Experimental|healthy controls|
9795796|NCT01546168|Experimental|esophageal deviation|esophageal deviation with IDE device during AF ablation
9795797|NCT01546168|No Intervention|temperature monitoring|luminal esophageal temperature monitoring, standard temperature monitoring alone
9795798|NCT01546194||Morning consent|Consent process consisting of information only provided on the morning of surgery
9795799|NCT01546194||Phone call and morning consent|Consent process consisting of information provided on the morning of surgery. In addition, a phone call on the day prior to surgery will be provided to subjects explaining that they will be approached about participation in a clinical research project
9795800|NCT01546285|Experimental|Blood Pressure Reading|Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
9795801|NCT01546402|Experimental|Phacoemulsification with IOL implant|This group (Group B) includes patients who will undergo phacoemulsification with intraocular lens implantation. The dexamethasone implant will not be injected at the beginning of cataract surgery. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
9795802|NCT01546402|Experimental|Phacoemulsification with Ozurdex|This group (Group A) includes patients who will undergo phacoemulsification with intraocular lens implantation with intraoperative long acting steroid injection (Ozurdex ®). The dexamethasone implant will be injected at the beginning of cataract surgery, 4mm from the limbus using the specially designed injector. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
9795803|NCT01546454|Experimental|Non-steroidal effects|Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
9795804|NCT01546454|Experimental|Contraceptive effects|Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
9795805|NCT01546454|Experimental|Steroid effects|Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
9795806|NCT01546519|Experimental|1|Control cohort with normal renal and normal hepatic function
9795807|NCT01546519|Experimental|2|Severe renal impairment and normal hepatic function
9795808|NCT01546519|Experimental|3|Mild hepatic impairment and normal renal function
9795809|NCT01546519|Experimental|4|Moderate hepatic impairment and normal renal function
9795810|NCT01546519|Experimental|5|Severe hepatic impairment and normal renal function
9795811|NCT01546623|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
9795812|NCT01546623|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
9795813|NCT01546636|Placebo Comparator|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
9795814|NCT01546636|Active Comparator|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
9795815|NCT01546649|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
9795816|NCT01546649|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
9795817|NCT01546675|Active Comparator|Traditional 1, Skeletal Stabilization 2|Subjects using the Traditional Socket and socket hypothesized to increase skeletal stabilization in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
9867620|NCT00183560|Experimental|1|Participants will receive mindfulness based cognitive therapy
9867621|NCT00183560|Active Comparator|2|Participants will receive maintenance antidepressant pharmacotherapy
9867622|NCT00183560|Placebo Comparator|3|Participants will receive placebo plus clinical management
9867623|NCT00183573|Experimental|1|Brief Motivational Intervention only
9867624|NCT00183573|Experimental|2|Brief Informational Intervention only
9867625|NCT00183573|Experimental|3|Brief Motivational Intervention + Intensive Informational Intervention
9867626|NCT00183573|Experimental|4|Brief Motivational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
9867627|NCT00183573|Experimental|5|Brief Informational Intervention + Intensive Informational Intervention
9867628|NCT00183573|Experimental|6|Brief Informational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
9867629|NCT00183586|Experimental|1|Participants will receive family-based treatment
9867630|NCT00183586|Active Comparator|2|Participants will receive individual adolescent focused therapy
9867631|NCT00183599|Experimental|1|
9867632|NCT00183599|Experimental|2|
9867633|NCT00183599|Experimental|3|
9867634|NCT00183638|Experimental|1|Participants will receive Internet-based tailored prevention messages
9867635|NCT00183638|Active Comparator|2|Participants will receive non-tailored messages containing information on reproductive health
9867636|NCT00183651|Experimental|S-DBT|Participants receive standard dialectical behavior therapy
9867637|NCT00183651|Active Comparator|DBT-I|Participants receive individual dialectical behavior therapy plus activities group
9867638|NCT00183651|Active Comparator|DBT-S|Participants receive dialectical behavior therapy group skills plus case management
9867639|NCT00183690|Experimental|1|Participants receiving prolonged exposure therapy
9867640|NCT00183690|Active Comparator|2|Participants receiving active psychotherapy
9867641|NCT00183703||Qualitative Interview|Participants with rapid cycling bipolar disorder (RCBPD)
9867642|NCT00183716|Experimental|1|Participants will receive Trauma Recovery and Empowerment Model and usual care
9867643|NCT00183716|Active Comparator|2|Participants will receive usual care
9867644|NCT00183755||1|Control participants
9867645|NCT00183755||2|Participants with MDD
9867646|NCT00183820|Experimental|1|
9867647|NCT00183833|Experimental|A|Xeloda plus gleevec
9867648|NCT00183859|Experimental|A|Intraperitoneal Irinotecan
9867649|NCT00183885|Experimental|Cisplatin + Mitomycin-C|CDDP 60mg/m2 + Mitomycin-C 12mg/m2
9867650|NCT00183898|Experimental|Oxaliplatin and Capecitabine|Oxaliplatin given every 21 days Capecitabine given daily x 14 days every 21 days
9867651|NCT00183937|Experimental|Bortezomib and Docetaxel|Bortezomib 1.6 mg/m2 Docetaxel 75 mg/m2
9867652|NCT00184015|Experimental|Schedule A|
9867653|NCT00184015|Experimental|Schedule B|
9867654|NCT00184041|Experimental|Intensified Post-Remission: MTX/LV/PEG-Asparaginase|Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 & 15
9867655|NCT00184067|Experimental|Peptide vaccine with Montanide ISA 51 + GM-CSF|Peptide vaccine with Montanide ISA 51 GM-CSF
9867656|NCT00184067|Active Comparator|Peptide vaccine with Montanide ISA 51|Peptide vaccine with Montanide ISA 51
9867657|NCT00184106|Active Comparator|Cognitive Therapy|Cognitive Therapy
9867658|NCT00184106|Active Comparator|Seroxat and SE|SSRI with Self exposure
9867659|NCT00184106|Active Comparator|Seroxat and Cognitive Therapy|Combination of Seroxat and Cognitive Therapy
9867660|NCT00184106|Placebo Comparator|Pill-Placebo|Pill Placebo
9867661|NCT00184119|Experimental|Psychiatric Intensive Care Unit|
9867662|NCT00184119|Active Comparator|Whole acute unit|
9927702|NCT00895908|Active Comparator|Individual Tutoring|Participants will receive individual academic tutoring.
9927703|NCT00895960|Experimental|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
10210565|NCT04800939|Other|Placebo Acupressure Group|The control group will be given plasebo acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
10210566|NCT04795674|Experimental|ADHD EWM|Participants will receive EWM training sessions.
9867663|NCT00184132|Experimental|Norwegian home style ward|The walls received wainscots, colourful wallpaper and paintings; the ceilings were lowered and had multiple lighting spots, the windows tasteful curtains; we put wardrobes, chairs, flowers and personal items in the patient rooms; and Italian ceramic tile covered the entire bathroom
9867664|NCT00184132|Active Comparator|sparsely furnished ward|traditional interior design and furnishings. The rooms had sparse furniture, walls in grey colours lacking pictures, no window curtains, single lamps in the ceiling 4 m high, bathroom with grey, laminated paint all over, and patient rooms with a single bed and a chair of metal tubes
10210567|NCT04795674|Placebo Comparator|ADHD Placebo|Participants will receive placebo training sessions.
9867665|NCT00184145|Experimental|EMDR|The experimental group was treated for animal phobia by EMDR, control group received an attention placebo (relaxation plus breathing exercises). Afterwards, both groups were treated by exposure therapy (therapy of choice for animal phobia).
9867666|NCT00184171|Experimental|Budesonide|Budesonide 9mg
9867667|NCT00184171|Experimental|bismuth|Bismuth mixture
9867668|NCT00184171|Sham Comparator|Fiber|Fiber preparation
9867669|NCT00184197|Experimental|Botox|
9867670|NCT00184197|Placebo Comparator|placebo|
9867671|NCT00184223|Experimental|motivational interviewing|Manual guided motivational interviewing in addition to treatment as usual
9867672|NCT00184223|Other|control group|treatment as usual
9867673|NCT00184236|Active Comparator|Aerobic interval training|Aerobic interval training (AIT)
9867674|NCT00184236|Active Comparator|Multitreatment approach|multitreatment approach (MTG)
9867675|NCT00184249|Experimental|Bipolar radiofrequency ablation|
9867676|NCT00184262|Active Comparator|ERP cognitive therapy|
9867677|NCT00184262|Experimental|ERP behavioral therapy|
9867678|NCT00184301|Experimental|inpatient treatment|inpatient treatment during 1 year
9867679|NCT00184301|Active Comparator|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
9867680|NCT00184353||brain metastases|6 patients
9867681|NCT00184353||healthy|13 volunteers
9867682|NCT00184379|Experimental|1 S+E|Relatives of patients with schizophrenia, who receive education
9867683|NCT00184379|No Intervention|2 S-E|Relatives of patients with schizophrenia, who do not receive education
9867684|NCT00184379|Experimental|3 B+E|Relatives of patients with bipolar disorder, who receive education
9867685|NCT00184379|No Intervention|4 B-E|Relatives of patients with bipolar disorder, who do not receive education
9867686|NCT00184392|Experimental|debridement or saline irrigation|1 arm undergo debridement of the nose 1 week and 2 weeks after surgery the other arm rinse their nose with saline irrigation
9867687|NCT00184418||All patients admitted to a psychiatric acute ward|
9867688|NCT00184431|Experimental|A|Intensive task specific balance training
10210568|NCT04794543||e-cigarettes and/or e-liquid vaping smokers|actively use e-cigarettes or e-liquid vaping
10210569|NCT04794543||cigarette smokers|actively use burning leaf tobacco cigarettes
10210570|NCT04794543||Non-smokers|no use of e-cigarettes or vape or active smoking in the past 5 years (and less than a total of 10 pack-years lifetime use)
10210571|NCT04793685|Experimental|Active Drug|Prazosin (16mg/day) versus Placebo comparator, administered in t.i.d schedule, in capsules, over a 12 week period, with 2 weeks titration in weeks 1-2 and a 5-day taper in week 12.
10210572|NCT04793685|Placebo Comparator|Placebo Drug|Placebo for 12 weeks.
10210573|NCT04786119|Experimental|CORI Robotics|Subjects having robotic assisted knee arthroplasty as decided by their doctor and treated with CORI Robotics.
9867689|NCT00184431|Active Comparator|B|Traditional physical therapy
9867690|NCT00184444|Experimental|Hypoxic Interval training|4 x 4 minutes interval training with 100% oxygenated air
9867691|NCT00184444|Experimental|Normoxic interval training|4 x 4 minutes interval training in normoxic air
9867692|NCT00184483|Experimental|Lichtenstein's operation|Patients with a primary unilateral inguinal hernia are randomized to Lichtenstein's operation to repair their groin hernia
9867693|NCT00184483|Active Comparator|Prolene Hernia System|Patients with a primary unilateral inguinal hernia are randomized to Prolene Hernia System to repair their groin hernia
9867694|NCT00184496|Active Comparator|methadon|Morphine methadone stop and go switch
9867695|NCT00184496|Active Comparator|Methadone|Methadon morphine overlap switch
9867696|NCT00184522|Experimental|Aflurax|pectin-containing natural product
9867697|NCT00184522|Active Comparator|esomeprazole (Nexium)|esomeprazole (Nexium)
9867698|NCT00184587|Experimental|candesartan|candesartan cilexetil 16 mg (one tablet/day) in week 1 and 32 mg (2 tablets/day) in week 3, provided for the study by AstraZeneca
9867699|NCT00184587|Placebo Comparator|placebo|placebo one tablet/day in week 1 and 2 tablets/day in week 3, provided for the study by AstraZeneca. Same size, weight, taste and appearance as experimental drug
9867700|NCT00184795|Experimental|ALD 0.1|
9867701|NCT00184795|Experimental|ALD 0.25|
9867702|NCT00184795|Placebo Comparator|Placebo|
9867703|NCT00184873|Active Comparator|Lifestyle counseling|Patients receiving lifestyle counseling
10210574|NCT04785898|Other|Screening patients COVID-19 test|"As part of the patient's management, two nasopharyngeal swabs will be taken from the same nostril:~The first swab will be sent to the microbiology laboratory for analysis with the Simplexa ™ COVID-19 Direct assay so as not to impact the patient's diagnostic result.~The second swab taken as part of the research will be analyzed with the ID NowTM COVID-19 test located in the UAS by one of the nurses trained and authorized to use it. The choice to perform the ID Now ™ COVID-19 test in the emergency room and not in the laboratory is based on the supplier's instructions. Indeed, the nasopharyngeal swab is intended to be analyzed directly and not to be transported in a container which could hinder the quality of the sample.~The discomfort or pain felt by the patient during the first sample can possibly influence the quality of the second. This could induce a bias. To minimize this bias, staff will be specifically trained in sampling."
9867704|NCT00184873|No Intervention|Regular care|Patients receiving regular care
9867705|NCT00184925|Active Comparator|subglottic drainage|suctioning of subglottis with cannula
9927704|NCT00895973|Experimental|Stirrups delivery|Mom will be assigned to deliver with legs positioned in stirrups
9927705|NCT00895973|Experimental|Bed delivery|Mom will be assigned to deliver with the legs positioned in bed in the supine position
9927706|NCT00895986|Experimental|1|Conversation Maps Diabetes Education
9927707|NCT00895986|Experimental|2|Heart Healthy Living Diabetes Education
9927708|NCT00895999|Experimental|1|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to 8 individual sessions of IPT adapted for depression and pain.
10210575|NCT04785287|Experimental|Arm I (BMS-986218, SBRT)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 IV over 30 minutes on day 1. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT on days 36-39 (days 8-11 of cycle 2).
9927709|NCT00895999|Other|2|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to Enhanced Support and Connection to Counseling (ESCC).
9927710|NCT00896077|Active Comparator|Subcutaneous|Subcutaneous administration of LSF
9927711|NCT00896077|Active Comparator|IV|IV administration arm
9927712|NCT00896129||Study population|
9927713|NCT00896155|Experimental|Concurrent Tamoxifen and Radiotherapy|ARM 1 will receive Tamoxifen given concurrently with radiotherapy. Tamoxifen will continue for a period of 5 years.
9927714|NCT00896155|Active Comparator|Sequential radiotherapy and tamoxifen|ARM-2 shall receive radiotherapy followed by tamoxifen sequentially. Again tamoxifen will continue for a period of 5 years.
9927715|NCT00896194|Active Comparator|1: Standard Behavioral Treatment (SBT)|This group receives standard behavioral treatment for weight loss as described below.
9927716|NCT00896194|Experimental|2: Modified SBT + Self-Efficacy|This group receives modified SBT with an additional self-efficacy component as described below.
9927717|NCT00896207|Experimental|Arm I|Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
9927718|NCT00896207|Experimental|Arm II|Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
9927719|NCT00896207|Experimental|Arm III|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
9927720|NCT00896207|Experimental|Arm IV|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
9927721|NCT00896207|Experimental|Arm V|Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
10210576|NCT04785287|Experimental|Arm II (BMS-986218, SBRT, nivolumab)|Patients receive anti-CTLA4 monoclonal antibody BMS-986218 and SBRT as in Arm 1. Beginning cycle 2, patients also receive nivolumab IV over 30 minutes starting on day 1. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10210577|NCT04784598|Experimental|Experimental group|Group 1- The intervention group I will receive a customized strip slipper with a 3mm EVA horseshoe piece (Shore A 32). And 2.5mm EVA cover (Shore A 28).
10210578|NCT04784598|Sham Comparator|Sham group|Group 2- The control group will receive a slipper with a 2.5mm EVA cover (Shore A 32) identical to the one used by the intervention group, but without corrective par
10210579|NCT04772157||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
10210580|NCT04754542||Discontinuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to discontinue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
10210581|NCT04754542||Continuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to continue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
10210582|NCT04754087|Other|G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners|Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.
10210583|NCT04736056|Experimental|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|"Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills (MBTI+)~The MBTI+ intervention will train participants in mindfulness-based sleep strategies and behavioral symptom management techniques. The MBTI+ intervention will consist of 6 weekly sessions that will last between 60 and 75 minutes."
10210584|NCT04720417|Experimental|Treatment (defactinib, VS-6766)|Patients receive defactinib PO BID and VS-6766 PO BIW (Monday and Thursday or Tuesday and Friday) for 3 weeks in every cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10210585|NCT04703036|Experimental|Active arm|The active supplements are glycine and N-acetylcysteine
10210586|NCT04703036|Placebo Comparator|Placebo arm|The placebo arm is alanine
10210587|NCT04701671||Normal Weight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are not randomly assigned to undergo MRI scans at baseline and 18-months.
10210588|NCT04701671||Normal Weight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile under 85% who are randomly assigned to undergo MRI scans at baseline and 18-months.
10210589|NCT04701671||Overweight Control, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are not randomly assigned to undergo MRI scans at baseline and 18-months.
9867706|NCT00185159|Experimental|1|olmesartan medoxomil
9867707|NCT00185159|Placebo Comparator|2|placebo
9867708|NCT00185172|Placebo Comparator|1|2 week placebo run-in
9867709|NCT00185172|Experimental|2|Olmesartan medoxomil tablets for 8 weeks
9867710|NCT00185172|Experimental|3|Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks
9867711|NCT00185185|Experimental|1|olmesartan medoxomil
9867712|NCT00185185|Active Comparator|2|atenolol
9867713|NCT00185198|Active Comparator|Arm 1|
9867714|NCT00185198|Placebo Comparator|Arm 2|
9867715|NCT00185224|Experimental|Arm 1|
9867716|NCT00185224|Active Comparator|Arm 2|
9867717|NCT00185237|Experimental|Arm 1|
9867718|NCT00185237|Placebo Comparator|Arm 2|
9867719|NCT00185250|Experimental|Arm 1|
9867720|NCT00185250|Experimental|Arm 2|
9867721|NCT00185250|Placebo Comparator|Arm 3|
9867722|NCT00185250|Placebo Comparator|Arm 4|
9867723|NCT00185263|Experimental|1|Ad5FGF-4
9867724|NCT00185263|Experimental|2|Ad5FGF-4
9867725|NCT00185263|Placebo Comparator|3|Placebo
9867726|NCT00185276|Experimental|Arm 1|
9867727|NCT00185276|Experimental|Arm 2|
9867728|NCT00185289|Experimental|Arm 1|
9867729|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 3 mg|Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity
9867730|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 7 mg|Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity
9867731|NCT00185315|Experimental|Arm 1|
9867732|NCT00185328|Experimental|Arm 1|
9867733|NCT00185341|Experimental|CCR-1 Receptor Antagonist|Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily
9867734|NCT00185341|Placebo Comparator|Placebo|Subjects received placebo corresponding to verum
9867735|NCT00185354|Experimental|Arm 1|
9867736|NCT00185354|Active Comparator|Arm 2|
9867737|NCT00185367|Experimental|Arm 1|
9867738|NCT00185367|Active Comparator|Arm 2|
9867739|NCT00185393|Experimental|Arm 1|
9867740|NCT00185393|Other|Arm 2|
9867741|NCT00185419|Active Comparator|Arm 1|
9867742|NCT00185419|Active Comparator|Arm 2|
9867743|NCT00185445|Experimental|Arm 1|
9867744|NCT00185484|Experimental|Arm 1|
9867745|NCT00185510|Experimental|Arm 1|
9867746|NCT00185510|Placebo Comparator|Arm 2|
9927722|NCT00896207|Experimental|Arm VI|Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
9867747|NCT00185523||CML in first Chronic Phase or Accelerated Phase|Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs** Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion
9867748|NCT00185523||AML and ALL in first or second remission|FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion
9867749|NCT00185601|Other|on-line self management intervention|
9867750|NCT00185601|No Intervention|usual care control group|
9867751|NCT00185601|Experimental|on-line self management intervention with email reinforcement|
9867752|NCT00185757|Experimental|Cytokine-induced Killer Cells|The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
9867753|NCT00185796|Experimental|TLI/ATG conditioning|Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).
9867754|NCT00185848|Experimental|[18F]FHBG arm|
9867755|NCT00185887|Active Comparator|Terbutaline|
9867756|NCT00185887|Active Comparator|Nitroglycerine|
9867757|NCT00185952|Active Comparator|Nifedipine|Maintenance tocolysis with nifedipine.
9867758|NCT00185952|Placebo Comparator|Placebo|Maintenance tocolysis with placebo tablets.
9867759|NCT00185991|Active Comparator|Once daily Gentamicin|
9867760|NCT00185991|Active Comparator|Every eight hour Gentamicin|
9867761|NCT00186082|Active Comparator|Cefotetan, Cefoxitin or Clindamycin|
9867762|NCT00186082|Placebo Comparator|Normal Saline|
9867763|NCT00186147||Graft recipients and donors|
9867764|NCT00186173|Experimental|After school sports|After school team sports intervention designed specifically for overweight and obese children
9867765|NCT00186173|Active Comparator|After school health education|After school heath and nutrition education program
9867766|NCT00186342|Experimental|CIK cell|The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
9867767|NCT00186745|Experimental|1|All patients in this cohort receive treatment with weight-adjusted, standard-dose tinzaparin for treatment of venous thromboembolism. Trough anti-Xa level measurements done on any 2 of days 3, 5 or 7 of treatment. Patients with a trough anti-Xa level > 0.5 IU/mL receive dose adjustment of the tinzaparin.
9927723|NCT00896220||ICU Survivors and Their Family Caregiver|ICU Survivors who required one week or more of mechanical ventilation during their critical illness and their primary family caregiver
9927724|NCT00896246|Active Comparator|Klean-Prep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
9927725|NCT00896246|Experimental|Moviprep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
9927726|NCT00896259||THA control|those with THA not participating in exercise and education program
9927727|NCT00896259||THA exercise|those with THA and participating in exercise and education program
9927728|NCT00896259||healthy control|Healthy control, people with no lower limb gait abnormalities
9927729|NCT00896285|Active Comparator|1|
9927730|NCT00896285|Active Comparator|2|
9927731|NCT00896285|Active Comparator|3|
9927732|NCT00896285|Active Comparator|4|
9927733|NCT00896311|Active Comparator|1|Treatment solution consisted of 100 micrograms/mL of nitroglycerin. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
10210590|NCT04701671||Overweight Control with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher who are randomly assigned to undergo MRI scans at baseline and 18-months.
10210591|NCT04701671||Overweight/Obese Experimental, no MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are not randomly assigned to undergo MRI scans at baseline and 18-months.
10210592|NCT04701671||Overweight/Obese Experimental with MRI-scan (30 participants)|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes and are randomly assigned to undergo MRI scans at baseline and 18-months.
10210593|NCT04695652|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
10210594|NCT04695652|Placebo Comparator|MVC-COV1901(Saline)|Saline/0.5 mL
10210595|NCT04677595|Experimental|Cohort 1|Treatment Naive participants
10210596|NCT04677595|Experimental|Cohort 2|Participants received one or two prior lines of treatment
10210597|NCT04669379|Experimental|Intervention group (IG/EXPECT)|
10210598|NCT04669379|No Intervention|Standard of Care (SOC)|
10210599|NCT04653597|Experimental|Conservative airway management|decision to intubate will be withheld as long as the patient's state allows it. The patient will be closely monitored and decision of intubation will be made upon presence of regurgitation, seizure, shock, or sign of respiratory distress.
10210600|NCT04653597|Other|Routine practice|decision of intubation left at the discretion of the emergency physician
9927734|NCT00896311|Placebo Comparator|2|Placebo solution was saline. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
9927735|NCT00896324|Active Comparator|Cognitive Rehabilitation (Breast Cancer(BC) with chemotherapy)|Cognitive rehabilitation is a very low-risk method of treatment for cognitive deficits that involves restoring impaired function and/or training the individual to compensate for the area of deficit. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
9927736|NCT00896324|Active Comparator|Active Neurofeedback (BC pre-chemotherapy)|"In active Neurofeedback session subjects will be trained to increase brain activation in regions associated with executive function (EF) function deficits (as determined by neuroimaging measures) by viewing their own brain activation in real-time. The dose will be 2-3 sessions, each lasting approximately 30 minutes."
9867768|NCT00186758|Sham Comparator|1, Phase l, True or Sham|this treatment will be True or Sham (placebo) on one side of the head, phase I
9867769|NCT00186758|Active Comparator|2, phase ll, Sham or True|This treatment will be Sham(placebo)or True on the other side of the head phase II.
9867770|NCT00186771|Active Comparator|True Transcranial Magnetic Stimulation|True treatment with TMS over the temporoparietal cortex.
9867771|NCT00186771|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham treatment with rTMS over the temporoparietal cortex.
9867772|NCT00186810|Other|1|
9867773|NCT00186823|Other|1|
9867774|NCT00186849|Other|1|
9867775|NCT00186862|Other|1|
9867776|NCT00186914|Other|1|
9867777|NCT00186927|Experimental|Participants|"Participants will be studied in three cohorts:~Healthy seropositive children 3 years up to 6 years~Healthy seropositive toddlers 12 months up to 24 months~Healthy seronegative toddlers 12 months up to 24 months.~Each cohort will receive Sendai virus vaccine."
9867778|NCT00186940||1|
9867779|NCT00186953|Other|1|
9867780|NCT00186966|Other|FLAG|
9867781|NCT00186966|Other|FLAG and LP Dox|
9867782|NCT00186979|Other|1|
9867783|NCT00187005|Other|1|
9867784|NCT00187031|Other|1|
9867785|NCT00187044|Other|1|
9867786|NCT00187057|Other|1|Acute Lymphoblastic Leukemia (ALL) Low Risk
9867787|NCT00187057|Other|2|Acute Lymphoblastic Leukemia (ALL) - High Risk
9867788|NCT00187057|Other|3A|B-Cell Non-Hodgkins Lymphoma (Group A)
9867789|NCT00187057|Other|3B|B-Cell Non-Hodgkins Lymphoma (Group B)
9867790|NCT00187057|Other|4|Hodgkins Disease
9867791|NCT00187070|Other|1|
9867792|NCT00187083|Experimental|1|Native asparaginase
9867793|NCT00187083|Experimental|2|PEG-asparaginase
9867794|NCT00187122|Other|1|See Detailed Description section for description of treatment plan.
9867795|NCT00187148|Other|1|
9867796|NCT00187161|Experimental|A|"Group A: Resected Stage I and resected abdominal Stage II~Subjects will receive two courses (3 weeks apart) of COPAD."
9867797|NCT00187161|Experimental|B|"Group B: Other Stage II, Stage III, Stage IV or B-ALL M blast <70%; no CNS involvement.~Subjects in Group B will receive one week of treatment of COP."
9867798|NCT00187161|Experimental|C|"Group C: B-ALL with >70% BM blasts; CNS involvement, Group B COP failures i.e., <20% reduction Treatment Pre-Induction~Subjects will receive one week of treatment of COP."
9867799|NCT00187174|Experimental|Phase 1|
9867800|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) VVI-40|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
9867801|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) AAI-70|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
9867802|NCT00187239|Active Comparator|AICS On|Patients in this arm have Autointrinsic conduction search programmed ON.
9867803|NCT00187239|No Intervention|AICS Off|Patients assigned to this arm do not have Autointrinsic Conduction Search programmed on.
9867804|NCT00187252|Experimental|1|CRT + AF Suppression turned ON
9867805|NCT00187252|Active Comparator|2|CRT + AF Suppression turned OFF
9867806|NCT00187317|Experimental|PERT|Perturbation-based balance training.
9867807|NCT00187317|Placebo Comparator|CON|Flexibility and relaxation training.
10210601|NCT04647084|Experimental|Intradermal Lidocaine 2%|
10210602|NCT04647084|Experimental|Buzzy|
10210603|NCT04637698|Experimental|Dose expansion|OH2 injection will be administered at 1E+07 CCID50/mL .
10213687|NCT03520491|Experimental|Cohort 2|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.
10213688|NCT03520491|Experimental|Cohort 3|Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.
10213689|NCT03520491|Experimental|Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.
10213690|NCT03520101|Other|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
10213691|NCT03520101|Other|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
10213692|NCT03519581|Active Comparator|Micropulse Laser Treatment|"Subjects assigned to the micropulse laser arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~Application of subthreshold micropulse laser using the Iridex IQ577 laser unit. (intermittent pulsed energy) in a 7 X 7 grid pattern surrounding the fovea."
10213693|NCT03519581|Placebo Comparator|Sham Treatment|"Subjects assigned to the sham arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~No Actual laser treatment will occur"
10213694|NCT03498781|Experimental|Exercise-only intervention|Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
10213695|NCT03498781|Sham Comparator|Control intervention|Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.
9867808|NCT00187356|Experimental|Surgical Conduit|The surgical arm will be composed of the experimental arm (the use of the radial artery) versus an active comparator (the use of the saphenous vein graft).
9867809|NCT00187421|No Intervention|1|Graft patency assessment by routine clinical assessment with/without intraluminal coronary probe
9867810|NCT00187421|Experimental|2|Graft patency assessment by indocyanine green angiography and transit-time flowmetry
9867811|NCT00187460|Active Comparator|Early Feedback Arm|Hospital corporations randomized to receive early feedback in the form of a report card
9867812|NCT00187460|Active Comparator|Delayed Feedback Arm|Hospitals randomized to receive delayed feedback in the form of a hospital report cared, 21 months after the early feedback arm.
9867813|NCT00187538|Active Comparator|1|
9867814|NCT00187538|Active Comparator|2|
9867815|NCT00187538|Active Comparator|3|
9867816|NCT00187538|Active Comparator|4|
9867817|NCT00187551|Experimental|interruption of enfuvirtide|enfuvirtide interruption
9867818|NCT00187577|Active Comparator|application to eyelid of latanoprost solution|Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
9867819|NCT00187577|Active Comparator|Application of bimatoprost to eyelid|Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
9867820|NCT00187590|Experimental|Intervention|Phone call after an ER visit.
9867821|NCT00187590|No Intervention|Control|No phone call after an ER visit.
9867822|NCT00187629|Experimental|1|dietary phosphorus
9867823|NCT00187629|Active Comparator|2|other
9867824|NCT00187707|Other|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
9867825|NCT00187733||Fasting|Other: Fasting blood and urine collection
9867826|NCT00187746|Experimental|Age 18-25 years|African American subjects between the ages 18 to 25 years given Adefovir dipivoxil.
9867827|NCT00187746|Experimental|Age 48-55 years|African American subject between the ages 48 to 55 years given Adefovir dipivoxil.
9867828|NCT00187798|Other|Metformin|Metformin HCl
9867829|NCT00187837|Experimental|SW intervention|Stepwise Excavation
9867830|NCT00187837|Other|DCE intervention|Control intervention Direct complete excavation. The updated terminology for completed excavation is non-selective excavation to hard dentin
9867831|NCT00187850|Experimental|PP|Partial pulpotomy
9867832|NCT00187850|Other|DPC|Direct pulp capping
9867833|NCT00187863||Exercise induced pain perception|
9867834|NCT00187863||Surgical pain perception|
9867835|NCT00187915|Other|CellCept + Prograf|Standard of Care Regime
9867836|NCT00187915|Other|CellCept + Neoral|Standard of Care Regime
9867837|NCT00187941|Other|CellCept|CellCept + Prograf or Neoral + Steroids
9867838|NCT00188058|Active Comparator|Minimal alveolar distension|PEEP is set for a total PEEP (PEEP + intrinsic PEEP) between 5 and 9 cm H2O
9867839|NCT00188058|Experimental|Maximal alveolar distension|PEEP is set for a plateau pressure between 28 and 30 cm H20
9867840|NCT00188175|Experimental|IMRT for lower limb soft tissue sarcoma|
9867841|NCT00188214|Other|CT perfusion scan|
9867842|NCT00188266|Experimental|5-Fluorouracil (5FU) and Cisplatin with Radiation|
9867843|NCT00188279|Experimental|MnDCT|
9867844|NCT00188292||High-grade disease|Those who had histologic anal high-grade disease.
9867845|NCT00188292||Control|Those who had less than highgrade histologic anal disease
9867846|NCT00188305|Experimental|1 In person|In person general health, colorectal cancer risk information and screening recommendations.
10210604|NCT04636060|Experimental|Iron-treatment group|
10210605|NCT04632927|Experimental|Secukinumab|AIN457
10210606|NCT04632927|Experimental|Ustekinumab|
10210607|NCT04631731|Experimental|Single agent PD-1/L1 inhibitor|
10210608|NCT04631731|Experimental|PD-1/L1 inhibitor + CTLA-4 inhibitor|
10210609|NCT04631731|Experimental|Platinum-based chemotherapy + PD-1/L1 inhibitor|
10210610|NCT04631731|Experimental|PD-1/L1 inhibitor + tyrosine kinase inhibitor|
10210611|NCT04631731|Experimental|PD-1/L1 inhibitor + VEGF inhibitor|
10210612|NCT04620798|Experimental|Intervention|Participants will be given their results of their antibody test immediately (within 24 hours) and will be followed and surveyed to see if having this knowledge changes their engagement with SARS-CoV-2 prevention behaviors.
10210613|NCT04620798|No Intervention|Control (Delayed)|Participants will be given their results of their antibody test after 4 weeks. Their engagement with SARS-CoV-2 prevention behaviors will also be assessed following testing.
10210614|NCT04612283|Active Comparator|NGA-01 gel|A formulation with natural ingredients expected to be used for joint pain in Osteoarthritis
10210615|NCT04612283|Placebo Comparator|Placebo gel|Placebo gel with no active ingredient
10210616|NCT04582383|Experimental|Spironolactone|In this arm, participants will receive spironolactone 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
10210617|NCT04582383|Active Comparator|Doxycycline hyclate|This arm is an active-comparator arm in which participants will receive doxycycline hyclate 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
10210618|NCT04576078|Experimental|NEFOPAM 60mg PO/ 8 hours|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h.
10210619|NCT04576078|Placebo Comparator|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h.
10210620|NCT04575207|Experimental|caFFR-guided|Participants who are randomly assigned to caFFR-guided group will receive the detection of Coronary Angiography-Derived Fractional Flow Reserve (caFFR) Measurement System. The online caFFR value is used to guide the PCI strategy. If caFFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when caFFR > 0.80.
10210621|NCT04575207|Active Comparator|FFR-guided|Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR > 0.80.
9867847|NCT00188305|Active Comparator|2 Telephone|Telephone general health counselling, colorectal cancer risk information and screening recommendations.
9867848|NCT00188305|Placebo Comparator|3 Control|Standard care for 2 months followed by summary letter with general health information, colorectal cancer risk information and screening recommendations.
9927737|NCT00896324|Sham Comparator|Neurofeedback placebo (Sham) (BC pre-chemotherapy)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
9927738|NCT00896350|Experimental|BOLD MRI|Determine the amount of oxygen supply to tumors.
9927739|NCT00896376|Experimental|trastuzumab|
9927740|NCT00896402|Active Comparator|Chlorhexidine|skin antisepsis with chlorhexidine
9927741|NCT00896402|Active Comparator|Povidone-iodine|skin antisepsis with povidone-iodine
9927742|NCT00896428|Experimental|1|16 patients with a diagnosis of severe asthma under gallopamil treatment
9927743|NCT00896428|Placebo Comparator|2|16 patients with a diagnosis of severe asthma under placebo treatment
9927744|NCT00896493|Experimental|Total lymphoid irradiation & anti-thymocyte immunoglobulin|TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.
9927745|NCT00896545|Experimental|5-keys feeding program|Counseling in small groups aimed at enhancing children's self control over eating
9927746|NCT00896545|Active Comparator|Healthy lifestyle counseling|Counseling in small groups aimed at achieving healthy eating patterns aimed at both the family and young children
9927747|NCT00896558|Experimental|Cohort A|A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
9927748|NCT00896558|Experimental|Cohort B|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
9927749|NCT00896558|Experimental|Cohort C|Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.
9927750|NCT00896558|Experimental|Cohort D|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
9927751|NCT00896558|Experimental|Cohort E|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
9927752|NCT00896571|Experimental|Arm 1|
9927753|NCT00896597|Experimental|NRL972|A single dose of 2 mg NRL972 will be administered on four occasions over a period of up to 6 weeks.
9927754|NCT00896610||Diabetes|Individuals who have been diagnosed with or are at risk for developing diabetes
9927755|NCT00896636||Luteal|Pre-menopausal women who undergo rFNA procedure during the luteal phase of their menstrual cycle.
9927756|NCT00896636||Follicular|Pre-menopausal women who undergo rFNA procedure during the follicular phase of their menstrual cycle.
9927757|NCT00896636||Menopause|Women who have entered menopause.
9927758|NCT00896675||patients treated with EGFR inhibitors and/or VEGF inhibitor|
9927759|NCT00896675||NOT treated with EGFR inhibitors and/or VEGF inhibitor|
9927760|NCT00896688||Healthy Volunteers|It will involve 5 volunteers and they will undergo C arm fluoroscopic guided cervical medial branch blocks (C2-C7) on unilateral position and then followed by the 3D ultrasound machine for visualization of needle position.
9927761|NCT00896688||Candidates for upper and lower cervial medical branch blocks|This will involve 25 patients and they will follow the same procedures as the healthy volunteers.
9927762|NCT00896701||Patient samples from C9621, C9720 and C19808|This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who have previously provided their consent. Diagnostic and follow-up samples from acute myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665 will be used.
9927763|NCT00896714|Experimental|Closed loop anesthesia|
9935858|NCT03071757|Experimental|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer [TNBC]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
9867849|NCT00188318|Experimental|Hyperfractionated Accelerated Radiotherapy|Hypofractionated Accelerated Radiotherapy with integrated neck surgery
9867850|NCT00188331||1|adjuvant/neoadjuvant chemotherapy
9867851|NCT00188331||2|non-chemotherapy group
9867852|NCT00188331||3|limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
9867853|NCT00188344|Active Comparator|1|pneumatic dilatation
9867854|NCT00188344|Active Comparator|2|Laparoscopic myotomy
9867855|NCT00188513|Experimental|Conformal intensity modulated radiotherapy (IMRT)|All patients shall receive a continuous course of intensity modulated conformal radiotherapy consisting of 66 Gy in 22 (3 Gy) fractions over 4.5 weeks.
9867856|NCT00188578|Experimental|IMRT Gynecological Cancers|
9867857|NCT00188630|Active Comparator|N-Acetylcysteine|IV NAC as a 100mg/kg bolus at the start of the surgical procedure (prior to the initiation of CPB), followed by a 10 mg/kg/hr infusion until 4 hours after completion of surgery
9867858|NCT00188630|Placebo Comparator|Placebo|The control arm will instead receive placebo (5% dextrose solution), both as a bolus and infusion.
9867859|NCT00188708|Experimental|hypoxia measurement|Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
9867860|NCT00188721||1|Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)
9867861|NCT00188721||2|Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.
9867862|NCT00188825|Experimental|basiliximab|
9867863|NCT00188825|Placebo Comparator|placebo|
9867864|NCT00188890||1|prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
9867865|NCT00188942|Active Comparator|Fluoxetine + Olanzapine|
9867866|NCT00189007|Experimental|Allopurinol|500 mg allopurinol/ 50 mL water for injection intravenously
9867867|NCT00189007|Placebo Comparator|Placebo|500 mg mannitol/50 mL water for injection intravenously
9867868|NCT00189020|Experimental|2-dose|PCV7 at age 2 and 4 months
9867869|NCT00189020|Experimental|2+1-dose|PCV7 at age 2, 4 and 11 months
9867870|NCT00189020|No Intervention|Control|Control group
9867871|NCT00189163|Active Comparator|Pioglitazone|30 mg, taken orally, once per day
9867872|NCT00189163|Placebo Comparator|Placebo|Sugar pill, taken orally, once a day
9867873|NCT00189176|Experimental|Tetrathiomolybdate|
9867874|NCT00189514|Experimental|1|
9867875|NCT00189514|Experimental|2|
9867876|NCT00189514|Experimental|3|
9867877|NCT00189514|Placebo Comparator|4|
9867878|NCT00189527|Experimental|respiratory support|a mode of ventilation in comparison
9867879|NCT00189527|Active Comparator|Assist Control|an other mode of ventilation in comparison
9867880|NCT00189553|Active Comparator|Standard|Paclitaxel-Carboplatin
9867881|NCT00189553|Experimental|Experimental|Caelyx-Carboplatin
9867882|NCT00189592|Experimental|A|Percutaneous Fasciotomy
9867883|NCT00189592|Active Comparator|2|Standard Fasciotomy
9867884|NCT00189605|Active Comparator|1|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
9867885|NCT00189605|Experimental|2|Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
9867886|NCT00189618|Placebo Comparator|1|
9867887|NCT00189618|Active Comparator|2|
9867888|NCT00189709|Experimental|1|
9867889|NCT00189709|Active Comparator|2|
9867890|NCT00189826|Active Comparator|1|
9867891|NCT00189826|Experimental|2|
9867892|NCT00189839|Active Comparator|1|
9867893|NCT00189839|Experimental|2|
9867894|NCT00189852|Experimental|Docobo|telemonitoring at home system for heart failure
9867895|NCT00189852|No Intervention|Control|No telemonitoring system in place
9927764|NCT00896753||patients with metastatic colon cancer|
9927765|NCT00896831|Active Comparator|L-ornithine-L-aspartate|5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
9927766|NCT00896831|Placebo Comparator|placebo|5 g (1 sachet) of placebo comparator three times per day for 60 days
9927767|NCT00896844|Experimental|emotional disclosure|writing about emotional events from the past
9927768|NCT00896844|Placebo Comparator|placebo writing|writing about how they spent their time the previous day
9927769|NCT00896883|Experimental|Middle Turbinate Implant|Subjects to receive Middle Turbinate Implant
9927770|NCT00896961|Experimental|Observational (EF5)|Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
9927771|NCT00896974|Experimental|Arm I|Participants receive a single dose of oral 9cUAB30 on day 1.
9927772|NCT00896987|Experimental|1|lamotrigine
9927773|NCT00896987|Active Comparator|2|carbamazepine
9867896|NCT00189878|Active Comparator|1 methotrexate|patient to receive methotrexate
9867897|NCT00189878|Placebo Comparator|2 Placebo|given placebo capsules
9867898|NCT00189917|Experimental|GP 1: healthy, no AD|Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
9867899|NCT00189917|Experimental|GP2: prev. allerg. rhinitis|Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
9867900|NCT00189917|Experimental|GP3: history of AD|Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
9867901|NCT00189917|Experimental|GP4: active AD|Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
9867902|NCT00189930|Active Comparator|1|High dose
9867903|NCT00189930|Active Comparator|2|Low dose
9867904|NCT00189930|Placebo Comparator|3|
9867905|NCT00189956|Active Comparator|Group 1|healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
9867906|NCT00189956|Active Comparator|Group 2|healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
9867907|NCT00189956|Active Comparator|Group 3|"healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous"
9867908|NCT00190060|Active Comparator|1|Transdermal testosterone gel (Testogel 1% )
9867909|NCT00190060|Placebo Comparator|2|Matched transdermal placebo gel
9867910|NCT00190164|Experimental|1|Macular hole surgery with alleviated positioning
9867911|NCT00190164|No Intervention|2|Macular hole surgery with no alleviated positioning
9867912|NCT00190190|Experimental|1|With Peeling of Limiting the Intern of the Retina
9867913|NCT00190190|Active Comparator|2|Traditional Procedure Without Peeling of Limiting
9867914|NCT00190203|Experimental|A|HEMICRANIECTOMY
9867915|NCT00190216|Experimental|A|
9867916|NCT00190229|Experimental|1|Cyclophosphamide
9867917|NCT00190242|Experimental|group1:3 administrations of Havrix|group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24
9867918|NCT00190242|Active Comparator|group2: 2 administrations of Havrix|group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24
9867919|NCT00190268|Experimental|3,4-diaminopyridine|3,4-diaminopyridine
9867920|NCT00190294|Experimental|1|MIFEPRISTONE 200 mg and misoprostol 400 µg
9867921|NCT00190307|Experimental|1|Aspirin:KARDEGIC
9867922|NCT00190333|Active Comparator|A|
9867923|NCT00190372|Other|A|
9867924|NCT00190385|Active Comparator|A|
9867925|NCT00190398|Experimental|1|Carotid angioplasty and stenting with cerebral protection
9867926|NCT00190411|Experimental|Treatment|Celiprolol
9867927|NCT00190424|No Intervention|control|
9867928|NCT00190424|Experimental|CpG-ODN|
9867929|NCT00190437|Experimental|1|Amoxicillin-clavulanic
9867930|NCT00190450|Experimental|1|Early Graft (Early G)
9867931|NCT00190450|Experimental|2|Late Graft (Late G)
9867932|NCT00190515|Active Comparator|1|5-FU/l-LV
9867933|NCT00190515|Experimental|2|UFT/LV
9867934|NCT00190528|Active Comparator|Surgery|
9867935|NCT00190528|Experimental|Chemotherapy + Surgery|
9867936|NCT00190541|Active Comparator|1|Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
9867937|NCT00190541|Experimental|2|Procedure/Surgery: Mesorectal excision without lateral lymph node excision
9867938|NCT00190580|Experimental|1|
9867939|NCT00190580|Experimental|2|
9867940|NCT00191126|Other|A|
9867941|NCT00191126|Experimental|B|
9867942|NCT00191243|Experimental|A|
9867943|NCT00191243|Experimental|B|
9927774|NCT00897026||Group 1|Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
9927775|NCT00897130|Experimental|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.
9927776|NCT00897169|Experimental|A|
9927777|NCT00897169|Experimental|B|
9927778|NCT00897182||Group 1|This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
9927779|NCT00897221|Experimental|Dose 1|Deferiprone oral solution 20 mg/kg/day
9927780|NCT00897221|Experimental|Dose 2|Deferiprone oral solution 40 mg/kg/day
9867944|NCT00191698|Experimental|A|Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
9867945|NCT00191698|Placebo Comparator|B|Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
9867946|NCT00192127|Active Comparator|1|FluMist
9867947|NCT00192127|Placebo Comparator|2|Placebo
9867948|NCT00192140|Active Comparator|1|FluMist
9867949|NCT00192179|Experimental|CAIV-T|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
9867950|NCT00192179|Placebo Comparator|Placebo|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
9867951|NCT00192218|Experimental|1|FluMist
9867952|NCT00192270|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|All subjects were scheduled to receive 2 doses of CAIV-T.The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
9867953|NCT00192283|Experimental|1|CAIV-T
9867954|NCT00192283|Placebo Comparator|2|Placebo
9867955|NCT00192309|Experimental|Cold-adapted influenza vaccine (CAIVT)|A single intranasal dose of 10^7 fluorescent focus units.
9927781|NCT00897234||Healthy Volunteers|Non-smoking healthy volunteers
9867956|NCT00192309|Active Comparator|Trivalent inactivated vaccine (TIV)|A single dose of commercially available Flushield was administered intramuscularly.
9867957|NCT00192309|Placebo Comparator|Placebo|The 0.2 mL administered intranasally.
9867958|NCT00192322|Experimental|CAIV-T 10^5|a single intranasal 0.2 mL dose of liquid CAIV-T 10^5 (approximately 0.1 mL into each nostril)
9867959|NCT00192322|Experimental|CAIVT 10^7|A single intranasal 0.2 mL dose of liquid CAIV-T 10^7 (approximately 0.1 mL into each nostril)
9867960|NCT00192322|Placebo Comparator|Placebo|A single intranasal 0.2 mL dose of placebo
9867961|NCT00192322|Active Comparator|Trivalent inactivated vaccine (TIV)|A single intramuscular injection of commercially available vaccine
9867962|NCT00192335|Active Comparator|1|CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
9867963|NCT00192335|Active Comparator|2|FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
9867964|NCT00192413|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|A single 0.2 mL dose of 10^7 fluorescent focus units was administered intranasally.
9867965|NCT00192413|Active Comparator|Trivalent Inactivated Vaccine (TIV)|A single dose was administered by intramuscular injection.
9867966|NCT00192465|Experimental|1|MEDI-524 (Numax-TM)
9867967|NCT00192465|Experimental|2|MEDI-524 (Numax-TM)
9867968|NCT00192465|Experimental|3|MEDI-524 (Numax-TM)
9867969|NCT00192465|Experimental|4|MEDI-524 (Numax-TM)
9867970|NCT00192465|Experimental|5|MEDI-524 (Numax-TM)
9867971|NCT00192478|Active Comparator|1|MEDI-524
9867972|NCT00192491|Active Comparator|2|FluMist
9867973|NCT00192491|Placebo Comparator|3|Placebo
9867974|NCT00192491|Active Comparator|1|FluMist with other solution
9867975|NCT00192517|Active Comparator|1|MEDI-522
9867976|NCT00192517|Placebo Comparator|2|Placebo
9867977|NCT00192543|Active Comparator|case|diet of fish and fruit addition compared to regular diet
9867978|NCT00192543|Placebo Comparator|control|regular diet
9867979|NCT00192569|Experimental|Treated|Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)
9867980|NCT00192569|No Intervention|Untreated|Subjects will be followed for natural history of newly acquired HCV
9867981|NCT00192595|Active Comparator|Arm 1:|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
9867982|NCT00192595|Experimental|Arm 2|Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)
9867983|NCT00192595|Experimental|Amr 3|Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)
9867984|NCT00192608|Experimental|saquinavir at baseline|patients receiving NRTIs + saquinavir + ritonavir 1000/100 mg BID at entry switch from 200 mg SQV capsules to 500 mg SQV tablets following PK at day 0. After PK at day 8 NRTIs ceased and regimen changed to ATV/SQV/RTV 300/1500/100 QD using 500 mg SQV formulation and continued to week 48
9867985|NCT00192608|Experimental|other boosted PI at baseline|Patients receiving NRTIs + PI/RTV randomised at baseline to receive ATV/SQVRTV 300/1500/100 QD using 500 mg SQV formulation or ATV/SQV/RTV 300/1600/100 QD using 200 mg formulation. Following PK at day 7, SQV formulation switched with second PK assessment at day 15. Patients then receive ATV/SQV/RTV 300/1500/100 QD to week 48.
9867986|NCT00192634|Active Comparator|1|Abacavir 600mg/Lamivudine 300mg
9867987|NCT00192634|Active Comparator|2|Tenofovir 300mg/emtricitabine 200mg
9867988|NCT00192699||Group 1: Cemented Bi-Metric femoral stem|Cemented Bi-Metric femoral stem
9927782|NCT00897234||Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer.
9927783|NCT00897260|Experimental|1|
9927784|NCT00897325||Ancillary-Correlative (Collecting and banking ALL specimens)|Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
9927785|NCT00897377|Experimental|Total resection with early radiation|Total resected LGGs treated with early radiation
9927786|NCT00897377|No Intervention|Total resection without radiation|Total resected LGGs treated without radiation
9927787|NCT00897377|Experimental|Residual LGGs with radiation|Residual LGGs treated with early radiation
9927788|NCT00897377|Experimental|Residual LGGs with chemo|Residual LGGS treated with temozolomide
9927789|NCT00897429||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.
9867989|NCT00193011|Experimental|1|Docetaxel
9867990|NCT00193011|Experimental|2|Cyclophosphamide + Methotrexate + 5-fluorouracil
9867991|NCT00193154|Experimental|OSI-774 & bevacizumab|OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.
9517864|NCT03302195|Experimental|Intervention group C|"Heparin dose and cardiopulmonary bypass pump flow rate are adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
9867992|NCT00193635|Active Comparator|1|oral MMF
9867993|NCT00193648|Active Comparator|1|Avandia (rosiglitazone)
9867994|NCT00193648|Active Comparator|2|Humira (adalimumab)
9867995|NCT00193674|Experimental|1|
9867996|NCT00193674|Placebo Comparator|2|
9867997|NCT00193726|Experimental|Arm B- Experimental|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
9867998|NCT00193726|Placebo Comparator|Arm A - Placebo|Tab Placebo once a day for 5 days prior to each cycle of chemotherapy
9867999|NCT00193739|Active Comparator|NACT followed by surgery|3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy & lower para aortic lymph node sampling)
9868000|NCT00193739|Active Comparator|Concurrent chemoradiotherapy|Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.
9868001|NCT00193765|Active Comparator|Wait and Watch|Therapeutic neck dissection on developing nodal relapse
9868002|NCT00193765|Experimental|Elective Neck dissection|Elective neck dissection in early oral cancer at the time of primary surgery
9868003|NCT00193778|Experimental|Loco Regional Treatment Arm (LRT)|Surgery for breast cancer. (MRM/BCT)
9868004|NCT00193778|Active Comparator|No Loco-regional Treatment Arm|No surgery for Breast cancer
9868005|NCT00193791|No Intervention|Radiation (RT) Alone|Standard radical radiation therapy alone
9868006|NCT00193791|Experimental|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
9868007|NCT00193804||2|Patients with histologically proven, cervical cancer FIGO Stage IIB eligible will be invited for the study. The patients will recieve either 3D conformal radiation or IMRT external radiation with concomitant cisplatin chemotherapy followed by brachytherapy.
9868008|NCT00193856|Active Comparator|A|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
9868009|NCT00193856|Active Comparator|B|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
9868010|NCT00193856|Experimental|C|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
9868011|NCT00193856|Experimental|D|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
9868012|NCT00193882|Active Comparator|A: Radiotherapy|Radiotherapy alone
9868013|NCT00193882|Experimental|B: Chemo-radiotherapy|Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy
9868014|NCT00193895|Active Comparator|Radiotherapy alone|Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
9868015|NCT00193895|Experimental|Radiotherapy plus chemotherapy|Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
9868016|NCT00193908|Experimental|1|
9868017|NCT00193908|Experimental|2|
9868018|NCT00193921|Experimental|A|Vinorelbine + cisplatin + high-dose palliative radiotherapy
9868019|NCT00193921|Active Comparator|B|Gemcitabine + high-dose palliative radiotherapy
9868020|NCT00193934||1|Cervical Cancer Patients
9868021|NCT00193947||women initiating ARV therapy during pregnancy with neveripine|
9868022|NCT00193973|Active Comparator|1|
9868023|NCT00194038|Experimental|1|
9868024|NCT00194064|Experimental|Olanzapine|Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg
9868025|NCT00194103|No Intervention|TAU|
9868026|NCT00194103|Active Comparator|Telephone Monitoring|
9868027|NCT00194103|Experimental|Telephone Monitoring and Counseling|
9868028|NCT00194194|Active Comparator|moderate|moderate behavioral management
9868029|NCT00194194|Experimental|intensive|intensive behavioral management
9868030|NCT00194311||pregnancy complications|prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR).
9868031|NCT00194402|Active Comparator|1|Atorvastatin 10 mg for 12 weeks followed by Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) taken with atorvastatin 10 mg for an additional 12 weeks
9868032|NCT00194402|Active Comparator|2|Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) for 12 weeks followed by atorvastatin 10 mg taken with Slo-Niacin 1500 mg for an additional 12 weeks
9868033|NCT00194415|Other|1|HSV-2 antepartum testing
9868034|NCT00194415|Other|2|Subjects will receive safer-sex counseling during pregnancy
9868035|NCT00194428|Experimental|1|Almond enriched diet
9868036|NCT00194428|Active Comparator|2|Low-fat diet
9868037|NCT00194441|Experimental|1|Highly visible continually updating color coded bar computer display of cerebral perfusion pressure.
9868038|NCT00194441|Placebo Comparator|2|Bedside computer display with a blank screen except for a message indicating that the program is running.
9868039|NCT00194454|Experimental|1|Nine session psychosocial/behavioral counseling with homework
9868040|NCT00194454|Active Comparator|2|Usual clinic care with booklet describing depression following stroke
9868041|NCT00194467|Experimental|1|
9868042|NCT00194467|Placebo Comparator|2|
9868043|NCT00194480|Experimental|PegInterferon|Arm 1: 24 weeks of weekly injections of peginterferon Arm 2: control (no treatment)
9868044|NCT00194493|Experimental|1|Patient's clinician receives graphical report of patient-reported symptoms and quality of life issues.
9868045|NCT00194493|No Intervention|2|
9868046|NCT00194519|Active Comparator|Acyclovir|
9868047|NCT00194519|Placebo Comparator|Placebo|
9868048|NCT00194545|Experimental|1|Medication diary
9868049|NCT00194545|No Intervention|2|Caregivers only receive counseling which is the standard of care
9868050|NCT00194584|Experimental|1|
9868051|NCT00194584|No Intervention|0|
9927790|NCT00897442||Ancillary-Correlative (biomarker sampling and analysis)|Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
9927791|NCT00897468||breast cancer patients|
9927792|NCT00897637||Observational|Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
9927793|NCT00897650||Lung cancer|Patients with a diagnosis of invasive lung cancer.
9927794|NCT00897663||Single group|Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
9927795|NCT00897793||patients with epithelial cancers|Patients with head and neck cancer, and lung, breast, colorectal, and prostate cancers who are to undergo radiation therapy
9927796|NCT00897806||Genetic Markers|
9927797|NCT00897832||pancreatic cancer|Patients with pancreatic cancer
9927798|NCT00897858||Pediatric CNS tumor patients|Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy
9927799|NCT00897884|Experimental|Metformin|Patients will take metformin three times a day for two to three weeks prior surgery.
9927800|NCT00897962||Metastatic Breast Cancer|Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
9927801|NCT00897962||Non-cancer medical illness|Patients with non-cancer medical condition
9927802|NCT00897962||Healthy Controls|Healthy patients being seen for an annual exam
9927803|NCT00897975|Experimental|red yeast rice (RYR) plus phytosterol|arm will take red yeast rice and phytosterol supplement
9927804|NCT00897975|Placebo Comparator|red yeast rice plus placebo|
9927805|NCT00897975|Active Comparator|TLC plus red yeast rice plus placebo|subjects attend 12 week therapeutic lifestyle program and take above supplement
9927806|NCT00897975|Experimental|TLC plus RYR plus phytosterol|Therapeutic lifestyle program for 12 weeks plus red yeast rice plus phytosterol
9927807|NCT00898053||Correlative studies|Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
9927808|NCT00898079||Observational|Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
9927809|NCT00898092||Group 1|Peripheral blood and bone marrow samples are analyzed to assess gene expression using polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays. Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
9927810|NCT00898170|Experimental|myoma, with or without hypertension|those with myoma with or without hypertension in holter monitoring
9868052|NCT00194649|Experimental|1|100 mg Miglustat BID (twice daily) for six weeks
9868053|NCT00194714|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once per month for 6 months in the absence of disease progression or unacceptable toxicity.
9868054|NCT00194727|Experimental|1|Vinorelbine (20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle) and capecitabine (825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle). Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
9868055|NCT00194740|Experimental|1|
9868056|NCT00194753|Experimental|1|Weekly doxorubicin (24 mg/m2 IV) with daily oral cyclophosphamide (60 mg/m2 PO) for 12 weeks with G-CSF support days 2 - 7 of each week followed by weekly paclitaxel (80 mg/m2 IV) for 12 weeks.
9868057|NCT00194766|Experimental|1|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
9868058|NCT00194805|Experimental|1|Subjects randomized into the treatment group received the computer treatment
9868059|NCT00194818|Active Comparator|1|Asacol 6 tablets BID (4.8 grams/day)
9868060|NCT00194818|Active Comparator|2|Asacol 4 tablets TID (4.8 grams/day)
9868061|NCT00194844|Experimental|1|Nurse Caring
9868062|NCT00194844|Experimental|2|Self Caring
9868063|NCT00194844|Experimental|3|Combined Caring
9868064|NCT00194844|No Intervention|4|This group is not treated and serves as control.
9868065|NCT00194870|Other|Digital EEG|Digital EEG
9868066|NCT00194922|Placebo Comparator|A|
9868067|NCT00195104|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], 0.25mg/kg/dose administered intravenously over 1 to 4 hours
9868068|NCT00195117|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal.
9868069|NCT00195117|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their participation in this study.
9868070|NCT00195182||1. No intervention|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
9868071|NCT00195182||2. Experimental|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
9868072|NCT00195195||1|Sirolimus
9868073|NCT00195728|Experimental|hydrocodone/acetaminophen extended release|
9868074|NCT00195845|Experimental|Double-Blind Galantamine vs Placebo|Double-Blinded, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction
9868075|NCT00195845|Placebo Comparator|Placebo Control Group|Placebo-Controlled Group
9868076|NCT00195858|Active Comparator|Diet and Aerobic Exercise|
9868077|NCT00195858|Active Comparator|Diet and Resistane Exercise|
9868078|NCT00195858|Active Comparator|Diet and Combined Aerobic and Resistance Exercise|
9868079|NCT00195858|Other|Diet-only control group|
9868080|NCT00195884|Experimental|Aerobic Group|Aerobic training is divided into three stages: the Starter phase (during the run-in period), the Progression phase, and the Maintenance phase. All aerobic activities are performed on a cycle ergometer, treadmill, elliptical exercise machine or stairclimber. Subjects are free to vary the machine(s) used from one visit to the next. Exercise intensity is standardized using Polar Heartminder heart rate monitors that display the subject's heart rate and emits a warming signal when heart rate is outside the prescribed training zone, thus guiding the subject in adjustment of the work load up or down to achieve the desired intensity.
9868081|NCT00195884|Experimental|Resistance Group|"Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row (back), seated biceps curls, supine bench press (chest), leg press, shoulder press (shoulders and neck); leg extension (quadriceps)~Group B: abdominal crunches, lat pulldown (back), sitting chest press (chest), leg press, upright row (shoulders and neck), triceps pushdown, leg curls (hamstrings).~Subjects are instructed to exhale while lifting a weight and inhale while lowering it, in order to minimize blood pressure excursions. Warm-up and cooldown are the same as for aerobic training."
9868082|NCT00195884|Experimental|Combined Aerobic and Resistance Training|Combined aerobic and resistance training. This group will perform both aerobic and resistance training programs, as described above. The aerobic and resistance components are performed on the same days, in varying orders.
9868083|NCT00195884|No Intervention|Control Group|Members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
9868084|NCT00195910|Active Comparator|Morphine|"single dose of intravenous (IV) morphine, 0.1 mg/kg~intervention: 0.1 mg/kg IV morphine"
9868085|NCT00195910|Experimental|Hydromorphone|"single dose of intravenous (IV) hydromorphone, 0.015 mg/kg~intervention: 0.015 mg/kg IV hydromorphone"
9868086|NCT00195936|Experimental|Overall Study|Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
9868087|NCT00195975||1|Children with FD
9868088|NCT00195975||4|Healthy controls
9868089|NCT00196092|Other|1|Roll-in
9868090|NCT00196092|Other|2|Surgical
9868091|NCT00196092|Other|3|Standard Risk
9868092|NCT00196092|Other|4|High Risk
9868093|NCT00196092|Other|5|Compassionate Use
9868094|NCT00196092|Other|6|Treatment for females.
9868095|NCT00196092|Other|7|Standard Risk Continued Access
9868096|NCT00196092|Other|8|High Risk Continued Access
9868097|NCT00196131|No Intervention|0|
9868098|NCT00196144|Experimental|1|Optimization of the postventricular atrial blanking period to avoid far-field R-wave sensing.
9868099|NCT00196144|Experimental|2|Programming of the nominal setting for the post-ventricular atrial blanking period (100 ms)
9868100|NCT00196157|Experimental|1|linear lesions to ablate persistent atrial fibrillation
9868101|NCT00196157|Experimental|2|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
9868102|NCT00196170|Experimental|1|8mm tip ablation catheter for ablation of cavotricuspid isthmus
9868103|NCT00196170|Experimental|2|irrigated tip ablation catheter for ablation of cavotricuspid isthmus
9868104|NCT00196170|Experimental|3|cryo 10mm tip ablation catheter for ablation of cavotricuspid isthmus
9868105|NCT00196170|Experimental|4|Cryo 6.5mm tip ablation catheter for ablation of cavotricuspid isthmus
9868106|NCT00196183|Experimental|1|trigger-guided ablation of paroxysmal atrial fibrillation
9868107|NCT00196183|Experimental|2|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
9868108|NCT00196209|Experimental|1|catheter ablation to treat persistent atrial fibrillation
9868109|NCT00196209|Experimental|2|cardioversion and drug prophylaxis to treat persistent atrial fibrillation
9868110|NCT00196222|Experimental|1|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
9868111|NCT00196222|Experimental|2|cryo energy ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
9927811|NCT00898209||Health Volunteers|Blood and exhaled breath condensate will be collected.
9927812|NCT00898209||Patients at risk or already identified as having lung cancer|Blood and exhaled breath condensate will be collected.
9927813|NCT00898274||High risk for developing prostate cancer|Male subjects age 45-65 at high risk for developing prostate cancer.
9927814|NCT00898274||Healthy participants|Aged matched healthy participants
9927815|NCT00898287|Experimental|P276-00 plus Gemcitabine|"Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/m2/day x 5 q 3 weeks Level 2 - 140 mg/m2/day x 5 q 3 weeks Level 3 - 185 mg/m2/day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.~Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity."
9927816|NCT00898300||Patients with confirmed or suspected head and neck cancer|
9927817|NCT00898313||Sample Collection|
9927818|NCT00898326||Biopsy 36 month after breacchytherapy|Biopsy 36 month after breacchytherapy on protocol JUSMH-BRI-GU05-01.
9517627|NCT03304587|Active Comparator|Arm 2: Dim red light|"Dim red light (5 lux) (control group) for 30 minutes once a day.~--For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
9927819|NCT00898378||Colorectal Cancer Patients|Patients with stages I/II, III and IV colorectal cancer
9927820|NCT00898378||Colorectal Polyps Patients|Patients with adenomatous polyp(s) after colonoscopy.
9927821|NCT00898378||Healthy Controls|No abnormalities after colonoscopy.
9935859|NCT03071757|Experimental|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
9868112|NCT00196352|Experimental|1|
9868113|NCT00196365|Experimental|1|
9868114|NCT00196365|Active Comparator|2|
9868115|NCT00196378|Experimental|1|
9868116|NCT00196378|Placebo Comparator|2|
9868117|NCT00196391|Experimental|1|
9868118|NCT00196391|Experimental|2|
9868119|NCT00196391|Experimental|3|
9868120|NCT00196391|Experimental|4|
9868121|NCT00196391|Experimental|5|
9868122|NCT00196391|Placebo Comparator|6|
9868123|NCT00196404|Experimental|1|
9868124|NCT00196404|Experimental|2|
9868125|NCT00196404|Placebo Comparator|3|
9868126|NCT00196560|Experimental|exernal rotation|external rotation at 90 degrees
9868127|NCT00196573|Active Comparator|Shoulder bursectomy and acromioplasty|
9868128|NCT00196755|Experimental|Sevelamer Hydrochloride (Renagel®)|
9868129|NCT00196755|Active Comparator|Calcium acetate (PhosLo® )|
9868130|NCT00196781|Experimental|the Information + Decision Aid group|
9517628|NCT03304574|No Intervention|Control|Participants will complete the electronic health assessment only and will not receive integrated personalized feedback
9517629|NCT03304574|Experimental|Intervention|Participants will complete the electronic health assessment and will receive integrated personalized feedback
9868131|NCT00196781|Active Comparator|Information Only group|
9868132|NCT00196807|Experimental|Information plus DA at home|
9868133|NCT00196807|Active Comparator|UC Information at home|
9868134|NCT00196807|Experimental|Information plus decision aid at clinic|
9868135|NCT00196807|Active Comparator|UC Information at clinic|
9868136|NCT00196820|Experimental|A|Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study
9868137|NCT00196859|Active Comparator|A|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
9868138|NCT00196859|Experimental|B|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
9868139|NCT00196872|Experimental|ETC-with Ibandronat|ETC follwoed by Ibandronat
9868140|NCT00196872|Experimental|ETC without Ibandronat|ETC not followed by Ibandronat
9868141|NCT00196872|Experimental|EC-TX with Ibandronat|EC-TX followed by Ibandronat
9868142|NCT00196872|Experimental|EC-TX without Ibandronat|EC-TX not followed by Ibandronat
9868143|NCT00197444|Experimental|1|Chemoradiotherapy
9868144|NCT00197548|Active Comparator|Multivitamins|Multivitamins-vitamins B-complex, C, and E
9868145|NCT00197548|Placebo Comparator|Placebo|Placebo pill
9868146|NCT00197561|Active Comparator|Selenium|Selenium (200 ug as selenomethionine)
9868147|NCT00197561|Placebo Comparator|Placebo|Placebo
9868148|NCT00197587|Active Comparator|maternal nevirapine|
9868149|NCT00197587|Placebo Comparator|maternal placebo|
9868150|NCT00197652||Diarrheal specimens from infants born to HIV infected mothers|400 diarrheal specimens will suffice to determine the prevalence of specific pathogens in the region. Of these, 300 specimens will be collected from infants born to HIV infected mothers, and 100 specimens will be collected from infants born to HIV uninfected mothers.
9868151|NCT00197652||Breast milk from HIV infected and HIV uninfected women|Breast milk from HIV infected and HIV uninfected women who are breastfeeding is collected at 2 days, 2 weeks, 2 months, and 5 months post-partum. This breast milk will be compared for in vitro functional quality of immunoglobulins to selected diarrheal and respiratory pathogens.
9868152|NCT00197678|Experimental|Multivitamins-Single RDA|Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
9868153|NCT00197678|Active Comparator|Multivitamins-Multiples of RDA|Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
9868154|NCT00197704|Placebo Comparator|Placebo|Placebo
9868155|NCT00197704|Experimental|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium
9868156|NCT00197730|Experimental|Multivitamins|Vitamin E, Vitamin C, and Vitamin B complex
9868157|NCT00197730|Placebo Comparator|Placebo|Placebo
9868158|NCT00197743|Active Comparator|Vitamin A|Vitamin A + Beta Carotene
9868159|NCT00197743|Active Comparator|Multivitamins|Vitamins B, C, and E
9868160|NCT00197743|Active Comparator|Vitamin A + Multivitamins|Vitamin A + Beta Carotene, Vitamins B, C, and E
9868161|NCT00197743|Placebo Comparator|Placebo|Placebo
9868162|NCT00197756||Vitamin A|Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
9868163|NCT00197756||No Vitamin A|Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
9868164|NCT00197756||Multivitamins|Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
9868165|NCT00197756||No Multivitamins|Participants from the parent study who had been randomized to vitamin A alone or placebo
9868166|NCT00197808|Experimental|Vaccine schedule 1|Menjugate vaccine at 2 and 3 months
9868167|NCT00197808|Experimental|Vaccine schedule 2|Menjugate vaccine at 2 and 4 months
9868168|NCT00197808|Experimental|vaccine schedule3|Neissvacc at 2 and 3 months
9868169|NCT00197808|Experimental|vaccine schedule 4|Neissvacc at 2 and 4 months
9868170|NCT00197808|Experimental|Vaccine schedule 5|Meningitec at 2 and 3 months
9868171|NCT00197808|Experimental|Vaccine schedule 6|Meningitec at 2 and 4 months
9927822|NCT00898391||Ancillary-Correlative|Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
9927823|NCT00898404||Arm I|Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
9927824|NCT00898430||Head and neck squamous cell carcinoma patients (HNSCC)|
9927825|NCT00898456||Group 1|Leukemia blast cells obtained from bone marrow aspirate or peripheral blood at diagnosis are used to study polymorphisms and haplotypes of ATP-binding cassette (ABC) B1, ABCC1, ABCG2, and other candidate genes. Multidrug resistance (MDR) protein expression and function are also analyzed using leukemia blast cells from patients enrolled on CALGB-9760.
9927826|NCT00898482||Healthy individuals|
9927827|NCT00898482||At risk individuals|
9927828|NCT00898482||Cancer patients|
9927829|NCT00898508||Normal benign breast disease or ductal carcinoma in situ|
9927830|NCT00898508||Invasive breast cancer|
9927831|NCT00898521|Experimental|DGD|
9927832|NCT00898534|Experimental|Immediate Feedback|Subjects receive point-of-care hemoglobin A1c testing prior to their diabetes clinic visit, with results made available to the provider during the visit.
9927833|NCT00898534|No Intervention|Conventional Feedback|Subjects receive laboratory hemoglobin A1c testing at the clinic visit, with results made available to the provider several days later.
9927834|NCT00898547||Group 1|Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
9927835|NCT00898599|Placebo Comparator|Maltodextrin|
9927836|NCT00898599|Experimental|Prebiotic|Inulin type fructooligosaccharides
9795818|NCT01546675|Experimental|Skeletal Stabilization 1, Traditional 2|Subjects using the socket hypothesized to increase skeletal stabilization and Traditional Socket and in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
9927837|NCT00898716|Experimental|BMS-754807|
9927838|NCT00898742||head and neck cancer patients|
9927839|NCT00898768|Other|capsule endoscopy|capsule endoscopie at baseline and after 2 years
9927840|NCT00898781||Metastatic Breast Cancer|
9927841|NCT00898781||Metastatic Ovarian Cancer|
9927842|NCT00898781||Metastatic Pancreatic Cancer|
9795819|NCT01546688|Active Comparator|Zonisamide at targeted daily doses of 100-500 mg/day|
9795820|NCT01546688|Placebo Comparator|Placebo administered to match daily doses of 100-500 mg/day|
9795821|NCT01546857|Placebo Comparator|placebo|Placebo one dose in the evening of surgery and post op day #1.
9795822|NCT01546857|Active Comparator|Gabapentin|Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
9795823|NCT01546922|Active Comparator|First low dose HC followed by high dose HC|First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
9795824|NCT01546922|Active Comparator|First high dose HC followed by low dose HC|First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight
9795825|NCT01547000|Placebo Comparator|Inactive placebo|
9795826|NCT01547000|Experimental|Extended-release Guanfacine|
9795827|NCT01547130|Active Comparator|BLS and Yoga exercise|Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
9795828|NCT01547130|Active Comparator|PEG (HalfLytely)|Patients followed the preparation method according to the manufacturer's standard instructions.
9795829|NCT01547247|Experimental|cap-assisted water immersion colonoscopy|Cap-fitted colonoscopy using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
9795830|NCT01547247|Active Comparator|water immersion colonoscopy|Standard colonoscopy without attached cap using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
9795831|NCT01547286|Experimental|Allergic asthmatic|
9927843|NCT00898781||Metastatic Colon Cancer|
9927844|NCT00898781||Stage 3 Ovarian Cancer|
9927845|NCT00898781||Locally Advanced Pancreatic Cancer|
9927846|NCT00898833||Group 1|Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.
9927847|NCT00898846||UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
9795832|NCT01547299|Experimental|Enzalutamide alone|Enzalutamide 160 mg, orally, once daily
9795833|NCT01547299|Experimental|Enzalutamide & Leuprolide & Dutasteride|Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
9795834|NCT01547390|Experimental|Aspirin|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
9795835|NCT01547390|Placebo Comparator|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
9795836|NCT01547598|Active Comparator|LUMIGAN® RC|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
9795837|NCT01547598|Active Comparator|DuoTrav®|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
9795838|NCT01547715|Experimental|MenACWY - 2 - 10 Years old|Subjects between 2 and 10 years of age who received one injection of Meningococcal ACWY conjugate vaccine -CRM vaccine on day 1.
9795839|NCT01547715|Experimental|MenACWY - 11 - 18 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
9795840|NCT01547715|Experimental|MenACWY - 19 - 75 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
9795841|NCT01547780|Experimental|Baseline brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to baseline brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
9795842|NCT01547780|Experimental|Repeat brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to repeat brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
9795843|NCT01547780|Experimental|Single brain PET in Chronic TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Chronic (5 months - 5 years post-injury) traumatic brain injury (TBI) patients.
9795844|NCT01547780|Experimental|Single brain PET in healthy subjects|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Healthy Subjects.
9795845|NCT01547806|Experimental|Hematopoietic Progenitor Cells (HPC)|Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.
9795846|NCT01548040|Experimental|quadriceps NMES using Kneehab XP|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation (NMES) using Kneehab XP on the affected leg, 20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
9795847|NCT01548040|Sham Comparator|quadriceps TENS|The sham device will look identical to the Kneehab XP device. All subjects in the control group will receive quadriceps Transcutaneous Electrical Nerve Stimulation (TENS) at a minimal sensory input using Kneehab XP on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
9795848|NCT01548287|Experimental|AZD5213 doseA|AZD5213 doseA daily
9795849|NCT01548287|Experimental|AZD5213 doseB|AZD 5213 doseB daily
9795850|NCT01548287|Experimental|AZD5213 doseC|AZD5213 doseC daily
9795851|NCT01548287|Placebo Comparator|Placebo|Placebo daily
9795852|NCT01548339|Active Comparator|Delayed|Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
9795853|NCT01548339|Experimental|Early|Laparoscopic cholecystectomy performed directly after the initial diagnosis
9795854|NCT01548404|Placebo Comparator|Placebo|Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
9795855|NCT01548404|Experimental|Dupilumab 300 mg|Dupilumab 300 mg once weekly for 12 weeks by SC injection.
9795856|NCT01548417|Active Comparator|Korlym (mifepristone)|600 mg daily taken orally for one week
9795857|NCT01548417|Placebo Comparator|Sugar Pill|placebo pill daily taken orally for one week
9795858|NCT01548573|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
9795859|NCT01548599|Experimental|Multi-sectoral agricultural intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
9795860|NCT01548599|No Intervention|Control|Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.
9795861|NCT01548638|Experimental|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
9795862|NCT01548690|Experimental|Ornithine·Phenylacetate|Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.
9795863|NCT01548742|Experimental|Arm 1: Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR)
9868172|NCT00198055|Experimental|Aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
9868173|NCT00198068||Group 1: aPL+/SLE-|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units; no SLE
9868174|NCT00198068||Group 2: aPL+/SLE+|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.
9868175|NCT00198068||Group 3: aPL-/SLE+|No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.
9868176|NCT00198068||Group 4: aPL-/SLE-|Healthy controls: no antiphospholipid antibodies; no SLE
9868177|NCT00198120|Experimental|1|Participants will receive D-Cycloserine for 8 weeks.
9868178|NCT00198120|Placebo Comparator|2|Participants will receive placebo for 8 weeks.
9868179|NCT00198341|Experimental|1|Radiological arm (Clinical Visit + X-Ray Chest)
9868180|NCT00198341|Experimental|2|Scan ARM : Clinical Visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous type)
9868181|NCT00198354|Experimental|A: pre-operative chemotherapy|pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
9868182|NCT00198354|Experimental|B: pre-operative chemotherapy|pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
9868183|NCT00198354|Experimental|C: peri-operative chemotherapy|peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
9868184|NCT00198354|Experimental|D: peri-operative chemotherapy|peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
9868185|NCT00198367|Experimental|Cisplatin-Gemzar|Cisplatin-Gemzar
9868186|NCT00198367|Experimental|Cisplatin-Navelbine-Radiotherapy|Cisplatin-Navelbine-Radiotherapy
9868187|NCT00198367|Experimental|Carboplatin-Taxol-Radiotherapy|Carboplatin-Taxol-Radiotherapy
9868188|NCT00198380|Experimental|1|
9868189|NCT00198393|Experimental|A|Gefitinib
9868190|NCT00198393|Experimental|B|Gemcitabine
9868191|NCT00198393|Experimental|C|Docetaxel
9868192|NCT00198419|Experimental|Vitrase|a single intradermal dose of 3 USP Units of Vitrase (ovine hyaluronidase) at one site and the same volume of saline at a distant site for comparative control
9868193|NCT00198445|Experimental|Bromfenac|Topical bromfenac ophthalmic solution 0.1%
9868194|NCT00198445|Placebo Comparator|Placebo|Vehicle of bromfenac
9868195|NCT00198458|Experimental|Vitrase|A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control.
9868196|NCT00198471|Experimental|Vitrase|A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.
9868197|NCT00198484|Experimental|Vitrase|ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery
9868198|NCT00198497|Experimental|Vitrase|Single Hyaluronidase ophthalmic intravitreal injection
9868199|NCT00198497|Placebo Comparator|Placebo|Single Saline solution intravitreal injection
9868200|NCT00198510|Experimental|Vitrase|A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
9868201|NCT00198510|No Intervention|Observation|Observation only, no medication or intravitreal injection
9868202|NCT00198523|Experimental|Prednisolone and Tobramycin|Prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
10210622|NCT04568590|Experimental|Vaccine Hesitant|Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention.
10210623|NCT04566731|Active Comparator|tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of tDCS for 20 minutes using a montage in which an anode (1.5 mA) is placed over F7 (left frontotemporal lobe) and the cathode will be place on O1 (left occipital) using the 10-20 EEG mapping system. Subjects will participate in a modified constraint-induced language therapy.
10210624|NCT04566731|Sham Comparator|Sham tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham tDCS for 20 minutes using a montage in which an anode is placed of F7 and cathose is placed over O1. Subjects will participate in a modified constraint-induced language therapy,
10210625|NCT04557449|Experimental|1A Monotherapy Escalation Arm 1|PF-07220060 Monotherapy Escalation
10210626|NCT04557449|Experimental|1A Monotherapy Escalation Arm 2|PF-07220060 Monotherapy Escalation
10210627|NCT04557449|Experimental|1A Monotherapy Escalation Arm 3|PF-07220060 Monotherapy Escalation
10210628|NCT04557449|Experimental|1A Monotherapy Escalation Arm 4|PF-07220060 Monotherapy Escalation
10210629|NCT04557449|Experimental|1B Combination Dose Finding Arm 1|PF-07220060 with Letrozole combination Escalation
10210630|NCT04557449|Experimental|1B Combination Dose Finding Arm 2|PF-07220060 with Letrozole Combination Escalation
10210631|NCT04557449|Experimental|1C Combination Dose Finding Arm 1|PF-07220060 with Fulvestrant Combination Escalation
10210632|NCT04557449|Experimental|1C Combination Dose Finding Arm 2|PF-07220060 with Fulvestrant Combination Escalation
10210633|NCT04557449|Experimental|2B Combination Dose Expansion|PF-07220060 with Letrozole Combination Expansion
10210634|NCT04557449|Experimental|2C Combination Dose Expansion|PF-07220060 with fulvestrant Combination Expansion
10210635|NCT04557449|Experimental|1D Monotherapy Food Effect|PF-07220060 Monotherapy Food Effect
10210636|NCT04557449|Experimental|1A Monotherapy Escalation Arm 5|PF-07220060 Monotherapy Escalation
10210637|NCT04530409|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
10210638|NCT04530409|No Intervention|Late CS|Dexamethasone is to be used lately upon the deterioration of cases i.e. sPO2 < 92%
10210639|NCT04510545||Treatment Group|All patients will undergo CAD of any diminutive polyps found in the rectosigmoid on colonoscopy
10213696|NCT03496259|Experimental|On-Q Group|Patients in this group will have an On-Q pump placed at the end of the operation
9868203|NCT00198523|Active Comparator|Prednisolone|Prednisolone acetate 1.0% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
9868204|NCT00198536|Experimental|Ecabet 2.83%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
9868205|NCT00198536|Experimental|Ecabet 3.70%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
9868206|NCT00198536|Placebo Comparator|Vehicle|One drop of vehicle in study eye 4 times daily for 90 days.
9868207|NCT00198562|Active Comparator|1|target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
9868208|NCT00198562|Active Comparator|2|antihypertensive drug (amlodipine vs losartan)
9868209|NCT00198666|Experimental|Treatment|Children with severe pneumonia were randomly assigned to receive supplementation with elemental zinc.
9868210|NCT00198666|No Intervention|Control|Children with severe pneumonia were randomly assigned to receive supplementation with placebo tablets.
9868211|NCT00198718|Experimental|Infant vitamin A Mother vitamin A|Infant received 50,000 IU vitamin A, mother received 400,000 IU vitamin A
9868212|NCT00198718|Experimental|Infant vitamin A Mother placebo|Infant received 50,000 IU vitamin A, mother received placebo
9868213|NCT00198718|Experimental|Infant placebo, mother vitamin A|Infant received placebo, mother received 400,000 IU vitamin A
9868214|NCT00198718|Experimental|Infant received placebo, mother received placebo|Infant and mother received placebo
9868215|NCT00198770|Experimental|Crossover design - 1 arm|Meat week followed by mushroom week, counterbalanced order
9868216|NCT00198796|Experimental|H10407|H10407
9868217|NCT00198861||Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors
9868218|NCT00198874|Active Comparator|Psychoeducation|
9868219|NCT00198874|Experimental|Conitive Behavorial Therapy|
9868220|NCT00198874|Experimental|Family Therapy|
9868221|NCT00198874|Experimental|Intergrated Family|
9868222|NCT00198939|Active Comparator|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
9868223|NCT00198939|Experimental|Conitive Behavorial Therapy|The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
9868224|NCT00198939|Experimental|Family Therapy|Participants assigned to the Family Therapy arm received a family-centered intervention to support targeted adolescent behavior change. The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases.
9868225|NCT00198939|Experimental|Intergrated Family and Cognitve Behavioral Therapy|Participants assigned to the IFCBT arm received the Cognitive Behavioral Therapy and Family Therapy intervention components.
9868226|NCT00199134|Other|Letrozole|Letrozole 2.5 mg per day
9868227|NCT00199290|Placebo Comparator|P|
9868228|NCT00199290|Experimental|L|low dose (0.2 %)
9868229|NCT00199290|Experimental|M|medium dose (0.3 %)
9868230|NCT00199290|Experimental|H|high dose (0.4 %)
9927848|NCT00898846||Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
9927849|NCT00898859||1|Healthy, non-smoking
9927850|NCT00898859||2|healthy, ex-smoking
9927851|NCT00898859||3|healthy, current-smokers
9927852|NCT00898859||4|COPD, ex-smokers
9927853|NCT00898859||5|COPD, smokers
9927854|NCT00898885||Bone Marrow Transplantation|
9927855|NCT00898898||Arm I|Tissue samples from protocol NCCTG-N9831 are obtained for immunohistochemistry and fluorescence in situ hybridization analysis of MYC, IGF- 1R, PTEN, and TOP2A genes. Exons 9 and 20 of PIK3CA gene are amplified via polymerase chain reaction; mutations in exons 9 and 20 of PIK3CA gene are identified.
9927856|NCT00898924||Group 1|Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
9927857|NCT00898950|Experimental|Aspirin low dose|Effects of using aspirin 75 mgs/day for 2 weeks.
9868231|NCT00199485|Experimental|1|Angelica Sinensis
9868232|NCT00199485|Placebo Comparator|2|placebo
9868233|NCT00199498|Experimental|Septal RV lead placement|patient randomized to Septal RV lead placement
9868234|NCT00199498|Active Comparator|Apical RV lead placement|patient randomized to Apical RV lead placement (current standard placement)
9868235|NCT00199524|Active Comparator|1|ureteroscopy with ureteral access sheath
9517117|NCT03309345||Case group, PKU group|Children and adults (10 - 45 years old) with PKU attending the metabolic medicine clinics in the area of National Health Services (NHS) Greater Glasgow and Clyde (GGC) will be approached for recruitment. Participants will be free from history of acute and chronic illness (other than PKU) requiring regular appointments to the doctor and/or chronic use of medication or major gastrointestinal surgery where major part of the gut has been resected as these conditions are known to impact on energy expenditure and dietary intake. Pregnant or lactating women will also be excluded from participation. People with learning or mobility difficulties or those with incapacity to provide informed consent will be excluded too. The clinical treatment team will evaluate patients' capacity to consent before considering them to participate in the study.
9868236|NCT00199524|No Intervention|2|ureteroscopy without ureteral access sheath
9868237|NCT00199550|Active Comparator|2|Bipolar Electrosurgical Unit
9868238|NCT00199550|Active Comparator|1|Monopolar Electrosurgical Unit
9868239|NCT00199563|Active Comparator|active drug|Viagra 100 mg / daily for 12 weeks.
9868240|NCT00199563|Placebo Comparator|Placebo|placebo/daily for 12 weeks
9868241|NCT00199602|No Intervention|lack of drug prophylaxis|
9868242|NCT00199602|Experimental|HBPM 2500 UI anti Xa in one subcutaneous injection per day|
9868243|NCT00199602|Experimental|warfarine 1mg daily|
9868244|NCT00199927|Active Comparator|standard therapy|Standard therapy
9868245|NCT00199927|Active Comparator|fluvastatin|40-80 mg/day
9868246|NCT00200005|Experimental|InterStim therapy|Patients being treated with sacral neuromodulation with InterStim therapy.
9868247|NCT00200044|Sham Comparator|Sham|This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
9868248|NCT00200044|Active Comparator|Treatment|The treatment arm has the Gatekeeper devices implanted.
9868249|NCT00200083|Active Comparator|A|"All subjects enrolled will be implanted with an IGS system. The active group are those randomized to on and will receive active stimulation for 12 months."
9868250|NCT00200083|Placebo Comparator|B|"All subjects enrolled will be implanted with an IGS system. The placebo group are those randomized to off and will receive no stimulation for 12 months."
9868251|NCT00200096|Active Comparator|1|Acupuncture and questionnaires
9868252|NCT00200096|Sham Comparator|2|placebo acupuncture and questionnaires
9868253|NCT00200109|Other|Group 1|See protocol
9868254|NCT00200109|Other|Group 2|See protocol
9868255|NCT00200109|Other|Group 3|See protocol
9868256|NCT00200109|Other|Group 4|See protocol
9868257|NCT00200135||1|Treated and released from ED (minor injuries)
9868258|NCT00200135||2|Trauma, admitted to the hospital (injured)
9868259|NCT00200135||3|Fatalities reported by the coroner (deaths)
9868260|NCT00200135||4|Reported by the police (No medical treatment)
9868261|NCT00200148|Experimental|1|For patients randomized to ANH
9868262|NCT00200148|Active Comparator|2|standard intraoperative management
9868263|NCT00200174|Active Comparator|A|Raloxifene followed by combination therapy
9868264|NCT00200174|Active Comparator|B|Exemestane followed by combination therapy
9868265|NCT00200226|Placebo Comparator|1|Vitamin B6
9868266|NCT00200226|Active Comparator|2|misoprostol
9868267|NCT00200239|Experimental|1|Behavioral: eating breakfast from portioned and unportioned foods
9868268|NCT00200239|Experimental|2|Behavioral: eating breakfast with portioned and unportioned foods
9868269|NCT00200252|Active Comparator|group B|women in group B will receive 10 uts oxytocin IM
9868270|NCT00200252|Active Comparator|group C|women in group C will receive oxytocin 5 uts IV
9868271|NCT00200252|Active Comparator|group A|women in group A will receive oxytocin 5 uts IM
9868272|NCT00200265|Experimental|1|Behavioral: diet
9868273|NCT00200265|Experimental|2|Behavioral: diet
9868274|NCT00200265|Placebo Comparator|3|Behavioral: diet
9868275|NCT00200291|Experimental|1|Behavioral: hypocaloric low-fat diet
9868276|NCT00200291|Placebo Comparator|2|Behavioral: hypocaloric, low-fat diet
9868277|NCT00200395|Experimental|OSI-774 (Tarceva)|Oral treatment with OSI-774 (Tarceva) will be given as a 150 mg tablets daily for 14 days. On day 15 and if there are no adverse effects the dose will be increased to 200 mg.
9868278|NCT00200408||smokers|college students who smoke
9868279|NCT00200408||non smokers|college students who don't smoke
9868280|NCT00200577|Experimental|TIL+IL2|TIL + IL2
9868281|NCT00200577|No Intervention|control|Patients are not treated
9868282|NCT00200707|Experimental|The treatment group|Intracoronary Injection of Autologous Bone Marrow Mononuclear C
9868283|NCT00200707|No Intervention|the control group|
9927858|NCT00898950|Experimental|Aspirin medium dose|Effects of using aspirin 300 mgs/day
9868284|NCT00200720|Experimental|Atkins Diet|Participants randomized to this arm will consume a low carbohydrate diet as described by Dr. Robert Atkins in his book: Dr. Atkins' New Diet Revolution New York: Avon Books, 2002.
9868285|NCT00200720|Active Comparator|DASH Diet|Participants randomized to this arm will consume the Dietary Approaches to Stop Hypertension (DASH) diet as described here: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf
9868286|NCT00200746|Experimental|2|Moderate Arginine
9868287|NCT00200746|Sham Comparator|3|Polycose control arm
9868288|NCT00200746|Experimental|1|High Arginine
9868289|NCT00200863|Experimental|1|420 nm light
9868290|NCT00200863|Experimental|2|480 nm
9868291|NCT00200863|Experimental|3|507 nm
9868292|NCT00200863|Experimental|4|555 nm
9868293|NCT00200863|Experimental|5|620 nm
9868294|NCT00200863|Experimental|6|460 nm
9868295|NCT00200876|Active Comparator|pain challenge|
9868296|NCT00200876|Sham Comparator|non-painful control|
9868297|NCT00200954|Placebo Comparator|placebo|placebo group
9868298|NCT00200954|Active Comparator|2|Probiotic bacteria group
9868299|NCT00201019|Experimental|1|Active intervention participants receive a physician-pharmacist collaborative intervention.
9868300|NCT00201019|No Intervention|2|Control participants do not receive recommendations from a clinical pharmacist.
9868301|NCT00201019|No Intervention|3|Passive intervention participants receive care by the same physicians caring for participants in the active intervention arm but are not seen by a clinical pharmacist. They are not actively enrolled in the study and do not have study visits for measuring blood pressure.
9927859|NCT00898950|Experimental|aspirin high dose|aspirin 900mgs QID orally for 2 weeks
9927860|NCT00898950|Placebo Comparator|placebo|
9927861|NCT00898976||Group I|Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R. PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150 from Caucasian women) will be accrued for this study.
9927862|NCT00898989||Inclusion Body Myositis|
9927863|NCT00898989||Control|
9927864|NCT00899041|Active Comparator|Standard knee prosthesis|'standard' knee prosthesis (Sigma FB, J&J, UK).
9927865|NCT00899041|Active Comparator|High flexion knee prosthesis|'high flexion' knee prosthesis (Sigma RP-F, J&J, UK).
9927866|NCT00899054|Experimental|P276-00 plus Radiation|"P276-00:~Level 1:100 mg/m2/day x 5 q 3 weeks, level 2:140 mg/m2/day x 5 q 3 weeks, level 3: 185 mg/m2/day x 5 q 3 weeks.~External beam radiotherapy (EBRT):~2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 2 cycles (6 weeks)followed by upto 10 additional Gy if required"
9927867|NCT00899093||Ancillary-Correlative (serum collection for YKL-40 and CA125)|Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
9927868|NCT00899145||Ancillary-Correlative (biomarker sampling and analysis)|Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
9927869|NCT00899223||Group 1|Previously untreated patients on a CALGB treatment protocol for leukemia (acute or chronic) or myelodysplasia are eligible. Patients must be registered to CALGB 9665 prior to receiving any therapy for their disease.
9927870|NCT00899288|Experimental|tamoxifen and no bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
9927871|NCT00899288|Experimental|Letrozole and no bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
9927872|NCT00899288|Experimental|Tamoxifen and bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
9996966|NCT01504685|Active Comparator|Banded laparoscopic gastric bypass|Placement of a premeasured band or ring around the gastric reservoir, adjacent to the gastroenterostomy.
9927873|NCT00899288|Experimental|Letrozole and bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
9927874|NCT00899301||Patients with Breast Cancer|
9927875|NCT00899301||Patients without breast cancer|
9927876|NCT00899457||Healthy, non-smokers|
9927877|NCT00899483|Active Comparator|1|Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L
9927878|NCT00899483|No Intervention|2|Normal departmental practice using dextrose insulin infusion
10210640|NCT04507321|Experimental|GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension|Participants will receive a single oral dose of GSK3640254 200 milligram (mg) (2×100 mg) tablets with a moderate fat meal. Participants will then be administered a 100 microgram (mcg) dose (approximately 3.7 kilobecquerel; 100 nano Curie) of [14C]-GSK3640254 as an IV infusion for 1 hour on Day 1 in treatment Period 1, On Day 1 in treatment Period 2, participants will receive a single oral dose of 85 mg (approximately 3.15 megabecquerel; 85 micro Curie) [14C]-GSK3640254 administered as an oral suspension with a moderate fat meal. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
10210641|NCT04505774|Other|Therapeutic Dose Anticoagulation|"increased dose of heparin above standard of care.~1.0 - This arm was stopped in severe patients in December 2020 and results are published in PMID: 34351722 (NEJM, August, 2021) (see reference section for citation) 1.1 - this arm was stopped for moderate patients in June 2021"
10210642|NCT04505774|Other|Prophylactic Dose Anticoagulation|"Heparin standard of care~1.0 - this arm was stopped for all patients in January, 2021 and results are published in PMID: 34351721 (NEJM, August, 2021) (see reference section for citation) 1.1 - this arm was reinstated for severe patients."
10210643|NCT04505774|Other|Therapeutic Dose Anticoagulation + P2Y12 inhibitor|"increased dose of heparin above standard of care with an added P2Y12 inhibitor~This Arm enrolled moderate illness patients only. Enrollment of moderate illness patients in the trial was ended per DSMB on June 19, 2021."
9517630|NCT03304561|Experimental|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
10210644|NCT04505774|Other|Prophylactic Dose Anticoagulation + P2Y12 inhibitor|"Heparin standard of care with an added P2Y12 inhibitor~This Arm enrolled severe illness patients only."
10210645|NCT04505774|Other|Standard of Care + Crizanlizumab|"Standard of care plus crizanlizumab infusion~This arm will enroll moderate and severe illness patients"
9795864|NCT01548742|Active Comparator|Arm 2: Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT)
9795865|NCT01548768|Experimental|Patients - DMARDs + TNF Inhibitors|Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.
9795866|NCT01548768|Active Comparator|Patients - DMARDs only|Patients will receive their current treatment in an open label protocol in the context of standard of care.
9795867|NCT01548768|No Intervention|Healthy Volunteers|Subjects without RA who will function as controls.
9795868|NCT01548833|Experimental|Dailies Total 1|Delefilcon A, followed by narafilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
9795869|NCT01548833|Active Comparator|TruEye|Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
9795870|NCT01548833|Active Comparator|Clariti|Filcon II 3, followed by narafilcon A and delefilcon A in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
9795871|NCT01548885|Experimental|Study Staff Test BGMSs|All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
9795872|NCT01549002|Experimental|Intranasal Fentanyl|"Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).~The abscess I&D will be followed according to protocol using topical and local anesthetic."
9795873|NCT01549002|Active Comparator|Intravenous Morphine|"Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.~The abscess I&D will be followed according to protocol using topical and local anesthetic."
9795874|NCT01549041|Experimental|asenapine 10 mg daily in the evening|Patients will receive their entire daily dose of asenapine as a single dose in the evening
9795875|NCT01549041|Active Comparator|asenapine 5 mg twice daily|Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
9795876|NCT01549223|Active Comparator|Standard Care Group|"Standard Care Group (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion oxytocin. If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
9795877|NCT01549223|Active Comparator|Protocol Group|"Protocol Group will receive 3 mL syringes marked study solution-oxytocin which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).~If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked study solution-9 min, containing methylergonovine maleate (methergine) 0.2mg, will be given IM.~If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked study solution-12 min, containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
9795878|NCT01549314||Subjects with CF taking ivacaftor|Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months
9795879|NCT01549314||Subjects with CF not taking ivacaftor|Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1
9795880|NCT01549314||Healthy subjects|Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.
9795881|NCT01549340||Participants with Allergic Rhinitis (AR)|Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
9795882|NCT01549392|Active Comparator|DECT/MR Spectroscopy +Avastin|-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
9795883|NCT01549392|Active Comparator|DECT/MR Spectroscopy no Avastin|15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
9795884|NCT01549405|No Intervention|Control group|Control group: Group that without intercostal nerve block
9795885|NCT01549405|Experimental|nerve block|Group that performing intercostal block
9795886|NCT01549587|Active Comparator|Regular Oral Hygiene|toothpaste, toothbrush and dental floss
9795887|NCT01549587|Experimental|Advanced Oral Hygiene plus counseling|toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
9795888|NCT01549613|Active Comparator|standard treatment with daptomycin|Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol
9795889|NCT01549613|Active Comparator|standard treatment of vancomycin|Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
9795890|NCT01549652|Experimental|Prevention of Opioid Withdrawal|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days, and then will be randomized to take either ondansetron 8 mg or matching placebo thirty minutes prior to naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will return to their titrated morphine dose for one week and then return for the opposite pre-treatment followed by naloxone-induced withdrawal in clinic. Participants will then taper back to their original dose of morphine for one week.
9795891|NCT01549652|Experimental|Prevention of Physical Dependence|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days; during morphine treatment, participants will be randomized to take either ondansetron 8 mg or matching placebo three times daily along with the oral morphine treatment. After thirty days, participants will return to the lab to undergo naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will then taper back to their original dose of morphine for one week.
9795892|NCT01549860|No Intervention|Standard of Care|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
9795893|NCT01549860|Experimental|SOC + Mist Therapy|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
9795894|NCT01549873|Active Comparator|Total intravenous anesthesia (TIVA)|
9795895|NCT01549873|Active Comparator|Inhaled anesthesia|
9795896|NCT01549886|Experimental|MGD + Rituximab + Y-90-Zevalin|"Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie / kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL."
9795897|NCT01549886|Active Comparator|Rituximab + Y-90-Zevalin|Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
9795898|NCT01549925|Other|standard surgical resection|standard surgical resection using clamps and surgical ligatures
9795899|NCT01549925|Active Comparator|LIGASURE|Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
9795900|NCT01549951|Experimental|Orteronel+Prednisone|
9795901|NCT01549964|Experimental|Fasiglifam (TAK-875) 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
9795902|NCT01549964|Experimental|Fasiglifam (TAK-875) 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
9868302|NCT00201045|Experimental|Intervention|Intervention patients receive care from a clinical pharmacist to improve blood pressure.
9868303|NCT00201045|No Intervention|Control|Control patients receive usual care and do not have a clinical pharmacist included in their care.
9868304|NCT00201058|Experimental|1|Receives tailored web-based program
9868305|NCT00201058|Active Comparator|2|Control students receive existing web-based, generic asthma education
9868306|NCT00201071||South Bronx, Harlem, Lower East Side|
9868307|NCT00201084|Active Comparator|1|Uncertainty reduction tools, at physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
9868308|NCT00201084|No Intervention|2|Usual primary care
9868309|NCT00201110|Experimental|1|Intensive Intervention: CVD Risk Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
9868310|NCT00201110|Active Comparator|2|Brief Intervention: CVD Risk Education (1 session) + Brief Health Problem-Solving Training (1 session)
9868311|NCT00201136|No Intervention|MD-C/PT-C|Physician and patient control group.
9868312|NCT00201136|Experimental|MD-I/PT-C|MD CQI-type intervention; Patient control
9868313|NCT00201136|Experimental|MD-C/Pt-I|MD control; patient behavioral intervention
9868314|NCT00201136|Experimental|MD-I/Pt-I|MD CQI-type intervention; Patient behavioral intervention
9868315|NCT00201149|Experimental|1|In one team of clinicians we will implement only the patient-centered counseling program.
9868316|NCT00201149|No Intervention|3|The control group will provide usual care
9868317|NCT00201149|Experimental|2|In a subset of those clinicians receiving the patient-centered counseling program intervention, we will augment it with cultural competency training.
9868318|NCT00201162|Experimental|Intervention|dietary supplement soy protein containing isoflavones
9868319|NCT00201162|Placebo Comparator|Placebo|dietary supplement casein placebo
9868320|NCT00201188|Experimental|1|Participants will receive feedback and peak flow monitoring reports from their doctors.
9868321|NCT00201188|No Intervention|2|Participants will receive usual care.
9868322|NCT00201227|Experimental|Practice Change|Enhancement of primary care practice performance and practice guideline adherence
9868323|NCT00201227|No Intervention|Control|Usual care
9868324|NCT00201266||Exacerbation resistant asthma|Control group
9868325|NCT00201266||Exacerbation prone asthma|Cases
9868326|NCT00201396|Active Comparator|A arm|CCRT
9868327|NCT00201396|Experimental|B arm|Induction/CCRT
9868328|NCT00201422|Experimental|Omeprazole, Amoxicillin, Clarithromycin|Anti-H. pylori Therapy (Triple therapy)
9868329|NCT00201461|Active Comparator|1|Best medical therapy
9868330|NCT00201461|Experimental|2|STARFlex arm
9868331|NCT00201474||brief depressive periods|brief depressive periods together with other fluctuating psychiatric symptoms
9868332|NCT00201474||major depressive disorder|
9868333|NCT00201500||preeclampsia|women with preeclampsia
9868334|NCT00201500||controls|healthy pregnant women
9868335|NCT00201513|Experimental|TrA exercise|Isolated Transversus abdominis (TrA) exercises (low load)
9868336|NCT00201513|Experimental|sling exercise|Sling exercises (high load)
9868337|NCT00201513|Active Comparator|group exercise|Non-specific group exercises
9868338|NCT00201539|Active Comparator|double dose once|double dose immediate-release oral morphine at bedtime in cancer patients, placebo after 4 hours
9868339|NCT00201539|Experimental|single dose twice|single dose immediate-release oral morphine at bedtime in cancer patients, second single dose after 4 hrs
9868340|NCT00201617||1|normal hearing sensitivity
9868341|NCT00201617||2|Unilateral deafness who are implanted with a Bone Anchored Hearing Aid
9868342|NCT00201656|Active Comparator|1 Retention of Cerclage|Group one = Subject whose Cerclage is retained after randomization.
9868343|NCT00201656|Active Comparator|2 - Removal of Cerclage|Group 2 = Subjects who will have cerclage removed after randomization
9868344|NCT00201669|Experimental|Arm I|
9868345|NCT00201682|Experimental|Arm I|Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).
9868346|NCT00201708|Active Comparator|Arm A (Docetaxel before doxorubicin/cyclophosphamide)|"Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles."
9868347|NCT00201708|Active Comparator|Arm B (Docetaxel after doxorubicin/cyclophosphamide)|"A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles."
9868348|NCT00201786|Experimental|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
9868349|NCT00201799|Experimental|Infliximab|Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
9868350|NCT00201890|Experimental|1|Standard of Care plus Lymphatic massage (Decongestive Lymphatic Therapy)
9868351|NCT00201890|No Intervention|2|Standard of Care
9868352|NCT00201916|Experimental|1|5250 cGy in 20 fractions over 28 days
9996967|NCT01504698|Experimental|Treatment with manipulation|
9795903|NCT01549964|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. TAK-875 placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
9795904|NCT01549964|Placebo Comparator|Placebo|Fasiglifam (TAK-875) placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
9795905|NCT01550224|Active Comparator|Participant Group 1 (methylated MGMT promoter)|Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
9795906|NCT01550224|Active Comparator|Participant Group 2 (non-methylated MGMT promoter)|Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
9795907|NCT01550341|Active Comparator|Buprenorphine|
9795908|NCT01550341|Placebo Comparator|Placebo|
9795909|NCT01550367|Experimental|Hydroxychloroquine + IL-2|One course of treatment (84 days) will consist of high dose (600,000 IU/kg) bolus IL-2 administered intravenously every 8 hours on days 1-5 and 15-19 (maximum 14 doses/5 days of administration) and hydroxychloroquine (HCQ) orally started two weeks prior to IL-2 infusions and continued while able to take oral medication for up to 3 courses.
9795910|NCT01550471|Experimental|1 Treatment Sequence-A and O, Q and B, P and P|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
9795911|NCT01550471|Experimental|2 Treatment Sequence-A and O, P and P, Q and B|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
9795912|NCT01550471|Experimental|3 Treatment Sequence-Q and B, A and O, P and P|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
9795913|NCT01550471|Experimental|4 Treatment Sequence-Q and B, P and P, A and O|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
9795914|NCT01550471|Experimental|5 Treatment Sequence-P and P, A and O, Q and B|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
9795915|NCT01550471|Experimental|6 Treatment Sequence-P and P, Q and B, A and O|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
9795916|NCT01550705|Experimental|Isoniazid|Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
9795917|NCT01550731|Experimental|PREPARE|The intervention group will review the PREPARE advance care planning website and PREPARE materials plus receive an advance directive. The control group will only receive an advance directive.
9795918|NCT01550731|Active Comparator|CONTROL|The control group will only receive an advance directive.
9795919|NCT01550744|Experimental|Group 1: Approved q12w maintenance regimen|Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
9795920|NCT01550744|Experimental|Group 2: Subject-tailored fixed-interval maintenance regimen|Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.
9795921|NCT01550757|No Intervention|Arm 1|Normal PACT Clinical Care
9795922|NCT01550757|Experimental|Arm 2|Normal PACT Clinical Care + Embedded Peer Mentor
9795923|NCT01550757|No Intervention|Arm 3|Normal Homeless Oriented PACT Clinical Care
9795924|NCT01550757|Experimental|Arm 4|Normal Homeless Oriented PACT Clinical Care + Embedded Peer Mentor
9795925|NCT01550809|Active Comparator|tBolus (traditional bolus)|Traditional mealtime insulin bolus based on the individual insulin-to-CHO ratio
9795926|NCT01550809|Experimental|iBolus (CGM-based insulin administration)|This is a CGM-based algorithm for prandial insulin administration. An individual patient's model characterizing a 5-hour postprandial period (0-5h PP) is obtained from a 6-day CGM period. A model with interval parameters accounting for patient's variability is calculated considering 20% uncertainty in insulin sensitivity and 10% in carbohydrates (CHO) estimation. Based on this model, constraints on plasma glucose are posed and a set-inversion problem lead to a set of solutions (the iBolus) that contains a bolus insulin dose, a specific mealtime basal insulin dose and the time for restoration of basal to baseline values.
9795927|NCT01550965|Experimental|Participants Receiving Adalimumab|Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.
9795928|NCT01551030|Experimental|Buparlisib|This is an open-label phase II study of the pan-class I selective phosphoinositide 3-kinase (PI3K) inhibitor Buparlisib in patients with metastatic urothelial carcinoma which has progressed despite treatment with prior cytotoxic chemotherapy.
9868353|NCT00201916|Active Comparator|2|6600 cGy in 33 fractions over 45 days
9795929|NCT01551056|Experimental|AC-170 0.24%|
9795930|NCT01551056|Placebo Comparator|AC-170 0%|
9795931|NCT01551095|Experimental|PEGJ|Patients in this arm will receive self-propelled balloon PEGJ tube.
9795932|NCT01551173|Experimental|Fluvastatin sodium Extended Release Tablet|Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks
9795933|NCT01551173|Active Comparator|Fluvastatin sodium Immediate Release Capsule|Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks
9795934|NCT01551186|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis
9795935|NCT01551186|No Intervention|Standard of Care|Patients in the control arm will receive standard care
9795936|NCT01551199|Experimental|Multiple Channel Exposure Therapy|MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
9795937|NCT01551212|Experimental|EVR/TAC|Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: < 5 ng/mL)
9795938|NCT01551212|Active Comparator|TAC|Tacrolimus (C0-h: 6-10 ng/ml)
9795939|NCT01551264|Other|4-Year Bracing Arm|This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
9795940|NCT01551264|Other|2-Year Bracing Arm|This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.
9795941|NCT01551303|Placebo Comparator|Placebo|Matched nasal spray placebo.
9795942|NCT01551303|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
9795943|NCT01551355|Experimental|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
9795944|NCT01551355|No Intervention|children - control group|The control preschool facilities continued with their usual preschool curriculum
9795945|NCT01551420|Active Comparator|Advanced upper limb prosthetic device IMU controlled|Subjects with upper limb amputation who are trained to use a DEKA Arm with IMU controls
9795946|NCT01551420|Active Comparator|Advanced upper limb prosthetic EMG-PR controlled|Subjects with TR or TH upper limb amputation who are trained to use a DEKA Arm with EMG-PR Controls
9795947|NCT01551550|Experimental|GDD & Amniotic Membrane Graft|After GDD implantation, amniotic membrane graft (AmnioGuard™, Bio-Tissue inc, Miami, FL) is used to cover the GDD tube.
9795948|NCT01551550|Active Comparator|GDD & Pericardial Graft|After GDD implantation, a pericardial graft (Tutoplast®, IOP Inc, Costa Mesa, CA) is used to cover the GDD tube.
9795949|NCT01551693|Experimental|STA-9090 Cohort A|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
9795950|NCT01551693|Experimental|STA-9090 Cohort B|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort B patients received STA-9090 150 mg/m2 twice weekly (d1, 4, 8, 11, 15, 18 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
9795951|NCT01551745|Experimental|Vigil™ Vaccine|Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
9795952|NCT01551758|Experimental|FF/VI|once daily via a Novel Dry Powder Inhaler
9795953|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:~Long acting bronchodilator therapy alone~ICS alone or in combination with a long acting bronchodilator~Triple maintenance therapy"
9795954|NCT01551888|Experimental|Aclidinium/formoterol 400/12μg FDC|Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
9795955|NCT01551888|Active Comparator|Formoterol|Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
9795956|NCT01551979|Active Comparator|Active rTMS|High frequency rTMS stimulation of the vermis(lobule VII) of the cerebellum.
9795957|NCT01551979|Sham Comparator|Sham rTMS|Sham rTMS to the vermis (lobule VII) of the cerebellum.
9795958|NCT01552057|Experimental|Duloxetine 60 mg|Duloxetine hydrochloride up to 60 milligrams (mg) orally for 15 weeks
9795959|NCT01552057|Placebo Comparator|Placebo|Placebo orally for 15 weeks
9795960|NCT01552213|Active Comparator|Treatment for glucose intolerance|Regular visit with dietician, exercise, self blood glucose monitoring, Insulin therapy if determined necessary.
9795961|NCT01552213|Active Comparator|Minimum intervention control group|Single visit with dietician or health educator followed by routine care per provider.
9868354|NCT00201968|Other|FES training|Arm 1 receives functional electrical stimulation while walking on body weight suspension training.
9868355|NCT00201968|Other|Control Group training|Aerobic and resistance training program
9868356|NCT00201981|Active Comparator|1|rebamipide 1%
9868357|NCT00201981|Active Comparator|2|Rebamipide 2%
9868358|NCT00201981|No Intervention|3|placebo
9868359|NCT00202033|Experimental|1|self monitor blood glucose 3 times a day per usual diabetes class curriculum
9868360|NCT00202033|Experimental|2|only self monitor blood glucose when fasting
9868361|NCT00202033|Experimental|3|no self monitoring of blood glucose
9868362|NCT00202046||Patients with lymphedema|Identification of risk factors for lymphedema in women who have had axillary surgery for breast cancer.
9868363|NCT00202046||Control patients without lymphedema|Controls matched on type of axillary surgery and surgery date for comparison in quality of life (QOL) ratings from women who have lymphedema.
9868364|NCT00202098|Experimental|1|ALI/ARDS patients
9868365|NCT00202137|Active Comparator|1|home blood pressure monitoring with automatic blood pressure device
9868366|NCT00202137|Active Comparator|2|physician monitoring of blood pressure by 3 monthly office visits
9868367|NCT00202176|Experimental|1|Ipratropium Bromide
9868368|NCT00202176|Placebo Comparator|2|Saline Solution (0.9% NaCl)
9868369|NCT00202189|Experimental|1|Budesonide
9795962|NCT01552343|Experimental|Female - Desmopressin 25 μg|Female participants took 1 tablet of 25 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
9795963|NCT01552343|Placebo Comparator|Female - Placebo|Female participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
9795964|NCT01552343|Experimental|Male - Desmopressin 75 μg|Male participants took 1 tablet 75 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
9868370|NCT00202189|Placebo Comparator|2|Saline Solution (0.9% NaCl)
9868371|NCT00202228|Experimental|1|Individuals living with HIV who are naive to antiretroviral treatment, or who have been on a treatment interruption for at least six months
9868372|NCT00202228|Experimental|2|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT
9868373|NCT00202228|Experimental|3|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT and have liver disease.
9868374|NCT00202228|Experimental|4|HIV negative control group
9868375|NCT00202267|Active Comparator|1|Clients randomized to short-stretch bandaging application
9868376|NCT00202267|Active Comparator|2|Clients randomized to four-layer bandaging application
9868377|NCT00202280|Placebo Comparator|Placebo pill|Placebo pill daily for 3 months
9868378|NCT00202280|Experimental|5mg folic acid, 0.4mg B12, 50mg B6|5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months
9868379|NCT00202293|Experimental|Lithium and olanzapine|
9868380|NCT00202293|Active Comparator|Lithium and chlorpormazine|
9868381|NCT00202358|Placebo Comparator|placebo|
9868382|NCT00202358|Experimental|atenolol|
9868383|NCT00202397|Placebo Comparator|2|placebo bid for 8 weeks
9868384|NCT00202397|Experimental|1|Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks
9868385|NCT00202410|Placebo Comparator|physiologic solution|subcutaneous administration of physiologic solution
9868386|NCT00202410|Experimental|Bacille Calmette-Guèrin (BCG) Vaccine|Anti-Tubercular Vaccination
9868387|NCT00202436|Active Comparator|1|Phlebotomy
9868388|NCT00202436|Active Comparator|2|Erythrocytapheresis
9868389|NCT00202475|Active Comparator|1|
9868390|NCT00202475|Active Comparator|2|
9927879|NCT00899535||Group 1|This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
9927880|NCT00899587|Experimental|Oxygen|
9927881|NCT00899587|Experimental|Enalapril|
9927882|NCT00899587|Placebo Comparator|Control|
9927883|NCT00899652||All Patients|Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
9868391|NCT00202670||1|SPECT
9868392|NCT00202670||2|dobutamine echocardiography
9868393|NCT00202696|Experimental|1|Nalmefene 40 mg
9868394|NCT00202696|Experimental|2|Nalmefene 80 mg
9868395|NCT00202696|Other|3|Placebo
9868396|NCT00202709|Experimental|Thought Field Therapy (TFT)|Treatment with TFT, first one hour, then 1/2 hour.
9868397|NCT00202709|No Intervention|Wait list control|
9868398|NCT00202735|Active Comparator|Immobilization in internal rotation|"Immobilization in internal rotation:All patients in this group are immobilized with the arm in internal rotation.~The arm is immobilized with a normal collar and cuff device."
9868399|NCT00202735|Experimental|Immobilization in external rotation.|Immobilization in external rotation (ER. All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling ER, 15˚ version.To control the position, a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed
9868400|NCT00202787|Experimental|1|FOLFOX-4+cetuximab
9868401|NCT00202787|Active Comparator|2|FOLFOX-4
9868402|NCT00202852|Placebo Comparator|1|
9868403|NCT00202852|Experimental|2|
9868404|NCT00202865|Experimental|1|
10210646|NCT04505774|Other|Standard of Care + SGLT2 inhibitor|"Standard of care plus SGLT2 inhibitor~This arm will enroll moderate and severe illness patients"
9868405|NCT00202865|Placebo Comparator|2|
9868406|NCT00202969|Experimental|1|S-1
9868407|NCT00202969|Active Comparator|2|S-1 plus CDDP
9517118|NCT03309345||Control group, healthy control|Gender, BMI and age matched healthy people will be recruited as a control group. Pregnant or lactating women will be excluded from participation. Those with any chronic illnesses or bone injuries will also be excluded.
9868408|NCT00202969|Active Comparator|3|5-FU plus CDDP
9868409|NCT00202982|Active Comparator|glatiramer acetate 20 mg|glatiramer acetate 20 mg
9868410|NCT00202982|Active Comparator|glatiramer acetate 40 mg|glatiramer acetate 40 mg
9868411|NCT00202995|Experimental|1|Glatiramer Acetate 20 mg s.c. daily
9868412|NCT00202995|Active Comparator|2|Betaseron 250 ug every other day or Rebif 44 ug 3 times a week
9868413|NCT00203008||Observational procedure|Patients will be examined and any suspicious skin abnormalities will be biopsied
9868414|NCT00203034|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
9868415|NCT00203034|Experimental|Experimental 2|1.0 mg rasagiline mesylate oral once daily
9868416|NCT00203034|Placebo Comparator|Placebo|Placebo Comparator
9868417|NCT00203060|Experimental|A|Rasagiline treatment
9868418|NCT00203060|Placebo Comparator|B|placebo arm
9868419|NCT00203073|Active Comparator|Copaxone 20 mg|Copaxone 20 mg
9868420|NCT00203073|Active Comparator|Copaxone 20mg with Novantrone induction|Copaxone 20mg with Novantrone induction
9868421|NCT00203099|Active Comparator|Glatiramer Acetate, N-Acetylcysteine|
9868422|NCT00203112|Active Comparator|Glatiramer Acetate injection with oral minocycline|Glatiramer Acetate 20mg with oral minocycline 100mg
9868423|NCT00203112|Experimental|Glatiramer Acetate with placebo|Glatiramer acetate injection 20mg with oral placebo
9868424|NCT00203151|Experimental|1|
9868425|NCT00203151|Placebo Comparator|2|
9868426|NCT00203164|Experimental|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
9868427|NCT00203177|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
9868428|NCT00203177|Experimental|Expermental 2|1.0 mg rasagiline mesylate oral once daily
9868429|NCT00203372|Experimental|Bevacizumab 7.5 and TAC|one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.
9868430|NCT00203372|Placebo Comparator|Placebo 7.5 and TAC|Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.
9868431|NCT00203372|Experimental|Bevacizumab 15 and TAC|one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.
9868432|NCT00203372|Placebo Comparator|Placebo 15 and TAC|Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.
9868433|NCT00203385|Experimental|Divalproex|Divalproex; oral up to 2000mg/d; open label
9868434|NCT00203450|Experimental|Zonegran|Zonegran
9868435|NCT00203450|Placebo Comparator|Placebo|Placebo pill
9868436|NCT00203567|Active Comparator|Equetro|Equetro
9868437|NCT00203606|Experimental|Active Treatment|Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin
9868438|NCT00203606|No Intervention|Observation|Observation with no active treatment for Hepatitis C. Observation period is based on standard treatment duration based on genotype of Hepatitis C. Active treatment offered to participants at conclusion of observation. (Protocol Amendment #1, October 30, 2001. Ethics approval Jan 19, 2004).
9868439|NCT00203619|Experimental|1|Wireless capsule endoscopy
9868440|NCT00203619|Active Comparator|2|Standard care
9868441|NCT00203645|Experimental|Brief self-directed treatment|self-help workbook plus motivational telephone intervention
9868442|NCT00203645|Experimental|Self-directed plus telephone support|Self-help workbook, motivational telephone intervention plus telephone booster calls
9868443|NCT00203645|Active Comparator|Workbook only|Workbook only
9868444|NCT00203645|No Intervention|Waitlist|Six week waitlist
9868445|NCT00203749|Experimental|1|Intervention communities will receive the community-based VCT intervention community mobilization, mobile VCT, and post-test support services), as well as standard clinic-based VCT
9868446|NCT00203749|Active Comparator|2|Comparison communities will receive standard clinic-based VCT
9868447|NCT00203788|Experimental|1|Individual Placement and Support Plus Workplace Fundamentals Module
9868448|NCT00203788|Active Comparator|2|Brokered Vocational Rehabilitation
9868449|NCT00203879|Experimental|1|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
10210647|NCT04504812|Active Comparator|Phase 1: Best Practices|Participants will receive an intervention from the best practices.
10210648|NCT04504812|Active Comparator|Phase 1: Best Practices + Duloxetine|Participants will receive Duloxetine in addition to an intervention from the best practices.
9868450|NCT00203879|Experimental|2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 without IL-2
9868451|NCT00203905|Active Comparator|A|Hydroxyurea at 500 mg PO q 12 hours x 6 days (11 total doses); Infusion of 5-FU (600 mg/m2/day x 5 days [120 hours]
10210649|NCT04504812|Active Comparator|Phase 1:Best Practices + Duloxetine + Pain coping skills|Participants will receive Duloxetine and pain coping skills training in addition to an intervention from the best practices.
10210650|NCT04504812|Active Comparator|Phase 2: Intra-Articular Injection (HA+)|Participants will receive an intra-articular injection of hyaluronic acid mixed with steroid and bupivacaine.
10210651|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Long Acting Blocks|Participants will receive a nerve blocking procedure, long-acting local anesthetic, and steroid injection.
9868452|NCT00203905|Experimental|B|Bevacizumab: 10 mg/kg will be given as a 90-minute infusion
9868453|NCT00203918||Prostate biopsies|Males undergoing prostate biopsies
9868454|NCT00203944||international adopted infants|international adoptees making their first visit to international adoption clinic
9868455|NCT00203944||Control infants|
9868456|NCT00203957|Experimental|Group A|Patients who completed double-blind treatment studies 6002-US-013, 6002-US-013, 6002-US-018 immediately prior to entering this open-label trial and may have had an interuption of study drug of 14 days or less.
9868457|NCT00203957|Experimental|Group B|Patients who previously completed double-blind treatment studies 6002-US-013, 6002-US-018 or 6002-EU-007 or discontinued from open label study 6002-US-007 and have had an interuption of study drug greater than 14 days.
9868458|NCT00204022|Experimental|1|Mycophenolate mofetil (target dose 2g/day)
10210652|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Nerve Ablation|Participants will receive a nerve ablation procedure and steroid injection.
10210653|NCT04502121|Experimental|Intervention group (IG)|
10210654|NCT04502121|No Intervention|Standard of Care (SOC)|
10210655|NCT04489108|Experimental|Tranexamic Acid with Standard Medical Treatment|Arm A will Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours along with standard medical and interventional (Endoscopy) therapy.
10210656|NCT04489108|Active Comparator|Placebo + Standard Medical treatment|Arm B will receive similar volume of isotonic solution (saline) along with standard medical and interventional (Endoscopy) therapy.
9517119|NCT03309319|Experimental|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
9868459|NCT00204022|Active Comparator|2|Azathioprine (target dose 2mg/kg/day)
9868460|NCT00204061|Placebo Comparator|supportive management|needs-focused, unspecific supportive management
9868461|NCT00204061|Experimental|amisulpride|24 months amisulpride 50 to 800 mg, needs-focused, unspecific supportive management.
9868462|NCT00204243|Experimental|Naltrexone implant|Naltrexone implant (GoMedical Inc. 6 months implant)
9868463|NCT00204243|Active Comparator|Methadone|Methadone Maintenance Treatment
9927884|NCT00899704||Group 1|Patient tissue samples are screened using polymerase chain reaction (PCR) for human papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to quantify expression levels for targeted genes. Initial data analysis is performed using Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes.
9927885|NCT00899782||Ancillary-Correlative (lung cancer tissue bank)|Grossly viable tumor and grossly normal lung tissue are identified and removed from patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue Bank for future use in research. Blood specimens are also collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant therapy) and shipped immediately to the Tissue Bank.
9927886|NCT00899834||Tumor Samples|fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.(peripheral blood is applicable only to patients with focal brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at diagnosis)
9927887|NCT00899860||patients with renal cell cancer|
9927888|NCT00899951||Cohort 1|receiving fentaly citrate
9927889|NCT00899964|Active Comparator|1|automated tailored feedback per E-mail
9927890|NCT00899964|Active Comparator|2|1 + active contact per E-mail possible
9927891|NCT00899964|Active Comparator|3|2 + active contact by trainer in case of exercise-related problems
9927892|NCT00899964|Active Comparator|4|3 + regular active contact by trainer
10210657|NCT04487210|Experimental|Phase 1a (Low Dose)|15 subjects will be enrolled to receive Low-dose S-protein with adjuvant MVC-COV1901.
10210658|NCT04487210|Experimental|Phase 1b (Medium Dose)|15 subjects will be enrolled to receive Medium-dose S-protein with adjuvant MVC-COV1901.
10210659|NCT04487210|Experimental|Phase 1c (High Dose)|15 subjects will be enrolled to receive High-dose S-protein with adjuvant MVC-COV1901.
10210660|NCT04480411|Experimental|COVID-19 Patients|Patients that are admitted to the hospital with COVID 19.
9517120|NCT03309293|Other|controls|biological samples bank
9517121|NCT03309293|Experimental|cases|
9927893|NCT00900003||pancreatic cancer patients|pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
9935860|NCT03071757|Experimental|Part 3A: 18F-AraG Imaging Substudy in TNBC Participants|Part 3A: Additional participants (with TNBC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
10210661|NCT04471675|Experimental|Experimental: solid tumors|Albumin-bound docetaxel by intravenous infusion.Patients receive albumin-bound docetaxel once every three weeks (a Cycle), starting at a dose of 50mg/m2.
10210662|NCT04468633|Active Comparator|Baerveldt 350 implant|
10210663|NCT04468633|Active Comparator|Ahmed ClearPath 350 implant|
10210664|NCT04463979||Cerebellar Tumors|Thirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection.
10210665|NCT04463979||Brain Tumors|Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison.
10213697|NCT03496259|Active Comparator|Epidural Group|Patients in this group will have an epidural catheter placed at the end of the operation
9868464|NCT00204308|Experimental|combination tenofovir-emtricitabine|
9868465|NCT00204308|No Intervention|control arm|
9868466|NCT00204412|Experimental|1|flax lignan
9868467|NCT00204412|Placebo Comparator|2|placebo
9868468|NCT00204425|Experimental|1|exercise/soy isoflavone
9868469|NCT00204425|Experimental|2|exercise/isoflavone placebo
9868470|NCT00204425|Experimental|3|exercise placebo/soy isoflavone
9868471|NCT00204425|Placebo Comparator|4|exercise placebo/isoflavone placebo
9868472|NCT00204516|Experimental|mRNA Vacc|
9868473|NCT00204529|Experimental|PegIFN|pegylated interferon-alpha-2a
9868474|NCT00204529|Active Comparator|IFN|interferon-alpha-2a
9868475|NCT00204542|Active Comparator|A|Solaraze(R) 2x/day for 3 months
9868476|NCT00204542|Active Comparator|B|Solaraze(R) 2x/day for 6 months
9868477|NCT00204568|Active Comparator|1|Adriamycin mono
9868478|NCT00204568|Experimental|2|Trofosfamide
9868479|NCT00204594|Experimental|Antibody|
9868480|NCT00204698|Active Comparator|1|All subjects will be given active drug.
9868481|NCT00204711||Outpatient Surgery with Sedation|SNAP II EEG data will be recorded continuously during the sedation and intermittently compared to routinely monitored parameters of sedation adequacy including vital signs, patient movement, grimacing, verbal complaints, and patient responsiveness to verbal and tactile stimuli. Following surgery, patients will be questioned to determine recall or memory of discomfort.
9868482|NCT00204737|Active Comparator|Prednisone|Prednisone 20mg daily x 2 weeks
9868483|NCT00204737|Placebo Comparator|placebo|placebo
9868484|NCT00204750|Active Comparator|1|Bougie dilation
9868485|NCT00204750|Experimental|2|Needle-knife incision
9868486|NCT00204763|Active Comparator|2|Solid state catheter
9868487|NCT00204763|Experimental|A|
9868488|NCT00204828||1.|Children with asthma
9868489|NCT00204828||2.|Children without asthma
9868490|NCT00204867||A|In vivo surveillance of 6-9 mm polyps detected at CTC
9868491|NCT00204893|Experimental|Open label|Each participant will be treated with three 3900 mg doses of calcium formate on each study day (i.e., days 1-14).
9868492|NCT00204919|Placebo Comparator|1|
9868493|NCT00204919|Active Comparator|2|
9868494|NCT00204971|Experimental|1|Nutritional supplement
9868495|NCT00204971|Placebo Comparator|2|placebo
9868496|NCT00204997|Experimental|1|Laparoscopic Ovarian Transposition
9868497|NCT00205023|Experimental|A|
9868498|NCT00205075||Case|
9868499|NCT00205075||Control|
9868500|NCT00205101||1|Triad allograft
9868501|NCT00205101||2|other anterior lumbar interbody fusion (ALIF)
9868502|NCT00205101||3|transforaminal lumbar interbody fusion (TLIF)
9868503|NCT00205101||4|posterior lumbar interbody fusion (PLIF)
9868504|NCT00205153|Experimental|TEAM Care|Intervention pharmacies implement 6-month TEAM program.
9868505|NCT00205153|No Intervention|Usual Care|"Control pharmacies provide usual care only."
9868506|NCT00205166|Active Comparator|1|Caffeine 400 mg PO 1 hour before adenosine infusion
9868507|NCT00205166|Active Comparator|2|Caffeine 200 mg po one hour before adenosine infusion
9868508|NCT00205270||Pre-transplant Vaccine|Cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
9868509|NCT00205270||0-6 Months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 0-6 months post transplant.
9868510|NCT00205270||13-60 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 13-60 months post transplant.
9868511|NCT00205270||Greater than 110 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine greater than 110 months post transplant.
9868512|NCT00205270||Healthy Controls|Healthy controls to measure normal immune response to the influenza vaccine
9868513|NCT00205335|Other|glucose monitoring|Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar.
9868514|NCT00205361||1|well-nourished
9868515|NCT00205361||2|malnourished
9868516|NCT00205426|Experimental|Natrecor infusion|Nesiritide
9868517|NCT00205439||Fluorescence bronchosopy with sputum cytology|Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.
9868518|NCT00205543|Experimental|1|suture palate after resection
9868519|NCT00205543|Experimental|2|suture one side of palate afer resection
9868520|NCT00205543|Experimental|3|no sutures in palate after resection
9868521|NCT00205556|Other|1: low flux hemodialysis|standard treatment
9868522|NCT00205556|Active Comparator|2 on-line hemodiafiltration|
9868523|NCT00205569||1|Individuals with traumatic brain injury requiring inpatient rehabilitation.
9868524|NCT00205829|Experimental|Active Therapy|Occipital nerve stimulation (ONS) therapy delivered to a subject implanted with a bion ONS device
9868525|NCT00205907|Experimental|single|BLVR treatment
9868526|NCT00205920|Experimental|single|BLVR Treatment
9868527|NCT00205946|Placebo Comparator|Placebo|
9868528|NCT00205946|Active Comparator|Bupropion|
9868529|NCT00206011|Experimental|1|
9868530|NCT00206011|Other|2|
9868531|NCT00206232|Active Comparator|Spironolactone|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
9868532|NCT00206232|Placebo Comparator|Placebo|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
9868533|NCT00206388|Experimental|Zolendric acid with Cyclophosphamide|Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
9868534|NCT00206414|Experimental|Iressa Day 1 with Arimidex and Faslodex|Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
9868535|NCT00206414|Active Comparator|Iressa Day 21 with Arimidex and Faslodex|Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex
9868536|NCT00206466|Active Comparator|One|Taxotere
9868537|NCT00206492|Experimental|Iressa and Tamoxifen|Iressa and Tamoxifen
9868538|NCT00206544|Active Comparator|1|Tamoxifen 40 mg daily
9868539|NCT00206544|Active Comparator|2|Progesterone 20 mg daily
9868540|NCT00206544|Placebo Comparator|3|Placebo daily
9868541|NCT00206583|Experimental|EV/DNG (Qlaira, BAY86-5027)|Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
9868542|NCT00206596|Experimental|Arm 1|
9868543|NCT00206596|Placebo Comparator|Arm 2|
9868544|NCT00206622|Active Comparator|Arm 1|
9868545|NCT00206622|Active Comparator|Arm 2|
9868546|NCT00206622|Placebo Comparator|Arm 3|
9868547|NCT00206635||Group 1|
9868548|NCT00206648|Experimental|Arm 1|
9868549|NCT00206648|Active Comparator|Arm 2|
9868550|NCT00206661|Experimental|Arm 1|
9868551|NCT00206661|Experimental|Arm 2|
9868552|NCT00206674|Experimental|Arm 1|
9868553|NCT00206674|Placebo Comparator|Arm 2|
9868554|NCT00206700|Experimental|Arm 1|
9868555|NCT00206713|Experimental|Arm 1|
9868556|NCT00206713|Placebo Comparator|Arm 2|
9868557|NCT00206752|Experimental|unilateral radiation therapy|definitive external beam radiation in the ipsilateral neck.
9868558|NCT00206830|No Intervention|Control-Blinded from Results|
9868559|NCT00206830|Experimental|Access to Results|
9868560|NCT00206843|Experimental|Results available|
9868561|NCT00206843|No Intervention|Results blinded|
9868562|NCT00206934|Placebo Comparator|1|
9868563|NCT00206934|Placebo Comparator|2|
9868564|NCT00206947|Active Comparator|1|
9868565|NCT00206947|Placebo Comparator|2|
9868566|NCT00206960|Active Comparator|1|
9868567|NCT00206960|Active Comparator|2|
9868568|NCT00206986|Experimental|1|
9868569|NCT00206986|Experimental|2|
9868570|NCT00206999|Experimental|1|
9868571|NCT00207051|Experimental|1|
9868572|NCT00207064|Experimental|1|
9868573|NCT00207077|Experimental|A|
9868574|NCT00207103|Experimental|1|
9868575|NCT00207103|Experimental|2|
9868576|NCT00207103|Experimental|3|
9868577|NCT00207103|Experimental|4|
9868578|NCT00207103|Experimental|5|
9868579|NCT00207103|Experimental|6|
9868580|NCT00207116|Experimental|A|
9868581|NCT00207129|Experimental|A|
9868582|NCT00207129|Experimental|B|
9868583|NCT00207155|Experimental|A|
9868584|NCT00207194|Active Comparator|Automated Telephone Program|The intervention was a totally automated, computer-based, interactive telephone counseling system called Telephone- Linked-Care, designed to monitor, educate, and counsel African-American adults with hypertension and to provide summary data regularly to the patient's primary care provider.
9868585|NCT00207194|Placebo Comparator|Health Behavior Education|The comparator group received health education relating to the management of hypertension. Members of this group also received standard primary medical care.
9868586|NCT00207220||3|subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls
9868587|NCT00207233|Active Comparator|1|Will receive MCT study oil to supplement into liquid meal replacements.
9868588|NCT00207233|Placebo Comparator|2|Will receive LCT oil to supplement into their liquid meal replacements.
9868589|NCT00207259|No Intervention|Control|Standard weekly treatments with radiation oncologist and nurse. All control patients offered intervention at end of 8-week course of radiotherapy.
9868590|NCT00207259|Experimental|Relaxation Therapy|Weekly relaxation therapy with PhD psychologist and home cognitive restructering practice
9868591|NCT00207259|Experimental|Reiki|Weekly Reiki therapy with a Reiki therapist, involves laying of the therapist's hands on the patient to rechannel energy, considered pleasant and calming
9868592|NCT00207285|Other|In Person Training|These firefighters received the sleep education and sleep disorders screening in person by one of our research staff.
9868593|NCT00207285|Other|Train the Trainer|These firefighters received the education and sleep disorder screening in person with someone taught by our research staff.
9868594|NCT00207285|Other|Online Group|These firefighters took the sleep disorder screening and education online.
9868595|NCT00207311|Placebo Comparator|Xenical placebo|Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
9868596|NCT00207311|Active Comparator|Xenical (orlistat)|Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
9927894|NCT00900224||Group 1|Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
9927895|NCT00900250||Ancillary-correlative (specimen collection and baking)|"Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.~Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.~Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation."
9927896|NCT00900328||Ancillary-Correlative (biomarkers in resected AC specimens)|Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, Kras, p53, and c-CBL via standard PCR and sequencing; gene amplification of c-Met via real time quantitative PCR; LOH analysis of c-CBL; expression levels of met/HGF protein in serum via ELISA; and expression levels of c-Met, EGFR, p53, c-CBL, DUB3, ALK, and EMT via IHC.
9927897|NCT00900406||Recipients of stem cells with graft versus host disease|
9927898|NCT00900406||Recipients of stem cells at risk of graft versus host disease|
9927899|NCT00900406||Donator of stem cells|
9927900|NCT00900445||Basic science (pharmacokinetics)|Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.
9927901|NCT00900458|Active Comparator|1|formerly preeclamptic women with low plasma volume
9927902|NCT00900458|Active Comparator|2|formerly preeclamptic women with normal plasma volume
9927903|NCT00900458|Other|3|Healthy controls
9927904|NCT00900497|Experimental|White Blood Cells/Granulocytes|Fresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors
9927905|NCT00900510|Experimental|Drainage and placebo|Incision and drainage with placebo.
9927906|NCT00900510|Active Comparator|Drainage with TMP/SX|Drainage with Bactrim
9927907|NCT00900523||Known or suspected ovarian cancer|Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
9927908|NCT00900549|Experimental|CRT|
9927909|NCT00900549|Sham Comparator|No CRT|
9927910|NCT00900588|Experimental|10 ug|10 microgram split-virion vaccine per dose
9927911|NCT00900588|Experimental|15 ug|15 microgram split-virion vaccine per dose
9927912|NCT00900588|Experimental|30 ug|30 microgram split-virion vaccine per dose
9927913|NCT00900588|Active Comparator|5 ug|5 microgram whole-virion vaccine per dose
9927914|NCT00900640||ERCP group|All patients who have been scheduled for an ERCP due to medical necessity will be considered for this study.
9927915|NCT00900653|Experimental|Gynoflor|
9927916|NCT00900653|No Intervention|Control|
9927917|NCT00900692|Experimental|Dynasplint Group|Along with the standard of care Botox and manual therapy, patients will use the Supination Dynasplint every day
9927918|NCT00900692|No Intervention|Standard of care|Patients in the standard of care group will have the standard Botox treatments and manual therapy with no additional interventions.
9996968|NCT01504698|Active Comparator|Treatment without manipulation|
9517122|NCT03309280||Patient at risk for OSA scheduled for Cardiac surgery|Patients with a positive STOP-Bang and DES-OSA score (that means patients at risk for OSA)
9868597|NCT00207350|Other|Brain tumor|Neurosurgical use of Interstitial Laser therapy
9868598|NCT00207363|Experimental|Initial induction therapy|Receive Peg Intron 3.0mcg/kg/wk for 12 weeks followed by Peg Intron 1.5 mcg/kg/wk for 36 weeks
9868599|NCT00207363|Active Comparator|Standard of Care|Peg Inter 1.5mcg/kg/wk for 48 weeks
10210666|NCT04439513|Experimental|Dual Artery Compression|time to hemostasis and incidence of radial artery occlusion will be monitored while using a dual artery compression device (Terry-2-band) to achieve hemostasis.
10210667|NCT04439513|Active Comparator|Radial Artery-Only|time to hemostasis and incidence of radial artery occlusion will be monitored while using the device currently approved by the institution (Hemo-Stop) and following institutional protocols for hemostasis.
10210668|NCT04437810|Experimental|Albumin+ SMT|Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3) along with standard medical therapy
9868600|NCT00207389||Laparoscopic gastric bypass|Patients undergoing Laparoscopic gastric bypass
9868601|NCT00207389||Open gastric bypass|Patients undergoing Open gastric bypass
9868602|NCT00207402|Active Comparator|rosiglitazone|Treatment with rosiglitazone 4 mg twice a day for 3 months prior to and during the course of 48 weeks of treatment with interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin.
9868603|NCT00207402|No Intervention|No Avandia|Monitoring period without rosiglitazone for 3 months prior to 48 weeks of interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin
9868604|NCT00207441|Experimental|Arthritis self management program|
9868605|NCT00207441|Experimental|Chronic Disease Self Management Program|
9868606|NCT00207688||Infliximab 5 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
9868607|NCT00207688||Infliximab 10 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
9868608|NCT00207688||Placebo|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
9868609|NCT00207831|Experimental|Tegafur uracile + radiotherapy|
9868610|NCT00207831|Active Comparator|radiotherapy|
9868611|NCT00207857||With and Without PFTs|
9868612|NCT00207948||Therapeutic Dose Adjustment|To adjust the doses of medications to meet target therapeutic concentrations
9868613|NCT00208078|No Intervention|Usual medical therapy|Usual CF care
9868614|NCT00208078|Experimental|Non-invasive ventilation|Pressure support ventilator (SAIME,AIROX)
9868615|NCT00208104|Experimental|Motivational Interview Condition|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
9868616|NCT00208104|No Intervention|Non-supportive Counseling|A non-supportive counseling session will consist of regular nurse-patient interaction.
9868617|NCT00208117|Active Comparator|1|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
9868618|NCT00208117|Placebo Comparator|2|To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
9868619|NCT00208156|Experimental|mifepristone|
9868620|NCT00208169|Experimental|1|Aripiprazole start dose at 5 mg/day by day 4-6 increase to 10 mg/da and day 7 and subsequent visits flexible dosing from 10 up to 30 mg/day.
9868621|NCT00208234|Placebo Comparator|Control|Placebo
9868622|NCT00208234|Experimental|2|Omalizumab
9868623|NCT00208247|Experimental|CBT|The cognitive behavioural treatment developed by Salkovskis, Warwick and co-workers was used, with adaptations for the specific setting.
9868624|NCT00208247|Experimental|STPP|The short-term psychodynamic psychotherapy (STPP).
10210669|NCT04437810|Placebo Comparator|Placebo+SMT|- Patients in placebo arm will receive similar volume of isotonic fluid (saline) over same duration of time along with standard medical therapy
10210670|NCT04437719|Experimental|Obvio-19 App|"If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. After enrollment, patients will be sent an invitation via email to download the Obvio-19 mobile app. After downloading the Obvio-19 app, patients will receive instructions as to how they may communicate with the study investigator. Communication may occur through the chat function of the app or live telephone conversations.~Patients must log into the Obvio-19 app daily to complete the questionnaires. The Obvio-19 system is designed to identify responses that indicate the participant is at an increased risk for serious illness or exhibiting serious symptoms, such as coughing up blood. Such patients will be notified by the app of this status and prompted to seek medical attention."
10210671|NCT04431375|Experimental|plasma Exchange+Tenofovir+FMT|Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
10210672|NCT04431375|Active Comparator|Tenofovir|TabletTenofovir [antiviral] 300mg per oral once a day
9517123|NCT03309280||Patient not at risk for OSA scheduled for Cardiac surgery|Patients with a negative STOP-Bang and DES-OSA score (that means patients not at risk for OSA)
9868625|NCT00208247|Experimental|Waiting List|Patients in the waiting-list group were asked to keep in touch with their GP, who had been informed of the trial in writing. The patients and their GPs were instructed not to begin any other treatment during the study period. After 6 months, the patients on the waiting list were re-evaluated for inclusion and exclusion criteria and, if they still met the criteria, re-randomized to CBT or STPP.
9868626|NCT00208260|Active Comparator|A|FOLFIRI
9868627|NCT00208260|Active Comparator|B|FOLFOX-4
9868628|NCT00208260|Experimental|C|FOLFIRI-HD
9868629|NCT00208260|Experimental|D|FOLFOX-7
10210673|NCT04431219|Experimental|Ascending Dose Cohort|"The AD cohort will be first recruited and will include 5 patients: 1 patient per dose, sequentially recruited, the recruitment of the next dose level patient will be assessed by Data Safety Monitoring Board :~Patient 1: 0.6 mg/Kg/day~Patient 2: 1 mg/Kg/day~Patient 3: 3 mg/Kg/day~Patient 4: 6 mg/Kg/day~Patient 5: 8 mg/Kg/day~Once the 5 AD patients complete LIS1 treatment, the sponsor and the DSMB will rule on the LIS1 dose to obtain an optimal CD3+ cells depletion, with a good safety profile and will determine the therapeutic dose."
9868630|NCT00208260|Experimental|E|FOLFIRINOX
9868631|NCT00208273|Experimental|A|Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
9868632|NCT00208273|Experimental|B|Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.
9868633|NCT00208286|Other|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
9868634|NCT00208286|Active Comparator|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
9868635|NCT00208299|Experimental|1|Regadenoson
10210674|NCT04431219|Experimental|Therapeutic Dose Cohort|"The TD cohort will be recruited once the therapeutic dose is defined. This cohort will be divided in 2 subgroups of respectively 2 and 3 patients sequentially recruited.~DSMB will review the safety and efficacy profile of the first 2 patients (Subgroup1) and decide:~To continue at the same dose and recruit the next 3 patients of Subgroup 2~To recruit the next 3 patients with a lower dose, estimated from AD as bringing efficient depletion~To recruit the next patient with a higher dose (+2 mg/kg), if the depletion is not considered satisfactory and if the safety profile is considered acceptable~To end the trial if LIS1 toxicity is too important vs its efficacy in CD3+ depletion.~If the decision to increase the dose after the first two TD patients is made, an additional DSMB review will be planned after patient 8. The DSMB will decide to maintain the dose for the last 2 patients or to get back to the previous dose"
9868636|NCT00208299|Active Comparator|2|Adenoscan
9868637|NCT00208312|Experimental|1|Regadenoson
9868638|NCT00208312|Active Comparator|2|Adenoscan
9868639|NCT00208338|Experimental|1|Rotator cuff repair with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
9868640|NCT00208338|Active Comparator|2|Standard rotator cuff repair
10210675|NCT04410913|Experimental|Visual Healing Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Visual Healing Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
9868641|NCT00208351|Active Comparator|1) Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
10210676|NCT04410913|Active Comparator|Standard Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Standard Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
10210677|NCT04393779|Other|HARPOON™ MVRS|Subjects who were treated with the HARPOON MVRS.
10210678|NCT04369664|Experimental|Type 2 Diabetes group|All participants with type 2 diabetes will be given cholesterol-lowering medicine (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
10210679|NCT04369664|Other|Control group|The participants in the control group are subjects with elevated cholesterol who do not have diabetes. All participants will be given cholesterol-lowering medicines (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
9868642|NCT00208351|Active Comparator|2) Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
10210680|NCT04368156|No Intervention|Control|
10210681|NCT04368156|Experimental|Gammacore treatment|
10210682|NCT04354272||Questionnaire|
10210683|NCT04343807|Active Comparator|PECS block|For patients in PECS group (PG), after induction of general anesthesia, the nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
9868643|NCT00208351|Active Comparator|3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
9868644|NCT00208351|Active Comparator|4) Ultima LX Collarless Stem - Polished Finished|A collarless polished finished cementless femoral component for use in total hip replacement.
9868645|NCT00208364|Other|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
9868646|NCT00208377|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
9868647|NCT00208390|Other|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
9868648|NCT00208403|Active Comparator|1|Acryloc™ GHV
9868649|NCT00208403|Active Comparator|2|Palacos R
9868650|NCT00208416|Active Comparator|1|DePuy MI System
9868651|NCT00208416|Active Comparator|2|Conventional surgical technique
9868652|NCT00208429|Other|Pinnacle Acetabular System|
9868653|NCT00208442|Active Comparator|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
9868654|NCT00208442|Active Comparator|Enduron™|Standard UHMWPE polyethylene liner in a modular acetabular component
9868655|NCT00208455|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
9868656|NCT00208468|Other|European Hip|A cementless femoral component for use in total hip replacement
9868657|NCT00208468|Active Comparator|Zweymüller|A cementless femoral component for use in total hip replacement
9868658|NCT00208468|Active Comparator|CLS Spotorno|A cementless femoral component for use in total hip replacement
9868659|NCT00208533|Other|1 Open Label|Open Label Aripiprazole
9868660|NCT00208546|Experimental|1Capecitabine + bevacizumab + oxaliplatin + cetuximab|
9868661|NCT00208546|Active Comparator|21Capecitabine + bevacizumab + oxaliplatin|
9868662|NCT00208559|Other|1 Open Label|Open Label
9868663|NCT00208611|Experimental|Open-Label Treatment|Levodopa-treated Parkinson's Disease subjects with vitamin B12 < 200 pg/ml given oral vitamin B12 supplement
9868664|NCT00208702|Experimental|sertraline + triiodothyronine|
9868665|NCT00208702|Placebo Comparator|sertraline + placebo|
9927919|NCT00900718|Experimental|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
9927920|NCT00900718|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
9927921|NCT00900744||Tamoxifen|20mg daily
9927922|NCT00900770||PIB+ NC|PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
9927923|NCT00900770||PIB- NC|PIB negative, cognitively normal individuals without amyloid deposition
9927924|NCT00900848||8|8 patients
9927925|NCT00900861||1|Asthmatic patients above 18 y, treated with ICS or bronchodilators
9927926|NCT00900874|Active Comparator|1|Salbutamol + steroid
9927927|NCT00900874|Active Comparator|2|Formoterol + steroid
9927928|NCT00900887|Active Comparator|Ketorolac|ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation
9517124|NCT03309267||Intercostal block|Anesthesia induction was performed to all patients .At the end of the operation some patients were performed with intercostal block by the chest surgeon. For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
9927929|NCT00900887|Active Comparator|Nepafenac|ocular topic nepafenac 3 times a day during one week after selective photocoagulation
9927930|NCT00900887|Placebo Comparator|Polietilenglicol 400, propilenglicol|ocular lubricant drops 3 times a day for a week after selective photocoagulation
9927931|NCT00900939|Experimental|Low-fat, vegan diet|
9927932|NCT00900939|Placebo Comparator|Control|
9927933|NCT00900952||1|Infected elderly patients
9927934|NCT00900965|Active Comparator|Electroacupuncture treatment|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
9868666|NCT00208780|Experimental|Dose-response of oral BH4|Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
9868667|NCT00208780|Experimental|Onset & duration of action of oral BH4|Eight hypertensive subjects were assigned to either 5 mg kg-1 day-1 (n=4) or 10 mg kg-1 day-1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
9868668|NCT00208793|Experimental|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with food
9868669|NCT00208793|Experimental|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
9868670|NCT00208793|Experimental|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months
9868671|NCT00208793|Placebo Comparator|Placebo|
10210684|NCT04343807|Active Comparator|Control Group|For patients in control group, after induction of general anesthesia, no nerve block will be performed and only intravenous nalbuphine will be given.
9868672|NCT00208806||congenital heart patients with congestive heart failure|20 effected patients with congestive heart failure patients total 50 patients
9868673|NCT00208845||adult ED patients|
9868674|NCT00208923|Active Comparator|1|Chemotherapy-only conditioning regimen comprising busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA) followed by an allogeneic stem cell transplant.
9868675|NCT00208962|Active Comparator|1|
9868676|NCT00209001|Sham Comparator|Sham acupuncture therapy|Sham acupuncture therapy
9868677|NCT00209001|Active Comparator|Acupuncture|Acupuncture
9868678|NCT00209001|No Intervention|Observation|Observation
9868679|NCT00209040|Experimental|1|Subjects with posttraumatic stress disorder
9868680|NCT00209040|Active Comparator|2|Healthy controls
9868681|NCT00209040|Active Comparator|3|Combat controls
9868682|NCT00209053|Experimental|Off Pump CABG|CABG without cardiopulmonary bypass.
9868683|NCT00209053|Active Comparator|On-Pump CABG|CABG with cardiopulmonary bypass.
9868684|NCT00209079|Active Comparator|1|
9868685|NCT00209105||1|Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
9868686|NCT00209144|Experimental|Angioplasty with Insulin|Coming in with acute infarct and received angioplasty with intensive insulin therapy
9868687|NCT00209144|No Intervention|Angioplasty w/o Insulin|Coming in with acute infarct and received angioplasty
9868688|NCT00209196||pediatric solid organ transplants|Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.More recently, researchers have started to look at adherence with children who have undergone solid organ transplantation. This is because about 50% of these children are to some degree non-adherent with their medical regimen. This comes at a costly price as ongoing non-adherence in pediatric transplant can lead to the child's body rejecting the new organ and even death. This study has been designed to look at the reasons that pediatric patients may choose to be non-adherent.
9868689|NCT00209209|Active Comparator|1|"randomisation: R-CHOP~randomisation: IFN maintenance"
9868690|NCT00209209|Experimental|2|"randomisation: R-FC~randomisation: Rituximab maintnenance"
9868691|NCT00209222|Active Comparator|1|induction: R-CHOP consoldiation : TBI/Cyclo
9868692|NCT00209222|Experimental|2|induction: R-CHOP/DHAP consolditaion: TBI/TAM
9868693|NCT00209235|Experimental|AHO:neurocognitive and pyschosocial|Neurocognitive and psychosocial testing
10210685|NCT04338893|Active Comparator|ROSA Total Knee Robotic Instrumentation|Total knee arthroplasty performed with ROSA Total Knee Robotic instrumentation
10210686|NCT04338893|Active Comparator|Conventional TKA Instrumentation|Total knee arthroplasty performed with conventional instrumentation
10210687|NCT04321317|Other|Undernourished Patients|All patients included will be included in the unique arm of the study
10210688|NCT04315038||All patients|Spinal anesthesia
10210689|NCT04304144|Experimental|Part A: CAEL-101 combined with SoC CyBorD|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The initial cohort dose assignments of CAEL-101 will be: Cohort 1 - 500 mg/m^2 Cohort 2 - 750 mg/m^2 Cohort 3 - 1000 mg/m^2. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study. Patients from Part A who are in the Continued Treatment Period and who, in the Investigator's judgment, should have their SoC treatment complemented with daratumumab may do so.
10213698|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
9868694|NCT00209261|Active Comparator|1|
9868695|NCT00209261|Active Comparator|2|
9868696|NCT00209313|Other|1|Acyclovir 800 mg twice daily for 8 weeks, two week washout, 8 weeks placebo
9868697|NCT00209313|Other|2|8 weeks placebo, 2 week washout, 8 weeks 800 mg acyclovir twice daily
9868698|NCT00209378|Active Comparator|heparin|Citrate regional anticoagulation is compared with standard systemic heparinization.
9868699|NCT00209378|Active Comparator|Citrate|regional anticoagulation with citrate containing replacement solution
9868700|NCT00209391|Experimental|Gadodiamide Injection|All subjects will receive a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide injection) at a dose of 0.1 mmol/kg.
9868701|NCT00209443|Experimental|Gadodiamide Injection|All subjects received a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide Injection) at a dose of 0.1 mmol/kg
9868702|NCT00209495|Placebo Comparator|A|
9868703|NCT00209495|Experimental|B|Pregabalin
9868704|NCT00209495|Experimental|C|Pregabalin + dexamethasone
9868705|NCT00209521|Experimental|fospropofol|
9868706|NCT00209521|Active Comparator|propofol|
9868707|NCT00209612|Experimental|1|Paclitaxel+Irinotecan
9868708|NCT00209651|Experimental|1|Irinotecan and S-1
9868709|NCT00209690|Experimental|1|
9868710|NCT00209716|Experimental|1|
9868711|NCT00209729|Experimental|1|Docetaxel plus S-1
9795965|NCT01552343|Placebo Comparator|Male - Placebo|Male participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
9795966|NCT01552369|Experimental|Preemptive Therapy|900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
9795967|NCT01552369|Active Comparator|Prophylaxis|900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88
9795968|NCT01552408|Active Comparator|0.3 mg Ranibizumab|Cohort 1: Subjects will receive 4 IVT of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will be seen monthly (+/- 7 days) & will receive IVT of 0.3 mg ranibizumab on a pro re nata (PRN) schedule per retreatment criteria.
9868712|NCT00209742|Experimental|2|
9868713|NCT00209742|Experimental|3|
9868714|NCT00209742|Active Comparator|1|
9868715|NCT00209807|Experimental|1|subjects with MDD randomized to Escitalopram
9868716|NCT00209807|Active Comparator|2|MDD patients receiving reboxetine
9868717|NCT00209807|Other|3|Healthy volonteers
9868718|NCT00209898|Active Comparator|Rapid standard of care|Rapid standard of care treatment after screening
9868719|NCT00209898|Active Comparator|Ordinary standard of care|Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
9868720|NCT00210132|Experimental|Ropivacaine|
9868721|NCT00210275|No Intervention|Control|Usual practice; no additional information provided.
9868722|NCT00210275|Experimental|Printed Educational Message #1|Information about Angiotensin-converting enzyme inhibitors, hypertension treatment, and cholesterol lowering agents for diabetes
9868723|NCT00210275|Experimental|Printed Educational Message #2|Retinal screening for diabetes
9868724|NCT00210275|Experimental|Printed Educational Message #3|Diuretics for hypertension
9927935|NCT00900965|Sham Comparator|Sham acupunture treatment|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
9927936|NCT00900978|Experimental|7v-PCV (Prevenar)|Biological/vaccine
9927937|NCT00900991|Experimental|10 ug|10 microgram per dose
9927938|NCT00900991|Experimental|15 ug|15 microgram per dose
9927939|NCT00901004||1|Reflux esophageal minimal change in the endoscopic finding
9927940|NCT00901030||Patients with PCI on blood thinners|Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
9927941|NCT00901043|Experimental|Walnut supplementation|Eight weeks with walnut supplementation to an ad lib diet
9927942|NCT00901043|Active Comparator|Ad lib diet|Eight weeks ad lib diet without walnut supplementation
9927943|NCT00901056|Active Comparator|Treated Group|This group will receive actual shockwave treatment
9927944|NCT00901069|Other|Azacitidine|
9927945|NCT00901082|Active Comparator|information and relaxation|will receive the intervention that consist of information and relaxation
9927946|NCT00901082|No Intervention|No intervention|No specific intervention before the medial branch block.
9927947|NCT00901095|No Intervention|Control|Usual Care
9927948|NCT00901095|Experimental|Lifestyle intervention|The Lifestyle intervention group consists of in-person meetings co-led by an exercise specialist and dietician as well as follow-ups with an interventionist by phone.
9927949|NCT00901108|Active Comparator|Trabectome-IOL|Combined Trabectome and cataract extraction with intraocular lens insertion
9927950|NCT00901108|Active Comparator|Trab-IOL|Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion
9927951|NCT00901121|Experimental|BoneCeramic|Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
9927952|NCT00901121|Active Comparator|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
9927953|NCT00901134||hypothermia|Patients with therapeutic hypothermia after cardiac arrest in hospitals
9927954|NCT00901147|Experimental|panobinostat and bortezomib|Oral Panobinostat and intravenous bortezomib
9868725|NCT00210314|Active Comparator|High-dose methotrexate alone|
9868726|NCT00210314|Experimental|High-dose methotrexate associated with high dose cytarabine|
9868727|NCT00210405|Active Comparator|Food aid only|Children in this arm received fortified food aid commodities supplied through the maternal and child health and nutrition program implemented by World Vision. They received fortified corn-soy blend, which contained iron.
9868728|NCT00210405|Experimental|Micronutrient sprinkles + food aid|Children in this arm were enrolled in the food assisted program, and therefore received fortified food aid, as well as 60 sachets of a multiple micronutrient powder (Sprinkles) containing iron, zinc, vitamin A, vitamin C and folic acid
9868729|NCT00210418|Experimental|Preventive targeting|This arm targeted pregnant and lactating women as well as children 6-23.9 months of age to receive BCC and food assistance. A total of 27 months of enrollment in this program arm was possible.
9868730|NCT00210418|Active Comparator|Recuperative targeting|This arm targeted pregnant and lactating women as well as mothers of malnourished children (WAZ <-2 zscores) between 6 and 59 months of age. A total of 18 months of enrollment was possible in this program arm.
9868731|NCT00210678||Group: 1|Men with premature ejaculation (PE)
9868732|NCT00210678||Group: 2|Men without PE
9868733|NCT00210899|Active Comparator|Vancomycin plus Ceftazidime|Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
9868734|NCT00210899|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
9868735|NCT00210951||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
9868736|NCT00210977||Erythropoietin receptor agonist|Participants with borderline serum anti erythropoietin (EPO) antibody (Ab) titers and who are treated with any erythropoietin receptor agonist (ERA) for any indication, having anti-EPO Ab identified by radioimmunoprecipitation (RIP), who are responding to ERA therapy, will be included in the study.
9868737|NCT00211029||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
9868738|NCT00211042||Pure Red Cell Aplasia (PRCA)|This study will examine the relationship of the presence of anti-erythropoietin antibodies to the clinical course and outcome of participants currently or previously treated with recombinant human erythropoietin and who have PRCA identified from all notified reports (spontaneous postmarketing reports or from clinical trials reports).
9868739|NCT00211068||Epoetin alfa|Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.
9868740|NCT00211263|Experimental|Enhanced Clinical Intervention|
9868741|NCT00211263|Active Comparator|Clinical Intervention|
9868742|NCT00211354|Experimental|anecortave acetate|anecortave acetate 15 mg. juxtascleral injection every 6 months for 24 months
9868743|NCT00211393|Experimental|Drug: ketoconazole|"Drug: ketoconazole~Other Names:~ketoconazole~600mg. /day for 6 weeks~--------------------------------------------------------------------------------"
9868744|NCT00211432|Experimental|Title: Treatment of Pseudovitellium Detachment|Open-Label Anecortave Acetate Sterile Suspension(15mg)
9868745|NCT00211562|Active Comparator|Olanzapine|
9868746|NCT00211562|Active Comparator|Omega 3|
9868747|NCT00211562|Active Comparator|Vitamin E +C|
9868748|NCT00211783||Autism|
9868749|NCT00211783||Control|
9927955|NCT00901160||Surgical patients|Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay. This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
9927956|NCT00901212|Active Comparator|LV Pacing|left univentricular pacing
9927957|NCT00901212|Active Comparator|BV Pacing|biventricular pacing
9927958|NCT00901251||1|
9927959|NCT00901264||1|Patients with pathological diagnoses of cancer or leukemia
9927960|NCT00901264||2|3.1.3 Patients for whom chemotherapy is planned.
9927961|NCT00901277|No Intervention|Control|Usual Care
9927962|NCT00901277|Experimental|Web Intervention|Web-based: interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
9927963|NCT00901277|Experimental|Nurse Intervention|Nurse: an interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
9927964|NCT00901290|Experimental|1|monophasic oral contraceptive
9927965|NCT00901290|Experimental|2|AZD7325
9927966|NCT00901329|Experimental|1: Gender prosthesis|
9927967|NCT00901329|Active Comparator|2: LPS flex prosthesis|
9927968|NCT00901368|Experimental|1|CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
9868750|NCT00211822||Pathologic Gamblers|
9868751|NCT00211822||Obsessive Compulsive Disorder|
9868752|NCT00211822||Healthy Controls|
9868753|NCT00211835|Experimental|Treatment Arm 1|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
9868754|NCT00211835|Experimental|Treatment Arm 2|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
9868755|NCT00211874|Experimental|Nurse-management|nurse-led intervention focused on specific management problems
9868756|NCT00211874|No Intervention|Usual Care|Usual care as control group
9868757|NCT00211900|Experimental|vaccine|single dose of StaphVAX in hemodialysis patients
9868758|NCT00211913|Experimental|vaccine|single dose of StaphVAX®
9868759|NCT00211913|Placebo Comparator|placebo|single dose
9868760|NCT00211926|Experimental|StaphVAX|
9868761|NCT00211926|Placebo Comparator|Placebo|
9868762|NCT00211939|Experimental|1|PhosLo + atorvastatin
9868763|NCT00211939|Active Comparator|2|Sevelamer + atorvastatin
9868764|NCT00211965|Experimental|vaccine|single dose
9868765|NCT00211965|Placebo Comparator|placebo|single dose
9868766|NCT00211978|Experimental|PhosLo|
9868767|NCT00211978|Placebo Comparator|placebo|
9868768|NCT00212004|Active Comparator|Pioglitazone|Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
9868769|NCT00212004|Active Comparator|Control|Participants assigned to Control group were treated with diet and exercise therapy or sulfonylurea (SU) or other additional drugs than pioglitazone.
9868770|NCT00212017|Active Comparator|the voglibose group|Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.
9868771|NCT00212017|Active Comparator|the control group|Participants assigned to the control group were treated only with diet and exercise therapy.
9868772|NCT00212030|Active Comparator|1|
9868773|NCT00212030|Placebo Comparator|2|
9517125|NCT03309267||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation some patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
9868774|NCT00212056|Active Comparator|ANP|
9868775|NCT00212056|Placebo Comparator|Control|
9868776|NCT00212095|Experimental|docetaxel and ketoconazole|
9868777|NCT00212108|Experimental|Celecoxib and ZD1839|Celecoxib and ZD1839 will be given twice a day and daily respectively for two consecutive weeks prior to further anti-cancer treatment.
9868778|NCT00212147|Active Comparator|I|General anesthesia that includes nitrous oxide
9868779|NCT00212147|Active Comparator|II|General anesthesia not including nitrous oxide
9868780|NCT00212160|Experimental|RYGB with omentectomy|Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.
9868781|NCT00212160|No Intervention|RYGB without omentectomy|Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.
9868782|NCT00212160|No Intervention|Normal body weight|Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.
9868783|NCT00212160|No Intervention|Tissue samples|Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.
9868784|NCT00212212|Experimental|1|200 µg selenium as selenate
9868785|NCT00212212|Experimental|2|400 µg selenium as selenate
9868786|NCT00212212|Experimental|3|200 µg selenium as selenomethionine
9868787|NCT00212212|Placebo Comparator|4|placebo tablet
9868788|NCT00212251|Experimental|Lifestyle counseling|10 ActiveMoms classes, 8 Moms Time Out nutrition classes, 6 coaching calls, supportive materials
9868789|NCT00212303|Experimental|Exercise training|Exercise training, 3 times per week, for 6 months.
9868790|NCT00212303|No Intervention|Control|Usual care no active exercise intervention
9868791|NCT00212342|Experimental|Norethisterone,Ethinylestradiol|
9868792|NCT00212342|Placebo Comparator|Sugar pill|
9868793|NCT00212381|Experimental|oral DIM (Active agent)|2mg/kg/day po of DIM
9868794|NCT00212381|Active Comparator|Red rice bran (Placebo)|this agent is not generally thought to be active but may be
9868795|NCT00212407|Experimental|Umbilical cord blood unit(s) transplant|Transplantation of cryopreserved umbilical cord blood unit(s)
9868796|NCT00212459|Experimental|1|Patients are contacted every two weeks after initial counseling to discuss completion of bleeding records.
9868797|NCT00212459|Active Comparator|2|After the initial counseling with regards to bleeding records, there are no more contacts made with the control patients.
9868798|NCT00212472|Active Comparator|1|Low-dose treatment (50 FVIII u/kg three times a week).
9868799|NCT00212472|Active Comparator|2|High-dose treatment (200 FVIII u/kg per day).
9868800|NCT00212498||TB diagnosis|
9868801|NCT00212550||TB diagnosis|
9868802|NCT00212576|Experimental|Building Blocks (0-3)|"Randomized at birth to receive Building Blocks Project from birth through 3 years of age.~Note: This arm not followed past 3 years of age; NOT re-randomized to any group at age 3."
9868803|NCT00212576|Experimental|VIP (0-3), VIP (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
9868804|NCT00212576|Experimental|VIP (0-3), Control (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive care as usual (control) from 3-5 years of age."
9868805|NCT00212576|Experimental|Control (0-3), VIP (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
9868806|NCT00212576|No Intervention|Control (0-3), Control (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive receive care as usual (control) from 3-5 years of age."
9868807|NCT00212615|Active Comparator|A|Standard XELOX
9868808|NCT00212615|Active Comparator|B|Chronomodulated XELOX
9868809|NCT00212745|No Intervention|2|Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation
9868810|NCT00212745|Experimental|1|Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing
9868811|NCT00212797|Experimental|Org 34517_1|low dose Org 34517
9868812|NCT00212797|Experimental|Org 34517_2|high dose Org 34517
9868813|NCT00212797|Placebo Comparator|Placebo|
9868814|NCT00212862||Patients with chemotherapy induced anemia|
9868815|NCT00212979||non intervention study|
9868816|NCT00213252|Experimental|1|
9868817|NCT00213252|Active Comparator|2|
9868818|NCT00213265|Active Comparator|1|
9868819|NCT00213265|Experimental|2|
9868820|NCT00213278|Experimental|1|
9868821|NCT00213291|Experimental|1|
9868822|NCT00213304|Experimental|varicella vaccine (VARIVAX)|varicella vaccine (VARIVAX)
9927969|NCT00901368|Active Comparator|2|Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)
9927970|NCT00901381|Experimental|G-CSF|
9927971|NCT00901381|No Intervention|Control|
9927972|NCT00901407|Experimental|1|lamotrigine
9927973|NCT00901407|Placebo Comparator|2|placebo
9927974|NCT00901420||Prostatectomy|
9927975|NCT00901420||Prostatectomy After Radiation Therapy|
9927976|NCT00901433||A|Usability study of the Personal Wheezometer
9927977|NCT00901446||Imaging|Subjects who receive intracoronary imaging with the investigative device.
9927978|NCT00901472||Stable type 2 Diabetes (ST2D)|Adults with Type 2 diabetes who receive medical care at the University of Chicago
9927979|NCT00901498|Experimental|Treatment A (Reference)|
9927980|NCT00901498|Active Comparator|Treatment B|
9927981|NCT00901498|Active Comparator|Treatment C|
9927982|NCT00901498|Active Comparator|Treatment D|
9927983|NCT00901498|Active Comparator|Treatment E|
9927984|NCT00901511|Experimental|WLL/GM-CSF|Whole lung lavage followed by inhaled GM-CSF
9927985|NCT00901511|Active Comparator|WLL alone|
9927986|NCT00901524|No Intervention|PegIFN- alpha 2a + RBV|
9927987|NCT00901537|Experimental|Azacitidine and Cisplatin|Every 4 weeks, azacitidine is given daily as subcutaneous injection for 5 days from day 1 to day 5, and cisplatin is given as intravenous injection on day 8. The dose of azacitidine will be dose escalated among each group of 3-6 patients, and the dose of cisplatin is fixed.
9927988|NCT00901550|Active Comparator|Methotrexate|A drug for RA patient
9927989|NCT00901550|Active Comparator|Infliximab|for RA treatment
9927990|NCT00901563|Active Comparator|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
9927991|NCT00901563|Placebo Comparator|Saline|Saline will be infused through-out the study.
9927992|NCT00901589|Active Comparator|Premenopausal women-fishoil|
9927993|NCT00901589|Placebo Comparator|Premenopausal-placebo|
9927994|NCT00901589|Active Comparator|Postmenopausal women-fishoil|
9927995|NCT00901589|Placebo Comparator|Postmenopausal-placebo|
9868823|NCT00213421||1|
9868824|NCT00213421||2|
9868825|NCT00213525||Patients With Scleroderma|Assessments of questionnary for environmental factors research
9868826|NCT00213525||Healthy Controls|Assessments of questionnary for environmental factors research
9868827|NCT00213590|No Intervention|1|the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L
9868828|NCT00213590|Experimental|2|the low-exposure group the cyclosporine AUC0-12h target was 50% usual target or 2.2 (2.0 to 2.6, range) mg•h/L
9868829|NCT00213629|Other|no arm|no arm
9868830|NCT00213655||Daily instillation of BCG for 3 weeks then every 6 months|Effect of daily instillation of BCG (27 mg) for 3 weeks then one instillation of BCG (27 mg) every 6 months for 36 months on bladder tumor recurrence
9868831|NCT00213655||Daily instillation of BCG for 2 weeks then every 3 months|Effect of daily instillation of BCG (27 mg) for 2 weeks then one instillation of BCG (27 mg) every 3 months for 36 months on bladder tumor recurrence
9868832|NCT00213759|Active Comparator|groupe filigrastin|
9868833|NCT00213759|Placebo Comparator|groupe placebo|
9868834|NCT00213928|No Intervention|Control|
9868835|NCT00213928|Active Comparator|Horse Chestnut Seed Extract|Horse chestnut seed extract (escins, aesins)
9868836|NCT00213954|Other|interscalene block|Locoregional anesthesia selection
9868837|NCT00213954|Other|axillary block|Locoregional anesthesia selection
9868838|NCT00213954|Other|lumbar block|Locoregional anesthesia selection
9868839|NCT00213954|Other|parasacral plexus block|Locoregional anesthesia selection
9868840|NCT00213993|Experimental|A|antiperspirant topically to one foot once daily
9868841|NCT00214032|Experimental|1|pycnogenol daily
9868842|NCT00214032|Placebo Comparator|2|placebo daily
9868843|NCT00214123|Experimental|Bin 1|bin assignment based on tumor volume
9868844|NCT00214123|Experimental|Bin 2|Bin assignment based on tumor volume
9868845|NCT00214123|Experimental|Bin 3|Bin assignment based on tumor volume
9868846|NCT00214123|Experimental|Bin 4|Bin assignment based on tumor volume
9868847|NCT00214123|Experimental|Bin 5|Bin assignment based on tumor volume
9868848|NCT00214162|Other|1|internet access and computer for 1 year
9868849|NCT00214162|Experimental|2|computer and Full CHESS
9868850|NCT00214175||patients|patients who will receive XRT
9868851|NCT00214175||matched volunteers|Spouse or sibling
9795969|NCT01552408|Experimental|Targeted PRP with 0.3 mg Ranibizumab|Cohort 2: Subjects will receive 4 it of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will then be seen monthly (+/- 7 days) & receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at Day 7 they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide field angiography. Ultra wide field angiography will be performed every 3 months to indicate areas of peripheral ischemia, which will be selectively be treated with PRP at Month 6, Month 18, and Month 25, preserving areas of more perfused retina.
9795970|NCT01552603|Experimental|Artificial Pancreas Control|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
9795971|NCT01552681|Experimental|Baminercept|Subcutaneous injections of 100 mg every week for 24 weeks
9795972|NCT01552681|Placebo Comparator|Placebo|Subcutaneous injections of matched placebo every week for 24 weeks
9795973|NCT01552694|Experimental|Sitagliptin|100 mg sitagliptin/day for 2 months
9795974|NCT01552694|Placebo Comparator|Placebo|Matching placebo daily for 2 months
9795975|NCT01552772|Experimental|Aripiprazole IM Depot|
9795976|NCT01552876|Other|etafilcon A / nelfilcon A / Filcon II 3|etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.
9795977|NCT01552876|Other|nelfilcon A / etafilcon A / Filcon II 3|nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.
9795978|NCT01552889|No Intervention|Usual Care (UC)|Patients will receive only the care provided by their primary care physicians or other medical professionals outside of the study.
9795979|NCT01552889|Experimental|Collaborative Care (CC)|Patients randomized to the Collaborate Care (CC) arm of this study will receive brief screening, consultative, and referral services. This collaborative approach includes the patient, the patient's PCP, the cardiologist, and the nurse case manager (NCM), using evidence based recommendations for depression treatment and follow-up care.
9795980|NCT01552902|Experimental|Lisdexamfetamine dimesylate|
9795981|NCT01552902|Active Comparator|Methylphenidate Hydrochloride|
9795982|NCT01552902|Placebo Comparator|Placebo|
9795983|NCT01552915|Experimental|Lisdexamfetamine Dimesylate|
9795984|NCT01552915|Active Comparator|Methylphenidate Hydrochloride|
9795985|NCT01552915|Placebo Comparator|Placebo|
9795986|NCT01552928|Experimental|Anagrelide Therapeutic (0.5 mg)|
9795987|NCT01552928|Experimental|Anagrelide Supratherapeutic (2.5 mg)|
9795988|NCT01552928|Active Comparator|Moxifloxacin|
9795989|NCT01552928|Placebo Comparator|Placebo|
9795990|NCT01552954|Experimental|Intensive education of low salt diet|"For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the intensity of education)"
9795991|NCT01552954|No Intervention|Conventional diet group|Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
9795992|NCT01553058|Active Comparator|Adalimumab (Humira)|Injection of the active drug Humira.
9795993|NCT01553058|Placebo Comparator|Placebo Injection|Injection of placebo in place of active Humira injection.
9795994|NCT01553058|Active Comparator|NB-UVB phototherapy|NB-UVB Phototherapy 3 times per week, no other intervention.
9795995|NCT01553084|Experimental|Effectiveness of Nicotine patch only|
9795996|NCT01553084|Experimental|Effectiveness of Combination NRT|
9795997|NCT01553084|Experimental|Effectiveness of Varenicline [Chantix]|
9795998|NCT01553136|Placebo Comparator|Sugar pill|
9795999|NCT01553136|Active Comparator|Varenicline|
9796000|NCT01553188|Experimental|Abiraterone, Prednisone and AMG|Abiraterone and prednisone will be given with maximum tolerated dose (MTD) of Trebananib (AMG)
9796001|NCT01553188|Active Comparator|Abiraterone and Prednisone only|Abiraterone and prednisone only
9796002|NCT01553188|Other|Run in|Dose escalation phase to determine MTD of AMG
9796003|NCT01553201|Experimental|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
9796004|NCT01553201|Placebo Comparator|Placebo|Saline, 4cc, one time intramuscular administration
9796005|NCT01553279|Experimental|V419 and MCC-TT|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-TT (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of a measles, mumps, and rubella (MMR) vaccine (at 12 months of age).
9796006|NCT01553279|Experimental|V419 and MCC-CRM|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-CRM (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of an MMR vaccine (at 12 months of age).
9796007|NCT01553292|Experimental|ECALMIST|Large volume 5ml/kg surfactant administered by vascular catheter while maintaining CPAP or ECALMIST; Early CPAP (continuous positive airway pressure) And Large volume Minimal Invasive Surfactant Therapy
9796008|NCT01553318|Active Comparator|Active Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 26 of the 51 participants will assigned to this arm of the study.
9796009|NCT01553318|Placebo Comparator|Placebo for Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
9868852|NCT00214240|Experimental|1|Cytogam in addition to standard of care (IV ganciclovir therapy)
9868853|NCT00214240|No Intervention|2|Receive standard of care therapy (IV ganciclovir)
9868854|NCT00214253|Experimental|1|Thiazolidinedione therapy
9868855|NCT00214253|No Intervention|2|
9868856|NCT00214266|Experimental|Campath-1H Induction Therapy Combined With CellCept® Therapy|Campath-1H Induction Therapy Combined With CellCept® Therapy
9868857|NCT00214279|No Intervention|1|Remain on 3-drug standard of care immunosuppression including prednisone
9796010|NCT01553539|Experimental|Treatment (antiangiogenesis therapy)|Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.
9796011|NCT01553591|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.
9796012|NCT01553591|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.
9796013|NCT01553591|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.
9796014|NCT01553708|Experimental|Epidermal growth factor with silver sulfadiazine cream|Epidermal growth factor with silver sulfadiazine cream was applied to the experimental wounds completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
9796015|NCT01553708|Active Comparator|Silver zinc sulfadiazine cream|Silver sulfadiazine cream was applied to cover the controlled-wound completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
9796016|NCT01553747|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
9796017|NCT01553747|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
9796018|NCT01553747|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
9796019|NCT01553851|Experimental|GSK1120212|GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
9796020|NCT01553916|Experimental|Arm 1: Lithium carbonate + prophylactic cranial irradiation|"Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.~PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium."
9796021|NCT01554176|Experimental|Filorexant 10 mg (Treatment Phase)|Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
9796022|NCT01554176|Placebo Comparator|Placebo (Treatment Phase)|Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
9796023|NCT01554176|Experimental|Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
9796024|NCT01554176|Placebo Comparator|Filorexant 10 mg/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
9796025|NCT01554176|Placebo Comparator|Placebo/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
9796026|NCT01554241|Experimental|vitamin D3 800 IU/day|recommended daily dosage of 800 IU/day D3
9796027|NCT01554241|Experimental|2000 IU/day D3|D3 2000 IU/day
9796028|NCT01554241|Experimental|vitamin D3 4000 IU/day|D3 4000 IU/day
9796029|NCT01554241|Experimental|50,000 IU/week D3|D3 50,000 IU weekly
9796030|NCT01554371|Experimental|Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
9796031|NCT01554371|Experimental|Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
9796032|NCT01554371|Experimental|Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)|Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.
9796033|NCT01554488|Experimental|Arm 1|High dose inhaled fluticasone (1760mcg/day)
9796034|NCT01554488|Active Comparator|Arm 2|Low dose inhaled fluticasone (88mcg/day)
9796035|NCT01554514|Experimental|low dose rituximab|this is a single-arm trial
9796036|NCT01554527|Experimental|CPAP treatment|Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use <4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
9796037|NCT01554527|Other|No CPAP treatment|Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
9868858|NCT00214279|Experimental|2|Corticosteroid withdrawal / prednisone taper over 14 weeks
9868859|NCT00214305|Experimental|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
9868860|NCT00214305|Placebo Comparator|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
9868861|NCT00214331||1|ciprofloxacin
9868862|NCT00214331||2|azithromycin
9868863|NCT00214331||3|gentamicin
9868864|NCT00214474|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support
9868865|NCT00214474|Active Comparator|GMV Intervention|GMV Intervention: Group Medical Visits
9868866|NCT00214474|No Intervention|Usual Care|Usual Care: Standard care for diabetic patients
9868867|NCT00214500|Experimental|Migalastat|"Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods.~Treatment Period:~Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14).~Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28).~Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42).~Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84).~Extension Period:~Migalastat 25 mg BID for Weeks 12 through 48.~Migalastat 50 mg QD for Weeks 48 through 96."
9868868|NCT00214669|Experimental|1|"Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.~Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Lorig's chronic disease self-management programme.~Improved follow-up in primary care through appointment-booking by the specialist nurse."
9868869|NCT00214669|No Intervention|2|Usual Care
9868870|NCT00214682|Experimental|Folic acid (400mcg) + Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
9517126|NCT03309254|Experimental|High Glycemic Index|White Bread with Turkey breast meat (2 slices) Turkey Breast (7 slices) Chamomile Tea with 25 grams glucose Almonds 15 grams
9868871|NCT00214682|Experimental|Mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
9868872|NCT00214682|Experimental|Mental health literacy|This MHL intervention comprised 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
9868873|NCT00214682|Placebo Comparator|Placebo tablet|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
9868874|NCT00214682|Active Comparator|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
9868875|NCT00214682|Active Comparator|Pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
9868876|NCT00214760|Experimental|PGET|
9868877|NCT00214760|Active Comparator|PMMA|
9868878|NCT00214773||Observational|No intervention. This is an observational program.
9868879|NCT00214825|Experimental|1|MR antagonist (Eplerenone) + placebo
9868880|NCT00214825|Placebo Comparator|2|Hydrochlorothiazide plus potassium
9927996|NCT00901615|Experimental|Lenalidomide and R-CHOP|Escalating Lenalidomide dose from 2.5 to 25 mg Lenalidomide and R-CHOP
9927997|NCT00901641|Experimental|cognitive training|CogniFit Personal Coach® computer cognitive training program. The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®). The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
9927998|NCT00901654|Experimental|ACE527|
9927999|NCT00901654|Placebo Comparator|Placebo comparator|
9928000|NCT00901706|Experimental|CGA plus APS Usual Care|Comprehensive geriatric assessment coupled with Adult Protective Services (APS) usual care for elders with self-neglect.
9928001|NCT00901706|Active Comparator|APS Usual Care|APS usual care consisting of social, medical, and legal interventions.
9928002|NCT00901719|Experimental|Sodium depletion|Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing >2000 kcal of energy, >60 g of protein, <12 mmol of sodium and <70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
9928003|NCT00901719|Placebo Comparator|Normal diet|Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
9928004|NCT00901745|Experimental|Infusion of apelin|Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
9517127|NCT03309254|Experimental|Low Glycemic Index|Multi-grain Bread with Turkey breast meat (2 slices) Turkey Breast (6 slices) Chamomile Tea with 25 grams fructose Cashews 10 grams
9796038|NCT01554579|Placebo Comparator|Sugar pill|
9796039|NCT01554579|Experimental|Gefapixant|
9796040|NCT01554618|Experimental|EQW|Exenatide once weekly
9796041|NCT01554618|Placebo Comparator|Placebo|Placebo once weekly
9796042|NCT01554683|Active Comparator|High Dose Levetiracetam|Low Dose Levetiracetam administration via IV infusion over 20 min
9796043|NCT01554683|Active Comparator|Low Dose Levetiracetam|High Dose Levetiracetam administration via IV infusion over 20 min
9796044|NCT01554683|Placebo Comparator|Placebo administration|Saline administration via IV infusion over 20 min
9796045|NCT01554891||Cohort 1|100 OEF/OIF/OND veterans returning to Joint Base Lewis-McChord and Fort Bragg who screen positive for TBI on the Post Deployment Health Assessment (PDHA) TBI screen
9796046|NCT01554891||Cohort 2|100 OEF/OIF/OND veterans seeking care at Northern New England VA Research Consortium (NNEVARC) VA Medical Centers (VAMCs) who screen positive for TBI on VA Level 1 TBI screen
9796047|NCT01554891||Cohort 3|200 participants in WRNMMC and Fort Belvoir Community Hospital Brain Indices Study (100 with mild TBI; 100 without mild TBI).
9796048|NCT01554904|Other|Facial-Flex|The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.
9796049|NCT01554982|Other|Ferric Citrate|Open label extension of those completing study KRX-0304
9796050|NCT01555125|Experimental|secukinumab 150 mg|Drug
9796051|NCT01555125|Experimental|secukinumab 300 mg|Drug
9796052|NCT01555125|Placebo Comparator|placebo|
9796053|NCT01555138|Experimental|Indacaterol|Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
9796054|NCT01555138|Active Comparator|Salmeterol/fluticasone propionate|Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)
9796055|NCT01555151|Experimental|Mometasone furoate 80 μg|Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
9796056|NCT01555151|Experimental|Mometasone furoate 200 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
9796057|NCT01555151|Experimental|Mometasone furoate 320 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
9796058|NCT01555151|Experimental|Mometasone furoate 800 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
9796059|NCT01555164|Experimental|Ranolazine+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.~Participants are required to maintain their diet and exercise regimen."
9796060|NCT01555164|Placebo Comparator|Placebo+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.~Participants are required to maintain their diet and exercise regimen."
9796061|NCT01555463|Experimental|Azelaic acid foam, 15% (BAY39-6251)|0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
9796062|NCT01555463|Placebo Comparator|Vehicle foam|0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
9796063|NCT01555541|Experimental|Single-arm study|
9796064|NCT01555567|Experimental|Electrical stimulation|Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
9796065|NCT01555567|No Intervention|Standard of Care|This group will undergo standard ACL rehabilitation
9986482|NCT01403337|Active Comparator|Preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
9986483|NCT01403350|No Intervention|Current Practice|Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
9517128|NCT03309241|Experimental|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
9517129|NCT03309241|Experimental|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
9986484|NCT01403350|Active Comparator|Intervention Arm|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
9986485|NCT01403363|Experimental|fentanyl patch|
9986486|NCT01403389|Experimental|Eculizumab|
9986487|NCT01403389|Placebo Comparator|0.9% Sodium Chloride|
10210690|NCT04304144|Experimental|Part B: CAEL-101 combined with SoC CyBorD and daratumumab|CAEL-101 is administered as an intravenous (IV) infusion at the RP3D dose level. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy and daratumumab. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study.
9868881|NCT00215046|Experimental|Drug|no randomization, all patients receive experimental drugs
10210691|NCT04302077|Active Comparator|Telemedicine Post Op|Patients with an even-ending medical record number (0,2,4,6,8) will be randomized to virtual visit/telemedicine. This will be done by using Epic and MyChart-integrated telemedicine functionality for video visits with the Principal Investigator's patients. This is considered standard of care.
10210692|NCT04302077|Active Comparator|In-Office Post Op|Patients with an odd-ending medical record number (1,3,5,7,9) will be randomized to the office visit.
9868882|NCT00215111|Experimental|Low carbohydrate, reduced glycemic load, control diet|
9868883|NCT00215293|Experimental|Cervical Cage|Cervical I/F Cage
9868884|NCT00215293|Active Comparator|Graft Spacer|Autograft or allograft with a plate, or autograft alone.
9868885|NCT00215306|Experimental|Lumbar TDR|CHARITÉ Artificial Disc
9868886|NCT00215306|Active Comparator|ALIF|Anterior Interbody Fusion with BAK Cage
9868887|NCT00215319|Experimental|TSM Cage|Lumbar I/F with cage and pedicle screws
9868888|NCT00215332||Training- CHARITE|Non-Randomized Training (TDR with CHARITE)
9868889|NCT00215332||CHARITE|Randomized Subjects treated by Lumbar Total Disc Replacment with CHARITE
9868890|NCT00215332||Control|Randomized Subjects treated by ALIF with BAK cage
9868891|NCT00215501|Experimental|Group A|Oral capecitabine
9868892|NCT00215501|Experimental|Group B|5-fluorouracil
9868893|NCT00215514|Experimental|ECF followed by 5-FU/RT followed by ECF|
10210693|NCT04299048|Experimental|PF-06946860|subcutaneous injection
10210694|NCT04293224|Experimental|DGA Mediterranean diet pattern, energy balance|Diet plan focused on energy balance (meets calorie needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
10210695|NCT04293224|Experimental|DGA Mediterranean diet pattern, negative energy balance|Negative energy balance (~25% calorie reduction compared to needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
10210696|NCT04293224|Experimental|TAD diet pattern|Typical American Diet (TAD) with negative energy balance (~25% calorie reduction compared to needs) which mimics intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium based on data from What We Eat in America (WWEIA).
9868894|NCT00215527|Experimental|intrathecal laronidase|laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months
9868895|NCT00215605|Experimental|1|
9868896|NCT00215618|Experimental|1|Uterine Balloon Therapy with post procedure curettage
9868897|NCT00215618|Experimental|2|Uterine Balloon Therapy without post-procedure curettage
9868898|NCT00215735|Experimental|APC Treatment|wound debridement and treatment with APC
9868899|NCT00215774|No Intervention|No antiarrhythmic treatment|Control group
9868900|NCT00215774|Experimental|B-Flecainide treatment|4 weeks treatment with flecainide
9868901|NCT00215774|Experimental|C-Flecainide treatment|6 months flecainide treatment
9868902|NCT00215826|Active Comparator|1|650 IU
9868903|NCT00215826|Active Comparator|2|1300 IU
9868904|NCT00215878|Placebo Comparator|1|Adjuvant 6 weeks treatment with placebo (~2g /day)
9868905|NCT00215878|Experimental|2|Adjuvant 6 weeks treatment with D-serine (~2g /day)
9868906|NCT00215904|Placebo Comparator|1|
9868907|NCT00215904|Experimental|2|
9868908|NCT00215956|Experimental|Dose Escalation and Radiation, Followed by Surgery|Preoperative treatment with radiation and oral topotecan for up to 5 weeks, followed by surgery.
9868909|NCT00215982|Experimental|Combination Therapy|Capecitabine in Combination with Irinotecan and Oxaliplatin
9868910|NCT00215995|Experimental|Cisplatin, Irinotecan and ZD1839|As outlined in Detailed Description.
9868911|NCT00216021|Experimental|Single Group Assignment|Capecitabine + Oxaliplatin
9868912|NCT00216034|Active Comparator|1|TS-1 Group: The group treated with TS-1 mono-therapy
9868913|NCT00216034|Experimental|2|TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
9868914|NCT00216047|Experimental|Single Group Assignment|Trastuzumab + PTK787 for HER2 positive patients
9868915|NCT00216073|Active Comparator|1|Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.
9868916|NCT00216112|Experimental|Investigational Treatment|Imatinib Mesylate + Docetaxel
9868917|NCT00216138|Active Comparator|1|Docetaxel + Capecitabine
9868918|NCT00216151|Active Comparator|A|Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
9868919|NCT00216151|No Intervention|B|Patients will be randomly assigned by study number to observation only.
9868920|NCT00216164|Experimental|1|Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
9868921|NCT00216190|Experimental|Dexmedetomidine|
9868922|NCT00216190|Active Comparator|Midazolam|
9868923|NCT00216216|Active Comparator|1|Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.
9868924|NCT00216281|Active Comparator|clozapine with AZT added|Clozapine augmented with Atomoxitine up to 40mg
9868925|NCT00216281|Placebo Comparator|placebo|Subjects will have a placebo pill added to their clozapine regimen.
9868926|NCT00216372|Experimental|1|
9868927|NCT00216372|Placebo Comparator|2|
9868928|NCT00216411|Experimental|Dysport|
9868929|NCT00216411|Placebo Comparator|Placebo|
9868930|NCT00216463|Experimental|A|Slow load with every other week maintenance
9868931|NCT00216463|Experimental|B|Slow load with every other week maintenance
10210697|NCT04280926||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
9868932|NCT00216463|Experimental|C|No load; once weekly maintenance
9868933|NCT00216463|Experimental|D|No load; once weekly maintenance
9868934|NCT00216463|Experimental|E|No load; once weekly maintenance
9928005|NCT00901745|Active Comparator|Sodium nitroprusside infusion|Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
9928006|NCT00901758|Placebo Comparator|2|Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
10210698|NCT04269551|Experimental|BIVV020 IV|Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.
10210699|NCT04265794|Experimental|Intervention|6-week community-based behavioral program consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. The intervention targets knowledge, attitudes, and skills related to sugar-sweetened beverage consumption and water consumption, with reduction in sugar-sweetened beverage consumption and increase in water consumption being the primary behavioral targets.
10210700|NCT04265794|No Intervention|Comparison|Parent-child pairs in comparison sites will receive usual care (standard Boys and Girls Club programming) during the study and the intervention upon study completion.
10210701|NCT04263766|Experimental|Healthy Adult Volunteers|The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.
10210702|NCT04256629|Experimental|Treatment ABC|Subjects will receive a single dose of all 3 treatments (A, B, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
10210703|NCT04256629|Experimental|Treatment BCA|Subjects will receive a single dose of all 3 treatments (B, C, and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
10210704|NCT04256629|Experimental|Treatment CAB|Subjects will receive a single dose of all 3 treatments (C, A, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
10210705|NCT04256629|Experimental|Treatment ACB|Subjects will receive a single dose of all 3 treatments (A, C, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
10210706|NCT04256629|Experimental|Treatment BAC|Subjects will receive a single dose of all 3 treatments (B, A, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
10210707|NCT04256629|Experimental|Treatment CBA|Subjects will receive a single dose of all 3 treatments (C, B and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
10210708|NCT04253314||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label. Decision to treat with Venetoclax was made prior to offering participation in this study.
10210709|NCT04231084|Active Comparator|Inhaled Nitric Oxide|Vasodilator testing will be performed with inhaled nitric oxide
10210710|NCT04231084|Experimental|Inhaled Epoprostenol|Vasodilator testing will be performed with inhaled epoprostenol
10210711|NCT04216589|Experimental|Semaglutide|All participants will receive a dose of 0.25 mg of semaglutide weekly starting at study entry, followed by 0.5 mg weekly starting at Week 2, and then 1.0 mg weekly from Weeks 4 through 24.
10210712|NCT04188964|Experimental|Treatment|Pediatric subjects > = 6 months to < 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects < 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
10210713|NCT04187612||Total body water measurement|Total body water will be measured using Bioelectrical Impedance Analysis (BIA).
10210714|NCT04186494|Active Comparator|Continuous positive airway pressure (CPAP)|Standard CPAP Therapy
10210715|NCT04186494|Experimental|Liraglutide-based weight loss regimen|Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise
10210716|NCT04186494|Experimental|Combination CPAP/Liraglutide|Combination of both interventions
10210717|NCT04180995|Experimental|Toripalimab, Axitinib|The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
10210718|NCT04177264|Experimental|Osteopathic Manipulative Treatment (OMT)|In 4 randomized study sessions, combinations of two different osteopathic manipulative treatment (OMT) techniques (occipito-atlantal decompression [OA DC] and splenic lymphatic pump technique [SpLPT]) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of OMT techniques or sham interventions will be performed.
10210719|NCT04177264|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|In 4 randomized study sessions, combinations of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), osteopathic splenic lymphatic pump technique (SpLPT) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of taVNS, SpLPT, or sham interventions will be performed.
9868935|NCT00216580|Experimental|Risperidone, long-acting injectable|
9868936|NCT00216619|Experimental|Open Label Phase|Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
9868937|NCT00216619|Experimental|Double Blind and Roll Out Phase|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
9868938|NCT00216710|Experimental|Home Visited Mothers|Mothers randomized to the home visited group received AK State-funded home visiting services. Frequency of home visits was determined by home visiting staff based on mothers' needs. Mothers could receive home visiting services until their child turned 3 years old
9868939|NCT00216710|No Intervention|Control Mothers|Mothers randomized to the control group did not receive home visiting services, but were offered referrals to other community-based services, as was usual protocol with home visiting agencies were operating at capacity.
9868940|NCT00216749||Cilostazol|Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)
9868941|NCT00216853||Patients with Recurrent UTI|
9868942|NCT00216853||Healthy controls|
9868943|NCT00216944|Active Comparator|1|Premedication with atropine and morphine
9868944|NCT00216944|Active Comparator|2|Premedication with glycopyrronium, thiopental, suxamethonium and remifentanil
9868945|NCT00216970|No Intervention|1|"Patients will receive nutritional support in which the contents of arginine = 0, glutamate = 0 and proline = 0.~Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients."
9868946|NCT00216970|No Intervention|2|In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
9868947|NCT00216983||1|"Fasting condition to measure:~quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients~Evaluating the rate of proline de novo synthesis from glutamate or ornithine in burn patients"
9986488|NCT01403402||Congenital Muscle Disease|The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.
9986489|NCT01403415|Experimental|Treatment (temsirolimus, combination chemotherapy)|Patients receive dexamethasone PO or IV on days 1-5 and 15-19; mitoxantrone hydrochloride IV over 30 minutes on days 1-2; temsirolimus IV over 30 minutes on days 1 and 8; vincristine sulfate IV on days 1, 8, 15, and 22; and pegaspargase IV over 1 hour on days 3 and 17. Some patients may also receive methotrexate IT up to 72 hours prior to or on day 1 and on day 8.
9986490|NCT01403428|Experimental|NPPV plus standard of care|Noninvasive positive pressure ventilation (NPPV) plus standard of care in the management of children admitted to the hospital with status asthmaticus
9986491|NCT01403428|No Intervention|Standard of care|standard of care treatment in the management of children admitted to the hospital with status asthmaticus
9986492|NCT01403454|No Intervention|usual care|
9986493|NCT01403454|Active Comparator|Health Communication Application|
9986494|NCT01403467|Experimental|NIPPV|
9986495|NCT01403493|Active Comparator|Multidisciplinary patient education|A multidisciplinary (nurse, gastroenterologist, dietician, physiotherapist, psychologist) group education with six sessions for patients with IBS.
9986496|NCT01403493|Active Comparator|Nurse based patient education|A nurse based patient education with three sessions for patients with IBS.
9986497|NCT01403506|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
9986498|NCT01403506|No Intervention|standard treatment|This group is without N-Acetyl Cysteine : just receives standard treatment
9986499|NCT01403519||Alzheimer's disease patients|Patients blood and CSF samples
9986500|NCT01403519||Control group|Blood and CSF samples
9986501|NCT01403519||FTD patients|Blood ad CSF samples
9986502|NCT01403532|Active Comparator|Traditional|
9517130|NCT03309241|Experimental|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
9986503|NCT01403532|Experimental|Sequential|
9986504|NCT01403532|Experimental|Sequential Plus|
9986505|NCT01403545|Experimental|Liposomal Curcumin|Single dose, dose escalation
9986506|NCT01403545|Placebo Comparator|5% Glucose|
9986507|NCT01403558|Experimental|Cognitive behavioral therapy|Ten weekly individual cognitive behavioral therapy sessions before bariatric surgery
9986508|NCT01403558|No Intervention|Control group|Usual preoperative care consisting of up to three voluntary sessions with nutritionist and physiotherapist before bariatric surgery
9986509|NCT01403571|Experimental|Salba supplement|30g/1000kal
9868948|NCT00216983||2|We will study the quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients. When the patients are receiving regular TPN or TPN depleted with proline - arginine - glutamate.
9868949|NCT00216983||3|We wull evaluate the rate of proline de novo synthesis from glutamate or ornithine in burn patients when the patients are receiving regular TPN or TPN depleted proline-arginine-glutamate.
9868950|NCT00216996||Burn patients|Receiving standard TPN with or without glutamine enrichment
9868951|NCT00217009|Active Comparator|Narrowband Ultraviolet B (TL-01UVB) Therapy|treatments - 3x weekly for 15 months
9868952|NCT00217009|Active Comparator|Topical Psoralen plus ultraviolet A (PUVA)|Treatments - 3x weekly for 15 months
9868953|NCT00217100|Active Comparator|Multi Vitamin Formulation|
9868954|NCT00217100|Placebo Comparator|Sugar pill|
9868955|NCT00217217|Experimental|Active EEP-MRSI treatment|20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
9868956|NCT00217217|Sham Comparator|Sham comparator EP-MRSI|Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).
9868957|NCT00217243||Pain study Netherlands|20 healthy subjects 20 patients with a traumatic unilateral peripheral nerve injury 20 patients with CRPS I
9868958|NCT00217256|Experimental|1|Endeavor Drug Eluting Stent
9868959|NCT00217256|Active Comparator|2|Cypher Drug Eluting Stent
9868960|NCT00217269|Experimental|1|Endeavor Drug Eluting Stent
9868961|NCT00217269|Active Comparator|2|Taxus Drug Eluting Stent
9868962|NCT00217308|Experimental|Lactobacillus|
9868963|NCT00217308|Placebo Comparator|Placebo capsules|
9868964|NCT00217373|Experimental|Arm I|"COURSE I: Patients receive recombinant vaccinia-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4 and IFN-α-2b* SC on days 9, 11, and 13.~COURSES II-IV: Patients receive recombinant fowlpox-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive GM-CSF as in course 1 and IFN-α-2b* SC on days 1, 3, and 5.~NOTE: *The initial cohort of 6 patients does not receive IFN-α-2b.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients who do not have progressive disease or unacceptable toxicity may receive recombinant fowlpox-CEA (6D)-TRICOM vaccine, GM-CSF, and IFN-α-2b every 28 days for 2 more courses and then every 3 months for up to 2 years."
9868965|NCT00217412|Experimental|Arm I|Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
9868966|NCT00217412|Experimental|Arm II|Group 2 (leukemia patients): Patients receive SAHA as in group 1 at the MTD.
9868967|NCT00217412|Experimental|Arm III|Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
9986510|NCT01403571|Placebo Comparator|Oat-bran based Control Supplement|36g/1000kcal
9986511|NCT01403597|Experimental|Treatment|The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
10210720|NCT04177264|No Intervention|Time Control|In 4 study sessions, no intervention will be performed. As with the two experimental arms, the 4 study sessions are at least one month apart and consist of 3 consecutive study days on which no intervention will be performed. This arm serves as a time control group.
10210721|NCT04174521||Mother-Child|Mothers who have delivered at VUMC and their children who are seen by Vanderbilt-affiliated physicians.
10210722|NCT04173702|Experimental|Healthy Group|Postural sway and stability limits in assessment of healthy individuals
9986512|NCT01403623|Active Comparator|Resuscitation with plastic bag|Plastic bag will be used during and after resuscitation to assist with temperature regulation.
9986513|NCT01403623|Sham Comparator|Standard resuscitation- no plastic bag|Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
10210723|NCT04165772|Experimental|Cohort 1|Patients with clinical Stage II or Stage III MRI-staged, MSI-H or dMMR, solid tumors will receive up to 6 months (9, 21-day cycles) of PD-1 blockade followed by radiological and surgical restaging of the tumor. If subject exhibits complete clinical response, non-operative management will be followed. If a complete clinical response is not reached after 6 months of PD-1 blockade, the participant will proceed with standard chemoradiation. After completing chemoradiation participant will be assessed for response if complete CR is not obtained then the participant will proceed with disease specific surgical resection or standard of care therapy.
10210724|NCT04165772|Other|Cohort 2|The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory
10210725|NCT04165161|Other|superior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation without positive tele-expiratory pressure
10210726|NCT04165161|Other|superior with 10 cmH2O positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
10210727|NCT04165161|Other|inferior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation without positive tele-expiratory pressure
10210728|NCT04165161|Other|inferior with 10 cmH2O positive tele-expiratory pressur|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
10210729|NCT04163952|Experimental|Treatment (talimogene laherparepvec, panitumumab)|Patients receive talimogene laherparepvec IM on day 1. Patients then receive talimogene laherparepvec IM and panitumumab IV over 30-90 minutes on day 22. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive up to 3 additional cycles of treatment per physician discretion.
10210730|NCT04136665|Experimental|Physical Activity Adapted program|
10210731|NCT04127331|Active Comparator|Routine|Patients who are scheduled for routine outpatient surgery.
10210732|NCT04127331|Active Comparator|Urgent|Patients who are scheduled for urgent surgery.
10210733|NCT04127331|Active Comparator|Emergent|Patients who are scheduled for emergency surgery.
10210734|NCT04123054|Active Comparator|Sensor-Augmented MDI + Mobile App (control)|Participants will continue their usual multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data.
10210735|NCT04123054|Experimental|Sensor-Augmented MDI + Mobile App + Basal-Bolus Optimization Algorithm|Participants will undergo multiple daily injections (MDI) therapy along with the use of Freestyle Libre glucose sensors (Abbott Diabetes Care) and a mobile application that facilitates insulin dose calculations while collecting insulin and meal data. Every week, participants' insulin doses will be updated by the optimization algorithm's recommendations.
10210736|NCT04118140|Experimental|True SA (Somatic Acupressure ) group|Receiving true somatic acupressure+usual care
10210737|NCT04118140|Sham Comparator|Sham SA group|Receiving sham somatic acupressure+usual care
10210738|NCT04118140|Other|Usual care group|Receiving usual care only (an education booklet regarding knowledge of BC and FSD symptom cluster management advice)
10210739|NCT04112199|Experimental|BIV201 plus Standard of Care|BIV201 continuous infusion - treatment for two 28 day cycles.
10210740|NCT04112199|No Intervention|Standard of care|Per AASLD guidelines: diuretics and therapeutic paracentesis
10210741|NCT04109846|Experimental|Non-euploid Transfer|Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).
10210742|NCT04109846|Active Comparator|Euploid Transfer|Patients desiring pregnancy who are undergoing euploid embryo transfer
10210743|NCT04099329|Experimental|Pre-game Safety Huddles|Pre-game safety huddles will occur before each game and athletes and coaches will be surveyed.
10210744|NCT04099329|No Intervention|Control|No intervention will be delivered by athletes and coaches will be surveyed.
10210745|NCT04094311|Other|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel per the Health Authority-approved tisagenlecleucel product information in the respective country/region are considered eligible for this study . Patients will be divided into 2 groups:~Group A: Pediatric and young adult patients with B-cell ALL (pALL) who meet the indication in Health Authority-approved tisagenlecleucel product information in the respective country/region whose final manufactured product is OOS for commercial release.~Group B: Adult patients with r/r LBCL including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the product information for tisagenlecleucel in respective country/region but whose final manufactured product is OOS for commercial release/acceptance."
10210746|NCT04083963|Other|Single arm|Low dose weekly carboplatin in combination with standard neoadjuvant chemotherapy
9868968|NCT00217477|Experimental|Paricalcitol IV in combination with Gemcitabine IV|Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9868969|NCT00217516|Experimental|Arm I|Patients receive oral selenium for 3-6 weeks.
9868970|NCT00217516|Placebo Comparator|Arm II|Patients receive oral placebo for 3-6 weeks.
9868971|NCT00217542|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive azacitidine SC once daily on days 1-4 and 15-17 and recombinant interferon alfa-2b SC on days 8, 10, 12, 15, 17, 19, 22, 24, and 26 during course 1. Beginning in course 2 and for all subsequent courses, patients receive azacitidine SC once daily on days 1-3 and 15-17 and interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 total courses in the absence of disease progression or unacceptable toxicity.
9868972|NCT00217607|Experimental|Paclitaxel|"Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)"
9868973|NCT00217633|Experimental|Treatment (pelvic exenteration)|Patients undergo pelvic exenteration within 14 days after study entry.
9868974|NCT00217646|Experimental|Arm I|Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
9868975|NCT00217646|Experimental|Arm II|Patients receive oral sorafenib once or twice daily on days 1-14.
9868976|NCT00217711|Active Comparator|Arm A|Oxaliplatin, Irinotecan, and Capecitabine
9868977|NCT00217776|Active Comparator|Open Airways Educational Intervention|Children in this arm will receive the Open Airways educational program which is an evidenced based asthma educational program for children, developed by the investigator.
9868978|NCT00217776|Active Comparator|Open Airways and Peer Asthma Action Intervention Education|Children in this arm will receive BOTH the Open Airways asthma education program and the Peer Asthma Action education program.
9868979|NCT00217776|No Intervention|Control Arm|Children in the Control Arm will be interviewed in person at baseline, 12 month and 24 months.
9868980|NCT00217854|Other|Open label inhaled fluticasone|Patients are treated with open label high dose fluticasone for 30 days then discontinued. Comparisons are pre- and post- treatment single arm.
9868981|NCT00217867|No Intervention|1|Usual Care, defined as the usual hospital discharge process as delivered by nurses and doctors.
9868982|NCT00217867|Experimental|2|Use of animated computerized character to prepare subjects for discharge by reviewing information provided to subjects in a printed After Hospital Care Plan packet, followed by telephone system to reinforce the discharge.
9868983|NCT00217893|Experimental|1|Combination of counseling, cotinine feedback, and contingent incentives.
9868984|NCT00217893|Active Comparator|2|Usual education program
9868985|NCT00217919|Experimental|1|Health-Counselor Mediated Telephone Counseling Intervention
9868986|NCT00217919|No Intervention|2|Usual care
9868987|NCT00217984|Experimental|Intensive intervention|Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
9868988|NCT00217984|Other|Usual care|Referral to the smoking cessation clinic
9868989|NCT00218010||Methadone maintained lactating women|Methadone maintained women who chose to breastfeed their infants provided breast milk and plasma samples for this study.
9868990|NCT00218049|Experimental|1|50 mg of GBR 12909
9868991|NCT00218049|Experimental|2|75 mg of GBR 12909
9868992|NCT00218049|Experimental|3|100 mg of GBR 12909
9868993|NCT00218114|Experimental|1|Divalproex sodium (Depakote). This is a parallel groups design lasting a total of six weeks. Participants will be on a fixed-flexible dosing schedule. The dose of depakote will be raised to 750mgs or 1000mgs, depending on weight, in two weeks to achieve blood levels between 50-130 micrograms per milliliter. If a patient does not achieve this blood level on 750mgs or 1000 mgs, the dose may be raised during the second week.
9868994|NCT00218114|Placebo Comparator|2|This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
9868995|NCT00218127|Experimental|1|LAAM WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day for 20 weeks
9868996|NCT00218127|Experimental|2|LAAM MaxEffect to 48 mg Adjust to effect (+/-)
9868997|NCT00218127|Experimental|3|LAAM Fixed Dose up to 48 mg 48 mg
9928007|NCT00901758|Active Comparator|1|Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
9928008|NCT00901784|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
9928009|NCT00901784|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
9928010|NCT00901797|Active Comparator|Arthroscopic Bankart repair|
9928011|NCT00901797|Active Comparator|ABR+ARIC|
9928012|NCT00901810|Active Comparator|Apex Locator|Working length for cleaning and shaping of the canal is measured by Electronic Apex Locator in this group.
9928013|NCT00901810|Active Comparator|Radiography|Working length for cleaning and shaping of the canal is measured by Radiography in this group.
9928014|NCT00901823|Experimental|Sequence 1|Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
9928015|NCT00901823|Experimental|Sequence 2|Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
9928016|NCT00901836|Experimental|Preoperative Proton Therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
9928017|NCT00901836|Active Comparator|Surgery|Standard of care surgery will be performed 4-6 weeks after the completion of radiation.
9928018|NCT00901862|Active Comparator|1 Active PEFs|The pulsed electromagnetic fields were directed to the wrist. The model used has the form of a bracelet called Quantum MH-2MR which uses, as a source of power, an alkaline battery of 1.5 volts connected to an electronic circuit formed by two hybrid circuits of magnetic oscillation and a control system of all the generating frequency system.
9928019|NCT00901862|Sham Comparator|2 Sham|The sham machines were identical to the machines in actual operation in both phases of the study. The only difference was that the hybrid circuits crucial for the generation of the electromagnetic field had been removed.
9928020|NCT00901875|Experimental|Suboxone, maximum 8mg|
9928021|NCT00901875|Experimental|Buprenorphine + naloxone|
9928022|NCT00901875|Experimental|Buprenorphine + naloxone (Suboxone)|
9935308|NCT03913559|Experimental|Inotuzumab ozogamicin|"Experimental:Inotuzumab Ozogamicin (InO) Patients with B cell acute lymphoblastic leukemia (B-ALL) that is showing early signs of relapsing (coming back) or is not responding to treatment (refractory).~Interventions:methotrexate, hydrocortisone and cytarabine into the central nervous system (called triple intrathecal chemotherapy or IT chemotherapy) during this study.~Premedication: diphenhydramine, acetaminophen and methylprednisolone"
9935309|NCT03912428|Other|Single arm|all groups get the same studies
9935310|NCT03911700|Experimental|Phasix™ Mesh|Prophylactic onlay placement of mesh.
9935311|NCT03911700|No Intervention|Primary Suture Closure|Standard Fascial closure.
9935312|NCT03910465||1/Cohort 1|Subjects with confirmed chordoma.
9935313|NCT03910452|Experimental|1|This is a single arm open-label pilot study.
9935314|NCT03908437|Experimental|Rapid initiation|Rapid initiation of buprenorphine/naloxone, counseling, peer support and case management
9935315|NCT03908437|Active Comparator|Treatment as usual|Seeking treatment from the BAC/CRC (treatment as usual)
9935316|NCT03898856|Experimental|Crofelemer and Diagnostic tests for cause of chronic diarrhea|125 mg tablets taken by mouth twice daily for 28 days
9935317|NCT03896516|Experimental|Active Drug|GOAT Inhibitor
9935318|NCT03896516|Placebo Comparator|Placebo|Placebo Participants will take GLWL-01 450 mg b.i.d. or matched placebo for up to 16 days
9935319|NCT03895658|Experimental|ECT|ECT treatment, Within subject cross-over
9935320|NCT03895658|Experimental|MRI|Structural and functional neuroimaging pre and post ECT treatment
9935321|NCT03895658|Experimental|TMS|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
9935322|NCT03895645||Study Participants|Participants on the studies' samples that are transferred to this protocol
9935323|NCT03892759|Other|Evaluation and Treatment|Subjects will be evaluated through inspection and palpation of the thoracic and lumbar spine, and other body regions as necessary. The provider will make a diagnosis of somatic dysfunction based off the TART (tissue texture change, asymmetry, restriction of motion, tenderness/pain) findings.
9935324|NCT03891446|Experimental|Lead-in study 192024-091 or -092 or -095|"Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.~Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
9935325|NCT03891446|Experimental|Lead-in study 192024-093 Stage 1|"Participants in Lead-in Study 192024-093 Stage 1 and participants in Stage 2 who received only 1 Bimatoprost administration due to safety concerns:~Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.~Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
9935326|NCT03891446|Experimental|Lead-in study 192024-093 Stage 2|"Participants in Lead-in Study 192024-093 Stage 2 who received only 2 Bimatoprost administrations or 1 Bimatoprost administration due to sustained efficacy:~Study eye (Eye that received Bimatoprost SR in the lead-in study): 2 additional administrations of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment."
9935861|NCT03071757|Experimental|Part 3B: 18F-AraG Imaging Substudy in HNSCC Participants|Part 3B: Additional participants (with HNSCC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
9935862|NCT03065335|Experimental|Metabolites Substudy|Open-label, single dose of 0.5 mg/kg IV ketamine
9868998|NCT00218166|No Intervention|A|Within subject design
9868999|NCT00218179||Cases|Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
9869000|NCT00218179||Controls|Subjects without lung cancer among smokers at baseline in the PLCO study
9869001|NCT00218218|Experimental|1|Transdermal nicotine, 42 mg
9869002|NCT00218218|Experimental|2|Transdermal nicotine, 21 mg
9869003|NCT00218218|Placebo Comparator|3|placebo patch
9869004|NCT00218231|Experimental|1|300 mg/day bupropion-sr
9869005|NCT00218231|Placebo Comparator|2|0 mg bupropion-sr
9869006|NCT00218244|Active Comparator|1 Controlled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under a controlled use condition.
9869007|NCT00218244|Active Comparator|2 Uncontrolled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under an uncontrolled use condition.
9869008|NCT00218244|Placebo Comparator|3 Behavioral|Reduction in smokeless tobacco use using behavioral techniques only.
9869009|NCT00218270|Experimental|1|Reduction of tobacco use by substituting tobacco free snuff.
9869010|NCT00218270|Placebo Comparator|2|Reduction of tobacco use by using behavioral techniques.
9869011|NCT00218283|Experimental|1 - Nicotine Lozenge|Use of nicotine lozenge plus behavioral counseling to help reduce tobacco use prior to quit date.
9869012|NCT00218283|Placebo Comparator|2 Behavioral counseling|Use of behavioral counseling alone to help reduce tobacco use prior to quit date.
9869013|NCT00218322|Placebo Comparator|1|Treatment with placebo or atomoxetine for 12 weeks.
9869014|NCT00218322|Experimental|2|
9869015|NCT00218413|Experimental|1|
9869016|NCT00218413|Experimental|2|
9869017|NCT00218413|Experimental|3|
9869018|NCT00218413|Experimental|4|
9869019|NCT00218413|Experimental|5|
9869020|NCT00218452|Experimental|Lifestyle counseling|
9869021|NCT00218517|Experimental|1|
9869022|NCT00218517|Placebo Comparator|2|
9869023|NCT00218556|Experimental|Depression prevention|Cognitive behavioral treatment for depression.
9869024|NCT00218556|No Intervention|Control|Treatment as usual.
9869025|NCT00218569|Experimental|1|Naltrexone
9869026|NCT00218569|Experimental|2|Placebo
9869027|NCT00218582|Experimental|1|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
9869028|NCT00218582|Active Comparator|2|Standard psychiatric day treatment
9869029|NCT00218595|Experimental|DBT|
9869030|NCT00218595|Active Comparator|I/GDC|
9869031|NCT00218608|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
9869032|NCT00218608|Active Comparator|Disulfiram at 62.5 mg|Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
9869033|NCT00218608|Active Comparator|Disulfiram at 125 mg|Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
9869034|NCT00218608|Active Comparator|Disulfiram at 250 mg|Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
9869035|NCT00218660|Experimental|1|Nal + BRENDA
9869036|NCT00218660|Placebo Comparator|2|Placebo + BRENDA
9869037|NCT00218660|Experimental|3|Nal + CBT
9869038|NCT00218660|Placebo Comparator|4|Placebo + CBT
9869039|NCT00218673|Experimental|experimental|social network
9869040|NCT00218673|No Intervention|control|testing and counseling
9869041|NCT00218686|Experimental|1|behavioral social network risk reduction intervention
9869042|NCT00218686|Active Comparator|2|voluntary counseling and testing (VCT
9869043|NCT00218712|Experimental|1|Participants will receive personalized cognitive counseling
9869044|NCT00218712|Active Comparator|2|Participants will receive standard counseling
9869045|NCT00218725|Other|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
9869046|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
9869047|NCT00218790|No Intervention|Control group|The control group received standard dialysis at a temperature of 37 degrees Celcius
9869048|NCT00218790|Experimental|Experimental group|Subjects in the experimental group received cool dialysate during treatment
9869049|NCT00218803|Experimental|1|
9869050|NCT00218803|Other|2|
9869051|NCT00218816|Experimental|1|
9796066|NCT01555567|Experimental|Eccentric Exercise|Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
9869052|NCT00218816|Other|2|
9517131|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
9869053|NCT00218842|Experimental|exercise group|individualized exercise
9869054|NCT00218842|No Intervention|control group|care as usal
9869055|NCT00218855|Placebo Comparator|A|
9869056|NCT00218855|Active Comparator|B|
9869057|NCT00218868||skin scrape|
9869058|NCT00218894||post cataract surgery|
9869059|NCT00218920|Experimental|strength training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
9869060|NCT00218920|Experimental|continuous moderate-intensity aerobic training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
9869061|NCT00218920|Experimental|high-intensity interval aerobic training|Over a 12-week period, 14 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
9869062|NCT00218933|Active Comparator|moderate exercise training|
9869063|NCT00218933|Experimental|high intensity exercise training|
9869064|NCT00218933|No Intervention|controls|
9869065|NCT00218946|No Intervention|control|no fluid, no pacifier
9869066|NCT00218946|Experimental|water|water, no pacifier
9869067|NCT00218946|Experimental|sucrose|Sucrose, no pacifier
9869068|NCT00218946|Experimental|pacifier|No fluid, pacifier
9869069|NCT00218946|Experimental|water and pacifier|water, pacifier
9869070|NCT00218946|Experimental|sucrose and pacifier|sucrose, pacifier
9869071|NCT00218959|Experimental|Narrative Exposure Therapy|carried out according to the manual as outlined by Schauer et al. (2005) (second revised edition 2011) 10 sessions of 90 min duration
9869072|NCT00218959|Active Comparator|treatment as usual|mainly help with such as sleep problems, depressive symptoms, problems related to asylum status, and other practical matters. Focus on everyday issues and the limited focus on the traumatic events, in line with reports from the National Center on Violence and Traumatic Stress.
9869073|NCT00218972|Active Comparator|AIT: aerobic interval training|High intensity interval training on treadmill at > 90% of maximal HR for four bouts of four minutes with warm up, active pauses and cool down, three times per week for 12 weeks.
9869074|NCT00218972|Active Comparator|MIT, moderate intensity training|Moderate intensity treadmill continuous exercise at 70% of maximum heart rate for 47 minutes (in order to ensure isocaloric training amount), three times per week for 12 weeks.
9869075|NCT00218972|Active Comparator|Recommendation of regular exercise|No training intervention, general advice as prescribed in guidelines.
9869076|NCT00218985|Experimental|exercise training|
9869077|NCT00218985|No Intervention|physician's advice|patients follow their physician's advice in regard to physical activity.
9869078|NCT00219271|Experimental|Zoledronic acid|4 mg IV infused over 15 minutes every 3 months
9869079|NCT00219336|Experimental|Self-motivational Choices|Students and nonstudents were mailed a brochure prepared as part of the PHC study intervention, Making Healthy Choices for a Healthy Baby in English or Mujeres y Salud Eligiendo Opciones Saludables in Spanish. This brochure allows women to make informed decisions about preventing an AEP. The MF materials included nonstigmatizing messages about drinking and contraception embedded among other health messages. Similar to Project CHOICES, this group also received a brochure on birth control practices.
9869080|NCT00219336|Active Comparator|Information Only|Students and nonstudents were mailed a brochure prepared by the CDC. The brochure (English: Think Before You Drink: You Can Hurt Your Unborn Baby; Spanish: Piénselo Antes de Beber: Puede Lastimar a Su Futuro Bebe), available at the CDC website, targets women of childbearing-age, discusses FAS and the negative effects of a mother's drinking on her unborn child, and recommends calling Alcoholics Anonymous or an alcohol treatment program for help to stop drinking. The CDC brochure did not contain information about how to contracept effectively.
9869081|NCT00219362|Experimental|ALVAC-HIV 4 injections|Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
9869082|NCT00219362|Experimental|ALVAC-HIV 3 injections|Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
9869083|NCT00219362|Placebo Comparator|Placebo - 4 injections|Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
9869084|NCT00219362|Placebo Comparator|Placebo - 3 injections|Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
9869085|NCT00219375|Experimental|E1|This arm is conducted as a separate study (12-601-0001)
9869086|NCT00219375|Experimental|E2|This arm is conducted as a separate study (12-603-0001).
9869087|NCT00219375|No Intervention|conventional therapy|This arm is conducted as a separate study (12-602-0001)
9869088|NCT00219401|Experimental|Neonatal 7vPCV|Receive study vaccine (Prevnar) at birth, 1 and 2 months
9869089|NCT00219401|Experimental|Infant 7vPCV|Receive the study vaccine (Prevnar) at 1, 2 and 3 months
9869090|NCT00219401|Placebo Comparator|Control|Do not receive study vaccine (Prevnar)
9869091|NCT00219427||1|
9869092|NCT00219440|Experimental|A|ACTOS plus standard diet
9869093|NCT00219440|Experimental|B|Actos plus structured diet
9869094|NCT00219440|Experimental|C|Metformin plus standard diet
9869095|NCT00219466|Active Comparator|1|
9517132|NCT03309215|Experimental|Patients with nickel allergy|Experimental stimulation with nickel discs
9517133|NCT03309215|Experimental|Persons without nickel allergy|Experimental stimulation with nickel discs
9986514|NCT01403649|Experimental|Increasing flu vaccination|Collect from billing records in the 10 intervention practice sites to test for an increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 months to 18 years during the season. The interventions include: 1. Develop practice-based intervention strategies (like use of reminder-recall of children due for influenza,2. Develop Private/public collaboration to increase flu vaccination between the intervention practices, their county public health department and visiting nursing associations, and 3. Implement both practice-based and private-public collaborative strategies in the intervention practices while monitoring only in the control practices
9986515|NCT01403649|Other|Usual care|Patients in control practices will continue to receive usual care with no change in practice regarding influenza immunization delivery.
9986516|NCT01403662|Experimental|Minocycline|
9986517|NCT01403675|Experimental|Ovarian autotransplantation|
9986518|NCT01403688||Random Fine Needle Aspiration (RPFNA)|RPFNA
9986519|NCT01403701|Experimental|Physical therapy|Standardized pelvic floor physical therapy
9986520|NCT01403701|No Intervention|routine care|Standard postoperative visits
9986521|NCT01403714|No Intervention|Medical Management|Patients may be randomized to medical management alone
9986522|NCT01403714|Active Comparator|Renal Artery Stenting|Those patients with recent heart failure exacerbations that cannot be attributed to poor left ventricular function and have a hemodynamically significant renal artery stenosis may be randomized to renal artery stenting
9986523|NCT01403727||Unassisted Biopsy - CONTROL GROUP|Routine biopsy needle placement and Physician blinded to needle location
9869096|NCT00219466|Active Comparator|2|
9869097|NCT00219531||control|subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
9869098|NCT00219531||IBS|women with IBS symptoms and normal menstrual cycle.
9869099|NCT00219674|Active Comparator|2|Group II
9869100|NCT00219674|Active Comparator|3|
9869101|NCT00219674|Active Comparator|4|
9869102|NCT00219674|Active Comparator|1|Group I
9869103|NCT00219687|Active Comparator|1|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions only
9869104|NCT00219687|Active Comparator|2|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions and breaths
10210747|NCT04076072|Active Comparator|Alcon Advanced Ultravit High-Speed Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
9869105|NCT00219739|Experimental|Imatinib mesylate 400 mg|
9796067|NCT01555567|Experimental|Stimulation and Eccentrics|Subjects placed into this group will undergo a combined electrical stimulation and eccentric exercise intervention following ACLr. The electrical stimulation intervention will be delivered immediately following ACLr and will end at 6 weeks post-ACLr. Subjects will receive the electrical stimulation therapy 2 times per week for the first 6 weeks post-ACLr. At six weeks post-ACLr, subjects will begin the eccentric strengthening protocol. Subjects will eccentrically train 2 times per week for 6 weeks. The eccentric strengthening will end at 12 weeks post-ACLr.
9796068|NCT01555671|Active Comparator|meperidine administration group|Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
9796069|NCT01555671|Placebo Comparator|plasebo group|Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
9796070|NCT01555697|Active Comparator|Memantine/high|memantine 20 mg
9796071|NCT01555697|Placebo Comparator|Placebo/high|placebo comparator for memantine 20 mg
9796072|NCT01555697|Active Comparator|Memantine/low|memantine 10 mg
9796073|NCT01555697|Placebo Comparator|Placebo/low|placebo comparator for memantine 10 mg
9796074|NCT01555762||Cohort|
9796075|NCT01555931|Experimental|Immediate|Placement within 48 hours of delivery
9796076|NCT01555931|Active Comparator|Control|Placement 4-8 weeks after delivery
9796077|NCT01555957|Experimental|low dose intravenous lipids|
9796078|NCT01555957|Placebo Comparator|high dose of intravenous lipids|
9796079|NCT01555983|Active Comparator|Vaporization of Cannabis 6.7% THC|Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
9796080|NCT01555983|Active Comparator|Vaporization of Cannabis 2.9% THC|Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
9796081|NCT01555983|Placebo Comparator|Vaporization of Cannabis Placebo THC|Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
9796082|NCT01556061|Experimental|D-MAC video laryngoscopy|The Dblade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with CMAC blade.
9796083|NCT01556061|Active Comparator|C-MAC video laryngoscopy|The CMAC blade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with D-blade
9796084|NCT01556100|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
9796085|NCT01556165|Experimental|rasagiline|
9796086|NCT01556165|Placebo Comparator|placebo|
9796087|NCT01556204|Experimental|Robotic Surgery|Robotic surgery using the da Vinci Surgical System
9796088|NCT01556204|Active Comparator|Laparoscopy|Laparoscopic assisted resection of endometriosis will be performed using up to five 5mm ports.
9796089|NCT01556347|Experimental|Elimination of Immunologic Memory|A single arm multi-drug regimen is used to delete immunologic memory in order to reduce or eliminate alloreactive anti-HLA antibodies in highly sensitized heart transplant candidates. The intervention includes a protocol of Thymoglobulin, Rituximab, plasmapheresis and Bortezomib.
9796090|NCT01556425|Experimental|Vivitrol Only|The VIVITROL group will be offered one injection of VIVITROL every 4 weeks. Participants in the VIVITROL group will be required to take their scheduled injections to work and earn wages. If a participant misses a scheduled VIVITROL injection (more than 3 days from the scheduled date of administration), the participant will not be allowed to work until the injection is accepted. Additionally, missing a scheduled injection will result in a base pay reset from $8 per hour to $1 per hour. After the reset, the participant's base pay will increase by $1/hour to the maximum of $8/hour for every day that the participant works at least 5 minutes.
9869106|NCT00219739|Experimental|Imatinib mesylate 600 mg|
9869107|NCT00219739|Experimental|Imatinib mesylate 400 mg +Peg interferon|
9869108|NCT00219739|Experimental|Imatinib mesylate 400 mg +Cytarabine|
9869109|NCT00219856|Experimental|1|Anesthesic induction and maintenance with intravenous propofol.
9869110|NCT00219856|Active Comparator|2|Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
9869111|NCT00219882|Experimental|1|standardized turmeric root extract
9869112|NCT00219934||Group A|acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
9935863|NCT03065335|Experimental|Phase I|Medication taper, drug-free period, and baseline assessments
9869113|NCT00219934||Group B|subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
9869114|NCT00219947||high risk|Blood draw from individuals known to be or at high risk for HIV-infection
9869115|NCT00219947||diagnosed|Blood draw f rom individuals diagnosed with HIV infection
9869116|NCT00219999||HCV infection|current HCV infection, including intravenous drug users
9869117|NCT00219999||cryoglobulinemia|cryoglobulinemia and without HCV infection
9869118|NCT00219999||chronic liver disease|chronic liver disease not due to hepatitis C virus infection
9869119|NCT00219999||Sustained Virologic responders|successfully treated for HCV infection
9869120|NCT00219999||normal|normal, healthy volunteers
9869121|NCT00220025|Experimental|NBUVB|
9869122|NCT00220038||Normal|700 healthy adult volunteers will be drawn from the New York City area
9869123|NCT00220285|Experimental|Arm 1|
9869124|NCT00220285|Experimental|Arm 2|
9869125|NCT00220298|Experimental|Arm 1|
9869126|NCT00220311|Experimental|Arm 1|
9869127|NCT00220324|Experimental|Arm 1|
9869128|NCT00220337|Experimental|1|Open label active treatment
9869129|NCT00220584|Experimental|Open donepezil|open donepezil
9869130|NCT00220753|Active Comparator|Active air cleaner|Two Icleen IQAir air cleaners with active filters supplied
9869131|NCT00220753|Placebo Comparator|Placebo air cleaner|Two Icleen IQAir air cleaners with placebo filters supplied
9869132|NCT00220766|Experimental|Group 1|Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
9869133|NCT00220766|Experimental|Group 2|Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
9869134|NCT00220818|Experimental|Lansoprazole 1.0 mg/kg QD|
9869135|NCT00220818|Experimental|Lansoprazole 2.0 mg/kg QD|
9869136|NCT00220844|Experimental|Nortriptyline|
9869137|NCT00220844|Experimental|Placebo|
9869138|NCT00220922|Experimental|1|injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
9869139|NCT00220922|Experimental|2|injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
9869140|NCT00220987|Experimental|Intensive Insulin therapy|Intensive Insulin therapy
9869141|NCT00220987|Active Comparator|Conventional Therapy|conventional insulin therapy
9869142|NCT00221013|Experimental|Higher intensity CRRT regimen|
9869143|NCT00221013|Active Comparator|Lower intensity CRRT regimen|
9869144|NCT00221026|Experimental|drug|ECP + Uvadex given for 12 weeks.
9869145|NCT00221039|Experimental|DRUG+ECP|UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.
9869146|NCT00221065|No Intervention|1|Control
9869147|NCT00221065|Experimental|2|CPAP
9928023|NCT00901888|Experimental|Angiotensin II infusion|Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
9928024|NCT00901888|Active Comparator|Noradrenaline|Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
9928025|NCT00901914|Placebo Comparator|1|Placebo
9928026|NCT00901914|Experimental|2|12.5 µg rBet v 1
9928027|NCT00901914|Experimental|3|25 µg rBet v 1
9928028|NCT00901914|Experimental|4|50 µg rBet v 1
9928029|NCT00901940|Active Comparator|MenACWY Plain Polysaccharide (ACWY Vax)|The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
9935864|NCT03065335|Experimental|Phase II, Arm 1|Double-blind, single dose of 0.5 mg/kg IV ketamine
9869148|NCT00221169|Other|surgical candidates|surgical candidates who underwent PET CT evaluation
9869149|NCT00221247|Active Comparator|Group 1|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy with acupuncture
9869150|NCT00221247|No Intervention|Group 2|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy without acupuncture
9869151|NCT00221325|Experimental|Rituximab Plus MTX|
9869152|NCT00221442|Active Comparator|zonisamide|zonegran (zonisamide)
9869153|NCT00221442|Placebo Comparator|Sugar pill|fake pill
9869154|NCT00221468|Experimental|Quetiapine|Patients will begin 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
9869155|NCT00221507|No Intervention|Historical Cohort|This study will first examine risk factors in a defined population of inner city children, using a historical cohort.
9869156|NCT00221507|Active Comparator|Reminder Recall Outreach|"To determine how well Reminder Recall Outreach will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
9869157|NCT00221507|Active Comparator|Case Management|"To determine how well Case Management will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
9869158|NCT00221507|Active Comparator|Patient Navigation|"To determine how well Patient Navigation will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
9869159|NCT00221546|Active Comparator|DHA-rich supplement|
9869160|NCT00221546|Placebo Comparator|Placebo|
9869161|NCT00221598|Experimental|hemodialysis|
9869162|NCT00221702|Experimental|A|Peg Intron 100 mcg SC/week for 36 months
9869163|NCT00221702|Active Comparator|B|Intron A 3 X 3 MIU, weekly, sc, for 18 months
9869164|NCT00221715|Experimental|1|bypass by autologous saphenous vein
9869165|NCT00221715|Active Comparator|2|bypass by dacron or PTFE Prosthesis
9869166|NCT00221767|Experimental|1|Brindley technique (bladder system)
9869167|NCT00221767|No Intervention|2|Reference group
9869168|NCT00221793|Experimental|1|Deep Brain Stimulation of the Subthalamic Nucleus
9869169|NCT00221793|Active Comparator|2|Later Deep Brain Stimulation of the Subthalamic Nucleus
9869170|NCT00221845|Active Comparator|Conventional BP Control|Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
9869171|NCT00221845|Experimental|Intensified BP Control|Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
9869172|NCT00221897||Healthy individuals|healthy controls with or without myopia
9869173|NCT00221897||Persons at risk for or with primary open angle glaucoma|with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension
9869174|NCT00221923||Healthy individuals|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
9869175|NCT00221923||Persons at risk for or with primary open angle glaucoma|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
9869176|NCT00221962|Other|Open label treatment with aripiprazole|After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.
9869177|NCT00221975|Active Comparator|Lithium + Divalproex + Lamictal|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the lamotrigine group were titrated up to a minimum dose of 150 mg and maximum dose of 200 mg per day.
9869178|NCT00221975|Placebo Comparator|Lithium + Divalproex + Placebo|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the placebo group were giving matching placebo.
9869179|NCT00222001||HMO Patients|Measurement of telephone triage outcome.
9869180|NCT00222014|Experimental|1|TIPS réalisé avec prothèse couverte de PTFE
9869181|NCT00222014|Active Comparator|2|Paracenthese and albumine perfusion
9869182|NCT00222040|Experimental|1|Levovist
9869183|NCT00222040|No Intervention|2|No specific intervention
9869184|NCT00222053|No Intervention|1|No specific intervention
9869185|NCT00222053|Active Comparator|2|Biphosphonates
9869186|NCT00222053|Experimental|3|Thalidomide
9869187|NCT00222066|Experimental|1|Fetal ovarian cyst aspiration performed as soon as possible
9869188|NCT00222066|No Intervention|2|Expectative
9869189|NCT00222118|Experimental|1|intervention group
9869190|NCT00222118|Other|2|Attention control
9869191|NCT00222118|Other|3|Usual care
9869192|NCT00222144|Experimental|1|Gleevec and Taxotere
9869193|NCT00222248|Experimental|Pelvic floor muscle training|Weekly group session of education and exercise to music incorporating pelvic floor muscle training incorporating motor control, strength, endurance, power and functional training in a variety of different positions.
9869194|NCT00222248|Active Comparator|Bladder training|Weekly group session of education regarding deferral techniques, timed voiding parameters and gentle exercise to music.
9869195|NCT00222261|Active Comparator|1, aspirin|Aspirin 160 mg
9869196|NCT00222261|Active Comparator|2, clopidogrel|Clopidogrel 75 mg
9869197|NCT00222274|Experimental|1|RSA Biofeedback: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
9869198|NCT00222274|Active Comparator|2|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
9869199|NCT00222326|Experimental|Pelvic floor muscle training|Pelvic floor muscle training: clinic and rooms exercise training
9869200|NCT00222326|No Intervention|Usual care|Usual care as provided by the surgeon and hospital staff
9869201|NCT00222352||central laboratory cTnI test|Control Group
9869202|NCT00222352||Point of Care cTnL testing|Experimental Group
9869203|NCT00222417||Myringoplasty|Patients subject to myringoplasty for tympanic membrane perforations.
9869204|NCT00222417||Otosclerosis|Patients subject to stapes surgery
9869205|NCT00222430|Active Comparator|A|Usual standard coronary angiographic procedure
9869206|NCT00222430|Experimental|B|Fluoroscopy-guided coronary angiography
9869207|NCT00222469|Experimental|1|3-agent treatment group
9869208|NCT00222534|Experimental|Acetazolamide|Acetazolamide 250 mg Three times a day for five days
9869209|NCT00222534|Placebo Comparator|Placebo|Placebo, one tablet Three times a day for five days
9928030|NCT00901940|Active Comparator|MenACWY conjugate|The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine.
9928031|NCT00901953||1|migrainous vertigo
9928032|NCT00901953||2|migraine without vertigo
9928033|NCT00901966||Agricultural workers and spouses|Melanoma risk factors among Ag workers and spouses who use pesticides.
9928034|NCT00901992|Experimental|MEDIAS 2 ICT|MEDIAS 2 ICT - education program for the initiation of intensive conventional insulin treatment (ICT) in type 2 diabetic patients
9928035|NCT00901992|Active Comparator|Current ICT program (ACC)|This education program consists of 10 lessons combining an insulin education program with an hypertension program
9928036|NCT00902005||Rheumatic patients|"Three groups:~RA patients: 30 starting on Methotrexate, 30 starting on combination of Methotrexate and TNFalpha inhibitor.~PSA patients: 20 starting on Methotrexate, 20 starting on combination of Methotrexate and TNFalpha inhibitor.~AS patients: 20 starting on TNFalpha inhibitor"
9928037|NCT00902031|Experimental|Docusate + Sennoside|
9928038|NCT00902031|Placebo Comparator|Sennoside + Placebo|
9928039|NCT00902057|Active Comparator|desmopressin 1.5|
9928040|NCT00902057|Active Comparator|desmopressin 3|
9928041|NCT00902057|Active Comparator|desmopressin 15|
9928042|NCT00902057|Placebo Comparator|placebo|
9928043|NCT00902070||1|Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation
9928044|NCT00902083|Experimental|surgery plus p53 gene|using p53 gene therapy before surgery
9869210|NCT00222612|Active Comparator|A or B with 2DI|3 or 4 drug induction plus 2 delayed intensifications
9869211|NCT00222612|Experimental|C plus 2DI|Intensified treatment including Capizzi maintenance
9869212|NCT00222612|Experimental|A or B with 1DI|Reduced intensity treatment
9869213|NCT00222716|Experimental|Structured|Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
9869214|NCT00222716|No Intervention|Usual Care|Control arm
9869215|NCT00222716|Experimental|Inidividualized|Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
9869216|NCT00222742|Experimental|A|Induced moderate hypothermia (32-33 C)
9869217|NCT00222755|Experimental|1|Behavioral Care Management
9869218|NCT00222755|No Intervention|2|Usual Care
9869219|NCT00222846|Active Comparator|A|Attention control
9869220|NCT00222846|Experimental|B|Intervention
9869221|NCT00222872|Active Comparator|1 - PTHrP Group|Group receiving study drug: PTHrP(1-36)
9869222|NCT00222872|Placebo Comparator|2 - Single Blind Placebo Group|Receives placebo injections daily via subcutaneous injection
9869223|NCT00222937|Experimental|A|Patients are enrolled in Lessac-Madsen Resonant Voice Therapy.
9869224|NCT00222937|Experimental|B|Patients are enrolled in Casper Based Confidential Flow Therapy.
9869225|NCT00222976|Experimental|1|A Naproxen PO + placebo PR
9869226|NCT00222976|Experimental|2|B Placebo PO + Naproxen PR
9869227|NCT00222989|Other|no label study|1
9869228|NCT00223002|Experimental|1|PI
9869229|NCT00223002|Experimental|2|Chlorohex
9869230|NCT00223041|No Intervention|A (therapy with fluvastatin 80mg retard)|kidney transplants receive in addition fluvastatin 80mg retard for 3 years
9869231|NCT00223041|Placebo Comparator|B|no therapy with fluvastatin
9869232|NCT00223145|Experimental|Arm 1|Androgen blockade for 6 months + Radiotherapy 70 Gy
9869233|NCT00223145|Experimental|Arm 2|Androgen blockade for 6 months + Radiotherapy 76 Gy
9869234|NCT00223145|Active Comparator|Arm 3|Radiotherapy alone with 76 Gy
9869235|NCT00223171|Active Comparator|Arm 1 : 36 months AB + RT|Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
9869236|NCT00223171|Experimental|Arm 2 : 18 months AB + RT|Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
9869237|NCT00223210|Active Comparator|Quetiapine|
9869238|NCT00223210|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
9869239|NCT00223249|Active Comparator|Quetiapine|Quetiapine
9869240|NCT00223249|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
9869241|NCT00223353||Lower Limb Amputee|
9869242|NCT00223353||Amputee and Normals and Clinical Case Study|"Amputee:~Lower limb below/above knee amputee~Normals:~Health adult~Clinical Case Study:~Individual case studies"
9869243|NCT00223405||metal-ceramic (D'Sign) o|Metal ceramic crown will be placed
9869244|NCT00223405||an all-ceramic crown (IPS Empress2, Eris EXC).|All ceramic crown will be placed
9869245|NCT00223444||1|Genotype group Pro/Pro
9869246|NCT00223444||2|Genotype group Pro/Ser
9869247|NCT00223587|Experimental|A|1 week of treatment discontinuation
9869248|NCT00223626|Experimental|Topiramate|
9869249|NCT00223626|Placebo Comparator|Placebo|
9869250|NCT00223639|Experimental|Topiramate|
9869251|NCT00223639|Placebo Comparator|Placebo|
9869252|NCT00223691|Experimental|1: active intervention|atomoxetine, pyridostigmine bromide, yohimbine, midodrine hcl, modafinil, octreotide, water intake, ranitidine hcl, diphenhydramine hydrochloride, tranylcypromine, ergotamine/ caffeine, celecoxib, pseudoephedrine, methylphenidate, indomethacin, ibuprofen, Oxymetazoline 0.05% nasal solution, acarbose, Rivastigmine tartrate, acetazolamide, carbidopa/levodopa, inflatable abdominal binder or bovril
9869253|NCT00223691|Placebo Comparator|2: Placebo or sham device|placebo pill or inflatable abdominal binder (sham)
9869254|NCT00223717|Experimental|1: Active drug or intervention|Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt, aliskiren, local heat stress
9869255|NCT00223717|Placebo Comparator|2: Placebo|placebo pill or patch
9869256|NCT00223730|Experimental|citrulline|Patients randomized to receive oral citrulline at 3.8 gm/m2 in split BID dosing
9869257|NCT00223730|Placebo Comparator|Placebo|Patients randomized to receive oral diluent for citrulline in BID dosing
9869258|NCT00223743|Experimental|Zonisamide|Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor
9869259|NCT00223756|Experimental|Arm 1|interdisciplinary, outpatient blind rehabilitation
9869260|NCT00223756|No Intervention|Arm 2|usual care
9869261|NCT00223782|Other|1|
9869262|NCT00223834|Other|1|Single session orientation to available services
9869263|NCT00223847|Other|1|
9869264|NCT00223860|Other|1|
9869265|NCT00223899|Experimental|A|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
9869266|NCT00223912|Other|1|Lower-extremity functional electrical stimulation
9869267|NCT00223925|Placebo Comparator|Placebo|
9869268|NCT00223925|Experimental|Maribavir (100 mg twice daily)|
9869269|NCT00223925|Experimental|Maribavir (400 mg twice daily)|
9869270|NCT00223925|Experimental|Maribavir (400 mg once daily)|
9869271|NCT00223938|Active Comparator|1|Oral Iron
9869272|NCT00223938|Experimental|2|sodium ferric gluconate
9869273|NCT00223938|Experimental|3|sodium ferric gluconate
9869274|NCT00223964|Experimental|dose level 1|1.5 mg/kg
9869275|NCT00223964|Experimental|dose level 2|3 mg/kg
9869276|NCT00224081|Experimental|Ferric gluconate|
9869277|NCT00224081|No Intervention|standard of care|
9869278|NCT00224094|Experimental|Sequence A|Oral ERT then transdermal ERT
9869279|NCT00224094|Experimental|Sequence B|Transdermal ERT then oral ERT
9928045|NCT00902083|Active Comparator|surgery alone|Surgery without pre-p53 gene therapy
9928046|NCT00902083|Experimental|p53 plus chemotherapy|p53 gene therapy with concurrent chemotherapy
9928047|NCT00902083|Experimental|p53 gene therapy alone|Intra-tumor injectio of rAd-p53 gene with no concurrent treatment
9928048|NCT00902096||Prenatal factors|Prenatal factors to predict cord blood IgE
9928049|NCT00902109||perimetry, HRT, OCT|perimetry, HRT, OCT
9928050|NCT00902122|Experimental|1|Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.
9928051|NCT00902122|Active Comparator|2|surgery
9928052|NCT00902122|Experimental|3|p53 gene therapy
9928053|NCT00902122|Active Comparator|4|p53 gene therapy plus radioactive iodine
9928054|NCT00902135||Group 1|
9928055|NCT00902135||Group 2|
9928056|NCT00902135||Group 3|
9928057|NCT00902148|No Intervention|Control Group|Colorectal Surgery without use of SurgiWrapTM
9928058|NCT00902148|Active Comparator|Test Group|Colorectal Surgery with use of SurgiWrapTM film secured directly below the abdominal incision
9928059|NCT00902187|Other|Reference|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
9928060|NCT00902187|Other|Test|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
9928061|NCT00902213|No Intervention|Minimal movement|Minimal movement group with usual care non-intervention.
9928062|NCT00902213|Active Comparator|Physical Therapy|
9928063|NCT00902252|Experimental|Usual/Natura®/Vitala™|All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.
9928064|NCT00902317|Active Comparator|Boston Scientific|The PolarCath peripheral balloon catheter (CryoVascular Systems, Inc., Los Gatos, CA) is a novel angioplasty system that simultaneously dilates and cools the plaque and vessel wall in the area of treatment. Cooling is achieved by inflating the balloon with nitrous oxide rather than the usual saline/contrast mixture.
9935865|NCT03065335|Experimental|Phase II, Arm 1b|Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG or MEG
9935866|NCT03065335|Placebo Comparator|Phase II, Arm 2|Double-blind, single dose of 0.5 mg/kg IV saline
9986524|NCT01403727||Assisted Biopsy - STUDY GROUP|The physician will be shown the PercuNav screen and will correct the desired approach path.
9986525|NCT01403740||Acquired haemophilia patients|
9986526|NCT01403753||Non-clinical sample of children|
9986527|NCT01403766||Pediatric post-kidney transplant|Patients having standard of care surviellance biopsies.
9986528|NCT01403779|Active Comparator|1-Hypofractionated IMRT|hypofractionated IMRT for right sided breast cancer
9986529|NCT01403779|Active Comparator|2-Normofractioated IMRT|normofractionated IMRT for left sided breast cancer
9986530|NCT01403792|Experimental|Up to 7mg P2G12|
9986531|NCT01403792|Experimental|Up to 14mg P2G12|
9986532|NCT01403792|Experimental|Up to 28mg P2G12|
9986533|NCT01403792|Placebo Comparator|Placebo (saline solution)|
9986534|NCT01403818|Experimental|Part 1|"Subjects will receive ASP1941 alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
9986535|NCT01403818|Experimental|Part 2|"Subjects will receive Mitiglinide calcium hydrate alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
9869280|NCT00224198||Lung Disease|All study individuals will be males or females that are 18 years or older and are able to provide informed consent and have been diagnosed with lung disease.
9869281|NCT00224211||I|Stable premature infants
9869282|NCT00224237||A|Participants will be self-identified, adult Latino men and women from the community setting. The sample will comprise of a convenience sample from community-based organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, or other Spanish-speaking culture.
9935867|NCT03065335|Placebo Comparator|Phase II, Arm 2b|Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG or MEG.
9986536|NCT01403831|Experimental|Text messages|Patients randomized to this arm will receive daily text messages to their mobile phones consisting of educational materials, motivational materials, trivia questions, and challenges to engage in healthy lifestyle choices
9986537|NCT01403831|No Intervention|Control|
9986538|NCT01403844|Other|Skin Carotenoids|Skin carotenoids will be measured under conditions of depletion or repletion
9986539|NCT01403857|Experimental|Whole Grain|Whole grain products as defined by the American Association of Cereal Chemists (AACC) given in a market basket that contains eight commonly used grain products over six weeks.
9986540|NCT01403857|Placebo Comparator|Refined Grains|Time control compared to experimental intervention.
9869283|NCT00224419|Active Comparator|1 - CBT Counseling|Participants in this arm received a tailored CBT (TCBT) intervention that included: a written self-help guide, feedback about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session.
9869284|NCT00224419|Experimental|2 - Counseling + NRT|Women in this arm received the TCBT described in Arm 1, plus their choice of NRT. To minimize fetal exposure to nicotine for women in the TCBT+NRT arm, the dose of NRT are customized to the woman's current level of smoking. Women who smoke 5-10 cigarettes a day will be given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smokes per day. Those who smoke 11 cigarettes or more per day will be given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smokes per day, not to exceed 15 lozenges or pieces of gum per day.
9869285|NCT00224445|Experimental|Truvada + Ritonavir-boosted Atazanavir|All participants received Truvada plus ritonavir-boosted atazanavir
9869286|NCT00224471|Experimental|Group A|
9869287|NCT00224471|Experimental|Group B|
9869288|NCT00224471|Experimental|Group C|
9869289|NCT00224523|Experimental|Arm 1|
9869290|NCT00224575|Experimental|1|Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
9869291|NCT00224640|Experimental|1|Iron chelating intervention
9869292|NCT00224718|Active Comparator|1|surgery - open repair
9869293|NCT00224718|Experimental|2|endovascular procedure
9869294|NCT00224744|Active Comparator|Classical surgical Inguinal curage|Classical Inguinal curage
9869295|NCT00224744|Experimental|Ultracision surgical Inguinal curage|
9869296|NCT00224757|Active Comparator|Aspirin|Ascal 100mg once daily
9869297|NCT00224757|Active Comparator|Coumarin derivates|Acenocoumarol or fenprocoumon
9869298|NCT00224783|Active Comparator|CAIV-T|CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
9869299|NCT00224783|Placebo Comparator|Placebo|Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
9869300|NCT00224835|Experimental|1|Mindfulness Based Stress Reduction Class
9869301|NCT00224835|Experimental|2|Cardiac Education Class
9869302|NCT00224848|Experimental|ATP III|A novel practice-based intervention, based on the ATP III Clinical Practice Guideline, which includes the use of a personal digital assistant (PDA) based decision support tool.
9869303|NCT00224848|Active Comparator|JNC 7|A novel practice-based intervention, based on the JNC-7 blood pressure Clinical Practice Guideline, which includes the use of am automated blood pressure measurement device.
9869304|NCT00225069|Experimental|1|T2 sympathectomy
9869305|NCT00225069|Experimental|2|T2-T3 sympathectomy
9869306|NCT00225121|Experimental|1|open label single arm trial
9869307|NCT00225173|Experimental|Treatment|"Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11~Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11~Cyclophosphamide 750 mg/m2 IV w 1, 5, 9~Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11~Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)~Bleomycin 5 u/m2 IV w 2,4,6,8,10,12~Gemcitabine 1250 mg/m2 IV w 13,15,17,19~Vinorelbine 25 mg/m2 IV w 13,15,17,19~Prednisone 40 mg/m2 PO qod w 1-10, taper"
9869308|NCT00225186|Experimental|Arm 1|
9869309|NCT00225199|Experimental|Arm 1|
9869310|NCT00225199|Placebo Comparator|Arm 2|
9869311|NCT00225225|Active Comparator|fixed calorie (500 kcal) Reduction|
9869312|NCT00225225|Placebo Comparator|Control (no diet change)|
9869313|NCT00225264|Experimental|Pioglitazone QD|
9869314|NCT00225264|Active Comparator|Glimepiride QD|
9869315|NCT00225381||metabolic gas exchange and cardiac output|
9869316|NCT00225381||mass spectrometer and anaerobic metabolism|
9869317|NCT00225381||metaboic gas exchange and type of anesthesia induction|
9869318|NCT00225381||metabolic gas exchange and PEEP|
9869319|NCT00225381||metabolic gas exchange and trendelenburg position|
9869320|NCT00225381||Patients requiring tourniquet during surgery|Patients undergoing orthopaedic surgeries requiring tourniquet intervention. Oxygen consumption and CO2 production were measured before, during and after tourniquet release.
9869321|NCT00225381||Patients prone to metabolic acidosis|Oxygen consumption and CO2 measurements taken during long surgeries prone to metabolic acidosis.
9869322|NCT00225433|Active Comparator|1|Follitropin beta
9869323|NCT00225433|Active Comparator|2|Ganirelix acetate
9869324|NCT00225563|Active Comparator|e-prescribing|Providers who used electronic prescriptions. electronic health records were used as opposed to paper based prescriptions
9869325|NCT00225563|No Intervention|Paper-based prescriptions|providers who used paper based prescriptions
9869326|NCT00225576|No Intervention|1|Paper prescribing, 2005 and 2007
9869327|NCT00225576|Experimental|2|Paper prescribing 2005 vs. electronic prescribing 2007
9869328|NCT00225641|Active Comparator|1 frequent control|Follow-up 6, 12, 18, 24 and 36 months after surgery
9869329|NCT00225641|Other|2 less frequent control|Follow-up 12 and 36 months after surgery
9928065|NCT00902317|Active Comparator|Spectranetics|The excimer laser has unique properties that make it ideally suited to debulk atheromatous and thrombotic arterial blockages. LASER is an acronym for Light Amplification by Stimulated Emission of Radiation. However, there are many types of lasers, each distinguished by the wavelength of the emitted light, the effective power of the light beam, and whether the light is pulsed (like a flashbulb) or continuous (like a light bulb). The effectiveness of a given laser for intraarterial applications depends on how the light interacts with tissue inside an artery.
9928066|NCT00902317|Active Comparator|Fox Hollow|"The SilverHawk peripheral catheter system and cutter driver (FoxHollow Technologies, Redwood City, CA) are designed for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries. The catheter consists of a flexible shaft designed to track over a 0.014 guidewire. At the distal end of the catheter is a small cutting assembly comprised of a rotating inner blade contained within a tubular housing. The proximal end of the catheter contains a connector and Positioning Lever designed to fit into a small, disposable, battery-driven Cutter Driver which powers the device."
9928067|NCT00902317|Active Comparator|WL Gore|Viabahn Endoprosthesis (W.L. Gore & Associates, Flagstaff, AZ) is a flexible self-expanding endoluminal device consisting of expanded polytetrafluoroethylene (ePTFE) lining with an external Nitinol (NiTi=Nickel:Titanium) support extending along its entire length. The device is compressed and attached to a catheter delivery system. The Gore Viabahn Endoprosthesis is available in a wide range of diameters and lengths.
9928068|NCT00902317|Placebo Comparator|Control Group, Guidant|Balloon angioplasty is a treatment that uses a catheter with a tiny balloon mounted on the end. The balloon is positioned through the narrowing/blockage in your leg artery, and then it is inflated to push the narrowing apart and restore a channel for blood flow. The balloon is then deflated and removed from your body. A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface. The FDA has approved the use of certain stents for the treatment of narrowing in the leg arteries. Stents have been widely used in various parts of the body, including blocked blood vessels in the arms, legs, heart (coronary arteries), and kidneys (renal arteries).
9928069|NCT00902343|Experimental|1|nomogram-based selection for acute normovolemic hemodilution
9928070|NCT00902343|Active Comparator|2|standard selection for ANH based on a planned resection of 3 or more segments.
9928071|NCT00902356|Active Comparator|B|Six female subjects in each of cohorts 1 to 5 will receive AMG 167; six male subjects in each of cohorts 6 and 8; three female subjects in each of cohorts 7 and 9.
9928072|NCT00902356|Placebo Comparator|A|Two female subjects in each of cohorts 1 to 5 will receive placebo; two male subjects in each of cohorts 6 and 8; and 1 female subject in each of cohorts 7 and 9.
9928073|NCT00902369|Experimental|AK106-001616|
9928074|NCT00902369|Placebo Comparator|Placebo|Part1: AK106-001616 and Placebo
9928075|NCT00902369|Active Comparator|Active comparator|Part2: AK106-001616 and Active comparator
9928076|NCT00902382||1|Infertile women who conceive spontaneously
9928077|NCT00902382||2|Infertile women who conceive on various ovulation stimulation medications
9928078|NCT00902395|Active Comparator|Midazolam|Oral midazolam
9869330|NCT00225745||1|Pancreatic cancer patients
9869331|NCT00225745||2|Healthy controls
9869332|NCT00225914|Experimental|1|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
10210748|NCT04076072|Active Comparator|Alcon Non-Beveled Tip Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
10210749|NCT04075916|Experimental|Epclusa (sofosbuvir/velpatasvir)|Epclusa is taken by mouth for 12 weeks as per the FDA label.
10210750|NCT04075331|Experimental|Mepolizumab|Mepolizumab
9869333|NCT00225914|Placebo Comparator|2|Subjects then enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill
9869334|NCT00225979|Experimental|SMS995|
9869335|NCT00226005|Active Comparator|Vatalanib|Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
9869336|NCT00226018|Active Comparator|1|Acceleromyography with Hand Adapter on dominant arm
9869337|NCT00226018|Active Comparator|2|Acceleromyography with Hand Adapter on non-dominant arm
9869338|NCT00226018|Placebo Comparator|3|Acceleromyography without Hand Adapter on dominant arm
9869339|NCT00226018|Placebo Comparator|4|Acceleromygraphy without Hand Adapter on non-dominant arm
9869340|NCT00226031|Active Comparator|1|Usual care.
9869341|NCT00226031|Experimental|2|Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
9869342|NCT00226044|No Intervention|Oral omeprazole|Standard of care: A single dose of 1 mg/kg orally administered omeprazole.
9869343|NCT00226044|Active Comparator|Rectal omeprazole|A single dose of 1 mg/kg rectally administered omeprazole.
9869344|NCT00226057|Experimental|Raptiva Open Label|Raptiva administered by weekly subcutaneous injections. First dose of 0.7mg/kg. Subsequent doses will be of 1mg/kg SQ weekly.
9869345|NCT00226109|Active Comparator|A|
9869346|NCT00226252|Experimental|Instruction Only (IO)|IO participants will train on the dynamometer for the same length of time as the Feedback Group. They will only be instructed to follow what they learned from the video presented at the beginning of the training session.
10210751|NCT04075331|Placebo Comparator|Placebo|Saline solution
10210752|NCT04069910|Experimental|Arm A (SRS/SRT, surgery)|Patients undergo 1, 5, or 10 fraction of SRS/SRT radiation. Surgery is performed within 72 hours of radiation therapy.
9869347|NCT00226252|Experimental|Instruction and Feedback Group (FB)|The FB group will receive video training, and real time feedback from the SMART Wheel as they push their wheelchair. A monitor displaying a random combination and amount of biomechanical feedback variables will be placed in front of subjects. Subjects will be instructed to adjust their stroke to optimize their biomechanics with feedback from the screen.
9869348|NCT00226252|No Intervention|Control Group|Wheelchair characteristics will be noted; however, no wheelchair manipulation or changes in equipment will be performed or recommended.
9869349|NCT00226291|Experimental|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
10210753|NCT04069910|Active Comparator|Arm B (surgery, SRS/SRT)|Within 2-5 weeks after standard of care surgery, patients undergo 1, 5, or 10 fraction of SRS/SRT.
10210754|NCT04057716|Experimental|Sleep restriction followed by extension|Children will spend 8 hours in bed for one week, engage in one week of wash-out, and then spend 11 hours in bed for one week.
10210755|NCT04057716|Experimental|Sleep extension followed by restriction|Children will spend 11 hours in bed for one week, engage in one week of wash-out, and then spend 8 hours in bed for one week.
10210756|NCT04044859|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
9869350|NCT00226291|No Intervention|No evidence report|
10210757|NCT04014075|Experimental|All participants|Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer will be treated with trastuzumab deruxtecan by intravenous (IV) infusion every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.
10210758|NCT04003285|Experimental|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
10210759|NCT04003285|Experimental|ALLO 50 nM|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
10210760|NCT04003285|Experimental|ALLO 150 nM|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
10210761|NCT03987009|Experimental|Without RAMP and without video|Sniffing position and a standard Macintosh laryngoscope
10210762|NCT03987009|Experimental|With RAMP and with video|Ramped position and a McGrath Mac videolaryngoscope
10210763|NCT03987009|Experimental|Without RAMP and with video|Sniffing position and a McGrath Mac videolaryngoscope
9869351|NCT00226317|Experimental|Aripiprazole in depression treatment|
9869352|NCT00226356|Experimental|Supplements of L-methionine, betaine and folate|
9869353|NCT00226434|Experimental|1|
9869354|NCT00226434|Active Comparator|2|
9869355|NCT00226486|Experimental|1|Identification of individual risk factors for falls and specified intervention aimed diminishing these risk factors in the individual.
9869356|NCT00226486|Placebo Comparator|2|Usual care
9869357|NCT00226668|Experimental|I|Patients will receive hCRf (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone that they may be taking
9928079|NCT00902395|Experimental|Midazolam/ketamine|Combined midazolam and ketamine
10210764|NCT03987009|Experimental|With RAMP and without video|Ramped position and a standard Macintosh laryngoscope
9986541|NCT01403870||Low Back Pain Subjects|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
9869358|NCT00226668|Placebo Comparator|II|Patients will receive placebo hCRF (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone they may be taking
9869359|NCT00226681|Experimental|1|
9869360|NCT00226681|Active Comparator|2|
9869361|NCT00226694|Active Comparator|Citalopram Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
9869362|NCT00226694|Placebo Comparator|Placebo Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
9869363|NCT00226720|Experimental|1|at the hospital
9869364|NCT00226720|Active Comparator|2|out of the hospital
9869365|NCT00226733|Experimental|A|Interval exercise training with high intensity
9869366|NCT00226733|Active Comparator|B|Exercise training with moderate intensity
9869367|NCT00226746|Experimental|Paclitaxel and Gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
9869368|NCT00226837|Placebo Comparator|1|0% nitrous oxide
9869369|NCT00226837|Active Comparator|2|33% nitrous oxide
9869370|NCT00226837|Active Comparator|3|66% nitrous oxide
9869371|NCT00226915|Active Comparator|1|Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
9869372|NCT00226915|Experimental|2|Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
9869373|NCT00226954|Experimental|Zoledronic Acid with Intermittent Hormonal Therapy|
9869374|NCT00227006|Experimental|Taste-Based Goal Setting|6-month intervention (14 lifestyle counseling classes)
9869375|NCT00227006|Active Comparator|Smart Consumers|6-month intervention (14 lifestyle counseling classes)
9869376|NCT00227006|Active Comparator|Community Access|Can enroll in behavioral treatment programs available in the community that do not include medication or very-low calorie diets
9869377|NCT00227032|Experimental|Subjects receiving EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
9869378|NCT00227032|Experimental|Subjects NOT taking EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
9869379|NCT00227110|Active Comparator|Pioglitazone|Pioglitazone 30 mg/d will be given for 8 weeks and titrated to 45 mg/d until the end of the 6-month study in a randomized, double-blind, study design.
9869380|NCT00227110|Placebo Comparator|Placebo|Placebo once daily is given following a randomized, double-blind, placebo-controlled study design.
9869381|NCT00227123|Active Comparator|1|Quetiapine versus Risperidone
9869382|NCT00227162|Active Comparator|Group 1|Positive affect
9869383|NCT00227162|Active Comparator|Group 2|Self-Affirmation
9869384|NCT00227162|Active Comparator|Group 3|Positive Affect and self-affirmation
9869385|NCT00227162|No Intervention|Group 4|Control group
9869386|NCT00227188||1|Children from 0-5 years of age evaluated for IPD
9928080|NCT00902395|Other|Protective stabilization|No drug or placebo administered
9928081|NCT00902408|Experimental|Lutein|Lutein enriched eggs
9928082|NCT00902408|Placebo Comparator|Placebo|Non enriched
9928083|NCT00902421|Active Comparator|Antimuscarinics|
9928084|NCT00902421|Experimental|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitor
9928085|NCT00902447||Human Blood Cell Disorders|Human Blood Cell Disorders Tissue Bank
9928086|NCT00902460|Experimental|Treatment Sequence 1|
9928087|NCT00902460|Experimental|Treatment Sequence 2|
9928088|NCT00902473|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
9928089|NCT00902473|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
9928090|NCT00902499||NC|Normal older controls, not cognitively impaired; MMSE 27-30 and performance above education adjusted cutoff scores on the Logical Memory II subscale (LM-II Delayed Paragraph Recall) of the Wechsler Memory Scale
9928091|NCT00902499||vMCI|Very mild cognitive impairment; less severe objective memory deficit, scoring .5 to 1.5 S.D. (standard deviation) below education adjusted norms on the LM-II
9928092|NCT00902499||sMCI|significant mild cognitive impairment; objective cut off of 1.5 S.D. level below education adjusted norms on the LM-II
9928093|NCT00902499||AD|Mild Alzheimer's disease; meet NINCDS/ADRDA criteria for probable AD with mild dementia severity (CDR Total = 1), MMSE 20-26
9928094|NCT00902512|Active Comparator|Treatment A|Viagra® 100 mg tablet, administered with water
9928095|NCT00902512|Active Comparator|Treatment B|Sildenafil 100 mg CT administered with water
9928096|NCT00902512|Active Comparator|Treatment C|Sildenafil 100 mg CT administered without water
9928097|NCT00902525|Experimental|90Y-Ibritumomab Tiuxetan double dose|90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3
9928098|NCT00902551||1|Subjects underwent cervical sample DNA image cytometry
9928099|NCT00902551||2|Subjects underwent cervical sample conventional cytology
9928100|NCT00902590||1|Patients with urothelial cancer
10210765|NCT03972124|Active Comparator|CBD 100 mg OD|The lower dose CBD group will start with CBD capsules 10 mg OD, then increase the dose every 4 days until on the target dose of 100 mg OD.
10210766|NCT03972124|Experimental|CBD 200 mg OD|The higher dose CBD group will start with CBD capsules 10 mg OD and will increase every 4 days until on a target dose of 200 mg OD.
9986542|NCT01403883|Active Comparator|Standard care|standard care of patient with psychological and enterostomal therapy clinic if necessary
9986543|NCT01403883|Experimental|Optimal care|Optimal care of patient with systematic and repeated psychological and enterostomal therapy follow up
9986544|NCT01403896|Active Comparator|Plerixafor Group|
9986545|NCT01403896|Experimental|Plerixafor + G-CSF group|
10210767|NCT03972124|Placebo Comparator|Placebo|
10210768|NCT03964337|Experimental|Cabozantinib Followed by Prostatectomy (Arm A)|Experimental group will received cabozantinib for 4 weeks, followed by a 2 week drug washout before a prostatectomy.
10210769|NCT03964337|Active Comparator|Immediate Prostatectomy (Arm B)|Control group will receive an immediate prostatectomy.
10210770|NCT03957369||Adult naive HIV positive individuals|HIV-diagnosed subjects, older than 18 years, with no prior exposure to antiretroviral drugs.
10210771|NCT03956238|Experimental|Males and Alcohol Intoxication|Men assigned to alcohol intoxication arm (target BAC .08%)
10210772|NCT03956238|Placebo Comparator|Males and Placebo Control|Men assigned to placebo control arm
10210773|NCT03956238|Experimental|Females and Alcohol Intoxication and Objectifying Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and objectifying gazes arm
10210774|NCT03956238|Experimental|Females and Alcohol Intoxication and Eye Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and eye gazes arm
10210775|NCT03956238|Experimental|Females and Placebo Control and Objectifying Gazes|Women assigned to placebo control arm and objectifying gazes arm
10210776|NCT03956238|Placebo Comparator|Females and Placebo Control and Eye Gazes|Women assigned to placebo control arm and eye gazes arm
10210777|NCT03945318|Experimental|Part 1: BION-1301|Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
10210778|NCT03945318|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of placebo administered by IV infusion.
10210779|NCT03945318|Experimental|Part 2: BION-1301|Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
10210780|NCT03945318|Placebo Comparator|Part 2: Placebo|Subjects will receive placebo by IV infusion.
10210781|NCT03945318|Experimental|Part 3: BION-1301|Up to 3 or more cohorts of subjects will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2+) at a dose and frequency to be determined.
10210782|NCT03931252|Experimental|High fat|Boost VHC (Very High Calorie), Nestle, 8 ounce can
10210783|NCT03931252|Experimental|High protein|Ensure High Protein 8 ounce can
10210784|NCT03925532|Experimental|Supportive Care (denosumab)|Patients receive 2 doses of denosumab SC between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
10210785|NCT03893500|Experimental|Initiating a new PAH medication|Participants will start a new PAH medication
10210786|NCT03893500|Active Comparator|Continuing previous PAH medication regimen|Participants will continue the medication regimen that they were on prior to enrollment
10210787|NCT03892967|Experimental|E2C2 Collaborative Care|A guideline-informed intervention that combines low touch automated provision of symptom self-management education, coupled with EHR clinical decision support, for moderate symptoms with conventional, high-touch, collaborative care provided by a nurse-physician team for more intense symptoms. Additionally, the E2C2 intervention will increase the frequency of symptom and function screening. Prior to E2C2 intervention initiation, patients will only be assessed in association with a physician or allied health provider encounter. They will not be assessed when seen for nurse-only visits, or for systemic treatments. Following E2C2 intervention activation, they will be assessed every other week which will require remote, portal-based assessment for patients who lack clinic appointments.
10210788|NCT03866187|Experimental|Group A1_Step A|Subjects aged 18-65 years receive one dose of each of the study vaccines, Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation at Day 1, Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169.
10210789|NCT03866187|Active Comparator|Group A2_Step A|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 low dose formulation, one dose each at Days 1, 57, 113 and 169.
10210790|NCT03866187|Placebo Comparator|Group A3_Step A|Subjects aged 18-65 years receive four doses of placebo, one dose each at Days 1, 57, 113 and 169.
10210791|NCT03866187|Experimental|Group B1_Step B|Subjects aged 18-65 years receive one dose of each of the study vaccines, ChAd155-hIi-HBV high dose formulation at Day 1, MVA-HBV high dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at Day 169.
10210792|NCT03866187|Active Comparator|Group B2_Step B|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 high dose formulation, one dose each at Days 1, 57, 113 and 169.
10210793|NCT03866187|Active Comparator|Group B3_Step B|Subjects aged 18-65 years receive two doses of placebo, one each at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation at Day 169.
10210794|NCT03866187|Experimental|Group C1_Step C|Subjects aged 18-65 years receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 1 and the 3 following doses of MVA-HBV high dose formulation co-administered with HBc-HBc-HBs/AS01B-4 high dose formulation at Day 57, 113 and Day 169.
10210795|NCT03866187|Active Comparator|Group C2_Step C|Subjects aged 18-65 years receive two doses of placebo at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 169.
10210796|NCT03838978|Experimental|Calypso Knee System|Calypso Knee System
9869387|NCT00227279|Experimental|1|
10210797|NCT03831256|Active Comparator|Standard of care (2nd tier NIPS)|For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
10213699|NCT03494192|Experimental|scapula retraction exercise group|"Manual Therapy~Stretching Exercises~Exercise training focus on scapulothoracic muscles will be applied two times per week total 12 week After 12 week follow-up, patients will proceed to reduced exercise program until the 6-month follow-up."
9869388|NCT00227279|Placebo Comparator|2|
9869389|NCT00227292|Placebo Comparator|A, 2, II|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
9869390|NCT00227292|Experimental|A, 1|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
9869391|NCT00227357||Buprenorphine|Study patients receiving buprenorphine treatment
9869392|NCT00227357||Comparison|Study patients receiving methadone or no agonist treatment
9869393|NCT00227461|Other|Wait control|Levitiracetam is started after a delay, with dosage and administration as described below.
9869394|NCT00227461|Experimental|Treatment first|Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
9869395|NCT00227487|Other|Stool collection, Carbohydrate administration, Questionnaires|"A stool sample will be obtained~A carbohydrate solution (lactulose plus rhamnose dissolved in tap water) will be administered during a clinically indicated endoscopic procedure.~Five questionnaires will be completed by parent/guardian"
9869396|NCT00227513|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) twice daily on days 1-14 in step A. Patients receive oral vorinostat (SAHA) twice daily on days 1-4 and 8-11 in Step B and bortezomib IV over 3-5 seconds on days 2, 5, 9, and 12 during the first course and on days 1, 4, 8, and 11 during subsequent courses in both steps A and B. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 6 additional patients receive bortezomib at the MTD. Subsequent cohorts of 3-6 patients receive escalating doses of SAHA until the MTD of that drug is determined."
9869397|NCT00227565|Experimental|pemetrexed + carboplatin + radiation|"Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years."
9869398|NCT00227656|Experimental|Capecitabine + PEG-interferon alfa-2a|Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.
9869399|NCT00227669|Active Comparator|Arm I: Gemcitabine|"Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.~1 cycle = 28 days.~Treatment duration: 8 months"
9869400|NCT00227669|Experimental|Arm II: Gemcitabine + Docetaxel|"Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.~1 cycle = 21 days.~Treatment duration: 6 months"
9869401|NCT00227682|Experimental|Arsenic Trioxide|Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid
9869402|NCT00227695|Active Comparator|Arm A: Rituximab every 2 months x4|Rituximab 375 mg/m2 every 2 months x4
9869403|NCT00227695|Active Comparator|Arm B: Rituximab (5 years)|Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity
9869404|NCT00227734|Active Comparator|Arm I|Patients receive oral capecitabine twice daily on days 1-15 and oxaliplatin IV over 2 hours on day 1.
9869405|NCT00227734|Active Comparator|Arm II|Patients receive capecitabine and oxaliplatin as in arm I and cetuximab IV over 1-2 hours on days 1 and 8
9869406|NCT00227747|Experimental|Radiothérapie + Xelox|
9869407|NCT00227747|Active Comparator|Radiothérapie + Capécitabine|
9869408|NCT00227864|Placebo Comparator|Treatment as Usual|Participants are administered assessments at baseline, 1, 3 and 6 months
9869409|NCT00227864|Experimental|Intervention|Participants complete assessments at baseline, 1, 3 and 6 months, and receive a 2-session behavioral intervention at the baseline and 1-month study appointments.
9869410|NCT00227890|Experimental|1|Motivational Interviewing followed by Cognitive Behavior Therapy (MI/CBT)
9869411|NCT00227890|Experimental|2|Relaxation Training followed by Treatment as Usual (RT/TU)
9869412|NCT00227942|Experimental|1|Participants will receive estrogen replacement therapy
9869413|NCT00227942|Experimental|2|Participants will receive treatment with zolpidem
9869414|NCT00227942|Placebo Comparator|3|Participants will receive treatment with placebo
9869415|NCT00228020|Experimental|Basiliximab|Patients will be on a regimen of Basiliximab, MMF, cyclosporine and steroids
9869416|NCT00228020|Active Comparator|Basiliximab-free|Patients will be on a regimen of MMF, cyclosporine and steroids.
9869417|NCT00228163|Experimental|Teriflunomide 7 mg|
9869418|NCT00228163|Experimental|Teriflunomide 14 mg|
9869419|NCT00228189|Active Comparator|A|Dendritic cells pulsed with CEA-peptide
9869420|NCT00228189|Experimental|B|Dendritic cells electroporated with CEA-mRNA
9869421|NCT00228189|Experimental|C|Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine
9869422|NCT00228215|No Intervention|Usual care|
9869423|NCT00228215|Experimental|TIPS Intervention|
9869424|NCT00228306|Experimental|1|
9869425|NCT00228306|No Intervention|2|Control Group
9869426|NCT00228319|Active Comparator|Standard of Care Group|carboplatin and paclitaxel chemotherapy
9869427|NCT00228319|Experimental|Standar of Care + Ascorbic Acid Group|carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E.
9869428|NCT00228358|Experimental|Group A (cellular infusions after cyclophosphamide)|Patients receive low-dose cyclophosphamide IV on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
9869429|NCT00228358|Experimental|Group B (cellular infusions after ONTAK conditioning)|Patients receive denileukin diftitox IV over 1 hour on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
9869430|NCT00228371|Other|1|The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase
9869431|NCT00228371|Other|2|The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase
9869432|NCT00228436|Experimental|Cohort 1|Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
9869433|NCT00228436|Experimental|Cohort 2|Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
9869434|NCT00228436|Experimental|Cohort 3|Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
9869435|NCT00228436|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
9869436|NCT00228436|Experimental|Cohort 5|Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
9869437|NCT00228436|Experimental|Cohort 6|Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
9869438|NCT00228436|Experimental|Cohort 7|Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
9869439|NCT00228436|Experimental|Cohort 8|Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
9869440|NCT00228449|Experimental|Cohort 1|Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
9869441|NCT00228449|Experimental|Cohort 2|Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
9869442|NCT00228449|Experimental|Cohort 3|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
9869443|NCT00228449|Experimental|Cohorts 4 and 9|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
9869444|NCT00228449|Experimental|Cohort 5|Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
9869445|NCT00228449|Experimental|Cohort 6|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa . Doses were administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
9869446|NCT00228449|Experimental|Cohorts 7 and 8|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
9928101|NCT00902590||2|unrelated adults accompanying patients to clinic
9928102|NCT00902603||1|Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.
9869447|NCT00228449|Experimental|Cohorts 10 and 11|Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
9869448|NCT00228579||Bariatric Surgery|Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.
9869449|NCT00228631||Sickle Cell Disease Bone Marrow Transplant|Sickle Cell Disease Bone Marrow Transplant candidates
9869450|NCT00228670||IPF-Clinic|Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
9869451|NCT00228670||Controls - Clinic|Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
9869452|NCT00228670||IPF-Transplant|IPF patient undergoing lung transplant
9869453|NCT00228670||Controls-Transplant|Lung tissue from organ donor
9869454|NCT00228696|No Intervention|screening|this is a screening study and no intervention.
9869455|NCT00228865|Experimental|1|Testing performed on diabetic patients with decline in cognitive function at baseline and quarterly after the start of receiving pulsatile intravenous insulin therapy to assess continuing cognitive function ability.
9869456|NCT00228878|Experimental|Effects of Pulsatile IV insulin on QoL|Effects of Pulsatile IV insulin on Diabetic Quality of Life
9869457|NCT00228891|Active Comparator|2|Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
9869458|NCT00228891|Placebo Comparator|1|Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
9869459|NCT00228904|Placebo Comparator|1|Control patients with diagnosed diabetic neuropathy will receive baseline testing and testing every six months thereafter to compare and analyze results with patients treated with pulsatile intravenous insulin therapy.
9869460|NCT00228904|Active Comparator|2|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after the start of pulsatile intravenous insulin therapy.
9928103|NCT00902616|Active Comparator|1. L-arginine|3 gm TDS for 3 months
9928104|NCT00902616|Placebo Comparator|2. Placebo - Lactose powder|3 gm TDS for 3 months
9928105|NCT00902629|Experimental|Intervention|Intervention group contains the patients randomized for early treatment of their epiretinal fibrosis.
9928106|NCT00902629|No Intervention|Control|Control contains patients not randomized for early surgery.
9928107|NCT00902642|No Intervention|control group|
9928108|NCT00902642|Active Comparator|Course on psychosocial factors|an eight day university training course for physical therapists designed to integrating psychosocial factors in clinical practice on a patient level
9928109|NCT00902655|Experimental|Desmopressin|
9928110|NCT00902681|Other|Reference|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Zwickau
9928111|NCT00902681|Other|Test|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Vega Baja (Test)
9928112|NCT00902694|Experimental|ACHIEVE Intervention|Group and individual weight counseling and group physical activity classes for 18 months.
9928113|NCT00902694|Other|Control|Control arm receives group health classes quarterly with topics not related to weight
9928114|NCT00902707|Experimental|Mucinex 1200mg|Pill
9928115|NCT00902707|Placebo Comparator|Placebo|Pill
9928116|NCT00902720|Experimental|Cryopreservation|The ovarian tissue is frozen and banked at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
9928117|NCT00902759|No Intervention|Usual Care Group|"Participants randomized to the usual care group will be encouraged to return to their usual or pre-surgical levels of activity. Usual care of post-surgical PC and peri-ampullary patients typically includes encouragement to walk and be active as they can be by the surgeons, surgical nurses and the nurse practitioners. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry. The usual care group will perform a baseline walk. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry nor will they will a telephone call every month. Repeat questionnaires will be performed at 6 months."
9935868|NCT03065335|Experimental|Phase III|Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
9935869|NCT03065335|No Intervention|Phase IV|Follow-up evaluations
10210798|NCT03831256|Experimental|First-tier NIPS|For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
10210799|NCT03823651|Experimental|Patient|These are patients undergoing hematopoetic stem cell transplant. Patients will complete Interval training, undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
10210800|NCT03823651|Experimental|Caregiver|These are the assigned caregivers for transplant patients. Caregivers will undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
10213700|NCT03494192|Experimental|Scapula Retraction +Glenohumeral Rotational Exercise Group|"Manual Therapy~Stretching Exercises~Exercise training focus on scapulothoracic muscles~Exercise training focus on rotator cuff muscles will be applied two times per week total 12 week After 12 week follow-up, patients will proceed to reduced exercise program until the 6-month follow-up."
10213701|NCT03494192|No Intervention|Control Group|Age-sex and hand-dominancy matched healthy controls will be included as a control group (CG) for acromiohumeral distance (AHD) normative data
9869461|NCT00228982|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
9869462|NCT00228982|Active Comparator|Vancomycin|Vancomycin 1g q12h as 1h infusion, 7-14d
9869463|NCT00229047||Vein Stripping|Patients undergoing elective varicose vein stripping in our vascular OR. Observe circulation in the exposed soleus/gastrocnemius muscle.
9869464|NCT00229138|Experimental|reduced Tacrolimus|
9869465|NCT00229138|Active Comparator|Reference Tacrolimus|
9869466|NCT00229151|Experimental|Sleep deprivation|Sleep deprivation and sleep phase advancement
9869467|NCT00229151|Active Comparator|usual treatment|
9869468|NCT00229177|Placebo Comparator|P|
9869469|NCT00229177|Experimental|E1|
9869470|NCT00229177|Experimental|E2|
9869471|NCT00229229|Other|1|Low glycemic load diet
9869472|NCT00229229|Other|2|Canada Food Guide Diet
9869473|NCT00229229|Other|3|Low glycemic index diet
9869474|NCT00229229|Other|4|Low carbohydrate diet
9869475|NCT00229242|Active Comparator|1|Diuretic-Based Hypertension Therapy
9869476|NCT00229242|Active Comparator|2|Non-Diuretic-Based Hypertension Therapy
9869477|NCT00229255|Active Comparator|high frequency meals group|High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
9869478|NCT00229255|Active Comparator|twice-a -day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks
9869479|NCT00229307|Active Comparator|1|
9869480|NCT00229307|Active Comparator|2|
9869481|NCT00229385|Active Comparator|1|
9869482|NCT00229385|Active Comparator|2|
9869483|NCT00229424|Experimental|1|Lafutidine group
9869484|NCT00229424|Active Comparator|2|Famotidine group
9869485|NCT00229424|Placebo Comparator|3|Placebo group
9869486|NCT00229437|Experimental|TAK-128 5 mg QD|
9869487|NCT00229437|Experimental|TAK-128 50 mg QD|
9869488|NCT00229437|Experimental|TAK-128 100 mg QD|
9869489|NCT00229437|Placebo Comparator|Placebo QD|
9869490|NCT00229450|Experimental|Treatment|0.625 mg/day of conjugated estrogen
9869491|NCT00229450|Placebo Comparator|Placebo|Daily placebo for conjugated estrogen
9869492|NCT00229502||1|Subjects receiving Avonex
9869493|NCT00229502||2|Subjects receiving Rebif
9869494|NCT00229502||3|Subjects receiving Copaxone
9869495|NCT00229502||4|Healthy controls
9869496|NCT00229515|Active Comparator|1|Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
9869497|NCT00229515|Experimental|2|Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
9869498|NCT00229515|Experimental|3|tirofiban infusion followed by bare metal stent implantation
9869499|NCT00229515|Experimental|4|tirofiban and sirolimus-eluting stent
9869500|NCT00229541|Experimental|IG|intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
9869501|NCT00229541|No Intervention|KG|control group, receives usual care
9869502|NCT00229554||Group 1|Male and female veterans age 50-75 who have had one or more primary care visits at a VA Medical facility in the past two years.
9869503|NCT00229580|Experimental|1|Motivational feedback
9869504|NCT00229580|Active Comparator|2|treatment as usual
9869505|NCT00229593|Active Comparator|1|100 mg Testosterone gel daily for 3 weeks
9869506|NCT00229593|Active Comparator|2|2 mg Nestorone gel daily for 3 weeks
9869507|NCT00229593|Active Comparator|3|4 mg Nestorone gel daily for 3 weeks
9869508|NCT00229593|Active Comparator|4|100 mg Testosterone gel + 2 mg Nestorone gel
9869509|NCT00229593|Active Comparator|5|100 mg Testosterone gel + 4 mg Nestorone gel
9869510|NCT00229593|Active Comparator|6|100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
9869511|NCT00229593|Active Comparator|7|100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
9869512|NCT00229671|Experimental|Patients with prescriptions under 21|Pediatric visits with prescriptions. These patients parents will be given survey 1.
9869513|NCT00229671|Experimental|Patients who completed Survey 1|Patients with prescriptions under 21 whose parents complete survey 1 will be given survey 2
9869514|NCT00229697|Experimental|1|ZD1839 + Nolvadex
9869515|NCT00229697|Other|2|Nolvadex + placebo
9869516|NCT00229736|Experimental|AAV-hAADC-2 (9x10^10 vector genomes)|
9869517|NCT00229736|Experimental|AAV-hAADC-2 (3x10^11 vector genomes)|
9869518|NCT00229801|No Intervention|MRI|
9869519|NCT00229983|Experimental|Motivational Enhancement Therapy|Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
9869520|NCT00229983|No Intervention|Enhanced Standard Care|Adolescents who are randomized to Enhanced Standard Care will receive the usual care at the outpatient adolescent substance abuse program. This will include an evaluation by pediatric and mental health staff and could include treatment in a group therapy program, urine drug testing, buprenorphine replacement therapy (for those dependent on opioids), and psychopharmacology evaluation and management.
9869521|NCT00230035|Experimental|1|high dose immunosuppressie therapy (HDIT) followed by HSCT (hemopoietic stem cell transplantation).
9869522|NCT00230035|Active Comparator|2|Currently available immunosuppressive/immunomodulatory therapy
9869523|NCT00230113|Active Comparator|1|
9869524|NCT00230113|Placebo Comparator|2|
9869525|NCT00230165||Normal|Normal, healthy volunteers 18 years of age or older of either sex and any ethnic background
9869526|NCT00230165||Glanzmann thrombasthenia|Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation
9869527|NCT00230321|Experimental|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
9869528|NCT00230438|Experimental|External Beam Radiation Therapy|
9869529|NCT00230477|Active Comparator|Mono therapy|Hepsera
9869530|NCT00230477|Active Comparator|Combo therapy|
9935870|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
9935871|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
9869531|NCT00230542|Experimental|Carboplatin / Pemetrexed|Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
9869532|NCT00230594|Active Comparator|1|desmopressin
9869533|NCT00230594|Placebo Comparator|2|placebo
9869534|NCT00230607|Experimental|Agalsidase beta|Commercially available Fabrazyme treatment at prescribed dose and regimen as determined by their treating physician
9869535|NCT00230659||HHT patients|Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
9869536|NCT00230659||Controls|People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
9869537|NCT00230711|Experimental|Exercise Counseling|
9869538|NCT00230711|Placebo Comparator|Contact Control|
9869539|NCT00230750|Experimental|2|100 subjects to receive 90 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
9869540|NCT00230750|Placebo Comparator|3|40 subjects to receive saline placebo on days 0, 28, and 6 months following the 1st vaccination.
9869541|NCT00230750|Experimental|1|100 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
9869542|NCT00230763|Experimental|Active|
9869543|NCT00230763|Other|Procedure|
9869544|NCT00230815|Experimental|Follitropin alfa injected by Pen device|
9869545|NCT00230880|Experimental|Treatment|follow-up phone counseling
9869546|NCT00230880|No Intervention|Control|Usual care
9869547|NCT00230932||Group 1|outpatients selected from random visits in primary care, oncology, and cardiology clinics
9869548|NCT00230945|Experimental|1|Patient-oriented education and support intervention
9869549|NCT00230945|Experimental|2|Couple-oriented education and support intervention
9869550|NCT00231166|Experimental|HCD122|
9869551|NCT00231244|Experimental|1|CYPHER Sirolimus-Eluting Coronary Stent
9869552|NCT00231296|Active Comparator|Treatment with CryoCor Cryoablation System|Intervention includes ablation therapy with the CryoCor catheter for the treatment of symptomatic PAF.
9869553|NCT00231296|Active Comparator|Treatment with standard medical therapy|Intervention includes treatment with ant-arrhythmic medications alone.
9869554|NCT00231452|Experimental|Late exposure group|Participants received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months of age.
9869555|NCT00231452|Experimental|Early exposure group|Participants received monthly placebo from 2.5-4.5 months of age and monthly SP+AS from 5.5-9.5 months of age.
9869556|NCT00231452|Placebo Comparator|Control group|Participants received monthly placebo from 2.5 to 9.5 months of age.
9869557|NCT00231569|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
9869558|NCT00231569|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
9869559|NCT00231569|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
9869560|NCT00231569|Experimental|Cohort D|Loading doses followed by weekly maintenance doses
9869561|NCT00231569|Experimental|Cohort E|Loading doses followed by weekly maintenance doses
9869562|NCT00231569|Experimental|Cohort F|Loading doses followed by extended weekly maintenance doses
9869563|NCT00231569|Experimental|Cohort G|Loading doses followed by extended weekly maintenance doses
9869564|NCT00231582|Experimental|1|1
9869565|NCT00231673|Experimental|001|Topiramate Increasing dosing of topiramate gradually to 200 mg daily by mouth dose maintenance for 12 weeks then decreasing dose until stopped over 12 weeks
9869566|NCT00231790|Experimental|MK-0634 50 mg|All participants will receive placebo for the 1 week prior to randomization
9869567|NCT00231790|Experimental|MK-0634 125 mg|All participants will receive placebo for the 1 week prior to randomization
9869568|NCT00231790|Experimental|MK-0634 375 mg|All participants will receive placebo for the 1 week prior to randomization
9869569|NCT00231790|Placebo Comparator|Placebo|All participants will receive placebo for the 1 week prior to randomization
9869570|NCT00231907|Active Comparator|Vaccine 1: TIV. Vaccine 2: TIV.|Vaccine 1: TIV. Vaccine 2: TIV.
9986546|NCT01403909|Experimental|With compression|The patients randomized to this group will have intermittent pneumatic venous compression of the lower limbs during surgery.
9986547|NCT01403909|Active Comparator|Without compression|The patients randomized to this group will not have intermittent pneumatic venous compression of the lower limbs during surgery. (Standard care)
9986548|NCT01403922|Experimental|1|TC-5214
9986549|NCT01403922|Experimental|2|TC-5214 with placebo
9986550|NCT01403922|Experimental|3|TC-5214 with placebo
9869571|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: TIV.|Vaccine 1: LAIV. Vaccine 2: TIV.
9869572|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: LAIV.|Vaccine 1: LAIV. Vaccine 2: LAIV.
9869573|NCT00231907|Experimental|Vaccine 1: TIV. Vaccine 2: LAIV.|Vaccine 1: TIV. Vaccine 2: LAIV.
9869574|NCT00231933|Active Comparator|1|Participants will receive standard care incorporating illness management recovery
9869575|NCT00231933|Experimental|2|Participants will receive illness management recovery plus person-centered planning
9869576|NCT00231933|Experimental|3|Participants will receive illness management recovery plus person-centered planning and community integration
9869577|NCT00231959|Placebo Comparator|Sugar pill|Placebo
9869578|NCT00231959|Experimental|Pramipexole|
9869579|NCT00231972|Experimental|Project Enhance|Participants will receive the risk reduction program, Project Enhance
9869580|NCT00231972|Active Comparator|Active Comparison Condition|Participants will receive standard prevention case management
9869581|NCT00231985|Placebo Comparator|1|Participants will receive supportive psychotherapy.
9869582|NCT00231985|Active Comparator|2|Participants will receive habit reversal therapy.
9869583|NCT00231998|Experimental|1|
9869584|NCT00232011|Experimental|1|
9928118|NCT00902759|Experimental|Walking Program|Participants in the intervention arm will participate in a walking program consisting of a 6 week graduated walking program. There are three phases to the walking program, Phase 1 is Warm-up, Phase 2 is Brisk Walking and Phase 3 is Cool Down. Phase 1 is the same for all 6 weeks, and consists of a slow 5 minute walk. In Months 1 and 2, Phase 2 is a 10 minute brisk walk. In Months 3 and 4, Phase 2 is a 20 minute brisk walk. In Months 5 and 6, Phase 2 is a 25 - 30 minute brisk walk. Phase 3 is the same for all 6 weeks and consists of a 5 minute rest/cool down period.
9928119|NCT00902772|Placebo Comparator|A|Placebo
9928120|NCT00902772|Active Comparator|B|Lorazepam
9928121|NCT00902772|Active Comparator|C|Lorazepam
9928122|NCT00902772|Active Comparator|D|Lorazepam
9928123|NCT00902772|Experimental|E|AZD7325
9928124|NCT00902772|Experimental|F|AZD7325
9928125|NCT00902772|Experimental|G|AZD7325
9928126|NCT00902785||no drug|no drug
9928127|NCT00902798|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
9928128|NCT00902798|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
10210801|NCT03790111|Experimental|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg plus 1L therapy for the duration of the study
10210802|NCT03787758|Experimental|SAGE-718|
9928129|NCT00902811|Active Comparator|AM(LT)|Artesunate (Arsumax®, Sanofi)
9928130|NCT00902811|Experimental|AM(FDC)|Artesunate-mefloquine fixed dose combination
9928131|NCT00902811|Experimental|AL|artemether 20 mg - lumefantrine 120 mg co-formulated tabs
9928132|NCT00902811|Experimental|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/Piperaquine 160 mg tablets
9928133|NCT00902811|Experimental|AA (FDC)|Artesunate-amodiaquine fixed dose combination
9928134|NCT00902824|Active Comparator|Group A|"ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months~Number of volunteers: 12"
9928135|NCT00902824|Active Comparator|Group B|"TBC-M4 at 0,1,6 months~Number of volunteers: 12"
9928136|NCT00902824|Placebo Comparator|Placebo|Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
10210803|NCT03771586|Experimental|SAGE-718|
10210804|NCT03771586|Placebo Comparator|Placebo|
9928137|NCT00902837|Active Comparator|oxycodone Tablet|OxyCodone Prolonged release tablets
10210805|NCT03769181|Experimental|Phase 1: cHl/DLBCL/PTCL|Isatuximab dose 1 or 2 depending on dose limiting toxicities (DLTs) observed and cemiplimab predefined dose
10210806|NCT03769181|Experimental|Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
10210807|NCT03769181|Experimental|Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
9928138|NCT00902837|Experimental|oxycodone naloxone tablet|Oxycodone naloxone prolonged release tablets (OXN)
9928139|NCT00902863|Experimental|YOGA patients|Patients assessed for chronic pain at our Pain Management Centre
9928140|NCT00902876|Experimental|Mucograft + CAF|Mucograft in combination with coronally advanced flap (CAF)
9928141|NCT00902876|Experimental|CAF|Coronally advanced flap (CAF) alone
9928142|NCT00902889|Experimental|1|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation with GPE (upper cranial two contacts).
9928143|NCT00902889|Experimental|2|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
9928144|NCT00902902||1|
9928145|NCT00902902||2|
9928146|NCT00902915|Experimental|Lenalidomide - Dexamethasone|
9928147|NCT00902941|Experimental|Rasagiline|
9928148|NCT00902941|Placebo Comparator|Placebo|
9928149|NCT00902954|Experimental|A|anastrozole/letrozole 2-3 years switching to exemestane 3-2 years
9928150|NCT00902954|Active Comparator|B|anastrozole/letrozole 5 years
9928151|NCT00902967|Active Comparator|1|Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
9869585|NCT00232115|Experimental|1|Pimecrolimus
9869586|NCT00232115|Placebo Comparator|2|Vehicle
9869587|NCT00232193||IFNβ+DS group|IFNβ+DS group received lyophilized Avonex 30mcg IM weekly plus dexamethasone 160 mg IV every 4 weeks for 52 weeks and was treated with Avonex 30mcg IM weekly from week 53 to 104
10210808|NCT03769181|Experimental|Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
9869588|NCT00232193||IFNβ group|IFNβ group received lyophilized Avonex 30mcg IM weekly for 104 weeks
9869589|NCT00232219|No Intervention|Control|No fish oil exposure
9869590|NCT00232219|Experimental|Fish oil|Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
9869591|NCT00232232|No Intervention|Control|No fish oil
9869592|NCT00232232|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
9869593|NCT00232245|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
9869594|NCT00232245|No Intervention|Control|No fish oil exposure
9869595|NCT00232271|Active Comparator|clexane|patients received clexane
9869596|NCT00232271|No Intervention|non clexane|no clexane given
9869597|NCT00232284|Active Comparator|Sertaline|8 week course of sertraline 50-100mg for those who fail to respond to CBT within first 4 weeks of study entry
9869598|NCT00232284|Placebo Comparator|Placebo|8 week course of placebo
9869599|NCT00232349|Experimental|Intervention group|All subjects enrolled in study are in the intervention group.
9869600|NCT00232466|No Intervention|2|conservative therapy (no intervention)
9869601|NCT00232466|Active Comparator|1|Vertebroplasty
9869602|NCT00232492|Placebo Comparator|Placebo males|Saline physiological placebo males
9869603|NCT00232492|Active Comparator|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine males
9869604|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine males
9869605|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine males
9869606|NCT00232492|Placebo Comparator|Placebo females|Saline physiological as placebo females
9869607|NCT00232492|Active Comparator|Ketamine 0.1 mg/kg females|0,1 mg/kg ketamine females
9869608|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg females|0,3 mg/kg ketamine females
9869609|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg females|0,5 mg/kg ketamine females
9869610|NCT00232622|Active Comparator|Standard infusion of streptokinase|Standard infusion of streptokinase
9869611|NCT00232622|Experimental|Accelerated infusion of streptokinase|Accelerated infusion of streptokinase
9869612|NCT00232687|Active Comparator|A1|
9869613|NCT00232687|Active Comparator|A2|
9869614|NCT00232765|Experimental|1|Cypher Bx Velocity
9869615|NCT00232765|Active Comparator|2|Uncoated Bx Velocity
9869616|NCT00232791|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
9869617|NCT00232791|Active Comparator|2|CYPHER™ Sirolimus-eluting Coronary Stent
9869618|NCT00232804|Other|1|
9869619|NCT00232817|Experimental|1|Propofol anesthetic with and without nicotine
10210809|NCT03769181|Experimental|Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
10210810|NCT03767582|Experimental|Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist|
10210811|NCT03767582|Experimental|Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist|
10210812|NCT03767582|Experimental|Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist|
10210813|NCT03729999|Experimental|Ultrasonography|Patients requiring single lung ventilation for a surgical procedure will have a bedside ultrasound to evaluate lung isolation.
10210814|NCT03706885|Placebo Comparator|Placebo|Treatment with placebo - 1 pill per day for 20 weeks
10210815|NCT03706885|Active Comparator|Sustiva 50mg|Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
10210816|NCT03706885|Active Comparator|Sustiva 200mg|Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
10210817|NCT03698084||Active|200 infants enrolled; family demographics collected and samples at day 5 (venepuncture, nasopharyngeal swab, urine and stool), actively followed up through their first RSV season for signs of respiratory symptoms. If respiratory symptoms are due to RSV infection (by point of care testing) samples as taken at day 5 are repeated at time of infection and again 7 weeks later. Annual questionnaire enquiring into respiratory illness, hospitalisations and family health and health quality of life, for up to 3 years.
10210818|NCT03698084||Passive|1800 infants enrolled; family demographics collected. Questionnaire follow up at 1 year of age enquiring into respiratory illness, hospitalisations and family health and health quality of life. If infant was hospitalised in first year of life, follow up will continue for up to 3 years.
9869620|NCT00232817|Experimental|2|isoflurane anesthetic with and without nicotine
9869621|NCT00232830|Experimental|1|Cypher Sirolimus-eluting Coronary Stent
9869622|NCT00232830|Active Comparator|2|Bare-metal stent
9869623|NCT00232843|Experimental|1|Cordis SMART™ nitinol self-expanding stent.
9869624|NCT00232843|Active Comparator|2|balloon angioplasty
9869625|NCT00232856|Other|1|Cypher™ sirolimus-eluting stent
9869626|NCT00232869|Experimental|1|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
9869627|NCT00232869|Active Comparator|2|SMART™ bare-metal stent
9869628|NCT00232882|Active Comparator|1|Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
9869629|NCT00232882|Active Comparator|2|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
9869630|NCT00232882|Active Comparator|3|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
9869631|NCT00232908|Experimental|1|
9869632|NCT00233077|Experimental|Behavioral: Patient Assistance|Patient assistance programs
9928152|NCT00902967|Placebo Comparator|2|Placebo tablets of similar shape and color given at night time dosing
9986551|NCT01403922|Experimental|4|TC-5214
10210819|NCT03669627|Active Comparator|Group 1: aTIV primer, QIV booster|Two doses (0.25 mL) aTIV (FLUAD )received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.
9869633|NCT00233077|Other|Control: Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
9869634|NCT00233129|Active Comparator|Standard Treatment|cognitive rehabilitation day treatment program
9869635|NCT00233129|Experimental|Top-Down|"cognitive rehabilitation day treatment program that incorporates systematic top down treatment of executive function deficits (problem solving and emotional regulation training), systematic treatment of attention deficits, and modular, contextual and embedded approaches to treatment."
9869636|NCT00233142|Experimental|Expressive writing|Expressive writing
9869637|NCT00233142|Sham Comparator|Neutral writing|Non-expressive writing
9869638|NCT00233168|Experimental|1|Peer medication adherence counseling
9869639|NCT00233168|Active Comparator|2|Peer life skills counseling
9869640|NCT00233194||Cohort 2|Children scheduled for adenotonsillectomy and healthy subjects, for comparison, not scheduled for such surgery.
9869641|NCT00233220|Experimental|1|Patients and doctors will take part in a multicomponent, multi-level intervention.
9869642|NCT00233220|Active Comparator|2|Patients will receive usual care.
9869643|NCT00233259|Active Comparator|1|Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
9869644|NCT00233259|Placebo Comparator|2|Control group
9869645|NCT00233506|Experimental|CPG 7909 IV|Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
9869646|NCT00233506|Experimental|CPG 7909 SQ|Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
9869647|NCT00233532|Other|1|
9869648|NCT00233532|Other|2|
9869649|NCT00233532|Other|3|
9869650|NCT00233571|Experimental|Adalimumab 40mg subcutaneous (SC) every other week (EOW)|Adalimumab 40mg subcutaneous (SC) every other week (EOW)
9869651|NCT00233688|Experimental|1|QUANTUM LP™ STENT GRAFT SYSTEM
9869652|NCT00233688|Active Comparator|2|Surgical intervention
9928153|NCT00902980||1. Community Based Clinics|Patient charts from community based nephrology clinics
9928154|NCT00902980||2. Regional Clinics|Patient charts from regional transplant clinics
9928155|NCT00902993|Experimental|1|Part A single and multiple dose and part B fractionated dose
9928156|NCT00902993|Placebo Comparator|2|
9928157|NCT00903019|Experimental|1|Participants will receive problem-solving therapy (PST) delivered via teleconferencing (tele-PST).
9928158|NCT00903019|Active Comparator|2|Participants will receive problem-solving therapy (PST) delivered in-person.
9928159|NCT00903019|Placebo Comparator|3|Participants will receive monitoring phone calls.
9928160|NCT00903045|Experimental|1|
9928161|NCT00903045|Placebo Comparator|2|
9928162|NCT00903071|Active Comparator|REAL PPL|REAL+PPL profiles PCP performance using real electronic medical record derived data to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
9928163|NCT00903071|Active Comparator|SIM PPL|SIM+PPL, profiles PCP performance using simulated cases to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
9928164|NCT00903071|No Intervention|Control|No intervention -control group
9928165|NCT00903084|Active Comparator|1|Participants will receive 7 doses per week, then 4 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
9928166|NCT00903084|Active Comparator|2|Participants will receive 7 doses per week, then 2 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
9928167|NCT00903084|Active Comparator|3|Participants will receive 4 doses per week, then 7 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
9928168|NCT00903084|Active Comparator|4|Participants will receive 4 doses per week, then 2 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
9869653|NCT00233714|Active Comparator|1|Single-dose Sirolimus-Eluting Coronary stent
9869654|NCT00233714|Active Comparator|2|Double-dose Sirolimus-Eluting Coronary stent
9869655|NCT00233727|Active Comparator|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
9869656|NCT00233727|Active Comparator|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
9869657|NCT00233727|No Intervention|Delayed Evaluation and Treatment|Patients will undergo a similar screening process at entry, but will be randomized to have evaluation and treatment delayed until 6 months after screening.
9869658|NCT00233792|Other|1|sirolimus coated Bx VELOCITY stent - fast release
9869659|NCT00233792|Other|2|sirolimus coated Bx VELOCITY stent - slow release
9869660|NCT00233805|Active Comparator|1|Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
9869661|NCT00233805|Experimental|2|Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
9869662|NCT00233818|Other|1|
9869663|NCT00233883|Experimental|1|
9869664|NCT00233883|Active Comparator|2|
9869665|NCT00233935|Experimental|Arm I (1 capsule)|Patients receive 1 capsule of defined green tea catechin extract PO BID for the next 6 months.
9869666|NCT00233935|Experimental|Arm II (2 capsules)|Patients receive 2 capsules of defined green tea catechin extract PO BID for the next 6 months.
9869667|NCT00233935|Experimental|Arm III (3 capsules)|Patients receive 3 capsules of defined green tea catechin extract PO BID for the next 6 months.
9869668|NCT00233935|Placebo Comparator|Arm IV (placebo)|Patients receive 1-3 capsules of placebo PO BID for the next 6 months.
9869669|NCT00233974|Experimental|PET negative|Traditional breast Surgery and full axillary dissection
9869670|NCT00233974|Experimental|PET positive|PET-probe-guided breast resection and full axillary dissection
9869671|NCT00234000|Experimental|Arm 1|see description in intervention
9869672|NCT00234091|Active Comparator|1|Immediate treatment; individuals receive HAART on Day 1 of the study
9869673|NCT00234091|Active Comparator|2|Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness
9869674|NCT00234143|Active Comparator|Aranesp and Neupogen|solution for subcutaneous injection , syringe 500 mcg and 300 mcg respectively
9869675|NCT00234143|Active Comparator|Aranesp|solution for subcutaneous injection, 500 mcg
9869676|NCT00234143|No Intervention|Best supportive care|Red cell transfusion support
9869677|NCT00234156|Active Comparator|renal disease|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
9869678|NCT00234156|Active Comparator|normal|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
9869679|NCT00234208|Experimental|Medical thoracoscopy|
9869680|NCT00234208|Active Comparator|Simple chest tube drainage|
9869681|NCT00234221|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
9869682|NCT00234221|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's alcohol use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized alcohol treatment; or 2) provide a strategy to self-monitor alcohol use, consider consequences, and later seek assessment.
9869683|NCT00234221|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
9986552|NCT01403948|Experimental|Patients with relapsed or refractory NHL|Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
9986553|NCT01403961||HbA1c > 7|Diabetic patients with HbA1c > 7
9986554|NCT01403961||HbA1c ≤ 7|Diabetic patients with HbA1c ≤ 7
9986555|NCT01403974|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every week, monotherapy
9869684|NCT00234273|Experimental|Therapeutic education combining dietary and rehabilitation|Therapeutic education combining dietary and rehabilitation (APA)
9869685|NCT00234273|Active Comparator|Therapeutic education primarily focused on dietary|Therapeutic education primarily focused on dietary
9869686|NCT00234299|Active Comparator|Group A|Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
9869687|NCT00234299|Placebo Comparator|Group B|Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
9986556|NCT01404000|Active Comparator|Iodinated Active Charcoal|Iodinated activated charcoal 3 gram daily in the morning for 56 days +- 2 days (=8 weeks)
9986557|NCT01404000|Placebo Comparator|non-iodinated activated charcoal|3g non-iodinated activated charcoal is given daily for 8 weeks
9986558|NCT01404013|Active Comparator|Montelukast|Monotherapy with Montelukast 10mg, take orally ,every night,for 8 weeks
9986559|NCT01404013|Active Comparator|ICS/LABA and Montelukast|Combination therapy with inhaled corticosteroid/β2 agonist 160/4.5ug,twice a day and Montelukast 10mg，take orally,every night for 8 weeks
9986560|NCT01404013|Active Comparator|ICS/LABA|Monotherapy with corticosteroid/β2 agonist 160/4.5ug,inhaled, twice a day, for 8 weeks
9986561|NCT01404026|Active Comparator|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
10210820|NCT03669627|Other|Group 2: QIV primer, QIV booster|"Standard of care control group:~Two doses (0.5 mL) QIV (Fluzone) received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2."
9869688|NCT00234455|Other|1|stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group)
9869689|NCT00234455|Other|2|stents in both the main and side branches (stent/stent group)
9869690|NCT00234546|Experimental|1|Dysport
9869691|NCT00234546|Placebo Comparator|2|Placebo
9869692|NCT00234598|No Intervention|Control group, usual care|Usual care with no study interventions provided; no tooth brushing intervention and no chlorhexidine intervention. Usual care
9869693|NCT00234598|Active Comparator|Tooth brushing only|Tooth brushing by study personnel three times per 24 hours (TID) without chlorhexidine application.
9869694|NCT00234598|Active Comparator|Chlorhexidine only|Oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID) without tooth brushing.
9869695|NCT00234598|Active Comparator|Toothbrushing and chlorhexidine|Tooth brushing by study personnel three times per 24 hours (TID) and oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID)
9869696|NCT00234676|Experimental|1|Premarin
9869697|NCT00234702|Experimental|1|
9869698|NCT00234702|Placebo Comparator|2|
9869699|NCT00234754|Active Comparator|1|Trans-vaginal tape Surgery
9869700|NCT00234754|Experimental|2|Trans-obturator tape surgery
9869701|NCT00234806|Experimental|Telemedicine intervention group|
9869702|NCT00234806|Placebo Comparator|Control group|
9869703|NCT00234858|Active Comparator|1|
9869704|NCT00234858|Active Comparator|2|
9869705|NCT00234871|Active Comparator|1|
9869706|NCT00234871|Active Comparator|2|
9869707|NCT00234910|Experimental|A|2 drug arm
9869708|NCT00234910|Active Comparator|B|3 drug arm, SOC
9869709|NCT00234923|Active Comparator|1|Kaletra Monotherapy: lopinavir/ritonavir
9869710|NCT00234923|Active Comparator|2|Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine
9869711|NCT00234975|Active Comparator|HCV +|
9869712|NCT00234975|Active Comparator|HCV -|
9869713|NCT00234988|Experimental|1|
9869714|NCT00235001|Experimental|1|
9869715|NCT00235014|Active Comparator|A-1, B-1|A-1 pertains to Phase 1; B-1 pertains to Phase 2
9869716|NCT00235014|Active Comparator|A-2, B-2|A2 pertains to Phase 1; B-2 pertains to Phase 2
9869717|NCT00235014|Placebo Comparator|A-3|
9869718|NCT00235014|Active Comparator|A-4|
10213702|NCT03489746|Experimental|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
9869719|NCT00235027|Experimental|Adverse Drug Event Monitoring|In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
9869720|NCT00235027|No Intervention|Care as Usual|In this arm, clinicians did not receive the medication safety alerts.
9869721|NCT00235040|Other|1|Intervention
9869722|NCT00235040|No Intervention|2|Control
9869723|NCT00235066|Experimental|1|Cypher Sirolimus-Eluting Stent
9869724|NCT00235079|Experimental|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
9869725|NCT00235079|Placebo Comparator|Placebo|Placebo 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
9869726|NCT00235131|Experimental|1|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
9869727|NCT00235131|Active Comparator|2|Bard® Luminexx™ 6F Vascular Stent
9869728|NCT00235144|Experimental|1|drug-eluting stent
9869729|NCT00235144|Active Comparator|2|bare-metal stent
9869730|NCT00235157|Experimental|1|Sirolimus-eluting Palmaz Genesis peripheral stent
9869731|NCT00235170|Experimental|1|Cypher Sirolimus-eluting Coronary stent
9869732|NCT00235183|Active Comparator|Quarantined FFP|Quarantined FFP
9869733|NCT00235183|Active Comparator|Methylene blue FFP|Methylene blue FFP
9869734|NCT00235183|Active Comparator|Solvent detergent FFP|Solvent detergent FFP
9928169|NCT00903084|Active Comparator|5|Participants will receive 2 doses per week, then 7 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
9928170|NCT00903084|Active Comparator|6|Participants will receive 2 doses per week, then 4 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
9928171|NCT00903149||MITP exposure or not|Mothers of children born preterm and term.
9928172|NCT00903188|Active Comparator|Cyclosporine|Simulect + cyclosporine + Myfortic + steroid stop at 3 months
9928173|NCT00903188|Active Comparator|Everolimus|Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance
9928174|NCT00903227|Experimental|Low Dose|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
9928175|NCT00903227|Experimental|Combined|One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).
9928176|NCT00903227|Experimental|High dose|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
9928177|NCT00903266|Experimental|MIT|Melodic Intonation Therapy
9928178|NCT00903266|Active Comparator|SRT|Speech-Repetition-Therapy
9928179|NCT00903266|No Intervention|NTC|No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
9928180|NCT00903279|Placebo Comparator|Placebo|
10213703|NCT03489746|Active Comparator|Standard care|Patients will continue on their current recommended regimen including ICS.
9869735|NCT00235235||A|Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 2 of every 21-day cycle
9869736|NCT00235235||B|Capecitabine 1000mg/m2 bid days 1-14 of every 21-day cycle
9869737|NCT00235235||C|Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
9869738|NCT00235235||D|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
9869739|NCT00235248|Experimental|Clopidogrel-aspirin|Clopidogrel-aspirin
9869740|NCT00235248|Active Comparator|Warfarin|Warfarin
9869741|NCT00235287|Active Comparator|A,AIIA|24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
9869742|NCT00235287|Active Comparator|A, ACE-I|24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
9869743|NCT00235287|Active Comparator|C, AIIA|8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
9869744|NCT00235287|Active Comparator|C, ACE|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
9869745|NCT00235300|Active Comparator|1 Control|Simulect (basiliximab)
9869746|NCT00235300|Experimental|2|Thymoglobulin (anti-thymocyte globulin (rabbit))
9869747|NCT00235313|Experimental|1|adaptation of the nicotine patch with salivary cotinine
9869748|NCT00235313|Other|2|normal following with a nicotine patch
9869749|NCT00235339|Active Comparator|1|Standard exercise training rehabilitation at the hospital
9869750|NCT00235339|Experimental|2|Interval exercise training on treadmills, with high intensity
9869751|NCT00235365|Experimental|meta-cognitive therapy|meta-cognitive therapy
9869752|NCT00235365|Active Comparator|waiting list|waiting list control
10210821|NCT03669627|Experimental|Group 3: aTIV primer, aTIV booster|"This arm is experimental in that some participants will be receiving the MF59-adjuvanted TIV (FLUAD) in year two of the study, after the age of two years, which is off label.~Two doses (0.25 mL) TIV (FLUAD) received one month apart in year 1. One dose (0.25 mL) TIV (FLUAD) received as booster in year 2."
10210822|NCT03667599|Experimental|Home care|This is the arm for patients who receive their transplant care in their homes.
9869753|NCT00235378||1|SLE patients
9869754|NCT00235378||2|Unaffected family members of SLE patients
9869755|NCT00235378||3|Control participants
9869756|NCT00235404|Experimental|Intermediate community hospital|
9869757|NCT00235404|Active Comparator|Usual care|
9869758|NCT00235508|Active Comparator|1|Escitalopram oxalate 10 mg at bedtime
9869759|NCT00235508|Active Comparator|2|Eszopiclone 3 mg at bedtime
10210823|NCT03667599|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
10210824|NCT03667599|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
10210825|NCT03651830|Experimental|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
10210826|NCT03651830|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
10210827|NCT03605550|Experimental|Treatment (PTC596)|PTC596 administered orally twice weekly (M/Th or T/F schedule) concomitantly with radiotherapy. One cycle is defined as 28 days. Post RT patients will continue to receive PTC596 twice weekly for up to 25 cycles.
10210828|NCT03603314|Experimental|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
10210829|NCT03603314|Experimental|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
10210830|NCT03603314|Placebo Comparator|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
10210831|NCT03589300|Other|Persona TM Tibia subjects|Subjects that receive the Persona TM Tibia implant
10210832|NCT03584932|Experimental|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
10210833|NCT03584932|No Intervention|Control arm|Standard of care as set forth by the national HIV care guidelines.
9869760|NCT00235534|Experimental|Immediate start|Initiate selected birth control method before leaving the clinic at the time of the abortion procedure.
9869761|NCT00235534|Active Comparator|Sunday start|Begin birth control the first Sunday after leaving the clinic
9869762|NCT00235690|Other|blood draws|all patients enrolled will have PK blood samples obtained around a colistin dosing
9869763|NCT00235729|Experimental|1|Lofexidine 0.8 mg QID
9869764|NCT00235729|Placebo Comparator|2|Placebo QID
9869765|NCT00235807|Other|1|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
9869766|NCT00235807|Other|2|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
9869767|NCT00235807|Other|3|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
9869768|NCT00235820|Active Comparator|A|
9869769|NCT00235820|Active Comparator|B|
9869770|NCT00235820|Placebo Comparator|C|
9928181|NCT00903279|Experimental|Altabax|
10210834|NCT03563417|Active Comparator|PCI|
10210835|NCT03563417|Other|OMT|
10210836|NCT03560960|Experimental|Probable AD|Participants with probable AD with positive imaging AD pathology will receive the pramlintide challenge test.
9869771|NCT00235846|Active Comparator|Conventional vein harvest|Conventional open vein harvest from the lower leg
9869772|NCT00235846|Experimental|Endoscopic vein harvest|Endoscopic vein harvest from the calf
9869773|NCT00235898|Experimental|1|CoFactor, 5-FU
9869774|NCT00235898|Active Comparator|2|Leucovorin, 5-FU
9869775|NCT00236002|Placebo Comparator|placebo|
9869776|NCT00236119|Experimental|CEP-701 20mg|Patient Cohort 1
9869777|NCT00236119|Experimental|CEP-701 40mg|Patient Cohort 2
9869778|NCT00236119|Experimental|CEP-701 60mg|Patient Cohort 3
9869779|NCT00236119|Experimental|CEP-701 80mg|Patient Cohort 4
10210837|NCT03560960|Active Comparator|Amnestic MCI|Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test.
10210838|NCT03560960|Active Comparator|Control- Normal Cognition|Participants with normal cognition without any memory complaints will receive the pramlintide challenge test.
9869780|NCT00236158|Other|AAIR|
9869781|NCT00236158|Other|DDDR|
9869782|NCT00236210|Active Comparator|VIP program|Risk assessment, lifestyle counselling, exercise program
9869783|NCT00236210|No Intervention|Standard Care|
9869784|NCT00236223|Experimental|1|
9869785|NCT00236223|Placebo Comparator|2|
9869786|NCT00236275|Experimental|1|Fluoro-L-thymidine-(18F)
9869787|NCT00236301|Active Comparator|1|17 Beta-estradiol (2mg/day)and (1mg/day)
9869788|NCT00236301|Active Comparator|2|CLIMASTON
9869789|NCT00236301|Placebo Comparator|3|placebo
9869790|NCT00236379|Experimental|001|Risperidone Target oral dose of 6 milligrams per day for for 6 months
9869791|NCT00236379|Experimental|002|Olanzapine Target oral dose of 20 milligrams per day for 6 months
9928182|NCT00903292|Active Comparator|A, erlotinib|If EGFR mutation found then assigned to thyrosine kinase inhibitor (erlotinib)
9928183|NCT00903292|Active Comparator|B, pemetrexed|If EGFR wild type found then assigned to chemotherapy (pemetrexed)
9928184|NCT00903305|Experimental|Group II (SNIP)|Patients undergo SNIP comprising four visits over 2 months and four monthly telephone calls from the APN. The APN will provide 24 hour access during the study. Patients complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
10210839|NCT03518606|Experimental|Breast cancer cohort|Patients presenting advanced refractory breast cancer
10210840|NCT03518606|Experimental|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
10210841|NCT03518606|Experimental|Cervix cohort|Patients presenting advanced refractory cervix cancer
10210842|NCT03518606|Experimental|Prostate cohort|Patients presenting advanced refractory prostate cancer
10210843|NCT03518606|Experimental|Miscellaneous cohort|Patients presenting advanced refractory solid tumour with high mutational load
10210844|NCT03505203|Experimental|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
10210845|NCT03505203|Active Comparator|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
10210846|NCT03504423|Experimental|CPI-613, mFolfirinox|"CPI-613, mFolfirinox~CPI-613 at 500 mg/m2 IV infusion at a rate of 4mL/min via a central venous port on day 1 and 3 of a 14-day cycle.~mFolfirinox (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 140mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
9928185|NCT00903305|Active Comparator|Group I (usual care intervention)|Patients undergo usual care and complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
9928186|NCT00903318||Mexican American Men and Women|Rural and urban Mexican American men and women , aged 18 to 40, in urban Baytown, TX and rural Rio Grande Valley (Hidalgo County) communities along the Texas-Mexico border
9928187|NCT00903422|Active Comparator|Eltrombopag|Eltrombopag
9928188|NCT00903422|Placebo Comparator|Placebo|Placebo
9928189|NCT00903461|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Subjects will receive a total of up to 7 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive a total EGFR AS dose of 1.92 milligrams in 1.78 milliliters on each weekly treatment. This dose may be delivered equally in the same tumor site per weekly session, the primary tumor or cervical lymph nodes.
9928190|NCT00903526||candidemia|
9928191|NCT00903578||Kidney transplant recipients|
9928192|NCT00903604|Experimental|AP214|Infusions of sequential ascending dosages of AP214
9928193|NCT00903604|Placebo Comparator|Placebo|Infusions of saline solution
9928194|NCT00903643||Healthy subjects|
9928195|NCT00903643||PBS subjects|
9928196|NCT00903656|Experimental|Caelyx/Lapatinib|
9928197|NCT00903669||Peripheral Facial Paralysis (PFP)|Patients who are diagnosed with peripheral facial paralysis.
9928198|NCT00903708|Experimental|LY2275796|
9928199|NCT00903734|Experimental|Erlotinib Hydrochloride|Those eligible for umbrella of studies and have not received Erlotinib hydrochloride in past, will first receive Erlotinib hydrochloride alone.
9928200|NCT00903747|Experimental|1|Prucalopride
9928201|NCT00903747|Placebo Comparator|2|Placebo/moxifloxacin
9928202|NCT00903799|Other|1|"Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months.~After the cross-over period, device activated until the end of the trial"
9928203|NCT00903799|Other|2|"Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months.~After the cross-over period, device activated until the end of the trial"
9928204|NCT00903812||A|No intervention - observational study
9869792|NCT00236925|Active Comparator|Low dose Hydrocortisone|Low Dose Hydrocortisone
9869793|NCT00236925|Placebo Comparator|Placebo|Placebo
9869794|NCT00236990|Experimental|001|pentosan polysulfate sodium
9869795|NCT00237003|Active Comparator|1) assessment plus motivational interview|Participants are assigned, in this 6 month study, to an assessment-only condition or an assessment plus motivational interview condition. Two motivational interview sessions are conducted during the first month of study participation.
9869796|NCT00237107|Experimental|curettage|
9869797|NCT00237133|Experimental|Letrozole|
9869798|NCT00237146|Experimental|Zoledronic Acid|
9869799|NCT00237159|Experimental|ZOL446|
9869800|NCT00237172|Experimental|Imatinib Mesylate|400 mg once daily
9869801|NCT00237198|Experimental|Letrozole|
9869802|NCT00237211|Experimental|Letrozole|
10210847|NCT03504423|Active Comparator|Folfirinox|"Folfirinox~Folfirinox: Oxaliplatin (Eloxatin) at 85 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 180mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
10210848|NCT03473769|Experimental|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
9869803|NCT00237224|Experimental|FEM345|
9869804|NCT00237380|Experimental|Ataluren|"Cycle 1: Within the first 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 4 milligrams/kilogram (mg/kg) (breakfast), 4 mg/kg (lunch), and 8 mg/kg (dinner); there will then be an interval of 14 days without treatment.~Cycle 2: Within the second 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 10 mg/kg (breakfast), 10 mg/kg (lunch), and 20 mg/kg (dinner); there will then be an interval of 14 days without treatment."
9869805|NCT00237393|Experimental|1|Quetiapine
9869806|NCT00237393|Placebo Comparator|2|
10210849|NCT03473769|No Intervention|No Intervention|No intervention. Patient treated per standard of care.
10210850|NCT03424525|Experimental|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
9869807|NCT00237484|Experimental|Arm A|Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks
9869808|NCT00237484|Active Comparator|Arm B|PEGETRON treatment for up to 48 weeks
9869809|NCT00237497|Experimental|Ramelteon 8 mg QD|
9869810|NCT00237497|Active Comparator|Zopiclone 7.5 mg QD|
9869811|NCT00237497|Placebo Comparator|Placebo QD|
9869812|NCT00237549|Experimental|Intervention|The 334 general practices in Denmark, United Kingdom and the Netherlands have been randomised to screening for diabetes followed by routine care (RC group) according to national guidelines, or screening followed by multifactorial treatment (IT group).
9869813|NCT00237601||1|Women with the intention to give birth at home
9869814|NCT00237601||2|Women with the intention to give birth in a short-stay hospital setting
9869815|NCT00237627|Experimental|Part 1|Doxil + PS-341
9869816|NCT00237627|Experimental|Part 2|Doxil + Velcade
10213704|NCT03488420||Atrial Fibrillation and/or Atrial Flutter|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
9869817|NCT00237640|Placebo Comparator|1|
9869818|NCT00237640|Active Comparator|2|
9869819|NCT00237679|Active Comparator|Neuromuscular Electrical Stimulation|Subjects will receice Neuromuscular Electrical Stimulation (NMES)-stimulated swallowing combined with exercise therapy.
9869820|NCT00237679|Sham Comparator|Unstimulated|Subjects will receive sham (unstimulated) swallow therapy combined with exercise therapy.
9869821|NCT00237731|Experimental|1|morphine 0.05
9869822|NCT00237731|Active Comparator|2|morphine 0.10
9869823|NCT00237757|Experimental|Arm 1|The experimental arm consisted of a six month staff training period with an emphasis on effective team functioning to improve patient outcomes. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing
9869824|NCT00237757|Active Comparator|Arm 2|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
9869825|NCT00237783|Active Comparator|standard dialysate sodium (140 mmol/L)|dialysate sodium (140 mmol/L)
9869826|NCT00237783|Experimental|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
9869827|NCT00237913|Active Comparator|A1|
9869828|NCT00237913|Active Comparator|B1|
9869829|NCT00237926|Experimental|1|aerobic exercise
9869830|NCT00237926|Experimental|2|Resistance Training
9869831|NCT00237978|Active Comparator|1|VIS and wIRA
9869832|NCT00237978|Active Comparator|2|VIS, wIRA and Adapalen
9869833|NCT00237978|Active Comparator|3|Adapalen
9869834|NCT00238030|Active Comparator|po thyroxine|placebo is iv
9869835|NCT00238030|Active Comparator|iv thyroxine|placebo is po
9869836|NCT00238212|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9869837|NCT00238251|Active Comparator|Arm I|Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
9869838|NCT00238251|Active Comparator|Arm II|Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
9869839|NCT00238290|Experimental|Arm A|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
9869840|NCT00238316|Active Comparator|Letrozole|
9869841|NCT00238316|Placebo Comparator|Placebo|
9928205|NCT00903825|Active Comparator|Manual palpation|Local anesthetic before femoral artery puncture will be injected with the classic manual palpation technique
9928206|NCT00903825|Experimental|Ultrasound guidance|Local anesthetic before femoral artery puncture will be performed with the use of duplex ultrasound guidance
9928207|NCT00903838|Experimental|1|
9928208|NCT00903838|Active Comparator|2|
9935327|NCT03891446|Experimental|Lead-in study ARGOS|Study eye (Eye that received Bimatoprost SR first in the lead-in study): 2 additional administrations of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart. Treated Fellow eye (Eye that received Bimatoprost SR second in the lead-in study): 2 additional administrations of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart. Untreated Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Untreated fellow eye will receive only standard of care, based on the investigator's judgment.
9935328|NCT03884075|Experimental|Arm A: Steatosis|Participants with steatosis on baseline biopsy
9935329|NCT03884075|Experimental|Arm B: NASH|Participants with NASH on baseline biopsy
9935330|NCT03884075|No Intervention|Arm C: Healthy|Healthy Volunteers
9935331|NCT03882034|Experimental|1|Intervention arm, Patient received pegvisomant
9935332|NCT03878121|Experimental|A1|Ad4-Env150KN at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
9935333|NCT03878121|Experimental|A2|Ad4-Env145NFL at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
9935334|NCT03878121|Experimental|B1 (exploratory)|Previously vaccinated; Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
9935335|NCT03878121|Experimental|B2 (exploratory)|Previously vaccinated; Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
9935336|NCT03877757||Family Planning Elevated Contraceptive Access Clinics Program|This group consists of community clinics who apply and are accepted for FPE CAP membership during the Family Planning Elevated initiative. These clinics will receive the intervention and will provide monthly service delivery data to the FPE evaluation team.
9935337|NCT03877757||Control Clinics|This group consists of non-participating community clinics matched on clinic size, geography, and client populations who are not interested in participating in the initiative but are willing to provide monthly service delivery data to the FPE evaluation team.
9935338|NCT03871348|Experimental|SAR441000 Dose Escalation Phase|SAR441000 will be administered as intratumoral injection as monotherapy in patients with solid tumors over a 28-day cycle
9935339|NCT03871348|Experimental|SAR441000 + cemiplimab - Dose Escalation Phase|SAR441000 will be administered as intratumoral injection in patients with solid tumors in combination with cemiplimab over a 21-day cycle
9935340|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 failure|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced melanoma who have failed anti-PD-1/PD-L1 therapy. Treatment is administered over a 21-day cycle
9935341|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve melanoma over a 21-day cycle
9935342|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion CSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Cutaneous Squamous Cell Carcinoma (CSCC) over a 21-day cycle
9935343|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion HNSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Head and Neck Squamous Cell Cancer (HNSCC) over a 21-day cycle
9869842|NCT00238381|Other|Arm I|Patients undergo total mesorectal excision (TME) by standard methods or laparoscopically and side-to-end anastomosis rectal reconstruction.
9869843|NCT00238381|Other|Arm II|Patients undergo TME and colon-J-pouch anastomosis rectal reconstruction.
9869844|NCT00238381|Other|Arm III|Patients undergo straight coloanal anastomosis with/without temporary protective ileostomy
9869845|NCT00238394|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing disease progression within 5 years after completion of study treatment may receive additional courses of study treatment.
9869846|NCT00238407|Active Comparator|Arm I|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
9869847|NCT00238459||Recently infected patients|Cohort 1)Patients elcted to be immediately treated with licensed drugs:21 patients Cohort 2) Or to delay treatment until clinically indicated:16 patieints
9869848|NCT00238459||A vaccine,HIV-1 immunogen was not provided for evaluation|In the intial design, acandiate HIV vaccine was to be evaluated, but in August 2007 the manufacturer refused to provide vaccine to allow this study to evaluate the effect of a vaccine on control of HIV. Therefore the study became an observational study of the effects of early versus delayed initiation of antiretrovral therapy on the preservation of anti-HIV immune responses and the ability of patients to control virus after a closely monitored discontinuation of therapy.
9869849|NCT00238667|Active Comparator|Anti-platelet therapy|Aspirin, Dipyridamole, clopidogrel alone or in dual therapy
9869850|NCT00238667|Active Comparator|Anti-coagulant|Warfarin, unfractionated heparin, enoxaparin, dalteparin, tinzaparin aiming for an INR in range of 2-3. Local protocols for Heparin can be used
9869851|NCT00238875|Experimental|1|Procedure/Surgery: stereotactic body radiation therapy
10210851|NCT03424525|Experimental|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
10210852|NCT03372161|Experimental|SP-102|SP-102
9869852|NCT00238888|Experimental|Asthma control awareness|Multifaceted intervention to increase the patient awareness of the leve of asthma control
9869853|NCT00238888|Active Comparator|Usual care|Usual care
9869854|NCT00238914|Active Comparator|CE plus oral naltrexone|Compliance enhancement plus oral naltrexone
9869855|NCT00238914|Active Comparator|BNT plus oral naltrexone|Behavioral naltrexone therapy plus oral naltrexone
9869856|NCT00238953|Experimental|EC MPS|
9869857|NCT00239031|Experimental|1|
9869858|NCT00239083|Experimental|EC-MPS|
9869859|NCT00239239|Experimental|test treatment period|
9869860|NCT00239551|Experimental|Prevacid|Effect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 & EGD at 8 weeks
9869861|NCT00239564|Experimental|Experimental: carbidopa and levodopa|Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.
9869862|NCT00239707|Experimental|Infusion 1|Normal Saline
9869863|NCT00239707|Placebo Comparator|Infusion 2|GIP or modified GIP
9869864|NCT00239707|Placebo Comparator|Infusion 3|GIP or modified GIP, opposite of Infusion 2
9869865|NCT00239746|Experimental|1|
9869866|NCT00239746|Placebo Comparator|2|
9869867|NCT00239824|Experimental|1|Strength training of the pelvic floor muscles with follow up instructions by a physiotherapist
9869868|NCT00239824|Active Comparator|2|Strength training of the pelvic floor muscles without follow up instructions
9935872|NCT03049475||Control|Healthy, between age 18-80, African/African decent
10210853|NCT03372161|Placebo Comparator|Placebo|Placebo
10210854|NCT03284853|Experimental|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
10210855|NCT03284853|Active Comparator|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
10210856|NCT03272373|Other|Monoblock|Subjects that receive the NexGen TM Monoblock Tibia
10210857|NCT03272373|Other|Modular|Subjects that receive the NexGen TM Modular Tibia
10210858|NCT03263416|Experimental|Arm A|
10210859|NCT03263416|Other|Arm B|Standard
10210860|NCT03250247|Experimental|Endovascular Therapy - Intervention|"All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.~Subjects randomized to EVT will receive the following:~imaging-guided iliac vein stent placement, and~endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.~optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care"
10210861|NCT03250247|No Intervention|Non-Endovascular Therapy - Control|All subjects will receive optimal PTS care as noted above.
10210862|NCT03233555|Active Comparator|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
10210863|NCT03233555|Experimental|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
10210864|NCT03233555|Experimental|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
10210865|NCT03233555|Experimental|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
10210866|NCT03206463|Experimental|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
9869869|NCT00239980|Active Comparator|A|50 IU/kg
9869870|NCT00239980|Active Comparator|B|100 IU/kg
9869871|NCT00239980|Active Comparator|C|150 IU/kg
9869872|NCT00239993|Experimental|1|skin reactions with the use of warm compress prior to performing a Copaxone® injection
9869873|NCT00239993|Experimental|2|skin reactions without the use of warm compress prior to performing a Copaxone® injection
9869874|NCT00240006|Experimental|1|Shared Solutions®
9869875|NCT00240006|Experimental|2|Shared Solutions® and MS Center/Office Practice Partnership
9869876|NCT00240032|Active Comparator|Copaxone® with Zyrtec|
9869877|NCT00240032|Experimental|Copaxone® with placebo|
9869878|NCT00240045|Experimental|1|
9869879|NCT00240058|Other|phenylephrine infusion with and without nitric oxide clamp|Participants received phenylephrine infusion with saline followed by phenylephrine infusion with nitric oxide clamp
9869880|NCT00240084|Experimental|Nesiritide infusion|Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
9869881|NCT00240188|Other|1|
9869882|NCT00240214||1|sirolimus
9869883|NCT00240253|Active Comparator|Pramlintide|
9869884|NCT00240461|Active Comparator|1|200 mg COLD-fX Natural health products 2 times daily for six months
10210867|NCT03206463|Experimental|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
10210868|NCT03206463|Placebo Comparator|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
9869885|NCT00240461|Active Comparator|Arm 2|Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months
9869886|NCT00240461|Placebo Comparator|3|Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.
9869887|NCT00240513|Active Comparator|Minocycline 3 mo|Minocycline 3 mo
9869888|NCT00240513|Experimental|Minocycline plus Tretinoin|Minocycline plus Tretinoin for 3 months
10210869|NCT03166761|Experimental|Dexamethasone|dexamethasone injected into the sacroiliac joint
10210870|NCT03166761|Active Comparator|Triamcinolone|triamcinolone injected into the sacroiliac joint
10210871|NCT03153410|Experimental|Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4|
9869889|NCT00240565|Experimental|Arm 1|Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
9869890|NCT00240617|Active Comparator|arm 1|Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA
9869891|NCT00240617|Placebo Comparator|arm 2|placebo to match
9869892|NCT00240630|Placebo Comparator|Arm 1|placebo to match
9869893|NCT00240630|Experimental|Arm 2|Treximet (sumatriptan/naproxen sodium)
9869894|NCT00240682|Experimental|cetuximab|cetuximab
9869895|NCT00240773|Experimental|001|acetaminophen 4 grams daily for 12 months
9869896|NCT00240773|Active Comparator|002|naproxen 750 mg daily for 12 months
9869897|NCT00240773|Experimental|003|acetaminophen 4 grams daily for six months
9869898|NCT00240773|Active Comparator|004|naproxen 750 mg daily for six months
9869899|NCT00240799|Experimental|001|acetaminophen extended release
9869900|NCT00240799|Placebo Comparator|002|placebo
9869901|NCT00240825|Experimental|001|Acetaminophen
9869902|NCT00240825|Experimental|002|Ibuprofen
9869903|NCT00240825|Placebo Comparator|003|Placebo
9869904|NCT00240851|Experimental|001|acetaminophen extended release
9869905|NCT00240864|Experimental|001|acetaminophen
9869906|NCT00240864|Experimental|002|ibuprofen
9869907|NCT00240864|Placebo Comparator|003|placebo
9869908|NCT00240877|Experimental|1|Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
9869909|NCT00240877|Placebo Comparator|2|Placebo
9869910|NCT00240968|Experimental|3|Subjects will receive a single 45 mcg IM dose of the influenza A/H5N1 virus vaccine.
9869911|NCT00240968|Experimental|4|Subjects will receive a single 90 mcg IM dose of the influenza A/H5N1 virus vaccine.
9869912|NCT00240968|Experimental|1|Subjects will receive a single 7.5 mcg IM dose of the influenza A/H5N1 virus vaccine.
9869913|NCT00240968|Experimental|2|Subjects will receive a single 15 mcg IM dose of the influenza A/H5N1 virus vaccine.
9869914|NCT00241020|Experimental|Octreotide|
9869915|NCT00241059|Experimental|EC-MPS arm|
9869916|NCT00241111|Other|Zometa|
9869917|NCT00241189|Experimental|Rapamycin|Patients take oral rapamycin 6 mg daily (and dose adjusted to keep a serum trough level of 5-15 ng/ml) for one year
9869918|NCT00241189|Active Comparator|Methotrexate|Methotrexate 20 mg taken orally weekly for one year
9869919|NCT00241228|Experimental|High Volume|ultra filtration : High volume : 70 ml/kg/h
9869920|NCT00241228|Active Comparator|Medium Volume|Ultra filtration : conventional volume : 35 ml/kg/h
9869921|NCT00241254|Experimental|1|Cyclophosphamide
9869922|NCT00241254|Active Comparator|2|Methylprednisolone
9928209|NCT00903851|Experimental|(1) Lidoderm|(1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain
9928210|NCT00903864||stethoscopy|
9928211|NCT00903864||BPM|blood pressure monitor
10210872|NCT03143660|Active Comparator|Coaching|A parent support component consisting of eight weekly telephone counseling calls by centrally located nutritionists to provide parents coaching tailored to their family's unique needs to help them set goals and make targeted lifestyle changes recommended by the American Academy of Pediatrics (AAP) for Stage 1, Prevention Plus, accompanied by a parent booklet
9869923|NCT00241345|Experimental|Group A|IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load >5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load >= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is <= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
9869924|NCT00241345|Experimental|Group B|PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load >5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load >= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load <= to previous viral load then 900 mg every 12 hours for another 7 days.
9869925|NCT00241371|Experimental|Clofarabine|4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
9869926|NCT00241384|Active Comparator|Pd-103 with 20Gy External Beam|Pd-103 with 20Gy External Beam
9869927|NCT00241384|Active Comparator|Pd-103 alone|Pd-103 alone
9869928|NCT00241410|Experimental|1|4 consecutive groups, dose escalation
9869929|NCT00241410|Placebo Comparator|2|4 consecutive groups
9869930|NCT00241423|Experimental|Exenatide|Exenatide and the subject's current oral antidiabetic agent regimen
9869931|NCT00241423|Placebo Comparator|Placebo|Placebo and the subject's current oral antidiabetic agent regimen
9869932|NCT00241449|Active Comparator|1|Tamoxifen
9869933|NCT00241449|Experimental|2|Fulvestrant
9928212|NCT00903890||A|Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
9928213|NCT00903903||1|RA patients with at least one active synovitis
9928214|NCT00903903||2|Non-RA patients with at least one active synovitis
9928215|NCT00903955||Chronic Obstructive Pulmonary Disease|Subjects diagnosed with COPD are classified according to standards set forth by the Global Initiative on Obstructive Lung Disease. This study recruits subjects in each of three GOLD categories.
9928216|NCT00903981|Experimental|Avanafil 100mg|
9928217|NCT00903981|Experimental|Avanafil 200mg|
9928218|NCT00903981|Placebo Comparator|Placebo|
9928219|NCT00903994|Other|Single Arm|Single Arm
9928220|NCT00904020|Experimental|(1) Lidoderm|(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
9928221|NCT00904059|Experimental|Treatment Group A|
9928222|NCT00904059|Experimental|Treatment Group B|
9928223|NCT00904059|Experimental|Treatment Group C|Treatment Groups A and B are followed by Treatment Group C: A combination of BMS-650032 (200 mg) and BMS-790052 (30 mg)
9928224|NCT00904072||accepted|The suggestions provided by the CDSS which were accepted by the physicians.
9928225|NCT00904072||denied|The suggestions provided by the CDSS which were denied by the physicians.
9928226|NCT00904085|Active Comparator|Oxymorphone|
9928227|NCT00904085|Placebo Comparator|Placebo|
9928228|NCT00904098|Experimental|Frovatriptan|Frovatriptan 2.5 mg oral tablet
9928229|NCT00904098|Active Comparator|Usual Care|Usual care includes the current treatment used to treat all episodes of migraine headache
9928230|NCT00904111|Experimental|Lidocaine 5% Patch|Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)
9928231|NCT00904111|Placebo Comparator|Placebo Topical Patch|Matching placebo patch, 2 patches applied directly to the most painful area of the low back once daily (q24h)
9928232|NCT00904124|Placebo Comparator|Control|No regular flour replaced
9928233|NCT00904124|Experimental|5% Cellulose|5% regular flour is replaced by cellulose
9928234|NCT00904124|Experimental|2.5% Alginate|2.5% regular flour is replaced by Alginate
9928235|NCT00904124|Experimental|5% Alginate|5% regular flour is replaced by Alginate
9928236|NCT00904124|Experimental|2.5% Guar gum|2.5% regular flour is replaced by Guar gum
9928237|NCT00904124|Experimental|1.25% Guar gum|1.25% regular flour is replaced by Guar gum
9928238|NCT00904137|Active Comparator|Cast|Above elbow fiberglass cast with a collar-and-cuff
9928239|NCT00904137|Active Comparator|Splint|Long arm posterior plaster splint with a collar-and-cuff
9928240|NCT00904137|Active Comparator|Tape|Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff
9928241|NCT00904176|Active Comparator|Dapagliflozin + Warfarin|
9928242|NCT00904176|Active Comparator|Warfarin|
9928243|NCT00904176|Active Comparator|Dapagliflozin + Digoxin|
9928244|NCT00904176|Active Comparator|Digoxin|
9928245|NCT00904202|Placebo Comparator|placebo capsules + placebo patch|Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
9928246|NCT00904202|Experimental|placebo capsules + Lidoderm patch (Lidocaine Group)|Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
9869934|NCT00241670|Experimental|5-aminolevulinic acid|
9869935|NCT00241670|No Intervention|Conventional resection|
9869936|NCT00241722|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally twice daily (BID) for 12 months.
9869937|NCT00241722|Placebo Comparator|Placebo|Placebo was administered orally BID for 12 months.
9869938|NCT00241748||1|Rhabdomyolysis Case Subjects
9869939|NCT00241748||2|Heart and Vascular Health Study statin users - control group 1
9869940|NCT00241748||3|Cardiovascular Health Study statin users - control group 2
9869941|NCT00241774||NSHS95 samples|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
9869942|NCT00241813|Active Comparator|Health Education Control Program (CTL)|Health Education Control Program (CTL)
9869943|NCT00241813|Experimental|Mindfulness Meditation|Mindfulness Meditation (MM) Program
9869944|NCT00241813|Experimental|Lifeskills|Lifeskills Program (LP)
9869945|NCT00241813|Experimental|MM plus LP|Mindfulness Meditation (MM) Program plus Lifeskills Program (LP)
9869946|NCT00241852|Experimental|Behavioral Intervention: Asthma: It's a Family Affair|Separate student and parent intervention groups.
9869947|NCT00241852|Active Comparator|Behavioral Control Group|Students and parents participate in an education only control group
9869948|NCT00241878|Experimental|1|Teacher-Delivered Weight Control Intervention
9869949|NCT00241878|Other|2|Teacher-Delivered General Health Intervention
9869950|NCT00241891|Other|Healthy Lifestyle (Active Intervention)|Parents and children in this program which will participate in a series of consultations and activities focused on multiple healthy interventions including healthy eating, drinking, and physical activity. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on healthy eating, drinking, and physical activity. In addition, your child will receive information on developing healthy interpersonal and social skills.
9869951|NCT00241891|Other|Healthy Drinks (Active Intervention)|Parents and children in this program will participate in a series of consultations and activities focused on a single intervention, the effects of beverage choices on diet, general health and teeth health. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on beverages and health. In addition, your child will receive information on healthy nutrition, physical activity, and interpersonal and social skills.
9869952|NCT00241891|Other|Social and Leadership Skills (Control Intervention)|Parents and children in this program will participate in a series of consultations that are designed to help your child learn strategies to make and keep friends, to express feelings appropriately, and to successfully decrease conflicts that often occur at school among children. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on these friendship making strategies. In addition, your child will receive information on healthy nutrition and physical activity. There is o intervention with regards to healthy weight.
9869953|NCT00241917|Experimental|Video|
9869954|NCT00241917|No Intervention|Control|
9869955|NCT00242112|Other|MRI - pathology|
9869956|NCT00242203|Experimental|Zometa|"Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.~Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
9928247|NCT00904202|Active Comparator|Gabapentin capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
9928248|NCT00904202|Other|Gabapentin capsules 1800 mg/day + Lidoderm patch|Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
9928249|NCT00904228|Experimental|Plastic Cap|Plastic lined stockinet cap (polyethylene bag)
9928250|NCT00904228|Active Comparator|Stockinet Cap|Usual practice
9928251|NCT00904254|Experimental|1, diagnostic comparison|EP 1645/Solution For Injection
9928252|NCT00904280|Experimental|Oxymorphone ER|
10210873|NCT03143660|Active Comparator|Materials|Parents will receive the same educational materials provided in the Fitline family workbook mailed over 8 weeks to control for weekly contact and educational curriculum, but no Fitline counseling.
10210874|NCT03080753|Experimental|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
10210875|NCT03072147|Active Comparator|Group 1- Treatment|20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
10210876|NCT03072147|Placebo Comparator|Group 2- Placebo|Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.
10210877|NCT03032250|Experimental|Group I Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
10210878|NCT03032250|Experimental|Group II Control Group|Caregivers received standard of care throughout course of intervention, with option to receive study intervention at end of study
10210879|NCT03023202||PMMTB|"This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.~All standard of care functions will be performed by standard procedures."
10210880|NCT03017898|Experimental|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
10210881|NCT03016533|Experimental|Dolutegravir (Tivicay)|All participants will receive dolutegravir film-coated tablets or film-coated dispersible tablets at appropriate doses selected as per their age and weight bands. For those participants who were previously receiving dolutegravir in study P1093 (parent study), dolutegravir will be supplied as film-coated tablets containing 10 milligram (mg), 25 mg and 50 mg; and 5 mg film-coated dispersible tablets of dolutegravir. Participants will receive dolutegravir until age-appropriate formulations are available to them from some other source, or until participant is no longer deriving benefit from treatment, or participant is discontinued, or until development of dolutegravir is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
10210882|NCT03016533|Experimental|ABC/DTG/3TC|All participants will receive ABC/DTG/3TC immediate release tablets or film-coated dispersible tablets at appropriate doses selected as per their weight bands. For those participants who were previously receiving ABC/DTG/3TC in study P2019 (parent study), ABC/DTG/3TC will be supplied as immediate release tablets containing 600 mg, 50 mg and 300 mg of ABC, DTG, and 3TC respectively and film-coated dispersible tablets containing 60 mg, 5 mg and 30 mg of ABC, DTG, and 3TC respectively. Participants will receive ABC/DTG/3TC until age-appropriate formulations are available to them from some other source, until participant is no longer deriving benefit from treatment, or until participant is discontinued, or until development of ABC/DTG/3TC is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
10210883|NCT03011814|Experimental|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
10210884|NCT03011814|Experimental|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
10210885|NCT02997462||Heart Failure|"Heart Failure patients admitted to the ICU or Heart Failure Service.~No changes in service-directed plan of care for patients."
10210886|NCT02997462||Healthy Control|Healthy, age-matched controls.
10210887|NCT02990377|Experimental|RL-supported IVR intervention|Participants in the intervention group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED plus the RL-supported IVR intervention.
10210888|NCT02990377|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED.
10210889|NCT02962414|Experimental|everolimus|everolimus, 2mg dispersible tablets
10210890|NCT02962128|Experimental|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
10210891|NCT02962128|Experimental|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
10210892|NCT02947165|Experimental|NIS793|
10210893|NCT02947165|Experimental|NIS793 + PDR001|
10210894|NCT02942966|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.
10210895|NCT02923778|Experimental|Treatment (talimogene laherparepvec, radiation therapy)|Patients receive talimogene laherparepvec IT at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy at weeks 2-6.
10210896|NCT02905318|Experimental|Palbociclib|125mg orally days 1-21 every 28 day cycle
10210897|NCT02889627|Experimental|FMT with microbiota suspension|Participants undergo repeated FMT with ~50ml microbiota suspension.
9869957|NCT00242203|Active Comparator|No Zometa|"Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
9869958|NCT00242320|Active Comparator|1|Roflumilast 500 µg
9869959|NCT00242320|Placebo Comparator|2|Placebo
9869960|NCT00242359|Other|omalizumab|open-label
9869961|NCT00242424|Placebo Comparator|1|0.25 ml normal saline placebo given as injection to infants at 2 and 3 months of age
9869962|NCT00242424|Experimental|2|2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age
9869963|NCT00242463|Experimental|nandrolone|Patients receive weekly injections of nandrolone
9869964|NCT00242463|Placebo Comparator|Placebo|
9869965|NCT00242541|Experimental|Octreotide acetate|
9869966|NCT00242593|Experimental|A|oral rosiglitazone 4 mg twice daily for 18 months
9869967|NCT00242593|Placebo Comparator|B|placebo pill twice daily for 18 months
9869968|NCT00242606|Active Comparator|1|Levetiracetam 2000mg/day
9869969|NCT00242606|Active Comparator|2|Lamotrigine
9869970|NCT00242866|Experimental|Arm 1|GW274150 - 5mg or 30mg
9869971|NCT00242866|Placebo Comparator|Arm 2|Placebo to match GW274150
9869972|NCT00242892|Experimental|1|Intra coronary measures of pressure
9869973|NCT00242931|Experimental|Fludarabine, TBI, Cyclosporine, MMF|"Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
9869974|NCT00242944|Active Comparator|1|Pitavastatin
9869975|NCT00242944|Active Comparator|2|Atorvastatin
9869976|NCT00243035|Experimental|Treatment (bortezomib, tipifarnib)|"Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD."
9928253|NCT00904293|Experimental|Genotype-guided warfarin dosing|A dosing algorithm including clinical factors and genotype information (VKORC1 and CYP2C9) will be used to determine initial warfarin doses.
9928254|NCT00904293|Active Comparator|Non-genotype guided warfarin dosing|Initial warfarin dosing will be determined using the same algorithm as in the experimental group, but only including the clinical factors and not including the genotype information
9928255|NCT00904306|Placebo Comparator|Sugar pill|6 months treatment with placebo
10210898|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 2 doses (Escalation Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
10210899|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 4 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 4th dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
10210900|NCT02872025|Experimental|Pembrolizumab intralesional (IL) x 2 doses + intralesional mRNA 2752 x 2-4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab and intralesional mRNA 2752 injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
10210901|NCT02872025|No Intervention|No active treatment|The control group will proceed to surgery alone within a 4 month timeframe following the diagnosis of high risk DCIS.
9928256|NCT00904306|Active Comparator|low dose|600ug/day chromium picolinate for 6 months
9928257|NCT00904306|Active Comparator|high dose chromium picolinate|1000 ug/day
9928258|NCT00904319|Experimental|Aquatic|Aquatic Power Training
9928259|NCT00904358||cross sectional area|internal jugular cross sectional area measured by ultrasound
9928260|NCT00904384||HIV+|Patients with HIV infection living in the Autonomous Community of the Balearic Islands (CAIB), Spain
9928261|NCT00904384||Reference group|Same determinations as in HIV+ cases will be obtained in the control group of COPD patients without HIV infection as part of the study PAC-EPOC (FIS 05/2082)
9928262|NCT00904397|Experimental|Lidoderm|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
9928263|NCT00904397|Active Comparator|Celecoxib|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
9928264|NCT00904410|Experimental|1|
9928265|NCT00904436|Experimental|1|Spinal Cord Injury: subjects who have cervical spinal cord injury and complaints of dyspnea
9928266|NCT00904436|No Intervention|2|Controls
9928267|NCT00904449|Experimental|Open Label|
9928268|NCT00904462|Experimental|Lidocaine 5% patch|Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied on each affected knee once every 24 hours
9928269|NCT00904462|Placebo Comparator|Placebo patch|Matching placebo patch, 1⅓ patches applied on each affected knee once every 24 hours
9928270|NCT00904475|Experimental|1- Lidoderm®|Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
9869977|NCT00243100|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and gemcitabine IV over 1-2 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD"
9869978|NCT00243126|Experimental|Family-Based Risk Reduction Intervention|The intervention will be delivered in five, two-hour, small group sessions, across five weeks (group will meet once per week). Each of the 5 modules consists of 3 sessions: a one-hour session for the daughters meeting together with each other, a one-hour session for the mothers meeting together with each other; and a one-hour session in which the daughters and mothers meet together. Therefore, each week, the daughters will meet as a group for one hour of each module, while the mothers meet as a group for one hour, and for one hour the mothers and daughters will all meet together.
9869979|NCT00243126|No Intervention|No Treatment Control Group Condition|A no treatment control group condition will be utilized for this preliminary feasibility study. Participants in this condition, both mothers and adolescents will be assessed at baseline, immediate post-intervention, at 3-month follow-up and at 6-month follow-up.
9869980|NCT00243282|No Intervention|1|Control (Support Group)
9869981|NCT00243282|Other|2|Intervention (Mindfulness Based Breathing Therapy)
9869982|NCT00243321|Experimental|HDR brachytherapy -> IMRT|Radiotherapy
9869983|NCT00243334|Experimental|1|Decision Support integrated with Order Entry
9869984|NCT00243334|No Intervention|2|Decision Support Only (not integrated with order entry)
9869985|NCT00243399|Experimental|Oxandrolone|
9869986|NCT00243438||1|Patients who have received a Vision stent and who have diabetes and/or complex lesions.
9869987|NCT00243477|Active Comparator|Treatment|Escitalopram given
9869988|NCT00243477|Placebo Comparator|Placebo|Placebo given
9869989|NCT00243529|Active Comparator|MHC Class I restricted epitopes|HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase
9869990|NCT00243529|Experimental|MHC Class I and II restricted epitopes|HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase
9869991|NCT00243529|Experimental|mRNA transfected DC|HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase
9869992|NCT00243607|Experimental|immediate treatment group (SBG)|immediate start of hydrotherapy (self treatment) in immediate treatment group (SBG)
9869993|NCT00243607|No Intervention|waiting group (WG)|start of hydrotherapy (self treatment) after waiting period of 12 weeks
9869994|NCT00243646|Active Comparator|no hormones|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
9869995|NCT00243646|Active Comparator|9 months of hormone therapy|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy
9869996|NCT00243685|Experimental|II and III|
9869997|NCT00243776||Cardiac Tissue|Cardiac tissue and cells will be obtained from participants undergoing cardiac surgical repair
9869998|NCT00243789|Active Comparator|1|Pentoxifylline
9869999|NCT00243789|No Intervention|2|Placebo
9870000|NCT00243880|Experimental|lovastatin|lovastatin at escalating dosages: 1 mg/kg/day, 3 mg/kg/day, 6 mg/kg/day, 8 mg/kg/day, 10 mg/kg/day
9870001|NCT00243893|Active Comparator|Brain AVMs|This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
9870002|NCT00243893|Active Comparator|Aneurysms|
9870003|NCT00243997|Active Comparator|1|Subjects receiving the Becoming Parents Program
9870004|NCT00243997|Placebo Comparator|2|Subjects not receiving the Becoming Parents Program
9870005|NCT00244023|Experimental|1|Testosterone gel (intervention)
9870006|NCT00244023|Placebo Comparator|2|one sachet of placebo gel once a day, possibly titrated to 2 sachets if insufficient efficacy
9870007|NCT00244049|Experimental|Brief clinician advice|
9870008|NCT00244075|Active Comparator|1|nutrition supplementation, recombinant human growth hormone, and exercise
9870009|NCT00244075|Active Comparator|2|nutrition supplementation only
9870010|NCT00244114||A|
9870011|NCT00244114||B|
9870012|NCT00244218|Experimental|Treatment Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
9986562|NCT01404026|Sham Comparator|Sham tDCS|Subjects will undergo sham tDCS stimulation, where the current is only active for 30 seconds.
9870013|NCT00244218|Placebo Comparator|Control Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
9870014|NCT00244257|Experimental|1|Cohort 1
9870015|NCT00244257|Experimental|2|Cohort 2
9870016|NCT00244257|Experimental|3|Cohort 3
9870017|NCT00244257|Experimental|4|Cohort 4
9870018|NCT00244257|Experimental|5|Cohort 5
9870019|NCT00244270|Experimental|1|totally implantable vascular access device
9870020|NCT00244335||1|PTSD Subjects
9870021|NCT00244335||2|Trauma Controls: subjects who have experienced a trauma but never developed PTSD
9870022|NCT00244426|Experimental|1|
9870023|NCT00244426|Active Comparator|2|
9870024|NCT00244439|Experimental|1|MALG
9870025|NCT00244439|Active Comparator|2|Ovide
9870026|NCT00244439|Active Comparator|3|Permethrin 1%
9870027|NCT00244478|Experimental|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
9870028|NCT00244478|Placebo Comparator|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
9870029|NCT00244504|Active Comparator|I|moxonidine group
9870030|NCT00244504|Placebo Comparator|II|placebo group
9870031|NCT00244517|Active Comparator|I|Isoflurane (only in part I)
9870032|NCT00244517|Active Comparator|II|Sevoflurane
9870033|NCT00244517|Active Comparator|III|Desflurane
9928271|NCT00904475|Placebo Comparator|2-Placebo|Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
9928272|NCT00904501|Placebo Comparator|A|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL). A placebo cell-product (30 mL saline with 4 ml peripheral blood) is implanted and the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. After 6 months, it is possible to use previously cryo-conserved BM-MNC.
9928273|NCT00904501|Experimental|B|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL) . The BM-MNC are implanted on the same day. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted
9928274|NCT00904527|Experimental|Relaxation|Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
9928275|NCT00904527|No Intervention|without relaxation|Patients have no relaxation (only medical treatment+ education)
9928276|NCT00904540|Experimental|Lidoderm®|Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
9928277|NCT00904553||Novalis Shaped Beam Surgery|Patients with limited brain metastases (mostly solitary brain metastasis) treated with Novalis Shaped Beam Surgery followed by planned craniotomy and resection of the metastases.
9928278|NCT00904579||1|Cancer patients who have had organ transplants identified through the transplant and cancer registries.
9928279|NCT00904592|Experimental|Qi ming granula|"Study group(combined therapy with Intervention of TCM): Basic therapy ＆ treating both on deficiency and stasis of blood.~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education.~Qi ming granula, Usage: 4.5g，po，tid."
9928280|NCT00904592|Placebo Comparator|placebo comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
9928281|NCT00904605|Experimental|1- Lidoderm®|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
9928282|NCT00904605|Active Comparator|2-Celecoxib 200mg|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
9928283|NCT00904631|Experimental|Treatment|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
9928284|NCT00904644||Salvage group|In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
9928285|NCT00904644||Switch group|In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
9928286|NCT00904709|Experimental|Tranexamic acid, Menorrhagia, Bleeding|Tranexamic acid with titrated doses. All women with menorrhagia will take .
9928287|NCT00904735|Experimental|Arm I|Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
9870034|NCT00244738|Active Comparator|Intervention|Patients who received castor oil for labor induction
9870035|NCT00244738|Placebo Comparator|Control|Patients who received sunflower oil as a placebo
9517631|NCT03304561|Experimental|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
9870036|NCT00244790|Experimental|low protein|
9870037|NCT00244803||HIV Positive FRAM 1 Participant|
9870038|NCT00244842|Placebo Comparator|1|
9870039|NCT00244842|Active Comparator|2|
9870040|NCT00244842|Active Comparator|3|
9870041|NCT00244842|Active Comparator|4|
9870042|NCT00244907|Active Comparator|Genistein vs. Risedronate|Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
9870043|NCT00244907|Active Comparator|Genistein dose and source|Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
9870044|NCT00244946|Experimental|Autologous lymphocytes,carmustine,etoposide, melphalan, PBSCT|"minus Day 8 ADMIT for Hydration~minus Day 7 Carmustine 300 mg/m2 x 1 dose~minus Day 6 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 5 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 4 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 3 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 2 Melphalan 140 mg/m2 x 1 dose~minus Day 1 Day of Rest~Day 0 Transplant"
9870045|NCT00244959|Experimental|Anastrozole|Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer
9870046|NCT00244972|Experimental|Treatment (sorafenib tosylate, tipifarnib)|Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
9870047|NCT00245154|Experimental|Arm I|Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
9870048|NCT00245154|Active Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel and carboplatin as in arm I.
9870049|NCT00245180|No Intervention|control|Primary and secondary data collected as in intervention arm. Dental screenings will be done once a year as a service.
9870050|NCT00245206|Experimental|1: Risperdal|Participants randomized to this arm will be prescribed risperdal. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
9870051|NCT00245206|Experimental|3: Aripiprazole|Participants randomized to this arm will be prescribed aripiprazole. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
9870052|NCT00245206|Experimental|4: Olanzapine|Participants randomized to this arm will be prescribed olanzapine. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
9870053|NCT00245336|Experimental|1|rThrombin
9870054|NCT00245336|Active Comparator|2|bThrombin
9870055|NCT00245349||FLT|Study group receiving FLT for imaging
9870056|NCT00245414|Experimental|1|Interferon (IFN)-Treated
9870057|NCT00245414|Experimental|2|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is positive at week 1
9870058|NCT00245414|Experimental|3|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
9517632|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
9870059|NCT00245414|Experimental|4|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
9870060|NCT00245427|Other|1 All macrolide antibiotics|
9870061|NCT00245427|Other|2 All beta lactam antibiotics|
10210902|NCT02852213|Experimental|Single treatment arm|"Single-stage dose-escalation, open-label safety study of AAV2-hAADC delivered by image-guided convection-enhanced delivery bilaterally into the substantia nigra pars compacta and the ventral tegmental area of pediatric patients with AADC deficiency.~6 subjects will be divided in 2 groups of 3. Primary aim is to determine the dose for future studies based on safety, biomarkers of pharmacological activity of AADC and clinical outcomes.~Subjects will be enrolled into 2 dose groups. Group 1 of 3 subjects will receive a single low dose of AAV2 hAADC. The total AAV2-hAADC dose will be infused via MR guided infusion into 4 sites in both the left and right SNc and VTA. Dosing intervals will be 90 days between the first 3 subjects. Group 2 dosing level will be determined by Group 1 results."
9870062|NCT00245440|Active Comparator|1|Subjects assigned Azithromycin
9870063|NCT00245440|Active Comparator|2|Subjects assigned Telithromycin
9870064|NCT00245453|Active Comparator|1 Azithromycin|
9870065|NCT00245453|Active Comparator|2 Clarythromycin|
9870066|NCT00245453|Active Comparator|3 Telithromycin|
9870067|NCT00245479|Other|1|
9870068|NCT00245492|Experimental|1|Chromocolonoscopy
9870069|NCT00245531||+IDU/+HIV or -HIV|
9870070|NCT00245531||-IDU and -HIV (controls)|
9870071|NCT00245726|Active Comparator|1|Passive (Motor Assist) Cycle
9870072|NCT00245726|Active Comparator|2|
9870073|NCT00245726|Experimental|3|
9870074|NCT00245752|Active Comparator|A|in points bilaterally inBL 67, LI 4, SP6, one in GV20.
10210903|NCT02774889|Active Comparator|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.~Fall prevention tips~Fall prevention exercise videos noting technique and safety~Guest expert videos and communication with expert~Tools to set exercise goals, reminders and track progress~Fall prevention specialist for feedback and group activities~Discussion and messaging (1:1, small and large group)~Fall prevention resources."
10210904|NCT02774889|No Intervention|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
10210905|NCT02767804|Experimental|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
10210906|NCT02767804|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
10210907|NCT02721069|Experimental|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
9870075|NCT00245752|Sham Comparator|2|sham acupuncture
9870076|NCT00245804||Adult dyslexia|Adult dyslexia
9870077|NCT00245804||Minor-Dyslexia|Minor-Dyslexia
9870078|NCT00245804||Adult-Control|Adult-Control
9870079|NCT00245804||Minor-Control|Minor-Control
9870080|NCT00245830|No Intervention|No Hepatic Ischemic Preconditioning|donor will act as a sham control.
9870081|NCT00245830|Experimental|Hepatic Ischemic Preconditioning|blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
9870082|NCT00245882|Active Comparator|Care Coordination|Care Coordination with monthly follow-up by a diabetes nurse educator
9870083|NCT00245882|Active Comparator|Home Telemedicine|Active Care Management with Home Telemedicine
9870084|NCT00245895|Active Comparator|1|Aranesp
9870085|NCT00246051|Other|Sleep Hygiene Education|
9870086|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|
9870087|NCT00246051|Other|Online Sleep Disorders Screening|
9870088|NCT00246103|Experimental|Dose Escalation and Possible Expansion|Escalating doses of Valproic acid and one dose escalation step of epirubicin. Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
9870089|NCT00246194||Patients with schizophrenia|Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
9870090|NCT00246350|Active Comparator|1|8 light massage treatments
9870091|NCT00246350|Active Comparator|2|16 light massage treatments
9870092|NCT00246350|Experimental|3|8 spinal manipulation treatments
9870093|NCT00246350|Experimental|4|16 spinal manipulation treatments
9870094|NCT00246363|Experimental|Silymarin|Silymarin
9870095|NCT00246363|Placebo Comparator|Placebo|Placebo
9870096|NCT00246428|Experimental|1|MI
9928288|NCT00904735|Experimental|Arm II|Patients receive oral hydroxyurea twice daily in the absence of disease progression or unacceptable toxicity.
9928289|NCT00904761|Experimental|exercise|arm: intervention
9928290|NCT00904774||premature neonates|gestational age less than 28 weeks
9928291|NCT00904787|Experimental|1|
9928292|NCT00904800|Experimental|1|Low dose
9928293|NCT00904800|Experimental|2|Middle dose
9928294|NCT00904800|Experimental|3|High dose
9928295|NCT00904800|Placebo Comparator|4|placebo
9928296|NCT00904852|Experimental|Tandutinib, bevacizumab, and temozolomide|tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.
9928297|NCT00904865|Other|1|SPA cholecystectomy
9928298|NCT00904865|Other|2|laparoscopic cholecystectomy
9928299|NCT00904891|Experimental|1|Participants will receive a cognitive-behavioral group intervention.
9928300|NCT00904891|Active Comparator|2|Participants will receive cognitive-behavioral bibliotherapy.
9928301|NCT00904891|No Intervention|3|Participants will only complete study assessments.
9928302|NCT00904904|Experimental|Indomethacin|Indomethacin ophthalmic solution 0.1% for post-surgical inflammation
9870097|NCT00246454||1|People with delayed sleep phase syndrome (DSPS).
9870098|NCT00246454||2|People with advanced sleep phase syndrome (ASPS).
9870099|NCT00246454||3|Control group (people with intermediate sleep patterns).
9870100|NCT00246506|Active Comparator|I.|Those randomized to have clomiphene/IUI treatments first will initiate therapy with two cycles of the fertility pill called clomiphene combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
9870101|NCT00246506|Active Comparator|II.|Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
9870102|NCT00246506|Active Comparator|III.|Those couples randomized to (IVF) in vitro fertilization will bypass IUI treatments and start IVF therapy immediately.
9870103|NCT00246532|Placebo Comparator|1: Placebo Pill|This arm contains placebo medication.
10210908|NCT02719613|Experimental|Elotuzumab|This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All participants will receive elotuzumab and/or other study drugs as per previous protocol.
9517633|NCT03304509|No Intervention|Face-to-face follow-up|Face-to-face follow-up after hospital discharge
9517634|NCT03304509|Experimental|Telematic follow-up|Telematic follow-up after hospital discharge
9517635|NCT03304496|Experimental|Nitroglycerin|"The intervention group will receive a subcutaneous cocktail with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine."
9870104|NCT00246532|Active Comparator|2: Morphine|Patients will receive oral morphine therapy.
9870105|NCT00246610|Experimental|Open-label|Non-randomized, open-label, single-arm
9870106|NCT00246636|Active Comparator|OM5/LOV111859 (double-blind study) - Antara|Antara (fenofibrate) + placebo
9870107|NCT00246636|Experimental|OM5X/LOV111860 (extension study) - Open-Label Antara + Lovaza|Open-label Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
9870108|NCT00246636|Experimental|OM5/LOV111859 (double-blind study) - Antara + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
9870109|NCT00246662|Experimental|Sch A (18 mg/m2 vosaroxin initially)|Once weekly intravenous on days 1, 8, 15 up to 4 cycles
9870110|NCT00246662|Experimental|Sch B (9 mg/m2 vosaroxin initially)|Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
9870111|NCT00246675|Other|Standard Care|Patients will only receive frusemide as per the treating physicians treatment
9870112|NCT00246675|Other|Intervention|Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
9870113|NCT00246688|Experimental|Sagopilone, 0.5 h infusion|Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
9870114|NCT00246688|Experimental|Sagopilone, 3 h infusion|Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
9870115|NCT00246701|Active Comparator|Simvastatin|Simvastatin + placebo
9870116|NCT00246701|Experimental|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
9870117|NCT00246727|Placebo Comparator|Study 1: Chemotherapy plus SV or Placebo|For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
10210909|NCT02717507|Experimental|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
10210910|NCT02717507|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
10210911|NCT02658981|Experimental|A1 Anti-LAG-3|"Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
10210912|NCT02658981|Experimental|A2 Anti-CD137 (Urelumab)|"Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity~Pharmacological Study~Laboratory Biomarker Analysis"
10210913|NCT02658981|Experimental|B1 Anti-LAG3 + Anti-PD-1 (nivolumab)|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
10210914|NCT02658981|Experimental|B2 Anti-CD137 + Anti-PD-1|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~(2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)~Pharmacological Study~Laboratory Biomarker Analysis"
10210915|NCT02658981|Experimental|Intratumoral Studies|"Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1), or urelumab (Arm A2), or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)), or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection, patients post-operatively receive drug from one of the four arms.~(3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)"
10210916|NCT02582164|Experimental|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
10210917|NCT02582164|Experimental|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
10210918|NCT02582164|Experimental|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
10210919|NCT02582164|Experimental|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
10210920|NCT02575794|Experimental|Treatment (terameprocol)|"Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study"
9870118|NCT00246727|Placebo Comparator|Study 2: SV vs Placebo without chemotherapy|For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
9870119|NCT00246974|Active Comparator|1|Cisplatin + Gemcitabin
9870120|NCT00246974|Experimental|2|Cisplatin + Gemcitabin + Gefitinib
9870121|NCT00247039|Experimental|Garlic extract|Garlic extract capsules
9870122|NCT00247039|Placebo Comparator|Placebo|Placebo capsules
9870123|NCT00247052|Active Comparator|diclofenac|diclofenac
9870124|NCT00247052|Placebo Comparator|2|
9870125|NCT00247078|Experimental|1|Patients with moderate or severe pain due to Black Widow envenomation
9870126|NCT00247078|Placebo Comparator|2|Patients with moderate to severe pain due to Black Widow envenomation
10210921|NCT02541838|Experimental|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
9870127|NCT00247130|Active Comparator|Omeprazole|Omeprazole (20 mg), intravenous, 2x /day
9870128|NCT00247130|Active Comparator|Ranitidine|Ranitidine (100 mg), intravenous drip infusion, 2x /day.
9870129|NCT00247182|Other|Step 1|Minimal Intervention
9870130|NCT00247182|Active Comparator|Step 2-A|Brief motivational intervention (BMI)
9870131|NCT00247182|Active Comparator|Step 2-B|Assessment-only control
9870132|NCT00247195|Experimental|Culturally congruent assessment and treatment|Outreach by phone to primary care patients interested in mental health referral. Engagement and evaluation approach conducted using the DSM-IV cultural formulation model. Same treatment choices as in control arm (medication, interpersonal psychotherapy, and combination treatment).
10210922|NCT02511522|Active Comparator|Best Supportive Care|Patients will be randomized 1:1 to receive best supportive care alone
9870133|NCT00247195|Active Comparator|Usual referral and treatment|Usual referral procedure from primary care: PC clinician gives patient information on how to access mental health care at research site. Usual engagement and evaluation approach without using cultural formulation model. Same treatment choices (medication, interpersonal psychotherapy, and combination treatment) as in experimental arm.
9870134|NCT00247208|Active Comparator|1|Express 2 bare metal stent
9870135|NCT00247208|Experimental|2|Taxus, paclitaxel-eluting stent
9870136|NCT00247221|Experimental|1) MI/Family Check-Up|Brief integrated individual and family intervention -- the experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up
9870137|NCT00247221|Active Comparator|2) MI only|
9870138|NCT00247234|Experimental|schema therapy|
9870139|NCT00247234|Active Comparator|standard care|standard psychiatric out-patient care
9870140|NCT00247286|Experimental|a|Weighted vaginal cones used to perform pelvic floor exercises
9870141|NCT00247286|Active Comparator|b|Biofeedback
10210923|NCT02511522|Experimental|Best Supportive Care + RT 8 Gy/1|Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
9870142|NCT00247312|Active Comparator|125Gy prescription dose Pd-103|125Gy prescription dose Pd-103
9870143|NCT00247312|Active Comparator|110 Gy prescription dose Pd-103|110 Gy prescription dose Pd-103
9870144|NCT00247390|Experimental|Ramelteon 8 mg QD|
9870145|NCT00247390|Placebo Comparator|Placebo QD|
9870146|NCT00247403|Experimental|2DG|
9870147|NCT00247663|Experimental|Letrozole|
9870148|NCT00247715|Other|Step-up|"Stepwise treatment:~step1: antacid (+placebo proton pump inhibitor)~step2: H2-receptor antagonist~step3: proton pump inhibitor (+ placebo antacid)"
9870149|NCT00247715|Other|step-down|"Stepwise treatment:~step1: proton pump inhibitor (+placebo antacid)~step2: H2-receptor antagonist~step3: antacid (+proton pump inhibitor)"
9870150|NCT00247741|Active Comparator|lidocaine|
9870151|NCT00247741|Experimental|articaine|
9870152|NCT00247832|No Intervention|1|
9870153|NCT00247832|Experimental|2|Self-directed motivation
9870154|NCT00247832|Experimental|3|Personal motivational interviewing
9870155|NCT00247936|Active Comparator|1|Combined Thoracoscopic and Laparoscopic Esophagectomy
9870156|NCT00247936|Active Comparator|2|Hand-Assisted Transhiatal Esophagectomy
9928303|NCT00904904|Active Comparator|Ketorolac|Ketorolac ophthalmic solution 0.5% for post-surgical inflammation
9928304|NCT00904930||no periodontal disease|33 dental students (13 male, 20 female) with a mean age of 24.7 years (min. 19.8; max. 36.5) with no periodontal disease or dental trauma
9928305|NCT00905008||DES|Patients underwent percutaneous coronary intervention and received at least one drug-eluting stent during their index hospitalisation.
9928306|NCT00905008||BMS|Patients underwent percutaneous coronary intervention and received at least one uncoated stent during their index hospitalisation.
9928307|NCT00905047|Other|XELODA|
9928308|NCT00905047|Other|UFT|
9928309|NCT00905073|Experimental|cyclosporin+Methotrexate|cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.
9928310|NCT00905112|Experimental|MOMS|Receives manual therapy, stabilization exercise and patient education
9928311|NCT00905112|Active Comparator|STOB|Receive standard obstetrical care
9928312|NCT00905138|Experimental|1|single ascending doses
9928313|NCT00905138|Placebo Comparator|2|single dose placebo
9928314|NCT00905138|Experimental|3|multiple dose, 5 days, oral solution
9928315|NCT00905138|Placebo Comparator|4|multiple dose, 5 days, oral solution
9928316|NCT00905190|Experimental|Fed|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast
9928317|NCT00905190|Experimental|Fasting|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
9870157|NCT00248053|Other|Lower GI|
9870158|NCT00248105|Experimental|PAM|
9870159|NCT00248105|No Intervention|PC|Participants not in the PAM group will be in the PC (physician counseling) group and will receive advice on lifestyle physical activity from their rheumatologist or primary care physician.
10210924|NCT02489617|Experimental|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).~-- Pathologic evaluation of excised tissue"
9870160|NCT00248118|Active Comparator|Active medication|300mg bupropion HCL
9870161|NCT00248118|Placebo Comparator|Placebo|Placebo pill
9870162|NCT00248209|Placebo Comparator|Wellbutrin XL or placebo|1 arms - Wellbutrin XL or placebo
9870163|NCT00248235|Experimental|PRET|Progressive Resistance Exercise Training: upper extremity 6-8 exercises
9870164|NCT00248235|Active Comparator|Standard Care|Standard Care: physical therapy - range of motion, 6-8 strengthening exercises
9870165|NCT00248326||1|Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
9870166|NCT00248326||2|Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
9870167|NCT00248339|Active Comparator|1|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
9870168|NCT00248339|Active Comparator|2|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
9870169|NCT00248339|Active Comparator|3|PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
9870170|NCT00248365|Experimental|Low PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM
9870171|NCT00248365|Experimental|High PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM
9870172|NCT00248482|Experimental|Irinotecan, Cisplatin & Gleevec™|"Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles~Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease.~Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles"
9870173|NCT00248586|Experimental|Standard CBT (S-CBT)|
9870174|NCT00248586|Experimental|Minimal contact CBT (MC-CBT)|
9870175|NCT00248586|No Intervention|Control|
9870176|NCT00248677|No Intervention|No Contact Control|
9870177|NCT00248677|Experimental|Behavior Family Intervention|
9870178|NCT00248677|Experimental|Behavioral Parent-Only Intervention|
9870179|NCT00248768|Other|Arm 1|
9870180|NCT00248846|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal.
9870181|NCT00248846|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their study participation.
9870182|NCT00248872|No Intervention|control group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
9870183|NCT00248872|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
9870184|NCT00248885|Active Comparator|1|In this group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB.
9870185|NCT00248885|Experimental|2|In this group (High), the goal was to maintain MAP between 80-100 mm Hg during CPB.
9870186|NCT00248911|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
9870187|NCT00248976|No Intervention|1|This is the control group, which will be monitor. No intervention will be delivered to this group.
9870188|NCT00248976|Experimental|2|This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age. Net-present value of individual health behaviors in years.
9870189|NCT00248989|Experimental|Placebo|
9870190|NCT00248989|Experimental|DHEA|
10210925|NCT02457845|Experimental|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.~Intervention: Biological: G207"
10210926|NCT02415621|Other|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
10210927|NCT02414139|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID as second or third line
10210928|NCT02414139|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mg BID as second or third line
10210929|NCT02414139|Experimental|cMET GCN < 4|Pre-treated patients with cMET GCN < 4 treated with INC280 at 400mg BID as second or third line
10210930|NCT02414139|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID as second or third line
10210931|NCT02414139|Experimental|cMET dysregulation - treatment-naïve|Treatment-naïve patients with cMET dysregulation treated with INC280 at 400mg BID
9928318|NCT00905203|Experimental|1|moderate exercise training (three times/ week including one home-based training and two supervised training)
10210932|NCT02414139|Experimental|cMET dysregulation - second line|Pre-treated patients with cMET deregulation treated with INC280 at 400 mg BID as second line
10210933|NCT02414139|Experimental|cMET mutations treatment-naïve|Treatment-naïve patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
10210934|NCT02389465|No Intervention|Control|This arm is for participants who are not depressed.
10210935|NCT02389465|Experimental|Experimental - treatment|Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.
10210936|NCT02335060|Experimental|Active N-acetylcysteine and Active Delta-9-THC|
10210937|NCT02335060|Placebo Comparator|Placebo and Active Delta-9-THC|
10210938|NCT02335060|Experimental|Active N-acetylcysteine and Placebo|
10210939|NCT02335060|Placebo Comparator|Placebo and Placebo|
10210940|NCT02308111|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|Obeticholic Acid (OCA) 5 mg for a minimum 3 months and then titrating up to a maximum 10 mg for the remainder of the trial (based on tolerability and Child Pugh Score).
10210941|NCT02308111|Placebo Comparator|Placebo|
10210942|NCT02297438|Experimental|Palbociclib + Letrozole|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
10210943|NCT02297438|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
10210944|NCT02297412|Experimental|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
10210945|NCT02297412|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
10210946|NCT02292758|Experimental|Arm I (cetuximab, bevacizumab, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10210947|NCT02292758|Active Comparator|Arm II (cetuximab, placebo, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10210948|NCT02250326|Experimental|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
10210949|NCT02250326|Experimental|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
10210950|NCT02250326|Experimental|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
10210951|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
10210952|NCT02180958||Cerebral Arteriovenous Malformations|Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.
10210953|NCT02102113|Other|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
10210954|NCT02102113|Experimental|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
10210955|NCT01922076|Experimental|Treatment (adavosertib, radiation therapy)|Patients undergo radiation therapy 5 days a week for 6 weeks (up to 30 fractions). Patients also receive adavosertib PO on days 1-5 of weeks 1, 3, and 5; days 1-5 of weeks 1, 3, and 5 AND days 1, 3, and 5 of weeks 2, 4, and 6; OR days 1-5 of weeks 1-6 depending on dose level assignment. Treatment continues in the absence of disease progression or unacceptable toxicity.
10210956|NCT01864018|Experimental|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
10210957|NCT01856270|Experimental|Amitriptyline Immediate|The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
10210958|NCT01856270|Experimental|Amitriptyline Delayed|The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
10210959|NCT01833806|Experimental|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
10210960|NCT01588041||Vitreoretinal Interface Disease Group|A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
10210961|NCT01588041||Macular Hole Group|A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
10210962|NCT01588041||Retinal Detachment Group|A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
9870191|NCT00249015|Experimental|1|Combined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
9870192|NCT00249015|Active Comparator|2|Moderate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
9870193|NCT00249015|Experimental|3|High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
9870194|NCT00249041|Experimental|Etanercept liquid|
9870195|NCT00249054|Active Comparator|ASR hip prosthesis|DuPuy ASR hip prosthesis
9870196|NCT00249054|Active Comparator|ReCap hip prosthesis|Biomet ReCap hip prosthesis
9870197|NCT00249106|Experimental|HIV vaccine|dosage escalation of ADVAX
9870198|NCT00249106|Placebo Comparator|Placebo|Sodium phosphate
9870199|NCT00249301|Experimental|1|MLN8054
9870200|NCT00249366|Active Comparator|Fixed-schedule treatment|Fixed-schedule administration of lorazepam for alcohol withdrawal
9870201|NCT00249366|Active Comparator|Symptom-triggered treatment|Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
9870202|NCT00249405|Experimental|1|citalopram
9870203|NCT00249405|Placebo Comparator|2|Placebo
9870204|NCT00249431|Placebo Comparator|Placebo and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus placebo
9870205|NCT00249431|Active Comparator|Sertraline and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus Sertraline.
9870206|NCT00249457|Experimental|Therapeutic Workplace|Contingency management. Invited to work in the Therapeutic Workplace. Completed monthly assessments.
9870207|NCT00249457|No Intervention|Usual Care Control Group|No intervention. Not invited to work int the Therapeutic Workplace. Completed monthly assessments.
9870208|NCT00249483|Placebo Comparator|Placebo|Placebo
9870209|NCT00249483|Experimental|Venlafaxine|Venlafaxine 300mg daily
9870210|NCT00249535|Experimental|1|standard treatment plus usual magnitude prize CM
9870211|NCT00249535|Experimental|2|standard treatment plus higher magnitude prize CM
9870212|NCT00249535|Experimental|3|standard treatment plus voucher CM
9870213|NCT00249561|Experimental|Recovery by Choice|A modified Therapeutic Community program.
9870214|NCT00249561|Active Comparator|Intensive Outpatient Program|Designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism.
9870215|NCT00249574|Experimental|pegInterferon|Open label, observational trial to determine the safety of HCV treatment in active IDUs stabilized on buprenorphine/naloxone
9870216|NCT00249587|Experimental|1|Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
9870217|NCT00249587|Active Comparator|2|Methadone plus behavioral counseling consisting of adherence
9870218|NCT00249652|Experimental|TAP|MI-based phone intervention.
9870219|NCT00249652|Other|TAU|Treatment As Usual
9928319|NCT00905203|Experimental|2|intensive exercise training (four times/ week including one home-based training and three supervised training)
10210963|NCT01588041||Diabetic Retinopathy Group|A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
10210964|NCT01588041||Rare Related Macular Disease Group|Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
10210965|NCT01588041||Generation 2 MIOCT Transition Group|80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
10210966|NCT01588041||Endothelial Keratoplasty Group|150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
9928320|NCT00905216|Experimental|Test|Heparin sodium - Bergamo
9928321|NCT00905216|Active Comparator|Comparator|Heparin APP
10210967|NCT01588041||Anterior Lamellar Keratoplasty Group|150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
9928322|NCT00905229|Active Comparator|PO (by mouth)|2.5 mg P.O Vitamin K
9928323|NCT00905229|Active Comparator|IV (intravenous )|0.5 mg IV Vitamin K
9928324|NCT00905281|Experimental|Action Group|
9928325|NCT00905281|Other|Standard care|
9928326|NCT00905294||coronary artery disease|Subjects with coronary artery disease undergoing percutaneous coronary intervention
9928327|NCT00905320|Active Comparator|Metallic Fasteners and Sutures|Laparoscopic ventral hernia repair with mesh fixation using both metallic fasteners and transabdominal sutures
9928328|NCT00905320|Experimental|Metallic Fasteners Alone|Laparoscopic ventral hernia repair with mesh fixation using metallic fasteners alone
9928329|NCT00905333|Other|Single-arm|3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)
9928330|NCT00905398|Experimental|nilotinib|single arm study
9928331|NCT00905411|No Intervention|Attention Control / Usual Care|
9928332|NCT00905411|Experimental|Intervention|
9928333|NCT00905463||Transplantation|Lung transplantation candidates
9928334|NCT00905476||NPPV|Patients with chronic respiratory failure receiving domiciliary NPPV
9928335|NCT00905502|Experimental|1: Restricted protocol (RG) group|Received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period.
9517636|NCT03304496|Placebo Comparator|Control|The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
9870220|NCT00249691|Experimental|Topiramate|
9870221|NCT00249691|Placebo Comparator|Placebo|
9870222|NCT00249704|Experimental|C|
9870223|NCT00249704|Experimental|B|
9870224|NCT00249704|Experimental|A|
9870225|NCT00249704|Placebo Comparator|D|
9870226|NCT00249756|Experimental|Re-entry Modified Therapeutic Community (Re-entry MTC)|
9870227|NCT00249756|Active Comparator|Parole Supervision and Case Management|
9870228|NCT00249847|Experimental|Paroxetine|Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
9870229|NCT00249847|Experimental|Conjugated equine estrogen|Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)
9870230|NCT00249860|Experimental|Interferon-beta-1a|
9870231|NCT00249860|Active Comparator|Ribavarin plus interferon-beta-1a|
9870232|NCT00249899|Experimental|Lapaquistat Acetate 100 mg QD|(and stable statin therapy)
9870233|NCT00249899|Active Comparator|Stable statin therapy|
9870234|NCT00249912|Experimental|Lapaquistat Acetate 50 mg QD + Rosuvastatin|
9870235|NCT00249912|Experimental|Lapaquistat Acetate 100 mg QD + Rosuvastatin|
9870236|NCT00249912|Active Comparator|Rosuvastatin|
9870237|NCT00249964|Experimental|Combination Treatment|"Paclitaxel at 175 mg/m2 + Carboplatin at area under the curve (AUC) 5 on day 1. Then, Temozolomide at the doses described under Interventions from day 2 to day 6 (a total of 5 days).~Cycle length is 21 days."
9870238|NCT00250081|Active Comparator|Therapy Group|Therapy only
9870239|NCT00250081|Active Comparator|Surgery Group|surgical intervention
9870240|NCT00250081|Active Comparator|Botox Injections|botulinum toxin
9870241|NCT00250224|Experimental|Stent|
9870242|NCT00250237|Active Comparator|A|Patients receiving blinded medication (Haloperidol or Placebo)
9870243|NCT00250237|Placebo Comparator|B|Patients receiving blinded medication (Haloperidol or Placebo)
9870244|NCT00250263|Placebo Comparator|1|Matching placebo- control arm (first year)
9870245|NCT00250263|Active Comparator|2|Drug Staloral (active group)
9870246|NCT00250406|Active Comparator|1|Percuflex Plus Ureteral Stent
9870247|NCT00250406|Experimental|2|TRIUMPH stent (triclosan-eluting stent)
9870248|NCT00250510|No Intervention|1|
9870249|NCT00250510|Experimental|2|EatRight Program inquirers with BMI's of 30 kg/m2 or greater were told that they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if certain conditions were met.
9870250|NCT00250523||Traumatic injury|ICU Patients with blunt or penetrating injury
9870251|NCT00250523||2|Healthy volunteers
9870252|NCT00250549|No Intervention|HIV counselor|Patients who tested for HIV and consent to participate in the study receive a posttest educational session with an HIV counselor. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
9870253|NCT00250549|Experimental|Post test video|Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
9870254|NCT00250575|Experimental|1|
9870255|NCT00250640||Group 1|
9870256|NCT00250731|Experimental|1|Telephone support and behavior change for couples
9870257|NCT00250731|Active Comparator|2|Telephone support and behavior change for individuals
9870258|NCT00250731|Placebo Comparator|3|Limited diabetes self-management education
9870259|NCT00250744|Experimental|Arm A|
9870260|NCT00250744|Active Comparator|Arm B|
9870261|NCT00250770||1|"Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.~Women undergoing hysterectomy for benign conditions."
9870262|NCT00250796|Active Comparator|Arm 1|Thalidomide+alpha interferon
9870263|NCT00250796|Experimental|Arm 2|Thalidomide+interferon+Octreotide
9870264|NCT00250939|Experimental|1|
9870265|NCT00251017|Active Comparator|Vancomycin|Effects of OCT2 genetic variation in renal elimination of Vancomycin
9870266|NCT00251043|Experimental|1|Participants will Psychotherapy weekly for 12 weeks
9870267|NCT00251043|Active Comparator|2|Parenting Education will include 45-minute weekly sessions for 12 week
9870268|NCT00251056|Active Comparator|1|
9870269|NCT00251056|Active Comparator|2|
9870270|NCT00251056|Active Comparator|3|
9870271|NCT00251056|Active Comparator|4|
9870272|NCT00251082|Experimental|A|
9870273|NCT00251082|Active Comparator|B|
9870274|NCT00251082|Placebo Comparator|C|
9870275|NCT00251095|Active Comparator|Taxol|Taxol 80mg/m2/week
9870276|NCT00251095|Experimental|TOCOSOL|TOCOSOL Paclitaxel
9870277|NCT00251121|Experimental|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
9870278|NCT00251134|Active Comparator|1|omega-3-acid ethyl ester 90
9870279|NCT00251134|Placebo Comparator|2|olive oil
9870280|NCT00251147|Active Comparator|Open Repair|
9870281|NCT00251147|Active Comparator|Mini-open Repair|
10210968|NCT01503632|Experimental|Arm I (intervention program and mercaptopurine)|See detailed description.
10210969|NCT01503632|Active Comparator|Arm II (standard of care and mercaptopurine)|Patients receive the usual standard of care and the mercaptopurine from the MEMS® medication bottle with TrackCap™ as patients in arm I. Patients and caregivers also view an interactive multimedia educational program on day 29.
10210970|NCT01503515|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
9517637|NCT03304483|Experimental|Athletes|246-km running
10210971|NCT01503515|Active Comparator|Arm II (fluconazole or voriconazole)|Patients receive fluconazole IV over 1-2 hours QD or PO QD; or voriconazole IV over 1-2 hours QD or PO BID beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
10210972|NCT01491893|Experimental|Dose Level 1 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210973|NCT01491893|Experimental|Dose Level 2 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convention-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210974|NCT01491893|Experimental|Dose Level 3 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210975|NCT01491893|Experimental|Dose Level 4 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210976|NCT01491893|Experimental|Dose Level 5 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^10 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210977|NCT01491893|Experimental|Dose Level 4 (dose de-escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210978|NCT01491893|Experimental|Dose Level 2 (dose expansion)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210979|NCT01491893|Experimental|Dose Level -1 (dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210980|NCT01491893|Experimental|Dose Level -2 (dose expansion)|Participants received a single intratumoral infusion of 1.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210981|NCT01491893|Experimental|Dose Level -1 (selected dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
10210982|NCT01415323||Acutely admitted psychiatric in-patients|
10210983|NCT01180374|Experimental|Active Canabidiol and Active Delta-9-THC|
10210984|NCT01180374|Placebo Comparator|Placebo and Active Delta-9-THC|
10210985|NCT01180374|Experimental|Active Cannabidiol and Placebo|
10210986|NCT01180374|Placebo Comparator|Placebo and Placebo|
10210987|NCT00853632|Other|Device - CEP Mitral Valve|
10210988|NCT00734487||1. AREDS2 subjects|Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.
10210989|NCT00734487||2. Controls|Age-matched subjects without retinal pathology
10210990|NCT00389610|Experimental|Stratum I|Patients receive booster vaccination comprised of an allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given subcutaneously (SC). Treatment repeats every 6 months.
10210991|NCT00389610|Experimental|Stratum II|Patients receive priming vaccinations comprised of allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given SC once a month for 3 months and then receive booster vaccinations as in stratum I.
10210992|NCT00357565|Experimental|Double Unit UCB Transplantation|Patients that receive 2 units of umbilical cord blood transplantation (UCBT).
10210993|NCT00357565|Experimental|Single Unit UCB Transplantation|Patients that receive one unit of umbilical cord blood transplantation (only if 2 adequate size and matched units are not available).
10210994|NCT00284986|Experimental|Prochymal®|
10210995|NCT00245960|Active Comparator|A|Period 1 (Double Blind): 50mg bi-weekly (BIW) for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW).
10210996|NCT00245960|Active Comparator|B|Period 1 (Double Blind): 50mg weekly (QW) with matching placebo for weeks 1-12. Period 2 (Open Label): 50 mg weekly (QW) for weeks 13-24.
10210997|NCT00136903|Active Comparator|Prochymal® - 2 Million cells/kg|Participants will receive Prochymal® consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
10210998|NCT00136903|Active Comparator|Prochymal® - 8 Million cells/kg|Participants will receive Prochymal® consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.
9870282|NCT00251160|Active Comparator|ETAC|
9517638|NCT03304470|Experimental|ATx201 2% CREAM|
9517639|NCT03304470|Placebo Comparator|ATx201 Cream Vehicle|
9870283|NCT00251160|Active Comparator|Open ICS|
9870284|NCT00251173|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
9870285|NCT00251173|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's substance use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized substance treatment; or 2) provide a strategy to self-monitor substance use, consider consequences, and later seek assessment.
9870286|NCT00251173|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
9870287|NCT00251212|Active Comparator|1|Therapist delivered adapted motivational enhancement therapy and skills training
9870288|NCT00251212|Active Comparator|2|Computer delivered adapted motivational enhancement therapy and skills training
9870289|NCT00251212|No Intervention|3|3: Control brochure
9870290|NCT00251251|Active Comparator|1. Optimal Medical therapy plus ICD|
9870291|NCT00251251|Active Comparator|2. Optimal Medical Therapy plus CRT/ICD|
9870292|NCT00251264|Active Comparator|Open|
9870293|NCT00251264|Active Comparator|Arthroscopic|
9928336|NCT00905502|Active Comparator|2: Liberal protocol (LG) group|Received 10 ml/kg•hr of RL solution intraoperatively.
9928337|NCT00905528||A|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
9928338|NCT00905528||B|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
9928339|NCT00905541|No Intervention|No treatment|Phase A: No treatment
9928340|NCT00905541|Experimental|simvastatin chronic|Phase B: 40 mg/day simvastatin
9928341|NCT00905541|Experimental|simvastatin acute-on-chronic|Phase C: 80 mg simvastatin acute-on-chronic
9928342|NCT00905619||Control|No kidney disease
9928343|NCT00905619||PreHD kidney disease|Kidney disease stage 4 or below
10210999|NCT00073671|Experimental|1= Cognitive behavioral prevention of depression program|Participants receive a group cognitive-behavioral prevention program, which involved 8 weekly sessions and 6 monthly sessions of CBT skills such as cognitive restructuring, problem-solving, assertivenss, and behavioral activation. Participants in this arm also were able to seek the same kinds of nonstudy treatments as described in the usual care arm.
10211000|NCT00073671|Active Comparator|2 = Usual care|Participants receive usual care, which involves any type of treatment (e.g., psychotherapy, counseling, pharmacotherapy).
10211001|NCT05219188||Heart failure with preserved ejection fraction and BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
10211002|NCT05219188||Heart failure with preserved ejection fraction and BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
10211003|NCT05219188||Healthy controls with BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
10211004|NCT05219188||Healthy controls with BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
10211005|NCT05219175|Experimental|Postpartum co-occurring PTSD and OUD prior and after treatment with MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions each using initial dose of 120 mg MDMA HCL (~100 mg MDMA) with supplemental dose of 60 mg MDMA HCL (~50 mg MDMA). Total dose range for each session is 120 mg MDMA HCL (~100 mg MDMA) to 180 mg MDMA HCL (~150 mg MDMA).~Total cumulative dose range for the three sessions is 360mg MDMA HCL (~300 mg MDMA) to 540 mg MDMA HCL (~450 mg MDMA)"
10211006|NCT05219149||Patients with CNS Tumors|feasibility study of family interviews of those who are making decisions about treatment for newly diagnosed or relapsed CNS tumors. For patients 12 years of age and younger, caregivers only will be included in the interviews. For patients 13-17 years of age, caregivers will have the option to include the patient in the interviews. For patients 18 years of age and older, patients will have the option to include their caregivers in the interviews.
10213705|NCT03486730|Experimental|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 50-60 patients with advanced solid tumours will be entered in the study.
9928344|NCT00905619||Hemodialysis|Kidney disease receiving hemodialysis
9928345|NCT00905645|Experimental|Primary Augmentation|Silimed Gel-Filled Mammary Implant
9928346|NCT00905645|Experimental|Primary Reconstruction|Silimed Gel-Filled Mammary Implant
9928347|NCT00905645|Experimental|Revison|Silimed Gel-Filled Mammary Implant
9928348|NCT00905658|No Intervention|Arm I|Patients are monitored via standard follow-up assessments every 3 weeks.
9928349|NCT00905658|Experimental|Arm II|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks.
9928350|NCT00905658|Experimental|Arm III|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.
9928351|NCT00905671|Experimental|LCP+ Bifurcation Lesion|Bifurcating lesions that are positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
9928352|NCT00905671|Experimental|LCP- Bifurcation Lesion|Bifurcating lesions that are not positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
9928353|NCT00905684||Group 1|
9928354|NCT00905684||Group 2|
9928355|NCT00905697||Living donor lung transplantation|Living lung transplantation donors
9928356|NCT00905710|No Intervention|1|Conventional colonoscopy
9870294|NCT00251355|Experimental|5-FU/gemcitabine/RT|
9870295|NCT00251407|Experimental|taxotere, cisplatin, irinotecan|
9870296|NCT00251433|Experimental|Phase I|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
9870297|NCT00251433|Experimental|Phase II-A|Patients will receive OTR of lapatinib, docetaxel, trastuzumab dose determined in phase I.
9870298|NCT00251433|Active Comparator|Phase II-B|Patients will receive docetaxel and trastuzumab combination.
9870299|NCT00251602|Experimental|1|II ACE genotype
9870300|NCT00251602|Experimental|2|ID ACE genotype
9870301|NCT00251602|Experimental|3|DD ACE genotype
9870302|NCT00251602|Placebo Comparator|4|II ACE genotype
9870303|NCT00251602|Placebo Comparator|5|ID ACE genotype
9870304|NCT00251602|Placebo Comparator|6|DD ACE genotype
10211007|NCT05219123||No PD cannulation|Patients with native papilla undergoing ERCP for biliary indications with no inadvertent pancreatic duct cannulation
10211008|NCT05219123||Single PD cannulation|Patients with native papilla undergoing ERCP for biliary indications with a single inadvertent pancreatic duct cannulation with a guide wire
10211009|NCT05219097||Cell Based Assay (CBA)|Use AChR/MuSK IgG CBA Kit (Tianjin New Terrain Biological Technology Co., Ltd, China) to detect AChR and MuSK IgG of myasthenia gravis
10211010|NCT05219097||CBA-TSA Assay|Modified CBA method, Use AChR/MuSK CBA-TSA Kit (Tianjin New Terrain Biological Technology Co., Ltd, China) to detect AChR and MuSK IgG of myasthenia gravis
10211011|NCT05219097||RIPA Assay|Use AChR/MuSK Radioimmunoassay Kit (RSR Limited, UK) to detect AChR and MuSK IgG of myasthenia gravis
10211012|NCT05219097||ELISA Assay|Use AchR ELISA Kit (RSR Limited, UK) and MuSK ELISA Kit (IBL Limited, Germany) to detect AChR and MuSK IgG of myasthenia gravis
10211013|NCT05219084|Placebo Comparator|placebo group|5ml of normal; saline-injected subcutaneously
10211014|NCT05219084|Active Comparator|Hip denervatiopn|Hip denervation with lidocaine 2% to each genicular branch, 2ml at each point
10211015|NCT05219084|Active Comparator|Inra-articular hydration|10 ml of normal saline injected inside the hip under ultrasound guidance
10211016|NCT05219084|Active Comparator|compined group|hip denervation and intra-articular hydration were conducted together in this group
10211017|NCT05219045|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
10211018|NCT05219045|No Intervention|Control|Medical providers who treat both treatment and control group enrollees receive training on stay-at-work/return-to-work best practices
10211019|NCT05219032|Experimental|Interpreter|Professional Spanish interpreter
10211020|NCT05219032|No Intervention|Usual Care|Usual care provided to patients
10211021|NCT05218980|Experimental|Investigational|Yale Dining menu + 6 olives daily
10211022|NCT05218980|No Intervention|Standard|Yale Dining menu only
10211023|NCT05218954||patients with heterotopic ossification|patients with heterotopic ossification following THR
10211024|NCT05218954||patients without heterotopic ossification|patients without heterotopic ossification following THR
10211025|NCT05218941|Experimental|Passive robotic group|Implant surgery without flap assisted by passive robotics
10211026|NCT05218941|Active Comparator|Control group|Implant surgery with flap
10211027|NCT05218915|Experimental|GLP1-ra plus basal insulin (BGLP)|Dulaglutide and insulin degludec in combination with CGM
10211028|NCT05218915|Active Comparator|Basal bolus insulin (BB)|Insulin aspart/lispro and insulin degludec in combination with CGM
10211029|NCT05218902||Retrospectively enrolled cohort|Participants who initiate Azacitidine (AZA) before enrollment
10211030|NCT05218902||Prospectively enrolled cohort|Participants who initiate AZA initiation at enrollment
10211031|NCT05218889|Experimental|Arm A|
10211032|NCT05218889|Active Comparator|Arm B|
10211033|NCT05218876|Experimental|Low- to moderate intensity strength and endurance training|Participants will perform a combination of strength and endurance training with low-to moderate-intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
10211034|NCT05218876|Experimental|High intensity strength and endurance training|Participants will perform a combination of strength and endurance training with high intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
10211035|NCT05218863||Confirmed AMI|Patients in whom diagnosis of acute mesenteric ischaemia (AMI) was confirmed. For these patients full data collection is required, including 1-year outcome. Maximum 500 patients in this group.
10211036|NCT05218863||AMI suspected but not confirmed|"Patients in whom acute mesenteric ischaemia (AMI) was suspected but not confirmed. For these patients minimal data will be collected, only hospital survival as outcome.~Maximum 2000 patients in this group."
10211037|NCT05218772||Elderly people with moderate or severe haemophilia|
10211038|NCT05218759|Experimental|arm A|Progressive disease (PD) after anlotinib administration
10211039|NCT05218759|Experimental|arm B|Stable disease (SD) after anlotinib administration
10211040|NCT05218707||Group A|An appropriate size oropharyngeal airway (GUEDEL) will be inserted immediately after removal of LMA and time will be noted. (Size will be chosen by placing the flange at the corner of the mouth and tip at the angle of the jaw).
10211041|NCT05218707||Group B|In Group B No oropharyngeal airway (GUEDEL) will be inserted.
10211042|NCT05218694|Experimental|CT-guided algorithm (CTGA)|In the CTGA group only the artery suspected of having obstructive coronary disease is examined. Anatomy of the vessel, optimal viewing projections and choice of catheter is determined. A guiding catheter is used as first choice based on the artery involved and the aortic anatomy. Time is recorded according to the ST group, with timepoint 1 after conclusion of the angiogram, timepoint 2 after FFR.
9986563|NCT01404052|Experimental|Active tDCS + transcranial ultrasound|Subjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
9986564|NCT01404052|Sham Comparator|Sham tDCS + transcranial ultrasound|Subjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
9986565|NCT01404065|Experimental|Active tDCS + visual illusion|Subjects will receive active tDCS while watching a visual illusion movie (legs walking on a treadmill). Stimulation will last for 20 minutes.
9986566|NCT01404065|Sham Comparator|Sham tDCS + visual illusion|Subjects will receive sham tDCS stimulation (30 seconds ramp up/ramp down) while watching a visual illusion movie (legs walking on a treadmill)
9986567|NCT01404065|Other|Healthy Subjects|Healthy subjects will receive both interventions (active and sham) in a randomized and counterbalanced order. Each stimulation session will be at least 1 week apart to prevent carry-over effects
9986568|NCT01404091|Experimental|Cohort 1: 40 milligram (mg) LY2940094|"40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered).~If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration [tmax] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
9986569|NCT01404091|Experimental|Cohort 2: 10 mg LY2940094|"The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
9986570|NCT01404091|Experimental|Cohort 3: 4 mg LY2940094|"The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
9986571|NCT01404091|Experimental|Cohort 4: 20 mg LY2940094|"The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
9986572|NCT01404104|Experimental|Temsirolimus (pre-surgery)|
9986573|NCT01404117|Experimental|Laquinimod 0.6|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
9986574|NCT01404117|Experimental|Laquinimod 1.2|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
9986575|NCT01404117|Experimental|GA or IFN + Placebo|GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
9986576|NCT01404130|Experimental|Isotretinoin therapy|0.5-1mg /kg titrated by clinical need and tolerance of each patient according to normal clinical practice
9986577|NCT01404143|Active Comparator|Subscapularis Tenotomy|"This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.~After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity."
9986578|NCT01404143|Experimental|Subscapularis Peel|This treatment group will use a technique that involves elevation of the tendon off the bone in order to gain access to the shoulder.The subscapularis will be elevated from the lesser tuberosity.
9996969|NCT01504724|Experimental|IVB group|Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
9996970|NCT01504724|No Intervention|only PRP group|Patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
9870305|NCT00251628|Active Comparator|Group A|
9870306|NCT00251628|Active Comparator|Group B|
9870307|NCT00251628|Experimental|Group C|
9870308|NCT00251680|Experimental|Lapaquistat Acetate 50 mg QD|(and stable lipid-lowering therapy)
9870309|NCT00251680|Active Comparator|Stable Lipid-lowering therapy|
9870310|NCT00251732|Active Comparator|Standard dose (PPI) plus low dose TCA|Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)
9870311|NCT00251732|Active Comparator|Double dose PPI|Double dose proton pump inhibitor plus placebo
9870312|NCT00251732|Placebo Comparator|Standard dose PPI plus placebo x 2|Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime
9870313|NCT00251771|Experimental|I|
9870314|NCT00251771|No Intervention|II|
9870315|NCT00251810||general anaesthesia|
9870316|NCT00251836||Left-sided donor nephrectomy|Left-sided laparoscopic hand-assisted donor nephrectomy
9870317|NCT00251836||Right-sided donor nephrectomy|Right-sided laparoscopic hand-assisted donor nephrectomy
9870318|NCT00252122|Experimental|1|Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.
9870319|NCT00252148|Active Comparator|ADMVA|ADMVA dosage escalation
9870320|NCT00252148|Placebo Comparator|Placebo|Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7
9870321|NCT00252161|Active Comparator|1|Procedure/Surgery: Gastrectomy with more than D2 dissection
9870322|NCT00252161|Experimental|2|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
9870323|NCT00252304|Experimental|Zinc|Zinc sulphate 10 or 20 mg per day
9870324|NCT00252304|Placebo Comparator|Placebo|Placebo
9870325|NCT00252317|Active Comparator|1|Captopril test dose and Trandolapril
9870326|NCT00252317|Placebo Comparator|2|
9870327|NCT00252421|Active Comparator|Nitroglycerin|Nitroglycerin ointment 15 mg/day daily for 24 month
9870328|NCT00252421|Placebo Comparator|Placebo|Placebo ointment daily for 24 month
9870329|NCT00252486|Placebo Comparator|Flax oil, placebo oil|
9870330|NCT00252525||Group 1|This is an observational study of patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.
9870331|NCT00252551|Experimental|1|osteosynthesis
9870332|NCT00252551|Active Comparator|2|Simple surgery
9870333|NCT00252616|Experimental|1|trophic feeds
9870334|NCT00252616|Active Comparator|2|Full-calorie feeds
9870335|NCT00252746|Experimental|ZD6474 100mg|Daily dose
9870336|NCT00252746|Experimental|ZD6474 200mg|daily dose
9870337|NCT00252746|Experimental|ZD6474 300mg|daily dose
9870338|NCT00252915|Experimental|Verum|GM-CSF therapy
9870339|NCT00252928|Placebo Comparator|A|Placebo group does not receive Aquatabs.
9870340|NCT00252928|Experimental|B|Intervention arms receives Aquatabs.
9870341|NCT00252954|Placebo Comparator|1|
9928357|NCT00905710|Experimental|2|Colonoscopy using chromoendoscopy
9928358|NCT00905723|Experimental|Estrogen|Women randomized to this group will receive daily pills containing 1 mg of estradiol
9928359|NCT00905723|Experimental|Isoflavone|Women randomized to this group will receive daily pills of 150 mg isoflavone
9928360|NCT00905723|Placebo Comparator|Placebo|Women randomized to this group will be administered daily placebo pills
9928361|NCT00905736|Experimental|current controlled|a current controlled microcurent device providing a primarily monophasic waveform of typical amplitude 40 microamps
9928362|NCT00905736|Experimental|voltage controlled|constant voltage amplitude delivering high frequency AC waveform
9928363|NCT00905762|Experimental|Besifloxacin|Besifloxacin one drop instilled into study eye.
9928364|NCT00905762|Active Comparator|Gatifloxacin|Gatifloxacin one drop instilled into study eye.
9928365|NCT00905762|Active Comparator|Moxifloxacin|Moxifloxacin one drop instilled into study eye.
9928366|NCT00905775||1 Isoflurane|The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
9928367|NCT00905775||2 Propofol|The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-
9928368|NCT00905788|No Intervention|Control Group|Embryo transfer without any intervention
9928369|NCT00905788|Experimental|Embryo Expulsion|
9928370|NCT00905801|Other|Arm A CT Perfusion|"Arm A Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~CTP imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Subject will stand up and walk around, and then lay back down~CT Perfusion imaging: Second single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from their clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
9928371|NCT00905801|Other|Arm B CT Perfusion|"Arm B Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~- CT Perfusion imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
9928372|NCT00905814|Other|Sequence 1 (BABA)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
9928373|NCT00905814|Other|Sequence 2 (ABAB)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B -> A -> B
9935344|NCT03868618|Experimental|Genio Therapy|The Genio™ system is an implantable neurostimulation system comprised of one implanted device
9935345|NCT03867448||Adults with Endocrine Disorder|Adults referred to NIH with posssible endocrine conditions.
9996971|NCT01504737|Experimental|Supervised Exercise Training|12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
9870342|NCT00253045|Experimental|Motivational group|Group counseling using motivational interviewing
9870343|NCT00253071|Active Comparator|A,2|Standard treatment: treatment as usual at a community psychiatric center, private psychiatrist or general practitioner.
9870344|NCT00253071|Experimental|A, 1|"Behavioral: Prophylactic combined medical and psychological treatment~Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
9870345|NCT00253084|Other|IPX054 - CD-LD IR|Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.
9870346|NCT00253084|Other|CD-LD IR - IPX054|Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.
9870347|NCT00253097|No Intervention|Control|Patients in the control group had the usual care provided at the stroke unit, that is counselling on avoiding risky health behavior, compliance with preventive medication, measurement of blood pressure and a 3 months' visit in the outpatient clinic
9870348|NCT00253097|Experimental|Intervention|Patienta allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
9870349|NCT00253110|Active Comparator|risperidone|
9870350|NCT00253110|Active Comparator|haloperidol|
9870351|NCT00253266|Experimental|Verum|Quetiapine augmentation
9870352|NCT00253266|Placebo Comparator|Placebo|"Placebo augmentation"
9870353|NCT00253279||1|16 healthy subjects will be studied. Each patient will undergo one PET Scan to measure muscle protein synthesis rate.
9870354|NCT00253279||2|48 burn patients will be studied. Each patient will have a maximum of 3 PET Scans, which will be done at different times during the first 24 months after injury. A maximum of 2 of these scans will be done while they are inpatient; one after discharge.
9870355|NCT00253318|Experimental|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
9870356|NCT00253383|Experimental|ENABLE (concurrent palliative care)|telephone based ENABLE educational intervention
9870357|NCT00253383|Active Comparator|Usual Care|Supportive and palliative usual care services at DHMC, Behavioral
9870358|NCT00253500|Experimental|Epirubicin|
9870359|NCT00253539|Experimental|Arm I|Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
9870360|NCT00253539|Experimental|Arm II|Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
9870361|NCT00253539|Placebo Comparator|Arm III|Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
9870362|NCT00253578|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9870363|NCT00253682||1|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission Study (WITS).
9870364|NCT00253682||2|Historical cohort of HIV-uninfected infants born to HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV Study (P2C2 HIV) who were not exposed to HAART.
9870365|NCT00253721|Experimental|All subjects|
9870366|NCT00253734|Active Comparator|4|31 subjects to receive 15 mcg of TIV administered intramuscularly.
9870367|NCT00253734|Experimental|2|31 subjects to receive 6 mcg of TIV administered intradermally.
9870368|NCT00253734|Experimental|1|31 subjects to receive 9 mcg of TIV administered intradermally.
9870369|NCT00253734|Experimental|3|31 subjects to receive 3 mcg of TIV administered intradermally.
9870370|NCT00253734|Active Comparator|5|31 subjects to receive 9 mcg of TIV administered intramuscularly.
9870371|NCT00253734|Active Comparator|7|31 subjects to receive 3 mcg of TIV administered intramuscularly.
9870372|NCT00253734|Active Comparator|6|31 subjects to receive 6 mcg of TIV administered intramuscularly.
9870373|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
9870374|NCT00253786|Active Comparator|Standard therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
9870375|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
9870376|NCT00253786|Active Comparator|Standard therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
9870377|NCT00253838|Active Comparator|Restoration HA Stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating
9870378|NCT00253838|Sham Comparator|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
9870379|NCT00253877|Active Comparator|Conserve Plus Hip Resurfacing|Conserve Plus Hip Resurfacing group. Complication rate will be compared between groups.
9870380|NCT00253877|Other|Total Hip Replacement|Historical Total Hip Replacement control group of recently published conventional total hip replacement results (Williams, 2002). Complication rate will be compared between groups.
9870381|NCT00253903|Experimental|1|5 mg/day
9870382|NCT00253903|Placebo Comparator|2|
9870383|NCT00253916|No Intervention|Control Arm|No exercise measured
9870384|NCT00253916|Experimental|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
9870385|NCT00253916|Experimental|Resistance Exercise Program|Resistance Exercise Program
9870386|NCT00253955|Experimental|1|
9870387|NCT00253955|Active Comparator|2|
9870388|NCT00254046|Placebo Comparator|002|Placebo 2 tablets b.i.d.96 weeks
9870389|NCT00254046|Active Comparator|001|TMC125 2 X100 mg tablets b.i.d.96 weeks
9870390|NCT00254176|Active Comparator|Cysteine|Subjects that receive cysteine
9870391|NCT00254176|Placebo Comparator|No-cysteine placebo|Subjects that do not receive cysteine but an isonitrogenous placebo
9870392|NCT00254254|Experimental|Sequence 1|Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
9870393|NCT00254254|Experimental|Sequence 2|Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
9870394|NCT00254254|Experimental|Sequence 3|Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg
9870395|NCT00254267|Experimental|Arm One|AMG 706 125mg, oral, once a day
9870396|NCT00254306||1|"ex-ecstasy users"
9870397|NCT00254306||2|control subjects
9870398|NCT00254384|Experimental|Treatment (docetaxel, cisplatin, erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning within 90 days following definitive surgical resection, patients receive erlotinib hydrochloride PO daily for up to 1 year.
9870399|NCT00254423|Experimental|Arm A (once daily dasatinib)|Patients receive dasatinib PO QD for up to 15-18 years.
9870400|NCT00254423|Experimental|Arm B (twice daily dasatinib)|Patients receive dasatinib PO BID for up to 15-18 years.
9870401|NCT00254436|Experimental|Epoetin Alfa|
9870402|NCT00254553|Active Comparator|Arm 1|Testim 1% (testosterone gel)
10211043|NCT05218694|No Intervention|Standard treatment (ST)|"ST includes the use of two diagnostic cathers and examination of both coronary arteries by at least 6 different standard projections best optimizing the view of the coronary lesions.~Additional projections may be included if deemed necessary for optimal angiographic evaluation"
9870403|NCT00254553|Placebo Comparator|Arm 2|Placebo
9870404|NCT00254618|Experimental|30 mg|30 mg/kg/day mesalamine
9870405|NCT00254618|Experimental|60 mg|60 mg/kg/day mesalamine
9870406|NCT00254618|Experimental|90 mg|90 mg/kg/day mesalamine
9870407|NCT00254631|Active Comparator|study group|pre operative medication with 20 mg oxycontine PO
9870408|NCT00254631|Placebo Comparator|placebo group|pre operative medication with placebo tablet PO
10211044|NCT05218681|Other|"Control: Unit-based Person First Anti-stigma Awareness Rounds"|"The Person First Initiative was developed independent of this study by bedside nurses (including McFadden) in collaboration with HUP Nursing Executive Leadership. The objective of this initiative is to provide (1) unit-based huddles on person-first language as a mechanism to reduce the stigma around substance use; (2) socialize best practices and resources for patients with substance use disorder; and (3) provide overdose reversal training and kits, including Narcan nasal spray, to nurses. The planning and implementation of these activities fall under the purview of Nursing Shared Governance (NOT the research team), and oversight for these activities will be provided by HUP Nursing Executive Leadership."
10211045|NCT05218681|Other|"Unit-based Person First stigma rounds + Text-based Messaging"|Participating nurses will be randomized to receive weekly short text messages that employ evidence-based strategies to reduce stigma towards individuals with substance use disorder over the course of 6-months.
10211046|NCT05218655|Experimental|Vatiquinone|Participants will receive vatiquinone oral solution (100 milligrams [mg]/milliliter [mL]), up to 400 mg, administered orally or via feeding tube 3 times daily (TID).
10211047|NCT05218616|Other|Sequence TR|
9870409|NCT00254644||Dyslexia|adults from 18-35 ans.
9870410|NCT00254644||Control|adults from 18-35 ans.
9870411|NCT00254657|Placebo Comparator|Placebo|
9870412|NCT00254657|Experimental|Levetiracetam|
9928374|NCT00905853|Active Comparator|Ventricular Tachycardia Ablation|Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
9928375|NCT00905853|Active Comparator|Escalated Antiarrhythmic Drug Therapy|Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.
9928376|NCT00905866||Quality of life|All participants undergoing parathyroidectomy
9928377|NCT00905879||Group 1|
9928378|NCT00905905|Experimental|Ezetimibe-Simvastatin 10/40 mg|
9928379|NCT00905905|Active Comparator|Simvastatin 40 mg|
9928380|NCT00905918|No Intervention|Arm I|Patients receive no intervention before undergoing planned surgery.
9928381|NCT00905918|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
9928382|NCT00905918|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
9928383|NCT00905931|Experimental|Active|
9928384|NCT00905931|Placebo Comparator|Placebo|
9928385|NCT00905944|No Intervention|Control|
9928386|NCT00905944|Experimental|Intervention|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
9928387|NCT00905957|Active Comparator|Transversus abdominis plane (TAP) Group|Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia
9928388|NCT00905957|Placebo Comparator|Control Group|Patients will receive a TAP block using a placebo after induction of anaesthesia
9928389|NCT00905970||1|Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.
9928390|NCT00905970||2|Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.
9928391|NCT00905970||3|Patients with LTBI diagnosed time ago.
9928392|NCT00905970||4|Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.
10211048|NCT05218616|Other|Sequence RT|
9870413|NCT00254683|Experimental|PET/CT|Single arm study evaluating the use of PET/CT to assess rectal cancer response to neoadjuvant therapy
9870414|NCT00254722|Experimental|I|single arm study
9870415|NCT00254748|Placebo Comparator|1|Placebo
9870416|NCT00254748|Experimental|2|Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate
9870417|NCT00254761|Experimental|1|High dose cannabis (7.5% THC by weight)
9870418|NCT00254761|Experimental|2|Low dose cannabis (3.5% THC by weight)
10211049|NCT05218577|Experimental|HSFF group|the group was given high selenium funtion selenium for 3 months
10211050|NCT05218577|Experimental|Selenium suplemen group|the group was given selenium suplemen
9870419|NCT00254761|Placebo Comparator|3|Placebo cannabis
9870420|NCT00254800|Experimental|Sequence 1|Oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide/oral contraceptive alone
9870421|NCT00254800|Experimental|Sequence 2|Oral contraceptive 30 minutes after exenatide/oral contraceptive alone/oral contraceptive 1 hour prior to exenatide
9870422|NCT00254800|Experimental|Sequence 3|Oral contraceptive alone/oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide
9870423|NCT00254826|Other|YF-VAX® plus saline|Drug: YF-VAX® plus saline
9870424|NCT00254826|Experimental|17D YF Vaccine plus Ig|Drug: 17D YF Vaccine plus Ig; one vaccine on day 0
9870425|NCT00254852|Active Comparator|O|This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
9870426|NCT00254852|Active Comparator|A|This treatment arm includes autograft harvested from local bone and / or the iliac crest.
9870427|NCT00254917|Experimental|1|Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age
9870428|NCT00254917|Experimental|2|Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.
9870429|NCT00254969|Experimental|1|
9870430|NCT00255021|Experimental|1|
9870431|NCT00255112|No Intervention|1|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel. The study consists of 40 participants (5-7 years old) with SAD and their families. Participants were randomly assigned to 12 weeks of SAD-specific family-based CBT treatment or to waitlist condition.
9870432|NCT00255112|Active Comparator|2|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel in comparison to a global CBT treatment. The study consists of 60 participants (between 8 and 13 years old), randomly assigned to one of the two treatments.
9870433|NCT00255229|Active Comparator|1|Irinotecan, 5FU, Glutamine
10211051|NCT05218577|Placebo Comparator|Control group|the group was given placebo
10211052|NCT05218564|Experimental|Group 1, consisting of participants with COPD and usually using O2|In this group, in addition to the standard care, the participant undergoes the 6 Minute Walking Test (6MWT) using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The same, then, in addition to the standard care, is subjected to the execution of the 6 Minute Walking Test (6MWT), thanks to the use of cylinders of Oxygen (O2), believing that inside the cylinder there is Oxygen (O2). The sequence of this group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen).
10211053|NCT05218564|Placebo Comparator|Group 2, consisting of participants with COPD and usually not using O2|In this group, in addition to standard care, the participant is given the 6 Minute Walking Test (6MWT) using oxygen (O2) cylinders, believing that there is oxygen (O2) inside the cylinder. Next, the participant undergoes the 6 Minute Walking Test (6MWT), using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The sequence of this group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
9870434|NCT00255229|Placebo Comparator|2|Irinotecan, 5FU, Placebo
10211054|NCT05218525|Experimental|Intervention group|The specialized COPD community nurses, who are responsible for patients in the intervention group, will experience an extra alarm option in the telehealth system. The COPD prediction algorithm has been implemented by the Danish Company, OpenTeleHealth, into their commercially available telehealth system, Telekit, and thus, the COPD prediction algorithm is approved for clinical use as a part of the existing telehealth system´s CE marking (class I and IIa).
10213706|NCT03486730|Experimental|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that up to 70 patients with tumour types known to commonly overexpress MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment (i.e. squamous non-small cell lung cancer) will be entered in the study.
9870435|NCT00255372|Experimental|1|
9870436|NCT00255372|Active Comparator|2|
9870437|NCT00255515|Experimental|1|quetiapine fumarate
9870438|NCT00255515|Active Comparator|2|Conventional treatment for schizophrenia
9870439|NCT00255515|Experimental|3|quetiapine fumarate + Cognitive Remediation Therapy
9870440|NCT00255567|Active Comparator|1|Sodium Stibogluconate (30 days)
9870441|NCT00255567|Experimental|2|Paromomycin Sulphate (21 days)
9870442|NCT00255567|Experimental|3|Sodium Stibogluconate + Paromomycin Sulphate (17 days)
9870443|NCT00255580|Experimental|1|Active cannabis (1-8% THC by weight)
9870444|NCT00255580|Placebo Comparator|2|Placebo cannabis
9870445|NCT00255606|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9870446|NCT00255606|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9928393|NCT00905983|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
9928394|NCT00905996|Active Comparator|Endoscopic Cyanoacrylate injection|Endoscopic injection of cyanoacrylate in the gastric varix until obturation
9928395|NCT00905996|No Intervention|No Intervention|No treatment offered for gastric varix
9870447|NCT00255658|Experimental|Treatment (sorafenib tosylate, temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. They also receive oral sorafenib* twice daily starting on day 8 of course 1. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *On the days of the temsirolimus infusion, temsirolimus should be taken concurrently with the morning dose of sorafenib.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
9870448|NCT00255749|Experimental|early intervention epoietin alfa|Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
9870449|NCT00255749|Other|standard intervention epoietin alfa|Patients receive epoetin alfa as in arm I once their hemoglobin level is ≤ 10.5 g/dL.
9870450|NCT00255762|Experimental|Treatment (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9870451|NCT00255788|Active Comparator|Arm A|Everolimus - 28 days q 4 wk
9870452|NCT00255788|Active Comparator|Arm B|Everolimus - days 1, 8, 15 and 22 q 4wks
9870453|NCT00255814|Other|Radiation therapy dose level II: 4.0 Gy/fx|Radiation therapy dose level II: 4.0 Gy/fraction
9870454|NCT00255814|Other|Radiation therapy dose level III: 4.5 Gy/fx|Radiation therapy dose level III: 4.5 Gy/fraction
9870455|NCT00255814|Other|Radiation therapy dose level IV: 5.0 Gy/fx|Radiation therapy dose level IV: 5.0 Gy/fraction
9870456|NCT00255892||Part A - Provider Interviews|The provider interviews will be comprised of participants who are clinical providers, mental health providers, and case managers with at least 1 year of experience working with HIV-positive youth; one from each category from all 15 ATN sites will be targeted for a total of 45 participants.
9870457|NCT00255892||Part B - Youth Focus Groups|"The focus groups will be comprised of 6-8 participants per group who are between the ages of 16 and 24, diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive services at three selected ATN sites or their community partners for a total of 36-48 participants.~For the purposes of this study, youth who acquired HIV perinatally will be excluded from participation in this study."
9870458|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 75 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)
9870459|NCT00255918|Placebo Comparator|Placebo|Participants will take placebo.
9870460|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 150 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)
9870461|NCT00255931|Experimental|1|
9870462|NCT00255931|Placebo Comparator|2|
9870463|NCT00255931|No Intervention|3|Usual Care
9870464|NCT00255983|Experimental|1|faropenem medoxomil
9870465|NCT00255983|Placebo Comparator|2|
9870466|NCT00256022|Active Comparator|Lactobacillus Acidophilus Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
9870467|NCT00256022|Active Comparator|Lactobacillus Fermentum Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
9870468|NCT00256022|Active Comparator|Lactobacillus Fermentum and Lactobacillus Acidophilus|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
9870469|NCT00256022|Placebo Comparator|Placebo|The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
9870470|NCT00256035|Other|Unstable coronary artery disease|Patients with unstable coronary artery disease will have daily IL6 levels
9870471|NCT00256035|Other|Coronary Angioplasty Patients|Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
9870472|NCT00256035|Other|Coronary bypass grafts patients|Patients will have levels collected immediately after and 24 hours post procedure
9870473|NCT00256035|Other|Stable coronary Artery Diseaese Patients|Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
9870474|NCT00256048|No Intervention|Standard Care|Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
9870475|NCT00256048|Active Comparator|Nasojejunal Arm|Patient will receive feeding via a nasojejunal feeding tube
9870476|NCT00256074|Other|Standard Therapy Group|Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
9870477|NCT00256074|Other|Alternative Therapy Group|2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.
9870478|NCT00256087|Placebo Comparator|Standard Care|Two capsules containing placebo will be given 12 hourly
9870479|NCT00256087|Active Comparator|First active treatment|Two capsules containing probiotic lactobacillus fermentin given 12 hourly
9870480|NCT00256087|Active Comparator|Second active reatment|Two capsules containing probiotic lactobacillus acidiphilus given 12 hourly
9870481|NCT00256100|Active Comparator|One|Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
9870482|NCT00256100|Active Comparator|Two|Fondaparinux will be used as the anticoagulant in the sencond arm of the study
9870483|NCT00256152|No Intervention|AF Suppression OFF|
9870484|NCT00256152|Experimental|AF Suppression ON|
9870485|NCT00256178|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
10211055|NCT05218525|No Intervention|Control group|"The specialized COPD community nurses responsible for patients in the control group will only experience the usual alarms that are activated in the telehealth system, named Telekit, and are based on low or high values of vital signs. The specialized COPD community nurses are not instructed to act differently compared to how they act normally. This involves that the specialized COPD community nurses monitor as usual and respond to divergent data as usual.~The participants in the control group receive the usual practice, which includes the general offer of the telehealth intervention. The participants in the control group are instructed to do exactly the same procedures as the participants in the intervention group.~The specialized COPD community nurses, who are responsible for patients in the control group continue to monitor the participants as usual, but are informed that more oxygen saturation measurements will be present for the included participants."
10211056|NCT05218512||WB-EMS|Young recreationally active males without any disease.
10211057|NCT05218486|Active Comparator|Isotretinoin group|Patients will be treated with Isotretinoin in a dose (from 20 to 40) for 3 months and serum YKL40 will be assessed before and after treatment
10211058|NCT05218486|No Intervention|Control group|Assessment of serum YKL40 in healthy individuals
10211059|NCT05218460|Experimental|All subjects will have an MRI examination|
9870486|NCT00256178|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
9870487|NCT00256178|Active Comparator|Simvastatin|
9870488|NCT00256230|Experimental|Disulfiram|
9870489|NCT00256269|Experimental|Oxaliplatin plus Irinotecan|Drug: Oxaliplatin-40 mg/m2 IV over 60 minutes Every 21 days. Drug: Irinotecan-60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days.
9870490|NCT00256321|Experimental|Celecoxib/Oxaliplatin/Capecitabine|"Oxaliplatin 70mg/m2 IV on Days 1 and 8. Capecitabine 1000mg/m2 PO BID from Days 1 through 14. Celecoxib 400mg PO BID from Days 1 through 21.~1 Cycle = 21 days."
9870491|NCT00256334|Experimental|Resveratrol|GM-CSF administration to all subjects in addition to chemotherapy treatment.
9870492|NCT00256412|Placebo Comparator|1|
9870493|NCT00256412|Active Comparator|2|Low Dose
9870494|NCT00256412|Active Comparator|3|High Dose
9928396|NCT00905996|Other|Beta-blocker (propranolol)|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
9928397|NCT00906022|Experimental|Astron Pulsar Stent|Device: Astron Pulsar Stent
9928398|NCT00906022|Active Comparator|PTA alone|Device: Balloon angioplasty alone
9928399|NCT00906048|Experimental|1|Levofloxacin and Rifampicin
9928400|NCT00906061|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
9928401|NCT00906113|Experimental|Intra-arterial melphalan|The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
9928402|NCT00906126|Experimental|Oral Misoprostol 1|Oral misoprostol 25 micrograms every 4 hours for up to two doses.
9928403|NCT00906126|Experimental|Oral Misoprostol 2|Oral misoprostol 50 micrograms every 4 hours for up to two doses.
9928404|NCT00906126|Experimental|Oral Misoprostol 3|Oral misoprostol 100 micrograms every 4 hours for up to two doses.
9928405|NCT00906126|Experimental|Oral Misoprostol 4|Oral Misoprostol 50 micrograms every 2 hours for up to two doses.
9928406|NCT00906126|Experimental|Oral Misoprostol 5|Oral Misoprostol 75 micrograms every 4 hours for up to two doses.
9928407|NCT00906139|Active Comparator|Propofol|To receive propofol (0.5 mg/kg up to 400 mg) and fentanyl (0.05 mg);
9928408|NCT00906139|Active Comparator|Midazolam|To receive midazolam (0.1 mg/kg) and fentanyl (0.05 mg).
9928409|NCT00906152||Subacute low back pain; chronic low back pain|Patients with subacute or chronic low back pain seen in the Primary Care Centers participating in the study.
9928410|NCT00906191|Experimental|1|Single oral dose
9928411|NCT00906217||elderly patients|patients older than 70 years with normal renal function
9928412|NCT00906256|Active Comparator|AZD7295|AZD7295
9928413|NCT00906256|Placebo Comparator|Placebo capsule|Placebo
9928414|NCT00906269|Active Comparator|1|
9928415|NCT00906269|Sham Comparator|2|
9928416|NCT00906295|Active Comparator|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
9928417|NCT00906295|Experimental|Allowed drop in hemoglobin to 5.6-6.5 mmol/L|Transfusion with red blood cells to level between 5.6-6.5 mmol/L
9928418|NCT00906308|Placebo Comparator|Placebo|
9928419|NCT00906308|Experimental|MF101 5 g/day|
9928420|NCT00906308|Experimental|MF101 10 g/day|
9928421|NCT00906360|Experimental|Treatment (enzyme inhibitor and monoclonal antibody therapy)|Patients receive sunitinib malate orally or by percutaneous gastrostomy tube once daily, cetuximab IV over 60-120 minutes once weekly, and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 7-9 weeks in the absence of disease progression or unacceptable toxicity. Patients with persistent disease undergo surgical resection.
9928422|NCT00906386|Experimental|1|
9928423|NCT00906386|Placebo Comparator|placebo|
9928424|NCT00906412||ET Group|Total of 25 participants with ET
9928425|NCT00906412||Controls|25 controls without ET
9928426|NCT00906438|Placebo Comparator|Control|
9928427|NCT00906438|Experimental|Treated|
9928428|NCT00906451|No Intervention|No lipid-lowering|No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
9928429|NCT00906451|Experimental|Simvastatin 20 mg|Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
9928430|NCT00906451|Experimental|Simvastatin 40 mg|Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
9986579|NCT01404156|Active Comparator|Neoadjuvant Chemotherapy|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)"
9986580|NCT01404156|Experimental|Neoadjuvant Chemoradiation|"1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment."
9986581|NCT01404169|Experimental|1|
9986582|NCT01404169|Placebo Comparator|2|
9986583|NCT01404182|Experimental|Influenza vaccination|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
9986584|NCT01404195|Experimental|Ensure Plus Advance, Supplement|Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.
9986585|NCT01404195|No Intervention|Control|without supplementation
9986586|NCT01404247|Experimental|OCT imaging in neonates|OCT imaging of all neonates, 38-42 weeks, enrolled in this study
9986587|NCT01404273|Experimental|Meditation/Relaxation Response Training|
9986588|NCT01404286|Experimental|physical exercise|Experimental group: physical exercise Control group: no physical exercise
9986589|NCT01404286|No Intervention|Control group|
9986590|NCT01404299|Experimental|Supplementary Group|
9986591|NCT01404299|No Intervention|Control Group|
9986592|NCT01404312|Experimental|RPT plus INH Regimen (Arm A)|Participants received RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants did not receive any study medications.
9986593|NCT01404312|Active Comparator|INH Regimen (Arm B)|Participants received 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.
9986594|NCT01404338|Active Comparator|Active Arm|1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
9986595|NCT01404338|Placebo Comparator|Vehicle Arm|Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
9986596|NCT01404351|Experimental|PEAK PlasmaBlade|
9986597|NCT01404351|Active Comparator|Standard of Care|The Standard of Care arm will consist of the scalpel for the skin incision and traditional electrosurgery for subcutaneous dissection.
9986598|NCT01404364|Active Comparator|Intravitreal Triamcinolone|Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
9986599|NCT01404364|Active Comparator|Retrobulbar Chlorpromazine|Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
9986600|NCT01404377|Active Comparator|ropivacaine|treated group (ropivacaine infiltration)
9986601|NCT01404377|Placebo Comparator|placebo|placebo group : infiltration with saline solution
9986602|NCT01404390|Experimental|Arm 1|
9986603|NCT01404390|Experimental|Arm 2|
9986604|NCT01404403|Other|Stroke patients|
9986605|NCT01404442|Active Comparator|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
9986606|NCT01404442|Active Comparator|midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
9986607|NCT01404442|Placebo Comparator|placebo|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
9986608|NCT01404455|Other|Normal pulse pressure|pulse pressure <60mmHg
9986609|NCT01404455|Other|Wide pulse pressure|pulse pressure ≥60mmHg
9986610|NCT01404468|Active Comparator|pulsed|
9986611|NCT01404468|Sham Comparator|control|
9986612|NCT01404468|Active Comparator|continuous|
9986613|NCT01404481||Single use group|New catheter for each Clean Intermittent Self Catheterisation (CISC), then discard.
9986614|NCT01404481||Re use of catheters group|"Use same catheter for 1week- Cleaning with sunlight liquid soap, air dry or dry with lint free towel, store in a snap lock bag.~Discard catheter and snap lock bag at end of each week."
9986615|NCT01404507|Active Comparator|Intracoronary abciximab|Intracoronary injection of bolus abciximab
9986616|NCT01404507|Active Comparator|Aspiration thrombectomy|Aspiration thrombectomy
9986617|NCT01404507|Active Comparator|Both use|Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy
9986618|NCT01404520|Experimental|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme
9986619|NCT01404520|No Intervention|Control Group|Control group receives usual care
9986620|NCT01404533|Experimental|Iron supplement without food|
9986621|NCT01404533|Experimental|Iron supplement with food|
9986622|NCT01404533|Experimental|Iron fortificant with food|
10211060|NCT05218434|Experimental|Drug (AX-158 or Placebo)|Rising single doses of AX-158 oral or placebo.
9870495|NCT00256503|Experimental|Insomnia|Insomnia subjects who receive 8 session cognitive behavioral therapy for insomnia.
9870496|NCT00256503|No Intervention|Good Sleeper|Good sleeper controls who receive no intervention
9870497|NCT00256516|Experimental|Eco-Atkins diet|
9870498|NCT00256516|Active Comparator|NCEP diet|
9870499|NCT00256529||I|All subjects presenting in with dysphagia will be in this cohort.
9870500|NCT00256568||Primary Care Practices|One hundred and three prescribers, managers, nurses and office staff at seven primary care practices in Vermont
9870501|NCT00256607||coronary artery calcium (CAC)|Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
9870502|NCT00256633||Group 1|enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.
9870503|NCT00256646||Group 1|"Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2."
9870504|NCT00256672|Active Comparator|1|High-dose Thoraco-Lumbar-Sacral Orthoses wear (>23hrs/day) will be compared to low-dose Thoraco-Lumbar-Sacral Orthoses wear (12hrs/day)
9870505|NCT00256672|Active Comparator|2|Low-dose Thoraco-Lumbar-Sacral-Orthoses wear (12hrs/day)
9870506|NCT00256932|Placebo Comparator|Placebo|
9870507|NCT00256932|Experimental|Alvimopan 0.5 mg once daily|
9870508|NCT00256932|Experimental|alvimopan 0.5 mg twice daily|
9870509|NCT00257127|Experimental|1|Patients will receive PCV, HBV, and MMR at study entry
9870510|NCT00257127|Experimental|2|Patients will receive PPV, HBV, and MMR at study entry
9870511|NCT00257296|Experimental|Screening and Intervention|Use a computer-based screening tool for intimate partner violence and provide a multi-faceted intervention based on the needs of the woman and services should would like to utilize.
9870512|NCT00257296|Active Comparator|Usual Care|Use a computer-based screening tool for intimate partner violence and provide list of resources available. Also, all physicians were trained on intimate partner violence and were told they could help anyone regardless of randomization.
9870513|NCT00257400|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
9870514|NCT00257400|Active Comparator|Individual Psychotherapy|Individual Psychotherapy
9870515|NCT00257439||CKD|Elevated se-creatinine + proteinuria
9870516|NCT00257439||Healthy controls|Healthy controls, normal se-creatinine, no proteinuria
9870517|NCT00257465|Experimental|A|'Autologous, DNP-modified vaccine (M-Vax)'
9870518|NCT00257465|Experimental|B|Autologous, DNP-Modified Vaccine (MVax)
9870519|NCT00257465|Experimental|C|Autologous, DNP-Modified Vaccine (MVax)
9870520|NCT00257465|Placebo Comparator|D|0 cells
9870521|NCT00257543|Experimental|single arm study|this is a single arm study
9870522|NCT00257673|Experimental|A|Active 30 mg MEM 1003
9870523|NCT00257673|Experimental|B|90 mg MEM 1003
9870524|NCT00257673|Placebo Comparator|C|Placebo for MEM 1003
9870525|NCT00257699|Placebo Comparator|I|Ciprofloxacin placebo and Metronidazole placebo
9870526|NCT00257699|Experimental|II|Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight
9870527|NCT00257712|Experimental|1|
9870528|NCT00257712|Placebo Comparator|2|
9870529|NCT00257738|Experimental|MAGE -A3 vaccine|for those individuals in which tumor tests positive for MAGE-A3
9870530|NCT00257738|Experimental|HPV 16 vaccine|for patients with HPV 16 positive tumor
9870531|NCT00257803|Experimental|1|In the other group, the women will receive a small injection of oxytocin directly into the vein via their intravenous (bolus) after their baby is born.
9870532|NCT00257803|Placebo Comparator|2|In one group, women will receive a small injection of saline (salt water) directly into the vein via their intravenous (bolus) after their baby is born.
9870533|NCT00257816|Experimental|Topotecan|Adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
9928431|NCT00906451|Experimental|Simvastatin 80 mg|Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment
9928432|NCT00906477|Experimental|Early intervention|Modified CI therapy starting between 7 and 28 days post stroke.
9928433|NCT00906477|Active Comparator|Delayed intervention|Modified CI Therapy starting 6 months post stroke
9928434|NCT00906516|Experimental|Neuradiab in combination with Avastin|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
9928435|NCT00906529|Active Comparator|Conservative Blood Glucose Control|Goal Pre-prandial blood glucose <180 mg/dl.
9928436|NCT00906529|Active Comparator|Aggressive Blood Glucose Control|Pre-prandial goal blood glucose <110 mg/dl
9928437|NCT00906542||Acute ischemic stroke patients|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke unit within 24 hours after stroke onset in whom ischemic brain lesion was clearly assessed on CT and/or MRI
9928438|NCT00906555|No Intervention|1|hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7)
9928439|NCT00906555|Experimental|2|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
9928440|NCT00906568||Sensitized vs non-sensitized|CF with and without SAD defined by MEF25 <50%
9928441|NCT00906581|Experimental|Behavioral|Behavioral
9928442|NCT00906581|No Intervention|Waitlist control|Waitlist control
9928443|NCT00906594|Active Comparator|Latanoprost|Latanoprost mono therapy
9928444|NCT00906594|Experimental|Latanoprost + Fixed combination|Latnoprost + Fixed combination
9928445|NCT00906607||Group I|10-18 years
9986623|NCT01404546|Experimental|Cost Free Pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
9986624|NCT01404546|Active Comparator|Usual Care Group|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
9986625|NCT01404598|Experimental|naproxcinod 750 mg bid|
9986626|NCT01404598|Experimental|naproxcinod 3000 mg od|
9928446|NCT00906607||Group II|20-35 years
9986627|NCT01404598|Active Comparator|naproxen 500 mg bid|
9996972|NCT01504737|Active Comparator|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
9996973|NCT01504750|Experimental|lighting room|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals.
9996974|NCT01504750|No Intervention|control room|Normal lighted patient room
9996975|NCT01504763|Experimental|Massage|Chair massage for 15 minutes once a week for 10 weeks.
9996976|NCT01504776|Experimental|Open Label Drug Therapy|Single arm
9996977|NCT01504802||Growth hormone deficient|Children with short stature, a peak growth hormone response on stimulation testing of less than 7 ng/ml, and no other identifiable cause of short stature
9996978|NCT01504802||Idiopathic short stature|Children with short stature, a peak growth hormone response on stimulation testing of greater than or equal to 7 ng/ml, and no identifiable cause for the short stature
9996979|NCT01504815|Active Comparator|Cisplatinum + conventional RT|Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
9996980|NCT01504815|Experimental|Cisplatinum + adaptive high dose RT|Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
9996981|NCT01504828|Experimental|Ramipril|Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function
10211061|NCT05218434|Experimental|Drug (AX-158)|Oral single dose with and without food
9928447|NCT00906607||Group III|45-60 years
9928448|NCT00906607||Group IV|65-75 years
9928449|NCT00906620|Experimental|QPR intervention|"QPR intervention (Question, Persuade & Refer): The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
9928450|NCT00906620|Experimental|Awareness program|The awareness programme is comprised of a leaflet, six posters and four seminars. The seminars are made up of one introductory lesson, and two interactive follow-up lessons with role play and one final meeting as a closing/debriefing lesson.
9998305|NCT01516931|Experimental|active rTMS and venlafaxine|"rTMS：Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.~venlafaxine：150-225mg/day"
10211062|NCT05218434|Experimental|Drug (AX-158 and Placebo)|Rising multiple doses of AX-158 oral or placebo for 10 days.
10211063|NCT05218421||Participants|Patients with a carotid artery stenosis ≥50% according to clinically performed imaging (i.e. duplex, computed tomography angiography (CTA), or magnetic resonance angiography (MRA)) that are scheduled for a CEA.
10211064|NCT05218408|Experimental|Phase 1Surgical rGBM CYNK-001 infusion ( IV and IC) in combination with IL-2|Phase 1 dose escalation will utilize a 3+3 dose escalation design and will evaluate safety, feasibility, and preliminary efficacy of four cohort dose levels of CYNK-001 administered after a 6M IU subcutaneous dose of rhIL-2 for both IV and IC cycles. Up to 21 patients will be enrolled over 4 dosing cohorts in Phase 1.
10211065|NCT05218408|Experimental|Phase IIa Surgical rGBM CYNK-001 at MPD IV and IC|To evaluate efficacy and safety of CYNK-001 administrations in recurrent GBM at maximum tolerated dose for IV and IC per Phase 1 outcome. No patients staggering will be implemented in phase 2a. DMC will review the phase 2a entirely
10211066|NCT05218369||Critically ill COVID-19 patients|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) IL-6 antagonist therapy at the consultant's discretion.
10211067|NCT05218356|Experimental|Codivir treatment|20 mg administrated by subcutaneous (SC) injection, twice a day, for 7 days
10211068|NCT05218356|Placebo Comparator|Placebo treatment|Placebo administrated in subcutaneous (SC) injection, twice a day, for 7 days
10211069|NCT05218317||MS-Relapse|"Twenty-seven patients (MS-Relapse) for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse.~The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings These subjects underwent Corneal Confocal Microscopy (IVCM)."
10211070|NCT05218317||MS-Control|"Thirty-one patients (MS-Control) who were followed up with the diagnosis of RRMS The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings.~These subjects underwent Corneal Confocal Microscopy (IVCM)."
10211071|NCT05218317||Healthy Controls|Thirty healthy age and gender similar population These subjects underwent Corneal Confocal Microscopy (IVCM).
10211072|NCT05218304|No Intervention|Sample|questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure)
10211073|NCT05218304|Experimental|Sub-sample - blood test|questionnaires physical measurements (height, weight, perimeter abdominal and blood pressure) Blood samples
10211074|NCT05218278||Patients with favorable neurlogical outcome|CPC 1/2
10211075|NCT05218278||Patients with non-favorable neurological outcome|CPC3-5
9870534|NCT00258050|Experimental|Subjects with cancer|"In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.~In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study."
9870535|NCT00258076|Experimental|001|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
9986628|NCT01404637|Experimental|Tamsulosin 0.4mg|
10211076|NCT05218252|Other|Hand soft tissue defects|Patients with mild to moderate hand soft tissue defects with exposed bone, tendons or cartilage resulting from trauma, tumor ablation or postburn deformities.
9870536|NCT00258115|Active Comparator|salsalate|4.0 g/d divided dosing
10211077|NCT05218239|Active Comparator|Routine education group|Routine education, including postpartum lifestyle, Kegel exercise and Knack method.
10211078|NCT05218239|Experimental|Global training group|Global training was added on the basis of routine education.
10211079|NCT05218226|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take Avatrombopag at the indicated dose.
9870537|NCT00258115|Placebo Comparator|placebo|placebo for salsalate
9870538|NCT00258245|Experimental|Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day
10211080|NCT05218200|Experimental|experimental group|In addition to the routine care in the hospital, the patient will be given deep breathing and coughing exercises.
10211081|NCT05218200|No Intervention|Control group|There will be no intervention other than routine nursing care practices in the hospital.
10211082|NCT05218174|Experimental|Exercise training program|"Participants in this arm will complete an 8-week exercise training program comprised of an initial functional assessment to create an exercise prescription, followed by 7 in-person weekly sessions. Each session consisting of approximately 50 minutes of individualized exercise training and approximately 10 minutes of cognitive training via the Sports Academy CogPT iPad app. All participants will receive exercise and cognitive training delivered weekly in a group-based setting at Sports Academy within the Star in Frisco, Texas during the intervention period. Additionally, they will have access to daily workouts pushed to their phone via the MOVE exercise app developed by our team."
9870539|NCT00258284|Experimental|Docetaxel & Capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
9870540|NCT00258388|Active Comparator|OGX011, Docetaxel and Prednisone|
9870541|NCT00258388|Active Comparator|Docetaxel plus prednisone|
9870542|NCT00258401|Active Comparator|low-residue diet|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.
10211083|NCT05218174|Sham Comparator|No training program|Participants in this arm will be wearing the WHOOP band for 8-weeks but will not be exposed to any active intervention.
10211084|NCT05218161|Active Comparator|DA|Group DA: will be assigned to patients in whom dexmedetomidine alone will be used.
10211085|NCT05218161|Experimental|KD|Group KD: will be assigned to patients receiving ketamine plus dexmedetomidine.
10211086|NCT05218135||Intervention|Breakthrough improvement collaborative
10211087|NCT05218122||LKD syndrome|liver and kidney deficiency syndrome
10211088|NCT05218122||PBS syndrome|phlegm and blood stasis syndrome
10211089|NCT05218122||NC group|Normal Control group
10211090|NCT05218044|Other|Cryoablation|Phase I, single-arm study to evaluate the ability of cryoablation to achieve complete ablation of DCIS in the cryoablation zone of necrosis as a potential alternative to surgery.
10211091|NCT05218031|Experimental|ACT Intervention|"5-week ACT Group Intervention based on the Self-Help Booklet by the World Health Organization Doing What Matters in Times of Stress: An Illustrated Guide."
10211092|NCT05218031|No Intervention|Control group|Waiting-list
10211093|NCT05218018|Other|Intervention|Only one arm of study
10211094|NCT05217992||Carriers or potential carriers of hemophilia A and B|All obligate and potential carriers among families of patient with hemophilia followed at the hemophilia treatment center of the Cliniques universitaires Saint-Luc, Brussels. Belgium
10211095|NCT05217979|Active Comparator|Transcutaneous pulsed radiofrequency|After signing informed consent, patients assigned to the intervention group by randomization will receive a single treatment with transcutaneous pulsed radiofrequency.
10211096|NCT05217979|Sham Comparator|Sham|After signing informed consent, patients assigned to the sham group by randomization will receive a single treatment with sham, which is indistinguishable from the active treatment. This is achieved by putting the device in demo mode, which gives all the same audiovisual signals as the active mode, but no treatment. Given that the treatment is not felt by patients, this ensures blinding.
10211097|NCT05217966|Experimental|Preoperative radiotherapy for early breast cancer|Radiation: Single Pre-Operative Radiation Therapy
10211098|NCT05217940||Women With Prior HPV for Anal Neoplasia|Standard of care anal cancer screening with anal cytology, HPV testing and high resolution anoscopy.
10211099|NCT05217771|Experimental|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
10211100|NCT05217771|Experimental|control group|Patients in control group will receive high tone sham therapy 3 times per week and self-stretch for hand and shoulder.
10211101|NCT05217732|Experimental|Single dose of ZX-7101A treatment A|Administrated as a single oral dose in healthy subjects
10211102|NCT05217732|Experimental|Single dose of ZX-7101A treatment B|Administrated as a single oral dose in healthy subjects
9870543|NCT00258401|Active Comparator|no dietary intervention|At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.
9870544|NCT00258479|Experimental|Modafinil|
9870545|NCT00258479|Placebo Comparator|Placebo|
9870546|NCT00258479|No Intervention|Nicotine Replacement Therapy|The effects of nicotine replacement therapy will be investigated - alone and in combination with modafinil - on nicotine withdrawal in nicotine-dependent adolescents.
9870547|NCT00258518||1|ALI/ARDS patients
9870548|NCT00258557|Experimental|002|TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
9870549|NCT00258557|Active Comparator|001|LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
9870550|NCT00258661|Experimental|Osteopathic Manipulative Treatment|10-minute standardized OMT protocol + 5-minute nonstandardized component, twice daily for duration of hospitalization
9870551|NCT00258661|Sham Comparator|Light-touch Treatment|10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs, twice daily for duration of hospitalization
9870552|NCT00258661|No Intervention|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
9870553|NCT00258687|Experimental|Treatment Arm A|GVAX for Sarcoma / Renal Cell Patients
9870554|NCT00258687|Experimental|Treatment Arm B|GVAX for Pediatric Melanoma Patients
9870555|NCT00258713|Active Comparator|1|
9870556|NCT00258713|Active Comparator|2|
9870557|NCT00258713|Active Comparator|3|
9870558|NCT00258739|Experimental|1|Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
9870559|NCT00258739|Experimental|2|docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
9870560|NCT00258752|Experimental|1|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
9870561|NCT00258752|Experimental|2|Enhanced IPT-AST
9870562|NCT00258752|Active Comparator|3|Typical school counseling
9870563|NCT00258765|Experimental|Zoledronic Acid|
9870564|NCT00258765|Active Comparator|Docetaxel|
9870565|NCT00258843|Experimental|Group 1|Children at 18 months of age
9870566|NCT00258843|Experimental|Group 2|Infants at 2 months of age
9870567|NCT00258869||1|Emergency department patients with sepsis
9870568|NCT00258934|Experimental|1|
9870569|NCT00258934|Active Comparator|2|
9870570|NCT00259038|Experimental|Experimental Drug|
9870571|NCT00259038|Placebo Comparator|Placebo|
9870572|NCT00259064|Experimental|Gefitinib|ZD1839 + BSC (best supportive care)
9870573|NCT00259064|Placebo Comparator|Placebo|Placebo + BSC (best supportive care)
9870574|NCT00259103|Experimental|7.5 µg/kg/d|Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.
9870575|NCT00259103|Experimental|25 µg/kg/d|Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.
9870576|NCT00259103|Experimental|75 µg/kg/d|Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.
9870577|NCT00259103|Experimental|Placebo|Participants who received IV infusion of placebo, some during part A and others during part B.
9870578|NCT00259129|Experimental|Arm 1|
9870579|NCT00259194|Active Comparator|Alternative Observation|Moving in bed during observation after coronary angiography
9870580|NCT00259194|Experimental|Standard Observation|No moving in bed during observation after coronary angiography
9870581|NCT00259207|Active Comparator|classic surgery|classic surgery
9870582|NCT00259207|Experimental|medical surgery hybride|medical surgery hybride
9870583|NCT00259220|Experimental|drug|erythromycine
9870584|NCT00259220|Other|2|gastric lavage alone
9870585|NCT00259220|Active Comparator|3|erythromycine and gastric lavage
9870586|NCT00259324|Experimental|1|Diet and Activity
9870587|NCT00259324|Experimental|2|Diet and Activity
9870588|NCT00259324|Placebo Comparator|3|Education
9870589|NCT00259337|Experimental|1|
9870590|NCT00259376|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
9870591|NCT00259376|Experimental|Placebo|matching placebo tablets
9870592|NCT00259402|Experimental|Oxaliplatin|
9870593|NCT00259428|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
9870594|NCT00259428|Placebo Comparator|Placebo|matching placebo tablets
9870595|NCT00259519|No Intervention|1|Expectant management
9870596|NCT00259519|Active Comparator|2|Induction of delivery
9870597|NCT00259688|No Intervention|1|Women with gestational hypertension
9870598|NCT00259688|No Intervention|2|Women with uncomplicated pregnancies
9870599|NCT00259688|No Intervention|3|Re-test of women one to two years post-partum.
9935873|NCT03049475||Subjects in steady State|Steady state is defined as the period from at any time 8 weeks prior to or after a crisis and samples obtained during this time would be considered steady state samples .
9935874|NCT03049462|Experimental|Cohort 1|Females taking 100 mg of mirabegron
9935875|NCT03049462|Active Comparator|Cohort 2A|Males taking 200 mg mirabegron
9935876|NCT03049462|Placebo Comparator|Cohort 2B|Males taking placebo drug
9870600|NCT00259714|Active Comparator|standard dialysate sodium|In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
9870601|NCT00259714|Experimental|dialysate sodium individualization|".Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
9870602|NCT00259727||1|
9870603|NCT00259753|Experimental|1|0.2 mg/eye
9870604|NCT00259753|Experimental|2|1.5 mg/eye
9870605|NCT00259753|Experimental|3|3.0 mg/eye
9870606|NCT00259805|Experimental|IV Infusion|
9870607|NCT00259883|Experimental|paroxetine|paroxetine 20 to 40mg/day
10211103|NCT05217732|Experimental|Single dose of ZX-7101A treatment C|Administrated as a single oral dose in healthy subjects
9870608|NCT00259909||Subjects with COPD|Subject has a confirmed clinical diagnosis of COPD, with or without chronic bronchitis.
9870609|NCT00259922|Placebo Comparator|Placebo|
9870610|NCT00259922|Experimental|Alvimopan 0.5 mg once daily|0.5 mg once daily (QD)
9870611|NCT00259922|Experimental|Alvimopan 0.5 mg twice daily|0.5 mg twice daily (BID)
9870612|NCT00259935|Experimental|All treated subjects|Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.
9870613|NCT00259974|Experimental|1|Rituximab
9870614|NCT00260039|Active Comparator|1|Gardasil
9870615|NCT00260039|Experimental|2|HPV VLP vaccine -Dose regimen 1
9870616|NCT00260039|Experimental|3|HPV VLP vaccine -Dose regimen 2
9870617|NCT00260039|Experimental|4|HPV VLP vaccine -Dose regimen 3
9870618|NCT00260091|Active Comparator|I.|Conventional infertility therapy
9870619|NCT00260091|Active Comparator|II.|Fast track to in vitro fertilization therapy
9870620|NCT00260130|Active Comparator|1|Consuming fruit and vegetable juice
9870621|NCT00260130|Active Comparator|2|Consuming whole fruits and vegetables
9870622|NCT00260143|Experimental|Testosterone enanthate|300 mg of testosterone enanthate by intramuscular injection once weekly for 16 weeks
9870623|NCT00260143|Placebo Comparator|Placebo|Placebo (sesame oil) by intramuscular injection once weekly for 16 weeks
9870624|NCT00260169|Experimental|1|Participants will receive collaborative care
9870625|NCT00260169|Active Comparator|2|Participants will receive enhanced usual care
9870626|NCT00260221|Experimental|1|Arm one uses Virtual Reality Hypnosis post hypnotic suggestions to reduce pain durng wound care procedures.
9870627|NCT00260221|Experimental|2|Arm two uses Virtual Reality distraction that is administered at times other than during burn care procedure to control for both for attention and high technology.
9870628|NCT00260221|Experimental|3|Arm three use Audio administered Hypnosis without the visual technology.
9870629|NCT00260234|Experimental|PEG Islet Cells|
9870630|NCT00260273|Active Comparator|1|cognitive Behavioural Therapy
9870631|NCT00260273|No Intervention|2|supportive therapy
9870632|NCT00260338|Active Comparator|Mesenchymal stromal cell|Mesenchymal stromal cell
9870633|NCT00260351|Experimental|Group 1|Participants on Thai Red Cross, TRC-ID regimen
9870634|NCT00260351|Experimental|Group 2|Participants on Zagreb-IM regimen
9870635|NCT00260351|Experimental|Group 3|Participants on Essen-IM regimen.
9870636|NCT00260442|Placebo Comparator|Placebo|< 200 mg/day dietary cholesterol, resistance training, sedentary
9870637|NCT00260442|Experimental|Average intake|400 mg/day dietary cholesterol, resistance training, sedentary
9870638|NCT00260442|Experimental|High intake|800 mg/day dietary cholesterol, resistance training, sedentary
10211104|NCT05217732|Experimental|Single dose of ZX-7101A treatment D|Administrated as a single oral dose in healthy subjects
10211105|NCT05217732|Experimental|Single dose of ZX-7101A treatment E|Administrated as a single oral dose in healthy subjects
10211106|NCT05217732|Experimental|ZX-7101A food effect|Administered as a selected, single oral dose of ZX-7101A in fasting state and non-fasting (with food) state.
10211107|NCT05217719|Experimental|the TPO group|Patients in TPO group will be treated with rhTPO at a dose of 15000u/d, subcutaneous injection, for 7 consecutive days.
10211108|NCT05217719|Placebo Comparator|the control group|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously, for 7 consecutive days.
10211109|NCT05217693|Experimental|dose escalation|Drug: BB-1705 BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
10211110|NCT05217693|Experimental|cohort expansion|BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
10211111|NCT05217602|Experimental|AC+ARwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards only if they meditate using their anchoring plan on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
10211112|NCT05217602|Experimental|AC+RwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards if they meditate on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
9935346|NCT03867383|Experimental|Calcium Chloride|"Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
9986629|NCT01404637|Active Comparator|tamsulosin 0.2mg|
9986630|NCT01404663|Experimental|stem cell recipients|The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation
9986631|NCT01404676|Experimental|Vildagliptin + Metformin|Adding Vildagliptin to metformin users
9986632|NCT01404676|Active Comparator|Glimepiride + Metformin|Adding Glimepiride to metformin users
9986633|NCT01404689|Experimental|Midazolam-Meperidine-Dexmedetomidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
9986634|NCT01404689|Sham Comparator|Midazolam-Meperidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
9986635|NCT01404702|Experimental|Zoledronic Acid and Interleukin-2|
9986636|NCT01404715|Experimental|Metformin and Imatinib Co-Adminisdered|Subjects will be dosed with Metformin (1850 mg) in conjunction with imatinib (600mg).
9986637|NCT01404715|Experimental|Metformin Alone|Subjects will be dosed with Metformin alone (1850mg)
9986638|NCT01404728||Pelvic Malignancies|Women with Vaginal Stenosis
9986639|NCT01404741|Active Comparator|5-azacytidine treatment until progress|5-azacytidine until progress
9986640|NCT01404741|Experimental|allogeneic stem cell transplantation|after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning
9986641|NCT01404767|Active Comparator|Metoprolol oral dose or Placebo infusion|
9986642|NCT01404767|Experimental|Esmolol infusion or Placebo oral dose|
9986643|NCT01404780|Experimental|The GlideScope (GVL)|
9986644|NCT01404780|Active Comparator|Macintosh direct laryngoscope (MDL)|
9986645|NCT01404793||Liver transplant recipient|
9986646|NCT01404806|Experimental|GSK1349572|
9986647|NCT01404819|Experimental|Experimental arm|Patients in this arm undergo anesthesia with Xenon.
9986648|NCT01404819|Active Comparator|Standard arm|Patients in this arm undergo standard anesthesia
9986649|NCT01404845|Active Comparator|B: patients with wet AMD in one eye.|group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.
9986650|NCT01404845|Active Comparator|A :patients without retinal pathology|"group A :patients without retinal pathology who underwent cataract surgery 1 month previously.~In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin."
9986651|NCT01404858||Patients undergoing IVF|
9986652|NCT01404871|Active Comparator|Randomization to ECIT or CMI|Randomized trial of clomipramine or escitalopram
9986653|NCT01404871|Active Comparator|Open label Duloxetine|Open label trial of duloxetine
9986654|NCT01404884|Experimental|SUPRACOR|Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
9986655|NCT01404897|Experimental|Dietary Intervention: Control Diet|
9986656|NCT01404897|Experimental|Dietary Intervention: DASH-based diet|
9986657|NCT01404897|Experimental|Dietary Intervention: Modified DASH diet|
9986658|NCT01404910|Experimental|Apheresis|Apheresis using Liposorber LA-15 System
9986659|NCT01404962|Other|Group 1|
9986660|NCT01404975|Experimental|Paravertebral Block|Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
9986661|NCT01404975|Active Comparator|Standard intravenous opioid analgesia|"Patient Controlled Analgesia (PCA) :~PCA: the patients who are randomized to PCA group will receive standard of care for this modality."
9986662|NCT01405014|Experimental|Relationship enhancement group|One group, all involved in the intervention
9870639|NCT00260481|Placebo Comparator|Control Group|During the Infusion periods, participants in the placebo condition will receive pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg), delivered at the same rate and delivery system to match the active condition. All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
9870640|NCT00260481|Active Comparator|Prometa|During the infusion periods, participants assigned to the PROMETA pharmacotherapy condition will receive pre-treatment with hydroxyzine (50mg) followed by intravenous flumazenil (2mg) over a 2-hour period. Before bedtime, patients will again take 50mg of hydroxyzine orally, as well as 300mg of oral gabapentin (participants will titrate up their dosage of gabapentin each day - 300mg on day 0, 600mg on day 1, 900mg on day 2). All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
9870641|NCT00260494|Experimental|acupuncture|acupuncture to lower extremity postoperatively
9870642|NCT00260494|Sham Comparator|sham acupuncture|sham acupuncture at same sites.
9870643|NCT00260494|No Intervention|control|no acupuncture, otherwise the same care and measurements
9870644|NCT00260611|Experimental|Oxaliplatin and Taxotere|Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or >50% increase in serum PSA.
9870645|NCT00260650|Experimental|Heart PACT Program|Heart PACT Program - patient activation intervention
9870646|NCT00260650|No Intervention|Usual Care|Usual Care
9870647|NCT00260663|Other|Arm 1|
9870648|NCT00260676|Other|conventional ventilation, protective ventilation|
9870649|NCT00260728|Experimental|Arm 1|
9870650|NCT00260806||1|Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
9870651|NCT00260806||2|Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
9870652|NCT00260819|Experimental|1|Experimental and Placebo Comparator administered in random order during to successive experimental phase
9870653|NCT00260819|Placebo Comparator|2|Experimental and Placebo Comparator administered in random order during to successive experimental phase
9870654|NCT00260936||HIV-negative|HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
9870655|NCT00260936||HIV-positive, has never been on ART|HIV-positive, has never been on ART
9870656|NCT00260936||HIV-positive, non PI containing NNRTI-based regimen|HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
9870657|NCT00260936||HIV-positive, non-NNRTI-containing PI-based regimen|HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
9870658|NCT00260975||Chemotherapy patients|Breast cancer patients treated with adjuvant chemotherapy of various types.
9870659|NCT00260975||Hormonal patients|Breast cancer patients treated with adjuvant hormonal therapy but not chemotherapy.
9870660|NCT00260988|Active Comparator|Dalteparin|Dalteparin 200 IU/kg/day for three days prior to surgery and dalteparin 5000IU daily for 3-5 days post-surgery
9870661|NCT00260988|Active Comparator|Tinzaparin|Tinzaparin 175 IU/kg/day for three days prior to surgery and Tinzaparin 4500 IU for 3-5 days post surgery
9870662|NCT00261001|Experimental|Transcutaneous|
9870663|NCT00261001|Active Comparator|Intramuscular|
9870664|NCT00261053|Other|1|Open-label i.v. administration of 100 U/kg rhC1INH
9870665|NCT00261118|Active Comparator|1 (i)|Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
9870666|NCT00261118|Placebo Comparator|2 (ii)|500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
9870667|NCT00261170|Active Comparator|1|bupropion and behavioral counseling
9870668|NCT00261170|Placebo Comparator|2|placebo medication
9870669|NCT00261196|Experimental|Collagenase|Collagenase Injection
9870670|NCT00261196|Placebo Comparator|Placebo|Placebo Injection
9870671|NCT00261209|Experimental|Collagenase Injection|Injection of collagenase into adhesion restricting tendon gliding
9928451|NCT00906620|Experimental|ProfScreen|The program's primary objective is to help young people and their parents through the early identification of mental health problems, such as anxiety, depression, substance abuse, and suicide. Screening strategies are based on the valid premise that suicidal adolescents are under-identified, suffer from an active, often treatable mental illness such as depression and exhibit identifiable risk factors (Gould et al. 2003). A potential shortcoming of screening programs is that asking about suicide could increase suicidal ideation and behaviour. About this issue a recent study (Gould et al . 2005) on over 2300 students reported no evidence of iatrogenic effects of suicide screening and that screening in high schools is a safe component of youth suicide prevention efforts.
9986663|NCT01405040||EV1000 Observational Group|Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.
9986664|NCT01405079|Experimental|Gefitinib|Gefitinib 250 mg/day oral daily
9986665|NCT01405079|Active Comparator|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
9986666|NCT01405092|Placebo Comparator|Standard volume management|patients on this arm will receive usual care volume management during continuous renal replacement therapy
9986667|NCT01405092|Active Comparator|continuous volume management|use of Critline, Hemametrics USA, in conjunction with continuous renal replacment therapy to determine volume removal
9986668|NCT01405105||Patients with Flares of IBD|Active flare of Crohn's or UC
9986669|NCT01405105||Control Group|Patients with quiescent Crohn's disease or UC
9986670|NCT01405118|Experimental|Metformin/CP-690,550|
9986671|NCT01405131|Experimental|methylprednisolone suspension|
9986672|NCT01405131|Active Comparator|methylprednisolone tablets|
9986673|NCT01405144|Active Comparator|5% 5-fluoruracil cream|30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
9986674|NCT01405144|Active Comparator|5% 5-fluoruracil peeling|The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
9986675|NCT01405157|Experimental|methylprednisolone suspension|
9986676|NCT01405157|Active Comparator|methylprednisolone tablets|
9986677|NCT01405170|Experimental|methylprednisolone suspension|
9986678|NCT01405170|Active Comparator|methylprednisolone tablets|
9986679|NCT01405183||Renal Cell Carcinoma patients|Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
9986680|NCT01405183||Colorectal cancer patients|Newly diagnosed (6 months) colon cancer patients
9986681|NCT01405209||Atrial Fibrillation|Patients who develop atrial fibrillation
9986682|NCT01405209||Non Atrial FIbrillation|Patients without atrial fibrillation
9986683|NCT01405222||Acute COPD exacerbation|Patients admitted in to hospital with an acute exacerbation of COPD
9986684|NCT01405235|Active Comparator|Arm B: Cisplatin/Topotecane|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
9986685|NCT01405235|Experimental|Arm A: Paclitaxel/Topotecan|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
9986686|NCT01405248|Experimental|Butylphthalide|Single center of the placebo control a double-blind randomized control study to evaluate Butylphthalide prevention stents restenosis effect
9986687|NCT01405248|Placebo Comparator|control|Placebo
9986688|NCT01405261|Experimental|NNC 0113-0987 (gastro)|
9986689|NCT01405261|Experimental|NNC 0113-987 (coated)|
9986690|NCT01405261|Experimental|NNC 0113-987 (i.v)|
9986691|NCT01405274|Experimental|Physiotherapy intervention|
9986692|NCT01405274|No Intervention|standard care|
9986693|NCT01405287|Experimental|Combo Stent|PTCA with Combo Stent
9986694|NCT01405287|Active Comparator|Everolimus Eluting Stent (EES)|PTCA with DES (Everolimus Eluting Stent: Xience V or Promus)
9986695|NCT01405300|Experimental|Peanut|
9986696|NCT01405300|Placebo Comparator|Control|
9986697|NCT01405326|Experimental|Adalimumab|Adalimumab treatment for 6 months
9986698|NCT01405326|Placebo Comparator|Pacebo|Corresponding placebo for active treatment group
9986699|NCT01405339|Experimental|Budesonide via MAD|The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
9986700|NCT01405339|Active Comparator|Budesonide via Sinus Rinse Bottle|Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
9986701|NCT01405352|Active Comparator|Non obese/ vitamin A|Non obese individuals with body mass index 18.5-24.9 kg/m2 who receive 25000 IU/day vitamin A for 4 months .
9986702|NCT01405352|Placebo Comparator|obese/ placebo|obese individuals with body mass index greator than 30 kg/m2 who receive 1 cap placebo per day for 4 months .
9986703|NCT01405352|Active Comparator|Obese/ vitamin A|obese individuals with body mass index greater than 30 kg/m2 who receive 25000 IU/day vitamin A for 4 months
9986704|NCT01405365|Experimental|Metronidazole|
9986705|NCT01405365|Placebo Comparator|Placebo|
9986706|NCT01405378|Experimental|Robot Therapy and Real Transcranial Direct Current Stimulation|This group will involve carrying out robot therapy and real transcranial Direct Current Stimulation (tDCS).
9986707|NCT01405378|Placebo Comparator|Robot Therapy and sham tDCS|Participants will be randomised to group 2 whereby they will carry out the same robot therapy programme however, receiving sham stimulation.
9986708|NCT01405391|Experimental|A|Patients will receive PM01183 on Days 1 and 8 q3wk (three weeks = one treatment cycle) as an i.v. infusion, starting at 3.0 mg/day, flat dose (FD), over a minimum total volume of 100 ml dilution (on 5% glucose or 0.9% sodium chloride) via a central catheter or over a minimum total volume of 250 ml via a peripheral line, over one hour (at a fixed rate) and through a pump device.
9986709|NCT01405404|No Intervention|No intervention control|Parents complete surveys only
9986710|NCT01405404|Experimental|parent training but no discount|parent enrolled in the parent training intervention but do not receive childcare discounts for attending
9986711|NCT01405404|Experimental|Parent training with discount|parents receive parent training and a childcare discount for attending
10211113|NCT05217602|Active Comparator|Usual Calm Control (UC)|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; $20 incentive for completing the baseline, week 8, and week 16 surveys
10211114|NCT05217576|Other|Comparison|"Comparison study:~The participants (at least 300) will be tested once with each of the 3 devices. First, a measurement with the NBM-200 will be performed according to the user manual. The best finger to use, in order of preference: 1) right thumb 2) left thumb 3) right index 4) left index.~The POC capillary test will follow the NBM-200 test, and the venous test will be performed last. A venous blood sample will be obtained from all participants in the comparison study, even if a subject is designated to donate and is deferred from donation because of low hemoglobin."
9517640|NCT03304457|Active Comparator|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
9870672|NCT00261274|Experimental|Test Group A-ECO|
9870673|NCT00261274|Placebo Comparator|Control Group|
9870674|NCT00261300|Experimental|1|Pantoprazole 40 mg
9870675|NCT00261313|Experimental|Aranesp|
9870676|NCT00261313|Experimental|Neulasta|
9870677|NCT00261326|Active Comparator|B|simvastatin tablets 80 mg daily
9870678|NCT00261326|Placebo Comparator|A|calcium tablets 80 mg
9870679|NCT00261365|Active Comparator|A1|
9870680|NCT00261365|Active Comparator|A2|
9870681|NCT00261378|Active Comparator|Transarterialchemoembolisation (TACE)|Conventional TACE with doxorubicin
9870682|NCT00261378|Other|DC Bead|DC Bead with doxorubicin
9870683|NCT00261547|Experimental|Rituximab|this study has only one arm as the treatment group
9870684|NCT00261690|Experimental|1|Virtual Reality distraction
9870685|NCT00261703|Experimental|1|(Docetaxel + Cisplatin + 5-FU) + Cisplatin + Radiotherapy
9870686|NCT00261703|Experimental|2|(Cisplatin + 5-FU) + Cisplatin + Radiotherapy
9870687|NCT00261703|Experimental|3|Cisplatin + Radiotherapy
9870688|NCT00261729|Experimental|1|paroxetine
9870689|NCT00261729|Placebo Comparator|2|placebo
9870690|NCT00261729|Experimental|3|prazosin
9870691|NCT00261755|Experimental|Acupuncture Group|Acupuncture treatment during labor
9870692|NCT00261755|Active Comparator|TENS Group|Transcutaneous Electric Nerve Stimulation (TENS treatment)during labor
9870693|NCT00261755|Active Comparator|Traditional Group|Traditional pain treatment during labor
9870694|NCT00261768|Experimental|1|Noise reduction on
9870695|NCT00261781|Experimental|Treadmill training|Home-based treadmill training
9870696|NCT00261781|No Intervention|Usual care|Control group
9870697|NCT00261794|Experimental|1|computer-assisted cognitive remediation (CACR)
9870698|NCT00261794|Active Comparator|2|computer-based cognitive activity
9870699|NCT00261859|No Intervention|SCA|Standard Care with Assessment
9870700|NCT00261859|No Intervention|SCNA|Standard Care No Assessment
9870701|NCT00261859|Experimental|BNI|Brief Negotiated Interview
9870702|NCT00261859|Experimental|EBNI|Enhanced Brief Negotiated Interview
9870703|NCT00261924|Experimental|Intercept Platelets|Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system
9870704|NCT00261924|Active Comparator|Conventional Platelets|Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system
9870705|NCT00261976||Patients in infliximab clinical studies|All patients enrolled in selected Centocor sponsored infliximab clinical studies.
9870706|NCT00262054|Experimental|A|bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
9870707|NCT00262054|Active Comparator|B|UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
9870708|NCT00262288|Experimental|Recombinant Human C1INH|
9870709|NCT00262340|Experimental|1|This arm will have treatment changed based on measures of inflammation
9870710|NCT00262340|Active Comparator|2|Treatment will be changed on the basis of reported asthma symptoms
9870711|NCT00262379|No Intervention|Group A|HCV treatment with peginterferon plus ribavirin during 48 weeks
9870712|NCT00262379|Active Comparator|Groupb|HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions
9870713|NCT00262392|Experimental|Pamidronate|Pamidronate
9870714|NCT00262392|Active Comparator|radiation|radiation
9870715|NCT00262405|Experimental|zileuton|Zileuton
9870716|NCT00262405|Active Comparator|azathioprine/prednisone|azathioprine/prednisone
9870717|NCT00262431|Active Comparator|Early (A)|Patients of the EARLY group (A) will be submitted to tracheostomy on day 3-5 from oro/nasotracheal intubation.
9870718|NCT00262431|Active Comparator|Late (B)|Patients of the LATE group (B) will undergo tracheostomy on day 10-12 from oro/nasotracheal intubation.
9870719|NCT00262457|Other|Arm 1|
9870720|NCT00262470|Experimental|1|Acetazolamide
9870721|NCT00262470|Experimental|2|Atomoxetine
9870722|NCT00262470|Experimental|3|NO Drug
9870723|NCT00262470|Experimental|4|Clonidine
9870724|NCT00262470|Experimental|5|Entacapone
9870725|NCT00262470|Experimental|6|Indomethacin
9870726|NCT00262470|Experimental|7|Isosorbide Dinitrate
9870727|NCT00262470|Experimental|8|Mecamylamine
9870728|NCT00262470|Experimental|9|Memantine
9870729|NCT00262470|Experimental|10|Melatonin
9870730|NCT00262470|Experimental|11|Midodrine
9870731|NCT00262470|Experimental|12|Modafinil
9870732|NCT00262470|Experimental|13|Octreotide
9870733|NCT00262470|Placebo Comparator|14|Placebo (lactose tablet)
9870734|NCT00262470|Experimental|15|Propranolol
9870735|NCT00262470|Experimental|16|Sertraline
9986712|NCT01405417|Experimental|Peroral endoscopic myotomy|"Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips."
9986713|NCT01405430|Experimental|Bevacizumab + blood samples|
9986714|NCT01405443||Basic training|Theory lecture esophagogastroduodenoscopy (EGD). One hour simulator training for EGD. 30 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. One hour simulator training for Colonoscopy. 30 minutes supervised training. Supervised endoscopy. Group will be followed up for 2 weeks training time.
9986715|NCT01405443||Intermediate training|Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
9986716|NCT01405443||Extended training|Theory lecture EGD. Five hours simulator training for EGD. 90 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Five hours simulator training for Colonoscopy. 90 minutes supervised training. Supervised endoscopy. Group will be followed up for 6 weeks training time.
9986717|NCT01405482|Active Comparator|Botulinum Toxin Type A injection|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of BTX-A into the scalene muscles and pectoralis minor muscle under EMG guidance.
9986718|NCT01405482|Placebo Comparator|Normal Saline|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of placebo into the scalene muscles under EMG guidance.
9986719|NCT01405495||PTSD group|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
9986720|NCT01405495||Exposed without PTSD|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
9986721|NCT01405495||Healthy Controls|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
9986722|NCT01405521|Experimental|M01ZH09 vaccine|
9986723|NCT01405521|Placebo Comparator|Vaccine placebo|
9986724|NCT01405521|Other|Ty21a vaccine|Positive control
9986725|NCT01405534||Central venous catheter|All patients who require the placement of a central venous catheter
9986726|NCT01405573|Active Comparator|A: Best Supportive Care|best supportive care
9986727|NCT01405573|Experimental|B: Sorafenib 400 mg, twice a day + Best Supportive Care|sorafenib + best supportive care
9986728|NCT01405586|Active Comparator|gemcitabine|
9986729|NCT01405586|Experimental|gemcitabine + cisplatin|
9986730|NCT01405599|Experimental|Control|Healthy subjects
9986731|NCT01405599|Experimental|Severe hepatic impairment|CTP class C
9986732|NCT01405599|Experimental|Moderate hepatic impairment|CTP class B
9986733|NCT01405599|Experimental|Mild hepatic impairment|CTP class A
9986734|NCT01405612|Experimental|Midazolam|Those subjects to receive Treatment A will receive a single dose of midazolam on Day 1 and will be discharged from the study unit on Day 2, at least 30 hours after midazolam dosing.
9986735|NCT01405612|Experimental|Ulimorelin|Those subjects to receive Treatment B will receive once daily ulimorelin on Days 1 to 5. Midazolam will be administered on Day 5 with the last dose of ulimorelin and subjects will be discharged from the study unit on Day 6, at least 30 hours after midazolam dosing.
9986736|NCT01405625|Active Comparator|AAAAI Action Plan|Asthma Action Plan from the American Academy of Allergy, Asthma, and Immunology
9986737|NCT01405625|Experimental|Asthma pictogram written action plan|Cartoon/pictogram-based written action plan sheet
9986738|NCT01405638|Experimental|Motivational Interviewing|The use of a one-on-one motivational interviewing counseling intervention, 4 visits over 5 months, focusing on changes to behavior related to blood pressure control.
9986739|NCT01405638|Experimental|Patient Navigation|The use of a patient navigation intervention to guide participants through the process of getting screened for colorectal cancer.
9986740|NCT01405638|Experimental|PLUS|This group receives both the motivational interviewing intervention and the patient navigation intervention.
9986741|NCT01405651|Experimental|E|ONO-6950
9986742|NCT01405651|Placebo Comparator|P|Placebo
9986743|NCT01405664|No Intervention|Non-Weight Bearing x 6 weeks|
9986744|NCT01405664|Experimental|Immediate Weight-Bearing as Tolerated|
9986745|NCT01405677|Experimental|Epaxal 0.25 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
9986746|NCT01405677|Active Comparator|Epaxal 0.5 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
9986747|NCT01405677|Active Comparator|Havrix Junior|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
9986748|NCT01405703||percuataneous plate fixation|an approach with three small longitudinal incisions
9986749|NCT01405703||open plate fixation|large transverse incision
9986750|NCT01405716|Active Comparator|Behavioral-Mindfulness|Mindfulness Meditation
9986751|NCT01405716|Placebo Comparator|Behavioral-Health|Health Education Class
9986752|NCT01405755|Experimental|National Vaccine Program Plus Radio|Appropriate complementary feeding messages delivered using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio.
9986753|NCT01405755|No Intervention|Comparison (no intervention)|No complementary feeding messages delivered.
9870736|NCT00262470|Experimental|17|Normal Saline (0.9%) 1 liter
9870737|NCT00262470|Experimental|18|Drinking Water
9870738|NCT00262470|Experimental|19|Dead Space Breathing Device
9870739|NCT00262470|Experimental|Abdominal Binder|Abdominal binder with inflatable pressure over abdomen
9870740|NCT00262561|Active Comparator|Aspirin|All participants get Aspirin, and platelet reactivity measurements are performed.
9870741|NCT00262587|Placebo Comparator|Placebo|Placebo inhaler (sugar powder)
9870742|NCT00262587|Active Comparator|Seretide|Seretide inhaler
9870743|NCT00262665|Experimental|Org 24448|ampa receptor potentiator for the treatment of MDD
9870744|NCT00262665|Placebo Comparator|Placebo|matching placebo pill
9870745|NCT00262704|No Intervention|Group A|Control group
9870746|NCT00262704|Active Comparator|Group B|Simulated case-based customized learning
9870747|NCT00262704|Active Comparator|Group C|Simulated case based customized learning + leader feedback
9870748|NCT00262769|Experimental|A - Gemcitabine|Gemcitabine alone
9870749|NCT00262769|Experimental|B - Gemcitabine and Cisplatin|Gemcitabine and Cisplatin
9870750|NCT00262782|Experimental|Fludarabine|
9870751|NCT00262782|No Intervention|watch & wait|
9870752|NCT00262795|Experimental|F|Fludarabine
9870753|NCT00262795|Active Comparator|CLB|Chlorambucil
9870754|NCT00262899|Experimental|Rapid genetic counseling|Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
9870755|NCT00262899|No Intervention|Usual Care|Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
9870756|NCT00262938|Active Comparator|Lifestyle counseling|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling.Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
9870757|NCT00262938|Active Comparator|Without Counseling|Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
9870758|NCT00263029|Experimental|1|
9928452|NCT00906620|Experimental|Control group|The control group will comprise 250 subjects. After the baseline assessment, subjects will be randomized in one of the three intervention arms or in the control group. Individuals in the control group will undergo the same baseline and follow-up evaluations as subjects in the intervention arms and will receive the same leaflet about healthy lifestyles with information about the possibility to seek help for unhealthy, suicidal behaviour and mental health problems. In this arm, no additional intervention will be performed although the possibility of seeking help from mental health resources will be available.
9928453|NCT00906633||Outcome of combination antifungal therapy|
9928454|NCT00906646|Experimental|Metabolic therapy|Metabolic therapy with antioxidants and cellular energisers
9928455|NCT00906646|Placebo Comparator|Placebo|Placebo tablets
9928456|NCT00906659||diabetic macular edema|type 2 patients who had been treated with selective photocoagulation for clinically significant macular edema
9928457|NCT00906672|Experimental|INTEGRA®|
9928458|NCT00906672|Active Comparator|Flap technique|
9928459|NCT00906685|Active Comparator|Intravitreal bevacizumab|
9928460|NCT00906685|Sham Comparator|Sham injection|
9928461|NCT00906711||Group I|(G1): 10 - 18 years old
9928462|NCT00906711||Group II|(G2): 20 - 35 years old
9928463|NCT00906711||Group III|(G3): 45 - 60 years old
9928464|NCT00906711||Group IV|(G4): 65 - 85 years old
9986754|NCT01405807|Experimental|Alemtuzumab - high dose (60mg)|Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months
9986755|NCT01405807|Experimental|Alemtuzumab - low dose (30mg)|Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months
9986756|NCT01405833|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010
9986757|NCT01405833|Placebo Comparator|Placebo|Participants may be randomised to a matching placebo
9986758|NCT01405846|Other|Gefitinib|Single arm study
9986759|NCT01405859||TS controls|10
9986760|NCT01405859||Non TS Controls|11
9986761|NCT01405859||TS remission|0
9986762|NCT01405885|Experimental|Arm A - 0.9mg of INO-3605|
9986763|NCT01405885|Experimental|Arm B - 0.9mg of INO-3609|
9986764|NCT01405885|Experimental|Arm C- 0.9mg of INO-3401|
9986765|NCT01405885|Experimental|Arm D- 0.3mg of INO-3609|
9986766|NCT01405885|Experimental|Arm E - 0.45mg each INO-3605 , INO-3609|
9986767|NCT01405885|Experimental|Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609|
9986768|NCT01405885|Experimental|Arm G - 0.9mg of INO-3609|
9986769|NCT01405885|Experimental|Arm H - 0.9mg of INO-3609|
9986770|NCT01405885|Active Comparator|Arm I - Seasonal influenza vaccine|
9986771|NCT01405885|Experimental|Arm J - 1.8mg of INO-3609|
9986772|NCT01405963|Experimental|Active Arm|One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.
9986773|NCT01405963|Placebo Comparator|Placebo Arm|Placebo comparator administered as a multiple IV doses in subjects with mild atopic asthma
9986774|NCT01405976|Active Comparator|1|NIV for severe OSA group
9986775|NCT01405976|Active Comparator|2|CPAP for severe OSA group
9986776|NCT01405976|Active Comparator|3|Life stile modification for severe OSA group
9986777|NCT01405976|Active Comparator|4|NIV for non-severe OSA group
9986778|NCT01405976|Active Comparator|5|Life stile modification for non-severe OSA group
9986779|NCT01405989|Experimental|Treatment arm A|darexaban, wash-out, ketoconazole + darexaban
9986780|NCT01405989|Experimental|Treatment arm B|ketoconazole + darexaban, wash-out, darexaban
9986781|NCT01406002|Experimental|Treatment arm 1|darexaban, wash-out, rifampicin + darexaban
9986782|NCT01406028|No Intervention|Standard of Care|Standard of care includes discharge instructions from one of our IVF nurses regarding medications and timing of follow-up, at which point patients are told what day they need to return for their pregnancy test. Patients have access to phone numbers for their IVF nurses and physicians, as well as information about how to contact the social workers if additional support is needed. They also are provided the emergency phone numbers for after-hour calls to the fellow on call. However, during the time between the embryo transfer and the pregnancy test, the current standard of care is that contact between the patient and our team is patient-initiated.
9986783|NCT01406028|Active Comparator|Intervention phone calls|The intervention consisted of two phone calls from an IVF social worker during the time between embryo transfer and pregnancy test. The first phone call occurred between days 2-4 after transfer and the second phone call occurred between days 5 and 9 after embryo transfer. Standard language for introductions to phone calls and for voice mails was established prior to the start of the study.
9986784|NCT01406041||Diseases|1. Pituitary adenomas; 2. Craniopharyngioma; 3. Sellar germinoma; 4. Sellar tuberalis meningioma; 5. Hypophystis; 6. Sellar glioma; 7. Rathke's cleft cyst; 8. Hypothalamic hamartoma
9986785|NCT01406054|Experimental|neuromuscular training|subjects in this arm will be exposed to a neuromuscular warm-up before practices and games
9986786|NCT01406054|No Intervention|control|
9986787|NCT01406067|Experimental|Social Skills Training|
9986788|NCT01406067|Active Comparator|Play group|
9986789|NCT01406080|Active Comparator|Adapalene|Differin® gel 0.3% (adapalene Gel 0,3%)
9986790|NCT01406080|Active Comparator|Tretinoin|Tretinoin 0,05% emollient cream
9986791|NCT01406093||Candidemia patients|Patients with diagnosis of candidemia
9986792|NCT01406106|Experimental|Liquid yoghurt with plant stanol esters|"Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).~It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg."
9986793|NCT01406106|Placebo Comparator|Yoghurt without plant stanol esters|Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
9986794|NCT01406119|Experimental|ABT-806 Arm|
9986795|NCT01406132|Experimental|ASP015K|
9986796|NCT01406145|Experimental|ASP0777 low dose|ASP0777 low dose for 6 weeks
9986797|NCT01406145|Experimental|ASP0777 low dose, then high dose|ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks
9517641|NCT03304457|Experimental|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
9870759|NCT00263068|Experimental|1|Up to 6.75 mg/day (optimal dosing)
9870760|NCT00263081|Experimental|Lapaquistat Acetate QD|(and current lipid-lowering treatment)
9870761|NCT00263081|Placebo Comparator|Current lipid-lowering treatment|
9870762|NCT00263185|Experimental|Active Treatment Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 8 weeks and then once a month for a total of 6 months."
9870763|NCT00263185|Placebo Comparator|Control Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 8 weeks and then once a month for a total of 6 months."
9870764|NCT00263185|Other|Observational Group|"Patients with a baseline Vitamin D level below 10 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily."
9870765|NCT00263198|Experimental|Letrozole + PTK787/ZK222584|"Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)~Start cycle 1 with:~Letrozole 2.5 mg PO once daily~PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.~Subsequent cycles:~PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily~Letrozole 2.5 mg PO once daily"
9870766|NCT00263276|Experimental|Arm 1|
9870767|NCT00263276|Experimental|Arm 2|
9870768|NCT00263276|Experimental|Arm 3|
9870769|NCT00263276|Experimental|Arm 4|
9870770|NCT00263276|Experimental|Arm 5|
9870771|NCT00263276|Placebo Comparator|Arm 6|
9870772|NCT00263276|Active Comparator|Arm 7|
9870773|NCT00263367|Other|hyperbaric oxygen at 1.3 ATA|Hyperbaric Oxygen at 1.3 ATA for one hour followed by measurement of glutathione in the blood
9870774|NCT00263393|Other|Algorithm-based care|An algorithm based approach to increase the identification of high-risk individuals in the community through encouraging opportunistic screening, and to increase the use of appropriate evidence based prevention strategies.
9870775|NCT00263393|Other|Health-promotion|The health promotion arm has been designed to increase knowledge of the causes of cardiovascular disease and enhance use of preventive behaviours in the general population
9870776|NCT00263432|Experimental|1|Implantation of fresh human allogenic chondrocytes
9870777|NCT00263458|Experimental|Integrated|Buprenorphine maintenance treatment delivered at an HIV primary care clinic
9870778|NCT00263458|Active Comparator|Non-integrated|Buprenorphine maintenance treatment delivered at a public health substance use disorder clinic
9870779|NCT00263484|Experimental|"dtZ regimen, Initial therapy"|"To test the efficacy of the dtZ regimen in previously untreated patients with multiple myeloma."
9870780|NCT00263601|Experimental|Allergovit 6-grasses immunotherapy|Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
9870781|NCT00263601|Placebo Comparator|Placebo|Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
9870782|NCT00263627|Placebo Comparator|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
9870783|NCT00263627|Experimental|Specific Immunotherapy|Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
9870784|NCT00263640|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
9870785|NCT00263640|Experimental|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
9870786|NCT00263705|Experimental|capecitabine|capecitabine 2000 mg/m² daily
9870787|NCT00263731||Group 1 (Experimental Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will receive 13-C-glucose prior to surgery
9870788|NCT00263731||Group 2 (Control Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will not receive 13-C-glucose prior to surgery
9870789|NCT00263731||Group 3 (Healthy Subjects)|250 healthy subjects (must be at least 30 years of age and have no prior history of diagnosed lung cancer) will provide 1 blood sample and 1 urine sample.
9870790|NCT00263744|Experimental|1|MEDI517
9870791|NCT00263744|Active Comparator|2|Aluminum hydroxide
9870792|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
9870793|NCT00263770|Active Comparator|outpatient surgical procedure|where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
9870794|NCT00263770|Sham Comparator|Sham surgery|an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
9870795|NCT00263783|Experimental|1|MEDI-522
9870796|NCT00263796|Experimental|Pitocin|
9870797|NCT00263796|Placebo Comparator|Placebo|
9870798|NCT00263809|Experimental|1|Treatment, Mirasol-treated platelets
9870799|NCT00263809|No Intervention|2|Reference, Untreated platelets
9870800|NCT00263939|Experimental|1 - In home intervention|In home (face to face) delivery of the study intervention, Homing in on Health
9870801|NCT00263939|Experimental|2 - Telephone intervention|Telephone delivery of the study intervention, Homing in on Health
9870802|NCT00263939|No Intervention|3 - Usual care|Patients receiving the care their usual health providers supply, without an study intervention
9870803|NCT00264030|Other|1|PTCA
9870804|NCT00264030|Other|2|PTCA with angioguard
9870805|NCT00264043|Experimental|1|AngioGuard™ device and Bx Velocity™ stent
9870806|NCT00264069||001|
9870807|NCT00264069||002|
9870808|NCT00264095||001|
9870809|NCT00264108||1|Epoetin alfa 40 000 IU once weekly variable treatment length.
9870810|NCT00264108||2|Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
9517865|NCT03302182|Experimental|fasting group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.~For group1:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group2:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
9870811|NCT00264160|Experimental|AMN107|
9870812|NCT00264199|Active Comparator|1|
9870813|NCT00264199|Placebo Comparator|2|
9870814|NCT00264264|Active Comparator|Direct Compression|
9870815|NCT00264264|Active Comparator|Closure Device|
9870816|NCT00264394|Experimental|Updated CHD risk profiles|Provision of regularly updated CHD risk profiles
9870817|NCT00264394|Active Comparator|Guidelines|Physicians received guidelines only
9870818|NCT00264420|Experimental|1|zoledronic acid plus radiation therapy
9870819|NCT00264459|Placebo Comparator|Placebo|Placebo was given the same way as a sublingual preparation.
9870820|NCT00264459|Experimental|Liquid formulation of an extract of a 6 grass pollen mixture|"Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose."
9870821|NCT00264511|Experimental|Hyperbaric oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
9870822|NCT00264511|No Intervention|No hyperbaric oxygenation|Patients randomised to this group will receive standard trauma care.
9870823|NCT00264563||Behavioral|The intervention is basically by letting the care givers to be aware that there is active recording of iatrogenesis
9870824|NCT00264589|Other|Study Population|"non-diabetic obese subjects and type 2 diabetic subjects~Intervention: 8 weeks individualized training program"
9928465|NCT00906724||aerobic exercise|Aerobic exercise in Insulin Resistant Minority Adolescents
9928466|NCT00906737|Experimental|Ankle-Bot Training|Subjects in this group receive focused ankle training using the ankle-bot device.
9928467|NCT00906737|Active Comparator|Conventional Therapy|Subjects in this group will receive conventional focused ankle physical therapy.
9928468|NCT00906737|No Intervention|Control|Subjects in this group will not receive treatment; they will continue their usual care.
9928469|NCT00906750|Experimental|1|
9928470|NCT00906750|Active Comparator|2|
9928471|NCT00906763|Active Comparator|Dark Chocolate (85% cocoa)|Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
9928472|NCT00906763|Active Comparator|White chocolate (0% cocoa)|Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.
9928473|NCT00906802|Experimental|R-Y reconstruction|the reconstruction was performed by R-Y anastomosis
9928474|NCT00906802|No Intervention|conventional reconstruction|the anastomosis was performed by B-II
9928475|NCT00906828|Active Comparator|1. Duodopa, optimised dose|
9928476|NCT00906828|Experimental|2. 80% Duodopa + entacapone|80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours
9870826|NCT00264693||P - A|Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
9870827|NCT00264693||P - B|Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
9870828|NCT00264693||P - C|Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
9870829|NCT00264693||P - CAPD|Prophylactic Dosage, CAPD
9870830|NCT00264693||T - A|Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
9870831|NCT00264693||T - B|Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
9870832|NCT00264693||T - C|Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
9870833|NCT00264693||T - CAPD|Therapeutic Dosage, CAPD
9870834|NCT00264706|Other|Participant|Internal control study
9870835|NCT00264719|Active Comparator|A|Mothers with pre-term deliveries will receive metoclopramide 10 mg three times a day for the first 7 days and 2 times a day for the 8th to 10th day, and once a day for the 11th to 12th day
9870836|NCT00264719|Placebo Comparator|B|Mothers with pre-term deliveries will receive metoclopramide 10 mg 3 times a day, 2 times a day from 8th to 10th day and once a day from 11th to 12th day
9870837|NCT00264719|Active Comparator|C|Mothers with full term deliveries will receive 10 mg metoclopramide, 3 times a day for the first 7 days, 2 times a day from 8th to 10th day, and once a day for day 11 to 12
9870838|NCT00264719|Placebo Comparator|D|Mothers with full term deliveries will receive the placebo 10 mg three times a day, for 7 days, and two times a day from day 8 to day 10, and once a day from 11th to 12th day
9870839|NCT00264745|Experimental|1|
9870840|NCT00264745|Active Comparator|2|
9870841|NCT00264758|Active Comparator|Conventional hemodialysis|Three times per week in-center hemodialysis
9870842|NCT00264758|Experimental|Frequent hemodialysis|Six times per week in-center hemodialysis
9870843|NCT00264823|Experimental|1 - Experimental|
9870844|NCT00264823|No Intervention|2 - Control|
9870845|NCT00264953|Active Comparator|A|4x ABVD plus 30Gy IF-RT
9870846|NCT00264953|Experimental|C|4x BEACOPP baseline plus 30Gy IF-RT
9870847|NCT00264953|Experimental|B|4x ABVD plus 20Gy IF-RT
9870848|NCT00264953|Experimental|D|4x BEACOPP baseline plus 20Gy IF-RT
9870849|NCT00264979|Other|1|Simultaneous surgery of colorectal cancer and synchronous liver metastases
9870850|NCT00264979|Other|2|Sequential surgeries of colorectal cancer and synchronous liver metastases
9870851|NCT00265005|Experimental|All|All subjects receive active drug up to a total of 3 doses
9870852|NCT00265018|Active Comparator|Arm A|
9870853|NCT00265018|Experimental|Arm B|
9870854|NCT00265018|Experimental|Arm C|
9870855|NCT00265018|Experimental|Arm D|
9870856|NCT00265044|Other|Arm 1|
9870857|NCT00265135|Experimental|Part 1 (CNTO 328)|In Part 1 of the study, 4 intravenous infusions (IV) [injection of a substance into a vein] of CNTO 328 will be administered to patients in 4 dose levels ranging from 1, 3, 6, and 12 mg/kg on days 1, 29, 43, and 57 to determine the maximum tolerated dose for Part 2 of the study.
9870858|NCT00265135|Experimental|Part 2 (CNTO 328)|In Part 2 of the study, 2 well tolerated dose levels of CNTO 328 from Part 1 of the study will be administered every 3 weeks as 4 IV infusions to patients.
9870859|NCT00265135|Experimental|Part 3 (CNTO 328)|In Part 3 of the study, CNTO 328 at a dose level of 6 mg/kg will be administered as IV infusion every 2 weeks for at least 6 doses.
9870860|NCT00265226|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category II ATT according to RNTCP guidelines
9870861|NCT00265226|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category II ATT drugs according to RNTCP guidelines
9870862|NCT00265356|Experimental|1|PET diagnostic imaging
9870863|NCT00265356|No Intervention|2|No PET
9870864|NCT00265408|Experimental|aspirin|
9870865|NCT00265408|Experimental|warfarin|
9870866|NCT00265434|Active Comparator|Dornase alfa|DBPC-cross over trial
9870867|NCT00265434|Placebo Comparator|isotonic saline|
9870868|NCT00265447|Active Comparator|Strength training|3 months of strength training
9870869|NCT00265447|Active Comparator|Aerobic conditioning|3 months of aerobic conditioning
9870870|NCT00265447|Other|Delayed exercise|delayed exercise control group
9870871|NCT00265603|Experimental|1 Arm|The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
9870872|NCT00265629|Experimental|1|RF ablation
9870873|NCT00265642|Experimental|group verum|Drug: Irbesartan
9870874|NCT00265642|Placebo Comparator|group placebo|
9870875|NCT00265720|Placebo Comparator|Control|Written materials only
9870876|NCT00265720|Experimental|Reduced out-of-pocket expense|Reimbursed up to $500 out-of-pocket expense for colorectal cancer screening
9870877|NCT00265720|Experimental|One-on-one education|Individual education with a health educator on CRC screening
9870878|NCT00265720|Experimental|Group Education|Education on CRC screening in a small group with a health educator
9870879|NCT00265733|Experimental|paclitaxel + capecitabine|"Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for up to 5 years."
9870880|NCT00265811|Experimental|Folfox+Cetuximab|FOLFOX-4 Cetuximab alone every 2 weeks
9870881|NCT00265811|Active Comparator|Folfox|FOLFOX-4 alone every 2 weeks
9870882|NCT00265824|Active Comparator|bevacizumab alone|
9870883|NCT00265824|Experimental|Bevacizumab + erlotinib|
9870884|NCT00265863|Experimental|Patients with Malignant Ascites|Patients meeting protocol criteria enrolled with malignant ascites.
9870885|NCT00265876|Experimental|AZD0530 + Gemcitabine|
9870886|NCT00265954|Experimental|1|Individuals in this arm receive a 6 month behavioral weight loss intervention delivered on-line. Groups meet via a web chat weekly for 24 weeks and monthly for the following 12 months.
9870887|NCT00265954|Experimental|2|In-person; Individuals in the in-person condition attend weekly group behavioral weight loss sessions for 24 weeks and then monthly sessions for the following 12 months.
9870888|NCT00265954|Experimental|3|In-person+internet; Individuals in this condition receive a behavioral weight loss intervention over the internet weekly for 24 weeks and monthly for the following 12 months. Every month during the first 24 weeks and every third month during the following year they have an in-person meeting.
9870889|NCT00265967|Experimental|1|Irbesartan
9870890|NCT00265993|Experimental|1|enoxaparin
9870891|NCT00266058|Active Comparator|Lopinavir/ritonavir, artemethr/lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.
9870892|NCT00266058|Active Comparator|efavirenz, artemether, lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.
9870893|NCT00266097|Experimental|Part I|Oxaliplatin + Gemcitabine + Radiation
9870894|NCT00266097|Experimental|Part II|Erlotinib + Oxaliplatin + Gemcitabine + Radiation
9870895|NCT00266214|Experimental|Lidocaine Patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
9870896|NCT00266214|Placebo Comparator|Placebo|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
9870897|NCT00266240|Experimental|1|
9870898|NCT00266240|Experimental|2|
9870899|NCT00266240|Experimental|3|
9870900|NCT00266240|Experimental|4|
9870901|NCT00266240|Placebo Comparator|5|
9870902|NCT00266253|Experimental|1|
9870903|NCT00266253|Experimental|2|
9870904|NCT00266253|Experimental|3|
9870905|NCT00266253|Experimental|4|
9870906|NCT00266253|Experimental|5|
9870907|NCT00266253|Active Comparator|6|
9870908|NCT00266305|Experimental|Fish oil|
9870909|NCT00266305|Placebo Comparator|Olive oil|Control group
9870910|NCT00266305|No Intervention|High fish|Reference group
9870911|NCT00266331|Active Comparator|Group A, RayGel Topical Cream|RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
9870912|NCT00266331|Placebo Comparator|Arm B Placebo Topical Cream|Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
9870913|NCT00266396|Experimental|weight-bearing recommendation|Weight-bearing recommendation after THA and TKA
9870914|NCT00266474||Cross sectional CF study|Multicentric study, including 187 CF patients of all age groupr in 5 CF centres.
9928477|NCT00906828|Experimental|3. 80% Duodopa + tolcapone|80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours
9928478|NCT00906841|Experimental|90Y-DOTA-hLL2|Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
9928479|NCT00906854||Group I|practice of weight training exercises
9928480|NCT00906854||Group II|aerobic exercises as part of lessons jump, step and dance classes
9928481|NCT00906854||Group III|swimming (crawl mode)
9928482|NCT00906867||Vocal cord dysfunction|Patients with suspicion of VCD
9928483|NCT00906893|Experimental|1|
9928484|NCT00906906||1|Patient to receive CPB
9928485|NCT00906919|Active Comparator|Regular diabetes patient education|Regular professionally-led diabetes patient education
9928486|NCT00906919|Experimental|Augmented Diabetes Patient Education|Regular professionally-led diabetes patient education augmented by participation in the Stanford Chronic Disease Self-Management Program
9928487|NCT00906932||Trachview videoscope, direct laryngoscopy|Each subject served as their own control - the Trachview videoscope and direct laryngoscopy was performed on by all subjects in a sequential fashion.
9928488|NCT00906932||See above|See above
9935877|NCT03049462|Active Comparator|Cohort 3A|Females taking 100 mg of mirabegron
9935878|NCT03049462|Placebo Comparator|Cohort 3B|Females taking placebo drug
9935879|NCT03048201|Other|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
9870915|NCT00266565|Experimental|Anti-IL5 (Mepolizumab)|The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.
9870916|NCT00266773|No Intervention|1|Control - standard care only
9870917|NCT00266773|Experimental|2|Attention Control - standard care plus 6 months TIVR receiving minimal monthly feedback
9870918|NCT00266773|Experimental|3|Standard care plus 6 months TIVR receiving detailed monthly feedback
9870919|NCT00266786|Experimental|Intranasal Ketorolac Tromethamine|
9870920|NCT00266786|Placebo Comparator|Intranasal Placebo|
9870921|NCT00266838|Placebo Comparator|Lacrystat|Lacrystat
9870922|NCT00266838|Active Comparator|Maxidex|Applying Maxidex
9870923|NCT00266929||Surgical|Subjects receiving surgical treatment for Type II odontoid fracture per discretion of investigator (non-randomized allocation)
9870924|NCT00266929||Non-surgical|Subjects treated with non-operative treatment options
9870925|NCT00267033|Experimental|1|injection of orthopaedic cement into vertebral bodies
9870926|NCT00267124||1|elderly people who have normal cognition
9870927|NCT00267124||2|elderly people who have mild to moderate Alzheimer's disease
9870928|NCT00267163|Experimental|1.|
9870929|NCT00267163|Placebo Comparator|2.|
9870930|NCT00267241|Experimental|1|ALI/ARDS patients
9870931|NCT00267319|Experimental|single group|
9870932|NCT00267358|Active Comparator|RC-1291 HCl|50 mg
9870933|NCT00267358|Placebo Comparator|Placebo|
9870934|NCT00267514|Other|1|sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks
9870935|NCT00267514|Other|2|sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks
9870936|NCT00267566|Experimental|Treatment|50% random assignment to receive Family Help Anxiety Treatment
9870937|NCT00267566|Experimental|Control|50% random assignment to control group to receive usual/standard care for anxiety
9870938|NCT00267579|Experimental|Treatment|50% randomized to receive Strongest Families (formerly Family Help Program): Behaviour treatment
9870939|NCT00267579|Active Comparator|Control|50% randomized to control group: standard/usual care for behaviour disorder
9870940|NCT00267605|Experimental|Treatment|FHPADHD 50% randomized to receive Strongest Families (formerly Family Help Program): behavioural distance intervention
9870941|NCT00267605|Active Comparator|Control|ADHD Standard Care 50% randomized to receive standard/usual care for ADHD
9870942|NCT00267618|Experimental|Treatment|50% randomized to receive FHP Pain intervention
9870943|NCT00267618|No Intervention|control|50% randomized to receive standard/usual care for recurrent headache/abdominal pain
9870944|NCT00267735|No Intervention|Module 1 Only|
9870945|NCT00267735|Experimental|Modules 1, 2, and 3|
9870946|NCT00267826|Experimental|1|Patients with atopic dermatitis.
9870947|NCT00267852||1.0|As per routinary clinical practice
9870948|NCT00267930|Placebo Comparator|1|Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d
9870949|NCT00267930|Experimental|2|Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d
9870950|NCT00267930|Experimental|3|Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d
9870951|NCT00268307|Experimental|Cell therapy|Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
9928489|NCT00906984|Other|TheraSphere® treatment|TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
9928490|NCT00906997|Active Comparator|Fecal occult blood testing|
9928491|NCT00906997|Active Comparator|Colonoscopy|
9928492|NCT00907010||Group I|11 to 18 years - composed of 12 adolescent with six women and six men
9928493|NCT00907010||Group II|20 to 26 years - composed of 12 young with six women and six men
9928494|NCT00907010||Group III|45 to 60 years - composed of 12 adult with six women and six men
9928495|NCT00907010||Group IV|66 - 82 years - composed of 12 aged with six women and six men
9928496|NCT00907023||SOT|Patients that have had a solid organ transplant
9928497|NCT00907049||Subacute neck pain; chronic neck pain|Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study.
9928498|NCT00907062|Experimental|Gingko biloba|60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
9928499|NCT00907075|Active Comparator|NES With Energy Restriction|
9928500|NCT00907075|Active Comparator|NES Without Energy Restriction|
9935880|NCT03048201|Other|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
9870952|NCT00268372|Active Comparator|cisplatin/RT alone|cisplatin and radiation therapy
9870953|NCT00268372|Experimental|induction chemo followed by cisplatin/RT|docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy
9870954|NCT00268398|Active Comparator|FOLFOX4|
9870955|NCT00268398|Experimental|FOLFOX7 followed by FOLFIRI|
9870956|NCT00268489|Experimental|pemetrexed + bevacizumab|"Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for 5 years."
9870957|NCT00268528||Health service research (electronic pill monitoring system)|Patients receive an electronic pill monitoring system comprising an empty MEMS^? medication bottle with TrackCap? CR. The mercaptopurine prescription is filled using this system. Beginning on day 1 of the third or later course of maintenance therapy, patients take all doses of mercaptopurine from the MEMS^? medication bottle with TrackCap? CR for at least 169 days. The MEMS^? TrackCap? CR is mailed to the Coordinating Center at the end of study. Patients also receive methotrexate PO as indicated by their individual chemotherapy regimen.
9870958|NCT00268580|Experimental|Intervention|Asthma care provided using care pathway
9870959|NCT00268580|No Intervention|Control|Standard of care provided
9870960|NCT00268593|Experimental|130 mg PI-88 + docetaxel|130 mg PI-88 7 days/week + docetaxel 75 mg/m2
9870961|NCT00268593|Experimental|250 mg PI-88 + docetaxel|250 mg PI-88 4 days/week + docetaxel 75 mg/m2
9870962|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD|
9870963|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD + Ezetimibe|
9870964|NCT00268697|Active Comparator|Ezetimibe|
9870965|NCT00268723|Experimental|1|levalbuterol HFA MDI 90 mcg QID
9870966|NCT00268723|Placebo Comparator|2|Placebo MDI QID
9870967|NCT00268749|Experimental|1|
9870968|NCT00268788|Active Comparator|1|Subcutaneous Ig given twice a week.
9870969|NCT00268788|Active Comparator|2|Intravenous Ig
9870970|NCT00268814|Experimental|MTF, Psycho-education, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
9870971|NCT00268814|Experimental|MTF, Case management, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
9870972|NCT00268814|Active Comparator|MTF, Psycho-education, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
9870973|NCT00268814|Active Comparator|MTF, Case management, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
9870974|NCT00268814|Experimental|NIT, Psycho-education, Heroin|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
9870975|NCT00268814|Experimental|NIT, Case management, Heroin|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
9870976|NCT00268814|Active Comparator|NIT, Psycho-education, Methadone|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
9870977|NCT00268814|Active Comparator|NIT, Case management, Methadone|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
9870978|NCT00268840|Experimental|unique|Taxotère - Gemzar
9870979|NCT00268853|Experimental|1|
9870980|NCT00268853|Active Comparator|2|
9870981|NCT00268879|Placebo Comparator|1|Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
9870982|NCT00268879|Experimental|2|Renzapride 4 mg QD. Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
9870983|NCT00268879|Experimental|3|Renzapride 2 mg BID: Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
9870984|NCT00268918|Experimental|Docetaxel / PTK787|"Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle.~PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day."
9870985|NCT00268931|No Intervention|True Control|This group is being enrolled as a true control group. This group will not participate in the movement training or social training however, they will be evaluated in the same way.
9870986|NCT00268931|Experimental|Social Training|This group underwent specific social interactions two times each day with their parents.
9870987|NCT00268931|Experimental|Movement Training|This group of preterm infants underwent movement training two times per day with their parents.
9870988|NCT00268944|Experimental|1|
9870989|NCT00268957|Experimental|1|sevelamer carbonate powder
9870990|NCT00268957|Active Comparator|2|Sevelamer hydrochloride
9870991|NCT00269035|Experimental|Treatment Group 1|Subjects in group 1 will receive SB-773812 tablet once daily till still steady Cp
9870992|NCT00269035|Experimental|Treatment Group 2|Subjects in group 2 will receive SB-773812 tablets once daily over 6 weeks. Risperidone tablets 6 mg once daily from Days 1-7 two tablets of 3 mg and days 8 until stable Cp 6 mg tablets
9870993|NCT00269048|Experimental|Arm 1|SB-480848
9870994|NCT00269048|Placebo Comparator|Arm 2|placebo
9870995|NCT00269282|Active Comparator|1|Self-Management (SM) (Standard Care Group)
9870996|NCT00269282|Experimental|2|Motivational Interviewing plus Self-Management Training (MI+SM)
9870997|NCT00269295|Experimental|Cohort 1: Arm 1|12 subjects to receive vaccine dose 1: 5 X 10^7 cfu.
9870998|NCT00269295|Placebo Comparator|Cohort 1: Arm 2|6 subjects to receive placebo.
9870999|NCT00269295|Experimental|Cohort 2: Arm 1|12 subjects to receive vaccine dose 2: 5 X 10^8 cfu.
9871000|NCT00269295|Experimental|Cohort 3: Arm 1|12 subjects to receive vaccine dose 3: 5 X 10^9 cfu.
9871001|NCT00269295|Placebo Comparator|Cohort 3: Arm 2|6 subjects to receive placebo.
9871002|NCT00269295|Placebo Comparator|Cohort 2: Arm 2|6 subjects to receive placebo.
9871003|NCT00269308|Experimental|1|Chiropractic Manual Treatment + Home Exercise
9871004|NCT00269308|Experimental|2|Supervised Rehabilitative Exercise + Home Exercise
9871005|NCT00269308|Active Comparator|3|Home Exercise
9871006|NCT00269321|Experimental|1|
9871007|NCT00269321|Experimental|2|
9871008|NCT00269321|Active Comparator|3|
9871009|NCT00269360|Experimental|1|
9871010|NCT00269360|Experimental|2|
9871011|NCT00269360|Active Comparator|3|
9871012|NCT00269386|Active Comparator|1 (i)|Clarithromycin S/R 1g od From April 2004, clarithromycin S/R (Klaricid XL) ceased to be available and subsequent patients will receive either standard clarithromycin 500mg bd or placebo tables of identical size, colour and taste
9871013|NCT00269386|Placebo Comparator|2 (ii)|placebo tablets of identical size, colour and taste
9871014|NCT00269425|Experimental|Mediterranean diet,|
9871015|NCT00269425|Experimental|American Heart Association Step 2 diet|
9871016|NCT00269425|No Intervention|Case controlled|
9871017|NCT00269516|Experimental|1|
9871018|NCT00269516|Experimental|2|
9871019|NCT00269516|Experimental|3|
9871020|NCT00269516|Placebo Comparator|4|
9871021|NCT00269542|Experimental|1|
9871022|NCT00269542|Placebo Comparator|2|
9871023|NCT00269581|Other|1|Educational CD-Rom
9871024|NCT00269581|Experimental|2|Headstrong CD-rom
9871025|NCT00269620|Experimental|2|OrthoEvra
9871026|NCT00269620|Experimental|1|NuvaRing
9871027|NCT00269776|Experimental|001|OROS (methylphenidate HCl) Treatment A: 1 2 or 3 OROS methylphenidate 18-mg tablets + 0 1 or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
9871028|NCT00269776|Experimental|002|Ritalin (methylphenidate) Treatment B: 5 10 or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
9871029|NCT00269776|Experimental|003|Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
9871030|NCT00269789|Experimental|001|OROS Methylphenidate HCl
9871031|NCT00269789|Active Comparator|002|Ritalin
9871032|NCT00269789|Placebo Comparator|003|Placebo
9871033|NCT00269802|Experimental|001|OROS methylphenidate HCl
9871034|NCT00269802|Active Comparator|002|Ritalin
9871035|NCT00269802|Placebo Comparator|003|Placebo
9871036|NCT00269815|Experimental|001|methylphenidate HCl
9871037|NCT00269841|Experimental|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
9871038|NCT00269841|Experimental|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
9871039|NCT00269841|Placebo Comparator|Placebo|Matching placebo will be administered at Week 0, 2 and 6.
9871040|NCT00269854|Experimental|Infliximab 5 mg/kg|
9871041|NCT00269854|Experimental|Infliximab 10 mg/kg|
9871042|NCT00269854|Experimental|Infliximab 20 mg/kg|
9871043|NCT00269854|Placebo Comparator|Placebo|
9871044|NCT00269867|Placebo Comparator|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
9871045|NCT00269867|Experimental|Infliximab 3 mg/kg every 8 weeks|Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
9871046|NCT00269867|Experimental|Infliximab 3 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
9871047|NCT00269867|Experimental|Infliximab 10 mg/kg every 8 weeks|Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
9871048|NCT00269867|Experimental|Infliximab 10 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
9871049|NCT00269880|Placebo Comparator|Placebo and Standard Dose of Heparin|Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
9871050|NCT00269880|Active Comparator|Abciximab and Low Dose of Heparin|Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
9871051|NCT00269880|Active Comparator|Abciximab and Standard Dose Heparin|Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.
9935881|NCT03048201|Other|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
9871052|NCT00269893|Placebo Comparator|Placebo|Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
9871053|NCT00269893|Experimental|Abciximab and Placebo|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
9871054|NCT00269893|Experimental|Abciximab|Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.
9871055|NCT00269906|Experimental|Abciximab (c7E3 Fab)|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
9871056|NCT00269906|Placebo Comparator|Placebo|Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
9928501|NCT00907114|Active Comparator|Ketorolac tromethamine|ocular topic ketorolac used 4 times a day during a week after panphotocoagulation
9928502|NCT00907114|Placebo Comparator|Polivynilic alcohol|ocular lubricant drops 4 times a day during one week after panphotocoagulation
9928503|NCT00907127|Active Comparator|Mediterranean Diet and Exercise|Mediterranean Diet and Exercise
9928504|NCT00907140|Other|Chemoradiation therapy|
9928505|NCT00907166|Experimental|Phase I, Arm A|CPI-613 + Gemcitabine
9928506|NCT00907166|Experimental|Phase II, Arm A|CPI-613 + Gemcitabine
9928507|NCT00907166|Active Comparator|Phase II, Arm B|Gemcitabine
9928508|NCT00907179|Experimental|Dose escalation|"Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.~Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given"
9928509|NCT00907192||Opioids|Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
9928510|NCT00907205|Experimental|SF1126|Twice weekly IV infusion
9928511|NCT00907270|Active Comparator|Cholecalciferol: 400 IU/day|Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)
9928512|NCT00907270|Experimental|Cholecalciferol 4000 IU/day|Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D
9928513|NCT00907283|Experimental|deferiprone|15 mg/Kg/twice for 1 year
9928514|NCT00907309|No Intervention|Treatment as usual|Participants will receive treatment as usual from their provider.
9928515|NCT00907309|Experimental|iMET|Participants will receive the iMET intervention.
9928516|NCT00907309|Experimental|iMET/TE|Participants will receive the iMET intervention and Technological Extenders (TEs).
9928517|NCT00907322|Experimental|Dimbeon 20 mg|
9928518|NCT00907322|Experimental|Dimebon 40 mg|
9928519|NCT00907322|Experimental|Dimebon 60 mg|
9928520|NCT00907322|Experimental|Placebo|
9928521|NCT00907348|Experimental|Cohorts 1 - 2 - 3 - 4|Chemiotherapy
9928522|NCT00907400|Experimental|1|PN400
9928523|NCT00907400|Active Comparator|2|Naprosyn E
9928524|NCT00907413|Experimental|ERCP and PDT|Endoscopic Retrograde Cholangio Pancreatography (ERCP) and stenting combined with Photodynamic Dynamic Therapy ERCP and PDT
9928525|NCT00907413|Active Comparator|ERCP alone|Endoscopic Retrograde Cholangio Pancreatography (ERCP) with stenting alone
9928526|NCT00907452|Active Comparator|melphalan-prednisone-thalidomide|
9928527|NCT00907452|Active Comparator|lenalidomide-dexamethasone|
9928528|NCT00907465||Calibration study|These individuals were used to develop cut points for sedentary behavior using accelerometers and a metabolic chamber.
9928529|NCT00907491||A|
9928530|NCT00907504|Experimental|CP-751,871 + Gemcitabine + Cisplatin|investigational arm
9928531|NCT00907504|Active Comparator|Gemcitabine + Cisplatin|standard of care
9928532|NCT00907530|Active Comparator|MULTIHANCE|gadobenate dimeglumine
9928533|NCT00907530|Active Comparator|GADOVIST|gadobutrol
9928534|NCT00907543|Other|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy treatment
9928535|NCT00907543|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy treatment
9928536|NCT00907582|Experimental|ASCT in relapsed APL|autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission
9928537|NCT00907595|Active Comparator|Ramelteon|Subjects randomized to Ramelteon
9928538|NCT00907595|Placebo Comparator|Placebo|Subjects randomized to placebo
9935347|NCT03867383|Placebo Comparator|Placebo|"Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
9935348|NCT03866499|Experimental|BPI-7711|180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD
9935349|NCT03866499|Active Comparator|Gefitinib|180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD
9871057|NCT00270153|Placebo Comparator|enalapril|
9871058|NCT00270153|Placebo Comparator|Placebo|
9871059|NCT00270218|Experimental|1|Arm 1 participants will be given an injection of VRC-HIVADV014-00-VP vaccine on Days 0 and 168.
9871060|NCT00270218|Placebo Comparator|2|Arm 2 participants will be given an injection of final formulation buffer (FFB) on Days 0 and 168.
9871061|NCT00270218|Experimental|3|Arm 3 participants will be given an injection of VRC-HIVDNA009-00-VP vaccine on Days 0 and 28. Participants will also be given an injection of VRC-HIVADV014-00-VP on Day 168.
9871062|NCT00270218|Placebo Comparator|4|Arm 4 participants will be given an injection of phosphate buffered saline (PBS) on Days 0 and 28 and an injection of FFB on Day 168.
9871063|NCT00270244|Active Comparator|1|Participants will receive treatment as usual
9871064|NCT00270244|Experimental|2|Participants will receive group interpersonal psychotherapy for depressed adolescents
9871065|NCT00270335|Active Comparator|A|General anesthesia titrated according to a cerebral state monitor
9871066|NCT00270335|Active Comparator|B|General anesthesia titrated according to usual clinical criteria
9871067|NCT00270361|Experimental|001|nesiritide
9871068|NCT00270361|Experimental|002|nesiritide
9871069|NCT00270361|Active Comparator|003|usual long term cardiac medications
9871070|NCT00270374|Experimental|001|nesiritide
9871071|NCT00270387|Experimental|001|Natrecor (nesiritide)
9871072|NCT00270400|Experimental|001|nesiritide
9871073|NCT00270413|Experimental|1|sutent
9871074|NCT00270413|No Intervention|2|
9871075|NCT00270439|Experimental|single arm|Removed omentum of patients with type 2 diabetes
9871076|NCT00270621|Experimental|Treatment|FHP Night time Enuresis intervention
9871077|NCT00270621|No Intervention|Control|To receive standard/usual care for Nocturnal Enuresis- No FHP Night time Enuresis INtervention
9871078|NCT00270647|Experimental|Vitamin E|Active or placebo vitamin E
9871079|NCT00270647|Experimental|Vitamin C|Active or placebo vitamin C
9871080|NCT00270647|Experimental|Multivitamin|Active or placebo multivitamin
9871081|NCT00270647|Experimental|Beta-carotene|Active or placebo beta-carotene
9871082|NCT00270699|Experimental|1|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^5 PFU dose) into the deltoid region of either arm.
9871083|NCT00270699|Experimental|2|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
9871084|NCT00270699|Experimental|3|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
9871085|NCT00270699|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
9871086|NCT00270712||Retrospective Cohort|537 transplant recipient records used retrospectively
9871087|NCT00270712||Prospective Cohort|3137 transplant recipients enrolled prospectively
9871088|NCT00270738|Experimental|1|TrA training group
9871089|NCT00270738|Active Comparator|2|PFMT group
9871090|NCT00270738|Active Comparator|3|control group (PFM exercise at home)
9871091|NCT00270764||Full cohort|Adult ART patients at 3 treatment facilities in South Africa
9871092|NCT00270803|Placebo Comparator|A|Low nicotine cigarettes without THC
9871093|NCT00270816|Experimental|interferon beta cyclical administration|Interferon ß-1b Treatment by Cyclical Administration
9871094|NCT00270816|Active Comparator|Interferon ß-1b Treatment|Interferon ß-1b Treatment
9871095|NCT00270829|Experimental|1|Nesiritide given intrarenally
9871096|NCT00270829|No Intervention|2|No intrarenal drug administration
9871097|NCT00270907|Experimental|CT-2103 + Gemcitabine|CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
9871098|NCT00270959|Experimental|1|Stepped collaborative care (combination of behavioral therapy and drug therapy)
9871099|NCT00270959|Active Comparator|2|Standard care provided to injured trauma survivors
9871100|NCT00270985|Active Comparator|nut free diet|ADA recommended diabetes diet without any nuts
9871101|NCT00270985|Experimental|almond group|calorie controlled diet with prescribed daily amount of almonds
9871102|NCT00271050|Experimental|1|
9871103|NCT00271115|Other|Moms w/preterm infants|Mothers of preterm infants who are admitted to the newborn intensive care unit.
9871104|NCT00271193|No Intervention|1|Control group, receives physician advice for weight loss and materials
9871105|NCT00271193|Active Comparator|2|Active treatment group, receives physician advice, materials, and brief weight loss counseling
9871106|NCT00271206|Active Comparator|Progesterone|200 mg to 400mg of progesterone
9871107|NCT00271206|Placebo Comparator|Sugar Pill|Will mirror active medication
9871108|NCT00271245|Experimental|1|200 µg selenium as selenate
9871109|NCT00271245|Experimental|2|400 µg selenium as selenate
9871110|NCT00271245|Experimental|3|200 µg selenium as selenomethionine
9871111|NCT00271245|Placebo Comparator|4|placebo
9871112|NCT00271284|Experimental|I|
9871113|NCT00271284|Active Comparator|II|
9871114|NCT00271323|Experimental|1|Induction chemotherapy followed by concurrent chemoradiotherapy
9871115|NCT00271323|Active Comparator|2|Concurrent chemo-radiotherapy followed by consolidation chemotherapy
9871116|NCT00271336|Placebo Comparator|A|
9871117|NCT00271336|Experimental|B|
9871118|NCT00271362|Active Comparator|1|comparing 2 surgical procedures
9871119|NCT00271388|Experimental|Parameter Determination|Testing potential effects of GVS on the symptoms of neglect
9871120|NCT00271401|Experimental|Angioplasty With Abciximab Plus Low-Dose Heparin|Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
9871121|NCT00271401|Experimental|Intracoronary Stent With Reo Pro Plus Low Dose Heparin|Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
9871122|NCT00271401|Placebo Comparator|Intracoronary Stent With Placebo Plus Standard Dose Heparin|Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).
9871123|NCT00271440|Experimental|CHX 1.0%|1.0% CHX wiping
9871124|NCT00271440|Experimental|CHX 0.5%|0.5% Chlorhexidine
9871125|NCT00271440|Experimental|CHX 0.25%|chlorhexidine cleansing with pre-soaked pre-sealed wipe
9928539|NCT00907608|Experimental|1|Receive Darbepoetin alfa
9928540|NCT00907608|No Intervention|2|
9928541|NCT00907660|Active Comparator|Full Dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 2 meals per day of portion-controlled foods (shakes and entrees)
9928542|NCT00907660|Experimental|Half dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 1 meal per day of portion-controlled foods (shakes and entrees)
9928543|NCT00907673|Active Comparator|Patient condition pre-implant|
9928544|NCT00907686||LBWIs of CMV-positive mother|LBWIs born to CMV-positive mothers
9928545|NCT00907686||CMV Sero-negative & Sero-postive LBWIs|LBWIs of CMV sero-negative & sero-positive mothers
9928546|NCT00907712|No Intervention|cardiovascular|cardiac echo
9928547|NCT00907725|Other|1|serum BhCG follow-up
9928548|NCT00907725|Other|2|ultrasonographic follow-up
9928549|NCT00907751|Experimental|1|Microangiopathic hemolytic anemia (< 12 g/dL) with thrombocytopenia (<50 G/L)
9928550|NCT00907764|Experimental|Regadenoson alone|
9928551|NCT00907764|Experimental|Regadenoson with exercise|
9928552|NCT00907764|Experimental|Regadenoson with contrast agent|
9928553|NCT00907764|Experimental|Regadenoson with contrast agent (perfusion)|
9928554|NCT00907790|Experimental|Comprehensive Self-Management (CSM)|"Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS~--------------------------------------------------------------------------------"
9928555|NCT00907790|Other|Usual Care (Control Group)|Includes the usual care provided by the person and their health care provider.
9928556|NCT00907816||intervention|PCPs at MGH who receive display of utilization and quality during computer order entry
9928557|NCT00907816||control|
9928558|NCT00907829|Active Comparator|Arm 1|persons with severe hand impairment following hemiparetic stroke
9928559|NCT00907829|Active Comparator|Arm 2|persons with severe hand impairment following hemiparetic stroke
9928560|NCT00907842|Experimental|mesh placement|
9928561|NCT00907894|Experimental|Stratum 1|
9928562|NCT00907894|Experimental|Stratum 2|
9928563|NCT00907894|Experimental|Stratum 3|
9935350|NCT03864406|Experimental|A|Phase 1: a single dose of rivaroxaban on day 1 followed by serial PK/PD blood sampling Phase 2: cobicistat once daily (Days 2 7), followed by single dose of rivaroxaban and serial PK/PD blood sampling on day 7 Phase 3: darunavir /cobicistat once daily (days 8-13) followed by single dose of rivaroxaban and serial PK /PD blood sampling on day 13.
9935882|NCT03047070|Active Comparator|Lidocaine|IV Lidocaine infusion
9935883|NCT03047070|Placebo Comparator|Control|IV normal saline infusion
9871126|NCT00271492|Active Comparator|I|Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
9871127|NCT00271492|Placebo Comparator|2|placebo group to be compared to the actual medication
9871128|NCT00271518|Experimental|LB03002, sustained release human hGH|LB03002
9871129|NCT00271531||1|150 subjects greater than 48 weeks post-conception and less than 18 years of age who are mechanically ventilated and have presumed bacterial pulmonary infection.
9871130|NCT00271635|Experimental|1|Ascorbic acid
9871131|NCT00271635|Placebo Comparator|2|Placebo
9871132|NCT00271700|No Intervention|Usual Care|admission to medical team floor to usual care
9871133|NCT00271700|Experimental|Intervention|consists of usual care as well as an admission order set built into BWH's proprietary computer provider order entry (CPOE) system
9871134|NCT00271713|Active Comparator|ibandronate|150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily
9871135|NCT00271713|Placebo Comparator|2|placebo monthly plus 500mg calcium and 800 UI vitamin D daily
9871136|NCT00271752|Experimental|PCT guided|Procalcitonin guided treatment of infections in the ICU. Intervention: Intensification of antibiotics, surgery, microbiologic testing and diagnostic imaging, when Procalcitonin levels are increasing
9871137|NCT00271752|Sham Comparator|Control|"These patients receive Standard of Care which is the recommended treatment in the given ICU"
9871138|NCT00271791|Experimental|1|Prednisone
9871139|NCT00271791|Placebo Comparator|2|Placebo
9871140|NCT00271908||Cohort #1|Venue-tracking survey subjects recruited annually for 4 years: N= 320-640 (10-20 members of the population of focus per site, per year). The purpose of this cohort is to identify and track venues at which the population of focus congregates.
9871141|NCT00271908||Cohort #2|HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody [Ab] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
9871142|NCT00271960|Active Comparator|Individual Care|Participants will receive usual care for their prenatal visits
9871143|NCT00271960|Active Comparator|CenteringPregnancy|Participants will receive CenteringPregnancy(R) group prenatal care
9871144|NCT00271960|Experimental|CenteringPregnancyPlus|Participants will receive CenteringPregancy with an HIV/STD prevention component
9871145|NCT00271999|Active Comparator|1|Three times a week conventional at home hemodialysis
9871146|NCT00271999|Experimental|2|Six times a week nocturnal home hemodialysis
9871147|NCT00272025|Active Comparator|1|There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
9871148|NCT00272025|Placebo Comparator|2|to be filled in
9871149|NCT00272064|Other|1|Telecare system
9871150|NCT00272064|Other|2|Self Monitoring Blood Glucose (SMBG)system.
9871151|NCT00272116|Experimental|1|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children and Vitamin A 100,000 IU to infants and 200,000 IU to older children
9871152|NCT00272116|Placebo Comparator|2|
9871153|NCT00272181|Experimental|Dose Determination|The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
9871154|NCT00272220|Experimental|1|receive 6-week intervention of peer-delivered mDOT
9871155|NCT00272220|No Intervention|2|
9871156|NCT00272272|Experimental|Balance and Music Listening|Music therapy
9871157|NCT00272285|Experimental|1|Intravenous (IV)
9871158|NCT00272285|Active Comparator|2|Intravenous (IV)
9871159|NCT00272402|Other|1|Simulated case-based learning
9871160|NCT00272402|Other|2|EMR clinical decision support tool.
9871161|NCT00272402|No Intervention|3|Control group
9871162|NCT00272415|Experimental|1|
9871163|NCT00272467|Experimental|Rebamipide|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) Rebamipide 100mg, t.i.d. (before breakfast, evening, before bed).~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
9935351|NCT03864406|Experimental|B|Phase 1: a single dose of apixaban on day 1 followed by serial PK/PD blood sampling Phase 2: cobicistat once daily (Days 2-7), followed by single dose of apixaban and serial PK /PD blood sampling on day 7 Phase 3: darunavir /cobicistat once daily (days 8-13) followed bysingle dose of apixaban and serial PK/PD blood sampling on day 13.
10211115|NCT05217576|Other|Precision A & B|"Precision study:~At least 12 subjects will be tested 6 consecutive times with the NBM-200, on either the right or left thumb, and then 6 times with the capillary device (with a separate finger-prick for each test).~At least 3 males and 3 females at 2 study sites (total of 12), preferably with hemoglobin levels close to the cutoff levels of 12.5 g/dL for females and 13 g/dL for males. Each subject will be tested on each of their right and left thumbs and indices (4 fingers) using at least two operators and two NBM-200 instruments on each finger.~A laboratory test with venous blood is not required for participants in the precision study."
9986798|NCT01406145|Experimental|ASP0777 high dose|ASP0777 high dose for 6 weeks
9986799|NCT01406145|Placebo Comparator|Placebo|Placebo for 6 weeks
9986800|NCT01406158|Experimental|Treatment A|
9986801|NCT01406158|Experimental|Treatment B|
9986802|NCT01406158|Experimental|Treatment T|
10211116|NCT05217563|No Intervention|Standard Care|Standard Care Control Group (Group 1). Parents in the standard care control group will receive a pamphlet containing evidence-based information on needle pain management. Parents in the standard care control group will not receive any information regarding pain memory reframing, nor will they be encouraged to talk about their children's pain vaccine injection experience. Parents in the standard care control group will receive text/email reminders to use needle pain management strategies before each second vaccination appointment.
9986803|NCT01406171|Experimental|Isavuconazole and Midazolam|Isavuconazole three times per day (TID) for 2 days followed by once a day (QD) for 9 days. Midazolam single doses on days 1 and 12
9986804|NCT01406197|Experimental|Vaginal progesterone|vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)
9986805|NCT01406197|Experimental|Topical progesterone|topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily
9986806|NCT01406197|Experimental|Intramuscular progesterone|injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)
9986807|NCT01406210||Prospective Group|Those patients that will be consented and data collected prospectively
9986808|NCT01406210||Retrospective Group|Those charts that will be utilized to collect retrospective data, waiver of consent will be granted by the IRBs.
9986809|NCT01406236|Other|Transradial PCI|
9986810|NCT01406236|Other|Transfemoral PCI|
9986811|NCT01406249|Active Comparator|S-1,Cisplatin|
9986812|NCT01406249|Experimental|Capecitabine, Cisplatin|
9986813|NCT01406262|Active Comparator|Albiglutide + moxifloxacin placebo|Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
9986814|NCT01406262|Active Comparator|Albiglutide matching placebo + moxifloxacin|Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
9986815|NCT01406275||Pediatrics patients prescribed amoxicillin and clavulanate|Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
9996982|NCT01504893|Experimental|protective|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure streets ≤ 25 cm H2O, I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 4 mL / kg, peak airway pressure ≤ 35 cmH2O, respiratory rate <30, I:E = 1:2 / 1:3.~During OLV in case of desaturation (before increasing the FiO2) and / or within 1 hour you perform recruitment maneuvers followed by the setting of a PEEP of 5 cmH2O"
9996983|NCT01504893|No Intervention|conventional|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure ≤ 25 cmH2O airway; I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 8 mL / kg, peak airway pressure ≤ 35 cmH2O; I: E = 1:2."
9996984|NCT01504906|Experimental|A|cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor
9996985|NCT01504906|Experimental|B|single dose cyclosporine 600 mg
9996986|NCT01504906|Experimental|C|single dose 180 mg ticagrelor
9996987|NCT01504919|Experimental|Health Education (HE)|HE of brief counseling and self-help materials addressing 3 risk behaviors, referrals to available resources, and a home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed.
9996988|NCT01504919|Experimental|Motivation and Problem Solving (MAPS)|HE counseling, self-help materials, and resource referrals, and home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed. Plus 9 proactive, telephone counseling sessions over the 18 month period.
9996989|NCT01504932|Experimental|Arm I: BRB Lozenge|"Former oral cancer patients receive lozenges containing freeze-dried black raspberry (BRB) powder. They will take the lozenges four times each day (QID) by mouth (PO) for up to 6 months.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Black Raspberry (BRB) Lozenge Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
9996990|NCT01504932|Other|Arm II: Biomarker Control|"Former oral cancer patients will not receive lozenges containing freeze-dried black raspberry (BRB) powder.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
9996991|NCT01504945|Active Comparator|RBC transfusion|
9996992|NCT01504945|Placebo Comparator|Normal saline infusion|
9996993|NCT01504984|Experimental|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
9996994|NCT01504984|Active Comparator|Glivec film coated tab 4T(400mg)|100mg/tablet, po, 4 tablets once daily for period I&II D1(crossover)
9871164|NCT00272467|Active Comparator|Omeprazole|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) omeprazole 20mg, once daily (before breakfast)~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
9871165|NCT00272480|Placebo Comparator|Placebo|Placebo in HAM/TSP 24
9871166|NCT00272480|Active Comparator|Zidvoudine plus lamivudine|Zidvoudine plus lamivudine in HAM/TSP 24
9871167|NCT00272493|Active Comparator|A|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
9871168|NCT00272493|Experimental|B|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
9871169|NCT00272519|Experimental|Adolescent/caregiver dyads|Eight to ten adolescent/caregiver dyads
9871170|NCT00272545|Experimental|1|Participants will receive the normalization of eating program
9871171|NCT00272545|Active Comparator|2|Participants will receive treatment as usual
9871172|NCT00272597|Other|Risperidone LAI|"Subjects treated with any antipsychotic can be switched to Risperidone LAI.~If the subject is currently treated with an antipsychotic other than risperidone, the dosage will be tapered gradually and discontinued. Simultaneously, oral risperidone will be started at 2 mg/day and increased to no more than 6 mg/day. The subject will be treated with risperidone monotherapy for at least five days prior to entering the stabilization phase of the study.~On the other hand, if the patient has already been treated for more than 5 days with risperidone monotherapy then he/she may enter the stabilization phase of the study immediately."
9871173|NCT00272662|Experimental|Cohort 1|Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.
9871174|NCT00272662|Experimental|Cohort 2|Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.
9871175|NCT00272662|Experimental|Cohort 3|Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.
9871176|NCT00272662|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.
9871177|NCT00272831|Active Comparator|Cilostazol|Cilostazol 100 mg twice daily
9871178|NCT00272831|Placebo Comparator|Placebo|
9871179|NCT00272857|Experimental|Single arm|
9871180|NCT00272909|Experimental|1|piclozotan IV infusion, low dose, for 72 hours.
9871181|NCT00272909|Experimental|2|piclozotan IV infusion, high dose, for 72 hours.
9871182|NCT00272909|Placebo Comparator|3|placebo (normal saline) IV infusion, for 72 hours.
9871183|NCT00272935|Experimental|1|
9871184|NCT00272935|Placebo Comparator|2|
9871185|NCT00272948|Experimental|Prophylaxis Arm|
9871186|NCT00272948|Active Comparator|Control Arm|
9871187|NCT00273013|Experimental|Sequence 1|Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3.
9871188|NCT00273013|Experimental|Sequence 2|Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3.
9871189|NCT00273013|Experimental|Sequence 3|Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3.
9871190|NCT00273013|Experimental|Sequence 4|Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3.
9871191|NCT00273013|Experimental|Sequence 5|Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3.
9871192|NCT00273013|Experimental|Sequence 6|Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3.
9928564|NCT00907920||Correlative studies|"Tumor DNA samples are examined by mutation analysis for germline and somatic mutations in the ALK tyrosine kinase domain. Samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for DNA alterations in the entire ALK coding sequence. Samples are also examined for SNPs by polymorphism analysis. Exploratory multivariable analysis is performed to test for the prognostic ability of ALK mutations in the presence of other known prognostic variables (i.e., age, International Neuroblastoma Staging System stage, MYCN status, International Neuroblastoma Pathology Classification, and diploidy).~A subset of tumor DNA samples from high-risk patients will be resequenced for DNA alterations to determine whether or not additional regions in ALK, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel."
9928565|NCT00907933|Experimental|Part 1 - Arm 1|HVTs
9928566|NCT00907933|Placebo Comparator|Part 2 - Arm 3|HVTs
9928567|NCT00907933|Experimental|Part 1 - Arm 2|HVTs
9928568|NCT00907933|Experimental|Part 1 - Arm 3|HVTs
9928569|NCT00907933|Experimental|Part 1 - Arm 4|HVTs
9928570|NCT00907933|Experimental|Part 1 - Arm 5|HVTs
9928571|NCT00907933|Placebo Comparator|Part 1 - Arm 6|HVTs
9928572|NCT00907933|Experimental|Part 2 - Arm 1|HVTs
9928573|NCT00907933|Experimental|Part 2 - Arm 2|HVTs
9928574|NCT00907946|Experimental|NT prior to PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
9935352|NCT03860987|Experimental|1|Treatment
9986816|NCT01406288||HUS epidemy in Bordeaux, E. coli of the O104H4 serotype|
9871193|NCT00273104|Active Comparator|Bariatric surgery|Bariatric surgery (gastric bypass) offered to patients after informed consent and shared decision. The surgical procedure was performed at Vestfold Hospital Trust by experienced bariatric surgeons.
9871194|NCT00273104|Active Comparator|Intensive lifestyle intervention|Intensive lifestyle intervention (1-year endurance) at a rehabilitation centre. The intervention consisted of motivation for behaviour change including calorie restriction and increased physical activity.
9871195|NCT00273286|Experimental|family diabetes management intervention|A trained health advisor will be responsible for interactions with parents and patients prior to each diabetes clinic visit (Preparation Phase), at the time of the diabetes clinic visit (Consolidation Phase) and by phone, e-mail, etc. after the clinic visit (Follow-up Phase). Using educational modules developed for the study, families will be engaged in problem identification and solving activities to improve shared parent-youth responsibility for diabetes management and foster increased adolescent's independent management capabilities.
9871196|NCT00273312|Experimental|Patupilone|was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks
9871197|NCT00273559||1|subjects who remain on steroids after discharge
9871198|NCT00273559||2|Subjects will be off steroids at the time of discharge
9871199|NCT00273572|Active Comparator|Moderate lifestyle intervention|Moderate lifestyle intervention including two group sessions and one individual counselling session with a nutritionist, at recruitment. Individual sessions with a nutritionist after 6 and 12 months on follow-up.
9871200|NCT00273572|Experimental|Intensive lifestyle intervention|Intensive lifestyle intervention, including bi-monthly group sessions with a physical activity instructor; a monthly group session with a nutritionist, and a monthly individual session with a nutritionist.
9871201|NCT00273611|Experimental|Pharmacist education|Pharmacist education about vitamin D
9871202|NCT00273611|No Intervention|Usual care|Usual care
9871203|NCT00273624|Experimental|olanzapine|10 mg Olanzapine
9871204|NCT00273624|Placebo Comparator|placebo|Placebo
9871205|NCT00273689|Other|I|This is a crossover trial- Patients get randomly assign to albuterol or singulair and then cross overed to the alternate active medication.
9871206|NCT00273715|No Intervention|Staples|
9871207|NCT00273728|Active Comparator|HES, Septic shock, resuscitation|study group with HES 6%
9871208|NCT00273741|Experimental|1|methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
9871209|NCT00273741|Placebo Comparator|2|placebo capsules
9871210|NCT00273767|Experimental|1|epoetin beta
9871211|NCT00273767|Placebo Comparator|2|placebo of NaCl
9871212|NCT00273780|Active Comparator|Adherence counseling|
9871213|NCT00273780|Active Comparator|Alarm device|
9871214|NCT00273780|Active Comparator|Counseling and alarm|Participants in this arm will receive both education counseling and a pocket alarm device.
9871215|NCT00273780|No Intervention|Control|
10211117|NCT05217563|Active Comparator|Intervention Group (Pamphlet and video only)|Intervention Group (Group 2; Pamphlet and video Only). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management and a pamphlet summarizing memory reframing principles. The pamphlet will have a link to a video summarizing the memory reframing strategies.
9871216|NCT00273806|Experimental|1|Medical assistant identification and referral for behavioral risk factors.
9871217|NCT00273806|No Intervention|2|Usual care for behavioral risk factors.
9871218|NCT00273845|Experimental|1|One session of motivational interviewing
9871219|NCT00273845|Experimental|2|Five sessions of strengths-based case management
9871220|NCT00274209||IBD patients at risk for neoplasia|Patients with long-standing ulcerative colitis or Crohn's colitis at risk for neoplasia.
9871221|NCT00274443|Experimental|ABI-007 and Carboplatin|ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
9928575|NCT00907946|No Intervention|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
9928576|NCT00907972|Experimental|Vitamin D3 supplementation|1000 IU/day of Vitamin D3
9928577|NCT00907972|Placebo Comparator|Placebo|Placebo
9928578|NCT00907985|Experimental|Treatment sequence A|Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
9928579|NCT00907985|Experimental|Treatment sequence B|Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
9928580|NCT00907985|Experimental|Treatment sequence C|Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
10211118|NCT05217563|Active Comparator|Intervention Group (Pamphlet, video, and verbal Instructions).|Intervention Group (Group 3; Handout and Verbal Instructions). Parents in this intervention group will receive a pamphlet containing evidence-based information on needle pain management, a pamphlet summarizing memory reframing principles (with a video link), and verbal instructions on how to use the intervention principles with their children. The instructions will be provided via telephone or video conferencing and will last approximately 10 to 15 minutes. Trained graduate students or post-doctoral fellows will deliver the instructions. Similar to previous interventions, to boost mastery of the material, the researcher will provide suggestions for specific questions and remarks to make while reminiscing. The instructions will be audio-recorded to allow fidelity coding.
10211119|NCT05217550|Experimental|Intervention (Veggie Brek)|Nursery staff will present vegetables (raw carrot and cucumber batons) to children alongside their main breakfast food for five consecutive days every weekday morning for three weeks.
9871222|NCT00274677|Placebo Comparator|Placebo|
9871223|NCT00274677|Experimental|lamotrigine|
9871224|NCT00274794|Other|Rituxan + Etoposide + G-CSF|
9871225|NCT00274794|Other|Etoposide + G-CSF|
9871226|NCT00274833|Experimental|Radiation Therapy, Temozolomide, and Erlotinib|
9871227|NCT00274989|Experimental|Bendamustine plus Rituximab|
9871228|NCT00275015|Experimental|High dose therapy + autologous PBSCT|"Cytoreductive treatment: (preferentially) FC (2-4 cycles)~Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)~Myeloablation:~fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)~autologous peripheral blood stem cell transplantation (PBSCT) (d 0)"
9871229|NCT00275041|Experimental|cetuximab + irinotecan|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for up to 5 years."
9871230|NCT00275054|Experimental|Cohort I (FCR)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort I receive Fludarabine, Cyclophosphamide and Rituximab (FCR) chemoimmunotherapy.
9871231|NCT00275054|No Intervention|Cohort II (W&W)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort II receive no treatment at all (watch & wait).
9871232|NCT00275054|No Intervention|Cohort III (W&W)|Patients with less than 2 risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) are assigned directly to cohort III and receive no treatment at all (watch & wait).
9871233|NCT00275067|Experimental|Radiation + temozolomide and arsenic trioxide|Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
9871234|NCT00275080|Experimental|Treatment (enzyme inhibitor, chemotherapy)|"Regimen 1 (sequential dosing): Patients receive oral vorinostat two or three times daily on days 6-21 or days 6-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Regimen 2 (concurrent dosing): Patients receive oral vorinostat two or three times daily on days 1-21, days 1-14 (patients with hematological malignancies only), or two times daily on days 1-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5."
9871235|NCT00275093|Experimental|Treatment (temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
9871236|NCT00275132|Experimental|Erlotinib|Tarceva (OSI-774, erlotinib) PO 150mg daily
9871237|NCT00275132|Placebo Comparator|Matched placebo|Matched placebo PO daily
9871238|NCT00275145|Experimental|Resistance Training|8 months of Resistance Exercise Training
9871239|NCT00275145|Experimental|Aerobic Exercise|8 months of Aerobic Exercise Training
9871240|NCT00275145|Experimental|Combination RT & AT|8 months of Combined Aerobic and Resistance Exercise Training
9871241|NCT00275145|Experimental|Control|Control/sedentary intervention
9871242|NCT00275171|Active Comparator|rhTSH|proceeded by 0.1 mg rhTSH
9871243|NCT00275171|Placebo Comparator|Placebo|1 ml isotonic saline
9871244|NCT00275288||Healthy Normal|
9871245|NCT00275288||Active Disease|
9871246|NCT00275366|Other|1|
9871247|NCT00275496|Active Comparator|WEX only|
9871248|NCT00275496|Active Comparator|WEX + SLND|
9871249|NCT00275496|Active Comparator|WEX+SLND+CLND|
9871250|NCT00275535|Active Comparator|Tacrolimus|Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
9871251|NCT00275535|Active Comparator|Sirolimus|Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
9871252|NCT00275548|Other|The Preventative (Prophylaxis) Group:|This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
9871253|NCT00275548|Other|The Observational Group:|This group of patients will receive the study drugs for the treatment of recurring hepatitis C only if they develop the clinical symptoms of hepatitis C infection.
9871254|NCT00275574|Experimental|acupuncture|four acupuncture treatments over a period of two weeks
9871255|NCT00275613|Experimental|Rituximab, IV infusion|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
9871256|NCT00275756|Experimental|1|
9871257|NCT00275756|Experimental|2|
9871258|NCT00275756|Experimental|3|
9935353|NCT03859752|Experimental|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
9871259|NCT00275951|Experimental|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
9871260|NCT00275990|Experimental|thrombectomy before stenting|thrombectomy before stenting
9871261|NCT00275990|Active Comparator|directing stenting alone|directing stenting alone
9871262|NCT00276055|Experimental|Cohort 1|1000mg/m2 gemcitabine
9871263|NCT00276055|Experimental|Cohort 2|1250 mg/m2 gemcitabine
9871264|NCT00276055|Experimental|Cohort 3|1500 mg/m2 gemcitabine
9871265|NCT00276172|Experimental|Natalizumab|Open-label natalizumab
9871266|NCT00276198|Experimental|1|Supplementation with daily sprinkle package
9871267|NCT00276198|Active Comparator|2|Supplementation with Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms. According to Ministry of Health routine recommendations.
9871268|NCT00276198|No Intervention|3|No intervention except for checking outcomes at approprite times.
9871269|NCT00276263|Experimental|1|
9928581|NCT00907985|Experimental|Treatment sequence D|Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
9928582|NCT00907985|Experimental|Treatment sequence E|Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
9928583|NCT00907985|Experimental|Treatment sequence F|Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
9928584|NCT00907985|Experimental|Treatment sequence G|Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
9928585|NCT00907985|Experimental|Treatment sequence H|Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
9928586|NCT00907985|Experimental|Treatment sequence I|Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
9928587|NCT00907985|Experimental|Treatment sequence J|Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
9928588|NCT00907985|Experimental|Treatment sequence K|Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
9928589|NCT00907985|Experimental|Treatment sequence L|Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
9928590|NCT00907985|Experimental|Treatment sequence M|Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
9928591|NCT00907985|Experimental|Treatment sequence N|Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
9928592|NCT00907985|Experimental|Treatment sequence O|Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
9928593|NCT00907985|Experimental|Treatment sequence P|Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
9928594|NCT00907985|Experimental|Treatment sequence Q|Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
9928595|NCT00907985|Experimental|Treatment sequence R|Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
9928596|NCT00907985|Experimental|Treatment sequence S|Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
9928597|NCT00907985|Experimental|Treatment sequence T|Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
9928598|NCT00907998|Experimental|APL180 (first dose level)|
9928599|NCT00907998|Experimental|APL180 (second dose level)|
9928600|NCT00907998|Placebo Comparator|Placebo|
9928601|NCT00908024|Experimental|BMS-754807 + cetuximab|Combination
9928602|NCT00908050|Placebo Comparator|Placebo|Placebo arm
9928603|NCT00908050|Active Comparator|botulinum toxin type A|Active arm
9928604|NCT00908063|Experimental|Oxycyte|"Single intravenous infusion of Oxycyte (Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v)~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
9928605|NCT00908063|Placebo Comparator|Normal Saline|"Single intravenous infusion of Normal Saline~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
9996995|NCT01505023|Active Comparator|Partial meal replacement|
9871270|NCT00276302|Experimental|1|Schedule A: Doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration.
9871271|NCT00276302|Experimental|2|Schedule B: Doses occur on Days 1, 4, 8, 11, 15, and 18 (twice weekly for 3 weeks continuously).
9871272|NCT00276510|Experimental|1|
9871273|NCT00276510|Placebo Comparator|2|
9871274|NCT00276523|Active Comparator|Control|Control (no treatment), conventional surgery.
9871275|NCT00276523|Experimental|PEG-Intron 0.5 mg/kg|PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.
9871276|NCT00276523|Experimental|PEG-Intron 2.5 mg/kg|PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.
9871277|NCT00276523|Experimental|PEG-Intron 5.0 mg/kg|PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.
9871278|NCT00276536|Experimental|Treatment|IFN weekly
9871279|NCT00276575|Experimental|Bevacizumab, Everolimus, and Erlotinib|"Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---~10 5 ---~10 10 ---~10* 10* 75~10* 10* 150"
9871280|NCT00276627|Active Comparator|communication lecture|
9871281|NCT00276627|Experimental|lecture plus CD-ROM|
9871282|NCT00276640|Active Comparator|vincristine, carboplatin|standard chemotherapy group
9871283|NCT00276640|Active Comparator|vincristine, carboplatin, etoposide|intensified induction chemotherapy group
9871284|NCT00276640|Active Comparator|radiation|radiation therapy group
9871285|NCT00276640|No Intervention|Control|Control group: wait and see strategy
9871286|NCT00276783|Experimental|Treatment Arm|Pemetrexed 900 mg/m2 every 21 days until disease progression.
9871287|NCT00276835|Experimental|Genistein and Interleukin-2|
9871288|NCT00276848|Active Comparator|Fludarabine plus Cyclophosphamide|
9871289|NCT00276848|Active Comparator|Fludarabine|
9871290|NCT00276874|Experimental|Aripiprazole|Subjects receive oral aripiprazole.
9871291|NCT00276874|Placebo Comparator|Placebo|Subjects receive oral placebo
9871292|NCT00276939|Experimental|1|Low-fat, low-Glycemic Index, vegan diet
9871293|NCT00276939|Active Comparator|2|ADA diet
9871294|NCT00276965|Experimental|A|Participants will take lithium only.
9871295|NCT00276965|Experimental|B|Participants will take lithium and sertraline.
9871296|NCT00276965|Experimental|C|Participants will take sertraline only.
9871297|NCT00276978|Experimental|Aripiprazole|Aripiprazol augmentation therapy
9871298|NCT00276991|Other|"Kallunk oxide (Immunotherapy)"|"The participants were received a daily regimen of Kallunk oxide(Immunotherapy) ."
9871299|NCT00277043|Experimental|1 Test Dose|
9871300|NCT00277043|Active Comparator|2) Non test dose arm|
9871301|NCT00277160|Experimental|Treatment Group 1 (Primary Prophylaxis)|Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
9871302|NCT00277160|Active Comparator|Treatment Group 2 (Secondary Prophylaxis)|Per Investigator's discretion
9871303|NCT00277186|Active Comparator|Intervention|Patients entering new care continuum
9871304|NCT00277186|Active Comparator|Control|Patient enter existing conventional approach
9871305|NCT00277368||001|
9871306|NCT00277433||Atopic Dermatitis|
9871307|NCT00277433||Non-atopic control|
9871308|NCT00277472|Experimental|valsartan HCTZ|
9871309|NCT00277472|Active Comparator|HCTZ|
9871310|NCT00277537|Experimental|1|
9871311|NCT00277537|Other|2|
9871312|NCT00277589|Experimental|1|
9871313|NCT00277589|Active Comparator|2|
9871314|NCT00277589|Active Comparator|3|
9871315|NCT00277589|Placebo Comparator|4|
9871316|NCT00277641|Experimental|1|lamotrigine
9871317|NCT00277641|Placebo Comparator|2|
9871318|NCT00277654|Active Comparator|Risperidone|
9871319|NCT00277654|Placebo Comparator|Sugar pill|
9871320|NCT00277706|Experimental|FORTEO|
9871321|NCT00277706|Placebo Comparator|Placebo|
9871322|NCT00277758|Experimental|1|Interventions: 12 weeks of interleukin-2 administration, followed by 48 weeks of interleukin-2 + Ribavirin + interferon-alpha therapy, followed by 24 weeks off therapy
9871323|NCT00277758|Active Comparator|2|48 weeks of therapy with Ribavirin + interferon-alpha, followed by 24 weeks off therapy
9871324|NCT00277784||1|Individuals with age related macular degeneration
9871325|NCT00277797|Active Comparator|Biowave first|First Treatment: Biowave; Second Treatment: TENS
9871326|NCT00277797|Active Comparator|TENS first|First Treatment: TENS; Second Treatment: Biowave
9871327|NCT00277862|Active Comparator|1|"Pegylated IFN- alpha 2b~Ribavirin for 24 weeks (patients with RVR)"
9871328|NCT00277862|Active Comparator|2|"Pegylated IFN- alpha 2b~Ribavirin for 36 weeks (patients with complete EVR)"
9871329|NCT00277862|Active Comparator|3|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (patients with partial EVR)"
9871330|NCT00277862|Active Comparator|4|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (control)"
9871331|NCT00277888|Experimental|Femoral route|
9871332|NCT00277888|Experimental|Jugular route|
9935884|NCT03043313|Experimental|Cohort A: Tucatinib + Trastuzumab|Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
9871333|NCT00278070|Active Comparator|1|
9871334|NCT00278070|Active Comparator|2|
9871335|NCT00278070|Active Comparator|3|
9871336|NCT00278135|Active Comparator|1|
9871337|NCT00278135|Placebo Comparator|2|
9871338|NCT00278265|Experimental|MTX followed by fludarabine|MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles
9871339|NCT00278278|Experimental|Arm I|"Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
9871340|NCT00278278|Active Comparator|Arm II|"Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
9871341|NCT00278330|Experimental|Arm I|Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.
9871342|NCT00278343|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
9871343|NCT00278369|Experimental|A|6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
9871344|NCT00278369|Experimental|B|9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
9871345|NCT00278369|Experimental|C|9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
9871346|NCT00278382|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.
9871347|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21|Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9871348|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21 + radiotherapy|Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
9871349|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14|Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9871350|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14 and radiotherapy|Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.
9871351|NCT00278421|Active Comparator|Interventional: 6 R-CHOP-21|Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
9871352|NCT00278421|Active Comparator|Interventional: 4 R-CHOP-21 + 2 x R|Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.
9871353|NCT00278434|Experimental|Zoledronate|"100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
9935885|NCT03043313|Experimental|Cohort B: Tucatinib + Trastuzumab|Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
9871354|NCT00278434|Placebo Comparator|Saline|"100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
9871355|NCT00278447|Active Comparator|1) CDM|Chronic Disease Management
9871356|NCT00278447|Active Comparator|2) Standard care|Standard care
9871357|NCT00278486|Experimental|stem cell transplantation|
9871358|NCT00278499||1|Female sex workers
9871359|NCT00278499||2|Female sex workers' clients (miners)
9871360|NCT00278551|Experimental|heatopoietic stem cell transplant|
9871361|NCT00278577|Experimental|Autologous Hematopoietic Stem Cell Transplant|
9871362|NCT00278590|Experimental|allogeneic stem cell transplantation|allogeneic stem cell transplantation will be performed
9871363|NCT00278642|Experimental|stem cell transplantation|
9871364|NCT00278681|Experimental|I|Zinc and ORS
9871365|NCT00278694|Experimental|Chemoradiation|Neoadjuvant chemotherapy and chemoradiation
9871366|NCT00278746|Experimental|1|Zinc and ORS were promoted for treatment of diarrhea in underfive children
9871367|NCT00278746|Other|2|Promoted routine management of diarrhea in underfive with ORS
9871368|NCT00278772|Experimental|1|Divalproex
9871369|NCT00278772|Placebo Comparator|2|
9871370|NCT00278785|No Intervention|1|Control group to receive informational pamphlet on alcohol use and list of self referral agencies
9871371|NCT00278785|Experimental|2|Intervention group receives pamphlet on alcohol and self referral information in addition to brief motivational interview
9871372|NCT00278824|Experimental|50 mcg/hr matrix fentanyl patch|active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
9871373|NCT00278824|Placebo Comparator|Placebo Patch|placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
9871374|NCT00278837|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress reduction and cognitive-affective-behavioral learning.
9871375|NCT00278902|Experimental|ARRY-334543|
9871376|NCT00279019|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.
9871377|NCT00279019|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.
9871378|NCT00279019|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.
9871379|NCT00279019|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.
9871380|NCT00279019|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.
9871381|NCT00279019|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.
9871382|NCT00279019|Experimental|Subjects receiving treatment sequence 7|Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.
9871383|NCT00279019|Experimental|Subjects receiving treatment sequence 8|Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.
9871384|NCT00279019|Experimental|Subjects receiving treatment sequence 9|Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.
9871385|NCT00279019|Experimental|Subjects receiving treatment sequence 10|Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.
9871386|NCT00279019|Experimental|Subjects receiving treatment sequence 11|Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.
9871387|NCT00279019|Experimental|Subjects receiving treatment sequence 12|Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.
9871388|NCT00279019|Experimental|Subjects receiving treatment sequence 13|Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.
9871389|NCT00279019|Experimental|Subjects receiving treatment sequence 14|Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.
9986817|NCT01406301||Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI|Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI)
9871390|NCT00279019|Experimental|Subjects receiving treatment sequence 15|Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.
9871391|NCT00279019|Experimental|Subjects receiving treatment sequence 16|Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.
9871392|NCT00279110|Experimental|A|
9871393|NCT00279110|No Intervention|B|
9871394|NCT00279149|Experimental|surgery|surgery
9871395|NCT00279175|Experimental|BMC|Intracoronary infusion of autologous bone marrow derived cells
9871396|NCT00279175|Placebo Comparator|Placebo|Intracoronary infusion of Placebo medium
9871397|NCT00279422|Placebo Comparator|placebo|
9871398|NCT00279422|Experimental|visilizumab|
9871399|NCT00279435|Placebo Comparator|placebo|
9871400|NCT00279435|Experimental|visilizumab|
9871401|NCT00279448|Experimental|A|
9871402|NCT00279448|Active Comparator|B|
9871403|NCT00279461|Experimental|A,|Arm A: Vitamin D 2,000 units daily all in one capsule for 6 months
9871404|NCT00279461|Placebo Comparator|B|Arm B: matching placebo one capsule daily for 6 months
9871405|NCT00279487|Active Comparator|Arm 1|Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
9871406|NCT00279487|Placebo Comparator|Arm 2|Patients will receive placebo 1-2 hours prior to surgery.
9928606|NCT00908089|Active Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 35 mg/kg/week)+ Prednisolon 7.5 mg/day + infliximab 3 mg/kg at weeks 4, 6, 10, 18, 26
10211120|NCT05217550|No Intervention|Control|Children will be served their normal breakfast (with no vegetables) across the three-week intervention period.
9928607|NCT00908089|Placebo Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 25 mg/kg/week)+ Prednisolon 7.5 mg/day + placebo at weeks 4, 6, 10, 18, 26
10211121|NCT05217524||Pennington and Univ. of Hawaii cohorts|Same protocol but two different sites.
10211122|NCT05217524||Pennington|Primarily non-Hispanic (NH) White and NH Black at PBRC and more Asian and Native Hawaii or Pacific Islander (NHOPI) at Hawaii.
10211123|NCT05217485|Experimental|Infection and reverted atrial fibrillation|Patients who have developed first-diagnosed atrial fibrillaiton in the context of sepsis or infection
10211124|NCT05217472|Experimental|Ravagalimab|Participants will receive a loading dose of intravenous (IV) ravagalimab dose A at Week 0 followed by subcutaneous (SC) ravagalimab dose A every other week (eow)
10211125|NCT05217472|Placebo Comparator|Placebo|Participants will receive a loading dose of intravenous (IV) placebo at Week 0 followed by subcutaneous (SC) placebo every other week (eow)
9928608|NCT00908102|Active Comparator|BB|"Subjects received the back book booklet, which is an self-information booklet about managing low back symptoms.~Included in the Mild and Mild vs. NC interventions."
9928609|NCT00908102|Experimental|BB+A|"Subjects received a back book booklet and also oral advice based on the back book by the occupational health professional (OH Nurse or OH Physician in mild or moderate intervention, respectively).~Included in the Mild and Mild vs. NC interventions. Arm was also used as a control at the Moderate and Moderate vs. NC interventions."
9986818|NCT01406314|Experimental|Intervention|Intravenous infusion for approximately 48 hours followed by subcutaneous injection
9996996|NCT01505023|Experimental|Partial meal replacement with inulin|
10211126|NCT05217459|Experimental|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
10211127|NCT05217433|Experimental|Investigational product|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
10211128|NCT05217433|Placebo Comparator|Control arm|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
10211129|NCT05217394|Experimental|OTHIG|"Occupational Therapy Handwriting Intervention Guideline - this is the experimental guideline to be tested in this study.~Section C: Intervention for Handwriting Readiness Skills~Handwriting development~Pre-writing skills~Gross motor skills activities~Fine motor skills activities~Motor visual skills activities Section D: Intervention for Handwriting Skills~Handwriting tools~Pencil grasp~Posture and position~Hand dominance~Writing capitals, lowercase, and numbers~Handwriting speed Section E: Handwriting Intervention Module~Session 1: Development of Handwriting Skills Activities~Session 2: Pre-writing Skills Activities~Session 3: Gross and Fine Motor Skills Activities~Session 4: Writing Capital Letters~Session 5: Writing Lowercase Letters~Session 6: Writing Numbers"
10211130|NCT05217394|No Intervention|NOTi|"Natural Occupational Therapy Intervention - this means, the participants in this group are not exposed to the OTHIG. They receive natural OT intervention without exposure to the OTHIG.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia."
10211131|NCT05217355|Experimental|MBA-P01|Experimental group, Dose: 20U
10211132|NCT05217355|Placebo Comparator|Placebo|Placebo gorup, Normal saline
10211133|NCT05217342|Experimental|PVP-Guided|Peripheral venous pressure guided therapy arm
10211134|NCT05217342|Active Comparator|Control|Standard medical therapy arm
10211135|NCT05217329|Experimental|smart phone intervention group|smart phone intervention group stroke subjects completed smart phone App tasks with affected arm or bilateral arm movement
10211136|NCT05217329|Active Comparator|conventional group|stroke subjects receive conventional rehabilitation home program
10211137|NCT05217316|No Intervention|Control Group|Control group will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth.
10211138|NCT05217316|Experimental|Intervention Group|Both groups will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth. The intervention lies in which the intervention group will receive a supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child.
10211139|NCT05217303|Experimental|HL-085|12 mg BID HL-085
10211140|NCT05217290|Experimental|experiment group|
10211141|NCT05217290|No Intervention|control group|
10211142|NCT05217238|Experimental|Age range of 18 to 44 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
10211143|NCT05217238|Experimental|Age range of 45 to 59 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
9871407|NCT00279617|Active Comparator|Levetricetam|open label treatment
9871408|NCT00279630|Experimental|type of exericse|type of exercise
9871409|NCT00279695||1|Subjects with glaucoma and age-matched normals
9871410|NCT00279695||2|normal volunteers, two age groups, one 18-25 years old, one 50 years and older.
9871411|NCT00279695||3|subjects with tumors of the iris and ciliary body
9871412|NCT00279695||4|subjects with age-related macular degeneration and age-matched normals
9871413|NCT00279734|Experimental|Group 1|
9871414|NCT00279734|Active Comparator|Group 2|
9871415|NCT00279734|Active Comparator|Group 3|
9871416|NCT00279734|Active Comparator|Group 4|
9871417|NCT00279773|Experimental|TKI258 - dose escalation|Dose-Escalation
9871418|NCT00279773|Experimental|TKI258 - dose expansion|Dose-Expansion
9871419|NCT00279799|Experimental|Afiya group intervention + HIV prevention phone sessions|Afiya group-based intervention plus individually tailored HIV prevention phone sessions
9871420|NCT00279799|Active Comparator|Afiya group session + nutrition phone sessions|Afiya group-based intervention plus individually tailored nutrition phone sessions
9871421|NCT00279825|Other|Sequence 1|Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
9871422|NCT00279825|Other|Sequence 2|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo.
9871423|NCT00279825|Other|Sequence 3|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Third treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
9871424|NCT00279825|Other|Sequence 4|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
9871425|NCT00279877|Active Comparator|vertebroplasty|vertebroplasty
9871426|NCT00279877|Active Comparator|kyphoplasty|kyphoplasty
9871427|NCT00279903|Active Comparator|Cortisone|
9871428|NCT00279903|Experimental|Low Dose Btx-A|
9871429|NCT00279903|Experimental|High Dose Btx-A|
9871430|NCT00279942|Active Comparator|Soy|A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
9871431|NCT00279942|Placebo Comparator|Placebo|A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
9871432|NCT00280007|Experimental|1|bevacizumab infusion evey 2 weeks
9871433|NCT00280007|Placebo Comparator|2|placebo infusion
9871434|NCT00280020|Experimental|CBT|
9871435|NCT00280020|Experimental|TCC|
9871436|NCT00280020|Active Comparator|SS|
9871437|NCT00280033|Placebo Comparator|9|Saline administered on days 0 and 28.
9871438|NCT00280033|Experimental|8|45 mcg alone administered on days 0 and 28.
10211144|NCT05217238|Experimental|Age range of 60 to 80 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
9871439|NCT00280033|Experimental|7|30 mcg plus aluminum hydroxide administered on days 0 and 28.
9871440|NCT00280033|Experimental|6|30 mcg alone administered on days 0 and 28.
9871441|NCT00280033|Experimental|5|15 mcg plus aluminum hydroxide administered on days 0 and 28.
9871442|NCT00280033|Experimental|4|15 mcg plus MF59 administered on days 0 and 28.
9871443|NCT00280033|Experimental|3|15 mcg alone administered on days 0 and 28.
9871444|NCT00280033|Experimental|2|7.5 mcg plus aluminum hydroxide administered on days 0 and 28.
9871445|NCT00280033|Experimental|1|7.5 mcg plus MF59 administered on days 0 and 28.
9871446|NCT00280098|Experimental|single group|
9871447|NCT00280111|Experimental|1|116E AGMK
9871448|NCT00280111|Experimental|2|I321 AGMK
9871449|NCT00280111|Placebo Comparator|3|Placebo
9871450|NCT00280215|Active Comparator|1|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
9871451|NCT00280215|Placebo Comparator|2|Patients will take placebo for 24 months.
9871452|NCT00280228|Experimental|1|Home Based Treatment
9871453|NCT00280228|Active Comparator|2|Treatment as Usual
9871454|NCT00280280|Experimental|1|This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.
9871455|NCT00280319|Experimental|IPT arm|interpersonal psychotherapy for groups (IPT-G). this consists of psychotherapy provided to participants in a group format.
9871456|NCT00280319|Experimental|CP arm|Creative Play therapy consists of play activities provided to participants in groups.
9871457|NCT00280319|No Intervention|control|those who are wait-list controls
9871458|NCT00280332||A|colonic adenoma
9871459|NCT00280332||B|colonic without adenoma
9871460|NCT00280462|Active Comparator|1|Nifedipine
9871461|NCT00280462|Active Comparator|2|L-Arginin
9871462|NCT00280462|Placebo Comparator|3|Placebo
9871463|NCT00280475|Active Comparator|1|Device: Whole brain radiation therapy arm
9871464|NCT00280475|Experimental|2|Device: Salvage stereotactic radiosurgery arm
9871465|NCT00280488|Active Comparator|1) MI with SO|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with inclusion of a significant other (SO) in prolonged, intensive alcohol treatment.
9871466|NCT00280488|Active Comparator|2) MI with patient only|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with the individual patient
9871467|NCT00280488|Active Comparator|3) Assessment only|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
9871468|NCT00280501|Active Comparator|1|Quetiapine
9871469|NCT00280501|Active Comparator|2|Sulpiride
9871470|NCT00280501|Placebo Comparator|3|Placebo
9871471|NCT00280553|No Intervention|patient controlled analgesia (PCA) only|
9871472|NCT00280553|Other|PCA and pump with saline infusion for up to five days|
9871473|NCT00280553|Other|PCA and bupivicaine infusion for up to five days|
9871474|NCT00280579||Cases|Cases would have had their blood cyanide concentration measured
9871475|NCT00280592|Placebo Comparator|Placebo|
9871476|NCT00280592|Experimental|Cranberry|Cranberry
9871477|NCT00280631|Experimental|1|Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
9871478|NCT00280657|Experimental|Arm 1|
10211145|NCT05217160|Experimental|KeraStat® Gel with Morphine|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
9871479|NCT00280657|Active Comparator|Arm 2|
9871480|NCT00280657|Placebo Comparator|Arm 3|
9871481|NCT00280670|Experimental|Cognitive Behavioral Therapy|
9871482|NCT00280670|No Intervention|Waitlist|
9871483|NCT00280696|Experimental|Lev 0.5 g|Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
9871484|NCT00280696|Experimental|Lev 1 g|Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
9871485|NCT00280696|Experimental|Lev 2 g|Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
9871486|NCT00280696|Experimental|Lev 3 g|Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
9986819|NCT01406327||Subjects prescribed ambrisentan|Subjects with pulmonary arterial hypertension (PAH) prescribed ambrisentan during study period
9986820|NCT01406340|Experimental|Normal subjects and subjects with Stage 3/4 renal function|Subjects will receive 5mg GSK1278863 for 14 days.
9986821|NCT01406340|Experimental|Subjects with Stage 5 renal function|Subjects will receive 5mg GSK1278863 for 15 days.
9986822|NCT01406353|Active Comparator|Early Percutaneous Mitral Intervention|early elective percutaneous mitral commissurotomy within 3 months of enrollment
9986823|NCT01406353|No Intervention|Conventional Treatment|All patients in the conventional treatment group regularly visit their attending physicians at 3 monthly interval for maintenance of anticoagulation therapy or every year for annual re-evaluation. Patients who become symptomatic during follow-up are referred for percutaneous mitral commissurotomy or mitral valve surgery.
9986824|NCT01406366||Group 1|Group 1: 16 programs / 148 residents
9986825|NCT01406366||Group 2|Group 2: 16 programs / 142 residents
9986826|NCT01406379|Experimental|Prophylactic clip|Prophylactic clip
9986827|NCT01406379|Active Comparator|Detachable snare|Detachable snare
9986828|NCT01406392|Active Comparator|Sublingual Misoprostol 12,5mcg|Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
9986829|NCT01406392|Active Comparator|Vaginal Misoprostol 25 mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.
9986830|NCT01406405||PEEK cages|Patients will have fusion surgery performed using polyetheretherketone (PEEK) cages
9986831|NCT01406405||Allograft spacers|Patients will have fusion surgery performed using allograft spacers
9986832|NCT01406418|Experimental|Cohort 1: CR6261|2 mg/kg CR6261
9986833|NCT01406418|Placebo Comparator|Cohort 1: Placebo|5% dextrose in water
9986834|NCT01406418|Experimental|Cohort 2: CR6261|5 mg/kg CR6261
9986835|NCT01406418|Placebo Comparator|Cohort 2: Placebo|5% dextrose in water
9986836|NCT01406418|Experimental|Cohort 3: CR6261|15 mg/kg CR6261
9986837|NCT01406418|Placebo Comparator|Cohort 3: Placebo|5% dextrose in water
9986838|NCT01406418|Experimental|Cohort 4: CR6261|30 mg/kg CR6261
9986839|NCT01406418|Placebo Comparator|Cohort 4: Placebo|5% dextrose in water
9986840|NCT01406418|Experimental|Cohort 5: CR6261|50 mg/kg CR6261
9986841|NCT01406418|Placebo Comparator|Cohort 5: Placebo|5% dextrose in water
9986842|NCT01406418|Experimental|Cohort 6: CR6261|30 mg/kg CR6261
9871487|NCT00280696|Placebo Comparator|Placebo|Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
9986843|NCT01406418|Placebo Comparator|Cohort 6 Placebo|5% dextrose in water
9986844|NCT01406431|Active Comparator|Pitavastatin + Valsartan|Intervention: Drug: Pitavastatin, Valsartan
9986845|NCT01406431|Experimental|Livalo fixed combination drug|Intervention: Drug: Livalo® fixed combination drug
9986846|NCT01406470|Experimental|IVIG-SN™|Immune Globulin Intravenous (Human) 5% Liquid
9986847|NCT01406483|Other|CABG|
9986848|NCT01406496|Experimental|Timing of insulin administration|
9986849|NCT01406509|Experimental|children aged 2-5 years (1 dose)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 2-5 years, on day 0
9986850|NCT01406509|Experimental|children aged 6-23months (2 doses)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 6-23 months old, on day 0, 28
9986851|NCT01406522|Placebo Comparator|Oral placebo|Inactive treatment
9871488|NCT00280709|Active Comparator|1|Covered metal stent
9871489|NCT00280709|Active Comparator|2|Uncovered metal stent
9871490|NCT00280800|Active Comparator|1|constant CPAP
9871491|NCT00280800|Experimental|2|automatic CPAP
9871492|NCT00280813|Active Comparator|Supportive Treatment in Alcohol Recovery (STAR)|
9871493|NCT00280839|Active Comparator|topiramate|
9871494|NCT00280839|Placebo Comparator|placebo|
9871495|NCT00280969|Experimental|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
9871496|NCT00280969|Active Comparator|efavirenz arm|Patients are treated with efavirenz 300mg along with Epzicom.
9871497|NCT00280995|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
9871498|NCT00280995|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
9871499|NCT00280995|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
9871500|NCT00280995|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
9871501|NCT00281008|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
9871502|NCT00281008|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
9871503|NCT00281008|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
9871504|NCT00281008|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
9871505|NCT00281034||OASIS Study Group|
9871506|NCT00281073|Active Comparator|TEE and ICE|Serial use of TEE and ICE for comparative analysis
9871507|NCT00281073|Active Comparator|ICE or TEE|
9871508|NCT00281190||Healthy smokers|Smokers with normal pulmonary function
9871509|NCT00281190||COPD patients|COPD patients
9871510|NCT00281203||healthy smokers|Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.
9986852|NCT01406522|Experimental|Oral tacrine|Oral tacrine
9986853|NCT01406548|Experimental|BPS804 dosing frequency 1|
9986854|NCT01406548|Placebo Comparator|placebo dosing frequency 1|
9986855|NCT01406548|Experimental|BPS804 dosing frequency 2|
9986856|NCT01406548|Placebo Comparator|placebo dosing frequency 2|
9986857|NCT01406548|Experimental|BPS804 dosing frequency 3|
9986858|NCT01406548|Placebo Comparator|Placebo dosing frequency 3|
9871511|NCT00281242||Research subjects|All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
9871512|NCT00281255|Experimental|allopurinol|
9871513|NCT00281255|Placebo Comparator|placebo|
9871514|NCT00281346|Experimental|transthoracic Doppler echocardiography|
9871515|NCT00281359|Experimental|With heat|heat applied to contracted tissues prior to using the active stretching orthosis.
9871516|NCT00281359|Placebo Comparator|Without heat|No heat applied to the contracted tissues prior to using the stretching orthosis
9871517|NCT00281424|No Intervention|control|no pedometer
9871518|NCT00281424|Experimental|pedometer|given pedometer
9871519|NCT00281489|Experimental|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
9871520|NCT00281489|Active Comparator|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
9871521|NCT00281515|Experimental|Lonafarnib / Paclitaxel /Carboplatin|
9871522|NCT00281515|Other|Paclitaxel/Carboplatin|Standard Chemotherapy
9871523|NCT00281554|Experimental|1|
9871524|NCT00281606|Active Comparator|LPV/r (800/200 mg) 10 ml liquid|Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
9871525|NCT00281606|Active Comparator|LPV/r (800/200 mg) 6 gel capsules|Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
9871526|NCT00281619||Mycophenolic Acid (CellCept)|purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose
9871527|NCT00281736|Experimental|Arm I|Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.
9871528|NCT00281736|Experimental|Arm II|Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.
9871529|NCT00281892|Experimental|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
9871530|NCT00281892|Active Comparator|fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
9871531|NCT00281944|Experimental|Treatment (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9871532|NCT00281983|Experimental|Allogeneic stem cell transplantation|"Cytoreductive therapy for inducing a state of partial remission:~FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)~Conditioning regimen:~FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)~allogeneic-PBSCT (from HLA-identical donor)~GVHD prophylaxis: CSA + MTX or MMF~+/- DLI (Donor lymphocyte infusions)"
9871533|NCT00282009|Active Comparator|Basic Internet|Basic Internet
9871534|NCT00282009|Experimental|Enhanced Internet|Enhanced Internet
9871535|NCT00282009|Experimental|Enhanced Internet plus Phone|Enhanced Internet + proactive telephone counseling
9871536|NCT00282035|Experimental|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
9871537|NCT00282035|Other|Whole breast irradiation|Whole breast irradiation
9871538|NCT00282100|Experimental|Gefitinib (Iressa)|Open label single arm study of Gefitinib (Iressa) 250mg daily as adjuvant therapy in patients with resectable Hepatocellular Carcinoma
9871539|NCT00282126|Experimental|1|Participants will receive 90 meq of potassium citrate.
9871540|NCT00282126|Experimental|2|Participants will receive 60 meq of potassium citrate.
9871541|NCT00282126|Placebo Comparator|3|Participants will receive placebo.
9871542|NCT00282165|Placebo Comparator|placebo|four week double blind placebo treatment phase
9871543|NCT00282165|Active Comparator|naratriptan|four week double blind experimental treatment using daily naratriptan tablets
9871544|NCT00282178|Active Comparator|1|Candesartan 16-32 mg once daily
9871545|NCT00282178|Active Comparator|2|Hydrochlorothiazide 25-50 mg once daily
9871546|NCT00282178|Placebo Comparator|3|
9871547|NCT00282204|No Intervention|Control|Usual care control
9871548|NCT00282204|Experimental|Hypnosis + CD|Hypnosis plus audio cd on hypnosis
9871549|NCT00282204|Active Comparator|Audio CD on Hypnosis|Audio CD on hypnosis sessions weekly on three occasions after 34 weeks gestation
9871550|NCT00282399|Experimental|DACO-019 2mg/m^2|DACO-019 2mg/m^2 twice daily (BID)
9871551|NCT00282399|Experimental|DACO-019 5mg/m^2|DACO-019 5mg/m^2 BID
9871552|NCT00282399|Experimental|DACO-019 10mg/m^2|DACO-019 10mg/m^2 BID
9871553|NCT00282425|Experimental|Allogeneic Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
9871554|NCT00282503|Active Comparator|methylprednisolone equivalent.|2mg/kg daily will be administered initially and may be tapered according to a tapering schedule provided in the protocol.
9871555|NCT00282503|Experimental|Uvadex+ECP|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days"
9871556|NCT00282581|Placebo Comparator|placebo|
9871557|NCT00282646|Active Comparator|1|intraarterial application of bone marrow mononuclear cells
9871558|NCT00282646|Placebo Comparator|2|intraarterial application of placebo
9871559|NCT00282685|Experimental|Intra-arterial stemcell therapy|Patients were treated with intra-arterial stemcells delivered via catheter examination
9871560|NCT00282711||1|Standard Exercise treadmill test
9871561|NCT00282711||2|Exercise treadmill testing with nuclear imaging
9871562|NCT00282776|Active Comparator|TAU|Participants will receive treatment as usual
9871563|NCT00282776|Experimental|DCM|Participants will receive care management for postpartum depression
9871564|NCT00282802||1|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort
9871565|NCT00282854||Group I: Cases|Children with rolandic epilepsy
9871566|NCT00282854||Group II: Controls|Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
9871567|NCT00282893|Experimental|pTBA|Prophylactic Transluminal Ballooning Angioplasty
9871568|NCT00282893|Active Comparator|Control|currently existing therapies for the treatment of vasospasm
9871569|NCT00282906|Experimental|PET-CT|
9871570|NCT00283010|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
9871571|NCT00283010|Active Comparator|Active Control|Educational DVDs
9871572|NCT00283023|Experimental|A|Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
9928610|NCT00908102|Experimental|DBC|A graded activity back school program was carried out in a physiotherapy out-patient clinic that consisted of one-hour session twice or three times per week, lasting for 12 weeks, supervised by a specially trained physiotherapist. Arm is included in the MOderate and Moderate vs. NC interventions.
9928611|NCT00908102|Experimental|PMU|An intensive, multidisciplinary LBP rehabilitation program was carried out in a physical medicine out-patient unit at the local Central Hospital. The program included a 3-week pre-course of 1,5 hour session at 3 days per week, closely followed by a 3-week intensive rehabilitation course of 6.5 hours per day for 5 days per week. A personal graded activity training program was made for each subject and patients were later called for follow-up visit within 1 year of the initial course. Arm is included in the MOderate and Moderate vs. NC interventions.
9928612|NCT00908102|Placebo Comparator|NC|Natural course of low back pain
9928613|NCT00908154|Other|Cohort 1|
9928614|NCT00908154|Other|Cohort 4|
9928615|NCT00908154|Other|Cohort 3|
9928616|NCT00908154|Other|Cohort 2|
9928617|NCT00908167|Other|Research Participants|Participants treated with sorafenib, cytarabine and clofarabine.
9928618|NCT00908193|Experimental|1|robot-assisted coelioscopy
9928619|NCT00908193|Active Comparator|2|conventional coelioscopy
9928620|NCT00908206|Placebo Comparator|Placebo|Placebo to match GSK598809.
9928621|NCT00908219|Experimental|Bevacizumab IV|All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study.
9928622|NCT00908245|Experimental|Preconditioning|Surgery with ischemic preconditioning
9928623|NCT00908245|Active Comparator|Control|Surgery without preconditioning ischemia
9928624|NCT00908271|Other|Dapagliflozin|PO and IV
9928625|NCT00908284|Active Comparator|Control Group|Participants will take part in a 12-week control group.
9928626|NCT00908284|Experimental|Exercise Program|Participants will take part in a 12-week exercise program.
9928627|NCT00908323||A|Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
9928628|NCT00908323||B|Participants receiving the placebos of the JS7 DNA and MVA/HIV62 vaccines in HVTN 205
9928629|NCT00908336|Experimental|Docetaxel and Erlotinib|"Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.~After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment."
9928630|NCT00908336|Active Comparator|Erlotinib|Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
9928631|NCT00908362|Active Comparator|A|Inhalation of Fluticasone (via discus) twice daily for 28 days
9928632|NCT00908362|Active Comparator|B|Inhalation of Fluticasone and Salmeterol (via discus) twice daily for 28 days
9928633|NCT00908362|Placebo Comparator|C|Inhalation of Placebo (via discus) twice daily for 28 days.
9928634|NCT00908401|Active Comparator|sucrose|This group will receive oral sucrose for procedural pain
9928635|NCT00908401|Experimental|breastmilk|this group will receive breastmilk as analgesic product to avoid procedural pain
9928636|NCT00908414|Experimental|Panel 1: Single Dose Escalation|Panel 1 will receive doses of 40 milligram (mg) (Session Ia), 100 mg (Session IIa), 200 mg (Session IIIa) and 400 mg (Session IVa) of TMC589337 or placebo.
9928637|NCT00908414|Experimental|Panel 2: Single Dose Escalation|Panel 2 will receive doses of 40 mg (Session Ib), 100 mg (Session IIb), 200 mg (Session IIIb) and 400 mg (Session IVb) of TMC589354 or placebo.
9935886|NCT03043313|Experimental|Cohort C: Tucatinib Monotherapy|Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
9986859|NCT01406587|Experimental|PP4001 50 mg|
9986860|NCT01406587|Experimental|PP4001 100 mg|
9986861|NCT01406587|Experimental|PP4001 200 mg|
9986862|NCT01406587|Placebo Comparator|Placebo|
9986863|NCT01406600|Active Comparator|rhCG 250mcg|For final oocyte maturation triggering in ART, rhCG 250mcg will be administrated.
9986864|NCT01406600|Experimental|rhCG 500mcg|For final oocyte maturation triggering in ART, rhCG 500mcg will be administrated.
9986865|NCT01406613||Particpants of previous TRIO study|All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
9986866|NCT01406626|Experimental|Peer Navigation Intervention Arm|"Subjects will receive the following peer navigation services:~1) 10 Navigator meetings: Navigators will meet with participants in person to teach linkage/retention skills and knowledge~2a) 2 Navigator accompaniment sessions: the peer navigator will accompany participants to HIV care appointment. Before and after the appointment, participants and navigators will review linkage and retention skills/knowledge and things that make it hard or easy for him/her to get regular HIV care~2b) Optional peer navigator accompaniment sessions: If the participant requests, the peer navigator will provide accompaniment to supportive HIV care appointments (one per month max)~3) 14 peer navigator care calls: During these calls, navigators and participants will talk about any problems that could make it difficult to get regular HIV care."
9986867|NCT01406626|No Intervention|Usual Care|Participants assigned to the control arm will receive the transitional case management (TCM) services that are currently offered at the jail
9986868|NCT01406639|Experimental|Ranibizumab|Patients treated with topical ranibizumab.
9986869|NCT01406665||increased diabetes risk|the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes
9986870|NCT01406678|Active Comparator|RIPC|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
9986871|NCT01406678|Placebo Comparator|Control|Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol
10211146|NCT05217160|Active Comparator|KeraStat® Gel|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
10211147|NCT05217147||Patient group|60 patients with laryngeal carcinoma
9986872|NCT01406691|Experimental|Light|three hours of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during three hours immediately prior to desired waketime
9986873|NCT01406691|Placebo Comparator|Fake light|during three hours immediately prior to desired waketime, subjects will receive no light (light flash device will be disabled)
9986874|NCT01406704|No Intervention|Control|
9986875|NCT01406704|Experimental|Rosiglitazone|Rosiglitazone (8 mg/day)
10211148|NCT05217147||Control group|20 healthy age- and sex- matched controls
9986876|NCT01406704|Experimental|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
9986877|NCT01406704|Experimental|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
9986878|NCT01406730|Experimental|exercise|16 weeks of running exercise
9986879|NCT01406730|No Intervention|control|
9986880|NCT01406743||EOS™ Acquisition|
9986881|NCT01406769|Experimental|Diagnostic (bioimpedance to measure lymphedema)|Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy.
9986882|NCT01406808|Other|standard of care plus genetic information|
9986883|NCT01406808|No Intervention|usual standard of care without genetic information|
9986884|NCT01406821|Sham Comparator|Dry needling|Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.
9986885|NCT01406821|Experimental|Platelet-rich plasma (PRP)|Blood will be drawn, and platelet-rich plasma will be injected into the tendon.
9986886|NCT01406847|Experimental|Spinal Manipulation|High-velocity manual technique applied to the pelvis with the participant in supine
9986887|NCT01406847|Sham Comparator|Static Touch|Practitioner hands are placed on the lumbar spine with the participant in prone.
9986888|NCT01406847|Active Comparator|Spinal Mobilization|Oscillation of the third lumbar level performed with the participant in prone
10211149|NCT05217121|Active Comparator|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
9517866|NCT03302182|Experimental|Fed group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.~For group3:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group4:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
9986889|NCT01406886|Experimental|Energy density|Low or high energy density meal
9986890|NCT01406899|No Intervention|Treatment as Usual|Standard treatment as usual (TAU) in the VA Connecticut Healthcare System substance abuse clinic consisting of individual and group therapy sessions and regular urine monitoring.
9996997|NCT01505023|Active Comparator|Inulin|
9996998|NCT01505023|No Intervention|No intervention|
9517867|NCT03302169|Experimental|Posterior Rhabdosphincter Reconstruction|Patients in who posterior rhabdosphincter reconstruction is performed
9517868|NCT03302169|Active Comparator|Standard Technique|Patients in who posterior rhabdosphincter reconstruction is NOT performed, Standard technique.
9871573|NCT00283088|Active Comparator|Group 1|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
9871574|NCT00283088|Active Comparator|Group 2|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
9871575|NCT00283088|No Intervention|Group 3|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
9871576|NCT00283088|Active Comparator|Group 4|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
9871577|NCT00283088|Active Comparator|Group 5|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
9871578|NCT00283088|Active Comparator|Group 6|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
9871579|NCT00283101|Experimental|1|SGN-40
9871580|NCT00283114|Experimental|1|
9871581|NCT00283153|Experimental|FAR|Facial affect recognition training (with computer assistance)
9871582|NCT00283153|Experimental|SEI|Stories of Emotional Inference
9871583|NCT00283166|Experimental|A|Tailored Coaching and Education
9871584|NCT00283166|Other|B|Active Control
9871585|NCT00283309|Active Comparator|Memantine|Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
9871586|NCT00283309|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
9871587|NCT00283309|Active Comparator|Riluzole|Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.
9871588|NCT00283322||Medical ICU patients|Patients admitted to a medical intensive care unit
9871589|NCT00283322||Surgical ICU patients|Patients admitted to a surgical-trauma intensive care unit
9871590|NCT00283322||Neuro ICU patients|Patients admitted to a neuro-trauma intensive care unit
9871591|NCT00283335|Active Comparator|Gemfibrozil|1200 mg slow-release gemfibrozil (Lopid-SR) once per day
9996999|NCT01505036|Experimental|SMARTCARE service|U-Health service
9871592|NCT00283335|Placebo Comparator|Placebo|Matching placebo tablets taken once per day
9871593|NCT00283413|Experimental|1|Symbiot Covered Stent System
9871594|NCT00283413|Active Comparator|2|Commercially available bare metal stent
9871595|NCT00283452|Experimental|Intervention Group|Participation in phone/mail-based intervention to maintain physical activity.
9871596|NCT00283452|No Intervention|Control|No intervention; participation in surveys only
9871597|NCT00283491|Active Comparator|A|
9871598|NCT00283491|Placebo Comparator|B|
9871599|NCT00283517||001|
9871600|NCT00283556|Experimental|Cohort #1|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
9871601|NCT00283556|Experimental|Cohort #2|"Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
9871602|NCT00283556|Experimental|Cohort #3|"Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
9871603|NCT00283608||Anastrozole|Blood draws for baseline and six to twelve weeks.
9871604|NCT00283608||Exemestane|Blood draws for baseline and six to twelve weeks
9871605|NCT00283621|Experimental|Growth Factors + Adriamycin/Ifosfamide|Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)
9871606|NCT00283660|Experimental|Active|Dietary Supplement: 10 mg zinc oxide
9871607|NCT00283660|Placebo Comparator|Placebo|Placebo (double blinded)
9871608|NCT00283699|Active Comparator|1|"albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy~placebo plus standard symptomatic therapy"
9871609|NCT00283699|Placebo Comparator|2|
9871610|NCT00283725||Galantamine|
9871611|NCT00283725||No Alzheimer's disease (AD) treatment|
9871612|NCT00283738|Active Comparator|1|
9871613|NCT00283738|Placebo Comparator|2|Sham control
9871614|NCT00283829|Other|I|Docetaxel followed by IL-2
9871615|NCT00283855|No Intervention|Control Group|No intervention
9871616|NCT00283855|Active Comparator|Online Self-Management|RAHelp.org
9871617|NCT00283946|Experimental|1|
9871618|NCT00283946|Active Comparator|2|
9871619|NCT00283959|Experimental|Migalastat|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week extension period.
9871620|NCT00284011|Active Comparator|SAMe|Two 400 mg pills.
9871621|NCT00284011|Placebo Comparator|Placebo|Two placebo pills (identical in appearance to SAMe).
9871622|NCT00284063|Active Comparator|Group 1: N; SPP; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
9871623|NCT00284063|Active Comparator|Group 2: N; SMT; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
9871624|NCT00284063|Active Comparator|Group 3: N; SMT; SP|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
9871625|NCT00284063|No Intervention|Group 4: N and SP|N = neutral MRI SP = side posture MRI SPP = side posture position SMT = side posture manipulation
9871626|NCT00284102|Experimental|1|ALI/ARDS patients
9997000|NCT01505036|No Intervention|Usual care|Usual care
9986891|NCT01406899|Experimental|Computer-based treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
9986892|NCT01406912|Active Comparator|Recreational Activity Arm|recreational activity includes playing cards, ominoes, jenga or a ball game.
9986893|NCT01406912|Experimental|Wii Gaming System Arm|Use of Wii gaming technology (e.g. commercially available games)
9986894|NCT01406925|Placebo Comparator|Control|Placebo control
9986895|NCT01406925|Experimental|Low dose NRL001|0.5% NRL001 cream
9986896|NCT01406925|Experimental|Intermediate dose NRL001|0.75% NRL001 cream
9986897|NCT01406925|Experimental|High dose NRL001|1.0% NRL001 cream
9986898|NCT01406951||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
9986899|NCT01406951||sepsis|SIRS + infection
9986900|NCT01406951||VAP|(1) after 48-72h endotracheal intubation, X-ray film displays new or progressive infiltrating focus; (2)The patient is in two of the following conditions: a. fever (temperature >38 ℃ or higher than basal temperature; b. peripheral WBC count≥10×10∧9/L，or <4×10∧9/L; c. appearance or increase of purulent respiratory tract secretion. Besides the diagnostic norms above, it is suggested that lower respiratory tract secretions be collected under the bronchoscope and half-quantitative etiological culture be carried out through the medium of BALF samples (diagnostic threshold value:104cfu/mL ).
9986901|NCT01406964|Experimental|Arm A|Arm A performs a CAT test to study tubal factor causes
9986902|NCT01406964|Experimental|Arm B|In Arm B a histerosalpingography is performed.
9986903|NCT01406977|Experimental|BPS804 dose escalation|
9986904|NCT01407016|Experimental|1.0|
9986905|NCT01407042||mb-UKA|Patients with unicondylar osteoarthritis of the knee
9986906|NCT01407055|No Intervention|Standard Medical Care|Patients receive standard treatment protocol for Coronary Artery Bypass Graft Surgery
9986907|NCT01407055|Active Comparator|Attention Control Group|In addition to standard medical care patients receive a comparable amount of therapist´s attention (common and unspecific factors = supportive therapy) to the intervention group, without targeting patients' expectations.
9986908|NCT01407055|Experimental|Expectation Manipulation Intervention|In addition to standard medical care patients' expectations prior to surgery are targeted in a brief psycho-educational intervention.
9986909|NCT01407081|Experimental|Training|telerehabilitation cognitive strategy training
9986910|NCT01407120|Experimental|Mother Program|11 session program focused on parenting skills
9986911|NCT01407120|Experimental|Mother Plus Child Program|11 session Mother Program focused on parenting skills plus 11 session Child program focused on child coping skills
9986912|NCT01407120|No Intervention|Literature Control|Families received books on children's post-divorce adjustment
9986913|NCT01407133|Experimental|Active rTMS|"48 subjects will receive active temporal rTMS, applied with the following combined parameters:~intensity: 100% of resting motor threshold~stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz)~number of stimulations per session: 300, 900 or 1800 per session~number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week)~total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions)."
9986914|NCT01407133|Sham Comparator|Sham rTMS|16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)
9986915|NCT01407159||Thoracic Stentgraft plus E-XL|male and female patients with complicated type B aortic dissection involving the infra-diaphragmatic aorta treated with any thoracic stentgraft extended by the E-XL aortic stent
9986916|NCT01407159||Control group|"historical control group fulfilling the following criteria:~Age +/- 3 years~Sex matched~Same follow-up period"
9871627|NCT00284115|Experimental|Mechanical gait repetitive training|Body weight support treadmill training technique enabling nonambulatory patients to have the repetitive practice of a gate-like movement
9871628|NCT00284115|Active Comparator|Conventional rehabilitation program|Physiotherapeutic conventional rehabilitation program
9871629|NCT00284193|Experimental|feiba-VIIa, hemophilia A-inhibitor therapy|COMBINED PATIENT- TAILORED THERAPY WITH CONCOMITANT ADMINISTRATION OF BOTH DRUGS , FOLLOWING EX VIVO THROMBIN GENERATION PREDICTING ASSAYS
9871630|NCT00284219|Active Comparator|Real high frequency rTMS|The patients will undergo a series of treatments of high frequency rTMS
9871631|NCT00284219|Sham Comparator|Sham high frequency rTMS|The patients will receive a series of sham treatments.
9871632|NCT00284258|Experimental|1|CPT-11 and TS-1
9871633|NCT00284258|Active Comparator|2|CPT-11, 5-FU and l-LV
9871634|NCT00284297|Experimental|knee arthrodesis|
9871635|NCT00284310|Experimental|wrist surgery|
10211150|NCT05217121|Active Comparator|Group M = mTLIP block group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
9871636|NCT00284427|Experimental|1|Vitamin C
9871637|NCT00284453||1|Forty(40)subjects that have received >2 appropriate ICD shock therapies
9871638|NCT00284453||2|Twenty(20)subjects that have received 1-2(low level)appropriate ICD therapies
9871639|NCT00284453||3|Ten(10)subjects that received inappropriate therapies from their ICD
9871640|NCT00284492|Active Comparator|Lifestyle advice|
9871641|NCT00284492|Experimental|Lifestyle advice and acupuncture therapy|
9871642|NCT00284609|Experimental|1|
9871643|NCT00284609|Active Comparator|2|
9871644|NCT00284661|Experimental|FAST FIX|Inetrvention is Fast Fix repair of meniscal tear
9871645|NCT00284661|Experimental|Meniscal suturing|Intervention is Standard suturing of meniscal tear
9928638|NCT00908414|Experimental|Panel 3: Multiple dosing|AA mg (Final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. (twice daily) during 7 days (Session Va) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIa).
9928639|NCT00908414|Experimental|Panel 4: Multiple dosing|BB mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session Vb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIb).
9928640|NCT00908414|Experimental|Panel 5: Multiple dosing|CC mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. during 7 days (Session VIa) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXa).
9928641|NCT00908414|Experimental|Panel 6: Multiple dosing|DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
9928642|NCT00908414|Experimental|Panel 7: Multiple dosing|EE mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) or YY mg TMC589354 (n=6) b.i.d. or q.d. during 7 days (Session VII) ) plus a single oral dose of 300 mg or 600mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg or 600 mg TMC310911, single dose (Session X).
9928643|NCT00908427|Active Comparator|1|PVP group
9928644|NCT00908427|Active Comparator|2|TURP group
9928645|NCT00908453|Experimental|15mg/kg of loading dose|
9928646|NCT00908453|Experimental|18mg/kg of loading dose|
9928647|NCT00908453|Experimental|22.5mg/kg of loading dose|
9928648|NCT00908479|Experimental|LE|Leg Exercise group
9928649|NCT00908479|Experimental|LM|Leg Management (Control group)
9928650|NCT00908492|Active Comparator|Education Control|
9928651|NCT00908492|Experimental|Environmental Skill Building|
9928652|NCT00908505|Experimental|physiotherapy|
9928653|NCT00908518||Total Intravenous Anesthesia|Propofol based anesthesia
9928654|NCT00908518||Inhaled anesthesia|Isoflurane based anesthesia
9928655|NCT00908531|Active Comparator|Postoperative letrozole|Definitive surgery without preoperative AI treatment
9928656|NCT00908531|Experimental|Preoperative letrozole|Treatment with letrozole for 4 months before definitive surgery.
10211151|NCT05217108|Other|Fit Bit (Study Groups)|Participants wear a Fitbit every day for 8 weeks to record the number of steps you take
10211152|NCT05217082||Cohort 1|Participants with relapsed/refractory multiple myeloma (RRMM) who have already received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody
10211153|NCT05217069|Other|RAS wild-type Avelumab|"Induction therapy:~FOLFIRI 5-FU: 400 mg/m2 (i.v. bolus) Folinic acid: 400mg/m2 Irinotecan: 180 mg/m2 5-FU: 2.400 mg/m2 (i.v. 46h)~Cetuximab 400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w~Maintenance therapy:~Avelumab 10mg/kg IV (day 1 q2w)"
10211154|NCT05217056||1/Measurement|All of the infants with high risk of cerebral palsy
10211155|NCT05217004|Experimental|Dementia Talk|Participants in this group will be asked to use the mobile app Dementia Talk over a 2-week period.
10211156|NCT05217004|Experimental|CLEAR Dementia Care|Participants in this group will be asked to use the mobile app CLEAR Dementia Care over a 2-week period.
9928657|NCT00908557|Experimental|1|Patients receiving an information and consent form that has been modified using the LISYCOM methods.
9928658|NCT00908557|Active Comparator|2|Patients receiving a standard information and consent form.
9928659|NCT00908570|Experimental|1Topical estriol cream|
9928660|NCT00908570|Placebo Comparator|2Placebo cream|
9928661|NCT00908609||1|Patients who undergo routine ultrasound guided biopsy will be studied by optical imaging technique.
10211157|NCT05217004|No Intervention|Waitlist Control Group|Participants in this group will not use any of the apps.
10211158|NCT05216965|Experimental|9MW2821|
10211159|NCT05216939|Experimental|Flannel mask with earl loops|Participants will wear a flannel mask with earl loops
10211160|NCT05216939|Experimental|Flannel mask with ties|Participants will wear a flannel mask with earl ties
10211161|NCT05216939|Experimental|Twill mask with ear loops|Participants will wear a twill mask with ear loops
9871646|NCT00284752|Experimental|ABI-007|
10211162|NCT05216939|Experimental|Twill mask with ties|Participants will wear a twill mask with ties
10211163|NCT05216900|Experimental|Neoadjuvant radiotherapy group|Twenty breast cancer patients will be included after they have given informed consent. Patients are eligible if they have an indication for mastectomy and RT, and a wish for an immediate reconstruction, either implant-based or autologous, in MUMC, UMCU, Alexander Monro hospital and Amsterdam UMC.
10211164|NCT05216861|Experimental|Experimental|The rehabilitation coordinators are trained in the intervention (0,5 day).
10211165|NCT05216861|Active Comparator|Active comparator|the rehabilitation coordinators participate in a 1 hour lectur including a brief overview about work ability. Thereafter, they provide care-as-usual (collaboration) to patients and employer.
10211166|NCT05216848||nulliparas with no existing complications in the third trimester|"The investigators involve every nullipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language"
9871647|NCT00284817|Experimental|1|MEDI-522
9871648|NCT00284817|Experimental|2|MEDI-522
9871649|NCT00284817|Experimental|3|MEDI-522
9871650|NCT00284817|Experimental|4|MEDI-522
9871651|NCT00284817|Experimental|5|MEDI-522
9871652|NCT00284830|Active Comparator|1|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
9871653|NCT00284830|No Intervention|2|conventional dual-chamber pacing
9871654|NCT00284908|Experimental|I STU-Na|Cross-over study with escalating doses
9871655|NCT00284947|Experimental|Maintenance immunosuppression|"40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)~1g MMF or 720mg EC-MPS p.o twice daily~Oral corticosteroids"
9871656|NCT00285051|Experimental|Group 1|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 300 mcg of delta-8-THC per dose
9871657|NCT00285051|Experimental|Group 2|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 600 mcg of delta-8-THC per dose
9871658|NCT00285051|Experimental|Group 3|Chemo cycle 1 - 300 mcg of delta-8-THC per dose, Chemo cycle 2 - IV Ondansetron
9871659|NCT00285051|Experimental|Group 4|Chemo cycle 1 - 600 mcg of delta-8-THC per dose Chemo cycle 2 - IV Ondansetron
9871660|NCT00285090|Experimental|Early Treatment|
9871661|NCT00285090|Experimental|LateTreatment|
9871662|NCT00285090|Experimental|Total Treatment|
9871663|NCT00285090|Placebo Comparator|No Treatment|
9871664|NCT00285168||1 - Control|Usual Bone Density Report
9871665|NCT00285168||2 - Intervention|Bone Density Report with Absolute 10-year Fracture Risk Decision Aide
9871666|NCT00285233|Experimental|1|
9871667|NCT00285298|Experimental|Pentoxifylline|
9871668|NCT00285298|Placebo Comparator|Placebo|
9871669|NCT00285376|Experimental|1|vilazodone
9871670|NCT00285376|Placebo Comparator|2|
9871671|NCT00285389|Experimental|VAD Clorambucil Rituximab|
9871672|NCT00285402|Experimental|A|
9871673|NCT00285402|Experimental|B|
9871674|NCT00285402|Placebo Comparator|C|
9871675|NCT00285415|Other|Doc and Car|Receiving Doc and Car
9871676|NCT00285428|Experimental|Dose level 1|120 mg/m2
9871677|NCT00285428|Experimental|Dose level 2|200 mg/m2
9871678|NCT00285428|Experimental|Dose Level 3|375 mg/m2
9871679|NCT00285428|Experimental|Dose level 1B|80 mg/m2
9871680|NCT00285532||Home test kit|
9871681|NCT00285545||Good blood flow|Group with normal blood flow to small intestine
9871682|NCT00285545||Poor blood flow|Group with partial ischemia to small intestine
9871683|NCT00285558|Experimental|CBT with peer-enhanced activities|Cognitive behavioral treatment (CBT) with peer-enhanced adventure therapy. The peer intervention, ''adventure therapy,'' is based on the principles of Outward Bound and was expected to affect weight status through a positive effect on self-concept.
9871684|NCT00285558|Active Comparator|CBT with supervised aerobic exercise|Cognitive behavioral treatment (CBT) with supervised aerobic exercise. Activities for the supervised exercise intervention included use of treadmills, stationary bicycles, and other aerobic activities selected by participants, including dance videos and brisk walking within the clinic setting.
9871685|NCT00285662|Active Comparator|1|1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
9871686|NCT00285662|Active Comparator|2|1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
9871687|NCT00285662|Placebo Comparator|3|children of this gorup will receive only placebo dugs
9871688|NCT00285688||1|Gastroscope positive for H. pylori and resistant to clarithromycin
9871689|NCT00285688||2|Gastroscope positive for H. pylori and not resistant to clarithromycin
9871690|NCT00285805|Other|Rosiglitazone-placebo|
9871691|NCT00285805|Other|placebo-rosiglitazone|
9871692|NCT00285844|Experimental|pioglitazone|IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention
9871693|NCT00285844|Experimental|Dietary Weight Loss|IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention
9871694|NCT00285896|Active Comparator|Active|GLP-1
9871695|NCT00285896|Placebo Comparator|Placebo|Placebo
9871696|NCT00285974|Experimental|hip prosthesis|
9928662|NCT00908609||2|Patients who have advanced breast cancers and are under neoadjuvant chemotherapy treatment will be studied by optical technique.
9928663|NCT00908622|Experimental|Skeletal myoblasts|Percutaneous autologous myoblast implantation
9871697|NCT00286026|Experimental|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); will be treated with Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
9871698|NCT00286026|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with Azithromycin; will receive a second dose of Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
9871699|NCT00286104|Active Comparator|1|Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
9871700|NCT00286104|Placebo Comparator|2|Plain ventricular catheter
9871701|NCT00286117|Experimental|1|Anastrozole
9871702|NCT00286117|Active Comparator|2|Tamoxifen
9871703|NCT00286130|Active Comparator|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
9871704|NCT00286130|Active Comparator|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
9871705|NCT00286143|Active Comparator|A|Fentanyl added to Bupivacaine via epidural catheter.
9871706|NCT00286195|No Intervention|I|Consecutive patients, open label
9871707|NCT00286208|Active Comparator|Sublingual Misoprostol|400 mcg of sublingual misoprostol
10211167|NCT05216848||multiparas with no existing complications in the third trimester|"The investigators involve every multipara giving birth in a period of two years.~Exclusion criteria: unwilling to participate, minors (under 18 years old), high risk pregnancy, foetus mortus or perinatal death of the newborn, with slovak language, previous caesarean section"
9871708|NCT00286208|Active Comparator|Oral Misoprostol|Misoprostol administered orally
9871709|NCT00286273|Active Comparator|citrate|regional anticoagulation with citrate
10211168|NCT05216822|Experimental|children received ORS and racecadotril as treatment|25 children received ORS and racecadotril as treatment (at a dose of 1.5 mg/kg/day, an oral single daily dose for three days)
10211169|NCT05216822|Active Comparator|children received ORS alone as treatment|25 children received ORS alone for treatment as a control group
10211170|NCT05216796|Experimental|Low-carbohydrate diet|Participants assigned to the Low-carbohydrate diet will be instructed to limit carbohydrate intake to <30 g/d.
10211171|NCT05216796|Active Comparator|Low-calorie diet|Participants assigned to the Low-calorie diet will be instructed to reduce their energy intake to match the LoCHO block (we are predicting ~1200 kcal/d for women and ~1500 kcal/d for men, following current recommendations for treatment of NAFLD).
10211172|NCT05216783|Experimental|Experimental|The Personal Information Form, the Traumatic Childbirth Perception Scale (TCPS), and the short-form Childbirth Self-Efficacy Inventory (CBSEI-32) were utilized for the collection of research data. First of all, the TCPS was applied to the pregnant women, and the pregnant women who obtained a score above 53 points (moderate-level traumatic childbirth perception) from the TCPS were invited to the research. Next, the Personal Information Form and the CBSEI-32 were applied to the pregnant women who agreed to participate in the research. The motivational interviews were held with the pregnant women in the experimental group once a week for four weeks. No initiative was applied to the pregnant women in the control group. The TCPS and CBSEI-32 were applied to all participant pregnant women after four weeks following the first application. The application of the measurement tools took 10-15 minutes.
10211173|NCT05216783|No Intervention|Control|The researchers applied no initiative to the control group, and the pregnant women in the control group solely had the routine checks performed at the city hospital. At the end of the study, the questions of pregnant women in the cotrol group about childbirth were answered. Before applying the initiative to the experimental group, the researcher (SB) had had training about motivational interview techniques.
10211174|NCT05215470|Experimental|Nivolumab+Ipilimumab|Nivolumab IV 3mg/kg 3/3w + Ipilimumab 1mg/kg 3/3w 4 doses, followed by Nivolumab IV 480mg 4/4w until progression, toxicity, or up to 2 years of use.
10213707|NCT03482349|Experimental|Total Knee Robotically-Assisted|The intervention is then performed with a new device and surgical procedure. At first the femur and the tibia are fixed to the operating table with a special clamp and the knee bones are exposed with the standard technique; then the surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
9871710|NCT00286273|Active Comparator|nadroparin|nadroparin is a low molecular weight heparin
9871711|NCT00286299|Experimental|Aerobic interval training (AIT)|AIT is 4x4 minutes interval training on a treadmill at 85 to 95 % HRpeak interspersed with 3 min of active resting periods at a work load corresponding to 70 % HRpeak between each interval. Patients performed the intervals walking or running with a minimum of 5 % inclination.
10213708|NCT03482349|No Intervention|Total Knee Manual-Executed by Surgeon|Your orthopaedic surgeon will remove the damaged cartilage and bone, and then position the new metal and plastic implants to restore the alignment and function of your knee.
9871712|NCT00286299|Active Comparator|Computer game training (CG)|36 minutes playing supervised computer games, Tetris, Xbox
9871713|NCT00286299|Experimental|Maximal strength training (MST)|MST is performed in a leg press machine. The weight is lowered in a controlled manner in the eccentric phase until the patient reached 90 degrees in the knee joint. Then the patients has a short stop (~0.5 second) before the weight is moved as rapidly as possible to complete extension. The training volume is 4 sets of 4RM (i.e. 85-90 % 1RM). The training load is increased with 2.5-5 kg each time patients managed to perform 4 sets with the determined load or each training session.
10213709|NCT03478579||Emergency physicians|The observational group will be composed of emergency physicians working in the French Midi-Pyrenees region. Physicians must work since 2 years in emergency service
9928664|NCT00908622|Placebo Comparator|No cells|Percutaneous culture medium without cells implantation
9928665|NCT00908635||survivor|survivors of patients
9928666|NCT00908635||fatalities|non-survivors of patients
9871714|NCT00286481|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
9871715|NCT00286481|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
10211175|NCT05209737|Experimental|Trendelenburg position|Position: 10-degree Head-down position
9871716|NCT00286481|Active Comparator|Simvastatin|
9871717|NCT00286507|Active Comparator|ILM peeling|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
9871718|NCT00286507|Active Comparator|No ILM peeling|combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
9871719|NCT00286533|Experimental|Placed implants|
9871720|NCT00286585|Active Comparator|Inhalational anesthetic|Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
9871721|NCT00286585|Active Comparator|Intravenous anesthetic, propofol|Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
9871722|NCT00286598|Experimental|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
9871723|NCT00286598|No Intervention|Control|Usual care
9871724|NCT00286611||Amifostine|Those individuals enrolled who have received amifostine as part of standard care.
9871725|NCT00286624|Experimental|1|Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
9871726|NCT00286780|Experimental|1|
9871727|NCT00286819|Experimental|the FEC75 regimen|"Arm A: the FEC75 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles."
9871728|NCT00286819|Experimental|FEC90 regimen|"Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle."
9871729|NCT00286832||Single group study|
9871730|NCT00286845||II|
9871731|NCT00286845||1|
9871732|NCT00286962|Experimental|CIPII|Intraperitoneal insulin infusion by means of an implanted insulin pump
9871733|NCT00286962|Active Comparator|CSII/ MDI|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
9871734|NCT00287001|Other|1|1= cool air cooling
9871735|NCT00287040|No Intervention|1 - Usual Care|This arm looks at mammogram adherence in those individuals who at this time are not receiving booster mammogram interventions.
9871736|NCT00287040|Experimental|2. DVD Intervention|This arm will receive the initial information provided in usual care and will also receive booster mammography interventions via DVD.
9871737|NCT00287040|Experimental|3. Telephone Counseling|This arm will receive the initial information provided in usual care and receive boosters through tailored telephone counseling.
9871738|NCT00287092|Experimental|Group 1|Participants will receive PEDIACEL vaccine
9871739|NCT00287092|Active Comparator|Group 2|Participants will receive Infanrix-IPV+Hib vaccines
9871740|NCT00287105|Other|Good risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
9871741|NCT00287105|Other|Poor risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
9871742|NCT00287183|Active Comparator|PF-04494700 (TTP488)|
9871743|NCT00287183|Placebo Comparator|Placebo|
9871744|NCT00287196|Active Comparator|Post-operative RADIOTHERAPY|Immediate post-operative RADIOTHERAPY
9871745|NCT00287196|Experimental|Delayed Radiotherapy|OBSERVATION with delayed radiotherapy for relapse
9871746|NCT00287235|Experimental|Group 1: Standard Medical Therapy + MARS|Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
9871747|NCT00287235|Active Comparator|Group 2: Standard Medical Therapy Only|Patients who were randomized to Group 2 received standard medical treatment only.
10211176|NCT05209737|Active Comparator|Semirecumbent position|Position: 30-degree Head-up position
10211177|NCT05198622|Experimental|Intercostobrachial Nerve Preservation Arm|Intercostobrachial nerve preserving axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
9871748|NCT00287248|Experimental|Assess [123I] IMPY & SPECT Imaging|To assess [123I] IMPY & SPECT Imaging
9871749|NCT00287261|Experimental|zometa|3-weekly infusion of zometa (zoledronic acid) 4 mg
9871750|NCT00287352|Placebo Comparator|Double-Blind Treatment|Olanzapine continuing with placebo
9871751|NCT00287352|Active Comparator|Olanzapine, Amantadine|Standard combine with Amantadine
9871752|NCT00287378|Experimental|1|
9871753|NCT00287495|Experimental|A|Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
10213710|NCT03476330|Experimental|Quercetin|All patients will be treated with oral quercetin.
10213711|NCT03473977|Experimental|Benralizumab|Subcutaneous dose of 30 mg of Benralizumab every 4 weeks
10213712|NCT03473977|Placebo Comparator|Placebo|Subcutaneous dose of Placebo every 4 weeks
9986917|NCT01407172||Symptomatic PAD|Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
9986918|NCT01407172||Patients without PAD|Patients without PAD as defined by ABI>0.9 and <1.3.
10211178|NCT05198622|Active Comparator|Intercostobracial Nerve Sacrifice Arm|Intercostobrachial nerve sacrificing axillary lymph node dissection will be carried out. Post-operatively, the patients will be monitored in the post anesthesia care unit (PACU). Acute Post-Operative pain will be controlled using a standardized pain management regimen in accordance with World Health Organization (WHO) analgesia ladder. The patients will be discharged from PACU and admitted to surgical ward once numerical rating score (NRI) is below 4.
9986919|NCT01407172||Asymptomatic PAD|Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms.
9986920|NCT01407185|Experimental|Resistive Training|Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue ~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.
9986921|NCT01407198|Experimental|Nilotinib/XRT|Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
9986922|NCT01407211|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
9986923|NCT01407211|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
9986924|NCT01407224|Experimental|Only training|Training on Early Breastfeeding Practices to front line health workers
9986925|NCT01407224|Active Comparator|Training and supervision|Training as well as supervision by field supervisor for six months intervention
9986926|NCT01407224|No Intervention|Control|No intervention such as training or supervision
9986927|NCT01407237||HIV-infected Individuals|
9986928|NCT01407237||non-HIV-infected Individuals|
9986929|NCT01407289|Experimental|Insulin titration protocol|Patients in care at the Division of Endocrinology will be treated by enhanced version of published best paper based practice insulin titration protocol to control glycaemia in hospitalised patients with type 2 diabetes.
9986930|NCT01407289|No Intervention|Standard care|Patients in care of the Division of Cardiology will be treated using antihyperglycaemic therapy according to standard care.
9986931|NCT01407302||LMA group|patients undergoing general anesthesia with LMA insertion
9986932|NCT01407302||E-tube group|patients undergoing general anesthesia with e-tube
9986933|NCT01407315|Experimental|GlucoMenDay - Multiple sampling (A)|
9986934|NCT01407315|Experimental|GlucoMenDay - Meal/Insulin test (B)|
9986935|NCT01407341|Experimental|Supportive care (ChronOS)|Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
9986936|NCT01407393|Experimental|Glucosanol|Glucosanol
9986937|NCT01407393|Placebo Comparator|Placebo|Placebo
9986938|NCT01407406|Experimental|Chinese Subjects - low dose BIIB023 IV|
9986939|NCT01407406|Experimental|Chinese Subjects - high dose BIIB023 IV|
9986940|NCT01407406|Experimental|Japanese Subjects - low dose BIIB023 IV|
9986941|NCT01407406|Experimental|Japanese Subjects - high dose BIIB023 IV|
9986942|NCT01407406|Experimental|Causasian Subjects - low dose BIIB023 IV|
9986943|NCT01407406|Experimental|Caucasian Subjects - high dose BIIB023 IV|
9986944|NCT01407419|Experimental|Treat to Target Intervention Strategy|Subjects at sites randomized to this arm will be expected to return to the clinic for Monthly Assessments until low disease activity (LDA) defined as CDAI of 10 or less has been achieved. Providers are prompted to accelerate therapy (Treatment Acceleration) at each visit that CDAI is >10 (unless not felt to be medically appropriate or refused by the subject.) Accelerations are expected at least every 3 months, until/unless LDA has been achieved.
9986945|NCT01407419|No Intervention|Control Group Treated with Usual Care|Subjects in this arm will be expected to complete study visits with their rheumatologist/study doctor at Baseline, Month 3, Month 6, Month 9 and Month 12. Data collection will occur at each of those visits. Subjects and Providers will continue managing disease per usual practices and do not receive protocol prompts relative to visit frequency or acceleration of therapy, regardless of disease activity level (by CDAI)
9986946|NCT01407432|Experimental|Folic acid|tablets of 5 mg of folic acid
9986947|NCT01407432|Placebo Comparator|Placebo|Tablets of placebo of folic acid
9986948|NCT01407445|Placebo Comparator|Placebo|1 tablet of placebo/ oral/ 3 times a day for three months
9986949|NCT01407445|Active Comparator|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for three months
9986950|NCT01407458|Active Comparator|Experimental Group|Children doing additional exercises with upper limbs in physical education class
9986951|NCT01407458|Active Comparator|Control Group|Children doing normal physical education exercises
9986952|NCT01407471|Experimental|Clobetasol + Spironolactone|0.05% clobetasol and 5% spironolactone
9986953|NCT01407471|Active Comparator|Clobetasol + Placebo|0.05% clobetasol + inert excipient
9986954|NCT01407471|Active Comparator|Placebo + Spironolactone|Inert excipient + 5% spironolactone
9986955|NCT01407471|Placebo Comparator|Placebo + placebo|Inert excipient
9986956|NCT01407484|Experimental|Treatment|Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
9986957|NCT01407484|Placebo Comparator|Placebo|Placebo
10211179|NCT05197647||Patients with mild COVID-19|Patients with symptomatic COVID-19 disease not requiring hospitalization.
10213713|NCT03469362|Experimental|Extracorporeal Urinary Diversion (ECD)|Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
10213714|NCT03469362|Experimental|Intracorporal Urinary Diversion (ICD)|Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
9986958|NCT01407497|Active Comparator|IA|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
9871754|NCT00287495|Experimental|B|Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
9871755|NCT00287521|Experimental|AL-37807 Suspension|
9871756|NCT00287521|Active Comparator|Xalatan|
9871757|NCT00287521|Placebo Comparator|AL-37807 Vehicle|
9871758|NCT00287521|Experimental|Timolol Maleate|
9871759|NCT00287534|Experimental|1|Anastrozole
9871760|NCT00287534|Active Comparator|2|Tamoxifen
9871761|NCT00287573|Experimental|Arm 1|
9871762|NCT00287573|Active Comparator|Arm 2|
9871763|NCT00287612|Active Comparator|1|Arms:Lap. Fundo. with Mobilization of the Esophageal Junction
9871764|NCT00287612|Experimental|2|
9871765|NCT00287625|Active Comparator|1|PRP
9871766|NCT00287625|No Intervention|2|control
9871767|NCT00287638|Active Comparator|1|CPAP
9871768|NCT00287638|Placebo Comparator|2|no CPAP
9871769|NCT00287651|Active Comparator|2|Patients with diagnosed Diabetic Retinopathy are enrolled as treated with pulsatile intravenous insulin or as a control patient with weekly treatment sessions. Baseline and quarterly fundus photography is performed to measure and monitor progress.
9871770|NCT00287651|No Intervention|1|Patients diagnosed with Diabetic Retinopathy are enrolled as control patients that do not receive the pulsatile intravenous insulin therapy. Control patients come into the center receive baseline fundus photography and quarterly fundus photography to measure progress and outcomes of diabetic retinopathy and are compared to the patients who receive pulsatile intravenous insulin therapy.
9871771|NCT00287677|Experimental|A|growth hormone + vaccination + HAART
9871772|NCT00287677|Experimental|B|growth hormone + HAART
9871773|NCT00287677|Experimental|C|vaccination + HAART
9871774|NCT00287677|Active Comparator|D|control healthy HIV negative + vaccination
9871775|NCT00287703|Experimental|1|Active Pulsating Electro Magnetic Fields (PEMF) treatment
9871776|NCT00287703|Sham Comparator|2|5 days a week for 5 weeks for 30 minutes Sham PEMF
9871777|NCT00287755|Experimental|1|
9871778|NCT00287768|Experimental|1|Docetaxel + S-1
9871779|NCT00287768|Active Comparator|2|S-1
9871780|NCT00287820|Active Comparator|1|olanzapine
9871781|NCT00287820|Active Comparator|2|risperidone
9871782|NCT00287833|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
9871783|NCT00287833|Placebo Comparator|Arm II (placebo)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
9871784|NCT00287846|Experimental|Imatinib|400 to 800 mg/day for a maximal 12 months study duration.
9871785|NCT00287859|Experimental|Escalating Cohorts|"Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD."
9871786|NCT00287885|Experimental|Metronomic Docetaxel|Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
9871787|NCT00287898|Experimental|Telephone Genetic Counseling|Participants randomized to this arm will receive all genetic counseling via telephone.
9871788|NCT00287898|Active Comparator|Usual Care|Participants randomized to usual care will receive standard in-person genetic counseling.
9871789|NCT00287911|Experimental|Combo Chemotherapy and Radiation|"Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9871790|NCT00287937|Experimental|Treatment (vorinostat, paclitaxel, carboplatin)|Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.
9871791|NCT00287963|Experimental|Vinorelbine + topotecan|
9928667|NCT00908661|Active Comparator|Prophylactic mesh|All patients will have a permanent ostomy and a randomisation with prophylactic mesh
9928668|NCT00908661|No Intervention|without prophylactic mesh|All patients will have a permanent ostomy and a randomisation without prophylactic mesh
9928669|NCT00908674||Group 1|
9928670|NCT00908700|Experimental|Occlusion arm|Surgical intervention: Occlusion of the left atrial appendage (LAA) using 'cut-and-sew' technique appendage occlusion.
9928671|NCT00908700|Active Comparator|Medical arm|Medical arm: The comparator is best medical practice for atrial fibrillation related stroke prevention as per guidelines.
9928672|NCT00908713|Experimental|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
9928673|NCT00908713|Placebo Comparator|Placebo|
9928674|NCT00908726|Experimental|Microemulsion propofol|
9928675|NCT00908726|Active Comparator|Lipid emulsion propofol|
9928676|NCT00908765|Active Comparator|Aerobe Interval Training|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
9871792|NCT00288028|Experimental|Bortezomib|Bortezomib is administered as a 5 second IV bolus on days 1, 4, 8,11 or 1,8 and 15 of a 21-35 days cycle (Depending on the Dosing schedule). The dosage will be calculated based on actual weight of the patient unless the actual weight is greater than 40% above the ideal body weight. In this instance the dosage will be based on the adjusted ideal body weight. The Adjusted IBW (kg) = IBW + 0.25 x (actual body weight - IBW). The dosage will be adjusted based on the safety and toxicity profile, until a MTD is determined.
9871793|NCT00288041|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|Patients will receive an infusion of bortezomib twice in week 1 and once in week 2. They will also receive a 3-hour infusion of paclitaxel and an infusion of carboplatin once in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown.
10211180|NCT05195970|Experimental|Walnut Consumption|Following enrollment, participants will start a 7-day wash-out period where they will be asked to avoid foods and beverages high in ellagitannins. These include pomegranates, hazelnuts, pistachios, walnuts (besides the samples given by the researchers), strawberries, raspberries, blackberries, oak-aged wines and spirits; a full list of foods and beverages to avoid will be provided. Then, participants will consume 2 ounces of walnuts daily with their usual diet while continuing to avoid ellagitannins for 21 days prior to their routine colonoscopy.
10211181|NCT05195242|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
9871794|NCT00288093|Experimental|Treatment (triapine, radiation therapy)|Patients undergo radiotherapy once daily, 5 days a week, for approximately 5.5 weeks (a total of 28 fractions). Patients also receive 3-AP (Triapine) IV over 2 hours 3 days a week every other week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine) until the maximum tolerated dose (MTD) is determined.
9871795|NCT00288106||Long Term Follow-Up|Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
9871796|NCT00288119||Cases|Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
9871797|NCT00288119||EGD Screening|Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
9871798|NCT00288119||Colon Screening|Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
9871799|NCT00288119||Controls|Patients scheduled for EGD who do not meet criteria for screening
9871800|NCT00288132|Active Comparator|Usual Care|
9871801|NCT00288132|Experimental|Intervention|
9871802|NCT00288145|Active Comparator|T|Treatment arm comprises one worksite in a matched site pair; one site assigned to treatment, the other site assigned to comparison. Treatment site worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
9871803|NCT00288158|Experimental|Allopurinol|
9871804|NCT00288158|Experimental|Probenecid|
9871805|NCT00288158|Active Comparator|Placebo|
9871806|NCT00288171|Experimental|Allopurinal|Hypertensive renal transplant recipients with elevated uric acid will the treated with allopurinol and placebo in an randomized cross over fashion. Subjects will serve as their own controls.
9871807|NCT00288171|Placebo Comparator|Placebo|
9871808|NCT00288184|Experimental|Allopurinol|Hypertensive children received both placebo and allopurinol in a cross over design.
9871809|NCT00288184|Placebo Comparator|Placebo|
9871810|NCT00288223|Experimental|1|telithromycin
9871811|NCT00288249|Experimental|Arm 2|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
9871812|NCT00288249|Experimental|Arm 3|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
9871813|NCT00288249|Experimental|Arm 4|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
9871814|NCT00288249|Experimental|Arm 1|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
9871815|NCT00288288||1|Epicardial left ventricular lead placement during a clinically indicated open chest surgery
9871816|NCT00288288||2|Transvenous left ventricular lead implant during a clinically indicated CRT system implant
10211182|NCT05195242|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
10211183|NCT05194761|Active Comparator|using nebulization|extubated neonates will be divided in two group , one will receive saline nebulization for 3 days postextubation ,
10211184|NCT05194761|No Intervention|No nebulization|the other group will only receive the standard only
10213715|NCT03469297|Experimental|Brown Glaucoma Implant|
9871817|NCT00288301|Experimental|1|Special Intervention
9871818|NCT00288301|Experimental|2|Delayed intervention
9871819|NCT00288314||PTSD|
9871820|NCT00288314||CONTROLS|
9871821|NCT00288327|Experimental|1|Enhanced New Leaf Intervention
9871822|NCT00288327|Other|2|Minimum Intervention
9871823|NCT00288340|Active Comparator|1,2|
9871824|NCT00288353|Active Comparator|1|aripiprazole (Abilify)
9871825|NCT00288353|Active Comparator|2|ziprasidone (Geodon)
9871826|NCT00288418|Active Comparator|ARROWgard Blue® CVC|7-French x 20-cm, triple lumen, short-term CVC
9986959|NCT01407497|Placebo Comparator|IB|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
9871827|NCT00288418|Experimental|Angiotech CVC|A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
9871828|NCT00288431|Experimental|1|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
9871829|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
9871830|NCT00288444|Active Comparator|Docetaxel 30 mg/ m2and Lonafarnib 150 mg|Docetaxel 30 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
9871831|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 and Lonafarnib 100 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily
9871832|NCT00288444|Active Comparator|Docetaxel 30 mg/m2 and Lonafarnib 100 mg|Docetaxel30 mg/m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.
9871833|NCT00288691|Experimental|Arm 1|
9871834|NCT00288691|Experimental|Arm 2|
9871835|NCT00288691|Experimental|Arm 3|
9871836|NCT00288691|Placebo Comparator|Arm 4|
9871837|NCT00288730|Experimental|001|nesiritide
9871838|NCT00288769|Other|2|
9871839|NCT00288795|No Intervention|1|Standard Care
9871840|NCT00288795|Other|2|Massage Treatment
9871841|NCT00288795|Other|3|Polarity Treatment
9871842|NCT00288899|Other|Arm 1|standard VA surgical iMedConsent process
9871843|NCT00288899|Experimental|Arm 2|enhanced version of VA surgical iMedConsent process (repeat-back)
9871844|NCT00288977|Experimental|islet cell transplant|
9871845|NCT00288990||1|subjects who are NAb positive
9871846|NCT00288990||2|Subjects who are antibody negative
9871847|NCT00288990||3|subjects who are BAb positive
9871848|NCT00289055|Experimental|1|Cordis SMART™ Nitinol Stent
9871849|NCT00289055|Active Comparator|2|balloon angioplasty
9871850|NCT00289068||Phacoemulsification Sleeve 2.2mm|Phacoemulsification Sleeve setting 2.2 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
9871851|NCT00289068||Phacoemulsification Sleeve 2.8mm|Phacoemulsification Sleeve setting 2.8 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
9871852|NCT00289068||Phacoemulsification Sleeve 3.0mm|Phacoemulsification Sleeve setting 3.0 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
9871853|NCT00289081|Active Comparator|1|Rotating Platform Cruciate Retaining Knee implant
9871854|NCT00289081|Active Comparator|2|Rotating Platform Cruciate Substituting Knee implant.
9871855|NCT00289224|Experimental|1|Cholera Vaccine
9871856|NCT00289224|Placebo Comparator|2|Placebo
9871857|NCT00289237|Experimental|High intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
9871858|NCT00289237|Experimental|Low intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
9871859|NCT00289237|No Intervention|Control group|"Questionnaires regarding lifestyle and general health were sent to all participants in this group.~The importance of healthy lifestyle was not mentioned, and no intervention was offered."
9871860|NCT00289380||Nutrition support|Nutrition support cohort means accept nutrition support，it was defined as ≥15kal/kg/d and < 30kal/kg/d of non-protein calories (carbohydrate and/or fat) and amino acids or protein≥1g/kg/d for 5~28 consecutive days.
9871861|NCT00289380||Without nutritional support|Group received only intravenous 5 to 10% glucose and electrolyte infusions
9871862|NCT00289419|Active Comparator|A|
9871863|NCT00289419|Experimental|B|
9871864|NCT00289432|Experimental|1|Behavioral: Psychoeducative intervention
9871865|NCT00289432|Active Comparator|2|The Hospitals standard follow-up support group
9871866|NCT00289523||Escitalopram|
9871867|NCT00289523||Bupropion XL|
9871868|NCT00289523||Combination Therapy|Escitalopram and Bupropion XL
9871869|NCT00289627|Experimental|ipilimumab (MDX-010, BMS-734016)|
9871870|NCT00289705|Experimental|Surgery|Laparoscopic gastric bypass
9871871|NCT00289705|No Intervention|2|Traditional treatment for obesity
9986960|NCT01407497|Active Comparator|IIA|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
9986961|NCT01407497|Placebo Comparator|IIB|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
9986962|NCT01407510|Experimental|Arm 1|
9986963|NCT01407549|Experimental|Intervention group|The intervention group will participate in the Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention.
9986964|NCT01407549|No Intervention|Control group|Participants in the control group will be assigned to a waiting list group. Participants will be told that they will be eligible for the intervention three months after the completion of a preliminary documentation of their symptoms and additional measures. Participants will complete the same battery of measures according to the same time table as participants in the intervention group.
9986965|NCT01407562|Experimental|Pazopanib with paclitaxel and carboplatin|
9986966|NCT01407588|Experimental|Magnetic navigation|
9986967|NCT01407588|Experimental|Manual navigation|
9986968|NCT01407601|Experimental|45 µg MK-7|45 µg MK-7 daily over 6 weeks
9986969|NCT01407601|Experimental|135 µg MK-7|135 µg MK-7 daily over 6 weeks
9986970|NCT01407601|Experimental|360 µg MK-7|360 µg MK-7 daily over 6 weeks
9986971|NCT01407614|Active Comparator|external lumbar drainage|Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
9986972|NCT01407614|No Intervention|No intervention|In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage
9986973|NCT01407627|Experimental|Fructose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest fructose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest dextrose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
9986974|NCT01407627|Active Comparator|Dextrose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest dextrose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest fructose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
9986975|NCT01407640|Experimental|1|Allergy tests
9986976|NCT01407653|Experimental|virtual reality|
9986977|NCT01407653|Other|usual care|
9986978|NCT01407666|Experimental|Bilateral paravertebral blocks|Bilateral continuous paravertebral blocks for open liver resection
9986979|NCT01407666|No Intervention|epidural block|received thoracic epidural block for open liver resection
9986980|NCT01407679|Experimental|Alitretinoin|
9986981|NCT01407705||Control Group|"No diagnosis of cervical degenerative or traumatic disease~30 to 80 years of age~Ability of volunteers to tolerate 1 hr examination"
9986982|NCT01407705||Disease (Non-healthy) Group|"Cervical Spinal Cord:~Clinical and Radiographic evidence of cervical spondylotic myelopathy~18 to 80 years of age~Safe and stable clinical scenario to undergo imaging~Awake, alert patient able to cooperate with physical examination~Give written informed consent prior to any testing under this protocol~Degenerative Disease Group:~Have signs or symptoms consistent with spinal cord injury.~Be diagnosed with cervical spondylosis (degenerative disease).~Traumatic Group:~• A spinal cord injury associated with a traumatic event."
9986983|NCT01407744||Correlative studies|Archived tumor tissue samples are analyzed by laboratory biomarker analysis for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix MIP arrays, and FISH. Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
9871872|NCT00289796|Active Comparator|Infanrix hexa Group|Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
9928677|NCT00908765|Active Comparator|Moderate Continous Training|Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
9928678|NCT00908778|Experimental|Vitreosolve I|Intravitreal injection
9928679|NCT00908778|Experimental|Vitreosolve|Intravitreal injection
9928680|NCT00908804|Active Comparator|open appendectomy|
9928681|NCT00908804|Active Comparator|laparoscopic appendectomy|
9928682|NCT00908817|Active Comparator|triamcinolone|
9928683|NCT00908817|Placebo Comparator|chlorhexidine|
9928684|NCT00908843|Experimental|(I) BICARBONATE INTRAVENOUS INFUSION|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
9928685|NCT00908843|Active Comparator|(II) ORAL SODIUM SOLUTION|Oral hydration with Sodium solution (Casen solution of rehydratation) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
9928686|NCT00908856|Placebo Comparator|Placebo|Placebo
9928687|NCT00908856|Active Comparator|autologous mononuclear cells|a single intravenous autologous bone marrow mononuclear cell transfusion
9928688|NCT00908856|Active Comparator|autologous marrow stromal cells|a single intravenous autologous marrow stromal cell transfusion
9928689|NCT00908921|Experimental|1|"The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) >7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.~At every visit if FBG<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.~Patients who have been on 4mg for 4 weeks and FBG>11.0mmol/L at visit, another treatment can be added at the physician's discretion."
9928690|NCT00908934|Experimental|1|50 or 400 mg AZD9056, Test formulation
9928691|NCT00908934|Experimental|2|50 or 400 mg AZD9056, Reference formulation
9928692|NCT00908973||Good responders|Excess weight loss of > 60% 1 year after gastric bypass surgery
9928693|NCT00908973||Poor responders|Excess weight loss of =< 50% 1 year after gastric bypass surgery
9928694|NCT00908973||Lean controls|Non-gastric bypass operated lean individuals, matched for age and sex
9928695|NCT00908986|Experimental|Rituximab|Subjects receive rituximab in an open label manner
9928696|NCT00908999||Controls|The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
9928697|NCT00908999||amnestic Mild Cognitive Impairment|Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
9928698|NCT00908999||Alzheimer's disease|Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.
9928699|NCT00909012|Placebo Comparator|1|
9928700|NCT00909012|Experimental|2|
10211185|NCT05193630|Experimental|A Single Arm Intervention Study|To investigate the effect of intake of Milnutri Sure™ (1kcal/ml) during 12 weeks on top of regular feeding counselling in children from ≥ 1 to ≤ 6 years of age with faltering growth.
10211186|NCT05193565|Experimental|RaparoBell Tablet|RaparoBell Tablet
10211187|NCT05193565|Active Comparator|Mycophenolate Mofetil Tablet/Capsule|Myrept Tablet/Capsule
10211188|NCT05192460|Experimental|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subject will only receive neoantigen tumor vaccine. In dose expansion phase, subject will receive neoantigen tumor vaccine combination with PD-1/L1.
9928701|NCT00909012|Experimental|3|
9928702|NCT00909012|Experimental|4|
9928703|NCT00909012|Experimental|5|
9928704|NCT00909025|Experimental|Claudiximab|
9928705|NCT00909051||Group 1|
9928706|NCT00909077|Active Comparator|1|Combination therapy with Dexamethasone and Rituximab
9928707|NCT00909077|Active Comparator|2|Dexamethasone as monotherapy
9928708|NCT00909103||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histological confirmation
10211189|NCT05191966|Active Comparator|Group S-QLB3|S-QLB3 block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
10211190|NCT05191966|Active Comparator|Group TPVB|TPVB block (0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline) + iv morphine-PCA
10211191|NCT05189587|Experimental|TES group|Intervention: Device (transcranial electrical stimulation, TES)
10211192|NCT05189587|Sham Comparator|sham TES group|Intervention: Device (transcranial electrical stimulation, TES)
10211193|NCT05189587|No Intervention|Control group|Intervention: none
10211194|NCT05186779||Cohort A|Early Pregnancy Bleeding/Recurrent Pregnancy loss
10211195|NCT05186779||Cohort B|IVF/ART
10211196|NCT05186766|Experimental|Intervention Group|Video-Assisted Operating Room Introduce Program (VIASP-OR)
10211197|NCT05186766|No Intervention|Control Group|Standart Nursing Care
10211198|NCT05185440|Active Comparator|GIFTSS Training Only|Training for college health center clinicians and staff in implementation of GIFTSS Training
10211199|NCT05185440|Experimental|GIFTSS Training and Learning Collaborative|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative to support implementation
10211200|NCT05185440|Experimental|GIFTSS Training and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with provider scripts to support implementation
9871873|NCT00289835|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
9871874|NCT00289835|Other|Standard medical treatment|
9871875|NCT00289861|Active Comparator|risperdone|
9871876|NCT00289861|Placebo Comparator|placebo|
9871877|NCT00289926|Experimental|dehydroepiandrosterone|50.0mg dehydroepiandrosterone capsule, by mouth, daily for 12 months
9871878|NCT00289926|Placebo Comparator|Placebo|Placebo capsule consists of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF manufactured to mimic dehydroepiandrosterone capsule
9871879|NCT00289952|Experimental|Group 1|HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.
9871880|NCT00289952|Experimental|Group 2|HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.
9871881|NCT00289965|Active Comparator|1|in-person brief motivational intervention
9871882|NCT00289965|Active Comparator|2|Alcohol 101plus
9871883|NCT00289965|Active Comparator|3|AlcoholEdu (a Web-based tutorial).
9871884|NCT00290082|Active Comparator|loxapine|agitated patients were randomly assigned either to loxapine, either to midazolam group
9871885|NCT00290082|Active Comparator|midazolam|midazolam is compared to loxapine in terms of efficacy and tolerance
9871886|NCT00290121|Active Comparator|Olanzapine|
9871887|NCT00290420|Experimental|Chloroquine profilaxis|"Prevention: chloroquine profilaxis~Prevention of malaria attacks with chloroquine profilaxis taken once a week"
9871888|NCT00290420|No Intervention|No prevention|Treatment of malaria attack with chloroquine when they occur
9871889|NCT00290550|Other|1|MK-0457
9871890|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x 2-weekly rituximab|Arm I (2-weekly rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days 0, 14, 28, 42, 56, 70, 84, and 98. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
9871891|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x dose-dense rituximab|Arm II (pharmacokinetic-based dose-dense rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days -1, 0, 3, 7, 14, 21, 28, and 42. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
9871892|NCT00290758|Experimental|Arm I (genistein)|Patients receive oral genistein once daily for up to 6 months.
9871893|NCT00290758|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for up to 6 months.
9871894|NCT00290823|Experimental|1|Participants will receive 6 mg dexamethasone daily for 10 days Participants will also receive albendazole and omeprazole.
9871895|NCT00290823|Experimental|2|Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
9871896|NCT00290862|Experimental|CORTOSS|Patients prospectively randomized to be treated with Cortoss constitute treatment group.
9871897|NCT00290862|Active Comparator|PMMA|Patients prospectively randomized to be treated with PMMA constitute active control group.
9871898|NCT00290875|Other|Arm 1|We randomly allocated sites to either intervention or control. At the intervention sites, active strategies were employed to implement the rule into practice, including education, policy, and real-time reminders on radiology requisitions.
9871899|NCT00291031|Experimental|IRT|Patients randomly assigned to the IRT condition receive Imagery Rehearsal Therapy after 4 weeks since the entrance into the trial next to their treatment as usual.
9871900|NCT00291031|No Intervention|TAU|Patients that are randomly assigned to the waiting list control condition get treatment as usual (TAU) and complete the daily nightmare logs for a period of three months. These patients get the IRT intervention after waiting for 6 months.
9871901|NCT00291057|Experimental|1|MALG
9871902|NCT00291148|Active Comparator|Paroxetine|
9871903|NCT00291148|Active Comparator|pregabalin|
9871904|NCT00291200||1|Participants with basic symptoms of psychosis
9871905|NCT00291200||2|Control participants
9871906|NCT00291213|Experimental|Levetiracetram Administration|
9871907|NCT00291213|Placebo Comparator|Placebo|
9871908|NCT00291616|Active Comparator|1|Pegylated Interferon-alpha2a
9871909|NCT00291616|Active Comparator|2|Thymosin alpha1 & Pegylated Interferon-alpha2a
9871910|NCT00291720|Active Comparator|Spironolactone|25mg spironolactone daily
9871911|NCT00291720|Placebo Comparator|Placebo|matching placebo medication for the control group
9871912|NCT00291733|Active Comparator|1|500mg levetiracetam for one week and 1000mg levetiracetam for one week
9871913|NCT00291733|Placebo Comparator|2|placebo
9871914|NCT00291733|Active Comparator|3|After crossover arm 3 equals arm 1
9871915|NCT00291733|Placebo Comparator|4|After crossover arm 4 equals arm 2
9928709|NCT00909103||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
9928710|NCT00909116||Chronic constipation - ODS|Adult Patients with ODS
9928711|NCT00909129|Experimental|HIV-1 HCV coinfected patients|HIV-1 HCV coinfected patients undergoing HCV therapy
9928712|NCT00909142||Group1|
9928713|NCT00909168|Experimental|Efficacy of FLAIMy|
9928714|NCT00909194|Experimental|Intervention|Educational Seminar on Juvenile Primary Fibromyalgia Syndrome and CD-guided total body relaxation technique
9928715|NCT00909194|No Intervention|Control|Control Arm consisted of an educational seminar on skin care
9928716|NCT00909207||Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
9928717|NCT00909233||Group 1|
9928718|NCT00909259|Experimental|Phrenic Stimulation|
9928719|NCT00909272||US-guided lumbar medial branch block|Patients who have low back pain and/or leg pain due to possible lumbar facet joint disease .
9871916|NCT00291928|Placebo Comparator|Dose ranging|A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
9871917|NCT00291928|Placebo Comparator|Parallel Arm RCT|a parallel group part with randomization into one of 4 treatment arms (Part B).
9871918|NCT00291941|Experimental|1|Henogen HB vaccine
9871919|NCT00291941|Active Comparator|2|Fendrix vaccine
9871920|NCT00291954|Experimental|1|Henogen hepatitis B vaccine
9871921|NCT00291954|Active Comparator|2|HBVAXPRO hepatitis B vaccine
9871922|NCT00291980|Experimental|1|HB-AS02V vaccine
9871923|NCT00291980|Active Comparator|2|HBVAXPRO vaccine
9871924|NCT00292019||Robotic prostatectomy|Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
9871925|NCT00292032||Cardiac Arrest Survivors or Post Mortem Unexplained Cardiac|Probands - Unexplained Cardiac Arrest Survivors and Post Mortem Unexplained Cardiac Arrest Cases
9871926|NCT00292032||First Degree Family Members|First Degree Family Members of those affected by Sudden Unexplained Cardiac Arrest
9871927|NCT00292071|Other|1|IV caspofungin acetate (50 mg/m²/day)
9871928|NCT00292071|Other|2|IV caspofungin acetate (70 mg/m²/day)
9871929|NCT00292097|Experimental|1|Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
9871930|NCT00292097|Active Comparator|2|Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
9871931|NCT00292110|Active Comparator|Arm Four|
9871932|NCT00292110|Experimental|Arm One|
9871933|NCT00292110|Active Comparator|Arm Three|
9871934|NCT00292110|Active Comparator|ArmTwo|
9871935|NCT00292201|Experimental|1|Atorvastatin
9871936|NCT00292201|Placebo Comparator|2|Placebo Pill
9871937|NCT00292253|Experimental|Rebif® with Rebiject™Mini|
9871938|NCT00292253|Active Comparator|Rebif® without Rebiject™Mini|
9871939|NCT00292266|Experimental|Rebif®|
9871940|NCT00292266|Active Comparator|Avonex®|
9871941|NCT00292279|Experimental|A|
9871942|NCT00292279|Active Comparator|B|
9871943|NCT00292305|Experimental|T-crush stenting|Percutaneous coronary intervention with implantation of a stent
9871944|NCT00292305|Active Comparator|Culotte stenting|Percutaneous coronary intervention with stent
9871945|NCT00292474|Experimental|TAXUS Express|
9871946|NCT00292474|Placebo Comparator|Express Bare|
9871947|NCT00292500|No Intervention|C-Port|Automated distal anastomotic device
9871948|NCT00292526|Experimental|enalapril arm|treatment with enalapril
9871949|NCT00292552||COPD subjects|Subjects with GOLD stage II-IV COPD
9871950|NCT00292552||Smoker controls|Subjects with smoking history but normal lung function
9871951|NCT00292552||Non-smoker controls|Normal healthy non-smokers
10211201|NCT05185440|Experimental|GIFTSS Training, Learning Collaborative, and Provider Scripts|Training for college health center clinicians and staff in implementation of GIFTSS Training combined with learning collaborative as well as provider scripts to support implementation
10211202|NCT05181436||Malaysian children aged ≥ 6 months to ≤ 36 months|The study population consists of Malaysian children aged ≥ 6 months to ≤ 36 months seen at Mother and Child Health Clinic (MCHC).
9871952|NCT00292695|Experimental|chemoradiation|Chemoradiation: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
9871953|NCT00292721|No Intervention|Control|
9871954|NCT00292721|Active Comparator|Celecoxib|
9871955|NCT00292747|Experimental|drotaverine + Ibuprofen placebo|Drotaverine 80 mg plus ibuprofen placebo orally
9871956|NCT00292747|Active Comparator|Drotaverine placebo + ibuprofen|Drotaverine placebo plus ibuprofen 400 mg orally
10211203|NCT05180851|Experimental|Safety and efficacy of recombinant L-IFN adenovirus injection in relapsed/refractory solid tumors|"1.Only 1 lesion: If the tumor volume is less than or equal to 10 cm3, the whole tumor is injected radially and evenly.~If the tumor volume was >10 cm3, the tumor was evenly divided into five quadrants and injected into one quadrant at a time.~2. If there are 2 or more lesions, the most manageable tumor injection is selected; 3. Priority should be given to the body surface metastases that meet the evaluation criteria for tumor efficacy.~4. According to patients' conditions (e.g., patients with thorax and ascites), the investigator and the research group and cooperative units jointly explored other drug administration approaches (e.g., bladder infusion, thorax and abdominal cavity administration)"
10211204|NCT05179954|Other|Control group|Healthy control group
10211205|NCT05179954|Active Comparator|T1D group|T1D group
10211206|NCT05177133|Experimental|Capecitabine, oxaliplatin and retifanlimab|IV and PO Capecitabine 1000 mg/m2, oxaliplatin 130 mg/m2, every three weeks (up to 2 cycles) IV retifanlimab 500mg, every four weeks
10211207|NCT05176964||HFRT with concurrent chemotherapy and immunotherapy|CAPOX chemotherapy plus tislelizumab treatment plus split-course HFRT
10213716|NCT03462706|Experimental|Cold Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold snare techniques.
10213717|NCT03462706|Experimental|Hot Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot snare techniques.
9871957|NCT00292747|Active Comparator|Drotaverine + ibuprofen|Drotaverine 80 mg plus ibuprofen 400 mg orally
9871958|NCT00292903|Experimental|A|
9871959|NCT00292903|Active Comparator|B|
9871960|NCT00293085|Active Comparator|Docetaxel|"Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
9871961|NCT00293085|No Intervention|Comparative arm|No chemotherapy will be administered. No specific salvage therapy after progression is defined.
9871962|NCT00293137||1|Patients enrolled into the trial must have left ventricular ejection fraction of <40% by echocardiogram within 6 months of enrollment
9871963|NCT00293150|Active Comparator|Eplerenone|Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
9871964|NCT00293150|Placebo Comparator|Placebo|Placebo dosed daily
9871965|NCT00293176|Experimental|1|
9871966|NCT00293176|Placebo Comparator|2|
9871967|NCT00293228|Experimental|A|Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
9871968|NCT00293228|Active Comparator|B|B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
9871969|NCT00293228|Experimental|C|C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
9871970|NCT00293228|Active Comparator|D|D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
9871971|NCT00293345|Experimental|Treatment (gemcitabine hydrochloride, triapine)|Patients receive 3-AP (TriapineÃÂ®) IV over 24 hours followed by gemcitabine hydrochloride IV over 100-125 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
9871972|NCT00293475|Experimental|Treatment (rituximab, mannitol, methotrexate, carboplatin)|Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9871973|NCT00293592|Active Comparator|Dexamethasone|
9871974|NCT00293592|Placebo Comparator|Placebo|
9871975|NCT00293605||1|C-stem implant
9871976|NCT00293605||2|Charnley Implant
9871977|NCT00293605||3|Exeter Implant
9871978|NCT00293618|Experimental|Intervention|Arm of anesthesiologists and senior residents who receive a patient's individual predicted PONV risk intraoperatively
9871979|NCT00293618|Active Comparator|Usual Care|Anesthesiologists and senior residents who provide usual care: they provide PONV prophylaxis as they always have
9871980|NCT00293644|Experimental|Pre-emptive Treatment Group|As soon as a patient becomes aware of the pregnancy, and before the Nausea and Vomiting of Pregnancy (NVP) starts, she will begin taking Diclectin®. When NVP starts, the dose will be adjusted to match symptoms.
9871981|NCT00293644|Active Comparator|Standard Treatment Group|Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
9871982|NCT00293644|No Intervention|Natural Course Group|A third group will be randomly matched from Motherisk NVP callers who did not participate in our pre-emptive intervention and experienced severe Nausea and Vomiting of Pregnancy/Hyperemesis Gravidarum (NVP/HG) in their previous pregnancy. This group will serve as a control group for the potential effect of the early counselling. (These women will have called for the first time after NVP symptoms (of any degree) started in the current pregnancy).
9928720|NCT00909272||Cadavers for Ultrasound landmarks|Cadavers donated to the Department of Anatomy in McMaster University will be used to determine the landmarks for ultrasound.
9928721|NCT00909285|Experimental|Treatment Group (#1)|
9928722|NCT00909285|Sham Comparator|Control group (#2)|
9928723|NCT00909311|Active Comparator|1|Non-fasting
9928724|NCT00909311|Active Comparator|2|Fasting
9928725|NCT00909337|Other|Bosentan|"In this study, all participants have normal pulmonary arterial pressure at rest and elevated pulmonary arterial pressure during exercise. First, they were followed up for a year and were controlled after 1 year without specific therapy for pulmonary hypertension. Then Bosentan was introduced. A second control showing the effects of the therapy was done after 6 months. The changes in the therapy period can be compared with the changes in the follow up period."
9928726|NCT00909350||No treatment|genetic research project; to meet inclusion criteria, participants must have normal upper GI tract upon upper endoscopy, for study biopsies to be taken
9928727|NCT00909376||1 - transabdominal sonography|Women who will have a transabdominal sonography done in the early second trimester.
9928728|NCT00909376||2 - transvaginal sonography|Women who will have a transvaginal sonography done in the early second trimester.
9928729|NCT00909402|Experimental|All Subjects|
9928730|NCT00909441|Experimental|SNB + ALND|Intervention: Sentinel Lymph Node Biopsy followed by Axillary Node Dissection.
9928731|NCT00909454|Experimental|Daily 2000 IU vitamin D supplement|
9928732|NCT00909454|Active Comparator|Daily Vitamin D supplement 400 IU|
9928733|NCT00909467||myeloproliferative, -dysplastic disease|
10213718|NCT03462706|Experimental|Cold EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold EMR techniques.
10213719|NCT03462706|Experimental|Hot EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot EMR techniques.
10213720|NCT03461445|Active Comparator|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
9928734|NCT00909493|Experimental|Access to Pain Specialist|Network
9928735|NCT00909506|Placebo Comparator|Placebo|Placebo
9928736|NCT00909506|Active Comparator|Metformin 500 mg/d|Metformin 500 mg/d
9928737|NCT00909506|Active Comparator|Metformin 1000 mg/d|Metformin 1000 mg/d
9935887|NCT03040778|Experimental|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
9935888|NCT03040778|Placebo Comparator|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
9871983|NCT00293735|Active Comparator|1. Labetolol|
9871984|NCT00293735|Active Comparator|2. Magnesium Sulfate|
10211208|NCT05175781|Active Comparator|Dexmedetomidine|"patients will receive two NIV sessions during which intravenous continuous infusion of dexmedetomidine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. Dexmedetomidine will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions accounting for 1-h contextual half-life of dexmedetomidine. Patients received neither tested drug nor NIV during this 6-h interval."
10211209|NCT05175781|Active Comparator|Ketamine|"patients will receive two NIV sessions during which intravenous continuous infusion of ketamine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, infusion of ketamine will be at the dose of 0.20 mg/kg/h (or 3.3 mg/kg/min). to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of the infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
9871985|NCT00293761|Experimental|Travatan, Investigational|
9871986|NCT00293761|Active Comparator|Travatan|
9871987|NCT00293774||Standard|Standard hip replacement subjects (polyethylene)
9871988|NCT00293774||Alternative Bearing|Subjects with ceramic on ceramic total hip replacement or metal on metal hip resurfacing.
9871989|NCT00293787|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months
9871990|NCT00293787|Active Comparator|Xalatan + Timolol 0.5%|Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months
9871991|NCT00293800|Experimental|Travoprost/Timolol|One drop Travoprost 0.004%/Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Timolol vehicle in the study eye(s) each evening at 8 p.m. for 3 months
9871992|NCT00293800|Active Comparator|Xalatan + Timolol 0.5%|One drop Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Xalatan in the study eye(s) each evening at 8 p.m. for 3 months
9871993|NCT00293826|Experimental|1|196 subjects
9871994|NCT00293826|Experimental|3|196 subjects
9871995|NCT00293826|Experimental|2|196 subjects
9871996|NCT00293826|Placebo Comparator|4|196 subjects
9871997|NCT00293852|No Intervention|Usual Care|
9871998|NCT00293852|Experimental|Collaborative Care|
9871999|NCT00293956||1|Full-term and near-term infants with respiratory distress in the first 24 hours of life
9872000|NCT00294008||001|Risperdal Consta flexible dosage for 24 months
9872001|NCT00294099|Experimental|2|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
9872002|NCT00294099|Experimental|3|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
9872003|NCT00294099|Experimental|4|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
9872004|NCT00294099|Experimental|8|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
9872005|NCT00294099|Experimental|7|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
10211210|NCT05175781|Placebo Comparator|Placebo|"patients will receive two NIV sessions during which intravenous continuous infusion of placebo (0.9% sodium chloride solution) will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of any infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
10211211|NCT05174533||with schizophrenia|"with schizophrenia group : patients aged 40 and more with schizophrenia"
10211212|NCT05173753|Active Comparator|Novel self-adhesive composite restoration (Surefil one)|
10211213|NCT05173753|Active Comparator|conventional composite resin restoration(VOCO Grandio)|
10211214|NCT05161832|Experimental|nocebo|Ultrasound with fake results of rotator cuff injury.
10211215|NCT05161832|Active Comparator|placebo|Ultrasound with fake results of the healthy rotator cuff.
10211216|NCT05160714|Experimental|Adaptive SBRT Boost|Dose-escalated SBRT boost to an ADC-based high risk subvolume in HNC
9872006|NCT00294099|Experimental|1|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
9872007|NCT00294099|Experimental|5|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
9872008|NCT00294099|Experimental|6|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
9872009|NCT00294112|Experimental|High dose|High dose (8 million cells per kg of body weight)
9872010|NCT00294112|Experimental|Low dose|Low dose: 2 million cells per kg body weight
9872011|NCT00294125|Experimental|1|Participants will receive daily flavocoxid for 12 weeks.
9872012|NCT00294125|Placebo Comparator|2|Participants will receive placebo for 12 weeks.
9872013|NCT00294164|Experimental|Serostim® 4 mg daily|
9872014|NCT00294164|Experimental|Serostim® 4 mg alternate days|
9872015|NCT00294164|Placebo Comparator|Placebo|
9872016|NCT00294190|Experimental|Topotecan|
9872017|NCT00294203|Active Comparator|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
9928738|NCT00909519|Active Comparator|naproxen|
9928739|NCT00909519|Experimental|naproxcinod|
9928740|NCT00909519|Placebo Comparator|placebo|
9928741|NCT00909571|Experimental|1. FK506E high dose group|
9928742|NCT00909571|Experimental|2. FK506E low dose group|
9928743|NCT00909584|Experimental|1|4-Week dose equilibration period with Telintra followed by 4 month treatment period
9928744|NCT00909584|No Intervention|2|4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period
9928745|NCT00909636|Active Comparator|1. ABT-333 Tablet|Three 400mg ABT-333 Tablets, BID
9928746|NCT00909636|Active Comparator|2. ABT-333 Tablet|Four 400mg ABT-333 Tablets, BID
9928747|NCT00909636|Placebo Comparator|3. Placebo|Three or four placebo tablets, BID
9928748|NCT00909662||Patients|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy
9928749|NCT00909662||Participants|Female control subjects will be recruited, consisting predominantly of age-matched (i.e.+/- 10 years of age) friends or family members of the patients.
9928750|NCT00909688|Experimental|1|BLI-489
9928751|NCT00909688|Placebo Comparator|2|placebo
9928752|NCT00909701|Experimental|Test|PreOP Booster (Fresenius Kabi, Bad Homburg, Germany)
9928753|NCT00909701|Active Comparator|Comparator|PreOP (Nutricia Clinical Care, Trowbridge, UK)
9928754|NCT00909714|Experimental|Anodal tDCS|Direct Current (DC)-Stimulator to apply tDCS + Training
9928755|NCT00909714|Sham Comparator|Sham tDCS|Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
9928756|NCT00909740|Experimental|1|
9928757|NCT00909805|Experimental|Cutaneous suture with glue|Inguinal surgical incision closing using Dermabond® glue instead of cutaneous suture with surjet
9928758|NCT00909805|Active Comparator|Conventional suture|Inguinal surgical incision closing with conventional cutaneous suture (surjet)
9928759|NCT00909818|Active Comparator|standard fractionated radiotherapy|50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
9928760|NCT00909818|Experimental|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
9928761|NCT00909896||Robotic Surgery candidates|Group of patients receive Robotic approach for endometrial cancer staging
9928762|NCT00909896||Open Laparotomy Surgical Candidates|Patients receiving open laparotomy for endometrial cancer surgical staging
9928763|NCT00909922||Lower Limb Amputees|Unilateral Above knee amputees
9928764|NCT00909948|Active Comparator|Fludarabine|The patients in this cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
9928765|NCT00909948|Active Comparator|TBI only|Patients will be given 200 centiGray (cGy) total body irradiation (TBI) in one fraction. TBI will be given on day 0, 4 to 6 hours prior to HCT.
9928766|NCT00909961|Experimental|Zoledronic acid|
9928767|NCT00909974|Experimental|Food supplement (FS)|Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
9928768|NCT00909974|Active Comparator|UNIMMAP|UNIMMAPin tablet form: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
9928769|NCT00909987|Experimental|Single arm|"Neoadyuvant chemotherapy with XELOX: Xeloda 1000mg/m2/12h dayly, day one in the afternoon until day 15 in the morning; plus oxaliplatin 130mg/m2 (day 1); and Bevacizumab 7.5 mg/kg (day 1)during 3 cycles (each cycle of 3 weeks).~Followed by a selective use of chemoradiotherapy with radiotherapy (50.4Gy, 28 sesions of 1.8Gy during 5 weeks) plus Xeloda 825mg/m2/12h dayly."
9928770|NCT00910013|Experimental|Ropivacaine + femoral block|After the surgery is proceeded and after the closure of the joint capsule, 20 cc of ropivacaine 0.5% is inserted intra-articular through a catheter.
9928771|NCT00910026|Experimental|low tidal volume ventilation|6 ml/kg tidal volume ventilation
9872018|NCT00294203|Placebo Comparator|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
9872019|NCT00294255|Experimental|Risperidone|patients will receive risperidone for up to 20 weeks
9872020|NCT00294268|Other|1|20 weekly sessions of CBT integrated with motivational enhancement strategies
9872021|NCT00294281|Experimental|1|Participants will undergo surgical implantation of the VNS system. This will be followed by a 2-week recovery period, then a 2-week period of gradually increasing the electrical output of the VNS system, and finally a 12-week VNS treatment period during which the electrical output level will remain constant. Follow-up will occur until Month 24.
9872022|NCT00294307||Advanced Practice Nurse Care (APNC)|Hospital to Home
9872023|NCT00294307||Augmented Standard Care (ASC)|Hospital only
9872024|NCT00294307||Resource Nurse Care (RNC)|Hospital only
9872025|NCT00294385|Active Comparator|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
9872026|NCT00294385|Active Comparator|Docetaxel|Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
9872027|NCT00294437|Experimental|zoledronic acid|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
9872028|NCT00294437|No Intervention|no intervention|no reference therapy
9872029|NCT00294567|Active Comparator|1|Amlodipine
9872030|NCT00294567|Active Comparator|2|Azelnidipine
9872031|NCT00294619|Experimental|LB03002|
9872032|NCT00294619|Placebo Comparator|Placebo|
9872033|NCT00294736|Experimental|Arm A|Arm A (Tarceva MTD established in Part I)
9872034|NCT00294736|Experimental|Arm B|Arm B (150 mg Tarceva daily).
9872035|NCT00294827|Experimental|Liver transplantation|
9872036|NCT00294866|Active Comparator|A|Receive Paricalcitol
9872037|NCT00294866|No Intervention|B|Paricalcitol on hold
9872038|NCT00294892|Active Comparator|Carbamazepine|An oral dose of 400mg Carbamazepine is added to the 200mg oral dose Nevirapine intake prior delivery
9872039|NCT00294892|Placebo Comparator|Nevirapine|Standard therapy of 200mg Nevirapine oral prior to delivery
9872040|NCT00294918|Experimental|Serostim® (1 mg)|
9872041|NCT00294918|Experimental|Serostim® (2 mg)|
9872042|NCT00294918|Experimental|Serostim® (4 mg)|
9872043|NCT00294970||PTSD|Patients with diagnosis of PTSD
9872044|NCT00294970||OCD|Patients with diagnosis of OCD
9872045|NCT00294970||PTSD/OCD|Patients with diagnosis of comorbid PTSD and OCD
9872046|NCT00295165|Experimental|Arm 1|
9872047|NCT00295165|Placebo Comparator|Arm 2|
9872048|NCT00295191|Active Comparator|1|high-flux dialyser
9872049|NCT00295191|Active Comparator|2|low-flux dialyser
9872050|NCT00295191|Active Comparator|3|conventional dialysate
9872051|NCT00295191|Active Comparator|4|ultrapure dialysate
9928772|NCT00910026|Experimental|high tidal volume ventilation|12 ml/kg tidal volume ventilation
9928773|NCT00910052|Experimental|Fibrin sealant|received intraoperative fibrin sealant
9928774|NCT00910052|No Intervention|Control|No fibrin sealant
9928775|NCT00910065|Experimental|Arm 1|
9928776|NCT00910065|Experimental|Arm 2|
9928777|NCT00910065|Active Comparator|Arm 3|
10211217|NCT05157516|Active Comparator|group ESPB|Erector Spinae Plane Block
9872052|NCT00295282|Experimental|1|patients will receive active MDX-1100
9872053|NCT00295295|Experimental|Vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
9872054|NCT00295295|Active Comparator|Standing|Standing 10 min/day
9872055|NCT00295308|Experimental|Arm 1|
9872056|NCT00295308|Placebo Comparator|Arm 2|
9872057|NCT00295438|Experimental|Robot-Based Tele-Echography (TER)|ultrasound performed according to the method Tele-Echography
9872058|NCT00295438|Active Comparator|ultrasound method FAST|ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)
9872059|NCT00295529|Experimental|Multifaceted Educational Intervention|Intervention group received an interactive workshop, portfolio of primary care appropriate genomics tools, and Gene Messengers
9872060|NCT00295529|No Intervention|No education|Educational materials at end of study
9872061|NCT00295542|Active Comparator|1|Treatment on awakening
9872062|NCT00295542|Active Comparator|2|Treatment at bedtime
9872063|NCT00295594|Active Comparator|1|
9872064|NCT00295594|Experimental|2|
9872065|NCT00295607|Active Comparator|1|
9872066|NCT00295607|Experimental|2|
9872067|NCT00295646|Active Comparator|AZ (Arimidex+Zoledronate)|Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)
9872068|NCT00295646|Active Comparator|TZ (Tamoxifen+Zoledronate)|Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)
9872069|NCT00295646|Active Comparator|AC (Arimidex Control)|Study Drug Arimidex (Anastrozole)
9872070|NCT00295646|Active Comparator|TC (Tamoxifen Control)|Study Drug Nolvadex (Tamoxifen)
9872071|NCT00295763|Other|1|
9872072|NCT00295789|Active Comparator|1|Drug: chemotherapy: Paclitaxel/Cisplatin
9872073|NCT00295789|Experimental|2|Drug: chemotherapy: Paclitaxel/Carboplatin
9872074|NCT00295802|Experimental|HIFU|Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
9872075|NCT00295802|Active Comparator|Cryotherapy|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
9872076|NCT00295815|Experimental|A|
9872077|NCT00295815|Active Comparator|B|
9872078|NCT00295828|Active Comparator|1|Panretinal Photocoagulation (PRP)
9872079|NCT00295828|Active Comparator|2|Panretinal Photocoagulation and Macugen Intravitreal Injection
9872080|NCT00295893|Active Comparator|Arm I|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.
9872081|NCT00295893|Experimental|Arm II|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
9872082|NCT00295893|Experimental|Arm III|Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.
9872083|NCT00295945||PCA|Patient-controlled intravenous analgesia
9872084|NCT00295945||PCEA|Perioperative patient-controlled epidural analgesia
9872085|NCT00295971|Experimental|Single arm of transplant|Receiving haplocompatible T cell depleted peripheral blood stem cell transplant
9872086|NCT00296010|Experimental|CASA-nil PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
9872087|NCT00296010|Active Comparator|CASA-Nil|No adjuvant therapy
9872088|NCT00296010|Experimental|CASA-CM PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
9872089|NCT00296010|Active Comparator|CASA-CM CM|Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
9872090|NCT00296023|Experimental|stem cell transplant|
9872091|NCT00296049|Active Comparator|vancomycin|
9872092|NCT00296049|Experimental|daptomycin|
9872093|NCT00296153|Active Comparator|1|Omacor 1000mg x 4 / day
9872094|NCT00296153|Placebo Comparator|2|
9872095|NCT00296309|Active Comparator|1|
9872096|NCT00296309|Experimental|2|
9872097|NCT00296348|Active Comparator|1|
9872098|NCT00296348|Experimental|2|
9872099|NCT00296361|Active Comparator|1|
9872100|NCT00296361|Experimental|2|
9872101|NCT00296413||1|Valproate monotherapy
9872102|NCT00296413||2|Valproate monotherapy with combined oral contraceptive
9872103|NCT00296413||3|Lamotrigine monotherapy
9872104|NCT00296413||4|Lamotrigine monotherapy with combined oral contraceptive
9872105|NCT00296426|No Intervention|Usual Care|control patients admitted to hospital floors received usual care
9872106|NCT00296426|Experimental|Intervention|computerized medication reconciliation tool and process redesign involving physicians, nurses, and pharmacists
9872107|NCT00296465|Experimental|Lutrepulse® 5mcg IV|5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
9872108|NCT00296465|Experimental|Lutrepulse® 10 mcg IV|10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
9935889|NCT03032328|Experimental|vitamin D supplement|patient's will be given a vitamin D
10211218|NCT05157516|Active Comparator|In group CEA|Caudal epidural block
10211219|NCT05152992|Experimental|Video and stimulation-based induction of emotion|Participants viewed visual stimuli while undergoing stimulation of brain regions involved in emotion during their inpatient hospitalization at the University of California, San Francisco (UCSF).
10211220|NCT05152706|Experimental|Intervention aerobic (IAER)|Patients assigned to the IAER participated in fourty-eigth aerobic exercise therapy sessions over the course of six months.
10211221|NCT05152706|Experimental|Intervention photobiomodulation (IPBM)|Patients assigned to the IPBM participated in fourty-eigth transcraneal photobiomodulation (PBM) theraphy sessions, using a therapeutic laser console, over the course of six months.
10211222|NCT05152706|Experimental|Intervention aerobic and photobiomodulation (IAER+PBM9|Patients assigned to the IAER+PBM participated in the aerobic exercise therapy and the PBM one at the same time, during six months.
9928778|NCT00910104|Experimental|Omegaven|1g/kg/day for duration of study participation for all participants
9928779|NCT00910117|Experimental|nimotuzumab|nimotuzumab plus PF regimen
9928780|NCT00910130||End Stage Renal Disease|Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes
9928781|NCT00910130||Control|"Healthy people, with normal Renal Function and without Diabetes, matched with ESRD group for age, gender, BMI"
9928782|NCT00910143||1|patients operated before summer 1995, that is before the introduction of TME
9928783|NCT00910143||2|patients operated after summer 1995, that is after the introduction of TME.
9928784|NCT00910156|Active Comparator|Airtraq|
9928785|NCT00910156|Active Comparator|Glidescope|
9928786|NCT00910156|Active Comparator|Macintosh|
9928787|NCT00910169||inpatient treatment|naturalistic treatment no modification: observational study
9928788|NCT00910182||1|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 and treated non-operatively
9928789|NCT00910182||2|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 who underwent emergency surgical treatment
9928790|NCT00910182||3|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 treated non-operatively plus transcatheter arterial embolisation
9928791|NCT00910195|Experimental|CPAP before Bi-Level-APAP|receiving CPAP treatment during the first night and then Bi-level-APAP treatment during second night
9928792|NCT00910195|Experimental|Bi-Level-APAP before CPAP|receiving Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
9928793|NCT00910221|Active Comparator|1|
9928794|NCT00910221|Placebo Comparator|2|
9928795|NCT00910234|Active Comparator|Drug: rhEpo, low dose|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
9928796|NCT00910234|Active Comparator|Drug: rhEpo, high dose|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
9928797|NCT00910234|Placebo Comparator|Control Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
9928798|NCT00910286|Other|VENTILATOR WEANING|Two ventilators with different flow termination criteria (TC) were compared: Servo 300 (Siemens-Elema, Sweden) with fixed TC (5% of peak inspiratory flow) and Newport E500 (Newport Medical Instruments, CA) with automatic TC (varies between 5% to 55%). Each patient remained three hours in the protocol, one hour in each ventilator, after been randomized to one of two sequences of 3 steps: Fixed 5% / Automatic / Fixed 5% or Automatic / Fixed 5% / Automatic . The PS, the positive end expiratory pressure (PEEP), the inspiratory oxygen fraction (FiO2) and the pressure trigger sensitivity levels were unchanged during the protocol.
9928799|NCT00910312|Experimental|Breast Fibroadenoma|
9928800|NCT00910338|Experimental|PFMT with Extracorporeal Biobeedback|
9928801|NCT00910351|Experimental|Arm 1|
9928802|NCT00910364|Experimental|Exercise testing|Feasibility study; all participants receive intervention
9928803|NCT00910377|Experimental|visit with grandmother|Teenagers mothers and their grandmothers receive counseling sessions about breastfeeding and complementary feeding.
9928804|NCT00910377|Experimental|visit without grandmother|Teenagers mothers don´t live with their grandmothers and receive counseling sessions about breastfeeding and complementary feeding.
9928805|NCT00910377|No Intervention|no visit with grandmother|Teenagers mothers live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
9928806|NCT00910377|No Intervention|no visit without grandmother|Teenagers mothers don´t live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
9928807|NCT00910390|Placebo Comparator|Slow Freezing|Standard freezing protocol (slow freezing) of preimplantation embryos
9928808|NCT00910390|Experimental|VIT-Irvine|Vitrification with Irvine solution (rapid freezing) of preimplantation embryos
9928809|NCT00910390|Experimental|VIT-Vitrolife|Vitrification (rapid freezing) with Vitrolife solution
9928810|NCT00910416||patients receiving iv anesthesia|
9928811|NCT00910416||patients receiving balanced anesthesia|
9928812|NCT00910442|Experimental|Patient Group|Dietary supplement:N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
9928813|NCT00910442|Active Comparator|Control Group|Healthy HIV negative subjects submitted to the same dietary supplement than experimental group: N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
9928814|NCT00910455|Experimental|Active|Single oral dose of SRX246 capsule
9928815|NCT00910455|Placebo Comparator|Placebo|Single oral dose of placebo capsule
9928816|NCT00910468||Robot Assisted Laparoscopic Myomectomy|
9928817|NCT00910468||Myomectomy via Laparotomy|
9928818|NCT00910494|Experimental|12 Gray IORT|
9928819|NCT00910494|Experimental|15 Gray IORT|
9935890|NCT03030417|Experimental|Treatment Arm|LMP744 will be administered IV over 1 hour on days 1-5 of each 28-day cycle
9872109|NCT00296465|Experimental|Lutrepulse® 20 mcg SC|20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
9872110|NCT00296465|Placebo Comparator|Placebo IV|Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
9872111|NCT00296465|Placebo Comparator|Placebo SC|Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
9872112|NCT00296465|Active Comparator|Clomiphene Citrate/Placebo IV|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
9872113|NCT00296465|Active Comparator|Clomiphene Citrate / Placebo SC|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
9872114|NCT00296478|Experimental|1|Endometrin 100mg BID
9872115|NCT00296478|Experimental|2|Endometrin 100mg TID
9872116|NCT00296478|Active Comparator|3|Crinone
9872117|NCT00296595|Placebo Comparator|Placebo|Placebo capsules + 500 mL/day of placebo juice
9872118|NCT00296595|Experimental|Cranberry Juice|Placebo capsules + 500 mL/day of cranberry juice
9872119|NCT00296595|Experimental|Fish Oil|2 g/day of fish oil + 500 mL/day of placebo juice
9872120|NCT00296595|Experimental|Cranberry Juice + Fish Oil|2 g/day of fish oil + 500 mL/day of cranberry juice
9872121|NCT00296608|Active Comparator|Radiotherapy|RT was delivered with photons from a linear accelerator with an energy level of 8MVor above.
9872122|NCT00296608|Experimental|Chemotherapy and radiotherapy|The first CT cycle was administered from days 1 to 5 of the RT treatment. LV 20 mg/m2/d was delivered intravenously immediately before administration of FU. FU 350 mg/m2/d was delivered during 20 minutes in 100 mL of saline infusion, 1 hour before RT. The second cycle was administered from days 29 to 33 of the RT treatment using the same schedule.
9872123|NCT00296621|Experimental|1|
9872124|NCT00296621|Placebo Comparator|2|
9872125|NCT00296634|Experimental|1|45 microgram dose Hemagglutinin (HA), 120 subjects receiving Aluminum hydroxide and 120 not receiving Aluminum hydroxide.
9872126|NCT00296634|Experimental|2|15 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
9935891|NCT03030404||Cohort 1|Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.
10211223|NCT05152706|No Intervention|Control (CO)|Patients assigned to the control (CO) did not participated in any kind of therapy, they just followed their usual weekly routine during six months
10211224|NCT05150847|Other|Prone Positioning|Patients will be ventilated in volume-controlled mode with Vt at 6 ml/kg of predicted body weight. Prone positioning will be performed over periods of 16 hours when PaO2/FiO2 was persistently lower than 150 mm Hg. Flow, volume, and airway pressure will bw measured by ventilators. Measurements of oxygenation and respiratory mechanics were performed at 5 and 15 cmH20 PEEP levels and will be repeated every season as before first period of prone positioning, before supine positioning, and again before second period of prone positioning. Total PEEP and plateau pressure will be measured by a short end-expiratory and an end-inspiratory occlusion respectively. Complete airway closure will be assessed by performing a low-flow (4 L/min) inflation( PV tool) (9). The potential for lung recruitment will be assessed by means of the R/I ratio (10).
10211225|NCT05150678|Experimental|removal of cs scar|gruop 1 will remove the scar
10211226|NCT05150678|Experimental|non removal of the scar|gruop2 will not remove the scar
10211227|NCT05146232|Active Comparator|Opioid free group|After induction of aesthesia, anesthesia maintained by sevoflurane and continuous unfusion of lidocaine, ketamine, dexmeditomedine and Paracetamol.
10211228|NCT05146232|Active Comparator|Opioid based group|After induction of aesthesia, anesthesia maintained by continuous remifentanyl infusion
10211229|NCT05145062||BIVV003 Cohort|All participants treated in parent and future studies with BIVV003
10211230|NCT05145062||ST-400 Cohort|All participants treated in parent studies with ST-400
10211231|NCT05143658|Active Comparator|Laparoscopic Lateral Suspension Group (LLS)|Anterior and apical prolapse repair via LLS
9872127|NCT00296634|Experimental|4|3.75 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
9872128|NCT00296634|Experimental|3|7.5 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
9872129|NCT00296660||1|Proven acute HIV-1 infection
9872130|NCT00296660||1A|Sexual partners of members of Group 1
9872131|NCT00296660||2|Established HIV-infection
9872132|NCT00296660||3|HIV-1 uninfected
9872133|NCT00296686|Experimental|tranylcypromine|sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3
9872134|NCT00296712|Experimental|escitalopram + bupropion|patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d
9872135|NCT00296777|Experimental|escitalopram|escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
9872136|NCT00296777|Experimental|bupropion|bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
9872137|NCT00296777|Experimental|imipramine|imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
9872138|NCT00296855|Experimental|Arm 1|
9872139|NCT00296894|Experimental|1|Drug - adalimimab sc
9872140|NCT00296894|Placebo Comparator|2|Placebo
9872141|NCT00296907|Experimental|Psychological Intervention|2-session psychological intervention
9928820|NCT00910507|Experimental|Exercise counseling|Each participant in the experimental group receives exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
9928821|NCT00910507|Active Comparator|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
9928822|NCT00910533|Active Comparator|Early Lyme neuroborreliosis patients|
9928823|NCT00910533|No Intervention|control subjects|Control subjects without a history of Lyme borreliosis.
9928824|NCT00910546|Experimental|Implantation of gold marker|CT guided implantation of gold marker into early stage lung tumors. Extra 4DCT scans and fluoroscopies during planning and the 3 fraction radiotherapy course.
9928825|NCT00910585|Experimental|Active coaching|Telephone and in person coaching
9928826|NCT00910585|Active Comparator|Usual care|Return to PCP for usual care
9928827|NCT00910598|Experimental|glatiramer acetate|glatiramer acetate 20 mg s.c. daily for 1 year
9928828|NCT00910598|No Intervention|no treatment|No disease modifying treatment allowed
9928829|NCT00910637|Experimental|Arm 1|
9928830|NCT00910676|Experimental|DIPROSONE|
9928831|NCT00910702|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
9928832|NCT00910741|Experimental|Nanoplatin|"Nanoplatin (NC-6004) had to be administered once every 3 weeks, on Day 1, Day 22 and Day 43 etc.~Gemcitabine had to be administered to every patient 2 times on Day 1 and Day 8 every 3 weeks after the infusion of Nanoplatin (NC-6004)."
9928833|NCT00910754|Experimental|Abiraterone acetate|Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.
9928834|NCT00910767|Experimental|Closed loop (algorithm)|
9928835|NCT00910767|Placebo Comparator|Open loop|
9928836|NCT00910780|Active Comparator|Staying on Risperdal|
9928837|NCT00910780|Active Comparator|Risperdal switched to Abilify|
9928838|NCT00910780|Active Comparator|Staying on Zyprexa|
9928839|NCT00910780|Active Comparator|Zyprexa switched to Abilify|
9928840|NCT00910793|Other|Inuvair|
9928841|NCT00910806|Experimental|TMC207, nevirapine|
9928842|NCT00910832|Experimental|Eductyl suppository|
9928843|NCT00910832|Placebo Comparator|Placebo suppository|
10211232|NCT05143658|Experimental|Laparoscopic Pectopexy (LP)|Anterior and apical prolapse repair via LP
9872142|NCT00297024|Experimental|MRI for brain mets|
9872143|NCT00297128|Active Comparator|1|
9872144|NCT00297141|Experimental|single arm (radiochemotherapy)|single arm study (capecitabine, oxaliplatin)
9872145|NCT00297154|No Intervention|Control|Patients continue receive a single educational session and continue medical managment of heart failure as per their physician
9872146|NCT00297154|Experimental|Lifestyle modification|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
9872147|NCT00297193|Experimental|Transplant Arm|Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
9872148|NCT00297193|Experimental|Delayed Transplant|Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation
9872149|NCT00297206|Experimental|Cohort 1|Subjects in the age group of 2 to less than 6 years will be included
9872150|NCT00297206|Experimental|Cohort 2|Subjects in the age group of 1 to less than 2 years will be included
9872151|NCT00297206|Experimental|Cohort 3|Subjects in the age group of 6 months to less than 1 year will be included
9872152|NCT00297206|Experimental|Cohort 4|Subjects in the age group of 3 months to less than 6 months will be included
9872153|NCT00297206|Experimental|Cohort 5|Subjects in the age group of 1 month to less than 3 months will be included
9872154|NCT00297219|Active Comparator|2|high dialysate calcium
9872155|NCT00297219|Active Comparator|1|low dialysate calcium
9872156|NCT00297271||Mild cognitive impairment or dementia|Patients with mild cognitive impairment or dementia.
9872157|NCT00297323||001|
9872158|NCT00297336||001|
9872159|NCT00297349||001|
9872160|NCT00297362||Galantamine hydrobromide|
9872161|NCT00297414||Patients with mild cognitive impairment|Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
9872162|NCT00297453|Experimental|Internet|Individual counseling + nicotine replacement. 6 sessions across a 3 month period.
9872163|NCT00297453|Experimental|Counseling|Individual counseling plus nicotine replacement treatment.
9517869|NCT03302156|Other|Healthy Control Non-Dosimetry Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6
9872164|NCT00297453|Active Comparator|Self-Help|Self-help Manual plus nicotine replacment treatment.
9872165|NCT00297752|Active Comparator|'ceriumnitrate silversulfadiazine (flammacerium)|facial burns treatment with Cerium nitrate silver sulfadiazine
9872166|NCT00297752|Active Comparator|flammazine|facial burns treatment with silver sulfadiazine
9872167|NCT00297791|Other|1|surgery (open or laparoscopic) and observation
9872168|NCT00297804|Experimental|Arm 1|
9872169|NCT00297804|Active Comparator|Arm 2|
9872170|NCT00297817|Experimental|Arm 1: rMenB|
9872171|NCT00297817|Experimental|Arm 2: rMenB + OMV|
9872172|NCT00297817|Placebo Comparator|Arm 3: Placebo|
9872173|NCT00297856||Boostrix cohort|
9872174|NCT00297856||Historical Td cohort|
9872175|NCT00297869|No Intervention|1|
9872176|NCT00297869|Experimental|2|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
9872177|NCT00297895|Active Comparator|Ultrasound observation + delayed CLND if recurrence detected|
9872178|NCT00297895|Active Comparator|CLND|
9872179|NCT00297947|Experimental|600 mg/day quetiapine (Group B)|Patients qualifying for the Double Blind Phase will be randomly assigned to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double-blind fashion for 8 weeks
9872180|NCT00297947|Experimental|1200 mg/day quetiapine (Group A)|Patients qualifying for the Double Blind Phase will be randomly assigned to high dose 1200 mg quetiapine daily (Group A) on the assigned dose in a double-blind fashion for 8 weeks
9872181|NCT00297986||1|healthy subjects
9872182|NCT00298025|Experimental|Cetrotide®|
9872183|NCT00298025|Active Comparator|Antagon ™|
9928844|NCT00910884||Arm I|Patients receive oral GRAS supplements daily for 12 months or as possible within the patient's parameters.
9928845|NCT00910884||Arm II|Patients do not receive supplements.
9872184|NCT00298051|No Intervention|Early umbilical cord clamping (control)|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
9872185|NCT00298051|Experimental|Delayed umbilical cord clamping|Umbilical cord was clamped at 2 minutes after delivery of the infant's shoulder's with the infant held at the level of the mother's uterus.
9872186|NCT00298168|Experimental|1|
9872187|NCT00298168|Experimental|2|
9872188|NCT00298168|Placebo Comparator|3|
9872189|NCT00298220|Active Comparator|training|tailored multi-component implementation program
9872190|NCT00298220|No Intervention|control|
9872191|NCT00298259|Active Comparator|ORIF|open reduction internal fixation of fractured ribs in flail chest patients
9872192|NCT00298259|No Intervention|conservative management|current standard conservative management
9872193|NCT00298298|Experimental|1|5 million autologous, DNP-modified NSCLC cells
9872194|NCT00298298|Experimental|2|2.5 million autologous, DNP-modified NSCLC cells
9872195|NCT00298298|Experimental|3|0.5 million autologous, DNP-modified NSCLC cells
9872196|NCT00298311|Experimental|mci guidance & peer social support|home visits to promote maternal-child interaction & social support
9872197|NCT00298311|Sham Comparator|peer social support|social support
9872198|NCT00298324|Active Comparator|Myfortic|Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
9872199|NCT00298324|Other|Standard Care/ Placebo|In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine
9872200|NCT00298415|Active Comparator|A|Chemotherapy (mono)
9872201|NCT00298415|Experimental|B|Chemotherapy (doublet)
9872202|NCT00298428|Other|SPACE group|
9872203|NCT00298506|Active Comparator|FK506+MMF|
9872204|NCT00298532|No Intervention|standard therapy|"The use of a before-after controlled study design and 36-month time periods will mirror the approach of our Adult OPALS Study. The Control (before) Period represents the 36 months immediately prior to the introduction of ALS programs at each study community. The Intervention (after) Period is comprised of the 36 months immediately after each community has met all standards for a full ALS program, as defined below. Data will be pooled across communities but the start date for the periods will vary for each community as each will require different amounts of time to prepare their ALS program. A 6- to 36-month Run-in period will separate the Control and Intervention Periods and will allow for training and implementation of the ALS program. Data from the Run-in period will not be considered in the primary analysis. The study periods may be summarized as follows: a) Control (Before) Period b) Run-in Period c) Intervention (After) Period."
9872205|NCT00298545|Placebo Comparator|placebo and Calcitriol|placebo tablets together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
9872206|NCT00298545|Active Comparator|2|calcium together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
9928846|NCT00910897|Active Comparator|Velcade-Dexamethasone|
9928847|NCT00910897|Active Comparator|Velcade-Thalidomide-Dexamethasone|
9928848|NCT00910936|Experimental|Intervention|
9928849|NCT00910936|No Intervention|Control|
9928850|NCT00910949||Painfree|Thoracotomy patients without chronic pain
9928851|NCT00910949||With Pain|Thoracotomy patients with chronic pain
9928852|NCT00910975|Active Comparator|Standard of care|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment is given for 24, 48 or 72 weeks depending on the time point (week 4, 12 or 24) when HCV RNA becomes undetectable by the Cobas Taqman assay. If HCV RNA has not declined 2 logs by week 12 or is detectable at week 24, treatment is stopped.
9928853|NCT00910975|Experimental|Tailored treatment|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment duration is flexible, 24-72 weeks, depending on the time point when the HCV RNA level is calculated to be 1 copy/mL. If the decline between day 14 and 28 is poor, treatment is stopped after 5 weeks.
9928854|NCT00911001||Group 1|
9928855|NCT00911014||Vesicovaginal fistula repair|Women undergoing repair of vesicovaginal fistula
9928856|NCT00911027|Experimental|SonoVue guided biopsy|
9928857|NCT00911027|Other|Systematic biopsy|
9928858|NCT00911066|Experimental|MLN4924|
9928859|NCT00911066|Experimental|Azacitidine|
9928860|NCT00911079|Experimental|Hyperthermia with HDR brachytherapy|Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session
9928861|NCT00911105||Patients with multiple myeloma|Patients with multiple myeloma receiving second line therapy or higher.
9928862|NCT00911118|Experimental|Radiation|Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
9935892|NCT03027440||CPP Cohort|offspring born to historic CPP cohort participant mothers between 1959 and 1966 who were known to be alive at age 7 (if still alive at the time of NDI search, ages 50 to 57 years old)
9935893|NCT03027427||Patients|Patients with confirmation of, or suspicion of, a heritable gastric malignancy disorder
10211233|NCT05142774|Experimental|tapinarof cream|Tapinarof 1%, cream
10211234|NCT05142176|Placebo Comparator|control group|will receive general anesthesia with bilateral sham erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg normal saline on each side.
10211235|NCT05142176|Active Comparator|Erector spinae plane block group|will receive bilateral ultrasound-guided erector spinae plane block at the level of T6 transverse process using 0.3 ml/kg bupivacaine 0.25% (on each side) with a maximum dose of 2 mg/kg.
10211236|NCT05141955|Active Comparator|Group Erector Spinae Plane Block (ESPB)|
10211237|NCT05141955|Active Comparator|Group Quadratus Lumborum Block (QLB)|
10211238|NCT05141955|Other|Group (C) (Control group)|
10211239|NCT05141305|Experimental|rhTNK-tPA ( 0.25 mg/kg, Max 25 mg )|rhTNK-tPA ( 0.25 mg/kg ) is given as a single, intravenous bolus ( within 5-10 seconds ) immediately upon randomization. Maximum dose 25mg.
10211240|NCT05141305|Active Comparator|standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of local neurologists
10211241|NCT05140902|Experimental|Glioblastoma patients|glioblastoma patients with newly or enlarged enhancing lesion within 3 months after completing 6 weeks of adjuvant chemoradiation therapy
9872207|NCT00298623|Placebo Comparator|Placebo|
10211242|NCT05138406|Experimental|Graded Motor Imagery|Individuals will receive standard rehabilitation and graded motor imagery treatment.
10211243|NCT05138406|Active Comparator|Standard Rehabilitation Group|Standard rehabilitation will be applied.
10213721|NCT03461445|Experimental|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
9872208|NCT00298623|Experimental|XP13512 (GSK1838262)|
9872209|NCT00298675|Experimental|Iniparib|
9872210|NCT00298675|Experimental|Iniparib/irinotecan|
9872211|NCT00298727|Active Comparator|1|SHIPS: Face-to-Face Workshop
9872212|NCT00298727|Active Comparator|2|ePBL: Online Problem-Based Course
9872213|NCT00298792|Experimental|Individualized Assessment & treatment|Individualized treatment for alcohol dependent persons, based on momentary assessment of high-risk situations and recorded coping abilities.
9872214|NCT00298792|Active Comparator|Packaged Cognitive-Behavioral Treatment|Manualized cognitive-behavioral treatment for alcohol dependent persons.
9872215|NCT00298870|Experimental|PGx-treatment|NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2*4: slow acetylators)
9872216|NCT00298870|Active Comparator|STD-treatment|Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)
9872217|NCT00298883|Experimental|Treatment|This is a single arm, interventional trial.
9872218|NCT00298909|Experimental|1|niacin
9872219|NCT00298909|Active Comparator|2|physical exercise
9872220|NCT00298909|Placebo Comparator|3|control
9872221|NCT00298922|Active Comparator|Azithromycin|participants taking 500 mg tablets orally thrice weekly for 24 weeks
9872222|NCT00298922|Placebo Comparator|Placebo|Participants taking 500 mg tablets orally thrice weekly for 24 weeks
9872223|NCT00298974|Experimental|hydrocodone/acetaminophen extended release|
9872224|NCT00298974|Placebo Comparator|Placebo|
9872225|NCT00299013|Active Comparator|1|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
9872226|NCT00299013|Experimental|2|COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
9872227|NCT00299013|Experimental|3|COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
9872228|NCT00299013|Experimental|4|COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
9872229|NCT00299039|Active Comparator|1|
9872230|NCT00299039|Active Comparator|2|
9872231|NCT00299052|Active Comparator|A|Bone reamings with 5cc of DMB putty
9872232|NCT00299052|Active Comparator|B|Bone reamings
9872233|NCT00299091|No Intervention|Control|Efavirenz capsules 600 mg
9872234|NCT00299091|Experimental|Experimental|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
9872235|NCT00299169|Experimental|1|N of 1 trials of statin therapy
9872236|NCT00299169|Other|2|usual care
9872237|NCT00299234|Placebo Comparator|2|placebo
9872238|NCT00299234|Experimental|1|atomoxetine
9872239|NCT00299260|Active Comparator|vaccine|glycoprotein B plus MF59 adjuvant
9872240|NCT00299260|Placebo Comparator|placebo|normal saline
9872241|NCT00299273|Experimental|Low calorie high fat/protein diet|Low calorie high fat/protein diet
9872242|NCT00299286|Experimental|Lapatinib|lapatinib oral 1500mg daily taken as 6 tablets as one dose 10-14 days presurgery
9872243|NCT00299286|Placebo Comparator|Lapatinib-Placebo|placebo comparator 6 tablets taken as one dose daily
9872244|NCT00299390|Experimental|Sagopilone|
9872245|NCT00299403|Active Comparator|1|Right frontal low frequency rTMS
9872246|NCT00299403|Active Comparator|2|electroconvulsive therapy (ECT). Right unilateral ECT 3 time a week in 3 weeks
9872247|NCT00299429|Active Comparator|MIDCAB Surgery|MIDCAB Surgery
9872248|NCT00299429|Experimental|PCI with drug-eluting stent|PCI with DES
9872249|NCT00299442|Experimental|1|Self-help Triple P Behavioural Family Intervention
9872250|NCT00299442|No Intervention|2|Wait-list control
9872251|NCT00299455|Experimental|1|Reconstituted amoxicillin-clavulanate at 40/5.7 mg/kg/day in 2 divided doses for 7 days.
9872252|NCT00299455|Placebo Comparator|2|Reconstituted placebo in 2 divided doses for 7 days.
9872253|NCT00299559|Other|1|cross over application of both specimen
9872254|NCT00299611|Active Comparator|1|Levetiracetam
9872255|NCT00299611|Placebo Comparator|2|there is no active ingredient in the pills.
9872256|NCT00299650|Placebo Comparator|A|
9872257|NCT00299650|Active Comparator|B|
9872258|NCT00299676||001|Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet
9872259|NCT00299819|Active Comparator|1|MEDI-545
9872260|NCT00299819|Active Comparator|2|MEDI-545
9872261|NCT00299819|Active Comparator|3|MEDI-545
10211244|NCT05136638|Active Comparator|Digital Sleep Hygiene and Self-Monitoring Control|Participants assigned to this condition will receive an app to track sleep and offers sleep hygiene recommendations
9872262|NCT00299819|Active Comparator|4|MEDI-545
9872263|NCT00299819|Active Comparator|5|MEDI-545
9872264|NCT00299858|Active Comparator|Study Group|Patients will be given theophylline, titrated to optimal blood levels, for a period of 4 weeks.
9872265|NCT00299858|Placebo Comparator|Placebo group|Patients will receive placebo pills for a period of 4 weeks.
9872266|NCT00299884||1|Lipitor 20 mg
9872267|NCT00299884||2|Lipidil Supra 160 mg and Ezetrol 10 mg
9872268|NCT00299962|Experimental|Dose level 4|
9872269|NCT00299962|Experimental|Dose level 5|
9872270|NCT00299962|Experimental|Dose Level 1|on Days 1 and 15
9872271|NCT00299962|Experimental|Dose Level 2|On Days 1 and 15
9872272|NCT00299962|Experimental|Dose Level 3|On Days 1 and 15
9872273|NCT00300040|Experimental|1|Hemoglobin glutamer 250 - bovine
9872274|NCT00300040|Active Comparator|2|6% Hydroxyethylstarch
9872275|NCT00300092|No Intervention|No antibioitcs|Group 1 received no antibiotics
9872276|NCT00300092|Active Comparator|Cephalexin|Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days
9872277|NCT00300118|Experimental|A|
9872278|NCT00300118|Active Comparator|B|
9872279|NCT00300131||1|Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
9872280|NCT00300196|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
9872281|NCT00300196|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
9872282|NCT00300261|No Intervention|1|receives home care
9872283|NCT00300261|Experimental|2|receives telehealth monitoring in addition to home care
9872284|NCT00300300|No Intervention|1|applying a patellar graft using conventional surgical technique.
9872285|NCT00300300|No Intervention|2|applying a hamstring graft using conventional surgical technique.
9872286|NCT00300300|Experimental|3|applying a patellar graft using a computer-assisted surgy technique.
9872287|NCT00300300|Experimental|4|hamstring graft CAOS
9935894|NCT03027388|Experimental|1/LB100|Treatment with LB100
9935895|NCT03027310||Healthy Volunteers|adult healthy volunteers
9935896|NCT03027310||tremor patients|adult patients with tremor
9935897|NCT03024684|Experimental|Statin|Atorvastatin 10mg oral once daily
9935898|NCT03024684|Placebo Comparator|Placebo|Matched placebo (sugar pill) once daily
9935899|NCT03018288|Other|1/Radiation Therapy|Standard radiation therapy
9935900|NCT03018288|Experimental|2/RT+TMZ+Pembrolizumab|Standard treatment with experimental treatment (pembro) added
9935901|NCT03018288|Experimental|3/RT+TMZ+Pembrolizumab+HSPPC96 Vaccine|Standard treatment with experimental treatment (pembro+ vaccine) added
9935902|NCT03018288|Placebo Comparator|4/RT+TMZ+Pembrolizumab+ Placebo Vaccine|Standard treatment with experimental treatment and placebo added
9935903|NCT03010176|Experimental|Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)|Participants with cutaneous (cut) or subcutaneous (subcut) lesions receive escalating doses of ulevostinag monotherapy via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond for up to 35 cycles (up to approximately 2 years).
9935904|NCT03010176|Experimental|Part 1 Arm 2: Ulevostinag +Pembro (Cut/Subcut Lesions)|Participants with cut or subcut lesions receive escalating doses of ulevostinag via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond PLUS pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
9935905|NCT03010176|Experimental|Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)|Participants with visceral lesions receive escalating dose frequencies of ulevostinag via IT injection at escalating dose frequencies (Day 1 of each 21-day cycle for up to 35 cycles, then Days 1 and 8 of each 21-day cycle for two cycles, then Day 1 of each 21 day cycle up to 35 cycles, then Days 1, 8 and 15 of each 21-day cycle for two cycles followed by Day 1 of each 21-day cycle up to 35 cycles, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
9935906|NCT03010176|Experimental|Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory|Participants with HNSCC who are anti-programmed cell death-1 or anti-programmed cell death-ligand 1 refractory receive ulevostinag at the preliminary Recommended Phase 2 Dose (RP2D) determined by dose escalation in Part 1 Arm 1 and 2 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
9935907|NCT03010176|Experimental|Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC|Participants with TNBC who are anti-PD-1/PD-L1 treatment-naïve or who have refractory unresectable locally advanced or metastatic TNBC receive ulevostinag at the preliminary RP2D determined by dose escalation in Part 1 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
9935908|NCT03010176|Experimental|Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver|Participants with solid tumors with liver metastases/lesions who are anti-PD-1/PD-L1 treatment-naïve receive ulevostinag at the preliminary RP2D based on Part 1: ulevostinag +pembro (visceral lesions) treatment arm via IT injection in a to-be-determined dose and frequency, based on data from Arm 3, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
9935909|NCT03000439|Experimental|Tofacitinib 5 mg BID|oral, twice daily, tablet or solution.
9935910|NCT03000439|Placebo Comparator|Placebo|
9935911|NCT03000244||1/Patients|Patients who underwent hematopoietic stem cell transplant for any indication (malignant ornon-malignant).
9935912|NCT03000244||2/Donors|Related stem cell donors of those in Patients cohort.
10211245|NCT05136638|Experimental|dCBTi without coaching|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with no coaching support
10211246|NCT05136638|Experimental|dCBTi with virtual coaching|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with a virtual coach in the form of a text-based force-choice conversation coach. The virtual coach will check participants' understanding of the treatment materials and lead them to come up with action plans to implement CBTi strategies.
10211247|NCT05136638|Experimental|dCBTi with non-therapist coaching support|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with the virtual coach. They will get additional support from a non-therapist support person who provides support after modules 1, 3, and 6 to address any questions or concerns.
10211248|NCT05136638|Experimental|dCBTi with therapist coaching support|Participants assigned to this condition will receive a 6-module digital cognitive behavioral therapy for insomnia (dCBTi) with the virtual coach. They will get additional support from a clinical psychology trainee who provides therapeutic support that aims to enhance the usage of CBTi treatment strategies.
9796091|NCT01556425|Experimental|VIVITROL&Opiate Abstinence Reinforcement|This group will be offered VIVITROL and will be required to take it to attend the workplace and to maintain maximum pay. This group will also receive employment-based opiate abstinence reinforcement. This contingency will require participants to provide opiate-negative urine samples on M,W, and F to maintain their maximum pay. If a participant in this group provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
9796092|NCT01556425|Experimental|Opiate Abstinence Reinforcement Only|This group would receive employment-based opiate abstinence reinforcement, but this group will not receive VIVITROL.
9796093|NCT01556425|Other|Usual Care Control|This group will receive neither abstinence reinforcement nor VIVITROL injections, but they will be invited to attend the workplace and outpatient drug abuse counseling.
9796094|NCT01556438|Experimental|100 mg Tabalumab+Bortezomib (BTZ)IV+Dexamethasone (Dex)|Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle, each cyle is 21 days. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
9796095|NCT01556438|Experimental|300 mg Tabalumab+BTZ IV+Dex|Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
9796096|NCT01556438|Experimental|300 mg Tabalumab+BTZ SC+Dex|Cohort 2-SC. 300 mg tabalumab (LY2127399)IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.
10211249|NCT05131191||patients with coronary metal stents implantation|
10211250|NCT05127200|Experimental|Anodal tsDCS (cervical active, lumbar sham)|"Participants will receive:~20 minutes of 2.5 milliampere (mA) anodal tsDCS at the cervical level.~sham tsDCS at the lumbar level."
9796097|NCT01556451|Experimental|Zoster Vaccine Live|Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1
9796098|NCT01556581|Active Comparator|Usual Care (UC)|The usual care (UC) group will be managed with stepped care approach, receiving a screening exam, advice, education, activity limitation profile and medications if needed, but no early physical therapy.
9796099|NCT01556581|Active Comparator|Early Physical Therapy (PT)|All subjects in this group will get usual care approach in addition to immediately receiving eight sessions of physical therapy based on a pragmatic treatment based classification system for treating low back pain.
9796100|NCT01556594|Experimental|Nasal Glucagon 1 mg|Nasal glucagon (NG) administered as single dose of 1 milligram (mg).
9796101|NCT01556594|Experimental|Nasal Glucagon 2 mg|NG administered as single dose of 2 mg.
9796102|NCT01556594|Active Comparator|SC Glucagon|Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.
9796103|NCT01556594|Experimental|Nasal Glucagon 3 mg|NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).
9796104|NCT01556633|Experimental|Volunteers on dialysis|
9796105|NCT01556633|Experimental|Volunteers with reduced creatinine clearance|
9796106|NCT01556724|Active Comparator|0.2% ropivacaine nerve block (standard of care)|0.2% ropivacaine in lumbar plexus nerve catheter infusions for postoperative analgesia
9796107|NCT01556724|Experimental|0.1% ropivacaine infusion in nerve block catheter|0.1% ropivacaine in lumbar plexus nerve catheter infusions
9796108|NCT01556763|Placebo Comparator|Placebo|Matching placebo was administered as one capsule per day for 21 days.
9796109|NCT01556763|Experimental|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
9796110|NCT01556763|Experimental|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
9796111|NCT01556906|Experimental|Lomitapide|This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses
9872288|NCT00300313|Active Comparator|1|
9872289|NCT00300313|Placebo Comparator|2|
9872290|NCT00300326|No Intervention|1|Using the same knee implant with a conventional surgical technique.
9872291|NCT00300326|Active Comparator|2|Using the same knee implant using a computer-assist surgery group is the comparator
9872292|NCT00300534|No Intervention|Abbott Laboratories Determine test for syphilis|Abbott Laboratories Determine rapid test for syphilis
9872293|NCT00300573|Experimental|Dexelvucitabine (DFC)|200 mg once daily
9872294|NCT00300573|Active Comparator|lamivudine (3TC)|300 mg once daily
9872295|NCT00300586|Sham Comparator|A (supervision)|medical supervision, second line chemotherapy if progression
9872296|NCT00300586|Active Comparator|B (gemcitabicine)|Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
9872297|NCT00300586|Experimental|C (Erlotinib)|Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression
9872298|NCT00300599|Active Comparator|A|Continue positive airway pressure
9872299|NCT00300599|Placebo Comparator|B|Placebo
9872300|NCT00300612|Experimental|vaccine group|
9872301|NCT00300638||1- MRI and interviews|In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using Magnetic Resonance Imaging (MRI) scans, we observe how the brain works when people purposefully respond to the words and pictures. Interviews, cognitive tests, and emotional measurements will also be done. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
9872302|NCT00300729|Active Comparator|Celecoxib|Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
9872303|NCT00300729|Placebo Comparator|Placebo|Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
9872304|NCT00300768|Experimental|2 mg moxidectin|2 mg moxidectin (Dose-escalation 1st step)
9872305|NCT00300768|Active Comparator|Ivermectin 150 mcg/kg|Active comparator arm (ivermectin 150 mcg/kg).
9872306|NCT00300768|Experimental|4 mg moxidectin|4 mg moxidectin (dose escalation second step)
9872307|NCT00300768|Experimental|8 mg moxidectin|8 mg moxidectin (dose escalation third step)
9872308|NCT00300846|Active Comparator|A1|
9872309|NCT00300846|Placebo Comparator|A2|
9872310|NCT00300872|Active Comparator|1|Continuous positive airway pressure (CPAP)
9872311|NCT00300872|Sham Comparator|2|Sham Continuous positive airway pressure (CPAP)
9872312|NCT00300898|Active Comparator|Nucleoplasty|Procedure/Surgery: Nucleoplasty
9872313|NCT00300898|Active Comparator|Percutaneous decompression|Procedure/Surgery: Percutaneous decompression
9872314|NCT00300898|Active Comparator|Electrothermal disc decompression (IDET)|Procedure/Surgery: Intervertebral electrothermal disc decompression (IDET)
9872315|NCT00300898|Experimental|Behavioral:Conservative treatment|Conservative treatment with oral medications, physical therapy, epidural steroid injections
9872316|NCT00300937|Experimental|A|
9872317|NCT00300950|Active Comparator|1|Gencitabine
9872318|NCT00300950|Experimental|2|Gemcitabine with GI-4000
9872319|NCT00300976|Experimental|Intensive therapy|
9872320|NCT00300976|Active Comparator|Conventional therapy|
9872321|NCT00301015|Experimental|1|Malaria diagnosis aided with rapid diagnostic test
9872322|NCT00301015|Active Comparator|2|Malaria diagnosis based on clinical judgement only
9872323|NCT00301106|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
9872324|NCT00301184|Experimental|1A|One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^7 TCID50 MVA or placebo at Months 4 and 6
9872325|NCT00301184|Experimental|1B|One 3.0 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^8 TCID50MVA or placebo administered at Months 4 and 6
9872326|NCT00301184|Experimental|2A|One MTD (determined in Part 1) of DNA HIV vaccine or placebo administered at study entry. One dose of placebo or MTD of MVA at Months 2 and 6
9872327|NCT00301184|Experimental|2B|One dose of placebo or MTD of MVA administered at study entry and Months 2 and 6
9872328|NCT00301210|Experimental|1|tramadol dose 1
9872329|NCT00301210|Experimental|2|tramadol dose 2
9872330|NCT00301249||Family Investigation of Nephropathy and Diabetes (FIND)|Individuals with diabetic nephropathy, their parents, and selected siblings
9872331|NCT00301249||African American MALD|Case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring were genotyped when available to provide haplotype data.
9872332|NCT00301249||Mexican American MALD|Case-control study of unrelated individuals of Mexican American heritage in which both cases and controls had diabetes, but only the case had nephropathy
9872333|NCT00301379||1|Patients with unresectable cholangiocarcinoma.
9872334|NCT00301392|Other|Pitavastatin|Administration of Pitavastatin
9872335|NCT00301405|Active Comparator|Thalidomide|Open Label drug
9872336|NCT00301457|Experimental|1|6 years adjuvant anastrozole therapy
9872337|NCT00301457|Experimental|2|3 years adjuvant anastrozole therapy
9872338|NCT00301483|Experimental|1|HBOC-201 followed by standard therapy
9872339|NCT00301483|Active Comparator|2|Standard Therapy
9872340|NCT00301522|Experimental|Arm 1|
9872341|NCT00301522|Active Comparator|Arm 2|
9872342|NCT00301535|Experimental|1|
9872343|NCT00301535|No Intervention|2|
9872344|NCT00301561|Experimental|1|Simplify treatment follow-up
9872345|NCT00301561|Active Comparator|2|Standard treatment follow-up
9872346|NCT00301600|Active Comparator|Mycophenolate mofeti|
9872347|NCT00301613|Active Comparator|Mycophenolate mofetil|
9872348|NCT00301652|Experimental|mycophenolate mofetil|
9872349|NCT00301769|Experimental|Arm I|Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
9872350|NCT00301795|Experimental|Treatment (oblimersen sodium and rituximab)|"Induction therapy (month 1): Patients receive oblimersen IV continuously on days 1-7 and 15-21 and rituximab IV on days 3, 10, 17, and 24 in month 1.~Extended induction therapy (months 3, 5, 7, and 9): Patients receive oblimersen IV continuously on days 22-28 and rituximab IV on day 24 in months 3, 5, 7, and 9.~Treatment continues for 9 months in the absence of disease progression or unacceptable toxicity."
9872351|NCT00301847|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9872352|NCT00301886|Experimental|zoledronate|zoledronate
9872353|NCT00301886|Experimental|ibandronate|ibandronate
9872354|NCT00301925|Active Comparator|Epi-CMF|
9872355|NCT00301925|Experimental|Accelerated Epi-CMF|
9872356|NCT00301925|Experimental|Epi-Capecitabine|
9872357|NCT00301925|Experimental|Accelerated Epi-Capecitabine|
9872358|NCT00301938|Experimental|Arm I (enzyme inhibitor, chemotherapy)|Patients receive a loading dose of oral perifosine every 6 hours on day 1 followed by a maintenance dose once daily on days 2-28 of course 1 and then once daily on days 1-28 in all subsequent courses. Patients also receive 7-hydroxystaurosporine IV over 3 hours on day 4. Cohorts of 3-6 patients receive escalating doses of 7-hydroxystaurosporine until the MTD is determined.
9872359|NCT00301938|Experimental|Arm 2 (enzyme inhibitor, chemotherapy)|Patients receive 7-hydroxystaurosporine IV over 3 hours on day 1 at the MTD determined in group I. Patients also receive oral perifosine as a loading dose every 6 hours on day 4 followed by a maintenance dose once daily on days 5-28 of course 1 and then once daily on days 1-28 in all subsequent courses.
9872360|NCT00301951|Experimental|cord blood transplant|
9928863|NCT00911131|Active Comparator|Screening esophagoduodenoscopy (EGD)|"EGD will be performed utilizing conscious sedation. During EGD, the endoscopist will capture pictures of the esophageal body, Z-line, lower esophagus and proximal gastric folds. Grading of esophageal varices will be performed by all investigators using the Italian Liver cirrhosis project.~Patients who are found to have small grade varices and meet the inclusion and exclusion criteria will be enrolled in the study."
9928864|NCT00911131|Active Comparator|Capsule Endoscopy|The capsule endoscope will be swallowed by the participant with 100cc of water and simethicone in the supine position. Recording is done for 2 minute in this position and then the head will be elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient will sip10cc of water and after 15 seconds, they will sit upright and sip water again. They can then walk and resume normal activity for 15 minutes. The videos will be reviewed and graded by a gastroenterologist experienced with capsule endoscopy and will be blinded to the patient's clinical and procedural history as well as the most recent EGD. The varices will be graded using the Given Imaging software that grades varices as no varices (C0), small varices or < 25% of esophageal circumference (C1), and large varices or > 25% of esophageal circumference (C2).
9928865|NCT00911131|Active Comparator|Capsule Endoscopy with abdominal binder|Before swallowing the capsule endoscope, an inflatable girdle is wrapped around the waist above the umbilicus and held in place by a an abdominal binder. The pressure is increased by 10mmHg for 10 minutes. The PillCam ESO is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
9928866|NCT00911183|Experimental|Arm I (R-COP regimen)|Patients receive rituximab IV, cyclophosphamide IV, and vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment repeats every 21 days for at least 3 courses.
9928867|NCT00911183|Experimental|Arm II (R-COPY regimen)|Patients receive rituximab, cyclophosphamide, vincristine sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days for at least 3 courses.
9928868|NCT00911196||Group A|
9517870|NCT03302156|Other|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40
9517871|NCT03302156|Other|Dosimetry Group|Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6
9872361|NCT00302029||CMV positive|CMV +, N=500/167
9872362|NCT00302029||CMV negative|CMV -, N=500/167
9872363|NCT00302172|Experimental|ARQ 197|
9872364|NCT00302185|Active Comparator|Nurse-led supportive care|Visit with a Palliative Care nurse once weekly for 4 weeks
9872365|NCT00302185|Experimental|Acupuncture|Patients received acupuncture once a week for 4 weeks.
9872366|NCT00302237||1|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
9872367|NCT00302341|Experimental|1|pafuramidine maleate, oral tablet, 100 mg bid X 14 days
9872368|NCT00302341|Active Comparator|2|TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days
9872369|NCT00302380||un-medicated subjects with ADHD|
9872370|NCT00302380||subjects without ADHD|
9872371|NCT00302393|Active Comparator|IR-MPH|Immediate Release Methylphenidate administered before PET Scan
9872372|NCT00302393|Active Comparator|Concerta|OROS Methylphenidate (Concerta) administered before PET Scan
9872373|NCT00302419|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
9872374|NCT00302419|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
9872375|NCT00302471|Experimental|1600 mg twice a day|MK0429
9872376|NCT00302471|Experimental|200 mg twice a day|MK0429
9872377|NCT00302471|Experimental|800 mg twice a day|MK0429
9872378|NCT00302471|Experimental|400 mg twice a day|MK0429
9872379|NCT00302510|Placebo Comparator|immunoadsorption|
9872380|NCT00302523|Active Comparator|FK506|
9872381|NCT00302536|Experimental|Tacrolimus|
9872382|NCT00302549|Active Comparator|FK506|
9872383|NCT00302601|Other|None relevant|Not relevant
9872384|NCT00302627|Experimental|Pamidronate, Vitamin D, and Calcium|"60mg or 90mg given at baseline, 6,12,18, and 24 months~vitamin D 800 units/day~calcium carbonate 1500 milligrams/day"
9872385|NCT00302640|Active Comparator|Nitazoxanide|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
9872386|NCT00302640|Placebo Comparator|Placebo|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
9872387|NCT00302653|Experimental|1|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
9872388|NCT00302666|Sham Comparator|Arm 1|
9872389|NCT00302666|Sham Comparator|Arm 2|
9872390|NCT00302705|Active Comparator|Valsartan|160 mg/day on awakening
9872391|NCT00302705|Active Comparator|Enalapril|10-20 mg/day on awakening
9872392|NCT00302796|Experimental|Group A, Antibiotic|1 antibiotic tablet 45 patients Group
9872393|NCT00302796|Placebo Comparator|Group B: 1 placebo|1 placebo tablet
9872394|NCT00302796|Experimental|Group C: Antibiotics|2 antibiotic tablets 45 patients
9872395|NCT00302796|Placebo Comparator|Group D, Placebo|2 placebo tablets 36 patients
9872396|NCT00302822|Experimental|Intensification|lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)
9872397|NCT00302822|Active Comparator|Standard|lopinavir or efavirenz and emtricitabine/tenofovir
9872398|NCT00302900|Experimental|1|Pre-donation water and muscle tension during donation
9872399|NCT00302900|Experimental|2|Pre-donation water
9872400|NCT00302900|Sham Comparator|3|Pre-donation muscle tension
9872401|NCT00302900|No Intervention|4|Standard donation
9872402|NCT00303017|Experimental|flavocoxid|medical food
9872403|NCT00303017|Active Comparator|naproxen|NSAID
9872404|NCT00303030|Active Comparator|1. Anal injection|
9872405|NCT00303030|Active Comparator|2. Biofeedback|
9872406|NCT00303043||1|
9872407|NCT00303134|Experimental|Islet Cell Transplantation|
9872408|NCT00303199|Experimental|Single Arm|
9517872|NCT03302143|Active Comparator|Control|Guided bone regeneration with Bovine Bone Mineral
9517873|NCT03302143|Experimental|Experimental|Guided bone regeneration with freeze dried bone allograft
9872409|NCT00303212|No Intervention|UC|Usual HF guideline-base care
9872410|NCT00303212|Experimental|TM|Telemonitoring group plus usual guideline-based HF care
9872411|NCT00303277|Active Comparator|1|simvastatin
9872412|NCT00303277|Active Comparator|2|pravastatin
9872413|NCT00303290|Experimental|PEG-Intron + ARA-C|Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
9872414|NCT00303303|Experimental|1|Active initial and maintenance therapy
9872415|NCT00303303|Experimental|2|Active initial therapy; placebo maintenance therapy.
9872416|NCT00303303|Placebo Comparator|3|Placebo initial and maintenance therapy.
9872417|NCT00303342|Experimental|mind body treatment|regulation of attention, respiration and posture
9872418|NCT00303342|Active Comparator|desensitization|mentation on insomnia behaviors and cognitive activity
9872419|NCT00303381|Experimental|Interferon-beta-1a, 44 microgram|
9872420|NCT00303381|Experimental|Interferon-beta-1a, 66 microgram|
9872421|NCT00303381|Placebo Comparator|Placebo|
9517874|NCT03302130|Experimental|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
9517875|NCT03302078|Experimental|Treatment T|Fed state
9872422|NCT00303420|Active Comparator|1|Alteplase used by normal dwell procedure
9872423|NCT00303420|Experimental|2|"Alteplase given by an new push protocol"
9872424|NCT00303524|Experimental|1|Zoladex 3-month depot
9872425|NCT00303524|Experimental|2|Zoladex 1-month depot
9872426|NCT00303563|Experimental|1|
9872427|NCT00303563|Experimental|2|
9872428|NCT00303563|Experimental|3|
9872429|NCT00303563|Placebo Comparator|4|
9872430|NCT00303589|Experimental|1|
9872431|NCT00303589|Experimental|2|
9872432|NCT00303589|Active Comparator|3|
9872433|NCT00303732|Experimental|PTK787, RAD001|PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily
9872434|NCT00303758|Active Comparator|LV5FU2 simplifié + cisplatine puis gemcitabine si progression|LV5FU2 simplifié + cisplatine puis gemcitabine si progression
9872435|NCT00303758|Experimental|gemcitabine puis LV5FU2 simplifié + cisplatine si progression|gemcitabine puis LV5FU2 simplifié + cisplatine si progression
9928869|NCT00911209|Experimental|Intervention|The Intervention group at each session will receive information on Heart healthy diet, lifestyle recommendations and diet and exercise counseling with a dietitian in order to achieve at least 7% weight loss (for example a person weighing 200 pounds will be encourage to lose at least 14 pounds).
9928870|NCT00911209|No Intervention|No Intervention|The standard of care group will receive information on Heart healthy diet at baseline visit and will return to a final visit about 28 weeks later.
9928871|NCT00911222||antiemetic treatment|epidemiological registry
9928872|NCT00911235|Experimental|Fesoterodine Alone|Reference treatment
9928873|NCT00911235|Other|fesoterodine plus fluconazole|Test treatment
9928874|NCT00911261|Experimental|Single Arm|
9928875|NCT00911287|Experimental|Single Arm|
9928876|NCT00911313|Experimental|Letrozole|
9928877|NCT00911313|Active Comparator|Metformin-CC|
9928878|NCT00911339|Active Comparator|Atorvastatin 10 mg|
9928879|NCT00911339|Active Comparator|Atorvastatin 80 mg|
9928880|NCT00911352|Experimental|Frozen gel glove (Elasto-Gel Mitten)|Cryotherapy hand
9928881|NCT00911352|No Intervention|No frozen glove therapy|Usual care
9928882|NCT00911365|Placebo Comparator|normal saline|
9928883|NCT00911365|Experimental|autologous mesenchymal stem cells|
9928884|NCT00911378|Active Comparator|Pressure support ventilation|Patients in this arm are weaned by gradual reduction of pressure support
9928885|NCT00911378|Active Comparator|Spontaneous breathing trials|Patients in this arm are weaned by T piece trials
9928886|NCT00911391|Active Comparator|Fluid restriction|Current best practice of intraoperative fluid restriction
9928887|NCT00911391|Experimental|Oesophageal Doppler|Oesophageal Doppler-guided fluid administration
9928888|NCT00911404|Experimental|Low CHO|Diet with 40% total calories from carbohydrates.
9928889|NCT00911404|Active Comparator|High CHO|Diet with 55% total calories from carbohydrates.
9935913|NCT03000244||3/Parents of patients|Parents/guardians of minors enrolled in cohort 1
9935914|NCT02994446|Experimental|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
9872436|NCT00303771|Active Comparator|LV5FU2 classique|LV5FU2 classique
9872437|NCT00303771|Experimental|LV5FU2 classique + irinotécan|LV5FU2 classique + irinotécan
9872438|NCT00303771|Active Comparator|LV5FU2 simplifié|LV5FU2 simplifié
9872439|NCT00303771|Experimental|LV5FU2 simplifié+ irinotécan|LV5FU2 simplifié + irinotécan
9872440|NCT00303784|Active Comparator|LHRH agonists|"Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended anti-flare medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice."
9872441|NCT00303784|Experimental|Oestrogen Patches|Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
9872442|NCT00303797|Experimental|Treatment (bortezomib, sorafenib tosylate)|"GROUP I (solid tumors-dose-escalation group): Patients receive oral sorafenib twice daily on days 1-21 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~GROUP II (multiple myeloma or chronic lymphocytic leukemia-maximum tolerated dose [MTD] group): Patients receive oral sorafenib at the MTD twice daily on days 3-21 of course 1 and on days 1-21 of each subsequent course. Patients also receive bortezomib IV over 3-5 seconds at the MTD on days 1, 4, 8, and 11.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
9872443|NCT00303836|Experimental|Arm I|Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.
9872444|NCT00303836|Experimental|Arm II|Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9872445|NCT00303875|No Intervention|Wait-list control|Wait-list control received diet & exercise counseling during year 2 as a courtesy
9872446|NCT00303875|Experimental|Lifestyle counseling|subjects randomized to receive diet & exercise counseling for one year
9872447|NCT00303888|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
9872448|NCT00303888|Experimental|Arm II|Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
9872449|NCT00303992|Experimental|Trastuzumab and Irinotecan|
9872450|NCT00304018|Experimental|cord blood transplant|
9872451|NCT00304135|Active Comparator|Radio-chimiothérapie|Radio-chimiothérapie
9872452|NCT00304135|Experimental|GEMOX|GEMOX
9872453|NCT00304148||CRIC Cohort|
9872454|NCT00304148||CRIC Subcohort|
9872455|NCT00304174||Subjects with bulimia nervosa|Participants with bulimia nervosa
9872456|NCT00304174||Controls between 80-120% of ideal weight|Controls without bulimia nervosa
9872457|NCT00304200|Experimental|Single arm, Open Label|Single arm, Open Label Temodar and Sutent
9872458|NCT00304304|Active Comparator|Intervention - asthma education|CCC received asthma education in the first 6 months of the study
9872459|NCT00304304|Placebo Comparator|Wait-list control|CCC received asthma education in second 6 months of study
9872460|NCT00304317|Experimental|I|Celecoxib
9872461|NCT00304317|Placebo Comparator|II|Placebo
9872462|NCT00304382|Experimental|PPV-PCV|Patients receive Pneumovax, and 6 months later Prevnar
9872463|NCT00304382|Experimental|PCV-PPV|Patients receive Prevnar, and 6 months later Pneumovax
9872464|NCT00304382|Experimental|PCV-PCV|Patients receive Prevnar, and 6 months later Prevnar again
9872465|NCT00304382|Experimental|PCV only|Patients receive Prevnar only
9872466|NCT00304434|Other|1|
9872467|NCT00304551|Experimental|1|
9872468|NCT00304551|Experimental|2|
9872469|NCT00304551|No Intervention|3|
9872470|NCT00304564|Experimental|geriatric community|Subject will stand on a computerized posturography force plate and stability scores are measured
9872471|NCT00304603||Patients from previous topiramate obesity and diabetes studies|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study.
9872472|NCT00304759|Experimental|1|6000 cGy / 20 fractions in 4 weeks
9872473|NCT00304759|Active Comparator|2|7800 cGy / 39 fractions in 8 weeks
9872474|NCT00304772|Active Comparator|1|
9872475|NCT00304772|Active Comparator|2|
9872476|NCT00304798|Experimental|Admission|Admission
9872477|NCT00304798|No Intervention|Discharge|Discharge
10211251|NCT05127200|Active Comparator|Anodal tsDCS (cervical sham, lumbar active)|"Participants will receive:~20 minutes of 2.5 milliampere (mA) anodal tsDCS at the lumbar level.~sham tsDCS at the cervical level."
10211252|NCT05123066|Experimental|Aquatic group|group I
9517876|NCT03302078|Experimental|Treatment R|Fasted state
9517877|NCT03302065|Experimental|Test Product 1 Tiotropium|4 inhalations
9517878|NCT03302065|Experimental|Test Product 2 Tiotropium|4 inhalations
9796112|NCT01556932|Experimental|Placebo then ABH|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
9796113|NCT01556932|Experimental|ABH then placebo|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
9796114|NCT01556997|Experimental|XOMA 985|fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
9796115|NCT01556997|Active Comparator|Amlodipine Besylate (AMLb)|
9796116|NCT01556997|Active Comparator|Perindopril Erbumine (PERe)|
9796117|NCT01557166|Experimental|Liraglutide 3.0 mg|
9796118|NCT01557166|Placebo Comparator|Placebo|
9796119|NCT01557244|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
9796120|NCT01557244|Experimental|Fesoterodine PR 8 mg|Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
9796121|NCT01557244|Active Comparator|Oxybutynin|Oxybutynin
9796122|NCT01557244|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
9796123|NCT01557244|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
9796124|NCT01557283||Plaque psoriasis patients|Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria
9796125|NCT01557322||Biologic|
9796126|NCT01557322||non-biologic DMARD|
9796127|NCT01557348||Rituximab|Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
9796128|NCT01557348||Alternative TNFi|Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
9796129|NCT01557400|Experimental|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, fruit juice (except apple juice) fruit punch, or in semi-solid food (for example, yogurt, pudding, or applesauce). The dose level for ataluren will be 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. Administration within 30 minutes after a meal will be recommended. Study drug dosing will be based on milligrams of drug per kilogram of body weight. Because of potential changes in participant body weight over time, weight-based dose adjustment can occur every 24 weeks as required. Study drug will be taken for up to 240 weeks.
9796130|NCT01557452|Experimental|Givinostat|Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014
9796131|NCT01557504|Experimental|Sitagliptin/metformin XR followed by placebo|Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
9796132|NCT01557504|Placebo Comparator|Placebo only|Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
9796133|NCT01557517|Experimental|Clobetasol|Patients will rinse oral cavity with 10cc of clobetasol 0.05% for 2 minutes 3 times a day.
9796134|NCT01557517|Placebo Comparator|Placebo|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
9796135|NCT01557569|Active Comparator|Atomoxetine|Group receiving atomoxetine
9796136|NCT01557569|Placebo Comparator|Placebo|Group will receive placebo instead of atomoxetine
9796137|NCT01557582|Other|Right ventrical volumn comparison|Single arm study comparing Ventripoint Medical System (VMS) right ventricle volume measurement to gold standard cardiac Magnetic Resonance Imaging (cMRI) measurement in patients with Pulmonary Arterial Hypertension.
9796138|NCT01557595|Experimental|Adults with ADHD|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. Subjects will 19 years or older and have ADHD"
9796139|NCT01557699|Experimental|PMV via Puffhaler® Device|The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
9796140|NCT01557699|Experimental|PMV via SoloventTM device|The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
10211253|NCT05123066|Experimental|Land Exersises group|group II
10211254|NCT05122624|Experimental|Score intervention arm|The PredicTB score will be implemented in this arm.
9796141|NCT01557699|Active Comparator|Licensed Subcutaneous Measles Vaccine|Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.
9796142|NCT01557790|Experimental|Proton RT|Subjects receive proton radiation for seminoma
9796143|NCT01557842|Active Comparator|Treatment Group|This group receives radiofrequency catheter ablation and drug treatment.
9796144|NCT01557842|Experimental|Control Group|This group receives only drug treatment.
9796145|NCT01557868|Active Comparator|Synvisc (hylan G-F 20)|
9796146|NCT01557868|Active Comparator|Euflexxa (1% sodium hyaluronate)|
9796147|NCT01557894|Experimental|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for Social Phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
9796148|NCT01557894|No Intervention|Waitlist control group|Waitlist control group
9796149|NCT01557920|Active Comparator|Propofol|The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
9796150|NCT01557920|Active Comparator|Sevoflurane|The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
9796151|NCT01557946|Experimental|Major Depression|Participants with major depressive disorder received citalopram 20-40 mg daily for 6 weeks. MRI scans were acquired at baseline and days 3, 7, and 42.
9796152|NCT01557946|No Intervention|Healthy Volunteers|Healthy volunteer participants did not receive citalopram and performed one MRI scan.
9796153|NCT01557959|Experimental|Treatment (chemo, chemoprotection, antiangiogenesis therapy)|Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
9796154|NCT01558063|Active Comparator|Ketamine Dose 1|0.1 mg/kg, IV (in the vein) of Ketamine and MRI scan
9796155|NCT01558063|Active Comparator|Ketamine Dose 2|0.2 mg/kg, IV (in the vein) of Ketamine and MRI scan
9796156|NCT01558063|Active Comparator|Ketamine Dose 3|0.3 mg/kg, IV (in the vein) of Ketamine and MRI scan
9796157|NCT01558063|Active Comparator|Ketamine Dose 4|0.4 mg/kg, IV (in the vein) of Ketamine and MRI scan
9796158|NCT01558063|Active Comparator|Ketamine Dose 5|0.5 mg/kg, IV (in the vein) of Ketamine and MRI scan
9796159|NCT01558063|Placebo Comparator|Saline Solution|Saline infused over 40 minutes and MRI scan
9796160|NCT01558089||etanercept + methotrexate|
9796161|NCT01558128|Other|Amiodarone with cardioversion|If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.
9796162|NCT01558271|Experimental|LY2189265|Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
9796163|NCT01558271|Placebo Comparator|Placebo/LY2189265|Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
9796164|NCT01558271|Active Comparator|Liraglutide|Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
9796165|NCT01558297|Experimental|Motivational Interviewing|
9796166|NCT01558297|Active Comparator|Nutritional Counseling|
9796167|NCT01558297|Active Comparator|Treatment as usual|
9796168|NCT01558596|Placebo Comparator|Sham|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
9796169|NCT01558596|Experimental|RIPC|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
9796170|NCT01558635|Experimental|Cardioblate CryoFlex Surgical Ablation|Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.
9796171|NCT01558661|Experimental|AG-013736 (AXITINIB)|This is a single-arm phase II study evaluating the clinical efficacy of axitinib in the treatment of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (ACC).
9796172|NCT01558674|Experimental|MK-7145 8 mg (Part I:Period 1)|Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
9796173|NCT01558674|Active Comparator|Furosemide 40 mg (Part I:Period 2)|Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
9796174|NCT01558674|Experimental|MK-7145 16 mg (Part I:Period 3)|Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
9796175|NCT01558674|Active Comparator|Furosemide/Torsemide Run-in (Part II:Period1)|Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
10211255|NCT05122624|No Intervention|Control arm|The standard of care will be conducted in this arm.
9517879|NCT03302065|Experimental|Test Product 3 Tiotropium|4 inhalations
9517880|NCT03302065|Active Comparator|Reference Tiotropium|2 inhalations
9872478|NCT00304850|Experimental|R+ / K+|
9872479|NCT00304850|Experimental|R+ / K-|
9872480|NCT00304850|Experimental|R- / K+|
9872481|NCT00304850|Placebo Comparator|R- /K-|
9872482|NCT00304863|No Intervention|Arm 1|This are will not receive Lactobacillus
9872483|NCT00304863|Experimental|Arm 2|This arm will receive lactobacillus
9872484|NCT00305032|Experimental|1|
9872485|NCT00305045|Active Comparator|High-frequency Left (HFL)|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 29 - 5 second trains with 30 second inter-train interval."
9872486|NCT00305045|Active Comparator|Bilateral|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: i) low-frequency right: 4 trains of 100 second duration and one train of 65 second duration, with a 30 second inter-train interval, followed by ii) HFL: 15 - 5 second trains with 30 second inter-train interval."
9872487|NCT00305045|Sham Comparator|Sham Stimulation|Stimulation will occur over the site of active treatment, but with only the side-edge resting on the scalp. It will be administered as HFL for 17 minutes, with the coil angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
10211256|NCT05114486|Experimental|Pilocarpine 2% Ophthalmic Spray|2% pilocarpine ophthalmic spray administered with the Optejet dispenser
9872488|NCT00305097|Experimental|Caffeinated coffee|Caffeinated coffee
9872489|NCT00305097|Experimental|Decaffeinated coffee|Decaffeinated coffee
9872490|NCT00305097|Active Comparator|No coffee|
9872491|NCT00305123||1|12,000 children 5 to 16 years of age attending the 4 public elementary schools in Djikoroni-para-Sébénikoro, Bamako, Mali.
9872492|NCT00305175||Patients With Prior Hydroxyurea|Patients who have received hydroxyurea therapy before entering the study.
9872493|NCT00305175||Patients Without Prior Hydroxyurea|Patients who have not received hydroxyurea before study entry.
9872494|NCT00305279|Active Comparator|1|
9872495|NCT00305279|Active Comparator|2|
9872496|NCT00305279|Active Comparator|3|
9872497|NCT00305435|Experimental|romiplostim (AMG-531)|
9872498|NCT00305461|Active Comparator|1|Ciclesonide 160µg
9872499|NCT00305461|Active Comparator|2|Ciclesonide 320µg
9872500|NCT00305539|Active Comparator|1|
9872501|NCT00305539|Placebo Comparator|2|placebo
9872502|NCT00305552|Experimental|1|THALIDOMIDE
9928890|NCT00911469|Experimental|1|
10211257|NCT05114486|Placebo Comparator|Placebo Spray|Placebo ophthalmic spray administered with the Optejet dispenser
10211258|NCT05114382|Other|A prospective, multi-center, open-label, single arm study|Patients undergoing assessment and ablation of cardiac arrhythmiast. who are scheduled for an electrophysiology (EP) procedure and meet all inclusion criteria will be enrolled in the study and undergo the EP procedure. Intracardiac signals will be passively recorded using the CathVision Cube® System in parallel with the commercial (CE marked) EP recording system for post procedure evaluation. The investigational device will not be used for direct clinical care decisions or therapy. The EP procedure will be guided by the study site Standards Of Care.
9928891|NCT00911469|Placebo Comparator|2|
9928892|NCT00911482||Diabetes/weight loss|12 individuals with type 2 diabetes and hypertriglyceridemia
9928893|NCT00911482||Nondiabetic/hypertriglyceridemic|10 insulin resistant nondiabetic individuals with dyslipidemia
9928894|NCT00911482||Normotensive/nondiabetic|10 insulin resistant, normotensive, nondiabetic individuals
9928895|NCT00911482||Insulin resistant/dyslipidemic|14 insulin resistant nondiabetic individuals with dyslipidemia
9928896|NCT00911521|Active Comparator|Vaccine arm|subjects receiving vaccination
9928897|NCT00911560|Experimental|vaccine group one|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a inimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to in Group 1 will receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
9928898|NCT00911560|Experimental|vaccine group two|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to Group 2 will receive oral β glucan (40 mg/kg/day) starting week 1 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
10211259|NCT05103982|Experimental|Coping with Infertility Program|"The program consists of brief weekly videos, each addressing a particular psychological technique to be implemented that week. Participants receive the videos by email from the researcher and watch them on their own. Each video also assigns a homework exercise for the participant to complete that week."
10213722|NCT03455855|Experimental|treated with the Jetstream System|It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Jetstream System.
10213723|NCT03451006|Experimental|Metformin|Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
9935915|NCT02991469|Experimental|Sarilumab|Participants will receive one of two ascending doses (or an additional intermediate dose based on available data) of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose once the selected dose is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144- week extension treatment phase.
10211260|NCT05099263|Experimental|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will undergo bilateral treatment of the nasal airway in a single study procedure session. Each side of the nose will be treated as follows:~• Two (2) to six (6) nonoverlapping applications of RF energy are performed at the SSB per nostril.~The default treatment settings will be used for the study: temperature 60 C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (36 months)."
9796176|NCT01558674|Experimental|MK-7145 10 mg (Part II:Period 2)|Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
10211261|NCT05099237|Active Comparator|1. Colorectal Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with colorectal cancer who are about to start treatment. Participants will be asked to:~Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-C survey).~Report specific symptoms on an ad-hoc basis as they wish."
10211262|NCT05099237|Active Comparator|2. Lung Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with lung cancer who are about to start treatment. Participants will be asked to:~Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-L survey).~Report specific symptoms on an ad-hoc basis as they wish."
10211263|NCT05099237|Active Comparator|3. Haematological Cancer|"Participants (with haematological malignancy about to start treatment with CAR T-cell therapy or another cellular therapy product) will be asked to:~Wear an OURA ring and Withings ScanWatch for approx five weeks including whilst they are in hospital (prior to CAR T-cell therapy and continue for 28 days post infusion)~Wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.~Supported to take daily weights using Withings Body Scale.~Asked to complete weekly electronic quality of life surveys~Provide a series of 12 blood samples to measure inflammatory molecules at various intervals"
10213724|NCT03451006|Active Comparator|Placebo|Placebo by mouth every 6 to 8 hours for one year
9796177|NCT01558674|Experimental|MK-7145 16 mg (Part II:Period 3)|Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
9796178|NCT01558674|Experimental|MK-7145 24 mg (Part II:Period 4)|Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state
9796179|NCT01558700|Experimental|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
9796180|NCT01558700|Placebo Comparator|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
9796181|NCT01558739|Experimental|INC424|Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
9796182|NCT01558752|Experimental|Titanium Shell with CORAIL stem|Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.
9796183|NCT01558752|Active Comparator|Modular Titanium Femoral Stem (Tri-Lock)|Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).
9796184|NCT01558791|No Intervention|Arm 1|"Participants will be screened as usual. These participants will have the TBI screening as usual, without the educational intervention."
9796185|NCT01558791|Experimental|Arm 2|Participants will be given the TBI handout (educational intervention) along with the usual TBI screen.
9796186|NCT01559012|Other|clonidine first - placebo second|in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
9796187|NCT01559012|Other|placebo first - clonidine second|in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days
9796188|NCT01559064||Age group A|Subjects 30 to 40 years old
9796189|NCT01559064||Age group B|Subjects 40 to 50 years old
9796190|NCT01559064||Age group C|Subjects over 50 years old
9796191|NCT01559090|Experimental|1|MEDI-546 100 mg IV
9796192|NCT01559090|Experimental|2|MEDI-546 300 mg IV
9796193|NCT01559090|Experimental|3|MEDI-546 1000 mg IV
9796194|NCT01559116|Experimental|tiotropium+olodaterol FDC low dose|tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
9796195|NCT01559116|Experimental|tiotropium+olodaterol FDC high dose|tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
9796196|NCT01559116|Active Comparator|tiotropium low dose|tiotropium low dose; 2 inhalations once daily (a.m. dosing)
9796197|NCT01559116|Active Comparator|tiotropium high dose|tiotropium high dose; 2 inhalations once daily (a.m. dosing)
9796198|NCT01559116|Active Comparator|olodaterol|one dose only; 2 inhalations once daily (a.m. dosing)
9796199|NCT01559116|Placebo Comparator|placebo|2 inhalations once daily (a.m. dosing)
9796200|NCT01559129|Placebo Comparator|Placebo|
9796201|NCT01559129|Experimental|Pomalidomide|Participants received 1 mg pomalidomide orally once a day for 52 weeks during the treatment phase and for up to 2 years during the open-label extension phase.
9796202|NCT01559259|Experimental|Ibuprofen/acetaminophen (lower dose)|
9796203|NCT01559259|Experimental|Ibuprofen/acetaminophen (middle dose)|
9796204|NCT01559259|Experimental|Ibuprofen/acetaminophen (high dose)|
9796205|NCT01559259|Active Comparator|Ibuprofen|
9796206|NCT01559259|Placebo Comparator|Placebo|
9872503|NCT00305669|Experimental|GM-CSF before surgery|GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks
9935916|NCT02990611||Cohort 1: Nivolumab/Ipilimumab combination therapy|Participants who start a new systemic therapy with nivolumab/ipilimumab combination therapy for the first time
9872504|NCT00305734|Experimental|Treatment (bortezomib, gemcitabine hydrochloride)|"Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses of treatment with bortezomib.~Patients who experience disease progression on single-agent bortezomib and did not receive prior gemcitabine hydrochloride may begin combination therapy within 10-28 days of the last dose of bortezomib. Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and bortezomib IV on days 1, 4, 8, 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond the confirmed CR."
9872505|NCT00305747|Experimental|BR-DIM|BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.
9872506|NCT00305825|Experimental|Study intervention|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9872507|NCT00305851|Experimental|"Low Dose Control Books on Tape"|Individuals randomly assigned to low-dose control group will have the same amount and timing of contacts as TMV group. A trained music therapist delivers the low-dose intervention (music therapy). Low-dose control group AYA initially choose up to three books-on-CD from a library selection of popular recordings. During the six sessions with the music therapist, AYA listens to the book and/or discusses their impressions and thoughts about he contents. Our rationale for having options of either listening to or discussing is to ensure the intervener has activities that will provide comparable contact time compared to the TMV group. As a parallel activity to the TMV protocol during which participants can work on their music video between sessions, AYA in the low-dose control group are provided with a portable CD player to listen to the books anytime during their hospitalization. As books ar e completed, or if the AYA changes their mind about the choice, the intervener offers other books.
9872508|NCT00305851|Experimental|"Experimental Music Video"|Intervention includes six 1-hour sessions (two sessions per week over 3 weeks) designed specifically for the pre-transplant and acute phase of treatment. The initial TMV session with the therapist occurs within 3 days of hospital admission. The phases of the intervention that require patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout work sheet (determining the contents of the video), taking photos or making drawings for the video, and viewing clip art and pictures on a computer. The protocol concentrates many of these cognitive and active components to produce the video at the beginning, when patients experience less fatigue and malaise
9872509|NCT00305890|Experimental|1|Participants will partake in a lifestyle behavioral weight management program for 24 weeks.
9872510|NCT00305890|Experimental|2|Participants will partake in pain-coping skills training for 24 weeks.
9872511|NCT00305890|Experimental|3|Participants will partake in lifestyle behavioral weight management program plus pain-coping skills training for 24 weeks.
9872512|NCT00305890|Active Comparator|4|Participants will receive standard care for 24 weeks.
9872513|NCT00305916|Active Comparator|1|conventional coronary angiography
9872514|NCT00305916|Experimental|2|multislice spiral computed tomography coronary angiography
9872515|NCT00305929|Experimental|1|Treatment with Tookad VTP
9872516|NCT00306007||English prenatal|English speaking women recruited from the general OB/GYN clinic
9872517|NCT00306007||Spanish prenatal|Spanish speaking (monolingual) women recruited from the general OB/GYN clinic
9872518|NCT00306007||English abortion clinic|English speaking women recruited from the abortion clinic
9872519|NCT00306007||Spanish abortion clinic|Spanish speaking (monolingual) women recruited from the abortion clinic
9872520|NCT00306059|Experimental|patients having acute kidney injury|
9872521|NCT00306111|Experimental|Pegfilgrastim|Pegfilgrastim for stem cell mobilization (single arm)
9872522|NCT00306137|Experimental|Arm 1|
9872523|NCT00306137|Placebo Comparator|Arm 2|
9872524|NCT00306150|Experimental|Arm 1|
9872525|NCT00306150|Placebo Comparator|Arm 2|
9872526|NCT00306215|Experimental|1|Blinded study arm
9872527|NCT00306215|Experimental|2|Blinded study arm
9872528|NCT00306215|Experimental|3|Blinded study arm
9872529|NCT00306215|Experimental|4|Blinded study arm
9872530|NCT00306228|Active Comparator|bare-metal stent without tirofiban|implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
9872531|NCT00306228|Active Comparator|bare-metal stent with tirofiban|implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
9872532|NCT00306228|Active Comparator|paclitaxel-eluting stent without tirofiban|implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
9872533|NCT00306228|Active Comparator|paclitaxel-eluting stent with tirofiban|implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
9872534|NCT00306397|Active Comparator|A|Rapamycin - MMF after 3 months
9872535|NCT00306397|Active Comparator|B|Low dose tacrolimus - MMF - Rapamycin after 3 months
9872536|NCT00306462|Active Comparator|1|Intravenous magnesium sulfate or placebo
9872537|NCT00306462|Active Comparator|2|Oral nifedipine or placebo
9872538|NCT00306475|Active Comparator|1|
9872539|NCT00306475|Placebo Comparator|2|
9872540|NCT00306501|Other|Button Press|Training with button press
9872541|NCT00306501|Other|Vibtrotactile|Sensory Stimulation - Vibrotactile device with button press to initiate swallowing during retraining
9872542|NCT00306501|Other|Cortical Stimulation|Training with Cortical stimulation - cortical stimulation during training with button press
9872543|NCT00306501|Other|Combined|Combined vibrotactile and cortical stimulation with button press training
9872544|NCT00306540|Active Comparator|1|Placebo Seroquel + existing therapy
9872545|NCT00306540|Experimental|2|Seroquel + existing therapy
9872546|NCT00306631|Experimental|1|
9872547|NCT00306644|Experimental|Arm 1|study drug
9872548|NCT00306709|Experimental|Teaching|
9872549|NCT00306735|Experimental|Palonosetron|
9872550|NCT00306774|Experimental|1|Participants will receive vitamin D (cholecalciferol)
9872551|NCT00306774|Placebo Comparator|2|Participants will receive a matched placebo
9872552|NCT00306839|Other|1|Tissel group
9872553|NCT00306839|Other|2|Suture group
9872554|NCT00306904|Experimental|1|3.0 mg/eye dose group
9872555|NCT00306904|Experimental|2|1.5 mg/eye dose group
9872556|NCT00306904|Experimental|3|0.2 mg/eye dose group
9872557|NCT00306930|Other|A|Acetabular cup replacement with total hip arthroplasty
9872558|NCT00306956|Experimental|A|Recommendation to offer a pacifier to 15 days old newborn infants with successful breastfeeding
9872559|NCT00306956|Active Comparator|B|Recommendation not to offer a pacifier to normal newborn infant with successful breastfeeding at 15 days of age
9872560|NCT00307008|Experimental|Group A|
9872561|NCT00307021|Active Comparator|Group A|
9872562|NCT00307021|Experimental|Group B|
9872563|NCT00307099|Experimental|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
9872564|NCT00307099|Active Comparator|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
9872565|NCT00307177|Experimental|Arm D|25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
9872566|NCT00307177|Experimental|Arm C|25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
9872567|NCT00307177|Experimental|Arm B|25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
9872568|NCT00307177|Active Comparator|Arm A|25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
9872569|NCT00307190||Binge Eating Disorder|Women with Binge Eating Disorder
9872570|NCT00307190||Controls|Weight, age, and gender-matched control subjects
9872571|NCT00307203|Experimental|I|Experiment group received 300 mgs of bupropion, in addition to weekly CBT and nicotine replacement therapy
9872572|NCT00307203|Placebo Comparator|II|Placebo group received placebo, in addition to weekly CBT and nicotine replacement therapy
9872573|NCT00307216|Experimental|1|Participants will receive Graduated Recovery Intervention Program plus treatment as usual
9872574|NCT00307216|Active Comparator|2|Participants will receive treatment as usual
9872575|NCT00307281||Registry|10 pack year tobacco smoking history required, current or former smokers accepted.
9872576|NCT00307320|No Intervention|1|
9872577|NCT00307320|Experimental|2|Relaxation techniques
9928899|NCT00911560|Experimental|vaccine group three|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Group 3 will include patients who have previously received vaccine and oral β glucanglucan. Patients in this group will not be randomized using the MSK CRDB system. They will be treated as patients in Group 1 and receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination . They will not be eligible for primary endpoint.
9928900|NCT00911573|Experimental|A|Tigecycline
9928901|NCT00911573|Active Comparator|B|Clindamycin (or Vancomycin if needed)
9928902|NCT00911599|Active Comparator|Conserve Total Hip with BFH|CONSERVE® A-Class Total Hip with BFH technology. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
9928903|NCT00911599|Active Comparator|Metal with Polyethylene Liner|Metal on polyethylene total hip replacement. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
9928904|NCT00911638|Experimental|1: Patient decision aid|Patient decision aid focused on treatment options for osteoarthritis of the hip or knee and preference report for surgeons. The patient decision aid used is from the Informed Medical Decisions Foundation
9928905|NCT00911638|Active Comparator|2: Usual care|Usual patient educational resources for patients undergoing hip or knee replacement surgery.
9928906|NCT00911651|Active Comparator|salbutamol|6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
9872578|NCT00307463|Active Comparator|strict volume control policy|strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
9872579|NCT00307463|Other|antihypertensive drugs administration|antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.
9872580|NCT00307502|Experimental|NVP|Nevirapine
9872581|NCT00307502|Experimental|EFV|Efavirenz
9872582|NCT00307502|Experimental|INV|Indinavir/ritonavir
9872583|NCT00307502|Experimental|NFV|Nelfinavir
9872584|NCT00307502|Experimental|SQV|Saquinavir/ritonavir
9872585|NCT00307502|Experimental|LPV|Lopinavir/ritonavir
9872586|NCT00307502|Experimental|ATV|Atazanavir
9872587|NCT00307502|Experimental|ATV/rtv|Atazanavir/ritonavir
9872588|NCT00307502|Experimental|Fos-APV|Fos-amprenavir/ritonavir
9872589|NCT00307502|Experimental|TPV|Tipranavir/ritonavir
9872590|NCT00307502|Experimental|DRV|Darunavir/ritonavir
9872591|NCT00307515|Experimental|1|Fibrin Sealant 2 (FS2)
9872592|NCT00307515|Active Comparator|2|Oxidized Regenerated Cellulose (Surgicel)
9872593|NCT00307528|Active Comparator|Group A|
9872594|NCT00307528|Experimental|Group B|
9872595|NCT00307528|Experimental|Group C|
9872596|NCT00307528|Experimental|Group D|
9872597|NCT00307528|Experimental|Group E|
9872598|NCT00307528|Experimental|Group F|
9872599|NCT00307593|Active Comparator|1|Rituximab
9872600|NCT00307593|Active Comparator|2|Infliximab
9872601|NCT00307632|Experimental|Norelgestromine (NLGM)/Ethinyl Estradiol (EE)|
9872602|NCT00307671|Other|A|conventional treatment
9872603|NCT00307671|Experimental|B|reduction dose
9872604|NCT00307710|Experimental|A: Trivalent Subvirion Vaccine|Group A: Trivalent subvirion vaccine - standard inactivated influenza vaccine by intramuscular injection.
9872605|NCT00307710|Experimental|B: Vaccine 15 μg|Group B: Trivalent rHA0 vaccine 15 μg per rHA0 (total 45 μg rHA0)
9872606|NCT00307710|Experimental|C: Vaccine 45 μg|Group C: Trivalent rHA0 vaccine 45 μg per rHA0 (total 135 μg rHA0)
9872607|NCT00307710|Experimental|D: Vaccine 135 μg|Group D: Trivalent rHA0 vaccine 135 μg per rHA0 (total 405 μg rHA0)
9872608|NCT00307723|Experimental|Regimen Level 1|Radiation/Oxaliplatin/5-FU
9872609|NCT00307723|Experimental|Regimen Level 2|Radiation/Oxaliplatin/Bevacizumab/5-FU
9872610|NCT00307749|Placebo Comparator|1|
9872611|NCT00307749|Experimental|2|
9872612|NCT00307749|Experimental|3|
9872613|NCT00307749|Experimental|4|
9872614|NCT00307762|Experimental|1|Gait trainer exercise actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
9872615|NCT00307762|Active Comparator|2|Overground walking exercises actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
9872616|NCT00307762|No Intervention|3|Control patients with ordinary therapy
9872617|NCT00307827|Experimental|Arm 1|Visilizumab low dose level
9872618|NCT00307827|Experimental|Arm 2|Visilizumab middle dose level
9872619|NCT00307827|Experimental|Arm 3|Visilizumab high dose level
9872620|NCT00307853|Active Comparator|1|TraumeelS
9872621|NCT00307853|Placebo Comparator|Placebo|
9872622|NCT00307866|Experimental|Arm 1|
9872623|NCT00307892|Active Comparator|A|TRAUMEEL S
9872624|NCT00307892|Placebo Comparator|B|comparable placebo remedy (injection and oral)
9872625|NCT00307905|Active Comparator|A|TRAUMEEL S
9872626|NCT00307905|Placebo Comparator|B|placebo remedy
9872627|NCT00308009|Active Comparator|1|Group I, Prolapse repair and TVT concomitantly
9872628|NCT00308009|Active Comparator|2|Group II, Prolapse repair and TVT 3 months afterwards if necessary
9872629|NCT00308100|Experimental|1|
9872630|NCT00308100|Active Comparator|2|
9872631|NCT00308152|No Intervention|Control|Observation only
9872632|NCT00308152|Active Comparator|Active|Infusion of 1 liter normal saline before sedated colonoscopy
9872633|NCT00308165|Experimental|Topotecan|Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
9872634|NCT00308204|Experimental|Raptiva|raptiva injection
9872635|NCT00308256|Experimental|Nurse counseling|Phone calls performed by nurse 15 days after each monthly visit
9796207|NCT01559311|Active Comparator|CRT-P OFF|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF"
9796208|NCT01559311|Experimental|CRT-P ON|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON"
9796209|NCT01559311|Active Comparator|DDDR|Patients randomized into the Control Group were implanted with a DDDR device (St. Jude Medical) standard therapy.
9796210|NCT01559389|Experimental|Female Partners|This arm comprises female partners who receive up to 16 weeks of solifenacin treatment for their UUI symptoms
9796211|NCT01559389|No Intervention|Male Partners|This arm comprises healthy male partners
9796212|NCT01559454|Active Comparator|Methadone|10-60 mg/day divided by 2-4 times a day
9796213|NCT01559454|Experimental|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day
9796214|NCT01559506|No Intervention|No device|Subject does not receive ABS system
9796215|NCT01559506|Experimental|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
9796216|NCT01559649||Group 1|Veterans admitted to MEDVAMC with a suspected ischemic or hemorrhagic stroke will be recruited. Individuals with a history of neurological disease other than stroke, head and neck structural surgery, or history of dysphagia unrelated to the current stroke will be excluded from participation. Individuals who are obtunded, medically unstable, greater than 5 days post-admission will be excluded. Patients with language or cognitive deficits who are judged by the attending neurologist to not have capacity to provide informed consent will be eligible to participate, but they must have an authorized representative available within 24 hours of admission to provide consent. Patients will undergo swallowing screening and videofluoroscopic swallowing study to establish validity of screening items
9796217|NCT01559649||Group 2|Stroke ward nurses. The nurses will administer and interpret the swallowing screening items. Speech pathologists will also make blinded, simultaneous interpretations of the screening items. Nurse and speech pathologist interpretation will be used to establish nursing reliability.
9796218|NCT01559675|Active Comparator|Hydrocortisone High Dose|Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
9796219|NCT01559675|Experimental|Hydrocortisone Low Dose|Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
9796220|NCT01559844|Experimental|SOF+RBV|Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
9796221|NCT01559857|Active Comparator|Pioglitazone|50% of participants will be allocated to 12 weeks of treatment with 30 mg/day of Pioglitazone.
9796222|NCT01559857|Placebo Comparator|Sugar pill|50% of participants will be randomized to 12 weeks of treatment with placebo pill.
9796223|NCT01559922|Placebo Comparator|Placebo|Normal Saline
9796224|NCT01559922|Experimental|Artefill|Dermal Filler
9796225|NCT01559935|Experimental|Car-BiRD Therapy|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
9796226|NCT01559948|Experimental|Lumbopelvic stabilization exercises plus sacroiliac joint belt|The participants will be instructed in the lumbopelvic stabilization program. Additionally, during the initial session, these participants receive a sacroiliac compression belt and be instructed to wear the belt during all waking hours for the first four weeks of the study.
9796227|NCT01559948|Active Comparator|Lumbopelvic stabilization exercise|The participants will be instructed in the lumbopelvic stabilization program.
9796228|NCT01560143|Other|Tigecycline|All subjects receive a single dose of tigecycline
9796229|NCT01560234|Experimental|AZD8848|
9796230|NCT01560234|Placebo Comparator|Placebo|
9796231|NCT01560260|Experimental|Treatment (linsitinib)|Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9796232|NCT01560286|Experimental|Group 1|4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
9796233|NCT01560377|Experimental|Subjects Imaged with PINPOINT|Colonic tissue perfusion assessed with PINPOINT for laparoscopic left colectomy in the lower tract.
9796234|NCT01560403|Experimental|Teduglutide|0.05 mg/kg/day
9796235|NCT01560416|Active Comparator|ARM A - Fulvestrant|Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.
9796236|NCT01560416|Active Comparator|Arm B - Fulvestrant+Ganetespib|"Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle~Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression."
10211264|NCT05098743|Experimental|Participants using the medication adherence mobile application.|Participants in this arm will use the Medisafe app to receive medication reminders for thirty days.
10211265|NCT05098743|Active Comparator|Participants using a printed copy of their medication list.|Participants in this arm will use a printed out copy of their medication list for thirty days.
10211266|NCT05096741||OCS Liver|
10211267|NCT05096741||Control|
10211268|NCT05093491||Stroke patients|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio of stroke patients. Spirometry evaluation was performed by another investigator. Diagnostic Test: Bilaterally diaphragm and abdominal muscle thickness and thickening ratio with ultrasonography
10211269|NCT05093491||Healthy individuals|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio. Spirometry evaluation was performed by another investigator. Diagnostic Test: Dominant side diaphragm and abdominal muscle thickness and thickening ratio with ultrasonography
9796237|NCT01560429|Experimental|Patient controlled epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion until stable pain scores of ≤ 3 were reached while in PACU. Once stable, they were allocated to their preoperatively determined randomization which meant they still received 2/3rd of the anesthetic as a background infusion but also had the option to self-administer the remaining 1/3rd dose as patient controlled epidural analgesia (PCEA). Rescue analgesia was available upon request.
9796238|NCT01560429|Active Comparator|continuous epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion rate until stable pain scores of ≤ 3 were reached while in PACU (as described in the PCEA group). Once stable, they were allocated to their preoperatively determined randomization assignment which for the CEA group meant they remained on the continuous background epidural infusion rate previously determined to maintain pain scores ≤ 3 while in PACU. Rescue analgesia was available as needed.
9796239|NCT01560624|Experimental|UT-15C|Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID
9796240|NCT01560624|Placebo Comparator|Placebo|Matching placebo tablets (oral)
9796241|NCT01560780|Experimental|Arm 1: Prasugrel|prasugrel 10 mg by mouth daily
9796242|NCT01560780|Placebo Comparator|Arm 2: Placebo|placebo by mouth once daily
9796243|NCT01560819|Experimental|Study Participants|Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
9796244|NCT01560871|Sham Comparator|Low-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 15% PImax. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion (RPE) scale. Participants were encouraged to walk at 10 to 15 minutes, once to twice a day initially, then progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
9796245|NCT01560871|Experimental|High-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 60% PImax.~The walking program was the same as the one for the control group."
9796246|NCT01560923|Experimental|Sipuleucel-T + Oral Indoximod|Oral Indoximod will be self-administered by mouth twice daily (1200 mg) for 6 months starting after the last (3rd) infusion of sipuleucel-T. Indoximod is a sterile tan powder compounded in capsule form of 200 mg.
9796247|NCT01560923|Placebo Comparator|Sipuleucel-T + Placebo|Placebo is identical-looking to Indoximod and provided in the same manner.
9872636|NCT00308256|No Intervention|Control|Normal monthly follow-up without phone calls
9872637|NCT00308269|Experimental|Vintafolide 1.2 mg IV Bolus|Vintafolide 1.2 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
9872638|NCT00308269|Experimental|Vintafolide 2.5 mg IV Bolus|Vintafolide 2.5 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
10211270|NCT05089708|Experimental|Trifarotene (CD5789) 50 mcg/g Cream|
10211271|NCT05089708|Placebo Comparator|Trifarotene Vehicle Cream|
9872639|NCT00308269|Experimental|Vintafolide 4.0 mg IV Bolus|Vintafolide 4.0 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
9872640|NCT00308269|Experimental|Vintafolide 2.5 mg IV Infusion|Vintafolide 2.5 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
9872641|NCT00308269|Experimental|Vintafolide 3.0 mg IV Infusion|Vintafolide 3.0 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
9872642|NCT00308334|Experimental|Domperidone|Domperidone
9872643|NCT00308334|Placebo Comparator|placeob- Sugar pill|
9872644|NCT00308412|Experimental|1|Two 10^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
9872645|NCT00308412|Placebo Comparator|2|Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
9872646|NCT00308438|Experimental|1|All subjects in the study dosed at 0.1 mg/kg teduglutide
9872647|NCT00308503|Experimental|1|5 mg/day
9872648|NCT00308503|Placebo Comparator|2|
9872649|NCT00308724|Experimental|1|Cognitive Behavior Therapy
9872650|NCT00308724|Active Comparator|2|Usual Care
9872651|NCT00308763|Active Comparator|1|Nicotine patch plus placebo sustained-release bupropion
9872652|NCT00308763|Active Comparator|2|Placebo nicotine patch plus sustained-release bupropion
9872653|NCT00308763|Active Comparator|3|Nicotine patch plus sustained-release bupropion
9872654|NCT00308776|Experimental|Cholecystokinin|Participants will receive intravenous saline plus cholescystokinin.
9872655|NCT00308776|Placebo Comparator|Saline|Participants will receive intravenous saline only.
9872656|NCT00308789|Experimental|1|Biphasic NCPAP
9872657|NCT00308789|Active Comparator|2|Continuous CPAP
9872658|NCT00308854|Active Comparator|1|PD P 506 A-PDT
9872659|NCT00308854|Placebo Comparator|2|Placebo-PDT
9872660|NCT00308893|Experimental|Escitalopram|Treatment response after 3 and 6 weeks
9872661|NCT00308906||1|Hospitalized, untreated infants and children
9872662|NCT00308906||2|Aminoglycoside treated infants and children without renal injury
9872663|NCT00308906||3|Aminoglycoside treated infants with renal injury
9872664|NCT00308919|Experimental|WST 09|Treatment with WST09 Vascular Photodynamic therapy
9872665|NCT00308945|Experimental|2|cross-over comparison of two substances
9872666|NCT00308945|Experimental|1|
9872667|NCT00308971|Active Comparator|1|
9872668|NCT00308971|Placebo Comparator|2|
9872669|NCT00309049|Active Comparator|A1|
9872670|NCT00309049|Active Comparator|A2|
9872671|NCT00309049|Active Comparator|A3|
9928907|NCT00911651|Active Comparator|ipratropium bromide|COPD patients GOLD stage II and III
9928908|NCT00911664|Placebo Comparator|1|
9928909|NCT00911664|Experimental|2|
9928910|NCT00911664|Experimental|3|
9928911|NCT00911677||Open Aortic Repair|Patients 60 years of age and older undergoing open repair of the abdominal aorta
9928912|NCT00911690||Cognitively Impaired|Patients in this cohort with be diagnosed with mild to moderate cognitive impairment, Alzheimers disease, Dementia, or any other form of cognitive impairment.
9928913|NCT00911690||Non-cognitively impaired|Patients in this cohort will be normal healthy adults over the age of 60 years that have no cognitive impairment.
9928914|NCT00911703||Acute heart failure|Subjects with an ED diagnosis of acute decompensated heart failure .
9928915|NCT00911716|Experimental|cyclophosphamide, Docetaxel, bevacizumab|
9928916|NCT00911755|Other|Laryngoscopy|
9928917|NCT00911755|Other|Videolaryngoscopy|
9928918|NCT00911781||Infants with infantile hemangiomas|
9928919|NCT00911794|Experimental|Written Disclosure Therapy|
9928920|NCT00911794|Sham Comparator|Controls|
9928921|NCT00911846||Buprenorphine|opioid-dependent patients with buprenorphine substitution
9928922|NCT00911846||methadone|opioid-dependent patients substituted with methadone
9928923|NCT00911846||no substitution|opioid-dependent patients without substitution
9928924|NCT00911846||therapists|therapists of the patients
9928925|NCT00911872|Experimental|aging|
9928926|NCT00911885|Experimental|High Fiber Diet|A single dietary change condition that focuses exclusively on increasing fiber.
9928927|NCT00911885|Active Comparator|AHA Diet|The AHA Diet is the current recommendation for patients with the metabolic syndrome.
9928928|NCT00911911|Experimental|FEC 100 + TAXOTERE|"FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE~TAXOTERE 100 mg/m²/cycle~1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100"
9928929|NCT00911924|Experimental|iStent|
9928930|NCT00911976|Experimental|Xience V|Implantation of the Xience V stent in saphenous vein graft lesions
9928931|NCT00912054|Experimental|1|DuoTrav APS
9928932|NCT00912054|Active Comparator|2|Xalacom
9928933|NCT00912067||hematopoietic stem cell transplantation|
9928934|NCT00912080|Experimental|good signature|"Patients who have a good signature for the genomic analysis. They will receive the standard chemotherapy."
9928935|NCT00912106||HA injection|Patients with osteoarthritis of knee. They are going to received HA injection 1 vial per week for 5 weeks.
9928936|NCT00912119|Experimental|Group A|Group A - Low Dose
9928937|NCT00912119|Experimental|Group B|Group B - Intermediate Dose
10211272|NCT05086068|Other|Arthrosamid Inj|Single arm study - no comparator
10211273|NCT05077735|Experimental|Treatment (hypofractionated RT)|Patients undergo hypofractionated RT over 10 fractions. Patients who achieve progression undergo up to 2 retreatment courses.
10211274|NCT05072184|Active Comparator|ESP block|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
10211275|NCT05072184|Sham Comparator|Control|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of saline on each side
9796248|NCT01560949|Experimental|Chemotherapy + Radiation|"SYSTEMIC PHASE: Chemotherapy with Oxaliplatin followed by Irinotecan followed by 5-FU. m FOLFIRINOX - oxaliplatin 75 mg/m2 d1 + irinotecan 150 mg/m2 d1 + 5-FUl 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks).~CHEMORADIATION PHASE: This phase will start at least 2 weeks, but no more than 6 weeks after completion of the last cycle of mFOLFIRINOX. Chemoradiation with Gemcitabine: 350 mg/m2 IV over 35 minutes every week for 5 doses beginning day 1 (days 1, 8, 15, 22, 29)~Radiation: External beam radiation therapy will be delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions) to the GTV + 1.5 cm margin.~SURGERY- At least 4-6 weeks after last dose of Gemcitabine, if no local progression or distant metastasis. Patients whose scans show unequivocal local or distant progression are not candidates for surgery."
9796249|NCT01560975|Experimental|Sensimed Triggerfish|
9800038|NCT01677741|Experimental|Part 1: Dabrafenib treatment|Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg [+1] and may be further to 4.5 mg/kg [+2] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg [-1] and may be further to 1.5 mg/kg [-2]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
9800039|NCT01677741|Experimental|Part 2: Cohort 1 Low-Grade Gliomas with BRAF V600 mutations|Subjects with low-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
9800040|NCT01677741|Experimental|Part 2: Cohort 2 High-Grade Gliomas with BRAF V600 mutations|Subjects with high-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
9800041|NCT01677741|Experimental|Part 2: Cohort 3 LCH with BRAF V600 mutations|Subjects with LCH with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
9800042|NCT01677741|Experimental|Part 2: Cohort 4 Melanoma and PTC with BRAF V600 mutations|Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
9800043|NCT01677767||Cohort|
10211276|NCT05070117|Experimental|Resistance/strength training|
10211277|NCT05068427|Experimental|Chidamide + Envafolimab|Patients receive Chidamide 20mg or 30mg orally twice per week and Envafolimab 400mg subcutaneous infusions every 4 weeks untile disease progression or unacceptable toxicity.
10211278|NCT05066737|Experimental|patients who has pelvic organ prolapse and underwent lateral suspension via V-notes surgery|
10211279|NCT05065294|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.
10211280|NCT05062330|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days|
9800044|NCT01677858|Experimental|Carfilzomib|"In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study."
9800045|NCT01677910|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose somatostatin analog (SSA) therapy (octreotide or lanreotide) participants were randomized to receive one 250 mg telotristat etiprate tablet plus one placebo-matching telotristat etiprate tablet administered three times daily for 12 Weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
9800046|NCT01677910|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive, one telotristat etiprate 250 mg plus one placebo-matching telotristat etiprate tablet administered 3 times daily for 1 week, followed by two telotristat etiprate (250 mg) tablets administered three times daily for 11 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
9800047|NCT01677910|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
9872672|NCT00309075|Experimental|Arm 1|
9872673|NCT00309088|Experimental|1|
9872674|NCT00309088|Placebo Comparator|2|
9872675|NCT00309101|Experimental|1. tacrolimus|
9872676|NCT00309114|Experimental|Interventions for Experimental Arm|Bacterial Interference with Escherichia coli 83972. Each bladder inoculation contains the study organism, E. coli 83972, suspended as a clear solution in sterile physiological saline.
9872677|NCT00309114|Placebo Comparator|Interventions for Control Arm|Each bladder inoculation contains sterile physiological saline that does not contain the study organism.
9872678|NCT00309218|Active Comparator|A|Steroid withdrawal
9872679|NCT00309218|Placebo Comparator|B|continuos Steroid treatment
9872680|NCT00309257|Experimental|ACE inhibitor, ATA II antagonists and Statins|
9872681|NCT00309283|Experimental|somatostatin|
9872682|NCT00309283|Placebo Comparator|Saline solution|
9872683|NCT00309296|Experimental|Longitudinal Care|One year of combined behavioral and pharamcological tobacco dependence treatment, with interim smoking reduciton for smokers who fail initial quit attempt.
9872684|NCT00309296|Active Comparator|Usual Care|Evidence based, state-of-the-science tobacco treatment; combined behavioral and pharmacological treatment for 8 weeks
9872685|NCT00309348|Experimental|Weekly measurement of graft flow|The surveillance group was measured with the FloMon instrument weekly, and all procedures related to their access-grafts recorded
9872686|NCT00309348|No Intervention|Control|The control group was questioned weekly with regard to their graft status and whether there had been any graft-related procedures
9872687|NCT00309413|Active Comparator|1|Cannabidiol/Placebo
9872688|NCT00309413|Placebo Comparator|2|Placebo/Cannabidiol
9872689|NCT00309478|Experimental|2 (CMF scheme)|6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil)
9872690|NCT00309478|Experimental|1 (Nol + Zol)|Zoladex (3 years) combined with Nolvadex (5 years)
9872691|NCT00309491|Experimental|Group I|Tamoxifen alone
9872692|NCT00309491|Experimental|Group II|Tamoxifen + Aminoglutethimide
9872693|NCT00309556|Active Comparator|A (experimental group)|Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
9872694|NCT00309556|Active Comparator|B (control group)|Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease
9872695|NCT00309569|Experimental|A (pre- + postoperative chemotherapy)|3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil) followed by surgery. Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
9872696|NCT00309569|Experimental|B (conventional postoperative chemotherapy)|Surgery followed by 3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil). Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
9872697|NCT00309595|Experimental|1|Cordis SMART™ nitinol self expandable stent
9872698|NCT00309595|Active Comparator|2|balloon
9872699|NCT00309647|Experimental|H5N1 Formulation 1 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval
9872700|NCT00309647|Experimental|H5N1 Formulation 2 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval
9872701|NCT00309647|Experimental|H5N1 Formulation 3 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval
9872702|NCT00309647|Experimental|H5N1 Formulation 4 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval
9872703|NCT00309647|Active Comparator|H5N1 Formulation 5 Group|Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval
9872704|NCT00309647|Active Comparator|H5N1 Formulation 6 Group|Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval
9872705|NCT00309647|Active Comparator|H5N1 Formulation 7 Group|Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval
9872706|NCT00309647|Active Comparator|H5N1 Formulation 8 Group|Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval
9872707|NCT00309699|Placebo Comparator|003|Placebo Daily for 3 weeks
9872708|NCT00309699|Active Comparator|002|Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
9872709|NCT00309699|Experimental|001|Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks
9872710|NCT00309855|Placebo Comparator|Double Placebo|(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)
9872711|NCT00309855|Other|Testosterone IM and oral placebo|IM injections weekly x three injections and oral placebo once daily x 21 days
9872712|NCT00309855|Other|Testosterone and Oral Anastrozole|IM injections weekly x 3 injections and oral daily x 21 days
9872713|NCT00309855|Other|Testosterone and Dutasteride|IM injections weekly x 3 injections and oral once daily x 21 days
9872714|NCT00309972|Active Comparator|Sequential arm (SEQ)|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
9872715|NCT00309972|Experimental|Experimental arm (CON)|Concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
9872716|NCT00310024|Experimental|Treatment (vorinostat, bortezomib)|"Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.~Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies."
9872717|NCT00310063|Experimental|Arm I|Sea Band elastic acupressure wristband
9872718|NCT00310063|Sham Comparator|Arm II|Sham wristband
9872719|NCT00310115||Smoking Prevention Usual Care|Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
9872720|NCT00310115||MRP|Arm II (motivational relapse prevention [MRP]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 & 36 weeks gestation then at 2, 4, 7, & 16 weeks postpartum.
9872721|NCT00310115||Enhanced MRP +|Arm III (enhanced MRP [MRP+]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation & 8 weeks postpartum.
9872722|NCT00310141|Active Comparator|Standard Care Group|Written self-help materials, counseling, and 6-week nicotine patch supply
9872723|NCT00310141|Active Comparator|Computer Treatment Group (CDT)|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
9872724|NCT00310141|Experimental|CDT Pilot|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
9872725|NCT00310167|Experimental|4 Gy|4 Gy in 2 fractions
9872726|NCT00310167|Active Comparator|24 Gy|24 Gy in 12 fractions
9872727|NCT00310206|Experimental|ID injection-9 mcg|25 subjects to receive 9 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
9872728|NCT00310206|Experimental|IM injection-15 mcg|25 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
9872729|NCT00310206|Experimental|IM injection-45 mcg|25 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
9872730|NCT00310206|Experimental|ID injection-3 mcg|25 subjects to receive 3 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
9872731|NCT00310219|Experimental|Arm 1|Two radiation oncologists are randomly assigned to develop either a 3DCRT plan using CT only, or a 3DCRT plan using fused PET/CT
9872732|NCT00310323|Experimental|1|Children with OSAS identified via sleep study
9872733|NCT00310388|Experimental|Retigabine (INN), Ezogabine (USAN)|Retigabine (Ezogabine): all subjects
9872734|NCT00310492|Active Comparator|Subcutaneous immunotherapy|Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
9872735|NCT00310492|Placebo Comparator|Subcutaneous injections|placebo injections
9872736|NCT00310531|Experimental|Arm 1|
9872737|NCT00310531|Active Comparator|Arm 2|
9872738|NCT00310544|Experimental|Arm 2|
9872739|NCT00310544|Experimental|Arm 1|
9872740|NCT00310557|Experimental|Arm 1|
9872741|NCT00310596|Experimental|Arm 1|
9872742|NCT00310596|Experimental|Arm 2|
9872743|NCT00310596|Experimental|Arm 3|
9872744|NCT00310596|Experimental|Arm 4|
9872745|NCT00310596|Active Comparator|Arm 5|
9872746|NCT00310596|Placebo Comparator|Arm 6|
9872747|NCT00310609|Experimental|Arm 1|
9872748|NCT00310661|Placebo Comparator|Placebo|Placebo hard gelatin capsules matching the investigational medication
9872749|NCT00310661|Experimental|Sarizotan HCI|Sarizotan HCI is administered at various doses ranging from 2-7mg.
9872750|NCT00310713|Experimental|Group 1|
9872751|NCT00310713|Experimental|Group 2|
9872752|NCT00310713|Experimental|Group 3|
9872753|NCT00310713|Experimental|Group 4|
9872754|NCT00310713|Experimental|Group 5|
9872755|NCT00310726|Experimental|Abrupt Weaning|Women were counseled to abruptly wean their child at 4 months of age.
9872756|NCT00310726|Active Comparator|Exclusive breastfeeding per WHO guidelines|Women were counseled to adhere to the WHO recommendations for duration of exclusive breastfeeding.
9928938|NCT00912119|Experimental|Group C|Group C - High Dose
9928939|NCT00912119|Experimental|Group D|Group D - Extra Low
9928940|NCT00912145|Experimental|1|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
9928941|NCT00912145|Active Comparator|2|Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company)
9928942|NCT00912171|Active Comparator|Nasal steroid|
9928943|NCT00912171|Active Comparator|Anti-leukotrienes|
9928944|NCT00912171|Active Comparator|Nasal steroid + anti-leukotrienes|
9928945|NCT00912184|Experimental|1|CVVH with high cut-off polyamide membrane (P2SH) using standard continuous veno-venous hemofiltration (CVVH) settings
9928946|NCT00912184|Active Comparator|2|CVVH using standard high flux membrane with standard CVVH settings
9928947|NCT00912210|Active Comparator|Higher protein|
9928948|NCT00912210|Placebo Comparator|Higher carbohydrate|
9928949|NCT00912236||1|BMI 20-25 kg/m2
9928950|NCT00912236||2|BMI > 30 kg/m2 with low TG (<150) and normal HDL (>50 for females, >40 for males)
9928951|NCT00912236||3|BMI > 30 kg/m2 with high TG (>150) and low HDL (<50 for females, <40 for males)
9928952|NCT00912249|Experimental|Horticultural Therapy|
9928953|NCT00912262|Active Comparator|Low and High Concentration Capsaicin Topical Liquids|
9928954|NCT00912275|Experimental|Lapatinib plus Oral Vinorelbine|Oral vinorelbine on day 1 and day 8 q3w plus lapatinib 1000mg/day.
9928955|NCT00912314|Active Comparator|Monthly Maintenance PTNS|After 12 weeks of PTNS, patients will be randomized to either the monthly PTNS arm, or the no maintenance PTNS arm.
9928956|NCT00912314|No Intervention|No maintenance PTNS|After 12 weeks of PTNS, patients will either be randomized to the Monthly PTNS arm or the No maintenance PTNS arm.
9928957|NCT00912327||Stage 1|
9517881|NCT03302039|Experimental|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
9796250|NCT01560988|Experimental|Active Borage and Echium Seed Oils|Borage and echium oil capsules administered daily for six weeks, then a 6 week washout period, followed by ingestion of placebo (corn oil capsules) daily for 6 weeks.
9796251|NCT01560988|Experimental|Corn oil pills|Corn oil capsules daily for six weeks, then a 6 week washout period, followed by ingestion of Borage and echium oil capsules daily for 6 weeks.
9796252|NCT01561053|Experimental|High Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
10211281|NCT05062330|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days|
10211282|NCT05059132|Experimental|Tele-rehabilitation|Participants in the tele-rehabilitation arm will receive a home-based, remotely delivered rehabilitation program.
10211283|NCT05059132|Active Comparator|Education only|Participants in the education arm will receive educational materials only, delivered through telecommunication messages.
10211284|NCT05053867|Experimental|Group A: Inhaled tranexamic acid|will receive 500 mg/5ml nebulized tranexamic acid every 8 hours for at least 3 days, and up to 5 days
10211285|NCT05053867|Other|Group B: Usual Care|usual care
10211286|NCT05052970|Experimental|12 mg/m ^ 2 dose group (ArmA)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2
10211287|NCT05052970|Experimental|16 mg/m ^ 2 dose group (ArmB)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2
10211288|NCT05052970|Experimental|20 mg/m ^ 2 dose group (ArmC)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2
10213725|NCT03437421|Experimental|Type II diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
9796253|NCT01561053|Experimental|Low Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
9796254|NCT01561053|Experimental|Low Albumin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
9796255|NCT01561053|No Intervention|Control (sham) group|Simulated plasma exchange procedure
9796256|NCT01561079|Experimental|Maternal buprenorphine treatment|Buprenorphine maintenance during pregnancy
9796257|NCT01561300|Placebo Comparator|Control|Nutrition intervention study with a control
9796258|NCT01561300|Experimental|Tea extract|Nutrition intervention study with a black tea extract
9796259|NCT01561313|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
9796260|NCT01561313|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
9796261|NCT01561469||Linezolid observational cohort|
9796262|NCT01561469||Vancomycin observational cohort|
9796263|NCT01561560|Other|DAILIES TOTAL1, then TRUEYE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
9796264|NCT01561560|Other|TRUEYE, then DAILIES TOTAL1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
9796265|NCT01561703|Experimental|Anitibiotic|Patients will receive postoperative antibiotic after surgery.
9796266|NCT01561703|No Intervention|Control|Patients will NOT receive postoperative antibiotic
9796267|NCT01561716|Experimental|Crossover sequence 1|Resting/Wii Fit Free Run/Wii Fit 3 bouts/treadmill
9796268|NCT01561716|Experimental|Crossover sequence 2|Resting/Wii Fit Free Run/treadmill/Wii Fit 3 bouts
9796269|NCT01561716|Experimental|Crossover sequence 3|Resting/Wii Fit 3 bouts/Wii Fit Free Run/treadmill
9796270|NCT01561716|Experimental|Crossover sequence 4|Resting/Wii Fit 3 bouts/treadmill/Wii Fit Free Run
9796271|NCT01561716|Experimental|Crossover sequence 5|Resting/treadmill/Wii Fit Free Run/Wii Fit 3 bouts
9796272|NCT01561716|Experimental|Crossover sequence 6|Resting/treadmill/Wii Fit 3 bouts/Wii Fit Free Run
9796273|NCT01561755|Experimental|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
9796274|NCT01561755|Placebo Comparator|Placebo|Saline 2gr/kg over 2 days of saline
9796275|NCT01561833|Experimental|Sorafenib|Sorafenib, 400 mg PO twice daily
9796276|NCT01561898|Experimental|Paliperidone extended-release (JNS007ER)|
9796277|NCT01561963|Experimental|Apremilast and Rifampin|"Participants received the following 3 treatment regimens:~A single oral dose of 30 mg apremilast on Day 1 (Period 1);~A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 (Period 2);~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 (Period 3)."
9796278|NCT01561976|Active Comparator|Metformin hydrochloride prolonged release|1000mg in fasting state
9796279|NCT01561976|Active Comparator|metformin hydrochloride prolonged release|1000mg In fed state
9796280|NCT01561976|Active Comparator|Metformin hydrochloride sustained release/Glimepiride|1000/2mg In fed state
9796281|NCT01562028|Experimental|Erlotinib plus bevacizumab|Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
9796282|NCT01562041|Experimental|Ranolazine 500 mg|Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.
9986984|NCT01407783|Experimental|Problem Solving Tools|The home visitation nurse will teach and utilize the problem solving tools to help low-income depressed mothers. It is a brief treatment with the a non-pathologizing intervention being done in 4-8 sessions.
9986985|NCT01407783|No Intervention|Enhanced Referral|
9986986|NCT01407796|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS
9986987|NCT01407809|Experimental|Intervention|
9986988|NCT01407822|Experimental|Erlotinib arm|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
9986989|NCT01407822|Active Comparator|Chemo arm|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
9986990|NCT01407835|Experimental|1|"Dactylis glomerata allergen extract at 4 different concentrations~Positive control~Negative control"
9986991|NCT01407848|Experimental|Furosemide|1 mg/kg/Ed
9986992|NCT01407848|Active Comparator|Saline 0,9%|1ml/kg/Ed
9997001|NCT01505049||Previously received all three doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received their third dose of vaccine three or more years ago. Recruitment of this group was completed in Sept 2012.
9997002|NCT01505049||Previously received two doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received two doses of the HPV vaccine. The second dose must have been received six or more months ago.
9997003|NCT01505049||Unvaccinated Cohort|This group will consist of 45 women who have not received their HPV vaccination. Women ages 18-26 are eligible for this cohort. Recruitment for this group was completed in January 2013.
9997004|NCT01505075|Experimental|Hypofractionated radiation|40 Gy in 5 fractions over 29 to prostate; 30 Gy in 5 fractions over 29 days to seminal vesicles
9997005|NCT01505088|Experimental|Iontophoretic Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
9997006|NCT01505088|Active Comparator|Prednisolone Acetate Ophthalmic Suspension (1%)|Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
9997007|NCT01505101|Experimental|Mindfulness-Oriented Recovery Enhancement|
9997008|NCT01505101|Active Comparator|Conventional Support Group (SG)|
9997009|NCT01505127|Experimental|TAK-438 20 mg BID|"TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
9997010|NCT01505127|Experimental|Lansoprazole 30 mg BID|"TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
9796283|NCT01562132|Experimental|5FC plus fluconazole|Combination therapy with oral fluconazole and flucytosine
9997011|NCT01505140|No Intervention|Usual Western style diet|Participants will consume their usual Western style diet avoiding tree nuts
9997012|NCT01505140|Experimental|Whole walnuts|Participants will consume usual Western style diet adding 75 gm whole walnuts per day
9997013|NCT01505153|Experimental|pbi-shRNA STMN1 LP|pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
9997014|NCT01505218|Active Comparator|Propofol sedation by nurse anaesthetist|Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.
9997015|NCT01505218|Active Comparator|Patient-controlled propofol sedation|"Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
9997016|NCT01505218|No Intervention|Midazolam sedation by the ERCP-team|Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
9997017|NCT01505231|Active Comparator|Norepinephrine group|Blinded norepinephrine
9997018|NCT01505231|Active Comparator|Vasopressin Group|Blinded vasopressin
9997019|NCT01505244|Experimental|Physical Activity|Before-school moderate to vigorous physical activity 3 days/week
9997020|NCT01505257|Experimental|END-DSD Intervention|
9997021|NCT01505257|No Intervention|Control|
9997022|NCT01505270||Autistic Children|
9997023|NCT01505283|Placebo Comparator|Group Saline|Epidural administration of saline
9997024|NCT01505283|Experimental|Group Sufentanil|Epidural administration of sufentanil
9997025|NCT01505283|Experimental|Group Lidocaine|Epidural administration of lidocaine
9997026|NCT01505296|Active Comparator|Antiarrhythmic drug|Class I or III antiarrhythmic drug
9997027|NCT01505296|Experimental|Catheter ablation|Pulmonary vein isolation
9998306|NCT01516931|Placebo Comparator|sham rTMS and venlafaxine|Sham stimulation will be given at the same site and frequency, using a Magstim sham-coil system. During rTMS, participants will be instructed to keep their eyes open and relax.
9872757|NCT00310765|Active Comparator|1|75-150 mg of pregabalin po BID
9872758|NCT00310765|Placebo Comparator|2|Placebo 75 or 150 mg po BID
9872759|NCT00310778|Experimental|1|treatment
9872760|NCT00310843||All study population|
10211289|NCT05045404|Experimental|Treatment (poziotinib hydrochloride, ramucirumab)|Patients receive poziotinib hydrochloride PO BID on day 1 and ramucirumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9872761|NCT00310869|Experimental|E|
9872762|NCT00310895|Experimental|Dose escalation|Treatment Schedule 3 will consist of dosing on Days 1, 4, 8, and 11 of each 21 day cycle (3 weeks equals 1 cycle) and Treatment Schedule 4 will consist of dosing on Day 1 of each 28 day cycle (4 weeks equals 1 cycle)
10211290|NCT05035368|Experimental|Ladarixin - placebo|"In this arm the treatment sequence is ladarixin 400 mg twice-a-day, followed by placebo, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Ladarixin 24 weeks, washout 21 days, Placebo 24 weeks)."
10211291|NCT05035368|Experimental|Placebo - Ladarixin|"In this arm the treatment sequence is placebo followed by ladarixin 400 mg twice-a-day, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Placebo 24 weeks, washout 21 days, Ladarixin 24 weeks)."
10211292|NCT05032859|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
10211293|NCT05032859|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
10211294|NCT05029973|Experimental|Treatment Group|HAIC Combined With Sintilimab and Bevacizumab Biosimilar
9872763|NCT00311103|No Intervention|Care in the Control Group (CG)|Care in the Control Group (CG): was that provided by the General Practitioners, with basic diagnostic and therapeutic procedures without specified protocols.
9872764|NCT00311103|Experimental|Early Intervention Programa (IG)|Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
9872765|NCT00311129|Experimental|Arm 1|
9872766|NCT00311129|Active Comparator|Arm 2|
9872767|NCT00311298|Placebo Comparator|No micronutrients|Biscuit without additional micronutrients
9872768|NCT00311298|Experimental|Micronutrients|Biscuit with additional micronutrients
9872769|NCT00311298|Active Comparator|1 biscuit|1 biscuit with micronutrients
9872770|NCT00311298|Experimental|6 biscuits|1 biscuit with micronutrients, plus 5 biscuits without additional micronutrients
9872771|NCT00311324|Experimental|Special Intervention|One individual counseling visit, twelve group sessions, three postcards, and twelve telephone calls.
9872772|NCT00311324|Experimental|Delayed Intervention|"Direct mailing of two American Dietary Association pamphlets (Healthy Eating and Staying Alive) and three bimonthly newsletters providing general health information and study updates."
9872773|NCT00311389|Experimental|Travoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
9872774|NCT00311389|Active Comparator|Latanoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
9872775|NCT00311415|Experimental|Group 1: 2+4 Months (2-doses)|
9872776|NCT00311415|Experimental|Group 2: 2 Months (1-dose)|
9872777|NCT00311415|Experimental|Group 3: 6 Months (1-dose)|
9872778|NCT00311415|Active Comparator|Group 4: 12-16 Months (1 dose in the second year of life)|
9872779|NCT00311467|Active Comparator|Capecitabine and Interferon|Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
9872780|NCT00311467|Active Comparator|Interferon|"Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
9872781|NCT00311545|Experimental|CNTO 328|CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
9872782|NCT00311558|Experimental|SSG & INF|1 arm study: SSG & interferon
9872783|NCT00311597|Experimental|Single fractionated radiation adjusted for tumor size|Single fractionated radiation adjusted for volume of tumor tissue encompassed by desired isodose line
9872784|NCT00311610|Experimental|SN-38 liposome|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months for up to 3 years."
9872785|NCT00311662|Experimental|1|Tonabersat 40mg
9872786|NCT00311662|Placebo Comparator|2|
9872787|NCT00311675|Experimental|1|
9872788|NCT00311688||1|Individuals will follow the schedule of the study they are participating in
10211295|NCT05025514||Patients treated for cancer, vaccinated or eligible for anti-COVID vaccination.|"Patients undergoing treatment with anti-PD immunotherapy, anti-PDL1 or anti-CTLA4 immunotherapy for any tumour (solid, liquid) treated in the medical oncology departments of the Occitanie area.~who have been vaccinated or who are eligible for inoculation with one of the available anti-COVID19 vaccines."
10211296|NCT05025085|Experimental|Monotherapy with AGEN1777|3+3 Dose escalation of AGEN1777 will be administered by Intravenous (IV) infusion every 3 weeks (each cycle is 21 days [3 weeks]).
10211297|NCT05025085|Experimental|AGEN1777 in combination with a PD-1 inhibitor|3+3 Dose escalation of AGEN1777 in combination with a PD-1 inhibitor will be administered by IV infusion with specified dose on specified days.
10213726|NCT03437421|Experimental|Type I diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
9872789|NCT00311727|Experimental|Influenza A/H5N1|232 subjects receiving Influenza A/H5N1 vaccine.
9872790|NCT00311753|Experimental|1|Certoparin
9872791|NCT00311753|Active Comparator|2|Heparin
9872792|NCT00311792|Experimental|1|Simulator training
9872793|NCT00311792|Active Comparator|2|Traditional Clinical education at operating room
9872794|NCT00311805|Active Comparator|1|
9872795|NCT00311805|Active Comparator|2|
9872796|NCT00311805|Placebo Comparator|3|
9872797|NCT00311831|Active Comparator|1|
9872798|NCT00311831|Experimental|2|
9872799|NCT00311896|Experimental|Bemiparin|
9872800|NCT00311896|Placebo Comparator|Placebo|
9872801|NCT00311922|Active Comparator|Control|Active Control Arm receives Comprehensive Diabetes Education
9872802|NCT00311922|Experimental|Intervention Arm|Receives comprehensive education that is literacy/numeracy sensitive
9872803|NCT00311948|Active Comparator|Telephone counseling + interactive website|Teen has access to interactive website and receives tailored telephone counseling
9872804|NCT00311948|Other|Control with interactive website|Teen only has access to interactive website.
9872805|NCT00312000|Active Comparator|1Capecitabine-irinotecan|1st line- 2nd line (3rd line oxaliplatin plus capecitabine)
9872806|NCT00312000|Experimental|2capecitabine plus irinotecan|1st line (2nd line oxaliplatin plus capecitabine)
9872807|NCT00312013|No Intervention|No Nadroparin|Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
9872808|NCT00312013|Experimental|Nadroparin|Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
9872809|NCT00312039|Experimental|A|
9872810|NCT00312039|Active Comparator|B|
9872811|NCT00312065|Experimental|Patient|Once stabilized, a trimmed reflective shield to cover only the probe itself will be placed over the thermistor probe. Changes in measured skin temperature and warmer power output will be recorded non-invasively, as well as the time taken to reestablish baseline status. A full-sized reflective shield will then be placed over the thermistor probe and the same observations recorded, then repeated 15 minutes later. At the time of a subsequent routine change in thermistor position, the same procedure will be followed, but omitting the intermediate step of using the smaller trimmed shield. Continuous core temperatures will be monitored via a short rectal probe during the study periods.
9872812|NCT00312247||Boys taking steroids|Boys who are taking prednisone or deflazacort
9872813|NCT00312247||Boys who are steroid naive|Boys who are not taking steroids for a variety of reasons
9872814|NCT00312260|Experimental|1|
9872815|NCT00312260|Active Comparator|2|
9872816|NCT00312299|Experimental|Arm 1 A - Square edge PMMA IOL|50 patientes will recieve square edge PMMA IOL
9872817|NCT00312299|Active Comparator|1B|In group 1, 50 eyes will receive round edge PMMA IOL
9872818|NCT00312299|Experimental|2A|In group 2, 50 eyes will receive square edge PMMA IOL
9872819|NCT00312299|Active Comparator|2B|In group 2, 50 eyes will receive acrysof IOL
9872820|NCT00312390|Other|Healthy Control Subjects|
9872821|NCT00312390|Other|Subjects with amblyopia|
9872822|NCT00312403|Other|1|Patients with primary open angle glaucoma
9872823|NCT00312403|Other|2|Age- and sex-matched control subjects
9928958|NCT00912327||Stage 2|
9928959|NCT00912353|Experimental|AZD7268|
9928960|NCT00912353|Placebo Comparator|Placebo|
9928961|NCT00912366||Group A|VATS
9928962|NCT00912366||Group B|Open Surgery
9928963|NCT00912379||hemoglobin determination|ICU and emergency unit patients
9928964|NCT00912392|Experimental|Etoposide-Carboplatin with Endostar|Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
9928965|NCT00912392|Active Comparator|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
9928966|NCT00912431|Experimental|1|
9928967|NCT00912431|Placebo Comparator|2|
9928968|NCT00912444|Experimental|TAC Arm|six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide
9872824|NCT00312442|Experimental|WST 09|Treatment with WST09-mediated VTP
9872825|NCT00312455|Experimental|1|Drug Treatment
9872826|NCT00312455|Placebo Comparator|2|Placebo treatment
9872827|NCT00312481|Experimental|1|MOVIPREP
9872828|NCT00312481|Active Comparator|2|Picolax
9872829|NCT00312546|Experimental|2A|Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
9872830|NCT00312546|Experimental|2B|Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
9872831|NCT00312546|Experimental|3A|VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
9872832|NCT00312546|Experimental|3B|Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
9872833|NCT00312585|Experimental|Acupuncture|
9872834|NCT00312585|Sham Comparator|Sham Acupuncture|
9872835|NCT00312585|No Intervention|Usual care only|
9872836|NCT00312598||aripiprazole|observational measures of metabolic parameters of subjects who are making clinically determined medication switch to aripiprazole
9872837|NCT00312780|Experimental|Arm 1: XL784|
9872838|NCT00312780|Placebo Comparator|Arm 2: Placebo Gel capsules|
9872839|NCT00312936|No Intervention|Wait List|
9872840|NCT00312936|Experimental|MBSR|8 week mindfulness based stress reduction
9872841|NCT00312949|Experimental|1|Participants will use the interactive website
9872842|NCT00312949|Active Comparator|2|Participants will read written materials and watch a video
9872843|NCT00312962|Active Comparator|1|Participants will use commercially available computer games
9872844|NCT00312962|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
9872845|NCT00313053|Experimental|Human mAb 216|
9872846|NCT00313105|Experimental|Smokeless Tobacco|Smokeless Tobacco and individual visits
9872847|NCT00313105|Active Comparator|Nicotine tablets|Nicotine tablets
9872848|NCT00313105|Placebo Comparator|3|7-mg nicotine patch acts as placebo
9872849|NCT00313157|Active Comparator|Metoprolol|Treatment with Metoprolol 100 mg x 1 for three weeks
9872850|NCT00313157|Active Comparator|Diltiazem|Treatment with Diltiazem 360 mg x 1 for three weeks
9872851|NCT00313157|Active Comparator|Verapamil|Treatment with Verapamil 240 mg x 1 for three weeks
9872852|NCT00313157|Active Comparator|Carvedilol|Treatment with Carvedilol 25 mg x 1 for three weeks
9872853|NCT00313183|Experimental|1|single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects
9872854|NCT00313235|Experimental|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
9872855|NCT00313339|No Intervention|Control Group|A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
9872856|NCT00313339|Experimental|Treatment Group|Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.
9872857|NCT00313378|Experimental|ketamine|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
9872858|NCT00313378|Other|placebo|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
9872859|NCT00313404|Experimental|Norovirus in groundwater|We dosed volunteers with safety tested infectious norovirus in groundwater (that met EPA standards for drinking water). The length of time norovirus remained in groundwater varied by volunteer.
9872860|NCT00313417|Active Comparator|1|
9872861|NCT00313417|Placebo Comparator|2|
9872862|NCT00313430||Dialysis patients|
9872863|NCT00313430||with or wthout glucose added to dialysis fluid|
9872864|NCT00313508|Experimental|A: Peptide-pulsed DC, ALI and Low Dose Fludarabine|Fludarabine: 5 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
9872865|NCT00313508|Experimental|B: Peptide-pulsed DC, ALI and High Dose Fludarabine|Fludarabine: 25 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
9928969|NCT00912444|Experimental|TC Arm|six cycles of neoadjuvant Docetaxel and Cyclophosphamide
9928970|NCT00912457|Experimental|Donepezil|Donepezil-treated sleep apnea patients
9928971|NCT00912457|Placebo Comparator|Placebo|Placebo-treated sleep apnea patients
9872866|NCT00313599|Experimental|Lapatinib and Paclitaxel|Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.
9872867|NCT00313807|Active Comparator|1|Intravenous saline infusion plus amino acid infusion
9872868|NCT00313807|Placebo Comparator|2|Intravenous saline infusion plus placebo infusion
9872869|NCT00313872|Experimental|FOLFIRI|
9872870|NCT00313872|Experimental|DP|"D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr~D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan"
9872871|NCT00313885|Experimental|1|1 mg daily
9872872|NCT00313885|Experimental|2|5 mg daily
9872873|NCT00313885|Placebo Comparator|3|
9872874|NCT00313950|Experimental|Group 1|
9872875|NCT00313950|Experimental|Group 2|
9872876|NCT00313950|Experimental|Group 3|
9872877|NCT00313963|Experimental|1|
9872878|NCT00313963|Placebo Comparator|2|
9872879|NCT00313976|Experimental|Arm 1|
9872880|NCT00313976|Experimental|Arm 2|
9872881|NCT00313989|Experimental|Evaluation of implants of patients receiving radiotherapy.|
9872882|NCT00314015|Experimental|Patients with immediately loaded implants.|
9872883|NCT00314028|Active Comparator|1|Standard of care treatment
9872884|NCT00314028|Experimental|2|Educational program designed to motivate and provide information on the correct use of condoms
9872885|NCT00314054|Experimental|1|HCV-796 1000mg single dose
9872886|NCT00314067|Experimental|1|
9872887|NCT00314067|Experimental|2|
9872888|NCT00314067|Active Comparator|3|
9872889|NCT00314158|Experimental|Brinzolamide +Timolol|
9872890|NCT00314158|Active Comparator|Brinzolamide|
9872891|NCT00314158|Active Comparator|Timolol|
9872892|NCT00314171|Experimental|Brinzolamide + Timolol|
9872893|NCT00314171|Active Comparator|Dorzolamide + Timolol|
9872894|NCT00314275|Experimental|ENDEAVOR|Drug Eluting Stent
9928972|NCT00912483|Experimental|Test|Heparin Sodium 5.000UI/0.25mL
9928973|NCT00912483|Active Comparator|Ative comparator|Heparin Sodium 5.000USP/mL
9928974|NCT00912496|Experimental|Group 9: 2 dose prime|Received two doses of A/Vietnam/1203/04 90mcg vaccine as prime (on Days 0, 28 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
9928975|NCT00912496|Experimental|Group 8: 1 dose prime|Received A/Vietnam/1203/04 90mcg vaccine as prime (Day 0 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
9928976|NCT00912496|Experimental|Group 10: unprimed control/dose response group|Unprimed control and dose response group of H5 vaccine naive volunteers will be added in DMID 08-0013 to receive two doses of A/Anhui/05 vaccine (A) with or without MF59 adjuvant or placebo on Day 0 and Day 28.
9928977|NCT00912522|Active Comparator|LT PFC HIGH FREQ TMS|
9928978|NCT00912522|Active Comparator|LT PFC LOW FREQ TMS|
9928979|NCT00912522|Active Comparator|RT PFC HIGH FREQ TMS|
9928980|NCT00912522|Active Comparator|RT PFC LOW FREQ TMS|
9928981|NCT00912522|Sham Comparator|SHAM STIMULATION|
9928982|NCT00912535|Active Comparator|Quetiapine extended release tablet|Quetiapine orally at a flexible dose fo 50-300mg/day according to the judgment by the investigator for 8 weeks, as adjunct to the same antidepressant at the same dose.
9928983|NCT00912535|Placebo Comparator|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
9928984|NCT00912548|Experimental|TAM+OFS(E) group|"Patients should be premenopausal women ,prior to the start of chemotherapy, less than or equal to 45 years of age with oestrogen receptor positive ± progesterone receptor positive who have undergone a primary mass excision, received an neo-/adjuvant chemotherapy ± radiotherapy for their stage I, II or III breast cancer. This arm is ovarian suppression group which have a various starting time of ovarian function suppression after neo-/adjuvant chemotherapy.~Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. After that, the patients will complete taking tamoxifen 20mg/day for 5 years."
10211298|NCT05014841|Experimental|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 20-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
10211299|NCT05014568|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
10211300|NCT05014568|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
10211301|NCT05008783|Experimental|AK104 + Oxaliplatin + Capecitabine|AK104 in combination with Oxaliplatin and Capecitabine
10211302|NCT05008783|Placebo Comparator|Placebo + Oxaliplatin + Capecitabine|Placebo in combination with Oxaliplatin and Capecitabine
10211303|NCT05006885|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
10211304|NCT05006885|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
10211305|NCT05006885|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
10211306|NCT05006885|Placebo Comparator|Placebo|Administered once a week for 12 weeks
9796284|NCT01562132|Active Comparator|fluconazole alone|Fluconazole monotherapy
9796285|NCT01562275|Experimental|Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
9796286|NCT01562275|Experimental|Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
9796287|NCT01562275|Experimental|Stage 2 (Indication specific dose expansion cohort)|Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
9796288|NCT01562314|Experimental|GWP42003|GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
9796289|NCT01562314|Placebo Comparator|Placebo|Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
9796290|NCT01562327||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.
9796291|NCT01562379|No Intervention|No food|A control in which mothers will receive nutrition education about continued breastfeeding and adequate complementary feeding throughout the period of 6-18 months of age.
9796292|NCT01562379|Active Comparator|Plumpy Doz|In this control arm children will receive prepackaged, lipid-based Plumpy'Doz (Nutriset, Mulaunay, France) for daily consumption as a snack.
9796293|NCT01562379|Experimental|Wheat Soy Blend (WSB++)|Children will receive a WFP-developed Wheat-Soy Blend (WSB++) snack to be consumed daily.
9796294|NCT01562379|Experimental|Chickpea based complementary food supplement|Children will receive a Chickpea based complementary food supplement to be consumed daily.
9796295|NCT01562379|Experimental|Rice based complementary food supplement|Children will receive a locally developed rice based complementary food supplement.
9796296|NCT01562444|Other|TBE_R Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to rapid (R) schedule i.e., on days 0, 7 (+3) and 21 (+7) in the parent study (V48P7) and who were administered 1 booster dose of Encepur adults either 12-18 months after R schedule completion or in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination (for those subjects boostered before V48P7E1 study start, the blood draw occurred annually starting from >6 years up to >10 years after booster vaccination).
9796297|NCT01562444|Other|TBE_C Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
9796298|NCT01562444|Other|TBE_AC Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to accelerated conventional (AC) schedule i.e., on days 0, 14 (+3) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
9796299|NCT01562548|Experimental|Arm 1|Guaifenesin 1 tablet BID
9872895|NCT00314314|Experimental|1|
10211307|NCT05006807||Twitch Monitoring|Patients undergoing surgery with general anesthesia requiring neuromuscular blockade.
10211308|NCT05005728|Experimental|Cohort A - AVPCa|XmAb20717 + carboplatin + cabazitaxel
10211309|NCT05005728|Experimental|Cohort B - HRD/CDK12 PARP - Progressors|XmAb20717 + carboplatin + cabazitaxel
10211310|NCT05005728|Experimental|Cohort C - HRD/CDK12 PARP Naïve|XmAb20717 + olaparib
10211311|NCT05005728|Experimental|Cohort D - MSI-H or MMRD|XmAb20717 monotherapy
10211312|NCT05005728|Experimental|Cohort E - No Targetable Mutations|XmAb20717 + carboplatin + cabazitaxel
9796300|NCT01562548|Experimental|Arm 2|Guaifenesin 2 tablets BID
10211313|NCT04997395|Experimental|MediCabilis Cannabis sativa 50|"The medicinal cannabis used for this study is MediCabilis Cannabis sativa 50, a full spectrum CBD dominant plant based medicinal cannabis containing 50 mg/ml CBD and 2 mg/ml THC.~On commencing the oral medication, it will be titrated over a 2 week period to a dose of 1 ml twice a day (total dose 2 ml = 100 mg CBD and 4 mg THC). Participants will be given a written titration schedule at the initial clinic visit. There will be the potential for a further dose increase to a total dose of 3 ml per day (150 mg CBD and 6 mg THC) at the 1-month follow-up visit."
10211314|NCT04992754||Pregnant women over 18 years old coming to consult at the gynecology department|Pregnant women over 18 years old coming to consult at the gynecology department in the Montpellier's hospital
10211315|NCT04986579|Experimental|ERIBULIN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with Eribulin.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
10211316|NCT04986579|Active Comparator|ERIBULIN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with Eribulin.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
10211317|NCT04986579|Experimental|SACITUZUMAB GOVITECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1 and 21 of each of their standard of care (SOC) treatment cycles with SACITUZUMAB GOVITECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
10211318|NCT04986579|Active Comparator|SACITUZUMAB GOVITECAN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with SACITUZUMAB GOVITECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
10211319|NCT04986579|Experimental|TRASTUZUMAB DERUXTECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)|"Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with TRASTUZUMAB DERUXTECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
9796301|NCT01562548|Placebo Comparator|Arm 3|Placebo 1 tablet BID
9796302|NCT01562548|Placebo Comparator|Arm 4|Placebo 2 tablets BID
9796303|NCT01562613||Hypertensive patients|All eligible hypertensive patients treated with eprosartan
9796304|NCT01562678|Experimental|Liraglutide|
9796305|NCT01562678|Placebo Comparator|Placebo|
9796306|NCT01562743|Experimental|SPM 962|Rotigotine transdermal patch
9796307|NCT01562756|Experimental|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
9796308|NCT01562782|Experimental|South Asians|Participants in this group have only South Asian heritage. The intervention is Fructose + Glucose Beverage.
9796309|NCT01562782|Active Comparator|Caucasians|Participants in this group have only Caucasian heritage. The intervention is Fructose + Glucose Beverage.
9796310|NCT01562873|Experimental|Ruxolitinib-Cohort A|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
9796311|NCT01562873|Experimental|Ruxolitinib-Cohort B|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
9796312|NCT01562886|Experimental|Rilpivirine and Truvada|TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily
9796313|NCT01563003|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 16 weekly CBT sessions. This intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposures to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases
9796314|NCT01563003|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
9796315|NCT01563029|Active Comparator|Arm 1|Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
9796316|NCT01563029|Active Comparator|Arm 2|Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
9796317|NCT01563029|Active Comparator|Arm 3|Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
9796318|NCT01563029|Active Comparator|Arm 4|Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
9796319|NCT01563029|Placebo Comparator|Arm 5|Placebo inhalation powder once daily in the evening Placebo powder
9796320|NCT01563055|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
9872896|NCT00314314|Placebo Comparator|2|
9872897|NCT00314548|Experimental|Cases|PGE1 drug
9872898|NCT00314548|Placebo Comparator|Placebo|normal saline via same nebulizer
9872899|NCT00314626|Experimental|A|abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h
9872900|NCT00314626|No Intervention|B|efavirenz + 2 NUCS
9872901|NCT00314743|Active Comparator|Control (No aprepitant)|"Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)"
9872902|NCT00314743|Experimental|Experimental (with aprepitant)|"Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.~Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)"
9872903|NCT00314782|Experimental|Part A|Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
9872904|NCT00314782|Experimental|Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)|Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
9872905|NCT00314782|Experimental|Part B|Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
9872906|NCT00314782|Experimental|Part B (placebo)|Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
9872907|NCT00314847|No Intervention|Control|IABP, inotropic drugs, antiplatelet agents according to site habits.
9872908|NCT00314847|Experimental|Experimental|ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.
9872909|NCT00314925|Experimental|1|
9872910|NCT00314977|Experimental|A|Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
9872911|NCT00314977|Experimental|B|Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel
9872912|NCT00315016|Placebo Comparator|1|placebo (double dummy)
9872913|NCT00315016|Active Comparator|2|eplerenone
9872914|NCT00315016|Active Comparator|3|doubling of fosinopril dose
9872915|NCT00315029|Experimental|1|Receives combined patient centred intervention
9872916|NCT00315029|No Intervention|2|Standard treatment
9872917|NCT00315094|Experimental|1|
9872918|NCT00315094|No Intervention|2|After a control period, this group crosses over to experimental interventions (Arm 1)
9872919|NCT00315133|Experimental|Transplant arm|This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.
9872920|NCT00315159|No Intervention|No intervention|Patients with negative SLN will be followed on no intervention arm
9872921|NCT00315198|Active Comparator|Near activities|2 hours of daily patching combined with near visual activities while patching
9872922|NCT00315198|Active Comparator|Distance activities|2 hours of daily patching combined with distance visual activities while patching
9872923|NCT00315211|Other|Arm A|Weekly intravenous topotecan with intravenous docetaxel
9872924|NCT00315237|Experimental|1|
9872925|NCT00315237|No Intervention|2|best supportive care for 18 week duration
9872926|NCT00315354|Experimental|1|Low glycemic index diet
9872927|NCT00315354|Active Comparator|2|Low fat diet
9872928|NCT00315354|Active Comparator|3|Very low carbohydrate diet
9872929|NCT00315562|Experimental|Early|Early
9872930|NCT00315562|Active Comparator|Delayed|Delayed
9872931|NCT00315575||1|Individuals with high risk for Alzheimer's disease
9872932|NCT00315575||2|Individuals with low risk for Alzheimer's disease
9872933|NCT00315692||Premenopausal women|
9872934|NCT00315692||Postmenopausal women|
9872935|NCT00315744|Experimental|Subjects receiving salmeterol/fluticasone|Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.
9872936|NCT00315744|Active Comparator|Subjects receiving fluticasone|Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.
9872937|NCT00315900|Experimental|Depakote ER|Depakote ER
9872938|NCT00315900|Active Comparator|Seroquel|Seroquel
9872939|NCT00315913|Experimental|IV Propranolol|IV dose propranolol
9872940|NCT00315913|Placebo Comparator|IV Placebo|IV Placebo of saline solution equal to propranolol in volume
9935917|NCT02990611||Cohort 2: Nivolumab monotherapy|Participants who start a new systemic therapy with nivolumab monotherapy for the first time
9935918|NCT02990611||Cohort 3: Nivolumab adjuvant therapy|Participants who start adjuvant treatment with nivolumab after complete surgical tumor resection and no evidence of disease
9986993|NCT01407861|Active Comparator|Relaxation training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
9986994|NCT01407861|Active Comparator|Aerobic endurance training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
9986995|NCT01407887|Active Comparator|artesunate, amodiaquine methylene blue|two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
9986996|NCT01407887|No Intervention|artesunate amodiaquine|The control group will receive once daily a fixed dose AS-AQ over three days.
9986997|NCT01407900|Placebo Comparator|5% Dextrose in Water|Infusion of D5W
9986998|NCT01407900|Active Comparator|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
9986999|NCT01407939||Children, Adults|3- to 15-year old children and their parent (adults
9987000|NCT01407965|Experimental|Ertapenem|"Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L~Free and bound plasma concentration of ertapenem or meropenem in mg/L"
10211320|NCT04986579|Active Comparator|TRASTUZUMAB DERUXTECAN WITHOUT PAXMAN SCALP COOLING SYSTEM|"Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with TRASTUZUMAB DERUXTECAN.~Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years."
9987001|NCT01407965|Experimental|Meropenem|Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
9987002|NCT01407978|Active Comparator|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
9987003|NCT01407978|Active Comparator|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
9987004|NCT01407978|Experimental|Vaccination with Fluval P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
9987005|NCT01407991|Experimental|Length or graph method|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
9987006|NCT01407991|Active Comparator|NEM method for NG/OG tube placement|Standard method- measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length. Nose to ear to mid-xiphoid-umbilicus (NEM).
9987007|NCT01408004|Experimental|Alternating regimen|In the experimental arm (Arm A) alternating treatment will consist of 8 weeks of Pazopanib 800 mg qd alternated by 8 weeks of Everolimus 10 mg qd until first progression(PD per RECIST 1.1)followed thereafter by Pazopanib (when PD after 8 weeks of Everolimus)or Everolimus (when PD after 8 weeks of Pazopanib) monotherapy until second progression.
9987008|NCT01408004|Active Comparator|Sequential treatment|The comparative arm (Arm B) will be the standard regimen of Pazopanib (800 mg qd continuously) until progression, followed thereafter by Everolimus (10 mg qd continuously) until progression.
9987009|NCT01408056|Experimental|Timolol 0.5% Gel Forming Solution (GFS)|Half of enrolled subjects will receive topical Timolol
9987010|NCT01408056|Active Comparator|Mupirocin 2% ointment|Half of enrolled subjects will receive Mupirocin
9987011|NCT01408069|Experimental|MIGRANE|1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg
9987012|NCT01408069|Active Comparator|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
9987013|NCT01408095|Experimental|LY2608204|80 to 400 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. The starting dose level depends on the participant's HbA1c level measured at Screening. Administered orally, daily for 12 weeks
9987014|NCT01408095|Active Comparator|Glimepiride|1 to 6 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. Administered orally, daily for 12 weeks
9987015|NCT01408108|Active Comparator|Lightweight mesh repair|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
10211321|NCT04985682|Experimental|Haemophilia A Group|Participants with hemophilia A will be treated with ADVATE according to a regimen determined by the study site treating physician study site and in accordance with the national product label under standard clinical practice.
10211322|NCT04975438|Experimental|Group 1: Biologic Naïve participants receiving GSK1070806|
10211323|NCT04975438|Placebo Comparator|Group 1: Biologic Naïve participants receiving Placebo|
10211324|NCT04975438|Experimental|Group 2: Dupilumab inadequate responders receiving GSK1070806|
10211325|NCT04975438|Placebo Comparator|Group 2: Dupilumab inadequate responders receiving Placebo|
10211326|NCT04969250|Experimental|Group I1|Immediate, one dose. Vaccination at study entry
10211327|NCT04969250|Experimental|Group I2|Immediate, two doses. Vaccination at study entry and Week 4
10211328|NCT04969250|Experimental|Group D1|Deferred, one dose. Vaccination at Week 12 only
10211329|NCT04969250|Experimental|Group D2|Deferred, two doses. Vaccination at Week 12 and Week 16
9987016|NCT01408108|Active Comparator|Primary crural repair|Laparoscopic primary posterior crural repair
9987017|NCT01408121||African-American on clopidogrel|
9987018|NCT01408121||African-American on prasugrel|
9987019|NCT01408121||Caucasian on clopidogrel|
9987020|NCT01408121||Caucasian on prasugrel|
10211330|NCT04967287|Experimental|MyopiaX|MyopiaX treatment
10211331|NCT04967287|Sham Comparator|Sham|Sham comparator using the same device and components but without the actual treatment
9872941|NCT00315926|Experimental|Melatonin|
9872942|NCT00315926|Placebo Comparator|Placebo|
9872943|NCT00315991|Experimental|BGAT Intervention|Blood Glucose Awareness Training for Parents
9872944|NCT00315991|No Intervention|Control|Enter PDA data and complete questionnaires only. No intervention received.
9872945|NCT00316108|Experimental|Arm 1|
9872946|NCT00316134||Pts scheduled to remove pleural fluid|
9872947|NCT00316290|Experimental|1|Participants will receive integrated parent training.
9872948|NCT00316290|Active Comparator|2|Parents will receive behavioral parent training.
9872949|NCT00316316|Active Comparator|1|Participants will receive motivational interviewing plus exposure and response prevention
9872950|NCT00316316|Active Comparator|2|Participants will receive exposure and response prevention only
9872951|NCT00316563|Active Comparator|1|
9872952|NCT00316563|Placebo Comparator|2|
9872953|NCT00316745|Active Comparator|1|mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）
9872954|NCT00316745|Experimental|2|IRIS ( Irinotecan and S-1 ) → mFOLFOX6
9872955|NCT00316758|Experimental|1|
9872956|NCT00316797|Experimental|123-I INER|To assess 123-I INER
9872957|NCT00316810|Experimental|Campath|"Day 0: Before revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by Campath 30 mg i.v. infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose of Tacrolimus 0.05 - 0.1 mg/kg/d orally.~till Month 6: Aim at blood level of 12-15 ng/ml (try to prevent the Tacrolimus trough level falling below 12 ng/ml in the first 6 months).~Month 7-12: Maintain the Tacrolimus blood level at 6-12 ng/ml after 6 months."
9998307|NCT01516931|Placebo Comparator|venlafaxine alone|responders will be maintained on the same effective dose of venlafaxine for the entire duration of the RCT, unless they relapse and will have to exit the protocol and enter a naturalistic follow-up
9872958|NCT00316810|Active Comparator|ATG|"Day 0: Prior to revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by a single shot of a polyclonal antilymphocyte preparation. Tacrolimus will be given immediately after transplantation(0.05-0.1 mg/kg/d) orally. Preoperative loading dose MMF: 2 g orally.~From Day 1: Total initial daily dose of 0.05-0.1 mg/kg administered orally in 2 doses. Blood trough levels 12-15 ng/ml during the first 6 months and maintain blood levels 6-12 ng/ml after 6 months. Total daily dose of MMF is 2 g administered orally in 2 doses. Patients will receive Methylprednisolone 250 mg IV 12h post surgery and 125 mg of Methylprednisolone 24 h post transplantation.~Steroid taper (orally):~Day 2: 100 mg of Prednisolon Day 3: 80 mg of Prednisolon Day 4: 60 mg of Prednisolon Day 5: 40 mg of Prednisolon Day 6: 25 mg of Prednisolon Day 21: 20 mg of Prednisolon~Reduction by 5 mg in two week intervals/complete withdrawal by 3 months post-tx."
9872959|NCT00316836||Group 1|Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
9872960|NCT00316849|Experimental|Treatment (temsirolimus, temozolomide, radiation therapy)|GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9872961|NCT00316875|Experimental|Lapatinib Ditosylate and Doxil|
9872962|NCT00316953|Experimental|Stratum 1 (solid tumors)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9872963|NCT00316953|Experimental|Stratum 2 (leukemia)|Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.
9872964|NCT00316992|Experimental|Ramelteon 8 mg and Placebo|
9872965|NCT00317018|Other|Arm 1|Implementation Group
9872966|NCT00317018|No Intervention|Arm 2|Control Group
9872967|NCT00317031|Active Comparator|1|Acamprosate
9872968|NCT00317031|Active Comparator|2|Naltrexone
9872969|NCT00317031|Placebo Comparator|3|Placebo
9872970|NCT00317070|Active Comparator|DMSO|Intravesical installation
9872971|NCT00317070|Experimental|Cocktail|
9872972|NCT00317096|Active Comparator|FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The FCM combination comprised:~25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
10211332|NCT04963205|Experimental|Adjustable bed backrest|Sleeping in elevated body position (>30 degrees from supine position) for 4 weeks is a requirement for the intervention group. Patients can define their own most comfortable position during the night.
10211333|NCT04963205|Active Comparator|Usual bed|"Sleeping in a standard bed and flat (<30 degrees from supine position) position for 4 weeks. Patients can define their own most comfortable position during the night."
10211334|NCT04962776|Active Comparator|Low-concentration carbohydrate and nitrates group (CHON group )|
10211335|NCT04962776|Active Comparator|Low-concentration carbohydrate group (CHO group)|
9872973|NCT00317096|Experimental|R-FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The R-FCM combination comprised:~375 mg/m2 rituximab on the day before the respective FCM course. 25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
9872974|NCT00317096|Other|Observation only|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
9872975|NCT00317096|Other|rituximab maintenance|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~Courses of rituximab consisted of 4 doses of 375 mg/m2 per day given at 4 consecutive weeks.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
9872976|NCT00317135|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
9517882|NCT03302039|Active Comparator|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
9872977|NCT00317135|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
9872978|NCT00317135|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
9872979|NCT00317135|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
9872980|NCT00317148|Experimental|Placebo|
9872981|NCT00317148|Experimental|DHEA|
9872982|NCT00317187|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
9872983|NCT00317187|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
9872984|NCT00317187|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
9872985|NCT00317187|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
9872986|NCT00317200|Active Comparator|1|Paclitaxel + Devacizumab in patients with chemosensitive relapsed small cell lung cancer.
9872987|NCT00317252|Experimental|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
9872988|NCT00317252|Other|Continue ACE1 or ARB|Randomized to continue on prescribed ACE1 or ARB
9872989|NCT00317278|Experimental|A,1|Massage therapy
9872990|NCT00317278|Sham Comparator|A,2|
9872991|NCT00317291|Experimental|Acupuncture/Moxibustion|Acupuncture/Moxibustion for Peripheral Neuropathy in HIV
9872992|NCT00317291|Sham Comparator|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion for Peripheral Neuropathy in HIV
9872993|NCT00317304|Experimental|MBSR|
9872994|NCT00317382|No Intervention|No Ultrasound|Standard LP without ultrasound use
9872995|NCT00317382|Experimental|Ultrasound Use|Ultrasound used to assess spine and best location for lumbar puncture.
9872996|NCT00317460|Active Comparator|1|Physician Management
9998308|NCT01516944|Active Comparator|postoperative chemotherapy,SOX|
9872997|NCT00317460|Experimental|2|Physician Management and counseling (drug counseling and medication adherence)
9872998|NCT00317499|Experimental|Etanercept|
9872999|NCT00317499|Placebo Comparator|Placebo|
9873000|NCT00317512|Active Comparator|1|Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
9873001|NCT00317512|Active Comparator|2|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
9873002|NCT00317512|Experimental|3|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by HBOC-201 at 7.7 ml/min over 15 minutes
9873003|NCT00317629|Active Comparator|1|
9873004|NCT00317629|Experimental|2|
9928985|NCT00912548|Active Comparator|TAM(D) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 0, 6, 12, 18 and 24 months since the baseline asTsessment(0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. The latter will complete taking tamoxifen 20mg/day for 5 years.
9928986|NCT00912548|No Intervention|Permanent postmenopausal(A) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. Eligible patients except for premenopausal status at the baseline will be followed up until 2 years after the baseline assessment for evaluating the menopausal status. This group still remains to postmenopausal status and will taking tamoxifen 20mg/day for 5 years if they remain in the study.
9928987|NCT00912548|Active Comparator|TAM(B)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. This group, patients are premenopausal women, they will be randomized into tamoxifen only group, complete taking tamoxifen 20mg/day for 5 years.
9928988|NCT00912548|Experimental|TAM+OFS (C)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized. This group, patients are premenopausal women, they will be randomized into the additional ovarian function suppression group. Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. Then, Patients will complete taking tamoxifen 20mg/day for 5 years.
9928989|NCT00912561|No Intervention|Sedentary|patients who train after an 8 week observational period
9928990|NCT00912561|Active Comparator|patients who train immediately after enrollment|patients who train immediately after enrollment
9928991|NCT00912574|Active Comparator|Saline|first of 4 arms: injection: 1 ml saline
9873005|NCT00317707|Experimental|N-3 PUFA|
9873006|NCT00317707|Placebo Comparator|Olive oil|
9873007|NCT00317746|Placebo Comparator|Placebo|Placebo + PEG-interferon-alfa2b + ribavirin
9873008|NCT00317746|Experimental|Citalopram|Citalopram + PEG-interferon-alpha2b + ribavirin
9873009|NCT00317837|Active Comparator|1|Patients treated with a cemented modular hemiarthroplasty, with a unipolar head
9873010|NCT00317837|Active Comparator|2|Patients treated with a modular cemented hemiarthroplasty with a bipolar head.
9873011|NCT00317889|Experimental|Compaction|Compaction technique for femoral bone preparation prior to cementless femoral stem insertion.
9873012|NCT00317889|Active Comparator|Broaching|Broaching technique for femoral bone preparation prior to cementless femoral stem insertion.
9873013|NCT00317967|Experimental|1|Atorvastatin
9873014|NCT00317967|Placebo Comparator|2|Placebo
9873015|NCT00317980|Experimental|Low dose|Meglumine antimoniate 5 mg/kg/d for 20 days
9873016|NCT00317980|Active Comparator|Standard dose|Meglumine antimoniate 15 mg/kg/d for 20 days
9873017|NCT00318006|Active Comparator|Spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
9873018|NCT00318006|Experimental|Irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
9873019|NCT00318019|Experimental|OPC Factor(TM)|
9873020|NCT00318019|Placebo Comparator|Placebo|
9873021|NCT00318032|Other|Intensive Treatment|Frequent specialised diabetes clinician contact. DESMOND self-management programme
9873022|NCT00318071|Experimental|Treatment|Treatment arm patients had at least one Merci Retriever deployed
9873023|NCT00318097||MAS patients|patient with clinical diagnosis of MAS
9873024|NCT00318097||controls|age matched, tanner stage matched controls
9873025|NCT00318110|Experimental|MUD treatment|NST using MUD for metastatic renal cell carcinoma
9873026|NCT00318123|Experimental|A|Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD
9873027|NCT00318123|Experimental|B|Abacavir 600mg + lamivudine 300mg in ine tablet QD * lopinavir/ritonavir 400/100 mg BID
9873028|NCT00318188|Experimental|Intervention group|The patients in this group will do a personalized standardized rehabilitation program on the quality of life.
9873029|NCT00318188|No Intervention|Control group|Habitual care
9873030|NCT00318201|Experimental|1|Altered efficacy for drug to drug interaction of diltiazam with erythromycin
9873031|NCT00318227|Active Comparator|Liberal Red cell transfusion arm|Transfusion if Hgb <100g/L
9873032|NCT00318227|Active Comparator|Restrictive Red Cell transfusion|Transfusion if Hgb <70g/L
9873033|NCT00318240|Experimental|1|High Intensity Focused
9873034|NCT00318266||patients with suerficial transitional cell carcinoma|
9873035|NCT00318331|Active Comparator|A|Will receive enteral glutamine
9873036|NCT00318331|No Intervention|B|No enteral glutamine given
9873037|NCT00318383|Experimental|1|200 mcg NicVAX in each of 4 doses
9873038|NCT00318383|Experimental|2|200 mcg NicVAX in each of 5 doses
9873039|NCT00318383|Experimental|3|400 mcg NicVAX in each of 4 doses
9873040|NCT00318383|Experimental|4|400 mcg NicVAX in each of 5 doses
9873041|NCT00318383|Placebo Comparator|5|Placebo in 4 or 5 doses
9873042|NCT00318383|Experimental|6|200 mcg NicVAX formulation 2 in each of 5 doses
9873043|NCT00318396|Experimental|Compaction|The bone is pressed very hard together before implantation of femoral component.
9873044|NCT00318396|Active Comparator|Conventional technique|The bone is broached before implantation of femoral component.
9873045|NCT00318487|Experimental|Bilateral sinus augmentation|
9873046|NCT00318630|Experimental|Subjects receiving treatment 1|Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.
9873047|NCT00318630|Experimental|Subjects receiving treatment 2|Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
9873048|NCT00318695|Experimental|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
9873049|NCT00318695|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
9873050|NCT00318721|Experimental|Intervention|
9873051|NCT00318721|No Intervention|control|
9873052|NCT00318760|Experimental|ARM 1|
9873053|NCT00318760|Placebo Comparator|ARM 2|
9873054|NCT00318799|Experimental|Arm 1|
9873055|NCT00318799|Active Comparator|Arm 2|
9873056|NCT00318838|Placebo Comparator|1|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
9873057|NCT00318838|Experimental|2|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
9873058|NCT00318851|Experimental|Carotid Artery Stenting|
9873059|NCT00318877|Experimental|After school sports|After school team sports
9873060|NCT00318877|Active Comparator|Health and Nutrition Education|Health and Nutrition Education Active Placebo Control
9928992|NCT00912574|Active Comparator|GM-CSF|Second of 4 arms: injection: specified dose of GM-CSF in 1 ml saline
9998309|NCT01516944|Experimental|Perioperative chemotherapy,SOX|
9873061|NCT00318890|Experimental|Docetaxel + cisplatin followed by radiation|Docetaxel with cisplatin is given for three cycles, followed by concomitant therapy with weekly docetaxel for 4 weeks. Radiation therapy is given 5 days each week on Days 64-106 with a concomitant boost in the last 2 weeks of treatment. Amifostine is given as an injection on a daily basis during radiotherapy.
9873062|NCT00318903|Experimental|Taxotere/Irinotecan|Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
9873063|NCT00318942|Active Comparator|1|Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
9873064|NCT00318942|Experimental|2|Colloids, including albumin, gelatines, starch any other synthetic colloids
9873065|NCT00318955|Experimental|Dexmedetomidine group|
9873066|NCT00318955|Active Comparator|Propofol group|
9873067|NCT00319124||Case|Patients with hip Osteoarthritis
9873068|NCT00319124||Control|Healthy controls without hip osteoarthritis
9873069|NCT00319150|No Intervention|Standard of Care|Epo dose to remain constant throughout study
9873070|NCT00319150|Active Comparator|Dosage Decrease Arm|Arm 2 is to have an decrease of erythropoietin at regular intervals.
9873071|NCT00319202|Experimental|1|
9873072|NCT00319202|Placebo Comparator|2|
9873073|NCT00319228|Experimental|Antithrombin III|
9873074|NCT00319267|Experimental|Bosentan|The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
9873075|NCT00319280|Experimental|1|Minced Iliac Crest autograft in osteotomysite
9873076|NCT00319280|Experimental|2|Injectable calcium phosphate cement in osteotomysite
9873077|NCT00319280|Active Comparator|3|Local autograft in the osteotomysite serves as control
9928993|NCT00912574|Active Comparator|0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline|Third of 4 arms: injection: 0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline
9928994|NCT00912574|Active Comparator|GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant|Fourth of 4 arms: injection: specified dose of GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant
9928995|NCT00912600||1|Elderly individuals presenting to one of 15 emergency departments and possibly qualifying for admission to an ICU
9928996|NCT00912613|No Intervention|Discussion with nurse|Brief discussion with ICU follow-up nurse about the patients' critical illness
9928997|NCT00912613|Experimental|ICU Diary|Receipt of ICU Diary at 1 month post critical illness
9928998|NCT00912626|Experimental|FU-1 feedback|
9928999|NCT00912626|No Intervention|control group|
9929000|NCT00912639|Experimental|Genexol-PM|"All the patients are recurrent breast cancer after taxane treatment. Patients with a measurable lesion (at least 1 measurable lesion)~Spiral CT : lesion ≥ 10mm (unidimension)~X-ray, MRI, ultrasound : lesion ≥ 20 mm (unidimension)"
9929001|NCT00912652|Experimental|High Intensity Lifestyle Intervention|High intensity group will receive 48 sessions of lifestyle intervention over a two-year period
9929002|NCT00912652|Experimental|Mod. Intensity Lifestyle Intervention|Moderate intensity group will receive 32 sessions of lifestyle intervention over a two-year period.
9929003|NCT00912652|Experimental|Low Intensity Lifestyle Intervention|Low intensity group will receive 16 sessions of lifestyle intervention over a two-year period.
9929004|NCT00912652|Active Comparator|Health Education Control|Health education control group will receive 16 sessions of health education related to diet and exercise over a two-year period.
9929005|NCT00912665|Experimental|Healthy Volunteer|
9929006|NCT00912678|Active Comparator|MMF and Steroid Group|Group of Patients randomized to MMF and Steroid maintenance immunosuppression after 3 months (Tacrolimus withdrawal)
9929007|NCT00912678|Active Comparator|Low-Dose Tacrolimus Group|Patients randomized to withdrawal of MMF after 3 months and maintenance immunosuppression with low-dose tacrolimus and Steroids
9929008|NCT00912717||Pancreatic Cancer|individuals who have been diagnosed with pancreatic cancer
9929009|NCT00912717||Unaffected|individuals who have not been diagnosed with pancreatic cancer
9929010|NCT00912756|Experimental|1cilostazol|Cilostazol group: Treatment with cilostazol 200 mg/day BID (morning and evening) and aspirin at 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
9929011|NCT00912756|Active Comparator|2aspirin|Non-cilostazol group: Treatment with aspirin 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
9517642|NCT03304444|Active Comparator|Bupivacaine HCl in TAP block|"When performing a bilateral TAP with Bupivicaine 0.25% and the incision is below the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials).~When performing a bilateral TAP with Bupivicaine 0.25% and the incision extends above the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials). A 3rd vial of 30 ml 0.25% bupivacaine will be drawn up and is directly infiltrated into the surgical site (above and below the fascia prior to closure of fascia) extending above the umbilicus by the surgeon."
9929012|NCT00912769||subvastus approach/ midvastus approach|subvastus: vastus medialis oblique was not cut during operation midvastus: vastus medialis oblique was cut during operation
9929013|NCT00912769||Cybex|Knee extension/ flexion isometric and isokinetic performance of all cases were tested using Cybex
9929014|NCT00912821|Active Comparator|8 L dialysate|8 L peritoneal dialysis solution
9929015|NCT00912821|Experimental|6 L dialysate|6 L peritoneal dialysis solution
9929016|NCT00912834||1|tract and field athletes
9929017|NCT00912834||2|swimming athletes
9929018|NCT00912834||3|tennis athletes
9929019|NCT00912834||4|football athletes
9929020|NCT00912834||5|basketball athletes
9929021|NCT00912834||6|Badminton athletes
9929022|NCT00912834||7|control group
9873078|NCT00319358|Active Comparator|Antioxidants|Intervention was done with antioxidants
9873079|NCT00319358|Placebo Comparator|Placebo|
9873080|NCT00319371||1|women with vasospasm and difficulties of initiating sleep
9873081|NCT00319371||2|women without vasospasm and no difficulties of initiating sleep
9873082|NCT00319423|Active Comparator|Patient education|Patient education according to Klassbo et al 2003
9873083|NCT00319423|Experimental|Patient education and supervised exercise|Patient education according to Klassbo et al 2003. Supervised exercise containing strengthening, functional and flexibility exercises.
9873084|NCT00319488|Active Comparator|1|Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
9873085|NCT00319488|Active Comparator|2|Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
9873086|NCT00319488|Placebo Comparator|3|Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
9873087|NCT00319527||Observation|Living Kidney Donors with controls who have not donated a kidney or had certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
9873088|NCT00319657|Experimental|Immune tolerance, kidney transplantation|Intervention: Participants will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance in HLA-matched living donor kidney transplantation, to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
9873089|NCT00319826||1|Subjects with Staphylococcus Bacteremia
9873090|NCT00319826||2|Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
9873091|NCT00319852|Experimental|1|
9873092|NCT00319852|Active Comparator|2|
9873093|NCT00319878|Experimental|1|Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
9873094|NCT00319917|Experimental|1|
9873095|NCT00319917|Placebo Comparator|2|
9873096|NCT00320008|Active Comparator|Standard Treatment Arm|This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.
9873097|NCT00320008|Experimental|Intensive Treatment Arm|This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.
9873098|NCT00320047|Experimental|1|Participants will take baclofen for 10 weeks.
9873099|NCT00320073|Experimental|Arm A|Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam
9873100|NCT00320073|Experimental|Arm B|Vinflunine, Erlotinib, Ondansetron, Midazolam
9873101|NCT00320099|Active Comparator|1|Hydrocortisone and convention glycemic control
9873102|NCT00320099|Experimental|2|Hydrocortisone and fludrocortisone and conventional glucose control
9873103|NCT00320099|Experimental|3|Hydrocortisone and intensive insulin therapy
9873104|NCT00320099|Experimental|4|hydrocortisone, fludrocortisone and intensive insulin therapy
9873105|NCT00320125|No Intervention|1|Usual diet
9873106|NCT00320125|Active Comparator|2|Orange juice fortified with calcium
9873107|NCT00320125|Active Comparator|3|Dairy products
9873108|NCT00320138|Active Comparator|Acupuncture|
9873109|NCT00320138|No Intervention|Wait List|Usual Care
9873110|NCT00320164||Group A: Leukapheresis|Subject's peripheral blood mononuclear cells are collected via leukapheresis.
9873111|NCT00320164||Group B: Buffy Coats Collection|Subject's peripheral blood mononuclear cells are collected via the buffy coats from blood.
9873112|NCT00320359|Active Comparator|Arm A|Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
9873113|NCT00320359|Experimental|Arm B|Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
9873114|NCT00320567|Experimental|001|norgestimate/ethinyl estradiol
9873115|NCT00320580|Experimental|001|norelgestromin/ethinyl estradiol
9873116|NCT00320619|Experimental|1|Participants will receive either EACA.
9873117|NCT00320619|Placebo Comparator|2|Participants will receive placebo.
9873118|NCT00320658|Experimental|A|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
9873119|NCT00320658|Experimental|B|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
9873120|NCT00320658|Experimental|C|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
9929023|NCT00912847||JHC|AFP > 20 ng/ml and USG positive
9929024|NCT00912847||Non JHC|patient without AFP > 20 or USG negative
9929025|NCT00912860|Experimental|1|serum-free avonex given IM
9796321|NCT01563081|Experimental|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution
9796322|NCT01563172|Experimental|Experimental dentifrice 0.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
9796323|NCT01563172|Experimental|Experimental dentifrice 1.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
9796324|NCT01563172|Experimental|Experimental dentifrice 0.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
9796325|NCT01563172|Experimental|Experimental dentifrice 1.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
9796326|NCT01563172|Active Comparator|Contol group|Participants brush twice a daily for 2 minutes with controll dentifrice.
9796327|NCT01563185|Experimental|DUEXIS|800 mg ibuprofen/26.6 mg famotidine
9796328|NCT01563198|Experimental|Comfort Talk® Training|The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests
9796329|NCT01563237|Experimental|MIDI Arrow|Implantation of MIDI Arrow
9796330|NCT01563354|Experimental|Pasireotide LAR|Pasireotide long acting release (LAR) 60 mg will be administered as an intra muscular (i.m.) depot injection once every 28 days starting on Day 1
9796331|NCT01563354|Experimental|Everolimus|Everolimus 10 mg taken orally (p.o) once daily starting on Day 1
9796332|NCT01563354|Experimental|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily starting on Day 1
9796333|NCT01563406|Experimental|Alcohol with 5 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
9796334|NCT01563406|Experimental|Alcohol with 15 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
9796335|NCT01563406|Experimental|Chlorhexidine with 5 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
9796336|NCT01563406|Experimental|Chlorhexidine with 15 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
9796337|NCT01563536|Experimental|ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
9796338|NCT01563536|Experimental|ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
9796339|NCT01563913|Experimental|Arm 1|Docosahexaenoic Acid (DHA)
9796340|NCT01563913|Placebo Comparator|Arm 2|Placebo
9796341|NCT01563978|Experimental|Dosing Regimen A|Oral treatment
9796342|NCT01563978|Placebo Comparator|Dosing Regimen B|Oral treatment
9796343|NCT01564277|Experimental|Arm I (1.5mg rasburicase)|Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
9796344|NCT01564277|Experimental|Arm II (3 mg rasburicase)|Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
9796345|NCT01564394|Experimental|Qigong|Qigong originated in China hundreds of years ago and has been practiced for centuries. It consists of a sequence of slow, flowing physical movements with concentration on the breath and awareness and may promote physical and mental relaxation and energy balance.
9796346|NCT01564394|Sham Comparator|Stretching control|The non-aerobic stretching will serve as an attention control group to control for non-specific factors; dose of attention and to mimic being in a group setting.
9796347|NCT01564407|Experimental|Safety Cohort|"Stable restrictive scar contractures resulting from abdominal surgical incision, not transversing a joint. The minimum scar length of 7 cm and a maximum scar area size of 80cm². The scar is divided into five injection areas with a minimum of 0.5 cm uninjected areas between the 5 sites.Drug Dosing for Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4 Subjects in Cohort 1 will undergo elective surgeries, at which time the treated scars will be removed, at week 6-8 post-treatment of the first dosed subject."
9796348|NCT01564407|Active Comparator|2.5M cells/cm2|Participants receive intervention treatment of 2.5 million cells/ cm2, single administration injected into the scar.
9796349|NCT01564407|Active Comparator|5M cells/cm2|Participants receive intervention treatment of 5 million cells /cm2, single administration
9796350|NCT01564407|Active Comparator|2.5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 2.5 million cells/ cm2, repeat dose administration @ 4 weeks
9796351|NCT01564407|Active Comparator|5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 5 million cells / cm2 repeat dose administration @ 4 weeks
9796352|NCT01564459|Experimental|MK-6096 10 mg→MK-6096 10 mg|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period.
9796353|NCT01564459|Placebo Comparator|MK-6096→Placebo|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.
9796354|NCT01564485|Experimental|Cardiac CT|Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
9796355|NCT01564485|Active Comparator|Usual Care|Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
9929026|NCT00912886||1: Case|Patients with early and moderate AD
9929027|NCT00912886||2: Controls|AD free volunteer-controls matched for gender and age
9929028|NCT00912899|Experimental|One|Noscapine HCl
9929029|NCT00912938|Experimental|Zoledronic acid|Patients with advanced breast cancer with radiographic confirmation of bone metastases. This arm will be receiving zoledronic acid administration. The primary endpoint is to find the correlation between bone turnover markers and the frequency of skeletal-related-events for one year. Skeletal related events are defined as pathologic fractures, the need for radiation therapy, orthopaedic surgery, hypercalcemia of malignancy and spinal cord compression. A total of 237 patients will be included.
9929030|NCT00912977||Group 1|Groups are defined by another study
9929031|NCT00912977||Group 2|Groups are defined by another study
9929032|NCT00912977||Group 3|Groups are defined by another study
9929033|NCT00913016||letrozole (Femara)|
9929034|NCT00913029|Active Comparator|Stent|One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
9929035|NCT00913029|Active Comparator|Medication|One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.
9929036|NCT00913042||1|febrile neutropenia patient
9929037|NCT00913055|Experimental|One hydrated 84mg Octreotide implant|hydrated implant
9929038|NCT00913055|Experimental|One non-hydrated 84mg Octreotide implant|
9929039|NCT00913094||ICG|Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
9929040|NCT00913107|Experimental|Lamictal®|"Lamictal® was used as the active medication in this study."
9929041|NCT00913107|Active Comparator|Tegretol®|"Tegretol® was employed as the control for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®."
9929042|NCT00913120|Experimental|YM150 group-1|YM150 low dose group
9929043|NCT00913120|Experimental|YM150 group-2|YM150 high dose group
9929044|NCT00913120|Placebo Comparator|Placebo group|
9929045|NCT00913120|Active Comparator|Enoxaparin group|
9929046|NCT00913146||index|child with fever and a negative malaria RDT
9929047|NCT00913146||control|apparently healthy child with a negative RDT
9929048|NCT00913159|Active Comparator|Using HM3 lithotripter|This is an older generation lithotripter
9929049|NCT00913159|Active Comparator|F2 lithotripter|This is a newer generation lithotripter
9929050|NCT00913172||Intervention group|Directly Observed Treatment under Health Extension Workers
9929051|NCT00913172||Control group|Directly observed treatment under general health workers
9929052|NCT00913198|Experimental|IV CP-4126|
9929053|NCT00913211|Experimental|rTMS only|brain stimulation to non-stroke primary motor area
9929054|NCT00913211|Experimental|Finger tracking training|Motor learning training using finger flexion/extension tracking movements toward a target.
9929055|NCT00913211|Experimental|rTMS and finger tracking|Combination of rTMS and tracking
9929056|NCT00913211|Placebo Comparator|Sham|Sham rTMS treatment
9929057|NCT00913224|Experimental|1|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
9929058|NCT00913224|Active Comparator|2|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)
9929059|NCT00913237|Experimental|1|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
9929060|NCT00913237|Active Comparator|2|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
9929061|NCT00913250|Experimental|Sequence 1|Serum containing Avonex followed by serum free Avonex
9929062|NCT00913250|Experimental|Sequence 2|Serum free Avonex followed by serum containing Avonex
9929063|NCT00913276|Other|Sevoflurane anesthesia|
9929064|NCT00913276|Other|Propofol anesthesia|
9929065|NCT00913289|Other|adipose tissue derived stromal cells|
9929066|NCT00913302|Experimental|Training|cardiovascular training
9929067|NCT00913315|Experimental|tolterodine + tamsulosin|
9929068|NCT00913315|Active Comparator|tamsulosin + placebo|
9929069|NCT00913328|Active Comparator|Montelukast|Oral montelukast 10 mg once daily for 12 weeks
9929070|NCT00913328|Placebo Comparator|Placebo|Oral placebo once daily for 12 weeks
9929071|NCT00913341|Experimental|1|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
9929072|NCT00913341|Active Comparator|2|Alprazolam Tablets, 1 mg (The Upjohn Company)
9929073|NCT00913354|Experimental|1|30 minutes of acupuncture just before and just after embryo replacement
9929074|NCT00913354|Placebo Comparator|2|Sham acupuncture for 30 minutes just before and just after embryo transfer
9935919|NCT02987959|Experimental|TAK-228 treatment|Patients with complex genomic sarcomas exhibiting PI3K pathway dysregulation will be treated with TAK-228
9935920|NCT02985541|Experimental|Levonorgestrel IUS (Mirena, BAY86-5028)|Mirena during extended use (Years 6 to 8).
9935921|NCT02979873|Experimental|Sirolimus|sirolimus
9873121|NCT00320658|Experimental|D|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.
9873122|NCT00320684||1|Women who have had anorexia nervosa but are now maintaining a healthy weight
9873123|NCT00320684||2|Women who have never had anorexia nervosa and are maintaining a healthy weight
9873124|NCT00320697|Other|Bupropion + Nicotine patch + Nicotine gum or lozenges|Open label phase All enrolled subjects received weekly CBT group sessions, bupropion 300 mg/daily (if medically eligible), nicotine patch 21 mg/day, and up to 20 mg/day of nicotine gum or lozenge for prn use. Subjects set a quit date between weeks 3 and 4; a ½ hour individual CBT session to help prepare them for the quit date. The open phase groups consisted of 8 weekly CBT meetings.
9873125|NCT00320697|Active Comparator|Bupropion + Nicotine Patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial.Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
9873126|NCT00320697|Placebo Comparator|Placebo pill + placebo patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial. Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
9873127|NCT00320775|Experimental|Part A|Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).
9873128|NCT00320775|Active Comparator|Part B|Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
9873129|NCT00320775|Active Comparator|Part C|Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.
9873130|NCT00320814|Experimental|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
9873131|NCT00321074|Active Comparator|1|
9873132|NCT00321074|Experimental|2|
9873133|NCT00321087|Experimental|1|T2000 dose escalation
9873134|NCT00321087|Experimental|2|Placebo followed by T2000 dose escalation
9873135|NCT00321087|Experimental|3|Placebo followed by T2000 dose escalation
9873136|NCT00321113|Active Comparator|1|oral
9873137|NCT00321113|Experimental|2|oral
9873138|NCT00321152|Experimental|1|Deplin/Deplin = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
9873139|NCT00321152|Experimental|2|placebo/Deplin = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
9873140|NCT00321152|Placebo Comparator|3|placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
9873141|NCT00321178|Experimental|SR4/CR4|after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
9873142|NCT00321178|Active Comparator|SR8|standard treatment consisting of 8 weeks of streptomycin and rifampicin
9873143|NCT00321191|Experimental|N2O|
9873144|NCT00321191|Placebo Comparator|No N2O|
9929075|NCT00913367|Active Comparator|Amaryl group|
9929076|NCT00913367|Experimental|Amaryl M group|
9929077|NCT00913406|Experimental|1|Experimental=Standard formula with lutein added to the formula
9929078|NCT00913406|Active Comparator|2|Active Comparator=Standard formula
9929079|NCT00913419|Experimental|1|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
9929080|NCT00913419|Active Comparator|2|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
9929081|NCT00913432|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day
9929082|NCT00913432|Experimental|masitinib 6 mg|masitinib 6 mg/kg/day
9929083|NCT00913445|Active Comparator|surgery, absorbable stitches|wound healing after absorbable and nonabsorbable stitches are compared
9929084|NCT00913445|Active Comparator|surgery, nonabsorbable stitches|
9929085|NCT00913471||Acute-Longitudinal SCI|
9929086|NCT00913471||Chronic SCI|
9929087|NCT00913471||Healthy volunteers|
9929088|NCT00913484|Experimental|Disulfiram|Disulfiram 250 mg per day
9929089|NCT00913484|Placebo Comparator|Placebo|Placebo
9873145|NCT00321334|Active Comparator|Docetexel|Chemotherapy+Surgery
9873146|NCT00321451|Experimental|1|
9873147|NCT00321451|Sham Comparator|2|
9873148|NCT00321451|Active Comparator|3|
9873149|NCT00321516|Experimental|1|
9873150|NCT00321659|Experimental|Aerobic and flexibility exercise|16 weeks of aerobic and flexibility exercise. Three days per week for 1 hour of walking and cycling.
9873151|NCT00321659|Experimental|Strength, aerobic, and flexibility|16 weeks of strength training, aerobic, and flexibility exercise (ST) intervention;
9873152|NCT00321659|Experimental|Fibromyalgia Self-Help Course|7 weeks of FSHC behavior change education
9873153|NCT00321659|Experimental|a Combination of ST and FSHC|16 wks of a combination of ST and FSHC (ST-FSHC) exercise and behavior change education
9873154|NCT00321724|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9873155|NCT00321802|Experimental|1|Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
9873156|NCT00321802|Placebo Comparator|2|Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.
9873157|NCT00321867|Active Comparator|1|Native tissue repair
9873158|NCT00321867|Experimental|2|Posterior repair with graft
9873159|NCT00322010|Experimental|Early PT OT|Early PT/OT Therapy assessments to begin on the first day that consent is obtained. Therapy is delivered by a team consisting of a physical and occupational therapist and coordinated with daily sedative interruption.
9873160|NCT00322010|No Intervention|Standard Care|PT/OT delivered as ordered by the primary ICU team
9873161|NCT00322036|Experimental|1|Oral 800 mg BID dosing
9873162|NCT00322036|Placebo Comparator|2|Oral BID dosing
9873163|NCT00322062|Experimental|1|"1 pack (contains 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets)= 2L NRL994 . 2 sachets (one of each) will be dissolved in 1L of water. Each litre will be drunk within 1 hour. Furthermore, at least 1000ml (or more) of any additional clear fluid (except milk) has to be drunk after the 2L of NRL994."
9873164|NCT00322062|Active Comparator|2|1 pack consists of 2 flasks of 45ml. Each flask has to be dissolved within 125ml of water. Each intake of NaP solution has to be preceded and followed by 250ml (or more if necessary)of clear liquids(excluding milk)and a delay of at least 12 hours between the intake of the 2 x 45ml of NaP solution has to be completed. In addition, 750ml more of clear liquids (excluding milk)or more if needed must be drunk between the 2 intakes.
9873165|NCT00322114|Experimental|Arm I|Participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks.
9873166|NCT00322114|Experimental|Arm II|Participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks.
9873167|NCT00322114|Placebo Comparator|Arm III|Participants receive oral placebo twice daily for 3 weeks.
9873168|NCT00322127|Experimental|1|AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
9873169|NCT00322127|Experimental|2|AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
9873170|NCT00322127|Experimental|3|AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
9873171|NCT00322127|Experimental|4|randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.
9873172|NCT00322166|Active Comparator|Group A, Sunlight|Participants in this arm are required to sit in the sun most days of the week for 15 minutes
9873173|NCT00322166|Active Comparator|Group B, sunlight and calcium|Participants in this group receive sunlight and a calcium supplement
9873174|NCT00322166|No Intervention|Group C|Control group
9873175|NCT00322179||Obese|
9873176|NCT00322179||Non-Obese|
9873177|NCT00322283|Experimental|Oglemilast|
9873178|NCT00322283|Placebo Comparator|Placebo|
9873179|NCT00322322|Experimental|1|L-Carnitine
9873180|NCT00322361|Experimental|1|Modified Process Hepatitis B Vaccine
9873181|NCT00322361|Active Comparator|2|Recombivax HB™
9873182|NCT00322400|Experimental|B1|AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
9873183|NCT00322400|Experimental|A4|75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days)
9873184|NCT00322400|Experimental|A1|AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days)
9873185|NCT00322400|Experimental|B4|75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days)
9873186|NCT00322400|Experimental|B5|MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days)
9873187|NCT00322400|Experimental|B3|100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days)
9873188|NCT00322400|Experimental|B2|AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
9873189|NCT00322400|Experimental|A2|AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days
9796356|NCT01564628||All study participants|Population from 2 sites, sequential design with all patients undergoing CADScor1 intervention followed by the diagnostic testing the patients were referred to (procedure done according to standard of care and not part of study; computerized tomographic angiography (CTA) and, if relevant, coronary angiography (CAG) at Site 1 and CAG at site 2).
9796357|NCT01564654||iTotal KRS|
10211336|NCT04962776|Placebo Comparator|W group|
10211337|NCT04955327|Experimental|A. Paniculata150 mg|Extract from Andrographis Paniculata
9796358|NCT01564693||ANOREXIC CANCER PATIENTS|Nine lung cancer patients were diagnosed as anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
9796359|NCT01564693||NON-ANOREXIC CANCER PATIENTS|Four lung cancer patients were diagnosed as non-anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
9796360|NCT01564693||CONTROL GROUP|Two healthy volunteers with normal appetite were studied by fMRI regarding the hypothalamic activity.
10211338|NCT04955327|Experimental|A. Chilensis 300 mg|Extract from A. Chilensis
9796361|NCT01564706|Experimental|Healthy Volunteers|Healthy male or female subjects, between 18 and 85 years of age.
9796362|NCT01564758||Group 1|Subjects that are diagnosed with gram positive infection
9796363|NCT01564784|Experimental|Arm A|
9796364|NCT01564784|Active Comparator|Arm B|
9796365|NCT01564862|Experimental|Vortioxetine (Lu AA21004) QD|Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
9796366|NCT01564862|Active Comparator|Duloxetine QD|Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
9796367|NCT01564862|Placebo Comparator|Placebo QD|Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
9796368|NCT01564914|Experimental|TRC105, Bevacizumab|Single arm study
9796369|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m^2) followed by 30-35 mg/m^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
9796370|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
9796371|NCT01565148|Experimental|Group 1|"Drug: iCo-007 350 mcg~iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4"
9796372|NCT01565148|Experimental|Group 2|"Drug: iCo-007 700 mcg~iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4"
9796373|NCT01565148|Experimental|Group 3|"Drug: iCo-007 350 mcg and Laser~iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation"
9796374|NCT01565148|Experimental|Group 4|"Drug: Ranibizumab and iCo-007 350 mcg~Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later"
9796375|NCT01565291|Experimental|Subjects With AD|Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
9796376|NCT01565291|Experimental|Healthy Elderly Subjects|Cognitively normal with MMSE of 29 or higher; age 50 years or older
9796377|NCT01565330|Experimental|111 MBq (3 mCi) AD Group|Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel
9796378|NCT01565330|Experimental|111 MBq (3 mCi) Control Group|Healthy controls who received 111MBq (3 mCi) of florbetapir F 18
9796379|NCT01565330|Experimental|370 MBq (10 mCi) AD Group|Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18
10211339|NCT04955327|Experimental|A. Panicluata 150 mg + A. Chilensis 300 mg.|combination of extract of A. Paniculata and A. Chilensis
10211340|NCT04955327|Placebo Comparator|Microcrystalline Cellulose +/-450 mg|Comparator
10211341|NCT04952077|Experimental|Experimental|
10211342|NCT04950257|Active Comparator|waiting list control group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination after a 6-week wait.
10211343|NCT04950257|Experimental|treatment group|Participants randomly allocated to this arm will be offered self-help components within a mobile phone app to target worry and rumination immediately.
9987021|NCT01408160|Experimental|Treatment (Combotox, cytarabine)|Patients receive high-dose cytarabine IV over 2-3 hours every 12 hours on days 1-3 and deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins IV over 4 hours on days 8, 10, and 12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9998310|NCT01516944|Experimental|Perioperative chemotherapy,XELOX|
9796380|NCT01565330|Experimental|370 MBq (10 mCi) Control Group|Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.
9796381|NCT01565343|Experimental|AD Subjects|Two bolus IV injections followed by brain PET scan up to 4 weeks apart
9873190|NCT00322400|Experimental|A3|100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
9796382|NCT01565343|Experimental|AD Subjects: Slow vs. Fast Bolus|"Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.~The first injection given as a rapid bolus (< 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration)."
9796383|NCT01565343|Experimental|Healthy controls|Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart
9796384|NCT01565499|Experimental|Nab-Paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
9796385|NCT01565538|Experimental|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression.
9796386|NCT01565538|Experimental|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.
9796387|NCT01565551||Early-Presenting TBI: Acute Sites|This cohort of patients are studied after acute presentation within 24 hours of TBI to one of the three TRACK-TBI acute Level I Trauma Centers (SFGH, UPMC, UMCB).
9796388|NCT01565551||Late-Presenting TBI: Rehabilitation Center|This cohort of patients are studied after presentation to the TRACK-TBI rehabilitation site (MSMC).
9796389|NCT01565564|Active Comparator|The usual care arm|
9796390|NCT01565564|Active Comparator|The shared care arm|
9796391|NCT01565616|Experimental|Bone Marrow Transplant Recipients|Adults with sickle cell disease undergoing a bone marrow transplant from an HLA-identical sibling donor or an unrelated HLA-matched donor.
9796392|NCT01565642|Experimental|Decision support intervention|Decision aid and care plan meeting
9796393|NCT01565642|No Intervention|Control|Attention control information on dementia care
9796394|NCT01565668|Experimental|AC220 Dose Level 1|
9796395|NCT01565668|Experimental|AC220 Dose Level 2|
9796396|NCT01565694|Experimental|Solifenacin succinate|"Participants aged 5 years to < 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52)."
9796397|NCT01565707|Placebo Comparator|Placebo Children|Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
9796398|NCT01565707|Experimental|Solifenacin Succinate Suspension Children|Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
9796399|NCT01565707|Placebo Comparator|Placebo Adolescents|Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
9796400|NCT01565707|Placebo Comparator|Solifenacin Succinate Suspension Adolescents|Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
9796401|NCT01565850|Experimental|D/C/F/TAF|D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
9796402|NCT01565850|Active Comparator|DRV+COBI+FTC/TDF|DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
9796403|NCT01565889|Experimental|Part A: SOF+EFV/FTC/TDF (Cohort 1)|Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
9796404|NCT01565889|Experimental|Part A: SOF+EFV+ZDV/3TC (Cohort 2)|Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
9796405|NCT01565889|Experimental|Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3)|Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
9873191|NCT00322478|Other|GlucoMON-ADMS enabled|Patients who are equipped with the automated technology vs. standard/conventional care
9873192|NCT00322530|Active Comparator|SLED|
9873193|NCT00322530|Active Comparator|CVVHD|
9873194|NCT00322543|Experimental|Drug eluting stent|Corio™ Pimecrolimus-eluting stent
9873195|NCT00322569|Experimental|1|Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
9873196|NCT00322569|Experimental|2|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
9873197|NCT00322569|Active Comparator|Control Arm|Costar ™ Paclitaxel-Eluting Coronary Stent System
9873198|NCT00322608|Experimental|Dose escalation|
9873199|NCT00322686|Experimental|Oglemilast followed by placebo|
9873200|NCT00322686|Experimental|Placebo followed by Oglemilast|
9873201|NCT00322699|Experimental|A single arm, non-randomized Phase II Study|Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
9873202|NCT00322946|Experimental|1|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^5 PFU dose) into the deltoid region of either arm.
9873203|NCT00322946|Experimental|2|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
9873204|NCT00322946|Experimental|3|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
9873205|NCT00322946|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
9873206|NCT00322972|Other|A|Annual mass treatment
9873207|NCT00322972|Other|B|Biannual mass treatment
9873208|NCT00322972|Experimental|C|Mass administration of antibiotic; treatment of children (1-10 years of age) only
9873209|NCT00322972|No Intervention|D|Delayed initiation of mass administration of antibiotic
9873210|NCT00322972|Other|F|One-time mass administration only
9873211|NCT00322972|Experimental|G|One-time mass administration of antibiotics, plus intensive latrine construction
9873212|NCT00323011|Active Comparator|Arm A: 5-FU/LV/CPT-11/Bevacizumab|5-FU 400 mg/m2, days 1, 15, & 29 Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29
9873213|NCT00323011|Experimental|Arm B: 5-FU/LV/CPT-11/Bevacizumab + Dalteparin|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, days 1, 15, & 29
9873214|NCT00323011|Experimental|5-FU/LV/CPT-11/Bevacizumab+Dalteparin daily|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, daily
9873215|NCT00323076|Experimental|1|18F-FAZA PET Imaging
9873216|NCT00323089|Experimental|Surgical Arm|Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)
9873217|NCT00323141|Active Comparator|Ventralex|
9873218|NCT00323141|Active Comparator|Leight Weight Vypro II prothesis|
9873219|NCT00323206|Experimental|Intra-tumoral Electroporation of pIL-12|Participants will receive intra-tumoral injection of pIL-12 followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid DNA into tumor cells. For each lesion selected for therapy, a total of three electroporation treatments will be performed.
9873220|NCT00323323|Experimental|Alemtuzumab/CHOP|For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
9873221|NCT00323375|Experimental|AQ-13 (Investigational 4-Aminoquinoline)|Arm: Experimental: AQ-13 AQ-13 capsules with 350 mg AQ-13 base per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
9873222|NCT00323375|Active Comparator|CQ (Chloroquine)|Arm: Active Comparator: CQ CQ Capsules with 300 mg CQ base per capsule per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
9929090|NCT00913497|Active Comparator|insulin glulisine|
9929091|NCT00913497|Active Comparator|insulin aspart|
9929092|NCT00913536|Experimental|Cone beam CT in Bladder Cancer|
9929093|NCT00913549|Experimental|1|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
9929094|NCT00913549|Experimental|2|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
9929095|NCT00913562|Active Comparator|Patients with diabetes|Rosuvastatin
9873223|NCT00323401|Experimental|Interventon|Antenatal classes for the parents
9873224|NCT00323401|No Intervention|Control|No programme are offered
9873225|NCT00323440||Group 1|FMF patients in remission
9873226|NCT00323440||Group 2|FMF patients during attack
9873227|NCT00323440||Group 3|FMF patients without colchicine in remission
9873228|NCT00323440||Group 4|FMF patients without colchicine in attack
9873229|NCT00323466|Experimental|IMRT|
9873230|NCT00323531|Active Comparator|1|Video assisted thoracoscopic decortication
9873231|NCT00323531|Experimental|2|Fibrinolysis through the chest tube
9873232|NCT00323648|Experimental|postoperatively antibiotics|
9873233|NCT00323661|Experimental|1|Rate-adaptation by Closed Loop Stimulation
9873234|NCT00323661|Active Comparator|2|Accelerometer based pacing rate adaptation
9873235|NCT00323674|Active Comparator|Light Weight Mesh|
9873236|NCT00323674|Active Comparator|Polysoft Mesh|
9873237|NCT00323713|Experimental|VLPD diet|Adavnced CKD patients (stage 4-5) on a very low protein diet
9873238|NCT00323713|Active Comparator|LPD diet|Adavnced CKD patients (stage 4-5) on a low protein diet
9873239|NCT00323804|Experimental|Randomised PegIFN alfa 2b + ribavirin (RBV) arm|Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
9873240|NCT00323804|Placebo Comparator|Randomised PegIFN alfa 2b + ribavirin-placebo arm|Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
9873241|NCT00323830|Experimental|capecitabine/cisplatin/radiotherapy|postoperative XP/RT
9873242|NCT00323830|Active Comparator|capecitabine/cisplatin|postoperative XP
9873243|NCT00323856|Experimental|Coagulation factor VIII (Human)|Anti-Hemophilic coagulation factor VIII (Human) Alphanate SD/HT
9873244|NCT00323895|Experimental|1|group with intra-Cypher™ restenosis
9873245|NCT00323895|Active Comparator|2|group with intra-Taxus™ restenosis
9873246|NCT00323895|Active Comparator|3|group with intra-BMS restenosis
9873247|NCT00323908||1|Women at high risk for developing breast cancer
9873248|NCT00323934|Experimental|1|MGCD0103 Oral 2 times weekly
9873249|NCT00323947|Active Comparator|1|Participants will take OROS-MPH then switch to placebo
9873250|NCT00323947|Placebo Comparator|2|Participants will take placebo then switch to OROS-MPH
9873251|NCT00323973|Experimental|1|
9873252|NCT00323973|Placebo Comparator|2|Placebo
9873253|NCT00324012|Experimental|treatment|taxotere and cisplatin day one every three weeks
9873254|NCT00324025|Experimental|1|Mycograb
9873255|NCT00324025|Active Comparator|2|biological
9873256|NCT00324129|Experimental|1|
9873257|NCT00324194|Experimental|1|MGCD0103 oral dose 2 times per week.
9873258|NCT00324311|Experimental|DGD|
9873259|NCT00324311|Active Comparator|SOC|
9873260|NCT00324324|Active Comparator|moxifloxacin hydrochloride|Moxifloxacin 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
9873261|NCT00324324|Placebo Comparator|Sugar pill|Placebo 1 capsule orally once a day through D+100 after bone marrow transplant, then discontinue
9873262|NCT00324363|Experimental|Exenatide|Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
9873263|NCT00324363|Placebo Comparator|Placebo|Placebo in volume equal to exenatide
9873264|NCT00324402||1|Healthy pregnant women, 18-40
9873265|NCT00324428|Experimental|Transcranial Magnetic Stimulation (TMS)|This arm provides active 1Hz repetitive TMS (rTMS) applied to SII
9873266|NCT00324428|Sham Comparator|Transcranial Magnetic Stimulation Sham|This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII
9929096|NCT00913562|Active Comparator|Patients with glaucoma|Rosuvastatin
9929097|NCT00913562|Placebo Comparator|Control patients with diabetes|Placebo
9929098|NCT00913562|Placebo Comparator|Control patients with glaucoma|Placebo
9929099|NCT00913575|Experimental|preoperative neuromuscular training|preoperative neuromuscular training
9929100|NCT00913575|Placebo Comparator|education|knee school
9873267|NCT00324467|Active Comparator|R-CHOP (Negative Mid-Treatment PET Scan)|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a negative mid-treatment PET scan (no evidence of abnormal 18F-FDG uptake) will complete therapy with two additional cycles of R-CHOP for a total of 6 cycles of chemotherapy. Patients with a mid-treatment PET scan interpreted to be indeterminate or equivocal will be recorded as such, but should be considered negative for the purpose of treatment planning and should not prompt a change in therapy."
9873268|NCT00324467|Active Comparator|R-ICE (Positive Mid-Treatment PET Scan|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a mid-treatment PET scan (abnormal 18F-FDG uptake) will be switched to R-ICE chemotherapy and receive 4 cycles of R-ICE for a total of 8 cycles of chemotherapy.~Following completion of R-ICE chemotherapy, patients will undergo a post-treatment PET scan along with routine restaging investigations. The post-treatment PET scan will be performed between days 28 and 35 following the final cycle of R-ICE. Patients with a negative post-treatment PET scan will undergo no further therapy. Patients with a positive post-treatment PET scan corresponding to persistent abnormalities on CT scan will be considered for radiation therapy to PET positive sites."
9873269|NCT00324480|Experimental|Treatment (chemotherapy, enzyme inhibitor)|Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib IV over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9873270|NCT00324506|Active Comparator|Cellcept and Avonex|
9873271|NCT00324519|Active Comparator|Misoprostol Drug|This is the misoprostol drug.
9873272|NCT00324519|Experimental|The Foley Bulb|This is the experimental portion to test the Foley Bulb.
9873273|NCT00324558|Experimental|1|Bemiparin 3,500 IU
9873274|NCT00324558|No Intervention|Control|
9873275|NCT00324623|Experimental|Lymphodepletion, vaccine, IMP321 adjuvant|
9873276|NCT00324727|Experimental|Arm I|"Patients undergo an isolated hepatic arterial infusion of melphalan over 30 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response undergo 2 additional courses~in the absence of ongoing or increasing toxicity."
9873277|NCT00324727|Active Comparator|Arm II|"Patients receive the best alternative therapy comprising supportive care, systemic or regional chemotherapy, hepatic artery (chemo)-embolization, or any other appropriate therapy at the National Cancer Institute or therapy at the discretion of their physician.~Patients may cross over to arm I if they have evidence of disease progression."
9873278|NCT00324766|Active Comparator|1|levosimendan
9873279|NCT00324766|Placebo Comparator|2|Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
9873280|NCT00324922|Active Comparator|1|trimethoprim-sulfamethoxazole
9873281|NCT00324922|Active Comparator|2|vancomycin
9873282|NCT00324974|Experimental|Lansoprazole QD|
9873283|NCT00324974|Placebo Comparator|Placebo QD|
9873284|NCT00325013|Experimental|II|
9873285|NCT00325182|Experimental|Intervention: Levetiracetam|Levetiracetam dose schedule Days 1-4 250 mg bid Days 5- 19 500 mg bid Days 20 -70 1000 mg bid Days 71-78 500 mg bid Days 79-85 250 mg bid Days 86-91
9873286|NCT00325182|Placebo Comparator|Historical controls|Historical controls from COMBINE study who receive a placebo
9873287|NCT00325221|Experimental|Home Monitoring On|Home Monitoring activated after implantation (Intervention HM On)
9873288|NCT00325221|Experimental|Home Monitoring Off|Home Monitoring activated 9 months after implantation (Intervention HM Off)
9873289|NCT00325273|Experimental|probiotics & allergy|"To understand the preventive effect of probiotics in neonatal peroid~To investate the possible mechanism"
9873290|NCT00325286|Experimental|1|Treatment with lithium and extended release carbamazepine
9929101|NCT00913588|Experimental|1|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
9929102|NCT00913588|Experimental|2|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
9929103|NCT00913588|Active Comparator|3|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
9873291|NCT00325351|Experimental|Arm 1|
9873292|NCT00325494|Experimental|Cohort 1|MORAb-009 weekly dose of 12.5 mg/m^2
9873293|NCT00325494|Experimental|Cohort 2|MORAb-009 weekly dose of 25 mg/m^2
9873294|NCT00325494|Experimental|Cohort 3|MORAb-009 weekly dose of 50 mg/m^2
9873295|NCT00325494|Experimental|Cohort 4|MORAb-009 weekly dose of 100 mg/m^2
9873296|NCT00325494|Experimental|Cohort 5|MORAb-009 weekly dose of 200 mg/m^2
9873297|NCT00325494|Experimental|Cohort 6|MORAb-009 weekly dose of 400 mg/m^2
9873298|NCT00325520||Anorexia nervosa|Individuals with anorexia nervosa receiving inpatient treatment
9873299|NCT00325520||Healthy controls|
9873300|NCT00325533|Experimental|Screening & Enhanced Intervention|After an intensive 10-week baselne screening, the enhanced intervention group barbers will be trained to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit.
9873301|NCT00325533|Active Comparator|Screening|After the intensive 10-week baseline BP screening (an intervention in itself), the barbershops in the comparison arm received a continual supply of American Heart Association pamphlets on Hypertension in African Americans.
9873302|NCT00325637|Active Comparator|A,1,III|To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke
9873303|NCT00325689|Active Comparator|Quetiapine or Risperidone + Aripiprazole|
9873304|NCT00325689|Placebo Comparator|Quetiapine or Risperidone + placebo|
9873305|NCT00325715|Experimental|1|
9873306|NCT00325715|Active Comparator|2|
9873307|NCT00325728|Experimental|Ramelteon 8 mg QD|
9873308|NCT00325728|Placebo Comparator|Placebo|
9873309|NCT00325936|Active Comparator|Nifedipine|parrallel design
9873310|NCT00325936|Experimental|Cilnidipine|
9873311|NCT00325949|Experimental|arm label (1) hydrocodone/acetaminophen extended release|
9873312|NCT00325949|Experimental|arm label (2) hydrocodone/acetaminophen extended release|
9873313|NCT00325949|Placebo Comparator|Arm label (3) placebo|
9873314|NCT00326014|Experimental|A|
9873315|NCT00326027|Active Comparator|1|Pantoprazole 20 mg
9873316|NCT00326027|Active Comparator|2|Pantoprazole 40 mg
9873317|NCT00326040|Experimental|A|
9873318|NCT00326066|Active Comparator|1|
9873319|NCT00326066|Placebo Comparator|2|
9873320|NCT00326079|Active Comparator|1|
9873321|NCT00326079|Active Comparator|2|
9873322|NCT00326157|Experimental|1|AmBisome® will be administered for a duration of 8 weeks
9873323|NCT00326222|Experimental|1|Lifestyle counseling
9873324|NCT00326222|No Intervention|2|Usual care
9873325|NCT00326248|Experimental|Arm 1|
9873326|NCT00326339|Experimental|1|R788 50 mg PO bid
9873327|NCT00326339|Experimental|2|R788 100 mg PO bid
9873328|NCT00326339|Experimental|3|R788 150 mg PO bid
9873329|NCT00326339|Placebo Comparator|4|Placebo PO bid
9873330|NCT00326378|Active Comparator|CCRT arm without consolidation chemotherapy|Docetaxel 20mg/m2 & Cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy
9873331|NCT00326378|Experimental|CCRT arm with consolidation chemotherapy|docetaxel 20mg/m2 & cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy, and followed by consolidation chemotherapy with 3-weekly docetaxel 35mg/m2 & cisplatin 35mg/m2 (D1,8) every 3 weeks (#3).
9873332|NCT00326404|Experimental|1|
9873333|NCT00326404|Active Comparator|2|
9873334|NCT00326443|Experimental|1|14 subjects Oral CVD 909 with buffer on Day 0. Parental Vi polysaccharide vaccine on Day 21.
9873335|NCT00326443|Placebo Comparator|2|14 subjects oral buffer placebo. Parental Vi polysaccharide vaccine on Day 21.
9873336|NCT00326456|Experimental|carboplatin and liposomal doxorubicin|
9873337|NCT00326456|Active Comparator|carboplatin and paclitaxel|
9873338|NCT00326469|Experimental|1|
9873339|NCT00326534||Controls|Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy
9873340|NCT00326534||Sarcoidosis patients|Patients with newly diagnosed sarcoidosis
9873341|NCT00326586|Experimental|1|
9873342|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks.~3DCRT 7800 cGY/39 Fractions/ STD Technique*~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
9873343|NCT00326638|Experimental|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks.~IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16"
9873344|NCT00326664|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
9873345|NCT00326820|Experimental|Ibandronic Acid|50mg tablet once daily over 96 weeks
9873346|NCT00326820|Active Comparator|Zoledronic Acid|4 mg via intravenous infusion (iv) over a minimum of 15 minutes in at least 100mls of saline every 4 weeks over 96 weeks
9873347|NCT00326976|Experimental|1|400 mg injected in 2 divided boluses
9873348|NCT00326976|Placebo Comparator|2|Matching placebo
9873349|NCT00326989|Active Comparator|Low-dose shock wave treatment & Placebo|
9873350|NCT00326989|Active Comparator|low-dose shock-wave treatment & Cell therapy|
9873351|NCT00326989|Active Comparator|High-dose shock-wave treatment & Placebo|
9873352|NCT00326989|Active Comparator|High-dose shock-wave treatment & cell therapy|
9873353|NCT00326989|Active Comparator|Placebo shock-wave treatment & cell therapy|
9873354|NCT00327054|Experimental|Nigella sativa seed|
9873355|NCT00327054|No Intervention|Control|
9873356|NCT00327093|Experimental|1|Bevacizumab
9873357|NCT00327093|Experimental|2|Cetuximab
9873358|NCT00327106|Active Comparator|1|Exacyl
9873359|NCT00327106|Placebo Comparator|2|Physiologic serum
9929104|NCT00913601|Experimental|Dextra|Unilateral sacral nerve stimulation dextra for 4 weeks
9873360|NCT00327132|Experimental|Experimental Arm|
9873361|NCT00327184|Experimental|Group Hib-MenC|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
9873362|NCT00327184|Active Comparator|Group NeisVac-C|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.
9873363|NCT00327197|Experimental|Intermittent mild steroid-naïve asthmatic group|Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 >=80% and normal peak expiratory flow between attacks will be included.
9873364|NCT00327197|Experimental|Mild to moderate persistent asthmatic group|Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 >= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
9873365|NCT00327197|Experimental|Severe asthma group|Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS >=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1<80% and FEV1/FVC ratio <70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of >= twice a year in at least one of the last two years.
9873366|NCT00327197|Placebo Comparator|Healthy subjects group|Non-asthmatic and non-smokers with FEV1 > 85% predicted, on no regular medication.
9873367|NCT00327210|Experimental|BGATHome|Blood Glucose Awareness Training at Home Internet Intervention
9873368|NCT00327210|No Intervention|Control|No intervention
9873369|NCT00327223|Experimental|imexon|Dose escalation of imexon
9873370|NCT00327288|Experimental|A|Docetaxel plus imexon
9873371|NCT00327379|Experimental|Arm 1|
9873372|NCT00327379|Placebo Comparator|Arm 2|
9873373|NCT00327509||1-HTG|high tension glaucoma highest IOP > 21 mmHg
9873374|NCT00327509||2-NTG|normal tension glaucoma highest measured IOP < 21 mmHg
9873375|NCT00327509||3-PEX|pseudoexfoliation glaucoma PEX material visible
9873376|NCT00327509||4-Juvenile|juvenile glaucoma
9873377|NCT00327509||5-Control1|healthy subjects (age group 1)
9873378|NCT00327509||6-Control2|healthy subjects (age group 2)
9873379|NCT00327535|Experimental|Mircera 6.3 micrograms/kg|
9873380|NCT00327535|Experimental|Mircera 9 micrograms/kg|
9873381|NCT00327535|Experimental|Mircera 12 micrograms/kg|
9873382|NCT00327535|Active Comparator|Darbepoetin alfa|
9873383|NCT00327600|Experimental|imexon + DTIC|
9873384|NCT00327665|Experimental|Group A|
9873385|NCT00327665|Experimental|Group B|
9873386|NCT00327665|Experimental|Group C|
9873387|NCT00327665|Active Comparator|Group D|
9873388|NCT00327665|Active Comparator|Group E|
9873389|NCT00327704|Active Comparator|Albumin|
9873390|NCT00327704|Placebo Comparator|Saline|
9873391|NCT00327769|Active Comparator|1|Anastrozole
9873392|NCT00327769|Experimental|2|Anastrozole + Fulvestrant
9873393|NCT00327808|Experimental|Inhaler|TPI 1020
9873394|NCT00327808|Active Comparator|Inhaler cortico.|Budesonide inhaler
9873395|NCT00327873|Experimental|A|Oxygen
9873396|NCT00327873|Active Comparator|B|Medical Air
9873397|NCT00327912|Experimental|1|Laparoscopic Biliopancreatic diversion with Duodenal switch
9873398|NCT00327912|Active Comparator|2|Laparoscopic Roux-en-Y Gastric Bypass
9873399|NCT00327964||study population|601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.
9873400|NCT00328068||Back pain / peripheral arthritis|Patients with chronic back pain of unknown origin and onset of back pain <45 years of age or patients with peripheral arthritis / enthesitis / dactylitis of unknown origin and onset <45 years of age
9873401|NCT00328107|Experimental|Low Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
9873402|NCT00328107|Experimental|Full Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
9873403|NCT00328107|Placebo Comparator|Placebo|0.9% Sodium Chloride
9873404|NCT00328146||Observation of Sternal Re-entry|All subjects.
9873405|NCT00328211|Experimental|Bile Acid|To assess the role of bile acid pool size changes on cholesterol absorption, synthesis and intralumenal cholesterol solubilization.
9873406|NCT00328211|Experimental|Cholesterol Absorption|To determine whether cholesterol absorption, synthesis and solubilization will be significantly altered by changes in phospholipid content, specifically sphingolipids and phosphatidylcholine in the intestinal lumen.
10211344|NCT04947917|Experimental|Lymph Node SpotTM Tattoo|"Spot™ ink tattooing will be administered once prior to surgery.~Initial test set of participants with previous sampled lymph nodes positive for metastasis will have SpotTM ink administered at time of standard of care pre-surgery radioseed localization.~A feasibility set of participants will have SpotTM ink administered at time standard of care lymph nodes sampling."
9873407|NCT00328211|Experimental|Intralumenal|To assess intralumenal solubilization and absorption of biliary and dietary cholesterol.
9873408|NCT00328250|Experimental|1|Participants will receive the online CBT intervention immediately and will use the online program for 8 weeks
9873409|NCT00328250|Active Comparator|2|Participants will receive the online CBT intervention after a 4-month waiting period
9873410|NCT00328367|Experimental|A|clozapine plus aripiprazole
9873411|NCT00328367|Placebo Comparator|B|clozapine plus placebo
9873412|NCT00328393|Active Comparator|Pioglitazone|Pioglitazone 45 mg, 8 weeks
9873413|NCT00328393|Placebo Comparator|Placebo|Placebo
9873414|NCT00328419|Experimental|1|photoprotected parenteral nutrition
9873415|NCT00328419|Active Comparator|2|Non-photoprotected parenteral nutrition
9873416|NCT00328445|No Intervention|Control|Business as usual
9873417|NCT00328445|Experimental|Treatment|Positive Action
9873418|NCT00328458|Experimental|Cohort 1 Brain Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
9873419|NCT00328458|Experimental|Cohort 2 Head and Neck Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
9873420|NCT00328484|Experimental|1|Eleven month lifestyle activity program
9873421|NCT00328484|Active Comparator|2|Three month exercise program
9873422|NCT00328497|Experimental|1|Panzem NCD will be dosed orally at a level of 1,000 mg, four times daily for 28 consecutive days and bevacizumab will be administered at a dose of 5 mg/kg as an intravenous bolus on Day 1 and Day 15 of the Treatment Period
9873423|NCT00328575|Experimental|Intensity-Modulated Radiotherapy (IMRT)|Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
9873424|NCT00328588|Experimental|1|7 days continuous infusion
9873425|NCT00328679|Experimental|A|
9873426|NCT00328692|Experimental|2|
9873427|NCT00328692|Placebo Comparator|1|
9929105|NCT00913601|Experimental|Sinistra|Unilateral sacral nerve stimulation sinistra 4 weeks
9929106|NCT00913601|Experimental|Bilateral|Bilateral sacral nerve stimulation 4 weeks
9929107|NCT00913614|Experimental|Age Group 6-11 year old - Dose level 1|
9929108|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 2|
9929109|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 3|
9929110|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 1|
9929111|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 2|
9929112|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 3|
9929113|NCT00913640||PD Group|
9929114|NCT00913640||Control Group|
9929115|NCT00913653|Experimental|Stable heart failure patients|
9929116|NCT00913666|No Intervention|Group 1|Healthy Volunteers
9929117|NCT00913666|Experimental|Group 2|MS patients previously naïve to interferon therapy
9929118|NCT00913666|Experimental|Group 3|MS patients on Interferon beta-1a treatment with no history of breakthrough disease (clinically stable)
9929119|NCT00913666|Experimental|Group 4|MS patients on interferon beta-1a treatment with a history of breakthrough disease.
9929120|NCT00913679|Active Comparator|Posterior approach|Posterior surgical approach in hip resurfacing arthroplasty
9929121|NCT00913679|Active Comparator|Anterolateral approach|Anterolateral surgical approach in hip resurfacing arthroplasty
9929122|NCT00913705|Experimental|1|The patients will be randomized to receive taxol (Paclitaxel) and carboplatin as adjuvant or as neoadjuvant regimen or to surgery alone
9929123|NCT00913718|Experimental|1|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
10211345|NCT04936724|Experimental|Condition A (Lesser-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting lesser-known harms of tobacco use.
10211346|NCT04936724|Experimental|Condition B (Well-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting the well-known harms of tobacco use.
10211347|NCT04936477|Experimental|Assessment of alveolar surface area by functional morphometry|Non-invasive measurements of V/Q
10211348|NCT04930315|Experimental|neoadjuvant and adjuvant group|Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles
10211349|NCT04930315|Active Comparator|adjuvant group|Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 12 cycles
9929124|NCT00913718|Active Comparator|2|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
9929125|NCT00913731||psychotic patients|psychotic patients, acute ward, symptom rating scale.
9929126|NCT00913757||Group 1|400 patients with primary HCC (Hepatocellular carcinoma)
9929127|NCT00913757||Group 2|800 patients with chronic liver disease (high risk non-cancer cases)
9929128|NCT00913757||Group 3|800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency
9929129|NCT00913783|Experimental|1|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
9935922|NCT02979873|No Intervention|Standard of Care|no intervention
10211350|NCT04922502|Active Comparator|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
9987022|NCT01408173|Experimental|NPC-11|"Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.~Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists."
9987023|NCT01408186|Active Comparator|Rabeprazole|Tablet 20mg daily for 12 months
9987024|NCT01408186|Active Comparator|Famotidine|Tablet 40mg daily for 12 months
9987025|NCT01408199|Experimental|Lenalidomide Group|
9987026|NCT01408212|Experimental|Acupuncture therapy|
9987027|NCT01408238|Experimental|1|"Secale cereale allergen extract at 4 different concentrations~Positive control~Negative control"
9987028|NCT01408264|Active Comparator|0.035 guidewire|conventional 0.035 guidewire
9987029|NCT01408264|Active Comparator|Olympus Visiglide 0.025 guidewire|Olympus Visiglide 0.025
9987030|NCT01408290|Experimental|FAB-6011|- One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 2A/ and 32 subjects aged over 60 years /Group 2E/).
9987031|NCT01408290|Experimental|FAB-9011|- One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 3A/ and 32 subjects aged over 60 years/Group 3E/).
9987032|NCT01408290|Experimental|FLUVALAB|- One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 4A/ and 32 subjects aged over 60 years/Group 4E/).
9987033|NCT01408290|Experimental|FAB-3511|- One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 1A/ and 32 subjects aged over 60 years /Group 1E/).
9987034|NCT01408316|Experimental|Part 1 (Crystalline vs. Amorphous)|Volunteers in part 1 of the study will initially receive either crystalline PX-866 tablets or amorphous PX-866 capsules, then after seven days, the same volunteers will respectively cross-over to receive the alternate amorphous PX-866 capsules or crystalline PX-866 tablets.
9987035|NCT01408316|Experimental|Part 2 (Crystalline Food Effect)|Volunteers in part 2 of the study will receive two single dose treatments of PX-866 crystalline tablets initially administered in either fed or fasted state, then after at least seven days, the same volunteers will respectively cross-over to receive PX-866 tablets in the alternate fed or fasted state.
9987036|NCT01408342|Other|Rituximab, Alemtuzumab|
9987037|NCT01408355|Experimental|50 microgram PF-06273588 intravenous|Subjects will receive a single intravenous microdose of PF-06273588 in period one
9987038|NCT01408355|Experimental|50 microgram PF-06273588 oral|Subjects will receive a single oral microdose of PF-06273588 in period two
9987039|NCT01408368|Active Comparator|Bilateral subtotal thyroidectomy|
9987040|NCT01408368|Experimental|Total thyroidectomy|
9987041|NCT01408381|No Intervention|Control|No cell therapy
9987042|NCT01408381|Experimental|Low dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
9987043|NCT01408381|Experimental|Intermediate dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
9987044|NCT01408381|Experimental|High dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
9987045|NCT01408394|Active Comparator|100 mg immediate release form|This is the formulation currently in use
9873428|NCT00328744|Experimental|1|Behavioral: Behavioral weight loss (Standard)
9873429|NCT00328744|Experimental|2|Behavioral: Behavioral weight loss (Limited Variety)
9873430|NCT00328809|Experimental|Spirnolactone|
9873431|NCT00328822|Experimental|A|Quetiapine
9873432|NCT00328822|Placebo Comparator|B|Placebo
9873433|NCT00328848|Experimental|Intervention care management|post dischsrge care management by a nurse care manager who performs in-home vistis and reports to a interdisciplinary team. Team generates care recommendations based on patient goals. PCP and care manager implement the care plan that is based on patient goals. Includes education, behavioral interventions, and coaching.
9873434|NCT00328874|Placebo Comparator|Placebo|
9873435|NCT00328874|Active Comparator|Coenzyme Q10|
9873436|NCT00328887|Experimental|CD40 Gene Transfer|Recruitment will be random from the referral base of the investigators from the popula¬tion of individuals with esophageal cancer defined by the protocol inclu¬sion/exclusion criteria.
9873437|NCT00328965|Other|Lacidipine|All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.
9873438|NCT00329004|Experimental|1|
9873439|NCT00329017||1|Post-menopausal women who are at increased risk for development of breast cancer on the basis of family or personal history.
9873440|NCT00329056|Experimental|1|40 mg MitoQ OD
9873441|NCT00329056|Experimental|2|80 mg MitoQ OD
9873442|NCT00329056|Placebo Comparator|3|Placebo
9873443|NCT00329342|Experimental|1|
9873444|NCT00329342|No Intervention|2|
9873445|NCT00329381|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
9873446|NCT00329381|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
9873447|NCT00329459|Experimental|arm 1|Treximet (sumatriptan/naproxen sodium)
9873448|NCT00329459|Placebo Comparator|arm 2|placebo to match
9873449|NCT00329472|Experimental|Gem/Cis|neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
9517883|NCT03302039|Active Comparator|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
9873450|NCT00329472|No Intervention|no neoadjuvant chemotherapy|
9873451|NCT00329511|Active Comparator|A|methyldopa
9873452|NCT00329511|Active Comparator|B|clonidine patch
9873453|NCT00329537|Experimental|Arm 1|
9873454|NCT00329537|Placebo Comparator|Arm 2|
9873455|NCT00329563|Experimental|Cold fluid|
9873456|NCT00329563|No Intervention|control, standard of care|
9873457|NCT00329589|Experimental|CNS|Velcade (bortezomib)
9873458|NCT00329589|Experimental|Head and Neck|Velcade (bortezomib)
9873459|NCT00329589|Experimental|Cervix|Velcade (bortezomib)
9873460|NCT00329628|Experimental|Arm 1|
9873461|NCT00329628|Active Comparator|Arm 2|
9873462|NCT00329654|Experimental|Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation.
9873463|NCT00329680|Experimental|1|Experimental arm will receive an enteral diet enriched with EPA, GLA and Antioxidant vitamins
9873464|NCT00329680|Placebo Comparator|2|"This arm will receive an enteral diet considered as a standard ICU diet, isocaloric to the control diet but not enhanced with EPA, GLA and antioxidant vitamins"
9987046|NCT01408394|Experimental|90 mg controlled release|This is the low dose of the controlled release form
9987047|NCT01408394|Experimental|180 mg controlled release form|This is the medium controlled release dose
9987048|NCT01408407|Active Comparator|Arm A: standard of care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment
9987049|NCT01408407|Experimental|Arm B: standard of care plus Alkagin paste|Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.
9987050|NCT01408420|No Intervention|Standard blood pressure|Extracorporeal circulation during the surgery are conducted using standard blood pressure
9987051|NCT01408420|Active Comparator|MAP > 60 mmHg|A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
9796406|NCT01565889|Experimental|Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4)|Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
9987052|NCT01408433|Other|Single Embryo Transfer|Patients will have a single, chromosomally normal embryo transferred.
9987053|NCT01408433|Other|Double Embryo Transfer|Patients will have two (2) untested embryos transferred.
9987054|NCT01408446|Active Comparator|Menthol|Interventions Drug: Menthol Arms: Group 1
9987055|NCT01408446|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
9987056|NCT01408472|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye.
9987057|NCT01408498|No Intervention|Placebo Control|Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
9987058|NCT01408498|Experimental|Testosterone administration group|Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
9987059|NCT01408511|Experimental|Arm 1|
9987060|NCT01408524|Active Comparator|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
9987061|NCT01408524|Active Comparator|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
9987062|NCT01408550|Active Comparator|NPB-01|Active Comparator: 1 Intravenous immunoglobulin
9987063|NCT01408550|Placebo Comparator|Placebo|Placebo Comparator: 2 Physiological saline
9987064|NCT01408589|Placebo Comparator|Sugar Pill|
9987065|NCT01408589|Experimental|Atomoxetine 40 mg|
9987066|NCT01408589|Experimental|Atomoxetine 60 mg|
9987067|NCT01408589|Experimental|Atomoxetine 80 mg|
9987068|NCT01408602|Experimental|MRC375 75 mg|MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
9987069|NCT01408602|Experimental|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
9987070|NCT01408602|Placebo Comparator|Placebo|Placebo
9987071|NCT01408654|Experimental|Peer Companionship|Behavioral intervention: Receipt of peer companionship provided by trained, supervised volunteer companions.
9987072|NCT01408654|No Intervention|Care-as-Usual|Care-as-Usual in Primary Care
9987073|NCT01408667|Placebo Comparator|Placebo|
9987074|NCT01408667|Active Comparator|TRC150094|
9987075|NCT01408680|Active Comparator|Coenzyme Q10 600 mg|
9987076|NCT01408680|Active Comparator|Coenzyme Q10 1200 mg|
9987077|NCT01408680|Placebo Comparator|Placebo|
9987078|NCT01408693|Active Comparator|Anterior minimal invasive approach, AMIS|AMIS in 95 randomized patients.
9987079|NCT01408693|Active Comparator|Trans-gluteal approach, CLAS|CLAS in 95 randomized patients.
9987080|NCT01408745|Experimental|Sternumfix|sternotomy closure with Sternumfix
9987081|NCT01408745|Active Comparator|Steel wire|sternotomy closure with steel wire
9987082|NCT01408758|Other|VCRT|This group will have 2 visits with a study physician in addition to using the VCRT.
9987083|NCT01408758|Other|no VCRT|This group will have 2 visits with study physician only, no VCRT.
9987084|NCT01408797|Experimental|Donor specific transfusion|Subjects with uremia will undergo donor specific transfusion before transplantation
9987085|NCT01408797|Experimental|Clonal deletion|
9987086|NCT01408797|Experimental|Drugs Added When Needed|
9987087|NCT01408810|Experimental|Infliximab|Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
9987088|NCT01408823||Idiopathic Scoliosis|
9987089|NCT01408823||Non-idiopathic Scoliosis|
9987090|NCT01408836|Experimental|1|Plasma exchange x 7 over 14 days
9987091|NCT01408836|Active Comparator|2|Methyl prednisolone 1g x 3
9987092|NCT01408849|Experimental|Maytenus|Tea of Martens ilicifolia leaves
9987093|NCT01408849|Active Comparator|Omeprazole|Omeprazole as active comparator
9987094|NCT01408875|Experimental|Rehabilitation and EMS Group|Patient Heart Failure who follows physical training and sessions of electrical quadricipital myostimulation.
9987095|NCT01408875|No Intervention|Rehabilitation Group only|Patient Heart Failure who follows physical training
9987096|NCT01408953|Experimental|bevacizumab for all patients|This is a single arm trial. All patients receive treatment with bevacizumab.
9987097|NCT01408966|Experimental|DarkChocolate|11 patients were randomized to receiving dark chocolate 0.55 g/kg of body weight (Lindt Excellence 85% Cocoa, Lindt & Sprüngli España) together with the test meal
9987098|NCT01408966|Placebo Comparator|White chocolate supplementation|11 patients received 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight.
9987099|NCT01408979|Experimental|12 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 12 hours after delivery
9987100|NCT01408979|Active Comparator|24 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 24 hours after delivery
9987101|NCT01409005|Experimental|Gemcitabine plus UFTE|Gemcitabine plus UFTE chemotherapy (Single arm)
9987102|NCT01409018|Experimental|Itraconazole|
9873465|NCT00329693|Placebo Comparator|1|Daily Tablets Dosing
9873466|NCT00329693|Experimental|2|Daily Tablets Dose
10211351|NCT04922502|Active Comparator|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
9873467|NCT00329693|Experimental|3|Daily Tablets Dosing
9873468|NCT00329693|Experimental|4|Daily Tablets Dosing
9873469|NCT00329706|Experimental|1|Experimental arm will have an immediate release of the PET report
9873470|NCT00329706|Active Comparator|2|Active Comparator arm will have a delayed release of 2 years
9873471|NCT00329758|Active Comparator|1|
9873472|NCT00329758|Placebo Comparator|2|
9873473|NCT00329810|Experimental|Switch|
9873474|NCT00329914|Placebo Comparator|Placebo|
9873475|NCT00329914|Active Comparator|Progesterone|
9873476|NCT00329940|Experimental|Letrozole|to evaluate the rheumatological tolerability of Femara
9873477|NCT00329979||1|Radial access
9873478|NCT00329979||2|Femoral access
9873479|NCT00329992|Experimental|Treatment group|16 sessions Brief Eclectic Psychotherapy
9873480|NCT00329992|Placebo Comparator|Control group|Minimal attention waitlist group
9873481|NCT00330018|Experimental|1|PO Valganciclovir
9873482|NCT00330018|Active Comparator|2|PO Acyclovir
9873483|NCT00330044|Experimental|Drug|Carboplatin and Pemetrexed
9873484|NCT00330096|Experimental|Hesperidin-rich food|
9873485|NCT00330096|Placebo Comparator|No intervention: Placebo|
9873486|NCT00330135|Experimental|1|Sodium hyaluronate 2.5 ml - 1 injection
9873487|NCT00330135|Placebo Comparator|2|Placebo injection - 1 injection
9873488|NCT00330226||Psychopharmacotherapy|patients under antipsychotic or mood stabilizer treatment
9873489|NCT00330252|Experimental|Alemtuzumab & Rituximab|"Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)"
9873490|NCT00330265|Experimental|1|KC-002
10211352|NCT04921007|Active Comparator|Group (A) Sacral ESP block|Ultrasound guided sacral erector spinae plane (ESP) block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
9873491|NCT00330265|Other|2|Conventional Wound Therapy
10211353|NCT04921007|Active Comparator|Group (B) Caudal block|Ultrasound guided caudal block will be performed in the lateral position under sterile conditions, and bupivacaine will be administered.
10211354|NCT04920994|Active Comparator|Group A (M-TAPA )|Ultrasound-guided M-TAPA block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
10211355|NCT04920994|Active Comparator|Group B (SCTAP)|Ultrasound-guided SCTAP block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
9873492|NCT00330304|Experimental|Isoniazid preventive therapy|HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
9873493|NCT00330304|Placebo Comparator|Placebo|HIV infected children living in a high TB prevalence area receive placebo once daily
9873494|NCT00330317|Experimental|Letrozole|
9873495|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
9873496|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
9873497|NCT00330447||Studygroup|Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy
9873498|NCT00330447||Control group|Children from the general population
9873499|NCT00330499|Experimental|A|Synchronous chemo / radiation therapy
9873500|NCT00330499|Active Comparator|B|Radiation Alone
9929130|NCT00913783|Active Comparator|2|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
9929131|NCT00913796|Experimental|Postassium citrate|Aim: correction of metabolic acidosis
9929132|NCT00913796|Active Comparator|Potassium chloride|Potassium chloride is given to compensate for any possible effects of potassium in potassium citrate (primary treatment).
9929133|NCT00913809|Experimental|1|Desipramine HCL 100 mg Tablets Cord Laboratories
9929134|NCT00913809|Active Comparator|2|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
9929135|NCT00913822|Experimental|1|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
9929136|NCT00913822|Active Comparator|2|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
9929137|NCT00913848|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
9929138|NCT00913848|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
9929139|NCT00913861|Active Comparator|standard sedation|propofol and fentanyl
9929140|NCT00913861|Active Comparator|structured attention-standard sedation|structured attention
9929141|NCT00913861|Experimental|hypnosis-standard sedation|hypnosis
9929142|NCT00913874|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
9929143|NCT00913874|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
9929144|NCT00913887|Experimental|1|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
9929145|NCT00913887|Experimental|2|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
9929146|NCT00913887|Active Comparator|3|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
9929147|NCT00913900|Active Comparator|Autologous Stem cells (CD133+)|Intramuscular injection
9929148|NCT00913900|Placebo Comparator|Control|Intramuscular Injection
9929149|NCT00913926||Group 1|
9929150|NCT00913939|Active Comparator|1: Salvage After EBRT|Patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C).
9873501|NCT00330629|Active Comparator|Standard Behavioral Treatment|"Goal setting: daily/weekly goals for calorie and fat consumption, exercise time, and behavior change.~Self-monitoring: systematically observing and recording one's behavior,45,46 which will be reviewed by the therapists, and written feedback will be provided to reinforce positive behaviors.~Feedback: therapists monitor the recorded behavior changes and provide feedback/encouragement."
9873502|NCT00330629|Active Comparator|SBT+LOV Group|In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
9873503|NCT00330694|Experimental|I|Implementation of ParkNet within 8 regions
9873504|NCT00330694|Other|II|Usual Care in 8 regions
9873505|NCT00330746|Experimental|A|cetuximab and gemcitabine combination
9873506|NCT00330746|Experimental|B|gemcitabine followed by cetuximab (sequential)
9873507|NCT00330798|Experimental|Nevanac|One drop, three times daily, in the assigned eye for the first three postoperative days
9873508|NCT00330798|Placebo Comparator|Acular LS|One drop, three times daily, in the assigned eye for the first three postoperative days
9873509|NCT00330824|Experimental|antibiotic steroid (single vial)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
9873510|NCT00330824|Active Comparator|antibiotic / steroid (2 vials)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
9873511|NCT00330902|Active Comparator|1|Sulfadoxine pyrimethamine plus three daily doses of artesunate
9873512|NCT00330902|Experimental|2|Sulfadoxine pyrimethamine plus artesunate plus primaquine
9873513|NCT00330980|Experimental|1|Participants will receive 20 mg of simvastatin for 6 months.
9873514|NCT00330980|Experimental|2|Participants will receive 40 mg of pravastatin for 6 months.
9873515|NCT00330980|Placebo Comparator|3|Participants will receive placebo for 6 months.
9873516|NCT00331032|Experimental|1: 3% w/w SPL7013 Gel|40 subjects VivaGel™.
9873517|NCT00331032|Placebo Comparator|2: Placebo|20 subjects placebo.
9873518|NCT00331045|Placebo Comparator|Placebo|
9873519|NCT00331045|Experimental|Alvimopan 0.25 mg/yday|
9873520|NCT00331045|Experimental|Alviompan 0.5 mg/day|
9873521|NCT00331045|Experimental|Alvimopan 1 mg/day|
9873522|NCT00331058|Other|healthy volunteers|control group not receiving prednisolone
9873523|NCT00331058|Other|asthmatic volunteers|receive prednisolone for 14-16 days
9873524|NCT00331071||001|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE worn for 1 week and replaced for 3 consecutive weeks fourth week is patch free
9873525|NCT00331071||002|Monophasic or triphasic Oral contraceptive tablet 35 mcg EE for 21 consecutive days followed by no or drug-free tablet for 7 days
9873526|NCT00331084|Experimental|antibiotic steroid drops/single vial|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
9873527|NCT00331084|Active Comparator|antibiotic steroids drops|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
9873528|NCT00331097|Active Comparator|A|Standard chemotherapy with CMF
9873529|NCT00331097|Experimental|B|Weekly docetaxel
9873530|NCT00331123|Placebo Comparator|Placebo|Placebo patch
9873531|NCT00331123|Experimental|Testosterone Patch|
9873532|NCT00331214|Sham Comparator|Placebo|placebo patch for 6 months
9873533|NCT00331214|Experimental|Testosterone|Testosterone patch
9873534|NCT00331279|Active Comparator|Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
9873535|NCT00331279|Placebo Comparator|Placebo|
9873536|NCT00331435|Active Comparator|1|FA-guided PDT
9873537|NCT00331435|Experimental|2|ICG-guided PDT
9873538|NCT00331487|Experimental|Pioglitazone QD|
9873539|NCT00331487|Active Comparator|Rosiglitazone QD|
9873540|NCT00331500|Experimental|Olopatadine Hydrochloride 0.2%|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks
9873541|NCT00331500|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks
9873542|NCT00331513|Active Comparator|Arm I (vorinostat, idarubicin)|Patients receive oral SAHA three times daily on days 1-14 and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
9873543|NCT00331513|Active Comparator|Arm II (vorinostat, idarubicin)|Patients receive oral SAHA three times daily and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
9873544|NCT00331565|Experimental|Surgery|Bariatric surgery
9873545|NCT00331604|Experimental|A|
9873546|NCT00331604|Active Comparator|B|
9873547|NCT00331604|Active Comparator|C|
9873548|NCT00331643|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
9873549|NCT00331669|Placebo Comparator|1|device
9873550|NCT00331695|Experimental|1|17 alpha-hydroxyprogesterones caproate
9873551|NCT00331708|Experimental|Artesunate plus sulphadoxine-pyrimethamine|
9873552|NCT00331721|Active Comparator|1|Enecadin
9873553|NCT00331721|Placebo Comparator|2|Placebo
9873554|NCT00331838|Experimental|Semuloparin 5 mg|Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
9873555|NCT00331838|Experimental|Semuloparin 10 mg|Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
9873556|NCT00331838|Experimental|Semuloparin 20 mg|Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
9873557|NCT00331838|Experimental|Semuloparin 40 mg|Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
9873558|NCT00331838|Experimental|Semuloparin 60 mg|Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
9873559|NCT00331838|Active Comparator|Enoxaparin 40 mg|Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
9873560|NCT00331838|Experimental|Placebo pre-op / Semuloparin 20 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
9873561|NCT00331838|Experimental|Placebo pre-op / Semuloparin 40 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
9873562|NCT00331890|Experimental|Active|Receives active drug
9873563|NCT00331890|Placebo Comparator|Placebo|Receives a placebo
9873564|NCT00331929|Experimental|A|Cohort of school children that evaluated with questionnaire and spirometry with MINATO 500 JAPAN spirometer
9873565|NCT00331955|Experimental|Treatment (vorinostat, doxorubicin hydrochloride)|Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.
9873566|NCT00331994|Experimental|1|
9873567|NCT00331994|Active Comparator|2|
9873568|NCT00332007|Experimental|1|Tonabersat 40 mg daily
9873569|NCT00332007|Placebo Comparator|2|
9873570|NCT00332020|Experimental|Arm 1|
9873571|NCT00332020|Active Comparator|Arm 2|
9873572|NCT00332098|Experimental|1|Family-Focused Treatment Plus Pharmacotherapy
9873573|NCT00332098|Active Comparator|2|Enhanced Care Plus Pharmacotherapy
9873574|NCT00332124|Placebo Comparator|1|Participants will take placebo
9873575|NCT00332124|Active Comparator|2|Participants will take choline
9873576|NCT00332176|Experimental|1|
9873577|NCT00332176|Experimental|2|
9873578|NCT00332176|Active Comparator|3|
9873579|NCT00332228|Active Comparator|CE plus oral +depot naltrexone|Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;
9873580|NCT00332228|Placebo Comparator|CE plus oral naltrexone+ placebo|CE with oral naltrexone plus two placebo injections
9873581|NCT00332228|Experimental|BNT plus Depot naltrexone|BNT plus two doses of depot naltrexone prior to hospital discharge
9873582|NCT00332228|Placebo Comparator|BNT plus PBO injection|BNT plus two placebo injections
9873583|NCT00332254|Experimental|1|Intra-articular IL-1Ra
9873584|NCT00332254|Placebo Comparator|2|Intra-articular saline
10211356|NCT04915677|Active Comparator|Subepithelial Connective Tissue Graft (SCTG)|Soft tissue augmentation at edentulous area with subepithelial connective tissue graft harvested from the patient's palate
9873585|NCT00332280|Experimental|AMT2003|
9873586|NCT00332293|Experimental|Moxifloxacin|
9873587|NCT00332293|Active Comparator|VIGAMOX|
9873588|NCT00332306|Experimental|2|Didanosine + Lamivudine + Nevirapine
9873589|NCT00332306|Active Comparator|1|Didanosine + Lamivudine + Efavirenz
9873590|NCT00332371|Experimental|1|
9873591|NCT00332371|No Intervention|2|
9873592|NCT00332397|Active Comparator|A|Rapamycin-eluting Stent (Cypher)
9873593|NCT00332397|Active Comparator|B|Zotarolimus-eluting Stent (Endeavor)
9873594|NCT00332397|Active Comparator|C|Rapamycin-eluting Stent
9929151|NCT00913939|Active Comparator|2: Boost to EBRT|Patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.
9929152|NCT00913952|Experimental|1|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
9929153|NCT00913952|Experimental|2|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
9929154|NCT00913952|Active Comparator|3|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
9929155|NCT00913965|Experimental|1|Atenolol Tablets 100 mg (Cord Laboratories)
9929156|NCT00913965|Active Comparator|2|Atenolol Tablets 100 mg (Stuart Pharmaceutical)
9929157|NCT00913991|Experimental|Stress Management #1|8 weeks of individual stress management training sessions
9929158|NCT00913991|Active Comparator|Stress Management #2|8 weeks of individual stress management training sessions
9929159|NCT00914004|Experimental|1|Desipramine HCl 50 mg Tablets Cord Laboratories
9929160|NCT00914004|Active Comparator|2|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
9929161|NCT00914017|Experimental|Atorvastatin|40 mg of Lipitor (atorvastatin) daily for 1 year
9929162|NCT00914017|Placebo Comparator|Sugar Pill|Sugar pill daily for 1 year
9929163|NCT00914030||A1|Patients with schizophrenia
9929164|NCT00914030||A2|Control subjects matched individually with patients with schizophrenia
9929165|NCT00914030||B1|Adult subjects with autism
9873595|NCT00332514|Other|Patients offered follow-up phone call|Patients offered follow-up telephone call
9873596|NCT00332566|Experimental|Group A|
9873597|NCT00332566|Active Comparator|Group B|
9873598|NCT00332670|Active Comparator|1|10.000lux bright blue light 1hour every morning 1 hour after wake-up time during three weeks
9873599|NCT00332670|Placebo Comparator|2|50lux dim red light 1 hour every morning 1 hr after wake-up time during 3 weeks
9873600|NCT00332683|Active Comparator|Control|Patients randomly assigned to this group will have no changes in the ETT during surgery
9873601|NCT00332683|Experimental|Treatment group|Patients in this group will undergo same surgery as control group but with a monitoring and manipulation of ETT pressure
9873602|NCT00332774|Experimental|Nevanac|
9873603|NCT00332774|Active Comparator|Acular|
9873604|NCT00332774|Placebo Comparator|Vehicle|
9873605|NCT00332852|Experimental|Letrozole|
9873606|NCT00332878|Experimental|1|Stepping Stones
9873607|NCT00332878|Active Comparator|2|A 3 hour intervention on HIV and safer sex
9873608|NCT00332904|Active Comparator|beta|patients with liver cirrhosis, treated with betablocker
9873609|NCT00332904|Active Comparator|spiron|patients with liver cirrhosis, treated with aldosterone antagonist
9873610|NCT00332904|No Intervention|control|patients with liver cirrhosis, no treatment
9873611|NCT00332917|Experimental|1|
9873612|NCT00332969|Experimental|Sandostatin|
9873613|NCT00333073|Experimental|Bulkamid|Submucosal injection of Bulkamid into urethra
10211357|NCT04915677|Experimental|Volume Stable Collagen Matrix (VCMX)|Soft tissue augmentation at edentulous area with xenogenic volume stable collagen matrix
10211358|NCT04914702||Everion® only|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
10211359|NCT04914702||CORE® only|A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
9873614|NCT00333099|Placebo Comparator|nutrition|study of immuno-modulating enteral nutrition
9873615|NCT00333112|Experimental|1|
10213727|NCT03437161|Experimental|Radiation Therapy (RT)|Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.
9873616|NCT00333112|Placebo Comparator|2|
9873617|NCT00333125|Experimental|Travoprost/Timolol|
9873618|NCT00333125|Active Comparator|Dorzolamide/Timolol|
9873619|NCT00333203|Experimental|NGOIS|
9873620|NCT00333203|Active Comparator|BSS Plus|
9873621|NCT00333268|Experimental|NGOIS|
9873622|NCT00333268|Active Comparator|BSS Plus|
9873623|NCT00333320|Placebo Comparator|- Control|
9873624|NCT00333320|Experimental|-postconditioning group|
9873625|NCT00333333||SGA infants|Infants who are thought to be small for gestational age (SGA)
9873626|NCT00333333||Pre-eclampsia exposed|Infants who are born to mothers who had pre-eclampsia
9873627|NCT00333398|Experimental|1|250 subjects-Lot #1 multiple-dose vial (thimerosal-containing).
9873628|NCT00333398|Experimental|2|250 subjects-Lot #2 multiple-dose vial (thimerosal-containing).
9873629|NCT00333398|Experimental|3|250 subjects-Lot #3 multiple-dose vial (thimerosal-containing).
9873630|NCT00333398|Placebo Comparator|4|250 subjects-multiple-dose vial placebo (thimerosal-containing).
9873631|NCT00333398|Experimental|5|250 subjects-Prefilled Lot #1, #2, or #3 (TBD) (thimerosal-free).
9873632|NCT00333424|Placebo Comparator|Placebo|placebo containing diluent alone
9873633|NCT00333463||Intervention group|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
9873634|NCT00333463||Non-Intervention Group|The control group was told to take drops as prescribed and received no additional intervention.
9873635|NCT00333515|Experimental|1|Administration of one of 3 doses (dose escalation) of the active drug (HuBChE). (Dose-escalation proceeds only after safety evaluation and after the previous dosage has been found to be acceptable by an independent Data Safety Monitoring Board.)
9873636|NCT00333515|Placebo Comparator|2|Administration of placebo
9873637|NCT00333528|Experimental|1|Administration of one dose of the active drug (6 volunteers)
9873638|NCT00333528|Placebo Comparator|2|Administration of placebo (2 volunteers)
9873639|NCT00333541|Experimental|Treatment|follow-up via e-mail link to survey
9873640|NCT00333541|No Intervention|Control|standard follow-up by phone and in-person interview
9873641|NCT00333554|Experimental|DHA Treatment Group|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
9873642|NCT00333554|Placebo Comparator|Control Group|Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.
9873643|NCT00333580||Group 1|
9873644|NCT00333658|Experimental|1|Intervention
9873645|NCT00333658|No Intervention|2|Work Services
9873646|NCT00333684|Active Comparator|receive bioalcamid at baseline|half subjects received bioalcamid at baseline
9873647|NCT00333684|Active Comparator|Receive bioalcamid at 24 weeks|other half of subjets received bioalcamid at 24 weeks
9873648|NCT00333749|Experimental|1|55 children < 5 years with acute oral ulcer disease.
9873649|NCT00333749|Placebo Comparator|2|55 Children < 5 years with acute oral ulcer disease.
9873650|NCT00333827|Active Comparator|Optimal Therapy|Optimal therapy for cardiac failure
9873651|NCT00333827|Experimental|cell therapy|stem cell
9873652|NCT00333918|Experimental|1-bromfenac ophthalmic solution|sterile ophthalmic solution
9873653|NCT00333918|Placebo Comparator|2-placebo comparator|sterile ophthalmic solution
9873654|NCT00334022|Placebo Comparator|Did not receive enfuvirtide|patients were randomized to either receive enfuviratide or not receive it
9873655|NCT00334022|Active Comparator|enfuvirtide|enfuvirtide 1ml BID
9873656|NCT00334100|Other|Arm 1|
9873657|NCT00334139|Experimental|zoledronic acid|
9873658|NCT00334217|Experimental|1|PSS CogRehab exercises
9873659|NCT00334217|No Intervention|2|On-line computer games
9929166|NCT00914030||B2|Control subjects matched individually with adult subjects with autism
9929167|NCT00914030||C1|Children with autism
9929168|NCT00914030||C2|Control subjects matched individually with children with autism
9929169|NCT00914056|Experimental|Lactulose withdrawal|Patients who were started on lactulose as a result of a precipitated HE episode underwent analysis while they were on lactulose; after this they underwent a controlled lactulose withdrawal with 3 visits post-withdrawal at 2 days, 14 days and 30 days after lactulose withdrawal
9929170|NCT00914082|Experimental|antenatal classes in self hypnosis|3 antenatal classes in self hypnosis. 3 audio compact discs for homework in self hypnosis and 1 audio compact disc for birth
9929171|NCT00914082|Active Comparator|relaxation and awareness|3 antenatal classes including training in relaxation methods and mindfulness.3 audio compact discs for homework and 1 for birth.
9929172|NCT00914082|Other|Control|Only receive ordinary antenatal care and no additional interventions
9929173|NCT00914095|Active Comparator|methylphenidate|methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
9929174|NCT00914095|Placebo Comparator|placebo|tablets of placebo 3 time a day
9929175|NCT00914121|Experimental|1|SKI-606 alone
9929176|NCT00914121|Placebo Comparator|2|Placebo
10211360|NCT04914702||Everion® first, CORE® second|"Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.~Then a CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene."
10211361|NCT04914702||CORE® first, Everion® second|"A CORE® device will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.~Then two Everion® devices, one for the day and one for the night, to be switched every morning and evening, will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene."
9929177|NCT00914121|Active Comparator|3|Moxifloxacin
9929178|NCT00914121|Experimental|4|SKI-606 plus ketoconazole
9929179|NCT00914121|Placebo Comparator|5|Placebo plus ketoconazole
9929180|NCT00914134|Experimental|Levodopa Infusion|Patients with advanced Parkinson's disease and motor fluctuations that cannot be adequately controlled with oral medication.
9929181|NCT00914147|Other|Pulmonary Function Test (PFT)|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)
10211362|NCT04914702||Everion® and CORE® simultaneously|Two Everion® devices, one for the day and one for the night, to be switched every morning and evening, and one CORE® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
9929182|NCT00914160|Experimental|1|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
9929183|NCT00914160|Experimental|2|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
9929184|NCT00914160|Active Comparator|3|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
9929185|NCT00914173|Experimental|Pain/No Pain Stimuli|One Arm is used in this trial. The comparator is within the arm. The different types of stimuli levels and types are compared.
9929186|NCT00914199|Experimental|Kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent using kissing balloon dilatation
9929187|NCT00914199|Experimental|No kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent and not using kissing balloon postdilatation
9929188|NCT00914212|Active Comparator|1|Sibutramine
9929189|NCT00914212|Placebo Comparator|2|Placebo
9929190|NCT00914225||Intervention|Cohort 1 is the intervention group who received long-lasting insecticide treated bednets and a water filtration device
9929191|NCT00914225||Comparison|"Cohort 2 is the comparison group included from the control arm of the study, Empiric therapy of helminth coinfection to reduce HIV-1 disease progression ClinicalTrials.gov identifier: NCT00507221~As part of the RCT (NCT00507221), we have enrolled 948 HIV infected ART naïve individuals to compare HIV disease progression in those receiving standard of care versus empiric deworming. Subjects are followed for 24 months and have serial measurements of HIV disease progression, and are evaluated serially for evidence of malaria, diarrhea and other co-morbidities. Participants in this study will have been consented for the collection of data on the frequency of malaria and diarrheal disease, their use of a bednet and water filtration and their compliance with TMP/SMX."
9929192|NCT00914238|Experimental|5 year|5 years OPUS treatment
9929193|NCT00914238|Active Comparator|2 years of OPUS treatment|2 years OPUS treatment and 3 years of treatment as usual
9929194|NCT00914264||COPD with OSA with CPAP treatment|COPD with OSA: CPAP treatment
9929195|NCT00914264||COPD without OSA|COPD without OSA, not treat with CPAP
9929196|NCT00914264||COPD with OSA but without CPAP treatment|COPD with OSA but patient refused CPAP treatment
9987103|NCT01409044|Experimental|Music|Research participant listened to music
9987104|NCT01409057||No heart lung machine|Coronary-artery-disease
9987105|NCT01409057||Heart lung machine|Coronary artery disease
9987106|NCT01409070||Azacitidine|200 MDS patients taking Azacitidine will be assessed
9987107|NCT01409070||Decitabine|100 MDS patients taking Decitabine will be assessed
9796407|NCT01565889|Experimental|Part A: SOF+RAL+FTC/TDF (Cohort 5)|Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
9796408|NCT01565889|Experimental|Part B: SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
9796409|NCT01565902|Experimental|Mild hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
9796410|NCT01565902|Experimental|Moderate hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
9796411|NCT01565902|Experimental|Severe hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
9796412|NCT01565902|Experimental|Matched healthy subjects|Treatment with a single oral dose of 0.25 mg BAF312
9796413|NCT01565928|Experimental|MDV3100|
9796414|NCT01565941|Active Comparator|Tight Glycemic Control 1 (TGC-1)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
9796415|NCT01565941|Active Comparator|Tight Glycemic Control 2 (TGC-2)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
9796416|NCT01565980|Active Comparator|symptom assessment|6 weeks of symptom assessment phone calls.
9796417|NCT01565980|Experimental|Mindfulness intervention|Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
9796418|NCT01565993|Active Comparator|Hemoclip|In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
9796419|NCT01565993|Active Comparator|Conventional Polipectomy|In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique
9796420|NCT01566084|Other|Normal sodium|Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
9796421|NCT01566084|Other|Low sodium|Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
9796422|NCT01566162|Experimental|Lurasidone|Lurasidone 40 - 80mg flexible dose
9796423|NCT01566214|Experimental|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
9796424|NCT01566214|No Intervention|Usual Care|For those randomly assigned to the usual care group, they will receive standard-of-care by their regular primary care provider.
9796425|NCT01566331|Experimental|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet.
9796426|NCT01566331|No Intervention|no intervention|Baby-guardTM system, without inflation
9796427|NCT01566409|Active Comparator|Active maintenance treatment|
9796428|NCT01566409|Placebo Comparator|Placebo maintenance treatment|
9796429|NCT01566435|Experimental|Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy|"ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15~Cisplatin 75 mg/m^2 on Day 1~5-FU 750 mg/m^2 on Days 1-3~If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.~Definitive Therapy~Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43~Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.~If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks"
9796430|NCT01566448|Experimental|Ketamine|Ketamine oral mouthwash 20mg/5ml swish and spit four times daily
9796431|NCT01566461|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
9796432|NCT01566461|Active Comparator|Standard PTA|Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty
9796433|NCT01566526||Patients Previously Treated with OZURDEX®|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
9796434|NCT01566539|Experimental|Healthy Volunteers - Intranasal Vasopressin (AVP)|The AVP group of healthy volunteers will self-administer vasopressin solution prior to completing the PD task.
9873660|NCT00334321|Experimental|IMRT with chemotherapy|"IMRT (upper third of vagina & para-vaginal tissue and the common, external and internal iliac nodal regions) 160-180 cGy daily fractions for a total dose of 4500-5120 cGy. Once a day treatment four to five days a week for approximately 6 weeks.~Intracavitary vaginal brachytherapy - some patients will be given this and it will be decided by the treating physician.~Carboplatin - AUC 6, IV over 30-60 minutes following completion of paclitaxel, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles~Paclitaxel - 175 mg/m2, 3 hour continuous IV infusion, administered prior to carboplatin, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles"
9873661|NCT00334347|Active Comparator|Depakote ER|
9873662|NCT00334347|Active Comparator|Depakote DR|
9873663|NCT00334360|Experimental|1|dexmedetomidine
9873664|NCT00334360|Experimental|2|Buspirone
9873665|NCT00334360|Experimental|3|Buspirone and dexmedetomidine
9873666|NCT00334360|Placebo Comparator|Control|No drug
9873667|NCT00334373|Experimental|Post conditioning|Balloon inflations-deflations
9873668|NCT00334373|Placebo Comparator|Standard care|No balloon inflations
9873669|NCT00334438|Other|Zevalin + Velcade Single Arm Study|Zevalin (Ibritumomab Tiuxetan) and Velcade (Bortezomib)
9873670|NCT00334490|Active Comparator|1|Oral Sildenafil 12.5 mg
9873671|NCT00334490|Placebo Comparator|2|Placebo in 5 mls distilled water
9873672|NCT00334555|Active Comparator|usual care|patient told to refer her partner for treatment
9873673|NCT00334555|Active Comparator|partner delivered|patient given medication to deliver to her partners
9873674|NCT00334555|Active Comparator|field intervention|field intervention to find partners
9873675|NCT00334568|Experimental|Rosi XR|Rosi XR
9873676|NCT00334568|Placebo Comparator|Placebo|Placebo (matched)
9873677|NCT00334581|Experimental|1|Irbesartan 150mg
9873678|NCT00334581|Experimental|2|Irbesartan 300mg
9873679|NCT00334594|Active Comparator|No radiotherapy|
9873680|NCT00334594|Experimental|Radiotherapy|
9873681|NCT00334646|Experimental|Arm A|cyclophosphamide + dexamethasone + ondansetron
9873682|NCT00334646|Experimental|Arm B|cyclophosphamide + dexamethasone + ondansetron + GW679769
9873683|NCT00334685|Experimental|[S,S]-Reboxetine + Pregabalin|
9873684|NCT00334685|Active Comparator|Pregabalin|
9873685|NCT00334724|Active Comparator|1|Home blood pressure group
9873686|NCT00334724|Active Comparator|2|Office blood pressure group
9873687|NCT00334750||There is no intervention in this study|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
10211363|NCT04914286|Experimental|GFH018+Toripalimab|Patient will be dosed in GFH018 in combination with Toripalimab. In the PhaseIb part, the dose levels will be escalated following the Bayesian optimal interval (BOIN) design. In the Phase II part, patients will be assigned based on tumor type(s).
10211364|NCT04909515|Experimental|naxitamab + GM-CSF + isotretinoin|8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
10211365|NCT04908579|Active Comparator|- GROUP (I): 30 patients|
9796435|NCT01566539|Experimental|Healthy Volunteers - Intranasal Oxytocin (OT)|The OT group of healthy volunteers will self-administer oxytocin solution prior to completing the PD task.
9873688|NCT00334789|Experimental|Treatment (belinostat, isotretinoin)|"Patients receive belinostat IV over 30 minutes on days 1-5 and isotretinoin PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of belinostat until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.~Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies.~All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies."
9873689|NCT00334867|Active Comparator|Arm I|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-15; doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 1, 7, and 13; cyclophosphamide IV over 1 hour on day 1 in weeks 1, 7, and 13; and ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4, 10, and 16. Patients undergo local therapy comprising conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19.
9873690|NCT00334867|Experimental|Arm II|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-16; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 13; cyclophosphamide IV over 30 minutes on days 1-5 in weeks 1 and 13 and IV over 1 hour on day 1 in weeks 7 and 16; ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4 and 10; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 7 and 16. Patients also undergo local therapy comprising of conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19. Patients then proceed to combination chemotherapy.
9873691|NCT00334945||Growth Hormone|Patient ages 3-14 years receiving growth hormone for growth hormone deficiency or short stature
9873692|NCT00334945||Healthy Children|Children with normal stature ages 3-18 years.
9873693|NCT00334971|Other|1|Healthy Caucasian women 18-35 years old
10211366|NCT04908579|Active Comparator|- GROUP (II): 30 patients|
10211367|NCT04908579|Active Comparator|- GROUP (III) (Control): 30 patients|
9796436|NCT01566539|Placebo Comparator|Healthy Volunteers - Intranasal Placebo|The placebo group of healthy volunteers will self-administer a placebo spray prior to completing the PD task.
10211368|NCT04903210|Experimental|NMN group|NMN10000 WRIGHT LIFE® + lifestyle modification.
10211369|NCT04903210|Other|Control group|Lifestyle modification only.
10213728|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
9873694|NCT00334971|Other|2|Healthy African-American women 18-35 years old
9873695|NCT00334971|Other|3|Healthy Caucasian women 36-45 years old
9873696|NCT00334971|Other|4|Female fragile X premutation carriers 18-45 years old
9873697|NCT00335023|Active Comparator|Red blood cell transfusion|At least one unit of red blood cells will be administered.
9873698|NCT00335023|No Intervention|Control|No red blood cell transfusion. Iron suppletion is allowed and can be administered according to local protocol. If suppletion is prescribed, the type and duration will be registered
9873699|NCT00335036|Active Comparator|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
9873700|NCT00335036|Active Comparator|Gore PTFE-coated|ICD lead with PTFE-coated coils
9873701|NCT00335049|Experimental|PAL|Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
9873702|NCT00335049|Active Comparator|SVL|Single Vision Lenses (SVLs) worn both years of the study.
9873703|NCT00335075|Experimental|Temodal group|Subjects treated with temozolomide.
9873704|NCT00335075|Active Comparator|Semustine group|Subjects treated with semustine.
9873705|NCT00335166|Experimental|1|
9873706|NCT00335166|Active Comparator|2|
9873707|NCT00335166|Placebo Comparator|3|
9873708|NCT00335179|Active Comparator|Imiquimod cream|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks
9873709|NCT00335179|Placebo Comparator|Vehicle cream|Vehicle cream 250 mg Applied 3 times per week for 4 weeks
9873710|NCT00335192|Experimental|1|"Phase I: 3TC + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv"
9873711|NCT00335192|Experimental|2|"Phase I: ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv"
9873712|NCT00335192|Experimental|3|"Phase I: 3TC + ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv"
9873713|NCT00335218|Experimental|Arm 1|
9873714|NCT00335218|Placebo Comparator|Arm 2|
9873715|NCT00335231|Experimental|gatifloxacin|one group will receive topical application of gatifloxacin prior to surgery,
9873716|NCT00335231|No Intervention|no eye drops|this group will receive no eye drops.
9873717|NCT00335309|Experimental|1|The Investigational arm is treated with sinus irrigation with normal saline 0.9% and intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
9873718|NCT00335309|Active Comparator|2|The control arm is treated with the same intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. There is no sinus irrigation with normal saline for this arm. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
9873719|NCT00335335|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
9873720|NCT00335348|Experimental|Bortezomib and Dexamethasone|
9873721|NCT00335374|Experimental|1|
9873722|NCT00335595|Active Comparator|1|XELOXA
9873723|NCT00335595|Experimental|2|XELOXA-A
9873724|NCT00335686|No Intervention|1|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
9873725|NCT00335686|No Intervention|2|Nevirapine (Viramune): 1 comp (200mg)/12h
9873726|NCT00335751|Experimental|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
9929197|NCT00914277|Experimental|Sequence 1|"Period 1: placebo~Period 2: sildenafil~Period 3: SAR407899 dose level 2~Period 4: SAR407899 dose level 1"
9929198|NCT00914277|Experimental|Sequence 2|"Period 1: sildenafil~Period 2: SAR407899 dose level 1~Period 3: placebo~Period 4: SAR407899 dose level 2"
9929199|NCT00914277|Experimental|Sequence 3|"Period 1: SAR407899 dose level 1~Period 2: SAR407899 dose level 2~Period 3: sildenafil~Period 4: placebo"
9929200|NCT00914277|Experimental|Sequence 4|"Period 1: SAR407899 dose level 2~Period 2: placebo~Period 3: SAR407899 dose level 1~Period 4: sildenafil"
9929201|NCT00914303|Experimental|AZD3241|AZD3241 Tablets
9929202|NCT00914303|Experimental|Placebo|Placebo Tablets
9929203|NCT00914329|Experimental|Gelsemium 5CH|Globules of Gelsemium sempervirens 5CH
9929204|NCT00914329|Experimental|Gelsemium 15CH|Globules of Gelsemium Sempervirens 15CH
9929205|NCT00914329|Placebo Comparator|Placebo|Globules of placebo
9929206|NCT00914342||Upper-GI symptoms in primary-care patients|
9929207|NCT00914355|Experimental|SBRT for Hepatocellular Carcinoma|
9929208|NCT00914368|Active Comparator|1|Patients with previously experienced stent thrombosis while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
9929209|NCT00914368|Active Comparator|2|Patients with previously experienced myocardial infarction while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
9929210|NCT00914368|Active Comparator|3|Patients without previously experienced myocardial infarction or stent thrombosis 6 within months after coronary stenting for coronary artery disease(matched controls for group 1 and 2)
9929211|NCT00914381|Active Comparator|CRA + CM|Community Reinforcement Approach (CRA) combined with Contingency Management (CM)
9873727|NCT00335985|Experimental|1|
9873728|NCT00335985|Placebo Comparator|2|
9873729|NCT00335998|Experimental|Treatment (triapine)|"Group 1: Patients undergo external-beam pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive 3-AP IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33 and cisplatin IV over 1½ hours on day 2, 9, 16, 23, and 30.~Group 2: Patients undergo external-beam pelvic radiotherapy and receive 3-AP as in group 1.~In both groups, patients undergo intracavitary or interstitial brachytherapy at least once weekly for 3-5 weeks during or after external-beam radiotherapy as per standard of care."
9873730|NCT00336076||Participants evaluated for mastocytosis|Observational study of all patients referred for suspected mast cell disease. Collection of blood or bone marrow for analysis during diagnostic procedures.
9873731|NCT00336102||Group 1 Breast Cancer Patient Cases|"Patients between the ages of 25 and 75, diagnosed with primary, operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin / Cytoxan (AC) plus a taxane are trial candidates.~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
9873732|NCT00336102||Group 2 Healthy Controls|"Controls will be women from the same general demographic area as Group 1 Cases, have no prior history of cancer and be within 5 years of the Group 1 case's age (+/- 5 years).~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
9873733|NCT00336141|Experimental|Vorinostat|
9873734|NCT00336180|Experimental|HW|The experimental group (HW) receives 18 classroom-based lessons on leisure motivation, life skills, and skills to avoid substance use and sexual risk.
9873735|NCT00336193|Experimental|Home visitation|In the intervention condition, nurse home visitors receive enhanced training to improve delivery of parenting interventions to mothers
9873736|NCT00336219|Active Comparator|1|Pantoprazole 40 mg
9873737|NCT00336245|Experimental|Copper T Intrauterine Contraceptive Device|
9796437|NCT01566539|Experimental|Within Subject Group|Some healthy volunteer participants who received drug in their first session will receive placebo in their second session and vice-versa prior to completing the PD task. For each gender, half will receive AVP in one session and placebo in the other session, and half will receive OT in one session and placebo in the second session. In each group, half of the subjects will receive drug first and half will receive placebo first. Additionally, a group of subjects who receive placebo the first time will receive placebo the second time.
9796438|NCT01566539|Experimental|Faces Task - Vasopressin (AVP)|Healthy volunteers between the ages of 21-30 years will receive Faces Intranasal Vasopressin (AVP) prior to completing the Faces task during fMRI scanning.
9873738|NCT00336245|Active Comparator|Hormonal Contraception|
9873739|NCT00336336|Experimental|1|N-3PUFA
9873740|NCT00336336|Placebo Comparator|2|
9873741|NCT00336336|Experimental|3|Rosuvastatin
9873742|NCT00336336|Placebo Comparator|4|
9873743|NCT00336362|Active Comparator|1|Participants will receive hydroxyurea pretreatment.
9873744|NCT00336362|No Intervention|2|Participants will not receive hydroxyurea pretreatment.
9873745|NCT00336375|Experimental|1|All treatment doses accompanied with intake of fatty food
9873746|NCT00336375|Active Comparator|2|All treatment doses not-accompanied with intake of fatty food.
9873747|NCT00336453|Experimental|FluBlok-22.5 μg, 6-35 months old|6-35 months old, FluBlok-22.5 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
9796439|NCT01566539|Placebo Comparator|Faces Task - Placebo|Healthy volunteers between the ages of 21-30 years will receive placebo prior to completing the Faces task during fMRI scanning.
9796440|NCT01566539|Experimental|Empathy Task - Oxytocin (OT)|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and OT at scan 2 prior to completing an empathy task.
9873748|NCT00336453|Experimental|FluBlok-45 μg, 6-35 months old|6-35 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
9873749|NCT00336453|Active Comparator|TIV-7.5 μg, 6-35 months old|6-35 months old, 2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
9873750|NCT00336453|Active Comparator|TIV-15 μg, 36-59 months old|36-59 months old, 2006-2007 formulation of Fluzone (sanofi-pasteur, Swiftwater, PA)-15 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
9873751|NCT00336453|Experimental|FluBlok-45 μg, 36-59 months old|36-59 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
9873752|NCT00336557||Regularly Scheduled NAb Testing Arm|Subjects will be scheduled for 5 study visits over the course of 12 months and any NAbs test results will be available to the investigator during the study.
9873753|NCT00336557||Usual Care Arm|Subjects will be scheduled for 2 study visits over the course of 12 months and any NAbs test results will be unknown by the investigator until the conclusion of the subject's study participation.
9873754|NCT00336622|Experimental|Experimental|Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
9873755|NCT00336622|Active Comparator|Control|Off-the-shelf splint
9873756|NCT00336648|Experimental|Gemcitabine + Avastin + Surgery|Gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy
9929212|NCT00914381|Active Comparator|TSF + CM|Twelve-Step Facilitation (TSF) combined with Contingency Management (CM)
9873757|NCT00336674|Active Comparator|DV001|Recombinant human intranasal insulin formulation in a buffered solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product is formulated at a dose strength of 1100 IU / mL (40mg/mL) manufacturing formulation. The product will be self administered by eligible participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
9873758|NCT00336674|Placebo Comparator|Placebo|Placebo insulin carrier solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product will be self administered by participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
9873759|NCT00336752|Active Comparator|1|Non operative treatment of Weber B ankle fracture. Use of cast, with no surgical intervention
9873760|NCT00336752|Active Comparator|2|Operative treatment of Weber B ankle fracture. Open reduction and internal fixation to repair a broken bones.
9873761|NCT00336791|Experimental|Paclitaxel + Additional FAC/FEC|"12 weekly Paclitaxel treatments 80 mg/m^2 by vein (IVPB) over 1 hour + 4 additional FAC or FEC combination chemotherapy treatments; FAC or FEC treatments given once every 3 weeks.~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
9873762|NCT00336791|Active Comparator|FAC/FEC|"6 courses FAC or FEC Combination Chemotherapy~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
9873763|NCT00336830|Active Comparator|Usual Care|Comparator without MD endorsement of Cardiac Rehabilitation
9873764|NCT00336830|Experimental|MD Endorsment of CR|Provided with MD endorsement of participation in Cardiac Rehabilitation
9873765|NCT00336843|Experimental|Zevalin-BuCyE|histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.
9873766|NCT00336882|Active Comparator|1|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
9873767|NCT00336882|Experimental|2|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
9873768|NCT00336921|Active Comparator|1|Alfuzosin 10mg
9873769|NCT00336921|Placebo Comparator|2|Placebo
9873770|NCT00336960|Experimental|treatment intervention|
9873771|NCT00337051|Experimental|S|General Anesthesia with sevoflurane (inhalation) as hypnotic
9873772|NCT00337051|Active Comparator|P|General Anesthesia With Propofol TCI
9873773|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1|25 kBq/kg b.w., 3 times at 6 week intervals
9873774|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2|50 kBq/kg b.w., 3 times at 6 week intervals
9873775|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3|80 kBq/kg b.w., 3 times at 6 week intervals
9873776|NCT00337259|Experimental|Gemcitabine|"histologically confirmed marginal zone lymphoma~gemcitabine 1,250 mg/m2 on days 1 and 8 of each cycle, repeated every 3 weeks and continued for 6 cycles, until disease progression, withdrawal due to toxicity, or withdrawal of consent."
9873777|NCT00337298|Experimental|1|Crossover design. Arm is same all the way
9873778|NCT00337376|Experimental|1|
9873779|NCT00337389|Experimental|1|CoFactor, 5-FU, Avastin
9873780|NCT00337389|Active Comparator|2|Leucovorin, 5-FU, Avastin
9873781|NCT00337480|No Intervention|conventional|This arm is the conventional way of taking care of patients after an acute coronary syndrome
9873782|NCT00337480|Active Comparator|structured|This arm is an active way to monitor and educate patients after their acute coronary syndrome, with the intervention of health members in a House of Education
9873783|NCT00337493|Experimental|1|
9873784|NCT00337493|Experimental|2|
9873785|NCT00337493|Experimental|3|
9873786|NCT00337519|Experimental|1|see detailed description
9873787|NCT00337558|Experimental|1|Solifenacin succinate
9873788|NCT00337558|Experimental|2|Solifenacin succinate and simplified bladder training
9873789|NCT00337636|Experimental|HuCNS-SC|human central nervous system stem cells
9873790|NCT00337649|Experimental|1|
9873791|NCT00337701|Experimental|1|
9873792|NCT00337701|Experimental|2|
9873793|NCT00337714|Placebo Comparator|A|in this arm conventional CVCs will be inserted
9873794|NCT00337714|Active Comparator|B|group B will receive medicated silver nanoparticles CVC
9873795|NCT00337753|Active Comparator|Cognitive Behavioral Therapy|Weekly Cognitive Behavior therapy
9796441|NCT01566539|Placebo Comparator|Empathy Task - Placebo|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and placebo at scan 2 prior to completing an empathy task.
9796442|NCT01566539|Experimental|Anxious and Depressed Subjects - OT|Depressed or anxious men between the ages of 18 and 22 will receive intranasal OT prior to completing the Prisoner's Dilemma game task and MRI scan.
9796443|NCT01566539|Placebo Comparator|Anxious and Depressed Subjects - Placebo|Depressed or anxious men between the ages of 18 and 22 will receive intranasal placebo prior to completing the Prisoner's Dilemma game task and MRI scan.
9796444|NCT01566539|Experimental|Healthy Volunteers - Lorazepam|Healthy normal men between the ages of 18 and 22 will receive lorazepam prior to completing the Prisoner's Dilemma game task and MRI scan.
9796445|NCT01566604|Experimental|NVA237|NVA237 50 µg once daily delivered via a single dose dry powder inhaler
9796446|NCT01566604|Placebo Comparator|Placebo|Placebo once daily delivered via a single dose dry powder inhaler
9796447|NCT01566630|Experimental|RLX030|"In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030.~In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1."
9796448|NCT01566630|Placebo Comparator|Placebo|"In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts.~In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours"
9796449|NCT01566682||Indeterminate Pulmonary Lesions|Patients with Pulmonary Lesions as seen by CT
9796450|NCT01566721|Experimental|Cohort A: SC Herceptin by Needle/Syringe|Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
9796451|NCT01566721|Experimental|Cohort B: SC Herceptin by SID|Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
9796452|NCT01566773|Experimental|PT001 MDI (Dose 1)|
9796453|NCT01566773|Experimental|PT001 MDI (Dose 2)|
9796454|NCT01566773|Experimental|PT001 MDI (Dose 3)|
9796455|NCT01566773|Experimental|PT001 MDI (Dose 4)|
9796456|NCT01566773|Experimental|PT001 MDI (Dose 5)|
9796457|NCT01566773|Experimental|PT001 MDI (Dose 6)|
9796458|NCT01566773|Placebo Comparator|PT001 Placebo MDI|
9796459|NCT01566773|Active Comparator|Spiriva® Handihaler® (Tiotropium Bromide)|
9796460|NCT01566838|Active Comparator|On-q pump|Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
9800048|NCT01677910|Experimental|Telotristat Etiprate Open-Label Extension|Patients previously assigned to 250 mg or 500 mg three times daily of telotristat etiprate were administered two 250 mg telotristat etiprate tablets three times daily in a 36 week open-label extension (OLE) period. Patients previously assigned to placebo were administered one 250 mg telotristat etiprate tablet plus one placebo-matching tablet three times daily for one week, followed by two 250 mg telotristat etiprate tablets three times daily for 35 weeks.
9873796|NCT00337753|Other|Wait-list|Subjects in wait-list for six-weeks
9873797|NCT00337766|Active Comparator|Desmopressin (DDAVP)|
9873798|NCT00337766|Placebo Comparator|Placebo|
9873799|NCT00337805|Active Comparator|1 colloid|Boluses of fluids are a pentastarch (up to 1000 ml)
9873800|NCT00337805|Active Comparator|2. Crytalloid|Boluses are given as normal saline
9873801|NCT00337870|Experimental|Treatment|50% randomized to receive distraction intervention during painful procedure
9873802|NCT00337870|No Intervention|Control|50% RANDOMIZED TO RECEIVE NO INTERVENITON
9873803|NCT00337896||observation|healthy adults ages 18-64 years, enrolled at Stanford University Hospital and participating in another clinical trial (DMID Protocol 04-062)
9929213|NCT00914381|Active Comparator|CRA + VC|Community Reinforcement Approach (CRA) combined with Voucher Control (VC)
9929214|NCT00914381|Active Comparator|TSF + VC|Twelve-Step Facilitation (TSF) combined with Voucher Control (VC)
9929215|NCT00914394|Active Comparator|NG-monomethyl-L-arginine (L-NMMA)|
9929216|NCT00914394|Active Comparator|Phenylephrine|
9929217|NCT00914394|Placebo Comparator|Physiological saline solution|
9929218|NCT00914407|Experimental|Healthy subjects|
9929219|NCT00914420|Experimental|Intrepide|Group A- Primary stenting with Intrepide trapidil eluting stent
9929220|NCT00914420|Experimental|Taxus|Group B Stenting with Taxus DES
9929221|NCT00914433|Experimental|TPI 1100|Drug to be given by inhalation.
9929222|NCT00914446|Other|morbid obese subject|
9929223|NCT00914446|Other|overweight and NASH subjects|
9929224|NCT00914446|Other|control subjects|
9929225|NCT00914472|Experimental|Test|Heparin - Hipolabor
9929226|NCT00914472|Active Comparator|Ative comparator|Heparin - APP
9929227|NCT00914498|Experimental|Xylocaine|Participants will receive local injection of 20 ml 1% Xylocaine to the skin incision site
9929228|NCT00914498|Placebo Comparator|Controls|Participants will receive injection of 0.9% NaCl 20 ml to the incision site
9929229|NCT00914511|Experimental|Healthy young males|Healthy young males age 18-45, inclusive
9929230|NCT00914511|Experimental|Elderly males|Elderly males 65 years of age and older
9929231|NCT00914524|Experimental|Treatment|16 weeks of treatment starting with 5 mg of olmesartan medoxomil. If tolerated, the dose was increased to the next higher dose at weeks 4, 8, and 12.
9929232|NCT00914537||1|Human immunodeficiency virus (HIV) positive adult men who have sex with men that are members of KPNC (Kaiser Permanente Northern California) and do not have a current anal cancer diagnosis.
9929233|NCT00914550||Procalcitonin level, caregiver informed|Procalcitonin level for patients with lung infiltrates:caregivers know/ do not know results
9929234|NCT00914563|Experimental|LIDCO|The extensively burnt patients (age range 18-75 years) with second and the third degree burns, with TBSA above 15%, with or without inhalation injury will be included to the study. We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. We will use in the LIDCO group the continuous real-time hemodynamic monitoring through transpulmonal lithium dilution additionally. The monitor Lithium Dilution Cardiac Output (LIDCO) Plus permits, through analysis of the arterial blood pressure trace, to acquire items about CO, SVR and DO2. In fluid resuscitation, we will use a combination of the balanced crystalloids and synthetic colloids (of the middle molecular weight) in the ratio 2 ml/kg/% TBSA: 1 ml/kg/% TBSA.
9929235|NCT00914563|No Intervention|Standard care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
9929236|NCT00914576|Active Comparator|1|
9929237|NCT00914576|Placebo Comparator|2|
9929238|NCT00914615|Experimental|SBRT for liver mets from colorectal cancer|
9929239|NCT00914641|Other|Apixaban Cross-over|
9929240|NCT00914654|Other|Healthty|10 healthy men
9929241|NCT00914654|Other|Asthmatics|10 male asthmatic subjects
9929242|NCT00914654|Other|Elite asthmatics|10 male elite athletes with asthma
9929243|NCT00914667|Experimental|Warfarin Alone|Reference treatment
9929244|NCT00914667|Experimental|Warfarin Concomitantly With Fesoterodine|Test treatment
9929245|NCT00914680|Experimental|MST|
9929246|NCT00914693|Experimental|Arm 1|
9929247|NCT00914719|Active Comparator|Information only|
9929248|NCT00914719|Active Comparator|sexual risk reduction intervention|
9929249|NCT00914719|Experimental|SRRI+ETOH|
9929250|NCT00914758||MS patients on Campath®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Campath® treatment arm of the Care-MS II trial, for which this study is a sub-study
9929251|NCT00914758||MS patients on Rebif®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Rebif® treatment arm of the Care-MS II trial, for which this study is a sub-study
9929252|NCT00914758||Control group|This group is comprised of non-MS, non-CNS compromised control participants matched in age, education level, and socioeconomic status to the participants in the 2 MS treatment groups
9929253|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 3.75µg|
9929254|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 7.5µg|
9929255|NCT00914797|Active Comparator|asthmatics|10 male asthmatic subjects
9929256|NCT00914797|Active Comparator|healthy|10 male healthy volunteers
9929257|NCT00914797|Active Comparator|elite athletes with asthma|10 elite athletes with asthma.
9929258|NCT00914836|Active Comparator|1 cc - Betamethasone Sodium Phosphate|1 cc - Betamethasone Sodium Phosphate
9929259|NCT00914836|Active Comparator|2 cc - Betamethasone Sodium Phosphate|2 cc - Betamethasone Sodium Phosphate
9929260|NCT00914875||group tramadol plus ketorolac|
9796461|NCT01566838|Active Comparator|Standard of care|"Patients in this arm will not receive a pain catheter in addition to the standard of care for pain management. Standard of care will consist of a standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and maintained on a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures. Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV once, neuromuscular reversal agents, and an antiemetic (ondansetron 4mg). Patients will also be given additional narcotics (fentanyl) upon emergence, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will also be provided. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
9796462|NCT01566981|Experimental|Diabetes with ICT support (E-diabetes)|The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
9796463|NCT01566981|No Intervention|Diabetes without support|The group of randomly selected patients with DM type II, without software application and web-based support.
9796464|NCT01567020||Control|Non-blast-exposed and non-TBI, aged younger than 50
9796465|NCT01567020||Blast|Blast-exposed with or without a TBI diagnosis
9796466|NCT01567020||Non-Blast-Exposed TBI|Non-blast-exposed with TBI diagnosis
9796467|NCT01567020||Older|Non-blast-exposed and non-TBI, aged 50 or older
9800049|NCT01677936|Experimental|Raisin|Subjects randomized to the raisin treatment arm will consume raisins three times a day, prior to meals, and with a glass of water or non-caloric beverages (i.e. tea). Subjects will consume the raisins over a 12 week period.
9800050|NCT01677936|Active Comparator|Snack Group|Subjects randomized to the snack group will consume 100 calorie snack packs three times a day, before meals, and with water or other non-caloric beverages (i.e. tea). Subjects will consume the snack packs over a 12 week period.
9800051|NCT01677988|Experimental|Chemotherapy, Chemoradiation, Surgery|Neoadjuvant Chemotherapy- Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles for 3 cycles with growth factor support Chemoradiation Surgical Resection
9800052|NCT01678131|Experimental|Vaniprevir 600 mg|Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
9800053|NCT01678131|Experimental|Vaniprevir 600 mg + Peg-IFN + RBV|Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
9800054|NCT01678131|Experimental|Vaniprevir 300 mg + Peg-IFN + RBV|Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
9800055|NCT01678144|Experimental|Medtentia Annuloplasty Ring (MAR)|All eligible patients underwent surgical mitral valve repair using annuloplasty device - Medtentia Annuloplasty Ring (MAR)
9800056|NCT01678196|Experimental|VA-CRAFT|Family participants complete an on-line training course (VA-CRAFT) over a 3 month period
9800057|NCT01678196|Placebo Comparator|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
9800058|NCT01678209|Active Comparator|fMRI scans|Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
9800059|NCT01678209|Experimental|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
9800060|NCT01678209|Experimental|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
9800061|NCT01678313|Experimental|Study group|Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
9800062|NCT01678313|Experimental|Control group|Doxazosin 4 mg every day (QD)
9800063|NCT01678443|Experimental|Treatment (yttrium-90 anti-CD45 monoclonal antibody BC8)|Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
9800064|NCT01678560|Active Comparator|Usual Care|Monitoring every 3 months by face-to-face visits:These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
9800065|NCT01678560|Active Comparator|Wireless Care|Frequent remote monitoring:These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.
9800066|NCT01678794|Experimental|Candesartan|
9800067|NCT01678794|Placebo Comparator|Placebo|
9800068|NCT01678807|Experimental|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days
9800069|NCT01678807|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days
9800070|NCT01678807|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily for 28 days
9800071|NCT01678820|Experimental|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
9873804|NCT00337909|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
9873805|NCT00337909|Active Comparator|Active Control|Educational DVDs
9873806|NCT00337909|No Intervention|No Contact Control|
9873807|NCT00337974|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
9873808|NCT00337974|Active Comparator|Active Control|Educational DVDs
9873809|NCT00337974|No Intervention|No Contact Control|
9873810|NCT00338026|Experimental|ECO-4601|
9873811|NCT00338130|Active Comparator|1|Temozolomide
9873812|NCT00338130|Experimental|2|AZD6244
9873813|NCT00338182|Experimental|AZD1152|AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment)
9873814|NCT00338195|No Intervention|Delayed intervention control|
9873815|NCT00338208|No Intervention|No training|Subjects will be fitted with low vision devices; no extra training will be provided.
9873816|NCT00338208|Experimental|Training in the Use of Low Vision Devices|Subjects will be fitted with low vision devices and will receive 6 training sessions with prescribed devices for up to 1 hour each time
9873817|NCT00338234||Cardiac surgery|Successive cardiac surgery patients
9873818|NCT00338234||Surgical ICU|Successive patients admitted to the surgical ICU for more than 7 days, and experiencing anemia
9873819|NCT00338273|Active Comparator|A1|
9873820|NCT00338273|Placebo Comparator|A2|
9873821|NCT00338312|Placebo Comparator|1|Placebo patch
9873822|NCT00338312|Experimental|2|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
9873823|NCT00338325|Experimental|Treatment|50% randomized to receive treatment: reading pre-operatively
9873824|NCT00338325|No Intervention|Control|50% randomized to receive no intervention pre-operatively: no reading
9873825|NCT00338364|Experimental|Treatment|50% randomized to receive distraction during painful procedure
9873826|NCT00338364|No Intervention|Control|50% randomized to receive no distraction during painful procedure
9929261|NCT00914875||group tramadol plus dypirone|
9929262|NCT00914888|Experimental|A|Tigecycline
9929263|NCT00914888|Active Comparator|B|Ceftriaxone regimen
9929264|NCT00914901|Other|Healthy|10 healthy men
9929265|NCT00914901|Other|Asthmatics|10 male asthmatic subjects
9929266|NCT00914901|Other|Elite athletes with asthma|10 male elite athletes with asthma
9796468|NCT01567085|Experimental|Eculizumab|"Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days."
9796469|NCT01567150|Active Comparator|novel dressing|Treatment with novel dressing
9796470|NCT01567150|No Intervention|Control|Control is treatment without novel dressing
9796471|NCT01567163|Experimental|ramucirumab (IMC-1121B) and docetaxel|"Cycle 1: docetaxel administered on Day 1 of 3-week cycle~Cycle 2: ramucirumab and docetaxel administered on Day 1 of 3-week cycle~Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle~Extension Phase: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
9796472|NCT01567306|Experimental|Allergovac Depot Group 1 Active|
9796473|NCT01567306|Experimental|Allergovac Depot Group 2 Active|
9796474|NCT01567306|Experimental|Allergovac Depot Group 3 Active|
9796475|NCT01567306|Experimental|Allergovac Depot Group 4 Active|
9796476|NCT01567306|Experimental|Allergovac Depot Group 5 Active|
9796477|NCT01567306|Placebo Comparator|Placebo - Group 6|
9796478|NCT01567371|Experimental|LiDCO rapid monitor|
9796479|NCT01567462|Active Comparator|Monopolar Electrocautery|The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.
9796480|NCT01567462|Active Comparator|PK Button Vaporization Electrode|Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.
9796481|NCT01567527|Active Comparator|1|Active Comparator: Treatment of Aripiprazole IM Depot
9796482|NCT01567527|Placebo Comparator|2|Placebo Comparator: Treatment of IM Depot Placebo
9796483|NCT01567826|Active Comparator|standard of care lipid therapy|standard-care lipid-lowering therapy: Zocor or Lipitor
9796484|NCT01567826|Experimental|aggressive lipid therapy|aggressive lipid therapy: Crestor
9796485|NCT01567839|Experimental|4% Lidocaine|1.8 mL of 4% lidocaine with 1:100,000 epinephrine
9796486|NCT01567839|Experimental|4% Articaine|1.8 mL of 4% articaine with 1:100,000 epinephrine
9796487|NCT01567839|Experimental|4% Prilocaine|1.8 mL of 4% prilocaine with 1:200,000 epinephrine
9796488|NCT01567852|Experimental|Ketamine First|This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
9796489|NCT01567852|Experimental|Methohexital First|This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
9796490|NCT01567865|Active Comparator|Reference Lot|Lot of Vaccine produced in existing facility
9796491|NCT01567865|Experimental|New Lot #1|First lot of vaccine produced in new facility
9796492|NCT01567865|Experimental|New Lot #2|Second lot of vaccine produced in new facility
9796493|NCT01567865|Experimental|New Lot #3|Third lot of vaccine produced in new facility
9796494|NCT01567891|Experimental|Cohort 1|This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells.
9796495|NCT01567943|Experimental|Contingency Management|Contingency Management plus treatment as usual
9796496|NCT01567943|No Intervention|Non-contingent control group|Treatment as usual plus reinforcement for attendance
9796497|NCT01568008||All participants|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
9796498|NCT01568021||OZURDEX®|Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.
9796499|NCT01568034|Experimental|Treatment Sequence A|"Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9796500|NCT01568034|Experimental|Treatment Sequence B|"Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9796501|NCT01568034|Experimental|Treatment Sequence C|"Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9796502|NCT01568034|Experimental|Treatment Sequence D|"Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9796503|NCT01568047|Placebo Comparator|Placebo|"PLC, Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9796504|NCT01568047|Experimental|BIA 9-1067 - 5 mg|"5 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9796505|NCT01568047|Experimental|BIA 9-1067 - 15 mg|"15 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9987108|NCT01409083|Experimental|intravenous bicarbonate|Diluted sodium bicarbonate will be injected to s new IV catheter expecting a rise in end-tidal CO2
9987109|NCT01409083|Placebo Comparator|control|equal volume of normal saline will be randomely injected
9987110|NCT01409109||Patient volunteers|This group is comprised of persons with Schizophrenia and Schizoaffective.
9987111|NCT01409109||Healthy volunteers|This group is comprised of individuals who have no current or past psychiatric diagnosis.
9987112|NCT01409122|Experimental|Part A Multiple Dose|Ascending multiple dose administration (every 8 hours, [Q8H]) of AIR001 or placebo for 16 consecutive doses
9987113|NCT01409122|Experimental|Part B Single Dose with Sildenafil|Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)
9987114|NCT01409122|Experimental|Part C, administration of AIR001 to patients with PAH|Four doses of AIR001 will be administered via nebulization to patients with PAH.
9987115|NCT01409122|Experimental|Part D, device crossover study|PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.
9987116|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 1|
9987117|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 2|
9987118|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 3|
9987119|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 4|
9987120|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 5|
9987121|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 6|
9987122|NCT01409135|Experimental|ASG-22CE Expansion Cohort 1|Breast Cancer
9987123|NCT01409135|Experimental|ASG-22CE Expansion Cohort 2|Bladder Cancer
9987124|NCT01409135|Experimental|ASG-22CE Expansion Cohort 3|Lung plus other solid tumor cancers
9987125|NCT01409148|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
9987126|NCT01409161|Experimental|Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)|"INDUCTION: Patients receive tretinoin PO BID, arsenic trioxide IV over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at weeks 1-4.~CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks 1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
9987127|NCT01409174|Experimental|Ipilimumab + Chemotherapy|Ipilimumab starting 1 mg/kg by vein (IV) Day 1 each cycle; Temozolomide 200 mg/m^2 orally Days 2-5 of Induction; Cisplatin 25 mg/m^2 IV for Days 2-4 of Induction; Interferon alfa-2b 5 million U/m2 subcutaneously on Days 1-5 of each cycle Induction + Consolidation; and Interleukin-2 9 million IU/m^2 IV as a continuous infusion on Days 2-5 of Induction + Consolidation.
9987128|NCT01409187|Experimental|Ipilimumab + Interferon + Interleukin-2|Ipilimumab starting dose 2 mg/kg intravenous (IV) day 1 only; IFN alfa-2b at 5 million U/m2 subcutaneously daily for 5 days starting day 1; IL-2 at 9 million IU/m^2 daily IV continuous infusion for 4 days on days 2-5.
9987129|NCT01409226|Experimental|MRI|
9987130|NCT01409252||Hemorrhagic stroke patients|
9987131|NCT01409265||No treatment|
9987132|NCT01409278|Experimental|Ropivacaine infiltration and infusion.|Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
9987133|NCT01409278|Experimental|Ropivacaine and Saline|Ropivicaine infiltration followed by normal saline infusion.
9987134|NCT01409278|Placebo Comparator|Saline infiltration and infusion.|Normal saline infiltration followed by saline infusion.
9796506|NCT01568047|Experimental|BIA 9-1067 - 30 mg|"30 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
9987135|NCT01409317|Experimental|Deep Transcranial Magnetic Stimulation|
9987136|NCT01409317|Active Comparator|Repetitive Transcranial Magnetic Stimulation|
9987137|NCT01409330|Experimental|hypocaloric diet containing increased fibers and coffee|In the intervention group the patients are allowed to eat only white meat and fish. They also need to increase their daily fiber intake to 50grams and drink 5 cups of coffee a day.
9987138|NCT01409330|Active Comparator|hypocaloric diet containing red meat|control group (n=20): diet according to the ADA/EASD guidelines (50% carbohydrates, 20% proteins, 30% fat). In the control group the patients should eat 150 grams of red meat a day and are not allowed to consume alcohol, coffee and whole grains.
9987139|NCT01409343|Experimental|TrasGEX|A total of 37 patients with advanced HER2-positive carcinomas and progressive disease.
9987140|NCT01409356|Experimental|Diet+Exercise|Program of weight loss through diet+exercise (=intervention)
9987141|NCT01409369|Experimental|1|
9987142|NCT01409369|Active Comparator|2|
9987143|NCT01409395|Experimental|Metformin|Subjects will be dosed with Metformin alone (850 mg)
9987144|NCT01409395|Experimental|Metformin and Nizatidine|Subjects will be dosed with metformin in conjunction with nizatidine
9987145|NCT01409408|Active Comparator|Aliskiren|
9987146|NCT01409408|Active Comparator|Amlodipine|
9987147|NCT01409421|Experimental|motivational interviewing|3 phone and 3 in person counseling support sessions with glaucoma educator
9987148|NCT01409421|Active Comparator|reminder calls|behavioral: three phone calls to remind patients to take their eye drops
9987149|NCT01409421|No Intervention|standard care|standard care for glaucoma
9987150|NCT01409447|Experimental|Biphasic osteochondral composite|feasibility study for the new medical device & technique
9987151|NCT01409460|Experimental|True Obturator Nerve Block|
9987152|NCT01409460|Sham Comparator|Sham Block|
9987153|NCT01409473|Experimental|Prostate SBRT|Prostate SBRT with concurrent boost to intraprostatic lesion (IPL) will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
9987154|NCT01409499|Experimental|A, surgery|The patients in this group will receive palliative resection of HCC, then take sorafenib as remain therapy.
9987155|NCT01409499|Experimental|B, TACE|Patients in group B will receive transcatheter hepatic arterial chemoembolization, then take sorafenib as remain therapy.
9987156|NCT01409499|Experimental|C, sorafenib|Patients in group C will receive monotherapy of sorafenib.
9873827|NCT00338377|Experimental|Group A: Chemotherapy + IL-2 plus T-cells|"Cyclophosphamide 60 mg/kg/d by vein (IV) over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.~Group A has been closed to new patient entry as of January 14, 2016."
9873828|NCT00338377|Experimental|Group B: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
9873829|NCT00338377|Experimental|Group C: Prior Treatment with BRAF Inhibitor|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
9873830|NCT00338377|Experimental|Group D: Leptomeningeal Disease|"T-cells: 5.0x109 TIL administered on Day 1 and 10x109 TIL on Day 15.~IL-2: 1.2 MIU of IL- 2 on Days 2, 4, 9, 11, 16 and 18 as tolerated. After this period, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks, patients switched to IL-2."
9873831|NCT00338377|Experimental|Group E: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
9873832|NCT00338390|No Intervention|1|Maintain antiretroviral treatment
9873833|NCT00338390|Experimental|2|Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
9873834|NCT00338390|Experimental|3|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
9873835|NCT00338429|Experimental|Treatment: FHP Sleep Program|Stratified with or without behavior Disorder Diagnosis (ADHD): 50% randomized to receive Better Days, Better Nights- sleep distance intervention
9873836|NCT00338429|No Intervention|Control: Usual Care|Stratified with/without behavior diagnosis (ADHD): 50% randomized to receive usual care for sleep disorder
10211370|NCT04896658|Experimental|Arm A|"Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.~Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 3 weeks cycles."
9873837|NCT00338481|Active Comparator|1|
9873838|NCT00338481|Active Comparator|2|
9873839|NCT00338494|Experimental|1|
9873840|NCT00338520||Healthy Controls (HC)|Healthy control children will be enrolled from out-patient well-baby visits.
9873841|NCT00338520||Uncomplicated Malaria (UM)|Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
10211371|NCT04896658|Experimental|Arm B|"Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.~Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 6 weeks cycles."
10211372|NCT04894747|Experimental|Mycoprotein|Bolus ingestion of mycoprotein providing 25g of protein.
10211373|NCT04894747|Experimental|Pea protein|Bolus ingestion of pea protein providing 25g of protein.
10211374|NCT04894747|Experimental|Mycoprotein/pea protein dry blend|Bolus ingestion of mycoprotein/pea protein dry blend providing 25g of protein.
10211375|NCT04889469||Breast hypertrophy operated|Women who have had a breast reduction in the public health care system
10211376|NCT04889469||Breast hypertrophy controls|Women with symptoms of breast hypertrophy, who do not fulfill the requirements to have a breast reduction in the public health care system
10211377|NCT04889469||Augmented controls|Patients who have breast hypertrophy due to cosmetic breast augmentation
10211378|NCT04889469||The general public|Random sample of the general public
10211379|NCT04879810|Active Comparator|Ginger exosomes|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
10211380|NCT04879810|Active Comparator|Curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
10211381|NCT04879810|Active Comparator|Ginger exosomes plus curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
10211382|NCT04879459||Intervention Group IG|"The IG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0 (same video as in CG). Participants undertake 3 times a one-day CUS course consisting in 2 practical sessions of 10 times 10 minutes on 10 healthy volunteers on day 0, day 7 and day 10. One practical session takes place before lunchtime, the second one after lunchtime.~Participants of IG don't have any contact with CG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
10213729|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
9796507|NCT01568073|Experimental|BIA 9-1067|OPC, Opicapone
9796508|NCT01568073|Active Comparator|Entacapone|Comtan®; Active comparator
9796509|NCT01568073|Placebo Comparator|Placebo|PLC, Placebo
9796510|NCT01568112|Experimental|BG00012|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
9796511|NCT01568112|Placebo Comparator|Placebo|Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
9796512|NCT01568112|Experimental|BG00012 + ASA|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
9796513|NCT01568112|Experimental|BG00012 Slow Titration|Participants received BG00012 for 8 weeks (120 mg once daily [QD] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
9796514|NCT01568255|Experimental|Vitamin D Treatment|Vitamin D Treatment Group
9796515|NCT01568255|Placebo Comparator|Placebo Group|Placebo at 50,000IU for 8 weeks
9796516|NCT01568320|Experimental|Endovascular|Endovascular Treatment (Zenith)
9796517|NCT01568424|Other|Treatment Group|Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.
9796518|NCT01568528|Experimental|Oxytocin|The intranasal oxytocin intervention will be the administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. Each puff is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
9796519|NCT01568528|Placebo Comparator|Placebo|"Intranasal placebo The PBO/control will consist of the OT vehicle administered as three puffs in each nostril. Each puff is is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally.~Treatment assignment will be by random allocation in blocks of six. Both experimenters and subjects will be blind to the treatment they are receiving."
9796520|NCT01568528|Other|Healthy Controls|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will not receive oxytocin or placebo. They will only receive psychiatric screening interview, MATRICS Consensus Cognitive Battery (MCCB) assessment, urine drug screen, vision testing, and the three social cognition tasks.
9796521|NCT01568593|Experimental|T2750|
9796522|NCT01568593|Active Comparator|Vismed|
9796523|NCT01568606|Experimental|Body Composition Analysis InBody Scale|
9796524|NCT01568827|Experimental|Blackraspberry slurry, washout, water|Blackraspberry slurry daily x 5 days, 2 day washout, 8 oz. water daily x 5 days
9796525|NCT01568827|Experimental|Water, washout, Blackraspberry slurry|8 oz. water daily x 5 days, 2 day washout, Blackraspberry slurry daily x 5 days
9796526|NCT01568866|Experimental|Carfilzomib plus Dexamethasone|Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
9796527|NCT01568866|Active Comparator|Bortezomib plus Dexamethasone|Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
9796528|NCT01568892|Experimental|DTG 50 mg BID|Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
9796529|NCT01568892|Experimental|Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase|Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
10211383|NCT04879459||Control Group CG|"The CG is constituted of participants, naïve to ultrasound use. Participants undergo a web-based video learning about gallbladder evaluation using CUS on day 0. Participants of CG undertake 2 practical CUS sessions of 10 times 10 minutes on 10 volunteers, at least 50% of them suffering from gallstones on day 0, day 7 and day 10. One session takes place before lunchtime, the second one after lunchtime.~Participants of CG don't have any contact with IG during study days. An evaluation is organized on day 60 to evaluate primary and secondary endpoints."
9796530|NCT01568905|Experimental|Arm 1 Low Level Nicotine Cigarette|(0.4 mg/g)
9796531|NCT01568905|Experimental|Arm 2 Intermediate Nicotine Level Cigarette|(5.7-5.8 mg/g)
9796532|NCT01568905|Experimental|Arm 3 High Level Nicotine Cigarette|(11.4-12.8 mg/g)
9796533|NCT01568944|Experimental|Oral Antibiotic and Oral Rinse|Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
10211384|NCT04878952|No Intervention|Arm I: Usual Care|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.
10211385|NCT04878952|Experimental|Arm II: Usual Care + Continuous physical activity monitoring via a wearable device|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.
10211386|NCT04875338|Active Comparator|saline injection|2ml %0.9 NACI(Saline )injection to effected lateral epicondyle
9796534|NCT01568944|Other|Standard Treatment|Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
9796535|NCT01569022|Active Comparator|CPAP First, MAD|"CPAP treatment for sleep apnea~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks"
9796536|NCT01569022|Experimental|MAD First, CPAP|"MAD treatment for sleep apnea~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks"
9796537|NCT01569074|Experimental|Dosing A regimen|Oral treatment
9796538|NCT01569074|Experimental|Dosing B regimen|Oral treatment
9796539|NCT01569074|Experimental|Dosing C regimen|Oral treatment
9796540|NCT01569074|Experimental|Dosign D regimen|Oral treatment
9796541|NCT01569074|Placebo Comparator|Dosing E regimen|Oral treatment
9796542|NCT01569087|Experimental|Empegfilgrastim 3 mg|Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy
9796543|NCT01569087|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy
9796544|NCT01569087|Active Comparator|Filgrastim|Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
9796545|NCT01569126|Experimental|5 milligrams (mg) LY110140 (SD)|5 mg administered once in the fasted state on Day 1
9796546|NCT01569126|Experimental|20 mg LY110140 (SD)|20 mg administered once in the fasted state on Day 1
9796547|NCT01569126|Experimental|40 mg LY110140 (SD)|40 mg administered once in the fasted state on Day 1
9796548|NCT01569126|Placebo Comparator|Placebo (MD)|Placebo once daily oral dosing for 28 consecutive days
9796549|NCT01569126|Experimental|20 mg LY110140 (MD)|20 mg once daily oral dosing for 28 consecutive days
9796550|NCT01569126|Experimental|40 mg LY110140 (MD)|40 mg once daily oral dosing for 28 consecutive days
9796551|NCT01569152|Experimental|Base Study Phase IIa: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
9796552|NCT01569152|Placebo Comparator|Base Study Phase IIa: Placebo|Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
9796553|NCT01569152|Experimental|Safety Extension Period 3: MK-8457|Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
9796554|NCT01569191|No Intervention|No Treatment|Exposure to grass pollen only
9796555|NCT01569191|Active Comparator|Artificial Tear Supplement|Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
9796556|NCT01569191|Active Comparator|Cold compress|Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
9796557|NCT01569191|Active Comparator|Anti-allergic Medication|ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
9796558|NCT01569295|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib plus bendamustine and rituximab
9796559|NCT01569295|Placebo Comparator|Placebo to match idelalisib+bendamustine+rituximab|Participants will receive placebo to match idelalisib plus bendamustine and rituximab
9796560|NCT01569438|Experimental|Gefapixant|Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
9796561|NCT01569438|Placebo Comparator|Placebo|Female participants receive dose matched placebo tablets, BID, orally, with food for 4 weeks.
9796562|NCT01569451|Active Comparator|(Placebo and) Glatiramer Acetate|Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
9796563|NCT01569451|Experimental|Rituximab and Glatiramer Acetate (R-GA)|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
9796564|NCT01569464|Active Comparator|Rotigotine|Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.
9796565|NCT01569464|Placebo Comparator|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours~7 weeks"
9796566|NCT01569529||No ad exposure|Young adults, who enroll in the cessation program, one month prior to presenting the online advertisements (intervention).
9796567|NCT01569529||Ad exposure|Young Adults, who register for the cessation program, by clicking through the online advertisements (intervention).
9796568|NCT01569568||Subjects with OTCD|"males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
9796569|NCT01569568||Healthy controls|"males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
9796570|NCT01569594||Carotid Endarterectomy Subjects|Subjects undergoing patch angioplasty of the carotid artery following carotid endarterectomy using the CorMatrix ECM for Carotid Repair
9796571|NCT01569607|Experimental|Hebbian-type Stimulation|Participants will be randomized to receive motor training with Hebbian-type stimulation.
9796572|NCT01569607|Sham Comparator|Sham Stimulation|Participants will be randomized to receive sham stimulation.
9796573|NCT01569737||ella|
9796574|NCT01569763|Active Comparator|hysteroscopic rollerball resection/ablation|
9796575|NCT01569763|Experimental|Aurora Endometrial Ablation|
9796576|NCT01569815|Experimental|LCZ696 400 mg|LCZ696 400 mg once daily for 5 days
9796577|NCT01569828|Experimental|Renal Impaired Subjects|once daily administration of 400 mg LCZ696 for 5 days
9796578|NCT01569828|Experimental|Healthy Volunteers|once daily administration of 400 mg LCZ696 for 5 days
9796579|NCT01569841|Experimental|IDeg|
9796580|NCT01569841|Active Comparator|IGlar|
9873842|NCT00338520||Cerebral Malaria (CM)|Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
9873843|NCT00338520||Non-malaria CNS disease (NMC)|Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
9873844|NCT00338559||LMA group|Patients in which laryngeal mask airway (LMA) is used.
9873845|NCT00338559||ET group|Patients in which endotracheal tube (ET) is used.
9873846|NCT00338572|Active Comparator|1|12-week exercise program
9873847|NCT00338572|Experimental|2|12-week combined exercise and diet program
9873848|NCT00338572|No Intervention|3|Non-intervention group
9873849|NCT00338689|Experimental|Lower protein formula|"Intervention: Infant formula with relatively low protein content (1.25 g/ 100 ml) during the first year of life; described as Lower protein formula"
9873850|NCT00338689|Placebo Comparator|Higher protein formula|"Intervention: Infant formula with a relatively high protein content (2.05 g/ 100 ml) during the first year of life; described as Higher protein formula"
9873851|NCT00338689|No Intervention|Breastfed reference group|Non-randomized breastfed group of infants at least 3 months exclusively breastfed
9873852|NCT00338715|Experimental|A|Prophylactic Pulmonary Vein Isolation in Addition to CABG for the prevention of postoperative Atrial Fibrillation
9873853|NCT00338767|Experimental|Treatment|Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
9873854|NCT00338767|No Intervention|Control|Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project
9873855|NCT00338832|Experimental|1|Participants will receive the Physically Ready for Invigorating Movement Every Day program
9873856|NCT00338832|Active Comparator|2|Participants will receive the Program for Activity, Leisure Skills, and Socialization
9873857|NCT00338845|Experimental|1|Participants will receive the Share Safer Sex counseling program
9873858|NCT00338845|Active Comparator|2|Participants will receive a standard didactic safer-sex counseling session
9873859|NCT00338858|Active Comparator|1|TD
9873860|NCT00338858|Experimental|2|TBI
9873861|NCT00338858|Experimental|a|Cerebral palsy
9873862|NCT00338871|Experimental|study|home exercise
9873863|NCT00338871|No Intervention|control|regular therapy
9873864|NCT00338923|Active Comparator|Treatment arm|One Arm - Active Compound (HO/03/03)
9873865|NCT00338975|Experimental|1|Cognitive Behavioral Social Skills Training (CBSST)
9873866|NCT00338975|Active Comparator|2|Goal-Focused Supportive Contact (GFSC)
9873867|NCT00339014|Active Comparator|Group 1|Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day
9873868|NCT00339014|Active Comparator|Group 2|Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day
9873869|NCT00339014|Active Comparator|Group 3|Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day
9873870|NCT00339014|Active Comparator|Group 4|Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day
9873871|NCT00339014|Active Comparator|Group 5|Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day
9873872|NCT00339014|Active Comparator|Group 6|Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day
9873873|NCT00339014|Placebo Comparator|Group 7|
9873874|NCT00339027||Preschool children|Children aged 3-5 years who are enrolled in federally-subsidized early care and education centers in underserved communities in Miami-Dade County
9873875|NCT00339092|Experimental|Treatment|Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
9873876|NCT00339092|Active Comparator|Control|Participants who receive standard care
9873877|NCT00339170|Experimental|1|Participants receive a 12-month cognitive enhancement training program plus a 12-month work therapy program.
9873878|NCT00339170|Active Comparator|2|Participants receive a 12-month work therapy program alone.
9873879|NCT00339196|Experimental|1|5-azacytidine VALPROIC acid and ATRA
9873880|NCT00339222||1|Melanoma-prone families from dermatology clinics.
9873881|NCT00339326||Cases with Kaposi's Sarcoma|Cases with Kaposi's Sarcoma from Southern Italy.
9796581|NCT01570036|Experimental|Herceptin + NeuVax vaccine|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. Patients will be blinded regarding assigned arm. After completion of primary vaccine series, patients will receive 4 NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.
9796582|NCT01570036|Active Comparator|Herceptin + GM-CSF only|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF only. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.
9796583|NCT01570192|Experimental|IV meropenem; parenteral aminoglycoside|"Subjects assigned to this group will receive:~IV meropenem (2 g infused over 3 hrs q 8 hr);~a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)~tobramycin nebulization~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens."
9796584|NCT01570192|Active Comparator|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.~**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion."
9796585|NCT01570244|Experimental|Reference|multiple doses of Microgynon
9796586|NCT01570244|Active Comparator|Test|multiple doses of Microgynon + BI 201335
9796587|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Prophylaxis|Cohort 1 prophylaxis: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
9796588|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Treatment|Cohort 1 treatment: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
9796589|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Prophylaxis|Cohort 2 prophylaxis: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
9796590|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Treatment|Cohort 2 treatment: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
9796591|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Prophylaxis|Cohort 3 prophylaxis: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
9796592|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Treatment|Cohort 3 treatment: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
9796593|NCT01570309|Active Comparator|Ergocalciferol|50,000 units of ergocalciferol once a week for 12 weeks
9796594|NCT01570309|Placebo Comparator|Sugar pill|
9796595|NCT01570348|Experimental|Treatment (allogeneic BMT)|"CONDITIONING THERAPY: Patients receive fludarabine phosphate IV over 30-60 minutes QD on days -6 to -2 and cyclophosphamide IV over 1-2 hours QD on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo donor BMT on day 0.~IMMUNOSUPPRESSIVE THERAPY: Patients receive high-dose cyclophosphamide IV over 1-2 hours QD on days 3-4, tacrolimus IV daily or PO BID on days 5-180 with taper to day 365, and mycophenolate acid enteric coated or mycophenolate mofetil PO TID on days 0-35."
9796596|NCT01570361|Experimental|Catheter Ablation|Radiofrequency catheter ablation treatment in subjects with Paroxysmal Atrial Fibrillation (PAF)
9796597|NCT01570361|Active Comparator|Drug Treatment|Drug therapy (either rate or rhythm control) using current AF management guidelines
9796598|NCT01570387|Experimental|Phase I - cohort 1 (Pomalidomide 2mg) plus Dexamethasone|Pomalidomide 2 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
9796599|NCT01570387|Experimental|Phase I - cohort 2 (Pomalidomide 3mg) plus Dexamethasone|Pomalidomide 3 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
9796600|NCT01570387|Experimental|Phase I - cohort 3 (Pomalidomide 4mg) plus Dexamethasone|Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
9796601|NCT01570387|Experimental|Phase II Expansion- (Pomalidomide 4mg) plus Dexamethasone|"Expansion Phase:~Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle"
9796602|NCT01570491|Active Comparator|ultrasound-guided spinal anesthesia|participants will randomly assigned to use ultrasound-guided technique for block placement by Anesthesiologist.
9796603|NCT01570491|Placebo Comparator|standard spinal anesthesia|randomized participants will be given standard spinal anesthesia insertion technique for block placement by Anesthesiologist
9796604|NCT01570686|Experimental|Aliskiren: Fed|Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
9796605|NCT01570686|Experimental|Aliskiren: Fasting|Aliskiren 300 mg once daily taken after after an overnight fast
9796606|NCT01570751|Experimental|IDeg followed by IGlar|
9796607|NCT01570751|Experimental|IGlar followed by IDeg|
9796608|NCT01570829|Experimental|Dietressa|Tablet for oral use. 1 tablet 6 times a day. The duration of Dietressa therapy is 24 weeks.
9796609|NCT01570829|Placebo Comparator|Placebo|Tablet for oral use. 1 tablet 6 times a day. The duration of Placebo therapy is 24 weeks.
9796610|NCT01570868|Experimental|Ponatinib 45 mg|Ponatinib at a dose of 45 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
9796611|NCT01570868|Experimental|Ponatinib 30 mg|Ponatinib at a dose of 30 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
9796612|NCT01571232|Active Comparator|Ozurdex|Patients in this group receive Ozurdex at initial visit and at month 4
9796613|NCT01571232|Active Comparator|Avastin|Patients in this group receive Avastin Q1 month for 5 months.
9796614|NCT01571284|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
9796615|NCT01571362|Experimental|ALO-02|
9796616|NCT01571362|Placebo Comparator|Placebo|
9796617|NCT01571427|Placebo Comparator|Control group|No daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
9796618|NCT01571427|Active Comparator|Active social engagement group|Engage in 30 minutes video chat daily (5 times per week, except weekend) with interviewers for 6 weeks. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
9796619|NCT01571453|Experimental|Vortioxetine (Lu AA21004)|
9796620|NCT01571453|Active Comparator|Venlafaxine extended release|
9796621|NCT01571557||OZURDEX®|OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care.
9796622|NCT01571596|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)
9796623|NCT01572038|Experimental|Pertuzumab + Trastuzumab + Taxane|Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
9796624|NCT01572298|Active Comparator|allograft alone|guided bone regeneration with allograft alone (includes tenting screws and overlying allograft membrane material)
9796625|NCT01572298|Experimental|allograft with autograft|guided bone regeneration with allograft and autograft combined (includes tenting screws and overlying allograft membrane material)
9796626|NCT01572389|Experimental|Arm 1: HOPE|The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals.
9796627|NCT01572389|Active Comparator|Arm 2: EUC|The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions.
9796628|NCT01572428|Active Comparator|Narrow-Band Imaging (NBI)|Inspection with Narrow-Band Imaging(NBI) versus inspection with standard white light(usual care)
9796629|NCT01572428|Active Comparator|Standard White Light|Inspection with Standard White Light versus Narrow-Band Imaging(NBI)
9796630|NCT01572727|Experimental|BKM120 and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel.
9873882|NCT00339326||Controls without KS|Controls from Southern Italy.
9873883|NCT00339352||1|Cases
9873884|NCT00339352||2|Controls
9873885|NCT00339352||3|first-degree relatives of cases/controls
9873886|NCT00339365|Experimental|1|Promoting first relationships group
9873887|NCT00339365|Active Comparator|2|Early education support group
9873888|NCT00339469|Other|2|Controlled feeding study.
9873889|NCT00339521||Case-Parent Triad|Childhood Asthmatics (aged 4-17) are Cases; biologic parents of cases are genetic Controls.
9929267|NCT00914914|Experimental|p28 Phase I Safety|A total of 15 patients were administered p28 i.v. as a short infusion three times per week for 4 weeks followed by a 2-week rest under an accelerated titration 3þ3 dose escalation design.
9929268|NCT00914953|Experimental|oxytocin|
9929269|NCT00914979|Experimental|1|Single Arm - Interventional
9929270|NCT00915044||IBD patients|Approximately 40 patients (adults and children) suffering from IBD will be enrolled.
9929271|NCT00915044||Controls|Approximately 100 healthy controls
9929272|NCT00915057|Experimental|NRL972|Single 2mg intravenous dose of NRL972, administered on up to seven occasions
9929273|NCT00915070|Active Comparator|BQ-123|
9929274|NCT00915070|Placebo Comparator|Physiological saline solution|
9929275|NCT00915083|Experimental|Amrubicin 40mg/m^2|Amrubicin 40mg/m^2 given as a 5 minute IV infusion on Days 1, 2 & 3 of a 21 day cycle
9935354|NCT03855215|Experimental|Intervention|"The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.~Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.~The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:~CRP level < 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level > 40 mg/L: antibiotics are recommended."
9935355|NCT03855215|No Intervention|Control|Working as routine
9935356|NCT03854318||Family|Direct family members of enrolled patients will be asked to enroll in the study to provide specimens for genetic testing, next-generation sequencing, and other related studies.
9935357|NCT03854318||RUNX1|Patients enrolled in this protocol will have been referred with a known or suspected RUNX1 mutation.
9935358|NCT03850782|Experimental|Bimatoprost SR - Dose A|"Study Eye: Participants will receive 1 - 3 Cycles of Bimatoprost SR administrations of Dose A~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
9935359|NCT03850782|Experimental|Bimatoprost SR - Dose B|"Study Eye: Participants received 1-3 Cycles of Bimatoprost SR administrations of Dose B~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
9935360|NCT03845218||single arm|participants with and without RP
9935361|NCT03844750|Experimental|Treatment (vactosertib, pembrolizumab, surgery)|"Neoadjuvant pembrolizumab will be administered at a fixed dose of 200 mg (IV) for 1 cycle plus 200 mg vactosertib (PO QD, 5 days per week x 2 weeks).~Adjuvant pembrolizumab (400 mg IV) + vactosertib (200 mg PO QD Cycle 1, 5 days per week, Cycles 2 and beyond (200 mg BID, 5 days per week) will be administered for up to eight 6-week cycles"
9935362|NCT03841617|Active Comparator|124I PET/CT scan after rhTSH|124I PET/CT scan after preparation with human recombinant TSH
9935363|NCT03841617|Active Comparator|124I PET/CT scan after thyroid hormone withdrawal|124I PET/CT scan after preparation with thyroid hormone withdrawal
9935364|NCT03835767|Experimental|Milk DBPCFC|There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: -All participants who eat baked milk less than once per month. -Participants who never eat baked milk or straight milk. .On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
9935365|NCT03835767|Experimental|One-Step Open Feeding|Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
9935366|NCT03835767|Experimental|Peanut DBPCFC|The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: -All participants who eat peanut less than once per month -Participants who never eat peanut. never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
9935367|NCT03835767|Experimental|Two-Step Open Feeding|Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
9935368|NCT03833206|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
9935369|NCT03833206|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
9935370|NCT03831958||Family member|Family member of survivor of pediatric Cushing disease
9935371|NCT03831958||Subjects|survivor of pediatric Cushing disease
9873890|NCT00339534||Cases|Cases were recruited at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012.
9873891|NCT00339534||Controls|Controls were selected in a population-based component using a probability sample designed with the 2000 Ghana Population and Housing Census data between 2004 and 2006.
9873892|NCT00339560||Cases will bile duct CA|Patients with bile duct cancer
9873893|NCT00339560||Cases with Gallbladder CA|Patients with gallbladder cancer
9873894|NCT00339560||Controls with gall stones|Patients undergoing cholecystectomy for gall stones
9873895|NCT00339560||Controls without cancer|Hospital controls with cancer
9873896|NCT00339573||National Housing Stock|The target population of this study was the national housing stock (1998-1999) ofapproximately 95 million housing units.
9873897|NCT00339612||HIV-infected children who acquired HIV infection through mothe|HIV-infected children in who acquired HIV infection through mother-to-child transmission (MTCT).
9873898|NCT00339625|Experimental|1|low fat, high fiber, high fruit and vegetable eating plan
9873899|NCT00339625|No Intervention|2|Usual Diet
9873900|NCT00339651||Cases|Women in one large U.S. health care plan. Cases will consist of women who developed endometrial carcinoma or censored complex atypical hyperplasia at least 1 year after receiving a diagnosis of endometrial hyperplasia.
9873901|NCT00339651||Controls|Women in one large U.S. health care plan. Controls will consist of individually matched women who received a diagnosis of endometrial hyperplasia at the same age and date as the cases and were cancer-free and hysterectomy-free until the date at which the index cases were diagnosed with endometrial carcinoma or censored complex atypical hyperplasia.
9873902|NCT00339664||1/ patients|Patients on approved clinical trials
9873903|NCT00339677||Volunteers|Volunteers
9873904|NCT00339690|Experimental|Test Kit Homes|Households assigned to use the in-home test kit.
9873905|NCT00339703||Control|Subjects between the ages of 18 and 65 without a diagnosis of asthma or other inflammatory disease were enrolled from the patient population at Wilford Hall Medical Center. Subjects underwent a single blood draw and spirometer.
9873906|NCT00339703||Mild to Moderate Asthma|Subjects between the ages of 18 and 65, who were previously diagnosed with moderate to severe persistent asthma as defined by the National Asthma Education and Prevention Program (NAEPP), were enrolled from the Allergy and Immunology clinic at Wilford Hall Medical Center. Subjects on inhaled corticosteroids or other controller medications were allowed in the study, but subjects on oral corticosteroids were excluded. Subjects underwent a single blood draw and spirometer.
9873907|NCT00339716||Belarus in utero|subjects exposed to I131 in utero
9873908|NCT00339716||Main BelAm|subjects exposed to I131 at age less than 18 year
9873909|NCT00339742||Clinic Referral controls|Controls referred by the endoscopy clinic
9873910|NCT00339742||Esophageal Cancer cases|Histologically confirmed squamous cell cancer of the esophagus
9873911|NCT00339742||Neighborhood controls|Controls recruited from the neighborhood
9873912|NCT00339768|Experimental|Amox/omepr|2 weeks; placebo controlled
10211387|NCT04875338|Active Comparator|platet riched plasma injection|2 ml prp )injection to effected lateral epicondyle
10211388|NCT04875338|Active Comparator|betametazon injection|2 ml betametazon )injection to effected lateral epicondyle
10211389|NCT04867759||Study group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
10211390|NCT04867759||Control group|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
9873913|NCT00339768|Experimental|Garlic|Supplement for 7 years; placebo controlled
9873914|NCT00339768|Experimental|Vitamins|Supplement for 7 years; placebo controlled
9873915|NCT00339859||1|The population controls are collected from DMV records in the Baltimore region of MD. The cases are patients at the University of Maryland Medical System, including the associated Veterans' Association Hospital.
9873916|NCT00339885||AADM|Family and Population based individuals
10211391|NCT04864392|Experimental|LNA043 Dosing Regimen A|LNA043 injection to the knee with dosing regimen A
10211392|NCT04864392|Experimental|LNA043 Dosing Regimen B|LNA04 injection to the knee with dosing regimen B
10211393|NCT04864392|Experimental|LNA043 Dosing Regimen C|LNA043 injection to the knee with dosing regimen C
9873917|NCT00339885||Action-LADA|Population based individuals
9873918|NCT00339885||D2D 2004|Population based individuals
9873919|NCT00339885||DIAGEN (Dresden Biobank)|Population based individuals
9873920|NCT00339885||FINRISK 1987|Population based individuals
9873921|NCT00339885||FINRISK 2002|Population based individuals; Test DNA
9873922|NCT00339885||Fusion 1|Affected-sib pair (ASP) families and elderly controls
9873923|NCT00339885||Fusion 2|275 Replication ASP Families; Trios
9873924|NCT00339885||Fusion 3|Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
10211394|NCT04864392|Experimental|LNA043 Dosing Regimen D|LNA043 injection to the knee with dosing regimen D
10211395|NCT04864392|Placebo Comparator|Placebo|Injection to the knee
9873925|NCT00339885||Fusion 4/5|Spouses, Offspring of FUSION 1 and 2 Families
9873926|NCT00339885||FUSION Finnish Groups|Family and Population based (including METSIM and DR's EXTRA): Tissue samples
9873927|NCT00339885||Health-2000|Population based individuals
9873928|NCT00339885||HUNT 2|Population based individuals
9873929|NCT00339885||METSIM|Population based individuals
9873930|NCT00339885||Savitaipale|Population based individuals
9873931|NCT00339885||UEF - Laakso|Monogenic disease individuals and family members
9873932|NCT00339937||Cases|Adults in Italy with Kaposi's sarcoma
9873933|NCT00339937||Controls|Adults in Italy without Kaposi's sarcoma
9873934|NCT00339950||1|Asymptomatic women between the ages of 40 and 75 referred to regional military medical centers for routine colorectal screening
9873935|NCT00339989||Women undergoing colposcopy|women attending the University of Oklahoma Colposcopy Clinic
9873936|NCT00340210||Serum Bank Participants|The Columbia MO Serum Bank recruited 6915 women living in and around Columbia MO between 1977-1987 who were cancer-free except for non-melanoma skin cancer and at least 18 years of age.
9873937|NCT00340262||FIT Participants|
9873938|NCT00340288||Premenopausal fibroid cases|Premenopausal women (18 years or older) with at least one uterine leiomyoma diagnosis confirmed by ultrasound
9873939|NCT00340340||Cases|Newly diagnosed lung cancer cases
9873940|NCT00340340||Controls|Population-based controls
9873941|NCT00340457||Cases|African American patients with renal cancer from two geographic areas of the US
9873942|NCT00340457||Controls|African American participants without renal cancer from two geographic areas of the US
9873943|NCT00340535||Individuals|Individuals recruited at U of Pittsburgh
9873944|NCT00340600||DES Exposed|DES-exposed mothers, daughters and sons, and identified subjects
9873945|NCT00340600||DES Unexposed|DES-unexposed mothers, daughters and sons, and identified subjects
9873946|NCT00340626||Control|healthy individuals with no history of oral cleftsto serve as controls
9873947|NCT00340626||Oral Cleft Family Members|individuals with unilateral or bilateral cleft lip with or without cleft palate and their unaffected relatives
9873948|NCT00340808||endometrial cancer cases|endometrial cancer cases
9873949|NCT00340860||Norweigian Population-Based Pregnancy Cohort|Norwegian-speaking pregnant women, their children born post enrollment, and enrolled children's fathers
9873950|NCT00340873||Cases|Individuals exposed to digoxin
9873951|NCT00340873||Controls|Individuals not exposed to digoxin
9873952|NCT00340977||Case-Control Parent-Triad|Norwegian infants born with cleft lip or palate over a 5 year period
9873953|NCT00341016||Cohort of Chernobyl cleanup workers (liquidators) in Ukraine|Cases with leukemia and related diseases, and matched controls in the cohort
9929276|NCT00915096||High Tumor Burden Follicular Lymphoma|
10211396|NCT04861831|Experimental|Immediate PCS Intervention|After the pre-intervention clinical assessments, immediate (within one week) begin with the PCS exercise program (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required). Post-intervention clinical assessments within one week after the last intervention class, followed by a 12-week follow-up period (continuation of exercise program at home recommended but not required). Final clinical assessments within one week after the 12-week follow-up period.
9873954|NCT00341068||Cleft|children and adults with a cleft lip and/or cleft palate and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
9873955|NCT00341068||NTD|children and adults with an NTD (neural tube defects) and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
9873956|NCT00341094||Main UkrArm|Subjects exposed to I131 before the age of 18 years
9873957|NCT00341094||Ukraine in utero|Subjects exposed to I131 in utero
9929277|NCT00915109||vascular|People with a unilateral below-knee amputations due to a vascular reason
9929278|NCT00915109||nonvascular|People with a below-knee amputation due to nonvascular reasons
9929279|NCT00915109||Control|People with no gait impairments.
9929280|NCT00915135|Experimental|Ramelteon QD and Placebo QD (25 possible combinations total)|
9929281|NCT00915187|Active Comparator|Control|
9929282|NCT00915187|Experimental|CCS/C (Adjuvant Formulation)|
9929283|NCT00915200|Placebo Comparator|Placebo|N-acetylcysteine placebo + silibin placebo
9929284|NCT00915200|Experimental|N-acetylcysteine|N-acetylcysteine active + silibin placebo
9929285|NCT00915200|Experimental|silibin|N-acetylcysteine placebo + silibin active
9929286|NCT00915200|Experimental|N-acetycysteine + silibin|N-acetylcysteine active + silibin active
9929287|NCT00915200|Experimental|N-acetylcysteine + high-dose silibin|N-acetylcysteine active + high-dose silibin active
9929288|NCT00915213||Repeat Prostate Biopsy|Men who undergo repeat prostate biopsy
9929289|NCT00915239|Active Comparator|Pantoprazole|
9929290|NCT00915239|Placebo Comparator|Placebo|
9929291|NCT00915252|Experimental|5-azacytidine|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.
9929292|NCT00915252|Active Comparator|standard chemotherapy|Patients enrolled in this arm will receive standard chemotherapy treatment.
9929293|NCT00915291|No Intervention|Usual education|"Participants randomized into the no intervention arm were not exposed to the web-based educational modules"
9929294|NCT00915291|Experimental|Web-based educational modules|Participants randomized into the intervention arm were exposed to the web-based educational modules
9929295|NCT00915330|Active Comparator|TBNA alone|Arm A: TBNA alone.
9929296|NCT00915330|Experimental|TBNA with ROSE|Arm B: TBNA with ROSE.
9929297|NCT00915382|Active Comparator|3 weekly regimen of S-1 and cisplatin|
9929298|NCT00915382|Active Comparator|5 weekly regimen of S-1 and cisplatin|
9929299|NCT00915408|Experimental|CRD|
9929300|NCT00915421||Prehospital hypothermia group|All patients included to the study
9929301|NCT00915447||Cat Allergic Rhinitis|Individuals with cat allergic rhinitis, yet without routine cat exposure
9987157|NCT01409512||Women with OAB|Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
9987158|NCT01409525||cardiac surgery patients|
9987159|NCT01409538|Placebo Comparator|Placebo|Asymptomatic control participants receive Natural History and Placebo instructions in a within-subject design. There are no patients, or active agents in this study. It is not a Clinical Trial.
9987160|NCT01409538|Active Comparator|Control condition|"The control condition represents a no-intervention, repeated baseline control, since the active intervention in this study is placebo."
9987161|NCT01409551|Active Comparator|VATS hyperthermic pleural chemoperfusion|The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
9987162|NCT01409551|Active Comparator|Bedside talc slurry pleurodesis|The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
9987163|NCT01409577||FFR|Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible > 9months clinical follow-up
9987164|NCT01409590|Other|Exercise and Diet program|All patients recruited in the study, participated in an homogeneous exercise program and diet.
9987165|NCT01409603|Experimental|Treatment arm A|darexaban, wash-out, naproxen, wash-out, combination therapy
9987166|NCT01409603|Experimental|Treatment arm B|darexaban, wash-out, combination therapy, wash-out, naproxen
9987167|NCT01409603|Experimental|Treatment arm C|naproxen, wash-out, darexaban, wash-out, combination therapy
9987168|NCT01409603|Experimental|Treatment arm D|naproxen, wash-out, combination therapy, wash-out, darexaban
9987169|NCT01409603|Experimental|Treatment arm E|combination therapy, wash-out, naproxen, wash-out, darexaban
9987170|NCT01409603|Experimental|Treatment arm F|combination therapy, wash-out, darexaban, wash-out, naproxen
9987171|NCT01409616|Experimental|Treatment arm A|ASA, wash-out (w.o.), ASA + darexaban
9987172|NCT01409616|Experimental|Treatment arm B|ASA + darexaban, w.o., ASA
9987173|NCT01409616|Experimental|Treatment arm C|ASA, w.o., darexaban (double dose) + ASA
9987174|NCT01409616|Experimental|Treatment arm D|darexaban (double dose) + ASA, w.o., ASA
9987175|NCT01409616|Experimental|Treatment arm E|ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban
9987176|NCT01409616|Experimental|Treatment arm F|ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel
9987177|NCT01409616|Experimental|Treatment arm G|ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel
9987178|NCT01409616|Experimental|Treatment arm H|darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel
9997028|NCT01505309|Experimental|Stent Graft|TEVAR procedure using devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
9997029|NCT01505322||Thoracic surgery|Lung cancer patients
9997030|NCT01505335||Implant osteotomy measurements|Drilled implant locations
9997031|NCT01505348|Experimental|Fasting|Overnight fast
9997032|NCT01505348|No Intervention|Feeding|Normal breakfast
9997033|NCT01505361|Experimental|Probiotic|Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)
9997034|NCT01505361|Placebo Comparator|Placebo|Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)
9997035|NCT01505400||Advanced cancer|Advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas; as well as patients who are phase I trial candidates
9997036|NCT01505413|Experimental|Tarceva, Gemcitabine, Oxaliplatin|"Erlotinib 100 mg po qd daily AND~Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1~Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2 weeks~Each two weeks is a cycle. If at end of 12 cycles response continues, will administer Gemcitabine and erlotinib until progression."
9997037|NCT01505426|Experimental|ASP1941 group|ASP1941 + metformin
9517643|NCT03304444|Experimental|Liposomal Bupivicaine in TAP block|When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
9997038|NCT01505426|Placebo Comparator|placebo group|placebo + metformin
9997039|NCT01505439|Experimental|Solifenacin group|Once daily
9997040|NCT01505478||Patients admitted with infection|All consecutive ED patients during the study period that have been admitted and identified to have a suspected infection at ED disposition using a data collection tool
9997041|NCT01505517||individuals with low back pain|
9997042|NCT01505517||healthy controls|
9997043|NCT01505543||chronic obstructive pulmonary disease|
9997044|NCT01505543||healthy matched controls|
9997045|NCT01505556||Diaphragm paresis|
9997046|NCT01505556||Healthy controls|
9997047|NCT01505582|Experimental|Inspiratory muscle training|
9997048|NCT01505582|Sham Comparator|Sham inspiratory muscle training|
9997049|NCT01505595|Experimental|Proprioceptive training|
9873958|NCT00341263||Cases - twin pregnancies|Maternal and cord hormones in twins
9873959|NCT00341263||Controls - singleton pregnancies|Maternal and cord hormones in singletons
9873960|NCT00341302||Cohort 1|HIV Infected Pregnant Women
9873961|NCT00341302||Pediatric Cohort 2|HIV exposed , uninfected children born to HIV infected women
9873962|NCT00341302||Pediatric Cohort 3|HIV exposed, uninfected children 6 months to 5 years of age
9873963|NCT00341315||Cohort|A primarily African-American population living in the vicinity of a DDT production plant inAlabama.
9873964|NCT00341328|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
9873965|NCT00341328|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
9873966|NCT00341380||Patients|Undergoing resection of lung tumor
9873967|NCT00341406||Healthy volunteers|healthy, non-overweight or other medical conditions
9517644|NCT03304431|No Intervention|Control group(Group C)|After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
9873968|NCT00341406||Patients overweight|Those who are generally healthy but overweight
9873969|NCT00341406||Patients with health conditions|Those with diabetes and cardiovascular disease.
9873970|NCT00341458||Cancer Cases|Women 20-74 years old, residents of Warsaw and Lodz that were newly diagnosed with confirmed in situ or invasive breast cancer or ovarian or endometrial cancer
9873971|NCT00341549||Myopia|The subject population will be adult individuals and their children, in good health with the exception of myopia.
9873972|NCT00341588||Cases|Male U.S. serviceman, age 18-45 years old with TGCT
9873973|NCT00341588||Controls|Male U.S. serviceman, age 18-45 years old without TGCT
9873974|NCT00341627||1|Population-based sampling of individuals affected with Chordoma
9873975|NCT00341692||Samples of normal breast tissue|Samples of normal breast tissue from organ donors for assessment of histology.
9873976|NCT00341835||High risk lung cancer families|Individuals from families with a high risk of lung cancer, both affected and unaffected family members
9873977|NCT00341900||Case|Male pilots with high cosmic radiation exposure
9987179|NCT01409642|Active Comparator|Individual Child CBT|12 sessions of individual child-focused cognitive behavior therapy with a parent component
9987180|NCT01409642|Experimental|Positive Family Interaction Therapy|12 sessions of standard individual child CBT plus six sessions of positive family interaction therapy (PFIT)
9987181|NCT01409655|Experimental|cognitive-behavioral therapy intervention|Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
9987182|NCT01409668|Experimental|L. Amylovorus|
9987183|NCT01409668|Experimental|L. Fermentum|
9987184|NCT01409681||Observational Group|NSCLC subject undergoing bronchoscopy
9987185|NCT01409694|Active Comparator|Intervention|All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
9987186|NCT01409694|Placebo Comparator|Placebo|Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
9987187|NCT01409720|Experimental|A|patients in arm A carry out daily physical training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home.
9987188|NCT01409720|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min manual therapy (i.e. massage, etc) starting from day one of radiotherapy.
9987189|NCT01409733|Experimental|Stage IV melanoma patients|
9987190|NCT01409746||twins|twin pairs
9987191|NCT01409759|Experimental|Perforator based interposion flap|In our concept the flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
9987192|NCT01409759|Other|Full thickness graft|
9987193|NCT01409772||Intestinal Rehab|
9987194|NCT01409785||LMA Supreme|
9987195|NCT01409785||LMA unique|
9987196|NCT01409824|No Intervention|without CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will not be implemented
9987197|NCT01409824|Experimental|with CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will be implemented, parallel to the performance based incentive package
9987198|NCT01409850|Active Comparator|Aqualizer|
9987199|NCT01409850|Active Comparator|Soft splint|elastic splint made of copolyester foil
9987200|NCT01409850|No Intervention|Counselling|
9987201|NCT01409863|No Intervention|laser and standard diamond fraise dermabrasion|laser and standard diamond fraise dermabrasion
9987202|NCT01409876|Experimental|Brachytherapy|
9987203|NCT01409889|Active Comparator|Diabetes Prevetion Program|Individuals in this group will receive the Diabetes Prevention Program
9987204|NCT01409889|Active Comparator|Healthy Living Program|Individuals in this group will receive the Healthy Living Program
10211397|NCT04861831|Experimental|Delayed PCS Intervention|During the 12 weeks that the Immediate Intervention (II) group participates in the PCS intervention, the Delayed Intervention (DI) group waits (there is no control intervention) and serves as a control arm comparison for the II group during this time. After the 12 weeks, the DI group will undergo a second pre-intervention assessment to document any change in baseline measures that may have occurred in those 12 weeks. No significant changes are expected. The DI group then begins the same exercise intervention (75-minute group class, twice weekly for 12 weeks; home practice of exercises recommended but not required) that the II group underwent, given by the same instructors. Post-intervention clinical assessments, 12-week follow-up period, and final clinical assessments after the follow-up period as described for the II group. After the trial, pooled data from both groups will provide results on the overall changes in outcome measures post- versus pre-intervention.
10211398|NCT04860375|Experimental|Multidisciplinary, holistic and patient-centered care|Based on the outcome from the assessment and disease phenotype, personalized care plans will be prepared and given to the patients, including dietary program, adjusted exercise program, psychological counselling, treatment of comorbidities etc. Patients will come for planned follow-up visits, according to the protocol (total 5 visits).
10211399|NCT04860375|Active Comparator|Standard care|The control group will be recruited from the Swedish Airway Register at the end of the study. Selection will be based on propensity score matching to the intervention group.
10211400|NCT04858932||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
10211401|NCT04858932||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
9987205|NCT01409954||Spinal decompression|Spinal decompression with an instrumented posterolateral fusion
9987206|NCT01409980||Triphalangeal Thumb|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit) at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and Hutchinson operated on with a delta phalanx.
9987207|NCT01410019|Experimental|1|Gene transfer
9987208|NCT01410032|Active Comparator|Plate fixation|Reconstruction plate
9987209|NCT01410032|Active Comparator|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
9987210|NCT01410045|Experimental|Surgery|Ovariectomy
9987211|NCT01410071||sphincter of oddi dysfunction|endoscopic therapy vs conservative care
9987212|NCT01410123|Other|Treatment as Usual (TAU)|
9796631|NCT01572727|Active Comparator|Placebo and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel.
9796632|NCT01572740|Experimental|Lira+Insulin|
9796633|NCT01572740|Placebo Comparator|Placebo+Insulin|
9796634|NCT01572792|Experimental|1|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
9796635|NCT01572792|Experimental|2|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
9796636|NCT01572792|Active Comparator|3|Aclidinium bromide 400 μg
9796637|NCT01572792|Active Comparator|4|Formoterol Fumarate 12 μg
9873978|NCT00341952||Cases|individuals diagnosed with incident, first primary non-Hodgkin lymphoma
10211402|NCT04858932||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement, metabolism, body weight composition, glucose levels, and nutritional scale in healthy adults.
9796638|NCT01572792|Placebo Comparator|5|Placebo
10211403|NCT04857788|Experimental|Pandah Application only|Design is a controlled randomized Study with two parallel arms after randomization with a three months follow-up of the two arms that are (Group 1) Care as usual for patients in follow-up list; (Group 2) PANDAH App proposed alone with only 15-20 minutes setup with investigator at start-up (digital accompaniment only); Patients of the 2 groups will have a three months follow-up period before secondary evaluation and entering into the so-called extension period.
9796639|NCT01572844|Experimental|Treatment lesion|Lesion A, target lesion, 2cm x 2cm (+/- 1cm) treated with 1 pass Fractionated Carbon Dioxide (FCO2) Laser followed by application of 4 ml of 5% topical sodium thiosulfate solution (STS), 8 to 10 treatments over 6 months.
9796640|NCT01572844|No Intervention|No Treatment Lesion|Lesion B, similar area of calcinosis on the same patient, which did not receive treatment is evaluated.
10211404|NCT04857788|No Intervention|Care as usual|Design is one period of 3 months with 2 parallel groups (with or without application) following by extension period of 3 months with all subject accessing to the application.
10211405|NCT04856319|Active Comparator|Prophylaxis|2 g amoxicillin+clavulanic acid 1 hour prior to dental implant surgery
10211406|NCT04856319|Placebo Comparator|Placebo|placebo 1 hour prior to dental implant surgery
10211407|NCT04855786|Experimental|Thoracic Duct Drainage|This is the main study group of patients with thoracic duct drainage
10211408|NCT04848038|Active Comparator|Core and Fusion Training|150 minutes/week of Core and Fusion exercise, a mix of low impact toning, strengthening, flexibility and balance exercises.
10211409|NCT04848038|Active Comparator|Endurance Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. In addition 0-2 days of Core and Fusion control exercise will also be recommended.
10211410|NCT04848038|Active Comparator|Weight Training|Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (~75 minutes/week). Progression based on repetition completion and 1-repetition maximum. In addition 3 days of Core and Fusion control exercise will also be recommended.
9796641|NCT01572909|Active Comparator|Bendavia™|Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
9796642|NCT01572909|Placebo Comparator|Placebo|Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
9796643|NCT01572922|Other|Iron-overloaded|"Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.~Interventions: R2*-UTE, R2*-GRE, and if clinically indicated, liver biopsy."
9796644|NCT01572948|Placebo Comparator|Placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
9796645|NCT01572948|Active Comparator|Daliresp|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
9796646|NCT01573000|Experimental|Open-label, two-arm, Arm A and Arm B Crossover|Arm A Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 milliCurie (mCi) (35 mg) of I-131 TST infused over 30 minutes (inclusive of a 10-minute flush).• Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by a subject-specific mCi activity (35 mg) of I-131 TST to deliver the desired total body dose (TBD) infused over 30 minutes (inclusive of a 10-minute flush). The desired TBD was 65 cGy for subjects with a baseline platelet count of 100,001-149,999 cells/mm3 and 75 cGy for subjects with a baseline platelet count ≥150,000 cells/mm3. Obese subjects (subjects weighing more than 137% of their calculated lean body weight) were dosed based upon 137% of their calculated lean body mass
9796647|NCT01573000|Experimental|Arm B Crossover|Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
9796648|NCT01573052|Active Comparator|Chlordiazepoxide|Chlordiazepoxide 25mg capsule or matching placebo capsule
9796649|NCT01573052|Experimental|Gabapentin|Gabapentin 300mg capsule or matching placebo capsule
9796650|NCT01573169|Experimental|low weight molecular heparin|enoxaparin 0.4 ml subcutaneous per day
9796651|NCT01573169|Placebo Comparator|standard therapy|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
9796652|NCT01573260|Experimental|Argentinean Tango|A biweekly class of argentinean tango for a period of 3-months the intervention for this arm
9873979|NCT00341952||Controls|individuals identified in the same geographical areas without non-Hodgkin lymphoma or othercancers
9873980|NCT00341991||1|Cases from hospitals
9873981|NCT00341991||2|Controls from the general populations
9873982|NCT00341991||3|Biological Samples
9873983|NCT00342004||Healthy Volunteers|Healthy female urban residents in Shanghai between ages of 40-70.
9873984|NCT00342108|Experimental|1|Diagnosis: CP, moderate to severe MR and CVI
10211411|NCT04848038|Active Comparator|Combined Endurance and Weight Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (~75 minutes/week). Progression based on repetition completion and 1-repetition maximum.
10211412|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, standard dose|Combination of a standard dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
10211413|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, high dose|Combination of a high dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
9873985|NCT00342108|Experimental|2|Diagnosis: CP, Moderate to severe MR, no visual impairment
9873986|NCT00342121||1|Corn farmers enrolled in the Agricultural Health Study who are non-smokers, and who plan to apply specific pesticides.
9873987|NCT00342121||2|Control subjects selected from agricultural extension workers in Iowa who are non-smokers
9873988|NCT00342147||1|This is a high risk population of families for NPC
9873989|NCT00342173||Women in Costa Rica|Examining the natural history of HPV and cervical neoplasia in Costa Rican women.
9873990|NCT00342316|Experimental|Stem cell transplant (RICT)|Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
9873991|NCT00342316|No Intervention|Control arm|Treatment according to standard of care, i.e. not undergoing RICT
9873992|NCT00342342||Beaver Dam Eye Study|Individuals over 45 years of age enrolled in Beaver Dam Wisconsin
9873993|NCT00342342||Framingham Eye Study|Subset of individuals from the Framingham Heart Study who received eye examinations
9873994|NCT00342368|Active Comparator|1|CPAP through an helmet
9873995|NCT00342368|No Intervention|2|O2 therapy with conventional face mask
9873996|NCT00342381|Active Comparator|3.4 diaminopyridine|Single dose 3,4 diaminopyridine
9873997|NCT00342381|Placebo Comparator|Placebo|Two tablets identical to active treatment
9873998|NCT00342407||Cohort|Female flight attendants
9873999|NCT00342433||Localized Prostate Cancer cases|Cases enrolled between Jan 2000 and Apr 2004 at five locations. Study subject eligibility: Age >=18; scheduled for radical prostatectomy; and newly diagnosed with localized prostate cancer.
9874000|NCT00342472||1|Two of the oldest individuals (a male and a female greater than 18 years of age) from each of 10-15 nonsmoking households from the high-risk region of Linxian, China
9874001|NCT00342771||NCI Maryland pop-based controls|population-based controls
10211414|NCT04847349|Placebo Comparator|Placebo for live microbial (probiotic) consortium|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics, taken once per day with breakfast for 21 days.
9874002|NCT00342771||NCI-Maryland Prostate Cancer Cases|prostate cancer cases
9929302|NCT00915460|Experimental|1|Patients previously enrolled in BIogen Idec study C95-812.
9929303|NCT00915460|Experimental|2|Patients previously enrolled in Biogen Idec study C96-823.
9929304|NCT00915460|Experimental|3|Patients previously enrolled in Biogen Idec study C97-830.
9929305|NCT00915486|Experimental|Good Standard of Care (GSoC)|Twice per week
9929306|NCT00915486|Experimental|GSoC + vehicle|Twice per week
9929307|NCT00915486|Experimental|GSoC + I-020201 (33microg)|Twice per week
9929308|NCT00915486|Experimental|GSoC + I-020201 (100microg)|Twice per week
9929309|NCT00915486|Experimental|GSoC + I-020201 (300microg)|Twice per week
9929310|NCT00915512|Experimental|Paliperidone extended-release (ER)|
9929311|NCT00915564|Experimental|TMC435 + methadone|Supervised intake of individualized methadone dose (range, 30 to 150 mg once daily) from Day -14 to Day -1; followed by addition of 150 mg dose of TMC435 once daily from Day 1 to Day 7 along with methadone; and later followed by continued intake of individualized methadone 30 to 32 days follow-up.
9929312|NCT00915577|Experimental|1st Injection|Manual injection with pre-filled syringe.
9929313|NCT00915577|Experimental|Single-use autoinjector|Single-use autoinjector with Avonex pre-filled syringe
9929314|NCT00915616|No Intervention|control|9 healthy normal subjects.
9929315|NCT00915616|Active Comparator|Group II|Included 9 patients suffering from GERD; receiving melatonin alone for treatment of GERD in a dose of 3 mg once daily at the bed time.
9929316|NCT00915616|No Intervention|Group III, combined group|Included 9 patients suffering from GERD; receiving omeprazole alone for treatment of GERD in a dose of 20 mg twice daily.
9929317|NCT00915616|Active Comparator|Group IV|Included 9 patients suffering from GERD receiving omeprazole and melatonin for treatment of GERD in the same dose of each of them.
9929318|NCT00915629|Experimental|Probiotic|Dietary supplement
9929319|NCT00915642||Normal volunteers|Volunteers, body mass index 17 to 25
9929320|NCT00915642||Obese volunteers|Volunteers body mass index higher than 30
9929321|NCT00915694|Experimental|Single arm|NFV-RT-Tem
9929322|NCT00915707|Experimental|Baseline|Subjects are tested under normal sleep conditions for carbohydrate metabolism and appetite regulation.
9929323|NCT00915707|Experimental|Sleep restriction|Subjects are tested under sleep restriction for carbohydrate metabolism and appetite regulation.
9929324|NCT00915707|Experimental|Reduced sleep quality|Subjects are tested under a poor sleep quality condition for carbohydrate metabolism and appetite regulation.
9987213|NCT01410123|Other|Integrated Stepped Care (ISC)|
10211415|NCT04844138|Experimental|Online Self-Directed Program|Participants in this condition will complete our six-week online self-directed program as soon as it's available.
9987214|NCT01410136|Other|Chondrofix|Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
9987215|NCT01410149|Active Comparator|PAV|Proportional Assist Ventilation (PAV+ on PB840 ventilator)
9987216|NCT01410149|Active Comparator|PSV|Pressure Support Ventilation (PSV on PB840 ventilator)
9987217|NCT01410149|Active Comparator|ACV|Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
9987218|NCT01410162|Active Comparator|Advagraf|
9987219|NCT01410162|Active Comparator|Prograf|
9987220|NCT01410175|Experimental|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layer.
9987221|NCT01410175|No Intervention|Electric scalpel|Use of electric scalpel to incise the skin and subcutaneous layer.
9987222|NCT01410201|Experimental|PPV + MP + DEX|Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
9987223|NCT01410201|Active Comparator|PPV + MP|Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.
9987224|NCT01410214|Experimental|Erlotinib arm|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
9987225|NCT01410214|Active Comparator|Chemo arm|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
9987226|NCT01410253|Experimental|Group 1|
9987227|NCT01410253|Experimental|Group 2|
9987228|NCT01410253|Experimental|Group 3|
9987229|NCT01410253|Placebo Comparator|Group 4|
9987230|NCT01410266|No Intervention|Standard of care|Standard of care includes a routine clinic visit two weeks after misoprostol administration. At the clinic visit, the woman undergoes a bimanual examination. In the event the woman fails to return for the follow-up visit, clinic procedure is followed for contacting her to determine abortion status and the need for further intervention, if any.
9987231|NCT01410266|Active Comparator|Alternative follow-up|At a clinic visit, before mifepristone administration, the woman completes a semi-quantitative pregnancy test. After mifepristone administration, she is provided with another pregnancy test and a checklist to be self-administered two weeks after she takes misoprostol. On an assigned date, the woman is contacted by phone by the clinic staff and asked to report on the results of both tests. The provider then confirms whether, based on the woman's responses, she should return for a follow-up visit.
9987232|NCT01410292|Experimental|meal D|low fiber and low GI
9987233|NCT01410292|Experimental|meal C|low Fiber and High GI
9987234|NCT01410292|Experimental|meal B|high Fiber and low GI
9987235|NCT01410292|Experimental|meal A|high fiber and high GI meal
9987236|NCT01410305||HIV+|HIV Positive children or young people between the ages of 8 and 25
9987237|NCT01410305||HIV Negative|HIV Negative matched controls by age and race
9987238|NCT01410331|Experimental|Cohort 1|Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
9987239|NCT01410331|Experimental|Cohort 2|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
9987240|NCT01410331|Experimental|Cohort 3|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
9987241|NCT01410331|Experimental|Cohort 4|Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
9987242|NCT01410370|Experimental|treatment|Radiotherapy plus Endostar
9987243|NCT01410370|Active Comparator|control|Radiotherapy
9987244|NCT01410383|Placebo Comparator|Placebo|
9987245|NCT01410383|Experimental|Eprotirome I|
9987246|NCT01410383|Experimental|Eprotirome II|
9987247|NCT01410422||COPD|COPD
9987248|NCT01410422||Bronchiectasis|Bronchiectasis
9987249|NCT01410435|Experimental|Treatment|
9987250|NCT01410461||Patients with painful bladder syndrome|Patients with diagnosis of PBS Will be offered to take part in the following study.
9987251|NCT01410487||Obese group|
9987252|NCT01410513|Experimental|SAR245409 + rituximab|Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
9987253|NCT01410513|Experimental|SAR245409 + rituximab + bendamustine (iNHL, MCL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
9987254|NCT01410513|Experimental|SAR245409 + rituximab+ bendamustine (CLL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
9987255|NCT01410526||VAC group|Patients with intra-abdominal sepsis treated with Vacuum Assisted Closure (VAC) system plus the dynamic sutures
9987256|NCT01410526||Control group|Patients suffering major abdominal surgery
9987257|NCT01410539|Experimental|Stent Thrombosis|Consecutive patients with stent thrombosis with stent strut assessment by OCT
9987258|NCT01410539|Active Comparator|Controls|Control subjects without stent thrombosis from the RHR OCT database
9987259|NCT01410578||systemic inflammatory response syndrome|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
9987260|NCT01410578||sepsis|SIRS + infection
9987261|NCT01410578||bacteremia|(1) The blood culture tested positive at least for the same pathogen;(2) The patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites.
9987262|NCT01410591|Active Comparator|10-mm covered stent group|Patients treated with 10-mm covered stent.
9987263|NCT01410591|Active Comparator|8-mm covered stent group|Patients treated with 8-mm covered stent.
9987264|NCT01410617|Active Comparator|dialysis|the patients who undergo 3 sessions prophylactic hemodialysis
9874003|NCT00342849|Experimental|1|Scuccimer Treatment Group
9874004|NCT00342849|Placebo Comparator|2|In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.
9874005|NCT00342862||1. Amevive Exposure|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown prospectively
9517645|NCT03304431|Other|Group L|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
9874006|NCT00342875||Population Controls|Control subjects were selected randomly from state Department of Motor Vehicle and Centers for Medicare and Medicaid Services (CMS) beneficiary records.
9874007|NCT00342875||Urinary Bladder Cases|patients with histologically confirmed carcinoma of the urinary bladder
9874008|NCT00342953||Cohort|Women receiving implants and other plastic surgery.
9874009|NCT00342992||Healthy Volunteers|Male smokers in Southwestern Finland
9874010|NCT00343031||Pregnant women delivering male infants|Male newborns and their mothers living in Tapachula (Chiapas, Mexico) and surrounding areas exposed to DDT through house spraying programs to control malaria, grouped by level of DDT exposure.
9874011|NCT00343135|Experimental|ARM 1|
9874012|NCT00343200|Placebo Comparator|Placebo|
9874013|NCT00343200|Experimental|Sildenafil|
9874014|NCT00343239|Experimental|Docetaxel/Cisplatin/Fluorouracil (DCF)|DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability
9874015|NCT00343265|Active Comparator|1|Progesterone gel
9874016|NCT00343265|Placebo Comparator|2|Vaginal gel with no medication
9874017|NCT00343395|Active Comparator|Avandamet|AVANDAMET 2/500 mg
9874018|NCT00343395|Placebo Comparator|Placebo|
9874019|NCT00343421|Experimental|Group 1|PEDIACEL co-administered with Prevenar
9874020|NCT00343421|Active Comparator|Group 2|Infanrix-IPV+Hib co-administered with Prevenar
9874021|NCT00343616|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomization.
9874022|NCT00343616|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomization.
9874023|NCT00343616|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
9874024|NCT00343616|Experimental|Letrozole for 2 years plus tamoxifen for 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
9874025|NCT00343681|Experimental|1|
9874026|NCT00343798|Experimental|Treatment (umbilical cord blood transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1.~TRANSPLANTATION : Patients undergo double-unit umbilical cord blood transplantation comprising unmanipulated umbilical cord blood unit IV over 20-30 minutes, and 4-6 hours later patients receive ex vivo-expanded umbilical cord blood cells IV over 30 minutes on day 0.~GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS: Patients receive cyclosporine IV every 8 or 12 hours on days -3 to 100, followed by a taper to at least day 180. Patients also receive MMF IV every 8 hours on days -3 to 5 and then PO, if tolerated, on days 6-30."
9874027|NCT00343824|Experimental|aquacel AG hydrofiber|
9874028|NCT00343824|Experimental|Acticoat burn dressing|
9874029|NCT00343928|Experimental|1|
9874030|NCT00343980|Experimental|A|
9874031|NCT00343980|Active Comparator|B|
9874032|NCT00344006|Experimental|Arm 1|
9874033|NCT00344123|Other|Tipranavir/ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin.~Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
9874034|NCT00344149|Experimental|Rituximab|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
9874035|NCT00344149|Placebo Comparator|Placebo|I.V infusion of NaCl 0.9%
9874036|NCT00344214|Experimental|1|Participants will receive the tri-focal cognitive behavioral therapy - social skills training counseling program
9874037|NCT00344214|Active Comparator|2|Participants will receive the standard care comparison condition
9874038|NCT00344253|Experimental|1|Interferon beta 3x weekly
9874039|NCT00344253|Active Comparator|2|Methotrexate sc 20 mg weekly
9987265|NCT01410617|No Intervention|control group|the patients who do not undergo hemodialysis
9987266|NCT01410630||FLT-PET/CT and FDG-PET/CT scan|Patients will have FLT-PET/CT and FDG-PET/CT scans performed 18-24 days after the second cycle of R-CHOP.
9987267|NCT01410643|Active Comparator|Reduced Carbohydrate|42% carbohydrate macronutrient modification
9987268|NCT01410643|Active Comparator|STandard Carbohydrate|60% carbohydrate macronutrient modification
9987269|NCT01410656|No Intervention|Standard PA Recommendation|Received the standard physical activity recommendation.
9987270|NCT01410656|Experimental|Telephone Implementation Intention|Behavioural Telephone Assisted Implementation Intention Intervention
9987271|NCT01410656|Experimental|Self-completed implementation intention|Self-administered implementation intention intervention.
9987272|NCT01410669|Experimental|Motivational Interviewing (MI)|
9987273|NCT01410682|Experimental|0.12% Chlorhexidine Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
9987274|NCT01410682|Placebo Comparator|tothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
9987275|NCT01410721|Experimental|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
9987276|NCT01410721|Active Comparator|Cognitive Rehabilitation Control Arm|Baseline training and follow-up at two months and four months.
9987277|NCT01410734|Experimental|ICG|Patient will received IV injection of ICG intra-operatively. Surgeon will view bile ducts under fluorescence imaging mode to see if ICG helps to identify biliary ducts.
9987278|NCT01410747||tacrolimus group|Oral
9987279|NCT01410786|Active Comparator|Conventional Oxford instrumentation|Patients who receive an Oxford Partial Knee with Conventional instrumentation.
9987280|NCT01410786|Experimental|Signature Guides Oxford|Patients who receive an Oxford Partial Knee with Signature Custom Guides
9987281|NCT01410838|Placebo Comparator|Broth- NaCl|Sodium chloride containing broth matched for sodium content to the MSG broth
9987282|NCT01410838|Active Comparator|Broth- MSG|MSG containing broth with the same sodium content as the placebo comparator.
9987283|NCT01410851|Experimental|Pasta, tomato sauce & added chickpeas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
9987284|NCT01410851|Experimental|Pasta, tomato sauce and added lentils|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
9987285|NCT01410851|Experimental|Pasta, tomato sauce and added navy beans|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
9987286|NCT01410851|Experimental|Pasta, tomato sauce with yellow peas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
9987287|NCT01410851|Experimental|Pasta and tomato sauce|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
9987288|NCT01410864||DuraSeal Arm|Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
9987289|NCT01410864||Control Arm|Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
9517646|NCT03304418|Experimental|Radium Ra 223 dichloride and radiation, all patients|
9987290|NCT01410877||Inhaler naive healthy volunteers|
9987291|NCT01410903|Experimental|TheraSorb Ig|
9997050|NCT01505595|Sham Comparator|Sham proprioceptive training|
9874040|NCT00344474|Experimental|learning to cope with your impulsivity|cognitive behavioural intervention teaching high impulsive youth how to manage their impulsive thinking and behaviours
9874041|NCT00344474|Experimental|learning to cope with your sensation seeking|cognitive-behavioural intervention teaching high sensation seeking youth how to manage their need for stimulation and excitement
9874042|NCT00344474|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention targeting catastrophic thinking in high anxiety sensitive youth
9874043|NCT00344474|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
9874044|NCT00344539|Experimental|B|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
9874045|NCT00344539|Experimental|C|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
9874046|NCT00344539|Experimental|A|20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.
9874047|NCT00344552|Experimental|1|
10211416|NCT04844138|Other|Waitlist|Participants in this condition will receive treatment as usual for six weeks, after which point they will be invited to complete our online program.
10211417|NCT04838613|Experimental|PET/CT imaging with [18F]CTT1057 followed by [68Ga]Ga-PSMA-11 or vice versa|"All eligible participants will be assigned to one of the following two PET/CT scan sequences at random in a 1:1 ratio:~Sequence 1: [18F]CTT1057 on Day 1 (investigational imaging agent of interest) followed by [68Ga]Ga-PSMA-11 at least 14 days apart (as part of CTS if required, and for secondary endpoint)~Sequence 2: [68Ga]Ga-PSMA-11 (as part of CTS if required, and for secondary endpoint) on Day 1 followed by [18F]CTT1057 (investigational imaging agent of interest) at least 14 days apart"
10211418|NCT04833816|Experimental|Ketamin|Patient will get a bolus of ketamine at 0.1 mg / kg followed by a continuous infusion of ketamine at a dose of 0.15 mg / kg / hour
10211419|NCT04833816|Placebo Comparator|Placebo|Patient will get a bolus of NaCL at 0.1 mg / kg followed by a continuous infusion of NaCl at a dose of 0.15 mg / kg / hour
10211420|NCT04822610|Experimental|Study group: interscalene block + IV PCA|preop usg guided interscalene block and IV PCA
10211421|NCT04822610|Experimental|Study group: suprascapular block + axillary block + IV PCA|preop usg guided suprascapular block + axillary block and IV PCA
10211422|NCT04822610|No Intervention|Control group: IV PCA|no block + IV PCA
9874048|NCT00344565|Placebo Comparator|Placebo|Placebo, was matched to modafinil up to 400 mg/day. Patients also receive motivational interviewing and Cognitive Behavioral Therapy-Relapse Prevention (CBT-RP)
9874049|NCT00344565|Active Comparator|Modafinil|Modafinil (Active comparator). Patients received motivational interviewing and Cognitive Behavioral Therapy--relapse prevention (CBT-RP)
9874050|NCT00344591|Experimental|Tailored SET program|tailored SET program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
9874051|NCT00344591|Active Comparator|Individually focused therapy|Individually focused therapy program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
10211423|NCT04811898|Experimental|Experimental single arm|Single group with 5 dose escalation for each cohort (0,5 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg; 5 mg/kg)
10211424|NCT04805996|Experimental|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|This study has only one arm and no comparator.
10211425|NCT04802837|Experimental|Ridinilazole|Ridinilazole dosed BID and a comparator placebo dosed QID, to maintain blind, for 40 doses over 10 days.
10211426|NCT04802837|Active Comparator|Vancomycin|Vancomycin dosed QID and a Ridinilazole placebo dosed BID, to maintain blind, for 40 doses over 10 days.
10211427|NCT04797065|Experimental|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 6 minutes then in 9 minutes during the segmental withdrawal.~At 6-minute withdrawal, the left colon, transverse colon and right colon will take 2 minutes each. Then at 9-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 3 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
9929325|NCT00915733|Active Comparator|triple group|"Additive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) in patients with acute myocardial infarction (AMI).~Received cilostazol 100 mg twice daily in addition to aspirin 100 mg and clopidogrel 75 mg once daily."
10211428|NCT04797065|Active Comparator|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 9 minutes then in 6 minutes during the segmental withdrawal.~At 9-minute withdrawal, the left colon, transverse colon and right colon will take 3 minutes each. Then at 6-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 2 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
9997051|NCT01505621||Young|Healthy adults 18-30 years old
10211429|NCT04792372|Other|Periodontitis patients|Single-group receiving periodontal treatment. The data will be evaluated according to the healing potential of individuals in the group and also site-specifically.
10211430|NCT04786444|Active Comparator|VLA1553 Lot 1|
10211431|NCT04786444|Active Comparator|VLA1553 Lot 2|
10211432|NCT04786444|Active Comparator|VLA1553 Lot 3|
10211433|NCT04782869|Experimental|tDCS (transcranial direct current stimulation)|Patient will be treated for 3 cycles. A cycle is composed of 5 bi-sessions (one per day) of 20 minutes each.
10211434|NCT04781283|Experimental|specular microscopy|The density measurement is a painless and very brief examination (less than a minute) during which the patient places his head on a chin rest while maintaining his forehead on a bar provided for this purpose while looking straight ahead. The measurements are then taken without contact with the patient's eye.
10211435|NCT04780685|Experimental|hMSCs|hMSCs will be given via IV administration.
10211436|NCT04780685|Placebo Comparator|Lactated Ringer's Solution|Lactated Ringer's Solution will be given via IV administration.
9874052|NCT00344656||Subjects and Controls|Patients with DSM-IV Anorexia Nervosa
9796653|NCT01573260|Placebo Comparator|A 'wait-list' control group|Intervention: Patient will receive information about exercise in PD. After 12 weeks, these patients will then start the same 12-weeks tango program.
9874053|NCT00344721|Active Comparator|EPA/DHA/flaxseed|Study patients in the active comparator arm will take four soft-gel capsules containing omega-3 fatty acids (a nutritional supplement) orally daily for 3 months. Each daily dose contains eicosapentaenoic acid (450 mg), docosahexaenoic acid (300 mg) and flaxseed oil (1000 mg).
9874054|NCT00344721|Placebo Comparator|Wheat germ oil|Study patients in the placebo arm will take four doses of soft-gel capsules containing wheat germ oil orally daily for 3 months.
9874055|NCT00344760|Active Comparator|Standard Treatment|Efavirenz 600mg once daily, Lamivudine 300mg once daily and Tenofovir 300mg once daily
9796654|NCT01573273|Experimental|TSST Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
9874056|NCT00344760|Experimental|Standard Treatment Plus Enfuvirtide|Efavirenz 600mg once daily, Lamivudine 300mg once daily, Tenofovir 300mg once daily and enfuvirtide 90mg subcutaneously twice a day until the viral load is less than 50copies for 2 consecutive visits or 12 weeks (whichever comes first).
9874057|NCT00344786|Experimental|CNF2024|
9796655|NCT01573273|Placebo Comparator|TSST Women Placebo|Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
9796656|NCT01573273|Experimental|MRI 1 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
9796657|NCT01573273|Placebo Comparator|MRI 1 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
9796658|NCT01573273|Experimental|MRI 2 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
9874058|NCT00344825||Group 1|
9874059|NCT00344890|Experimental|Preservon|
9874060|NCT00344890|Active Comparator|Control|
9874061|NCT00344942|Experimental|1|
9874062|NCT00344942|Placebo Comparator|2|
9874063|NCT00345059|Active Comparator|docetaxel|single agent docetaxel
9874064|NCT00345059|Experimental|docetaxel + vinorelbine OR gemcitabine|docetaxel in combination with either vinorelbine or with gemcitabine
9874065|NCT00345059|Experimental|docetaxel + capecitabine|docetaxel in combination with capecitabine
9874066|NCT00345163|Experimental|1|
9874067|NCT00345163|Experimental|2|
9874068|NCT00345189|Other|Dosing Schedule 1|Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.
9874069|NCT00345189|Other|Dosing Schedule 2|Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
9796659|NCT01573273|Placebo Comparator|MRI 2 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
9874070|NCT00345319|Active Comparator|Group 1|
9874071|NCT00345319|Active Comparator|Group 2|
9874072|NCT00345358|Active Comparator|Synflorix <6M Group|This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of Synflorix™ vaccine co-administered with Infanrix™ IPV/Hib at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (Synflorix™) or the left (Infanrix™ IPV/Hib ) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
9874073|NCT00345358|Experimental|Synflorix 7-11M Group|This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
9874074|NCT00345358|Experimental|Synflorix 12-23M Group|This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose 2 months later. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
9874075|NCT00345358|Experimental|Synflorix >=24M Group|This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of Synflorix™. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
9874076|NCT00345475||AED treatment|Women being treated with UCB AEDs while pregnant.
9874077|NCT00345501|Experimental|1|Iloprost
9874078|NCT00345501|Placebo Comparator|2|Placebo
9874079|NCT00345514|No Intervention|1|
9874080|NCT00345514|Active Comparator|2|
9874081|NCT00345514|Active Comparator|3|
9874082|NCT00345644|Experimental|1|
9874083|NCT00345644|Placebo Comparator|2|
9874084|NCT00345670|Experimental|1|MEDI-534
9874085|NCT00345670|Experimental|2|MEDI-534
9874086|NCT00345670|Experimental|3|MEDI-534
9874087|NCT00345709||National Research Registry Enrollment|Patient, living or deceased, with a pathologically-confirmed diagnosis of Ovarian Cancer.
9874088|NCT00345761|Experimental|Step 1|
9874089|NCT00345761|Experimental|Step 2|
9874090|NCT00345761|Experimental|Step 3|
9874091|NCT00345787|Placebo Comparator|0|
9874092|NCT00345787|Experimental|1|
9874093|NCT00345800|Experimental|Sodium Oxybate|"Active Substance: Sodium Oxybate~Pharmaceutical form: Oral Solution~Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~Route of administration: Oral"
9874094|NCT00345813|Experimental|Arm I|Patients receive oral soy supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy supplementation.
9997052|NCT01505621||Elderly|Healthy adults greater than 65 years old
9987292|NCT01410942|Placebo Comparator|Placebo + Sham Exercise|Placebo capsules by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
9987293|NCT01410942|Experimental|Methylphenidate + Sham Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
9987294|NCT01410942|Placebo Comparator|Exercise + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Placebo capsules by mouth twice daily.
9987295|NCT01410942|Placebo Comparator|Cognitive Therapy + Placebo|Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily.
9987296|NCT01410942|Experimental|Methylphenidate + Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
9987297|NCT01410942|Experimental|Methylphenidate + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
9987298|NCT01410942|Placebo Comparator|Exercise + Cognitive Therapy + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily
9987299|NCT01410942|Experimental|Methylphenidate + Exercise + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
9987300|NCT01410955|Experimental|Probiotics|Patients receiving probiotics.
9987301|NCT01410955|Placebo Comparator|Placebo|Patients receiving placebo
9987302|NCT01410968|Experimental|Vaccination|vaccination with investigational Poly-ICLC & peptide-pulsed dendritic cells
9987303|NCT01410981||Multiple Myeloma subjects with bone marrow aspirate/biopsy|All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.
9987304|NCT01411007||Smokers|Nicotine addicted smokers, smoking an average of at least 10 cigarettes per day.
9987305|NCT01411007||Non-Smokers|
9987306|NCT01411020|Experimental|Grupo 1|Doses of induction: propofol 4 mcg/ml and fentanyl 3 mcg/kg
9987307|NCT01411020|Experimental|Grupo 2|Dose of induction: propofol 4.5 mcg/ml and fentanyl 3 mcg/kg
9796660|NCT01573273|Experimental|TSST Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
9987308|NCT01411020|Experimental|Grupo 3|Doses of propofol: propofol 5 mcg/ml and fentanyl 3 mcg/kg
9987309|NCT01411020|Experimental|Grupo 4|Doses of induction: propofol 5.5 mcg/ml and fentanyl 3 mcg/kg
9987310|NCT01411020|Experimental|Grupo 5|Doses of induction: propofol 6 mcg/ml and fentanyl 3 mcg/kg
9987311|NCT01411020|Experimental|Grupo 6|Doses of induction: propofol 4 mcg/ml and fentanyl 5 mcg/kg
9987312|NCT01411020|Experimental|Grupo 7|Doses of induction: propofol 4.5 mcg/ml and fentanyl 5 mcg/kg
9987313|NCT01411020|Experimental|Grupo 8|Doses of induction: propofol 5 mcg/ml and fentanyl 5 mcg/kg
9987314|NCT01411020|Experimental|Grupo 9|Doses of induction: propofol 5.5 mcg/ml and fentanyl 5 mcg/kg
9987315|NCT01411020|Experimental|Grupo 10|Doses of induction: propofol 6 mcg/ml and fentanyl 5 mcg/kg
9987316|NCT01411033||Newly diagnosed diabetes mellitus type 1|
9987317|NCT01411046||RA treated with prednisolone|Patients with RA treated with prednisolone, minimum 5 mg/day for minimum 6 months. Patients are grouped according to haplotype of 4 SNPs of the glucocorticoid recepror gene. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not. Adrenal function is evaluated with a Synacthen test.
9987318|NCT01411059|Experimental|yoga|32 weeks of yoga training
9987319|NCT01411072|Experimental|Gemcitabine|
9987320|NCT01411072|Experimental|5-fluorouracil|
9987321|NCT01411098|Experimental|Treatment (radiation therapy and chemotherapy)|Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
9987322|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 30mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 30 mg/day for 7 days in treatment period 2A.
9987323|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 100mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 100 mg/day for 7 days in treatment period 2B.
9987324|NCT01411124|Experimental|Gabapentin Enacarbil|600 mg of Gabapentin Enacarbil
9987325|NCT01411124|Active Comparator|diphenhydramine|50 mg
9987326|NCT01411124|Placebo Comparator|placebo|placebo to match
9987327|NCT01411176|Active Comparator|Menthol|20 ml NPO-11
9987328|NCT01411176|Placebo Comparator|Placebo|20 ml NPO-11(Placebo)
9987329|NCT01411189|Other|Menthol|20 mL NPO-11
9987330|NCT01411202|Experimental|Doxycycline|Pleurx insertion with injection of 500mg of doxycycline in 50cc of normal saline.
9987331|NCT01411202|Placebo Comparator|Normal Saline|Pleurx insertion with placebo injection of 50cc of normal saline
9987332|NCT01411254|Experimental|1|
9987333|NCT01411254|Experimental|2|
9987334|NCT01411254|Sham Comparator|3|
9987335|NCT01411280|Placebo Comparator|Laboratory trial|Compare methylphenidate to placebo in an acute laboratory trial
9987336|NCT01411280|Experimental|Home/School trial|Low dose and moderate dose methylphenidate are compared to placebo in a home and school trial
9987337|NCT01411293|Experimental|Low-Fat Dairy|Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
9987338|NCT01411293|Active Comparator|Rice Milk|Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
9987339|NCT01411306||Med/Surg ICU Inpatients, Intubated ≥ 48 hours|
9987340|NCT01411358|Experimental|AdimFlu-S 2011-2012|
9987341|NCT01411371|Experimental|Catheter Ablation|Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.
9987342|NCT01411371|Active Comparator|Medical treatment alone|Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
9987343|NCT01411397|Active Comparator|mesh repair|MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION
9987344|NCT01411397|Active Comparator|mesh repair without intestinal resection|mesh repair of strangulated hernia without resection
9987345|NCT01411410|Experimental|Copanlisib (BAY80-6946)|The treatment of consists of repetitive cycles, each over 4 weeks. It continues until disease progression or limiting toxicity. If paclitaxel is discontinued for toxicity, BAY80-6946 may continue at the discretion of the investigator if a clinical benefit (response or stable disease for 6 months) is noted.
9987346|NCT01411423||Group 1|
9997053|NCT01505660|No Intervention|Usual Care|Patients not randomized to the intervention will receive usual care which includes a patient reported outcomes assessment every 6 months as part of routine clinical procedures and patient-initiated interactions with case managers.
9997054|NCT01505660|Experimental|Care management|The intervention will include frequent healthcare delivery team notification of PROs including medication adherence and adherence barriers such as depression symptoms along with tailored intervention recommendations and targeted care management using a stepped care approach.
9997055|NCT01505686|Experimental|study group|All patients in this study have MRI scan prior to hernia repair surgery. If inflammatory changes are present, the scan is repeated 6 months after surgery. If not, the scan is performed only if the patient has pain problems at 6 months.
10211437|NCT04779138|Experimental|Increasing Uptake of COVID-19 Vaccination|"This is a pre-experimental one group pretest-posttest design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our ACTIVATE triad leaders and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
10211438|NCT04769739|Active Comparator|CO2 insufflation|Colonoscopy will be performed in the traditional fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal.
10211439|NCT04769739|Active Comparator|WE with water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual decal debris, predominantly during insertion.
10211440|NCT04769739|Experimental|WE with 50% saline|Residual air in the colon will be removed, 50% salline (1:1 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
9997056|NCT01505738||bacterial cultures|Bacterial samples are collected preoperatively from urine, nose and possible lower limb ischaemic wounds, perioperatively from inguinal area and wound edges, and twice postoperatively. In addition, in case of a wound infection, bacterial samples are taken for diagnosis as usual.
9997057|NCT01505751||cervical cancer|
9997058|NCT01505777|Experimental|Probiotics(Medirac) 10/mosapride 10mg|
9997059|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 10mg|
9997060|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 15mg|
9997061|NCT01505777|Experimental|Probiotics(Medirac) 30/mosapride 15mg|
9997062|NCT01505777|Placebo Comparator|Probiotics(Medirac) placebo/mosapride placebo|
9997063|NCT01505790|Experimental|CLOPIDOGREL GROUP|
9997064|NCT01505790|Active Comparator|PRASUGREL GROUP|
9997065|NCT01505803|Active Comparator|Zinc supplement|
9997066|NCT01505803|Active Comparator|Omega 3 supplement|
9997067|NCT01505803|Active Comparator|Zinc and omega 3 supplements|
9997068|NCT01505803|Placebo Comparator|Placebo supplement|
9997069|NCT01505816|No Intervention|Toric|Multifocal Toric IOL implantation
9997070|NCT01505829||Biological validation cohort 1|
9997071|NCT01505829||Response assessment cohort 2|
9874095|NCT00345813|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of placebo supplementation.
9874096|NCT00345826|Experimental|Dasatinib|
9874097|NCT00345982|Experimental|A|Sertindole 16 mg
9874098|NCT00345982|Placebo Comparator|B|Placebo
9874099|NCT00346021|Experimental|Sun Protection Intervention|School based sun protection education, provision of free hats.
9874100|NCT00346021|No Intervention|Control arm|Usual sun protection practices
9874101|NCT00346047|Placebo Comparator|0|
9874102|NCT00346047|Experimental|1|
9874103|NCT00346177|Active Comparator|1|Stem Cells
9874104|NCT00346177|Placebo Comparator|2|Placebo
9874105|NCT00346229|Experimental|Thermodox|ThermoDox20-40mg/m2 every 21-35 days followed by Chest Wall Hyperthermia
9874106|NCT00346294|Other|Single-Arm|Open-lable Single Arm Study
9874107|NCT00346320|Experimental|Radiotherapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
9874108|NCT00346437|Experimental|1|Ad5FGF-4
9874109|NCT00346437|Experimental|2|Ad5FGF-4
9874110|NCT00346437|Placebo Comparator|3|Placebo
9929326|NCT00915733|Active Comparator|high maintenance dose group|"High maintenance dose dual antiplatelet therapy in patients with acute myocardial infarction (AMI).~Received clopidogrel 150 mg/day with aspirin 100 mg once daily."
9929327|NCT00915785|Experimental|5 azacytidine|
9929328|NCT00915811|Experimental|FBATG|Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
9929329|NCT00915824|Experimental|STOPP/START intervention|STOPP/START intervention group
9929330|NCT00915837|Experimental|Slow release formulation|Slow release formulation, helical intravitreal triamcinolone implant
9929331|NCT00915837|Experimental|fast release formulation|fast release formulation, helical intravitreal triamcinolone implant
9929332|NCT00915850|Experimental|Anticancer drug|docetaxel, cisplatin and 5-FU
9929333|NCT00915863|Active Comparator|Billroth-II-type|Billroth-II-type reconstruction after pancreaticoduodenectomy
9929334|NCT00915863|Experimental|Isolated Roux-en-Y|Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
9929335|NCT00915889|Active Comparator|Group I|Patients receive a survivorship booklet in the mail that contains information about cervical cancer. Patients then receive a follow-up telephone call at 3 months to clarify any issues relevant to the survivorship booklet.
9929336|NCT00915889|Experimental|Group II|Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
9929337|NCT00915915|Experimental|Arm 1|
9929338|NCT00915915|Experimental|Arm 2|
9929339|NCT00915980||Patients without diabetes undergoing gastric bypass|
9929340|NCT00916019|Experimental|exercise|mild exercise training
9929341|NCT00916045|Other|Myeloblative conditioning regimen|
9929342|NCT00916045|Other|Reduced intensity conditioning regimen - FluCyTBI|
9929343|NCT00916045|Other|Reduced intensity conditioning regimen - FluMel|
9929344|NCT00916071||Eating Disorders|Study subjects will be individuals with a history of eating disorder(s) diagnosis
9929345|NCT00916084|Experimental|Group A|
9929346|NCT00916084|Experimental|Group B|
9929347|NCT00916097|Experimental|1|docetaxel 75mg/m2 in combination with cisplatin 75mg/m2 given every 3 weeks for 3 cycles
9929348|NCT00916110|Experimental|1.5mgSC|ATN-103
9929349|NCT00916110|Experimental|4mgSC|ATN-103
9929350|NCT00916110|Experimental|10mgSC|ATN-103
9929351|NCT00916110|Experimental|25mgSC|ATN-103
9929352|NCT00916110|Experimental|25mgIV|ATN-103
9929353|NCT00916110|Experimental|50mgSC|ATN-103
9929354|NCT00916110|Experimental|100mgSC|ATN-103
9929355|NCT00916110|Experimental|200mgSC|ATN-103
9929356|NCT00916110|Experimental|200mgIV|ATN-103
9929357|NCT00916123|Experimental|Dose Level 1|177Lu-J591 at 20 mCi/dose
9929358|NCT00916123|Experimental|Dose Level 2|177Lu-J591 at 25 mCi/dose
9929359|NCT00916123|Experimental|Dose Level 3|177Lu-J591 at 30 mCi/dose
10211441|NCT04769739|Experimental|WE with 25% saline|Residual air in the colon will be removed, 25% saline (1:3 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
10211442|NCT04769401|Experimental|Normal Progesterone group|Progesterone level ≥ 10 ng/mL on ET day.
10211443|NCT04769401|Active Comparator|Low Progesterone group|Progesterone level <10 ng/mL on ET day.
9874111|NCT00346502|Experimental|Ointment|Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
10211444|NCT04749901|Other|Patients with epilepsy|
10211445|NCT04749901|Other|Patients with PTSD|
10211446|NCT04749901|Other|Patients with type 1 diabetes|
9874112|NCT00346528|Experimental|NGOIS|
10211447|NCT04749901|Other|Patients with a heart rhythm disorder|
10211448|NCT04742023|Experimental|Intervention Arm|
10211449|NCT04742023|Placebo Comparator|Control Arm|
10211450|NCT04738071||Sex|Female and male patients
10211451|NCT04738071||Age >60 years of age|Patients younger or oder than 6o years of age
10211452|NCT04738071||World region|Patients from different world regions: North America, Europe, Asia, Latin America
10211453|NCT04738071||Stroke vs. TIA|Index event: stroke vs. TIA
9874113|NCT00346528|Active Comparator|BSS Plus|
9874114|NCT00346567|Active Comparator|1|AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
9874115|NCT00346567|Experimental|2|AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP
9874116|NCT00346671|Placebo Comparator|Supine Rest|30min supine rest listening to soft music
9874117|NCT00346671|Sham Comparator|Sham Reiki|30 min intervention by sham practitioner
9874118|NCT00346671|Experimental|Reiki|30 min session with Reiki practitioner
9874119|NCT00346749|Experimental|Arm 1|
9874120|NCT00346762||1|HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
9874121|NCT00346788|Experimental|MIS|minimally invasive incision
9874122|NCT00346788|Active Comparator|Standard|Standard incision length
9874123|NCT00346801|Experimental|CPT-11 + Celecoxib/Cisplatin with RT|CPT-11 + Celecoxib + Cisplatin + Radiation Therapy (RT)
9874124|NCT00346840|Experimental|MVI 25|Misoprostol vaginal insert 25 mcg
9874125|NCT00346840|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg
9874126|NCT00346840|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg
9874127|NCT00346840|Experimental|MVI 200|Misoprostol vaginal insert 200 mcg
9874128|NCT00346853|Experimental|1|
9874129|NCT00346853|Placebo Comparator|2|saline
9874130|NCT00346918|Active Comparator|1|Treatment of hypertension, cyst infections and flank pain
9874131|NCT00346918|Active Comparator|2|Sirolimus plus Standard Treatment
9874132|NCT00346944|Experimental|Treatment group|
9874133|NCT00346944|No Intervention|Reference group|
9874134|NCT00346957|Experimental|Anecortave Acetate 30|
9874135|NCT00346957|Experimental|Anecortave Acetate 15|
9874136|NCT00346957|Experimental|Anecortave Acetate 3|
9874137|NCT00346957|Placebo Comparator|Anecortave Acetate Vehicle|
9874138|NCT00346970|Experimental|1|Extended-release Niacin
9874139|NCT00346970|Placebo Comparator|2|Placebo
9874140|NCT00346983|Experimental|A|
9874141|NCT00346983|Placebo Comparator|B|
9874142|NCT00346996|Active Comparator|1|HUman Insulin
9874143|NCT00346996|Experimental|2|Analogue insulin
9874144|NCT00347048|Experimental|1|
9874145|NCT00347048|Placebo Comparator|2|
9874146|NCT00347100|Experimental|1|Administration of Insulin Glargine and Sulfonylurea or Metformin
9874147|NCT00347100|Active Comparator|2|Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
9874148|NCT00347139|Experimental|GW642444|
9874149|NCT00347139|Active Comparator|Salmeterol|
9874150|NCT00347152|Active Comparator|2|Slow Progressive Divalproex DR to Divalproex ER switch
9874151|NCT00347152|Active Comparator|1|Immediate, Progressive Divalproex DR to Divalproex ER switch
9874152|NCT00347321|Experimental|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
9874153|NCT00347386|Experimental|Zinc|Administration of zinc sulphate every day during illness
10211454|NCT04738071||Neurocardiology Teams|Patients assessed by a neurocardiology team
10211455|NCT04735432|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
10211456|NCT04735432|Experimental|efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
10211457|NCT04733157|Experimental|Study group/Group A|The study group will receive TXA 1g intravenously at the onset of skin incision.
10211458|NCT04733157|Placebo Comparator|Control group/Group B|There is an equivalent volume of normal saline for the control group.
10211459|NCT04732117|Experimental|Secukinumab Arm|Secukinumab 150 mg PFS s.c.
10211460|NCT04732117|Placebo Comparator|Placebo Arm|Placebo 150mg PFS s.c.
10211461|NCT04728711|Experimental|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week|
10211462|NCT04728711|Placebo Comparator|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week|
10211463|NCT04727424|Active Comparator|Fluvoxamine Maleate + Budesonide Inhalation powder|"Fluvoxamine 100 mg oral tablets:~One tablet right after randomization (Day 0) followed by 100 mg BID for the following 09 days PLUS~Budesonide Inhalation powder 400 mcg capsule:~One 400 mcg capsule (inhalation) right after randomization (Day 0) followed by 400 mcg BID for the following 09 days"
10211464|NCT04727424|Active Comparator|Fluvoxamine Maleate|"Fluvoxamine 100 mg oral tablets:~One tablet right after randomization (Day 0) followed by 100 mg BID for the following 09 days"
9874154|NCT00347386|Placebo Comparator|Placebo|Placebo tablet
9874155|NCT00347412|Experimental|A|NOV-002 Injection in combination with Carboplatin and Paclitaxel
9874156|NCT00347412|Active Comparator|B|Paclitaxel and Carboplatin Alone
9874157|NCT00347425|Other|A|
9874158|NCT00347425|Other|B|
9874159|NCT00347555|Experimental|Group D|18 subjects 160 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
9874160|NCT00347555|Experimental|Group A|18 subjects 5 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
9874161|NCT00347555|Experimental|Group B|18 subjects 20 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
9874162|NCT00347555|Experimental|Group C|18 subjects 80 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
9874163|NCT00347594|Experimental|Next Generation Diagnostic Instrument|Next Generation Diagnostic Instrument (NGDI)
9874164|NCT00347594|Active Comparator|Zyoptix Diagnostic Workstation|Zyoptix Diagnostic Workstation (ZDW)
10211465|NCT04727424|Placebo Comparator|Placebo (mild disease)|"Placebo SC normal saline syringe (single day dosing schedule):~Matching syringes containing 0,5 ml normal saline will be administered by SC route just after randomization Day 0 (single dose SC administration).~OR~Placebo oral tablets (10-day dosing schedule):~Matching tablets started right after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS~Placebo Inhalation Therapy:~One dosing (inhalation) right after randomization (Day 0) followed by one dose BID for the following 09 days"
9874165|NCT00347646|Experimental|Plasmin|Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.
9874166|NCT00347659|Experimental|Single Treatment|Experimental Treatment
9874167|NCT00347672|Experimental|1|Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose
9874168|NCT00347672|Experimental|2|One vaccination of H5N1 VN 2004/AA vaccine at a dose in-between the lowest and highest doses
9874169|NCT00347672|Experimental|3|One vaccination of H5N1 VN 2004/AA vaccine at the lowest dose
9874170|NCT00347737|Experimental|1|Teriparatide
10211466|NCT04727424|Active Comparator|Peginterferon Lambda|"Peginterferon Lambda 180 mcg syringe:~One syringe of Peginterferon Lambda will be administered by SC route just after randomization (Day 0 - single dose SC administration)."
10211467|NCT04727424|Placebo Comparator|Placebo (SpO2 < 94%)|One tablet right after randomization (Day 0) followed by 100 mg BID for the following 09 days
10211468|NCT04724252|Active Comparator|Gabapentin Treatment|Given at a dose of 10mg/kg (max 600mg) perioperatively (immediately prior to surgery) followed by 3mg/kg/dose TID with first dose to be given starting at 8 hours post perioperative dose.
10211469|NCT04724252|Placebo Comparator|Control Group|Given placebo which coincides with the active treatment group
10211470|NCT04720781|Active Comparator|Vonoprazan|Vonoprazan (20mg/day) is prescribed for patients with erosive esophagitis
9874171|NCT00347763|No Intervention|control|no active fly spray intervention
9874172|NCT00347763|Active Comparator|intervention|aerial spray of permethrin daily for two weeks and weekly as needed by assessment of fly density
9874173|NCT00347854|Experimental|FID 105783|
9874174|NCT00347854|Active Comparator|Visine|
9874175|NCT00347854|Active Comparator|Refresh Liquigel|
9874176|NCT00347854|Active Comparator|Refresh Plus|
9929360|NCT00916123|Experimental|Dose Level 4|177Lu-J591 at 35 mCi/dose
9929361|NCT00916123|Experimental|Dose Level 5|177Lu-J591 at 40 mCi/dose
10211471|NCT04720781|Placebo Comparator|Esomeprazole|Esomeprazole (20mg/day) is prescribed for patients with erosive esophagitis
10211472|NCT04719208|Experimental|Chlorhexidine gluconate (A)|Mouth rinse with 0.2% Chlorhexidine gluconate,
10211473|NCT04719208|Experimental|Hydrogen peroxide (B)|Mouth rinse with 1.5% hydrogen peroxide
10211474|NCT04719208|Experimental|Betadine (C)|Mouth rinse with betadine mouthwash,
9929362|NCT00916175|Placebo Comparator|P1&P2|Food product P1&P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;
9929363|NCT00916175|Experimental|P1&CC|Food Product P1&CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;
10211475|NCT04719208|Experimental|Mouth wash (D)|Mouth rinse with alcohol-based mouthwash
10211476|NCT04719208|Placebo Comparator|Water (E)|Mouth rinse with water
9929364|NCT00916175|Experimental|AG&P2|Food product AG&P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.
9929365|NCT00916175|Experimental|AG&CC|Food product AG&CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml
9929366|NCT00916175|Experimental|TA (concentrated 5:1 aloe vera gel)|Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.
9929367|NCT00916175|Placebo Comparator|P3|Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.
9929368|NCT00916188|Experimental|Black Tea-Four Doses|One, 2, 3 and 4 cups (150 ml/cup) of Black tea/day for week 1, 2, 3, and 4, respectively.
9929369|NCT00916188|Active Comparator|Black Tea-One Dose|One cup (150 ml) of Black tea/day during study.
9929370|NCT00916201|Experimental|Intranasal Insulin|Intranasal administered insulin
9929371|NCT00916201|Experimental|Cannabidiol CR|Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.
9929372|NCT00916201|Experimental|URB597|URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.
9929373|NCT00916214|Experimental|Intervention|
9929374|NCT00916227|Experimental|ARRY-614|
9929375|NCT00916240|Experimental|1|Participants will receive Multisystemic Therapy (MST).
9929376|NCT00916240|Active Comparator|2|Participants will receive home-based, non-directive family support.
10211477|NCT04718116|Active Comparator|tapentadol 50 mg|tapentadol 50mg p.o 3 times daily for two days
10211478|NCT04718116|Active Comparator|tapentadol 75 mg|tapentadol 75 mg p.o 3 times daily for two days
10211479|NCT04718116|Active Comparator|tramadol 100 mg|tramadol 100 mg p.o 3 times daily for two days
10211480|NCT04714047|Experimental|Group 1:|PRT
10211481|NCT04714047|Experimental|Group 2:|PRT + Booster sessions
9987347|NCT01411436||Group 1|
9987348|NCT01411449||Group 1|
9987349|NCT01411462||VIBE-DEB|
9987350|NCT01411475||Bifurcation restenosis|Patients with either a main vessel or a side branch restenosis following succesful percutaneous coronary intervention
9987351|NCT01411514|Experimental|Prednisone|
9987352|NCT01411514|Placebo Comparator|Placebo|
9987353|NCT01411540|Experimental|Whole grain diet|Subjects will eat a whole grain based diet for eight weeks. Pre-and post-diet intervention testing will determine effects on body composition. Whole grain-based are will be compared to the refined grain based diet.
9987354|NCT01411540|Active Comparator|Refined grain diet|Subjects will eat a refined grain diet for 8 weeks matched with the whole grain arm for calorie and macro nutrient intake. Pre-and post-diet testing will determine effects on body composition.
9987355|NCT01411553|No Intervention|Reusable ECG leadwires-ICU|Current ECG leadwires will be used
9987356|NCT01411553|Active Comparator|Disposable ECG leadwires-ICU|Disposable ECG-LW
9987357|NCT01411566|Experimental|Treatment|
9987358|NCT01411566|Active Comparator|Control|
9987359|NCT01411579||Clinical Benefit|The patients responding to the chemotherapy, i.e. who show at least a non progressive disease
9987360|NCT01411579||Non responder|The patients non responding to the chemotherapy, i.e. who show a progressive disease
9987361|NCT01411605|Experimental|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
9987362|NCT01411618|Experimental|free alcohol essential oil moutwash|
9987363|NCT01411618|Active Comparator|alcohol containing essential oil mouthwash|
9987364|NCT01411631|Active Comparator|Grape juice|Participants will drink 100% concord grape juice daily for 12 weeks
9987365|NCT01411631|Placebo Comparator|Placebo drink|Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
9987366|NCT01411657|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye
9987367|NCT01411670|Experimental|Human protein C concentrate|
9987368|NCT01411670|Active Comparator|activated protein C|Continuous infusion of Activated Protein C
9987369|NCT01411670|Placebo Comparator|Placebo|Standard treatment
9987370|NCT01411683|Experimental|4 mini dental implants|Retention of an overdenture by means of 4 mini implants.
9987371|NCT01411683|Experimental|2 mini dental implants|Retention of an overdenture by means of 2 mini implants.
9987372|NCT01411683|Active Comparator|2 conventional dental implants|Retention of an overdenture by means of 2 conventional implants associated to ball attachments.
9987373|NCT01411709|Active Comparator|Vitano|
9987374|NCT01411709|No Intervention|Control|No tablets - control group
9987375|NCT01411722|Other|EADIWEANING|Patients mechanically ventilated for more than 48 hours during the weaning process.
9987376|NCT01411735|Active Comparator|Enalapril|2.5mg titrated up to 10mg- twice daily
10211482|NCT04714047|Active Comparator|Group 3:|NEMEX
10211483|NCT04714047|Experimental|Group 4:|NEMEX + Booster sessions
10211484|NCT04711148|Placebo Comparator|placebo|"The Core Part：Participants receive placebo~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
10211485|NCT04711148|Experimental|orelabrutinib(low dose)|"The Core Part：Participants receive low dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
10211486|NCT04711148|Experimental|orelabrutinib(medium dose)|"The Core Part ：Participants receive medium dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
10211487|NCT04711148|Experimental|orelabrutinib (high dose)|"The Core Part：Participants receive high dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
10211488|NCT04707872||Heart transplant protocol and for cause biopsies|The study population includes patients with a functioning heart transplant undergoing a biopsy for clinical indications as standard of care, or protocol biopsies of heart in high-risk patients, or follow-up after treatment.
10211489|NCT04707781||prospective patient cohort|patients who will undergo the prospective ILD Screening algorithm
10211490|NCT04707781||retrospective patient cohort|patients with diagnosed ILD
9987377|NCT01411735|Placebo Comparator|placebo|2.5 mg titrate up to 10mg twice daily placebo comparator
9987378|NCT01411748|Experimental|S. boulardii|The patients in this group will be given 5 million unit/day S. boulardii until discharge.
9987379|NCT01411748|Active Comparator|nystatin|
9987380|NCT01411761|Experimental|Saccharomyces boulardii|study group
9987381|NCT01411761|Placebo Comparator|placebo|serum physiologic
9987382|NCT01411787|No Intervention|Control Group|Patient will continue normal activities. Ki-67 will be measured in the initial core biopsy and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to initiation of neoadjuvant chemotherapy, and then again after the last chemotherapy dose. Body mass index, percent body fat, and improving fitness levels will also be measured.
10211491|NCT04707768|Experimental|Vadadustat low dose|Participants previously receiving Mircera® will receive a low dose of vadadustat for up to 52 weeks.
10211492|NCT04707768|Experimental|Vadadustat high dose|Participants previously receiving Mircera® will receive a high dose of vadadustat for up to 52 weeks.
9987383|NCT01411787|Experimental|Exercise|"Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.~Ki-67 will be measured in the initial core biopsy specimen and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to inititation of neoadjuvant chemotherapy and then again after the last chemotherapy dose in both arms. Body mass index, percent body fat, and improving fitness levels will also be measured."
9987384|NCT01411800|Experimental|Treatment A|500 mg LX1033, capsules administered two times per day orally
9987385|NCT01411800|Experimental|Treatment B|500 mg LX1033, tablets administered two times per day orally
9987386|NCT01411813||Alprazolam|Patients receiving Alprazolam.
9987387|NCT01411826|Active Comparator|Information|
9987388|NCT01411826|Experimental|Information + Narratives + Support group|
9987389|NCT01411865|Experimental|Intervention|
9987390|NCT01411865|Other|Control|
9987391|NCT01411878|Experimental|Reducing the Risk|Students will be randomly assigned to participate in Reducing the Risk training
9987392|NCT01411878|Experimental|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov).
9987393|NCT01411904|Experimental|MagProbe (TM)|"Patients whose bone marrow aspirates are exposed to the MagProbe and CD34 nanoparticles.~Leukemia patients~MagProbe (TM)~Diagnosed or suspected leukemia~Non-leukemia patients~MagProbe (TM)~Requiring bone marrow biopsy"
9987394|NCT01411930|Experimental|Olanzapine -> Aripiprazole|Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
9987395|NCT01411930|Experimental|Aripiprazole -> Olanzapine|Crossover design. Order of agents is randomized. For this arm, the order will be IM aripiprazole (1st clamp study) and IM olanzapine (2nd clamp study).
9987396|NCT01411956|Experimental|Treatment Group|"This group viewed the intervention video, a 24-minute episode of the sitcom White Coats, deliberately scripted with the five health behavior theory constructs we are testing."
9987397|NCT01411956|Placebo Comparator|Control Group|The control group viewed a 25-minute video on an unrelated subject (depression).
9987398|NCT01411969||External nasal dilator, decongestion|
9987399|NCT01412008|No Intervention|botox diffusion|Each subject was given 3 injections in lateral gastrocnemius muscle:2 botox, 1 saline, each injection was 2.5mL. MRI of the lower leg was taken prior to injections and 2 months post for a comparison of diffusion properties.
9987400|NCT01412073|Active Comparator|oxytocin bolus|"5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.~Hemoglobin level and haematocrit value will be done as follow:-~After admission of each case in the pre-operative period.~Immediately post- operative.~24 hours post- operative."
9987401|NCT01412073|Active Comparator|oxytocin bolus & oxytocin infusion|5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby
9987402|NCT01412073|Active Comparator|misoprostol intrauterine|misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity
9987403|NCT01412099|Experimental|Feedback report plus peer counseling|
9987404|NCT01412099|Experimental|Feedback report|
9987405|NCT01412125||Patient|Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status
9987406|NCT01412125||Healthy subject|Voluntary controls with no family history of huntington's disease
9987407|NCT01412138||ARM 1|ENDOMETRIAL SAMPLE
9987408|NCT01412190|Other|Untreated|
9987409|NCT01412190|Active Comparator|Restylane Vital Light|Restylane Vital Light administered at 3 treatment sessions 4 weeks apart
9987410|NCT01412203|No Intervention|Usual Practice|School continues with regular programming
9987411|NCT01412203|Experimental|Action Schools! BC|School adopts the AS!BC model
9987412|NCT01412216|Experimental|Fish Oil (Omega-3 Fatty Acids)|High-dose, short-duration dietary omega-3 fatty acids supplementation
9987413|NCT01412216|Placebo Comparator|Placebo|Placebo control
9987414|NCT01412242|Experimental|Extensive search for isolated calf DVT|As this is a prospective cohort study, for definition there is only 1 arm
9987415|NCT01412294|Experimental|Capecitabine, Cisplatin|
9987416|NCT01412307|Experimental|lenalidomide plus bendamustine|
9987417|NCT01412320|Experimental|Flavanol rich cocoa|
9987418|NCT01412320|Experimental|Flavanol poor|
9987419|NCT01412346|Active Comparator|Plant-based food and fish with salt restr.|The subjects consume plant based foods (fruits, berries, vegetables, whole grain) and fish in addition to a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
10211493|NCT04707768|Active Comparator|Mircera®|Participants will continue to receive Mircera® for up to 52 weeks.
10211494|NCT04706715|Experimental|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval. After completion of imaging, patients will start treatment with cemiplimab with or without platinum-based chemotherapy.
10211495|NCT04706715|Experimental|Feasibility cohort|The purpose of part B of the study is to analyze the PK of 89Zr-DFO-REGN3767 in patients before and during treatment with cemiplimab with or without platinum-based chemotherapy.
9874177|NCT00347997|Experimental|LASIK|LASIK correction of myopia and myopic astigmatism
9874178|NCT00348036|Experimental|Group therapy|Participants will receive interpersonal group therapy.
9874179|NCT00348036|Active Comparator|Control|Participants will receive information only on PTSD.
9874180|NCT00348075|Experimental|Neurovision|
9874181|NCT00348153|Experimental|Adalimumab + corticosteroids + immunosuppressive treatments|Adalimumab 40 mg eow, stable immunosuppression, corticosteroids in 1 mg/kg/Bodyweight (max. 80 mg) and taper
9874182|NCT00348153|Active Comparator|immunosuppressive treatment + corticosteroids|corticosteroids upped to 1mg/kg/Bodyweight and taper, stable immunosuppressive treatment
9874183|NCT00348335|Active Comparator|1: Restasis|
9874184|NCT00348335|Active Comparator|2: Refresh Endura|
9874185|NCT00348387|Experimental|Group 1|
9874186|NCT00348387|Active Comparator|Group 2|
9874187|NCT00348439|Experimental|Plasmin Injection|human-derived plasmin
9874188|NCT00348439|Placebo Comparator|Vehicle|Plasmin formulation, without active ingredient.
9874189|NCT00348517|Experimental|Systane|
10211496|NCT04701190|Active Comparator|Noradrenaline 0.05/10|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
10211497|NCT04701190|Active Comparator|Noradrenaline 0.075/5|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
9874190|NCT00348517|Active Comparator|Refresh|
10211498|NCT04701190|Active Comparator|Noradrenaline 0.1/0|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute without bolus dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
10211499|NCT04700423|Experimental|A: moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
10211500|NCT04700423|Active Comparator|B: ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using 3 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
9874191|NCT00348569|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed 2 to 21 days later by catheter coronary angiography (CATH).
9874192|NCT00348608|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
9874193|NCT00348621|Active Comparator|Visual impairment intervention program|enhanced access to eye care services
9874194|NCT00348621|No Intervention|Usual care|family and nursing home was apprised of ocular exam results; eye care services left to family/nursing home arrangements
9874195|NCT00348699|Experimental|Treatment (AFP464)|Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9874196|NCT00348712|Active Comparator|A|
9874197|NCT00348712|Active Comparator|B|
9874198|NCT00348738|Experimental|1|Patients assigned to this group are receiving Erythropoietin medication
9874199|NCT00348738|No Intervention|2|control group receiving no treatment
9874200|NCT00348777|Active Comparator|1|group with 18 days thermal cure
9874201|NCT00348777|Sham Comparator|2|group with no thermal cure but only access 3 days to watering place 6 months after inclusion
9874202|NCT00348829|Active Comparator|1|Surgical mitral valve reconstruction
9874203|NCT00348829|No Intervention|2|conservative treatment
9874204|NCT00348855|Experimental|1|"Intervention with one day training, electronic device to measure bood pressure, leaflet with goals and drug strategies according to guidelines, six specific cardiovascular consultations during two years, feed back on results of the intervention group at inclusion, year 1 and year 2.~Specific consultations will be focused on goals to be reach, compliance, exercise and diet."
9874205|NCT00348855|No Intervention|2|
9874206|NCT00348868|Experimental|1|enhanced behavioral motivation counseling
9874207|NCT00348868|Active Comparator|2|
9874208|NCT00348894|Experimental|Open Treatment|[S,S]-reboxetine
9874209|NCT00348894|Other|Standard Care|Standard Care
9796661|NCT01573273|Placebo Comparator|TSST Men Placebo|Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
9796662|NCT01573273|Experimental|MRI I Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
9987420|NCT01412346|Placebo Comparator|Diet with salt restriction|The subjects follow a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
9987421|NCT01412385|Experimental|Epoch 1 (intravenous pre-study treatment) + Epoch 2|Study Epoch 1 (13 weeks): treatment with KIOVIG (once every 3 or 4 weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
10211501|NCT04700423|Active Comparator|C: albendazole (400 mg)|Monotherapy of albendazole (400 mg) administered orally at day 0 Other names: Zentel®
10211502|NCT04700423|Active Comparator|D: ivermectin (200 µg/kg)|Monotherapy of ivermectin ( 200 µg/kg using 3 mg tablets) administered orally at day 0 Other names: Stromectol®
10211503|NCT04700423|Active Comparator|E: moxidectin (8 mg)|Monotherapy of moxidectin (8 mg using 2 mg tablets) administered orally at day 0
10211504|NCT04693221|Sham Comparator|Control|VNS therapy with randomly-set combination of parameters (similar to current practice)
10211505|NCT04693221|Experimental|Experimental|VNS therapy with set combination of parameters chosen based on the lowest phase lag index
10211506|NCT04692701|Experimental|Pulvinar stimulation|Medial pulvinar deep brain stimulation
10211507|NCT04690998|Other|Without treatment for SMA|Patient that will not take treatment for SMA during the two years of the study.
9796663|NCT01573273|Placebo Comparator|MRI I Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
9796664|NCT01573273|Experimental|MRI 2 Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
10211508|NCT04690998|Other|Under treatment for SMA|Patient that will take treatment for SMA during the two years of the study
10211509|NCT04687215||Diabetic patients receiving a spinal cord stimulator|Patients that have been seen in the diabetic foot clinic will be evaluated for participation in the study once they have been referred to one of our pain clinics.
10211510|NCT04683692|Experimental|Cerebral protection with the Sentinel device|Subjects who received the Sentinel device in the parent study
10211511|NCT04683692|Active Comparator|Control group without cerebral protection|Subjects who did not received the Sentinel device in the parent study
10211512|NCT04668248|Experimental|Simulation intervention|Providers assigned to the intervention arm will participate in a short simulation training at the beginning of their 2-week block (planned for their second day). The training will take place at the Neil and Elise Wallace STRATUS Center for Medical Simulation at Brigham and Women's Hospital and will follow all of their recommended and hospital-recommended practices on social distancing, including the learning limits.
10211513|NCT04668248|Active Comparator|Online education intervention|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines.
10211514|NCT04666454|Active Comparator|Randomisation 1: Adenosine and Dipyridamole|Adenosine infusion 70 µg/kg/min for 3 hours, followed (first dose 60 minutes apart from the end of the adenosine infusion) by daily oral treatment with the adenosine reuptake inhibitor dipyridamole (200 mg b.i.d.) until normalization of Left Ventricular (LV) function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or at any subsequent echocardiographic examination, or for 30+7 Days.
10211515|NCT04666454|Other|Randomisation 1: Control|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology.
10211516|NCT04666454|Active Comparator|Randomisation 2: Apixaban|Apixaban 5mg b.i.d. per oral until normalization of LV function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or any subsequent echocardiographic examination, or for 30+7 Days.
10211517|NCT04666454|No Intervention|Randomisation 2: No anticoagulant therapy|
9796665|NCT01573273|Placebo Comparator|MRI 2 Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
10213730|NCT03435510|Other|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
10213731|NCT03432806||presumptive Stage II or III colon cancer|
10213732|NCT03432806||Stage IV colon cancer with resectable hepatic metastases|
9796666|NCT01573442|Experimental|Arm I|Patients receive testosterone (0.264mL) topical application daily for six months.
9796667|NCT01573442|Placebo Comparator|Arm II|Patients receive placebo (0.264mL) topical application daily for six months.
9796668|NCT01573533|Experimental|Rituximab|
9796669|NCT01573572|Experimental|Intravitreal Injections of Macugen|
9796670|NCT01573624|Active Comparator|Fluticasone Furoate (FF)|100mcg, inhaled
9796671|NCT01573624|Active Comparator|Fluticasone Furoate /Vilanterol (VI)|100/25mcg inhaled
9796672|NCT01573624|Experimental|Fluticasone Furoate/GSK573719|100/15.6-250mcg inhaled
9796673|NCT01573702|Other|Stereotactic Radiosurgery Followed by Erlotinib|Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib
9796674|NCT01573767|Active Comparator|Arm 1|Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
9796675|NCT01573767|Active Comparator|Arm 2|Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
9796676|NCT01573767|Active Comparator|Arm 3|Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
9796677|NCT01573767|Placebo Comparator|Arm 4|Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
9874210|NCT00348907|Active Comparator|1|immediate thermal cure (1st year)
9874211|NCT00348907|Sham Comparator|2|late thermal cure (2 years)
9874212|NCT00348920|No Intervention|1- General Anesthesia|General Anesthesia includes administration of a routine cardiac anesthetic as per institutional norms.
9874213|NCT00348920|Experimental|2- High Spinal and General Anesthesia|High Spinal and General Anesthesia includes a high dose intrathecal anesthetic administered prior to the induction of a standardized cardiac general anesthetic.
9874214|NCT00348985|Experimental|PXD101 in Combination with Bortezomib (PS-341)|Patients receive PXD101 IV over 30 minutes on days 1-5 and bortezomib IV on days 1, 4, 8, and 11 (2, 5, 8, and 11 during course 1).
9874215|NCT00349050|Active Comparator|1|laboratory pain assessment
9874216|NCT00349050|Active Comparator|2|transcranial magnetic stimulation
9874217|NCT00349076|Experimental|1|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil und Oxaliplatin:~Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours; repeat day 15, 8 cycles"
9874218|NCT00349076|Active Comparator|2|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; 5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
9874219|NCT00349089|Active Comparator|1|Cisplatin/Vinorelbine
9874220|NCT00349089|Experimental|2|Cisplatin/Pemetrexed
9874221|NCT00349102|Active Comparator|A|Free breathing during conformal radiation
9874222|NCT00349102|Experimental|B|Breath holding during conformal radiation
9517647|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
9874223|NCT00349167|Experimental|PR-104|PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2
9874224|NCT00349193|Active Comparator|Laquinimod 0.3 mg|Laquinimod 0.3 mg
9874225|NCT00349193|Active Comparator|Laquinimod 0.6 mg|Laquinimod 0.6 mg
9874226|NCT00349193|Placebo Comparator|Placebo|Blinded Placebo
9874227|NCT00349206|Experimental|Arm 1|Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
9874228|NCT00349219|Experimental|1|erlotinib followed at progression by gemcitabine and cisplatin
9874229|NCT00349219|Active Comparator|2|cisplatin and gemcitabine chemotherapy for 6 cycles, followed at progression by erlotinib
9874230|NCT00349271|Experimental|Stem Cell therapy|Stem Cell therapy
9874231|NCT00349271|Active Comparator|Standart therapy|Standart therapy
9874232|NCT00349362|Experimental|Testosterone|Testosterone injections- 200mg- every 2 weeks
9874233|NCT00349362|Placebo Comparator|Placebo|Normal saline injections- every two weeks
9874234|NCT00349375|Experimental|1|
9874235|NCT00349375|Experimental|2|
9874236|NCT00349375|Active Comparator|3|
9874237|NCT00349427|Experimental|Rosiglitazone|4mg
9874238|NCT00349427|Placebo Comparator|Rosiglitazone placebo|4mg
9874239|NCT00349440|Active Comparator|1|
9874240|NCT00349440|Placebo Comparator|2|
9874241|NCT00349453|Experimental|Deferiprone (L1) monotherapy|Deferiprone (L1) monotherapy
9874242|NCT00349453|Experimental|Combination therapy|Deferiprone (L1) and desferrioxamine combination treatment
9874243|NCT00349479|Active Comparator|Intervention|
9874244|NCT00349479|No Intervention|Control|
9874245|NCT00349492|Active Comparator|EP|etoposide + cisplatin
9929377|NCT00916253|Experimental|Modafinil First|Treatment by Modafinil during first condition then placebo during second condition
9929378|NCT00916253|Experimental|Placebo First|Treatment by Placebo during first condition then Modafinil during second condition
9929379|NCT00916253|No Intervention|H|Healthy Volunteers
9929380|NCT00916266|Experimental|stem cell transplantation|Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control.
9929381|NCT00916292|Experimental|Low dose|Four subjects will receive low dose FGF-1
9929382|NCT00916292|Experimental|High Dose|Four subjects will receive high dose FGF-1
9929383|NCT00916318|Experimental|A: experimental|"(A) internet based information and communication tool Sundabarn.se("
9874246|NCT00349596|Experimental|Decitabine|Decitabine administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
9874247|NCT00349726|Experimental|Inositol low volume|Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes
9874248|NCT00349726|Experimental|Inositol high volume|Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes
9874249|NCT00349726|Placebo Comparator|Placebo low volume|Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.
9874250|NCT00349726|Placebo Comparator|Placebo high volume|Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes
9874251|NCT00349791|Placebo Comparator|1|placebo patch replaced twice a week for two years
9874252|NCT00349791|Experimental|2|testosterone patch replaced twice a week for two years
9874253|NCT00349804|Other|Air cooled (COOL)|Subjects will complete the intermitent exercise protocol with cool dry air blown under the shoulder pads during the rest periods and recovery session
9874254|NCT00349856|Active Comparator|1|
9874255|NCT00349869|Experimental|1|8-week yoga program
9874256|NCT00349869|No Intervention|2|Usual care control
9874257|NCT00349934|Experimental|A|IMP321
9874258|NCT00349947|Active Comparator|1|Participants will take part in an exercise program.
9874259|NCT00349947|No Intervention|2|Participants will take part in a usual activity group.
9874260|NCT00349999||1|18 males and non pregnant females, ages 18-45, with acute cholera.
9874261|NCT00350012||1|Persons who have had a stroke and either have, or do not have, a pathological asymmetry of perception, attention and action causing functional disability (spatial neglect; Barrett and Burkholder, 2006).
9874262|NCT00350012||2|Healthy age- and education-matched volunteers
9874263|NCT00350051|Experimental|Arm 1|
9874264|NCT00350129||1|healthy vasospastic subjects
9874265|NCT00350129||2|healthy non-vasospastic subjects
9874266|NCT00350181|Experimental|Regimen Treatment 1|For subjects 18-60 years old with lymphoma: (BCNU+ VP-16 +CY) BCNU 15 mg / kg (maximum dose 550 mg/m² actual body weight) on day -6. VP 60 mg / kg on day 4 and CY 100 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
9874267|NCT00350181|Experimental|Regimen Treatment 2|For subjects 18-50 years old with AML, ALL or CML: (VP-16 +CY+ FBI) Patients aged 18-50 years with AML, ALL or CML: FTBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days -8 through -5. VP 60 mg / kg on day -4 and CY 60 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
9874268|NCT00350181|Experimental|Regimen Treatment 3|For subjects 51-60 years with MDS, AML or ALL or 18-60 with MDS, secondary AML pr non-CML myeloproliferative disease: (BU+ VP-16 +CY) BU 1 mg/kg every 6 hours X 14 doses on days -9 through -6 with target concentration at steady state of X 800 ng / ml based on first dose pharmacokinetics. VP 60 mg / kg on day -5 and CY 45 mg / kg per day -2 days on day -3 and day -2. Followed by Sirolimus and MMF as prophylaxis
9874269|NCT00350194|Placebo Comparator|1|Omega-3 fatty acid vs. placebo comparator
9874270|NCT00350233|Experimental|ExAblate MRgFUS|
9874271|NCT00350285|Experimental|1|Motivational enhancement therapy
9874272|NCT00350285|Active Comparator|2|Marijuana education
9874273|NCT00350285|No Intervention|3|Delayed treatment control condition
9874274|NCT00350350||elderly people|elderly people over 70 years residents of old's people homes with symptoms of dry mouth
9874275|NCT00350389|Experimental|1|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
9874276|NCT00350389|No Intervention|2|Usual care, updated multifocal glasses if required
9874277|NCT00350415|Experimental|1|Asacol 2.4 g/day (400 mg tablet)
9874278|NCT00350415|Active Comparator|2|Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
9874279|NCT00350454|Active Comparator|A|Drug eluting stent using biodegradable polymer BP stent
9874280|NCT00350454|Active Comparator|B|polymer-free drug eluting stent PF stent
9874281|NCT00350454|Active Comparator|C|permanent polymer using stents PP stent
9874282|NCT00350506|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed by catheter coronary angiography (CATH).
9874283|NCT00350571|Active Comparator|Standard care follow up|Standard care counselor follow up care phone calls or letters.
9874284|NCT00350571|Experimental|Drop out reengagement motivational intervention|Single session office based or phone based motivational counseling session designed to promote participant re-engagement in standard treatment.
9874285|NCT00350584|Experimental|Mindfulness Telehealth for PTSD|Participants receive two in-person sessions and 6 sessions over the phone. Participants are introduced to mindfulness concepts. CDs with guided meditation exercises are given to participants and they are asked to practice between sessions.
9874286|NCT00350584|Active Comparator|Psychoeducation Telehealth for PTSD|Participants receive two in-person sessions and six telehealth sessions with education about symptoms of PTSD and coping strategies. In addition, participants are asked to read short homework assignments and think about them during the week; these are discussed in weekly sessions.
9874287|NCT00350610|Active Comparator|1|Standard treatment as usual (TAU) in a community based clinic consisting of individual and group therapy sessions and regular urine monitoring.
9929384|NCT00916318|Experimental|(B): experimental|(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A
9874288|NCT00350610|Experimental|2|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping cocaine use and increasing coping skills twice weekly for 8 weeks.
9874289|NCT00350649|Experimental|1|manualized delivery of CBT by trained clinicians
9874290|NCT00350649|Active Comparator|2|CBT with Contingency Management reinforcement for attendance and completing homework (CBT+CM/adherence)
9874291|NCT00350649|Experimental|3|Contingency Management for abstinence alone (CM/abstinence)
9874292|NCT00350649|Active Comparator|4|Contingency Management integrated with CBT (CM/abstinence+CBT)
9874293|NCT00350662|Experimental|Deferiprone + Desferrioxamine|
9874294|NCT00350662|Experimental|Deferiprone single agent|
9874295|NCT00350662|Active Comparator|Desferrioxamine single agent|
9874296|NCT00350688|Other|Helical tomotherapy IMRT|Helical tomotherapy IMRT
9874297|NCT00350714|Experimental|MBT|C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.
9874298|NCT00350753|Experimental|Erlotinib and bevacizumab|
9874299|NCT00350766|Experimental|Treated Group|Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
9874300|NCT00350766|Placebo Comparator|Control Group|Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.
9874301|NCT00350805||Healthy volunteers|
9874302|NCT00350805||Patients|
9874303|NCT00350818|Experimental|Azacitidine|Azacitidine after Allogeneic Transplantation
9874304|NCT00350857|Active Comparator|Equetro active|
9874305|NCT00350883|Other|Treatment as Usual|
9874306|NCT00350883|Experimental|Cognitive Therapy|
9874307|NCT00350909|Experimental|1|One arm was a 2-session brief intervention with both sessions involving only the adolescent. Each session was a 60 minute individual session with the counselor.
9874308|NCT00350909|Active Comparator|2|The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
9874309|NCT00350935||Healthy volunteers|Healthy controls
9874310|NCT00350935||Patients|Patients with schizophrenia
9874311|NCT00350948|Experimental|Telcyta + Liposomal Doxorubicin|Telcyta at 1000 mg/m2 followed by Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
9874312|NCT00350948|Active Comparator|Liposomal Doxorubicin|Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
9874313|NCT00350974||End-stage Renal Disease|on maintenance hemodialysis 3 x per week for more than 12 months
9874314|NCT00350974||No kidney disease|eGFR greater than 60 ml/Min
9874315|NCT00350974||Hypertensive group|Blood pressure greater than 130/80
9874316|NCT00350987|Experimental|PCT|PCT guidance
9874317|NCT00350987|Active Comparator|Guidelines|enforced guidelines
9874318|NCT00351013|Experimental|1|
9874319|NCT00351026|Active Comparator|1|25 HIV negative opiate dependent patients all treated with methadone
9874320|NCT00351026|Active Comparator|2|25 HIV positive opiate dependent patients all treated with methadone
9874321|NCT00351052|Experimental|1|Pimecrolimus
9874322|NCT00351052|Placebo Comparator|2|Vehicle
9874323|NCT00351078|Experimental|PTC124 PO|4-, 4-, and 8-mg/kg TID first 14 days of cycle 10-, 10-, and 20-mg/kg TID second 14 days of cycle 28 day study
9874324|NCT00351117|Experimental|1|St. John's wort 300mg PO TID
9874325|NCT00351117|Placebo Comparator|2|Lactose in capsule matching the St. John's wort. 300mg PO TID
9874326|NCT00351143|Experimental|Interventional group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2
9874327|NCT00351143|Active Comparator|Control group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2
9874328|NCT00351143|Experimental|Subjects receiving salmeterol/fluticasone propionate: Period 1|All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1
9929385|NCT00916318|Experimental|(c): experimental|(C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A
9929386|NCT00916318|Active Comparator|(D): control group|
9929387|NCT00916331|Experimental|subcutaneous group|Vacuum drainage is indwelled in subcutaneous layer
9929388|NCT00916331|Experimental|intraarticular group|Vacuum drainage is indwelled in intraarticular space
9929389|NCT00916396|Active Comparator|real drug|
9929390|NCT00916396|Placebo Comparator|placebo|
9929391|NCT00916409|Experimental|NovoTTF-100A device in combination with Temozolomide|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
9929392|NCT00916409|Active Comparator|Temozolomide alone, as the best known standard of care|Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.
9929393|NCT00916422|Experimental|Depigoid Phleum pratense 1000DPP/Ml|Depigmented and Polymerized Allergen extract of Phleum Pratense.Subcutaneous Immunotherapy in an up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years.
9929394|NCT00916422|Placebo Comparator|2|Placebo. Dosing regimen: An up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years
9929395|NCT00916448|Placebo Comparator|Placebo|placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
9929396|NCT00916448|Active Comparator|Atazanavir|Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
9929397|NCT00916461|Active Comparator|Minocycline|
9929398|NCT00916461|Placebo Comparator|Sugar Pill|
10213733|NCT03432806||Stage IV colon cancer with unresectable hepatic metastases|
9874329|NCT00351325|Experimental|dose escalation|
9874330|NCT00351364|Active Comparator|Montelukast sodium|Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
9874331|NCT00351364|Placebo Comparator|2|No drug given - no placebo available. To compare with active drug.
9874332|NCT00351390|Placebo Comparator|SOC|Standard of care HF therapy without NT-proBNP guidance
9874333|NCT00351390|Active Comparator|NT-proBNP arm|NT-proBNP plus standard HF management
9874334|NCT00351403|Experimental|Individualized therapy|Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
9874335|NCT00351403|Other|Historical control|48 week standard therapy
9874336|NCT00351429|Experimental|1|
9874337|NCT00351442||1|Inidividuals who have been exposed to HIV but remain uninfected.
9874338|NCT00351442||2|HIV infected regular sexual partners of Group 1 participants.
9874339|NCT00351442||3|HIV uninfected individuals or couples who have not been exposed to HIV.
9874340|NCT00351598||1|Patients with loco-regional, NSCLC treated by definitive radiotherapy.
9874341|NCT00351624|Active Comparator|DHA|
9874342|NCT00351624|Placebo Comparator|placebo|
9874343|NCT00351663|Active Comparator|IV by weight|intravenous dose of 0.5 mg/kg enoxaparin once daily
9874344|NCT00351663|Active Comparator|SC fixed dose|subcutaneous fixed dose of 40 mg enoxaparin once daily
9874345|NCT00351663|Active Comparator|SC by weight|subcutaneous dose of 0.5 mg/kg enoxaparin once daily
9874346|NCT00351702|Active Comparator|Isoniazid|Isoniazid (300mg) daily for 36 months
9874347|NCT00351715|Experimental|Pharmacokinetic|One episode of breakthrough pain was to be evaluated per patient. Clinical status and bloodwork was evaluated prior to entering into this phase of the trial, and patients were eligible if bloodwork demonstrated a HgB of >90 g/L with no concurrent bleeding. A peripheral intravenous catheter was inserted and saline locked. When breakthrough pain was experienced, methadone was administered, and the patient completed a pain intensity numeric rating scale at time 0 and every 10 minutes for one hour. A 10 cc specimen of blood was collected prior to administration of methadone, and again every 10 minutes for one hour. Blood was collected without anticoagulant, allowed to clot, separated by centrifugation, and serum samples flash frozen. Serum methadone levels were quantified by LC/MS/MS with comparison to isotopically labeled internal standards
9874348|NCT00351793||Combined Deformity <30 degrees|
9874349|NCT00351793||Combined Deformity >30 degrees|
9874350|NCT00351806|Experimental|Chinese herbal medicine|
9874351|NCT00351806|Placebo Comparator|placebo|
9874352|NCT00351884|Experimental|vildagliptin am|
9874353|NCT00351884|Experimental|vildagliptin pm|
9874354|NCT00351884|Placebo Comparator|placebo|
9874355|NCT00351962|Experimental|Schedule I (10 fractions)|Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
9874356|NCT00351962|Experimental|Schedule II (4 fractions)|Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
9874357|NCT00351975|Experimental|Arm I (chemotherapy)|Patients receive azacitidine SC on days 1-5.
9874358|NCT00351975|Experimental|Arm II (chemotherapy, enzyme inhibitor therapy)|Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.
9874359|NCT00352079|Active Comparator|Intravesicle BCG|"Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)"
9874360|NCT00352079|Active Comparator|Iressa and Intravesicle BCG|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)~Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)"
9874361|NCT00352144|Experimental|1|eszopiclone 3 mg tablet
9874362|NCT00352144|Placebo Comparator|2|Placebo tablet
9874363|NCT00352170|Experimental|1|calcium supplementation
9874364|NCT00352170|Experimental|2|calcium and vitamin D3 supplementation
9874365|NCT00352170|Experimental|3|placebo
9874366|NCT00352183|Experimental|1|
9874367|NCT00352183|Active Comparator|2|
9874368|NCT00352196|Experimental|Magnetic Resonance Spectroscopy|Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
9874369|NCT00352196|Other|NO-MRS|Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
9874370|NCT00352300|Experimental|Treatment (carboplatin, paclitaxel, pegfilgrastim)|Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
9929399|NCT00916474||Cohort A|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
9874371|NCT00352313|Experimental|Phase I|Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
9796678|NCT01573910|Experimental|Moxifloxacin|Moxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
9796679|NCT01573910|Active Comparator|Ofloxacin|Ofloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
9796680|NCT01573949|Experimental|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
9796681|NCT01574079|Active Comparator|Traditional Physical Therapy|The control group will receive traditional physical therapy interventions directed at neuromuscular rehabilitation.
9796682|NCT01574079|Experimental|Physical Therapy plus Mirror Therapy|The mirror therapy will entail 15 minutes of exercises for the lower extremities focusing on ankle dorsiflexion, knee flexion, and hip flexion.
9796683|NCT01574105||Heparin Resistant|Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
9796684|NCT01574105||Heparin Sensitive|Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.
9796685|NCT01574144||AVIVO™ PiiX Patch Monitor System|Heart failure patients monitored continuously for 30 days post-discharge.
9796686|NCT01574157|Active Comparator|Sodium Bicarbonate|Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
9796687|NCT01574157|Placebo Comparator|Placebo|Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
9796688|NCT01574183|Experimental|Vilazodone|Flexible dose up to 40 mg capsule daily
9796689|NCT01574183|Placebo Comparator|Placebo|Flexible dose up to 40 mg capsule daily
9796690|NCT01574248|Experimental|icatibant|30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
9796691|NCT01574248|Placebo Comparator|Placebo|Subcutaneous at time 0 and 6 hours
9800072|NCT01678820|Active Comparator|Sitagliptin|Sitagliptin 100 mg plus placebo to simvastatin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
9929400|NCT00916474||Cohort B|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
9987422|NCT01412385|Experimental|Epoch 1 (subcutaneous pre-study treatment) + Epoch 2|Study Epoch 1 (12 weeks): treatment with SUBCUVIA (once every week or once every two weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
9987423|NCT01412398||Group 1|Drug (incl. Placebo)
9987424|NCT01412411|Active Comparator|Nutrition Education plus Multiple Micronutrient Fortification|In this group along with the nutritional education, multiple micronutrient fortification was given in the form of Sprinkles
9987425|NCT01412411|Active Comparator|OIS plus Nutritional Eductaion|In this group, along with the nutritional education, Oral Iron Supplementation was given.
9987426|NCT01412411|Active Comparator|Nutrition Education Group|This is group was followed for the growth of the child and was given Nutritional Education to children's mothers.
10213734|NCT03432806||Stage I colon cancer, pre-neoplastic or benign colon lesions|
10213735|NCT03425422|Experimental|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
10213736|NCT03425422|No Intervention|Control|Stable guideline-directed medical therapy
10213737|NCT03424213||white low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
10213738|NCT03424213||white high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
10213739|NCT03424213||white intermediate aggressive|intermediate aggressive = all other cases
9796692|NCT01574287|Experimental|FACBC|
9929401|NCT00916487|Experimental|Arm1|single arm of study in cross-over design
9929402|NCT00916500|Experimental|CISPLATIN|Patients With Locally Advanced Cervical Cancer Who Underwent Concurrent Chemoradiation; Cisplatin 75mg/m2 IV Every 3 Week For 3 Cycles; External Pelvic Radiation 40 Gy; Brachytherapy Up to 85-90 Gy To Point A
9929403|NCT00916513||1|Patients ³ 40 years old, with T2DM diagnosed and followed up in the participating site at least 1 year prior to entry in the study, treated with diet, OADs and/or insulin for at least the past three months
9929404|NCT00916526|Experimental|bronchial provocation test with mannitol|"Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.~After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests."
9929405|NCT00916552|Experimental|Erythropoeitin|40.000 IU, epoetin alfa; Janssen-Cilag
9929406|NCT00916565||Experimental milk-based infant formula|
9929407|NCT00916565||Control milk-based infant formula|
9929408|NCT00916565||Breastfed Reference Group|
9929409|NCT00916604|Experimental|A|3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
9929410|NCT00916604|Placebo Comparator|B|Placebo oral suspension given to 3 groups (2 on placebo in each group)
9929411|NCT00916630|Other|Single-arm treatment|Dose finding study
9929412|NCT00916656|Experimental|Prospective Arm|
9929413|NCT00916656|Other|Historical Control|
9929414|NCT00916669|Active Comparator|Group A|Cisplatin and Etoposide
9929415|NCT00916669|Experimental|Group B|Cisplatin and etoposide, plus low-dose enoxaparin sodium
9929416|NCT00916669|Experimental|Group C|Cisplatin and etoposide, plus high-dose enoxaparin sodium
9929417|NCT00916682||Cystic Fibrosis|
9929418|NCT00916695|Active Comparator|Complex PCI strategy for bifurcation coronary lesions|Stenting main vessel and T-stenting for the side branch
9929419|NCT00916695|Active Comparator|Simple PCI strategies for bifurcation coronary lesions|Stenting main vessel, with provisional stenting for the side branch.
9929420|NCT00916708|Experimental|Intensive follow up|Intensive follow up in low-risk patients Intensive follow up in high-risk patients
9929421|NCT00916708|Experimental|Minimalist follow up|Minimalist follow up in low-risk patients Minimalist follow up in high-risk patients
9929422|NCT00916734|Experimental|Spinal Manipulation Group|Subjects who received spinal thrust manipulation as an intervention.
9929423|NCT00916734|Active Comparator|McKenzie MDT Group|
9929424|NCT00916760|Experimental|1|A Subcutaneous Depigmented and Polymerized Allergen extract of Parietaria Judaica 1000 DPP/ml. Depigoid Parietaria judaica 1000 DPP/ml.
9929425|NCT00916760|Placebo Comparator|2|
9929426|NCT00916786||OROS-methylphenidate|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
9929427|NCT00916786||Atomoxetine group|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
9929428|NCT00916786||Control group|Healthy controls matching for the distribution of age and sex of the case groups
9929429|NCT00916799|Experimental|Oximeter arm and non-oximetry arm|
9929430|NCT00916825|Experimental|3-week family oriented rehabprogramme|waiting control group
9929431|NCT00916838||Type 1 Diabetes Mellitis|Children with Type 1 Diabetes Mellitis (T1DM) between 4 and 16 were recruited.
9929432|NCT00916838||Non diabetic Control|62 healthy siblings also enrolled in the study between the ages of 4 and 17.
9929433|NCT00916851||Control group|Normally developing children and adolescents
9929434|NCT00916851||ADHD group|Children and adolescents with ADHD
9929435|NCT00916851||ASD group|Children and adolescents with ASD
9929436|NCT00916890|Active Comparator|Oral extended-release morphine|
9929437|NCT00916890|Active Comparator|Oral extended-release oxycodone|
9929438|NCT00916890|Active Comparator|Transdermal fentanyl|
9929439|NCT00916890|Active Comparator|Transdermal buprenorphine|
9929440|NCT00916903||1|Patients with genetic condition being studied.
9929441|NCT00916903||2|Matched controls
9929442|NCT00916916||Lanreotide|Patients taking lanreotide for the treatment of acromegaly.
9929443|NCT00916942|Experimental|NGX-4010 patch|
9929444|NCT00916942|Experimental|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
9874372|NCT00352313|Experimental|Phase II|Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9796693|NCT01574326|Placebo Comparator|FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
9796694|NCT01574326|Experimental|FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.
9796695|NCT01574352|Experimental|Intervention camp|Children's behavior are controlled each week day for six weeks, and children participate in three hours of physical activity every day
9929445|NCT00916955||Individuals with 22q11.2 deletions|Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
9929446|NCT00916968|Active Comparator|Standard CR-Flex|
9796696|NCT01574352|Experimental|Small intervention|Children are only informed of healthy behavior
9796697|NCT01574612|Experimental|topical cream acyclovir/hydrocortisone|topical cream acyclovir/hydrocortisone used
9796698|NCT01574651|Experimental|QVA149 plus placebo to tiotropium and placebo to formoterol|QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
9796699|NCT01574651|Active Comparator|Tiotropium plus Formoterol and placebo to QVA149|Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
9796700|NCT01574703|Experimental|placebo|
9796701|NCT01574703|Experimental|varenicline|
9796702|NCT01574703|Experimental|bupropion|
9796703|NCT01574703|Experimental|Nicotine Replacement Therapy Patch|
9796704|NCT01574716|Experimental|MORAb-004, gemcitabine, docetaxel|
9796705|NCT01574716|Active Comparator|Placebo, gemcitabine, docetaxel|
9796706|NCT01574807|Experimental|mepivacaine + lidocaine followed by lidocaine + lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine (3% mepivacaine/2% lidocaine with epinephrine - combination 1) and 2.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two seperate appointments spaced 2 weeks apart.
9796707|NCT01574807|Experimental|lidocaine + lidocaine followed by mepivacaine plus lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
9796708|NCT01575054|Experimental|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
9796709|NCT01575054|Other|Normal Saline (Placebo) Followed by botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
9796710|NCT01575080|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use Contour TS Blood Glucose Monitoring System.
9796711|NCT01575106|Experimental|Arm 1|There is only one cohort in this study. All subjects receive the same intervention, the application of heat pain using TSA or CHEPS.
9796712|NCT01575197|Active Comparator|Rotavirus Vaccine at age 6 & 10 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6 & 10 weeks of age.
9796713|NCT01575197|Experimental|Rotavirus vaccine at age 10 & 14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 10 & 14 weeks of age.
9796714|NCT01575197|Experimental|Rotavirus vaccine at age 6,10,&14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6, 10, & 14 weeks of age.
9796715|NCT01575275|Experimental|Diagnostic (aminolevulinic acid)|Patients receive aminolevulinic acid PO 2-4 hours before surgery.
9796716|NCT01575522|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 mg PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.
9796717|NCT01575561|Experimental|Lurasidone|Lurasidone 20, 40, 60,80 mg flexible dose
9796718|NCT01575756|Experimental|Octafibrin followed by Haemocomplettan® P or RiaSTAPTM|Participants received Octafibrin 70 mg/kg intravenously once followed by Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once 45 days later.
9796719|NCT01575756|Experimental|Haemocomplettan® P or RiaSTAPTM followed by Octafibrin|Participants received Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once followed by Octafibrin 70 mg/kg intravenously once 45 days later.
9796720|NCT01575769|Experimental|1|
9796721|NCT01575808|Experimental|GP1101|Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
9987427|NCT01412437|Experimental|Diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
9987428|NCT01412437|Experimental|sapropterin dihydrochloride|Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months
9987429|NCT01412450|Experimental|nitinol stent|Protégé EverFlex stent
9987430|NCT01412463|Experimental|Protégé EverFlex+|Stenting with Protégé EverFlex+
9987431|NCT01412476||case group|Subjects with metabolic syndrome
9987432|NCT01412476||control group|Healthy individuals
9987433|NCT01412489|Experimental|1|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
9987434|NCT01412502||Brain death with organ donation|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues."
9987435|NCT01412502||Limitation/cessation of active treatment|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death."
9987436|NCT01412502||Sudden death|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death."
9987437|NCT01412515|Experimental|Everolimus|everolimus 10 mg per day
9987438|NCT01412528|Other|Eight different allergens will be standardized in this study|
9987439|NCT01412567|Active Comparator|Vaccine+HBIG|
9987440|NCT01412567|Placebo Comparator|Vaccine+Placebo|
9987441|NCT01412580||observational followup|This was an observational follow-up to a larger study in which treatment group was given 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid
9987442|NCT01412593|Experimental|Stem cell transplant|
9987443|NCT01412593|No Intervention|Control|
9987444|NCT01412606|Experimental|Scrathcing|scratching of endometrium on day 21-26 of a spontaneous menstrual cycle
9987445|NCT01412606|Placebo Comparator|Control|Uterine sounding on day 21-26 of a spontaneous menstrual cycle
9987446|NCT01412632|Experimental|General vs deep sedation|General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest
9987447|NCT01412645|Placebo Comparator|Placebo|
9987448|NCT01412645|Experimental|High-dose Resveratrol|
9987449|NCT01412645|Experimental|Low-dose Resveratrol|
9987450|NCT01412658|Experimental|Milk Peptides|
9987451|NCT01412658|Placebo Comparator|Placebo|Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
9987452|NCT01412671||Group 1|
9987453|NCT01412697|Experimental|Fruit and Vegetable Intake Behavioral Intervention|measure fruit and vegetable intake in rural youth based on specific behavioral intervention.
9987454|NCT01412697|No Intervention|Control Group|control group received the standard health information
9987455|NCT01412723|Active Comparator|Ferrous sulphate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin, which will be supplied with ferrous sulfate-fortified milk
9987456|NCT01412723|Experimental|Iron Amino acid chelate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin , which will be supplied with iron amino acid chelate-fortified milk
9987457|NCT01412736|Experimental|2mg|sterile lyophilized formulation, 2mg
9987458|NCT01412736|Experimental|20mg|sterile lyophilized formulation, 20mg
9987459|NCT01412736|Experimental|100mg|sterile lyophilized formulation, 100mg
9987460|NCT01412736|Placebo Comparator|Placebo|two SC administration on day 1
9874373|NCT00352326|Experimental|Children (with dystonia and controls)|"Participants sat in a chair or their own wheelchair in front of a table whose surface height was adjusted at the midpoint between the hip and the Xiphoid process. They placed the hand that was not used for the task on their lap.~An iPad® (Apple Inc, Cupertino, California) was located on the table in portrait mode in front of the participants at a distance that ranged between 40 and 55 cm. An adjustable metal bookstand supported the iPad® to allow the participants a comfortable screen view. The size of the screen was 19.5 × 14.6 cm. Custom software was developed for the experimental task (XCode 3.2 development environment, iOS 4.2 operating system; Apple Inc, Cupertino, California)."
9874374|NCT00352339|Experimental|Aripiprazole|switching group (from risperidone to aripiprazole)
9874375|NCT00352339|Active Comparator|Risperidone|Start with risperidone and keep it through the end of study
9874376|NCT00352339|Active Comparator|Abilify|Start with aripiprazole and keep it through the end of study
9874377|NCT00352378|Experimental|Adriamycin plus Cyclophosphamide|Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1.
9874378|NCT00352378|Experimental|Taxotere plus Xeloda|Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
9874379|NCT00352391||Vanguard Study|Patients with Head and Neck or Non-Small Cell Lung Cancer who are Current or Former Smokers.
9874380|NCT00352443|Experimental|everolimus/lapatinib|Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28
9874381|NCT00352469|Placebo Comparator|2|Subjects will be randomized to receive either Seroquel SR or placebo
9874382|NCT00352495|Experimental|Vinblastine sulfate and carboplatin|The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
9874383|NCT00352521|Experimental|Bevacizumab and irinotecan|The bevacizumab will be dosed at 10 mg/kg every 14 days (days 1, 15 and 29) and the irinotecan on days 2, 15, and 29 of the first six week schedule. The irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). If the patient is on an EIAED, the patient will receive 340 mg/m2 on days 2, 15, and 29 of the first six week schedule. If the patient is not on an EIAED, the dose of irinotecan will be 125 mg/m2 on days 2, 15, and 29 of the first six week schedule. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29.
9874384|NCT00352599|Active Comparator|Lovastatin|Lovastatin
9874385|NCT00352599|Placebo Comparator|Placebo pill|Placebo pill
9874386|NCT00352703|Experimental|Kepivance (palifermin) 60 μg/kg/day IV|60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
10213740|NCT03424213||AA low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
10213741|NCT03424213||AA high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
9874387|NCT00352729|Active Comparator|A|
9874388|NCT00352742|Experimental|1|ATN-224 + bortezomib
9874389|NCT00352768|Experimental|F|
9874390|NCT00352768|Placebo Comparator|P|
9874391|NCT00352820||Interview + Questionnaire|
9874392|NCT00352859|Experimental|Arm 1|
9874393|NCT00352859|Experimental|Arm 2|
9874394|NCT00353015|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m2 and Cisplatin 25 mg/m2 intravenous (IV) days 1, 8 of a 21-day cycle
9874395|NCT00353028|Experimental|F|
9874396|NCT00353028|Placebo Comparator|P|
9929447|NCT00916968|Experimental|Gender specific CR-Flex|
9929448|NCT00916994|Experimental|SpaceGuard Balloon implantation|
9929449|NCT00917007||ABO compatible|
9929450|NCT00917007||ABO incompatible, antiglobulin positive|
9929451|NCT00917007||ABO incompatible, antiglobulin negative|
9929452|NCT00917033|Experimental|GlideScope|Orotracheal intubation using the GlideScope videolaryngoscope
9929453|NCT00917033|Active Comparator|Macintosh|Orotracheal intubation using the Macintosh direct laryngoscope
9929454|NCT00917046|Experimental|1 Interval training|high-intensity Interval Training
10213742|NCT03424213||AA intermediate aggressive|intermediate aggressive = all other cases
10213743|NCT03421964|Active Comparator|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, virtual sessions.
9929455|NCT00917046|Experimental|2 Moderate Training|Moderate continuous training
9929456|NCT00917046|Active Comparator|3 Recommendation of exercise|Recommendation of regular exercise at moderate intensity at individual choice
9929457|NCT00917059|Active Comparator|1|Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
9929458|NCT00917059|Active Comparator|2|Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
9929459|NCT00917072|Experimental|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
9935372|NCT03830229||1/Germline positive mesothelioma|Individuals with mesothelioma who have a BAP1 or other DNA repair/cancer predisposition mutation regardless of CLIA confirmation
9935373|NCT03830229||2/CLIA confirmed germline mutation without mesothelioma|Individuals with a CLIA confirmed BAP1 or other DNA repair/cancer predisposition mutation who do not have a diagnosis of mesothelioma
9874397|NCT00353106||Patients|Patients with chronic GVHD
9874398|NCT00353106||Content Expert Panel|Content expert panel with 5 years experience caring for patients with cGVHD.
9874399|NCT00353106||Caregivers|Caregivers of patients with cGVHD
9874400|NCT00353145|Experimental|Gemcitabine + Oxaliplatin|Gemcitabine 1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 and Oxaliplatin 100 mg/m^2 by vein infused on Day 2 over two hours. Repeated every 14 days (one cycle).
9874401|NCT00353223|Experimental|A|Participants will receive combined interpersonal and behavioral psychotherapy aimed at reducing depression in patients with heart failure.
9874402|NCT00353223|Active Comparator|B|Participants will receive the attention control condition.
9874403|NCT00353249|Experimental|1|Participants will receive adapted cognitive behavioral therapy treatment
9874404|NCT00353249|No Intervention|2|Participants will receive no treatment for the course of the study; they will be offered courtesy PTSD 5 weeks after the experimental intervention.
9874405|NCT00353379|Experimental|guanfacine|Participants will take guanfacine.
9874406|NCT00353379|Placebo Comparator|placebo|Participants will take placebo.
9874407|NCT00353405|Experimental|1|Participants receiving social skills training and mass media messages
9874408|NCT00353405|Experimental|2|Participants receiving social skills training and no mass media messages
9874409|NCT00353405|Experimental|3|Participants receiving mass media messages and no social skills training
9874410|NCT00353405|Experimental|4|Participants receiving no social skills training and no mass media messages
9874411|NCT00353470|Experimental|1|Participants will receive panic focused psychodynamic psychotherapy for 12 weeks
9874412|NCT00353470|Active Comparator|2|Participants will receive cognitive behavioral therapy-panic control treatment for 12 weeks
9874413|NCT00353470|Active Comparator|3|Participants will receive applied relaxation training for 12 weeks
9874414|NCT00353548||1-Anorexia Nervosa|Women ages 16-50 who meet DSM-IV criteria for anorexia nervosa
9874415|NCT00353548||2-Bulimia Nervosa|Women age 16-50 who meet DSM-IV criteria for bulimia nervosa
9874416|NCT00353548||3-Binge Eating Disorder|Women with binge eating disorder
9874417|NCT00353548||4-Healthy Controls|Healthy control subjects ages 16-50 of normal weight
9874418|NCT00353548||5-Obese Controls|Healthy obese control subjects
9874419|NCT00353561|Active Comparator|1, Boric acid|600 mg vaginal pessaries for 14 days
9874420|NCT00353561|Other|2, Fluconazole|
9874421|NCT00353587|Experimental|MBX-102 200 mg|MBX-102 200 mg once daily for 16 weeks
9874422|NCT00353587|Experimental|MBX-102 400 mg|MBX-102 400 mg once daily for 16 weeks
9874423|NCT00353587|Experimental|MBX-102 600 mg|MBX-102 600 mg once daily for 16 weeks
9874424|NCT00353587|Placebo Comparator|Sugar Pill|Placebo comparator once daily for 16 weeks
9874425|NCT00353587|Active Comparator|Actos|Actos 30 mg once daily for 16 weeks
9874426|NCT00353613|Other|1|LBJ Hospital
9874427|NCT00353613|Other|2|Ben Taub Hospital
9874428|NCT00353639||IBD subjects|Subjects with Inflammatory Bowell Disease
9796722|NCT01575808|No Intervention|Retrospective Surgical Bypass Outcomes|Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.
9796723|NCT01575834|Experimental|Romosozumab|Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
9796724|NCT01575834|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
9796725|NCT01575860|Experimental|Phase I/II (Maintenance Lenalidomide in Lymphoma)|Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.
9874429|NCT00353665|Experimental|1 - active|memantine + riluzole
10211518|NCT04663503|Experimental|Intervention arm -Exercise Program|This structured exercise program will incorporate a specially designed, low intensity, resistance based exercise regime created by our physical therapist. It consists of strengthening, endurance, stretching and relaxation exercises tailored according to age and their ability to perform activities throughout their hospitalization (Appendix 3). This exercise program will be done three times a week for 30-45 mins supervised by the same physiotherapist throughout hospitalization and will be self-administered every weekend. A home exercise program printout with the appropriate resistance exercises will be provided to the family upon discharge, with instructions on how often to complete throughout the week. Discharged children will attend one supervised exercise session per week with the physiotherapist for six weeks. The family and patient will also be provided a weekly sheet to check off the days they completed strengthening and endurance exercises.
9874430|NCT00353665|Placebo Comparator|2|riluzole + placebo
9874431|NCT00353717|Experimental|1|
10211519|NCT04663503|No Intervention|Control arm- No intervention|The second arm of the study involves patients following standard of care during the HSCT period in the hospital with PT evaluation and management prescribed as needed by their transplant medical team including any additional PT interventions as a result of clinical indications. No additional intervention is incorporated in this group
10211520|NCT04653467|Experimental|GLPG4399 SAD|Single doses of GLPG4399 at up to 6 dose levels in ascending order
10211521|NCT04653467|Placebo Comparator|Placebo SAD|Single doses of placebo
10211522|NCT04653467|Experimental|GLPG4399 MAD|Multiple ascending doses of GLPG4399
10211523|NCT04653467|Placebo Comparator|Placebo MAD|Multiple doses of placebo
10211524|NCT04653467|Experimental|GLPG4399 FE-rBA|Single dose of GLPG4399 in fed and fasted state
10211525|NCT04653467|Experimental|GLPG4399 FE|Single dose of GLPG4399 in fed and fasted state
10211526|NCT04641156|Experimental|Low level LASER Therapy|Subjects in this group received low-level laser therapy
9796726|NCT01575873|Experimental|Denosumab|Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
9796727|NCT01575873|Experimental|Risendronate|Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
9796728|NCT01575899|Experimental|Levofloxacin-Amoxicillin/clavulanate|7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
9796729|NCT01575899|Active Comparator|Clarithromycin-Amoxicillin|7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.
9796730|NCT01575912||schizophrenia SC|subjects with a diagnosis of schizophrenia (SC) according to the DSM-IV-TR, submitted to experimental pain tests
9796731|NCT01575912||major depression MD|subjects with a diagnosis of major depression (MD) according to the DSM-IV-TR, submitted to experimental pain tests
9796732|NCT01575912||controls C|subjects without any diagnosis of psychiatric disorder (C) submitted to experimental pain tests
9796733|NCT01576003|Experimental|Glutamine|Infants randomized to the Glutamine group will receive L-Glutamine (GLN) administered enterally at a dose of 0.6g/kg body weight/day (0.3g/kg/dose) in 2 divided daily doses for 6 months. GLN will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
9796734|NCT01576003|Placebo Comparator|L-alanine|Infants randomized to the placebo group will receive L-alanine (ALA) administered enterally at a dose of 0.6g/kg body weight/day in 2 divided doses (0.3g/kg/day twice a day) for 6 months. ALA will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
9796735|NCT01576003|No Intervention|Healthy Control|Healthy age-matched infants (n=12) will have serial stools collected on 4 occasions, each separated by 60 days.
9796736|NCT01576016|Experimental|Lead Safety|Patient implanted with an Accent MRI system to evaluate safety of the Tendril MRI lead
9796737|NCT01576016|Experimental|Accent MRI system MRI Scan Group|Patient implanted with an Accent MRI system will receive an MRI scan to evaluate safety and efficacy of the Accent MRI system in an MRI environment
9796738|NCT01576042|Other|Catheter ablation|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults
9796739|NCT01576042|Other|Antiarrhythmic medication|The choice of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
9796740|NCT01576055|Experimental|TIGRIS Vascular Stent|GORE TIGRIS Vascular Stent
9796741|NCT01576055|Active Comparator|BARD LifeStent|BARD LifeStent
9796742|NCT01576120|Experimental|bowel prep regimen first boost 6 oz. and second boost 3 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 6 oz. SuPrep administered and 3hrs later 3 oz. SuPrep was administered if needed depends on the capsule progress in the GI
10211527|NCT04641156|Experimental|Exercise group|Subjects in this group received additional planned exercise therapy program
9796743|NCT01576120|Experimental|bowel prep regimen first boost 3 oz. and second boost 6 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 3 oz. SuPrep administered and 3hrs later 6 oz. SuPrep was administered if needed depends on the capsule progress in the GI
9796744|NCT01576146|Experimental|Etelcalcetide|Participants received a bolus IV injection of etelcalcetide 3 times a week (TIW) at the end of each hemodialysis session for up to 144 weeks in the extension study. The starting dose was the same as the final dose administered in the parent study (20120331); the dose was adjusted per protocol-specified guidelines to achieve or maintain parathyroid hormone values in the 150 to 300 pg/mL range.
10211528|NCT04629664|Active Comparator|FX-322|FX-322, 1 dose (N=24)
10211529|NCT04629664|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
10211530|NCT04628442||TIP-OB (Office-Based)|Those in TIP-OB will be undergoing regularly scheduled office-based procedures at the otolaryngology clinic at UCSF Mount Zion campus. The investigators will be collecting nasal mucus and blood samples during each of their visits to the clinic, up to 9 times.
10211531|NCT04628442||TIP-OR (Operating Room)|Those in TIP-OR will be undergoing regularly scheduled surgeries in the operating room at UCSF Parnassus or Mount Zion campus. The investigators will be collected nasal polyp tissue, nasal mucus if possible, and blood samples during each of their surgeries, up to 9 times. The investigators will also collect inferior turbinate tissue if consented to.
10211532|NCT04618614|Experimental|HD-tDCS S1 1 mA|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
10211533|NCT04618614|Active Comparator|HD-tDCS M1 1 mA|Single session of 15-min HD-tDCS to the right primary motor cortex with an intensity of 1 mA. The session will last approximately one hour.
10211534|NCT04618614|Sham Comparator|Sham control|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
10211535|NCT04607369||Groups in General all were done under the wcgIRB, even those that were Practice groups|"Groups 1-3 were practice groups, gathering smartphone app installation, functional and usability feedback in preparation for later phase groups~Groups 4a and 4b Cohort 1 and 2 is the FDA application finalized and submitted study groups~Group 5-6 currently in continuing clinical trial during FDA application process"
10211536|NCT04607369||1-3,5 Developmental team(1), Technician(2) and Non-Clinical Groups(3) 5. Retinal practice|Individuals on the developmental team, staff members and outside clinic people 5 Retinal Practice (to do after FDA approval)
10211537|NCT04607369||4a. Cohort 1. FDA group|Patients in Neuro-Ophthalmology of Texas (NOT) PLLC practice which has referrals from multiple practices including retinal patients.
10211538|NCT04607369||4b. Cohort 2. FDA group|Patients in NOT practice
10211539|NCT04607369||6 At Home use of app in continuing clinical trial during FDA decision|Patients are educated on the app at home via app video clips and brochure, and as necessary, online training with COA (ophthalmic assistants/technicians or other trained educators) in order to do remote physiologic vision monitoring or preclinic near vision check.
9796745|NCT01576159|Experimental|High-Impact Loading|Performed high-impact running exercise during intervention period.
9796746|NCT01576159|Experimental|Moderate-Impact Loading|Performed moderate-impact cycling exercise during intervention period.
9796747|NCT01576159|Experimental|Non-Impact Loading|Performed low-impact swimming exercise during intervention period.
9796748|NCT01576159|No Intervention|Control Group|Didn't participate any organized physical exercises
9796749|NCT01576172|Active Comparator|Arm I (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9796750|NCT01576172|Experimental|Arm II (abiraterone acetate, prednisone, and veliparib)|Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9796751|NCT01576276|Experimental|Morphine condition|
9796752|NCT01576276|Experimental|Ketorolac condition|
9796753|NCT01576341|Experimental|HX575 epoetin alfa (Sandoz)|Single arm
9796754|NCT01576367|Experimental|canakinumab|Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)
9796755|NCT01576406|Experimental|A1: normal hepatic function|
9796756|NCT01576406|Experimental|A2: normal hepatic function|
9796757|NCT01576406|Experimental|B: mild hepatic impairment|
9796758|NCT01576406|Experimental|C: moderate hepatic impairment|
9796759|NCT01576406|Experimental|D: severe hepatic impairment|
9796760|NCT01576471|Placebo Comparator|Placebo|
9796761|NCT01576471|Experimental|TSO 7500|
9796762|NCT01576484|Placebo Comparator|Placebo Matched to Alirocumab|Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
9796763|NCT01576484|Experimental|Alirocumab 150 mg|Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.
9796764|NCT01576523|Experimental|Low, then medium, C1-esterase inhibitor dose|
9796765|NCT01576523|Experimental|Medium, then low, C1-esterase inhibitor dose|
9796766|NCT01576523|Experimental|Medium, then high, C1-esterase inhibitor dose|
9796767|NCT01576523|Experimental|Low, then high, C1-esterase inhibitor dose|
9796768|NCT01576523|Experimental|High, then low, C1-esterase inhibitor dose|
9796769|NCT01576523|Experimental|High, then medium, C1-esterase inhibitor dose|
9796770|NCT01576536||Healthy volunteers|Normal healthy volunteers
9874432|NCT00353743|Active Comparator|1|Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
9874433|NCT00353743|Placebo Comparator|2|Patients that do not receive antibiotics, only placebo
9874434|NCT00353808|Experimental|s, s reboxetine|
9874435|NCT00354081|Active Comparator|1|folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg)
9874436|NCT00354081|Active Comparator|2|folic acid (0.8 mg) plus vitamin B12 (0.4 mg)
9874437|NCT00354081|Active Comparator|3|vitamin B6 (40 mg)
9874438|NCT00354081|Placebo Comparator|4|placebo
9874439|NCT00354120|Experimental|1|Alentuzumab
9874440|NCT00354120|Active Comparator|2|Globulina antilinfocitaria
9874441|NCT00354133|Active Comparator|DBS treatment|Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment
9874442|NCT00354133|Active Comparator|BMT treatment|Patients in this arm get best medical treatment only.
9874443|NCT00354185|Experimental|Treatment (tanespimycin, belinostat)|"Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, and 11 and PXD101 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 17-AAG and PDX101 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.~Patients undergo blood collection on days 1 and 4 of course 1 for pharmacokinetic studies."
9874444|NCT00354198|Active Comparator|corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
9874445|NCT00354198|Experimental|pentoxifylline + corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90
9874446|NCT00354211||1|FLOTRAC™ SYSTEM
9874447|NCT00354211||2|Control Group
9874448|NCT00354237|Other|B|No intensive treatment
9874449|NCT00354237|Experimental|A|Intensive insulin treatment
9874450|NCT00354250|Experimental|Treatment (ispinesib)|Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9874451|NCT00354263|Placebo Comparator|A|PBS injected alone in step 1 or mixed with Aggripal in step 2
9874452|NCT00354263|Experimental|B|
9874453|NCT00354315|Experimental|1|Immediate Continuous medical education (CME)
9874454|NCT00354315|No Intervention|2|control, 6 months delay CME intervention
9874455|NCT00354354|Experimental|1|Combivent
9874456|NCT00354354|Placebo Comparator|2|Saline Solution (0.9% NaCl)
9874457|NCT00354406|Experimental|A|Patients in Arm A (Early abciximab arm) will receive abciximab at time of STEMI diagnosis, before transfer to the Cath Lab to undergo primary angioplasty.
9874458|NCT00354406|Active Comparator|B|Patients in Arm B (Late abciximab arm) will receive abciximab at time of primary angioplasty, directly in the Cath Lab.
9874459|NCT00354419|Experimental|Arm I|See Detailed Description
9874460|NCT00354458|Placebo Comparator|1|
9874461|NCT00354458|Experimental|2|
9874462|NCT00354523|Experimental|Capecitabine + Dacarbazine + Imatinib|Capecitabine starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
9874463|NCT00354536|Active Comparator|albiglutide|albiglutide injection
9874464|NCT00354536|Placebo Comparator|albiglutide placebo|placebo injection
9874465|NCT00354562|Active Comparator|A|Docetaxel + ABT-751
9874466|NCT00354562|Placebo Comparator|B|Docetaxel + placebo
9874467|NCT00354575|Experimental|A|Chinese Herb (CCH1)
9874468|NCT00354575|Placebo Comparator|B|Starch powder as placebo
9874469|NCT00354627|Experimental|TMC125|TMC125 200 mg b.i.d. till commercially available.
9874470|NCT00354692|Experimental|Experimental|
9874471|NCT00354705||Colon Cancer Patients|Patients with colon cancer recently removed by surgery.
9874472|NCT00354731|Active Comparator|corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
9935374|NCT03829501|Experimental|KY1044 monotherapy phase 1|KY1044 monotherapy dose escalation
9935375|NCT03829501|Experimental|KY1044 and atezolizumab phase 1|KY1044 and atezolizumab combination dose escalation
9874473|NCT00354731|Experimental|Pentoxifylline + corticosteroid|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M + oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
9874474|NCT00354757|Active Comparator|2 arms|PPI 1
9874475|NCT00354757|Active Comparator|PPI|PPI 2
9874476|NCT00354861|Experimental|A|IMP321
9874477|NCT00354861|Placebo Comparator|B|Saline
9874478|NCT00354861|Active Comparator|C|Engerix B
9874479|NCT00354874|Experimental|GW642444 50mcg|
9874480|NCT00354874|Experimental|GW642444 100mcg|
9874481|NCT00354874|Experimental|GW642444 200mcg|
9874482|NCT00354874|Active Comparator|salmeterol 50mcg|
9874483|NCT00354874|Placebo Comparator|placebo|
9874484|NCT00354926|Experimental|AME 133v|All subjects will receive weekly intravenous infusions of AME-133v. Each subject will receive a total of 4 infusions administered once a week for 3 consecutive weeks.
9929460|NCT00917072|Experimental|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center.
9929461|NCT00917072|Placebo Comparator|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
9929462|NCT00917085|No Intervention|Control group|Control infants received the same standard care as infants who were not in the study. Infants were kept warm in incubators or warmer beds and were wrapped in blankets when held by their mothers. Hospital staff was responsible for providing standard care.
9929463|NCT00917085|Experimental|Skin-to-Skin group|
9929464|NCT00917098|Experimental|Behavior Therapy|Participants will receive behavior therapy during Phases 1 and 2.
9929465|NCT00917098|Placebo Comparator|Supportive Counseling|Participants will receive supportive counseling during Phase 1 and will not participate in Phase 2.
9929466|NCT00917137||Peripheral pulmonary lesions|
9929467|NCT00917163|Experimental|Supralimus(R) Sirolimus Eluting Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
9929468|NCT00917163|Active Comparator|Xience V™ Everolimus Eluting Stent|The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2
9929469|NCT00917176|Experimental|Effective stimulation|Effective stimulation at sub-threshold level
9929470|NCT00917176|Placebo Comparator|Placebo stimulation|Stimulation at non-effective strength
9929471|NCT00917189|Experimental|Computerized Cognitive Skills Training|Participants will receive the Challenging Our Minds intervention, delivered in-person in Phase 1 and remotely in Phases 2 and 3.
9929472|NCT00917202|Experimental|MB3|3 days
9929473|NCT00917202|Experimental|MB5|5 days
9929474|NCT00917202|Experimental|MB7|
9929475|NCT00917215|Experimental|Active acupuncture|
9929476|NCT00917215|Sham Comparator|Sham acupuncture|
9929477|NCT00917215|No Intervention|Waiting list control|
9929478|NCT00917228||Feedback|Subjects of this group are equipped with the biofeedback system
9929479|NCT00917228||Control|Subjects of this group are not equipped with the biofeedback system
9929480|NCT00917241|Experimental|MMI+IID group|MMI,methimazole；IID,intrathyroid injection of dexamethasone
9874485|NCT00354965|Experimental|ARM 1|
9874486|NCT00354991|Experimental|1|Losartan/HCTZ
9874487|NCT00355069|Experimental|1|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt AND family education
9874488|NCT00355069|Experimental|2|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt but NOT family education
9874489|NCT00355069|Experimental|3|Received the Basic Pediatric Chronic Care Model AND family education but NOT the Medication Assessment Prompt
9874490|NCT00355069|Placebo Comparator|4|Received the Basic Pediatric Chronic Care Model only (NO Medication Assessment Prompt and NO family education)
9874491|NCT00355095|Active Comparator|1|erythropoietin
9874492|NCT00355095|No Intervention|2|Placebo
9874493|NCT00355186|No Intervention|Control|
9874494|NCT00355186|Experimental|Early|
9874495|NCT00355186|Experimental|Late|
9874496|NCT00355251|Experimental|A|4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
9874497|NCT00355251|No Intervention|B|4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento
9874498|NCT00355303|Active Comparator|Misoprostol tablet, PGE2 gel|participants are assigned to one of two arms for the duration of the study In one group induction of labour is done by intravaginal misoprostol tablets at 4 hrly interval with maximum of five doses.In other group PGE2 gel is applied in poaterior fornix at six hourly interval.
9874499|NCT00355316|Experimental|Stage IV Breast Cancer|Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
9874500|NCT00355316|Other|Healthy Volunteers|Baseline blood draw.
9874501|NCT00355485|Experimental|Microdermabrasion Treatment|Bilateral, split-face comparison in which one half of the face will be randomly assigned to receive the microdermabrasion treatment(s) while the other half of the face will not. Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart. In all cases, microdermabrasion treatment parameters will be within those accepted in cosmetic work.
9874502|NCT00355498||1|Controls
10211540|NCT04607369||7a Cohort 1 FDA group responding to AI|Normal patients were tested with standard near vision tests compared with the smartphone app near vision tests. All patients were trained at home with app videos and by COA via telemedicine before coming to clinic.
10211541|NCT04607369||7b Cohort 2 FDA group responding to AI|Normal patients were tested with standard near vision tests compared with the smartphone app near vision tests. All patients were trained at home with app videos and by COA via telemedicine before coming to clinic.
9874503|NCT00355498||2|Mild Cognitive Impairment
9874504|NCT00355498||3|Alzheimer's disease
9874505|NCT00355498||4|FTD
9874506|NCT00355524|Experimental|Group A with >= 20 kg to < 30 kg body weight|300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
9874507|NCT00355524|Experimental|Group A with >= 30 kg to < 40 kg body weight|300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
9874508|NCT00355524|Experimental|Group A with >= 40 kg to < 50 kg body weight|450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
10211542|NCT04606407|Experimental|Treatment|Inhaled NO delivered using LungFit™ in addition to standard of care
10211543|NCT04606407|No Intervention|Standard of care|Standard of care
10211544|NCT04606316|Experimental|Nivolumab and Ipilimumab Before and After Surgery|"One dose of nivolumab plus ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
10211545|NCT04606316|Experimental|Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab After Surgery|"One dose of nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab alone every 4 weeks."
10211546|NCT04606316|Experimental|Placebo-Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab and Ipilimumab After Surgery|"One dose of placebo-nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 12 weeks and then nivolumab alone every 4 weeks."
10211547|NCT04603274|Other|upper extremity diagnosed with carpal tunnel syndrome|8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians
10211548|NCT04601883|Experimental|Colchicine|Tablet colchicine 0.5 mg administered two times daily
10211549|NCT04601883|Placebo Comparator|Placebo|Tablet placebo administered two times daily
9874509|NCT00355524|Experimental|Group B with >= 20 kg to < 30 kg body weight|375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
9874510|NCT00355524|Experimental|Group B with >= 30 kg to < 40 kg body weight|450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
9874511|NCT00355524|Experimental|Group B with >= 40 kg to < 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
9874512|NCT00355524|Experimental|Participants with >= 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
9874513|NCT00355537|Experimental|Active|
9874514|NCT00355537|Placebo Comparator|Placebo|
9874515|NCT00355550|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
9874516|NCT00355550|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
9874517|NCT00355576|Experimental|Minocycline + Creatine|Minocycline 100 mg BID and Creatine 10 g BID
9874518|NCT00355576|Experimental|Celecoxib + Creatine|Celecoxib 400 mg BID and Creatine 10 g BID
9874519|NCT00355628|Experimental|1|KW-2246 (fentanyl citrate)
9874520|NCT00355641|Experimental|Open Label|All subjects will receive ropinirole XR in this study. The total daily dose range of ropinirole XR will be 0.5mg to 6.0mg daily
9874521|NCT00355654|Experimental|Group 1|Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
9874522|NCT00355654|Active Comparator|Group 2|Participants will receive Infanrix hexa with Prevenar at Visit 1
9874523|NCT00355667|Active Comparator|A|Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
9874524|NCT00355667|Active Comparator|B|Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
9874525|NCT00355680|Experimental|1|Aurolab Green Laser
9874526|NCT00355680|Active Comparator|2|Available Green Laser
9874527|NCT00355719|Experimental|Nevirapine-atazanavir|Atazanavir/ritonavir 300/100 mg once daily for ≥2 weeks. Nevirapine was added at a dose of 200 mg once daily from days 0 to 14, and 200 mg twice daily from days 14 to 28.
9874528|NCT00355771|Experimental|Treatment Group 1|
9874529|NCT00355771|Placebo Comparator|Treatment Group 2|
9874530|NCT00355810|Experimental|placebo followed by probiotic|placebo, then washout period, then Lactobacillus plantarum MF1298
10211550|NCT04600921|Active Comparator|Ertugliflozin|The subject will receive Ertugliflozin 5mg.
10211551|NCT04600921|Placebo Comparator|Placebo|The subject will receive Placebo 5mg.
9874531|NCT00355810|Experimental|probiotic followed by placebo|Lactobacillus plantarum MF1298, then washout period, then placebo
9874532|NCT00355862|Active Comparator|1|Center specific immunosuppressive regimen (mTOR inhibitor free)
9874533|NCT00355862|Experimental|2|Sirolimus containing regimen
9874534|NCT00355888|Experimental|Open label study of MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
9874535|NCT00355940|Experimental|1|
9874536|NCT00355940|Active Comparator|2|
9874537|NCT00355966|Active Comparator|A|In group A, immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
9874538|NCT00355966|Active Comparator|B|In Group B immediate induction of labour will be done by application of vaginal PGE2 gel 0.5 gm at an interval of 6 hours , a maximum of 2 doses.
9874539|NCT00356005|Experimental|Azithromycin + Artesunate|Azithromycin + Artesunate treatment
10211552|NCT04597151|Experimental|Supportive care (diet education)|Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).
9874540|NCT00356005|Active Comparator|Artesunate|Artesunate treatment controls
9874541|NCT00356083|Experimental|switch from morphine to methadon|
9874542|NCT00356174||Children with food allergy|340 longitudinally followed children with egg and/or milk allergy without elevated peanut specific Immunoglobulin E (IgE), less than 5 kUA/L
9874543|NCT00356174||Full sibling controls for genetic studies|Approximately 250 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for genetic studies.
9874544|NCT00356174||Full sibling controls for mechanistic studies|Approximately 50 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for mechanistic studies. A subset of this cohort will be without food allergy,
9874545|NCT00356213|Experimental|A|laparoscopic sleeve gastrectomy
10211553|NCT04586751|Active Comparator|study group|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed. In specific, using the in-plane insertion technique, after visualization of the entire needle as a bright hyperechoic line and aiming between pectoralis major and pectoralis minor at the 3rd rib level, 2 ml of normal saline 09% will be injected first, to verify the correct position of the needle. Followingly, 10 mL ropivacaine 0.5% will be injected in order to block the lateral and medial pectoral nerves. Finally, another 15 ml of ropivacaine 0.5% plus 4 mg of dexamethasone will be injected between the pectoralis minor muscle and the anterior serratus muscle,at the level of the 4th and 5th ribs, after negative aspiration, to block the intercostal and intercostobrachial nerves. Using the color Doppler the vessels will be identified, so that their puncture is avoided during the procedures.
10211554|NCT04586751|Sham Comparator|control group|no regional block will be performed
10211555|NCT04573777|Experimental|Intervention Repatha|
9874546|NCT00356213|Active Comparator|B|laparoscopic gastric bypass
9874547|NCT00356291|Experimental|1|Participants will receive Skill-Building and Motivational Interviewing.
9874548|NCT00356291|Active Comparator|2|Participants will receive Skill-Building.
9874549|NCT00356317|Experimental|1|Participants will receive a 15-week family therapy
10211556|NCT04565353|No Intervention|Holdout control|Participants will only receive the standard appointment reminders from their providers.
10211557|NCT04565353|Experimental|Default Reservations Opt-Out Condition|"The day before their scheduled appointment, participants receive a text reading: A flu shot has been reserved for you to receive at your appointment tomorrow. Reply Y if you want this shot held for you, N if you don't. The text will include a picture of a vial that says Your Flu Shot on it."
10211558|NCT04565353|Experimental|Default Reservations Opt-In Condition|"The day before their scheduled appointment, participants receive a text reading: Reply Y if you would like to receive a flu shot at your appointment tomorrow, N if not. The text will include a picture of vial with no text on it."
9796771|NCT01576588|Experimental|R-HDMP|"Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion."
9796772|NCT01576705|Experimental|Thyroxin + folinic acid|
9796773|NCT01576705|Active Comparator|Thyroxin+folinic acid placebo|
9796774|NCT01576705|Active Comparator|Thyroxin placebo+ folinic acid|
9796775|NCT01576705|Placebo Comparator|Thyroxin placebo+ folinic acid placebo|
9796776|NCT01576718|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9796777|NCT01576718|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9796778|NCT01576718|Experimental|Fp MDPI 200 mcg|"Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9796779|NCT01576718|Experimental|Fp MDPI 400 mcg|"Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9796780|NCT01576718|Placebo Comparator|Placebo MDPI|"Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9796781|NCT01576718|Active Comparator|Flovent Diskus 250mcg|"Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
9796782|NCT01576783|Experimental|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
9796783|NCT01576783|Placebo Comparator|Placebo|Corn oil supplement
9796784|NCT01576809|Experimental|Upper Respiratory Tract Infection|
9796785|NCT01576874|Experimental|oxytocin|Participants will be administered 40 IUs of oxytocin nasal spray at one study visit.
9796786|NCT01576874|Placebo Comparator|placebo|Participants will be administered 40 IUs of placebo nasal spray at one study visit.
9796787|NCT01576939|Experimental|IMRT Modulation|"All patients will undergo a computed tomography (CT) simulation study +/- a positron emission tomography (PET) scan using ≤ 3mm slices for radiation treatment planning. A standard, non-filling optimized IMRT (Intensity Modulated Radiation Therapy) plan will be generated and patients will be treated with megavoltage radiation over a course of > 6 weeks with a planned tumor dose of > 60 Gy. A medical doctor will perform weekly mucositis evaluation and grading for the measured site once a week during radiation therapy~Modulation of an IMRT plan to reduce the dose to less than 35 Gy delivered to adjacent normal mucosa surrounding the dental filling without compromising normal tissue or tumor doses."
9796788|NCT01576952|Experimental|ISV-303|0.075% bromfenac in DuraSite vehicle dosed BID
9796789|NCT01576952|Placebo Comparator|DuraSite Vehicle|DuraSite Vehicle dosed BID
9796790|NCT01577108|Experimental|Probiotics, GBS Test|Treated with 2 oral probiotics once daily before sleeping for 14 days
9796791|NCT01577108|Placebo Comparator|Non-probiotics, GBS test|Treated with 2 placebo capsules once daily before sleeping for 14 days
9796792|NCT01577160|Experimental|Paliperidone Extended Release (ER)|
9796793|NCT01577186|Experimental|Paliperidone Extended Release (ER)|
9796794|NCT01577238|Experimental|VivaGel|
9796795|NCT01577238|Placebo Comparator|HEC Placebo|
9796796|NCT01577329|Experimental|mindfulness meditation class|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
9796797|NCT01577329|No Intervention|wait list|Subjects assigned to the control group will continue with medical treatment as usual and be allowed to attend the mindfulness meditation class after week eight.
9796798|NCT01577381|Experimental|PF-04382923|
9796799|NCT01577381|Placebo Comparator|Placebo|
9796800|NCT01577537|Experimental|VivaGel|
9796801|NCT01577537|Placebo Comparator|HEC Placebo|
9796802|NCT01577706|Active Comparator|Alprazolam (A)|Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
9874550|NCT00356317|Active Comparator|2|Participants will receive a 3-week family therapy (treatment as usual)
9874551|NCT00356343|Experimental|NMES Strengthening Group|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
9874552|NCT00356343|No Intervention|Control Group|No Intervention Control Group
10211559|NCT04565353|Experimental|Intergroup Competition Treatment Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind another region in flu shot rate last year (your region and another region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
10211560|NCT04565353|Experimental|Intergroup Competition Control Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind the target flu shot rate of 70% last year (your region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
9874553|NCT00356343|Active Comparator|Volitional Strengthening|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
9874554|NCT00356356|Experimental|All subjects|257 subjects
9874555|NCT00356447|Active Comparator|Arm 1|
9874556|NCT00356447|Placebo Comparator|Arm 2|
9874557|NCT00356460|Experimental|1 - Part 1|Dose Group
9874558|NCT00356460|Experimental|2 - Part 1|Dose Group
9874559|NCT00356460|Experimental|3 - Part 1|Dose Group
9874560|NCT00356460|Experimental|4 - Part 1|Dose Group
9874561|NCT00356460|Experimental|5 - Part 1|Dose Group
9874562|NCT00356460|Experimental|6 - Part 1|Dose Group
9874563|NCT00356460|Experimental|1 (Part 2)|
9874564|NCT00356460|Experimental|2 (part 2)|
9874565|NCT00356473|Placebo Comparator|Placebo|Placebo
10211561|NCT04565353|Experimental|Flu Shot for You Symbolic Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity to dedicate getting the flu shot to someone by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
10211562|NCT04565353|Experimental|Flu Shot for You Herd Immunity Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity of getting the flu shot to protect a vulnerable loved one by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
9874566|NCT00356473|Experimental|Atorvastatin|Atorvastatin
9874567|NCT00356486|Experimental|A|Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks
9874568|NCT00356486|Experimental|B|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
9874569|NCT00356616|Experimental|A|Trizivir+ Tenofovir 2/day
9874570|NCT00356616|No Intervention|B|antiretroviral treatment optimizated by genotyp
9874571|NCT00356642|Experimental|Single dose 1 cohort|Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
9874572|NCT00356642|Experimental|Repeat dose 1 cohort|Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1
9874573|NCT00356642|Experimental|Repeat dose 2 cohort|Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1
9874574|NCT00356642|Experimental|Repeat dose 3 cohort|Subjects with BSA disease involvement >=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1
9874575|NCT00356707||1|This cohort comprises women from the Black Women's Health Study, a prospective study of African American women, who lived in the Los Angeles, New York, or Chicago metropolitan areas at the time of completion of the 1995, 1997, or 1999 questionnaires.
10211563|NCT04565353|Experimental|Flu Shot for You Control Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also receive a reminder message on the day of the appointment. They will not receive any further information, nor will they be asked to respond with initials of an individual.
10213744|NCT03421964|Experimental|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
9874576|NCT00356733|Experimental|EPO rise|EPO administration
9874577|NCT00356733|Experimental|EPO stable|EPO and stable Hemoglobin
9874578|NCT00356733|No Intervention|control|standard treatment
9874579|NCT00356746||1|elective CABG only patients
9874580|NCT00356746||2|elective ICD replacement surgical patients requiring general anesthesia
9874581|NCT00356824||1|HIV-infected children in Uganda
9874582|NCT00356837|Experimental|A|Those with extremity fractures.
9929481|NCT00917241|Active Comparator|MMI Group|MMI,methimazole
9929482|NCT00917254|Experimental|YM150 group-1|YM150 low dose group
9929483|NCT00917254|Experimental|YM150 group-2|YM150 high dose group
9929484|NCT00917254|Placebo Comparator|Placebo group|
9929485|NCT00917254|Active Comparator|Enoxaparin group|
9929486|NCT00917280||Parkinson's Disease|Parkinson Disease participants without dementia
9929487|NCT00917280||Control|Non-PD participants, matched for age, education and gender.
9929488|NCT00917319|Experimental|Infection control measure|Bundling Infection Control Interventions
9874583|NCT00356928|Experimental|Cyclophosphamide + T cells|Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.
9874584|NCT00356941|Experimental|Chemoradiation Treated Patients|Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
9874585|NCT00357149|Active Comparator|A|Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.
9874586|NCT00357149|Experimental|B|Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).
9874587|NCT00357188|Active Comparator|A|
9874588|NCT00357188|Active Comparator|B|
9874589|NCT00357240|Active Comparator|A1|
9874590|NCT00357240|Active Comparator|A2|
10211564|NCT04565353|Experimental|Prosocial Condition|The day before their scheduled appointment, participants will receive a message describing the pro-social benefits of getting a flu shot, and a reminder to ask for their flu shot. The described pro-social benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting loved ones from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting loved ones from serious complications from the flu). Participants will also receive a reminder message on the day of the appointment.
10211565|NCT04565353|Experimental|Self-Oriented Condition|The day before their scheduled appointment, participants will receive a message describing the self-oriented benefits of getting a flu shot, and a reminder to ask for their flu shot. The described self-oriented benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting oneself from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting oneself from serious complications from the flu).
9874591|NCT00357240|Experimental|A3 I|
9874592|NCT00357240|Experimental|A3 II|
9874593|NCT00357240|Active Comparator|B1|
9874594|NCT00357240|Active Comparator|B2|
9874595|NCT00357240|Experimental|B3 I|
9874596|NCT00357240|Experimental|B3 II|
10211566|NCT04565353|Experimental|Information Vivid Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain vivid information about getting the flu. Participants will also receive a reminder message the day before the appointment.
10211567|NCT04565353|Experimental|Information Basic Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain basic information about getting the flu. Participants will also receive a reminder message the day before the appointment.
9874597|NCT00357305|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral SAHA two or three times daily on days 1-7 and cytarabine IV over 3 hours twice daily and etoposide IV over 1 hour once daily on days 11-14. Treatment repeats approximately every 6-7 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9874598|NCT00357318|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9874599|NCT00357357|Placebo Comparator|Group1|4x 7 day rising dose
9874600|NCT00357357|Placebo Comparator|Group2|4x, 7 day rising dose
9874601|NCT00357357|Placebo Comparator|Group3|28 day fixed lower dose
9874602|NCT00357357|Placebo Comparator|Group4|28 day fixed upper dose
9874603|NCT00357422|Active Comparator|surgery|
10213745|NCT03420950|Other|Sedative first|Rapid sequence intubation: sedative first
10213746|NCT03420950|Other|Paralytic agent first|Rapid sequence intubation: paralytic first
10213747|NCT03420274|Experimental|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
9874604|NCT00357422|Active Comparator|local therapy|
9874605|NCT00357448|Experimental|Arm I|Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9874606|NCT00357474|Active Comparator|chemotherapy|Transarterial chemoembolization (TACE)
9874607|NCT00357474|Active Comparator|ethanol|Percutaneous ethanol injection therapy (PEIT)
9874608|NCT00357591|Active Comparator|Control|
9874609|NCT00357604|Active Comparator|A1|
9874610|NCT00357604|Experimental|A2|
9874611|NCT00357669|Placebo Comparator|Placebo|
9874612|NCT00357669|Experimental|Brivaracetam 50 mg/day|BRV 50 mg/day
9874613|NCT00357669|Experimental|Brivaracetam 150 mg/day|BRV 150 mg/day
9874614|NCT00357682|Experimental|Arm A|20mg Esomeprazole
9874615|NCT00357682|Experimental|Arm B|80mg Esomeprazole
9874616|NCT00357682|Experimental|Arm C|20mg Esomeprazole + 300mg Aspirin
9874617|NCT00357682|Experimental|Arm D|80mg Esomeprazole + 300mg Aspirin
9874618|NCT00357708|Experimental|Treatment (decitabine, vorinostat)|"Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat (SAHA) three times daily on days 6-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine and SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
9874619|NCT00357721|Active Comparator|A1|
9874620|NCT00357721|Active Comparator|A2|
9874621|NCT00357721|Active Comparator|A3|
9874622|NCT00357747|Experimental|AEG35156 plus docetaxel|
9874623|NCT00357786|Experimental|A|Enzyme replacement for Fabry's Disease
9874624|NCT00357799|Active Comparator|VeinViewer Arm|Attempts at IV placement will be made with use of the VeinViewer Machine
9874625|NCT00357799|No Intervention|Conventional Method|IV attempted with conventional method
9874626|NCT00357890|Experimental|Pump therapy (CSII)|Use of pump therapy
9874627|NCT00357890|Active Comparator|Multiple daily injections (MDI)|Use of MDI (basal bolus therapy with glargine)
9874628|NCT00357942|Experimental|C group I|Morphine mouthwash and placebo i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
9874629|NCT00357942|Active Comparator|C group II|Placebo mouthwash and morphine i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
9874630|NCT00357942|Placebo Comparator|C group III|Placebo mouthwash and placebo i.v. (24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
9874631|NCT00357981|Experimental|ORTHO EVRA|"The approximate first two months of women's participation will be spent documenting baseline information about their health and well-being, work patterns and performance, and the economic impact of their menstruation. Subjects will then initiate two, two month intervals of continuous use of ORTHO EVRA.~Over this four month treatment period, subjects will document their health and well-being, work patterns and performance, and the economic impact of their menstruation while being treated with ORTHO EVRA. This will allow us to compare subjects' experiences pre- and post-treatment. The study's instruments will focus on eliciting information on the personal and economic costs of menstruation such as measuring time missed from work, changes in productivity and work satisfaction, and impact on quality of life."
9874632|NCT00358033|Experimental|group intervention|pharmacist-led group intervention in behavioral and pharmacologic therapy
9874633|NCT00358033|Active Comparator|individual|pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction
9874634|NCT00358033|No Intervention|usual care|usual care
9874635|NCT00358072|Experimental|1|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
10211568|NCT04565353|Experimental|Information Control Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain information about exercising. Participants will also receive a reminder message the day before the appointment.
9874636|NCT00358202|Active Comparator|1 cefepime|
9874637|NCT00358202|Active Comparator|2 ceftriaxone|
9874638|NCT00358267|Active Comparator|RFA|Radiofrequency Ablation (RFA) involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
10211569|NCT04565353|Experimental|Sharing Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
10211570|NCT04565353|Experimental|No Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot.
10211571|NCT04565353|Experimental|Healthy Habits Easy Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of easy health behaviors (e.g., whether they walked 500 feet yesterday, at least two serving of fruits and vegetables in the last week, and slept at least 6 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
9874639|NCT00358267|Active Comparator|PRIT|Partial Resection of Inferior Turbinate (PRIT) involves surgically removing a small piece off the turbinate, which also reduces its size.
9874640|NCT00358306||a|those with previous history of Acute kidney injury
9874641|NCT00358319|Experimental|Phase I|Dose escalation phase
9874642|NCT00358319|Experimental|Phase II|All patients enrolled in the Phase II will be treated with Valproic Acid (VPA) and Karenitecin using the dosing schedule determined to be the Maximum Tolerated Dose (MTD) in Phase I.
9874643|NCT00358345||1|Intermediate AMD
9874644|NCT00358345||2|Newly diagnosed CNV
9874645|NCT00358371|Experimental|Subjects receiving flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
9874646|NCT00358371|Experimental|Subjects receiving flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
9874647|NCT00358384|Experimental|Subjects receiving treatment A|Eligible subjects will receive 0.1 percent pazopanib ointment.
9874648|NCT00358384|Experimental|Subjects receiving treatment B|Eligible subjects will receive 0.5 percent pazopanib ointment.
9874649|NCT00358384|Experimental|Subjects receiving treatment C|Eligible subjects will receive 1 percent pazopanib ointment.
9874650|NCT00358384|Placebo Comparator|Subjects receiving treatment D|Eligible subjects will receive pazopanib vehicle as negative control.
9874651|NCT00358384|Placebo Comparator|Subjects receiving treatment E|Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
9874652|NCT00358384|Placebo Comparator|Subjects receiving treatment F|Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
9874653|NCT00358397|Experimental|Treatment arm|
10211572|NCT04565353|Experimental|Healthy Habits Difficult Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of difficult health behaviors (e.g., whether they walked 3 miles yesterday, ate 4-6 servings of fruits and vegetables yesterday, and slept at least 9 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
10211573|NCT04565353|Experimental|Healthy Habits Control Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot.
10213748|NCT03420274|Placebo Comparator|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
9987461|NCT01412749||eHNS Participant Registry|Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.
9987462|NCT01412775|Experimental|Psychological stress and exhaustion|Twenty four male and female nurses from the cardiac intensive-care unit (CCU) of Meir Hospital, who consent to take part in the offered intervention program, will participate in the study. The participants will be randomly assigned to an experiment group of 12 participants and a control group of 12 participants.
9987463|NCT01412788|Experimental|peri-areolar incision|Peri-areolar incision was used to carry out lumpectomy
9987464|NCT01412788|Active Comparator|traditional incision|traditional incision above tumor was used to carry out lumpectomy
9987465|NCT01412814|Experimental|Experimental|These patients will carry out the specified intervention of the study with the AposTherapy Biomechanical System in addition to the typical physical therapy regiment prescribed to them by their physician.
9987466|NCT01412814|Active Comparator|Control|The patients within this group will also carry out the typical physical therapy program for total knee replacement as prescribed by their physician. The patients will carry out a similar therapy program to the experimental group, but without the study intervention device (placebo walking shoe).
9987467|NCT01412827|Other|Comparison of radioisotope dosing|
9987468|NCT01412840|Experimental|Standard care and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
9987469|NCT01412840|Placebo Comparator|Standard care and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
9987470|NCT01412840|No Intervention|Standard care|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac.
9987471|NCT01412853|Experimental|MR-spectroscopy|
9987472|NCT01412892|Experimental|Everolimus|RAD001: Everolimus
10211574|NCT04565353|Experimental|Just-In-Time Reminders 24-Hour Condition|Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 24 hours before their appointment.
10211575|NCT04565353|Experimental|Just-In-Time Reminders 15-Minute Condition|Just-In-Time Reminders 15-Minute Condition: Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 15 minutes before their appointment.
10211576|NCT04565275|Experimental|ICP-192|"Dose Escalation Phase ICP-192~Dose Expansion Phase ICP-192"
10211577|NCT04563325|Active Comparator|Experimental|"< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~=/> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
9874654|NCT00358410|Experimental|GW679769|120mg once a day
9874655|NCT00358410|Placebo Comparator|Placebo|Placebo once a day
9874656|NCT00358423|Experimental|A|
9874657|NCT00358423|Placebo Comparator|B|
9874658|NCT00358488|Experimental|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
10211578|NCT04563325|Active Comparator|Standard|"IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:~< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings."
10213749|NCT03396211|Experimental|Apatinib (also known as rivoceranib) with Nivolumab|Oral daily doses of apatinib (as its mesylate salt) with a fixed dose of nivolumab given intravenously every 2 weeks
10213750|NCT03392441|Experimental|Insulin Deprivation|Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.
10213751|NCT03391778|Experimental|Participants receiving GSK adoptive cell therapy|
10213752|NCT03389243|Experimental|metamizol|analgesic drug
10213753|NCT03389243|Experimental|paracetamol|analgesic drug
10213754|NCT03389243|Experimental|metamizole & paracetamol|analgesic drugs
10213755|NCT03373773|Active Comparator|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter at home."
9874659|NCT00358488|Experimental|salbutamol|salbutamol
9874660|NCT00358488|Experimental|salmeterol 50mcg|salmeterol 50mcg
9874661|NCT00358488|Placebo Comparator|placebo|placebo
9874662|NCT00358540|Experimental|Group B|Group B is a dose escalation phase designed to determine the optimal biological dose of eltrombopag in subjects with sarcoma who received chemotherapy treatment with Adriamycin and Ifosfamide
9874663|NCT00358540|Experimental|Group A|Group A will be used for further exploration of the optimal biological dose (as initially established by completion of Group B), by using 2 different dosing schedules of eltrombopag.
9874664|NCT00358566|Active Comparator|Gemcitabine|Gemcitabine alone treatment.
9874665|NCT00358566|Experimental|GV1001|GV1001 in sequential combination with Gemcitabine
9987473|NCT01412931||1) Pregnant women with a single intrauterine pregnancy|50 women with uncomplicated pregnancies and no history of preterm birth.
9987474|NCT01412931||2) Pregnant women with a single intrauterine pregnancy|50 multiparous women with history of spontaneous preterm labor or preterm premature rupture of membranes (PPROM).
9987475|NCT01412931||3) Pregnant women with a single intrauterine pregnancy|20 women evaluated on the labor and delivery unit because they are deemed to be at high risk for preterm birth.
9987476|NCT01412970|Other|study group|comparison of ability to predict volume responsiveness and precision of measurement of stroke volume variation assessed by electrical impedance tomography in comparison to clinically established invasive hemodynamic monitoring devices, i.e. arterial pulse contour analysis during volume loading procedures
9987477|NCT01412996|Active Comparator|single ACCESS cholecystectomy|single ACCESS laparoscopic cholecystectomy
9987478|NCT01412996|Active Comparator|traditional|conventional laparoscopic cholecystectomy
9987479|NCT01413009||ICU patients|
9987480|NCT01413022|Active Comparator|Group A (FOLFIRINOX chemotherapy)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~Treatment is repeated every 14 days for 6 cycles."
9987481|NCT01413022|Experimental|Group B (FOLFIRINOX and PF-04136309)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~PF-04136309 500 mg PO BID on days 1-14~Treatment is repeated every 14 days for 6 cycles."
9987482|NCT01413035|Experimental|MSC and the oral hypoglycemic drugs|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
9987483|NCT01413035|Experimental|MSC and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
9987484|NCT01413035|Experimental|MSC and the combination of drugs and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
9987485|NCT01413048|Experimental|AGSCT101|
9987486|NCT01413048|Active Comparator|Carvedilol|
9987487|NCT01413061|Active Comparator|AlloStem Live Cellular Allograft|AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.
9987488|NCT01413061|Active Comparator|Control: Autologous Bone Marrow Aspirate|Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.
9987489|NCT01413074|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only oberseve therapy treatment
9987490|NCT01413074|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only oberseve therapy treatment
9987491|NCT01413113|Experimental|Treatment (enzyme inhibitor and radioactive drug therapy)|Patients receive iodine I 131 IM QD 5 days a week in weeks 5-6. Patients also receive pazopanib hydrochloride PO QD beginning in week 1 and continuing for 8 weeks post-radioactive iodine therapy.
9987492|NCT01413126|Experimental|Peanut butter|42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
9987493|NCT01413126|Experimental|Whole peanut|42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
9987494|NCT01413126|No Intervention|No peanuts (control)|
9987495|NCT01413139|Other|4F portfolio products from Biotronik|The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.
9987496|NCT01413152|Experimental|0|
9987497|NCT01413217||Egg Breakfast|This group will be given a breakfast consisting of eggs. A breakfast consisting of eggs induces greater satiety and reduces Lunch Time intake.
9987498|NCT01413217||Cereal Breakfast|This breakfast will consist of a breakfast that will include cereal. A breakfast cereal or white bread increases lunchtime energy intake.
9987499|NCT01413243|Experimental|Drug: Trichuris suis ova|Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months
9987500|NCT01413243|Placebo Comparator|Placebo|Drug: Placebo, fluid every 2 weeks
9997072|NCT01505842|Experimental|Colonoscopy with chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
9997073|NCT01505842|Active Comparator|Conventional colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
9997074|NCT01505855|Experimental|anti-TNF only|Crohn's disease, on an anti-TNF agent [infliximab or adalimumab] only
9997075|NCT01505855|Experimental|Combined immunosuppression|Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator [azathioprine or 6-MP])
9997076|NCT01505855|Experimental|Immunomodulator only|Crohn's disease, on an immunomodulator only
9997077|NCT01505855|Experimental|Non-immunosuppression|Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)
9997078|NCT01505894|Experimental|BI 409306 low dose|Film-coated tablet
9997079|NCT01505894|Experimental|BI 409306 medium dose|Film-coated tablet
9997080|NCT01505894|Experimental|BI 409306 high dose|Film-coated tablet
9997081|NCT01505894|Experimental|BI 409306 high dose II|Film-coated tablet
9997082|NCT01505894|Placebo Comparator|Placebo|Film-coated tablet
9997083|NCT01505907|Experimental|CXB909 15mg|CXB909 15mg
9997084|NCT01505907|Experimental|CXB909 30mg|
9997085|NCT01505907|Experimental|CXB909 60mg|
9997086|NCT01505907|Experimental|CXB909 120mg|Dose
9997087|NCT01505907|Experimental|CXB909 250mg|
9998311|NCT01516983|Experimental|Icotinib+WBRT|"Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to 3+3 until disease progression or intolerable toxicity."
9987501|NCT01413269|Experimental|hypofractionation radiotherapy|irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
9987502|NCT01413269|Active Comparator|conventional fractionation radiotherapy|irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
9987503|NCT01413282|Active Comparator|Cardiac CT|Triage based on cardiac CT results.
9987504|NCT01413282|No Intervention|Standard Care|Standard diagnostic management according to the European guidelines.
9987505|NCT01413295|Experimental|Dendritic Cells Vaccine|Dendritic Cells Vaccine after 2 lines of chemotherapy
9987506|NCT01413295|Other|Supportive treatment|Supportive treatment after 2 lines of chemotherapy
9987507|NCT01413321||SHABI|Subacute hemiparetic ABI subjects group
9987508|NCT01413321||CHABI|Chronic hemiparetic ABI subjects group
9987509|NCT01413347|Active Comparator|pillow|confirmation of double-lumen tube position with a head on a pillow
9987510|NCT01413347|Experimental|neutral|confirmation of double-lumen tube position in neutral position of a head
9987511|NCT01413386|Experimental|Paclitaxel Eluting Covered Metal Stent|
9987512|NCT01413386|Active Comparator|Covered Metal Stent|
9987513|NCT01413412|Experimental|Hernia repair using full-thickness skin graft|25 patients
9987514|NCT01413412|Experimental|Hernia repair using Mesh|25 patients
9987515|NCT01413477|Active Comparator|Calcipotriol ointment|
9987516|NCT01413477|Active Comparator|Betamethasone dipropionate ointment|
9987517|NCT01413477|Active Comparator|Calcipotriol and betamethasone ointment|
9987518|NCT01413477|Placebo Comparator|Vaseline Petroleum Jelly|
9987519|NCT01413555|Experimental|Blood Culture QI Program|
9987520|NCT01413568|Experimental|Donor (Phase I and Phase II)|"On Day 1 (and possibly Day 2) POL6326 IV Infusion with increasing dose levels in Phase I or with random dose assignment (from the 2 selected from Phase I) in phase II~Leukapheresis collection on Day 1 (and possibly Day 2)"
9987521|NCT01413568|Experimental|Recipient|Day 0 - PBSC transplant with stem cells mobilized with IV POL6326
9987522|NCT01413581|Experimental|rhBSSL|rhBSSL (recombinant human bile-salt-stimulated lipase)
9987523|NCT01413581|Placebo Comparator|Placebo|Placebo
9517648|NCT03304392|Experimental|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
9987524|NCT01413594|Experimental|HABIT|Hand-Arm Bimanual Intensive Therapy (HABIT)
9987525|NCT01413594|No Intervention|Ongoing usual and customary rehabilitation care|Subjects are tested over 6 months while receiving their ongoing usual and customary care schedule of physical and occupational therapy or following constraint-induced movement therapy received as usual and customary care independent of the study, and then are crossed-over to receive HABIT.
9987526|NCT01413607|Experimental|Quill knotless tissue-closure device|During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
9987527|NCT01413607|Active Comparator|2-0 absorbable vicryl suture|Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.
9987528|NCT01413620|Experimental|Vitamin E Treated|
9987529|NCT01413620|No Intervention|Untreated|
9987530|NCT01413633|Experimental|cholecystectomy|single incision laparoscopic cholecystectomy
9987531|NCT01413646|Experimental|Walnut Supplementation|Eight weeks with walnut supplementation to an ad lib diet
9987532|NCT01413646|Placebo Comparator|2|Eight weeks ad lib diet without walnut supplementation
9987533|NCT01413659|Experimental|Symbiotic|Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host
9987534|NCT01413672||person with ostomy|Community dwelling subject with either colostomy or ileostomy and at least 3 months post-surgery.
9987535|NCT01413685|No Intervention|Tacrolimus|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
9987536|NCT01413698||Patient with chronic cough|
9987537|NCT01413711|Experimental|Vigabatrin|
9987538|NCT01413724||Surgical patients|PAtients who had surgery the previous day and are still hospitalized
9987539|NCT01413763|Active Comparator|Imiquimod cream|
9987540|NCT01413763|Placebo Comparator|Placebo cream|
9987541|NCT01413776|Experimental|Dietary supplement|Pregnant women in 37 villages.
9987542|NCT01413776|No Intervention|Control group|Pregnant women in 38 villages
9987543|NCT01413789|Experimental|Patients and healthy volunteers|Patients with healed full thickness burns and healthy volunteers will be included in the study
9987544|NCT01413802|Experimental|Thyroid surgery.|Patients who undergo thyroid surgery during which intra operative continuous nerve monitoring will be used.
9987545|NCT01413815|Active Comparator|L-arginine|L-Arginine
9796803|NCT01577706|Active Comparator|Dextroamphetamine (D)|Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
10211579|NCT04563078|Experimental|Transcranial Magnetic Stimulation (TMS)|TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
10211580|NCT04563078|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS)|Sessions of Sham Transcranial Magnetic Stimulation (TMS) will be conducted.
10211581|NCT04561011|Experimental|Persons with Mild Traumatic Brain Injury (mTBI)|
9796804|NCT01577706|Placebo Comparator|Placebo (P)|Placebo gel-capsule, single-dose, 1-day
9796805|NCT01577732|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
9796806|NCT01577745|Experimental|MEDI0639 Cohort 1|Participants received MEDI0639 dose level 1 as a 60-minute intravenous (IV) infusion on Day 1 of each 21-day cycle.
9796807|NCT01577745|Experimental|MEDI0639 Cohort 2|Participants received MEDI0639 dose level 2 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
9796808|NCT01577745|Experimental|MEDI0639 Cohort 3|Participants received MEDI0639 dose level 3 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
9796809|NCT01577745|Experimental|MEDI0639 Cohort 4|Participants received MEDI0639 dose level 4 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
9796810|NCT01577745|Experimental|MEDI0639 Cohort 5|Participants received MEDI0639 dose level 5 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
9796811|NCT01577745|Experimental|MEDI0639 Cohort 6|Participants received MEDI0639 dose level 6 as a 60-minute IV infusion on Day 1 of each 21 day cycle.
9796812|NCT01577758|Experimental|MLN0264|MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.
9796813|NCT01577966|Experimental|Sulfasalazine|
9796814|NCT01578031|Active Comparator|Obese Patients with Obstructive Sleep Apnea|Obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
9796815|NCT01578031|Active Comparator|Non-obese Patients with Obstructive Sleep Apnea|Non-obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
9796816|NCT01578031|Other|Obese subjects without OSA|Control.
9796817|NCT01578031|Other|Non-obese subjects without OSA|Control.
9796818|NCT01578044|Experimental|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription.~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
9796819|NCT01578044|Placebo Comparator|Control|Usual care
9796820|NCT01578187|Experimental|Hair2Go device|
9796821|NCT01578278|Experimental|Bepotastine besilate formulation|Nasal Spray
9796822|NCT01578278|Experimental|Fluticasone propionate|Nasal Spray
9796823|NCT01578278|Experimental|Bepotastine besilate-fluticasone propionate|Nasal Spray
9796824|NCT01578278|Placebo Comparator|Placebo Comparator|Nasal Spray
9796825|NCT01578317|Experimental|AS03 adjuvanted|Adminsitered day 1, booster at Day 21
9796826|NCT01578317|Experimental|unadjuvanted|Administer day 1 and booster at Day 21
9796827|NCT01578330|Experimental|Fingolimod, FTY720|Patients received fingolimod 0.5 mg oral capsules daily with or without food.
9796828|NCT01578486|Experimental|salsalate|open-label trial of salsalate 3g/day
9796829|NCT01578499|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
9796830|NCT01578499|Active Comparator|Methotrexate or Bexarotene|Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
9796831|NCT01578551|Experimental|Arm A|Paclitaxel, Carboplatin, Bevacizumab, and Metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning chemotherapy, if possible, but chemotherapy will not be delayed for metformin loading.
9796832|NCT01578551|Active Comparator|Arm B|Paclitaxel, Carboplatin, and Bevacizumab
9796833|NCT01578577|No Intervention|Standard Care|This arm will serve as a control group and will not receive any intervention.
9796834|NCT01578577|Experimental|EHMI|Electronic Health Record-based Health Literacy Medication Therapy Management Intervention (EHMI)arm consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
9796835|NCT01578577|Experimental|Nurse Educator + EHMI|
9796836|NCT01578707|Active Comparator|Ofatumumab (Arm A)|An anti-CD20 monoclonal antibody
9796837|NCT01578707|Experimental|ibrutinib (Arm B)|A Bruton Tyrosine Kinase Inhibitor
9796838|NCT01578772|Experimental|Telmisartan|Open label
9796839|NCT01578850|Experimental|Group A|
9874666|NCT00358787|Active Comparator|1|Crossed K wire orientation for surgical management of a type III Supracondylar fracture.
9874667|NCT00358787|Active Comparator|2|Lateral K wire orientation for surgical management of a type III Supracondylar fracture.
9874668|NCT00358813|Experimental|Subjects receiving casopitant|Eligible subjects will receive a 100 milligrams oral dose of casopitant once daily for five consecutive days.
9874669|NCT00358852||Patients with Schizophrenia|
9874670|NCT00358995|Active Comparator|1|Cognitive Behavior Therapy (CBT) may include keeping a diary of significant events and associated feelings, thoughts and behaviors; questioning and testing cognitions, assumptions, evaluations and beliefs that might be unhelpful and unrealistic; gradually facing activities which may have been avoided; and trying out new ways of behaving and reacting and using relaxation and distraction techniques.
9874671|NCT00358995|Active Comparator|2|Stress Management Therapy (SMT) includes relaxation, interaction, biofeedback, exercises, such as muscle stretching exercises, yoga, meditation, time management techniques, and many more.
9874672|NCT00359008||1|Intermediate AMD
9874673|NCT00359008||2|New untreated CNV subject
9874674|NCT00359047|Experimental|Documentation|Written educational material on osteoporosis for the participant and the physician.
9874675|NCT00359047|Experimental|Video|A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
9874676|NCT00359125|Active Comparator|1|RU-486, 600 mg/day for 1 week.
9874677|NCT00359125|Placebo Comparator|2|Placebo, 600 mg/day for 1 week
9874678|NCT00359151|Experimental|Celecoxib|Celecoxib
9874679|NCT00359151|Placebo Comparator|Placebo|Placebo
9874680|NCT00359164|Active Comparator|1|Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.
9874681|NCT00359164|Active Comparator|2|Bevacizumab with verteporfin at Very Low Photodynamic Therapy.
9874682|NCT00359164|Sham Comparator|3|Bevacizumab with verteporfin with Sham Photodynamic Therapy.
9874683|NCT00359177|Experimental|Healthy subjects receiving GW679769|Healthy Subjects will receive single 100 milligram (mg) oral doses of GW679769 for five consecutive days.
9874684|NCT00359177|Experimental|Subjects with hepatic impairment receiving GW679769|Subjects with hepatic impairment will receive single 100 mg oral doses of GW679769 for five consecutive days.
9874685|NCT00359190|Experimental|Lapatinib receivers|Subjects with treatment-naïve breast tumors will be administered lapatinib 1500 mg once daily, 1000 mg once daily, or 500 mg twice daily for a minimum of 9 days and maximum of 15 days prior to surgical resection..
9874686|NCT00359229|Experimental|1|For 3 weeks
9874687|NCT00359242|Experimental|1|Soothing and Calming instructions given at 2 weeks of life
9874688|NCT00359242|Experimental|2|Repeated food exposure instructions given between 4 and 6 months of life
9874689|NCT00359242|Experimental|3|Receive both interventions: Soothing and Calming and Repeated food exposure
9874690|NCT00359242|No Intervention|4|Group receiving neither of the interventions.
9874691|NCT00359255|Active Comparator|1|
9874692|NCT00359255|Experimental|2|
9874693|NCT00359268||1|Any patient with a condition or disease whose etiology is unknown.
9874694|NCT00359320|Experimental|Mucosa-to-jejunal mucosa technique of pancreaticojejunosto|Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
9874695|NCT00359333|Experimental|Single Group|
9874696|NCT00359359|Experimental|Sagopilone and cisplatin|The study drug sagopilone was administered in combination with a fixed dose of cisplatin
9874697|NCT00359385|Active Comparator|Alendronate 70mg weekly|Alendronate 70mg weekly
9874698|NCT00359385|Placebo Comparator|placebo of alendronate 70mg weekly|placebo of Alendronate 70mg weekly
9874699|NCT00359398|Experimental|Platelet sequestration|Sequestration of platelet rich plasma before cardiopulmonary bypass
9874700|NCT00359398|No Intervention|Standard care|No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
9874701|NCT00359463|Active Comparator|Healthy subjects|Subjects will receive a single 50 mg oral dose of eltrombopag.
9874702|NCT00359463|Experimental|Subjects with hepatic impairment|Subjects with mild, moderate or severe hepatic impairment will receive a single 50 mg oral dose of eltrombopag.
9874703|NCT00359567|Experimental|1|palonosetron
9874704|NCT00359567|Active Comparator|2|granisetron hydrochloride
9874705|NCT00359606|Experimental|Treatment (5-fluoro-2-deoxycytidine, tetrahydrouridine)|Patients receive tetrahydrouridine PO on day 1; 5-fluoro-2-deoxycytidine PO on days 1 and 8; tetrahydrouridine IV over 3 hours on days 2-5, 8, and 9-12; and 5-fluoro-2-deoxycytidine IV over 3 hours on days 2-5 and 9-12 of course 1. For all subsequent courses, patients receive tetrahydrouridine IV over 3 hours and 5-fluoro-2-deoxycytidine IV over 3 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9874706|NCT00359645|No Intervention|Control|Annual auto questionnaire
9874707|NCT00359645|Experimental|Screening|Annual screening of Head and Neck cancer
9874708|NCT00359658|Experimental|1|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml
9874709|NCT00359671|Experimental|1|Arm 1: study drug
9874710|NCT00359671|Other|2|Arm 2: study drug + comparator
9874711|NCT00359723|Experimental|Methylphenidate 0.4 mg/kg TID followed by placebo TID|As above
9874712|NCT00359723|Experimental|Placebo TID followed by methylphenidate 0.4 mg/kg TID|As above
9929489|NCT00917332|Experimental|intervention|"55 third trimester women will receive a CD of relaxation and guided imagery (of safe place), to practice daily at home until childbirth"
9874713|NCT00359814|Experimental|1|Azathioprine administration: was stopped at day 0; Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily; Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
9874714|NCT00359866|Experimental|Pelvic IMRT with Tomotherapy|"Helical tomotherapy will be used to plan and deliver the radiation treatment.~Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.~External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.~Receive treatment once a day for five days a week for approximately 6 weeks.~Treating physician will make determination if patient is to receive intracavitary brachytherapy.~Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated)."
9874715|NCT00359879|Experimental|1 - exenatide before breakfast and dinner|
9874716|NCT00359879|Active Comparator|2 - exenatide before lunch and dinner|
9874717|NCT00359892|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 60mg
9874718|NCT00359905|Experimental|Silodosin|
9874719|NCT00359905|Active Comparator|Tamsulosin|
9874720|NCT00359905|Placebo Comparator|Placebo|
10211582|NCT04560166|Experimental|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"A treatment cycle is 21 days. The patients will receive irinotecan 50 mg/m2/day IV and temozolomide 100 mg/m2/day orally (both on Days 1-5) in combination with naxitamab 2.25 mg/kg/day IV (Days 2, 4, 8 and 10) (total 9 mg/kg per cycle), and GM-CSF 250 ug/m2/day sc, (Days 6-10).~Patients will receive up to 18 IT cycles after enrollment. Naxitamab and GM-CSF will be given for at least 8 cycles."
10211583|NCT04559646||"Group A Haemoblock"|"100 patients. Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
9874721|NCT00359918|Experimental|Prehospital facilitated PCI|
9874722|NCT00359918|Active Comparator|Primary PCI|
9874723|NCT00359957|Experimental|1|ADDED condition - behavioral intervention for modifying diet and physical activity, with greater emphasis on physical activity than the STANDARD condition
9874724|NCT00359957|Active Comparator|2|STANDARD condition - behavioral intervention for modifying diet, with little emphasis on physical activity
10211584|NCT04559646||"Group B Control"|100 patients. Saline solution will be used after pocket formation during pacemaker implantation.
10211585|NCT04551846|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
10211586|NCT04551846|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
10211587|NCT04546126|Experimental|Dexamethasone (Group 2)|"Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take~1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am."
10211588|NCT04546126|Experimental|Cosyntropin (Group 3)|Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
10211589|NCT04546126|Experimental|Adrenal pathology (Group 4)|Whole-body PET/CT scans will be done on 4 patients at 1 hr and the other 4 patients at 6 hours. All the patients will have a whole-body PET/CT scan at 3 hours.
10211590|NCT04543539||IN.PACT™ AV Access PAS Primary Cohort|The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.
10211591|NCT04543539||IN.PACT™ AV Access PAS Extended Cohort|The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.
9796840|NCT01578850|Placebo Comparator|Group B|
9796841|NCT01578902|Experimental|Hypofractionated radiotherapy using SABR|Stereotactic radiation: 35Gy in 5 fractions over 29 days
9796842|NCT01578980|Experimental|Outpatient Control-to-Range|Outpatient Control-to-Range: Testing system connectivity
9796843|NCT01579006||Cohort|
9796844|NCT01579045|Experimental|Sequence 1|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3"
9796845|NCT01579045|Experimental|Sequence 2|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A"
9796846|NCT01579045|Experimental|Sequence 3|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3"
9796847|NCT01579045|Experimental|Sequence 4|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A"
9874725|NCT00359970|Active Comparator|Azithromycin 500 mg plus Placebo|a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
9874726|NCT00359970|Active Comparator|Azithromycin 1000 mg plus Placebo|a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
9874727|NCT00359970|Experimental|Azithromycin 500 mg plus Loperamide|a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
9874728|NCT00359996|Active Comparator|Health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
9874729|NCT00359996|Active Comparator|Control|No additional educational sessions added to usual care of patients.
9935376|NCT03829501|Experimental|KY1044 monotherapy phase 2|KY1044 monotherapy
9874730|NCT00360022|Experimental|Joint Visits|Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
9874731|NCT00360022|No Intervention|Control|Transition patients in the control group will transfer care to adult GI provider in typical manner.
9874732|NCT00360152|Active Comparator|Positive Axillary Ultrasound|Positive Axillary Ultrasound -> Fine Needle Aspiration Biopsy -> Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -> Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -> Pathology
9874733|NCT00360152|Active Comparator|Negative Axillary Ultrasound|Negative Axillary Ultrasound -> Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -> Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology
9874734|NCT00360256||Control|
9874735|NCT00360256||Case group|
9874736|NCT00360438|Experimental|Rasburicase|
9874737|NCT00360451|Experimental|1|Adolescent only Penn Resiliency Program
9874738|NCT00360451|Experimental|2|Adolescent plus parent Penn Resiliency Program
9874739|NCT00360451|No Intervention|3|Control
9874740|NCT00360477|Active Comparator|1|Floseal
9874741|NCT00360477|Active Comparator|2|Cope-Loop/Nephrostomy Tube
9874742|NCT00360477|Active Comparator|3|Fascial Stitch
9874743|NCT00360594|Experimental|1|Acamprosate
9874744|NCT00360594|Placebo Comparator|2|Placebo
9874745|NCT00360737|Active Comparator|NP-018|Subjects received one or two vials of NP-018 administered intravenously.
9929490|NCT00917332|No Intervention|control|55 third trimester women who does not receive the relaxation and guided imagery CD.
9929491|NCT00917345||aldosteronism, hypertension|
9929492|NCT00917345||hypertension|
9929493|NCT00917358|Experimental|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
9929494|NCT00917358|No Intervention|Observation|Retrospectively chart review of dialysis patients with acute hepatitis C who did not receive any intervention
9929495|NCT00917371||atomoxetine group|
9929496|NCT00917371||methylphenidate group|
9929497|NCT00917371||psychological counseling group|
9929498|NCT00917397|Experimental|psychotherapy|Trauma-focused cognitive behavioral therapy
9929499|NCT00917397|Experimental|Drug|drug treatment and psychoeducation
9929500|NCT00917397|No Intervention|Waiting list|subjects randomized to waiting list
9929501|NCT00917397|Experimental|Combination|Both drug and psychotherapy
9929502|NCT00917410|Experimental|SMS intervention|
9929503|NCT00917423||Inpatients with anorexia nervosa|Hospital inpatients with anorexia nervosa
9929504|NCT00917423||Normal weight controls|Healthy, normal-weight volunteers
9929505|NCT00917449|Active Comparator|L-arginine|L-arginine (3.2 gr bid) plus lifestyle counselling vs placebo plus lifestyle counselling
9929506|NCT00917449|Placebo Comparator|placebo|placebo plus lifestyle counselling for 18 months
9929507|NCT00917475||Preterm infants|birth weight<1500 grams and gestational age<30 weeks
9929508|NCT00917488|Experimental|A|Four concentrations of Glycyphagus domesticus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, was tested in every patient in duplicate on the volar surface of the forearm.
9929509|NCT00917527|Placebo Comparator|Control|
9929510|NCT00917527|Experimental|Atorvastatin|
9929511|NCT00917566|Active Comparator|Airtraq group|Use Airtraq for intubation
9929512|NCT00917566|Active Comparator|Macintoch gorup|Use Macintoch laryngoscope for intubation
9929513|NCT00917592|Experimental|Short intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days
9929514|NCT00917592|Active Comparator|Long intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days
9929515|NCT00917618|Active Comparator|Exercise intervention|Patients began the exercise intervention after randomization for 12 weeks
9874746|NCT00360776|Experimental|Arm I|"Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.~Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years."
9874747|NCT00360802|Active Comparator|CBT|Cognitive Behavioral Treatment
9874748|NCT00360802|Active Comparator|MBSR|Mindfulness Based Stress Reduction
9874749|NCT00360841|Experimental|A|The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
9874750|NCT00360841|Sham Comparator|B|The subjects in arms A and B will receive auricular acupuncture. The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
9874751|NCT00360841|No Intervention|C|No treatment received.
9874752|NCT00360919|Experimental|A|Cheese
9874753|NCT00360919|Placebo Comparator|B|Fruits and vegetables
9874754|NCT00360958|Experimental|Ultrafiltration|Ultrafiltration treatment
9874755|NCT00360958|Active Comparator|Usual treatment|Usual HF treatment
9874756|NCT00360997|Other|Behavioural|Conventional UK physical therapy (Con UK PT)
9874757|NCT00360997|Experimental|Con UK PT + MTS|Con UK PT + 30/60 or 120 minutes MTS
9874758|NCT00361036|Experimental|1|BeadBlock treatment arm
9874759|NCT00361036|Active Comparator|2|Embospheres control arm
9874760|NCT00361088|Experimental|Phase I|
9874761|NCT00361088|Experimental|Phase II|
9874762|NCT00361114|Active Comparator|A|SP in symptomatic children aged 6-59 months
9874763|NCT00361114|Experimental|B|SP to asymptomatic infected children aged 2-10 months
9874764|NCT00361114|Experimental|C|Chlorproguanil/dapsone in symptomatic 6-59 month old children
9874765|NCT00361127|Experimental|CMPD patients|Patients with CMPD with evaluation of ACE I/D polymorphism
9874766|NCT00361153|Active Comparator|1|Colesevelam hydrochloride
9874767|NCT00361153|Placebo Comparator|2|placebo
9874768|NCT00361309|Experimental|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
9874769|NCT00361348|Active Comparator|Palifermin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period
9874770|NCT00361348|Experimental|Palifermin + Heparin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
9874771|NCT00361348|Active Comparator|Heparin|unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
9874772|NCT00361413|Experimental|1|Alefacept
9874773|NCT00361413|Placebo Comparator|2|
9874774|NCT00361465||Parkinsonian patients presenting of the dystonia|15 Parkinsonian patients presenting of the dystonia of ONE or OFF at the time of the phases of driving fluctuations. These patients must present a dystonia of the upper limb, mainly localised than the level of the segment brachial or in distality.
9874775|NCT00361465||patients carrying a primary education dystonia affecting|15 patients carrying a primary education dystonia affecting at least one of the two upper limbs, without excessive involuntary movements
9874776|NCT00361465||patients carrying a secondary dystonia|15 patients carrying a secondary dystonia (consecutive with a perinatal suffering) affecting at least one of the two upper limbs, without excessive involuntary movements
9874777|NCT00361465||pilot subjects|30 healthy pilot subjects paired in sex, age (± 5 years), dominant laterality and level of schooling (15 subjects paired with the Parkinsonian patients and 15 subjects paired with the patients dystonic
9874778|NCT00361478|Experimental|1|"Mother and Baby Program comprising exercise and education."
9874779|NCT00361478|Active Comparator|2|Education only
9874780|NCT00361517|Experimental|GM test|Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
9874781|NCT00361517|No Intervention|no GM monitoring|in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.
9874782|NCT00361530|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
9874783|NCT00361530|No Intervention|No intervention|Patient has no intervention.
9874784|NCT00361543|Active Comparator|1|Raloxifene Hydrochloride
9874785|NCT00361543|Placebo Comparator|2|placebo tablet
9874786|NCT00361556|Active Comparator|1|The Back Book
9874787|NCT00361556|Active Comparator|2|The Back Guide
9874788|NCT00361556|Active Comparator|3|General health book
9874789|NCT00361660|Experimental|1|Therapy is provided every other day 3 days per week (Monday, Wednesday, Friday).
9874790|NCT00361660|Active Comparator|2|The same therapy is provided daily Monday through Friday
9874791|NCT00361699|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
9874792|NCT00361699|No Intervention|No intervention|Patient has no intervention.
9874793|NCT00361777||Possible Cushing's|Patients with possible cushion's syndrome
9874794|NCT00361790|Other|1|
9874795|NCT00361803|Experimental|All treated subjects|All subjects received Topotecan, administered intravenously over 30 minutes at 4 milligrams per meter^2 weekly for 3 weeks every 28 days.
9874796|NCT00361868|Experimental|1|
9874797|NCT00361868|Active Comparator|2|
9874798|NCT00361881|Experimental|1|ME-609
9874799|NCT00361881|Active Comparator|2|Acyclovir in ME-609 vehicle
9874800|NCT00361881|Placebo Comparator|3|Vehicle
9874801|NCT00361894|Experimental|Arm 1|
9874802|NCT00361894|Active Comparator|Arm 2|
9874803|NCT00361907|Active Comparator|2|Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
9874804|NCT00361907|Placebo Comparator|1|Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy
9874805|NCT00361933|Experimental|1|
9874806|NCT00361946||lean subjects|BMI <85th for age, normal glucose tolerance
10211592|NCT04542343|Experimental|Risk Reduction of COVID-19 Among African American Parishioners|"This arm will implement one group pretest-posttest design to improve COVID associated health outcomes of AA older parishioners in collaboration with trained young church-based health educators."
9874807|NCT00361946||obese subjects|BMI> 95th for age normal glucose tolerance
9874808|NCT00361946||Type diabetes|BMI > 85th for age , history of Type 2 diabetes as per ADA criteria
9874809|NCT00361985|Experimental|1|Nexium group
9874810|NCT00362063|Experimental|growth hormone|children with proven growth hormone deficiency
9874811|NCT00362063|No Intervention|healthy controls|No growth hormone is given
9874812|NCT00362089|Active Comparator|Marinol|Intervention group with Marinol D40 fish oil capsules
9874813|NCT00362089|No Intervention|Nutrition counseling|Control group
9874814|NCT00362206|Experimental|1|
9874815|NCT00362206|Experimental|2|
9874816|NCT00362206|Active Comparator|3|
10211593|NCT04538352|Experimental|Once-weekly sc semaglutide combined with once-daily insulin|Patients randomized to continue with MDI will be transitioned from their existing regimen to the rapid-acting insulin product insulin aspart and their basal insulin switched to once-daily insulin degludec.
10211594|NCT04538352|Experimental|MDI requiring multiple daily injections of insulin|Patients randomized to MDI will be allowed to continue correction rapid-acting insulin, in addition to their prandial doses of rapid-acting insulin, throughout the duration of the study.
10211595|NCT04532827|Experimental|Case formulation with web-program|"The intervention will start with two video meetings with a psychologist to build up and present an individual case formulation, based on behavioural analysis, and to build up a shared decision of individual goals for the web program. The intervention continues with a web program consisting of ten manualized web-based modules, each at one-week intervals based on relational frame theory (RFT) and acceptance and commitment therapy (ACT). The pilot programme included six two-weeks modules and it was in use until 5/2021. The programme is in Finnish.~Both participants in the intervention arm and in the treatment as the usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU, all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
10213756|NCT03373773|Active Comparator|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter in a medical office."
9874817|NCT00362219|Placebo Comparator|Placebo|Gel with no active ingredient
9874818|NCT00362219|Active Comparator|Morphine .25 mg|Gel with 0.25 mg morphine per 100cm2 square of wound
9874819|NCT00362219|Active Comparator|Morphine - .75 mg.|Gel with 0.75 mg morphine per 100cm2 square of wound.
9874820|NCT00362219|Active Comparator|Morphine 1.25 mg.|Gel with 1.25 mg morphine per 100cm2 square of wound.
9874821|NCT00362271|Other|1|
9874822|NCT00362323|Experimental|1|
9874823|NCT00362323|Active Comparator|2|
9874824|NCT00362349|Experimental|1|IVIg
9874825|NCT00362427|Experimental|Group A|
9874826|NCT00362427|Experimental|Group B|
9874827|NCT00362427|Active Comparator|Group C|
9874828|NCT00362479|Experimental|1|
9874829|NCT00362518|Placebo Comparator|1|Study Arm A - Control: no vitamins (placebo only).
9874830|NCT00362518|Active Comparator|2|Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU
9874831|NCT00362518|Active Comparator|3|Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU
9874832|NCT00362518|Active Comparator|4|Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.
9929516|NCT00917618|Placebo Comparator|Control|Patients were asked not to change their baseline exercise program
9929517|NCT00917631|Experimental|Co-bedding|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
9929518|NCT00917631|No Intervention|Standard care|For infants who are randomized to receive standard care, the twin pair will remain in separate incubators as per current NICU policy. The infant will be nested in boundaries consistent with neonatal care practices. The heelstick may occur at any time following randomization (within 10 days) to maintain consistency between groups.
9796848|NCT01579045|Experimental|Sequence 5|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3"
9796849|NCT01579045|Experimental|Sequence 6|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A"
9796850|NCT01579045|Experimental|Sequence 7|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3"
9796851|NCT01579045|Experimental|Sequence 8|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A"
9796852|NCT01579045|Experimental|Sequence 9|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3"
9796853|NCT01579045|Experimental|Sequence 10|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A"
9796854|NCT01579045|Experimental|Sequence 11|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3"
9796855|NCT01579045|Experimental|Sequence 12|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A"
9796856|NCT01579084|Experimental|AGN-199201 Formulation A and B|AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
9796857|NCT01579084|Experimental|AGN-199201 Formulation B and C|AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
9796858|NCT01579084|Experimental|AGN-199201 Formulation C and A|AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
9796859|NCT01579084|Other|AGN-199201 Formulation A and Vehicle|AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
9796860|NCT01579084|Other|AGN-199201 Formulation B and Vehicle|AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
9796861|NCT01579084|Other|AGN-199201 Formulation C and Vehicle|AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
9796862|NCT01579084|Experimental|AGN-199201 Formulation A|AGN-199201 Formulation A applied to both sides of the face twice daily.
9796863|NCT01579084|Experimental|AGN-199201 Formulation B|AGN-199201 Formulation B applied to both sides of the face twice daily.
10211596|NCT04532827|No Intervention|Treatment as usual|"Treatment as usual includes all the routine care that individual receives when he or she is presenting his or her symptoms at the primary or the occupational health care unit (corresponds primary care level treatment) or other unit that recommends the study for the participant. In practice, TAU may vary between the study participants based on their individual needs e.g. treatments for co-morbid somatic diseases or psychiatric disorders that this study will not interfere.~Both participants in the intervention arm and in the treatment as usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
10211597|NCT04532489|Other|Group 1|These subjects, 6 planned (3 male, 3 female), will be to obtain normal tissue distribution of [18F]NP-59 and confirm calculated radiation dosimetry and optimal uptake time.
9796864|NCT01579084|Experimental|AGN-199201 Formulation C|AGN-199201 Formulation C applied to both sides of the face twice daily.
9796865|NCT01579084|Placebo Comparator|AGN-199201 Vehicle|AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
10211598|NCT04531176|Experimental|Obesity-centric approach + AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
10211599|NCT04531176|Experimental|Obesity-centric approach without AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
9796866|NCT01579162|Experimental|Healthy Controls|Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
9796867|NCT01579162|Experimental|chronic HCV patients with F0-F2 fibrosis|
10211600|NCT04531176|Active Comparator|Usual care approach (Comorbidity-centric approach)|Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.
9796868|NCT01579162|Experimental|chronic HCV patients with F3-F4 fibrosis|
9796869|NCT01579162|Experimental|NASH patients with F0-F2 fibrosis|
9796870|NCT01579162|Experimental|NASH patients with F3-F4 fibrosis|
9796871|NCT01579214|Active Comparator|Direct Text Message|Participants in the intervention period (September 2012 - November 2013) received daily short message service (SMS) messages for up to seven days with messages reporting an abnormal result
9796872|NCT01579214|No Intervention|Pre-Intervention|Participants enrolled in the pre-intervention period (January - August 2012) served as a control group.
10211601|NCT04526561|Active Comparator|Breast reconstruction TDAP|Breast reconstruction performed with TDAP
10211602|NCT04526561|Active Comparator|Breast reconstruction latissimus dorsi|Breast reconstruction performed with latissimus dorsi
9874833|NCT00362687|Experimental|1|Truvada 1 tablet once a day.
10211603|NCT04526561|Active Comparator|Breast reconstruction with DIEP|Breast reconstruction performed with a deep inferior epigastric artery perforator flap
10211604|NCT04522856||A|Local
10211605|NCT04522856||B|Nested
10211606|NCT04514926||Healthy Controls|Participants with no history of asthma or other lung diseases.
9796873|NCT01579305|Experimental|Juvéderm® Volbella with Lidocaine|Subjects injected with Juvéderm® Volbella with Lidocaine in their lips
9796874|NCT01579305|Active Comparator|Restylane-L®|Subjects injected with Restylane-L® in their lips
9874834|NCT00362687|Experimental|2|Emtricitabine 1 capsule once a day
9796875|NCT01579318|Experimental|Treatment|Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
9796876|NCT01579474|Experimental|1. BI 201335 low dose plus PegIFN/RBV|low dose BI 201335 NA once daily for 12 or 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
9796877|NCT01579474|Experimental|2. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 12 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
9796878|NCT01579474|Experimental|3. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-experienced (relapser) patients
9796879|NCT01579474|Experimental|4. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 48 weeks in treatment-experienced (null responder, partial responder, breakthrough) patients
9796880|NCT01579513|Active Comparator|Intraoperative Methylprednisone|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass(CPB) in the first month of life that receive one dose of intravenous methylprednisolone (30 mg/kg) during anesthetic induction.
9796881|NCT01579513|Placebo Comparator|Placebo|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass (CPB) in the first month of life that receive one dose of placebo (normal saline) during anesthetic induction.
9796882|NCT01579565|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
9796883|NCT01579565|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
9796884|NCT01579578|Experimental|1|
9796885|NCT01579578|Placebo Comparator|2|
9796886|NCT01579669|Experimental|Use of Toolkit|All participants will have access to the toolkit
9796887|NCT01579747|Placebo Comparator|Nerve stimulation sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach using nerve stimulation
9796888|NCT01579747|Active Comparator|Ultrasound guided sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach when using an ultrasound
9796889|NCT01579812|Experimental|Metformin|
9796890|NCT01579916|Experimental|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
9796891|NCT01579916|Placebo Comparator|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
9796892|NCT01580020|Experimental|Ranibizumab (Arm A)|"The PRN injection scheme applied in the core study will also be followed during this extension study:~Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month"
9796893|NCT01580020|Sham Comparator|Dexamethasone (Arm B)|A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
9796894|NCT01580072|No Intervention|Control group|Participants in the control group receive usual care.
9796895|NCT01580072|Experimental|Self monitoring for patients with COPD|
9796896|NCT01580072|Experimental|Nurse monitoring for patients with COPD|
9796897|NCT01580098|No Intervention|Control group|treatment as usual
9796898|NCT01580098|Experimental|Self-monitoring for patients with Diabetes mellitus type 2|Patients are self-monitoring and submitting their vital parameters.
9796899|NCT01580098|Experimental|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are measuring and entering the vital parameters of the patients.
9796900|NCT01580293|Experimental|Arm 1|On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
9796901|NCT01580293|Experimental|Arm 2|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
9796902|NCT01580293|Experimental|Arm 3|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
9796903|NCT01580293|Experimental|Arm 4|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
9874835|NCT00362713|Experimental|A|3 mg/kg or 10 mg/kg
9874836|NCT00362726|Active Comparator|A|
9874837|NCT00362726|Active Comparator|B|
9874838|NCT00362726|Active Comparator|C|
9874839|NCT00362726|Active Comparator|D|
9874840|NCT00362726|Active Comparator|E|
9796904|NCT01580306|Experimental|BI 201335 relevant treatment dose (A)|Capsule for oral administration
9796905|NCT01580306|Experimental|BI 201335 relevant treatment dose (B)|Capsule for oral administration
9796906|NCT01580410|Experimental|Arm I (mitomycin C)|Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
9874841|NCT00362739||1: Lung Disease|Individuals with at least one of the following: (1)symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; (7) individuals suspected of history of lung diseased based on history and/or physical examination
9874842|NCT00362739||2: Normal Controls|Individuals without a history of lung disease
9874843|NCT00362752|Placebo Comparator|Placebo|
9874844|NCT00362752|Experimental|Norfloxacin 400 mg bid|
10211607|NCT04514926||Asthmatics newly prescribed therapeutic proteins|Participants with asthma, have been newly prescribed therapeutic proteins and have yet to start on those therapeutics at the time of enrollment.
10211608|NCT04514926||Asthmatics already being treated with therapeutic proteins|Participants with asthma who have already started on therapeutic proteins.
10211609|NCT04514913||Healthy Controls|Participants with no history of asthma or other lung diseases.
10211610|NCT04514913||Asthmatics without mucus plugs|Participants with asthma and no evidence of mucus plugging.
9874845|NCT00362765|Experimental|1|
9874846|NCT00362765|Active Comparator|2|
9874847|NCT00362765|Active Comparator|3|
9874848|NCT00362765|Placebo Comparator|4|
9987546|NCT01413815|Placebo Comparator|corn starch|Placebo: Corn Starch
9796907|NCT01580410|Experimental|Arm II (oxaliplatin)|Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
9796908|NCT01580423|Experimental|aprepitant|
9796909|NCT01580423|Placebo Comparator|inert powder|
9796910|NCT01580592|Experimental|Omalizumab 150mg|
9796911|NCT01580592|Experimental|Omalizumab 300mg|
9796912|NCT01580592|Placebo Comparator|Placebo|
9796913|NCT01580618|Placebo Comparator|Normal Saline|Loculated pleural effusion infused with normal saline twice a day for three days.
9796914|NCT01580618|Active Comparator|TNKase|Loculated pleural effusion infused with TNK twice a day for three days.
9874849|NCT00362778|Sham Comparator|Serum saline|
9874850|NCT00362830|Experimental|1|
9874851|NCT00362856|Placebo Comparator|Placebo + Gluten|placebo TID + gluten 800 mg TID administered orally in capsules
10211611|NCT04514913||Asthmatics with mucus plugs|Participants with asthma and evidence by MDCT lung scan showing mucus plugging.
10211612|NCT04508192|Experimental|Copenhagen Adduction|The CA is a high-intensity partner exercise where the player is lying on their side using the elbow of the lower forearm to support their body and the other arm placed along their body. The upper arm is supported by the partner who places their one hand under the knee and the other under the ankle, holding the leg approximately in the height of their hip. The player performs a 3-second concentric movement lifting their body until it reaches a straight line. At the same time, the other leg is adducted so that it touches the other leg. A 3-second eccentric adduction then follows with the body lowered halfway to the ground and the foot of the lower leg touching the ground without supporting the body.
10211613|NCT04508192|Active Comparator|Adductor Squeeze|The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees. The player lies supine with the ball placed between the knees with the knees and hips flexed and the feet flat on the surface with the first toe is pointed straight forward.the player is asked to press against the ball as hard as they can The contraction is held for 10 seconds
10211614|NCT04505956|Experimental|Moses Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique using Moses laser technology.
10211615|NCT04505956|Active Comparator|Standard Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.
9874852|NCT00362856|Placebo Comparator|Placebo + Gluten placebo|placebo TID + gluten placebo TID administered orally in capsules
9874853|NCT00362856|Other|Larazotide acetate 8 mg + Gluten placebo|Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
9874854|NCT00362856|Active Comparator|Larazotide acetate 0.25 mg + Gluten|Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
9874855|NCT00362856|Active Comparator|Larazotide acetate 1 mg + Gluten|Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
9874856|NCT00362856|Active Comparator|Larazotide acetate 4 mg + Gluten|Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
9929519|NCT00917683||1|Autistic patients.
9929520|NCT00917683||2|Matched controls
9929521|NCT00917696|Active Comparator|1|ATP
9929522|NCT00917696|Placebo Comparator|2|Saline
10211616|NCT04503018||Interviewed -implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
10211617|NCT04503018||Questionnaires - implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
9874857|NCT00362856|Active Comparator|Larazotide acetate 8 mg + Gluten|Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
9874858|NCT00362869|Experimental|1|Dosage 1X10^9 given orally in a sodium bicarbonate solution
9874859|NCT00362869|Experimental|2|Dosage 5X10^9 given orally in a sodium bicarbonate solution
9874860|NCT00362869|Placebo Comparator|5|Sodium bicarbonate placebo solution
10211618|NCT04503018||Questionnaires - controls|Patients who have had immediate breast reconstruction without complications
10211619|NCT04497038|Experimental|Cabozantinib|Cabozantinib 20-60 mg by mouth once daily.
9874861|NCT00362869|Experimental|4|Dosage 5X10^10 given orally in a sodium bicarbonate solution
9874862|NCT00362869|Experimental|3|Dosage 1X10^10 given orally in a sodium bicarbonate solution
9874863|NCT00362895|Experimental|Tobradex AF|
9874864|NCT00362895|Active Comparator|TOBRADEX|
10211620|NCT04496362|Experimental|subcutaneous heparin anticoagulation|Experimental arm
10211621|NCT04496362|No Intervention|systemic intravenous anticoagulation|SOC arm
10211622|NCT04495400||Percutaneous Screw Fixation|Patients who have had a Percutaneous Screw fixation procedure.
10211623|NCT04495400||Open Fixation|Patients who have had an Open Fixation procedure.
9874865|NCT00362908|Active Comparator|Group 1|"Subjects consume study diets in the following order:~Diet 1 (20% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 2 (40% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
9874866|NCT00362908|Active Comparator|Group 2|"Subjects consume study diets in the following order:~Diet 2 (40% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 1 (20% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
9874867|NCT00362921|Experimental|Gliadel wafers in combination with O6-benzylguanine|
9874868|NCT00362934|Experimental|1|
9874869|NCT00362934|Active Comparator|2|
9874870|NCT00362947|Placebo Comparator|A|A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days
9874871|NCT00362947|Active Comparator|B|B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days
10211624|NCT04488185|Experimental|Secukinumab 300mg|Randomized in a 2:1 ratio to secukinumab or placebo
10211625|NCT04488185|Placebo Comparator|Placebo|Randomized in a 2:1 ratio to secukinumab or placebo
9874872|NCT00362947|Active Comparator|C|C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days
9874873|NCT00362973||Hormone Receptor Positive Breast Cancer|Patients with hormone receptor positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of aromatase inhibitor and ovarian suppression (if premenopausal).
9874874|NCT00362973||HER-2/neu Positive Breast Cancer|Patients with HER-2/neu positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of trastuzumab.
9874875|NCT00362986|Experimental|sunscreen|"Patients apply sunscreen generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
9874876|NCT00362986|Placebo Comparator|placebo|"Patients apply placebo generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
9874877|NCT00363116|Active Comparator|5 Dose Daclizbumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
9874878|NCT00363116|Active Comparator|2 Dose Daclizaumab|daclizumab 2 mg/kg/dose every 14 days for 2 doses
9874879|NCT00363116|Active Comparator|Control|no antibody induction
10211626|NCT04484987|Other|TRE group|Time-restricted eating group
9517649|NCT03304392|Active Comparator|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
9874880|NCT00363194|Experimental|Lead-In cohort|In Part 1 of Lead-In cohort, subjects will be dosed with a single dose of pazopanib with a high-fat breakfast to establish safety and tolerability.
9874881|NCT00363272|Experimental|Arm I|Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
9874882|NCT00363363|Experimental|1|
9874883|NCT00363363|Active Comparator|2|
9874884|NCT00363376|Experimental|Sugar pill|"olanzapine and placebo (sugar pill)"
9874885|NCT00363376|Experimental|Zonisamide|olanzapine and zonisamide (active drug)
9874886|NCT00363428|Placebo Comparator|Control|Receive standard care and educational material on exercise and lifestyle choices of well-being
10211627|NCT04484987|Other|Control group|Time-unrestricted eating group
10211628|NCT04475536||Coronary Artery Disease (CAD)|
10211629|NCT04470895||Usual falling patients|"a group enrolling the patients who completed the inclusive criteria and have had at least one fall in the last 12 months in addition to the possible fall causing the index fracture.~These patients must answer positively the following question Have you fallen in the last 12 months, regardless of the current fracture?"
10211630|NCT04470895||Unusual falling patients|"a group enrolling the patients who also completed the inclusive criteria, but are defined as unsual falling patients. These patients must answer negatively the following question: Have you fallen in the last 12 months, regardless of the current fracture?"
9796915|NCT01580670|Experimental|TA-650|"Responder criteria: Case where PCDAI score on the evaluation day was decreased by at least 15 points from that in the screening period and was ≤30.~Criteria for dose-increasing: When either of the following 2 items was satisfied after Week 14, the relevant patient would be considered to satisfy the criteria for dose increasing to 10 mg/kg.~PCDAI score on the evaluation day was increased by at least 15 points compared to the lowest PCDAI score observed at Week 2, 6 or 10~PCDAI score on the evaluation day exceeds 30"
9796916|NCT01580904|No Intervention|control group|Patients will not be followed by the pharmacist.
9796917|NCT01580904|Experimental|Intervention group|"Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.~Intervention: Pharmaceutical Care"
9796918|NCT01580969|Experimental|Dose Level 0: 100 mg bid|Patients receiving minocycline 100 mg bid, bevacizumab, and radiation therapy.
9796919|NCT01580969|Experimental|Dose Level 1: 200 mg bid|Patients receiving minocycline 200 mg bid, bevacizumab, and radiation therapy.
9796920|NCT01580969|Experimental|Dose Level 2: 400 mg bid|Patients receiving minocycline 400 mg bid, bevacizumab, and radiation therapy.
9796921|NCT01580995|Experimental|Valacyclovir|Valacyclovir 500 mg po bid
9796922|NCT01580995|Placebo Comparator|Placebo|Matching placebo twice daily
9796923|NCT01581008|Experimental|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
9796924|NCT01581008|Active Comparator|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
9796925|NCT01581021|Active Comparator|Thoracic Pedicle Screws|Group treated with pedicle screws in the thoracic spine
9796926|NCT01581021|Active Comparator|Laminar Hooks|Group treated with hooks in the thoracic spine
9796927|NCT01581281|Active Comparator|Amitriptyline|Drug to be administered twice daily.
9796928|NCT01581281|Active Comparator|Topiramate|Drug to be administered twice daily.
9796929|NCT01581281|Placebo Comparator|Placebo|To be administered twice daily.
9796930|NCT01581307|Experimental|2nd Line Chemotherapy With Radiotherapy|"Administration of 2nd line chemotherapy will consist of a modified FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) will take place at least 2 weeks after the completion of first-line chemotherapy. Generally, second-line chemotherapy is given every two weeks for 6-10 cycles.~The goal of treatment with TheraSpheres is to allow a large dose of radiation to be delivered directly to the tumor(s) with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue."
9796931|NCT01581437|Other|64 pole basket catheter|all patients participating undergo mapping using the 64 pole basket catheter to assess for Atypical areas of drivers that may cause atrial fibrillation
9796932|NCT01581541|Experimental|PU-H71|PU-H71 will be administered intravenous (IV) over one hour, once weekly, 2 weeks out of 3, (i.e., on days 1 and 8) every 21 days
9796933|NCT01581593|Experimental|Kedrion IVIG 10%|Kedrion IVIG 10% treatment.
9796934|NCT01581619|Experimental|Partial Breast Irradiation|Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks
9796935|NCT01581658|Experimental|BI10773 medium dose group 1|BI10773 medium dose tablet single dose group 1
9796936|NCT01581658|Experimental|BI10773 medium dose group 2|BI10773 medium dose tablet single dose group 2
9796937|NCT01581658|Experimental|BI10773 Medium dose group 3|BI10773 medium dose tablet single dose group 3
9796938|NCT01581658|Experimental|BI10773 Medium dose group 4|BI10773 medium dose tablet single dose group 4
9796939|NCT01581684|Experimental|BI 411034 low dose - group 1|Solution for oral administration
9796940|NCT01581684|Experimental|BI 411034 low dose - group 2|Solution for oral administration
9796941|NCT01581684|Experimental|BI 411034 medium dose - group 3|Solution for oral administration
9796942|NCT01581684|Experimental|BI 411034 medium dose - group 4|Solution for oral administration
9796943|NCT01581684|Experimental|BI 411034 medium dose - group 5|Solution for oral administration
9796944|NCT01581684|Experimental|BI 411034 high dose - group 6|Solution for oral administration
9796945|NCT01581684|Experimental|BI 411034 high dose - group 7|Solution for oral administration
9796946|NCT01581684|Experimental|BI 411034 high dose - group 8|Solution for oral administration
9796947|NCT01581684|Placebo Comparator|Placebo|Solution for oral administration
9874887|NCT00363428|Experimental|Lifestyle intervention|
9874888|NCT00363454|Experimental|Dose Escalation|Phase I: Triciribine Phosphate Monohydrate
9796948|NCT01581710|Active Comparator|montelukast to placebo|14 days
9796949|NCT01581710|No Intervention|Washout|14 days
9796950|NCT01581710|Active Comparator|Placebo to montelukast|14 days
9796951|NCT01581931|Experimental|Linagliptin/metformin|fixed dose combination tablet (FDC)
9796952|NCT01581931|Experimental|Linagliptin and metformin|single tablets
9796953|NCT01581970|Experimental|Cetuximab/low dose Cyclophosphamide|Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
9796954|NCT01582009|Experimental|Arm I: Oral Panobinostat and Oral Everolimus|Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9796955|NCT01582061|Experimental|Pasireotide 600 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose < 1500 μg /day.
9796956|NCT01582061|Experimental|Pasireotide 900 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
9796957|NCT01582139|Experimental|Experimental Condition: (Heart-Rate Informed SSM+HMM)|An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
9796958|NCT01582139|No Intervention|Control Condition (SSM+HMM)|A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
9796959|NCT01582152|Experimental|TPI 287 + Bevacizumab|"Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.~Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.~Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I."
9796960|NCT01582152|Experimental|Bevacizumab Group|"Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.~Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone."
9796961|NCT01582178|Experimental|Warm Water Immersion Colonoscopy|Colonoscopy using purely warm water (37°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
9796962|NCT01582178|Active Comparator|Cool Water Immersion Colonoscopy|Colonoscopy using purely room temperature water (20-24°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
9796963|NCT01582243|Experimental|Vildagliptin plus metformin (SPC)|Eligible participants received oral vildagliptin 50 mg plus metformin 500 mg (SPC) twice daily from week 1 to week 24.
9796964|NCT01582282|Placebo Comparator|placebo|matched placebo BID
9796965|NCT01582282|Active Comparator|psyllium 3.4g BID|3.4g psyllium BID for a Total of 6.8g daily
9796966|NCT01582282|Active Comparator|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day
9796967|NCT01582308|Experimental|Treatment Sequence 1|Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
9796968|NCT01582308|Experimental|Treatment Sequence 2|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
9874889|NCT00363519|Placebo Comparator|P|
9874890|NCT00363519|Experimental|E|
9874891|NCT00363714|Experimental|1|Single intravitreal injection
9874892|NCT00363714|Experimental|2|Single intravitreal injection
9874893|NCT00363714|Experimental|3|Single intravitreal injection
9874894|NCT00363714|Experimental|4|Single intravitreal injection
9874895|NCT00363714|Experimental|5|Single intravitreal injection
9874896|NCT00363714|Experimental|6|Single intravitreal injection
9874897|NCT00363831|Experimental|1|Oxaliplatin
9874898|NCT00363844|Experimental|E|
9874899|NCT00363909|Experimental|low-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
9874900|NCT00363909|Experimental|medium-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
9874901|NCT00363909|Experimental|high-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
9874902|NCT00363909|Placebo Comparator|placebo|"Patients receive 1-3 placebo tablets once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
9874903|NCT00363922|Experimental|1|Rehabilitation in institution
9874904|NCT00363922|Active Comparator|2|Rehabilitation at home
9874905|NCT00363948|Placebo Comparator|P|
9874906|NCT00363948|Experimental|E|
9874907|NCT00363961|Experimental|1|resistance exercise
9874908|NCT00363961|Sham Comparator|2|flexibility exercises
9874909|NCT00363987|Experimental|1|
9874910|NCT00363987|Other|2|
9874911|NCT00364000|Active Comparator|I|Calcium acetate 670 mg tablets
9874912|NCT00364000|Experimental|II|label sevelamer (RenagelR) 800 mg tablets
9874913|NCT00364104|Experimental|A|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
9874914|NCT00364104|Experimental|B|The 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
9874915|NCT00364104|Experimental|C|6-weeks of iron supplementation only plus 10-days of matching placebo of Hp infection eradication therapy
9874916|NCT00364104|Placebo Comparator|D|
9874917|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 1|Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
9874918|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
9874919|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.
9874920|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.
9874921|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.
9874922|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 2|Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).
9874923|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 2|Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.
9874924|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 2|Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.
9874925|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 2|Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.
9874926|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 3|Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.
9874927|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 3|Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.
9874928|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 3|Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.
9935377|NCT03829501|Experimental|KY1044 and atezolizumab phase 2|KY1044 and atezolizumab combination
9987547|NCT01413828|Experimental|concurrent|trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen
9987548|NCT01413828|Active Comparator|sequential|trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen
9987549|NCT01413841|Active Comparator|Nasal oxygen|3 liter per minute
9987550|NCT01413841|Placebo Comparator|Nasal Air|3 l regular nasal air
9987551|NCT01413854|Active Comparator|diclofenac|
9796969|NCT01582308|Experimental|Treatment Sequence 3|Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
9987552|NCT01413854|Placebo Comparator|sugar pill|
9987553|NCT01413867|Experimental|EEA group|Group of patients with III degree hemorrhoids treated by EEA stapler
9987554|NCT01413867|Active Comparator|PPH group|group of patients with III degree hemorrhoids treated by PPH stapler
9987555|NCT01413893|Experimental|linifanib|
9987556|NCT01413906|Experimental|Arm 1: BMS-833923 (XL139)|
9987557|NCT01413945||Normal volunteers|Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
9987558|NCT01413945||Irritable bowel syndrome|Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.
9997088|NCT01505920|Experimental|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
9874929|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.
9874930|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.
9874931|NCT00364325||001|
9929523|NCT00917709|Experimental|DLB with extrapyramidal syndrome|patients dementia with Lewy bodies with extrapyramidal syndrome
9929524|NCT00917709|Other|DLB without extrapyramidal syndrome|patients dementia with Lewy bodies without extrapyramidal syndrome
9929525|NCT00917709|Sham Comparator|healthy volunteers|healthy volunteers
9929526|NCT00917748|Experimental|1|docetaxel chemotherapy + modafinil 100 mg capsules
9929527|NCT00917748|Placebo Comparator|2|docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug)
9929528|NCT00917761|Experimental|Entecavir and peginterferon (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
9929529|NCT00917761|Experimental|Peginterferon (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
9929530|NCT00917761|Active Comparator|Peginterferon (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
9929531|NCT00917774|Active Comparator|Standard LPS Flex|Nexgen LPS-Flex total knee design used for TKA
9929532|NCT00917774|Experimental|Gender specific LPS-Flex|Gender specific LPS flex design used for TKA in female patients
9929533|NCT00917787||Healthy, Non-asthmatic|
9929534|NCT00917787||Asthma|
9929535|NCT00917800||suspected coronary artery disease|patients referred to angiography because of suspected coronary artery disease
9929536|NCT00917813|Experimental|KD-247|
9929537|NCT00917813|Placebo Comparator|Placebo|
9929538|NCT00917839|Experimental|lamotrigine|7 weeks initial phase with increasing dose beginning with 25 mg oral 12 months treatment phase with fixed dose of 100 mg oral
9929539|NCT00917839|Placebo Comparator|Placebo|300mg Mannitol with 2% Aerosil
9929540|NCT00917878|Experimental|Milk|500 mL low-fat milk added to high-fat meal
9929541|NCT00917878|Experimental|Protein|Milk protein in 500 mL water added to high-fat meal
9929542|NCT00917878|Experimental|Calcium|Milk calcium in 500 mL water added to high-fat meal
9929543|NCT00917878|Experimental|Control|Lactose in 500 mL water added to high-fat meal (control condition)
9929544|NCT00917891|Placebo Comparator|vehicle placebo gel|
9929545|NCT00917891|Experimental|dapivirine gel|
9929546|NCT00917904|Placebo Comparator|vehicle placebo gel|
9929547|NCT00917904|Experimental|dapivirine gel|
9929548|NCT00917930||physical training|
9929549|NCT00917943|Experimental|Tailored Counseling Intervention Arm|Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
9929550|NCT00917943|No Intervention|Control Arm|Women randomized to the control arm receive the booklet, Forever Free for Baby and Me: A Guide to Remaining Smoke Free and usual prenatal and postpartum care.
9929551|NCT00917982|Other|Vision therapy|
9929552|NCT00917995|Experimental|Colostomy with a prophylactic mesh|
9987559|NCT01413984|Experimental|cognitive behavioral group treatment|Helping Women Recover/Beyond Trauma integrated substance abuse and trauma treatment group. (Dr. Covington)
9998312|NCT01516996|Active Comparator|Neoadjuvant and CCRT|
9874932|NCT00364403|Experimental|1|Low glycemic load diet
9874933|NCT00364403|Active Comparator|2|Low fat diet
9874934|NCT00364416||001|
9874935|NCT00364442|Experimental|Arm 1|investigational drug
9874936|NCT00364520||Shanghai Workers|Shanghai Workers
9874937|NCT00364559|Experimental|B|A, Active B, Historical Register
10211631|NCT04466995|Experimental|laparoscopic gynecologic surgery|25 laparoscopic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
9874938|NCT00364572|Placebo Comparator|1|Two injections of epidural saline 2 weeks apart
9874939|NCT00364572|Experimental|Epidural injection of etanercept|Two injections of epidural etanercept 2 weeks apart
9874940|NCT00364650|Placebo Comparator|I|Placebo
9874941|NCT00364650|Experimental|II|Probiotic supplement
9874942|NCT00364676|Experimental|1|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
9874943|NCT00364676|Experimental|2|Patients are dosed on Day 1 of a 21-day cycle.
9874944|NCT00364741|Active Comparator|A|Fraction of inspired oxygen (FiO2) = 0.30
9874945|NCT00364741|Active Comparator|B|FiO2 = 0.80
9874946|NCT00364767|Experimental|A|Whiskey (32 gram of alcohol/day)
9874947|NCT00364767|Placebo Comparator|B|Water (0 gram alcohol/day)
9874948|NCT00364871|Experimental|1|Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
9874949|NCT00364871|Experimental|2|Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
9874950|NCT00364871|Active Comparator|3|Bupropion SR (400 mg/day)
9874951|NCT00364871|Active Comparator|4|Naltrexone (48 mg/day)
9874952|NCT00364871|Placebo Comparator|5|B-Placebo plus N-Placebo
9874953|NCT00364871|Placebo Comparator|6|B-Placebo plus N-Placebo
9874954|NCT00364871|Experimental|7|Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
9874955|NCT00364910|Experimental|Cognitive behavioral therapy (CBT)|Participants will receive cognitive behavioral therapy
9874956|NCT00364910|Active Comparator|Educational session and treatment as usual|Participants will receive an educational session and treatment as usual
9874957|NCT00365001|Experimental|1|
9874958|NCT00365001|Active Comparator|2|
9874959|NCT00365014||Blood disease patients|People with blood diseases presenting at Shanghai hospitals
9874960|NCT00365183|Experimental|Xcytrin® (motexafin gadolinium)|
9874961|NCT00365222|Experimental|1|
9874962|NCT00365339|Active Comparator|A|
9874963|NCT00365339|Experimental|B|
9874964|NCT00365339|Experimental|C|
9874965|NCT00365339|Experimental|D|
9874966|NCT00365339|Experimental|E|
9874967|NCT00365469|Experimental|Probiotic|Commercially available cow's milk based infant formula with Bifidobacterium longum [BL999} and Lactobacillus rhamnosus [LPR]
9874968|NCT00365469|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
9874969|NCT00365677|Experimental|Zyoptix Tissue Saving Aspheric|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
9874970|NCT00365677|Active Comparator|Zyoptix Tissue Saving|The Bausch & Lomb Zyoptix Tissue Saving algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
9874971|NCT00365690|Active Comparator|1|Participants will receive individual therapy upon request
9874972|NCT00365690|Active Comparator|2|Participants will receive telephone-administered supportive-expressive group therapy
9874973|NCT00365690|Experimental|3|Participants will receive telephone-administered coping improvement group therapy
9874974|NCT00365703|Experimental|1|Orogastric feeding tube.
9874975|NCT00365703|Experimental|2|Nasogastric feeding tube.
9874976|NCT00365807|Active Comparator|Brief Family Intervention (Primarily education)|Behaviorally based family group intervention using standard education and nutrition counseling. Three hours of client contact
9874977|NCT00365807|Experimental|Positively Fit|12 week (90 minute per session) behavioral group intervention for children and their parents. Children and parent attend parallel group with identical (but developmentally appropriate) information presented.
9874978|NCT00365833||Recipients of Kidney Transplant|Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.
9874979|NCT00365885|Experimental|1|electronic mail notifications to care managers about sentinel health events
9874980|NCT00365885|Experimental|2|feedback reports with notifications to clinic managers about sentinel health events
9874981|NCT00365885|Experimental|3|letters to patients with notifications about sentinel health events
9874982|NCT00365885|No Intervention|4|electronic mail notifications to care managers about sentinel health events -- generated but withheld
9874983|NCT00365885|No Intervention|5|feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
9874984|NCT00365885|No Intervention|6|letters to patients with notifications about sentinel health events -- generated but withheld
9874985|NCT00365924|Other|Forteo|
9874986|NCT00365937|Experimental|Group A|The eight HLA-A2 peptides
10211632|NCT04466995|Other|laparotomic gynecologic surgery|25 laparotomic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
10211633|NCT04465266|Experimental|50 mg Tolperisone|50 mg tablets (2 days SD, 2 days TID)
10211634|NCT04465266|Experimental|100 mg of Tolperisone|100 mg tablets (2 days SD, 2 days TID)
10211635|NCT04465266|Experimental|200 mg Tolperisone|200 mg tablets (2 days SD, 2 days TID)
10211636|NCT04458649||No increased risk of hypoglycemia|Infants born with no obvious risk factors for hypoglycemia in the neonatal period.
10211637|NCT04458649||Increased risk of hypoglycemia|"Infants considered at increased risk for hypoglycemia after birth including the following criteria:~Infant born to a diabetic mother~Very large for gestational age (VLGA) infant with weight >97%"
9874987|NCT00365937|Experimental|Group B|The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
9874988|NCT00365937|Experimental|Group C|the eight peptides HLA-A2 + IMP321
9874989|NCT00365937|Experimental|Group D|The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)
9874990|NCT00366002|Experimental|1|Darifenacin
9874991|NCT00366041|Experimental|Cellularised LG002|Cellularised LG002
9796970|NCT01582308|Experimental|Treatment Sequence 4|Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
9874992|NCT00366041|Experimental|UnCellularised LG002|UnCellularised LG002
9874993|NCT00366093|Experimental|1|eszopiclone 3 mg
9874994|NCT00366093|Placebo Comparator|2|Placebo tablet
9874995|NCT00366158|Experimental|1|Ventricular Instrinsic Preference (VIP) turned ON
9874996|NCT00366158|Active Comparator|2|Ventricular Instrinsic Preference (VIP) turned OFF
9874997|NCT00366210|Experimental|Expanded CI therapy|3.5 hours of training for the more-affected arm set in the laboratory for 15 consecutive weekdays
9874998|NCT00366210|Placebo Comparator|Placebo Control|Stretching, movement exercises, and EMG biofeedback for the same duration as the experimental intervention.
9874999|NCT00366210|No Intervention|Usual & Customary Care Control|Treatments available to participants as part of their regular medical care, such as conventional physical or occupational therapy. For some participants, this would involve no treatment, since all participants were more than one year post stroke.f standard clinical care.
9875000|NCT00366288||1|
9875001|NCT00366288||2|
9875002|NCT00366288||3|
9875003|NCT00366288||4|
9875004|NCT00366288||5|
9875005|NCT00366288||6|
9875006|NCT00366288||7|
9796971|NCT01582308|Experimental|Treatment Sequence 5|Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
9796972|NCT01582308|Experimental|Treatment Sequence 6|Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
9875007|NCT00366353|Other|1|Sedation suring a spontaneous breathing trial.
9875008|NCT00366353|Other|2|No sedation during spontaneous breathing trial
9929553|NCT00917995|No Intervention|Colostomy without a prophylactic mesh|
9929554|NCT00918008||Blood sample|the blood sample only collected prior to surgery
9929555|NCT00918021|Active Comparator|olanzapine (B)|Group B: In addition to clozapine, the participants receive their normal dosage of olanzapine (=the same as on the hospital ward) for 12 weeks, next the decreasing dosage of olanzapine for four weeks and subsequently placebo for 8 weeks.
9929556|NCT00918021|Placebo Comparator|placebo (A)|Group A: : In addition to clozapine the participants receive the decreasing dosage of olanzapine for four weeks, next placebo for 8 weeks, after that the increasing dosage of olanzapine for four weeks and subsequently the normal dosage of olanzapine for 8 weeks.
9929557|NCT00918034|Experimental|LS11 (talaporfin sodium)|
9929558|NCT00918047|Experimental|SPN-804O 150mg/Day|Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
9929559|NCT00918047|Experimental|SPN-8040 300mg/Day|Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
9929560|NCT00918047|Experimental|SPN-8040 450mg/Day|Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
9929561|NCT00918047|Experimental|SPN-8040 600mg/Day|Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
9929562|NCT00918060|Experimental|gel a|
9929563|NCT00918060|Placebo Comparator|gel b|
9929564|NCT00918073||HIV positive smokers|50 HIV infected patients who enroll in a parent protocol to quit smoking and elect to participate in this sub-study.
9929565|NCT00918086|Experimental|Vitamin D pill|
9929566|NCT00918086|Placebo Comparator|Placebo|
9929567|NCT00918099|Active Comparator|Avaulta mesh|Avaulta mesh
9929568|NCT00918099|Active Comparator|Anterior repair|Anterior repair
9929569|NCT00918151||A|
9929570|NCT00918164|Experimental|Healthy adult volunteers|Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex
9929571|NCT00918177|Experimental|Early patients|
9929572|NCT00918177|Experimental|Moderate Patients|
9929573|NCT00918190|Active Comparator|Ondansetron-Dexa group|Use 2 different antiemetics
9929574|NCT00918190|Active Comparator|Midazolam, Dexa group|use of midazolam and dexamethasone
9929575|NCT00918190|Placebo Comparator|Placebo|Saline will be given
9929576|NCT00918268|Experimental|Influenza vaccine|
9929577|NCT00918294|Experimental|QuickOpt|QuickOpt is an optimization algorithm to program the AV, PV and VV delays
9929578|NCT00918307|Experimental|Varenicline|Varenicline titrated to 2 x 0.5 mg twice daily for 12 weeks
9929579|NCT00918307|Placebo Comparator|Placebo|placebo titrated to 2 pills twice daily for 12 weeks
9929580|NCT00918320|Experimental|Toptecan + temozolomide|
9929581|NCT00918359||HI|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance .
9929582|NCT00918359||HT|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance .
9929583|NCT00918372||Extreme fitness|Female competitive long distance runners
9929584|NCT00918372||Control|Age and Risk matched controls
9929585|NCT00918398|Experimental|1|AZD1981, 100 mg iv infusion
9929586|NCT00918398|Experimental|2|AZD1981, 514 mg oral solution
9875009|NCT00366379|Experimental|1|
9875010|NCT00366379|Experimental|2|
9875011|NCT00366379|Experimental|3|
9875012|NCT00366379|Experimental|4|
9875013|NCT00366379|Experimental|5|
9875014|NCT00366470|Experimental|A|Vitamin D in doses of 100,000 IU
9875015|NCT00366470|Placebo Comparator|B|
9875016|NCT00366509||1|Lung Disease
9875017|NCT00366509||2|Healthy volunteer
9875018|NCT00366639||001|
9875019|NCT00366782|Experimental|1|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
9875020|NCT00366782|Experimental|2|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to HPIV3-seropositive children 15 to 59 months of age). This arm may enroll after Arm 1 depending on the effect of the vaccine on Arm 1.
9875021|NCT00366782|Experimental|3|One vaccination with rB/HPIV3 vaccine (at lower dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
9875022|NCT00366782|Experimental|4|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
9875023|NCT00366782|Placebo Comparator|5|One vaccination with placebo vaccine given as nose drops to adults, HPIV3-seropositive children, or seronegative children or infants
9875024|NCT00366821||1|Examine the outcomes following cardiac surgery in those newborns with genetic abnormalities.
9875025|NCT00366821||2|Examine the outcomes following cardiac surgery in newborns without genetic abnormalities.
9875026|NCT00366834|Placebo Comparator|Control|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
9875027|NCT00366834|Experimental|Single dose oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
9875028|NCT00366834|Experimental|3-day oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 & 3
9875029|NCT00366834|Experimental|3-day IV/oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 & 3
9875030|NCT00366860|Experimental|Soy bread|Soy bread (75-100 mg isoflavone/day) for 12 weeks
9875031|NCT00366860|Active Comparator|Wheat bread|Wheat bread for 12 weeks
9875032|NCT00366873|Active Comparator|1|cow-milk based infant formula
9875033|NCT00366873|Experimental|2|cow-milk based infant formula with prebiotics
9875034|NCT00366964|No Intervention|Device|
9875035|NCT00366990|Active Comparator|weight loss and sodium intake reduction|Behavioral and weight loss intervention, including a low sodium diet. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking, and a 50% reduction in sodium intake.
9875036|NCT00366990|Placebo Comparator|weight loss and normal sodium intake|Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
9875037|NCT00367029|Active Comparator|1|Print-based, individually tailored motivational program
9875038|NCT00367029|Experimental|2|Enhanced version of the print-based, individually tailored motivational program
9875039|NCT00367042|No Intervention|1|
9875040|NCT00367198|Active Comparator|1|30 ml per serving
9875041|NCT00367198|Active Comparator|2|60 ml per serving
9875042|NCT00367198|No Intervention|3|chronic hemodialysis patients
9875043|NCT00367198|No Intervention|4|healthy subjects
9875044|NCT00367276|Experimental|Arm 1|
9875045|NCT00367302|Experimental|1|Buprenorphine maintenance
9875046|NCT00367302|Active Comparator|2|Methadone maintenance
9875047|NCT00367328|Active Comparator|A|Oral Antibiotics in standard care vs. Laser treatment
9875048|NCT00367393|Experimental|1|Pimecrolimus cream 1%
9875049|NCT00367406|Experimental|Treatment with a Gamma 3 nail.|
9875050|NCT00367471|Active Comparator|Group A|Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion. Doses of paclitaxel and carboplatin will be administered weekly (Day 1, 8, and 15). Trastuzumab is administered on Day 1, 8, 15, and 22. Treatment cycles are repeated every four weeks.
9875051|NCT00367471|Active Comparator|Group B|Subjects in Treatment Group B (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by a ≥15 minute intravenous infusion of carboplatin. Doses of paclitaxel, and carboplatin will be administered weekly (Day 1, 8, and 15) for three weeks with cycles repeated every four weeks.
9875052|NCT00367653|Experimental|1|
9875053|NCT00367653|Experimental|2|
9875054|NCT00367705|Active Comparator|T|VSL-#3
9875055|NCT00367705|Placebo Comparator|P|
9875056|NCT00367757|Other|PVI group|Trigger-based ablation guided by pulmonary vein antrum isolation
9875057|NCT00367757|Other|CFAE group|Substrate-based ablation using an approach targeting CFAEs
9875058|NCT00367757|Other|Combined group|Combined trigger and substrate based approach
9875059|NCT00367809|Experimental|1|
9875060|NCT00367809|Active Comparator|2|
9875061|NCT00367809|No Intervention|3|
9875062|NCT00367861|Experimental|interruption of Glivec®|
9875063|NCT00367900||NIH-AARP Diet and Health Study sub study: PAGE|Diet and Health Study members who self-reported a Parkinson's disease (PD) diagnosis on a follow-up questionnaire, and randomly selected controls, will participate in the PAGE sub study.
9875064|NCT00367952|Experimental|ATC 800mg BID|800mg ATC BID
9875065|NCT00367965|Experimental|1|eszopiclone 3 mg
9875066|NCT00367965|Placebo Comparator|2|placebo tablet
9875067|NCT00368017|Active Comparator|1|
9875068|NCT00368017|Placebo Comparator|2|
9875069|NCT00368030|Experimental|A|Eszopiclone 3 mg QD
9875070|NCT00368030|Placebo Comparator|B|Placebo tablet
9929587|NCT00918398|Experimental|3|AZD1981, 500 mg oral tablet A
9929588|NCT00918398|Experimental|4|AZD1981, 500 mg oral tablet B
9929589|NCT00918411|Experimental|Ramosetron group|oral
9929590|NCT00918411|Placebo Comparator|Placebo group|oral
9929591|NCT00918437||RAUP treatment|Patients referred to the hospital for a snoring problem
10211638|NCT04453150|Experimental|Standard hypocaloric diet|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits 3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
10211639|NCT04453150|Experimental|Intermittent fasting 16/8 (early fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 12 am. to 8 pm.), maintaining 16 fasting hours (from 8 pm. to 12 am. the following day).
10211640|NCT04453150|Experimental|Intermittent fasting 16/8 (late fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 8 am. to 4 pm.), maintaining 16 fasting hours (from 4 pm. to 8 am. the following day).
10211641|NCT04453150|Experimental|Alternate-day fasting|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
9929592|NCT00918450|Experimental|1|
9929593|NCT00918476|Experimental|1. filibuvir + Oral Contraceptives|
9929594|NCT00918489|Experimental|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
9929595|NCT00918515|Experimental|AZD3043|Intravenous solution
9929596|NCT00918528|Active Comparator|1. Internal urethrotomy|
9929597|NCT00918528|Experimental|2. Internal urethrotomy + mitomycin C|
9929598|NCT00918541||A|asymptomatic patients with mild to moderate carotid artery stenosis
9929599|NCT00918554|Experimental|Methotrexate|
9929600|NCT00918554|Placebo Comparator|Placebo|
9929601|NCT00918593|Experimental|Electrochemotherapy|
9929602|NCT00918593|Active Comparator|radiotherapy|
9929603|NCT00918606|Experimental|LIPO-102|
9929604|NCT00918619|Experimental|Sangustop|
9929605|NCT00918619|Active Comparator|Tachosil|
9929606|NCT00918632|Other|Sequence 1 (ABC)|"The following treatments will be administered in the following order A -> B-> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
9929607|NCT00918632|Other|Sequence 2 (ACB)|"The following treatments will be administered in the following order A -> C -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
9929608|NCT00918632|Other|Sequence 3 (BCA)|"The following treatments will be administered in the following order B -> C -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
9929609|NCT00918632|Other|Sequence 4 (BAC)|"The following treatments will be administered in the following order B -> A -> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
9929610|NCT00918632|Other|Sequence 5 (CAB)|"The following treatments will be administered in the following order C -> A -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
9998313|NCT01516996|Experimental|Neoadjuvant and CCRT and Nimotuzumab|
9875071|NCT00368056|Experimental|1|eszopiclone 3 mg
9875072|NCT00368056|Placebo Comparator|2|Placebo tablet
9875073|NCT00368121|Experimental|Cetuximab + Dexamethasone|
9875074|NCT00368160|Experimental|1|eszopiclone 3 mg
9875075|NCT00368160|Placebo Comparator|2|Placebo tablet
9875076|NCT00368212|Experimental|1|"Participants will receive psychoeducational counseling (termed health care counseling)"
9875077|NCT00368212|Active Comparator|2|Participants will receive relaxation response training
9875078|NCT00368264|Experimental|1|azathioprine plus 4 infusions of infliximab (5 mg/kg)
10211642|NCT04453150|Experimental|Ketogenic diet|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein.
9875079|NCT00368264|Placebo Comparator|2|azathioprine plus 4 placebo infusions
9875080|NCT00368368|Experimental|1|
9875081|NCT00368368|Experimental|2|
9875082|NCT00368368|Experimental|3|
9875083|NCT00368381|Active Comparator|Hydrocortision and fludrocortisone|Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.
9875084|NCT00368511|No Intervention|1|Listening to music and posture changes
9875085|NCT00368602|Experimental|1|This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
9875086|NCT00368602|Placebo Comparator|2|The group will be given standard of care with placebo medication.
9875087|NCT00368706|Experimental|1|
9875088|NCT00368706|Active Comparator|2|
9875089|NCT00368719|No Intervention|1|
9875090|NCT00368771|Active Comparator|1|IBS Stress Management
9875091|NCT00368771|Active Comparator|2|IBS Symptom Management
9875092|NCT00368771|Active Comparator|3|IBS Educational Training
9875093|NCT00368784||1|Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
9875094|NCT00368784||2|Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
9875095|NCT00368901|Experimental|Single arm|Every other week dosing of Aranesp SC
9875096|NCT00368953|Experimental|1|
9875097|NCT00368953|Active Comparator|2|
9875098|NCT00369018|Active Comparator|MAL 3|
9875099|NCT00369018|Active Comparator|MAL 12|
9875100|NCT00369018|Active Comparator|HAL 10, 3|
9875101|NCT00369018|Active Comparator|HAL 10, 12|
9875102|NCT00369018|Active Comparator|HAL 40, 3|
9875103|NCT00369018|Active Comparator|HAL 40, 12|
9875104|NCT00369031|Experimental|1|Human Immunodeficiency Virus glycoprotein 140 (vaccine)
10211643|NCT04437108|Active Comparator|Li-SWT (suprapubic approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through suprapubic approach.
10211644|NCT04437108|Active Comparator|Li-SWT (perineal approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through perineal approach.
10211645|NCT04437108|Active Comparator|Li-SWT (combined approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through suprapubic and perineal approaches during each session.
10211646|NCT04437108|Sham Comparator|Sham treatment|Patients will be treated by 8 sessions of sham treatment with one week interval, applied through suprapubic and perineal approaches.
10211647|NCT04437108|Active Comparator|antimuscarinics|Patients will be treated by solifenacin 10 mg once daily for 6 months.
10211648|NCT04434300|Other|Dapto SC-IV|"First stage :~Subcutaneous injection of daptomycin 10mg/kg~Subcutaneous injection of placebo (physiological serum)~Second stage :~- Intravenous injection of daptomycin 10mg/kg"
10211649|NCT04434300|Other|Dapto IV-SC|"First stage :~- Intravenous injection of daptomycin 10mg/kg~Second stage :~Subcutaneous injection of daptomycin 10mg/kg~Subcutaneous injection of placebo (physiological serum)"
10211650|NCT04433767|Experimental|Transdermal Nicotine Patch|Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.
10211651|NCT04429126|Experimental|4-point acupressure group|"The 5-point acupressure group will be instructed on the following acupressure points: sanyinjiao (SP6), Zu San Li (ST36), shenmen (TF4), Yongquan (KI-1), and He Gu (LI4).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
10211652|NCT04429126|Active Comparator|4 -point acupressure group|"The 2-point acupressure group will be instructed on the following acupressure points: He Gu (LI4) and Tai Chong (LV3).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
10211653|NCT04429126|No Intervention|Usual care|The usual care group will be required to maintain their daily activities. Weekly telephone follow-up will be conducted by principle investigator.
10211654|NCT04428658|Experimental|Home-based video visits|Participants in the intervention arm will receive home-based video visits with a pediatric endocrinologist every 12 weeks for the duration of 1 year in addition to usual care (which includes initial assistance with setting up secure platforms for diabetes data-sharing and usual quarterly in-person care at the UCD Pediatric Diabetes Clinic).
10211655|NCT04428658|Active Comparator|Standard of Care|The control group will receive usual care, which includes initial assistance with setting up secure platforms for diabetes data-sharing and usual quarterly in-person care at the UCD Pediatric Diabetes Clinic.
10211656|NCT04427306|Experimental|Treatment (talimogene laherparepvec)|
9875105|NCT00369031|Active Comparator|2|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant
9875106|NCT00369031|Active Comparator|3|Labile Toxin mutant LTK63 adjuvant
9935378|NCT03827343||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols in the NCI.
9875107|NCT00369174|Experimental|Treatment (rosiglitazone maleate)|Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.
9875108|NCT00369200|Experimental|Arm I|"Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 2-6 patients receive escalating doses of AFP464 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which ≤ 1 of 6 patients experience dose-limiting toxicity. An additional 10 patients whose tumor is amenable to biopsy are treated at the MTD.~Patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies. Patients treated at the MTD also undergo tumor tissue biopsies periodically for additional pharmacodynamic and correlative biomarker studies.~After completion of study treatment, patients are followed for 4 weeks."
9875109|NCT00369291|Experimental|CpG 7909|Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
9875110|NCT00369356|Sham Comparator|1|Bare Metal Stenting
9875111|NCT00369356|Active Comparator|2|Stenting with DES
9875112|NCT00369356|Experimental|3|Bare metal stenting and administration of prednisone
9875113|NCT00369395|Experimental|Volociximab|Volociximab 15 mg/kg
9875114|NCT00369408|Experimental|1|naltrexone (50 mg orally) for 12-week treatment period
9875115|NCT00369408|Placebo Comparator|2|placebo for 12-week treatment period
9875116|NCT00369447|Experimental|1|200 mg dose
9875117|NCT00369447|Placebo Comparator|2|
9875118|NCT00369538|Active Comparator|1|losartan, hydrochlorothiazide
9875119|NCT00369538|Active Comparator|2|hydrochlorothiazide, losartan
9875120|NCT00369551|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab, radiation)|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.~Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
9875121|NCT00369603|Experimental|Razadyne ER|galantamine treatment group
9875122|NCT00369603|Experimental|Aricept|Aricept Treatment Group
9875123|NCT00369616|Experimental|NicQb vaccine|
9875124|NCT00369616|Placebo Comparator|Placebo vaccine|
9875125|NCT00369694|Active Comparator|1|72 hours of Terlipressin
9875126|NCT00369694|Placebo Comparator|2|24 hours of Terlipressin & then next 48 hours of Dummy of Terlipressin
9875127|NCT00369733|Experimental|Single arm|Aranesp adminsitered every other week for 52 weeks
9875128|NCT00369759||1|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
9875129|NCT00369759||2|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
9875130|NCT00369759||3|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
9875131|NCT00369837|Experimental|clevidipine|A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.
9875132|NCT00369850|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomisation.
9987560|NCT01413984|No Intervention|comparison group|a comparison group of incarcerated women will receive the pre and post assessments with no interventions.
9987561|NCT01413997||Chronic Low Back Pain|
9987562|NCT01413997||No Low Back Pain|
9987563|NCT01414023|Experimental|CCT|Cognitive Control Training - Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
9987564|NCT01414023|Placebo Comparator|PVT|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
9987565|NCT01414049|Experimental|On-pump CABG|
9987566|NCT01414049|Experimental|Off-pump CABG|
9987567|NCT01414062|Active Comparator|Arm A|Participants receiving written dietary recommendations for breast cancer survivors (control arm)
9987568|NCT01414062|Experimental|Arm B|Participants attending Cocinar Para Su Salud Program held over a 12-week period
9987569|NCT01414088|Placebo Comparator|glucose|glucose 5 %
9987570|NCT01414088|Active Comparator|isotonic saline|isotonic saline 0.9 mg/ml
9987571|NCT01414088|Active Comparator|hypertonic saline|hypertonic saline 2.9 mg/ml
9987572|NCT01414101|Experimental|Group A|Dose 1 ISIS CRP Rx versus Placebo
9987573|NCT01414101|Experimental|Group B|Dose 2 ISIS CRP Rx versus Placebo
9987574|NCT01414101|Experimental|Group C|Dose 3 ISIS CRP Rx versus Placebo
9987575|NCT01414140||Group 1|
9987576|NCT01414218|Experimental|Humor as Way of Life Seminar|See description of study in previous section for further details.
9987577|NCT01414231|Active Comparator|Cytarabine low dose|This is the golden standard of AML treatment
9987578|NCT01414231|Active Comparator|Cytarabine intermediate dose|This is the OSHO internal arm
9987579|NCT01414283|Experimental|Arm 1|
9987580|NCT01414296|Experimental|Arm 1|
9987581|NCT01414309||Observational patients|Heart Failure patients with moderate to severe central sleep apnea
9987582|NCT01414322||Group 1: Patients ages 0 - 3|
9987583|NCT01414322||Group 2: Patients ages 3 - 7|
9987584|NCT01414322||Group 3: Patients ages 7 - 15|
9987585|NCT01414335|Placebo Comparator|placebo|
9987586|NCT01414335|Active Comparator|amino acid composition|
9987587|NCT01414348|Active Comparator|Conventional rehabilitation|In-home work on problems in daily living.
9987588|NCT01414348|Experimental|Novel rehabilitation approach|
9987589|NCT01414361||intermediate lesion|intermediate lesions evaluated by both IVUS and FFR
9987590|NCT01414374|Active Comparator|Iron|
9987591|NCT01414374|Experimental|Herbal|
9987592|NCT01414387|Active Comparator|Carotid filter|For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
9987593|NCT01414387|Active Comparator|Carotid reversal of flow|For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.
9987594|NCT01414439||Congestive Heart Failure Patients|40 patients diagnosed with heart failure at levels III and IV, according to the classification of the NYHA will participate in the research. The researchers will randomly allocate the patients to the treatment group or the control group. The subjects in the treatment group will participate in Existential Group Therapy, while the subjects in the control group will not participate in the treatment until after the completion of the study. Psychological data will be collected in the form of a self-reported questionnaire completed by all participants prior to the beginning of the research and again upon completion of the final group session.
9987595|NCT01414452||STEMI patients|Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI
9987596|NCT01414465|No Intervention|low caloric diet|10 health obese women (BMI 30 to 40 kg/m2)
9987597|NCT01414465|Experimental|Orlistat|10 obese women treated with Orlistat 120mg 3 times per day
9987598|NCT01414465|Sham Comparator|lifestyle counseling|Women with BMI < 30 kg/m2, no taking drug in study
9987599|NCT01414478|Active Comparator|High Protein Shake|Protein shake that contain 30 grams of protein in 11 fluid ounces.
9987600|NCT01414478|No Intervention|Ice Chips|Patients allowed consumption of ice chips only during labor.
9987601|NCT01414504|Active Comparator|Neonatal PCV + PPV 9 months|Group 1: Children receiving 7VPCV at 0-1-2 months of age and PPV at 9 months of age
9987602|NCT01414504|Active Comparator|Infant PCV + PPV at 9 months|Group 2: Children receiving 7VPCV at 1-2-3 months of age and PPV at 9 months of age
9987603|NCT01414504|Active Comparator|No PCV + PPV at 9 months|Group 3: Children who only received PPV at 9 months of age
9987604|NCT01414504|Active Comparator|Control|Group 4: Children who have not received any previous pneumococcal vaccine
9987605|NCT01414517|Active Comparator|FOS|Prebiotic (FructoOligoSaccharide-FOS.
9987606|NCT01414517|Placebo Comparator|Placebo|Maltodextrin (non-prebiotic carbohydrate).
9987607|NCT01414530|Experimental|oral contraceptive|
9987608|NCT01414530|Active Comparator|NSAID|
9875133|NCT00369850|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomisation.
9875134|NCT00369850|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
9875135|NCT00369850|Experimental|Letrozole 2 years plus tamoxifen 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
9875136|NCT00370084|Placebo Comparator|Placebo|
9875137|NCT00370084|Experimental|Itopride|
9929611|NCT00918632|Other|Sequence 6 (CBA)|"The following treatments will be administered in the following order C -> B -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
9929612|NCT00918658||Patients with hematologic cancer|Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
9929613|NCT00918658||Patients without cancer|Patients who do not have cancer.
9935379|NCT03825718|Experimental|CAR-T treatment group|The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
9935380|NCT03824561||Vedolizumab 300 mg|Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
9935381|NCT03814889|Active Comparator|Vibration pattern 1|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935382|NCT03814889|Active Comparator|Vibration pattern 2|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935383|NCT03814889|Active Comparator|Vibration pattern 3|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935384|NCT03814889|Active Comparator|Vibration pattern 4|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935385|NCT03814889|Active Comparator|Vibration pattern 5|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935386|NCT03814889|Active Comparator|Vibration pattern 6|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935387|NCT03814889|Active Comparator|Vibration pattern 7|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935388|NCT03814889|Active Comparator|Vibration pattern 8|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935389|NCT03814889|Active Comparator|Vibration pattern 9|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935390|NCT03814889|Active Comparator|Vibration pattern 10|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
9935391|NCT03814889|Placebo Comparator|No vibration|A light will blink instead of a vibration pattern being displayed.
9935392|NCT03811015|Experimental|Arm A (cisplatin, IMRT, nivolumab)|Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions. Within 4 weeks after completion of concurrent therapy, patients receive nivolumab IV once weekly over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
9935393|NCT03811015|Active Comparator|Arm B (cisplatin, IMRT, observation)|"Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions, and then go on observation.~Patients will be offered the option to cross-over to Arm C if they have clearly documented progression within 12 months from the end of cisplatin/radiation therapy."
9935394|NCT03811015|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
9935395|NCT03805932|Experimental|1 - Dose Escalation|Moxetumomab Pasudotox-tdfk + Rituximab
9935396|NCT03805932|Experimental|2- Dose Expansion|Moxetumomab Pasudotox-tdfk + Ruxience
9935397|NCT03805919||Cohort 1|Participants with germline pathogenic or likely pathogenic variants in prostate cancer-related risk genes
9935398|NCT03801915|Experimental|1/Arm 1|Pre-operative escalation doses of MVT-5873,pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
9935399|NCT03801915|Experimental|2/Arm 2|Pre-operative RD of MVT-5873, pancreatectomy orhepatectomy and post-operative MVT-5873 treatment
10211657|NCT04423588|Other|Dexlansoprazole|The PPI Dexilant (active substance: dexlansoprazole) is administered to the study participants in a prophylactic Regimen for 6 months after the PRYGB-surgery. This drug is already approved by Swissmedic and on the markets in Switzerland. The dosage is 1 capsule 60 mg per os daily in the morning.
9935923|NCT02977403|Sham Comparator|AB Control|Control condition - the probe is equally likely to replace the food picture and the neutral picture. There is no correlation between picture type and probe location, and no training of attention should occur.
10211658|NCT04421482|Other|Very Low Birth Weight Preterm Infants|Very Low Birth Weight Preterm Infants (birth weight less than 1,500g and less than 32 weeks gestation) admitted to NYU Winthrop NICU. (n=42)
10211659|NCT04411849|Experimental|Group I (early intervention)|During year 2, participants receive the HPV self-testing intervention consisting of mailed HPV self-test devices. Participants also receive an information about cervical cancer. Participants who do not return their self-test within a few weeks receive telephone-based patient navigation. Participants then complete a satisfaction survey and have their medical record reviewed. During years 3-5, this intervention is repeated among women who remain unscreened/underscreened.
9987609|NCT01414543|Other|providing information sheet|providing participants with information regarding the purpose of the research
9987610|NCT01414543|Other|Seeking consent|
9987611|NCT01414543|Other|Interview Participant|
9987612|NCT01414543|Other|Debrief|The Participants will be debriefed after the interview.
9987613|NCT01414556|Experimental|hyperglycemia|
9987614|NCT01414556|Experimental|fasting glycemia|
9987615|NCT01414556|Experimental|hypoglycemia|
9987616|NCT01414569|Active Comparator|8 mg dexamethasone|
9987617|NCT01414569|Placebo Comparator|Placebo, saline|
9987618|NCT01414569|Experimental|40 mg dexamethasone|
9987619|NCT01414582|Experimental|Anodal tDCS and Motor Training|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
9987620|NCT01414582|Sham Comparator|Sham tDCS and Motor Training|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
9987621|NCT01414595||Group 1|CALGB 140202 outlines the standard procedures for sample procurement. Samples to be used for this project have already been obtained and are currently banked at the CALGB Pathology Coordinating Office (PCO) and the Lung Cancer Tissue Bank at Brigham and Women's Hospital.
9987622|NCT01414608|Experimental|Arm I (cisplatin, radiation therapy, brachytherapy)|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.
9987623|NCT01414608|Experimental|Arm II (cisplatin, radiation therapy, brachytherapy, chemo)|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9987624|NCT01414621||CABG patients|atrial tissue samples from CABG patients
9987625|NCT01414647|Experimental|SRC|Strawberry, raspberry and cloudberry intervention for 8 weeks
9987626|NCT01414647|Experimental|BB|Bilberry intervention for 8 weeks
9987627|NCT01414647|Experimental|C|Control diet with restricted berry consumption
9987628|NCT01414660||islet|type 1 diabetic patients undergoing islet transplantation
9987629|NCT01414660||liver|non diabetic patients undergoing a liver transplantation
9987630|NCT01414660||kidney|non diabetic patients undergoing a kidney transplantation
9987631|NCT01414673|Other|spontaneous LH|
9987632|NCT01414673|Experimental|HCG|
9987633|NCT01414686|Experimental|Immediate Treatment Group|
9987634|NCT01414686|No Intervention|Delayed Treatment Group|
9987635|NCT01414699|Active Comparator|One-Course, Variety|Participants will receive a snack in one course with a variety of fruit.
9987636|NCT01414699|Active Comparator|Two-Course, Variety|Participants will receive a snack in two courses with a variety of fruit.
9987637|NCT01414699|Active Comparator|One-course, Non-Variety|Participants will receive a snack in one course with no variety of fruit.
9796973|NCT01582308|Experimental|Treatment Sequence 7|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
9987638|NCT01414699|Active Comparator|Two-Course, Non-Variety|Participants will receive a snack in two courses with no variety of fruit.
9987639|NCT01414712||prostate cancer patients|
9987640|NCT01414725|Experimental|Core Stability Training|
9987641|NCT01414725|Placebo Comparator|Relaxation|
9987642|NCT01414725|Active Comparator|Standard Physiotherapy Exercises|
9987643|NCT01414751|Active Comparator|Absolute risk reduction information|Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
9987644|NCT01414751|Active Comparator|Prolongation of life information|Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
9987645|NCT01414764|Active Comparator|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The red blood cells will be discarded, and the supernatant containing ACP (with additional CaCl to activate the ACP and local anaesthetic) is injected into the tendon bone junction and adjacent area under ultrasound guidance. No adverse consequences are anticipated by using the Arthrex ACP injection.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively~Other Names:~Platelet rich plasma (PRP)"
9987646|NCT01414764|Placebo Comparator|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
9987647|NCT01414790|Experimental|ADM group|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
9987648|NCT01414790|No Intervention|control group|41 patients (control group) had a total parotidectomy alone
9987649|NCT01414803|Experimental|rosuvastatin/fenofibrate combination|rosuvastatin 10 mg/fenofibrate 160 mg per day
9987650|NCT01414803|Active Comparator|rosuvastatin monotherapy|rosuvastatin 10 mg per day
9987651|NCT01414816||Group 1|
9987652|NCT01414842|Active Comparator|Standard|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
9875138|NCT00370097|Experimental|Subjects receiving HFA|Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily
9875139|NCT00370110|Experimental|Itopride|
9875140|NCT00370110|Other|Placebo|
10211660|NCT04411849|Active Comparator|Group II (delayed intervention)|During year 2, participants receive usual care consisting of a reminder letter to get a clinic-based cervical cancer screening test and information about cervical cancer. During years 3-5, participants receive the HPV self-testing intervention described for Group I.
9875141|NCT00370240|Experimental|Ropivacaïne|
9875142|NCT00370240|Placebo Comparator|placebo|
9875143|NCT00370253|Active Comparator|2|Terlipressin
9875144|NCT00370253|Experimental|1|Noradrenalin
9875145|NCT00370279|Active Comparator|1|scleral buckling
9875146|NCT00370279|Active Comparator|2|Primary vitrectomy without encircling band
9875147|NCT00370279|Active Comparator|3|Primary vitrectomy with encircling band
9875148|NCT00370279|Active Comparator|4|Triamcinolone assisted vitrectomy
10211661|NCT04408417|Experimental|Harnessing Sequence A|Participants will harness their child into the 2 different child safety seats in the following order: control, prototype, prototype, control.
10211662|NCT04408417|Experimental|Harnessing Sequence B|Participants will harness their child into the 2 different child safety seats in the following order: prototype, control, control, prototype.
10211663|NCT04408417|Experimental|Harnessing Sequence C|Participants will harness their child into the 2 different child safety seats in the following order: control, control, prototype, prototype.
10211664|NCT04408417|Experimental|Harnessing Sequence D|Participants will harness their child into the 2 different child safety seats in the following order: prototype, prototype, control, control.
10211665|NCT04407377|Experimental|Tolperisone 200 mg|Study Drug, Tolperisone 200mg TID
10211666|NCT04407377|Experimental|Tolperisone 400 mg|Study Drug, Tolperisone 400mg TID
10211667|NCT04407377|Active Comparator|Cyclobenzaprine|Active Comparator, Cyclobenzaprine 10mg TID
9875149|NCT00370305|Experimental|Rosiglitazone treatment|Rosiglitazone will be given to the subjects. All subjects will be analyzed before and after treatment
9875150|NCT00370344|Active Comparator|Laparoscopic cholecystectomy|Operation by experts in laparoscopy.
9875151|NCT00370344|Active Comparator|Small-incision open cholecystectomy|Operation by experts in small-incision cholecystectomy.
9875152|NCT00370370|Active Comparator|1|Injection of intravitreal bevacizumab
9875153|NCT00370370|Active Comparator|2|Injection of bevacizumab + triamcinolone acetonide
9875154|NCT00370409|Experimental|1|Cryotherapy
9875155|NCT00370409|Placebo Comparator|2|
9875156|NCT00370448|Experimental|1|Training gatekeeper recruited from students and tutors and counselors
9875157|NCT00370448|Active Comparator|2|
9875158|NCT00370448|No Intervention|3|
9875159|NCT00370500|Experimental|A|There is only one arm in this study. All probands receive quetiapine.
9875160|NCT00370513|Experimental|Pazopanib Arm|Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
9875161|NCT00370591|Experimental|Arm 1|
9875162|NCT00370604|Experimental|1|19g needle, 23g catheter
9875163|NCT00370604|Active Comparator|2|traditional =>18g needle
9875164|NCT00370721|Experimental|I|
9875165|NCT00370747|Experimental|Ecabet|Ophthalmic solution in the Study eye four times daily for 90 days.
9875166|NCT00370747|Placebo Comparator|Placebo|Ophthalmic solution in the Study eye four times daily for 90 days.
9875167|NCT00370760|Active Comparator|1|
9875168|NCT00370760|Placebo Comparator|2|
9875169|NCT00370786|Experimental|1|
9875170|NCT00370799|Active Comparator|local anesthetic|Group 1. local anesthetics only
9875171|NCT00370799|Active Comparator|Local anesthetic with generic Celestone|Group 2. local anesthetic with 6mg of non-particulate Celestone
9875172|NCT00370799|Active Comparator|Local anesthetic with Celestone|Group 3. local anesthetic with 6 mg of brand nameCelestone
9875173|NCT00370799|Active Comparator|Local anesthetic with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
9875174|NCT00370812|Active Comparator|A|AMT with conventional medical therapy
9875175|NCT00370812|Active Comparator|B|Medical treatment alone
9875176|NCT00370851|Experimental|1|Intravitreal injection of Avastin
9875177|NCT00370851|Sham Comparator|2|
9875178|NCT00370877|Active Comparator|Standard care for post-partum hemorrhage|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
9875179|NCT00370877|Experimental|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
9875180|NCT00370916|Experimental|Arm 1|Physician-initiated medication reconciliation
9875181|NCT00370916|Experimental|Arm 2|Pharmacist-initiated medication reconciliation
9875182|NCT00370916|No Intervention|Arm 3|No formal medication reconciliation
9875183|NCT00370929|Experimental|Meditation|
9875184|NCT00370942|Placebo Comparator|GW823093C A|A=45 mg
9875185|NCT00370942|Placebo Comparator|GW823093C B|B=30 mg
9875186|NCT00370942|Placebo Comparator|GW823093C C|C=15 mg
9875187|NCT00370955|Active Comparator|High vacuum group|Those patients who underwent phacoemulsification using high hydrodynamic parameter: 400 mmHg vacuum and 40 ml/min flow rate.
10211668|NCT04407377|Placebo Comparator|Placebo|Placebo, TID
10211669|NCT04397796|Experimental|BM-Allo.MSC|Subjects in the experimental arm will be administered BM-Allo.MSC
10211670|NCT04397796|Placebo Comparator|Placebo|Subjects in the control arm will be treated with placebo
10211671|NCT04396756|Experimental|Placebo|Placebo
10211672|NCT04396756|Experimental|PLN-74809 Dose Level 1 (Part A)|PLN-74809 Dose Level 1 (Part A) - 4 weeks
10211673|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part A)|PLN-74809 Dose Level 2 (Part A) - 4 weeks
9875188|NCT00370955|Active Comparator|Low vacuum group|Patients who underwent phacoemulsification using low hydrodynamic parameters: 200 mmHg vacuum and 20 ml/min flow rate.
9875189|NCT00371033|Active Comparator|1|Pregabalin
9875190|NCT00371033|Placebo Comparator|2|Placebo
9875191|NCT00371085|Experimental|1|Video-based patient education on heart failure self care
9875192|NCT00371098|Experimental|active vaccine|patients received active influenza vaccine for season 2004/2005
9875193|NCT00371098|Placebo Comparator|placebo vaccine|patients received placebo influenza vaccine for season 2004/2005 containing all vaccine compounds except viral antigens
9875194|NCT00371111|Active Comparator|1|Intravitreal injection of Triamcinolone
9875195|NCT00371111|Active Comparator|2|Intravitreal injection of Avastin
9875196|NCT00371163||Contact Dermatitis|Males or females with contact dermatitis
9875197|NCT00371163||Psoriasis|Males or females with psoriasis
9875198|NCT00371163||No skin disease|Males or females with no skin diseases
9875199|NCT00371163||Atopic Dermatitis|Males of females with atopic dermatitis
9875200|NCT00371189|Experimental|Group C: Ad35.CS.01-10^10 vp/ml|15 subjects will receive dosage 10^10 vp/mL; 3 subjects will receive placebo.
9875201|NCT00371189|Experimental|Group D: Ad35.CS.01-10^11 vp/ml|15 subjects will receive dosage 10^11 vp/mL; 3 subjects will receive placebo.
9875202|NCT00371189|Experimental|Group A: Ad35.CS.01-10^8 vp/ml|15 subjects will receive dosage 10^8 vp/mL; 3 subjects will receive placebo.
9875203|NCT00371189|Experimental|Group B: Ad35.CS.01-10^9 vp/ml|15 subjects will receive dosage 10^9 vp/mL; 3 subjects will receive placebo.
9875204|NCT00371215|Experimental|1|rThrombin
9875205|NCT00371228|Experimental|1|Umbilical cord not cut until pulsation stops, in order to provide additional blood to newborn.
10211674|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part B)|PLN-74809 Dose Level 2 (Part B) - 12 weeks
10211675|NCT04396756|Experimental|PLN-74809 - Dose Level 3 (Part C)|PLN-74809 Dose Level 3 (Part C) - 12 weeks
9875206|NCT00371228|No Intervention|2|Umbilical cord cut soon after birth without waiting for pulsing to stop.
9875207|NCT00371280|Active Comparator|1|Pegged unpegged hydroxyapatite orbital implantation
9875208|NCT00371280|Active Comparator|2|Unpegged hydroxyapatite orbital implantation
9875209|NCT00371319|Active Comparator|Tacrolimus|Tacrolimus treatment
9875210|NCT00371319|Active Comparator|mycophenolate mofetil|mycophenolate mofetil
10211676|NCT04396756|Experimental|PLN-74809 - Dose Level 4 (Part C)|PLN-74809 Dose Level 4 (Part C) - 12 weeks
10211677|NCT04379050|Experimental|ABBV-951|Participants will receive ABBV-951 solution by continuous subcutaneous infusion (CSCI), at the discretion of the investigator, for up to 144 weeks.
10211678|NCT04375085|Other|DESyne X2 Novolimus Eluting Coronary Stent System|
10211679|NCT04373434|Experimental|Healthy Homes/Healthy Families (HH/HF) Intervention|Participants randomized to the HH/HF study intervention will work with a coach through phone calls and text messages for 12 weeks to set goals targeting home-based environmental determinants of dietary behaviors.
10211680|NCT04373434|Active Comparator|Control|Participants in the control condition will receive two mailings which focus on the same dietary outcomes as the HH/HF intervention but without the home environment emphasis.
9875211|NCT00371371|Experimental|BM-MNC|autologous bone marrow-derived mononuclear cells
9875212|NCT00371371|Placebo Comparator|Placebo|Placebo
9875213|NCT00371384|Experimental|2|structural massage
9875214|NCT00371384|Experimental|1|relaxation massage
9875215|NCT00371423|Experimental|Arm 1|
9875216|NCT00371423|Other|Arm 2|Control data derived from ATLAS Workhorse Trial
9875217|NCT00371475|Experimental|Arm 1|
9875218|NCT00371475|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V clinical trials
9875219|NCT00371488|Experimental|GW572016 in combination with trastuzumab|"Lapatinib:~A specified dose of lapatinib will be orally taken once daily, at least one hour before or one hour after the morning meal. Lapatinib should be taken at the same time of day wherever possible.~The starting dose of lapatinib should be 750 mg/day, which will be increased to 1000 mg/day (dose escalation group) according to the dose escalation criteria.~Trastuzumab:~Trastuzumab (4 mg/kg/day in the first week and 2 mg/kg/day for the 2nd and subsequent weeks) will be administered by intravenous infusion over at least 90 minutes immediately after administration of lapatinib. The fifth (Day 36) and subsequent doses may be administered up to 3 days after the scheduled date. In this case, however, the all following doses should be administered at one-week intervals."
9875220|NCT00371501|Active Comparator|treatment arm 1|
9875221|NCT00371501|Placebo Comparator|Treatment arm 2|
9875222|NCT00371501|Active Comparator|treatment arm 3|aspirin
9875223|NCT00371501|Placebo Comparator|treatment arm 4|placebo
9875224|NCT00371592|Experimental|1|Participants will receive acyclovir for 24 weeks
9875225|NCT00371592|Placebo Comparator|2|Participants will receive acyclovir placebo for 24 weeks
9875226|NCT00371709|Experimental|Arm 1|
9875227|NCT00371709|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
9875228|NCT00371735|Experimental|Arm 1|
9875229|NCT00371748|Experimental|Arm 1|
9987653|NCT01414842|Experimental|Automated profiled|Automate sodium profiling in endogenous hemodiafiltration
10211681|NCT04368845|Active Comparator|Experimental Intervention Arm: Telerehabilitation|The treatment arm will be given up to 1-hour resistive training exercises, breathing exercises and aerobic exercises administered by an expert physiotherapist via teleconference (telerehabilitation). Every ten days one physiotherapist will record the individualized exercise program, will reevaluate the magnitude of exercise for each patient and reinforce to continue or increase exercise magnitude.
10211682|NCT04368845|No Intervention|No Intervention: Conventional teleconference|The usual care arm will receive standard communication via teleconference every ten days for a six-month period without any specific recommendations and exercise prescription for home training. The control arm will be subject to the same assessments as the experimental arm at the start, and at the 3 and 6 months period.
9875230|NCT00371748|Other|Arm 2|Historical Comparator: control data derived from a TAXUS V de novo lesion and stent size-matched cohort randomized to receive a single, planned 2.25 mm DES
9875231|NCT00371748|Other|Arm 3|Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS
9875232|NCT00371774||1|Dermatologic patients in Canada for which Amevive is clinically indicated
9929614|NCT00918697|Active Comparator|Mechanical debridment|In this arm, corneal epithelium was removed during PRK using conventional mechanical method.
9929615|NCT00918697|Experimental|Alcohol-asstisted debridement|In this arm, corneal epithelium was removed using ethanol 20% during PRK.
9929616|NCT00918710||1|Patients with oropharyngeal squamous cell carcinomas
9929617|NCT00918762|Experimental|daVinci® Robotic Surgical System|Participants will undergo a planned surgical procedures via the robotic approach.
9929618|NCT00918801||Type 1 Diabetes Mellitus|Adolescents ages 13-18 with T1DM
9929619|NCT00918801||Non Controls|Healthy adolescents ages 13-18 without T1DM
9929620|NCT00918840||DermaVir + HAART|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every 4 weeks~Duration: 8 weeks (3 DermaVir treatments)"
9929621|NCT00918840||Placebo + HAART|"Dosage form: 3.2 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every four weeks~Duration: 8 weeks (3 Placebo treatments)"
9929622|NCT00918853|Experimental|resection for adenocarcinoma|quality standard resection for adenocarcinoma of the head of the pancreas
9929623|NCT00918905|Experimental|1 Telemonitor|Within 24 hours after the patient was discharged the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with a doctor. The patient was planned to have the equipment for approximately one week and had at least one follow-up phone call within the four weeks period. Telemonitoring video conferences could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period of time (hot-line).
9929624|NCT00918905|No Intervention|Control group|No tele-monitor at home. The COPD patients discharged after an acute exacerbation living outside Svendborg or Faaborg-Midtfyn municipalities in the recruiting area were included in the control group and assigned to conventional care.
9929625|NCT00918918|Experimental|Treatment B|Vodka + orange juice
9929626|NCT00918918|Placebo Comparator|Treatment A|Orange juice
9929627|NCT00918944|Other|Control arm|Practices with the EHR implemented will be randomized have the asthma disease management tools available passively (the control group).
9929628|NCT00918944|Other|Intervention arm|The intervention sites will have decision support alerts and reminders activated to guide providers toward these tools in the appropriate situations.
9929629|NCT00918970||SNA group|This group will have a real-time analysis of autonomic nervous system activity during its intensive care hospitalisation
9929630|NCT00918970||Clinical group|This group will have a conventional clinical analysis during its intensive care hospitalisation
9929631|NCT00918996|Experimental|No Bladder Flap Group|Uterine incision made 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
9929632|NCT00918996|No Intervention|Bladder Flap Group|Standard cesarean section technique with incision and dissection of a bladder flap prior to uterine incision.
9929633|NCT00919009|Experimental|Sorafeinb|Oral sorafenib (400 mg BID) will be start the 3 day after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
9929634|NCT00919022||Group 1|
9929635|NCT00919048||Urodynamic patients|Uroflow studies of patients who underwent urodynamics as part of an incontinence work-up.
9929636|NCT00919074|Active Comparator|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
9929637|NCT00919074|Active Comparator|Pancreatic wire|Placement of a guidewire into the pancreatic duct to facilitate bile duct cannulation.
9987654|NCT01414881|Experimental|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
9875233|NCT00371904|Experimental|1|
9875234|NCT00371904|Active Comparator|2|
9875235|NCT00371956|Active Comparator|1|raloxifene
9875236|NCT00371956|Placebo Comparator|2|placebo arm
9875237|NCT00371969|Active Comparator|1 - enhanced MI|Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes)
9875238|NCT00371969|Active Comparator|2- standard MI|The intervention consists of a standard motivational interview or viewing a DVD on HIV self-care.
9875239|NCT00371995|Experimental|1|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
9875240|NCT00372125|Active Comparator|Norditropin SimpleXx|0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
9875241|NCT00372125|Placebo Comparator|Placebo|Placebo for 12 months
9875242|NCT00372138|Experimental|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
9875243|NCT00372151|Experimental|L-Theanine|
9875244|NCT00372151|Placebo Comparator|Placebo|
9875245|NCT00372177|Active Comparator|EP1645|Single-Dose
9875246|NCT00372203|Experimental|Endobronchial ultrasound|
9875247|NCT00372216|Active Comparator|1|Pre-hospital loading dose of 600 mg Clopidogrel as early as possible (in addition to standard infarction therapy)
9875248|NCT00372216|No Intervention|2|Standard infarction therapy (without study-specific additions, no Clopidogrel before angiography)
9875249|NCT00372229|Experimental|Valganciclovir Cytomegalovirus (CMV) Prophylaxis|
9875250|NCT00372229|Active Comparator|Pre-emptive CMV Therapy|
9875251|NCT00372268|Active Comparator|B|Administration of ropivacaïne 0,2% by direct intra-abdominal administration at the end of the surgery
9875252|NCT00372268|Active Comparator|C|Administration of ropivacaïne 0,75% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
9875253|NCT00372268|Placebo Comparator|A|Administration of Nacl 0,9% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
9875254|NCT00372268|Placebo Comparator|D|Administration of Nacl 0,9% by direct intra-abdominal administration at the end of the surgery
9875255|NCT00372281|Experimental|Cliavist|
9875256|NCT00372294|Active Comparator|1|Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
9875257|NCT00372294|Active Comparator|2|Intravitreal Clindamycin & Dexamethasone
9875258|NCT00372476|Experimental|Imatinib + Vinorelbine|
9875259|NCT00372502|Active Comparator|1|
9875260|NCT00372502|Experimental|2|
9875261|NCT00372515|Experimental|High dose gefitinib|
9875262|NCT00372632|Placebo Comparator|placebo|
9875263|NCT00372632|Experimental|sulfadoxine-pyrimethamine|
9875264|NCT00372645|Experimental|Diet|200 µg folate per day from folate-rich foods
9875265|NCT00372645|Experimental|Folic acid supplement|200 µg folate per day from supplemental folic acid
9875266|NCT00372645|Experimental|Metfolin supplement|200 µg folate per day from supplemental Metafolin®
9875267|NCT00372645|Placebo Comparator|Placebo|Placebo
9875268|NCT00372684||1|with severe malaria hospitalized in ICU
9875269|NCT00372684||2|with uncomplicated malaria
9875270|NCT00372762|Active Comparator|Furosemide|Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
9875271|NCT00372762|Active Comparator|Bumetanide|Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
9875272|NCT00372788|Active Comparator|1|Pemetrexed
9875273|NCT00372788|Experimental|2|AZD6244
9875274|NCT00372814|Experimental|Multisystemic Therapy (MST)|Adolescents receiving MST will receive Intensive Home-Based Family Therapy which will consist of home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their daily diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
9875275|NCT00372814|Active Comparator|Telephone Support Calls|Adolescents receiving Supportive Telephone Calls (TS) will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
9935924|NCT02977403|Experimental|AB Retraining|Active treatment - the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
9875276|NCT00372840|Experimental|Arm I|Patients receive a specific print intervention manual entitled Facing Forward Series: Life After Cancer Treatment and a general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
9875277|NCT00372840|Active Comparator|Arm II|Patients receive the general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
9875278|NCT00372853|Experimental|Arm A|
9875279|NCT00372853|Experimental|Arm B|
9875280|NCT00372879|Experimental|Crossover group 1|Vitamin E first and placebo second
9875281|NCT00372879|Experimental|Crossover group 2|Placebo first then vitamin E
9875282|NCT00372892|Active Comparator|A|Rituximab
9875283|NCT00372892|Placebo Comparator|B|Saline placebo iv infusion
9875284|NCT00372918|Other|1|Transnasal Esophagoscopy
9875285|NCT00373009|Experimental|Core stabilization and psychosocial education|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale. In addition, a psychosocial education program (PSEP) will be used for this group.
9875286|NCT00373009|Active Comparator|Core stabilization exercise only|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale.
10211683|NCT04354922|Placebo Comparator|Attention control|Subjects in this group will receive one session of 75 minutes stretching exercise per week throughout the 12 weeks experimental period
10211684|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 50 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
10211685|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 150 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
10211686|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 25 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
9875287|NCT00373009|Active Comparator|Psychosocial education class only.|A psychosocial education program (PSEP) will be used in this group.
9875288|NCT00373009|Other|Traditional Army training|Traditional Army training will be used in this group.
9875289|NCT00373048|Placebo Comparator|Placebo, tablet|
9875290|NCT00373048|Experimental|mefloquine, tablet|
9875291|NCT00373061||Pregnant Women Exposed to Xolair®|Women who are exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies.
9875292|NCT00373074|Active Comparator|15 cc|15 cc of blood used for Epidural Blood Patch
9875293|NCT00373074|Active Comparator|20 cc|20 cc of blood used for Epidural Blood Patch
9875294|NCT00373074|Active Comparator|30 cc|30cc of blood used for Epidural Blood Patch
9875295|NCT00373087|Active Comparator|L-dopa + entacapone|L-dopa + entacapone
9875296|NCT00373087|Experimental|L dopa / placebo|L dopa / placebo
9875297|NCT00373100|Experimental|Zinc|Zinc acetate
9875298|NCT00373100|Placebo Comparator|Placebo|Placebo
9875299|NCT00373152|Experimental|RadioFrequency Ablation for Breast Cancer|
9875300|NCT00373178|Active Comparator|Metformin,lifestyle counselling|
9875301|NCT00373204|Experimental|Xcytrin® (motexafin gadolinium)|
9875302|NCT00373217|Experimental|Group 1|Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
9875303|NCT00373217|Experimental|Group 2|Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.
9875304|NCT00373230|Experimental|1|Internet based telemedicine weight maintenance program
9875305|NCT00373230|Active Comparator|2|In person weight maintenance monthly consultations
10211687|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 75 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
9875306|NCT00373243|Experimental|Subjects receiving GW406381|Subjects will receive single oral dose of 20 milligram (mg) of GW406381.
9875307|NCT00373373|Placebo Comparator|A|Chemotherapy + Placebo
9875308|NCT00373373|Active Comparator|B|Chemotherapy + Sorafenib
9875309|NCT00373438|No Intervention|A|
9875310|NCT00373438|Experimental|B|Fetoscopic tracheal occlusion
9875311|NCT00373451|Experimental|Abciximab+UFH|Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI
9875312|NCT00373451|Active Comparator|Bivalirudin|Bivalirudin given only during PCI
9875313|NCT00373503|Experimental|lofexidine, dronabinol, marijuana|lofexidine (.6 mg qid), dronabinol (20 mg tid)
9875314|NCT00373581|Experimental|Vigabatrin, cocaine|
9875315|NCT00373581|Placebo Comparator|placebo, cocaine|
9875316|NCT00373607|Experimental|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
10211688|NCT04341194|No Intervention|Standard care with glucose|Control Group with standard care comprises facilitated tucking done by a nurse or the parent, oral glucose (300 mg/ml) and the opportunity to suck on a pacifier or on a parent's or a nurse's plastic gloved finger. The infant is placed on an examination table for the venipuncture.
9875317|NCT00373607|Active Comparator|Mefloquine + Artesunate (MAS3)|The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
9875318|NCT00373633|Experimental|Continuous extra-pleural intercostal local anesthesia|intra-operatively placed extrapleural intercostal catheter
9875319|NCT00373633|Active Comparator|Thoracic Epidural|gold standard
9929638|NCT00919165||control and study group|severe carotid artery stenosis in asymptomatic patients defined as greater than 80% stenosis angiographically or greater than 400 cm/sec peak systolic velocity on carotid doppler evaluation
9929639|NCT00919178|Experimental|1|Participants will receive a single immunization for Dengue virus serotype 4 (DEN4)
9929640|NCT00919178|Placebo Comparator|2|Participants will receive a single immunization in the form of placebo resembling vaccine for DEN 4
9929641|NCT00919204|Experimental|Cohort 1|
9929642|NCT00919230|No Intervention|no treatment|no iron given
9929643|NCT00919230|Experimental|ferrous sulphate|iron given
9929644|NCT00919243|Experimental|prednisone|
9929645|NCT00919243|Active Comparator|allopurinol|
9929646|NCT00919282|Experimental|Gemcitabine/folinic acid/5-FU|Gemcitabine 1g/m² 5-FU 750mg/m² FS 500 mg/m²
9929647|NCT00919295|Placebo Comparator|placebo|placebo
9929648|NCT00919295|Placebo Comparator|mirtazapine 15|mirtazapine 15 mg
9929649|NCT00919295|Placebo Comparator|mirtazapine 30|mirtazapine 30mg
9929650|NCT00919308||Control, traditional bedside training|Postgraduate year 1 and 2 residents who are trained in central venous catheter insertion according to the traditional, bedside apprenticeship model.
9929651|NCT00919308||Simulation training|Postgraduate year 1 and 2 residents who complete a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by: the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous cannulator on a partial task training simulator with no technical errors.
9929652|NCT00919321|Other|PPV|
9929653|NCT00919334|No Intervention|single vision soft contact lens|Single vision soft contact lenses with same materials of the DISC lens
9929654|NCT00919334|Experimental|Defocus Incorporated Soft Contact (DISC) lens|The use of DISC lens to slow down the progression of myopia
9929655|NCT00919360||Controls|Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, mode of delivery, maternal age, and race.
9929656|NCT00919360||Preeclamptics|Gravidas at 32-42 weeks gestation, delivered by Caesarean Section, who have preeclampsia as defined by Sibai et al, 1997.
9929657|NCT00919373|Active Comparator|ICD-Implantation|Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.
9929658|NCT00919373|Active Comparator|ICD + Ablation|Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation
9929659|NCT00919386||1 Direct ureteric measurement|This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
9929660|NCT00919386||2 Based on patient height|"We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2 will receive a 22 cm stent, 5'3-5'7 will get a 24 cm stent, 5'8-5'10 will get a 26 cm stent, 5'11 to 6'1 will get a 28 cm stent, and all patients greater than 6'2 will receive a 30 cm stent."
9929661|NCT00919386||3 Based on a predetermined formula|We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
9929662|NCT00919412||Preterm delivery (< 37 weeks)|
9929663|NCT00919412||Term delivery (>=37 weeks)|
9929664|NCT00919438||Dialysis|
9929665|NCT00919451|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
9929666|NCT00919464|Other|Needle Insertion into Femur|Data gathering with monitoring of pressures in the thigh via via needle in femur.
9929667|NCT00919490|Experimental|Group 1|Single dose of 400 mg
9929668|NCT00919490|Experimental|Group 2|Single dose of 800 mg after safety evolution of Group I
9929669|NCT00919490|Experimental|Group 3|Single dose of 1200 mg after safety evolution of Group 2
9929670|NCT00919490|Experimental|Group 4|Single dose of 1600 mg after safety evolution of Group 3
9929671|NCT00919490|Placebo Comparator|Group 5|Single dose of placebo
9929672|NCT00919516|Experimental|Stem Cell Implantation|
9929673|NCT00919542|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
9929674|NCT00919542|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
9929675|NCT00919555|Active Comparator|Tretionoin and Pioglitazone HCL|20 patients will be randomized blindedly to Tretinoin and Pioglitazone HCL
9929676|NCT00919555|Placebo Comparator|Sugar Pill|10 Patients will randomly receive placebo
9929677|NCT00919581||Healthy controls|
9929678|NCT00919581||Subjects with spinal cord injury|
9929679|NCT00919594|Experimental|Interpersonal Psychotherapy for Mothers|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
9935925|NCT02977403|Other|Booster Training|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
9875320|NCT00373672|Active Comparator|1|armodafinil (Nuvigil) 150 mg
9875321|NCT00373672|Placebo Comparator|2|identical in appearance to active comparator
10211689|NCT04341194|Experimental|Skin-to-skin contact|Skin-to-skin contact is a method widely used in neonatal care globally. The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
9875322|NCT00373750|Experimental|Family Spirit Intervention|The Family Spirit Intervention included 43 structured lessons and followed a culturally congruent format. Positive parenting lessons were focused on reducing behaviors (i.e., poor monitoring; coercive interactions;harsh, unresponsive, or rejecting parenting; and abuse/ neglect) associated with early childhood behavior problems, including externalizing, internalizing, and dysregulation problems.
9875323|NCT00373750|No Intervention|Optimized Standard Care Control Group|Optimized standard care consisted of transportation to recommended prenatal and well-baby clinic visits, pamphlets about child care and community resources, and referrals to local services. It also addressed access barriers to health care for young mothers and children, and it overcame concerns that home-visiting programs have operated in parallel, not in partnership, with pediatric care. Family health liaisons conducted the optimized standard care and were not trained in the Family Spirit intervention, to avoid contamination of the control condition.
9875324|NCT00373789|Experimental|Botox A|up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
9875325|NCT00373789|Placebo Comparator|Placebo|up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks
9875326|NCT00373867|Active Comparator|Standard|Standard treatment-based classification physical therapy
9875327|NCT00373867|Active Comparator|Graded exercise|Treatment-based classification physical therapy plus graded exercise
9875328|NCT00373867|Experimental|Graded exposure|Treatment-based classification physical therapy plus graded exposure
9875329|NCT00373932|Experimental|MOBILE-A|Coached exercise persistence intervention
9875330|NCT00373932|Active Comparator|MOBILE-B|Self-monitored exercise persistence intervention
9875331|NCT00374036|Experimental|1|ECC
9875332|NCT00374036|Experimental|2|FOLFIRI
9875333|NCT00374049|Experimental|One|MUC1 vaccine in conjunction with GM-CSF and Poly-ICLC (Hiltonol)in Arm ONE
9875334|NCT00374062|Experimental|I|relaxation tape 1
9875335|NCT00374062|Experimental|II|relaxation tape 2
9875336|NCT00374062|Placebo Comparator|III|relaxation tape 3
9875337|NCT00374153|Experimental|1|Online personal feedback report.
9875338|NCT00374153|Experimental|2|In-person Motivational Interview with personal feedback report
9875339|NCT00374153|Experimental|3|In-person Motivational Interview only (without a personal feedback report)
9875340|NCT00374153|No Intervention|4|Assessment only
9875341|NCT00374153|No Intervention|5|Delayed Assessment
9875342|NCT00374192|Experimental|1|Eszopiclone
9875343|NCT00374192|Placebo Comparator|2|Placebo
9875344|NCT00374205|Experimental|AL|Artemether plus Lumefantrine 6 dose 3 days treatment
9875345|NCT00374205|Active Comparator|ASAQ|Artesunate plus Amodiaquine
9875346|NCT00374361||Caucasian Adolescents|Caucasian Adolescents
9875347|NCT00374361||African-American Adolescents|African-American Adolescents
9875348|NCT00374439|Experimental|Cognitive-behavioral|Participants in this arm received a cognitive-behavioral program
9875349|NCT00374439|Experimental|Interpersonal Therapy|Participants in this arm received a prevention program based on interpersonal therapy for depression
9875350|NCT00374439|No Intervention|No intervention|Participants in this arm did not receive an intervention, but complete assessments only
9875351|NCT00374569|Experimental|Gymnastics|Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
9875352|NCT00374569|Experimental|Non Gymnasts|Non Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
9875353|NCT00374621|Active Comparator|Misoprostol|
9875354|NCT00374621|Active Comparator|Misoprostol with Isosorbide Mononitrate|
9875355|NCT00374634|Active Comparator|"Individual or standard rFSH dose"|"Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64)."
9875356|NCT00374634|Active Comparator|"Standard rFSH dose"|"Standard dose of rFSH"
9875357|NCT00374673|Experimental|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation of the motor cortex
9875358|NCT00374673|Sham Comparator|placebo stimulation|repetitive placebo stimulation of the motor cortex
9875359|NCT00374738|Experimental|GIFT Intervention|Guided Imagery for Trauma (GIFT)
9875360|NCT00374738|No Intervention|Music Control|Relaxing Music Audio control; same music used in guided imagery, with no narrative voice.
9875361|NCT00374751|Experimental|Samarium (153SM)|Injection of Samarium (153SM)
9875362|NCT00374777|Experimental|1|
9875363|NCT00374777|Experimental|2|
9875364|NCT00374777|Active Comparator|3|
9875365|NCT00374777|Placebo Comparator|4|
9875366|NCT00374881|Active Comparator|1|Morphine High Dose
9875367|NCT00374881|Placebo Comparator|2|Morphine Low Dose
9875368|NCT00374881|Placebo Comparator|3|Sorbitol Phenylephrine
9875369|NCT00374881|Experimental|4|Sorbitol high concentration+Phenylephrine+Morphine
9875370|NCT00374881|Experimental|5|Sorbitol low concentration+Phenylephrine+Morphine
9875371|NCT00374933|Experimental|1|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
9875372|NCT00374946||A|THA. Bearing of Zirconia head and UHMWPE liner
9875373|NCT00374946||B|THA. Bearing of CO-Cr-Mo head and liner
9875374|NCT00374946||C|THA. Head og Zirconia head and UHMWPE moulded in shell (Asian)
9875375|NCT00374946||D|THA. Head and shell og Alumina ceramic
9875376|NCT00374972||combined contraceptives|combined contraceptives
9875377|NCT00374972||pregesterone only contraceptives|pregesterone only contraceptives
9875378|NCT00374985|Experimental|one arm|
9875379|NCT00375024|Other|1: Patient Navigator|Patients will meet with a Patient Navigator regarding their treatment and any related concerns.
9875380|NCT00375024|Other|2: Without Navigator|Patient will work with existing clinic staff, which does not include a Patient Navigator.
9875381|NCT00375037|Experimental|Hand hygiene|Hand hygiene promotion
9875382|NCT00375037|Active Comparator|Usual care|usual care
9875383|NCT00375050|Experimental|Riluzole|
9875384|NCT00375050|Placebo Comparator|Placebo|
9875385|NCT00375089||Group 1|Individuals with Prader-Willi syndrome.
9875386|NCT00375089||Group 2|Individuals with Early-onset Morbid Obesity
9875387|NCT00375102|Experimental|Acup|Acupuncture
9875388|NCT00375102|Experimental|RR|Relaxation Response
9875389|NCT00375102|No Intervention|UC|Usual Care
9875390|NCT00375245|Experimental|Rapamycin + Grapefruit juice|
9875391|NCT00375258|Experimental|1|Active
9875392|NCT00375258|Placebo Comparator|2|
9929680|NCT00919594|Active Comparator|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
9929681|NCT00919607|Active Comparator|1|quetiapine fumarate extended-release 300mg,administered once-daily Day1~5
9929682|NCT00919607|Experimental|2|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2~6,administered once-daily
9929683|NCT00919607|Experimental|3|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3~7,administered once-daily
9929684|NCT00919620|Experimental|case management (4 yrs)|4-year case management and standard care
9929685|NCT00919620|Active Comparator|case management (2 yrs) and standard care (2 yrs)|2-year case management and standard care
9929686|NCT00919620|No Intervention|standard care (4 yrs)|standard care for 4 years
9929687|NCT00919659|Experimental|parenteral nutrition|25kcal/kg/bw /day via parenteral support
9929688|NCT00919672|Active Comparator|Sacral nerve stimulation ON-OFF|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
9929689|NCT00919672|Active Comparator|Sacral nerve stimulation OFF-ON|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
9929690|NCT00919698||Sedated mechanically ventilated patients|
9929691|NCT00919737|Experimental|NPC-08|
9929692|NCT00919750||Ancillary-Correlative (tissue and blood sample collection)|Brain tumor tissue and blood specimens are collected from patients and banked for future study.
9929693|NCT00919776|Experimental|ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
9929694|NCT00919776|Active Comparator|Prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
9929695|NCT00919815|Experimental|ciclosporin arm|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
9875393|NCT00375310|Experimental|Gemcitabine + Sorafenib & radiotherapy|"Induction: Gemcitabine with Sorafenib for 4 weeks (1 cycle). Chemo-radiotherapy: Gemcitabine with Sorafenib and Radiotherapy for 5 weeks. Sorafenib will be given in escalating dose cohorts.~Sorafenib only: Sorafenib alone for 4 weeks. Consolidation: Gemcitabine with Sorafenib for 16 weeks (4 cycles). Maintenance: Sorafenib alone until disease progression."
9875394|NCT00375336||1|Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
9875395|NCT00375336||2|Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
9875396|NCT00375336||3|Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
9875397|NCT00375453|Experimental|Arm 1|
9875398|NCT00375466|Experimental|Tranexamic Acid|
9875399|NCT00375466|Placebo Comparator|placebo|
9875400|NCT00375557|Active Comparator|1|Quetiapine
9875401|NCT00375557|Active Comparator|2|Divalproex ER
9875402|NCT00375570|Experimental|1|ME-609
9875403|NCT00375648|Experimental|zoledronate|
9875404|NCT00375661|No Intervention|interferon|
9875405|NCT00375726|Experimental|1|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^3 PFU dose) into the deltoid region of either arm.
9875406|NCT00375726|Experimental|2|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
9875407|NCT00375726|Experimental|3|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
9875408|NCT00375726|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
9875409|NCT00375843|Active Comparator|Level 1 Treatment: Escitalopram|Level 1 participants who are assigned to escitalopram
9875410|NCT00375843|Active Comparator|Level 2: Sertraline|Participants from Level 1 who do not achieve remission with escitalopram enter Level 2 and switch to sertraline
9875411|NCT00375856|No Intervention|1|DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee
9875412|NCT00375856|Experimental|2|Rotating Platform Knee
9875413|NCT00375869|Active Comparator|Darbopoeitin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
9875414|NCT00375869|Placebo Comparator|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
9875415|NCT00375882|Other|cochlear implantation with mild hypothermia|
9875416|NCT00375895|Experimental|Ciclosporin|
9875417|NCT00375947|Experimental|1|Home-based hand exercise program
9875418|NCT00375947|Placebo Comparator|2|Sham hand cream
9875419|NCT00376012|Active Comparator|1|2EHRZ3/4RH3
9875420|NCT00376012|Experimental|2|2EHRZ3/7RH3
9875421|NCT00376064|Experimental|SMS995 + Carbegolin, Somavert + SMS995|
9875422|NCT00376077|Active Comparator|Placebo and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
9875423|NCT00376077|Experimental|Methylprednisolone and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
9875424|NCT00376090|Experimental|Group I Vaccine|
9875425|NCT00376090|Placebo Comparator|Group I Placebo|
9875426|NCT00376090|Experimental|Group II Vaccine|
9875427|NCT00376090|Placebo Comparator|Group II Placebo|
9875428|NCT00376090|Experimental|Group III Vaccine|
9875429|NCT00376090|Placebo Comparator|Group III Placebo|
9875430|NCT00376090|Experimental|Group IV Vaccine|
9875431|NCT00376090|Placebo Comparator|Group IV Placebo|
9875432|NCT00376129|Experimental|I|
9875433|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 20 mg QD|
9875434|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 40 mg QD|
9875435|NCT00376181|Active Comparator|Pioglitazone 45 mg QD|
9875436|NCT00376272|Experimental|1|
9875437|NCT00376272|Placebo Comparator|2|
9875438|NCT00376337|Active Comparator|1|infusion for 3-12 weeks
9875439|NCT00376337|Experimental|2|infusion for 3-12 weeks
9875440|NCT00376350|Experimental|High dose manipulation|High dose spinal manipulation + ultrasound
9875441|NCT00376350|Experimental|Moderate dose manipulation|Moderate dose manipulation + low dose massage + ultrasound
9875442|NCT00376350|Experimental|Low dose manipulation|low dose spinal manipulation + moderate dose massage + ultrasound
9875443|NCT00376350|Other|High dose masssage|high dose massage + ultrasound
9875444|NCT00376415|Experimental|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
9875445|NCT00376415|Placebo Comparator|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
9875446|NCT00376480|Experimental|administration of adoptive donor lymphocyte infusion|administration of donor lymphocytes made using costimulatory blockade ex vivo
9875447|NCT00376493|Active Comparator|1|Use of antibiotics after hospital discharge
9875448|NCT00376493|Placebo Comparator|2|Use of placebo
9875449|NCT00376519|Experimental|Transplant with Treg Cells|Patients receive preparative therapy with Fludarabine, cyclophosphamide, total body irradiation and Treg infusion followed by umbilical cord blood transplantation.
9875450|NCT00376571|Experimental|Stenting of main vessel and side branch|Percutaneous coronary intervention
9875451|NCT00376571|Experimental|No side branch treatment|Percutaneous coronary intervention
9875452|NCT00376584|Placebo Comparator|Placebo → MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).
9875453|NCT00376584|Active Comparator|Placebo → Extended Release (ER)-Niacin 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)
9875454|NCT00376584|Experimental|MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).
9875455|NCT00376701|Experimental|1|Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
9875456|NCT00376701|Experimental|2|Reduced fluence PDT plus intravitreal Avastin
9875457|NCT00376701|Experimental|3|Intravitreal Avastin and sham reduced fluence PDT
9875458|NCT00376727|Experimental|Phase I dose escalation study|
9875459|NCT00376740|Experimental|Immediate zoledronic acid|Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
9875460|NCT00376740|Active Comparator|Delayed zoledronic acid|Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
9875461|NCT00376831|Active Comparator|0|fentanyl
9875462|NCT00376831|Active Comparator|1|ketamine
9875463|NCT00376870|Active Comparator|Pioglitazone|Pioglitazone 30mg/d
9875464|NCT00376870|Placebo Comparator|Placebo|
9875465|NCT00376896|Experimental|GW876008 20mcg|GW876008 20mcg
9875466|NCT00376896|Experimental|GW876008 200mcg|GW876008 200mcg
9875467|NCT00376896|Placebo Comparator|Placebo|Placebo
9875468|NCT00376909|Experimental|Intervention|Series of telephone support calls from a trained prevention care manager
9875469|NCT00376909|No Intervention|Usual Care|Usual care
9875470|NCT00376922|No Intervention|usual care|
9875471|NCT00376922|Experimental|Music therapy|
9875472|NCT00377026|Experimental|lifestyle|participants receive lifestyle intervention
9929696|NCT00919815|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 24 weeks
9929697|NCT00919841||Postpartum women|Women who deliver a singleton vaginally
9929698|NCT00919880|Experimental|Experimental|
9929699|NCT00919880|Active Comparator|Active Comparator|
9929700|NCT00919906|No Intervention|Handwriting without Tears|Standard practice
9929701|NCT00919906|Experimental|Haptic guidance|
9929702|NCT00919919|Experimental|Progesterone vaginal tablet|Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
9929703|NCT00919919|Other|Activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
9929704|NCT00919945|Experimental|1|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
9929705|NCT00919945|Experimental|2|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.
9929706|NCT00919958|Experimental|PLX-PAD low dose|
9929707|NCT00919958|Experimental|PLX-PAD intermediate dose|
9929708|NCT00919958|Experimental|PLX-PAD high dose|
9929709|NCT00919984|Experimental|IP Chemotherapy|Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
9987655|NCT01414881|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) once weekly
9987656|NCT01414894|Active Comparator|Normal Fluids & Normal Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).
9987657|NCT01414894|Active Comparator|Increased Fluids & Normal Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)
9987658|NCT01414894|Active Comparator|Normal Fluids & Higher Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
9987659|NCT01414894|Active Comparator|Increased Fluids & Higher Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
9987660|NCT01414907|Active Comparator|Health Promotion activities|
9987661|NCT01414907|No Intervention|No Intervention|
9987662|NCT01414946|Experimental|Glucose and amino acids|Perioperative nutrition with glucose and amino acids
9987663|NCT01414946|Active Comparator|Amino acids only|Perioperative nutrition with amino acids only
9997089|NCT01505920|Active Comparator|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally to the four quadrant of the cervix, 3 minutes before starting cervical excision
9997090|NCT01505946||LOW RESPONDERS|Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre >0.6 and < 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre >0.6 and < 5 BU/ml and no increase in the INH titer > 5 BU over treatment with FVIII)
9997091|NCT01505946||HIGH RESPONDERS|Patients who documented high response after FVIII exposure (FVIII inhibitors titre > 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI
9997092|NCT01505959|Experimental|Conventional|
9997093|NCT01505959|Active Comparator|Telemedicine|
9997094|NCT01505972|Experimental|Six and three time schedule|
9997095|NCT01505972|Experimental|Four and two time schedule|
9997096|NCT01505985|Experimental|Specialized Oral Nutritional Supplement|
9997097|NCT01505985|Placebo Comparator|Placebo|
9997098|NCT01505998|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
9997099|NCT01505998|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
9997100|NCT01506011|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
9997101|NCT01506011|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
9997102|NCT01506024|Active Comparator|THA Direct lateral|Total hip arthroplasty (THA) carried out by direct lateral approach (DLA)
9997103|NCT01506024|Experimental|THA Posterior|Total hip arthroplasty (THA) carried out by posterior approach (DLA)
9997104|NCT01506024|Experimental|THA Anterior|Total hip arthroplasty (THA) carried out by anterior approach (DLA)
9997105|NCT01506037|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
9997106|NCT01506037|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
9997107|NCT01506050|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
9997108|NCT01506050|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
9997109|NCT01506063|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
9997110|NCT01506063|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
9997111|NCT01506076|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
9997112|NCT01506076|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
9997113|NCT01506089|Experimental|36 degree group|36 degrees Celsius for the incubators is the experimental condition in this study.
9875473|NCT00377052|Experimental|Bortezomib + Gemcitabine|
9796974|NCT01582308|Experimental|Treatment Sequence 8|Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
9796975|NCT01582308|Experimental|Treatment Sequence 9|Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
9796976|NCT01582308|Experimental|Treatment Sequence 10|Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
9796977|NCT01582451|Experimental|LY2605541|Administered by subcutaneous (SQ) injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications (OAMs) whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
9796978|NCT01582451|Active Comparator|Insulin glargine|Administered by SQ injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG. Insulin glargine will be used alone or in combination with up to 3 pre-study OAMs whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
9796979|NCT01582477|Experimental|EXPAREL 20 mL (undiluted)|20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
9796980|NCT01582477|Active Comparator|EXPAREL 40 mL (diluted)|20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
9796981|NCT01582490|Active Comparator|Infiltration - EXPAREL|Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
9796982|NCT01582490|Experimental|Instillation - EXPAREL|Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
9796983|NCT01582789|Active Comparator|enfilcon A/senofilcon A|Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.
9796984|NCT01582789|Active Comparator|senofilcon A/enfilcon A|Subjects were randomized to wear senofilcon A then enfilcon A for two weeks
9796985|NCT01582854|Active Comparator|Actovegin|Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
9796986|NCT01582854|Placebo Comparator|Placebo|Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.
9796987|NCT01582880|Experimental|Riboflavin Cross-linked donor cornea|the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
9796988|NCT01582945|Experimental|Ketamine IV|Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks
9796989|NCT01582971|Experimental|Intervention|Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member
9796990|NCT01582971|No Intervention|Control|Standard medical care: no reflexology
9796991|NCT01583101|Experimental|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
9796992|NCT01583101|Active Comparator|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
9796993|NCT01583166|Active Comparator|Bupivacaine + epinephrine|
9796994|NCT01583166|Placebo Comparator|Saline + epinephrine|
9796995|NCT01583179|No Intervention|Control group|will get only local anesthetic and epinephrine in block. no additive in block
9796996|NCT01583179|Experimental|buprenorphine|will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block
9987664|NCT01414972|Active Comparator|patients with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
9987665|NCT01414972|Placebo Comparator|patients with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
9987666|NCT01414972|Active Comparator|people without athrosclerosis/ vitamin a|people in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
9987667|NCT01414985|Experimental|Group A|Group A consists of 2 subjects who received 9x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 900,000,000,000 molecules of the study drug. The drug will be administered only once in the study.
9987668|NCT01414985|Experimental|Group B|Group B will consist of 6 subjects who will receive 2.85x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 285,000,000,000 molecules of the drug. The drug will be administered only once in the study.
9987669|NCT01414998|Active Comparator|Stress Ball|This is the active comparator for study 1
9987670|NCT01414998|Experimental|De-nicotinised Cigarette|This will be the experimental arm for study 2
9987671|NCT01414998|Experimental|Nicotine-free Electronic Cigarette (1)|This will be the experimental arm for study 1
9987672|NCT01414998|Active Comparator|Nicotine-free Electronic Cigarette (2)|This will be the active comparator for study 2
9987673|NCT01415011|Experimental|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
9987674|NCT01415037||Annular Array Ultrasound|Subject with possible or with known posterior vitreous detachment. Subjects with diabetic retinopathy will receive annular array ultrasound exam.
9987675|NCT01415050|Active Comparator|Alendronate|
9987676|NCT01415050|Active Comparator|Raloxifane|
9987677|NCT01415063|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
9987678|NCT01415063|Experimental|TACE-RFA|TACE first, then RFA within 2 weeks
9987679|NCT01415076|Placebo Comparator|Insertion without CO2 insufflation|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
9987680|NCT01415076|Experimental|Insertion with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
9987681|NCT01415102|Experimental|Cohort 1|Subjects will be assigned to receive either PF-05212372 or placebo in each period
9987682|NCT01415102|Experimental|Cohort 2|Subjects will be assigned to receive either PF-05212372 or placebo in each period
9987683|NCT01415115||Type 1 Diabetes|Must have been diagnosed with type 1 diabetes. Subject group will be measured on SCOUT and compared to Type 2 diabetes cohort.
9517134|NCT03309176|Active Comparator|Standard group|Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
9987684|NCT01415115||Type 2 Diabetes|Must have been diagnosed with Type 2 diabetes. This group will be compared to the Type 1 cohort.
9987685|NCT01415128|Active Comparator|Omeprazole|Omeprazole with single dose of avanafil (200 mg)
9987686|NCT01415128|Active Comparator|Rosiglitazone|Rosiglitazone with single dose of avanafil (200 mg)
9987687|NCT01415128|Active Comparator|Desipramine|Desipramine with single dose of avanafil (200 mg)
9987688|NCT01415141|Active Comparator|PR|"Treatment with Peginterferon and Ribavirin for up to 48 weeks~Those who achieve eRVR will receive 24 weeks of treatment"
9987689|NCT01415141|Active Comparator|TPR|"Treatment with Telaprevir, Peginterferon and Ribavirin. Patients will receive all 3 drugs for 12 weeks then switch to Peginterferon and Ribavirin for 36 weeks~Those who achieve eRVR will receive 12 weeks of treatment with all 3 drugs and then 12 weeks of treatment with the 2 drugs."
9997114|NCT01506089|No Intervention|37 degree group|37 degrees Celsius is the standard incubator temperature for the culture of embryos.
9987690|NCT01415154|Experimental|Scheduled Treatment Arm|3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
9987691|NCT01415154|Experimental|Monthly Observational Follow up Arm|3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.
9987692|NCT01415180||Children: previously healthy|Previously healthy children, without chronic disease prior to the sepsis episode, expected to comprise about 50-60% of the total study population.
9987693|NCT01415180||Children: chronic, complex conditions|Children with chronic, complex conditions prior to the sepsis episode, expected to comprise about 40-50% of the study population.
9987694|NCT01415193|Experimental|Selective Tibial Nerve Block|
9987695|NCT01415193|Active Comparator|Control: Sciatic Nerve Block|
9987696|NCT01415206|Experimental|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
9987697|NCT01415206|Other|Usual Care|Participants in the usual care condition will complete the core assessments and the Staging Health Risk Assessment (S-HRA) online at baseline, 3, 6, 12, and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
9987698|NCT01415219|Active Comparator|active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
9987699|NCT01415219|No Intervention|conventional care|community based physiotherapy
9987700|NCT01415245|Experimental|Treatment|Device applied to saphenous vein graft
9987701|NCT01415245|No Intervention|Control|Saphenous vein graft without device support
9987702|NCT01415271|Experimental|Internet Intervention|
9987703|NCT01415284|Experimental|Hydroxyethylstarch 130/0.4|
9987704|NCT01415297|Experimental|NKP-1339|"NKP-1339 will be administered in single patient cohorts until ≥ Grade 2 toxicity encountered, at which time cohorts converted to a standard 3 + 3 dose escalation scheme.~When MTD is reached, an expanded cohort of up to 25 patients will be enrolled at the MTD."
9987705|NCT01415310||Geriatric psychiatry|Elderly patients with psychiatric disorders in geriatric psychiatry units
9987706|NCT01415336|Active Comparator|AC|doxorubicin 60 mg/m², iv, day 1 Cyclophosphamide 600 mg/m², iv, day 1 every 3 weeks for 4 cycles
9987707|NCT01415336|Experimental|AX|doxorubicin 60 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 4 cycles
9987708|NCT01415362|Active Comparator|Active tDCS|The subject will receive sessions of active tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
9517650|NCT03304366||Patients with primary pterygium|"All eyes have primary pterygium and seeking for surgery due to Cosmetic problems, ocular irritation, and, or visual impairment.~All selected patients will undergo complete ophthalmological examination including refraction, best corrected visual acuity, keratometry, and pentacam (scheimpflug imaging) preoperatively then will be followed up 2 and 6 months post pterygium excision."
9517651|NCT03304353|Experimental|Self-managed protocol|
9517652|NCT03304353|Active Comparator|Predetermined protocol|
9987709|NCT01415362|Sham Comparator|Sham tDCS|The subject will receive sessions of sham tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
9987710|NCT01415375|Experimental|Prostate Cancer Screening Education|Men in the experimental intervention group received an educational pamphlet on prostate cancer testing as well as tailored telephone education in which the interventionist provided information, answered questions, and conducted a values clarification exercise with the participant.
9987711|NCT01415375|Other|Fruit and Vegetable Intake Education|Men in the attention control group received an educational pamphlet on daily recommended servings of fruits and vegetables as well as tailored telephone education in which the interventionist provided information, answered participant's questions, and discussed any barriers to eating fruits and vegetables.
9987712|NCT01415414||Group 1|
9987713|NCT01415466|Experimental|R|multiple dose of Rosuvastatin 20mg
9987714|NCT01415466|Experimental|O|multiple dose of CS-866 40mg
9987715|NCT01415466|Experimental|R+O|multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg
9987716|NCT01415479|Experimental|Quantitative|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)"
9987717|NCT01415479|Experimental|Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
9987718|NCT01415479|Experimental|Quantitative + Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
9997115|NCT01506115|Experimental|HCC with bile duct invasion|Photodynamic therapy with biliary drainage in patients with bile duct invasion of unresectable HCC
9987719|NCT01415479|Active Comparator|Control|Subjects view a computer-based presentation regarding colorectal cancer (CRC) and available screening tests for CRC, primarily a video produced by the American Cancer Society.
9987720|NCT01415492|No Intervention|Usual Care|At recruitment this group only received five pamphlets from the study. Four of these pamphlets were from the American Cancer Society, and one from Quitworks (a smoking cessation program).
9987721|NCT01415492|Active Comparator|HD2|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
9987722|NCT01415492|Active Comparator|HD2+|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
9987723|NCT01415505|Other|1|Nebivolol and Valsartan free tablet combination
9987724|NCT01415544||Type 2 Diabetes|Those previously diagnosed with type 2 diabetes
9987725|NCT01415544||Type 1 Diabetes|Those previously diagnosed with type 1 diabetes
9987726|NCT01415544||Gestational Diabetes|Those that are currently diagnosed with gestational diabetes
9987727|NCT01415544||Healthy Human Volunteers|Those that have not been diagnosed with any type of diabetes
9987728|NCT01415557|Placebo Comparator|Non-Fortified Control Product|Non-fortified control beverage
9987729|NCT01415557|Active Comparator|Micronutrient Fortified Test Product|Micronutrient fortified test beverage
9987730|NCT01415570||Chronic Hemodialysis Patients|Adult hemodialysis patients
9987731|NCT01415570||Chronic hemodialysis patients|Adult hemodialysis patients
9987732|NCT01415596|Placebo Comparator|Placebo|
9987733|NCT01415596|Active Comparator|Salbutamol|
9987734|NCT01415622|Experimental|PlasmaDerm|Treatment of small to medium-sized Ulcera crurum with the PlasmaDerm VU-2010 device in addition to standard care.
9987735|NCT01415622|Other|standard care|standard care of Ulcera crurum
9987736|NCT01415635|Experimental|Nutritional intervention|"The study will compare standard nutritional care (control group) with tailored nutritional care (the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)(intervention group)."
9987737|NCT01415648|Experimental|open NIRS|continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
9987738|NCT01415648|Sham Comparator|Blinded NIRS|Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre
9987739|NCT01415661|Experimental|obese patient|
9987740|NCT01415661|Experimental|non obese patient|
9987741|NCT01415687|Active Comparator|PEG Arm|Patients randomized to this arm of the trial will be following preparation instructions using Polyethylene Glycol-Based Lavage in a split dose format
9987742|NCT01415687|Active Comparator|Pico-Salax + Bisacodyl Arm|Patients randomized to this arm will follow preparation instructions using Pico-Salax preparation plus Biscacodyl in a split dose format
9987743|NCT01415700|Experimental|Stimulator|
9987744|NCT01415700|Active Comparator|Orthosis|
9796997|NCT01583218|Experimental|Betrixaban|Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
9987745|NCT01415713|Experimental|Statin dose titration|"SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians."
9987746|NCT01415726|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
9987747|NCT01415726|Experimental|Stem Cell Educator|used for the isolation and purification of cord blood stem cells.
9987748|NCT01415739||Novel Molecular NSCLC Classification (H & E staining, IHC)|Previously collected tissue samples are analyzed via H&E staining and IHC.
9987749|NCT01415778|Experimental|Active 1|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
9987750|NCT01415778|Experimental|Active 2|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
9987751|NCT01415778|Experimental|Active 3|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
9987752|NCT01415778|Experimental|Active 4|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
9987753|NCT01415791|Experimental|Active 1|8 subjects will receive ICI176,334-1
9987754|NCT01415804|Active Comparator|stentgraft|Stentgraft
9987755|NCT01415804|No Intervention|Medical management|Antihypertensive medication
9987756|NCT01415817|No Intervention|Baseline Data collection|
9875474|NCT00377104|Experimental|Treatment (chemotherapy)|Patients receive alvocidib IV over 30 minutes (loading dose), followed by alvocidib IV over 4 hours on days 1, 8, and 15. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9875475|NCT00377130|No Intervention|Arm I- Usual psychological care|Usual psychological care- no intervention
9875476|NCT00377130|Experimental|Self administered Stress Management|Self-Administered Stress Management Training Plus Usual Psychosocial Care
9875477|NCT00377195|Experimental|1|
9875478|NCT00377208|Active Comparator|Intervention Condition|Receives web-based feedback specific to their blood-pressure and other health-related conditions.
9875479|NCT00377208|No Intervention|Control Condition|The control group receives preventative feedback, general to the population.
9875480|NCT00377247|Experimental|Dendritic Cells w/Tumor DNA|
9875481|NCT00377286|Placebo Comparator|2|1500 mg of lite lemonade
9875482|NCT00377286|Active Comparator|1|1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
9875483|NCT00377325|Experimental|1|Participants will receive full dose cyclosporin.
9875484|NCT00377325|Experimental|2|Participants will receive active drug full dose until cleared, then one dose every 4 days.
9875485|NCT00377325|Placebo Comparator|3|Participants will receive active drug full dose until clear, then full dose every 4 days with placebo on the intervening days.
9875486|NCT00377390||Cockroach sensitive|
9875487|NCT00377390||Control (cockroach insensitive)|
9875488|NCT00377416|Experimental|1|rAAV2-CB-hAAT Gene Vector
9875489|NCT00377442|Experimental|1|
9875490|NCT00377442|Experimental|2|
9875491|NCT00377442|Experimental|3|
9875492|NCT00377481|Experimental|1|
9875493|NCT00377481|Active Comparator|2|
9875494|NCT00377507|Experimental|catechin|mask containing catechins
9875495|NCT00377559|Experimental|1.|Myocet+docetaxel
9875496|NCT00377598|Experimental|TAK-583 5 mg QD|
9875497|NCT00377598|Experimental|TAK-583 25 mg QD|
9875498|NCT00377598|Experimental|TAK-583 50 mg QD|
9875499|NCT00377598|Experimental|TAK-583 100 mg QD|
9875500|NCT00377598|Placebo Comparator|Placebo QD|
9875501|NCT00377663|Experimental|1|Participants will use the AsthmaNet web site.
9875502|NCT00377663|No Intervention|2|Participants will not use the AsthmaNet Web site.
9875503|NCT00377715|Experimental|Dimebon|Dimebon 20 mg three times a day x 26 weeks
9875504|NCT00377715|Placebo Comparator|Placebo|Placebo 20 mg three times a day x 26 weeks
9875505|NCT00377780|Experimental|1|Myocet + docetaxel + trastuzumab
9875506|NCT00377793|Experimental|Arm 1|
9875507|NCT00377793|Placebo Comparator|Arm 2|
9875508|NCT00377871|Active Comparator|1|Valve design 1
9875509|NCT00377871|Active Comparator|2|Valve design 2
9875510|NCT00377871|No Intervention|Control|Healthy control
9875511|NCT00377910|Active Comparator|1, drug|Injections of polidocanol
9875512|NCT00377910|Placebo Comparator|2 drug|injections of lidocaine
9875513|NCT00377936|Active Comparator|1|Gemcitabine
9875514|NCT00377936|Experimental|2|EndoTag-1 + Gemcitabine
9875515|NCT00377936|Experimental|3|EndoTag-1 + Gemcitabine
9875516|NCT00377936|Experimental|4|EndoTag-1 + Gemcitabine
9875517|NCT00377988||001|Transdermal Contraceptive System In each 4-week period exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
9875518|NCT00377988||002|Norgestimate-containing oral contraceptives with EE NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days then no pill or a drug-free pill 7 days.
9875519|NCT00378027||Stable Acute Pulmonary Embolism|Administer weight dosed Fondaparinux
9875520|NCT00378066|Active Comparator|Bevacizumab|Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
9875521|NCT00378092|Experimental|Risperidone Long-Acting Injection (RLAI) (Period 1)|Participants will receive 25 milligram (mg) to 50 mg of RLAI intramuscularly (into the muscle) which will be tapered and discontinued over a period of up to 6 weeks. Participants will be followed-up until their first disease relapse or maximum of 36 months.
9875522|NCT00378092|Experimental|Oral risperidone and RLAI (Period 2)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus (a muscle) for up to 24 months. Supplementation with oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injections becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
9875523|NCT00378131|Placebo Comparator|1|
9875524|NCT00378131|Experimental|2|RC-1291 50mg
9875525|NCT00378131|Experimental|3|RC-1291 100mg
9875526|NCT00378144|Experimental|1|Pseudoephedrine/Paracetamol
9875527|NCT00378196|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
9875528|NCT00378196|Experimental|B|0.5 mg /0.05 ml dose of ranibizumab
9875529|NCT00378248|Experimental|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy
9796998|NCT01583218|Active Comparator|Enoxaparin|Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
9796999|NCT01583296|Experimental|CBT and HRVB|Cognitive Behavioral Therapy (CBT) and Heart Rate Variability Biofeedback (HRVB)
9797000|NCT01583296|Active Comparator|Music Relaxation Therapy (MRT)|Music Relaxation Therapy (MRT): music relaxation and breathing at resting respiration rate
9797001|NCT01583374|Experimental|Apremilast 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
9797002|NCT01583374|Experimental|Apremilast 30 mg|Apremilast 30 mg was taken orally twice a day
9797003|NCT01583374|Placebo Comparator|Placebo|Identically matched placebo tablets were taken orally twice a day
9797004|NCT01583452|Experimental|Chewing Gum Group|Group of patients given chewing gum as part of the treatment for prevention of post-operative ileus right after surgery, besides the standard pharmacologic treatment and post-operative care.
9797005|NCT01583452|No Intervention|No intervention|By observing the clinical evolution of the participants not given chewing gum as a prevention for post-operative ileus, and just given the standard pharmacologic treatment and post-operative care.
9797006|NCT01583530|Active Comparator|Belimumab IV 240 mg|
9797007|NCT01583530|Experimental|Belimumab SC 2 x 120 mg|
9797008|NCT01583530|Experimental|Belimumab SC 1 x 240 mg|
9797009|NCT01583530|Experimental|Belimumab SC 1 x 200 mg|
9797010|NCT01583530|Experimental|Belimumab SC 2 x 120 mg weekly|
9797011|NCT01583530|Experimental|Belimumab SC 1 x 200 mg weekly|
9797012|NCT01583543|Experimental|Olaparib|400mg PO BID Continuous
9797013|NCT01583686|Experimental|1/Phase I|Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) plus low dose aldesleukin.
9797014|NCT01583686|Experimental|2/Phase II|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) + low-dose aldesleukin
9797015|NCT01583868|Experimental|B&L RD2135-01 lens C|Investigational Silicone hydrogel soft contact lens
9797016|NCT01583868|Experimental|B&L RD2135-01 lens D|Investigational Silicone hydrogel soft contact lens
9797017|NCT01583868|Active Comparator|PureVision2|Bausch & Lomb High definition soft contact lenses
9797018|NCT01583868|Active Comparator|Ciba Vision Air Optix Aqua|Ciba Vision Air Optix Aqua soft contact lens
9797019|NCT01583894||Chronic pain patients|
9797020|NCT01583985|Active Comparator|Opioid-intensive|Opioid-intensive prescribing strategy
9797021|NCT01583985|Active Comparator|Opioid-avoidant|Opioid-avoidant prescribing strategy
9797022|NCT01584024|Active Comparator|Resin infiltration|Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
9797023|NCT01584024|Sham Comparator|Control|Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
9797024|NCT01584232|Experimental|LY2189265 + OAM|"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
9797025|NCT01584232|Active Comparator|Insulin glargine + OAM|"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
9797026|NCT01584388|Experimental|Rituximab|
9797027|NCT01584440|Placebo Comparator|Placebo|Participants will receive placebo during Stage 1 and Stage 2 of the study.
9797028|NCT01584440|Experimental|AVP-923|Participants will receive AVP-923-20 and AVP-923-30 in a sequential manner during Stage 1 and Stage 2 of the study.
9797029|NCT01584440|Experimental|Placebo then AVP-923|Participants will receive placebo in Stage 1 followed by AVP-923 in Stage 2.
9797030|NCT01584479||Low Risk Experimental Group|"1 visit - Low Risk~~1200 subjects~- Low Risk Experimental Group = 1 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
9797031|NCT01584479||Low risk Control Group|"2 visits - Low Risk~~1200 subjects~- Low risk Control Group = 2 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
9875530|NCT00378248|Active Comparator|Outpatient individual psychotherapy|Eclectic individual psychotherapy in outpatient private practice
9875531|NCT00378365|Experimental|1|Arsenic trioxide
9875532|NCT00378404|Experimental|1|
9875533|NCT00378547|Placebo Comparator|Paracetamol|Oral paracetamol 1 g + placebo + placebo
9875534|NCT00378547|Experimental|Paracetamol + Pregabalin|Oral paracetamol 1g + oral pregabalin 300 mg + placebo
9875535|NCT00378547|Experimental|Paracetamol + pregabalin + dexamethasone|Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg
9875536|NCT00378612|Experimental|Cypher® sirolimus eluting coronary stent|All pts were given the Cypher sirolimus eluting coronary stent in this open-label, single-arm, non-randomized trial
9875537|NCT00378664|Experimental|Intervention|All enrollees are included in the intervention - lumbar to sacral ventral nerve re-routing procedure surgical nerve re-routing procedure.
9875538|NCT00378690|Active Comparator|Continuous Androgen Deprivation (CAD)|
9875539|NCT00378690|Experimental|Intermittent Androgen Deprivation (IAD)|
9875540|NCT00378716|Active Comparator|Group 1|5-FU + Leucovorin
9875541|NCT00378716|Experimental|Group 2|Uracil/Ftorarur + leucovorin
9875542|NCT00378729|Active Comparator|A|
9875543|NCT00378729|Active Comparator|B|
9875544|NCT00378781|Experimental|Arm I|Minocycline hydrochloride + Edetate Calcium Disodium (M-EDTA) flush solution into CVC once daily.
9875545|NCT00378781|Experimental|Arm II|Heparin flush solution into CVC once daily.
9929710|NCT00919997||Specimen collection|Single group study. Blood, saliva, anal cytology, and penile cytology samples, and questionnaire responses will be collected from participants at a single study visit.
9929711|NCT00920036|Experimental|Arm 1|Eight subjects were trained to utilize a handheld biofeedback device
9929712|NCT00920036|No Intervention|Arm 2|usual care
9929713|NCT00920088|Experimental|Cohort 1|GSK2248761 with LPV/RTV arm and probes
9929714|NCT00920088|Experimental|Cohort 2|GSK2248761 with DRV/RTV
9929715|NCT00920101|Active Comparator|Atorvastatin|
9929716|NCT00920101|Placebo Comparator|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
9929717|NCT00920114|Experimental|Lupus disease|
9929718|NCT00920114|Active Comparator|Healthy witnesses|
9929719|NCT00920114|Active Comparator|Healthy witnesses with an other auto-immune disease|
9929720|NCT00920127|Placebo Comparator|Placebo|
9929721|NCT00920127|Active Comparator|AKL1|
9929722|NCT00920153|Experimental|Group 1 (favorable prognosis)|Patients receive ABVD and VABEM chemotherapy.
9929723|NCT00920153|Experimental|Group 2 (intermediate prognosis)|Patients receive ABVD and VABEM chemotherapy.
9929724|NCT00920153|Experimental|Group 3 (poor prognosis)|Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.
9929725|NCT00920166|Experimental|Modilac Pétunia 1|Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic
9929726|NCT00920166|Active Comparator|Modilac 1|Regular milk
9929727|NCT00920179||Dry eye group|Dry eye patients with Primary Sjogren's syndrome
9929728|NCT00920179||Controls|Healthy subjects without dry eyes
9929729|NCT00920192|Experimental|Foretinib|Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day
9929730|NCT00920257|Experimental|GSK2141795|Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified.
9929731|NCT00920270|Active Comparator|antibiotic|conventional antibiotics
9929732|NCT00920270|Experimental|colistin group|nebulized colistin
9929733|NCT00920283|Experimental|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
9929734|NCT00920283|Active Comparator|Driver, Cobalt Alloy Coronary Stent|
9929735|NCT00920296|Experimental|Cohort 1|All subjects
9929736|NCT00920322|Active Comparator|five times weekly|Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
9929737|NCT00920322|Experimental|three times weekly|Patients will receive rTMS three times weekly for four weeks
9929738|NCT00920348||Group 1|COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
9929739|NCT00920348||Group 2|COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
9929740|NCT00920348||Group 3|COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
9929741|NCT00920348||Group 4|"Healthy control never smokers without respiratory disease (post-BD FEV1/FVC>=0.70."
9929742|NCT00920413|Active Comparator|vitamin C|vitamin C 500mg orally once a day
9929743|NCT00920413|Placebo Comparator|placebo|
9929744|NCT00920465|Experimental|one-visit|
9929745|NCT00920465|Active Comparator|two-visit|
9929746|NCT00920478|Active Comparator|Control Group|Inflammatory disease activity assessed using DAS28
9987757|NCT01415817|Experimental|Randomization and Training Arm|
9987758|NCT01415830|Experimental|Anti-scorpion venom serum Birmex|Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
9987759|NCT01415830|Active Comparator|Anti-scorpion venom serum Alacramyn|Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
9987760|NCT01415856|Placebo Comparator|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
9987761|NCT01415856|Active Comparator|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
9987762|NCT01415869||Cross Sectional|Patients with implanted non-pulsatile ventricular assist devices of any type and at any time after implantation
9987763|NCT01415869||Prospective|Patients with usual VAD indications will be invited to participate, when, in the opinion of their treating physician a VAD will be highly likely within one month.
9987764|NCT01415895|Experimental|ATNC05 - a study drug capsule|Naltrexone and Clonidine Combination (ATNC05)
9987765|NCT01415895|Placebo Comparator|placebo|
9987766|NCT01415973|Experimental|3 ounces of cooked, 85% lean ground beef|Subjects would consume 3 ounces of cooked, 85% lean ground beef at one setting on one day.
9987767|NCT01415973|Experimental|20 grams of Beef protein isolate|Subjects would consume 20 grams of beef protein isolate dissolved into 200mL water at one setting on one day.
9987768|NCT01415999||patient|adult survivors of childhood malignancies
9987769|NCT01415999||control|healthy age-matched individuals
9987770|NCT01416012|Experimental|Group Kinect|Use of the available Kinect games on the Xbox to train balance and gait
9987771|NCT01416012|Active Comparator|Physical Therapy Standard|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
9987772|NCT01416012|Experimental|Group Nintendo|Use of video games available Balance and Gait training in Individualized training sessions.
9987773|NCT01416012|Experimental|Group Xbox Kinect (MK)|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
9987774|NCT01416038|Experimental|Vaccine|Cohort A: 0.5 mL of DPX-Survivac (injection)
9987775|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide|Cohort B: 0.1 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
9987776|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide.|Cohort C: 0.5 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
9987777|NCT01416051|Active Comparator|Test|Subjects consumed a vegetable oil emulsion in yogurt at a food intake test and were asked to consume the product twice daily for 12 weeks.
9987778|NCT01416051|Placebo Comparator|Control Group|Subjects were given a placebo of milk fat in yogurt at food intake tests and asked to consume the placebo twice daily for 12 weeks.
9987779|NCT01416077|No Intervention|standard treatment|Fluid and inotropic drugs are given based on conventional parameters such as blood pressure and heart rate as judged by the individual anesthesiologists judgement.
9987780|NCT01416077|Active Comparator|goal-directed fluid treatment|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
9987781|NCT01416103|Experimental|Intervention group|Intervention group
9987782|NCT01416103|Placebo Comparator|Intervention control|Control group
9987783|NCT01416116|Experimental|Tramadol|Tramadol prior to QUTENZA
9987784|NCT01416116|Experimental|Lidocaine|Lidocaine prior to QUTENZA
9987785|NCT01416168|No Intervention|Control Arm|Usual post-surgical care
9987786|NCT01416168|Experimental|Intervention arm|In addition to usual post-surgical care, the patients will receive a 4 week geriatric nurse practitioner-centered intervention, based on the McCorkle model.
9987787|NCT01416207|Experimental|Avonex|4 weekly injections of Avonex (IM)
9987788|NCT01416220|Experimental|Lithium|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l).
9987789|NCT01416220|Active Comparator|Paroxetine|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or Paroxetine.Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7.At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
9987790|NCT01416233|Experimental|autologous fat grafting|There is one arm of this study. People with anophthalmic sockets and orbital atrophy are given a single session of autologous fat grafting by a closed cannula technique and are observed to measure, by MRI, the amount of fat retained at one year
9987791|NCT01416246|Experimental|Fractionated Stem Cell Infusions|A single arm, open-label, single institution pilot trial is planned. Patients with chemosensitive MM and at least 7 x 10^6 CD34+ stem cells/kg (+/- 0.5 x 10^6 CD34+ stem cells/kg)available for use will be enrolled following initial induction or salvage therapy.
9987792|NCT01416259||APF530 Exposure, Granisetron and Moxifloxacin, Placebo|Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
9987793|NCT01416311||Subjects prescribed REVOLADE|Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
9987794|NCT01416324|Experimental|GSK2330672|experimental study drug
9987795|NCT01416324|Placebo Comparator|Placebo|placebo
9987796|NCT01416337|Experimental|Treatments A & B|Single 2 mg GSK1120212 oral tablet, fasted Single IV dose of 5 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK1120212 Both doses are given together.
9987797|NCT01416350|Active Comparator|Part A - randomized, open-label parallel group|Part A is a randomized, open-label parallel group study evaluating PK/PD of a single azithromycin dose of 250 or 1000 mg. Data from Part A will be used to assess the dose resulting in induction/inhibition of various ex vivo biomarkers relative to a 250 mg dose of azithromycin (the clinical dose used in treatment of neutrophil-induced inflammatory conditions). This information will guide the range of doses to be studied in a FTIH study of a new chemical entity.
9997116|NCT01506128||HPV|Premenopausal women with HSIL in Pap test or high-risk HPV
9875546|NCT00378911|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
9875547|NCT00378950|Active Comparator|1|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups.
9875548|NCT00378950|Experimental|2|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups, as well as additional information on diuretic self adjustment. This group will then get several follow-up phone calls over the course of the year to reinforce these topics and help them master the knowledge and encourage behavior and lifestyle changes to align with these topics.
9875549|NCT00378976|Experimental|1|
9875550|NCT00378976|Placebo Comparator|2|
9875551|NCT00378989|Active Comparator|Intervention|A letter with personal feedback of the results of a health risk appraisal and invitation to a consultation at the occupational health services.
9875552|NCT00378989|No Intervention|Control|Care as usual
9875553|NCT00379015|Experimental|HER2 over-expressing primary breast cancer group|"Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.~Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks."
9875554|NCT00379067|Active Comparator|1|Tamsulosin OCAS tablet
9875555|NCT00379067|Placebo Comparator|2|Placebo tablet
9875556|NCT00379106|Active Comparator|Group1|
9875557|NCT00379106|Experimental|Group 2|
9875558|NCT00379184||A|Osteoarthritis patients scheduled for Total Knee Arthroplasty.
9875559|NCT00379184||B|Osteoarthritis patients not scheduled for Total Knee Arthroplasty.
9875560|NCT00379184||C|Healthy volunteers
9875561|NCT00379223|No Intervention|1|Standard treatment of central retinal vein occlusion : the rheologic correction
9875562|NCT00379223|Experimental|2|Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy
9875563|NCT00379262|Experimental|1A|Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy
9875564|NCT00379262|Experimental|1B|Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy
9875565|NCT00379262|Experimental|2A|Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy
9875566|NCT00379262|Experimental|2B|Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy
9875567|NCT00379262|Experimental|3A|Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy
9875568|NCT00379262|Experimental|3B|Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy
9875569|NCT00379301|Active Comparator|Group 1|Pulmonary vein isolation (PVI) combined with ablation of documented non-PV triggers of atrial fibrillation --- (sites away from the pulmonary veins where consistent abnormal impulses that can trigger AF are identified during the procedure)
9875570|NCT00379301|Active Comparator|Group 2|PVI combined with ablation at documented sites of non-PV triggers, PLUS ablation at sites where non-PV triggers are commonly found
9875571|NCT00379301|Active Comparator|Group 3|PVI combined with ablation at documented sites of non-PV triggers and ablation at sites in the left atrium that demonstrate disorganized electrical impulses called complex fractionated electrograms (CFE).
9875572|NCT00379327|Experimental|Real Accupuncture|Acupuncture with a real needle that punctures the skin versus acupuncture needle that does not puncture the skin.
9875573|NCT00379327|Placebo Comparator|Non-puncturing Acupuncture|Acupuncture needle that touches but does not puncture the skin
9875574|NCT00379366|Active Comparator|1|14 Gy ionizing radiations
9875575|NCT00379366|No Intervention|2|
9875576|NCT00379392|Experimental|Mental Imagery and CIT|Mental Imagery and Constraint Induced Therapy
9875577|NCT00379392|Active Comparator|Mental Imagery only|Mental Imagery only
9875578|NCT00379405|Experimental|A|Saquinavir (Invirase): 2 capsules (500 mg) / 12 hours
9875579|NCT00379405|No Intervention|2|IP o NNUCS + 2 NUCS as a HAART therapy .
9875580|NCT00379431|Experimental|Administration of rituximab and methylprednisolone|
9875581|NCT00379470|Active Comparator|Best Standard of Care|Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center.
9875582|NCT00379470|Experimental|NovoTTF-100A|
9875583|NCT00379483|Experimental|Arm 1|
9875584|NCT00379509|Experimental|GW572016|
9875585|NCT00379522|Active Comparator|Vasopressin|Vasopressin, 10 I.U./4 ml, Solution for Injection
9875586|NCT00379522|Placebo Comparator|Saline|Saline placebo 4 ml, Solution for Injection
9875587|NCT00379535|Experimental|1|Daily dose of 200 µg of potassium iodide
9875588|NCT00379535|Placebo Comparator|2|Daily dose of placebo
9875589|NCT00379548|No Intervention|1|Control group- subjects are on the Asian diet for the entire duration of the study
9875590|NCT00379548|Experimental|2|Asian and Caucasian subjects switch from an Asian Diet to a Western Diet midway through the study.
9875591|NCT00379561|Experimental|Intervention PSA-PAH1|Determination of the therapeutic activity of different concentrations of PSA-PAH1 at increasing doses of per gram of prostate.
9875592|NCT00379613|Placebo Comparator|1|rocuronium + 16.0 mg/kg Org 25969
9875593|NCT00379613|Experimental|2|rocuronium + 2.0 mg/kg Org 25969
9875594|NCT00379613|Experimental|3|rocuronium + 4.0 mg/kg Org 25969
9875595|NCT00379613|Experimental|4|rocuronium + 8.0 mg/kg Org 25969
9875596|NCT00379613|Experimental|5|rocuronium + 12.0 mg/kg Org 25969
9875597|NCT00379626|Experimental|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
9875598|NCT00379652|Active Comparator|A|Patient-based intervention
9875599|NCT00379652|Active Comparator|B|Health center-based intervention
9875600|NCT00379652|Active Comparator|C|Combination of patient and health center-based intervention
9875601|NCT00379652|No Intervention|D|Control group: Neither patient-based nor center-based intervention
9875602|NCT00379665|Experimental|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
9875603|NCT00379678||Information not available|
9875604|NCT00379743|Active Comparator|2|Individuals randomized to this arm receive the following interventions: 1) educational materials on recommended cancer-preventive services, plus 2) a health coordinator (patient navigator) who helps the participant schedule and keep appointments for cancer screening and/or treatment.
9875605|NCT00379756|Active Comparator|Levitra|10mg x 4 weeks, with option to increase to 20mg aat that time if desired
9875606|NCT00379756|Placebo Comparator|placebo|
9875607|NCT00379847|Experimental|1|Lower dose
9875608|NCT00379847|Experimental|2|Higher dose
9875609|NCT00379925|Experimental|Behavioral|Participants will take part in the Physical Activity and Dietary Health Promotion Program.
9875610|NCT00379925|No Intervention|Delayed intervention|Participants are assigned to a delayed intervention group and serve as a no-intervention control group.
9875611|NCT00379951|Experimental|1|Arm 1: ertapenem sodium
9875612|NCT00380042|Active Comparator|Active Stimulation|
9875613|NCT00380042|Sham Comparator|Sham|
9875614|NCT00380055|Experimental|Screening Navigation|Individuals without a study cancer who receive services of a navigator.
9875615|NCT00380055|Experimental|Treatment Navigation|Individuals with a study cancer who receive navigation services.
9875616|NCT00380055|Active Comparator|Screening Education|Rather than receiving navigation, these participants receive general cancer education appropriate to Medicare enrollees.
9875617|NCT00380055|Active Comparator|Treatment Education|Rather than receiving navigation services, these participants receive cancer education appropriate to Medicare recipients.
9875618|NCT00380120|Experimental|1|Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
9875619|NCT00380120|Active Comparator|2|Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)
9875620|NCT00380133|Experimental|Randomised, double-blind, five-way crossover|A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
9875621|NCT00380146|Experimental|SP plus artesunate|SP (Fansidar®, Roche South Africa) at a dose of 25/1.25mg/kg of sulfadoxine/pyrimethamine respectively on day 0 only, and artesunate (Arsumax®, Sanofi-Aventis, South Africa) at a dose of 4mg/kg on days 0, 1, and 2
9875622|NCT00380185||1|Subjects with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries
9875623|NCT00380185||2|Subjects with coronary artery disease only
9875624|NCT00380185||3|Subjects with both coronary artery disease and peripheral arterial disease
9875625|NCT00380237|Experimental|1|Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
9875626|NCT00380276|Other|Open Label Arm|Treatment is open-label
9875627|NCT00380406|Placebo Comparator|Placebo|Placebo
9875628|NCT00380406|Active Comparator|depot GnRHa (Leuprolide acetate (LA) 11.25 mg intramuscularly)|
9875629|NCT00380419|Experimental|1|Participants will receive 16 sessions of interpersonal psychotherapy
9875630|NCT00380484|Experimental|1|Budesonide
9875631|NCT00380484|Active Comparator|2|Montelukast
9929747|NCT00920478|Experimental|Ultrasound Group|Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)
9929748|NCT00920491||patients with non-specific complaints|patients who do not have specific presenting symptoms (e.g. dyspnea, chest pain etc.)
9929749|NCT00920504|Experimental|German PRO-SELF(c) Plus PCP|Group receives 10 weeks German PRO-SELF(c) Plus PCP intervention program
9929750|NCT00920504|Active Comparator|Standard Care|control group receives attention control and standard care
9929751|NCT00920517|Active Comparator|1|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 180
9929752|NCT00920517|Active Comparator|2|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 120
9929753|NCT00920530||Real time PCR monitoring|Women giving birth at the St Etienne Teaching Hospital
9929754|NCT00920543|Active Comparator|Fluticasone propionate|
9929755|NCT00920543|Active Comparator|Fluticasone propionate/salmeterol combination|
9935926|NCT02977403|Active Comparator|Booster Training - active comparator|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
9935927|NCT02974608||Children 0-10 years|Children living in selected villages surrounding the district of Ouelessebougou
9875632|NCT00380497|Experimental|Pico-Salax|
9875633|NCT00380497|Active Comparator|PEGlyte|
9875634|NCT00380536|Experimental|1|Participants will participate in peer-led medical illness self-management group sessions.
9875635|NCT00380536|No Intervention|2|Participants will receive treatment as usual.
9875636|NCT00380549|Active Comparator|CONSERVE® A-Class THA BFH|CONSERVE® A-Class Total Hip with BFH technology. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® acetabular component and the CONSERVE® A-Class BFH femoral head. Blood ion levels will be collected and analyzed.
9875637|NCT00380549|Active Comparator|CONSERVE® Plus Total Resurfacing Hip System|CONSERVE® Plus Total Resurfacing Hip System. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® Plus Total Resurfacing Hip System. Blood ion levels will be collected and analyzed.
9875638|NCT00380562|Experimental|Volunteer|High intensity volunteering (15 hours a week or greater) in Baltimore City Schools with children in grades K-3
9875639|NCT00380562|No Intervention|Control|Usual activities
9875640|NCT00380601|Experimental|1|
9875641|NCT00380640|Experimental|1|
9875642|NCT00380640|Experimental|2|
9875643|NCT00380666|Other|PET/CT defined target|Target defined by use of fluoro-deoxy-glucose (FDG)-PET/CT scan for planning af stereotactic radiotherapy.
9875644|NCT00380731|Experimental|1|Participants will receive immediate cognitive behavioral therapy
9875645|NCT00380731|Experimental|2|Participants will receive cognitive behavioral therapy with a 16-week delayed start
9875646|NCT00380757|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations
9875647|NCT00380757|Active Comparator|CPR 15:2|15 chest compressions to 2 ventilations
9875648|NCT00380770|Experimental|HAART alone|Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
9875649|NCT00380770|Active Comparator|Combination HAART and chemotherapy|Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
9875650|NCT00380796||Cohort 1|
9875651|NCT00380809|Active Comparator|Rotational Atherectomy + PES|Elective lesion preparation with rotational atherectomy priot to stent implantation
9875652|NCT00380809|Active Comparator|Standard Treatment (PES without Rotational Atherectomy)|Stenting without prior rotational atherectomy, usually preceeded with balloon dilatation
9875653|NCT00381108|Experimental|Pomegranate Tablet|
9875654|NCT00381108|Placebo Comparator|Placebo Tablet|
9875655|NCT00381160|Experimental|1|Provision of non-caloric beverages to home
9875656|NCT00381160|No Intervention|2|
9875657|NCT00381173|Experimental|1|
9875658|NCT00381212|Experimental|1|AGS-004 immunotherapeutic injections.
9875659|NCT00381225|Experimental|Ultra-sound guided radio-frequency ablation|
9875660|NCT00381290|Active Comparator|1|Participants will follow an exercise regimen
9875661|NCT00381290|Active Comparator|2|Participants will follow a calorie-restricted diet
9875662|NCT00381290|Active Comparator|3|Participants will follow a calorie-restricted diet and an exercise regimen
9875663|NCT00381316|Active Comparator|1|Thallous Chloride T1-201
9875664|NCT00381316|Active Comparator|2|Technetium Tc99m Tetrofosmin injections
9875665|NCT00381329|Active Comparator|1|Motivational Interviewing (MI)
9875666|NCT00381329|Active Comparator|2|Structured Brief Advice (SBA)
9875667|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 5 mcg|Exenatide 5 mcg; then exenatide 5 mcg
9875668|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 10 mcg|Exenatide 5 mcg, then exenatide 10 mcg
9875669|NCT00381342|Placebo Comparator|Placebo|Placebo in volumes equivalent to exenatide
9875670|NCT00381407|Experimental|1|Participants will receive organizational skills training program
9875671|NCT00381407|Experimental|2|Participants will receive contingency management program
9875672|NCT00381407|No Intervention|3|Participants will receive wait list condition
9875673|NCT00381420|Experimental|1|sirolimus-coated Bx Velocity stent
9875674|NCT00381420|Active Comparator|2|uncoated Bx Velocity stent
9875675|NCT00381576|Experimental|A|12 weeks of resistance training
9875676|NCT00381589|Experimental|A|Random assignment to investigational spray
9875677|NCT00381654|Experimental|A|Daily oral administration of AV-412
9875678|NCT00381667|Experimental|GW642444M 12.5|
9987798|NCT01416350|Active Comparator|Part B - repeat dose group|Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
9875679|NCT00381667|Experimental|GW642444M 100mcg|
9875680|NCT00381667|Experimental|GW642444M 400mcg|
9875681|NCT00381667|Experimental|GW642444H 100mcg|
9875682|NCT00381667|Experimental|Placebo|
9875683|NCT00381719|Experimental|1|3 mg
9875684|NCT00381719|Experimental|2|20 mg
9875685|NCT00381719|Experimental|3|60 mg
9875686|NCT00381719|Placebo Comparator|4|Placebo
9875687|NCT00381732|Placebo Comparator|1|placebo tablet
9875688|NCT00381732|Active Comparator|2|2.5 mg tadalafil tablet
9875689|NCT00381732|Active Comparator|3|5 mg tadalafil tablet
9875690|NCT00381771||Objective salivary function|"Based on the salivary scintigraphy,~Objective salivary normo-function~Objective salivary dysfunction"
9875691|NCT00381784|Experimental|Community PROMISE|Community PROMISE is a community level HIV/STD prevention program that relies on role model stories and peer advocates from the community. Sites will adapt PROMISE for local use remaining faithful to the core elements.
9875692|NCT00381784|Experimental|Mpowerment|MPowerment is a community level HIV/STD prevention program that relies on peer advocates from the community to lead outreach activities including discussion groups (Mgroups), venue-based outreach, social events and a publicity campaign. Sites will adapt MPowerment for local use remaining faithful to the core elements.
9875693|NCT00381914|Experimental|1|400 IU / day vitamin D
9875694|NCT00381914|Experimental|2|800 IU / day vitamin D
9875695|NCT00381914|Experimental|3|1200 IU / day vitamin D
9875696|NCT00381953|Active Comparator|360 PEG IFN|360 mug peginterferon alfa-2a QW
9875697|NCT00381953|Active Comparator|9 MU + 180 PEG IFN|9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
9875698|NCT00381953|Active Comparator|4,5 MU IFN + 180 PEG IFN|4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
9875699|NCT00381979|Experimental|1|set
9875700|NCT00382135|Placebo Comparator|1|placebo tablet
9875701|NCT00382135|Active Comparator|2|20 mg tadalafil tablet
9875702|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms|
9875703|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 15 micrograms|
9875704|NCT00382187|Experimental|non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen|
9875705|NCT00382200|Experimental|Decitabine and All-Trans Retonoic Acid (Tretinoin)|Decitabine and All-Trans Retonoic Acid (Tretinoin)
9875706|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 10 mcg|
9875707|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 5 mcg|
9875708|NCT00382239|Experimental|Exenatide 2.5 mcg/exenatide 2.5 mcg|
9875709|NCT00382239|Placebo Comparator|Placebo/placebo|
9875710|NCT00382343|Experimental|sulfamethoxazole/trimethoprim|Antibiotic prophylaxis with sulfamethoxazole/trimethoprim [1-2 mg/kg trimethoprim and 5-10 mg/kg sulfamethoxazole once daily]; in case of intolerance (leucopoenia) and for children younger than 6 months: nitrofurantoin [2 mg/kg once daily]
9875711|NCT00382343|No Intervention|No prophylaxis|
9875712|NCT00382356|Experimental|study drug|Open label, single arm
9875713|NCT00382382|Other|Children with Autism|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in high functioning austistic children.
9875714|NCT00382382|Other|Healthy Volunteers|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in healthy volunteers.
9875715|NCT00382395|Experimental|1|SOLX Gold Shunt
9875716|NCT00382395|Active Comparator|2|Control Ahmed FP7 Shunt
9875717|NCT00382434||EPh Present|the emergency pharmacist is present in the ED when the medical care is provided
9929756|NCT00920595|Experimental|1|CEP-9722 alone and in combination therapy with temozolomide.
9929757|NCT00920608|Experimental|A|AZD9056 400 mg and Methotrexate
9929758|NCT00920660|Experimental|Treatment Group|"Subjects will be required to attend the research unit in a fasted state (at least 10 hours without food) on six separate occasions (treatment visits) during the study. At approximately the same time every morning, subjects will consume a standard, non-high-fat meal (approximately 650 kcal with 30% of calories derived from fat). Test material (per treatment) will be administered within 15-30 minutes following the meal. There will be at least a 7-day washout period between treatment visits.~During the first five treatment visits, subjects will receive one of the following treatments in the form of 8 capsules: 0.25g SRT2104, 0.5g SRT2104, 1g SRT2104, 2g SRT2104, or placebo.~During the last treatment visit, subjects will receive 30 mg of open-label prednisolone tablets."
9929759|NCT00920712|Experimental|Weiqi decoction|
9929760|NCT00920712|Placebo Comparator|low dose of Weiqi decoction|
9929761|NCT00920725|Active Comparator|Subcutaneous Insulin|Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
9929762|NCT00920725|Active Comparator|IV Regular Insulin|Intravenous Regular Insulin 0.1 units/kg/hour
9929763|NCT00920725|Active Comparator|Intravenous Novolog Insulin|Intravenous Novolog Insulin 0.1 units/kg/hour
9929764|NCT00920738||Cancer Survivors|Subjects who are cancer survivors must have survived childhood cancer (diagnosed < or = 18 years) for a minimum of 5 years and be in remission.
9929765|NCT00920738||Healthy Siblings of Cancer Survivor|Healthy populations similar in age and gender distribution, derived from a frequency matched control population of 350 healthy siblings.
9929766|NCT00920751|Experimental|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
9929767|NCT00920751|Active Comparator|Air insufflation|Conventional air insufflation colonoscopy
9929768|NCT00920777|Experimental|8 weeks CBT|
9929769|NCT00920777|Active Comparator|Control group|
9929770|NCT00920777|Experimental|16 weeks CBT|
9929771|NCT00920803|Active Comparator|5g SRT501|5.0 g of SRT501 will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, SRT501 will be administered approximately 15-30 minutes following the consumption of a standardized breakfast. On all other days, SRT501 will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of SRT501 administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive SRT501 for a minimum of 10 days and a maximum of 21 days.
9929772|NCT00920803|Placebo Comparator|Placebo|Placebo will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, placebo will be administered approximately 15-30 minutes following the consumption of a standardized breakfast to allow for PK sample collection. On all other days, placebo will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of placebo administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive placebo for a minimum of 10 days and a maximum of 21 days.
9929773|NCT00920868|Experimental|Dasatinib 50mg|Cohort 1
9929774|NCT00920881||Diabetes|
9929775|NCT00920894|Experimental|yoghurt type minidrink containing plant stanol ester|
9929776|NCT00920894|Placebo Comparator|yoghurt type minidrink without plant stanol ester|
9929777|NCT00920933|Experimental|AIN457|
9929778|NCT00920933|Placebo Comparator|Placebo|
9929779|NCT00920933|Active Comparator|oral corticosteroid|
9929780|NCT00920959|Experimental|Fluticasone propionate/salmeterol combination|study drug
9929781|NCT00920959|Experimental|Fluticasone propionate|study drug
9929782|NCT00920959|Experimental|Placebo|placebo
9929783|NCT00920972|Experimental|Stratum 1|Recipients with non-malignant disorders, excluding thalassemia. Related or unrelated 8/8 HLA-matched bone marrow
9929784|NCT00920972|Experimental|Stratum 2|Recipient with transfusion dependent thalassemia. Related or unrelated. 8/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
9929785|NCT00920972|Experimental|Stratum 3|Recipient with hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
9929786|NCT00920972|Experimental|Stratum 4|Recipient with non-malignant disorder, excluding hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
9929787|NCT00920998|Experimental|1. Z-338|3-way cross-over study (drug administration 3-times in fasted and 2 fed conditions)
9929788|NCT00921011||Perimenopausal women|Women at the beginning stages of menopause
9929789|NCT00921037|Experimental|Erbium YAG Laser|Patients with Neurofibromatosis Type 1 (Recklinghausen)
9929790|NCT00921050|Experimental|Levothyroxine|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
9929791|NCT00921050|Placebo Comparator|Placebo|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
9929792|NCT00921063|Experimental|PD 0332334 250 mg|
9929793|NCT00921063|Experimental|PD 0332334 100 mg|
9929794|NCT00921063|Placebo Comparator|placebo|
9929795|NCT00921063|Active Comparator|Alprazolam extended release|
9875718|NCT00382447|Experimental|1|Standard nebulizer versus standard breath actuated nebulizer
9875719|NCT00382473|Experimental|exercise|
9875720|NCT00382499|Experimental|Lidocaine|IV lidocaine in OR as described in methods
9875721|NCT00382525||Patients with Cardiac Rhythm Management device|Patients receiving a Medtronic Cardiac Rhythm Device, worldwide
9875722|NCT00382642|Experimental|Ondansetron|Arm 1 = Ondansetron 4 mcg/kg b.i.d.+ Cognitive behavioral therapy
9875723|NCT00382642|Placebo Comparator|Placebo|Arm 2 = Placebo + Cognitive behavioral therapy
9875724|NCT00382668||A|
9875725|NCT00382668||B|
9875726|NCT00382668||C|
9875727|NCT00382681|Experimental|FID 107027|Contact lens solution used as instructed for 90 days.
9875728|NCT00382681|Active Comparator|ReNu MultiPlus|Contact lens solution used as instructed for 90 days.
9875729|NCT00382850|Active Comparator|open nissen fundoplication|open repair through surgical midline incision
9875730|NCT00382850|Active Comparator|laparoscopic nissen fundoplication|use of laparoscope to do repair
9875731|NCT00382915||1|Smokers with schizophrenia
9875732|NCT00382915||2|Smokers with bipolar disorder
9875733|NCT00382915||3|Smokers without any mental illness
9875734|NCT00382954|Experimental|Phase 1 escalation|
9875735|NCT00382980|Experimental|7.5-|7.5 mcg of vaccine without adjuvant administered on Days 0 and 28.
9875736|NCT00382980|Experimental|45-|45 mcg of vaccine without adjuvant administered on Days 0 and 28.
9875737|NCT00382980|Placebo Comparator|Placebo|Placebo administered on Days 0 and 28.
9875738|NCT00382980|Experimental|15+|15 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
9875739|NCT00382980|Experimental|7.5+|7.5 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
9875740|NCT00382980|Experimental|15-|15 mcg of vaccine without adjuvant administered on Days 0 and 28.
9875741|NCT00383136|Experimental|1|Tirofiban
9875742|NCT00383136|Active Comparator|2|Abciximab
9875743|NCT00383214|Active Comparator|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
9875744|NCT00383214|Placebo Comparator|Placebo|Intravenous
9875745|NCT00383253|Experimental|10%|
9875746|NCT00383253|Experimental|25%|
9875747|NCT00383253|Experimental|50%|
9875748|NCT00383253|Placebo Comparator|Control|
9875749|NCT00383370|Experimental|ITV-1|VEGF Trap formulation 1
9875750|NCT00383370|Experimental|ITV-2|VEGF Trap formulation 2
9875751|NCT00383370|Experimental|ITV-2 OL|VEGF Trap formulation 2 open label, higher concentration
9875752|NCT00383474|Experimental|Arm I|Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
9875753|NCT00383526|Experimental|Study Group 1|
9875754|NCT00383526|Active Comparator|Study Group 2|
9875755|NCT00383539|Experimental|1|Lot 1
9875756|NCT00383539|Experimental|2|Lot 2
9875757|NCT00383539|Experimental|3|Lot 3
9875758|NCT00383539|Active Comparator|4|Control
9875759|NCT00383656|Experimental|Pulsatile GnRH|All participants will be administered GnRH intravenously by means of a portable infusion pump that delivers boluses at specific intervals.
9875760|NCT00383669|Active Comparator|Multiple RDA multivitamins|Multivitamins (including B, C, and E)
9875761|NCT00383669|Active Comparator|Single RDA Multivitamins|Multivitamins (including B, C, and E)
9875762|NCT00383708|Experimental|1|
9875763|NCT00383734|Experimental|1|newfill
9875764|NCT00383734|Experimental|2|Eutrophill
9875765|NCT00383799|Active Comparator|Group 1|IV procainamide (single dose: 10 mg/kg over 20 min)
9875766|NCT00383799|Active Comparator|Group 2|IV Amiodarone (single dose: 5 mg/kg over 20 min)
9875767|NCT00383890|Experimental|Dexmedetomidine|Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
9875768|NCT00383890|Placebo Comparator|Placebo (PBO)|Placebo load for 10 min and Placebo maintenance for 15 min
9875769|NCT00383929|Experimental|1|Candesartan Cilexetil (CC) /HCT 32/12.5mg
9875770|NCT00383929|Experimental|2|Candesartan Cilexetil (CC) /HCT 32/25mg
9875771|NCT00383929|Experimental|3|Candesartan Cilexetil monotherapy
9875772|NCT00383994|Experimental|Immunotherapy with NK Cell, Rituximab + GM-CSF|"Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation~GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor"
9875773|NCT00384046|Experimental|1|300mcg/day testosterone
9875774|NCT00384046|Placebo Comparator|2|Placebo arm
9875775|NCT00384137|Experimental|1|
9875776|NCT00384202|Experimental|1|
9875777|NCT00384228|Experimental|Nilotinib|
9875778|NCT00384254|No Intervention|1|Usual Care Control: Patients receive treatment as usual
9875779|NCT00384254|Experimental|2|"5 A Intervention Condition: Patients in this condition receive all five A components (Ask, Advise, Assess, Assist, Arrange) recommended in the Clinical Practice Guideline: Treating Tobacco Use and Dependence."
9875780|NCT00384254|Experimental|3|"3 A Condition: Patients receive Ask, Advise, Arrange intervention consisting of the first two A components recommended by the Clinical Practice Guideline: Treating tobacco Use and Dependence, plus Fax-to-Quit referral to a tobacco quit line."
9875781|NCT00384267||Neonates|Inpatient
9875782|NCT00384371|Experimental|1|Botulinum Toxin A
9875783|NCT00384371|Placebo Comparator|2|Placebo
9929796|NCT00921076|Active Comparator|Ankle Arthoplasty|Patients will undergo a Total Ankle Replacement procedure
9929797|NCT00921076|Active Comparator|Ankle fusion|Patients will undergo an Ankle Arthrodesis procedure
9929798|NCT00921089||Hemodialysis group|End stage renal disease patients aged lower than 70 years, treated for more than 6 months with hemodialysis
9929799|NCT00921089||Control group|Normotensive healthy controls
9929800|NCT00921102|Placebo Comparator|Control|Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator.
9875784|NCT00384462||1|Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
9875785|NCT00384462||2|Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year.
9875786|NCT00384527|Experimental|1|
9875787|NCT00384527|Active Comparator|2|
9875788|NCT00384540|Other|Cardiovascular events vs Dobutamine stress echocardiography|
9875789|NCT00384566|Experimental|1|
9875790|NCT00384566|Active Comparator|2|
9875791|NCT00384579|Experimental|1|Botulinum Toxin B
9875792|NCT00384579|Placebo Comparator|2|Placebo
9875793|NCT00384605|Experimental|1|Arm 1: MK0364 2 mg capsule once daily
9875794|NCT00384605|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
9875795|NCT00384605|Experimental|3|Arm 3: MK0364 0.5 mg capsule once daily.
9875796|NCT00384605|Placebo Comparator|4|Arm 4: Pbo capsule once daily.
9875797|NCT00384631|Sham Comparator|2|
9875798|NCT00384631|Experimental|1|
9875799|NCT00384644||1|sepsis, septic shock ptients
9875800|NCT00384644||2|cardiogenic shock patients
9875801|NCT00384657|Experimental|Group I|iv iron sucrose
9875802|NCT00384657|No Intervention|Group II|Patients will receive conventional treatment of Chronic Heart Failure.
9875803|NCT00384683||Endothelial Dysfunction|Participants are scheduled for major chest (lung or esophagus) surgery or are a healthy volunteer. A blood test will quantify the number of cells that are destined to become endothelial cells.
9875804|NCT00384696||Smoking Cessation|Treatment to help quit smoking, including written self-help materials, counseling, and 4 week supply of nicotine patch plus 5 MD Anderson Visits.
9875805|NCT00384735||1A|Intensive - 3 monthly follow up
9875806|NCT00384735||1B|Intensive - 6 monthly follow up
9875807|NCT00384735||IIA|Cost Effective - 3 monthly follow up
9875808|NCT00384735||IIB|Cost Effective - 6 monthly follow up
9875809|NCT00384787|Experimental|1|Group 1 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intramuscularly at Month 6.
9875810|NCT00384787|Experimental|2|Group 2 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intradermally at Month 6.
9875811|NCT00384787|Experimental|3|Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
9875812|NCT00384826|Experimental|1|
9875813|NCT00384826|Experimental|2|
9875814|NCT00384891|Experimental|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
9875815|NCT00384891|Active Comparator|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
9875816|NCT00384969|Experimental|1|RAD001 and Sorafenib
9875817|NCT00384982|Experimental|A, B, C, D|Early or late; percutaneous intracoronary or combined (intramyocardial and intracoronary) administration of BM-MNCs
9875818|NCT00384995|Experimental|Bicarbonate|Bicarbonate solution infusion
9875819|NCT00384995|Active Comparator|Saline|Standard volume expansion
9875820|NCT00385047|Experimental|Group A|FMP 2.1 50 μg FMP2.1/AS01B
9875821|NCT00385047|Experimental|Group B|FMP 2.1 50 μg FMP2.1/AS02A
9875822|NCT00385086|Experimental|TNF-alpha blocker|Treatment with TNF-alpha blocker
9875823|NCT00385086|Active Comparator|Placebo|Treatment with placebo
9875824|NCT00385177|Experimental|A|SN2310 Injectable Emulsion
9875825|NCT00385229|Experimental|Induction|induction of labor at gestational age 289(41 weeks+2 days)
9875826|NCT00385229|No Intervention|expectant management|expectant management at gestational age 289(41 weeks+2 days)
9875827|NCT00385242|Active Comparator|PET guided Therapy|Patients will be randomized to undergo positron emission tomography aspart of their clinical work up
9875828|NCT00385242|Active Comparator|Standard care|Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.
9875829|NCT00385346|Experimental|A 1|Expressive writing
9875830|NCT00385411|Experimental|valproate|
9875831|NCT00385450|Experimental|Nelfinavir/placebo|
9875832|NCT00385476||Patient Medication Knowledge Tool|Assessment of Cancer patients' knowledge of their medications in an outpatient acute care setting
9875833|NCT00385502|Experimental|EcoNail™|econazole 5%/SEPA® 18% nail lacquer
9875834|NCT00385632||1|Participants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
9875835|NCT00385632||2|Participants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
9875836|NCT00385710|Experimental|valproic acid|Depakine
9875837|NCT00385710|Placebo Comparator|Placebo|Placebo
9875838|NCT00385853|Experimental|PTK787|Single arm study of PTK787
9997117|NCT01506154|Placebo Comparator|Placebo|Therapy with placebo
9797032|NCT01584479||High Risk Experimental Group|"1 visit - High Risk~~800 subjects High Risk Experimental Group = 1 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
9797033|NCT01584479||High Risk Control Group|"2 visits - High Risk~~800 subjects High Risk Control Group = 2 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
9797034|NCT01584518|Active Comparator|CHF peptide|Diuresis based on CHF-P
9797035|NCT01584518|Active Comparator|Non CHF peptide|Diuresis based on clinical judgement without data for CHF-P
9797036|NCT01584544|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.
9797037|NCT01584544|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9797038|NCT01584544|Experimental|1350mg|capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9797039|NCT01584544|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9797040|NCT01584544|Experimental|1650mg|capecitabine 1650mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
9797041|NCT01584609|Experimental|Penumbra System with Separator 3D|
9797042|NCT01584609|Active Comparator|Penumbra System alone|
9797043|NCT01584648|Experimental|Dabrafenib + Trametinib|Dabrafenib and Trametinib combination
9797044|NCT01584648|Active Comparator|Dabrafenib + Placebo|Dabrafenib and Trametinib placebo
9797045|NCT01584843|No Intervention|Non-treatment (10-20 PD)|Receive no treatment on Week 0
9797046|NCT01584843|Active Comparator|GSK1358820 1.25 U (10-20 PD)|Receive 1.25 U of GSK1358820 on Week 0
9797047|NCT01584843|Active Comparator|GSK1358820 2.5 U (10-20 PD)|Receive 2.5 U of GSK1358820 on Week 0
9797048|NCT01584843|No Intervention|Non-treatment (20-50 PD)|Receive no treatment on Week 0
9797049|NCT01584843|Active Comparator|GSK1358820 2.5 U (20-50 PD)|Receive 2.5 U of GSK1358820 on Week 0
9797050|NCT01584843|Active Comparator|GSK1358820 5.0 U (20-50 PD)|Receive 5.0 U of GSK1358820 on Week 0
9797051|NCT01585025|Experimental|Primary BAD|Defined as SeHCAT <10% without other causes such as Crohn's disease and/or ileal resection
9797052|NCT01585025|Experimental|Secondary BAD|With Crohn's disease or ileal resection
9797053|NCT01585025|Experimental|Idiopathic Diarrhoea Controls|Chronic diarrhoea with SeHCAT >15% and no Crohn's or ileal resection
9797054|NCT01585038|Active Comparator|Efavirenz|Efavirenz 600mg given nightly without food for 30 days
9797055|NCT01585038|Active Comparator|Rilpivirine|Rilpivirine 25mg given daily with meals for 30 days
9797056|NCT01585129|Experimental|Postpartum Antibiotics|Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
9797057|NCT01585129|Placebo Comparator|No postpartum antibiotics|No further postpartum antibiotics
9797058|NCT01585155|Experimental|TA-650|
9797059|NCT01585168|Experimental|Family history positive, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
9797060|NCT01585168|Placebo Comparator|Family history positive, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
9797061|NCT01585168|Experimental|Family history negative, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
9797062|NCT01585168|Placebo Comparator|Family history negative, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
9797063|NCT01585194|Experimental|Treatment (nivolumab, ipilimumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
9875839|NCT00385866|Active Comparator|Comparison Group|The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.
9875840|NCT00385866|Active Comparator|Intervention group|The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.
9875841|NCT00385970|Active Comparator|1|UFT+LV Group: The group treated with UFT and LV
9875842|NCT00385970|Experimental|2|UFT+PSK Group: The group treated with of UFT and PSK
9875843|NCT00386035||1: DC Group|HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
9875844|NCT00386035||2: VS Group|HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
9935928|NCT02974608||Pregnant Women + Newborns|Pregnant women of any age and their newborn children
9987799|NCT01416363|Experimental|Treatment Arm ACB: Part 1|Subjects will receive treatment sequence ACB; A : Firategrast immediate release tablet 1200 milligram (mg) once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
9987800|NCT01416363|Experimental|Treatment Arm BAC: Part 1|Subjects will receive treatment sequence BAC; B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
9987801|NCT01416363|Experimental|Treatment Arm CBA: Part 1|Subjects will receive treatment sequence CBA; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
9987802|NCT01416363|Experimental|Treatment Arm BCA: Part 1|Subjects will receive treatment sequence BCA; B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
9987803|NCT01416363|Experimental|Treatment Arm CAB: Part 1|Subjects will receive treatment sequence CAB; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
9987804|NCT01416363|Experimental|Treatment Arm ABC: Part 1|Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
9987805|NCT01416363|Experimental|Treatment Arm D: Part 2|Subject will receive D: Firategrast immediate release tablet 600 mg twice daily for 7 days
9987806|NCT01416363|Experimental|Treatment Arm E: Part 2|Subject will receive E: Firategrast 3 hour release tablet 1200 mg twice daily for 7 days
9987807|NCT01416363|Experimental|Treatment Arm F: Part 2|Subject will receive F: Firategrast simulated gastro-retentive solution 1200 mg twice daily for 7 days
9987808|NCT01416376|Active Comparator|50mg SRT2379|Single oral administration of 50mg SRT2379
9987809|NCT01416376|Active Comparator|250mg SRT2379|Single oral administration of 250mg SRT2379
9987810|NCT01416376|Active Comparator|1000mg SRT2379|Single oral administration of 1000mg SRT2379
9987811|NCT01416376|Placebo Comparator|Placebo|Single oral administration of placebo
9987812|NCT01416415|Experimental|Educational intervention|The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
9987813|NCT01416415|Placebo Comparator|Attention placebo|The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.
9987814|NCT01416454||Elective Cesarean delivery, age <35 yrs|Women undergoing elective cesarean delivery with a spinal anesthetic who are less than 35 y of age (at the time of delivery).
9987815|NCT01416454||Elective Cesarean delivery, age =>35 yrs|Women undergoing elective Cesarean delivery with a spinal anesthetic who are => 35 yrs of age (at the time of delivery).
9987816|NCT01416480|Experimental|Theobromine|Theobromine capsule 300mg
9987817|NCT01416480|Active Comparator|levodropropizine|levodropropizine syrup
9987818|NCT01416493|Experimental|bIAP treatment|
9987819|NCT01416506||Group 1|
9987820|NCT01416519|Experimental|Group 1|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
9987821|NCT01416519|Experimental|Group 2|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
9987822|NCT01416545|Active Comparator|Lifestyle counseling|Children received the same educational material for their parents and, additionaly, were exposed to a weekly educational program directed for cardiovascular prevention.
9987823|NCT01416545|Placebo Comparator|Control group|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
9987824|NCT01416597||Cross-Protection Studies|
9987825|NCT01416623|Experimental|Henatinib|Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
9987826|NCT01416662|Other|gemcitabine|gemcitabine
9987827|NCT01416688||Observation and Questionnaires|Patients will be given questionnaires for the assessment of therapy complications, psychosocial assessment and care, and quality-of-life assessment.
9797064|NCT01585207|Experimental|Vigabatrin|3 tablets, bid for 8 weeks
9875845|NCT00386048||Standard of Care Observation Group|This group is randomized to continue their current medical management strategies for pain as recommended/prescribed by health care providers. Primary and secondary outcomes are collected at the same time intervals as the biopsychosocial intervention group.
9875846|NCT00386048||Biopsychosocial Intervention Group|This group continues all standard of care procedures for managing pain and adds to this additional cognitive-behavioral treatment (CBT) strategies for managing pain. The intervention explicitly frames the CBT strategies as added, complimentary pain management methods to add to the standard of care treatment.
9875847|NCT00386165|Experimental|Larazotide acetate|Larazotide acetate capsules: 12 mg QD x 3 days
9875848|NCT00386165|Placebo Comparator|Placebo|Placebo capsules: QD x 3 days
9875849|NCT00386178|Experimental|1|Vitamin E supplement rich in gamma tocopherol
9875850|NCT00386191|Experimental|1|50 mg
9875851|NCT00386191|Experimental|2|75 mg
9875852|NCT00386217||Telephone Survey|90 minute Telephone survey of female cancer survivors
9875853|NCT00386230|Experimental|1|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
9875854|NCT00386230|Experimental|2|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
9875855|NCT00386230|Experimental|3|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
9875856|NCT00386230|Active Comparator|4|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.
9929801|NCT00921102|Experimental|Intrathecal Atropine|Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding.
9929802|NCT00921102|Active Comparator|IV Atropine|Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding.
9929803|NCT00921141||study population|Patient with cancer requiring a long-term central venous catheter
9929804|NCT00921154|Experimental|Ivermectin|Ivermectin
9929805|NCT00921167|Experimental|Bevacizumab/Irinotecan|
9929806|NCT00921180|Experimental|Entecavir and peginterferon|Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
9929807|NCT00921180|Active Comparator|Placebo and peginterferon|Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
9929808|NCT00921206|Active Comparator|VAX102 given i.m.|Universal influenza candidate vaccine
9929809|NCT00921206|Active Comparator|VAX102 given s.c.|Universal influenza candidate vaccine
9929810|NCT00921219|Experimental|Ivermectin|ivermectin
9929811|NCT00921232|Other|dyad|life-ending patient and its caregiver
9929812|NCT00921245||Group 1|
9929813|NCT00921258||control group|Patient with latent prostate cancer who agree to be controled instead of to be treated
9929814|NCT00921271||At risk for compartment syndrome.|"Patients admitted to Selly Oak Hospital, Birmingham, Uk, meeting one or more of the following inclusion criteria:~Patients with one or more of the following injuries:~tibial fracture.~crush injury/soft tissue injury to lower limb without fracture.~pelvic fracture.~major vascular injury below the aortic bifurcation.~2 or more long bone fractures.~Any patient sustaining a traumatic injury with a base deficit ≥ 6 mEq/L within 12 hours of Hospital admission.~Any patient receiving ≥ 6 units packed red blood cells within 12 hours of hospital admission."
9929815|NCT00921284|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
9929816|NCT00921284|Experimental|dexmedetomidine|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine
9929817|NCT00921297|Active Comparator|Immediate Cataract Surgery|Subjects randomly selected into the Immediate Surgery group will have their cataract surgery scheduled one month from the time their initial study visits are completed. The subjects will be followed monthly for a period of 6 months for surgical and non-surgical adverse events. At the 6-month point, subjects will receive a final comprehensive eye exam and neuropsychological testing. The research partners will complete final activities of daily living and resource utilization questionnaires.
9929818|NCT00921297|No Intervention|Delayed Cataract Surgery|Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.
9929819|NCT00921323|Placebo Comparator|Control|The control group will be advised to continue to be physically active and record daily steps
9929820|NCT00921323|Active Comparator|Goal-setting group|This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months.
9929821|NCT00921336|Experimental|KW-2450|
9929822|NCT00921349|Experimental|Ligation+Nadolol|"Multi-ligators were applied. Patients received regular ligation treatment at an interval of 3-4 weeks until variceal obliteration.~Intervention; ligation of varices plus beta blockers (Nadolol)."
9929823|NCT00921349|Active Comparator|Nadolol only|
9929824|NCT00921362||1|Schizophrenia patients under Seroquel treatment
9929825|NCT00921375|Experimental|Tuly, uric acid lowering drug|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
9929826|NCT00921388|Experimental|1|Exercise program
9929827|NCT00921388|Other|2|Relaxation program
9935929|NCT02974608||Women of Child Bearing Age Potential|Non-pregnant women of child-bearing age
9935930|NCT02974595||1|Participants age 0-99 will have a known autoinflammatory disease
9935931|NCT02974595||2|Unaffected relatives age 3-99 years
9935932|NCT02974595||3|Healthy Volunteers age 18-99 years
9987828|NCT01416701|Active Comparator|Vitamin D (D3, cholecalciferol)|
9987829|NCT01416701|Placebo Comparator|Placebo (cellulose)|
9935933|NCT02974582|Experimental|1/Part 1|60 Participants of high and low SES
9935934|NCT02974582|Experimental|2/Part 2 - Discount Coupons|Randomized to view direct mail marketing
9935935|NCT02974582|Experimental|3/Part 2 - No Discount Coupons|Randomized to view direct mail marketing
9935936|NCT02974582|Experimental|4/Part 2 - Control|Randomized to view direct mail marketing
9935937|NCT02968108|Experimental|Group1: Ustekinumab Dose Regimen 1|Subjects will receive a single intravenous (IV) induction dose of 3 milligram per kilogram (mg/kg) for subjects less than < 40 kilogram (kg) or 130 milligram (mg) for subjects greater than or equal to >= 40 kg at Week 0 followed by subcutaneous (SC) maintenance dose of 2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at week 8.
9935938|NCT02968108|Experimental|Group2: Ustekinumab Dose Regimen 2|Subjects will receive a single Intravenous (IV) dose of 9 mg/kg for subjects <40 kg or 390 mg for subjects >= 40 kg at Week 0 followed by SC maintenance dose of 2 mg/kg for subjects <40 kg or 90 mg for subjects >= 40 kg at week 8.
9935939|NCT02960893|Experimental|Troriluzole|"Troriluzole - Randomization Phase: Participants received Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.~Troriluzole/Troriluzole - Extension Phase: Participants received Troriluzole 140 mg capsules orally QD for 48 weeks."
9935940|NCT02960893|Placebo Comparator|Placebo|"Placebo - Randomization Phase: Participants received matching placebo capsules orally QD for 8 weeks.~Placebo/Troriluzole - Extension Phase: Participants who received placebo during randomization phase, received Troriluzole 140 mg capsules orally QD for 48 weeks."
9935941|NCT02960659|Active Comparator|1|RCT: Metformin and liraglutide vs. metformin alone
9935942|NCT02960659|Experimental|2|Substudy: Metformin treated vs. control (no treatment)
9935943|NCT02942095|Experimental|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
9935944|NCT02942095|Experimental|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
9935945|NCT02942095|Experimental|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
9935946|NCT02941263||Affected Participants|Participants with unilateral or bilateral GA associated with AMD.
9935947|NCT02940522|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector
9935948|NCT02940522|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle
9935949|NCT02939404||healthy volunteers|non-diabetic healthy volunteers at a stable weight
9935950|NCT02938923|Experimental|Exercise + Testosterone (EX + T)|Supervised exercise training 2 times per week and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.
9935951|NCT02938923|Placebo Comparator|Exercise + Placebo (EX + P)|Supervised exercise training 2 times per week and placebo gel daily, both for six months duration.
9935952|NCT02938923|Other|Enhanced Usual Care (EUC)|Home exercise program 3 times per week and monthly health education modules, both for six months duration.
9935953|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
9935954|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
9935955|NCT02933255|Experimental|Lead-in mCRPC Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F every 2 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo sigmoidoscopies on week 9 and restaging scans on week 12. If no PD, option to continue treatment every 2 weeks until intolerance or progression. Option to extend nivolumab interval to 4 weeks after 1 year
9935956|NCT02933255|Experimental|Neoadjuvant Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo prostatectomy on week 9.
9935957|NCT02928497|Experimental|WATCHMAN (Device)|WATCHMAN LAAC Device implant including modified post-implant drug regimen.
9935958|NCT02928497|Active Comparator|Control|Single antiplatelet therapy or no therapy (Control) at the discretion of the study physician for the duration of the trial.
9935959|NCT02927236|Experimental|Cocaine - Active (EFS)|designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
9935960|NCT02927236|Sham Comparator|Cocaine - Sham (EFS)|To test the efficacy of the iTBS.
9935961|NCT02927236|Other|Healthy Control-Main (EFS)|Population comparison of acute experimental iTBS.
9935962|NCT02927236|Experimental|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
9875857|NCT00386282|Other|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
9875858|NCT00386373|Experimental|Imatinib Mesylate|
9875859|NCT00386386|Other|1|Subject receives two infusions: One by EASI Access and one by IV access, at different sites
9875860|NCT00386399|Experimental|Arm 1|Patients with BRCA2 gene will be treated with Mitomycin-C (MMC) on Day 1 at a dose of 10mg/m2 intravenously. This will be repeated every 28 days, which is one cycle. Treatment will continue until disease progression, serious toxicity, patient withdrawal or maximum cumulative dose of 60 mg/m2
9875861|NCT00386490|Experimental|Larazotide acetate 0.25 mg|larazotide acetate 0.25 mg capsule TID for 10 days
9875862|NCT00386490|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsule TID for 10 days
9875863|NCT00386490|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsule TID for 10 days
9875864|NCT00386490|Experimental|Placebo|Placebo capsule TID for 10 days
9875865|NCT00386516|Experimental|GM-CT-01, 5-FU|GM-CT-01 (280 mg/m2) combined with 5-FU (600 mg/m2) given 4 consecutive days in a 28 days cycle until disease progression.
9875866|NCT00386542|Experimental|ID-JI-0.1|"Group ID-JI-0.1 (n = 16) - reduced 0.1 mL INF doses administered intradermally (ID) by needle-free jet injector (JI) (Biojector® 2000 subcutaneous syringe no. 2 [green color code], with 2 cm investigational spacer, Bioject Medical Technologies, Inc., Portland, OR, USA)"
9875867|NCT00386542|Active Comparator|IM-NS-0.1|"Group IM-NS-0.1 (n = 16) - reduced 0.1 mL INF doses administered intramuscularly (IM) needle-syringe (NS) (via 22-25 gauge needle, minimum 25 mm/1-inch length)"
9875868|NCT00386542|Active Comparator|IM-NS-0.25 control|"Group IM-NS-0.25 (controls) (n = 16) - full 0.25 mL INF doses administered intramuscularly (IM) by needle-syringe (NS) (22-25 gauge needle, minimum 25 mm/1-inch length)"
9875869|NCT00386620||Survey + ED|"Part 1: Survey + Electronic Diaries (ED)~Part 2: 3 Month, 6 Month Survey + ED"
9875870|NCT00386633|Other|1|Lower dosage: 10E7_TCID50
9875871|NCT00386633|Active Comparator|2|10E8_TCID50
9875872|NCT00386672|Experimental|Lite OJ with Ca and VitD|240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
9875873|NCT00386672|Active Comparator|Lite OJ without Ca and VitD|240ml of reduced energy (lite) OJ beverage, 3 times per day.
9875874|NCT00386841|Active Comparator|A Escitalopram 10 mg|Escitalopram 10 mg
9875875|NCT00386841|Placebo Comparator|Placebo|Placebo
9875876|NCT00386893|Other|Treatment as usual|simultaneous EEG/fMRI
9875877|NCT00386906|Other|Sentinel Lymph Node (SLN) Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
9875878|NCT00386945|Other|1|Non-Experiment Intervention consisting of an intervention based on the Clinical Practice Guideline: Treating Tobacco Use and Dependence and modified for use in chiropractic settings.
9875879|NCT00386971|Active Comparator|1|L-carnitine
9875880|NCT00386971|Placebo Comparator|2|Placebo
9875881|NCT00387049|Experimental|Anxiety-specific smoking cessation care|
9875882|NCT00387049|Active Comparator|Standard smoking cessation care|
9875883|NCT00387166||1|Mexican-American women, aged 40-65
9875884|NCT00387179|Experimental|Dim Light Melatonin and/or methylxanthine|Dim Light Melatonin and/or methylxanthine
9875885|NCT00387179|Experimental|Placebo and Dim Light or bright light|Placebo and Dim Light or bright light
10211690|NCT04341194|Experimental|Skin-to-skin contact/breastfeeding/parental singing|Parent-driven interventions are skin-to-skin care, breastfeeding and multi-sensory stimulation like vocalisation. They are all a combination of multiple sensory inputs comprising auditory, tactile and olfactory recognition. Research has started to investigate breastfeeding in combination with Kangaroo-mother- care for example, which has shown to be an effective mix. A multimodal approach that includes a combination of non-pharmacological approaches is considered more effective during venipuncture than single strategies and provides greater pain relief.
9875886|NCT00387179|Experimental|Bright light melatonin and/or methylxanthine|Bright light, melatonin, and/or methylxanthine
9875887|NCT00387205|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
10211691|NCT04329481|Active Comparator|mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder. These include Shiitake, Maitake, Trametes Coriolus Versicolor, Agaricus.~Compliance to treatment will be considered as taking 80% of supplement/placebo treatment, and will be monitored by telephone calls and emails to patients during the study phase, and by counting the pills which were not taken at the end of the trial.~Treatment with Mycodigest supplement will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
9875888|NCT00387270|Experimental|A|Dimebon
9875889|NCT00387322|Experimental|Group 1|Patients receive oral erlotinib hydrochloride once on days 2, 9, and 16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression
9875890|NCT00387322|Experimental|Group 2|Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
9875891|NCT00387361|Experimental|1|
9875892|NCT00387361|No Intervention|2|
9875893|NCT00387374|Experimental|Stratum I (radiotherapy, bevacizumab, chemotherapy)|Patients undergo prophylactic radiotherapy on days 1-5 and 8-12. Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 15. Patients also receive paclitaxel IV over 3 hours or carboplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 36 (course 2).
9935963|NCT02923739|Active Comparator|Arm I (paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 and bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9987830|NCT01416714||Gastric Cancer|
9987831|NCT01416714||Gastrointestinal Stromal Tumors (GIST)|
9797065|NCT01585246|Other|Phase 1: The dose finding phase (DFP)|Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
9987832|NCT01416714||Esophageal Cancer|
9987833|NCT01416714||Pancreas Cancer|
9987834|NCT01416714||Hepatocellular Cancer|
9987835|NCT01416714||Biliary Cancer|
9987836|NCT01416714||Neuroendocrine Cancer|
9797066|NCT01585246|Active Comparator|Phase 2: RCT phase- Saw Palmetto|Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
9797067|NCT01585246|Placebo Comparator|Phase 2: RCT phase- Placebo|Patients received Soybean Oil Soft Gel as the placebo treatment
9797068|NCT01585272|Experimental|Rivastigmine|Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
9797069|NCT01585298|Experimental|Fingolimod|Fingolimod 0.5 mg by mouth once daily for 7 days.
9797070|NCT01585324|Experimental|Single Arm|
9797071|NCT01585428|Experimental|Cervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin.
9797072|NCT01585428|Experimental|NonCervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin
9797073|NCT01585441|Experimental|Finasteride 5 mg|Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
9797074|NCT01585441|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.
9797075|NCT01585558|Experimental|Treatment Group 1|
9797076|NCT01585558|Experimental|Treatment Group 2|
9797077|NCT01585558|Placebo Comparator|Treatment Group 3|
9797078|NCT01585584|Experimental|Boceprevir|
9797079|NCT01585597|Experimental|Mild Hypothermia|Reduction of body temperature to 34 degrees centigrade. This will be accomplished using the Zoll Coolguard .
9797080|NCT01585766|Experimental|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
9797081|NCT01585766|Experimental|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
9797082|NCT01585766|Experimental|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
9797083|NCT01585766|Experimental|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
9797084|NCT01585766|Experimental|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
9797085|NCT01585766|Placebo Comparator|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.
9797086|NCT01585779||Contour 3D® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Contour 3D® ring will occur in conjunction with another concomitant surgical repair procedure
9797087|NCT01585779||Tri-Ad® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Tri-Ad® ring will occur in conjunction with another concomitant surgical repair procedure
9797088|NCT01585831|Experimental|Testosterone gel 1%|Testosterone gel 1% applied to skin once per day for 1 year. Starting dose 1.25mL per day, titrated in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day. Titration based on testosterone levels with target level in mid-range of normal for Tanner stage.
9797089|NCT01585831|Placebo Comparator|Placebo gel|Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
9797090|NCT01585961||Catheter Ablation|These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
9797091|NCT01585987|Experimental|Arm A: Ipilimumab|Ipilimumab 10 mg/kg solution intravenously, 90 minute infusion, once every 3 weeks for 4 doses, then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
9797092|NCT01585987|Other|Arm B: Best Supportive care (BSC)|BSC may include the continuation of the Fluoropyrimidine that was used during the lead-in chemotherapy, but no other systemic anti cancer therapy
9797093|NCT01586026||Group A|Maintenance flushes at days 1-28
9797094|NCT01586026||Group B|Maintenance flushes at days 29-56
9797095|NCT01586026||Group C|Maintenance flushes at days 57+
9797096|NCT01586039|Active Comparator|Compact Fluorescent Light 90 lux|90 lux exposure of a commercially available Compact Fluorescent Light (CFL).
9797097|NCT01586039|Experimental|Blue-depleted LED light 90 lux|90 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
9797098|NCT01586039|Active Comparator|Compact Fluorescent Light 50 lux|50 lux exposure of a commercially available Compact Fluorescent Light (CFL).
9797099|NCT01586039|Experimental|Blue-depleted LED light 50 lux|50 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
9797100|NCT01586091|Placebo Comparator|Placebo|Placebo per os at time 0 hours + placebo per os at 12 hours.
9797101|NCT01586091|Active Comparator|Levocetirizin|Levocetirizin 5mg at time 0 and placebo per os at 12 hours
9797102|NCT01586091|Active Comparator|Fexofenadine|Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours
9875894|NCT00387374|Experimental|Stratum II (radiotherapy, chemotherapy, bevacizumab)|Patients undergo prophylactic radiotherapy and receive paclitaxel and carboplatin as in stratum I. Patients also receive bevacizumab IV over 30-90 minutes on day 15 (course 1). In both strata, treatment with paclitaxel, carboplatin, and bevacizumab repeats every 21 days for 5-6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease may continue to receive single-agent bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
9875895|NCT00387387|Experimental|FOLFOX 6 + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.
9875896|NCT00387387|Experimental|CapeOx + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m^2 twice daily.
9875897|NCT00387413|Experimental|Treatment Arm A1|In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
9875898|NCT00387413|Experimental|Treatment Arm A2|In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2.
9875899|NCT00387413|Experimental|Treatment Arm B1|In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
9875900|NCT00387413|Experimental|Treatment Arm B2|In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2.
9875901|NCT00387439|Experimental|standard medical treatment|standard medical treatment
9875902|NCT00387439|Experimental|standard medical treatment + anoperineal physiotherapy|standard medical treatment + anoperineal physiotherapy
9875903|NCT00387452|Active Comparator|1|
9875904|NCT00387452|Active Comparator|2|
9875905|NCT00387452|No Intervention|3|No intervention, only testing during 6 months.
9875906|NCT00387478|Experimental|1|modified Tree pollen allergen absorbed to Tyrosine and containing MPL adjuvant
9875907|NCT00387478|Experimental|2|modified Tree pollen allergen absorbed to Tyrosine
9875908|NCT00387478|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
9875909|NCT00387530|Other|Single Arm Study of Biopsy|
9875910|NCT00387556|Experimental|Ketamine + Ondansetron|ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
9875911|NCT00387556|Placebo Comparator|Ketamine + Placebo|ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo
9875912|NCT00387569|Experimental|Cohort 1|Experimental (20ug); Active Comparator/Placebo
9875913|NCT00387569|Experimental|Cohort 2|Experimental (60ug); Active Comparator/Placebo
9875914|NCT00387569|Experimental|Cohort 3|Experimental (200ug); Active Comparator/Placebo
9875915|NCT00387582|Experimental|I|Lucentis injections for the first three months of the study and then per the protocol for the duration of the trial.
9875916|NCT00387582|Active Comparator|II|Argon Laser treatment at enrollment and then per the protocol for the duration of the study.
9875917|NCT00387634|Active Comparator|Arm 1|Blood draw only, no vaccine
9875918|NCT00387634|Active Comparator|Arm 2|Blood draw only, no vaccine
9875919|NCT00387634|Active Comparator|Arm 3|Blood draw only, no vaccine
9875920|NCT00387634|Active Comparator|Arm 4|Blood draw only, no vaccine
9875921|NCT00387738|Experimental|1|TOLAMBA™ dose-intense regimen
9875922|NCT00387738|Experimental|2|TOLAMBA™ lower-dose regimen
9875923|NCT00387738|Placebo Comparator|3|
9875924|NCT00387855|Experimental|1|receive SOS program
9875925|NCT00387868|Other|Registration|Cisplatin, Etoposide & concurrent radiotherapy
9875926|NCT00387868|Other|Surgical Resection|No distant Progression post Registration Arm
9875927|NCT00387868|Other|Post Resection|Assessment post surgical procedure to determine if at higher risk of recurrence or if complete resection could not be achieved.
9875928|NCT00387920|Experimental|Treatment (enzyme inhibitor therapy)|"PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience."
9875929|NCT00387933|Experimental|Gleevec + PTK787/ZK 22584 + Hydroxyurea|Patients with recurrent or relapsing glioblastoma multiforme (GBM) will be given daily doses of Gleevec and PTK787/ZK 22584 orally in combination with fixed doses of hydroxyurea.
9875930|NCT00387998|Experimental|Risk primer|"Booklet written by investigators know your chances"
9875931|NCT00387998|Active Comparator|Control booklet|AHRQ staying healthy booklet
9875932|NCT00388011|Experimental|1|Intranasal morphine 3.75 mg
9875933|NCT00388011|Experimental|2|Intranasal morphine 7.5 mg
9875934|NCT00388011|Experimental|3|Intranasal morphine 15 mg
9875935|NCT00388011|Experimental|4|Intranasal morphine 30 mg
9875936|NCT00388011|Active Comparator|5|Intravenous morphine 7.5 mg
9875937|NCT00388011|Placebo Comparator|6|Intranasal placebo
9875938|NCT00388024||cancer patients about to be treated with radiation therapy|Patienta with histologically confirmed squamous cell or lymphoepithelioma of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or unknown primary of the head and neck about to be treated with radiation therapy
9875939|NCT00388050|Experimental|Diabetes Medication Choice decision aid|Patients in this arm will discuss diabetes medication for glucose control with the help of a decision aid that covers five commonly prescribed anti-hyperglycemic medications.
9875940|NCT00388050|Other|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
9875941|NCT00388076|Experimental|Part 1|pazopanib and paclitaxel
9875942|NCT00388076|Experimental|Part 2|pazopanib, paclitaxel, and carboplatin
9875943|NCT00388076|Experimental|Part 3|pazopanib, paclitaxel, and lapatinib
9929828|NCT00921401|Experimental|Asthma Feedback|Each month and before all visits with their asthma care provider, participants will be encouraged to go online and answer a series of questions regarding the types of asthma medications they use and how often they use them, asthma symptoms they have experienced, emergency department visits in the past year, the care they have received for their asthma (e.g., specialist visits) in the past year, and the planned date of their next visit with their asthma care provider. Participants will receive tailored feedback about what questions they should ask their doctor during a subsequent visit, whether or not they should schedule a visit sooner, and links to read more about each recommendation.
9929829|NCT00921401|Active Comparator|Preventive Feedback|Each month and before all visits with their primary care provider, participants will be encouraged to go online and answer a series of questions regarding their preventive care. They will receive tailored feedback regarding preventive services, such as pap testing, cancer screenings, and flu shots. Participants will receive tailored feedback regarding preventive services (e.g., cancer screening) that they should discuss with their primary care provider.
9987837|NCT01416714||Peritoneal Mesothelioma|
9987838|NCT01416714||Anal Cancer|
9875944|NCT00388115|Experimental|RFA prior to surgery|
9875945|NCT00388128|Placebo Comparator|A|
9875946|NCT00388141|Experimental|NIDCAP|In the intervention NIDCAP group the staff has been introduced and trained in the principles of the NIDCAP-care, where main core is to see, organize and conduct the care of the preterm infant on behalf of the childs actually resources and competences
9517653|NCT03304340|Experimental|TENS+SR|For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device & Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
9875947|NCT00388167||1|Caspofungin
9875948|NCT00388193|Experimental|1|
9875949|NCT00388271|Active Comparator|1|xatral
9875950|NCT00388271|Placebo Comparator|2|standard treatment
9875951|NCT00388310|Active Comparator|Cephalexin|Cephalexin 250 mg PO q6h x5 days
9875952|NCT00388310|Active Comparator|Clindamycin|Clindamycin 300 mg PO q6h x5 days
9875953|NCT00388310|Active Comparator|trimethoprim/sulfamethoxazole|trimethoprim/sulfamethoxazole 160 mg/800 mg PO q12h x 5 days
9875954|NCT00388310|Placebo Comparator|Placebo|
9875955|NCT00388323|Experimental|1|
9875956|NCT00388375|No Intervention|CVC Internal Jugular or Subclavian Vein|
9875957|NCT00388388|Experimental|1|Losartan treatment
9875958|NCT00388388|Active Comparator|2|Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
9875959|NCT00388427|Other|Advanced Solid Malignancies|
9875960|NCT00388544|Experimental|1|
9875961|NCT00388544|Experimental|2|
9875962|NCT00388544|Experimental|3|
9875963|NCT00388544|No Intervention|4|Recreational activities are not tailored to either style of interest or function
9875964|NCT00388557|Experimental|1|
9875965|NCT00388661|Active Comparator|Melatonin|melatonin 3mg
9875966|NCT00388661|Placebo Comparator|Placebo|
9875967|NCT00388700|Experimental|GM-CT-01|
9875968|NCT00388739|Active Comparator|Usual care|Systemic steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day). Subjects will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor. Children in the control group that do not own a nebulization compressor will be given a prescription for an albuterol MDI with mask and spacer with instructions to deliver 2 puffs (90mcg per actuation) 3 times a day as a standard chronic care regimen. Instructions to follow-up with their primary care physician in 3-5 days (as is standard care practice) will be given at discharge for patients in the control or treatment arm.
9875969|NCT00388739|Experimental|Usual care + 6 months of inhaled steroids|In addition to the usual care described above, patients randomized to the intervention/experimental arm will also be given a one month supply as well as a prescription (for a 6 month supply) for Budesonide respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
9875970|NCT00388843||Dose Increased|Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
9875971|NCT00388843||Dose Maintained|Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
9875972|NCT00388934|Experimental|Drug eluting stent (Cypher)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Cypher)
9875973|NCT00388934|Experimental|Drug eluting stent (Taxus)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Taxus)
9875974|NCT00388986|Experimental|1|
9875975|NCT00388986|Experimental|2|
9875976|NCT00388986|Experimental|3|
9875977|NCT00388999|Other|0 mg/kg|
9875978|NCT00388999|Other|0.5 mg/kg|
9875979|NCT00388999|Other|1.0 mg/kg|
9875980|NCT00389038|Active Comparator|Coping Skills Training + Amitriptyline|Behavioral coping skills training--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
9875981|NCT00389038|Active Comparator|Headache Education + Amitriptyline|Behavioral headache education
9875982|NCT00389090|Experimental|Temozolomide + O6BG|
9875983|NCT00389103|Placebo Comparator|placebo|
9875984|NCT00389116|Experimental|1|
9875985|NCT00389116|Placebo Comparator|2|
9875986|NCT00389181|Experimental|Medical management|Patients with unruptured BAVMs will receive symptomatic medical management alone.
9875987|NCT00389181|Active Comparator|Interventional therapy|Patients with unruptured BAVMs will receive symptomatic medical management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy).
9875988|NCT00389220|Active Comparator|BioMatrix Flex stent|Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer
9875989|NCT00389220|Active Comparator|Cypher Select stent|Coronary stent placement with Sirolimus coated stent with durable polymer
9875990|NCT00389233|Experimental|1|2L gut cleansing solution
9875991|NCT00389233|Active Comparator|2|4L preparation
9875992|NCT00389259|Experimental|A|IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
9875993|NCT00389259|Placebo Comparator|B|IV Look alike drug Q 4h
9875994|NCT00389311|Active Comparator|Nonoxynol-9|Gynol-II, 2% N-9, 5 mL
9875995|NCT00389311|Other|Normosol-R|Normosol-R, 5 mL, single administration, negative control
9875996|NCT00389311|Experimental|Normosol with simulation, endoscopy and biopsy|Normosol-R, 5 mL following simulation, endoscopy and biopsy
9875997|NCT00389376|Other|Group 1|Placebo and 140 mg single dose + every 8 hours
9875998|NCT00389376|Other|Group 2|Placebo and 280 mg single dose
9875999|NCT00389376|Other|Group 3|Placebo and 280mg every 8 hours
9876000|NCT00389376|Other|Group 4|Placebo and 280 single dose + every 8 hours
9876001|NCT00389376|Other|Group 5|Placebo and 560 mg single dose + every 8 hours
9876002|NCT00389376|Other|Group 6|Placebo and 560 mg single dose + every 8 hours
9876003|NCT00389376|Other|Group 7|Placebo and 700 mg single dose + every 8 hours
9876004|NCT00389480|Experimental|I|Dose escalating
9876005|NCT00389558|Active Comparator|2|Biseptine
9876006|NCT00389558|Active Comparator|1|Amukin
9876007|NCT00389636|Active Comparator|1|TheraGauze alone
9876008|NCT00389636|Active Comparator|2|Theragauze + Regranex
9876009|NCT00389727|Experimental|Group 1 Patients|Radiotherapy Patients
9876010|NCT00389727|No Intervention|Group 2|
9876011|NCT00389792|No Intervention|ATI-2042 200 mg|
9876012|NCT00389792|No Intervention|ATI-2042 400 mg|
9876013|NCT00389792|No Intervention|ATI-2042 600 mg|
9876014|NCT00389792|No Intervention|ATI-2042 Placebo|
9876015|NCT00389883|Active Comparator|1|propofol et remifentanil
9876016|NCT00389883|Experimental|2|sevoflurane et sufentanil
9876017|NCT00389909|Active Comparator|1|Treatment based on patient weight;
9876018|NCT00389909|Active Comparator|2|Treatment based on a chart taking into account weight, age and gender
9876019|NCT00389922|Experimental|A (Daily Dosing)|"Oral lapatinib given daily for 28 days plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
9876020|NCT00389922|Experimental|B (Intermittent Dosing)|"Oral lapatinib given days 2-5, 9-12 and 16-25 plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
9876021|NCT00389935|Experimental|Treatment|
9929830|NCT00921414|Active Comparator|1|observation : 3 years maintenance period with assesments and surveillance every 2 months
9929831|NCT00921414|Experimental|2|maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
9935964|NCT02923739|Experimental|Arm II (paclitaxel, bevacizumab, emactuzumab)|Patients receive paclitaxel and bevacizumab as in Arm I. Patients also receive emactuzumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9935965|NCT02913313|Experimental|Part 1A: Dose Escalation Monotherapy|
9987839|NCT01416714||Colorectal Cancer|
9876022|NCT00390000|Experimental|Arm I|See Detailed Description
9876023|NCT00390039|Experimental|A|MNS075 7.5mg
9876024|NCT00390039|Placebo Comparator|B|Placebo
9876025|NCT00390039|Active Comparator|C|IV Morphine
9876026|NCT00390039|Experimental|E|MNS075 15mg
9876027|NCT00390039|Placebo Comparator|D|Placebo
9876028|NCT00390039|Placebo Comparator|F|Placebo
9876029|NCT00390052|Experimental|Arm I|Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
9876030|NCT00390065|Experimental|Study group|Hypoxemic Respiratory Failure treated by Nitric Oxide;
9876031|NCT00390065|Placebo Comparator|Control|Hypoxemic Respiratory Failure control (Placebo);
9876032|NCT00390065|No Intervention|Reference|Reference (Non hypoxemic respiratory failure)
9876033|NCT00390078|Active Comparator|1|20 Subjects, 1x 10E8_TCID50 MVA-mBN32
9876034|NCT00390078|Placebo Comparator|2|10 Subjects 1x 10E8_TCID50 IMVAMUNE
9876035|NCT00390117|Experimental|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
9876036|NCT00390130|Active Comparator|Pentacel|The subjects in this arm will be vaccinated with Pentacel
9876037|NCT00390130|Active Comparator|Prevnar|The subjects in this arm will be vaccinated with Prevnar
9876038|NCT00390195|Experimental|1. Daily|Taking orally the investigational drug daily
9876039|NCT00390195|Experimental|2. Weekly|Taking orally the investigational drug weekly
9876040|NCT00390208|Other|Group 1|Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy
9876041|NCT00390208|Other|Group 2|Monotherapy: One 0.5 mg intravitreal Ranibizumab injection
9876042|NCT00390312|Active Comparator|4|Intravenous morphine
9876043|NCT00390312|Experimental|1|Intranasal morphine 7.5 mg
9876044|NCT00390312|Experimental|2|Intranasal morphine 15 mg
9876045|NCT00390312|Active Comparator|3|Oral morphine 60 mg
9876046|NCT00390312|Placebo Comparator|5|Intranasal placebo
9876047|NCT00390312|Placebo Comparator|6|Oral placebo
9876048|NCT00390312|Placebo Comparator|7|Intravenous placebo
9876049|NCT00390338|Experimental|peptide-pulsed type-1-polarized dendritic cells|intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
9876050|NCT00390338|Experimental|peptide-pulsed mature non-polarized dendritic cells (cDCs)|intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
9876051|NCT00390481|Other|Intervention|EC-IC Bypass
9876052|NCT00390481|No Intervention|Control|Best Medical Therapy
9876053|NCT00390585|Experimental|A|Iodixanol 320
9876054|NCT00390585|Active Comparator|B|Iomeprol 350
9876055|NCT00390598|Active Comparator|senna 36 mG + PEG 2L|Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
9876056|NCT00390598|Active Comparator|4 L PEG|Bowel preparation with 4 L PEG prior to colonoscopy.
9876057|NCT00390637|Experimental|1|Low Protein, Low GI Diet
9876058|NCT00390637|Experimental|2|Low Protein, High Glycemic Index Diet
9876059|NCT00390637|Experimental|3|High Protein, Low Glycemic Index diet
9876060|NCT00390637|Experimental|4|High Protein, High glycemic index diet
9876061|NCT00390637|Experimental|5|Control diet (current recommendations)
9876062|NCT00390702|Experimental|VSD occluder|transcatheter implantation of a VSD occluder (Nitinol coil)
9876063|NCT00390754|Experimental|Pregnancy Test Group|Group got free home pregnancy test kits
9876064|NCT00390754|No Intervention|2|Group did not receive free home pregnancy test kits
9876065|NCT00390767|Experimental|MultiGeneAngio|Escalating doses of MultiGeneAngio
9876066|NCT00390793|Experimental|Treatment (chemotherapy, dasatinib)|See detailed description in outline.
9876067|NCT00390832|Active Comparator|A|recombinant human erythropoietin beta
9876068|NCT00390832|Placebo Comparator|B|0.9% NaCl solution
9876069|NCT00390871|Active Comparator|Fentanyl/Propofol sedation first|Patient given fentanyl only first, then sedated with fentanyl/propofol as needed to have Richmond Agitation Sedation Scale (RASS) Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/dexmedetomidine to have RASS Score 0 to -1.
9876070|NCT00390871|Active Comparator|Fentanyl/Dexmedetomidine sedation first|Patient given fentanyl only first, then sedated with fentanyl/dexmedetomidine as needed to have RASS Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/propofol to have RASS Score 0 to -1.
9876071|NCT00390923|Experimental|1|
9876072|NCT00390923|Placebo Comparator|2|
9876073|NCT00390936|No Intervention|1|4 dosages
9876074|NCT00391001|Experimental|1|
9876075|NCT00391001|Placebo Comparator|2|
9876076|NCT00391014|Experimental|1|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
9876077|NCT00391131|Experimental|Ig NextGen 16%|
9876078|NCT00391183|Active Comparator|Endoscopic stenting|patients with biliary obstruction will undergo endoscopic stenting.
9876079|NCT00391183|No Intervention|Best supportive care|
9876080|NCT00391235||BPD|Children with bipolar disorder
9876081|NCT00391235||HC|Healthy comparison children
9876082|NCT00391287||erythropoietin treatment in CRF|Patients exposed to EPREX or other marketed erythropoietin products administered by the subcutaneous route of administration for the treatment of anemia of Chronic Renal Failure
9876083|NCT00391352||MS|MS patient is matched to healthy volunteer
9876084|NCT00391352||Control|
9876085|NCT00391404|Active Comparator|Alendronate|Oral alendronate 70 mg weekly
9876086|NCT00391404|Placebo Comparator|Placebo|Conventional drug treatment
9876087|NCT00391521|Active Comparator|1|Regimen 1
9876088|NCT00391521|Active Comparator|2|Regimen 2
9876089|NCT00391521|Active Comparator|3|Regimen 3
9876090|NCT00391534|Experimental|Oxcarbazepine MR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
9876091|NCT00391534|Active Comparator|Oxcarbazepine IR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
9876092|NCT00391612|Sham Comparator|2|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy but no stents are placed
9876093|NCT00391612|Experimental|1|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy during which up to six Exhale drug-eluting stents are placed in the lungs
9876094|NCT00391638|Experimental|HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg|Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
9876095|NCT00391651|Active Comparator|1|Nitrofurantoin 100mg BID x 5 days
9876096|NCT00391651|Active Comparator|2|TMP/SMX DS BID x 3 days
9876097|NCT00391677|Experimental|1|Participants will receive social skills training with attention shaping procedures
9876098|NCT00391677|Active Comparator|2|Participants will receive social skills training without attention shaping procedures
9876099|NCT00391703|Experimental|1|Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
9876100|NCT00391703|Active Comparator|2|Usual sport activity, performed prior to an endurance retraining program using a cycloergometer
9876101|NCT00391729|Placebo Comparator|1|
9876102|NCT00391729|Experimental|2|
9876103|NCT00391755|Active Comparator|1|ramelteon 8 mg po qhs with sleep and migraine journal
9876104|NCT00391755|Placebo Comparator|2|Placebo po qhs with sleep and migraine journal
9876105|NCT00391794|Experimental|ESSG|eight weekly 90-minute sessions
9876106|NCT00391794|Active Comparator|ES|one 4-hour educational program
9876107|NCT00391859|Experimental|Health service provision|Health service provision within the first few months of diagnosis which includes physical examination, radiographs, education, exercise, weight loss, assistive devices and pharmacologic therapy.
9876108|NCT00391911|Active Comparator|NAC and CRRT|N-Acetylcysteine and CRRT Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label,
9876109|NCT00391911|Other|NAC and non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
9876110|NCT00391911|Other|Placebo and CRRT|Patients are assigned to placebo treatment and CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT is open label.
9876111|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. This is the standard of care arm. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
9876112|NCT00391937|Experimental|1|ASR prosthesis placed using CAS
9876113|NCT00391937|Active Comparator|2|ASR prosthesis placed by conventional method
9929832|NCT00921427|Active Comparator|VRT and active tDCS|Patients will receive tDCS (noninvasive brain stimulation) concurrently with vision restoration therapy. TDCS is delivered using a small battery-operated device. Electrical leads from the device are connected to saline soaked sponges that are placed at strategic locations on the skull corresponding to areas of the brain that need to be stimulated (in this case, the visual cortex). The dosage will be set to 2 mA/min for 30 minutes, twice a day for 3 days a week for 12 weeks.
9929833|NCT00921427|Sham Comparator|VRT combined with sham tDCS|Patients will receive sham tDCS concurrently with vision restoration therapy. Electrical leads from the tDCS device will be connected to saline soaked sponges placed at strategic locations on the skull, in a similar maner as in the active tDCS group. Current will be turned on for 30 seconds but will be slowly ramped down and turned off. Treatment will continue for 3 days a week for 12 weeks.
9929834|NCT00921453||Intervention 1|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
9876114|NCT00392080|Placebo Comparator|3|
9876115|NCT00392080|Experimental|1|75 mg BID
9876116|NCT00392080|Experimental|2|
9876117|NCT00392106|Active Comparator|Control|Class I or III anti-arrhythmic drug for the treatment of AF
9876118|NCT00392106|Experimental|Treatment|Pulmonary vein ablation with HIFU
9876119|NCT00392145|Active Comparator|1|
9876120|NCT00392145|Experimental|2|
9876121|NCT00392184|Experimental|APBI|Accelerated Partial Breast Irradiation with interstitial Brachytherapy
9876122|NCT00392314|Experimental|Early favorable|patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
9876123|NCT00392314|Experimental|Early Unfavorable|Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or >50 , lymphocytic depleted or mixed cellularity
9876124|NCT00392314|Experimental|advanced disease|patients with advanced disease low IPS score 0-2 will start chemotherapy with ABVD for 2 cycles followed by PET/CT further therapy will be given according to PET/CT results
9876125|NCT00392314|Experimental|advanced disease IPS 3-7|Patients with advanced disease IPS score 3-7 will start chemotherapy with escalated beacopp. following 2 cycles PET/CT will be carried out and according to results further chemotherapy will be given
9876126|NCT00392509|Experimental|2|Unfractionated Autologous Mononuclear Bone Marrow
9876127|NCT00392535|Active Comparator|Control arm|conventional radiotherapy (74 Gy delivered in 37 fractions over 7·4 weeks)
9876128|NCT00392535|Experimental|Hypofractionated arm 1|Hypofractionated radiotherapy (60 Gy in 20 fractions over 4 weeks)
9876129|NCT00392535|Experimental|Hypofractionated arm 2|Hypofractionated radiotherapy (57 Gy in 19 fractions over 3·8 weeks)
9876130|NCT00392561|Experimental|1|Selenium
9876131|NCT00392561|Experimental|2|Vitamin E
9876132|NCT00392561|Experimental|3|Vitamin E + Selenium
9876133|NCT00392561|No Intervention|Arm 4|
9876134|NCT00392639|Experimental|1-2|Comparison of 2 cooling procedures
9876135|NCT00392652|Experimental|Arm I (low-dose oral diindolylmethane)|Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.
9876136|NCT00392652|Experimental|Arm II (high-dose oral diinolylmethane)|Participants receive high-dose oral BR-DIM twice daily for 4 weeks.
9876137|NCT00392691|Experimental|Zevalin, Rituximab, Melphalan|
9876138|NCT00392730||1|Preterm infants in NICU and age-matched controls
9876139|NCT00392730||2|Term infants in NICU and age-matched controls
9876140|NCT00392730||3|Children on home PN (to age 6) and age-matched controls
9876141|NCT00392743||pet/spect scan|
9876142|NCT00392756|No Intervention|off treatment|Subjects undergo the baseline evaluation off treatment
9876143|NCT00392756|Experimental|GnRH Treatment|Subjects receive long term pulsatile GnRH therapy
9876144|NCT00392847|Active Comparator|2|The first group will receive routine follow-up as currently provided by national community health and social services.
9876145|NCT00392847|Experimental|1|will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.
9876146|NCT00392873|Experimental|EAMD+Calories|This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy expenditure.
9876147|NCT00392873|No Intervention|EAMD Control|This group contains women with exercise-associated menstrual disturbances (EAMD) and undergoes the same procedures as the EAMD+Calories group. However, this group is instructed to maintain exercise and eating habits.
9876148|NCT00392873|No Intervention|Heathy Control|This group contains exercising women with regular, ovulatory menstrual cycles. this group is instructed to maintain body weight and exercise and eating habits.
9876149|NCT00392886|Experimental|Regimen C|Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
9876150|NCT00392886|Experimental|Regimen D2|In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
9876151|NCT00392899|Active Comparator|UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
9876152|NCT00392899|No Intervention|Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
9876153|NCT00393055|Experimental|xylitol lozenge|1g xylitol lozenge. Five/day, dissolved in mouth
9876154|NCT00393055|Placebo Comparator|inactive lozenge|1g placebo lozenge. Five/day, dissolved in mouth
9876155|NCT00393172|Experimental|exercise|5 days per week exercise for 4 months
9876156|NCT00393172|No Intervention|no exercise|
9876157|NCT00393198|Experimental|Arm 1|
9876158|NCT00393198|Placebo Comparator|Arm 2|
9876159|NCT00393198|Active Comparator|Arm 3|
9876160|NCT00393224||cohort|hospital based family cohort
9876161|NCT00393250|Experimental|1|Hypnosis
9876162|NCT00393250|Active Comparator|2|Control
9876163|NCT00393263|Experimental|1|pimecrolimus
9876164|NCT00393263|Active Comparator|2|clobetasol
9876165|NCT00393276|Experimental|A|HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.
9876166|NCT00393276|Experimental|B|HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.
9876167|NCT00393276|Experimental|C|HCV/HIV-coinfected as defined above in Arms A and B.
9876168|NCT00393302||1 & 2|"Retrospective chart review: HIV testing rates~Prospective cohort group: HIV testing rates"
9876169|NCT00393328|Active Comparator|A|
9876170|NCT00393328|Active Comparator|B|
9876171|NCT00393341||Case|Women with breast cancer
9876172|NCT00393341||Control|Women without breast cancer
9876173|NCT00393445|Experimental|Intravenous infusion|intravenous infusion of test substances
9876174|NCT00393575|Experimental|Community Mobilization|The intervention population is defined as the community each site is attempting to mobilize.
9876175|NCT00393627|Experimental|1|Sleep Education Program: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
9876176|NCT00393627|Placebo Comparator|2|Routine medical care
9876177|NCT00393640|Active Comparator|A|Breast pump given and used on regular intervals
9876178|NCT00393640|No Intervention|B|
9876179|NCT00393640|Active Comparator|c|Breast pump given to be used on regular interval
9876180|NCT00393640|No Intervention|D|
9876181|NCT00393679|Experimental|1|AS-AQ
9876182|NCT00393679|Experimental|2|"DHAPQ~TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities."
9876183|NCT00393679|Experimental|3|AL
9876184|NCT00393679|Experimental|4|"Lapdap + AS~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
9876185|NCT00393744|Experimental|1|
9876186|NCT00393744|Active Comparator|2|
9876187|NCT00393770|Experimental|L-acetylcarnitine|
9876188|NCT00393783|Experimental|1|HER2 ECD DNA.
9876189|NCT00393822|Experimental|Palifermin|50 subjects to receive palifermin 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
9876190|NCT00393822|Placebo Comparator|Control Group|50 subjects to receive matched placebo 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
9876191|NCT00393900||1|Children with tympanostomy tubes for chronic OME
9876192|NCT00394017|Active Comparator|Intervention group|Reminder letters and usual implementations vs. usual implementation
9876193|NCT00394017|No Intervention|Control group|usual implementations
9876194|NCT00394030|Experimental|Group A|In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.
9876195|NCT00394030|Experimental|Group B|In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
9876196|NCT00394030|Experimental|Group C|In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.
9876197|NCT00394030|Experimental|Group D|In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.
9876198|NCT00394030|Experimental|Group E|In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.
9876199|NCT00394030|Experimental|Group F|In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
9876200|NCT00394030|Experimental|Group G|In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.
9876201|NCT00394030|Experimental|Group H|In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.
9876202|NCT00394043|Experimental|Osteopathic Manipulative Treatment|A protocol of specific osteopathic manipulative techniques was applied.
9876203|NCT00394043|Placebo Comparator|Placebo ultrasound|Sub-therapeutic ultrasound was applied.
9876204|NCT00394043|No Intervention|Standard Medical care|Subjects did not receive either study treatment, but continued to receive standard medical care.
9876205|NCT00394056|Other|Period 1|
9876206|NCT00394056|Other|Period 2|
9876207|NCT00394056|Other|Period 3|
9876208|NCT00394134|Other|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
9876209|NCT00394173|Experimental|1|
9876210|NCT00394173|Placebo Comparator|2|
9876211|NCT00394290|Experimental|PPC|Night time device for positive pulmonary pressure
9876212|NCT00394303|Experimental|1|Intervention
9876213|NCT00394303|No Intervention|2|Control
9876214|NCT00394381|Experimental|CIK infusion|Infusion of autologous CIK cells in study group. There is only one arm to this study
9876215|NCT00394407|Active Comparator|sliding scale regular insulin|sliding scale insulin given acqhs
9876216|NCT00394407|Active Comparator|glargine insulin and glulisine insulin|glargine basal insulin once a day with prandial glulisine insulin tid
9876217|NCT00394459|Active Comparator|A|Perifix Standard
9876218|NCT00394459|Experimental|B|Perifix New
9876219|NCT00394511|Experimental|Arm I|Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
9876220|NCT00394511|No Intervention|Arm II|No further treatment.
9876221|NCT00394576|Experimental|usual care plus Internet-based nutrition module|usual care plus Internet-based nutrition module
9876222|NCT00394576|Active Comparator|usual care|usual care
9876223|NCT00394602||Patients|Patients receiving chemoradiation for abdominal-pelvic tumors.
9876224|NCT00394602||Caregiver Controls|Healthy controls with no prior cancer diagnosis.
9876225|NCT00394810|Experimental|1|
9876226|NCT00394849|Experimental|suture one tonsillar fossa|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
9876227|NCT00394849|No Intervention|One side not sutured|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
9876228|NCT00394966|Experimental|SCH 619734 Dose 1|
9876229|NCT00394966|Experimental|SCH 619734 Dose 2|
9876230|NCT00394966|Experimental|SCH 619734 Dose 3|
9876231|NCT00394966|Experimental|SCH 619734 Dose 4|
9876232|NCT00394966|Placebo Comparator|Placebo|
9876233|NCT00394992|Active Comparator|1 oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
9876234|NCT00394992|Experimental|2 oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
9876235|NCT00395031|Other|Ziprasidone|Open label
9876236|NCT00395070|Experimental|Treatment Arm|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
9876237|NCT00395070|Active Comparator|Control Arm|DTIC 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR TMZ 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
9876238|NCT00395174|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2005-2006 formulation containing 45μg of each hemagglutinin derived from A/New Caledonia (H1N1), A/Wisconsin (H3N2) and B/Ohio~135μg total"
9876239|NCT00395174|Active Comparator|TIV (Fluzone)|"Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and B/Malaysia~45μg total~(Fluzone, sanofi pasteur)"
9876240|NCT00395200|Experimental|MSC Treatment|
9876241|NCT00395213||1|Children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
9876242|NCT00395239|Experimental|1|
9876243|NCT00395252|Experimental|one arm study|Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months
9876244|NCT00395278||HIV negative|HIV negative without Kaposi sarcoma
9876245|NCT00395278||HIV positive|HIV positive without Kaposi sarcoma
9876246|NCT00395278||HIV positive KS|HIV positive with Kaposi sarcoma
9876247|NCT00395382|Active Comparator|1|Alendronate
9876248|NCT00395382|Placebo Comparator|2|Placebo
9876249|NCT00395421|Experimental|A|NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW)
9876250|NCT00395551|Active Comparator|ranibizumab|ranibizumab 0.5mg intravitreal injection
9876251|NCT00395681|Active Comparator|propofol|propofol 200 mg versus 350 mg
9876252|NCT00395681|Active Comparator|Propofol|Propofol 350 mg versus 200 mg
9876253|NCT00395707|Active Comparator|1|Lucentis 0.3mg/0.05 ml
9876254|NCT00395707|Active Comparator|2|Lucentis 0.5mg/0.05 ml
9876255|NCT00395720|Active Comparator|1|Group 1 (10 volunteers): 5 x 10^7 pfu
9876256|NCT00395720|Active Comparator|2|Group 2 (10 volunteers): 1 x 10^8 pfu
9876257|NCT00395772|Active Comparator|Arm 4|
9876258|NCT00395772|Experimental|Arm 1|
9876259|NCT00395772|Experimental|Arm 2|
9876260|NCT00395772|Experimental|Arm 3|
9876261|NCT00395889|Experimental|Rehabilitation + Lifestyle Counseling|Multicomponent Pulmonary Rehabilitation Program including structured exercise training
9876262|NCT00395889|Active Comparator|Lifestyle Counseling|
9876263|NCT00395941|Active Comparator|Control|Acitretin
9876264|NCT00395941|Experimental|Experimental|Pioglitazone
9876265|NCT00396071|Experimental|1|Vildagliptin 100 mg qd
9876266|NCT00396071|Placebo Comparator|2|Matching placebo
9876267|NCT00396149|Placebo Comparator|Placebo|Placebo group
9876268|NCT00396149|Experimental|Active group|rBet v 1 tablets
9876269|NCT00396188||Normals|"Patients seeking initial laser vision correction that were screened to be good candidates for the procedure.~No history of refractive or other ocular surgery.~No corneal pathologies.~Normal corneal topography.~Contact lens wearers should discontinue use at least 2 weeks for hard contacts, and 3 days for soft lenses prior to imaging."
9876270|NCT00396188||Keratoconus|"An irregular cornea determined by distorted keratometry mires, distortion of the retinoscopic, or ophthalmoscopic red reflex (or a combination of these)~At least one of the following biomicroscopic signs: Vogt's striae, Fleischer's ring of >2 mm arc, or corneal scarring consistent with keratoconus.~Contact lens wearers should discontinue use preferably 1 day or at least half an hour prior to imaging."
9876271|NCT00396188||Myopic Laser Vision Correction|"Patients who have undergone myopic:~LASIK~PRK~LASEK"
9876272|NCT00396188||Hyperopic Laser Vision Correction|"Patients who have undergone hyperopic:~LASIK~PRK~LASEK"
9876273|NCT00396188||Orthokeratology|1. Patients using specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error.
9876274|NCT00396188||Others|1. Corneal conditions (diseases/ pathologies/surgeries) that can potentially affect the corneal surface that are not listed above (e.g. pellucid marginal degeneration; postoperative corneal transplant, intra-corneal ring segments, refractive keratotomy, conductive keratoplasty; peripheral ulcerative keratitis, Terrien's marginal degeneration; etc.).
9876275|NCT00396214|Experimental|1|
9876276|NCT00396214|Experimental|2|
9876277|NCT00396214|Active Comparator|3|
9876278|NCT00396227|Experimental|1|Vildagliptin 100mg + Met
9876279|NCT00396227|Active Comparator|TZD|TZD + metformin
9929835|NCT00921453||Control 1|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
9929836|NCT00921453||Intervention 2|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
9929837|NCT00921453||Control 2|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
9929838|NCT00921466||Hospital Patients/Hospital Employees|
9929839|NCT00921466||Hospital employees|A group of 10 hospital employees used as baseline
9929840|NCT00921479||Females|Norwegian females Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar.
9929841|NCT00921479||Males|Norwegian males of Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar
9929842|NCT00921492|Experimental|Low-frequency electro-acupuncture|
9929843|NCT00921492|Active Comparator|Meeting a therapist - attention|
9929844|NCT00921505|Active Comparator|Ibuprofen 400 mg|Ibuprofen oral single dose
9929845|NCT00921505|Active Comparator|Ibuprofen 1200 mg|Ibuprofen oral single dose
9929846|NCT00921505|Active Comparator|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) oral single dose
9929847|NCT00921505|Active Comparator|Ibuprofen 400 mg + paracetamol 1000 mg|Paracetamol (acetaminophen) + ibuprofen oral single dose
9929848|NCT00921531|Experimental|Thalidomide and TACE|Thalidomide is used for adjuvant therapy for TACE
9929849|NCT00921531|Active Comparator|TACE only|
9929850|NCT00921544|Active Comparator|Oral Sucrose|Oral sucrose administered 2 mins prior to eye exam
9929851|NCT00921544|Placebo Comparator|Sterile water|0.2 mls of sterile water
9929852|NCT00921570|Experimental|Amlodipine|
9929853|NCT00921570|Experimental|Valsartan|
9929854|NCT00921570|Experimental|Valsartan+Amlodipine|
9929855|NCT00921583||1|Examination of dental implants 20 years in function
9929856|NCT00921596|Other|Totally endoscopic cardiac operation|Patients with cardiac diseases undergo cardiac operations with totally endoscopic and cardiopulmonary bypass
9929857|NCT00921609||Acromegaly patients|All patients will undergo oral glucose tolerance test at postoperative day 1, 6 weeks, 3 months, and 1 year
9929858|NCT00921622|Active Comparator|Vitamin D|1000 IU twice daily for up to 10 days
9929859|NCT00921622|Active Comparator|Vitamin C|500 mg twice daily for up to 10 days
9929860|NCT00921635|Experimental|Maintain hemoglobin level above 120 g/L|Hemoglobin level from 120 g/L to 130 g/L
9929861|NCT00921635|Active Comparator|Maintain hemoglobin level above 100 g/L|Hemoglobin level from 100 g/L to 110 g/L
9876280|NCT00396305|Experimental|Group 2, Control Double Dose|12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.
9876281|NCT00396305|Experimental|Group 3-Control late booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.
9876282|NCT00396305|Active Comparator|Group 1, Control|12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.
9876283|NCT00396305|Experimental|Group 4-Control early booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.
9876284|NCT00396344|Placebo Comparator|1|Saline control
9876285|NCT00396344|Experimental|2|
9876286|NCT00396344|Experimental|3|
9876287|NCT00396370|Experimental|Group A: BCG ID/Placebo PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): Placebo ID/Placebo PO.
9876288|NCT00396370|Experimental|Group B: BCG ID/Placebo PO; BCG ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): BCG ID (Danish)/Placebo PO.
9876289|NCT00396370|Experimental|Group C: Placebo ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
9876290|NCT00396370|Experimental|Group D: Placebo ID/BCG PO; Placebo ID/BCG PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/BCG PO (Danish).
9876291|NCT00396370|Experimental|Group E: BCG ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
9876292|NCT00396370|Experimental|Group F: BCG ID/BCG PO; BCG ID/BCG PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): BCG ID (Danish)/BCG PO (Danish).
9876293|NCT00396370|Experimental|Group G: Connaught strain BCG ID|Primary vaccination: Connaught strain BCG ID; secondary vaccination (1 year later): none.
9876294|NCT00396435|Experimental|Group A|High Hb target
9876295|NCT00396435|Active Comparator|Group B|Low Hb Target
9876296|NCT00396461|Active Comparator|TPN A (Group I)|Emulsion based on 20% MCT/LCT (50:50 ratio)
9876297|NCT00396461|Experimental|TPN B (Group II)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides
9876298|NCT00396474||SGA patients|Infants born small for SGA who either received GH, no GH, or growth within normal ranges.
9876299|NCT00396552|Experimental|1|
9876300|NCT00396552|Sham Comparator|2|
9876301|NCT00396643|Experimental|A|
9876302|NCT00396643|Placebo Comparator|B|Coconut oil
9876303|NCT00396669|Experimental|Dopamine release|
9876304|NCT00396721|Active Comparator|A|
9876305|NCT00396721|Experimental|B|
9876306|NCT00396747|Active Comparator|A|Methotrexate
9876307|NCT00396747|Active Comparator|B|MTX + MP
9876308|NCT00396747|Active Comparator|C|MTX + IFX
9876309|NCT00396786|Experimental|Arm 1|
9876310|NCT00396786|Experimental|Arm 2|
9876311|NCT00396786|Experimental|Arm 3|
9876312|NCT00396786|Experimental|Arm 4|
9876313|NCT00396786|Experimental|Arm 5|
9876314|NCT00396786|Active Comparator|Arm 6|
9876315|NCT00396825|Experimental|Active treatment|Subjects randomized to this arm will receive the Family Caregiver Kit composed of the Williams LifeSkills Family Caregiver Video and Workbook and will also receive telephone coaching
9876316|NCT00396825|No Intervention|Control|Subjects randomized to this arm will receive no intervention and serve as wait list controls. They will undergo the same evaluations as the Intervention arm subjects at comparable times. In a crossover design, once subjects have finished serving as controls, they will be given the video, workbook, and telephone calls from a social worker and tested one more time.
9876317|NCT00396864|Experimental|NPI-0052|Advanced Solid Tumor Malignancies and Refractory Lymphoma
9876318|NCT00396994|Experimental|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
9876319|NCT00396994|Placebo Comparator|2|10 minutes per day standing on sham low mechanical stimulation platform
9876320|NCT00397072|Experimental|ZK-EPO|administered iv for 3 h every 21 days; dose reductions to 12 or 9 mg/m2 ZK-EPO were allowed in order to manage any treatment-related toxicity.
9876321|NCT00397137|Experimental|Stapled Anopexy|Circular stapled anopexy
9876322|NCT00397137|Active Comparator|Conventional Haemorrhoidectomy|Closed diathermy haemorrhoidectomy
9876323|NCT00397163|Active Comparator|Remote preconditioning|Simultaneous inflation (5min) and deflation (5min) of cuffs placed on upper arm and thigh - cycle repeated 2 times
9876324|NCT00397163|Placebo Comparator|Placebo|Deflated cuffs placed on upperarm and thigh for 20 minutes
9876325|NCT00397202|Active Comparator|The DivaCupTM|
9997118|NCT01506154|Experimental|MRX-7EAT|Therapy with experimental drug
9876326|NCT00397384|Experimental|Treatment (cetuximab and erlotinib hydrochloride)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9876327|NCT00397423|Active Comparator|1|1,G-CSF,intervention
9876328|NCT00397423|Placebo Comparator|2|2,NS,intervention
9876329|NCT00397436|Experimental|1|Comparing irradiated skin to non irradiated skin.
9876330|NCT00397449|Experimental|1, 2, 3|
9876331|NCT00397501|Active Comparator|HER-2 positive subjects|HER-2 positive subjects treated with trastuzumab
9876332|NCT00397501|Active Comparator|HER-2 negative subjects|HER-2 negative subjects not treated with trastuzumab
9876333|NCT00397553|Experimental|Insulin Glulisine|
9876334|NCT00397605|Experimental|Crossover|
9876335|NCT00397657|Active Comparator|Extended release niacin|
9876336|NCT00397657|Active Comparator|Ezetimibe|
9876337|NCT00397735|Experimental|N-Acetylcysteine|The subjects enrolled in our research protocol must have evidence of infection/inflammation at amniocentesis in order to receive N-acetylcysteine. Women with positive amniocentesis results The dose of N-acetylcysteine is the one recommended to be used in humans to prevent acetaminophen toxicity: 150 mg/kg loading dose (60 min), followed by 50mg/kg IV continuous infusion rate for 4 hours, and followed by 100 mg/kg IV continuous infusion rate for the following 16 hours. Acetadote (Cumberland Pharmaceuticals) is the only FDA-approved intravenous N-acetylcysteine formulation and will be used in our study.
9876338|NCT00397735|Placebo Comparator|Placebo|The subjects enrolled in our research protocol must have infection/inflammation in order to be randomized to receive N-acetylcysteine or placebo. Placebo-assigned patients will receive sodium chloride solution without N-acetylcysteine
9876339|NCT00397774|Active Comparator|Exercise|Physical exercise twice a week for 8 weeks, and best supportive care
9876340|NCT00397774|Other|No exercise|Best supportive care, no exercise
9876341|NCT00397787|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
9876342|NCT00397826|Other|MK0733,simvastatin|20 patients with total cholesterol ≧ 240 mg/dL or LDL-C > 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.
9876343|NCT00397865|Experimental|A|
9876344|NCT00397917|Active Comparator|400 micrograms of folic acid|Blinded study with two arms one of 400ug in arm 1
9876345|NCT00397917|Active Comparator|4mg of folic acid|Second arm is 4mg of folic acid in arm 2
9876346|NCT00398008|Experimental|1|DC-HIV plus buprenorphine maintenance.
9876347|NCT00398008|Experimental|2|DC-HIV plus naltrexone maintenance
9876348|NCT00398060|Experimental|A|
9876349|NCT00398190|Active Comparator|Control|Students receive standard anti-tobacco education
9876350|NCT00398190|Experimental|Media Literacy|Students receive media literacy based anti-smoking education
9876351|NCT00398229|Active Comparator|A|receiving hCG injection
9876352|NCT00398229|Placebo Comparator|B|
9929862|NCT00921648||Mr Q, 40 years old|Dementia, sensory aphasia, irritability, hallucination MRI showed cortical lesion, mesial temporal lobe atrophy.
9929863|NCT00921648||Mr Guo,35 years old|Dementia, sensory aphasia, tremor, gait disturbance MRI showed cortical lesion, enlarged ventricle, white matter lesion, cerebral atrophy
9517654|NCT03304340|Experimental|FES + SR|For each participant in the functional electrical stimulation (FES) group, standard rehabilitation (SR) in addition two dual-channel FES stimulators (MEDTRONIC Respond Select; EmpiInc) were used. The FES was delivered with 0.3-ms pulses at 30 pps and the stimulation intensity was set to the movement threshold to induce visible muscle contractions. For the FES group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
9929864|NCT00921648||Mr Zhang,40 years old|Dementia, apraxia of speech, gatism , irritability, insomnia, gait disturbance MRI showed white matter lesion, cerebral atrophy.
9929865|NCT00921648||Mr Liu,40 years old|Dementia, apraxia of speech, irritability, insomnia MRI showed normal.
9929866|NCT00921648||Mr Zhang,54 years old|Dementia, apraxia of speech MRI showed white matter lesion, cerebral atrophy.
9929867|NCT00921661|Experimental|AVE0005 (aflibercept)|
9929868|NCT00921674|Experimental|Ivermectin|ivermectin
9929869|NCT00921700|Experimental|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg
9929870|NCT00921700|Experimental|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg + codeine 60 mg
9929871|NCT00921700|Active Comparator|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg + codeine 60 mg
9987840|NCT01416727|Experimental|OSkER|"Observed SKills in the Emergency Room - workplace-based supervision."
9987841|NCT01416727|Experimental|EPIC|"Emergency Psychiatry Immersion Course - simulation-based training."
9987842|NCT01416740|Experimental|Indirect MRA|After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
9987843|NCT01416753|Active Comparator|UCR|regulation of ultrafiltration and conductivity
9517655|NCT03304340|Active Comparator|SR-only|All the participants received functional training and motor relearning physiotherapy treatment as early standard rehabilitation (SR) for 30 minutes per day, 5 days a week throughout the study. Subjects in the SR group received only SR .
9987844|NCT01416753|Active Comparator|UTR|regulation of ultrafiltration and temperature
9987845|NCT01416753|No Intervention|conventional dialysis|dry weight reduction without BVM
9987846|NCT01416766|No Intervention|Control|Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
9987847|NCT01416766|Experimental|Intervention|Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
9987848|NCT01416779|Experimental|Writing Group|This group will receive the writing intervention.
9987849|NCT01416779|No Intervention|No Intervention|Non Writing Group
9987850|NCT01416792|Experimental|Multiple-pass hemofiltration|
9987851|NCT01416818|Experimental|group 1|
9987852|NCT01416818|Active Comparator|group 2|
9987853|NCT01416818|Placebo Comparator|group 3|
9987854|NCT01416831|Active Comparator|High-dose IL-2|Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2.
9987855|NCT01416831|Experimental|Radiation therapy and high-dose IL-2|Patients 1-20 who are assigned to receive radiation therapy will receive a single dose of radiation before IL-2; patients 21-44 assigned to receive radiation will receive two doses of radiation before receiving high-dose IL-2.
9987856|NCT01416857|No Intervention|MOD|Group evaluated using the currently available ED measure of disability (MOD)
9987857|NCT01416857|Experimental|RDDT|Group will be evaluated using ED Rasch Disability Diagnostic Tool (RDDT)
9987858|NCT01416870|Experimental|Active 1|34 subjects will receive ICI176,334-1without water
9987859|NCT01416870|Experimental|Active 2|34 subjects will receive ICI176,334-1 with water
9987860|NCT01416870|Experimental|Active 3|34 subjects will receive Casodex 80 mg tablet
9987861|NCT01416883|Experimental|Active 1|8 subjects will receive ICI176,334-1
9987862|NCT01416896|Experimental|"New venous needle, the BME needle"|"Hemodialysis using the new venous needle, the BME needle."
9987863|NCT01416896|Active Comparator|"Standard venous needle, the standard needle"|"One hemodialysis using the standard venous needle, the standard needle (device)."
9987864|NCT01416909|Active Comparator|Dose Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on the dose of the opioid pain medication they are receiving.
9987865|NCT01416909|Active Comparator|Assessment Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be determined based on their severity of constipation.
9987866|NCT01416909|Other|Control Group - Opioid|Standard of Care: Participants Receiving Opioids for the Treatment of Pain will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
9997119|NCT01506167||Bevacizumab and Capecitabine/Oxaliplatin|Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
9876353|NCT00398281|Experimental|Arm I|Patients receive oral dutasteride once daily on days 1-14.
9876354|NCT00398281|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-14.
9876355|NCT00398333|Experimental|Eicosapentaenoic acid enriched nutritional supplement|
9876356|NCT00398333|No Intervention|No supplementation|
9876357|NCT00398359|Experimental|1|
9876358|NCT00398463|Experimental|1|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
9876359|NCT00398463|Placebo Comparator|2|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo
9876360|NCT00398515|Experimental|Treatment (antiangiogenesis, chemotherapy, enzyme inhibitor)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
9876361|NCT00398554|Experimental|VECOPA|dose and time intensified consoloditation chemotherapy cycle
9876362|NCT00398645|Experimental|Arm 1|
9876363|NCT00398684|Experimental|1|One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
9876364|NCT00398684|Experimental|2|One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
9876365|NCT00398684|Placebo Comparator|3|One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
9876366|NCT00398723|Experimental|Vitiligo|adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
9876367|NCT00398749||Epoetin alfa|Epoetin alfa 40 000 IU once weekly variable treatment length
9876368|NCT00398814|Experimental|Perifosine + Sorafenib|
9876369|NCT00398827|Experimental|Dexmedetomidine 0.5 mcg/kg load|
9876370|NCT00398827|Experimental|Dexmedetomidine 1 mcg/kg load|
9876371|NCT00398827|Placebo Comparator|Placebo|
9876372|NCT00398853|Experimental|Chromium Picolinate|Chromium
9876373|NCT00398853|Other|Placebo|Placebo
9876374|NCT00398892|Other|1|Crossover - placebo then active
9876375|NCT00398892|Other|2|Crossover - active then placebo
9876376|NCT00398905|Experimental|Arm 1|
9876377|NCT00398905|Experimental|Arm 2|
9876378|NCT00398905|Experimental|Arm 3|
9876379|NCT00398905|Experimental|Arm 4|
9876380|NCT00398905|Experimental|Arm 5|
9876381|NCT00398905|Active Comparator|Arm 6|
9876382|NCT00398970|Active Comparator|Traditional flouroscopy guided sampling|
9876383|NCT00398970|Experimental|Ultrasound guide sampling|
9876384|NCT00398996|Active Comparator|1 - Early integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment
9876385|NCT00398996|Active Comparator|2 - Late integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment
9876386|NCT00398996|Active Comparator|3 - Sequential-therapy group|Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment
9876387|NCT00399061|Active Comparator|1|Systane
9876388|NCT00399061|Active Comparator|2|Optive
9876389|NCT00399061|Placebo Comparator|3|Restasis
9876390|NCT00399074|No Intervention|chloroquine|Weekly CQ
9876391|NCT00399074|No Intervention|Sulfadoxine-pyrimethamine|Monthly SP
9876392|NCT00399087|Experimental|Perifosine D1 + Docetaxel|
9876393|NCT00399087|Experimental|Perifosine D1+ Docexatel+Prednisone|
9876394|NCT00399087|Experimental|Perifosine+ D1,8 and 15+Docetaxel+Prednisone|
9876395|NCT00399152|Experimental|Perifosine+Sunitinib malate|
9876396|NCT00399165|Active Comparator|1|Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
9876397|NCT00399165|Active Comparator|2|Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
9876398|NCT00399204|Active Comparator|Control|Metformin
9876399|NCT00399204|Experimental|Experimental|Pioglitazone
9876400|NCT00399334||001|
9876401|NCT00399373||Quality Improvement Initiative|The initial step in the quality improvement initiative was a letter sent from JHHC Care Management Department to the quality improvement initiative group, inviting them to take advantage of the case management services that are part of their current benefits in the Priority Partners MCO. It is similar to the standard letter sent to PPMCO members who are appropriate for a JHHC disease or case management program. A substance abuse outreach staff initiated telephonic contact with the members in the intervention group. The staff member then refered to substance abuse treatment when possible and appropriate and refered to medical case management.
9876402|NCT00399373||Control group|No additional improvement modalities
9876403|NCT00399412||LQTS|Long QT syndrome
9876404|NCT00399412||HF|Heart Failure
9876405|NCT00399412||CRT|Cardiac Resynchronization Therapy
9876406|NCT00399412||Wide QRS|QRS > 120 milliseconds
9876407|NCT00399438|Other|1|0 mg
9876408|NCT00399438|Other|2|25 mg
9876409|NCT00399438|Other|3|100 mg
9876410|NCT00399477|Active Comparator|Rasagiline mesylate|
9876411|NCT00399477|Experimental|Rasagiline mesylate plus adjunct therapy|Rasagiline mesylate with one of three adjunct therapies
9876412|NCT00399555||One|Patients with HLHS that have had surgical palliation with the Norwood procedure (Stage I palliation) at Children's Healthcare of Atlanta after January 1, 2001. These patients must be between the ages of 2.5 years and 6 years of age.
9876413|NCT00399581|Experimental|HFOV-Lo|High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
9876414|NCT00399581|Experimental|HFOV-Hi|High Frequency Oscillatory Ventilation using higher mean airway pressures
9876415|NCT00399594|Experimental|A|Targeted LV lead placement
9876416|NCT00399594|Active Comparator|B|Usual LV lead placement
9876417|NCT00399607||Aim 1|Participants previously randomized for the parent study will be eligible for a portion of the adjunct biomarker study.
9876418|NCT00399607||All aims|Participants entering the parent study will be eligible for all sample collections of the adjunct biomarker study.
9876419|NCT00399672|Active Comparator|1|The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
9876420|NCT00399672|Active Comparator|2|The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
9876421|NCT00399685|Active Comparator|A|
9876422|NCT00399685|Active Comparator|B|
9876423|NCT00399685|Active Comparator|C|
9876424|NCT00399685|Active Comparator|D|
9876425|NCT00399776||Group A|Adolescents taking haloperidol, risperidone, or olanzapine
9876426|NCT00399776||Group B|Healthy adolescents
9876427|NCT00399919|Experimental|PLC|Investigational drug
9876428|NCT00399919|Placebo Comparator|Placebo|
9876429|NCT00399971|Experimental|Hemathera|Patients will receive cell-based immunotherapy.
9876430|NCT00399984|Experimental|1|
9876431|NCT00399984|No Intervention|2|
9876432|NCT00400010|Experimental|Expert System Intervention|Computerized Expert System Intervention based on the Transtheoretical Model of Change: 1. Normative feedback and feedback on motivational variables during the first week of hospital stay 2. Ipsative feedback on drinking behavior and motivation to change after three months
9876433|NCT00400010|No Intervention|Control group|Controls received a brochure on health behavior
9929872|NCT00921700|Placebo Comparator|Placebo|Single oral dose of lactose as placebo
9929873|NCT00921713|Active Comparator|Enhanced Usual Care|An extensive packet of information including cancer education materials and treatment resources will be mailed to patients.
9929874|NCT00921713|Experimental|Oncology Nurse Care Management|In addition to this mailed information packet, patients in OCNM will be contacted by an experienced Oncology nurse with additional training in self-management support and psychosocial care. The intervention nurse, supported by a Medical Oncologist and Clinical Psychologist, will work closely with patients, their primary care physicians, and other clinicians to assure that patient needs discussed are met. The nurses will be trained in and employ proven counseling and psychotherapeutic approaches-behavioral activation and problem-solving treatment. The multi-component intervention will be based on the Chronic Care Model's six elements (health care organization, community resources, self-management support, delivery system design, decision support, and clinical information system).
9929875|NCT00921726|Experimental|1|Participants will receive treatment in the following order: Study Regimens A, B, C, D
9929876|NCT00921726|Experimental|2|Participants will receive treatment in the following order: Study Regimens B, A, C, D
9929877|NCT00921739|Experimental|IMRT concurrent with chemotherapy|6 fractions of esophageal sparing IMRT weekly for 5-6 weeks (dependent on dose cohort) concurrent with standard chemotherapy: Cisplatin 50 mg/m2 /d intravenously (IV) on days 1, 8, 29, and 36. Etoposide 50 mg/m2 /d IV on days 1 through 5 and 29 through 33.
9929878|NCT00921752||Patients at high cardiovascular risk|
9929879|NCT00921765|Placebo Comparator|Placebo + Placebo|Saline single bolus dose iv + saline single bolus dose iv
9929880|NCT00921765|Active Comparator|Placebo + Ketamine|Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw
9929881|NCT00921765|Active Comparator|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
9929882|NCT00921765|Active Comparator|Naloxone + Ketamine|Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
9929883|NCT00921791|Experimental|Home Blood Pressure Monitoring|Automatic oscillometric device for blood pressure measurement at home plus usual care.
9929884|NCT00921791|Experimental|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.
9929885|NCT00921791|Active Comparator|Pharmaceutical care|Consultations with the pharmacists plus usual care.
9929886|NCT00921791|Active Comparator|Control|Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.
9929887|NCT00921804|Experimental|1|AZD8529 40 mg
9929888|NCT00921804|Placebo Comparator|2|Placebo
9876434|NCT00400023|Experimental|1|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
9876435|NCT00400023|Active Comparator|2|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
9876436|NCT00400062||ICU survivors|The investigators will measure the independent contribution of risk factors such as delirium and exposure to sedative and analgesic medications to the incidence of long-term CI.
9876437|NCT00400088|Experimental|lithium group|Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
9876438|NCT00400088|Active Comparator|paroxetine group|Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
9876439|NCT00400114|Experimental|sunitinib|
9876440|NCT00400127|Experimental|amputee|
9876441|NCT00400140|Experimental|A|
9876442|NCT00400166|Experimental|1|Recovery Mentor: peer-based supportive care
9876443|NCT00400166|No Intervention|0|No Recovery Mentor, services as usual
9876444|NCT00400231|Active Comparator|1|Metformin
9876445|NCT00400231|Active Comparator|2|Fenofibrate
9876446|NCT00400231|Active Comparator|3|Fenofibrate and Metformin
9876447|NCT00400231|Placebo Comparator|4|
9876448|NCT00400257||1|People at high risk of heart failure.
9876449|NCT00400296|Experimental|1|
9876450|NCT00400309|Experimental|REPEVAX® after REVAXIS®|REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
9876451|NCT00400309|Active Comparator|REPEVAX® after Placebo|Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
9876452|NCT00400322|Active Comparator|Valganciclovir|
9876453|NCT00400322|Placebo Comparator|Placebo|
9876454|NCT00400361|Experimental|1|
9876455|NCT00400374|Experimental|Erlotinib, Celecoxib|
9876456|NCT00400387|Other|Multivitamin supplement|
9876457|NCT00400387|Experimental|Multivitamin supplement + dalteparin sodium|
9876458|NCT00400465|Active Comparator|Control group|Pressure dressing
9876459|NCT00400465|Experimental|Experimental group|Normal dressing
9876460|NCT00400478|Active Comparator|A|Treatment
9876461|NCT00400478|No Intervention|B|Observation
9876462|NCT00400491|Experimental|1|
9876463|NCT00400491|Placebo Comparator|2|
9876464|NCT00400595|Experimental|1|Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
9876465|NCT00400595|Active Comparator|2|Mupirocin
9876466|NCT00400647|Experimental|EC MPS|Up to 1440mg taken in two doses
9876467|NCT00400647|Active Comparator|Mycophenolate mofetil|250 mg or 500 mg in two equal doses
9876468|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
9876469|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
9876470|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
9876471|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
9876472|NCT00400660|Experimental|Subjects receiving GSK615915A: Part 3|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms.
9876473|NCT00400660|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo.
9876474|NCT00400673|Other|Chemotherapy|Risk-oriented chemotherapy for remission induction (application of sequential high-dose cytarabine course to patients unresponsive to standard chemotherapy course 1) and postremission consiolidation(standard risk: blood stem cell supported high-dose cytarabine course [x3]; high risk: allogeneic SCT)
9876475|NCT00400699|Other|REview|
9876476|NCT00400725|Experimental|1|
9876477|NCT00400725|Placebo Comparator|2|
9876478|NCT00400738|Experimental|1|different dose per arm
9876479|NCT00400738|Experimental|2|different dose per arm
9876480|NCT00400738|Experimental|3|different dose per arm
9876481|NCT00400738|Experimental|4|different dose per arm
9876482|NCT00400816|Experimental|Temozolomide|Temozolomide, 150 mg/m2/d x days 1-7 and 15-21
9876483|NCT00400842|Experimental|L|
9876484|NCT00400842|Experimental|H|
9876485|NCT00400842|Placebo Comparator|P|
9876486|NCT00400855|Experimental|Arm 1|study drug
9876487|NCT00400868|Active Comparator|standard joint protection education|psycho-educational joint protection vs. usual care (standard joint protection education)
9876488|NCT00400933|Experimental|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
9876489|NCT00400998|Placebo Comparator|Vienna Challenge Chamber in season (Phase 3)|"Phase 3 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200micrograms (μg) fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy."
9876490|NCT00400998|Placebo Comparator|Vienna Challenge Chamber out of season (Phase 1)|"Phase 1 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200μg fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy.~An intermediate study follow-up visit will take place 7-14 days after the last dose is received in treatment period 2."
9876491|NCT00400998|Placebo Comparator|Park In Season (Phase 2)|"Phase 2 will consist of 2 treatment periods lasting either 8 to 14 days (D) (depending on out-door conditions). There will be a 10D wash-out between this treatment period in Phase 2 and that in Phase 3.~Subjects will administer 200μg fluticasone propionate (or fluticasone propionate matched placebo nasal spray, once daily up to 14D, with dosing supervised on the first and last days of each treatment period (D1 and either D8 or up to D14).~Immediately following the last dose received on either D8 or up to D14 baseline measures will be taken (time = 0). The subject is then taken by bus to the Park and the first measurement will be taken 15 minutes after the subjects leave the bus and enter the Park.~Immediately following the last dose received on D8 or up to D14 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy"
9876492|NCT00401024|Experimental|Treatment|Imatinib mesylate 600mg orally once a day for seven consecutive days prior to surgery with last dose taken one day prior to surgery
9876493|NCT00401063|Other|Single arm|Acupuncture treatment
9876494|NCT00401076|Experimental|1|
9876495|NCT00401089|Experimental|Ginsana-115|Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
9876496|NCT00401089|Placebo Comparator|Sugar Pill|Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
9876497|NCT00401115|Experimental|1|Subconjunctival injection
9876498|NCT00401115|Experimental|2|Intraocular injection
9876499|NCT00401154|Experimental|Intervention Stationary Cycling|Subjects receiving the intervention performed stationary cycling 3 times a week for 30 sessions over 12 weeks.
9876500|NCT00401232|Other|Arm 1|
9876501|NCT00401310|Placebo Comparator|1|Placebo
9876502|NCT00401310|Experimental|2|MK0724
9876503|NCT00401323|Experimental|docetaxel plus cisplatin|Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
9876504|NCT00401323|Active Comparator|cisplatin plus 5-FU|Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
9876505|NCT00401323|Experimental|docetaxel plus 5-FU|"Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5~Arm only in the phase II part of the study"
9876506|NCT00401336|Experimental|Magnetic Resonance Imaging|New magnetic resonance imaging multiecho gradient-echo sequence
9876507|NCT00401362|Experimental|Arm 1|
9876508|NCT00401362|Placebo Comparator|Arm 3|
9876509|NCT00401362|Experimental|Arm 2|
9876510|NCT00401440|Active Comparator|A|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
9876511|NCT00401440|Active Comparator|B|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
9876512|NCT00401466|Experimental|1|Prolonged follow-up intervals every 12 months
9876513|NCT00401466|Active Comparator|2|Standard follow-up intervals of 3 months
9876514|NCT00401583|Experimental|Pazopanib receivers|During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
9876515|NCT00401661|Experimental|1|Alfuzosin for 24 weeks
9876516|NCT00401674|Experimental|SINGLE ARM|
9876517|NCT00401739|Experimental|I|Treatment with CSL360
9876518|NCT00401765|Experimental|Cohort 1A (Docetaxel and CNTO 328)|In cohort 1A, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel every 3 weeks and 6 mg/kg CNTO 328 every 2 weeks will be administered in the treatment phase.
9929889|NCT00921804|Other|3|Risperidone 4 mg (2mg on Day 1)
9929890|NCT00921830|Experimental|Ibuprofen|ibuprofen
9929891|NCT00921869|Experimental|1|
9876519|NCT00401765|Experimental|Cohort 1B (Docetaxel and CNTO 328)|In cohort 1B, 6 mg/kg CNTO 328 will be administered in run-in phase and 75 mg/m2 docetaxel will be administered every 3 weeks plus 6 mg/kg CNTO 328 will be administered every 2 weeks in the treatment phase.
9876520|NCT00401765|Experimental|Cohort 2 (Docetaxel and CNTO 328)|In cohort 2, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel plus 9 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
9876521|NCT00401765|Experimental|Cohort 3 (Doctaxel and CNTO 328)|In cohort 3, 75 mg/m2 docetaxel will be administered in the run-in phase and 75 mg/m2 docetaxel plus 12 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
9876522|NCT00401791|Experimental|1|
9876523|NCT00401791|No Intervention|2|
9929892|NCT00921882||Oral glucose tolerance test|oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.
9929893|NCT00921908||epidural catheter|subfascial placement of a triple-orifice epidural catheter
9929894|NCT00921908||multiholed catheter|subfascial placement of a multi-orifice 15 cm catheter
9929895|NCT00921921|Experimental|Extra-fine particle steroid inhaler|
9929896|NCT00921921|Placebo Comparator|Placebo control|
9929897|NCT00921960|No Intervention|Usual Care|Usual Care will involve ongoing management from the general practitioner, nurse-led assessment of cardiovascular risk at the general practice and referral to specialist services as deemed necessary.
9929898|NCT00921960|Other|Intervention|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate
9929899|NCT00921973|Active Comparator|VAX102|Simultaneous administration of VAX102 1 ug i.m. plus TIV
9929900|NCT00921973|Placebo Comparator|Placebo|
9929901|NCT00921986||Arrhythmias|Patients with arrhythmias
9929902|NCT00921986||Control Subjects|Subjects that do not have a history of cardiac arrhythmias.
9929903|NCT00922012|Experimental|Electromagnetic stimulation|Electromagnetic stimulation therapy
9929904|NCT00922025||1|Male patients with non-small cell lung cancer (NSCLC) of adeno histology
9929905|NCT00922038|Experimental|High reward|
9929906|NCT00922038|Experimental|Low reward|
9929907|NCT00922038|No Intervention|Control|
9929908|NCT00922051|Experimental|Group 1|Application of Acu-TENS
9929909|NCT00922051|Placebo Comparator|Group 2|
9929910|NCT00922064|Experimental|ECT|
9929911|NCT00922103|Experimental|INRA|Patients treated for medical refractory Ulcerative Colitis
9929912|NCT00922103|Active Comparator|IPAA|Patients treated for medical refractory Ulcerative Colitis
9929913|NCT00922129|Experimental|Conversion to sirolimus|
9929914|NCT00922129|Active Comparator|Calcineurim inhibitor reduction|
9929915|NCT00922155|No Intervention|EBUS|After the PPLs been localized by endobronchial ultrasound(EBUS), patients in the EBUS group received transbronchial biopsy and bronchial washing at the bronchus located by EBUS.
9929916|NCT00922155|Active Comparator|EBUS-GS|After PPLs been localized by EBUS, the EBUS and guide sheath were then inserted to localize the lesion again. Transbronchial biopsy and brushing were done through the guide sheath after the probe been removed.
9929917|NCT00922168||Cardiac Surgeries: CABG, valve replacements|
9929918|NCT00922181|Experimental|MWA|Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
9929919|NCT00922181|Active Comparator|RFA|Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
9929920|NCT00922220|Active Comparator|stationary bike|Participants rode a stationary bike for five minutes
9929921|NCT00922220|Active Comparator|lumbar extension exercises|Participants performed four sets of fifteen lumbar extension exercises over five minutes
9929922|NCT00922220|Experimental|spinal manipulative therapy|Participants received spinal manipulative therapy to the low back
10211692|NCT04329481|Placebo Comparator|placebo|"will be be identical in size, shape and color to Mycodigest Treatment with Mycodigest placebo will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
9935966|NCT02913313|Experimental|Part 1B: Dose Escalation Combination Therapy|
9935967|NCT02913313|Experimental|Part 2A: Expansion Monotherapy|
9935968|NCT02913313|Experimental|Part 2B: Expansion Combination Therapy|
9935969|NCT02913313|Experimental|Part 1C: Triplet Cohort|
10211693|NCT04318015|Experimental|High-risk Treatment|Hydroxychloroquine 200mg per day for 60 days.
10211694|NCT04318015|Placebo Comparator|High-risk Placebo|Placebo tablet per day for 60 days.
10211695|NCT04318015|Experimental|Low-risk Treatment|Hydroxychloroquine 200mg per day for 60 days
10211696|NCT04318015|Placebo Comparator|Low-risk Placebo|Placebo tablet per day for 60 days.
10211697|NCT04315896|Active Comparator|treatment|Hydroxychloroquine tablet 200mg every 12 hours for 10 days.
10211698|NCT04315896|Placebo Comparator|placebo|identical placebo, one tablet every 12 hours for 10 days
10211699|NCT04314778|Experimental|Intervention|Participants in the intervention arm will have a postoperative daily step goal that increases from baseline by 500 steps each day.
10211700|NCT04314778|No Intervention|Control|Participants in the control group will have data collected passively via Fitbit.
10211701|NCT04311216||Shoulder instability participants|Participants with previous a previous episode(s) of shoulder instability
10211702|NCT04311216||Age matched controls (no instability)|Participants with no previous a previous episode(s) of shoulder instability
10211703|NCT04306250|Experimental|anterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the anterior access, ie dissection through the anterior vaginal wall.
10211704|NCT04306250|Active Comparator|posterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the posterior access, ie fixation through the vaginal posterior wall.
10211705|NCT04300478|Other|Sedentary Control/REx|Subjects will complete the Sedentary control testing sessions, have a 7-14 day washout period, and then complete the REx
9876524|NCT00401856|Experimental|1|This arm will receive eplerenone
9876525|NCT00401856|Placebo Comparator|2|This group will receive the placebo
9876526|NCT00401895|Active Comparator|1|patients treated with 10 mm stent
9876527|NCT00401895|Active Comparator|2|patients treated with 8 mm stent
9876528|NCT00401921|Placebo Comparator|Minocycline arm|Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
9876529|NCT00401921|Placebo Comparator|Placebo arm|Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
9876530|NCT00402012|No Intervention|1|
9876531|NCT00402012|Experimental|2|
9876532|NCT00402038|Experimental|Arm 1|
9876533|NCT00402038|Placebo Comparator|Arm 2|
9876534|NCT00402077|Experimental|1|
9876535|NCT00402077|Experimental|2|
9876536|NCT00402077|Experimental|3|
9876537|NCT00402077|Placebo Comparator|4|
9876538|NCT00402142|Active Comparator|Pulsed dendritic cells untreated patients|Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
9876539|NCT00402142|Placebo Comparator|non pulsed dendritic cells untreated patients|
9876540|NCT00402142|Active Comparator|pulsed dendritic cell treated patient|treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
9876541|NCT00402142|Active Comparator|pulsed dendritic cell in treated patients|patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
9876542|NCT00402142|Placebo Comparator|non pulsed dendritic cells|
9876543|NCT00402155||1|Normal subjects
9876544|NCT00402155||2|Reading discomfort subjects
9876545|NCT00402181|Experimental|Treatment Plan A|Siltuximab 6 milligram per kilogram (mg/kg) as intravenous (directly into the vein) infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days (if participant have complete or partial response) along with dexamethasone (starting from Cycle 2, If participant do not have complete or partial response) 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles.
9876546|NCT00402181|Experimental|Treatment Plan B|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks along with dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles (duration of each cycle is 28 days) after that on Day 1 to 4 up to 12 cycles.
9876547|NCT00402220|Active Comparator|1|active TMS
9876548|NCT00402220|Placebo Comparator|2|Sham TMS
9876549|NCT00402272|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
9876550|NCT00402350|Placebo Comparator|Placebo|Subjects (2) from each of the 4 dose escalation arms
9876551|NCT00402350|Experimental|25 mcg IV and Inhaled Crossover|Single dose crossover (IV vs Inhaled)
9876552|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 2|Inhaled Staccato fentanyl, 25 mcg x 2
9876553|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 4|Inhaled Staccato fentanyl, 25 mcg x 4
9876554|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 6|Inhaled Staccato fentanyl, 25 mcg x 6
9876555|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 12|Inhaled Staccato fentanyl, 25 mcg x 12
9876556|NCT00402389|Experimental|1|Participants assigned to take omega-3 fatty acids
9876557|NCT00402389|Placebo Comparator|2|Participants assigned to take placebo
9876558|NCT00402415|Experimental|1|
9876559|NCT00402467|Experimental|Arm 6|
9876560|NCT00402467|Experimental|Arm 1|
9876561|NCT00402467|Experimental|Arm 2|
9876562|NCT00402467|Experimental|Arm 3|
9876563|NCT00402467|Experimental|Arm 4|
9876564|NCT00402467|Experimental|Arm 5|
9876565|NCT00402493|Active Comparator|Latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
9876566|NCT00402493|Active Comparator|Brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
9876567|NCT00402493|Active Comparator|ibuprofen|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
9876568|NCT00402519|Experimental|APBI|Accelerated Partial Breast Irradiation with multicatheter brachytherapy
9876569|NCT00402519|Active Comparator|EBRT|Standard External Beam Whole Breast Irradiation
9876570|NCT00402532|Active Comparator|Everolimus|
9876571|NCT00402532|Active Comparator|Mycophenolatmofetil|
9876572|NCT00402558|Experimental|Thymoglobulin + Busulfan + Fludarabine|"Thymoglobulin 1.5 mg/kg by vein for 3 days. Busulfan 130 mg/m^2 by vein for 4 days. Fludarabine 40 mg/m^2 by vein for 4 days. Alloreactive NK infusion from haploidentical donor on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7 NK Cells plus systemic interleukin-2 treatment. The 4th dose level is 3 x 107 NK cells/kg plus systemic interleukin-2 at a dose of 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4.~G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count is > 500 x 109/L for 3 consecutive days. Tacrolimus starting dose of 0.015 mg/kg daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present. Methotrexate 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant."
9876573|NCT00402623|Placebo Comparator|1|placebo
9876574|NCT00402623|Active Comparator|2|quercetin (food supplement)
9876575|NCT00402636|Experimental|1|rapamycin plus 17beta estradiolvalerat-eluting stent
9876576|NCT00402636|Experimental|2|rapamycin-eluting stent
9876577|NCT00402675|Active Comparator|Immediate Intervention|Patients with NSTEMI undergo immediate invasive angiography (< 2 hours)
9876578|NCT00402675|Active Comparator|Early Intervention|Patients with NSTEMI undergo early invasive angiography (12-48 hours)
9876579|NCT00402675|Active Comparator|Selective invasive angiography|Patients with NSTEMI undergo selective invasive angiography
9876580|NCT00402701|Experimental|1|Students in school with active walk-to-school promotion programs.
9876581|NCT00402701|No Intervention|2|Students in schools with access to standard school district transportation resources.
9876582|NCT00402753|Experimental|Group 1|Physical exercise group: Combined supervised physical activity: Endurance and Resistive strength
9876583|NCT00402753|No Intervention|Group 2|Usual care control group
9876584|NCT00402766|Experimental|Cisplatin + Imatinib + Pemetrexed|Cisplatin 60 mg/m^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m^2 by vein, Over 40 Minutes. Dexamethasone 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
9876585|NCT00402792|Experimental|Arm 1: hydrocodone / acetaminophen extended release|
9876586|NCT00402792|Experimental|Arm 2: hydrocodone / acetaminophen extended release|
9876587|NCT00402792|Placebo Comparator|Arm 3: Placebo|
9876588|NCT00402857|Experimental|1|Participants will receive the Incredible Years Program, a group parenting intervention
9876589|NCT00402857|Other|2|Participants assigned to the waitlist condition will receive the Incredible Years Program after a 1-year waiting period
9876590|NCT00402948|Experimental|TPI ASM8|ASM8 0.25mg
9876591|NCT00402948|Experimental|ASM8 as TPI ASM8|TPI ASM8 0.5mg
9876592|NCT00402961|Active Comparator|1|Acupuncture is the insertion of needles at certain body points.
9876593|NCT00402961|Sham Comparator|2|sham acupuncture
9876594|NCT00403013|Experimental|1|lateral, head-down position during axillary plexus block
9876595|NCT00403013|Active Comparator|2|standard position during axillary plexus block
9876596|NCT00403039|Other|Open-label ranibizumab|Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
9876597|NCT00403052|Experimental|1|Low dose of 1018 ISS
9876598|NCT00403052|Experimental|2|Middle dose of 1018 ISS
9876599|NCT00403052|Experimental|3|High dose of 1018 ISS
9876600|NCT00403091|Experimental|Intervention|
9876601|NCT00403091|Active Comparator|Control|
9876602|NCT00403104|Experimental|E|ONO-2506PO in the presence of Riluzole
9876603|NCT00403104|Placebo Comparator|P|Placebo in the presence of Riluzole
9876604|NCT00403247|Experimental|A|vitamin capsule
9876605|NCT00403247|Placebo Comparator|B|placebo capsule
9876606|NCT00403286|Experimental|C 10/1|
9876607|NCT00403286|Experimental|C 5/2|
9876608|NCT00403286|Experimental|C 5/1|
9876609|NCT00403286|Experimental|FP 1000|
9876610|NCT00403286|Experimental|FF 20|
9876611|NCT00403286|Active Comparator|AD 250/50|
9876612|NCT00403286|Placebo Comparator|Plc|
9876613|NCT00403286|Experimental|C 10/2|
9876614|NCT00403351||ARM-CAD 1|Cross-sectional analysis using coronary angiogram results
9876615|NCT00403351||ARM-CAD 2|Prospective cohort for incident cardiovascular events and mortality
9876616|NCT00403377|Experimental|Intervention|Phase II include two arms. In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
9876617|NCT00403377|No Intervention|Control|Phase II include two arms. In the control arm, a souvenir photograph is taken of the participants and they then receive product samples that are irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel, chewing gum). Participants also receive educational materials at the completion of the study.
9876618|NCT00403429|Experimental|Capecitabine|
9876619|NCT00403507|No Intervention|Clean Control|Probable Alzheimer's disease in the context of no excluding medical conditions.
9876620|NCT00403507|No Intervention|CoMorbid Control|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
9876621|NCT00403507|Experimental|Clean Exercise|Probable Alzheimer's disease in the context no comorbid medical conditions.
9876622|NCT00403507|Experimental|CoMorbid Exercise|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
9876623|NCT00403520|Experimental|Experimental 1|
9876624|NCT00403520|Placebo Comparator|Placebo Comparator|
9876625|NCT00403611|Active Comparator|Praziquantel 40mg/kg|Praziquantel (Distocide) 40mg/kg single oral dose
9876626|NCT00403611|Experimental|Praziquantel 60mg/kg|Praziquantel (Distocide) 60mg/kg single oral dose
9876627|NCT00403650|Experimental|1|
9876628|NCT00403676|Experimental|Follow up by nurse|Patient randomized for follow-up by a nurse
9876629|NCT00403676|Experimental|follow up by medical doctor|Patients randomized for follow up by a medical doctor
9876630|NCT00403689|Experimental|x|capsules containing beta glycan
9876631|NCT00403689|Placebo Comparator|y|capsules containing placebo (waxy maize starch)
9929923|NCT00922246|No Intervention|control group|Conscript used their own ankle boots instead of custom made insoles.
9929924|NCT00922246|Experimental|shoe insoles|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length. The insole was strong enough to fill the arch area thus providing support to the mid foot. It also influences the position of the foot. The insoles were individually customized by heating the polyethylene in form of individual foot with standing and walking in them. The conscripts were advised to use these insoles in their ankle boot.
9929925|NCT00922259|Experimental|H7N7 Vaccine|Participants will be administered two doses of the candidate live influenza A H7N7 vaccine
9929926|NCT00922285|Experimental|Art Therapy|
9929927|NCT00922311|Experimental|Aliskiren|
9929928|NCT00922324|Experimental|STP206|STP206 administered either as a single dose or as a daily dose for seven consecutive days
9929929|NCT00922324|Placebo Comparator|Vehicle Control|STP206 vehicle administered as either a single dose or as a daily dose for 7 consecutive days
9929930|NCT00922337||MGuard|eligible patients implanted with minimum one MGuard stent
9929931|NCT00922350|Experimental|heliox|The patients in this group underwent nebulization with heliox carried by the trunk erect
9929932|NCT00922350|Experimental|heliox+posture|The patients in this group carried out the mist carried by heliox and the trunk tilted forward
9929933|NCT00922350|Experimental|oxygen+posture|The patients in this group carried out the mist carried by oxygen and the trunk tilted forward
9929934|NCT00922350|Active Comparator|oxygen|The patients in this group carried out the mist carried by the oxygen and the trunk upright
9929935|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 alone|
9929936|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|
9929937|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|
9929938|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|
9929939|NCT00922376|Active Comparator|T+ Intervention|The intervention group patients will use the T+ telemedicine application whilst completing repeated measures aiming to compare them to a control group receiving standard care.
9929940|NCT00922376|No Intervention|Usual care|The control group will be receiving the standard care offered by the NHS to patients suffering from diabetes.
9929941|NCT00922389|Experimental|G-CSF + Stem cells|
9929942|NCT00922389|Other|No stem cell group|
9929943|NCT00922389|Active Comparator|Standerd theraphy|Any therapy for diabetic foot CLI which is routinely practiced and accepted in India
9929944|NCT00922402|Experimental|Treatment|All patients will be submitted to a shared intensive protocol of insulin infusion supported by continuous glucose monitoring
9929945|NCT00922415||cases|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal resection for complicated Crohn's disease
9929946|NCT00922454|Experimental|Talent Stent-Graft|
9929947|NCT00922454|Experimental|Cook Zenith Stent-Graft|
9929948|NCT00922467|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
9929949|NCT00922467|Experimental|Esmolol|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol
9929950|NCT00922506|Experimental|doxazosin plus tolterodine SR 2 mg|doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
9929951|NCT00922506|Experimental|doxazosin plus tolterodine SR 4 mg|doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
9929952|NCT00922519||1|
9929953|NCT00922532|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
9929954|NCT00922532|Placebo Comparator|Nitrogen|Nitrogen Placebo
9929955|NCT00922558|No Intervention|normal children|Normal children ages 5-12 years.
9876632|NCT00403780|Active Comparator|A|Active intervention with pregabalin
9876633|NCT00403780|Placebo Comparator|B|placebo arm with capsule Lyrica Placebo
9876634|NCT00403806|Active Comparator|1|Intravenous dexamethasone 0.05 mg per kg bodyweight
9876635|NCT00403806|Active Comparator|2|Intravenous dexamethasone 0.15 mg per kg bodyweight
9876636|NCT00403806|Active Comparator|3|Intravenous dexamethasone 0.5 mg per kg bodyweight
9876637|NCT00403806|Placebo Comparator|4|Intravenous saline
9876638|NCT00403897|Experimental|1|Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 & 5 = 2 sachets BID;
9876639|NCT00403923||Patients with known lactose intolerance|
9876640|NCT00403949|Active Comparator|Azelaic acid 15% Gel|Azelaic acid 15%
9876641|NCT00403949|Placebo Comparator|Placebo|Non-active base from Azelaic acid 15% gel
9876642|NCT00404144|Experimental|Drug Eluting Balloon|treatment of small vessel with drug eluting balloon
9876643|NCT00404170|Experimental|B-CIT and SPECT imaging|To assess B-CIT injection and SPECT scanning. Optional ongoing B-CIT SPECT imaging scans at follow-up visits
9876644|NCT00404183|Experimental|hydrocodone/acetaminophen extended release|
9876645|NCT00404183|Placebo Comparator|Placebo|
9876646|NCT00404222|Experimental|hydrocodone / acetaminophen extended release|
9876647|NCT00404222|Active Comparator|Hydrocodone/Acetaminophen Immediate Release (Norco ®)|
9876648|NCT00404222|Placebo Comparator|Placebo|
9876649|NCT00404261|Other|Arm 1|Fluticasone/Salmeterol HFA MDI without counter
9876650|NCT00404261|Other|Arm 2|Fluticasone/Salmeterol HFA MDI with counter
9876651|NCT00404274|Experimental|Treatment regimen A|In treatment regimen A subject will co-administer casopitant and warfarin over three-day period (Day 1 150 milligram per day [mg/day], Day 2 50 mg/day, Day 3 50 mg/day) and from Days 4 to 10 subject will administer only warfarin.
9876652|NCT00404274|Experimental|Treatment regimen B|In treatment regimen B subject will co-administer casopitant 60 mg/day and warfarin for 14 days.
9876653|NCT00404274|Experimental|Treatment regimen C|In treatment regimen C subject will co-administer warfarin and casopitant 30 mg/day for 14 days.
9876654|NCT00404287|Active Comparator|fluvastatin|fluvastatin 80 mg
9876655|NCT00404287|Placebo Comparator|placebo|
9876656|NCT00404313|Experimental|1|MK0633 10 mg
9876657|NCT00404313|Experimental|2|MK0633 50 mg
9876658|NCT00404313|Experimental|3|MK0633 100 mg
9876659|NCT00404313|Placebo Comparator|4|placebo
9876660|NCT00404365|Experimental|Arm I (control)|Arm I (control): Patients complete screening questionnaires about their mood and experience with lung cancer once before and once after a visit with their physician. Neither the patient nor physician receives the screening results before the visit.
9876661|NCT00404365|Experimental|Arm II|Arm II: Patients complete screening questionnaires as in arm I. Only the patient receives the screening results before their visit with the physician; the physician remains blinded to the results.
9876662|NCT00404365|Experimental|Arm III|Arm III: Patients complete screening questionnaires as in arm I. Only the physician receives the screening results before their visit with the patient; the patient remains blinded to the results.
9876663|NCT00404365|Experimental|Arm IV|"Arm IV: Patients complete screening questionnaires as in arm I. Both physician and patient receive the screening results before the visit.~All patients and physicians are notified of the screening results before the patient leaves the clinic. All patients are offered supportive counseling."
9876664|NCT00404378|Experimental|Cohort 1 Treatment Period 1|Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
9876665|NCT00404378|Experimental|Cohort 1 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
9876666|NCT00404378|Experimental|Cohort 2 Treatment Period 1|Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.
9876667|NCT00404378|Experimental|Cohort 2 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
9876668|NCT00404391|Experimental|Arm 1: hydrocodone/acetaminophen extended release|
9876669|NCT00404391|Experimental|Arm 2: hydrocodone/acetaminophen extended release|
9876670|NCT00404391|Placebo Comparator|placebo|
9876671|NCT00404417|Experimental|1|Botox/Placebo
9876672|NCT00404417|Experimental|2|Botox/Botox
9876673|NCT00404417|Experimental|3|Placebo/Botox
9876674|NCT00404417|Placebo Comparator|4|Placebo/Placebo
9876675|NCT00404430||Exacerbated COPD patients|Patients with exacerbated COPD
9876676|NCT00404430||Stable COPD patients|Patients with stable COPD
9876677|NCT00404443|Sham Comparator|1|arm 1: placebo needle
9876678|NCT00404469|Active Comparator|CORT|Peritendinous corticosteroid injections at 0 and 4 weeks. 12 weeks total
9876679|NCT00404469|Experimental|ECC|12 weeks of eccentric unilateral decline squats
9876680|NCT00404469|Experimental|HSR|Heavy slow resistance training. 3/week. 12 weeks
9876681|NCT00404521|Experimental|Arm 1|
9876682|NCT00404534|Experimental|1|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
9929956|NCT00922558|Experimental|postural control|
9876683|NCT00404534|Placebo Comparator|2|Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
9876684|NCT00404586|Experimental|Treatment period 1|In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
9876685|NCT00404586|Experimental|Treatment period 2|In treatment period subjects will receive once daily 200 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
9876686|NCT00404586|Experimental|Treatment period 3|In treatment period subjects will receive once daily 400 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
9876687|NCT00404586|Placebo Comparator|Treatment period 4|In treatment period subjects will receive once daily Placebo and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive Placebo and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
9876688|NCT00404612|Placebo Comparator|Placebo|
9876689|NCT00404612|Active Comparator|LX211, 0.2 mg/kg|
9876690|NCT00404612|Active Comparator|LX211, 0.4 mg/kg|
9876691|NCT00404612|Active Comparator|LX211, 0.6 mg/kg|
9876692|NCT00404677|Placebo Comparator|Standard|Methacholine challenges are performed using the standardized two minute tidal breathing method
9876693|NCT00404677|Active Comparator|Modified|Five deep inhalation maneouvers are incorporated into the standardized methacholine challenge
9876694|NCT00404690|Active Comparator|1|Operative attempt at closure
9876695|NCT00404690|Experimental|2|bedside silo
9876696|NCT00404703|Experimental|1|
9876697|NCT00404729|Other|Citicoline treatment|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
9876698|NCT00404742|Placebo Comparator|Placebo|
9876699|NCT00404742|Active Comparator|LX211, 0.2 mg/kg|
9876700|NCT00404742|Active Comparator|LX211, 0.4 mg/kg|
9876701|NCT00404742|Active Comparator|LX211, 0.6 mg/kg|
9876702|NCT00404781|Experimental|optimal antiplatelet|cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
9876703|NCT00404781|Active Comparator|standard antiplatelet|aspirin and clopidogrel for all patients
9876704|NCT00404885|Placebo Comparator|Placebo|
9876705|NCT00404885|Active Comparator|LX211, 0.2 mg/kg|
9876706|NCT00404885|Active Comparator|LX211, 0.4 mg/kg|
9876707|NCT00404885|Active Comparator|LX211, 0.6 mg/kg|
9876708|NCT00404911|Experimental|MFG therapy|Participants will receive multi-family group therapy
9876709|NCT00404911|Active Comparator|Standard of Care|Participants will receive standard care
9876710|NCT00405002||1|ALI/ARDS patients
9876711|NCT00405015|Experimental|1|Placebo first
9876712|NCT00405015|Experimental|2|Rosiglitazone first
9876713|NCT00405041|Experimental|A|
9876714|NCT00405054|Other|1|continuous infusion every 14 days
9876715|NCT00405080|Experimental|Treatment Period 1|Subject will receive single oral dose of 150 milligram (mg) of Casopitant. There will be wash out period of 7 days.
9876716|NCT00405080|Experimental|Treatment Period 2|Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin.
9876717|NCT00405262|Active Comparator|1|
9876718|NCT00405262|Experimental|2|
9876719|NCT00405262|Experimental|3|
9876720|NCT00405301|Other|Arm 1|Arm 1: will receive Isoniazide(5mg/kg/day), Rifampicin(10mg/kg/day) and Pyrazinamide(25mg/kg/day) in full doses on day 1 and continued further
9876721|NCT00405301|Other|Arm 2|Arm 2 : will receive Rifampicin(10mg/kg/day) in full dose on day 1 and continued, Isoniazide(5mg/kg/day)in full dose on day 8 and continued, Pyrazinamide(25mg/kg/day)on day 15 and continued
9876722|NCT00405301|Other|Arm 3|Arm 3 will receive 100 mg/day of Isoniazide on day 1 which is gradually increased to maximum dose (5mg/kg/day) by day 4 and continued. Rifampicin is introduced on day 8 in a dose of 150 mg/day which is gradually increased to maximum dose (10mg/kg/day) by day 11 and continued. Pyrazinamide is introduced on day 15 in a dose of 500mg/day which is gradually increased to maximum dose (25mg/kg/day) by day 18 and continued.
9876723|NCT00405340|Experimental|Drug|Rituximab
9876724|NCT00405366|Other|Single Arm Study|
9876725|NCT00405405|Experimental|Treatment|A combination of Cisplatin, Docetaxel, Bevacizumab, Erlotinib, and Radiotherapy
9935970|NCT02913313|Experimental|Part 2C: Triplet Expansion|
9876726|NCT00405418|Experimental|1|Insulin Glargine
9876727|NCT00405418|Active Comparator|2|Insulin Detemir
9876728|NCT00405431|Active Comparator|1|Patients received restasis eyedrops during 6 month post-operative period
9876729|NCT00405431|Placebo Comparator|2|Patients receive artificial tears (Endura) during 6 month post-operative period
9876730|NCT00405444|Experimental|1|
9876731|NCT00405444|Placebo Comparator|2|
9876732|NCT00405457|Other|A|
9876733|NCT00405470|Active Comparator|Medial Pivot|
9876734|NCT00405470|Active Comparator|Posterior Stabilized|
9876735|NCT00405483|Active Comparator|Minimally invasive exposure|Surgical technique, minimal incision
9876736|NCT00405483|Active Comparator|Standard exposure|Standard Incision
9876737|NCT00405535|Experimental|A|glycine powder
9876738|NCT00405535|Placebo Comparator|B|placebo powder
9876739|NCT00405561|Experimental|AMT2003|
9876740|NCT00405574|Experimental|High Dose|ATN-224 dose 300mg
9876741|NCT00405574|Experimental|Low Dose|ATN-224 dose: 30mg
9876742|NCT00405600|Active Comparator|Device|Device used in surgery with or without instrumentation
9876743|NCT00405665|Experimental|1|
9876744|NCT00405665|Experimental|2|
9876745|NCT00405678|Experimental|1|Subjects receiving chemo and exercise training
9876746|NCT00405678|Experimental|2|Subjects receiving chemo only
9876747|NCT00405730|Experimental|Nepafenac|One drop in the study eye 3 times daily for 23 days
9876748|NCT00405730|Active Comparator|Ketorolac Trometamol|One drop in the study eye 3 times daily for 23 days
9876749|NCT00405730|Placebo Comparator|Nepafenac Vehicle|One drop in the study eye 3 times daily for 23 days
9876750|NCT00405769|Placebo Comparator|1|placebo control
9876751|NCT00405769|Active Comparator|2|red yeast rice
9876752|NCT00405782|Active Comparator|Immediate Exercise Group|Exercise Intervention begins immediately
9876753|NCT00405782|Active Comparator|Delayed Exercise Group|Exercise intervention delayed by 16 weeks
9876754|NCT00405808|Experimental|1|Administration of one tablet containing 20 mg of Rimonabant
9876755|NCT00405808|Placebo Comparator|2|Administration of one Rimonabant placebo tablet.
9876756|NCT00405873|Experimental|AMT2003|
9876757|NCT00405886|Experimental|Neramexane 25mg/d|
9876758|NCT00405886|Experimental|Neramexane 50mg/d|
9876759|NCT00405886|Experimental|Neramexane 75mg/d|
9876760|NCT00405886|Placebo Comparator|Placebo|
9876761|NCT00405899||Immunotherapy|Patients starting immunotherapy
9876762|NCT00405899||Non-immunotherapy|Patients being treated using methods other than immunotherapy
9876763|NCT00405925|Active Comparator|combivir/kaletra|All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
9876764|NCT00405925|Experimental|Trizivir|patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
9876765|NCT00405977|Placebo Comparator|Physiologic saline|
9876766|NCT00405977|Active Comparator|Magnesium sulphate|
9876767|NCT00406003|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
9876768|NCT00406003|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
9876769|NCT00406003|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
9876770|NCT00406003|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
9876771|NCT00406003|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
9876772|NCT00406003|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
9876773|NCT00406016|Experimental|1|
9876774|NCT00406055||1|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
9876775|NCT00406081||Participants with AD|Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
9876776|NCT00406081||Nonatopic controls|Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
9876777|NCT00406094|Experimental|1|montelukast
9876778|NCT00406094|Placebo Comparator|2|placebo
9876779|NCT00406237|Experimental|1|
9876780|NCT00406250|Experimental|Bevacizumab|
9876781|NCT00406432|Experimental|Subjects receiving paroxetine|Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
9876782|NCT00406471|Active Comparator|1|500 micrograms of ranibizumab
9876783|NCT00406471|Active Comparator|2|300 microgram ranibizumab
9876784|NCT00406484|Experimental|1|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
9876785|NCT00406484|Active Comparator|2|Standard drug counseling
9876786|NCT00406536|Active Comparator|1|
9876787|NCT00406536|Placebo Comparator|2|
9876788|NCT00406575|Placebo Comparator|Placebo|Participants receive diluent via continuous IV infusion for 48 hours.
9876789|NCT00406575|Experimental|Low Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).
9876790|NCT00406575|Experimental|High Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).
9876791|NCT00406614|Experimental|1|Literacy-focused high blood pressure intervention. The intervention group will receive the health literacy -focused hypertension management intervention that will be delivered through 6 weeks of highly interactive group sessions in a classroom setting, followed by telephone counseling once a month for 12 months. Also, the intervention group will concurrently use home blood pressure monitoring with telephone transmission for 12 months.
9876792|NCT00406614|Active Comparator|2|Wait-list control group will initially receive usual care from a regular medical provider. Participants in the control group will take part in the intervention once the study has been completed.
9876793|NCT00406679|Experimental|1|
9876794|NCT00406679|Placebo Comparator|2|
9876795|NCT00406679|Active Comparator|3|
9876796|NCT00406757|Active Comparator|Pediatric Arm 1|"Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose."
9876797|NCT00406757|Active Comparator|Pediatric Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
9876798|NCT00406757|Active Comparator|Adult Arm 1|"Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose."
9876799|NCT00406757|Active Comparator|Adult Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
9876800|NCT00406757|Active Comparator|Pediatric Arm 3|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
9876801|NCT00406796|Active Comparator|1|0.5mg Ranibizumab
9876802|NCT00406796|Active Comparator|2|0.3mg Ranibizumab
9876803|NCT00406913|Experimental|Mupirocin ointment|
9876804|NCT00406913|Active Comparator|Standard of Care sterilization|
9876805|NCT00406978|Experimental|MPTD|
9876806|NCT00407069||Active Atopic Dermatitis (AD)|Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
9876807|NCT00407069||Inactive Atopic Dermatitis (AD)|Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
9876808|NCT00407069||Psoriatics|Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
9876809|NCT00407069||Asthmatics (without a history of AD)|Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
9876810|NCT00407069||Eczema Herpeticum (EH|Pediatric and adult AD subjects with a history of EH.
9876811|NCT00407069||Healthy Volunteers|Healthy individuals with no history of skin or respiratory disease.
9876812|NCT00407082|Experimental|Fluocinolone acetonide 0.59mg|Fluocinolone acetonide ocular implant 0.59mg
9876813|NCT00407082|Experimental|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
9876814|NCT00407082|No Intervention|No intervention|Fellow eye
9876815|NCT00407095|Experimental|1|
9876816|NCT00407147|No Intervention|Control|Standard treatment
9876817|NCT00407147|Experimental|PCT|PCT guided arm
9876818|NCT00407160||Group 1 Standard Immunosuppression|"Anti-thymocyte Globulin (Rabbit)] ,tacrolimus, mycophenolate mofetil and prednisone~Patients with End Stage Renal Disease (ESRD) and high Panel Reactive Antibody (PRA) who randomize to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.~They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone."
9876819|NCT00407160||Group 2 Campath Immunosuppression|"Alemtuzumab,tacrolimus~Patients with ESRD and high PRA who randomize to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy)."
9876820|NCT00407173|Experimental|1|HCV-796 1000mg single dose
9876821|NCT00407186|Experimental|1chemoradiotherapy|5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.
9876822|NCT00407186|Active Comparator|2chemotherapy|3 adjuvant courses epirubicin, cisplatin, capecitabine.
9929957|NCT00922584|Experimental|sorafenib|Patients with stage IIIB/IV NSCLC who failed EGFR-TKI therapy will receive oral sorafenib 400 mg twice daily until disease progression or unacceptable toxicity.
9929958|NCT00922597||Group 1|
9929959|NCT00922610|Experimental|1|
9929960|NCT00922649|Other|A|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of ≥ 2 OAs
9929961|NCT00922649|Other|B|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of basal insulin ± OAs
9929962|NCT00922649|Other|C|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen basal-bolus insulin ± OAs
9929963|NCT00922675|Experimental|Postconditioning|Active arm:Postconditioning protocol before routine PCI/stenting of an occluded coronary artery
9929964|NCT00922675|Other|Control|Control arm: Routine PCI/stenting of an occluded coronary artery without postconditioning
9929965|NCT00922688|Active Comparator|Dipeptiven Arm Enteral|
9929966|NCT00922688|Placebo Comparator|Placebo Arm Enteral and Intravenously|
9929967|NCT00922688|Active Comparator|Dipeptiven ARM Intravenously|
9929968|NCT00922714|Experimental|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
9929969|NCT00922714|Placebo Comparator|Control|saline
9876823|NCT00407277|Experimental|1A|
9876824|NCT00407277|Placebo Comparator|1B|
9876825|NCT00407277|Experimental|2A|
9876826|NCT00407589|Experimental|BOL-303224-A|Systemic exposure of BOL-303224-A following single and multiple topical doses
9876827|NCT00407641|Experimental|Tinzaparin|Patients will receive Tinzaparin as anticoagulant during the HD session.
9876828|NCT00407641|Active Comparator|Heparin|Patients will receive Heparin as an anticoagulant during the HD session
9876829|NCT00407667|Experimental|1|patients receive 20 min of anodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
9876830|NCT00407667|Experimental|2|patients receive 20 min of cathodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
9876831|NCT00407667|Sham Comparator|3|patients receive 20 min of sham transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
9876832|NCT00407732|No Intervention|SC|standard care
9876833|NCT00407732|Experimental|INT|psychosocial intervention
9876834|NCT00407836|Experimental|Vaccination|One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
9876835|NCT00407875|Active Comparator|Permanent interstitial prostate brachytherapy (PIPB)|patient will undergo permanent interstitial prostate brachytherapy (PIPB) using a transperineal approach to deliver 125Iodine Rapidstrand® seeds at the facilities of the British Columbia Cancer Agency (BCCA) by one or more of the certified prostate brachytherapists in the BCCA Prostate Brachytherapy Program. The minimum peripheral dose (MPD) to the prostate gland of the implant will be 144 Gy as per TG 43 protocol. A modified peripheral loading technique will be utilized in an effort to maintain the periurethral dose to < 150% of the MPD. Within 48 hours of the implant, the patient will undergo a day 0 CT scan of the pelvis to assess post implant dosimetry using the standard BCCA protocol.
9876836|NCT00407875|Experimental|Intensity modulated external beam radiation therapy (IMRT)|patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) to a volume encompassing the prostate gland. The total radiation dose will be 70 Gy delivered in 28 fractions, so that the minimum dose to the PTV is 70 Gy, with CT simulation used for planning the treatment. Prior to starting the course of IMRT, fiducial markers will be placed in the prostate to assist in localization of the prostate for planning and quality assurance during treatment.
9876837|NCT00407901||A, B|A: High functioning visually challenged (legally blind) B: Low-functioning visually challenged (legally blind)
9876838|NCT00407979||People with Atopic Dermatitis|
9876839|NCT00407979||People with Psoriasis|
9876840|NCT00407979||Generally healthy people|
9876841|NCT00407979||People with Atopic Dermatitis and Eczema Herpeticum|
9876842|NCT00407992|Experimental|Occipital nerve stimulation ON|
9876843|NCT00407992|Other|Occipital nerve stimulation OFF|
9876844|NCT00408031|Experimental|1|Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.
9876845|NCT00408083|Experimental|1|MultiHance MRI contrast agent
9876846|NCT00408083|Active Comparator|2|Magnevist contrast agent for MRA
9876847|NCT00408096|Active Comparator|1|The Copeland uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
9876848|NCT00408096|Active Comparator|2|The Global Cap uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
9876849|NCT00408148|Placebo Comparator|2|Administration of one rimonabant placebo tablet once daily in the morning
9876850|NCT00408148|Experimental|1|Administration of one tablet containing 20 mg of active rimonabant once daily in the morning
9876851|NCT00408161|Active Comparator|1|prize contingency management (CM) plus standard case management treatment -- patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals
9876852|NCT00408161|Active Comparator|2|standard case management treatment
9876853|NCT00408187|Active Comparator|1.|
9876854|NCT00408187|Placebo Comparator|3.|
9876855|NCT00408187|Active Comparator|2.|
9876856|NCT00408213|Experimental|1|
9876857|NCT00408213|Placebo Comparator|2|
9876858|NCT00408226|Experimental|1|
9876859|NCT00408239|Experimental|1|Dose regimen 1
9876860|NCT00408239|Active Comparator|2|
9876861|NCT00408239|Experimental|3|Dose regimen 2
9876862|NCT00408252|Experimental|Arm A|patients will receive SU011248 in monotherapy
9876863|NCT00408291||1|Winsta PH osteosynthesis device (Fischer Medical)for treatment of humeral fracture
9876864|NCT00408330|Active Comparator|1|azelaic acid 15%
9876865|NCT00408330|Placebo Comparator|2|Inactive 15% gel base
9876866|NCT00408395|Experimental|1: Trivalent Seasonal Influenza Vaccine|
9876867|NCT00408395|Experimental|2: Adjuvanted Trivalent Seasonal Influenza Vaccine|
9876868|NCT00408447|Other|SCD group|Sickle Cell Disease patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
9876869|NCT00408447|Other|BT group|Beta Thalassemia patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
9876870|NCT00408512|Active Comparator|Thiazides|Thiazidic diuretic
9876871|NCT00408512|Active Comparator|Non Tiazidic|Non tiazidic diuretic treatment: Any other therapy can be considered in this arm: example: CCB, BB, ACEi, ARB
9876872|NCT00408525|Experimental|1|Donepezil
9876873|NCT00408551|Experimental|FOLFOX6|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
9876874|NCT00408551|Experimental|FOLFIRI|Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
9876875|NCT00408551|Experimental|FUDR|Patients receive floxuridine IV continuously on days 1-14.
9876876|NCT00408616|Experimental|1|Grazax treatment
9876877|NCT00408616|Placebo Comparator|2|Grazax Placebo
9876878|NCT00408642|Experimental|1|enhanced adherence support for patients initiating antiretroviral therapy
9876879|NCT00408642|Active Comparator|2|standard adherence support
9876880|NCT00408655|Experimental|Arm I|"PART A: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1 and temsirolimus IV over 30 minutes on days 8 and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive paclitaxel and carboplatin as in part A. They also receive temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
9876881|NCT00408733|No Intervention|1|
9876882|NCT00408733|Experimental|2|Intervention
9876883|NCT00408772|Experimental|Unresectable colorectal liver mets|
9876884|NCT00408785|Experimental|A|Injection
9876885|NCT00408785|Placebo Comparator|B|Injection
9876886|NCT00408850|Active Comparator|Pioglitazone|pioglitazone 15 mg for 6 weeks followed by 30 mg for 6 weeks
9876887|NCT00408850|Placebo Comparator|sugar pill|Placebo comparator
9876888|NCT00408967|Experimental|Tucotuzumab celmoleukin (EMD 273066)|
9876889|NCT00409019|Experimental|1|Study cancelled: Withdrawn before enrollment of any participants
9876890|NCT00409019|Experimental|2|Study cancelled: Withdrawn before enrollment of any participants
9876891|NCT00409019|Experimental|3|Study cancelled: Withdrawn before enrollment of any participants
9876892|NCT00409058|Experimental|Teen Online Problem Solving|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
9876893|NCT00409058|Experimental|Internet Resources Comparison|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
9876894|NCT00409071|Experimental|1|cocculine
9876895|NCT00409071|Placebo Comparator|2|placebo
9876896|NCT00409084|Active Comparator|1|endoscopic variceal band ligation
9876897|NCT00409084|Active Comparator|2|subjects will receive nadolol (beta blocker) at 20mg/day with dose titration
9929970|NCT00922727|Active Comparator|L. reuteri|Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract microflora and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.
9929971|NCT00922727|Placebo Comparator|Sunflower Oil|Placebo will be the equivalent number of drops of suspended sunflower oil (without LR), provided by Biogaia.
9929972|NCT00922740|Placebo Comparator|Sugar pill|
9929973|NCT00922740|Experimental|VA106483 1 mg|
9929974|NCT00922740|Experimental|VA106483 2 mg|
9929975|NCT00922740|Experimental|VA106483 4 mg|
9929976|NCT00922753|Active Comparator|BiPAP6 assisted preoxygenation|
9929977|NCT00922753|Active Comparator|BiPAP4 assisted preoxygenation|
9929978|NCT00922753|Active Comparator|Standard preoxygenation (VS)|
9929979|NCT00922792|Experimental|A|
9929980|NCT00922792|Experimental|B|
9929981|NCT00922805|Active Comparator|fiber-enriched formula then fiber-free formula|Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
9929982|NCT00922805|Active Comparator|fiber-free formula then fiber-enriched formula|Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
9929983|NCT00922818||Radical perineal prostatectomy patients|Radical perineal prostatectomy patients
9929984|NCT00922844|Active Comparator|Sevoflurane|Administration of the volatile anesthetic Sevoflurane.
9929985|NCT00922844|Active Comparator|Isoflurane|Administration of the volatile anesthetic Isoflurane.
9929986|NCT00922857|Experimental|Respiratory rehabilitation|
9929987|NCT00922870|Active Comparator|Standard treatment|
9929988|NCT00922870|Experimental|Cascade|
9929989|NCT00922896|Experimental|GPE|Gemcitabine-Cisplatin-Erlotinib
9929990|NCT00922909|Active Comparator|2|Day 1 : morning : Medication on ; Stimulation : off afternoon : Medication : on ; Stimulation : on Day 2 : morning : Medication : off ; Stimulation : off afternoon : medication : off ; stimulation : on
9929991|NCT00922909|Active Comparator|3|Day 1 : morning : Medication off ; Stimulation : on afternoon : Medication : off ; Stimulation : off Day 2 : morning : Medication : on ; Stimulation : on afternoon : medication : on ; stimulation : off
9929992|NCT00922909|Active Comparator|4|Day 1 : morning : Medication off ; Stimulation : off afternoon : Medication : off ; Stimulation : on Day 2 : morning : Medication : on ; Stimulation : off afternoon : medication : on ; stimulation : on
9929993|NCT00922909|Active Comparator|1|Day 1 : morning : Medication on ; Stimulation on afternoon : Medication on ; Stimulation off Day 2 : morning : Medication off ; Stimulation on afternoon : Medication off ; Stimulation off
9929994|NCT00922948|Experimental|Cryoablation|
9929995|NCT00922948|Active Comparator|Radiofrequency ablation|Radiofrequency ablation
9929996|NCT00922961|Experimental|cellular apoptosis|
9929997|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g|
9929998|NCT00923000|Active Comparator|Nalbuphine|
9929999|NCT00923000|Active Comparator|Morphine|
9930000|NCT00923000|Experimental|Morphine with Long dan xie gan tang|
9876898|NCT00409136||Alert|Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
9876899|NCT00409136||No Alert|Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
9876900|NCT00409149|Experimental|CALM BP|dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques.
9876901|NCT00409149|Active Comparator|DASH|standard dietary DASH approach in hypertensive patients
9876902|NCT00409227|Active Comparator|1|double blind placebo control
9876903|NCT00409227|Placebo Comparator|2|placebo control blinded arm
9876904|NCT00409253|Active Comparator|Urapidil|
9876905|NCT00409253|Active Comparator|Nicardipine|
9876906|NCT00409279|Experimental|1|multi-component psychosocial intervention
9876907|NCT00409279|No Intervention|2|
9876908|NCT00409318|Active Comparator|1|Etanercept
9876909|NCT00409318|Placebo Comparator|2|Placebo
9876910|NCT00409396|Experimental|1|Fecal calprotectin and urinary PGEm levels will be tested on all participants.
9876911|NCT00409448|Experimental|CAPS|Participants will receive the Internet-based counselor-assisted problem-solving group treatment
9876912|NCT00409448|Active Comparator|IRC|Participants will receive the Internet resource comparison group treatment
9876913|NCT00409487|Experimental|1|8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
9876914|NCT00409487|Experimental|2|8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments
9876915|NCT00409552|Experimental|1|Virtual Reality with head display
9876916|NCT00409552|Active Comparator|2|Virtual Reality with flat projection display
9876917|NCT00409552|Active Comparator|3|non-interactive video with head display
9876918|NCT00409552|Active Comparator|4|non-interactive video with flat projection display
9876919|NCT00409552|No Intervention|5|No distraction
9876920|NCT00409591|Active Comparator|1|"NVP-NVP:~In women, one NVP 200 mg tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
9876921|NCT00409591|Experimental|2|"PL-NVP:~In women, one placebo tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
9876922|NCT00409591|Experimental|3|"LPV/r:~In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery"
9876923|NCT00409604|Experimental|1|Standard PCI procedure + pacing post conditioning
9876924|NCT00409604|No Intervention|2|Standard PCI procedure
9876925|NCT00409695|Experimental|High Dose Thymoglobulin (ATG)|High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
9876926|NCT00409695|Experimental|Low Dose Thymoglobulin (ATG)|Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
9876927|NCT00409721|Experimental|Memantine Low Dose|
9876928|NCT00409721|Experimental|Memantine High Dose|
9876929|NCT00409734||Children with pyloric stenosis|Male or female children age two to nine weeks with history of vomiting and feeding intolerance, and abdominal sonogram showing presence of pyloric stenosis
9876930|NCT00409734||Children without pyloric stenosis|Male or female children age two to nine weeks without pyloric stenosis admitted to the hospital for other reasons
9876931|NCT00409799|Experimental|1|Experimental - high dose
9876932|NCT00409799|Experimental|2|Experimental - low dose
9876933|NCT00409799|Active Comparator|3|Autograft
9876934|NCT00409864|Active Comparator|PTBD|percutaneous biliary drainage
9876935|NCT00409864|Active Comparator|Endoscopic stenting|ERCP and stenting
9876936|NCT00409916|Placebo Comparator|Standard Care Arm|In the Standard Care Arm, the treating clinician will adjust therapy according only to the clinical assessment of signs and symptoms of heart failure since the ICG information is blinded to the treating clinician.
9876937|NCT00409916|Active Comparator|ICG Arm|In the ICG Arm, the treating clinician will adjust therapy according to the clinical assessment of signs and symptoms of heart failure, in addition to the ICG hemodynamic information obtained from the printed report.
9876938|NCT00409942|Experimental|1|Torasemide prolonged released
9876939|NCT00409942|Active Comparator|2|Furosemide
9876940|NCT00409968||Screening Study|Screening study to find out if Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body are eligible to take part in 1 of 4 different research studies.
9876941|NCT00409994|Experimental|Rapamycine|rapamycine 6 mg dd
9876942|NCT00410007|Other|Patients with ADPKD, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
9876943|NCT00410007|Other|Patients with ADPKD, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
9876944|NCT00410007|Other|Healthy Control Subjects, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
9876945|NCT00410007|Other|Healthy Control Subjects, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
9876946|NCT00410215|Active Comparator|1|sodium phosphate
9876947|NCT00410215|Active Comparator|2|picosalax
9876948|NCT00410215|Active Comparator|3|picosalax plus bisacodyl
9876949|NCT00410306||Group 1|
9876950|NCT00410332|Active Comparator|A|TRAUMEEL S
9876951|NCT00410332|Placebo Comparator|B|
9876952|NCT00410345|Experimental|Pitocin|Treatment with Pitocin after mifegine
9876953|NCT00410345|Active Comparator|Cytotec|Treatment with cytotec after mifegine
9876954|NCT00410358|Experimental|LBQ707|
9876955|NCT00410371|Experimental|GI267119|25 mg ODT tablet strength
9876956|NCT00410397|Experimental|A|Osteopathic Manipulative Medicine
9876957|NCT00410397|Placebo Comparator|B|
9876958|NCT00410436|Experimental|Resistance Training Group|Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM).
9876959|NCT00410436|Active Comparator|Control Group|Subjects will not be performing resistance exercise but will continue performing aerobic exercise at the same volume, duration and intensity as they did at baseline.
9876960|NCT00410475||U.S. radiologic technologists|Radiologic technologists certified by the American Registry of Radiologic Technologists (ARRT) during 1923-1980 and residing in any U.S. state or territory.
9876961|NCT00410553|Experimental|Treatment (combination chemotherapy)|Patients receive eribulin mesylate IV and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 OR on days 1 and 8. Courses repeat every 28 or 21 days* in the absence of disease progression or unacceptable toxicity.
9876962|NCT00410566|Experimental|1|
9876963|NCT00410566|Experimental|2|
9876964|NCT00410566|Experimental|3|
9876965|NCT00410566|Experimental|4|
9876966|NCT00410566|Experimental|5|
9876967|NCT00410579||Patients treated in NSABP R-02, R-03, C-05, C-06 or C-07|Study population to be interviewed comprises patients who were treated at least 5 years ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07
9876968|NCT00410683|Experimental|Radiotherapy|Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
9876969|NCT00410683|Active Comparator|No radiotherapy|Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
9876970|NCT00410696|Active Comparator|Filgrastim|Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
9876971|NCT00410696|Experimental|Pegfilgrastim|Pegfilgrastim administered the day after autologous stem-cell reinfusion
9876972|NCT00410722|Experimental|Full-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts (at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
9876973|NCT00410722|Experimental|Half-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts as well as the control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
9876974|NCT00410722|Active Comparator|Control|Subjects will be given a control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
9876975|NCT00410735|Placebo Comparator|P|
9876976|NCT00410735|Experimental|E|
9876977|NCT00410852|Experimental|A|
9876978|NCT00410852|Experimental|B|
9876979|NCT00410852|Active Comparator|C|
9876980|NCT00410865|Experimental|INGN 201|INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
9876981|NCT00410956|Experimental|UNRESECTABLE PRIMARY HEPATIC MALIGNANCY|All patients enrolled in the study will receive HAI FUDR (0.16 mg/kg X pump volume / pump flow rate), Dexamethasone (1 mg/m2/day) and IV Bevacizumab at 5mg/kg. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days post surgical placement of HAI pump; patients will receive their first treatment with Bevacizumab no sooner than 28 days post surgical placement of HAI pump.
9876982|NCT00410982|Experimental|Gemcitabine + Busulfan + Melphalan + HCT|HCT = Hematopoietic Cell Transplantation
9930001|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g tid|
9800073|NCT01678820|Active Comparator|Simvastatin|Simvastatin 40 mg plus placebo to sitagliptin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
9876983|NCT00411177|Active Comparator|Post-dilution on-line hemodiafiltration|Post-dilution on-line hemodiafiltration
9876984|NCT00411177|Other|High-flux hemodialysis|High-flux hemodialysis
9876985|NCT00411190|Experimental|Session 1|Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.
9876986|NCT00411190|Experimental|Session 2|Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.
9876987|NCT00411203|Active Comparator|Tamoxifen Citrate|
9876988|NCT00411203|Placebo Comparator|Placebo|
9876989|NCT00411229|Active Comparator|1|Capecitabine + Oxalipatin
9876990|NCT00411229|No Intervention|2|
9876991|NCT00411281|Experimental|Group I|Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation.
9876992|NCT00411281|Other|Group II|Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I.
9876993|NCT00411320|Active Comparator|Group 1|Smokers with asthma
9876994|NCT00411320|Active Comparator|Group 2|Ex-smokers with asthma
9876995|NCT00411320|Active Comparator|Group 3|Non-smokers with asthma
9876996|NCT00411320|No Intervention|Group 4|Non smokers without asthma
9930002|NCT00923039||Exposed/ Not exposed|
9800074|NCT01678846|Experimental|Good School Toolkit|Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
9800075|NCT01678846|No Intervention|Control|Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.
9800076|NCT01678885|Experimental|Sub-study 1, Dig Photo, Actical & IDEEA|During one week of the doubly labeled water (DLW), participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Intelligent Device for Energy Expenditure and Activity (IDEEA) monitor and Actical monitor. Whether the participants wear the monitors first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
9800077|NCT01678885|Experimental|Sub-study 2 - Dig Photo & Sensewear|During one week of the doubly labeled water (DLW) period, participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Sensewear armband. Whether the participants wear the monitor first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
9800078|NCT01678898|Experimental|0.2 mg/kg|PRX-102 0.2 mg/kg every 2 weeks
9800079|NCT01678898|Experimental|1 mg/kg|PRX-102 1 mg/kg every 2 weeks
9800080|NCT01678898|Experimental|2 mg/kg|PRX-102 2 mg/kg every 2 weeks
9800081|NCT01678911|Placebo Comparator|Placebo then Gralise|Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
9800082|NCT01678911|Active Comparator|Gralise then Placebo|Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.
9800083|NCT01678924|Experimental|AGN-214868 Dose 1|AGN-214868 Dose 1 given as injections into the area of pain on Day 1.
9800084|NCT01678924|Experimental|AGN-214868 Dose 2|AGN-214868 Dose 2 given as injections into the area of pain on Day 1.
9800085|NCT01678924|Placebo Comparator|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
9800086|NCT01678924|Experimental|AGN-214868 Dose 3|AGN-214868 Dose 3 given as injections into the area of pain on Day 1.
9800087|NCT01678976|Experimental|Group 1 BIA 2-093 + Oxcarbazepine|Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
9800088|NCT01678976|Active Comparator|Group 2 Oxcarbazepine + BIA 2-093|Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
9800089|NCT01679002|Experimental|Group A|"BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period~BIA 2-093 450 mg od - BIA 2-093 450 mg bid - OXC 900 mg bid"
9800090|NCT01679002|Experimental|Group B|"BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period~BIA 2-093 450 mg bid - OXC 450 mg bid - BIA 2-093 900 mg od"
9800091|NCT01679002|Experimental|Group C|"oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period~OXC 450 mg bid - BIA 2-093 900 mg od - BIA 2-093 450 mg bid"
9800092|NCT01679028|Placebo Comparator|Placebo Group A|150mg Placebo Single dose
9800093|NCT01679028|Experimental|T89 Group A|150mg T89 single dose
9800094|NCT01679028|Placebo Comparator|Placebo Group B|300mg placebo single dose
9800095|NCT01679028|Experimental|T89 Group B|300mg T89 single dose
9800096|NCT01679028|Placebo Comparator|Placebo Group C|225mg Placebo bid for 14 days
9800097|NCT01679028|Experimental|T89 Group C|225mg T89 bid for 14 days
9876997|NCT00411320|No Intervention|Group 5|Smokers without asthma or COPD
9876998|NCT00411359|Experimental|Cardiac rehabilitation|8-week cardiac rehabilitation programme
9876999|NCT00411359|No Intervention|Monitoring|Carry on life as normal
9877000|NCT00411424|Experimental|1|
9877001|NCT00411424|Placebo Comparator|2|
9877002|NCT00411580|Experimental|1|CAD106
9877003|NCT00411580|Placebo Comparator|2|Placebo
9877004|NCT00411593|Experimental|Avastin® + Bortezomib|"Phase I - 3 * 3 design, enrolling patients to receive Avastin® at a fixed dose of 15 mg/kg every 3 weeks and Bortezomib dosed at 1.6 mg/m2 weekly for 2 weeks out of 3.~Phase II - The MTD for Bortezomib from the weekly schedule that is chosen will be combined with Avastin® to estimate the rate of progression-free survival."
9877005|NCT00411606||1|Subjects with no allergies
9877006|NCT00411658|Experimental|Investigational Device|
9877007|NCT00411658|Active Comparator|Cryopreserved|
9877008|NCT00411697|Experimental|Group A|
9877009|NCT00411723|Experimental|1|
9877010|NCT00411723|Placebo Comparator|2|
9877011|NCT00411736|Experimental|A|Stratification group: Age under 8 years, no CF siblings at home.
9877012|NCT00411736|Experimental|B|Stratification group: Age >/= 8 years, no CF siblings at home.
9877013|NCT00411736|Experimental|C|Stratification group: Age >/= 8 years, CF siblings at home.
9877014|NCT00411814|Placebo Comparator|Placebo|Saline
9877015|NCT00411814|Active Comparator|Active|GSK679586
9877016|NCT00411827|Active Comparator|1|PRK
9877017|NCT00411827|Active Comparator|2|LASIK
9877018|NCT00411866|Experimental|Subjects receiving ketoconazole for 8 days|In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
9877019|NCT00411866|Experimental|Subjects receiving ketoconazole for 14 days|In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
9877020|NCT00411879|Placebo Comparator|Control Group|Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
9877021|NCT00411879|Experimental|Study Group|Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock
9877022|NCT00411957|Active Comparator|1|ATV/r 300/100 mg
9877023|NCT00411957|Active Comparator|2|ATV/r 200/100 mg OD
9877024|NCT00411996|Other|1|IDV/r 600/100 mg + rifampicin
9877025|NCT00412022|Active Comparator|A|Triptorelin 3.75 mg IM every 4 weeks and Tamoxifen 20 mg daily, for 5 years
9877026|NCT00412022|Active Comparator|B|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily, for 5 years
9877027|NCT00412022|Experimental|C|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily for 5 years + zoledronic acid 4 mg every 6 months.
9877028|NCT00412035|Active Comparator|Botox|Botulinum toxin A injection
9877029|NCT00412035|Placebo Comparator|Placebo|saline injection
9877030|NCT00412048|Other|ALZHEIMER DISEASE|
9877031|NCT00412048|Other|MOLD COGNITIVE IMPAIRMENT|
9877032|NCT00412048|Other|CONTROLS|
9877033|NCT00412165|No Intervention|usual care|Usual care arm receives standard physical activity, nutrition and weight loss information from their primary care provider. The study offers and pays for a series of weight management sessions provided by Rady's Children's Hospital and Health Center's Nutrition Dept.
9877034|NCT00412165|Experimental|Intervention - Web|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition.
9997120|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
9800098|NCT01679197|Experimental|Treatment|Metreleptin
9800099|NCT01679236|Active Comparator|Mindfulness Training for Smokers|Mindfulness Training for Smokers (MTS) is a 7-week intervention that provides instruction in mindfulness very similar to the way it is taught in Mindfulnes-Based Stress Reduction. In addition MTS provides mindfulness training targeted to specific smoking relapse challenges. The MTS intervention was designed around a weekly curriculum that provides instruction to help participants learn practices including mindfulness meditation, mindful walking and mindful eating. MTS participants are instructed to practice meditation 30 minutes per day with a guided meditation CD.
9877035|NCT00412165|Experimental|Intervention - Group|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and has access to monthly group session with other teen and parent participants.
9877036|NCT00412165|Experimental|Intervention - Cell Phone|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and are provided with cell phones to use during the program. The cell phone allows for the transfer of text messages from the study to the participant that are tailored to their health goals. In addition, self-monitoring and uploading capabilities to the program website are included.
9877037|NCT00412191|Experimental|Subjects in treatment regimen A|Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.
9877038|NCT00412191|Experimental|Subjects in treatment regimen B|Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.
9877039|NCT00412191|Experimental|Subjects in treatment regimen C|Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.
9877040|NCT00412204|Active Comparator|1|Tiotropium
9877041|NCT00412204|Placebo Comparator|2|Placebo
9877042|NCT00412230||no treatment|
9877043|NCT00412230||2|
9877044|NCT00412321|Experimental|Cohort 1 (CNTO 328)|Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
9877045|NCT00412321|Experimental|Cohort 2 (CNTO 328)|Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
9877046|NCT00412321|Experimental|Cohort 3 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
9877047|NCT00412321|Experimental|Cohort 4 (CNTO 328)|Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
9877048|NCT00412321|Experimental|Cohort 5 (CNTO 328)|Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
9877049|NCT00412321|Experimental|Cohort 6 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
9877050|NCT00412321|Experimental|Cohort 7a (CNTO 328)|Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
9877051|NCT00412321|Experimental|Cohort 7b (CNTO 328)|Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
9877052|NCT00412334|Experimental|1|
9877053|NCT00412334|Experimental|2|
9877054|NCT00412334|Experimental|3|
9877055|NCT00412334|Experimental|4|
9877056|NCT00412386||BAV|patients with BAV
9877057|NCT00412386||Normal control|normal patients
9877058|NCT00412412|Experimental|A|Patients with HER2- Breast Cancer
9877059|NCT00412412|Experimental|B|Patients with HER2+ Breast Cancer
9877060|NCT00412477|Experimental|Group 1 - LFn-p24 ISOug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
9877061|NCT00412477|Experimental|Group 2 - LFn-p24 300ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
9877062|NCT00412477|Experimental|Group 3 - LFn-p24 450ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
9877063|NCT00412490||Smoking Behavior Group|Individuals Having Surgery for Oral Cavity Cancer.
9877064|NCT00412555|Experimental|1|
9877065|NCT00412568|Active Comparator|1|PRK control group
9877066|NCT00412581|Experimental|Lenalidomide + Dacarbazine|
9877067|NCT00412594|Experimental|Treatment (cladribine and rituximab)|Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.
9877068|NCT00412620|Placebo Comparator|Sugar Pill|
9877069|NCT00412620|Experimental|Group 1 Part 1 - ABT-925|
9877070|NCT00412620|Experimental|Group 1 Part 2 - ABT-925|
9877071|NCT00412620|Experimental|Group 2 - ABT-925|
9877072|NCT00412659|Active Comparator|Midline excision|Midline excision for pilonidal sinus disease.
9877073|NCT00412659|Active Comparator|Karydakis|Karydakis operation for pilonidal sinus disease.
9877074|NCT00412685||TGA group|The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation.
9877075|NCT00412685||TOF group|The TOF group consists of 15 patients with surgically corrected TOF.
9877076|NCT00412685||Control group|The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations.
9877077|NCT00412698|Experimental|1|
9877078|NCT00412698|Placebo Comparator|2|
9877079|NCT00412776|Experimental|1|Proxinium plus Best Supportive Care
9877080|NCT00412776|No Intervention|2|Best Supportive Care
9877081|NCT00412789|Experimental|EPO906|
9877082|NCT00412802|Experimental|1|dose adaptation of Enoxaparine at the renal deficient patients
9877083|NCT00412802|Active Comparator|2|No dose adaptation of Enoxaparine at renal normal patients
9877084|NCT00412997|Experimental|LBH589|
9877085|NCT00413075|Experimental|oral belinostat|
9877086|NCT00413101|Experimental|1|
9877087|NCT00413127|Experimental|1|Lidocaine i.v
9877088|NCT00413127|Active Comparator|2|intraoperatively lidocaine epidural postoperatively lidocaine i.v.
9877089|NCT00413127|Active Comparator|3|intraoperatively lidocaine i.v. postoperatively lidocaine epidural
9877090|NCT00413127|Active Comparator|4|lidocaine epidural
9877091|NCT00413127|Placebo Comparator|5|placebo i.v.
9930003|NCT00923182|Experimental|Alemtuzumab|The starting dose of alemtuzumab was 3 mg. The dose was gradually escalated on a daily basis (3 mg, 10 mg, and then 30 mg) until the patient tolerated a dose of 30 mg IV infusion over 2 hours. All subsequent doses of alemtuzumab were 30 mg IV 3 times a week (every other day).
9930004|NCT00923234|Experimental|Azacitidine and Lenalidomide|Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
9930005|NCT00923247|Experimental|Phase 1 - vandetanib and bortezomib|Patients will be treated with vandetanib and bortezomib to find the maximally tolerated dose
9930006|NCT00923247|Active Comparator|Phase 2 B - vandetanib alone|Patients will be treated with vandetanib alone.
9930007|NCT00923247|Active Comparator|Phase 2 A - vandetanib and bortezomib at the MTD|Patients will be treated with vandetanib and bortezomib at the maximally tolerated dose (MTD) of the Phase I study
9930008|NCT00923299|Other|cetuximab, trastuzumab|
9930009|NCT00923312|Experimental|CV9201|CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.
9930010|NCT00923338|Experimental|Vesico-vaginal fistula plug|Vesico-vaginal fistula plug
9930011|NCT00923403|Placebo Comparator|Placebo Comparator|control dairy milk
9930012|NCT00923403|Experimental|experimental|plant sterol enriched soymilk
9930013|NCT00923416||Prostate Cancer|
9930014|NCT00923429|Active Comparator|S-A|
9930015|NCT00923429|Active Comparator|S-A+stretch|
9930016|NCT00923429|Experimental|S-A+stretch+manther|
9930017|NCT00923429|Experimental|S-A+stretch+manther+sterinject|
9930018|NCT00923494|Active Comparator|Group R20|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
9930019|NCT00923494|Active Comparator|Group R30|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
9930020|NCT00923494|Active Comparator|Group R40|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
9930021|NCT00923520|Experimental|1|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
9930022|NCT00923533|Active Comparator|Part A|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
9930023|NCT00923533|Active Comparator|Part B|Hydrochlorothiazide (7day) Hydrochlorothiazide + Fimasartan (7day)
9997121|NCT01506167||Bevacizumab and Capecitabine|Participants who receive bevacizumab in combination with capecitabine
9930024|NCT00923572||Group 1|
9930025|NCT00923611|Placebo Comparator|Placebo|3 tablets of placebo will be taken 30minutes after breakfast for 8 weeks
9930026|NCT00923611|Active Comparator|Fimasartan 20mg|2 tablets of placebo and 1 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
9930027|NCT00923611|Active Comparator|Fimasartan 60mg|3 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
9930028|NCT00923611|Active Comparator|Fimasartan 120mg|3 tablets of fimasartan 40mg will be taken 30minutes after breakfast
9930029|NCT00923611|Active Comparator|Fimasartan 240mg|3 tablets of fimasartan 80mg will be taken 30minutes after breakfast for 8 weeks
9930030|NCT00923624|Active Comparator|staff emails|Attention control that includes staff sending emails with information about using health information technology system.
9930031|NCT00923624|Experimental|study nurse messages|A series of 6 proactive secure messages and 3 proactive booster messages (for a total of 9 secure and personalized messages) sent by the study nurse via the EMR patient web portal.
9930032|NCT00923663|Experimental|Lenalidomide|Lenalidomide administered orally at a dose of 25 mg daily
9930033|NCT00923676|Active Comparator|Fenofibrate|Fenofibrate pills
9930034|NCT00923676|Active Comparator|Rosuvastatin|Rosuvastatin pills
9930035|NCT00923676|Active Comparator|fenofibrate + rosuvastatin|fenofibrate pills + rosuvastatin pills
9930036|NCT00923702|Other|2 doses of vaccine|The participants will receive two doses of the vaccine at Day 1 and Day 180.
9930037|NCT00923702|Other|3 doses of vaccine|The participants will receive three doses of the vaccine at Day 1, Day 60, and Day 180.
9930038|NCT00923793|Active Comparator|Titanium|Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
9930039|NCT00923793|Experimental|Hydroxylapatite|Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
9930040|NCT00923806|Experimental|Gene Therapy Treatment|
9930041|NCT00923819|Experimental|Group A|Laparoscopic Gastric Bypass
9930042|NCT00923819|Active Comparator|Group B|Standard conservative treatment. Patients from Child Obesity Registry of Vestfold.
9877092|NCT00413257|Experimental|1|nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
9877093|NCT00413257|Experimental|2|nefopam administration will start at the end of the surgery and will be continued until postoperative H48
9877094|NCT00413257|Placebo Comparator|3|control group that will receive a placebo from the induction time of anesthesia until H48
9877095|NCT00413296|Placebo Comparator|1|Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.
9877096|NCT00413296|Active Comparator|2|Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.
9877097|NCT00413322|Experimental|Single-arm dose escalation|
9877098|NCT00413361|Placebo Comparator|A|placebo
9877099|NCT00413361|Experimental|B|versus hydroxychloroquine
9877100|NCT00413387|Experimental|1|chf1535
9877101|NCT00413387|Active Comparator|2|Symbicort
9877102|NCT00413439|Experimental|Low dose isavuconazole intravenous solution|
9877103|NCT00413439|Experimental|High dose isavuconazole intravenous solution or oral capsules|
9877104|NCT00413452|Experimental|50 mg|50 mg once weekly
9877105|NCT00413491|Experimental|1|Comparison of MR and mammography
9877106|NCT00413543|Experimental|interventional, rehabilitation|'early pulmonary lung rehabilitation'
9877107|NCT00413543|No Intervention|control|"standard care"
9877108|NCT00413556|Active Comparator|1|
9877109|NCT00413556|Placebo Comparator|2|
9877110|NCT00413595||Observation|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease
9877111|NCT00413608|Experimental|1|Clopidogrel
9877112|NCT00413608|Experimental|2|Clopidogrel
9877113|NCT00413647|Experimental|CardioPET|
9877114|NCT00413673|Experimental|1|PRK
9877115|NCT00413686|Experimental|1|AZD7762 monotherapy followed by AZD7762 + gemcitabine
9877116|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 2|Patients enrolling from Phase 2 studies
9877117|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 3|Patients enrolling from Phase 3 studies
9877118|NCT00413790|Experimental|1|Darifenacin
9877119|NCT00413790|Active Comparator|2|Tolterodine
9877120|NCT00413790|Placebo Comparator|3|Placebo
9877121|NCT00413803|Other|1|Four-hour dialysis session, blood flow rate 300-400 ml/min
9877122|NCT00413803|Active Comparator|2|Eight-hours dialysis session, blood flow rate 200-250 ml/min
9877123|NCT00413829|Other|1|
9877124|NCT00413881|Active Comparator|2|Conventional LASIK Enhancement
9877125|NCT00413881|Experimental|1|Wavefront guided LASIK Enhancement
9877126|NCT00413933|Experimental|Intrevention group|each subject in intervention group will get 15 weekly sessions (each session - 45 minutes) of specified exercise from a physical therapist that specializes in fall prevention and walking device recommendations. All subjects will get brochure for home exercise. It will be expected for intervention group to exercise twice daily, each time for 20 minutes in addition to the PT sessions
9877127|NCT00413933|No Intervention|Control group|"Those who agree to participate in the study will fill in questionnaire about falls (causes, circumstance, results). All will pass through: cognitive assessment by the Mini-Mental State Examination (MMSE), affective assessment by the 15-item Geriatric Depression Scale (GDS), functional assessment by Barthel Index (BI), visual assessment by Snellen charts and basic gait assessment by a Timed get Up and Go test (TU&G).~Participants that fulfill inclusion criteria will be randomly assigned to the intervention group or the control group"
9877128|NCT00413946|Experimental|Erythropoietin|Three doses of rErythropoietin (3000 U/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth.
9877129|NCT00413946|Placebo Comparator|saline|Three doses of placebo (0.9% saline 1 ml/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth
9877130|NCT00413998|Experimental|CABG + Mitral valve repair|
9877131|NCT00413998|Active Comparator|CABG only|
9877132|NCT00414037|Experimental|eszopiclone (Lunesta) 3mg|Subchronic (1-week) administration of 3mg Lunesta (eszopiclone)
9877133|NCT00414037|Placebo Comparator|Placebo|Placebo-treated group
9877134|NCT00414102|Experimental|Ramelteon 8 mg QD|
9877135|NCT00414102|Placebo Comparator|Placebo QD|
9877136|NCT00414128|Experimental|mycophenolate mofetil|Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
9877137|NCT00414128|Active Comparator|cyclophosphamide|pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
9877138|NCT00414141|Experimental|1|Grass MATA MPL
9877139|NCT00414141|Placebo Comparator|2|
9877140|NCT00414297|Active Comparator|1 ECP|active ECP Therapy
9877141|NCT00414297|Placebo Comparator|2|Sham ECP Treatment
9877142|NCT00414349|Experimental|1|
9877143|NCT00414349|Active Comparator|2|
9877144|NCT00414349|Experimental|3|
9877145|NCT00414375|Active Comparator|1|Drainage with interval appendectomy
9877146|NCT00414375|Experimental|2|appendectomy on presentation
9877147|NCT00414401|Other|Arm 1|
9877148|NCT00414414|Active Comparator|prednisone|
9877149|NCT00414414|Placebo Comparator|placebo|
9877150|NCT00414479||children 9-12 years of age|Children with schistosomiasis, malaria and anaemia
9877151|NCT00414531|Other|SIM|Patients diagnosed to have or not to have Statin induced Myopathy
9877152|NCT00414570|Experimental|[18]F-FLT PET scan|Radioactive dose of 2.59 MBq/kg (range 100 - 350 MBq) [18]F-FLT per injection prior to Positron Emission Tomography (PET) imaging. [18]F-FLT PET scans at baseline/pre-treatment and at disease progression, up to a maximum of two separate [18]F-FLT PET scans per participant.
9877153|NCT00414583||Observation|all adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology
9877154|NCT00414648|Experimental|1|Participants will receive sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
9877155|NCT00414648|Placebo Comparator|2|Participants will receive placebo sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
9877156|NCT00414687|Experimental|Arm 1|
9877157|NCT00414713|Active Comparator|1|Regular transfusion
9877158|NCT00414713|Active Comparator|2|Restricted transfusion
9877159|NCT00414804|Active Comparator|Spinal Cord Stimulation (SCS) Group|Spinal Cord Stimulation (SCS) Treatment Group
9877160|NCT00414804|Active Comparator|Nerve Blocks and PT|
9877161|NCT00414869|Experimental|NCX-1000|Experimental drug under evaluation
9877162|NCT00414869|Placebo Comparator|Placebo|Placebo powder
9877163|NCT00414921|Active Comparator|1|clonidine
9877164|NCT00414921|Active Comparator|2|methylphenidate
9877165|NCT00414921|Active Comparator|3|methylphenidate and clonidine
9877166|NCT00414921|Placebo Comparator|4|
9877167|NCT00414934||metastatic bone lesion for patients with cancer|
9877168|NCT00414986|Experimental|1|Practice in this arm will receive the Chronic Care Improvement intervention
9877169|NCT00414986|Experimental|2|Practices in this arm will receive the standard CQI intervention. An in-practice CQI coordinator will assist the practices in implement a chronic disease registry.
9877170|NCT00414986|Active Comparator|3|Practice in this arm will have access to all chronic care tools, but will not have an in-practice change agent.
9877171|NCT00415038|Experimental|Rostafuroxin 50 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
9877172|NCT00415038|Experimental|Rostafuroxin 150 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
9877173|NCT00415038|Experimental|Rostafuroxin 500 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
9877174|NCT00415038|Experimental|Rostafuroxin 1.5 mg capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
9877175|NCT00415038|Experimental|Rostafuroxin 5 mg capsule|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
9877176|NCT00415077|Active Comparator|2|LASEK- laser-assisted subepithelial keratectomy
9877177|NCT00415077|Active Comparator|3|Mitomycin C PRK
9877178|NCT00415077|Active Comparator|1|PRK- Photorefractive keratectomy
9877179|NCT00415090|No Intervention|1|Follow with same ARV treatment
9877180|NCT00415090|Experimental|2|Switch one of ARV drugs to Nevirapine
9877181|NCT00415103|Experimental|1|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days Palonosetrón: 0.25 mg iv every 48 horas starting day 1
9987867|NCT01416909|Active Comparator|Assessment Intervention - Vinca Alkaloid|Laxative Treatment: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on their level of constipation.
9987868|NCT01416909|Other|Control Group - Vinca Alkaloid|Standard of Care: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Patients will receive standard of care while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
9987869|NCT01416922||LSIL|Women 21 years of age or older with an LSIL diagnosis
9987870|NCT01416948|Placebo Comparator|Sugar Pill|
9987871|NCT01416948|Active Comparator|Galantamine|
9987872|NCT01416948|Experimental|Methylphenidate|
9987873|NCT01416974|Experimental|consolidative therapy with autologous T cells genetically|A phase I trial of consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 for patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab.
9987874|NCT01417013|Active Comparator|Systane Ultra|Systane Ultra Lubricant Eye Drops
9987875|NCT01417013|Active Comparator|Optive|Optive Lubricant eye drops
9987876|NCT01417052|Experimental|50 mg LX3305 QD|
9987877|NCT01417052|Experimental|100 mg LX3305 QD|
9987878|NCT01417052|Experimental|150 mg LX3305 QD|
9987879|NCT01417052|Experimental|200 mg LX3305 QD|
9987880|NCT01417052|Experimental|250 mg LX3305 QD|
9987881|NCT01417052|Experimental|300 mg LX3305 QD|
9987882|NCT01417052|Experimental|400 mg LX3305 QD|
9987883|NCT01417052|Experimental|250 mg LX3305 BID|
9987884|NCT01417052|Experimental|500 mg LX3305 QD|
9987885|NCT01417052|Placebo Comparator|Placebo|
9987886|NCT01417065|Experimental|Temsirolimus|Starting dose 0.02 mg intravenous administered once.
9987887|NCT01417117||Spontaneous Intracerebral Hemorrhage|Patients with primary intracerebral hemorrhage within 24 hours of admission diagnosed by non-contrast head computed tomography (CT)
9987888|NCT01417130||Naproxen sodium (220 mg b.i.d)|Original assignment in the ADAPT trial
9987889|NCT01417130||Celecoxib (200 mg b.i.d.)|Original assignment in the ADAPT trial
9987890|NCT01417130||Placebo|Original assignment in the ADAPT trial
9987891|NCT01417143|Experimental|TKI258 (Dovitinib)|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
9987892|NCT01417169|Experimental|Micafungin|
9987893|NCT01417182|Experimental|Melanoma|
9987894|NCT01417208||SNaP® Wound Care System|
9987895|NCT01417221|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with essential hypertension.
9987896|NCT01417221|No Intervention|Absolute medicine therapy|Maintenance of anti-hypertensive medications only
9987897|NCT01417247|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with metabolic syndrome.
9987898|NCT01417247|No Intervention|Absolute medicine therapy|Maintenance of anti-metabolic syndrome medications only
9987899|NCT01417260||Nocebo|Told breastfeeding may worsen pain
9987900|NCT01417260||No treatment|Told nothing
9987901|NCT01417260||Placebo|Told will improve pain
9987902|NCT01417273|Active Comparator|vitamin A, multiple sclerosis,|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A for 6 months and 10000 IU/day for next 6 months
9987903|NCT01417273|Placebo Comparator|placebo/Multiple Sclerosis|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
9987904|NCT01417299|Active Comparator|RPh201 group|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
9987905|NCT01417299|Placebo Comparator|placebo group|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
9987906|NCT01417312|Active Comparator|Green tea extract|
9987907|NCT01417312|Placebo Comparator|Placebo|
9987908|NCT01417338||Pulmonary hypertension group|Patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
9987909|NCT01417351|Placebo Comparator|400 IU Vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
9987910|NCT01417351|Experimental|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
9987911|NCT01417364|Active Comparator|Testosterone weekly injections continuously|Testosterone enanthate 100 mg Intramuscular (IM) weekly injections throughout the study
9987912|NCT01417364|Experimental|Cyclic testosterone administration|Testosterone injections 100 mg. IM weekly for one month alternating with placebo injections weekly for one month throughout the study
9987913|NCT01417364|Placebo Comparator|Placebo injections|Placebo injections weekly throughout the study.
9987914|NCT01417390|Experimental|Concurrent chemoradiotherapy|Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy
9987915|NCT01417390|Experimental|Inductive and concurrent|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
9997122|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
9877182|NCT00415103|Active Comparator|2|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment.
9930043|NCT00923858||Control - participants from cycles 1 & 2|no intervention. Control group is composed of participants from Cohort I (recruited during our first grant cycle) and from Cohort II (recruited during our second grant cycle). Continued observation is planned for those controls, partial tears and full tears who enrolled in study at age 65 years or younger and have less than 11 years of follow up.
9930044|NCT00923858||Cuff Tear Cohort III|These participants are being recruited from our clinical population and have been scheduled to undergo a standard of care rotator cuff repair and post op therapy. One shoulder has been indicated for rotator cuff repair and the contralateral shoulder is asymptomatic. Both shoulders will be monitored.
9930045|NCT00923871|Experimental|Cone Beam CT|
9930046|NCT00923897|Experimental|RT for Liver Mets and HCC|
9930047|NCT00923923|Experimental|levels of stress|
9930048|NCT00923962|Active Comparator|Type 2 Diabetes patients|
9930049|NCT00923962|Active Comparator|Healthy|
9930050|NCT00923962|Active Comparator|Artherosclerosis|
9930051|NCT00924014|Active Comparator|Conivaptan|Conivaptan will be given via IV bolus
9930052|NCT00924014|Active Comparator|Furosemide|Furosemide will be given via IV bolus
9930053|NCT00924014|Active Comparator|conivaptan and furosemide|on day 3 subjects will receive both study drugs
9930054|NCT00924079|Experimental|nalbuphine|
9930055|NCT00924105|Experimental|1|
9930056|NCT00924105|Placebo Comparator|2|
9930057|NCT00924183||Treatment-as-usual|All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements.
9930058|NCT00924222|Experimental|Sevoflurane|
9930059|NCT00924222|Experimental|Propofol|
9930060|NCT00924248||Group 1|
9930061|NCT00924261|Experimental|Hip Stretching|Kneeling Hip flexor stretch - 3 minutes a day, daily, for 10 weeks
9930062|NCT00924261|Experimental|Shoulder Stretch|Shoulder Stretch - 3 minutes daily for 10 weeks
9930063|NCT00924274|Experimental|Lifestyle counseling|
9930064|NCT00924274|Active Comparator|sunflower oil|
9930065|NCT00924300||patients|children and/or adolescents with psychiatric disorder
9930066|NCT00924300||controls|typically-developing children/adolescents
9930067|NCT00924339|Placebo Comparator|Rapeseed oil|Control-Group (n = 15) : Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
9930068|NCT00924339|Experimental|Soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
9930069|NCT00924391|Active Comparator|dairy milk|Control phase with 1% milk.
9930070|NCT00924391|Experimental|phytosterol enhanced soy based beverage|Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.
10211706|NCT04300478|Other|REx/Sedentary Control|Subjects will complete the REx testing sessions, have a 7-14 day washout period, and then complete the Sedentary control
10211707|NCT04297852|Active Comparator|Vegan drink|Treatment group
10211708|NCT04297852|Placebo Comparator|Control|Placebo group
9935405|NCT03789240|Experimental|1|Window of treatment with Copanlisib 60mg via IV for a single 28 day cycle, once weekly for the first 3 weeks and then a 1 week break followed by induction therapy with copanlisib and rituximab. Induction therapy will be 6 cycles (28 days) of: copanlisib dose and administration same as window, rituximab 375mg/m2 via IV, once weekly for the first 4 weeks during cycle 1, subsequent cycles (cycles 2-6), rituximab will be dosed only once on day 1 of the cycle.
9997123|NCT01506167||Bevacizumab and Capecitabine/Irinotecan|Participants who receive bevacizumab in combination with capecitabine/irinotecan
10211709|NCT04297150||Patients that satisfy inclusion criteria|Patients who satisfy the inclusion criteria and sign the informed consent.
10211710|NCT04283864||Group A|
10211711|NCT04283864||Group B|
10211712|NCT04283864||Group C|
10211713|NCT04273555|Experimental|[18F]-Fluorodeoxyglucose (FDG) PET/ MRI|
10211714|NCT04267003|Experimental|DLPFC Stimulation + Task|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during cognitive task completion.
10211715|NCT04267003|Experimental|DLPFC Stimulation + Rest|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during rest.
10211716|NCT04267003|Sham Comparator|Sham Stimulation + Task|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during cognitive task completion.
10211717|NCT04267003|Sham Comparator|Sham Stimulation + Rest|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during rest.
10211718|NCT04254302|No Intervention|Control|Participants randomized into the control arm will receive usual care as per the service delivery models and pathways planned in their region. As a pragmatic trial, no attempt will be made to standardize practices which may vary across professionals. Usual practices may be categorised as either reference to online websites deemed appropriate by their healthcare professional, general recommendations, referral for services, or none of the above.
10211719|NCT04254302|Experimental|Experimental|WECARE intervention include: 1) 30-minute appointments with an occupational therapist or a physiotherapist, as part of a multidisciplinary team, to problem-solve the child's motor performance issues, provide recommendations to stimulate the child's motor development, and intervene online directly with the child, if needed; offered bimonthly during the first three months, then on a patient-identified needs-basis. 2) A chat function where participants can privately contact the therapist; flexible access as per participant needs. 3) A forum open to all intervention group participants where they can communicate with each other or with the therapist, who will also act as a forum moderator; flexible access as per participant needs. 4) Access to static online information via relevant websites and resources on child development; flexible access based on participant needs.
9987916|NCT01417403|Experimental|Treatment (radiosensitization therapy)|Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
9987917|NCT01417416||with combat training stress|
9987918|NCT01417416||without combat training stress|
9987919|NCT01417429|Active Comparator|Galantamine|galantamine will be given with intravenous nicotine
9987920|NCT01417429|Experimental|Nicotine|Subject will be given IV Nicotine
9987921|NCT01417442|Experimental|BRAF V600E POSITIVITY|This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
9987922|NCT01417468|Experimental|CLSI - Known|Participants will be assigned to a specific learning group via the Canfield Learning Style Inventory (CLSI).
9987923|NCT01417468|Active Comparator|CLSI - Unknown|Participants will be assigned to a traditional learning group (Control).
9987924|NCT01417494|Experimental|Chemotherapy associated with bevacizumab|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab
9987925|NCT01417494|Active Comparator|Chemotherapy|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)
9987926|NCT01417507||Supportive care (neurocognitive assessment and MRI)|"Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.~Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure."
9987927|NCT01417520||ECD|ECD patients of any gender and ethnicity age 2-80 years are eligible to enroll in this protocol
9987928|NCT01417546|Experimental|1|NHS-IL12 escalating doses on a 4 week schedule (Completed).
9987929|NCT01417546|Experimental|2|NHS-IL12 escalating doses on a 2 week schedule
9987930|NCT01417546|Experimental|3|NHS-IL12 expansion group on a 4 week schedule (Completed).
9987931|NCT01417572|Experimental|lidocaine|
9987932|NCT01417598|Experimental|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
9987933|NCT01417598|Experimental|Gait and balance trainig + nordic walking|(only for Osteoporosis group)
9987934|NCT01417598|No Intervention|Control group|
9987935|NCT01417611|Experimental|i-scan-CE/SE|Study Group using i-scan SE and CE mode: i-scan-CE/SE group was explored whole colon from the cecum to the rectum with i-scan-CE 2+ and SE 2+ mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
9987936|NCT01417611|Experimental|i-scan-CE/SE/TE-c|Study Group using i-scan SE & CE mode as well as TE-c mode: i-scan-CE/SE/TE-c group was explored whole colon from the cecum to the rectum with i-scan CE2+, SE2+, TE-c mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
9987937|NCT01417624|Placebo Comparator|Control Group - Standard|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation. Patients will be randomised to one of two groups (1:1 randomisation)~Conventional LV lead placement - the LV lead will be placed according to standard techniques without knowledge of the patient's CMR findings"
9987938|NCT01417624|Active Comparator|Active CMR guided Arm|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation.Patients will be randomised to one of two groups (1:1 randomisation):~CMR guided LV lead placement - an expert panel will decide pre-operatively the optimal branch of the coronary sinus for LV lead placement based on the presence of myocardial scar tissue and coronary sinus anatomy. The operator will informed as to the optimal vein to target for delivery of the LV lead. Should this be technically unfeasible (e.g. due to pacing considerations or stability of LV lead position), then the most suitable vein will be used at the time of implantation."
9987939|NCT01417637|Active Comparator|low level laser|"In this group, the 890 nm diode laser (Ga As) Mustang 2000+, Russia) with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles.~Laser therapy for both the treatment and placebo groups will be applied on all painful muscles three times a week for four weeks."
9987940|NCT01417637|Placebo Comparator|Placebo|In Group 2 (placebo) the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
9987941|NCT01417650|Active Comparator|laser|In this group, the 890 nm diode laser (Mustang 2000+,Russia) will be used with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
9987942|NCT01417650|Placebo Comparator|placebo|In this group the low power laser will be applied with minimal dose that is very lower than the threshold necessary for therapeutic effects.
9987943|NCT01417663|Placebo Comparator|Alagebrium|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
9877183|NCT00415129|Experimental|Study Group 1|Vaccine with adjuvant
9877184|NCT00415129|Experimental|Study Group 2|Vaccine without adjuvant
9877185|NCT00415155|Experimental|A|
9877186|NCT00415233|Experimental|1.1Gbq with rhTSH|Patients receive 1.1GBq dose of radioactive iodine and rhTSH
9877187|NCT00415233|Experimental|3.2 GBq with rhTSH|Patients receive 3.2GBq dose of radioactive idodine and rhTSH
9877188|NCT00415233|Experimental|1.1GBq without rhTSH|Patients only receive 1.1GBq dose of radioactive iodine and no rhTSH
9877189|NCT00415233|Experimental|3.2GBq without rhTSH|Patients only receive 3.2GBq dose of radioactive iodine and no rhTSH
9877190|NCT00415259|Experimental|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
9877191|NCT00415259|Other|Flat control insoles|
9877192|NCT00415311|Other|0 mg/kg|
9877193|NCT00415311|Other|0.5 mg/kg|
9877194|NCT00415311|Other|1.0 mg/kg|
9877195|NCT00415324|Experimental|Arm 1|Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.
9877196|NCT00415350|Active Comparator|Azithromycin treatment 1|
9877197|NCT00415350|Placebo Comparator|Placebo 2|
9877198|NCT00415389|Active Comparator|1|interactive educational program
9877199|NCT00415389|Active Comparator|2|usual medical care
9877200|NCT00415402|Placebo Comparator|placebo|non vitamin D containing sugar granules
9877201|NCT00415402|Experimental|Vitamin D3|vitamin D granules
9877202|NCT00415428||1.|
9877203|NCT00415441|Experimental|Active physiotherapy|Manual therapy and home exercise program
9877204|NCT00415441|Placebo Comparator|Placebo physiotherapy|Manual therapy and home exercise program
9877205|NCT00415454|Experimental|Gene therapy|Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation
9877206|NCT00415467|Experimental|GliaSite Radiation Therapy System (RTS)|Surgical removal of brain tumor followed by GliaSite RTS targeted brachytherapy to the specific brain tumor site
9877207|NCT00415545|Experimental|1|Fluid Watchers LITE program
9877208|NCT00415545|Experimental|2|Fluid Watchers PLUS program
9877209|NCT00415545|No Intervention|3|Usual care control group
9877210|NCT00415584|Experimental|Cinacalcet HCl|
9877211|NCT00415649|Experimental|A|DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6.
9877212|NCT00415649|Placebo Comparator|B|Placebo vaccine
9877213|NCT00415675||Respiratory Tumor + Normal Tissue Motion|
9877214|NCT00415701|Experimental|1|Etomidate as a single induction dose
9877215|NCT00415701|Active Comparator|2|Propofol as a single induction dose
9877216|NCT00415701|Other|3|Hydrocortisone substitution or placebo (50-50%) in etomidate-group
9877217|NCT00415766|Active Comparator|rHCG 250 ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
9877218|NCT00415766|Active Comparator|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
9877219|NCT00415766|Active Comparator|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
9877220|NCT00415805|Experimental|1|
9877221|NCT00415805|Active Comparator|2|
9877222|NCT00415818|Experimental|Arm 1|MVA-MUC1-IL2 in combination with 1st line Chemotherapy
9877223|NCT00415818|Active Comparator|Arm 2|1st line Chemotherapy without a MVA-MUC1-IL2 combination
9877224|NCT00415961|Experimental|1|CoStar Paclitaxel drug eluting stent
9877225|NCT00415974|Other|Enhanced Usual Care|"Enhanced Usual Care Arm: This group will receive 2 face-to-face sessions with a health educator for dietary and health counseling in addition to an initial physician-patient visit. Educational materials that a patient might receive at his/her physician's office will also be provided at the initial health educator visit and monthly thereafter. This condition is called Enhanced Standard Care because it is, in fact, more than most obese adolescents currently receive in primary care offices in San Diego."
9930071|NCT00924417|Experimental|Distraction|"Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement."
9930072|NCT00924417|Other|Routine care|Patient managed as routine care.
9930073|NCT00924430|Other|1|
9930074|NCT00924430|Other|2|
9930075|NCT00924495|Active Comparator|Cortical function|Activity/inhibition of the cortex
9930076|NCT00924495|Active Comparator|Cortical regulation|
9877226|NCT00415974|Experimental|Stepped Care|"PACE-PC is a 1-year stepped-care intervention (subdivided into three 4-month blocks) utilizing multiple modalities including clinician and tailored health educator counseling, phone counseling, mailed content for overweight adolescents and their family to promote improved diet and physical activity behaviors aimed at weight loss and weight loss maintenance.~PACE-PC is designed to be based in the primary care setting and promotes involvement, management, and decision-making by the primary care provider about the level of PACE-PC step for each enrolled patient~Participants randomized to the PACE-PC condition will be enrolled in Step 1 (the most intensive) for the first 4 months. Depending upon response at the end of Step 1, for the next 4 months adolescents will be triaged to Step 2 (less intensive) or will repeat Step 1. At 8 months, again based upon treatment response, triage will occur to either Step 3 (least intensive) or repetition of the previous step."
9877227|NCT00416039|Experimental|1|Midazolam and morphine
9877228|NCT00416039|Placebo Comparator|2|placebo, Nacl 0.9 %, morphine 0.5 mg/kg
9877229|NCT00416130|Experimental|Vorinostat|A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
9877230|NCT00416208|Experimental|Bortezomib|Bortezomib 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
9877231|NCT00416208|No Intervention|Observation|Observational arm
9877232|NCT00416234|Active Comparator|1|Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
9877233|NCT00416234|Active Comparator|2|preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
9877234|NCT00416260|Experimental|HFO-TGI|Patients with severe Acute Respiratory Distress Syndrome receiving sessions of high frequency oscillation and tracheal gas insufflation according to the study protocol
9877235|NCT00416260|No Intervention|CMV|Patients with severe Acute Respiratory Distress Syndrome receiving only conventional mechanical ventilation according to the study protocol
9877236|NCT00416273|Experimental|Treatment group|Participants in the treatment group will receive Bortezomib at a dosage of 1.6 mg/m2.
9877237|NCT00416273|Experimental|Observation group|Participants in the observation group will not receive any consolidation therapy.
9877238|NCT00416351|Experimental|Clofarabine|Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.
9877239|NCT00416364||1|
9877240|NCT00416364||2|
9877241|NCT00416364||3|
9877242|NCT00416364||4|
9877243|NCT00416403|Experimental|Arm I|Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
9877244|NCT00416403|Experimental|Arm II|Patients receive oral fluvastatin sodium as in arm I at a higher dose.
9877245|NCT00416403|Experimental|Arm III|Patients do not receive fluvastatin sodium. breast Cancer surgery only
9877246|NCT00416481||Patient assessment|"Patients undergo assessments of cognition and performance status using the healthcare professional-rated Karnofsky performance scale. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed.~Patients also complete self-administered questionnaires that measure level of functioning and need for services. It also includes questionnaires that measure higher levels of physical functioning, performance related to survival and clinically significant illness and measures of comorbidity and the impact on daily activities. Lastly, questionnaires are administered to measure the impact of cancer on patients' social functioning and perceived availability of social support.~Patients then begin planned treatment."
9877247|NCT00416637|Experimental|Bevacizumab (Avastin)|Bevacizumab given and then BP checked and skin biopsies obtained.
9877248|NCT00416650|Experimental|Therapeutic Intervention|Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.
9877249|NCT00416663|Experimental|single arm|open label,single arm,intervention is Angiogenic Cell Precusors(ACPs)
9877250|NCT00416689||Breast or lung CA pt undergoing chemoTx|
9877251|NCT00416702|Experimental|1|QAB149
9877252|NCT00416741||1 Usual Care-Lifestyle counseling|Metabolic syndrome
9877253|NCT00416741||2 Intensive care-Lifestyle counseling|Metabolic Syndrome Implementation of guidelines
9877254|NCT00416767|Experimental|FOLFIRI|
9930077|NCT00924521|Active Comparator|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
9930078|NCT00924521|Experimental|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
9930079|NCT00924534|Placebo Comparator|1|
9930080|NCT00924534|Experimental|2|
9930081|NCT00924534|Experimental|3|
9930082|NCT00924534|Experimental|4|
9930083|NCT00924547|Experimental|Docosahexanoic Acid Supplement|In this arm, participants took two different doses of a DHA supplement. Each dose of the DHA supplement was taken for 4 weeks.
9930084|NCT00924547|Placebo Comparator|Placebo|In this arm, participants took a placebo pill that did not contain any DHA.
9930085|NCT00924573|Experimental|1|"Metformin on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks"
9930086|NCT00924573|Placebo Comparator|2|"Placebo on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks"
9930087|NCT00924586|Placebo Comparator|P|
9930088|NCT00924586|Experimental|E|
9930089|NCT00924599|Experimental|Intervention Group-English|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
9930090|NCT00924599|Experimental|Intervention Group-Spanish|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
9930091|NCT00924599|Active Comparator|Lifestyle education-English|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
9930092|NCT00924599|Active Comparator|Lifestyle education-Spanish|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
9930093|NCT00924625|Experimental|Neuromuscular electrical stimulation|NMES will be used as in clinical practice based on an evidence-based approach. NMES will be applied at the participant's maximum tolerance. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions.
9930094|NCT00924625|Active Comparator|Volitional exercises|VE will be used as in clinical practice based on an evidence-based approach. VE program will be the one shown to positively affect muscle hypertrophy and will follow the resistance training principles. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions
9930095|NCT00924677|Sham Comparator|lidocaine|Local injection with lidocaine through the RF cannula without activation of RF generator.
9930096|NCT00924677|Active Comparator|lidocaine, radiofrequency current|After lidocaine injection through the RF cannula, the temperature of the electrode tip was raised to 70℃ for 90 seconds by RF generator.
9930097|NCT00924690|Experimental|1|Behavioral Message Arm
9930098|NCT00924690|Active Comparator|2|Generic Message Arm
9930099|NCT00924742|Experimental|Test drug|
9930100|NCT00924768|Experimental|Endotoxin|Inhalation of 20K EU CCRE
9930101|NCT00924794||Cohort A|Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.
9997124|NCT01506167||Bevacizumab and Fluorouracil +/- Folinic Acid|Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
9930102|NCT00924846|Active Comparator|HFOV plus iNO|HFOV plus iNO: high frequency oscillatory ventilation plus inhaled nitric oxide
9930103|NCT00924846|Active Comparator|CMV plus iNO|CMV (conventional mechanical ventilation) iNO (inhaled nitric oxide)
9930104|NCT00924859||1|Patients with clinical suspicion of CVT
9930105|NCT00924872|Experimental|intervention|receive wheelchair skills training
9930106|NCT00924872|No Intervention|control|no formalized wheelchair skills training provided
9930107|NCT00924911|Experimental|Part 1|A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
9930108|NCT00924911|Experimental|Part 2|A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
9930109|NCT00924924|Experimental|Act Healthy!|Immediate treatment group of six-weeks of classes in self-management training for healthy behaviors
9930110|NCT00924924|Active Comparator|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
9877255|NCT00416819|Experimental|methotrexate, leucovorin calcium, rituximab, and temozolomide|Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.
9877256|NCT00416910|Active Comparator|FCM|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
9877257|NCT00416910|Experimental|FCM + G-CSF|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles
9877258|NCT00416923|Experimental|intrathecal rituximab|3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg
9877259|NCT00416975|Other|Breast Cancer Risk Assessment Screening|Counseling Intervention and Eduation Intervention
9877260|NCT00417040|Other|(Internet-based STAR database)|"Patients are registered into the STAR database, obtain a password, undergo STAR training, and complete a patient-STAR questionnaire after seeing their clinician (baseline self-report) on day 1 of course 2* of chemotherapy. Patients are reminded to complete online STAR questionnaire before seeing their clinician on day 1 of courses 3, 4, 5, and 6* of chemotherapy. Clinicians review these patient reports before creating their own assessment. Patients also complete a patient feedback survey on day 1 of course 4* of chemotherapy. Clinicians complete feedback survey at study completion.~NOTE: *All time points are based on scheduled therapy with clinical trial CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603, CALGB-40502, CALGB-70604, CALGB-80405, or CALGB-40503."
9877261|NCT00417105||1|hemodialysis twice weekly 4 hours
9877262|NCT00417105||2|nocturnal dialysis twice weekly 8 hours
9877263|NCT00417105||3|nocturnal hemodialysis, 8 hours every other night
9877264|NCT00417105||4|nocturnal hemodialysis, 8 hours, six times per week
9877265|NCT00417222|Active Comparator|Olmesartan medoxomil|olmesartan medoxomil
9877266|NCT00417222|No Intervention|Standard therapy|Standard therapy
9877267|NCT00417235|Experimental|3-days dressing frequency/CHX sponge|"Interventions:~Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
9877268|NCT00417235|Experimental|7-days dressing frequency/CHX sponge|"Interventions:~Behavioural: 7-day catheter dressing frequency Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
9877269|NCT00417235|No Intervention|3-days dressing frequency/No CHX sponge|No intervention, classical protocol of dressing frequency every 3-days and no other device
9877270|NCT00417235|Experimental|7-days dressing change/No CHX sponge|Interventions:Behavioural: 7-day catheter dressing frequency
9877271|NCT00417261|Experimental|1|ATF936
9877272|NCT00417261|Experimental|2|AXT914
9877273|NCT00417261|Placebo Comparator|3|Placebo
9877274|NCT00417326|Placebo Comparator|P|
9877275|NCT00417326|Experimental|E|
9877276|NCT00417339||hemodialysis, 4h, twice weekly|hemodialysis, four hours, twice weekly
9877277|NCT00417339||hemodialysis, 8h, twice weekly|hemodialysis, eight hours, twice weekly
9877278|NCT00417339||hemodialysis, 8h, every other day|hemodialysis, eight hours, every other day
9877279|NCT00417339||hemodialysis, 8h, six days per week|hemodialysis, eight hours, six days per week
9877280|NCT00417378|Active Comparator|1|Intraaortic balloon counterpulsation (IABP)
9877281|NCT00417378|Experimental|2|Left Ventricular Assist Device (Impella LP2.5)
9877282|NCT00417391|Experimental|1 mg RR110|1 mg RR110
9877283|NCT00417391|Experimental|4 mg RR110|4 mg RR110
9877284|NCT00417404|Active Comparator|vitamin A|
9877285|NCT00417404|Sham Comparator|sham injection|
9877286|NCT00417456|Active Comparator|1|Office Visits
9877287|NCT00417456|Experimental|2|Evisit
9877288|NCT00417508|Experimental|Nutritional supplement|2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
9877289|NCT00417508|Active Comparator|Dietary advice|ordinary dietary advice with a recommendation of four meals per day or similar dietary advice
9877290|NCT00417521|Experimental|Family therapy|
9877291|NCT00417560|Experimental|Influenza A/H5N1 Vaccine|Two 90ug Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine
9877292|NCT00417599|Experimental|Lifestyle intervention|Behavioral lifestyle intervention versus control group. The Behavioral intervention consists of behavioral lessons delivered over the internet.
9877293|NCT00417599|Experimental|control|The intervention for the waiting list control group was usual care.
9877294|NCT00417638|Experimental|patients with acute STEMI - treatment with Hypothermia +PCI|"Hypothermia using endovascular cooling with the Celsius Control System as an adjunct therapy.~Hypothermia before reperfusion by a combination of infusion of cold saline and endovascular catheter cooling as an adjunct therapy in patients with a STEMI scheduled to undergo primary percutaneous coronary intervention (PCI)."
9877295|NCT00417638|Active Comparator|Patients with an acute STEMI eligible for primary PCI|Standard of care treatment or the control group Patients with an acute STEMI eligible for primary PCI
9877296|NCT00417690|Experimental|A|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
9877297|NCT00417690|Placebo Comparator|P|One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks
9877298|NCT00417729|Active Comparator|acarbose, glibenclamide|acarbose vs. glibenclamide (background metformin therapy)
9877299|NCT00417768|Active Comparator|Tissue Plasminogen Activator|tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
9930111|NCT00924937|Active Comparator|Low Fat Diet|Dietary Intervention with a Low fat diet: <30% fat (12% monounsaturated fatty acids; 6-8%polyunsaturated fatty acids; <10% saturated fatty acids)
9987944|NCT01417663|Other|Exercise training|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
9987945|NCT01417676|Experimental|Radiation|
9987946|NCT01417689|Active Comparator|Open-eyes|Patients in this arm are encourage to attempt eye drop instillation using the most commonly used technique that involves looking up, pulling inferior lid down and putting the drop in the inferior cul de sac.
9987947|NCT01417689|Experimental|Closed-eyes|Patients in this group are encouraged to attempt eye drop instillation with both eyes closed near the medial canthal region. After feeling contact with the drop on the skin the drop is expected to enter the eye when opening the eye and resuming blinking.
9987948|NCT01417702||Crohn´s disease - active|Patients in the active phase of the disease
9987949|NCT01417702||Crohn´s disease - quiescent|Patients in the quiescent phase of the disease
9987950|NCT01417702||Ulcerative colitis - active|Patients in the active phase of the disease
9987951|NCT01417702||Ucerative colitis - quiescent|Patients in the quiescent phase of the disease
9987952|NCT01417715||Crohn´s disease - active|Patients with Crohn´s disease in the active phase.
9987953|NCT01417715||Crohn´s disease - quiescent|Patients with Crohn´s disease in the quiescent phase.
9987954|NCT01417715||Ulcerative colitis - active|Patients with ulcerative colitis in the active stage.
9987955|NCT01417715||Ucerative colitis - quiescent|Patients with ulcerative colitis in the quiescent stage.
9987956|NCT01417754|Other|Toremifene|
9987957|NCT01417767|Experimental|CHG regimen|one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)
9987958|NCT01417767|Active Comparator|Decitabine|one course of Decitabine (5-aza-deoxycytidine,Dacogen)
9987959|NCT01417793|Experimental|Smoking Cessation Program|
9987960|NCT01417819|Other|SMS reminder|SMS reminders four days and one day before their appointments
9987961|NCT01417832|Experimental|Treatment with Infiltrant/Adhesive|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
9987962|NCT01417832|Placebo Comparator|Placebo, placebo treatment|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.
9987963|NCT01417845|Experimental|High Intensity Exercise|High intensity resistance and aerobic training
9987964|NCT01417845|Active Comparator|Moderate Intensity Exercise|Moderate intensity resistance and aerobic training
9987965|NCT01417858|Active Comparator|brimonidine 0.2%|
9987966|NCT01417858|Active Comparator|brimonidine 0.1%|
9987967|NCT01417871||case goup|Lifestyle counseling, ABC program
9987968|NCT01417871||control group|usual care
9987969|NCT01417884||ischemic heart disease|stable coronary artery disease, acute coronary syndromes
9987970|NCT01417884||non-ischemic heart disease|inflammatory heart disease, heart failure (non-ischemic), valvular heart disease
9987971|NCT01417897|Experimental|Insulin Glulisine: bolus injections before each main meal|Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.
9987972|NCT01417897|Active Comparator|Insulin Aspart: bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.
9987973|NCT01417897|Active Comparator|Regular human insulin:bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.
9987974|NCT01417910||Peripheral vascular disease|Subjects who have peripheral vascular disease
9987975|NCT01417923|Experimental|vitamin D|We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks
9987976|NCT01417949|Active Comparator|Immediate arm|Immediate arm: ART should be initiated as soon as possible but no later than 3 days after initiation of OI treatment.
9987977|NCT01417949|Active Comparator|Deferred arm|Deferred arm: ART should be initiated after the completion of OI treatment which is achieved at the earliest at day 21 for PCP and at day 28 for TE. ART should be initiated no later than 6 weeks after initiation of OI treatment.
9987978|NCT01417962||Fetuses|Still birth and Termination of pregnancies
9987979|NCT01417962||Children|Includes Newborns, Infants and Children
9987980|NCT01417975|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants waking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise is defined as 40-68% of heart rate reserve (HRR). Heart rate (HR) will be monitored using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
9987981|NCT01417975|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively in a chair for 10 minutes. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) with regards to distraction effects and researcher contact.
9987982|NCT01417988|Experimental|Empiric TB treatment|Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
9987983|NCT01417988|Active Comparator|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
9997125|NCT01506167||Other|Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
9987984|NCT01418014||Infected Cohort|Perinatally HIV-infected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment, engaged in care with ART treatment history available.
9987985|NCT01418014||Uninfected Cohort|HIV-uninfected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment born to HIV-infected mothers.
9987986|NCT01418027|Experimental|Intensive exercise|The subjects receive an intensive exercise for 6 months and a subsequent conventional exercise for another 6 months.
9987987|NCT01418027|No Intervention|Lifestyle counseling|Subjects receive a general lifestyle counseling for 12 months
9987988|NCT01418027|Experimental|Regular exercise|Subjects receive conventional exercise for 12 months
9987989|NCT01418040||High risk prostate cancer|Histologically confirmed patients with high risk prostate cancer seen at Calvary Mater Newcastle.
9987990|NCT01418053|Experimental|Hot Cataplasm with Caraway Oil|
9987991|NCT01418053|Active Comparator|Hot Cataplasm with Olive oil|
9987992|NCT01418053|Active Comparator|Cold cataplasm with Olive oil|
9987993|NCT01418066|Placebo Comparator|Placebo|Tea decoction made of Graminis Flores abd Maidis stigmata.
9987994|NCT01418066|Experimental|Ayurvedic herbs|Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
9987995|NCT01418079|Experimental|PMS-3000|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
9987996|NCT01418105|Active Comparator|Videofluroscopic swallow study (VFSS)|To investigate the swallowing ability of patients with neurologic problems
9987997|NCT01418105|Active Comparator|cervical spine isometric excercises|isometric exercises in patients with cervical spine scoliosis
9987998|NCT01418105|Active Comparator|Fiberoptic endoscopic esophageal study (FEES)|To investigate the anatomic structures during swallowing of patients with neurologic problems
9987999|NCT01418118|Experimental|Pressors|Epinephrine, Norepinephrine, Dobutamine, Dopexamine
9988000|NCT01418131|Active Comparator|Rectal tacrolimus|Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
9988001|NCT01418131|Placebo Comparator|Rectal Placebo|Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus
9988002|NCT01418144|Experimental|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block with ropivacaine
9988003|NCT01418144|Placebo Comparator|Block with saline|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
9988004|NCT01418157|Active Comparator|Acetazolamide|
9988005|NCT01418157|Placebo Comparator|Placebo|
9988006|NCT01418170|Experimental|Two rcSMT group|A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
9988007|NCT01418170|Sham Comparator|One scSMT + One rcSMT Group|A scSMT will be performed with the contact hand of the clinician resting lightly on the paraspinal area of the neck of the subject. The subject's head will be rotated to 45 degrees and supported by the clinician's forearm, lying on headpiece. A inferior drop thrust will be applied to the drop piece. After the first scSMT maneuver the subject will turn over on the chiropractic table to lie in the prone position for a post-scSMT PPT measurement. PPT measurements will be taken at 5-minute intervals for 30 minutes. A rcSMT will be performed 30 minutes after the first scSMT. The subject will turn over to the prone position for repeat PPT measurements in 5-minute intervals for 30 minutes post-rcSMT. Once the subject has left the treatment area the clinician will mark on the treatment card weather the scSMT was performed adequately without cavitation and whether a cavitation occurred with the rcSMT.
9988008|NCT01418183|Experimental|5ml 5% levobupivacaine|5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
9988009|NCT01418183|Placebo Comparator|5ml normal saline|5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
9988010|NCT01418183|Experimental|2.5ml 5% levobupivacaine|2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
9988011|NCT01418235|Experimental|Group 1: MVA-C + gp140/MF59|
9988012|NCT01418235|Experimental|Group 2: MVA-C + gp140/MF59|
9988013|NCT01418235|Experimental|Group 3: DNA-C2 + MVA-C|
9988014|NCT01418235|Experimental|Group 4: DNA-C2 + MVA-C + gp140/MF59|
9988015|NCT01418274|Experimental|Single arm|
9988016|NCT01418287||Hospitalized|Subjects who are hospitalized due to influenza-like illness
9988017|NCT01418287||Non-hospitalized|Subjects who are not hospitalized
9988018|NCT01418300|Active Comparator|sequential therapy|first five day amoxicillin+PPI later five day PPI+clarithromycin+metronidazole
9988019|NCT01418300|Active Comparator|conventional triple thearpy|PPI+amoxicillin+clarithromycin
9988020|NCT01418313||DCE-MRI|Magnetic resonance imaging (MRI) with and without FDA approved contrast agents: MRI is a non invasive imaging technique used to visualize the internal structure of the body in detail. The MRI machine is an oversized magnet that is always on. It will be used in this study to provide anatomical and functional (MRI with contrast) information about atherosclerotic plaques.
9997126|NCT01506180||Patients admitted to Geriatric Department|The patients receive comprehensive geriatric assessment
9997127|NCT01506180||Patients admitted to general medical departments|This group do not receive comprehensive geriatric assessment
9997128|NCT01506219|Experimental|Geriatrician-performed CGC|Geriatrician-performed CGC in addition to the usual care at Community Rehabilitation Unit.
9997129|NCT01506219|No Intervention|Usual care|Usual services at Community Rehabilitation Unit.
9997130|NCT01506232||ADHD|Youth diagnosed with ADHD.
9988021|NCT01418313||PET/CT and PET/MR|Positron emission tomography (PET)/ computer tomography (CT): PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. Nowadays PET imaging is most useful in combination with anatomical imaging, such as CT scanners, thereby PET scanners are now available with integrated high-end multi-detector row CT scanners. Because the two scans can be performed in immediate sequence during the same session and with the patient not changing position between the two scans, areas of abnormality on PET images can be directly correlated with anatomy on the CT images.
9988022|NCT01418313||PET/MR|Positron emission tomography (PET)/MRI: PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. To avoid the additional radiation deriving from the CT scan during PET/CT imaging, nowadays PET imaging can be paired with MR anatomical images.
9988023|NCT01418326||Sevoflurane|Sevoflurane exposure for radical cancer surgery
9988024|NCT01418326||Propofol|Propofol exposure for cancer surgery
9988025|NCT01418391|Experimental|morphine consumption|
9997131|NCT01506232||ASD|Youth diagnosed with an Autism Spectrum Disorder (ASD).
9997132|NCT01506232||BPD|Youth diagnosed with Bipolar Disorder.
9997133|NCT01506232||Healthy Controls|Youth not diagnosed with any psychiatric/psychological disorder.
9997134|NCT01506245|No Intervention|Control|
9997135|NCT01506245|Experimental|Family-based behavioral therapy|Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
9997136|NCT01506258|No Intervention|Patients not infused with stem cells|Historic Controls
9997137|NCT01506258|Experimental|Patients infused with stem cells|
9997138|NCT01506284||Anesthetized patients ASA I-II|ASA classification I-II, scheduled for elective surgery requiring general anesthesia.
9997139|NCT01506310|No Intervention|Diet alone|
9997140|NCT01506310|Experimental|Behavioral therapy|
9997141|NCT01506310|Experimental|Exercise|
9997142|NCT01506310|Experimental|Behavioral therapy and exercise|
9997143|NCT01506336|Experimental|masitinib|masitinib 12 mg/kg/day
9997144|NCT01506336|Active Comparator|sunitinib|sunitinib 50 mg/day
9997145|NCT01506349|Experimental|Crossover Group 1|"Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3."
9997146|NCT01506349|Experimental|Crossover Group 2|"Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3."
9997147|NCT01506375|Experimental|gpASIT|grass pollen peptides alone
9997148|NCT01506375|Experimental|gpASIT/adjuvant|grass pollen peptides + adjuvant
9997149|NCT01506388|Experimental|folye catheter plus vaginal IMN|intracervical foley catheter plus vaginal IMN
9997150|NCT01506388|Active Comparator|Misoprostol vaginally|intravaginal misoprostol
9997151|NCT01506401|Active Comparator|Conventional Ventilation|Low tidal volumes, relatively high PEEP.
9997152|NCT01506401|Experimental|High Frequency Oscillation|Open-lung strategy for high frequency oscillation.
9997153|NCT01506414|Experimental|combination treatment|
9997154|NCT01506427|Experimental|[F-18] HX4|
9997155|NCT01506440||Supportive Care (cognitive assessment)|Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
9997156|NCT01506466|Other|additional examinations/measurements|
9997157|NCT01506492|No Intervention|Usual Care|Usual care includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed.
9997158|NCT01506492|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
9997159|NCT01506505|Experimental|Polypill in the morning|Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
9997160|NCT01506505|Experimental|Polypill in the evening|Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
9997161|NCT01506505|Active Comparator|Individual agents of the polypill)|"Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.~Simvastatin 40 mg used 18.00-00.00 in the evening."
9997162|NCT01506518||Duchenne muscular dystrophy and age 5-6 years|Boys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
9997163|NCT01506518||Duchenne muscular dystrophy and age 7-8 years|Boys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
9997164|NCT01506518||Duchenne muscular dystrophy and age 9-10 years|Boys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
9997165|NCT01506518||No known neuromuscular disorders and age 5-14 years|Volunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.
9997166|NCT01506531|Active Comparator|primary closure of gastroschisis|Attempt primary skin closure of gastroschisis shortly after birth
9997167|NCT01506531|Active Comparator|silo for gastroschisis|Surgical placement of silo over gastroschisis shortly after birth
9997168|NCT01506544|Experimental|Arm 1 Pharmacokinetic study|This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
9998314|NCT01517022|No Intervention|Control arm|Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
9877300|NCT00417768|Sham Comparator|Instillation of Normal Saline|Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
9877301|NCT00417794|Active Comparator|1|Atomoxetine HCL (Strattera)
9877302|NCT00417794|Placebo Comparator|2|
9877303|NCT00417807|Experimental|Gleevec/Glivec|
9877304|NCT00417911|Active Comparator|No treatment|
9877305|NCT00417911|Experimental|Bortezomib consolidation|Bortezomib consolidation : 20 injections starting 3 months after ASCT
9877306|NCT00417937|Active Comparator|1|Azelaic acid 15 % gel once daily
9877307|NCT00417937|Active Comparator|2|Azelaic acid 15 gel twice daily
9877308|NCT00418067|Active Comparator|Cypher|Sirolimus-eluting stent
9877309|NCT00418067|Active Comparator|Taxus Liberte|Paclitaxel-eluting stent
9877310|NCT00418067|Experimental|Endeavor|Zotarolimus-eluting stent
9877311|NCT00418106||1|Mothers who are pumping breast milk and who are willing to kangaroo hold their infant.
9877312|NCT00418132|Experimental|1|Participants will receive thalidomide.
9877313|NCT00418132|Placebo Comparator|2|Participants will receive placebo thalidomide.
9877314|NCT00418210|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
9877315|NCT00418288|Active Comparator|A|
9877316|NCT00418288|Placebo Comparator|P|
9877317|NCT00418392|Experimental|Minocycline group|After successful simple aspiration, minocycline pleurodesis will be performed.
9877318|NCT00418392|Placebo Comparator|Control group|After successful simple aspiration, nothing will be performed.
9877319|NCT00418418|Active Comparator|A|Patient group receiving the stem cell injections during the CABG
9877320|NCT00418418|Placebo Comparator|B|The patient group receiving autologous serum injections during the CAGB operation
9877321|NCT00418470|Experimental|A|Higher concentration of antibiotic in NS
9877322|NCT00418470|Experimental|B|Lower concentration of antibiotic in NS
9877323|NCT00418483|Experimental|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg
9877324|NCT00418483|Experimental|Plasmin (Human) 50 mg|Plasmin (Human ) 50 mg
9877325|NCT00418483|Experimental|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg
9877326|NCT00418483|Experimental|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
9877327|NCT00418483|Experimental|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg
9877328|NCT00418483|Experimental|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg
9877329|NCT00418483|Experimental|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg
9877330|NCT00418496|Experimental|Aldekleukin Plus Dose Escalation Sorafenib|Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
9930112|NCT00924937|Experimental|Mediterranean Diet|Dietary Intervention with a Mediterranean Diet: 35-38% fat (22% monounsaturated fatty acids; 6% polyunsaturated fatty acids; <10% saturated fatty acids).
9930113|NCT00924963|Experimental|Jet injection lidocaine|J-Tip jet injection of 1% buffered lidocaine
9930114|NCT00924963|Placebo Comparator|Jet injection saline|J-Tip jet injection of sterile saline
9930115|NCT00924963|Active Comparator|Lidocaine cream|Lidocaine 4%cream applied for 30 minutes prior to IV insertion or venipuncture
9930116|NCT00924976|Experimental|1|Subjects will be offered the Steps for Achieving Financial Empowerment (SAFE) which helps facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
9930117|NCT00924976|No Intervention|2|Representative payeeship as usual
9930118|NCT00925028|Experimental|Group A|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. After four months the groups will switch to the alternate management strategy.
9930119|NCT00925028|Experimental|Group B|Patients of group B will continue to be managed by their physician. After four months the groups will switch to the alternate management strategy.
9930120|NCT00925041|Experimental|Kxl Vedera|
9930121|NCT00925067|Experimental|lightweight TiMesh|
9930122|NCT00925067|Experimental|lightweight VyproII|
9930123|NCT00925067|Experimental|Heavyweight Marlex|
9930124|NCT00925080||A|
9930125|NCT00925093|Active Comparator|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
9930126|NCT00925093|Active Comparator|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
9930127|NCT00925093|Active Comparator|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
9930128|NCT00925106|Active Comparator|Celebrex capsule|Commercial capsule
9930129|NCT00925106|Experimental|D1|Test formulation D1
9930130|NCT00925106|Experimental|D2|Test formulation D2
9930131|NCT00925106|Experimental|D3|Test formulation D3
9930132|NCT00925145||1|
9930133|NCT00925158|Experimental|Surgical instrument (DAME)|Surgical dissector instrument created to malar elevation.
9930134|NCT00925171|Experimental|Pulmonary Rehabilitation Group|Intervention with exercise management
9930135|NCT00925171|No Intervention|Control Group|"Patients will receive the standard advice to undertake strength and endurance exercises at home and invitation to attend the Norwich Breath Easy Group~Patients will be stratified according to whether the initial programme took place in the outpatient hospital or community setting"
9988026|NCT01418404|Experimental|Noxious TS in study A|Noxious TS in study A
9988027|NCT01418404|Active Comparator|Innocuous TS|Innocuous TS in study A
9988028|NCT01418404|Experimental|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
9988029|NCT01418404|Active Comparator|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
9988030|NCT01418404|Experimental|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
9988031|NCT01418404|Active Comparator|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
9988032|NCT01418430|Experimental|CHOP-daclizumab|
9988033|NCT01418456|Experimental|Active Antibiotic Group|Patients in the antibiotic group will remain on antibiotics until their foot ulcer heals or up to 20 weeks
9988034|NCT01418456|No Intervention|Non antibiotic group|
9988035|NCT01418469|Experimental|Caseinate protein intake|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
9988036|NCT01418469|Experimental|Whey protein isolate intake|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
9988037|NCT01418469|Experimental|Soy protein intake|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
9988038|NCT01418469|Experimental|soy+BCAA protein intake|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
9988039|NCT01418495||Ancillary-Correlative (pharmacokinetics of ch14.18)|Patients undergo blood sample collection at baseline and during and after course 1, 3, or 5 of treatment for pharmacokinetic analysis. Some patients undergo blood sample collection at baseline and during and after two treatment courses (1 and 3, 1 and 5, or 3 and 5).
9988040|NCT01418508|No Intervention|low protein diet|Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
9988041|NCT01418508|Experimental|low protein diet plusα-keto acid|0.6g of proteins per kilo of body weight per day
9988042|NCT01418508|Experimental|very low protein diet plus α-keto acid|0.3g of proteins per kilo of body weight per day
9988043|NCT01418521|Active Comparator|Ringer-albumin|Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
9988044|NCT01418521|Experimental|Tetraspan|patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
9988045|NCT01418560|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with chronic renal failure.
9988046|NCT01418560|No Intervention|Absolute medicine therapy|Maintenance of anti-renal failure medications only
9988047|NCT01418573|Experimental|Palaeolithic-type meal 1|
9988048|NCT01418573|Experimental|Palaeolithic-type meal 2|
9988049|NCT01418573|Placebo Comparator|The reference meal|
9988050|NCT01418638||30 Patients with MDD.|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
9988051|NCT01418651|Experimental|Milnacipran|Drug
9988052|NCT01418664|Active Comparator|Study group|Each woman in above group will recieve in addition to routine ferrous sulphate and calcium lactate, 4000IU of vitamin D
9988053|NCT01418664|No Intervention|control group|Women in this group will recieve ferrous sulphate and calcium lactate
9988054|NCT01418677|Active Comparator|Cohort 1|
9988055|NCT01418677|Active Comparator|Cohort 2|
9988056|NCT01418677|Active Comparator|Cohort 3|
9988057|NCT01418690||Non-invasive near infra-red device (NIRS)|
9988058|NCT01418716|Experimental|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
9988059|NCT01418716|Active Comparator|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
9988060|NCT01418729|Active Comparator|Sorafenib plus Pravastatin|The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
9988061|NCT01418729|Placebo Comparator|Sorafenib plus Placebo|The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.
9988062|NCT01418742|Active Comparator|Doxycycline 100 mg BID oral use|
9988063|NCT01418742|Placebo Comparator|Placebo 100 mg BID oral use|
9988064|NCT01418755|Experimental|platelet rich plasma injection|Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
9988065|NCT01418768|Experimental|Rehabilitation|
9988066|NCT01418781||Gout|Patients with ICD-9 for gout
9988067|NCT01418781||No Gout|Patients withOUT ICD-9 for gout
9988068|NCT01418781||Tophaceous gout|Patients with ICD-9 for tophaceous gout
9988069|NCT01418781||non-tophaceous gout|those with ICD-9 for gout other than the codes specific for tophaceous gout
9988070|NCT01418794|Active Comparator|Low dose rapamycin group|Concentration of rapamycin was 1.5%
9988071|NCT01418794|Experimental|High dose rapamycin group|Concentration of rapamycin is 2.5%
9988072|NCT01418807|Experimental|TRANSVAGINAL EXTRACTION|
9988073|NCT01418807|Active Comparator|TRANSUMBILICAL EXTRACTION|
9988074|NCT01418820|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
9988075|NCT01418820|Sham Comparator|Placebo stimulation|compared to verum stimulation the same electrode montage set-up is used during placebo stimulation, except that placebo patients receive a minimal stimulation
9988076|NCT01418846||adult hematology patients|
9988077|NCT01418846||pediatric patients age 5-18years|
9988078|NCT01418846||adult pneumology patients|
9877331|NCT00418587|Experimental|1|800 IU oral daily dose level
9877332|NCT00418587|Experimental|2|2000 IU oral daily dose level
9877333|NCT00418587|Experimental|3|4000 IU oral daily dose level
9877334|NCT00418600|Other|1|Hectorol capsules at 1.0 times current injection dose
9877335|NCT00418600|Other|2|Hectorol capsules at 1.5 times current injection dose
9877336|NCT00418600|Other|3|Hectorol capsules at 2.0 times current injection dose
9877337|NCT00418613|Experimental|1|MK0633
9877338|NCT00418613|Placebo Comparator|2|Placebo
9877339|NCT00418626|Experimental|Nilotinib|
9877340|NCT00418652|No Intervention|No TMS stimulation|The patients performed 2 tasks: a study and a control assignments with no TMS stimulation.
9877341|NCT00418652|Experimental|TMS over the dorsal stream|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the dorsal stream area (PO3 EEG site).
9877342|NCT00418652|Sham Comparator|TMS over the vertex|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the vertex area.
9877343|NCT00418730|Experimental|1|
9877344|NCT00418730|Active Comparator|2|
9877345|NCT00418730|Placebo Comparator|3|
9877346|NCT00418756|Experimental|Rifampin + nilotinib|
9877347|NCT00418769|Experimental|Nilotinib Tablet Formulations|
9877348|NCT00418769|Active Comparator|Established Nilotinib Capsule Formulation|
9877349|NCT00418782|Active Comparator|1|
9877350|NCT00418782|Experimental|2|
9877351|NCT00418782|Placebo Comparator|3|
9877352|NCT00418847|Experimental|1|
9877353|NCT00418860|Experimental|A|
9877354|NCT00418873|Experimental|1. Zotepine|
9877355|NCT00418873|Active Comparator|2. Risperidone|
9877356|NCT00418899||GLIOGENE|International Multi-Center, Multidisciplinary Study Consortium
9877357|NCT00419029|Active Comparator|control|brief telephone check-in (no motivational interviewing)
9877358|NCT00419029|Experimental|telephone-administered motivational interviewing|motivational interviewing sessions
9877359|NCT00419055||1 Control|Patients are discharged the day after PCI
9877360|NCT00419055||2 Study group|Patients will be discharged 4-6 hrs after PCI
9877361|NCT00419133|Experimental|1|Cholera Vaccine
9877362|NCT00419133|Placebo Comparator|2|Placebo
9877363|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E + C (active)|
9877364|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E+C (placebo)|
9877365|NCT00419146|Experimental|Ethyl EPA (placebo) and Vitamins E+C (active)|
9877366|NCT00419146|Placebo Comparator|Ethyl EPA (placebo) and Vitamins E+C (placebo)|
9877367|NCT00419198|Experimental|1|Post-conditioning during angioplasty
9877368|NCT00419198|Active Comparator|2|standard angioplasty
9877369|NCT00419211|Experimental|Lifestyle counseling|Tailored exercise program
9877370|NCT00419211|No Intervention|No Intervention|Usual care group
9877371|NCT00419237|Active Comparator|Healthy subjects|Subjects with normal liver function test will be administered a single oral inhaled dose of 400 micrograms (mcg) GW685698X in the morning of the study day. Each healthy subject will be matched as closely as possible for age, gender, bodyweight and race to a subject with impaired liver function.
9877372|NCT00419237|Experimental|Subjects with hepatic impairment|Subjects with Child Pugh B hepatic dysfunction will be administered a single oral inhaled dose of 400 mcg GW685698X in the morning of the study day.
9877373|NCT00419250|Experimental|dose-escalation to 5 mg lenalidomide (len)|escalate up to 5 mg once daily / 28-day cycle
9877374|NCT00419250|Experimental|dose-escalation to 10 mg lenalidomide (len)|escalate up to 10 mg once daily / 28-day cycle
9877375|NCT00419250|Experimental|dose-escalation to 15 mg lenalidomide (len)|escalate up to 15 mg once daily / 28-day cycle
9877376|NCT00419250|Experimental|dose-escalation to 20 mg lenalidomide (len)|escalate up to 20 mg once daily / 28-day cycle
9877377|NCT00419250|Experimental|dose-escalation to 25 mg lenalidomide (len)|escalate up to 25 mg once daily / 28-day cycle
9877378|NCT00419276|Experimental|Prolonged infusion|At least 100 hours of femoral perineural ropivacaine infusion.
9877379|NCT00419276|Placebo Comparator|Standard-of-Care|Overnight femoral perineural ropivacaine infusion followed by a femoral perineural normal saline infusion (placebo) until postoperative day 4.
9877380|NCT00419328|Experimental|A|
9877381|NCT00419406|Experimental|A: UVA1|
9877382|NCT00419406|Experimental|B: NB UVB|
9877383|NCT00419432|Active Comparator|Group A (standard pre-operative analysis)|
9877384|NCT00419432|Experimental|Group B (additional pre-operative analysis)|
9877385|NCT00419471|Experimental|Escitalopram|
9877386|NCT00419471|Placebo Comparator|Placebo pill|
9877387|NCT00419497|Active Comparator|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
9877388|NCT00419549|Active Comparator|1|Valdecoxib
9877389|NCT00419549|Active Comparator|2|
9877390|NCT00419549|No Intervention|3|
9877391|NCT00419588||1-Healthy Infants|"Group 1: We have recruited 50 healthy infants born >37 weeks gestation, and between 2 and 36 months of age. Infants were excluded for any of the following reasons.~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications for more than one time~Small for gestational age at birth~More than one respiratory illness~More than one episode of wheezing"
9877392|NCT00419588||3-Premature Infants|"Group 3: We will recruit 115 infants born prematurely, 23-35 weeks gestation. Subjects will be evaluated at the corrected age between 2 and 24 months. The subjects will have no oxygen requirements, and be clinically stable outpatients when evaluated. Infants will be excluded for any of the following reasons.~Congenital cardio-respiratory disease~Severe developmental delay"
9877393|NCT00419588||2-Healthy Infants CT|"Group 2: The investigators recruited 50 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
9877394|NCT00419601|Active Comparator|2|Fentanyl
9877395|NCT00419601|Experimental|1|Remifentanyl
9877396|NCT00419640|Experimental|LAS + DAO ON|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.
9877397|NCT00419640|Experimental|LAS + DAO OFF|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.
9877398|NCT00419640|Experimental|RAA + DAO ON|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.
9877399|NCT00419640|Active Comparator|RAA + DAO OFF|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.
9877400|NCT00419653|Experimental|1|
9877401|NCT00419653|Active Comparator|2|
9877402|NCT00419653|Active Comparator|3|Haloperidol
9877403|NCT00419692|Experimental|Sequence WAXBYZCDE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).
9877404|NCT00419692|Experimental|Sequence WAXBYZCED|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
9877405|NCT00419692|Experimental|Sequence WAXBYZDCE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).
9877406|NCT00419692|Experimental|Sequence WAXBYZDEC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).
9877407|NCT00419692|Experimental|Sequence WAXBYZECD|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
9877408|NCT00419692|Experimental|Sequence WAXBYZEDC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).
9877409|NCT00419705|Experimental|Transcranial Laser Therapy|
9877410|NCT00419705|Sham Comparator|Sham control procedure|
9877411|NCT00419731|Active Comparator|1|Bupropion+Placebo
9877412|NCT00419731|Experimental|2|Bupropion+Naltrexone
9877413|NCT00419783|Experimental|1|Bilastine 20 mg
9877414|NCT00419783|Experimental|2|Bilastine 100 mg
9877415|NCT00419783|Active Comparator|3|Bilastine 20 mg + Ketoconazole 400 mg
9877416|NCT00419783|Active Comparator|4|Moxifloxacin 400 mg
9877417|NCT00419783|Placebo Comparator|5|Placebo
9877418|NCT00419822|Active Comparator|Acupuncture|
9877419|NCT00419822|Sham Comparator|Sham Acupuncture|
9877420|NCT00419822|Placebo Comparator|Standard of Care|
9877421|NCT00419848|Experimental|1|
9877422|NCT00419848|Active Comparator|2|
9877423|NCT00419861||Group 1|Adults >/= 50 years of age, hospitalized for respiratory illness in Davidson County, TN.
9877424|NCT00419913|Experimental|A|Dehydroepiandrosterone (DHEA) 25mg tid
9877425|NCT00419913|Placebo Comparator|B|
9877426|NCT00419939||1|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), >18 år, PTA phase at the end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing
9877427|NCT00419991|No Intervention|1 Tigecycline|
9877428|NCT00420030|Active Comparator|1|Arm 1 - routine upfront administration of Reopro (Abciximab)
9877429|NCT00420030|Other|2|Reopro (Abciximab) only if needed - according to physician
9877430|NCT00420043|Experimental|imatinib 800mg|
9877431|NCT00420043|Active Comparator|imatinib 400mg|
9877432|NCT00420082|Experimental|1|Bilastine 20 mg
9877433|NCT00420082|Active Comparator|2|Fexofenadine 120 mg
9877434|NCT00420082|Active Comparator|3|Cetirizine 10 mg
9877435|NCT00420082|Placebo Comparator|4|Placebo
9877436|NCT00420160|Experimental|Exercise|3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos
9877437|NCT00420160|Other|Health Education|Contact control group attending 3x/wk 50 minutes of health education videos
9877438|NCT00420173||Patients with CLE|
9877439|NCT00420186|Experimental|1|
9877440|NCT00420277|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
9877441|NCT00420277|Active Comparator|Control|Voluven (HES 130/0.4)
9877442|NCT00420355|Experimental|Arm A|Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.
9877443|NCT00420355|Experimental|Arm B|Subjects on lopinavir/ritonavir will add atazanavir.
9930136|NCT00925184||medical students, graduate year,|medical students at graduate year will be invited to participate in this study.
9930137|NCT00925210|Experimental|Sequential pEBUS - ENB|
9930138|NCT00925223||irritable bowel syndrome|patients with diarrhea-predominant IBS will be enrolled in this group.
9930139|NCT00925223||control group|patients with colon cancer or colon polyp will be enrolled as control group.
9930140|NCT00925249||1|The study group will consist of RA patients of the Walter Reed Army Medical Center (WRAMC) rheumatology clinic being considered for treatment with anti-TNF alpha therapy. We will enter patients into the study over a projected course of 12-24 months or until we reach the statistical requirement of 60 subjects.
9930141|NCT00925249||2|The control group will consist of healthy subjects without known immune-dysregulation or history of treatment with biologic agents who present to the WRAMC Allergy- Immunology clinic for routine screening TST as a part of current WRAMC policy.
9930142|NCT00925262|Experimental|Cognitive Processing Therapy|An adaptation of cognitive behavioral therapy, focusing on treatment for persons suffering mental health effects of trauma
9930143|NCT00925262|Experimental|Behavioral Activation|A form of counseling therapy that emphasizes enhancing pleasurable behaviors and minimizing negative behaviors as a means to reducing depression symptomatology.
9930144|NCT00925262|Experimental|non-specific counseling|a collection of counseling skills suitable for a broad range of mental health and psychosocial problems and not designed for specific disorders. This particular version was developed by a collaborator -Heartland Alliance - for use with torture survivors.
9930145|NCT00925262|No Intervention|wait control|persons in this study arm will not receive active treatment as part of the study but will be monitored during the study and offered treatment after 3-5 months of waiting.
9930146|NCT00925275|Experimental|Dosimetric|
9930147|NCT00925314|Experimental|Transgenic Lymphocyte Immunization|Open Label, Single Arm
9930148|NCT00925327|Experimental|Corneal collagen cross-linking with riboflavin and UVA light|
9930149|NCT00925340|Experimental|1 - Family Check Up|Brief family intervention that employs Motivational Interviewing.
9930150|NCT00925340|Active Comparator|2 - Psychoeducation|
9930151|NCT00925366|Other|Shoulder rotator cuff tear|Shoulder rotator cuff tear
9930152|NCT00925392|Experimental|Doripenem 500 mg|
9930153|NCT00925392|Experimental|Doripenem 1000 mg|
9930154|NCT00925405||Breast MRI Screening|
9930155|NCT00925418|No Intervention|Without Glove|Patients do not use frozen glove during chemotherapy with Taxotere®
9930156|NCT00925418|Experimental|With Glove|Patients use frozen glove during chemotherapy with Taxotere®
9930157|NCT00925431|Experimental|Lifestyle Modification|Behavioral: cognitive-motivational enhancement to lifestyle management plus nutritional education.
9930158|NCT00925431|Active Comparator|Supportive education|General fibromyalgia education plus nutritional education.
9930159|NCT00925444|Experimental|FOREseal|
9930160|NCT00925444|Active Comparator|Stapling|
9930161|NCT00925457||001|Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
9930162|NCT00925457||002|Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
9930163|NCT00925457||003|No Intervention Neither current domperidone nor current PPI
9930164|NCT00925470||1|
9930165|NCT00925483|Experimental|daily long|daily long (4 hours, 6 times weekly) dialysis for 6 months
9877444|NCT00420433||1|Patients with breast cancer that has spread to the bones.
9877445|NCT00420485|Experimental|Daily times five schedule|
9877446|NCT00420485|Experimental|Continuous schedule, twice daily|
9877447|NCT00420524|Experimental|Arm A (Normal liver function)|
9877448|NCT00420524|Experimental|Arm B (Mild liver dysfunction)|
9877449|NCT00420524|Experimental|Arm C (Moderate liver dysfunction)|
9877450|NCT00420537|Active Comparator|mycophenolate|Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
9877451|NCT00420537|Active Comparator|Everolimus|Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
9877452|NCT00420563|Experimental|CYCLOPHOSPHAMIDE|
9877453|NCT00420563|Active Comparator|MEGESTROL|
9877454|NCT00420576|Experimental|1|Low Dose Danggui Buxue Tang (1.5g)
9877455|NCT00420576|Experimental|2|Middle Dose Danggui Buxue Tang(3g)
9877456|NCT00420576|Experimental|3|High Dose Danggui Buxue Tang (6g)
9877457|NCT00420589|Placebo Comparator|1|Arm 1: MK0364 Pbo capsules once daily
9877458|NCT00420589|Experimental|2|Arm 2: MK0364 0.5 mg capsule once daily
9877459|NCT00420589|Experimental|3|Arm 3: MK0364 1 mg capsule once daily
9877460|NCT00420589|Experimental|4|Arm 4: MK0364 2 mg capsule once daily
9877461|NCT00420602|Other|Single Arm, Open Label|Single Arm, Open Label
9877462|NCT00420615|Experimental|Patupilone and Omeprazole|patupiloe + omeprazole
9877463|NCT00420615|Experimental|patupilone + midalzolam|patupilone + midalzolam
9877464|NCT00420654|Active Comparator|A1|
9877465|NCT00420654|Placebo Comparator|A2|
9877466|NCT00420654|Other|A3|
9877467|NCT00420680|Experimental|Arm 1|Sugammadex 2.0 mg/kg
9877468|NCT00420680|Experimental|Arm 2|Sugammadex 4.0 mg/kg
9877469|NCT00420680|Placebo Comparator|Arm 3|Placebo
9877470|NCT00420758|No Intervention|Control|
9877471|NCT00420758|Experimental|LNS|Lipid-based nutrient supplement
9877472|NCT00420758|Experimental|CSB|Corn-soy blend supplement
9877473|NCT00420823|Placebo Comparator|Placebo pill|4 placebo pills daily for 3 months
9877474|NCT00420823|Experimental|Taurine 4g|Taurine 4g daily comprising four 1g pills
9877475|NCT00420940|Experimental|90 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
9877476|NCT00420940|Experimental|30 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
9877477|NCT00420940|No Intervention|control|control group (receiving no vibration)
9877478|NCT00421005|Experimental|1|Fluvastatin 80mg
9877479|NCT00421005|Active Comparator|2|Fluvastatin 20, tapered up according to LDL concentration
9877480|NCT00421018|Sham Comparator|Symptom-guided group|Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
9877481|NCT00421018|Active Comparator|FeNO-guided group|Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
9877482|NCT00421044|Experimental|Arm A (Normal liver function)|
9877483|NCT00421044|Experimental|Arm B (Mild liver dysfunction)|
9877484|NCT00421044|Experimental|Arm C (Moderate liver dysfunction)|
9877485|NCT00421057||Exercise Group|Taught to perform a specific regimen for strength-training and walking exercises.
9877486|NCT00421057||Nonexercise Group|Follow usual routines of standard care but not taught to perform a specific regimen for strength-training and walking exercises; will keep record of any exercises done that are not a part of this study.
9877487|NCT00421070|No Intervention|Treatment as usual|Observational component
9877488|NCT00421070|Active Comparator|Intervention|Massage therapy adjunct comparator
9877489|NCT00421096|Experimental|patient with cervix cancer|will receive gemcitabine + cisplatin + radiotherapy
9877490|NCT00421109|Experimental|1|Bilastine 20 mg
9877491|NCT00421109|Active Comparator|2|Levocetirizine 5 mg
9877492|NCT00421109|Placebo Comparator|3|Placebo
9877493|NCT00421122|Active Comparator|1|Bricasol®
9877494|NCT00421122|Experimental|2|Bricasol® + Pulmicort®
9877495|NCT00421122|Experimental|3|Bricasol® + Symbicort®
9877496|NCT00421135|Experimental|Single Arm|ZIO-201
9877497|NCT00421187|Experimental|1|AmBisome® will be given on day 0 (10 mg/kg), day 2 (5 mg/kg), and day 5 (5 mg/kg)
9877498|NCT00421187|Active Comparator|2|AmBisome as a constant daily dose of 3 mg/kg for a maximum of 14 days or until the resolution of fever and neutropenia
9877499|NCT00421200|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
9877500|NCT00421200|Active Comparator|Control|Voluven (HES 130/0.4)
9877501|NCT00421213|Experimental|Single Arm|
9877502|NCT00421239||A|
9877503|NCT00421239||B|
9877504|NCT00421252|Active Comparator|Clopidogrel 600 mg pre-treatment|Patients will receive 600 mg Clopidogrel load >2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
9877505|NCT00421252|Active Comparator|No clopidogrel 600 mg pretreatment|Patients will receive 600 mg Clopidogrel load after PCI, if performed
9877506|NCT00421252|Active Comparator|5Fr arterial access sheath|Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
9877507|NCT00421252|Active Comparator|6Fr arterial access sheath|Patients will have angiography performed using 6Fr sheath
9877508|NCT00421278|Experimental|1|Arm 1: Drug
9877509|NCT00421330|Active Comparator|OR|Open Aneurysm Repair
9877510|NCT00421330|Experimental|EVAR|Endovascular Aneurysm Repair
9877511|NCT00421356||Transfemoral Power Knee group|Transfemoral amputees who used the power assisted Ossur Power Knee who used the knee daily without adjustments for at least 90 days prior to the study.
9877512|NCT00421356||Transfemoral C-Leg knee group|Transfemoral amputees who used the stance control Otto Bock C-Leg who used the knee daily without adjustments for at least 90 days prior to the study.
9877513|NCT00421356||Transfemoral Mauch knee group|Transfemoral amputees who used the mechanical fluid controlled Mauch Swing and Stance Knee who used the knee daily without adjustments for at least 90 days prior to the study.
9877514|NCT00421356||Non amputee control group|Healthy, non-amputee control group
9877515|NCT00421395|Experimental|multi|escalating in increments of 2.5 mCi/m2
9877516|NCT00421434|Experimental|Nitazoxanide-Peginterferon|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.
9877517|NCT00421434|Experimental|Nitazoxanide-Peginterferon-Ribavirin|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.
9877518|NCT00421434|Active Comparator|Peginterferon-Ribavirin|Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
9877519|NCT00421447||Breast Cancer patients|A group of women with breast cancer prescribed Anastrozole
9877520|NCT00421447||Healthy women wit no breast Cancer|A group of healthy women wit no breast cancer prescribed Anastrozole
9877521|NCT00421538|Active Comparator|LMWH|Therapeutic dose of Nadroparin
9877522|NCT00421538|Placebo Comparator|Placebo|Injectable placebo
9877523|NCT00421551|Experimental|1|
9877524|NCT00421551|Active Comparator|2|
9877525|NCT00421655|Experimental|1|
9877526|NCT00421655|Placebo Comparator|2|
9877527|NCT00421668|Experimental|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate, and B12
9877528|NCT00421668|Experimental|Multivitamins + Zinc|Vitamins C, E, B1, B2, niacin, B6, folate and B12, and zinc
9877529|NCT00421668|Experimental|Zinc|zinc
9877530|NCT00421668|Placebo Comparator|Placebo|placebo
9877531|NCT00421681|Experimental|A|"Treatment Arm A will develop tailored/negotiated contracts with the exercise instructor to maintain post intervention exercise adherence at home or in the community. Half of the participants in this negotiated maintenance arm will be randomly assigned to receive telephone calls to reinforce adherence and half will be assigned to a no telephone calls group."
9877532|NCT00421681|Experimental|B|"Treatment Arm B will be mainstreamed into an ongoing facility-based exercise program for post intervention exercise adherence. Persons in this mainstream follow up arm will be randomly assigned such that half will receive regular telephone reinforcement follow up and half will not."
9877533|NCT00421759|Experimental|1|85 elderly individuals with somatosensory deficits
9877534|NCT00421759|Experimental|2|85 elderly individuals with recurrent falls
9877535|NCT00421824|Experimental|A|
9877536|NCT00421824|Experimental|B|
9877537|NCT00421837||controls|household and other close contacts
9877538|NCT00421837||cases|elderly (>55) subjects hospitalized with Influenza
9877539|NCT00421863|Other|Intensive Strategy|
9877540|NCT00421863|Other|Usual Strategy|
9877541|NCT00421902|Experimental|Acupuncture|Acupuncture of the patients
9877542|NCT00421967|Experimental|1|
9877543|NCT00421967|Active Comparator|2|
9877544|NCT00422006|Experimental|1|Non diabetic non dyslipidemic patient
9877545|NCT00422006|Experimental|2|Patient with metabolic syndrome
9877546|NCT00422006|Experimental|3|Patients with type II diabetes
9877547|NCT00422006|Experimental|4|Patient with a single lipidic anomaly
9877548|NCT00422045|No Intervention|2|No Laser done. All outcome measures are the same.
9877549|NCT00422045|Experimental|1|Low Level Laser Therapy
9930166|NCT00925483|Experimental|daily short|daily short (2 hours 6 times weekly) dialysis for 6 months
9930167|NCT00925483|Experimental|alternate day conventional|alternate day conventional (4 hours, 3 times weekly) dialysis for 6 months
9930168|NCT00925483|Experimental|alternate day long|alternate day long (8 hours, 3 times weekly) dialysis for 6 months
9930169|NCT00925496||Standard PROMOS prosthesis|Patients receiving a standard PROMOS prosthesis
9877550|NCT00422149|Active Comparator|1|SUBLIVAC® Grasses treatment
9877551|NCT00422149|Placebo Comparator|2|Placebo treatment
9877552|NCT00422188|Experimental|Deoxycholic Acid Injection 0.5%|Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
9877553|NCT00422188|Experimental|Deoxycholic Acid Injection 1.0%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
9877554|NCT00422188|Experimental|Deoxycholic Acid Injection 2.0%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
9877555|NCT00422188|Experimental|Deoxycholic Acid Injection 4.0%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
9877556|NCT00422188|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
9877557|NCT00422305||1-Healthy Infants|"Group 1: The investigators will recruit 80 healthy infants born at > 37 weeks gestation, and between 2 and 36 months of age. Infants will be excluded for any of the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications~Small for gestational age at birth"
9877558|NCT00422305||2-Healthy Infants computerized Tomography|"Group 2: The investigators recruited 4 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
9877559|NCT00422305||3-Premature Infants|"Group 3: The investigators have recruited 45 infants born prematurely at 23-35 weeks gestation. Subjects were evaluated at corrected age at between 2 and 24 months. The subjects had no oxygen requirements, and were clinically stable outpatients when evaluated. Infants were excluded for any of the following reasons:~Congenital cardio-respiratory disease~Severe developmental delay"
9877560|NCT00422344|Experimental|RAD001 AND SUNITINIB|RAD001 AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA PATIENTS
9877561|NCT00422435|Experimental|Drug eluting stent|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
9877562|NCT00422487|Experimental|MBX-2044 1.5 mg|
9877563|NCT00422487|Experimental|MBX-2044 4.5 mg|
9877564|NCT00422487|Experimental|MBX-2044 15 mg|
9877565|NCT00422487|Experimental|MBX-2044 30 mg|
9877566|NCT00422487|Experimental|MBX-2044 60 mg|
9877567|NCT00422487|Experimental|MBX-2044 90 mg|
9877568|NCT00422487|Placebo Comparator|Placebo|
9877569|NCT00422500||Chemotherapy Symptoms|Study participants with advanced-stage lung cancer.
9877570|NCT00422565|Experimental|Endeavor|Zotarolimus-eluting stent
9877571|NCT00422565|Active Comparator|Cypher|Sirolimus-eluting stent
9877572|NCT00422565|Active Comparator|Taxus|Paclitaxel-eluting stent
9877573|NCT00422630|Active Comparator|Average American Diet|
9877574|NCT00422630|Active Comparator|The DASH diet|
9877575|NCT00422630|Active Comparator|The Low Glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
9877576|NCT00422682|Experimental|1|BSI-201 + topotecan
9877577|NCT00422682|Experimental|2|BSI-201 + temozolomide
9877578|NCT00422682|Experimental|3|bsi-201 + gemcitabine
9877579|NCT00422682|Experimental|4|bsi-201 + carboplatin/paclitaxel
9877580|NCT00422747|Experimental|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
9877581|NCT00422773|Experimental|Cetuximab+ FOLFOXIRI|Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid
9877582|NCT00422786|Experimental|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
9877583|NCT00422825|Experimental|Imatinib 800mg|
9877584|NCT00422825|Active Comparator|Imatinib 400mg|
9877585|NCT00422838||1|Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
9877586|NCT00422838||2|Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
9877587|NCT00422851||1|Normal tympanic membrane
9877588|NCT00422851||2|tympanosclerosis
9877589|NCT00422851||3|dimeric (atrophic)
9877590|NCT00422877|Experimental|Taxoprexin|Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.
9877591|NCT00422916|Experimental|intervention arm|Lifestyle Intervention based on Nutrition Treatment, exercise Treatment and behavorial treatment
9877592|NCT00422916|No Intervention|waiting list|waiting 6 months for Intervention without any intervention
9930170|NCT00925496||Reverse PROMOS prosthesis|Patients receiving a reverse PROMOS prosthesis
9930171|NCT00925561||No treatment|
9877593|NCT00422929||chronic otitis media with effusion (OME)|history of chronic effusion (3 months if both ears, 6 months if one ear, or 3 episodes of effusion each lasting for 2 months or longer)
9877594|NCT00422929||recurrent AOM|recurrent acute otitis media (3 episodes in 6 months or 4 episodes in 1 year)
9877595|NCT00422929||no OM|no history of significant otitis media (i.e., does not meet criteria for chronic OME or recurrent AOM)
9877596|NCT00422955|Experimental|Arm 1|
9877597|NCT00422968|Active Comparator|coronary artery bypass graft|coronary artery bypass graft
9877598|NCT00422968|Experimental|percutaneous coronary intervention|Using silorimus eluting stent
9877599|NCT00423007|Experimental|Bromfenac|Ophthalmic Solution
9998315|NCT01517022|Active Comparator|Intervention arm|Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
9877600|NCT00423007|Placebo Comparator|Placebo|Vehicle ophthalmic solution
9877601|NCT00423072||1|children with cleft palate birth-24 months of age
9877602|NCT00423124|Experimental|A|
9877603|NCT00423215||Patients with Type II diabetes|
9877604|NCT00423228|Experimental|ZT-1|ZT-1 (investigational product)
9877605|NCT00423228|Active Comparator|Donepezil|Donepezil
9877606|NCT00423241|Experimental|SEMPERFLO Pain Management System|
9877607|NCT00423241|Active Comparator|ON-Q PainBuster Post-Op Pain Relief System|
9877608|NCT00423254|Experimental|Low Dose Cohort|
9877609|NCT00423254|Experimental|High Dose Cohort|
9877610|NCT00423280|Active Comparator|1|700mg/day 6R-BH4
9877611|NCT00423280|Active Comparator|2|400mg/day 6R-BH4
9877612|NCT00423280|Placebo Comparator|3|Placebo
9877613|NCT00423306|Experimental|Single Arm|
9877614|NCT00423371|Experimental|EUFLEXXA™|
9877615|NCT00423371|Placebo Comparator|Placebo|
9877616|NCT00423384|Experimental|1|Ibandronate
9877617|NCT00423384|Placebo Comparator|2|
9877618|NCT00423410|Experimental|EPC2407 (crinobulin)|
9877619|NCT00423475|Active Comparator|I|Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
9877620|NCT00423475|Experimental|II|Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
9877621|NCT00423501|Experimental|1|
9877622|NCT00423501|Experimental|2|
9877623|NCT00423501|Experimental|3|
9877624|NCT00423501|Experimental|4|
9877625|NCT00423501|Experimental|5|
9877626|NCT00423501|Placebo Comparator|6|
9877627|NCT00423514|Experimental|cytoreduction regimen & stem cell transplant|This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).
9877628|NCT00423618|Active Comparator|Control arm|Radiotherapy Conventional treatment arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The first 50 Gy in 25 fractions will be given to CTV1 and subsequent 16 Gy in 8 fractions will be delivered to CTV2.
9877629|NCT00423618|Experimental|Research arm|Radiotherapy Research arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The 66Gy in 33 fractions will be delivered to CTV2 alone. No attempt will be made to include drain/biopsy sites or the surgical scar.
9877630|NCT00423631|Experimental|Standard Care and Web|Standard care plus a web site based on cognitive behavioral principals.
9877631|NCT00423631|Active Comparator|Standard Care|Subject recieve standard care from their primary care provider.
9877632|NCT00423644|Experimental|Single Arm|
9877633|NCT00423696|Experimental|bevacizumab + FOLFIRI|
9877634|NCT00423696|Experimental|bevacizumab + XELIRI|
9877635|NCT00423787|Experimental|Ragweed MATA MPL|modified Ragweed pollen allergen absorbed to Tyrosine and containing MPL adjuvant
9877636|NCT00423787|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
9877637|NCT00423865|Experimental|cisplatin & RAD001|This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid tumors
9877638|NCT00423956|Sham Comparator|Sham Comparator|One side is experimental and the opposite side is Sham control.
9877639|NCT00423982|Active Comparator|Rifampicin-combination therapy|Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
9877640|NCT00423982|Active Comparator|Monotherapy|Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
9877641|NCT00424125|Experimental|Enhanced Pharmacy Care|Received enhanced community pharmacy based services.
9877642|NCT00424138|Experimental|Group A - 3 FDG-PET/CT Scans|Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
9877643|NCT00424138|Experimental|Group B - 2 FDG-PET/CT + 1 Optional|One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
9877644|NCT00424138|Experimental|Group C - Test-Retest|Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.
9877645|NCT00424164|Experimental|Tamoxifen-lapatinib|Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
9877646|NCT00424164|Experimental|Lapatinib-tamoxifen|Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
9877647|NCT00424203|Experimental|Myocet, Endoxan|
9930172|NCT00925613|No Intervention|Control|The double lumen tube is kept until extubation; there is no exchange with any tracheal tube or LMA.
9930173|NCT00925613|Active Comparator|Proseal|The double lumen tube is exchanged with a Proseal (LMA) before emergence according to the study protocol.
9930174|NCT00925613|Active Comparator|Tracheal tube|The double lumen tube is exchanged with a tracheal tube before emergence according to the study protocol.
9930175|NCT00925626|Experimental|Sub - Vastus arthrotomy|Sub-vastus arthrotomy
9930176|NCT00925626|Active Comparator|Mid-Vastus arthrotomy|Mid-vastus arthrotomy
9930177|NCT00925639|Experimental|Isoflavone|Patients will receive daily doses of 150 mg of concentrated extract of soy per os
9930178|NCT00925639|Placebo Comparator|Control|Patients will receive daily placebo pills
9930179|NCT00925665||Glidescope|Patients intubated with the Glidescope technique
9930180|NCT00925665||Macintosh|Patients intubated via the conventional direct laryngoscopy with a Macintosh laryngoscope
9930181|NCT00925691|Active Comparator|APICAL|implantation at the apex
9930182|NCT00925691|Experimental|SEPTAL|implantation at the interventricular septum
9930183|NCT00925717||2500 patients|Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.
9930184|NCT00925730|Experimental|Pimecrolimus cream 1%|Pimecrolimus
9930185|NCT00925743|Experimental|1|"5, 15, 20 or 25 mg/m2~one injection of cabazitaxel on day 1 of each cycle (3 weeks)"
9930186|NCT00925795|Active Comparator|Group A (1. EVOO; 2. ROO)|
9930187|NCT00925795|Active Comparator|Group B (1. ROO; 2. EVOO)|
9930188|NCT00925808||Unsuspected VTE|Prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis
9930189|NCT00925821|Experimental|Allogeneic stem cell transplant|Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine
9930190|NCT00925821|Active Comparator|High-dose melphalan chemotherapy|Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells
9930191|NCT00925834|Placebo Comparator|Sodium chloride|"Control arm A: Hidden intracoronary infusion of 5ml sodium chloride"
9930192|NCT00925834|Experimental|Sodium chloride and verbal suggestions|"Experimental arm A: Open intracoronary infusion of 5ml sodium chloride plus the suggestion of a vasodilatory effect on coronary vessels"
9930193|NCT00925834|Active Comparator|Nitroglycerin|"Control arm B: Hidden intracoronary infusion of 0.01mg nitroglycerin in 5 ml sodium chloride"
9930194|NCT00925834|Experimental|Nitroglycerin and verbal suggestions|"Control arm B: Open intracoronary infusion of 0.01 mg nitroglycerin in 5 ml sodium chloride plus the suggestion of a vasodilatory effect on cardiac vessels"
9930195|NCT00925847|Experimental|1|
9930196|NCT00925860|Experimental|non invasive ventilation approach|pure hypoxemic patients admitted to ICU treated by non-positive pressure mechanical ventilation
9930197|NCT00925860|No Intervention|conventionally ventilated|pure hypoxemic patients treated by conventional ventilatory support
9930198|NCT00925873|Active Comparator|1|"Control arm without fludarabine~Induction course: Ara-C 100mg/m2 days 1-7, idarubicin 8mg/m2 days 1-5, GM-CSF (molgramostim, Novartis) 5 microg/kg days 1 to neutrophil recovery;~Consolidation course: Ara-C 1g/m2 q12h days 1-3, idarubicin 10mg/m2 days 2-3;~and 3 quarterly reinduction courses during maintenance including Ara-C 80mg/m2 days 1-5, CCNU 40mg and mitoguazone 350mg/m2 day 1, ± fludarabine days 1-2."
9930199|NCT00925873|Experimental|2|"Fludarabine arm~The same regimen with fludarabine 20 mg/m2/day IV for 30 minutes~induction course + fludarabine days 2-7;~consolidation course + fludarabine days 4-5;~during reinduction courses + fludarabine days 1-2."
9930200|NCT00925886|Experimental|Acrysof Toric intraocular lens|A One piece, acrylic intraocular lens is implanted in the lens bag.
9877648|NCT00424242|Experimental|Escalating doses of Pemetrexed|Escalating doses of Pemetrexed beginning at 500 mg/m2
9877649|NCT00424450||PAD patients|30 PAD patients
9877650|NCT00424606|Experimental|1|
9877651|NCT00424606|Experimental|2|
9877652|NCT00424710|Other|Single Arm study|"Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year"
9877653|NCT00424801|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure
9877654|NCT00424814|Experimental|1|Kaletra (lopinavir/ritonavir)
9877655|NCT00424814|Active Comparator|2|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
9877656|NCT00424853|Experimental|A|
9877657|NCT00424853|Experimental|B|
9877658|NCT00424866|Placebo Comparator|Placebo|The dosing groups correspond to total doses of 0 µg/kg of FGF-1.
9877659|NCT00424866|Active Comparator|Human FGF-1|The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.
9877660|NCT00424905|Experimental|1|Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
9877661|NCT00424905|No Intervention|2|No treatment (reference group)
9877662|NCT00424931|Experimental|001|JNJ-17216498 10mg one time
9877663|NCT00424931|Experimental|002|JNJ-17216498 50mg one time
9877664|NCT00424931|Active Comparator|003|Modafinil 200 mg X 2
9877665|NCT00424944|Experimental|I, GMZ2 vaccine arm|20 volunteers will receive GMZ2 vaccine on days 0, 28, and 56
9877666|NCT00424944|Active Comparator|II, Rabies vaccine arm|20 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
9877667|NCT00424970|Placebo Comparator|acetazolamide|acetazolamide 250mg /day oral administration, for 6 months
9877668|NCT00424983|Experimental|Zometa q 4 weeks|
9877669|NCT00424983|Active Comparator|Zometa q 12 weeks|
9877670|NCT00425074|Experimental|SR-ASA|slow release acetylsalicylic acid 150 mg
9877671|NCT00425074|Active Comparator|ASA|normal release acetylsalicylic acid
9877672|NCT00425191|Experimental|1|
9877673|NCT00425191|Experimental|2|
9877674|NCT00425191|Experimental|3|
9877675|NCT00425204|Experimental|Open Label|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
9877676|NCT00425295|Active Comparator|1|
9877677|NCT00425295|Experimental|2|
9877678|NCT00425334|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
9877679|NCT00425334|Active Comparator|Control|Ringer's lactate
9877680|NCT00425451|Experimental|PerioChip Plus|
9877681|NCT00425451|Experimental|Flurbiprofen Chip|
9877682|NCT00425451|Active Comparator|PerioChip|
9877683|NCT00425451|Placebo Comparator|Placebo Chip|
9877684|NCT00425516|No Intervention|standard (A)|3 FEC100 followed 3 Taxotere
9877685|NCT00425516|Experimental|Modulated (B)|possibility treatments receive: 2 FEC100 followed by 4 Taxotere 4 FEC100 followed by 2 Taxotere 6 FEC 100
9877686|NCT00425542|Experimental|Outpatient treatment|
9877687|NCT00425542|No Intervention|Inpatient care|
9877688|NCT00425620|Experimental|Amphotericin B|
9877689|NCT00425659|Active Comparator|3|
9877690|NCT00425659|Experimental|1|
9877691|NCT00425659|Other|2|usual practice
9988079|NCT01418859||radiation therapy only|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
9988080|NCT01418859||concurrent chemoradiotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy. radiation therapy regimen is the same with radiation therapy only group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy.
9988081|NCT01418859||concurrent and additional chemotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy, and additional chemotherapy after concurrent treatment. radiation therapy regimen is the same with radiation therapy group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy. Additional chemotherapy regimen is the same with concurrent chemotherapy, and will be carry out in the 4th and 8th week after radiation therapy.
9988082|NCT01418872|Active Comparator|Healthy Breakfast|"The activity will be performed at the school dining hall, scheduling 1 hour for breakfast,within the school hours, with maximum 50 children per turn It involves placing a table mat, a cup, a plate and two slices of bread per child, plus 1-liter bottle of milk for each four children and 1-liter bottle of oil for each twelve. The dining hall will be all set up before the students come in.~Participatory lesson : Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, The role of dairy products at breakfast,The role of fruits at breakfast, Importance of exercise for cardiovascular health, The role of unhealthy habits: sedentary lifestyle.~The students will be invited to take the table mat and the cup, in which is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity.~A pamphlet of the NAOS strategy will also be delivered."
9988083|NCT01418872|Experimental|Didactic concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
9988084|NCT01418885||SIVD,VaD|vascular disease in patients with SIVD
9988085|NCT01418885||SIVD,VCIND|vascular cognitive impairment no dementia in patients with SIVD
9988086|NCT01418885||normal controls|normal elderly controls
9988087|NCT01418898|Experimental|Nutrient Fortified Beverage|
9988088|NCT01418898|Placebo Comparator|Control|
9988089|NCT01418911||diabetes type 2|type 2 diabetes patients 40-70 years of age hebrew speaking members of maccabi healthcare services
9988090|NCT01418950|Active Comparator|Control group|The control group will receive standard verbal counseling regarding outcome of premature infants
9988091|NCT01418950|Experimental|Study Group|Study Group will receive gestational age specific written information prior to receiving standard verbal counseling about outcome of premature infants.
9988092|NCT01418963|Experimental|Active|
9988093|NCT01418963|Placebo Comparator|Placebo|
9988094|NCT01418976|Experimental|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
9988095|NCT01418989|Experimental|1|
9988096|NCT01418989|Experimental|2|
9988097|NCT01419002|Experimental|Neoadjuvant RTx|
9988098|NCT01419002|Active Comparator|Surgery|
9988099|NCT01419041|Other|Arm A|CLCR: Creatinine clearance
9988100|NCT01419041|Other|Arm B|CLCR: Creatinine clearance
9988101|NCT01419093|No Intervention|5A Communication|Behavioral: 5 A intervention for physical activity
9988102|NCT01419106|No Intervention|Control|This arm of the study will NOT receive point of care ultrasound. They will receive all other standard care implemented during their visit to the ED (currently, ultrasound is NOT standard of care). The same blood tests will be done in both groups, as this will offer a means of comparing physiological changes between the two arms.
9988103|NCT01419106|Experimental|Ultrasound|This group WILL receive point of care ultrasound. The protocol they will receive is the ACES protocol (described above).
9988104|NCT01419119|Experimental|Group 1|Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
9988105|NCT01419119|Experimental|Group 2a|Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
9988106|NCT01419119|Experimental|Group 2b|Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
9988107|NCT01419119|Experimental|Group 3|Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L
9988108|NCT01419132|Placebo Comparator|High doses furosemide|administration of furosemide alone
9988109|NCT01419132|Experimental|HSS plus furosemide|administration of hypertonic saline solution plus high doses of furosemide bid
9988110|NCT01419145|Experimental|Multimodal intervention|
9988111|NCT01419145|Active Comparator|Standard Care|
9988112|NCT01419210|Experimental|Complementary and Alternative Medicine (CAM) therapies|This pilot program attends to the need for appropriate patient-centered interventions that integrate CAM with traditional care to maximize both quantity and QOL for women with ovarian cancer.
9988113|NCT01419223||Consent to participate (Group 1)|Active military and veterans who consent to participate in an INTRuST PTSD or TBI research trial.
9988114|NCT01419223||Decline to participate (Group 2)|Active military and veterans who decline to participate in an INTRuST PTSD or TBI research trial.
9988115|NCT01419262|Experimental|2000 IU per day vitamin D|
9988116|NCT01419262|Active Comparator|400 IU per day vitamin D|
9988117|NCT01419288|Active Comparator|No Body weight support|
9988118|NCT01419288|Experimental|Body weight support|
9988119|NCT01419327||Group 1|Drug (incl. Placebo)
9930201|NCT00925912|Active Comparator|1|"spinal anesthesia: Active Comparator~The SA group were received a subarachnoid block with 1.5-2.0 ml of 0.5% bupivacaine."
9930202|NCT00925912|Experimental|2|Perianal block with 0.25% bupivacaine
9930203|NCT00925925||Normal Birth Weight (NBW)|Term, healthy infants born at normal birth weights
9930204|NCT00925925||Low Birth Weight (LBW)|Infants born at > or equal to 34 0/7 weeks with a birth weight at < or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
9930205|NCT00925951|Experimental|Wet Cupping|
9930206|NCT00925951|No Intervention|Waiting Control|They can't use any other specific treatment except exercises and behavior modification (we'll offer a brochure which includes exercise method and directions about behavior modifications).
9930207|NCT00925964||Patients exposed|Patients with Systolic Pressure Index <0,9 ou >1,4.
9930208|NCT00925964||Patients not exposed|Patients with Systolic Pressure Index >0,9 ou <1,4.
9930209|NCT00925977|Active Comparator|insulin Glargine + insulin Apidra|insulin Glargine + insulin Apidra
9930210|NCT00925977|Active Comparator|Insulin NPH + Insulin Apidra|12 weeks treatment with Insulin NPH + Insulin Apidra
9930211|NCT00926016|Active Comparator|pioglitazone|Treatment with pioglitazone 45 mg a day for 3 months
9930212|NCT00926016|No Intervention|No intervention|Monitoring period without pioglitazone for 3 months
9930213|NCT00926042||Healthy Control|Healthy control group for research on autoimmune diseases
9930214|NCT00926055|No Intervention|Control|
9930215|NCT00926055|Active Comparator|Ezetimibe|
9930216|NCT00926055|Experimental|Ezetimibe/Simvastatin|
9930217|NCT00926068|Experimental|HO/03/03 10µg|
9930218|NCT00926068|Placebo Comparator|Placebo|
9930219|NCT00926081|No Intervention|Best medical treatment|Patients with peripheral artery disease receiving best medical treatment only
9930220|NCT00926081|Active Comparator|Supervised exercise training|Patients with peripheral artery disease receiving best medical treatment plus supervised exercise training
9930221|NCT00926094||1|
9930222|NCT00926094||2|
9930223|NCT00926120|Experimental|Mogroside sweetener|All subjects will received Mogroside. Mogroside sweetener administered at a dosage level of 5 g every 6 hours for 14 days.
9930224|NCT00926133||STEMI patients|Patients with acute STEMI treated by PCI without previously known type 2 diabetes.
9930225|NCT00926146|Experimental|NCMIT|Nurse Case Management Plus Contingency Management and Tracking and the HBV vaccine
9930226|NCT00926146|Active Comparator|SCMIT|Standard with Contingency Management and Tracking (SCMT) and HBV vaccine
9930227|NCT00926159||ICD eligible|Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.
9930228|NCT00926250|Experimental|PS-IPC supplementation|
9930229|NCT00926250|Placebo Comparator|Placebo supplementation|
9930230|NCT00926276|Active Comparator|Surgical Treatment Group-Fundoplication|Re-evaluated 1 month post-op Re-evaluated 2 months post-op
9930231|NCT00926276|Active Comparator|Medical Therapy|Treated by primary clinician for GERD Re-evaluated 1 month Proceed to Fundoplication if GERD persist by pH-MII Re-evaluated at 2 months (1 month post-op) Worsening BPD will be given option of immediate surgery
9930232|NCT00926302|Experimental|Test drug|Levetiracetam one period
9930233|NCT00926302|Active Comparator|Reference drug|Keppra one period
9930234|NCT00926315|Experimental|calcitriol|calcitriol supplementation (0.25 mcg 2x/d)
9930235|NCT00926341|No Intervention|Active control|1. Active Control: (n=20), intervention: no intervention
9930236|NCT00926341|Active Comparator|PIO arm|PIO arm (n=30), Pioglitazone 30 mg/day, given for 24 weeks.
9930237|NCT00926341|Active Comparator|Telmi arm|Telmia arm (n=30): Tab. Telmisartan 40 mg/day given for 2 weeks.
9930238|NCT00926354|Experimental|AS101 infusion|Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
9930239|NCT00926354|No Intervention|Control group|Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly.
9988120|NCT01419353|Experimental|Follicular Estrogen, Antagonist, IVF|Follicular Estrogen in Antagonist IVF protocol
9988121|NCT01419353|Active Comparator|long IVF protocol|long IVF protocol
9988122|NCT01419379||1|
9988123|NCT01419392|Experimental|Sildenafil citrate|
9988124|NCT01419392|Placebo Comparator|placebo|
9988125|NCT01419405|Experimental|Pregabalin/placebo|
9988126|NCT01419405|Active Comparator|placebo/remifentanil|
9988127|NCT01419405|Placebo Comparator|placebo/placebo|
9988128|NCT01419405|Experimental|Pregabalin/Remifentanil|
9988129|NCT01419418||Peripheral Arterial Disease (PAD)|This is a longitudinal observational study. There were no interventions administered.
9988130|NCT01419431||Colon cancer patients|Laparoscopic resection
9988131|NCT01419444|Active Comparator|Traditional, Onsite Treatment|Onsite treatment using airflow exercises. Patients will receive face-to-face treatment with the research speech pathologist two times per week.
9988132|NCT01419444|Experimental|Telemedicine Treatment|Participants will receive treatment via telemedicine at select AHEC sites around the state of Arkansas. Treatments will occur twice per week with the research speech pathologist.
9988133|NCT01419457|Experimental|Group 1|Normal hepatic function
9988134|NCT01419457|Experimental|Group 2|Mild hepatic impairment
9988135|NCT01419457|Experimental|Group 3|Moderate hepatic impairment
9988136|NCT01419457|Experimental|Group 4|Severe hepatic impairment
9988137|NCT01419470|Experimental|YHD1044 I|
9988138|NCT01419470|Experimental|YHD1044 III|
9988139|NCT01419470|Experimental|YHD1044 V|
9988140|NCT01419483|Experimental|Ketogenic diet|Diet designed to maintain elevated ketone levels during therapy
9988141|NCT01419587|Experimental|Ketogenic diet|Diet formulated to maintain elevated ketones during therapy
9988142|NCT01419600|Experimental|Group 1 - 4, single ascending dose AZD 8683|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
9988143|NCT01419600|Placebo Comparator|Group 1-4 single ascending dose Placebo|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
9988144|NCT01419613|Experimental|Motivational Interviewing|
9988145|NCT01419613|Active Comparator|Physical Activity Counseling|
9988146|NCT01419652|Active Comparator|continue hypglycemic meds|
9988147|NCT01419652|No Intervention|control - hold drug|
9988148|NCT01419678|Experimental|'collection of blood samples for PK testing'|collection of PK samples around a dosing of Posaconazole
9988149|NCT01419691|Experimental|Phase 2 Dose|Auranofin 6 mg orally in the morning / 6 mg orally in the evening
9988150|NCT01419704|Experimental|Hemoglobinopathies diagnosed patients|Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
9988151|NCT01419730|Active Comparator|Vitamin D3 50,000 IU|Vitamin D3 50,000 IU: Patients will be assigned to receive a daily multivitamin, calcium supplement and 50,000 IU/week of vitamin D for a period of 24 weeks.
9988152|NCT01419730|Active Comparator|Vitamin D3 50,000 IU and Physical Activity|Vitamin D3 50,000 IU and Physical Activity: Patients will be assigned to receive a daily multivitamin, calcium supplement, 50,000 IU/week of vitamin D, and a progressive walking and resistance band exercise prescription for a period of 24 weeks.
9988153|NCT01419730|No Intervention|Control|Patients will be assigned to receive a daily multivitamin, calcium supplement, vitamin D placebo, and standard care monitoring.
9988154|NCT01419743||patients with Vit D level of < 20ng/mL: Group 1|randomized to receive 400 IU of vitamin D per day
9988155|NCT01419743||patients with Vit D levels <20ng/mL: Group 2|Randomized to receive 2000IU of Vitamin D per day
9988156|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 3|Randomized to receiving placebo
9988157|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 4|Randomized to receive 400IU of vitamin D per day
9988158|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 5|Randomized to receive 2000IU of vitamin D per day
9988159|NCT01419743||patients with vit D levels > 30ng/mL: Group 6|No treatment
9988160|NCT01419756||Single Arm|Imaging comparison study. No intervention.
9988161|NCT01419782|Experimental|Whole-body vibration|whole body vibration will be applied the right lower limb.
9988162|NCT01419808|Active Comparator|Vascularized Bone Graft|Patients randomized to a vascularized bone graft will undergo a 1, 2-ICRSA vascularized bone graft based upon the 1,2 supra-retinacular vessels as described by Zaidemberg . (9. Zaidemberg C, Siebert JW, Angrigiani C. A new vascularized bone graft for scaphoid nonunion. J Hand Surg. 1991; 16A: 474-478.)
9988163|NCT01419808|Active Comparator|Non-Vascularized Bone Graft|Patients randomized to the non-vascularized group will undergo trapezoidal bone grafting from the iliac crest as described by Fernandez . (10. Fernandez DL. A technique for anterior wedge-shaped grafts for scaphoid nonunions with carpal instability. J Hand Surg [Am]. 1984 Sep;9(5):733-7.)
9988164|NCT01419821|Active Comparator|Vit D supplementation|Group 2-Infants with 25(OH)D below 15ng/ml receiving continued vitamin D supplementation of 800IU (4gtt/d) for one year.
9988165|NCT01419821|Placebo Comparator|Placebo group|Group 3- Infants with 25(OH)D below 15ng/ml those receiving the placebo.
9988166|NCT01419821|No Intervention|Normal group|Group 1- infants with 25(OH)D above 15ng/ml (normal levels) will receive no intervention.
9988167|NCT01419834|Experimental|Humanized 3F8 Monoclonal Antibody (Hu3F8)|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
9988168|NCT01419847|Active Comparator|topical Penlac nail lacquer|3-1 randomization of active to placebo
9988169|NCT01419847|Placebo Comparator|Placebo|
9988170|NCT01419860|Experimental|Pixel intensity|Pixel intensity of fluorescence signal describing pixel microcirculation of colon
9988171|NCT01419886||Dysphagia|
9988172|NCT01419899|Experimental|Brief Intervention|This arm of the study will receive an assessments survey followed by a brief intervention concerning the relationship between the participants use of drugs and/or sexual risk and rik for HIV and hepatitis C infections. Following the intervention the participants will be offered free rapid testing for HIV and hepatitis C.
9988173|NCT01419899|No Intervention|Standard Care|This arm of the study will receive an assessments survey. Following the assessment the participants will be offered free rapid testing for HIV and hepatitis C.
9988174|NCT01419912|Experimental|soy milk|
9988175|NCT01419912|Experimental|cow's milk|
9988176|NCT01419925|Experimental|Group A|Two Multimeric-001 administrations followed by TIV
9988177|NCT01419925|Experimental|Group B|One administration of Multimeric-001 followed by TIV
9988178|NCT01419925|Experimental|Group C|One administration of adjuvanted M-001 followed by TIV
9988179|NCT01419925|Active Comparator|Group D|One administration of placebo followed by TIV
9988180|NCT01419938|Active Comparator|Light therapy for two weeks|
9988181|NCT01419938|Active Comparator|Light therapy and CBT|Two weeks of light therapy and after that 4 weeks of Cognitive behaviour therapy (CBT)
9988182|NCT01419951|Active Comparator|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
9988183|NCT01419951|Active Comparator|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
9988184|NCT01419951|Experimental|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
9988185|NCT01419964|Experimental|Group 01|ACH24
9988186|NCT01419964|Placebo Comparator|Group 02|Placebo
9988187|NCT01419990|Experimental|GLPG0634 capsules|
9988188|NCT01419990|Placebo Comparator|Placebo capsules|
9997169|NCT01506544|Active Comparator|Arm 2: Relative bioavailability study|This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
9997170|NCT01506557|Experimental|choecalciferol|
9997171|NCT01506557|Placebo Comparator|placebo|
9997172|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV003 in their upper arm at Day 0 and Day 180.
9997173|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV005 in their upper arm at Day 0 and Day 180.
9997174|NCT01506570|Placebo Comparator|Placebo|Participants will receive one SC injection of placebo in their upper arm at Day 0 and Day 180.
9997175|NCT01506583||General population|This group of participants is primarily an out-patient population.
9997176|NCT01506583||In-patient population|This group of participants is primarily an in-patient population.
9997177|NCT01506583||Pediatric Group|Participants in this group are children 18 years or younger.
9997178|NCT01506622|Active Comparator|Propofol group|intravenous administration of propofol 1 mg/kg at the end of anesthesia
9997179|NCT01506622|Active Comparator|Fentanyl group|intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia
9997180|NCT01506622|Active Comparator|Control group|intravenous administration of saline at the end of anesthesia
9997181|NCT01506635|Placebo Comparator|Control group|included patients who received artificial tear twice a day as control group.
9997182|NCT01506635|Experimental|Timolol group|included the patients with myopic regression who received timolol 0.5% eye drop twice a day
9997183|NCT01506661|Experimental|Rheumatoid Arthritis|10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
9997184|NCT01506661|Active Comparator|Healthy Subjects|10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
9997185|NCT01506687|Experimental|Navigator intervention|
9997186|NCT01506687|Active Comparator|Usual Care Control|Usual care
9997187|NCT01506713|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
9997188|NCT01506713|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
9877692|NCT00425711|Experimental|DUI Court Participants|Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.
9877693|NCT00425763|Experimental|AQAS|
9877694|NCT00425776|Active Comparator|Real acupuncture|
9877695|NCT00425776|Sham Comparator|Sham acupuncture|
9877696|NCT00425776|No Intervention|No intervention|
9877697|NCT00425815|Experimental|Org 24448 250 mg|Two capsules (one Org 24448 250 mg capsule and one placebo capsule that is identical to the active treatment) will be ingested orally daily for eight weeks.
9877698|NCT00425815|Experimental|Og 244448 500 mg|Two capsules (two Org 24448 250 mg capsules) will be ingested orally daily for eight weeks.
9877699|NCT00425815|Placebo Comparator|Inactive Capsule|Two capsules (two placebo capsules that are identical to the active treatment) will be ingested orally daily for eight weeks.
9877700|NCT00425880||Pregnant Asthmatics|
9877701|NCT00425880||Pregnant Smokers|
9877702|NCT00425880||Healthy Pregnant Controls|
9877703|NCT00425893|Active Comparator|1|health education
9877704|NCT00425893|Experimental|2|hand hygiene
9877705|NCT00425893|Experimental|3|masks and hand hygiene
9877706|NCT00425906|Experimental|Nicotine inhaler|
9877707|NCT00425906|Placebo Comparator|Placebo inhaler|
9877708|NCT00425932|No Intervention|Rituximab/Placebo|Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is >2.6, patient will be retreated with open label Rituximab.
9877709|NCT00425932|Active Comparator|Open Label|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
9877710|NCT00426010|Active Comparator|1|overt then covert caffeine
9877711|NCT00426010|Active Comparator|2|covert then overt caffeine
9877712|NCT00426010|Active Comparator|3|overt then covert placebo
9877713|NCT00426010|Active Comparator|4|covert then overt placebo
9877714|NCT00426023|Experimental|1|this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily
9877715|NCT00426023|Active Comparator|2|
9877716|NCT00426101|Experimental|Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids|"As compared to the HLH-94 treatment, the main changes are that~Cyclosporin A is administered from day 1 and~Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below."
9877717|NCT00426140|Experimental|EPO906|
9877718|NCT00426166|Experimental|1|Low Level Laser Therapy
9877719|NCT00426166|No Intervention|2|No Laser Therapy. Outcome Measures the same.
9930240|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
9930241|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
9930242|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
9930243|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
9930244|NCT00926419|Active Comparator|Varicella (full dose) - SC - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle-free Syringe Jet Injector
9930245|NCT00926419|Active Comparator|Varicella (full dose) - SC - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle Syringe
9930246|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
9930247|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
9930248|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle-free Syringe Jet Injector
9930249|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle Syringe
9930250|NCT00926432|Other|Healthy volunteers|Small group of aged healthy volunteers
9930251|NCT00926432|Other|Patients|Patients consulting for spine disorders that may or may not have postural troubles
9930252|NCT00926445||Preterm (BW < 1500 grams)|
9930253|NCT00926445||Critically ill term newborn|ventilation > 48 hours
9930254|NCT00926445||Healthy term newborn|
9930255|NCT00926471|Experimental|Cognitive Behavioral Therapy (CBT) Program|Participants will receive a treatment program involving CBT plus adjunctive group counseling and parent training.
9930256|NCT00926471|No Intervention|Wait list control|Participants will be placed on a 12-week wait list with no active treatment
9930257|NCT00926484||Tooth Mousse|
9930258|NCT00926484||fluoride varnish|
9930259|NCT00926484||Tooth Mousse + fluoride varnish|
9930260|NCT00926510|Experimental|Language Toolkit|Language toolkit composed of simple tools that parents can use to interact with child and help language acquisition.
9930261|NCT00926510|Placebo Comparator|2|Safety counseling and smoke detector
9930262|NCT00926523||Healthy Controls|Subjects are made up of healthy adults
9930263|NCT00926523||Affected|Subjects have Pulmonary Hypertension
9930264|NCT00926549|Experimental|spectral domain-OCT|Spectral domain-OCT scanning performed.
9930265|NCT00926562|Experimental|Iopromide|Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
9930266|NCT00926562|Active Comparator|Iodixanol|Drug: Visipaque 320 mgl/ml, injection of intra-artery
9877720|NCT00426218|Experimental|1|ACZ885
9877721|NCT00426244|Sham Comparator|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
9877722|NCT00426244|Active Comparator|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
9877723|NCT00426244|No Intervention|Standard Care|Subject only receives care from her OB provider. Subjects were allowed to receive conventional obstetrical care with the exception of OMT, massage therapy, physical therapy, chiropractic manipulation, or therapeutic ultrasound intended to treat musculoskeletal disorders.
9877724|NCT00426257|Experimental|1|Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy
9877725|NCT00426257|Active Comparator|2|Secondary debulking surgery
9877726|NCT00426322|Active Comparator|1|small particles
9877727|NCT00426322|Active Comparator|2|large particles
9877728|NCT00426348|Active Comparator|1|In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
9877729|NCT00426348|Experimental|2|Valsartan(80-160mg/day) + Probucol(750mg/day)
9877730|NCT00426413||1|Obese AA subjects with DKA or severe hyperglycemia
9877731|NCT00426413||2|obese nondiabetic subjects, age 19-65.
9877732|NCT00426413||3|Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
9877733|NCT00426426|Active Comparator|Meta-Cognitive Therapy|first Meta-cognitive therapy then Cognitive Behaviour Therapy
9877734|NCT00426426|Active Comparator|Cognitive Behaviour Therapy|first Cognitive Behaviour Therapy then Meta-cognitive therapy
9877735|NCT00426426|Other|Waiting List|Waiting List
9877736|NCT00426439|Experimental|1 Coartem|Treatment of documented malaria in children following the dosages recommended by the manufacturer.
9877737|NCT00426439|Active Comparator|2 Chloroquine|The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
9877738|NCT00426491|Active Comparator|A|Four 200 ug tablets of Misoprostol
9877739|NCT00426491|Placebo Comparator|B|
9877740|NCT00426504|Experimental|radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
9877741|NCT00426530|Experimental|RAD001 Daily Schedule|5mg or 10mg
9877742|NCT00426530|Experimental|RAD001 Weekly Schedule|30mg
9877743|NCT00426582|Experimental|Patupilone only|Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
9877744|NCT00426582|Active Comparator|Carboplatin alone|Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
9877745|NCT00426608|Experimental|Session 1|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
9877746|NCT00426608|Experimental|Session 2|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
9877747|NCT00426608|Experimental|Session 3|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
9877748|NCT00426608|Experimental|Session 4|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
9877749|NCT00426608|Experimental|Session 5|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days.
9877750|NCT00426621|Experimental|1|
9877751|NCT00426621|Placebo Comparator|2|
9877752|NCT00426647|Experimental|Buprenorphine|Norspan transdermal patch
9877753|NCT00426647|Active Comparator|Tramadol|Tramadol SR tablets
9877754|NCT00426712|Experimental|1|Low dose
9877755|NCT00426712|Experimental|2|Middle dose
9877756|NCT00426712|Experimental|3|High dose
9877757|NCT00426712|Active Comparator|4|
9877758|NCT00426725|Experimental|A|This group uses the EasyLabour device according to the protocol
9877759|NCT00426725|No Intervention|Control|
9877760|NCT00426777|Active Comparator|risedronate|
9877761|NCT00426777|Placebo Comparator|placebo|
9877762|NCT00426816|Experimental|Crossover population|All study population receive placebo and doses of SB-649868 at 10mg, 30mg and 60mg in a crossover desing
9877763|NCT00426829|Experimental|Proton Therapy + Bevacizumab|Proton Therapy + Bevacizumab
9877764|NCT00426868|Experimental|Treatment|
9877765|NCT00426868|Placebo Comparator|Placebo|
9877766|NCT00426881|Experimental|1|Twice weekly resistance training for 52 weeks.
9877767|NCT00426881|Experimental|2|Once weekly resistance training for 52 weeks.
9877768|NCT00426881|Experimental|3|Twice weekly balance and tone training for 52 weeks.
9877769|NCT00426907|Experimental|1|Full postoperative weightbearing
9877770|NCT00426907|Active Comparator|2|Partial weightbearing 6 weeks postoperative
9877771|NCT00427076|Experimental|A|Cotrimoxazole
9877772|NCT00427076|Active Comparator|B|Vancomycin
9877773|NCT00427089|Experimental|1|2L gut cleansing solution
9877774|NCT00427089|Active Comparator|2|
9877775|NCT00427206|Active Comparator|1|acetaminophen 4 g/day
9877776|NCT00427206|Placebo Comparator|2|placebo undistinguishable from active drug
9877777|NCT00427310|Experimental|Arm 1: Postoperative 5 FU + sodium heparin|Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.
9877778|NCT00427310|Active Comparator|Arm 2: Postoperative observation|
9877779|NCT00427375|Experimental|1|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
9877780|NCT00427375|Active Comparator|2|Standard surgery
9877781|NCT00427388|Experimental|Treatment|500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
9877782|NCT00427388|Placebo Comparator|Placebo|500 mg of matching placebo (normal saline solution) divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
9877783|NCT00427414|Experimental|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
9877784|NCT00427492|Active Comparator|Magnesia|Medical laxative
9877785|NCT00427492|Placebo Comparator|Placebo|Placebo
9877786|NCT00427583|Experimental|STI571|
9877787|NCT00427609|Placebo Comparator|1|
9877788|NCT00427609|Active Comparator|2|
9877789|NCT00427674|Experimental|injection of 5 mCi of 123-I mZINT|
9877790|NCT00427739||CCT exam|
9877791|NCT00427752|Experimental|Whipple|Patients with pancreatic cancer who will proceed to a Whipple procedure.
9877792|NCT00427843|Experimental|Exercise Home-Based Program|Patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. The exercise program will be performed 3 times per week for 8 weeks.
9877793|NCT00427947|Experimental|1|Continuous sciatic nerve bloc : ropivacaine infusion
9877794|NCT00427947|Placebo Comparator|2|Continuous sciatic nerve bloc : NaCl Infusion
9877795|NCT00428012|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
9877796|NCT00428012|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
9877797|NCT00428012|No Intervention|Standard Care|
9877798|NCT00428025|Placebo Comparator|placebo suppository|
9877799|NCT00428025|Active Comparator|diclofenac suppository|
9877800|NCT00428038||1|"Group 1:~Infants born prematurely at a gestational age < 32 weeks with a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
9877801|NCT00428038||2|"Group 2:~Infants born prematurely at a gestational age < 32 weeks without a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
9877802|NCT00428038||3|"Group 3:~Infants born full term at a gestational age > 37 weeks. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Hospitalization for a respiratory illness~History of wheezing, asthma, or treatment with asthma medications~Congenital heart disease"
9877803|NCT00428051||All eligible patients|
9930267|NCT00926614|Experimental|Pioglitizone and Atorvastatin|Pioglitazone and Atorvastatin added to standard of care Pegasys and weight based ribavirin
9930268|NCT00926627|Placebo Comparator|Placebo|placebo b.i.d.
9930269|NCT00926627|Experimental|Bosentan|62.5 mg/125 mg bosentan b.i.d.
9930270|NCT00926640|Experimental|1|Belinostat dose escalation
9930271|NCT00926640|Experimental|2|Belinostat UGT1A1 wild type/*28 variant
9930272|NCT00926640|Experimental|3|Belinostat UGT1A1*60 or 2/3/4 variant
9930273|NCT00926653||Depressed|Elderly participants with depression
9930274|NCT00926653||Control|Elderly participants who have never experienced depression
9930275|NCT00926692||Healthy Subjects|All subjects are considered healthy
9930276|NCT00926705|Active Comparator|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
9988189|NCT01420003|Experimental|Allergen Challenge|
9877804|NCT00428129|Experimental|1|
9877805|NCT00428142|Experimental|Bortezomib + BCVP-R|BCVP-R - q 21 days x 4 cycles Bortezomib: 1.3 mg/m2 Days 1 & 8 Cyclophosphamide: 750 mg/m2 IV Day 1 Vincristine: 1.4 mg/m2 IV Day 1 (dose capped at 2 mg) Prednisone: 40 mg/m2 po Days 1-5 Rituximab: 375 mg/m2 IV Day 1
9877806|NCT00428168|Experimental|Betahistine 24 mg|
9877807|NCT00428168|Placebo Comparator|Placebo|
9877808|NCT00428181|Active Comparator|1 Brief Intervention|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
9877809|NCT00428181|Active Comparator|2) Booster|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
9877810|NCT00428194|Experimental|Cohort 1|Erlotinib 100 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
9877811|NCT00428194|Experimental|Cohort 2|Erlotinib 125 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
9877812|NCT00428194|Active Comparator|Cohort 3|Erlotinib 150 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
9877813|NCT00428233|No Intervention|Leukemia Cell Harvest|Procedure/Surgery: Leukemia cell harvest Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
9877814|NCT00428272|Experimental|1|Lexatumumab alone dose escalation
9877815|NCT00428272|Experimental|2|Lexatumumab with interferon - dose escalation
9877816|NCT00428272|Other|3|Lexatumumab 10mg/kg with interferon expansion at
9877817|NCT00428285|Experimental|Single Arm|
9877818|NCT00428337|Experimental|1|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0 and 28 and one injection of MVA-mBN32 or placebo in each arm on Days 84 and 168
9877819|NCT00428337|Experimental|2|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0, 28, 84, and 168
9877820|NCT00428337|Experimental|3|Participants will receive one injection of MVA-mBN32 or placebo in each arm on Days 0, 28, 84, and 168
9877821|NCT00428402||Focus Group|Participant is a 4th-8th grade student in select schools from Bastrop Independent School District (BISD).
9877822|NCT00428428|Placebo Comparator|1|Saline irrigation
9877823|NCT00428428|Active Comparator|2|ISO irrigation
9877824|NCT00428454|Experimental|Zotarolimus eluting stent|Zotarolimus eluting stent
9877825|NCT00428454|Active Comparator|Sirolimus eluting stent|Sirolimus eluting stent
9877826|NCT00428480|Experimental|1|Daily reinforcement of walking speed
9877827|NCT00428480|Active Comparator|2|No reinforcement of walking speed
9877828|NCT00428519|Placebo Comparator|1|
9877829|NCT00428519|Active Comparator|2|
9877830|NCT00428519|Active Comparator|3|
9877831|NCT00428545|Experimental|Bevacizumab + Bortezomib|Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days.
9877832|NCT00428558|Active Comparator|2|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
9877833|NCT00428558|Experimental|1|BRAS INDUCTION SEQUENTIAL
9877834|NCT00428571|Placebo Comparator|Intensive Medical Management|Medical management of obesity including medication optimization and lifestyle and dietary advice.
9877835|NCT00428571|Active Comparator|Laparoscopic Gastric Bypass|
9877836|NCT00428571|Active Comparator|Laparoscopic Adjustable Gastric Band|
9877837|NCT00428649|Experimental|1|20 µg selenium as selenomethionine
9877838|NCT00428649|Experimental|2|40 µg selenium as selenomethionine
9877839|NCT00428649|Experimental|3|60 µg selenium as selenomethionine
9877840|NCT00428649|Experimental|4|80 µg selenium as selenomethionine
9877841|NCT00428649|Experimental|5|100 µg selenium as selenomethionine
9877842|NCT00428649|Experimental|6|120 µg selenium as selenomethionine
9877843|NCT00428649|Placebo Comparator|7|placebo
9877844|NCT00428727|Experimental|1|Nitric oxide patches
9877845|NCT00428727|Placebo Comparator|2|Placebo patches
9877846|NCT00428779|Experimental|1|patients running during 24 hours without sleep
9877847|NCT00428779|Placebo Comparator|2|patients without sleep during 24 hours
9877848|NCT00428805|Experimental|intervention 1|This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
9877849|NCT00428805|No Intervention|control 2|measurement only control arm
9877850|NCT00428831||1|Patients with respiratory illnesses.
9877851|NCT00428870|Experimental|Arthroscopic acromioplasty|Arthroscopic acromioplasty
9877852|NCT00428870|Placebo Comparator|Sham surgery|Shoulder arthroscopy without active treatment and subacromial arthroscopy without bursectomy, decompression or other active interventions
9877853|NCT00428870|Active Comparator|Conservative treatment|Standardized exercise rehabilitation (supervised by physiotherapist)
9877854|NCT00428896|Experimental|1|ZD1839
9877855|NCT00428909|Other|Drug-Drug interaction|
9877856|NCT00428935|Experimental|Low Dose|Low dose cohort - 2.0E10 vg/kg
9877857|NCT00428935|Experimental|High Dose|High Dose - 1.0E11 vg/kg
9877858|NCT00429013|No Intervention|2|no medical device
9877859|NCT00429013|Experimental|1|medical device
9877860|NCT00429091|Placebo Comparator|1|
9877861|NCT00429091|Experimental|2|
9877862|NCT00429091|Active Comparator|3|
9877863|NCT00429117||Survey|Physician members of the International Gynecologic Oncologists Society or the Society of Gynecologic Oncologists.
9877864|NCT00429156|Active Comparator|1|Home non-invasive ventilation
9877865|NCT00429156|Sham Comparator|2|Home sham non-invasive ventilation with CPAP 5 cm H2O
9877866|NCT00429234|Experimental|Dasatinib + Gemcitabine|Dasatinib starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks. Gemcitabine starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
9877867|NCT00429247|Experimental|1|Her
9877868|NCT00429247|No Intervention|2|Follow up
9877869|NCT00429312|Experimental|Single Arm|Intratumoral injection(s) of Recombinant Vaccinia GM-CSF, JX-594
9877870|NCT00429338|Experimental|AIR-MRSI|Endorectal MRSI with Air
9877871|NCT00429338|Experimental|PFC-MRSI|Endorectal MRSI with PFC
9877872|NCT00429442|Active Comparator|1|
9877873|NCT00429442|Placebo Comparator|2|
9877874|NCT00429455||Survey Participants|Female patients who had a hematopoietic stem cell transplantation between January 1987 and September 2004 at M. D. Anderson Cancer Center.
9877875|NCT00429546|Experimental|Intervention|Participants will receive a cognitive-behavioral intervention designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child
9877876|NCT00429546|Active Comparator|Control|Participants will receive treatment as usual
9877877|NCT00429559|Experimental|A|
9877878|NCT00429650|Experimental|1|Increased amount of exercise to maintain weight loss.
9877879|NCT00429650|Experimental|2|Combination of Exercise and Diet to maintain weight loss
9877880|NCT00429650|Active Comparator|3|Use diet alone to maintain weight loss.
9877881|NCT00429715|Experimental|Alum-ALM + BCG|Alum-ALM + BCG
9877882|NCT00429715|Active Comparator|BCG|BCG
9877883|NCT00429715|Placebo Comparator|BCG diluent|Diluent
9877884|NCT00429754|Other|aprepitant|Aprepitant treatment
9877885|NCT00429780|No Intervention|Alum-ALM + BCG|Alum-ALM + BCG
9877886|NCT00429780|No Intervention|Placebo|BCG diluent
9877887|NCT00429806|Placebo Comparator|Placebo|Placebo suppository; once daily for 7 days.
9877888|NCT00429806|Experimental|DHEA 0.50%|DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
9877889|NCT00429806|Experimental|DHEA 1.0%|DHEA 1.0% (13 mg) suppository; once daily for 7 days.
9877890|NCT00429806|Experimental|DHEA 1.8%|DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.
9877891|NCT00429871|Experimental|1|DF
9877892|NCT00429871|Experimental|2|DC
9930277|NCT00926705|Experimental|Dexmedetomidine and Fentanyl|This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
9930278|NCT00926718|Experimental|Dose 1a|
9930279|NCT00926718|Experimental|Dose 2a|
9930280|NCT00926718|Experimental|Dose 3a|
9930281|NCT00926718|Experimental|Dose 1b|
9930282|NCT00926718|Experimental|Dose 2b|
9930283|NCT00926718|Experimental|Dose 3b|
9930284|NCT00926731|Experimental|1|AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)
9930285|NCT00926744|Experimental|Intervention|Physically inactive participants receiving both physical activity and dietary counseling
9988190|NCT01420042|Placebo Comparator|Placebo (lemon flavoured cordial)|NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
9988191|NCT01420042|Experimental|NNZ-2566|
9988192|NCT01420055|Experimental|fingolimod|
9988193|NCT01420094|Experimental|Arm 1|
9988194|NCT01420094|Active Comparator|Arm 2|
9988195|NCT01420094|Placebo Comparator|Arm 3|
9988196|NCT01420133|Experimental|Normal regimen|without special regimen for corticosteroid therapy
9988197|NCT01420133|Active Comparator|Standard arm|with diet low in salt and sugar
9988198|NCT01420159|Experimental|Methoxyflurane|
9988199|NCT01420159|Placebo Comparator|Normal Saline|
9988200|NCT01420172||Post hematopoietic stem cell transplantation|Patients who were seen post hematopoietic stem cell transplantation between 01Jan2000 and 30Jun2011
9988201|NCT01420198|Experimental|Lifestyle intervention|Lifestyle intervention: 500 participants from Iraq with obesity and/or prediabetes (impaired fasting glucose) and we expect to recruit 308 participants. Half of them will be randomized to lifestyle intervention i.e. group counseling and physical activity during a period of 1 year. An equal amount of controls will have treatment as usual. Every third month blood tests and a physical exam will be conducted in the intervention group.
9988202|NCT01420198|No Intervention|Controls|Controls have treatment as usual. Every third month blood tests and a physical exam will be conducted in the control group.
9988203|NCT01420211|Experimental|Primovist|
9988204|NCT01420224||Healthy volunteers|
9988205|NCT01420224||Chuvash polycythaemia|
9988206|NCT01420237|Other|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
9988207|NCT01420250|Experimental|Cabazitaxel with Intensity Modulated Radiation Therapy (IMRT)|Weekly Cabazitaxel with concurrent IMRT
9988208|NCT01420263|Active Comparator|Re-feeding gastric residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
9988209|NCT01420263|Active Comparator|Fresh feeding breastmilk/formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
9988210|NCT01420302|Experimental|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
9988211|NCT01420302|Active Comparator|Nurse-directed|Nurse-directed blood glucose control (80-110 mg/dL)
9988212|NCT01420328|Placebo Comparator|Placebo Arm|Obese subjects with near normal cholesterol
9988213|NCT01420328|Active Comparator|Vytorin Arm|Obese subjects with near normal cholesterol
9988214|NCT01420341|Active Comparator|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
9988215|NCT01420341|Experimental|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
9988216|NCT01420367|Experimental|Single dose of antibiotics|This group will receive one dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) in the pre-operative period and two post-operative IV 'doses' of normal saline 8 and 16 hours after the pre-operative dose, which will act as a placebo and facilitate blinding.
9988217|NCT01420367|Active Comparator|Three doses of antibiotics|This group will receive one pre-operative dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) and two post-operative doses of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) 8 and 16 hours after the pre-operative dose.
9988218|NCT01420393|Active Comparator|Rhythm Control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
9988219|NCT01420393|Active Comparator|Rate Control|Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
9988220|NCT01420406|Placebo Comparator|0 mg retinol|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
9988221|NCT01420406|Experimental|12 mg BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule.
9988222|NCT01420406|Experimental|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
9988223|NCT01420406|Experimental|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
9988224|NCT01420419|Experimental|Lanolin|Pea sized amount of lanolin to be applied to nipple and areola after every breast feed (approximately every 2-3 hours), until pain is completely resolved for a maximum of 7 days
9997189|NCT01506739|Active Comparator|1|
9997190|NCT01506739|Active Comparator|2|
9997191|NCT01506739|Active Comparator|3|
9997192|NCT01506752|Active Comparator|E2020 improved 10 mg without water|
9877893|NCT00429936|Active Comparator|100 mg fenretinide softgel capsules|Three (3) 100-mg fenretinide softgel capsules
9877894|NCT00429936|Active Comparator|Fenretinide and placebo softgel capsules|One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
9877895|NCT00429936|Placebo Comparator|Placebo softgel capsules|Three (3) placebo softgel capsules
9877896|NCT00429962|Experimental|A|intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
9877897|NCT00429962|Active Comparator|B|intravitreal ranibizumab
9877898|NCT00430014|Experimental|Atiprimod|
9877899|NCT00430066|Experimental|Imatinib Mesylate|400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
9877900|NCT00430079|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.
9877901|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot III|
9877902|NCT00430118|Experimental|Induction Prot I/Pred - reinduction Prot III|
9877903|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot II|
9877904|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction Prot II|
9877905|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 2x Prot III|
9877906|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 2x Prot III|
9877907|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III|
9877908|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III|
9877909|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 6 HR courses + Prot II|
9877910|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction 6 HR courses + Prot II|
9877911|NCT00430144|Experimental|CKD-602|
9877912|NCT00430170|Active Comparator|1|dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg
9877913|NCT00430170|Placebo Comparator|2|dipyridamol during 7 days and before ischemic exercise placebo
9877914|NCT00430287||1: Primary open angle glaucoma|Patients with a form of primary open angle glaucoma
9877915|NCT00430287||2: No known eye disease (controls)|Patients with no known eye disease (controls)
9877916|NCT00430365|Placebo Comparator|placebo group|Administration of oral placebo
9877917|NCT00430365|Experimental|lenalidomide group|Administration of lenalidomide
9877918|NCT00430378|Experimental|Acupuncture|Acupuncture Before the Radiation Treatment
9877919|NCT00430378|Experimental|Standard Care|Standard Care Without Acupuncture
9877920|NCT00430391|Experimental|DVD patient high risk|Patients with a diagnosis of schizophrenia/schizoaffective disorder randomized to the DVD, high risk version
9877921|NCT00430391|Experimental|DVD patient low risk|Patient with a diagnosis of schizophrenia/schizoaffective disorder randomized to DVD consent, low risk version
9877922|NCT00430391|Experimental|DVD normal high risk|Participants with no psychiatric diagnosis randomized to DVD consent, high risk version
9877923|NCT00430391|Experimental|DVD normal low risk|Participants with no psychiatric diagnosis randomized to DVD consent, low risk version
9877924|NCT00430391|Experimental|Routine control high risk|Participants with no psychiatric diagnosis randomized to routine consent, high risk version
9877925|NCT00430391|Experimental|Routine control low risk|Participants with no psychiatric diagnosis randomized to routine consent, low risk version
9877926|NCT00430391|Experimental|Routine patient low risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, low risk version
9877927|NCT00430391|Experimental|Routine patient high risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, high risk version
9877928|NCT00430404|No Intervention|Usual care (controlled group)|Usual care for management of depression
9877929|NCT00430404|Experimental|collaborative care (Intervention)|Collaborative care for management of depression for intervention group. We provided multidisciplinary groups of care from psychiatrist, psychologist, social counselor, general practitioners and case managers for intervention group.
9877930|NCT00430417||3 groups|Group 1: post-partum breastfeeding women
9877931|NCT00430417||Group 2|Group 2: post-partum bottlefeeding women
9877932|NCT00430417||Group 3|Group 3: normal non-pregnant controls who are age and race-matched to Group 1
9877933|NCT00430430|Experimental|High MUFA|high monounsaturated fat background diet to portfolio diet
9877934|NCT00430430|Active Comparator|Low MUFA|low monounsaturated fat background diet to portfolio diet
9877935|NCT00430456|Other|Arm 1|Higher Intensity, Shorter Duration Treadmill Training
9877936|NCT00430456|Active Comparator|Arm 2|Lower Intensity, Longer Duration Treadmill Training
9877937|NCT00430560|Active Comparator|1|work therapy
9877938|NCT00430560|Experimental|2|work therapy plus cognitive remediation
9877939|NCT00430586|Experimental|20 U NT 201|
9877940|NCT00430586|Placebo Comparator|Placebo|
9877941|NCT00430586|Experimental|10 U NT 201|
9877942|NCT00430586|Experimental|30 U NT 201|
9877943|NCT00430612||1|Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site
9877944|NCT00430651|Experimental|1|Docetaxel + Carboplatin
9877945|NCT00430651|Experimental|2|Docetaxel
9877946|NCT00430690||1|Cocaine dependent subjects
9877947|NCT00430690||2|Healthy controls
9877948|NCT00430690||3|Siblings of cocaine dependent subjects
9877949|NCT00430703|Experimental|1|Patients with severe traumatic brain injury
9877950|NCT00430703|Experimental|2|Healthy volunteers
9877951|NCT00430742|Experimental|1|Arm 1: MK0364 0.5 mg capsule once daily
9877952|NCT00430742|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
9877953|NCT00430742|Experimental|3|Arm 3: MK0364 2 mg capsule once daily
9877954|NCT00430742|Placebo Comparator|4|Arm 4: Pbo capsule once daily
9877955|NCT00430820||1|30 patients
9877956|NCT00430820||2|30 patients
9877957|NCT00430820||3|30 patients
9877958|NCT00430846|Experimental|A|
9877959|NCT00430859|Experimental|1|BIAP
9877960|NCT00430859|Placebo Comparator|Placebo|Placebo, saline
9877961|NCT00430872||MDASI-Spine Tumor Module Survey|M. D. Anderson Symptom Inventory-Spine (survey) of patients with a tumor on the spine or spinal cord.
9877962|NCT00430885|Placebo Comparator|Saline|
9877963|NCT00430885|Experimental|Octagam (IVIG)|Octagam (IVIg) is intravenous immunglobulin
9877964|NCT00430898|Placebo Comparator|1. Placebo|Placebo to mimic 40 mg of Simulect
9877965|NCT00430898|Experimental|2. 40 mg Simulect|40 mg of Simulect
9877966|NCT00430924|Active Comparator|1|Eplerenone
9877967|NCT00430924|No Intervention|2|Control
9877968|NCT00430963|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
9877969|NCT00430963|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
9877970|NCT00431028|No Intervention|colirio|prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops
9877971|NCT00431054|Experimental|Perifosine + Docetaxel|
9877972|NCT00431080|Experimental|1|FEC -> TXT
9877973|NCT00431080|Experimental|2|FEC -> TXL
9877974|NCT00431106|Active Comparator|1|Vinorelbine/Gemcitabine (VG)
9877975|NCT00431106|Active Comparator|2|Capecitabine (Cap)
9877976|NCT00431158|Active Comparator|1|ARDSnet Protocol
9877977|NCT00431158|Active Comparator|2|OLA Protocol
9877978|NCT00431210|Experimental|Biological/Vaccine|Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
9877979|NCT00431223|Active Comparator|Active Group|7 patients were assigned to Cognitive Remediation Therapy..
9877980|NCT00431223|No Intervention|Control Group|4 patients were assigned to Control group or no cognitive remediation therapy.
9877981|NCT00431249|Other|one|
9877982|NCT00431275|Experimental|Commercial Formulation|Commercial Formulation
9877983|NCT00431275|Experimental|Current Formulation|Current Formulation
9877984|NCT00431301||Case|PSP Cases
9877985|NCT00431301||Control|Healthy Controls
9877986|NCT00431353|Experimental|1|
9877987|NCT00431353|Experimental|2|
9877988|NCT00431418|Active Comparator|1|Sildenafil oral solution.
9877989|NCT00431418|Placebo Comparator|2|Placebo oral solution.
9877990|NCT00431457|Active Comparator|Implantation intracranial electrode with immediate stimulation|
9877991|NCT00431457|Placebo Comparator|Implantation intracranial electrode without stimulation|
9877992|NCT00431457|Active Comparator|Resective surgery: amygddohyppocampertomy|
9877993|NCT00431483|Other|Pharmaceutical counseling|
9877994|NCT00431561|Experimental|AP 12009 10 µM|
9877995|NCT00431561|Experimental|AP 12009 80 µM|
9877996|NCT00431561|Active Comparator|Chemotherapy|
9877997|NCT00431600|Experimental|1|12 healthy male subjects
9877998|NCT00431613|Experimental|1|DG -> RT
9877999|NCT00431613|Experimental|2|DG -> RT -> DCarbo
9878000|NCT00431639|Active Comparator|Comparison|For the comparison condition, subjects will be asked to choose one of four topics that will be determined thatday with a recreational therapist for 20 minutes.
9878001|NCT00431639|Active Comparator|Treatment|The treatment condition will consist of a 20-minute visit by a therapy dog and its owner. Therapy dogowners will be instructed to limit conversation with the patient to topics of the therapy dog, thepatients pets, and pets in general.
9878002|NCT00431678|Experimental|Arm 1|
9878003|NCT00431678|Active Comparator|Arm 2|
9878004|NCT00431691|Active Comparator|1|
9878005|NCT00431691|Placebo Comparator|2|
9878006|NCT00431704|Experimental|vinorelbine, carboplatin, trastuzumab|
9930286|NCT00926744|No Intervention|Active|Physically active participants receiving only dietary counseling
9930287|NCT00926744|No Intervention|Control|Physically inactive participants receiving only dietary counseling
9930288|NCT00926757|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
9930289|NCT00926757|Active Comparator|Therapeutic arm|In patients with HBV reactivation and ALT flare > 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission
9930290|NCT00926770||Pretem infants (GG < 37+0)|
9930291|NCT00926809|Active Comparator|Eradication|Helicobacter pylori eradication
9930292|NCT00926809|Placebo Comparator|No eradication|No eradication for Helicobacter pylori
9930293|NCT00926835|Experimental|Paroxetine|Paroxetine monotherapy
9930294|NCT00926835|Active Comparator|Escitalopram|Escitalopram monotherapy
9930295|NCT00926835|Active Comparator|Venlafaxine|Venlafaxine monotherapy
9930296|NCT00926835|Active Comparator|Paroxetine+Bupropion|
9930297|NCT00926835|Active Comparator|Paroxetine+Lamotrigine|
9930298|NCT00926835|Active Comparator|Paroxetine+Lithium|
9930299|NCT00926835|Active Comparator|escitalopram+mirtazapine|
9930300|NCT00926835|Active Comparator|Escitalopram+Aripiprazole|
9930301|NCT00926835|Active Comparator|Paroxetine + Venlafaxine|
9930302|NCT00926861||Dry AMD|male or female persons aged over 50 years with dry age-related macular degeneration
9930303|NCT00926874||1|patients who presented an ischaemic stroke(full stroke or TIA)
9930304|NCT00926874||2|patients who present an acute coronary syndrome (ACS).
9930305|NCT00926900|Active Comparator|D-cycloserine|
9930306|NCT00926900|Placebo Comparator|Placebo|
9930307|NCT00926913||Group 1|
9930308|NCT00926926|Experimental|Active OTG|
9930309|NCT00926926|Placebo Comparator|Placebo|
9930310|NCT00926939|Experimental|Abstinence Contingent (AC)|This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
9930311|NCT00926939|Experimental|Submission Contingent (SC)|This group receives vouchers for submitting videos of their CO breath test.
9930312|NCT00926965|Experimental|Olanzapine group|randomized to Olanzapine group with dose range of 2.5-30mg/day
9930313|NCT00926965|Experimental|Amisulpiride group|the subjects were randomized to the amisulpiride group with dose range of 100 to 800mg/day
9930314|NCT00926965|Active Comparator|FGA group|The subjects were randomized to maintain the conventional antipsychotics
9930315|NCT00926978|Other|Radiopharmacokinetics|"1-2 mCi I-124 orally, once per day, twice total 0.9mg rhTSH intravenous injection, once per day, four total~After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
9930316|NCT00926991||traumatic rib fractures|
9930317|NCT00927004|Experimental|Etoricoxib 60 mg|
9930318|NCT00927004|Placebo Comparator|Sugar pill|
9930319|NCT00927017|Active Comparator|Liquorice 66 g/day|Liquorice given 66 grams per day for two weeks
9930320|NCT00927017|Active Comparator|Liquorice 102 g/day|Liquorice given 102 grams per day for two weeks
9930321|NCT00927030|Experimental|Pharmacokinetic|We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
9997193|NCT01506752|Active Comparator|E2020 current 10 mg without water|
9878007|NCT00431769|Experimental|Bortezomib|
9878008|NCT00431795|Experimental|1|Epi
9878009|NCT00431795|Experimental|2|Cael
9878010|NCT00431808|Experimental|I, AMA1 vaccine|20 volunteers will receive 3 doses of the vaccine
9878011|NCT00431821|Other|Arm 1|Home-based exercise prescriptions with weekly motivational telephone calls.
9878012|NCT00431821|Other|Arm 2|Stroke education program with matched attention phone calls
9878013|NCT00431912|Experimental|Single-arm, trinomial 2-stage design|
9878014|NCT00432029|Other|1|IDDM
9878015|NCT00432029|Other|2|Hypercholesterolemia and/or Hypertension
9878016|NCT00432029|Other|3|age/sex matched healthy control subjects
9878017|NCT00432055|Experimental|I|Botox
9878018|NCT00432055|Placebo Comparator|II|
9878019|NCT00432068|Experimental|Octreotide pamoate|
9878020|NCT00432094|Experimental|2 Transplants|Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.
9878021|NCT00432094|Active Comparator|1 Transplant|Patients with Germ cell tumors who receive one transplant only.
9878022|NCT00432107|Experimental|2-stage mono therapy of APO866|The treatment period consists of 3 consecutive 28 day cycles. Each cycle starts with a 4 day continuous infusion of the study medication followed by a 24 day break
9878023|NCT00432120|Active Comparator|A|"nonselective - clopidogrel 600 mg >6 hours before coronary angiography;"
9878024|NCT00432120|Active Comparator|B|"selective - clopidogrel 600 mg in the cath-lab after coronary angiography, only in case of percutaneous coronary intervention"
9878025|NCT00432133|Experimental|1|Protection motivation theory-based tailored intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
9878026|NCT00432133|Experimental|2|Environmental access and awareness intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
9878027|NCT00432133|Experimental|3|Combination intervention combining protection motivation and environmental intervention components to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
9878028|NCT00432198|Experimental|1|Oral
9878029|NCT00432198|Experimental|2|Oral
9878030|NCT00432198|Placebo Comparator|3|Oral
9878031|NCT00432211|Placebo Comparator|1|Complete Scar Excision
9878032|NCT00432211|Placebo Comparator|2|Staged Excision of scar
9878033|NCT00432302|Experimental|Sagopilone|Subjects received 28 mg ZK 219477, containing 14 kBq/7.8 µg [14C]-ZK 219477 in the first infusion (Treatment course 1) followed by subsequent infusions (Treatment courses 2 to n [till disease progression]) of 16 mg/m2 ZK 219477 without radioactive label. Interval between the treatments was at least 21 days.
9878034|NCT00432315|Experimental|1|Resectable NSCLC
9878035|NCT00432315|Experimental|2|Unresectable NSCSC
9878036|NCT00432367|Experimental|1|OptiMAL® antigen screening and treatment with SP plus LLIN
9878037|NCT00432367|Experimental|2|OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
9878038|NCT00432367|Active Comparator|3|SP-IPTp plus LLIN
9878039|NCT00432406|Active Comparator|1|infliximab
9878040|NCT00432406|Active Comparator|2|etanercept
9878041|NCT00432432|Placebo Comparator|2|placebo with infliximab
9878042|NCT00432471|Experimental|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
9878043|NCT00432484|Placebo Comparator|1|Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San
9878044|NCT00432510|Experimental|Single Dose|1,000 Units (U) of C1INH-nf administered intravenously (IV).
9878045|NCT00432510|Experimental|First Dose Followed by Second Dose|1,000 U of C1INH-nf administered IV, followed by a second 1,000 U dose 60 minutes later.
9878046|NCT00432575|Placebo Comparator|1|
9878047|NCT00432575|Active Comparator|2|surinabant 2,5 mg/day
9878048|NCT00432575|Active Comparator|3|surinabant 5 mg/day
9878049|NCT00432575|Active Comparator|4|surinabant 10 mg/day
9878050|NCT00432614|Experimental|Group 1|SR58611A 350mg twice daily with escitalopram 10mg once daily
9878051|NCT00432614|Active Comparator|Group 2|placebo with escitalopram 10mg once daily
9878052|NCT00432614|Placebo Comparator|Group 3|placebo
9878053|NCT00432627|Experimental|Mild hepatic impaired|
9878054|NCT00432627|Experimental|Moderate hepatic impaired|
9878055|NCT00432627|Experimental|Severe hepatic impaired|
9878056|NCT00432627|Experimental|Healthy volunteers|Controlled group
9878057|NCT00432640|Experimental|1|Endoscopic ultrasound staging
9878058|NCT00432640|Active Comparator|2|Surgical staging
9988225|NCT01420419|Other|Standard postpartum nursing care|Women in standard care control group may receive any other nursing intervention to manage their nipple pain, including (but not limited to): recommending application of expressed breast milk, analgesics (such as acetaminophen or ibuprofen), breast shells, air drying, changing position / latch, cold or warm compresses
9988226|NCT01420432|Experimental|Human umbilical cord-derived MSCs and DMARDs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
9988227|NCT01420432|No Intervention|DMARDs|DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
9988228|NCT01420445|Experimental|YHD001 dose level 1|YHD001 dose level 1
9988229|NCT01420445|Experimental|YHD001 dose level 2|YHD001 dose level 2
9988230|NCT01420445|Active Comparator|Pelargonium sidoides extract|Pelargonium sidoides extract (Syrup)
9988231|NCT01420445|Placebo Comparator|Placebo|Placebo for YHD001 & active comparator(syrup)
9988232|NCT01420471|Active Comparator|Saline-impregnated spacer|Saline-impregnated spacers are actively being used as the standard of care. It does not contain any active ingredients.
9988233|NCT01420471|Experimental|Triamcinolone-impregnated spacer|This study arm receives the experimental treatment, a Triamcinolone-impregnated spacer.
9988234|NCT01420484||different blood pressure intervals|
9988235|NCT01420497|Active Comparator|methylprednisolone,infiltration|
9988236|NCT01420497|Active Comparator|epidural injection|
9988237|NCT01420510|Experimental|Adelmidrol|Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients
9988238|NCT01420510|Placebo Comparator|Placebo|Efficacy of Placebo in preventing vaginitis in oncologic patients
9988239|NCT01420523|Experimental|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
9988240|NCT01420562||Posaconazole oral suspension|"One group of patients will receive posaconazole oral suspension as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
9988241|NCT01420562||Posaconazole oral tablet|"Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
9988242|NCT01420575|Experimental|Visual Decision Making Aid|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower overweight patients with schizophrenia/schizoaffective disorder and help them efficiently arrive at a treatment decision that can be successfully implemented.
9988243|NCT01420575|Active Comparator|Usual Care|Usual care reflects the standard of care in psychiatry. Psychiatrists will recommend treatment for overweight patients with schizophrenia on olanzapine who have failed to lose weight despite life style and dietary modifications. They may recommend switching to a comparable antipsychotic with a lower incidence of weight gain.
9988244|NCT01420588||gastric cancer|
9988245|NCT01420588||gastritis|
9988246|NCT01420588||gastric ulcer|
9988247|NCT01420588||normal|
9988248|NCT01420614|Experimental|Radial|group of patients undergoing primary angioplasty by transradial approach
9988249|NCT01420614|Active Comparator|Femoral|group of patients undergoing primary angioplasty by transfemoral approach
9988250|NCT01420640|Active Comparator|Tai Chi|
9988251|NCT01420640|Active Comparator|Aerobic Exercise Training|
9988252|NCT01420666|Active Comparator|Maxigesic 325|Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food
9988253|NCT01420666|Active Comparator|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
9988254|NCT01420666|Active Comparator|Ibuprofen|ibuprofen 97.5mg, three tablets four times a day, orally, with food
9988255|NCT01420666|Placebo Comparator|Placebo|Placebo tablets
9988256|NCT01420692|Active Comparator|Gliclazide MR|
9988257|NCT01420692|Active Comparator|Insulin Detemir|Early initiation of insulin detemir in contrast to Gliclazide MR treatment
9988258|NCT01420705||Low birth-weight cohort|Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area
9988259|NCT01420718|Active Comparator|Mineral Trioxide Aggregate|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
9988260|NCT01420718|Experimental|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
9988261|NCT01420744|Experimental|BT086 infusion|
9988262|NCT01420744|Placebo Comparator|1% Human Albumin infusion|
9988263|NCT01420757|Active Comparator|open|open incisional hernia repair
9988264|NCT01420757|Active Comparator|laparoscopic|laparoscopic incisional hernia repair
9988265|NCT01420796|Experimental|Swallowing and breathing exercises|This group will perform both swallowing and breathing exercises for five weeks.
9988266|NCT01420796|Experimental|Swallowing exercises|This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will perform sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
9988267|NCT01420796|Experimental|Breathing exercises|Expiratory Muscle Training will be performed with Threshold® (Respironics HealthScan, Inc, Cedar Grove, Nova Iorque, EUA).
9988268|NCT01420822||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
9988269|NCT01420835|Active Comparator|Without Protocol Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Five points will be chosen to treat stress according to the symptoms and Chinese diagnosis."
9988270|NCT01420835|Active Comparator|Auriculotherapy with protocol|Auriculotherapy with stress protocol points. Five points are indicated for stress (Liver yang1, Liver yang2, Shenmen, Brainstem and Kidney).
9988271|NCT01420835|No Intervention|Control Group|Control Group won't receive any treatment and will be evaluated at the same time and the same way of interventions group
9988272|NCT01420861|Experimental|1000 mg GTx-758|subjects will receive daily doses of 1000 mg GTx-758
9988273|NCT01420887|Experimental|Continuous Passive Motion|Subjects randomized to CPM therapy.
9988274|NCT01420887|Active Comparator|Physical Therapy|Subjects randomized to physical therapy.
9988275|NCT01420900|Active Comparator|ABG II / Trident|
9988276|NCT01420900|Active Comparator|CLS / Trilogy|
9988277|NCT01420913|Active Comparator|Lyrica capsule(Pregabalin 150mg)|
9988278|NCT01420913|Experimental|YHD1119 A(Pregabalin SR 300mg)|
9988279|NCT01420913|Experimental|YHD1119 B(Pregabalin SR 300mg)|
9988280|NCT01420913|Experimental|YHD1119 C(Pregabalin SR 300mg)|
9988281|NCT01420978|Experimental|High volume CSF diversion|The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
9988282|NCT01420978|Active Comparator|Conventional CSF diversion|The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician. Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
9988283|NCT01421004|Experimental|500 mg FMI capsule + 250 mg FMI tablet|BE phase sequence 1= 3 weeks on FMI capsule then 1 week on FMI tablet
9988284|NCT01421004|Experimental|500 mg TKI258 FMI capsule +250 mg FMI tablet|BE phase sequence 2= 3 weeks on FMI tablet then 1 week on FMI capsule
9988285|NCT01421030|Other|quality of life, clinical outcomes and costs|Quality of life, clinical outcomes and costs after two different treatment options in patients and closest relatives
9988286|NCT01421043|Experimental|triazolam liquid oral drops|
9988287|NCT01421043|Active Comparator|triazolam tablets|
9988288|NCT01421069|Experimental|1|
9988289|NCT01421082|Experimental|LVRC Treatment|
9988290|NCT01421095|Experimental|Basal Testing|
9988291|NCT01421108|Experimental|Loss-framed messages|
9988292|NCT01421108|Experimental|gain-framed messages|"Adolescents will randomly assign to three groups: gain-framed message , loss-framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images (6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
9988293|NCT01421121|Experimental|100U EV71 vaccine with adjuvant|120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
9988294|NCT01421121|Experimental|200 U EV71 vaccine with adjuvant|120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
9988295|NCT01421121|Experimental|400U EV71 vaccine with adjuvant|120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
9797103|NCT01586156|Active Comparator|Open Label Carvedilol|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
9988296|NCT01421121|Experimental|200U EV71 vaccine without adjuvant|60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
9797104|NCT01586156|Placebo Comparator|Placebo Arm|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.
9797105|NCT01586195|Experimental|Vemurafenib|Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.
9797106|NCT01586312|Experimental|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
9797107|NCT01586312|Active Comparator|Hyaluronic acid (Durolane)|Intraarticular injection of hyaluronic acid (60 mg)
9797108|NCT01586338|Experimental|Synvisc|Three intra-articular (IA) injections of Synvisc (2.25 ml glass syringe containing 16 mg hylan G-F 20) at intervals of one week. The total duration of observation was 26 weeks.
9797109|NCT01586364|Experimental|Ospemifene 60 mg Oral Tablet|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
9797110|NCT01586624|Experimental|Dose Escalation Phase Cohort 1 (Steady state dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
9797111|NCT01586624|Experimental|Dose Escalation Phase Cohort 2 (Steady state dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
9797112|NCT01586624|Experimental|Dose Escalation Phase Cohort 3 (Steady state dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
9797113|NCT01586624|Experimental|Dose Escalation Phase Cohort 4 (Steady state dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
9797114|NCT01586624|Experimental|Dose Escalation Phase Cohort 5a (Steady state dose of 100 mg OD Vandetanib + 125 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
9797115|NCT01586624|Experimental|Dose Escalation Phase Cohort 5b (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
9797116|NCT01586624|Experimental|Dose Escalation Phase Cohort 6 (Steady state dose of 300 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
9797117|NCT01586624|Experimental|Expansion Phase (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Expansion cohort at the recommended phase 2 dose of vandetanib and selumetinib defined in the escalation phase.
9797118|NCT01586741|Active Comparator|Polypropylene mesh|Reconstruction of the abdominal wall diastasis with insertion of a polypropylene mesh on 30 patients.
9797119|NCT01586741|Active Comparator|quill suture|Reconstruction of the abdominal wall diastasis with double row absorbable suture ( Quill Self-retaining system) on 30 patients.
9797120|NCT01586741|No Intervention|conservative treatment|Regular abdominal exercises workout for three months for 30 patients.
10211720|NCT04249323|Experimental|Part 1: SAD Cohorts A through H CORT113176|Cohorts will receive a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 50-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT113176 dose from the previous cohort in a fasted or fed state; the dose and prandial state will be determined after evaluation of safety and PK data from previous cohorts. Following interim review of PK data, an alternative lipidic formulation may be administered beginning with Cohort B.
10211721|NCT04249323|Placebo Comparator|Part 1: SAD Cohorts A through H Placebo|Cohorts will receive a single dose of placebo matching CORT113176 lipid capsule formulation by mouth on Day 1. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding SAD cohorts receiving CORT113176.
9797121|NCT01586806|Placebo Comparator|Control|
9797122|NCT01586806|Active Comparator|Dexamethasone 1 mg|
9797123|NCT01586806|Active Comparator|Dexamethasone 4 mg|
9797124|NCT01586819|Active Comparator|Botulinum Toxin|The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
9988297|NCT01421121|Placebo Comparator|Placebo|120 infants received 2 doses of placebo 28 days apart.
9878059|NCT00432796|Active Comparator|1|"patients are randomized post-operative to receive either active treatment or placebo.~Active treatment is Dalteparin injectable. Patients randomized to active treatment will receive Dalteparin 5,000 iu or 200 iu/kg once daily depending on the type of surgery they have had."
9878060|NCT00432796|Experimental|2|patients will be randomized post-operative to receive either active treatment or placebo
9878061|NCT00432861|Active Comparator|1|Pancrecarb(R) MS-16 Capsules
9878062|NCT00432861|Placebo Comparator|2|
9878063|NCT00432874|Experimental|1|"Anterior stromal hydration (Wong method)"
9878064|NCT00432874|Active Comparator|2|Traditional lateral wound hydration
9878065|NCT00432900|Active Comparator|Healthy Volunteer|Healthy Volunteers
9878066|NCT00432900|Experimental|Patient|Multiple Sclerosis Patients
9878067|NCT00432913|Active Comparator|1g EPA per day|
9878068|NCT00432913|Active Comparator|2g EPA per day|
9878069|NCT00432913|Placebo Comparator|Placebo|
9878070|NCT00432926|Experimental|1|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
9878071|NCT00432926|Experimental|2|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
9878072|NCT00432926|Active Comparator|3|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
9878073|NCT00433043|Active Comparator|1|CRT and b-blocker uptitration to target dose
9878074|NCT00433043|Active Comparator|2|CRT and continuation of entry b-blocker dose to 6 month evaluation
9878075|NCT00433056|Experimental|1|STI
9878076|NCT00433056|Active Comparator|2|stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
9878077|NCT00433069|Experimental|Intervention|Pioglitazone 15 mg QD + pegylated interferon Alfa-2a 180 μg QW + ribavirin 1000-1200 mg QD for 12 weeks, to be continued to a total of 48 weeks in case of complete early virological response, defined as undetectable serum HCV RNA after 12 weeks of triple therapy
9878078|NCT00433121|Experimental|A|Discontinuation of neuroleptic or anti depressants
9878079|NCT00433173|Placebo Comparator|1|1) Group 1: Placebo
9878080|NCT00433173|Active Comparator|2|2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
9878081|NCT00433173|Active Comparator|3|3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
9878082|NCT00433186|Experimental|A|Mycophenolate
9878083|NCT00433212|Active Comparator|A|Non-invasive respiratory support via nasal intermittent positive pressure ventilation
9878084|NCT00433212|Active Comparator|B|Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
9878085|NCT00433316|Experimental|study|Receiving 10ml of 1% ropivacaine
9878086|NCT00433316|Placebo Comparator|Control|Receiving 10ml of saline
9878087|NCT00433342|Experimental|I|Flucloxacillin
9878088|NCT00433342|No Intervention|II|
9878089|NCT00433394|Experimental|Stratum 1: No Consent for personal identification|Data to be collected for this stratum include histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries.
9878090|NCT00433394|Experimental|Stratum 2: Consent for personal identification - No Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries. No contact for future to ask me to consider taking part in Research Network approved studies
9878091|NCT00433394|Experimental|Stratum 3: Consent for personal identification - Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries Someone from the Childhood Cancer Research Network may contact me in the future to ask me to consider taking part in Research Network approved studies
9878092|NCT00433407|Experimental|trastuzumab|blood sample collected on different days from patients receiving trastuzumab
9878093|NCT00433433|Active Comparator|Favorable - Standard - any PET outcome|ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
9878094|NCT00433433|Experimental|Favorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx2 without further RT (total of 4 cycles!)"
9878095|NCT00433433|Experimental|Favorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions)."
9878096|NCT00433433|Active Comparator|Unfavorable - Standard - Any PET outcome|ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual lesions). FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
9878097|NCT00433433|Experimental|Unfavorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx 4 cycles, without RT (total of 6 cycles)"
9878098|NCT00433433|Experimental|Unfavorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT 30Gy (+boost 6Gy to residual lesions)."
9878099|NCT00433459|Active Comparator|COPP|procarbazine-containing consolidation chemotherapy arm
9878100|NCT00433459|Experimental|COPDAC|procarbazine-free consolidation chemotherapy arm
9878101|NCT00433472|Other|MRI -|"MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI~Procedure/surgery magnetic resonance imaging (MRI)"
9930322|NCT00927030|Placebo Comparator|flavored inert liquid|Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
9930323|NCT00927043||1|
9930324|NCT00927056|Active Comparator|Minimally Invasive Microdiscectomy|
9930325|NCT00927056|Active Comparator|Conventional Open Microdiscectomy|
9930326|NCT00927121|Active Comparator|Group 1 : G_1|G_1: stimulation for 4 - 6 hours a day, 4 tones per sequence
9930327|NCT00927121|Active Comparator|Group 2 :G_2|G_2: stimulation for 4 - 6 hours a day with 12-tone sequences
9930328|NCT00927121|Active Comparator|Group3 : G_3|G_3: stimulation for 4 - 6 hours a day, 4 tones per sequence with a signal controlled by EEG measurement
9930329|NCT00927121|Active Comparator|Group 4 : G_4|G_4: stimulation for 1 hour a day, 4 tones per sequence
9930330|NCT00927121|Placebo Comparator|Group5 : G_5|G_5: stimulation with placebo-tone
9930331|NCT00927147|Experimental|BNCT plus cetuximab|Patients treated with BNCT followed by cetuximab administration
9930332|NCT00927173|Sham Comparator|Sham|Sham treatment
9930333|NCT00927173|Active Comparator|Active|Active Deep Transcranial Magnetic Stimulation treatment
9930334|NCT00927199|Experimental|High-Oleic Canola Oil|
9930335|NCT00927199|Experimental|High-Oleic Canola/Flaxseed Oil Blend|
9930336|NCT00927199|Active Comparator|Western Diet|
9930337|NCT00927212|Experimental|Group 1|2% AS101 ointment
9930338|NCT00927212|Experimental|Group 2|4% AS101 ointment
9930339|NCT00927225|Active Comparator|active|subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
9930340|NCT00927225|Placebo Comparator|placebo|subcutaneous wound infiltration with 50 mL saline
9930341|NCT00927238|Experimental|XL TDR|The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
9930342|NCT00927238|Other|Outcomes from lumbar fusion study|
9930343|NCT00927277|Placebo Comparator|placebo laser|inactive light on the laser device.
9930344|NCT00927277|Active Comparator|Erchonia (R) LipoLASER PL|The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
9930345|NCT00927290|Active Comparator|1|Pioglitazone, 16 weeks before and during antiviral combination therapy
9930346|NCT00927290|Placebo Comparator|2|Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
9930347|NCT00927303||Group 1|Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
9930348|NCT00927303||group 2|intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
9930349|NCT00927303||group 3|intervention 2 sequence of observers: 1,2,1,2
9930350|NCT00927303||group 4|intervention 2 sequence of observers: 2,1,2,1
9930351|NCT00927303||group 5|intervention 1 sequence of observers 1,1,2,2
9930352|NCT00927303||group 6|intervention 1 sequence of observers 2,2,1,1
9930353|NCT00927303||group 7|intervention 2 sequence of observers: 1,1,2,2
9930354|NCT00927303||group 8|intervention 2 sequence of observers: 2,2,1,1
9930355|NCT00927316|Active Comparator|Active arm|E. coli 83972 bacteriuria
9930356|NCT00927316|Placebo Comparator|Placebo arm|Monitoring
9930357|NCT00927329|Experimental|dust mite|
9930358|NCT00927342|Active Comparator|Vivostat|
9930359|NCT00927342|Active Comparator|BioGlue|
9930360|NCT00927381||Severe envenomation|Patients with a calculated severity score of 5 or 6 were included in this group.
9930361|NCT00927381||Minimal/Moderate Envenomation|Severity Score less than 5
9930362|NCT00927407|Experimental|Malathion gel 0.05%|Malathion gel 0.5% topical treatment for head lice
9930363|NCT00927407|Active Comparator|Malathion lotion 0.5%|Malathion lotion 0.5% treatment for head lice
9930364|NCT00927420||1|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
9930365|NCT00927433|No Intervention|Standard care|Patients received standard education about fatigue by clinicians.
9930366|NCT00927433|Experimental|Education arm|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions.
9930367|NCT00927446||Endoscopy screening|Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.
9930368|NCT00927459|Experimental|PRO-040201|PRO-040201 with placebo control in each cohort
9930369|NCT00927459|Placebo Comparator|Placebo|PRO-040201 with placebo control in each cohort
9935406|NCT03789201|Experimental|Healthy Volunteers|thematic permission to use non-invasive techniques regarded as having minimal risk in healthy individuals, such as, MRI, EEG, EMG, lowfrequency stimulation(= 1 Hz), electrical stimulation of the skin to mimic thesomatosensory artifact of TMS, and behavioral tests
9878102|NCT00433498|Experimental|Carboplatin/cisplatin and Etoposide with Pravastatin|
9878103|NCT00433498|Placebo Comparator|Carboplatin/cisplatin and Etoposide with Placebo|
9878104|NCT00433563|Experimental|Once daily radiotherapy|Once daily radiotherapy
9878105|NCT00433563|Active Comparator|Twice daily radiotherapy|Twice daily radiotherapy
9878106|NCT00433576|Experimental|Treatment (resveratrol, colorectomy)|"STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm colorectal adenocarcinoma histology and require surgical resection continue on study stage 2.~STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day 9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes."
9878107|NCT00433615|Experimental|1|
9878108|NCT00433615|Experimental|2|
9878109|NCT00433641|Placebo Comparator|1|placebo tablet
9878110|NCT00433641|Experimental|2|sibutramine
9878111|NCT00433641|Experimental|3|sibutramine
9878112|NCT00433693|Experimental|1|
9878113|NCT00433706|Experimental|Control position by 3DOBI daily|
9878114|NCT00433706|Active Comparator|Standard imaging|
9878115|NCT00433719|Experimental|1|Combivir, efavirenz for 12 months
9878116|NCT00433719|Placebo Comparator|2|Placebo for 2 months followed by Combivir and efavirenz for 10 months
9878117|NCT00433797|Experimental|1|Tomato
9878118|NCT00433797|Experimental|2|Multi-diet
9878119|NCT00433797|Active Comparator|3|Control
9878120|NCT00433849|Experimental|1|
9878121|NCT00433849|Experimental|2|
9878122|NCT00433888|Experimental|1|
9878123|NCT00433888|Experimental|2|
9878124|NCT00433927|Active Comparator|Arm A|FOLFIRI plus Cetuximab
9878125|NCT00433927|Active Comparator|Arm B|FOLFIRI plus Bevacizumab
9878126|NCT00433940||Infantile Hemangioma Patients|Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
9878127|NCT00434005|Experimental|Diesel Exhaust|
9878128|NCT00434005|Sham Comparator|Filtered Air|
9878129|NCT00434096|Experimental|1|
9878130|NCT00434096|Placebo Comparator|2|
9878131|NCT00434135|Experimental|A|Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks
9878132|NCT00434135|Active Comparator|B|Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks
9878133|NCT00434174|Experimental|everolimus + Pemetrexed - daily|Daily treatment
9878134|NCT00434174|Experimental|everolimus + Pemetrexed - weekly|Weekly treatment
9878135|NCT00434239|Experimental|Treatment: Lenalidomide and Ancestim|Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
9878136|NCT00434317|Experimental|ZOL446|
9878137|NCT00434408|Experimental|1|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
9878138|NCT00434408|Experimental|2|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
9878139|NCT00434408|Active Comparator|3|dry cord care
9878140|NCT00434447|Experimental|Zoledronic Acid|ZOL446
9878141|NCT00434460||1|Patients receiving invasive mechanical ventilation > 48 hours.
9878142|NCT00434525|Experimental|1 Sleeve gastrectomy with omentectomy|
9878143|NCT00434525|Active Comparator|2 Sleeve gastrectomy|
9878144|NCT00434551||1|Patients with suspected Crohn's disease
9878145|NCT00434616|Placebo Comparator|1|saline injections
9878146|NCT00434616|Active Comparator|2|autologous bone marrow transplantation into the ischemic leg
9878147|NCT00434655|Active Comparator|1 LAP BAND|
9878148|NCT00434655|Experimental|2 Sleeve gastrectomy|
9878149|NCT00434824|Active Comparator|Arm 1|Oral testosterone undecanoate (Andriol)
9878150|NCT00434824|Placebo Comparator|Arm 2|Placebo
9878151|NCT00434889||1|Memory problems
9878152|NCT00434889||2|No memory problems
9878153|NCT00434941|Experimental|Radiotherapy + Capecitabine|Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
9878154|NCT00434980|Experimental|Treatment|Participant and family take part in FCA treatment program.
9878155|NCT00435032|Active Comparator|1|Early appendectomy
9878156|NCT00435032|Active Comparator|2|Interval appendectomy
9878157|NCT00435071|Active Comparator|1|
9878158|NCT00435071|Active Comparator|2|
9878159|NCT00435084|Experimental|Single-arm mono therapy|APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
9878160|NCT00435123|Active Comparator|A|Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
9878161|NCT00435123|Placebo Comparator|B|Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64
9878162|NCT00435149|Active Comparator|1|
9878163|NCT00435149|Active Comparator|2|
9878164|NCT00435227|Experimental|Motavizumab|Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
9878165|NCT00435227|Placebo Comparator|Placebo|Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.
9878166|NCT00435253|Experimental|BLVR Treatment|BLVR Treatment
9878167|NCT00435266|Experimental|1|Remote ischemic preconditioning
9878168|NCT00435266|No Intervention|2|
9878169|NCT00435279|Experimental|Eszopiclone|
9878170|NCT00435279|Experimental|Placebo|
9878171|NCT00435292|Experimental|flavocoxid 250 mg|flavonoid mixture
9878172|NCT00435292|Active Comparator|flavocoxid 500 mg|flavonoid mixture
9878173|NCT00435292|Active Comparator|naproxen|nonsteroidal antiinflammatory drug
9878174|NCT00435331|Experimental|1|Open Label
9878175|NCT00435357|Experimental|mobile-bearing TKA|
9878176|NCT00435357|Active Comparator|fixed- bearing TKA|
9878177|NCT00435383||Observational|Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics.
9930370|NCT00927498|Active Comparator|Arm A Daunorubicin and Cytarabine|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
9930371|NCT00927498|Experimental|Arm B Daunorubicin and Cytarabine and Mylotarg|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
9930372|NCT00927511|Experimental|A - Dose Tritation|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity
9930373|NCT00927511|Active Comparator|B- Control|Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
9930374|NCT00927524|Active Comparator|Apidra (insulin glulisine)|Administration of Apidra at three meals during a 24 hour period.
9930375|NCT00927524|Active Comparator|70/30 insulin|Administration of 73/30 insulin at three meals during a 24 hour period.
9930376|NCT00927537||Group 1|
9930377|NCT00927537||Group 2|
9930378|NCT00927550|Experimental|lithium plus usual care|
9930379|NCT00927550|Active Comparator|usual care without lithium therapy|
9930380|NCT00927602|Experimental|fondaparinux|
9930381|NCT00927615|Experimental|intracoronary abciximab|intracoronary administration of abciximab (0.25 mg/kg body weight)
9930382|NCT00927615|Active Comparator|intravenous abciximab|intravenous administration of abciximab (0.25 mg/kg body weight)
9930383|NCT00927628||Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
9930384|NCT00927654|Experimental|Iloprost|
9930385|NCT00927654|Placebo Comparator|Isotonic Sodium Chloride solution 0.9 %|
9930386|NCT00927667|Experimental|Arm 1|
9930387|NCT00927667|Experimental|Arm 2|
9930388|NCT00927667|Experimental|Arm 3|
9930389|NCT00927667|Experimental|Arm 4|
9930390|NCT00927667|Experimental|Arm 5|
9930391|NCT00927680||Colorectal cancer cases|
9930392|NCT00927680||Controls|
9930393|NCT00927693|Experimental|Scan group|"Scan group undergoes complete cardiac risk assessment and CAC scanning at baseline."
9930394|NCT00927693|No Intervention|No scan group|"No scan group undergoes only complete cardiac risk assessment (without CAC scan) at baseline."
9797125|NCT01586819|Active Comparator|Chemical Peel Only|"After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly."
9797126|NCT01586897|Experimental|Use of Medication Metronome|Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
9797127|NCT01586897|Active Comparator|Usual Care|PCPs allocated to the control arm will continue with usual care practices for laboratory monitoring.
9797130|NCT01586962|Experimental|Upper Respiratory Infections|
9797131|NCT01586975|Active Comparator|Clopidogrel 75 mg|Clopidogrel 75 mg daily
9797132|NCT01586975|Active Comparator|Aspirin 81 mg|open-label Aspirin 81 mg daily
9797133|NCT01586975|Active Comparator|Aspirin > 300mg|open-label Aspirin over 300 mg daily
9797134|NCT01587001|Active Comparator|Oral N-acetyl-cysteine|oral NAC 900mg three times daily for 8 weeks
9797135|NCT01587001|Placebo Comparator|Matching Placebo|oral placebo three times daily for 8 weeks
9797136|NCT01587027|Active Comparator|Sequence A|Aminophylline, Methazolamide, Aminophylline and Methazolamide
9797137|NCT01587027|Active Comparator|Sequence B|Methazolamide, Aminophylline, Aminophylline and Mathazolamide
9797138|NCT01587079|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
9797139|NCT01587079|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
9797140|NCT01587079|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
9797141|NCT01587079|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
9797142|NCT01587079|Experimental|PT003 (Dose 5)|PT003 MDI Dose 5
9797143|NCT01587079|Experimental|PT001|PT001 MDI
9797144|NCT01587079|Experimental|PT005|PT005 MDI
9797145|NCT01587079|Active Comparator|Spiriva® Handihaler®|Tiotropium Bromide
9797146|NCT01587105|No Intervention|Control|Usual Care Group
9797147|NCT01587105|Experimental|Comprehensive Care Management Service|Care Coordination through the Comprehensive Care Management Service at Seattle Children's Hospital
9797148|NCT01587118|Experimental|antidepressant plus asenapine|adjunctive asenapine
9800100|NCT01679236|Active Comparator|Interactive Learning for Smokers|Interactive Learning for Smokers (ILS) is a 7-week intervention that provides a closely matched active control group for MTS, but with substantive education and skills training for smoking cessation. To this end, ILS combines elements of two smoking cessation programs, the American Lung Association, Freedom from Smoking program and The Mayo Clinic Nicotine Dependence Center program. ILS participants were asked to practice 30 minutes of silent non-directed walking per day throughout the intervention and were instructed to use non-directed walking for relaxation, stress reduction and as a strategy for managing urges and withdrawal symptoms.
9800101|NCT01679301|Active Comparator|Continuous dose|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator.
9878178|NCT00435396|Experimental|Group A|
9878179|NCT00435474|Active Comparator|1|Silver product
9878180|NCT00435474|Experimental|2|Honey product
9878181|NCT00435513||Transsexual group|Female-to-male and male-to-female transsexuals
9878182|NCT00435513||Controls|Healthy blood donors
9878183|NCT00435617|Experimental|A|Hand Mentor
9878184|NCT00435630|Other|1|Completing simulator training sessions
9878185|NCT00435643|Active Comparator|A|10 patients with severe OSAS (Apnea Hypopnea Index of more than 30 events per hour of sleep) were treated with nCPAP for three months and all mentioned measurements above were repeated.
9878186|NCT00435695|Active Comparator|GSK163090|one infusion only
9878187|NCT00435708|No Intervention|1|
9878188|NCT00435708|Experimental|2|5 portions fruit and vegetables/day
9878189|NCT00435760|Active Comparator|Tiotropium|1 puff, 1 day treatment
9878190|NCT00435760|Placebo Comparator|Placebo|Tiotropium or Aclidinium Placebo, 1 day treatment
9878191|NCT00435760|Experimental|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
9878192|NCT00435799|Active Comparator|A|
9878193|NCT00435864|Other|allogeneic donor from a file|
9878194|NCT00435864|Other|Registry geno-identical donor family|
9878195|NCT00435864|Other|transplantation of HSCs derived from placental blood|
9878196|NCT00435890|No Intervention|1|No triage liaison physician
9878197|NCT00436020|Active Comparator|1|Active
9878198|NCT00436020|Placebo Comparator|2|Sham TMS
9878199|NCT00436033|Placebo Comparator|Placebo|
9878200|NCT00436033|Experimental|Minalcipran|
9878201|NCT00436098|Experimental|1|physical training
9878202|NCT00436098|No Intervention|2|
9878203|NCT00436137|Experimental|1|Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach
9878204|NCT00436150|Experimental|A|Participants will receive interpersonal therapy-based treatment
9878205|NCT00436150|Active Comparator|B|Participants will receive standard care
9878206|NCT00436176|Experimental|1|Intervention clinicians receive monthly performance reports, cultural competency training, and health navigation training
9878207|NCT00436176|No Intervention|2|Control clinicians function within the context of the generic chronic care model.
9878208|NCT00436241|Experimental|1|
9878210|NCT00436293|Experimental|1|Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
9878211|NCT00436293|Active Comparator|2|Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
9878212|NCT00436306|Experimental|Individualized Intervention: stage-matched/tailored counseling|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
9878213|NCT00436306|Placebo Comparator|Control: Enhanced usual care counseling|The Enhanced Usual Care arm was the control group. It provided computer-based information regarding contraceptive methods, but was not individualized or tailored to the participant stage of change.
9878214|NCT00436319|No Intervention|1|In the control group (group 1) the initiation of the ovarian stimulation will be realized according to the typical long luteal protocol, two weeks after the initiation of the GnRH agonist administration.
9878215|NCT00436319|Other|2|In the study group (group 2) the initiation of the ovarian stimulation will be effectuated on the second day of the menstrual period.
9878216|NCT00436358||Group A|IS case deemed children
9878217|NCT00436358||Group B|LRTI-related post-neonatal deaths deemed Children
9878218|NCT00436358||Group C|A random sample of children from an annual birth cohort within the electronic IMSS dataset
9878219|NCT00436358||Group D|All children from a single annual birth cohort with IS identified in their electronic IMSS data
9878220|NCT00436358||Group E|A sample of children from the electronic IMSS dataset selected to match the selected IS cases on age, gender, and hospital of birth.
9878221|NCT00436371|Experimental|1|Amisulpride 400-800mg per day on a twice-a-day regimen
9878222|NCT00436423|Experimental|1|Gemcitabine with TS-1
9878223|NCT00436527|Other|1|
9878224|NCT00436540|Active Comparator|1|clobetasol propionate (Clobex®) spray
9878225|NCT00436540|Active Comparator|2|clobetasol propionate (Olux®) foam
9878226|NCT00436579|Experimental|Arm I (higher-dose enzyme inhibitor therapy)|Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
9878227|NCT00436579|Active Comparator|Arm II (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate three times daily on days 15-36.
9878228|NCT00436579|Active Comparator|Arm III (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate twice daily on days 15-36. (closed to accrual as of 4/29/2009)
9878229|NCT00436592|Experimental|1|
9878230|NCT00436631|Experimental|diet|
9935407|NCT03785210|Experimental|1/Arm 1|Nivolumab, tadalafil and oral vancomycin
9935408|NCT03783403|Experimental|CC-95251|
9935409|NCT03783403|Experimental|CC-95251 in combination with rituximab|
9935410|NCT03783403|Experimental|CC-95251 in combination with cetuximab|
9797149|NCT01587274|Active Comparator|Opioid|Naproxen + opioid
9797150|NCT01587274|Active Comparator|Skeletal muscle relaxant|Naproxen + skeletal muscle relaxant
9797151|NCT01587274|Active Comparator|Naproxen alone|Naproxen + placebo
9797152|NCT01587651|Experimental|Prasugrel Maintenance Dose|Prasugrel 10 mg QD MD
9797153|NCT01587651|Active Comparator|Ticagrelor Maintenance Dose|Ticagrelor 90 mg twice-daily (BID) MD
9797154|NCT01587651|Experimental|Prasugrel Loading Dose|Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)
9797155|NCT01587703|Experimental|Single and Repeat Dose finding cohort|All subjects will follow a 3+3 dose escalation design for GSK525762 and the dose will be escalated based on all available data, including PK data and the safety profile of prior cohorts, as well as the recommended dose from the Neuenschwander- Continuous Reassessment Method (N-CRM) design.
9797156|NCT01587703|Experimental|Expansion Cohort|Up to 150 additional subjects with NMC and other solid tumors may be enrolled in expansion cohorts. The recommended Phase 2 (Part 2) dose (RP2D) of GSK525762 will be determined based on the MTD or biologically active dose (example: clinical response), the safety profile and available pharmacodynamic data generated from all subjects in Parts 1
9797157|NCT01587703|Experimental|Besylate Sub study|Tablet and amorphous tablet in one of the two sequences (ABCD or BACD). Where Treatment A: RP2D/MTD as amorphous free-base tablet + low dose stable isotope in solution, fasted Treatment B: RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment C: half to one-third of RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment D: RP2D/MTD as besylate tablet, fed
9797158|NCT01587885|Experimental|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
9797159|NCT01587885|Active Comparator|Omeprazole 20 mg|Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
9797160|NCT01587898|Experimental|0.5mg GSK1278863|Once daily
9797161|NCT01587898|Experimental|2mg GSK1278863|Once daily
9797162|NCT01587898|Experimental|5mg GSK1278863|Once daily
9797163|NCT01587898|Experimental|Placebo|Once daily
9797164|NCT01587924|Experimental|0.5 mg GSK1278863|once daily
9797165|NCT01587924|Experimental|2 mg GSK1278863|once daily
9797166|NCT01587924|Experimental|5 mg GSK1278863|once daily
9797167|NCT01587924|Active Comparator|rhEPO|as required
9797168|NCT01587950|Placebo Comparator|Sterile water|Participants to receive 250 microlitres (μL) of sterile water.
9797169|NCT01587950|Experimental|Potassium nitrate 5% solution|Participants to receive 250 μL of potassium nitrate 5% solution.
9797170|NCT01587950|Experimental|Potassium nitrate 2.5% solution|Participants to receive 250 μL of potassium nitrate 2.5% solution.
9797171|NCT01587989|Active Comparator|A Methotrexate|
9797172|NCT01587989|Experimental|B Methotrexate Placebo|
9797173|NCT01588106||Test group|patients using CONTOUR Next USB
9797174|NCT01588106||Control group|patients using standard CONTOUR
9797175|NCT01588158|Active Comparator|Vicodin 5/325 mg|Half of the patients will be randomized to Vicodin
9797176|NCT01588158|Active Comparator|Acetaminophen 325 mg|Half of the patients will be randomized to Acetaminophen
9797177|NCT01588184|Experimental|Breast Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
9797178|NCT01588184|Experimental|Ovarian Cancer or Peritoneal Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
9797179|NCT01588184|Experimental|Renal Cell Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
9797180|NCT01588184|Experimental|Colorectal Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
9797181|NCT01588184|Experimental|Non-Squamous, Non-Small Cell Lung Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
9797182|NCT01588184|Experimental|Glioblastoma Multiforme|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
9797183|NCT01588197|Experimental|ACC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy.~The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the rACC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
9878231|NCT00436657|Experimental|Surgery + CHPP of Escalating Cisplatin|Abdominal Surgery + CHPP of Escalating Cisplatin (Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.)
9878232|NCT00436696||Ancillary-correlative (SNP analysis)|DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
9878233|NCT00436800|Experimental|1|Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
9878234|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (DB period)|Participants received cladribine tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 milligram per kilogram (mg/kg) along with interferon (IFN)-beta therapy (Rebif® new formulation [RNF] 44 mcg three times a week, subcutaneously; Avonex® 30 microgram (mcg) every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the Double blind period (DBP) of 96 weeks.
9878235|NCT00436826|Placebo Comparator|Placebo, IFN-beta (DB period)|Participants received matching placebo tablets orally over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the DB period of 96 weeks.
9878236|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the open label (OL) extension (Ext.) period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
9878237|NCT00436826|Placebo Comparator|Placebo, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received placebo initially and completed DB period entered in the OL Ext. period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
9878238|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (Safety follow up)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
9878239|NCT00436826|Placebo Comparator|Placebo, IFN-beta (Safety follow up)|Participants who received placebo initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
9878240|NCT00436839|Experimental|1|Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
9878241|NCT00436839|Active Comparator|2|Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
9878242|NCT00436865|Other|PCOS|PCOS women receiving weight loss intervention
9878243|NCT00436865|Other|Control|Non-PCOS women receiving weight loss intervention
9878244|NCT00436878|Experimental|Portion Size|Each experiment manipulated food portion size of beverages, entrees, and side dishes
9878245|NCT00436930|Experimental|Arm I|Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
9878246|NCT00436930|Experimental|Arm II|Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
9878247|NCT00436943||A|Smokers
9878248|NCT00436995|Other|Single|
9930395|NCT00927706|Experimental|Immediate intervention|Subjects and their caregivers randomized to this arm receive the intervention immediately after baseline data is collected.
9878249|NCT00437060||Ancillary/Correlative (neurocognitive assessment, biomarkers))|"Patients complete neurocognitive tests to assess thinking, memory, attention, and concentration. The baseline test is administered during the consolidation phase of chemotherapy and further tests are done at 1 year from baseline and 1 year after* the completion of study therapy.~Patients undergo blood and cerebrospinal fluid collection periodically for biomarker, genotypic polymorphisms, and pharmacokinetic analysis. Patients undergo MRI diffusion-tensor imaging to correlate imaging with neuropsychological outcomes."
9878250|NCT00437086|Experimental|PS-341|Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
9878251|NCT00437099|Experimental|1|subjects with BPD receiving Omacor 1.680 mg/d
9878252|NCT00437099|Experimental|2|BPD patients randomized to Omacor 3.360 mg/d
9878253|NCT00437099|Placebo Comparator|3|patients with BPD randomized to Placebo
9878254|NCT00437151|Active Comparator|1|More frequent than normal office visits
9878255|NCT00437151|Active Comparator|2|Electronic reminders (voice, e-mail, text messages)
9878256|NCT00437151|Active Comparator|3|Parental involvement / intervention reminders
9878257|NCT00437151|Active Comparator|4|No intervention or reminders
9878258|NCT00437190|Active Comparator|Anterior Cervical Discectomy Fusion|
9878259|NCT00437190|Experimental|BRYAN Cervical Disc Prosthesis|BRYAN Cervical Disc Prosthesis is a cervical intervertebral disc prosthesis designed to provide for motion like the normal cervical functional spinal unit.
9878260|NCT00437216||1|Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®
9878261|NCT00437216||2|Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment
9878262|NCT00437229|Experimental|Subjects in Part A|In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily [QD] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily [BID] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).
9878263|NCT00437229|Experimental|Subjects in Part B|In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
9878264|NCT00437255|Active Comparator|1|Clobex® Spray
9878265|NCT00437255|Active Comparator|2|Taclonex® Ointment
9930396|NCT00927706|Experimental|Delayed Intervention|Subjects and their caregivers who are randomized to this group will receive the intervention after baseline measurements are administered twice (6 weeks apart).
9930397|NCT00927732|Experimental|hydroquinidine|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
9930398|NCT00927732|Placebo Comparator|capsules of sugar|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
9930399|NCT00927745|Experimental|With AutoFlow|Assist-controlled ventilation with activation of AutoFlow mode
9930400|NCT00927745|Active Comparator|Without AutoFlow|Assist-controlled ventilation without activation of AutoFlow mode
9930401|NCT00927771|Experimental|Azelaic Acid|
9930402|NCT00927771|Active Comparator|Hydroquinone|
9930403|NCT00927797|Experimental|Immunochemotherapy, Maintencance|
9930404|NCT00927836|Experimental|AX200|
9930405|NCT00927836|Placebo Comparator|Placebo|
9930406|NCT00927875|Experimental|All Subjects|
9930407|NCT00927966|Experimental|RAD001 in combination with figitumumab|
9930408|NCT00927979|Experimental|Ropivacaine|
9930409|NCT00927979|Placebo Comparator|Water for injection|
9930410|NCT00928005|Active Comparator|Weight loss diet|Participants will follow a low-calorie, low-fat weight loss diet for 6 months.
9930411|NCT00928005|Active Comparator|Weight loss diet plus exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
9930412|NCT00928044||control groups|They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded.
9935411|NCT03783143||Clinical Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
9935412|NCT03783143||Cross-sectional Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
9878266|NCT00437307|Active Comparator|1|Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.
9878267|NCT00437307|No Intervention|2|Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.
9878268|NCT00437320|Experimental|1|
9878269|NCT00437320|Placebo Comparator|2|
9878270|NCT00437346|Active Comparator|Group A|Patients is given thorough information based on the tests taken plus medical treatment.
9878271|NCT00437346|Active Comparator|Group B|Patients receive simple written information based on the tests taken plus medical treatment.
9878272|NCT00437359|Other|Fareston|Toremifene citrate: 40-mg tablets by mouth once daily.
9878273|NCT00437359|Other|Arimidex|Anastrozole: 1-mg tablets by mouth once daily.
9878274|NCT00437372|Experimental|Sunitinib plus Radiation|Sunitinib plus Radiation
9878275|NCT00437385|Active Comparator|1|Continuation-Medication with Antidepressants (after WBS Guidelines)
9878276|NCT00437385|Experimental|2|Continuation-ECT with Antidepressants
9878277|NCT00437385|Experimental|3|"Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP)"
9878278|NCT00437411|Experimental|Workshop|Affective Self Awareness intervention
9878279|NCT00437411|No Intervention|Control|Waiting-list control.
9878280|NCT00437424|Experimental|1|
9878281|NCT00437437|Experimental|1|
9878282|NCT00437463|Experimental|1|Ramipril
9878283|NCT00437463|No Intervention|2|
9878284|NCT00437476|Experimental|A|LPV/r + selected NRTIs for 26 weeks, followed by LPV/r monotherapy and anti HCV drugs for 48 weeks. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
9878285|NCT00437476|Active Comparator|B|LPV/r+ selected NRTIs for 24 weeks, followed by the same HAART and anti-HCV drugs for 48 weeks. At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decision. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
9878286|NCT00437502|Experimental|tumor peptide vaccine|2 cohorts: High and low dose tumor peptide vaccine
9878287|NCT00437567|Active Comparator|Prebiotics|Babies randomized to this arm will receive galacto-oligosaccharide supplements
9878288|NCT00437567|Placebo Comparator|Placebo|Babies randomized to this arm will receive placebo
9878289|NCT00437606|Experimental|1|
9878290|NCT00437606|Experimental|2|
9878291|NCT00437606|Experimental|3|
9878292|NCT00437619|Experimental|1|
9878293|NCT00437632|Experimental|Subjects in Cohort-1 of Section 1|Subjects will be randomized to receive either GSK598809 10 mg or Placebo.
9878294|NCT00437632|Experimental|Subjects in Cohort-2 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
9878295|NCT00437632|Experimental|Subjects in Cohort-3 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
9878296|NCT00437632|Experimental|Subjects in Cohort-4 of Section 1|Subjects will be randomized to receive either GSK598809 40 mg or Placebo.
9878297|NCT00437632|Experimental|Subjects in Cohort-5 of Section 2|Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
9878298|NCT00437632|Experimental|Subjects in Cohort-6 of Section 3|Subjects will receive caffeine on day -1 and after randomization subject will either receive GSK598809 or Placebo on Day 1. After washout period of 1-week subject will either receive GSK598809 or Placebo for 28 days.
9878299|NCT00437671|Experimental|Entered study|
9878300|NCT00437684|Experimental|A|LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
9878301|NCT00437684|Active Comparator|B|LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
9878302|NCT00437723|Experimental|1|
9878303|NCT00437723|No Intervention|2|
9878304|NCT00437736|Experimental|Single arm dose escalation|
9878305|NCT00437749|Active Comparator|CBT-1|
9878306|NCT00437749|Placebo Comparator|Placebo|
9878307|NCT00437762|Experimental|1|Botulinum Toxin A Injection
9878308|NCT00437762|Placebo Comparator|2|Placebo injection
9997194|NCT01506752|Active Comparator|E2020 improved 10 mg with water|
9997195|NCT01506752|Active Comparator|E2020 current 10 mg with water|
9878309|NCT00437827|Active Comparator|1|Each subject in this arm will receive depression therapy similar to that used by the Star*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Am J Psychiatry 2006; 163:1905-1917)
9878310|NCT00437827|Experimental|2|Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.
9878311|NCT00437840|Experimental|Treatment Arm A|In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
9878312|NCT00437840|Experimental|Treatment Arm B|In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
9878313|NCT00437840|Experimental|Treatment Arm C|In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
9878314|NCT00437840|Experimental|Treatment Arm D|In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
9878315|NCT00437892|Experimental|Atorvastatin and lipid lowering diet|
9878316|NCT00437892|Active Comparator|lipid lowering diet|
9878317|NCT00437931||A|patients with subclinical hypothyroidism
9878318|NCT00437931||B|patients with subclinical hyperthyroidism
9878319|NCT00437931||C|patient with normal thyroid function.
9878320|NCT00437957|Experimental|Temazolomide, Valproic Acid and Radiation|Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
9878321|NCT00437970|Active Comparator|A|Arm A- Metformin
9878322|NCT00437970|Active Comparator|B|Arm B- Pioglitazone
9878323|NCT00438009|Experimental|CAVATAK|
9878324|NCT00438022||1|Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)
9878325|NCT00438022||2|Group 2 will include participants with AD and recurring HSV infections but without EH
9878326|NCT00438022||3|Group 3 will include participants with AD but without EH or HSV infection
9878327|NCT00438022||4|Group 4 will include participants in good general health without AD, EH, or HSV infection
9878328|NCT00438048|Active Comparator|a,b|Compare Pilocarpine and Artificial saliva
9878329|NCT00438087|Placebo Comparator|2|placebo versus methylprednisolone
9878330|NCT00438087|Experimental|1|placebo versus methylprednisolone
9878331|NCT00438113|Active Comparator|Aggressive Blood Pressure control|"The experimental arm will receive open label therapy to achieve a target systolic blood pressure less than or equal to 120 mmHg.~If the average BP is found to be > 120 mmHg at the baseline, telephone or clinic followup visits, treatment will be recommended based on the following regimen (For details, please see Appendix 4):~Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od. Step 3 - Addition of Atenolol 50 mg po od. Step 4 - Addition of Norvasc 2.5-10 mg po od. Step 5 - Addition of Terazosin 1 mg po od."
9878332|NCT00438113|No Intervention|Standard Blood Pressure control|Treatment will be carried out as per the CHEP guidelines. These patients may require ACEi or ARBs for their treatment. No changes to their drug regimen will be made as long as BP measurements are congruent with current guidelines. These modifications will be made as per standard practice by the physician who is primarily involved with their care (this may be a family physician or a specialist, depending on the patient). Patients with diabetes in the standard arm will be treated to a target BP of <130/80 as per the CHEP guidelines.
9878333|NCT00438152|Active Comparator|Invirase® tablets|
9878334|NCT00438152|Active Comparator|Kaletra® tablets|
9878335|NCT00438165|No Intervention|1|Control group
9878336|NCT00438165|Experimental|2|Nurse home visits
9878337|NCT00438243|Placebo Comparator|1|1 drop affected eye twice daily.
9878338|NCT00438243|Experimental|2|Bromfenac (Xibrom) 1 drop to affected eye twice a day.
9878339|NCT00438282|No Intervention|1|Control group
9878340|NCT00438282|Experimental|2|Paraprofessional home visits
9878341|NCT00438282|Experimental|3|Nurse home visitation
9878342|NCT00438308||1|Subjects who begin therapy immediately after fracture.
9878343|NCT00438308||2|Subjects delay therapy for 3 weeks after injury.
9878344|NCT00438321|Placebo Comparator|Placebo|Placebo injection, gel and pill
9878345|NCT00438321|Active Comparator|Testosterone only|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
9878346|NCT00438321|Active Comparator|Testosterone and Estrogen|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
9878347|NCT00438347||group 1|Intervention Group- aerobic exercise
9878348|NCT00438347||group 2|Control Group- stretching and toning
9878349|NCT00438425|Experimental|Intensive Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 7 visits during a 6-month period with the study dietitian.
9878350|NCT00438425|Experimental|Routine Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 2 visits during a 6-month period with the study dietitian.
9878351|NCT00438425|Active Comparator|Control|Advice focused on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
9878352|NCT00438477|Experimental|Injection Methods|One injection site with radioactive tracer intraparenchymal/peritumoral (around the tumor), and other subareolar (around the nipple)
9878353|NCT00438516|No Intervention|1|Control group
9878354|NCT00438516|Experimental|2|Nurse home visitation
9878355|NCT00438555|Experimental|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
9878356|NCT00438555|Experimental|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
9878357|NCT00438555|No Intervention|Control group|control group, no intervention, medical follow up only
9878358|NCT00438568|Placebo Comparator|1|saline
9878359|NCT00438568|Experimental|2|10 Units
9878360|NCT00438568|Experimental|3|20 Units
9878361|NCT00438594|No Intervention|Control group|Control group
9878362|NCT00438594|Experimental|Paraprofessional home visits|home visitation by Paraprofessional
9878363|NCT00438594|Experimental|Nurse home visits|home visitation by Nurse
9878364|NCT00438607|Other|1|BIIB014 at MTD from Part A
9878365|NCT00438607|Other|2|BIIB014 at dose immediately below MTD from Part A
9878366|NCT00438607|Placebo Comparator|3|
9878367|NCT00438698|Experimental|Low Glycemic Index Diet|Diet with low glycemic index carbohydrates
9878368|NCT00438698|Active Comparator|High Fiber Diet|Diet with high cereal fibre choices
9878369|NCT00438763||1|Subjects using the neoprene splint.
9878370|NCT00438763||2|Subjects using the orthoplast splint.
9878371|NCT00438776|Active Comparator|olanzapine|active zyprexa (olanzapine)
9878372|NCT00438776|Placebo Comparator|sugar pill|Placebo (fake pill)
9878373|NCT00438828|Experimental|Dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
9878374|NCT00438867|Experimental|1|
9878375|NCT00438867|Experimental|2|
9878376|NCT00438867|Placebo Comparator|3|
9878377|NCT00438893|Other|A portfolio of cholesterol-lowering foods|Dietary advice to consume a dietary portfolio of cholesterol-lowering foods
9878378|NCT00438919|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
9930413|NCT00928044||operation group|1. They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded. 2. Operations were performed for benign ovarian tumors, leiomyoma or adenomyosis
9997196|NCT01506765|Active Comparator|patients who receive NAC first|this group will receive 2g/day of NAC (2 caps of 0.5g twice day)for a duration of 8 weeks first, and after this 8 weeks their receive placebo for 8 weeks.
9997197|NCT01506765|Placebo Comparator|patients who receive placebo first|this patients will receive first placebo for a duration of 8 weeks, and after this 8 weeks their receive NAC for 8 weeks
9878379|NCT00438958|Active Comparator|Arm I|Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
9878380|NCT00438958|Experimental|Arm II|Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
9878381|NCT00438984|Experimental|Treatment (chemotherapy, immunosuppressive, lymphocytes)|"All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.~COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.~COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5."
9878382|NCT00439036|Experimental|Behavior Therapy: Acceptance and Commitment Therapy|"The Act-ODT intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.~--------------------------------------------------------------------------------"
9878383|NCT00439036|Active Comparator|Drug Counseling|The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
9878384|NCT00439049||A|Cocaine Dependent Subjects
9878385|NCT00439075|Experimental|CPAP|positive airway pressure
9878386|NCT00439075|Active Comparator|standard medical therapy|conventional oxygen therapy
9878387|NCT00439101|Experimental|1|
9878388|NCT00439101|Placebo Comparator|2|Placebo
9878389|NCT00439166|Experimental|1 AD combined doxycycline + rifampin|Doxycycline 100 mg b.i.d. plus rifampin 300 mg o.d. for 12 months.
9878390|NCT00439166|Experimental|2 AD Doxycycline only|Doxycycline 100 mg b.i.d. plus placebo matched to rifampin o.d. for 12 months.
9878391|NCT00439166|Experimental|3 Rifampin only|Rifampin 300 mg o.d. plus placebo matched to doxycycline b.i.d. for 12 months.
9878392|NCT00439166|Placebo Comparator|4 Double Placebo|Placebo matched to Doxycycline b.i.d. plus placebo matched to rifampin o.d. for 12 months.
9878393|NCT00439205||MDM + FastEEM4|Multispectral digital microscope (MDM) + FastEEM4 Systems
9878394|NCT00439257||Group 1|
9878395|NCT00439322||Group 1|
9878396|NCT00439348|Experimental|Electronic prescription|Patients receive a prescription for specific over-the-counter medications.
9878397|NCT00439348|Active Comparator|Verbal advice|
9878398|NCT00439361|Experimental|Bortezomib + ICE|"Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):~Bortezomib 1.0 mg/m^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m^2 IV continuous infusion Day 1; 2 Gm/m^2 IV continuous infusion over 12 Hours."
9878399|NCT00439400|Active Comparator|A|
9878400|NCT00439400|Placebo Comparator|B|
9878401|NCT00439426|Experimental|1|
9878402|NCT00439439|Sham Comparator|A|Sham Procedure
9878403|NCT00439439|Active Comparator|B|Verum Beamer ablation of heterotopic gastric mucosa
9878404|NCT00439452|Active Comparator|Telemedicine-Based Collaborative Care|Telemedicine-Based Collaborative Care - Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
9878405|NCT00439452|Active Comparator|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
9878406|NCT00439582|Experimental|1|
9878407|NCT00439582|Experimental|2|
9878408|NCT00439595|Experimental|1|Hemocue 210 meter
9878409|NCT00439595|Experimental|2|Copack HBCS
9878410|NCT00439595|No Intervention|3|Control
9878411|NCT00439621|Experimental|1|
9878412|NCT00439621|Experimental|2|
9878413|NCT00439621|Experimental|3|
9878414|NCT00439621|Placebo Comparator|4|
9878415|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(4)|vaccine dose of 1 X 10(4) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
9878416|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(5)|vaccine dose of 1 X 10(5) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
9878417|NCT00439686|Experimental|Single Arm|
9878418|NCT00439699|Experimental|Memantine|Tremor reduction
9878419|NCT00439712|Experimental|Treatment Group 1|
9878420|NCT00439712|Placebo Comparator|Treatment Group 2|
9878421|NCT00439751|Other|Immediate ADT|
9878422|NCT00439751|Other|Deferred ADT|
9878423|NCT00439764|Active Comparator|1|Routine clinical practice and talk on general health
9878424|NCT00439764|Active Comparator|2|Talk on back health and handout of The Back Book
9878425|NCT00439764|Active Comparator|3|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
9878426|NCT00439803|Active Comparator|T1|
9878427|NCT00439803|Placebo Comparator|C1|
9878428|NCT00439803|Active Comparator|T2|
9878429|NCT00439803|Placebo Comparator|C2|
9878430|NCT00439803|Active Comparator|T3|
9878431|NCT00439803|Placebo Comparator|C3|
9878432|NCT00439803|Active Comparator|T4|
9878433|NCT00439803|Placebo Comparator|C4|
9878434|NCT00439816|Other|Arm 1|
9878435|NCT00439829|Experimental|1|Initiation of ovarian stimulation therapy on day 1 (i.e., first day of menses)
9878436|NCT00439829|Active Comparator|2|Initiation of ovarian stimulation therapy on day 4 (day 1= first day of menses)
9878437|NCT00439842|Experimental|HF group clinic appointments|HF group clinic appointments Heart failure multidisciplinary group clinic appointments (Arm 1 - HFcareGroup) includes 6 teaching sessions with patients led by nurse practitioner.
9878438|NCT00439842|No Intervention|Standard HF care|Standard HF care Standard heart failure education includes cardiologists instructions and hospital discharge information.
9878439|NCT00439868|Experimental|Treatment Group 1|Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.
9878440|NCT00439868|Experimental|Treatment Group 2|Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.
9878441|NCT00439894||blood draw|One time blood draw
9878442|NCT00439907|Active Comparator|End-to-end|End-to-end repair
9878443|NCT00439907|Active Comparator|Overlap|Overlap repair
9878444|NCT00439920|Experimental|High-dose anthracycline|
9878445|NCT00439972|Active Comparator|Group 1|Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R)
9878446|NCT00439972|Active Comparator|Group 2|Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
9878447|NCT00439972|Active Comparator|Group 3|Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R)
9878448|NCT00439972|Active Comparator|Group 4|Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R)
9878449|NCT00439972|Active Comparator|Group 5|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
9878450|NCT00439972|Active Comparator|Group 6|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R)
9878451|NCT00439985|Other|Behavioral: Cognitive Behavior Therapy|
9878452|NCT00440024|Experimental|Cell A|Study controlled daily skin care regimen during 'rest period' consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
9878453|NCT00440024|Placebo Comparator|Cell B|Subject controlled normal skin care regimen during 'rest period, followed by study controlled daily skin care regime consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
9878454|NCT00440102|Active Comparator|1|ketamine
9878455|NCT00440102|Active Comparator|2|Etomidate
9878456|NCT00440128|Active Comparator|Docetaxel|Docetaxel
9878457|NCT00440128|Experimental|Docetaxel/Casopitant|Docetaxel/Casopitant
9878458|NCT00440141|Experimental|1|
9878459|NCT00440141|Active Comparator|2|
9878460|NCT00440154|Experimental|1|oral administration 5 mg breakfast timing
9878461|NCT00440154|Experimental|2|oral administration 25 mg breakfast timing
9878462|NCT00440154|Experimental|3|oral administration 50 mg breakfast timing
9878463|NCT00440154|Experimental|4|oral administration 100 mg breakfast timing
9878464|NCT00440154|Experimental|5|oral administration 25 mg dinner timing
9878465|NCT00440154|Placebo Comparator|6|oral administration
9878466|NCT00440154|Active Comparator|7|oral administration 10mg breakfast timing
9878467|NCT00440167|Active Comparator|Arm A|
9878468|NCT00440167|Active Comparator|Arm B|
9878469|NCT00440219|Experimental|Prednisone group|Prednisone 50 mg daily for 10 days immediately pre-op
9878470|NCT00440219|Placebo Comparator|Placebo group|Placebo pill for 10 days immediately pre-operative
9878471|NCT00440245|Other|salbutamol|There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
9878472|NCT00440323|Experimental|ADBC sequence|In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
9878473|NCT00440323|Experimental|BACD sequence|In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
9878474|NCT00440323|Experimental|CBDA sequence|In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
9878475|NCT00440323|Experimental|DCAB sequence|In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.
9878476|NCT00440362|Active Comparator|T1|
9878477|NCT00440362|Active Comparator|T2|
9878478|NCT00440362|Active Comparator|T3|
9878479|NCT00440362|Active Comparator|T4|
9878480|NCT00440362|Active Comparator|T5|
9878481|NCT00440362|Active Comparator|T6|
9878482|NCT00440362|Active Comparator|T7|
9878483|NCT00440362|Active Comparator|T8|
9878484|NCT00440362|Placebo Comparator|C1|
9878485|NCT00440362|Placebo Comparator|C2|
9878486|NCT00440362|Placebo Comparator|C3|
9878487|NCT00440362|Placebo Comparator|C4|
9878488|NCT00440414|Experimental|1|Alimta
9878489|NCT00440414|Experimental|2|Tarceva
9878490|NCT00440440|Active Comparator|1|testosterone gel
9878491|NCT00440440|Placebo Comparator|2|placebo gel
9878492|NCT00440453|No Intervention|1|Normal hospital food
9878493|NCT00440453|Experimental|2|Nutritional treatment
9878494|NCT00440479||001|Bortezomib dose as determined (observational study) by treating physician
9878495|NCT00440544|Experimental|1|100 ug H1 antigen alone in BCG naive subjects
9878496|NCT00440544|Experimental|2|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
9878497|NCT00440544|Experimental|3|50 ug H1 antigen in BCG immunized subjects
9878498|NCT00440544|Experimental|4|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
9878499|NCT00440544|Experimental|5|100 ug H1 antigen in BCG immunized subjects
9878500|NCT00440544|Experimental|6|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
9878501|NCT00440583|Experimental|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
9878502|NCT00440609|Active Comparator|0.5mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
9878503|NCT00440609|Active Comparator|1.0 mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
9878504|NCT00440622|Experimental|1|GHer
9878505|NCT00440622|Experimental|2|CapHer
9878506|NCT00440648|Other|1|sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
9878507|NCT00440648|Other|2|sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
9878508|NCT00440674|Experimental|1|Direct stenting technique
9878509|NCT00440674|Experimental|2|Conventional stenting with pre-dilatation strategy
9878510|NCT00440739|Placebo Comparator|1|1=placebo
9878511|NCT00440739|Active Comparator|2|2= etoricoxib
9878512|NCT00440739|Active Comparator|3|3=falvoxate
9878513|NCT00440739|Active Comparator|4|etoricoxib and flavoxate
9878514|NCT00440752||AL|Cohort of study participants receiving treatment with artemether-lumefantrine
9878515|NCT00440765||001|bortezomib dose as determined (observational study) by treating physician
9878516|NCT00440778|Experimental|Gr 1 - intracoronary + infusion|abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion
9878517|NCT00440778|Experimental|Gr 2 - intracoronary|100% abciximab bolus dose 0.3 mg/kg ic
9878518|NCT00440778|Active Comparator|Gr 3 - intravenous|abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion
9878519|NCT00440778|Experimental|Gr 4 - intravenous|100% abciximab bolus dose 0.3 mg/kg iv
9878520|NCT00440817||Patients with lymphoma|Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
9930414|NCT00928109|Experimental|Cognitive Behavioral Couples Therapy (CBCT)|CBCT is a 20-week program consisting of 1-hour sessions between a couple and a therapist. In this program, couples learn about ways to communicate about their relationship in the context of experiencing anorexia nervosa. CBCT focuses on couple-specific skills such as communication and targets relationship domains such as exercise, body image and sexuality, eating together as a couple, and broader relationship concerns outside of anorexia nervosa.
9930415|NCT00928109|Active Comparator|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
9930416|NCT00928122|Experimental|1 / Presbyopia|Presbyopic patients, slightly hyperopes
9930417|NCT00928122|Experimental|2 / Myopia|Myopic patients without Astigmatism
9930418|NCT00928122|Experimental|3 / Hyperopia|Hyperope patients without Astigmatism
9930419|NCT00928122|Experimental|4 / Myopia with Astigmatism|Myopic patients incl. Astigmatism
9930420|NCT00928122|Experimental|5 / Hyperopia with Astigmatism|Hyperope patients incl. Astigmatism
9930421|NCT00928148|Experimental|SPD465 (50 or 75 mg)|
9930422|NCT00928148|Active Comparator|Immediate Release Amphetamine salt (25 mg)|
9930423|NCT00928148|Placebo Comparator|Placebo|
9930424|NCT00928161|No Intervention|Group 1|Patients with no acid reflux.
9930425|NCT00928161|Active Comparator|Group 2|Patients with acid reflux.
9930426|NCT00928213|Experimental|1|Control not treated, no placebo
9930427|NCT00928213|Experimental|2|Patient treated with low molecular weight heparin after repeated pregnancy loss
9930428|NCT00928213|Experimental|3|Patient super from first trimester bleeding treated with progesterone
9930429|NCT00928226|Experimental|Arm 1 - 24 Grey SRS|24 Grey administered as 8 Gy x 3 fractions
9930430|NCT00928226|Experimental|Arm 2 - 27 Grey SRS|27 Grey administered as 9 Gy x 3 fractions
9930431|NCT00928226|Experimental|Arm 3 - 30 Grey SRS|30 Grey administered as 10 Gy x 3 fractions
9930432|NCT00928226|Experimental|Arm 4 - 33 Grey SRS|33 Grey administered as 11 Gy x 3 fractions
9997198|NCT01506778|Active Comparator|Group 1(With Tenaculum)|This group consisted of the patients whose had been applied tenaculum at cervix during the endometrial sampling procedure
9997199|NCT01506778|No Intervention|Group 2 (Without Tenaculum)|This group consisted of the patients whose had been not applied tenaculum during the endometrial sampling procedure.
9800102|NCT01679301|Experimental|Pulse dose ('sleep mode')|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator
9800103|NCT01679314|Active Comparator|Active AlphaCore device|AlphaCore active stimulation treatment
9878521|NCT00440843|Experimental|OLZ|
9997200|NCT01506791|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
9800104|NCT01679314|Sham Comparator|Sham AlphaCore device|AlphaCore sham device
9800105|NCT01679405|Experimental|Dose level 1 (Part A)|30 mg BIBW 2992, Gemcitabin (1.000 mg/m² BSA i.v.)/Cisplatin (25 mg/m² BSA i.v.)
9800106|NCT01679405|Experimental|Dose level -1 (Part A)|30 mg BIBW 2992, Gemcitabin (800 mg/m² BSA i.v.)/Cisplatin (20 mg/m² BSA i.v.)
9800107|NCT01679600|Experimental|FC-RATE|Feedback-controlled robotics-assisted treadmill exercise
9800108|NCT01679600|Active Comparator|RATE|Robotics-assisted treadmill exercise
9800109|NCT01679613|Experimental|1 Nintedanib (Reference)|single dose, oral with 240 ml water
9800110|NCT01679613|Experimental|2 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
9800111|NCT01679613|Experimental|3 Nintedanib (Reference)|single dose, oral with 240 ml water
9800112|NCT01679613|Experimental|4 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
9800113|NCT01680016|Experimental|Zagreb(≥6 to ≤17 Years)|
9800114|NCT01680016|Experimental|Zagreb(≥51 Years)|
9800115|NCT01680016|Active Comparator|Essen(≥6 to ≤17 Years)|
9800116|NCT01680016|Active Comparator|Essen(≥51 Years)|
9800117|NCT01680159|Experimental|TA-650|
9800118|NCT01680172|Experimental|Ketamine|Single dose of ketamine (0.5 mg/kg)
9800119|NCT01680172|Placebo Comparator|Placebo|Single dose of placebo
9800120|NCT01680328|Other|Different injection speed and volume combinations|The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
9800121|NCT01680341|Experimental|IDegAsp Simple|
9800122|NCT01680341|Experimental|IDegAsp Step wise|
9800123|NCT01680458||fluconazole|Infant Subjects who are treated with fluconazole
9800124|NCT01680497|Experimental|JUVÉDERM VOLIFT™|All subjects receiving treatment with JUVÉDERM VOLIFT™.
9800125|NCT01680549|Active Comparator|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
9800126|NCT01680549|Placebo Comparator|Placebo|Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
9800127|NCT01680640|Active Comparator|Synbiotic|Fructo-oligosacharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis (BB-12) as minimum of 10 billion colony forming unit (CFU)/day (1 capsule a day).
9800128|NCT01680640|Placebo Comparator|Maltodextrin|4 grams of maltodextrin daily.
9800129|NCT01680653|Experimental|Mini-Glucagon and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
9800130|NCT01680653|Other|Carbohydrates and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administration of carbohydrate per camp protocol to treat nocturnal hypoglycemia. Expected treatment is 15-45g."
9800131|NCT01680653|Other|Carbohydrates No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with standard camp protocol administration of carbohydrates. Expected treatment is 15g-45g."
9800132|NCT01680653|Other|Mini-Glucagon and No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with mini-glucagon.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
9800133|NCT01680666|Active Comparator|landmark guided|central line placement
9800134|NCT01680666|Active Comparator|ultrasound guided|central line placement
9878522|NCT00440843|Active Comparator|Typicals|
9878523|NCT00440856|No Intervention|Control|
9878524|NCT00440856|Experimental|experimental|Participants are given their disc fragments following their operation
9878525|NCT00440869|Experimental|N-acetylcysteine|Active
9878526|NCT00440869|Placebo Comparator|placebo|placebo
9878527|NCT00440895|Experimental|1 intracoronary + infusion|Bolus abciximab i.c. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
9878528|NCT00440895|Active Comparator|2 intravenous|Bolus abciximab i.v. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
9878529|NCT00440895|Placebo Comparator|3 Placebo|Bolus of placebo followed by 12 h infusion (placebo).
9878530|NCT00440973|Other|treatment arm|PI relocated, currently data is no longer available
9878531|NCT00441025|Active Comparator|1|1 Alemtuzumab
9878532|NCT00441038|Active Comparator|1|Education on postural hygiene and handout of The Back Guide
9878533|NCT00441038|Active Comparator|2|Education on active management and handout of The Back Book
9878534|NCT00441038|Active Comparator|3|Education on cardiovascular and general health
9878535|NCT00441155|Experimental|Monotherapy: AMN107|initial dose of imatinib (dose level 1) was 400 mg bid was administered orally on a continuous daily schedule and was not escalated during the study
9878536|NCT00441155|Active Comparator|Combination Therapy: AMN107 + Imatinib|six possible doses of Nilotinib (100 mg once daily (qd), 200 mg qd, 400 mg qd, 200 mg bid, 300 mg bid, and 400 mg bid). four possible doses of Imatinib (0 mg, 400 mg qd, 600 mg qd, and 400 mg bid).the initial dose of nilotinib (dose level 1) was 200 mg qd and could have been escalated up to 400 mg bid
9878537|NCT00441220||A|Patients must have lupus nephritis and previously had therapy with intravenous cyclophosphamide.
9878538|NCT00441220||B|Patients must have lupus nephritis and are currently receiving therapy with intravenous cyclophosphamide.
9878539|NCT00441298|Experimental|1|Tenofovir gel (a reverse transcriptase inhibitor)
9878540|NCT00441298|Placebo Comparator|2|Universal HEC placebo
9878541|NCT00441311|Experimental|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
9878542|NCT00441311|No Intervention|Service-as-Usual|Control Arm
9878543|NCT00441376|Experimental|ThermoDox + RFA|ThermoDox administered as single dose intravenously over 30 minutes in combination with radiofrequency ablation. Dose is determined by dose cohort patient enters study.
9878544|NCT00441454|Active Comparator|A|Retropubic Tension-free Vaginal Tape (TVT)
9878545|NCT00441454|Active Comparator|B|Transobturator Tension-free Vaginal Tape (TVT-O)
9878546|NCT00441597|Active Comparator|1|first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
9878547|NCT00441597|Active Comparator|2|first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
9878548|NCT00441597|No Intervention|3|3 days treatment with placebo twice
9878549|NCT00441610|Experimental|Gimatecan|
9878550|NCT00441636|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)for 4 weeks
9878551|NCT00441636|No Intervention|No CPAP|routine psychiatric care for 4 weeks followed by CPAP titration and initiation after followup measures.
9878552|NCT00441636|No Intervention|Control group|No obstructive sleep apnea detected.
9878553|NCT00441675||Salmeterol/Fluticasone|Previous Salmeterol/Fluticasone treatment
9878554|NCT00441675||Fluticasone|Previous Fluticasone propionate treatment
9878555|NCT00441688|Experimental|GI265235|
9878556|NCT00441740|Experimental|1|VG
9878557|NCT00441740|Experimental|2|DG
9878558|NCT00441779||1|Traumatic injury
9878559|NCT00441779||2|Elective orthopedic surgery
9878560|NCT00441779||3|Burn injury
9878561|NCT00441909|Experimental|1A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 8 hours
9878562|NCT00441909|Placebo Comparator|1B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 8 hours
9878563|NCT00441909|Experimental|2A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 4 hours
9878564|NCT00441909|Placebo Comparator|2B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 4 hours
9878565|NCT00441909|Experimental|3A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 2 hours
9878566|NCT00441909|Placebo Comparator|3B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 2 hours
9878567|NCT00441909|Experimental|4A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 0 hours
9878568|NCT00441909|Placebo Comparator|4B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 0 hours
9878569|NCT00441922|Experimental|1|D
9878570|NCT00441922|Experimental|2|V
9878571|NCT00441935||Interstim Neuromodulation|Subjects undergoing implantation of an Interstim device for neuromodulation.
9878572|NCT00442026|Experimental|1|DG
9878573|NCT00442026|Experimental|2|G
9878574|NCT00442065|Active Comparator|Open label, single arm|A prospective, open label, single-arm (non-randomized) multi-center, international clinical device investigation to collect safety and performance data concerning the Aorfix™ Stent Graft System in the treatment of abdominal aortic aneurysm and aorto-iliac aneurysm where a significant degree of vessel angulation exists
9878575|NCT00442091|Other|10 ml of dandelion juice twice daily|
9878576|NCT00442130|Experimental|GM-K562 Vaccine|"Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation"
9878577|NCT00442156||Laser|People with diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns), who were already intended to receive focal photocoagulation
9878578|NCT00442442|No Intervention|1|No treatment control
9878579|NCT00442442|Active Comparator|2|LLIN Nets
9878580|NCT00442442|Experimental|3|Mosquito Coils
9878581|NCT00442442|Experimental|4|Mosquito coils & LLIN
9878582|NCT00442455|Experimental|Erlotinib, radiotherapy.|There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation therapy being fixed (63 Gy during 5 days a week during 7 weeks)
9878583|NCT00442494|Other|Study couldn´t start due to investigator|Study couldn´t start due to investigator
9878584|NCT00442520||2|colorectal cancer patients
9878585|NCT00442520||3|head and neck cancer patients
9878586|NCT00442520||1|lung cancer patients
9878587|NCT00442533|Experimental|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
9878588|NCT00442546|Experimental|1|
9878589|NCT00442546|Experimental|2|
9878590|NCT00442546|Placebo Comparator|3|
9878591|NCT00442624||1|Patients with chronic insomnia
9878592|NCT00442624||2|age, sex, bmi matched healthy controls
9878593|NCT00442637|Experimental|1|observation
9878594|NCT00442637|Active Comparator|2|capecitabine plus bevacizumab
9878595|NCT00442676|Experimental|1|Celecoxib, 200 mg/day
9878596|NCT00442676|Placebo Comparator|2|Placebo
9878597|NCT00442741|Experimental|Patupilone + Midazolam|
9878598|NCT00442741|Experimental|Patupilone + Omeprazole|
9878599|NCT00442780|Placebo Comparator|1|Dose Level A of BIIB014
9878600|NCT00442780|Placebo Comparator|2|Dose Level B of BIIB014
9878601|NCT00442780|Placebo Comparator|3|Dose Level C of BIIB014
9878602|NCT00442780|Placebo Comparator|4|Dose Level D of BIIB014
9930433|NCT00928239|Experimental|1|Arm1: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment to the caudal part of the vagina and the apex.
9930434|NCT00928239|Active Comparator|2|Arm 2: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment of the dorsal mesh at distal end of vagina at dorsal vaginal wall
9930435|NCT00928278|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
9930436|NCT00928278|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
9930437|NCT00928278|Experimental|Treatment C - PF-04764793|PF-04764793 using inhaler A
9930438|NCT00928278|Active Comparator|Treatment D - PF-04764793|PF-04764793 using inhaler B
9930439|NCT00928291|Experimental|Group 1 - PCT group|interventions on antibiotic therapy will be based on circulating PCT levels
9878603|NCT00442793|Experimental|1|
9997201|NCT01506791|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
9800135|NCT01680783|Other|Usual Care|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
9800136|NCT01680783|Experimental|Non invasive ventilation via helmet|Patients requiring more than 8 hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet instead of face mask for treatment of respiratory failure
9800137|NCT01680835|Experimental|Study cohort|All patients enrolled in this study will be treated with the EverFlex™ Self-Expanding Peripheral Stent System.
9800138|NCT01680861|Experimental|Tacrolimus and Everolimus|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml."
9800139|NCT01680861|Active Comparator|Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day."
9800140|NCT01680887|Experimental|Varenicline|Oral 1.0 mg BID.
9800141|NCT01680887|Placebo Comparator|Placebo|Oral 1.0 mg BID.
9800142|NCT01680900|Experimental|experimental 1|vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks
9800143|NCT01680900|Placebo Comparator|placebo capsules (sugar pill)|Placebo capsules matched to the drug dose for 8 weeks
9800144|NCT01680991|Experimental|CLL: 1000 mg Obinutuzumab|Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
9800145|NCT01680991|Experimental|DLBCL: 1000 mg Obinutuzumab|Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
9800146|NCT01680991|Experimental|FL: 1000 mg Obinutuzumab|Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
9800147|NCT01681004|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
9800148|NCT01681004|Active Comparator|Non-Surgical Management|Medications, SI joint injection, physical therapy and RF ablation of SI joint
9800149|NCT01681030|Experimental|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
9800150|NCT01681030|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
9800151|NCT01681030|Active Comparator|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
9800152|NCT01681069|Active Comparator|IQP-VV-102|2 tablets twice a day
9800153|NCT01681069|Placebo Comparator|Placebo|2 tablets twice a day
9800154|NCT01681095|Experimental|Cardioplegia: Custodiol HTK Solution|"Custodiol HTK (histidine-tryptophan-ketoglutarate) cardioplegia: One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.~Custodiol-HTK was delivered to establish and maintain cardiac arrest. After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. Custodiol-HTK was delivered at a temperature of 4°C - 10°C."
9800155|NCT01681095|Active Comparator|Cold Blood Cardioplegia|"Cold Blood Cardioplegia: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution), contains the following in a 500 cc bag of D5W (dextrose 5% in water): 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.~After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 8°C."
9800156|NCT01681121|Experimental|ADX-N05|ADX-N05 to be taken once a day for 12 weeks
9800157|NCT01681121|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 12 weeks
9800158|NCT01681186|Experimental|LY2940680 (Part A)|Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
9800159|NCT01681186|Placebo Comparator|Placebo (Part A)|Placebo given once orally in up to 1 of 2 study periods
9800160|NCT01681186|Experimental|LY2940680 Capsule Fasted (Part B)|100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
9800161|NCT01681186|Experimental|LY2940680 Tablet Fasted (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
9878604|NCT00442793|Active Comparator|2|
9878605|NCT00442806|Placebo Comparator|Placebo|Placebo is injected
9878606|NCT00442806|Experimental|Treatment|ADRC's are injected
9878607|NCT00442832|Experimental|TD-1792|
9878608|NCT00442832|Active Comparator|Vancomycin|
9878609|NCT00442871|Experimental|Eltrombopag|Eltrombopag 50 mg oral (single dose)
9878610|NCT00442910|Active Comparator|3% SPL7013|Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
9878611|NCT00442910|Placebo Comparator|Placebo for SPL7013 Gel|Intravaginal application of 3.5 g placebo gel twice daily for 14 days
9878612|NCT00442910|Placebo Comparator|HEC Placebo Gel|Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
9878613|NCT00442923|Placebo Comparator|CTRL|
9878614|NCT00442923|Experimental|TREAT|
9878615|NCT00442949|Active Comparator|2|Catheterization immediate PCI
9878616|NCT00442949|Experimental|1|delayed PCI
9878617|NCT00443014|Experimental|A Cognitive stimulation therapy|Patients with recently diagnosed dementia in five of the study municipality.
9878618|NCT00443014|No Intervention|B Care as usual|
9878619|NCT00443027|Experimental|Vaginal Heat Wash-Out Device|
9878620|NCT00443092|Experimental|1|proprietary tart cherry juice blend (8 oz., BID)
9878621|NCT00443092|Placebo Comparator|2|control juice (color matched kool aid blend),(8 oz., BID)
9878622|NCT00443131|Experimental|Group A|
9878623|NCT00443131|Experimental|Group B|
9878624|NCT00443131|Experimental|Group C|
9878625|NCT00443183|Experimental|Brief Negotiation Interview|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
9878626|NCT00443183|Placebo Comparator|Discharge Instructions|Scripted discharge instructions to be read by emergency practitioner and designed to be less than 1 minute in length.
9878627|NCT00443196|Experimental|Experimental|
9878628|NCT00443235|Active Comparator|A|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
9878629|NCT00443235|Experimental|B|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
9878630|NCT00443248|Experimental|Vaginal Heat Wash-Out Device|
9878631|NCT00443300||Protective environment|Participants in a Protective environment
9878632|NCT00443300||Not a protective environment|Participants not in a protective environment
9878633|NCT00443365|No Intervention|1|Coronary Artery Bypass Grafting with no Mitral Valve intervention
9878634|NCT00443365|Active Comparator|2|Coronary Artery Bypass Grafting + Mitral Annuloplasty
9878635|NCT00443378|Experimental|1|"Arm 1, CARE+ arm is the study arm that receives the CARE+ computer intervention."
9878636|NCT00443378|No Intervention|2|Arm 2, the control arm, is the study arm that receives computerized risk assessment only.
9878637|NCT00443404|Active Comparator|1|perioperative epidural analgesia
9878638|NCT00443404|Active Comparator|2|Iv PCA Fentanyl preoperative, Epidural analgesia postoperative
9878639|NCT00443404|Active Comparator|3|perioperative IV PCA Fentanyl, epidural anesthesia
9878640|NCT00443404|Active Comparator|4|perioperative IV PCA Fentanyl general anesthesia
9878641|NCT00443404|Placebo Comparator|5|IV PCA with saline 0.9% and sc saline 0.9%in the L3-L4 area. IM meperidine, po codeine/acetaminophen, IV acetaminophen and IV parecoxib
9878642|NCT00443417|Placebo Comparator|1|
9878643|NCT00443417|Active Comparator|2|200mg qd
9878644|NCT00443417|Active Comparator|3|200mg bid
9878645|NCT00443417|Active Comparator|4|400mg qd
9878646|NCT00443469|Experimental|Magnetic Stimulation|
9878647|NCT00443469|Placebo Comparator|Magnetic Stimulation with tilted coil|Magnetic Stimulation with tilted coil
9878648|NCT00443586|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
9878649|NCT00443586|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
9878650|NCT00443586|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
9878651|NCT00443586|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
9878652|NCT00443612|Experimental|1|"12 weeks on treatment 1~2 week washout period~12 weeks on treatment 2"
9878653|NCT00443612|Experimental|2|"12 weeks on treatment 2~2 week washout period~12 weeks on treatment 1"
9878654|NCT00443638|No Intervention|Control Group|Control Group
9878655|NCT00443638|Experimental|Home visitation through pregnancy|Nurse home visitation through pregnancy
9878656|NCT00443638|Experimental|Home visitation through age 2|Nurse home visitation through child age 2.
9878657|NCT00443677|Active Comparator|abvd|
9878658|NCT00443677|Experimental|beacopp|
9878659|NCT00443677|Experimental|coppebvcad|
9878660|NCT00443690|Placebo Comparator|2|placebo control
9878661|NCT00443690|Experimental|1|KW-3902IV
9878662|NCT00443768||1|
9878663|NCT00443768||2|
9878664|NCT00443794|Experimental|1, POLYCAP|Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
9878665|NCT00443794|Active Comparator|2 B|Diuretic antihypertensive
9878666|NCT00443794|Active Comparator|3 C|Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
9878667|NCT00443794|Active Comparator|4 D|Diuretic with Beta blocker combination antihypertensive
9878668|NCT00443794|Active Comparator|5, E|ACE inhibitor plus Beta blocker combination antihypertensive
9878669|NCT00443794|Active Comparator|6, F|Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
9878670|NCT00443794|Active Comparator|7,G|Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
9517656|NCT03304327|Experimental|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
9878671|NCT00443794|Active Comparator|8,H|Lipid lowering agent
9878672|NCT00443794|Active Comparator|9,A|Antiplatelet
9878673|NCT00443859||PPHN|Infants with persistent pulmonary hypertension (PPHN)
9878674|NCT00443924|Placebo Comparator|1|Arm 1
9878675|NCT00443924|Experimental|2|Arm 2
9878676|NCT00443924|Experimental|3|Arm 3
9878677|NCT00443924|Experimental|4|Arm 4
9878678|NCT00443924|Experimental|5|Arm 5
9878679|NCT00443963|Experimental|PPI|PPI Medication
9878680|NCT00443963|Experimental|H2RA|H2RA Medication
9878681|NCT00443976|Experimental|AT9283|
9878682|NCT00444002||Hepatitis C - Steatosis|Patients with chronic Hep C infection undergoing liver biopsy with >=5% steatosis on liver biopsy
9878683|NCT00444002||Hepatitis C - no steatosis|Patients with chronic Hep C infection without steatosis on liver biopsy (<5% of hepatocytes involved)
9517657|NCT03304314|Experimental|Pseudotumor cerebri (PTC) patients|
9517658|NCT03304314|Experimental|Control|
9878684|NCT00444015|Experimental|Dose Escalation|
9878685|NCT00444041|Experimental|Xelox, Bev|
9878686|NCT00444054|Experimental|Dietary modification|Patients are placed on a low carbohydrate diet (<30 grams/day) for 28 days.
9878687|NCT00444093|Experimental|Opii normata treatment|Treamtment with opii normata in case of diarrhea
9878688|NCT00444093|Experimental|Loperamid Treatment|Treatment with Loperamid in case of diarrhea
9878689|NCT00444184|Active Comparator|Travoprost/Timolol therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost/timolol drops
9878690|NCT00444184|Active Comparator|Travoprost therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost drops
9878691|NCT00444223|Experimental|fluorine F 18 FEQA + positron emission tomography|
9878692|NCT00444236|Active Comparator|1|
9878693|NCT00444236|Placebo Comparator|2|
9878694|NCT00444249|Active Comparator|1|White Alcon IOL
9878695|NCT00444249|Active Comparator|2|Yellow Alcon IOL
9878696|NCT00444249|Active Comparator|3|White Hoya IOL
9878697|NCT00444249|Active Comparator|4|Yellow Hoya IOL
9878698|NCT00444262|Active Comparator|1|conventional treatment
9878699|NCT00444262|Experimental|2|stroke volume optimisation
9878700|NCT00444314|Experimental|A|
9878701|NCT00444314|Experimental|B|
9878702|NCT00444379|Active Comparator|PI-based HAART regimen|PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)
9878703|NCT00444379|Active Comparator|non-nucleoside reverse transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)
9878704|NCT00444418|Experimental|1|Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
9878705|NCT00444418|Experimental|2|Placebo combined with Modified Behavioral Self-Control Psychotherapy
9878706|NCT00444418|Experimental|3|Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
9878707|NCT00444418|Placebo Comparator|4|Placebo + Brief Behavioral Compliance Enhancement Therapy
9878708|NCT00444470|Active Comparator|A|Active drug being tested in this study is Tranexamic Acid
9878709|NCT00444470|Placebo Comparator|B|Normal saline was used as the Placebo
9878710|NCT00444509|Experimental|Treatment 1|Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
9878711|NCT00444509|Experimental|Treatment 2|Subjects will receive GW685698X 800 mcg containing magnesium stearate inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
9878712|NCT00444561|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
9878713|NCT00444574|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
9878714|NCT00444574|Placebo Comparator|Placebo|Placebp matching MTS and Concerta for 7 weeks
9878715|NCT00444574|Active Comparator|Concerta|Methylphenidate HCL 18mg tablet 7 weeks
9930440|NCT00928291|Active Comparator|Group 2 - Control group|antibiotic therapy will be guided by appropriate guidelines, and will be left at the discretion of caregivers.
9930441|NCT00928317|Experimental|ART621 A|ART621 0.75mg/kg per week
9930442|NCT00928317|Experimental|ART621 B|ART621 1.5 mg/kg per week
9930443|NCT00928317|Experimental|ART621 C|ART621 3.0mg/kg per week
9930444|NCT00928317|Placebo Comparator|Placebo arm|
9930445|NCT00928330|Experimental|A|
9930446|NCT00928330|Experimental|B|
9930447|NCT00928330|Experimental|C|
9930448|NCT00928343|Experimental|GLPG0187|Single dose
9930449|NCT00928343|Placebo Comparator|Placebo|
9930450|NCT00928356|Experimental|Hybrid CABG/PCI|Patients undergo hybrid, same sitting CABG/PCI as described.
9930451|NCT00928356|Other|Off-pump CABG|Standard of Care Off Pump CABG
9935413|NCT03782376|Experimental|Group 1: Ustekinumab (IV re-induction)|Participants who experience a secondary loss of response (LoR) to 90 mg ustekinumab maintenance treatment, administered subcutaneously every 8 weeks (q8w) will receive a weight-tiered based ustekinumab IV re-induction dose of approximately 6 mg/kg and matching placebo subcutaneously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
9935414|NCT03782376|Active Comparator|Group 2: Ustekinumab (Continuous q8w SC maintenance)|Participants who experience a secondary LoR to 90 mg ustekinumab maintenance treatment, administered subcutaneously q8w will receive ustekinumab 90 mg subcutaneously and matching placebo intravenously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
9935415|NCT03776071|Active Comparator|RT plus TMZ and ENZ; ENZ alone; TMZ and ENZ|Radiotherapy (RT) plus temozolomide (TMZ) and enzastaurin (ENZ) (Concurrent Phase) followed by enzastaurin alone (Single-Agent Phase), then temozolomide and enzastaurin (Adjuvant Phase)
9935416|NCT03776071|Placebo Comparator|RT plus TMZ and placebo; placebo; TMZ and placebo|Radiotherapy (RT) plus temozolomide (TMZ) and placebo followed placebo then by temozolomide and placebo
10211722|NCT04249323|Experimental|Part 2: MAD Cohorts A through D CORT113176|Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.
10211723|NCT04249323|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT113176 lipid capsule formulation by mouth for 14 days. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding MAD cohorts receiving CORT113176.
9935419|NCT03774485||Healthy controls|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in healthy controls. The investigator does not change the routine medical care of study participants.
9935420|NCT03774485||Crohn's disease (remission state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (remission state). The investigator does not change the routine medical care of study participants.
9997202|NCT01506804|Experimental|Training of painful shoulder|Steroid injection X 2 and 10 weeks exercise program of painful shoulder
9878716|NCT00444613|Experimental|E0302 25 mg|
9878717|NCT00444613|Experimental|E0302 50 mg|
9878718|NCT00444613|Placebo Comparator|3|
9878719|NCT00444639|Experimental|1|triptorelin 11.25mg given 12 weekly by subcutaneous formulation
9878720|NCT00444639|Active Comparator|2|triptorelin 11.25mg given 12 weekly by intramuscular injection
9878721|NCT00444743|Active Comparator|1|
9878722|NCT00444743|Placebo Comparator|2|
9878723|NCT00444834|Experimental|1|Egalet carvedilol
9878724|NCT00444834|Active Comparator|2|Coreg
9878725|NCT00444860|Experimental|1|Zostavax
9878726|NCT00444873|Experimental|28 day dose interval|
9878727|NCT00444873|Experimental|42 day dose interval|
9878728|NCT00444873|Experimental|56 day dose interval|
9878729|NCT00444886|Active Comparator|1|To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
9878730|NCT00444886|Active Comparator|2|To assess the effect of BOTOX injection on numbness and tingling and quality of life.
9878731|NCT00444899|Experimental|Intensive treatment|Submitted to an intensive follow-up by the dietician.
9878732|NCT00444899|Active Comparator|Usual treatment|Subjects will remain under the care of their endocrinologist and/or general practitioner.
9878733|NCT00444977|Experimental|Case-management linkage intervention|"The intervention represents a brief, real world intervention that could easily be adopted by HIV care clinics to facilitate linkage and increase use of oral services by their HIV+ patients (if shown to be effective). We are seeking to compare this intervention to usual practice in these clinics."
9878734|NCT00444977|No Intervention|Standard of Care|Subjects will receive standard of care services.
9878735|NCT00445042|Experimental|A|Intrapatient dose escalation study of sorafenib
9878736|NCT00445055|Experimental|1|Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
9878737|NCT00445055|Experimental|2|Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
9878738|NCT00445055|Placebo Comparator|3|Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
9878739|NCT00445081|Active Comparator|1|
9878740|NCT00445081|Active Comparator|2|
9878741|NCT00445120|Experimental|1|
9878742|NCT00445120|Placebo Comparator|2|
9878743|NCT00445172|Experimental|1|
9878744|NCT00445185|Experimental|1|Henogen Hepatitis B vaccine for uremic patients
9878745|NCT00445185|Active Comparator|2|Fendrix hepatitis B vaccine for uremic patients
9878746|NCT00445367||Case|
9878747|NCT00445367||Control|
9878748|NCT00445445||Patients|Histologically confirmed breast cancer that was diagnosed between the years 2002-2004
9878749|NCT00445445||Healthy participants|Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
9878750|NCT00445471|Other|A|Mifne Approach to PDD
9878751|NCT00445471|Other|B|Treatment as usual
9878752|NCT00445523|Experimental|1|TroVax® alone
9878753|NCT00445523|Experimental|2|TroVax® plus IFN-α
9878754|NCT00445575|Experimental|1|treatment duration: 1 year
9878755|NCT00445575|Placebo Comparator|2|treatment duration: 1 year
9878756|NCT00445575|Experimental|3|duration treatment: 3 years
9878757|NCT00445575|Placebo Comparator|4|treatment duration: 3 years
9878758|NCT00445614|Experimental|Marine trout|150 g/day of trout fed on marine based feed
9878759|NCT00445614|Experimental|Vegetable trout|150 g/d of trout fed on vegetable based feed
9878760|NCT00445614|Other|Poultry|150 g/d of poultry (for comparison)
9878761|NCT00445718||Observational|Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.
9878762|NCT00445809||1|High Risk population for developing AKI during/after CABG surgery.
9878763|NCT00445809||2|Medium Risk population for developing AKI during/after CABG surgery.
9878764|NCT00445835|Other|BA :Active arm|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
9878765|NCT00445835|Other|BC: Conservative arm|Conservative medical approach
9878766|NCT00445913|Experimental|control dendritic cells|autologous dendritic cells that are not treated
9878767|NCT00445913|Experimental|AS ODN dendrtitic cells|autologous dendritic cells treated ex vivo with the mixture of the antisense oligonucleotides
9878768|NCT00445965|Experimental|131I-3F8|This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.
9878769|NCT00446004|Other|A|On an 18-day schedule, Omeprazole (PPI) once daily on days 10 through 16; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and PPI on day 15).
9878770|NCT00446004|Other|B|On an 18-day schedule, Omeprazole (PPI) once daily on days -4 through 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and PPI on day 1, Gleevec® alone on day 15).
9878771|NCT00446069|Experimental|Egalet® morphine|
9878772|NCT00446069|Active Comparator|MST Continus®|
9878773|NCT00446082|Experimental|SOM230 LAR|
9878774|NCT00446173|Experimental|Busulfan + Cyclophosphamide + G-CSF + GM-CSF|
9878775|NCT00446212|Active Comparator|1|Propofol based anaesthetic maintenance with propofol effect-site steered target-controlled infusion, in addition to fentanyl and non-opioid analgesics
9878776|NCT00446212|Active Comparator|2|Desflurane based anaesthetic maintenance with manually controlled administration in 100% oxygen in addition to fentanyl and non-opioid analgesics
9878777|NCT00446225|Experimental|A|Erlotinib (Tarceva)150 mg /day
9878778|NCT00446225|Active Comparator|B|"4 cycles of Chemotherapy:~Cisplatin / Gemcitabine; Cisplatin /Docetaxel; Carboplatin / Gemcitabine; Carboplatin / Docetaxel."
9878779|NCT00446238|Experimental|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
9878780|NCT00446238|Active Comparator|Standard of Community Care Treatment|Standard of Community Care Treatment
9878781|NCT00446316|Experimental|Gleevec plus antacids|Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
9878782|NCT00446316|Experimental|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
9878783|NCT00446342|Experimental|Dose-escalation of SNS-032 injection|Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group.
9878784|NCT00446368|Experimental|RAD001|Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
9878785|NCT00446381|Experimental|1|Patients with Proliferative Diabetic Retinopathy
9878786|NCT00446381|Experimental|2|Patients with Clinically Significant Macular Edema
9878787|NCT00446394|Experimental|1|
9878788|NCT00446394|Active Comparator|2|
9878789|NCT00446407|Experimental|Collaborative Stepped Care|Screening, Antidepressants, Psychosocial interventions (psychoeducation, IPT, adherence management) by Health Counselor, support and supervision by Psychiatrist.
9878790|NCT00446407|Active Comparator|Enhanced Usual Care|
9878791|NCT00446420|Active Comparator|1|These patients will only receive intravenous propofol which will be titrated to an OAA/S score of 3. They will not receive fentanyl, midazolam or any other drugs
9878792|NCT00446420|Active Comparator|2|These patients will receive propofol plus midazolam and/or fentanyl. Midazolam and fentanyl will be given in fixed doses first and propofol will be titrated to effect. All drugs will be given intravenously.
9878793|NCT00446472|Experimental|1|Randomized to Regranex gel
9878794|NCT00446472|Active Comparator|2|Placebo hydrogel will be used for a total of 16 weeks
9878795|NCT00446485|Active Comparator|1|Ginkgo Biloba standardized extract 24/6
9878796|NCT00446485|Placebo Comparator|3|placebo
9878797|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg|Valsartan 80 mg or Amlodipine 5 mg ---> Valsartan + Amlodipine 80 / 5 mg
9878798|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg + Diuretic|Valsartan + Amlodipine 80 / 5 mg + Diuretic
9878799|NCT00446589|Experimental|F|HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide
9878800|NCT00446589|Experimental|I|Hemodialysis pts suffering from osteoporosis who received iv ibandronate
9878801|NCT00446602|Experimental|001|Epoetin alfa Type=exact unit=units number=80 000 form=solution for injection route=subcutaneous use once every week or once every 2 weeks.
9878802|NCT00446628|Experimental|intervention|Five elementary school received intervention consistin of training in hand and respiratory hygiene, and access to hand sanitizer
9878803|NCT00446628|No Intervention|control|Five elementary school received no training or hand sanitizer.
9930452|NCT00928460||Regular preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to current protocol, including routine preoperative ECG.
9930453|NCT00928460||New preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to a new protocol, in which a routine preoperative ECG is no longer provided.
9930454|NCT00928473|Experimental|Lifestyle counseling|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
9930455|NCT00928525|Experimental|Imatinib Mesylate|Patients affected by Desmoid Tumor and Chondrosarcoma will receive Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
9930456|NCT00928538|No Intervention|Usual NFP Care|Usual NFP care includes pregnancy planning and contraceptive advice during nurse home visits, with the prescription and dispensing of contraceptives provided through the women's primary care settings.
9930457|NCT00928538|Experimental|Enhanced NFP Care|Enhanced NFP intervention includes usual NFP care plus the intervention that includes contraceptive administration and distribution in the home
9930458|NCT00928551|Experimental|1|
9930459|NCT00928577||ACAM2000 Smallpox Vaccine Group|Participants are vaccinia vaccine-naive and have received ACAM2000 Smallpox vaccine as part of their Service Member readiness process.
9878804|NCT00446667|Experimental|1|
9878805|NCT00446680|Experimental|1|
9878806|NCT00446680|Placebo Comparator|2|
9878807|NCT00446693|Experimental|I|Use of EndoFast Reliant System
9878808|NCT00446732|Active Comparator|1|
9878809|NCT00446732|No Intervention|2|
9878810|NCT00446745||Abdominal obesity|60 males were recruited according to waist circumference, from lean to obese values
9878811|NCT00446758|Experimental|Zinc|zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children < 12 mo)
9878812|NCT00446758|Placebo Comparator|Placebo|
9878813|NCT00446810|Active Comparator|A1|Benfotiamine
9878814|NCT00446810|Active Comparator|A2|
9878815|NCT00446836|Other|Single arm|Open label use of Xyotax
9878816|NCT00446875|Experimental|Sucrose|Participants received oral sucrose (0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
9878817|NCT00446875|Placebo Comparator|Placebo|Participants received Placebo (sterile water, 0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
9878818|NCT00446888|Active Comparator|1|"these subjects will get a standard protein supplement milkshake during thei study."
9878819|NCT00446888|Experimental|2|"these subjects will receive an enhanced protein supplement milkshake during their study. Product 4808."
9878820|NCT00446901|Placebo Comparator|Placebo|Placebo
9878821|NCT00446901|Experimental|Selenium (selenized yeast)|Selenium (selenized yeast) tablets, 300 ug/day
9878822|NCT00446953|Experimental|1|2x 12 mg betamethazone
9878823|NCT00446953|Placebo Comparator|2|no drugs
9878824|NCT00446979|Experimental|1|UC 781 0.1% carbomer gel
9878825|NCT00446979|Experimental|2|UC 781 0.25% carbomer gel
9878826|NCT00446979|Placebo Comparator|3|Placebo vaginal gel
9878827|NCT00447044|Experimental|2|Subjects drink essential amino acid supplement 3x day for 2 days.
9878828|NCT00447044|Placebo Comparator|1|Subjects receive inert substance versus protein supplement.
9878829|NCT00447044|Experimental|3|Resistance exercise.
9878830|NCT00447096|Experimental|Treatment Arm|Treatment arm will receive treatment 5 days a week for 6 weeks. Repetitive transcranial magnetic stimulation (rTMS) treatment.
9878831|NCT00447096|Sham Comparator|Sham Arm|Sham Arm will not receive any stimulation 5 days a week for 6 weeks. Sham transcranial magnetic stimulation.
9878832|NCT00447148|No Intervention|1|Paired comparison of 2 angiographic techniques
9878833|NCT00447161|Experimental|1|Bacillus Clausii Multi ATB Resist
9878834|NCT00447161|Placebo Comparator|2|Placebo
9878835|NCT00447174|Experimental|treatment|treatment manual
9878836|NCT00447174|No Intervention|control group|
9878837|NCT00447187|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
9878838|NCT00447187|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
9878839|NCT00447187|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
9878840|NCT00447213|Experimental|1|
9878841|NCT00447213|Experimental|2|
9878842|NCT00447317|Experimental|A|Intervention
9878843|NCT00447317|Other|B|Attention control, standard dietary education
9878844|NCT00447343||Treatment group|"Patients with cervical myelopathy undergoing decompressive cervical spine surgery will have two scans (pre-operatively and 6 months post-operatively).~A blinded investigator will administer questionnaires at each time point."
9878845|NCT00447343||Control group|"Healthy Volunteers will have two scans 6 months apart.~A blinded investigator will administer questionnaires at each time point."
9878846|NCT00447395||GROUP 1|Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
9878847|NCT00447395||GROUP 2|•Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, oligozoospermia (1-5 mill/ml), normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
9878848|NCT00447395||GROUP 3|•Oligozoospermia (1-5 mill/ml), < 40 year-old-men, no recurrent miscarriages
9878849|NCT00447395||GROUP 4|•Healthy young sperm donors
9878850|NCT00447408|Active Comparator|A|Education in the hemodialysis diet.
9878851|NCT00447408|Experimental|B|Education in the hemodialysis diet. Behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
9878852|NCT00447473|Other|A|GM-CSF given in combination with ketoconazole and mitoxantrone in patients with progressive prostate cancer despite androgen deprivation and prior taxane containing chemotherapy
9878853|NCT00447525|Experimental|1|
9878854|NCT00447525|Active Comparator|2|
9878855|NCT00447551|Experimental|single group|
9878856|NCT00447577|Experimental|Zylet|Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
9878857|NCT00447577|Active Comparator|Tobradex|Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
9878858|NCT00447642|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
9878859|NCT00447642|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
9878860|NCT00447642|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
9878861|NCT00447668|Experimental|1|
9878862|NCT00447668|Active Comparator|2|Exercise
9878863|NCT00447668|Active Comparator|3|Self-care book recommendations
9878864|NCT00447720|Experimental|PATH counseling|These participants received the PATH intervention
9878865|NCT00447720|Active Comparator|Treatment as Usual|These individuals receive treatment as they normally would receive in the community
9878866|NCT00447733|Experimental|Integrated treatment|Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
9878867|NCT00447733|Active Comparator|Treatment as usual|Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
9878868|NCT00447759|Experimental|Celecoxib|Celecoxib. Celebrex 200-400mg daily in divided doses
9878869|NCT00447759|Active Comparator|Diclofenac|continue usual nsNSAID
9878870|NCT00447798|Experimental|Prevention Care Advocate|Prevention Care Advocate (PCA) intervention contains elements based on cognitive-behavioral theories and strengths-based case management. Intervention arm participants will undergo an 8 session intervention comprised of three components: 1) An individual strengths-based case management approach aimed at motivating participants to seek or maintain their engagement with HIV primary care and drug treatment; 2) A cognitive-behavioral, skills-building approach to increase participants' risk reduction knowledge, skills, and perceived self-efficacy as well as intention to change high risk transmission behaviors; and 3) A community placement in which study participants will have the opportunity to practice their advocacy skills in prevention and care setting.
9878871|NCT00447798|No Intervention|Standard of Care|"Standard of Care (SOC) condition involves standard practice, consisting of usual inpatient/hospital services provided within normal clinical practice, plus a brief educational session consisting of the review of the topics in the Living with HIV brochure published by the Centers for Disease Control and Prevention (CDC)."
9878872|NCT00447837|Experimental|1|
9878873|NCT00447837|Experimental|2|
9878874|NCT00447837|Placebo Comparator|3|
9878875|NCT00447915|Experimental|1|
9878876|NCT00447915|Experimental|2|
9878877|NCT00447915|Active Comparator|3|
9878878|NCT00447967|Experimental|1|IOX
9878879|NCT00447967|Experimental|2|FLOX
9878880|NCT00448045|Experimental|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough peak flow. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough peak flow. Subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
9878881|NCT00448045|Active Comparator|Incentive spirometry|The active control group will consist of individuals assigned to the oximetry with incentive spirometry group. These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
9878882|NCT00448097|Other|Data not available PI relocated|No verifiable data available, PI relocated
9878883|NCT00448110|Experimental|A|intravenous diclofenac dosage level 1
9878884|NCT00448110|Experimental|B|intravenous diclofenac dosage level 2
9878885|NCT00448110|Active Comparator|C|intravenous ketorolac
9878886|NCT00448110|Placebo Comparator|D|placebo
9878887|NCT00448149|Experimental|1|To establish the maximally tolerated dose (MTD) of RAD001 in combination with Nexavar®
9878888|NCT00448214|Experimental|1|Low dose
9878889|NCT00448214|Experimental|2|Middle dose
9878890|NCT00448214|Experimental|3|High dose
9878891|NCT00448214|Active Comparator|4|
9878892|NCT00448253|Experimental|1|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.
9878893|NCT00448253|Placebo Comparator|2|Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)
9878894|NCT00448266|Experimental|2|1 course ddAc, 2 courses IAA with PBPC support
9878895|NCT00448266|Active Comparator|1|3 courses ddAC
9878896|NCT00448292|Experimental|1|PRX-00023 taken twice daily, escalating from 40 mg to 80 mg to 120 mg
9878897|NCT00448292|Placebo Comparator|2|Placebo taken twice daily, escalating from 40 mg to 80 mg to 120 mg
9878898|NCT00448305|Experimental|1|EndoTAG-1 + Paclitaxel
9878899|NCT00448305|Experimental|2|EndoTAG-1
9878900|NCT00448305|Active Comparator|3|Paclitaxel
9878901|NCT00448331||positive screen, negative screen|Positive screens are those who received positive feedback regarding their answers to a mental illness screening assessment. Negative screens received feedback stating that they did not screen positive for any mental illness.
9878902|NCT00448383|Experimental|1|Open-label adalimumab
9878903|NCT00448396|Experimental|Patupilone|
9878904|NCT00448409|Experimental|1|TroVax alone
9878905|NCT00448409|Experimental|2|TroVax plus GM-CSF
9878906|NCT00448461|Active Comparator|1|heparin
9878907|NCT00448461|Active Comparator|2|bivalirudin
9930460|NCT00928577||Other vaccinia vaccine Group|Participants did not receive ACAM2000 Smallpox vaccine as part of their Service Member readiness process because they are still protected by previous vaccinia vaccination or are ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia vaccination or for reasons solely attributable to conditions or characteristics of their contacts (such as a healthy soldier who is married to someone with a contraindicated condition).
9930461|NCT00928603|Experimental|cryotherapy|Focal Cryotherapy of localized tumor of prostate after spatial definition by in-house extended perineal core biopsy using a template biopsy strategy under local or general anesthesia
9930462|NCT00928616|Experimental|plant sterol esters|Participants consume plant sterol ester supplemented margarine (3 g/day)
9930463|NCT00928616|Placebo Comparator|Placebo|Placebo is a non-sterol ester supplemented margarine
9930464|NCT00928629|Other|All Subjects|ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
9930465|NCT00928655|Experimental|acetazolamide|combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
9930466|NCT00928655|Placebo Comparator|placebo capsules|combination of placebo and nocturnal continuous positive airway pressure ventilation
9930467|NCT00928681|Other|0.03 mg/kg or placebo iv|
9930468|NCT00928681|Other|0.1 mg/kg or placebo iv|
9930469|NCT00928681|Other|0.3 mg/kg or placebo iv|
9930470|NCT00928681|Experimental|1.0 mg/kg or placebo iv|
9930471|NCT00928681|Other|3.0 mg/kg or placebo sc|
9930472|NCT00928681|Other|10 mg/kg or placebo iv|
9930473|NCT00928681|Other|0.3 mg/kg or placebo sc|
9930474|NCT00928681|Other|0.1 mg/kg or placebo iv (multiple dose)|
9930475|NCT00928681|Other|0.3 mg/kg or placebo iv (multiple dose)|
9930476|NCT00928681|Other|3.0 mg/kg or placebo iv|
9930477|NCT00928681|Other|0.1 mg/kg or placebo sc|
9930478|NCT00928681|Other|0.3 mg/kg or placebo sc (multiple dose)|
9930479|NCT00928733|Experimental|alcohol|Intraduodenal infusion of ethanol
9930480|NCT00928733|Other|Ethanol|
9930481|NCT00928733|Experimental|Placebo|Intraduodenal infusion of tap water
9930482|NCT00928759||peripubertal obese girls|Peripubertal obese girls, aged 8 - 16 years, who are obese (BMI-for-age percentile greater or equal to 95)
9930483|NCT00928785|Experimental|REPEVAX|
9930484|NCT00928785|Active Comparator|Monovalent tetanus vaccine|
9930485|NCT00928798|Experimental|rapamycin|one facial side rapamycin and one facial side placebo
9930486|NCT00928811|Other|Control|Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
9930487|NCT00928811|Experimental|Simulect|"Simulect (basiliximab) intravenously day of transplant and day 4.~Chronic Simulect (basiliximab) administration monthly for one year duration.~Concomitant decrease in Prograf administration."
9930488|NCT00928837|Active Comparator|flavocoxid 250 mg|Medical Food product
9930489|NCT00928837|Active Comparator|Naproxen|antiinflammatory
9930490|NCT00928837|Placebo Comparator|Placebo|Placebo
9930491|NCT00928837|Experimental|flavocoxid 500 mg|medical food product
9935421|NCT03774485||Crohn's disease (flare state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (flare state). The investigator does not change the routine medical care of study participants.
9878908|NCT00448513|Experimental|catechin|catechin capsule group
9878909|NCT00448643|Experimental|Whole-Abdominal Radiation Therapy and Chemotherapy|
9878910|NCT00448734|Experimental|1|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
9878911|NCT00448734|Active Comparator|2|Docetaxel
9878912|NCT00448786|Other|Arm C|Arm C - AMG 706 75 mg BID 5-days on and 2-days off
9878913|NCT00448786|Other|Arm B|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
9878914|NCT00448786|Other|Arm A|Arm A = AMG 706 125 mg PO daily continuously
9878915|NCT00448825|Experimental|Topiramate|Topiramate + Cognitive Behavioral Therapy
9878916|NCT00448825|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
9878917|NCT00448851|Experimental|1|inhaled allergen challenge
9878918|NCT00448903|Experimental|A|Bemiparin
9878919|NCT00448903|Placebo Comparator|2|Placebo
9878920|NCT00448929|Experimental|Trabeculectomy with Oculusgen|
9878921|NCT00448929|No Intervention|Trabeculectomy without Oculusgen or antifibrotic agents|
9878922|NCT00449098|Experimental|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
9878923|NCT00449098|Active Comparator|MMC|Trabeculectomy with MMC
9878924|NCT00449124|Experimental|Part I-group 1|Part I/Group 1: Cycle 1-TG4040 10^6 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
9878925|NCT00449124|Experimental|Part IIa-group 1|Part IIa/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
9878926|NCT00449124|Experimental|Part IIa-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
9878927|NCT00449124|Experimental|Part I-group 3|Part I/Group 3: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-TG4040 10^8 PFU days 0, 7 and 14.
9878928|NCT00449124|Experimental|Part I-group 2|Part I/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^7 PFU days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
9878929|NCT00449124|Experimental|Part IIb-group 1|Part IIb/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
9878930|NCT00449124|Experimental|Part IIb-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
9878931|NCT00449137|Experimental|Single Arm|
9878932|NCT00449267|Experimental|1|
9878933|NCT00449280|Experimental|A|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
9878934|NCT00449280|Experimental|B|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
9878935|NCT00449280|Experimental|C|Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
9878936|NCT00449280|Experimental|D|Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
9878937|NCT00449293|Active Comparator|1|
9878938|NCT00449293|Active Comparator|2|
9878939|NCT00449488|No Intervention|Control|
9878940|NCT00449488|Active Comparator|Epoetin alfa|i.v bolus 60.000 IU epoetin alfa
9878941|NCT00449553||Pioglitazone 15 mg QD + Sulphonylurea|
9878942|NCT00449553||Pioglitazone 30 mg QD + Sulphonylurea|
9878943|NCT00449553||Pioglitazone 15 mg QD + Metformin|
9997203|NCT01506804|Placebo Comparator|Contralateral training|Steroid injection X 2 and 10 weeks exercise program of asymptomatic shoulder
9878944|NCT00449553||Pioglitazone 30 mg QD + Metformin|
9878945|NCT00449592|Experimental|1|Oral zinc therapy, intervention
9878946|NCT00449592|Placebo Comparator|2|oral placebo
9878947|NCT00449618|Active Comparator|1|Aspirin 100 mg on awakening
9878948|NCT00449618|Active Comparator|2|Aspirin 100 mg at bedtime
9878949|NCT00449618|Placebo Comparator|3|Placebo on awakening
9878950|NCT00449618|Placebo Comparator|4|Placebo at bedtime
9878951|NCT00449683|Experimental|terazosin|open-label treatment group
9878952|NCT00449774|Experimental|Subjects in Treatment regimen C|Subjects in treatment regimen C will receive 200 milligram (mg) orally disintegrating tablets (ODT) of lamotrigine disintegrate in mouth without water in fasting condition.
9878953|NCT00449774|Experimental|Subjects in Treatment regimen D|Subjects in treatment regimen D will receive 200 mg Immediate Release (IR) tablets of lamotrigine with water in fasting condition.
9878954|NCT00449774|Experimental|Subjects in Treatment regimen E|Subjects in treatment regimen E will receive 200 mg ODT disintegrate of lamotrigine in mouth without water in fed state.
9878955|NCT00449774|Experimental|Subjects in Treatment regimen F|Subjects in treatment regimen F will receive 200 mg ODT of lamotrigine, that subjects will swallow with water in fasting condition.
9878956|NCT00449813|Active Comparator|1.|40 mg Pantoprazole
9878957|NCT00449839|Other|A, CSII without bolus|Period A: A constant subcutaneous infusion rate of insulin aspart (0.5 U/hr) is given for 8 hours. Following 3 hours of blood sampling.
9878958|NCT00449839|Other|B; CSII with bolus|Period B: A constant subcutaneous infusion of insulin aspart (0.5 U/hr) is given for 8 hours and upon start a s.c.bolus (1.4 U)of insulin aspart is given. Hereafter follows 3 hours of blood sampling.
9878959|NCT00449839|Other|C; CSII with bolus, optional|A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
9878960|NCT00449852|Experimental|Interactive Voice Response Group|
9878961|NCT00449852|No Intervention|Usual Care Group|
9878962|NCT00449969|Experimental|1. Extended feedback|
9878963|NCT00449969|Active Comparator|2. Limited feedback|
9878964|NCT00450008|Other|A|Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
9878965|NCT00450034|Experimental|1|
9878966|NCT00450086|Experimental|A|
9878967|NCT00450086|Experimental|B|
9878968|NCT00450086|Placebo Comparator|C|
9878969|NCT00450099|Experimental|1|Epidural, bupivacaine
9878970|NCT00450125||Six-Minute Walk Test|Two Six-minute walk tests where total distance walked measured. Tests performed within 15 days of an exercise stress test.
9878971|NCT00450138|Experimental|1|Radiation + vandetanib
9878972|NCT00450138|Experimental|2|Radiation + cisplatin + vandetanib
9878973|NCT00450203|Experimental|ECX + Bevacizumab|ECX + Bevacizumab
9878974|NCT00450203|Active Comparator|Epirubicin, Cisplatin and Capecitabine|ECX chemotherapy
9878975|NCT00450203|Experimental|ECX + Lapatinib|ECX + Lapatinib
9878976|NCT00450229|Experimental|Arm I|Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
9878977|NCT00450229|Experimental|Arm II|Patients receive high-dose, nutritional-grade oral DIM twice daily as in arm I.
9878978|NCT00450229|Placebo Comparator|Arm III|Patients receive oral placebo twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
9878979|NCT00450281||Male, Never-smokers|Male subjects who smoked less than 100 cigarettes during their lifetime.
9878980|NCT00450281||Male, Ever-smokers|Male subjects who have smoked at least 100 cigarettes during their lifetime.
9878981|NCT00450281||Female, Ever-smokers|Female subjects who have smoked less than 100 cigarettes during their lifetime.
9878982|NCT00450281||Female, Never-smokers|Female subjects who have smoked at least 100 cigarettes during their lifetime.
9878983|NCT00450307|Experimental|3F8 and GM-CSF|One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously ~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over ~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.
9878984|NCT00450320|Active Comparator|Rapamycin|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen.
9878985|NCT00450398|Experimental|1|YSPSL (rPSGL-Ig)
9878986|NCT00450398|Placebo Comparator|2|
9930492|NCT00928850|Active Comparator|urethral irrigation but no fascial suturing, QOL forms|The anterior two-thirds of the urethra is divided exposing a Foley catheter that was placed at the beginning of the procedure. Irrigation of the urethra may prevent spread of prostate cancer cells to tissue that is not removed during surgery. The urethra is irrigated with 60 cc of sterile water as it is withdrawn from the patient to 'wash' the urethra.
9930493|NCT00928850|Active Comparator|fascial suturing but no urethral irrigation, QOL forms|For patients undergoing fascial suturing only, after the initial placement of the suture through the urethra a second bite is taken deeply into the fascia of the lateral pelvic fascia.
9878987|NCT00450515|Experimental|vinflunine + capecitabine|"Patients receive vinflunine IV over 20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed periodically for up to 5 years."
9878988|NCT00450541||Fatigue Questionnaire + Interview|
9878989|NCT00450684|Experimental|Group A|Implantation and testing of CRT
9878990|NCT00450684|Experimental|Group B|IImplantation and testing of CRT
9878991|NCT00450697||observation|
9878992|NCT00450736|Experimental|Single Arm|
9878993|NCT00450775|Other|1|
9878994|NCT00450827|Experimental|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab|Patients will be administered a therapeutic doses of intravenous (IV) 131I-3F8 given in a single dose per the dose escalation regimen on day 0 of study. This will be followed by blood draws for pharmacokinetic and dosimetry studies and by gamma camera scan, where feasible. Bevacizumab will be administered at a fixed dose of 15mg/kg on days 1 and 15. Thyroid protection is commenced 10 days prior to administration of 131I-3F8 and continued for 28 days after the therapeutic dose of 131I-3F8. ASCR will be carried out if ANC < 500/ul on day 28 (blood radioactivity will be confirmed to be <1 uCi/ml prior to ASCR). ASCR will be carried out sooner in the case of life-threatening infection in the setting of neutropenia (ANC<500). G-CSF can be used to maintain ANC>500/ul but should not be used for 24 hours immediately before and after ASCR. Blood product support will be provided with platelet and red cell transfusions as required.
9878995|NCT00450853|Experimental|Granisetron SC-Granisetron IV|Granisetron SC followed by Granisetron IV
9878996|NCT00450879|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
9878997|NCT00450892|Other|arm 1|
9878998|NCT00450892|Other|arm 2|
9878999|NCT00450892|Experimental|arm 3|
9879000|NCT00450944|Experimental|Combination Therapy with Immunotoxins Imtox 19 Plus Imtox 22|
9879001|NCT00450957|Experimental|Arm I (high-dose lycopene)|Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
9879002|NCT00450957|Experimental|Arm II (low-dose lycopene)|Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days
9879003|NCT00451087|Experimental|1|
9879004|NCT00451087|Active Comparator|2|
9800162|NCT01681186|Experimental|LY2940680 Tablet Fed (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods
9879005|NCT00451100|Experimental|Sugammadex|2.0 mg/kg Org 25969 (sugammadex)
9879006|NCT00451100|Active Comparator|Neostigmine|50 ug/kg neostigmine
9879007|NCT00451165||colon|
9879008|NCT00451165||rectum|
9879009|NCT00451295|Placebo Comparator|1|
9879010|NCT00451295|Experimental|2|
9879011|NCT00451308|Experimental|1|Foley balloon wih 60cc fluid
9879012|NCT00451308|Active Comparator|2|Foley balloon with 30cc
9879013|NCT00451412|Experimental|Certoparin|
9879014|NCT00451412|Active Comparator|Unfractionated Heparin|
9879015|NCT00451425|No Intervention|control|standard maternity care
9879016|NCT00451503|Experimental|1|surgery
9879017|NCT00451568|Active Comparator|1|metformin
9879018|NCT00451568|Active Comparator|2|desorelle
9988298|NCT01421173|Experimental|Vorinostat + GemBuMel|Vorinostat 200 mg by mouth on Days -8 to -2. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion. Remaining dose is 10 mg/m2/min on Day -8 and -3. Busulfan pharmacokinetics (PK) will be performed with the first dose of 105 mg/m2 by vein on Day -8. The doses of days -6 and -5 will be subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting were not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5. Melphalan 60 mg/m2 by vein on Days -2 and -3. Stem cells by vein over about 30-60 minutes on Day 0. Rituximab 375 mg/m2 on days +1 and +8 for cluster of differentiation antigen 20 (CD20+) tumors. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented. Palifermin 60 mcg/kg by vein daily for 6 doses starting on Day 0. Dexamethasone 8 mg by vein twice a day from day -8 AM to day -2 PM.
9988299|NCT01421199|Other|Myringotomy|On arm
9988300|NCT01421238|Experimental|Resuscitation Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive resuscitation, unless their parents object. If you decline resuscitation please check the box below:~Please check if you decline resuscitation []"
9988301|NCT01421238|Experimental|Comfort Care Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive comfort care, unless their parents object. If you decline comfort care please check the box below:~Please check if you decline comfort care []"
9988302|NCT01421251||Matched cohorts - population based|Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
9988303|NCT01421264|Experimental|Gabapentin|
9988304|NCT01421290|Active Comparator|Conservative treatment|
9988305|NCT01421290|Active Comparator|Surgery|
9988306|NCT01421368|Experimental|DMPA and tenofovir 1% gel|
9988307|NCT01421368|Experimental|Oral contraceptive and tenofovir 1% gel|
9988308|NCT01421394||single group study|
9988309|NCT01421407|Active Comparator|High Intensity Focused Ultrasound|
9988310|NCT01421407|No Intervention|Control group|
9988311|NCT01421420||Alzheimer's Disease|
9988312|NCT01421420||Mild Cognitive Impairment|
9988313|NCT01421420||Other forms of Dementia, not AD|
9988314|NCT01421420||Normal Elderly Individuals|
9988315|NCT01421433|Active Comparator|Tandrilax|Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)
9988316|NCT01421433|Experimental|Dolamin Flex|Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)
9988317|NCT01421485|Experimental|Integrated treatment Program|
9988318|NCT01421485|Active Comparator|Treatment as Usual|
9988319|NCT01421524|Experimental|CC-122 MM-2|A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
9988320|NCT01421524|Experimental|CC-122- DLBCL-2|A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week [5/7 days] and/or 21 continuous days out of 28 days per cycle [21/28 days]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
9988321|NCT01421524|Experimental|CC-122- GBM-2|A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
9988322|NCT01421524|Experimental|Primary Central Nervous System Lymphoma (PCNSL)|During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
9988323|NCT01421550|Active Comparator|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
9988324|NCT01421550|Active Comparator|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
9988325|NCT01421563|Active Comparator|Anplag|
9988326|NCT01421563|Experimental|DP-R202|
9988327|NCT01421576|Active Comparator|High fat meal|
9800163|NCT01681186|Experimental|LY2940680 Tablet Fasted + PPI (Part B)|30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
9988328|NCT01421576|Experimental|DP-R202|under fed condition
9988329|NCT01421615|Placebo Comparator|lotion|lotion:the patients in control group receive washing medicine and are followed up to the 4rd～7th days of postpartum.
9988330|NCT01421615|Experimental|lactobacilli capsule|
9988331|NCT01421615|Experimental|lactobacilli capsules|
9988332|NCT01421628|Experimental|exercise|
9988333|NCT01421680|Active Comparator|Ensure powder|Oral Nutritional Supplements with carbohydrate, lipid, protein, vitamin and minerals
9879019|NCT00451568|Active Comparator|3|desorelle + metformin
9879020|NCT00451620|Experimental|2.|GlucoNorm
9879021|NCT00451620|Experimental|1.|Glyburide
9879022|NCT00451646|Experimental|1|SMOFlipid
9879023|NCT00451646|Active Comparator|2|Intralipid
9879024|NCT00451776|Experimental|1|patients who received etomidate
9879025|NCT00451776|Active Comparator|2|patients who received propofol
9879026|NCT00451841||1|Chronic cough caused by GERD
9879027|NCT00451841||2|Chronic cough without GERD
9879028|NCT00451867|Active Comparator|A|2000 mg per day of CellCept (MMF) divided into 2 equal doses.
9879029|NCT00451867|Placebo Comparator|B|Placebo
9879030|NCT00451880|Experimental|Arm 1|XL281 administered once a day
9879031|NCT00451880|Experimental|Arm 2|XL281 administered twice a day
9879032|NCT00451880|Experimental|Arm 3|XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle.
9879033|NCT00451893|Active Comparator|Heavy-weight|Lichtenstein operation performed with a heavy-weight mesh.
9879034|NCT00451893|Active Comparator|Light-weight|Lichtenstein operation performed with a light-weight mesh.
9879035|NCT00451997|Experimental|Gleevec + Low-Dose Ara-C|
9879036|NCT00452010|Experimental|1|transcutaneous electrical nerve stimulation
9879037|NCT00452010|Placebo Comparator|2|No transcutaneous electrical nerve stimulation
9879038|NCT00452036||Minor head injury|patients with minor head injury
9879039|NCT00452036||minor head injury|patients with minor head injury
9879040|NCT00452075|Experimental|arm 1 medicine|erlotinib daily
9879041|NCT00452088|Experimental|1|15 microgramme candidate vaccine group
9879042|NCT00452088|Active Comparator|2|Hepatitis B comprator group
9879043|NCT00452088|Experimental|3|30 microgrammes candidate vaccine group
9879044|NCT00452088|Active Comparator|4|Hepatitis B vaccine group
9879045|NCT00452153|Experimental|Characterization Legionnella|Characterization Legionnella by polymerase chain reaction (PCR)
9930494|NCT00928850|Active Comparator|both urethral irrigation and fascial suturing, QOL forms|
9930495|NCT00928850|Active Comparator|neither urethral irrigation nor fascial suturing, QOL forms|
9930496|NCT00928863||Haemorrhagia post partum|Women with a high risk for haemorrhagia post partum.
9930497|NCT00928876|Experimental|Anakinra group|Anakinra 150 mg/day during four weeks
9930498|NCT00928876|Placebo Comparator|Placebo|Placebo during four weeks
9930499|NCT00928902|Active Comparator|Peptides with GM-CSF-in-adjuvant, with upfront IL-2|Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 1 and ending at week 7.
9930500|NCT00928902|Active Comparator|Peptides plus GM-CSF-in-adjuvant, delayed IL-2|"Peptides plus GMCSF-in-adjuvant, with delayed IL-2.~Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 4 and ending at week 10."
9930501|NCT00928915|Experimental|Prothrombin complex concentrate (PCC)|intravenously, 30 IU/kg
9930502|NCT00928915|Experimental|Fresh frozen plasma (FFP)|intravenously, 20ml/kg
9930503|NCT00928928|Active Comparator|Open group|Group of patients operated with open approach for colorectal cancer
9930504|NCT00928928|Active Comparator|laparoscopic group|Group of patients operated with laparoscopic approach for colorectal cancer
9930505|NCT00928941|Experimental|Arm 1|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units.
9930506|NCT00928941|Active Comparator|Arm 2|A computer game control condition will be implemented for 3-4 training exercises a week for 40 hours.
9930507|NCT00928967||Group 1|
9930508|NCT00928980|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy and withdrawal of antidepressant medication between the 4th and 5th session, patients being off medication until the end of study period (15 months).
9930509|NCT00928980|Experimental|Combination|Mindfulness Based Cognitive Therapy combined with the use of antidepressant medication during the study (15 months).
9930510|NCT00928980|Active Comparator|Optimal Medical Care|Treatment with optimal medical care: therapeutic dose of antidepressant medication during at least 15 months, administered in accordance with current guidelines.
9930511|NCT00928993||Main group|pediatric patients receiving overnight sleep study
9930512|NCT00929006|Experimental|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
9930513|NCT00929006|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
9930514|NCT00929019|Experimental|dendritic cell vaccination|HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
9879046|NCT00452218|Experimental|Open|
9879047|NCT00452244|Experimental|study arm|Iressa (gefitinib) + simvastatin
9879048|NCT00452244|Active Comparator|control arm|Iressa (gefitinib) only
9879049|NCT00452257|Experimental|A|
9879050|NCT00452465|Experimental|Intervention|A research nurse will meet with participants, complete a detailed nursing assessment and develop of a care plan to help connect participants with resources to allow them to stay in their homes longer.
9879051|NCT00452465|No Intervention|Control|Usual Care
9879052|NCT00452478|Experimental|1|
9879053|NCT00452491|Experimental|1|
9879054|NCT00452491|Active Comparator|2|
9879055|NCT00452556|Active Comparator|Standard Radiotherapy Sequence Arm|Standard sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) first, then prostate/prostate bed last
9879056|NCT00452556|Experimental|Experimental Radiotherapy Sequence Arm|Experimental sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) last, prostate/prostate bed first
9879057|NCT00452569|Experimental|A|Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
9879058|NCT00452569|Experimental|B|Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
9879059|NCT00452569|Experimental|C|Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
9879060|NCT00452569|Active Comparator|D|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
9879061|NCT00452582|Experimental|Sildenafil|Orally administered sildenafil in addition to usual care.
9879062|NCT00452582|Active Comparator|Usual post-stroke care|Usual post-stroke treatment including physical, occupational, and speech therapy.
9879063|NCT00452608|Placebo Comparator|amido pill|
9879064|NCT00452608|Experimental|atorvastatina|atrovastatina 80 mg/d by mouth for 10 days
9879065|NCT00452634|Experimental|study arm|
9879066|NCT00452660|Experimental|evaluating the effect of -Exjade|evaluating the effect of -Exjade (Deferasirox)_on oxidative stress parameters of blood cells in patients with Low risk Mylodysplastic syndrome ( MDS) with Iron over load
9879067|NCT00452777|Experimental|BVT.115959|Capsules containing 7 mg BVT.115959 administered orally three times daily
9879068|NCT00452777|Placebo Comparator|Placebo|Placebo capsules administered orally three times daily
9879069|NCT00452803|Active Comparator|study arm|pre-operative chemotherapy (Pac/Cis)
9879070|NCT00452803|Active Comparator|study arm 2|Pre-operative concurrent chemoradiation therapy
9879071|NCT00452816|Experimental|Intervention|Intervention Group - Workplace Solutions Consulting
9879072|NCT00452816|Active Comparator|2|Delayed Intervention
9879073|NCT00452829|Experimental|Study Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD) and 1 g inositol,
9879074|NCT00452829|Placebo Comparator|Control Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD)and 1 g placebo
9879075|NCT00452881|Experimental|study arm|GemOx
9879076|NCT00452881|Active Comparator|control arm|GemCis
9879077|NCT00452907|Experimental|1|Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
9879078|NCT00452907|Active Comparator|2|Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
9879079|NCT00452907|Active Comparator|3|Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
9879080|NCT00452985||1|"Injection of Docetaxel~3-hour gap~Injection of carboplatin"
9879081|NCT00453037|Active Comparator|group I (early intervention)|"We refer to the results of the DAFNE-study. This study showed the merits of an educational program in diabetics. In accordance to the protocol of DAFNE, we developed a design as follows: For each participating center patients are randomly assigned to two groups. Group I receives an early educational intervention at time of randomization, which should lead to better control of blood pressure after 6 months compared to the control group. The protocol design was chosen for proving an independent effect of the educational program despite optimal management by the GP. Group II is designated to receive the educational intervention 6 months after enrollment into the study.~for further details please see brief description section"
9879082|NCT00453037|Other|delayed education|"delayed educational intervention~for further details please see brief description section"
9879083|NCT00453076|Experimental|Paclitaxel eluting covered metal stent|Paclitaxel eluting covered metal stent group
9879084|NCT00453076|Active Comparator|Control covered metal stent|Control covered metal stent group
9879085|NCT00453115|Experimental|study arm|GemOx
9879086|NCT00453167|Experimental|study arm|
9879087|NCT00453219||1|Women ages 18-35 years with regular ovulatory menstrual cycles
9879088|NCT00453219||2|Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation
9879089|NCT00453219||3|Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).
9879090|NCT00453258||Study Subject|Subjects receiving eye examination
9879091|NCT00453323|Experimental|study arm|
9879092|NCT00453375|Experimental|1|BHT-3021
9879093|NCT00453375|Placebo Comparator|2|BHT-Placebo
9879094|NCT00453453|Experimental|Nesiritide|Subjects who come into the ED with CHF will be treated with nesiritide
9879095|NCT00453453|No Intervention|Standard care|Subjects who come into the ED with CHF will receive standard care treatment
9879096|NCT00453544|Experimental|Enhanced consent - A|The intervention was an enhanced consent process, including a multimedia aid for a moderate risk hypothetical protocol
9879097|NCT00453544|Experimental|Enhanced consent - B|The intervention was an enhanced consent process, including multimedia aide for a higher risk hypothetical protocol
9879098|NCT00453544|Active Comparator|Routine consent - A|This was a comparison condition - a routine consent process, including a printed consent document, for a moderate risk hypothetical protocol
9879099|NCT00453544|Active Comparator|Routine consent - B|This was a comparison condition - a routine consent process, including a printed consent document, for a higher risk hypothetical protocol
9879100|NCT00453570|Experimental|1|DTacP IPV// PRP~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
9879101|NCT00453570|Experimental|2|DTacP-IPV// PRP~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
9879102|NCT00453570|Active Comparator|3|Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age
9879103|NCT00453635|Experimental|1|Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
9879104|NCT00453635|Experimental|2|Vinorelbine + Herceptin (VHer)
9879105|NCT00453648|Placebo Comparator|White-fleshed Sweet Potato|0 ug retinol activity equivalents (RAE)/d as boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule, 6d/wk for 10 wk
9879106|NCT00453648|Experimental|Orange-fleshed Sweet Potato (boiled)|600 ug RAE/d as boiled orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
9879107|NCT00453648|Experimental|Orange-fleshed Sweet Potato (fried)|600 ug RAE/d as fried orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
9879108|NCT00453648|Active Comparator|White-fleshed Sweet Potato and retinyl palmitate capsule|0 ug RAE/d as white-fleshed sweet potato and 600 ug retinol/d as retinyl palmitate, 6d/wk for 10 wk
9879109|NCT00453661||Intervention Group|Patient Navigator (PN) + Educational Materials + Annual Questionnaires
9879110|NCT00453661||Comparison Group|Educational Materials + Exit Questionnaire
9879111|NCT00453674||Adrenocortical carcinoma|Adrenocortical carcinoma
9879112|NCT00453687|Experimental|Arm 1|Drug
9879113|NCT00453700||serological testing|In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.
9879114|NCT00453765|Experimental|A|montelukast
9879115|NCT00453765|Placebo Comparator|B|placebo
9879116|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).
9879117|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
9879118|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.
9879119|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
9879120|NCT00453791|Experimental|Subjects receiving GW805858: Part 3|Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.
9879121|NCT00453791|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo administered using MDI.
9879122|NCT00453817|Experimental|Study subjects|One-arm observational study
9879123|NCT00453843|Experimental|proximal to distal training|
9879124|NCT00453843|Experimental|distal to proximal|
9879125|NCT00453843|Experimental|proximal and distal on alternate days|
9879126|NCT00453843|Experimental|proximal and distal same day|
9930515|NCT00929019|No Intervention|control arm|For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).
9930516|NCT00929032||Liver transplant recipient|Liver transplant recipient
9930517|NCT00929045|Experimental|Growth Hormone|
9930518|NCT00929058|Experimental|Bevacizumab|
9930519|NCT00929084|Other|Survivor Stories Arm|Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
9930520|NCT00929084|Other|Control Arm|Women in the Control Arm will receive standard care.
9930521|NCT00929097|Experimental|Implementation aids|
9930522|NCT00929097|Active Comparator|Control|
9930523|NCT00929123|Experimental|neural mobilization|manual therapy technique known to directly stress the median nerve
9930524|NCT00929123|Placebo Comparator|sham neural mobilization|manual therapy technique known to directly stress the median nerve without any stimulation.
9930525|NCT00929123|Active Comparator|Healthy Controls|People without carpal tunnel syndrome for comparison
9930526|NCT00929136|Experimental|Endotoxin|
9930527|NCT00929175|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
9988334|NCT01421680|No Intervention|Standard care|Standard care without oral nutritional supplements
9988335|NCT01421693|Active Comparator|Gatifloxacin|Gatifloxacin 10mg/kg/day for 7 days
9988336|NCT01421693|Active Comparator|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days"
9988337|NCT01421706|Active Comparator|sibutramine-clopidogrel|sibutramine-clopidogrel
9988338|NCT01421706|Active Comparator|sibutramine-clarithromycin|sibutramine-clarithromycin
9988339|NCT01421732||Suspected dengue fever|Children aged 1-15 presenting at participating hospitals with symptoms of dengue fever
9988340|NCT01421745|Experimental|Cultural Competence Module|The module will include lecture, case studies, and discussion of cultural competence.
9988341|NCT01421758|Experimental|online social network|
9988342|NCT01421758|Active Comparator|web education control|
9988343|NCT01421771|Active Comparator|Treatment to an intensive BP goal|Treatment to a pre-dialysis standardized dialysis unit systolic blood pressure of 110-140 mm Hg
9988344|NCT01421771|Placebo Comparator|Treatment to standard BP goal|Treatment to a pre-dialysis Standardized dialysis unit systolic BP of 155-165 mm Hg
9988345|NCT01421784|Other|Cine-MRI|Rapid Cine-MRI
9997204|NCT01506817||Fibromyalgia|patients with fibromyalgia fulfilling the 1990-ACR research criteria and with pain in the hands as a prominent clinical feature
9997205|NCT01506817||Controls|healthy aged matched pain-free controls
9997206|NCT01506830|Active Comparator|Absolute isolation|Absolute isolation of the operatory field with rubber dam: Moisture control is provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
9997207|NCT01506830|Experimental|Relative isolation|Relative isolation of the operatory field with cotton rolls: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
9997208|NCT01506843|Active Comparator|mite allergen drop|Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.
9997209|NCT01506843|Active Comparator|mite plus bacterial extracts|Vaccine constituted with mite and bacterial extracts will be compared to placebo.
9997210|NCT01506843|Placebo Comparator|Placebo|Placebo will be constituted by the same solution used to make dilution of the allergen extracts.
9997211|NCT01506856|Active Comparator|Standard treatment: dd-TCiv therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
9997212|NCT01506856|Experimental|Study treatment: dd-TCip therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
9997213|NCT01506869||Type 2 diabetes|
9997214|NCT01506869||Prediabetes|
9997215|NCT01506869||Normal glucose regulation|
9997216|NCT01506895|Experimental|darapladib|darapladib dosed at 160 mg once daily
9997217|NCT01506895|Placebo Comparator|placebo|Placebo to match once daily
9997218|NCT01506921|Active Comparator|Racemic ketamine|
9997219|NCT01506921|Active Comparator|S-ketamine|All subjects receive both study drugs in a cross- over design. Equipotent doses are used. 0,6 mg/kg racemic ketamine equals 0,3 mg/kg s-ketamine
9997220|NCT01506934|Experimental|linifanib|Single Doses
9997221|NCT01506986|Active Comparator|H. pylori eradication treatment|Active treatment will consist of seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
9997222|NCT01506986|Placebo Comparator|Placebo H. pylori eradication treatment|Placebos to seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
9997223|NCT01506999||Stable phase of ischemic heart disease|patients with history of angina pectoris, or myocardial infarction
9997224|NCT01506999||acute phase of ischemic heart disease|patients with unstable angina or acute myocardial infarction
9997225|NCT01506999||control group|subjects without ischemic heart disease (IHD)
9997226|NCT01507012|Experimental|Powdered berryfruit extract|Powdered berry extract containing 500mg of polyphenols
9997227|NCT01507012|Placebo Comparator|Placebo|
9997228|NCT01507012|Experimental|Berryfruit juice|Berryfruit juice containing 500mg polyphenols
9997229|NCT01507025||horizontal flap|patients were scheduled to undergo LASIK and with horizontal flaps(nasal- or temporal-hinge)
9997230|NCT01507025||vertical flap|patients were scheduled to undergo LASIK and with vertical flaps(superior- hinge)
9997231|NCT01507038|Experimental|Group A|
9997232|NCT01507038|Experimental|Group B|
9997233|NCT01507038|Experimental|Group C|
9997234|NCT01507038|Placebo Comparator|Group D|
9997235|NCT01507064|Active Comparator|Group A|Patients who undergo to LA without sorafenib pretreatment
9997236|NCT01507064|Experimental|Group B|Patients who are treated with sorafenib before LA
9879127|NCT00453960|Experimental|Genistein|Genistein 54 mg/day
9879128|NCT00453960|Active Comparator|Norethisterone Acetate|Norethisterone Acetate 10mg/day
9879129|NCT00453960|Placebo Comparator|Placebo|Placebo tablets, daily
9879130|NCT00454025||Glaucoma|Patients with Glaucoma
9879131|NCT00454025||Healthy Patients|Patients without glaucoma
9879132|NCT00454064|Active Comparator|1|cognitive-behavioral treatment
9879133|NCT00454064|Active Comparator|2|cognitive-behavioral treatment with biofeedback elements
9879134|NCT00454155|Experimental|Opebacan|
9879135|NCT00454168|Experimental|Arm I|Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
9879136|NCT00454168|Active Comparator|Arm II|Patients receive placebo vaccine and GM-CSF subcutaneously.
9879137|NCT00454233|Experimental|1|Dose 1
9879138|NCT00454233|Experimental|2|Dose 2
9879139|NCT00454233|Experimental|3|Dose 3
9879140|NCT00454233|Experimental|4|Dose 4
9879141|NCT00454233|Active Comparator|5|
9879142|NCT00454233|Placebo Comparator|6|
9879143|NCT00454259|Experimental|1|0,5 µg/kg
9879144|NCT00454259|Experimental|2|0,05 µg/kg
9879145|NCT00454259|Experimental|3|0,005 µg/kg
9879146|NCT00454259|Placebo Comparator|4|NaCl 0,9 %
9879147|NCT00454272|Active Comparator|1, Vancomycin|Vancomycin
9879148|NCT00454272|Active Comparator|2, Teicoplanin|Teicoplanin
9879149|NCT00454298|Active Comparator|A|AGG-523 1800 mg QD PO (12 capsules) for 28 days
9879150|NCT00454298|Active Comparator|B|AGG-523 900 mg BID PO (12 capsules) for 28 days
9879151|NCT00454298|Placebo Comparator|C|Placebo QD PO (12 capsules) for 28 days
9879152|NCT00454298|Placebo Comparator|D|Placebo BID PO (12 capsules) for 28 days
9879153|NCT00454311|Active Comparator|One cell biopsy|
9879154|NCT00454311|Other|Two cell biopsy|
9879155|NCT00454337|Experimental|Intensification arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
9879156|NCT00454337|Active Comparator|Standard arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir
9879157|NCT00454389|Experimental|A|Epi-Rad90™ Ophthalmic System procedure + Lucentis
9879158|NCT00454389|Active Comparator|B|Lucentis only
9879159|NCT00454454||No treatment|
9879160|NCT00454493|Active Comparator|fish oil|
9879161|NCT00454493|Placebo Comparator|placebo|
9879162|NCT00454519|Experimental|A|cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
9879163|NCT00454519|Active Comparator|B|cytoreductive surgery alone, postoperative chemotherapy.
9879164|NCT00454558|Experimental|Arm 1|
9879165|NCT00454662|Active Comparator|1|olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
9879166|NCT00454662|Active Comparator|2|AT1 subtype angiotensin II receptor antagonist/low dose diuretic
9879167|NCT00454688|Placebo Comparator|Placebo|
9879168|NCT00454688|Experimental|Asimadoline 0.15 mg|
9879169|NCT00454688|Experimental|Asimadoline 0.5 mg|
9879170|NCT00454688|Experimental|Asimadoline 1.0 mg|
9879171|NCT00454701||1. Amevive Exposure|Patients treated with alefacept for chronic plaque psoriasis
9879172|NCT00454714|Active Comparator|A|Sildenafil arm
9879173|NCT00454714|Placebo Comparator|B|Placebo arm
9879174|NCT00454740|Experimental|1|
9879175|NCT00454766||Questionnaire|Questionnaire Regarding Tailored Educational Materials
9879176|NCT00454792|Active Comparator|Exercise and advise to stay active|The exercise group received exercises for the stabilising muscles in the low back and abdomen together with dynamic exercises, exercises for postural instability and light physical fitness training.
9879177|NCT00454792|Experimental|Rest and use of flexible lumbar belt|The rest group was instructed to avoid hard physical activity and to rest twice daily for one hour, by lying down
9879178|NCT00454831|Active Comparator|HEP 400mg TID|HEP-40 400 mg three times a day
9879179|NCT00454831|Active Comparator|HEP 800mg BID|HEP-40 800 mg twice a day
9879180|NCT00454831|Active Comparator|HEP 800mg TID|HEP-40 800 mg three times a day
9879181|NCT00454831|Active Comparator|HEP 2400mg QD|HEP-40 2400 mg once a day
9879182|NCT00454831|Placebo Comparator|Placebo|Placebo, three times a day
9879183|NCT00454883||1 cohort of patients treated with ziprasidone|
9879184|NCT00454896|Experimental|1|
9879185|NCT00454896|Placebo Comparator|2|
9879186|NCT00454922|Active Comparator|1|education
9879187|NCT00454922|Placebo Comparator|2|standard of care
9879188|NCT00455000|Experimental|Active treatment|5 possible active doses
9879189|NCT00455000|Placebo Comparator|Placebo|
9879190|NCT00455026|Placebo Comparator|1|0 ng/ml target effect site concentration remifentanil
9879191|NCT00455026|Active Comparator|2|2 ng/ml target concentration remifentanil
9879192|NCT00455026|Active Comparator|3|4 ng/ml target effect site concentration remifentanil
9879193|NCT00455052|Experimental|XMT-1001|XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m^2, the next dose level is 30 mg/m^2, followed by dose levels: 50 mg/m^2, 80 mg/m^2, 120 mg/m^2, 150 mg/m^2, and 190 mg/m^2 until disease progressions or unacceptable side effects are experienced.
9879194|NCT00455117|Placebo Comparator|1|placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
9879195|NCT00455117|Active Comparator|2|parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy
9879196|NCT00455169||1|Premature infants
9879197|NCT00455169||2|Full term infants
9879198|NCT00455182|Placebo Comparator|1|Standard medical care
9879199|NCT00455182|Experimental|2|Acupuncture
9879200|NCT00455182|Sham Comparator|3|Sham acupuncture
9879201|NCT00455221|Experimental|Peptide Vaccine|
9879202|NCT00455299|Active Comparator|a|a: suture anchoring + tackers and approximation of defect
9879203|NCT00455299|Active Comparator|b|b: suture anchoring + tackers without approximation of defect
9879204|NCT00455299|Active Comparator|c|c: only tacker fixation and approximation of defect
9879205|NCT00455299|Active Comparator|d|d: only tacker fixation without approximation of defect
9879206|NCT00455325|Placebo Comparator|Placebo Comparator Limb 1|Chloroquine placebo one tablet daily for 3 weeks
9879207|NCT00455325|Active Comparator|Chloroquine Limb 2|80mg chloroquine or placebo tablet weekly for Weeks 1-3
9879208|NCT00455325|Active Comparator|Chloroquine Limb 3|80mg tablet daily for 3 weeks
9879209|NCT00455325|Active Comparator|Chloroquine Limb 4|250mg tablet daily for 3 weeks
9879210|NCT00455351|Experimental|A I|Study drug
9879211|NCT00455507|Experimental|1|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
9879212|NCT00455507|Experimental|2|40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
9879213|NCT00455507|Placebo Comparator|3|Two placebo tablets once daily for 12 weeks
9879214|NCT00455572|Experimental|Cohort 1|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
9879215|NCT00455572|Experimental|Cohort 2|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
9879216|NCT00455572|Experimental|Cohort 3|Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
9879217|NCT00455572|Experimental|Cohort 4|Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
9879218|NCT00455598|Placebo Comparator|A|Sulfonylurea + 100 mg/week ISIS 113715 or placebo
9879219|NCT00455598|Placebo Comparator|B|Sulfonylurea + 200 mg/week ISIS 113715 or placebo
9879220|NCT00455637|Experimental|Dysport 5 units|
9879221|NCT00455637|Experimental|Dysport 10 units|
9879222|NCT00455637|Experimental|Dysport 15 units|
9879223|NCT00455767|Active Comparator|1|Depelestat
9879224|NCT00455767|Placebo Comparator|2|Placebo
9879225|NCT00455780|Experimental|MR-/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy for weight loss maintenance.
9930528|NCT00929175|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
9879226|NCT00455780|Experimental|MR+/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy and use of meal replacements for weight loss maintenance.
9879227|NCT00455780|Experimental|MR-/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy as well as Reduced Energy Density Education for weight loss maintenance.
9879228|NCT00455780|Experimental|MR+/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy, as well as Reduced Energy Density Education and continued meal replacement use, for weight loss maintenance.
9879229|NCT00455793||1|HIV
9879230|NCT00455793||2|Non-HIV infected controls
9879231|NCT00455845|Active Comparator|1 levonorgestrel IUD|
9879232|NCT00455845|No Intervention|2 control|
9879233|NCT00455871|Active Comparator|Lucentis plus Reduced Fluence PDT same day|
9879234|NCT00455871|Active Comparator|Lucentis plus reduced fluence PDT 1-2 weeks later|
9930529|NCT00929227||1|Stress MRI perfusion, and cardiac CT will have observed sensitivity, specificity, and accuracyof at least 0.80 in predicting CAD in a patient population with prior equivocal stress testing.
9930530|NCT00929253|Active Comparator|Computer delivered CRA + CM + Suboxone|"In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples."
9930531|NCT00929253|Active Comparator|Therapist delivered CRA + CM + Suboxone|In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer deliver therapy, only therapist delivered therapy.
9930532|NCT00929266|Experimental|1|"The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects."
9930533|NCT00929279|Active Comparator|Abciximab bolus plus infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen.
9930534|NCT00929279|Experimental|bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
9930535|NCT00929292|Experimental|Modilac Dahlia 1|Formula enriched with alpha-lactalbumin and containing a probiotic
9930536|NCT00929292|Placebo Comparator|Modilac 1|Regular milk
9930537|NCT00929318|Active Comparator|benign|patients after surgery because of a benign disease
9930538|NCT00929318|Active Comparator|DTC|Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
9930539|NCT00929370|Experimental|GSK1018921|Glycine Transporter-1 inhibitor to modulate the NMDA receptor.
9930540|NCT00929396|Experimental|Latent TB infection group|The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
9930541|NCT00929396|Experimental|BCG vaccinated group|The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart
9930542|NCT00929409|Active Comparator|Peroral iron - ferrous sulfate tablets|Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
9930543|NCT00929409|Active Comparator|Ferric carboxymaltose|Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
9930544|NCT00929422||spinal cord injury 1|
9930545|NCT00929422||spinal cord injury 2|
9930546|NCT00929422||spinal cord injury 3|
9930547|NCT00929422||normal control|
9930548|NCT00929435||MRSA surveillance|Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.
9930549|NCT00929448||Immunoglobulin|
9879235|NCT00455897|Experimental|GMCSF-RCHOP|
9879236|NCT00455936|Experimental|study arm|Gefitinib 250mg table/QD, daily every 3 weeks
9879237|NCT00455936|Active Comparator|control arm|gemcitabine 1250mg/m2 iv on D1 & D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
9879238|NCT00456105|Active Comparator|1|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician, post operatively until hospital discharge and post discharge in the community.
9879239|NCT00456105|Experimental|2|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team post operatively until hospital discharge and post discharge in the community. The Diabetes Action team will consist of a nurse coordinator who is a Certified Diabetes Educator (CDE) and a team of physicians specialized in the management of diabetes.
9879240|NCT00456105|Placebo Comparator|3|Subjects without diabetes will have their blood glucose levels monitored while in the hospital.
9879241|NCT00456118||repeated miscarriages|60 womens for repeated miscarriages will be included
9879242|NCT00456118||Preeclampsia|70 women for pre-eclampsia will be included
9879243|NCT00456118||intervillites|20 women for intervillites will be included
9879244|NCT00456131|Experimental|Intervention|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
9879245|NCT00456144||Group 1|GnRH agonist for 24 months
9879246|NCT00456144||Group 2|GnRH agonist for 6 months
9879247|NCT00456222||Luteal|
9879248|NCT00456222||Follicular|
9879249|NCT00456235|Experimental|adjument MMF|adjusting the dose according to the MMF AUC of mycophenolic acid
9879250|NCT00456235|Active Comparator|continued treatment|Continued treatment empirically usual
9879251|NCT00456248|Experimental|1|Infergen 15 ug QD plus RBV for 36 weeks
9879252|NCT00456248|Experimental|2|Infergen 15 ug QD plus RBV for 48 weeks
9879253|NCT00456248|Active Comparator|3|
9879254|NCT00456274|Other|1|
9879255|NCT00456313|Active Comparator|arm 1|
9879256|NCT00456326||HIT Patients|Patients at Brigham and Women's Hospital diagnosed with Heparin Induced Thrombocytopenia.
9879257|NCT00456482|Experimental|Fluocinolone Acetonide 0.59mg|Fluocinolone acetonide intravitreal implant 0.59mg
9879258|NCT00456482|Experimental|Fluocinolone Acetonide 2.1mg|Fluocinolone acetonide intravitreal implant 2.1mg
9879259|NCT00456482|No Intervention|No Intervention|Fellow eye
9879260|NCT00456638|Experimental|Depodur|Depodur arm
9879261|NCT00456638|Active Comparator|Traditional|traditional management
9879262|NCT00456677|Experimental|Minocycline|Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
9879263|NCT00456677|Placebo Comparator|Placebos|Addition of placebo capsules po twice daily to current asthma treatment regimen
9879264|NCT00456690|Experimental|1|Thalassemia Mayor Patients
9879265|NCT00456703|Active Comparator|restriction|In this group, the fluids will be restricted compared to a standard procedure
9879266|NCT00456781|Experimental|Augmentation|Rotator Cuff Repair augmented with the Graft Jacket Device
9879267|NCT00456781|Active Comparator|No Augmentation|Rotator Cuff RFepair
9879268|NCT00456833|Experimental|RAD 5mg/day + erlotinib|
9879269|NCT00456833|Active Comparator|erlotinib 150mg/day|
9879270|NCT00456872|Experimental|buffered lidocaine|Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
9879271|NCT00456872|Experimental|unbuffered lidocaine|lidocaine is injected without sodium bicarbonate added
9879272|NCT00456963|Experimental|Diet, exercise and Enalapril|one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
9879273|NCT00456963|Active Comparator|Diet, Exercise and Losartan|one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
9879274|NCT00456963|Placebo Comparator|Diet, exercise and Placebo|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
9879275|NCT00457119|Experimental|Step 1 Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel
9879276|NCT00457119|Experimental|Step 1, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel
9879277|NCT00457119|Experimental|Step 2, Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
9997237|NCT01507077|Placebo Comparator|ZGN-440 sterile diluent|
9988346|NCT01421797|Experimental|Dexamethasone, Cortrosyn|Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
9988347|NCT01421810|Experimental|dexamethasone, rhCG (Ovidrel)|rhCG (Ovidrel) administered 25 mcg IV; dexamethasone administered 1 mg PO
9988348|NCT01421823|Experimental|alpha agonist ointment|
9988349|NCT01421823|Placebo Comparator|Placebo|
9988350|NCT01421836|Active Comparator|ERCP guided stent insertion|
9988351|NCT01421836|Active Comparator|EUS guided stent insertion|
9988352|NCT01421849|Experimental|Elderly with an unstable mandibular denture.|
9988353|NCT01421901|Experimental|Ertapenem|
9988354|NCT01421901|Active Comparator|appendectomy|Appendectomy is compared to Ertapenem
9988355|NCT01421914|Other|Bupivacaine 0,5%|Single arm study
9988356|NCT01421927|Experimental|lenalidomide|
9879278|NCT00457119|Experimental|Step 2, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab
9879279|NCT00457158|Experimental|1|ALN optional filter
9879280|NCT00457158|No Intervention|2|No ALN optional filter
9879281|NCT00457223|Experimental|1Fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®)
9879282|NCT00457223|Active Comparator|2 Suture|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using continuous suture with nylon 10-0
9879283|NCT00457314|Experimental|1|Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
9879284|NCT00457314|Experimental|2|Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
9879285|NCT00457353|Active Comparator|1|Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
9879286|NCT00457353|Placebo Comparator|2|Administration of Oral rehydration therapy
9879287|NCT00457405|Active Comparator|1|first 7 day treatment with dipyridamol and at least two weeks later 7 day treatment with placebo
9879288|NCT00457405|Active Comparator|2|first 7 day treatment with placebo and at least two weeks later 7 day treatment with atorvastatin
9879289|NCT00457431|No Intervention|Control|Standard therapy as used in the hospital's ICU
9879290|NCT00457431|Active Comparator|Hypothermia|Standard therapy as used in the hospital's ICU plus Hypothermia
9879291|NCT00457496|Active Comparator|A|
9879292|NCT00457509|Experimental|Group 1|Dose 1 with Adjuvant
9879293|NCT00457509|Experimental|Group 2|Dose 2 with adjuvant
9879294|NCT00457509|Experimental|Group 3|Dose 3 with adjuvant
9879295|NCT00457509|Experimental|Group 4|Dose 4 with adjuvant
9879296|NCT00457509|Active Comparator|Group 5|Control
9988357|NCT01421940|Placebo Comparator|Control|Individuals who take placebo after total mesorectal excision
9988358|NCT01421940|Experimental|Udenafil|Individuals who take udenafil after total mesorectal excision
9988359|NCT01421953|Experimental|Patients|
9988360|NCT01421966|Experimental|CureXcell®|
9988361|NCT01421966|Sham Comparator|Sham injection|
9988362|NCT01421979|Experimental|exposure under sleep deprivation|Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
9988363|NCT01421979|Experimental|Exercise after consumption|Examination of the effects of EDs in combination with alcohol consumption and exercise.
9879297|NCT00457652|Active Comparator|1|7 day treatment rosuvastatin
9879298|NCT00457652|Placebo Comparator|2|7 day treatment placebo
9879299|NCT00457756|Active Comparator|I|Cohort I subjects will take supplement for 12 weeks
9879300|NCT00457756|Placebo Comparator|II|Cohort II will take placebo for 12 weeks
9879301|NCT00457769|Experimental|Aricept- A|Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.
9879302|NCT00457769|Experimental|A2-12-week waiting period|The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks
9879303|NCT00457782|Experimental|I|Intravenous KW-2478 (ascending dose cohorts)
9879304|NCT00457938|Other|"Low fat diet is the drug"|Diet 10% fat versus 35% fat
9879305|NCT00457964|Experimental|Administration of RAD001|
9879306|NCT00458003|Experimental|Phenylephrine|Subject will receive a phenylephrine infusion to prevent and to treat hypotension associated with spinal anesthesia
9879307|NCT00458003|Active Comparator|Ephedrine|Subject will receive an ephedrine infusion to prevent and to treat hypotension associated with spinal anesthesia
9879308|NCT00458016|Experimental|1|
9879309|NCT00458016|Experimental|2|
9879310|NCT00458016|Experimental|3|
9879311|NCT00458016|Experimental|4|
9879312|NCT00458016|Placebo Comparator|5|
9879313|NCT00458029|Experimental|School based intervention|Integration of activities, events, and programs affecting total school food service environment, physical education class, behavior change, promotion, and communications
9879314|NCT00458029|No Intervention|Control|Observational control
9879315|NCT00458081|Experimental|Rimonabant|
9879316|NCT00458081|Placebo Comparator|Placebo|
9879317|NCT00458094|Experimental|1|Participants will receive the peer-supported physical activity intervention
9879318|NCT00458094|Active Comparator|2|Participants will receive physical activity without peer support
9879319|NCT00458120|Experimental|1|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
9879320|NCT00458120|Experimental|2|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.
9879321|NCT00458120|Experimental|3|Participants previously vaccinated with rDEN2/4delta30(ME) will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
9879322|NCT00458120|Experimental|4|Participants previously vaccinated with rDEN1delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) vaccine into the deltoid region of either arm.
9879323|NCT00458120|Placebo Comparator|5|One subcutaneous vaccination with placebo into the deltoid region of either arm.
9879324|NCT00458133|Experimental|1|We randomly assigned 72 individuals to an aerobic exercise training only group.
9879325|NCT00458133|Experimental|2|We randomly assigned 73 individuals to an resistance exercise training only group.
9879326|NCT00458133|Experimental|3|We randomly assigned 76 individuals to a combination of aerobic plus resistance training group.
9879327|NCT00458133|Placebo Comparator|4|We randomly assigned 41 individuals to a stretching and relaxation group.
9879328|NCT00458146|Experimental|1|MM-093
9879329|NCT00458146|Placebo Comparator|2|Placebo
9879330|NCT00458159|Experimental|1|
9879331|NCT00458198|Experimental|1|Participants will receive integrated behavioral therapy
9879332|NCT00458198|Active Comparator|2|Participants will receive integrated behavioral therapy after a 12-week waitlist period
9879333|NCT00458224|Experimental|Parental counseling|Life style counseling
9879334|NCT00458263|Experimental|single arm|
9879335|NCT00458289|No Intervention|1|P-containing meal alone
9879336|NCT00458289|Active Comparator|2|P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
9879337|NCT00458289|Active Comparator|3|P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
9879338|NCT00458354|Experimental|Spinal Sealant|Dural repair with the Spinal Sealant System.
9879339|NCT00458354|Active Comparator|Standard Methods|Dural repair with standard methods such as the closing of the dura with stitches.
9879340|NCT00458367||001|Open label risperidone long acting injectable intramuscular injections every 2 weeks for 26 weeks flexible dose 25 to 50 mg
9879341|NCT00458419|Placebo Comparator|A: naloxone; B: normal saline|Arm A: IV naloxone Arm B: IV normal saline
9879342|NCT00458445|Experimental|SPD465 then Placebo|
9879343|NCT00458445|Experimental|Placebo then SPD465|
9879344|NCT00458458|Active Comparator|NA alone|Norethindrone Acetate (NA) 5mg taken 1-3 tabs orally every night for duration of treatment
9935422|NCT03774082|Experimental|INC424 (ruxolitinib)|Subjects who will be administered 5mg ruxolitinib tablet or ruxolitinib oral pediatric formulation twice a day.
9879345|NCT00458458|Active Comparator|LD then NA|Lupron Depot(LD) given intramuscularly every 12 weeks for total of 24 weeks then switched to Norethindrone Acetate (NA) taken 1-3 tablets orally every night for remainder of treatment
9879346|NCT00458497|Experimental|1|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
9879347|NCT00458497|Placebo Comparator|2|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.
9879348|NCT00458510|Experimental|Fentanyl, Open-Label treatment|All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day
9879349|NCT00458549|Experimental|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
9879350|NCT00458549|Placebo Comparator|Corn Oil|Oral 8g once a day for 21 days prior to (biopsy) surgery
9879351|NCT00458562||HIV+, <CIN2|HIV positive women without CIN2-3 or worse
9879352|NCT00458562||HIV-, no >=CIN3 biopsy, HR HPV+|HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
9879353|NCT00458562||HIV-, <=CIN1, HPV- at screening|HIV negative women who are <= CIN1 and HPV negative at screening
9879354|NCT00458575|Experimental|CNTO 2476|Participants 1 to 4: advanced retinitis pigmentosa (RP) with light perception only (LP); Participant 5: combination visual acuity of LP in the treated eye and no better than hand motion (HM) in the fellow eye; and Participants 6 to 9: advanced RP with hand motion (HM) will receive different dose levels of CNTO 2476.
9879355|NCT00458653|Experimental|Group A|Post-transplant vaccination
9879356|NCT00458653|Experimental|Group B|Pre- and post-transplant vaccination
9879357|NCT00458679|Experimental|Vaccine|autologous B-CLL vaccine expressing CD40L and IL2
9879358|NCT00458731|Experimental|Treatment (cediranib maleate and bevacizumab)|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bevacizumab and cediranib maleate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
9879359|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2
9879360|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2
9879361|NCT00458874|Experimental|Receive CIMT Results (R-CIMT)|This group will receive visual feedback of their CIMT results on a weekly basis.
9879362|NCT00458874|No Intervention|Withhold CIMT Results (W-CIMT)|The W-CIMT group will not receive their CIMT results until the end of their study participation.
9879363|NCT00458887||Ancillary/Correlative (ototoxicity assessment)|"Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) for management of therapy complications before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.~Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests for management of therapy complications before the transplantation and 4 weeks after transplantation."
9879364|NCT00458900|Experimental|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
9879365|NCT00459030|Experimental|Print Communication|Cancer screening educational information mailed to patient's home one time after signing consent.
9879366|NCT00459030|Experimental|Electronic communication|Cancer screening educational information delivered via a password protected internet site.
9879367|NCT00459030|Active Comparator|No Health Communication|No additional cancer screening education information sent to patient.
9879368|NCT00459160|Experimental|Low MAP Group|Hypotensive Group with a target minimum MAP of 50 mmHg
9879369|NCT00459160|No Intervention|High MAP group|Non experimental group: These patients will have a target minimum MAP of 65 mm Hg
9879370|NCT00459212|Experimental|Arm I|Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
9879371|NCT00459225|Active Comparator|1|The parent/guardian will be educated on the iron study and provided the opportunity to ask questions. If the parent/guardian chooses to participate in the study, the parent/guardian will give informed consent for the patient to be placed in either Group I or Group II, based upon guardian/parents' choice for participation in the iron arm of the study. Group I will be randomized in a 1:1 ratio in this open label trial to either receive or not receive iron. Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
9879372|NCT00459225|No Intervention|2|Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
9879373|NCT00459264|Active Comparator|1|Folic Acid
9879374|NCT00459264|Placebo Comparator|2|Matching placebo for folic acid
9988364|NCT01421992|Placebo Comparator|Arm 1: Methylphenidate versus baseline|
9997238|NCT01507077|Experimental|ZGN-440|
9879375|NCT00459407|Experimental|Arm I (green tea catechin extract)|"Patients receive oral defined green tea catechin extract daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
9879376|NCT00459407|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
9879377|NCT00459420|Placebo Comparator|Placebo|
9879378|NCT00459420|Experimental|Caffeine|
9879379|NCT00459433|Experimental|1|psychosocial intervention
9879380|NCT00459433|Active Comparator|2|Usual care
9879381|NCT00459472|Other|Training|laparoscopic training curriculum: all general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
9879382|NCT00459485|Experimental|Zinc supplement (20 mg)|Daily intake of 20 mg supplementary zinc
9879383|NCT00459485|Experimental|Zinc supplement (10 mg)|Daily intake of 10 mg supplementary zinc
9879384|NCT00459485|Placebo Comparator|Placebo supplement|Daily intake of placebo supplement
9879385|NCT00459524||Questionnaire|AML and MDS Patients
9879386|NCT00459550|Experimental|Part A|Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
9879387|NCT00459550|Experimental|Part B|"Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:~First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow"
9879388|NCT00459563|Placebo Comparator|Placebo|
9879389|NCT00459563|Active Comparator|Cholecalciferol|Cholecalciferol
9879390|NCT00459563|Active Comparator|Calcitriol|Calcitriol
9930550|NCT00929461|Other|Omega-3 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
9930551|NCT00929461|Other|Omega 3 + Omega 6 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter.
9930552|NCT00929487|Experimental|Contact lens solution #1|
9930553|NCT00929487|Experimental|Contact lens solution #2|
9930554|NCT00929487|Experimental|Contact lens solution #3|
9930555|NCT00929487|Experimental|Contact lens solution #4|
9930556|NCT00929487|Active Comparator|Saline/blister pack solution|
9930557|NCT00929552|Experimental|Fish oil|Daily dose = 6g fish oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day. The fish oil was micro-incapsulated.
9930558|NCT00929552|Active Comparator|Vegetable oil (Mix of canola, palm and soy oil)|Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
9930559|NCT00929565||Lung cancer|Comparison between individuals with and without pulmonary malignancy
9930560|NCT00929591|Active Comparator|tamoxifen for five years|tamoxifen for five years
9930561|NCT00929591|Experimental|CAF followed by tamoxifen for five years|intermittent CAF X 6 courses followed by tamoxifen for five years
9930562|NCT00929591|Experimental|CAF with concurrent tamoxifen for five years|intermittent CAF X 6 courses with concurrent tamoxifen for five years
9930563|NCT00929604|No Intervention|Standard of care|Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
9930564|NCT00929604|Experimental|Routine HIV-1 viral load testing|Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
9930565|NCT00929617|Experimental|1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
9930566|NCT00929617|Other|2. Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
9930567|NCT00929630|Experimental|glue (Tissucol ) treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
9930568|NCT00929630|Active Comparator|Seton treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
9930569|NCT00929682|Experimental|Levobupivacaine 0.568mg.mL|
9930570|NCT00929682|Other|Levobupivacaine 1.136mg.mL|
9930571|NCT00929721|Other|Subjects with Community-Acquired Pneumonia|Subjects with Community-Acquired Pneumonia
9930572|NCT00929747|Active Comparator|Toric IOL|AcrySof IQ Toric IOL
9930573|NCT00929747|Active Comparator|Limbal Relaxing Incision|AcrySof IQ with Limbal Relaxing Incision
9930574|NCT00929760|Active Comparator|nephrologists|Combined management PCP: nephrologists (at least 4 nephrology visits/year)
9930575|NCT00929760|Active Comparator|Primary Care Physicians|Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG
9930576|NCT00929786||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
9930577|NCT00929799|Experimental|Growth Hormone|Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD
9930578|NCT00929812|Active Comparator|Glucagon hydrochloride|GlucaGen® 1 mg/1 ml intramuscularly
9930579|NCT00929812|Placebo Comparator|Placebo|1 ml NaCl 0.9%
9930580|NCT00929825|Experimental|Elastomers|Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
9930581|NCT00929825|Experimental|TENS|TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
9930582|NCT00929825|Experimental|Elastomers+TENS|Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
9930583|NCT00929825|No Intervention|No therapy (control)|Patients will not receive intervention
9930584|NCT00929851|Experimental|BDP/FF|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
9930585|NCT00929851|Active Comparator|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
9930586|NCT00929877|Experimental|Ketoprofen lysinate 12.5 mg|
9930587|NCT00929877|Experimental|Ketoprofen lysinate 6.25 mg|
9930588|NCT00929877|Placebo Comparator|Matching placebo|
9930589|NCT00929890|Active Comparator|Lifestyle counseling|Patients will receive dietary counseling and a general advice on physical activity
9879391|NCT00459589|Experimental|1|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
9879392|NCT00459589|Active Comparator|2|
9879393|NCT00459602||Laparoscopic incisional hernia repair|Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh.
9879394|NCT00459628|Active Comparator|Conventional radiotherapy|Conventional Long schedule Radiotherapy Arm
9879395|NCT00459628|Experimental|Tomotherapy|Short course schedule by tomotherapy
9879396|NCT00459641|Experimental|1|I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
9879397|NCT00459641|Active Comparator|2|Standard of care (bone marrow aspirate or steroids)
9879398|NCT00459654|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of the investigational drug radium-223 (EBR+Radium-223)
9879399|NCT00459654|Placebo Comparator|Saline|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of saline (EBR+placebo)
9879400|NCT00459680|Experimental|Acupuncture|
9879401|NCT00459680|Experimental|Laser Acupoint|
9879402|NCT00459719|Experimental|1|In combination with steroids
9879403|NCT00459719|Active Comparator|2|In combination with steroids
9879404|NCT00459771|Placebo Comparator|Placebo|Placebo
9879405|NCT00459771|Active Comparator|Candesartan|Candasartan
9879406|NCT00459797|Active Comparator|Conventional Glidescope|
9879407|NCT00459797|Experimental|Single-use Glidescope|
9879408|NCT00459823|Experimental|1|
9879409|NCT00459914|Active Comparator|1 CPAP|Nasal continuous positive airway pressure
9879410|NCT00459914|No Intervention|2|Pharmacological treatment alone
9879411|NCT00460018|Experimental|Intervention|Women receiving the DEBI Intervention
9879412|NCT00460018|No Intervention|No intervention|Women receiving standard care
9879413|NCT00460057|Placebo Comparator|Alendronate, Placebo|All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
9879414|NCT00460083|Active Comparator|Elidel(r)|
9879415|NCT00460083|Experimental|Epiceram(r)|
9879416|NCT00460135|Experimental|RT|resistance training
9879417|NCT00460135|No Intervention|Routine care|General counseling on increasing physical exercise
9879418|NCT00460161|Active Comparator|1|true acupuncture
9879419|NCT00460161|Placebo Comparator|2|placebo/sham acupuncture
9879420|NCT00460174|Experimental|Treatment Arm|Concurrent gemcitabine, bevacizumab, and radiation therapy
9879421|NCT00460213|Experimental|Valsartan|
9879422|NCT00460226||lamotrigine|there is only one group.
9879423|NCT00460343|Experimental|max|
9879424|NCT00460343|Active Comparator|min|
9879425|NCT00460356||Ancillary-Correlative (glycoprotein and glycan profiling)|Primary and metastatic tumor specimens are collected during lymphadenectomy and used for tissue microarray analysis, mutational analysis of T-synthase and Cosmc, immunohistochemical staining of Tn antigen and sialyl Tn antigen, and customized gene expression array analysis of 400 genes associated with glycobiology. Pre-lymphadenectomy blood is collected from patients at baseline for customized glycan array analysis of 300 carbohydrates.
9879426|NCT00460369|Active Comparator|1|sulfadoxine-pyrimethamine
9879427|NCT00460369|Active Comparator|2|artemether-lumefantrine
9879428|NCT00460369|Active Comparator|3|amodiaquine-artesunate coformulation
9879429|NCT00460473|Experimental|Dexmedetomidine|
9879430|NCT00460473|Placebo Comparator|Placebo (PBO)|
9879431|NCT00460499|Active Comparator|B Low dose GIK|This group will have low doses of glucose and insulin
9879432|NCT00460499|Active Comparator|C High Dose GIK|This group will have high doses of insulin and glucose
9879433|NCT00460499|Active Comparator|A Insulin|This group will receive only an intravenous insulin infusion
9879434|NCT00460512|Experimental|Paliperidone Extended Release (ER)|
9879435|NCT00460538|Placebo Comparator|2|
9879436|NCT00460538|Active Comparator|1|
9879437|NCT00460590|Experimental|1|12 adults with prior BCG
9879438|NCT00460590|Experimental|2|12 adults without prior BCG
9879439|NCT00460590|Experimental|3|12 Adolescents
9879440|NCT00460616||1|Patients already receiving treatment with cabergoline.
9879441|NCT00460616||2|healthy controls sex and age-matched with the patients
9879442|NCT00460668|Experimental|Pulmonary rehabilitation post-thoracotomy|Pulmonary rehabilitation post-thoracotomy
9879443|NCT00460668|No Intervention|Control|Control
9879444|NCT00460707|Experimental|Cohort 1|All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.
9930590|NCT00929890|Experimental|Exercise training|patients will receive dietary counseling and will be enrolled in supervised exercise training
9997239|NCT01507116||People with Diabetes|
9997240|NCT01507116||Family Members|
9879445|NCT00460707|Placebo Comparator|Cohort 2, Group A|Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.
9879446|NCT00460707|Experimental|Cohort 2, Group B|In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
9879447|NCT00460720||001|
9879448|NCT00460733|Experimental|1|
9879449|NCT00460733|Active Comparator|2|
9879450|NCT00460759|Experimental|Moxifloxacin and Rifapentine|
9879451|NCT00460837|Active Comparator|1 A|gastrofin & Picolax
9879452|NCT00460837|Active Comparator|2|senna
9879453|NCT00460850|Experimental|1|
9879454|NCT00460902|Experimental|Deep TMS stimulation|
9879455|NCT00460902|Experimental|DTMS with positive cognitive-emotional provocation|
9879456|NCT00460902|Experimental|DTMS with negative cognitive-emotional provocation|
9879457|NCT00460928|Experimental|intravenous immune globulin (IVIG)|
9879458|NCT00460967|Experimental|1|Rheopheresis treatment
9879459|NCT00460967|Sham Comparator|2|Sham treatment
9879460|NCT00460980|Other|Virtual reality laparoscopic simulator|"Virtual reality laparoscopic simulator training:~Residents will participate in a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience."
9879461|NCT00461019|Experimental|Implantation of the CardioFit system|
9879462|NCT00461058|Active Comparator|Actos|
9879463|NCT00461058|Experimental|Aleglitazar|
9879464|NCT00461071|Active Comparator|Internet-based self-help|Internet-based self-help behavioural
9879465|NCT00461071|Active Comparator|Bibliotherapy|bibliotherapy
9879466|NCT00461084||1|lymphoma follicular
9879467|NCT00461084||2|lymphoma non-follicular
9879468|NCT00461110|Experimental|1|Active
9879469|NCT00461110|Experimental|2|Active
9879470|NCT00461162|Experimental|1: i-DSMP|Internet Dyspnea Self-management Program (i-DSMP)
9879471|NCT00461162|Experimental|2: f-DSMP|Face-to-Face Dyspnea Self-management Program (f-DSMP)
9879472|NCT00461162|Active Comparator|3: AC|Attention Control (AC)
9879473|NCT00461240||acromegaly|
9879474|NCT00461240||growth hormone deficiency|
9879475|NCT00461266|Experimental|1|
9879476|NCT00461266|Active Comparator|2|
9879477|NCT00461279|Other|1|
9879478|NCT00461279|Other|2|
9879479|NCT00461396||Group 1|
9879480|NCT00461422|Experimental|1|Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
9879481|NCT00461422|No Intervention|2|Standard Flexible antagonist protocol
9930591|NCT00929903|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
9930592|NCT00929916||AM dosing of MoviPrep®|Take prep morning of exam
9930593|NCT00929916||PM/AM dosing of MoviPrep®|half of the volume of prep(1L) solution the evening prior, and half (1L) the morning of, colonoscopy.
9930594|NCT00929929|Experimental|L-Leucine|This arm receives a supplement of leucine along with a progressive resistance exercise program.
9930595|NCT00929929|Placebo Comparator|Maltodextrin|This arm receives a supplement of maltodextrin along with a progressive resistance exercise program.
9930596|NCT00929942|Experimental|DV Stent|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
9930597|NCT00929955|Active Comparator|Ondansetron|
9930598|NCT00929955|Active Comparator|Simvastatin|
9988365|NCT01421992|Placebo Comparator|Arm 2: Placebo versus baseline|One table placebo per day during 3 week
9988366|NCT01422005|Experimental|Experimental group|Simultaneous Bimanual training: Patients who have had either an acute/subacute and a Chronic stroke will get training on the devices.
9988367|NCT01422005|Active Comparator|Control Group|Conventional Occupational Therapy: Patients who have had either an acute/subacute and Chronic Stroke with hemiperisis will get conventional therapy.
9988368|NCT01422018|Experimental|one arm for Anastin injection|intravitreal Avastin injection
9988369|NCT01422031||Regular Family Doctor (RFD)|People had a regular primary care doctor who is a family doctor
9988370|NCT01422031||Regular not Family doctor (RnFD)|People had a regular primary care doctor who is not a family doctor
9988371|NCT01422031||Not regular doctor (NRD)|People had no regular primary care doctor
9988372|NCT01422096|Experimental|leuprolide|leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection
9988373|NCT01422109|Experimental|Group A|
9988374|NCT01422109|Active Comparator|Group B|
9988375|NCT01422122|Experimental|Vitamin D|Oral vitamin D3 in syrup form
9988376|NCT01422122|Placebo Comparator|placebo|Placebo syrup identical in colour and taste to that of intervention
9988377|NCT01422174||ICD implantation|Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
9988378|NCT01422174||Non ICD implantation|Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
9988379|NCT01422252|Experimental|Persons equipped|Precocious fall detection device
9988380|NCT01422252|No Intervention|Persons non-equipped|No fall detection device
9988381|NCT01422265||Cohort|
9988382|NCT01422291|Active Comparator|morphine|
9988383|NCT01422291|Experimental|Paracetamole, dexketoprofen|Paracetamole, dexketoprofen
9988384|NCT01422317|Experimental|n-3 fatty acids|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each capsule containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters, in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
9988385|NCT01422317|Active Comparator|Corn Oil|Two gelatine capsules twice a day, each containing 1 gram of corn oil. Alpha-Tocopherol (4 mg) was added to each capsule.
9988386|NCT01422330|Experimental|Etravirine|
9988387|NCT01422343||1|
9988388|NCT01422395|Experimental|freezing|
9988389|NCT01422395|No Intervention|No freezing|
9997241|NCT01507116||Healthcare Professionals|
9988390|NCT01422421|Active Comparator|intensive control|systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
9988391|NCT01422421|Active Comparator|standard control|systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
9988392|NCT01422447|Experimental|community intervention|Feedback on assessment results: distribute relevant brochures and hold regular lectures on depression, anxiety and alcohol-abuse.
9988393|NCT01422447|Active Comparator|regular intervention control|the subjects in the control group live in the used model
9988394|NCT01422460|Experimental|Platelet Rich Plasma|intra articular injection 2ml of platelet-derived preparation rich in growth factors
9988395|NCT01422473|Experimental|EnSeal Device|EnSeal Trio Tissue Sealing Device
9988396|NCT01422486|Experimental|ezatiostat hydrochloride (Telintra®)|Patients received ezatiostat at a starting dose of 2000 mg total daily dose in divided doses (1000 mg PO b.i.d.) for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles.
9988397|NCT01422512|Experimental|cell culture derived TIV|single dose of cell culture derived seasonal trivalent influenza vaccine (TIV)
9988398|NCT01422525||Trabeculectomy RNFL thickness OCT|
9988399|NCT01422551|Experimental|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
9988400|NCT01422551|Active Comparator|Psycho-educational Control|a single day group-based psycho-educational seminar
9988401|NCT01422564|Active Comparator|Metal on Metal|Metal on Metal articulation system
9988402|NCT01422564|Active Comparator|HCLPC|THA using Highly Cross Linked Polyethylene cup System
9988403|NCT01422577|Active Comparator|Bright Narrow Band Imaging|Bright Narrow Band Imaging
9988404|NCT01422577|Active Comparator|White Light Endoscopy|White Light Endoscopy
9988405|NCT01422590|Active Comparator|Sitagliptin|
9988406|NCT01422590|Active Comparator|Mitiglinide|
9988407|NCT01422590|Experimental|Sitagliptin + Mitiglinide|
9988408|NCT01422603|Experimental|Clofarabine and Full intensity SCT|Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned allogeneic stem cell transplant (SCT).
9988409|NCT01422603|Experimental|Clofarabine and Reduced intensity SCT|Cohort 2: Patients not suitable for a full intensity TBI-based transplant due to age or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and Campath 1H.
9988410|NCT01422616|Experimental|Low-dose rtPA (Recruitment completed in August 2015)|low-dose 0.6 mg/kg (maximum of 60 mg) i.v. rtPA
9988411|NCT01422616|Active Comparator|Standard-dose rtPA (Recruitment completed in August 2015)|standard-dose 0.9 mg/kg (maximum of 90 mg) i.v. rtPA
9988412|NCT01422616|Experimental|Early intensive BP lowering|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents (e.g. Labetalol Hydrochloride, Metoprolol tartrate, Hydralazine Hydrochloride, Glycerol Trinitrate, Phentolamine mesylate, Nicardipine, Urapidil, Esmolol, Clonidine, Enalaprilat, Nitroprusside) will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA."
9988413|NCT01422616|Active Comparator|Control / guideline-based BP management|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved."
9988414|NCT01422629|Experimental|High Intensity Focused Ultrasound (HIFU)|
9988415|NCT01422642|Experimental|legacy posterior stabilized high-flexion|NexGen LPS-Flex total knee system
9988416|NCT01422642|Experimental|legacy posterior stabilized standard|standard NexGen LPS prosthesis
9988417|NCT01422668|Active Comparator|GI of Khalas dates|The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.
9988418|NCT01422668|Experimental|GI of the Khalas dates with Coffee|measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.
9879482|NCT00461448|Active Comparator|1 Potassium supplement|Patients received an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
9879483|NCT00461448|Placebo Comparator|2 Grape Juice|Patients received same amount of grape juice for 28 days.
9879484|NCT00461487|Experimental|1|Participants will receive sex education information during the physical exam
9879485|NCT00461487|Active Comparator|2|Participants will receive information on hygiene and nutrition during the physical exam
9879486|NCT00461487|No Intervention|3|Passive control participants will not receive any additional information during the physical exam
9879487|NCT00461526|Experimental|125 mg crofelemer|
9879488|NCT00461526|Placebo Comparator|placebo|
9879489|NCT00461539|Active Comparator|2|Participants will receive treatment as usual
9879490|NCT00461539|Experimental|1|Participants will receive the behavioral health intervention
9879491|NCT00461565|Active Comparator|Part A1|
9879492|NCT00461565|Placebo Comparator|Part A2|
9879493|NCT00461565|Experimental|Part B1|
9879494|NCT00461565|Placebo Comparator|Part B2|
9879495|NCT00461617|Active Comparator|2|Nateglinide 120 mg TID
9879496|NCT00461643|Active Comparator|Strategy A|clomiphene followed by clomiphene plus metformin followed by gonadotropins
9879497|NCT00461643|Active Comparator|Strategy B|metformin followed by metformin plus clomiphene followed by gonadotropins
9879498|NCT00461643|Active Comparator|Strategy C|metformin plus clomiphene followed by gonadotropins
9879499|NCT00461695|Other|CMV-seropositive|Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
9879500|NCT00461695|Other|CMV-seronegative|Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
9879501|NCT00461747|Active Comparator|A|"Four alternating cycles of VBMCP/VBAD + Velcade VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20. The interval between VBMCP and VBAD is 5 weeks and between VBAD and VBMCP is 4 weeks. The patients will received two cycles of VBMCP and two cycles of VBAD. After 4 weeks of last cycle of VBAD, patients will received two cycles of Velcade, 1,3 mg/ m2 iv twice a week (days 1, 4, 8 and 11), followed by 10 days without treatment"
9879502|NCT00461747|Experimental|B|"Six cycles of 4 weeks of Thalidomide/Dexamethasone. Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
9879503|NCT00461747|Experimental|C|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose will be increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days."
9879504|NCT00461760|Active Comparator|1|Women with normal cytology at recruitment will be recalled for their next routine screen at 2 years and if negative again, for their exit screen at 4 years, all according to current provincial guidelines.
9879505|NCT00461760|Active Comparator|2|Women with abnormal cytology at recruitment or at the 2 year screen will be followed according to provincial guidelines based on their cytology results.
9879506|NCT00461838||1|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.
9879507|NCT00461903|Placebo Comparator|Placebo (for perindopril)|Sugar pill manufactued to mimic perindopril
9879508|NCT00461903|Active Comparator|Perindopril|Perindopril (coversyl) 4 mg tablets
9879509|NCT00461955|Experimental|1|autologous peripheral blood stem cell transplantation
9879510|NCT00462007|Experimental|1|Stalevo
9879511|NCT00462098|Experimental|HBO|Subject receives 40 HBO sessions at 2 atmospheres of pressure over 4 weeks
9879512|NCT00462098|Active Comparator|Control|non-HBO comparison group
9879513|NCT00462137||1|control group
9879514|NCT00462137||2|hypnotic group
9930599|NCT00929955|Placebo Comparator|Placebo|
9930600|NCT00930007||Hyperandrogenemic|Girls with elevated free testosterone concentrations
9930601|NCT00930007||Controls|Girls with normal free testosterone concentrations
9879515|NCT00462176||1|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of the colorectal surgeon performing a bowel resection were selected retrospectively from the list of all patients (n=more than 400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and July 2006.
9879516|NCT00462215|Experimental|1|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
9879517|NCT00462215|Experimental|2|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
9879518|NCT00462215|Experimental|3|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
9879519|NCT00462215|Experimental|4|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
9879520|NCT00462215|Experimental|5|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
9879521|NCT00462215|Experimental|6|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
9879522|NCT00462241|Experimental|chiropractic treatment|Individualised chiropractic treatment, pragmatic approach
9879523|NCT00462241|Sham Comparator|self-management|Self-management: Minimal intervention - practice as usual.
9879524|NCT00462254|Other|A|Day 1-3: placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: continue placebo.
9879525|NCT00462254|Other|B|Day 1-3: Placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: continue placebo. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime.
9879526|NCT00462267|No Intervention|Usual care|
9879527|NCT00462267|Experimental|Enriched lifestyle intervention|
9879528|NCT00462358|Experimental|ARRY-520|
9879529|NCT00462358|Experimental|ARRY-520 + G-CSF support|
9879530|NCT00462553|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.
9879531|NCT00462592|Active Comparator|1|montelukast - montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
9879532|NCT00462592|Active Comparator|2|budesonide - inhaled budesonide turbuhaler 200ug (& matching placebo) taken 1 puff morning & 1 puff evening.
9879533|NCT00462592|Placebo Comparator|3|placebo
9879534|NCT00462592|Active Comparator|4|montelukast budesonide combination - montelukast 5mg ( < 15 years) or 10 mg (& matching placebo)will be taken 1 tab in the evening together with inhaled budesonide turbuhaler 200 ug (& matching placebo) taken 1 puff morning & 1 puff evening.
9879535|NCT00462618|Active Comparator|CBT|
9879536|NCT00462631|Experimental|1|paclitaxel eluting balloon followed by bare metal stent
9879537|NCT00462631|Active Comparator|2|Paclitaxel eluting stent
9879538|NCT00462787|Experimental|Clofarabine|This is a single arm phase I clinical trial to assess safety (morbidity and mortality) of a novel leukemia re-induction regimen. The first component of this trial is a phase I dose escalation study to determine the maximum tolerated dose (MTD) of the novel agent Clofarabine, when used in combination with topotecan, vinorelbine, thiotepa and dexamethasone. A total of three dose levels will be explored in this study.
9879539|NCT00462891|Experimental|IT System|IT system to send reminder letters to patients overdue for breast cancer screening.
9879540|NCT00462891|No Intervention|Usual Care|
9879541|NCT00462956|Experimental|lapatinib 1500mg daily|Subjects will self-administer lapatinib 1500 mg orally once daily.
9879542|NCT00462969|Experimental|1|pre-surgical SHG
9879543|NCT00462995|Active Comparator|Erlotinib|Erlotinib 150mg once a day p.o
9879544|NCT00463086|Experimental|1.Isoniazid (INH)|A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
9879545|NCT00463086|Placebo Comparator|2. Placebo|A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
9879546|NCT00463268|Active Comparator|1|Alendronate 70 mg every 2 weeks
9879547|NCT00463268|Placebo Comparator|2|Alendronate 70 mg placebo tablet every 2 weeks
9879548|NCT00463294|Active Comparator|On Pump Arm|
9879549|NCT00463294|Experimental|Off Pump Arm|
9879550|NCT00463398||Patients operated at the LUFc|All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008.
9879551|NCT00463450|Experimental|Arm 1|
9879552|NCT00463450|Active Comparator|Arm 2|
9879553|NCT00463489|Active Comparator|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
9879554|NCT00463489|Experimental|Individualized Lifestyle Intervention|Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
9930602|NCT00930020|Placebo Comparator|matching placebo pill|matching placebo
9930603|NCT00930020|Active Comparator|Oral minocycline|Minocycline 200mg
9930604|NCT00930033|Active Comparator|A|Nephrectomy + sunitinib
9930605|NCT00930033|Experimental|B|Sunitinib alone
9930606|NCT00930072|Experimental|Block|
9930607|NCT00930072|No Intervention|Standard Care|
9930608|NCT00930085|Experimental|SELDI-TOF MS|The proteic profiling is performed by SELDI-TOF mass spectroscopy.
9930609|NCT00930111|Active Comparator|2 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 2 weeks.
9930610|NCT00930111|Placebo Comparator|4 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 4 weeks.
9930611|NCT00930124|Experimental|1|Group 1 will receive Conventional orthognathic surgery
9930612|NCT00930124|Active Comparator|2|Group 2 will receive distraction osteogenesis
9930613|NCT00930137|Experimental|High dairy trans fat|a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)
9930614|NCT00930137|Active Comparator|Low dairy trans fat diet|a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)
9930615|NCT00930150|Experimental|Posit Science Intervention|Participants will receive targeted cognitive training and participate in a bridging group.
9930616|NCT00930150|Active Comparator|Control|Participants will play commercially available computer games and participate in weekly groups to discuss health and wellness.
9930617|NCT00930202|Experimental|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
9930618|NCT00930202|No Intervention|Standard Care|No intervention
9930619|NCT00930215|Experimental|D961H 40 mg gelatin capsule|2 way crossover
9930620|NCT00930215|Experimental|D961H 40 mg HPMC capsule|2 way crossover
9930621|NCT00930228|Experimental|Flutamide|Flutamide 250 mg taken by mouth twice a day for 4 weeks. Flutamide is an androgen-receptor blocker.
9930622|NCT00930228|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
9930623|NCT00930241|Experimental|Advagraf|Advagraf® (one daily dose of Tacrolimus)
9930624|NCT00930241|Active Comparator|Prograf|Prograf® (two daily doses of Tacrolimus)
9930625|NCT00930254|Experimental|Ultrasound|Vascular puncture guided by vascular ultrasound
9930626|NCT00930280||Hemorrhagic stroke cases|People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
9930627|NCT00930280||Healthy Control Subjects|Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
9930628|NCT00930306|Experimental|1|12 AZD2066 Capsule, 2 mg & 8 mg 2 Caffeine Tablet, 2 x 50 mg 2 Tolbutamide Tablet, half of 500 mg 2 Omeprazole Tablet, 20 mg 2 Midazolam Tablet, 7.5 mg 2 Metoprolol Tablet, 100 mg 2 Bupropion Tablet, 150 mg
9930629|NCT00930319||1|Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC
9930630|NCT00930332|Active Comparator|Arm A: Methadone|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
9930631|NCT00930332|Active Comparator|Arm B: Methadone|"Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
9930632|NCT00930345|Other|SUTENT before nephrectomy|
9930633|NCT00930358|Experimental|MEOPA|MEOPA : equimolar nitrous oxide/oxygen mixture
9930634|NCT00930358|Active Comparator|General anesthesia|Gold standard
9935423|NCT03773653|Experimental|BMT to be combined with BAT|Participants in this group will receive bilateral robotic priming and bilateral arm training or mirror therapy within the 90-minute training sessions.
9935424|NCT03773653|Experimental|BMT to be combined with MT|Participants in this group will receive bilateral robotic priming and mirror therapy within the 90-minute training sessions.
9935425|NCT03773653|Active Comparator|BMT to be combined with IOT|Participants in this group will receive bilateral robotic priming and impairment-oriented training within one 90-minute training session.
9935426|NCT03770273|Active Comparator|placebo|8 SC injections of placebo
9935427|NCT03770273|Active Comparator|sarilumab|8 (SC) injections of 200 mg/1.14 mL of sarilumab over 16 weeks
9935428|NCT03762733||Patient Relatives|Biological relatives (1st-3rd degree) of participants with histologically confirmed malignancy
9879555|NCT00463541|Experimental|1|
9879556|NCT00463593||2|children enrolled in formal schools and children not enrolled in formal schools
9879557|NCT00463658|Experimental|1|Subjects in the interdisciplinary group received home care services from a team of professional service providers (CCAC Case Manager, Registered Nurse, Occupational Therapist, Physiotherapist, Registered Dietician) with experience and training in falls prevention. The team provided a comprehensive, coordinated and evidence based approach to falls prevention through regular home visits, weekly case conferencing, a single accessible fall prevention plan,and joint client visits.
9879558|NCT00463658|No Intervention|2|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessing client's eligibility for in-home health services, arrangement and coordination of professional (i.e. nursing, occupational therapy, physiotherapy, social work, speech-language pathology, nutrition) and non-professional HSS, information and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessments with clients.
9879559|NCT00463697|Experimental|GW642444M 25mcg|Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.
9879560|NCT00463697|Experimental|GW642444M 100mcg|Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.
9879561|NCT00463697|Experimental|GW642444M 400mcg|Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.
9879562|NCT00463697|Experimental|GW642444H 100mcg|Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.
9879563|NCT00463697|Placebo Comparator|placebo|Subject will inhale single dose of Placebo via a DISKUS device in morning.
9879564|NCT00463736|Active Comparator|Magnesium sulfate|x 48 hours IV
9879565|NCT00463736|Placebo Comparator|Normal saline|x 48 hours IV
9879566|NCT00463749|Active Comparator|1|High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
9879567|NCT00463749|Placebo Comparator|2|Placebo (NaCl)
9879568|NCT00463827|Active Comparator|2|Atorvastatin 40
9879569|NCT00463827|Placebo Comparator|placebo|matched placebo
9879570|NCT00463853|Experimental|Arm 1|direct intramyocardial injection of cells as adjunct to CABG
9879571|NCT00463905|No Intervention|1|Current management for identifying postmenopausal women with osteoporotic vertebral fractures in primary care i.e. nothing
9879572|NCT00463905|Experimental|2|Intervention arm: simple clinical assessment to identify high risk 30% (approximately) who will then be offered lateral thoraco-lumbar X-rays
9879573|NCT00463970|Active Comparator|1|Brief Intervention
9879574|NCT00463970|Experimental|2|Cognitive Behavioural Therapy
9879575|NCT00463970|Experimental|3|Seal oil
9879576|NCT00463970|Placebo Comparator|4|Soy oil
9879577|NCT00463983|Experimental|octreotide|octreotide SR 30 mg intra muscularly every 4 weeks
9879578|NCT00464009|Active Comparator|A|Group A practices (n=39) received didactic training and course materials in oral health screening, referral, counseling and application of fluoride varnish.
9879579|NCT00464009|Active Comparator|B|Group B practices (n=41) received the same as Group A and were offered weekly conference calls providing advice and support.
9879580|NCT00464009|Active Comparator|C|Group C practices (n=41) received the same as Group B and were also offered in-office follow-up visits providing hands-on advice and support.
9879581|NCT00464113|Experimental|1|once-weekly dosing
9879582|NCT00464113|Experimental|2|twice-weekly dosing
9879583|NCT00464126|Active Comparator|Colloid|5% albumin for volume resuscitation
9879584|NCT00464126|Placebo Comparator|Crystalloid|Saline for volume resuscitation
9879585|NCT00464139||1|"The electronic files of all patients who consulted the LUFC since 2003 were searched to select women with at least 1 year of infertility, a regular cycle (variation 21 - 35 days), whose partner had normal sperm according to World Health Organization (WHO) criteria (n = 304).~After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of endometriosis before referral to our centre, 221 (72,7%) infertile women were included in our study."
9879586|NCT00464178|Experimental|Bortezomilb and bevacizumab|Bortezomilb will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
9879587|NCT00464321|Experimental|Cohort A|Dose Group
9879588|NCT00464321|Experimental|Cohort B|Dose Group
9879589|NCT00464321|Experimental|Cohort C|Dose Group
9879590|NCT00464321|Experimental|Cohort D|Dose Group
9879591|NCT00464373|Experimental|1|Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
9879592|NCT00464373|Placebo Comparator|2|4ml NaCl 0.9%
9879593|NCT00464386|No Intervention|POC Glucose Testing|Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
9935429|NCT03762733||Patients|Participants with histologically confirmed malignancy
9988419|NCT01422681|Experimental|DECOPD|patients with severe COPD exacerbation on NIV treated with the minimally invasive extracorporeal carbon dioxide removal device (Decap Smart)
9988420|NCT01422707|Experimental|hydrocortisone|4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
9988421|NCT01422733|Experimental|hydrocortisone, dexamethasone, Cosyntropin (ACTH), rhCG|12 weeks hydrocortisone, dexamethasone, and Cosyntropin (ACTH) to perform standardized adrenal stimulation testing; dexamethasone, and rhCG to perform standardized ovarian stimulation testing
9988422|NCT01422746|Experimental|metformin|12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
9988423|NCT01422759|Experimental|spironolactone|12 weeks spironolactone with pre- and post-intervention dexamethasone, and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
9988424|NCT01422772|Experimental|Cohort I|0.5mg/1mL of VM202RY was intramuscularly injected into 4 sites
9988425|NCT01422772|Experimental|Cohort II|1mg/2mL of VM202RY was intramuscularly injected into 8 sites
9988426|NCT01422772|Experimental|Cohort III|2mg/4mL of VM202RY was intramuscularly injected into 8 sites
9988427|NCT01422785|Active Comparator|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|
9988428|NCT01422785|Active Comparator|clindamycin / tretinoin gel plus benzoyl peroxide|
9988429|NCT01422811|Experimental|Intervention|
9988430|NCT01422811|Other|Control|No Intervention
9988431|NCT01422863|Experimental|Lifestyle Intervention|
9988432|NCT01422902|Experimental|Plasticity-based Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 130 hours
9988433|NCT01422902|Active Comparator|Non-plasticity-based Training|Commercially available computerized training, up to 130 hours
9988434|NCT01422928|No Intervention|Standard treatment|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
9988435|NCT01422928|Experimental|Acupuncture|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers with concurrent acupuncture once a week for 4 weeks.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
9988436|NCT01422941|Experimental|CAVU Attune Device|
9988437|NCT01422954|Active Comparator|Chloroquine immunisation|This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
9988438|NCT01422954|Experimental|Mefloquine immunisation|This group will receive mefloquine prophylaxis and infected mosquito-bites.
9988439|NCT01422954|Placebo Comparator|Mefloquine control|This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
9988440|NCT01422967|Active Comparator|Osteoarthritis group|
9988441|NCT01422967|Active Comparator|without osteoarthritis|
9988442|NCT01422980|Active Comparator|1 = Test product|Arm 1 - intervention 1 (test product)
9988443|NCT01422980|Placebo Comparator|2 = Control product|Arm 2 - intervention 2 (control product)
9988444|NCT01422993|Experimental|Excercise and Questionnaire|12 week exercise program followed by questionnaire.
9988445|NCT01423006|Experimental|Focal Prostate Radio-Frequency Ablation|Treatment is performed under a spinal or general anesthetic and will include the one to three regions of the prostate containing cancer based on the mapping biopsy.
9988446|NCT01423019|Active Comparator|Advantra Z|Proprietary ingredient for: stimulating thermogenesis, reducing weight, increasing lean muscle mass to total body mass, improving athletic performance, and suppressing appetite
9988447|NCT01423019|Active Comparator|Advantra Z + Naringin + Hesperiden|
9988448|NCT01423019|Placebo Comparator|Sugar pill|Capsule contains inert ingredient.
9988449|NCT01423032|Experimental|Bendamustine|
9988450|NCT01423032|Active Comparator|Fludarabine|
9988451|NCT01423071||COPD with PH|COPD patients with confirmed diagnosis of PH.
9988452|NCT01423071||COPD without PH|COPD patients without confirmed diagnosis of PH
9988453|NCT01423071||PAH without COPD|PAH patients who do not suffer from COPD
9879594|NCT00464386|Experimental|Continuous Glucose Monitoring|Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
9879595|NCT00464425|Experimental|Electroacupuncture (EA)|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
9879596|NCT00464425|Sham Comparator|Sham Acupuncture (SA)|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
9879597|NCT00464425|No Intervention|No Acupuncture (NA)|Control
9879598|NCT00464451|Experimental|1|Dexmedetomidine sedated pediatric patients undergoing EEG study.
9879599|NCT00464451|Active Comparator|2|Chloral hydrate sedated pediatric patients undergoing sedated EEG study.
9879600|NCT00464516|Experimental|estetrol|
9879601|NCT00464516|Placebo Comparator|placebo|
9879602|NCT00464659|Experimental|Effective CPAP treatment|Effective Continuous Positive Airway Pressure treatment (CPAP) applied for 6 weeks
9879603|NCT00464659|Sham Comparator|Sham CPAP treatment|Ineffective Continuous Positive Airway Pressure treatment (sham CPAP) applied for 6 weeks
9879604|NCT00464724|Experimental|3T MRSI Prostate|3T Magnetic Resonance Spectroscopic Imaging
9879605|NCT00464763|Experimental|Dexmedetomidine|
9879606|NCT00464763|Placebo Comparator|Placebo (PBO)|
9879607|NCT00464776|Experimental|1|Various sequences of 3 doses of Aliskiren plus placebo
9879608|NCT00464776|Experimental|2|Various sequences of 3 doses of Aliskiren plus placebo
9879609|NCT00464776|Experimental|3|Various sequences of 3 doses of Aliskiren plus placebo
9879610|NCT00464776|Experimental|4|Various sequences of 3 doses of Aliskiren plus placebo
9879611|NCT00464841|Experimental|1|Tsui test for combined spinal-epidural
9879612|NCT00464841|Experimental|2|Tsui test for intrathecal catheter
9879613|NCT00464893|Active Comparator|catumaxomab arm|Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
9879614|NCT00464919|Experimental|A|
9879615|NCT00464958|Experimental|Sublingual tizanidine|Once nightly dosing of 12 mg sublingual tizanidine tablet
9879616|NCT00464984|Active Comparator|ILI-group|Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
9879617|NCT00464984|Active Comparator|MLI|Moderate lifestyle intervention at a secondary care outpatient center. Treatment included moderate changes in dietary habits (calori restriction) and physical activity.
9879618|NCT00465023|Experimental|Proton Beam Radiation|Proton radiation therapy
9879619|NCT00465049|Experimental|primary closure|suture after I&D
9879620|NCT00465049|Placebo Comparator|SECONDARY CLOSURE|LEAVE TO HEAL BY SECONDARY INTENTIN AFTER I&D
9879621|NCT00465153|Experimental|1|Flax oil
9879622|NCT00465153|Placebo Comparator|2|corn oil
9879623|NCT00465166||1|Patients who had a documented, accidental dural puncture during placement of their labor epidural.
9879624|NCT00465205|Experimental|I|
9879625|NCT00465218||1|High dose aspirin (325 mg)
9879626|NCT00465218||2|Low dose aspirin (81 mgs) plus warfarin
9879627|NCT00465231|Active Comparator|1|Epidural
9879628|NCT00465231|Placebo Comparator|2|Epidural - saline solution
9879629|NCT00465244|Experimental|1|Levetiracetam 1 g IV + Lorazepam 2 mg IV
9879630|NCT00465244|Other|2|Placebo + Lorazepam 3 mg IV
9879631|NCT00465283|Active Comparator|Donepezil|
9879632|NCT00465283|Placebo Comparator|placebo|
9930635|NCT00930384||Psoriasis group|All adult patients fulfilling inclusion criteria will be considered as cases in which psoriasis is detected and diagnosed by our principal investigator based on the clinical criteria accepted by American Academy of Dermatology. They will have an abdominal ultrasound performed by a radiologist to assess for the presence of nonalcoholic fatty liver disease. They will be referred to the research clinic to have a blood drawn.
9930636|NCT00930384||Control group|For every case an age, sex and body mass index (BMI range - kg/m2) matched control will be selected from the same dermatologic/radiologic clinic. The controls will be invited to voluntarily participate and informed consent will be obtained for performing ultrasonography and analytical tests to ensure the absence of manifest hepatic disease.
9930637|NCT00930397||Low risk women|Women without any personal risk.
9930638|NCT00930397||High risk women|Women at high risk for pre-eclampsia with personal of pre-eclampsia and/or IUGR in a previous pregnancy, diabetes, auto-immune syndrome such as lupus, hypertension, renal insufficiency and anti-phospholipid.
9930639|NCT00930410|Experimental|endomicroscopy|Utilisation of an intra-ductal confocal endomicroscopy during the endoscopic Retrograde Cholangio-Pancreatography
9930640|NCT00930423||cases|patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
9930641|NCT00930423||controls|patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
9930642|NCT00930436|Active Comparator|Saline infusion|Saline will be given as an active control agent to compare with sodium bicarbonate. Each bag of solution will be blinded, and given in the same manner.
9930643|NCT00930436|Experimental|Sodium Bicarbonate|Infusion of sodium bicarbonate will be given prior to,during and after the contrast agent for a total of 6 to 10 hours
9930644|NCT00930449|Experimental|Cogmed Working Memory Training Program|
9930645|NCT00930449|Active Comparator|Academy of Math® program|
9930646|NCT00930449|Active Comparator|Special Education/Individualized Tutoring|
9930647|NCT00930462|No Intervention|Conventional colonoscopy|No cap fitted on the colonoscopes for this group.
9930648|NCT00930462|Experimental|Cap-assisted colonoscopy|
9930649|NCT00930488||Group 1|
9930650|NCT00930501||Cancer patients|women 5-45 yr olf pre and post chemotherapy
9930651|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)|
9930652|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)|
9930653|NCT00930514|Experimental|Rituximab SC 1400 mg (Stage 2: Cohort F)|
9930654|NCT00930514|Experimental|Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)|
9930655|NCT00930514|Experimental|Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)|
9930656|NCT00930514|Experimental|Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)|
9930657|NCT00930566|Experimental|Extracorporal Photopheresis|
9930658|NCT00930579|Experimental|Metformin|
9930659|NCT00930592||Children with Psoriasis|Children and adolescents from 10-17 years of age with moderate to severe psoriasis.
9930660|NCT00930592||Control: children with warts|Children and adolescents from 10-17 years of age with warts.
9930661|NCT00930605|Experimental|Alemtuzumab combination with CHOP and ESHAP|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
9930662|NCT00930618|Experimental|IMN|Isosorbide mononitrate
9930663|NCT00930618|Placebo Comparator|Placebo|Administration of placebo of IMN
9930664|NCT00930631|Other|Single Arm|Single arm PK study
9930665|NCT00930670|Experimental|Rosuvastatin-omeprazole|Rosuvastatin-omeprazole
9930666|NCT00930670|Experimental|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
9930667|NCT00930670|Experimental|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
9930668|NCT00930670|Active Comparator|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months
9930669|NCT00930670|Experimental|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
9930670|NCT00930670|Experimental|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months
9930671|NCT00930670|Experimental|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
9930672|NCT00930670|Active Comparator|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
9930673|NCT00930683|Other|1|MEDI-546
9930674|NCT00930683|Other|2|MEDI-546
9930675|NCT00930683|Other|3|MEDI-546
9930676|NCT00930683|Other|4|MEDI-546
9930677|NCT00930683|Other|5|MEDI-546
9930678|NCT00930683|Other|6|MEDI-546
9879633|NCT00465426||1|HIV Positive men and women 18-65 years of age
9879634|NCT00465426||2|HIV negative men and women 18-65 years of age
9879635|NCT00465465|Active Comparator|1|Dose of 1 x 10^7
9879636|NCT00465465|Active Comparator|2|Dose of 1 x 10^8
9879637|NCT00465491|Experimental|1|Picoplatin
9879638|NCT00465491|Other|2|BSC
9879639|NCT00465543|Placebo Comparator|II|Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
9879640|NCT00465543|Placebo Comparator|I|Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
9879641|NCT00465556|Experimental|1|Dove Intervention
9879642|NCT00465556|Active Comparator|2|Intimate Partner Violence (IPV) Protocol
9879643|NCT00465608|Experimental|1|propranolol
9879644|NCT00465686|Experimental|A|
9879645|NCT00465712|Experimental|A|Transabdominal amnioinfusion performed before external cephalic version
9879646|NCT00465712|No Intervention|V|Without transabdominal amnioinfusion
9879647|NCT00465725|Experimental|1|two-period crossover, open label study in which a single dose (Cycle 1) of picoplatin will be given either IV or PO, followed 4 weeks later by a single dose (Cycle 2) of picoplatin given by the route not used for Cycle 1. Subjects subsequently may continue to receive IV picoplatin commencing with Cycle 3 in a Continuation Study.
9879648|NCT00465751|Active Comparator|A|chenodeoxycholic acid treatment
9879649|NCT00465751|Placebo Comparator|B|placebo treatment
9879650|NCT00465764|Experimental|Protein formula|Feed as per HCP direction
9879651|NCT00465764|Active Comparator|Standard infant formula|Feed as per HCP instructions
9879652|NCT00465842||A - Normal Volunteers|"Normal volunteers without any history of liver disease and with normal liver functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total bilirubin, direct and indirect bilirubin and do not belong to group B.~Volunteers will be screened using questionnaires. Those deemed suitable will then be asked to have the blood test done. All blood tests are done free of charge to subjects."
9879653|NCT00465842||B - Hepatitis B or C carriers with normal liver functions|
9879654|NCT00465842||C - Hepatitis B or C carriers with abnormal liver functions|
9879655|NCT00465842||D - Liver Cirrhosis|Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as varices on CT scan indicative of portal hypertension.
9879656|NCT00465842||E - Hepatocellular Carcinoma (HCC) with Resection|HCC patients with resection.
9879657|NCT00465842||F - Unresectable HCC|Unresectable HCC patients with treatment
9879658|NCT00465842||G - Malignant HCC|HCC patients with active malignant disease and only palliative care are offered.
9879659|NCT00465855|Active Comparator|Hyperbaric Oxygen (HBO2) - 3 sessions|Subjects undergo 3 hyperbaric oxygen sessions within 24 hours following carbon monoxide poisoning.
9879660|NCT00465855|Sham Comparator|Hyperbaric Oxygen (HBO2) - 1 session|Subjects undergo 1 hyperbaric oxygen session and then 2 sham chamber sessions within 24 hours of carbon monoxide poisoning.
9879661|NCT00465907|Experimental|Paclitaxel, Carboplatin and Irinotecan|Study of Weekly Paclitaxel, Carboplatin and Irinotecan in patients with Non-Small Cell Lung Carcinoma
9879662|NCT00466024|Experimental|1|Health coach and 2 HEPA air cleaners
9879663|NCT00466024|Active Comparator|2|Standard asthma education and 2 HEPA air cleaners
9879664|NCT00466024|Active Comparator|3|Standard asthma education and delayed receipt of 2 HEPA air cleaners
9879665|NCT00466063||ICL670|ICL670
9879666|NCT00466089|Experimental|1|RT + Tarceva
9879667|NCT00466089|No Intervention|2|RT
9879668|NCT00466102|Active Comparator|1|Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
9879669|NCT00466102|Placebo Comparator|2|Patients with stable disease after 8 week run in receive placebo (blinded)
9879670|NCT00466232|Experimental|1|Weekly Topetecan in combination with Sorafenib
9879671|NCT00466245|Experimental|A|Previously vaccinated for smallpox, 1x10-8 dose
9879672|NCT00466245|Experimental|B|Smallpox vaccine naive, 1x10-8 dose
9879673|NCT00466245|Experimental|C|Previous smallpox vaccination, 1x10-7 dose
9879674|NCT00466245|Experimental|D|Smallpox vaccine naive, 1x10-7 dose
9879675|NCT00466245|Experimental|E|Previous smallpox vaccination, 1x10-6 dose
9879676|NCT00466245|Experimental|F|Smallpox vaccine naive, 1x10-6 dose
9879677|NCT00466245|Experimental|G|Previous smallpox vaccination, placebo dose
9930679|NCT00930683|Other|7|MEDI-546
9879678|NCT00466245|Experimental|H|Smallpox vaccine naive, placebo dose
9879679|NCT00466375||A|Patients with a hemangioma.
9879680|NCT00466375||B.|Patients with a vascular anomaly.
9879681|NCT00466388|Experimental|Cevimeline|Evoxac tid for xerostomia
9879682|NCT00466388|Placebo Comparator|Placebo|sugar pill
9879683|NCT00466466|Experimental|Daily dosing RAD001|
9879684|NCT00466466|Experimental|Weekly dosing RAD001|
9879685|NCT00466492|Other|No sedatation intervention|The intervention group is the normal care in our institution, the control group is the golden standard
9879686|NCT00466518|Experimental|1|
9879687|NCT00466609|Experimental|Quetiapine (fluoxetine plus quetiapine)|fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks
9879688|NCT00466609|Active Comparator|Clomipramine (fluoxetine plus clomipramine)|Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks
9879689|NCT00466609|Placebo Comparator|Placebo (fluoxetine plus placebo)|Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks
9879690|NCT00466622|Experimental|1|Metformin 1000mg x 2 daily. Orally. From Weifa
9879691|NCT00466622|Placebo Comparator|2|Placebo 2 tablets x 2 daily. Orally From Weifa
9879692|NCT00466674|Experimental|Allogenic Transplant|
9879693|NCT00466791|Active Comparator|Methylphenidate Transdermal System|Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
9879694|NCT00466791|Placebo Comparator|Placebo|Transdermal patch, 0mg, daily for 11 weeks
9879695|NCT00466804||Heart Transplant Recipients|People who will have a heart transplant
9879696|NCT00466843|Experimental|1|Participants will be treated with ATG
9879697|NCT00466856|Experimental|Sir-Spheres|
9879698|NCT00466882||Inamed Lap-Band System|The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
9879699|NCT00466895|Experimental|Stratum 1 Acute Leukemias|Patients must have a diagnosis of Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia(ALL)according to the WHO (World Health Organization) classification.
9879700|NCT00466895|Experimental|Stratum 2 Chronic lymphocytic leukemia|Patients must have diagnosis of B-Cell, Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Leukemia (SLL) (including Waldenstrom's Macroglobulinemia) requiring therapy (see eligibility criteria for definition of this) and have previously received treatment with one or more prior chemotherapy regimens.
9879701|NCT00466973|Active Comparator|Dry bipolar radiofrequency (RF) clamp|used for ablation during surgical procedure
9879702|NCT00466973|Active Comparator|Unipolar microwave antenna|used for ablation during surgical procedure
9879703|NCT00466973|Active Comparator|Unipolar cryothermic probe|used for ablation during surgical procedure
9879704|NCT00466973|Active Comparator|Irrigated unipolar RF antenna|used for ablation during surgical procedure
9879705|NCT00466973|Active Comparator|Irrigated bipolar RF clamp|used for ablation during surgical procedure
9879706|NCT00466973|Active Comparator|Hi-intensity focused ultrasound wand|used for ablation during surgical procedure
9879707|NCT00466999|Active Comparator|surgery|standard surgical treatment (either dilation and curettage or manual vacuum aspiration)
9879708|NCT00466999|Active Comparator|misoprostol|400 mcg misoprostol
9879709|NCT00467012|Experimental|step 1|6 enrollment for 1 cycle(4 weeks)
9879710|NCT00467012|Experimental|step 2|114 enrollment through to meet the stopping criteria
9879711|NCT00467064|Experimental|Arthritis self-management workshop|Comparison of two-week, lay led, scripted self-management workshop emphasizing action planning, problem-solving, and content specific to arthritis.
9879712|NCT00467064|Other|Delayed treatment control|After 4 month delay, participants in Control Group receive Experimental intervention.
9930680|NCT00930683|Other|8|MEDI-546
9930681|NCT00930683|Other|9|MEDI-546
9930682|NCT00930696|Experimental|Extensive Abdominal Lavage|women with full thickness excision of deep endometriosis involving the bowel
9930683|NCT00930696|Active Comparator|Standard Rinsing|women with full thickness excision of deep endometriosis involving the bowel
9930684|NCT00930709|Active Comparator|Active strength training and stretching|Active strength training and stretching
9930685|NCT00930709|Active Comparator|Botulinum toxin type A injections|Botulinum toxin type A injections
9930686|NCT00930722||quinapril|quinapril
9930687|NCT00930735||Myocardial fibrosis, outcomes|Groups with none and variable amounts of myocardial fibrosis
9930688|NCT00930800|Other|Exercise|Dance Dance Revolution (DDR)
9930689|NCT00930839||Controls|Normal, healthy controls, males and females, ages 30-80
9930690|NCT00930865|Active Comparator|Bumetanide|
9930691|NCT00930865|Active Comparator|Dapagliflozin|
9930692|NCT00930865|Active Comparator|Bumetanide + Dapagliflozin|
9879713|NCT00467116|Experimental|Therapeutic Intervention|
9879714|NCT00467194|Experimental|Phase I study of rapamycin and bevacizumab|"Rapamycin (available as 1mg per tablet; Wyeth) will be given orally once in the morning before meal. The starting dose of rapamycin will be 1mg administered once daily. All doses of rapamycin will be preceded by an oral loading dose three times the maintenance dose on day 1. The dose of rapamycin will be increased at each dose level.~Bevacizumab (100mg/4ml; Roche) will start concurrently with rapamycin. It will be diluted in a total of 100ml of 0.9% sodium chloride given via intravenous injection. The first dose will be infused over 90 minutes. If the first infusion is tolerated without any adverse infusion-related events (fever and/or chills), the second infusion may be delivered over 60 minutes. If the 60- minute infusion is well tolerated, the subsequent doses may be delivered over 30 minutes."
9879715|NCT00467207|Active Comparator|BoNT A|Botulinum toxin A injections in muscles of the arm (biceps brachii and brachialis)
9879716|NCT00467207|Experimental|Resistance training|8 weeks resistance training
9879717|NCT00467220|No Intervention|Control|Subjects will follow all study tasks but will not be required to follow a calorie-restricted meal plan.
9879718|NCT00467220|Other|Alternate Day Fasting Arm|Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
9879719|NCT00467220|Other|Calorie Restriction|Subjects in this arm will be asked to follow a calorie-restricted meal plan, daily, for three months.
9879720|NCT00467376|Experimental|1|Administration of Insulin Glulisine
9879721|NCT00467376|Active Comparator|2|Administration of Lispro
9879722|NCT00467454|Active Comparator|1|Naltrexone
9879723|NCT00467454|Placebo Comparator|2|Placebo
9879724|NCT00467493|Experimental|Anastrozole - A|Treatment for 26 consecutive days
9879725|NCT00467493|Experimental|Anastrozole -B|Treatment for 7 consecutive days early in menstrual cycle
9879726|NCT00467493|Experimental|Anastrozoe - C|Treatment for 7 consecutive days mid follicular phase
9879727|NCT00467493|Experimental|Anastrozole - D|Treatment for 7 consecutive days - mid cycle
9879728|NCT00467493|Experimental|Anastrozole - E|Treatment for 7 consecutive days - luteal
9879729|NCT00467493|Placebo Comparator|Anastrozole - F|Treatment with placebo for 26 consecutive days
9879730|NCT00467571|Experimental|I|Drug: lansoprazole, clarithromycin, amoxycillin
9879731|NCT00467636|Experimental|Insulin Glulisine|Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose < 4 mmol/l.
9879732|NCT00467636|Active Comparator|2|Blood glucose monitoring for comparison with treatment arm (1)
9879733|NCT00467688|No Intervention|A,1|Real time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
9879734|NCT00467688|No Intervention|A,2|Retrospective analysis of glucose values
9879735|NCT00467714|No Intervention|1|2.5 cm Cartilage as columella strut
9879736|NCT00467727|Experimental|1|Phase Contrast Mammography Exam
9879737|NCT00467883|Experimental|amphotericin B|Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks
9879738|NCT00467974|Experimental|1|TEA with LEM
9879739|NCT00467974|Active Comparator|2|TACE
9879740|NCT00467987|Experimental|androgel|androgel
9879741|NCT00467987|Placebo Comparator|placebo|placebo gel
9879742|NCT00467987|No Intervention|no treatment|eugonadal comparison arm
9879743|NCT00468013|Experimental|1|Computer-based exercises to be executed at home.
9879744|NCT00468013|Sham Comparator|2|Computer-based exercises to be executed at home.
9879745|NCT00468065|Experimental|A|TO use Veinviewer to improve the effectiveness of IV starts in children
9879746|NCT00468065|No Intervention|B|Standard approach to placing IV s in children
9879747|NCT00468078|Experimental|A|Parkinson's disease
9879748|NCT00468078|Active Comparator|B|ET+Normal
9879749|NCT00468091|Placebo Comparator|saline-saline|"saline IV~+ saline IV"
9879750|NCT00468091|Active Comparator|saline-exendin(9-39)amide|"saline IV~+ exendin(9-39)amide IV"
9879751|NCT00468091|Active Comparator|saline-atropine|"saline IV~+ atropine IV"
9879752|NCT00468091|Active Comparator|exendin(9-39)amide-atropine|"exendin(9-39)amide IV~+ atropine IV"
9879753|NCT00468156|Active Comparator|1|written materials only
9879754|NCT00468156|Experimental|2|written materials plus asked to form implementation intentions
9879755|NCT00468156|Experimental|3|same as arm 2 plus telephone support
9879756|NCT00468182||1|MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
9879757|NCT00468182||2|MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
9879758|NCT00468247|Active Comparator|1|Device , Navigator used for guiding haemodynamic care
9879759|NCT00468247|Placebo Comparator|2|Conventional care
9879760|NCT00468325|Active Comparator|Multi-slice Computed Tomography|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to a multi-slice computed tomography arm where they will receive a CT scan of their heart.
9879761|NCT00468325|Active Comparator|Standard of Care|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to the Standard of Care arm and receive rest-stress nuclear myocardial perfusion imaging test.
9879762|NCT00468338||BIS monitor used for all subjects|BIS monitor applied to all subjects
9879763|NCT00468468|Experimental|CHESS Condition|Subjects who receive the CHESS (Comprehensive Health Enhancement Support System)
9879764|NCT00468468|Experimental|Mentor Condition|Subjects who receive access to a Human Cancer Mentor only
9879765|NCT00468468|Experimental|CHESS + Mentor|Subjects who receive the CHESS system plus a Human Cancer Mentor
9879766|NCT00468468|No Intervention|Internet Only|Subjects receive routine care and nothing else
9879767|NCT00468572|Experimental|1|Participants will receive treatment with affectionate writing
9879768|NCT00468572|Active Comparator|2|Participants will receive treatment with meaningless writing
9879769|NCT00468611|Experimental|1|
9879770|NCT00468611|Placebo Comparator|2|
9879771|NCT00468715|Experimental|bicalutamide|This is a multicenter, open-label, phase II study to evaluate the antitumor activity and safety of bicalutamide administered orally daily to patients with ER(-)/PR(-)/AR(+) metastatic breast cancer. Eligible patients who have consented to trial participation will receive bicalutamide at a dose of 150mg PO daily.
9879772|NCT00468741|No Intervention|1|subjects receive internet access and computer
9879773|NCT00468741|Experimental|2|CHESS informational services only
9879774|NCT00468741|Experimental|3|CHESS social support and informational services
9879775|NCT00468741|Experimental|4|Full CHESS
9879776|NCT00468754|Experimental|A|
9879777|NCT00468754|Experimental|B|
9879778|NCT00468767|Experimental|1|Atrial fibrillation (AF) duration of 3 hours to 7 days.
9879779|NCT00468767|Experimental|2|AF duration of >7 days to <45 days
9879780|NCT00468793|Active Comparator|2|Fluid therapy guided by blood pressure and urine production
9879781|NCT00468793|Experimental|1|ScvO2 guided fluid therapy
9879782|NCT00468832||Ongoing Duchenne Muscular Dystrophy (DMD) Cohort|340 patients currently enrolled participants with DMD.
9879783|NCT00468832||New Young Duchenne Muscular Dystrophy (DMD) Cohort|Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
9879784|NCT00468832||Typically Developing Control Cohort|Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.
9935430|NCT03748472|Experimental|Bolus feeding|
9879785|NCT00468871|Experimental|Fluocinolone acetonide|Intravitreal fluocinolone acetonide implant
9879786|NCT00468871|Active Comparator|Standard care|Standard of Care
9879787|NCT00468897|Experimental|Treatment Arm AB|A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses.
9879788|NCT00468897|Experimental|Treatment Arm BA|A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses.
9879789|NCT00468923|Placebo Comparator|Rosuvastatin|Rosuvastatin 10 mg vs placebo
9879790|NCT00468923|Placebo Comparator|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 mg vs placebo
9879791|NCT00468936|No Intervention|1|Usual medications (Cellcept)
9879792|NCT00468936|Active Comparator|2|Patients taking Myfortic
9879793|NCT00468949||1|Patients undergoing excision surgery for their dupuytren's contracture
9879794|NCT00468949||2|Patients not undergoing surgery for their excision surgery
9879795|NCT00469027|Experimental|eNOS transfected EPCs|eNOS transfected EPCs will be delivered by injection via a PA line, incremental doses over three days
9879796|NCT00469040|Experimental|GW642444M 25mcg|In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
9879797|NCT00469040|Experimental|GW642444M 50mcg|Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
9879798|NCT00469040|Experimental|GW642444M 100mcg|In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
9879799|NCT00469040|Experimental|GW642444M 200mcg|Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
9879800|NCT00469040|Experimental|GW642444M 400mcg|Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.
9879801|NCT00469105|Active Comparator|Control|Control Arm receives standard diabetes disease management
9879802|NCT00469105|Experimental|Intervention Arm|Receives numeracy/literacy sensitive diabetes management
9879803|NCT00469118|Experimental|DRX Treatment|20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000™ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles.
9879804|NCT00469118|No Intervention|Conservative Care|Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment
9879805|NCT00469131|Active Comparator|1 Drug:|tacrolimus + steroid
9879806|NCT00469131|Active Comparator|2 Drug:|tacrolimus + mycophenolate mofetil
9879807|NCT00469157|Other|1.|
9879808|NCT00469170|Experimental|A|vaginal ring first 12 weeks & observational safety last 12 weeks
9879809|NCT00469170|Experimental|B|observational safety first 12 weeks & vaginal ring last 12 weeks
9930693|NCT00930878||Promus|Patients intended to be treated with a Promus™ stent system
9930694|NCT00930878||Endeavor|Patients intended to be treated with an Endeavor™ stent system (excluded the Endeavor™ Resolute™ stent)
9930695|NCT00930878||Cypher|Patients intended to be treated with a Cypher™ stent system
9930696|NCT00930891|Active Comparator|Arm A|4 additional cycles of chemotherapy
9930697|NCT00930891|Experimental|Arm B|4 additional cycles of chemotherapy + bevacizumab
9930698|NCT00930917|Experimental|cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
9930699|NCT00930917|Active Comparator|wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
9930700|NCT00930917|Other|conventional group|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
9930701|NCT00930956|Active Comparator|Dextrose|30 g of carbohydrate via Sun-Dex OGTT beverage
9879810|NCT00469235|Placebo Comparator|1|50ng dose group
9879811|NCT00469235|Placebo Comparator|2|200ng dose group
9879812|NCT00469261|Experimental|Doxycycline|Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy
9879813|NCT00469261|Active Comparator|Standard Therapy|Pts with AMI treated with Primary PCI and current medical therapy
9879814|NCT00469326|Active Comparator|atorvastatin|atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)
9879815|NCT00469326|No Intervention|control|PCI without atorvastatin pretreatment
9879816|NCT00469378|Experimental|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
9879817|NCT00469430|No Intervention|Op|traditional surgery
9879818|NCT00469430|Experimental|Ab|antibiotic treatment
9879819|NCT00469443|Experimental|1|FOLFIRI/Avastin
9879820|NCT00469443|Experimental|2|XELIRI/Avastin
9879821|NCT00469482|Active Comparator|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS Targeted)
9879822|NCT00469482|Active Comparator|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring.
9879823|NCT00469547|Experimental|1|62% ethanol in emollient gel
9879824|NCT00469547|Placebo Comparator|2|15% ethanol in emollient gel
9879825|NCT00469560|Experimental|Deferasirox|
9879826|NCT00469573|Other|1.|
9879827|NCT00469586|Experimental|A|
9879828|NCT00469586|Experimental|B|
9879829|NCT00469586|Active Comparator|C|
9879830|NCT00469599|Active Comparator|1|alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
9879831|NCT00469599|Active Comparator|2|paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks
9879832|NCT00469638|Experimental|Agilis sheeth group|
9879833|NCT00469638|Active Comparator|Non-steerable sheeth group|
9879834|NCT00469651|Experimental|1|15 microgramme candidate vaccine
9879835|NCT00469651|Active Comparator|2|Hepatitis B vaccine
9879836|NCT00469651|Experimental|3|30 microgramme MSP3 candidate malaria vaccine
9879837|NCT00469651|Active Comparator|4|Hepatitis B control vaccine
9879838|NCT00469690|Other|1|
9879839|NCT00469690|Other|2|
9879840|NCT00469729|Experimental|StemEx|
9879841|NCT00469755|Active Comparator|1|Differin® Gel, 0.1% for 12 weeks
9879842|NCT00469755|Active Comparator|2|Tazorac® Cream, 0.1% for 12 weeks
9879843|NCT00469755|Active Comparator|3|Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
9879844|NCT00469768|Experimental|A|
9879845|NCT00469768|Experimental|B|
9879846|NCT00469768|Placebo Comparator|C|
9879847|NCT00469781|Active Comparator|1|
9879848|NCT00469781|Other|2|
9879849|NCT00469872|Active Comparator|Child Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to improve child functioning
9879850|NCT00469872|Experimental|Context Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to change the task or environment around a child
9879851|NCT00469885|Other|1|Usual care
9879852|NCT00469885|Other|2|Reduction
9879853|NCT00469924|Experimental|Alerting system ON|Alerting system is ON
9879854|NCT00469924|No Intervention|Alerting system OFF|Alerting system is OFF
9879855|NCT00469937|Experimental|Therapeutic Intervention|
9879856|NCT00469963|Experimental|SIR-SPHERES|
9879857|NCT00470015|Experimental|MART1 Analog, gp100 and Survivin|
9879858|NCT00470080|Experimental|1|venepuncture
9879859|NCT00470119|No Intervention|Control|
9879860|NCT00470119|Other|Caloric Restriction|Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.
9879861|NCT00470119|Other|Exercise Intervention|Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months
9879862|NCT00470119|Other|Caloric Restriction AND Exercise Intervention|Combined caloric restriction & exercise intervention
9879863|NCT00470197|Experimental|Arm I|Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
9879864|NCT00470210|Experimental|1|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)
9879865|NCT00470223|Experimental|Chemotherapy + zoledronic acid|
9879866|NCT00470223|Active Comparator|chemotherapy|
9879867|NCT00470236|Active Comparator|Arm 1 (Standard WB Fractionation)|Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
9879868|NCT00470236|Experimental|Arm 2 (Shorter WB Fractionation)|Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
9879869|NCT00470236|Active Comparator|Arm 3 (Standard WB fractionation+Boost)|Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)
9879870|NCT00470236|Experimental|Arm 4 (Shorter WB fractionation + Boost)|Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
9879871|NCT00470249|Experimental|Patients with (HER-2)-negative and anthracycline- and taxane-resistant|Patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that was anthracycline- and taxane-resistant
9879872|NCT00470340|Experimental|1|Oxaliplatin, gemcitabine, cisplatin, lipiodol
9879873|NCT00470340|Experimental|2|Oxaliplatin, gemcitabine, cisplatin, lipiodol
9879874|NCT00470379|Experimental|Immunization with NY-ESO-1b|Efficacy of maximal dose of topical resiquimod as immune adjuvant to intradermally administered NY-ESO-1b peptide vaccine.
9879875|NCT00470405|Experimental|Therapeutic Intervention|
9879876|NCT00470444|Active Comparator|1|Liberal transfusion strategy
9879877|NCT00470444|Active Comparator|2|Restrictive transfusion strategy
9879878|NCT00470483|Active Comparator|arm 1|Paroxetine treatment during 8 weeks
9879879|NCT00470483|Placebo Comparator|arm 2|Placebo treatment during 8 weeks
9879880|NCT00470496|Experimental|Treatment (intraoperative PDT)|Patients receive HPPH IV over 1 hour on day 1. Patients undergo surgery followed by laser light exposure to the entire tumor bed on day 2.
9879881|NCT00470509|Experimental|Adalimumab|adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
9879882|NCT00470509|Placebo Comparator|Placebo|2 placebo injections on day 0 and 7
9879883|NCT00470561|Active Comparator|Aspirin|
9879884|NCT00470561|Placebo Comparator|Placebo|
9879885|NCT00470613|Experimental|SGT-53|SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 & 7 when it will be administered biweekly on days 1 & 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 & 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
9879886|NCT00470652||1|Pre-intervention patients admitted to our ED in the month prior to the intervention, before the 'computer-assisted decision support' is turned on (the intervention)
9879887|NCT00470652||2|Short-term post-intervention cohort of patients admitted in the month following the initiation of the 'computer-assisted decision support' for pain management
9879888|NCT00470652||3|long-term post-intervention cohort of patients admitted on the 6th month following the initiation of the 'computer-assisted decision support' for pain management
9879889|NCT00470678|Experimental|1|Ranibizumab
9879890|NCT00470691|Experimental|complete plaster cast|reduction and a complete plaster cast,
9879891|NCT00470691|Active Comparator|dorsal plaster splint|reduction and a dorsal plaster splint.
9879892|NCT00470743|Experimental|Ibuprofen|Compare ibuprofen
9879893|NCT00470743|Placebo Comparator|Normal saline|Compared against ibuprofen -- placebo
9879894|NCT00470756||evertors, invertors|
9879895|NCT00470795|Experimental|A|Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
9879896|NCT00470795|Placebo Comparator|B|Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
9879897|NCT00470821|Placebo Comparator|A - placebo|Identical tablets without the active principles. Each evening, nurses are requested to give 2 tablets at 8 PM and 12 PM
9879898|NCT00470821|Active Comparator|B - melatonin|Identical tablets containing melatonin 3 mg Nurses are requested to give two tablets daily, at 8 PM and 12 PM.
9879899|NCT00470873||Group 1|
9879900|NCT00470886||Group 1|
9879901|NCT00470899|Experimental|placental drainage|
9879902|NCT00470899|No Intervention|no drainage of fetal blood|
9879903|NCT00470925|Experimental|Access [123I]MZINT and SPECT Imaging|
9879904|NCT00470951|Active Comparator|open rectal resection|conventional open resection
9879905|NCT00470951|Active Comparator|laparoscopic rectal resection|laparoscopic rectal resection
9930702|NCT00930956|Experimental|RS Type 2|30g Resistant Starch Type 2 (Hi-Maize 260, National Starch)
9935431|NCT03748472|Experimental|continuous gavage feeding|
9988454|NCT01423123|Experimental|Neratinib|Paclitaxel (80 mg/m2 IV on days 1, 8, and 15 every 28 days) and trastuzumab (4 mg/kg/ loading dose, then 2 mg/kg) IV weekly beginning on day 1 of paclitaxel, neratinib orally daily beginning on day 1 of paclitaxel until disease progression.
9988455|NCT01423136||Routine postop care + Holter Monitoring|With sham remote ECG ST Monitoring
9988456|NCT01423136||Routine postop care + Holter + remote ECG monitoring|
9988457|NCT01423175|Experimental|ClAraC|
9988458|NCT01423175|Active Comparator|FLAMSA|
9988459|NCT01423188|Experimental|RVX000222, 200 mg daily|
9988460|NCT01423188|Placebo Comparator|Placebo|
9988461|NCT01423214|Experimental|Robotic LAR|Individuals who underwent robot-assisted surgery for primary rectal cancer
9988462|NCT01423214|Active Comparator|Lap LAR|Individuals who underwent laparoscopic surgery for primary rectal cancer
9988463|NCT01423227|Experimental|Home-based pulmonary rehabilitation|Home visit plus 8 weeks of once-weekly telephone calls
9988464|NCT01423227|Active Comparator|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
9988465|NCT01423240|Experimental|Lurasidone 20 mg|
9988466|NCT01423240|Experimental|Lurasidone 60 mg|
9988467|NCT01423240|Placebo Comparator|Placebo|
9988468|NCT01423266|Experimental|High Protein Group|12-week supervised weight loss program consisting of a HP diet defined as 30% of energy from protein, 40% from carbohydrates and 30% from fat
9988469|NCT01423266|Active Comparator|Standard Protein Group|12-week supervised weight loss program consisting of a SP diet defined as 15% of energy from protein, 55% from carbohydrates and 30% from fat
9988470|NCT01423292|Active Comparator|an odd numbered patients|TAP block with local anesthetics
9988471|NCT01423292|Placebo Comparator|an even numbered patients|TAP block without local anesthetics
9988472|NCT01423305|Experimental|Treatment A|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
9988473|NCT01423305|Experimental|Treatment B|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
9988474|NCT01423318|Experimental|A|
9988475|NCT01423318|Placebo Comparator|B|
9988476|NCT01423357|Experimental|Condom distribution and peer education|Youth peer educators distribute condoms and conduct condom demonstration in venues where people meet new sexual partners, i.e. bars, night clubs, sherbeens, guest houses
9988477|NCT01423357|No Intervention|Business as usual|
9988478|NCT01423370|Experimental|Group A|
9988479|NCT01423370|Experimental|Group B|
9988480|NCT01423370|Experimental|Group C|
9988481|NCT01423370|Active Comparator|Group D|
9988482|NCT01423370|Placebo Comparator|Group E|
9988483|NCT01423383||Random Populations|The aim of this study is to determine the prevalence and incidence of keloid in large populations.
9988484|NCT01423396|Other|standard care|Follow up with city doctor with recommendation HAS French guidelines
9988485|NCT01423396|Experimental|optimal care of VRF|Monitoring according to the strict recommendations of the HAS French guidelines
9988486|NCT01423409|Active Comparator|pictorial VAS|VAS with colours and 6 expressive faces
9988487|NCT01423409|Sham Comparator|usual VAS|VAS
9988488|NCT01423422||Frequency exposed patients|Patients exposed to the magnetic field with the specific frequency
9988489|NCT01423435|Experimental|Japanese|
9988490|NCT01423435|Experimental|Chinese|
9988491|NCT01423435|Experimental|South Korean|
9988492|NCT01423448|Experimental|Bulletin board|Participants will be given access to the online bulletin board (intervention) for a 6 month period
9988493|NCT01423448|No Intervention|Control|After 6 months participants allocated to the control group will receive access to the intervention
9988494|NCT01423474|Experimental|Short treatment time (11 days)|
9988495|NCT01423474|Experimental|Long treatment time (29 days)|
9997242|NCT01507142||cART-unresponsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, <200 CD4 Tcells/mm3 and Viral Load >5000 copies/ml
9997243|NCT01507142||cART-responsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, >350 CD4 Tcells/mm3 and Viral Load<50 copies/ml
9997244|NCT01507142||Acute or early HIV infection|Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease
9997245|NCT01507142||HIV-negative Hepatitis B|Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load
9997246|NCT01507168|Placebo Comparator|Placebo|
9997247|NCT01507168|Experimental|GC33 (RO5137382)|
9997248|NCT01507194|Active Comparator|Ondansetron 4 mg|
9997249|NCT01507194|Experimental|Vestipitant 6 mg|
9997250|NCT01507194|Experimental|Vestipitant 12 mg|
9997251|NCT01507194|Experimental|Vestipitant 18 mg|
9997252|NCT01507194|Experimental|Vestipitant 24 mg|
9997253|NCT01507194|Experimental|Vestipitant 36 mg|
9879906|NCT00470977|Experimental|(Ranibizumab) Lucentis|(Ranibizumab)Lucentis 0.5%
9879907|NCT00471003||Arm 1|
9879908|NCT00471055|Experimental|A|Capsaicin and placebo controlled,Cross-over design study
9879909|NCT00471055|Placebo Comparator|B|Capsaicin and placebo controlled,Cross-over design study
9879910|NCT00471094|Experimental|Ilaprazole 5 mg QD|
9879911|NCT00471094|Experimental|Ilaprazole 20 mg QD|
9879912|NCT00471094|Experimental|Ilaprazole 40 mg QD|
9879913|NCT00471094|Active Comparator|Lansoprazole 30 mg QD|
9879914|NCT00471120|Experimental|P2x7 Assay|Compare assay results with biopsy
9879915|NCT00471133|Experimental|Xenogeneic Tyrosinase|
9879916|NCT00471185|Experimental|A|Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week
9879917|NCT00471224||Patients who have received drug.|Patients who have received drug.
9879918|NCT00471289|Experimental|1|PTA with primary placement of Drug (paclitaxel) Eluting Stent
9879919|NCT00471289|Active Comparator|2|PTA
9879920|NCT00471471|Experimental|Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil|"The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year)."
9879921|NCT00471510|Experimental|1|NEOSH101 2%
9879922|NCT00471510|Experimental|2|NEOSH101 1%
9879923|NCT00471510|Experimental|3|NEOSH101 0.5%
9879924|NCT00471510|Placebo Comparator|4|
9879925|NCT00471601|Experimental|Interviews/Questionnaires|The primary intervention in part 1 includes the interview for item generation with 50 women and the pilot-testing with a separate group of n = 30 women. The primary intervention in part 2 and 3 is the administration of the questionnaire. In part 3, along with the questionnaire being developed, the Body Image Scale (BIS), the Life Orientation Test-Revised (LOT-R), and the upcoming MSKCC BREAST-Q will be given to determine convergent and discriminant construct validity. No other therapeutic or diagnostic agents will be administered.
9879926|NCT00471614|Experimental|1|NucleomaxX
9879927|NCT00471614|Placebo Comparator|2|Placebo
9879928|NCT00471640|Active Comparator|1|dexamethasone
9879929|NCT00471640|Placebo Comparator|2|Placebo
9879930|NCT00471679|Experimental|Ethanol-Lock Treatment|Ethanol instillation and removal will be carried out by one of the investigating physicians, a pediatric surgical nurse practitioner, or a dedicated research nurse. Syringes containing a 70% ethanol solution will be pre-filled in the PDH pharmacy and dispensed to the nurse caring for a particular patient. The volume of ethanol to be administered into each lumen of the central line will be specific to each patient's catheter and will be determined at enrollment.
9879931|NCT00471692|Placebo Comparator|placebo|Normal saline placebo
9879932|NCT00471692|Active Comparator|Ropivocaine|Ilioinguinal nerve block with ropivocaine
9879933|NCT00471770||1|1.Core group: enrolled subjects who have isolated pneumococcal
9879934|NCT00471770||2|2.SPN group:enrolled subjects who have no isolated pneumococcal
9879935|NCT00471770||3|3.DCF group: Subjects screened but not enrolled
9879936|NCT00471952|Experimental|1|Maxalt 10mg with Caffeine 75mg
9879937|NCT00471952|Active Comparator|2|Maxalt 10mg plus Placebo
9879938|NCT00471952|Placebo Comparator|3|Double placebo
9879939|NCT00471965|Experimental|A|Oxaliplatin + 5-Fluorouracil/Leucovorin
9879940|NCT00471965|Active Comparator|B|Doxorubicin
9879941|NCT00471991|Active Comparator|Arm 1|
9879942|NCT00471991|Experimental|Arm 2|
9879943|NCT00472004|Active Comparator|1|17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration
9879944|NCT00472004|Active Comparator|2|Tibolone 2.5 mg 1 daily, 1 year duration
9879945|NCT00472017|Experimental|Pediatric Diffuse Brainstem Glioma Patients|Patients with newly diagnosed diffuse brainstem gliomas receive vandetanib.
9879946|NCT00472069|Experimental|A|transplantation of the squeletic muscular cells
9879947|NCT00472095|Experimental|diabetes fotonovela|spanish language comic book describing diabetes care and consequences
9879948|NCT00472095|Placebo Comparator|placebo fotonovela|
9879949|NCT00472121||1: AMG|
9879950|NCT00472121||2: MMG|
9879951|NCT00472134|Active Comparator|Bupivicaine via Elastomeric pump|Bupivicaine via elastomeric pump
9879952|NCT00472134|Placebo Comparator|Placebo via elastomeric pump|Placebo via elastomeric pump
9879953|NCT00472160|Experimental|1|Non Invasive Ventilation
9879954|NCT00472173|Active Comparator|Calcium hydroxide|
9879955|NCT00472173|Experimental|MTA|
9879956|NCT00472212|Experimental|Spectacles|Spectacles with hyperopic lenses
9879957|NCT00472212|Placebo Comparator|Control|Spectacles with placebo lenses
9879958|NCT00472225|Experimental|1|Rituximab treatment arm
9879959|NCT00472238|Experimental|1, Training|Group for training therapy
9879960|NCT00472238|Active Comparator|2, Control|
9879961|NCT00472264||Single arm study (Healthy volunteers & COPD subjects)|A single arm study PET imaging is carried out twice during the first week of the study and again 4 weeks later in both Healthy volunteers and COPD subjects.
9879962|NCT00472329|No Intervention|Fludarabine and 400cGY TBI|
9879963|NCT00472368|Experimental|LBH589|
9879964|NCT00472381|Experimental|2|Insulin
9879965|NCT00472472|Placebo Comparator|1|PTA
9879966|NCT00472472|Active Comparator|2|PTA with Paccocath
9879967|NCT00472498||1|"Case:~Patients resuscitated after 2001"
9879968|NCT00472498||2|"Control:~Patients who suffer cardiac arrests after 2001."
9879969|NCT00472589||1|Healthy women
9879970|NCT00472589||2|Women with breast cancer
9879971|NCT00472667|Experimental|1|Procalcitonin guided strategy
9879972|NCT00472706|Active Comparator|1|Excision
9879973|NCT00472706|Active Comparator|2|Photodynamic therapy
9879974|NCT00472719|Experimental|1|Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
9879975|NCT00472719|Experimental|2|Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
9879976|NCT00472719|Experimental|3|Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
9879977|NCT00472719|Experimental|4|Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
9879978|NCT00472758|Active Comparator|1|MEDI 545
9879979|NCT00472758|Placebo Comparator|2|Placebo IV
9930703|NCT00930956|Experimental|RS Type 4 (cross linked)|30g of cross linked RS type 4 (Fibersym RW, MGP Ingredients, Inc.)
9930704|NCT00930995|Active Comparator|A|
9930705|NCT00930995|Placebo Comparator|B|
9930706|NCT00931008|Experimental|SID530|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
9930707|NCT00931008|Active Comparator|Taxotere|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
9930708|NCT00931021|Active Comparator|Varenicline (Chantix)|
9930709|NCT00931021|Active Comparator|Nicotine Patch|
9930710|NCT00931034|Active Comparator|South Beach Diet with SBD Products|
9930711|NCT00931034|Active Comparator|ADA Diabetes meal plan|
9930712|NCT00931060|Experimental|Branched chain amino acids|Patients with cirrhosis. Healthy subjects age and sex matched
9930713|NCT00931073|Experimental|Period 1|
9930714|NCT00931073|Experimental|Period 2|
9930715|NCT00931073|Experimental|Period 3|
9930716|NCT00931099||Low risk pregnant women|300 women in the third trimester of a singleton uncomplicated pregnancy, who attend a low risk obstetric surveillance
9930717|NCT00931099||High risk pregnant women|100 women hospitalized at the Antenatal department due to pregnancy related hypertensive disorder, IUGR, diabetes mellitus or premature labor
9930718|NCT00931099||Pregnant women in labor|200 women of a singleton uncomplicated full term pregnancy will be recruited during labor at the delivery room
9930719|NCT00931099||Newborns|400 newborns belong to women in first two groups
9930720|NCT00931112|Other|exercise|
9930721|NCT00931125|Active Comparator|vitrectomy with ranibizumab|Patients receiving adjunct preoperative intravitreal ranibizumab (3±1 days) before vitrectomy surgery
9930722|NCT00931125|Placebo Comparator|vitrectomy without ranibizumab|Patients receiving sham treatment before vitrectomy as a comparator arm
9930723|NCT00931138|Active Comparator|Arm1 = Aracytine + Daunorubicin|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
9930724|NCT00931138|Active Comparator|Arm 3 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
9930725|NCT00931138|Active Comparator|Arm 2 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
9930726|NCT00931151|Experimental|Casein|Protein source in the high fat meal is casein
9930727|NCT00931151|Experimental|Milk soluble protein|Protein source in the high fat meal are milk soluble protein
9930728|NCT00931151|Experimental|Alpha lactalbumin|Protein source in the high fat meal is alpha-lactalbumin
9930729|NCT00931177||Dehydrated children|children with dehydration
9930730|NCT00931216|Experimental|Integrated ANC, PMTCT and HIV Services|HIV care and treatment services are integrated into antenatal care (ANC) services for women testing positive within the ANC at this facility.
9930731|NCT00931216|No Intervention|Non-Integrated Services|Women testing positive in the ANC department are referred for care at the HIV clinic. HIV care and treatment services are not provided within the ANC at facilities randomized to this arm.
9930732|NCT00931229|Experimental|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines.
9930733|NCT00931281|Active Comparator|1|ABT-450/ritonavir
9930734|NCT00931281|Placebo Comparator|2|Placebo for ABT-450/placebo for ritonavir
9930735|NCT00931320||3000 patients|Who have at least made 1 visit to the outpatient clinic within previous 6 months .
9930736|NCT00931333|Experimental|1|
9930737|NCT00931346|Experimental|FTC/TDF Daily|Daily dosing
9930738|NCT00931346|Experimental|FTC/TDF Intermittent|Dosed intermittently
9930739|NCT00931346|Placebo Comparator|Placebo Daily|Placebo dosed daily
9930740|NCT00931346|Placebo Comparator|Placebo Intermittent|Placebo dosed intermittently, orally.
9930741|NCT00931372|Experimental|Sequence 1: AVE0010/Placebo|"Period 1: lixisenatide 20 µg in 200 µL, one single dose~Period 2: placebo 200 µL, one single dose"
9879980|NCT00472810|Experimental|1|20 patients will be recruited according to the enrollment acceptance criteria.Randomisation is performed using a sealed envelope system, where 40 shuffled envelopes designating the surgery to either trabeculectomy with mitomycin-C (MMC) and trabeculectomy with ologen™ Collagen matrix must be open before surgery. Then, patients are allocated and trabeculectomy is performed.If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
9879981|NCT00472810|Active Comparator|2|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be randomised to trabeculectomy with mitomycin -C. Randomisation is performed. Then, trabeculectomy is performed
9879982|NCT00472823|Experimental|vitamin D3 400 IU daily|vitamin D3 400 IU daily
9879983|NCT00472823|Experimental|vitamin D3 800 IU daily|vitamin D3 800 IU daily
9879984|NCT00472823|Experimental|vitamin D3 1600 IU daily|vitamin D3 1600 IU daily
9879985|NCT00472823|Experimental|vitamin D3 2400 IU daily|vitamin D3 2400 IU daily
9879986|NCT00472823|Experimental|vitamin D3 3200 IU daily|vitamin D3 3200 IU daily
9879987|NCT00472823|Experimental|vitamin D3 4000 IU daily|vitamin D3 4000 IU daily
9879988|NCT00472823|Experimental|vitamin D3 4800 IU daily|vitamin D3 4800 IU daily
9879989|NCT00472823|Placebo Comparator|placebo|matched to vitamin D tablet
9879990|NCT00472862|Experimental|2|Cognitive training
9879991|NCT00472862|Active Comparator|1|OPUS psychosocial treatment alone
9879992|NCT00472953|Experimental|A|
9879993|NCT00472953|Active Comparator|B|
9879994|NCT00472966|Other|1|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
9879995|NCT00473109|Experimental|Dialysis without systemic heparinization|Dialysis without systemic heparinization
9879996|NCT00473122|Other|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Reconstruction: If radiation therapy (XRT) not needed, immediate reconstruction. If XRT is needed, delayed reconstruction until XRT complete.
9879997|NCT00473135|Experimental|1|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
9879998|NCT00473135|Experimental|2|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
9879999|NCT00473135|Placebo Comparator|3|Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.
9880000|NCT00473148|Experimental|1|BNP-guided treatment (Furosemide)
9880001|NCT00473148|No Intervention|2|
9880002|NCT00473174|Active Comparator|1|Ramipril on awakening
9880003|NCT00473174|Active Comparator|2|Ramipril at bedtime
9880004|NCT00473200|Active Comparator|S-adenosylmethionine|S-adenosylmethionine
9880005|NCT00473200|Placebo Comparator|Placebo|Placebo
9880006|NCT00473239|Experimental|cholecalciferol|A single dose of 100,000 IU vitamin D
9880007|NCT00473239|No Intervention|Control|No drug was given
9880008|NCT00473252||Hemodialysis patients|
9880009|NCT00473252||Renal transplant patients|
9880010|NCT00473291||Patients with pleural effusion|Patients diagnosed with pleural effusion and presenting for treatment
9880011|NCT00473317|Experimental|1|All subjects in this study will be in the active arm
9880012|NCT00473356|Active Comparator|1|to receive amino acid supplement
9880013|NCT00473356|No Intervention|2|no amino acid supplement
9880014|NCT00473460|Experimental|Arm 1|
9880015|NCT00473460|Placebo Comparator|Arm 2|
9880016|NCT00473473|Experimental|1|potassium bichromate
9880017|NCT00473473|Placebo Comparator|2|placebo
9880018|NCT00473486|Active Comparator|1|Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC
9997254|NCT01507259||100 g containing 70% or 34% cocoa|Healthy controls
9880019|NCT00473486|Placebo Comparator|2|Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC
9880020|NCT00473499|Experimental|DEBlue stent|Paclitaxel coated balloon with CoCr stent mounted on it
9880021|NCT00473499|Active Comparator|Cypher stent|
9880022|NCT00473499|Placebo Comparator|Coroflex Blue stent|
9880023|NCT00473551|Experimental|Anti-Third Party T Lymphocytes + Nonmyeloablative SCT|"Anti-Third Party CTL (Cytolytic T-lymphocytes) with Nonmyeloablative SCT (Stem Cell Transplantation)~Rituximab 375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8; + Cyclophosphamide 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine; + Fludarabine 40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6; + Radiation 2Gy Total body radiation day before transplantation + Stem Cell Transplantation + Intravenous infusion of Anti-third Party CTLs."
9880024|NCT00473603|Experimental|LHI|to perform an i.v. lipid heparin infusion for 4 h
9880025|NCT00473603|Sham Comparator|SHI|to perform an i.v. saline heparin infusion for 4 h
9880026|NCT00473616|Experimental|1|AZD7762 monotherapy followed by AZD7762 + irinotecan
9880027|NCT00473707|Active Comparator|1|Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
9880028|NCT00473707|Other|2|Expectant management of the third stage of labor
9880029|NCT00473720|Experimental|satraplatin abraxane|Satraplatin and abraxane will be given in escalating cohorts on a 3 + 3 design from satraplatin 40mg/m2 and abraxane 80mg/m2
9880030|NCT00473772|Active Comparator|Cypher Stent|
9880031|NCT00473772|Experimental|DEBlue Stent|
9880032|NCT00473798||A|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
9880033|NCT00473798||A'|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
9880034|NCT00473798||B|Patients who have consented to participate in a randomized trial of optical spectroscopy.
9880035|NCT00473798||C|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
9880036|NCT00473798||D|Health care providers.
9880037|NCT00473811|Active Comparator|ADA diet|Patients will be encouarged to consume foods consisted with ADA dietary recommendation
9880038|NCT00473811|Experimental|Low-GI|a low GI dietary education
9880039|NCT00473863|Experimental|intervention|Receives CCTA
9880040|NCT00473863|No Intervention|Control|
9880041|NCT00473941|No Intervention|1|Writing in a journal 15 minutes a day
9880042|NCT00473941|No Intervention|2|Control Writing in a journal 15 minutes a day
9880043|NCT00473954|Experimental|EGEN-001|
9880044|NCT00473967|Experimental|10 mcg Na-ASP-2/Alhydrogel|Na-ASP-2 Hookworm Vaccine
9880045|NCT00473967|Active Comparator|Butang hepatitis B vaccine|Hepatitis B Vaccine - comparator vaccine
9880046|NCT00473980|Experimental|Drug|Treatment with indomethacin or celecoxib
9880047|NCT00473980|Sham Comparator|SHAM|Sham treatment
9880048|NCT00474006|Active Comparator|arm I|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days
9880049|NCT00474019|Experimental|1|Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg
9880050|NCT00474110|Experimental|1|Ketamine and hydromorphone for patient-controlled relief in children's mucositis.
9880051|NCT00474136|Experimental|1|
9880052|NCT00474136|Experimental|2|
9880053|NCT00474136|Active Comparator|3|
9880054|NCT00474227|Experimental|A|behavioral intervention, group therapy including nutritional guidance and physical exercise
9880055|NCT00474227|No Intervention|B|comparison group, one time explanation of importance of proper nutrition. This group receives no group therapy or organized exercise sessions or nutritional guidance. They are wait listed for this program.
9880056|NCT00474318||Adolescents with severe obesity|Adolescents and young adults with severe obesity
9880057|NCT00474357|Experimental|1|Bipolar patients participating in psychoeducation intervention
9880058|NCT00474357|No Intervention|2|bipolar patients who do not participate in psychoeducation group
9880059|NCT00474357|No Intervention|3|Therapists will complete questionnaires regarding myths about bipolar patients, no intervention
9880060|NCT00474370|Experimental|Test Arm|Vicriviroc 30 mg QD
9880061|NCT00474370|Placebo Comparator|Placebo Control Arm|Placebo
9880062|NCT00474461|Experimental|Treatment group|Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
9880063|NCT00474461|No Intervention|Control group|Patients in this arm did not receive any intervention.
9880064|NCT00474552|Experimental|1|Experimental-Placebo Comparator
9930742|NCT00931372|Experimental|Sequence 2: Placebo/AVE0010|"Period 1: placebo 200 µL, one single dose~Period 2: lixisenatide 20 µg in 200 µL, one single dose"
9930743|NCT00931398|Experimental|Methylphenidate HCl (Concerta)|
9930744|NCT00931398|Placebo Comparator|Placebo|
9930745|NCT00931424|Experimental|reconstruction|patients in this group will have both valve reconstruction and superficial vein surgery
9930746|NCT00931424|No Intervention|unreconstruction|patients in this group will only have superficial vein surgery
9930747|NCT00931437|Experimental|vitamin K-rich dairy product|one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.
9935432|NCT03747458|Active Comparator|OPN-375 186 μg BID|"Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks"
9880065|NCT00474669|Experimental|Docetaxel|Intraperitoneal Docetaxel administered with heat
9880066|NCT00474695||1|Active approved treatment
9880067|NCT00474799|Experimental|A|MNS075 7.5mg q1h
9880068|NCT00474799|Experimental|B|MNS075 15mg q3h
9880069|NCT00474825|Active Comparator|1|Hyperbaric Oxygen twice weekly (Monday & Friday) with Radiation and Chemotherapy
9880070|NCT00474825|Active Comparator|2|Hyperbaric Oxygen three times per week (Monday, Wednesday & Friday) with Radiation and Chemotherapy.
9880071|NCT00474825|Active Comparator|3|Hyperbaric Oxygen Five times per week (Monday through Friday) with Radiation and Chemotherapy
9880072|NCT00474838|Active Comparator|Oral AntiDiabetic Drug|glimepiride and metformin and/or once daily glargine
9880073|NCT00474838|Experimental|intensive insulin group|insulin glargine insulin glulisine
9880074|NCT00474916|Experimental|KRN5500|KRN5500 escalating dose of .6, 1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
9880075|NCT00474916|Placebo Comparator|Normal Saline|Placebo consists of IV infusion of normal saline
9880076|NCT00474981|Experimental|1|IMNCI
9880077|NCT00474981|No Intervention|2|Control
9880078|NCT00475007|Experimental|1|The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
9880079|NCT00475007|Sham Comparator|2|The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
9880080|NCT00475059|Experimental|1|patients who received cimétidine
9880081|NCT00475072|Experimental|1|
9880082|NCT00475098|Active Comparator|A|
9880083|NCT00475098|Experimental|B|
9880084|NCT00475111|Experimental|1|People in Group 1 will participate in CBT for Pain (CBT-P), which will focus on altering thought processes as a way to cope more effectively with pain.
9880085|NCT00475111|Experimental|2|People in Group 2 will participate in Mindfulness Medication for Emotion Regulation (MM-ER), a type of CBT that focuses on being more aware of one's emotions and regulating them.
9880086|NCT00475111|Experimental|3|Group 3 participants will serve as controls and receive educational information on the causes of, course of, and treatment for RA.
9880087|NCT00475124|Experimental|1|Home Monitoring ON
9880088|NCT00475124|Active Comparator|2|Home Monitoring OFF
9880089|NCT00475137|Experimental|Lamotrigine Plus Antidepressant|Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
9880090|NCT00475137|Active Comparator|2. Lamotrigine Monotherapy|Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.
9880091|NCT00475189|Active Comparator|1|
9880092|NCT00475189|Active Comparator|II|loestrin 1/20 given 1 tab 21/7
9880093|NCT00475280|Other|Geriatric assessment|
9880094|NCT00475293|Experimental|1|
9880095|NCT00475371|Experimental|1|MKC253 Inhalation Powder
9880096|NCT00475410|Experimental|ASCs|
9880097|NCT00475410|Experimental|ASCs+fibrin glue|
9880098|NCT00475410|Active Comparator|Fibrin glue|
9880099|NCT00475436|Experimental|Arm 1|
9880100|NCT00475475|Experimental|1|Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
9880101|NCT00475475|Experimental|2|Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
9880102|NCT00475475|Placebo Comparator|3|Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
9880103|NCT00475488|Other|Group 1|Radial Artery versus Right Internal Thoracic Artery when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
9880104|NCT00475488|Other|Group 2|Radial Artery versus Saphenous Vein when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
9880105|NCT00475527|No Intervention|iron only|Only iron therapy
9880106|NCT00475527|Experimental|iron + HP therapy|Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
9880107|NCT00475540|Active Comparator|Prolift mesh|vaginal prolapse repair with mesh
9880108|NCT00475540|Active Comparator|Prolapse repair without mesh|vaginal prolapse repair without mesh
9930748|NCT00931450|Active Comparator|Group 1|Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
9797184|NCT01588197|Experimental|PFC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy. The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the PFC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
9988496|NCT01423487|Experimental|efficacy and safety|To investigate the efficacy and safety of Metformin in preventing patients with Risperidone from weight gain and amenorrhea.
9797185|NCT01588236|Experimental|high dose KYG0395|Patients received high dose KYG0395 capsule (tid)
9797186|NCT01588236|Experimental|lower dose KYG0395|Patients received lower dose KYG0395 capsule (bid)
9797187|NCT01588236|Placebo Comparator|placebo|Patients received placebo (tid)
9797188|NCT01588353|Experimental|AK160 0.58 mg|
9797189|NCT01588366|Placebo Comparator|Placebo|Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
9797190|NCT01588366|Experimental|15 mg LY2409021|Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
9797191|NCT01588366|Experimental|60 mg LY2409021|Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
9797192|NCT01588405|Experimental|UT-15C SR|
9797193|NCT01588418|Experimental|Exenatide first, then Placebo|Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
9797194|NCT01588418|Experimental|Placebo first, then Exenatide|Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
9797195|NCT01588444|Experimental|cancellous FDBA (LifeNet)|grafting with cancellous mineralized freeze-dried bone allograft (LifeNet Health)
9797196|NCT01588444|Experimental|cortical FDBA (LifeNet)|CORTICAL FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
9797197|NCT01588457|Active Comparator|Lithium|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [Li] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
9797198|NCT01588457|Active Comparator|Divalproex|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
9797199|NCT01588457|Active Comparator|Lithium plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].
9797200|NCT01588457|Active Comparator|Lithium plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
9797201|NCT01588457|Active Comparator|Divalproex plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].
9797202|NCT01588457|Active Comparator|Divalproex plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
9797203|NCT01588470|Experimental|Pioglitazone|Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
9797204|NCT01588496|Experimental|Part A: Evolocumab|Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
9797205|NCT01588496|Experimental|Part B: Evolocumab|Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
9797206|NCT01588496|Placebo Comparator|Part B: Placebo|Participants received double-blind placebo subcutaneously once a month for 12 weeks.
9988497|NCT01423487|Placebo Comparator|placebo comparator|To investigate whether plcebo also could preventing patients with Risperidone from weight gain and amenorrhea.
9797207|NCT01588509|Experimental|Romosozumab 140 mg|Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
9797208|NCT01588509|Experimental|Romosozumab 210 mg|Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
9797209|NCT01588548|Active Comparator|AZD1208|
9797210|NCT01588561|Active Comparator|Intravenous Nicotine (1.5 mg/70 kg)|Participants are given a siingle infusion of nicotine (1.5 mg/70 kg), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
9797211|NCT01588561|Placebo Comparator|Saline - placebo|Participants are given physiological saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
9797212|NCT01588821|Experimental|Treatment Arm|Cabozantinib
9797213|NCT01588951|Experimental|No Leukemia Stem Cells - Consolidation|Without LSC, standard cytarabine consolidation
9797214|NCT01588951|Experimental|Leukemia Stem Cells - Consolidation|LSC present, randomized to cytarabine consolidation
9797215|NCT01588951|Experimental|Leukemia Stem Cells - Transplant|LSC present, randomized to allogeneic transplant
9797216|NCT01588990|Experimental|Bevacizumab: Phase A and Phase B|The trial will consist of 2 phases of treatment. Phase A: Participants will receive bevacizumab 7.5 mg/kg intravenous (IV) infusion on Day 1 every 3 weeks in combination with XELOX (capecitabine and oxaliplatin) or bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluouracil) until first disease progression or occurrence of unmanageable toxicity. Phase B: Upon documented first disease progression, participants will continue receiving bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluouracil) until second disease progression or occurrence of unmanageable toxicity. Phase B treatment should commence within 4 weeks of the date of documented first disease progression.
9797217|NCT01589094|Experimental|Gemcitabine and Cisplatin (DD GC)|This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
9797218|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 1|1 mg/kg KBSA301
9797219|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 2|3 mg/kg KBSA301
9797220|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 3|10 mg/kg KBSA301
9797221|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 4|20 mg/kg KBSA301
9797222|NCT01589185|Experimental|Placebo|KBSA301-placebo
9797223|NCT01589237|Experimental|LCQ908|Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
9797224|NCT01589263|Active Comparator|ARM 1: onaBoNT-A + placebo|onaBoNT-A 200 U prostate injection and placebo oral capsule daily
9797225|NCT01589263|Active Comparator|ARM 2: Saline + Tamsulosin|Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.
9800164|NCT01681212|Experimental|Ipilimumab, 10 mg/kg + Dacarbazine, 850 mg/m^2|During the Induction Period, participants received ipilimumab, 10 mg/kg, as tolerated by intravenous (IV) infusion as 1 single dose during Weeks 1 (Day 1), 4, 7, and 10 for a total of 4 separate doses. During the Maintenance Phase, participants received ipilimumab, 10 mg/kg, as tolerated by IV infusion every 12 weeks, beginning at Week 24, until disease progression or unacceptable toxicity occurred or the patient withdrew consent. Participants also received dacarbazine, 850 mg/m^2, by IV infusion over 30 to 60 minutes, starting on Week 1 and repeated every 3 weeks until Week 22. Dacarbazine was dosed on the same day as ipilimumab, when applicable, after the ipilimumab dose.
9800165|NCT01681277|Experimental|BI 113608 high dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
9935433|NCT03747458|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
9800166|NCT01681277|Experimental|BI 113608 low dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
9800167|NCT01681277|Experimental|BI 113608 medium dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
9800168|NCT01681277|Experimental|BI 113608 high dose qd|powder in the bottle for oral solution, oral administration with 240 ml water
9800169|NCT01681368|Experimental|Birinapant for Advanced Ovarian,Fallopian Tube & Peritoneal Ca|single arm
9800170|NCT01681433|Experimental|Experimental: Arm A|OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone
9800171|NCT01681433|Active Comparator|Control Arm: Arm B|Continuation of standard therapy with abiraterone acetate and prednisone
9800172|NCT01681472|Active Comparator|Levoleucovorin 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
9800173|NCT01681472|Active Comparator|Levoleucovorin 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
9800174|NCT01681472|Experimental|6R-MTHF 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
9800175|NCT01681472|Experimental|6R-MTHF 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
9800176|NCT01681511|Experimental|ICET™ TIC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
9800177|NCT01681511|Active Comparator|BARD® LUBRI-SIL® IC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
9800178|NCT01681576|Experimental|LCZ696 followed by Valsartan|Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
9800179|NCT01681576|Experimental|Valsartan followed by LCZ696|Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks
9800180|NCT01681628|Experimental|Thought Field Therapy|Thought Field Therapy delivered by trained community leaders.
9800181|NCT01681628|Other|Wait list|"Delayed intervention.~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test)."
9800182|NCT01681771|Experimental|Cogntive behaviour therapy|Internet based Cognitive behaviour therapy during 9 weeks
9800183|NCT01681771|Active Comparator|Discussion group|Internet moderated discussion group during 9 weeks
9800184|NCT01681810|Experimental|14Nitrogen sodium nitrite|sodium nitrite 40 mg three times a day for 12 weeks
9800185|NCT01681836|Experimental|Oral 15N-labeled sodium nitrate|Oral sodium nitrate 1,000 mg once first, then washout followed by oral sodium nitrite 20 mg once
9800186|NCT01681836|Experimental|Oral 15N-labeled sodium nitrite|Oral sodium nitrite 20 mg once first, then washout followed by oral sodium nitrate 1,000 mg once
9800187|NCT01681849|Experimental|Paroxetine Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive paroxetine for a three month period followed by an open label phase of three months.
9800188|NCT01681849|Placebo Comparator|Placebo Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive placebo for a three month period followed by an open label phase of paroxetine for three months.
9800189|NCT01681849|Other|PTSD Negative|Women who have experienced early childhood abuse and do not have PTSD will serve as a control group and complete baseline assessments. They do not undergo intervention therefore they are assessed at baseline only.
9800190|NCT01681992|Experimental|Inv_MMR_Min Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
9880109|NCT00475553|Other|Group 2|Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
9880110|NCT00475553|Other|Group 1|Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
9880111|NCT00475566|Other|1|This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.
9880112|NCT00475592|Experimental|Capsule Endoscopy|
9880113|NCT00475592|Active Comparator|Upper Gastrointestinal Endoscopy|
9880114|NCT00475605||1. Protopic Exposure|Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus ointment exposure
9880115|NCT00475618|Experimental|Fluoride Varnish|Professional cleaning + education + fluoride vanish
9880116|NCT00475618|Active Comparator|Fluoride Toothpaste 500 ppm|Professional cleaning + education + fluoride toothpaste 500 ppm
9880117|NCT00475618|Active Comparator|No fluoride toothpaste|Professional cleaning + education + no fluoride toothpaste
9880118|NCT00475683|Sham Comparator|regular measurments|Mouth wash with chlorexidin
9880119|NCT00475683|Experimental|Curucmol|mouth wash with curcumol and mouth wash with chlorexidin
9880120|NCT00475839|Active Comparator|Tension-free Vaginal Tape|
9880121|NCT00475839|Active Comparator|Monarc Sub-fascial hammock|
9880122|NCT00475917|Experimental|1|
9880123|NCT00475930|Experimental|1|2% chlorhexidine gluconate impregnated cloths, self applied three times weekly
9880124|NCT00475930|Placebo Comparator|2|Comfort Bath cloths, self applied three times weekly
9880125|NCT00475956|Experimental|1|AZD2171 Monotherapy
9880126|NCT00475956|Experimental|2|AZD2171 + AZD0530
9880127|NCT00476060|Experimental|A|
9880128|NCT00476060|Placebo Comparator|B|
9880129|NCT00476099|Experimental|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|
9880130|NCT00476099|Active Comparator|Budesonide 200 µg plus formoterol 6 µg DPI|
9880131|NCT00476099|Active Comparator|Formoterol 12 µg DPI|
9880132|NCT00476112|Experimental|1|Atrial flutter duration of 3 hours to <45 days
9880133|NCT00476125|Experimental|3 day ketogenic diet|
9880134|NCT00476125|Experimental|12 day ketogenic diet|
9880135|NCT00476125|Experimental|16 hour fast|
9880136|NCT00476164|Experimental|Rituximab|Infusion of 2 x 1g of rituximab, 14 days apart
9880137|NCT00476164|Sham Comparator|2|
9880138|NCT00476190|Experimental|Arm A|Complete remission achieved after Induction Phase
9880139|NCT00476190|Experimental|Arm B|Failure to achieve complete remission after the Induction Phase
9880140|NCT00476203|Experimental|1|Immediate yoga classes offered
9880141|NCT00476203|Other|2|Delayed yoga classes (after 6 months) offered [wait list control group]
9880142|NCT00476216|Experimental|Combination of Arixtra with chemotherapy|Carboplatin 6 AUC q 21 days; Paclitaxel 200 mg/m2 q 21 days. Cohort I: Arixtra 2.5 mg SQ qd x 21 days; Cohort II: Arixtra weight-based dose (D1-2)followed by Arixtra 2.5 SQ q day (D3-21)
9880143|NCT00476255|Active Comparator|Enhanced Standard Care|Instructional materials
9880144|NCT00476255|Experimental|Motivational Intervention|Motivational interview
9880145|NCT00476268|Experimental|beclometasone /formoterol|beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
9880146|NCT00476268|Active Comparator|Beclomethasone|Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
9880147|NCT00476268|Active Comparator|Formoterol powder 12 µg/unit dose|Formoterol powder 12 µg/unit dose (Foradil™)
9880148|NCT00476281|Other|abnormal glucose tolerance|abnormal glucose tolerance
9880149|NCT00476294||Group 1: G + Placebo|G-CSF plus Placebo Arm (G + Placebo)
9880150|NCT00476294||Group 2: G + AMD3100|G-CSF plus AMD3100 Arm (G + AMD3100)
9880151|NCT00476346|Active Comparator|Calcium|Daily calcium supplementation Intervention: Calcium 2000mg / daily
9880152|NCT00476346|Experimental|Vitamin D|Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
9880153|NCT00476359|Other|double-boosted PI|double-boosted protease inhibitor combination
9880154|NCT00476372||Parkinson's disease|Pt with parkinsons disease
9880155|NCT00476385|Experimental|somatropine|
9880156|NCT00476398|No Intervention|Diagnostic capsule endoscopy|Patient with non-cardiac chest pain will undergo capsule endoscopy
9880157|NCT00476411|Experimental|1|HBV vaccine
9880158|NCT00476424|Active Comparator|1|400 mg EFV
9880159|NCT00476424|Active Comparator|2|600 mg EFV
9880160|NCT00476463|Active Comparator|1|AZT+FTC+EFV
9880161|NCT00476463|Active Comparator|2|TDF+FTC+EFV
9880162|NCT00476502||1|patients involved in structured interruption therapy
9880163|NCT00476515|Experimental|Rituximab|this study has only one arm as treatment group.
9880164|NCT00476541|Experimental|1|Gemtuzumab 5 mg / m2 two courses with three week interval
9880165|NCT00476541|No Intervention|2|No further therapy
9880166|NCT00476567|Experimental|exercise|Regular exercise 45-60 minutes minimum three times per week
9880167|NCT00476567|Active Comparator|control|standard antenatal care
9880168|NCT00476580||Sri Lankan Sinhalese|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area, but born in Sri Lanka.
9880169|NCT00476580||Siblings or Cousins in Sri Lanka|Siblings or the first cousins of the study participants living in Sri Lanka of same sex and of an age plus or minus 10 years.
9930749|NCT00931450|Experimental|Group 2|Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
9930750|NCT00931541|Experimental|A|AZD6088 oral solution
9930751|NCT00931541|Experimental|B|Placebo oral solution
9930752|NCT00931554|Active Comparator|Early drain removal|Drain removal in postoperative day 3
9930753|NCT00931554|Active Comparator|Standard drain removal|Drain removal on postoperative day 5
9930754|NCT00931567|Active Comparator|Vaselitulle|after surgery, the loss of substance is treated using vaseline dressing
9930755|NCT00931567|Experimental|Autologous platelets gel|after surgery, the loss of substance is treated with Autologous platelets gel
9930756|NCT00931580|Placebo Comparator|Placebo|placebo tablet
9930757|NCT00931580|Experimental|400 IU|Vitamin D3 tablet, 400 IU
9930758|NCT00931580|Experimental|1,000 IU|Vitamin D3 tablet, 1,000 IU
9930759|NCT00931580|Experimental|2,000 IU|Vitamin D3 tablet, 2,000 IU
9930760|NCT00931580|Experimental|4,000 IU|Vitamin D3 tablet, 4,000 IU
9930761|NCT00931593|Experimental|volunteers|"This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control.~The date of perfused manometry is randomized to avoid bias due to examinations' order."
9930762|NCT00931645|No Intervention|Complete responders|watch and wait policy
9930763|NCT00931645|Experimental|arm 2: complete responders patients|ABMT : TBI, 10 grays d-3-1 & cyclophosphamide 60 mg/sqm d-5-4
9930764|NCT00931645|Experimental|Non CR patients arm 3|Rescue chemotherapy and ABMT (see arm 2)
9930765|NCT00931645|Active Comparator|Non CR patients at random : arm 4|Rescue DHAP, F+C
9930766|NCT00931671|Other|Exercise|Exercise
9930767|NCT00931697|Experimental|AD 452 (+) mefloquine|
9930768|NCT00931697|Active Comparator|Racemic mefloquine|
9930769|NCT00931697|Placebo Comparator|Placebo|
9930770|NCT00931736|Active Comparator|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
9930771|NCT00931736|Active Comparator|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
9930772|NCT00931749|Experimental|Low intensity Ultrasound group|
9930773|NCT00931749|Sham Comparator|Sham ultrasound group|
9930774|NCT00931775|Placebo Comparator|Citalopram + placebo|Citalopram 20 mg/day t.i.d
9930775|NCT00931775|Experimental|Citalopram + pindolol|Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
9930776|NCT00931788|Experimental|Intensive pharmacist case management|
9930777|NCT00931788|Active Comparator|Usual care|
9930778|NCT00931814|Other|exercise|
9930779|NCT00931827||Group 1|
9930780|NCT00931827||Group 2|
9930781|NCT00931840|Experimental|EZN-2208|"EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.~PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL."
9930782|NCT00931840|Experimental|Cetuximab + EZN-2208|Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
9930783|NCT00931840|Active Comparator|Irinotecan + cetuximab|Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
9930784|NCT00931853|Experimental|SENNA + CASSIA (Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
9930785|NCT00931866|Experimental|Diclofenac Sodium Patch|
9930786|NCT00931866|Placebo Comparator|Topical Placebo Patch|
9930787|NCT00931905|Experimental|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.
9930788|NCT00931905|Placebo Comparator|hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.
9930789|NCT00931931|Experimental|HSV1716 - Intratumoral route|Research participants with localized disease receiving HSV1716 as an intratumoral injection
9930790|NCT00931931|Experimental|HSV1716 - intravenous|Research participants with metastatic disease receiving HSV1716 intravenously
9930791|NCT00931957|Active Comparator|Etanercept-MTX-Prednisolone|Methotrexate + Prednisolone + Etanercept
9930792|NCT00931957|Other|B, MTX-Prednisolone|Methotrexate + Prednisolone
9930793|NCT00932009||Human papillomavirus|Tanzanian men with HPV and Tanzanian men without
9930794|NCT00932048|No Intervention|Control|
9930795|NCT00932048|Experimental|Atorvastatin|
9930796|NCT00932061|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
9930797|NCT00932061|Sham Comparator|Sham Treatment|Sham acupuncture is used.
9930798|NCT00932074|Experimental|3% KP-413 Ointment|
9930799|NCT00932074|Experimental|1% KP-413 Ointment|
9930800|NCT00932074|Placebo Comparator|Placebo|
9930801|NCT00932087||type 2 diabetics with metabolic syndrome|
9930802|NCT00932087||metabolic syndrome without diabetes|
9930803|NCT00932087||type 1 diabetes|
9930804|NCT00932087||control|
9930805|NCT00932100|Experimental|REG1-a|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
9930806|NCT00932100|Experimental|REG1-b|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
9930807|NCT00932100|Experimental|REG1-c|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
9930808|NCT00932100|Experimental|REG1-d|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
9930809|NCT00932100|Active Comparator|Heparin|Heparin per standard of care at the local institution
9930810|NCT00932139|Experimental|Electro-acupuncture control|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the Electro-acupuncture control treatment."
9930811|NCT00932139|Experimental|Electro-acupuncture test|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the active Electro-acupuncture treatment."
9930812|NCT00932178|Experimental|Calmer Life|Skills-based intervention to reduce anxiety and worry in adults age 50+.
9930813|NCT00932191|Active Comparator|Ultrasound phacoemulsification|Cataract nucleus is removed using standard amounts of ultrasound energy.
9930814|NCT00932191|Active Comparator|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
9935434|NCT03745339||Abstinent OUD|Men and women with history of OUD, but abstinent for at least 3 weeks and not in agonist treatment
9935435|NCT03745339||Controls|Men and women with no history of a substance-use disorder (except nicotine, for matching purposes) and not using any drug for nonmedical purposes
9935436|NCT03745339||In-treatment OUD|Men and women with opioid use disorder (OUD) being treated with an agonist (buprenorphine or methadone)
9935437|NCT03745326|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12D mTCR PBL + highdose aldesleukin
9880170|NCT00476619|Placebo Comparator|Erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
9880171|NCT00476632||Control|Person with no history of cancer.
9880172|NCT00476671||1|HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART
9880173|NCT00476684|Experimental|radiofrequency neurotomy|Radiofrequency-neurotomy of the medial branch at 80 degr. C for 70 seconds, after diagnostic blocks
9880174|NCT00476684|Sham Comparator|sham controls|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
9880175|NCT00476697|Experimental|UVA1 Irradiation|UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
9880176|NCT00476710||Normal Glucose Metabolism|Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
9880177|NCT00476710||Impaired Glucose Tolerance|Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
9880178|NCT00476710||Frank type 2 diabetes|Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl
9880179|NCT00476723||1|HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
9880180|NCT00476775|Experimental|After school ethnic dance and home-based screen time reduction|After school ethnic dance classes and home-based screen time reduction intervention
9880181|NCT00476775|Active Comparator|Health and Nutrition Education|Health and nutrition education active placebo control intervention
9880182|NCT00476801|Experimental|UVA1 irradiation|The dose and scheduling will be similar to those being successfully used in Germany: up to 130J/cm2 from a UVA1 Sellamed irradiation device (German manufactured UVA1 light emitting device) with irradiations up to 5 times per week for up to 14 weeks on one side of the face. Then a cross-over treatment an equal length of time.
9880183|NCT00476801|No Intervention|Control|No treatment on the opposite side of the face as the UVA1 treatment for up to 14 weeks. Then a cross-over treatment an equal length of time.
9880184|NCT00476853|Active Comparator|1|NVP 400 mg
9880185|NCT00476853|Active Comparator|2|NVP 600 mg
9880186|NCT00476879|Experimental|1|12 hours of fasting and a GH bolus
9880187|NCT00476879|Experimental|2|36 hours of fasting and a GH bolus
9880188|NCT00476879|Experimental|3|36 hours of fasting and Pegvisomant
9880189|NCT00476879|Experimental|4|36 hours of fasting and NaCl injection
9880190|NCT00476892|Other|1|"It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise."
9880191|NCT00476892|No Intervention|2|Women allocated to the control group will be sent a lifestyle advice leaflet only, and will have no planned contact with the centre until their consultant review appointment at six months. The leaflet gives instructions on seeking advice where appropriate about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause prolapse to worsen.
9880192|NCT00476905||Spectral-Diagnosis|Method for noninvasive detection of cutaneous malignancies
9880193|NCT00476970|Experimental|Patient Navigation Intervention|Participants randomized to this arm will receive language-concordant patient navigation in the form of an introductory letter with educational material followed by phone or in-person contact to provide individually tailored interventions.
9880194|NCT00476970|No Intervention|Usual Care|Participants randomized to this arm will receive no additional navigation beyond the usual care for the duration of the 9-month intervention. Participants will be offered navigation services after the completion of the intervention period.
9880195|NCT00476983|Experimental|1|SQV/r 1500/100 mg OD + Truvada OD
9880196|NCT00477009|Experimental|1|Adjustable mandibular repositioning appliance
9880197|NCT00477009|Placebo Comparator|2|Placebo device in upper jaw
9880198|NCT00477035|Experimental|Autologous Cytokine-induced Killer Cells|
9880199|NCT00477048|Other|1|Replace Indinavir with SQV in patients with indinavir toxicity
9880201|NCT00477126|Active Comparator|1|start generic product cross over to reference product
9880202|NCT00477126|Active Comparator|2|start reference product cross over to generic product
9880203|NCT00477178||chronic non-malignant pain codeine|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - on long-term codeine therapy
9880204|NCT00477178||chronic non-malignant pain|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - NOT on long-term codeine therapy
9880205|NCT00477178||healthy|healthy controls
9880206|NCT00477217|Other|1|
9880207|NCT00477243||Palliative Care Clinic Patients|Department of Symptom Control and Palliative Care Center Patients
9880208|NCT00477256||Child|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer.
9880209|NCT00477256||Parent|Parent(s) or caregiver(s) of children with cancer.
9880210|NCT00477256||Medical Staff|Medical staff (i.e., physicians, nurse practitioners) involved in the children's medical decision-making.
9880211|NCT00477282|Experimental|Karenitecin|
9880212|NCT00477282|Active Comparator|Topotecan|
9880213|NCT00477308|Other|salvage therapy|Children with drug resistance were treated using the drug resistant profile
9880214|NCT00477321|Experimental|CYT107|CYT107 vs Placebo (4:1 ratio)
9880215|NCT00477347|Active Comparator|1|Manual administration
9880216|NCT00477347|Experimental|2|Closed-loop administration
9880217|NCT00477360|Experimental|1|C.A.P
9880218|NCT00477373|Experimental|1|If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.
9880219|NCT00477477|Experimental|1|Low glycemic load diet
9880220|NCT00477477|Active Comparator|2|Low fat diet
9880221|NCT00477503|Active Comparator|Group A|Ga-67 citrate injection alone for individuals with cancer cells in cerebral spinal fluid (CSF), no earlier treatment for disease.
9880222|NCT00477503|Active Comparator|Group B|Ga-67 + In 111 DTPA injection for individuals who have cancer cells in CSF, no earlier treatment for disease.
9880223|NCT00477503|Active Comparator|Group C|Individuals with tumors in the CSF that have been treated and are now cleared from the CSF, receive standard follow-up care (baseline injection of Ga-67 citrate and In-111 DTPA).
9880224|NCT00477516|Experimental|1|
9880225|NCT00477581|Experimental|Sequence A|
9880226|NCT00477581|Experimental|Sequence B|
9880227|NCT00477646|Experimental|Prevention Care Management|Telephone support over 18 months from trained Prevention Care Managers, to help women overcome barriers to colon, breast, and cervical cancer screening
9880228|NCT00477646|No Intervention|Usual Care|Usual Care. A sample of patients receive a single telephone call to validate claims data and collect basic demographic information.
9880229|NCT00477711|Experimental|C225+Chemotherapy|
9880230|NCT00477724|Placebo Comparator|sedentary control group|patients are treated by conventional rehabilitation
9880231|NCT00477724|Active Comparator|exercise and respiratory therapy|rehabilitation with exercise and respiratory therapy
9880232|NCT00477763|Active Comparator|1|
9880233|NCT00477763|Placebo Comparator|2|
9880234|NCT00477776|Active Comparator|a|Mother with diet-controlled diabetes receive Metoclopramide 10 mg 3 times a day for the first 7 days, and 2 times a day for day 8 to 10, and once a day from day 11 to day 12
9880235|NCT00477776|Placebo Comparator|b|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day for day 11 to 12
9880236|NCT00477776|Active Comparator|c|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day from day 11 to 12
9880237|NCT00477776|Placebo Comparator|d|Placebo 10 mg 3 times a day for 7 days, 2 times a day for day 8 to 10; and once a day from day 11 to 12
9880238|NCT00477802|Experimental|Botox|Randomized into receiving Botox first. At cross-over, patients will receive placebo.
9880239|NCT00477802|Placebo Comparator|Placebo|Randomized to receive placebo first. At cross-over, patients will receive the active Botox.
9880240|NCT00477815|Experimental|Rituximab + Zevalin|Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.
9880241|NCT00477854|Experimental|Visual Analogue Scale Ratings|Food intake data and its coefficients, including total food intake, food not eaten, duration of the meal, and bite rate. A mixed model analysis of variance will also be conducted on ratings of food cravings and eating atttudes. Changes in hunger and satiety ratings between, before, and after the meals will be compared for difference across treatment conditions.
9880242|NCT00477854|Experimental|Consuming less Lunch allows consumption of more dinner|Test whether chromium picolinate supplementation affects food cravings, eating attitudes, and satiety in healthy, overweight and/or obese, adult women who are determinded to be carbohydrate cravers. Whether participants who eat less at a lunch test meal consume more food at an ad lib dinner test meal with a diversity of foods.
9880243|NCT00477880|Experimental|Cetuximab|Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.
9880244|NCT00477893|Placebo Comparator|Placebo|
9880245|NCT00477893|Active Comparator|Adalimumab|
9880246|NCT00477906|Experimental|1|"MVax + BCG + cyclophosphamide + IL2~2:1 randomization - MVax:Control"
9880247|NCT00477906|Placebo Comparator|2|Placebo Vaccine + BCG + cyclophosphamide + IL2
9880248|NCT00477919||Weekly assessment by E-MOSAIC|Patients complete a weekly assessment comprising visual analogue scales (VAS) of pain, fatigue, drowsiness, nausea, anxiety, depression, shortness of breath, loss of appetite, and overall well-being; up to 3 optional symptoms selected by the patient; and an estimated nutritional intake using an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC). Nurses record the patient's weight, KPS score, body mass index, and assessment of current medication for pain (i.e., morphine-equivalent daily dose), fatigue, and anorexia/cachexia syndromes weekly. A Longitudinal Monitoring Sheet (LoMoS) is printed (comprising VAS of pain, pain medication, fatigue, KPS, medication for fatigue [i.e., methylphenidate hydrochloride or epoetin alfa], anorexia, weight change, nutritional intake, medication, supplements, counseling for anorexia, VAS of individually selected symptoms) and stored.
9880249|NCT00477919||Palm-based monitoring tool|Patients complete a weekly symptom assessment and nutritional intake using a Palm-based monitoring tool. Nurses record weight and Karnofsky performance status (KPS) scores weekly. A proof of electronic transfer sheet is printed and stored.
9880250|NCT00477984|Experimental|A|alcohol and placebo
9880251|NCT00477997|Placebo Comparator|1|Saline bolus + OGTT
9880252|NCT00477997|Other|2|GH-bolus and OGTT
9880253|NCT00477997|Other|3|GH-bolus
9880254|NCT00478049|Active Comparator|1|Docetaxel
9880255|NCT00478049|Experimental|2|Gefitinib
9880256|NCT00478114|Experimental|1|Sorafenib
9880257|NCT00478270|Experimental|1|
9880258|NCT00478309|No Intervention|Arm I|Participants receive standard primary care.
9880259|NCT00478309|Experimental|Arm II|Participants receive standard primary care followed by the Genetic Epidemiology and Risk Assessment (GERA) intervention. Participants also participate in a discussion session regarding the GERA including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk.
9880260|NCT00478322|Experimental|INCB013739|
9880261|NCT00478322|Placebo Comparator|Matching Placebo|
9880262|NCT00478348|Other|Drain|
9880263|NCT00478348|Other|No drain|
9880264|NCT00478374|Experimental|1|
9880265|NCT00478400||Participants who have had a TBI|"(recruited by invitation only)~Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
9880266|NCT00478400||Participants with No history of TBI|"(Recruited by invitation only)~No history of TBI~Must have an informant (friend, spouse, child etc.)"
9880267|NCT00478400||Veterans with History of TBI|"Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
9997255|NCT01507272|Experimental|NNC 90-1170 (liraglutide)|
9880268|NCT00478400||US Veterans with No history of TBI|"No history of TBI~Must have an informant (friend, spouse, child etc.)"
9880269|NCT00478439|Placebo Comparator|Placebo Comparator|
9880270|NCT00478452|Experimental|DC Ova|DC Ova vaccine administered day 2 and week 3,6,9
9880271|NCT00478452|Active Comparator|DC Ova with Cyclophosphamide|Cyclophosphomide administered at day 0 prior to administration of DC Ova vaccine administered day 2 and week 3,6,9
9880272|NCT00478478||Acute Ischemic Stroke patients|Patients presenting with signs and symptoms consistent with a diagnosis of Acute Ischemic Stroke, who are treated with the Merci Retrieval System during a Mechanical Thrombectomy procedure.
9880273|NCT00478491||1|Persons with a parent with Alzheimer's disease
9880274|NCT00478491||2|Persons whose parents survived to old age without memory problems
9880275|NCT00478491||3|Persons with diagnosed mild cognitive impairment
9880276|NCT00478491||4|Persons without memory problems
9880277|NCT00478504|Active Comparator|Clomiphene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
9880278|NCT00478504|Active Comparator|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
9880279|NCT00478543|Experimental|Diuretic|Furosemide
9880280|NCT00478621|Experimental|Group A|
9880281|NCT00478621|Experimental|Group B|
9880282|NCT00478621|Experimental|Group C|
9880283|NCT00478621|Experimental|Group D|
9880284|NCT00478621|Experimental|Group E|
9880285|NCT00478621|Active Comparator|Group F|
9880286|NCT00478634|Experimental|A1: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
9880287|NCT00478634|Experimental|B1 dose: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
9930815|NCT00932204|Experimental|Active stimulation|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d)."
9930816|NCT00932204|Sham Comparator|Sham stimulation|For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
9930817|NCT00932217|Active Comparator|filgrastim|patients mobilized with filgrastim
9930818|NCT00932217|Active Comparator|lenograstim|patients mobilized with lenograstim
9930819|NCT00932230|Experimental|Group 1|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
9935438|NCT03745326|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12D mTCR PBL + high-dose aldesleukin
9935439|NCT03741101|Experimental|single arm study|children treated with trametinib
9935440|NCT03739827||1/Cohort 1|Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year)
9935441|NCT03739827||2/Cohort 2|Relatives of subjects with a rare tumor who have a germline genetic variant that predispose to a rare solid tumor or a subject who has a germline genetic variant that predispose to a rare solid tumor
9935442|NCT03739827||3/Cohort 3|Relatives of subjects with a diagnosis of rare tumor that do NOT have known germline genetic variants that predispose to a rare solid tumor.
9935443|NCT03739827||4/ Cohort 4|Parents/guardians of children with a diagnosis of rare tumor participating in focus groups (if not enrolled in Cohorts 1, 2 or 3)
9935444|NCT03735121|Experimental|Atezolizumab (Part 2)|Atezolizumab
9935445|NCT03735121|Experimental|Cohort 1: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
9935446|NCT03735121|Experimental|Cohort 2: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
9880288|NCT00478686||Severe Toxicity|Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy
9880289|NCT00478686||Dose-Limiting Toxicity|Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy
9880290|NCT00478686||Low/No Toxicity|Patients who have experienced low/no toxicity (none or only side effects at grade 1 & 2) with capecitabine chemotherapy.
9880291|NCT00478699|Active Comparator|1|
9880292|NCT00478699|Experimental|2|
9880293|NCT00478725|Experimental|Part A|Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
9880294|NCT00478725|Experimental|Part B|characterize the pharmacokinetics of a single IV dose of GW786034
9880295|NCT00478790|Experimental|1|ologen™ collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy. After operation with ologen™ Collagen Matrix, anti-inflammatory eye-drops will be prescribed
9880296|NCT00478803|Experimental|1, preservation|aortic valve surgery(Remodeling associated with a subvalvular aortic ring annuloplasty or double sub and supra valvular aortic annuloplasty)
9880297|NCT00478803|Sham Comparator|2, Bentall|Mechanical aortic valve replacement(isolated or composite valve and graft replacement);actual surgical standard for dystrophic aortic roots
9880298|NCT00478816|Active Comparator|Group 1|Primed subject with pandemic Vaccine
9880299|NCT00478816|Active Comparator|Group 2|Non Primed subject with pandemic Vaccine
9880300|NCT00478842|Experimental|1|Deep brain stimulation
9880301|NCT00478946|Experimental|1|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
9880302|NCT00478946|Active Comparator|2|FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
9880303|NCT00478959|Experimental|Lenalidomide|Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma.
9880304|NCT00478985|Experimental|1|Imatinib treatment ending
9880305|NCT00479024||observation|patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
9880306|NCT00479063||Cases|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Cases had been referred for a lumbar MRI for LBP lasting > 90 days.
9880307|NCT00479063||Controls|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Controls were headache patients who had been referred for a cranial MRI, which turned out to be normal, and who either had no history of LBP or had only experienced one episode in their life, which had lasted for less than 7 days.
9880308|NCT00479128|Experimental|Bortezomib + Gemcitabine + Doxorubicin|Starting dose of Bortezomib 0.8 mg/m^2 IV Over 3-5 Seconds. Starting dose of Gemcitabine 225 mg/m^2 IV Up to 90 Minutes. Starting dose of Doxorubicin 12.5 mg/m^2 IV Over 15-30 minutes.
9880309|NCT00479141|Experimental|1|HIV infected participants and their families
9880310|NCT00479141|Experimental|2|Popular Opinion Leaders (POL) participants
9880311|NCT00479180|Experimental|AVG1|Vascugel
9880312|NCT00479180|Placebo Comparator|AVG2|Gelfoam
9880313|NCT00479180|Experimental|AVF3|Vascugel
9880314|NCT00479180|Placebo Comparator|AVF4|Gelfoam
9880315|NCT00479193|Other|1|There is one arm to the study. The same subjects are their own control. One of the investigators will identify two sites that appear to be the same depth on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale.The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
9880316|NCT00479219|Experimental|A|
9880317|NCT00479219|Placebo Comparator|B|
9997256|NCT01507272|Placebo Comparator|Placebo|
9880318|NCT00479245|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
9880319|NCT00479271|Active Comparator|Home Care|"A flexible home-care program tailored to the needs of the individual and the family. The components of the intervention will include:~Basic education about dementia (what is the disease, its course, its features etc)~Education about common behaviour problems and how they can be managed~Support to the carer, for example for an elderly carer living alone with the patient, in activities of daily living~Referral to specialists when behaviour problems are severe and warrant medication intervention (sedatives)."
9880320|NCT00479271|Other|Wait-list|This group will be put on a waiting list to receive the intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
9880321|NCT00479323|Other|1|Immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera.
9880322|NCT00479349|Active Comparator|1|SAM 531 + placebo
9880323|NCT00479362|Experimental|1 Warfarin Uninterrupted|Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
9880324|NCT00479362|Active Comparator|2 Warfarin Interrupted|Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
9880325|NCT00479362|Sham Comparator|3 Aspirin Group|Patients with aspirin therapy during implantation
9880326|NCT00479362|Other|4 No Antithrombotic Group|No antithrombotic treatment during operations
9880327|NCT00479479|Experimental|Cobalamin|An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
9880328|NCT00479479|No Intervention|No intervention|No intervention
9880329|NCT00479570|Experimental|Study period 1, 2 or 3|
9880330|NCT00479570|Placebo Comparator|Placebo Study period 1, 2 or 3|
9880331|NCT00479583|Active Comparator|A|
9880332|NCT00479583|Active Comparator|B|
9880333|NCT00479609|Placebo Comparator|1|Placebo gel
9880334|NCT00479609|Active Comparator|2|Transdermal testostrone therapy
9880335|NCT00479622|Experimental|1|
9880336|NCT00479622|Experimental|2|
9880337|NCT00479648|Active Comparator|1|Inactivated trivalent influenza vaccine
9880338|NCT00479648|Experimental|2|CSL412 formulation
9880339|NCT00479648|Experimental|3|CSL412 formulation
9880340|NCT00479648|Experimental|4|CSL412 formulation
9880341|NCT00479661|Experimental|1|Dexmedetomidine
9880342|NCT00479661|Active Comparator|2|Propofol
9880343|NCT00479739|Experimental|Arm 1|
9997257|NCT01507285|Experimental|NNC 90-1170|
9880344|NCT00479752|Active Comparator|A|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m²."
9997258|NCT01507285|Placebo Comparator|Placebo|
9880345|NCT00479752|Active Comparator|B|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
9880346|NCT00479830||Group 1|South Asian, Subgroup: Asian Indian, population in the Greater Houston area.
9880347|NCT00479830||Group 2|South Asian, Subgroup: Bangladeshi, population in the Greater Houston area.
9880348|NCT00479830||Group 3|South Asian, Subgroup: Pakistani, population in the Greater Houston area.
9880349|NCT00479830||Group 4|South Asian, Subgroup: Sri Lankan, population in the Greater Houston area.
9880350|NCT00479895|Other|1|Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
9880351|NCT00479895|Other|2|Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
9880352|NCT00479934|Experimental|1|6 month treatment with Imtinib 400mg/day
9880353|NCT00479934|Placebo Comparator|2|6 month treatment with Placebo 400mg/day
9880354|NCT00479973|Active Comparator|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
9880355|NCT00479973|Placebo Comparator|Placebo|
9880356|NCT00479986|Experimental|Pioglitazone|
9880357|NCT00479986|Active Comparator|placebo|
9880358|NCT00480038|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
9880359|NCT00480090|Experimental|Cytarabine|eligible patients will receive cytarabine, starting at 075g/m2 and escalating to a maximum of 1.25g/m2, BID IV for 2 days every three weeks for 6 or more cycles if tolerated.
9880360|NCT00480116|Active Comparator|1|
9880361|NCT00480116|Active Comparator|2|
9880362|NCT00480116|Active Comparator|3|
9880363|NCT00480155|Active Comparator|1|FluMist
9880364|NCT00480155|Placebo Comparator|2|Placebo
9880365|NCT00480181|Experimental|Active|
9880366|NCT00480181|Placebo Comparator|placebo|
9880367|NCT00480207|Experimental|omega-3, folic acid, vitB12|folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
9880368|NCT00480207|Experimental|omega-3, folic acid placebo, vit B12|omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
9880369|NCT00480207|Experimental|omega-3 placebo, folic acid, vit B12|folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
9880370|NCT00480207|Experimental|omega-3 placebo, folic acid placebo, vit B12|omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
9880371|NCT00480220|Experimental|1|Specific Intervention as Global care and support program
9880372|NCT00480220|No Intervention|2|'No specific intervention'
9880373|NCT00480259|Active Comparator|Standard Nutrition|
9880374|NCT00480259|Experimental|Hyperprotein Nutrition|
9880375|NCT00480272|Experimental|group A|"adalimumab 40 mg subcutaneous injections every other week from baseline to month 12~methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6"
9880376|NCT00480272|Placebo Comparator|group B|"adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12~methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~placebo orally, stopped at month 6"
9880377|NCT00480311||1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
9880378|NCT00480363|Experimental|1|Lenalidomide + Dexamethasone for 9 cycles and maintenance
9880379|NCT00480363|No Intervention|2|Observation
9880380|NCT00480389|Experimental|Sorafenib|"All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week washout period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs."
9880381|NCT00480402|Experimental|400 mg Progesterone|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.
9880382|NCT00480402|Experimental|200 mg Progesterone Group|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.
9880383|NCT00480402|Active Comparator|Placebo|Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.
9880384|NCT00480454|Active Comparator|1|Stage 1 would require 12 per group low dose and 12 per group high dose (total 72)
9880385|NCT00480454|Active Comparator|2|Stage 2 would require 48 per group (total 144)
9930820|NCT00932256|Experimental|STAHIST for seasonal allergic rhinitis|STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
9930821|NCT00932269||Seroimmunity 2007|Cord blood from 400 newborns, 1800 children (2 - 18 years) and 2400 adults (above 18 years), randomly selected and stratified in age groups, from which blood samples are taken.
9997259|NCT01507311|Experimental|NNC 90-1170|
9880386|NCT00480558|Active Comparator|1|Group 1: M. tb
9880387|NCT00480558|Active Comparator|2|Group 2: HIV (not on antiretrovirals [ARV])
9880388|NCT00480558|Active Comparator|3|Group 3: M. tb and HIV (not on ARV)
9880389|NCT00480558|Active Comparator|4|Group 4: M. tb and HIV (on ARV)
9880390|NCT00480571|Experimental|1|BL 1020 low dose
9880391|NCT00480571|Experimental|2|BL 1020 High Dose
9880392|NCT00480584|Experimental|GemCap-T Dose Escalation|GemCap-T, capecitabine in combination with gemcitabine. Dose Escalation 6 Cycles @ 28 Days.
9880393|NCT00480610|Experimental|1|
9880394|NCT00480610|Placebo Comparator|2|
9880395|NCT00480649|Active Comparator|Sal/FP 50/250mcg|SERETIDE 50/250
9880396|NCT00480649|Active Comparator|Sal/FP 50/500mcg|SERETIDE 50/500
9880397|NCT00480675|Experimental|1|Trochanteric bursa injections done into the bursa under fluoroscopic guidance
9880398|NCT00480675|Active Comparator|2|Trochanteric bursa injection done with sham fluoroscopy using only landmarks as guidance.
9880399|NCT00480727|Placebo Comparator|Control|No fortnightly re-tensioning. Placebo treatment utilises the re-tensioning procedure, pt experiences clicking sensation, however, the pin is not tightened.
9880400|NCT00480727|Experimental|Treatment (Re-tensioning) Group|Pins are re-tensioned fortnightly back to initial fitting tension of 8lb/inch.
9880401|NCT00480792|Active Comparator|A|GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
9880402|NCT00480792|Experimental|B|GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
9880403|NCT00480792|Experimental|C|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
9880404|NCT00480844|Experimental|Sertindole|
9880405|NCT00480844|Active Comparator|Risperidone|
9880406|NCT00480870|Experimental|A|Donepezil treated Alzheimer patients
9880407|NCT00480870|Placebo Comparator|B|Placebo treated Alzheimer patients
9880408|NCT00480883|Active Comparator|1|injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
9880409|NCT00480883|Experimental|2|injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
9880410|NCT00480896|Experimental|1|
9880411|NCT00480896|Placebo Comparator|2|
9880412|NCT00480922|Experimental|1|A low glycemic load diet
9880413|NCT00480922|Active Comparator|2|Low fat diet
9880414|NCT00480935|Experimental|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
9880415|NCT00480948|Active Comparator|1|Infant formula with InFat™ oil(containing ~49% of C16:0 at sn-2 position).
9880416|NCT00480948|Placebo Comparator|2|Standard vegetable oil based infant formula
9880417|NCT00480974||1|Patients with Sickle cell anemia treated by Hydroxyurea
9880418|NCT00481000|No Intervention|1|Waitlist; Treatment as usual
9880419|NCT00481013|Placebo Comparator|1a|For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
9880420|NCT00481013|Active Comparator|1b|Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
9797226|NCT01589302|Experimental|Treatment (ibrutinib)|Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.
9797227|NCT01589315|Experimental|FEAST|Active right unilateral focal ECT
9797228|NCT01589445|Experimental|Pioglitazone (001 group)|The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
9797229|NCT01589445|Experimental|Metformin (002 group)|The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.
9797230|NCT01589484|Experimental|Shockwave lithotripsy (SWL)|All patients will be submitted to a noncontrast computed tomography before to shockwave lithotripsy (SWL). Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
9797231|NCT01589497|Active Comparator|RHZE-RHZE|Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.
9797232|NCT01589497|Active Comparator|RHZE-RZE|Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.
9797233|NCT01589497|Active Comparator|RHZE-RMZE|Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.
9797234|NCT01589497|Active Comparator|RZE-RZE|Participants were administered only RZE from Day 1 through Day 14.
9880421|NCT00481026|Sham Comparator|Placebo|Placebo tDCS
9517659|NCT03304301|Experimental|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
9880422|NCT00481026|Active Comparator|active tDCS|active tDCS
9880423|NCT00481039||1|Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
9880424|NCT00481091|Experimental|Phase 1: Dose Escalation Portion|Participants will receive escalating doses of ABT-263 to determine the recommended phase 2 dose (RPTD). Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
9880425|NCT00481091|Experimental|Phase 2a: Dose Expansion Portion|Participants will receive ABT-263 at the RPTD determined in Phase 1 portion. Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
9880426|NCT00481143|Experimental|deferasirox|
9880427|NCT00481156|Experimental|Patients: Cognitive Remediation|Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
9880428|NCT00481156|Active Comparator|Patients: Cognitive-Behavioral Social Skills Training|Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
9880429|NCT00481156|Other|Controls: Retest control group|Estimate of normal brain functioning and retest effects
9880430|NCT00481221||1|Screened pregnant women
9880431|NCT00481286|Experimental|Group Clinic|Patients in Group Clinic arm will meet every 3rd week for 12 weeks, for a total of 4 visits. At each visit, BP will be measured, home BP and glucose measurements collected. Each visit will include group-based education and feedback sessions, with an individualized process of selecting and modifying process of care goals for systolic BP, H1C, and LDL cholesterol. Short-term health behavior change goals will also be discussed.
9880432|NCT00481286|Placebo Comparator|Uusual Care|Older diabetes patients will attend regular clinician visits and one targeted primary care physician visit during the 12 weeks post-enrollment. They will be enrolled in a diabetes education class. Blood pressure, H1C and lipids will be measured at enrollment, 6 weeks , and 12 weeks.
9880433|NCT00481312|Active Comparator|1|Dexmedetomidine
9880434|NCT00481312|Active Comparator|2|Midazolam
9880435|NCT00481338|Experimental|Study specific procedure|X-rays, biological samples and medical information about osteoarthritis
9880436|NCT00481364|Active Comparator|Statin|Atorvastatin 40 mg/day
9880437|NCT00481364|Placebo Comparator|Placebo|placebo
9880438|NCT00481390||HIV-1 infected adults|HIV-1 infected adults
9880439|NCT00481429||1|Rosiglitazone
9880440|NCT00481429||2|Diet control +/- metformin
9880441|NCT00481455|Experimental|1|
9880442|NCT00481481|Experimental|1|
9880443|NCT00481572|Experimental|1|Terlipressin
9880444|NCT00481572|Experimental|2|Vasopressin
9880445|NCT00481572|Active Comparator|3|titrated norepinephrine
9880446|NCT00481624|Experimental|Epoetin Alfa plus Iron|
9880447|NCT00481637||Cancer patients|SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.
9880448|NCT00481637||Normal|Normal volunteers
9880449|NCT00481663|Experimental|Sitagliptin 25 mg once daily|Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
9880450|NCT00481663|Experimental|Sitagliptin 50 mg once daily|Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
9880451|NCT00481663|Experimental|Sitaglipin 100 mg once daily|Sitagliptin, 100 mg, once daily for 158 weeks, orally
9880452|NCT00481663|Experimental|Sitagliptin 50 mg twice daily|Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
9930822|NCT00932269||Sub Study|800 immigrated children (14 - 16 years) from which blood samples are taken.
9930823|NCT00932295|Active Comparator|Own brand cigarette|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
9997260|NCT01507311|Placebo Comparator|Placebo|
9517660|NCT03304301|No Intervention|control group|Participants will receive routine care.
9517661|NCT03304288|Experimental|low-dose rituximab & ATRA|rituximab 100mg once weekly for 6 weeks and oral all-trance retinoid acid 20mg/m^2 qd for 12 weeks.
9880453|NCT00481663|Placebo Comparator|Placebo to Sitagliptin → Metformin|Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
9880454|NCT00481715|Experimental|1|Web-based weight loss program
9880455|NCT00481715|Experimental|2|Cash incentive weight loss program
9880456|NCT00481715|Experimental|3|Web-based program plus the cash incentive program
9880457|NCT00481715|No Intervention|4|No intervention
9880458|NCT00481728|Experimental|Tolterodine|
9880459|NCT00481754||Females with ovarian cancer|Recruited from Magee Women's Hospital
9880460|NCT00481819|Experimental|1|In combination with MMF and steroids
9880461|NCT00481819|Active Comparator|2|In combination with MMF and steroids
9880462|NCT00481884|Experimental|RadiaPlexRx Gel|RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
9880463|NCT00481884|Active Comparator|Aquaphor Gel|Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
9880464|NCT00481936|Experimental|Dose Escalating|"Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met.~Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33."
9880465|NCT00482027|Active Comparator|1 AAV-2 HIV Vaccine|64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization
9880466|NCT00482027|Placebo Comparator|2|16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES
9880467|NCT00482066|Active Comparator|1|Abatacept (Orencia)
9880468|NCT00482066|Placebo Comparator|2|saline placebo
9880469|NCT00482105|Other|A|"This research study proposes to use a non-invasive method to capture superficial cells on pigmented skin lesions that are suspected of being early melanomas. This non-invasive biopsy technology has been developed and patented by DermTech International. RNA in skin cells captured by this method will be profiled in order to diagnose the nature of the lesion (i.e. malignant melanoma or not). A successful outcome of this proposal would create a candidate non-invasive diagnostic assay based on a gene expression profile for identifying early stage melanomas"
9880470|NCT00482118||Cases|Non smoking women with lung cancer
9880471|NCT00482118||Controls|Non smoking women without lung cancer
9880472|NCT00482144|Active Comparator|Treatment: PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
9880473|NCT00482144|Active Comparator|Treatment: PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
9880474|NCT00482144|No Intervention|Control|The scar will be randomly divided into three equal fields. One third of the scar will not receive treatment
9997261|NCT01507337|Experimental|Elderly|
9797235|NCT01589510||Lumigan® 0.01%|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
9880475|NCT00482209|Active Comparator|1|200mg mifepristone followed by 400mcg misoprostol
9880476|NCT00482209|Active Comparator|2|200mg mifepristone followed by 800mcg misoprostol
9880477|NCT00482222|Active Comparator|OxMdG / IrMdG chemotherapy|OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
9880478|NCT00482222|Experimental|OxMdG / IrMdG chemotherapy with cetuximab|OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
9880479|NCT00482261|Experimental|len-dex|Drug: Lenalidomide 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards; Drug: dexamethasone 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
9880480|NCT00482287|Other|1|Dose level 0.3 mg/kg with 6 active and 2 placebo
9880481|NCT00482287|Other|2|Dose level 0.6 mg/kg 6 patients active and 2 placebo
9880482|NCT00482287|Other|3|Dose level 1.2 mg/kg 6 active and 2 placebo
9880483|NCT00482287|Other|4|Dose level 2.4 mg/kg 6 active and 2 placebo
9930824|NCT00932295|Sham Comparator|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
9930825|NCT00932295|Experimental|Electronic cigarette Version One C7|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
9930826|NCT00932295|Experimental|Electronic cigarette version 2: NJ|"10 puffs from a so-called electronic cigarette named NJOY (16 mg cartridge; 30 second inter puff interval)"
9930827|NCT00932308|Active Comparator|1|Western-style, high-fat, low-calcium diet (WD)
9930828|NCT00932308|Active Comparator|2|Prudent, low-fat, calcium sufficient diet (PD)
9930829|NCT00932334|Experimental|TALK Plus|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
9930830|NCT00932334|Experimental|TALK Standard|Participants receive and educational video and booklet about living kidney donation
9930831|NCT00932334|Other|Usual Care|Participants receive their usual medical care
9930832|NCT00932347|Experimental|Mouthwash A|Mouthwash A: Camellia sinensis mouthwash
9517662|NCT03304288|Active Comparator|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
9797236|NCT01589601|No Intervention|Usual heart failure care|Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
9930833|NCT00932347|Placebo Comparator|Mouthwash B|Mouthwash B: Placebo mouthwash
9930834|NCT00932386|Experimental|dexmedetomidine Hcl infusion|Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist, which possesses hypnotic, sedative, anxiolytic, sympatholytic and analgesic properties.
9930835|NCT00932386|Placebo Comparator|normal saline|
9930836|NCT00932412|Experimental|CLARA|Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
9930837|NCT00932412|Active Comparator|HDAC|High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
9930838|NCT00932464|Experimental|1|Neratinib Fasted
9930839|NCT00932464|Experimental|2|Neratinib Fed
9930840|NCT00932490|Experimental|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and an advanced practice nurse will suggest individualized strategies to overcome barriers to adherence
9930841|NCT00932490|No Intervention|Control|
9930842|NCT00932503|No Intervention|PDS II|PDS II® loop suture was used for abdominal wall closure
9797237|NCT01589601|Active Comparator|Usual care + palliative care|Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.
9797238|NCT01589653|Experimental|Subject-driven titration|
9797239|NCT01589653|Experimental|Investigator-driven titration|
9797240|NCT01589770|Other|rheumatoid arthritis patients|People who have rheumatoid arthritis underwent cMRI
9797241|NCT01589770|Other|controls|people who do not have RA or other inflammatory disease underwent cMRI
9797242|NCT01589822|Experimental|EVICEL Fibrin Sealant: Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.
9797243|NCT01589822|No Intervention|Standard of Care|Standard surgical technique for GI anastomosis.
9797244|NCT01589822|Experimental|Experimental: EVICEL Fibrin Sealant: Non-Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
9997262|NCT01507337|Experimental|Young|
9797245|NCT01589978|Experimental|PROMUS Element|Subjects who receive the PROMUS Element everolimus-eluting coronary stent
9797246|NCT01590017|Experimental|Cistplatin and Radiation Therapy|Cisplatin 40 mg/m2 (max = 70 mg) IV over 30-60 minutes given weekly on days 1, 8, 15, 22, 29 and 36 for a total of 6 weekly cycles. Radiation therapy over 8 weeks: External pelvic radiation therapy (41.4-45.0 Gy/1.8 Gy per fraction/23-25 fractions/five weeks), intracavitary brachytherapy (low dose: 35-43.6 Gy/1-2 implants; high dose: 18-28 Gy/2-4 implants), with parametrial boost to involved parametria (5.40 - 9.00 Gy/1.8 Gy/3-5 fractions/3-5 days).
9797247|NCT01590082|Experimental|Doxycycline, Ipilimumab, and Temozolomide|Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.
9797248|NCT01590212|No Intervention|Care as usual|Participants received care in line with local guidelines
9797249|NCT01590212|Active Comparator|Mellow Bumps + care as usual|MB is a six week group-based antenatal programme designed to support families with additional health and social care needs. MB is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation.
9797250|NCT01590212|Active Comparator|Chill-out in Pregnancy + care as usual|CHiP is a relaxation programme that includes all the mother-centred components of Mellow Bumps but none of the baby or mother-baby relationship components. It runs for six weeks at two hours per week. It aims to decrease maternal stress levels.
9797251|NCT01590238|Experimental|Treatment with PRFM|Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp. Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
9797252|NCT01590264|Other|Bimodal rTMS|"Open-label and single-arm rTMS bimodal treatment with placement of magnet over Dorsolateral Prefrontal Cortex (DLPFC) and Temporoparietal Junction (TPJ) for 2 weeks of treatment (10 days)~Stimulation Settings:~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
9797253|NCT01590433|Experimental|Exenatide|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive exenatide will not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of study team will know which they are receiving.
9797254|NCT01590433|Placebo Comparator|Placebo|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive placebo will be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of the study team will know which they are receiving.
9797255|NCT01590550||Single arm|Single arm for all patient receiving inpatient HD
9797256|NCT01590563|Experimental|SCu300A IUB|Insertion of a spherical IUD (intrauterine device) with one year follow-up
9797257|NCT01590758|Placebo Comparator|Topical placebo control|
9797258|NCT01590758|Experimental|Topical pexiganan cream 0.8%|
9880484|NCT00482313|Experimental|Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
9880485|NCT00482313|Placebo Comparator|Sugar pill|Placebo given orally once daily for 5 weeks.
9880486|NCT00482352||Ancillary-Correlative (marker identification, molecular test)|Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia).
9880487|NCT00482378|Experimental|Sm 153 lexidronam|
9880488|NCT00482430|Other|1|MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
9880489|NCT00482430|Other|2|MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
9880490|NCT00482443|Experimental|1|To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
9880491|NCT00482443|Active Comparator|2|Control Arm. Patients will receive standard education programme.
9880492|NCT00482482|Experimental|Yoga|Yoga was offered twice a week for 8 weeks, 1.5 hours per session
9880493|NCT00482482|Active Comparator|Psychoeducation|Psychoeducation was offered twice a week for 8 weeks, 1.5 hours per session
9880494|NCT00482521|Experimental|CC-4047|
9880495|NCT00482573|Experimental|Group LE|Seventeen (54.8%) patients, composed group LE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution with epinephrine 1:100,000. Their ages were ranging from 18 to 44 years (mean:29.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 28 to 36 weeks (mean:31.8), and the BMI from 18.7 to 32.9 (mean:23.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
9880496|NCT00482573|Active Comparator|Group LNE|Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
9880497|NCT00482586||Image-guided Therapy|Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
9880498|NCT00482599|Active Comparator|Normal renal function|Org 25969 given to subjects with normal renal function
9880499|NCT00482599|Experimental|Impaired renal function|Org 25969 given to subjects with impaired renal function
9880500|NCT00482651|Experimental|UAP, SAP|
9880501|NCT00482742|Other|Lifestyle counseling|
9880502|NCT00482742|Other|Metformin|
9880503|NCT00482768|Experimental|1|Intervention clinics will receive practice facilitation visits at regular intervals over a 12-month period.
9880504|NCT00482768|No Intervention|2|Control clinics will deliver usual care for patients with diabetes.
9880505|NCT00482820|Experimental|1|attention training away from threat
9880506|NCT00482820|Placebo Comparator|2|placebo attention training
9880507|NCT00482846|Experimental|Palifermin & Melphalen|"Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3~Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
9930843|NCT00932503|Active Comparator|Vicryl plus|"antiseptic coated Vicryl plus was used for abdominal wall closure"
9930844|NCT00932516|Active Comparator|South Beach Diet™ with SBD™ Products|
9517663|NCT03304275|Experimental|Emergency Department vaccination group|Pertussis (Tdap) vaccine offered/administered in the Emergency Department
9880508|NCT00482924||Overweight/obese|"The cohort consists of age and sex matched normal weighted controls and overweight/obese persons.~Definition for overweight: BMI >90th and <97th percentile, if under 18 years of age, and BMI >25 and <29.9 kg/m2 if over 18 years of age.~Definition for obese: BMI >97th percentile, if under 18 years of age, and BMI >30kg/m2, if over 18 years of age."
9880509|NCT00482924||Interventional branch|A lifestyle intervention following a holistic schedule was done in a subgroup of obese juveniles.
9880510|NCT00482963|Experimental|levonorgestrel, efavirenz|healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz
9880511|NCT00482989|Experimental|1|MEDI-545
9880512|NCT00482989|Other|2|Placebo
9880513|NCT00483054|Experimental|Efavirenz|Efavirenz 600 mg/day + stavudine +lamivudine
9880514|NCT00483054|Experimental|Nevirapine|Nevirapine 400 mg/day + stavudine +lamivudine
9880515|NCT00483067|Experimental|2-CdA + Ara-C + G-CSF|2-CdA 12 mg/m^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9
9880516|NCT00483080|Experimental|A: NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every 3 weeks or weekly
9880517|NCT00483093|Experimental|A|
9880518|NCT00483106|Active Comparator|Ritalin|
9880519|NCT00483106|Placebo Comparator|Placebo|
9880520|NCT00483145|Active Comparator|1|Long-pulsed dye laser (Candela)
9880521|NCT00483145|Active Comparator|2|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
9880522|NCT00483158|Placebo Comparator|A|Rising Single Dose
9880523|NCT00483158|Placebo Comparator|B|Rising Multiple Dose
9880524|NCT00483158|Experimental|C|Open Label H. pylori cohort
9880525|NCT00483249|Experimental|Interventional|Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).
9880526|NCT00483314|Experimental|1|
9880527|NCT00483366|Other|Imatinib/Gemcitabine/Capecitabine|"Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.~Dose limiting toxicity (DLT) will be determined after cycle two for each patient.~Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14~Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2~Treatment cycle: 21-days~Treatment duration: Until disease progression or unacceptable toxicity defined in protocol."
9880528|NCT00483431|Placebo Comparator|PLACEBO|MK7 dosage 0 mcg, 4 capsules, orally, daily for 12 weeks.
9880529|NCT00483431|Active Comparator|MK7_10|MK7 dosage 10 mcg, 1 capsule of 10 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
9880530|NCT00483431|Active Comparator|MK7_20|MK7 dosage 20 mcg, 2 capsules of 10 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
9880531|NCT00483431|Active Comparator|MK7_45|MK7 dosage 45 mcg, 1 capsules of 45 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
9880532|NCT00483431|Active Comparator|MK7_90|MK7 dosage 90 mcg, 2 capsules of 45 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
9880533|NCT00483431|Active Comparator|MK7_180|MK7 dosage 180 mcg, 4 capsules of 45 mcg, orally, daily for 12 weeks.
9880534|NCT00483431|Active Comparator|MK7_360|MK7 dosage 360 mcg, 1 capsule of 360 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
9880535|NCT00483444|No Intervention|2|Control group were recruited in the emergency department after concussion and received standard care as directed by the ED physician and PCP.
9880536|NCT00483444|Experimental|1|Persons with concussion recruited in the emergency department received 5-6 scheduled telephone counseling calls focused on symptom management and self-management.
9880537|NCT00483470|Experimental|1|
9880538|NCT00483470|Active Comparator|2|
9880539|NCT00483483|Experimental|1|Healthy Relationships Intervention (HRI)
9880540|NCT00483483|Active Comparator|Attention-control group|health education & support
9880541|NCT00483522|Experimental|1|Scheduled telephone counseling over 2 years time.
9880542|NCT00483522|No Intervention|2|This control group will receive standard care after hospital rehabilitation discharge as directed by their physician.
9880543|NCT00483535|Experimental|Sequence ABC|All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
9880544|NCT00483600|Experimental|no arms/one group|
9880545|NCT00483678|Experimental|Intimacy-Enhancing Couples Therapy|Patients and their partners receive Intimacy-Enhancing Couples Therapy over 6 weeks comprising the following four 90-minute sessions: the Story of Cancer; Understanding the Couple, Ways of Relating and Key Influences; Intimacy; and Coping, Support, and Adaptation. Patients and their partners complete treatment satisfaction questionnaires after completion of study intervention.
9880546|NCT00483678|Active Comparator|standard psychosocial care|Patients and their partners receive standard psychosocial care. All participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention
9880547|NCT00483743|Experimental|TPI 1020|TPI 1020 500 mcg BID x 42 days
9880548|NCT00483743|Active Comparator|Budosenide cortico|Budesonide 800 mcg BID x 42 days
9880549|NCT00483743|Placebo Comparator|Placebo|Placebo inhaler
9880550|NCT00483808|Experimental|Denervation|Renal denervation using the Symplicty Catheter
9517664|NCT03304275|Experimental|Public Health referral group|Public Health referral for Pertussis (Tdap) vaccine administration offered
9517665|NCT03304262|Active Comparator|Cathodal tDCS + rTMS|Participant will receive 10 minutes of cathodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
9880551|NCT00483834|Experimental|Bevacizumab, Irinotecan and Capecitabine|Evaluate the efficacy and toxicity of bevacizumab, irinotecan and capecitabine as first-line treatment for patients with metastatic colorectal cancer
9880552|NCT00483860|Experimental|Topotecan|once a day
9880553|NCT00483886|Active Comparator|1|Prucalopride 2 mg
9880554|NCT00483886|Placebo Comparator|3|Placebo
9880555|NCT00483886|Active Comparator|2|Prucalopride 4 mg
9880556|NCT00483899|Experimental|Cohort 1: Part A|Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.
9880557|NCT00483899|Experimental|Cohort 2: Part A|Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.
9880558|NCT00483899|Experimental|Part B|Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.
9880559|NCT00483951||Patients with known or suspected cardiovascular disease|Patients referred to protocol with known or suspected cardiovascular disease for further evaluation.
9880560|NCT00483964|Experimental|A|The group getting the study drugs, Bacopa monnieri and Nardostachys jatamansi
9880561|NCT00483964|Active Comparator|B|The group getting Olanzapine
9880562|NCT00484055|Active Comparator|treatment|"Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt."
9930845|NCT00932516|Active Comparator|South Beach Diet™ alone|
9930846|NCT00932516|Active Comparator|Calorie restricted diet w/ SBD™ Products|
9930847|NCT00932516|Active Comparator|Calorie Restricted Diet alone|
9930848|NCT00932529|Active Comparator|Olanzapine|
9930849|NCT00932529|Active Comparator|Quetiapine|
9930850|NCT00932529|Active Comparator|Risperidone|
9930851|NCT00932529|Active Comparator|Ziprasidone|
9930852|NCT00932542|Experimental|Eutectic mixture|
9930853|NCT00932542|Placebo Comparator|placebo|
9930854|NCT00932542|Active Comparator|Medicaina|
9930855|NCT00932555||Group 1|
9930856|NCT00932581||Full Exam|The first group will receive the full motor examination section in its original order.
9930857|NCT00932581||Subscale|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
9930858|NCT00932594|Active Comparator|1.Arthrocentesis only|Patients only have Arthrocentesis, but without adjusting the pressure of the TMJ
9930859|NCT00932594|Active Comparator|3.Arthroscopic Treatment|Patient receives Arthroscopic treatments without adjusting the TMJ pressure
9930860|NCT00932594|Active Comparator|4.Arthroscopic with Adjust Pressure|Arthroscopic Treatment with Adjust TMJ Pressure Treatment, during the Arthroscopic treatment adjust the pressure of TMJ to normal value
9930861|NCT00932594|Active Comparator|5.The TMJ Orperation Treatment|The TMJ Operation Treatment without adjusting the pressure of TMJ
9930862|NCT00932594|Active Comparator|6.The TMJ Operation with Adjust Pressure|The TMJ Operation with Adjust TMJ Pressure Treatment, during the treatments to adjust the TMJ pressure to normal value
9930863|NCT00932594|Active Comparator|7.Bite Plate Treatment|Bite Plate Treatment for Temporomandibular Disorders without adjusting the pressure of TMJ
9930864|NCT00932594|Active Comparator|8.Bite Plate with Adjust pressure|Bite Plate and Adjust Pressure Treatment for Temporomandibular Disorders, during the treatments adjust the pressure of TMJ to normal value
9930865|NCT00932594|Active Comparator|2.Arthrocentesis with adjust pressure|Arthrocentesis with adjust pressure according to the pressure of TMJ
9930866|NCT00932607|Active Comparator|Staloral Birch|"Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
9930867|NCT00932607|Experimental|SUBLIVAC Birch|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
9930868|NCT00932672|Experimental|Atkins group|Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to <20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
9930869|NCT00932672|No Intervention|Control group|Subjects assigned to the control group will be asked to make no changes in their dietary habits. At the completion of the study subjects will meet with the nutritionist and receive standard nutrition AHA recommendations.
9930870|NCT00932685|Active Comparator|2. Video Game|
9930871|NCT00932685|Active Comparator|1. Midazolam 0.5mg/kg|
9880563|NCT00484120|Experimental|1|3% Diclofenac NE cream
9880564|NCT00484120|Placebo Comparator|2|
9880565|NCT00484211|Experimental|A|
9880566|NCT00484263|Active Comparator|1|
9880567|NCT00484276|Experimental|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly
9880568|NCT00484302|Experimental|CapOpus|
9880569|NCT00484302|Active Comparator|Treatment as usual|
9880570|NCT00484328|Experimental|1|
9880571|NCT00484328|Experimental|2|
9880572|NCT00484341|Experimental|A: low-dose NGR-hTNF|0.8 mcg/m² of NGR-hTNF
9880573|NCT00484341|Experimental|B: high-dose NGR-hTNF|45 mcg/m² of NGR-hTNF
9880574|NCT00484341|Experimental|C: low-dose NGR-hTNF + doxorubicin|0.8 mcg/m² of NGR-hTNF + doxorubicin
9880575|NCT00484341|Experimental|D: high-dose NGR-hTNF + doxorubicin|45 mcg/m² of NGR-hTNF + doxorubicin
9880576|NCT00484367|Active Comparator|1 AGT|
9880577|NCT00484367|Active Comparator|2 TFT|
9880578|NCT00484432|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
9880579|NCT00484458|Experimental|1|Wallis Stabilization System
9880580|NCT00484458|Active Comparator|2|Total Disc Replacement
9880581|NCT00484484|Experimental|1|Ketamine
9880582|NCT00484484|Experimental|2|Ketamine
9880583|NCT00484510|Experimental|Ascorbic Acid|
9880584|NCT00484510|Placebo Comparator|Placebo|
9880585|NCT00484562|Active Comparator|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
9880586|NCT00484562|Active Comparator|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
9880587|NCT00484562|Active Comparator|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
9880588|NCT00484562|Active Comparator|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
9880589|NCT00484575|Active Comparator|propofol|propofol for sedation minimum 2 hours in CTICU after CABG
9880590|NCT00484575|Experimental|sevoflurane|Sevoflurane via AnaConDa for minimum 2 hours in CTICU after CABG
9880591|NCT00484601|Experimental|Ifosfamide and Doxorubicin|Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma
9880592|NCT00484614|Active Comparator|1 PEM|
9880593|NCT00484614|Active Comparator|2 MRI|
9880594|NCT00484705|Experimental|Low-frequency electro-acupuncture|
9880595|NCT00484705|Experimental|Physical exercise|
9880596|NCT00484705|Active Comparator|Untreated control|
9880597|NCT00484731|Placebo Comparator|Injection with Saline|Injection with Saline instead of Bupivacain
9880598|NCT00484731|Active Comparator|Injection with Bupivacaine|Injection with Bupivacaine
9880599|NCT00484744|Experimental|Acetaminophen|
9880600|NCT00484744|Experimental|Ibuprofen|
9880601|NCT00484744|Placebo Comparator|Avicel|
9880602|NCT00484770|Other|Congestion Score Strategy|
9880603|NCT00484770|Other|BNP Strategy|
9880604|NCT00484783|Experimental|Prospective|Subjects scheduled to receive procedure
9880605|NCT00484783|Other|Historical|Chart review control group
9880606|NCT00484796||1|Patients undergoing carotid surgery
9880607|NCT00484822|Experimental|1|Brazo 1: Bemiparina Sódica 3.500 UI/día.
9880608|NCT00484822|Placebo Comparator|2|Brazo 2: Heparina Cálcica 10.000 UI/día.
9880609|NCT00484926|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
9880610|NCT00484926|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
9880611|NCT00485004|Experimental|Cutting balloon|Cutting balloon
9880612|NCT00485004|Active Comparator|Sirolimus-eluting stent|Sirolimus-eluting stent
9880613|NCT00485017|Experimental|1|THR-4109: 115 mg orally in am, 115 mg orally in pm for 24 weeks
9880614|NCT00485017|Experimental|2|THR-4109: 100 mg orally in am, 100 mg orally in pm for 24 weeks
9880615|NCT00485017|Experimental|3|THR-4109: 15 mg orally in am, 15 mg orally in pm for 24 weeks
9880616|NCT00485017|Placebo Comparator|4|
9880617|NCT00485030|Experimental|Cypher|sirolimus-eluting stent
9880618|NCT00485030|Active Comparator|Xience-V|everolimus-eluting stent
9880619|NCT00485056|Placebo Comparator|Placebo|Crossover arm
9880620|NCT00485056|Active Comparator|Pioglitazone|Pioglitazone 45mgs daily
9880621|NCT00485108|Active Comparator|1|Prednisolone 1% eye drop
9880622|NCT00485108|Active Comparator|2|ketorolac 0.5% eye drop
9880623|NCT00485108|Placebo Comparator|3|Artificial Tears (methyl cellulose eye drop)
9880624|NCT00485186||1|
9880625|NCT00485186||2|
9880626|NCT00485251|Active Comparator|1|hand assisted right hemicolectomy
9880627|NCT00485251|Active Comparator|2|laparoscopic right hemicolectomy
9880628|NCT00485329|Experimental|Low dose papain|Ratio of drug to placebo treated patients will be 4:1
9988498|NCT01423500|Other|MSD - Matched Sibling Donor|patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
9988499|NCT01423500|Other|MD - Matched Donor|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
9988500|NCT01423500|Other|MMD - Mismatched Donor|Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
9988501|NCT01423513|Experimental|Fibular Taping|With the ankle in a neutral position, two strips of nonrigid hypoallergenic tape will be applied beginning at the distal aspect of the fibula, wrapping around the posterior aspect of the leg, and finishing superior and medial to the starting point. Next,a strip of rigid zinc oxide tape will be applied to the distal aspect of the fibula with tension.
9988502|NCT01423513|Sham Comparator|Sham Taping|Sham taping will be applied in the same manner as the fibular taping, but tension will not applied to the zinc oxide tape
9988503|NCT01423526|Placebo Comparator|Placebo|"Drug: Placebo tablets, oral administration, single administrations~Arms: Placebo"
9988504|NCT01423526|Experimental|DWP10292|"Drug: DWP10292 tablets, oral administration, single administrations~Arms: DWP10292"
9988505|NCT01423539|Active Comparator|A|
9988506|NCT01423539|Experimental|B|
9988507|NCT01423552||Post-heart transplant|All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
9988508|NCT01423565|Experimental|Deep Brain Stimulation|
9988509|NCT01423578|Active Comparator|Hatha Yoga (HY)|Exercise and Smoking Cessation Counseling
9988510|NCT01423578|Experimental|Cardiovascular Exercise (CE)|Exercise and Smoking Cessation Counseling
9988511|NCT01423578|Other|Smoking Cessation Counseling Only|Control Group - Smoking Cessation Counseling
9988512|NCT01423591|Experimental|infliximab|
9988513|NCT01423591|Placebo Comparator|inactive powder|
9988514|NCT01423643||Main cohort|Adults infected with both HIV and Hepatitis C
9988515|NCT01423643||Control Group|Adults at risk for liver disease, but not infected with both HIV and Hepatitis C
9988516|NCT01423656|Experimental|LEO 29102|
9988517|NCT01423656|Placebo Comparator|LEO 29102 vehicle|
9988518|NCT01423669||Community dwelling adult population|
9988519|NCT01423695|Experimental|paclitaxel/trastuzumab|Single experimental arm in a phase II trial
9988520|NCT01423708|No Intervention|Control|Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).
9988521|NCT01423708|Experimental|Everolimus|Administration of Everolimus in association with Tacrolimus and steroids.
9988522|NCT01423721|Experimental|Bromihexine hydrochloride granules|16 mg granules
9988523|NCT01423721|Experimental|Bromihexine hydrochloride syrup|16 mg syrup
9988524|NCT01423734||MRI|Patients will be consented for a second MRI without additional intravenous contrast, referred to from now on as 'research MRI', to be performed later on the same day as their clinical liver MR examination, on one of two 3.0 Tesla MR 750 GE scanners at the Breast and Imaging Center. The research MRI will consist only of the localizer and diffusion weighted imaging (DWI) sequences, with acquisition parameters identical to our clinical MRI. The reproducibility of DWI is best assessed in separate MR imaging sessions, although the examinations can be performed the same day.
9988525|NCT01423747|Other|MSD - matched sibling donor|patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
9988526|NCT01423747|Other|MD - matched donor|patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
9988527|NCT01423747|Other|MMD - mismatched Donor|Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
9988528|NCT01423786|Other|Please help|"Dr. Kumar left Nationwide Children's Hospital in 2014 and efforts to get ahold of her to complete her ct.gov entries have been unsuccessful as we are not able to get ahold of her.~In July 2014, she wrote in her Continuing Review application to the NCH IRB: 34 patients have been recruited and data has mostly been collected. Follow up calls have been made and no adverse events occurred during the study period.~No other information is available."
9988529|NCT01423799|Experimental|Nutritional product|Nutritional intervention containing immuno-nutrients
9988530|NCT01423799|Active Comparator|Control Group|Isocaloric and isonitrogenous control without immuno nutrients.
9988531|NCT01423825|Experimental|Sub C gp140/MF59C.1 Vaccine|Participants will receive Sub C gp140 vaccine (100 mcg) admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid at baseline and Month 3.
9988532|NCT01423825|Placebo Comparator|Sodium chloride for injection|Participants will receive placebo injection administered as 0.5 mL IM in either deltoid at baseline and Month 3.
9988533|NCT01423838|Active Comparator|Solifenacin|Anticholinergic molecule used in the treatment of overactive bladder.
9880629|NCT00485329|Experimental|Medium dose papain|Ratio of drug to placebo treated patients will be 4:1
9880630|NCT00485329|Experimental|High dose papain|Ratio of drug to placebo treated patients will be 4:1
9880631|NCT00485342|No Intervention|standard dose|"the reference strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg)"
9880632|NCT00485342|Experimental|adjusted dose|individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
9880633|NCT00485355|Active Comparator|1|Conventional Laparoscopic Hysterectomy
9880634|NCT00485355|Active Comparator|2|Robotic Assisted Laparoscopic Hysterectomy
9880635|NCT00485394|Experimental|1|OT-551 0.3% ophthalmic solution
9880636|NCT00485394|Experimental|2|OT-551 0.45% ophthalmic solution
9880637|NCT00485394|Placebo Comparator|3|vehicle placebo
9880638|NCT00485420|Active Comparator|Usual Care|Member with recurrent or chronic depression receives usual specialty mental health care
9880639|NCT00485420|Experimental|Internet-based disease managment program|Usual care is augmented with internet based education, self monitoring and clinical monitoring
9880640|NCT00485615|Experimental|1|OMEGA 3
9880641|NCT00485667|Active Comparator|Moxifloxacin tablet|
9880642|NCT00485667|Experimental|Placebo tablet|
9880643|NCT00485667|Experimental|SKY0402 300mg|
9880644|NCT00485667|Experimental|SKY0402 450mg|
9880645|NCT00485667|Placebo Comparator|Placebo injection|
9880646|NCT00485719|Experimental|1|Twice daily (bid) dosing
9880647|NCT00485719|Experimental|2|Once daily (qd) dosing
9930872|NCT00932711|Experimental|Educational intervention|Subjects in this group will receive educational brochures about management of COPD
9930873|NCT00932724|Experimental|CY-503|
9930874|NCT00932724|Placebo Comparator|Placebo|
9930875|NCT00932750|Placebo Comparator|MOS Weight maintenance|
9930876|NCT00932750|Placebo Comparator|MOS weight loss|
9930877|NCT00932776|Experimental|TBA|
9930878|NCT00932776|Active Comparator|Control|
9930879|NCT00932802||Group 1|
9930880|NCT00932841|Placebo Comparator|Placebo|
9930881|NCT00932841|Active Comparator|VSL#3 90 billion bacteria|
9930882|NCT00932841|Active Comparator|VSL#3 900 billion bacteria|
9930883|NCT00932854|Experimental|EBUS|All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
9930884|NCT00932867||Group 1|
9930885|NCT00932906|Placebo Comparator|Instructor based training; <21 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
9935447|NCT03735121|Experimental|Cohort 3: Atezolizumab+rHuPH20(Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
9935448|NCT03735121|Experimental|Atezolizumab + rHuPH20 (Part 2)|Atezolizumab + rHuPH20
9935449|NCT03733093||1|HIV Positive
9517666|NCT03304262|Active Comparator|Anodal tDCS + rTMS|Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
9880648|NCT00485784|Sham Comparator|control group|control group
9880649|NCT00485784|Experimental|prééclampsies group|prééclampsies group
9880650|NCT00485784|Experimental|RCIU group|RCIU group
9880651|NCT00485784|Experimental|MFIU group|MFIU group
9880652|NCT00485888|Active Comparator|1|
9880653|NCT00485888|Placebo Comparator|2|
9880654|NCT00485914|Experimental|On-site work evaluation|Participants will receive one-to-one contact with an occupational therapist and an individualized work plan
9880655|NCT00485914|Active Comparator|Educational material|Participants will receive educational materials to develop strategies to compensate for limitations caused by their condition
9880656|NCT00485940|Active Comparator|1|Prucalopride 2 mg
9880657|NCT00485940|Placebo Comparator|3|Placebo
9880658|NCT00485940|Active Comparator|2|Prucalopride 4 mg
9880659|NCT00485979|Experimental|Arm A1|Cohort 1: Her2-ve breast cancer
9880660|NCT00485979|Active Comparator|Arm B1|Cohort 1: Her2-ve breast cancer
9880661|NCT00485979|Experimental|Arm A2|Cohort 2: Her2+ve breast cancer
9880662|NCT00485979|Active Comparator|Arm B2|Cohort 2: Her2+ve breast cancer
9880663|NCT00486135|Experimental|1|Daily dosing for 21 days/7 days off
9880664|NCT00486135|Experimental|2|Continuous daily dosing
9880665|NCT00486135|Experimental|3|Continuous daily dosing
9880666|NCT00486148|No Intervention|"group S"|Breast milk
9880667|NCT00486148|No Intervention|"group A"|Control Infant formula
9880668|NCT00486148|Experimental|"group B"|Infant formula supplemented with 0.4 g/100 ml of oligosaccharides
9880669|NCT00486174|Active Comparator|1|standard sepsis therapy plus Methylene Blue
9880670|NCT00486174|No Intervention|2|standard sepsis therapy
9880671|NCT00486187|Experimental|1|"Treatment-naive subjects randomly assigned to rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking metformin before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking glyburide before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day)."
9880672|NCT00486187|Active Comparator|2|"Treatment-naive subjects randomly assigned to metformin (250 mg twice per day [BID] titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%).~Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID titrated to 10 mg BID if baseline A1C >8.0%).~Subjects taking glyburide before randomization were randomly assigned to the addition of metformin (250 mg BID titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0% or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%)."
9880673|NCT00486213|Active Comparator|Pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
9880674|NCT00486213|Placebo Comparator|Placebo|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
9880675|NCT00486304|Experimental|Antioxidant-deficient diet (ADD)|
9880676|NCT00486304|Placebo Comparator|Placebo|
9880677|NCT00486343|Experimental|1|Zileuton CR
9880678|NCT00486343|Placebo Comparator|2|Placebo
9880679|NCT00486356|Experimental|Capecitabine, Epirubicin, and Carboplatin|
9880680|NCT00486382|Experimental|Low dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
9880681|NCT00486382|Experimental|Medium dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
9880682|NCT00486382|Experimental|High dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
9880683|NCT00486395|Active Comparator|1|Mechanical ventilation
9880684|NCT00486395|Experimental|2|CPAP
9880685|NCT00486408|Experimental|1|MRKAd5 HIV-1 gag/pol/nef vaccine administered as 1 ml in either deltoid at study entry and Weeks 4 and 26
9880686|NCT00486421|Experimental|PRED & RITUX|
9880687|NCT00486486|Active Comparator|Bimatoprost/Timolol AM therapy|
9880688|NCT00486486|Active Comparator|Bimatoprost/Timolol PM therapy|
9880689|NCT00486577|Experimental|1|
9880690|NCT00486577|Experimental|2|
9880691|NCT00486629|Experimental|Intervention|Lifestyle intervention
9880692|NCT00486629|No Intervention|Control|No intervention
9880693|NCT00486668|Active Comparator|Group 1: AC then paclitaxel + trastuzumab|AC followed by paclitaxel plus trastuzumab
9880694|NCT00486668|Experimental|Group 2: AC then paclitaxel + lapatinib|AC followed by paclitaxel plus lapatinib
9880695|NCT00486668|Experimental|Group 3: AC then paclitaxel + trastuzumab + lapatinib|AC followed by paclitaxel plus trastuzumab plus lapatinib
9880696|NCT00486681||1|period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated)
9880697|NCT00486681||2|period II (warning activated).
9880698|NCT00486707||Patients with ovarian cancer|
9880699|NCT00486733|No Intervention|Standard of Care|Standard of Care Treatment; no study treatment
9880700|NCT00486733|Experimental|Standard of Care plus Study Treatment|Standard of Care Treatment plus study treatment
9880701|NCT00486746|Experimental|Lifestyle intervention|
9880702|NCT00486746|Active Comparator|General health counseling|
9880703|NCT00486785|Experimental|1|
9880704|NCT00486876|Placebo Comparator|1|Placebo
9880705|NCT00486876|Experimental|2|100 mg BID
9880706|NCT00486876|Experimental|3|200 mg BID
9880707|NCT00486876|Experimental|4|300 mg BID
9880708|NCT00486915|Active Comparator|Left Atrial Appendage Exclusion|
9880709|NCT00486915|No Intervention|Control|
9880710|NCT00486928||AVR|All consecutive patients in the study period
9930886|NCT00932906|Placebo Comparator|Instructor based training; 21-50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
9935450|NCT03733080||1|ages 18 and older
9880711|NCT00486967||Heart Failure|CHF patients were identified from inpatients as well as patients attending outpatient clinics and from the general practice in the community. Diagnosis of CHF was based on the European Society of Cardiology guidelines for CHF. All patients with stable CHF were included in the study. Inpatients with CHF who were hospitalized were also included, except patients with acutely decompensated CHF requiring intravenous therapy. CHF patients with a previous diagnosis of diabetes mellitus were excluded from the study.
9880712|NCT00486967||Controls|A group of healthy subjects were also studied. They were recruited from the community and were clinically healthy based on history, physical examination, and blood laboratory results and were not taking any medication.
9880713|NCT00486993||asuriesgo|unselected outpatient population
9880714|NCT00487006|Active Comparator|At risk for CIH/with CIH|In hyperglycemic patients who will be starting insulin infusions to control hyperglycemia, blood will be drawn just prior to initiation of insulin infusion for the following levels: insulin, glucose, and C-peptide. These levels will be re-drawn upon achieving euglycemia, at 24 hours following that, then every three days. Levels will be again drawn once the insulin infusion is stopped/when CIH has resolved, and 24 hours following discontinuation of insulin infusion. At each timepoint the patient's clinical status will be documented and significant interval changes (intubation/extubation, change in pressor need), amount of dextrose (mg/kg/hour) supplied, and other concurrent medicines and doses will be recorded.
9880715|NCT00487006|Active Comparator|At risk for CIH/without CIH|"For comparative controls, insulin, C-peptide, and glucose levels will be drawn from ICU patients aged 2-12 years at similar risk (mechanical ventilation or vasoactive medications) but without CIH. The above labs will be drawn and data gathered near the time of risk, 24 hours later, then in 3 days following, for a total of three timepoints."
9880716|NCT00487006|Active Comparator|Not at risk for CIH/without CIH|"In addition, other ICU patients aged 2-12 years that are deemed NOT at risk for critical illness hyperglycemia will also be evaluated to serve as a group not at risk but admitted to the PICU as a further control population. Like Group B, the above labs will be drawn and data gathered at the time consent is obtained, 24 hours later, then in 3 days following, for a total of three timepoints"
9880717|NCT00487019||1|Neonates aged <72 h and needing antibacterial therapy for early onset neonatal sepsis
9880718|NCT00487019||2|Same as group 1
9880719|NCT00487032|Experimental|1|Prazosin 1mg challenge to block alpha 1 adrenoreceptors
9880720|NCT00487032|Placebo Comparator|2|Placebo to Prazosin
9880721|NCT00487045|Experimental|1|Hem-Avert Perianal Stabilizer, single use, disposable, sterile, individually packaged instrument
9880722|NCT00487045|No Intervention|2|
9880723|NCT00487071|Experimental|Anal fistula plug|
9880724|NCT00487097|Experimental|Study Group|Enteral Nutrition with Omega 3 (Eicosapentanoic acid, docosahexaenoic acid)
9935451|NCT03733067|Experimental|abatacept|Adult and pediatric dosing will be based on weight per protocol
9880725|NCT00487097|No Intervention|Control Group|Patients in control group will receive nutritional support composed of a standard formula
9880726|NCT00487136|Active Comparator|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
9880727|NCT00487136|Experimental|Warfarin plus ABT-335 plus Rosuvastatin|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
9880728|NCT00487136|Experimental|Warfarin plus ABT-335 mg plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
9880729|NCT00487227|Placebo Comparator|Placebo|
9880730|NCT00487227|Experimental|2.5mg caffeine|
9880731|NCT00487227|Experimental|5mg caffeine|
9880732|NCT00487227|Experimental|10mg caffeine|
9880733|NCT00487253|Active Comparator|Group 1|"Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.~presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)"
9880734|NCT00487253|Active Comparator|Group 2|Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.
9880735|NCT00487318|Experimental|Arm 1 Plus statin|The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
9880736|NCT00487318|Active Comparator|2|Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
9880737|NCT00487331|Experimental|Acupuncture|Acupuncture sessions 1-3 times per week. 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment.
9880738|NCT00487357||MATCh Parents' Supplemental Survey|Parent/Guardian Survey
9880739|NCT00487409|Other|Group A|Standard of Care
9880740|NCT00487409|Other|Group B|Standard of Care
9880741|NCT00487422|Active Comparator|1|Prucalopride
9880742|NCT00487422|Active Comparator|2|Prucalopride
9880743|NCT00487422|Placebo Comparator|3|Placebo
9880744|NCT00487474||Sculptra|
9880745|NCT00487500|Experimental|Ultrabrief, Right Unilateral ECT|Right unilateral ECT administered with an ultrabrief pulse width (0.3 ms), at a dose 6 times the initial seizure threshold
9880746|NCT00487500|Experimental|Ultrabrief, Bilateral ECT (2.5 X ST)|Bilateral (frontotemporal) ECT with an ultrabrief pulse width with dosage 2.5 times the initial seizure threshold
9880747|NCT00487500|Active Comparator|Brief Pulse, Right Unilateral ECT|Right unilateral ECT, with a standard brief pulse (1.5 ms), with dosage 6 times the initial seizure threshold
9880748|NCT00487500|Active Comparator|Brief Pulse, Bilateral ECT|Bilateral (frontotemporal) ECT with a standard brief pulse (1.5 ms), with dosage 2.5 times the initial seizure threshold
9880749|NCT00487591||Simva+Omacor|
9880750|NCT00487591||Simva + Placebo|
9930887|NCT00932906|Placebo Comparator|Instructor based training; >50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
9930888|NCT00932906|Experimental|Video Skill Training; <21 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
9930889|NCT00932906|Experimental|Video Skill Training; 21-50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
9930890|NCT00932906|Experimental|Video Skill Training; >50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
9930891|NCT00932906|Experimental|Video scenario training; <21 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
9930892|NCT00932906|Experimental|Video scenario training; 21-50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
9930893|NCT00932906|Experimental|Video scenario training; >50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
9930894|NCT00932906|Experimental|Video demonstration training; <21 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
9935452|NCT03733067|Placebo Comparator|placebo|will be given as the same IV volume as abatacept
9880751|NCT00487617|Experimental|fruit juice|300 mL of fruit juice
9880752|NCT00487617|Placebo Comparator|placebo|300 mL of fruit juice without polyphenols
9880753|NCT00487682|Experimental|1|ASP2151 low dose
9880754|NCT00487682|Experimental|2|ASP2151 middle dose
9880755|NCT00487682|Experimental|3|ASP2151 high dose
9880756|NCT00487682|Active Comparator|4|Valacyclovir hydrochloride
9880757|NCT00487708|Experimental|1|ACZ885
9880758|NCT00487734|Experimental|1|Subjects in this arm will receive testosterone gel
9880759|NCT00487734|Placebo Comparator|2|
9880760|NCT00487773|Active Comparator|1|budesonide
9880761|NCT00487773|Active Comparator|2|D3 vitamin
9880762|NCT00487773|Active Comparator|3|montelukast sodium
9880763|NCT00487773|Active Comparator|4|salbutamol
9880764|NCT00487786|Experimental|A|Each patient receives OGX-427
9880765|NCT00487851|Active Comparator|1|Endoscopic treatment strategy
9880766|NCT00487851|Active Comparator|2|Surgical treatment strategy
9880767|NCT00487929|Experimental|CPAP|Continuous positive airway pressure
9880768|NCT00487929|Sham Comparator|Sham CPAP|Sham nasal continuous positive airway pressure
9880769|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD|
9880770|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD|
9880771|NCT00487994|Active Comparator|Atorvastatin 10 mg QD|
9880772|NCT00488007|Experimental|Active Hearing aids|Active
9880773|NCT00488007|Placebo Comparator|Inactive Hearing aids|Hearing aids turned off
9880774|NCT00488046|Experimental|1|Two, 0.5 ml doses of vaccine in nasal spray form administered at study entry and sometime between 4 and 8 weeks after initial vaccination
9880775|NCT00488072|Experimental|Mirtazapine|Mirtazapine 15 mg by mouth (PO) daily for 15 days; Day 22-29, increased to 30 mg PO daily.
9880776|NCT00488072|Placebo Comparator|Placebo|One placebo tablet by mouth daily.
9880777|NCT00488111|Active Comparator|1|Participants were treated with normal Ringer's solution 15 min before the operation.
9880778|NCT00488111|Active Comparator|2|6% Starch was used 15min before operation followed epidural anesthesia.
9880779|NCT00488137|Active Comparator|1|Prucalopride 2 mg
9880780|NCT00488137|Placebo Comparator|3|Placebo
9880781|NCT00488137|Active Comparator|2|Prucalopride 4 mg
9880782|NCT00488163|Active Comparator|Atomoxetine|Atomoxetine 40 mg compounded into capsules.
9880783|NCT00488163|Placebo Comparator|Placebo|Inactive matching compounding of placebo capsules
9880784|NCT00488176|Active Comparator|1|monteluksat sodium
9880785|NCT00488176|Active Comparator|2|cetirizine
9880786|NCT00488176|Active Comparator|3|montelukast sodium and cetirizine
9880787|NCT00488176|Placebo Comparator|4|placebo
9880788|NCT00488189|No Intervention|1|baseline, collecting rectal swab samples
9880789|NCT00488189|Active Comparator|2|use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab
9880790|NCT00488215|Active Comparator|1|Prucalopride
9880791|NCT00488215|Placebo Comparator|2|Placebo
9880792|NCT00488228|Experimental|1|Participants in the behavioral self-regulation intervention will receive a modified standard treatment that incorporates daily weighing and training in self-regulation methods for weight loss. All treatment modules are adapted for a young adult age group.
9880793|NCT00488228|Experimental|2|Participants in the Standard group will receive a brief version of standard behavioral weight loss treatment with treatment modules tailored to better meet the needs of young adults.
9880794|NCT00488241|Active Comparator|1|Topically applied daily for 2 weeks
9880795|NCT00488280|Experimental|Kids Step Study: Locomotor Training|All children who participate will be in the experimental cohort, KSS-#, and receive 60 sessions of daily locomotor training. This experimental cohort will also undergo clinical and neurophysiological testing pre, during, and post 60 sessions of locomotor training.
9880796|NCT00488332||OCT + FS + Questionnaire|Optical Coherence Tomography (OCT) + Fluorescence Spectroscopy (FS) and Questionnaire
9880797|NCT00488384|Other|a|single arm only. Only open label treatment anticipated
9880798|NCT00488397||1|
9880799|NCT00488423|Active Comparator|Lap-band|Patient undergoing Lap-band Bariatric Surgery
9880800|NCT00488423|Active Comparator|Gastric Bypass|Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
9880801|NCT00488462|No Intervention|Control|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the control arm, half of the study clinics will not use the NASG but the NASG will be available at the referral hospital for patients transported there.
9880802|NCT00488462|Other|Intervention|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the intervention arm, half of the study clinics will use the NASG on patients before transporting to the referral hospital.
9880803|NCT00488527|Experimental|1|
9880804|NCT00488540|Active Comparator|Paracetamol (Acetaminophen)|Paracetamol (Acetaminophen) given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
9880805|NCT00488540|Placebo Comparator|Placebo|Placebo given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
9880806|NCT00488553||Cases|Participants of study with newly diagnosed lymphoma.
9880807|NCT00488553||Control|Participants of study from matched control group.
9880808|NCT00488566|Other|Part 1|Single dose escalation
9880809|NCT00488566|Other|Part 2|Pharmacodynamic assessment
9880810|NCT00488579|Active Comparator|routine iron prophylaxis|giving 60 mg ferrous sulphate daily (+folic acid)
9880811|NCT00488579|Active Comparator|screening and therapy|doing Hb measurement on each visit, Hb>9g/dl giving only folic acid, Hb<9g/dl giving 60-120 mg of ferrous sulphate daily (+folic acid)
9880812|NCT00488605|Active Comparator|Treatment Arm A|
9880813|NCT00488605|Experimental|Treatment Arm B|
9880814|NCT00488657|Experimental|1|In the ear device to provide altered auditory feedback
9880815|NCT00488696|Experimental|Interventional|Endovascular Bifurcated Stent Graft: The investigational operation involves placing a stent-graft over the aortic aneurysm.
9880816|NCT00488787|Experimental|A|Intranasal ketamine low dose
9880817|NCT00488787|Experimental|B|intranasal ketamine medium dose
9880818|NCT00488787|Experimental|C|intranasal ketamine high dose
9880819|NCT00488787|Placebo Comparator|D|placebo
9880820|NCT00488878||Observational (electronic health record review)|Patients' medical records are reviewed for retrospective and prospective data collection. Patients may also have residual tissue samples collected and stored.
9880821|NCT00488891||Paliperidone extended release (ER)|Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
9880822|NCT00488891||Atypical antipsychotics agent (AAP)|AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
9880823|NCT00488904|Experimental|a|
9880824|NCT00488904|Placebo Comparator|b|
9880825|NCT00488969|Active Comparator|Modified-release morphine then Placebo|up to a ceiling dose of 120 mg
9880826|NCT00488969|Placebo Comparator|Placebo then modified-release morphine|Matching placebo
9880827|NCT00489008|Experimental|Cohort 1|Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC
9880828|NCT00489008|Experimental|Cohort 2|Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC
9880829|NCT00489008|Experimental|Cohort 3|Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC
9880830|NCT00489034||Index Participants|HIV-infected females, ages 13- 23 years, recruited from ATN sites in New York, Chicago, Miami, Los Angeles, and New Orleans will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic and/or gender interviewing.
9880831|NCT00489034||Network Participants|Closest friends of index participants s and parents/guardians of index participants who know the index participant's HIV status will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic interviewing.
9880832|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot A|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
9880833|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot B|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
9880834|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot C|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
9880835|NCT00489099|Active Comparator|V232 Current Process Hepatitis B Vaccine|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
9880836|NCT00489138|Experimental|1|Noradrenalin infusion
9880837|NCT00489138|No Intervention|2|No adrenalin infusion
9880838|NCT00489177|Active Comparator|A|QuickOpt
9880839|NCT00489177|Placebo Comparator|B|Usual care
9880840|NCT00489372|Placebo Comparator|Arm I (placebo)|Participants receive oral placebo on day 1.
9880841|NCT00489372|Experimental|Arm II (Se-methyl-seleno-L-cysteine)|Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.
9930895|NCT00932906|Experimental|Video demonstration training; 21-50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
9930896|NCT00932906|Experimental|Video demonstration training; >50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
9930897|NCT00932919|Experimental|Thought field therapy|24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
9930898|NCT00932919|Active Comparator|Cognitive therapy|Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
9930899|NCT00932919|Other|Wait list|24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
9930900|NCT00932932||PWS not receiving Growth Hormone|
9930901|NCT00932932||Control subjects healthy or obese|
9930902|NCT00932932||PWS subjects starting Growth Hormone|
9930903|NCT00932945|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Treatment duration: 21 consecutive days
9930904|NCT00932958||All comers >18 yrs old|This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded.
9930905|NCT00932971|Placebo Comparator|PEG-IFN alfa-2a plus placebo|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally
9930906|NCT00932971|Active Comparator|PEG-IFN alfa-2a plus Tenofovir|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally
9988534|NCT01423838|Active Comparator|Oxybutynin|Anticholinergic molecule used in the treatment of overactive bladder.
9988535|NCT01423864|Sham Comparator|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
9988536|NCT01423864|Experimental|Drug: intrapleural steroid instillation|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
9988537|NCT01423890|Other|Early Stage Breast Cancer|Women and men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
9988538|NCT01423903|Experimental|OPDC-51602|Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
9988539|NCT01423929|Experimental|10 L O2/min|Oxygen breathing via Oxymask TM
9988540|NCT01423929|Sham Comparator|Room air|Room air breathing via Oxymask TM
9988541|NCT01423955|Placebo Comparator|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
9988542|NCT01423955|Experimental|Erythropoietin|• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.
9988543|NCT01423968|Experimental|Lipopolysaccharide infusion|Lipopolysaccharide infusion; dosage 4ng/kg body weight
9988544|NCT01423968|Placebo Comparator|saline|0.9% saline infusion
9988545|NCT01423981||Patients with keloid disorder.|All participants have a clinical diagnosis of keloid.
9988546|NCT01423994|Active Comparator|implantable loop recorder|
9988547|NCT01423994|Active Comparator|pacemaker|
9988548|NCT01424007|Experimental|Lower fat diet|Participants in this group will be individually counseled and receive print materials on a higher-carbohydrate, lower-fat diet.
9988549|NCT01424007|Experimental|Lower carbohydrate diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, higher-monounsaturated fat diet.
9988550|NCT01424007|Experimental|Walnut-rich diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, walnut-rich higher-fat diet.
9988551|NCT01424020|Experimental|questionnaire|Patients suspected of peripheral artery disease and, as such, referred for a vascular investigations and submitted the WELCH questionnaire
9988552|NCT01424046|Experimental|basal insulin approach|Participants will be treated primarily with a daily basal insulin injection ( glargine) with later introduction of prandial coverage with a shortacting insulin.
9988553|NCT01424046|Active Comparator|standard therapy|Participants will continue current mixed insulin management and education
9988554|NCT01424059||fear of labor|Parous women with fear of labor
9988555|NCT01424085||Those receiving antibiotics|Patients who received one prophylactic dose of antibiotics.
9988556|NCT01424085||Placebo|Patients who did not receive one prophylactic dose of antibiotics (received placebo).
9988557|NCT01424098|Experimental|Balance Training|The treatment group will complete a specific balance training program in addition to conventional pulmonary rehabilitation.
9988558|NCT01424098|No Intervention|Usual care|The control group will undergo the usual pulmonary rehabilitation program offered at our centre with no additional balance training classes.
9988559|NCT01424111||Treatment|Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.
9988560|NCT01424111||Healthy Control|Those not receiving treatment.
9988561|NCT01424124|Experimental|YHD001 dose level 1|
9988562|NCT01424124|Experimental|YHD001 dose level 2|
9988563|NCT01424124|Active Comparator|Singulair|
9988564|NCT01424124|Placebo Comparator|Placebo|
9988565|NCT01424137|Other|Easyhaler type A|
9988566|NCT01424137|Other|Easyhaler type B|
9988567|NCT01424137|Other|Diskus inhaler|
9988568|NCT01424150|Experimental|Liberal|At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
9997263|NCT01507363|Active Comparator|"Gabapentin high"|Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
9988569|NCT01424150|Experimental|Restrictive|Will provide less than 2.0 L water and 120 mmol sodium per day. Induction of anaesthesia will limit IV bolus fluid to ≤5 ml/kg; no other IV fluids will be used at the commencement of surgery (unless indicated by goal-directed device [see below]). Hartmann's balanced salt crystalloid 5 ml/kg/h will be administered until the end of surgery, and bolus colloid/blood used intraoperatively to replace blood loss (ml for ml); then an infusion at 1 ml/kg/h until expedited cessation of IV fluid therapy within 24 hours. The rate of postoperative fluid replacement can be reduced if there is evidence of fluid overload and no hypotension, and can be increased if there is hypotension AND evidence of hypovolaemia.
9988570|NCT01424163|Experimental|Treatment 1 (Part A)|Dexpramipexole single dose (reduced dose)
9988571|NCT01424163|Experimental|Treatment 2 (Part A)|Dexpramipexole single dose (Standard dose)
9988572|NCT01424163|Experimental|Treatment 3 (Part A)|Dexpramipexole multiple dosing
9988573|NCT01424163|Experimental|Treatment for Part B|Dexpramipexole multiple dosing
9988574|NCT01424176|Experimental|Dexpramipexole (dose 1)|Subjects with mild or moderate renal impairment.
9988575|NCT01424176|Experimental|Dexpramipexole (dose 2)|Subjects with severe renal impairment and end stage renal disease (ESRD).
9988576|NCT01424202|Experimental|Group B|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications plus daily sessions of mechanical in-exsufflation (MI-E).
9988577|NCT01424202|No Intervention|Group A|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications.
9988578|NCT01424241|Experimental|Sandostatin LAR|This is a 9 month, open label dose escalation study of Sandostatin LAR therapy.
9988579|NCT01424254|Experimental|Video-Capsule Endoscopy|VCE will be performed in the early morning following 200 mg of simethicone and 250 - 500 mg of erythromycin (as per physician's prescription), ingestion also in the absence of contra-indications
9988580|NCT01424254|Experimental|Push Enterosopy|
9988581|NCT01424267||1|
9988582|NCT01424280|Experimental|Active drug|
9988583|NCT01424280|Placebo Comparator|Placebo|
9988584|NCT01424319|Experimental|ABT-627, Low dose|
9988585|NCT01424319|Experimental|ABT-627, High dose|
9988586|NCT01424319|Placebo Comparator|ABT-627, Placebo|
9988587|NCT01424332|Experimental|Treatment arm 1|darexaban, wash-out, ASA, wash-out, darexaban plus ASA
9988588|NCT01424332|Experimental|Treatment arm 2|darexaban, wash-out, darexaban plus ASA, wash-out, ASA
9988589|NCT01424332|Experimental|Treatment arm 3|ASA, wash-out, darexaban, wash-out, darexaban plus ASA
9988590|NCT01424332|Experimental|Treatment arm 4|ASA, wash-out, darexaban plus ASA, wash-out, darexaban
9988591|NCT01424332|Experimental|Treatment arm 5|darexaban plus ASA, wash-out, darexaban, wash-out, ASA
9988592|NCT01424332|Experimental|Treatment arm 6|darexaban plus ASA, wash-out, ASA, wash-out, darexaban
9988593|NCT01424345|Active Comparator|control group|Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab
9988594|NCT01424345|Experimental|ImmuKnow Study group|The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab
9988595|NCT01424358|Experimental|Web-based Educational|
9988596|NCT01424371||Adjuvanted Vaccine Group|
9988597|NCT01424371||Unadjuvanted Vaccine Group|
9988598|NCT01424371||Unvaccinated Elderly|
9988599|NCT01424384|Active Comparator|Citalopram|Marketed comparitor
9988600|NCT01424384|Experimental|Investigational Medicinal Product|GSK424887
9988601|NCT01424384|Placebo Comparator|Placebo To Match Treatment|Placebo control
9988602|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 1|Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.
9988603|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 1|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
9988604|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 2|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.
9988605|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 2|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
9988606|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 3|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.
9988607|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 3|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
9880842|NCT00489515||patients with gastrointestinal cancer scheduled for surgery|
9880843|NCT00489567||Group A|Children hospitalised with community-acquired severe RV GE and children acquiring nosocomial severe RV GE.
9880844|NCT00489593|Experimental|Olanzapine|Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
9880845|NCT00489632||Questionnaire|Children with leukemia and their families/caregivers.
9880846|NCT00489645|Placebo Comparator|1|Placebo, euglycemia
9880847|NCT00489645|Experimental|2|Pramlintide, euglycemia
9880848|NCT00489645|Placebo Comparator|3|placebo, hyperglycemia
9880849|NCT00489645|Experimental|4|pramlintide, hyperglycemia
9880850|NCT00489671||pre cancerous condition (pancreatitis)|
9880851|NCT00489697|Experimental|1 (single arm)|patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
9880852|NCT00489710|Experimental|Talabostat|Talabostat 600 mcg PO QD x 14 days (21 day cycle); 2 cycles
9880853|NCT00489801|Other|Exercise intervention|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
9880854|NCT00489814||1|Patients who are planned to undergo local proton radiotherapy for biopsy-proven, untreated, prostate adenocarcinoma.
9880855|NCT00489840|Experimental|anecortave acetate|
9880856|NCT00489957||Normals|
9880857|NCT00489957||Cardiomyopathy|
9880858|NCT00490074|Experimental|3 DNA-C + 1 NYVAC-C|
9880859|NCT00490074|Active Comparator|2 DNA-C + 2 NYVAC-C|
9880860|NCT00490087|Experimental|Hysteroscopic resection plus IUD|
9880861|NCT00490087|No Intervention|Hysteroscopic resection without IUD|
9880862|NCT00490113|Experimental|1|
9880863|NCT00490126||Laparoscopic Surgery Database|
9880864|NCT00490152||1|Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
9880865|NCT00490152||2|Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
9880866|NCT00490152||3|Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
9880867|NCT00490230|Experimental|WR 279,396|CL lesions treated with WR 279396
9880868|NCT00490230|No Intervention|Natural Healing|CL lesions healed naturally
9880869|NCT00490230|Placebo Comparator|vehicle control|CL lesions were treated with the vehicle alone
9880870|NCT00490295||newborn cardiac surgical study group|
9880871|NCT00490334||Cancer patients|Children with cancer aged 8 to 16 years
9880872|NCT00490334||Control (non-cancer)|Normal children aged 8 to 16 years, age- and gender-matched to the cancer cohort
9880873|NCT00490412|Experimental|A: tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group A (who are already taking Tenofovir) once every four weeks during study visits.
9880874|NCT00490412|Placebo Comparator|B: tenofovir/placebo|A placebo will be administered orally to subjects in Group B (who are already taking Tenofovir).
9880875|NCT00490412|Experimental|C: no tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group C (who are not taking Tenofovir) once every four weeks during study visits.
9880876|NCT00490412|Placebo Comparator|D: no tenofovir/placebo|A placebo will be administered orally to subjects in Group D (who are not taking Tenofovir).
9880877|NCT00490503||MRI + MRS|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to start systemic chemotherapy.
9880878|NCT00490516|Experimental|1|
9880879|NCT00490516|Experimental|2|
9880880|NCT00490516|Placebo Comparator|3|
9880881|NCT00490581|Experimental|Study group|These patients are assigned to the intervention of early supportive housing with case management integrated into the medical system. These subjects are offerred respite care/interim housing upon discharge from enrolling hospitalizations, followed by stable housing within 90 days. They have a case manager at each stage (hospital, respite/interim housing, and stable housing)
9880882|NCT00490581|No Intervention|Usual Care|These patients receive usual social services for hospital discharge planning.
9880883|NCT00490620|Placebo Comparator|1|blinded placebo control
9880884|NCT00490620|Active Comparator|2|Antiretroviral therapy
9880885|NCT00490633|Experimental|Facemask and hand hygiene|Facemask and hand hygiene provided for participants.
9880886|NCT00490633|Experimental|Facemask only|Facemask only provided for participants.
9880887|NCT00490633|No Intervention|Control|Control, no intervention.
9880888|NCT00490672|Other|Control Arm|Conventional Patient Management on Hypertension, Diabetes Mellitus and Hyperlipidaemia by Malaysian GP
9880889|NCT00490672|Active Comparator|CORFIS Arm|Community based Multiple Risk Factor Intervention Strategies
9880890|NCT00490737|Experimental|Hemodialysis (HD) Participants|Participants will receive daptomycin 6 mg/kg by intravenous infusion (i.v.) at 48-hours intervals (with dialysis) for a total of 3 doses.
9880891|NCT00490737|Experimental|Continuous Ambulatory Peritoneal Dialysis (CAPD) Participants|Participants will receive daptomycin 6 mg/kg, i.v., at 48-hours intervals for a total of 3 doses.
9880892|NCT00490750|Active Comparator|Laparoscopic Dor fundoplication|Heller myotomy followed by Dor fundoplication
9880893|NCT00490750|Active Comparator|Laparoscopic Toupet fundoplication|Heller myotomy followed by Toupet fundoplication
9880894|NCT00490828|Placebo Comparator|A|
9880895|NCT00490828|Active Comparator|B|Stress doses of hydrocortisone
9880896|NCT00490854|Experimental|1|
9880897|NCT00490854|Experimental|2|
9880898|NCT00490906||1|Patients receive Copaxone
9880899|NCT00490906||2|Patients receive interferons
9880900|NCT00490997|Active Comparator|1|Ketamine only arm
9880901|NCT00490997|Active Comparator|2|Ketamine-Propofol arm
9880902|NCT00491036|Active Comparator|Intraaortic balloon pump|Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
9880903|NCT00491036|No Intervention|No intraaortic balloon pump|Patients in cardiogenic shock in this group get no intraaortic balloon pump
9880904|NCT00491062|Active Comparator|Control|
9880905|NCT00491062|Experimental|Parkinson stade 1|
9880906|NCT00491062|Experimental|Parkinson stade2|
9880907|NCT00491062|Experimental|Parkinson stade 3|
9880908|NCT00491101||1|Children with asthma, both genders, from 7-18 years old.
9880909|NCT00491140||Observation|Colorectal cancer patients
9880910|NCT00491257|Experimental|Study Group 1|Participants aged 18 to 60 years at enrollment
9880911|NCT00491257|Experimental|Study Group 2|Participants aged 61 years or older at enrollment.
9930907|NCT00932984|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
9930908|NCT00933023|Experimental|Mild steroid|1%hydrocortisone for 8 weeks
9930909|NCT00933023|Experimental|Potent Steroid|
9930910|NCT00933036|Experimental|Treatment arm|Crosstrees Pod System for PVA.
9930911|NCT00933049|Active Comparator|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo
9930912|NCT00933049|Active Comparator|Amoxicillin|Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo
9930913|NCT00933062|Active Comparator|SRT2104|Subjects will receive a dose of 2.0 g SRT2104 (administered as eight 250 mg capsules) on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
9930914|NCT00933062|Placebo Comparator|Placebo|Subjects will receive placebo on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
9930915|NCT00933075|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also usedas a control sample.
9930916|NCT00933101||HgbA1c <8|Adolescents with HgbA1c < or equal to 8% for the previous 12 months
9930917|NCT00933101||HgbA1c >10|Adolescents with HgbA1c > or equal to 10% for previous 12 months
9930918|NCT00933114||Functional Imaging|Functional imaging with MRI and PET
9930919|NCT00933140||HIV infected women|HIV infected women between ages 18 - 64 years of age due for cervical cancer screening were enrolled.
9930920|NCT00933153|Active Comparator|Meals on Wheels|Participants will receive two meals daily from Meals on Wheels.
9930921|NCT00933153|Experimental|Meals on Wheels + Ensure Plus supplement|Participants will receive two meals from Meals on Wheels daily plus Ensure Plus supplements with meals.
9930922|NCT00933179|Experimental|Arm 1|
9930923|NCT00933179|Active Comparator|Arm 2|
9930924|NCT00933192||Group 1: young healthy patients|
9930925|NCT00933192||Group 2: old healthy patients|
9930926|NCT00933218|Active Comparator|polyphenols (non-alcoholic beer)|
9930927|NCT00933218|Placebo Comparator|beverage without polyphenols|
9930928|NCT00933231|Active Comparator|Tacrolimus Standard Dose with ACEi/ARB|Participants receive a standard dose of tacrolimus with ACEi/ARB.
9930929|NCT00933231|Active Comparator|Tacrolimus Standard Dose without ACEi/ARB|Participants receive a standard dose of tacrolimus without ACEi/ARB.
9930930|NCT00933231|Experimental|Tacrolimus Low Dose with ACEi/ARB|Participants receive a low dose of tacrolimus with ACEi/ARB.
9930931|NCT00933231|Experimental|Tacrolimus Low Dose without ACEi/ARB|Participants receive a low dose of tacrolimus without ACEi/ARB.
9930932|NCT00933257|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
9930933|NCT00933283|Experimental|Telaprevir + Methadone|Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.
9930934|NCT00933296||A Patients with the Schnitzler syndrome|Patients with the Schnitzler syndrome
9930935|NCT00933296||B Control subjects:|B1 healthy B2 other diseases
9930936|NCT00933309|Experimental|Group 1|Exemestane alone
9930937|NCT00933309|Experimental|Group 2|Exemestane plus Avandamet
9930938|NCT00933322|Active Comparator|ruminant TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
9930939|NCT00933322|Active Comparator|industrial TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
9930940|NCT00933322|Placebo Comparator|without TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.
9930941|NCT00933348|Active Comparator|OPAL A plus standard wound care|
9930942|NCT00933348|Placebo Comparator|Placebo plus standard wound care|
9930943|NCT00933361|Experimental|ghrelin|Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS) receptor. When administered peripherally it stimulates growth hormone secretion, food intake, triggers a positive energy balance, produces weight gain through a central mechanism involving hypothalamic neuropeptides and has anti-inflammatory effects
9930944|NCT00933374|Experimental|Paclitaxel and RAD001|175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
9930945|NCT00933387|Experimental|open label|an open-labelled, single-arm
9935453|NCT03719599||Children|Children 6 -12 months of age presenting for routine clinic visits
9935454|NCT03719599||Pregnant Women|Pregnant Women 18 years and older presenting for routine clinic visits
9880912|NCT00491309|Active Comparator|exercise training group|exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
9880913|NCT00491309|No Intervention|Control group without exercise training|continuation of sedentary lifestyle without advice for specific exercise training
9880914|NCT00491426||<26 weeks|Subjects <26 weeks gestational age
9880915|NCT00491426||26-29 weeks|Subjects 26-29 weeks gestational age
9880916|NCT00491426||30-32 weeks|Subjects 30-32 weeks gestational age
9880917|NCT00491439||Corneal wounds after Epi-LASIK|Corneal wounds after Epi-LASIK
9880918|NCT00491439||penetrating keratoplasty|Corneal wound after penetrating keratoplasty
9880919|NCT00491439||corneal epithelial debridement|Corneal wound after pars plana vitrectioy with corneal epithelial debridement for diabetic retinopathy
9880920|NCT00491517|Experimental|Sirolimus|
9880921|NCT00491517|Active Comparator|conventional therapy|
9880922|NCT00491582|No Intervention|Athletes, controls, patients|Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal >50 mlO2/KG body weight
9880923|NCT00491621|Other|1|surgery or biopsy of the kidney tumor
9880924|NCT00491634|Experimental|1|treosulfan
9880925|NCT00491673|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
9880926|NCT00491673|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
9880927|NCT00491790|Sham Comparator|1|Sterile Water
9880928|NCT00491790|Active Comparator|Montelukast|Dissolved granules in sterile water
9880929|NCT00491803|Active Comparator|1|Sildenafil 20mg
9880930|NCT00491803|Active Comparator|2|Sildenafil 40mg
9880931|NCT00491816|Experimental|erlotinib with neoadjuvant chemotherapy|Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
9880932|NCT00491855|Experimental|Bevacizumab + Oxaliplatin + Paclitaxel|One cycle of treatment is 21 days. Bevacizumab starting dose level 2.5 mg/kg given intravenously on day 1. Oxaliplatin starting dose level 25 mg/m^2 given intraperitoneally on day 2. Paclitaxel starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
9880933|NCT00491868|Experimental|1|
9880934|NCT00491868|Experimental|2|
9880935|NCT00491868|Active Comparator|3|
9880936|NCT00491868|Active Comparator|4|
9880937|NCT00491985|Experimental|Study Group 1|Subjects aged 9 to 17 years
9880938|NCT00491985|Experimental|Study Group 2|Subjects aged 3 to 8 years
9880939|NCT00491985|Experimental|Study Group 3|Subjects aged 6 to 35 months
9880940|NCT00491998|Experimental|2-hourly dosing|6 Doses of IMP at 2-hourly intervals
9880941|NCT00491998|Experimental|3-hourly dosing|4 doses of IMP at 3-hourly intervals
9880942|NCT00491998|Active Comparator|3-hourly dosing plus Entacapone|4 doses of IMP plus Entacapone at 3-hourly intervals
9880943|NCT00492011|Experimental|Ramelteon 1 mg QD|
9880944|NCT00492011|Experimental|Ramelteon 4 mg QD|
9880945|NCT00492011|Experimental|Ramelteon 8 mg QD|
9880946|NCT00492011|Placebo Comparator|Placebo|
9880947|NCT00492050|Experimental|Bortezomib + Rituximab|Bortezomib 1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).
9880948|NCT00492076|Active Comparator|1|Pangramin Plus Dermatophagoides pteronyssinus 100%
9880949|NCT00492076|Placebo Comparator|2|Pangramin Plus placebo
9880950|NCT00492102|Experimental|1|Nine VLBW pre-term infants older than 7 days will be enrolled in the study and receive one oral dose of Montelukast based on weight. Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
9880951|NCT00492128|Experimental|Losartan/hydrochlorothiazide|Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg
9880952|NCT00492128|Active Comparator|Losartan/amlodipine|Combination therapy with losartan 50mg and amlodopine 5mg
9880953|NCT00492141|Experimental|L9-NC + Temozolomide|Liposomal 9-nitro-20(S)-camptothecin (L9-NC) alone, total 10 ml of 0.4 mg/ml in aerosol reservoir once a day for 5 days in row each 2 weeks, followed by 2 weeks off; then in combination with Temozolomide 100 mg/m^2 oral/day for Cycle 2 Days 1-5.
9880954|NCT00492219|Active Comparator|1|Patients undergoing total knee replacement
9880955|NCT00492219|No Intervention|2|Healthy volunteers that are not undergoing knee replacement surgery
9880956|NCT00492219|Experimental|3|Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
9880957|NCT00492219|Experimental|4|Patients undergoing partial knee replacement with the Vanguard M implant system
9880958|NCT00492271|Experimental|1|Experimental arm with increasing dosage
9880959|NCT00492310|Experimental|1|Cognitive-behavioral smoking cessation with yoga
9880960|NCT00492310|Active Comparator|2|smoking cessation with twice weekly wellness program
9880961|NCT00492362|Active Comparator|A|Ergometer during hemodialysis
9880962|NCT00492362|Active Comparator|B|Pedometer use outside of hemodialysis
9880963|NCT00492388|Experimental|A|PMI-150 (intranasal ketamine)
9880964|NCT00492388|Placebo Comparator|B|placebo
9880965|NCT00492427|Active Comparator|2|
9880966|NCT00492427|Experimental|1|
9880967|NCT00492440|Experimental|CYT107 (r-hIL-7)|
9880968|NCT00492453|Active Comparator|1|Laparoscopic cholecystectomy under spinal anesthesia
9880969|NCT00492453|Active Comparator|2|Laparoscopic cholecystectomy under general anesthesia
9880970|NCT00492466|Experimental|1|
9880971|NCT00492492|Other|trans-styloid and intrafocal pinning on the one side|trans-styloid and intrafocal pinning on the one side
9880972|NCT00492492|Other|volar fixed-angle plating on the other side|volar fixed-angle plating on the other side
9880973|NCT00492609||1|PATIENTS WITH COMPUTER-ASSISTED
9880974|NCT00492609||2|PATIENTS WITHOUT COMPUTER-ASSISTED
9880975|NCT00492635|Experimental|Arm 1|
9880976|NCT00492635|Experimental|Arm 2|
9880977|NCT00492635|Placebo Comparator|Arm 3|
9880978|NCT00492661|Experimental|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
9880979|NCT00492713|Active Comparator|1|Dark chocolate
9880980|NCT00492713|Active Comparator|2|Milk chocolate 1
9880981|NCT00492713|Active Comparator|3|Milk chocolate 2
9880982|NCT00492739|Other|Varicella vaccine|2-3 doses of Varicella vaccine to seronegative patients two months apart
9880983|NCT00492765|Experimental|1|interferon beta-1a and Simvastatin
9880984|NCT00492765|Placebo Comparator|2|Interferon beta-1a and Placebo
9880985|NCT00492778|Experimental|Arm I (brachytherapy, radiation therapy)|Patients undergo EBRT to the pelvis daily on days 1-5 for 5 weeks. After completion of EBRT, patients undergo intracavitary low-dose rate or high-dose rate brachytherapy or low-dose rate interstitial brachytherapy.
9880986|NCT00492778|Experimental|Arm II (brachytherapy, radiation therapy, cisplatin)|Patients undergo EBRT as in Arm I and receive cisplatin IV over 1-2 hours on days 1, 8, 15, 22, and 29. Patients then undergo brachytherapy as in Arm I.
9880987|NCT00492791||Endoscopic Capsule|Patient enrolled for performing an endoscopic capsule
9880988|NCT00492804|Other|Neurectomy|
9880989|NCT00492804|Other|Nerve preservation|
9880990|NCT00492817|Experimental|Single Session Stereotactic Body Radiotherapy (SBRT)|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
9880991|NCT00492843|Experimental|A|Intravenous infusion of either 6mg Bondronat on three consecutive days
9880992|NCT00492843|Active Comparator|B|Intravenous infusion of 6mg Bondronat on one day
9880993|NCT00492895|Other|A|one arm only. Crossover study
9880994|NCT00492908|Active Comparator|Titanium Nitride Oxide Coated Stent|Stent
9880995|NCT00492908|Active Comparator|Zotarohlimus Eluting Stent|Stent
9880996|NCT00492934|Active Comparator|1|Daily injections with a small dose of gonadotrophins from day 2 of the cycle
9880997|NCT00492934|No Intervention|2|No daily injections with hormones
9880998|NCT00492986|Experimental|Arm 1|
9880999|NCT00493051|Other|1|Standardized Wound Care
9881000|NCT00493051|Placebo Comparator|2|Placebo 1 dose
9881001|NCT00493051|Placebo Comparator|3|Placebo 2 doses
9881002|NCT00493051|Active Comparator|4|Active 1 dose
9881003|NCT00493051|Active Comparator|5|Active 2 doses
9881004|NCT00493077|Experimental|1|
9881005|NCT00493116|Experimental|1|
9881006|NCT00493129|Experimental|Ontak|Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
9881007|NCT00493142|Experimental|1|Usual care
9881008|NCT00493155|Experimental|1|
9881009|NCT00493233|Experimental|1|
9881010|NCT00493233|Placebo Comparator|2|
9881011|NCT00493272|Placebo Comparator|Placebo|Nacl
9881012|NCT00493272|Active Comparator|Fibrinogen|Fibrinogen
9881013|NCT00493298||natalizumab|According to the local prescribing information
9930946|NCT00933400|Active Comparator|Traditional Strategy (Group A)|In the traditional-care arm (Group A), all management and disposition decisions will be made by the healthcare providers caring for the participant. Participants will receive disposition (admit to hospital, admit to cardiac diagnostic unit, or discharge to home), diagnostic testing (none, stress testing, or cardiac catheterization), and treatment according to the team caring for the participant.
9930947|NCT00933400|Experimental|CT Coronary Angiography (Group B)|"In the study CT coronary angiography-based rapid rule out arm (Group B), participants will receive initial cardiac troponin and creatinine tests. Upon return of normal laboratory values (including a calculated creatinine clearance), the participants will receive a CT coronary angiography an estimated 90 minutes or as soon as the CT scanner is available following the initial values assessment. Participants with negative test results will be discharged unless other indications for admission per standard of care and follow up will comprise telephone interviews 30 days and 1 year after triage/presentation. Participants with positive test results will be admitted to the hospital for further management as dictated by the admitting team."
9930948|NCT00933413|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Application of Lactic acid during 21 consecutive days
9930949|NCT00933426|Experimental|Lenalidomide and Paclitaxel|"Phase I: Up to 5 differing doses of Lenalidomide tested plus fixed dose of Paclitaxel.~Phase II: Lenalidomide at highest tolerated dose from Phase I plus Paclitaxel."
9930950|NCT00933439|Experimental|Duloxetine|
9930951|NCT00933452|Experimental|low dose group|single oral administer 15mg duloxetine
9930952|NCT00933452|Experimental|moderate dose group/multiple dose group|single oral duloxetine 30mg, after that repeat 7 oral duloxetine 30mg/d
9930953|NCT00933452|Experimental|high dose group/crossover group|single oral duloxetine 60mg, after that single oral innovator duloxetine 60mg
9930954|NCT00933465|Experimental|tablets first followed by syrup|first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
9930955|NCT00933465|Experimental|Syrup first followed by tablets|first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
9930956|NCT00933478||Patients with Patulous Eustachian Tube Dysfunction|
9930957|NCT00933504|Experimental|Dermacyd Silver Floral (Lactic Acid)|Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
9930958|NCT00933530|Experimental|Cohort 1 - Dose Level A (0.03g/day)|"0.03g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.03g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.03g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
9930959|NCT00933530|Experimental|Cohort 2 - Dose Level B (0.1g/day)|"0.1g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.1g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.1g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
9935455|NCT03712618|Active Comparator|Group A|Group A: Long Transfusion followed by Short Transfusion in the first block
9881014|NCT00493324|Experimental|1|
9881015|NCT00493337|No Intervention|Control group|
9881016|NCT00493337|Experimental|Advanced counseling|
9881017|NCT00493337|Active Comparator|Compliance Card only|
9881018|NCT00493350||1|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.
9881019|NCT00493363|Experimental|arm 1|
9881020|NCT00493363|Active Comparator|arm 2|
9881021|NCT00493402|Experimental|combined chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.
9881022|NCT00493402|Experimental|combined chemotherapy without embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.
9881023|NCT00493402|Experimental|single agent chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
9881024|NCT00493415|Experimental|1|nitroglycerine iv
9881025|NCT00493415|Placebo Comparator|2|nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
9881026|NCT00493480|Active Comparator|carvedilol|
9881027|NCT00493480|Active Comparator|propranolol|Cirrhotic patients treated with propranolol
9881028|NCT00493571|Experimental|Gimatecan|Gimatecan Starting dose: 0.6 mg capsules administered orally once daily.
9881029|NCT00493584|Experimental|1|Primary PCI in patients with acute Non-STEMI
9881030|NCT00493584|Active Comparator|2|Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.
9881031|NCT00493610|Other|1|
9881032|NCT00493623|Experimental|1|
9881033|NCT00493623|Placebo Comparator|2|
9881034|NCT00493688||Cardiopulmonary Exercise Testing (CPET)|
9881035|NCT00493701|Other|Lifestyle|Measurement of body weight in a fown with light undercloting (30 minutes) and height.
9881036|NCT00493701|Other|DEXA Scanner|Low-dose X0rays to determine the amount of fat, bone and muscle in your body.
9881037|NCT00493714||Arm 1 (Patient)|Cancer patient who recently experienced confusion or restlessness.
9881038|NCT00493714||Arm 2 (Caregiver)|Caregivers of cancer patients who recently experienced confusion or restlessness.
9881039|NCT00493727|Other|1|
9881040|NCT00493766|Experimental|oral LBH589 alone|
9881041|NCT00493766|Experimental|oral LBH589 + IV docetaxel + oral prednisone|
9881042|NCT00493792|Other|1|Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
9881043|NCT00493792|Other|2|X3 Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
9881044|NCT00493844|Experimental|1|Discharge if clinical risk score <3 points + Nt-proBNP <110 ng/L
9881045|NCT00493844|Active Comparator|2|Discharge if negative exercise testing
9881046|NCT00493857|Experimental|2|Nimotuzumab 400mg every week or every two weeks
9881047|NCT00493870|Experimental|TC|docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2
9881048|NCT00493870|Active Comparator|TAC|doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2
9881049|NCT00493883|Other|TheraSphere|"Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver~--------------------------------------------------------------------------------"
9881050|NCT00493909|Active Comparator|1|thoracic epidural analgesia
9881051|NCT00493909|Active Comparator|2|intrathecal opioids and thoracic paravertebral analgesia
9881052|NCT00493922|Active Comparator|2|Microscopy for diagnosis of malaria
9881053|NCT00493922|Active Comparator|3|Clinical diagnosis for malaria
9881054|NCT00493922|Experimental|1|Rapid Diagnostic Test for Malaria
9881055|NCT00493987|Active Comparator|Testosterone enanthate|
9881056|NCT00493987|Placebo Comparator|Duatesteride|Duatesteride
9881057|NCT00494052|Experimental|1|Heart to Heart intervention
9881058|NCT00494052|No Intervention|2|Usual care
9881059|NCT00494065|Experimental|1|Chiropractic Spinal Manipulative Therapy + Home exercise
9881060|NCT00494065|Active Comparator|2|Home exercise
9881061|NCT00494078|Active Comparator|1|Patients randomised to this arm are treated with intensive insulin therapy guided by the continuous glucose monitoring system.
9881062|NCT00494078|Active Comparator|2|intensive insulin therapy guided by an algorithm
9881063|NCT00494104|Active Comparator|200 IU/day Vitamin D|200 IU/day Vitamin D
9881064|NCT00494104|Experimental|400 IU/day Vitamin D|400 IU/day Vitamin D
9881065|NCT00494104|Experimental|600 IU/day Vitamin D|600 IU/day Vitamin D
9881066|NCT00494104|Experimental|800 IU/day Vitamin D|800 IU/day Vitamin D
9881067|NCT00494195|Experimental|1|The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
9881068|NCT00494195|Experimental|2|The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
9881069|NCT00494208|Active Comparator|1|
9881070|NCT00494208|Active Comparator|2|
9881071|NCT00494208|Active Comparator|3|
9881072|NCT00494208|Active Comparator|4|
9881073|NCT00494208|Active Comparator|5|
9881074|NCT00494260|Experimental|Social learning and cognitive behavioral therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
9881075|NCT00494260|Active Comparator|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
9881076|NCT00494286|Experimental|AF-CBT|Participants will receive abused-focused cognitive behavioral therapy
9881077|NCT00494286|Active Comparator|TAU|Participants will receive treatment as usual
9881078|NCT00494312|Experimental|Pioglitazone QD|
9881079|NCT00494312|Active Comparator|Glyburide QD|
9881080|NCT00494416|No Intervention|ANC approach|Passive health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
9881081|NCT00494416|Other|advanced strategies SP|Joint with advanced strategies delivery approach (JAS). In addition to passive delivery of IPT/sulphadoxine pyrimethamine (SP) at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages, such as immunization, health promotion, and even ANC visits.
9881082|NCT00494416|Other|Community based|Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs). Each approach will be implemented in a zone constituted by the catchment area of a number of health centres to achieve the required sample size. The zones will be randomly assigned to a delivery approach. The main outcomes to be measured are: a) the coverage of IPT, b) compliance, c) infection prevalence, d) Hb level, e) difficulties and constraints of each approach, f) the acceptability to population and health staff and g) the performance of each approach to deliver IPT /SP. Coverage by 10%, each group should be composed of n = 3841 pregnant women.
9881083|NCT00494429|Experimental|1|Gestational Age< 29 weeks will be administered a loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/hr.
9881084|NCT00494429|Experimental|2|Gestational Age>= 29 weeks will be administered a loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
9881085|NCT00494455|Active Comparator|1|Continuous subcutaneous glucose monitoring in patients without shock
9881086|NCT00494455|Active Comparator|2|continuous subcutaneous glucose monitoring in patients with shock
9881087|NCT00494520|Experimental|Errorful training condition|A type of anomia rehabilitation paradigm which allows for errors. The intervention involves providing minimal auditory cues to allow for errors in picture naming.
9881088|NCT00494520|Experimental|Errorless training condition|A type of anomia rehabilitation paradigm in which the situation surrounding the performance of the desired task (i.e., picture naming) is controlled to prevent errors. The intervention involves providing maximal auditory cues to prevent errors in picture naming.
9881089|NCT00494559|Experimental|Actos|Actos group: pioglitazone 15mg or 30mg
9988608|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 4|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.
9988609|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 4|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
9988610|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 5|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.
9988611|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 5|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
9988612|NCT01424436|Experimental|GSK933776 1mg/kg|single dose
9988613|NCT01424436|Experimental|GSK933776 0.1 or 3mg/kg|single dose
9988614|NCT01424436|Experimental|GSK933776 3 or 6mg/kg|single dose
9988615|NCT01424449|Experimental|no treatment|Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for [11C]PHNO.
9988616|NCT01424462|Experimental|Firategrast XRA|Low extended release tablet
9988617|NCT01424462|Experimental|Firategrast XRB|Medium extended releast tablet
9988618|NCT01424462|Experimental|Firategrast XRC|High extended release tablet
9988619|NCT01424462|Experimental|Firategrast IR|Immediate Release reference tablet
9988620|NCT01424475|Other|PKD Patients|PKD Patients with LRRK2 mutation
9988621|NCT01424475|Other|Healthy Controls|Healthy Controls with no LRRK2 mutation
9988622|NCT01424488|Experimental|sugammadex group|4 mg/kg of sugammadex for reversal of pipecuronium-induced neuromuscular blockade
9988623|NCT01424488|Placebo Comparator|placebo group|3 ml of saline (placebo) for reversal of pipecuronium-induced neuromuscular blockade
9988624|NCT01424527||Chronic Obstructive Pulmonary Disease|Males and females 40 years of age or older with a diagnosis of COPD
9988625|NCT01424540|Experimental|Treatment A|GSK2336805 150mg
9988626|NCT01424540|Placebo Comparator|Treatment B|GSK2336805 Placebo
9988627|NCT01424553|Other|Cohort|All patients
9988628|NCT01424579|Experimental|Actual Diacutaneous Fibrolysis|The group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of actual Diacutaneous Fibrolysis.
9988629|NCT01424579|Placebo Comparator|Placebo Diacutaneous Fybrolisis|This group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of placebo Diacutaneous Fibrolysis.
9988630|NCT01424579|Other|No Diacutaneous Fibrolysis|This group received only tree weeks of a daily protocolized treatment.
9988631|NCT01424592||Study Group|Hospitalized inpatients referred by a general medicine service for evaluation of obstructive sleep apnea.
9988632|NCT01424605|Experimental|DLT intubation|
9988633|NCT01424618|Active Comparator|GnRh agonist|This arm will use a GnRH agonist to suppress pituitary-ovarian function
9988634|NCT01424618|Experimental|GnRH antagonist|A GnRH antagonist will be used to suppress pituitary-ovarian function
9988635|NCT01424631|Active Comparator|single incision laparoscopic appendectomy|
9988636|NCT01424631|Placebo Comparator|conventional laparoscopic appendectomy|
9997264|NCT01507363|Active Comparator|"Gabapentin intermediate"|Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
9881090|NCT00494559|Placebo Comparator|Placebo|Placebo group: placebo without active medication
9881091|NCT00494572|Sham Comparator|Sterile Water|Sterile water
9881092|NCT00494572|Active Comparator|Montelukast|10mg rapid dissolving granules in sterile water orally once
9881093|NCT00494650|Experimental|1|Participants will receive cognitive behavioral therapy.
9881094|NCT00494650|Active Comparator|2|Participants will receive brief PTSD treatment.
9881095|NCT00494663|Experimental|1|150mg DIO-902 + 10mg atorvastatin
9881096|NCT00494663|Experimental|2|300mg DIO-902 + 10mg atorvastatin
9881097|NCT00494663|Experimental|3|450mg DIO-902 + 10mg atorvastatin
9881098|NCT00494663|Placebo Comparator|4|DIO-902 Placebo + 10mg atorvastatin
9881099|NCT00494663|Experimental|5|150mg DIO-902 + atorvastatin placebo
9881100|NCT00494663|Experimental|6|300mg DIO-902 + atorvastatin placebo
9881101|NCT00494663|Experimental|7|450mg DIO-902 + atorvastatin placebo
9881102|NCT00494663|Placebo Comparator|8|DIO-902 placebo + atorvastatin placebo
9881103|NCT00494702|Experimental|LOX|Low saturation group of premature infants that will be kept within preset limits of 85-89%
9881104|NCT00494702|Active Comparator|HOX|HOX group of premature infants will be kept within preset saturation limits of 90-93%
9881105|NCT00494715|Experimental|Benazepril|
9881106|NCT00494715|Experimental|valsartan|
9881107|NCT00494715|Experimental|benazepril/valsartan|
9881108|NCT00494728|Other|CBASP + ST|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) + Smoking Cessation Treatment (ST)
9881109|NCT00494728|Other|ST|Smoking Cessation Treatment (ST)
9881110|NCT00494741|Experimental|mycophenolate mofetil|
9881111|NCT00494741|Experimental|azathioprine|
9881112|NCT00494767|Experimental|GW869682 1000 mg thrice daily (TID)|Subjects will be randomized to receive GW869682 1000 mg TID
9881113|NCT00494767|Experimental|GSK189075 250 mg TID|Subjects will be randomized to receive GSK189075 250 mg TID
9881114|NCT00494767|Placebo Comparator|GW869682-Placebo TID|Subjects will be randomized to receive Placebo matching GW869682 for TID
9881115|NCT00494767|Placebo Comparator|GSK189075-Placebo TID|Subjects will be randomized to receive Placebo matching GSK189075 for TID
9881116|NCT00494793|Other|VAWC and mesh mediated fascial traction|This is a study aiming to evaluate one technique for temporary abdominal closure for open abdomen therapy in all patients applicable according to the inclusion criteria
9881117|NCT00494832|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion
9881118|NCT00494832|Placebo Comparator|Placebo|Normal Saline infusion
9881119|NCT00494845|Experimental|Intervention|8-week Mindfulness Program for chronic low back pain
9881120|NCT00494845|Active Comparator|Comparison|8-week health education program
9881121|NCT00494858|Active Comparator|CBT-EF|Participants will receive cognitive behavioral therapy - focused
9881122|NCT00494858|Experimental|CBT-EB|Participants will receive cognitive behavioral therapy - broad
9881123|NCT00494910|Experimental|1|Meaning Centered Group Psychotherapy (MCGP)
9881124|NCT00494910|Active Comparator|2|standardized Supportive Group Psychotherapy
9881125|NCT00494936||HIV/HCV|HIV and HCV coinfected
9881126|NCT00494936||HIV infected|HIV monoinfected
9881127|NCT00494936||HIV/HCV nonviremnic|HIV and HCV coinfected with HCV RNA less than 600 copies
9881128|NCT00494936||HCV infected|HCV monoinfected with HCV viremia
9881129|NCT00494949|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
9881130|NCT00494949|Active Comparator|Control|Ringer's lactate
9935456|NCT03712618|Active Comparator|Group B|Group B: Short Transfusion followed by Long Transfusion in the first block
9988637|NCT01424657|Experimental|ERCP|ERCP is an endoscopic examination that allows opacification of the biliary tree by direct injection into the common bile duct through its distal opening in the duodenum at the ampulla of Vater
9997265|NCT01507363|Placebo Comparator|Placebo|Placebo tablets for 7 days, starting on the day of surgery
9797259|NCT01590771|Experimental|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
9881131|NCT00495053|Experimental|hMaxi-K 5000 µg/mL|5000 micrograms (µg)/90 milliliter (mL) intravesical instillation
9881132|NCT00495053|Experimental|hMaxi-K 10000 µg/mL|10000 µg/90 mL intravesical instillation
9881133|NCT00495053|Placebo Comparator|Placebo|Matching placebo (PBS-20% sucrose)
9881134|NCT00495092|Experimental|1|This study arm will receive caffeine+placebo
9881135|NCT00495092|Experimental|2|this study arm will receive Caffeine+Biperiden
9881136|NCT00495092|Placebo Comparator|3|this study arm will receive placebo+placebo
9881137|NCT00495105|Experimental|Two Servings of Dairy Snacks|Intervention group received two servings of dairy food per day as a snack at school for 6 months as well as nutrition education.
9881138|NCT00495105|No Intervention|No Dairy Snacks|Control Group did not receive any snacks or education.
9881139|NCT00495183|Experimental|1|caffeine + placebo
9881140|NCT00495183|Experimental|2|caffeine + biperiden
9881141|NCT00495183|Placebo Comparator|3|Placebo+placebo
9881142|NCT00495196|Experimental|1|
9881143|NCT00495196|Active Comparator|2|
9881144|NCT00495209||Qigong|"Pre-surgical Qigong therapy for women with breast cancer~External Qi Therapy = EQT"
9881145|NCT00495235||Endometrial Cancer Group|Participants who have had endometrial cancer (cases).
9881146|NCT00495235||Control Group|Participants who have not had endometrial cancer (controls).
9881147|NCT00495248|Experimental|1|
9881148|NCT00495248|Active Comparator|2|
9881149|NCT00495261|Experimental|1|
9881150|NCT00495261|Active Comparator|2|
9881151|NCT00495274|Experimental|Healthy male subjects|In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
9881152|NCT00495287|Active Comparator|A|"Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)"
9881153|NCT00495287|Experimental|B|Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)
9881154|NCT00495313|Active Comparator|Cohort 1: doxycycline|Vibramycin plus metronidazole
9881155|NCT00495313|Active Comparator|Cohort 2|Oracea® delayed release plus metronidazole
9881156|NCT00495326|Experimental|1|Nevirapine-based ART
9881157|NCT00495326|Active Comparator|2|Efavirenz-based ART
9881158|NCT00495339|Experimental|1|Levofloxacin
9881159|NCT00495352|Active Comparator|High-dose NRT, Low-dose NRT, bupropion|
9881160|NCT00495404|Other|Arm 1|
9881161|NCT00495404|Other|Arm 2|
9881162|NCT00495417|Active Comparator|1|
9881163|NCT00495417|Active Comparator|2|
9881164|NCT00495482||1|Patients receiving palliative care due to incurable illness
9881165|NCT00495573||1|HSV-2 seropositive subjects who will receive a 5-day course of acyclovir for treatment of a genital herpes recurrence.
9881166|NCT00495573||2|HSV-2 seropositive subjects who will be observed during a genital herpes recurrence but not receive acyclovir.
9881167|NCT00495651|Active Comparator|I|Standard of care
9881168|NCT00495651|Experimental|II|Standard of care+Isoniazid Prophylaxis:
9881169|NCT00495651|Experimental|III|Early Antiretroviral therapy
9881170|NCT00495651|Experimental|IV|Early Antiretroviral therapy + Isoniazid prophylaxis
9881171|NCT00495664|Experimental|TITANOX|Titanium-nitride-oxide coated stent
9881172|NCT00495664|Active Comparator|PES|Paclitaxel-eluting stent
9881173|NCT00495703|Experimental|1|Exercise
9881174|NCT00495703|Active Comparator|2|Usual Care
9881175|NCT00495729|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.
9881176|NCT00495729|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.
9881177|NCT00495729|Experimental|Cohort 3|Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.
9881178|NCT00495807|No Intervention|1|No Words was delivered during the PCA management
9881179|NCT00495807|Active Comparator|2|Positive words was delivered as a positive control group during the therapy of the pain with PCA
9881180|NCT00495807|Active Comparator|3|Partially negative words was delivered during the PCA pain management
9881181|NCT00495807|Active Comparator|4|Totally negative words was delivered during the PCA pain management
9881182|NCT00495833|No Intervention|1|
9881183|NCT00495833|Experimental|2|photo and blood pressure personalization
9881184|NCT00495833|Experimental|3|photo personalization only
9881185|NCT00495833|Experimental|4|blood pressure personalization only
9881186|NCT00495833|Experimental|5|no personalization
9881187|NCT00495833|Experimental|A|receives gift card in blood pressure (BP) kit
9881188|NCT00495833|Experimental|B|does not receive gift card in BP kit
9881189|NCT00495846|Experimental|A|"Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of >6 cm in size or multiple nodules of >3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study"
9881190|NCT00495846|Other|B|Historical controls
9881191|NCT00495859|Active Comparator|1|Study group will receive formula enriched with arginine, ω-3 fatty acids, and nucleotides once daily
9881192|NCT00495859|Active Comparator|2|controls receive an isocaloric isonitrogenous non-specific nutritional support
9881193|NCT00495872|Experimental|VN|Valproic Acid + Sorafenib
9881194|NCT00495872|Experimental|VS|Valproic Acid + Sunitinib
9881195|NCT00495872|Experimental|VD|Valproic Acid + Dasatinib
9881196|NCT00495872|Experimental|VT|Valproic Acid + Erlotinib
9881197|NCT00495872|Experimental|VL|Valproic Acid + Lapatinib
9881198|NCT00495872|Experimental|VR|Valproic Acid + Lenalidomide
9881199|NCT00495898|Experimental|1|CYPHER sirolimus-eluting stent
9881200|NCT00495898|Active Comparator|2|uncoated Bx VELOCITY balloon-expandable stent
9881201|NCT00495924||PD|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
9881202|NCT00495950||Questionnaire|
9881203|NCT00496028|Experimental|1|AZD0530 + Paclitaxel
9881204|NCT00496028|Experimental|2|AZD0530 + Carboplatin
9881205|NCT00496028|Experimental|3|AZD0530 + Carboplatin + Paclitaxel
9881206|NCT00496041|Experimental|Smart Stent in the Superficial Femoral Artery .|
9881207|NCT00496067|Experimental|1|DUAO Device
9881208|NCT00496093|Experimental|Pneumococcal Vaccine, Polyvalent (23-valent)|Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1.
9881209|NCT00496106|Experimental|Control Arm|6 telephone counseling sessions
9881210|NCT00496106|Active Comparator|Usual Care Arm|6 telephone counseling sessions
9881211|NCT00496119|Experimental|70 Gray (Gy) Proton Beam Therapy|Participants treated to 70 cobalt Gray equivalent (CGE) only (the standard treatment).
9881212|NCT00496119|Experimental|Photon Beam Therapy|Proton beam therapy combined with photon radiation therapy where combination improves final dose distribution.
9881213|NCT00496145|Experimental|treatment|Spanish Diabetes Self-Management Program
9881214|NCT00496145|No Intervention|control|usual-care control group
9881215|NCT00496223|Experimental|1|
9881216|NCT00496288|Experimental|prophylactic irradiation|prophylactic contralateral breast irradiation
9881217|NCT00496288|No Intervention|controls|Those that do not opt for prophylactic irradiation or mastectomy
9881218|NCT00496327|Experimental|1|Open label
9881219|NCT00496418|Experimental|Prophylactic stoma mesh|Mesh
9881220|NCT00496418|Active Comparator|No mesh prophylaxis|No mesh
9881221|NCT00496444|Experimental|Azacitidine + Valproic Acid|
9881222|NCT00496457|Experimental|1|TRO19622
9881223|NCT00496457|Placebo Comparator|2|
9881224|NCT00496509|Experimental|ZD6474 (vandetanib) 100mg|
9881225|NCT00496509|Experimental|ZD6474 (vandetanib) 300mg|
9881226|NCT00496522|Other|Proton Beam Therapy|Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
9881227|NCT00496548|Experimental|1|Fecal calprotectin and urinary PGE-M levels will be tested on all participants.
9988638|NCT01424657|Experimental|MRCP|The magnetic resonance cholangiopancreatography (MRCP)allows direct visualization of the biliary tree and pancreatic duct, similar to contrast cholangiography, but without the need for administration of contrast medium
9988639|NCT01424683||Endoscopic Vein Harvest (EVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
9988640|NCT01424683||Open Vein Harvest (OVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
9988641|NCT01424696||Cystic Fibrosis in 1st 3 months of life|Early Diagnosis: Children diagnosed with CF in first 3 months of life
9988642|NCT01424709|Experimental|Arm 1|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
9988643|NCT01424709|Active Comparator|Arm 2|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
9988644|NCT01424735|Experimental|Mw.|Administration of immunomodulator Mw.
9988645|NCT01424748|Placebo Comparator|Placebo|Placebo juice
9988646|NCT01424748|Experimental|30 mL Tahitian Noni Juice|30 mL Tahitian Noni Juice per day dose
9988647|NCT01424748|Experimental|300 mL Tahitian Noni Juice|300 mL Tahitian Noni Juice per day
9988648|NCT01424748|Experimental|750 mL Tahitian Noni Juice|750 mL Tahitian Noni Juice per day
9988649|NCT01424761|Experimental|Placebo|Placebo:starch
9797260|NCT01590771|Placebo Comparator|Placebo|Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.
9797261|NCT01590797|Experimental|Sitagliptin|Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
9988650|NCT01424761|Experimental|Coenzyme Q10|
9988651|NCT01424787||OsvaRen treatment|Dialysis patients on OsvaRen treatment
9988652|NCT01424800|Experimental|change in blood pressure and blood flow|34 patients will form the experimental group, in which changes of blood pressure and blood flow will be induced and monitored.
9988653|NCT01424839|Other|Germinoma metastatic|"• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol~Radiotherapy~Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)"
9988654|NCT01424839|Other|germinoma non-metastatic|"Chemotherapy:~• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination~Radiotherapy~Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
9988655|NCT01424839|Other|Non-germinoma non-metastatic standard risk|"Chemotherapy:~• Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions"
9988656|NCT01424839|Other|Non-Germinoma metastatic standard risk|Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
9988657|NCT01424839|Other|Non-germinoma non-metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
9988658|NCT01424839|Other|Non-Germinoma metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
9988659|NCT01424839|No Intervention|Teratoma|collection of information on surgery, applied treatment and outcome
9988660|NCT01424852|Active Comparator|Probiotics in milk formula|B. lactis BB-12 and L. rhamnosus GG delivered in milk formula during the first year of infancy
9988661|NCT01424852|Placebo Comparator|Control milk formula|The children received milk formula with no probiotics
9988662|NCT01424891|Placebo Comparator|Placebo|Treatment with placebo over 8 weeks
9988663|NCT01424891|Active Comparator|Simvastatin 80 mg|treatment with 80 mg of simvastatin over 8 weeks
9988664|NCT01424891|Active Comparator|Sim10/Eze10|treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks
9988665|NCT01424904|Experimental|DGB-01|All subjects will receive DGB-01 during the study. Approximately one-half of the subjects during the first period and the other half during the second period.
9988666|NCT01424917||Heart Transplant|Heart Transplant subjects
9988667|NCT01424956||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
9988668|NCT01424969||PRFM Group|Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
9988669|NCT01424969||Control Group|The control group were recruited retrospectively. Patients who have undergone arthroscopic repair of rotator cuff tears with similar size characteristics without PRFM augmentation will be encouraged to participate by letter initially, and then by telephone invitation. The same inclusion and exclusion criteria applied. MRI, pain, and functional scores will be collected in the same manner as the PRFM group at one time point at least one year post operatively.
9988670|NCT01425008|Experimental|MLN2480|
9988671|NCT01425021||Total hip/knee joint revisions|All University of Utah orthopedic patients who have had total or partial joint arthroplasties at the time of revision surgery.
9988672|NCT01425034|Active Comparator|Cast group|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
9988673|NCT01425034|Active Comparator|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
9988674|NCT01425047||Females ingesting mangosteen juice|
9988675|NCT01425047||Males ingesting mangosteen juice|
9988676|NCT01425060|Experimental|Contraceptive management program|
9988677|NCT01425060|Active Comparator|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
9988678|NCT01425073|Experimental|Stop TMP/SMZ|Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.
9988679|NCT01425073|No Intervention|Standard of care TMP/SMZ prophylaxis|Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.
9988680|NCT01425086||Incubator temperature support|Infant will be cared for in the current ongoing policy-driven temperature support provided by the incubator and handling as per bedside nursing interventions. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 weeks).
9988681|NCT01425086||Embrace blanket warming|Infant will be placed and wrapped in the embrace blanket and cared for and monitored for temperature support and monitored by bedside nursing interventions, as needed. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 week
9988682|NCT01425099|Experimental|Part 1|In Part 1, approximately 12 healthy subjects will receive DTG 50mg q24h for 5 days in Period 1. Subjects will then be administered DTG 50mg q24h in combination with prednisone 60mg for 5 days followed by a 5 day taper (60 mg Days 1-5, 50 mg Day 6, 40 mg Day 7, 30 mg Day 8, 20 mg Day 9 and 10 mg Day 10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
9881228|NCT00496561|Active Comparator|1|subcutaneous immunotherapy (House Dust Mites)
9881229|NCT00496561|Placebo Comparator|2|placebo of subcutaneous immunotherapy (House Dust Mites)
9881230|NCT00496574|Active Comparator|1|
9881231|NCT00496574|No Intervention|2|no intevention
9881232|NCT00496652|Active Comparator|1|Radiotherapy (+cisplatin to stage 3+4)
9881233|NCT00496652|Experimental|2|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4) + Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
9881234|NCT00496665|Experimental|Vandetenib|Cyclophosphamide 50 mg daily, methotrexate 2.5 mg days 1-2 weekly, and daily vandetanib (zactima) in 3 dose-escalation cohorts (100mg=Cohort 1) (200mg=Cohort 2) (300mg=Cohort3)
9881235|NCT00496678|Experimental|Navigation|Navigation through the cancer care system is the intervention
9881236|NCT00496678|Active Comparator|Standard of Care|Cancer patient receives standard of care.
9881237|NCT00496691|Experimental|1|Parent-child
9881238|NCT00496691|Active Comparator|2|Adolescent only intervention focusing on condom use skills and assertiveness training around sexual discussions
9881239|NCT00496691|Placebo Comparator|3|Health promotion intervention including general health promotion topics such as smoking, diet, exercise, etc.
9881240|NCT00496717||1|There is only one arm and all patients will have their aortic calcium scoring by CT scan.
9881241|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
9881242|NCT00496847|Experimental|Drug Group|PERIOGEN
9881243|NCT00496847|Active Comparator|Control group|Beta TCP alone
9881244|NCT00496899||1|Women in active labor
9881245|NCT00496938|Other|1|Observational cohort using an all-comers design
9881246|NCT00496990|Active Comparator|control|Participants in this group receive the opportunity to attend a support group
9881247|NCT00496990|Experimental|Enhanced care|Participants in this arm receive the opportunity to have detoxification or methadone treatment as well as receive vouchers contingent upon drug free urine samples and individualized counseling
9797262|NCT01590797|Placebo Comparator|Placebo|Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
9881248|NCT00497068|Experimental|tobacco abstinent contingent voucher|Tobacco abstinent contingent voucher condition
9881249|NCT00497068|Experimental|non-contingent|Participants receive vouchers non-contingent upon tobacco use status
9797263|NCT01590810|Experimental|Panel A-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
9881250|NCT00497068|Other|no voucher|This is the standard care intervention
9881251|NCT00497094|Active Comparator|1|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations. Additionally patients will undergo carotid artery stenting using a filter wire protection device.
9881252|NCT00497094|No Intervention|2|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
9881253|NCT00497107|Active Comparator|1|The Control Group (UFT + Calcium Folinate)
9881254|NCT00497107|Experimental|2|The PSK Group (UFT + Calcium Folinate + PSK)
9881255|NCT00497172|Experimental|1|drug-eluting stent
9881256|NCT00497172|Active Comparator|2|bare-metal stent
9881257|NCT00497185|Other|A|Mindfulness-Based Cognitive Therapy
9881258|NCT00497185|No Intervention|B|Shared care: Treatment as usual augmented by psychiatric consultation intervention to optimise treatment in the present health care system.
9881259|NCT00497224|Experimental|Erlotinib|Eligible patients will receive erlotinib 150mg PO daily, with dose escalation occurring as tolerated.
9881260|NCT00497237|Experimental|1|Foster
9881261|NCT00497237|Active Comparator|2|Seretide
9881262|NCT00497250|Other|1|Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are >=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, >=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
9881263|NCT00497276|Experimental|I|Ultrasound guided placement of popliteal catheter
9797264|NCT01590810|Experimental|Panel B-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
9881264|NCT00497276|Experimental|II|Nerve stimulation guided placement of popliteal catheter
9881265|NCT00497302|Experimental|1|receives housing based on drug abstinence
9881266|NCT00497302|Active Comparator|2|Usual care treatment at the Center for Addiction and Pregnancy
9881267|NCT00497315|Experimental|A|pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed
9881268|NCT00497315|Experimental|B|thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin
9881269|NCT00497328|Other|N-acetylcysteine Group (NAC)|"N-acetylcysteine Group (NAC)~Intravenous infusion 154mEq/L of sodium chloride (0.9% normal saline) at a rate of 1mL/kg/hour from 12 hours before till 6 hours after cardiac catheterization Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses)"
9881270|NCT00497328|Other|Sodium Bicarbonate Group (SOB)|"Sodium Bicarbonate Group (SOB)~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 3 mL/kg/hour for 1 hour immediately before radiocontrast injection. For patients weighing more than 110 kg, the initial fluid bolus and drip will be limited to those doses administered to a patient weighing 110 kg.~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 1 mL/kg/hour during the contrast exposure and for 6 hours after the procedure"
9881271|NCT00497328|Other|Combination Group (COM: NAC and SOB)|"Combination Group (COM: NAC and SOB)~Intravenous infusion of 154 meq/l sodium bicarbonate at a rate of 3ml/kg/hour for 1 hour before cardiac catheterization and 1 ml/kg/hour till 6 hours after procedure Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses). All patients will be monitored regularly for pulmonary congestion and hemodynamics compromise hourly after PCI for 6 hours and every 4 hour thereafter for 24 hours."
9881272|NCT00497341|Experimental|1|antibiotic is given before tourniquet inflation and before tourniquet release
9881273|NCT00497341|Placebo Comparator|2|antibiotic is given before tourniquet inflation
9881274|NCT00497367|Experimental|TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent|This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.
9881275|NCT00497380|Experimental|Arginine enriched nutrition|
9881276|NCT00497380|Placebo Comparator|Nutrition|
9881277|NCT00497393|No Intervention|Control|regular use of the 2-bed areas in the Emergency department
9881278|NCT00497445|Experimental|Angioplasty / surgery and exercise therapy|Angioplasty / surgery followed by supervised exercise therapy
9881279|NCT00497445|No Intervention|Angioplasty / surgery|Angioplasty / surgery alone
9881280|NCT00497458|Placebo Comparator|Arimidex|Arimidex 1 mg plus placebo
9881281|NCT00497458|Active Comparator|Arimidex test 40mg|Arimidex 1mg and testosterone 40mg
9881282|NCT00497458|Active Comparator|Arimidex plus test 80mg|Arimidex 1mg and testosterone 80mg
9881283|NCT00497497|Experimental|1|
9881284|NCT00497497|Experimental|2|
9881285|NCT00497523|Experimental|Beclomethasone dipropionate|
9881286|NCT00497523|Experimental|Beclomethasone dipropionate/Salbutamol combination|
9881287|NCT00497523|Active Comparator|Salbutamol|
9881288|NCT00497536|Active Comparator|1|≈ bolus protocol.
9881289|NCT00497536|Active Comparator|2|≈ CSII protocol
9881290|NCT00497536|Active Comparator|3|≈ CIII protocol.
9881291|NCT00497549|Active Comparator|1|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
9881292|NCT00497549|Active Comparator|2|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
9881293|NCT00497588|Active Comparator|radiotherapy|patients receive radiotherapy
9881294|NCT00497588|Experimental|surgery|Patients undergo surgery
9881295|NCT00497601|Experimental|A|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3
9881296|NCT00497601|Experimental|B|Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3
9881297|NCT00497601|Experimental|C|Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3
9881298|NCT00497601|Experimental|D|Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1
9881299|NCT00497614|Other|No arm|
9881300|NCT00497653|Experimental|DCI|
9881301|NCT00497653|Placebo Comparator|Placebo|
9881302|NCT00497809|Experimental|1|AVI-014 2.5mcg/kg
9881303|NCT00497809|Experimental|2|AVI-014 5.0 mcg/kg
9881304|NCT00497809|Experimental|3|AVI014 10.0 mcg/kg
9881305|NCT00497809|Active Comparator|4|Filgrastim 5.0 mcg/kg
9881306|NCT00497848|Active Comparator|motivational interviewing|
9881307|NCT00497848|Experimental|The System Orientated Intervention|
9881308|NCT00497900|Experimental|1|Calcium and vitamin D
9881309|NCT00497900|Placebo Comparator|2|Calcium and placebo (cellulose)
9881310|NCT00497913|Active Comparator|A|
9881311|NCT00497913|Placebo Comparator|B|
9881312|NCT00497952|Experimental|Multiple Sclerosis Patients|Recipients treated with a hematopoetic stem cell infusion from a living donor
9881313|NCT00497978|Active Comparator|1|taurine will be given per capsule
9881314|NCT00497978|Placebo Comparator|2|placebo capsules containing microcrystalline cellulose will be given
9881315|NCT00498043|Experimental|R-CHOP-14|R-CHOP14 induction regimen
9881316|NCT00498043|Experimental|R-ACVBP14|R-ACVBP14 induction regimen
9881317|NCT00498056|Experimental|1|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP. Injections will occur at study entry and Weeks 4, 8, and 24.
9997266|NCT01507376|Experimental|A: recombinant hCG(250 µg Ovitrell)|1- Group A consisted of 60 infertile women who received recombinant hCG(250 µg Ovitrelle)
9881318|NCT00498056|Placebo Comparator|2|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP placebo followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP placebo. Injections will occur at study entry and Weeks 4, 8, and 24.
9881319|NCT00498069|Active Comparator|1|Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity
9881320|NCT00498069|Placebo Comparator|2|Injection of placebo into ischemic tissues of the lower extremity
9881321|NCT00498121||VAP patient|
9881322|NCT00498147||ADEC <6months|Patients new to the ADEC program who will be provided the ADEC interventions (prospective study)
9881323|NCT00498147||ADEC >6months|Patients who have been with the ADEC program as early as 2002 (coincides with ADEC's EMR initiation date) who continue to be provided the ADEC interventions (combined retrospective/prospective study)
9881324|NCT00498160|Experimental|Living or Deceased Donor Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same living donor. Recipients with the need for a deceased donor kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same deceased donor
9881325|NCT00498225|Experimental|1|Gemcitabine plus TS-1
9881326|NCT00498225|Experimental|2|TS-1
9881327|NCT00498225|Active Comparator|3|Gemcitabine
9881328|NCT00498277||Spinal MRI|
9881329|NCT00498290|Experimental|A|received enhanced recovery after surgery (ERAS) protocol in colorectal surgery
9881330|NCT00498290|No Intervention|B|normal recovery protocol in colorectal surgery
9881331|NCT00498316|Other|Cord Blood Infusion|"Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.~Fludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.~Rituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.~Cyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
9881332|NCT00498459|Experimental|ICAPS|Promotion Physical Activity
9881333|NCT00498459|No Intervention|Control|No specific physical activity promotion Ususal school program
9881334|NCT00498472|Active Comparator|A|Pre-discharge NT-ProBNP based
9881335|NCT00498472|No Intervention|B|Discharge date and treatment not based on the knowledge of pre-discharge NT-proBNP levels
9930960|NCT00933530|Experimental|Cohort 3 - Dose Level C (0.25g/day)|"0.25g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.25g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.25g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
9997267|NCT01507376|Experimental|B: recombinant hCG(500 µg Ovitrell)|2- Group B consisted of 60 infertile women who received recombinant hCG(500 µg Ovitrelle)
9997268|NCT01507376|Experimental|C: urinary hCG|3- Group C consisted of 60 infertile patients received 10,000 IU urinary hCG
9881336|NCT00498524||1|Sib who has received an ICD
9881337|NCT00498524||2|Sib who has not received an ICD
9881338|NCT00498537|Other|1|
9881339|NCT00498537|Other|2|
9881340|NCT00498576||1|kidney transplant with hypertension
9881341|NCT00498576||2|hypertensive patients with native kidneys
9881342|NCT00498576||3|healthy controls
9881343|NCT00498589|Placebo Comparator|1|Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks
9881344|NCT00498589|Placebo Comparator|2|1 IM or SC of placebo per week during 24 weeks
9997269|NCT01507389|Experimental|Mild|
9881345|NCT00498667||PET/CT|all patients with aggressive lymphoma who had a baseline and interim pet/ct study
9881346|NCT00498680|Active Comparator|Viagra 100mg|
9881347|NCT00498680|Active Comparator|Levitra 20mg|
9881348|NCT00498680|Active Comparator|Viagra 50mg+ Levitra 10mg|
9881349|NCT00498719||CTP Group|One-on-one cognitive training
9881350|NCT00498719||Control Group|Standard educational support.
9881351|NCT00498771|Active Comparator|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
9988683|NCT01425099|Experimental|Part 2|If DTG Cτ is reduced by more than 50% in Part 1, Part 2 will be carried out where a second cohort of subjects will receive DTG 50mg q24h DTG for 5 days in Period 1 followed by DTG 50mg q24h in combination with prednisone 20mg for 5 days followed by a 5 day taper (20 mg Days 1-5, 10 mg Days 6 and 7, 5 mg Days 8-10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
9988684|NCT01425112|Experimental|Topical/Subconjunctival|Depending upon the mode of administration
9988685|NCT01425125|Experimental|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
9997270|NCT01507389|Experimental|Moderate|
9997271|NCT01507389|Experimental|Severe|
9997272|NCT01507389|Experimental|Normal|
9997273|NCT01507402|Experimental|Cohort 1|Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
9997274|NCT01507402|Experimental|Cohort 2|Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
9997275|NCT01507402|Experimental|Cohort 3|Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
9997276|NCT01507402|Experimental|Cohort 4|Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
9997277|NCT01507402|Experimental|Cohort 5|Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
9997278|NCT01507402|Experimental|Cohort 6|Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
9997279|NCT01507402|Experimental|Cohort 7|Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
9997280|NCT01507402|Experimental|Cohort 8|Dose regimen 3 (Participants > 65 to ≤ 85 yrs old)
9997281|NCT01507402|Experimental|Cohort 9|Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
9997282|NCT01507415||Exacerbation|Patients with Chronic Obstructive Pulmonary Disease (COPD)
9988686|NCT01425138||Psoriasis|Published data on moderate-to-severe plaque psoriasis.
9988687|NCT01425151|Active Comparator|i-Gel|
9988688|NCT01425151|Experimental|ProSeal|
9988689|NCT01425164|Active Comparator|Carvedilol|
9988690|NCT01425164|Experimental|Ivabradine|
9988691|NCT01425177|Experimental|Normal saline irrigation|
9988692|NCT01425216|Experimental|Sorafenib arm|All patients will be treated with sorafenib.
9988693|NCT01425242|Experimental|Aliskiren|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
9988694|NCT01425242|Active Comparator|Amlodipine|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy
9988695|NCT01425255||Parents of children with Type 1 diabetes|before and several weeks after initiating using RT-CGM of their children.
9517667|NCT03304262|Sham Comparator|Sham tDCS + rTMS|Participant will receive 10 minutes of sham tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
9517668|NCT03304249|Experimental|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
9517669|NCT03304249|Active Comparator|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
9988696|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
9988697|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
9988698|NCT01425320|Active Comparator|dapsone 5% gel (ACZONE®)|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
9988699|NCT01425320|Active Comparator|adapalene 0.3% gel (Differin®)|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
9988700|NCT01425333|Active Comparator|Cystectomy|Patients undergoing cystectomy for ovarian endometrioma
9988701|NCT01425333|Active Comparator|Ablation|Patients undergoing ablation for ovarian endometrioma
9988702|NCT01425346||Normal Healthy|Normal, healthy males and females between the ages of 21 and 70 with healthy eyes as determined by a standard ophthalmic examination.
9988703|NCT01425385||Autoregulation monitoring|Patients will be grouped into Meld Score
9988704|NCT01425398|Experimental|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
9881352|NCT00498771|No Intervention|Control - No Exercise Arm|No exercise will be performed in Control arm. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL) at baseline, 6 week, 6 and 12 month.
9881353|NCT00498784|Experimental|Arm 1|
9881354|NCT00498888|Active Comparator|1|Women were prescribed a 3 month supply of Tolterodine SR 4 mg (Detrusitol SR 4 mg, Pfizer Pharmaceuticals Israel LTD) . After the randomization she needs to get the first prescription from her doctor, and followed this protocol every three weeks. Her doctor how already knows this research were explained how to take the drug. After finished this protocol she get the money she pay after sending the receipts and the empty boxes.
9881355|NCT00498888|Active Comparator|2|The Bladder training protocol aims o to increase the time interval between voids, either by a mandatory or self-adjustable schedule, so that incontinence is ultimately avoided and continence regained. It is generally comprised of three components: 1) patient education that includes information about bladder and how continence is usually maintained, 2) scheduled voiding- a 'timetable for voiding' which may fixed or flexible to suit the participant's rate of increase in interval between voids, commonly the aim is to achieve an interval of three to four hours between voids and 3) positive reinforcement- - psychological support and encouragement is generally considered important and usually provided by health care professional . Frequency volume chart (FVC) records the time and volumes of voided for 24 hours by the women between the appointments. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
9881356|NCT00498888|Active Comparator|3|The Pelvic floor muscle training (PFMT) protocol based on National Institute for health and clinical excellence (NICE clinical guideline 40, 2006), that the PFMT programs should comprise at least eight contractions performed three times per day, and the trial of supervised PFMT of at least 3 months' duration . Each appointment the women maid three sets of eight to 12 slow maximal contractions sustained for 6-8 second, and asked to made this protocol every day, and taught to contract these muscle to suppress urge filling. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
9881357|NCT00498888|Active Comparator|4|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for pelvic floor muscle training and bladder training and lifestyle advice and information about good bladder and bowel habits.
9881358|NCT00498979|Experimental|recombinant interferon alfa-2b|recombinant interferon alfa-2b
9881359|NCT00499005|Active Comparator|Primi|
9881360|NCT00499005|Active Comparator|Multi|
9881361|NCT00499018|Experimental|1|R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
9881362|NCT00499018|Experimental|1 BIS|R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
9881363|NCT00499018|Experimental|2|R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
9881364|NCT00499018|Experimental|2 BIS|R-CHOP14 x 4 Restaging + R-CHOP14 x 4
9881365|NCT00499044|Experimental|1|MATRICS Consensus Cognitive Battery
9881366|NCT00499044|Experimental|2|Cognitive Drug Research Computerized Cognitive Assessment System
9881367|NCT00499057|Other|single arm study|single arm study
9881368|NCT00499135|Experimental|Schedule A|Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
9881369|NCT00499135|Experimental|Schedule B|Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
9881370|NCT00499161|No Intervention|1|Control group received usual care
9881371|NCT00499161|Experimental|2|Received intervention New model of nursing care
9881372|NCT00499187||Fanconi Cases|This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
9881373|NCT00499187||Control Cases|This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
9881374|NCT00499200|Experimental|SRA-444 + Placebo|Experimental; Placebo
9881375|NCT00499265|Active Comparator|Gemcitabine|
9881376|NCT00499265|Experimental|Gemcitabine plus 200 mg WX-671|
9881377|NCT00499265|Experimental|Gemcitabine plus 400 mg WX-671|
9881378|NCT00499330|Other|Arm A|Patients undergo a standard operation for lung cancer called a lobectomy.
9881379|NCT00499330|Experimental|Arm B|Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
9881380|NCT00499382||PET/CT scan + NM cardiac scan|
9881381|NCT00499421||CT Scan|CT Scan with Fiducial markers + external beam radiation therapy
9881382|NCT00499499|Experimental|1|
9881383|NCT00499512||Spirituality Questionnaire|Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.
9881384|NCT00499525|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour once weekly for 3 weeks. Patients also receive oral sorafenib tosylate twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9881385|NCT00499525|Active Comparator|Arm II|Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9988705|NCT01425398|Placebo Comparator|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5
9988706|NCT01425411|Experimental|Valsartan treatment|
9988707|NCT01425424|Experimental|Fasting glucose (blood sugar)|This group is associated with a diagnosis of prediabetes
9988708|NCT01425424|Experimental|Resting Blood pressure|This group is associated with a diagnosis of prehypertension.
9988709|NCT01425424|Experimental|Fasting Glucose & Resting Blood Pressure|coexisting prediabetes and prehypertension
9988710|NCT01425437||Patients with keloid|All patients will have a clinical diagnosis of keloid and will consent to participate in this study.
9988711|NCT01425450|Experimental|HF1020|
9988712|NCT01425450|Placebo Comparator|Placebo|
9988713|NCT01425476|Placebo Comparator|Placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
9988714|NCT01425476|Active Comparator|Placebo & cholecalciferol 2,000 IU|
9797265|NCT01590810|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
9988715|NCT01425476|Experimental|celecoxib 400 mg & cholecalciferol 2,000 IU|
9988716|NCT01425489||Observation|Patients with Krabbe Disease
9988717|NCT01425502|Other|All practices|The design is a stepped-wedge cluster randomised trial. All participating practices therefore receive the intervention at a start time which is randomised.
9988718|NCT01425541|Experimental|estrogen, progesterone|Estrace, 0.5-1 mg once a day Micronized progesterone powder (Spectrum Chemical Manufacturing Corporation, Irving, CA), Three times a day at 0700, 1500, and 2300 hr
9988719|NCT01425554|No Intervention|Diagnostic study|
9988720|NCT01425580|Experimental|liraglutide|The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
9988721|NCT01425580|Active Comparator|glimepiride|4 mg p.o. (QD)
9988722|NCT01425606||blood test|to measure levels of sodium, albumin and acid - base status in venous blood
9988723|NCT01425619|Placebo Comparator|Placebo cream, Skin test, Anxiety, Pain|After placing a placebo cream on both arms, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
9998316|NCT01517035|Experimental|1|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
9998317|NCT01517087||1|neurologically normal, healthy adults, age 35 or older.
9881386|NCT00499577|Experimental|Group 1 (HLA-A2 positive)|Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
9881387|NCT00499577|Experimental|Group 2|Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
9881388|NCT00499577|Experimental|Second group 1|On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
9881389|NCT00499577|Experimental|Second group 2|On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
9881390|NCT00499629|Active Comparator|1|Arm 1: FXR 450
9881391|NCT00499629|Placebo Comparator|2|Placebo
9881392|NCT00499668|Experimental|ARM A|
9881393|NCT00499668|Experimental|ARM B|
9881394|NCT00499733|Experimental|Intervention|Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.
9881395|NCT00499785||patients admitted with acute leukemia|
9881396|NCT00499798||patients on temozolimide for brain cancer|
9881397|NCT00499811|Experimental|Treatment (enzyme inhibitor therapy)|"Vorinostat (SAHA) will be administered as a single oral dose on day -6 for all patients. Blood samples are obtained periodically on day -6 for pharmacokinetic studies.~One week later (day 1), the first course of oral vorinostat will be initiated on a continuous daily oral regimen. Each treatment course will consist of 21 days of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
9881398|NCT00499824|Experimental|1|Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
9881399|NCT00499824|No Intervention|2|Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
9881400|NCT00499837|Experimental|80 mg/kg AAT inhaled|80 mg/kg AAT inhaled
9881401|NCT00499837|Placebo Comparator|Placebo inhaled|Placebo inhaled
9881402|NCT00499876|Active Comparator|A|
9881403|NCT00499876|Placebo Comparator|B|
9998318|NCT01517139||Feasibility Cohort|100 pairs of children and their mothers recruited from 2 provinces.
9881404|NCT00499902|Other|2 stages|This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
9881405|NCT00499967|Experimental|Cohort 1|GS-9191 0.01% ointment
9881406|NCT00499967|Experimental|Cohort 2|GS-9191 0.03% ointment
9881407|NCT00499967|Experimental|Cohort 3|GS-9191 0.1% ointment
9881408|NCT00499967|Active Comparator|Cohort 4|GS-9191 0.3%
9881409|NCT00499967|Active Comparator|Cohort 5|GS-9191 1.0%
9881410|NCT00499967|Placebo Comparator|Cohorts 1, 2, 3, 4 & 5|Placebo in all cohorts
9881411|NCT00500006|Other|A|Arm A: Drug and comparator
9881412|NCT00500006|Other|B|Arm B: Drug and comparator
9881413|NCT00500019||1.|Elective Cesarean sections
9881414|NCT00500019||2.|Non-elective cesarean section
9881415|NCT00500032|Experimental|Arm 1|Active Comparator for all subjects enrolled in 6108A1-500
9881416|NCT00500058|Experimental|SB-485232+Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
9881417|NCT00500162|Active Comparator|1|
9881418|NCT00500162|Active Comparator|2|
9881419|NCT00500188|Experimental|7 Days|Imatinib Mesylate 300 mg orally twice daily starting 7 days before surgery.
9881420|NCT00500188|Experimental|5 Days|Imatinib Mesylate 300 mg orally twice daily starting 5 days before surgery.
9881421|NCT00500188|Experimental|3 Days|Imatinib Mesylate 300 mg orally twice daily starting 3 days before surgery.
9881422|NCT00500201|Experimental|Subjects in treatment sequence AB|In treatment sequence AB first subjects will be randomized to receive treatment A (two tablets of 60 milligram [mg] of SB-773812) and one placebo tablet. Then subjects will receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets . There will be a wash-out period of 20 days between.
9881423|NCT00500201|Experimental|Subjects in treatment sequence BA|In treatment sequence BA first subjects will be randomized to receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets. Then subjects will receive treatment A (two tablets of 60 mg of SB-773812) and one placebo tablet. There will be a wash-out period of 20 days between.
9881424|NCT00500253|Active Comparator|1|children with asthma with FeNO monitored treatment (study group)
9881425|NCT00500253|Other|2|group of children with treatment monitored by GINA's grade of disease clinical control (control group)
9881426|NCT00500344|Other|1|
9881427|NCT00500409|Experimental|Drug Group|Osteoform
9881428|NCT00500409|Active Comparator|Control group|SHELCAL
9881429|NCT00500422|Experimental|Doxil + Gemcitabine + Velcade|Doxil Starting dose of 20 mg/m^2 intravenous (IV) over 2 hours on Day 1 and Gemcitabine 500 mg/m^2 IV over 30 minutes on Days 1 and 8; Velcade Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles.
9881430|NCT00500435||Laparoscopy Procedure|Laparoscopy procedure in abdomen to remove para aortic lymph nodes of patients diagnosed with cervical cancer.
9881431|NCT00500461|Experimental|Subjects receiving GSK233705|Each subject will receive one or more ascending doses given as a constant rate IV infusion over 30 minutes and a single oral dose of 250 microgram GSK233705 solution. IV doses will include 30, 70, 110 microgram of GSK233705 at specified time points.
9881432|NCT00500487|Experimental|1|
9881433|NCT00500487|Active Comparator|2|
9881434|NCT00500487|Active Comparator|3|
9881435|NCT00500500|Experimental|EGb 761® (Tanakan®)|EGb 761® (Tanakan®)
9881436|NCT00500500|Placebo Comparator|Placebo|Placebo
9881437|NCT00500513|Experimental|Implanted Markers + CT + RT|
9930961|NCT00933530|Experimental|Cohort 4 - Dose Level D (0.5g/day)|"0.5g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.5g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.5g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
9935457|NCT03709472|Experimental|Computer Assisted CIFFTA|CA CIFFTA (Computer Assisted Culturally Informed and Flexible Family Based Treatment for Adolescents) consists of a hybrid intervention utilizing office-based CIFFTA and technology-delivered material. Over 16 weeks CIFFTA participants receive 45 minutes of face-to-face sessions plus approximately 45 minutes of web-based intervention per week. During the continuing care phase participants access website resources and receive targeted messages (e.g., handling family conflicts). CA CIFFTA will: 1) deliver psycho-educational modules (e.g., depression, emotion regulation), 2) collect diary-card information, and 3) provide additional resources. During videos parents and adolescents can report symptoms and information that is automatically transmitted to therapists and used in the next session
9998319|NCT01517165|Experimental|Group 1|
9988724|NCT01425619|Active Comparator|Anesthetic cream, pain and anxiety, skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
9988725|NCT01425619|Active Comparator|Medical clown, placebo cream, skin test|After placing a placebo cream on both arms and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
9988726|NCT01425619|Active Comparator|Medical clown, Anesthetic cream, Skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
9988727|NCT01425645|Active Comparator|Lifestyle and behavioural change support|Interventional arm will be offered a 12 month lifestyle program translating DM prevention issues to the family milieu
9988728|NCT01425645|No Intervention|control|Control arm will receive standard diabetes prevention care as outlined in the current Canadian diabetes association Clinical Practice Guidelines.
9988729|NCT01425658|Active Comparator|clonidine|The clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
9988730|NCT01425658|Active Comparator|Fentanyl|The fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
9988731|NCT01425658|Placebo Comparator|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
9988732|NCT01425684||schizophrenia|smokers and nonsmokers
9988733|NCT01425684||control|smokers and nonsmokers
9988734|NCT01425697|Active Comparator|2% Chlorhexidine Gluconate cloths|2% Chlorhexidine Gluconate wipes will be used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery
9988735|NCT01425697|Other|Standard of Care Preoperative Preparation|Subject will receive standard of care preoperative preparation for the clinical site.
9988736|NCT01425710||Pheochromocytoma Group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
9988737|NCT01425710||Control group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
9988738|NCT01425736|Placebo Comparator|Chemotherapy|"Chemotherapy~:Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)"
9998320|NCT01517165|Placebo Comparator|Group 2|
9988739|NCT01425736|Experimental|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment: Docetaxel(75mg/m²,1 time/21d, 6times，);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times),Nimotuzumab treatment:(200mg/w,18weeks )."
9988740|NCT01425762|Experimental|Choice Group|
9988741|NCT01425762|Active Comparator|No Choice Group|
9988742|NCT01425775|Active Comparator|Vitamin D|
9988743|NCT01425775|Placebo Comparator|Placebo|
9988744|NCT01425788|Active Comparator|Osiris Phleum pratense - Group A|"Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.~Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day"
9988745|NCT01425788|Active Comparator|Osiris Phleum pratense - Group B|"Group B Up-dosing schedule:~Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day"
9797266|NCT01590810|Experimental|Panel D-Healthy|Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.
9988746|NCT01425788|Active Comparator|Osiris Phleum pratense - Group C|"Group C up-dosing schedule:~Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day"
9988747|NCT01425840|Experimental|Liposomal lidocaine, topical anesthesia|Efficacy of Liposomal lidocaine in topical anesthesia.
9988748|NCT01425866|Experimental|2 years self management education|Long-term program including initial self-management education program (1 to 7 sessions, based on individual assessment), and follow-up group sessions maintained for 2 years (4-monthly assessment, empowerment, and contextual action planning; facultative additional specific thematic sessions being delivered if needed).
9881438|NCT00500526|Experimental|1 Singing Group|Patients who will receive singing classes
9881439|NCT00500526|Other|2 Control group|Patients who will attend hand craft classes
9881440|NCT00500565|Experimental|On-Q pump with Saline|On-Q Pump with Saline
9881441|NCT00500565|Experimental|On-Q Pump with Bupivicaine|On-Q Pump with bupivicaine
9881442|NCT00500591||Obese Women|
9881443|NCT00500604|Experimental|A|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 150/12.5mg tablet every morning for 8 weeks.~period 3: One 300/12.5mg tablet every morning for 8 weeks.~period 4: Two 150/12.5mg tablets every morning for 8 weeks."
9881444|NCT00500604|Active Comparator|B|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 80/12.5mg tablet every morning for 8 weeks.~period 3: One 160/12.5mg tablet every morning for 8 weeks.~period 4: Two 80/12.5mg tablets every morning for 8 weeks."
9881445|NCT00500617||segment 1|Gene discovery blood draw
9881446|NCT00500617||sement 2|Assay development blood draw
9881447|NCT00500617||segment 3|Assay validation blood draw
9881448|NCT00500617||segment 4|Additional assay testing blood draw (Note: post discovery diabetic subjects assigned to this group)
9881449|NCT00500669|Experimental|Betadine|
9881450|NCT00500669|Active Comparator|Saline|
9881451|NCT00500695|Experimental|Motivational Interviewing|Motivational Interviewing
9881452|NCT00500695|Active Comparator|Psychoeducation|Psychoeducation
9881453|NCT00500734||Heart Disease Patients|
9881454|NCT00500747|Experimental|Group C: 100 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 100 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
9881455|NCT00500747|Experimental|Group B: 20 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 20 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
9881456|NCT00500747|Experimental|Group A: 4 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 4 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
9881457|NCT00500786|Experimental|100 mcg CYT006-AngQb Healthy Volunteers|
9881458|NCT00500786|Experimental|100 mcg CYT006-AngQb Hypertensives|
9881459|NCT00500786|Experimental|300 mcg CYT006-AngQb Hypertensives|
9881460|NCT00500786|Placebo Comparator|Placebo Healthy Volunteers|
9881461|NCT00500786|Placebo Comparator|Placebo Hypertensives|
9881462|NCT00500825||1|Patients successfully resuscitated after cardiac arrest undergoing therapeutic hypothermia
9881463|NCT00500838|Experimental|1|Transthoracic impedance device implanted.
9881464|NCT00500851|Active Comparator|1|In case of meeting clinical criteria for jejunal feeding, tubes are placed using CORTRAK (electromagnetic imaging).
9881465|NCT00500851|Active Comparator|2|Endoscopic placement of jejunal feeding tubes fulfilling clinical indication for jejunal feeding.
9881466|NCT00500877|Active Comparator|Mood Management Phone counseling|Mood management phone counseling for smoking cessation
9998321|NCT01517191||Influenza Positive Case|Influenza cases are hospitalized adults who have tested positive for influenza.
9881467|NCT00500877|Placebo Comparator|Phone Counseling Standard|Phone counseling standard
9881468|NCT00500942||1|Patients having a standard procedure performed in Interventional Radiology.
9881469|NCT00500968|Active Comparator|Stent|
9881470|NCT00500968|Active Comparator|conventional distal pancreatectomy|
9881471|NCT00500981|Experimental|Intravenous fluid bolus|Administration of 500 ml of 10% pentastarch
9881472|NCT00501072|Experimental|Open|Real-Time Continuous Glucose monitoring System (RT-CGMS) with alarm setting active and ability to view glucose trend profiles
9881473|NCT00501072|No Intervention|Blind|RT-CGMS is applied without alarm setting and without the ability to watch glucose trend profiles
9881474|NCT00501098|Experimental|I|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
9881475|NCT00501111|No Intervention|1|Placebo
9881476|NCT00501111|Active Comparator|2|donepezil
9881477|NCT00501111|Experimental|3|AZD3480
9881478|NCT00501137|Active Comparator|16-26 year olds 3 doses HPV Vaccine|Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
9881479|NCT00501137|Active Comparator|3 dose 9-13 HPV Vaccine|Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
9881480|NCT00501137|Active Comparator|2 dose 9-13 yrs HPV Vaccine|Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths
9881481|NCT00501176|Active Comparator|plastic stent|Stent insertion
9881482|NCT00501176|Active Comparator|metalic stent|Stent inserttion
9881483|NCT00501189||1|Those getting Gardasil vaccination for low grade Pap abnormality.
9881484|NCT00501189||2|Historical group that did not get Gardasil.
9881485|NCT00501215|Experimental|Parathyroidectomy + Observation|
9881486|NCT00501215|Other|Observation Alone|
9881487|NCT00501241|Placebo Comparator|1|placebo twice daily
9881488|NCT00501241|Experimental|2|20 mg ATI-7505, BID for 4 weeks
9881489|NCT00501241|Experimental|3|40 mg ATI, BID, 4 weeks
9881490|NCT00501241|Experimental|4|80 mg ATI-4505, BID for 4 weeks
9881491|NCT00501241|Experimental|5|120 mg ATI-7505, BID for 4 weeks
9881492|NCT00501280||MSF Women + their children|Blood and urine samples and interviews of Migrant or seasonal farmworker (MSF) woman + their children
9881493|NCT00501280||Non-MSF Women + their Children|Blood and urine samples and interviews of non-MSF women (women who have never worked in agriculture) and their children
9881494|NCT00501319||1|Patients with Non-Small Cell Lung Cancer.
9881495|NCT00501332|Active Comparator|2|
9881496|NCT00501371|Active Comparator|MCS|Group A: MCS 30 mg/day for 12 weeks
9881497|NCT00501371|Placebo Comparator|Placebo|Placebo, 2 capsules per day
9881498|NCT00501410|Experimental|FOLFOX + Dasatinib + Cetuximab|5-FU 2400 mg/m^2 by vein over 46 Hours On Days 1 & 2. Cetuximab initial dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8. Dasatinib 100 mg by mouth daily on days 1-14. Leucovorin 400 mg/m^2 by vein on day 1. Oxaliplatin 85 mg/m^2 by vein on day 1.
9881499|NCT00501449||Multiple Endocrine Neoplasia (MEN)|Patients with multiple endocrine neoplasia (MEN).
9988749|NCT01425866|Active Comparator|Initial self-management education|Initial self-management group education: 1 to 7 sessions (< 3 months), based on individual assessment.
9881500|NCT00501462|Other|Mild renal impairmnent|
9881501|NCT00501462|Other|moderate renal impairment|
9988750|NCT01425905|Experimental|Depression Prevention|
9988751|NCT01425905|Active Comparator|Health Education|
9988752|NCT01425918|Experimental|Social Enhancement Intervention|"For 5 months children will come in 4 days a week for 2-2.5 hours a session to participate in a classroom in an attempt to increase social communication and understanding.~Parent education sessions once a week for 2 hours each session over the 5-month period."
9988753|NCT01425918|Active Comparator|Parent Education|o Parent education sessions once a week for 2 hours each session over the 5-month period.
9881502|NCT00501462|Other|Normal renal function|
9881503|NCT00501527|Experimental|A: Biological vaccine|The first active arm will receive a dose that is 10x less than the dose of the other arm
9881504|NCT00501527|Experimental|B: biological vaccine|The first active arm will receive a dose that is 10x more than the dose of the other arm
9881505|NCT00501527|Placebo Comparator|C|
9881506|NCT00501618|Other|Fazaclo|open label switch from generic clozapine to Fazaclo
9881507|NCT00501657|Experimental|Sitagliptin (100mg)|Active drug (sitagliptin)
9881508|NCT00501657|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
9881509|NCT00501670||Group A|Collection of lesion samples and blood sampling from subjects aged >=50 years with clinically diagnosed herpes zoster
9881510|NCT00501696|Other|1|A randomized placebo-controlled, parallel-group study, crossover-design
9881511|NCT00501696|Other|2|A randomized placebo-controlled, parallel-group study, crossover-design
9881512|NCT00501748|Experimental|Rituximab|
9881513|NCT00501761||1: Endometrial Cancer Survivors|
9881514|NCT00501761||2: Healthy Participants|Healthy participants that have no history of invasive cancer.
9881515|NCT00501787|Active Comparator|Group B|Non-tailoring
9881516|NCT00501787|Active Comparator|Group A|Tailoring
9881517|NCT00501800||Caucasian|
9881518|NCT00501800||African American|
9881519|NCT00501800||Chinese|
9881520|NCT00501800||Latina (Mexican or Central American)|
9881521|NCT00501800||Filipina|
9881522|NCT00501813|Active Comparator|surgery|initial palliative hepatectomy followed by TACE and/or local regional treatment
9881523|NCT00501813|Experimental|no surgery|TACE combined with local regional treatment without hepatectomy
9881524|NCT00501839|Active Comparator|Group A|Cyclic progestogens for nine months
9881525|NCT00501839|Active Comparator|Group B|CC treatment for further three cycles at the same ovulating doses followed by six months of cyclic progestogens
9881526|NCT00501839|Active Comparator|Group C|CC administration at the same ovulating doses for nine cycles
9881527|NCT00501865|Experimental|Sequence AB|Subjects will be randomized to sequence AB, where A represents fasted state and B represents fed state. Subjects will be administered a single oral dose of GW273225 50 milligrams (mg) in the fasted state in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 2. There will be at least 21 days between doses for the fasted and fed treatment phases of the study.
9881528|NCT00501865|Experimental|Sequence BA|Subjects will be randomized to sequence BA, where A represents fasted state and B represents fed state. Subjects will be orally administered a single dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg in the fasted state in dosing period 2. There will be at least 21 days between doses for the fed and fasted treatment phases of the study.
9881529|NCT00501904|Active Comparator|Group A|Short protocol
9881530|NCT00501904|Active Comparator|Group B|Long protocol
9881531|NCT00501956|Experimental|Intradialytic parenteral nutrition|Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
9881532|NCT00501956|No Intervention|Control Group|Observation over 28 weeks (16 + 12 weeks).
9881533|NCT00501982|No Intervention|1|N Cpap in delivery room and than rescue curosurf in case of need
9881534|NCT00501982|Experimental|2|Poractant alfa (Curosurf) + N Cpap in delivery room
9881535|NCT00502021|Experimental|1|Supplement of flaxseed powder (60 g/day)during 12 weeks
9881536|NCT00502021|Placebo Comparator|2|Placebo powder supplement 60 g/day during 12 weeks
9881537|NCT00502021|Experimental|3|Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks
9881538|NCT00502021|Placebo Comparator|4|Safflower oil 30 ml/day (no ALA) during 12 weeks
9881539|NCT00502034|Experimental|A-immunotherapy|Immunotherapy with interferon-alpha and interleukin
9881540|NCT00502034|No Intervention|B-follow-up|Wait-and-see
9988754|NCT01425931||Extracorporeal circulation|all patients were measured by microcirculation device O2C
9988755|NCT01425957|Other|MCI Patient with Lumbar puncture|PartB: Patients affected by amnestic Mild Cognitive Impairment (aMCI).
9988756|NCT01425983|Active Comparator|amino acid composition (asn01)|Dietary supplement: specific amino acid composition with micronutrients
9988757|NCT01425983|Placebo Comparator|Sugar powder|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties.
9988758|NCT01425996|Experimental|Lipotecan® (TLC388)|"Dosage form: 40mg TLC388 base/vial lyophilized cake Dose: Chemotherapy, i.v. q.w. x 6 doses (dose-escalation)~* The dosage regimen would be escalated gradually until MTD had been found out."
9988759|NCT01426022|Placebo Comparator|Alcohol|"3 glasses of sparkling white wine (30g alcohol) with dinner~3 glasses of alcohol free sparkling white wine (<2g alcohol) with dinner"
9988760|NCT01426022|Experimental|Ambiance|"Pleasant ambiance~Unpleasant ambiance"
9988761|NCT01426035|Experimental|GROUP 1|
9988762|NCT01426035|Active Comparator|GROUP 2|
9988763|NCT01426048||Patients operated on with the TVT|
9988764|NCT01426061|Experimental|Reflexology plus conventional treatment|
9988765|NCT01426061|Experimental|Homeopathy plus conventional treatment|
9988766|NCT01426061|No Intervention|Conventional treatment|
9881541|NCT00502086|Experimental|I|Viusid, three sachets daily during 96 weeks
9881542|NCT00502086|Placebo Comparator|2|Placebo three sachets daily during 96 weeks
9881543|NCT00502099|Active Comparator|1|Pegylated interferon alpha 2a plus ribavirin
9881544|NCT00502099|Active Comparator|2|Pegylated interferon alpha 2b plus ribavirin
9881545|NCT00502112|Experimental|1|lintuzumab and lenalidomide
9881546|NCT00502125||Patients with oral lesions|
9881547|NCT00502138|Experimental|A|Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion
9988767|NCT01426087|Experimental|endoscopic and somatostatin treatment|
9988768|NCT01426087|Other|endoscopic therapy|
9988769|NCT01426100|Experimental|CKD-828 40/2.5mg|
9988770|NCT01426100|Experimental|CKD-828 40/5mg|
9988771|NCT01426100|Active Comparator|Telmisartan 80mg|
9881548|NCT00502177||Quality of Life Questionnaire|Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their parents/caregivers.
9881549|NCT00502190|Experimental|1|Silicon ring positioned in the vagina, around the cervix
9881550|NCT00502190|Experimental|2|Silicon ring positioned in the vagina, around the cervix
9881551|NCT00502229|Active Comparator|Group A|Continuing treatment
9881552|NCT00502229|Active Comparator|Group B|Gonadotrophins
9881553|NCT00502255|Experimental|telemonitoring|Health Buddy in patients home situation
9881554|NCT00502255|Experimental|usual care|patients receive care as usual
9881555|NCT00502268|Placebo Comparator|Group 1|Doxercalciferol administration by DOQI and 2nd Gen PTH assay
9881556|NCT00502268|Active Comparator|Group 2|Doxercalciferol administered by 1-84-7-84 ratio between 1.4-1.6
9988772|NCT01426126|Experimental|Genexol PM|Genexol PM intravenous infusion every 3 weeks
9988773|NCT01426139|Experimental|Biotronik Orsiro DES|
9988774|NCT01426152||Low level progesterone group (1)|Progesterone < 1.50 ng/mL on day of ovulation induction
9988775|NCT01426152||Medium level progesterone group (2)|Progesterone 1.51-1.99 ng/mL on the day of ovulation induction
9881557|NCT00502281|Active Comparator|Group A|COS followed by TI
9881558|NCT00502281|Active Comparator|Group B|COS followed by IUI
9881559|NCT00502372|Experimental|Enriched product, dietary supplement|Subjects receiving enriched product compared to an unenriched product
9881560|NCT00502372|Active Comparator|1|Subjects not receiving enriched product
9881561|NCT00502411|Experimental|Doxorubicin + Radiation Therapy|Doxorubicin 17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4. Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
9881562|NCT00502502||Symptom-Related Cytokines Questionnaire|
9881563|NCT00502528|Placebo Comparator|1|Placebo
9881564|NCT00502528|Active Comparator|2|BQ-123
9881565|NCT00502541|Experimental|Fluocinolone acetonide|Fluocinolone acetonide intravitreal implant
9881566|NCT00502541|Active Comparator|Standard of Care|Standard of care
9881567|NCT00502554|No Intervention|1|Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
9881568|NCT00502554|Active Comparator|2|2-day cycles of photopheresis every 3 weeks for 3 months
9881569|NCT00502580||1|Patients with lesions of the oral cavity mucosa.
9881570|NCT00502606||patients with provisional crowns|the same patient would serve as control and test
9881571|NCT00502619|Experimental|Acupuncture plus Treadmill Exercise|Acupuncture plus Treadmill Exercise
9881572|NCT00502632|Experimental|1|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
9881573|NCT00502632|Placebo Comparator|2|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
9881574|NCT00502684|Experimental|1|Peri-operative etodolac and propranolol as described in protocol
9881575|NCT00502684|Placebo Comparator|2|peri-operative placebo as described in protocol
9881576|NCT00502723|Active Comparator|2|Radical laparoscopy prostatectomy
9881577|NCT00502723|Experimental|1|Radical retropubic prostatectomy
9881578|NCT00502736|Experimental|1|
9881579|NCT00502749|Experimental|Exercise program|Daily (Monday-Friday) 45-minute group physical exercise program during each hospital admission for three months or individual 20 minute session bedside.
9881580|NCT00502814||1|Patients with Breast Cancer.
9881581|NCT00502827|Other|Recommended Standard of Care|Recommended Standard of Care (RSOC) = Physician Advice + Written Materials
9881582|NCT00502827|Other|RSOC + Cell Phone Intervention|Recommended Standard of Care (RSOC) + Cell Phone Intervention
9881583|NCT00502866||breastfed children|children, 6-15 months old, predominately breastfed for at least 6 months without supplemental vitamin D
9881584|NCT00502892|Experimental|Topotecan + Ifosfamide + Carboplatin|
9881585|NCT00502918||1|
9881586|NCT00502970|Experimental|1|16 weeks Interferon Tiw with Ribavirin
9881587|NCT00502970|Active Comparator|2|24 weeks Interferon Tiw with Ribavirin
9881588|NCT00502983||Interview|AML Patients & Healthy Controls
9881589|NCT00503048||1|foster care children
9881590|NCT00503048||2|reference children (living with families)
9881591|NCT00503074|Experimental|1|Parents receive tailored health-behavior change messages designed to reduce their child's exposure to televised food commercials. Intervention is delivered by a case manager, by a website, and by periodic newsletters.
9881592|NCT00503074|Active Comparator|Control|Parents of children ages 2-5 receive behavioral-change counseling around toddler & preschooler safety and injury prevention.
9881593|NCT00503100||NICU full-term early pain group|
9881594|NCT00503100||NICU premature early pain group|
9881595|NCT00503100||NICU premature control group|
9881596|NCT00503100||Soroka- full-term control group|
9881597|NCT00503152|Experimental|benazepril|
9881598|NCT00503152|Experimental|valsartan|
9881599|NCT00503152|Experimental|benazepril/valsartan|
9881600|NCT00503178|Experimental|Patients undergoing imaging guided radiotherapy.|
9881601|NCT00503191|Experimental|Intention-based therapy treatment for autism|NeuroModulation Technique
9881602|NCT00503204|Experimental|1|Lomustine + Cediranib (AZD2171)
9881603|NCT00503230|Active Comparator|Standard Care Intervention (SCI)|
9881604|NCT00503230|Active Comparator|Culturally Tailored Intervention (CTI)|
9881605|NCT00503256||CLL - Linkage Families|Gene identification related to Chronic lymphocytic leukemia (CLL) development
9881606|NCT00503269|Active Comparator|1|30 ml of 1% Lignocaine with 1:10,000 Adrenaline
9881607|NCT00503269|Active Comparator|2|Standard General anaesthesia with Enflurane and Propofol.
9881608|NCT00503321|Experimental|Arm B|S-1 plus PSK group
9881609|NCT00503321|Active Comparator|Arm A|S-1 alone
9881610|NCT00503334|Experimental|preOP booster|
9881611|NCT00503334|Placebo Comparator|preOP booster placebo|
9881612|NCT00503347|Experimental|1|0.3 mg/kg
9881613|NCT00503347|Experimental|2|1 mg/kg
9881614|NCT00503347|Experimental|3|3 mg/kg
9881615|NCT00503347|Experimental|4|6 mg/kg
9881616|NCT00503451|Experimental|LBH589|
9881617|NCT00503490|Experimental|1|Inhaled Levofloxacin
9881618|NCT00503490|Placebo Comparator|2|Placebo
9881619|NCT00503516|Experimental|1|Megestrol acetate 160 mg b.i.d. during 24 weeks
9881620|NCT00503516|Placebo Comparator|2|1 sachet of powder of placebo b.i.d. during 24 weeks
9881621|NCT00503542|Experimental|Intervention|Patients primarily with itching or irritation are treated for candidal vaginitis. Patients primarily with vaginal odor are treated for bacterial vaginosis. Patients who did not fit either of the previous groups are treated for both candidal vaginitis and bacterial vaginosis.
9881622|NCT00503542|Active Comparator|Control|Patient are examined and a wet mount is prepared. If a definitive diagnosis is made patient is treated for the condition diagnosed. If no diagnosis is made the clinician has the option of either foregoing treatment (watchful waiting) or following the protocol in the experimental group
9881623|NCT00503568|Experimental|DS-1: gp96-ig Dose Schedule 1|Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10^7 cells bi-weekly, maximum 9 vaccines/patient;
9881624|NCT00503568|Experimental|DS-2: gp96-ig Dose Schedule 3|Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10^7 cells weekly, maximum 18 vaccines/patient;
9881625|NCT00503568|Experimental|DS-3: gp96-ig Dose Schedule 3|Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10^7 cells twice weekly, maximum 36 vaccines/patient
9881626|NCT00503594|Experimental|1|Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.
9881627|NCT00503594|Active Comparator|bras conventional|bras conventional
9881628|NCT00503659|Active Comparator|A|Methacholine challenge, five-breath dosimeter protocol
9881629|NCT00503659|Active Comparator|B|Methacholine challenge five incremental dosages protocol
9881630|NCT00503711|Experimental|100 mg Vandetanib eod|100 mg Vandetanib every other day dosing
9881631|NCT00503711|Experimental|100 mg Vandetanib od|100 mg Vandetanib once daily dosing
9881632|NCT00503711|Experimental|300 mg Vandetanib od|300 mg Vandetanib once daily dosing
9881633|NCT00503737|Active Comparator|Colorectal Cancer Screening Toolkit|Toolbox includes tools and guides designed increase screening by primary care physicians
9881634|NCT00503737|No Intervention|Standard of Care Colorectal Cancer Screening|Primary Care physician will screen for colorectal cancer as per his/her standard practice
9881635|NCT00503789|Active Comparator|1|cow-milk based infant formula
9881636|NCT00503789|Experimental|2|cow milk based infant formula with prebiotics
9881637|NCT00503789|Other|3|human milk reference group
9881638|NCT00503802|Active Comparator|1|Active RF treatment
9881639|NCT00503802|Sham Comparator|2|Sham RF treatment
9881640|NCT00503828|Active Comparator|naproxen|Naproxen 500 mg/day for 4 weeks
9881641|NCT00503828|Experimental|Derris Scandens Benth|Derris Scandens Benth
9881642|NCT00503854||Observational (questionnaire)|Patients complete a questionnaire on days 1, 2, and 6 regarding fatigue, sleep disturbance, depression, and other symptoms.
9881643|NCT00503893||Wilm's Tumor PO1|Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.
9881644|NCT00503919|Experimental|MDC|Multi-spectral Digital Colposcopy for Fluorescence Spectroscopy
9881645|NCT00503932|Experimental|Proton Therapy + Capecitabine|Capecitabine 825 mg/m^2 by mouth twice daily on Proton Therapy (radiation) days.
9881646|NCT00503971|Experimental|Vorinostat plus erlotinib|Vorinostat plus erlotinib
9881647|NCT00504010|Active Comparator|1|arnica containing cream
9881648|NCT00504010|Placebo Comparator|2|carrier cream without arnica
9930962|NCT00933530|Experimental|Cohort 5 - Dose Level E (1.0g/day)|"1.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 1.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 1.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
9881649|NCT00504036|Experimental|Intra-gastric balloon|Patients will receive either an air-filled or water-filled intra-gastric balloon.
9881650|NCT00504036|No Intervention|Usual care|Usual care will be given to the patients.
9881651|NCT00504114||1|Healthy volunteers without knee pain.
9881652|NCT00504114||2|Patients with mild arthritic symptoms and radiographic changes (Kellgren Lawrence score of 1, 2)
9881653|NCT00504114||3|Patients with severe pain and functional limitations associated with knee arthritis (Kellgren Lawrence score of 3, 4).
9881654|NCT00504114||4|Patients with acute anterior cruciate ligament (ACL) injuries with associated osseous contusion.
9881655|NCT00504114||5|Patients with posttraumatic knee injury or degenerative condition and will have cartilage resurfacing procedures.
9881656|NCT00504127|Experimental|naproxcinod 375 mg bid|
9881657|NCT00504127|Experimental|naproxcinod 750 mg bid|
9881658|NCT00504127|Active Comparator|naproxen 500 mg bid|
9881659|NCT00504127|Placebo Comparator|placebo|
9881660|NCT00504140|Experimental|Interferon Alpha + Etoposide|Interferon Alpha 5x10^6 mu/m^2 subcutaneously and Etoposide 100 mg/m^2 intravenously, both daily for 5 days
9881661|NCT00504296|Experimental|SB939|
9881662|NCT00504322|Placebo Comparator|placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
9881663|NCT00504322|Active Comparator|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
9881664|NCT00504335|Experimental|500 BIO 300 capsule|The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting
9881665|NCT00504335|Experimental|1000 BIO 300 capsule|the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program
9881666|NCT00504335|Experimental|1500 BIO 300 capsule|the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program
9881667|NCT00504335|Experimental|2000 BIO 300 capsule|the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program
9881668|NCT00504361||1: Lung Disease|Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
9881669|NCT00504361||2: Normal Control|Individuals without a history of lung disease.
9881670|NCT00504374||Symptoms Questionnaire|Patients with lung cancer.
9881671|NCT00504387||A: Patients|Patients with a primary burning mouth disorder Pain (VAS 0-10): 3<x<9 Patient understands and speaks german Age: >18 years
9881672|NCT00504387||B: Controls|Age and sex matched persons/patients who do not have any history of an oral burning sensation or a burning mouth disorder.
9881673|NCT00504400|Experimental|A|
9881674|NCT00504439|Experimental|Cohort 1|Subjects in Cohort 1 will receive 20 milligrams (mg) of SB-656933-AAA once daily or matching placebo once daily for 14 days.
9881675|NCT00504439|Experimental|Cohort 2|Subjects will be administered 40 mg simvastatin on day 1 followed by a washout period of two days. From day 3, the subjects will receive 50 mg of SB-656933-AAA once daily or matching placebo once daily for 14 days. On day 17, subjects will be administered 40 mg simvastatin along with SB-656933-AAA to assess statin interaction.
9881676|NCT00504439|Experimental|Cohort 3|Subjects will be administered 100 mg SB-656933-AAA/ day or matching placebo for 14 days. Dosing will initiate after cohort I and II have completed dosing.
9881677|NCT00504478|Experimental|1|8-weeks of high complex carbohydrate diet
9881678|NCT00504478|Experimental|2|omega-3 fatty acids supplements
9881679|NCT00504491|Experimental|1|"Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(*) (**) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5~(**) 1st course, 375 mg/m2 (*) If lymphocyte count is > 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1"
9881680|NCT00504543|Active Comparator|Neoral|
9881681|NCT00504543|Active Comparator|AEB071 high dose with Cetican reduced dose|
9881682|NCT00504543|Active Comparator|AEB071 low dose with Cetican standard dose|
9881683|NCT00504621||sarcoidosis|Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
9988776|NCT01426152||High level progesterone group (3)|Progesterone > 1.99 ng/mL on the day of ovulation induction
9988777|NCT01426165|Experimental|Magnesium 8 grams over 4 hours|
9881684|NCT00504621||pulmonary fibrosis|Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
9881685|NCT00504634|Experimental|Bortezomib|1 mg/m^2 intravenous (IV) Days 1, 4, 8, and 11.
9881686|NCT00504686|Active Comparator|1|manual therapy - thoracic spine thrust manipulation
9881687|NCT00504686|Active Comparator|2|therapeutic exercise
9881688|NCT00504699|Experimental|letrozole|ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
9881689|NCT00504699|No Intervention|control|No ovarian stimulation before breast cancer treatment
9881690|NCT00504712|Experimental|Active|Testosterone 200 mg intramuscular every 2 weeks
9881691|NCT00504712|Placebo Comparator|Placebo|Saline
9881692|NCT00504790|Experimental|GSK923295|anti-mitotic compound under study
9881693|NCT00504803|Experimental|1|MSC co-infusion with either HLA-mismatched PBSC or cord blood
9881694|NCT00504816|Other|Brevicon|Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.
9881695|NCT00504816|Experimental|GSK189075|Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.
9881696|NCT00504855|Active Comparator|Gortex (Waterproof) Cast Padding|Randomized application of one of two cast padding materials
9881697|NCT00504855|Active Comparator|Cotton/Cotton-Poly Cast Padding|Randomized application of one of two cast padding materials
9881698|NCT00504907|Experimental|Cohort A|Placebo or BTA9881 -10mg
9881699|NCT00504907|Experimental|Cohort B|Placebo or BTA9881 - 10mg
9881700|NCT00504907|Experimental|Cohort C|Placebo or BTA9881 - 25mg
9881701|NCT00504907|Experimental|Cohort D|Placebo or BTA9881 - 50mg
9881702|NCT00504907|Experimental|Cohort E|Placebo or BTA9881 - 100mg
9881703|NCT00504907|Experimental|Cohort F|Placebo or BTA9881 - 200mg
9881704|NCT00504907|Experimental|Cohort G|Placebo or BTA9881 - 400mg
9881705|NCT00504920||Symptom Assessment|Drawing blood samples and matching the test results with questionnaire responses for symptoms patients experience from transplant treatment.
9881706|NCT00504933|Experimental|A|Bilastine
9881707|NCT00504933|Active Comparator|B|Cetirizine
9881708|NCT00504933|Placebo Comparator|C|Placebo
9881709|NCT00504946|Active Comparator|I|
9881710|NCT00504946|Active Comparator|II|
9881711|NCT00504946|Placebo Comparator|III|
9881712|NCT00504946|Active Comparator|A|
9881713|NCT00504946|Placebo Comparator|B|
9881714|NCT00504959|Experimental|1|ranibizumab
9881715|NCT00504972|Experimental|Study Treatment|This study is a single arm study
9881716|NCT00504998|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
9881717|NCT00504998|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
9881718|NCT00504998|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
9881719|NCT00504998|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
9881720|NCT00504998|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
9881721|NCT00505024|Experimental|IVRS Only|
9881722|NCT00505024|Experimental|IVRS + Symptoms Report|
9881723|NCT00505037|Experimental|ASP1585 dose #1|
9881724|NCT00505037|Experimental|ASP1585 dose #2|
9881725|NCT00505037|Experimental|ASP1585 dose #3|
9881726|NCT00505037|Placebo Comparator|Placebo|
9881727|NCT00505037|Active Comparator|Sevelamer hydrochloride|
9881728|NCT00505050|No Intervention|1|Standard follow-up medical visits and treatment for control group were performed during the study period by the same cardiologist team that was not informed of the randomization.
9881729|NCT00505063|Other|A|Immunization Schedule patients <7 years.
9881730|NCT00505063|Other|B|Immunization Schedule patients > or = to 7 years and <11 years of age
9881731|NCT00505063|Other|C|Immunization Schedule patients > or = to 11 years of age
9881732|NCT00505089|Experimental|1|ACZ885 10mg/kg subcutaneous
9881733|NCT00505089|Experimental|2|ACZ885 5mg/kg intravenous
9881734|NCT00505089|Experimental|3|ACZ885 2mg/kg subcutaneous
9881735|NCT00505089|Experimental|4|ACZ885 1mg/kg intravenous
9881736|NCT00505102|Active Comparator|A|
9881737|NCT00505128|Other|1|to test the interest of early bile duct decompression by endoscopic sphincterotomy after early non invasive diagnosis by endosonography or MR cholangiography
9881738|NCT00505154|Placebo Comparator|2|Placebo tablets
9881739|NCT00505154|Active Comparator|1|rosuvastatin
9881740|NCT00505167|Active Comparator|1|Patients randomized to receive memantine
9881741|NCT00505167|Active Comparator|2|Patients randomized to receive donepezil
9881742|NCT00505232|Experimental|Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin|Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)
9881743|NCT00505245||Observational (questionnaire, QOL assessment, interview)|Participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.
9881744|NCT00505271|Experimental|1|Escalating doses of Rexin-G will be given two or three times a week for four weeks, with a 2 week rest period
9881745|NCT00505297||A|Subjects with potentiall rapidl progressing OA
9881746|NCT00505297||B|Age-matched healthy subjects with no knee pain
9881747|NCT00505336|Experimental|1|Eplerenone
9881748|NCT00505336|Active Comparator|3|no additional treatment
9881749|NCT00505336|Experimental|2|Atorvastatin
9881750|NCT00505349|No Intervention|No Intervention Arm|Phase I in this study will involve the evaluation of blood-derived neurotrophic factors in healthy, younger adults (18-30.) Individuals in this group will not undergo computerized, cognitive training.
9881751|NCT00505349|Experimental|Cognitive Training|Phase II of this study will involve an evaluation of the pre- and post- cognitive training levels of blood-derived neurotrophic factors in healthy, mature adults. Participants randomized to this arm will receive SAAGE-based computerized cognitive training.
9881752|NCT00505401|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
9881753|NCT00505401|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.
9881754|NCT00505440|Experimental|Computerized screening and referral|Computerized screening and referral: Intervention is a web-based screening and assessment tool completed by adolescents during primary care visits. Patient reported screening provided to primary care physicians in real time with recommendations for behavioral referrals.
9881755|NCT00505440|Active Comparator|Delayed feedback from screening|Active comparator is Usual pediatric care plus mailed screening results from computerized waiting room screens that arrive three days after screening.
9881756|NCT00505492|Experimental|Radiation + Chemotherapy|Radiation with weekly Cisplatin 40 mg/m^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m^2 IV) Chemotherapy every 28 days
9881757|NCT00505505|Experimental|A|Insulin infusion rate titrated to maintain glycemia between 80 and 100 mg/dl
9881758|NCT00505505|Active Comparator|B|Insulin infusion rate titrated to maintain glycemia between 80 and 220 mg/dl
9881759|NCT00505531||Tramadol ER- 200mg|Tramadol Extended Release capsules Weeks 1 & 6- 100 mg/day Weeks 2-5- 200 mg/day
9881760|NCT00505531||Tramadol ER- 300mg|Tramadol Extended Release capsules Weeks 1 & 7- 100 mg/day Weeks 2 & 6- 200 mg/day Weeks 3-5- 300 mg/day
9881761|NCT00505531||Placebo|Diphenhydramine capsules Weeks 1-6- 25 mg/day
9881762|NCT00505544||Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
9881763|NCT00505544||Questionnaire + Actigraphs|Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.
9881764|NCT00505570|No Intervention|Medical Management|
9881765|NCT00505570|Experimental|PFO Closure|
9881766|NCT00505596|Experimental|Computerized decision aid|Participants instructed to view the updated PT Tool and told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study (Informed free choice). They also participate in a baseline pre-randomization interview and one follow-up telephone interview.
9881767|NCT00505596|No Intervention|Usual care|Control group, in which participants receive no intervention beyond a baseline pre-randomization interview and one follow-up telephone interview.
9881768|NCT00505609|Experimental|A|The Institute for Reproductive Health trained health providers in teaching the Standard Days Method to study subjects and in study procedures. Providers counseled study participants in method use. Participants were followed for up to 13 cycles of method use.
9881769|NCT00505713|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
9881770|NCT00505713|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
9881771|NCT00505713|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
9881772|NCT00505713|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
9881773|NCT00505713|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
9881774|NCT00505726||Confocal Microscopy|
9881775|NCT00505739|Experimental|Mifepristone|
9881776|NCT00505791|Placebo Comparator|Sugar pill|Lactose, NF (monohydrate)
9881777|NCT00505791|Active Comparator|Nesiritide|Natrecor (nesiritide) is a commercially available B-type natriuretic peptide which is indicated for intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
9881778|NCT00505804|Experimental|1|
9881779|NCT00505804|Active Comparator|2|
9881780|NCT00505830||1|50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
9881781|NCT00505830||2|50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
9881782|NCT00505830||3|50 adolescents with psychiatric disorders but no autism syndrom.
9881783|NCT00505830||4|Sample of 50 healthy adolescents selected randomly from 200.
9881784|NCT00505843|Other|1|7mg MK0657 capsules + >/=1.0 mg/kg/hr dose of levodopa.
9881785|NCT00505843|Other|2|7mg MK0657 Pbo capsules + >/=1.0 mg/kg/hr dose of levodopa.
9881786|NCT00505869||1|Health & Wellness Intervention + Questionnaire
9881787|NCT00505869||2|Mood Management Intervention + Questionnaire
9930963|NCT00933530|Experimental|Cohort 6 - Dose Level F (2.0g/day)|"2.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 2.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 2.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
9930964|NCT00933530|Experimental|Cohort 7 - Dose Level G (3.0g/day)|"3.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 3.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 3.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period."
9930965|NCT00933556|Experimental|probiotic|subjects will be given a powder formulation of a probiotic VSL#3 to be taken once a day, at a dose of 6 gms
9930966|NCT00933556|Placebo Comparator|sugar pill|placebo identical to the active product will be given
9930967|NCT00933569|Experimental|Dermacyd Silver Floral (Lactic Acid)|Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
9930968|NCT00933595|Experimental|Smoking Cessation|The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
9930969|NCT00933621|Experimental|Autologous Bone Marrow infusion|Percutaneous intracoronary autologous bone marrow infusion
9930970|NCT00933634|Experimental|electrical cardioversion|Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
9930971|NCT00933634|Active Comparator|propafenone|Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
9930972|NCT00933647|Experimental|Yerba Mate Tea|Subjects will drink 1000ml/day of yerba mate tea for 8 weeks.
9930973|NCT00933647|Active Comparator|Green Tea|Subjects will drink 1000ml/day of green tea for 8 weeks.
9930974|NCT00933647|Placebo Comparator|Apple Tea|Subjects will drink 1000ml/day of apple tea for 8 weeks.
9930975|NCT00933660|Active Comparator|Control-1|ERC-training by instructor
9930976|NCT00933660|No Intervention|Control-2|No intervention
9930977|NCT00933660|Experimental|Experimental-1|Web-based training only
9988778|NCT01426165|Experimental|Magnesium 8 grams over 8 hours|
9881788|NCT00505882|Active Comparator|Insulin|
9881789|NCT00505882|Experimental|Pramlintide|
9881790|NCT00505947|Active Comparator|A|"Infliximab 5 mg/Kg body weight by intravenous infusion on visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, arm A will receive placebo at visits 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
9881791|NCT00505947|Placebo Comparator|B|"Arm B will receive placebo at visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, group B will receive infliximab 5 mg/Kg body weight by intravenous infusion at visit 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
9881792|NCT00505960|Experimental|1|
9881793|NCT00505999||Questionnaire|Patients diagnosed with Multiple Myeloma and healthy controls.
9881794|NCT00506012|Experimental|1|T2000
9881795|NCT00506051|Experimental|ZD6474 (vandetanib) 100mg|
9881796|NCT00506051|Experimental|ZD6474 (vandetanib) 300mg|
9881797|NCT00506090|Experimental|A|pulsed dye laser and dynamic cooling device at 3 weeks intervals
9881798|NCT00506090|Active Comparator|B|pulsed dye laser and dynamic cooling device at 6 weeks intervals
9881799|NCT00506090|Sham Comparator|C|dynamic cooling device
9881800|NCT00506181|Active Comparator|X|receiving probiotics
9881801|NCT00506181|Placebo Comparator|Y|
9881802|NCT00506181|No Intervention|Z|
9881803|NCT00506194|Experimental|Insulin|Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
9881804|NCT00506194|Active Comparator|OAD|Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was <70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose >160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
9881805|NCT00506233||Chronic Graft-Versus Host Disease (GvHD)|Participants with chronic graft-versus host disease (GvHD)
9881806|NCT00506246|Experimental|1|Propofol MCT/LCT
9881807|NCT00506246|Active Comparator|2|Propofol LCT
9881808|NCT00506272|Experimental|Standard care|Patients admitted for elective surgery will receive standard diabetes care, including but not limited to finger stick blood glucose determinations, and insulin injections delivered by the nursing staff.
9881809|NCT00506272|Experimental|Patient administered care|Patients will self-monitor and record finger-stick blood glucose measurements, and self administer insulin at doses agreed upon with the consulting endocrinology in-patient service.
9881810|NCT00506298|Experimental|A|CRx-401 (bezafibrate + diflunisal)
9881811|NCT00506298|Active Comparator|B|bezafibrate + placebo
9881812|NCT00506311|Experimental|Fibrin Sealant|
9881813|NCT00506311|No Intervention|No Fibrin Sealant|
9881814|NCT00506363|Experimental|A|pulsed dye laser and dynamic cooling device on the day of suture removal
9881815|NCT00506363|Active Comparator|B|pulsed dye laser and dynamic cooling device 2 months after suture removal
9881816|NCT00506363|Sham Comparator|C|dynamic cooling device
9881817|NCT00506376||Surgical Treatment Preferences|Assessment of patient's feelings toward risks associated with surgical treatment of cervical cancer.
9881818|NCT00506402|Experimental|1|
9881819|NCT00506467||VRI System|Vibration Response Imaging (VRI) System
9881820|NCT00506480|Experimental|OD|patients artificially prepared for OD will undergo a mock cycle consisting of estrogen and later by progesterone. a pipelle sample will be taken after 6 days of progesterone supplementation.
9881821|NCT00506480|Experimental|IVF|A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
9881822|NCT00506506|Experimental|1|N-acetylcysteine 1200 mg twice daily x 48 hours
9881823|NCT00506506|Placebo Comparator|2|
9881824|NCT00506545|Experimental|SCH 619734|
9881825|NCT00506545|Placebo Comparator|Placebo|
9881826|NCT00506558|Experimental|A|Ventral Decompression and Instrumented Fusion
9881827|NCT00506558|Active Comparator|B|Dorsal Decompression with or without fusion
9881828|NCT00506584|Experimental|Group 1, arm 1|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day, where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
9881829|NCT00506584|Experimental|Group1, Arm 2|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 40 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
9881830|NCT00506584|Active Comparator|Group 1, Arm 3|Human breast milk + bovine-based human milk fortifier (initiated when nutrition volume reaches 100 mL/kg/day) + pre-term formula (as needed)
9930978|NCT00933660|Experimental|Experimental-2|Web-based training with a personal training manikin
9881831|NCT00506584|Experimental|Group 2, Arm 1|Prolact20/Neo20 + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
9881832|NCT00506584|Active Comparator|Group 2, Arm 2|Pre-term/term formula (minimum 20 cal/oz)
9881833|NCT00506701|Experimental|Tadalafil treatment 40 mg|
9881834|NCT00506727|Experimental|Adderall XR|
9881835|NCT00506727|Active Comparator|Atomoxetine hydrochloride|
9881836|NCT00506740|Active Comparator|Electrocautery|Elesurgical instruments are used to cut and coagulate tissue using alternatig electric current focusing intense heat at the surgical site. In electrosurgery, the patient is included in the circuit and current enters the patient's body.
9881837|NCT00506805|Experimental|Single Arm|
9881838|NCT00506818|Active Comparator|2|Intensive risk factor intervention
9881839|NCT00506870|No Intervention|1|Conventional follow-up of anticoagulation
9881840|NCT00506870|Experimental|2|Self-monitoring of anticoagulation
9881841|NCT00506896|Active Comparator|1|
9881842|NCT00506935|Experimental|1|GVG
9881843|NCT00506935|Placebo Comparator|2|placebo
9881844|NCT00506961|Active Comparator|1|10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
9881845|NCT00506961|Active Comparator|2|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
9881846|NCT00506987|Experimental|SCH 486757|
9881847|NCT00506987|Placebo Comparator|Placebo|
9881848|NCT00507000|Active Comparator|A, Cholecalciferol|A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
9881849|NCT00507000|Placebo Comparator|Vitamin D and Tuberculosis|B, Lactose
9881850|NCT00507013|Other|2|
9881851|NCT00507039||grass allergy, bronchial challenge|subjects with known allergy against grass-pollen undergo bronchial challenges
9881852|NCT00507065|Experimental|Adderall XR (10 mg)|
9881853|NCT00507065|Experimental|Adderall XR (20 mg)|
9881854|NCT00507065|Experimental|Adderall XR (30 mg)|
9881855|NCT00507065|Experimental|Adderall XR (40 mg)|
9881856|NCT00507065|Placebo Comparator|placebo|
9881857|NCT00507091|Experimental|ZD6474 (vandetanib) 100mg|
9881858|NCT00507091|Experimental|ZD6474 (vandetanib) 300mg|
9881859|NCT00507117|Active Comparator|PSG|
9881860|NCT00507156|Experimental|Mek postcon|Re-opening of the infarcted coronary artery by several balloon inflations separated by reperfusion of the vessel.
9881861|NCT00507156|Active Comparator|Standard treatment|Standard treatment (primary PCI)
9881862|NCT00507182|Experimental|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
9881863|NCT00507221|Experimental|1|Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.
9881864|NCT00507221|Active Comparator|2|Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.
9881865|NCT00507247|Experimental|Daptomycin|6mg/kg/day intravenous (IV) for 10 days
9881866|NCT00507260|Experimental|Control Group|Control Group (Food Record)
9881867|NCT00507260|Experimental|Treatment Group|Treatment Group (Food Record + Nutritional Consults)
9881868|NCT00507273||GIST|Patients diagnosed with a gastrointestinal stromal tumor (GIST)
9881869|NCT00507312|Active Comparator|1|Healthy subjects (with no evidence of cardiovascular disease).
9881870|NCT00507312|Experimental|2|Patients with risk factors for heart failure
9881871|NCT00507312|Experimental|3|Patients with heart failure
9881872|NCT00507325||Blood Sample + Tumor Sample|Blood samples will be collected. Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
9881873|NCT00507338|Experimental|ARC1779 low dose|0.1 mg/kg
9881874|NCT00507338|Experimental|ARC1779 mid dose|0.3 mg/kg
9881875|NCT00507338|Experimental|ARC1779 high dose|1.0 mg/kg
9881876|NCT00507338|Active Comparator|abciximab|labeled regimen for primary PCI
9881877|NCT00507351||Cancer Pain Management|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.
9881878|NCT00507390|Active Comparator|A1|n-3 PUFAs
9881879|NCT00507390|Placebo Comparator|A2|olive oil capsules
9881880|NCT00507403|Active Comparator|Infliximab|Infliximab
9881881|NCT00507403|Experimental|Infliximab +methotrexate|Infliximab +methotrexate
9881882|NCT00507572||Observational (medical chart review)|Patients' medical records are reviewed prospectively and retrospectively.
9881883|NCT00507585|Experimental|Oxaliplatin + Fluorouracil + Leucovorin + Avastin|
9881884|NCT00507611|Other|Single-arm|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
9881885|NCT00507637|Experimental|NT 201 (IncobotulinumtoxinA/Xeomin®)|
9881886|NCT00507650|Active Comparator|Prescribed|Fluid volume and type prescribed by MD or provider.
9881887|NCT00507650|Experimental|Supplemental|Fluid volume and type prescribed by physician or provider plus 10 ml/kg X 5 days.
9881888|NCT00507663|Experimental|Atenolol|Atenolol given prior to and for up to 7 days after surgery
9881889|NCT00507663|No Intervention|routine care|routine clinical care
9881890|NCT00507676||Group 1|One hundred and sixty healthy infants between 1 and 24 months of age will be evaluated. Subjects will be recruited so that there are 40 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. The ethnic composition will be approximately 80% Caucasian and 20% African-American in each of the four groups, which represents the distribution within the cities where infants will be evaluated. Subjects will be excluded if they were born prematurely (<37 weeks gestation), have a history of congenital cardio-respiratory disease, or have history of lower respiratory illness.
9881891|NCT00507676||Group 2|Eighty infants between 1 and 24 months of age scheduled for CT scans of the abdomen or chest will be evaluated. Subjects will be excluded if they are born prematurely (<37 weeks gestation), have history of congenital cardio-respiratory disease, or have history of recurrent wheezing.
9881892|NCT00507676||Group 3|Eighty infants with recurrent wheezing between 1 and 24 months of age will be evaluated when they are not acutely symptomatic for at least 3 weeks. Subjects will be recruited so that there are 20 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. Subjects will be excluded if they were born prematurely (<37 weeks gestation) or have history of congenital cardio -respiratory disease.
9881893|NCT00507715|Experimental|1|Plantago ovata husk
9881894|NCT00507715|Placebo Comparator|2|hemicellulose crystalline
9881895|NCT00507754||Latent Tuberculosis Infection|Patients with cancer at risk for developing active tuberculosis (TB).
9930979|NCT00933673|Experimental|L-DICE|
9930980|NCT00933699|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Treatment duration: 21 consecutive days
9998322|NCT01517191||Influenza Negative Control|Control Controls are hospitalized adults who have tested negative for influenza.
9930981|NCT00933712|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
9930982|NCT00933725|Experimental|TCM intervention|Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone
9930983|NCT00933725|Active Comparator|Western intervention|Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs
9930984|NCT00933751||Patients before emergent major abdominal surgery|
9930985|NCT00933777|Experimental|Therapy with everolimus and sorafenib|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
9930986|NCT00933790|Active Comparator|2EHRZ3/4HR3|Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
9930987|NCT00933790|Experimental|2EHRZ7/4HR7|Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily)
9930988|NCT00933790|Experimental|2EHRZ7/4HR3|Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)
9930989|NCT00933816|Experimental|Sorafenib with Low-dose FP|
9930990|NCT00933829|Placebo Comparator|Non-absorbable arm|uses non-absorbable suture such as Prolene to repair lacerations
9930991|NCT00933829|Active Comparator|Absorbable Suture Arm|uses absorbable sutures to repair lacerations
9930992|NCT00933842|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Dermacyd PH_DESILSTY_FL (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
9881896|NCT00507832|Active Comparator|I|"Interindividual design:~active and comparator (one side each) applied twice daily"
9881897|NCT00507832|Active Comparator|II Hydrocortisone|Hydrocortisone, twice daily
9881898|NCT00507858|Experimental|Pemetrexed|Starting dose 500 mg/m^2 IV once every 3 weeks
9881899|NCT00507858|Experimental|Pemetrexed + IV Dexamethasone|Pemetrexed Starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 20 mg intravenous (IV) Day 1.
9881900|NCT00507858|Experimental|Pemetrexed + Oral Dexamethasone|Pemetrexed starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 4 mg orally twice daily for 3 Days.
9881901|NCT00507884||3 Tesla MRI|Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
9881902|NCT00507897||A|Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
9881903|NCT00507897||A1|Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
9881904|NCT00507897||B|Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
9881905|NCT00507897||B1|Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1
9881906|NCT00507949|Experimental|1|Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
9881907|NCT00507949|Placebo Comparator|2|The placebo is the excipient of the experimental drug.
9881908|NCT00507962|Experimental|Cisplatin + Liposomal Doxorubicin|Cisplatin 100 mg/m^2 Intraarterial and Liposomal Doxorubicin starting dose 20 mg/m^2 by vein on Day 1 every 4 weeks
9881909|NCT00507975|Placebo Comparator|A|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
9881910|NCT00507975|Experimental|B|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
9881911|NCT00507988|Experimental|A|Complex Problem Solving Training
9881912|NCT00507988|Active Comparator|B|Basic Cognitive Training
9881913|NCT00508014|Active Comparator|Control|usual care
9881914|NCT00508014|Experimental|Concurrent Peer Review Visit|See description of interventioin
9881915|NCT00508040|Experimental|A|To analyse the potential therapeutic effect of Interferon alpha2a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
9881916|NCT00508040|Active Comparator|B|
9881917|NCT00508053|Active Comparator|1|Mass closure
9881918|NCT00508053|Experimental|2|Small stitches
9881919|NCT00508092|Active Comparator|A|lanz incision appendectomy
9881920|NCT00508092|Active Comparator|B|lanz incision appendectomy
9881921|NCT00508131|Active Comparator|A|Milk fortified with, iron, zinc and vitamin C
9881922|NCT00508131|Placebo Comparator|B|Milk not fortified
9881923|NCT00508170||Patients with Oropharyngeal Cancer|
9881924|NCT00508170||Patients with Non-Oropharyngeal Cancer|
9881925|NCT00508235||Quality of Friendships|Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
9881926|NCT00508248|Active Comparator|A1|1 g omega 3 fatty acid supplements
9881927|NCT00508248|Placebo Comparator|A2|
9881928|NCT00508287|Experimental|A|
9881929|NCT00508287|Active Comparator|B|
9881930|NCT00508287|Placebo Comparator|C|
9881931|NCT00508313||With Lung Cancer|Patients with lung cancer.
9881932|NCT00508313||Healthy Participants|Healthy participants without cancer.
9881933|NCT00508326|Experimental|HAI Paclitaxel|Paclitaxel via Hepatic Artery Infusion (HAI)
9881934|NCT00508339||1|Patients with a diagnosis of soft tissue sarcoma.
9881935|NCT00508352|Experimental|Helical tomotherapy|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
9881936|NCT00508365|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
9881937|NCT00508365|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
9881938|NCT00508378||Interview & Questionnaires|
9881939|NCT00508430|Experimental|1|Low dose group
9881940|NCT00508430|Experimental|2|Middle dose group
9881941|NCT00508430|Experimental|3|High dose group
9881942|NCT00508430|Placebo Comparator|4|
9881943|NCT00508443|Experimental|Radiation Therapy|Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
9881944|NCT00508456|Experimental|Hominex®-2 + Temodar®|Dietary Methionine Restriction (Hominex®-2) Days 1-7 and 15-21 + Temodar® 150 mg/m^2 orally Days 8-15
9881945|NCT00508495|Experimental|Test drug|
9881946|NCT00508495|Active Comparator|Reference drug|
9881947|NCT00508495|Placebo Comparator|Placebo|
9881948|NCT00508508|Experimental|1|Behavioral: IVR
9881949|NCT00508508|Experimental|2|Behavioral: Nurse-Led Group Visits
9881950|NCT00508560|Experimental|Arm 1|Experimental
9881951|NCT00508560|Active Comparator|Arm 2|Active Comparator
9881952|NCT00508573||Lynch Syndrome Registry|Patient that has or is at risk for Lynch Syndrome.
9881953|NCT00508586|Experimental|1|PTC299 with an aromatase inhibitor
9881954|NCT00508599|No Intervention|1|Study 1 is the control arm in which participants continue with their normal activity.
9881955|NCT00508599|Experimental|2.|Study 2 consists of 48 hours of complete bed rest.
9881956|NCT00508612|Active Comparator|1|The 12-lesson Williams LifeSkills anger and stress management workshop (WLS) enhances awareness of thoughts and feelings in stressful situations, and provides training in evaluation, deflection, problem-solving, assertion, saying no, speaking, listening, empathy, and emphasizing positives.
9881957|NCT00508612|Placebo Comparator|2|Control group (will attend regular high school classes)
9881958|NCT00508664|Experimental|A|TP + Radiation (TPF until Feb 2009)
9881959|NCT00508664|Experimental|B|TP + Cetuximab + Radiation (TPF until Feb 2009)
9881960|NCT00508690|Active Comparator|IV|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
9881961|NCT00508690|Active Comparator|Oral/IV|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
9881962|NCT00508703||CT Scan + IMRT Radiation Therapy|
9881963|NCT00508807|Experimental|RTA 402|5 mg PO daily x 21 days
9881964|NCT00508846||HNPCC Patients|
9881965|NCT00508859|Experimental|Active, 1|sertraline
9881966|NCT00508859|Placebo Comparator|Placebo|placebo
9881967|NCT00508885|Experimental|1|Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily
9881968|NCT00508885|Placebo Comparator|2|Placebo
9881969|NCT00508898|Experimental|treatment group|Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
9881970|NCT00508898|Active Comparator|control group|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
9881971|NCT00508911|Experimental|Healthy female subjects|Each subject will be administered a monophasic combined oral contraceptive (COC) containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms for two complete cycles (Day 8 to Day 28) in Session 1. The subjects will be administered COC on Day 8 to Day 28 and GW876008 125 milligrams on Days 1 to 35 in Session 2.
9881972|NCT00508937|Active Comparator|1|
9881973|NCT00508937|Experimental|2|
9881974|NCT00508937|Experimental|3|
9881975|NCT00508937|Experimental|4|
9881976|NCT00508937|Experimental|5|
9881977|NCT00508950|Other|All subjects|All subjects
9881978|NCT00508976|Experimental|3|
9881979|NCT00508976|Experimental|2|
9881980|NCT00508976|Experimental|4|
9881981|NCT00508976|Active Comparator|1|
9881982|NCT00509015|Active Comparator|1|Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
9881983|NCT00509015|Placebo Comparator|2|Placebo: lactose tablets (Albochin)
9881984|NCT00509275|Experimental|1|W0027
9881985|NCT00509275|Experimental|2|W0027
9881986|NCT00509275|Experimental|3|W0027
9881987|NCT00509275|Placebo Comparator|4|Placebo
9881988|NCT00509301|Experimental|1|1.5 mCi/cc
9881989|NCT00509301|Experimental|2|2.0 mCi/cc
9881990|NCT00509301|Experimental|3|2.5 mCi/cc
9881991|NCT00509327|Active Comparator|1|bisacodyl 10mg twice daily from one day preoperative to day three postoperative
9881992|NCT00509327|Placebo Comparator|2|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
9881993|NCT00509340|No Intervention|1|Participants will receive usual clinical care, which may or may not include mental health treatment
9881994|NCT00509340|Experimental|2|Participants will receive cognitive behavioral intervention
9881995|NCT00509379|Experimental|1|All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
9881996|NCT00509405|Placebo Comparator|Potassium citrate|
9881997|NCT00509418|Experimental|A|Viusid, a nutritional supplement, in combination with controlled diet and exercise
9988779|NCT01426243|Active Comparator|Voluntary HIV positive subjects|40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
9988780|NCT01426243|Other|HIV negative subjects|Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year
9988781|NCT01426256|Experimental|Cholecalciferol (Vitamin D3)|Patients will be given 250,000 IU cholecalciferol in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take 50,000 IU oral cholecalciferol every other week for 9 months.
9988782|NCT01426256|No Intervention|Placebo|Patients will be given placebo pills in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take a placebo pill every other week for 9 months.
9988783|NCT01426282|No Intervention|control|
9988784|NCT01426282|Experimental|nurse education|
9988785|NCT01426295|Experimental|Caphosol|
9988786|NCT01426295|Active Comparator|Référence|•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
9988787|NCT01426308||Method Comparison Group|The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
9988788|NCT01426308||Clinical Specificity Group|The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
9988789|NCT01426321|Active Comparator|Imaging guided LV lead positioning|
9988790|NCT01426321|No Intervention|Standard LV lead positioning|The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
9988791|NCT01426334|Experimental|Treatment (dasatinib and cyclosporine)|Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
9988792|NCT01426399|Experimental|LC15-0444|LC15-0444 50mg qd
9988793|NCT01426399|Experimental|Metformin|Metformin 1000mg bid
9988794|NCT01426399|Experimental|LC15-0444+Metformin|LC15-0444 50mg qd +Metformin 1000mg bid
9988795|NCT01426451|Experimental|Theatre intervention|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
9988796|NCT01426451|Experimental|Group tutoring intervention|In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes weekly). Individualized student objectives on reading fluency and math will be implemented (one in math and one in reading per student).
9988797|NCT01426451|No Intervention|No intervention|Classes not participating neither in drama workshops nor in group tutoring activities will fill out a questionnaire as a basis for comparison.
9988798|NCT01426477||Veritas Collagen Matrix|Observational study of subjects who undergo open ventral hernia repair using Veritas Collagen Matrix in an underlay technique.
9988799|NCT01426490|Other|Vitamin C|Vitamin C as control group.
9988800|NCT01426490|Experimental|Vitamin B6|
9988801|NCT01426490|Experimental|Folic acid|
9988802|NCT01426490|Experimental|Vitamin B6 plus folic acid|
9988803|NCT01426542|Experimental|Topiramate|
9988804|NCT01426542|Active Comparator|Control|These infants will undergo surgery, but will not receive topiramate
9988805|NCT01426568|Active Comparator|Course of Multi-Convergent Thearpy|
9988806|NCT01426568|No Intervention|Waiting List for Multi-Convergent Therapy|
9988807|NCT01426607|Experimental|AMO|Adjustable mandibular repositioning appliance
9988808|NCT01426607|Placebo Comparator|placebo|placebo device in upper jaw
9988809|NCT01426620|Experimental|Blueberry powder|This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
9988810|NCT01426633|Experimental|Gemcitabine + Trabectedin|
9988811|NCT01426646|Experimental|S-1 treatment|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
9797267|NCT01590875|Experimental|Adenosine arm|25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
9797268|NCT01590875|No Intervention|Observation arm|25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.
9797269|NCT01590888|Experimental|PBT2 250mg|
9797270|NCT01590888|Experimental|PBT2 100mg|
9797271|NCT01590888|Placebo Comparator|Sugar pill|
9797272|NCT01590979|Active Comparator|Ranolazine|The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
9797273|NCT01590979|Placebo Comparator|Placebo|Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
9797274|NCT01591005|Experimental|CEA with sonolysis|endarterectomy with sonolysis (continual transcranial Doppler monitoring)
9797275|NCT01591005|Placebo Comparator|CEA without sonolysis|endarterectomy without sonolysis
9797276|NCT01591005|Experimental|carotid stenting with sonolysis|carotid stenting with sonolysis (continual transcranial Doppler monitoring)
9797277|NCT01591005|Placebo Comparator|carotid stenting without sonolysis|carotid stenting without sonolysis
9881998|NCT00509418|Active Comparator|B|Controlled diet and exercise
9797278|NCT01591018|Experimental|cardiac surgery with sonolysis|cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring)
9797279|NCT01591018|Placebo Comparator|cardiac surgery without sonolysis|cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring)
9797280|NCT01591044|Active Comparator|R940343 2mg, 2 puffs bid|R343 2mg, 2 puffs bid
9797281|NCT01591044|Placebo Comparator|Placebo|
9797282|NCT01591044|Active Comparator|R940343 1mg, 1 puff bid|R343 1mg, 1 puff bid
9797283|NCT01591161|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
9797284|NCT01591161|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
9797285|NCT01591317|Experimental|Prasugrel - 60 mg/10 mg|Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days
9797286|NCT01591317|Experimental|Prasugrel - 30 mg/7.5 mg|Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days
9797287|NCT01591317|Experimental|Prasugrel - 30 mg/5 mg|Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days
9797288|NCT01591330|Experimental|LY2140023 Reference Form|LY2140023: 80 mg, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
9797289|NCT01591330|Experimental|LY2140023 Test-Low|LY2140023: 80 mg, low particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
9797290|NCT01591330|Experimental|LY2140023 Test-Medium|LY2140023: 80 mg, medium particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
9797291|NCT01591330|Experimental|LY2140023 Test-High|LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
9797292|NCT01591382|Active Comparator|Ketamine|Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
9797293|NCT01591382|Placebo Comparator|Placebo|Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).
9797294|NCT01591408|Experimental|EEG biofeedback|Subjects will receive EEG biofeedback according to their own brain rhythms
9797295|NCT01591408|Sham Comparator|sham EEG biofeedback|Subjects will receive feedback according to someone else's brain rhythms collected during a different session.
9797296|NCT01591460|Experimental|Dual Combination Therapy|
9797297|NCT01591460|Experimental|Triple Combination Therapy|
9797298|NCT01591499|Experimental|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
9797299|NCT01591499|Active Comparator|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
9797300|NCT01591616|Other|Oraqix for tooth extraction|
9797301|NCT01591655|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
9797302|NCT01591655|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
9797303|NCT01591681|Active Comparator|Pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
9797304|NCT01591681|No Intervention|Standard of Care|The control algorithm will run passively and not recommend control the patient's pump.
9988812|NCT01426646|Experimental|S-1 plus cisplatin treatment|"S-1 plus cisplatin every 3 weeks, A total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
9988813|NCT01426659|Active Comparator|"Protocol say and do"|reeducation implicit 5 minutes every day at home and 30 minutes of speech therapy every week
9988814|NCT01426659|Active Comparator|"no stimulation say and do"|
9988815|NCT01426672|Experimental|Monovision Correctoin|Monovision correction
9988816|NCT01426698|Active Comparator|Immediate cord clamping|Infants in this arm will have had immediate cord clamping at birth which is routine care at the hospital
9988817|NCT01426698|Experimental|Delayed Cord Clamping|Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
9988818|NCT01426750|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
9988819|NCT01426776|Other|heart valve replacement|a normal surgery that rheumatic valvular heart disease patients received.
9988820|NCT01426802|Experimental|Vildagliptin 50 bid|
9988821|NCT01426815|Placebo Comparator|Placebo|
9988822|NCT01426815|Experimental|Golimumab 50mg (Simponi ®)|
9797305|NCT01591733|Experimental|Treatment Arm|All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
9988823|NCT01426880|Experimental|Carboplatin + background treatment|Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
9988824|NCT01426880|Active Comparator|background treatment only|background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
9988825|NCT01426893||1|The inhaler device usage in patients with asthma or COPD
9988826|NCT01426906|Experimental|Study A|
9988827|NCT01426906|Experimental|Study B|
9988828|NCT01426919||Suspected traumatic brain injury with head CT|
9988829|NCT01426971|Experimental|Ibuprofen+caffeine|2 capsules
9988830|NCT01426971|Active Comparator|Ibuprofen|2 capsules
9988831|NCT01426984|Experimental|BPD adults|adults with Borderline Personality Disorder (BPD)
9998323|NCT01517204|Experimental|Direct laryngoscope|Direct laryngoscope was used to facilitate the intubation of left-sided double lumen endobronchial tube.
9881999|NCT00509431|Experimental|Erlotinib + Sirolimus|This is an open-label,phase I single-arm dose-escalation and phase II study of continuous, once daily doses of erlotinib administered orally in combination with sirolimus in adult patients with malignant glioma at first, second or third recurrence
9882000|NCT00509444|Active Comparator|Educational materials|
9882001|NCT00509444|Experimental|Educational materials, plus patient navigation|
9882002|NCT00509470|Active Comparator|telmisartan plus low-dose hydrochlorothiazide|12 week combination therapy with telmisartan plus low-dose hydrochlorothiazide
9882003|NCT00509470|Active Comparator|Amlodipine|Amlodipine is continuously administered.
9882004|NCT00509548|Experimental|1|Dose 1
9882005|NCT00509548|Experimental|2|Dose 2
9882006|NCT00509561|Active Comparator|Chemo-radiotherapy|
9882007|NCT00509561|Experimental|Chemo-radiotherapy plus cetuximab|
9882008|NCT00509639|Experimental|Metronidazole 10% ointment|Metronidazole 10% ointment
9882009|NCT00509639|Placebo Comparator|Placebo ointment|Placebo ointment
9882010|NCT00509652|Experimental|Arm 1|Erythrocyte apheresis
9882011|NCT00509652|Active Comparator|Arm 2|Phlebotomy
9882012|NCT00509691|Experimental|Single arm study|
9882013|NCT00509717|Experimental|experimental|
9882014|NCT00509717|Active Comparator|control|
9882015|NCT00509743|Experimental|A|Low dose Diclofenac
9882016|NCT00509743|Experimental|B|High dose Diclofenac
9930993|NCT00933855||communication training workshop|"The patient intervention is a 1 hour communication workshop entitled: Getting the Most out of your Doctor's Visit. The workshops will be offered to both patients and family members, but data will be collected only for patients. The workshops will be held on location at Queens Cancer Center."
9930994|NCT00933868|Experimental|Magnesium infusion in patients breathing 100% oxygen|Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).
9930995|NCT00933868|Placebo Comparator|Placebo infusion|The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.
9930996|NCT00933881||Gestational Diabetes Mellitus (GDM)|
9935458|NCT03709472|Active Comparator|Behavioral: Traditional face-to-face treatment-no technology|Participants randomized to Treatment-As-Usual (TAU) work over a 16-week period with their community agency. They may receive individual or family treatment. The team coordinates with the TAU agencies to minimize the overlap of data collected. The team will refer out to service locations that are most convenient for the participant. A great deal of thought has gone into the selection of the Treatment as Usual condition. The investigators wanted to compare CA CIFFTA's ability to retain and bring about change in participants with what is typically done in the community. Although running an in-house comparison condition gives more control of the delivery of services and tracking of clients, it is difficult to know how that compared to the services that are typically provided in the community
9935459|NCT03699917||Patients with SVV < 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of less than 12.
9882017|NCT00509756|Active Comparator|1|Drug: FXR-450
9882018|NCT00509756|Placebo Comparator|2|Placebo
9882019|NCT00509782|Experimental|ZIO-101|
9882020|NCT00509808|Sham Comparator|electrostimulation|Use of device for predetermined length
9882021|NCT00509834|Experimental|hLF1-11|hLF1-11 0.5mg
9882022|NCT00509834|Placebo Comparator|Placebo|Placebo formulation is Similar to hLF1-11 iv formulation except for the active component
9882023|NCT00509860|Experimental|Irinotecan|Irinotecan 16 mg/m2 by vein daily over 1 hour for 5 Days
9882024|NCT00509886|Experimental|1|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
9882025|NCT00509886|Experimental|2|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
9882026|NCT00509938|Experimental|1|5mg hLF1-11, single dose iv
9882027|NCT00509951|Active Comparator|1|One-session exposure treatment (OST)
9882028|NCT00509951|Experimental|2|Family-enhanced (augmented) OST
9882029|NCT00509964|Active Comparator|1|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
9882030|NCT00509964|Active Comparator|2|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and infusional 5-fluorouracil, on day 1 every 2 weeks.
9882031|NCT00509977|Experimental|1|Light therapy
9882032|NCT00509977|Experimental|2|Laser Treatment
9882033|NCT00510016|Experimental|Clonidine treatment|Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.
9882034|NCT00510029|Other|GAP-134, IV and Oral|Experimental; Active Comparator; Placebo
9882035|NCT00510081|Experimental|1|subjects will receive filler injections
9882036|NCT00510094|Experimental|1|Participants will receive the Friend to Friend program
9882037|NCT00510094|Active Comparator|2|Participants will receive the psychoeducational attention control intervention
9882038|NCT00510107|Active Comparator|1|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
9882039|NCT00510107|Experimental|2|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
9882040|NCT00510120|Experimental|1|Participants will receive collaborative problem solving.
9882041|NCT00510120|Active Comparator|2|Participants will receive parent management training.
9882042|NCT00510120|Active Comparator|3|Participants assigned to waitlist control will receive one of the two treatments after a 10-weeks waitlist period.
9882043|NCT00510172|Active Comparator|1|Active treatment
9882044|NCT00510172|Placebo Comparator|2|Placebo
9882045|NCT00510185|Experimental|1|Coronary angiography within 72h and revascularization as clinical indicated
9882046|NCT00510185|Sham Comparator|2|Initially conservative treatment with coronary angiography only for recurrent ischemia
9882047|NCT00510211||olanzapine coated tablet|
9882048|NCT00510211||olanzapine orodispersable tablet|
9882049|NCT00510237|Experimental|1|5-7 females per group at each of the four sites.
9882050|NCT00510237|Experimental|2|5-7 males per group at each of the four sites.
9882051|NCT00510250|Experimental|Cisplatin and Radiation in Combination with Sorafenib|
9882052|NCT00510263|Experimental|1|
9882053|NCT00510263|Experimental|2|
9882054|NCT00510263|Experimental|3|
9882055|NCT00510263|Placebo Comparator|4|
9882056|NCT00510302||Melanoma Risk-Reduction|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
9882057|NCT00510315||Women treated with SCT/TBI|
9882058|NCT00510315||1:1 Matched group of women|"Current age + or - 2 years~Race and ethnicity~Cancer diagnosis~Interval from completion of cancer therapy to study + or - 2 years"
9882059|NCT00510341|Active Comparator|1|CMP program
9882060|NCT00510341|No Intervention|2|Control group
9882061|NCT00510354|Experimental|RAD001 + Imatinib|
9882062|NCT00510367|Experimental|Multimodality Treatment|"Multimodality (chemotherapy, surgery and radiation therapy) treatment:~5-Fluorouracil + Doxorubicin + Cyclophosphamide (FAC)"
9882063|NCT00510380||growth-restricted Chinese pregnancies|
9882064|NCT00510380||appropriately-grown Chinese pregnancies|
9882065|NCT00510393|Experimental|1|drug eluting stent
9882066|NCT00510393|Placebo Comparator|2|Bare Metal Stent
9882067|NCT00510406|Placebo Comparator|A|
9882068|NCT00510406|Active Comparator|B|
9882069|NCT00510406|Active Comparator|C|
9882070|NCT00510406|Active Comparator|D|
9882071|NCT00510406|Active Comparator|E|
9882072|NCT00510406|Active Comparator|F|
9882073|NCT00510406|Active Comparator|G|
9882074|NCT00510406|Active Comparator|H|
9882075|NCT00510432||s.c. anticoagulant therapy|All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)
9882076|NCT00510445|Experimental|Single Arm Trial|Patients will be enrolled in the order of confirmation of eligibility. Dose cohorts will be filled sequentially with a minimum of 3 patients. Once assigned to a dose cohort, each patient will continue to be treated at the same dose level throughout the course of the study.
9882077|NCT00510549|Active Comparator|1, PD|Peritoneal Dialysis
9882078|NCT00510549|Active Comparator|2, HD|Hemodialysis
9882079|NCT00510562|Experimental|1|Assessment for cranial strain patterns, followed by indirect osteopathic treatment of dysfunctions found on assessment, followed by reassessment.
9882080|NCT00510562|Sham Comparator|2|Assessment for cranial strain patterns, followed by laying on of hands, followed by reassessment.
9882081|NCT00510575|Active Comparator|1|Subjects in this arm will receive the 5.5mm stainless steel instrumentation rod.
9882082|NCT00510575|Active Comparator|2|Subjects in this arm will receive a 6.35mm stainless steel instrumentation rod.
9882083|NCT00510588|Other|1|regular physical exercise training
9882084|NCT00510588|Other|2|regular physical exercise training + metformin
9882085|NCT00510588|Other|3|regular physical exercise training + glitazon
9882086|NCT00510588|No Intervention|4|Control
9882087|NCT00510601|Experimental|1|
9882088|NCT00510614|Active Comparator|A|1 gram tinidazole twice weekly for 12 weeks
9882089|NCT00510614|Placebo Comparator|B|Placebo twice weekly for 12 weeks
9882090|NCT00510627|Experimental|A|Radiofrequency ablation in conjunction with chemotherapy
9882091|NCT00510627|Active Comparator|B|Standard of care chemotherapy regimen
9882092|NCT00510640|Experimental|Sunitinib|Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
9882093|NCT00510666|Experimental|1|Butorphanol basal infusion adjunct to morphine PCA
9882094|NCT00510666|Experimental|2|Saline infusion adjunct to morphine PCA
9882095|NCT00510666|Experimental|3|Premedication of Tramadol
9882096|NCT00510666|Experimental|4|Preemptive saline for morphine PCA
9882097|NCT00510705|Other|1|Regular physical exercise training alone
9882098|NCT00510705|Other|2|Regular physical exercise training + metformin
9882099|NCT00510705|Other|3|Regular physical exercise training + glitazone
9882100|NCT00510705|No Intervention|4|Control
9882101|NCT00510757||Males|
9882102|NCT00510757||Females|
9882103|NCT00510796||High Risk Group|Colon and/or Endometrial Cancer
9882104|NCT00510822|Placebo Comparator|Placebo|Placebo + Sertraline
9882105|NCT00510822|Experimental|Cimicoxib|Sertraline + Cimicoxib
9882106|NCT00510848|Experimental|1|Reconstruction with an autograft tendon (hamstrings)
9882107|NCT00510848|Experimental|2|Reconstruction with an allograft tendon (tibialis posterior)
9882108|NCT00510965|Experimental|A|
9882109|NCT00510978|Active Comparator|1|Bifidobacterium infantis 35624
9882110|NCT00510978|Active Comparator|2|Lactobacillus salivarius UCC118
9882111|NCT00510978|Placebo Comparator|3|Placebo
9882112|NCT00510991|Experimental|A|NIPPV
9882113|NCT00511017|Experimental|Doxercalciferol|
9882114|NCT00511056||HIVNAT 006|HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
9882115|NCT00511082|Experimental|Treatment group|
9882116|NCT00511160|Active Comparator|S|Study arm: Cardiac surgery group
9882117|NCT00511160|Active Comparator|C|Routine cardiology group
9882118|NCT00511186|Experimental|Bovine Intestinal AP|"Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10 bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)"
9882119|NCT00511186|Placebo Comparator|2|"Placebo Intravenous administration of 10 bolus and 48h continuous infusion"
9882120|NCT00511225|Active Comparator|1|Will receive 10,000 IU of cholecalciferol weekly
9882121|NCT00511225|Placebo Comparator|2|Will receive a identical appearing placebo weekly
9882122|NCT00511316|Experimental|Drug|20 mg montelukast daily for 6 months
9882123|NCT00511316|Placebo Comparator|Placebo|20 mg daily placebo
9882124|NCT00511368|Placebo Comparator|1|placebo
9882125|NCT00511368|Experimental|2|Bevirimat
9882126|NCT00511394|Active Comparator|I|Infusion of 100 mL of 20% Albumin
9882127|NCT00511394|Placebo Comparator|II|100 mL Normal Saline
9882128|NCT00511407|Experimental|I|RAD Treatment
9882129|NCT00511407|No Intervention|II|Conventional CVVHD
9882130|NCT00511420|Placebo Comparator|1|Cocoa and other ingredients (product type 1). This product is a control of type 2.
9882131|NCT00511420|Placebo Comparator|2|Cocoa plus hazelnuts and other ingredients (product type 2). This product is a control of type 3 and 4.
9882132|NCT00511420|Active Comparator|3|Cocoa plus hazelnuts and other ingredients (cocoa product type 3).
9882133|NCT00511420|Active Comparator|4|Cocoa, hazelnuts and other ingredients called LMN (cocoa product type 4).
9882134|NCT00511446|Experimental|1|docetaxel, oxaliplatin, capecitabine
9882135|NCT00511498|Placebo Comparator|Placebo Arm|Placebo nightly
9882136|NCT00511498|Active Comparator|Drug|Sildenafil 50mg nightly
9882137|NCT00511524|Experimental|Subjects receiving GW842166|Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.
9882138|NCT00511563|Experimental|GW876008 and GSK561679|GW876008 and GSK561679
9882139|NCT00511576|Active Comparator|Part 1|In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).
9882140|NCT00511576|Active Comparator|Part 2|Part 2 will begin once the MTD for MGCD0103 in combination with 60 mg/m2 IV docetaxel has been determined and further evaluated in the expansion phase. In Part 2, cohorts of three to six subjects will receive escalating doses of MGCD0103 administered orally TIW in combination with 75 mg/m2 docetaxel administered as a 1-hour IV infusion on Day 1 of each cycle. The starting dose of MGCD0103 administered in combination with 75 mg/m2 IV docetaxel will be the MTD from Part 1 minus 25 mg.
9882141|NCT00511602|Experimental|Technosphere Insulin Inhalation Powder|
9882142|NCT00511602|Placebo Comparator|Technosphere Inhalation Powder|
9882143|NCT00511615||1|Patients with cervical cancer scheduled to be treated with the LEEP procedure.
9882144|NCT00511628||001|Risperidone As prescribed
9930997|NCT00933907|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
9930998|NCT00933920|Active Comparator|Fed Group|
9930999|NCT00933920|Active Comparator|Fasted group|
9931000|NCT00933946|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
9931001|NCT00933959|Experimental|Mind-Body Bridging Program|"Subjects will undergo two approximately 1.5 hr training sessions using MBBP spaced one week apart at the VASLCHCS. Each training session will comprise a number of objectives:~Session 1:~The patient will discover the underlying cause of the insomnia.~The patient will learn how to use easy to apply tools to quieten the mind to sleep soundly.~Session 2:~The patient will learn how to reduce daytime stress.~The patient will experience a greater sense of self.~To be maximally effective, the participant should master these objectives and practice MBBP on a daily basis. Bridging and all the other MBBP techniques can be implemented at any time throughout the day and right up to the onset of sleep."
9931002|NCT00933959|Active Comparator|Sleep Hygiene|Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
9931003|NCT00933972|Experimental|1 (normal)|
9931004|NCT00933972|Experimental|2 (mild)|
9931005|NCT00933972|Experimental|3 (moderate)|
9931006|NCT00933972|Experimental|4 (severe)|
9931007|NCT00933985|Experimental|Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)|"STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate IV over 3 hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1 of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.~STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1."
9931008|NCT00933998|Experimental|Metanx|Metanx bid for 2 weeks then daily. Compare to non treated patient population
9931009|NCT00934011|Experimental|Group 1 - C-reactive protein (CRP) guided ab therapy|Intervention on antibiotic therapy will be based on circulating CRP levels
9931010|NCT00934011|Active Comparator|Group 2 - procalcitonin (PCT) guided ab therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
9931011|NCT00934037|Other|Combined CT Angiography and Myocardial Perfusion|Single Arm study. All patients underwent combined CT Angiography and Myocardial Perfusion.
9931012|NCT00934063||A|
9931013|NCT00934063||B|
9931014|NCT00934076|Experimental|AT-101 plus Erlotinib|"Subjects will begin study treatment at 150 mg of erlotinib taken once daily in a continuous regimen expressed in 3 week cycles.~Subjects will begin treatment with oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
9931015|NCT00934154|Experimental|Thalidomide|MPT
9931016|NCT00934154|Active Comparator|Control|MP
9931017|NCT00934167|Experimental|Test|Hipolabor
9931018|NCT00934167|Active Comparator|Comparator|5.000 USP/mL - APP
9931019|NCT00934193|Active Comparator|Gabapentin|
9931020|NCT00934193|Placebo Comparator|Placebo|
9931021|NCT00934206|Experimental|Training|One month of endurance training (running / walking at 60 % heart rate reserve for 45 min 4 times per week)
9931022|NCT00934219|Active Comparator|High dose Lovaza|Lovaza 4 g twice a day, if not effective then 4 g 3 times a day
9931023|NCT00934219|Active Comparator|Standard Dose|2 g twice a day
9931024|NCT00934232|Experimental|Busulfan|Busulfex given to patients who are either ≥65 years or have renal insufficiency
9931025|NCT00934245|Active Comparator|Inactivated Polio Vaccine (IPV)|Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
9931026|NCT00934245|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
9931027|NCT00934245|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
9931028|NCT00934271||Fractionated stereotactic radiotherapy|patients with active acromegaly
9882145|NCT00511641||Low Risk OVCA|Patient that is participating in an ovarian cancer (OVCA) screening program.
9882146|NCT00511654|Experimental|Subjects in Group 1 receiving GW823296|Subjects will receive single dose of GW823296 on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered GW823296 for 28 days in the repeat dosing period.
9882147|NCT00511654|Placebo Comparator|Subjects in Group 1 receiving placebo|Subjects will receive single dose of placebo on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered placebo for 28 days in the repeat dosing period.
9882148|NCT00511654|Experimental|Subjects in Group 2 and 3 receiving GW823296|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered GW823296 on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of GW823296 for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
9882149|NCT00511654|Placebo Comparator|Subjects in Group 2 and 3 receiving placebo|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered placebo on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of placebo for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
9882150|NCT00511680|Experimental|Behavioral based In-home Intervention|This group will recieve up to 10 1-hour sessions over a 4 month period.
9882151|NCT00511693|Experimental|1|hospitals randomly allocated to receive physician and patient osteoporosis recommendations from the regional coordinator
9882152|NCT00511693|Active Comparator|2|hospitals randomly allocated to receive falls prevention advice
9882153|NCT00511719|Experimental|Technosphere Insulin|Technosphere Insulin Inhalation Powder
9882154|NCT00511719|Active Comparator|Actrapid|Subcutaneous regular human insulin
9882155|NCT00511732|Experimental|Technosphere Insulin|
9882156|NCT00511732|Placebo Comparator|Technosphere Inhalation Powder|
9882157|NCT00511745||001|
9882158|NCT00511758||Digital Imaging Device|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.
9882159|NCT00511784||OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)|subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free
9882160|NCT00511784||levonorgestrel-containing oral contraceptives|subjects in insurance claims database who were first time users of triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol taken for 21 consecutive days followed by no pill or an inert pill for 7 days
9882161|NCT00511823|Experimental|Subjects in Part A|Subjects will receive 100 milligrams (mg) of oral dolasetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 100 mg oral dolasetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant on day 1 and 50 mg oral casopitant on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
9882162|NCT00511823|Experimental|Subjects in Part B|Subjects will receive 2 mg of oral granisetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 2 mg oral granisetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
9882163|NCT00511823|Experimental|Subjects in Part C|Subjects will receive 4 mg of oral rosiglitazone once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 4 mg oral rosiglitazone once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
9882164|NCT00511849|Experimental|1|
9882165|NCT00511927||GHD|Patients with Growth Hormone Deficiency
9988832|NCT01426997||High inflammation group (CRP>3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level >3 mg/L
9988833|NCT01426997||Medium inflammation group (CRP=1-3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level = 1-3 mg/L
9988834|NCT01426997||Low inflammation group (CRP<1 mg/L).|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level <1 mg/L
9988835|NCT01427010|Experimental|Reirradiation of recurrent and 2nd primary head/neck cancer.|
9988836|NCT01427036|Experimental|MISS surgery group|hip screw MISS® (Minimally Invasive Screw System) : minimally invasive approach
9988837|NCT01427036|Active Comparator|PHS surgery group|PHS® hip screw design for standard approach
9988838|NCT01427049||renal denervation|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug regimen including 3 or more antihypertensive medications, including a diuretic, or inability to follow a stable drug regimen due to unacceptable side-effects of antihypertensive medication.
9988839|NCT01427062|Experimental|anticipatory and compensatory postural control training|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
9988840|NCT01427062|Active Comparator|strength-focused training|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
9988841|NCT01427075|Experimental|lateral pharyngoplasty|lateral pharyngoplasty
9988842|NCT01427088|Experimental|repetitive TMS|repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
9988843|NCT01427114|Experimental|R-CVP|6 cycles of R-CVP followed by 2 cycles of rituximab
9988844|NCT01427127|Experimental|ramosetron|Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.
9988845|NCT01427127|Placebo Comparator|Normal saline|Patients received intravenous normal saline at end of surgery and 24hr after surgery.
9988846|NCT01427140|Active Comparator|Saturated fatty acid group|Addition of saturated fatty acids to the diet inte the form of pastries
9988847|NCT01427140|Active Comparator|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
9988848|NCT01427153|Active Comparator|Corticosteroid|Corticosteroid injection
9988849|NCT01427153|Active Comparator|Orthopaedic Manual Physical Therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
9988850|NCT01427166|Experimental|Ultrasound imaging|Cords that are present in the participant's axilla and/or arm will be imaged with an ultrasound
9988851|NCT01427192|Experimental|acetazolamide|1 week therapy, cross-over design
9988852|NCT01427192|Placebo Comparator|Placebo tablet|One week, cross-over design
9988853|NCT01427192|Experimental|supplemental oxygen during nights|One week, cross-over design
9988854|NCT01427192|Experimental|Non-invasive ventilation|One week, cross-over design
9988855|NCT01427192|Sham Comparator|room air|room air applied via sham-oxygen-concentrator
9988856|NCT01427205|Experimental|Group A: Cetuximab + OSI-906|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + OSI-906 150 mg orally twice a day. 21-Day Cycle.
9988857|NCT01427205|Experimental|Group B: Cetuximab + Placebo|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + Placebo orally twice a day. 21-Day Cycle.
9988858|NCT01427218|Experimental|Medication Therapy Management (MTM)|Medication Therapy Management visits with a pharmacotherapist will occur at a minimum of 6-9 weeks, 20-24 weeks, and 28-32 weeks. Additional interim face to face and telephonic visits may be scheduled based on patient's progress with meeting treatment goals and need for follow-up physical assessment and laboratory analysis.
9988859|NCT01427218|Placebo Comparator|Usual Care|Visits with a pharmacotherapist to create an accurate list of medications for those patients randomized to placebo (who receive usual care by their cardiologist and primary care provider).
9988860|NCT01427231|Active Comparator|Drink with 50 g glucose|The glucose drink contains 50 g of glucose soluted in 250 ml of water and lemon juice.
9988861|NCT01427231|Active Comparator|Drink with 100 gram of sacharose|The sacharose drink contains 100 g of sacharose soluted in 250 ml of water and lemon juice.
9988862|NCT01427231|Placebo Comparator|Placebo with sweeteners|The placebo contains a mixture of artificial sweeteners in order to have the same sweetness and appearance of the test drinks (the glucose drink and the sacharose drink).
9988863|NCT01427244|Experimental|Trastuzumab|Open Label
9882166|NCT00511927||non-GHD|Patients with CHF, without coexisting growth hormone deficiency
9882167|NCT00511940|Experimental|1|acamprosate
9882168|NCT00511940|Placebo Comparator|2|sugar pill
9882169|NCT00511953|Active Comparator|Gabapentin ER|Active drug, Gabapentin extended release
9882170|NCT00511953|Placebo Comparator|Sugar Pill|Comparator arm is Placebo
9882171|NCT00511966||001|
9882172|NCT00511966||002|
9882173|NCT00511979|Experimental|Technosphere insulin inhalation system, 25 units|
9882174|NCT00511979|Experimental|Technosphere insulin inhalation system, 50 units|
9882175|NCT00511979|Experimental|Technosphere insulin inhalation system, 100 units|
9882176|NCT00511979|Active Comparator|Subcutaneous regular human insulin|
9882177|NCT00512018|Active Comparator|Isokinetic Exercise only|Individuals were asked to perform a 8-session training, twice a week, in which they trained the knee extensors muscles in an isokinetic dynamometer, 3 sets of 10 repetitions.
9882178|NCT00512018|Experimental|Isokinetic exercise + NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES).
9882179|NCT00512044|Active Comparator|A: general|general anesthesia: spinal and general
9882180|NCT00512044|Experimental|B: pudendal|local anesthesia: pudendal block
9882181|NCT00512057|Experimental|1|
9882182|NCT00512057|Placebo Comparator|2|
9882183|NCT00512070|Experimental|IIA (0.3mg day melatonin)|0.3mg day melatonin
9882184|NCT00512070|Experimental|IIB (3.0 mg/day melatonin)|3.0 mg/day melatonin
9882185|NCT00512187|Experimental|first group|patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks
9882186|NCT00512200||Case|Patients aged 65 or older
9882187|NCT00512200||Control|Patients aged 20 to 40
9882188|NCT00512200||Control 2|Healthy volunteers aged 65 or older
9882189|NCT00512213|Active Comparator|1|Immunonutrition containing RNA, omega-3-FAs, arginine
9882190|NCT00512213|Active Comparator|2|Standard enteral nutrition: isocaloric and isonitrogeneous but w/o active ingredients
9882191|NCT00512239||EUPA cohort|Consecutive adult patients presenting to receive rheumatological care at the Sherbrooke University Hospital Centre (CHUS) with an immune-mediated inflammatory arthritis affecting at least 3 joints for a duration of more than 4 and less than 52 weeks.
9882192|NCT00512265|Active Comparator|1|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
9882193|NCT00512265|Placebo Comparator|2|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
9882194|NCT00512291|Experimental|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses
9882195|NCT00512304|Experimental|Preoperative chemoradiotherapy|
9882196|NCT00512304|Experimental|Postoperative chemoradiotherapy|
9882197|NCT00512356|Experimental|Investigational product group|"Anti-Adhesion Product was applied to the rectal stump and the incision line.~Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves."
9882198|NCT00512356|No Intervention|Control group|Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.
9882199|NCT00512382||A|Babies and small children 1-24 months
9882200|NCT00512382||B|Children 2-18 years old
9882201|NCT00512395|Active Comparator|1|epidural analgesia
9882202|NCT00512395|No Intervention|2|traditional analgesia with opioids
9882203|NCT00512408||A|
9882204|NCT00512408||B|
9882205|NCT00512421||A|navigation technique
9882206|NCT00512421||B|conservative surgery
9882207|NCT00512421||C|Historical control
9882208|NCT00512434|Active Comparator|Control in arm fields|Standard treatment Intervention no'Osteosynthesis'
9882209|NCT00512434|Experimental|IMOCA|Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
9882210|NCT00512460|Experimental|RTA 744|
9882211|NCT00512473|Placebo Comparator|A|I.v. saline for 8 hours
9882212|NCT00512473|Experimental|GH|Growth hormone (0.5 mg s.c. at t = 0 hours)
9882213|NCT00512473|Experimental|Pegvisomant|Pegvisomant injection 30 mg 36 hours prior to the study
9882214|NCT00512486|Active Comparator|1|MEDI-563
9882215|NCT00512499|Placebo Comparator|Group 1|CONTROL GROUP (first year only; maximum 300 patients): patients seen by CHUS orthopedists at the Hotel-Dieu site, where no nurse coordinator is available for inclusion. This is random but not randomized.
9882216|NCT00512499|Active Comparator|Group 2|"MINIMAL INTERVENTION GROUP: 1/2 of patients, randomly selected.~INTERVENTION: A nurse coordinator will identify patients with fragility fractures and inform the patient about osteoporosis as the cause of the fracture, the benefit of treatment, and the options of treatment adapted to the individual patient. Written information will be sent to his/her family physician containing a presumed osteoporosis diagnosis, investigation to be performed, correct interpretation of any osteodensitometry results in the context of a fragility fracture, the options of treatment, and alternatives if the first prescriptions are not tolerated or stopped. Intervention"
9882217|NCT00512499|Experimental|Group 3|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
9882218|NCT00512525|Placebo Comparator|2|
9882219|NCT00512551||Cervical cancer tumor biopsy + radiation therapy|Cervical cancer tumor biopsy + radiation therapy.
9882220|NCT00512564||1|Patients suffering from Sickle cell disease
9882221|NCT00512577|Active Comparator|A|Patients will not receive a pre-operative transfusion.
9882222|NCT00512577|Active Comparator|B|Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
9882223|NCT00512590|Experimental|Experimental|
9882224|NCT00512629|Experimental|Omegaven|Omegaven is a fish based intravenous fat emulsion
9882225|NCT00512629|Active Comparator|Intralipid|
9882226|NCT00512642||Patients at increased risk of lung cancer|Patients at increased risk of lung cancer
9882227|NCT00512655|Experimental|1|Intervention: 5 week training program, 2 sessions per week (total of 10 sessions). Training includes both the patient and the caregiver. The training consists of two components: a cognitive and a physical component.
9882228|NCT00512655|No Intervention|2|Usual care.
9882229|NCT00512668|Experimental|Treatment (hormone therapy, temsirolimus)|"Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90.* Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. Treatment with temsirolimus continues for up to 36 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry."
9882230|NCT00512746|Other|Surveillance|Screened arm
9882231|NCT00512746|Active Comparator|Control|Control arm
9882232|NCT00512759|No Intervention|Standard of care|Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).
9882233|NCT00512759|Experimental|Intervention|Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)
9882234|NCT00512785|Experimental|E1|
9882235|NCT00512785|Experimental|E2|
9882236|NCT00512824|Placebo Comparator|1|
9882237|NCT00512824|Active Comparator|2|
9882238|NCT00512824|Active Comparator|3|
9882239|NCT00512824|Active Comparator|4|
9882240|NCT00512837|Active Comparator|2|
9882241|NCT00512850|Other|Folic acid|Folic acid supplement 1g/day
9882242|NCT00512850|Other|Placebo|Placebo pill once per day
9882243|NCT00512889|Experimental|Cohort 1|Different dose of CTL
9882244|NCT00512889|Experimental|Cohort 2|Different dose of CTL
9882245|NCT00512889|Experimental|Cohort 3|Combination of CTL with GMCSF +/- radiation
9882246|NCT00512915|Active Comparator|1699T (Optisense)|Implantation of the Optisense Lead 1699T, programming of the shortest possible postventricular atrial blanking period (PVAB)
9882247|NCT00512915|Active Comparator|Standard lead|Implantation of a standard bipolar atrial pacing lead. Optimization of the postventricular atrial blanking period (PVAB) after implantation.
9882248|NCT00512941||1|HBV: Carrier
9882249|NCT00512941||2|HBV: cure
9882250|NCT00512941||3|HBV: isolate anti-HBc
9882251|NCT00512941||4|HBV: vaccinated
9882252|NCT00512941||5|HCV: anti-HCV positive test
9882253|NCT00512941||6|HBV/HCV co-infection
9882254|NCT00512941||7|Susceptible individuals
9882255|NCT00512967||sarcoidosis|21 onset patients, non-treated
9882256|NCT00512967||IPF|15 IPF patients, partially treated
9882257|NCT00512967||COPD|15 COPD patients within 24 hours after their last exacerbation
9882258|NCT00512967||controls|25 healthy controls, matched for age and gender
9882259|NCT00512980|Active Comparator|1|
9882260|NCT00512980|Active Comparator|2|
9882261|NCT00512993|Active Comparator|Treatment|Patients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
9882262|NCT00512993|No Intervention|Observation|Patients will be under observation and receive standard endocrine, radiologic and trastuzumab treatment, respectively
9882263|NCT00513032||methylene blue|
9882264|NCT00513032||C|
9882265|NCT00513045|Experimental|IRT|Intervention based on Imagery Rehearsal Therapy
9882266|NCT00513045|Active Comparator|Exposure|Treatment based on exposure
9882267|NCT00513045|No Intervention|Nightmare diary|Recording nightmares in a diary
9882268|NCT00513045|No Intervention|Waiting list|Waiting list
9882269|NCT00513058|Experimental|lapatinib + vinorelbine|"starting with loading dose of lapatinib per os for 7 days~then, combining lapatinib (oral daily continuous) + vinorelbine (intravenous, day 1 and 8 every 3 weeks)"
9882270|NCT00513084|Experimental|SDT Intervention|This arm will follow main experimental intervention, as described elsewhere
9882271|NCT00513084|No Intervention|Comparison Group|Comparison Group receiving standard care health promotion intervention
9882272|NCT00513097|Experimental|Smoking Prevention & Cessation Program|
9882273|NCT00513110|Experimental|1|Endotoxin and AMPD1 polymorphism
9882274|NCT00513110|Experimental|2|Endotoxin and intervention with caffeine
9882275|NCT00513110|Placebo Comparator|3|Endotoxin combined with placebo
9882276|NCT00513123||Digital Colposcopy|Digital Colposcopy for Fluorescence (DCF)
9882277|NCT00513136|Active Comparator|I|10 week group-based mind body medicine intervention
9882278|NCT00513136|Experimental|II|Group-based mind body medicine intervention with a family focus
9882279|NCT00513149|Active Comparator|c6|Clopidogrel 600 mg loading
9882280|NCT00513162|Experimental|Valproate + Etoposide|Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m^2 By Mouth Daily.
9882281|NCT00513214|Active Comparator|XOMA 052|
9882282|NCT00513214|Placebo Comparator|Placebo|
9931029|NCT00934284|Active Comparator|Injection only|Participants receive a therapeutic selective nerve root block and advice to return to normal activity as tolerated.
9931030|NCT00934284|Experimental|Injection plus physical therapy|Participants are referred to physical therapy within one week of receiving a therapeutic selective nerve root block. Physical therapy consists of end-range movements in a directional preference and/or mechanical traction to reduce radicular symptoms.
9931031|NCT00934297||Pilot group|Real-time US imaging with simultaneous display of dynamically corresponding MR images (from a previous MRI screening) will be used to re-locate the lesion previously reported as occult under a second-look ultrasound screening.
9931032|NCT00934310||Ambulatory Surgical Patients 1|"The nature of the operating room time out for ambulatory surgical patients will be examined before implementation of the World Health Organization's Surgical Safety Checklist."
9931033|NCT00934310||Ambulatory Surgical Patients 2|"The nature of the operating room time out for ambulatory surgical patients will be examined after implementation of the World Health Organization's Surgical Safety Checklist.Ambulatory surgical patients"
9931034|NCT00934323|Experimental|TR sequential group|Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
9931035|NCT00934323|Active Comparator|RT sequential group|Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
9931036|NCT00934336|Experimental|preprandial injection|pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.
9931037|NCT00934336|Experimental|post-prandial injection|post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.
9931038|NCT00934349||Patient|Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli) fulfilling the clinical definition of the dry beriberi.
9931039|NCT00934349||Control|Native to the Comoro Archipelago, living in the same household as the patient, sharing the same meals. Free from beriberi and with normal neurological examination.
9931040|NCT00934388|Experimental|Mesh placed in pre peritoneal plane|
9931041|NCT00934388|Active Comparator|No mesh placed|
9931042|NCT00934414|Experimental|Smokers|
9931043|NCT00934414|Experimental|Non-Smokers|
9931044|NCT00934427|Active Comparator|Vascana|
9931045|NCT00934427|Placebo Comparator|Vehicle|
9931046|NCT00934453|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) capsules containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
9931047|NCT00934453|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
9931048|NCT00934466|Experimental|1|MK2637 120 mg
9931049|NCT00934466|Experimental|2|MK2637 50 mg
9931050|NCT00934466|Placebo Comparator|3|Placebo
9931051|NCT00934466|Active Comparator|4|Dextromethorphan 220 mg
9931052|NCT00934466|Active Comparator|5|Dextromethorphan 110 mg
9931053|NCT00934479|No Intervention|Healthy Subjects|Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
9882283|NCT00513279|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334. The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
9882284|NCT00513279|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
9882285|NCT00513331||Algorithm #1|Patients without visable lesions
9882286|NCT00513331||Algorithm #2|Patients with a visable lesion that is less than 1cm
9882287|NCT00513331||Algorithm #3|Patients with a visable lesion greater than 1cm
9882288|NCT00513383|Experimental|Part A|Determine the best dosing of panitumumab, chemotherapy and radiation.
9882289|NCT00513383|Experimental|Part B|Determine the best dosing of induction chemotherapy combined with panitumumab prior to receiving panitumumab and chemoradiotherapy.
9882290|NCT00513396|Experimental|1|
9882291|NCT00513396|Active Comparator|2|
9882292|NCT00513396|Placebo Comparator|3|
9882293|NCT00513422|Experimental|1|Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)
9882294|NCT00513422|Experimental|2|Glucosamine sulfate 1500mg
9882295|NCT00513422|Experimental|3|Chondroitin sulfate 800mg
9882296|NCT00513422|Placebo Comparator|4|Matching glucosamine/chondroitin placebo capsules
9882297|NCT00513539|Active Comparator|Arm A|Biliary Stenting alone
9882298|NCT00513539|Experimental|Arm B|Photodynamic Therapy plus biliary stenting
9882299|NCT00513552|Experimental|Antibiotics|Antibiotics
9882300|NCT00513565|Placebo Comparator|placebo arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
9882301|NCT00513565|Experimental|GSK561679 arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
9882302|NCT00513565|Active Comparator|lorazepam arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
9882303|NCT00513591||1|Women with lupus
9882304|NCT00513591||2|Health women who are matched to women with lupus by age and race
9882305|NCT00513591||3|Women with other autoimmune diseases
9882306|NCT00513630|Active Comparator|metformin|
9882307|NCT00513630|Active Comparator|glipizide|
9882308|NCT00513643|Experimental|1|6 U insulin aspart
9882309|NCT00513643|Experimental|2|12 U insulin aspart
9882310|NCT00513643|Experimental|3|24 U insulin aspart
9882311|NCT00513643|Active Comparator|4|6 IU human regular insulin
9882312|NCT00513643|Active Comparator|5|12 IU human regular insulin
9882313|NCT00513643|Active Comparator|6|24 IU human regular insulin
9882314|NCT00513656|Active Comparator|Oxycodone Hydrochloride Tablets|
9882315|NCT00513656|Experimental|Oxycodone Naloxone Tablets|
9882316|NCT00513669|Experimental|1 PEV301&302|The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
9882317|NCT00513669|Active Comparator|2 Influenza vaccine|Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
9882318|NCT00513721||III|Prostate specimens with positive surgical margins.
9882319|NCT00513734|Active Comparator|1|Geliperm Hydrogel Dressing
9882320|NCT00513734|Active Comparator|2|Lacrilube ointment
9882321|NCT00513760|Experimental|1|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
9882322|NCT00513760|Active Comparator|2|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
9882323|NCT00513760|Placebo Comparator|3|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
9882324|NCT00513786|Experimental|carboplatin/paclitaxel with bevacizumab|A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
9882325|NCT00513825|Active Comparator|1|1075 cc of 77 mEq/L solution of NaCl 0.45% , prepared by adding 75 cc of 77 mEq/L NaCl 0.45 % to 1000 cc of 77 mEq/L NaCl 0.45%
9882326|NCT00513825|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate solution 8.4% to 1000 cc of NaCl 0.45%.
9882327|NCT00513851|Experimental|1|Once Daily Dosing
9882328|NCT00513851|Experimental|2|Twice Daily Dosing
9882329|NCT00513864|Active Comparator|CYP2D6-|This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
9797306|NCT01591746|Experimental|Group A - Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast
9797307|NCT01591746|Placebo Comparator|Group B - Placebo|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast
9882330|NCT00513864|Active Comparator|CYP2D6+|Extensive metabolizers (EM) of codeine
9882331|NCT00513877|Experimental|Bortezomib 1.6mg/m2|
9797308|NCT01591785|Active Comparator|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
9797309|NCT01591785|Placebo Comparator|Placebo ointment|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
9797310|NCT01591837|Experimental|Adults|Healthy volunteers aged 18 to 59 years received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
9797311|NCT01591837|Experimental|Older Adults|Healthy volunteers aged 60 years or older received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
9797312|NCT01591863|Experimental|fidaxomicin|
9797313|NCT01592006|Experimental|HCV, LT, Pegasys, ribavirin, telaprevir|Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir
9797314|NCT01592045|Experimental|Sequence 1|UTC ch14.18 for two courses and NCI ch14.18 for three courses
9797315|NCT01592045|Experimental|Sequence 2|NCI ch14.18 for two courses and UTC ch14.18 for three courses
9797316|NCT01592071|Experimental|Replace reactive w/ non-reactive foods|Test results, individual dietary plan: 'Replace reactive foods with non-reactive foods'
9797317|NCT01592240|Experimental|Q28d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
9797318|NCT01592240|Experimental|Q14d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.
9797319|NCT01592292||Rituximab|Participants who have inadequate response or were intolerant to the first anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis (RA), receiving rituximab as per physician's discretion for RA treatment were observed for 12 months.
9797320|NCT01592292||Other anti-TNF agent|Participants who have inadequate response or were intolerant to the first anti-TNF agent in RA, receiving other anti-TNF agent, including adalimumab, etanercept and infliximab, as per physician's discretion for RA treatment were observed for 12 months.
9797321|NCT01592344|Experimental|StimRouter - active stimulation|StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
9797322|NCT01592344|Sham Comparator|StimRouter - Control|StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.
9797323|NCT01592396|Experimental|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 milligram (mg), subcutaneously on Day 1.
9797324|NCT01592409|Active Comparator|Active cannabis|In this condition, participants will receive a cigarette containing 12.5% active THC.
9797325|NCT01592409|Placebo Comparator|Placebo|In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
9797326|NCT01592435||Pred. & Invest.-All Study Participants|"Cedera AccuStitch Software is standard of care software currently used at sites.~Carestream DR LLI software is investigational software used for reconstruction."
9797327|NCT01592500|Experimental|MOD-4023 low dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
9797328|NCT01592500|Experimental|MOD-4023 middle dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
9797329|NCT01592500|Experimental|MOD-4023 high dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
9797330|NCT01592500|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
9988864|NCT01427257|Active Comparator|PB1023 Formulation A|
9988865|NCT01427257|Active Comparator|PB1023 Formulation B|
9988866|NCT01427257|Active Comparator|PB1023 Formulation B (2-8C)|
9988867|NCT01427270|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
9988868|NCT01427270|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
9988869|NCT01427270|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
9988870|NCT01427283|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
9988871|NCT01427283|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
9988872|NCT01427283|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
9988873|NCT01427322|Experimental|lapatinib + radiation therapy|lapatinib given orally 2-4 hours prior to first fraction of radiation
9988874|NCT01427322|Active Comparator|No therapy prior to radiation|Radiation therapy alone
9988875|NCT01427335|Placebo Comparator|saline|0.9% saline intravenous infusion
9988876|NCT01427335|Experimental|calcium|Calcium intravenous infusion
9988877|NCT01427348|Experimental|with assistant|head extension by an assistant during direct laryngoscopy
9988878|NCT01427348|Active Comparator|without assistant|without the help of an assistant during direct laryngoscopy
9988879|NCT01427387|Experimental|Part-1 ASP group|ASP0456 receiving group
9988880|NCT01427387|Placebo Comparator|Part-1 Placebo group|Placebo treatment
9988881|NCT01427387|Experimental|Part-2 group|cross-over study group to evaluate food effect on ASP0456 plasma concentration
9988882|NCT01427400|Experimental|Expander Placement, Botulinum Toxin-A|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
9988883|NCT01427400|Placebo Comparator|Tissue expander Placement WITH Saline|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
9988884|NCT01427413||Hyper1|Only patients who achieved hyperstimulation pathology after external administration of gonadotrophin during IVF treatment
9988885|NCT01427426|Experimental|All Greens|Subjects will consume the All Greens product daily. Product is prepared by mixing with either water, juice or in a smoothie.
9988886|NCT01427426|Sham Comparator|Control formulation|Subjects will consume a product of similar consistency and comparable taste that does not have the same healthy ingredients as the All Greens.
9988887|NCT01427439||Major Depressive Disorder|
9988888|NCT01427452||Living Kidney Donor, Transplant Recipient, Healthy Control|Living kidney donors and their transplant recipient will be enrolled. Also, a smaller cohort of healthy controls (potential donors who were medically suitable but not used) will be enrolled.
9988889|NCT01427465|Experimental|Consult|Consult
9988890|NCT01427465|Experimental|Newsletter|Newsletter
9988891|NCT01427465|Experimental|Parent Letter|Parent Letter
9988892|NCT01427465|Active Comparator|Control|Control
9988893|NCT01427478|Experimental|AFATINIB|Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
9988894|NCT01427478|Placebo Comparator|PLACEBO|Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
9988895|NCT01427491|Active Comparator|Aquacel® Ag|
9988896|NCT01427491|Active Comparator|Mepilex® Border Ag|
9988897|NCT01427543|Experimental|MILE group sessions|Participants will attend 6 - 2 hour long, interactive, culturally congruent, group sessions that address knowledge, beliefs, attitudes, and skills related to reducing HIV risk behaviors.
9988898|NCT01427543|No Intervention|Control|These subjects will be provided with access to post-incarcerations services that will be provided by the Center for Health Justice.
9988899|NCT01427556||Breakfast Eaters|Women who self-report eating breakfast regularly.
9988900|NCT01427556||Non-Breakfast Eaters|Women who self-report skipping breakfast regularly.
9988901|NCT01427569|Experimental|IZN-6D4 Gel|patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel
9988902|NCT01427569|Placebo Comparator|Placebo Hydrogel|patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4
9988903|NCT01427621|Experimental|RIPCcom group|
9988904|NCT01427621|No Intervention|Control group|
9988905|NCT01427634|Active Comparator|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
9988906|NCT01427634|Other|Control|Usual Care
9988907|NCT01427647|Active Comparator|Control group|Control group: open surgery under general anesthesia
9988908|NCT01427647|Active Comparator|Epidural group|Epidural group: Open surgery under thoracic epidural anesthesia
9988909|NCT01427647|Active Comparator|Laparoscopic group|Laparoscopic group: Laparoscopic surgery under general anesthesia
9997283|NCT01507428|Active Comparator|Arm I (standard chemoradiotherapy)|Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.
9988910|NCT01427660|Active Comparator|Traditional CERSG Arm|CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.
9988911|NCT01427660|Experimental|Web-Based Materials Arm|Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.
9988912|NCT01427673|Active Comparator|CPAP Procedure control group|Overlap patients randomly assigned to the CPAP titrated per AASM guidelines.
9988913|NCT01427673|Experimental|Bipap procedure group|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
9988914|NCT01427686|Active Comparator|Dobutamine|Start Dobutamine. If no success switch to Dopamine.
9988915|NCT01427686|Active Comparator|Dopamine|Start Dopamine. If no success switch to Dobutamine.
9988916|NCT01427699|Experimental|T2-18C3 therapeutic antibody|9 subjects will receive the T2-18C3 therapeutic antibody.
9988917|NCT01427712||LipaCreon|those with an exposure
9988918|NCT01427725||LipaCreon|those with an exposure
9988919|NCT01427777||HPV Vaccine|People that receive HPV vaccine in V501-030
9988920|NCT01427816|Experimental|KCT-0809 ophthalmic solution, low dose|
9988921|NCT01427816|Experimental|KCT-0809 ophthalmic solution, high dose|
9988922|NCT01427816|Placebo Comparator|Placebo|
9988923|NCT01427829|Experimental|Intervention (CaPRA)|
9988924|NCT01427829|No Intervention|Control (usual care)|
9988925|NCT01427842|Experimental|DEVINE vancomycin regimen|This is the intervention arm and will be the pharmacokinetically derived vancomycin dosing regimen.
9988926|NCT01427855|Experimental|High Saturated Fat Red Meat Diet|
9988927|NCT01427855|Experimental|High Saturated Fat White Meat Diet|
9988928|NCT01427855|Experimental|High Saturated Fat Non-Meat Diet|
9988929|NCT01427855|Experimental|Low Saturated Fat Red Meat Diet|
9988930|NCT01427855|Experimental|Low Saturated Fat White Meat Diet|
9988931|NCT01427855|Experimental|Low Saturated Fat Non-Meat Diet|
9988932|NCT01427868|Experimental|LB80380 maleat salt|
9988933|NCT01427868|Active Comparator|LB80380 free base|
9988934|NCT01427894|Experimental|Maternal Singing|Maternal singing during Kangaroo Care of stable preterm infants
9988935|NCT01427894|No Intervention|Kangaroo Care|Kangaroo Care without singing
9988936|NCT01427946|Experimental|Retaspimycin HCl (IPI-504) and Everolimus|Retaspimycin HCl (IPI-504) and everolimus will be administered on a 21-day cycle. All patients will remain on study until progression of disease or intolerability to study treatments occurs.
9988937|NCT01427985|Experimental|Relaxation followed by analgosedation|Give Atropin, then Mivacurium, immediately followed by Fentanyl
9988938|NCT01427985|Active Comparator|Analgosedation followed by Relaxation|Give atropin, then Fentanyl, then Mivacurium
9988939|NCT01427998|Active Comparator|olive leaf extract|Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
9988940|NCT01427998|Placebo Comparator|placebo|matched placebo
9988941|NCT01428011||No treatment|African American/Black and Caucasian/White patients with hypertension
9988942|NCT01428037|Experimental|Misoprostol Vagianl Tablet|Misoprostol Vaginal Tablet 25 mcg.
9988943|NCT01428037|Placebo Comparator|Placebo|Tablet without active ingredient
9988944|NCT01428050|Experimental|3% saline|Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration
9988945|NCT01428050|Active Comparator|Lactated Ringers|15cc/kg/hr of lactated ringers solution intraoperatively
9988946|NCT01428089|Experimental|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml)
9988947|NCT01428089|Placebo Comparator|placebo|placebo at 1100, 1500, and 1900 h.
9988948|NCT01428102||RapidTEG|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent RapidTEG.
9988949|NCT01428102||Kaolin|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent Kaolin.
9988950|NCT01428141|Experimental|E7050|
9988951|NCT01428154|Experimental|Darbepoetin alfa|
9988952|NCT01428167||Thyroidectomy|All patients undergoing thyroidectomy for a variety of indications.
9988953|NCT01428180||Indomethacin|Infants treated with Indomethacin
9988954|NCT01428180||Ibuprofen|Infants treated with Ibuprofen
9988955|NCT01428180||Ligation|Infants undergoing surgical ligation
9988956|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway for dying at nursing homes
9988957|NCT01428206|No Intervention|control|Usual care is performed for the control group
9988958|NCT01428232|Experimental|BFHI steps 1-9|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems
9988959|NCT01428232|Experimental|BFHI steps 1-9 +well-child clinic|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems Provision of BF support during 1) clinic visit to obtain birth certificate or home visit if mother does not come into clinic and 2) well-child clinics Flyers to mother with culturally appropriate messages designed to address some of the most important local barrier to EBF
9988960|NCT01428232|No Intervention|usual care|
9988961|NCT01428271||Herniorrhapy with caudal block|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorrhapy under general anesthesia with caudal block
9988962|NCT01428284|Experimental|001|Canagliflozin/Probenecid
9988963|NCT01428297|Experimental|Cohort A and B, BPR277 and Placebo (vehicle)|
9988964|NCT01428297|Experimental|Part 2 BPR277|
9988965|NCT01428297|Placebo Comparator|Part 2 Placebo (vehicle)|
9988966|NCT01428297|Experimental|Part 3 BPR277 and Placebo (vehicle)|
9988967|NCT01428310|Active Comparator|Anatabloc(TM)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
9988968|NCT01428310|Active Comparator|CigRx(R)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
9988969|NCT01428349|Experimental|Attention to Context|
9988970|NCT01428349|Experimental|Affective Cognitive Control|
9988971|NCT01428375|Active Comparator|(1) Active (Paracetamol) arm: n=60|(Paracetamol)
9988972|NCT01428375|Placebo Comparator|(2) Placbo (Sterile water) arm: n=60|Sterile water
9988973|NCT01428388|Active Comparator|Bevacizumab|
9988974|NCT01428388|Active Comparator|Ranibizumab|
9988975|NCT01428401|Experimental|Arm A|
9988976|NCT01428401|Placebo Comparator|Arm B|
9988977|NCT01428414|Active Comparator|Trastuzumab+ Carboplatin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Carboplatin,Paclitaxel
9988978|NCT01428414|Active Comparator|Trastuzumab+Epirubicin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Epirubicin,Paclitaxel
9988979|NCT01428427|Experimental|Cohort|Dose escalation to maximum tolerated dose of GSK1120212 and Gemcitabine.
9988980|NCT01428440|Other|no treatment|
9988981|NCT01428466|Experimental|GSK2585823|external preparation
9988982|NCT01428466|Active Comparator|Benzoic peroxide 3%|external preparation
9988983|NCT01428466|Active Comparator|Benzoic peroxide 5%|external preparation
9988984|NCT01428466|Placebo Comparator|Vehicle|external preparation
9988985|NCT01428479|Experimental|Treatment Arm A|In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8
9988986|NCT01428479|Experimental|Treatment Arm B|In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8
9988987|NCT01428479|Experimental|Treatment Arm C|In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8
9988988|NCT01428492|Experimental|Part 1-Dose Escalation|GSK2110183 is administered in combination with bortezomib and dexamethasone until MTD is met.
9988989|NCT01428492|Experimental|Part 2- Pharmacokinetic/Pharmacodynamics Cohort|Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
9882332|NCT00513903|Active Comparator|Minimal intervention|Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
9882333|NCT00513903|Experimental|Enhanced intervention|Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
9882334|NCT00513903|No Intervention|Control|Control arm patients will not be seen by the clinical pharmacist.
9882335|NCT00513916|Experimental|Arm I|"Participants partake in a high soy diet consisting of 2 daily soy servings (approximately 50mg isoflavones).~The choice of soy foods will include ½ cup of tofu, ¾ cup of soy milk, or ¼ cup of soy nuts. Replacement of currently consumed foods with soy foods will be encouraged."
9882336|NCT00513916|Active Comparator|Arm II|Participants will be asked to keep their soy intake below 3 servings per week. The participants will also receive general nutrition counseling.
9882337|NCT00513929|Experimental|X: Zinc sulphate|
9882338|NCT00513942|No Intervention|A|These women will follow standard antenatal care according to the Norwegian Guidelines
9882339|NCT00513942|Active Comparator|B|Intervention group for Fetal Movement Counting
9882340|NCT00513955|Experimental|Bortezomib plus CHOP|"Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.~Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.~After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter."
9882341|NCT00513968|Experimental|I|HB-110 2mg, 4mg or 8mg combined with Adefovir
9882342|NCT00513968|Active Comparator|II|Adefovir
9882343|NCT00513994|Active Comparator|1|
9882344|NCT00514007|Experimental|OSI-906 QD|Once per day
9882345|NCT00514007|Experimental|OSI-906 BID|Twice per day
9882346|NCT00514033||Group A|PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
9882347|NCT00514059|Other|1|
9882348|NCT00514072|Experimental|Arm I|Patients receive ONY-P1 vaccine with BCG intradermally on days 1 and 15. Patients then receive ONY-P1 vaccine alone on day 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
9882349|NCT00514072|Placebo Comparator|Arm II|Patients receive placebo vaccine intradermally on days 1, 15, and 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
9882350|NCT00514085|Experimental|Recombinant human interleukin-21|
9882351|NCT00514111||HVC Patients|HVC patients attended in SAE e HD.
9882352|NCT00514150|Active Comparator|1|1075 cc of 154 mEq/L solution of NaCl 0.9% , prepared by adding 75 cc of 154 mEq/L NaCl 0.9 % to 1000 cc of 154 mEq/L NaCl 0.9%
9882353|NCT00514150|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate 8.4% to 1000 cc of 154 mEq/ L NaCl 0.9%.
9882354|NCT00514163|Experimental|1|gemcitabine + S-1
9882355|NCT00514163|Active Comparator|2|S-1
9882356|NCT00514189|Experimental|Autologous Dendritic Cells|
9882357|NCT00514202|Placebo Comparator|1|Placebo plus cognitive behavioral therapy
9882358|NCT00514202|Experimental|2|Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy
9882359|NCT00514228|Experimental|Continuous sunitinib treatment|
9882360|NCT00514241|Experimental|A|The arm utilizes the GPS™ II Platelet Concentrate Separation Kit.
9882361|NCT00514241|No Intervention|B|This arm utilizes standard leg wound closure procedures.
9882362|NCT00514254||case|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
9882363|NCT00514254||control|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
9882364|NCT00514306|Experimental|Schedule 1|OSI-906 days 1-3 every 14 days
9882365|NCT00514306|Experimental|Schedule 2|OSI-906 days 1-5 every 14 days
9882366|NCT00514306|Experimental|Schedule 3|OSI-906 days 1-7 every 14 days
9882367|NCT00514332|Experimental|A|primary surgery group
9882368|NCT00514358||gestational age|
9882369|NCT00514410|Experimental|Folic Acid|
9882370|NCT00514410|Placebo Comparator|Placebo|
9882371|NCT00514423|Experimental|2|Psychoeducation by peer-moderators
9882372|NCT00514423|Experimental|1|Psychoeducation by professionals
9882373|NCT00514423|Experimental|3|Video-education
9882374|NCT00514423|Placebo Comparator|4|Control group
9882375|NCT00514436|No Intervention|Usual care|Usual care consisted of referral back to primary care provider after index hospitalization
9882376|NCT00514436|Experimental|Behavioral|Asthma coaching, inperson contact followed by telephone contact
9882377|NCT00514462|Experimental|A|low level laser instrument (Painless Light PL-830, Advanced Chips & Products Crop., USA)
9882378|NCT00514527|Experimental|1|
9882379|NCT00514527|Experimental|2|
9882380|NCT00514527|Experimental|3|
9882381|NCT00514566|Active Comparator|1|Surgical Patient undergoing midline laparotomy closure
9882382|NCT00514579|Other|Myeloablative double unit UCBT|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
9882383|NCT00514618|Active Comparator|1|patients will be treated with misoprostol 50 mcg PO
9882384|NCT00514618|Placebo Comparator|2|patients will receive placebo (Vitamin C)
9882385|NCT00514644|Experimental|Panorama to Ultrasound|100 asymptotic patients that have findings of calcifications in the area of the carotid arteries when examined with panorama. These persons are examined with carotid ultrasound.
9882386|NCT00514644|Experimental|Ultrasound to Panorama|100 patients with a known carotid stenosis seen on ultrasound will be examined with panorama before any intervention is made. These patients must undergo surgery to be finally included.
9882387|NCT00514657|Placebo Comparator|P|
9882388|NCT00514657|Experimental|L|low dose (0.03 %)
9882389|NCT00514657|Experimental|M|medium dose (0.1 %)
9882390|NCT00514657|Experimental|H|high dose (0.3 %)
9882391|NCT00514670|Experimental|1|Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes.
9882392|NCT00514670|No Intervention|2|No hand sanitizer or disinfecting wipes were used.
9882393|NCT00514696|Experimental|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
9882394|NCT00514748|Active Comparator|1|Patients who receive breast reconstruction with bilateral DIEP flap based on bilateral vessel pedicles
9882395|NCT00514748|Experimental|2|Patient who receive breast reconstruction with vessel interconnected DIEP flap based on one vessel pedicle
9882396|NCT00514761|Active Comparator|1|Xeloda
9882397|NCT00514761|Experimental|2|AZD6244
9882398|NCT00514774|Experimental|A|
9882399|NCT00514774|Experimental|B|
9882400|NCT00514774|Placebo Comparator|C|
9882401|NCT00514800|Experimental|Intervention|"Patients will be given a home blood pressure monitor and taught how to use it and how to respond to the readings using a standardised protocol and blood pressure targets. The study nurse will follow up patients at home after a month with additional telephone support according to a defined protocol. Patients will consult their own GP for medication changes when above target.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
9882402|NCT00514800|Active Comparator|Control|
9882403|NCT00514839|No Intervention|C|Control group receiving a booklet on health behavior
9882404|NCT00514839|Experimental|MI|Counselling based on Motivational Interviewing plus individualized feedback
9882405|NCT00514878||1|Adult same-day outpatients scheduled for general anesthesia
9882406|NCT00514891|Active Comparator|1|Vitamin A supplementation
9882407|NCT00514891|Placebo Comparator|2|Placebo
9882408|NCT00514982|Other|1/Drug #1|Oral mesalamine will be used as initial therapy in patients who are not taking any medication or have not received any prior treatment for their IBD. Dosing will begin at 2.4 g PO QD and will be increased to 4.8 g QD within 2 weeks. Topical mesalamine (enema 4 g PR HS/BID or suppository 1 g PR HS/BID) may be added for patients with inflammation that is limited to the rectum (proctitis) or who have prominent complaints of urgency, incomplete evacuation or rectal bleeding.
9882409|NCT00514982|Other|1/Drug#2|Add oral corticosteroids (prednisone) to mesalamine. The standard induction dose will be 40 mg/day. After 1 week of therapy, if the total SCCAI score has decreased by greater than or equal to 2 points the patient will continue on another week of therapy. If the SCCAI has not decreased by greater than or equal to 2 points (indicative of a reduction in symptoms) at one week, then the dose will be increased to 60 mg/day. Patients on either dosage will have another SCCAI assessment done a week later (2 weeks after beginning corticosteroids), and if they are found to be in remission (SCCAI less than or equal to 2), a steroid-tapering schedule will be initiated.
9882410|NCT00514982|Other|1/Drug#3|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
9882411|NCT00514982|Other|1/Drug#4|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
9882412|NCT00514982|Other|1/Drug#5|Subjects with a SCCAI greater than 2 after 3 doses of infliximab will continue 6-MP, discontinue infliximab infusions and start adalimumab injections approximately 2 weeks after the 3rd dose of infliximab. Induction dosing will consist of a 160 Micro/g subcutaneous injection, followed by 80 Micro/g 2 weeks after.
9882413|NCT00514982|Other|1/Drug#6|Patients who have a SCCAI greater than 2 after 2 doses of adalimumab will continue 6-MP, discontinue adalimumab, and start therapy with tacrolimus 0.01 mg/kg PO BID approximately 2 weeks after the second dose of adalimumab.
9882414|NCT00514995|Experimental|1|
9882415|NCT00515047||Eczema Herpeticum (EH)|Participants with AD who currently have or have had EH
9882416|NCT00515047||Non-EH|Participants with AD who do not have and have never had EH
9882417|NCT00515047||Healthy Controls|Healthy participants without a history of AD
9882418|NCT00515060||Cancer Therapy-Induced Pain|Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
9882419|NCT00515125|Other|Dietary Advice|Dietary Advice
9882420|NCT00515125|Other|Oral Nutritional Supplements|Oral Nutritional Supplements
9882421|NCT00515151|Active Comparator|Oct/Alc|
9882422|NCT00515151|Active Comparator|Alc|
9882423|NCT00515164|Experimental|Group 1|Treatment will be administered in 2 treatment sessions.
9882424|NCT00515164|Experimental|Group 2|Treatment will be administered in a single treatment session.
9882425|NCT00515190|Active Comparator|A|(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
9882426|NCT00515190|Active Comparator|B|(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
9882427|NCT00515229|Active Comparator|1|Verum 1: Each individual capsule has a filling volume of 25 mg amitriptyline, given once an day in the evening over 28 days
9882428|NCT00515229|Active Comparator|2|Verum 1: Each individual capsule has a filling volume of 50 mg amitriptyline, given once an day in the evening over 28 days
9882429|NCT00515229|Active Comparator|3|Verum 3: Each individual capsule has a filling volume of 75 mg amitriptyline, given once an day in the evening over 28 days
9882430|NCT00515229|Placebo Comparator|0|Placebo: Each individual capsule has a filling volume of 25 mg placebo (corn starch), given once an day in the evening over 28 days
9882431|NCT00515242|Experimental|1|Therapeutic massage
9882432|NCT00515242|Active Comparator|2|Thermotherapy
9882433|NCT00515242|Placebo Comparator|3|Relaxation
9882434|NCT00515268|Experimental|Subjects receiving GSK256066|Eligible subjects will be randomized to receive GSK256066 with inhaled doses of 25 micrograms or 87.5 micrograms once daily for 7 days, administered via an ACCUHALER.
9882435|NCT00515268|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 7 days, administered via an ACCUHALER.
9935460|NCT03699917||Patients with SVV > or = 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of greater than or equal to 12.
9998324|NCT01517204|Experimental|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate left-sided double lumen endobronchial tube intubation.
9882436|NCT00515281|Experimental|INO Treatment|The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.
9882437|NCT00515281|Placebo Comparator|INO Control|INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
9882438|NCT00515307|Experimental|A|
9882439|NCT00515320|Experimental|Fluoxetine|
9882440|NCT00515320|Placebo Comparator|Placebo|
9882441|NCT00515333|Placebo Comparator|1|Placebo: 0 milligrams; t.i.d.
9882442|NCT00515333|Active Comparator|2|Treatment group: 30 milligrams; t.i.d.
9882443|NCT00515333|Active Comparator|3|Treatment group: 60 milligrams; t.i.d.
9882444|NCT00515333|Active Comparator|4|Treatment group: 100 milligrams; t.i.d.
9882445|NCT00515359|Active Comparator|Dose Comparison|continuous versus intermittent bolus dosing
9882446|NCT00515385|Experimental|1a|Cohort 1 completed
9882447|NCT00515385|Placebo Comparator|1b|Cohort 1 placebo completed
9882448|NCT00515385|Experimental|2a|Cohort 2 completed completed
9882449|NCT00515385|Placebo Comparator|2b|Cohort 2 placebo completed
9882450|NCT00515385|Experimental|3a|Cohort 3 active
9882451|NCT00515385|Placebo Comparator|3b|Cohort 3 placebo
9882452|NCT00515385|Experimental|4a|Cohort 4 active
9882453|NCT00515385|Placebo Comparator|4b|Cohort 4 placebo
9882454|NCT00515385|Experimental|5a|Cohort 5 active
9882455|NCT00515385|Placebo Comparator|5b|Cohort 5 placebo
9882456|NCT00515398||1|Group 1 (all subjects)
9882457|NCT00515450|Experimental|1|
9882458|NCT00515450|Active Comparator|2|
9882459|NCT00515489||001|Risperidone as prescribed
9882460|NCT00515554|Active Comparator|A|8 cycles BEACOPPesc
9882461|NCT00515554|Experimental|B|8 cycles BEACOPPesc plus rituximab
9882462|NCT00515554|Active Comparator|C|8 cycles BEACOPPesc
9882463|NCT00515554|Experimental|D|4 cycles BEACOPPesc
9882464|NCT00515580|Experimental|A|Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.
9882465|NCT00515632|Experimental|Balaglitazone 10 mg per day|
9882466|NCT00515632|Experimental|Balaglitazone 20 mg per day|
9882467|NCT00515632|Active Comparator|Pioglitazone 45 mg per day|
9882468|NCT00515632|Placebo Comparator|Placebo|
9882469|NCT00515645|Experimental|1|
9882470|NCT00515710||1|Prior gene therapy study subjects receiving AAV2-hFIX16.
9882471|NCT00515736|Experimental|AOX group|Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
9882472|NCT00515736|Placebo Comparator|0|Group receiving vehicle solution for 5 days (double dose for 48 hours)
9882473|NCT00515762|Experimental|1: scalp cooling|scalp cooling
9882474|NCT00515788|Experimental|DepoCyt + Temozolomide|DepoCyt Starting 50 mg Intrathecal Day 1 every 14 days for 12 weeks (6 treatments), then every 28 days for 40 weeks (10 treatments). Temozolomide 100 mg/m^2 by mouth daily for 7 days every 14 days.
9882475|NCT00515801|Experimental|A|Glibenclamide 5 mg tablets
9882476|NCT00515801|Placebo Comparator|B|placebo capsules
9882477|NCT00515814|Experimental|1, 2|During measurement/test periods, investigator sets implant into ON or OFF condition without subjects knowledge of when device is active.
9882478|NCT00515840|Sham Comparator|1|equal time with health care professional (asthma nurse)
9882479|NCT00515866|Experimental|1|Gemcitabine + KU-0059436
9882480|NCT00515918||1|Iron deficient
9882481|NCT00515918||2|Iron sufficient
9882482|NCT00515931|Experimental|Radiotherapy|GIST patients who have progressing metastases will be treated with radiotherapy.
9882483|NCT00515957|Experimental|Patients|Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies
9882484|NCT00515970|Experimental|1|Clinical or histologic diagnosis of nodular BCC
9882485|NCT00515970|Active Comparator|2|Clinical or histologic diagnosis of nodular BCC
9882486|NCT00515970|Experimental|3|Clinical or histologic diagnosis of superficial BCC
9882487|NCT00515970|Active Comparator|4|Clinical or histologic diagnosis of superficial BCC
9882488|NCT00515996||2|paroxetine treatment group vs. normal control group
9882489|NCT00516009|Experimental|1 TREATMENT GROUP|20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
9882490|NCT00516009|Placebo Comparator|2|20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
9882491|NCT00516022|Experimental|Investigator product|The patients randomized to this arm will receive the IP injections at home 3 times a week (the patients will inject the IP themselves).
9882492|NCT00516022|Other|Control|The patients randomized to this arm will continue to receive chemotherapy as usual without further treatment (unless prescribed by the Doctor).
9882493|NCT00516035|Experimental|1|0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)
9882494|NCT00516087|Experimental|Patients|Patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies.
9882495|NCT00516113|Active Comparator|1|Paroxetine 20mg during the luteal phase of the menstrual cycle
9882496|NCT00516113|Placebo Comparator|2|Placebo during the luteal phase of the menstrual cycle
9882497|NCT00516126||Point-of-Care managed|This arm includes all patients in which the hemostatic therapy is guided by POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
9882498|NCT00516126||Conventional hemostasis lab managed|This arm includes all patients in which the hemostatic therapy is guided by conventional hemostasis laboratory data e.g. INR, aPTT, fibrinogen concentration, platelet count but no POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
9882499|NCT00516178|Placebo Comparator|Placebo|Saline (No lipid emulsion)
9882500|NCT00516178|Experimental|Fish oil emulsion|3 infusions of 0.2 g/kg omega-3 PUFA within 24 hours in cardiac surgery (continuous infusion post-PTCA)
9882501|NCT00516204||Patients at very high risk|
9882502|NCT00516204||Patients at high risk|
9882503|NCT00516204||Patients at medium risk|
9882504|NCT00516204||Patients at low risk|
9882505|NCT00516243|Experimental|Arm I (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
9882506|NCT00516243|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
9882507|NCT00516256|Experimental|CHESS System|CHESS System - Internet-based computer program for 6 months.
9882508|NCT00516256|Experimental|Cancer Information Mentor|Cancer Information Mentor - Phone calls to the patient for 6 months.
9882509|NCT00516256|Experimental|CHESS System + Cancer Information Mentor|CHESS System + Cancer Information Mentor
9882510|NCT00516360|Experimental|1|Chlorhexidien as the antibacterial agent used to cleanse the hub of neonatal central lines
9882511|NCT00516360|Active Comparator|2|Isopropyl alcohol as the antibacterial agent used to cleanse the hub of neonatal central lines
9882512|NCT00516399|Experimental|I:|povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
9882513|NCT00516399|Active Comparator|II|natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.
9882514|NCT00516412|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9882515|NCT00516438|Experimental|1|Topotecan + KU-0059436
9882516|NCT00516451|Experimental|1|
9882517|NCT00516477|Experimental|dose cohort 1|1.5E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
9882518|NCT00516477|Experimental|dose cohort 2|4.8E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
9882519|NCT00516477|Experimental|dose cohort 3|1.5E11 vector genomes voretigene neparvovec-rzyl in 300 microliters administered subretinally
9882520|NCT00516490|Experimental|1|GnRH agonist administration
9882521|NCT00516490|Placebo Comparator|2|Sterile saline injection
9882522|NCT00516516|Experimental|I|Oral L-Carnitine, 1g PO twice daily
9882523|NCT00516516|Placebo Comparator|II|Placebo, similar in appearance to experimental drug, given orally twice daily.
9882524|NCT00516555||A, 07, 001|Pregnant women at term with a baby in breech presentation who will have an external cephalic version.
9882525|NCT00516581||no HAART|Patients that no received HAART
9882526|NCT00516581||with HAART|Patients that received HAART
9882527|NCT00516620|Active Comparator|1|Participants receive Health Canada's Food Guide and Physical Activity guide.
9882528|NCT00516620|Active Comparator|2|Participants receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
9882529|NCT00516620|Active Comparator|3|Participants receive intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products.
9882530|NCT00516620|Active Comparator|4|Participants receive intensive dietary counseling for 6 months to decrease intake of sweetened soft drink.
9882531|NCT00516633|No Intervention|CG|The control group had regular individual information and support in connection with ordinary clinical follow-ups
9988990|NCT01428492|Experimental|Part 2- Safety/Clinical Activity Cohort|"Enrolment into the safety/clinical activity cohort in Part 2 will begin prior to enrollment in the PK/PD cohort. Subjects with relapsed multiple myeloma who are either bortezomib sensitive or naive after failing one line of prior systemic therapy will be enrolled in the Safety/Clinical Activity cohort. Bortezomib sensitive is defined as having a response (PR or better) to the last bortezomib-containing therapy lasting at least 60 days beyond the end of therapy. A minimum of 15 subjects and a total of 40 subjects will be enrolled. This expansion cohort will further characterize the safety and clinical activity profile of GSK2110183 to inform the future development of this combination regimen."
9988991|NCT01428505|Other|no treatment|
9988992|NCT01428518||Patients with bipolar disorder|Patients with bipolar disorder prescribed lamotrigine tablets for the first time
9988993|NCT01428531||Patients prescribed fondaparinux|
9988994|NCT01428544||Patients with VTE treated with fondaparinux|Patients with VTE treated with fondaparinux
9988995|NCT01428557||Heart Failure patients|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
9988996|NCT01428570|Experimental|Pentax-AWS|Patients in this group will be intubated using Pentax-AWS
9988997|NCT01428570|Active Comparator|laryngoscopy|Patients in this group will be intubated using Macintosh laryngoscope.
9988998|NCT01428596|Experimental|Arm I|Lower dose HIVAX vaccine
9988999|NCT01428596|Placebo Comparator|Arm II|lower dose, placebo control
9989000|NCT01428596|Experimental|Arm III|Higher dose HIVAX vaccine
9989001|NCT01428622|Placebo Comparator|Placebo + BI 54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
9989002|NCT01428622|Experimental|Olodaterol low dose + BI54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
9989003|NCT01428622|Active Comparator|Olodaterol medium dose + BI54903|patient to receive 2 puffs of each device
9989004|NCT01428622|Experimental|Olodaterol high dose + BI54903|patient to receive 2 puffs of each device
9989005|NCT01428622|Experimental|Olodaterol l dose + BI54903|patient to receive 2 puffs of each device
9989006|NCT01428622|Experimental|Olodaterol m dose + BI54903|patient to receive 2 puffs of each device
9989007|NCT01428622|Experimental|Olodaterol h dose + BI54903|patient to receive 2 puffs of each device
9989008|NCT01428648|Active Comparator|intervention|group of patients receiving ballroom dancing classes
9989009|NCT01428648|No Intervention|control|group of patients who will not receive dancing classes.
9989010|NCT01428674|Experimental|10 minutes reading|
9989011|NCT01428674|Experimental|20 minutes touch|
9989012|NCT01428674|Experimental|20 minutes reading|
9989013|NCT01428674|Experimental|10 minutes touch|
9989014|NCT01428687|Active Comparator|Increase Sleep Gradually|Subjects in this condition are taught to increase their sleep by 30 minutes per night during week 1 of the intervention; 60 minutes during week 2; and 90 minutes during week 3. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
9989015|NCT01428687|Active Comparator|Increase Sleep Immediately|Subjects in this condition are taught to increase their sleep by 90 minutes per night starting in week 1. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
9989016|NCT01428687|Active Comparator|No Intervention: Control Group|This group is told to make no changes in their sleep habits. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
9997284|NCT01507428|Experimental|Arm II (experimental chemoradiotherapy)|Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
9997285|NCT01507454||Local treatment|
9997286|NCT01507467|Active Comparator|Accl. RT|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
9997287|NCT01507467|Experimental|Accl. RT + Nimorazole|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole
9997288|NCT01507480|Experimental|Bevacizumab|This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
9997289|NCT01507506|Active Comparator|Conventional arm|3-dimensional conformal radiotherapy + Temozolomide
9989017|NCT01428700||Non-Immune/Non-Viral (NINV)|Patients enrolled in ITN030ST transplanted for liver failure resulting from non-viral, non-immune causes
9989018|NCT01428700||Hepatitis C Virus (HCV) positive|Patients enrolled in ITN030ST transplanted for liver failure resulting from HCV genotype 1 infection
9989019|NCT01428726|Placebo Comparator|Placebo|
9882532|NCT00516633|Experimental|IG|The intervention group had extra support and information in the form of four group discussions with parents
9882533|NCT00516646|Active Comparator|1|ALT-711 200 mg bid
9882534|NCT00516646|Placebo Comparator|2|
9882535|NCT00516659|Active Comparator|Group 1|Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
9882536|NCT00516659|Placebo Comparator|Group 2|Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
9882537|NCT00516672|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib
9882538|NCT00516685|Experimental|Vaccine Group|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
9882539|NCT00516685|No Intervention|Control Group|Patients in this arm will only receive Best Supportive Care.
9882540|NCT00516698||Group 1|"Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.~Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy."
9882541|NCT00516802|Experimental|1|DTIC + KU-0059436
9882542|NCT00516828|Experimental|Sorafenib and Cytarabine|Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
9882543|NCT00516841|Experimental|volociximab|15 mg/kg volociximab once weekly
9882544|NCT00516867|Active Comparator|UVB 0.5%|
9882545|NCT00516867|No Intervention|Controls|
9882546|NCT00516867|Active Comparator|UVB 1.4%|
9882547|NCT00516958|Experimental|1|Topical Dermacyn
9882548|NCT00516958|Active Comparator|2|Topical Dermacyn and levofloxacin
9882549|NCT00516958|Active Comparator|3|Topical saline and levofloxacin
9882550|NCT00516984|Placebo Comparator|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
9882551|NCT00516984|Sham Comparator|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
9882552|NCT00516984|Active Comparator|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
9882553|NCT00517023|Active Comparator|ILR + Syncope Clinic|Patients will have ILR implanted and follow-up in Syncope Clinic
9989020|NCT01428726|Experimental|NT-KO-003 low dose|
9882554|NCT00517023|Active Comparator|ILR Only|Patients will have ILR implanted and routine follow up.
9882555|NCT00517023|Active Comparator|Routine Mx + Syncope Clinic|Patients will receive routine care and management plus follow up in Syncope Clinic
9882556|NCT00517023|Active Comparator|Routine Mx|Patients will receive routine care and management
9882557|NCT00517036|Experimental|A|Participants will take EPA
9882558|NCT00517036|Experimental|B|Participants will take DHA
9882559|NCT00517036|Placebo Comparator|C|Participants will take placebo
9882560|NCT00517062|Active Comparator|A|Growth hormone
9882561|NCT00517062|Placebo Comparator|B|Placebo
9882562|NCT00517088|Other|Other|Group Description
9989021|NCT01428726|Experimental|NT-KO-003 high dose|
9989022|NCT01428752||Family history|30- to 49-year-old asymptomatic subjects with a first relative history of colorectal cancer
9989023|NCT01428791|Active Comparator|Generations older adult member program|Rush Generations is a membership program for older adults, providing chronic disease prevention and management through educational programming, civic engagement, and individual and family consultations with social work staff.
9997290|NCT01507506|Experimental|Experimental arm|simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
9882563|NCT00517127|Active Comparator|1|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
9882564|NCT00517127|Active Comparator|2|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
9882565|NCT00517166||A|Individuals on whom tourniquet was used.
9882566|NCT00517244||A|Primary anxiety disorder
9882567|NCT00517244||B|Primary obsessive compulsive disorder
9882568|NCT00517244||C|Healthy children with no previous history of an anxiety disorder
9882569|NCT00517257|Experimental|A|Atorvastatin 80 mg orally once daily for 24 weeks
9882570|NCT00517257|Placebo Comparator|P|Placebo tablet orally once daily for 24 weeks
9882571|NCT00517283|Experimental|Sequence 1|Exenatide 5 mcg - Exentatide 10 mcg - Placebo
9882572|NCT00517283|Experimental|Sequence 2|Exenatide 10 mcg - Placebo - Exenatide 5 mcg
9882573|NCT00517283|Experimental|Sequence 3|Placebo - Exenatide 5 mcg - Exenatide 10 mcg
9882574|NCT00517322|Experimental|1|treatment with ramipril
9882575|NCT00517322|Experimental|2|treatment with irbesartan
9882576|NCT00517335||1|Women who are healthy controls
9882577|NCT00517335||2|Women who have recovered from bulimia
9882578|NCT00517335||3|Women who have recovered from anorexia
9882579|NCT00517387|Active Comparator|1|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
9882580|NCT00517400|Active Comparator|Exposure-Stimulation|
9882581|NCT00517400|Active Comparator|Sham exposure - Real stimulation|
9882582|NCT00517400|Active Comparator|Exposure - Sham Stimulation|
9882583|NCT00517426|Experimental|Active Acetazolamide|
9882584|NCT00517452||Platelet Rich Plasma|Group received platelet rich plasma and observed over a period of 30 days or until wound closure
9882585|NCT00517452||Standard Wound Care|Group was treated as per standard care
9882586|NCT00517465|Experimental|1|
9882587|NCT00517465|Experimental|2|
9882588|NCT00517465|Experimental|3|
9882589|NCT00517465|Placebo Comparator|4|
9882590|NCT00517491|Experimental|1|
9882591|NCT00517517|Experimental|1|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 7.5 µg of H5N1 HA antigen per 0.5 mL in a non-adjuvanted formulation
9882592|NCT00517517|Experimental|2|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 3.75 µg of H5N1 HA antigen per 0.25 mL in a non-adjuvanted formulation
9882593|NCT00517569|Experimental|1|GX-12 combined with HAART
9882594|NCT00517582|Experimental|HOE-140|Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
9882595|NCT00517582|Placebo Comparator|Placebo|Administration of placebo at time 0 and 6 hours
9882596|NCT00517673|Experimental|GSK945237|Active Study Drug
9882597|NCT00517673|Placebo Comparator|Sugar Pill|Placebo
9882598|NCT00517686|Experimental|1|The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
9882599|NCT00517686|No Intervention|2|Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
9882600|NCT00517712|Active Comparator|A|Duration of maintenance therapy with single agent ATO of 12 months
9882601|NCT00517712|Active Comparator|B|Duration of maintenance therapy with single agent ATO for 6 months
9882602|NCT00517725|Active Comparator|Carvedilol|
9882603|NCT00517725|Active Comparator|Bisoprolol|
9882604|NCT00517725|Active Comparator|Nebivolol|
9882605|NCT00517738|Experimental|Physical training - No encephalopathy|Patients randomized to the physical training program and diet intervention
9882606|NCT00517738|Active Comparator|Control - No encephalopathy|Patients not allocated to exercise program, but undergoing diet intervention
9882607|NCT00517738|Experimental|Physical training - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grade 1-2) randomized to the physical training program
9882608|NCT00517738|Active Comparator|Control - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grades 1-2) not allocated to the physical training program, but undergoing diet intervention
9882609|NCT00517764|No Intervention|Healthy control|Healthy matched control, no intervention
9882610|NCT00517764|Active Comparator|Escitalopram|Depressed subjects receiving escitalopram
9882611|NCT00517764|No Intervention|subjects with major depression|Depressed subjects not receiving study treatment, but taking part in study measures.
9882612|NCT00517777|Experimental|1|continuous positive airway pressure ventilation + dietary and life style recommendations
9882613|NCT00517777|Active Comparator|2|dietary and life style recommendations
9882614|NCT00517803|Experimental|1|
9882615|NCT00517803|Placebo Comparator|2|
9882616|NCT00517816|Experimental|1|
9882617|NCT00517816|Experimental|2|
9882618|NCT00517816|Experimental|3|
9882619|NCT00517816|Experimental|4|
9882620|NCT00517816|Experimental|5|
9882621|NCT00517816|Experimental|6|
9882622|NCT00517816|Experimental|7|
9882623|NCT00517816|Experimental|8|
9882624|NCT00517907|Experimental|1|6 steroid-resistant acute GVHD patients, post-matched BMT (serial)
9882625|NCT00517959|Experimental|1|Stereotactic conformal radiotherapy (SCRT)
9882626|NCT00517959|Other|2|Conventional radiotherapy Patients in this arm will be treated with conventional radiotherapy techniques being used at the moment in the department. This involves patient being immobilised with a customised thermoplastic mask after which they will have a contrast enhanced planning CT scan. The radiation oncologist will draw the tumour on the appropriate CT slices and a margin of 1-2 cms grown for the planning target volume. Beam arrangement will be relatively simple and typically consist of 2-3 coplanar fields using 6 MV photons. Conventional planning optimisation will be carried out by the use of wedges, beam weightage and corner shields as appropriate. Radiotherapy doses, prescription and fractionation schedules will be identical to the SCRT arm
9882627|NCT00517998|Experimental|Group1|Treatment will be administered in two sessions.
9882628|NCT00517998|Experimental|Group2|Treatment will be administered in a single session.
9882629|NCT00518024|Experimental|1|Bilateral theta burst stimulation to the secondary auditory cortex
9882630|NCT00518024|Experimental|2|Bilateral theta burst stimulation to the tertiary auditory cortex
9882631|NCT00518024|Sham Comparator|3|Bilateral theta burst stimulation to a non-cortical region
9882632|NCT00518050||Specific Aim 1- Focus Group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~Screening, skin self-examination, sun protection, and other cancer preventive practices;~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
9882633|NCT00518050||Specific Aim 2- Survey Study|A separate random sample of melanoma survivors will complete the pilot questionnaire. To enhance completion rates, survey instruments will be developed to be both self-administered and interviewer-administered. The survey will include questions from existing surveys, regarding demographics, sun sensitivity, eye and hair color, color of untanned skin, sun exposure, skin selfexamination, sun protection practices and frequency of sunburns, psychosocial/cognitive factors: skin cancer knowledge, skin awareness, cancer worry, perceived risk of recurrence, cancer risk and screening behaviors, and access to health care and insurance.
9882634|NCT00518102||001|REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
9882635|NCT00518102||002|REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
9882636|NCT00518128|Active Comparator|1|Surgical OSA Treatment Group: Moderate to Severe OSA patients who are unable to tolerate PAP (Positive Airway Pressure) and elect to proceed with surgical treatment (surgical cohort).
9882637|NCT00518128|Active Comparator|2|Positive Airway Pressure Therapy Comparison Group: Moderate to Severe OSA patients who tolerate PAP (Positive Airway Pressure).
9882638|NCT00518141|Experimental|1|FER
9882639|NCT00518141|No Intervention|2|FER
9882640|NCT00518141|Experimental|3|SET
9882641|NCT00518141|No Intervention|4|SET
9882642|NCT00518141|Experimental|5|DET
9882643|NCT00518141|No Intervention|6|DET
9882644|NCT00518167|Experimental|1|Intensive lifestyle intervention
9882645|NCT00518167|No Intervention|2|Standard counselling at baseline
9882646|NCT00518219|Experimental|immunosuppressor|TW 120mg/d，Valsartan,160mg/d
9882647|NCT00518245|Experimental|1|
9882648|NCT00518245|No Intervention|2|
9882649|NCT00518258||1|Patient Group
9882650|NCT00518258||2|Control Group
9882651|NCT00518297|Active Comparator|1|
9882652|NCT00518297|Active Comparator|2|
9882653|NCT00518297|Active Comparator|3|
9882654|NCT00518310|Placebo Comparator|0|Placebo
9882655|NCT00518310|Active Comparator|1|Azathiprine Prednisone
9882656|NCT00518362|Experimental|immunosuppressor|Valsartan,160mg/d,TW 120mg/d
9882657|NCT00518388||Focus Group + Questionnaire|Participants that are self identified as Korean, Filipino, or Vietnamese.
9882658|NCT00518414|Active Comparator|Marketed infant formula with DHA and ARA|Marketed milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
9882659|NCT00518414|Experimental|Milk-based infant formula with DHA and ARA|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
9882660|NCT00518414|Experimental|Milk-based formula with DHA, ARA, prebiotics|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) and prebiotic blend
9882661|NCT00518427|Experimental|1|insulin glargine
9882662|NCT00518453|Experimental|Arm 1: Fluvirin|
9882663|NCT00518466|Experimental|treatment 1|"One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2."
9882664|NCT00518466|Experimental|treatment 2|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
9882665|NCT00518466|Experimental|treatment 3|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
9882666|NCT00518466|Experimental|treatment 4|"Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2."
9882667|NCT00518479|Experimental|1|Neurohormonal stimulatory arm
9882668|NCT00518479|Experimental|2|Neurohormonal inhibitory arm
9882669|NCT00518492|Experimental|Arm 1|Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity
9882670|NCT00518505|Other|I|This is a single arm study. All patients will be asked to complete questionnaires and have their medical charts reviewed.
9882671|NCT00518518|Active Comparator|1|
9882672|NCT00518518|Placebo Comparator|2|
9882673|NCT00518557|Experimental|1|All patients of this arm are treated by TACE together with Andostatin.
9882674|NCT00518557|Active Comparator|2|All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.
9882675|NCT00518570|Experimental|Open-Label treatment|Patients prospectively diagnosed with premenstrual dysphoric disorder.
9882676|NCT00518596|Experimental|Probiotic Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, given L. plantarum preparations orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
9882677|NCT00518596|Placebo Comparator|Control Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, receiving placebo preparations (a control solution of sterile 2.0 cc 5% dextrose-saline)orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
9882678|NCT00518609||Indian Neonates|All hospitalized neonates (all live born infants <60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.
9882679|NCT00518635|Experimental|A|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
9882680|NCT00518648|Experimental|I|Multifactorial fall prevention program
9882681|NCT00518648|Other|II|Usual care
9882682|NCT00518726|Experimental|Arm 1|
9882683|NCT00518752|Active Comparator|A|Standard Oral Care
9882684|NCT00518752|Experimental|B|Comprehensive Oral Care
9882685|NCT00518765|Experimental|1|Various sequences of different doses of Aliskiren
9882686|NCT00518765|Experimental|2|Various sequences of different doses of Aliskiren plus placebo
9882687|NCT00518765|Experimental|3|Various sequences of different doses of Aliskiren
9882688|NCT00518765|Experimental|4|Various sequences of different doses of Aliskiren plus placebo
9882689|NCT00518791|Experimental|I|Multidisciplinary Care
9882690|NCT00518791|Other|II|Usual Care
9882691|NCT00518830|Experimental|PND-MCI|The multi-component intervention involved a psychoeducational group, treatment adherence support, and pharmacotherapy if needed
9882692|NCT00518830|Active Comparator|usual care|'Usual care' included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
9882693|NCT00518843|Experimental|FBT-BN|Family-based treatment
9882694|NCT00518843|Active Comparator|SPT|Individual Supportive Psychotherapy
9882695|NCT00518856|Experimental|intervention|TBAs who receive training and supplies for the intervention
9882696|NCT00518856|Active Comparator|control|TBAs continuing with current standard of practice
9882697|NCT00518869|Experimental|Treatment group|PG2 plus standard chemotherapies
9882698|NCT00518869|Placebo Comparator|Placeo group|Placebo plus standard chemotherapies
9882699|NCT00518895|Experimental|A|Dacarbazine with Genasense
9882700|NCT00518895|Active Comparator|B|Dacarbazine with placebo
9931054|NCT00934479|Experimental|Constipated Subjects|"Subjects with constipation included those with chronic constipation (CC) and those with constipation predominant irritable bowel syndrome (C-IBS). They completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing.~Following baseline test and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.~Following the 4-weeks treatment with lubiprostone, they completed another stool diary, fasting breath test, and stool sample for pyrosequencing."
9931055|NCT00934492|Active Comparator|Cotrimoxazole dispersible tablet|Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
9931056|NCT00934492|Placebo Comparator|Placebo dispersible tablet|Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
9931057|NCT00934518|Experimental|Radiation and Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
9931058|NCT00934531|Experimental|Donepezil|participants with MCI receiving donepezil
9931059|NCT00934531|Placebo Comparator|Placebo|Participants with MCI receiving placebo
9931060|NCT00934557|Experimental|Good prognosis/mismatched donor/BM|
9931061|NCT00934557|Experimental|Good prognosis/mismatched donor/PB|
9931062|NCT00934557|Experimental|Poor prognosis/matched donor/BM|
9931063|NCT00934557|Experimental|Poor prognosis/matched donor/PB|
9931064|NCT00934557|Experimental|Poor prognosis/mismatched donor/BM|
9931065|NCT00934557|Experimental|Poor prognosis/mismatched donor/PB|
9931066|NCT00934557|Experimental|Good prognosis/matched donor/BM|
9931067|NCT00934557|Experimental|Good prognosis/matched donor/PB|
9931068|NCT00934570|Active Comparator|Metformin, Standard exercise|Lifestyle intervention with metformin and standard exercise program.
9931069|NCT00934570|Placebo Comparator|Placebo, Standard exercise|Lifestyle intervention with placebo and standard exercise program
9997291|NCT01507519|Experimental|BioMime™|BioMime™ DES
9882701|NCT00518908|Experimental|Sevoflurane|Sevoflurane for pharmacological postconditioning
9882702|NCT00518908|Experimental|Propofol|Anesthesia maintenance with propofol instead of Sevoflurane postconditioning
9882703|NCT00518921|Experimental|Arm 1|
9882704|NCT00518921|Experimental|Arm 2|
9882705|NCT00518921|Experimental|Arm 3|
9882706|NCT00518921|Placebo Comparator|Arm 4|
9882707|NCT00518947|Active Comparator|1|Continued-Lithium
9882708|NCT00518947|Experimental|2.|Verapamil
9882709|NCT00518947|Experimental|3.|Verapamil plus Lithium
9882710|NCT00518999||1|Schizophrenia patients who performed earlier cognitive assessment as part of routine assessment for patients in the Shalvata Mental Health Center.
9882711|NCT00519012|Active Comparator|Arm-1|Sertraline to Paroxetine
9882712|NCT00519012|Active Comparator|2|Paroxetine to Sertraline
9882713|NCT00519038|Experimental|1|Patients treated according to clinical pathways
9882714|NCT00519038|Other|2|Patients treated according to usual care
9882715|NCT00519051|Active Comparator|control group|patients can receive pharmacotherapy and psychotherapy and specialized treatment
9882716|NCT00519064|Active Comparator|Arm 1|
9882717|NCT00519064|Active Comparator|Arm 2|
9882718|NCT00519103|Experimental|1|Active resistive excercise for 7 weeks
9882719|NCT00519155|Experimental|1|Open flap debridement + MD05
9882720|NCT00519155|Active Comparator|2|Open flap debridement
9882721|NCT00519207|Active Comparator|1|This group will receive lidocaine and sucrose placebo (water).
9882722|NCT00519207|Active Comparator|2|This group will receive lidocaine placebo and sucrose.
9882723|NCT00519207|Active Comparator|3|This group will receive lidocaine and sucrose.
9882724|NCT00519220||I|Patients will answer symptom questionnaires and have their charts reviewed for relevant medical information.
9882725|NCT00519233|Experimental|1.AGS-1C4D4|
9882726|NCT00519246|Placebo Comparator|I|No drug was delivered.
9882727|NCT00519246|Active Comparator|II|Butorphanol tartrate 1mg was given intravenously.
9882728|NCT00519246|Active Comparator|III|Butorphanol tartrate 2 mg was given intravenously.
9882729|NCT00519246|Active Comparator|IV|Flurbiprofen Axetil 50 mg was given intravenously.
9882730|NCT00519246|Active Comparator|V|Flurbiprofen Axetil 100 mg was given intravenously.
9882731|NCT00519246|Active Comparator|VI|Tramadol Hydrochloride 10 mg was given intravenously.
9882732|NCT00519246|Active Comparator|VII|Tramadol Hydrochloride 20 mg was given intravenously.
9882733|NCT00519272||Cervical Cancer Care Questionnaires|New cervical cancer patients through stage IVB presenting to the LBJ Gyn-Onc Clinic.
9882734|NCT00519298|Experimental|1|
9882735|NCT00519298|Placebo Comparator|2|
9882736|NCT00519298|Active Comparator|3|
9797331|NCT01592695|Experimental|Tailored Intervention Group|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
9797332|NCT01592695|Active Comparator|Enhanced Standard of Care Group|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
9882737|NCT00519311|Experimental|School based health intervention|Educational intervention based on health diary + health check
9797333|NCT01592708|Active Comparator|Antiemetic anesthesia protocol|Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po
9797334|NCT01592747|Experimental|Memantine 1|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.
9797335|NCT01592747|Experimental|Memantine 2|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.
9797336|NCT01592747|Placebo Comparator|Placebo|Dosing will be once daily for up to 12 weeks.
9797337|NCT01592760|Experimental|air-Q SP|air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
9797338|NCT01592760|Active Comparator|air-Q|air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
9882738|NCT00519311|No Intervention|Usual care|Normal school curriculum and usual medical care
9882739|NCT00519324|Experimental|RAD001|
9882740|NCT00519337|Active Comparator|1|Ascorbic acid
9797339|NCT01592760|Active Comparator|i-gel|i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA)
9797340|NCT01592773|Experimental|Memantine|"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.~Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
9797341|NCT01592786|Experimental|Memantine Hydrochloride (HCl)|Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
9797342|NCT01592799|Other|Influenza Group|Children <15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
9797343|NCT01592851|Experimental|Arm 1|Dentifrice containing stannous fluoride
9797344|NCT01592851|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
9797345|NCT01592864|Experimental|Arm 1|Dentifrice containing stannous fluoride
9797346|NCT01592864|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
9797347|NCT01593020|Experimental|Paclitaxel + FEC or FAC Group|"ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
9797348|NCT01593020|Experimental|Eribulin + FEC or FAC Group|"ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
9797349|NCT01593215|Active Comparator|Placebo first then yohimbine|placebo first, then yohimbine
9797350|NCT01593215|Active Comparator|Yohimbine first then placebo|Yohimbine first then placebo
9797351|NCT01593592|Experimental|Lactobacillus reuteri group|The active group that will receive the standard triple therapy and Lactobacillus reuteri
9797352|NCT01593592|Placebo Comparator|Control group|The control group that will receive the standard triple therapy and placebo
9882741|NCT00519337|Placebo Comparator|2|Identical placebo
9882742|NCT00519350||I|Liver surgery
9882743|NCT00519350||II|Colon surgery
9882744|NCT00519350||III|Femur Fracture
9882745|NCT00519402||Partial Tonsillectomy|Patients who received a partial tonsillectomy
9882746|NCT00519402||Complete Tonsillectomy|Patients who received a complete tonsillectomy
9882747|NCT00519415|Experimental|A|
9882748|NCT00519415|Experimental|B|
9882749|NCT00519441|Other|I|All patients in the study will have pH studies done in order to determine the degree of reflux after laparoscopic Heller myotomies.
9882750|NCT00519454||Female Lupus patients|Females who are still childbearing age, not on hormones, with Systemic Lupus Erythematosus, still cycling.
9882751|NCT00519480|Placebo Comparator|Subjects receiving treatment P|Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
9882752|NCT00519480|Experimental|Subjects receiving treatment A|Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
9882753|NCT00519480|Experimental|Subjects receiving treatment B|Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
9882754|NCT00519493|Active Comparator|Suture|A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
9989024|NCT01428791|Experimental|BRIGHTEN Heart Virtual Team|BRIGHTEN Heart provides older adults with an interdisciplinary team evaluation of physical and mental health and on-going support for mental health and health behavior change for a minimum of six months. The five core components of the BRIGHTEN intervention consist of: 1) Assessment; 2) Virtual team case review; 3) Patient centered action planning; 4) Plan implementation, and; 5) When indicated, short-term evidence-based geriatric specialty psychotherapy.
9989025|NCT01428804|Active Comparator|active tDCS|a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning and 1 afternoon) for 5 days with an electric current 2 mA
9989026|NCT01428804|Sham Comparator|sham tDCS|a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and sham tDCS.
9989027|NCT01428817|Active Comparator|Carbetocin 20mcg|
9989028|NCT01428817|Active Comparator|Carbetocin 40mcg|
9989029|NCT01428817|Active Comparator|Carbetocin 60mcg|
9989030|NCT01428817|Active Comparator|Carbetocin 80mcg|
9989031|NCT01428817|Active Comparator|Carbetocin 100mcg|
9989032|NCT01428830|Experimental|7-day catheterization|
9989033|NCT01428830|Active Comparator|14-day catheterization|
9989034|NCT01428843|Active Comparator|Ferrisat|Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
9989035|NCT01428843|Placebo Comparator|Placebo|Infusion of placebo at inclusion visit
9989036|NCT01428869||statin+ASA+dutasteride|
9989037|NCT01428869||statin+ASA|
9989038|NCT01428869||dutasteride+statin|
9989039|NCT01428869||dutasteride+ASA|
9989040|NCT01428908|Experimental|children group A|600 children aged 2-5 years old, will be vaccinated on day0
9989041|NCT01428908|Experimental|infants group A|600 infants aged 6-23 months old, will be vaccinated on day0, 28
9989042|NCT01428908|Active Comparator|children group B|600 children aged 2-5 years old, will be vaccinated on day0
9989043|NCT01428908|Active Comparator|infants group B|600 infants aged 6-23 months old, will be vaccinated on day0, 28
9989044|NCT01428921|Experimental|Extended Education|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
9989045|NCT01428921|No Intervention|Standard education|- Each subject will receive advice from Sleep Lab staff on the need for CPAP treatment, and the care of CPAP device and mask.
9989046|NCT01428934||Intermediate risk population|Population aged between 35 to 74 years who have an intermediate cardiovascular risk, defined as coronary risk between 5% -15% at 10 years according to the Framingham adapted risk equation or vascular mortality risk between 3-5% at 10 years according to the SCORE equation [27].
9989047|NCT01428947||Coronary angiography|Patents scheduled for elective coronary angiography
9989048|NCT01428960|Experimental|Palm Mid Fraction|
9989049|NCT01428960|Experimental|Shea Butter|
9989050|NCT01428960|Experimental|High Oleic Sunflower Oil|
9989051|NCT01428986||Maraviroc|Those whose take maraviroc as a part of their HIV treatment
9989052|NCT01428986||No maraviroc|Those who do not take maraviroc
9989053|NCT01428999|Experimental|probiotics|1 pack bid use for 3 weeks
9989054|NCT01428999|Placebo Comparator|Placebo|placebo 1pack bid for 3 weeks
9989055|NCT01429012|Experimental|Mesenchymal Stem Cells|"2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.~MSC will be injected even if the number of available cells is lower than 40 X 10E6.~The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist."
9989056|NCT01429012|Placebo Comparator|Culture medium without MSC.|Culture medium used to resuspend the Mesenchymal Stem Cells.
9989057|NCT01429025|Experimental|rituximab, bendamustine and lenalidomide|Patients receive rituximab IV on day 1, bendamustine IV on days 1-2, and lenalidomide PO on days 1-10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9997292|NCT01507532|Other|Ceftazidime|pharmacokinetic monitoring
9882755|NCT00519493|Active Comparator|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
9797353|NCT01593670|Experimental|Patients With High Risk MDS|Patients who received treatment for high risk myelodysplastic syndromes (MDS). Treatment Received: Decitabine 10 mg/m^2/day intravenous (IV) over 1 hour days 1-5; Vorinostat 200 mg by mouth (PO) twice a day days 6-15; Il-2 activated donor natural killer cells (NK) infusion IV over 15 to 60 minutes day 17; Interleukin-2 6 million units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17. Repeat treatment course 6 to 8 weeks after cycle 1 start date.
9797354|NCT01593696|Experimental|Lymphodepleting regimen of Fludarabine and Cyclophosphamide|Lymphodepleting regimen of Fludarabine and Cyclophosphamide.
9797355|NCT01593696|Experimental|Intensive standard of care chemotherapy|Intensive standard of care chemotherapy, in lieu of the lymphodepleting chemotherapy regimen, to decrease tumor burden in preparation for the administration of the Chimeric antigen receptor (CAR) T cells.
9797356|NCT01593722|Active Comparator|diethylcarbamazine|diethylcarbamazine 8 mg/kg single oral dose
9797357|NCT01593722|Active Comparator|ivermectin|ivermectin 200 mcg/kg single oral dose
9800191|NCT01681992|Experimental|Inv_MMR_Med Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
9800192|NCT01681992|Active Comparator|Com_MMR Group|Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
9800193|NCT01682031|Placebo Comparator|Arm I (placebo, cisplatin, and radiotherapy)|Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
9800194|NCT01682031|Experimental|Arm II (selenomethionine, cisplatin, and radiotherapy)|Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.
9800195|NCT01682044|Experimental|Treatment (colony-stimulating factor and monoclonal antibody)|Patients receive pegfilgrastim SC followed by rituximab IV 3 days later in weeks 1, 3, 5, 7, 15, 23, 31, and 39. Treatment continues in the absence of disease progression or unacceptable toxicity.
9800196|NCT01682083|Experimental|Dabrafenib and trametinib|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
9800197|NCT01682083|Placebo Comparator|Dabrafenib and trametinib placebos|Subjects received matching placebos orally for 12 months
9800198|NCT01682135|Experimental|Ramucirumab|Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram [mg/kg] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
9882756|NCT00519519|Active Comparator|2|regular dose versus high dose
9882757|NCT00519545|Experimental|1|scripted prayer group (intervention group)
9882758|NCT00519545|No Intervention|2|no prayer intervention group (non-intervention group)
9882759|NCT00519571|Experimental|1|
9882760|NCT00519597|Experimental|I|Asymptomatic OSA (CPAP)
9882761|NCT00519597|No Intervention|II|Asymptomatic OSA (no CPAP)
9882762|NCT00519597|Active Comparator|III|Symptomatic OSA (OSAS)
9882763|NCT00519597|No Intervention|IV|Non-OSA
9882764|NCT00519610||I|Patients will have charts reviewed for relevant medical information before and after surgery to assess patient outcome after placement of H-graft shunt for the treatment of portal hypertension.
9882765|NCT00519662|Experimental|Dose escalating cohorts of SNS-314|Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema.
9882766|NCT00519688|Experimental|Thalidomide plus Tegafur/Uracil1|Thalidomide plus Tegafur/Uracil
9882767|NCT00519701|Experimental|1|hydroxyurea
9882768|NCT00519714|Placebo Comparator|1|three placebo capsules PO three times daily.
9882769|NCT00519714|Active Comparator|2|1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily
9882770|NCT00519714|Active Comparator|3|1-MNA 270 mg daily: three active treatment capsules PO three times daily.
9882771|NCT00519727|Experimental|A|50 mg ISIS 325568 vs Placebo, s.c. injection
9882772|NCT00519727|Experimental|B|100 mg ISIS 325568 vs Placebo , s.c. injection
9882773|NCT00519727|Experimental|C|200 mg ISIS 325568 vs Placebo , s.c. injection
9882774|NCT00519727|Experimental|D|400 mg ISIS 325568 vs Placebo, s.c. injection
9882775|NCT00519727|Experimental|AA|50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
9882776|NCT00519727|Experimental|BB|100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
9882777|NCT00519727|Experimental|CC|200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
9882778|NCT00519727|Experimental|DD|400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
9882779|NCT00519753|Experimental|DuoTrav|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
9882780|NCT00519792|Experimental|1|Omega DUROS: Dose 25
9882781|NCT00519792|Experimental|2|Omega DUROS: Dose 50
9882782|NCT00519870|Active Comparator|I, II|I: nifedipine II: losartan
9882783|NCT00519883|Active Comparator|A|Arm A: Standard Supportive Care (no supervised exercise)
9882784|NCT00519883|Experimental|B|Arm B: Exercise Intervention
9882785|NCT00519909|Other|1|Diet with high content of calcium and high content of fat
9882786|NCT00519909|Other|2|Diet with low content of calcium and high content of fat
9882787|NCT00519909|Other|3|Diet with high content of calcium and normal content of fat
9882788|NCT00519909|Other|4|Diet with low content of calcium and normal content of fat
9882789|NCT00519909|Other|5|Diet with high content of calcium fra supplement and high content of fat
9882790|NCT00519922|Experimental|1|KBA = Kinesthesia, Balance, Agility Exercise Training
9882791|NCT00519922|Active Comparator|2|Standard Lower Extremity Strength Training
9882792|NCT00519935|Experimental|Multisystemic Therapy|In-home, intensive family therapy
9882793|NCT00519935|No Intervention|Standard Medical Care (TAU)|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
9882794|NCT00519961|Experimental|A|
9882795|NCT00519961|Experimental|B|
9882796|NCT00519987|Experimental|Treatment A|intranasal ketamine
9882797|NCT00520000|Active Comparator|Weekly Arm|Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle
9882798|NCT00520000|Experimental|Every 3 week Arm|Carboplatin day 1, abraxane day 1, every 21 day cycle
9882799|NCT00520000|Experimental|Arm C|Carboplatin day 1, abraxane day 1, 8 every 21 day cycle
9882800|NCT00520026|Active Comparator|1|Lithium treatment
9882801|NCT00520026|Placebo Comparator|2|Placebo treatment
9882802|NCT00520052|Active Comparator|LHRH Group|Patients on LHRH agonists and zoledronic acid
9882803|NCT00520052|Active Comparator|Bicalutamide Group|Patients on Bicalutamide and zoledronic acid
9882804|NCT00520065|Experimental|#1|Diabetes specific enteral product
9882805|NCT00520065|Active Comparator|#2|Standard enteral feeding
9882806|NCT00520091|Active Comparator|Cohort 1|Induction chemotherapy and chemoradiation without celecoxib
9882807|NCT00520091|Experimental|Cohort 2|Induction chemotherapy and chemoradiation with celecoxib
9882808|NCT00520104|Experimental|A|intranasal ketamine
9882809|NCT00520104|Experimental|B|oxymetazoline plus intranasal ketamine
9882810|NCT00520104|Experimental|C|intranasal steroid plus intranasal ketamine
9882811|NCT00520117||negative pap-smear|
9882812|NCT00520117||positive pap-smear|
9882813|NCT00520169|Active Comparator|A|oral ketamine
9882814|NCT00520169|Experimental|B|intranasal ketamine
9882815|NCT00520169|Active Comparator|C|intravenous ketamine
9882816|NCT00520182|Active Comparator|1|ADA 2003 diet
9882817|NCT00520182|Active Comparator|2|Low Glycemic index (LGI) diet
9882818|NCT00520182|Active Comparator|3|MUFA diet
9882819|NCT00520221||2|"Minocycline group: 300 mg of minocycline hydrochloride was instilled into the pleural space through the catheter.~Control group consisted of 33 patients who had successful simple aspiration alone between January 2004 and December 2005."
9882820|NCT00520260|Active Comparator|1|Active treatment arm bromfenac 0.09% BID for 6 weeks
9882821|NCT00520260|Active Comparator|2|ketorolac 0.4% BID for 6 weeks
9882822|NCT00520273|Experimental|A|
9882823|NCT00520325|Other|0.5 mg/kg|
9882824|NCT00520325|Other|1.0 mg/kg|
9882825|NCT00520338|Placebo Comparator|2|"placebo~celecoxib"
9882826|NCT00520338|No Intervention|1|1 placebo
9882827|NCT00520364||History of chemotherapy|IVF after chemotherapy
9882828|NCT00520364||IVF without history of chemotherapy|IVF without history of prior chemotherapy
9882829|NCT00520377|Experimental|1|MD05
9882830|NCT00520377|Active Comparator|2|Beta-TCP and autologous bone
9882831|NCT00520416||1|There is no control or experimental group. The same patients undergoing endovascular AAA repair with serve as their own control
9882832|NCT00520429|Other|1|This study is an open pilot; therefore all participants were given the opportunity to receive treatment.
9882833|NCT00520442|Experimental|Ibuprofen|
9882834|NCT00520442|Active Comparator|acetamin w codeine|
9882835|NCT00520455|No Intervention|Control|Control participants were advised where they could obtain hormonal contraception on a sliding scale basis. Participants were also advised where they could obtain hormonal contraception on a sliding scale basis.
9882836|NCT00520455|Experimental|Intervention|Study subjects were prescribed levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and a package of 30 condoms provided via a commerical pharmacy at no cost to the study subject. The subject could refill this prescription as many times as they wanted for 12 months
9882837|NCT00520507|Experimental|1|
9882838|NCT00520507|Placebo Comparator|2|
9882839|NCT00520598|Active Comparator|1|Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
9882840|NCT00520598|Experimental|2|Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
9882841|NCT00520598|Experimental|3|Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
9882842|NCT00520598|Experimental|4|Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
9882843|NCT00520598|Experimental|5|Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
9882844|NCT00520611|Active Comparator|Lottery|Participants are entered into daily lotteries to win $10 or $100 every day their weight is at or below daily targets.
9882845|NCT00520611|Active Comparator|Deposit|Participants receive $3/day if they are at or below their daily weight goals, plus have opportunity to deposit up to $3/day of their own money, which is then matched 1:1 every day they are at or below their daily weight goals.
9882846|NCT00520611|No Intervention|Control|Participants would receive usual care from their providers and have monthly weigh ins.
9797358|NCT01593748|Experimental|Experimental|Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
9797359|NCT01593748|Active Comparator|Standard of Care|Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
9797360|NCT01593787|Experimental|LCZ696 100 mg|All participants were started on LCZ696 100 mg once daily on day 1.
9797361|NCT01593787|Experimental|LCZ696 200 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
9797362|NCT01593787|Experimental|LCZ696 400 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
9797363|NCT01593917||Subjects previously implanted with a Trifecta™ valve in the Trifecta™ IDE Study|Subjects enrolled in this clinical study were implanted with the Trifecta™ aortic bioprosthetic valve during 2007, 2008 and 2009 as part of the Trifecta™ IDE Study conducted to obtain FDA approval.
9797364|NCT01594125|Experimental|Group I|patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
9797365|NCT01594125|Experimental|Group II|patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
9797366|NCT01594281|Experimental|Ranibizumab mono|Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
9797367|NCT01594281|Active Comparator|PRP mono|Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
9797368|NCT01594281|Experimental|Ranibizumab+PRP|Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed
9797369|NCT01594294|Experimental|AOSEPT Plus|AOSEPT® Plus contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
9797370|NCT01594294|Active Comparator|ReNu MultiPlus|ReNu MultiPlus® contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
9797371|NCT01594294|Other|Complete MPS Easy Rub|COMPLETE® MPS Easy Rub® Formula contact lens solution used with etafilcon A contact lenses (14 days) or lotrafilcon B contact lenses (30 days), Screening Phase
9797372|NCT01594333|Experimental|Methotrexate|Methotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week
9797373|NCT01594333|Placebo Comparator|Placebo|Placebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week
9797374|NCT01594385|Other|Seprafilm|The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.
9797375|NCT01594385|No Intervention|No Seprafilm|This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.
9797376|NCT01594411||All subjects|Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.
9797377|NCT01594424|Experimental|IVIG + Tocilizumab|
9797378|NCT01594476|Experimental|Levonorgestrel IUS insertion at 3 weeks|IUD placement at 3 weeks after delivery.
9797379|NCT01594476|Experimental|Levonorgestrel IUS insertion at 6 weeks|IUD placement at 6 weeks after delivery.
9797380|NCT01594515|Experimental|BI 1015550 low dose A|Powder for oral solution
9797381|NCT01594515|Experimental|BI 1015550 low dose B|Powder for oral solution
9797382|NCT01594515|Experimental|BI 1015550 low dose C|Powder for oral solution
9797383|NCT01594515|Experimental|BI 1015550 low dose D|Powder for oral solution
9797384|NCT01594515|Experimental|BI 1015550 medium dose A|Powder for oral solution
9797385|NCT01594515|Experimental|BI 1015550 medium dose B|Powder for oral solution
9797386|NCT01594515|Experimental|BI 1015550 medium dose C|Powder for oral solution
9797387|NCT01594515|Experimental|BI 1015550 high dose A|Powder for oral solution
9797388|NCT01594515|Experimental|BI 1015550 high dose B|Powder for oral solution
9797389|NCT01594515|Placebo Comparator|Placebo|Solution for oral administration
9797390|NCT01594528|Experimental|SC|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with schizophrenia
9797391|NCT01594528|Experimental|controls|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects without any psychiatric trouble
9797392|NCT01594528|Experimental|MD|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with major depression
9797393|NCT01594749|Experimental|Fosaprepitant Regimen|On Day 1, participants received fosaprepitant, 150 mg intravenous (IV) infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 12 mg, orally (PO) ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy, followed by 8 mg PO, 8 hours after first dose PLUS dexamethasone placebo, PO ~30 minutes prior to chemotherapy. On Days 2 and 3, participants received ondansetron placebo, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
9882847|NCT00520624|Experimental|1|Treatment 1, for those with high degree of EIL
9882848|NCT00520624|Experimental|2|Treatment 2, for those with high degree of EIL
9882849|NCT00520624|No Intervention|3|Control group of those with high degree of EIL
9882850|NCT00520624|Experimental|4|Treatment 1, for those with low degree of EIL
9882851|NCT00520624|No Intervention|5|Control group of those with low degree of EIL
9931070|NCT00934570|Active Comparator|Metformin, Intensive exercise|Lifestyle intervention with metformin and intensive exercise
9931071|NCT00934570|Placebo Comparator|Placebo, Intensive exercise|Lifestyle intervention with placebo and intensive exercise program.
9931072|NCT00934583|Experimental|Image and Mood (IaM) program|Participants will participate in the IaM program.
9931073|NCT00934583|No Intervention|Wait-list control|Participants will be placed on a wait list until after participants in the IaM group have completed all assessments. After that, these participants will be offered the option to complete the IaM program.
9931074|NCT00934609|Experimental|Training|12 weeks of endurance training on the cycle ergometer under supervision on a physician
9931075|NCT00934609|No Intervention|Control|Control condition
9931076|NCT00934674|Experimental|1|Commercial Tablet manufactured by Excella
9931077|NCT00934674|Experimental|2|Clinical Tablet manufactured by Wyeth Montreal
9931078|NCT00934687|Experimental|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
9931079|NCT00934687|Placebo Comparator|0.9% sodium chloride NaCl solution|0.9% NaCl solution will be injected like the experimental compound
9931080|NCT00934713|Active Comparator|montelukast|montelukast 4 mg once per day for 8 weeks
9931081|NCT00934726||1 group, schizophrenia patients|Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)
9931082|NCT00934739|No Intervention|Control|Standard postoperative concurrent chemoradiotherapy
9931083|NCT00934739|Experimental|Thalidomide, Celebrex|Adjuvant anti-angiogenesis therapy
9931084|NCT00934739|Active Comparator|Cyclophosphamide, Dexamethasone|Adjuvant anti-angiogenesis therapy
9931085|NCT00934752|Experimental|Lutonix Catheter|
9931086|NCT00934778|Experimental|Bronchoscopy|
9931087|NCT00934804|Experimental|Comparative Diagnostic system|Galilei dual Scheimpflug analyzer
9931088|NCT00934817|Experimental|TR sequential group|Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
9931089|NCT00934817|Active Comparator|RT sequential group|Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
9931090|NCT00934830|Active Comparator|Antibiotic|
9931091|NCT00934830|Experimental|Therapeutic ultrasound|
9931092|NCT00934869||Metacarpal Shaft Fractures|
9931093|NCT00934882|Experimental|Arm 1|
9931094|NCT00934895|Experimental|Phase I / Phase II|"Phase I:~Abraxane will be given by IV for 30 minutes on the first day of the first three weeks of each 28 day cycle.~RAD001 will be given by tablet. The first group of patients will receive RAD001 once daily depending on side effects seen drug could be increased later to twice a day for a 28 day cycle.~Once a safe and effective drug range is established, the study moves into Phase II.~Phase II:~The maximum tolerated dose (established in Phase I) will be given as scheduled below and we will measure the effectiveness of the study drug combination.~Abraxane will be given by IV (intravenous infusion) for 30 minutes on the first day of the first three weeks of each 28 day cycle (Day 1, Day 8, and Day 15 of each cycle).~RAD001 will be given by tablet based on the dose established in the Phase I part of the study."
9931095|NCT00934908|Placebo Comparator|1|"Non-active sugar pill"
9931096|NCT00934908|Active Comparator|2|Green Tea Capsules
9931097|NCT00934973|Active Comparator|mebeverine + no website|Mebeverine 135mg tds for 6 weeks
9931098|NCT00934973|Active Comparator|methylcellulose + no website|methylcellulose 3 tablets twice a day for 6 weeks
9931099|NCT00934973|Placebo Comparator|placebo + no website|placebo tablets
9931100|NCT00934973|Active Comparator|mebeverine + CBT website minimal support|mebeverine 135mg tds and access to website
9931101|NCT00934973|Active Comparator|methylcellulose + CBT website|methylellulose 3 tablets twice a day and access to website
9931102|NCT00934973|Placebo Comparator|placebo + CBT website minimal support|placebo tablets and access to website
9931103|NCT00934973|Active Comparator|mebeverine + CBT website with support|mebeverine 135mg tds and access to website with nurse support session
9931104|NCT00934973|Active Comparator|methylcellulose + CBT website support|methylcellulose 3 tablets twice a day and access to website with nurse support
9931105|NCT00934973|Placebo Comparator|placebo + CBT website with support|placebo tablets and access to website with nurse support
9882852|NCT00520663|Experimental|Healthy male subjects|Each subject will receive a single oral dose of 14C-SB649868 (containing approximately 70 microcuries of radiocarbon and 30 milligrams of SB649868).
9882853|NCT00520689|Active Comparator|1|
9882854|NCT00520689|Active Comparator|2|
9882855|NCT00520689|Active Comparator|3|
9882856|NCT00520689|Active Comparator|4|
9882857|NCT00520702|Active Comparator|3D CRT|3-Dimensional Conformal Radiation Therapy (3D CRT)
9882858|NCT00520702|Active Comparator|IMRT|Intensity-Modulated Radiation Therapy (IMRT)
9882859|NCT00520715||Patients at hospital admission|Patients at hospital admission in medical wards on our tertiray care hospital (Hôpital Beaujon, Clichy, France).
9882860|NCT00520728|Experimental|A|Experimental arm receives 12 week intervention along with standard care.
9882861|NCT00520780|Experimental|1|
9882862|NCT00520780|Placebo Comparator|2|
9882863|NCT00520806|Placebo Comparator|Placebo|48 hour iv infusion of placebo
9882864|NCT00520806|Experimental|Relaxin|48 hour iv infusion of relaxin at 30 ug/kg/day
9882865|NCT00520832|Experimental|MC-E|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
9882866|NCT00520832|Placebo Comparator|MC-P|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
9882867|NCT00520858|No Intervention|C|
9882868|NCT00520858|Active Comparator|RE|Resistance Exercise
9882869|NCT00520858|Active Comparator|AE|Aerobic Exercise
9882870|NCT00520858|Active Comparator|RAE|Resistance and Aerobic
9882871|NCT00520897|Experimental|MK0518 + cART|Raltegravir + standard of care combined antiretroviral therapy
9882872|NCT00520897|Placebo Comparator|Placebo + cART|Placebo + standard of care combined antiretroviral therapy
9882873|NCT00520949|Experimental|Quadruple Therapy|
9882874|NCT00520962||1,2,3|"First degree relatives of patients with type 2 diabetes~Patients with cardiovascular disease and stroke~patients with heart valve disease"
9882875|NCT00520962||4|Healthy controls
9882876|NCT00520988|Experimental|1|Usual care plus use of Interactive Voice Recognition system
9882877|NCT00520988|No Intervention|2|Usual care
9882878|NCT00521027|Other|Treatment|Debridement with Versajet Hydrosurgery system
9882879|NCT00521027|Other|Control|Conventional surgical debridement techniques
9882880|NCT00521066||1|Prosima Pelvic Floor Repair System
9882881|NCT00521092|Experimental|Arm I|Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
9882882|NCT00521105|No Intervention|1|Participants will be seen every 3-4 months with a physician-only visit alternating with a multidisciplinary visit (MD, RN and RD). This is the current standard of practice.
9882883|NCT00521105|Experimental|2|Participants will be seen every 3-4 months with a phone contact, with the diabetes nurse educator, alternating with a multidisciplinary visit (MD, RN and RD).
9882884|NCT00521118|Experimental|Treatment (second curettage)|Patients undergo a second curettage rather than standard treatment (immediate chemotherapy) within 14 days of registration.
9882885|NCT00521157|Experimental|intervention|Experimental group randomised after abstinence oriented treatment
9882886|NCT00521157|No Intervention|2|waiting list control
9882887|NCT00521183|Experimental|CldC + H4U|
9882888|NCT00521196|No Intervention|Baseline- 1 month|Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
9931106|NCT00934999|Active Comparator|Burch|Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
9931107|NCT00934999|Experimental|Mid-urethral sling|Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
9931108|NCT00935025|Experimental|1, AZD1305|
9931109|NCT00935025|Placebo Comparator|2, Placebo|
9931110|NCT00935051|Experimental|Arm 1|There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
9931111|NCT00935077|Experimental|24 Month PPCM BP|A 24 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
9882889|NCT00521196|Experimental|tDCS- 1 month|"There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.~During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests."
9882890|NCT00521196|No Intervention|Follow Up- 4 months|During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
9882891|NCT00521196|Other|Active tDCS- 1 month|Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
9882892|NCT00521209|Experimental|Clinic 1 - intervention|Clinic 1 will feature the Self-Care Stimulating Disease Prevention Program (SCSDPP) intervention
9882893|NCT00521209|Other|Clinic 2 - no intervention|Clinic 2 will continue with standard procedures no intervention
9882894|NCT00521222|Active Comparator|Arg/Arg genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Arg/Arg genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
9882895|NCT00521222|Active Comparator|Gly/Gly genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Gly/Gly genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
9882896|NCT00521222|Experimental|Arg/Arg genotype on Fluticasone HFA|Asthma patients with the Arg/Arg genotype who are randomized to fluticasone (Flovent HFA) alone.
9882897|NCT00521222|Experimental|Gly/Gly genotype on Fluticasone HFA|Asthma patients with the Gly/Gly genotype who are randomized to fluticasone (Flovent HFA) alone.
9882898|NCT00521248|Active Comparator|Oral morphine solution|Oral morphine solution
9517670|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
9517671|NCT03304223|Experimental|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
9882899|NCT00521248|Experimental|Buprenorphine|Sublingual buprenorphine
9882900|NCT00521274|Experimental|1|"Patients randomized to Arm 1 will receive treatment cycles of Docetaxel and vaccine.~PI relocated, data not available."
9882901|NCT00521274|Active Comparator|2|"Patients randomized to Arm 2 will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over).~PI relocated, data not available."
9882902|NCT00521287|Other|Early (E)|Early stage cancer
9882903|NCT00521287|Other|Advanced (A)|Advanced stage cancer (Stage IV without treatment)
9882904|NCT00521287|Other|Terminal (T)|Terminal stage cancer (Stage IV with chemotherapy)
9882905|NCT00521300|Experimental|octreotide|6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
9882906|NCT00521300|Active Comparator|standard surgery|Standard transphenoidal surgery soon after the diagnosis of acromegaly
9882907|NCT00521326||A|Patients with an acute coronary syndrome that are candidates for coronary angiography. Doppler results will be compared to angiographic findings.
9882908|NCT00521391|Experimental|A|a tailored physical activity intervention involving moderate-intensity exercise
9882909|NCT00521391|No Intervention|B|
9882910|NCT00521417|Experimental|short-term dynamic therapy|Group therapy 20 sessions, give insight
9882911|NCT00521417|Active Comparator|long-term dynamic therapy|Group therapy 80 sessions, give insight
9882912|NCT00521443||Normal|Embryos derived from morphologically normal MII oocytes
9882913|NCT00521443||Irregular Shapes|Embryos derived from irregularly shaped oocytes.
9882914|NCT00521443||Large PVS|Embryos derived from oocytes with large perivitelline space.
9882915|NCT00521443||Dark Zona|Embryos derived from oocytes with dark zona pellucida
9882916|NCT00521443||Dark cytoplasm|Embryos derived from oocytes with dark cytoplasm
9882917|NCT00521443||Vacuolar cytoplasm|Embryos derived from oocytes with vacuolated cytoplasm
9882918|NCT00521443||Central granulation|Embryos derived from oocytes with centrally granulated cytoplasm
9882919|NCT00521443||Double extra|Embryos derived from oocytes with double extracytoplasmic abnormalities
9882920|NCT00521443||Double combined|Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
9882921|NCT00521443||Double cytoplasmic|Embryos derived from oocytes with any two cytoplasmic anomalies
9882922|NCT00521443||Triple extra|Embryos derived from oocytes with triple extracytoplasmic anomaly
9882923|NCT00521443||Triple combined|Embryos derived from oocytes with triple combined anomalies
9882924|NCT00521482|Active Comparator|A|Temozolomide 75 mg/m2 daily for 21 days during each 28-day cycle until tumor progression.
9882925|NCT00521482|Experimental|B|Temozolomide 200 mg/m2 for 5 days during each 28-day cycle plus Thalidomide 100 mg for 2 weeks, thereafter 200 mg daily continuously until tumor progression.
9882926|NCT00521495|Experimental|A|Surface magnetic field strength at target 450 Gauss permanent magnet
9882927|NCT00521495|Experimental|B|Surface field strength at target 150 Gauss permanent magnet
9882928|NCT00521495|Active Comparator|C|
9882929|NCT00521508|Other|1|Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
9882930|NCT00521508|Other|2|Patient affected by Berger's disease with normal rate of Ig A
9882931|NCT00521508|Other|3|Healthy volunteers
9882932|NCT00521521|Active Comparator|docetaxel and cisplatin|
9882933|NCT00521521|Experimental|docetaxel|
9882934|NCT00521534||A|CRT programmed to VDD pacing mode
9882935|NCT00521534||B|CRT programmed to DDD with overdrive pacing based on first night average sinus rate.
9882936|NCT00521560|Experimental|1|
9882937|NCT00521612|Experimental|A|Sevoflurane group, experimental group
9882938|NCT00521612|Active Comparator|B|Isoflurane group, control group
9882939|NCT00521638|Experimental|1|
9882940|NCT00521651||Community Cohort|Men and Women from two Shanghai cohort studies.
9882941|NCT00521664|Active Comparator|1|Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
9882942|NCT00521664|Active Comparator|2|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
9882943|NCT00521677|Experimental|1|Procedure: Use of protocol that use special suction connected toothbrush to clean the teeth and the oral cavity, use of non alcoholic antiseptic solution and lubrication of the lips and the oral cavity.
9882944|NCT00521677|Active Comparator|2|The traditional method of oral care with cleaning of the oral cavity with a sponge soaked with antiseptic non alcoholic solution
9882945|NCT00521703|Experimental|1|group treated
9882946|NCT00521703|Placebo Comparator|2|control group
9882947|NCT00521716|Experimental|A|
9882948|NCT00521742|Experimental|Pioglitazone 15 mg to 45 mg QD|
9882949|NCT00521742|Active Comparator|Glyburide 2.5 mg to 15 mg, QD|
9882950|NCT00521742|Experimental|Pioglitazone 15 mg or 30 mg QD|
9882951|NCT00521742|Active Comparator|Glyburide 5 mg or 10 mg, QD|
9882952|NCT00521755|Experimental|A|
9882953|NCT00521781|Experimental|1|Treatment will be Abraxane/hormonal therapy (LHRH Agonist) for four nine-week cycles, followed by Total androgen blockade therapy (LHRH Agonist+ Anti-androgen) for 2 years from the time the hormonal therapy was started.
9882954|NCT00521807|No Intervention|A 1|
9882955|NCT00521807|Experimental|A 2|Treatment group
9882956|NCT00521820|Experimental|Pioglitazone QD|
9882957|NCT00521820|Active Comparator|Glyburide QD|
9882958|NCT00521833|Experimental|1|Temporal (right eye)
9882959|NCT00521833|Experimental|2|Nasal (Left eye)
9882960|NCT00521859|Experimental|Cloretazine + Fludarabine|
9882961|NCT00521898|Experimental|DMEK|DMEK as intervention
9882962|NCT00521911|Active Comparator|1|Cognitive Behavioural Therapy
9882963|NCT00521911|No Intervention|2|Treatment as Usual
9882964|NCT00521937|Experimental|A|Dermagen®
9882965|NCT00521937|Active Comparator|B|Conventional treatment
9882966|NCT00521950|Experimental|Intervention, TPMT genotyping|Pre-treatment TPMT genotyping to optimize initial thiopurine treatment dose. Intervention is based on the genotype.
9882967|NCT00521950|Active Comparator|control|Standard thiopurine treatment
9882968|NCT00521963|Experimental|E|
9882969|NCT00522015|Active Comparator|1|patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
9882970|NCT00522054|Other|A|Single group study
9882971|NCT00522067|Experimental|Arm 1|FLUAD
9882972|NCT00522106|Experimental|A|Behavioral graded activity
9882973|NCT00522106|Active Comparator|B|Exercise therapy
9882974|NCT00522132|Active Comparator|cohort 1|2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
9882975|NCT00522132|Experimental|cohort 2|4.0 mg/kg iv Artesunate at 0, 24 and 48 h
9882976|NCT00522184|Experimental|1|patient receiving etanercept intra-articular injection
9882977|NCT00522184|Active Comparator|2|patient receiving steroid intra-articular injection
9882978|NCT00522197|Active Comparator|ACAPHA|
9882979|NCT00522197|Placebo Comparator|Sugar Pill|
9882980|NCT00522210|Experimental|BID insulin with LA analogue|Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
9882981|NCT00522210|Active Comparator|Standard TID insulin|Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
9882982|NCT00522223||Questionnaire|Questionnaire
9882983|NCT00522236|Experimental|Arm 1|
9882984|NCT00522249|Experimental|1|One cycle of the combination therapy will be 42 days (6 weeks). All patients will receive PEG-Intron given subcutaneously on Day 1 each week. Patients will receive Sunitinib orally on Days 1-28 of each cycle. Patients will receive Tarceva orally on Days 1-42.
9882985|NCT00522262|Experimental|Exercise|Women randomized to the exercise intervention arm completed a one year aerobic exercise intervention of 225 minutes/week.
9882986|NCT00522262|No Intervention|Control|Women randomized to the control arm were asked to maintain their regular lifestyle which meant no changes to their exercise or dietary intake. Women eligible for this trial were inactive and hence were expected not to increase their levels of physical activity in the control arm.
9517672|NCT03304210|Experimental|Abraxane 35 mg/m²|PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
9517673|NCT03304210|Experimental|Abraxane 70 mg/m²|PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
9517674|NCT03304210|Experimental|Abraxane 90 mg/m²|PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
9882987|NCT00522288|Experimental|Contact Lens|Soft contact lenses
9882988|NCT00522288|Active Comparator|Spectacle|Spectacles
9882989|NCT00522314|Active Comparator|1|NIV & ACBT
9882990|NCT00522314|Placebo Comparator|2|Active cycle of breathing techniques
9882991|NCT00522327|Experimental|1|remote simult med interpret
9882992|NCT00522327|Active Comparator|2|Usual & Customary
9882993|NCT00522327|Other|3|comparison group
9882994|NCT00522340|Experimental|Aerobic Exercise Program|
9882995|NCT00522340|No Intervention|Usual Care|
9882996|NCT00522353|Active Comparator|1|Oligofructose
9882997|NCT00522353|Placebo Comparator|2|Placebo
9882998|NCT00522405|Active Comparator|1|Transarterial Chemoembolisation
9882999|NCT00522405|Active Comparator|2|TACE Plus oral chemotherapy
9931112|NCT00935077|Experimental|9 Month PPCM BP|A 9 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
9931113|NCT00935077|Sham Comparator|PPCM Asthma|A 9 month long physician/pharmacist collaborative intervention is implemented to manage asthma
9931114|NCT00935077|No Intervention|BP Control Arm|No PPCM intervention
9931115|NCT00935103|Active Comparator|Psychoeducation|Psycheducation
9931116|NCT00935103|No Intervention|Control|The control group will not take any intervention
9931117|NCT00935116|Active Comparator|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
9931118|NCT00935129|Experimental|OmniPod system|At this arm patients will be treated with the OmniPod system for 12 weeks
9931119|NCT00935129|Active Comparator|patient's conventional pump|At this arm patients will be treated with their conventional pump for 12 weeks
9931120|NCT00935155|Experimental|Acupuncture|Acupuncture in combination with exercise therapy
9931121|NCT00935155|Active Comparator|exercises|Coordination, mobilizing, endurance, strength
9931122|NCT00935168|Experimental|Hydroxy-ethyl starch|Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)
9989058|NCT01429038|Experimental|MSC Liver Transplantation|Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2
9989059|NCT01429038|Experimental|MSC Kidney Transplantation|Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2.
9989060|NCT01429090|Experimental|Test|Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
9989061|NCT01429090|Active Comparator|Reference|Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
9989062|NCT01429103||Early Perimenopause|Early perimenopause is defined as the presence of irregular periods (cycle length differs by 7 days from usual).
9989063|NCT01429103||Late Perimenopause|Late perimenopause is defined as at least 2 skipped periods over the past 12 months (cycle double usual length) and one period of amenorrhea (over 60 days without a period), with at least one menstrual cycle over the past 12 months.
9989064|NCT01429116|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
9989065|NCT01429129|Experimental|Nicotine Replacement Therapy|
9989066|NCT01429129|No Intervention|Control|
9989067|NCT01429142|Experimental|AIMS intervention|see http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-274
9989068|NCT01429142|Active Comparator|Treatment as usual|see http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.1001392
9989069|NCT01429155||Liver transplant recipeints|Patients suffering from chronic hepatitis C that required a living donor liver transplant.
9989070|NCT01429155||Liver Donors|Patients who donated part of their liver to a patient suffering from chronic hepatitis C
9989071|NCT01429181|Experimental|Non Racemic Methadone|Non-Racemic Methadone Hydrochloride 5 mg Capsules containing a non-racemic mixture of methadone isomers.
9989072|NCT01429181|Placebo Comparator|Placebo|Matching placebo capsules
9989073|NCT01429194|Experimental|ACE procedure|ACE procedure for the treatment of obesity
9989074|NCT01429246|Active Comparator|Normal Salt|100% Sodium Chloride
9517675|NCT03304210|Experimental|Abraxane 112.5 mg/m²|PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
9517676|NCT03304210|Experimental|Abraxane 140 mg/m²|PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.
9989075|NCT01429246|Experimental|Salt Substitute|65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
9989076|NCT01429311||ADEH+|Subjects classified as Atopic Dermatitis (AD) and history of previous Eczema Herpeticum (EH) as defined by the ADRN Standard Diagnostic Criteria
9989077|NCT01429311||ADEH-|Subjects classified as AD without a history of EH as defined by the ADRN Standard Diagnostic Criteria
9989078|NCT01429311||Non-atopic Controls|"Subjects classified as Non-Atopic controls as defined by the ADRN Standard Diagnostic Criteria"
9989079|NCT01429324||Cardiac disease|Aortic arch surgery
9989080|NCT01429337|Experimental|Normal hepatic function - group 1|Matched control for group 2 and 3 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in mild and moderate hepatic function groups. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
9989081|NCT01429337|Experimental|Mild hepatic impairment - group 2|Subjects with mild impaired hepatic function - Child Pugh A classification score 5-6. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
9989082|NCT01429337|Experimental|Moderate hepatic impairment - group 3|Subjects with moderate hepatic function - Child Pugh B classification score 7-9. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
9989083|NCT01429337|Experimental|Severe hepatic impairment - group 4|Subjects with severe hepatic impairment function - Child Pugh C classification score 10-15. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
9989084|NCT01429337|Experimental|Normal hepatic function - group 5|Matched control for group 4 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in severe hepatic function group. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
9989085|NCT01429363|Experimental|Targeted disc decompression|
9517677|NCT03304197|Experimental|Dehydrated|90 minutes cycling, without the ingestion of any fluids, followed by a 15 minute cycling time trial test
9989086|NCT01429402|Experimental|study group I|For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site
9989087|NCT01429402|Experimental|Study Group II|For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.
9989088|NCT01429402|Placebo Comparator|Control Group I|Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.
9989089|NCT01429402|Placebo Comparator|Control II|Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).
9989090|NCT01429415|Experimental|Experimental Group|Magnesium Sulfate Sandoz/PPC 600mg and Salbutamol (GlaxoSmithKline/Pharmascience) 5mg by inhalation via Aeroneb Go nebulizer (Philips) with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
9989091|NCT01429415|Placebo Comparator|Control Group|Sodium Chloride USP PPC/Omega (5.5%) placebo and salbutamol GlaxoSmithKline/Pharmascience 5 mg by inhalation via Aeroneb Go nebulizer Philips with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
9989092|NCT01429428|Placebo Comparator|Stockings side one|This side of the compression stockings is just the fabric (placebo).
9989093|NCT01429428|Active Comparator|Stocking side two|This side of compression stocking emits far-IR radiation.
9883000|NCT00522444|Experimental|nebulized magnesium sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
9883001|NCT00522444|Placebo Comparator|normal saline nebulization|standard of care
9883002|NCT00522535|Active Comparator|Open Surgical Repair|Open surgical repair of abdominal aortic aneurysm. All patient enrollment and 2-year follow-ups completed.
9883003|NCT00522535|Experimental|Endovascular Repair|"Endovascular treatment arm of 160 patients having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. Use of stent grafts in aortic angles greater than 60° has not been approved for other devices available in the US. As a result, a minimum of 120 patients in this arm will have an aortic angle between 60° and 90°.~Patient recruitment completed; 5-year follow-up evaluations continue."
9883004|NCT00522535|Experimental|Continued Access|"Endovascular treatment arm of 50 patients maximum having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. This Arm will provide active sites with ongoing device access while FDA reviews the PMA.~Patient recruitment completed; 5-year patient follow-ups continue."
9883005|NCT00522561|Other|1|healthy volunteers
9883006|NCT00522587|Experimental|1|Fixed sevoflurane dose 1
9883007|NCT00522587|Experimental|2|Fixed sevoflurane dose 2
9883008|NCT00522587|Experimental|3|Fixed sevoflurane dose 3
9883009|NCT00522587|Experimental|4|Fixed sevoflurane dose 4
9883010|NCT00522587|Experimental|5|Fixed sevoflurane dose 5
9883011|NCT00522587|Experimental|6|Fixed sevoflurane dose 6
9883012|NCT00522587|Experimental|7|Fixed remifentanil dose 1
9883013|NCT00522587|Experimental|8|Fixed remifentanil dose 2
9883014|NCT00522587|Experimental|9|Fixed remifentanil dose 3
9883015|NCT00522587|Experimental|10|Fixed remifentanil dose 4
9883016|NCT00522587|Experimental|11|Fixed remifentanil dose 5
9883017|NCT00522587|Experimental|12|Fixed remifentanil dose 6
9883018|NCT00522652|Experimental|Investigational Drug|Dose Escalation
9883019|NCT00522665|Active Comparator|Arm A: Irinotecan + Cetuximab +/- RAD001|
9883020|NCT00522665|Active Comparator|Arm B: Ironotecan + Cetuximab|
9883021|NCT00522678|Experimental|Cohort A|In Cohort A, subjects will be randomized (3:1) to receive once daily doses of GW685698X 400 microgram (mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
9883022|NCT00522678|Experimental|Cohort B|In Cohort B, subjects will be randomized (3:1) to receive once daily doses of GW685698X (600 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
9883023|NCT00522678|Experimental|Cohort C|InIn Cohort C, subjects will be randomized (3:1) to receive once daily doses of GW685698X (800 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
9883024|NCT00522691|Experimental|A: sacral first|Phase 1: sacral nerve stimulation crossover Phase 2 : sham stimulation
9883025|NCT00522691|Experimental|B: sham first|Phase 1: sham stimulation crossover Phase 2: sacral nerve stimulation
9883026|NCT00522717|Experimental|1|
9883027|NCT00522717|Active Comparator|2|
9883028|NCT00522730|Experimental|1|Parenteral nutrition
9883029|NCT00522730|Active Comparator|2|Enteral nutrition
9883030|NCT00522743|Experimental|1|GH & GNRHa treatment
9883031|NCT00522743|Active Comparator|2|GH treatment
9883032|NCT00522756|Experimental|Intervention|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
9883033|NCT00522756|Active Comparator|Control|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
9883034|NCT00522769|Active Comparator|Delayed Intervention|1/2 of participants are randomized to immediate intervention that starts within a week of randomization. The other 1/2 of the participants are randomized to delayed intervention which starts 6 months after randomization.
9883035|NCT00522769|Experimental|Immediate intervention|Immediate intervention starts within two weeks of randomization. Delayed interventions starts 6 months after randomization.
9883036|NCT00522782|Active Comparator|A|Nebulized budesonide
9883037|NCT00522821|Other|Antibiotics|"A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
9883038|NCT00522821|Other|intravenous immunoglobulins|"B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
9883039|NCT00522860|Experimental|Vicryl Suture|Vicryl sutures, 5/0, 3/8 curved cutting needle
9883040|NCT00522860|Active Comparator|Silk Suture|Silk suture, 4/0, 3/8 curved cutting needle
9883041|NCT00522899|Experimental|Aerobic exercise|Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
9883042|NCT00522899|Active Comparator|Stretching/toning|Study-specific stretching/toning exercise classes include 10' warm-up, 40' stretching/toning, 10' relaxation. Participants attend classes 60 minutes/day, 3 days/week for 12 weeks.
9883043|NCT00522899|Experimental|Computer-based mental activity training|Computer-based visual and auditory stimulation training programs developed by Posit Science corporation. Participants perform assigned mental activity on computers in their homes for 60 minutes/day, 3 days/week for 12 weeks.
9517678|NCT03304197|Experimental|Hypotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g sucrose, 3g glucose) drinks, followed by a 15 minute cycling time trial test
9883044|NCT00522899|Active Comparator|Educational DVD training|Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
9883045|NCT00522912|Experimental|A|Immediate posterior lamella tarsal rotation surgery for minor trichiasis
9883046|NCT00522912|Active Comparator|B|Regular epilation by another person
9883047|NCT00522964|Experimental|Intervention|
9883048|NCT00523003|Experimental|1,|2.2 g protein/kg LBM/day high protein diet
9883049|NCT00523003|Placebo Comparator|2, standard protein|1.1 g protein/kg LBM/day standard protein diet
9883050|NCT00523016|Experimental|Electroacupuncture|Subjects will receive Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP) electroacupuncture protocol for 20 minutes per treatment session; a total of 13 treatments will be administered over 3-4 weeks.
9883051|NCT00523016|Sham Comparator|Sham acupuncture|Subjects will receive simulated acupuncture that includes insertion of acupuncture needles on the head. During each treatment session, needles will be stimulated with electricity for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
9883052|NCT00523029|Experimental|1|Participants will receive a chronic disease self-management program
9883053|NCT00523068|Active Comparator|1|Tension Free Vaginal Tape
9883054|NCT00523068|Active Comparator|2|Tolterodine tartrate 4mg
9883055|NCT00523081|Experimental|Experimental|Teens in the experimental group will meet with a research counselor for five to nine individual, 50-minute weekly sessions. They will learn ways to deal with stress and feel better. The study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
9883056|NCT00523081|Active Comparator|Active Control|
9883057|NCT00523107|Experimental|PG2|PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.
9883058|NCT00523107|Placebo Comparator|Placebo|500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.
9517679|NCT03304197|Experimental|Isotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g glucose, 3g fructose) drinks, followed by a 15 minute cycling time trial test
9883059|NCT00523120|Active Comparator|1|voltaren ophta
9883060|NCT00523120|Active Comparator|2|dexotic
9883061|NCT00523159|Other|1|Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
9883062|NCT00523159|Other|2|No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
9883063|NCT00523172|Active Comparator|Group A|"1) Group A will receive 9 manipulative therapy treatments (adjustments) to one area: the hip with pre-manipulative static and post active-assisted stretch of tight hip muscles. After the last (or 9th) treatment these patients will receive general advice and recommendations on managing HOA and how to gently and safely increase general exercise.~• Based on a previous trial, Group A treatment appears superior than placebo. There will be a 3, 6 and 9 month follow up."
9883064|NCT00523172|Active Comparator|Group B|2) Group B will receive 9 treatments with manipulative therapy treatments (adjustments) to the entire kinetic chain (five areas): the lumbosacral, sacroiliac, hip, knee, ankle and foot joints with pre-manipulative static and post active-assisted stretch of tight hip muscles. There will be a 3, 6 and 9 month follow up.
9931123|NCT00935168|Active Comparator|Saline|Intravenous fluid resuscitation with saline (0.9% sodium chloride)
9935461|NCT03693300|Experimental|WHO/ECOG PS 0 to 1 Cohort|100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
9883065|NCT00523172|Other|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
9883066|NCT00523185|Active Comparator|2|
9883067|NCT00523185|Active Comparator|1|
9883068|NCT00523211|Experimental|Test Arm|Vicriviroc 30 mg QD
9883069|NCT00523211|Placebo Comparator|Placebo Control Arm|Placebo
9883070|NCT00523224|Experimental|single arm|open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)
9883071|NCT00523263|Active Comparator|Dacron|Patients receiving polyester above-knee femoro-popliteal bypass
9883072|NCT00523263|Active Comparator|HUV|patients receiving HUV femoro-popliteal bypass
9883073|NCT00523276||HCWs|Who may/may not have contact with SARS patients
9883074|NCT00523276||Family/close contacts|No illness but household/close contact
9883075|NCT00523276||SARS subjects|Diagnosed with active disease
9883076|NCT00523289|Active Comparator|B|Arm number B corresponds to the Bupivacaine group.
9883077|NCT00523289|Active Comparator|R|Arm number R corresponds to the Ropivacaine group.
9883078|NCT00523354|Experimental|1 (open-label)|prospective, open label, uncontrolled trial
9883079|NCT00523380|Experimental|A|
9883080|NCT00523393|No Intervention|1|
9883081|NCT00523393|Experimental|2|
9883082|NCT00523393|Active Comparator|3|
9883083|NCT00523406|Active Comparator|A|standard fluence photodynamic therapy and intravitreal triamcinolone combination
9883084|NCT00523406|Active Comparator|B|reduced fluence photodynamic therapy and intravitreal triamcinolone combination
9883085|NCT00523432|Experimental|A|Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
9883086|NCT00523432|Experimental|B|Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
9883087|NCT00523445|Experimental|Varenicline|The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
9883088|NCT00523445|Placebo Comparator|Placebo|The effect of placebo comparator is being compared to that of varenicline
9883089|NCT00523458|Active Comparator|1|Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
9883090|NCT00523458|Experimental|2|High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
9883091|NCT00523458|Active Comparator|3|Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
9883092|NCT00523458|Experimental|4|High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
9883093|NCT00523510|Experimental|Feasibility Study|HIV positive women [and a smaller number of HIV negative/unknown status (1 for every 3 infected women)] to avoid stigmatizing home-based counseling will be recruited at 1-2 postpartum and provided enhanced home-based infant feeding counseling by community health workers to exclusively breastfeed for 6 months. Mothers will also be told about the option to Flash-heat breastmilk during and after the transition from exclusive breastfeeding. Mothers who choose to Flash-heat will be provided continued home-based counseling and support. Feasibility data will be collected during the time mothers Flash-heat.
9883094|NCT00523510|Experimental|Pilot efficacy|We will collect infant health data to monitor and compare health outcomes among 3 groups of infants who had exclusive breast feeding (EBF) for the first months and then either: 1) fed Flash-heated breast milk and complementary foods (n=30), or 2) weaned to replacement foods and NO breast milk (n=15; per standard WHO recommendation for rapid cessation), or 3) continued feeding at the breast and providing other foods and/or fluids, i.e. mixed feeds (n=15; per WHO consensus that breastfeeding continue if replacement feeding is not AFASS94). We will collect infant growth and morbidity data. Infant health outcomes will be compared for the 3 groups noted above. These data will be collected primarily to pilot an efficacy trial.
9883095|NCT00523523|Experimental|A|This group will complete a 2 week program of functional task practice with auditory rhythm cuing.
9883096|NCT00523523|Active Comparator|F|This group will complete a 2 week program of functional task practice without auditory rhythm cuing.
9883097|NCT00523536|Experimental|1|Patient navigator-nurse disease management intervention
9997293|NCT01507558|Experimental|Intervention|Perivascular administration of dexamethasone following endovascular superficial femoral and popliteal artery angioplasty or atherectomy.
9883098|NCT00523536|No Intervention|2|Usual clinical care
9883099|NCT00523562|Experimental|normal weight male high fructose diet|"Effects of diet intervention  high fructose in normal weight subjects"
9883100|NCT00523562|Experimental|offsprings of T2DM high fructose diet|"Effect of diet intervention high fructose in healthy non-obese offsprings of patients with type 2 diabetes"
9883101|NCT00523562|Experimental|normal weight subjects high fat diet|"effects of diet intervention high fat in healthy male subjects"
9883102|NCT00523562|Experimental|Normal weight high fat+protein diet|"effect of diet intervention high fat + protein subjects in healthy male subjects"
9883103|NCT00523575|No Intervention|C|Usual nurse and dietetic care
9883104|NCT00523575|Experimental|I|Intensive nutritional support composed of oral dietary supplement combined with dietetic counselling.
9883105|NCT00523666|Active Comparator|1|
9883106|NCT00523666|Placebo Comparator|2|
9883107|NCT00523692|Experimental|1|Intensive therapy
9883108|NCT00523692|Active Comparator|2|Standard therapy
9883109|NCT00523757|Experimental|1|Spironolactone
9883110|NCT00523757|Placebo Comparator|2|
9883111|NCT00523770||Group A|Non-pneumococcal infected healthy elderly volunteers
9883112|NCT00523835||KS|Patients with Klinefelter syndrome verified by chromosome analysis
9883113|NCT00523835||Normal|Normal men Age matched to KS patients
9883114|NCT00523900|Experimental|Experimental|Malnourished adults who will be given a dietary supplement.
9883115|NCT00523952|Experimental|1|
9883116|NCT00523965|Experimental|A|AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8
9883117|NCT00523965|Experimental|B|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
9883118|NCT00523965|Experimental|C|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
9883119|NCT00523965|Active Comparator|D|amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions
9883120|NCT00524004|Experimental|Anti-CsbD Bovine IgG|Anti CsbD Bovine Milk Immunoglobulin
9883121|NCT00524004|Experimental|Placebo|Lacto-free milk supplement
9883122|NCT00524004|Experimental|Anti-CS17 Bovin IgG|Anti-CS17 Bovin Milk Immunoglobulin
9883123|NCT00524095|No Intervention|1|standard of care
9883124|NCT00524095|Experimental|2|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
9883125|NCT00524095|Experimental|3|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
9883126|NCT00524186|Experimental|Oral Sunitinib|Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
9883127|NCT00524199|Placebo Comparator|Placebo|Saline IV infusion over five minutes at the beginning of dialysis.
9883128|NCT00524199|Active Comparator|Mesna|12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
9883129|NCT00524212||IE confirmed IE rejected|Prospective, controlled, blinded study of clinical/TEE criteria of IE compare to clinical/blood test criteria of IE.
9883130|NCT00524212||IE confirmed IE rejected|
9883131|NCT00524238|Other|1|11 hypothyroid patients, newly diagnosed, examined before and after treatment
9883132|NCT00524238|No Intervention|2|10 healthy controls
9997294|NCT01507571|Experimental|Dignity Therapy|
9931124|NCT00935181|Experimental|exercise training program|The exercise training program consisted of three 90-minute sessions per week for eight weeks. Each session consisted of a stretching exercise, resistance that patients started at 70% of the initial one-repetition maximum (1RM: the maximum load which can be moved only once over the full range of motion without compensatory movements) in the first week (3x8 repetitions). Every week the load was increased by 5% of the 1RM, and endurance training (treadmill walking speed was set at 60% of the average speed obtained from the 6MWT (6MWTpeak) for 10 mins in the first week and was increased to 20 mins in week 8
9931125|NCT00935194|Experimental|blank|do not take antiviral therapy
9931126|NCT00935194|Experimental|Oseltamivir|antiviral therapy
9931127|NCT00935194|Experimental|chinese medicinary herbs|antiviral therapy
9931128|NCT00935194|Experimental|oseltalmivir and chinese medicinal herbs|combination antiviral therapy
9931129|NCT00935207||Pediatric Pain Diary|Patients will be give a pain diary to complete.
9931130|NCT00935246|Experimental|Antidepressant treated group|Antidepressant treated group: depressed patients treated with Escitalopram
9931131|NCT00935246|No Intervention|other antidepressant treated group|other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
9997295|NCT01507597|Other|Healthy Subjects|
9997296|NCT01507597|Other|T2DM|
9997297|NCT01507597|Other|T1DM|
9989094|NCT01429467|Other|Continuous Glucose Monitoring (CGM)|10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5. After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
9989095|NCT01429480|Active Comparator|TAP Block|
9989096|NCT01429480|Active Comparator|II/IH Block|
9989097|NCT01429480|Active Comparator|Control Group|
9989098|NCT01429493|Active Comparator|Conventional radiotherapy|
9989099|NCT01429493|Experimental|Biological image-guided radiotherapy with conventional dose.|
9989100|NCT01429493|Experimental|Biological image-guided SBRT with dose-escalation.|
9989101|NCT01429506|Active Comparator|Sleeve gastrectomy|Will undergo laparoscopic sleeve gastrectomy
9989102|NCT01429506|Active Comparator|Intensive medical management|Will receive VLCD, exenatide, metformin, insulin detemir
9989103|NCT01429519|Experimental|Treatment|
9989104|NCT01429545|Active Comparator|Group 1 - Atosiban|Patients on single agent atosiban alone
9800199|NCT01682148|Experimental|NMJ Targeted|NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
9989105|NCT01429545|Experimental|Group 2|Patients on combination of atosiban and nifedipine
9989106|NCT01429571||Systemic and local antibiotics|
9989107|NCT01429571||Local antibiotics|
9989108|NCT01429571||No antibiotics|
9989109|NCT01429597||Observation|All Patients with a diagnosis of Fabry disease with N215S
9989110|NCT01429610|Experimental|Rituximab+mVPDL|Patients who were CD20(+), newly-diagnosed adult ALL and treated with rituximab + mVPDL treatment plan
9989111|NCT01429636|Experimental|Applied Relaxation (AR)|
9989112|NCT01429636|Experimental|Modified Relaxation (MR)|
9989113|NCT01429649|Experimental|ablation|Cryoablation or Radiofrequency ablation for the pGGO
9989114|NCT01429649|No Intervention|Follow up CT scann|The patients will receive follow up with CT scan every 6-9 months.
9989115|NCT01429662|Sham Comparator|Lifestyle Education (LE)|Lifestyle Education (LE) Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
9989116|NCT01429662|Experimental|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
9989117|NCT01429675|Active Comparator|Bonviva|
9989118|NCT01429675|Experimental|DP-R206|
9989119|NCT01429688|Experimental|DP-R202|Multiple oral administration for 3 days
9989120|NCT01429688|Active Comparator|Anplag|Multiple oral administration for 3days
9989121|NCT01429701|Experimental|Test association cream|polymyxin B sulphate + prednisolone + benzocaine + clioquinol
9989122|NCT01429701|Active Comparator|Comparative association cream|betamethasone + gentamicin + tolnaftato + clioquinol
9989123|NCT01429714|Experimental|Intervention: individually tailored ECS|Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
9989124|NCT01429714|Active Comparator|Control: ECS 24 months|Elastic compression therapy with a standard duration of 24 months
9989125|NCT01429740|Experimental|PF-05180999|
9989126|NCT01429740|Placebo Comparator|Placebo|
9989127|NCT01429753|Active Comparator|Standard LV lead placement|
9989128|NCT01429753|Experimental|Advanced Imaging Guided LV Lead Placement|
9989129|NCT01429779|Experimental|Movicol|Administration of 1 sachet of Movicol® daily during one week preoperatively (experimental care) and 2 sachets of Movicol® daily postoperatively (standard care).
9989130|NCT01429779|No Intervention|Control|Control group; standard postoperative care (administration of 2 sachets of Movicol® postoperatively daily)
9989131|NCT01429818|Experimental|Glimepiride/metformin|
9989132|NCT01429818|Active Comparator|Metformin|
9989133|NCT01429831|Experimental|Aripiprazole|
9989134|NCT01429844|Active Comparator|Tacrolimus|Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
9989135|NCT01429844|Active Comparator|Cyclosporine|Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
9989136|NCT01429870|Active Comparator|Steroid active treatment|Triamcinolone acetonide 0.1% in unguentum leniens topically
9989137|NCT01429870|Placebo Comparator|Vehicle|unguentum leniens topically
9989138|NCT01429896|Experimental|Arm 1|Exercise followed by sleep restriction followed by control challenge
9989139|NCT01429896|Experimental|Arm 2|Sleep restriction followed by exercise followed by control challenge
9989140|NCT01429896|Experimental|Arm 3|control followed by sleep restriction followed by exercise
9989141|NCT01429896|Experimental|Arm 4|control followed by exercise followed by sleep restriction
9989142|NCT01429896|Experimental|Arm 5|Sleep Restriction followed by control followed by exercise
9989143|NCT01429896|Experimental|Arm 6|Exercise followed by control followed by sleep restriction
9989144|NCT01429935|Active Comparator|Ginger powder|
9989145|NCT01429935|Active Comparator|Ibuprofen|capsules of Ibuprofen 400 mg
9989146|NCT01429935|Placebo Comparator|placebo|capsules contain starch
9883133|NCT00524433|Experimental|1|tezosentan
9883134|NCT00524433|Placebo Comparator|2|
9883135|NCT00524446|No Intervention|ST-DI|Standard treatment - delayed intervention. Counselling on complementary feeding + Vitamin A (200,000 IU) every 6 months until 36 months + 1 kg maize / soy flour 2-weekly (71 g / day) between 18 and 30 months of age.
9883136|NCT00524446|Experimental|FSm|Fortified Spread (milk). Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
9883137|NCT00524446|Experimental|FSs|Counselling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
9883138|NCT00524446|Experimental|LP|Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
9883139|NCT00524498|Experimental|A|FAIT
9883140|NCT00524498|Active Comparator|B|BST
9883141|NCT00524615|Active Comparator|1|25 mg of Spironolactone oraly once daily
9883142|NCT00524615|Placebo Comparator|2|placebo oraly once daily
9883143|NCT00524667|Experimental|1|
9883144|NCT00524693|Active Comparator|1|4mg Singulair© sachets
9883145|NCT00524693|Placebo Comparator|2|
9883146|NCT00524719|Active Comparator|Open, internal fixation volar plate|Open reduction and internal fixation (ORIF) with volar locked plate
9883147|NCT00524719|Active Comparator|Closed reduction with external fixator|Surgical procedure - Closed reduction and non-spanning external fixation (Ex-FIX)
9883148|NCT00524719|Active Comparator|Closed reduction percutaneous pinning|Surgical procedure - Closed reduction with percutaneous pinning (CRPP) and the application of a cast
9883149|NCT00524732||1|18 to 30 months since last prior dose of TD/Td vaccine.
9883150|NCT00524732||2|30 to 42 months since last prior dose of TD/Td vaccine.
9883151|NCT00524732||3|42 to 54 months since last prior dose of TD/Td vaccine.
9883152|NCT00524732||4|54 to 66 months since last prior dose of TD/Td vaccine.
9883153|NCT00524732||5|66 to 78 months since last prior dose of TD/Td vaccine.
9883154|NCT00524732||6|78 to 90 months since last prior dose of TD/Td vaccine.
9883155|NCT00524732||7|90 to 102 months since last prior dose of TD/Td vaccine.
9883156|NCT00524732||8|102 to 114 months since last prior dose of TD/Td vaccine.
9883157|NCT00524732||9|Control - over 114 months since last prior dose of TD/Td vaccine.
9883158|NCT00524758|Experimental|Ologen in Trabeculectomy|Ologen in Trabeculectomy
9883159|NCT00524758|Active Comparator|MMC in Trabeculectomy|MMC in Trabeculectomy
9883160|NCT00524784|Experimental|A|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses
9883161|NCT00524797|Active Comparator|Main|50 patients will receive Profonycia 5 gr/day PO for 7 days
9883162|NCT00524810|Experimental|Caelyx - Taxotere|
9883163|NCT00524823||1|10 diagnosed men in age 60 - 90 with Prostate Cancer
9883164|NCT00524823||2|10 patients with benign growth
9883165|NCT00524823||3|10 health volunteers
9883166|NCT00524823||4|10 patients diagnosed with other cancer
9883167|NCT00524849|Active Comparator|conventional Zometa|Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
9883168|NCT00524849|Experimental|weekly Zometa|Weekly Zometa in combination with other antitumor agents one month after the initial dosing.
9883169|NCT00524862|Other|1|
9883170|NCT00524862|Other|2|
9883171|NCT00524875|Experimental|1|Intravitreal bevacizumab injection 1-2 weeks before surgery
9883172|NCT00524875|Sham Comparator|2|Sham injection (needleless syringe pressed against conjunctiva)
9883173|NCT00524888|Active Comparator|1|suturing lacerations of the hand
9883174|NCT00524888|Active Comparator|2|using bioadhesive on lacerations of hand
9883175|NCT00524901|Experimental|1|25 patients undergoing CABG for three vessel disease, receiving a single dose of erythropoietin periprocedural.
9883176|NCT00524901|Placebo Comparator|2|25 patients undergoing CABG for three vessel disease, receiving placebo (NaCl 0.9%) periprocedural.
9883177|NCT00524914|Experimental|1|Apomorphine
9883178|NCT00524914|Placebo Comparator|2|Placebo
9883179|NCT00524927|Active Comparator|A|
9883180|NCT00524927|Placebo Comparator|B|
9883181|NCT00524953|Experimental|I|10 patients after allogeneic BMT (non T-depleted).
9883182|NCT00524979||Schizophrenia|People who are diagnosed as schizophrenic by DSM-IV
9883183|NCT00524979||Mental diseases|Patients who are deagnosed as having mental disease other then schizophrenia
9883184|NCT00524979||Mentally healthy|People who have no mental disease
9883185|NCT00525005|Experimental|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
9883186|NCT00525096|Placebo Comparator|Placebo|Aromasin + placebo in place of Celebrex
9517680|NCT03304197|Experimental|Placebo|90 minutes cycling, with the ingestion of six 250 ml taste-matched water drinks, followed by a 15 minute cycling time trial test
9883187|NCT00525096|Experimental|Celebrex|Aromasin + Celebrex
9883188|NCT00525109||1|Single family cohort
9883189|NCT00525122||1|Patients with hyperthyroidism who are will be treated with radioactive iodine.
9883190|NCT00525200|Active Comparator|A|
9883191|NCT00525200|Experimental|B|
9883192|NCT00525213|Active Comparator|A|
9883193|NCT00525213|Active Comparator|B|
9883194|NCT00525213|Active Comparator|C|
9517681|NCT03304158|Experimental|FCHV visit-diabetes|
9883195|NCT00525213|Placebo Comparator|D|
9883196|NCT00525226||1|Women who have experienced symptoms of depression or anxiety during pregnancy.
9883197|NCT00525239|Experimental|1: Ritonaivr|Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir
9883198|NCT00525252|Placebo Comparator|2|A total of 42 alcoholic patients with liver cirrhosis treated with placebo
9883199|NCT00525252|Active Comparator|1|a total of 42 alcoholic patients with liver cirrhosis treated by baclofen
9883200|NCT00525291|Experimental|EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
9883201|NCT00525291|Active Comparator|EMG-biofeedback alone|
9883202|NCT00525304|Experimental|1|Participants will receive a self-management program for chronic illness
9883203|NCT00525304|No Intervention|Usaual Care|Usual Care; no additional intervention
9883204|NCT00525317|Active Comparator|Magnesium tablet suplementation (1)|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"
9883205|NCT00525317|Placebo Comparator|Placebo tablet suplementation (2)|Placebo (3 times daily for 2 weeks)
9883206|NCT00525356|Active Comparator|1|Anti-hypertensive medical treatment
9883207|NCT00525395|Experimental|A|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
9883208|NCT00525395|Active Comparator|B|Group B: 6 months non-stop treatment.
9883209|NCT00525408|Experimental|2|Docetaxel+Mw
9883210|NCT00525408|Active Comparator|1|Docetaxel
9883211|NCT00525434|Experimental|A|
9883212|NCT00525447|Experimental|1|
9883213|NCT00525486|Experimental|A|The treated group of pregnant women, after having successful treatment for PTL
9883214|NCT00525486|No Intervention|B|The no treatment arm of women treated with tocolysis for PTL.
9883215|NCT00525551|Active Comparator|1|
9883216|NCT00525551|Placebo Comparator|2|
9883217|NCT00525564|Placebo Comparator|A|Placebo diskus
9883218|NCT00525564|Active Comparator|B|Salmeterol diskus powder
9883219|NCT00525577|Experimental|1:A|Placebo
9989147|NCT01429948||Case group|Healthy subjects with silent cerebral infarction
9989148|NCT01429948||Control group 1|Patients with acute cryptogenic embolic stroke
9989149|NCT01429948||Control group 2|Patients with acute stroke with conventional stroke mechanisms
9989150|NCT01429961|Experimental|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1-14
9989151|NCT01429974||volunteers|
9989152|NCT01430013|Experimental|Endostar|CHOPT chemotherapy plus Endostar
9989153|NCT01430039||Crohn's, ulcerative colitis|Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.
9989154|NCT01430039||No disease|Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1
9989155|NCT01430052|Other|Gemcitabine , S-1|Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks
9989156|NCT01430052|Experimental|Gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions
9989157|NCT01430065|Experimental|Tacrolimus and ASP015K|
9989158|NCT01430078|Experimental|Regimen A|ASP015K oral tablet
9989159|NCT01430078|Experimental|Regimen B|ASP015K solution delivered to distal small bowel via oral capsule
9989160|NCT01430078|Experimental|Regimen C|ASP015K solution delivered to ascending colon via oral capsule
9989161|NCT01430078|Experimental|Regimen D|ASP015K solution delivered to distal transverse colon via oral capsule
9517682|NCT03304158|No Intervention|FCHV no visit-diabetes|
9989162|NCT01430117|Experimental|1|"Poa pratensis allergen extract at 4 different concentrations.~Positive control.~Negative control."
9989163|NCT01430143|Experimental|600 kcal/day|Exercise combusting 600 kcal/day, 7 days/week for 12 weeks.
9989164|NCT01430143|Experimental|300 kcal/day|Exercise combusting 300 kcal/day, 7 days/week for 12 weeks.
9989165|NCT01430143|No Intervention|Sedentary|Continued sedentary living.
9989166|NCT01430156|Active Comparator|Heme arginate (Normosang)|This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
9989167|NCT01430156|Placebo Comparator|0.9% saline|The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.
9989168|NCT01430195|Experimental|Afamelanotide + NB-UVB: Experimental|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 4 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total).
9989169|NCT01430195|Active Comparator|NB-UVB alone: Active Comparator|Subjects in this arm will receive NB-UVB light only (administered thrice weekly, 72 treatments in total).
9989170|NCT01430208|Active Comparator|mini-resectoscope|
9989171|NCT01430208|Active Comparator|tradiorional resectoscope|
9989172|NCT01430208|Active Comparator|bettocchi resectoscope|
9989173|NCT01430221|Experimental|MB-PHP Group|Mindfulness-based Personalized Health Planning (MB-PHP)with health coaching. MB-PHP includes weekly small group meetings for 22-weeks and 10 bi-weekly telephonic health coaching.
9989174|NCT01430221|Active Comparator|SAGE Group|Structure & Guided Education (SAGE) includes small group-education sessions once per week for 22 weeks. Subjects also participate in 10 bi-weekly telephone calls with education partners who use supportive listening techniques..
9883220|NCT00525577|Experimental|2:B|AGI-1067 75 mg
9883221|NCT00525577|Experimental|3:C|AGI-1067 150 mg
9883222|NCT00525616|Experimental|Rituximab|Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .
9883223|NCT00525642|Experimental|A|six cycles of adjuvant TAC
9883224|NCT00525642|Experimental|B|four cycles of T followed by 4 cycles of AC
9883225|NCT00525655|Experimental|Multimedia Intervention|
9883226|NCT00525668|Active Comparator|verum|Sunphenon plus glatiramer acetate
9883227|NCT00525668|Active Comparator|placebo|placebo plus glatiramer acetate
9883228|NCT00525681|Other|CsA|Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.
9883229|NCT00525681|Other|Tac|Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.
9883230|NCT00525694|Other|1|glucose tolerance test solution
9883231|NCT00525694|Other|2|Diet Coke
9883232|NCT00525694|Other|3.|Coke Zero
9883233|NCT00525707|Experimental|1|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
9883234|NCT00525707|Placebo Comparator|2|
9883235|NCT00525720|Experimental|Brachytherapy - Participants with < 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
9883236|NCT00525720|Experimental|Brachytherapy - Participants with > 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
9883237|NCT00525746||Cases|Patients with a confirmed diagnosis of AML or MDS (cases).
9883238|NCT00525746||Controls|Patients treated for a primary malignancy (controls).
9883239|NCT00525759|Active Comparator|A|Neoadjuvant chemotherapy alone
9883240|NCT00525759|Experimental|B|Neoadjuvant chemotherapy + zoledronic acid
9883241|NCT00525772|Active Comparator|1|ciclesonide 50 and 200ug
9883242|NCT00525772|Active Comparator|2|ciclesonide 100ug and 400ug
9883243|NCT00525811|Experimental|A|Interactive decision aid
9883244|NCT00525811|Active Comparator|B|Regular patient information
9883245|NCT00525850|Other|1|high saturated fat diet
9883246|NCT00525850|Other|2|low calorie low saturated fat low trans fat high fiber diet
9883247|NCT00525889|Experimental|Rapamycin/IL-2 combination therapy|IL-2 (Proleukin) was administered at 4.5 3 106 IU s.c., three times per week for 4 weeks for a total of 12 doses. Rapamycin (Rapamune or Sirolimus) was administered without a loading dose at 2 mg/day, with adjustments to maintain trough blood levels of 5-10 ng/mL for 3 months.
9883248|NCT00525967|Active Comparator|1|Methadone plus Placebo
9883249|NCT00525967|Experimental|2|Methadone plus Acetaminophen
9883250|NCT00525980|Experimental|Group 1: Written Materials|One group asked to read educational materials.
9883251|NCT00525980|Experimental|Group 2: Computer Program Only|Group 2 use an educational computer program to learn about breast cancer risk and genetic testing without guidance.
9883252|NCT00525980|Experimental|Group 3: Computer Program + Promotora|Group 3 use the computer program with the guidance of a promotora.
9883253|NCT00525993|Experimental|A|
9883254|NCT00525993|Active Comparator|B|
9883255|NCT00526019||Complete remission of their asthma|Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (>16 mg/ml) for more than two years (with no current treatment).
9883256|NCT00526019||Symptomatic remission ofasthma|Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine <16 mg/ml)
9883257|NCT00526019||Current asthma (mild asthma)|Subjects with current asthma (Mild asthma)
9883258|NCT00526019||Healthy controls|Healthy controls
9883259|NCT00526032||Spectroscopic Oblique-Incidence Reflectometry (OIR)|
9883260|NCT00526136|Placebo Comparator|1|Placebo (b.i.d.)
9883261|NCT00526136|Experimental|2|Vernakalant (oral), 150 mg (b.i.d.)
9883262|NCT00526136|Experimental|3|Vernakalant (oral), 300 mg (b.i.d.)
9883263|NCT00526136|Experimental|4|Vernakalant (oral), 500 mg (b.i.d.)
9883264|NCT00526201|Experimental|Exercise|Subjects will be randomized to exercise (12 week EnhanceFitness class) or a wait-list control group.
9883265|NCT00526201|Other|Control|Wait-list control group will receive intervention after 12-weeks.
9883266|NCT00526214|No Intervention|1|In the control group, patients will not take the drug. We do not use placebo drugs.
9883267|NCT00526214|Experimental|2|In the intervention group, patients will take celecoxib.
9883268|NCT00526253|Active Comparator|Low Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
9883269|NCT00526253|Active Comparator|High Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
9883270|NCT00526253|Placebo Comparator|Control|Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
9883271|NCT00526266|Experimental|1|
9883272|NCT00526266|Placebo Comparator|2|
9883273|NCT00526266|No Intervention|3|No Treatment
9931132|NCT00935298|Experimental|T|"The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation.After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*3 and *1/*1 ,expressors; CYP3A5*3/*3 nonexpressor）.~The objective is to determine the initial dosage Range of tacrolimus in Chinese renal transplantation patients by genotyping of the cytochrome P450 3A5"
9931133|NCT00935324||Group A: patients following allo-SCT|Patients scheduled for allo-SCT fulfilling all inclusion criteria
9931134|NCT00935324||Group B - healthy controls|healthy voluntary blood donors
9931135|NCT00935337|Experimental|Mind-Body Bridging Program|Mind Body Bridging subjects will be accessed with questionnaires and medical history evaluations for the impact of MBBP over the past 6 months since undertaking the program.
9883274|NCT00526344||1|Subjects with complete remission of asthma
9883275|NCT00526344||2|Subjects with symptomatic remission of asthma
9883276|NCT00526344||3|Subjects with asthma
9883277|NCT00526344||4|Healthy controls
9883278|NCT00526357|Other|A|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists alone to treat their asthma
9883279|NCT00526357|Other|B|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists and inhaled steroids to treat their asthma
9883280|NCT00526370||A|Women with at least moderate dysplasia in biopsies from cervix uteri
9883281|NCT00526370||B|Women with only normal PAP-smears
9883282|NCT00526383|Experimental|A|antidepressant versus medical dispositive
9883283|NCT00526383|Placebo Comparator|B|
9883284|NCT00526396|Active Comparator|A|standard fixed doses
9883285|NCT00526396|Experimental|B|toxicity adjusted dosing
9883286|NCT00526435|Experimental|Group WWE|Subjects will participate in a group-assisted 6 week WWE program.
9883287|NCT00526435|Experimental|Self-directed|Subjects will follow the self-directed WWE program.
9883288|NCT00526448|Experimental|1|Peginterferon alfa-2a 180 mcg/week + ribavirin 2000 mg/day + epoetin beta 450 UI/week
9883289|NCT00526448|Active Comparator|2|Peginterferon alfa-2a 180 mcg/week + ribavirin 1000-1200 mg/day
9883290|NCT00526461|Experimental|PDT using HPPH|Patients receive HPPH IV over 1 hour on day 1. Patients then receive photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
9883291|NCT00526487|Other|1|Endovascular Repair
9883292|NCT00526500|Experimental|P-T|
9883293|NCT00526500|Experimental|P- SAH|
9883294|NCT00526500|Experimental|P- A|
9883295|NCT00526500|Experimental|Control|
9883296|NCT00526565|Experimental|1|TAT (Tapas Acupressure Technique)
9883297|NCT00526565|Active Comparator|2|SS (Professionally facilitated social support groups)
9883298|NCT00526578||Questionnaire|Pancreatic cancer patients or family member.
9883299|NCT00526604|Active Comparator|2|The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.
9883300|NCT00526617|Experimental|Open Label|Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
9883301|NCT00526643|Experimental|Arm B|combination chemotherapy
9883302|NCT00526643|Active Comparator|Arm A|monochemotherapy
9883303|NCT00526682|Active Comparator|1|Comparison of actives for synergy
9883304|NCT00526747||Epo-resistant|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
9883305|NCT00526747||Epo-responsive|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
9883306|NCT00526760|Experimental|Dexmedetomidine|
9883307|NCT00526773|Other|1|Telephone management plus a motivational intervention
9883308|NCT00526773|Other|2|Telephone management with standard patient education
9883309|NCT00526812|Experimental|Group A (RTA 744)|Receive study drug for three consecutive days, Cycle repeated every 21 days.
9883310|NCT00526812|Experimental|Group C (RTA 744 Injection)|Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
9883311|NCT00526838|Experimental|1|once-weekly dosing
9883312|NCT00526838|Experimental|2|twice-weekly dosing
9883313|NCT00526864||Elderly patients|
9883314|NCT00526864||HIV infected patients|
9883315|NCT00526864||Immunosuppressed patients|
9883316|NCT00526877|Experimental|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
9883317|NCT00526903|Experimental|Fiber|Fiber added to diet for a total of 6 weeks.
9883318|NCT00526903|Placebo Comparator|Placebo|Placebo powder taken for a total of 6 weeks.
9883319|NCT00526929|Experimental|darbepoetin alfa|darbepoetin alfa (NESP)
9883320|NCT00526942|No Intervention|I|No contact control (NCC)
9883321|NCT00526942|Experimental|II|Computerized, SAAGE-designed, visual memory-based cognitive training
9883322|NCT00526968|Experimental|1|EVT 101 8 mg capsule
9883323|NCT00526968|Experimental|2|EVT 101 15 mg capsule
9883324|NCT00526968|Placebo Comparator|3|Matching placebo capsule
9883325|NCT00526981|Experimental|Treatment|Prone position + all conventional treatment.
9883326|NCT00526981|No Intervention|Control|Conventional treatment
9883327|NCT00527007|Experimental|A|
9883328|NCT00527007|No Intervention|B|
9883329|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort A|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
9883330|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort B|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
9883331|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort C|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
9883332|NCT00527020|Experimental|Part B: Subjects in 5 period crossover period|Eligible subjects (first 14 subjects) will be randomized to one of the following 14 sequences as a 5 period crossover with sequences; LMNOQ, MNOLQ, NOLMQ, OLMNQ, ONMLQ, NMLOQ, MLONQ, LONMQ, LNMOQ, NMOLQM MOLNQ, OLNMQ, OMNLQ and MNLOQ) (L= 80 milligrams GSK1018921 given in fasted state, M= 200 milligrams GSK1018921 given in fasted state, N= nicotine lozenge, O= placebo and Q= 80 milligrams GSK1018921 in fed state).
9883333|NCT00527020|Experimental|Part B: Subjects in 4 period crossover period|Eligible subjects (last 7 subjects) will be randomized to one of the following 7 sequences as a 4 period crossover with sequences; NLOM, LOMN, OLNM, LNMO, NMOL, MOLN, and MNLO.
9883334|NCT00527033|Experimental|1|Oral
9883335|NCT00527033|Experimental|2|Oral
9883336|NCT00527033|Experimental|3|Oral
9883337|NCT00527033|Placebo Comparator|4|Oral
9883338|NCT00527059|Experimental|1|patients with acute heart failure
9883339|NCT00527059|Active Comparator|2|standard therapy for heart failure
9883340|NCT00527085|Experimental|AMG 073|
9883341|NCT00527085|Placebo Comparator|Placebo|
9883342|NCT00527137|Active Comparator|rHuEPO|
9883343|NCT00527137|Experimental|darbepoetin alfa|
9883344|NCT00527150|Other|Cohort 1|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
9883345|NCT00527150|Other|Cohort 2|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
9883346|NCT00527150|Other|Cohort 3|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
9883347|NCT00527150|Other|Optional Cohort 4|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
9883348|NCT00527150|Other|Optional Cohort 5|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
9883349|NCT00527202|Experimental|botulinum toxin A|active treatment arm using botulinum toxin A max 200 U injected into the painful area using SC injections 2 cm apart
9883350|NCT00527202|Placebo Comparator|placebo|saline injection with the same dosages injected using the same procedure as botulinum toxin A
9883351|NCT00527215|Experimental|darbepoetin alfa|
9883352|NCT00527228|Active Comparator|A|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm B
9883353|NCT00527228|Placebo Comparator|B|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm A
9883354|NCT00527241|Experimental|1: A|
9883355|NCT00527241|No Intervention|2 B|wait-listed for intervention to begin in 6 months
9883356|NCT00527254|No Intervention|Control group|
9883357|NCT00527254|Active Comparator|Telemedicine group|
9883358|NCT00527267|Experimental|AMG 073|AMG 073
9883359|NCT00527267|Placebo Comparator|Placebo|Placebo
9883360|NCT00527280|Experimental|1|
9883361|NCT00527293|Experimental|MammoSite Brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
9883362|NCT00527293|Experimental|3-dimensional conformal radiotherapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
9883363|NCT00527306|Experimental|I - Multivitamin|The multivitamin will contain 100% of the US reference daily intakes (recommended daily amounts) of vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, and E. It also contains several inactive ingredients including sodium bisulfite and gelatin.
9883364|NCT00527306|Placebo Comparator|II - Inactive Medication|The placebo will be a gelatin capsule filled with lactose.
9883365|NCT00527345||1|children riding retrofitted school buses or private cars
9883366|NCT00527345||2|children riding old buses who will change to retrofitted buses during the first or second year of the study
9883367|NCT00527345||3|children who ride old diesel buses through the study
9883368|NCT00527358|Experimental|SAFER|"The intervention community will receive 4 services:~community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, and provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center: will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
9883369|NCT00527358|No Intervention|2|Business as usual.
9883370|NCT00527371|Experimental|PVP|Photoselective vaporization of the prostate.
9883371|NCT00527371|Active Comparator|TURP|Transurethral resection of the prostate.
9517683|NCT03304132||Upper aerodigestive squamous cell cancers (UADSCC) cases|From PLCO and ACS CPS II, identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
9517684|NCT03304132||Controls|From PLCO and ACS CPS II, we have identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
9883372|NCT00527410|Experimental|RTA 744|RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
9883373|NCT00527436|Other|Dietary Supplement|Fish oil pill
9883374|NCT00527436|Placebo Comparator|Placebo|Placebo matched corn oil pill
9883375|NCT00527527|Active Comparator|1|8 flexion distraction visits
9883376|NCT00527527|Active Comparator|2|12 flexion distraction visits
9883377|NCT00527527|Active Comparator|3|18 flexion distraction visits
9883378|NCT00527527|Placebo Comparator|4|8 placebo control visits
9883379|NCT00527553|Experimental|A|daily consumption of a regular egg
9883380|NCT00527553|Experimental|B|daily consumption of a lutein-enriched egg, eggs laid by chickens on a lutein-enriched feed.
9883381|NCT00527553|Experimental|C|daily consumtion of a zeaxanthin-enriched egg, eggs laid by chickens on a zeaxantin-enriched feed.
9883382|NCT00527553|Experimental|D|daily egg product from enriched eggs
9883383|NCT00527553|No Intervention|E|control subjects were not blinded as they did not receive any aditional supplementation. Only markers measured during the trial period as a control.
9883384|NCT00527657|Experimental|Lomustine + Temozolomide + Thalidomide|Lomustine starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily.
9883385|NCT00527670||Normal Controls|Healthy patients undergoing laparoscopic surgery for cholelithiasis, appendicitis, and adrenalectomy.
9883386|NCT00527670||Recurrent Hernia|Patients presenting for laparoscopic repair of ventral or incisional hernias.
9883387|NCT00527683|Active Comparator|A|Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
9883388|NCT00527683|Placebo Comparator|B|Orange juice and administration identical to Arm A.
9883389|NCT00527696|Active Comparator|TVT SECURE|sling
9883390|NCT00527696|Active Comparator|TVT O|sling
9883391|NCT00527761|Experimental|Temozolomide, Docetaxel + Cisplatin|
9883392|NCT00527774||A|HCV(+) maintenance hemodialysis patients
9883393|NCT00527774||B|HCV(-) maintenance hemodialysis patients
9883394|NCT00527800|Experimental|1|Treatment for episodes of uncomplicated malaria
9883395|NCT00527800|Active Comparator|2|Treatment for uncomplicated malaria
9883396|NCT00527800|Experimental|A|Prevention of malaria in HIV uninfected, exposed children
9883397|NCT00527800|No Intervention|B|Prevention of malaria in HIV uninfected, exposed children
9883398|NCT00527813|Experimental|A|prone position for at least 16 hours per day
9883399|NCT00527813|No Intervention|B|semi-recumbent position
9883400|NCT00527865|Experimental|1|6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo
9883401|NCT00527865|Experimental|2|6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo
9883402|NCT00527865|Experimental|3|6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo
9883403|NCT00527865|Experimental|4|6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo
9883404|NCT00527891||Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI Scan
9883405|NCT00527917|Experimental|Uracyst|Sodium chondroitin sulfate
9883406|NCT00527917|Placebo Comparator|Placebo|placebo
9883407|NCT00528008|Active Comparator|A|povidone-iodine
9883408|NCT00528008|Active Comparator|B|chlorhexidine gluconate
9883409|NCT00528034|Experimental|Lymphoscintigraphy|
9883410|NCT00528047|Experimental|PRLX 93936|
9883411|NCT00528073|Experimental|A|Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
9883412|NCT00528073|Experimental|B|Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
9883413|NCT00528073|Experimental|C|Rifaximin-EIR tablet 3x400 mg bid
9883414|NCT00528073|Placebo Comparator|D|Placebo 3 tablets bid
9931136|NCT00935337|Active Comparator|Sleep Hygiene|Sleep Hygiene subjects will be accessed with questionnaires and medical history evaluations for the impact of SH over the past 6 months since undertaking the program.
9931137|NCT00935350|Placebo Comparator|1|Control White bread containing 50g available carbohydrate
9931138|NCT00935350|Placebo Comparator|2|White bread and milk control
9931139|NCT00935350|Placebo Comparator|3|Granola control
9931140|NCT00935350|Placebo Comparator|4|Cornflakes and milk control
9931141|NCT00935350|Placebo Comparator|5|White rice control
9931142|NCT00935350|Placebo Comparator|6|Fruit yogurt control
9931143|NCT00935350|Placebo Comparator|7|Turkey dinner control
9931144|NCT00935350|Experimental|8|Granola
9931145|NCT00935350|Experimental|9|Cornflakes and milk
9931146|NCT00935350|Experimental|10|White Rice
9931147|NCT00935350|Experimental|11|Fruit yogurt
9931148|NCT00935350|Experimental|12|Turkey dinner
9931149|NCT00935350|Placebo Comparator|13|White Bread
9931150|NCT00935350|Placebo Comparator|14|White bread
9931151|NCT00935350|Experimental|15|Granola
9931152|NCT00935363|Experimental|glyburide + fluconazole|
9931153|NCT00935363|Experimental|glyburide + rifampin|
9931154|NCT00935363|Active Comparator|glyburide|
9931155|NCT00935363|Experimental|glyburide + fluconazole + rifampin|
9931156|NCT00935376|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
9997298|NCT01507610|Experimental|Investigational|OPTINOSE SUMATRIPTAN, single dose of 20 mg intranasally (10 mg to each nostril).
9883415|NCT00528086||1|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.
9883416|NCT00528086||2|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).
9883417|NCT00528125|Active Comparator|A|Active laser acupuncture
9883418|NCT00528125|Placebo Comparator|B|placebo laser acupuncture
9883419|NCT00528138||1|Simple appendicitis
9883420|NCT00528138||2|Perforated appendicitis
9883421|NCT00528151|Placebo Comparator|2|"curcumin~placebo"
9883422|NCT00528164|Experimental|Team PLAY Group|6-month family-centered intervention to increase physical activity and healthy eating patterns, primarily directed at parents. Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
9883423|NCT00528164|No Intervention|Standard Care Group|Participants receive standard care by primary care physician.
9883424|NCT00528177|Active Comparator|O|This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
9883425|NCT00528177|Active Comparator|M|This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.
9883426|NCT00528255|Experimental|1|
9883427|NCT00528281|Experimental|Lapatinib + pemetrexed|This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.
9517685|NCT03304093|Experimental|Nivolumab|Nivolumab 3mg/kg every 2 weeks
9883428|NCT00528294|Experimental|1|GRID-radiotherapy followed by biological imaging guided IMRT
9883429|NCT00528307|Active Comparator|1|First 3 months of biventricular pacing, second 3 months right ventricular apical pacing
9883430|NCT00528307|Active Comparator|2|First 3 months of right ventricular apical pacing, second 3 months biventricular pacing
9883431|NCT00528346|Active Comparator|1|Participants will see their own brain activation.
9883432|NCT00528346|Placebo Comparator|2|Participants will see simulated data that does not come from their own brains.
9883433|NCT00528359||A|36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years
9883434|NCT00528463|Experimental|sciatic block|One arm, all patient studied received a block
9883435|NCT00528476||1|Patients, who were treated because of recurrent (2 or more urinary tract infections per year) pyelonephritis or cystitis.
9883436|NCT00528476||2|Patients with nonrecurrent urinary tract infections (patients who had no history of more than one urinary tract infections in last year).
9883437|NCT00528489|Experimental|1|PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
9883438|NCT00528489|Experimental|2|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
9883439|NCT00528489|Experimental|3|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
9883440|NCT00528489|Experimental|4|PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
9883441|NCT00528502|Experimental|Saline|Saline misted into the air breathe during the surgery.
9883442|NCT00528502|Experimental|Lidocaine|Lidocaine misted into the air during the surgery.
9883443|NCT00528515|Active Comparator|1|propofol
9883444|NCT00528515|Experimental|2|desflurane
9883445|NCT00528554|Active Comparator|A|Active laser acupuncture
9883446|NCT00528554|Placebo Comparator|B|Placebo laser acupuncture
9883447|NCT00528593|Active Comparator|1|
9883448|NCT00528619|Experimental|A|
9883449|NCT00528632||Cholesterolosis|I. Patients with gallbladder cholesterolosis and symptomatic cholelithiasis
9883450|NCT00528632||Cholelithiasis|II. Patients without gallbladder cholesterolosis and with symptomatic cholelithiasis
9883451|NCT00528658|Experimental|1|
9883452|NCT00528658|Experimental|2|
9883453|NCT00528658|Experimental|3|
9883454|NCT00528671|Active Comparator|A|Low dose oral anticoagulation, INR self-management once a week
9883455|NCT00528671|Active Comparator|B|very low dose oral anticoagulation, INR self-management once a week
9883456|NCT00528671|Experimental|C|very low dose oral anticoagulation, INR self-management twice a week
9883457|NCT00528710|Placebo Comparator|P|Placebo Control Group
9883458|NCT00528723|Experimental|A|BDP/salbutamol HFA pMDI
9883459|NCT00528723|Active Comparator|B|BDP/salbutamol CFC pMDI
9883460|NCT00528762||Focus Group|Mexican American or African American females (aged 6-12 years old) and their parents
9883461|NCT00528814|Experimental|Two Step Hand-Hygiene|Hand washing plus hand sanitizer
9883462|NCT00528814|No Intervention|Usual Care Hand Hygiene|
9883463|NCT00528827|Placebo Comparator|1|
9883464|NCT00528827|Experimental|2|5 mcg
9883465|NCT00528827|Experimental|3|2.5
9883466|NCT00528827|Experimental|4|0.5
9883467|NCT00528892|Experimental|1|Switch current boosted-PI to raltegravir 400 mg BID.
9883468|NCT00528892|Active Comparator|2|Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
9883469|NCT00528905|Placebo Comparator|1|Placebo
9883470|NCT00528905|Experimental|2|AZD3480 oral
9883471|NCT00528905|Experimental|3|AZD3480 oral dose
9883472|NCT00528918|Active Comparator|Apidra|Direct 1:1 comparison of Apidra and Regular insulin.
9883473|NCT00528918|Active Comparator|Regular|Direct 1:1 comparison of Apidra and Regular insulin.
9883474|NCT00528944||Cohort A|Patients with obstructive defects and radiological evidence of emphysema
9883475|NCT00528944||Cohort B|Patients with obstructive ventilatory defects and no radiological evidence of emphysema
9883476|NCT00528944||Cohort C|Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
9883477|NCT00528983|Experimental|Subcutaneous (SC) Azacitidine and Oral Azacitidine|Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
9883478|NCT00528983|Experimental|Oral Azacitidine|Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.
9883479|NCT00529022|Experimental|Azacitidine + Valproic Acid + Carboplatin|Azacitidine 75 mg/m^2 subcutaneous injection or by vein daily for 5 Days. Valproic Acid 40 mg/kg by mouth daily for 7 days. Carboplatin area under the curve (AUC) 2 by vein on Days 3 and 10 over 60 Minutes.
9883480|NCT00529048||T2DM|T2DM patients (WHO-criteria)
9883481|NCT00529048||CTRL|Healthy control subjects matched individually to the cases.
9883482|NCT00529139|Active Comparator|A|
9883483|NCT00529139|Active Comparator|B|
9883484|NCT00529165|Experimental|A|with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month
9883485|NCT00529165|Experimental|B|without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month
9883486|NCT00529230||Chronic opioid therapy + Gonadal function|Males on chronic opioid therapy for cancer-related pain syndromes
9883487|NCT00529256|No Intervention|2|No intervention
9883488|NCT00529295|Experimental|1|Titrated oral misoprostol
9883489|NCT00529295|Active Comparator|2|Vaginal misoprostol
9883490|NCT00529334|Experimental|1|CyberKnife Partial Breast Irradiation (PBI)
9883491|NCT00529360|Experimental|Part A|Part A will be the dose escalation phase to determine the MTD and/or safe/tolerated dose of clofarabine.
9883492|NCT00529360|Experimental|Part B|Part B will accrue patients to further define the event free, disease free and overall survival at the MTD or safe/tolerated dose of clofarabine.
9883493|NCT00529412|No Intervention|control|no Seprafilm
9883494|NCT00529412|Active Comparator|Seprafilm|
9883495|NCT00529425|Active Comparator|Ropivacaine|
9883496|NCT00529425|Placebo Comparator|Saline|
9883497|NCT00529438|Experimental|Bardoxolone methyl capsules|"Bardoxolone methyl to be taken orally for 21 consecutive days, once a day, in the morning prior to food intake.~Patients to continue to receive treatment for the first 21 days of each 28-day cycle until they experience intolerable toxicity, show evidence of disease progression, or receive a maximum of 18 cycles (18 months)."
9883498|NCT00529477|Active Comparator|1|The Wright Nebulizer will be used to perform the methacholine challenge in arm 1.
9883499|NCT00529477|Active Comparator|2|The Pari LC nebulizer will be used to perform the methacholine challenge in arm 2.
9883500|NCT00529477|Active Comparator|3|The Pari Sinustar nebulizer will be used to perform the methacholine challenge in arm 3.
9883501|NCT00529490|Experimental|HL|Hypertonic lactate group
9883502|NCT00529490|Active Comparator|RL|Ringer's lactate
9883503|NCT00529594|Placebo Comparator|Control Group|Patients who received placebo
9883504|NCT00529594|Active Comparator|Treatment Group|Patients who received etoricoxib 120 mg
9883505|NCT00529607||1|- patients with acute ST elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery
9883506|NCT00529607||2|- 30 patients with stable CAD (control group 1)
9883507|NCT00529607||3|- 30 healthy volunteers regarding cardiovascular diseases (control group 2)
9883508|NCT00529620|Active Comparator|1|sulfalene pyrimethamine plus amodiaquine
9883509|NCT00529620|Active Comparator|2|dihydroartemisinin piperaquine
9883510|NCT00529620|Active Comparator|3|sulfadoxine-pyrimethamine plus piperaquine
9883511|NCT00529672|Active Comparator|1|Surgery: crossectomy plus short stripping
9883512|NCT00529672|Active Comparator|2|ultrasound guided sclerotherapy with foam (3% polidocanol)
9883513|NCT00529672|Active Comparator|3|Endovenous laser therapy (940 nm, about 70 J/cm)
9883514|NCT00529698|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
9883515|NCT00529698|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.
9883516|NCT00529711|Experimental|Group 1|Hypertonic lactate
9883517|NCT00529711|Active Comparator|Group 2|Ringer's lactate
9883518|NCT00529737|Experimental|Group 1|Post Procedure Mammogram Projection View A -- (view same projection as used in the biopsy procedure), then View B (view orthogonal projection to the first view).
9883519|NCT00529737|Experimental|Group 2|Post Procedure Mammogram Projection View B than View A
9883520|NCT00529750|Experimental|Irbesartan Group|150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
9883521|NCT00529750|Active Comparator|Atenolol Group|50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
9883522|NCT00529776|Active Comparator|1|Continuous lateral rotation therapy
9883523|NCT00529776|No Intervention|2|Standard manual positioning (Supine position)
9883524|NCT00529815|Experimental|1CGM and SBGM|Intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
9883525|NCT00529815|Active Comparator|2 SBGM|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
9883526|NCT00529841|Experimental|1 (Hydrocortisone sodium acetate)|Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
9883527|NCT00529854||1|Observational evaluation of current billing and documentation practices
9883528|NCT00529854||2|Use of SIC-IR Billing Module
9883529|NCT00529867|Active Comparator|A|
9883530|NCT00529867|Active Comparator|B|
9883531|NCT00529919|Active Comparator|1|MCT oil consumption
9883532|NCT00529919|Placebo Comparator|2|Olive oil consumption
9883533|NCT00529932|Active Comparator|1|Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
9883534|NCT00529932|Placebo Comparator|2|Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
9883535|NCT00529971|Experimental|1|Participants in the first arm participate in an 8-week MBSR group
9883536|NCT00529971|Active Comparator|2|Participants assigned to the control arm do not receive the MBSR program but may or may not be receiving current psychotherapy or counselling
9883537|NCT00529984|Experimental|Cohort 1|
9883538|NCT00529984|Experimental|Cohort 2|
9883539|NCT00529984|Experimental|Cohort 3|
9883540|NCT00529984|Experimental|Cohort 4|
9883541|NCT00529984|Experimental|Cohort 5|
9883542|NCT00529997|Experimental|1|Posterior Dynamic Stabilization with the Stabilimax NZ
9883543|NCT00529997|Active Comparator|2|Posteriolateral instrumented fusion
9883544|NCT00530036||Continent|"54% of 699 patients followed as outpatient by the Fondation des Services d'Aide et de Soins à Domicile in Geneva without urinary incontinence"
9883545|NCT00530036||Incontinent|"46% of 699 patients followed by the Fondation des Services d'Aide et de Soins à Domicile in Geneva and with an urinary incontinence"
9883546|NCT00530127|Placebo Comparator|A|Placebo solution
9883547|NCT00530127|Experimental|B|Deferiprone oral solution 20 mg/kg/day
9883548|NCT00530127|Experimental|C|Deferiprone oral solution 40 mg/kg/day
9883549|NCT00530127|Placebo Comparator|D|Placebo solution
9883550|NCT00530127|Experimental|E|deferiprone oral solution 60 mg/kg/day
9883551|NCT00530140|Experimental|A|All patients will receive the same vaccination schedule/formulation
9883552|NCT00530179|Active Comparator|Arm A|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)~Assigned interventions: Drug: R-CHOP (Rituximab, Cyclophosphamide, Etoposide, Cisplatin, Mesna, G-CSF 6 - 21 DAY Cycles of R-CHOP"
9883553|NCT00530179|Active Comparator|Arm B|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.~Assigned Interventions: Procedure/Surgery: Autologous Blood Stem Transplantation 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION"
9931157|NCT00935376|Experimental|Mindfulness Meditation Program|Mindfulness Meditation Program (MMP) is based on Mindfulness-Based Stress Reduction (MBSR), which teaches participants mindfulness skills such as meditation and yoga. Mindfulness may be defined as paying attention in a particular way, on purpose, in the present moment, and nonjudgmentally. The goal of MBSR is to provide participants with experiential tools and mindfulness practices to assist them to become more mindful of themselves, others and their external environment. The techniques are easy to learn and teach individuals to be aware of the present moment, with an open mind in which they can perceive their thoughts, physical sensations, and emotions nonjudgmentally.
9931158|NCT00935376|Active Comparator|Sleep Education Program|The Sleep Education Program (SEP) will serve as the control intervention in which participants will receive classes informing them how to change their habits to improve their sleep, and what to do if they have concerns about their sleep quality.
9931159|NCT00935389|Experimental|immunosuppressor|TW 30mg,q.d.*3 months and reduced into 20mg b.i.d
9931160|NCT00935402|Experimental|Short Sleep|Subjects are permitted to spend 4 hours in bed per night for 5 consecutive nights. Subjects are inpatients for a period of 6 days.
9931161|NCT00935402|Active Comparator|Regular Sleep|Subjects are permitted to spend 9 hours in bed per night for 5 nights. Subjects are inpatients for a period of 6 days.
9931162|NCT00935415|Active Comparator|Montelukast|capsules prepared in blindness
9931163|NCT00935415|Placebo Comparator|Placebo|matched placebo
9931164|NCT00935441|Experimental|Telemonitoring|Case management with home telemonitoring for blood sugar and blood pressure plus home HbA1c measurement
9931165|NCT00935441|Active Comparator|Usual case management|Case management
9931166|NCT00935467|Other|Saxagliptin|
9931167|NCT00935480|Experimental|HAART+Raltegravir 12 months (+/-) Maraviroc|
9931168|NCT00935480|No Intervention|HAART|
9931169|NCT00935506|Experimental|Clopidogrel + Aspirin|
9931170|NCT00935545|Experimental|Open Label|
9931171|NCT00935558|Experimental|Aromatase inhibitor and DC vaccination|the HLA-A2 positive patients will be treated with AI, DC vaccines, Zadaxin and IL-2
9931172|NCT00935558|Active Comparator|Aromatase inhibitor|the HLA-A2 negative patients will receive AI only
9931173|NCT00935571||Group I, Group II|"Group I: anesthetized with TIVA (Propofol + Remifentanil)~Group II: anesthetized with inhalation (sevoflurane)"
9931174|NCT00935597|Experimental|Group 1|Patients with Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion
9931175|NCT00935597|Experimental|Group 2|Patients with greater than Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion in conjunction with donor lymphocyte infusion (DLI)
9931176|NCT00935610|Active Comparator|Immunocal|20g of Immunocal
9931177|NCT00935610|Placebo Comparator|Casein|20g of Casein
9931178|NCT00935623|Experimental|Cohort 1|The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (>10 sporozoites in salivary gland).
9931179|NCT00935623|Experimental|Cohort 2|If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.
9931180|NCT00935662|Experimental|AZD8329|AZD8329 oral solution
9931181|NCT00935662|Placebo Comparator|Placebo|Placebo for AZD8329 oral solution
9931182|NCT00935675|Active Comparator|Antidepressant treatment|
9931183|NCT00935675|Placebo Comparator|Placebo|
9935462|NCT03693300|Experimental|WHO/ECOG PS 2 Cohort|up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
9935463|NCT03689543|Experimental|Arm 1|LY500307 at 25mg per day
9935464|NCT03689543|Active Comparator|Arm 2|LY500307 at 75mg per day
9935465|NCT03689543|Placebo Comparator|Arm 3|Matched placebo
9935466|NCT03685721||HbAS|HbAS genotype, of African American descent;Between 18 and 80 years of age
9935467|NCT03685721||Healthy control|African American descent;Between 18 and 80 years of age
9935468|NCT03685721||SCD|HbSS, HbSC, HbSbeta-thal has sickle cell disease and is of African American descent;Between 18 and 80 years of age
9935469|NCT03683940|Other|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
9935470|NCT03678636|Experimental|Intervention|The wound will be treated with a silver antimicrobial dressing appropriate for the exudate level as per manufacturer instructions for use for 2 weeks +/- 3 days, in addition to any necessary standard care (e.g. compression for a venous leg wound).
9883554|NCT00530244|Experimental|1|Infants will be fed formula supplemented with docosahexaenoic acid
9883555|NCT00530244|Placebo Comparator|2|Infants will be fed standard formula (Enfamil)
9883556|NCT00530283||A|Patients with Squamous cell cancer of neck nodes, unknown primary
9883557|NCT00530309|Experimental|Subjects receiving GSK716155 + placebo|Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
9883558|NCT00530322||A|"Patients who have had previous open colorectal surgery and are referred for a further operative procedure, at which time a second-look laparoscopy can be performed."
9883559|NCT00530322||B|"Patients who have had a previous laparoscopic colorectal procedure and are having a second-look procedure"
9883560|NCT00530374|Active Comparator|1|Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
9883561|NCT00530374|Placebo Comparator|2|Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days
9883562|NCT00530400|Experimental|1|intravenous 1.5g cefuroxime
9883563|NCT00530400|Placebo Comparator|2|intravenous placebo
9883564|NCT00530413|Experimental|1|Phenobarbital - dose based by weight range
9883565|NCT00530413|Placebo Comparator|2|Placebo group
9883566|NCT00530452|Experimental|A|2.0 mg (loading dose, Day 0) followed by 0.3 mg/day (Days 1-20)
9883567|NCT00530452|Experimental|B|4.0 mg (loading dose, Day 0) followed by 0.6 mg/day (Days 1-20)
9883568|NCT00530452|Experimental|C|8.0 mg (loading dose, Day 0) followed by 1.2 mg/day (Days 1-20)
9883569|NCT00530452|Placebo Comparator|D|Placebo (identical number of capsules to active drug groups) (Days 0-20)
9883570|NCT00530491|Active Comparator|1|conventional perioperative management for lung surgery
9883571|NCT00530491|Experimental|2|fast track management for lung surgery
9883572|NCT00530517|Experimental|1|
9883573|NCT00530530|Experimental|1|Dose 1
9883574|NCT00530530|Experimental|2|Dose 2
9883575|NCT00530530|Experimental|3|Dose 3
9883576|NCT00530530|Placebo Comparator|4|
9883577|NCT00530725|Active Comparator|chest drainage|This represents the best current standard of care although this is quite controversial
9883578|NCT00530725|Experimental|close observation|This is the novel approach that has some justification in the literature
9883579|NCT00530738|Experimental|1|treatment with Lipoplus & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
9883580|NCT00530738|Active Comparator|2|treatment with Lipofundin MCT & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
9883581|NCT00530829|Experimental|1|Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
9883582|NCT00530829|Active Comparator|2|Mothers recieve ORS satchets at home every two months for use when child in home under 5 years has diarrhea. Instructions on when and how to use ORS and when to take child in clinic are given by community health worker. Zinc will be given in clinic if child visits clinic with diarrhea.
9883583|NCT00530868|Experimental|Letrozole + Avastin|
9883584|NCT00530868|Experimental|Letrozole alone|
9883585|NCT00530881|Placebo Comparator|4|
9883586|NCT00530881|Placebo Comparator|3 active, 1 placebo|
9883587|NCT00530907|Experimental|Valproic Acid + Bevacizumab|"Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth.~Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks."
9883588|NCT00530933|Sham Comparator|1|Sham tibial nerve stimulation
9883589|NCT00530933|Experimental|2|Percutaneous tibial nerve stimulation
9883590|NCT00530933|Experimental|3|Transcutaneous tibial nerve stimulation
9883591|NCT00530972|Experimental|Peginterferon alfa-2a plus ribavirin|
9883592|NCT00530985|Experimental|1|Benefits Counseling
9883593|NCT00530985|Active Comparator|2|VA Orientation
9883594|NCT00530998||1|Group #1 NOTES Appendectomy - Transvaginal approach
9883595|NCT00530998||2|Group #2 NOTES Cholecystectomy - Transvaginal approach
9883596|NCT00531024|Experimental|1|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
9883597|NCT00531024|Placebo Comparator|2|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
9883598|NCT00531089|Experimental|Study group|"All patients in the study will be in the study group and will receive rituximab. There is no control arm."
9883599|NCT00531102|Experimental|1|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. All infants will have a pulse oximetry probe placed on the right hand (pre-ductal position) immediately after birth. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 1 - infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes."
9883600|NCT00531102|Active Comparator|2|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 2 - infants will receive 50% oxygen at a rate of 6 liters per minute continuously for at least 5 minutes using a modified neonatal T-piece resuscitator circuit that does not generate pressure. Fifty percent oxygen was chosen because it reflects the actual inspired oxygen concentration when 100% oxygen is blown towards the infant's face."
9883601|NCT00531115|Experimental|1|
9883602|NCT00531141||A|examination twice by examiner 1
9883603|NCT00531141||B|examination first by examiner 1 thereafter by examiner 2
9883604|NCT00531141||C|examination first by examiner 2 thereafter by examiner 1
9883605|NCT00531141||D|examination performed twice by examiner 2
9883606|NCT00531167|Experimental|A|combination therapy
9883607|NCT00531167|Active Comparator|B|entecavir
9883608|NCT00531180|Experimental|4-DCT Ventilation Validation|
9883609|NCT00531193|Other|1|Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
9883610|NCT00531219||1|Group #1 NOTES Appendectomy - Transgastric approach
9883611|NCT00531219||2|Group #2 NOTES Cholecystectomy - Transgastric approach
9883612|NCT00531258|Active Comparator|1|
9883613|NCT00531258|Placebo Comparator|2|
9883614|NCT00531297|Experimental|Treatment arm|endoscopic posterior mesorectal resection
9883615|NCT00531310|Experimental|Matched Family Donor|Matched Family Donor
9883616|NCT00531310|Experimental|Unrelated Donor|Unrelated Donor Transplant/ Cord Blood Transplant
9883617|NCT00531323|Other|1|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
9883618|NCT00531323|Other|2|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
9883619|NCT00531336|Experimental|1|Avastin first followed by retreatment of Macugen
9883620|NCT00531336|Active Comparator|2|Avastin intravitreally every 6 weeks
9883621|NCT00531336|Active Comparator|3|Macugen intravitreally every 6 weeks
9883622|NCT00531349|Active Comparator|A|General anesthesia and opioid analgesia for the treatment of pain after surgery.
9883623|NCT00531349|Active Comparator|B|Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.
9883624|NCT00531362||Patients|All patients (acute or stable) presenting to a cardiovascular clinic and on aspirin.
9883625|NCT00531466|Active Comparator|1|
9883626|NCT00531466|Placebo Comparator|2|
9883627|NCT00531492|Experimental|A|
9883628|NCT00531492|Active Comparator|B|
9883629|NCT00531505||2a|Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.
9883630|NCT00531557|Other|1|Darunavir 600mg BID with ritonavir 100mg BID administered orally.
9883631|NCT00531596|Active Comparator|A|EMSAM 6mg/24hr
9883632|NCT00531596|Active Comparator|B|EMSAM 9mg/24Hr
9883633|NCT00531596|Active Comparator|C|EMSAM 12mg/24Hr
9883634|NCT00531648||1|Families with toddlers that having feeding disorders and SPD
9883635|NCT00531674|Experimental|1|Nutritional supplementation for pregnant and lactating women
9883636|NCT00531674|Experimental|2|Nutritional supplementation for children
9517686|NCT03304080|Experimental|HR-positive, Her2-positive Metastatic Breast Cancer|Women and men with HR-positive, HER2-positive Metastatic Breast Cancer on trial of anastrozole, palbociclib, trastuzumab and pertuzumab
9883637|NCT00531687|Other|GCT|cisplatin Paclitaxel gemcitabine
9883638|NCT00531700|Experimental|I|Exposure to both tailored/targeted health messages about influenza and also to reports about contextualized influenza risk
9883639|NCT00531700|Experimental|II|Exposure to tailored/targeted health messages
9883640|NCT00531700|Experimental|III|Exposure to reports about influenza related contextualized risk
9883641|NCT00531700|Active Comparator|IV|Comparison group exposed to community level health promotion messages not generated by the study
9883642|NCT00531713|No Intervention|1|Usual T4 dose is given
9883643|NCT00531713|Active Comparator|2|20 microgram of T3 is given and 50 microgram of T4 is withdrawn
9883644|NCT00531726|Sham Comparator|B|
9883645|NCT00531726|Experimental|A|
9883646|NCT00531739|No Intervention|A|Colorectal Surgery without use of SurgiWrapTM
9883647|NCT00531739|Active Comparator|B|Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
9883648|NCT00531765|Active Comparator|1|hydration with normal saline
9883649|NCT00531765|Experimental|2|hydration with sodium bicarbonate
9883650|NCT00531778||NYU OCEDP Population|
9883651|NCT00531791|Active Comparator|1|
9883652|NCT00531791|Experimental|2|
9883653|NCT00531804|Experimental|1|
9883654|NCT00531830||1|Preschool children with PDD
9883655|NCT00531830||2|Preschool children without PDD
9883656|NCT00531856|Experimental|1|5.97 mg/L of carbon monoxide in 30% oxygen
9883657|NCT00531856|Placebo Comparator|2|Oxygen 30% in Nitrogen
9883658|NCT00531908|Experimental|A|To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
9883659|NCT00531921||Kidney transplants|patients from 5 specific sites
9883660|NCT00531921||Liver transplants|patients from 5 specific sites
9883661|NCT00531921||Heart transplants|patients from 5 specific sites
9883662|NCT00531921||Lung transplants|patients from 5 specific sites
9883663|NCT00531973|Experimental|A|Liposomal doxorubicin
9883664|NCT00531973|Active Comparator|B|epirubicin
9883665|NCT00531986|Experimental|Monotherapy|Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
9517687|NCT03304067|Experimental|Intervention|
9883666|NCT00531986|Active Comparator|Continued ART|Continuation Therapy, conventional triple HAART
9883667|NCT00531999|Active Comparator|1|Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
9883668|NCT00531999|Active Comparator|2|"Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.~Raltegravir 400 mg twice daily for the last 14 days of the study."
9883669|NCT05319912|Experimental|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883670|NCT05319912|Experimental|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883671|NCT05319912|Experimental|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883672|NCT05319912|Experimental|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883673|NCT05319912|Experimental|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9931184|NCT00935688|Experimental|Rapid diagnostic tests|malaria diagnosis by rapid diagnostic test
9931185|NCT00935688|No Intervention|Clinic Microscopy|malaria diagnosed with field light-microscopy
9931186|NCT00935688|No Intervention|Clinical Diagnosis|Malaria diagnosed on the basis of clinical symptoms alone (i.e. not laboratory diagnosis)
9931187|NCT00935714|Active Comparator|Muscle Group|Exercise
9517688|NCT03304067|No Intervention|Control|
9931188|NCT00935714|Active Comparator|Sequence|Exercise
9931189|NCT00935727|Other|1|normally functioning transplanted kidneys
9931190|NCT00935727|Other|2|transplanted kidney undergoing known rejection or other known abnormality
9931191|NCT00935727|Other|3|transplanted kidney with unknown diagnosis
9931192|NCT00935740||Age-Matched Healthy Controls|Age-Matched Healthy Controls
9931193|NCT00935740||Heart Failure|Subjects with LVEF < 40%
9931194|NCT00935753|Experimental|Kuvan|10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
9931195|NCT00935779||Gastric cancer|patients with operable local gastric adenocarcinoma were studied
9931196|NCT00935779||Control group|patients operated on for benign diseases served as controls, randomly selected among patients with chronic gastro-esophageal reflux disease who were considered good candidates for antireflux surgery and properly matched in sex and age to study group
9931197|NCT00935805||Treatment|124 patients attending the primary care unit included after formal consent.
9931198|NCT00935831|Experimental|Subjects with renal impairment, non-dialysis|Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
9931199|NCT00935831|Experimental|Healthy volunteers|Healthy subjects will be matched to the moderate and severe renally impaired subjects for gender, age, and BMI. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
9931200|NCT00935831|Experimental|Hemodialysis dependent subjects|The arm will consist of subjects with severe renal impairment (end-stage renal failure) who have been on stable hemodialysis treatment scheduled three times per week. Subjects will receive single oral doses of 150 mg GSK1278863A in each of 2 dosing periods in an open-label, fixed sequence. GSK1278863A will be administered just prior to receiving scheduled hemodialysis in Dosing Period 1. In Dosing Period 2, subjects will receive a single oral dose of GSK1278863 the morning after completion of a scheduled hemodialysis session.
9931201|NCT00935844|Experimental|TAK-901 Arm|
9931202|NCT00935870||A|DEPRESSED LATERAL CONDYLE FRACTURE
9931203|NCT00935870||B|BENIGN BONE TUMOR
9931204|NCT00935870||C|SPINAL FUSION
9931205|NCT00935896|No Intervention|high VT group|
9931206|NCT00935896|Experimental|Low tidal volume|
9931207|NCT00935922|Placebo Comparator|Soybean oil bar|A nutrition bar enriched with soybean oil
9931208|NCT00935922|Experimental|Flaxseed bar with low lignans|A nutrition bar enriched with flaxseed oil
9931209|NCT00935922|Experimental|Flaxseed bars with high lignans|A nutrition bar enriched with flaxseed oil and high lignans
9931210|NCT00935935||HIV older than 50 years|
9931211|NCT00935948|Active Comparator|Imescard ointment|
9931212|NCT00935948|Placebo Comparator|Placebo|
9931213|NCT00935961|Experimental|RAD001 + docetaxel + cisplatin|In this phase I trial, the primary endpoint will be considered to be reached when we have described a phase II recommended dose of RAD001 given with docetaxel + cisplatin as induction chemotherapy for head and neck cancer. Up to 3 dose levels of daily RAD001 will be studied. A standard 3 + 3 phase I dose escalation design will be used. The phase II recommended dose will be determined according to the dose escalation plan.
9931214|NCT00936000|Active Comparator|protandim therapy for 7 days|
9931215|NCT00936000|Placebo Comparator|placebo arm|Individuals will receive a placebo equivalent in two equally divided doses for seven days
9931216|NCT00936013|Experimental|oseltamivir|single antiviral treatment
9931217|NCT00936013|Experimental|oseltimivir and chinese medicinal herbs|combination treatment
9931218|NCT00936039|Experimental|unloading|2 weeks of unloading
9931219|NCT00936091|Placebo Comparator|placebo|125 schoolchildren were allocated randomly to receive placebo
9931220|NCT00936091|Active Comparator|vitamin A supplement|125 children received vitamin A supplements capsules (200 000 IU)
9931221|NCT00936104||SP in PDAC|Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
9931222|NCT00936130||Lifestyle counseling|This group will be comprised of participants on a low calorie diet program.
9931223|NCT00936130||Weight Loss Surgery|This group will be comprised of participants having weight loss surgery: Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy.
9931224|NCT00936143|Experimental|infliximab|200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
9935471|NCT03678636|Active Comparator|Control|The wound will be treated as per usual care.
9935472|NCT03665675|Experimental|Treatment (CMV-specific CTLs)|Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with partial response, may receive up to 2 additional doses at monthly intervals.
9989175|NCT01430234|Other|Panzytrat fixed dose vs. self-dosing|In Phase I (week 1-4) patients will use the fixed amount of lipase as was prescribed by their treating physician. Phase II (week 5-9) patients will start the self-dosage regimen with pancreatic enzymes (without exceeding the maximum amount of 16 capsules per day). They are properly educated by the researcher and dietician how to adjust the amount of pancreatic enzymes to the fat intake in their diet.
9989176|NCT01430247|Other|Amblyopia screening|
9989177|NCT01430260|Experimental|ciclesonide nasal spray|ciclesonide nasal spray, alone
9989178|NCT01430260|Active Comparator|Levocetirizine|Levocetirizine, alone
9989179|NCT01430260|Active Comparator|Ciclesonide nasal spray & Levocetirizine|Ciclesonide nasal spray & Levocetirizine in combination
9989180|NCT01430273||Planned hip or knee arthroplasty|Patients with planned hip or knee arthroplasty
9989181|NCT01430273||urgent hip or knee arthroplasty|Patients with hip or knee arthroplasty in emergency.
9989182|NCT01430286|Experimental|Psycho-educational program|This group is trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
9989183|NCT01430286|Active Comparator|Standard treatment|This group will receive treatment as usual : consultation in memory clinic every 6 months during the AD patient's consultation.
9989184|NCT01430312|Experimental|Verum|Topical application of verum (azelaic acid pre-foam formulation) on the skin
9989185|NCT01430312|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
9989186|NCT01430312|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
9989187|NCT01430312|Active Comparator|Positive control|Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin
9989188|NCT01430338||BAT|brown adipose tissue detected, undetected
9989189|NCT01430351|Experimental|Arm 1 (temozolomide)|Patients receive temozolomide PO QD on days 1-5.
9989190|NCT01430351|Experimental|Arm 2 (temozolomide, memantine hydrochloride)|Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO BID.
9989191|NCT01430351|Experimental|Arm 3 (temozolomide, mefloquine)|Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of week 1 and then days 2, 4, and 6 every other week.
9989192|NCT01430351|Experimental|Arm 4 (temozolomide, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.
9989193|NCT01430351|Experimental|Arm 5 (temozolomide, memantine hydrochloride, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and mefloquine PO QD as in Arm 3.
9989194|NCT01430351|Experimental|Arm 6 (temozolomide, memantine hydrochloride, metformin)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and metformin hydrochloride PO BID as in Arm 4.
9989195|NCT01430351|Experimental|Arm 7 (temozolomide, mefloquine, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and metformin hydrochloride PO BID as in Arm 4.
9989196|NCT01430351|Experimental|Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.
9989197|NCT01430364|Active Comparator|BIOSS implantation|
9989198|NCT01430377|Experimental|SB predilatation|
9989199|NCT01430416|Experimental|AEB071|
9997299|NCT01507610|Active Comparator|IMITREX Nasal Spray|IMITREX® (sumatriptan) Nasal Spray, single dose of 20 mg intranasally (20 mg to one nostril).
9997300|NCT01507610|Active Comparator|IMITREX Oral Tablet|IMITREX® (sumatriptan) Oral Tablet, single dose of 100 mg, administered orally with 240 mL water.
9517689|NCT03304041|Experimental|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
9997301|NCT01507610|Active Comparator|IMITREX Subcutaneous Injection|IMITREX® (sumatriptan) Subcutaneous Injection, single dose of 6 mg injected subcutaneously in the abdomen.
9997302|NCT01507623|Experimental|With Capnograpy|Intervention group with the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
9997303|NCT01507623|No Intervention|No Capnography|Control group without the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
9998197|NCT01515982|Experimental|Aerobic exercise|The training exercise intensity is established at 60% of VO2máx. Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
9998198|NCT01515982|No Intervention|Control group|All participants were asked not to commence any new exercise regimen.
9998199|NCT01516021|Experimental|high fat yoghurt intake|500 ml of a high fat yoghurt
9998200|NCT01516021|Experimental|low fat yoghurt intake|
9998201|NCT01516047|Experimental|Cohort 1|Patients with severe hepatic impairment.
9998202|NCT01516047|Experimental|Cohort 2|Healthy individuals with normal hepatic function.
9998203|NCT01516060|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
9883674|NCT05319912|Experimental|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883675|NCT05319899|Experimental|Sequence 1: ABC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883676|NCT05319899|Experimental|Sequence 2: ACB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment A): ALXN1840 following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883677|NCT05319899|Experimental|Sequence 3: BAC|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883678|NCT05319899|Experimental|Sequence 4: BCA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883679|NCT05319899|Experimental|Sequence 5: CAB|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment A): ALXN1840 following an overnight fast. Period 3 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9935473|NCT03664232|Experimental|JNJ-42165279|Participants will self-administer 25 milligram (mg) JNJ-42165279 tablets orally twice daily for 12 weeks.
9935474|NCT03664232|Placebo Comparator|Placebo|Participants will self-administer matching placebo tablets orally twice daily for 12 weeks.
9935475|NCT03663933|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm
9935476|NCT03663933|Experimental|2/IOC Arm|Immunosuppression Only Conditioning Arm
9989200|NCT01430429|Experimental|NI-0801|
9517690|NCT03304041|Placebo Comparator|Traditional dietary advice|"Traditional dietary advice (TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~Traditional dietary advice for 3 weeks"
9883680|NCT05319899|Experimental|Sequence 6: CBA|"Participants received each treatment on 1 occasion:~Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, approximately 30 minutes after the start of a high-fat breakfast. Period 2 (Treatment B): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 at Hour 0 on Day 1, following an overnight fast. Period 3 (Treatment A): ALXN1840 following an overnight fast.~There was a washout period of at least 14 days between each ALXN1840 dosing."
9883681|NCT05319886||Anlotinib and Penpulimab|
9883682|NCT05319873|Experimental|Phase Ib (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib PO BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9883683|NCT05319873|Experimental|Phase II, Arm C (ribociclib, tucatinib, trastuzumab)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, and trastuzumab IV over 30-90 minutes every 7 days. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9883684|NCT05319873|Experimental|Phase II,Arm A(ribociclib,tucatinib, trastuzumab, fulvestrant)|Patients receive ribociclib PO QD on days 1-21, tucatinib BID on days 1-28, trastuzumab IV over 30-90 minutes every 7 days and fulvestrant subcutaneously (SC) on days 1 and 15 of cycle 1 and day 1 of every subsequent cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9883685|NCT05319873|Active Comparator|Phase II,Arm B(docetaxel,carboplatin,trastuzumab,pertuzumab)|Patients receive docetaxel IV over 1 hour on day 1, carboplatin IV on day 1, trastuzumab IV over 30-90 minutes on day 1, and pertuzumab IV over 1 hour on day 1. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9883686|NCT05319847|Experimental|Intervention arm|Fountain of Youth skincare supplement
9883687|NCT05319834|Active Comparator|Progesterone with asprin|The included women will be randomly allocated to prophylactically receive either vaginal progesterone at a dose of 200 mg (prontogest 200mg every 12 hr) combined with oral aspirin at a dose of 100mg once daily both at the same time (group1),
9883688|NCT05319834|Placebo Comparator|Progesterone and placebo|vaginal progesterone (prontogest 200mg every 12 hr) and oral placebo (manufactured in a standard way to have the same size and shape of asprin tablet) also at the same time (group 2).
9931225|NCT00936156|Experimental|Chemotherapy|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
9931226|NCT00936169|Experimental|IVUS optimised stent implantation|
9931227|NCT00936169|Active Comparator|angiographically guided DES implantation|
9931228|NCT00936182|Experimental|Fluconazole|
9931229|NCT00936182|Placebo Comparator|Placebo|Placebo capsule daily for 30 days
9931230|NCT00936195|Active Comparator|Atripla (R)|
9931231|NCT00936195|Active Comparator|Combivir (R) + Kaletra (R) or Aluvia (R)|
9931232|NCT00936234|Active Comparator|Vildagliptin|starting with vildagliptin for 30 days followed by placebo for 30 days
9931233|NCT00936234|Placebo Comparator|Placebo|starting with placebo for 30 days followed by vildagliptin for 30 days
9931234|NCT00936247|Experimental|1|HES 130/0.42 + Sterofundin ISO
9931235|NCT00936247|Active Comparator|2|Albumin + NaCl 0.9%
9931236|NCT00936260|Experimental|alendronate 6 years|
9931237|NCT00936260|Experimental|alendronate 5 years|No treatment during year 6th
9931238|NCT00936260|Experimental|alendronate 5 years, not continued|No treatment during year 5th
9931239|NCT00936260|Experimental|alendronate 4 years|No treatment during year 5th and 6th
9931240|NCT00936260|Experimental|alendronate 5 years, uncontinued|No treatment during year 4th
9931241|NCT00936260|Experimental|alendronate 4 years, not continued|No treatment during year 4th and 6th
9931242|NCT00936260|Experimental|alendronate 4 years, uncontinued|No treatment during year 4th and 5th
9931243|NCT00936260|Experimental|Alendronato 3 years|No treatment during the last 3 years
9931244|NCT00936273||Suspected sleep apnea syndrome|Outpatients with suspected sleep apnea syndrome, age > 18 year
9931245|NCT00936286|Experimental|Respiratory Muscle Training|
9931246|NCT00936312||Females with Hemophilia|Females with severe or moderate Hemophilia A or B
9883689|NCT05319821|Active Comparator|Active Intervention|PCP participants in the practice cohort or the intervention group will receive the ECHO46 intervention via real-time, interactive videoconferencing through Zoom sessions held once weekly for 4 weeks (4 sessions total) at regularly scheduled times convenient to providers. Session topics will focus on training PCP participants to assess, advise, and refer patients to be more physically active, as well as provide evidence-based strategies they can use to supplement and sustain their communication efforts.
9883690|NCT05319821|Active Comparator|Delayed Intervention|PCP participants will be offered the intervention in year 5.
9883691|NCT05319808|Experimental|Group A, Telehealth using NeckCare equipment|Group A will receive a novel, remote computer based cervical joint positioning exercise and cervical kinasethetic exercise (CKE) program. In visit two, the PTs will teach the subjects the exercise regime and provide them the equipment they need to do the exercises at home in. Afterwards they will only do these exercises remotely. This group will continue and be followed up on CKE up to 6 months post baseline measurements, regardless of whether they are still being treated in-clinic or have been discharged. A technical consultant will be available to aid the participants should any technical difficulties arise over the course of the remote treatment process. In addition, the technical consultant will monitor the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so they can encourage the subjects with a friendly reminder.
9883692|NCT05319808|Active Comparator|Group B, Exercises without telehealth intervention|Group B will receive a non-computer based exercise regime at the need of each individual (pragmatic approach). This group will not be followed up on their exercises post intervention but will be encouraged to continue doing their exercises. They will be asked during follow-up measurements if they have been doing their exercises.
9883693|NCT05319808|No Intervention|Group C, no intervention provided by the researchers|"The treatment as usual group (group C) will/will not receive treatment at his/her own choice and/or convenience and without any instructions from research staff to reflect general practice. In addition to follow-up assessments, data will be collected which asks about treatment modalities used."
9883694|NCT05319795|Experimental|Effortful Swallow Maneuver|Adults with a confirmed diagnosis of Parkinson Disease who have radiographically confirmed difficulties with timely airway protection and/or bolus clearance during swallowing. Individuals will complete a 4-week intervention program with two 30-minute sessions of Effortful Swallow (ES) practice daily, 5 days per week.
9883695|NCT05319782|Experimental|Experimental arm|
9883696|NCT05319769||Zero fluoroscopy|"Zero fluoroscopy Patients undergoing AF ablation using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography.~Reconstruction of a bipolar map of the right atrium with a mapping catheter. Then, the interatrial septum is reconstructed and the oval fossa is defined. Transseptal puncture is performed using the steerable introducer (which can be viewed on the EAM) through which, a transseptal needle is introduced. The introducer is positioned at the fossa ovalis. The transseptal needle is advanced to perform the puncture of the septum. After accessing the left atrium, the mapping catheter is introduced iusing the introducer, with which all the structures of the left atrium are mapped. In addition, with intracardiac echocardiography, it is possible to identify important structures such as the pulmonary veins and the esophagus. The pulmonary veins are isolated by means of a catheter."
9883697|NCT05319769||Traditional approach|"Traditional approach Patients who have undergone atrial fibrillation ablation procedure using the traditional approach.~The procedure is based on 3D reconstruction using intracardiac ultrasound first and then electroanatomical mapping of the left atrium through a transseptal approach guided by integration of fluoroscopy and intracardiac ultrasound. The transseptal puncture is performed using a transseptal needle which is brought into place using a long introducer with a dilator. The fluoroscopic support is essential as the introducer is not viewable with 3D mapping systems. After accessing the left atrium, through the previously used introducer, a mapping catheter is taken to the left atrium for electro-anatomical reconstruction. Subsequently, the antral pulmonary veins are isolated by means of an ablator catheter with irrigated tip."
9883698|NCT05319756|Experimental|gabapentin 600 mg single dose|
9883699|NCT05319756|Experimental|gabapentin 1200 mg single dose|
9883700|NCT05319756|Experimental|gabapentin 600 mg and oxycodone HCl 20 mg|
9883701|NCT05319756|Experimental|gabapentin 1200 mg and oxycodone HCl 20 mg|
9883702|NCT05319756|Active Comparator|oxycodone HCl 20 mg single dose|
9883703|NCT05319756|Placebo Comparator|placebo single dose|
9883704|NCT05319743||Medicaid expansion states|Eight Medicaid expansion states: (experimental group): Arizona, California, Illinois, Massachusetts, New Jersey, Ohio, Washington
9883705|NCT05319743||Non-Medicaid expansion states|Five states that did not expand Medicaid (control group): Florida, Georgia, North Carolina, Texas, Virginia
9883706|NCT05319730|Experimental|Paclitaxel or irinotecan|Participants receive paclitaxel 80-100 mg/m^2 intravenously (IV) on days 1, 8, and 15 every 28-day cycle until progressive disease (PD) or discontinuation, or irinotecan 180 mg/m^2 IV on day 1 of every 14-day cycle until PD or discontinuation.
9883707|NCT05319730|Experimental|Pembrolizumab + MK-4830 + paclitaxel or irinotecan|Participants receive pembrolizumab 200 mg IV once every 3 weeks (Q3W) for up to 35 cycles (cycle=21 days) or until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + paclitaxel 80-100 mg/m^2 IV on days 1, 8, and 15 every 28-day cycle until PD or discontinuation or irinotecan 180 mg/m^2 180 mg/m^2 on day 1 every 14-day cycle until PD or discontinuation.
9883708|NCT05319730|Experimental|Pembrolizumab + MK-4830 + lenvatinib|Participants receive pembrolizumab 200 mg IV Q3W up to 35 cycles (cycle=21 days) until PD or discontinuation + MK-4830 800 mg IV Q3W up to 35 infusions + lenvatinib 20 mg oral administration every day until PD or discontinuation.
9883709|NCT05319717|Active Comparator|Ready-to-use therapeutic food, no rice bran (control/comparator)|Randomized participants will receive a locally produced ready-to-use therapeutic food to be consumed daily.
9883710|NCT05319717|Experimental|Ready-to-use therapeutic food, with heat stabilized rice bran (Experimental)|Randomized participants will receive a locally produced ready-to-use therapeutic food with 5% heat stabilized rice bran to be consumed daily.
9883711|NCT05319704|Active Comparator|Test of effort, sub-maximal, progressive, carried out in eccentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
9883712|NCT05319704|Placebo Comparator|Test of effort, sub-maximal, progressive, carried out in concentric mode|The exercise will start at 10% of VO2max. However, every six minutes, the level of VO2max will be increased by 10%, up to 50%.
9883713|NCT05319704|Active Comparator|Kinetic in eccentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
9883714|NCT05319704|Placebo Comparator|Kinetic in concentric mode|"The subjects will have to carry out a test of effort in eccentric or concentric mode during 30 minutes performed at 30% of VO2max.~The exercise will be followed by indirect oxygen calorimetry (with canopy) extended over a period of 6 hours to measure the energy expenditure, the nature of the oxidized substrates (carbohydrates and lipids) and oxidation rates. During each kinetic, 6 other blood samples will be collected at several times. On these samples, insulin and blood sugar will be measured."
9883715|NCT05319691|Active Comparator|Yoga Now (Treatment Group)|An initial 12-week Treatment Phase of weekly virtual yoga classes (Yoga Now) followed by a 12-week Follow-up Phase.
9883716|NCT05319691|No Intervention|Yoga Later (Wait List Control Group)|A wait-list control group (Yoga Later) will receive usual care. After the 24 week study period, participants in Yoga Later will be offered the yoga intervention in a non-study format.
9883717|NCT05319678||Cochlear implant users|Pre-or perilingual patients aged 6 to 17 years old, and postlingual adults who underwent cochlear implantation from 2000 to January 2023 at La Paz University Hospital
9883718|NCT05319678||Normal hearing subjects|Control group is set up with the normal hearing peers of cochlear implant users
9883719|NCT05319665|No Intervention|Control|The control group will have the standard-of-care treatment.
9883720|NCT05319665|Experimental|Interventional|The interventional group will have a head-mounted display whilst still in the operating theatre airing a live video of their newborn filmed by a 2D 360° camera to enable a visual and auditory contact.
9883721|NCT05319652|Experimental|Pain self-management program|Participants log in to the online program and develop practical strategies to manage CNCP.
9931247|NCT00936312||Control group|Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B.
9931248|NCT00936338|Active Comparator|splint|
9931249|NCT00936338|Active Comparator|joint mobilization self exercise|
9931250|NCT00936364|Experimental|Group I (Stage I of study)|Patients fast for 24 hours on day -1
9931251|NCT00936364|Experimental|Group II (Stage I of study)|Patients fast for 48 hours on days -2 and -1
9931252|NCT00936364|Experimental|Group III (Stage I of study)|Patients fast for 72 hours on days -3, -2, and -1
9931253|NCT00936364|Experimental|Group IV (Stage I of study)|Patients undergo a modified 48-hour fast with minimal caloric intake on day -2 and -1
9989201|NCT01430481|Active Comparator|Standard Rosehip Powder (A)|6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
9989202|NCT01430481|Experimental|New rosehip formulation (B)|6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
9989203|NCT01430481|Experimental|New rosehip formulation in half dose (C)|3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
9989204|NCT01430494||No treatment|
9989205|NCT01430507|Experimental|Medium Dose|Medium Dose Revamilast
9989206|NCT01430507|Experimental|High Dose|High Dose Revamilast
9989207|NCT01430507|Placebo Comparator|Placebo|Matching Placebo in Triple Dummy Format
9989208|NCT01430507|Experimental|Low dose|Low dose Revamilast
9989209|NCT01430520|Active Comparator|Escitalopram|
9989210|NCT01430520|Placebo Comparator|Placebo|
9989211|NCT01430533|Experimental|Verum|Topical application of verum (azelaic acid pre foam formulation) on the skin
9989212|NCT01430533|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
9517691|NCT03304028|Other|Refusal Group|"Refusal Questionnaires Intervention:~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal."
9989213|NCT01430533|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
9989214|NCT01430572|Experimental|Pazopanib + Everolimus|Pazopanib 200 mg and Everolimus 5.0 mg oral dosing every other day (except for lead in 5 days of Cycle 1 where both drugs administered daily).
9989215|NCT01430598|Active Comparator|A|Subacromial decompression before repair of a complete rotator cuff tear.
9989216|NCT01430598|Active Comparator|B|Subacromial decompression after repair of a complete rotator cuff repair.
9989217|NCT01430650|Experimental|Oral strogen|
9989218|NCT01430650|Experimental|Transdermal strogen|
9989219|NCT01430663||Hematological patients with proven or probable aspergillosis|
9989220|NCT01430663||Hematological patients with possible aspergillosis|
9989221|NCT01430676||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
9989222|NCT01430689|Experimental|Inactivated Influenza Vaccine Trivalent Types A and B|Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
9989223|NCT01430689|Active Comparator|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate|Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
9989224|NCT01430702|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
9989225|NCT01430715|Experimental|Outside play|
9989226|NCT01430715|Experimental|Active video game|
9989227|NCT01430728||Very low birthweight infants|
9989228|NCT01430767||Depression|Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
9989229|NCT01430767||ADHD|Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
9989230|NCT01430780||control group|placebo
9989231|NCT01430780||nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
9989232|NCT01430793|Active Comparator|Vitamin D 600,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
9989233|NCT01430793|Active Comparator|Vitamin D 600,000 orally|Vitamin D3 600,000 units will be given orally
9989234|NCT01430793|Active Comparator|Vitamin D 200,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
9989235|NCT01430793|Active Comparator|Vitamin D 200,000 orally|Vitamin D 200,000 units will be given orally
9989236|NCT01430806|Other|Dronedrone Arm|
9989237|NCT01430832||Normal Development|The infant's development level will be assessed using a phone interview with parents
9989238|NCT01430832||Abnormal Development|The infant's level of development will be assessed using a phone interview with parents
9989239|NCT01430858|Other|Strain Gauge|We wish to determine the relationship between tibial bone strain (recorded from implanted tibial strain gauges) and measured displacements of the limb and pelvis (using video motion analysis) during vibration exercise and a range of habitual locomotor activities. Only healthy volunteers will be recruited to this one arm.
9989240|NCT01430871||Carcinoid syndrome|Patients: Men and women age 18 years or older with carcinoid syndrome attending the Sheffield neuro-endocrine tumour clinic
9989241|NCT01430871||Healthy Volunteers|Control group: Healthy men and women individually matched to the patients by gender, age, height and BMI
9989242|NCT01430884||Aspirate Blood|
9989243|NCT01430910|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
9989244|NCT01430910|Active Comparator|2|500mg Avibactam
9989245|NCT01430910|Active Comparator|3|2000mg Ceftazidime
9989246|NCT01430923|Experimental|Refrigeration free Latanoprost|Latanoprost refrigeration free formulation as per randomization schedule.
9989247|NCT01430923|Active Comparator|latanoprost 2-8˚ C|latanoprost stored at 2-8˚ C
9989248|NCT01430949|Experimental|Over-the-Wire Mesh Ablation System|
9989249|NCT01430962||General Anesthesia|Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway.
9989250|NCT01430962||Moderate Sedation|Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol.
9989251|NCT01430988||Head Injured Group|Subjects who are suspected of a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury, as a result of insult to the head from an external force, e.g., the head being struck by an object, the head striking an object, the head being exposed to forces generated from a blast or explosion, and/or the brain undergoing an acceleration/deceleration movement without direct external trauma to the head will be recruited from patients who enter the Emergency Department at hospitals that are participating as clinical sites for this study
9989252|NCT01430988||Normal Control Group|A normal control group will be recruited for comparison and will consist of Emergency Department patients who have sustained an injury but do not exhibit any trauma above the clavicle and no history of Road Traffic Accident requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope.
9989253|NCT01430988||Head Injured Control Group|A 'head injured' control group will be recruited and will consist of Emergency Department patients who are suspected or who have sustained a head injury but do not report or manifest symptoms, e.g. facial lacerations and/or whiplash.
9989254|NCT01431001|Experimental|Coil Configuration A|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
9989255|NCT01431001|Experimental|Coil Configuration B|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
9989256|NCT01431027||Diastolic Function|Patients scheduled for cardiac catheterization.
9989257|NCT01431040|Active Comparator|Group A|Group A will have no bowel preparation and be permitted a regular diet the day prior to surgery until midnight.
9989258|NCT01431040|Active Comparator|Group B|Participants in this group will consume a clear liquid diet and perform 2 Fleets enemas in the late afternoon the day before surgery and nothing after midnight.
9989259|NCT01431053|Experimental|Exemestane + Aspirin|
9989260|NCT01431053|Active Comparator|Exemestane|
9989261|NCT01431066|Placebo Comparator|Control|Sham device that resembles the Actipatch PRFE device, including the light that illuminates when active, but the transmitting function has been disabled.
9989262|NCT01431066|Experimental|Actipatch|Use of the Actipatch PRFE device that is integrated into a viscoelastic heel pad for the treatment of plantar fasciopathy
9989263|NCT01431092|Experimental|Melatonin|
9989264|NCT01431092|Placebo Comparator|Placebo|
9989265|NCT01431118|Active Comparator|sports intervention male|male athletes of the german national dragon boat team
9989266|NCT01431118|Active Comparator|sports intervention women|women athletes of the german national dragon boat team
9989267|NCT01431183|Active Comparator|mailed reminder notice|Seasonal influenza vaccination reminder sent by postal mail
9989268|NCT01431183|No Intervention|No reminder notice|No seasonal influenza vaccination reminder sent by postal mail
9989269|NCT01431196|Experimental|DENDRITIC CELL VACCINATION|Px will receive standard neoadjuvant chemotherapy plus active vaccination. we will compare results with an historic cohort of patients treated with the same chemotherapy without the vaccines
9989270|NCT01431222|Active Comparator|percutaneous treatment|
9989271|NCT01431222|No Intervention|optimal medical treatment|
9989272|NCT01431235|No Intervention|standard addiction treatment|10 sessions of standard addiction treatment. No ADHD treatment.
9989273|NCT01431235|Experimental|addiction treatment and ADHD treatment|10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
9989274|NCT01431248||Azithromycin|Azithromycin 1gm PO once
9517692|NCT03304028|Other|Interventionnal Group|Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews
9517693|NCT03304015|Experimental|Intervention: Behavioral Change Communications|
9883722|NCT05319639|Experimental|POFI|"This study will include a sequential evaluation of 3 subjects per cohort. Irinotecan 135 → 150 → 165 mg/m2 and paclitaxel 45 → 67.5 mg/m2 on day 1.~The rest of regimen is that oxaliplatin (85 mg/m2) and Lev-leucovolin (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days); Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
9883723|NCT05319626|Experimental|Intervention group 1|Compression socks with Textured insoles
9883724|NCT05319626|Experimental|Intervention group 2|Compression socks with Smooth insoles
9883725|NCT05319626|Experimental|Intervention group 3|Smooth socks with Textured insoles
9883726|NCT05319626|Placebo Comparator|Control group|Smooth socks with Smooth insoles
9883727|NCT05319613|Other|Telemedicine Clinical Care|Rural participants who enter PrEP clinical care with University of Colorado HIV Prevention Program will receive care via telemedicine with mailed lab kits and mailed HIV PrEP.
9883728|NCT05319600|Experimental|Intervention|This arm will complete an intervention delivered remotely via an online website and online communication from the research team across the 12-week intervention period. This intervention has two parts, taking place simultaneously over the 12 weeks. First, participants will complete 8 web-delivered online behavior-change skills learning sessions which include reading and activities. Second, participants will be given daily and weekly personalized physical activity goals to meet, which will be tracked via their Garmin activity tracker and weekday text and if indicated video support. They have the opportunity to win money each week for meeting activity goals.
9883729|NCT05319600|No Intervention|Treatment as usual - Control|This arm will not complete an intervention. Participants will be instructed to wear a Garmin activity tracker but will be given no other specific instructions, other than to continue to follow their normal daily diabetes care plan.
9883730|NCT05319587|Experimental|Liposomal annamycin|
9883731|NCT05319574|Experimental|Neoadjuvant SBRT plus immunochemotherapy|Stereotactic body radiation therapy (8Gy*3d) followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 2 cycles before surgical resection
9883732|NCT05319548|Active Comparator|Starting with Purple-Red Carrot Juice|Participants are randomized to consume purple-red carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple carrot juice.
9883733|NCT05319548|Active Comparator|Starting with Purple Carrot Juice|Participants are randomized to consume purple carrot juice first (250 mL) in under 2 minutes. They will crossover to red carrot juice and to purple-red carrot juice.
9883734|NCT05319548|Active Comparator|Starting with Red Carrot Juice|Participants are randomized to consume red carrot juice first (250 mL) in under 2 minutes. They will crossover to purple-red carrot juice and to purple carrot juice.
9883735|NCT05319522|Active Comparator|Individuals with SCI|Male and female, Veteran and non-Veteran participants with traumatic SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
9883736|NCT05319522|Active Comparator|Controls (No SCI)|Male and female Veterans, age and sex-matched to participants with SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.
9883737|NCT05319470||Study Group|100 patients with diagnosed glaucoma receiving travoprost without preservatives
9883738|NCT05319457|Placebo Comparator|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
9883739|NCT05319457|Experimental|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA.
9883740|NCT05319444|Experimental|Healthy Scalp and one treatment|Participants with healthy scalps who will receive one treatment with the device and complete one in-person follow-up.
9883741|NCT05319444|Experimental|Healthy Scalp and three treatments|Participants with healthy scalps who will receive three treatments with the device and complete one in-person follow-up.
9883742|NCT05319444|Experimental|Dandruff and one treatment|Participants with dandruff who will receive one treatment with the device and complete one in-person follow-up.
9883743|NCT05319444|Experimental|Dandruff and three treatments|Participants with dandruff who will receive three treatments with the device and complete one in-person follow-up.
9883744|NCT05319444|Experimental|Hair loss disease and one treatment|Participants with hair loss disease who will receive one treatment with the device and complete one in-person follow-up.
9883745|NCT05319444|Experimental|Seborrheic Dermatitis with one treatment|Participants with seborrheic dermatitis disease who will receive one treatment with the device and complete one in-person follow-up.
9883746|NCT05319444|Experimental|Seborrheic Dermatitis and three treatments|Participants with seborrheic dermatitis who will receive three treatments with the device and complete one in-person follow-up.
9517694|NCT03304015|No Intervention|Control: No intervention|
9883747|NCT05319444|Experimental|Hair loss disease and three treatments|Participants with hair loss disease who will receive three treatments with the device and complete one in-person follow-up.
9883748|NCT05319431|Experimental|AK104+Lenvatinib+TACE|Participants will receive AK104 IV every 3 weeks (Q3W) and Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD The first Transarterial chemoembolization will be performed at the beginning of study.
9883749|NCT05319418|Experimental|Hypertensive Patients Monitored Daily|Physicians utilize DailyDoctor remote monitoring platform to virtually monitor daily BP of patients. Physicians use their independent medical judgement to recommend any clinical follow up or adjustment in medications/prescriptions for any patients whose daily reporting of BP triggers an alert based on physician-driven alert thresholds.
9883750|NCT05319405|Active Comparator|Sana plus Treatment as Usual|Subjects will be loaned a Sana Device to use for 28 days and will also receive mental health care through the Ralph H. Johnson VA Medical Center.
9883751|NCT05319405|No Intervention|Treatment as Usual|Subjects will receive mental health care at the Ralph H. Johnson VA Medical Center or community-based outpatient clinic (CBOC).
9883752|NCT05319392||Patients with Gastric Adenocarcinoma|Patients with origin of tumor in distal part of stomach who underwent total or partial gastrectomy after biopsy examination with availability of follow-up and archived FFPE tissue will be considered for this study.
9883753|NCT05319366||Stable angina|50 patients with stable angina will be included and tissue samples from balloon cathether and blood samples will be collected
9883754|NCT05319366||Unstable angina/non-ST-segment elevation myocardial infarction|50 patients with unstable angina/non-ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
9883755|NCT05319366||ST-segment elevation myocardial infarction|50 patients with ST-segment elevation myocardial infarction will be included and tissue samples from balloon cathether and blood samples will be collected
9883756|NCT05319366||Controls|50 patients without corornary arthery-related treatment will be included and tissue samples from balloon cathether and blood samples will be collected
9883757|NCT05319366||Vascular surgery|25 patients who undergo will be included and tissue samples and blood samples will be collected
9883758|NCT05319340|Other|anticoagulants arm|The study embraces patients who are advised to take the anticoagulant therapy (as per the European Society of Cardiology Guidelines). The study evaluates the compliance with the anticoagulant therapy, safety and effectiveness, mortality
9883759|NCT05319327|Active Comparator|Control Group|Participants in the control group will be provided with nutritional guidelines to follow a healthy diet based on a Mediterranean diet.
9883760|NCT05319327|Experimental|Intervention group|Participants in the intervention group will follow a nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.
9883761|NCT05319314|Experimental|GCC19CART|"Single infusion of GCC19CART at the dose assigned to an individual subject.~All subjects will receive the same investigational therapy with the dose administered dependent upon the dose level they are assigned to in a sequential manner.~Two dose level escalations are planned with one dose de-escalation listed if needed."
9883762|NCT05319301|Experimental|Patients with hypopituitarism|A single dose of melatonin administration
9883763|NCT05319301|Active Comparator|Healthy controls|A single dose of melatonin administration
9883764|NCT05319288|Active Comparator|Distal acupoints only group|The DPOG (n=51) will receive acupuncture of distal acupoints only(SI3, EX-UE7) for ALBP.
9883765|NCT05319288|Active Comparator|Local acupoints mainly combined with distal acupoints group|LPMG (n=51) will receive acupuncture of local acupoints mainly(BL23, BL25, BL32) combined with distal points(BL40) for ALBP.
9883766|NCT05319275|Experimental|Acetyllevocarnitine Hydrochloride Tablets|
9883767|NCT05319275|Placebo Comparator|Placebo|
9883768|NCT05319262|No Intervention|Control|Single study night with no noise exposure, to determine normal baseline sleep
9883769|NCT05319262|Experimental|Traffic noise|Single study night with traffic noise events, to determine consequences of sleep disturbance by traffic noise
9883770|NCT05319262|Experimental|Pink noise|Single study night to measure the effects of a non-pharmacological intervention to promote sleep, pink noise.
9883771|NCT05319262|Experimental|Traffic noise + pink noise|Single study night with concurrent traffic noise events and continuous pink noise sound exposure. Night is used to determine attenuation of sleep disturbance by traffic noise due to introduction of pink noise.
9883772|NCT05319249|Experimental|NK cells combined with PARP inhibition|Combination of NK cell therapy and PARP inhibition by Talazoparib after immunosuppression with cyclophosphamide and fludarabine
9883773|NCT05319236|Other|Gabi System|Subjects will wear the Gabi system each time they go to sleep or are resting, to measure and record their SpO2, pulse rate, respiratory rate and movements.
9883774|NCT05319223||Patient management group|patient blood management group
9883775|NCT05319223||Control|control
9883776|NCT05319210|Experimental|Buzzy application|It is fixed on the right upper arm area of the child one minute before the procedure. After cleaning the skin with the appropriate solution, venous catheter placement will be performed. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
9931254|NCT00936390|Active Comparator|Arm I|Patients undergo external-beam radiation therapy (EBRT) once daily on days 1-5. Some patients instead receive EBRT with high-dose rate or low-dose rate brachytherapy implant.
9997304|NCT01507636|Active Comparator|Group 1|Occupational therapy using a special arm function training.
9883777|NCT05319210|Experimental|Virtual Reality Glasses|A dinosaur movie suitable for the 7-12 age group will be watched 2-3 minutes before the venous catheter insertion. In this process, after cleaning the skin with the appropriate solution, a venous catheter will be inserted. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
9883778|NCT05319210|No Intervention|No intervention|The routine venous catheter placement protocol in the institution where the study is conducted will be applied. An evidence-based non-pharmacological method is not used to reduce pain during venous catheter insertion in children in the institution. A venous catheter is inserted by attaching a tourniquet to the child. During the procedure, the child's respiratory rate, heart rate and oxygen saturation will be observed.
9883779|NCT05319197||SLD Group|
9883780|NCT05319197||Healthy Control Group|
9883781|NCT05319119||1.CT-FFR Related Group|Coronary diseased artery CTFFR>80%, secondary prevention of coronary heart disease;Coronary diseased artery CTFFR≤80% revascularization at the lesion site and regular medication after PCI
9883782|NCT05319119||Coronary Angiography Related Group|Coronary diseased artery CTFFR≤80%, coronary angiography decision does not require revascularization but apply coronary heart disease secondary prevention medication;Coronary diseased artery CTFFR>80%,However, revascularization was performed according to conventional angiographic decisions and postoperative regular service was performed.For multivessel disease, although coronary revascularization is performed, there are still diseased artery with CTFFR≤80% and no revascularization is performed.
9883783|NCT05319106|Experimental|experimental group|Local transplantation stem cell preparation combined with silver ion dressing
9883784|NCT05319106|Placebo Comparator|control group|Local trantment with silver ion dressing
9883785|NCT05319080|Experimental|Individualized magnetic resonance imaging (MRI) guided rTMS|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive a 20-min once-daily rTMS sessions over a period of 2 weeks (weekends off), and therefore accrue a total of 10 rTMS stimulation sessions. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
9883786|NCT05319067||Cases|Children aged 1 to 3 years with vesico ureteral reflux of grade 3 or higher, under antibiotic prophylaxis
9883787|NCT05319067||Controls|Children aged 1 to 3 years with uropathy, without antibiotic prophylaxis
9883788|NCT05319067||Healthy Controls|Healthy children aged 1 to 3 years.
9883789|NCT05319054|No Intervention|Cohort|Patients who have undergone colonic resection for colorectal cancer in the last 10 years. Patient reported outcome measures collected at 3-monthly intervals.
9883790|NCT05319054|Active Comparator|Optimised Conservative Management|Cohort participants who are identified as having 'major LARS' at any point are treated with Optimised Conservative Managements, consisting of medication, dietary advice, lifestyle advice and physiotherapy.
9883791|NCT05319054|Active Comparator|Trans-Anal Irrigation|Cohort participants who are identified as having 'major LARS' at any point are treated with Trans-anal irrigation, in additional to receiving optimised conservative management. Transanal irrigation system will be decided upon with the participant and procured locally.
9883792|NCT05319054|Active Comparator|Sacral NeuroModulation|Cohort participants who are identified as having 'major LARS' at any point are treated with Sacral Neuromodulation system, in addition to receiving optimised conservative management. Medtronic Interstim system will be used.
9883793|NCT05319041|Experimental|Active herbal capsules|"Wei's Qi Ju Gan Lu Formula is a herbal formulation initiated by the senior TCM collaborator, Prof Wei QP. This TCM formulation is prescribed to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
9883794|NCT05319041|Placebo Comparator|Placebo capsules|Placebo capsule which contains 0.5g maltodextrin without any herbs medicine.
9883795|NCT05319028|Experimental|Continuous Dosing Schedule|Mivavotinib 100 mg once daily (QD)
9517695|NCT03303976|Experimental|Pneumo1-low dose|Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
9517696|NCT03303976|Experimental|Pneumo1-mid dose|Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
9883796|NCT05319028|Experimental|Induction Dosing Schedule|Mivavotinib 120 mg QD for 14 days, then 80 mg QD starting Day 15
9883797|NCT05319015|Experimental|Treatment Arm|Patients receive neoadjuvant lenvatinib (20 mg PO daily) for 12 weeks and pembrolizumab (200 mg IV every 3 weeks for four doses) prior to surgical resection of locally advanced RCC with IVC tumor thrombus. Following surgery, patients will receive adjuvant pembrolizumab (200 mg IV every 3 weeks for up to thirteen doses).
9883798|NCT05319002|Experimental|Group EMDR|Participants in the experimental group will undergo a 3-week group EMDR intervention with weekly 60-minute group sessions.
9883799|NCT05319002|No Intervention|Control|The control group will follow routine daily school activities
9883800|NCT05318989||Premenopausal women (PREM)|Control group
9883801|NCT05318989||Postmenopausal women (POSMA)|Test group A : postmenopausal women not treated with topical estrogens
9883802|NCT05318989||Postmenopausal women (POSMB)|Test group B: postmenopausal women treated with topical estrogens
9883803|NCT05318976|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 23 weeks.
9517697|NCT03303976|Experimental|Pneumo1-target dose|Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
9517698|NCT03303976|Active Comparator|Pneumovax23|Arm D: intramuscular injection multivalent plain polysaccharide vaccine
9883804|NCT05318976|Placebo Comparator|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 23 weeks.
9883805|NCT05318963|Experimental|LCAR-AIO cells product|Each subject will be given a single-dose LCAR-AIO cells infusion at each dose level.
9883806|NCT05318950|No Intervention|Control|No intervention
9883807|NCT05318950|Experimental|E-learning|E-learning: 8 lessons about nutrition and lifestyle
9883808|NCT05318950|Experimental|Diet A|MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids)
9883809|NCT05318950|Experimental|Diet B|MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
9883810|NCT05318937|Experimental|SAGE-718|Participants will receive SAGE-718 capsules, orally, once daily in the morning for 42 days.
9883811|NCT05318937|Placebo Comparator|Placebo|Participants will receive SAGE-718-matching placebo capsules, orally, once daily in the morning for 42 days.
9883812|NCT05318924|Experimental|Ghrelin infusion|To achieve approximately stable elevated ghrelin levels during the infusion procedure, the investigators will use a loading dose of 1 mcg/kg as well as an infusion rate of 0.051 mcg/kg/min in line with recent studies (Farokhnia, Grodin, Lee et al., 2017) and general recommendations (Garin, Burns, Kaul et al., 2013).
9883813|NCT05318924|Placebo Comparator|Placebo infusion|Saline
9883814|NCT05318924|No Intervention|Patients with MDD|Patients with major depressive disorder will be enrolled for comparison to healthy participants on the reward task battery, but not randomized to the ghrelin vs. saline infusion.
9883815|NCT05318911|Active Comparator|Supplement Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of novel yogurt drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any yoghurt drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
9883816|NCT05318911|Placebo Comparator|Placebo Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of placebo drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any placebo drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
9883817|NCT05318898|Experimental|Regular diet with vegetable protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetable protein sources.
9883818|NCT05318898|Active Comparator|Regular diet with animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
9883819|NCT05318885|Experimental|Forward leaning position|The children in asthma attacks were administered nebulization three times, during which the study group children were placed in the forward-leaning position.
9883820|NCT05318885|No Intervention|Fowler position|The children in asthma attacks were administered nebulization three times, during which the control group children in the routine Fowler's position.
9883821|NCT05318846|Experimental|Treatment group A|
9883822|NCT05318846|Placebo Comparator|Treatment group B|
9883823|NCT05318833|Experimental|HRS7415|
9883824|NCT05318820|Experimental|HMPL-523-TRR|Three cycle dose: TRR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
9883825|NCT05318820|Experimental|HMPL-523-RTR|Three cycle dose:RTR Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
9517699|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
9517700|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
9883826|NCT05318820|Experimental|HMPL-523-RRT|Three cycle dose:RRT Test product: HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Co., Ltd.; Reference product: HMPL-523 Tablets manufactured by WuXi STA
9883827|NCT05318807|Experimental|Personalised prehabilitation|A personalised plan of diet, exercise and emotional support for patients having chemotherapy or radiotherapy treatment for lung cancer.
9883828|NCT05318794|Experimental|Neoadjuvant systemic and peritoneal chemotherapy|Standard neoadjuvant systemic and pressurised intraperitoneal aerosol chemotherapy
9883829|NCT05318781||Patients undergoing bariatric surgery|Adult patients (≥ 30y yrs.) scheduled to undergo a first bariatric surgery recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal [N=120]
9883830|NCT05318781||Patients on the bariatric surgery waitlist|Age-, sex-, and BMI-matched waitlist control group [awaiting for bariatric surgery] recruited from the bariatric surgery clinic at the CIUSSS du Nord-de-l'Île-de-Montréal [N=60]
9883831|NCT05318781||Non-bariatric eligible individuals|"Age-and sex-matched individuals who are not eligible for bariatric surgery, as an additional non-bariatric comparison group [N=60]~*The 60 age-and sex-matched non-bariatric participants will have data captured just once [at baseline] on a limited number of key assessments"
9883832|NCT05318755||transgender men|People whose sex assigned at birth is female but whose self-identified gender is male.
9883833|NCT05318755||transgender women|People whose sex assigned at birth is male but whose self-identified gender is female.
9883834|NCT05318755||Healthy cisgender people|People whose sex assigned at birth corresponds with their self-identified gender.
9883835|NCT05318742|Active Comparator|Fewer Laser Spots|Group A patients underwent endolaser PRP with a range of 200-300 shots during PPV
9883836|NCT05318742|Active Comparator|Higher Laser Spots|Group B patients underwent endolaser PRP with a range of 500-600 shots during PPV
9883837|NCT05318729|Experimental|Vibration tool|"Use of the vibration tool 3 times per day for 10 minutes for each session Morning, mid-day, and evening.~Volarly for 5 minutes and dorsally for 5 minutes, for a total of 10 minutes during each session:"
9883838|NCT05318729|No Intervention|Control|Standard of care, no vibration tool.
9883839|NCT05318716|Experimental|Reconstructive group|This group of patients would be undergoing fat grafting following implant-based reconstruction. We will be excluding patients that have had autologous based reconstruction, including regional and free flaps. This group will be analyzed based on volume (<200cc or 50% and >200cc or 50%) as well as subgroup analysis based on adjuvant chemo or radiation therapy.
9883840|NCT05318716|Experimental|Cosmetic augmentation group|This group of patients will be undergoing a primary or secondary augmentation for cosmesis. They will be included if this is a primary augmentation using fat grafting or a secondary augmentation with no history of fat grafting to the breasts.
9883841|NCT05318703|Experimental|cognitively enhanced tai ji quan|Participants receive a cognitively enhanced tai ji quan exercise intervention for 16 weeks.
9883842|NCT05318703|Active Comparator|stretching exercise|Participants receive a stretching exercise intervention for 16 weeks.
9883843|NCT05318690|Experimental|PlayGait (Exoskeleton)|Experimental lower-limb device.
9883844|NCT05318690|Active Comparator|Baseline|Baseline condition without using any prescribed lower-limb orthoses.
9883845|NCT05318677||1|"Fifteen patients with spina bifida aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
9883846|NCT05318677||2|"20 healthy subjects as a control group aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
9883847|NCT05318664|Experimental|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
9883848|NCT05318664|No Intervention|Control|20 minutes of rest
9883849|NCT05318651|Experimental|mobile app users|
9883850|NCT05318638|Other|Study group|All participants in the study will perform arm/hand movement tasks in both of two conditions (with and without soft-robotic glove), so they constitute 1 study arm, but all receiving both intervention conditions (experimental - with glove and control - without glove).
9883851|NCT05318599||IPF patients (group 1)|Consenting adult patients >18 years old with with already-diagnosed IPF
9883852|NCT05318599||NSIP patients (group 2)|Consenting adult patients >18 years old with with already-diagnosed non-specific interstitial pneumonia (NSIP)
9883853|NCT05318599||COPD patients (group 3)|Consenting adult patients >18 years old with with already-diagnosed chronic obstructive pulmonary disease (COPD)
9883854|NCT05318599||Control subjects (group 4)|"Consenting age-matched (+/- 2.5 years) never smokers patients with normal lung function (spirometry, lung volume and Transfer Factor for Carbon Monoxide (TLCO)) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest, namely:~patients with obstructive sleep apnea.~patients followed-up for occupational lung diseases (miners, chemical workers, etc.).~patients followed-up for pulmonary nodules (considered benign after 2 years)."
9989275|NCT01431248||Erythromycin 250mg|Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
9989276|NCT01431261|Active Comparator|Pain Management + Training|Education in pain management strategies and treatment sessions including instructions in neck exercises and aerobic training
9989277|NCT01431261|Active Comparator|Pain Management|Education in pain management strategies
9989278|NCT01431352|Experimental|Letrozole+ Chinese herbal medicine granules|
9989279|NCT01431352|Placebo Comparator|Letrozole+ Chinese herbal medicine granules placebo|
9989280|NCT01431365|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants walking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise will be defined as 40-68% of the resting heart rate reserve. Heart rate (HR) will be monitored in participants using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
9989281|NCT01431365|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively for 10 minutes on a chair. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) in regards to distraction effects and researcher contact.
9989282|NCT01431378||CNS|CNS: Known or suspected pathology in the posterior fossa
9989283|NCT01431378||Thorax|Thorax: Patients referred for staging of a known or suspected lung cancer
9989284|NCT01431378||Abdomen 1|Abdomen: Patients with acute flank pain and suspected urolithiasis
9989285|NCT01431378||Abdomen 2|Abdomen: Patients with a known or suspected focal liver lesion
9989286|NCT01431404|Active Comparator|Enbrel, prefilled syringe|
9989287|NCT01431404|Experimental|HD203, prefilled syringe|
9989288|NCT01431417||Healthy volunteers|Healthy volunteers, less than 35 years old and presenting with no shoulder condition
9989289|NCT01431417||Patients with rotator cuff condition|Patients with rotator cuff condition, conservative treatment indicated
9989290|NCT01431417||Patients with shoulder instability|Patients with shoulder instability, conservative treatment indicated
9989291|NCT01431417||Patients with proximal humerus fracture|Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
9989292|NCT01431417||Patients with frozen shoulder|Patients with frozen shoulder, conservative treatment indicated
9989293|NCT01431430|Experimental|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
9989294|NCT01431430|Active Comparator|Cholecalciferol 12 000 UI (Control)|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
9989295|NCT01431443|Experimental|Dark chocolate|
9989296|NCT01431443|Placebo Comparator|Placebo chocolate|Placebo intervention
9989297|NCT01431456|Active Comparator|Dabigatran|Dabigatran
9989298|NCT01431456|Active Comparator|Rivaroxaban|Rivaroxaban
9989299|NCT01431456|Active Comparator|Nadroparin|Nadroparin
9989300|NCT01431469|Placebo Comparator|Cow's Milk|Powdered Whole Cow's Milk
9989301|NCT01431469|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
9989302|NCT01431495|Active Comparator|plavix|patient treated by the princeps
9989303|NCT01431495|Active Comparator|Pidogrel|patient treated by Pidogrel
9989304|NCT01431547|Experimental|Part 1: Dalotuzumab|
9989305|NCT01431547|Experimental|Parts 2 and 3: Dalotuzumab + ridaforolimus|
9989306|NCT01431560|Active Comparator|metallic implant|fixation of the ankle fracture with metallic implants
9989307|NCT01431560|Active Comparator|biodegradable implant|fixation of the ankle fracture with Freedom plate and screws
9989308|NCT01431586|Experimental|Single dose JDTic 1 mg, 3 mg, or 10 mg|
9989309|NCT01431599|Experimental|short-course|
9989310|NCT01431612|Active Comparator|Esmolol|50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours
9989311|NCT01431612|Active Comparator|Phenylephrine|Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.
9989312|NCT01431612|Placebo Comparator|Lactated Ringer´s solution|10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.
9989313|NCT01431625|Active Comparator|COPD with emphysema-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
9883855|NCT05318573|Experimental|Safety Run-in Phase|FF-10832 in combination therapy with pembrolizumab; FF-10832 will be dosed at 40 mg/m2 with a fixed dose of pembrolizumab (200 mg)
9883856|NCT05318560|Active Comparator|Local anesthetic injection|Patients will be injected with lidocaine and given upper trapezius muscle stretching exercises. Lidocaine injection 2cc 2% will be administered to all patients using a 26 gauge, 0.45x13 mm disposable sterile needle to the affected trigger point.
9883857|NCT05318560|Active Comparator|Ozone injection|Ozone injection will be performed on patients and upper trapezius muscle stretching exercises will be given. 8 cc of oxygen/ozone gas at a concentration of 15 µg/mL will be injected into the trigger point.
9883858|NCT05318560|Active Comparator|Stretching exercise|Patients will be given a home program that includes upper trapezius muscle stretching exercises. Upper trapezius stretching exercises will be performed twice a day for at least 15 seconds, ten sets each time, for three weeks, with one hand on the patient's back and the other hand holding the side of the head and tilting it to the side until a slight tension is felt. The exercises will be explained in the text, visual and verbal forms with the exercise form.
9883859|NCT05318547|Experimental|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
9883860|NCT05318547|Experimental|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
9883861|NCT05318534|Experimental|GL-0719|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Cohort 1: 4 subjects~Cohort 2: 8 subjects~Cohort 3: 8 subjects~Cohort 4: 8 subjects~Cohort 5: 8 subjects"
9883862|NCT05318534|Placebo Comparator|Placebo|"Dose level cohorts randomized in a 3:1 ratio to GL-0719 or placebo treatment, respectively.~The study will comprise a single-dose, sequential-group design.~Cohort 1: 4 subjects~Cohort 2: 8 subjects~Cohort 3: 8 subjects~Cohort 4: 8 subjects~Cohort 5: 8 subjects"
9883863|NCT05318508||patients with low back pain|
9883864|NCT05318508||patients without low back pain|
9883865|NCT05318495|Experimental|Standard Colonoscopy+CAD-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
9883866|NCT05318495|Active Comparator|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI)."
9883867|NCT05318495|Experimental|Standard Colonoscopy+CAD-EYE+G-EYE followed by Standard Colonoscopy|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
9883868|NCT05318495|Active Comparator|Standard Colonoscopy followed by Standard Colonoscopy+CAD-EYE+G-EYE|"CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.~The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).~The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning."
9935477|NCT03654079|Active Comparator|Simulation Arm|Subjects in this arm will participate in Interventions (In- Utero Simulation, Cesarean Section Simulation, and Pushing Simulation).
9935478|NCT03654079|No Intervention|Control Arm|Subjects in this arm will not participate in any simulations.
9517701|NCT03303924|Experimental|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
9883869|NCT05318482|Experimental|Motivational group|The patients of this group will be equipped with an electronic wristwatch and will be monitored every day by the physiotherapist (PT) through an application on their mobiles. The PT will follow these patients with a daily motivational session (15 minutes, modality 1 patient: 1 PT) and with an educational program about the definition, importance and benefits of physical activity.
9883870|NCT05318482|Sham Comparator|Control|The patients of this group will have an electronic wristwatch and will be advised by the PT only with generic recommendations of daily exercise during the hospitalization, besides the usual activities of the rehabilitation program.
9883871|NCT05318469|Experimental|Treatment (ivermectin, pembrolizumab)|Patients receive ivermectin PO QD on days 1-3, 8-10, and 15-17. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
9883872|NCT05318456|Experimental|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
9883873|NCT05318456|Active Comparator|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
9883874|NCT05318456|Placebo Comparator|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food starting on Day 0 for 42 days. If a dose is missed participants are instructed to take the dose as soon as they remember. Participants will be advised not to exceed 4 capsules daily.
9883875|NCT05318313||Telerehabilitation only|Participants choose to have all of their physical therapy provided virtually throughout the length of the study
9883876|NCT05318313||In-person only|Participants choose to have all of their physical therapy provided in-person throughout the length of the study
9883877|NCT05318313||Hybrid 1|The TR PT evaluation and follow-up visits in the initial 6 weeks will be performed via Zoom software and subsequent follow-up visits will switch to in person after 6 weeks
9883878|NCT05318313||Hybrid 2|The PT evaluation and follow-up visits in the initial 6 weeks will be performed in person and will switch to TR via Zoom software after 6 weeks
9883879|NCT05318300|Experimental|Tested formula LP-2018|infant formula containing fibers
9883880|NCT05318300|Placebo Comparator|Placebo formula CT-2018|infant formula without fibers
9883881|NCT05318287|Experimental|PeriGrief|A brief four-module intervention delivered via computer or mobile device. Modules utilize mindfulness and cognitive behavioral therapy strategies to reduce distress following perinatal loss.
9883882|NCT05318274|Experimental|ARM I|Radiotherapy treatment with high hypofractionation, 26 Gy in 5 fractions to the whole breast.
9883883|NCT05318274|Active Comparator|ARM II|Radiotherapy treatment with standard hypofractionation, 42.5 Gy in 16 fractions with simultaneous integrated increase of 5.5 Gy to the tumor bed in high-risk patients.
9883884|NCT05318248|Experimental|Clonidin|pill 0,15 mg clonidin
9883885|NCT05318248|Placebo Comparator|Placebo|placebo pill
9883886|NCT05318235||Children|Children between 6 weeks and 4 years of age who have a older sibling or attend day care
9883887|NCT05318222|Other|WGS arm|All 100 patients recruited will undergo WGS
9883888|NCT05318209|Experimental|Study grou[p|Closed-chain shoulder girdle scapular depression exercise
9883889|NCT05318209|Active Comparator|control group|Shoulder girdle depression against manual resistance exercise
9931255|NCT00936390|Experimental|Arm II|Patients receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin) subcutaneously or as an injection every 1 to 3 months AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily) for 6 months. Beginning 8 weeks after the first LHRH injection, patients undergo radiotherapy as in arm I.
9931256|NCT00936403|Experimental|NNC126-0083|
9931257|NCT00936403|Active Comparator|Norditropin NordiFlex®|
9517702|NCT03303872||AF-pacemaker registry|
9883890|NCT05318170||Women affected by gynecological cancer|Women affected by gynecological cancer (cervical, endometrial, ovarian and vulvar cancer)
9883891|NCT05318157|Experimental|Sublingual Immunotherapy group|
9883892|NCT05318157|Experimental|Placebo group|
9883893|NCT05318144||PCR (-) symptomatic|control group, pregnant women with negative COVID-19 Polymerase Chain Reaction (PCR) test
9883894|NCT05318144||PCR (+) asymptomatic|Pregnant women who have a positive COVID-19 PCR test and have had the infection without symptoms
9883895|NCT05318144||PCR (+) mild-moderate|Pregnant women with positive COVID-19 PCR test and mild to moderate symptoms and inpatient treatment
9883896|NCT05318144||PCR (+) severe COVID-19|Pregnant women with positive COVID-19 PCR test and severe symptoms
9883897|NCT05318131|Experimental|Single Arm Prospective Study|
9883898|NCT05318118|Active Comparator|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|
9883899|NCT05318118|Active Comparator|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|
9883900|NCT05318105|Experimental|Aquadex ultrafiltration therapy|
9883901|NCT05318105|Active Comparator|IV loop diuretics|
9883902|NCT05318092|Experimental|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for the treatment of acute pulmonary embolism
9883903|NCT05318066|Active Comparator|Arm Fluids (FL)|500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.
9883904|NCT05318066|Active Comparator|Arm Vasopressor (VP)|Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.
9883905|NCT05318053||2022 Cohort|"Successful completion of screening checklist to indicate one of the following conditions:~recurring, long-standing fantasies that focus on kink, in areas such as: power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities. By fetish, we mean a type of sexual desire in which gratification depends on or is significantly increased by particular objects, clothing items, parts of the body, or types of persons.~OR currently engaging, or have engaged in the past, in consensual kink activities such as power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities.~Age of majority in the legal jurisdiction (geographic location) where the survey is taken (usually age 18)~English-language proficiency sufficient to understand the study instruments~Completion of an electronically signed and dated informed consent form"
9883906|NCT05318040|Experimental|Single ascending dose - CMS121|Subjects will receive a single oral dose of CMS121 under fed conditions.
9883907|NCT05318040|Placebo Comparator|Single ascending dose - placebo|Subjects will receive a single oral dose of placebo under fed conditions.
9883908|NCT05318040|Experimental|Multiple ascending dose - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
9883909|NCT05318040|Placebo Comparator|Multiple ascending dose - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
9883910|NCT05318040|Experimental|Multiple ascending dose - Elderly cohort - CMS121|Subjects will receive multiple oral doses of CMS121 once daily (QD) for 7 days under fed conditions.
9883911|NCT05318040|Placebo Comparator|Multiple ascending dose - Elderly cohort - placebo|Subjects will receive multiple oral doses of placebo once daily (QD) for 7 days under fed conditions.
9883912|NCT05318040|Experimental|Food Effect - CMS121|On Day 1 of each of 2 treatment periods, a single oral dose of CMS121 will be administered following either a standard high fat/high calorie meal (Treatment A) or an overnight fast (Treatment B), as per each subject's assigned randomization sequence (AB or BA). There will be a washout of at least 7 days between doses.
9883913|NCT05318027|Experimental|Activity Monitoring and ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring and utilize a ChatBot
9883914|NCT05318027|No Intervention|Activity Monitoring without ChatBot|Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring alone
9883915|NCT05318014|Experimental|Intervention group|Regular nutrition education and supply one serving per day of 6% low protein formula.
9883916|NCT05318014|Placebo Comparator|Regular nutrition education|Regular nutrition education
9883917|NCT05317988|Experimental|Intervention|Text-based product information, video of step-by-step demonstration of detailed reconstituion procedures
9883918|NCT05317975|Experimental|Add-on telerehabilitation combined with usual home-based rehabilitation|Add-on telerehabilitation combined with usual home-based rehabilitation
9883919|NCT05317975|Experimental|Stand-alone usual home-based rehabilitation|Stand-alone usual home-based rehabilitation
9883920|NCT05317975|No Intervention|Usual care|Usual care
9883921|NCT05317962||COVID-19 positive patients admitted to hospital|
9883922|NCT05317936|Experimental|Pirtobrutinib+venetoclax|Pirtobrutinib by mouth at the same time each day Venetoclax by mouth at the same time each day.
9883923|NCT05317910|Experimental|Music intervention|Music intervention (duration 20 minutes) every day for 30 days
9883924|NCT05317871||Lewy Body Spectrum Diseases|
9883925|NCT05317871||Progressive Supranuclear Palsy|
9883926|NCT05317871||Corticobasal Syndrome|
9883927|NCT05317871||Frontotemporal Degeneration|
9883928|NCT05317858|Experimental|Pembrolizumab with Exablate BBBD|Using Exablate Model 4000 Type 2 for the treatment of NSCLC brain metastases in subjects who are undergoing planned pembrolizumab monotherapy.
9883929|NCT05317858|Active Comparator|Control Arm (Pembrolizumab only)|subjects will undergo planned pembrolizumab monotherapy.
9931258|NCT00936416|Experimental|GFR and RBF followed by MRI|Subjects will undergo GFR and renal blood flow estimation by Inulin and PAH clearance method, followed by a MRI test. The MRI examination will be performed on the same day as the inulin/PAH procedure.
9931259|NCT00936429|Experimental|10 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
9931260|NCT00936429|Experimental|50 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
9931261|NCT00936429|Placebo Comparator|Placebo|Administration of placebo vaccine at Weeks 0, 4, and 8.
9931262|NCT00936442||Group A|Standard treatment: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
9931263|NCT00936442||Group B|Standard treatment + educational material: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice plus reception of educational material on regular basis.
9931264|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (3.75ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 3.75ug given by IM injection to the upper deltoid.
9931265|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (7.5ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 7.5ug given by IM injection to the upper deltoid.
9931266|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (25ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 25ug given by IM injection to the upper deltoid.
9931267|NCT00936468|Experimental|Fluzone® vaccine alone|One vaccination on Day 0 with Fluzone vaccine at 45 ug given by IM injection in the upper deltoid.
9931268|NCT00936494|No Intervention|Control|No inferior turbinate surgery.
9931269|NCT00936494|Other|Intervention|Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).
9931270|NCT00936507|Experimental|Low-ED, small portion|
9931271|NCT00936507|Experimental|Low-ED, large portion|
9931272|NCT00936507|Experimental|High-ED, small portion|
9931273|NCT00936507|Experimental|High-ED, large portion|
9931274|NCT00936520|Experimental|Dose 1|SAR 1118 dose 0.1%
9931275|NCT00936520|Experimental|Dose 2|SAR 1118 dose 1.0%
9931276|NCT00936520|Experimental|Dose 3|SAR 1118 dose 5.0%
9931277|NCT00936546|Experimental|Rituximab|
9931278|NCT00936559|Experimental|1|Arm A
9931279|NCT00936559|Experimental|2|Arm B
9931280|NCT00936559|Experimental|3|Arm C
9931281|NCT00936572|Experimental|high dose|high dose of probiotics (109 cfu)
9931282|NCT00936572|Experimental|low dose|low dose of probiotics (107 cfu)
9931283|NCT00936572|Placebo Comparator|probiotics|Maltodoxtrin
9931284|NCT00936624|Experimental|SOTB07 100mg|
9931285|NCT00936624|Experimental|SOTB07 200mg|
9931286|NCT00936624|Placebo Comparator|Placebo|
9931287|NCT00936624|Active Comparator|Montelukast 10mg|
9931288|NCT00936637|Experimental|Extensively hydrolyzed infant formula|
9931289|NCT00936650|Experimental|cinacalcet|
9931290|NCT00936650|Placebo Comparator|placebo|
9931291|NCT00936676||Rasagiline mesylate|Enrollment by invitation to participates from the ADAGIO trial
9931292|NCT00936689|Sham Comparator|Traditional TACE|Chemoembolization by standard technique: epirubicin (maximum dose of 75 mg) conjugated with an oil-based contrast medium (Lipiodol) at the maximum dose of 15 ml + gelatin sponge particles(particles of transient embolization material, required to obstruct the treated vessel).
9931293|NCT00936689|Active Comparator|TACE with microsphere|
9931294|NCT00936728|Experimental|Arm A (white wine)|Patients consume white wine twice daily for 3-4 weeks.
9931295|NCT00936728|Active Comparator|Arm B (non-wine nutritional supplement)|Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
9931296|NCT00936754|Experimental|Treatment|Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
9931297|NCT00936754|Placebo Comparator|Placebo|Single administration of encapsulated placebo, taken 30 minutes before test meal
9931298|NCT00936767|Experimental|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
9931299|NCT00936767|Active Comparator|Artesunate/Mefloquine (MAS3)|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
9931300|NCT00936780|Experimental|Infinnium-Core™ Paclitaxel eluting Coronary Stent|
9931301|NCT00936806||Unilateral intracranial tumor|Subjects with unilateral intracranial tumor
9931302|NCT00936806||Control group|Subjects without intracranial pathology
9931303|NCT00936819|Placebo Comparator|Plasma-Lyte A and 25% autologous plasma|
9931304|NCT00936819|Experimental|Autologous EPCs|
9931305|NCT00936819|Experimental|Autologous EPCs Transfected with human eNOS|
9931306|NCT00936845||Females with Hemophilia|Females with severe or moderate Hemophilia A or B.
9931307|NCT00936923|Active Comparator|furosemide1|Patients will take furosemide 60mg per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
9931308|NCT00936923|Active Comparator|furosemide 2|Patients will take 120mg furosemide per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
9931309|NCT00936923|No Intervention|control|Patients in control group will not take furosemide
9931310|NCT00936936|Experimental|Cycle # 1|"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC"
9931311|NCT00936936|Experimental|Cycle #2|"Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC"
9935479|NCT03648905||Control patients (iatrogenic CAF)|Patients with iatrogenic chronic autonomic failure (CAF) (e.g., status-post cardiac transplantation, pre/post bilateral thoracic sympathectomies)
9935480|NCT03648905||Control patients (PD No OH)|Patients with Parkinson's disease (PD) without orthostatic hypotension (PD no OH)
9935481|NCT03648905||Healthy Volunteers|Healthy Volunteers, includes people with genetic risk of PD or studied as concurrent controls
9883931|NCT05317832|Active Comparator|Web-based physical activity intervention (WI) program|Participants in the WI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24).
9883932|NCT05317832|Experimental|Web-based physical activity intervention (WI) program + just-in-time adaptive intervention (JITAI)|Participants in the WI + JITAI arm will take part in the WI program (weeks 3 to 16). After the WI program is completed in week 16, the participants will transition to the physical activity sustainability phase which will include participants having continued access to the information provided during the WI program (weeks 17 to 24). In addition, participants will have access to the JITAI that will provide just-in-time feedback and physical activity recommendations (weeks 3 to 24). The type of the feedback and recommendation messages in the WI + JITAI arm will be delivered using micro-randomization, which involves random selection of intervention components at each possible time of delivery.
9883933|NCT05317806|Experimental|Metformin Treatment Group|Subjects with PAI-1 deficiency with or without cardiac fibrosis, receiving daily treatment with metformin for a daily range of 500-2000mg
9883934|NCT05317806|No Intervention|Observation Group|"Subjects with PAI-1 deficiency with or without cardiac fibrosis, not receiving treatment with metformin~Subjects are allowed to switch between the two groups"
9883935|NCT05317793||Professionals|150 knowledge workers from three Finnish companies.
9883936|NCT05317767|Experimental|Flu-M|300 children that will be vaccinated with a single dose of the Flu-M vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
9883937|NCT05317767|Active Comparator|Ultrix|300 children that will be vaccinated with a single dose of the Ultrix® vaccine intramuscularly at a dose of 0.5 mL (150 children aged 12 to 17 years, 150 children aged 6 to 11 years)
9883938|NCT05317741|Experimental|A mg IA-14069 or Placebo|
9883939|NCT05317741|Experimental|B mg IA-14069 or Placebo|
9883940|NCT05317741|Experimental|C mg IA-14069 or Placebo|Period 1: Fasted condition → Period 2: Fed condition
9883941|NCT05317741|Experimental|D mg IA-14069 or Placebo|
9883942|NCT05317715|Other|without device information|this group of patients will complete a questionnaire before receiving information on contraceptive intrauterine devices (copper or hormonal)
9883943|NCT05317715|Other|with device information|This group of patients will receive information about contraceptive intrauterine devices (copper or hormonal) before completing a questionnaire
9883944|NCT05317702|Experimental|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
9883945|NCT05317689|Active Comparator|Oral & Sublingual Psilocin, & Oral Psilocybin|Every participant will be administered Oral Psilocin, Sublingual Psilocin, and oral psilocybin in a randomized order.
9883946|NCT05317689|Active Comparator|Sublingual Psilocin|Depending on a number of factors, participants may complete a fourth session where they receive sublingual psilocin for the second time.
9883947|NCT05317676|Active Comparator|Palmitoylethanolamide|300 mg PEA twice a day for a total of 600 mg PEA daily 2-month supply upon discharge
9883948|NCT05317676|Placebo Comparator|Placebo|1 placebo tablet twice a day for a total of 2 tablet placebo daily 2-month supply upon discharge
9883949|NCT05317663|Experimental|Waterpipe with Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe with HWL for up to 45 minutes.
9883950|NCT05317663|Experimental|Absence of Waterpipe without Health Warning Label (HWL)|All participants will complete a lab visit where they will smoke waterpipe without HWL for up to 45 minutes.
9883951|NCT05317650|No Intervention|Control group|Control group, no exercise was performed, and the measurements were repeated at the end of 4 weeks.
9883952|NCT05317650|Experimental|M-Gravity group|Intervention group performed the exercise with the M-Gravity, 2 sessions per week, for 4 weeks, at the Outpatient Clinic of Department of Physical Therapy, Baskent University, one session for 60 minutes.
9883953|NCT05317637||Adults with OI|"18 participants will be enrolled through in this pilot study. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI.~This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. All efforts will be made to complete all data collection and testing on the same day. However, procedures completed within ±12 months will be accepted. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Participants will be enrolled regardless of OI type since BWT, a finding we are attempting to validate, was observed in all types of OI. Smokers will not be excluded."
9883954|NCT05317611|Active Comparator|Intraperitoneal instillation of ondansetron and bupivacaine (group A)|Patients will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % and (4 mg) 2 ml ondansetron through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
9883955|NCT05317611|Active Comparator|Intravenous ondansetron and intraperitoneal instillation of bupivacaine (group B)|Patient will receive intravenous (4 mg) 2 ml ondansetron and intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
9883956|NCT05317611|Sham Comparator|Intraperitoneal instillation of bupivacaine (group C)|patient will receive intraperitoneal instillation of (100 mg) 20 ml of bupivacaine 0.5 % through abdominal ports by simple instillation technique before removal of trocars then clamping of abdominal drains for 1h to avoid drainage of LA.
9883957|NCT05317598|Experimental|Intervention group|Students in the intervention group will be given a 5-week positive psychotherapy-based kindness and honesty psychoeducation.
9883958|NCT05317598|No Intervention|control group|Students in the control group will not receive any intervention during the 5-week period.
9883959|NCT05317585|Experimental|Continuous Glucose Monitoring (CGM)|Patients will be randomized to application of a continuous glucose monitor (CGM). They will apply the device in the clinical setting and be instructed how to download their information onto their smartphones or using the CGM device reader. They will use the CGM for the duration of the pregnancy until delivery.
9883960|NCT05317585|Active Comparator|Fingerstick Glucose Monitoring|Patients will be randomized to checking their blood glucose with fingerstick monitors at time of fasting in the AM, and 2 hours after each meal. This is the standard of care for patients in the pregnancy diabetes clinic.
9883961|NCT05317572|Active Comparator|Group 1|Group 1: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 80 mcg intrathecal morphine) + iv Fentanyl-PCA
9883962|NCT05317572|Active Comparator|Group 2|Group 2: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 120 mcg intrathecal morphine) + iv Fentanyl-PCA
9883963|NCT05317572|Active Comparator|Group 3|Group 3: Spinal Anesthesia (10 mg hyperbaric bupivacaine + 20 mcg fentanyl+ 160 mcg intrathecal morphine) + iv Fentanyl-PCA
9883964|NCT05317559|Experimental|room light|The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux).
9883965|NCT05317559|No Intervention|dim light|The dim light condition (n=10) included two consecutive nights of sleep in dim light.
9883966|NCT05316194||Participation in digital OA treatment|All participants that have participated in a digitally delivered first-line treatment program (Joint Academy) for hip or knee OA until May 2022.
9883967|NCT05316142|Active Comparator|AGV with intraoperation MMC|Patients with neovascular glaucoma undergoing shunt implant surgery with MMC during surgery. This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world. First, MMC at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed. The shunt is fixed and then the shunt tube is inserted into the eye and fixed with nylon 10.0 thread. The conjunctiva is also swabbed with 8.0 vicryl sutures. After the operation, patients undergo regular examinations according to a specific protocol to evaluate the effectiveness as well as possible complications.
9883968|NCT05316142|Active Comparator|AGV with intraoperation MMC and postoperation 5FU|Patients with neovascular glaucoma undergoing shunt implant surgery with MMC during and 5FU after surgery .This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world. First, 5FU at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed. The shunt is fixed and then the shunt tube is inserted into the eye and fixed with nylon 10.0 thread. The conjunctiva is also swabbed with 8.0 vicryl sutures. After the operation, patients undergo regular examinations according to a specific protocol to evaluate the effectiveness as well as possible complications. Also in the first, third and fifth weeks, 5FU injections are given as a subconjugate with a volume of 0.1 ml containing 5 mg of the drug.
9883969|NCT05306665|Experimental|ACT intervention|Participants assigned to this arm will complete a 1-day ACT workshop followed by a telephone booster after surgery
9883970|NCT05306665|No Intervention|Treatment As Usual|Participants assigned to this arm will receive treatment as usual.
9883971|NCT05306470|Experimental|Ethyl chloride|Pre cooling done by the application of single spray ethyl chloride on a cotton pellet and placed for 30 seconds at the injection site for numbing effect
9883972|NCT05306470|Experimental|5% lidocaine gel|5% lidocaine gel 2ml applied on a cotton pallet for 30 seconds on the oral mucosa at the site of injection for the numbing effect
9883973|NCT05306470|No Intervention|control|Local anesthesia infiltration is administrated without using any numbing agent
9883974|NCT05306015|Experimental|test group|Patients undergoing brain-computer interface-based mindfulness meditation training during the perioperative period of radiofrequency ablation.
9883975|NCT05306015|Active Comparator|control group|Patients receiving routine care for radiofrequency ablation.
9883976|NCT05305638|Experimental|Experimental Group|
9883977|NCT05305638|Experimental|Control Group|
9883978|NCT05305430||Prospective|All patients for whom the decision has been made to have the Synergy Disc implanted at participating investigative centers and give informed consent to participate in the prospective segment of this protocol, per country-specific requirements, will be enrolled in the prospective portion of this protocol.
9883979|NCT05305430||Retrospective|Patients who have previously had a Synergy Spine Solutions Synergy Disc implanted will be eligible for inclusion in the retrospective data collection; a waiver of consent, or informed consent, for retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations as applicable.
9883980|NCT05305170||HF|Patients with heart failure.
9883981|NCT05305170||Controls|Controls without heart failure.
9883982|NCT05304936|Experimental|HCW9218|Experimental Arm: HCW9218
9883983|NCT05304611|Experimental|Adult Dose-escalation study: Arm 1: 300 mg of L9LS|Participants will receive 300 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 2.
9883984|NCT05304611|Experimental|Adult Dose-escalation study: Arm 2: 600 mg of L9LS|Participants will receive 600 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 3.
9883985|NCT05304611|Experimental|Adult Dose-escalation study: Arm 3: 20 mg/kg of L9LS|Participants will receive highest dose of 20 mg/kg IV of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for subjects aged 6 -10 years.
9883986|NCT05304611|Experimental|Subject 6-10 years Dose-escalation study: Arm 1: 150 mg of L9LS|Subjects age 6-10 years will receive 150 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin arm 2.
9883987|NCT05304611|Experimental|Subject 6-10 years Dose-escalation study: Arm 2: 300 mg of L9LS|Subjects age 6-10 years will receive 300 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin weight de-escalation.
9883988|NCT05304611|Placebo Comparator|Subject 6-10 years Dose-escalation study: Arm 3: Placebo|Half of subjects age 6-10 will receive placebo of Normal Saline for comparison.
9883989|NCT05304611|Experimental|Efficacy study: Arm 1: 150 mg of L9LS|75 children age 6-10 will receive 150 mg of L9LS.
9883990|NCT05304611|Experimental|Efficacy study: Arm 2: 300 mg of L9LS|75 children age 6-10 will receive 300 mg of L9LS.
9883991|NCT05304611|Placebo Comparator|Efficacy study: Arm 3: Placebo|75 children age 6-10 will receive normal saline placebo.
9883992|NCT05304442|Experimental|Intravenous Ferric Derisomaltose|One single dose of ferric derisomaltose, 1000 mg Intravenous over at least 20 minutes.
9883993|NCT05304442|Active Comparator|Oral Iron|ferrous sulfate 65 mg once daily for 42 days.
9883994|NCT05304403||Chronic Opioid User|Patients identified to have chronic opioid use (identified in chronic pain clinic)
9883995|NCT05304403||Healthy Control|These patients will not be actively recruited in this study. The investigators will use national microbiome dataset as a comparison.
9883996|NCT05303935|Experimental|Quetiapine|Quetiapine 50mg in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
9883997|NCT05303935|Placebo Comparator|Placebo|Placebo sugar pill in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
9883998|NCT05303233|Experimental|TIBIAL group|All patients allocated to the TIBIAL group will receive an adductor canal block with 20ml of ropivacaine 0.75% and a selective tibial nerve block with 5 ml of ropivacaine 0.75% prior to surgery,
9517703|NCT03303833||Persons with Lynch syndrome|
9883999|NCT05303233|Active Comparator|IPACK group|All patients allocated to the IPACK group will receive an adductor canal block with 20ml of ropivacaine 0.75% and an IPACK with 20ml of ropivacaine 0.2% prior to surgery.
9884000|NCT05302947||Baricitinib|group included patients received Baricitinib in addition to standard of care therapy
9884001|NCT05302947||Tocilizumab|group included patients received Tocilizumab in addition to standard of care therapy
9884002|NCT05302947||Netakimab|group included patients received Netakimab in addition to standard of care therapy
9884003|NCT05302947||Control|group included patients received only standard of care therapy at the time of hospital admission according to the corresponding COVID-19 Russian guidelines 2020.
9884004|NCT05302804|Experimental|Menthol gel application|Menthol gel will be applied to the skin prior to exercise in the heat
9884005|NCT05302804|Placebo Comparator|Hypoallergenic gel application|A hypoallergenic gel will be applied to the skin prior to exercise in the heat
9997305|NCT01507636|Active Comparator|Group 2|Physical therapy using the Theraband for training of force.
9997306|NCT01507649|No Intervention|Control|
9884006|NCT05302388|Experimental|Experimental group|Drug: SIBP-R002 & Dexamethasone/Methyl prednisolone & Diphenhydramine Starting from the lowest dose, when the former dose does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD).
9884007|NCT05302388|Placebo Comparator|Placebo control group|Placebo control: The same volume of placebo as SIBP-R002 & Dexamethasone/Methyl prednisolone & Diphenhydramine The rule and dose of placebo were the same as SIBP-R002.
9884008|NCT05302089|Experimental|One-time physiotherapy instruction|One-time physiotherapy instruction and no usual rehabilitation care
9884009|NCT05302089|Active Comparator|Usual rehabilitation care|One-time physiotherapy instruction and usual rehabilitation care
9884010|NCT05301959|Experimental|Experimental group|A single weekly intervention of low intensity galvanic currents will be applied in an ultrasound-guided manner.
9884011|NCT05301959|Sham Comparator|Simulated group.|The application of a single weekly intervention of low intensity galvanic currents will be simulated in an echogenic way, with the equipment turned off.
9884012|NCT05301946||Stroke patients|The created-ICF Core Set for Stroke including activitiy, participation, and environmental factors was used show the meaningfulness of the clinical outcome measurements. The correlation of the created-ICF Core Set for Stroke's items and the outcome measurements were analyzed through Spearman or Pearson correlation analysis.
10213757|NCT03373253||Participants With Diagnosis of Depression|This study will evaluate participant's socio-demographic, disease-related and treatment-related characteristics along with outcomes in routine clinical practice across the European region. Only data available within clinical practice, through routine therapeutic procedures and diagnostic assessments, will be recorded. Individual participant information will be recorded from participant's medical records or by use of specific questionnaires.
9884016|NCT05299983|Experimental|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
9884017|NCT05299983|Active Comparator|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice:~North American Menopause Society: https://www.menopause.org/for-women~National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
9884018|NCT05298605|Experimental|Faith in Action!|"A train-the-trainer approach will be used to educate lay health navigators to present the culturally adapted Faith in Action! curriculum and to provide breast cancer screening navigation to Korean American women within faith-based settings"
9884019|NCT05298605|Active Comparator|Control|A presentation of lifestyle recommendations (e.g., physical activity, nutrition) will be provided to control groups.
9884020|NCT05298241|Experimental|Hand-grip Strength Game|Participants will receive a hand-grip strength game for 5-20 minutes twice a day for consecutive three days.
9884021|NCT05298241|No Intervention|routine care|The control group will not involve hand-grip strength game at night.
9884022|NCT05297825|Experimental|Vegan|Participants will be asked to consume a healthy vegan diet.
9884023|NCT05297825|Experimental|Omnivore|Participants will be asked to consume a healthy omnivore diet.
9884024|NCT05297695|Experimental|Study group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will receive H. pylori eradication therapy.
9884025|NCT05297695|No Intervention|Control group|Children with drug-resistant idiopathic generalized epilepsy and positive H. pylori stool antigen test who will not receive H. pylori eradication therapy.
9884026|NCT05296616|Experimental|MSQSLHRV|The group in which the mindfulness-based stress reduction intervention will be implemented.
9884027|NCT05296616|No Intervention|Control|The group to which mindfulness-based stress reduction intervention will not be applied
9884028|NCT05295940|Experimental|LY3841136 (Part A)|Single ascending doses of LY3841136 administered subcutaneously (SC).
9884029|NCT05295940|Experimental|LY3841136 (Part B)|Multiple ascending doses of LY3841136 administered SC.
9884030|NCT05295940|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
9884031|NCT05295940|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
9884032|NCT05293782|Active Comparator|Kinesiotaping on trunk flexor muscles|Kinesiotaping
9884033|NCT05293782|Active Comparator|Kinesiotaping on trunk extensor muscles|Kinesiotaping
9517704|NCT03303807|Other|Extracorporeal CO2 removal|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
9517705|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
9517706|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
9884034|NCT05293782|Placebo Comparator|Placebo Kinesiotaping on trunk flexor muscles|Kinesiotaping
9884035|NCT05293782|Placebo Comparator|Placebo Kinesiotaping on trunk extensor muscles|Kinesiotaping
9884036|NCT05291611|Experimental|Treatment with cbt|Treatment for 26 patients with obsessive-compulsive disorder, 14 sessions, each about 90 minutes.
9884037|NCT05291468|Active Comparator|C Acnes present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
9884038|NCT05291468|Placebo Comparator|C Acnes present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
9884039|NCT05291468|Active Comparator|C Acnes NOT present in granulomatous tissue, treatment with antibiotics|patients who are in this arm will receive azithromycin and doxycycline for 3 months
9884040|NCT05291468|Placebo Comparator|C. Acnes NOT present in granulomatous tissue, treatment with placebo|patients who are in this arm will receive placebo for 3 months
9884041|NCT05291078|Experimental|Experimental Group A|Tinnitus patients(n=12 people)
9884042|NCT05291078|Experimental|Experimental Group B|Tinnitus patients(n=12 people)
9884043|NCT05291078|Sham Comparator|Control Group|Tinnitus patients(n=12 people)
9884044|NCT05288218|Experimental|Leak-free bronchoscope adapter|"The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. The intervention is considered the leak-free bronchoscope adapter."
9884045|NCT05288218|Active Comparator|Standard bronchoscope adapter|The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. This arm utilizes the standard adapter.
9884046|NCT05287763|Active Comparator|Gelatin Sponge|The palatal wound will be protected with an absorbable gelatin sponge, which will be stabilized by non-resorbable sling sutures.
9884047|NCT05287763|Experimental|Collagen Sponge|The palatal wound will be protected with a collagen sponge, which will be stabilized by non-resorbable sling sutures.
9884048|NCT05286879|Other|Patient Navigator|Navigators will assist linking study participants to appropriate community service providers
9884049|NCT05286879|Other|Mobile Health Unit|Study participants will be linked to a MHU within their community
9884050|NCT05285202|Experimental|Hotspot-focused ACF/TPT|ACF/TPT intervention will be delivered in a community setting, in geographic areas judged likely to have a high burden of undiagnosed TB
9884051|NCT05285202|Experimental|Facility-based ACF/TPT|ACF/TPT intervention will be delivered on the grounds of a health facility (hospital or large public health center)
9884052|NCT05285202|No Intervention|No intervention|
9884053|NCT05284071|Experimental|Experimental: Single-Arm|This is a prospective, single-arm, post-market study to verify clinical performance, treatment satisfaction and adherence, and safety of Actiste 1.0 (Actiste) and the Companion app with TBL Backend when used as intended by subjects diagnosed with T1DM or T2DM.
9884054|NCT05279742|Experimental|HFpEF-CKD with MANP and oral placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug MANP and an oral placebo followed by a 1 week washout period.
9884055|NCT05279742|Experimental|HFpEF-EI with MANP and oral placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug MANP and an oral placebo followed by a 1 week washout period.
9884056|NCT05279742|Experimental|HFpEF-CKD with Sacbitril/Valsartan with an injected placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug Sacbitril/Valsartan and an injected placebo followed by a 1 week washout period.
9884057|NCT05279742|Experimental|HFpEF-EI with Sacbitril/Valsartan with an injected placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug Sacbitril/Valsartan and an injected placebo followed by a 1 week washout period.
9884058|NCT05279742|Placebo Comparator|HFpEF-CKD with an oral and injected placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive an oral and injected placebo followed by a 1 week washout period.
9884059|NCT05279742|Placebo Comparator|HFpEF-EI with an oral and injected placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive an oral and injected placebo followed by a 1 week washout period.
9884060|NCT05279677|Experimental|FMT|Fecal microbiota transplantation plus Sintilimab and Fruquintinib
9884061|NCT05273879|Other|decompression group|minimally invasive decompression without fusion
9884062|NCT05273879|Other|fusion group|minimally invasive decompression with trans-foraminal interbody fusion
9884063|NCT05273671|Experimental|nalbuphine|0.1 mg/kg nalbuphine diluted in 10 ml I.V 10 minutes before the end of surgery
9884064|NCT05273671|Experimental|dexmedetomedine|receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
9884065|NCT05273671|Placebo Comparator|saline|receive a saline solution 10 min before the end of surgery
9884066|NCT05268731||Extrahepatic bile duct obstruction and failed ERCP|"Patients with extrahepatic bile duct obstruction and obstructive jaundice have received a percutaneous transhepatic biliary drainage.~The choice between an insertion of an external or an external/internal drainage has been made during the procedure depending on whether the guide wire could be accessed to the jejunum/duodenum or not.~The choice between internal/external drainage or a primary metal stent has been made by the investigators preference or was made on the basis of an existing malign bile duct obstruction or not."
9884067|NCT05267574|Experimental|REN001|100 mg once daily
9884068|NCT05262387|Experimental|Lyumjev|Lyumjev administered subcutaneously (SC) during a meal and following different approaches for basal reduction prior to exercise
9989314|NCT01431625|Active Comparator|COPD with airway-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The helical scan is performed using 120 kVp, 50 mA, 3-mm collimation, and pith 1.0. The dimensions of the right apical segmental bronchus are measured and WA% is calculated. The cut-off level between high or low WA% is the mean + 2SD of WA% of the asymptomatic non-COPD smokers.
9989315|NCT01431651|Experimental|probiotic, lifestyle counseling|
9989316|NCT01431690|Experimental|Warfarin and Epanova|
9989317|NCT01431690|Active Comparator|Lovaza|
9989318|NCT01431729||mucositis|
9989319|NCT01431742|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
9989320|NCT01431781|Experimental|stilamin+common daily treatment|
9989321|NCT01431781|Active Comparator|common daily treatment|
9989322|NCT01431807|Experimental|SYR-472 group|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
9989323|NCT01431833|Experimental|Moderate hepatic|
9989324|NCT01431833|Experimental|Severe Hepatic|
9989325|NCT01431833|Experimental|Matched control|
9989326|NCT01431859|Placebo Comparator|Subcutaneous injection of placebo|
9989327|NCT01431859|Active Comparator|Birch pollen immunotherapy|
9989328|NCT01431872||Post menopausal breast cancer patients|
9989329|NCT01431885|Active Comparator|PLAT|Diagnosis of preterm labor will be made by the March of Dimes Preterm Labor Assessment Toolkit Algorithm B, incorporating transvaginal ultrasound measurement of cervical length, and vaginal fetal fibronectin
9989330|NCT01431885|Placebo Comparator|Cervical Change|Diagnosis of preterm labor will be made by cervical change by digital examination
9989331|NCT01431898|Experimental|Multiple-dose, dose-escalation study of GS-9669|Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
9989332|NCT01431911||Patients diagnosed with COPD|Patients diagnosed with COPD using ICD codes with a COPD-related exacerbation and receiving maintenance therapy
9989333|NCT01431924||Adolescent and adult patients with asthma|Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination
9989334|NCT01431937|Active Comparator|GSK2018682|Active Drug
9989335|NCT01431937|Placebo Comparator|Placebo Control|Placebo
9989336|NCT01432028|Active Comparator|Non-oral hormone therapy|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
9989337|NCT01432028|Active Comparator|oral homone therapy|estradiol 1mg and drospirenone 2 mg/day
9989338|NCT01432067|Other|Adaptated physical activity|Physical activity advices adaptated to physical status of patients
9989339|NCT01432067|Other|Standard physical activity|Daily physical activities based on a standard guide
9989340|NCT01432080|No Intervention|Standard of Care|Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
9989341|NCT01432080|Experimental|SAMS|Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).
9989342|NCT01432093|Active Comparator|Intensive glycemic management|Multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
9989343|NCT01432093|Active Comparator|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
9989344|NCT01432106|Active Comparator|Aliskiren/Valsartan (Valturna)|Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
9997307|NCT01507649|Experimental|Telephone-based intervention|
9884069|NCT05262387|Active Comparator|Humalog|Humalog administered SC during a meal and following different approaches for basal reduction prior to exercise
9884070|NCT05261009|Experimental|Peri-capsular Nerve Group (PENG)|Those subjects assigned to the PENG treatment arm will receive a PENG block using 20mL of 0.2% ropivacaine with 1:400,000 epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
9884071|NCT05261009|Active Comparator|Lumbar Plexus Block (LPB)|Those subjects assigned to the LPB treatment arm will receive a stimulation-based LPB dosed with 20cc of 0.2% ropivacaine with 1:400,000 dilution epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
9884072|NCT05260346|Placebo Comparator|Placebo|Cranberry flavored drink, once daily, in a 8fl oz bottle. Identical in appearance and taste compared with the treatment.
9884073|NCT05260346|Active Comparator|Cranberry juice|100% cranberry juice, once daily, in a 8fl oz bottle.
9884074|NCT05259696|Experimental|Dose Escalation - Monotherapy|"Subjects will receive E-602 as monotherapy.~Planned monotherapy dose levels: 1 mg/kg, 3 mg/kg, 10 mg/kg, and 20 mg/kg."
9884075|NCT05259696|Experimental|Dose Escalation - Combination|"Subjects will receive E-602 in combination with pembrolizumab.~E-602 dose(s): Will be initiated at dose level(s) that have previously completed dosing and DLT assessments as monotherapy.~Pembrolizumab dose: 200 mg."
9884076|NCT05259696|Experimental|Expansion - Monotherapy|Subjects will receive E-602 as monotherapy at the recommended Phase 2 dose determined in Phase 1.
9884077|NCT05259696|Experimental|Expansion - Combination|"Subjects will receive E-602 in combination with pembrolizumab.~E-602 dose: Subjects will receive E-602 at the recommended Phase 2 dose determined in Phase 1 in combination with pembrolizumab.~Pembrolizumab dose: 200 mg."
9884078|NCT05257551||Patients with Small Cell Lung Cancer (SCLC)|This protocol will include participants with newly diagnosed extensive stage (stage IV) small cell lung cancer with tissue collected from the primary lung tumor, or metastatic sites outside of the liver or biliary system.
9884079|NCT05254002|Experimental|Finerenone and empagliflozin|Participants will take finerenone and empagliflozin for up to 180 days.
9884080|NCT05254002|Experimental|Finerenone and empagliflozin placebo|Participants will take finerenone and placebo to empagliflozin for up to 180 days.
9884081|NCT05254002|Experimental|Empagliflozin and finerenone placebo|Participants will take empagliflozin and placebo to finerenone for up to 180 days.
9884082|NCT05251948|Active Comparator|Atezo + CAPOX (capecitabine + oxaliplatin)|Participants in the atezolizumab plus capecitabine plus oxaliplatin in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
9884083|NCT05251948|Experimental|Atezo + CAPOX +Tir|Participants in the atezolizumab plus capecitabine plus oxaliplatin plus tiragolumab arm in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
9884084|NCT05250856|Experimental|CNP-201 250 mg|200 mL intravenous infusion on Day 1 and Day 8: 250 mg CNP-201
9884085|NCT05250856|Experimental|CNP-201 450 mg|200 mL intravenous infusion on Day 1 and Day 8: 450 mg CNP-201
9884086|NCT05250856|Experimental|CNP-201 650 mg|200 mL intravenous infusion on Day 1 and Day 8: 650 mg CNP-201
9884087|NCT05250856|Placebo Comparator|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
9884088|NCT05248126|Active Comparator|Comparator arm|All patients randomized to this arm will participate in a standard patient education program.
9884089|NCT05248126|Experimental|Experimental arm|All patients randomised to this arm have the opportunity to participate in a patient education programme via a chatbot.
9884090|NCT05247528|Placebo Comparator|Placebo Comparator|"Subjects randomized to the placebo arm, will receive a single subcutaneous injection each morning daily.~Intervention: Placebo"
9884091|NCT05247528|Experimental|MANP|"Subjects randomized to the experimental arm, will receive a single subcutaneous injection each morning daily. (multiple ascending dose cohorts)~Intervention: Drug: MANP"
9884092|NCT05245357|Experimental|Lentil, then Control|Participants first received a meal with 140 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 0 g of lentils in the morning.
9884093|NCT05245357|Experimental|Control, then Lentil|Participants first received a meal with 0 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 140 g of lentils in the morning.
9935482|NCT03648905||Patients with neurodegenerative chronic autonomic failure (CAF)|Includes patients with orthostatic hypotension (OH) due to sympathetic neurocirculatory failure (nOH), and people with multiple system atrophy (MSA).
9935483|NCT03648892|Other|Main|Healthy volunteers, within three BMI strata, under controlled overnight fasting conditions following a period of dietary stabilization
9884094|NCT05243719|Experimental|Treatment Options 1, 2, 3, 4, 5|Participants will fall into 1 of 5 treatment options dependent on the treatment received (ADP101 or placebo) during the parent study and their tolerance of the treatment regimen during the parent study.
9884095|NCT05242315|Active Comparator|Envarsus|Envarsus tablet Dose 0.11 - 0.13 mg/Kg/day Frequency: once per day
9884096|NCT05242315|Other|Prograf (SOC)|Prograf tablet Dose 0.10 - 0.15mg/Kg daily Frequency: 2 doses per day (dose above split in half for each dose)
9884097|NCT05241613|Experimental|AC176 Dose Escalation as Single Agent|Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
9884098|NCT05240742||Dutch COVID-19 patients|"The study population consists of Dutch (former) COVID-19 patients who have been included in one of the cohorts and categorized in various subgroups:~Patients who suffered from (confirmed) COVID-19 and were admitted to the hospital ward.~Patient who suffered from (confirmed) COVID-19 and were admitted to the ICU.~Patients who suffered from (confirmed or suspected) COVID-19 at home.~Patients who suffered from (confirmed) COVID-19 and were in need of inpatient or outpatient rehabilitation after infection at home or in the hospital (ward and/or ICU)."
9884099|NCT05240742||Dutch controls who did not experience COVID-19|One of the cohorts, the POPCOrn cohort, is a community-based cohort which partly consists of controls who did not experience COVID-19
9884100|NCT05238896|Experimental|Baricitinib|Patients receiving baricitinib 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
9884101|NCT05238896|Placebo Comparator|Placebo|Patients receiving placebo 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
9884102|NCT05238545|Experimental|PD gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
9884103|NCT05238545|No Intervention|PD gluten-containing diet group|Subjects with PD on regular, gluten-containing diet, i.e. no restrictions during eating.
9884104|NCT05238545|Experimental|MSA gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
9884105|NCT05238545|No Intervention|MSA gluten-containing diet group|Subjects with MSA on regular gluten-containing diet, i.e. no restrictions during eating.
9884106|NCT05238233|Experimental|Eye Dilation and Constriction|"Participants screened for hyperopia >+1 diopter using a phoropter, have their intraocular pressures measured using a tono pen, and have their iridocorneal angle measured with a gonio lens.~Proparacaine hydrochloride 0.5% eye drops will be used to numb the eyes before measuring intraocular pressures and prior to gonio lens.~The following day, the participant will receive one drop of tropicamide and one drop of 1% pilocarpine in the left eye.~If the left eye has no response to the 1% pilocarpine, or if the diameter of the pupil returned to baseline size, we will ask participants to come back to the clinic on another day to have the process repeated in the right eye."
9884107|NCT05236725|No Intervention|Standard of Care (SOC)|Subjects randomized to SOC arm are provided with the appropriate standard of care depending upon their risk level (as determined by their individual provider or WFBMC Maternal-Fetal Medicine provider)
9884108|NCT05236725|Experimental|Remote Blood Pressure Monitoring (rBPM)|"Subjects randomized to rBPM arm receive the appropriate standard of care depending upon their risk level, as well as the remote BP monitoring app (BabyScripts) and Bluetooth enabled BP cuff/monitor, and will receive the following equipment and monitoring:~a specialized, Bluetooth enabled BP monitoring cuff (Clinically Validated, A&D Medical Wireless Blood Pressure Monitor-Upper Arm (Appendix 2) on loan to be used for the duration of the study (21 days total).~BP monitoring smart phone app, BabyScripts™~Verbal and written instructions, to conduct BP checks at home"
9884109|NCT05236114||Cohort 1|Cohort 1 will include patients with early-stage and locally advanced disease (stages I-IIIa) who are candidates for definitive surgical resection.
9884110|NCT05236114||Cohort 2|Cohort 2 will include patients who have advanced or metastatic disease (stages IIIB-IV) and are not surgical candidates.
9884111|NCT05234177||Participants with stage I-IV colorectal cancer (CRC)|This protocol will include participants with stage I-IV CRC who are scheduled to undergo or have undergone a surgical resection with curative intent.
9884112|NCT05233787|Experimental|Arm A: Tailored use of defunctioning stoma after TME|"The tailored use of defunctioning stoma includes two steps:~Firstly, the decision to use or not a defunctioning stoma will be based on the personalized risk of anastomotic leakage (according to AFOR score). This score is ranked from 0 to 6, and includes gender, Body Mass Index, smoking, diabetes, tumor size and preoperative radiotherapy.~Patients with AFORS equal to 0 or 1 (risk of anastomotic leakage less than 10%) will not have defunctioning stoma;~Patients with AFORS equal to or between 2 and 6 (risk of anastomotic leakage more than 20%) will have a defunctioning stoma.~Secondly, in patients with a defunctioning stoma, an early closure will be performed day 8-12 after TME if:~No fever postoperatively (≤ 38°C),~CRP at day 2 lower than 115mg/L (+/- 10 mg/L), decreasing at day 4,~CT-scan with colonic contrast retrograde enema showing no anastomotic leakage."
9884113|NCT05233787|Active Comparator|Arm B: Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 3 months after TME according to French national guidelines
9884114|NCT05231707|Experimental|Intervention|For couples who are prevalent sero-discordant, this will be a CHTC session. For couples who are prevalent concordant HIV-positive, the first visit will be the first Partner Steps session. For couples in which one or both do not know their sero-status or have not tested for HIV in the past 12 months, the first session will be a CHTC session.
9884115|NCT05231707|Active Comparator|Attention Matched Control|Participants in the control group will receive an intervention, with the same number of sessions as couples of the same sero-status in the intervention condition, delivered via one-on-one couples counseling sessions (i.e., one couple with one counselor).
9884116|NCT05229900|Experimental|SGN-ALPV|SGN-ALPV monotherapy
9884117|NCT05229484|Experimental|Intervention Group: an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
9884118|NCT05229484|No Intervention|Control group|The control group is the Treatment as Usual (TAU).
9884119|NCT05227365|Other|Single Treatment Arm Study|The Lenire device is a CE marked medical device intended to reduce the symptoms of tinnitus. It comprises a handheld controller, an intra-oral device called a Tonguetip that delivers gentle electrical stimulation to the tongue, and a set of wireless headphones that deliver audio stimulation to the ears. The sound and tongue stimulation are configured and calibrated to individual participant hearing and sensation characteristics during the initial fitting procedure completed by a trained clinician. The participants will receive 12 weeks of treatment, in which the first 6-weeks will consist of sound-only stimulation (PS6-No ETS) and the second 6-weeks will consist of bimodal stimulation (PS6, includes sound and tongue stimulation).
9884120|NCT05225857|Experimental|AGA2118|"In SAD part, various single doses of AGA2118 will be administered to the participants via either SC injection or IV infusion. The starting dose was 0.3 mg/kg, with sequential escalation up to 15 mg/kg.~In MAD part, various multiple doses of AGA2118 will be administered every four weeks (Q4W) to the participants via SC injection for 12 weeks. The starting dose was 1 mg/kg, with sequential escalation up to 6 mg/kg."
9884121|NCT05225857|Placebo Comparator|Placebo|"In SAD part, a single dose of placebo comparator will be used for each cohort of either SC or IV administration.~In MAD part, multiple doses of placebo comparator will be used for each cohort of SC administration."
9884122|NCT05225363|Experimental|Treatment (TAG72-CAR T cells)|Patients receive fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients receive TAG72-CAR T cells IP on day 0.
9884123|NCT05222750||Pre-COVID-19|
9884124|NCT05222750||COVID-19|
9884125|NCT05222750||COVID-19 vaccination roll - out|
9884126|NCT05221866|No Intervention|Control|UControlPain App with only data collection function. No provider-facing prescription intervention.
9884127|NCT05221866|Active Comparator|UControlPain educational app only|UControlPain app with education components. No provider-facing prescription intervention.
9884128|NCT05221866|Active Comparator|UControlPain app AND provider facing tool|UControlPain app with education components and provider-facing prescription intervention.
9884129|NCT05221866|Active Comparator|Provider facing tool only|UControlPain App with only data collection function. Provider-facing prescription intervention.
9884130|NCT05220722|Experimental|SD-101|Three weekly doses of SD-101 given over two cycles via HAI using the PEDD method of administration.
9884131|NCT05218967|Experimental|In-office procedure with VR-assistance|
9884132|NCT05218967|No Intervention|In-office procedure without VR-assistance|
9884133|NCT05217953|Experimental|Test Group|"The CGM will be integrated with the users mobile handset and all relevant measures taken will be entered. Participant will be provided with a smart watch and this will also be integrated with the users smartphone.~The user will then download and install the LovedBy mobile app. Once installed the user will set up an account and the account number will be recorded by the clinical research team to track the participant throughout the trial. The final step is to review the permissions of the mobile application and allow the mobile application to connect to the users handset"
9884134|NCT05217953|No Intervention|Control-Group|The same measurements will be taken as with the test group but here no app will be provided to the participants in this group.
9884135|NCT05216835|Experimental|Cohort A: Dose Escalation|Patients with anti-PD-1/PD-L1 exposed r/r cHL will receive AZD7789.
9884136|NCT05216835|Experimental|Cohort B1: Dose Expansion|Patients with anti-PD-1/PD-L1 exposed r/r cHL will receive AZD7789 once the recommended phase 2 dose (RP2D) has been determined.
9884137|NCT05216835|Experimental|Cohort B2: Dose Expansion|Patients with anti-PD-1/PD-L1 naïve r/r cHL will receive AZD7789 once the RP2D has been determined.
9884138|NCT05214456|Experimental|Interventional group|The interventional group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include dry needling plus sham mobilization for the lumbar spine and routine physiotherapy. The needles will be inserted to obtain local twitch responses, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes. Sham mobilization for the lumbar spine will be done in the same way as the real mobilization, with the difference that the mobilization will be applied only on the skin surface and less than the first degree of Maitland's mobilization. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
9884139|NCT05214456|Active Comparator|Control group|The control group will comprise 28 participants with chronic non-specific low back pain. The treatments of this group will include anterior-posterior mobilization based on the Maitland technique for the lumbar spine plus sham dry needling and routine physiotherapy. Based on the findings of the patient evaluation, the severity, rhythm, time, the degree of mobilization and the place of force (spine or lamina) will be determined. For sham dry needling The needles will be inserted subcutaneously and there will be no local twitch response. Then the needles will be left in place for 20 minutes. Routine physical therapy will include low-level laser therapy and motor control training. The treatment will last 4 weeks, 8 sessions, twice a week.
10211724|NCT04249323|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT113176 and the prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 3 will depend on data review for Part 1. Part 3 will proceed only if sufficiently high plasma CORT113176 exposure is achieved in Part 1.
10211725|NCT04227821||Hemodynamically instable pediatric patients|Pediatric patients admitted to the pediatric intensive care unit with the need of vasopressor and/or inotrope therapy due to hemodynamic instability
9884142|NCT05212727||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
9884143|NCT05212402|Experimental|Test Product|28 participants will be given the test product (TP)
10211726|NCT04227327|Experimental|Abemaciclib + aromatase inhibitors|Abemaciclib will be administered at 150 mg twice daily orally + Letrozole 2,5 mg daily or Anastrozole 1 mg daily
9884144|NCT05212402|Placebo Comparator|Placebo|28 participants will be given the placebo product.
9884145|NCT05208762|Experimental|SGN-PDL1V|SGN-PDL1V monotherapy
9884146|NCT05204927|Active Comparator|Standard Of Care Hormone Therapy|Abiraterone with Prednisone or Enzalutamide
9884147|NCT05204927|Experimental|Investigational Drug|Lu-177-PSMA-I&T
9884148|NCT05201014|Active Comparator|1 year follow-up|patients who were treated in the year before and are now returning for their 1-year follow-up.
9884149|NCT05201014|Active Comparator|Prior to anthracycline-based therapy|patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.
9884150|NCT05200975|Other|Adequate renal function|Patients with adequate renal function (egfr>30ml/min) receiving a regular cefuroxime dose
9884151|NCT05200975|Other|Impaired renal function|Patients with impaired renal function (egfr<30ml/min) receiving a guideline recommended reduced dose
9884152|NCT05198934|Experimental|Arm A: Sotorasib 960 mg once daily (QD) + panitumumab|
9884153|NCT05198934|Experimental|Arm B: Sotorasib 240 mg once daily (QD) + panitumumab|
9884154|NCT05198934|Active Comparator|Arm C : Investigator's choice|Participants will be administered trifluridine and tipiracil, or regorafenib
9884155|NCT05196399|Experimental|Aprocitentan (reference product)|25 mg film-coated tablet
9884156|NCT05196399|Experimental|Aprocitentan (test product)|25 mg film-coated tablet
9884157|NCT05193955|Experimental|Intervention Group|undergraduate students who practice laughter yoga and simulation education together
9884158|NCT05193955|No Intervention|Control Group|undergraduate students who practice simulation education
9884159|NCT05191940|Other|Particle radiotherapy|According to the radiation plan using protons or carbon ions (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
9884160|NCT05190588|No Intervention|Exercise|Quadriceps Strength 10 repetition in three-set, 5 times a week
9884161|NCT05190588|Active Comparator|Mesotherapy|Group 2: Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used. One time a week for a total of 3 times.
9884162|NCT05189470|Other|Control group|These participants will receive the usual care of the respective outpatient clinics.
9884163|NCT05189470|Experimental|Intervention group|Participants that are randomized to the intervention group will receive both inforatio technique and usual care. Inforatio technique will be applied at baseline, 3, 6, 9 and 12 week- follow-up as long as the ulcers have a diameter of minimum four mms and have not developed infection, necrosis, positive probe-to-bone test, exposure of joint or tendon; or underlying osteomyelitis. In addition, inforatio technique will not be applied on ulcers that are covered by scab if the wound care staff assess that the scab should not be removed from the ulcer.
9884164|NCT05189366|Experimental|Experimental arm : Speech therapy + Sophrology|"In the experimental arm, patients will receive 6 sessions of sophrology. The sessions are individual and last approximately 50 minutes.~In addition to the sophrology sessions, patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition."
9884165|NCT05189366|Active Comparator|Control arm : Speech therapy|Patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
9884166|NCT05188196|Active Comparator|Collagen Membrane|ridge preservation with collagen membrane + collagenated bovine bone mineral
9884167|NCT05188196|Experimental|Collagen Sponge|ridge preservation with collagen sponge + collagenated bovine bone mineral
9884168|NCT05187546|Experimental|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of PSP patients|All eligible PSP patients will receive two injections of the investigational imaging agent [18F]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 10 PSP patients will be required to complete the study arm.
9997308|NCT01507675||Military Veterans|Participants will be recruited from the Denver VA Medical Center (DVAMC), regardless of clinic.
9997309|NCT01507701|Experimental|Clonidine|
9517707|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
9517708|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
9989345|NCT01432106|Active Comparator|Ramipril|Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
9989346|NCT01432119|Experimental|Arm 1 SIR-Spheres + Cetuximab|"Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
9989347|NCT01432119|Experimental|Arm 2 SIR-Spheres + Cetuximab + Erlotinib.|"Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
9989348|NCT01432132||Head & Neck Patients|Patients undergoing surgical treatment for head and neck cancer.
9989349|NCT01432132||Clinicians|Clinical staff who care for head and neck surgical participants during active treatment.
9989350|NCT01432158|Experimental|PCV-13 group|1 dose of Prevenar-13
9989351|NCT01432158|Experimental|PPV-23 group|1 dose of Pneumovax-II
9989352|NCT01432184|Active Comparator|Intervention|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
9989353|NCT01432184|No Intervention|Control|the cerebral oxymetry screen will be blinded and changes in NIRS values will be unknown to the anesthesiologist. The management of the case will proceed as per normal local practice. The screen will remain blinded in the ICU and the intensivist will not see the values.
9989354|NCT01432197|Experimental|Occupational therapy intervention|"Intervention group: Standard treatment and care added with an ADL intervention program: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.~Control group: Standard treatment and care. No occupational therapy intervention."
9989355|NCT01432197|No Intervention|Standard treatment and care|Control group: Standard treatment and care. No occupational therapy intervention.
9989356|NCT01432210|Other|Tomato Meal|A tomato meal will be fed with and without avocado.
9989357|NCT01432210|Other|Carrot Meal|A carrot meal will be fed with and without avocado.
9989358|NCT01432223|Experimental|Nab-paclitaxel|Nab-paclitaxel q3w 260mg/m2
9989359|NCT01432249||Enbrel|The patients who are prescribed Enbrel for pediatric psoriasis
9517709|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
9517710|NCT03303742|Experimental|feather edge finish line marginal design|intervention
9997310|NCT01507714|No Intervention|control arm|vaginal wall repair surgery will be done to women in this arm, with no treatment for stress incontinence
9997311|NCT01507714|Active Comparator|TVT-O arm|the women in this arm will have a TVT-O procedure in addition to the vaginal wall repair
9997312|NCT01507727|Experimental|Drug: Tolvaptan|
9997313|NCT01507727|Placebo Comparator|Drug: Placebo|
9997314|NCT01507740||1|Control group n=20
9997315|NCT01507740||2|investigational group (cancer patients) n=40 patients treated with antiangiogenic agent
9997316|NCT01507753|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
9997317|NCT01507753|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
9997318|NCT01507753|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
9997319|NCT01507753|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
9997320|NCT01507766|Experimental|Early enteral nutrition|The enteral nutrition was started within 48h after admission
9997321|NCT01507766|Active Comparator|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
9997322|NCT01507805|Experimental|EA preconditioning|electroacupuncture five days pre-operation
9997323|NCT01507805|Sham Comparator|Sham EA preconditioning|Patients treated with sham EA preconditioning Intervention
9997324|NCT01507818|Active Comparator|Ivivi Torino II|Active treatment with Non-thermal Pulsed Radio Frequency device
9997325|NCT01507818|Sham Comparator|Inactive Sham|Sham treatment
9997326|NCT01507844|Sham Comparator|ventilation|
9997327|NCT01507857|Experimental|400U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
9997328|NCT01507857|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28
9997329|NCT01507870|Active Comparator|prophylactic onlay mesh|
9997330|NCT01507870|No Intervention|continuous running suture|continuous running suture of the linea alba
9517711|NCT03303742|Active Comparator|deep chamfer finish line marginal design|comparator
9517712|NCT03303729|Experimental|Meat hydrolysate & Cluster Dextrin|Meat hydrolysate containing 25g of protein given together with 75 grams of Cluster Dextrin.
9884169|NCT05187546|Experimental|Imaging characteristics of [18F]PI-2620 for detection of Tau deposition in the brain of NDC subjects|All eligible non-demented control (NDC) subjects will receive two injections of the investigational imaging agent [18F]PI-2620: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 NDC subjects will be required to complete the study arm.
9884170|NCT05187520|Active Comparator|Patient-controlled epidural analgesia (PCEA)|Patients assigned to PCEA group will receive epidural analgesia as the standard postoperative pain control strategy. After completion of cesarean section, a PCEA device will be connected to the epidural catheter to deliver mixture of local anesthetic (0.8 mg/ml) and fentanyl (2 mcg/ml) with preset continuous dose of 3-5 ml/h and a bolus dose of 3-4 ml.
9884171|NCT05187520|Experimental|Naldebain®|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance after completion of cesarean section.
9884172|NCT05185583|Experimental|Sequence A: Methylphenidate, Placebo|Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.
9884173|NCT05185583|Experimental|Sequence B: Placebo, Methylphenidate|Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.
9884174|NCT05183646|Experimental|DMX-200 (repagermanium)|Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the treatment period (104 weeks)
9884175|NCT05183646|Placebo Comparator|Placebo|Patients will receive 120 mg immediate release capsules of Placebo twice daily
9884176|NCT05176704||CDR = 0.5|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Questionable/very mild dementia (CDR = 0.5)
9884177|NCT05176704||CDR = 1|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Mild dementia/MCI (CDR = 1)
9884178|NCT05176704||CDR = 2|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Moderate dementia (CDR = 2)
9884179|NCT05176704||CDR = 3|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Severe dementia (CDR = 3)
9884180|NCT05176704||Healthy Control|50 Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
9884181|NCT05174130|Experimental|Patients undergoing mechanical ventilation in stable phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
9884182|NCT05174130|Experimental|Patients undergoing mechanical ventilation in weaning phase|15 Patients will be changed from a basal reference ventilator to the RESPIRA ADVANCED device. The patient will be ventilated for the next 24 hours with the investigational medical device or until one withdrawal criteria is met according to clinical investigation plan. After 24 hours of ventilation with the investigational medical device, the patient will be changed to the previous conventional ventilation device.
9884183|NCT05165212|Experimental|Patients receiving one dose of amoxicillin.|Patients receiving one dose of amoxicillin and then observed for one hour for signs/symptoms off allergic reaction.
9884184|NCT05162781|Experimental|CICT with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
9884185|NCT05162781|Experimental|CICT without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
9931312|NCT00936949|Active Comparator|posterolateral approach|The posterolateral approach was described by many authors, but all share a common muscular interval in reference to the gluteus medius tendon. Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
9997331|NCT01507883||human oocytes/embryos|Sibling oocytes cultured in single or sequential media until day6
9517713|NCT03303729|Active Comparator|Meat hydrolysate & placebo|Meat hydrolysate containing 25g of protein given together with 75 grams of Glucose.
9517714|NCT03303703|No Intervention|Control|Usual cardiac rehabilitation and social phone calls for attention control.
9517715|NCT03303703|Experimental|Intervention|RENEwS intervention is five 60-minute group educational sessions.
9517716|NCT03303690|Experimental|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
9884186|NCT05162781|Active Comparator|BF-HELP with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
9884187|NCT05162781|Active Comparator|BF-HELP without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
9884188|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Well State|Subjects with confirmed PCD in Well State
9884189|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Sick State|Subjects with confirmed PCD in Sick State
9884190|NCT05161286||Healthy pain-free cohort|Healthy pain-free Dutch-speaking men and women between the age of 18 and 65 years
9884191|NCT05160701|No Intervention|Usual Care|Usual Care: no intervention elements.
9884192|NCT05160701|Active Comparator|Existing Medherent|Group using the Medherent Device with no added intervention components.
9884193|NCT05160701|Experimental|New Medherent|Group using Medherent Device with added interventional components.
9884194|NCT05160181||Yogatherapy|Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
9884195|NCT05157802|Experimental|Physical Activity Coaching|Participants will receive up to 5 individualized coaching sessions delivered via telehealth to facilitate and optimize exercise uptake. The therapist will facilitate discussion on specific and measurable goals, and will provide options for tracking their progress, such as written or web-based exercise logs or an activity monitor. The recommended exercises will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. Balance and strengthening exercises will also be recommended as appropriate.
9884196|NCT05155345|Experimental|Non-fractionated/Dose-finding|Participants will receive a single dose of mosunetuzumab.
9884197|NCT05155345|Experimental|Fractionated/Dose-escalation|Participants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.
9884198|NCT05154890|Experimental|ACN00177 Cohort 1|Planned for 4 subjects ≥18 years of age dosing at Dose A weekly for a total of 4 doses
9884199|NCT05154890|Experimental|ACN00177 Cohort 2|Planned for 4 subjects ≥12 years of age dosing at Dose B weekly for a total of 4 doses
9884200|NCT05154890|Experimental|ACN00177 Cohort 3|Planned for 4 subjects ≥12 years of age dosing at Dose C weekly for a total of 4 doses
9884201|NCT05154890|Experimental|ACN00177 Cohort 4|Planned for 4 subjects ≥12 years of age dosing at Dose D weekly for a total of 4 doses
9884202|NCT05154890|Experimental|ACN00177 Cohort 5|Optional cohort for 4 subjects ≥12 years of age dosing at Dose E weekly for a total of 4 doses
9884203|NCT05149703|Experimental|Mezieres Group|This intervention includes a total of three postures of the Mézières therapy. Specifically, the postures maintained for 12 weeks consist of: supine dancer; in supine position with the upper extremities abducted 120 °; and dancer in a sitting position.
9884204|NCT05149703|Active Comparator|Isostretching Group|This study aims to follow a total of 6 isostretching postures, the most similar to the Mezieres method. In each of the isostretching positions, if it is symmetric, 3, 6 or 9 repetitions will be performed and if it is asymmetric, 2, 4, or 8 repetitions.
9884205|NCT05147662|Experimental|Main study (Part A) and the extension study (Part B)|Part A will last for 6 months. After completing Part A participants will continue in the extension study for another 6 months.
9884206|NCT05146843|Experimental|Mitoquinone|MitoQ, 20 mg per day for three months
9884207|NCT05146843|Placebo Comparator|Placebo|Placebo, 20 mg per day for three months
9884208|NCT05145764|Experimental|Suvorexant|Nightly dosing of suvorexant
9884209|NCT05145764|Placebo Comparator|Placebo|Nightly dosing of placebo
9884210|NCT05145413|Experimental|Drug: KarXT|
9884211|NCT05145413|Placebo Comparator|Placebo|
9884212|NCT05142293||Sites selected for the same-day organisation|Patients will be admitted to the hospital and leave it on the same-day of the procedure.
9884213|NCT05142293||Sites with standard overnight hospitalization|Standard organisation with a minimum of one night's stay
9884214|NCT05139355|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
9884215|NCT05139355|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
9884216|NCT05139355|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil C. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
9884217|NCT05139355|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil.
9884218|NCT05138614|Experimental|Full MISSION|CTI + DRT + PS + MOUD
9884219|NCT05138614|Experimental|CTI & DRT|CTI + DRT + MOUD
9884220|NCT05138614|Experimental|CTI & PS|CTI + PS + MOUD
9884221|NCT05138614|Experimental|DRT & PS|DRT + PS + MOUD
9884222|NCT05138614|Other|MOUD only|MOUD
9884223|NCT05137041|Experimental|ITP FIRTECH|ITP FIRTECH patch will be applied and remain in position for 5 days
9884224|NCT05137041|Other|No Patch Control Arm|No patch application
9884225|NCT05135052|Experimental|Treatment arm|Treatment with Rhenium-SCT, Single treatment.
9884226|NCT05134727|Experimental|Part 1a - fasted state|Healthy participants will be randomized to a single dose of AZD5055 or placebo.
9884227|NCT05134727|Experimental|Part 1b - fed state|Healthy participants will be randomized to a single dose of AZD5055 or placebo.
9884228|NCT05134727|Experimental|Part 2|Healthy participants will be randomized to repeated dosing with AZD5055 or placebo
9884229|NCT05132660|Experimental|Sinemet|25 mg carbidopa/100 mg levodopa
9884230|NCT05132660|Placebo Comparator|Placebo|Placebo pill of similar size/shape
9884231|NCT05132660|No Intervention|follow-up|Follow-up testing on participants previously prescribed levodopa
9884232|NCT05127291|Experimental|Study Group|Patients with type 2 diabetes mellitus
9884233|NCT05127291|Other|Control Group|People without type 2 diabetes and prediabetes
9884234|NCT05127174|Experimental|Phase 1: Dose Level 1|Participants will take 200 mg fedratinib once daily by mouth.
9884235|NCT05127174|Experimental|Phase 1: Dose Level 2|Participants will take 300 mg fedratinib once daily by mouth.
9884236|NCT05127174|Experimental|Phase 1: Dose Level 3|Participants will take 400 mg fedratinib once daily by mouth.
9884237|NCT05127174|Experimental|Phase 2: Treatment at Recommended Phase 2 Dose (RP2D)|Participants will take fedratinib at the dose determined in the phase 1 portion of this study, once daily by mouth.
9884238|NCT05125471|Experimental|Investigational Drug|Cobimetinib will be administered at a maximal dose of 60 mg daily for 21 days on, then 7 days off, in a 28-Day treatment cycle for 12 cycles (approximately 12 months). Cobimetinib should be taken once daily at approximately the same time each day, and no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal. Cobimetinib tablets should never be chewed, cut, or crushed. Therapy may continue for up to 12 cycles provided the subject meets the criteria for starting subsequent cycles and does not meet any of the criteria for cobimetinib discontinuation. At least 7 days off cobimetinib (within +7 days) is required prior to starting a new treatment cycle.
9884239|NCT05123144|Experimental|Behavioral Health Screener + ORCHID Intervention (BHS+ORCHID)|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
9884240|NCT05123144|No Intervention|Standard of Care|usual care
9884241|NCT05122637|Experimental|Treatment Arm|RapidPulseTM Aspiration System with commercially available Medtronic React 71 aspiration catheter and commercially available aspiration pump as frontline approach thrombectomy technique.
9884242|NCT05122637|Other|Control Arm|Treatment with commercially available aspiration catheter with commercially available aspiration pump as frontline approach thrombectomy technique.
9884243|NCT05121142|No Intervention|Arm 1: Existing patients with chronic GVHD|Participants with established diagnosis of chronic GVHD and currently on treatment with ruxolitinib for chronic GVHD for at least 3 weeks. Participants in this arm are receiving ruxolitinib clinically and will not receive ruxolitinib as part of this research study.
9884244|NCT05121142|Experimental|Arm 2: Acute GVHD ages 0-<12 years|Participants with acute GVHD will receive ruxolitinib on this arm.
9884245|NCT05121142|Experimental|Arm 3: New onset chronic GVHD ages 0-≤18 years|Participants with new onset chronic GVHD will receive ruxolitinib on this arm.
9884246|NCT05118854|Experimental|Sotorasib in Combination with Cisplatin/Carboplatin and Pemetrexed|4 cycles of at least one dose of sotorasib plus cisplatin (or carboplatin) and pemetrexed can be administered safely
9884247|NCT05113251|Experimental|Arm A|Trastuzumab deruxtecan
9884248|NCT05113251|Experimental|Arm B|T-DXd, followed by THP
9884249|NCT05113251|Active Comparator|Arm C|doxorubicin and cyclophosphamide, followed by THP
9884250|NCT05109143|Active Comparator|Group B|Standard Medical Treatment
9884251|NCT05109143|Experimental|Group A|Will be administered 100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia with Standard Medical Treatment
9884252|NCT05108454||Intervention group|Pregnant women who received MMS from the SMC program
9884253|NCT05108454||Comparison|Pregnant women who did not receive MMS
9884254|NCT05108233||Observational (survey)|"COHORT 1-TP1: Patients complete surveys over 20 minutes on post-op day 3 and on day of discharge (or within 1 week).~COHORT 1-TP2: Patients complete surveys over 15 minutes at all regularly scheduled follow-up appointments (approximately 1 month, 3 months, 6 months, 12 months).~COHORT 2: Patients complete surveys over 15 minutes once."
9884255|NCT05107856|Experimental|PRT1419|PRT1419 will be administered by intravenous infusion
9884256|NCT05106361|Experimental|MOSAIC Plus|"Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
9884257|NCT05106361|Active Comparator|MOSAIC|"Those in the active comparator will receive the Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV."
9884258|NCT05105087|Experimental|Diagnostic (perflubutane microbubble, ultrasound)|Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.
9884259|NCT05104502|Experimental|Fasting|Dietary fasting.
9884260|NCT05096702||Tafenoquine (TQ)|Patients aged ≥16 years, G6PD activity ≥ 6.1 IU/gHb, not pregnant or breastfeeding, will receive single-dose TQ in addition to standard blood schizonticidal drug.
9884261|NCT05096702||Daily primaquine (PQ) for 7 days|Patients aged ≥ 6 months, with G6PD activity between 4.1 and 6.0 IU/gHb, not pregnant or breastfeeding for < 1 month, will receive daily PQ in addition to standard blood schizonticidal drug.
9884262|NCT05096702||Weekly primaquine for 8 weeks|Patients aged ≥ 6 months, with G6PD activity ≤ 4.0 IU/gHb, not pregnant or breastfeeding for < 1 month, will receive weekly once-a-week PQ for eight weeks in addition to standard blood schizonticidal drug.
9884263|NCT05094206|Experimental|Indolent B-cell NHL Dose Level -1: 0.75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
9884264|NCT05094206|Experimental|Indolent B-cell NHL Dose Level 0: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
9884265|NCT05094206|Experimental|Indolent B-cell NHL Dose Level 1: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
9884266|NCT05094206|Experimental|Indolent B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of three doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg or 2.5x10^6 cells/kg.
9884267|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level -1: 0.75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
9884268|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 0: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
9884269|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 1: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
9884270|NCT05094206|Experimental|Aggressive B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of three doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg or 2.5x10^6 cells/kg.
9884271|NCT05088044|Experimental|staff nurses|firstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart
9884272|NCT05087056|Experimental|ABCWY-24 Group|Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441.
9884273|NCT05087056|Experimental|ABCWY-48 Group|Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721.
9931313|NCT00936949|Active Comparator|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
9931314|NCT00936962|Experimental|Group 1 NeisVac C vaccine - 0 doses|NeisVac C (Meningococcal C) vaccine - 0 doses
9884274|NCT05085808|Active Comparator|Quetiapine|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
9884275|NCT05085808|Experimental|Trazodone|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
9884276|NCT05085808|Placebo Comparator|Placebo|"Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
9884277|NCT05085561|Active Comparator|REC-994 200 mg|REC-994 200 mg po once daily (QD) (1 200 mg REC-994 tablet, 1 matching placebo tablet)
9884278|NCT05085561|Active Comparator|REC-994 400 mg|REC-994 400 mg po QD (2 200 mg REC-994 tablets)
9884279|NCT05085561|Placebo Comparator|Placebo|Matching Placebo po QD (2 matching placebo tablets)
9884280|NCT05085275|Experimental|Ferric citrate|Supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
9884281|NCT05085275|Placebo Comparator|Placebo|Tablets, matching in color and size to ferric citrate.
9884282|NCT05085067|No Intervention|Group A: no auto-cross linked hyaluronic acid gel|no auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
9884283|NCT05085067|Experimental|Group B: infusing auto-cross linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
9884284|NCT05079139|Other|surgical technique of Musset|
9884285|NCT05075980|Experimental|Arm A (IMPT, cisplatin)|Patients who already underwent surgical resection undergo IMPT for 18 sessions (Monday-Friday) over 24 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care.
9884286|NCT05075980|Experimental|Arm B (IMPT, cisplatin)|Patients undergo surgical resection and then IMPT for 15 sessions (Monday-Friday) over 19 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care.
9884287|NCT05073783||Cohort A|Pompe disease patients receiving Myozyme® (alglucosidase alfa) in a home-care setting.
9884288|NCT05073783||Cohort B|MPS I patients receiving Aldurazyme® (laronidase) in a home-care setting.
9884289|NCT05069896|Experimental|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS) at 3 different injection sites (arm, thigh, and abdomen).
9884290|NCT05069896|Experimental|Mirikizumab - Autoinjector|Mirikizumab administered by SC via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).
9931315|NCT00936962|Experimental|Group 2 NeiscVac C - 2 doses|2 priming doses of NeisVac C vaccine at 2 and 4 mths of age
9931316|NCT00936962|Experimental|Group 3 NeiscVac C - 1 dose|1 priming dose of NeisVac C vaccine at 2 mths of age
9931317|NCT00936988|Experimental|cinacalcet|
9931318|NCT00937014|Active Comparator|Standard infant formula|
9931319|NCT00937014|Experimental|Test formula|
9931320|NCT00937027|Active Comparator|Aminopterin one 1.0 mg tablet|
9931321|NCT00937027|Active Comparator|Aminopterin 1 four 0.25 mg tablets|
9931322|NCT00937053|Experimental|Hemoglobin below 120 g/dL|
9931323|NCT00937053|Active Comparator|Hemoglobin below 70 g/dL|
9931324|NCT00937066||1|Adult patients 18-65 years with moderate to severe uncontrolled asthma
9989360|NCT01432314|Experimental|Treatment group|Child A Hepatocellular carcinoma patients with unilobar portal vein invasion.
9989361|NCT01432340||Vaccinated group|Children between 6months- 10years of age who have received the influenza vaccine
9989362|NCT01432340||Unvaccinated group|Eligible children between 6months and 10years who didn't receive the influenza vaccine
9989363|NCT01432353|Experimental|Single Arm|
9989364|NCT01432392||1|
9989365|NCT01432418|Experimental|wheelchair training|
9989366|NCT01432418|No Intervention|Control|Standard of care only
9989367|NCT01432431|Experimental|Supportive care (spiritual care)|See Detailed Description.
9989368|NCT01432470|Experimental|Oxytocin, Intravaginal administration|
9989369|NCT01432470|Placebo Comparator|Placebo, Intravaginal administration|
9989370|NCT01432496|Experimental|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
9989371|NCT01432496|Placebo Comparator|Saline 15 ml|Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system
9989372|NCT01432522|Experimental|epinephrine IN, epinephrine IM, saline IN|"Intranasal saline~Intramuscular epinephrine~Intranasal epinephrine"
9989373|NCT01432613|Other|MRI-oriented muscle biopsy|Muscle sample will be done following the usual care.
9989374|NCT01432639|Experimental|Experimental group|Patients undergoing the exercise-based cardiac rehabilitation program (intervention)
9989375|NCT01432639|No Intervention|Control group|Usual medical care
9989376|NCT01432652||vascular surgery|Patients undergoing vascular surgery
9989377|NCT01432665|Experimental|Placebo|30 subjects administered a placebo
9989378|NCT01432665|Experimental|sildenafil + testosterone combination drug 1|30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)
9989379|NCT01432665|Experimental|Sildenafil and testosterone combination drug 2|Sildenafil 50mg and testosterone 0.25mg
9989380|NCT01432665|Experimental|Sildenafil and testosterone combination drug 3|30 subjects are given sildenafil 25mg and testosterone 0.50mg
9989381|NCT01432665|Experimental|Sildenafil and Testosterone Combination drug 4|30 subjects are given sildenafil 50mg and testosterone 0.50mg
9989382|NCT01432665|Experimental|Sildenafil 50mg|30 subjects are given sildenafil 50mg
9989383|NCT01432665|Experimental|Testosterone 0.50mg|30 subjects are given testosterone 0.5mg
9517717|NCT03303677|Active Comparator|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
9989384|NCT01432678||asthma patients|controlled asthma partly controlled asthma uncontrolled asthma
9989385|NCT01432691|Other|Surgery|RSA study on hemi
9989386|NCT01432704|Placebo Comparator|placebo capsules|Identically appearing placebo capsules not containing colecalciferol
9989387|NCT01432704|Active Comparator|colecalciferol capsules|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
9989388|NCT01432717|Experimental|ACE-536|Subjects assigned to 1 of 5 possible dosing groups.
9989389|NCT01432717|Placebo Comparator|Placebo|
9989390|NCT01432743|Experimental|Cartomerge|Use of Cartomerge to guide ablation
9989391|NCT01432743|Active Comparator|NavX Fusion|Use of NavX fusion to guide ablation
9989392|NCT01432769|Active Comparator|individualized diet|patients will receive a diet individualized to their calorie and protein requirements besides to dietary supplementation with a polymeric formula
9989393|NCT01432769|No Intervention|standardized diet|"patients in the standardized diet will receive the dietary management established by the hospital"
9989394|NCT01432782|Placebo Comparator|Placebo|Placebo arm: per-endoscopic injection of saline
9989395|NCT01432782|Active Comparator|Botulinum toxin|Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically
9989396|NCT01432795|Experimental|Test series of 6 types of gliding aids|"Each study subjects tests a series of gliding aids or stocking butlers:~4 gliding aids~2 stocking butlers, one with and without handle~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed stockings with closed tip, compression class 1 (18-21 mmHg)"
9989397|NCT01432821|Experimental|Apomorphine|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~-sequence A: 1 mg/kg and then 5 mg/kg of apomorphine"
9989398|NCT01432821|Placebo Comparator|Saline|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~sequence B: 2 injections of saline"
9989399|NCT01432834|Other|LASIK group (LG group)|Volunteers of this group received LASIK treatment.
9989400|NCT01432834|Other|PRK group (PG group)|Volunteers of this group received PRK treatment
9989401|NCT01432860|Active Comparator|In-person Counseling and Education|In the in-person training the Research Assistant demonstrates the use of a mm ruler, a lighted magnifying lens, a set of body maps and a scorecard, 4 pens, ABCDE rule on the skin exam card and discusses the ABCDE rule by pointing to the color examples on the skin exam card. 165 pairs (330 subjects) are randomized to this arm.
9997332|NCT01507922|Experimental|Fenoverine|Fenoverine 100mg three times a day will be administered for 8 weeks.
9997333|NCT01507922|Active Comparator|Trimebutine|Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
9517718|NCT03303677|Experimental|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
9884291|NCT05065437|Experimental|Virtual reality and spinal stimulation|Safety and feasibility of a virtual reality and spinal stimulation intervention will be tested.
9884292|NCT05064735|Experimental|semaglutide 2.4 mg|Participants will receive semaglutide subcutaneous (s.c) 2.4 mg once-weekly as adjunct to a reduced-calorie diet and increased physical activity
9884293|NCT05064735|Placebo Comparator|semaglutide 2.4 mg (placebo)|Participants will receive semaglutide subcutaneous (s.c) placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
9884294|NCT05061862||CIED Indicated Subjects|Subjects indicated to receive a cardiac implantable electronic devices (CIEDs)
9884295|NCT05061719|Experimental|Lumateperone 42 mg|
9884296|NCT05061706|Experimental|Lumateperone 42 mg|
9884297|NCT05061706|Placebo Comparator|Placebo|
9884298|NCT05061654|Experimental|Treatment arm|Eligible patients will be started on empiric ceftolozane-tazobactam in addition to standard care.
9884299|NCT05061446|Experimental|Etrasimod Dose 1|
9884300|NCT05061446|Experimental|Etrasimod Dose 2|
9884301|NCT05061446|Placebo Comparator|Placebo|
9884302|NCT05060016|Experimental|Part 1: Tarlatamab Low Dose|Participants will receive the low dose of Tarlatamab.
9884303|NCT05060016|Experimental|Part 1: Tarlatamab High Dose|Participants will receive the high dose of Tarlatamab.
9884304|NCT05060016|Experimental|Part 2: Dose Expansion|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1.
9884305|NCT05049213|Experimental|Topical medical treatment|Intranasal spray and oral gargling
9884306|NCT05049213|No Intervention|Standard of care|no intervention
9884307|NCT05048082|Experimental|Fluorescence imaging with pegsitacianine|Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
9884308|NCT05045144|Experimental|RSV1 Group|Participants randomized to the RSV1 Group receive one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
9884309|NCT05045144|Experimental|RSV2 Group|Participants randomized to the RSV2 Group receive one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
9884310|NCT05045144|Experimental|RSV3 Group|Participants randomized to the RSV3 Group receive one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants are also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
9884311|NCT05045144|Experimental|RSV1+Flu Group|Participants randomized to the RSV1+Flu Group receive one dose of RSV MAT Lot 1 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.
9884312|NCT05045144|Experimental|RSV2+Flu Group|Participants randomized to the RSV2+Flu Group receive one dose of RSV MAT Lot 2 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.
9884313|NCT05045144|Experimental|RSV3+Flu Group|Participants randomized to the RSV3+Flu Group receive one dose of RSV MAT Lot 3 vaccine co-administered with one dose of Flu D-QIV vaccine, intramuscularly, at Day 1.
9884314|NCT05045144|Active Comparator|Flu+P Group|Participants randomized to the Flu+P Group receive one dose of Flu D-QIV vaccine co-administered with one dose of Placebo, intramuscularly, at Day 1.
9884315|NCT05044455|Experimental|Arm 1: Experimental, intervention|The immediate intervention group will receive an online 9 week CBT intervention led by trained peers who have themselves recovered from postpartum depression. The CBT group will be two hours long, weekly and involves teaching and practice of core CBT skills. Core cognitive skills including thought records and cognitive restructuring are introduced and practiced from week 1. Behavioural techniques are introduced at week 2 and continue throughout the group, including behavioural activation, relaxation techniques, sleep strategies, exercise and goal setting. Each participant will receive a professionally design CBT manual to facilitate learning. Participants in the intervention group may also receive typical care or treatment as usual for new mothers.
9884316|NCT05044455|No Intervention|Arm 2: Control Group|The control group will receive treatment as usual (TAU) or typical care available for postpartum depression in participant's home communities, via participant's family doctor, mental health services, midwifery services, etc. Subjects in the control group will receive a list of resources where participants may seek treatment and will receive a monthly email encouraging them to seek treatment if symptoms worsen, including thoughts of self harm or harm to participant's child. Participants will also receive a copy of the Canadian Practice Guidelines for the treatment of PPD.
9884317|NCT05044065|Experimental|Exercise group|The experimental group will in addition to standard care receive supervised and home-based exercise training program with a specific focus to induce metabolic stress, and protein supplementation to ensure adequate protein intake.
9884318|NCT05044065|No Intervention|Usual care|The control group will in addition to standard care receive protein supplementation to ensure adequate protein intake.
9884319|NCT05042310|Experimental|LY3541860 (Part A)|Single doses of LY3541860 administered intravenously (IV) or subcutaneously (SC).
9884320|NCT05042310|Experimental|LY3541860 (Part B)|Multiple doses of LY3541860 administered either IV or SC.
9884321|NCT05042310|Placebo Comparator|Placebo (Part A)|Single doses of Placebo administered either IV or SC.
9884322|NCT05042310|Placebo Comparator|Placebo (Part B)|Multiple doses of Placebo administered either IV or SC.
9884323|NCT05039970|Experimental|Experimental Arm - WellQuest™ Users|Participants in National DPP groups randomized to the experimental arm will be instructed by lifestyle coaches to download the WellQuest™ game application and will receive instructions on how to use the game throughout the LCP.
9884324|NCT05039970|No Intervention|Control Arm|Participants in National DPP groups randomized to the control arm will proceed with their routine National DPP participation.
9884325|NCT05037877|Active Comparator|Intervention group|HUM supplement - 1 capsule per day
9884326|NCT05037877|Placebo Comparator|Placebo group|Placebo supplement - 1 capsule per day
9884327|NCT05037279|Experimental|Verity-BCG|"Bacillus Calmette-Guérin (BCG): Strain Russian BCG-I~Freeze-dried powder for bladder instillation"
9884328|NCT05037279|Active Comparator|OncoTICE|"Standard of Care~Bacillus Calmette-Guérin (BCG): Strain TICE~Freeze-dried powder for bladder instillation"
9884329|NCT05036616||Separation technique|
9884330|NCT05036616||Integration technique|
9884331|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
9884332|NCT05035810|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
9884333|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
9884334|NCT05035810|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
9884335|NCT05035316|Placebo Comparator|Placebo|125 BD participants will receive placebo. Patients, clinicians and researchers will be blinded for the intervention
9884336|NCT05035316|Active Comparator|Active|125 BD participants will receive active treatment. Patients, clinicians and researchers will be blinded for the intervention
9884337|NCT05034822|Experimental|Ruxolitinib cream|ruxolitinib 1.5% cream will be applied twice daily to all areas of the skin affected by AD
9884338|NCT05034536|Experimental|Pembrolizumab + Infliximab|"Participants will be randomly assigned to receive pembrolizumab and infliximab.~Pembrolizumab will be administered every 3 weeks for up to 2 years~Infliximab will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
9884339|NCT05034536|Experimental|Pembrolizumab + Placebo|"Participants will be randomly assigned to receive pembrolizumab and placebo.~Pembrolizumab will be administered every 3 weeks for up to 2 years~Placebo. will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
9884340|NCT05031416|Experimental|Consumers who smoke at outpatient community mental health clinic|Consumers with serious mental illness who attend outpatient community mental health clinic will participate in a smoking cessation with the LTQ application and nicotine replacement therapy
9884341|NCT05031351|Experimental|High dosage Withania somnifera|544mg oral twice a day
9884342|NCT05031351|Experimental|Medium dosage Withania somnifera|272mg oral twice a day
9884343|NCT05031351|Placebo Comparator|Placebo|Matched capsules twice a day
9884344|NCT05030571|Experimental|Intervention|Intervention group will receive DPMAS extracorporeal treatment one session per day for 3 consecutive days plus standard therapy. We plan to use blood flow rate of 100-120 ml/hour with filtration fraction for plasma separation of 25-30%. DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China) We do not use any anticoagulant.
9884345|NCT05030571|Active Comparator|Standard care|Standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017
9884346|NCT05027503|Active Comparator|Control Group|Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks
9884347|NCT05027503|Experimental|Training Group|In addition to home-based respiratory physiotherapy, 30 min exercises with the hippotherapy simulator will be done.
9884348|NCT05024279|Experimental|Intervention Arm|Patients are randomized to receive left bundle branch are pacing due to higher degree AV block
9884349|NCT05024279|Active Comparator|Control Arm|Patients are randomized to receive standard right ventricular pacing due to higher degree AV block.
9884350|NCT05021978|Experimental|Part A: Open-label 20 and 40 mg PRAX-944|Once daily, oral dosing with 7 days of 20 mg and 7 days of 40 mg
9884351|NCT05021978|Experimental|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded PRAX-944|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
9884352|NCT05021978|Active Comparator|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded placebo|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 14 days of 120 mg, 14 days placebo
9884353|NCT05021601|Experimental|Bi-atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with bi-atrial ablation procedure.
9884354|NCT05021601|Active Comparator|Left atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with left atrial ablation procedure.
9884355|NCT05020249|Experimental|Bimekizumab arm|Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
9884356|NCT05020249|Placebo Comparator|Placebo arm|Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.
9884357|NCT05018351|Active Comparator|Treatment as Usual-Integrated Care (TAU-IC)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-half of research participants will be randomized to integrated care alone.
9884358|NCT05018351|Experimental|Peer Navigator Program (PNP)|"Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~scheduling and attending healthcare appointments;~partnering with participant on tasks that arise from appointments;~health-related goal setting; and~taking action-steps toward health-related goals."
9931325|NCT00937092|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
9517719|NCT03303677|Experimental|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
9884359|NCT05016882|Experimental|NNC0194-0499 7.5 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884360|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884361|NCT05016882|Experimental|NNC0194-0499 15 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884362|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884363|NCT05016882|Experimental|NNC0194-0499 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884364|NCT05016882|Experimental|NNC0194-0499 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884365|NCT05016882|Active Comparator|Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884366|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884367|NCT05016882|Experimental|NNC0174-0833 2.4 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884368|NCT05016882|Placebo Comparator|Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
9884369|NCT05014919|Experimental|Vortioxetine -open label treatment period|"Vortioxetine - 5, 10, 15, and 20 mg/day, film-coated tablets, orally once daily.~Patients will receive a targeted dose of 10 mg/day vortioxetine, however the investigator has the possibility to adjust the dose in case of unsatisfactory response or in case of dose-limiting adverse events."
9884370|NCT05014919|Experimental|Vortioxetine -double-blind relapse prevention period|"Vortioxetine - 5, 10, 15, and 20 mg/day, encapsulated film-coated tables, orally once daily.~In the double-blind period, the patients will continue on the same fixed dose as during the end of the open label period"
9884371|NCT05014919|Placebo Comparator|Placebo -double-blind relapse prevention period|Placebo - encapsulated tablets, orally once daily.
9997334|NCT01507935|Active Comparator|Intervention Group I|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I
9884372|NCT05014139|Experimental|Enfortumab vedotin: Dose escalation cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
9884373|NCT05014139|Experimental|Enfortumab vedotin: Dose expansion cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
9884374|NCT05013892|Experimental|NTS-WBRT (normal tissue sparing whole brain radiation therapy) + Memantine|"Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive:~NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.~Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
9884375|NCT05013892|Experimental|HA-WBRT (hippocampal avoidance whole brain radiation Therapy) + Memantine|"Participants will be randomly assigned to HA-WBRT (hippocampal avoidance whole brain radiation Therapy) administration group and receive:~HA-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.~Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
9884376|NCT05012891||Study Population|Fifty (n=50) consecutive patients with lower-extremity disability or chronic pain (unilateral or bilateral), undergoing a rehabilitation course in a Day-Care Center setting.
9884377|NCT05011851|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
9884378|NCT05009303||Participants|Thirty healthy individuals and seventy patients suffering from chronic pain or disability in one or both of their lower extremities
9884379|NCT05008432||HFpEF Patients Diagnosed with Obstructive Sleep Apnea|Right heart cath patients who are diagnosed with HFpEF will undergo a home sleep apnea test (for patients hospitalized with HFpEF, the initial home sleep test will be performed in hospital overnight)
9884380|NCT04999436|Experimental|Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
9884381|NCT04998240|Experimental|Prime BBIBP-CorV, Boost Ad26.COV2.S (A1)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of Ad26.COV2.S vaccine (A1).
9884382|NCT04998240|Experimental|Prime BBIBP-CorV, Boost BBIBP-CorV (A2)|The randomized study participants will receive Prime BBIBP-CorV vaccine followed by Booster dose of BBIBP-CorV vaccine (A2).
9884383|NCT04998240|Experimental|Prime Ad26.COV2.S, Boost BBIBP-CorV (B1)|The randomized study participants will receive Prime Ad26.COV2.S vaccine followed by Booster dose of BBIBP-CorV vaccine (B1).
9884384|NCT04998240|Experimental|Prime Placebo, Boost Ad26.COV2.S (B2)|The randomized study participants will receive Prime Placebo vaccine followed by Booster dose of Ad26.COV2.S (B2).
9884385|NCT04994132|Experimental|Arm A (VAC, VINO-CPO)|"Patients receive vincristine sulfate IV on days 1, 8 and 15 of cycles 1-4, 7, 8, 11, and 12, and day 1 of cycles 5, 6, 9, 10, 13, and 14. Patients also receive dactinomycin IV over 1-15 minutes on day 1 of cycles 1-5, 8-10, and 11-14, and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.~MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
9884386|NCT04994132|Experimental|Arm B (vinorelbine, VAC, VINO-CPO)|"Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8, vincristine sulfate IV on day 15, dactinomycin IV over 1-15 minutes on day 1 of cycles 1-5 and 8-14, and cyclophosphamide IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.~MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
9884387|NCT04992312|Experimental|Glucagon Nasal Powder|A single dose of glucagon nasal powder administered intranasally.
9884388|NCT04991766|Experimental|[¹⁴C]-LY3484356 (Part 1)|Single dose of [¹⁴C]-LY3484356 administered orally.
9884389|NCT04991766|Experimental|LY3484356 + [¹⁴C]-LY3484356 (Part 2)|Single dose of LY3484356 administered orally followed by Single dose of [¹⁴C]-LY3484356 administered intravenously (IV).
9884390|NCT04988685||Treatment|The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of CAD patients treated with contemporary DCBs.
9884391|NCT04987775|Active Comparator|N-Acetyl Cysteine (NAC)|Participants who are randomized to the intervention arm will receive N-Acetyl-L-Cysteine (Free-Form/NAC) 900mg two times a day for 8 weeks after the initiation of the first dose of study drug.
9884392|NCT04987775|Placebo Comparator|Placebo|Participants who are randomized to the placebo arm will take matching placebo two times a day for 8 weeks after the initiation of the first dose of study drug.
9884393|NCT04985942|Experimental|Lumateperone 42 mg|
9884394|NCT04985942|Placebo Comparator|Placebo|
9884395|NCT04983368|Experimental|Xanamem® 5 mg|Oral Xanamem® capsules 5 mg, to be administered once daily
9884396|NCT04983368|Experimental|Xanamem® 10 mg|Oral Xanamem® capsules 10 mg, to be administered once daily
9884397|NCT04983368|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
9989402|NCT01432860|Active Comparator|Workbook|The workbook, which includes all of the information delivered in the in-person intervention, is 39 pages in length, and has 76 color figures. Each element of the in-person training represents a chapter in the workbook. The introduction explores the partners' understanding of melanoma and their personal risk of developing another melanoma, and attitudes about the benefit of early detection assisted by a partner. The early detection segment uses a skin diagram to illustrate the difference between thin and thick melanoma and presents the treatment based on the depth of the melanoma. 165 pairs (330 subjects) are randomized to this arm.
9989403|NCT01432860|No Intervention|Control|Education and counseling as usually delivered in clinical practice. 100 pairs (200 subjects) are randomized to this arm.
9989404|NCT01432860|Active Comparator|Tablet Computer-Based Education|Education will be given by an interactive tablet app. Each pair will view video recordings of certain parts of the in-person presentation as well as select slides from the in-person PowerPoint presentation. Parts of the workbook will be incorporated as well. 70 pairs (140 subjects) are randomized into this arm.
9989405|NCT01432873|Experimental|Experimental|Oral selenium therapy arm
9989406|NCT01432873|Placebo Comparator|Placebo|Oral placebo
9989407|NCT01432912|No Intervention|Patients|
9989408|NCT01432925|Other|evaluation surgical intervention at week 8|
9989409|NCT01432925|Other|evaluation surgical intervention at week 14|
9989410|NCT01432964||1|Adult patients (>18 years) presenting a unilateral orbital blow-out or blow-in fracture of ≥ 2.0cm2, causing an actual or expected functional or aesthetical deficit.
9989411|NCT01432977|Active Comparator|comparateur|paracetamol / droperidol
9989412|NCT01432977|Experimental|Eperimental|paracetamol / ondansetron
9989413|NCT01432990|Experimental|robotic gait training|conventional physical therapy plus robot gait training program for SCI patients.
9989414|NCT01432990|No Intervention|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
9989415|NCT01433003|Active Comparator|Standard-dose plasma exchange|50-75 ml/kg/day
9989416|NCT01433003|Experimental|High-dose Plasma Exchange|125 ml/kg/day up to 10 L/day
9989417|NCT01433029||Conventional Rater (CR)|CR Group receives conventional training from PI about how to rate coronary artery bypass (CAB) videos.
9989418|NCT01433029||Video Rater (VR)|VR Group receives conventional training from PI about how to rate CAB videos, along with a video rater training manual.
9989419|NCT01433029||CAB Recording|CAB recording of performance cardiothoracic surgeon or surgical trainee in 1st, 2nd, or 3rd year of training.
9989420|NCT01433068|Experimental|NBTXR3|
9989421|NCT01433094|Experimental|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving
9989422|NCT01433094|Active Comparator|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
9989423|NCT01433120|Experimental|Probiotic L. casei F19|
9989424|NCT01433120|Experimental|Flax seed fibres|
9989425|NCT01433120|Placebo Comparator|Placebo|
9989426|NCT01433133|Experimental|1|• Genotype 3 chronic HCV with detectable serum HCV RNA
9989427|NCT01433185|Experimental|Text message (SMS)|Text messages sent to women before and after delivery
9989428|NCT01433185|No Intervention|Usual care (current standard of care)|Current standard of care for women enrolled in PMTCT programs
9989429|NCT01433198|Active Comparator|Aquatic exercise group|
9989430|NCT01433198|No Intervention|Control group|
9989431|NCT01433211||No treatment|
9989432|NCT01433276|Experimental|Totilac|
9989433|NCT01433276|Active Comparator|Ringer's lactate|
9989434|NCT01433289|Experimental|Polyphenon E 1600 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Four capsules twice a day.
9989435|NCT01433289|Experimental|Polyphenon E 2400 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Six capsules twice a day.
9989436|NCT01433289|Experimental|Polyphenon E 3200 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Eight capsules twice a day.
9989437|NCT01433302||Punch Biopsy|
9989438|NCT01433328|Experimental|Lidocaine|
10211727|NCT04221451|Experimental|GZ402671|"Primary population: participant will receive venglustat dose 1 once daily during 104 weeks.~Secondary population: participant will receive venglustat at various doses once daily during 104 weeks (open label period)."
10211728|NCT04221451|Placebo Comparator|Placebo|Primary population: participants will receive placebo once daily during 104 weeks.
10211729|NCT04218357|Experimental|Probenecid|2g probenecid, one pill by mouth once, for one day
10211730|NCT04218357|Placebo Comparator|matching placebo|Placebo, one pill by mouth once, for one day
10211731|NCT04210843|Experimental|Ligelizumab Dose 1 and 3|Liquid in vial 72 mg/mL followed by 120 mg/mL PFS
10211732|NCT04210843|Experimental|Ligelizumab Dose 2 and 3|Liquid in vial 120 mg/mL followed by 120 mg/mL PFS
10211733|NCT04194437|Experimental|OCS Preserved Livers|This is a single-arm trial of OCS preserved livers used for transplantation.
10211734|NCT04192747|Experimental|Elixir Bioadaptor (ELX1805J)|The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length
9989439|NCT01433328|Placebo Comparator|Placebo|Remodulin only
9989440|NCT01433341||Young athletes|
9989441|NCT01433367||CerPass® Total Disc Replacement|
9989442|NCT01433380|Experimental|600 mg PF-05175157|Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
9989443|NCT01433380|Placebo Comparator|Placebo|Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
10211735|NCT04192747|Active Comparator|Medtronic Resolute Onyx Stent|The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length
9884398|NCT04982146|Experimental|Bromelain + N-Acetylcysteine|Patients with pseudomyxoma peritonei that are not candidates to surgical resection
9884399|NCT04981535|Experimental|Patients undergoing upper gastrointestinal endoscopy with head box|experimental group
9884400|NCT04981535|No Intervention|Patients undergoing upper gastrointestinal endoscopy without head box|standard of care group
9884401|NCT04975295|Experimental|LY3361237|LY3361237 administered subcutaneously (SC).
9884402|NCT04975295|Placebo Comparator|Placebo|Placebo administered SC.
9884403|NCT04974684|Experimental|Interventional group|
9884404|NCT04974684|No Intervention|Control group|
9884405|NCT04972760|Experimental|baricitinib arm|Patients receive baricitinib plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
9884406|NCT04972760|Placebo Comparator|placebo arm|Patients receive placebo plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
9884407|NCT04972331|Active Comparator|CONTROL|Arthroscopic Partial menisectomy
9884408|NCT04972331|Experimental|INTERVENTION|Platet- Rich-Plasma
9884409|NCT04958785|Experimental|Safety Run-in Cohort 1: Magrolimab + Nab-Paclitaxel or Paclitaxel|"Participants with untreated unresectable, locally advanced or metastatic TNBC whose tumors are not appropriate for immune checkpoint inhibitor therapy will receive the following:~magrolimab in de-escalating doses to establish RP2D~nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days."
9884410|NCT04958785|Experimental|Phase 2 Cohort 1 Arm A: Magrolimab + Nab-Paclitaxel or Paclitaxel|"Participants with mTNBC will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days.~Magrolimab will be continued until development of unacceptable toxicity that cannot be clinically managed by dose or schedule modifications. Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity."
9884411|NCT04958785|Active Comparator|Phase 2 Cohort 1 Arm B: Nab-Paclitaxel or Paclitaxel|"Participants with mTNBC will receive nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days.~Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity."
9884412|NCT04958785|Experimental|Safety Run-in Cohort 2: Magrolimab + Sacituzumab govitecan|"Participants with unresectable, locally advanced or metastatic TNBC who have received 1 prior line of treatment in the unresectable, locally advanced or metastatic setting will receive the following:~magrolimab in de-escalating doses to establish RP2D~sacituzumab govitecan on Days 1 and 8~Each cycle is 21 days."
9884413|NCT04958785|Experimental|Phase 2 Cohort 2: Magrolimab + Sacituzumab govitecan|"Participants with mTNBC will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with sacituzumab govitecan on Days 1 and 8. Each cycle is 21 days.~Magrolimab will be continued until development of unacceptable toxicity that cannot be clinically managed by dose or schedule modifications.sacituzumab govitecan will be continued until development of unacceptable toxicity."
9884414|NCT04958226|Experimental|Treatment (Midazolam + Capivasertib)|Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.
9884415|NCT04956692|Experimental|Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy|Participants receive pembrolizumab subcutaneous (SC) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.
9884416|NCT04956692|Active Comparator|Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy|Participants receive pembrolizumab intravenous (IV) administration on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous NSCLC.
9884417|NCT04950127|Experimental|Participants receiving linerixibat|
9884418|NCT04950127|Experimental|Participants receiving linerixibat followed by placebo|
9884419|NCT04950127|Placebo Comparator|Participants receiving placebo|
9884420|NCT04950127|Experimental|Participants receiving placebo followed by linerixibat|
9884421|NCT04949191|Experimental|Study Treatment 1: Pemigatinib (INCB054828)|Pemigatinib will be taken orally once daily
9884422|NCT04949191|Experimental|Study Treatment 2: Pemigatininb+ Retifanlimab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks
9884423|NCT04949191|Experimental|Study Treatment 3: Pemigatininb + Pembrolizumab|Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and pembroluzimab as per dosage instructions.
9884424|NCT04947319|Experimental|Tirabrutinib monotherapy|Patients with relapsed or refractory PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib monotherapy.
9884425|NCT04943471||All patients will be given a questionnaire|All patients will be given the Big Five Questionnaire
9884426|NCT04939428|Experimental|Molnupiravir|Participants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.
9884427|NCT04939428|Placebo Comparator|Placebo|Participants take placebo Q12H on Days 1 to 5.
9884428|NCT04935632||Before implementation|Prior to the implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
9884429|NCT04935632||After implementation|After implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia
9989444|NCT01433393|Experimental|TAK-875 25 mg|
9989445|NCT01433393|Experimental|TAK-875 50 mg|
9989446|NCT01433393|Placebo Comparator|Placebo|
10211736|NCT04190056|Experimental|Arm A (pembrolizumab, vorinostat, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1, vorinostat PO QD for 4 days weekly, and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
10211737|NCT04190056|Experimental|Arm B (pembrolizumab, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1 and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
10211738|NCT04186988|Experimental|Diagnostic ([18F]-AraG)|Patients receive [18F]-AraG IV and then undergo PET/CT over 2 hours at baseline and within 2 weeks after starting immunotherapy. Patients may also undergo blood sample collection.
10211739|NCT04186221|Experimental|Treatment arm|
10211740|NCT04181762|Experimental|secukinumab|secukinumab 300 mg s.c.
10211741|NCT04181762|Placebo Comparator|placebo|secukinumab placebo s.c.
10211742|NCT04179175|Active Comparator|secukinumab 1 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 2 weeks
10211743|NCT04179175|Active Comparator|secukinumab 2 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 4 weeks
10211744|NCT04179175|Placebo Comparator|placebo 1 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300mg every 2 weeks
10211745|NCT04179175|Placebo Comparator|placebo 2 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300 mg every 4 weeks
10211746|NCT04179175|Active Comparator|HiSCR non-responders|non-responder to core trial treatment; secukinumab 300mg every 2 weeks
10211747|NCT04153279|Experimental|CMV-TCR-T cells|The patients will receive one dose of CMV-TCR-T.The dosage ranges from 0.1×10^6 to 1×10^6 TCR+T/Kg.
10211748|NCT04143659|Experimental|LB injection 40mg intramuscular (IM) with 20 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg intramuscular (IM) using 20 mg/ml concentration
9884430|NCT04935632||at a distance from the implementation|Approximately 8 months after implementation of the measures resulting from the SFAR recommendations on the prevention of accidental perioperative hypothermia.
9884431|NCT04933695|Experimental|Sotorasib: 960 mg Daily|Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express < 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 960 mg daily. Participants will be stratified by known presence of STK11 mutation.
9884432|NCT04933695|Experimental|Sotorasib: 240 mg Daily|Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express < 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.
9884433|NCT04932681||Qualitative group|Interview about the use of Complementary and Alternative Medecine
9884434|NCT04932681||Quantitative group|Questionnaire about the use of Complementary and Alternative Medecine
9884435|NCT04927169|Experimental|CYT107|IM administration of CYT107 / Interleukin-7
9884436|NCT04927169|Placebo Comparator|PLACEBO|IM administration of Saline at the same volume
9884437|NCT04925544|Experimental|VK-2019_arm|1800 mg VK 2019 once daily, cycles will be defined as 28 days of treatment, subjects will receive VK 2019 until progression or dose limiting toxicity, for up to 12 cycles.
9884438|NCT04925466|Experimental|Treatment with CPAP at 10cmH2O|Patients with OSA will be treated with CPAP at 10cmH2O during sleep.
9884439|NCT04925466|Experimental|Treatment with CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
9884440|NCT04924257|Experimental|Intranasal Esketamine|
9884441|NCT04924257|Active Comparator|ECT|
9884442|NCT04924101|Experimental|Pembrolizumab + MK-4830 + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle (cycle length = 3 weeks) every 3 weeks (Q3W) up to 35 administrations (up to approximately 2 years) or until disease progression (PD) or discontinuation, MK-4830 800 mg IV infusion on Day 1 of each cycle Q3W, up to 35 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
9884443|NCT04924101|Experimental|Pembrolizumab + MK-5890 + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle Q3W up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, MK-5890 30 mg IV infusion on Day 1 of each cycle (cycle length = 6 weeks) every 6 weeks (Q6W), up to 18 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
9884444|NCT04924101|Experimental|Pembrolizumab + Lenvatinib + Chemotherapy|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each 3 week cycle (Q3W) up to 35 administrations (up to approximately 2 years) or until PD or discontinuation, lenvatinib 8 mg once daily (QD) orally up to Cycles 1-4 cycles and up to 20 mg QD orally for Cycles 5-31 or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1, 2, 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV, Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.
9884445|NCT04921969|Experimental|Ruxolitinib (1.5% Cream)|Study drug will be administered twice daiily.
9884446|NCT04921969|Experimental|Ruxolitinib (0.75% cream)|Study drug will be administered twice daily.
9884447|NCT04921969|Placebo Comparator|Vehicle Cream|Vehicle cream will be administered twice daily.
9884448|NCT04918342|Active Comparator|Individual Exercise Instruction|The participant will receive individual exercise instruction.
9884449|NCT04918342|Experimental|Group Exercise Instruction|The participant will receive the instruction in a group of up to 9 other participants.
9884450|NCT04916249|Experimental|Tibetree pain relieving plaster|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
9884451|NCT04916249|Placebo Comparator|Placebo plaster groups|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
9884452|NCT04915157|Other|Group A: High Density stimulation - No Stimulation|Patients in this group will receive high density stimulation (parasthesia free form of stimulation) during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive no stimulation during the final 6 months of the study period.
9884453|NCT04915157|Other|Group B: No Stimulation - High Density Stimulation|Patients in this group will receive no stimulation during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive high density stimulation (parasthesia free form of stimulation) during the final 6 months of the study period.
9884454|NCT04913220|Experimental|Cohort A: Melanoma|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9884455|NCT04913220|Experimental|Cohort B: cutaneous squamous cell carcinoma (CSCC)|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
9884456|NCT04908839||case: patient with otosclerosis|Diagnosis of otosclerosis with indication for primary stapedial surgery by the combination of arguments
9884457|NCT04908839||case: otosclerosis patient with surgery|otosclerosis patient with surgery
9884458|NCT04908839||controle: Absence of known otological pathology|Absence of known otological pathology
9884459|NCT04908215|Experimental|INM-755 (cannabinol) cream|Cannabinol cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
9884460|NCT04908215|Placebo Comparator|Vehicle cream|Vehicle cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
9884461|NCT04906668|Active Comparator|Pulmonary-vein isolation with any form of energy|
9884462|NCT04906668|Active Comparator|Ablation of atrioventricular-node and Pacemaker implantation|
9884463|NCT04906382|Experimental|Treatment (tislelizumab)|"Chemo naïve patients receive tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients who are chemotherapy naive with progressive disease, stable disease, or partial response, also receive carboplatin IV and paclitaxel IV every 21 days per standard of care for 6-9 cycles at the discretion of the treating physician.~Patients who have received prior chemotherapy will receive single agent tislelizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
9884464|NCT04904042|Experimental|Use of plasma of neutral argon|Use of plasma of neutral argon in the eradication of tumor implants at the mesentery level, with different doses (established according to the percentage of energy used) and distances of application and time. It will also be compared in-vivo with control therapy of Monopolar electrofulguration at a power of 100 in cut mode with ball-tip terminal.
9884465|NCT04902001|Experimental|Adolescents with obesity|Adolescents with obesity aged 12-16 years old
9884466|NCT04899180|Other|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
9884467|NCT04897347|Experimental|Robotic Trunk-Support-Trainer (TruST)|Postural-reaching control intervention with TruST
9884468|NCT04897347|Active Comparator|Static Trunk Support|Postural-reaching control intervention with Rigid Trunk Support
9884469|NCT04894656|Experimental|Gastroparesis patients|
9884470|NCT04894656|Active Comparator|Healthy volunteers|
9884471|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab (Cohort 1)|Concurrent weekly cisplatin with radiation and zimberelimab therapy followed by adjuvant zimberelimab
9884472|NCT04892875|Experimental|Concurrent Cisplatin/Radiation Therapy + Zimberelimab + Etrumadenant (Cohort 2)|Concurrent weekly cisplatin with radiation + etrumadenant + zimberelimab with adjuvant combined etrumadenant + zimberelimab
9884473|NCT04892875|Active Comparator|Concurrent Cisplatin/Radiation Therapy|Concurrent weekly cisplatin with radiation therapy control arm
9884474|NCT04891393|Experimental|Caffeine|Single-dose, orally ingested, instant coffee.
9884475|NCT04891393|Placebo Comparator|Inactive Placebo|Single-dose, orally ingested, instant decaffeinated coffee (equal weight to intervention dose).
9931326|NCT00937092|Active Comparator|low-dose dopamine + low-dose furosemide|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
9989447|NCT01433406|Experimental|TAK-875 25 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
9989448|NCT01433406|Experimental|TAK-875 50 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
9989449|NCT01433419|Experimental|TAK-875 25 mg|
9989450|NCT01433419|Experimental|TAK-875 50 mg|
9989451|NCT01433432|Active Comparator|Purinethol|Subjects who previously received 12 weeks of Purinethol (at 1-1.5 mg/kg)in the original study will now receive 80 mg DR-6MP (2 x 40 mg tablets) once dailyh, in the evening, for an additional 12 weeks
9989452|NCT01433432|Experimental|Test Drug|Subjects who previously received test drug (80 mg DR-6MP) for 12 weeks in the original study, will continue to receive 80 mg DR-6MP (2 x 40 mg tablets) once daily, in the evening, for an additional 12 weeks
9989453|NCT01433445|Experimental|Cohort 1|Subjects will be treated with ruxolitinib 5 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
9989454|NCT01433445|Experimental|Cohort 2|Subjects will be treated with ruxolitinib 10 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
9989455|NCT01433445|Experimental|Cohort 3|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
9989456|NCT01433445|Experimental|Cohort 4|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 15 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
9989457|NCT01433445|Experimental|Cohort 5|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 20 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
9989458|NCT01433445|Experimental|Cohort 6/6+|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 25 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
9989459|NCT01433458|Experimental|RLX030: Group 1 mild hepatic impairment|Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
9989460|NCT01433458|Experimental|RLX030: Group 2 moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
9989461|NCT01433458|Experimental|RLX030: Group 3 severe hepatic impairment|Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
9989462|NCT01433458|Active Comparator|RLX030: Group 4 - healthy volunteers|Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.
9989463|NCT01433484|Active Comparator|Maintenance of Weight Loss--Control|The control arm will receive bi-monthly telephone contacts during the one-year maintenance phase.
9989464|NCT01433484|Experimental|Maintenance of Weight Loss--Experimental|The experimental arm will receive monthly telephone contacts for one year during the maintenance phase.
9989465|NCT01433510|Experimental|Grazax Tablets 75000 SQT|Timothy Extract
9989466|NCT01433523|Placebo Comparator|Placebo|
9989467|NCT01433523|Experimental|ALK HDM AIT 6 DU|
9989468|NCT01433523|Experimental|ALK HDM AIT 12 DU|
9989469|NCT01433536||cranial trauma and fracture|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
9989470|NCT01433536||cranial trauma|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
9989471|NCT01433536||spinal trauma with fracture|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
9989472|NCT01433536||spinal trauma|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
9989473|NCT01433536||high velocity fracture, inferior limb|Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
9989474|NCT01433536||Control|Healthy individuals
9989475|NCT01433562|Experimental|DLBS1425|
9989476|NCT01433562|Placebo Comparator|Placebo|
9989477|NCT01433575|Experimental|A|
9989478|NCT01433575|Experimental|B|
9989479|NCT01433588|Active Comparator|Calmer|This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
9989480|NCT01433588|Placebo Comparator|Standard Care|Standard of care during bloodwork is receiving a soother and facilitated tucking.
9989481|NCT01433601|No Intervention|Self Supervised Treatment (SST)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
9997335|NCT01507935|Active Comparator|Intervention Group II|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II
10211749|NCT04143659|Experimental|LB injection 40 mg subcutaneous (SC) with 20 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 20 mg/ml concentration
10211750|NCT04143659|Experimental|LB injection 80mg intramuscular (IM) with 70 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 80mg intramuscular (IM) using 70 mg/ml concentration
10211751|NCT04143659|Experimental|LB injection 80mg Subcutaneous (SC) with 70 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 80mg subcutaneous (SC) using 70 mg/ml concentration
9884476|NCT04889638|Experimental|Cessation intervention|Participants will undergo pre-/post-comparisons of a personalized, remote smoking cessation intervention composed of two main elements: a) prescription and monitoring of nicotine (e.g., replacement therapy) and/or non-nicotine pharmacotherapies (e.g., varenicline) and b) cessation-centered motivational messaging.
9884477|NCT04886154|Experimental|ABCWY low dose Group|Participants receive MenABCWY-2Gen low dose vaccine and are followed up until Day 211 in study Phase I.
9884478|NCT04886154|Placebo Comparator|Placebo low dose Group|Participants receive NaCl as a control for ABCWY low dose group and are followed up until Day 211 in study Phase I.
9884479|NCT04886154|Experimental|ABCWY high dose Group|Participants receive MenABCWY-2Gen high dose vaccine and are followed up until Day 211 in study Phase I.
9884480|NCT04886154|Placebo Comparator|Placebo high dose Group|Participants receive NaCl as a control for ABCWY high dose group and are followed up until Day 211 in study Phase I.
9884481|NCT04886154|Experimental|ABCWY low dose_06 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
9884482|NCT04886154|Experimental|ABCWY low dose_02 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
9884483|NCT04886154|Experimental|ABCWY high dose_06 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
9884484|NCT04886154|Experimental|ABCWY high dose_02 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
9884485|NCT04886154|Active Comparator|Control Group|Participants randomized to Control Group receive 2 doses of Bexsero (MenB) vaccine and 1 dose of Menveo (MenACWY), 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
9884486|NCT04886154|Experimental|ABCWY low dose_01 Group|Participants receive MenABCWY-2Gen low dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
9884487|NCT04886154|Experimental|ABCWY high dose_01 Group|Participants receive MenABCWY-2Gen high dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
9884488|NCT04881799|Placebo Comparator|Placebo-Controlled Period|Participants in this phase of the study will be randomized 1:1 to receive either phentermine/topiramate or placebo.
9884489|NCT04881799|Experimental|Open Label Extension|Participants in this phase of the study will receive open label phentermine/topiramate.
9884490|NCT04880694|Experimental|Cohort 1: STC3141 58.3mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72 hours) N=10
9884491|NCT04880694|Experimental|Cohort 2: STC3141 87.5mg/hr|Drug: STC3141 Continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72 hours) N=10
9884492|NCT04880694|No Intervention|Cohort 3: Comparator|Only to receive appropriate standard of care N=5
9884495|NCT04875195|Experimental|Arm 1|Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.
9884496|NCT04874077||Case|
9884497|NCT04874077||Control|
9884498|NCT04872452|Experimental|Gastrointestinal dysmotility participants|
9884499|NCT04872452|Other|Healthy participants|
9931327|NCT00937144|Experimental|viagra|viagra versus placebo will be given to patients with sickle cell anemia
9931328|NCT00937144|Placebo Comparator|placebo|viagra versus placebo will be given to patients with sickle cell anemia
9931329|NCT00937170|Experimental|Gender Specific LPS flex|Participants in this arm will receive the Zimmer LPS flex Gender Specific Implant design
9931330|NCT00937170|Active Comparator|LPS flex|Participants in this arm will receive the Zimmer High Flex LPS implant
9931331|NCT00937170|Active Comparator|Triathlon|Participants in this arm will receive the Stryker Triathlon Implant design
9884500|NCT04870320|Experimental|Arm I (Endeavor)|Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks.
9884501|NCT04870320|Active Comparator|Arm II (Words!)|Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
9884502|NCT04866303|Experimental|Active delivery|For the participants randomized to the active arm will have their home collection kit registered on their behalf by bilingual (Spanish and English) community health workers, who are trusted community members. Home testing kits augmented with study developed materials will direct participants to contact the study team for assistance.
9884503|NCT04866303|Experimental|Passive delivery|Participants randomized to the passive arm will receive a home test kit augmented with instructions on how to self-register their kit online, and will be directed to contact Everlywell for assistance, if needed.
9884504|NCT04865835|Placebo Comparator|placebo and metformin|single dose of placebo + single dose of metformin-HCl 850 mg (approximately 663 mg metformin) (placebo will be dosed 1 hour prior to metformin administration)
9884505|NCT04865835|Experimental|SEP-363856 and metformin|single dose of SEP 363856 100 mg + single dose of metformin-HCl 850 mg (SEP 363856 will be dosed 1 hour prior to metformin administration)
9884506|NCT04864158|Experimental|RSA-group|Surgery
9884507|NCT04864158|Experimental|Exercise-group|Exercise
9884508|NCT04857307|Experimental|Staccato alprazolam|The study participants will receive a single dose of Staccato alprazolam.
9884509|NCT04850521||Remote monitoring|Remote monitoring software + connected devices
9884510|NCT04849416|Experimental|LOXO-305|LOXO-305 administered orally.
9884511|NCT04845074|Experimental|TSA-group|Surgery
9884512|NCT04845074|Experimental|Exercise-group|Exercise
9884513|NCT04843709|Experimental|MRG004A|All patients in Part A (dose escalation) and Part B (dose expansion) will be administrated MRG004A on Day 1 of every 3 weeks (21-day cycle).
9884514|NCT04841798|Other|Duloxetine|Assessment of MAO-B distribution volume in the prefrontal cortex before and after duloxetine at 60 mg daily.
9884515|NCT04841798|Other|Rasagiline|Assessment of regional MAO-B distribution volume before and after rasagiline at 1.0 mg daily.
9884516|NCT04841798|Other|Tranylcypromine|Assessment of regional MAO-B distribution volume before and after tranylcypromine at 30 to 60 mg daily.
9884517|NCT04841577|Experimental|Co-Ad Group|Participants randomized to Co-Ad Group receive 1 dose of RSVPreF3 OA investigational vaccine and 1 dose of FLU-QIV at Day 1 and are followed up until the study end.
9884518|NCT04841577|Active Comparator|Control Group|Participants randomized to Control Group receive 1 dose of FLU-QIV at Day 1, followed by 1 dose of RSVPreF3 OA investigational vaccine at Day 31 and are followed up until the study end.
9884519|NCT04840888|Experimental|LY3484356 (Cohort 1)|LY3484356 administered as single doses orally with (fed) or without food (fasted).
9884520|NCT04840888|Experimental|LY3484356 + Omeprazole (Cohort 2)|LY3484356 administered as single dose orally on Day 1 and omeprazole administered orally as single dose on Days 5 to 8 followed by a single dose of LY3484356 co-administered with a single dose of omeprazole on Day 9 orally.
9884521|NCT04840888|Experimental|LY3484356 + Itraconazole (Cohort 3)|LY3484356 administered as single dose orally on Day 1 and itraconazole administered orally as single dose on Days 5 to 9. The single dose of LY3484356 co-administered with a single dose of itraconazole on Day 10 orally followed by single dose of itraconazole administered orally on Days 11 to 16.
9884522|NCT04840888|Experimental|LY3484356 + Carbamazepine (Cohort 4)|LY3484356 administered as single dose orally on Day 1 and carbamazepine administered orally as single dose on Days 5 to 11. The single dose of LY3484356 co-administered with a single dose of carbamazepine on Day 12 orally followed by single dose of carbamazepine administered orally on Days 13 to 15.
9884523|NCT04839523|Experimental|Exufiber|Treatment with Exufiber gelling fiber dressing
9884524|NCT04839523|Experimental|Exufiber Ag+|Treatment with Exufiber Ag+ silver-coated, gelling fiber dressing
9884525|NCT04837222||Participants with CD30-positive Lymphoma|All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.
9884526|NCT04836910||Study Group: Women with Polycystic Ovary Syndrome|Woen diagnosed with Polycystic Ovary Syndrome according to the Rotterdam Criteria (requires 2 out of 3 symptoms: 1. Hyperandrogenism or excess levels of androgen. 2. Oligo or anovulation. 3. Polycystic ovaries on ultrasound - over 12 follicles, 2-9 mm or increased ovarian volume),who haven't started any treatment
9884527|NCT04836910||Cohort Group: Women without Polycystic Ovary Syndrome|
9884528|NCT04832516|Experimental|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
9989482|NCT01433601|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
9989483|NCT01433614|Active Comparator|Epirubicin + paclitaxel (Taxol)|Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.
9989484|NCT01433614|Active Comparator|Paclitaxel + epirubicin + capecitabine|Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.
9989485|NCT01433627|Experimental|trans-radial and short-term Bivalirudin|Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
9989486|NCT01433627|Experimental|trans-radial and long-term bivalirudin|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
9989487|NCT01433627|Experimental|trans-radial and standard of care pharmacology|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor"
9989488|NCT01433627|Experimental|trans-femoral and short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
9989489|NCT01433627|Experimental|Trans-femoral and long-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
9989490|NCT01433627|Active Comparator|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
9989491|NCT01433640||Contrast-enhanced Mammography|Subjects will undergo 2D imaging with iodine contrast.
9989492|NCT01433640||Contrast-enhanced Breast Tomosynthesis|Subjects will undergo 3D imaging with iodine contrast.
9989493|NCT01433640||Contrast-enhanced MRI|Each subject imaged with iodine contrast will also be imaged with contrast-enhanced MRI using gadolinium.
9989494|NCT01433653|Experimental|CG-CBT|
9989495|NCT01433653|No Intervention|wait list control|
9989496|NCT01433666|Experimental|roflumilast 100ug|
9989497|NCT01433666|Experimental|roflumilast 300ug|
9989498|NCT01433666|Experimental|roflumilast1000ug|
9989499|NCT01433666|Placebo Comparator|placebo|
9989500|NCT01433679|Experimental|Website intervention|Participants randomly assigned to the Website Intervention arm receive access to the motivational rewards website. The website displays the individual's physical activity data and allocates reward points based on the amount and intensity of physical activity. The website also allows reward points to be redeemed for various rewards such as gift cards to retail outlets, donations to charities, small tangible goods, and customization of participants' cartoon-like avatars on the website.
9989501|NCT01433679|No Intervention|Control|Participants in the control group will not have access to the motivational website. No other product or intervention will be introduced to the control group.
9989502|NCT01433692|Experimental|intervention group|
9517739|NCT03303456|Experimental|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
9989503|NCT01433692|Other|control group|
9989504|NCT01433705|Other|Rb-82 and N-13 ammonia Pet scans|Rest and vasodilator stress Rb-82 images and N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 and N-13 ammonia by intravenous administration (IV) in the patient's arm.
9989505|NCT01433705|Other|F-18 FDG Imaging and Rb-82|Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.
9989506|NCT01433705|Other|F-18 FDG Imaging and N-13 ammonia|Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.
9989507|NCT01433718|Experimental|ACL prevention training|
9989508|NCT01433744|Experimental|Chronic periodontal disease|C-reactive protein levels assesments and periodontal treatment
9989509|NCT01433744|No Intervention|Periodontally healthy|
9989510|NCT01433757|Active Comparator|Ampicillin|Patients who are randomly selected to receive the active drug will receive Ampicillin (2mg daily for adults and 1 mg daily for children).
9989511|NCT01433757|Placebo Comparator|Placebo|Patients who are randomly selected to receive the placebo will be given a sugar pill that resembles the active drug.
9989512|NCT01433770|Experimental|Alefacept action on memory T cells|
9989513|NCT01433796||Antiretroviral therapy, tuberculosis|Patients eligible for starting ART in health centres in Ethiopia
9989514|NCT01433835|Placebo Comparator|Placebo|
9989515|NCT01433835|Experimental|MBX-400|
9989516|NCT01433848||Child A liver cirrhosis|
9989517|NCT01433848||Child B liver cirrhosis|
9989518|NCT01433848||Child C liver cirrhosis|
9989519|NCT01433861|Active Comparator|LAPG|LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group
9989520|NCT01433861|Active Comparator|LATG|LATG : laparoscopy-assisted total gastrectomy group
9989521|NCT01433874|Experimental|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
9989522|NCT01433874|Experimental|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc we will leave the fluid in the abdominal cavity.
9989523|NCT01433874|Experimental|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH20. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
9989524|NCT01433874|Placebo Comparator|Control group|Co2 was removed by passive exsufflation through the port site
9989525|NCT01433887|Experimental|Genotype 6|Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
9989526|NCT01433887|Experimental|Genotype 1|Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
9989527|NCT01433887|Experimental|Genotype 2/3|Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks
9989528|NCT01433900|Active Comparator|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
9989529|NCT01433900|Active Comparator|Latanoprost|1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)
9989530|NCT01433952|Placebo Comparator|0 mg Thiamine|
9989531|NCT01433952|Experimental|100 mg Thiamine|
9989532|NCT01433952|Experimental|500 mg Thiamine|
9989533|NCT01433952|Experimental|1500 mg Thiamine|
9989534|NCT01434004|Experimental|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
9989535|NCT01434004|No Intervention|Control group|Usual care (watchful waiting).
9989536|NCT01434017|Active Comparator|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
9989537|NCT01434017|Active Comparator|Dexamethasone and Droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
9989538|NCT01434017|Active Comparator|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
9989539|NCT01434043||Myocardial ischemia patients|
9989540|NCT01434056||Liver transplantation waiting list|Patients waiting for liver transplantation with chronic end staged liver disease
9989541|NCT01434069|Experimental|Combination Therapy: FOLFIRI and SOM 230|"Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline.~SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days."
9989542|NCT01434095|Active Comparator|half-dose PDT(photodynamic therapy)|The study include single arm; treated group, and no control group was included.
9989543|NCT01434108|Experimental|Ornithine-phenylacetate|Administration of OP (OCR-002) during 5 days in addition to standard treatment of gastrointestinal bleeding.
9989544|NCT01434108|Placebo Comparator|Saline iv|Administration of control infusion (saline infusion) during 5 days in addition to standard treatment of gastrointestinal bleeding.
9989545|NCT01434134|Experimental|Metoprolol|Tablet, target dose 100 mg once daily
9989546|NCT01434134|Placebo Comparator|Placebo for Metoprolol|Tablet, target dose 100 mg once daily
9989547|NCT01434134|Experimental|Candesartan|Tablet, target dose 32 mg once daily
9989548|NCT01434134|Placebo Comparator|Placebo for Candesartan|Tablet, target dose 32 mg once daily
9997336|NCT01507935|Placebo Comparator|Control Group|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
9997337|NCT01507935|No Intervention|Reference group|Exclusively breast-fed infants
9997338|NCT01507948|Experimental|Immediate Prolonged Exposure Treatment|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
9997339|NCT01507948|No Intervention|Wait list, immediately followed by Prolonged Exposure|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
9997340|NCT01507974|No Intervention|control arm|The women in this arm will not receive preventive antibiotic treatment after delivery
9997341|NCT01507974|Active Comparator|preventive antibiotic treatment|The women in this arm will receive preventive antibiotic treatment after the delivery to 6 weeks
9997342|NCT01508000|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
9997343|NCT01508000|Experimental|Arm B: modified FOLFOX6 + Bevacizumab and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m2 2-h infusion~Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion*.~Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
9997344|NCT01508000|Experimental|Arm C: modified FOLFOX6 + Panitumumab and Surgery|"Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery~6 cycles before and 6 cycles after surgery consisting in:~Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) +/- 15 min. infusion*.~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
9997345|NCT01508039|Experimental|Treatment with chitin micro-particles|The study will involve 14-healthy subjects confirming to the inclusion criteria randomised to the treatments.
9997346|NCT01508065||controlled type one diabetes mellitus.|
9997347|NCT01508091|Experimental|Calorie restricted|25 % calorie restriction respect measured total energy expenditure, using a Mediterranean diet
9997348|NCT01508104|Experimental|BEZ235 and Everolimus|
9997349|NCT01508143|Experimental|400 microgram misoprostol|400 micrograms misoprostol each 6 hours for 8 dose
9997350|NCT01508143|Active Comparator|800 micrograms misoprostol|800 micrograms misoprostol each 12 hours for 4 dose
9997351|NCT01508156|Experimental|Group A: Healthy Participants|Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.
9997352|NCT01508156|Experimental|Group B: HCV Participants|Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.
9997353|NCT01508182|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
9997354|NCT01508182|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
9997355|NCT01508195|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
9997356|NCT01508195|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
9997357|NCT01508208|Other|Hypertensive disorder of pregnancy|Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.
9997358|NCT01508221|Experimental|Trental + Vitamin E|Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
9997359|NCT01508247|Experimental|vaccine against EV71|Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
9997360|NCT01508247|Placebo Comparator|placebo|0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
9884529|NCT04832516|Active Comparator|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
9884530|NCT04828070||Registry participant|Prospective collection of clinical information, completion of anxiety/depression, microaggressions, and quality of life questionnaires
9884531|NCT04825717|Experimental|Intervention group|Patients in this group will be administered nutrition and fluid plans prepared by the department dietitian using calorimetry-based measurements
9884532|NCT04825717|No Intervention|Control group|Nutrition plans of patients in this group will be calculated by the department dietitian using the standard, currently accepted RDI (recommended dietary intake) formula.
9884533|NCT04823455|Experimental|Allo Omero 2020|Humeral allograft group 12 patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.Included patients were clinically and radiographically re-evaluated for the purpose of this study by examiners not involved in the primary treatment at a mean of 66 months postoperatively. The clinical examination consisted of a physical examination and structured interview. Computed tomography (CT) was carried out at the medium follow-up of 66 months in all patients to evaluate OA progression and allograft resorption.
9884534|NCT04818450|Experimental|Gabapentin|Start gabapentin 100 mg at 9.00 PM on the second night of ICU admission and titrate gabapentin dose as needed. Maximum gabapentin dose in this study is 300 mg/day.
9884535|NCT04818450|No Intervention|Standard care|Not receiving gabapentin.
9884536|NCT04817072|Other|Chronic inflammatory rheumatic disease|Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19
9884537|NCT04817033|Active Comparator|High risk OSA Dexmedetomidine|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
9884538|NCT04817033|Active Comparator|High risk OSA Midazolam|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
9884539|NCT04817033|Active Comparator|Low&Medium OSA Dexmedetomidine|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
9884540|NCT04817033|Active Comparator|Low&Medium OSA Midazolam|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
9884541|NCT04813926||Patients diagnosed with PAH|
9884542|NCT04811196|Experimental|Metronomic dosing|"This Arm is an open-label, non-randomized, phase 1 study of metronomic dosing of selinexor in patients with locally advanced or metastatic MPNST, ESS, LMS. Up to seven dose levels of Selinexor will be investigated.~Patients will undergo 3+3 based dose escalation to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Selinexor.~Escalating doses of selinexor will be given starting with 2.5 mg (taken orally 4 days in a row followed by 3 days break from treatment, repeating this weekly as part of a 28-day cycle). The first dose for the first 2 patients at each dose level will be staggered by 7 days. Minimum number of patients treated in this trial arm is 18 patients, and maximum 36 patients.~Schedule:~Selinexor flat dosing with dose levels (DLs) of 2.5mg (DL1), 5mg (DL2), 7.5mg (DL3), 10mg (DL4), 12.5mg (DL5), 15mg (DL6), 17.5mg (DL7). A DL-1 (1.25 mg) is also incorporated."
9884543|NCT04811196|Experimental|Split dosing|The second arm of the study is an open-label, non randomized, phase 1b study of selinexor in patients with any histological subtype of STS administered orally one day per week, 40mg in the morning, 20mg in the afternoon and 20mg at night as part of a 28 day cycle. Twenty patients will be accrued to this arm.
9884544|NCT04810247|Experimental|Body Project intervention|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised.
9884545|NCT04809805|Experimental|Dose escalation of BAY2666605|Approximately 7 or 8 dose levels are planned.
9884546|NCT04809805|Experimental|Dose expansion of BAY2666605|Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
9884547|NCT04804748||Phase A|"Approximately 150 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery)~Data regarding standard of care post-operative pacing and treatment of POAF, if applicable, will be collected from time of surgery until discharge~No use of an external bi-atrial pacing device~No use of Defipace~In-hospital data will be collected for all patients~Patients that developed POAF (n=50) will be followed-up with a phone call 30 days after surgery"
9884548|NCT04804748||Phase B|"Approximately 300 consecutive patients undergoing elective cardiac surgery (bypass and / or valve surgery) with planned TMA implantation~In-hospital data will be collected for all patients~Use of the DefiPace system for the treatment (low-energy cardioversion) and post-operative prevention (bi-atrial pacing) of POAF will be documented (n=100). These patients will be followed-up with a phone call 30 days after surgery"
9884549|NCT04803214|Other|Treatment (ReActiv8)|Market-approved ReActiv8 device
9884550|NCT04803214|No Intervention|Control (OMM)|Standard of Care
9884551|NCT04794660|Active Comparator|Arm 1|In this arm, HPV-positive women will undergo a Visual Inspection with Acetic Acid (VIA) triage test followed by biopsies. Treatment by thermal ablation (or cryotherapy in South Africa) will be applied to VIA positive women eligible for ablative treatment. Non eligible women will be referred to colposcopy.
9884552|NCT04794660|Active Comparator|Arm 2|In this arm, HPV positive women will get biopsies and receive an ablative treatment by thermal ablation (or cryotherapy in South Africa) if they are eligible to ablative treatment. Non eligible women will be referred to colposcopy
9884553|NCT04789174|Active Comparator|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
9884554|NCT04789174|Placebo Comparator|Placebo|
9884555|NCT04781244|Active Comparator|EndWarts® FREEZE in Soft keratin|EndWarts® FREEZE were treated to 11 patients with wart at soft keratin
9884556|NCT04781244|Active Comparator|EndWarts® FREEZE in Hard keratin|EndWarts® FREEZE were treated to 11 patients with wart at hard keratin
9884557|NCT04781244|Active Comparator|Liquid nitrogen in Soft keratin|Liquid nitrogen were treated to 11 patients with wart at soft keratin
9884558|NCT04781244|Active Comparator|Liquid nitrogen in Hard keratin|Liquid nitrogen were treated to 11 patients with wart at hard keratin
9884559|NCT04778410|Experimental|Safety Run-in Cohort 1 (1L Unfit AML Mag+Ven+Aza)|"Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab, venetoclax and azacitidine.~THIS COHORT IS CLOSED FOR ENROLLMENT UNTIL FURTHER NOTICE."
9884560|NCT04778410|Experimental|Safety Run-in Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab and MEC.
9884561|NCT04778410|Experimental|Safety Run-in Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|"Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab and CC-486.~THIS COHORT IS CLOSED FOR ENROLLMENT UNTIL FURTHER NOTICE."
9884562|NCT04778410|Experimental|Phase 2 Cohort 1 (1L Unfit AML Mag+Ven+Aza)|"Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, venetoclax and azacitidine.~THIS COHORT IS CLOSED FOR ENROLLMENT UNTIL FURTHER NOTICE."
9884563|NCT04778410|Experimental|Phase 2 Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and MEC.
9884564|NCT04778410|Experimental|Phase 2 Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|"Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 3 and CC-486.~THIS COHORT IS CLOSED FOR ENROLLMENT UNTIL FURTHER NOTICE."
9884565|NCT04775082|Experimental|Liraglutide 3.0 mg|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
9884566|NCT04775082|Placebo Comparator|Placebo|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
9884567|NCT04773106|Other|Single-arm longterm Follow up ARGOS-SC Sensor Pressure system|The ARGOS-SC sensor was already implanted in a previous study as ARGOS-SC01.
9884568|NCT04763772|Experimental|Detailed Report|A detailed body composition profile report that consists of the following elements: basic demographic data, percent body fat, weight to muscle ratio, visceral fat and abdominal subcutaneous fat volume, visceral fat ratio (the fraction of visceral divided by total abdominal fat), muscle fat infiltration and liver fat (%), and thigh muscle volumes (also separated into right and left, anterior and posterior compartments). Each parameter is presented on a visual scale in the context of the individual value, general population defined by reference data (from United Kingdom (UK) Biobank population), a metabolic disease-free population (also from UK Biobank), low/high and very low/very high, corresponding to 15th and 5th percentiles, respectively. There are also descriptions of each biomarker and how they are derived to provide context for the recipient.
9884569|NCT04763772|Placebo Comparator|Basic Weight Information|A simple informational report consisting of weight, BMI, and a visual representation of their BMI. This report also categorizes their BMI into underweight, normal weight, overweight, or obese categories according to the World Health Organization categorization schema.
9884570|NCT04763772|Experimental|Patient Provided|Report provided directly to the patient.
9884571|NCT04763772|Placebo Comparator|Physician Provided|Report provided directly to the provider to translate/counsel the patient.
9884572|NCT04762589|Experimental|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
9884573|NCT04762589|Placebo Comparator|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
9884574|NCT04761081||South Asians who are lean|"The south Asian group who are lean will be of south Asian ethnicity and a waist circumference <90cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
9884575|NCT04761081||South Asians with central obesity|"The south Asian group with central obesity will be of south Asian ethnicity and a waist circumference of 90cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
9884576|NCT04761081||White Europeans who are lean|"The white European group who are lean will be of white European ethnicity and a waist circumference <94cm.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
9931332|NCT00937196|Active Comparator|Histaminum hydrochloricum globuli|To allow double-blind administration of the placebo pills going along with verbal suggestions of a blood-pressure-lowering effect
9931333|NCT00937196|Experimental|Placebo globuli|
9931334|NCT00937196|No Intervention|No treatment|
9884577|NCT04761081||White Europeans with central obesity|"The white European group with central obesity will be of white European ethnicity and a waist circumference of 94cm or greater.~The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes.~Metabolic markers will be analysed and presented in a participant characteristics table."
9884578|NCT04759144|Active Comparator|Faster insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with faster insulin aspart for 8 weeks.~Intervention: Use of faster insulin aspart with hybrid closed-loop insulin delivery"
9884579|NCT04759144|Active Comparator|Standard insulin aspart with hybrid closed-loop insulin delivery|"Unsupervised home use of hybrid closed-loop insulin delivery with standard insulin aspart for 8 weeks.~Intervention: Use of standard insulin aspart with hybrid closed-loop insulin delivery"
9884580|NCT04756414|Experimental|Treatment group|Patients recieve treatment from standard protocol at a gastroenterology unit. No specific adjustments is made for study purposes. Baseline data is collected before treatment and then again after treatment (POST).
9884581|NCT04752774|Experimental|Dose escalation|One single administration of study medication (IPN10200, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.
9884582|NCT04752774|Experimental|Dose ranging|Two fixed doses of IPN10200 will be administrated as a single injection into several muscle groups of the upper limb. Participants will be randomised in the ratio of 3:3:2 (total IPN10200 dose 1: 30 participants; total IPN10200 dose 2: 30 participants; Dysport: 20 participants)
9884583|NCT04752774|Experimental|Total dose|One single injection of study medication will be administered locally into several muscle groups of the upper limb. Participants will be randomised in the ratio of 2:1 (total IPN10200 dose: 30 participants; placebo: 15 participants).
9884584|NCT04752137|Other|ICG Dye and use of SPY-PHI Imaging|ICG will be administered in the pre-operative unit via IV injection at the time that they present to the pre-operative unit, which is approximately 4 hours before surgery. ICG Angiography (SPY PHI) will be performed to detect any residual signal
9884585|NCT04748172||Study Group: Women who are planning to be vaccinated|Women that are planning to be vaccinated, before receiving the first shot of the vaccine
9884586|NCT04747470|Experimental|GS-3583 Dose Escalation|Participants will receive an escalating dose of GS-3583 for up to 52 weeks or until the participant meets study treatment discontinuation criteria.
9884587|NCT04747418||Study Group: Women with low segment uterine scar following cesarean delivery|Women with low segment uterine scar following cesarean delivery, with no other abnormalities observed during diagnostic hysteroscopy
9884588|NCT04747418||Cohort Group: Women with no uterine scar|Women with no uterine scar, with no other abnormalities observed during diagnostic hysteroscopy
9884589|NCT04743661|Experimental|Recurrent Medulloblastoma|This arm aims to estimate event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 131I-omburtamab in patients with recurrent medulloblastoma. Patients with recurrent medulloblastoma will undergo surgery if feasible prior to study entry, followed by Induction Chemotherapy with irinotecan, temozolomide, and bevacizumab on study as per the Children's Oncology Group (COG) trial ACNS0821. Following 2 or 4 courses of chemotherapy and if radiographic disease status is stable or improved, patients will receive 2 therapeutic doses of 50 mCi cRIT 131I-omburtamab during Radioimmunotherapy. Following Radioimmunotherapy, patients may resume to Maintenance Chemotherapy with irinotecan, temozolomide, and bevacizumab for up to 12 total courses of chemotherapy or until disease progression, whichever occurs sooner.
9884590|NCT04743661|Experimental|Recurrent Ependymoma|This is a feasibility cohort. The primary objective is to assess feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma and to assess dosimetry. Patients must have progressed after initial surgery, radiation therapy, or other therapies. Patients will undergo surgery (if feasible) prior to study entry with the goal of achieving stable or better disease. Tumor tissue (archived or new) will be tested for B7H3 prior to enrollment. If positive, patients will enroll on Stratum 2 and receive one dosimetry dose (2 mCi) of cRIT 131I-omburtamab with nuclear medicine scintigraphy using SPECT during the Dosimetry Course (14 days in length). Following the Dosimetry Course and within 2 weeks of the dosimetry dose, patients may continue to Radioimmunotherapy to receive 2 therapeutic doses (50 mCi) of cRIT 131I-omburtamab.
9884591|NCT04739059|Experimental|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody administered subcutaneously
9884592|NCT04737304|Experimental|Dose Regimen Low Dose|Low Dose Strength
9884593|NCT04737304|Experimental|Dose Regimen High Dose|High Dose Strength
9884594|NCT04737304|Placebo Comparator|Placebo|Placebo
9884595|NCT04731519|Active Comparator|General Health Education Active Control Group|The control condition will receive General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
9931335|NCT00937261|Experimental|Risperdal|Risperdal 2-8mg per day
9931336|NCT00937261|Experimental|Invega|Invega 6-12mg per day
9931337|NCT00937274|Experimental|Test product|
9931338|NCT00937274|Active Comparator|Commercial product|
9884596|NCT04731519|Experimental|CI-CT Group|The experimental group will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
9884597|NCT04731519|Other|CI-CT Treatment Development Group|The 3 treatment development groups will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
9884598|NCT04729751|Experimental|Maralixibat|Participants will receive up to 600 μg/kg twice daily (PFIC) or up to 400 μg/kg once daily (ALGS) over 13 weeks in the core study and for the duration of the Long Term Extension (LTE) where applicable.
9884599|NCT04727554|Experimental|Part 1a: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
9884600|NCT04727554|Experimental|Part 1b: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
9884601|NCT04727554|Experimental|Part 1c: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
9884602|NCT04727554|Experimental|Part 2: Dose Expansion|Participants will be administered with the MTD or RP2D of AMG 994 identified in the dose escalation part of the study, in combination with AMG 404.
9884603|NCT04724109||Equfina|Participants with parkinson's disease will be administered Equfina 50 milligram (mg) tablets, orally, once daily in combination with levodopa-containing products. On the basis of symptoms, Equfina 100 mg tablet, orally, once daily may be selected for participants. All the participants will be observed for up to 24 weeks prospectively.
9884604|NCT04724044|Placebo Comparator|Placebo|These patients will be treated with 1 placebo tablet every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.
9884605|NCT04724044|Active Comparator|Clarithromycin|These patients will be treated with 1 tablet of 500 mg of clarithromycin every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.
9884606|NCT04718896|Experimental|Bimekizumab Dose A|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
9884607|NCT04718896|Experimental|Bimekizumab Dose B|Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
9884608|NCT04717791|Other|Procedure|Subjects will be followed from the Vivaer® treatment date out to 24 months post index procedure.
9884609|NCT04715932|Active Comparator|Hesperidin 1000mg|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
9931339|NCT00937274|Placebo Comparator|Standard care|
9931340|NCT00937287||youth and caregivers|
9931341|NCT00937313||Champagne wine|
9931342|NCT00937313||Placebo|alcohol with sparkling mineral water
9931343|NCT00937339|Active Comparator|Control|The control group will perform the same exercises on the vibration platform, as in the experimental group. However, the vibration device will be turned off during the exercises.
9931344|NCT00937339|Experimental|Whole body vibration|Subjects in the experimental group will undergo whole body vibration (1 session per day, 3 sessions per week) for 8 weeks. The vibration loading will be carried out using the Jet-Vibe System (Danil SMC Co., Ltd., Seoul, Korea). The vibration protocol used in this study will be 30Hz. While standing on the vibration platform, patients will be instructed to repeat the following set of light exercises: (1) light squatting,(2)deep squatting , (3) side-to-side weight-shift, (4) Forward and backward weight-shift, (5) forward lunge, (6) marching on the spot. The total duration of exposure of whole body vibration per session will be about 10 minutes.
9935484|NCT03644342|Experimental|Niraparib Arm|For the purposes of this study, two dose levels of Niraparib (100 mg and 200 mg) will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
9800200|NCT01682148|Active Comparator|Current Clinical Practice|"Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).~A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment."
9800201|NCT01682213|Experimental|dabrafenib|This is a single institution phase II trial assessing the efficacy of adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation.
9800202|NCT01682460|Experimental|Refresh Tears Lubricant Eye Drops (Allergan)|Artificial tears eye drops QID for 1 month
9800203|NCT01682512|Experimental|Part I BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
9800204|NCT01682512|Active Comparator|Part I Rituxan®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
9800205|NCT01682512|Active Comparator|Part I MabThera®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
9800206|NCT01682512|Experimental|Part II BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
9800207|NCT01682512|Active Comparator|Part II rituximab group|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
9800208|NCT01682538|Active Comparator|Orfadin capsules, fasting|Orfadin capsules, single dose, 30 mg
9800209|NCT01682538|Experimental|Orfadin suspension, fasting|Orfadin suspension 4 mg/mL, single dose 30 mg (7,5 mL)
9800210|NCT01682538|Experimental|Orfadin suspension, with food|Orfadin suspension 4mg/mL, single dose 30 mg (7,5 mL)
9800211|NCT01682603|Experimental|Botulinum toxin A|BoNT-A (BOTOX 300U)
9800212|NCT01682642|Active Comparator|Zoladex|After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
9800213|NCT01682642|No Intervention|vaporization only|Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.
9800214|NCT01682681||Topiramate|
9800215|NCT01682720|Placebo Comparator|Placebo 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
9800216|NCT01682720|Experimental|SOF 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
9800217|NCT01682720|Experimental|SOF 24 Weeks (GT3)|SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.
9800218|NCT01682759|Experimental|Omarigliptin|Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
9800219|NCT01682759|Active Comparator|Glimepiride|Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
9800220|NCT01682811|Experimental|Part 1 Levulan injection|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) injection and 3 hr incubation, and by Levulan treated lesions after 3 or 24 hr incubation.
9800221|NCT01682811|Experimental|Part 1 Levulan painting|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application and 3 hr incubation, and by Levulan treated lesions and 3 or 24 hr incubation.
9800222|NCT01682811|Experimental|Part 1 Levulan painted twice|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation.
9800223|NCT01682811|Experimental|Part 1 Levulan painted twice with microneedling|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation. All lesions prepared with microneedling.
9800224|NCT01682811|Experimental|Part 2 Dose level 1 50 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 - 50 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
9800225|NCT01682811|Experimental|Part 2 Dose level 2 100 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 - 100 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
9800226|NCT01682811|Experimental|Part 2 Dose level 3 200 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 - 200 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
9884610|NCT04715932|Placebo Comparator|Placebo 1000mg|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
9884611|NCT04711850||Imlifidase treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with imlifidase.
9884612|NCT04711850||Plasma exchange (PE) treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with PE.
9884613|NCT04707391|Experimental|ABCWY Group|All participants in this group receive 2 doses of the MenABCWY vaccine on Day 1 and Day 181 (0,6-month schedule) and 1 dose of placebo on Day 211.
9884614|NCT04707391|Active Comparator|ACWY Group|All participants in this group receive 1 dose of MenACWY vaccine on Day 1 and 2 doses of MenB vaccine on Day 181 and Day 211.
9884615|NCT04703855|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
9884616|NCT04702555||Vitalis Pharmaceuticals (VTS)-Aspirin and Ketamine|An oral combination drug of VTS-Aspirin and ketamine (VTS-K) would facilitate the shift from IV opioids to a non-IV therapy for patients presenting to the ED with acute MSK pain. This formulation has a potential to provide effective analgesia in the ED with reduced side effects. VTS-K's proprietary oral formulation of established, safe, and well-understood APIs, makes it uniquely appropriate for use in the ED. VTS-K is administered orally, which is suitable for resource-poor environments in which the healthcare setting may be inadequate as well as suitable to improve the throughput of ED Patients by reducing their length of stay. This is especially pertinent given the alternative of IV opioids for pain management of acute MSK pain, which requires both clinical monitoring and equipment, whereas VTS-K promotes weaning off opioids, alleviating the resource consumption.
9884617|NCT04702165|Experimental|VATS resection with J-bar|Each patient with a lung nodule meeting criteria will undergo a lung resection which could be one of three approaches: iVATS with Dyna-CT, VATS, or open. Each approach will use a the experimental device the Lung Resection Marker Locator Kit
9884618|NCT04701359|Experimental|Group A (TiN-coating)|Patients with knee osteoarthritis receive total knee arthroplasty with Titanium-Nitride (TiN)-coated implant.
9884619|NCT04701359|Active Comparator|Group B (CoCr-alloy)|Patients with knee osteoarthritis receive total knee arthroplasty with Cobalt-Chromium (CoCr)-alloy implant.
9884620|NCT04698187|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9884621|NCT04695977|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9884622|NCT04695977|Experimental|Nivolumab Monotherapy|All enrolled subjects will receive nivolumab monotherapy IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9884623|NCT04690595|Experimental|BAFFR-CAR T cells|B-cell activating factor receptor-Chimeric antigen receptor T cells
9884624|NCT04686305|Experimental|Arm 1A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
9884625|NCT04686305|Experimental|Arm 1B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
9884626|NCT04686305|Experimental|Arm 1C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
9884627|NCT04686305|Experimental|Arm 1D: T-DXd|T-DXd
9884628|NCT04686305|Experimental|Arm 2A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
9884629|NCT04686305|Experimental|Arm 2B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
9884630|NCT04686305|Experimental|Arm 2C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
9884631|NCT04686305|Experimental|Arm 2D: T-DXd, Durvalumab|T-DXd, Durvalumab
9884632|NCT04685239|Active Comparator|Unipolar cup|Patients randomized to receive a conventional unipolar acetabular cup
9884633|NCT04685239|Active Comparator|dual mobility cup|Patients randomized to receive a double mobility acetabular cup
9884634|NCT04684420|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants will receive a single oral dose of 500 milligrams (mg) of test GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There will be separate washout period of 7 days between each treatment period.
9884635|NCT04684420|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants will receive a single oral dose of 500 mg of reference GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR tablet on Day 8 in treatment period 2 under fasting conditions. There will be separate washout period of 7 days between each treatment period.
9884636|NCT04684420|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants will receive a single oral dose of 500 mg of test GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There will be separate washout period of 7 days between each treatment period.
9884637|NCT04684420|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants will receive a single oral dose of 500 mg of reference GXR tablet on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR tablet on Day 8 in treatment period 2 under fed conditions. There will be separate washout period of 7 days between each treatment period.
9884638|NCT04682769||Patients with medically stable coronary heart disease and Depressive Disorder|
10211752|NCT04143659|Experimental|LB injection 40 mg subcutaneous (SC) with 70 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 70 mg/ml concentration
10211753|NCT04136366|Experimental|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
9884641|NCT04680130||Neurodegenerative symptoms|
9884642|NCT04680052|Experimental|Arm A : tafasitamab + rituximab + lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
9884643|NCT04680052|Placebo Comparator|Arm B : placebo+rituximab+lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
9884644|NCT04673136|Experimental|Colonoscopy assisted by GI-GENIUS|
9884645|NCT04673136|Placebo Comparator|Standard colonoscopy|
9884646|NCT04669600|Experimental|BIVV0020|All eligible participants will receive BIVV020 for at least 52 weeks.
9884647|NCT04666610|Experimental|Brivaracetam 200 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
9884648|NCT04666610|Experimental|Placebo to 200 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period."
9884649|NCT04666610|Experimental|Brivaracetam 100 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
9884650|NCT04666610|Experimental|Placebo to 100 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period."
9884651|NCT04666610|Experimental|Optimal dose of BRV (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment Period (AT):~Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period."
9884652|NCT04666610|Experimental|Placebo to BRV optimal dose (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period."
9884653|NCT04666610|Experimental|Brivaracetam received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period."
9884654|NCT04666610|Experimental|Placebo received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks."
9884655|NCT04666441|Experimental|IV Dose 1|Combination therapy intravenous (IV) single dose
9884656|NCT04666441|Experimental|IV Dose 2|Combination therapy IV single dose
9884657|NCT04666441|Experimental|IV Dose 3|Combination therapy IV single dose
9884658|NCT04666441|Experimental|IV Dose 4|Combination therapy IV single dose
9884659|NCT04666441|Experimental|Placebo IV Dose|Matching placebo IV single dose
9884660|NCT04666441|Experimental|SC Dose 1|Combination therapy subcutaneous (SC) single dose
9884661|NCT04666441|Experimental|SC Dose 2|Combination therapy SC single dose
9884662|NCT04666441|Experimental|Placebo SC Dose|Matching placebo SC single dose
9884663|NCT04660201|Experimental|Group 1|AV7909 liquid formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
9884664|NCT04660201|Active Comparator|Group 2|AV7909 lyophilized formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
9931345|NCT00937365|Active Comparator|Exercise|Specific strengthening exercises demonstrated to improve pregnancy-related low back pain are taught to participants of this arm. Additionally, each participant will be evaluated and additional exercises will be prescribed relevant to her particular needs. Study participants of this arm are asked to perform the exercises at home at least once a day. Exercise is recorded in a diary. Participants follow the same study visit schedule as the two other arms.
10211754|NCT04136366|Active Comparator|Standard surgical care procedure|Standard procedure performed.
10211755|NCT04117490|Active Comparator|Epiitalis low dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
10211756|NCT04117490|Active Comparator|Epiitalis mid dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
10211757|NCT04117490|Active Comparator|Epiitalis high dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
10211758|NCT04117490|Placebo Comparator|Placebo|Two capsules twice daily 30 mins before meals (breakfast & dinner).
10211759|NCT04112641|Placebo Comparator|Placebo capsules|Subjects will take 2 capsules in the a.m. and 2 capsules in the p.m. daily for 84 days.
10211760|NCT04112641|Experimental|Nicotinamide Riboside (NIAGEN)|Subjects will take 2 250-mg capsules in the a.m. and 2 250- mg capsules in the p.m. daily (total daily dose is 1 g) for 84 days.
9884665|NCT04659044|Experimental|Treatment (rituximab, polatuzumab vedotin, venetoclax)|"INDUCTION: Patients receive rituximab IV on day 1 of cycle 1 and rituximab and hyaluronidase human SC over 5 minutes on day 1 of cycles 2-6. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 and venetoclax PO daily on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive venetoclax PO daily and rituximab and hyaluronidase human SC over 5 minutes every 60 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
9884666|NCT04651543||no control X-Ray|patients with a proximal humeral fracture without one-week X-Ray control
9884667|NCT04651543||one-week X-Ray control|patients with a proximal humeral fracture with one-week X-Ray control
9884668|NCT04649008|Experimental|Epilepsy patient volunteers|Patients recruited for the study with intractable epilepsy who are anticipated to undergo epilepsy surgery
9884669|NCT04648852||Participants in the third wave of the HUNT study|General population participating in the third wave of the HUNT study
9884670|NCT04648852||Participants in the second wave of the HUNT study|General population participating in the second wave of the HUNT study
9884671|NCT04647487|Experimental|LY3484356 Dose Level 1|Administered orally.
9884672|NCT04647487|Experimental|LY3484356 Dose Level 2|Administered orally.
10211761|NCT04111874|Experimental|Low-Intensity Therapist Assistance (LTA)|Parents will receive four 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
10211762|NCT04111874|Active Comparator|Standard Therapist Assistance (STA)|Parents will receive ten 60-minute supportive video calls with a therapist over the 12 weeks of treatment.
9884673|NCT04647487|Experimental|LY3484356 Dose Level 3|Administered orally.
9884674|NCT04647409|Other|participants|
9884675|NCT04644055||Chronic liver disease with liver cirrhosis|Evaluation of the right and left hepatic lobe with EUS-guided share wave evaluation. All patients with chronic liver disease will have a transient elastography evaluation, EUS- elastography of the liver and an EUS-guided liver biopsy.
9884676|NCT04644055||Control patients|Patients without history of chronic liver disease after clinical and transient elastography evaluation will be submitted for EUS-guided share wave evaluation of the liver. Patients were originally undergoing EUS evaluation for evaluation of suspected subepithelial lesions.
9884677|NCT04642690||Group 1-NSE|Patients found to have grossly normal squamous epithelium during endoscopy
9884678|NCT04642690||Group 2-EEG|Patients found to have grossly apparent erosive esophagitis >1cm with Los Angeles Classification A-D
9884679|NCT04642690||Group 3-NDBE Short|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Short Segment)
9884680|NCT04642690||Group 4-NDBE Long|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Long Segment)
9884681|NCT04642690||Group 5|Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
9884682|NCT04642690||Group 6-Esophagectomy|Patients undergoing resection of esophageal cancer
9884683|NCT04642690||Group -7 Pilot and Feasibility|Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques
9884684|NCT04642378|Experimental|iNCDSS group|Artificial intelligence assisted insulin titration system group
9884685|NCT04642378|Active Comparator|Routine treatment group|Physician decided insulin titration group
9884686|NCT04640077|Other|Part A Validation of Remote Scale Assessments|"Alternating at-home and on-site cognitive and functional scale assessments~Group 1: Cognitive/functional scale assessment at the study site (on-site), followed by an at-home assessment (VTC; video teleconference), or Group 2: Cognitive/functional scale assessment at home (VTC), followed by assessment on-site"
9884687|NCT04640077|Other|Part B Donanemab|Donanemab administered intravenously (IV)
9884688|NCT04638946|Experimental|Titration to high intensity exercise|
9884689|NCT04638946|Active Comparator|Low intensity exercise|
9884690|NCT04634240|Experimental|Complete Revascularization|Routine PCI (percutaneous coronary intervention) of all suitable coronary artery stenoses of ≥70% in vessels ≥2.5mm in diameter.
10211763|NCT04108962|Experimental|Treatment|Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment
10211764|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 1|"One stimulation will be conducted using Anodal treatment.~The Direct Current Anodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session."
10211765|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 2|A final stimulation will be conducted using Cathodal stimulation. Direct Current Cathodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session.
10211766|NCT04105530|Placebo Comparator|Sham treatment|"The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes.Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial:"
10211767|NCT04097379|Experimental|LRX712 Arm 1|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
10211768|NCT04097379|Placebo Comparator|Placebo|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
10211769|NCT04097379|Experimental|LRX712 Arm 2|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
9884691|NCT04634240|No Intervention|Medical Therapy Alone|No revascularization of coronary artery lesions.
9884692|NCT04633824||Patients with private insurance|
9884693|NCT04633824||Patients with public/self-payer insurance|
9884694|NCT04632056||Beovu|Brolucizumab (Genetical Recombination) 6 mg (0.05 mL) is administered by intravitreal injection every 4 weeks for the first three doses(loading phase). In the following maintenance phase, Brolucizumab is basically administered every 12 weeks. The interval between treatments is adjusted as appropriate according to the symptoms. The interval between two doses should not be shorter than 8 weeks
9998204|NCT01516060|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
9884695|NCT04630886|Experimental|Tranexamic acid|The TXA group will receive 2% lidocaine with 1:100,000 epinephrine mixed 50/50 with 50mg/ml TXA (with 50% dilution, this will yield 1% lidocaine with 1:200,000 epi).
9884696|NCT04630886|Active Comparator|Control|The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
9884697|NCT04630496|Experimental|PRE-OPERATIVE EXERCISE TRACKING|"Participant baseline information will be collected from their electronic medical records.~After enrollment, participants will be provided a mobile device (Fitbit) to wear for tracking steps for 1 week prior to their scheduled surgery.~Participants will keep a log of daily steps for the 1 week they are wearing the device and receive one progress check-in call during the week.~The device and log will be turned in either on a pre-surgery clinic visit or on the day of surgery whichever comes first."
9884698|NCT04627428|Experimental|50,000 cells|Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.
9884699|NCT04627428|Experimental|150,000 cells|Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.
9884700|NCT04627428|Experimental|250,000 cells|Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.
9884701|NCT04623983|Experimental|resilient bonding tray|Patients receiving resilient orthodontic bonding trays
9884702|NCT04623983|Experimental|rigid bonding tray|Patients receiving rigid orthodontic bonding trays
9884703|NCT04620057|Experimental|Butyrate + standard care for pediatric obesity|standard care for pediatric obesity + sodium butyrate (20 mg/kg body weight/day)
9884704|NCT04620057|Placebo Comparator|placebo + standard care for pediatric obesity|standard care for pediatric obesity + placebo (cornstarch)
9884705|NCT04615182|Experimental|OCS Preservation|
9884706|NCT04615143|Experimental|Tislelizumab|Tislelizumab is one kind of PD-1 inhibitors. Patients enrolled will receive Tislelizumab as neoadjuvant treatment before surgery (200mg q3w*2 cycles) and as adjuvant treatment after surgery for 1 year
9884707|NCT04615143|Experimental|Tislelizumab Combined Lenvatinib|Patients enrolled will receive Tislelizumab combined Lenvatinibas neoadjuvant treatment before surgery (Tislelizumab: 200mg q3w*2 cycles+Lenvatinib 8/12mg qd*4weeks) and as adjuvant treatment after surgery for 1 year
9931346|NCT00937365|Experimental|Spinal Manipulation|Women randomized to this arm will be evaluated for spinal subluxations and, if appropriate, treated with chiropractic manipulation. Type of manipulation is determined by presentation. Woman may be manipulated with high velocity low amplitude thrust, blocking, activator, or other appropriate means of manipulating.
9931347|NCT00937365|Experimental|Neuroemotional technique (NET)|"Neuroemotional technique (NET) is a mind-body technique which combines elements of chiropractic medicine, Chinese medicine, and behavioral psychology. Muscle response testing, a form of functional neurology, and visceral somatic reflexes are used to ascertain whether the pain or dysfunction experienced by the participant has an emotional component. If an emotional component is present, it is identified and the original triggering occurrence is identified. The participant creates a snapshot of that original occurrence and while she holds that image in her mind spinal levels which innervate the associated organ are adjusted."
9931348|NCT00937417|Experimental|Arm 1|vandetanib and docetaxel
9931349|NCT00937430|Experimental|Bowel preparation group|Patients randomized to this arm will perform a bowel preparation prior to their pelvic organ prolapse surgery.
9931350|NCT00937430|No Intervention|No Bowel preparation group|Patients randomized to this group will not be performing a bowel preparation prior to their pelvic organ prolapse surgery.
9931351|NCT00937443||Walking Exercise Group|Walking Exercise Group versus Control Group
9931352|NCT00937456|Experimental|Laparoscopically-assisted esophagectomy|Laparoscopically-assisted esophagectomy: standard abdominal procedure of gastric mobilisation but through laparoscopic route. Right thoracotomy as usual.
9931353|NCT00937456|Active Comparator|Open esophagectomy|Conventional open esophagectomy: Esophagectomy with extended 2-field lymphadenectomy through laparotomy and right thoracotomy (Ivor-Lewis standard procedure)
9931354|NCT00937469|Experimental|Social sk. tr., parent tr.,standard tr.|
9931355|NCT00937469|Active Comparator|Standard treatment|
9931356|NCT00937482|Experimental|Treatment (cediranib maleate and WBRT)|Patients receive oral cediranib maleate on day 1. Patients undergo whole-brain radiotherapy 5 days a week for 3 weeks beginning on day 3. Treatment continues treatment in the absence of disease progression or unacceptable toxicity.
9931357|NCT00937508|Placebo Comparator|Smoking counseling, Placebo|
9931358|NCT00937508|Experimental|Smoking counseling, Varenicline|
10211770|NCT04097002|Experimental|Phase I, Part A, Cohort 1|"Single dose-escalation of ORCA-010, Dose Cohort 1: 1x10*11 viral particles.~Single dose of ORCA-010 will be administered for the first subject only and all relevant safety data for this subject will be reviewed by the DSMB prior to enrolling additional subjects.~After the DSMB review, subjects will be enrolled in groups of three (including the first subject) and assessed for safety and Dose-Limiting Toxicity (DLT) after a single dose of ORCA-010.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
10211771|NCT04097002|Experimental|Phase I, Part A, Cohort 2|"Single dose-escalation of ORCA-010, Dose Cohort 2: 5x10*11 viral particles.~Group of 3 subjects.~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
10211772|NCT04097002|Experimental|Phase I, Part A, Cohort 3|"Single dose-escalation of ORCA-010, Dose Cohort 3: 1.5x10*12 viral particles.~Group of 3 subjects.~Dose will be considered as the Maximum Tolerated Dose based on safety and toxicity results from the 3 treated subjects."
10211773|NCT04097002|Experimental|Phase IIa, Part B, Cohort 4|"Two dose administration of ORCA-010 seperated by 2 weeks, Dose Cohort 4: The Maximum Tolerated Dose depending on Phase I/ Part A results.~Group of 12 subjects."
9884708|NCT04613492|Experimental|Single dose MEDI9253, sequential Durvalumab|Various dose level cohorts for single dose MEDI9253 with sequential Durvalumab dosing
9884709|NCT04613492|Experimental|Multiple dose MEDI9253, sequential Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with sequential Durvalumab dosing;
9884710|NCT04613492|Experimental|Multiple dose MEDI9253, concurrent Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with concurrent Durvalumab dosing.
9884711|NCT04612244|Experimental|FARAPULSE Pulsed Field Ablation System|
9884712|NCT04612244|Active Comparator|Force Sensing Radiofrequency Ablation and Cryoballoon Ablation|
9884713|NCT04608136|Experimental|Yolk ketogenic diet|consume carbohydrate < 10% and 3 whole eggs supplement per day in 12 weeks
9884714|NCT04608136|Experimental|White ketogenic diet|consume carbohydrate < 10% and 6 white eggs supplement per day in 12 weeks
9884715|NCT04608136|Active Comparator|Control group|decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
9884716|NCT04606030|Experimental|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
9884717|NCT04606030|Active Comparator|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
9884718|NCT04601818|Experimental|Interventional arm|During our study period, transplants with a planned recipient anesthesia starting time between 10:00pm-6:00am will be allowed to move to a 6:00-8:00am start at the earliest. To be eligible, donor lungs cross clamp time have to occur between 6pm and 4am and lungs need to be suitable for transplantation without the need for ex vivo lung evaluation. Lungs meeting criteria for direct transplantation will be transported in the usual fashion in a cooler of ice at 4oC and upon arrival to Shands UF Health they will immediately be transferred to cold static preservation at 10oC within a specific refrigerator placed in the Shands UF Health OR. The maximum preservation time from donor cold flush (cross clamp) to recipient anesthesia start should be 12 hours and the recipient procedure should not start before 6am.
9884719|NCT04601818|No Intervention|Retrospective arm|Outcomes will be compared to conventional transplant patients matched by age, medical diagnosis, BMI, lung allocation score and donor type ( DCD vs. NDD) using a 1:2 matching.
9884720|NCT04597684|Active Comparator|Treatment/Intervention|Total Knee Arthroplasty (TKA) with cementless knees
9884721|NCT04597684|Active Comparator|Control|Total Knee Arthroplasty (TKA) with cemented knees
9884722|NCT04593641|Experimental|Cohort 1 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
9884723|NCT04593641|Experimental|Cohort 2 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
9884724|NCT04593641|Experimental|Cohort 3 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
9884725|NCT04584632|Experimental|EVSS|Efemoral Vascular Scaffold System (EVSS)
9884726|NCT04584528|Other|EHR-embedded Individualized Pain Plan (IPP)|The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
9884727|NCT04583735|Other|TEPEZZA|8 infusions of TEPEZZA (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) with a final visit at Week 24 (Treatment Period)
9884728|NCT04583735|Placebo Comparator|Placebo|Placebo once every 3 weeks
9884729|NCT04580485|Experimental|Treatment Group A (TGA) - INCB106385|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
9884730|NCT04580485|Experimental|Treatment Group B (TGB) - INCB106385+INCMGA00012|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
9884731|NCT04577274|Experimental|smoothie with regular formulas (SM)|Participants were given 300 kcal smoothie with regular formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
9884732|NCT04577274|Experimental|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal smoothie with low carbohydrate formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
9884733|NCT04577274|Active Comparator|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal Glucerna within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
9884734|NCT04549168|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
9931359|NCT00937534|Active Comparator|Part A|Young male healthy volunteer
9931360|NCT00937534|Active Comparator|Part B|Elderly male healthy volunteer
10211774|NCT04095663|Active Comparator|Partial Colectomy|Elective segmental colectomy for diverticular disease involves removal of the segment of colon (most commonly sigmoid and/or left colon) where there has been disease identified by computed tomography imaging or colonoscopy. Elective colectomy usually removes the affected colon along with adjacent segments that have diverticula, with a primary anastomosis performed to reestablish bowel continuity. Most surgeons now perform the procedure using a laparoscopic approach, when possible, and sometimes use a temporary, protective stoma if the re-connection is considered high-risk. The technique for laparoscopic resection is not specified by the protocol (allows for any number of laparoscopic port sites, all incision types, hand-assistance and robotic) with details of the technique recorded. If randomized to elective colectomy, patients will be encouraged to undergo the procedure within 6 weeks of assignment.
10213758|NCT03373110|Experimental|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
9884735|NCT04549168|Placebo Comparator|Placebo|Participants will receive one placebo matched to lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
9884736|NCT04545489|Experimental|Intervention group|Participants randomized to the intervention will have 4 visits over 12 months with study staff. In addition, they will also receive focused communication from the interventionist (nurse or pharmacist), with additional BP monitoring support and medication management for 12 months.
9884737|NCT04545489|Active Comparator|Education control group|Participants randomized to the education control group will have 4 visits over 12 months and will receive education materials related to CVD risk reduction.
9884738|NCT04534738|Experimental|Mediterranean Diet|Participants in the Mediterranean Diet arm are asked to follow a Mediterranean Diet for 8 weeks. The diet is ad libitum. A combination of fresh, frozen, and shelf-stable meals are provided for the first 4 weeks. Also during the first 4 weeks, participants receive an education session to discuss how to effectively implement a Mediterranean Diet into their daily routine.
9884739|NCT04534738|No Intervention|Usual care|Participants in the usual care are will complete all the same study assessments as those in the intervention group. They will not receive any specific dietary advice, but they will be permitted to seek dietary advice outside the study. Data from this group are indispensable in understanding the nutritional habits and preferences of patients undergoing chemotherapy, and these data will be used to optimize nutritional interventions in future studies. At the end of the 8-week intervention, the participants in the usual care group will be provided the intervention materials gratis, including one-week of Mediterranean Diet food and education materials.
9884740|NCT04527380|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC).
9884741|NCT04527380|Active Comparator|Adalimumab|Adalimumab given SC. Participants may have the option to switch to ixekizumab given SC during the open label extension period.
9884742|NCT04525937||Patients with Severe Aortic Stenosis with Disparities|Patients will complete a survey and their aortic stenosis will be clinically followed at 30 days and one year
9884743|NCT04525937||Medical Providers with Disparities|Referring primary care providers complete a questionnaire on their referral practices for patients with severe aortic stenosis
9884744|NCT04525599|Experimental|Group 1, ASP3772 Low Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a low-dose level.
9884745|NCT04525599|Active Comparator|Group 1, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
9884746|NCT04525599|Experimental|Group 2, ASP3772 Medium Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a medium-dose level.
9884747|NCT04525599|Active Comparator|Group 2, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
9884748|NCT04525599|Experimental|Group 3, ASP3772 High Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a high-dose level.
9884749|NCT04525599|Active Comparator|Group 3, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
9884750|NCT04523766|Active Comparator|Mindfulness of Breath|
9884751|NCT04523766|Experimental|Mindful Interoceptive Mapping|
9884752|NCT04519619||Aflibercept (Eylea, BAY86-5321)|Decision of Eylea treatment is made by attending investigators according to the Japanese Package Insert
9884753|NCT04515459|Other|Patients treated for bone or soft-tissue sarcoma of the limbs|
9884754|NCT04513418|Experimental|Interventional group|Patients receive omega-3 fatty-acid enriched enteral nutritional emulsion during the neoadjuvant chemoradiotherapy. Patients are meanwhile encouraged to intake 25-30kcal/kg through regular food.
9884755|NCT04513418|No Intervention|Control group|Patients are encouraged to intake 25-30kcal/kg through regular food without supplemental nutritional support before esophagectomy.
9931361|NCT00937573||Xience V|Percutaneous coronary intervention with Xience V stent placement
9931362|NCT00937573||Historical BMS|Percutaneous coronary intervention with bare metal stent placement prior to availability of Cypher, Taxus, or Xience V drug eluting stents at WFUBMC
9931363|NCT00937573||Historical DES|Percutaneous coronary intervention with drug eluting stent placement prior to availability of Xience V drug eluting stents at WFUBMC
9931364|NCT00937573||Contemporary BMS|Percutaneous coronary intervention with bare metal stent placement after Xience V drug eluting stents were available for use at WFUBMC
9931365|NCT00937573||Contemporary DES|Percutaneous coronary intervention with Cypher or Taxus drug eluting stent placement after Xience V drug eluting stents were available for use at WFUBMC
9931366|NCT00937599|Experimental|Brazil Nuts|The first group consumed the brazil nuts and the other group placebo (lactose pills)
9931367|NCT00937612|Experimental|concurrent chemoradiation|patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.
9935485|NCT03641547|Experimental|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 & A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.~Stage A1: M6620 & palliative radiotherapy Stage A2: M6620 & palliative chemotherapy (Cisplatin & Capecitabine) Stage B: M6620 & definitive chemoradiotherapy"
9989549|NCT01434147|Experimental|induction chemotherapy + radiochemotherapy|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine induction chemotherapy: starts within 28 days after bioptical diagnosis. All patients are administered with capecitabine (Xeloda®) 1000 mg/m2 bid during 14 days (d1-d14), oxaliplatin 130 mg/m2 and bevacizumab (Avastin®) 7.5 mg/kg body weight on day 1; repetition days 22 and 43 (3 cycles) Combined radiochemotherapy: starts at the earliest one week after concluded third cycle of induction chemotherapy. Radiotherapy takes place on 5 x 5 days (dose: 1.8 Gy; cumulative dose: 45 Gy). For chemotherapy patients are administered with capecitabine (Xeloda®) 825mg/m² bid, on each radiation day during the first 4 weeks of radiochemotherapy.
9989550|NCT01434160|Experimental|Arm 1|
9989551|NCT01434173||Group 1|
9989552|NCT01434173||Group 2|
9989553|NCT01434199|Experimental|UPD guided group|Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure.
9989554|NCT01434199|No Intervention|non-UPD guided group|Conventional colonoscopy would be done without image guidance.
9989555|NCT01434212||Interferon and ribavirin|All the patients followed the standard treatment protocol.
9989556|NCT01434225|Experimental|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
9989557|NCT01434238|Experimental|Intervention participant|
9989558|NCT01434251|Active Comparator|Standard care|Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks.
9989559|NCT01434251|Other|Delayed intervention|Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is < (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion.
9989560|NCT01434264|Experimental|Self-selected energy healing|Self-selected healing in the self-selection arm
9989561|NCT01434264|No Intervention|self-selected control|Self-selected control in the self-selection arm
9989562|NCT01434264|Experimental|randomized to energy healing|Randomized to healing in the randomization arm
9989563|NCT01434264|No Intervention|Randomized control|Randomized to control in the randomization arm
9989564|NCT01434277|Experimental|Healthy Subjects|Healthy Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
9989565|NCT01434277|Experimental|Dry-Eye Subjects|Dry-Eye Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
9989566|NCT01434303|Experimental|Treatment (entinostat, lapatinib ditosylate and trastuzumab)|Patients receive entinostat PO on days 1 and 15 and lapatinib tosylate PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in the Phase I Trastuzumab Cohort also receive maintenance dose of trastuzumab IV over 30-90 minutes every 3 weeks.
9989567|NCT01434355||Correlative studies|Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
9989568|NCT01434381|Experimental|Pfs25-EPA/Alhydrogel|Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
9989569|NCT01434394|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.
9989570|NCT01434394|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
9989571|NCT01434407|Experimental|Low AGE meal|Test meal prepared by boiling/steaming the food
9989572|NCT01434407|Experimental|High AGE meal|Test meal prepared by frying/grilling the food
9989573|NCT01434420|Experimental|Triple negative breast cancer|Triple negative breast cancer
9989574|NCT01434459|Experimental|Gemcitabine with TheraSphere|
9989575|NCT01434485||Nexium|
9989576|NCT01434524|No Intervention|Control|normal dietary
9989577|NCT01434524|No Intervention|LIVACT|The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
9989578|NCT01434537||SCAN|Venepuncture performed with support of the AccuVein 300 vein scanner.
9989579|NCT01434537||NO_SCAN|Venepuncture without support of the vein scanner.
9989580|NCT01434550|Active Comparator|TBRI Subgroup: TBRI and SBRT|"Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing the participant's body's white blood cells taken by a procedure called leukapheresis.~Participants do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.~SBRT:~30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
9989581|NCT01434550|Active Comparator|SBRT Alone|"30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
9989582|NCT01434563||HIV positive|Subjects must have documented HIV, be english speaking, with life expectancy greater than 6 months, and must have adequate information available in their medical record to apply HAND predictive algorithm (HIV-associated neurological disease)
9884756|NCT04512066|Experimental|150 mg Once Daily (QD) RO6889450|Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
9884757|NCT04512066|Experimental|45 mg QD RO6889450|Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
9884758|NCT04512066|Placebo Comparator|Placebo|Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).
9884759|NCT04512066|Active Comparator|4 mg QD Risperidone|Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.
9884760|NCT04506905|Experimental|Part 1 (Panel A) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg once daily (QD), orally, over a course of 7-day treatment.
9884761|NCT04506905|Experimental|Part 1 (Panel B) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated up to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panel.
9884762|NCT04506905|Experimental|Part 1 (Panel C) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
9884763|NCT04506905|Experimental|Part 2 (Panel D) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
9884764|NCT04506905|Experimental|Part 2 (Panel E) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
9884765|NCT04506905|Experimental|Part 2 (Panel F) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
9884766|NCT04506905|Experimental|Part 2 (Panel G) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
9884767|NCT04506905|Placebo Comparator|Part 1 (Panels A, B, C) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
9884768|NCT04506905|Placebo Comparator|Part 2 (Panels D, E, F, G) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
9884769|NCT04506216|Experimental|cohort|adult patients with type 1 diabetes and insulin pump treatment . Duration of participation: 30 minutes
9884770|NCT04503772|Experimental|Experimental arm (all patients)|"Patients will receive preoperative hypofractionated stereotactic radiosurgery (SRS).~According to the association of french-speaking neuro-oncologists (ANOCEF) recommendations, total dose and fractionation will be 33 Gy in 3 fractions at the isocenter, 23.1 Gy in envelope (70% isodose), i.e. 30 Gy in growth tumor volume (GTV) envelope.) Surgery will take place within 3 days of the preoperative SRS."
9884771|NCT04502667|Experimental|cholecalciferol (Vitamin D)|Children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally during hospitalization
9884772|NCT04502667|No Intervention|Control|No intervention
9884773|NCT04498910|Experimental|LY3451838|LY3451838 given intravenously (IV)
9884774|NCT04498910|Placebo Comparator|Placebo|Placebo given IV
9884775|NCT04497168|Experimental|Citalopram|20mg daily
9884776|NCT04497168|Placebo Comparator|Placebo|matching placebo pills
9884777|NCT04493502|Experimental|LY3041658|LY3041658 given intravenously (IV).
9884778|NCT04493502|Placebo Comparator|Placebo|Placebo given IV. Participants will switch to LY3041658 given IV after week 16.
9884779|NCT04492917|Experimental|Cranial Technique CV4|"All subjects received a combination of the active technique (CV4) and the corresponding sham technique (shamCV4).~CV4: the lateral angles of the occipital squama are manually approximated slightly exaggerating the posterior convexity of the occiput and taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.~ShamCV4: sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch"
9884780|NCT04492917|Active Comparator|Sacral Technique ST|"All subjects received a combination of the active technique (ST) and the corresponding sham technique (sST).~ST: The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point.~ShamST: sham intervention was performed by placing the hands in the same position of the corresponding active technique, applying a light touch"
9931368|NCT00937638|Experimental|Modified-DASH Diet|
9931369|NCT00937638|Experimental|BOLD diet|
9931370|NCT00937638|Experimental|BOLD-X|
9931371|NCT00937651|Placebo Comparator|Placebo|Placebo, 3 tablets
9931372|NCT00937651|Active Comparator|BR-A-657•K 20 mg group|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
9931373|NCT00937651|Active Comparator|BR-A-657•K 60 mg group|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
9931374|NCT00937651|Active Comparator|BR-A-657•K 180 mg group|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
9931375|NCT00937664|Other|AZD7762 + gemcitabine|AZD7762 administered alone and in combination with gemcitabine
9931376|NCT00937677||1|63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
9931377|NCT00937677||2|22 age- and sex-matched normal controls who completed 1 year follow-up.
9931378|NCT00937690||infrared imaging of cutaneous lesions|patients and volunteers with cutaneous lesions, with and without clinically detectable melanoma, and with one or more palpable cutaneous lesions
9931379|NCT00937703|Placebo Comparator|Group1: Control group|face to face visit à T4mounths
9931380|NCT00937703|Active Comparator|Group2: IVS Group|face to face visit at T4mounths plus telephone visits each 2 weeks
9931381|NCT00937703|Active Comparator|Group3: PDAphone group|PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
9931382|NCT00937716||Diagnosis of Schizophrenia|Patients with a diagnosis of schizophrenia that have been off antipsychotic medicine and would like to resume treatment will be enrolled in the study.
9931383|NCT00937716||Healthy Volunteers|Healthy Volunteers without a psychiatric diagnosis, central nervous system condition, serious head injury, or current drug use will be matched on an individual basis to schizophrenic participants and used as a control population.
9931384|NCT00937729||enfuvirtide|all patients would received enfuvirtide and and optimised background
9931385|NCT00937742|Experimental|Non-tomato products|Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
9931386|NCT00937755||olanzapine|olanzapine 10-20 mg/day
9931387|NCT00937755||quetiapine|quetiapine 300-600 mg/day
9931388|NCT00937755||risperidone|risperidone monotherapy, 2-4 mg/day
9931389|NCT00937807|Active Comparator|sévoflurane|hypnotic use in standard general anesthesia
9931390|NCT00937807|Experimental|LENOXe™ (xénon 100 % v/v)|Safety of use in terms of hemodynamic stability to the LENOXe™ (xénon 100 % v/v) within the framework of the carotid surgery on the old person
9931391|NCT00937820|Experimental|YM150 group|
9931392|NCT00937846|Experimental|GSK1034702|Single oral 5 mg dose in liquid formulation
9931393|NCT00937872|Experimental|SRT2104|Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.
9931394|NCT00937885|Experimental|Implementation of reminiscence|Individual and group reminiscence sessions held with residents, supplemented by reminiscence boxes, posters and exhibitions.
9931395|NCT00937885|No Intervention|Usual nursing care|
9931396|NCT00937898|Experimental|DASH Diet|High fruit and vegetable, low sodium diet
9931397|NCT00937898|Active Comparator|Average American Diet|Typical American diet (16% protein, ~50% carbohydrate, 33% fat)
9931398|NCT00937911|Experimental|YM150 group|
9931399|NCT00937924|Placebo Comparator|1|Control. Normal Saline Injections.
9931400|NCT00937924|Experimental|2|Diphenhydramine injections given as adjunct sedative.
9931401|NCT00937924|Experimental|3|Promethazine given as an adjunct sedative.
9931402|NCT00937963|Experimental|Palm Oil|Traditional palm oil normally used in foods
9931403|NCT00937976|Other|Control-delayed periodontal therapy|
9931404|NCT00937976|Other|Intensive Periodontal Therapy|
9931405|NCT00938028||Microbiome, Metabolome, Stool, Toddler|healthy infant stool samples
9935486|NCT03633617|Experimental|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
9884781|NCT04484727||ICU-patients in ventilator treatment|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each is performed and data on airway pressure and tidal volume changes collected. The data is transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes, suctioning, inhalation, CO2 insufflation etc. is performed, and repeated during the whole period of ventilator treatment."
9884782|NCT04484727||Surgery-patients during general anaesthesia|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each, is performed in the same way as described for ICU patients. Data of airway pressure and volumes are transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes or suctioning is performed, and before and after implementation of pneumoperitoneum."
9884783|NCT04484142|Experimental|DS-1062a 6.0 mg/kg|Participants will receive 6.0 mg/kg of DS-1062a
9884784|NCT04480502|Experimental|Cohort A|Patients treated with 300 mg of single agent envafolimab every three weeks
9884785|NCT04480502|Experimental|Cohort B|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 300 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
9884786|NCT04480502|Experimental|Cohort C|Patients treated with 600 mg of single agent envafolimab every three weeks
9884787|NCT04480502|Experimental|Cohort D|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 600 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
9884788|NCT04472728|Experimental|BIO101|BIO101 350 mg bid
9884789|NCT04472728|Placebo Comparator|Placebo|Placebo
9884790|NCT04472429|Placebo Comparator|Group A : carboplatin+paclitaxel+placebo|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle
9884791|NCT04472429|Experimental|Group B : carboplatin+paclitaxel+retifanlimab|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle
9884792|NCT04471636|Experimental|Telemedicine Care|Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.
9884793|NCT04471636|No Intervention|Control|Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.
9884794|NCT04463771|Experimental|Group A - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
9884795|NCT04463771|Experimental|Group B - retifanlimab|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously
9884796|NCT04463771|Experimental|Group C - retifanlimab + epacadostat|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat (IDO1 inhibitor)
9884797|NCT04463771|Experimental|Group D - retifanlimab + pemigatinib|Select participants who are allowed on prior checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral pemigatininb (FGFR 1,2,3 inhibitor)
9884798|NCT04463771|Experimental|Group E - retifanlimab + epacadostat|Select participants naïve to checkpoint inhibitors will be administered retifanlimab intravenously in combination with oral epacadostat
9884799|NCT04461691|Other|Heart Failure|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
9884800|NCT04461691|Other|Normal cardiac function|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
9884801|NCT04460066|Experimental|PD-L1 group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
9884802|NCT04460066|Placebo Comparator|placebo group|All patients will receive 4 cycles of placebo ( IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
9884803|NCT04459611|Experimental|sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
9517740|NCT03303456|Experimental|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
9884804|NCT04459611|Experimental|sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
9884805|NCT04455841|Experimental|Treatment Group A (TGA)|INCB000928 will be administered once daily( QD).
9884806|NCT04455841|Experimental|Treatment Group B (TGB)|INCB000928 will be administered in combination with ruxolitinib.
9884807|NCT04451226|Experimental|Fezolinetant|Participants will receive fezolinetant once daily for 52 weeks.
9884808|NCT04447716|Experimental|Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)|Patient receive venetoclax PO QD on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) SC on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9884809|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
9884810|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
9884811|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
9884812|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
9884813|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
9884814|NCT04447040|Placebo Comparator|Placebo|Placebo tablets administered as a single two-tablet dose.
9884815|NCT04444895|Experimental|Lanadelumab|Rollover participants from SHP643-303 (NCT04206605) will receive 300 milligram (mg) of lanadelumab solution in prefilled syringe subcutaneously (SC) for 26 weeks once every 2 weeks (Q2W) or once every 4 weeks (Q4W) if well controlled during SHP643-303 (NCT04206605) with up to 13 doses.
9884816|NCT04442178|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
9989583|NCT01434563||HIV negative|Must have documented negative HIV test within 12 months of study entry, have no traumatic brain injury or history of chronic neurological illness/psychiatric conditions (such as bipolar or depression),be english speaking and have no history of drug or alcohol abuse.
9989584|NCT01434576|Experimental|HGS1025 2 mg/kg|
9989585|NCT01434576|Experimental|HGS1025 10 mg/kg|
9989586|NCT01434576|Placebo Comparator|Placebo|
9989587|NCT01434589|No Intervention|Wait list control|
9989588|NCT01434589|Experimental|STICA Intervention|
9989589|NCT01434615|Experimental|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
9989590|NCT01434615|Experimental|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
9989591|NCT01434628|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
9989592|NCT01434706|Other|Nucleic Acid Amplification Testing|Nucleic Acid Amplification Testing
9989593|NCT01434719||S.suis cases|This group consists of human cases with S.suis infection (confirmed or probable) admitted to National Hospital for Tropical Diseases in 2010.
9989594|NCT01434719||Sepsis controls|This group consists of hospital controls diagnosed with sepsis (not caused by S.suis) admitted to National Hospital for Tropical Diseases in 2010.
9989595|NCT01434732|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involved milking the umbilical cord at birth.
9989596|NCT01434732|Active Comparator|Immediate Cord Clamping|Umbilical cord is clamped soon after birth without any milking of the cord.
9989597|NCT01434758||Children|Children age 0-15 years presenting to NHP thought to have TB infection
9989598|NCT01434784||Surgery alone|Patients undergoing any kind surgery for lung cancer, no additional surgery, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
9989599|NCT01434784||Surgery in combination with any other tx|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
9989600|NCT01434784||Surgery (late effects)|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer moduleat least 3 months after surgery and 3 months after any other active treatment
9989601|NCT01434784||Chemotherapy alone|Patient undergoing any kind of chemotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
9989602|NCT01434784||Radiotherapy alone|Patient undergoing radiotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
9989603|NCT01434784||Sequential radiochemotherapy|Patient undergoing sequential radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
9989604|NCT01434784||Concurrent radiochemotherapy|Patient undergoing concurrent radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
9989605|NCT01434784||Targeted therapy alone|Patient undergoing targeted therapy for lung cancer, no surgery, no radiochemotherapy , quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
9989606|NCT01434784||Targeted therapy in combination|Patient undergoing targeted therapy for lung cancer, additional therapies permitted, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
9989607|NCT01434797||Confirmed CVCP infection before removal|Patients with permanent central venous catheter infection confirmed by conventional method
9989608|NCT01434797||Presumed CPVP infection before removal|Patients with probable permanent central venous catheter infection (standard methods for infection detection not conclusive)
9989609|NCT01434797||Uninfected CVCP before removal|Patients with planned permanent central venous catheter removal (no infection)
9989610|NCT01434836|Active Comparator|active tDCS and working memory training|
9989611|NCT01434836|Placebo Comparator|sham tDCS and working memory training|
9989612|NCT01434849|Experimental|Timolol|Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
9989613|NCT01434849|Placebo Comparator|Placebo|Application of 1-2 drops of placebo gel twice daily to hemangioma.
9997361|NCT01508260|Experimental|Pilot Phase Aquapheresis|The first portion of this study is an open label pilot experience to evaluate the safety of aquapheresis in leukemia patients with severe fluid overload non-responsive to diuretics. A total of 10 patients will be treated.
9884817|NCT04442178|Placebo Comparator|Placebo|Intramuscular (IM) administration of Saline twice a week for 3 weeks
9884818|NCT04438135|Active Comparator|active test|
9884819|NCT04438135|Placebo Comparator|placebo test|
9884820|NCT04438018||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
9884821|NCT04438018||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
9884822|NCT04438018||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
9884823|NCT04438018||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
9884824|NCT04429971|Experimental|Immediate PreP initiation|"PreP screening program with immediate PrEP (iPrEP) initiation in the ED using a PrEP starter pack with facilitated linkage to care."
9884825|NCT04429971|Active Comparator|Out-patient care for PrEP initiation|PrEP screening program with referral to out-patient care for PrEP initiation
9884826|NCT04429971|Experimental|PreP Screening Program|Part 1: Targeted ED-based patients
9884827|NCT04426201|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
9884828|NCT04426201|Placebo Comparator|Saline control|Intramuscular (IM) placebo (normal saline) at the same frequency
9884829|NCT04420598|Experimental|Trastuzumab deruxtecan (DS-8201a)|"Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);~Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;~Cohort 3: HER2-positive BC with progressing BMs after local treatment;~Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;~Cohort 5: HER2-positive or HER2-low expressing BC with LMC."
9884830|NCT04417725||Chronic kidney disease|
9884831|NCT04417725||Type 2 diabetes mellitus|
9884832|NCT04417725||Comorbid type 2 diabetes mellitus and chronic kidney disease|
9884833|NCT04416984|Experimental|ALLO-501A, ALLO-647|
9884834|NCT04410367|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
9884835|NCT04407767|Experimental|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
9884836|NCT04407767|Active Comparator|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
9884837|NCT04407689|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
9884838|NCT04407689|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
9884839|NCT04398433|Experimental|INO-3107|Participants will be administered one INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.
9884840|NCT04395703||Maternity staff|Interviews with maternity staff working within a maternity unit including midwifery managers and infant feeding lead staff members.
9884841|NCT04395703||Neonatal unit staff|Staff working within a local maternity unit.
9884842|NCT04389593||Single arm|This is a single arm study in which all participants have one MRI
9884843|NCT04381052|Experimental|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
9884844|NCT04381052|Placebo Comparator|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
9884845|NCT04380740|Placebo Comparator|Standard GVHD Prophylaxis + Abatacept + Placebo|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 4 doses of Abatacept (investigational product) + 4 doses of Placebo.
9884846|NCT04380740|Experimental|Standard GVHD Prophylaxis + Abatacept Extended dosing|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 8 doses of Abatacept.
9884847|NCT04376476|Experimental|Children group E1|Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
9884848|NCT04376476|Experimental|Children group E2|Children with confirmed COVID-19 infection requiring hospitalization will be recruited within participating centers (mostly in emergency and intensive care units). Data will be recorded (clinical examination, biology, immunology, virology measurements) during their hospital stay (day 0, day 7, in case of worsening) and a phone call performed at day 14 (or onsite visit if patient still hospitalized).
9884849|NCT04376476|Experimental|Children group E3|Children with confirmed non-COVID-19 viral infection requiring hospitalization will be recruited within participating centers (mostly in intensive care units). At inclusion, data will be recorded (clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
9884850|NCT04371809||control subjects|
9884851|NCT04371809||subjects with Atrial Fibrillation|
9884852|NCT04371809||subjects with Acute Coronary Syndrome|
9884853|NCT04371809||subjects with Acute Coronary Syndrome and Atrial Fibrillation|
9884854|NCT04360434|Experimental|NI006|Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.
9884855|NCT04360434|Placebo Comparator|Placebo|"Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase.~In the OLE phase, all subjects will be administered multiple doses of NI006."
9884856|NCT04351230|Active Comparator|Arm A (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9884857|NCT04351230|Experimental|Arm B (trastuzumab emtansine, abemaciclib)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 and abemaciclib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9884858|NCT04348747|Experimental|Treatment (anti-HER2/3 dendritic cell vaccine)|"TREATMENT PHASE: Patients receive anti-HER2/HER3 dendritic cell vaccine ID on days 1, 22, and 43. Patients will also receive pembrolizumab IV on the same days.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive a booster dose of anti-HER2/3 dendritic cell vaccine ID, every 3 months in the opinion of principal investigator."
9884859|NCT04342260|Experimental|Active Monitoring|Clinicians will receive symptom alerts if the survey suggests increased or worsening symptoms.
9884860|NCT04342260|Active Comparator|Passive Monitoring|Clinicians will not receive any symptom alerts.
9884861|NCT04338061|Experimental|Evobrutinib + Teriflunomide matched Placebo: DB Period|
9884862|NCT04338061|Active Comparator|Teriflunomide + Evobrutinib matched Placebo: DB Period|
9884863|NCT04338061|Experimental|Evobrutinib: Open-Label Extension Period|
9884864|NCT04331275|Experimental|Viral Specific T-cells (VSTs)|
9884865|NCT04326660|No Intervention|Control|Participants in the control group will receive a Fitbit Alta-Heart Rate (HR) and 12 weekly non-tailored educational modules via WeChat on general health topics that are important to 20-45 year-old women in China. Topics include intimate partner violence, anxiety, depression, sexually transmitted infections, HIV, unintended pregnancy, hepatitis B, and general cancer prevention.
9935487|NCT03633617|Experimental|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
9935488|NCT03633617|Experimental|Part C: Dupilumab|Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
9884866|NCT04326660|Experimental|SCOPE-Chinese Women Intervention|"SCOPE-Chinese Women intervention content and methods: SCOPE-Chinese Women is a smartphone- based intervention.~Component 1. All study participants will receive a Fitbit Alta-HR tracking device to wear daily. Each participant will receive in-person, training on how to access the app and their tracking data. If a participant has not used the fitness device and app for more than one week, a WeChat reminder message will be sent to the participant.~Component 2. Participants will receive 12 weekly culturally appropriate and evidence-based SCOPE-Chinese Women educational modules along with tailored tips and messages via WeChat. Each module will include three educational sessions that last less than 45 minutes total.~Component 3. Six bi-weekly messages will be sent to participants via WeChat to encourage positive behavioral changes. Each participant's message content will be based on the participant's tracker information, personal goals, and preferences."
9884867|NCT04325685|Placebo Comparator|Control group|
9884868|NCT04325685|Active Comparator|Antiseptic (Octenisept) group|
9884869|NCT04325685|Experimental|Bacteriophage (Sextaphag) group|
9884870|NCT04323150|Experimental|Closed suction systems|
9884871|NCT04323150|Other|Open (conventional) suction|control group
9884872|NCT04322084||Participants|Participants will be enrolled during induction therapy for ALL, before the first high-risk period of treatment, and will contribute data for two 5-day periods of continuous monitoring.
9884873|NCT04321759|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
9884874|NCT04321759|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health..
9884875|NCT04310475|Experimental|Active Treatment|This is a case series
9884876|NCT04297488|Experimental|INR(oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus)|Participants will receive oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus once daily for 6 months.
9884877|NCT04291469|Placebo Comparator|Control group|Identical-appearing Placebo (maltodextrin tables) ,oral, daily for 14 weeks
9884878|NCT04291469|Experimental|Probiotics group|Combined Bifidobacteria+lactobacillus+maltodextrin tables, each table contain more than 1.0*10^9 colony forming units, oral, daily for 14 weeks
9884879|NCT04291469|Experimental|Prebiotics group|Combined inulin+maltodextrin tables, oral, daily for 14 weeks
9884880|NCT04288323|Experimental|Single arm|This is a single arm study in which all participants have one ultrasound and one abbreviated MR exam
9884881|NCT04287608||Patients with qualifying conjunctivitis events|
9884882|NCT04287608||Patients with no clinical signs of eye inflammation|
9884883|NCT04287192|No Intervention|Control|Control: Control participants will complete surveys at 4 time points (baseline, 1-2 weeks, 1 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, and assess their quality of life. Aside from completion of these surveys, no changes to their usual care will occur.
9884884|NCT04287192|Experimental|(Digital Bridge intervention)|"Experimental (Digital Bridge intervention) participants will complete surveys at 4 time points (baseline, 1-2 weeks, 1 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, assess their quality of life, and goal attainment.~One to two days before discharge, patients will work with their team to develop the PODS in Care Connector. Once the PODS is created, the patient and hospital provider will be prompted to set transition goals using the ePRO tool."
9884885|NCT04283578|Experimental|Oxytocin|intranasal administration of OT
9884886|NCT04283578|Placebo Comparator|Placebo|intranasal administration of placebo
9884887|NCT04279847|Experimental|INCB057643 Monotherapy|INCB057643 dose escalation (Part 1) and dose expansion (Part 2: treatment group A).
9884888|NCT04279847|Experimental|INCB057643 Combination with Ruxolitinib|Combination arm in dose escalation (Part 1) and dose expansion (Part 2: Treatment Group B)
9884889|NCT04277598|Experimental|Lead In Phase: APO-2: 25U/ml|Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;
9884890|NCT04277598|Placebo Comparator|Lead In Phase: Placebo|Topical administration of placebo; 0.5 ml per square cm wound;
9884891|NCT04277598|Experimental|Main Phase: APO-2: 12.5 U/ml|Topical administration of APO-2, 12.5 U/ml; 0.5 ml per square cm wound;
9884892|NCT04277598|Experimental|Main Phase: APO-2: 25 U/ml|Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;
9884893|NCT04277598|Experimental|Main Phase: APO-2: 50 U/ml|Topical administration of APO-2, 50 U/ml; 0.5 ml per square cm wound;
9884894|NCT04277598|Placebo Comparator|Main Phase: Placebo|Topical administration of placebo; 0.5 ml per square cm wound;
9884895|NCT04276415|Experimental|Dose Escalation: DS-6157a|Participants with advanced gastrointestinal stromal tumor (GIST) who will receive an intravenous infusion of DS-6157a (escalating doses starting at 1.6 mg/kg).
9884896|NCT04276415|Experimental|Dose Expansion: Cohort 1 (3rd line or later) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
9884897|NCT04276415|Experimental|Dose Expansion: Cohort 2 (2nd line) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on imatinib (IM) and had not received a post-IM treatment (2nd line) will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
9884898|NCT04274192|Experimental|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with synchronized)|Subjects will first receive HFNC synchronized to his/her own efforts via NAVA at 6 LPM followed by continuous HFNC at 6 LPM and then HFNC synchronized to his/her own efforts via NAVA at 8 LPM followed by continuous HFNC at 8 LPM
9884899|NCT04274192|Active Comparator|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with continuous)|Subjects will first receive continuous HFNC at 6 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 6 LPM. Next, subjects will receive continuous HFNC at 8 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 8 LPM.
9884900|NCT04267939|Experimental|Dose escalation of BAY1895344 and fixed dose of Niraparib|"In participants with all solid tumor(excluding prostate cancer) and positive for DDR deficiency.~DDR: DNA-Damage Repair"
9884901|NCT04267939|Experimental|Participants PARPi naïve|"Participants with ovarian cancer, PARPi naïve and with a platinum resistant/refractory disease and DDR deficiency.~DDR: DNA-Damage Repair"
9884902|NCT04267939|Experimental|Participants with disease progression on PARPi|Participants with ovarian cancer and disease progression on PARPi
9884903|NCT04263038|Active Comparator|Anticoagulation|Patients in the anticoagulation group will receive rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for an overall treatment duration of 90 days.
9884904|NCT04263038|Placebo Comparator|No anticoagulation|Patients in the group without anticoagulation will receive placebo twice daily for the first 21 days, followed by one tablet daily for an overall treatment duration of 90 days.
9884905|NCT04259346|Experimental|Ixekizumab (Reference)|Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
9884906|NCT04259346|Experimental|Ixekizumab (Test)|Test formulation of 80 mg ixekizumab administered as a SC injection via AI.
9884907|NCT04257526|Active Comparator|Intervention|Colorectal cancer free participants receive evidence-based diet and lifestyle advice in addition to the 'usual care' following a positive FIT test and diagnostic colonoscopy
9884908|NCT04257526|No Intervention|Control|Colorectal cancer free participants receive the 'usual care' following a positive FIT test and diagnostic colonoscopy
9884909|NCT04256967||Sport sciences|Bachelor and master students who study sport science or physical activity and health science
9884910|NCT04256967||Controls|Bachelor and master students who study other fields not related to sport or physical activity and health sciences.
9884911|NCT04255927|Experimental|Coated Polyglactin 910 with Triclosan|Coated Polyglactin 910 with Triclosan
9884912|NCT04255927|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated Polyglactin 910 without Triclosan
9884913|NCT04254484|Experimental|SIESTA Rehab|"Stroke floor on which nurses will be receiving training (SIESTA Rehab Education) on how to minimize nighttime disruptions and batching overnight tasks to preserve sleep for patients hospitalized on that floor. Stroke patients admitted to the SIESTA Rehab Unit will be screening for sleep disordered breathing using ApneaLink.~Patients hospitalized on this unit will be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
9884914|NCT04254484|No Intervention|Control Unit|"Patients on this unit will receive usual care for stroke patients as outlined by SRALab. including routine nursing care without any intervention to promote sleep like SIESTA and routing sleep disorders screenings based on clinician judgement.~Patients hospitalized on this unit will also be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
10213759|NCT03373110|Experimental|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
9884917|NCT04251052|Experimental|Group I (bilateral salpingectomy)|Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery.
9884918|NCT04251052|Active Comparator|Group II (bilateral salpingo-oophorectomy)|Patients undergo bilateral salpingo-oophorectomy.
9884919|NCT04249232|Active Comparator|abaloparatide prefilled syringe|Abaloparatide-SC is supplied as a liquid, 3120 micrograms per 1.56 milliliter (2000 mcg/mL) in a single patient multi-use prefilled pen. The prefilled pen delivers 30 doses of abaloparatide, each containing 80 mcg of abaloparatide in 40 microliters of a sterile, clear, colorless solution. To be administered subcutaneously daily.
9884920|NCT04249232|Placebo Comparator|Placebo prefilled syringe|For the placebo-SC a prefilled multi-use pen injector cartridge is designed to deliver 30 doses of placebo each in 40 microliters of sterile, clear, colorless solution to be administered subcutaneously daily.
9884921|NCT04246489|Experimental|Bintrafusp alfa|
9884922|NCT04246086|Experimental|Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
9884923|NCT04246086|Experimental|Glofitamab + Lenalidomide (Non-randomized)|Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
9884924|NCT04246086|Experimental|Glofitamab + Obinutuzumab + Lenalidomide (Non-randomized)|Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab plus lenalidomide and obinutuzumab for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
9884925|NCT04246086|Experimental|Arm A: IV Mosunetuzumab + Len (Randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
9884926|NCT04246086|Experimental|Arm B: SC Mosunetuzumab + Len (Randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
9884927|NCT04244370|Experimental|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
9884928|NCT04242251|No Intervention|Usual Care|Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.
9884929|NCT04242251|Experimental|SPARKLE intervention group|Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.
9884930|NCT04237584|Active Comparator|Lead-in ARB followed by Radium-223/ARB|Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Radium-223 + ARB.
9884931|NCT04237584|Placebo Comparator|Lead-in ARB followed by Placebo/ARB|Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Placebo + ARB.
9884932|NCT04231968|Experimental|AK0529|Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .
9884933|NCT04231968|Placebo Comparator|Placebo|Participants in the control arm will be administered placebo at the matching dosage levels of active medications.
9884934|NCT04227899|Experimental|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
9884935|NCT04227899|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receives PTA treatment will be included in this arm
9884936|NCT04224688|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
9884937|NCT04224688|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
9884938|NCT04218903|Experimental|Combined Training 4 times per week (CT4)|The CT4 group will perform four sessions per week of combined exercise program. This intervention will last 12 weeks.
9884939|NCT04218903|Active Comparator|Combined Training 2 times per week (CT2)|The CT2 group will perform two sessions per week of combined exercise program. This intervention will last 12 weeks.
9884940|NCT04210206|Experimental|Diet|
9884941|NCT04210206|No Intervention|Control|
9884942|NCT04204668|Active Comparator|Targeted Muscle Reinnervation (TMR)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. These nerves are then cleaned up to be rerouted and connected to smaller nerves that control individual muscles. The connection to nerves that run into muscles is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
9884943|NCT04204668|Active Comparator|Regenerative peripheral nerve interface (RPNI)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. Then the surgeon takes a small sample from a muscle (usually one close by to the nerves that are being operated on but sometimes through a second incision in the arm or leg, depending on the exact medical situation) and form something called a muscle graft. The muscle graft is used to wrap the cleaned ends of the nerves mentioned above. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 1 - 3 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
9884944|NCT04204668|Active Comparator|Vascularized, denervated muscle target (VDMT )|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. The surgeon will then identify a local muscle along with a small artery and vein that supply blood to part of the muscle. A small sample of muscle, still attached to the artery and vein, is then created. The nearby nerves are then nestled into this segment of muscle that is still connected to the artery and vein. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
9935489|NCT03628534|Experimental|single arm|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
9884945|NCT04201457|Experimental|Phase 1 Stratum 1 BRAF V600E LGG or HGG|LGG or HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
9884946|NCT04201457|Experimental|Phase 1 Stratum 2 BRAF aberration or LGG with NF1|LGG with BRAF duplication or fusion with any partner or LGG with NF1 will received Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
9884947|NCT04201457|Experimental|Phase 2 Stratum 3 LGG with BRAF V600 mutation|LGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
9884948|NCT04201457|Experimental|Phase 2 Stratum 4 HGG with BRAF V600 mutation|HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria
9884949|NCT04201457|Experimental|Phase 2 Stratum 5 LGG with BRAF aberration|LGG with BRAF duplication or fusion with any partner will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
9884950|NCT04201457|Experimental|Phase 2 Stratum 6 LGG with NF Type 1|LGG with Neurofibromatosis Type 1 will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
9884951|NCT04200456|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
9884952|NCT04200456|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
9884953|NCT04173650|Experimental|AGLE 102|Treatment arm
9884954|NCT04167163|Active Comparator|Treatment group|"Those with clinical osteoporosis who elect ABL treatment.~ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay."
9884955|NCT04167163|No Intervention|Comparator group|Those with clinical osteopenia who receive no treatment.
9884956|NCT04164277|Experimental|Intervention|"The 16-week intervention includes three components:~Caregiver Component. Facebook-based program including four new habit-formation tasks/week, and 3 face-to-face or virtual caregiver meetings: MSU research staff will lead the meetings at Head Start centers (weeks 1, 8, & 16) to connect caregivers to each other, offer health information, and discuss behavioral change strategies.~Caregiver-Preschooler Learning. Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent privately to each caregiver , and caregivers will be asked to respond to the letters.~Center-based Preschooler Component. Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators."
9884957|NCT04164277|No Intervention|Control|Control group will receive usual Head Start activities during intervention period. After post-intervention data collection, each control caregiver will receive all intervention supplies and a mini program including a face-to-face or virtual caregiver meeting and 1-week preschooler program. The caregiver meeting will cover contents on alternative cooking ingredients, food labels, and portion sizes.
9884958|NCT04154332||Healthy Controls|
9884959|NCT04154332||Preeclampsia Group|
9884960|NCT04152551|Experimental|Adult Treatment Arm|Intervention treatment arm. Adults (18+ years) with type 1 OI. Must have at least mild hearing loss. Will receive Risedronate (35mg, 0-2x/week as clinically indicated) for duration of study. Changes in hearing, quality of life, and bone density will be monitored.
9884961|NCT04152551|No Intervention|Child (Bisphosphonate Arm)|Observational (no investigational intervention) arm. Children (6-17 years) with any type of OI who are already receiving bisphosphonate treatment as standard of care treatment for orthopedic symptoms. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
9884962|NCT04152551|No Intervention|Child (Control Arm)|Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
9884963|NCT04152551|No Intervention|Adult Control Arm|Observational arm. Adults (18+ years) with type 1 OI. Changes in hearing, quality of life, and bone density will be monitored.
9884964|NCT04151667|Experimental|A: Daratumumab & Dexamethasone|All participants will receive 1800 mg in 15 ml Daratumumab by subcutaneous injection weekly and be given 20 mg of Dexamethasone orally once a week for 2 months. Patients who receive a partial response or better will continue on this arm.
9935490|NCT03627026|Other|Patients treated with immune checkpoint inhibitor|
9989614|NCT01434862|Experimental|Closed loop with pramlintide|Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
9935491|NCT03623646|Other|Arm A (standard arm): Chemoradiotherapy arm|
9935492|NCT03623646|Experimental|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
9935493|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
9935494|NCT03610802||Biological relatives|Biological relative (mother, father, siblings, children, grandparents, aunts, uncles, or first cousins) of patient, with no clinical evidence of having a PID.
9935495|NCT03610802||Patients|Patients with PID, which may be defined by laboratory and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity.
9935496|NCT03610516|Experimental|CFZ533|Investigational drug CFZ533 will be administred as multiple doses
9935497|NCT03610516|Placebo Comparator|Placebo|Investigational drug matching placebo will be administered as multiple doses
9935498|NCT03606499||Inflammatory Bowel Disease (IBD) Participants with EIMs and/or IMIDs|IBD (Crohn's Disease [CD] or Ulcerative Colitis [UC]) participants with suspected extra-intestinal manifestations (EIMs) and/or one or more immune-mediated inflammatory diseases (IMIDs) will be enrolled into the study to assess effectiveness of ustekinumab on EIMs and/or IMIDs associated with IBD (both CD and UC). Participants will receive ustekinumab at study entry (Week 0) as treatment for IBD according to standard clinical practice and will be followed up to 24 weeks (+/- 3 weeks). Only data available per clinical practice will be collected within this study.
9935499|NCT03602612|Experimental|1/Conditioning chemotherapy plus CAR T-cells dose escalation|Patients will receive escalating doses (up to 5 planned) of CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
9935500|NCT03602612|Experimental|2/Conditioning chemotherapy plus CAR T-cells expansion phase|6.0x10^6 dose (maximum feasible dose) of CAR T Cells + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
9935501|NCT03602599||Healthy-controls Longitudinal Cohort|( Cohort HL ; approximate n=20) includes subjects who will participate in up to 4 study visits across 1 year.
9935502|NCT03602599||Healthy-controls Short-term Cohort|( Cohort HS ; approximate n=80) will participate in a single baseline visit.
9935503|NCT03602599||New Transplant Cohort|( Cohort NT ; approximate n=300) consists of patients who are scheduled to undergo allogeneic HSCT (under another protocol at the NIH).
9935504|NCT03602599||Prior Transplant Cohort|( Cohort PT ; approximate n=100) consists of patients who have already undergone allogeneic HSCT.
9935505|NCT03598257|Experimental|Group I (olaparib, radiation therapy)|Patients receive olaparib PO BID the day before standard RT commences (Day 0) and throughout the RT course until the last day of RT administration. Olaparib is also continued on weekends (routine days without RT) throughout the RT course. Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
9935506|NCT03598257|Active Comparator|Group II (radiation therapy)|Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity
9935507|NCT03596645|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
9935508|NCT03596645|Experimental|Group 2: Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
9935509|NCT03594487|Experimental|Interventional FMT Treatment Arm|"After providing written informed consent, subjects will undergo screening and baseline assessments of stool and blood sampling, questionnaires, physical examination, MS rating scales, and MRI. Subjects will then initiate an oral antibiotic regimen for 5 days to precondition the gut for the Fecal Microbiota Transplantation (FMT) of FMP30 donor stool and optimize engraftment of the FMP30 donor stool microbiome. Following standard bowel preparation for colonoscopy, subjects will undergo the FMT procedure by an experienced gastroenterologist. Subjects will return for scheduled assessments and follow-up MRI for 12 weeks, with additional safety and biomarker follow-up for 36 weeks.~The active study time is designed to be short (12 weeks active phase) to minimize time not on other MS disease modifying therapy (DMT). This arm of the study will last for approximately 52 weeks total (4 weeks of screening + 12 weeks active treatment phase + 36 weeks of safety follow up)."
9989615|NCT01434862|Experimental|Closed loop without pramlintide|This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
9989616|NCT01434862|Experimental|Open loop with pramlintide|The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.
9989617|NCT01434888|Active Comparator|Tafluprost 0.0015%|
9989618|NCT01434888|Active Comparator|Timolol 0.5%|
9989619|NCT01434888|Experimental|Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%|
9989620|NCT01434901|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
9989621|NCT01434901|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
9989622|NCT01434901|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
9989623|NCT01434914|Active Comparator|verum|
9989624|NCT01434914|Placebo Comparator|Placebo|
9989625|NCT01434927||Colonoscopy outpatients|All patients referred to our Unit to undergo colonoscopy for any indication
9989626|NCT01434940|Experimental|Alzheimer|Patients suffering of Alzheimer disease
9989627|NCT01434940|Experimental|Depression|Patients suffering from depression
9989628|NCT01434940|Experimental|Healthy|Healthy volunteers
9989629|NCT01434953|Experimental|Labeled|
9989630|NCT01434953|Active Comparator|Unlabeled|
9989631|NCT01434966|Experimental|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
9989632|NCT01434966|Experimental|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
9989633|NCT01434966|Experimental|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
9989634|NCT01434979||Controls|Active Duty,DoD Beneficiary, or civilian men and women between the ages of 18 and 45 years, with a waist circumference ≤ 39.4 inches (100 cm) will be asked to participate.
9989635|NCT01434979||Exertional Heat Illness / Stroke|Active duty men and women between the ages of 18 and 45 years will be asked to participate. They must have a clinically documented heat stroke within the last year; they will not be tested any sooner than six weeks following the heat stroke. Heat stroke for the purpose of this study is defined as: a syndrome of hyperthermia, physical collapse or debilitation, and encephalopathy as evidenced by delirium, stupor, or coma, occurring during or immediately following exertion or significant heat exposure.
9989636|NCT01434992||H. pylori gastritis|
9989637|NCT01435005|Active Comparator|High Volume|Participate in one year of high volume (300 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
9989638|NCT01435005|Active Comparator|Moderate Volume|Participate in one year of moderate volume (150 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
9989639|NCT01435057|Active Comparator|endurance training|"Endurance training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min tread mill, rawing device or bicycle training.~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
9989640|NCT01435057|Active Comparator|strength training|"Strength training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min circle training~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of two to three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
9989641|NCT01435070||Distal radius fracture|Patients aged 18 years and older with a fracture of the distal radius, within 3 cm of the radiocarpal joint
9989642|NCT01435083|Experimental|nocturnal polyuria patient with desmopressin MELT|
9989643|NCT01435096|Experimental|BN80927|
9884965|NCT04151667|Experimental|B: Daratumumab, Dexamethasone and Lenalidomide|Participants who have less than a partial response to Arm A may have Lenalidomide added to their treatment. Lenalidomide will be given orally on days 1-21 of each 28 day treatment cycle.
9884966|NCT04151667|Experimental|C: Daratumumab, Dexamethasone and Bortezomib|Participants who have less than a partial response to Arm A may have Bortezomib added to their treatment. Bortezomib will be given weekly in subcutaneous injections at a starting dose of 1/3 mg/m^2 Days 1,8 and 15 of each 28 day treatment cycle.
9884967|NCT04148430|Experimental|Arm 1 (CART Cell Group)|"Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days.~Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days"
9884968|NCT04145349|Experimental|Ramucirumab + Cyclophosphamide + Vinorelbine|Ramucirumab given intravenously (IV), Cyclophosphamide given orally and vinorelbine given IV.
9884969|NCT04145349|Active Comparator|Cyclophosphamide + Vinorelbine|Cyclophosphamide given orally and vinorelbine given IV.
9884970|NCT04139538|Experimental|Invisalign treatment|Aligner patients will be treated with Invisalign® aligners to correct malocclusion
9884971|NCT04139538|Active Comparator|selfligating bracket treatment|Multibracket patients will be treated with self ligating orthodontic brackets
9884972|NCT04137770|No Intervention|control|Patients will receive routine post-operative analgesics
9884973|NCT04137770|Experimental|intervention|Patients will receive routine post-operative analgesics plus scheduled ketorolac and surgical site ice packs
9884974|NCT04137224|Experimental|IgPro20|20% liquid formulation of human immunoglobulin for subcutaneous use
9884975|NCT04137224|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
9884976|NCT04110327||Claudication|Subjects presenting with claudication, identified as Rutherford category 1, 2, or 3
9884977|NCT04110327||Critical Limb Ischemia|Subjects presenting with rest pain (Rutherford category 4) or minor tissue loss (Rutherford category 5)
9884978|NCT04110327||Critical Limb Ischemia with major tissue loss|Subjects presenting with major tissue loss (Rutherford 6)
9884979|NCT04107675|Experimental|L-CsA 10 mg plus Standard of Care|Liposomal Cyclosporine A 10 mg bid for 12 weeks
9884980|NCT04107675|Experimental|L-CsA 5 mg plus Standard of Care|Liposomal Cyclosporine A 5 mg bid for 12 weeks
9884981|NCT04107675|Placebo Comparator|Liposomal Placebo plus Standard of Care|Liposomal Placebo 2.5 mL bid for 12 weeks
9884982|NCT04102189|Experimental|Semaglutide|2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly
9884983|NCT04102189|Placebo Comparator|Placebo|Placebo injected s.c. once weekly .
9884984|NCT04100044|Experimental|Health Services Research (physical therapist, exercise)|Patients meet with a physical therapist on day 0 and at 3 and 6 months and receive a personalized home exercise intervention consisting of aerobic and resistance training for 6 months. Patients also receive face-to-face sessions, video chats, or text message check-ins with physical therapist weekly for 6 weeks and then every other week for up to 24 weeks.
9884985|NCT04093167|Experimental|Pembrolizumab|200mg (or 2mg/kg) IV every 3 weeks for cycles 1-3 then as per standard of care for patients with PD-L1+ EGFR/ALK-NSCLC
9884986|NCT04091672|Experimental|All Participants (within patient control)|All subjects will receive both RECELL and skin graft. Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment (RECELL) will be randomly allocated to either Area A or Area B
9884987|NCT04091217|Experimental|Atezolizumab + Bevacizumab|
9884988|NCT04088396|Experimental|Baricitinib|Baricitinib given orally.
9884989|NCT04088396|Placebo Comparator|Placebo|Placebo given orally.
9884990|NCT04088331||AMS 800 Artificial Urinary Sphincter Recipients|Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
9884991|NCT04085458|Other|Severe hemophilia A patients|Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.
10213760|NCT03373110|Active Comparator|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
10213761|NCT03365102|Experimental|anodal tDCS over the rIFG,|anodal tDCS over the rIFG,
9989644|NCT01435109|No Intervention|Usual Care|
10213762|NCT03365102|Experimental|anodal tDCS over the lOFC|anodal tDCS over the lOFC
10213763|NCT03365102|Placebo Comparator|sham tDCS stimulation|sham tDCS stimulation
10213764|NCT03364491|Experimental|Tranexamic Acid|Tranexamic Acid for intravenous administration
10213765|NCT03364491|Placebo Comparator|Placebo|Normal saline for intravenous administration
10213766|NCT03360019|Active Comparator|Residents in memory care or skilled nursing Facility|
10213767|NCT03360019|Active Comparator|Resident in independent living setting|
10213768|NCT03360019|Other|Care Partners|
10213769|NCT03348306|Experimental|All patients|
10213770|NCT03338920|Experimental|Sumatriptan nasal powder|Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
10213771|NCT03338920|Placebo Comparator|Placebo|Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.
10213772|NCT03338218|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
10213773|NCT03338218|Active Comparator|Ionolyte|Ionolyte solution for infusion
10213774|NCT03318003|Experimental|Auto-PAP Therapy|
10213775|NCT03318003|No Intervention|No Therapy|
10213776|NCT03317743|Experimental|NOV140101 (IDX-1197)|
10213777|NCT03312881||neuropathic pain|Children with clinical diagnosis of neuropathic pain. Interventions: patient reported outcome measures, quantitative sensory testing, neuroimaging
9884994|NCT04077372|Experimental|Serious illness conversation guide (SICG)|"Patients have serious illness conversation within 3 wks of randomization and every 3 months thereafter."
9884995|NCT04077372|Active Comparator|Conversations by treating team|Patients have conversations as determined by treating team (but not using SICG tool).
9884996|NCT04075487|Experimental|User experiences with MEPS-Pain|This is a pilot study to assess user experience with MEPS-Pain App, there is only one arm.
9884997|NCT04067726|Experimental|Denosumab|"Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination.~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur.~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
9884998|NCT04067726|Placebo Comparator|Placebo|"Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur.~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
9884999|NCT04065971|Experimental|2LHERP® arm|Group N°1: 2LHERP® treatment (6 months of treatment)
9885000|NCT04065971|Placebo Comparator|Placebo arm|Group N°1: Placebo treatment (6 months of treatment)
9885001|NCT04061135|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
9885002|NCT04061135|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
9885003|NCT04059237|Experimental|Online Decision Aid|web-based psychosocial assessment questionnaires will be administered at baseline (T1; pre-intervention) and at one-month (T2) and three-month (T3) follow-up time points.
9885004|NCT04058028|Experimental|Rozibafusp Alfa, Dose A|Investigational product solution in vial
9885005|NCT04058028|Experimental|Rozibafusp Alfa, Dose B|Investigational product solution in vial
9885006|NCT04058028|Experimental|Rozibafusp Alfa, Dose C|Investigational product solution in vial
9885007|NCT04058028|Placebo Comparator|Placebo for Rozibafusp Alfa|Placebo Investigational product solution in vial
9885008|NCT04054050|Experimental|Light therapy|Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).
9885009|NCT04050436|Experimental|Cemiplimab in combination with RP1|Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks
9885010|NCT04050436|Active Comparator|Cemiplimab|Cemiplimab administered intravenously as a single therapy every 3 weeks
9885011|NCT04049799||Medically-supervised withdrawal (MSW)|
9885012|NCT04049799||Opioid agonist treatment (OAT)|
9885013|NCT04049175|Experimental|Treatment A|Administration of CHF 6532 Dose #1
9885014|NCT04049175|Experimental|Treatment B|Administration of CHF 6532 Dose #2
9885015|NCT04049175|Experimental|Treatment C|Administration of CHF 6532 Dose #3
10213778|NCT03312881||non-neuropathic pain|Children with clinical diagnosis of non-neuropathic pain. Interventions: patient reported outcome measures
9885016|NCT04049175|Placebo Comparator|Treatment D|Administration of CHF 6532 Placebo
9885017|NCT04046848|Experimental|Cohort 1|"50 IU/kg (n=4): single-period investigation with a single sc dose of 50 IU/kg OCTA101 profiled up to 72 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 2, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
9885018|NCT04046848|Experimental|Cohort 2|"100 IU/kg (n=4): single-period investigation with a single sc dose of 100 IU/kg OCTA101 profiled up to 96 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 3, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
9885019|NCT04046848|Experimental|Cohort 3|"50 IU/kg (n=8): two-period investigation of a single iv dose of 50 IU/kg Human-cl rhFVIII (Nuwiq) profiled for up to 72 hours after dosing followed by sc dose of 50 IU/kg OCTA101 profiled up to 72 hours in adult male patients with severe hemophilia A.~Treatments will be administered in fixed sequence, with Human-cl rhFVIII first.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 4 and 5 alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
9885020|NCT04046848|Experimental|Cohort 5|(n=4): Three-period investigation of single sc doses of 20, 40, and 60 IU/kg OCTA101 profiled up to 72 hours after dosing. Treatments were to be administered in fixed dose-ascending sequence.
10213779|NCT03309072|Experimental|active tDCS|active tDCS with Face Name associate Memory task
10213780|NCT03309072|Sham Comparator|sham tDCS|sham tDCS with Face Name associate Memory task
10213781|NCT03308188|No Intervention|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
10213782|NCT03308188|Experimental|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
10213783|NCT03286699|Active Comparator|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
10213784|NCT03286699|Active Comparator|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
10213785|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
9885021|NCT04046848|Experimental|Cohort 6|(n≥16): Following an initial 4 to 6-week run-in period with Nuwiq iv prophylaxis, >3-6 months daily prophylactic treatment with 12.5 IU/kg OCTA101 sc, then 25 IU/kg OCTA101 sc for a further 6-7 months (exact dosing depends on available vial sizes). In case of two spontaneous bleeding episodes, after having completed at least 3 months with 12.5 IU/kg OCTA101 daily treatment the individual treatment dose will be increased from 12.5 to 25 IU/kg. Site of administration (abdomen or thigh) to be chosen by the patient. A further treatment phase with 40 IU/kg OCTA101 will be discussed with the DMC, once results of earlier dosing phases are available.
9885022|NCT04044521|Experimental|Academic detailing only|Clinicians will attend an educational meeting and receive audit and feedback reports for 18 months.
9885023|NCT04044521|Experimental|Academic detailing+practice facilitation|"Clinicians of this group will attend an educational meeting and receive a monthly audit and feedback report for 18 months.~At month 3, clinics will be randomized to receive practice facilitation. Clinics will be asked to follow-up with the facilitators via phone or video chat monthly for months 4-6, then quarterly for months 7-18."
9885024|NCT04044521|Experimental|Academic detailing+practice facilitation+physician peer consul|Clinicians will receive academic detailing at month 0 and practice facilitation at month 3. At month 6, clinics will be randomized to receive physician peer consulting. Clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant.
9885025|NCT04044521|Experimental|Academic detailing+physician peer consulting|"Clinicians of this group will attend an educational meeting and will receive a monthly audit and feedback report for 18 months.~At month 6, clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant."
9885026|NCT04042337|Experimental|PRT Telehealth|Participating parents will receive 12 weekly 60-minute parent training sessions via secure videoconference to learn Pivotal Response Treatment
9885027|NCT04042337|No Intervention|Waitlist|Participants will continue stable community-based treatments
9885028|NCT04040608||experimental group|differences in responses to visual analog scales depending on screen sizes
9885029|NCT04034992||Retrospective CKD cohort|Retrospective (secondary) data refers to patient data extracted from existing electronic health records (EHRs)/registries/databases. It represents existing real-world data, regardless of reason for collection or location of storage and is analogous to those represented in the study protocol for which feasibility assessments are conducted. Retrospective data will be collected from registries, databases, and EHRs. The aim is to identify and extract clinical data retrospectively from a minimum of 100000 (no set maximum) CKD patients via existing databases/registries/EHRs across geographies. The retrospective data will be captured beginning 1 January 2008 through the most currently available data.
9885030|NCT04034992||Prospective CKD cohort|Prospective (primary and secondary) data refers to manual collection/extraction of data in a de novo manner for the purpose of addressing study objectives. Collection/extraction of patient data in the prospective cohort will be done via electronic case report form, questionnaires, and mobile phone/tablet application. The initial aim is to identify and collect/extract data from approximately 1000 (no set maximum) enrolled CKD patients until the decision to stop the study is taken, with the possibility of prospective follow-up for a minimum of approximately 1 year up to a maximum of approximately 3 years. The patient specific data in the prospective cohort will be collected by utilizing Rapid Assessment of Physical Activity (RAPA) questionnaire, Work Productivity and Activity Impairment (WPAI) questionnaire, Short Form (SF)-36 questionnaires, simple food diary, and other patient reported outcomes - including a set of questions to collect patient symptoms.
9885031|NCT04033419|Experimental|Memantine|
9885032|NCT04024423||Related M. abscess isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
9885033|NCT04024423||Unrelated M. abscessus isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
9885034|NCT04024423||Related M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
9885035|NCT04024423||Unrelated M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
9885036|NCT04024423||Related M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
9885037|NCT04024423||Unrelated M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
9885038|NCT04020172|Experimental|Dobutamine+fluid therapy|All patients will receive a baseline infusion of Ringer's lactate at 3ml/kg/hr to satisfy maintenance fluid requirements. The intervention will commence at anesthesia induction and continue for up to 4 hours postoperatively. In addition to maintenance fluids, patients will receive 250ml fluid challenges with crystalloid as required until they are no longer fluid responsive. The absence of fluid responsiveness will be defined as the absence of a sustained rise in stroke volume of at least 10% for 20 minutes or more, at which point, the patient will be considered fluid optimized. At this point, a low-dose dobutamine infusion at a fixed rate (2.5 μg/kg/min) will be commenced and maintained until 4h postoperatively. The infusion rate will be halved and/or discontinued if the patient develops a tachycardia (heart rate ≥ 100bpm) for more than 30 minutes despite adequate anesthesia/analgesia and fluid status.
9885039|NCT04020172|No Intervention|Standard of care|Patients in the control group will also receive a baseline infusion of Ringer's lactate at 3ml/kg/hr to satisfy maintenance fluid requirements, which will be commenced upon admission to the operating room. The anesthetic management will otherwise be according to standard practice. No specific cardiac output monitoring device will be used to guide fluid therapy. Likewise, perioperative dobutamine will not be used unless clinically indicated to improve cardiac function.
10213786|NCT03271489|Experimental|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
9885040|NCT04019444|Experimental|Arm A|One dose (1 ml (5x10^10 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
9885041|NCT04019444|Experimental|Arm B|One dose (1 ml (1x10^11 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
9885042|NCT04019444|Experimental|Arm C|Two doses (1 ml (1x10^11 vp) each) of ChAd155-RG vaccine administered intramuscularly on Day 1 (first dose) and Day 15 (second dose), and 1 ml of matching placebo administered intramuscularly on Days 8 and 22. N=10
9885043|NCT04019444|Active Comparator|Arm D|Three doses (1 ml each) of RABAVERT vaccine administered intramuscularly on Day 1 (first dose), Day 8 (second dose), and Day 22 (third dose), and 1 ml of matching placebo administered intramuscularly on Day 15. N=12 (2 sentinel, 10 non-sentinel)
9885044|NCT04016402||Study Group|All participants enrolled in the study
9885045|NCT04015011|Experimental|Low Calorie Diet (LCD) diet intervention|In person or video conference
9885046|NCT04013763|Experimental|Atopic dermatitis with stop using product|case wheat allergy with atopic dermatitis and stop using wheat containing skin care products
9885047|NCT04013763|Experimental|Atopic dermatitis with containing using product|case wheat allergy with atopic dermatitis and continue using wheat containing skin care products
9885048|NCT04013763|Experimental|Non atopic dermatitis with stop using product|case wheat allergy with normal skin and stop using wheat containing skin care products
9885049|NCT04013763|Experimental|Non atopic dermatitis with continue using product|case wheat allergy with normal skin and continue using wheat containing skin care products
9885050|NCT04013763|No Intervention|Atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and has atopic dermatitis
9885051|NCT04013763|No Intervention|Non atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and no atopic dermatitis
9885052|NCT04005144|Experimental|Treatment (brigatinib, binimetinib)|Patients receive brigatinib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9885053|NCT04003103|Experimental|Islatravir 60 mg|60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
9885054|NCT04003103|Experimental|Islatravir 120 mg|120 mg islatravir administered once monthly, orally in capsule form for 24 weeks
9885055|NCT04003103|Placebo Comparator|Placebo|Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
9885056|NCT04000854|Active Comparator|Calcium hydroxide|Root canal dressing with Ca(OH)2 (Calasept)
9885057|NCT04000854|Active Comparator|Chlorhexidine|Root canal dressing with clorhexidine digluconate 2 % gel
9885058|NCT03997370|Experimental|Treatment (iohexol, standard care carboplatin, blood samples)|Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.
9885059|NCT03994614|Experimental|the TEAS intervention group|Patients in this group will be given TEAS treatment for 12 weeks prior to COS.
9885060|NCT03994614|No Intervention|No intervention group|Patients in this group will not be given any interventions for 12 weeks prior to COS.
9885061|NCT03993873|Experimental|Phase 1 TPX-0022|"The dose-escalation part of the study will determine the safety, tolerability, MTD, and RP2D of TPX-0022.~The dose-expansion part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.~Dose expansion cohorts: Cohort I (NSCLC, METΔex14, treatment Naive), Cohort II (NSCLC with METΔex14, 1 or 2 lines prior systemic therapy, no prior MET TKI), Cohort III (NSCLC with METΔex14, MET TKI-pretreated, up to 2 additional lines of prior systemic therapy Cohort IV (MET amplified NSCLC, received 1 or 2 lines of prior systemic therapy, no prior MET TKI) Cohort V (MET amplified Gastric or GEJ Cancer, received 1 line of prior systemic therapy, no prior MET TKI Cohort VI (MET amplified Gastric or GEJ Cancer, received 2 lines prior systemic therapy, no prior MET TKI Exploratory Cohort VII (MET amplified NSCLC or Gastric/GEJ Cancer with gene copy number (GCN ≥ 5 and < 10), received 1 or 2 lines of prior systemic therapy, no prior MET TKI"
9885062|NCT03989661||Test group|This group corresponds to patients who had undergone preoperative embolization (with resorbable material) before myomectomy.
9885063|NCT03989661||Control group|This group corresponds to patients with myomectomy without embolization.
9885064|NCT03981341|Experimental|Post menopausal sleep apnea|Post menopausal women with severe sleep apnea
9885065|NCT03981341|Experimental|Post menopausal non sleep apnea|Post menopausal women without sleep apnea
9885066|NCT03978793||MyTPill|Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill.
9885067|NCT03977753|Experimental|2LVERU®/2LVERU® JUNIOR|Group N°1: 2LVERU® or 2LVERU® JUNIOR treatment (6 months of treatment)
9885068|NCT03977753|Placebo Comparator|Placebo|Group N°2: Placebo treatment (6 months of treatment)
9989645|NCT01435109|Experimental|Patient Behavioral Intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
10213787|NCT03271489|Placebo Comparator|Placebo|Placebo
10213788|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
10213789|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
10213790|NCT03243838|Experimental|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
10213791|NCT03237780|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10213792|NCT03237780|Experimental|Arm II (atezolizumab, eribulin mesylate)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and eribulin mesylate IV over 2-3 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10213793|NCT03223428||Carcinoid Syndrome patients initiating Xermelo|Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.
9989646|NCT01435109|Experimental|Provider Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
9989647|NCT01435109|Experimental|Patient and Provider Interventions|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
9989648|NCT01435135|Experimental|Group I|ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
9989649|NCT01435135|Experimental|Group II|AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
9989650|NCT01435135|Experimental|Group III|ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
9989651|NCT01435148|Experimental|Stimulation of SGC then VACNAC targets|Stimulation of the subgenual cingulate cortex (SGC) target will take place first, followed by stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) if no clinical response after a minimum of 4 months.
9989652|NCT01435148|Experimental|Stimulation of VACNAC then SGC targets.|Stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) will take place first, followed by stimulation of the subgenual cingulate cortex target (SGC) if no clinical response after a minimum of 4 months.
9989653|NCT01435161|Active Comparator|Nifedipine|Patients in arm 1 receive Nifedipine;
9989654|NCT01435161|Active Comparator|Telmisartan|Arm 2 receive telmisartan
9989655|NCT01435187||Infant Pulmonary Function Testing (iPFT)|A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.
9989656|NCT01435200|Experimental|Intravenous iron|Iron sucrose 200 mg intravenous infusion in 15 minutes
9989657|NCT01435200|Placebo Comparator|Oral iron|Ferrous fumarate 200 mg oral three times a day
9989658|NCT01435213|Experimental|Atipamezole|
9989659|NCT01435213|Experimental|Atomoxetine|
9989660|NCT01435213|Experimental|Ketamine|
9989661|NCT01435213|Experimental|Insulin-induced hypoglycemia|
9989662|NCT01435213|Experimental|Cold pressor test|
9989663|NCT01435213|Experimental|Placebo|
9989664|NCT01435239|Experimental|resting volume group|
9989665|NCT01435239|Active Comparator|maximum volume group|
9989666|NCT01435252|Experimental|Arm A|Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.
9989667|NCT01435252|Experimental|Arm B|Patients will be treated with chemoradiation in combination with concurrent cetuximab.
9989668|NCT01435278|Active Comparator|Glucosanol|2 tablets 3 times a day
9989669|NCT01435291|Experimental|Advagraf|
9989670|NCT01435291|Active Comparator|Prograf|
9989671|NCT01435317|Experimental|standard|Standard treatment with the ANM T30 CR®-System
9989672|NCT01435330|Experimental|BVS857|
9989673|NCT01435330|Placebo Comparator|Placebo|
9989674|NCT01435395|Experimental|Therapy|Therapy with temozolomide, bevacizumab and bortezomib
9989675|NCT01435408|Active Comparator|Conventional treatment.|Conventional primary PCI in STEMI.
9989676|NCT01435408|Experimental|IPost|Ischemic postconditioning in STEMI.
9989677|NCT01435408|Experimental|Deferred primary PCI.|Deferred strategy in STEMI.
9989678|NCT01435434|Experimental|sepax, ignite, fracture healing|the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
9989679|NCT01435447|Experimental|FLu-Bu-Cy|Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
9989680|NCT01435473||Children undergoing heart surgery|The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up
9885069|NCT03977714|Experimental|Group A - test implant and abutment|Zirconia implant and G3-coated abutment (test implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
9885070|NCT03977714|Experimental|Group B - test implant and control abutment|"Zirconia implant and control abutment (test implant, negative control abutment).~Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons."
9885071|NCT03977714|Experimental|Group C - control implant and test abutment|Titanium implant and G3-coated abutment (control implant, test abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
9885072|NCT03977714|Active Comparator|Group D - control implant and abutment|Titanium implant and control abutment (negative control implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
9885073|NCT03977714|Experimental|Group E - test and control implants|"Zirconia implant and titanium implant for histological and histomorphometric evaluation.~This study will be performed in the area of the wisdom teeth (a non useful site that will not interfere with the rest of the study or with the patient's life), so it can only be performed in patients who no longer have these teeth. The procedure will match the procedures described for Groups A-B-C-D. Group E implants will only remain in the mouth for 2 months, after which they will be removed for further analysis. The removal of these implants, for the patient, has exactly the same implications as a normal molar extraction."
9885074|NCT03974113|Experimental|Fitusiran|Participants will receive a selected dose of fitusiran on regular intervals, as per study protocol
9989681|NCT01435486|Active Comparator|caffeine Citrate|
9989682|NCT01435486|Placebo Comparator|Normal saline|
9989683|NCT01435499|Experimental|Cohort A|Cohort A will receive four doses of vaccine, each containing 5E7 melanoma GVAX cells.
9989684|NCT01435499|Experimental|Cohort B|Cohort B will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells.
9885075|NCT03971734|Experimental|Arm 1 regadenoson 0.05mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose.~Regadenoson 0.05mg"
9885076|NCT03971734|Experimental|Arm 2 regadenoson 0.1mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
9885077|NCT03971734|Experimental|Arm 3 regadenoson 0.2mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
9885078|NCT03971734|Experimental|Arm 4 regadenoson 0.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
9885079|NCT03971734|Experimental|Arm 5 regadenoson 0.7mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
9885080|NCT03971734|Experimental|Arm 6 regadenoson 1.0mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
9885081|NCT03971734|Experimental|Arm 7 regadenoson 1.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
9885082|NCT03970447|Active Comparator|Control Arm|"Newly Diagnosed GBM: Radiation therapy (XRT) 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 2-6 weeks from the last day of radiation, and the start of the first cycle of Maintenance Therapy 2-6 weeks after the last day of radiotherapy. The start of all subsequent maintenance therapy cycles (2-12) every 4 weeks + 7 days after the first daily dose of temozolomide of the preceding cycle. Total number of cycles should comply with institutional or country standards. During maintenance therapy, the first cycle of temozolomide will be at 150 mg/m2 for Days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for Days 1-5 of a 28-day cycle.~Recurrent GBM: Lomustine started at 110 mg/m2/day on Day 1 of a 42-day cycle as per local standards. Treatment will continue for up to 6 total cycles."
9885083|NCT03970447|Experimental|Regorafenib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).~Recurrent GBM: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)."
9885084|NCT03970447|Experimental|Paxalisib Treatment Arm|"Newly Diagnosed MGMT Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles.~Recurrent GBM: Paxalisib (Dosage Form: Tablet for oral administration; Strength: 15 mg per tablet) 45 mg orally (PO) every day for 21 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 21 days for all subsequent cycles."
9885085|NCT03970447|Experimental|VAL-083 Treatment Arm|"Newly Diagnosed MGMT Methylated and Unmethylated GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle.~Recurrent GBM: VAL-083 (Dosage Form: Infusion for intravenous administration; Strength: 30 mg/m2) on Day 1, 2 and 3 of 21-day cycle."
9885086|NCT03959423|Experimental|Subjects 7-75 years of age|Subjects who have been diagnosed with type 1 diabetes
9885087|NCT03958591|Experimental|Intensive-de-escalation group with intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Wearable devices and smart apps will be used to manage and follow-up patients.
9885088|NCT03958591|Experimental|Intensive-de-escalation group without intelligent management|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin will be applied. Then the oral hypoglycemic therapies will be prescribed. Traditional ways such as telephone contact will be used to follow-up patients.
9885089|NCT03958591|Active Comparator|Traditionally upgrading group|The combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks and thereafter the oral hypoglycemic therapies will be applied. Traditional ways will be used to follow-up patients.
9885090|NCT03956082|Other|This is a prospective single arm study|"The Ultravision™ System is an FDA-cleared medical device that removes surgical smoke by means of electrostatic precipitation from the visual field during laparoscopic surgical procedures. Surgical smoke refers to the suspended particulate matter that is generated as a by-product of the combustion and other processes that are associated with the use of energy-based surgical instruments."
9885091|NCT03954236|Experimental|topical ruxolitinib BID to left side of face/body|And topical moisturizer BID to right side of face/body.
9885092|NCT03954236|Experimental|topical ruxolitinib BID to right side of face/body|And topical moisturizer BID to left side of face/body.
9885093|NCT03950817|Active Comparator|0.75 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 0.75 mg/kg sub-dissociative dose ketamine (SDK) to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
9885094|NCT03950817|Active Comparator|SDK: 1 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses 1 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
9885095|NCT03950817|Active Comparator|SDK: 1.5 mg/kg.|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 1.5 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
9885096|NCT03933735|Experimental|Arm A: Dose Escalation|Up to 15 cohorts of participants receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
9885097|NCT03933735|Experimental|Arm B: Dose Expansion Dose A|An expansion cohort will be enrolled at the recommended phase 2 Dose A.
9885098|NCT03933735|Experimental|Arm B: Dose Expansion Dose B|An expansion cohort will be enrolled at the recommended phase 2 Dose B.
9885099|NCT03925025|No Intervention|Control|Standard therapy
9885100|NCT03925025|Active Comparator|Magnesium sulfate|Standard therapy plus magnesium sulfate
9885101|NCT03925025|Active Comparator|Nimodipine|Standard therapy plus nimodipine
9989685|NCT01435499|Experimental|Cohort C|Cohort C will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells. One day prior to each vaccination, patients in cohort C will receive a single, low dose of intravenous cyclophosphamide.
9989686|NCT01435525||Nexium|
9517741|NCT03303456|Experimental|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
9517742|NCT03303443||Younger|20-40 years old patients
9517743|NCT03303443||Elderly|over 60 years old patients
9885102|NCT03924440||PDG Test strip Users|"Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence).~Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered their tests and recorded their results. Test results were reported back researchers via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip."
9885103|NCT03917043|Experimental|APG-2449|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 30-40 patient at the MTD/RP2D dose level.
9885104|NCT03914742|Experimental|Phase 1: Dose Finding|"Recurrent IDH1/2-mutant grade II-III glioma: BGB290: Days 1-28, 60 mg PO BID TMZ: Days 1-28, 20 QD starting dose~TMZ de-escalated treatment schedule if necessary (days 1-21; days 1-14; days 1-7) BGG held constant at 60mg PO BID"
9885105|NCT03914742|Experimental|Phase 2: Arm A Alkylator-resistant|"Grade II-III: Recurrent IDH1/2-mutant glioma (WHO grades II/III) who have failed TMZ AND another alkylator~BGB290 + TMZ at dose combination established in Phase 1"
9885106|NCT03914742|Experimental|Phase 2: Arm B NOT Alkylator-resistant|"Grade II-III:Recurrent IDH1/2-mutant glioma (WHO grades II/III) Failed TMZ OR another alkylator;~>/=12 months since last treatment~BGB290 + TMZ at dose combination established in Phase 1"
9885107|NCT03914742|Experimental|GBM Arm|Exploratory grade IV patients only BGB290 at Ph II dose for 7 days pre-surgery Progressed following RT + Chemo
9885108|NCT03914742|Experimental|Surgical Arm|Recurrent IDH1/2-mutant glioma (WHO grade II-IV) eligible for re-resection BGB-290: 60mg PO BID for 6 days AND day once day of surgery (day 7)
9885109|NCT03905707|Experimental|Glepaglutide SC injections twice weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly.~In this long term safety study, there is no placebo arm."
9885110|NCT03905707|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly.~In this long term safety study, there is no placebo arm."
9885111|NCT03878056||Transvaginal mesh|Vaginal surgery (UpholdTM Lite Vaginal Support, Boston Scientific)
9885112|NCT03878056||Robotic sacral colpopexy|Robotic surgery (Artisyn® Y-Shaped Mesh - Ethicon)
9885113|NCT03876171|Experimental|CIFFTA|Family Therapy, Individual Therapy, and Psycho-educational Modules
9885114|NCT03876171|Active Comparator|Standard of Care|The Diversion Programs used by the Juvenile Services Department in Miami-Dade.
9885115|NCT03869190|Active Comparator|Atezolizumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885116|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885117|NCT03869190|Experimental|Atezolizumab + Niraparib for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885118|NCT03869190|Experimental|Atezolizumab + Hu5F9-G4 for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Hu5F9-G4 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885119|NCT03869190|Experimental|Atezolizumab + Tiragolumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885120|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885121|NCT03869190|Experimental|Atezolizumab + Tocilizumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9989687|NCT01435538|Experimental|Care pathway teams.|In this experimental arm, the interprofessional teams will develop and implement a care pathways.
9885122|NCT03869190|Experimental|Atezolizumab + RO7122290 for mUC Cohort (Stage 1)|Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885123|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885124|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
9885125|NCT03869190|Active Comparator|Atezolizumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+|Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
9885126|NCT03869190|Experimental|Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+|Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
9885127|NCT03869190|Active Comparator|Atezolizumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1-|Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
9885128|NCT03869190|Experimental|Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1-|Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
9885129|NCT03869190|Active Comparator|Cisplatin-eligible muscle invasive bladder cancer (MIBC) Cohort 3 Arm 1|Participants will receive 3 cycles of Cisplatin, Gemcitabine and Atezolizumab pre-surgery and 14 cycles of Atezolizumab only post-surgery.
9885130|NCT03869190|Experimental|Cisplatin-eligible muscle invasive bladder cancer (MIBC) Cohort 3 Arm 2|Participants will receive Cisplatin, Gemcitabine, Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles of Atezolizumab and Tiragolumab (Tira) post-surgery.
9885131|NCT03856593|Experimental|Letter A Intervention|The intervention arm will involve letter A sent to prescribers in Los Angeles County.
9885132|NCT03856593|Experimental|Letter B Intervention|The intervention arm will involve letter B sent to prescribers in Los Angeles County.
9885133|NCT03856515|Experimental|Observational (e-cigarettes with or without nicotine, visits)|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
9885134|NCT03851003|Experimental|Endometrial suturing|Uterine incision repair including suturing of the endometrium
9885135|NCT03851003|Experimental|Non - Endometrial suturing|Uterine incision repair without suturing of the endometrium
9931406|NCT00938067|Experimental|Staying Connected: Care Management|The intervention combines case management, psychopharmacological and culturally appropriate and individually tailored trauma support activities with evidence-based treatments.A key feature is the provision of a continuous healing relationship by a care management treatment team.The care manager, informed by the Native healer interviews, will provide a culturally appropriate and ongoing helping relationship to each intervention patient in the weeks and months post-injury and will remain in close contact with the trauma survivor subject for 6 months.Together, the care manager and trauma survivor subject will work on a plan to readjust to daily activities. The care management team will also coordinate psychopharmacological interventions for PTSD and related co-morbidities with primary care and or other community providers.
9931407|NCT00938080|Experimental|AG013: one mouth rinse/day|
9931408|NCT00938080|Experimental|AG013: three mouth rinses/day|
9931409|NCT00938080|Experimental|AG013: six mouth rinses/day|
9931410|NCT00938080|Placebo Comparator|one mouth rinse/day|
9931411|NCT00938080|Placebo Comparator|three mouth rinses/day|
9931412|NCT00938080|Placebo Comparator|six mouth rinses/day|
9931413|NCT00938093|Active Comparator|Cognitive-behavioral therapy|cognitive-behavioral therapy
9931414|NCT00938093|Placebo Comparator|Enhanced usual care|enhanced usual care
9931415|NCT00938106|Experimental|(MR BT) in Cervix Cancer|
9931416|NCT00938119||Diabetes patients with PCI|this is single group
9931417|NCT00938132|Experimental|Fimasartan|
9931418|NCT00938158|Experimental|Stage 1 normal renal function|Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
9931419|NCT00938158|Experimental|Stage 1 moderate/severe renal function|Subject with estimated GFR >= 20 mL/min and less than 50 mL/min
9931420|NCT00938158|Experimental|Stage 2 normal renal function|Subject with GFR greater than 80 mL/min
9931421|NCT00938158|Experimental|Stage 2 moderate renal impairment|Subject with estimated GFR >= 30 mL/min and less than 50 mL/min
9931422|NCT00938158|Experimental|Stage 2 subjects requiring hemodialysis|Subjects who require hemodialysis
9885136|NCT03843359|Experimental|Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort|
9885137|NCT03843359|Experimental|Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort|
9885138|NCT03841565|Experimental|Treatment (pomalidomide, daratumumab, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, days 1-15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Cycles every 28 days in the absence of disease progression or unacceptable toxicity.
9885139|NCT03836261|Experimental|Acalabrutinib, Venetoclax|Acalabrutinib in combination with Venetoclax
9885140|NCT03836261|Experimental|Acalabrutinib, Venetoclax, Obinutuzumab|Acalabrutinib in combination with Venetoclax with or without Obinutuzumab
9885141|NCT03836261|Active Comparator|Chemoimmunotherapy|"Chemoimmunotherapy~FCR: Fludarabine, Cyclophosphamide and Rituximab"
9885142|NCT03836040|Experimental|Dose level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
9885143|NCT03836040|Experimental|Dose level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
9885144|NCT03836040|Placebo Comparator|Placebo|Subjects will be randomized to a placebo comparator.
9885145|NCT03835585|Experimental|Gun lock|Participants will be provided a gun lock and video instructions for its proper use, in addition to standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling).
9885146|NCT03835585|Active Comparator|Standard intervention|Participants will be provided standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling) without a gun lock. A gun lock and video instructions will be provided upon completion of the study.
9885147|NCT03832998|Experimental|Dose Level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
9885148|NCT03832998|Experimental|Dose Level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
9885149|NCT03832998|Placebo Comparator|Placebo|
9885150|NCT03826043|Experimental|Experimental arm|Hospitalized patient
9885151|NCT03816176|Experimental|Isavuconazonium sulfate|Participants will receive a loading dose of isavuconazonium sulfate (via intravenous or oral administration at the investigator's discretion) every 8 hours (± 2 hours) on Days 1 and 2 followed by once-daily maintenance dosing
9885152|NCT03812302|Experimental|DOTATATE|All 15 GCA patients will undergo 68-Ga HA-DOTATATE PET/CT imaging at baseline, in addition to FDG PET/CTA (as part of standard of care). DOTATATE PET/CT imaging will be repeated at 6 months follow-up.
9885153|NCT03800823|Experimental|Parent group & mHealth component|The intervention in the present study is a 10 week parent training group session (More and Less Program) followed by a 6-month mobile phone based intervention. Both components aim to develop healthy lifestyle behaviours regarding dietary habits and physical activity in 2-6 year olds. The intervention is delivered towards the parents.
9885154|NCT03800823|Active Comparator|Standard care|Standard care for overweight and obesity
9885155|NCT03792282|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
9885156|NCT03792282|Active Comparator|Usual care|Participants in this group will receive a general lifestyle counseling.
9989688|NCT01435538|No Intervention|Usual care teams.|In the no intervention arm, the interprofessional teams will deliver usual care without implementing the intervention.
9989689|NCT01435564|Active Comparator|pedometer|
9989690|NCT01435564|Experimental|Mobile phone physical activity intervention|
9989691|NCT01435629||Norditropin®|
9989692|NCT01435642||A|
9989693|NCT01435668|Other|Control|A simple written advice.
9989694|NCT01435668|Experimental|Brief Motivational Intervention (BMI)|Brief Motivational Intervention (BMI)
9989695|NCT01435681||DYT-1 Postive|This group includes those participants who enroll having a genetically confirmed primary generalized dystonia diagnosis.
9989696|NCT01435681||Control|This group includes healthy subjects between the ages of 18 and 80.
9989697|NCT01435694|Experimental|Robot-assisted gait training|Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
9989698|NCT01435694|Active Comparator|Conventional Therapy|Training sessions will focus on locomotor function improvements. Subjects will receive 45 minutes of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that they will be trained on walking abilities (like walking at different speeds, rapid changes directions) for 30 minutes with or without assistive aids.
9989699|NCT01435707|Experimental|Caudal 40 group|subjects who undergo caudal epidural block with triamcinolone 40 mg
9989700|NCT01435707|Experimental|STE 20 group|subjects who undergo selective transforaminal block with triamcinolone 20 mg
9989701|NCT01435707|Experimental|Caudal 20 mg|subjects who undergo caudal epidural block with triamcinolone 20 mg
9989702|NCT01435707|Experimental|STE 40 group|subjects who undergo selective transforaminal block with triamcinolone 40 mg
9989703|NCT01435720|Experimental|Cohort 1|0.0125 mg/kg
9989704|NCT01435720|Experimental|Cohort 2|0.05 mg/kg
9989705|NCT01435720|Experimental|Cohort 3|0.2 mg/kg
9989706|NCT01435720|Experimental|Cohort 4|0.375 mg/kg
9989707|NCT01435733||Parents of children with ASD|Parents with one or more children diagnosed with Autism Spectrum Disorder
9989708|NCT01435746|Experimental|Liberal Transfusion|Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
9989709|NCT01435746|Active Comparator|Conservative Transfusion|Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
9989710|NCT01435811|Experimental|Norovirus challenge pool (GII.4, CIN-1)|
9989711|NCT01435811|Placebo Comparator|Sterile water|
9989712|NCT01435837|Experimental|Caffeine and hydration.|"200 mg of caffeine (over the counter caffeine tablet)~1 liter of water"
9989713|NCT01435837|Placebo Comparator|No caffeine, no hydration.|
9989714|NCT01435850|Sham Comparator|HIP STEM SL PLUS|study group
9989715|NCT01435850|Active Comparator|HIP STEM SL PLUS MIA|control group
9989716|NCT01435863|Experimental|SP-02L|
9989717|NCT01435876|Active Comparator|Surgical arm|UNIOCULAR/BINOCULAR RECESSION/RESECTION PROCEDURES
9989718|NCT01435876|Active Comparator|Exercises|ORTHOPTICS/MINUS LENS THERAPY
9989719|NCT01435876|Active Comparator|Postoperative Exercises|POST SURGICAL ORTHOPTICS/MINUS LENS
9989720|NCT01435876|Active Comparator|Surgical|
9989721|NCT01435902|Active Comparator|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
9885157|NCT03779230|Experimental|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
9885158|NCT03772730||Group 1|Multiply injured patients having at least one operative orthopaedic injury to the pelvis, acetabulum, femur, or diaphyseal tibia with planned definitive fixation to occur prior to discharge.
9885159|NCT03768999||Study group|All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
9885160|NCT03768063|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawl of study consent, unacceptable toxicity, pregnancy, patient non-compliance, or study termination by the Sponsor, whichever occurs first.
9885161|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in superficial tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors
9885162|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in deep/visceral tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in deep/visceral tumors
9885163|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in superficial tumors|Doses of RP1 (IT) in superficial tumors with nivolumab (IV)
9885164|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in deep/visceral tumors|Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)
9885165|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma
9885166|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors
9885167|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer
9885168|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1 Failed Cutaneous Melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy
9885169|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer who have been previously treated with anti-PD1/PD-L1 therapy
9885170|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NSCLC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non small cell lung cancer who have been previously treated with anti-PD1/PD-L1 therapy
9885171|NCT03766438|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care.
9885172|NCT03766438|No Intervention|Control|The comparison group will receive usual clinical care.
9885173|NCT03741530|Experimental|Glibenclamide group|Giving standard management for ICH plus glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
9885174|NCT03741530|Placebo Comparator|Control group|Giving standard management for ICH
9885175|NCT03740815|Experimental|Serratus plane block plus sedation|Serratus plane block plus intravenous sedation as anesthetic technique during axillary dissection procedure.
9885176|NCT03727685|No Intervention|Usual care|Patients admitted to the hospital will not receive information about Our Care Wishes.
9885177|NCT03727685|Active Comparator|Intervention: Our Care Wishes|Patients admitted to the hospital during the intervention phase will receive information from registration representatives regarding Our Care Wishes.
9885178|NCT03724890|Experimental|Part A: M3814 + Avelumab|
9885179|NCT03724890|Experimental|Part B: M3814 + Avelumab + Radiotherapy (RT)|
9885180|NCT03724890|Experimental|Part FE: M3814 + Avelumab (fasted/fed state)|
9885181|NCT03723681|Experimental|Quizartinib 20 mg|Participants receive 20 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
9931423|NCT00938158|Experimental|Stage 2 severe renal impairment not requiring hemodialysis|Subjects with GFR less than 30 mL/min
9989722|NCT01435902|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
9989723|NCT01435915|Experimental|Subjects receiving ropinirole|Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
9989724|NCT01435941||Respondents who report episodic migraines (EM)|Survey respondents whose headaches meet the diagnostic criteria for migraine and report that they experienced between 1 and 14 headache days in the month prior to the survey administration
9989725|NCT01435954||Patients with Benign Prostatic Hyperplasia (BPH)|Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
9997362|NCT01508260|Experimental|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
9997363|NCT01508260|Active Comparator|Diuretics|Furosemide by vein over about 15 minutes every 8 hours or by vein as a continuous (non-stop) infusion.
9997364|NCT01508273|Experimental|Exercise Intervention Program Group|At baseline study visit, participant shown how to complete the physical exercises performed while on study. Pedometer received to track physical activity. Resistance training bands given to use as part of the home-based exercise program. At the baseline study visit, directions received on how to use the study website. Access given to website that will allow tracking of exercise behavior and help set goals. Access given to an internet-based curriculum that will help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participant asked to visit website every week. Participant records activity and the number of steps taken every day on the website. Survey completed monthly about attitudes and beliefs about physical activity.
9997365|NCT01508273|Other|Sedentary Behavior and Dietary Intervention Group|Access given to internet-based curriculum to help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participants read information about improving the quality of their diet and cutting back on sedentary behavior. Participants record on the website how much television watched and how many fruits and vegetables eaten every day. Survey completed monthly about attitudes and beliefs about sedentary behavior and dietary intake.
9997366|NCT01508273|Experimental|Chair-based Study Group|Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
9997367|NCT01508299|Experimental|raw food skin test|skin test with the suspected raw food
9997368|NCT01508312|Experimental|FDG-PET abnormal|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
9997369|NCT01508312|Experimental|FDG-PET normalization|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
9997370|NCT01508338|Placebo Comparator|Placebo|
9997371|NCT01508338|Experimental|HMB|
9997372|NCT01508338|Experimental|ATP and HMB|
9997373|NCT01508338|Experimental|ATP|
9997374|NCT01508351||Propofol Induction|All patients receiving propofol induction of anesthesia who are ASA 1-3
9997375|NCT01508364||Group 1|
9989726|NCT01435967||Cohort A|Children aged <=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
9989727|NCT01435980|No Intervention|basal treatment|basal treatment
9989728|NCT01435980|Experimental|Gastric Bypass|basal treatment and Gastric Bypass
9989729|NCT01435980|Experimental|Exenatide|basal treatment and Exenatide
9989730|NCT01435993|Experimental|Active|GSK1223249 slow (60 minutes) intravenous infusion
9989731|NCT01435993|Placebo Comparator|Placebo|Saline slow (60 minutes) intravenous infusion
9989732|NCT01436019||anti-TNF treatment|Children or young adolescents with juvenile idiopathic arthritis receiving either infliximab, adalimumab or etanercept.
9989733|NCT01436058|Experimental|stem cell recipient|patients with ankle joint osteoarthritis
9989734|NCT01436097|Active Comparator|Usual Care arm|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
9989735|NCT01436097|Experimental|Information provision intervention|Participants in the Information provision group will receive the same care as those in the Usual Care arm. In addition, the Information provision group participants will receive weekly reminders about the benefits of eating five servings of fruits and vegetables a day and their Way to Health portal will provide graphical depictions of their produce purchase proportions through information from their Price Plus card. This data will be available to them throughout the entire intervention.
9989736|NCT01436097|Experimental|Information provision + flat incentive|Participants assigned to the Information provision + flat group will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the Information provision arm.
9989737|NCT01436097|Experimental|Information provision + tiered incentive|In addition to receiving all features of the Information provision treatment the participants assigned to the Information provision + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption. In this arm, the more participants spend on produce the more money they can earn back.
9989738|NCT01436123|Experimental|Stenting + Micro-infusion|Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
9989739|NCT01436123|Active Comparator|Stenting|Put in everolimus-eluting stent
9989740|NCT01436136|Active Comparator|Intervention group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
9989741|NCT01436136|Active Comparator|Usual care (control) group|Within the context of an open, cohort study, GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
9989742|NCT01436188|Other|001 (Healthy Elderly Cohort 1)|standard frequent CSF sampling procedure for 36 hours
9989743|NCT01436188|Other|002 (Healthy Elderly Cohort 2)|an alternative frequency of CSF sampling procedure for 36 hours
9989744|NCT01436188|Other|003 (Healthy Elderly Cohort 3)|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
9989745|NCT01436188|Other|004 (Elderly Volunteers with MCI or AD)|standard CSF sampling procedure for 36 hours
9989746|NCT01436188|Other|005 (Healthy Eldely Cohort 5)|an alternative lower frequency of CSF sampling in comparison to Cohort 1
9989747|NCT01436214|Experimental|APC-100|
9517744|NCT03303430||Surgery group|This patient's group will benefit from a endarteriectomy in order to treat their carotid stenosis.
9517745|NCT03303430||Stenting group|This patient's group will benefit from a stenting of their carotid in order to treat their stenosis.
9989748|NCT01436227|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 4 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may continue pazopanib hydrochloride in the absence of disease progression.
9989749|NCT01436240||Spanish-speaking Latino participants|The investigators will conduct up to two rounds of PRO-CTCAE (patient-reported outcome- Common Terminology Criteria for Adverse Events) version questionnaire administration followed by cognitive interviews in Spanish-speaking Latino patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites.
9989750|NCT01436292|Experimental|Albumin|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
9989751|NCT01436318||Respiratory Function|Children will undergo one session of pulmonary function and strength testing
9989752|NCT01436331|Active Comparator|Treatment As Usual (TAU)|
9989753|NCT01436331|Experimental|TAU+CBT for pts+Family Intervention+CM|
9989754|NCT01436344||1|"Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the cases group."
9989755|NCT01436344||2|Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
9989756|NCT01436409|Other|only vaginal touch|
9989757|NCT01436409|Experimental|vaginal touch +echography|
9517746|NCT03303391|No Intervention|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
9989758|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
9885182|NCT03723681|Experimental|Quizartinib 40 mg|Participants receive 40 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
9885183|NCT03721341|Active Comparator|Standard arm|Standard of care treatment: palliative radiotherapy, chemotherapy, immunotherapy, hormones, or observation, is at the discretion of the treating oncologist.
9885184|NCT03721341|Experimental|Stereotactic Arm|Stereotactic ablative radiotherapy, plus standard of care treatment: chemotherapy, immunotherapy, hormones, or observation given at the discretion of the treating oncologist.
9885185|NCT03718091|Experimental|Cohort T1: ATRX-mutant Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885186|NCT03718091|Experimental|Cohort T2: Truncating ATM Mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885187|NCT03718091|Experimental|Cohort T3: Other HR Gene Mutations|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885188|NCT03718091|Experimental|Cohort 1A: Osteosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885189|NCT03718091|Experimental|Cohort 1B: Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885190|NCT03718091|Experimental|Cohort 2: Truncating ATM mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885191|NCT03718091|Experimental|Cohort 3A: Germline BRCA mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885192|NCT03718091|Experimental|Cohort 3B: Other HR Alteration|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885193|NCT03718091|Experimental|Cohort 4A: MYC amplification, FBXW7 mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885194|NCT03718091|Experimental|Cohort 4B: Cyclin E amplification|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885195|NCT03718091|Experimental|Cohort 5: ARID1A mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885196|NCT03718091|Experimental|Cohort T4: SDH-Mutant GIST|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
9885197|NCT03713320|Experimental|Cobomarsen|Cobomarsen will be administered by intravenous 2-hour infusion at a dose of 282 mg on Days 1, 3, 5, 8, and weekly thereafter
9885198|NCT03713320|Active Comparator|Vorinostat|Vorinostat will be administered orally at a dose of 400 mg (four 100-mg capsules) once daily with food, at approximately the same time each day.
9885199|NCT03712228|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
9885200|NCT03712228|Active Comparator|CSL312 (low)|Subjects with C1-INH HAE receiving low dose CSL312
9885201|NCT03712228|Active Comparator|CSL312 (med)|Subjects with C1-INH HAE receiving medium dose CSL312
9885202|NCT03712228|Active Comparator|CSL312 (high)|Subjects with C1-INH HAE receiving high dose CSL312
9885203|NCT03712228|Active Comparator|CSL312 (med/high)|Subjects with C1-INH HAE receiving medium/high dose CSL312
9885204|NCT03712228|Active Comparator|CSL312-F|Subjects with FXII or plasminogen mutation (FXII/PLG) HAE receiving CSL312
9885205|NCT03708809|Experimental|Immediate insertion|The intrauterine system will be inserted immediately after surgical termination of pregnancy, before awakening from anesthesia
9885206|NCT03708809|Experimental|Delayed insertion|The intrauterine system will be inserted on the first menstruation after termination of pregnancy. Women allocated to this arm will be asked to contact the study coordinator in order to visit the hospital on the proper timing for IUD insertion.
9885207|NCT03708809|Other|Control|Women who refuse to actively participate in the intervention groups will be offered consultation on other options for contraception during gynecological clinic visit after fist menstruation from termination of pregnancy.
9885208|NCT03690206|Experimental|Glepaglutide SC injections twice weekly|Intervention: Glepaglutide
9885209|NCT03690206|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|Intervention: Glepaglutide
9885210|NCT03690206|Placebo Comparator|Placebo SC injections twice weekly|Intervention: Placebo
9885211|NCT03689166|Active Comparator|Probiotics group|Probiotic drug
9885212|NCT03689166|Placebo Comparator|Control group|This group will receive placebo
9885213|NCT03680456|Active Comparator|Intervention|due to postoperative Hemoglobin Level intravenous iron Ferriccarboxymaltose is Infuses, dosage is based on the Ganzoni-Algorithm
9885214|NCT03680456|Placebo Comparator|Placebo|Natriumchlorid is the placebo
9885215|NCT03673787|Experimental|Phase I|Increasing doses of ipatasertib in combination with a fixed dose of atezolizumab to establish the recommended phase II dose.
9885216|NCT03673787|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose of ipatasertib identified in Phase I, in combination with atezolizumab, in six patient cohorts: patients with solid tumours who have hyperactivation of the PI3K pathway; patients with castrate-resistant prostate cancer with PTEN loss; patients with glioblastoma; patients with melanoma; patients solid tumour types refractory to immune-checkpoint inhibitors; patients with gynaecological cancers.
9885217|NCT03670147|Experimental|Pain Returns|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
9885218|NCT03670147|Experimental|No Pain|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
9885219|NCT03665922|Experimental|BroccoMax®|Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
9885220|NCT03665922|Placebo Comparator|Placebo|Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
9885221|NCT03664648||Adult Pregnant Women Exposed to HEPLISAV-B|Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.
9885222|NCT03654807|Experimental|High Intensity Walking|HIW (70-80% HRmax)
9885223|NCT03654807|Experimental|Casual Speed Walking|Self selected pace
9885224|NCT03652740|Experimental|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
9885225|NCT03652740|Experimental|Additional Within-Subjects Dose Conditions|"As described previously, all participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms. We have created a second arm in the description of the trial on ClinicalTrials.gov to designate masking - this study involves administration of drug conditions in different dose sequence orders to which participants are randomly assigned."
9885226|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
9885227|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
9885228|NCT03626038|Experimental|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
9885229|NCT03615248|Experimental|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
9885230|NCT03615222||SERVE assessment only|Eligible veterans will complete 4 assessments over a two year period of time.
9885231|NCT03598790|Experimental|Bimekizumab dose regimen 1|"Subjects are randomized to receive either dose regimen 1 or dose regimen 2, those on dose regimen 1 will switch to dose regimen 2 at Week 24 or later.~Intervention Name: Bimekizumab"
9885232|NCT03598790|Experimental|Bimekizumab dose regimen 2|Subjects will receive bimekizumab dose regimen 2. Intervention Name: Bimekizumab
9885233|NCT03571802|Experimental|intervention arm|simvastatin 20mg once
9885234|NCT03568422|Experimental|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days
9885235|NCT03561207||Tumor tissue tested with EV3D Assay|Cancer tissue from multiple sites in the body, to include ovarian, brain, and other rare tumors.
9885236|NCT03561103|Experimental|RCT: Intervention|Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
9885237|NCT03561103|No Intervention|RCT: Control|Participants in the RCT control group will receive the standard of care.
9885238|NCT03561103|Experimental|Choice Intervention|Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care. They will not be randomly assigned.
9989759|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
9989760|NCT01436422|Placebo Comparator|Placebo|Participants will receive the placebo at Day 0 and Day 180.
9989761|NCT01436448|Experimental|Probiotics Lactobacillus Rhamnosus|dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
9989762|NCT01436448|No Intervention|Placebo|Microcrystalline cellulose/d each, up till deliver
9989763|NCT01436474|Experimental|Varenicline|We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
9989764|NCT01436474|Placebo Comparator|Placebo|We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
9989765|NCT01436513|Experimental|A|Premarin reference tablet as a single oral dose under fasted conditions
9989766|NCT01436513|Experimental|B|Premarin new tablet as a single oral dose under fasted conditions
9989767|NCT01436513|Experimental|C|Premarin reference tablet as a single oral dose under fed conditions
9989768|NCT01436513|Experimental|D|Premarin new tablet as a single oral dose under fed conditions
9989769|NCT01436539|Experimental|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
9989770|NCT01436539|Active Comparator|Adefovire Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
10211775|NCT04095663|Active Comparator|Medical Management|"Medical management for diverticular disease has been used for over 30 years and includes a set of interventions, all components of which have been the subject of small, but often positive trials. All patients randomized to medical management or who select it as their treatment in the observational cohort will view a video (provided in English and Spanish) that explains each element of the medical management toolbox: diet and exercise recommendations, fiber supplementation (e.g., augmenting dietary fiber or over the counter fiber supplements), with mesalazine tablets or suppositories, probiotics and rifamycin. In consultation with their physician, they will be recommended to a regimen of diet and exercise and fiber supplementation. Clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
10211776|NCT04090684|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
10211777|NCT04089527|Experimental|CC-95775|Escalating dose finding part A of study and extension Part B of the study. In Part A, subjects will be treated with oral capsules of CC-95775 with a schedule of 4d on/ 24d off (Q4W) and a starting dose of 100 mg/day on a 28-day cycle. Dose increments between cohorts will not exceed 100% of the dose in previous cohort. Patients in Part B will be treated with a schedule of 4d on/24d off (Q4W) at the Maximum tolerated dose (MTD) established from Part A.
10211778|NCT04083859|Experimental|mPATH-Lung|Participants randomized to the mPATH arm will complete a self-survey and a brief video decision aid, and then invites them to estimate their personal risks and benefits of screening by completing 8 survey items needed to calculate their predicted risk of developing lung cancer based on the validated Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Model 2012.
10211779|NCT04083859|Placebo Comparator|Usual care (CONTROL)|Participants randomized to the control arm will see an animated video about exercise for lung health based on recommendations from the European Lung Foundation. They will not be offered the opportunity to estimate their predicted benefits and harms of screening or to request a lung cancer screening visit.
9989771|NCT01436565|Experimental|dose escalation and expansion|SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose
9989772|NCT01436578||All Participants|All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
9989773|NCT01436604|Other|LV dysfunction group|Cardiac MRI
9989774|NCT01436604|Other|Control group|Cardiac MRI
10211780|NCT04051619|Experimental|oxytocin|The oxytocin will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
10211781|NCT04051619|Placebo Comparator|matching placebo|The oxytocin-matched placebo will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
10211782|NCT04045301|Experimental|Omalizumab 16 mg/kg|"Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
10211783|NCT04045301|Experimental|Omalizumab 8 mg/kg|"Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
10211784|NCT04045301|Placebo Comparator|Placebo|"Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant.~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
10211785|NCT04033107|Experimental|Treatment arm|Vitamin C combined with metformin
10213794|NCT03221309||Adults infected with HCV|"Phase 1 (first 100 enrolled participants) HCV-infected adults with on-going injection drug use use with opioids with 3 months of screening~Phase 2 (enrolled participants 101-200) HCV-infected adults with on-going opioid misuse of non-prescription opioids within twelve months of screening"
10213795|NCT03218384|Experimental|ferric carboxymaltose|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
10213796|NCT03218384|Active Comparator|Placebo|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
10213797|NCT03217682|Experimental|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
10213798|NCT03217682|Experimental|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
9989775|NCT01436630||Stroke|"To accomplish the study it was assessed a group of 12 post-stroke patients who were admitted in the Rehabilitation Clinic inside the University. As inclusion criteria it was established to be able to walk alone without supervision and with no aids.~All the patients signed an informed consent before performing the tests. To characterize the sample it were used the Fugl-Meyer scale, Orpington test, Mini Exam of the Mental State and some other data regarding the age, gender, type of the lesion and side of the lesion."
9989776|NCT01436669|Experimental|Home Monitoring|All participants will receive a home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home.
9989777|NCT01436695||Epicall group|patients will be connected to Epicall sensor
9989778|NCT01436721|No Intervention|Surgicel® absorbable Haemostat|
9989779|NCT01436734|Experimental|GIP|
9989780|NCT01436747|Active Comparator|Paricalcitol|
9989781|NCT01436747|Placebo Comparator|Matching placebo|
9989782|NCT01436773||Recent Acute Coronary Event|Patients admitted to the hospital for recent STEMI or NSTEMI.
9989783|NCT01436773||Stable Coronary Artery Disease|Patients with known Coronary Artery Disease without recent acute coronary event.
9989784|NCT01436773||No Coronary Artery Disease|Patients with no evidence of coronary artery disease, assessed by coronary angiography.
9989785|NCT01436786|Experimental|Guided Imagery Intervention|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
9989786|NCT01436786|No Intervention|Control group|continues usual plan of care
9989787|NCT01436812|Placebo Comparator|zero end-expiratory pressure|not applying PEEP during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
9989788|NCT01436812|Active Comparator|positive end expiratory pressure|applying PEEP 10cmH2O during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
9989789|NCT01436825||Group 1|
9989790|NCT01436838||Group 1|
9989791|NCT01436851|Experimental|Storage mite and placebo nasal challenge|Provocation in the nose with an allergen extract of a storage mite (A. Siro or L. Destructor) and with placebo allergen extract (physiologic salt water)
9989792|NCT01436864|Experimental|0.5 mg KH902|Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)
9989793|NCT01436864|Sham Comparator|Sham-injection|Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.
9989794|NCT01436877|Experimental|device|Insertion of Temporary Implantable Nitinol Device (TIND)
9989795|NCT01436890|Experimental|Low dose|Low dose revamilast
9989796|NCT01436890|Experimental|Medium dose|Medium dose Revamilast
9989797|NCT01436890|Experimental|High dose|High dose Revamilast
9989798|NCT01436890|Placebo Comparator|Placebo|Matching placebo in triple dummy format
9989799|NCT01436916|Active Comparator|oral cholecalciferol + lifestyle counselling|will receive Oral cholecalciferol
9989800|NCT01436916|Placebo Comparator|Placebo + lifestyle counselling|will receive placebo
9989801|NCT01436929|Experimental|Silymarin|Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs
9989802|NCT01436929|Placebo Comparator|Placebo|administration of placebo with anti-TB drugs
9989803|NCT01436942|Experimental|Exercise group|
9989804|NCT01436942|No Intervention|Control group|
9989805|NCT01436955|Experimental|A|
9989806|NCT01436955|Placebo Comparator|B|
9989807|NCT01436968|Experimental|ProstAtak®|Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT
9989808|NCT01436968|Placebo Comparator|Control|Placebo + valacyclovir + radiation therapy +/- ADT
9989809|NCT01436981||CABG with papaverine|Patients with CABG procedure
9989810|NCT01436994|Active Comparator|Block and Replace|Carbimazole is commenced in a dose of 0.75 mg/kg/day. The intention is to completely prevent endogenous thyroxine production. Thyroxine is then added in a replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
9989811|NCT01436994|Active Comparator|Dose Titration|"Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining the euthyroid state. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.~Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.~Drug: Carbimazole 5mg and 20 mg tablets. Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry Drug: propylthiouracil 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry."
9885239|NCT03561103|No Intervention|Choice Control|Participants in the RCT control group will receive the standard of care. They will not be randomly assigned.
9885240|NCT03554655|Experimental|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
9885241|NCT03554655|No Intervention|Control|Control Group will receive treatment as usual without the Momentum app.
9885242|NCT03539614|Experimental|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
9885243|NCT03539614|Experimental|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
9885244|NCT03532022|Experimental|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
9885245|NCT03532022|Active Comparator|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
9885246|NCT03522142|Experimental|INCB081776|Single-agent INCB081776.
9885247|NCT03522142|Experimental|INCB081776 + INCMGA00012|INCB081776 in combination with INCMGA00012.
9885248|NCT03499509|Experimental|Low Glycemic Diet|
9885249|NCT03499509|Placebo Comparator|High Glycemic Diet|
9885250|NCT03493919|Experimental|rMenB+OMV NZ Group|Approximately 510 healthy subjects vaccinated intramuscularly with Bexsero vaccine at Day 1 and Day 61 and have blood collected at Day -83, Day 8 and Day 98.
9885251|NCT03493919|Experimental|MenACWY 1 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -83, Day 8 and Day 151.
9885252|NCT03493919|Experimental|MenACWY 2 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -60, Day 31 and Day 151.
9885253|NCT03493919|Experimental|MenACWY 3 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -30, Day 61 and Day 151.
9885254|NCT03491683|Experimental|Cohort A: Unmethylated MGMT Promoter|Cohort A will include participants with a glioblastoma tumor with an unmethylated MGMT promoter. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ; only during radiation therapy), if clinically indicated.
9885255|NCT03491683|Experimental|Cohort B: Methylated MGMT Promoter|Cohort B will include participants with a glioblastoma tumor with a methylated MGMT promoter or with indeterminate MGMT status. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ), if clinically indicated. Participants will continue to receive TMZ following radiation therapy, for up to six additional cycles, if clinically indicated.
9885256|NCT03485365|Experimental|Part A: Cohort 1: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
9885257|NCT03485365|Experimental|Part A: Cohort 2: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
9885258|NCT03485365|Experimental|Part A: Cohort 3: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
9885259|NCT03485365|Experimental|Part A: Cohort 4: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
9885260|NCT03485365|Experimental|Part A: Cohort 5: GSK3858279|Eligible participants will receive GSK3858279 via IV route.
9885261|NCT03485365|Experimental|Part A: Cohort 6: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
9885262|NCT03485365|Placebo Comparator|Part A: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC or IV route.
9885263|NCT03485365|Experimental|Part B: GSK3858279|Eligible participants will receive GSK3858279 via SC route.
9885264|NCT03485365|Placebo Comparator|Part B: Placebo|Eligible participants will receive placebo matching to GSK3858279 via SC route.
9931424|NCT00938158|Experimental|Stage 2 mild renal impairment|Subjects with GFR >= 50 mL/min and <= 80 mL/min
9931425|NCT00938171|Active Comparator|local anesthesia|local anesthesia with propofol sedation Target-controlled infusion (TCI) system will be used to maintain proper sedation level)
9931426|NCT00938171|Active Comparator|General anesthesia|Patients receiving general anesthesia
9885265|NCT03481634|Experimental|Brolucizumab 3 mg|"Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
9885266|NCT03481634|Experimental|Brolucizumab 6 mg|"Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
9885267|NCT03481634|Active Comparator|Aflibercept 2 mg|"Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP)."
9885268|NCT03476980|Active Comparator|Randomized to Umbilical Cord Milking at birth|Milking the umbilical cord towards the infant at a speed of 20cm/2seconds at birth.
9885269|NCT03476980|Active Comparator|Randomized to Delayed Cord Clamping at birth|Delayed clamping of the umbilical cord at birth.
9885270|NCT03474471|Experimental|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
9885271|NCT03474471|Experimental|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
9885272|NCT03474471|Active Comparator|Group 3: EBV treatment|Only EBV treatment
9885273|NCT03472573|Experimental|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9885274|NCT03458728|Experimental|Dose escalation of BAY806946 in Phase 1|It is estimated that 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Safety and MTD/RP2D dose will be evaluated in 2 age groups (< 1 year old and ≥ 1 year old).
9885275|NCT03458728|Experimental|Patients with Neuroblastoma in Phase 2|Recommended Phase 2 dose (RP2D) for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
9885276|NCT03458728|Experimental|Patients with Osteosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
9885277|NCT03458728|Experimental|Patients with Rhabdomyosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
9885278|NCT03458728|Experimental|Patients with Ewing sarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
9885279|NCT03430310|Experimental|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
9931427|NCT00938184|Experimental|Treatment sequence A/B/C|Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
9989812|NCT01437020|Experimental|Dose escalating-IV infusion of SCH708980 and Ambisome|
9885280|NCT03430310|Placebo Comparator|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
9885281|NCT03429049|Placebo Comparator|Placebo|Matching placebo of 2.0 mL for IA injection
9885282|NCT03429049|Experimental|CNTX-4975-05|Pre-filled glass syringes administered as a single 2.0 mL IA injection
9885283|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
9885284|NCT03409731|Other|Absorb GT1 BVS|Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.
9885285|NCT03403569|Experimental|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
9885286|NCT03403569|Placebo Comparator|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
10211786|NCT04015362|Experimental|Pulsed magnetic stimulation of the spinal cord|Sub-threshold intermittent pulsed magnetic stimulation of spinal cord
10211787|NCT04015362|Sham Comparator|Sham magnetic stimulation|Sham - patient and machinery placed in same position as intervention arm but no magnetic stimulation delivered
10211788|NCT04015336|Experimental|Arm 1-3x10^10 E7 T-Cell Receptor (TCR) T cells|Up to 3x10^10 E7 T-Cell Receptor (TCR) T cells (based on the number of cells that can be generated in the shortened manufacturing process) will be administered intravenously over 20 to 30 minutes on day 0.
9885290|NCT03336203|Active Comparator|Hyperurecemia with gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
9885291|NCT03336203|Active Comparator|Hyperurecemia without gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
9885292|NCT03334266|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
9885293|NCT03334266|Other|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
9885294|NCT03330509|Experimental|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
9885295|NCT03330509|Experimental|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
9885296|NCT03330509|Experimental|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
9885297|NCT03330509|Experimental|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
9885298|NCT03319628|Experimental|Dose Escalation|"XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.~This cohort is closed to enrollment."
9885299|NCT03319628|Experimental|Dose Expansion - Ovarian Cancer|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~Patients with ovarian cancer will enroll until sites approve UPLIFT."
9885300|NCT03319628|Experimental|Dose Expansion - NSCLC adenocarcinoma|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
9885301|NCT03319628|Experimental|Pivotal Cohort (UPLIFT)|Patients with platinum-resistant ovarian cancer will receive XMT-1536 (upifitamab rilsodotin) to further confirm the efficacy
9885302|NCT03319628|Experimental|QTc Sub-Study|For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536.
9885303|NCT03315897|Active Comparator|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
9989813|NCT01437046|Experimental|Doxazosin|Doxazosin 16mg/day
10211789|NCT04006457|Experimental|Treatment sequence 1|"Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 given QD for 35 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 32 visit of the main B7981032 study."
9885304|NCT03315897|Placebo Comparator|Saline|12 intravenous infusions of saline (1 ml NaCl)
9885305|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
9885306|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
9885307|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
9885308|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
9885309|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
9885310|NCT03313011||Progressive Apraxia of Speech|
9885311|NCT03288545|Experimental|EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L|Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
9885312|NCT03288545|Experimental|Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
9885313|NCT03288545|Experimental|Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
9885314|NCT03288545|Experimental|Cohort D: Enfortumab Vedotin + Cisplatin in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days
9885315|NCT03288545|Experimental|Cohort E: Enfortumab Vedotin + Carboplatin in 1L|Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days
9885316|NCT03288545|Experimental|Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L|Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days
9885317|NCT03288545|Experimental|Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days
9885318|NCT03288545|Experimental|Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 every 21 days
9885319|NCT03288545|Experimental|Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
9885320|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin Monotherapy|Enfortumab vedotin on days 1 and 8 every 21 days
9885321|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
9885322|NCT03288545|Experimental|Cohort L: Enfortumab vedotin in MIBC in perioperative setting|Enfortumab vedotin on days 1 and 8 and every 21 days
9885323|NCT03283566|Active Comparator|Hydroxychloroquine|Administered pre-transplant through 3 months after surgery.
9885324|NCT03283566|Placebo Comparator|Placebo|Placebo treatment following the same schedule as Arm 1 (i.e. Hydroxychloroquine).
9885325|NCT03279276|Experimental|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
9885326|NCT03279276|Active Comparator|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
9885327|NCT03278925|Experimental|Prevention (defined green tea catechin extract)|Participants receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
9885328|NCT03266302|Experimental|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
9885329|NCT03266302|No Intervention|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
9885330|NCT03259204|No Intervention|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
9885331|NCT03259204|Experimental|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
9885332|NCT03254212|Experimental|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
9885333|NCT03250299|Experimental|Dose Finding|Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
9885334|NCT03228693|Active Comparator|Group 1|Baseline lesional and non-lesional biopsies and re-biopsy 6-8 weeks later with intralesional triamcinolone injections at 9-10, 12-16, and 24-32 weeks.
9885335|NCT03228693|Active Comparator|Group 2|Baseline lesional biopsy and re-biopsy at 6-8 weeks with intralesional triamcinolone injections at 3-4, 9-10, 12-16, and 24-32 weeks
9885336|NCT03228693|Active Comparator|Group 3|Baseline lesional and non-lesional biopsy and re-biopsy 3-4 months later with intralesional triamcinolone injections at 18-20 and 24-32 weeks.
9885337|NCT03228693|Active Comparator|Group 4|Baseline lesional biopsy and re-biopsy at 3-4 months with intralesional triamcinolone injections at 3-4, 6-8, 18-20 and 24-32 weeks.
9885338|NCT03228693|Active Comparator|Group 5|Normal patient skin (surgical or adjacent to other biopsy) from subjects with no self-reported history of keloids.
9885339|NCT03228693|Other|Earlobe Keloid|Complete excision of an earlobe keloid measuring > 10mm will be taken.
9885340|NCT03190382|Experimental|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
9885341|NCT03178552|Experimental|Cohort A: Alectinib 600 Milligrams (mg)|"This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort A is complete."
9885342|NCT03178552|Experimental|Cohort B: Dose Finding Phase (DFP) Alectinib|"This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose.~Enrollment to Cohort B is complete."
9885343|NCT03178552|Experimental|Cohort B: Dose Expansion Phase (DEP) Alectinib|"This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort B is complete."
9885344|NCT03178552|Experimental|Cohort C: Atezolizumab 1200 mg|"This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort C is complete."
9885345|NCT03178552|Active Comparator|Cohort C: Pemetrexed, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.~Enrollment to Cohort C is complete."
9885346|NCT03178552|Active Comparator|Cohort C: Gemcitabine, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.~Enrollment to Cohort C is complete."
9885347|NCT03178552|Experimental|Cohort D: Entrectinib 600 Milligrams (mg)|"This cohort includes participants with c-ros oncogene 1 positive (ROS1+) NSCLC. Participants will receive entrectinib 600 mg orally once a day (QD) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort D is complete."
9885348|NCT03178552|Experimental|Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib|This cohort includes participants with BRAF V600 mutation. Participants will receive: atezolizumab 1680 mg IV Q4W after the run-in period; cobimetinib 60 mg orally (PO) QD on Days 1-21 of each cycle during the run-in and triple-combination periods; and vemurafenib 960 mg PO twice daily (BID) on Days 1-21 of the initial run-in period, then 720 mg PO BID on Days 1-22 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
9885349|NCT03178552|Experimental|Cohort F: Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed|This cohort includes participants with EGFR exon 20+ NSCLC. Participants will receive atezolizumab + bevacizumab + carboplatin + pemetrexed for 4 or 6 induction cycles (cycle = 21 days). After induction therapy, participants will continue maintenance treatment with atezolizumab + bevacizumab + pemetrexed until disease progression, unacceptable toxicity, withdrawal of consent, or death.
9885350|NCT03176134|Experimental|Cohort 1: Tedizolid phosphate 6 to <12 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
9885351|NCT03176134|Active Comparator|Cohort 1 Comparator: 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
9885352|NCT03176134|Experimental|Cohort 2: Tedizolid phosphate 2 to <6 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
9885353|NCT03176134|Active Comparator|Cohort 2 Comparator: 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
9885354|NCT03176134|Experimental|Cohort 3: Tedizolid phosphate 28 Days to <2 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
9885355|NCT03176134|Active Comparator|Cohort 3: Comparator: 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
9885356|NCT03176134|Experimental|Cohort 4: Tedizolid phosphate Birth to <28 Days Neonates|Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
9885357|NCT03176134|Active Comparator|Comparator: Birth to <28 Days (Term and preterm neonates)|Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days
9885358|NCT03170453|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
9885359|NCT03170453|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
9885360|NCT03160638|Experimental|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
9885361|NCT03160638|No Intervention|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
9885362|NCT03160378|Experimental|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
9885363|NCT03160378|Other|Control|Control participants will receive treatment as usual.
9885364|NCT03157128|Experimental|LOXO-292|Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
9885365|NCT03153150|Experimental|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or~Direct thrombin inhibitor: Dabigatran or~Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
9885366|NCT03153150|No Intervention|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:~antiplatelet drug(s) or~no antithrombotic drugs."
9885367|NCT03151629||Castrate Resistant Prostate Cancer|
9885368|NCT03151629||Hormone Sensitive Prostate Cancer|
9885369|NCT03144765|Experimental|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
9885370|NCT03142984|Experimental|Phase 1|"An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash & Shampoo product and Baby Lotion.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
9885371|NCT03142984|Experimental|Phase 2|"An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
9885372|NCT03139266|Experimental|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
9885373|NCT03139266|Other|Control Group|Treatment-as-usual
9885374|NCT03126331|Experimental|Cohort I: Intermittent Nivolumab|Nivolumab monotherapy. Participants who have initial 10% or greater tumor burden reduction will discontinue nivolumab until they experience a pre-specified disease progression at which time nivolumab will be restarted
9885375|NCT03126331|Experimental|Cohort II: combination ipilimumab/nivolumab|"Combination of ipilimumab/nivolumab for previously untreated intermediate and poor risk mRCC~Includes participants treated front-line ipilimumab/nivolumab. Participants with treatment-naïve mRCC who receive up to four doses of induction ipilimumab/nivolumab and 24 weeks (+/- 8 weeks; minimum 3 infusions) of maintenance nivolumab and achieve stable disease (SD), complete response (CR), or partial response (PR) will be eligible for inclusion. Participants who achieve SD will continue with nivolumab maintenance per standard of care while those who achieve a PR or CR will enter an observation period off therapy. Upon disease progression, participants will be re-challenged with combination ipilimumab/nivolumab."
9885376|NCT03103490|Other|18F-FSPG PET/MRI|Patients undergoing 18F-FSPG PET/MRI scan
9885377|NCT03103490|Other|18F-FSPG PET/CT|Patients undergoing 18F-FSPG PET/CT scan
9931428|NCT00938184|Experimental|Treatment sequence A/C/B|Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
9931429|NCT00938184|Experimental|Treatment sequence B/A/C|Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
9931430|NCT00938184|Experimental|Treatment sequence B/C/A|Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
9931431|NCT00938184|Experimental|Treatment sequence C/A/B|Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
9931432|NCT00938184|Experimental|Treatment sequence C/B/A|Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
9931433|NCT00938197|Active Comparator|Part A|
9931434|NCT00938197|Active Comparator|Part B|
9931435|NCT00938210|No Intervention|Laparoscopic surgery|Patients undergoing laparoscopic colonic surgery are compared with a historical cohort of patients undergoing similar open colonic surgery (right hemicolectomy and sigmoid resections).
9931436|NCT00938223|Active Comparator|4-peptide vaccine|Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A 2) and a tetanus helper peptide.
9931437|NCT00938223|Active Comparator|12-peptide vaccine|Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
9931438|NCT00938236|Other|Inhaled cyclosporine|Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
9931439|NCT00938249|Experimental|Monascus Garlic Fermented Extract|
9931440|NCT00938249|Placebo Comparator|Placebo|
9931441|NCT00938262|Experimental|Fimasartan, Ketoconazole, Rifampicin|
9989814|NCT01437046|Placebo Comparator|Placebo|Placeno
9989815|NCT01437059|Active Comparator|ALN-PCS02|
9989816|NCT01437059|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
9989817|NCT01437072||Total study population|
9885378|NCT03086642|Experimental|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
9885379|NCT03077685|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
9885380|NCT03077685|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
9885381|NCT03077685|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
9885382|NCT03077685|Experimental|Second Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
9885383|NCT03077685|Experimental|Third Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.
9885384|NCT03077412|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
9885385|NCT03077412|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
9885386|NCT03077412|Experimental|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
9885387|NCT03074539|Active Comparator|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
9885388|NCT03074539|Active Comparator|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
9885389|NCT03074539|Active Comparator|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
9885390|NCT03069378|Experimental|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
9885391|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
9885392|NCT03036254|Experimental|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
9885393|NCT03036254|Sham Comparator|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
9989818|NCT01437137|Active Comparator|LMA group|
9885394|NCT03026504|Experimental|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
9885395|NCT03026049|Active Comparator|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
9885396|NCT03026049|No Intervention|conservative managment|Conservative management of complaints
9885397|NCT03019367|Active Comparator|Umbilical cord milking UCM|Milking the umbilical cord 4 times towards the infant at a speed of 20cm/2seconds.
9885398|NCT03019367|Active Comparator|Delayed cord clamping DCC|Delayed clamping of the umbilical cord for at least 60 seconds.
9885399|NCT03011372|Experimental|Pemigatinib|
9885400|NCT03005782|Experimental|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
9885401|NCT03005782|Experimental|Combination Therapy (REGN3767+cemiplimab)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
9885402|NCT02995889|Experimental|FLT-PET|
9885403|NCT02978391|Experimental|UI-EWD Hemostatic system|Patients with upper gastrointestinal bleeding treated with UI-EWD
9885404|NCT02978391|Active Comparator|epinephrine|Patients with upper gastrointestinal bleeding treated with submucosal epinephrine injection
9885405|NCT02971956|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
9885406|NCT02963766|Experimental|Dose 1 Dulaglutide|Dulaglutide given subcutaneously (SC).
9885407|NCT02963766|Experimental|Dose 2 Dulaglutide|Dulaglutide given SC.
9885408|NCT02963766|Placebo Comparator|Placebo|Placebo given SC.
9885409|NCT02946905||SCD participant|No intervention
9885410|NCT02946905||Non-SCD participant|No intervention
9885411|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
9885412|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
9885413|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
9885414|NCT02944682|Experimental|Liquefied petroleum gas cookstove|Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
9885415|NCT02944682|No Intervention|Control|Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.
9885416|NCT02915367|Experimental|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
9885417|NCT02915367|No Intervention|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
9885418|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
9885419|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
9885420|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
9885421|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
9885422|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
9885423|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
9885424|NCT02886572|Experimental|Stereotactic Radiosurgery|All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
9885425|NCT02872402|Experimental|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
9885426|NCT02872402|Active Comparator|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
9885427|NCT02849223|Experimental|Transcranial Direct Current Stimulation|Participants will receive 24 sessions (3 times a week) of anodal transcranial direct current stimulation concurrent with working memory training. Stimulation will be administered at 2 milliamps (mA) for 20 minutes over the left dorsal lateral prefrontal cortex.
9989819|NCT01437137|Experimental|I-gel group|
9885428|NCT02849223|Sham Comparator|Sham|Participants will receive 24 sessions of working memory training. The experience of transcranial direct current stimulation will be simulated by administering 30 seconds of stimulation at the beginning of the session.
9885429|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
9885430|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
9885431|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
9885432|NCT02836470|Experimental|LB1148|Active
9885433|NCT02836470|Placebo Comparator|Placebo|Placebo
9885434|NCT02834884||RP-1828 IMMUcan|"The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions.~Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary"
9885435|NCT02834884||RP-1759 AYA/TYA|"The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials.~Tumor type: CNS"
9885436|NCT02834884||RP-1843 Arcagen|"This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population.~Tumor types: all 10 EURACAN domains"
9885437|NCT02804828|Active Comparator|Arm 1|
9885438|NCT02804828|Sham Comparator|Arm 2|
9885439|NCT02788461|Active Comparator|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
9885440|NCT02788461|Experimental|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
9885441|NCT02736695|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive a Tau PET scan.
9885442|NCT02715518|Active Comparator|FFR-guided strategy arm|"FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180ug/kg/min) or intracoronary nicorandil (2mg bolus) injection. The FFR ≤ 0.80 will be targeted for PCI using 2nd generation drug-eluting stent. In case of non-IRA stenosis > 90%, we will judge FFR value of ≤ 0.80.~The evaluation of non-IRA stenosis by FFR will be recommended to perform during same intervention with primary PCI for IRA. However, exceptions can be made for complex lesions including ACC/AHA classification B2/C lesion where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
9885443|NCT02715518|Active Comparator|Angiography-guided strategy arm|"Non-IRA stenosis with > 50% stenosis will be the target of PCI using 2nd generation drug-eluting stent.~As for the angiography-guided strategy arm, PCI for non-IRA stenosis will be recommended during same procedure. However, exceptions can be made for complex lesions including ACC/AHA classification B2/C lesion where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
9885444|NCT02712814||Hormonally mediated PVD|"The entire vestibule is tender~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)"
9885445|NCT02712814||Congenital Neuroproliferative PVD|"The entire vestibule is tender~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule"
9885446|NCT02712814||Acquired neuroproliferative PVD|"The entire vestibule is tender~Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.~Normal appearing vestibule"
9885447|NCT02712814||Hypertonic pelvic muscle dysfunction|"The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule~Pelvic floor muscles are tight and tender~Primary or Secondary PVD"
9885448|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule~Pelvic floor muscles are tight and tender"
9885449|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)~Pelvic floor muscles are tight and tender"
9885450|NCT02670252|Experimental|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
9885451|NCT02670252|Active Comparator|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
9885452|NCT02665143|Experimental|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
9885453|NCT02663271|Experimental|Optune+Pulsed Bevacizumab|The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
9885454|NCT02663271|Other|Historical Controls|Historical controls treated with continuous bevacizumab alone or in combination with standard chemotherapy will be compared with the Optune arm. Information will be collected: Bevacizumab or additional chemotherapy, physical examination and quality of life questionnaires performed and brain MRI.
9885455|NCT02659800|Experimental|Arm A - Low Dexamethasone (LD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
9885456|NCT02659800|Experimental|Arm B High Dexamethasone (HD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
9885457|NCT02659800|Experimental|Arm A1 (LD) Control - Placebo|"Patients receive single dose Placebo IM (blinded). Patients also on Dexamethasone </=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
9885458|NCT02659800|Experimental|Arm A2 (LD) MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm A (Blinded) . Patients also on Dexamethasone <=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
9885459|NCT02659800|Experimental|Arm B1 HD MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm B (Blinded) . Patients also on Dexamethasone >= 4mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
9885460|NCT02649790|Experimental|Part A1: RRMM- KPT-8602 single agent; QoDx5/week|Participants received KPT-8602 once daily for 5 days per week (QDx5/week) at escalated doses (completed).
9885461|NCT02649790|Experimental|Part A2: RRMM- KPT-8602 single agent; QoDx3/week|Participants received KPT-8602 once daily for 3 days per week (QoDx3/week). The starting dose for Part A2 will be informed by Part A1 (completed).
9885462|NCT02649790|Experimental|Part B: RRMM- KPT-8602 with low-dose dexamethasone; QDx5/week|Participants received KPT-8602 for 5 consecutive days (QDx5/week) in combination with low dose dexamethasone (20 milligram [mg] on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle) (completed).
9885463|NCT02649790|Experimental|Part C: RRCRC- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
9885464|NCT02649790|Experimental|Part D: RRmCRPC- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that has been cleared in Part A (completed).
9885465|NCT02649790|Experimental|Part E: RRmCRPC- KPT-8602 with abiraterone and corticosteroids|Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A in combination with abiraterone and corticosteroids. Participants continued to receive the dose and schedule of abiraterone and corticosteroids that they were receiving at the time of enrollment (completed).
9885466|NCT02649790|Experimental|Part F: High-risk Myelodysplastic Syndrome (MDS)- KPT-8602 single agent|Participants were treated with KPT-8602 at a dose and schedule that had been cleared in Part A. In select cases (for example, participants achieving stable disease [SD], hematological improvement [HI], partial response [PR] and tolerating treatment, etc.), the dose may be escalated 1 level based on safety and efficacy considerations (completed).
9885467|NCT02649790|Experimental|Part F Phase 2: High-risk MDS- KPT-8602 single agent|Participants will be enrolled at recommended Phase 2 doses (RP2D) of 10 mg daily on Days 1 to 5 of each week, in a dose expansion, based upon the results from the Phase 1 portion of Part F.
9885468|NCT02649790|Experimental|Part G: Newly Diagnosed Intermediate/High-Risk MDS -KPT-8602 with ASTX727|Participants will receive KPT-8602 once daily at escalated doses. The starting dose for KPT-8602 is 5 mg orally once daily from Day 8 to Day 28 (Weeks 2 to 4) on a 28-day cycle in combination with ASTX727.
9885469|NCT02649790|Experimental|Part H: AML Maintenance Therapy- KPT-8602 single agent|Participants with high-risk Acute Myeloid Leukemia (AML) prior to transplant will be enrolled to receive maintenance therapy with KPT-8602 post-allogeneic stem cell transplantation. The dose for KPT-8602 will be 10 mg (RP2D from Part F) oral, to be administered once daily from Day 1 to Day 21 (Weeks 1 to 3) on a 28-day cycle.
9885470|NCT02625766|Experimental|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
9885471|NCT02625766|Experimental|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
9885472|NCT02605538|Active Comparator|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
9885473|NCT02605538|Active Comparator|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
9885474|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
9885475|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
9885476|NCT02598661|Experimental|Part 1: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
9885477|NCT02598661|Experimental|Part 2 (Main Study): Imetelstat|Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
9885478|NCT02598661|Placebo Comparator|Part 2 (Main Study): Placebo|Matching Placebo to Imetelstat will be administered.
9885479|NCT02598661|Experimental|Part 2 (Ventricular Repolarization Substudy): Imetelstat|Imetelstat will be administered at a starting dose of 7.5 mg/kg given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
9885480|NCT02598661|Placebo Comparator|Part 2 (Ventricular Repolarization Substudy): Placebo|Matching Placebo to Imetelstat will be administered.
9885481|NCT02572557|Experimental|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
9885482|NCT02566304|Experimental|RIC HSCT, GVHD prophylaxis|"RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -7.~TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
9885483|NCT02555189|Experimental|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9989820|NCT01437150|Experimental|Simple posterior wall fracture|Simple posterior wall fracture means the fracture was only occurred in the posterior wall of acetabular.
9989821|NCT01437150|Experimental|Complex posterior wall fracture|Complex posterior wall fracture means the fracture was not only occurred in the posterior wall of acetabular, but also occurred in other part of acetabular.
9989822|NCT01437163|Sham Comparator|Red Incandescent light source|
9989823|NCT01437163|Active Comparator|TopHat 655|
9989824|NCT01437176|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
9989825|NCT01437176|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
9989826|NCT01437202||high risk group|Identified by the predictive model using 2 genotypes and disease stage
9989827|NCT01437202||intermediate risk group|Identified by the predictive model using 2 genotypes and disease stage
9989828|NCT01437202||Low risk group|Identified by the predictive model using 2 genotypes and disease stage
9989829|NCT01437215|Experimental|Fenestrated Endografting|
9989830|NCT01437228|Other|povidone iodine|30-second vaginal scrub with povidone- iodine solution.
9989831|NCT01437228|Placebo Comparator|CONTROL|
9989832|NCT01437241||etravirine|Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)
9989833|NCT01437254|Experimental|Arm Number 1 CPERT|1 CPERT scan, blood and vital sign collection
9989834|NCT01437254|Active Comparator|Arm Number 2 GPERT|1 GPERT Scan
9989835|NCT01437280|Experimental|CGTG-102|CGTG-102 is an oncolytic adenovirus
9989836|NCT01437293|Experimental|Experimental|L-dopa / carbidopa / entacapone (LCE)
9989837|NCT01437306|Experimental|Lofexidine following overnight fast|A single dose of lofexidine (400 mcg or 2 x 200 mcg tablets) will be given to subjects following a minimum 10 hour overnight fast.
9989838|NCT01437306|Experimental|Lofexidine Following a High Fat Meal|A single dose of lofexidine 400 mcg (or 2 x 200 mcg tablets) will be administered to subjects following a standard high-fat meal.
9989839|NCT01437332||Diabetes|
9989840|NCT01437332||Nerve injury|
9989841|NCT01437332||Other|
9989842|NCT01437358||intensive care unit|
9989843|NCT01437371|Other|optimized|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
9989844|NCT01437371|Other|usual care|
9989845|NCT01437384|Experimental|E5501 plus minus verapamil; plus minus cyclosporine|
9989846|NCT01437410||EUS-FNA|
9989847|NCT01437436||obesity|otitis media patient with obesity
9989848|NCT01437436||non obesity|otitis media patient with non obesity
9989849|NCT01437475|Experimental|Sci-B-Vac|The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
9989850|NCT01437514|Experimental|lower risk group with pSRT|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients accept the preoperative short-course radiotherapy before the surgery
9989851|NCT01437514|No Intervention|lower risk group with operation only|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm,according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
9989852|NCT01437514|Experimental|higher risk group with pSRT|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.these patients have the preoperative short-course radiotherapy before the surgery.
9989853|NCT01437514|No Intervention|higher risk group with operation directly|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
9989854|NCT01437527|Experimental|Interventional arm|Body image therapy with Anamorphic Micro software
9989855|NCT01437527|Active Comparator|control arm|Body image therapy as usual
9885484|NCT02555189|Experimental|Enzalutamide + Ribociclib|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9989856|NCT01437553|Other|IVUS|Patients undergoing catheterization due to acute coronary syndrome will have IVUS done with grayscale and iMAP analysis performed.
9989857|NCT01437566|Placebo Comparator|GDC-0941 Matching Placebo + Fulvestrant (Arm E)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
9989858|NCT01437566|Experimental|GDC-0941-260 mg + Fulvestrant (Arm D)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
9989859|NCT01437566|Experimental|GDC-0941-340 mg + Fulvestrant (Arm A)|Participants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
9989860|NCT01437566|Placebo Comparator|GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)|Participants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
9989861|NCT01437566|Experimental|GDC-0980-30 mg + Fulvestrant (Arm B)|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
9989862|NCT01437579|Active Comparator|Botulinum toxin|Bladder intratrigonal injection of botulinum toxin (100 units) in 10 injection sites during cystoscopy under general anesthesia
9989863|NCT01437579|Sham Comparator|cystoscopy with hydrodistension|cystoscopy with hydrodistension under general anesthesia
9989864|NCT01437592|Experimental|IDeg|
9989865|NCT01437618||BRAF mutant mCRC|
9989866|NCT01437631|Experimental|endoclip|The group of patients who undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
9989867|NCT01437631|No Intervention|no endoclip|The group of patients who do not undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
9997376|NCT01508377|Experimental|Treatment of PTSD with cognitive restructuring|"In this arm the PTSD treatment can be divided into three phases.~First phase: self-confrontation (4 essays)~Second phase: cognitive restructuring (4 essays)~Third phase: parting (2 essays)"
9885485|NCT02550470||Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
9997377|NCT01508377|Experimental|Treatment of PTSD without cognitive restructuring|"In this arm the PTSD treatment can be divided into only two phases. Compared to the other arm the phase dealing with cognitive restructuring is excluded.~First phase: self-confrontation (4 essays)~Second phase: parting (2 essays)"
9885486|NCT02550470||Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
9885487|NCT02550470||Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
9885488|NCT02542696|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
9885489|NCT02532452|Experimental|Viral Specific VST Infusion|3rd party VST infusion
9885490|NCT02523469|Experimental|ALT-803 + Nivolumab dose escalation|"Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
9885491|NCT02523469|Experimental|Arm A: ALT-803 + Nivo naive|"Patients who have not received PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
9885492|NCT02523469|Experimental|Arm B: ALT-803 + Nivolumab progressor|"Patients who have had PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
9885493|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 1|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
9885494|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 2|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
9885495|NCT02522260|Active Comparator|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
9885496|NCT02522260|Active Comparator|Group 2|Intervention Aerobic exercise, bike or treadmill
9885497|NCT02522260|Active Comparator|Group 3|Standard supportive care
9885498|NCT02503839|Experimental|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
9885499|NCT02503839|Experimental|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
9885500|NCT02503839|No Intervention|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
9885501|NCT02503839|Experimental|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
9885502|NCT02467946|Experimental|Adcetris-Levact (BV-Be) Association|Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles
9885503|NCT02428985||Riociguat|Riociguat treatment group
9885504|NCT02427997|Experimental|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
9885505|NCT02427997|Active Comparator|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
9885506|NCT02396342|Experimental|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
9885507|NCT02396342|Experimental|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
9885508|NCT02384850|Experimental|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
9997378|NCT01508390|Experimental|Boost|CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day
9989868|NCT01437644|Active Comparator|Botulinum Toxin TypeA|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. A total of 2 ml of isotonic saline will be used to dissolve the contents of the trial vial of Botox. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo arm of the study."
9989869|NCT01437644|Placebo Comparator|Saline|The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Injections of normal saline will be administered in those children randomised to the placebo arm of the study. The volume of normal saline injected will be equal to the volume of normal saline that would have been used if the child had been randomised to botulinum toxin. The injector will be blinded, as the solution is drawn up by unblinded nurses.
9989870|NCT01437670||dry mouth patients with solifenacin|dry mouth patients with solifenacin 5mg, 10mg
9989871|NCT01437683||traumatic brain injury patients|a large group of traumatic brain injury patients
9989872|NCT01437696|Experimental|Vitamin D fortified food 500 IU|One portion of a specific food item will be provided each day. 500 IU Vitamin D added.
9989873|NCT01437696|Experimental|Vitamin D fortified food 1000 IU|One portion of a specific food item will be provided each day. 1000 IU Vitamin D added.
9989874|NCT01437696|Placebo Comparator|Placebo|One portion of a specific food item will be provided each day. No vitamin D added.
9989875|NCT01437709|Experimental|patients receiving Immunotherapy (This arm is closed)|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The study design will allow for an estimation of the single agent response of ofatumumab in patients at low biologic risk for immediate disease progression.
9989876|NCT01437709|Experimental|patients receiving Chemoimmunotherapy|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The combined regimen will assess the response rates of the combined chemo- immunotherapy program in patients with need for cytoreductive therapy, or high risk for disease progression. Patients with a leukemic phase only presentation of mantle cell lymphoma generally have clinically low-risk disease, regardless of mantle cell IPI calculations. Upon reciew with the principal investigator, these patients may be stratified to the immunotherapy only arm if clinically appropriate.
9989877|NCT01437748|Experimental|Indacaterol maleate|Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
9885509|NCT02354651||Pompe subjects receiving NeuDx DPS|Patients will receive resting breathing pattern evaluation, phrenic nerve stimulation, maximal inspiratory pressure (MIP) testing, forced expiratory testing, and EMG.
9885510|NCT02352090|Experimental|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
9885511|NCT02352090|Experimental|Natural estrogen + progestin|Estradiol valerate / dienogest
9885512|NCT02352090|Active Comparator|Progestin-Only|Dienogest
9885513|NCT02298257|Experimental|Treatment (BV + combination chemotherapy)|Patients receive doxorubicin hydrochloride given IV , vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9885514|NCT02274779|Experimental|Hight dose IMRT, ELIGARD|"PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy~PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy~PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.~PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
9885515|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
9885516|NCT02259413|Experimental|Exercise Rehabilitation|"Participants will receive baseline exercise counseling as per Standard Care group. Participants will then participate in a 26-week exercise rehabilitation program incorporating 3 components:~One-to-one self-management/resistance education once per week during the first 4 weeks of intervention. Participants will subsequently receive resistance training material to allow for home exercise for the remaining 22 weeks of the intervention.~Intradialytic aerobic exercise on a cycle ergometer 3 times weekly for 26 weeks at their usual hemodialysis sessions.~Four additional one-to-one standardized education sessions will be completed during the intervention period."
9885517|NCT02259413|No Intervention|Standard Care|Participants will receive one exercise counseling session as part of their baseline assessment. Participants in the control group will not undergo any other exercise counseling or formal exercise intervention, but will not be prohibited from participating in exercise outside of the study protocol.
9885518|NCT02200705|Other|single arm, open label|Early stage Breast cancers up to 1.5cm
9885519|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
9885520|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
9885521|NCT02143830|Experimental|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
9885522|NCT02143830|Experimental|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).~The maximum number of patients enrolled in this arm will be 10."
9885523|NCT02143830|Experimental|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
9885524|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
9885525|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
9885526|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
9517747|NCT03303391|Experimental|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
9517748|NCT03303378|Experimental|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
9885527|NCT02042287|Experimental|1: Gynofit®|Vaginal lactic acid gel
9885528|NCT02042287|Active Comparator|2: metronidazole|Oral antibiotic
9885529|NCT02037529|Experimental|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9885530|NCT02037529|Experimental|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9885531|NCT02008357|Experimental|Solanezumab|"Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks.~Participants who enter the open-label extension will receive solanezumab IV."
9885532|NCT02008357|Placebo Comparator|Placebo|"Placebo IV every 4 weeks for 240 weeks.~Participants who enter the open-label extension will receive solanezumab IV."
9885533|NCT01976091|Experimental|Cohort 1A: SRP-9004 Low Dose (Single Limb Perfusion)|Non-ambulant participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to a single limb on Day 0.
9885534|NCT01976091|Experimental|Cohort 1B Low Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to both limbs on Day 0.
9885535|NCT01976091|Experimental|Cohort 2 High Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 high dose of SRP-9004 via ILI to both limbs on Day 0.
9885536|NCT01964560|Experimental|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:~Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing <30 kg~LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to <50 kg~LCM 300 mg/day (tablets) for subjects weighing ≥50 kg~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
9885537|NCT01904188||SIRS positive|Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection. May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid
9885538|NCT01840566|Experimental|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
9885539|NCT01824537|Active Comparator|HPV vaccine, Gardasil 9|HPV vaccine intervention: The intervention vaccine will be Gardasil 9, a 9-valent vaccine by Merck. This vaccine was chosen because it allows for the observation of 9 HPV outcomes (HPV 6, 11, 16 and 18) (the other available vaccine, Cervarix, protects against HPVs 16 and 18, only).
9885540|NCT01824537|Placebo Comparator|Hepatitis A vaccine|"The placebo comparator will be Avaxim, by Sanofi Pasteur. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a placebo comparator. Gardasil 9 requires administration of 3 doses, while Avaxim only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Avaxim vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months."
9885541|NCT01798810|Experimental|Supplemental Perioperative Oxygen (80% FiO2)|After intubation, patients in the Treatment Group will receive intraoperative inspired oxygen set at 80 percent (FiO2 of 0.80). Post-extubation, patients in the treatment arm will be placed on high flow non-re-breather mask at 15L/min for up to 2 hours postoperatively and then transitioned to nasal cannula, which will be weaned as tolerated.
9885542|NCT01798810|No Intervention|Control (30% FiO2)|After intubation, patients in the control arm will receive typical standard of care intraoperative inspired oxygen of 30 percent (FiO2 of 0.30). Post-extubation, patients in the control arm of the study will be placed on a nasal cannula at 4L/min to maintain SaO2≥92% as determined by pulse oximetry. This will be maintained for up to 2 hours and then weaned as tolerated.
9885543|NCT01792531|Experimental|Treatment focus - Parenting vs lifestyle|To determine the effectiveness of two obesity treatment interventions: 1) parent training group (n=90) and 2) standard treatment with focus on lifestyle (n=90). The two treatment conditions will be evaluated with respect to child weight status (BMI SDS; primary outcome), psychosocial and metabolic health, lifestyle choices, and family functioning (secondary outcomes). This design will allow us to assess whether a program targeting only parents and focusing on parenting practices will result in better outcomes than treatment as usual emphasizing lifestyle changes.
9885544|NCT01792531|Experimental|Length of treatment|To understand the influence of treatment duration by comparing the effectiveness of two obesity treatment interventions: the parent training group administered for 12 wks only (n=45) and the parent training group with booster sessions which include additional booster sessions at 8-week intervals for the following year (n=45). Thus we will randomize families to either a group with booster sessions or without. This design will allow us to evaluate if prolonged care is necessary to maintain intervention effects, or if a 12-week program is equally effective.
9885545|NCT01730937|Experimental|Arm 1 (sorafenib tosylate)|Patients receive sorafenib tosylate orally PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
9997379|NCT01508403||Shuxuetong injection|a cohort using Shuxuetong injection
9517749|NCT03303378|Placebo Comparator|Control group|Patients will receive the same dose of placebo.
9997380|NCT01508416||Patients with Multiple Myeloma|Patients with newly diagnosed Multiple Myeloma required chemotherapy
9517750|NCT03303365|Experimental|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
9517751|NCT03303365|Active Comparator|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
9885546|NCT01730937|Experimental|Arm 2 (SBRT and sorafenib tosylate)|Patients undergo SBRT every 24-72 hours for a total of 5 fractions over 5 to 15 days. Within 1-5 days post-SBRT, patients receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
9885547|NCT01655836|Experimental|Treatment (HDR brachytherapy, SBRT)|Patients undergo HDR brachytherapy on day 0 followed by SBRT on days 15-30
9885548|NCT01655225|Experimental|Part A: LY3023414 Once Daily|LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
9885549|NCT01655225|Experimental|Part A2: LY3023414 Twice Daily|LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
9885550|NCT01655225|Experimental|Part B1 : LY3023414 + Midazolam|LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
9885551|NCT01655225|Experimental|Part B2: LY3023414 + Fulvestrant|LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
9885552|NCT01655225|Experimental|Part B3: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.
9885553|NCT01655225|Experimental|Part B4: LY3023414 + pemetrexed/cisplatin|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.
9885554|NCT01655225|Experimental|Part B5: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.
9885555|NCT01655225|Experimental|Part B6: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.
9885556|NCT01655225|Experimental|Part B7: LY3023414 + Abemaciclib + Letrozole|LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.
9885557|NCT01614171|Experimental|Growth hormone therapy|Growth hormone treatment for 6 months
9885558|NCT01582776|Experimental|Lenalidomide and GA101|Ga101 and lenalidomide
9885559|NCT01555905|Experimental|Exercise|Threshold PEP or IMT device Phillips-Respironics
9885560|NCT01534065|Experimental|Barricaid|CE Marked Device
9885561|NCT01430390|Experimental|Biological/Genetically Modified T cells|Utilizing our initial trial experience, it was amended to include three (3) expansion cohorts. Cohort 1: patients with CD19+ relapse/refractory (R/R) B cell malignancies occurring after allogeneic/autologous HSCT or solid organ transplant (SOT) infusion occurring following conditioning chemotherapy. Cohort 2:patients with CD10+ high risk B cell malignancies eligible for autologous HSCT followed by 19-28z CRA EBV-CTLs (auto-HSCT preparative regimen serves as conditioning chemotherapy. Cohort 3: patients with CD19+ high risk B cell malignancies eligible for allogeneic HSCT followed by consolidative 19-28z CAR EBV-CTLs (allo-HSCT preparative regimen serves as conditioning chemotherapy) Each expansion cohort has a target accrual of 6 patients treated with fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose.
9885562|NCT01368588|Active Comparator|Arm I|Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)* or 3D-conformal radiation therapy (3D-CRT)* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
9989878|NCT01437748|Active Comparator|Tiotropium bromide|Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
9989879|NCT01437761||2008 Sorbent system|Hemodialysis with the 2008 Sorbent system
9997381|NCT01508429|Active Comparator|misoprostol|800mcg misoprostol (four tablets of 200 mcg administered sublingually)
9997382|NCT01508429|Placebo Comparator|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
9997383|NCT01508468|Active Comparator|active comparator|"Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin."
9997384|NCT01508468|Experimental|experimental|NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)
9997385|NCT01508481||Diabetes high risk group|
9997386|NCT01508494|Active Comparator|Galantamine|16mg galantamine progressively
9997387|NCT01508494|Placebo Comparator|placebo|placebo
9997388|NCT01508507||Cholera cases group|"Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
9997389|NCT01508507||Control group|"A randomly selected age matched individual, who have been living in the study area and did not seek care for diarrheal illness in the study health center since vaccination is defined as control"
9997390|NCT01508533||Cohort 1|Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
9997391|NCT01508533||Cohort 2|Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
9885563|NCT01368588|Experimental|Arm II|Patients undergo whole-pelvic radiotherapy (WPRT)* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
9997392|NCT01508546|Experimental|Arm 1: breast surgery with axillary lymphnodes removal|
9997393|NCT01508546|Experimental|Arm 2: breast surgery without axillary lymphnodes removal|
9997394|NCT01508559||HIV infected|HIV infected MSM 18-50 years old
9997395|NCT01508559||HIV uninfected|HIV uninfected MSM 18-50 years old
9997396|NCT01508572|Experimental|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
9997397|NCT01508585|Active Comparator|Pre-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) before bariatric surgery
9997398|NCT01508585|Active Comparator|Post-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) after bariatric surgery
9997399|NCT01508611|Active Comparator|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
9885564|NCT01349322|Active Comparator|Arm I|Patients undergo standard whole-breast radiotherapy (WBI) comprising intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) 5 days a week for 3-5 weeks followed by a sequential radiotherapy boost to the lumpectomy area 5 days a week for 1-1½ weeks in the absence of disease progression or unacceptable toxicity.
9885565|NCT01349322|Experimental|Arm II|Patients undergo accelerated hypofractionated WBI comprising IMRT or 3D-CRT with a concurrent boost to the lumpectomy area 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
9885566|NCT01342952|Experimental|Ambrisentan|Open label, flexible dosing from 2.5 mg to 10 mg (not to exceed 0.25 mg/kg) per day
9885567|NCT01220583|Experimental|Arm I|Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
9885568|NCT01220583|Experimental|Arm II|Patients undergo 3D-CRT or IMRT as in arm I.
9885569|NCT01180881||Proton Radiation Patients at MGH|Pediatric brain and central nervous system (CNS) tumor patients treated with proton beam radiation therapy
9885570|NCT01148849|Experimental|Cohort 1: 0.1 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885571|NCT01148849|Experimental|Cohort 2: 0.3 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885572|NCT01148849|Experimental|Cohort 3: 1.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885573|NCT01148849|Experimental|Cohort 4: 3.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885574|NCT01148849|Experimental|Cohort 5: 6.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885575|NCT01148849|Experimental|Cohort 6: 10 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885576|NCT01148849|Experimental|Cohort 7: 15 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885577|NCT01148849|Experimental|Cohort 8: 18 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
9885578|NCT01145209|Experimental|FO Arm (fludarabine and ofatumumab)|For patients with non-high risk FISH changes
9885579|NCT01145209|Experimental|FCO Arm (fludarabine, cyclophosphamide, and ofatumumab)|For patients with high risk FISH changes
9885580|NCT01078662|Experimental|1|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions.
9885581|NCT00971867|Experimental|Paclitaxel|
9885582|NCT00959140|Experimental|CD3+ T-cell depletion|CD3+ T-cell depletion
9885583|NCT00891891||Spina Bifida|140 children with spina bifida (ages 8-15)
9885584|NCT00853307|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
9885585|NCT00583804|Experimental|Stimulation ON|Individuals implanted with stimulator/sensor device. Stimulator is turned on and is active.
9885586|NCT00583804|Active Comparator|Stimulation OFF|Function with stimulation turned off.
9885587|NCT00541268|Experimental|A - ICD implantation|Heart Failure nonischemic etiology treated by optimal medical treatment and receiving a prophylactic ICD
9885588|NCT00541268|Active Comparator|B - control|Heart Failure nonischemic etiology treated by optimal medical treatment
9885589|NCT00532025|Experimental|1|Sorafenib treatment
9885590|NCT00532064||Ancillary-correlative (biospecimen collection)|Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
9885591|NCT00532090|Experimental|1|
9885592|NCT00532090|Experimental|2|
9885593|NCT00532090|Experimental|3|
9885594|NCT00532116|Active Comparator|A|EMSAM 6mg
9885595|NCT00532116|Active Comparator|B|EMSAM (Selegiline Transdermal System) 12mg
9885596|NCT00532168|Experimental|1|tenofovir plus emtricitabine plus efavirenz
9885597|NCT00532168|Experimental|2|tenofovir plus emtricitabine plus lopinavir-ritonavir
9885598|NCT00532168|Experimental|3|tenofovir plus emtricitabine plus atazanavir-ritonavir
9885599|NCT00532194|Placebo Comparator|A (reference)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
9885600|NCT00532194|Active Comparator|B (concurrent cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.
9885601|NCT00532194|Active Comparator|C (concurrent and maintenance cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.
9885602|NCT00532207|Experimental|A|
9885603|NCT00532220|Active Comparator|A|
9885604|NCT00532220|Placebo Comparator|B|
9885605|NCT00532246|Experimental|A|raloxifene
9885606|NCT00532246|Placebo Comparator|B|placebo
9885607|NCT00532272|Experimental|letrozole|letrozole(2.5mg orally daily)
9885608|NCT00532272|Active Comparator|goserelin plus letrozole|goserelin (3.6mg subcutaneously every 28 days) plus letrozole(2.5mg orally daily)
9885609|NCT00532285|Experimental|Paclitaxel/Gemcitabine|paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8) every 3 weeks, 4 cycles
9885610|NCT00532324|No Intervention|A|Pregnant women not receiving CA-MRSA decolonization therapy.
9885611|NCT00532324|Other|B|Pregnant women receiving CA-MRSA decolonization therapy.
9885612|NCT00532337|Placebo Comparator|P|
9885613|NCT00532337|Experimental|E1|
9885614|NCT00532337|Experimental|E2|
9885615|NCT00532337|Experimental|E3|
9885616|NCT00532337|Active Comparator|A|
9885617|NCT00532350|Experimental|1|QAT370
9885618|NCT00532350|Placebo Comparator|2|Placebo
9885619|NCT00532350|Active Comparator|3|Tiotropium
9885620|NCT00532363||Obese asthmatics|Obese subjects with asthma (on inhaled corticosteroids)
9885621|NCT00532363||Non obese asthmatics|Non obese subjects with asthma (on inhaled corticosteroids)
9885622|NCT00532389|Experimental|Panobinostat (LBH589)|
9885623|NCT00532415|Experimental|Triamcinolone|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
9885624|NCT00532428|Active Comparator|1|
9885625|NCT00532428|Active Comparator|2|
9885626|NCT00532428|Placebo Comparator|3|
9885627|NCT00532454|Other|tamoxifen|observation for clinical efficacy on tamoxifen according to CYP2D6 genotype
9885628|NCT00532532|Experimental|1|AV650 low dose
9885629|NCT00532532|Experimental|2|AV650 high dose
9885630|NCT00532532|Experimental|3|Placebo
9885631|NCT00532545|Experimental|A|Teriparatide
9885632|NCT00532558|Experimental|Lapaquistat Acetate 50 mg QD|
9885633|NCT00532558|Placebo Comparator|Placebo QD|
9885634|NCT00532584|Experimental|treatment with inhaled beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
9885635|NCT00532584|No Intervention|Control - healthy smokers|Group B will act as control and include healthy smokers who receive no treatment.
9885636|NCT00532584|No Intervention|control - healthy non-smokers|Group C will act as control and include healthy non-smokers who receive no treatment.
9885637|NCT00532597|Experimental|O|
9885638|NCT00532597|Active Comparator|L|
9885639|NCT00532623|Active Comparator|Combination|
9885640|NCT00532623|Active Comparator|Seqeuntial|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
9885641|NCT00532636|Active Comparator|1|Children 1-5 years of age
9885642|NCT00532636|Active Comparator|2|Children 6-10 years of age
9885643|NCT00532662|Experimental|1|epidural s(+)-ketamine for supplementation of caudal anesthesia
9989880|NCT01437774|Active Comparator|Concentric Thrombectomy Catheter|Control Arm
9989881|NCT01437774|Experimental|Reverse ReStore mechanical thrombectomy|Reverse ReStore Device mechanical thrombectomy Each arm will use either ReStore or Merci as the primary thrombectomy device
9989882|NCT01437800|Experimental|Glimepiride / Extended release Metformin|Pharmaceutical Form: Tablets Dosage: (4/850 mg). Administration way: Oral On fasting conditions
9989883|NCT01437813|Experimental|Group A: Glimepiride / Extended Release Metformin|Pharmaceutical Form: Tablets Dosage: 4 mg / 850 mg Administration way: Oral
9989884|NCT01437826|Experimental|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
9989885|NCT01437826|Placebo Comparator|Sugar pill|placebo had an identical appearance as intervention
9989886|NCT01437839|Experimental|1|Period I: fasting state, Period II: fed state
9989887|NCT01437839|Experimental|2|Period I: fed state, Period II: fasting state
9989888|NCT01437865|Experimental|Gadofosveset enhanced MRI Axilla|
9989889|NCT01437904|Experimental|Outpatient|Outpatient recovery following Percutaneous nephrolithotomy
9989890|NCT01437904|Sham Comparator|In hospital|Inpatient recovery following Percutaneous nephrolithotomy
9989891|NCT01437917|Experimental|Bread with 20% amylose content|Bread with 20% amylose content
9989892|NCT01437917|Experimental|Bread with 10% amylose content|Bread with 10% amylose content
9989893|NCT01437917|Experimental|carbohydrates|50g of carbohydrates ingested with 400 ml of water
9989894|NCT01437930|Placebo Comparator|placebo|products (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
9989895|NCT01437982|Experimental|Loteprednol Etabonate|Ophthalmic Gel 0.5%
9989896|NCT01437982|Experimental|Prednisolone Acetate 1% Oph Susp|Ophthalmic suspension 0.5%
9989897|NCT01438021|Experimental|Treatment (intraventricular chemotherapy)|Patients receive intraventricular methotrexate continuously on days 1-14. Treatment continues in the absence of disease progression or unacceptable toxicity.
9989898|NCT01438034|Experimental|kisspeptin|intravenous administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg
9989899|NCT01438073|Experimental|kisspeptin, GnRH|24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
9989900|NCT01438086|Active Comparator|mecasermin low dose|
9989901|NCT01438086|Active Comparator|mecasermin high dose|
9989902|NCT01438086|Placebo Comparator|saline placebo|
9989903|NCT01438099||normal subjects|parturients admitted to the labor ward who request epidural analgesia with BMI < 30
9989904|NCT01438099||obese subjects|parturients admitted to the labor ward who request epidural analgesia with BMI > 30
9989905|NCT01438112|Experimental|CG0070 oncolytic virus|Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes
9989906|NCT01438112|Active Comparator|Chemotherapy or Interferon|"Quadruple Choice as interventions~Mitomycin C~Interferon~Valrubicin~Gemcitabine"
9989907|NCT01438125|Active Comparator|MF-4181|Scar halves randomized to treatment with device, opposite side treated per standard of care
9989908|NCT01438125|Active Comparator|Standard surgical wound closure|
9989909|NCT01438138||Correlative studies|Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay, the My Profile™ AML Risk of Relapse Assay. Molecular markers analyzed include Flt3-ITD, NPM1, and MRA. Results are then correlated with each patient's clinical data including patient's age, race/ethnic background, gender, treatment received, and outcomes.
9989910|NCT01438164||oncologic patients|initial staging
9989911|NCT01438190|Experimental|Experimental|Metformin plus step-down protocol
9989912|NCT01438190|Active Comparator|Control|Placebo and step-up protocol
9989913|NCT01438203|Experimental|Thrust manipulation|Clinicians will use thrust manipulation at a targeted level to provide the treatment on selected individuals
9989914|NCT01438203|Active Comparator|Non-thrust manipulation|Clinicians will apply non-thrust manipulation (targeted) as performed in a clinical manner for treatment for included individuals
9989915|NCT01438216||VUmc IC|Due to multicentre, 2 groups of patient in 1 cohort
9989916|NCT01438216||UMCN IC|Due to multicentre, 2 groups of patient in 1 cohort
9997400|NCT01508611|Active Comparator|cross-toothbrushing|Children will be oriented to proceed cross-toothbrushing in erupting molars
9517884|NCT03302026|Experimental|Real-time neurofeedback training group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
9885644|NCT00532662|Active Comparator|2|intravenous ketamine for supplementation of caudal anesthesia
9885645|NCT00532675|Experimental|PAN 5 mg|Panobinostat 5 mg
9885646|NCT00532675|Experimental|PAN 10 mg|Panobinostat 10 mg
9885647|NCT00532675|Experimental|PAN 20 mg|Panobinostat 20 mg
9885648|NCT00532675|Experimental|PAN 25 mg|Panobinostat 25 mg
9885649|NCT00532688|Experimental|1|5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.
9885650|NCT00532688|Placebo Comparator|2|28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
9885651|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
9885652|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
9885653|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 24 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
9885654|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 48 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
9885655|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 24 weeks|Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR
9885656|NCT00532714|No Intervention|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 (intravenously once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period) Capecitabine (orally at a dose of 1,000 mg/m2 twice daily 3-week cycles (2 weeks of treatment followed by a 1-week rest period))
9885657|NCT00532727|Experimental|Arm A|Carboplatin
9885658|NCT00532727|Active Comparator|Arm B|Docetaxel
9885659|NCT00532740||All Patients|Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.
9885660|NCT00532766|Experimental|2|Jusline Humulin
9885661|NCT00532792|Experimental|Group 1|
9885662|NCT00532792|Experimental|Group 2|
9885663|NCT00532792|Experimental|Group 3|
9885664|NCT00532792|Experimental|Group 4|
9885665|NCT00532792|Experimental|Group 5|
9885666|NCT00532792|Experimental|Group 6|
9885667|NCT00532792|Experimental|Group 7|
9885668|NCT00532792|Experimental|Group 8|
9885669|NCT00532792|Experimental|Group 9|
9885670|NCT00532792|Placebo Comparator|Group 10|
9885671|NCT00532818|Placebo Comparator|1|
9885672|NCT00532818|Experimental|2|
9885673|NCT00532831||Obese asthmatics|Obese subjects with asthma (on inhaled bd only)
9885674|NCT00532831||Non-obese asthmatics|Non-obese subjects with asthma(on inhaled bd only)
9885675|NCT00532857|Experimental|Paclitaxel/Gemcitabine/Trastuzumab|
9885676|NCT00532870|Active Comparator|1|laparoscopy
9885677|NCT00532896||bariatric surgery|patients with morbid obesity undergoing a bariatric surgery
9885678|NCT00532896||No bariatric surgery|patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
9885679|NCT00532922||1|Chinese asthma patient prescribed Symbicort® Turbuhaler®
9885680|NCT00532961|Experimental|Zylet|Zylet (loteprednol etabonate and tobramycin)
9885681|NCT00532961|Active Comparator|Tobradex|TobraDex (dexamethasone and tobramycin)
9885682|NCT00533000|Experimental|A|Smoking cessation
9885683|NCT00533000|No Intervention|B|
9885684|NCT00533013|Active Comparator|Usual care|Management of heart failure is provided by primary practitioners and consultant cardiologists
9885685|NCT00533013|Experimental|Disease Management|Disease management led by nurse specialists in regional Heart Failure Clinics and a national Call Center. Tele-Monitoring of body weight, pulse rate and blood pressure is performed at participants' homes.
9885686|NCT00533026|Active Comparator|A|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60mg QD, PO for the 14 days. Duloxetine doses were tapered, subjects received 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
9885687|NCT00533026|Active Comparator|B|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60 mg QD, PO for 4 days followed by duloxetine 120 mg QD, PO for 10 days. Duloxetine doses were tapered, subjects received 60mg QD, PO for 4 days followed by 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
9885688|NCT00533039|Placebo Comparator|Control|Subjects take 2 tablets BID. Placebo tablets are identical to active medication.
9885689|NCT00533039|Experimental|Varespladib (A-002)|Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
9885690|NCT00533052|Experimental|Affective and Cognitive Skills Training|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training
9885691|NCT00533078|Other|1|
9885692|NCT00533091|Active Comparator|1|MEDI-545
9885693|NCT00533091|Other|2|Placebo
9885694|NCT00533104|Experimental|BM-MNC|Patients are implanted with bone marrow - mononuclear cells
9885695|NCT00533104|Experimental|PB-MNC|Patients are implanted with peripheral blood - mononuclear cells
9885696|NCT00533130||1|Pediatric patients under 16 years old with long bones fractures
9885697|NCT00533143|Experimental|2|Non-invasive ventilation
9885698|NCT00533169|Experimental|ZD6474 + Retinoic Acid|Part A = ZD6474 Alone, Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
9885699|NCT00533195|Active Comparator|0|5-MOP photochemotherapy. Intake of Geralen capsules (1.2 mg/kg) 2 hours before irradiation. Determination of the minimal phototoxic dose (MPD) and Geralen serum level prior to treatment. Start with 70 % of the MPD, no dose increments in the first treatment week. From the second week increments of the UVA dose by 20 % in the absence of an erythemal reaction, respectively by 10 % in cases of a barely perceptible erythemal response. Increments of the UVA dose at the earliest 96 hours after the last increments. Treatment frequency 3 x week for 5 weeks (=15 exposures). No maintenance therapy except emollients.
9885700|NCT00533195|Experimental|1|UVA1 phototherapy. Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability. No maintenance therapy except emollients.
9885701|NCT00533221|Active Comparator|Somatotropin|subcutaneous application of somatotropin over 12 weeks followed by 8 weeks wash out period followed by 12 weeks subcutaneous placebo application
9885702|NCT00533221|Placebo Comparator|Placebo|12 weeks placebo subcutaneous application followed by 8 weeks wash out and 12 weeks subcutaneous application of somatotropin
9885703|NCT00533286|Placebo Comparator|A|placebo (2 tablets daily)
9885704|NCT00533286|Experimental|B|diazepam (2 x 5 mg)
9885705|NCT00533299|Experimental|1|Topotecan hydralazine valproate
9885706|NCT00533299|Placebo Comparator|2|Placebo, hydralazine, valproate
9885707|NCT00533338|Experimental|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling. Packet of questionnaires will be completed.
9885708|NCT00533338|Active Comparator|Standard Care Group|Packet of questionnaires will be completed.
9885709|NCT00533390|Experimental|EFAVIRENZ 800mg|Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
9885710|NCT00533390|Active Comparator|EFAVIRENZ 600mg|Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
9885711|NCT00533494|Active Comparator|B|Feedback to physicians + reminder letters to patients
9885712|NCT00533494|Active Comparator|A|Feedback information to physicians
9885713|NCT00533520|Active Comparator|0.5mg ranibizumab|Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
9885714|NCT00533520|Active Comparator|1.0mg ranibizumab|Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
9885715|NCT00533520|Active Comparator|2.0mg ranibizumab|Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
9885716|NCT00533559|Experimental|buphenyl|
9885717|NCT00533559|Placebo Comparator|Placebo|
9885718|NCT00533585|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin
9931442|NCT00938275|Experimental|0.5g SRT2104|"Cohort 1 (10 males) & Cohort 2 (10 females) must attend the clinic on 4 separate treatment visits during the study; each treatment visit will be one week apart. At each treatment visit, subjects will receive one of the following 4 treatments:~A) 0.5g SRT2104 administered as an oral suspension in the fasted state B) 0.5g SRT2104 administered as an oral suspension following consumption of a standard meal C) 0.5g SRT2104 administered as two 0.25g capsules in the fasted state D) 0.5g SRT2104 administered as two 0.25g capsules following consumption of a standard meal.~For treatments A and C, subjects will have fasted for at least 10 hours overnight. Water will be restricted from 1h prior to dosing until 1h post dose. A light lunch will be provided 4h post dose. For treatments B and D, subjects will receive SRT2104 within 30 min following the start of consumption of a standardized non high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat)."
9931443|NCT00938288|Other|1|Single group
9931444|NCT00938301|Active Comparator|Treatment|2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
9931445|NCT00938301|Placebo Comparator|Placebo|2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
9931446|NCT00938353|Experimental|BDP UDV|
9931447|NCT00938353|Placebo Comparator|Placebo|
9931448|NCT00938379|Experimental|20% deet insect repellent|experimental intervention
9931449|NCT00938379|Placebo Comparator|lotion without repellent active|
9931450|NCT00938405|Experimental|Colesevelam HCl|Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
9931451|NCT00938405|Placebo Comparator|Comparison group|Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
9931452|NCT00938444||Patients with moderate to severe RA|Patients with moderate to severe RA treated with Tocilizumab
9931453|NCT00938483|Experimental|Extensively hydrolyzed infant formula|New extensively hydrolyzed formula, NPS-202
9931454|NCT00938483|Active Comparator|Infant formula - Extensively hydrolyzed Nutramigen Lipil|Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
9997401|NCT01508624|No Intervention|Control|participants will receive standard usual care
9997402|NCT01508624|Experimental|Interaction|Participants will interact with nurses during their procedure
9931455|NCT00938522|Experimental|Cilostazol loading|
9931456|NCT00938522|Placebo Comparator|Placebo|
9931457|NCT00938535|Experimental|Obesity Prevention|
9931458|NCT00938535|No Intervention|Usual Care|This arm includes usual care.
9931459|NCT00938561||With and without Chronic Kidney Disease|A cohort of 10 patients subjects with and without kidney disease exhibiting a broad range of age and kidney function
9931460|NCT00938574|Experimental|Drug Atu027|
9931461|NCT00938600|Experimental|A1 - non-pregnant single-dose|
9931462|NCT00938600|Experimental|A2 - non-pregnant; weekly dose|
9931463|NCT00938600|Experimental|B1 - pregnant; single-dose|
9931464|NCT00938600|Experimental|B2 - pregnant; weekly dose|
9931465|NCT00938600|Active Comparator|C1 - active control; pregnant women|
9931466|NCT00938613|Experimental|Captisol-Enabled Budesonide|32 ug/spray
9931467|NCT00938613|Active Comparator|Rhinocort Aqua|32 ug/spray
9931468|NCT00938613|Placebo Comparator|Placebo|posphate buffered saline
9931469|NCT00938626|Experimental|Armed-activated T cells/Immunotherapy|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
9931470|NCT00938665||Control Group|
9931471|NCT00938665||AD Group|
9931472|NCT00938678|Experimental|Treatment Group 1|
9931473|NCT00938678|Active Comparator|Treatment Group 2|
9931474|NCT00938691|Experimental|Tepha|
9931475|NCT00938691|Active Comparator|Vicryl|
9931476|NCT00938730|Experimental|1. YM150, Dose W, twice daily|
9931477|NCT00938730|Experimental|2. YM150, Dose X, once daily|
9931478|NCT00938730|Experimental|3. YM150, Dose X, twice daily|
9931479|NCT00938730|Experimental|4. YM150, Dose Y once daily|
9931480|NCT00938730|Experimental|5. YM150, Dose Y twice daily|
9931481|NCT00938730|Experimental|6. YM150, Dose Z, once daily|
9931482|NCT00938730|Active Comparator|7. Warfarin|
9931483|NCT00938743|Active Comparator|Atomoxetine|Treatment with a final dosis of 40-80mg atomoxetine daily
9931484|NCT00938743|No Intervention|Waiting list|
9931485|NCT00938769|Other|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
9931486|NCT00938769|Other|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for support.
9931487|NCT00938795|Other|Uncertainty Management Intervention|The Uncertainty Management Intervention will consist of six 30-minute phone calls with a study educator to discuss issues of psychological distress, uncertainty management, symptom control, self efficacy for symptom management, and quality of life.
9931488|NCT00938795|Other|Comparison Conditions for Liver Disease|Six 30-minute telephone calls that provide structured education about liver disease.
9931489|NCT00938808|Active Comparator|One per day, Formula diet|The Cambridge Programme. Formula diet One-daily
9931490|NCT00938808|Experimental|Repeated formula diet|Dietary instruction (low-energy diet) 3x5 weeks per year
9931491|NCT00938821||Caudal Block|Review of charts of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B).
9931492|NCT00938834|Active Comparator|CFQ Qigong training group|"Qigong training con- sisted of an initial workshop conducted over three con- secutive half-days by a qualified CFQ instructor. Participants received training in level 1 CFQ; this con- sisted of instruction in seven key movements known as the hexagram and ancillary exercises. Hexagram move- ments consist of choreographed movements that emphasize softness, relaxation, downward releases and full body distribution of qi. Once initial training was complete, participants were asked to practice CFQ at home for 45 to 60 minutes per day for eight weeks; time could be broken up into shorter sessions during the day. Participants returned for a 60 minute weekly review/group practice sessions for these eight weeks."
9989917|NCT01438242|Experimental|Assay Guided Treatment - Genecept Asay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account. Genetic analysis is performed using the Genecept Assay, a genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
9989918|NCT01438242|Experimental|Clinician's utilizing Assay Guided Treatment in Psychiatry|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
9989919|NCT01438255||Alvesco|
9989920|NCT01438268||Reconstructive breast cancer patients|Patients having unilateral, bilateral immediate or delayed TRAM flaps who are discharged 18 hours postoperatively
9989921|NCT01438281|Experimental|SYL1001|
9989922|NCT01438320|Experimental|Quercetin|Quercetin is a bioflavonoid.
9989923|NCT01438333|Experimental|Lactobacillus brevis|
9989924|NCT01438333|Placebo Comparator|Placebo|5 tablets a day for 6 weeks
9989925|NCT01438346|Active Comparator|Substance Abuse Education (SED)|The Substance Abuse Education (SED) group will serve as the control intervention in which participants will receive instruction on a variety of topics included in the substance abuse treatment program curriculum. These will include, but are not limited to, information about anger management, smoking cessation, women's issues, and stress management, and approaches to help reduce cravings. Each week the TAU group will meet and a House of Hope (HOH) clinical staff member will discuss the above and related issues and how these may help individuals deal with their substance abuse and related psychological issues.
9989926|NCT01438346|Experimental|Mind-body Bridging (MBB)|Participants in the experimental Mind-Body Bridging (MBB) group, in addition to their usual treatment for substance abuse, will additionally receive instruction on the basics of MBB, and will learn MBB techniques to help deal with their cravings and comorbid psychological conditions. A workbook will be incorporated into the curriculum to provide MBB participants with daily exercises and activities to help facilitate adherence to the MBB program.
9989927|NCT01438359|Experimental|PA21 and Furosemide with food|
9989928|NCT01438359|Experimental|No PA21; Furosemide with food|
9989929|NCT01438359|Experimental|PA21 with food and Furosemide 2hrs later|
9989930|NCT01438372|Experimental|Intravenous iron sucrose arm|
9989931|NCT01438372|Active Comparator|Oral ferrous sulfate|
9989932|NCT01438385||Interventional Endoscopy|Any group that went Interventional Endoscopy procedures.
9989933|NCT01438398|Other|Submucosal Endoscopic Mucosal Flap Technique|Submucosal Endoscopic Mucosal Flap Technique
9989934|NCT01438437|Active Comparator|Percutaneous acetic acid|
9989935|NCT01438437|Active Comparator|Radiofrequency ablation|
9989936|NCT01438450|No Intervention|Supportive|Supportive therapy
9989937|NCT01438450|Active Comparator|Oral|Oral thalidomide and capecitabine
9989938|NCT01438463|Placebo Comparator|placebo|
9989939|NCT01438463|Experimental|PURETHAL Mites, 6,667 AU/ml|
9989940|NCT01438463|Experimental|PURETHAL Mites, 20,000 AU/ml|
9989941|NCT01438463|Experimental|PURETHAL Mites, 50,000 AU/ml|
9989942|NCT01438463|Experimental|PURETHAL Mites, 100,000 AU/ml|
9989943|NCT01438502||HyperHAES|
9989944|NCT01438515|Experimental|Systemic decolonization|7-day course of 4% chlorhexidine gluconate daily washes and 2% mupirocin ointment to the anterior nares twice daily in addition to oral rifampin (600mg daily), and doxycycline (100mg twice daily)
9989945|NCT01438515|Active Comparator|Standard decolonization|7-day course of 2% mupirocin ointment to the anterior nares twice daily and 4% chlorhexidine gluconate washes once per day.
9989946|NCT01438554|Experimental|Pazopanib and GSK1120212|Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
9989947|NCT01438567|Experimental|OXN PR tablets|
9989948|NCT01438567|Active Comparator|OxyPR tablets|
9989949|NCT01438580|Experimental|standard intensity warfarin group|Eligible 80 patients(83.14±4.05,33.0%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 2.1-3.0
9989950|NCT01438580|Experimental|low intensity warfarin group|Eligible 81 patients(84.0±4.71,33.5%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 1.5-2.0
9989951|NCT01438580|Active Comparator|aspirin group|Eligible 81 patients(83.4±5.13,33.5%)with chronic NVAF were randomly assigned to this group and 100mg aspirin was administrated every day
9989952|NCT01438593|Experimental|HUCB, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
9989953|NCT01438606|Experimental|1 x 10^4 PFU VSV-Indiana HIV gag vaccine (Group 1)|Participants will receive 1 x 10^4 PFU of the study vaccine by intramuscular (IM) injection in each deltoid at baseline and Week 8. (1 x 10^4 PFU is the nominal dose; the actual dose is 4.6 x 10^3 PFU given as 2.3 x 10^3 PFU in each deltoid)
9989954|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 1)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
9989955|NCT01438606|Experimental|1 x 10^5 PFU VSV-Indiana HIV gag vaccine (Group 2)|Participants will receive 1 x 10^5 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^5 PFU is the nominal dose; the actual dose is 4.6 x 10^4 PFU given as 2.3 x 10^4 PFU in each deltoid)
9989956|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 2)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
9989957|NCT01438606|Experimental|1 x 10^6 PFU VSV-Indiana HIV gag vaccine (Group 3)|Participants will receive 1 x 10^6 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^6 PFU is the nominal dose; the actual dose is 4.8 x 10^5 PFU given as 2.4 x 10^5 PFU in each deltoid)
9989958|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 3)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
9989959|NCT01438606|Experimental|1 x 10^7 PFU VSV-Indiana HIV gag vaccine (Group 4)|Participants will receive 1 x 10^7 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^7 PFU is the nominal dose; the actual dose is 4.2 x 10^6 PFU given as 2.1 x 10^6 PFU in each deltoid)
9989960|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 4)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
9989961|NCT01438606|Experimental|1 x 10^8 PFU VSV-Indiana HIV gag vaccine (Group 5)|Participants will receive 1 x 10^8 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^8 PFU is the nominal dose; the actual dose is 3.4 x 10^7 PFU given as 1.7 x 10^7 PFU in each deltoid)
9989962|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 5)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
9989963|NCT01438619||representitives of Goyang city|"Representative population of Goyang city who were randomly selected by digit dialing (RDD) method~Volunteers who are reside in Goyang city"
9989964|NCT01438632|Experimental|jet injector|Jet injectors deliver insulin at a high velocity (typically >100m/s) across the skin in the subcutaneous tissue, without the use of a needle
9989965|NCT01438632|Active Comparator|conventional insulin pen|
9989966|NCT01438645|Experimental|ScopeGuide-assisted colonoscopy|These patients will undergo colonoscopy with the assistance of the Olympus ScopeGuide system.
9989967|NCT01438645|No Intervention|Conventional colonoscopy|These patients will undergo colonoscopy identical to that in the intervention arm, except with endoscopes lacking the ScopeGuide system.
9989968|NCT01438658||All|A cohort of all the patients.
9989969|NCT01438671|Experimental|All participants|Nintendo Wii Fit Balance training followed by traditional balance training
9989970|NCT01438684|Active Comparator|RPh201 group|7 patients will receive the treatment
9989971|NCT01438684|Placebo Comparator|non RPh201 group|3 patients will receive placebo
9989972|NCT01438697|Experimental|Internet Intervention|Assigned to Sleep Healthy Using the Internet (SHUTi)
9989973|NCT01438697|Active Comparator|Patient Education Website|Assigned to Patient Insomnia Educational Website
9989974|NCT01438723|Experimental|metformin|
9989975|NCT01438723|Placebo Comparator|placebo|
9989976|NCT01438736|Experimental|Desogestrel, Etonogestrel|Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months
9989977|NCT01438736|Experimental|Etonogestrel|Arm 2: Women staring straight with Nexplanon implant for 6 months
9989978|NCT01438749|Active Comparator|A|
9989979|NCT01438749|Placebo Comparator|B|
9989980|NCT01438749|Experimental|C|
9989981|NCT01438762|Active Comparator|Information and patient education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
9989982|NCT01438762|Active Comparator|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas."
9997403|NCT01508624|Experimental|Music|Participants will listen to music using head phones during their procedure.
9885719|NCT00533624|Active Comparator|1: Myfortic|Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
9885720|NCT00533624|Active Comparator|2. Cellcept|Cellcept® 2,000 mg/day, in divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
9885721|NCT00533637|Experimental|1|NLA Nasal Spray
9885722|NCT00533637|Active Comparator|2|
9885723|NCT00533637|Placebo Comparator|3|
9885724|NCT00533663|Experimental|Healing Touch (HT)|A a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy. It occurs every other week (during their infusion).
9885725|NCT00533663|Active Comparator|Guided relaxation|Guided relaxation every other week (during their infusion).
9885726|NCT00533663|Active Comparator|standard care|Standard care
9885727|NCT00533715||>100|"The study included healthy children (2.5-6.5 years old) from a number of public kindergartens. An initial screening questionnaire based on the ATA-DLD-78-A for adults, adapted for children and translated into Hebrew, concerning the child's birth, past and present health status, was completed by the parents.~Exclusion criteria: Previous symptoms or treatment for asthma, current respiratory symptoms or other present respiratory diseases."
9885728|NCT00533741|Experimental|1c (10 mcg)|4 subjects randomized in a 1:3 fashion to receive a two dose regimen of placebo or vaccine with 10 mcg of antigen and no adjuvant.
9885729|NCT00533741|Experimental|2 (dose comparison stage)|54 subjects (9 per vaccine group) randomized 1:1:1:1:1:1 to receive vaccines containing, 2.5, 5.0, or 10.0 mcg of antigen without adjuvant, or 2.5 or 5.0 mcg of antigen with Alum, or placebo.
9885730|NCT00533741|Experimental|1a (2.5 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 2.5 mcg of antigen and no adjuvant, or 2.5 mcg of antigen and Alum adjuvant.
9885731|NCT00533741|Experimental|1b (5.0 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 5.0 mcg of antigen and no adjuvant, or 5.0 mcg of antigen and Alum adjuvant.
9885732|NCT00533793|Active Comparator|SoC|Standard of Care
9885733|NCT00533793|Active Comparator|SoC plus 0.133 mg/mL|
9885734|NCT00533793|Active Comparator|SoC plus 0.4 mg/mL|
9885735|NCT00533793|Active Comparator|SoC plus 1.0 mg/mL|
9885736|NCT00533806|Experimental|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy.
9885737|NCT00533806|Active Comparator|Relaxation therapy.|Participants will receive relaxation therapy.
9885738|NCT00533819|Experimental|1|
9885739|NCT00533819|No Intervention|2|would have routine physical activity
9885740|NCT00533832|Active Comparator|1|Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
9885741|NCT00533832|Placebo Comparator|2|Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
9885742|NCT00533871||Normotensive|Pregnant women in the third trimester with normal blood pressure this pregnancy and no history of HTN or pre-eclampsia in a previous pregnancy
9885743|NCT00533871||Chronic Hypertensive|Pregnant women in their third trimester with known hypertension prior to the current pregnancy
9885744|NCT00533871||Pre-eclampsia|Pregnant women in their third trimester who meet ACOG diagnostic criteria for pre-eclampsia
9885745|NCT00533884||Treatment|Patients undergoing treatment for head and neck, lung, and esophagus cancers
9885746|NCT00533988|No Intervention|5592|Standard triple lumen catheter
9885747|NCT00533988|Active Comparator|5593|Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
9885748|NCT00534014|Placebo Comparator|A|0 mg of Vitamin C
9885749|NCT00534014|Active Comparator|B|250 mg Vitamin C
9885750|NCT00534014|Active Comparator|C|500 mg Vitamin C
9885751|NCT00534014|Active Comparator|D|1000 mg Vitamin C
9885752|NCT00534053|Experimental|1|400 patients will be given a mailed educational reminder 10 days after picking up their FOBT cards from the VA laboratory.
9997404|NCT01508624|Experimental|Touch - stress balls|Participants will be provided with stress balls to use during their procedure
9989983|NCT01438762|No Intervention|Observational cohort|Those who do not wish to participate in the randomization procedure will be followed through an observational cohort. The observational cohort will be followed at the same time-points and they will be asked which treatment they have received.
9989984|NCT01438788|Experimental|All patients on a low protein diet|
9989985|NCT01438801|Experimental|NutropinAq|
9989986|NCT01438827|Active Comparator|Avanz Phleum pratense 15,000 SQ+|
9989987|NCT01438827|Active Comparator|Avanz Phleum pratense 4,000 SQ+|
9989988|NCT01438827|Placebo Comparator|Injection with no active grass component|
9989989|NCT01438853|Experimental|TNX-832|Anti-tissue factor antibody
9989990|NCT01438853|Placebo Comparator|Drug Placebo|Placebo control
9989991|NCT01438866|Experimental|Preventing occlusal caries|Comparing preventing effect of fissure sealants vs. fluoride varnish
9989992|NCT01438879||pleocytosis group|40 patients with clinical signs of CNS infection and having CSF pleocytosis.
9989993|NCT01438879||non-pleocytosis group|20 patients not having CNS infection clinically and not having CSF pleocytosis.
9989994|NCT01438892||tDMARDs Group|traditional DMARDs
9989995|NCT01438892||Biologics group|Biologics used in RA
9989996|NCT01438905|No Intervention|Control|Parameters will be identical to the lower intensity (Small amplitude oscillation mobilization; Grade IV) talocrural mobilization. No force, other than light hand contact will be applied by the therapist.
9989997|NCT01438905|Experimental|Lower intensity mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
9989998|NCT01438905|Experimental|Higher intensity mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
9989999|NCT01438918|Active Comparator|200 mg|High dose active comparator
9990000|NCT01438918|Active Comparator|50 mg|Low dose active comparator
9990001|NCT01438918|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
9990002|NCT01438931|Placebo Comparator|Placebo group|Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
9990003|NCT01438931|Active Comparator|DA-9501 0.5 mcg/kg group|Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
9990004|NCT01438931|Active Comparator|DA-9501 1.0 mcg/kg group|Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
9990005|NCT01438944|Other|Nicabate 21mg transdermal NRT|21mg Transdermal NRT applied for 24hrs over a 14day period.
9990006|NCT01438970|Other|ALFApump system implantation|Implantation of ALFApump system
9990007|NCT01438983||breastfeeding infants|
9990008|NCT01438983||bottle feeding infants|
9885753|NCT00534053|No Intervention|2|400 patients will not receive a mailed educational reminder to return their FOBT cards after they have picked up the FOBT cards from the VA laboratory
9885754|NCT00534066||Admitted|Patients presenting to the ED with acute exacerbation of CHF who require admission to the hospital directly from the ED
9885755|NCT00534066||Observational|Patients who present to the ED for acute exacerbation of CHF who are transferred to the Observation Unit from the ED for up to 24 hours.
9885756|NCT00534079|Experimental|Dornase alfa|28 days of sinonasal inhalation (Pari Sinus)
9885757|NCT00534079|Placebo Comparator|isotonic saline|28 days of sinonasal inhalation (Pari Sinus)
9885758|NCT00534131|Active Comparator|Arm 1|Patients for whom a standard abdominal approach is adequate to excise the distal third of the rectum (without jeopardising oncological clearance if appropriate).
9885759|NCT00534131|Experimental|Arm 2|Combined abdominal and trans-perineal approach to excise the distal third of the rectum, while preserving the anal canal
9885760|NCT00534131|Active Comparator|Arm 3|Standard proctectomy to excise the distal third of the rectum and the anal canal
9885761|NCT00534144|Active Comparator|Iron Sucrose|
9885762|NCT00534144|Active Comparator|Ferric Gluconate|
9885763|NCT00534170|Experimental|A,F,T,K|Two arms are for intervention and two are for control or placebo
9885764|NCT00534183|Experimental|1|Olanzapine
9885765|NCT00534183|Active Comparator|2|Risperidone
9885766|NCT00534183|Active Comparator|3|haloperidol
9885767|NCT00534196||Group under operation of brachytherapy|Patients with histologically confirmed adenocarcinoma of the prostate and who are planning to undergo brachytherapy with PI (permanent iodine) or combination of PI with other tratement.
9885768|NCT00534222||Quetiapine|
9885769|NCT00534222||Olanzapine|
9885770|NCT00534222||Risperidone|
9885771|NCT00534261|Experimental|1|patients received Avonex IM injections and be evaluated for quality of life criteria
9885772|NCT00534274|Experimental|TEP FLT|
9885773|NCT00534287|Active Comparator|MeroMono|Monotherapy with meropenem
9885774|NCT00534287|Active Comparator|MeroMoxi|Combination therapy with meropenem + moxifloxacin
9885775|NCT00534300|Experimental|A|
9885776|NCT00534300|Placebo Comparator|B|
9885777|NCT00534326|Active Comparator|1|Standard Reaming of femoral shaft fracture prior to intramedullary nailing
9885778|NCT00534326|Active Comparator|2|Reamer/Irrigator/Aspirating of femoral shaft fracture prior to intramedullary nailing
9885779|NCT00534378|No Intervention|1|
9885780|NCT00534391|Placebo Comparator|B|Artificial tear containing antibiotic solution base
9885781|NCT00534391|Experimental|A|combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
9885782|NCT00534443|Experimental|1|A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
9885783|NCT00534456|Experimental|Active|
9885784|NCT00534456|Placebo Comparator|Placebo|
9885785|NCT00534482|Experimental|A, 1, I|Practice-level treatment group
9885786|NCT00534482|Active Comparator|A, 1, II|Practice-level comparison group
9885787|NCT00534482|Experimental|B, 1, I|Patient-level treatment group
9885788|NCT00534482|Active Comparator|B, 1, II|Patient-level comparison group
9885789|NCT00534521|Active Comparator|Active Treatment Arm|Subjects will have their leg and foot draped to remain blinded to the test. They will be in a supine position with the knees abducted and flexed. The medial aspect of the lower extremity is palpated and a needle insertion site is identified. Between the posterior margin of the tibia and the soleus muscle, an acupuncture-like needle is inserted. An adhesive grounding pad is placed on the bottom of the foot just below the smallest toe. The needle and grounding pad are connected to the stimulator and the stimulation is increased as tolerated.
9885790|NCT00534521|Sham Comparator|Sham Arm|"Since subjects with the PTNS will feel foot stimulation, the sham was devised to mimic this feeling without the tibial nerve being stimulated. Again the leg and foot will be draped and out of view from the subject. The medial aspect of the lower extremity is palpated (Figure 4) and the tibial nerve site is identified approximately 5 cm cephalad from the medial malleolus. A Streitberger needle is used at the tibial nerve insertion site to simulate needle placement without puncturing the skin. The needle will be taped in place as in the PTNS procedure. The grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe."
9885791|NCT00534534|Active Comparator|1|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. In addition, they also will undergo repeated similar interventions at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
9885792|NCT00534534|No Intervention|Standard|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
9885793|NCT00534560|Experimental|1|
9885794|NCT00534560|Experimental|2|
9885795|NCT00534560|Placebo Comparator|3|
9885796|NCT00534573|Active Comparator|Moclobemide,|treatment during 2 weeks
9885797|NCT00534573|Active Comparator|Amisulpride|Comparison
9885798|NCT00534586|Active Comparator|1|remifentanil
9885799|NCT00534586|Active Comparator|2|propofol
9885800|NCT00534586|Active Comparator|3|sevoflurane
9885801|NCT00534586|Active Comparator|4|s-ketamine
9885802|NCT00534612|Experimental|1|fine needle aspiration biopsy of the parotid gland mass
9885803|NCT00534625|Placebo Comparator|1|
9990009|NCT01439022|Experimental|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist.
9990010|NCT01439022|Active Comparator|Hand writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
9990011|NCT01439048||Term infants|Infants born at greater than 37 weeks gestation
9990012|NCT01439048||Preterm Infants|Infants born at less than 37 weeks gestation
9990013|NCT01439100|Active Comparator|OXN PR|Oxycodone/Naloxone Prolonged Release tablets
9990014|NCT01439100|Placebo Comparator|Dummy tablet|Placebo
10213799|NCT03216499|Experimental|Treatment (HIF-2 alpha inhibitor PT2385)|"Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis~Pharmacogenomic Study"
9990015|NCT01439113|No Intervention|Standard of care|In this arm, patients who have difficult IV access will undergo the standard of care. The options include a) repeated attempts by a primary nurse, b) new attempts by a second nurse, c) central line placement by a physician, d) intraosseous line placement by a physician, e) physician use of ultrasound for peripheral IV placement
9990016|NCT01439113|Experimental|Ultrasound-guided IV|In this arm, the emergency nurse will apply the ultrasound machine to locate and cannulate a patient's peripheral veins
9990017|NCT01439152|Experimental|BAY94-9343 (Dose-Escalation)|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days. (ENROLLMENT CLOSED).
9990018|NCT01439152|Experimental|BAY94-9343 (Expansion)|"After Maximum tolerated dose (MTD) had been defined, expansion cohorts were conducted at the MTD dose. Overall up to 32 subjects were planned to be enrolled in the expansion cohort:~Ovarian Carcinoma, 20 subjects~Mesothelioma, 6-12 subjects (ENROLLMENT CLOSED)."
9990019|NCT01439152|Experimental|BAY94-9343 (1.8 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
9990020|NCT01439152|Experimental|BAY94-9343 (2.2 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
9990021|NCT01439178|Experimental|Intravitreal Avastin Day 2|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
9990022|NCT01439178|Active Comparator|Intravitreal Avastin Day 7|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
9990023|NCT01439191|Experimental|combination agent group|
9990024|NCT01439191|Experimental|single agent group|In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
9990025|NCT01439230|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
9990026|NCT01439230|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
9990027|NCT01439243|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
9990028|NCT01439243|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
10213800|NCT03205761|Experimental|olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
9885804|NCT00534625|Experimental|2|150 mg zileuton by intravenous injection
9990029|NCT01439256|Experimental|Computer Controlled Telephone Counseling|This arm intervenes with subjects and their treating physicians. The intervention is periodic medical adherence promotion counseling for subjects regarding their prescribed HTN medications through a computer-controlled telephone counseling program that has data on subject's recent BP values and their prescribed HTN medications. The subjects' treating physicians receive at regularly scheduled office visits information about subject's recent BP and medication adherence for each prescribed medication and also get physician information and management recommendations
10213801|NCT03202043|Experimental|High dose vegetable juice|Subject will consume high dose vegetable juice daily for 8 weeks.
10213802|NCT03202043|Experimental|Medium dose vegetable juice|Subject will consume medium dose vegetable juice daily for 8 weeks.
10213803|NCT03202043|Experimental|Low dose vegetable juice|Subject will consume low dose vegetable juice daily for 8 weeks.
10213804|NCT03202043|Other|Control bottled water|Subject will consume control bottled water daily for 8 weeks.
10213805|NCT03154190|Active Comparator|Arm A (usual care)|Patients receive usual care.
10213806|NCT03154190|Experimental|Arm B (health care coach support)|Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms.
10213807|NCT03151811|Experimental|Arm A: Melflufen+Dexamethasone|Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
10213808|NCT03151811|Active Comparator|Arm B: Pomalidomide+Dexamethasone|Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
10213809|NCT03138590|Experimental|Active tDCS|Active transcranial Direct Current Stimulation targeting the trigeminal nerve
10213810|NCT03138590|Sham Comparator|Sham tDCS|Sham transcranial Direct Current Stimulation targeting the trigeminal nerve
9885805|NCT00534625|Experimental|3|300 mg zileuton by intravenous injection
9885806|NCT00534677|Active Comparator|A|
9885807|NCT00534677|Active Comparator|B|
9885808|NCT00534690|Other|1|
9885809|NCT00534690|Other|2|
9885810|NCT00534755|Other|Breast database|Database
9885811|NCT00534768|Active Comparator|1|debridement on 1st, 3-5th and 7th postoperative days
9885812|NCT00534768|Active Comparator|2|
9885813|NCT00534781|Experimental|A|plasma microtenotomy
9885814|NCT00534781|Active Comparator|B|Standard Surgical Debridement
9885815|NCT00534846|Placebo Comparator|A placebo|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
9885816|NCT00534846|Active Comparator|B toremifene|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
9885817|NCT00534872|Experimental|SB649868|10 mg
9885818|NCT00534885|Experimental|1: Healive® Lot 1|
9885819|NCT00534885|Experimental|2: Healive® Lot 2|
9885820|NCT00534885|Experimental|3: Healive® Lot 3|
9885821|NCT00534885|Active Comparator|4: control vaccine (Havrix)|
9885822|NCT00534911|Experimental|Cognitive Behavioral Therapy|Primary & Secondary Control Enhancement Training (PASCET)
9885823|NCT00534911|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy
9885824|NCT00534924|Placebo Comparator|1|No intervention after IR injury
9885825|NCT00534924|Experimental|2|Postconditioning
9885826|NCT00534924|Experimental|3|Vit. C
9885827|NCT00535028|Experimental|A|AER 001 s.c. once daily for 28 days
9885828|NCT00535028|Placebo Comparator|P|placebo s.c. once daily for 28 days
9885829|NCT00535054|Experimental|Tears Again|All subjects shall be treated with Tears Again.
9885830|NCT00535067||Breast Cancer Survivors|
9885831|NCT00535093|No Intervention|1|All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
9885832|NCT00535106|Active Comparator|Standard resusc|Patients in this arm will be treated with standard resuscitation efforts, including the delivery of an immediate defibrillatory shock for all patients presenting in VF.
9885833|NCT00535106|Experimental|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
9885834|NCT00535106|Active Comparator|Delayed defib|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation. Data is being collected on this population as well, thereby providing a cohort population for comparative purposes.
9885835|NCT00535119|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
9885836|NCT00535197|Experimental|CD34+ stem/progenitor cell therapy|Patients presenting within 7 days of onset with severe anterior circulation ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score≥8). CD34+ cells were collected from the bone marrow of the subjects before being delivered by catheter angiography into the ipsilesional middle cerebral artery.
9885837|NCT00535210|Other|1|
9885838|NCT00535210|Other|2|
9885839|NCT00535275|Experimental|A|
9990030|NCT01439256|No Intervention|Usual Care|In this arm, patients with hypertension that is not adequately controlled receive usual care from their physicians. Usual care is defined as receiving regular care from the physician and no additional care or intervention from the study.
9990031|NCT01439269|No Intervention|Phase 1: Standard Care|Mothers are given infant care instruction as part of standard care
9990032|NCT01439269|Experimental|Phase 1: Facilitated infant care|Family Nurture Intervention (FNI)
9990033|NCT01439269|Experimental|Phase 2: Effectiveness|All participants who agree to participate will receive Family Nurture Intervention.
9990034|NCT01439295||Preterm less than 33 weeks|This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
9990035|NCT01439308|Placebo Comparator|Arm 1|3 incremental capsaicin doses
9990036|NCT01439308|Active Comparator|Arm 2|3 incremental capsaicin doses
9990037|NCT01439321||Patient with Chronic Immune Thrombocytopenic Purpura|Patients with chronic ITP who switch from their previous treatment of corticosteroids, rituximab, or eltrombopag or romiplostim to eltrombopag or romiplostim and have been on the new treatment for at least four weeks
9990038|NCT01439334|Experimental|Online Program Brief|Online Program Brief
9990039|NCT01439334|Experimental|Online Program Extended Length|Online Program Extended Length
9990040|NCT01439334|Active Comparator|Control|Control
9990041|NCT01439386|Active Comparator|AF ablation with or without AFL ablation|Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
9990042|NCT01439386|Active Comparator|AFL ablation only|Cavo-tricuspid isthmus ablation only
9990043|NCT01439399|Active Comparator|Lidocaine|Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
9990044|NCT01439399|Active Comparator|Ketamine|Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
9990045|NCT01439399|Active Comparator|Ketamine-Lidocaine|Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.
9990046|NCT01439399|Placebo Comparator|Saline 0,9%|Control group
9990047|NCT01439412|Experimental|Acupuncture and standard treatment|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
9990048|NCT01439412|Other|Standard treatment in general practice|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
9990049|NCT01439425|Experimental|weight loss|balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
9990050|NCT01439438|Active Comparator|Test formulation|Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2
9990051|NCT01439438|Active Comparator|Reference formulation|Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2
9990052|NCT01439451|Experimental|experimental|perturbation training during walking
9990053|NCT01439451|Active Comparator|controls|treadmill walking
9990054|NCT01439464|Active Comparator|Control device|
9990055|NCT01439464|Experimental|Investigational device|
9990056|NCT01439490|Experimental|FES-PET|Patients undergo FES-PET prior to obtaining histology
9990057|NCT01439503|No Intervention|Control|Men receiving the control condition will be comprised of standard of care counseling from the clinic plus a variety of free condoms and water-based lubricants. They will also provide a specimen for STD testing, and receive text message questions for 12 weeks. The text messaging system will be used to collect self-reported dependent variables from men on a weekly basis. Texting will also serve as a constant method of contact between the PD and the enrolled men to remind them of follow-up assessments. In addition, the participants will complete the ACASI questionnaire to assess their sexual behavior, as well as demonstrate their condom application ability.
9990058|NCT01439503|Experimental|Treatment|Men receiving the treatment condition will receive text messages each week after their enrollment date and this will continue for 12 weeks to collect self-reported dependent variables. Text messaging will also be used to confirm and remind men about the day of each follow-up assessment. Each participant will also provide a specimen for STD testing, as well complete the ACASI questionnaire to assess sexual behavior and demonstrate their condom application ability. These participants will also be provided with a variety of free condoms and water-based lubricants. In addition, men in the treatment condition will also be enrolled in an education program.
10213811|NCT03132753|Experimental|SUPPORT Group|Subjects enrolled in the intervention.
10213812|NCT03132753|No Intervention|Treatment as Usual|Subjects enrolled in standard services.
10213813|NCT03126968|Experimental|Prophylactic topical epinephrine|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy.
10213814|NCT03126968|Placebo Comparator|Placebo|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy.
10213815|NCT03111277|Experimental|Experimental: ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain. Ultrasound passes through the skin and skull and into the brain to focus on a spot the study investigator wants to treat.
9990059|NCT01439516|Experimental|Information|Participants randomized to this arm of the study will received the PREPARED educational book and video.
9990060|NCT01439516|Experimental|Information and Financial Assistance|Participants randomized to this arm of the study will receive the PREPARED educational book and video plus financial assistance for family members to cover costs associated with an evaluation for becoming a live kidney donor.
9990061|NCT01439516|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
9990062|NCT01439529|Active Comparator|Nominal|CRT device is programmed with the nominal values.
9990063|NCT01439529|Experimental|Narrow QRS|CRT device is programmed by QRS optimization
9990064|NCT01439542|Experimental|Radiotherapy|
9990065|NCT01439607|Experimental|Bone marrow and blood sampling|
9990066|NCT01439646||Non neutropenic, ICU, empiric ,antifungals|
9990067|NCT01439659|Other|Nutritional Counseling|For 6 months control group receives dietary counseling.
9990068|NCT01439659|Experimental|Daily Supplements|2 capsules (Juice Plus+) twice a day (morning and evening) plus Juice Plus+ Complete drink each evening for 6 months.
9990069|NCT01439685||Biliary Stent plus Photodynamic therapy|Biliary Stent plus Photodynamic therapy
9990070|NCT01439685||Biliary Stent group|Biliary Stent group
9990071|NCT01439698||RFA for Pancreatico-biliary disorders|Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.
9990072|NCT01439737||asthma|
9990073|NCT01439750|Experimental|Phase I|The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
9990074|NCT01439750|Experimental|Phase II|The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms. Rituximab 375 mg/m2 on day 5,12,19,26 for 1st cycles, then day 5 montly for next 5 cycles, then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days for 6 cycles (dose determined from phase I). Bortezomib 1.6 mg/m2 weekly on day 12,19,26 for 3 cycles then every 2 weeks as maintenance dose until toxicity or progression.
9990075|NCT01439776|No Intervention|Peginterferon alfa 2a+Ribavirin|standard of care for HCV : peginterferon alfa 2a and ribavirin
9990076|NCT01439776|Experimental|Vit D+Peginterferon alfa 2a+Ribavirin|VitD+Peginterferon alfa 2a+Ribavirin
9990077|NCT01439789|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
9990078|NCT01439789|Placebo Comparator|Plaebo|Excipient placebo in addition to basic therapy of chronic heart failure
9990079|NCT01439828|Experimental|Experimental : N-acetylcystein|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
9990080|NCT01439828|Placebo Comparator|Placebo Comparator|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
9990081|NCT01439841|Experimental|Probiotics|A multi-strain Probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk (Biola®, TINE SA, Oslo), 250 mL/day for 8 weeks.
9990082|NCT01439841|Placebo Comparator|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk (TINE SA) as active placebo.
9990083|NCT01439841|No Intervention|Control|No intervention
9990084|NCT01439893|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
9990085|NCT01439893|Placebo Comparator|Placebo|Excipient placebo in addition to basic therapy of chronic heart failure
9990086|NCT01439906||Adult degenerative scoliosis|Patients aged 40-75 years affected by lumbar or thoraco-lumbar degenerative kyphoscoliosis presenting chronic low back pain from six months at least and/or neurological deficits who underwent a surgical correction of the deformity
9990087|NCT01439932|Experimental|ankle mobilization for pain release|"stretching exercise for the plantar fascia and triceps surae muscles three times a day throughout the study period.~During each visit the exercise performance will be checked by the therapist. In addition, participants from both groups will get ultra sound therapy in frequency of 1 MHz, power of 1.5 watts per centimeter-squared, pulses of 50% for 5 minutes.~The study group will receive the same treatment and a number of manual techniques that include antero-posterior (AP) mobilization for talocrural joint in two variations (weight baring and non-weight baring) to improve the range of dorsi flexion, subtalar joint mobilization to improve range of eversion and mid-tarsal mobilization to improve pronation / supination of the forefoot. Each technique will be carried out for 1 to 1.5 minutes for a total of 5 minutes of manual treatment.~All patients will receive information and guidance to practice at home."
9990088|NCT01439958|Experimental|L-CsA|Twice daily inhalation of L-CsA
9990089|NCT01439984|Experimental|PED-1|PED-1 (Clomipramine 15 mg)
9990090|NCT01439984|Placebo Comparator|placebo|
9990091|NCT01439997|Experimental|Desmopressin Melt Therapy in Nocturnal Polyuria Patients|
9990092|NCT01440010||IORT with 50 kV x-rays, 20 Gy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
9997405|NCT01508624|Experimental|DVD|Participants will watch a DVD during their procedure and will listen to the accompanying audio through head phones
9997406|NCT01508637|Experimental|Diesel Exhaust + Terazosin|
9997407|NCT01508637|Experimental|Diesel Exhaust + placebo|
9885840|NCT00535275|Active Comparator|B|Docetaxel monotherapy
9885841|NCT00535314|Experimental|RTA 402 Dose1|Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
9885842|NCT00535314|Experimental|RTA 402 Dose2|Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
9885843|NCT00535379|Experimental|1|
9885844|NCT00535418|Experimental|Letrozole|
9931493|NCT00938873||Mindfulness Based Cognitive Therapy|The present study will use participants who have experienced more than three episodes of depression as judged by South London and Maudsley NHS Trust. No restrictions are placed in terms of participants' use of antidepressant medication. Participants will be 18 to 65 years old and would have participated in an MBCT course run by South London and Maudsley NHS Trust.
9931494|NCT00938925|Experimental|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
9931495|NCT00938925|Experimental|nail lacqer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
9931496|NCT00938938|Experimental|Press guide plus press release|Participants in the intervention group will receive a press guide (a one-page summary of study findings written by the investigators) in addition to the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
9931497|NCT00938938|No Intervention|Press release only|Participants in the control group will receive the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
9931498|NCT00938951|Experimental|Systane® Ultra|Systane® Ultra
9931499|NCT00938977|Active Comparator|CPAP|Response to treatment before/after treatment in patients with OSAS and SOH
9931500|NCT00938977|Active Comparator|Bilevel support ventilation|Before and after effect of Bilevel support ventilation in patients with SOH without OSA
9931501|NCT00938990|Active Comparator|Midazolam|
9931502|NCT00938990|Experimental|Etomidate|
9931503|NCT00939016|Active Comparator|High SD/ Low DR|This group contains females that exhibit characteristics of high social desirability and low dietary restraint.
9931504|NCT00939016|Active Comparator|High SD/ High Dr|This group contains females that exhibit characteristics of high social desirability and high dietary restraint.
9931505|NCT00939016|Active Comparator|Low SD/ High DR|This group contains females that exhibit characteristics of low social desirability and high dietary restraint.
9931506|NCT00939016|Active Comparator|Low SD/ Low DR|This group contains females that exhibit characteristics of low social desirability and low dietary restraint.
9931507|NCT00939042|Active Comparator|1|PCI plus BNNC Therapy after acute myocardial infarction
9931508|NCT00939042|Active Comparator|2|Percutaneous Coronary Intervention after acute myocardial infarction
9931509|NCT00939068|Experimental|Telbivudine|Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
9931510|NCT00939068|Other|Control|The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
9931511|NCT00939081|Active Comparator|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
9931512|NCT00939081|Experimental|Adaptive recommendation|The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
9931513|NCT00939133|Active Comparator|Tretinoin microsphere 0.04% gel|
9931514|NCT00939133|Placebo Comparator|Vehicle gel|
9931515|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
9885845|NCT00535431|Experimental|A|AER 001
9885846|NCT00535431|Placebo Comparator|P|sterile saline
9885847|NCT00535444|Active Comparator|Control|assisted appointment with physician
9997408|NCT01508637|Sham Comparator|Filtered Air + terazosin|
9885848|NCT00535457|Experimental|1|"Children will watch tricks (magic) before anesthesia induction"
9885849|NCT00535470|Experimental|1|Open label 0.04% Mechlorethamine gel
9885850|NCT00535522|Experimental|TAK-285|
9885851|NCT00535561|Active Comparator|1|Oral iron treatment only- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
9885852|NCT00535561|Active Comparator|2|Oral iron plus levothyroxine treatment- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
9885853|NCT00535574|Placebo Comparator|Bexarotene (Targretin LGD1069)|
9885854|NCT00535574|Active Comparator|placebo|
9885855|NCT00535665|Experimental|1: 10 ug, 14 days|
9885856|NCT00535665|Experimental|2: 5 ug, 28 days|
9885857|NCT00535665|Experimental|3: 10 ug, 28 days|
9885858|NCT00535665|Experimental|4: 15 ug, 28days|
9885859|NCT00535691|Active Comparator|1|Tacrolimus ointment 0.03% once daily, placebo once daily
9885860|NCT00535691|Active Comparator|2|Tacrolimus ointment 0.03% twice daily
9885861|NCT00535704|Experimental|1|The Strong AFrican American FAmilies-Teen program is a five part educational program has been designed to help teens and their parents create successful futures and avoid the risky behaviors that sometimes keep teens from reaching their goals.
9885862|NCT00535704|Other|2|The FUEL program is a family-based adaptation of a curriculum designed to assist teens to develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress.
9885863|NCT00535756|Experimental|1|
9885864|NCT00535756|Placebo Comparator|2|
9885865|NCT00535795|Active Comparator|1|Conventional Radiation Therapy (XRT), one fraction per day, from Sunday to Thursday every week.
9885866|NCT00535795|Experimental|2|Conventional Plus accelerated boost Radiation Therapy (XRT), from Sunday to Thursday every week.
9885867|NCT00535808|Experimental|1|Administration of nitroprusside
9885868|NCT00535808|Experimental|2|Administration of nitroglycerine
9885869|NCT00535808|Experimental|3|Administration of sevoflurane
9885870|NCT00535860|Experimental|50 mcg|ViaDerm transdermal delivery
9885871|NCT00535860|Experimental|80 mcg|Add Via-Derm transdermal delivery
9885872|NCT00535860|Active Comparator|20 mcg|Subcutaneous injection
9885873|NCT00535886|Active Comparator|Elaidic Acid|
9885874|NCT00535886|Experimental|Vaccenic Acid|
9885875|NCT00535886|Placebo Comparator|Oleic Acid|
9885876|NCT00535912|No Intervention|A|¨Chemotherapy by 12 courses of CHOP
9885877|NCT00535912|Active Comparator|B|¨Chemotherapy by 3 courses of CHOP, intensification and autograft
9885878|NCT00535951|Experimental|LBH589|
9885879|NCT00535964||1|Psychologically healthy adolescents, evenly divided across the various stages of smoking uptake
9885880|NCT00535977|Experimental|1|Dietary intervention of ITC-enriched broccoli
9885881|NCT00535977|Experimental|2|Dietary intervention of frozen peas
9885882|NCT00536003|Experimental|1|
9885883|NCT00536003|Placebo Comparator|2|
9885884|NCT00536029||A|Subject with pigmented skin lesion suspect for malignant melanoma
9885885|NCT00536042|Experimental|minocycline|addition of minocycline to standard asthma care as add-on therapy: 150 mg bid to 250 mg bid for up to one year
9885886|NCT00536068|Experimental|1, 2, 3, 4|"acetylsalicylic acid 100 mg/po,acetaminophen 3x1g/po~acetylsalicylic acid 100 mg/po,diclofenac 3x50mg/po~acetylsalicylic acid 100 mg/po,naproxen 3x250mg/po~acetylsalicylic acid 100 mg/po,placebo 3x1/po"
9885887|NCT00536081|Active Comparator|A|Pegfilgrastim during all 6 cycles of chemotherapy
9885888|NCT00536081|Experimental|B|Pegfilgrastim during the first two cycles of chemotherapy
9885889|NCT00536094|Experimental|1|Participants will receive cognitive behavioral therapy for anxiety that includes exposure
9885890|NCT00536094|Active Comparator|2|Participants will receive treatment as usual as delivered by school-based clinicians
9885891|NCT00536133|Experimental|Zinc group|children with recurrent acute lower respiratory infections receiving zinc supplementation
9990093|NCT01440023|Experimental|CBIT + Response Inhibition Training|CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
9990094|NCT01440023|Placebo Comparator|Experimental: CBIT + Placebo Computer Training|In this condition, participants receive the same package of CBIT treatment, which consists of awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). Additionally, the standard CBIT treatment is combined with computer-based placebo cognitive training that is irrelevant to the target cognitive ability (i.e., response inhibition). During the first 4 weeks of the CBIT treatment, participants will receive 8 sessions of placebo cognitive training.
9990095|NCT01440036||Carotid endarterectomy|Patients that have the common indication for the treatment of carotid artery stenosis by surgery - CEA (carotid endarterectomy), symptomatic and asymptomatic patients.
9990096|NCT01440062|Experimental|Verum (high dose)|verum arm receiving high dose Vitamin D oil
9990097|NCT01440062|Experimental|Verum (low dose)|low dose arm receiving neutral oil and low dose of Vitamin D
9990098|NCT01440075|Other|Patients KD|Adults with a history of KD disease in childhood
9990099|NCT01440075|Other|Case Control|Control group, healthy volunteers matched for age and sex with the KD group
9990100|NCT01440088|Experimental|TH-302 in Combination with Doxorubicin|
9990101|NCT01440088|Active Comparator|Doxorubicin|
9990102|NCT01440114|Active Comparator|fentanyl group|First arm: intervention group. Patient in this group received fentanyl 1 mcg/kg (concentration 10mcg/ml) intravenous route 15 minutes before the end of surgery.
9990103|NCT01440114|Placebo Comparator|controlled group|patient in this group received NSS 0.1 ml/kg 15 minutes before the end of surgery
9990104|NCT01440127|Experimental|Metformin|Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
9990105|NCT01440127|No Intervention|Observation|No metformin will be given prior to the scheduled surgery or biopsy.
9990106|NCT01440140|Experimental|Closed loop (algorithm)|
9990107|NCT01440140|Placebo Comparator|Open loop|
9990108|NCT01440153|Experimental|Active Intervention|
9990109|NCT01440153|Active Comparator|passive intervention|
9990110|NCT01440166|Experimental|Cohort 1 / Dose level 1|Single dose orally: CAT-1004 Dose level 1 or placebo
9990111|NCT01440166|Experimental|Cohort 2 / Dose level 2|Single dose orally: CAT-1004 Dose level 2 or placebo
9990112|NCT01440166|Experimental|Cohort 3 /Dose level 3|Single dose orally: CAT-1004 Dose level 3 or placebo
9990113|NCT01440166|Experimental|Cohort 4/ Dose level 4|Single dose orally: CAT-1004 Dose level 4 or placebo
9990114|NCT01440166|Experimental|Cohort 5/ Dose level 5|Single dose orally: CAT-1004 Dose level 5 or placebo
9990115|NCT01440166|Experimental|Cohort 2/ Dose level 2 ( FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo
9990116|NCT01440166|Experimental|Cohort 3/ Dose level 3 (FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo
9990117|NCT01440166|Experimental|Cohort 6 / Dose level 6 (FE)|Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.
9990118|NCT01440166|Experimental|Cohort 7 / Dose level 7 (FE)|Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.
9990119|NCT01440179|Experimental|SAR3419|Administered for one to two induction cycles, followed by maintenance cycles up to 6 cycles.
9990120|NCT01440192|Experimental|Cohort A: 1 Unit PDA001 (cenplacel-L)|
9990121|NCT01440192|Experimental|Cohort B: 1 Unit PDA001 (cenplacel-L)|1 unit PDA001(cenplacel-L)
9990122|NCT01440205|Experimental|Easy list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly easy, and thus most participants will answer yes to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how healthy their habits are, it will seem natural to them to engage in yet another healthy habit and receive a flu shot."
9990123|NCT01440205|Experimental|Challenging list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly difficult, and thus most participants will answer no to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how unhealthy their habits are, it will seem wise to engage in one healthy habit that is easy (to make up for other bad behaviors) and receive a flu shot."
9990124|NCT01440205|Experimental|Control|A control condition with no list of healthy behaviors.
9990125|NCT01440218||Patients with idiopathic diseases|Study population is limited to individuals with a rare severe illness, and/or their family members.
9990126|NCT01440231|Placebo Comparator|Arm 1|
9990127|NCT01440231|Experimental|Arm 2|
9990128|NCT01440231|Experimental|Arm 3|
9990129|NCT01440231|Experimental|Arm 4|
9990130|NCT01440231|Experimental|Arm 5|
9990131|NCT01440257|Placebo Comparator|Placebo (Group A)|
9990132|NCT01440257|Experimental|Active study medication (Group B)|CCX140-B
9990133|NCT01440270|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitux-based chemotherapy before surgery: Erbitux, Docetaxel, Cisplatin.
9990134|NCT01440309|Experimental|allogenic mesenchymal stem cells (MSCs)|Patients who have primary biliary cirrhosis.
9990135|NCT01440309|Active Comparator|ursodeoxycholic acid (UDCA)|Patients who have primary biliary cirrhosis.
9990136|NCT01440348|Experimental|Achilles allograft|
9990137|NCT01440361|Experimental|Belimumab|Reconstituted solution for intravenous infusion
9990138|NCT01440361|Placebo Comparator|Normal saline|Solution for intravenous infusion
9990139|NCT01440400|No Intervention|Conventional spinal anesthesia|
9990140|NCT01440400|Experimental|Ultrasound guided spinal anesthesia|
9990141|NCT01440426|Active Comparator|Autologous connective tissue graft|Soft tissue harvested from patient palate
9990142|NCT01440426|Experimental|Collagen Matrix Construct|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland
9990143|NCT01440439|Active Comparator|Insulin detemir|Metabolism during and after submaximal exercise during treatment with insulin detemir
9990144|NCT01440439|Active Comparator|Insulin glargine|Metabolism during and after submaximal exercise during treatment with insulin glargine
9990145|NCT01440478|Experimental|LY2140023 + ammonium chloride|1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
9990146|NCT01440478|Experimental|LY2140023 + sodium bicarbonate|4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
9990147|NCT01440478|Experimental|LY2140023|A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
9990148|NCT01440491|Other|physiotherapy orientated|"G1 patients were orientated by the physiotherapist during the performance of physiotherapy exercises, using the booklet~G2 received the booklet to self perform the physiotherapy exercises"
9990149|NCT01440530|Experimental|Educational Intervention|
9990150|NCT01440530|Active Comparator|Control Group (usual care)|
9990151|NCT01440582|Experimental|Panobinostat + Bortezomib + Lenalidomide + Dexamethasone|"Induction Starting Doses: Lenalidomide 25 mg orally daily on days 1-14; Bortezomib 1.3 mg/m^2 intravenous (IV) daily on days 1, 4, 8 and 11; Dexamethasone 20 mg orally daily on days 1, 2, 4, 5, 8, 9, 11, 12 and Panobinostat orally 10 mg on days 1, 3, 5, 8, 10 and 12. Induction therapy consists of 21 day cycle in Part A and 28 day cycle in Part B.~Symptom Questionnaire completed on day 1 of each cycle."
9990152|NCT01440608|Experimental|Zinc therapy|High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
9990153|NCT01440608|Experimental|Albendazole|Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
9990154|NCT01440608|Placebo Comparator|Placebo|Placebo will be given for 14 days
9990155|NCT01440621|Active Comparator|Arm M|Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.
9990156|NCT01440621|Placebo Comparator|Arm P|Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.
9990157|NCT01440660||Leaking Phenotype|Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.
9990158|NCT01440660||Ischemic Phenotype|Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate >= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.
9990159|NCT01440673|Active Comparator|aprepitant 125mg|NK1 receptor antagonist
9990160|NCT01440673|Active Comparator|Aprepitant 80 mg|
9990161|NCT01440686|Experimental|HL-032 30mg|A single dose 30mg administered orally
9990162|NCT01440686|Experimental|HL-032 60mg|A single dose 60mg administered orally
9990163|NCT01440686|Experimental|HL-032 120mg|A single dose 120mg administered orally
9990164|NCT01440699|Experimental|Treatment|For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
9990165|NCT01440712|Experimental|Gastrografin|Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
9990166|NCT01440712|Placebo Comparator|physiological serum|Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
9990167|NCT01440725|Experimental|PRP|Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
9990168|NCT01440725|Active Comparator|Evacuation of haematoma|Evacuation of the hematoma, and simulation of the administration of PRP
9990169|NCT01440738|Experimental|health workshops|Health promotion group intervention
9990170|NCT01440738|No Intervention|comparison group|usual care
9990171|NCT01440751|Experimental|ologen Collagen Matrix|When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva
9990172|NCT01440751|Active Comparator|Mitomycin-C (MMC)|When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva
9990173|NCT01440777|Active Comparator|Go! to Sleep|Participants access and utilize the 6-week online program that provides a set of various psycho-educational materials and behavioral techniques to treat insomnia.
9990174|NCT01440777|No Intervention|Control Group|No intervention provided. These participants will receive the Go! to Sleep program after the research trial has been completed (10 weeks after registration).
9990175|NCT01440790|Placebo Comparator|Glucose bolus alone|50g glucose dissolved in water and consumed within 5 minutes.
9990176|NCT01440790|Experimental|Glucose sipping alone|50g glucose dissolved in water and consumed gradually over 3 hours.
9990177|NCT01440790|Active Comparator|Glucose bolus plus 1g vitamin C|50g glucose dissolved in water and consumed in 5 minutes with 1g vitamin C
9990178|NCT01440790|Experimental|Glucose sipping plus 1g vitamin C|50g glucose dissolved in water and consumed gradually of 3 hours. In addition 1g vitamin C will be taken with the first mouthful of glucose solution.
9990179|NCT01440829|Experimental|LOLA group|Intervention: LOLA (30g per day) for a week.
9990180|NCT01440829|No Intervention|Control group|Patients will not be treated with LOLA.
9990181|NCT01440842|Experimental|Closed-loop (Model Predictive Control Algorithm)|
9990182|NCT01440842|Active Comparator|Open loop (Standard treatment)|
9990183|NCT01440855|Active Comparator|CIS Fact Sheet (CIS: Cancer Information Service)|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
9990184|NCT01440855|Experimental|Facing Forward booklet|NCI's Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
9990185|NCT01440868|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room
9990186|NCT01440868|No Intervention|Control|Preterm infants will be assisted in the delivery room without sustained lung inflation.
9990187|NCT01440894||Body Analysis|
9990188|NCT01440907|Experimental|Intervention Group|Those age 65 or older who are discharged from Maimonides Medical Center to home during the study period and enrolled in the Care Coordination Program
9990189|NCT01440907|No Intervention|Control Group|Those age 65 or older who are discharged from Maimonides Medical Center to home
9990190|NCT01440933|Active Comparator|Magnesiumsulphate|
9990191|NCT01440933|Placebo Comparator|Physiologic saline|
9997409|NCT01508637|Sham Comparator|Filtered air + placebo|
9885892|NCT00536133|Placebo Comparator|Placebo group|children with recurrent acute lower respiratory infections receiving placebo syrup
9885893|NCT00536159|Active Comparator|Community Care|Medicaid eligible/insured pregnant women and their infants are eligible for risk assessment and up to 18 home visits (9/pregnancy and 9/infancy) from community professional providers as part of a state-sponsored enhanced prenatal and postnatal Medicaid program.
9885894|NCT00536159|Experimental|Nurse-CHW Team|Nurse-CHW team provided both nursing care, with additional focus on mental health and stress, and intensive relationship-based support from a CHW similar in characteristics to women served in the context of state-sponsored Medicaid program.
9885895|NCT00536185|Experimental|1|
9885896|NCT00536185|Placebo Comparator|2|
9885897|NCT00536211|Experimental|1|Exercise
9885898|NCT00536211|Active Comparator|2|Metformin
9885899|NCT00536224|Active Comparator|2|Minimal counseling
9885900|NCT00536224|Experimental|1|Full counseling
9885901|NCT00536289|Active Comparator|1|Sharp needles
9885902|NCT00536289|Experimental|2|Blunt tipped needles
9885903|NCT00536302|Experimental|1|Collagen Hydrolysate
9885904|NCT00536302|Placebo Comparator|2|
9885905|NCT00536315||COPD|Patients with cough and/or shortness of breath who may have windpipe collapse.
9885906|NCT00536315||Healthy adults|Subjects without symptoms for comparison.
9885907|NCT00536315||Tracheomalacia|Patients with cough and/or shortness of breath who may have windpipe collapse.
9885908|NCT00536367||Patients seen for ADHF at OSUMC|
9885909|NCT00536393|Active Comparator|Doxorubicine|CHOP 8 courses every 21 days
9885910|NCT00536393|Experimental|Doxorubicine pegylated|CLOP 8 courses every 21 days
9885911|NCT00536406|Experimental|A|Participants will receive the BE-ACTIV treatment
9885912|NCT00536406|Active Comparator|B|Participants will receive treatment as usual
9885913|NCT00536419|Placebo Comparator|2|4 days of placebo
9885914|NCT00536419|Experimental|1|MPH-SODAS at day 1 (0.3/mg/kg/day); day 2 (0.7/mg/kg/day);days 3 and 4 (1.0 mg/kg/day)
9885915|NCT00536458|Experimental|radiotherapy|minichep + radiotherapy
9885916|NCT00536458|Active Comparator|B|MINI CHEP
9885917|NCT00536523||Patients Receiving Chemotherapy|Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned
9885918|NCT00536536|Active Comparator|Hospital|Care of Childhood Obesity Clinic (COCO)
9885919|NCT00536536|Active Comparator|Primary Care|Primary care clinics (x2)
9885920|NCT00536549|Experimental|A|Guardina RT monitoring
9885921|NCT00536549|Active Comparator|B|
9885922|NCT00536562|No Intervention|Usual Care|Usual Care as provided through the Stroke Prevention Clinic
9885923|NCT00536562|Active Comparator|Cardiac Rehabilitation|Usual Care plus Comprehensive Cardiac Rehabilitation Program
9885924|NCT00536588|Experimental|SCH 721015 with SCH 209702|
9885925|NCT00536614|No Intervention|A|arm A) gemcitabine/cisplatin in combination with Cetuximab arm B) gemcitabine/cisplatin alone
9885926|NCT00536627|Experimental|1|Patients will receive 5 injections of DNA vaccine at weeks 0, 8, 16, 40, 44.
9885927|NCT00536627|No Intervention|2|
9885928|NCT00536640|Experimental|Arm A (Erlotinib, Bevacizumab)|
9885929|NCT00536640|Active Comparator|Arm B (Gemcitabine, Cisplatin, Bevacizumab)|
9885930|NCT00536653|Active Comparator|Osteporosis Group|Patients with a presenting T score < -2.5 (osteoporosis), treated with bicalutamide and Ca/VitD
9885931|NCT00536653|Active Comparator|Osteopenia Group|Patients with a presenting T score between -1.0 and -2,4 (osteopenia), treated with LHRH agonists and Ca/VitD
9885932|NCT00536653|Active Comparator|Normal Group|Patients with a presenting T score > -1.0(normal BMD), treated with LHRH agonists
9885933|NCT00536666|Other|1|Iron oligosaccharide
9885934|NCT00536679|Experimental|Sequence ABC|Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
9990192|NCT01440985|Experimental|Nicotine Gum|After being randomized to the gum or tablet, dosage will be based on baseline level of nicotine dependence. Highly dependent smokers will receive nicotine 4 mg gum, while low nicotine-dependent smokers will receive nicotine 2 mg gum to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
9990193|NCT01440985|Active Comparator|Nicotine Microtab|After being randomized to the gum or tablet, subjects will receive instructions according to their baseline level of nicotine dependence. Highly dependent smokers will be instructed to use a 4 mg dosage of the Microtab (2 x 2 mg tablets), while low nicotine-dependent smokers will be instructed to use a 2 mg dosage of the Microtab to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
9990194|NCT01440998|Experimental|Treatment (dasatinib, paclitaxel, carboplatin)|Patients receive induction therapy comprising dasatinib PO QD for 14 days. *Beginning 7 days later, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1, and dasatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9990195|NCT01441011|Experimental|Group (GRP) phone counseling|The group phone counseling includes 26 bi-weekly phone sessions from 6 to 18 months and focuses on group problem-solving. Women continue in the same group as in weight loss intervention phase.
9990196|NCT01441011|Active Comparator|Mail-based Comparison Condition|Participants in this group will receive a newsletter by mail every other week for 12 months starting after the initial 6 month weight loss period. The newsletters will provide problem-solving tips and will review nutrition and physical activity information.
9990197|NCT01441024|Experimental|1|DAS181
9990198|NCT01441024|Placebo Comparator|2|Placebo
9990199|NCT01441128|Experimental|Arm 1|The starting doses will be 200 mg by mouth, twice a day of PF 02341066 in tablet form and 30 mg by mouth once a day of PF 0029804 in tablet form. Thedose of each drug in the combination will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
9990200|NCT01441128|Experimental|Arm 2|45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
9990201|NCT01441141||Arm 1|Subjects with SCD
9990202|NCT01441141||Arm 2|Subjects without SCD
9990203|NCT01441154||Group 1|Adults with clinical indication for withdrawal from thyroid hormone replacement therapy in preparation for nuclear medicine imaging or therapeutic procedures with radioactive iodine
9990204|NCT01441193|Experimental|HIV-1 Tat/delta-V2 Env combined vaccine|Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36
9990205|NCT01441193|Active Comparator|HIV-1 delta-V2 Env vaccine|delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
9990206|NCT01441193|Active Comparator|HIV-1 Tat vaccine 7.5 microg|Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
9990207|NCT01441193|Active Comparator|HIV-1 Tat vaccine 30 microg|Tat 30 microg administered i.d. at week 0, 4 and 8
9990208|NCT01441206|Other|rifampin|Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.
9990209|NCT01441206|No Intervention|rifampin per standard of care|Cohort 2: Receiving rifampin per standard of care
9990210|NCT01441219|Experimental|Colon 2|using Colon 2 capsule in detecting bleeding events in small bowel
9990211|NCT01441232|Experimental|Treatment A|
9990212|NCT01441232|Experimental|Treatment C|
9990213|NCT01441232|Active Comparator|Treatment B|
9990214|NCT01441258|Experimental|Dialectical Behavior Therapy Skills (DBT-S) Groups|Patients in the Dialectical Behavior Therapy Skills (DBT-S) group will receive the newly adapted 18-week group-skills training protocol, one-and-a-half hours in length, with weekly homework assignments to facilitate skill generalization.
9990215|NCT01441258|Placebo Comparator|Wait List-Treatment as Usual|Participants assigned to the wait-list condition will be given the opportunity to participate in a DBT skills group after their 18-week wait period has ended.
10211790|NCT04006457|Experimental|Treatment sequence 2|"Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 given QD for 36 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 32 visit of the main B7981032 study."
10211791|NCT04002102|Experimental|OLP treatment|Participants randomized to the treatment group will receive: 1) educational materials; 2) positive expectancy; 3) 2 placebo pills twice a day for 21 days.
9990216|NCT01441271|Active Comparator|total abdominal colectomy|the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
10211792|NCT04002102|Other|Usual care|Participants randomized to the no treatment group will remain in standard care alone for 21 days and receive educational materials.
10211793|NCT04002102|Active Comparator|Expectancy Group|Participants receive educational materials and positive expectancy orientation via Zoom or telephone
9990217|NCT01441271|Experimental|Ileal diversion and lavage|The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
9990218|NCT01441284|Active Comparator|Process 1|10 weeks of pramipexole treatment 2 weeks wash-out period (cross-over) 10 weeks placebo treatment
9990219|NCT01441284|Placebo Comparator|Process 2|10 weeks of placebo treatment 2 weeks wash-out period (cross-over) 10 weeks pramipexole treatment
9990220|NCT01441297|Experimental|study arm|BIBF 1120 study arm
9990221|NCT01441310|Experimental|Laparoscopic sentinel node navigation surgery|Laparoscopic sentinel node navigation surgery
9990222|NCT01441323|No Intervention|Control (C)|
9990223|NCT01441323|Experimental|Nutrition (N)|
10211794|NCT03972813|Experimental|cervical cancer - sexually transmitted (STD) - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
10211795|NCT03972813|Experimental|cervical cancer - STD - 12 years old (y.o.)|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
10211796|NCT03972813|Experimental|cervical cancer - STD - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
10211797|NCT03972813|Experimental|cervical cancer - infectious - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
10211798|NCT03972813|Experimental|cervical cancer - infectious - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
10211799|NCT03972813|Experimental|cervical cancer - infectious - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
10211800|NCT03972813|Experimental|cervical cancer - blank - standard|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
9990224|NCT01441323|Experimental|Strength Training & Nutrition (ST)|
9990225|NCT01441336|Experimental|Laparoscopic gastrectomy|"Laparoscopic gastrectomy procedure:~D2 lymphadenectomy & total omentectomy in case of tumor with serosa exposure under laparoscopic exploration"
9990226|NCT01441362|Active Comparator|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
9990227|NCT01441362|Experimental|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
9990228|NCT01441375||Sickle cell patients non-transfused|
10211801|NCT03972813|Experimental|cervical cancer - blank - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
10211802|NCT03972813|Experimental|cervical cancer - blank - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
10211803|NCT03972813|Experimental|many cancers - STD - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
9885935|NCT00536679|Experimental|Sequence ACB|Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
9885936|NCT00536679|Experimental|Sequence BAC|Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
9885937|NCT00536679|Experimental|Sequence BCA|Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
9885938|NCT00536679|Experimental|Sequence CAB|Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
9885939|NCT00536679|Experimental|Sequence CBA|Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
9885940|NCT00536770|Placebo Comparator|A|Placebo + gemcitabine
9885941|NCT00536770|Placebo Comparator|B|Placebo + gemcitabine + erlotinib
9885942|NCT00536770|Active Comparator|C|DN-101 + gemcitabine
9885943|NCT00536770|Active Comparator|D|DN-101 + gemcitabine + erlotinib
9885944|NCT00536796||Patients at very high risk|
9885945|NCT00536796||Patients at high risk|
9885946|NCT00536796||Patients at medium risk|
9885947|NCT00536796||Patients at low risk|
9885948|NCT00536835|Experimental|Stage A|Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.
9885949|NCT00536835|Experimental|Stage B|Evaluate safety, PK, pharmacodynamic (PD) & tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.
9885950|NCT00536848|Experimental|A|Metronidazole for 10 days, probiotics for 6 months
9885951|NCT00536848|Placebo Comparator|B|Metronidazole for 10 days, placebo for 6 months
9885952|NCT00536861|Experimental|1|
9885953|NCT00536900|Experimental|1|Advisor-Teller Money Manager
9885954|NCT00536900|Active Comparator|2|FIT (finance instruction therapy)
9990229|NCT01441375||Sickle cell patients transfused with no ICT|
9885955|NCT00536926|Active Comparator|A|home spirometry alone
9885956|NCT00536926|Experimental|B|Home spirometry with data transfer via cellphone to clinical database
9885957|NCT00536952|Experimental|Arm 1|Pulmozyme
9885958|NCT00536952|Placebo Comparator|Arm 2|Placebo
9885959|NCT00537108|Experimental|HV|Intervention arm.
9885960|NCT00537108|No Intervention|Cntr|Usual care control
9885961|NCT00537134|No Intervention|1|Conservative management (watchful observation)
9885962|NCT00537134|Active Comparator|2|Endovascular treatment
9885963|NCT00537147|Experimental|1|1 vaccination of a 10^4 plaque-forming units (PFU) dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
9885964|NCT00537147|Experimental|2|1 vaccination of a 10^5 PFU dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
9885965|NCT00537147|Placebo Comparator|3|1 vaccination of a placebo administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
9885966|NCT00537173||Arm 1|Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15
9885967|NCT00537186|Other|1|Iron oligosaccharide
9885968|NCT00537212|Active Comparator|1|"Subjects will receive phototherapy and dietary counselling consistent with The South Beach diet."
9885969|NCT00537212|Active Comparator|2|"Subjects will receive phototherapy and dietary counselling consistent with The Ornish Diet."
9885970|NCT00537212|Sham Comparator|3|Subjects will receive phototherapy alone, without dietary counselling.
9885971|NCT00537225|Experimental|A-Exercise group|Home based exercise
9885972|NCT00537225|No Intervention|B- Usual Care|Exercise as usually prescribed by provider
9885973|NCT00537264|Experimental|Computer|Health-related quality of life questionnaires will be administered using a computerised multimedia touchscreen system.
9885974|NCT00537264|Experimental|Interviewer|Health-related quality of life questionnaire will be administered via face-to-face interviews.
9885975|NCT00537342|Experimental|A|Biological Vaccine
9885976|NCT00537342|Placebo Comparator|B|
9885977|NCT00537355|Active Comparator|TOLAMBA™|
9885978|NCT00537355|Sham Comparator|Histamine|Histamine simulates mild redness/swelling effect seen with active comparator, TOLAMBA™. Prevents study staff from easily identifying subjects who received active comparator.
9885979|NCT00537420|Placebo Comparator|1|Nasal Placebo
9885980|NCT00537420|Placebo Comparator|2|Capsule Placebo
9885981|NCT00537420|Experimental|3|Nasal PYY3-36 200 ug
9885982|NCT00537420|Experimental|4|Nasal PYY3-36 400 ug
9885983|NCT00537420|Experimental|5|Nasal PYY3-36 600 ug
9885984|NCT00537420|Active Comparator|6|Sibutramine 10 mg
9931516|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
9931517|NCT00939172|Experimental|TTP607|
9931518|NCT00939224||Cohort Phase 1|Cardiac Catheterization
9931519|NCT00939250|Experimental|Diabetes and depression intervention|Measurement based care for diabetes and depression, disease self management for diabetes and depression
9931520|NCT00939250|Active Comparator|Diabetes intervention|Measurement based care for diabetes, disease self management for diabetes
9931521|NCT00939263||1|cohorts 1 (item weighting phase): 100 children with Eosinophilic Esophagitis, 150 adults with Eosinophilic Esophagitis
9931522|NCT00939263||2|cohorts 2 (evaluation phase): 200 children with Eosinophilic Esophagitis, 200 adults with Eosinophilic Esophagitis
9931523|NCT00939289||Adults with T1DM|Adults (18+ years-old) diagnosed with type 1 diabetes mellitus; treated with multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy
9931524|NCT00939380|Experimental|P-SCIP|Arm I (Parent Social-Cognitive Intervention Program [P-SCIP]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
9931525|NCT00939380|Experimental|BPC|"Arm II (Best-recommended Psychosocial Care [BPC]): Participants undergo usual care and receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks."
9931526|NCT00939406|No Intervention|Control|Control group consists of subjects randomized to the control arm who will receive lumbar decompression surgery (laminotomy or laminectomy) alone
9931527|NCT00939406|Experimental|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
9931528|NCT00939419|Other|Health worker TB care group|
9931529|NCT00939419|Other|Community health worker TB care group|
9931530|NCT00939419|Other|Self-administered treatment group|
9931531|NCT00939432||Gender|male/female
9931532|NCT00939432||Age|18-100 years
9931533|NCT00939432||Educational level|primary school, secondary school, university
9931534|NCT00939445|Active Comparator|Online HDF|Online HDF
9931535|NCT00939445|Active Comparator|Short Daily Hemodialysis|Short Daily Hemodialysis
9931536|NCT00939549|Experimental|High-dose cyclohosphamide|
9935510|NCT03594487|Active Comparator|Observational Control Arm|"Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.~After providing written informed consent, subjects will undergo screening and baseline assessments, including collection of blood and stool samples, demographic data collection, concomitant medication review, and an MS Relapse assessment. At week 2, subjects will mail in stool samples with a prepaid air bill and packaging. Weeks 4, 8, and 12 assessments will include concomitant medication review, relapse assessment, and blood and stool collection.~The duration of the study for the observational control arm will last for 12 weeks. All study procedures will be performed at the University of California, San Francisco."
9935511|NCT03591510|Experimental|Chemotherapy followed by Midostaurin|"In Part 1, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing fludarabine, cytarabine, daunorubicin/idarubicin) and consolidation (Block 3: cytarabine + mitoxantrone, Block 4: cytarabine + etoposide, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy.~In Part 2, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing cytarabine + mitoxantrone) and consolidation (Block 3: cytarabine + etoposide, Block 4: cytarabine + mitoxantrone, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy."
10211804|NCT03972813|Experimental|many cancers - STD - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
10211805|NCT03972813|Experimental|many cancers - STD - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
9990230|NCT01441375||Sickle cell patients transfused with ICT|
10211806|NCT03972813|Experimental|many cancers - infectious - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
10211807|NCT03972813|Experimental|many cancers - infectious - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
10211808|NCT03972813|Experimental|many cancers - infectious - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
9885985|NCT00537433|No Intervention|Standard counseling|Families in the control group receive standard care, including routine counseling regarding medications prescribed from their physician and post-visit counseling by the pediatric nursing staff. Dosing instruments are given at the discretion of the physician or nurse.
9885986|NCT00537433|Experimental|Pictogram|Parents randomized to the pictogram-based intervention group receive medication counseling utilizing the pictogram-based medication instruction sheets. These sheets help to facilitate medication counseling, including teaching about dosage and adherence.
9885987|NCT00537472|Experimental|I|
9885988|NCT00537472|Active Comparator|II|
9885989|NCT00537498|Experimental|1|Interventional group
9885990|NCT00537524|Experimental|Arm 1|0.5mL of H5N1 vaccine 7.5ug
9885991|NCT00537524|Active Comparator|Arm 2|0.25 or 0.5mL of H5N1 vaccine
9885992|NCT00537537|Active Comparator|1|Telbivudine
9885993|NCT00537537|Active Comparator|2|Telbivudine
9885994|NCT00537537|Active Comparator|3|Telbivudine
9885995|NCT00537602|Experimental|A|Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
9885996|NCT00537602|Placebo Comparator|B|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
9885997|NCT00537654|Experimental|Fasted state|Subjects will be required to fast overnight. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
9885998|NCT00537654|Experimental|Fed state|Subjects will be served high fat breakfast 30 minutes prior to dosing. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
9885999|NCT00537667|Active Comparator|A|anakinra
9886000|NCT00537667|Experimental|B|anakinra and PEGsTNF-R1
9886001|NCT00537693|Active Comparator|1|CRRT via Convection
9886002|NCT00537693|Active Comparator|2|CRRT via Diffusion
9886003|NCT00537719|Active Comparator|GSK716155|albiglutide subcutaneous injection
9886004|NCT00537719|Placebo Comparator|placebo|placebo injection
9886005|NCT00537732|Active Comparator|control group|3 tablets, only 20 mg omeprazole, genotype independent
9886006|NCT00537732|Active Comparator|intervention group|20 vs. 60 mg daily, genotype dependent
9886007|NCT00537758|Experimental|1|Cognitive Behavior Therapy
9886008|NCT00537758|Experimental|2|Behavioral Weight Loss Treatment
9886009|NCT00537758|Experimental|3|CBT + BWL
9886010|NCT00537784|Active Comparator|1|Injection of autologous platelet concentrate into repair site
9886011|NCT00537784|Placebo Comparator|2|No injection
9886012|NCT00537797|Experimental|Arm 1|"18-FDG-PET exam with SUV determination~Thyroid operation to remove nodule~Pathologic confirmation of nodule histology~Determine sensitivity and specificity of FDG-PET, correlative studies"
9886013|NCT00537836|Experimental|ZK 283197, 3 mg|Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks
9886014|NCT00537836|Placebo Comparator|Matching placebo|Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks
9886015|NCT00537836|Experimental|ZK 283197, 2 mg|Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks
9886016|NCT00537836|Active Comparator|17ß-estradiol|Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
9886017|NCT00537875|Active Comparator|1|
9886018|NCT00537875|Placebo Comparator|2|
9886019|NCT00537927|Active Comparator|0|fixation of mesh with a single crown of tacks and absorbable sutures
9886020|NCT00537927|Active Comparator|1|fixation of mesh with a double crown of tacks and no sutures
9886021|NCT00537927|Active Comparator|2|fixation of mesh with a single crown of tacks and non-absorbable sutures
9886022|NCT00537966|No Intervention|Control|Patients with primary HIV-1 infection who do not want to undergo early combination antiretroviral treatment
9886023|NCT00537966|Active Comparator|Intervention|In this arm patients with primary HIV-1 infection will receive early combination antiretroviral therapy with standard drugs approved by Swiss Medic.
9886024|NCT00538044|Experimental|1simvastatin group|before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
9886025|NCT00538044|No Intervention|2contral group|just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
9886026|NCT00538057|Experimental|arm 1|study drug
9886027|NCT00538070|Placebo Comparator|Placebo|You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
9886028|NCT00538070|Experimental|Sarcosine|You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
9886029|NCT00538083|Experimental|1, 2|acute phase, solid dark chocolate, placebo
9886030|NCT00538083|Experimental|3, 4, 5|acute phase, sugared cocoa, sugar-free cocoa, placebo
9886031|NCT00538083|Experimental|6, 7, 8|sustained phase, sugared cocoa, sugar-free cocoa, placebo
9886032|NCT00538096|Experimental|1|MEDI-538
9886033|NCT00538096|Experimental|2|MEDI-538
9886034|NCT00538096|Experimental|3|MEDI-538
9886035|NCT00538122||Thioridazine Group|Patients must have been treated with (Mellaril) thioridazine at least three months at time of enrollment.
9886036|NCT00538135|Experimental|1|"Cognitive Behaviour Therapy plus Treatment as Usual (CBT plus TAU) for borderline personality disorder.~CBT is a structured, time limited, psycho-social intervention developed to treat Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework. Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Thirty sessions of CBT over one year, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place"
9886037|NCT00538135|Active Comparator|2|"Treatment as Usual.~All participants received the standard treatment (TAU) they would have received if the trial had not been in place. Although standard treatment may vary across the three sites, and depend on the specific problems of the individual participant, it was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial."
9886038|NCT00538161|Experimental|Low tidal volume arm|
9886039|NCT00538161|Active Comparator|Conventional tidal volume arm|
9886040|NCT00538174|Experimental|Arm 1|2.5 mg
9886041|NCT00538174|Experimental|Arm 2|10 mg
9886042|NCT00538174|Experimental|Arm 3|20 mg
9886043|NCT00538174|Placebo Comparator|Arm 4|
9886044|NCT00538187|Experimental|Treatment (obatoclax mesylate, bortezomib)|Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
9886045|NCT00538200|Other|1|Dietary Advice
9886046|NCT00538200|Other|2|Supplements
9886047|NCT00538239|Experimental|Ridaforolimus|
9886048|NCT00538239|Placebo Comparator|Placebo|
9886049|NCT00538265|Active Comparator|A|tacrolimus + steroids
9886050|NCT00538265|Experimental|B|ATG+ tacrolimus without steroids in maintenance therapy
9886051|NCT00538265|Experimental|C|ATG+ Mycophenolate Mofetil + tacrolimus a reduced dosage without steroids in maintenance therapy
9886052|NCT00538317|Experimental|1|tirofiban bolus + perfusion started at the site of caring
9886053|NCT00538317|Active Comparator|2|tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)
9886054|NCT00538356|Experimental|Home Monitoring|ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events
9886055|NCT00538356|Active Comparator|Control|ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic
9886056|NCT00538369|Active Comparator|standard-of-care|The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
9886057|NCT00538369|Experimental|standard + BIS|Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.
9886058|NCT00538382|Experimental|Case|Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
9886059|NCT00538382|Active Comparator|Non-pregnant Control|Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
9886060|NCT00538382|Active Comparator|Internal Control|Internal controls are defined as the same women(cases)at three months postpartum.
9886061|NCT00538421|Active Comparator|1|
9886062|NCT00538421|Active Comparator|2|
9886063|NCT00538486|Experimental|Group T|Telmisartan
9886064|NCT00538486|Experimental|Group T+M|Telmisartan plus Metformin
9886065|NCT00538486|Experimental|Group C|Candesartan
9886066|NCT00538486|Experimental|Group C+M|Candesartan pus Metformin
9886067|NCT00538486|Active Comparator|Group A|Amlodipine
9886068|NCT00538486|Experimental|Group A+M|Amlodipine plus Metformin
9886069|NCT00538499|Other|Fentanyl citrate|
9886070|NCT00538499|Experimental|bupivcaine hydrochloride|
9886071|NCT00538499|Other|videothoracoscopy|
9886072|NCT00538525|Active Comparator|Arm 1|Doxorubicin, Docetaxel, Cisplatin
9886073|NCT00538538|Active Comparator|A|Does not receive Gas bubble
9886074|NCT00538538|Active Comparator|B|Does receive gas bubble
9886075|NCT00538564|Experimental|Tadalafil|Participants assigned to this arm were given oral 10 mg tadalafil tablets to take 3 times a week for 16 weeks.
9886076|NCT00538564|Placebo Comparator|Placebo|Participants assigned to this arm were given a placebo pill 3 times a week for the first 8 weeks, and then Tadalafil 10 mg 3 times a week for weeks 9-16.
9886077|NCT00538655|Experimental|modafinil|
9886078|NCT00538668|Experimental|1|20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886079|NCT00538668|Experimental|2|25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886080|NCT00538668|Experimental|3|30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886081|NCT00538668|Experimental|4|35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886082|NCT00538668|Experimental|5|40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886083|NCT00538668|Experimental|6|45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886084|NCT00538668|Experimental|7|50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886085|NCT00538668|Experimental|8|55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
9886086|NCT00538668|Experimental|9|25 mCi/m2 of 177Lu-J591 will be given every 2 weeks.
9886087|NCT00538707|Experimental|Young subjects|
9886088|NCT00538707|Experimental|Older subjects|
9886089|NCT00538720|Experimental|Vitamin D|Vitamin D starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
9886090|NCT00538746|Experimental|1|BIPAP (Bilevel Positive Airway Pressure) targeted on: TV 6-8 ml/kg, total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92% (with spontaneous RR between 20-40%)
9886091|NCT00538746|Experimental|2|PSV (pressure support ventilation) targeted on: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated.
9990231|NCT01441388|Experimental|Dose Escalation|Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
9886092|NCT00538746|Experimental|3|PSV+CPAP (continuous positive airway pressure) targeted on: PSV: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated, CPAP (5-10 cmH2O) at least 2 hours a day. If during the CPAP periods at least 1 of the criteria T tube test failure occurs, the patients will come back immediately to PSV.
9886093|NCT00538772||Biomarker|
9886094|NCT00538811|Experimental|1|Interferon alpha, ribavirin, interferon gamma
9886095|NCT00538811|Active Comparator|2|Interferon alpha, ribavirin, amantadine
9886096|NCT00538928|Experimental|1|Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
9886097|NCT00538928|Active Comparator|2|no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
9886098|NCT00538941|Active Comparator|1|daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
9886099|NCT00538941|Placebo Comparator|2|Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
9886100|NCT00538954|Active Comparator|1|Follow a standard Enhanced Recovery After Surgery protocol
9886101|NCT00538954|Experimental|2|Follow a standard Enhanced Recovery After Surgery protocol and will receive 1 g of Magnesium Oxide laxative twice daily from the day after surgery until discharge
9886102|NCT00538954|Experimental|3|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days
9886103|NCT00538954|Experimental|4|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days and will receive postoperative laxative in the form of 20 ml of Magnesium Oxide twice daily form the day after surgery until discharge
9886104|NCT00538967|No Intervention|1|
9886105|NCT00538967|Active Comparator|2|doxycycline 50 mg/day
9886106|NCT00538967|Active Comparator|3|doxycycline 100 mg
9886107|NCT00538967|Active Comparator|4|doxycycline 300 mg
9886108|NCT00538993|Experimental|1|Provider receives cue sheet to assist with counseling.
9886109|NCT00538993|No Intervention|2|Provider does not receive cue sheet.
9990232|NCT01441388|Experimental|Expansion Population 1|Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
9990233|NCT01441388|Experimental|Expansion Population 2|Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
9990234|NCT01441388|Experimental|Expansion Population 3|Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
9990235|NCT01441388|Experimental|Expansion Population 4|Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
9990236|NCT01441427|Experimental|G-CSF|
9990237|NCT01441427|Experimental|EPO|
9886110|NCT00539019||A, observed|measure REE via indirect calorimetry at various time points post burn
9990238|NCT01441427|Experimental|G-CSF and EPO|
9990239|NCT01441427|Placebo Comparator|Placebo|
9990240|NCT01441453|Other|Preoperative FibroScan|
9997410|NCT01508663|Experimental|PCI+OMT group|PCI (Everolimus Eluting Stent or Zotalolimus Eluting Stent) added to OMT after randomization and follow up for 12 months
9997411|NCT01508663|Active Comparator|OMT alone group|OMT alone after randomization and follow up for 12 months
9997412|NCT01508689|Other|Receive cereal bars first|This group will receive Kellogg's Nutri-Grain® cereal bars during the second three weeks of the study.
10211809|NCT03972813|Experimental|many cancers - blank - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
10211810|NCT03972813|Experimental|many cancers - blank - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
9886111|NCT00539045||A|The study population will consist of patients who are admitted to The New York Presbyterian Hospital-Weill Medical College of Cornell University (NYP-WMC) with ST elevation myocardial infarctions (STEMI). STEMI will be established based on standard clinical and ECG criteria.
9886112|NCT00539071|Active Comparator|Conventional dose|All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks (given as two injections - active 50 mg plus placebo injection).As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 3 unless symptoms warrant a quicker titration) along with the injections.Any oral risperidone the patients receive will be discontinued after Week 4.At Week 6, psychopathology will be assessed with a PANSS. Dose will remain at 50 mg q 2 weeks for those in the conventional Consta dose group.
9886113|NCT00539071|Active Comparator|High Dose group|Those who are randomized to high dose Consta will receive Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose after consent. As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 4 unless symptoms warrant a quicker titration) along with the injections. Any oral risperidone the patients receive will be discontinued after Week 4.Psychopathology will be assessed with a PANSS at Week 6. If no improvement since baseline, dose will be increased to two 50 mg injections q 2 weeks for the remainder of the study.
9886114|NCT00539084|Experimental|1|Intradermal injection of Lidocaine followed by a painful stimulus (venipuncture)
9886115|NCT00539084|Placebo Comparator|2|Intradermal injection of placebo followed by a painful stimulus (venipuncture)
9886116|NCT00539097|Experimental|A, treated|treated with Juven po supplement x 3 weeks postop
9886117|NCT00539097|No Intervention|B, control|Usual nutrition therapy received postop
9886118|NCT00539123|Experimental|NCB|Participants receive Physician Management (PM) and non-contingent provision of take-home doses of buprenorphine-naloxone (NCB).
9886119|NCT00539123|Experimental|ACB|Participants receive Physician Management (PM) and abstinence-contingent provision of take-home doses of buprenorphine-naloxone (ACB).
9886120|NCT00539149|Active Comparator|1|
9886121|NCT00539149|Placebo Comparator|2|
9886122|NCT00539162|Experimental|CA 125 Analysis|"Participants will have blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers.~Depending on CA-125 level:~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 1 year.~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 3 months, OR Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers, and a transvaginal ultrasound in 6 weeks +/- 2 weeks.~Questionnaires completed at baseline and during each follow up visit."
9886123|NCT00539175|Active Comparator|2|active treatment with infrared light
9886124|NCT00539175|Placebo Comparator|1|sham (placebo) treatment without infrared light
9886125|NCT00539227||NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC). Questionnaires taking about 20-30 minutes to complete.
9886126|NCT00539266|Active Comparator|1|non diabetic patients with Fontaine IIb-IV peripheral artery disease
9886127|NCT00539266|Placebo Comparator|2|non diabetic patients with Fontaine IIb-IV peripheral artery disease
9886128|NCT00539266|Active Comparator|3|diabetic patients with Fontaine IIb-IV peripheral artery disease
9886129|NCT00539266|Placebo Comparator|4|diabetic patients with Fontaine IIb-IV peripheral artery disease
9886130|NCT00539292|Experimental|1|Silastic Spring-Loaded Silo
9886131|NCT00539292|Active Comparator|2|Primary Closure of Abdomen
9886132|NCT00539318||GI Cancer|
9886133|NCT00539331|Placebo Comparator|1|Paclitaxel/Carboplatin
9886134|NCT00539331|Experimental|2|Paclitaxel/Carboplatin + AZD2171
9886135|NCT00539344|Experimental|1|
9886136|NCT00539357|Experimental|1|All patients self-administered stimulation for 60 consecutive minutes each day. Participants self-administered the treatment for a period of 6 weeks, 7 days a week between the hours of 15:00 and 19:00. Assessments took place every 2 weeks during the treatment period.
9886137|NCT00539383|Experimental|1|
9886138|NCT00539409|No Intervention|1|Diabetic patients will complete quality of life questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions.
9886139|NCT00539409|Active Comparator|Pulsatile Intravenous Insulin Therapy|
9886140|NCT00539422||I|group I of 15 women with benign breast lesion
9886141|NCT00539422||II|group II of 16 women with breast cancer
9886142|NCT00539422||III|13 women were taken as a control group
9886143|NCT00539435|Active Comparator|1|Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
9886144|NCT00539448|Experimental|1|combination of insulin Glargine & insulin Glulisine as basal bolus regimen
9886145|NCT00539474|Active Comparator|1|Wireguided localisation
9886146|NCT00539474|Experimental|2|Radioguided occult lesion localisation
9886147|NCT00539565|Active Comparator|A|oral corticosteroids
9886148|NCT00539565|Placebo Comparator|B|as for active regimen
9886149|NCT00539643|Active Comparator|Bead Arm|Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.
9886150|NCT00539643|Active Comparator|Bead + Dox Arm|Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
9886151|NCT00539708|Experimental|NIV|Non-invasive ventilation
9886152|NCT00539708|Active Comparator|Control|Oxygen therapy
9886153|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive GSK1827771 with the starting dose of 0.3 milligram (mg)
9886154|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
9886155|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
9886156|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
9886157|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
9886158|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
9886159|NCT00539799|Active Comparator|1|Long-term low-dose prednisolone (5 - 7.5 mg/day)
9886160|NCT00539799|Placebo Comparator|2|
9886161|NCT00539812|Other|1|Standard Care only (standard batterer intervention program)
9886162|NCT00539812|Other|2|Brief alcohol intervention combined with standard care
9886163|NCT00539916|Experimental|Jus d'orange|
9886164|NCT00539916|Placebo Comparator|Boisson contrôle|
9886165|NCT00539955|Other|1|Standard 40 hour state-mandated batterer intervention
9886166|NCT00539955|Other|2|Brief alcohol intervention combined with standard batterer intervention
9886167|NCT00539968|Experimental|Docetaxel plus lonafarnib (single arm)|Docetaxel plus lonafarnib
9886168|NCT00540020|Experimental|Cognitive-Didactic|Developed by Sohlberg & Mateer to target four cognitive domains often impaired by TBI: attention, memory, executive functions, and pragmatic communication. Subjects practiced progressively more difficult paper-and-pencil or computerized cognitive tasks in 1:1 cognitive therapy sessions (1.5-2.5 hours daily).
9886169|NCT00540020|Experimental|Functional-Experiential|The works of Giles and Clark-Wilson and Hartley guided the basic concepts and treatment of the functional-experiential arm (Functional). The objective of the functional protocol was to use real life performance situations and common tasks to remediate or compensate for functional deficits after brain injury. Functional protocol treatment interventions (1.5-2.5 hours daily) typically occurred in group settings and natural environments (hospital recreation areas, group rooms, simulated home environments in the dining room, community outings, etc.).
9886170|NCT00540033|Experimental|2|Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
9886171|NCT00540085|Active Comparator|A|Rocuronium dosed after ideal body weight
9886172|NCT00540085|Active Comparator|B|Rocuronium dosed after corrected body weight 20%
9886173|NCT00540085|Active Comparator|C|Rocuronium dosed after corrected body weight 40%
9886174|NCT00540098|Experimental|1|Paroxetine + aerobic exercise
9886175|NCT00540098|Active Comparator|2|Paroxetine + relaxation
9886176|NCT00540098|Active Comparator|3|Placebo + aerobic exercise
9886177|NCT00540098|Placebo Comparator|4|Placebo + relaxation
9886178|NCT00540111|Other|1|"Study of intervention, prospective,uncontrolled Group Number: 1~Group Type:Other - the subjects of group were compared the initial moment (M0 - moment without soluble fiber supplementation)with the others two moments: M1 (one month after soluble fiber supplementation) and M2 (four months after soluble fiber supplementation).~Group Description - HIV-positive individuals with hypertriglyceridemia (serum levels ≥ 200 to ≤ 500 mg/dL),who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study.~Intervention:Received 20g/day of soluble fiber® (partially hydrolyzed guar gum) for 4 months at pre-established times."
9886179|NCT00540137|Active Comparator|NRTIs plus NNRTI arm|nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone
9886180|NCT00540137|Active Comparator|NRTIs plus PI arm|atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone
9886181|NCT00540150|Active Comparator|1|Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
9886182|NCT00540150|Active Comparator|2|Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
9886183|NCT00540176|Experimental|Cohort A|Recurrent disease with previous surgery, radiation therapy and/or chemotherapy
9886184|NCT00540176|Experimental|Cohort B|Newly diagnosed disease with no previous therapy
9886185|NCT00540189|Other|Initial appendectomy|children with complicated appendicitis will undergo initial appendectomy
9886186|NCT00540189|Other|Interval appendectomy|children with complicated appendicitis will undergo initial antibiotic treatment followed by an interval appendectomy
9886187|NCT00540202|Experimental|1.Oral quinine|Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days
9886188|NCT00540202|Active Comparator|2. Coartem|Tablets
9886189|NCT00540215|Active Comparator|1|450 nmol GLP-2 SC
9886190|NCT00540215|Placebo Comparator|2|1 ml isotonic saline SC
9886191|NCT00540241||Second-line pemetrexed treatment in NSCLC|Patients with NSCLC who will start second-line treatment with pemetrexed.
9886192|NCT00540254|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
9886193|NCT00540254|Active Comparator|Arm 2|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
9517885|NCT03302026|No Intervention|No-feedback control group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
9886194|NCT00540267||Schizophrenia|Chronic schizophrenia with aged 18-80 years
9886195|NCT00540280|Active Comparator|Surgery alone|Surgery alone
9886196|NCT00540306||Diagnostic Tool|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
9886197|NCT00540332|Placebo Comparator|Placebo|"Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
9990241|NCT01441518|Experimental|Home care|
9990242|NCT01441518|Active Comparator|Hospital care|
9990243|NCT01441531|Experimental|Gabapentin|Gabapentin 600 mg po given 1 hour before surgery
9886198|NCT00540332|Experimental|Palifermin|"Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
9886199|NCT00540345|Active Comparator|A, RVR LD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV A, RVR LD RBV B, RVR SD RBV
9886200|NCT00540345|Active Comparator|B, RVR SD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV
9886201|NCT00540345|Active Comparator|C, non-RVR 24w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D) (C, non-RVR 24w) (D, non-RVR 48w)
9886202|NCT00540345|Active Comparator|D, non-RVR 48w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D)(C, non-RVR 24w) (D, non-RVR 48w)
9886203|NCT00540371||Port wine stain Birthmark|Port wine stain Birthmark
9886204|NCT00540384|Experimental|NESP - Schedule 1 Part A|Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
9886205|NCT00540384|Experimental|NESP - Schedule 2 Part A|NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
9886206|NCT00540384|Placebo Comparator|Placebo - Schedule 1 Part A|Placebo Q3W for 12 weeks
9886207|NCT00540384|Experimental|NESP - Schedule 1 Part B|Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb < 13.0g/dL and/or RBC transfusion in previous 2 weeks.
9886208|NCT00540384|Placebo Comparator|Placebo - Schedule 2 Part A|Placebo Q4W for 12 weeks
9517752|NCT03303352|Experimental|Fast Pass First, Slow Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as fast pass first, slow pass second."
9886209|NCT00540384|Experimental|NESP - Schedule 2 Part B|Open-label NESP at the dose of study drug administered at the end of Part A
9886210|NCT00540410|Experimental|1|
9886211|NCT00540410|Active Comparator|2|
9886212|NCT00540462|No Intervention|1|Medical Group
9886213|NCT00540462|Active Comparator|2|Surgical Group with gastric bypass
9886214|NCT00540462|Active Comparator|3|Sugical Group with Sleeve gastrectomy
9886215|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 50mg/hour|Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours
9886216|NCT00540501|Experimental|Zanamivir IV 50mg/hour|Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)
9886217|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 600mg|Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h
9886218|NCT00540501|Active Comparator|Oseltamivir 150mg|Oseltamivir 150mg PO q12h for 3 days
9886219|NCT00540527|Experimental|1|local intraarterial recombinant tissue plasminogen activator
9886220|NCT00540527|Active Comparator|2|intravenous (IV) rt-PA
9886221|NCT00540566||Optical Biopsy|Optical Biopsy imaging
9886222|NCT00540605|Experimental|1|4g tenofovir 1% gel applied vaginally 2 hours prior to expected time of cesarean delivery
9886223|NCT00540618|Active Comparator|1|MEDI-507
9886224|NCT00540618|Placebo Comparator|2|
9886225|NCT00540618|Active Comparator|3|MEDI-507
9886226|NCT00540618|Active Comparator|4|MEDI-507
9886227|NCT00540631|No Intervention|P|subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals
9886228|NCT00540631|Experimental|A|Active treatment with house dust mite extract
9886229|NCT00540657|Experimental|1|
9886230|NCT00540657|Placebo Comparator|2|
9886231|NCT00540670|Experimental|1|
9886232|NCT00540670|Experimental|2|
9886233|NCT00540670|Experimental|3|
9886234|NCT00540670|Placebo Comparator|4|
9886235|NCT00540696|Experimental|darbepoetin alfa|
9886236|NCT00540735|Experimental|1|PDT
9886237|NCT00540735|No Intervention|2|
9886238|NCT00540748|Experimental|A1|
9886239|NCT00540748|No Intervention|A2|
9886240|NCT00540761|Experimental|OFDI imaging|OFDI catheter advanced to the distal coronary artery
9886241|NCT00540761|Experimental|Intravenous Ultrasound|Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
9886242|NCT00540787|Active Comparator|Drug Treatment|
9886243|NCT00540787|Active Comparator|ThermoCool Radiofrequency Catheter|Radiofrequency catheter used.
9886244|NCT00540800|Active Comparator|A|Three-weekly chemotherapy
9886245|NCT00540800|Experimental|B|Weekly chemotherapy
9886246|NCT00540813|Experimental|Drug Eluting Balloon|
9886247|NCT00540826||A|A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
9886248|NCT00540826||B|B: ADHD-patients receiving stimulants
9886249|NCT00540852|Other|Diagnostic Tool|Diffuse Optical Spectroscopy Imaging
9886250|NCT00540865|Experimental|A|Participants will receive problem-solving therapy and case management
9886251|NCT00540865|Active Comparator|B|Participants will receive case management
9886252|NCT00540904|Active Comparator|sodium bicarbonate|Solution 154 mEq/L of sodium bicarbonate
9886253|NCT00540904|Active Comparator|Sodium chloride|Solution of 154 mEq/L of NaCl
9886254|NCT00540917|Experimental|cooling spray|cooling spray during laser treatment
9886255|NCT00540943|Experimental|Single Arm|irinotecan and cetuximab in combination with pazopanib.
9886256|NCT00541047|Experimental|RADICALS-RT: Early RT|
9886257|NCT00541047|Experimental|RADICALS-RT: Salvage RT|
9886258|NCT00541047|Experimental|RADICALS-HD: Radiotherapy Alone|
9886259|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 6 months|
9886260|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 24 months|
9886261|NCT00541060|Active Comparator|A|250 young patients presenting several carious lesions
9886262|NCT00541060|Placebo Comparator|B|160 young adults totally caries free
9886263|NCT00541086|Experimental|A - anastrozole|Up-front adjuvant anastrozole for 5 years
9886264|NCT00541086|Experimental|B - exemestane|Up-front adjuvant exemestane for 5 years
9886265|NCT00541086|Experimental|C - letrozole|Up-front adjuvant letrozole for 5 years
9886266|NCT00541086|Active Comparator|D - tamoxifen followed by anastrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by anastrozole for 3 years
9886267|NCT00541086|Active Comparator|E - tamoxifen followed by exemestane|Switch adjuvant treatment with tamoxifen for 2 years followed by exemestane for 3 years
9886268|NCT00541086|Active Comparator|F - tamoxifen followed by letrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by letrozolefor 3 years
9886269|NCT00541125|Other|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
9931537|NCT00939575||Preeclampsia|Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure > 90 mmHg recorded twice at least four hours apart or > 110 mmHg, with proteinuria > 300 mg/24h or > 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
9931538|NCT00939575||control|Women will be matched to women with pre-eclampsia according to gestational age at diagnosis of preeclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: <20, 20-25, 26-30, 31-35 and <35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
9931539|NCT00939588|Experimental|Aliskiren and Valsartan|
9931540|NCT00939588|Active Comparator|Telmisartan and Ramipril|
9931541|NCT00939601|Active Comparator|Motivational Enhancement Therapy|MET will involve counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
9931542|NCT00939601|Active Comparator|Educational Counseling|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
9931543|NCT00939601|No Intervention|Standard Care|
9931544|NCT00939666|Experimental|Wait&see or TEM with intensive follow-up|All patients will be included in this arm
9931545|NCT00939679|Experimental|Earlier gastric bypass surgery (7 weeks)|These patients will undergo gastric bypass surgery 7 weeks after starting a low calorie diet, and will continue the low calorie diet for 3 weeks following surgery.
10211811|NCT03972813|Experimental|many cancers - blank - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
10211812|NCT03970642|Experimental|Intervention group|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will receive the video directly observed therapy smartphone app. Research staff will be able to monitor these medication adherence video on a password protected server linked to the app. Upto 50 patients will be randomly assigned to this group.
9931546|NCT00939679|Active Comparator|Later gastric bypass surgery (10 weeks)|These patients will undergo gastric bypass surgery 10 weeks after starting a low calorie diet.
9931547|NCT00939718|Active Comparator|Vitamin B12 with antidepressants|Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
9931548|NCT00939718|Placebo Comparator|Placebo injections dextrose water|Subjects in this arm will receive placebo injections which will contain only dextrose water. They will also receive 6 injections on a weekly basis and the injection vials will be covered with foil to ensure masking.
9931549|NCT00939744||EAU2|Women who will have a c-section at the CHUS
9931550|NCT00939757|Experimental|1. mirabegron, lower dose|
9931551|NCT00939757|Experimental|2. mirabegron, higher dose|
9931552|NCT00939848|Experimental|B|The experimental arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with cediranib 20mg oral daily (continuous dosing).
9931553|NCT00939848|Placebo Comparator|Arm A|The control arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with a matching placebo 20mg oral daily (continuous dosing)
9931554|NCT00939861|Experimental|1|laparoscopy
9931555|NCT00939861|Experimental|2|laparotomy
9931556|NCT00939887|Experimental|Treatment|
9931557|NCT00939913|Placebo Comparator|intravenous N-acetlycysteine|"intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)as compared to placebo~Acetadote provided by Cumberland Pharmaceuticals Inc."
10211813|NCT03970642|No Intervention|Control|The control group will receive current standard of care. Upto 50 patients will be randomly assigned to this group.
10211814|NCT03970291|Experimental|Nociceptive-Level (NOL)|Analgesic component of anesthesia (fentanyl) will be guided using NOL
10211815|NCT03970291|No Intervention|Standard Clinical Care (SCC)|Standard Clinical Care guided fentanyl administration
10211816|NCT03967587|Experimental|Neosense Umbilical Catheter|
10211817|NCT03963427|Other|Irradiated women|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap.
10211818|NCT03963427|Other|Non-irradiated women|Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
10211819|NCT03954392|Experimental|CBT+SCT|Cognitive behavioral therapy plus social cognitive skills training (SCT)
10211820|NCT03954392|Active Comparator|CBT-only|Cognitive behavioral therapy only (without SCT)
9990244|NCT01441531|Placebo Comparator|Placebo sugar pill|
9886270|NCT00541164|Experimental|1|300 mg CoQ10 chewable wafer twice a day
9886271|NCT00541164|Placebo Comparator|2|Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
9886272|NCT00541177|Experimental|1|use 0.25% atropine once a week
9886273|NCT00541177|Active Comparator|2|use 0.5% tropicamide everyday
9886274|NCT00541281|Active Comparator|A|weekly docetaxel and prednisone
9886275|NCT00541281|Active Comparator|B|weekly docetaxel (35mg/m&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12
9886276|NCT00541333|Active Comparator|Copaxone|
9886277|NCT00541333|Sham Comparator|Sham|
9886278|NCT00541359|Experimental|Arm I|"PART I (completed as of 09/06/06; all patients enrolled in study after 09/06/06 are enrolled in part II): Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8 followed 6 hours later by bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive bortezomib IV on days 1, 4, 8, and 11 followed 6 hours later by escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~In both parts of the study, patients who achieve a response may receive additional courses of treatment."
9886279|NCT00541372|Experimental|1|Needle 5 mm
9886280|NCT00541372|Active Comparator|2|Needle length 8 mm
9886281|NCT00541398|Experimental|A|
9886282|NCT00541398|No Intervention|B|
9886283|NCT00541424||PET/CT Scanning|Patients that have newly diagnosed mantle cell lymphoma will first undergo CT colonography (CT or CTC) and PET followed by conventional colonoscopy.
9886284|NCT00541489|Placebo Comparator|1|
9886285|NCT00541489|Active Comparator|2|Naproxen 500 mg
9886286|NCT00541489|Experimental|3|Naproxcinod 750 mg
10211821|NCT03953599|Experimental|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
10211822|NCT03952923|Experimental|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
9886287|NCT00541515|Experimental|closed loop system|Device: continuous glucose sensors and insulin pump
9886288|NCT00541567|Placebo Comparator|1|
9886289|NCT00541567|Experimental|2|
9886290|NCT00541567|Experimental|3|
9886291|NCT00541567|Experimental|4|
9886292|NCT00541606|Experimental|Intervention|Received collaborative care including a clinical pharmacist practitioner.
9886293|NCT00541606|Active Comparator|Control|Patients received usual care directed by their physician.
9886294|NCT00541619||A|hypertensives with proteinuria
9886295|NCT00541710|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
9886296|NCT00541710|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
9886297|NCT00541723|Experimental|IncobutolinumtoxinA (Xeomin), 4-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 4 x 0.06 mL (4 x 3 units = 12 units); mode of administration: intramuscular injection."
9886298|NCT00541723|Placebo Comparator|Placebo 4-injection scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
9886299|NCT00541723|Experimental|IncobotulinumtoxinA (Xeomin), 3-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 3 x 0.08 mL (3 x 4 units = 12 units); Mode of administration: intramuscular injection."
9990245|NCT01441544|Experimental|VAREITY|
10211823|NCT03952208|Experimental|Concussion Group|Subjects diagnosed with concussion defined as a clinician-diagnosed disease by the International Classification of Diseases (ICD)-10 due to a head injury with a Glasgow Coma Score ≥13 undergoing a planned surgery/anesthetic standard of care will undergo neurocognitive testing pre and post surgery/anesthetic.
10211824|NCT03952208|Experimental|Matched Subjects Group|Matched subjects without concussion undergoing a planned surgery/anesthetic standard of care, matching for procedural type, sex, age ± 2 years, and adherence to the exclusion criteria will undergo neurocognitive testing pre and post surgery/anesthetic.
10211825|NCT03950245|Other|Gastric bypass operated patients|Four test days in a randomized, patient-blinded, cross-over design
10211826|NCT03950245|Other|Sleeve gastrectomy operated patients|Four test days in a randomized, patient-blinded cross-over, design
10211827|NCT03950245|Other|Un-operated controls|Four test days in a randomized, patient-blinded cross-over, design
10211828|NCT03947281|Experimental|Almond snack|The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
9517886|NCT03302013|Experimental|Vanguard XP Knee Replacement Surgery|Participants randomised in this group will receive the Vanguard XP Bi-cruciate Retaining Knee Replacement System. This total knee replacement device (Vanguard XP) and surgical procedure retain the anterior cruciate ligament in the knee.
9886300|NCT00541723|Placebo Comparator|Placebo 3-injection Scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 3 x 0.08 mL placebo solution; mode of administration: intramuscular injection.
9886301|NCT00541736|Experimental|Patients|GTN-infusion
9886302|NCT00541736|Active Comparator|Controls|GTN-infusion
9886303|NCT00541762|Other|A, 3; B, 3; C, 3|A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
9886304|NCT00541788|Experimental|1|Administration of Common Sage
9886305|NCT00541814|Active Comparator|1|CNI [Cyclosporine] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.
9886306|NCT00541814|Experimental|2|CNI [Cyclosporine] withdrawal Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to the point of withdrawal.
9886307|NCT00541853|Active Comparator|A|ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
9886308|NCT00541853|Experimental|B|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
9886309|NCT00541853|Active Comparator|C|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
9886310|NCT00541879|Experimental|I|Elementary school children -grades 2-6 participating in Program ENERGY
9886311|NCT00541879|Sham Comparator|II|Elementary school children in grades 2-6 matched to the intervention classes not receiving any intervention
9886312|NCT00541892|Experimental|1|Medium with no human serum albumine added
9886313|NCT00541892|Active Comparator|2|Conventional medium
9886314|NCT00541905|Experimental|NT 201 (50-300 Units)|"NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
9886315|NCT00541918|Active Comparator|1|propofol
9886316|NCT00541918|Experimental|2|sevoflurane
9886317|NCT00541957|Other|2|Medication prescribed by PCP
9886318|NCT00541957|Experimental|1|Medication prescribed by PCP + behavior therapy
9886319|NCT00541983|Active Comparator|1|
9886320|NCT00541983|Placebo Comparator|2|
9886321|NCT00542048|Experimental|1|
9886322|NCT00542061|Experimental|A|Device: monitoring services
9886323|NCT00542061|No Intervention|B|Control group: no monitoring procedures
9886324|NCT00542074|Experimental|1|
9886325|NCT00542074|Active Comparator|2|
9886326|NCT00542100|Experimental|1|
9886327|NCT00542100|Experimental|2|
9886328|NCT00542113|Experimental|1|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 1
9886329|NCT00542113|Experimental|2|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 2
9886330|NCT00542113|Sham Comparator|3|Parents of elementary school children in grades 2-6 participating in Program ENERGY matched to the intervention groups
9886331|NCT00542126|Active Comparator|1|GnRH analog administration following embryo transfer
9886332|NCT00542126|No Intervention|2|
9886333|NCT00542139|Experimental|1|
9886334|NCT00542139|Active Comparator|2|
9886335|NCT00542152|Active Comparator|CICLO|"Cyclosporine will be administered by continuous intravenous infusion at the initial dose regimen of 2mg/kg per day.~After 24 hours of treatment, cyclosporine trough level will be measured and the dose adapted in order to obtain a cyclosporinaemia level between 150 and 250 ng/ml. Cyclosporinaemia will be reassessed every 48 hours for the duration of the continuous intravenous treatment."
9886336|NCT00542152|Active Comparator|INFLIXIMAB|"INFLIXIMAB (REMICADE) Infliximab in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution, and slowly infused at the dose of 5mg/kg in 2 hours.~In patients with clinical response at D7 (Lichtiger Index score < 10 for 2 consecutive days), two additional infliximab infusions will be administered at the dose of 5mg/kg at D14 and D42."
9886337|NCT00542204|Experimental|Online disease management|The PAMFOnline-mediated Personalized Health Care Program, which couples a multidisciplinary diabetes care management team with an EHR-integrated Online Disease Management (ODM) system.
9886338|NCT00542204|No Intervention|Usual care|Usual medical care. No access to the PHCP electronic system and self-management tools supporting this care management.
9886339|NCT00542217|Placebo Comparator|Cohort 1|Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
9886340|NCT00542217|Placebo Comparator|Cohort 2|Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
9886341|NCT00542217|Placebo Comparator|Cohort 3|Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
9886342|NCT00542217|Placebo Comparator|Cohort 4|Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
9886343|NCT00542217|Placebo Comparator|Cohort 5|Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
9886344|NCT00542243|Active Comparator|Finasteride|"The recommended dosage of PROSCAR© is one 5 mg tablet daily with or without food. If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual.~PROSCAR© 5 mg tablets are blue, apple-shaped; film coated with the code MSD 72 on one side and PROSCAR on the other. They will be provided in bottles of 35 tablets."
9886345|NCT00542243|Placebo Comparator|Placebo|Patient will receive a placebo comparator each day for 6 months.
9990246|NCT01441544|Experimental|NON-VARIETY|
9886346|NCT00542256|Active Comparator|1|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each of the 10 weekday training sessions, participants will receive 40 minutes of active tDCS over the primary motor cortex.
9886347|NCT00542256|Sham Comparator|2|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each training day tDCS will be applied for 40 minutes with the current active for only 30 seconds over the primary motor cortex.
9886348|NCT00542282||1, 2, 3|known moderate to severe COPD, known moderate or severe Asthma, suspected obstructive moderate to severe airways disease
9886349|NCT00542295|Experimental|A|
9886350|NCT00542295|Placebo Comparator|B|
9886351|NCT00542347|Active Comparator|1|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
9886352|NCT00542347|Active Comparator|2|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
9886353|NCT00542360|Experimental|Social marketing program|Behavioral: Social marketing program to motivate exercise class participation
9886354|NCT00542360|No Intervention|Control|Control: No intervention
9886355|NCT00542373|Experimental|Diagnostic (fluorescent/reflectance imaging, spectroscopy)|Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.
9886356|NCT00542399|Experimental|1|once a day
9886357|NCT00542399|Experimental|2|twice a day
9886358|NCT00542438|Active Comparator|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
9886359|NCT00542438|Active Comparator|Environmental Assessment|Environmental assessments on a palm pilot either 3 times a day or once a day. Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
9886360|NCT00542464|Placebo Comparator|Cohort 1|1.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
9886361|NCT00542464|Placebo Comparator|Cohort 2|2.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
9886362|NCT00542464|Placebo Comparator|Cohort 3|4.0 mg/kg Imprime PGG administered daily over 2 hr for 7 consecutive days
9886363|NCT00542516|Experimental|HES 130/04|Pre-expansion with HES
9886364|NCT00542516|Active Comparator|Ringer's lactate|Pre-expansion with Ringer's lactate
9886365|NCT00542529|Placebo Comparator|Cohort 1|Placebo or 2.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
9886366|NCT00542529|Placebo Comparator|Cohort 2|Placebo or 4.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
9886367|NCT00542555|Placebo Comparator|Placebo bid|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
9886368|NCT00542555|Experimental|Naproxcinod 375 mg bid|
9886369|NCT00542555|Active Comparator|Naproxen 500 mg bid|
9886370|NCT00542555|Experimental|Naproxcinod 750 mg bid|
9886371|NCT00542568|Experimental|1|Cohort 1 (Low Dose group) 18-25 IU/kg/day
9886372|NCT00542568|Experimental|2|Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
9886373|NCT00542568|Experimental|3|Cohort 3 (High Dose group): 55-65 IU/kg/day
9886374|NCT00542581|Experimental|The Acrysof toric SN60T3 IOL|Multifocal Intraocular Lens
9886375|NCT00542698|No Intervention|Control|Control group uses 90 minutes of standard diabetes education/ 7 days using the International Diabetes Center curriculum & update phone call at 4 weeks.
9886376|NCT00542698|Experimental|Intervention|Interventional group received standard diabetes education, CGMS monitor, and extra educational topics including CGMS counceling.
9886377|NCT00542737|Active Comparator|Early Intervention Group|
10211829|NCT03947281|Experimental|Cereal-based snack|The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.
10211830|NCT03939104|Active Comparator|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
10211831|NCT03939104|Active Comparator|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|Triple ACTs
10211832|NCT03939104|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
10211833|NCT03939104|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs.
10211834|NCT03924804|Experimental|Group A: 2 ml/kg group|
10211835|NCT03924804|Experimental|Group B: 8 ml/kg group|
10211836|NCT03924804|Experimental|Group C: 16 ml/kg group|
10211837|NCT03920280|Experimental|LID015385|LID015385 contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
10211838|NCT03920280|Active Comparator|Biofinity|Comfilcon A contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
10211839|NCT03913091|Experimental|20 mL 0.5% Bupivacaine HCL|
10211840|NCT03913091|Experimental|Interscalene nerve block with Liposomal + Bupivacaine 0.5%|Administered in an Interscalene block for TSA
9886378|NCT00542737|Active Comparator|Delayed Intervention Group|
9886379|NCT00542776||1|IBD patients on immunosuppressive therapy
9886380|NCT00542776||2|IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
9886381|NCT00542802|Experimental|LEV|Levetiracetam
9886382|NCT00542802|Active Comparator|CAR|Carbamazepina
9886383|NCT00542841|Experimental|1|
9886384|NCT00542854||MP3|4 different brands of MP3 players will be tested at 3 distances from pacemakers and ICDs.
9886385|NCT00542893|Experimental|Group 1|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
9886386|NCT00542893|Experimental|Group 2|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
9886387|NCT00542906|Other|1|healthy volunteers
9886388|NCT00542932|No Intervention|I|
9886389|NCT00542932|Active Comparator|II|Exercise
9886390|NCT00542945|Experimental|A|Heart Failure nonischemic ethiology
9886391|NCT00542945|Active Comparator|B|
9886392|NCT00542958|Experimental|NK012|"This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group. Dose-escalation in each patient population will proceed according to the predefined dose level.~For UGT1A1*28 (wt/wt and wt/*28) patients, at least 3 evaluable patients will be treated at each dose level.~UGT1A1 homozygous (*28/*28) patients will be treated at 50% of the current dose level.~Patients will receive up to 6 cycles of NK012, unless they experience unacceptable toxicity or disease progression, requiring withdrawal from the study."
9886393|NCT00542984|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
9886394|NCT00542984|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
9931558|NCT00939913|Placebo Comparator|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
9931559|NCT00939939|Experimental|sitagliptin|
9931560|NCT00939939|Active Comparator|glimepirid|
9931561|NCT00939978|Active Comparator|Venoferrum|
9931562|NCT00939978|Placebo Comparator|saline|
9931563|NCT00940004|Active Comparator|cytokine matured DC|vaccination with autologous dendritic cells matured with standard cytokine cocktail and electroporated with mRNA encoding tumor associated antigens
9931564|NCT00940004|Experimental|TLR ligand matured DC|vaccination with autologous TLR-ligand matured dendritic cells electroporated with mRNA encoding tumor associated antigens
9931565|NCT00940030|Experimental|MBP+enema|mechanical bowel preparation and enema
9931566|NCT00940030|Active Comparator|enema|
9931567|NCT00940043||Rupture of fetal membranes|women with rupture of fetal membranes before onset of labor
9931568|NCT00940056|Experimental|Endoscopic ablation of atrial fibrillation|
9931569|NCT00940056|Active Comparator|Rate control|
9931570|NCT00940069|Experimental|TS high expression genotype|TS high expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
9931571|NCT00940069|Experimental|TS low expression genotype|TS low expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
9931572|NCT00940082||youth control group|healthy people which ages from 30 to 59
9931573|NCT00940082||youth diabetes group|type 1 and type 2 diabetes patients which ages from 30 to 59
9931574|NCT00940082||the elderly diabetes group|type 1 and type 2 diabetes patients which ages from 60 to 90
9931575|NCT00940082||elderly control group|healthy people which ages from 60 to 90
9931576|NCT00940121|Experimental|1. mirabegron, low dose|Oral mirabegron 25 mg
9931577|NCT00940121|Experimental|2. mirabegron, middle dose|Oral mirabegron 50 mg
9931578|NCT00940121|Experimental|3. mirabegron, higher dose|Oral mirabegron 100 mg
9931579|NCT00940134|Placebo Comparator|placebo|Study participants will receive a 3 hour IV infusion of saline while fasting.
9931580|NCT00940134|Experimental|PYY3-36 + GLP-1|Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.
9931581|NCT00940134|Active Comparator|GLP-1|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
9931582|NCT00940134|Active Comparator|PYY3-36|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
9931583|NCT00940147||1|patients with OAC, Score finding
9931584|NCT00940147||2|patients without OAC, Score finding
9931585|NCT00940160|Active Comparator|QAX576 1 mg/kg|
9931586|NCT00940160|Active Comparator|QAX576 3 mg/kg|
9931587|NCT00940160|Active Comparator|QAX576 10 mg/kg|
9931588|NCT00940160|Placebo Comparator|Placebo|
9931589|NCT00940173|Other|Group 1|Dose Group 1 (Receiving a dose of 10,000 IEQ/kg of DIABECELL(R))
9886395|NCT00543023|Experimental|A|teriparatide 20 micrograms/day subcutaneous
9886396|NCT00543023|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
9886397|NCT00543049|Other|1 non-continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 50.0 mg once daily. After 28 days, treatment will be paused for 14 days and cycle one is completed, followed by resumption of therapy as cycle one for up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
9886398|NCT00543049|Other|2 continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 37.5 mg once daily continuously. Treatment period up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
9886399|NCT00543114|Experimental|Lenalidomide, fludarabine and rituximab|Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle
9886400|NCT00543153||Patients diagnosed with cancer|
9886401|NCT00543166|Placebo Comparator|2|180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
9886402|NCT00543218|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
9886403|NCT00543218|Active Comparator|B|
9886404|NCT00543244||1|Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)
9886405|NCT00543257||Parents|Parents of children with ADHD will be recruited from the greater Boston community. We are interested in enrollment of parents with a range of educational and technical backgrounds, and specifically will look to enroll parents who may not have much computer experience.
9886406|NCT00543270|Experimental|Endovascular Repair - EVAR (Powerlink System)|EVAR (Powerlink System)
9886407|NCT00543270|Active Comparator|Open Surgical Control|Open Surgical Control
9886408|NCT00543335|Experimental|Sorafenib + Radiation Therapy|Sorafenib starting dose 200 mg orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
9886409|NCT00543413|Experimental|1|Arm 1: Drug 250 mg
9886410|NCT00543413|Experimental|2|Arm 2: Drug 500 mg
9886411|NCT00543413|Active Comparator|3|Arm 3: Active Comparator
9886412|NCT00543413|Placebo Comparator|4|Arm 4: Pbo Comparator
9886413|NCT00543426|Experimental|1|Fuzheng Huayu Tablets
9886414|NCT00543426|Sham Comparator|2|sham Fuzheng Huayu Tablets
9886415|NCT00543452|Active Comparator|oxygen|4 liters of oxygen a minute
9886416|NCT00543452|Placebo Comparator|air|4 liters of room air
9886417|NCT00543478|Active Comparator|1|Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.
9886418|NCT00543478|Placebo Comparator|2|Placebo will be given twice a day for 10 weeks
9886419|NCT00543504|Experimental|Bevacizumab + Sunitinib|Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
9886420|NCT00543504|Experimental|Bevacizumab + Sorafenib|Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
9886421|NCT00543504|Experimental|Bevacizumab + Erlotinib + Cetuximab|Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
9886422|NCT00543504|Experimental|Bevacizumab + Trastuzumab + Lapatinib|Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
9886423|NCT00543608|Experimental|1|Dose 1 iclaprim
9886424|NCT00543608|Experimental|2|Dose 2 iclaprim
9886425|NCT00543608|Active Comparator|3|vancomycin
9886426|NCT00543634|Active Comparator|1|
9886427|NCT00543634|Active Comparator|2|
9886428|NCT00543647|Experimental|1|
9886429|NCT00543647|Placebo Comparator|2|
9886430|NCT00543660|Experimental|Intervention arm DSEK|Intervention: DSEK
9886431|NCT00543673|Experimental|Milk based formula A|Experimental milk based infant formula
9886432|NCT00543673|Active Comparator|Standard formula|standard milk based infant formula
9886433|NCT00543673|Other|Reference|Human milk
9886434|NCT00543673|Experimental|Milk based formula C|Experimental milk based infant formula
9886435|NCT00543686|Active Comparator|1|Montelukast
9886436|NCT00543686|Active Comparator|2|Fluticasone
9886437|NCT00543790|Experimental|1|
9886438|NCT00543829|Experimental|1|4 cycles of doxorubicin and docetaxel with tamoxifen
9886439|NCT00543829|Active Comparator|2|4 cycles of doxorubicin and docetaxel without tamoxifen
9931590|NCT00940173|Other|Group 2|Dose Group 2 (Receiving a dose of 15,000 IEQ/kg of DIABECELL(R))
9931591|NCT00940173|Other|Group 3|Dose Group 3 (Receiving a dose of 20,000 IEQ/kg of DIABECELL(R))
9931592|NCT00940173|Other|Group 4|Dose Group 4 (Receiving a dose of 5,000 IEQ/kg of DIABECELL(R))
9800227|NCT01682837|Experimental|KMgCit, KCit, KCl, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800228|NCT01682837|Experimental|KMgCit, KCit, Placebo, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9886440|NCT00543842|Experimental|Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy|Bevacizumab 5 mg/kg intravenous (IV) every 2 weeks for 3 Doses (Weeks 1, 3, 5). Erlotinib starting dose 50 mg orally daily Weeks 1-3. Capecitabine starting dose 650 mg/m^2 orally twice daily Monday-Friday for 6 Weeks. Radiation Therapy 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments. At least 8 weeks after radiation therapy, surgical removal of rectal tumor.
9886441|NCT00543881|Experimental|1|Interventional group
9886442|NCT00543881|Active Comparator|2|Usual care group
9886443|NCT00543907||Pre programmatic development|Patients who have undergone mastectomy for breast cancer prior to implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
9886444|NCT00543907||Post programmatic development|Patients who have undergone mastectomy for breast cancer after implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
9886445|NCT00543933|Experimental|iNO administered|iNO administered at 40 ppm via a non-rebreather mask
9886446|NCT00543959|Experimental|Part1 - Arm 1|Part1: Arm 1: drug
9886447|NCT00543959|Placebo Comparator|Part1 - Arm 2|Part1 - Arm 2: Pbo comparator
9886448|NCT00543959|Placebo Comparator|Part 2 - Arm 1|Part 2 - Arm 1: Pbo
9886449|NCT00543959|Experimental|Part 2 - Arm 2|Part 2- Arm 2: drug 5mg
9886450|NCT00543959|Experimental|Part 2 - Arm 3|Part 2 - Arm 3: drug 15mg
9886451|NCT00543959|Experimental|Part 2 - Arm 4|Part 2 - Arm 4: drug 30mg
9886452|NCT00543959|Active Comparator|Part 2 - Arm 5|Part 2 - Arm 5: active comparator
9886453|NCT00543998||Optical Measurement transillumination|Optical Measurement of sinus
9886454|NCT00544024||Reference|Lariam was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
9886455|NCT00544024||T1|Mephaquin was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
9886456|NCT00544024||T2|Mefloquine-AC Farma was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
9886457|NCT00544037||Group 1|
9886458|NCT00544128|Active Comparator|Epzicom Arm|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
9886459|NCT00544128|Active Comparator|Truvada Arm|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
9886460|NCT00544206|Experimental|#1|Diabetes specific enteral feeding product
10211841|NCT03906136|Experimental|TREAT-TO-TARGET (T2T)|"Participants will receive secukinumab at a dose of 150 milligrams (mg) as subcutaneous (s.c.) injection at 150 mg dose at Baseline, Week 1, 2, 3, 4 and 8. From Week 12, only responders will continue to receive 4-weekly doses until Week 32 if they maintain the response. In case these patients experience a loss of response from week 24 they will be escalated to secukinumab 300 mg s.c. every 4 weeks until Week 32.~Patients who are non-responders at Week 12 will receive 4-weekly secukinumab 300 mg s.c. until Week 24. From Week 24, only responders will continue to receive 4-weekly secukinumab 300 mg s.c. until Week 32. Patients who are non-responders to secukinumab 300 mg at Week 24 will receive biweekly of adalimumab biosimilar 40 mg s.c. until Week 34"
10211842|NCT03906136|Active Comparator|Standard-of-care (SOC)|SOC treatment up to the maximum recommended dose at the discretion of the investigator as according to current recommendation for treatment of axSpA
9886461|NCT00544206|Active Comparator|#2|Standard enteral feeding product
9886462|NCT00544219|Other|R-Chop 14|Standard treatment
9886463|NCT00544232|Experimental|epirubicin, paclitaxel and CMF +/- darbepoetin|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
9886464|NCT00544232|Experimental|EC followed by paclitaxel +/- darbepoetin|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
9886465|NCT00544258|Experimental|1|Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
9886466|NCT00544284|Experimental|Treatment (temozolomide, bortezomib)|GROUP A: Patients receive oral temozolomide once a day on days 1-5 and bortezomib IV on days 2, 5, 9, and 12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. GROUP B: Patients receive temozolomide and bortezomib as in group A. Cohorts of patients in both groups receive escalating doses of both study drugs until the maximum tolerated doses are determined. All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only).
9886467|NCT00544310|Experimental|1|Post surgery adhesion prevention treatment
10211843|NCT03893955|Experimental|Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.
9800229|NCT01682837|Experimental|KMgCit, KCl, KCit, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800230|NCT01682837|Experimental|KMgCit, KCl, Placebo, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9886468|NCT00544336||Supportive|
9886469|NCT00544362|Experimental|Neoadjuvant chemoradiotherapy|Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5
9886470|NCT00544375||Neonatal Tissues|Optical measurement neonatal tissues
9886471|NCT00544401|Experimental|1|Hypnopuncture Treatment
9886472|NCT00544401|No Intervention|2|Conventional IVF/ICSI treatment only
9886473|NCT00544492|Experimental|A1|Buttonhole cannulation technique
9886474|NCT00544492|Active Comparator|A2|Rope ladder cannulation technique
9886475|NCT00544492|Experimental|B1|Catheter with bevel point
9886476|NCT00544492|Active Comparator|B2|Catheter with cylindrical point
9886477|NCT00544518|Experimental|2|
9886478|NCT00544518|Active Comparator|1|
9886479|NCT00544583|Active Comparator|A|Interrupted closure with Vicryl equivalent sutures (USP 2, 45 cm)
9886480|NCT00544583|Experimental|B|Continuous closure with PDS II equivalent sutures (USP 1, 150 cm loops)
9886481|NCT00544596|Experimental|Treatment (R-(-)-gossypol acetic acid, cisplatin, etoposide)|"Patients receive oral R-(-)-gossypol twice daily on days 1-3, cisplatin IV over 60 minutes on day 1*, and etoposide IV over 30 minutes on days 1*-3. Treatment repeats every 21 days for up to 6 courses during the dose escalation and 4 courses in the expanded extensive stage small cell lung cancer cohort, in the absence of disease progression or unacceptable toxicity.~Blood samples are collected on day 1 of courses 1 and 2 for pharmacokinetic analysis, biomarker assays, and correlative studies.~After completion of study treatment, patients are followed for 30 days.~[Note: *Cisplatin and etoposide will be started on day 2 during course 1; they will be given on day 1 during all subsequent courses.]"
9886482|NCT00544609|Other|Sorafenib|2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
9886483|NCT00544635|Experimental|A|scars will be treated with light
9886484|NCT00544635|Placebo Comparator|B|no intervention
9886485|NCT00544687|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
10211844|NCT03893955|Experimental|Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.
9886486|NCT00544687|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
9886487|NCT00544687|Active Comparator|3|0.1% mometasone furoate
9886488|NCT00544687|Active Comparator|4|0.1% nortriptyline HCl
9886489|NCT00544687|Active Comparator|5|Karison® Creme (clobetasol-17-propinate 0.05%)
9886490|NCT00544687|Placebo Comparator|6|Vehicle (placebo)
9886491|NCT00544700|Active Comparator|Arm A: Bevacizumab monotherapy|Bevacizumab maintenance monotherapy
9886492|NCT00544700|Other|Arm B: No maintenance|No antitumor treatment until progression
9886493|NCT00544726|Active Comparator|1|Physical training
9886494|NCT00544726|Placebo Comparator|2|No physical training
9886495|NCT00544739||1|323 women with established coronary artery disease before 55 year of age
10211845|NCT03893955|Experimental|Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.
10211846|NCT03893955|Experimental|Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.
10211847|NCT03893955|Experimental|Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC|Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.
10211848|NCT03893955|Experimental|Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.
9886496|NCT00544739||2|347 clinically healthy, age matched women selected from the National Health Survey WOBASZ study with negative history of CVD or negative exertional chest pain.
9886497|NCT00544752|Experimental|16|indoor temperature of 16 degrees celcius
9886498|NCT00544752|Experimental|20|indoor temperature 20 degrees celcius
10211849|NCT03893955|Experimental|Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors|Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.
10211850|NCT03889249|Active Comparator|Tenecteplase (tNK-TPA)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization. Tenecteplase has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
9886499|NCT00544752|Experimental|24|indoor temperature of 24 degrees celcius
9886500|NCT00544765|Experimental|resp: 4xTAC|Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC
9886501|NCT00544765|Experimental|resp: 6xTAC|Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC
9886502|NCT00544765|Experimental|nonResp: 4xTAC|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC
9886503|NCT00544765|Experimental|nonResp: 4xNX|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX
9886504|NCT00544791|Experimental|A|melatonin 5 mg, daily dose for 6 months
9886505|NCT00544791|Placebo Comparator|B|
9931593|NCT00940186||pikamilone|
9931594|NCT00940186||dosage|low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
9931595|NCT00940186||tablet|
9931596|NCT00940199||Standard of Care|I:Application of L-M-X topical anesthetic cream 4% to the breast within one hour of sub-areaolar injection of 4 ml 99mTc-sulfur colloid (1 mCi in normal saline)
9931597|NCT00940199||1 mCi in sodium bicarbonate|II. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate)
9931598|NCT00940199||1 mCi in 1% Lidocaine|III. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in 1% Lidocaine)
9931599|NCT00940199||1 mCi in sodium bicarbonate + 1% Lidocaine|IV. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate + 1% Lidocaine)
9517887|NCT03302013|Active Comparator|Vanguard CR Knee Replacement Surgery|Participants randomised to this group will receive the Vanguard CR Single Cruciate Retaining Knee Replacement Surgery. This total knee replacement device (Vanguard CR) and surgical procedure sacrifice the anterior cruciate ligament and replaces it with artificial support. This is currently the standard practice for knee replacement surgery in the NHS.
9931600|NCT00940212|Experimental|A|AZD2423
9931601|NCT00940212|Experimental|B|Placebo
9931602|NCT00940225|Experimental|Arm 1|RDT Open-Label
9931603|NCT00940225|Experimental|Arm 2|RDT Randomized Blinded-XL184
9931604|NCT00940225|Placebo Comparator|Arm 3|RDT Randomized Blinded
9931605|NCT00940225|Experimental|Non-Randomized Expansion (NRE) Cohorts|Drug: XL184
9931606|NCT00940251|Placebo Comparator|CORN STARCH|
9931607|NCT00940251|Active Comparator|Mersina, Diet and exercise|
9931608|NCT00940264||Given indication for cholecystectomy|
9931609|NCT00940277|Experimental|Enhanced Couples Group|Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
9931610|NCT00940277|Experimental|Support Group|Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
9931611|NCT00940303|Experimental|1|
9931612|NCT00940329|Active Comparator|Treatment A|
9931613|NCT00940329|Active Comparator|Treatment B|
9931614|NCT00940355|Experimental|Intervention pulmonary nurse|group III: intervention conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, increasing motivation to engage in additional treatment, and improving health status.
9931615|NCT00940355|No Intervention|Usual care|group II: usual care as delivered by the outpatient clinic.
9997413|NCT01508689|Other|Receive cereal bars second|This group will receive Kellogg's Nutri-Grain® cereal bars during the last three weeks of the study.
9886506|NCT00544804|Experimental|Lapatinib|Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
9886507|NCT00544856|Experimental|1|cognitive intervention
9886508|NCT00544856|Placebo Comparator|2|
9886509|NCT00544921|Experimental|50 mg|
9886510|NCT00544921|Experimental|100 mg|
9886511|NCT00544921|Experimental|250 mg|
9886512|NCT00544921|Experimental|500 mg|
9886513|NCT00544921|Experimental|750 mg|
9886514|NCT00544921|Experimental|1000 mg|
9886515|NCT00544921|Placebo Comparator|Placebo|
9886516|NCT00544934|Experimental|250 mg|
9886517|NCT00544934|Experimental|500 mg|
9886518|NCT00544934|Experimental|750 mg|
9886519|NCT00544934|Placebo Comparator|Placebo|
9886520|NCT00544947||D, F|"Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.~Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section."
9886521|NCT00545090|Experimental|1|
9886522|NCT00545116|Experimental|a|Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)
9886523|NCT00545116|Experimental|b|Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving
9886524|NCT00545116|Placebo Comparator|c|Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin
9886525|NCT00545116|Placebo Comparator|d|Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin
9886526|NCT00545129|Experimental|Tanezumab 10 mg IV + opioids|
9886527|NCT00545129|Placebo Comparator|Placebo + opioids|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
9886528|NCT00545194|Active Comparator|A|sustained release preparation of prostaglandin E2
9886529|NCT00545194|Active Comparator|B|short-acting (instant-released) preparation of prostaglandin E2
9886530|NCT00545207|Experimental|1|
9886531|NCT00545207|Placebo Comparator|2|
9886532|NCT00545220|Experimental|1|PST
9886533|NCT00545220|Sham Comparator|2|Attention Control
9886534|NCT00545246|Experimental|aflibercept + docetaxel|
9886535|NCT00545259|Experimental|1|AEB071
9886536|NCT00545285|Active Comparator|1|Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
9886537|NCT00545285|Active Comparator|2|Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
9886538|NCT00545285|Active Comparator|3|Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
9886539|NCT00545285|Active Comparator|4|Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
9886540|NCT00545311|Experimental|1|NVA237
9886541|NCT00545311|Experimental|2|NVA237
9886542|NCT00545311|Experimental|3|NVA237
9886543|NCT00545311|Experimental|4|NVA237
9886544|NCT00545311|Placebo Comparator|5|Placebo
9886545|NCT00545350|No Intervention|1|Usual activity / care
9886546|NCT00545350|Experimental|2|"Physical exercise classes plus home exercises:~Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home. The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
9886547|NCT00545376|No Intervention|1|This group will leave after the first visit without additional instruction and will be asked to return in two weeks for a follow up lung assessment.
9886548|NCT00545376|Experimental|2|This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
9886549|NCT00545376|Experimental|3|This arm is the physicians that I will recruit participants through. They will be exposed to education about the use of OMT for asthma.
9886550|NCT00545415|Experimental|1|
9886551|NCT00545415|Experimental|2|
9886552|NCT00545415|Experimental|3|
9886553|NCT00545415|Experimental|4|
9886554|NCT00545415|Experimental|5|
9886555|NCT00545415|Experimental|6|
9886556|NCT00545428|Experimental|1|Rhinoplasty
9886557|NCT00545467|Active Comparator|1|fast tapering of the previous medication within 1 week after initiating aripiprazole for 2 weeks
9886558|NCT00545467|Active Comparator|2|slow tapering of the previous medication within 4 weeks after initiating aripiprazole for 2 weeks
9886559|NCT00545480|Experimental|1|
9886560|NCT00545480|Active Comparator|2|
9886561|NCT00545493|Experimental|Group 1|"Tacrolimus capsules (Prograf; dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter)"
9886562|NCT00545493|Experimental|Group 2|"Intravenous immunoglobulins (IVIG) infusions (Octagam; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months)."
9886563|NCT00545519|Experimental|Dose Level 1|Thymoglobulin 2.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
9886564|NCT00545519|Experimental|Dose Level 2|Thymoglobulin 3.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
9886565|NCT00545519|Experimental|Dose Level 3|Thymoglobulin 4.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
9886566|NCT00545545|Experimental|Arm 1, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
9886567|NCT00545545|Experimental|Arm 1, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
9886568|NCT00545545|Experimental|Arm 1, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
9886569|NCT00545545|Experimental|Arm 2, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
9886570|NCT00545545|Experimental|Arm 2, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
9886571|NCT00545545|Experimental|Arm 2, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
9886572|NCT00545558|Experimental|1|Participants will receive ART consisting of efavirenz and the co-formulation of emtricitabine and tenofovir disoproxil fumarate. If participants are unable to tolerate the treatment, a different regimen will be prescribed.
9886573|NCT00545610||Test 1 (n=50)|1 x 10^5 (+/-10%) CD34+ cells/kg of body weight
9886574|NCT00545610||Test 2 (n=50)|5 x 10^5 (+/-10%) CD34+ cells/kg of body weight
9886575|NCT00545610||Placebo (n=50)|Saline plus 5% autologous plasma
9886576|NCT00545649|Experimental|1|Exercise and education
9886577|NCT00545649|Active Comparator|2|Education only
9886578|NCT00545675|Experimental|1|Abilify(aripiprazole) + Depakote(divalproate)
9886579|NCT00545675|Placebo Comparator|2|Divalproate + Placebo
9886580|NCT00545701|Experimental|1|
9886581|NCT00545727|Other|HGI|High/standard glycemic index diet
9886582|NCT00545727|Experimental|LGI|Low glycemic index diet
9886583|NCT00545805|Experimental|OM group|
9886584|NCT00545805|Active Comparator|CT group|Control group
9886585|NCT00545831|Experimental|A|Use of taurolidine in prevention of bloodstream infection related to central venous access
9886586|NCT00545831|Placebo Comparator|B|Use of Physiologic Serum to compare to arm A
9886587|NCT00545857|Experimental|Pioglitazone|
9886588|NCT00545857|Placebo Comparator|Placebo control|
9886589|NCT00545870|Experimental|A|Bevacizumab treatment
9886590|NCT00545870|Active Comparator|B|Ranibizumab treatment
9886591|NCT00545909|Experimental|1|
9886592|NCT00545909|Active Comparator|2|
9886593|NCT00545922|Experimental|A|7 weekly sessions of group cognitive behavioral therapy
9886594|NCT00545922|Active Comparator|B|Minimal Telephone Contact
9886595|NCT00545935|Active Comparator|1-Methylenblue-Amodiaquine|
9886596|NCT00545935|Active Comparator|2-Methylenblue-Artesunate|
9886597|NCT00545935|Active Comparator|3-Artesunate-Amodiaquine|
9886598|NCT00545961|Placebo Comparator|1|placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
9886599|NCT00545961|Active Comparator|2|amoxicillin-clavulanate acid
9886600|NCT00545987|Active Comparator|intramuscular injection|administration of an HIV-1 vaccine by conventional intramuscular injection
9886601|NCT00545987|Experimental|TriGrid Delivery System|electroporation-mediated intramuscular delivery using the TriGridTM device by Ichor Medical Systems, Inc.
9886602|NCT00546013||AAA group, control group|AAA group : with AAA Control group: without AAA
9886603|NCT00546026|Active Comparator|Active group|Receive assessment of placental function
9886604|NCT00546039|Active Comparator|1|
9886605|NCT00546039|Placebo Comparator|2|
9886606|NCT00546065|Other|ablation of Barretts with concomitant esomeprazole therapy|comparison of recurrence-free survival
9886607|NCT00546065|No Intervention|non ablation|non ablation only surveillance
9886608|NCT00546130|Experimental|1|Irinotecan hydrochloride + Cisplatin + Krestin Therapy
9886609|NCT00546143|Experimental|1|Omalizumab 900 mg
9886610|NCT00546143|Experimental|2|Omalizumab 1050 mg
9886611|NCT00546143|Experimental|3|Omalizumab 1200 mg
9886612|NCT00546169||A|
9886613|NCT00546208||1|adolescents and young adults who underwent, as newborns, unilateral low loop cutaneous ureterostomy for severe bilateral hydro-ureteronephrosis, and that, afterwards, underwent stomal closure
9886614|NCT00546221|Experimental|Psychosocial support|Comprising 22 participants engaging in the experimental exercise programme, exercising with psychosocial support.
9886615|NCT00546221|Active Comparator|Prescribed exercise|Comprising 21 participants engaging in a programme of typical prescribed exercise.
9886616|NCT00546234|Active Comparator|1|
9886617|NCT00546234|Active Comparator|2|
9886618|NCT00546286|Experimental|1|dorzolamide HCl/timolol maleate
9886619|NCT00546286|Experimental|2|dorzolamide hydrochloride/timolol maleate + prostaglandin
9886620|NCT00546325|Experimental|1|Rimonabant
9886621|NCT00546325|Placebo Comparator|2|Placebo
9886622|NCT00546403|Placebo Comparator|Placebo|Adjunctive treatment with placebo
9886623|NCT00546403|Experimental|Modafinil|Treatment with titrated dose of study drug, modafinil.
9886624|NCT00546442|Placebo Comparator|2|Placebo of metformine 850-2550 mg/daily for 48 weeks
9886625|NCT00546442|Experimental|1|Metformine 850-2550 mg/daily for 48 weeks
9886626|NCT00546468|Experimental|Laparoscopy assisted distal gastrectomy|Laparoscopy assisted distal gastrectomy with D2 lymph node dissection.Surgery will be done in similar operative extent with control open distal gastrectomy. Omentectomy will be omitted.
9886627|NCT00546468|Active Comparator|Open Distal Gastrectomy|Conventional standard D2 open distal gastrectomy without omentectomy.
9886628|NCT00546507|Placebo Comparator|A|placebo
9886629|NCT00546507|Active Comparator|B|celecoxib 200 mg qd p.o.
9886630|NCT00546507|Experimental|C|TDS-943 40 mg bid topically
9886631|NCT00546546|No Intervention|control = conventional treatment|conventional treatment: use of immunosuppressants only if steroid dependency or chronic active disease
9886632|NCT00546546|Experimental|Immunossuppresive treatment|Switch to different immunosuppresive treatment in case of relapse.
9886633|NCT00546611|Active Comparator|1|Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.
9886634|NCT00546650|Experimental|A|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
9886635|NCT00546650|Active Comparator|B|Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
9886636|NCT00546650|Active Comparator|C|Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
9886637|NCT00546650|Active Comparator|D|Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
9886638|NCT00546650|Experimental|E|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
9886639|NCT00546663|Experimental|Open-label|
9886640|NCT00546689||1 , 2|those with HIV
9886641|NCT00546741|Experimental|1|
9886642|NCT00546741|Active Comparator|2|
9886643|NCT00546741|Active Comparator|3|
9886644|NCT00546767|Experimental|Mail and Live Phone|
9886645|NCT00546767|Experimental|IVR|
9886646|NCT00546767|Experimental|Computer Kiosk|
9886647|NCT00546767|Active Comparator|Traditional|
9886648|NCT00546806|Experimental|1|"AVIVA Soft Tissue Injury Care Model"
9886649|NCT00546806|Experimental|2|Pre-approved Framework Guideline for Grade I and II Whiplash Associated Disorders (PAF)
9886650|NCT00546806|Active Comparator|3|Physician-based Education and Activation
9886651|NCT00546832|Placebo Comparator|1|placebo
9886652|NCT00546832|Active Comparator|2|celecoxib 200 mg qd p.o.
9886653|NCT00546832|Experimental|3|TDS-943 40 mg bid topically
9886654|NCT00546858||Survey|Patients with interstitial cystitis
9886655|NCT00546936|Experimental|ranibizumab intravitreal injection|0.5 mg intravitreal injection of ranibizumab
9886656|NCT00546936|Active Comparator|Photodynamic Therapy|Photodynamic therapy with Visudyne
9886657|NCT00546949|Active Comparator|decompression|Minimal invasive decompression
9886658|NCT00546949|Experimental|x-stop|X-stop, an interspinous decompression device
9886659|NCT00546975|Experimental|1|Resource Support® Novartis
9886660|NCT00546975|Active Comparator|2|Resource Protein®, Novartis
9886661|NCT00546975|Placebo Comparator|3|
9886662|NCT00546988|No Intervention|Standard risk IFN|Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
9886663|NCT00546988|No Intervention|Standard risk PEGIFN|Maintenance treatment with pegylated interferon following autologous stem cell transplantation
9886664|NCT00546988|Experimental|High risk allo|Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
9886665|NCT00546988|No Intervention|High risk auto|Second cycle of high-dose melphalan in subjects without an HLA-identical donor
9886666|NCT00547001|Active Comparator|1|Group A will be tapered over 4 weeks, starting at baseline (week 0). Subjects in this group will take one tablet of ET daily (effective dose, 0.75 mg) for week 1, then one 0.50 mg tablet daily for week 2, then one 0.25 mg tablet daily for week 3, and finally one 0.125 mg tablet daily for week 4.
9886667|NCT00547001|Placebo Comparator|2|Group B will be administered placebo. These tablets will appear identical to those administered to subjects in Group A, but the tablets will contain no estrogen. Subjects in this group will be instructed to take one pill every day for the 4 weeks. Thus, while patients will, in effect, be stopped abruptly from their therapy, there is still the potential of a placebo effect.
10211851|NCT03889249|Active Comparator|Alteplase ( tPA)|The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).
10211852|NCT03879161|Experimental|Device Arm|Study participants will be enrolled in the Device Arm and the Vu-Path™ Device will be used to access the femoral artery for intra-arterial chemoembolization.
10211853|NCT03874793|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
10211854|NCT03874793|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
10211855|NCT03868943|Experimental|Solriamfetol|Given orally daily
9886668|NCT00547001|No Intervention|3|"Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the real life scenario of stopping medication abruptly."
9886669|NCT00547014|Experimental|Cohort 1 1mg|
9886670|NCT00547014|Experimental|Cohort 2|
9886671|NCT00547014|Experimental|Cohort 3|
9886672|NCT00547014|Experimental|Cohort 4|
9886673|NCT00547014|Experimental|Cohort 5|
9886674|NCT00547040||A|incident renal transplant patients
9931616|NCT00940368|Experimental|Ginger arm|"The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day"
9931617|NCT00940368|Placebo Comparator|Placebo arm|"Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day"
9931618|NCT00940381|Experimental|Sirolimus + Cetuximab|Sirolimus beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle. Cetuximab Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
9931619|NCT00940394|Other|standard care|Families receive routine community and family mental health care services
9931620|NCT00940394|Experimental|mutual support group|bi-weekly, 12-session, family-led mutual support group
9931621|NCT00940394|Active Comparator|psychoeducation group|bi-weekly, 12-session, family psychoeducation group program
9931622|NCT00940420|Experimental|A|
9931623|NCT00940420|Experimental|B|
9931624|NCT00940433|Active Comparator|open properitoneal|patients undergoing open properitoneal hernia repair
9931625|NCT00940433|Active Comparator|Lechtenstien repair|Patients undergoing Lechtestien hernia repair
9931626|NCT00940433|Active Comparator|Laparoscopic transperitoneal repair|Patients undergoing TAPP repair
9931627|NCT00940433|Active Comparator|Lap totally extraperitoneal approach|Patients undergoing TEP approach
9931628|NCT00940459|Experimental|Acuvue Oasys|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
9931629|NCT00940459|Experimental|Biofinity|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
9931630|NCT00940459|Experimental|Air Optix|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
9931631|NCT00940459|Experimental|PureVision|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
9931632|NCT00940459|Active Comparator|Acuvue 2|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
9931633|NCT00940472|Experimental|Experimental Drug|DMMET-01 + Diet
9931634|NCT00940472|Active Comparator|Metformin|Metformin + Diet
9931635|NCT00940498|Experimental|1|PF-05212384 (also known as PKI-587)
9931636|NCT00940511|Experimental|Coordinated care|Individuals will be passively enrolled in Medicaid managed care. Those who do not opt out of managed care will be provided with care coordination.
9931637|NCT00940511|No Intervention|Usual care|The usual care group will remain in fee-for-service Medicaid and receive services normally available through that system.
9931638|NCT00940524|Experimental|Chemotherapy|A phase I study designed to determine the dose of dasatinib that can be safely administered with cytarabine and high-dose mitoxantrone in Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia patients.
9931639|NCT00940550|Experimental|Prolonged-release melatonin 2 mg|
9931640|NCT00940550|Active Comparator|Temazepam 20 mg|
9931641|NCT00940550|Active Comparator|Zolpidem 10 mg|
9931642|NCT00940550|Placebo Comparator|Placebo|
9931643|NCT00940563|Experimental|Imatinib|
9931644|NCT00940615|Experimental|1|participants in the aerobic exercise intervention
9931645|NCT00940615|Active Comparator|2|participants in the stretching/toning control condition
9931646|NCT00940628|Experimental|1|
9931647|NCT00940628|Other|2|
9931648|NCT00940641|Experimental|1|IV dose of AZD7325
9931649|NCT00940641|Experimental|2|14C oral dose of AZD7325
9886675|NCT00547092|Active Comparator|1|tadalafil given the first 12 weeks and after a 4 week washout sildenafil is given for 12 weeks.
9886676|NCT00547092|Active Comparator|2|sildenafil given the first 12 weeks and after a 4 week washout tadalafil is given for 12 weeks.
9886677|NCT00547144|Experimental|Gemcitabine|
9886678|NCT00547170|Experimental|1|Half of enrolled women will be randomly assigned to group 1.
9886679|NCT00547170|Active Comparator|2|Half of enrolled women will be randomly assigned to group 2
9886680|NCT00547183|Active Comparator|2|2.5 mg tadalafil
9886681|NCT00547183|Active Comparator|3|5 mg tadalafil
9886682|NCT00547183|Placebo Comparator|1|
9886683|NCT00547196|Experimental|Regimen I (age < 50 years, no contraindication to FTBI)|Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
9886684|NCT00547196|Experimental|Regimen II (age < 50 and unable to tolerate FTBI)|Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
9886685|NCT00547196|Experimental|Regimen III (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
9886686|NCT00547196|Experimental|Regimen IV (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
9886687|NCT00547209|Active Comparator|1|ventilation with air and oxygen
9886688|NCT00547209|Experimental|2|ventilation with nitrous oxide and oxygen
9886689|NCT00547261|Experimental|Arm A|1 hour IV infusion D1
9886690|NCT00547261|Experimental|Arm B|1 hour IV infusion D1, D8, D15
9886691|NCT00547287|Active Comparator|1|Currently prescribed dosage of sildenafil is continued until wash-out period.
9886692|NCT00547287|Active Comparator|2|20 mg tadalafil given after one week sildenafil wash-out period.
9886693|NCT00547326|Experimental|1|Treatement with osteopatic cranial techniques
9886694|NCT00547326|Placebo Comparator|2|Treatment with placebo
9886695|NCT00547352|Active Comparator|1|sildenafil treatment for at least 10 weeks prior to a 1 week wash out
9886696|NCT00547352|Active Comparator|2|Tadalafil treatment for 8 weeks following the 1 week washout period.
9886697|NCT00547391|No Intervention|1|patients on waiting list for a minimum of 5 months. These patients receive no prophylactic intervention for their recurrent pharyngitis episodes.
9886698|NCT00547391|Active Comparator|2|Tonsillectomy as soon as possible after randomization (within 2-3 weeks).
9886699|NCT00547417|Active Comparator|1|tadalafil
9886700|NCT00547443|Active Comparator|Arm I|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose external beam radiotherapy (HDRT) as in phase I. Patients also receive consolidation therapy comprising paclitaxel and carboplatin as in phase I.
9886701|NCT00547443|Experimental|Arm II|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and HDRT as in phase I. Patients also receive consolidation therapy comprising paclitaxel, carboplatin, and sorafenib tosylate at the MTD as in phase I, as well as maintenance therapy comprising sorafenib tosylate at the MTD as in phase I.
9886702|NCT00547482|Sham Comparator|Control|They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
9886703|NCT00547482|Active Comparator|Treatment|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation). They will be followed for the Initial Study Period (24 weeks), followed by the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA."
9886704|NCT00547495|Placebo Comparator|1|Placebo tablet
9886705|NCT00547495|Active Comparator|2|5 mg tadalafil
9886706|NCT00547495|Active Comparator|3|10 mg tadalafil
9886707|NCT00547495|Active Comparator|4|20 mg tadalafil
9886708|NCT00547508|Placebo Comparator|1|Placebo
9886709|NCT00547508|Placebo Comparator|2|Placebo
9886710|NCT00547508|Active Comparator|3|tadalafil
9886711|NCT00547508|Active Comparator|4|tadalafil
9886712|NCT00547508|Active Comparator|5|tadalafil
9886713|NCT00547508|Active Comparator|6|tadalafil
9886714|NCT00547547|Experimental|Treatment (high-selenium therapy and chemotherapy)|
9886715|NCT00547560|Other|GSI+Placebo|
9886716|NCT00547573|Active Comparator|2|10 mg tadalafil tablet
9886717|NCT00547573|Active Comparator|3|20 mg tadalafil tablet
9886718|NCT00547573|Placebo Comparator|1|placebo tablet
9886719|NCT00547599|Active Comparator|1|20 mg tadalafil tablet
9886720|NCT00547625|Placebo Comparator|1|Placebo run in followed by 5 mg treatment phase 1 and then 20 mg treatment phase 2 which both include a placebo control.
9886721|NCT00547625|Active Comparator|2|Treatment phase 1 includes 5 mg tadalafil 6 weeks then treatment phase 2 which includes 20 mg tadalafil for 6 weeks.
9886722|NCT00547664|Experimental|A|
9886723|NCT00547664|Placebo Comparator|B|
9886724|NCT00547690|Experimental|1|Acupuncture and strength training
9886725|NCT00547690|Other|2|Strength training
9886726|NCT00547716|Experimental|1.|Omega-3 Fatty Acids 4 grams/day
9886727|NCT00547716|Placebo Comparator|2.|Placebo comparator along with interferon.
9886728|NCT00547794||CRT-D + AVJ Ablation|
9886729|NCT00547794||Single-Chamber ICD + Pharmacological Therapy|
9886730|NCT00547820|Experimental|A|with application of urinary sensor
9886731|NCT00547820|Placebo Comparator|B|without use of urinary sensor
9886732|NCT00547833||Experimental|Children with language-learning disabilities reading at approximately a 6th grade level
9886733|NCT00547833||Age-Matched|Typical language learners each of whom is pair match to an experimental participant by age and gender.
9886734|NCT00547833||Language-Matched|Typical language learners, each of whom is pair-matched to an experimental participant by reading comprehension skills and gender.
9886735|NCT00547872|Experimental|1|Best medical/behavioral treatment according to guidelines suggestions plus CAD screening by ECG tolerance testing followed by revascularization in case of coronary stenosis.
9886736|NCT00547872|No Intervention|2|Best medical/behavioral treatment according to guidelines suggestions
9886737|NCT00547885|Active Comparator|1|Active dihydrocodeine, long acting and Placebo dihydrocodeine short acting
9886738|NCT00547885|Active Comparator|2|Placebo dihydrocodeine, long acting and active dihydrocodeine short acting.
9886739|NCT00547937|Sham Comparator|Sham-CPAP|The sham CPAP device consisted of a conventional CPAP device, in which the area of the exhalation port was amplified, thereby nearly cancelling nasal pressure; an orifice resistor was connected between the tubing and the CPAP unit that loads the blower with the same airflow resistance as in effective CPAP
9886740|NCT00547937|Active Comparator|CPAP|
9886741|NCT00547950|Experimental|1|drug
9886742|NCT00547963|Experimental|1|two brief counseling sessions delivered to ED patients who report conjoint alcohol and marijuana use
9886743|NCT00547989|Active Comparator|1|control
9886744|NCT00547989|Experimental|2|PVB with ropivacaine and postoperative pump 5ml/h
9886745|NCT00547989|Experimental|Experimental 1|PVB with ropivacaine, 10 patients included but not analysed
9886746|NCT00548002||1 and 2|Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
9931650|NCT00940654||Patients with fever|
9931651|NCT00940654||Patients without any fever|
9931652|NCT00940667|Experimental|amlodipine/losartan 5/50mg|
9931653|NCT00940667|Active Comparator|amlodipine 5mg|
9931654|NCT00940680|Experimental|amlodipine/losartan 5/100mg|
9931655|NCT00940680|Active Comparator|losartan 100mg|
9931656|NCT00940693|Active Comparator|duloxetine|
9931657|NCT00940693|Placebo Comparator|placebo|
9931658|NCT00940706|Experimental|Physical activity in groups|Exercises of physical activity
9931659|NCT00940706|Experimental|Activity monitoring with accelerometers|Each subject will wear the accelerometer 24 hours a day for 4 days The activity will be recorded and analyzed
9931660|NCT00940706|Active Comparator|Treadmill|Treadmill with safety adaptations for handicapped persons
9931661|NCT00940719|Experimental|Vitamin D3|Patients receive 1dd 500ug vitamin D3 for 3 months
9931662|NCT00940732|Experimental|Destigmatisation and Mental Health Literacy|
9931663|NCT00940732|Experimental|Help-seeking list|
9931664|NCT00940732|Experimental|Feedback|
9931665|NCT00940732|No Intervention|Control|
9931666|NCT00940745|Experimental|Stereotactic Aspiration and Thrombolysis|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
9931667|NCT00940745|Active Comparator|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
9931668|NCT00940758|Experimental|PEP02|
9931669|NCT00940784|Experimental|Clopidogrel|Subjects will be randomized to clopidogrel (oral-75 mg per day) in addition to low dose aspirin and hydroxyurea
9931670|NCT00940784|Placebo Comparator|Placebo|Subjects will be randomized placebo in addition to low dose aspirin and hydroxyurea
9931671|NCT00940797|Experimental|DMMET-01|
9931672|NCT00940797|Placebo Comparator|Control|
9931673|NCT00940810|Experimental|PDD procedure|
9931674|NCT00940810|Active Comparator|Conservative Care|
9931675|NCT00940836|Active Comparator|Resfenol|"Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
9931676|NCT00940836|Placebo Comparator|Placebo|"Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
9931677|NCT00940849|Experimental|Dietary Supplement: Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
9931678|NCT00940862|Experimental|adalimumab|A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
9931679|NCT00940862|Active Comparator|Non-systemic treatment.|A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).
9931680|NCT00940914|Other|pain disorders|patients with Parkinson's disease presenting pain disorders
9931681|NCT00940914|Other|without pain disorders|patients with Parkinson's disease without pain disorders
9931682|NCT00940940|Experimental|Live attenuated herpes zoster vaccine|
9931683|NCT00940940|Placebo Comparator|Placebo|
9931684|NCT00940953|Experimental|Captisol-Enabled Budesonide + Azelastine|
9931685|NCT00940953|Active Comparator|Rhinocort Aqua+Astelin|
9931686|NCT00940953|Placebo Comparator|Placebo|
9931687|NCT00940966|Experimental|energy restricted very-low carbohydrate|non-energy restricted ketogenic diet .
9931688|NCT00940966|Active Comparator|ADA diet|standard ADA diet
9931689|NCT00940966|Active Comparator|low glycemic index|restricted ketogenic diet
9931690|NCT00940979|No Intervention|No use of integuseal|
9886747|NCT00548015|Active Comparator|State of the Art strategy|education, reminders, performance feedback,
9886748|NCT00548015|Experimental|extended strategy|state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
9886749|NCT00548054|Experimental|Vaccine Group for Vibriocidal Assay|Killed whole cell cholera vaccine bled at day 42 for vibriocidal assay
9886750|NCT00548054|Experimental|Vaccine Group for EPI Assay|Killed whole cell cholera vaccine bled at day 56 for EPI immunogenicity testing
9886751|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal Assay|Placebo bled at day 42 for vibriocidal assay
9886752|NCT00548054|Placebo Comparator|Placebo Group for EPI Assay|Placebo bled at day 56 for EPI immunogenicity testing
9886753|NCT00548054|Experimental|Vaccine Group for Vibriocidal and Measles Assay|Killed whole cell cholera vaccine bled at day 14 and 28 for measles immunogenicity testing
9886754|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal and Measles Assay|Placebo bled at day 14 and 28 for measles immunogenicity testing
9886755|NCT00548067|Active Comparator|1|
9886756|NCT00548067|Active Comparator|2|
9886757|NCT00548067|Active Comparator|3|
9886758|NCT00548067|Experimental|4|
9886759|NCT00548093|Experimental|1|descriptive: adenocarcinoma histology
9886760|NCT00548093|Experimental|2|descriptive: non-adenocarcinoma histology
9886761|NCT00548106|Experimental|1|Infants will be fed the new hydrolyzate formula.
9886762|NCT00548106|Placebo Comparator|2|Nan HA infant formula
9886763|NCT00548223|Experimental|Dengzhan Shengmai capsule|Dengzhan Shengmai capsule 0.18g by mouth twice a day for 1year
9886764|NCT00548223|Placebo Comparator|Placebo|Placebo 0.18g by mouth twice a day for 1year
9886765|NCT00548275|Experimental|1|Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
9886766|NCT00548275|Active Comparator|2|Standard Sexual Risk Management (SSRM): In SSRM, patients will attend two 10-minute gender non-specific individual educational sessions about HIV/AIDS provided by one of the study physicians who will be trained in HIV testing and risk counseling. Session 1 will coincide with the physician visit at the time of randomization. The patient will receive pre-test counseling at this time and undergo HIV antibody testing. Session 2 will take place 7 days later when the patient returns to receive their HIV test results and post-test counseling. In addition, subjects will receive didactic prevention messages about HIV relevant to their reported risks and will be asked if they have questions regarding this information.
9886767|NCT00548314|Experimental|1|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
9886768|NCT00548314|Experimental|2|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5.
9886769|NCT00548314|Experimental|3|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
9886770|NCT00548314|Active Comparator|4|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5.
9886771|NCT00548353|Experimental|1|MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
9886772|NCT00548353|Placebo Comparator|2|MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
9886773|NCT00548366|Experimental|1|4 gram sodium diet
9886774|NCT00548366|Active Comparator|2|2 gram sodium diet
9886775|NCT00548379|Active Comparator|1|Vitamin D
9886776|NCT00548379|Placebo Comparator|2|
9886777|NCT00548444|Experimental|Group 1|Volunteers will receive a single dose of MVA85A followed by regular blood tests to measure the resulting cellular immune response.
9886778|NCT00548444|Experimental|Group 2|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
9886779|NCT00548444|Experimental|Group 3|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
9886780|NCT00548457||A|
9886781|NCT00548483|Active Comparator|1|dexamethasone 5mg was administered every 6 hour for 1 day
9886782|NCT00548483|Active Comparator|2|dexamethasone 10mg was administered every 6 hour for 1 day
9886783|NCT00548496|Experimental|Placebo-Controlled based on the two Intervention Groups below|Placebo-Controlled based on the two Intervention Groups below.
9886784|NCT00548522||1|Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
9886785|NCT00548522||2|Pregnant women (34-38 wks gestation) with Type 1 diabetes
9886786|NCT00548522||3|Post partum women with Type 1 diabetes
9886787|NCT00548522||4|Non pregnant women with Type 1 diabetes
9886788|NCT00548600|Experimental|1|Iridium implant plus external beam irradiation
9886789|NCT00548600|Active Comparator|2|Standard external beam irradiation alone
9886790|NCT00548613|Experimental|A|Patients with documented acute myocardial infarction (heart attack) occurring within 4-24 hours after onset of symptoms
9886791|NCT00548613|Experimental|B|Candidates for coronary artery bypass grafting that suffered a myocardial infarction (heart attack) within the past 12 months
9886792|NCT00548626|Active Comparator|A|Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
9886793|NCT00548626|Experimental|B|Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
9886794|NCT00548639|Experimental|Statin Choice|Statin Choice Decision Aid The provider will introduce the patient to the choice of statins using the decision aid. The patient may make a choice then or defer this choice; in all cases, the patient goes home with the Statin Choice decision aid and pamphlet.
9886795|NCT00548639|Sham Comparator|Usual Care|Control Pamphlet the provider meets with the patient to discuss treatment options in the usual fashion.
9886796|NCT00548665|Experimental|1|Carotid plaque screening and brief advice for smoking cessation: Smokers with at least one carotid plaque will receive pictures of their own plaques with a structured explanation on the general significance of plaques.
9886797|NCT00548665|Active Comparator|2|Brief advice for smoking cessation (without carotid ultrasound for plaque screening): to ensure equal contact conditions, smokers not undergoing ultrasound will receive a relevant explanation on the risks associated with tobacco smoking.
9886798|NCT00548678|Experimental|A|intravenous diclofenac sodium
9886799|NCT00548678|Active Comparator|B|intravenous ketorolac
9886800|NCT00548678|Active Comparator|C|oral diclofenac (Cataflam)
9886801|NCT00548678|Active Comparator|D|oral aspirin
9886802|NCT00548730||Observation|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy
9886803|NCT00548743|Experimental|1|Intervention arm
9886804|NCT00548743|Placebo Comparator|2|Usual care
9886805|NCT00548756|Experimental|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy
9886806|NCT00548756|Other|Observation|Observation
9886807|NCT00548769|Experimental|Sequence ADBC|Subjects will be administered formulation A, formulation D, formulation B and formulation C across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
9886808|NCT00548769|Experimental|Sequence BACD|Subjects will be administered formulation B, formulation A, formulation C and formulation D across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
9886809|NCT00548769|Experimental|Sequence CBDA|Subjects will be administered formulation C, formulation B, formulation D and formulation A across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
9886810|NCT00548769|Experimental|Sequence DCAB|Subjects will be administered formulation D, formulation C, formulation A and formulation B across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
9886811|NCT00548782|Active Comparator|A|Subjects will be placed on Paleolithic diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. a paleolithic diet excludes dairy, grains, legumes and processed foods.
9886812|NCT00548782|Active Comparator|B|Subjects will be placed on ADA ( American Diabetes Association) recommended diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. An ADA diet is lower fat and more whole grains.
9886813|NCT00548821|Experimental|2|ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
9886814|NCT00548821|Experimental|1|ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
9886815|NCT00548899|Other|Sorafenib|Single Arm: All patients receive sorafenib in addition to the established chemotherapy
9886816|NCT00548951|Active Comparator|1|Subject receives Snoezelen sessions once per week.
9886817|NCT00548951|Active Comparator|2|Subject receives Snoezelen sessions three times per week.
9886818|NCT00548951|Other|3|Subject receives no sessions per week.
9886819|NCT00548964|Experimental|Ketamine + Lithium|All participants receive the study drug, IV ketamine, open-label
9886820|NCT00548964|Active Comparator|Ketamine + Placebo|All participants receive the study drug, IV ketamine, open-label
9886821|NCT00548990|Experimental|1|a 10-month moderate aerobic exercise training program
9886822|NCT00548990|Placebo Comparator|2|flexibility/balance control group
9886823|NCT00549016|Experimental|1|
9886824|NCT00549029||1,2|Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
9931691|NCT00940979|Experimental|Use of Integuseal|Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
9931692|NCT00941018|Experimental|SAD cohort 1|Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.
9931693|NCT00941018|Experimental|SAD cohort 2|SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.
9931694|NCT00941018|Experimental|MAD cohort 1|Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
9931695|NCT00941018|Experimental|MAD cohort 2|MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
9931696|NCT00941018|Experimental|MAD cohort 3|MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
9931697|NCT00941018|Experimental|MAD cohort 4|MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
9931698|NCT00941044|Experimental|non-invasive NAVA|application of non-invasive neurally adjusted ventilatory assist in healthy volunteers
9931699|NCT00941057|Experimental|Estradiol + dienogest + levomefolate|Treatment A
9931700|NCT00941057|Active Comparator|Estradiol + dienogest|Treatment B
9931701|NCT00941057|Active Comparator|Levomefolate|Treatment C
9931702|NCT00941083|Experimental|RAL QD 800 mg/24 hs|
9931703|NCT00941083|Active Comparator|RAL BID 400 mg/12 hs|
9931704|NCT00941083|Experimental|RAL BID to QD|
9931705|NCT00941109|Experimental|1|
9931706|NCT00941109|Experimental|2|
9931707|NCT00941109|Experimental|3|
9931708|NCT00941109|Experimental|4|
9931709|NCT00941122||MRSA/VRE patients|patients known to be colonized with MRSA/VRE
9931710|NCT00941148|Active Comparator|Insulin glargine|Insulin glargine, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
9931711|NCT00941148|Active Comparator|NPH Insulin|NPH Insulin, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
9931712|NCT00941148|Active Comparator|Insulin detemir|Insulin detemir, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
9931713|NCT00941161|Experimental|combination|long acting Metformin/Glimepiride
9931714|NCT00941161|Active Comparator|metformin|metformin hydrocloride
9931715|NCT00941161|Active Comparator|glimepiride|glimepiride
9931716|NCT00941174|Active Comparator|Capsule: 400 microg 13C5-Calcium-L-Leucovorin|
9931717|NCT00941174|Active Comparator|IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin|
9931718|NCT00941187||patients after a first episode of pulmonary embolism|
9931719|NCT00941200||Blood collection|
9931720|NCT00941213|Active Comparator|Monopolar Electrosurgery|Preparation during the operation with Monopolar Electrosurgery
9931721|NCT00941213|Experimental|Ultrasound scissors|Preparation during the operation with ultrasound scissors
9931722|NCT00941226||Cerebral Palsy|Those kids who have cerebral palsy and are helped by carers
9931723|NCT00941239|Experimental|metformin ER|Extended Release Metformin
9931724|NCT00941239|Active Comparator|metformin|Immediate release metformin
9931725|NCT00941252|Active Comparator|Imiquimod|topical therapy for 16 weeks with imiquimod containing therapy
9931726|NCT00941252|Placebo Comparator|Placebo|topical therapy for 16 weeks with a placebo containing vaginal suppository
9931727|NCT00941265|Other|levodopa 100 mg and benserazide 25 mg|2 weeks with Daily CAT on list A+ levodopa and benserazide
9931728|NCT00941265|Other|placebo|2 weeks with Daily CAT on list B + placebo.
9931729|NCT00941278|Experimental|PH-10 Treatment|
9931730|NCT00941291||vitrectomy in pseudophakic eyes|
9931731|NCT00941291||vitrectomy and cataract:combined procedure|
9886825|NCT00549081|Experimental|1|IVF patients who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
9886826|NCT00549081|No Intervention|2|IVF patient who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
9886827|NCT00549107|Experimental|1|
9886828|NCT00549107|Active Comparator|2|
9886829|NCT00549120|Experimental|Propranolol alone|Propranolol 80 mg (5 doses at 6 hourly intervals)
9886830|NCT00549120|Experimental|Propranolol + salbutamol|Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)
9886831|NCT00549120|Experimental|Salbutamol alone|Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)
9886832|NCT00549120|Placebo Comparator|Placebo|Placebo (5 doses at 6 hourly)
9886833|NCT00549120|Experimental|Propranolol + ipratropium + salbutamol|Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
9886834|NCT00549120|Experimental|Placebo + ipratropium + salbutamol|Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
9886835|NCT00549159|Experimental|Cavaterm|
9886836|NCT00549159|Active Comparator|TCRE|Transcervical resection of the endometrium
10211856|NCT03858322|Experimental|Carboplatin + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Carboplatin will be administered intravenously 3 times per cycle"
9886837|NCT00549237|Active Comparator|Nutrition|Pre-operative Glucose load and post-operative immediate enteral nutrition
9886838|NCT00549237|No Intervention|Control|No pre-operative glucose load. No early post-operative nutrition
9886839|NCT00549315|Experimental|1|
10211857|NCT03858322|Experimental|Cyclophosphamide + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Cyclophosphamide will be administered once per cycle"
10211858|NCT03847467|Experimental|2'-Fucosyllactose|"Phase I: 36 young adult participants aged 18-25 years. Group 1: 1 gm per day n=12 (6UC/6CD) Group 2: 5 gm per day n=12 (6UC/6CD) Group 3: 10 gm per day n=12 (6UC/6CD)~Phase II (post Phase I interim safety analysis): 120 participants aged 11-25 years Group 1: 1 gm per day n=40 (20UC/20CD) Group 2: 5 gm per day n=40 (20UC/20CD) Group 3: 10 gm per day n=40 (20UC/20CD)"
10211859|NCT03847467|Placebo Comparator|Placebo|"Phase I: 20 young adult participants age 18-25 years dosed at 2 gm placebo per day. (10UC/10CD)~Phase II (post Phase I interim safety analysis): 40 participants age 11-25 years dosed at 2 gm placebo per day. (20UC/20CD)"
10211860|NCT03833817|Experimental|Intervention arm|This study is a single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
9886840|NCT00549341|Active Comparator|1|
9886841|NCT00549341|Placebo Comparator|2|
10211861|NCT03826433|Experimental|Treatment Group|Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)
10211862|NCT03826433|No Intervention|Control Group|Control Group: Using basic contrast .
10211863|NCT03825354|Experimental|Brief Intervention and contact (BIC)|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
10211864|NCT03825354|No Intervention|control|control will continue treatment as usual which is whatever the clinical team decides upon post discharge. data will be collected on repeated suicidal behaviour through medical records with consent.
10211865|NCT03822637|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC coadministered with albuterol and delivered via nebulizer three times per day for fourteen days.
10211866|NCT03822637|Placebo Comparator|0.9% saline|Normal saline will be coadministered with albuterol as the placebo agent via a nebulizer three times per day for fourteen days.
10211867|NCT03802591|Experimental|CS1001 monoclonal antibody|in combination with Oxaliplatin and Capecitabine
10211868|NCT03802591|Placebo Comparator|CS1001 placebo|in combination with Oxaliplatin and Capecitabine
10211869|NCT03802565|Experimental|Tolperisone 50 mg|TID (150 mg/day)
10211870|NCT03802565|Experimental|Tolperisone 100 mg|TID (300 mg/day)
9886842|NCT00549367|Other|1|Clients in the control arm of the study will receive nutrition assessment only for the first 24 weeks and the be transferred to nutrition counselling group
9886843|NCT00549380|Experimental|1|
9886844|NCT00549406|Experimental|1|computer-based visual-training program UFOV
9886845|NCT00549406|Experimental|2|video-game based visual training
9886846|NCT00549406|Placebo Comparator|3|computerized word puzzles
9886847|NCT00549419|Experimental|1|In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
9886848|NCT00549419|Active Comparator|2|
9886849|NCT00549432|Experimental|1|
9886850|NCT00549471|Experimental|BG|cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment. BG children will be given Botulinum Toxin A, as clinically required, in addition to an equivalent program of intensive therapy
9886851|NCT00549471|No Intervention|Control Group|control group: Twenty cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment.CG children will undergo a program of intensive therapy.
9886852|NCT00549484||1|10 mL/kg platelet transfusion
9886853|NCT00549484||2|15 mL / kg platelet transfusion
9886854|NCT00549497|Other|GW870086X|
10211871|NCT03802565|Experimental|Tolperisone 150 mg|TID (450 mg/day)
9886855|NCT00549523|Placebo Comparator|Placebo|Placebo (capsule filled with inert materials)
9886856|NCT00549523|Experimental|Low Dose|400 mg bid Lessertia Frutescens
9886857|NCT00549523|Experimental|Mid Dose|800 mg bid Lessertia Frutescens
9886858|NCT00549523|Experimental|High Dose|1200 bid Lessertia Frutescens
9886859|NCT00549536|No Intervention|2|
9886860|NCT00549536|Active Comparator|1|Patients on calcium supplementation
9886861|NCT00549575|Experimental|A|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
9886862|NCT00549575|Placebo Comparator|B|After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
9886863|NCT00549614|Experimental|1|
9886864|NCT00549614|Placebo Comparator|2|
9886865|NCT00549666|Experimental|Lurasidone 40 mg|
9886866|NCT00549666|Placebo Comparator|Placebo|
9886867|NCT00549666|Active Comparator|Ortho Tri-Cyclen|
9886868|NCT00549692|Experimental|Omacor|
9886869|NCT00549692|Placebo Comparator|Placebo Omacor|
9886870|NCT00549731||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study."
9886871|NCT00549731||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
9886872|NCT00549796|Active Comparator|1|PCI performed at a hospital with co-located (on-site) cardiac surgery
9886873|NCT00549796|Other|2|PCI performed at a hospitals without co-located (on-site) cardiac surgery
9886874|NCT00549809|Active Comparator|IMV, SIMV|
9886875|NCT00549835|Active Comparator|Real Acupuncture|Participants will have acupuncture performed at a rate of 3 times (Mon, Wed, Fri) / week for total of 2 weeks (total of 6 sessions). We will follow Saam Acupuncture methods, which have been the mainstream of acupuncture methodology in most Korean Oriental Medical Colleges and among clinical practitioners >400 years. Standardized acupuncture prescriptions for mucositis will be acupuncture points tonifying Spleen Meridian (R side) and Small Intestine Meridian (L side). In Oriental Medicine, the spleen has functions of promoting water metabolism, transporting nutrients, and controlling blood. Mouth belongs to the spleen system according to Five element theory. Small intestine is related with mucositis symptoms including thirst and tongue ulcers. We will use sterile, disposable, filiform needles, size 0.16 (40Gauge) - 0.30 mm (30Gauge) in diameter and 15-40 mm long. Total number of acupuncture needles will be 8 (4 needles each side) and needles will be retained for 20 minutes.
9886876|NCT00549835|Sham Comparator|Sham Acupuncture|Newly diagnosed leukemia patients will be recruited from the large patient population on the Leukemia Inpatient Services who will be receiving high dose preperative regimens such as Busulfan + Cytarabine for marrow transplantation.
9886877|NCT00549861|No Intervention|A1|CMR study for the assessment of irreversible tissue damage
9886878|NCT00549874|Experimental|1|
9886879|NCT00549874|Experimental|2|
9886880|NCT00549887||Rapid acting to short acting|Patients on rapid-acting analog insulins who switch to short-acting human insulin
9886881|NCT00549887||Short acting to rapid acting|Patients on short-acting human insulins who switch to rapid-acting analog insulin
9886882|NCT00549913|Experimental|1|10 subjects to receive lowest dose of NeoFuse (MPCs)
9886883|NCT00549913|Active Comparator|2|4 subjects standard posterolateral spinal fusion with instrumentation
9886884|NCT00549913|Experimental|3|10 subjects to receive middle dose of NeoFuse
9886885|NCT00549913|Active Comparator|4|3 subjects standard posterolateral spinal fusion with instrumentation
9886886|NCT00549913|Experimental|5|10 subjects to receive highest dose of NeoFuse
9886887|NCT00549913|Active Comparator|6|3 subjects with standard posterolateral spinal fusion with instrumentation
9886888|NCT00549926|Active Comparator|1|
9886889|NCT00549926|Active Comparator|2|
9886890|NCT00549926|Active Comparator|3|
9886891|NCT00549926|Active Comparator|4|
9886892|NCT00550004|Active Comparator|Arm 1|RP101 and Gemcitabine
9886893|NCT00550004|Placebo Comparator|Arm 2|Placebo and Gemcitabine
9886894|NCT00550030|Experimental|left/right|half-body comparison
9886895|NCT00550056|Experimental|1|NET
9886896|NCT00550056|Experimental|2|TC
9886897|NCT00550056|No Intervention|3|Monitoring Group
9886898|NCT00550095|Experimental|1|valsartan
9886899|NCT00550108|No Intervention|A|Observation of pancreatic cysts
9886900|NCT00550108|Experimental|B|Ethanol lavage of pancreatic cysts
9886901|NCT00550121|Experimental|1|
9886902|NCT00550121|Placebo Comparator|2|
9931732|NCT00941291||vitrectomy followed by cataract extraction|
9931733|NCT00941291||vitrectomy on phakic eyes|
9931734|NCT00941343|Experimental|1|XATRAL 10mg OD
9886903|NCT00550160|Active Comparator|1|The Home Management of Malaria (HMM) is a strategy aimed at improving access to prompt and effective antimalarial treatment of all fevers in children under 5 years. Community Drug Distributors (CDD) have been trained and equipped for this task.
9886904|NCT00550160|Experimental|2|An Intermittent Preventive Treatment (IPTc) schedule for asymptomatic pre-school children during high malaria transmission seasons alongside an ongoing Home Management of Malaria programme
9886905|NCT00550186|Placebo Comparator|1|No preload
9886906|NCT00550186|Active Comparator|2|Preload with cristalloid infusion
9886907|NCT00550186|Active Comparator|3|Preload with collid infusion
9886908|NCT00550199|Experimental|LBH589 and Gemcitabine|Phase I dose escalation study
9886909|NCT00550212|Experimental|1|240 mg
9886910|NCT00550225|Experimental|Sequence 1|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
9886911|NCT00550225|Experimental|Sequence 2|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
9886912|NCT00550225|Experimental|Sequence 3|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
9886913|NCT00550225|Experimental|Sequence 4|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
9886914|NCT00550225|Experimental|Sequence 5|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
9886915|NCT00550225|Experimental|Sequence 6|In session 1, subjects will receive placebo followed by 900 micrograms of GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
9886916|NCT00550225|Experimental|Sequence 7|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
10211872|NCT03802565|Experimental|Tolperisone 200 mg|TID (600 mg/day)
10211873|NCT03802565|Placebo Comparator|Placebo|TID
9886917|NCT00550225|Experimental|Sequence 8|In session 1, subjects will receive placebo followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
9886918|NCT00550251|Active Comparator|Acupressure Bands|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
9886919|NCT00550251|Placebo Comparator|Placebo|Elasticated wrist bands without active bead.
9886920|NCT00550264|Experimental|1|
9886921|NCT00550264|No Intervention|2|
9886922|NCT00550342|Experimental|Rituximab|Rituximab (375 mg/m2) will be administered intravenously as per current package label in a facility capable of handling infusion reactions. Subjects would be pre dosed with diphenhydramine and acetaminophen. Solu-Medrol, 1.5 mg/kg would be dosed 1 hour prior to the first dose of rituximab. Three subsequent doses of rituximab will be given at weekly intervals.
9886923|NCT00550355|Experimental|1|
9886924|NCT00550355|Experimental|2|
9886925|NCT00550355|Experimental|3|
9886926|NCT00550355|Placebo Comparator|4|
9886927|NCT00550381|Placebo Comparator|1|10mg
9886928|NCT00550381|Placebo Comparator|2|20mg
9886929|NCT00550381|Placebo Comparator|3|40mg
9886930|NCT00550381|Placebo Comparator|4|80mg
9886931|NCT00550381|Placebo Comparator|5|160mg
10211874|NCT03790683|Experimental|EnsoETM + Standard of Care|Participants receive esophageal warming in addition to standard of care surface warming from the time they enter the OR until released to the PACU.
10211875|NCT03790683|Active Comparator|Standard of Care|Participants receive standard of care surface warming from the time they enter the OR until released to the PACU.
10211876|NCT03787173|No Intervention|Manual standard ventilator settings|Inspiratory trigger set at 2 l/min, Expiratory trigger set at 25% of peak inspiratory flow
10211877|NCT03787173|Active Comparator|Manual optimized ventilator settings|Inspiratory trigger and Expiratory trigger settings optimized by investigator
10211878|NCT03787173|Experimental|Automated ventilator settings|Inspiratory trigger and Expiratory trigger settings automatized
10211879|NCT03786432|Experimental|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
10211880|NCT03783234||Older Adult Patients|ED patients age of ≥ 75 who have nurse assessed Clinical Frailty Scale ≥ 4.
10211881|NCT03780452||Tibiotalocalcaneal arthrodesis with DynaNail|Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
10211882|NCT03769194|Active Comparator|VLA15 low dose|VLA15 low dose with Alum.
10211883|NCT03769194|Active Comparator|VLA15 medium dose|VLA15 medium dose with Alum.
10211884|NCT03769194|Active Comparator|VLA15 high dose|VLA15 high dose with Alum.
10211885|NCT03769194|Placebo Comparator|Placebo|
10211886|NCT03763422|Experimental|Early Treatment arm|Radiotherapy + Temozolomide
10211887|NCT03763422|Active Comparator|Active surveillance arm|Treatment as per local practice
10211888|NCT03752307|Experimental|Corticosteroid & Isoxsuprine HCL|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive days and Isoxsuprine Hydrochloride one 10 mg Capsule 3 times daily for 5 consecutive days
10211889|NCT03752307|Placebo Comparator|Corticosteroid & Placebo|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive day and placebo one Capsule 3 times daily for 5 consecutive days
9886932|NCT00550381|Placebo Comparator|6|240mg
9886933|NCT00550381|Placebo Comparator|7|400mg
9886934|NCT00550381|Placebo Comparator|8|640mg
9886935|NCT00550381|Placebo Comparator|9|960mg
9886936|NCT00550381|Placebo Comparator|10|placebo
9886937|NCT00550472|Experimental|Probiotic|intervention
9886938|NCT00550485|Other|1|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype A)
9886939|NCT00550485|Other|2|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype B)
9886940|NCT00550498|Experimental|A|Behcet's Disease with ocular lesions
9886941|NCT00550511|Other|Ultrasound|Surgeon-performed ultrasound as intervention, as a complement to clinical investigation and standardized laboratory testing.
9886942|NCT00550511|No Intervention|Control|Control group examined with clinical examination including standardized laboratory tests.
9886943|NCT00550524|Experimental|A|Knee osteoarthritis
9886944|NCT00550563|Experimental|Oral Cholecalciferol|Patients receive oral cholecalciferol 2000 IU once daily for 1 year
9886945|NCT00550576|Experimental|digibind|Injection of digibind and psychological tests
9886946|NCT00550628||resection of a non-sarcomatous primary colon neoplasm|The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.
9886947|NCT00550641|Active Comparator|1|
9886948|NCT00550641|Experimental|2|
9886949|NCT00550693|Placebo Comparator|A|The patients in this arm continued with the local catheter care protocol.
9886950|NCT00550706||1Pediatric Dept A|Children's files from this department will be analysed once weekly and medication prescription data will be registered
9886951|NCT00550706||2 Pediatric Dept B|Children's files from this department will be analysed once weekly and medication prescription data will be registered
9886952|NCT00550797|Experimental|No.1 ASM8 (oligonucleotide)|TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation
9886953|NCT00550797|Placebo Comparator|Phosphate Buffer solution|Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation
9886954|NCT00550823|Experimental|A,1|
9886955|NCT00550849|Experimental|1|RTA 402
9886956|NCT00550849|Experimental|2|RTA 402
9886957|NCT00550849|Experimental|3|RTA 402
9886958|NCT00550875|Experimental|1|
9886959|NCT00550875|Experimental|2|10* concentration of arm 1
9886960|NCT00550875|Placebo Comparator|3|
9886961|NCT00550914||Control arm|The conventional therapy arm will undergo debridement with either a powered microdebrider or cold instrumentation excision as per the preference of the individual surgeon. Debridement will be deemed complete after removal of gross papilloma to the extent that the individual surgeon feels can be safely accomplished. Standard microsurgical principles of the larynx will guide debridement in that no opposing mucosal surfaces of the true vocal folds, laryngeal ventricle or inter-arytenoid space will be simultaneously debrided
9886962|NCT00550914||Experimental Arm|Patients enrolled into the conventional therapy plus PDL treatment arm will undergo debridement of the supraglottis and subglottis via conventional techniques as per the individual surgeons preferences followed by therapy to anterior commissure, true vocal folds, laryngeal ventricle and inter-arytenoid space with the pulsed dye laser. Standard laser settings will be a 450 microsecond pulse width, 5 J per pulse maximum of 1Hz, 1 mm spot fiber, 1-2 mm spot size and fluences of 38-255 J/cm2.
9886963|NCT00550966|Active Comparator|1|"Randomized controlled trial with a 12-month follow-up involving two groups, one of which is the intervention group that includes patients receiving a psychoeducative program and the other is the control group formed by patients treated for FM in the usual way.~Setting. Three urban PC centers in the province of Barcelona (Spain) Sample. The total sample comprises 218 patients (over 18 years of age) suffering FM, selected from a database (Rheumatology service-Viladecans hospital) of patients with this illness. Only those patients introduced in the database between the years 2005 and 2007 are included in the selection. Selected patients are asked for written informed consent to participate in the study."
9886964|NCT00550979||1|Black women with history of pregnancy/ies complicated by gestational diabetes mellitus
9886965|NCT00550979||2|Black women with history of normal, uncomplicated pregnancy/ies
9886966|NCT00550979||3|White women with a history of pregnancy/ies complicated by gestational diabetes.
9886967|NCT00550979||4|White women with a history of normal, uncomplicated pregnancy/ies.
9886968|NCT00551018|Experimental|Vicriviroc + Reyataz + ritonavir|vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
9886969|NCT00551018|Active Comparator|Truvada® + Reyataz + ritonavir|Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
9886970|NCT00551044|Active Comparator|Bicalutamide|Osteoporotic patients (T score ≤ -2.5) on bicalutamide
9931735|NCT00941356|Experimental|1|Bio-K+ CL1285 contains 50 billion of live bacteria
9931736|NCT00941356|Placebo Comparator|2|placebo devoid of bacteria
9931737|NCT00941369|Experimental|1|Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen
9931738|NCT00941369|Active Comparator|2|Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen
9935512|NCT03588286|Experimental|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length <200ms) are discharged without an ICD.~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
9935513|NCT03588286|Active Comparator|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
9935514|NCT03581318|Other|1|MRI
9935515|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
9935516|NCT03575221||Enrollees|Individuals with Osteogenesis Imperfecta
9935517|NCT03571022|Experimental|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
9935518|NCT03570892|Experimental|Tisagenlecleucel treatment strategy|Patients will receive investigator's choice of optional platinum-based immunochemotherapy followed by lymphodepleting chemotherapy and a single dose of tisagenlecleucel
9935519|NCT03570892|Active Comparator|Standard of care treatment strategy|Patients will receive investigator's choice of platinum-based immunochemotherapy followed in responding patients by high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
10211890|NCT03747328|Experimental|ABI-009|nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))
9935520|NCT03563482|Experimental|Experimental|Biopsy and PET scan
9935521|NCT03559192|Placebo Comparator|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
9935522|NCT03559192|Experimental|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
9935523|NCT03559192|Placebo Comparator|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
9935524|NCT03554473|Experimental|Arm A/M7824 Monotherapy|M7824 (IV) monotherapy once every 21 days on a 21-day cycle. If patients have progressive disease on arm A, they may receive combination therapy of M7824 and Temozolomide.
9935525|NCT03554473|Experimental|Arm B/M7824 plus topotecan|M7824 (IV) on day 1 plus topotecan (IV) on days 1-5 of a 21-day cycle. At least 6 subjects to receive M7824 plus topotecan to determine safety. 4 more patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 subjects enrolled.
9935526|NCT03554473|Experimental|Arm C/M7824 plus temozolomide|M7824 (IV) days 1 and 15 plus temozolomide (oral) on days 1-5 of a 28-day cycle. At least 6 subjects with SCLC to receive M7824 plus temozolomide to determine safety. 4 more SCLC patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 SCLC subjects enrolled. After the 6 safety SCLC cohort, subjects with extrapulmonary small cell cancers will be enrolled.
9935527|NCT03554382|Experimental|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
9935528|NCT03554382|No Intervention|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
9935529|NCT03549715|Experimental|ARM A: durvalumab + ddMVAC|Durvalumab + ddMVAC Durvalumab 1500 mg IV D1 every 28 days Durvalumab will be administered at the hospital every 28 days prior to administration of ddMVAC on D1.
10211891|NCT03740334|Experimental|Ribociclib (RIBO) + Dexamethasone (DEX)|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15"
9886971|NCT00551083|Experimental|CDSS-D|Computer Decision Support System for Depression (CDSS-D) - This arm provided physicians with a computerized treatment algorithm and a decision support system to treat their patients suffering Major Depressive Disorder
9886972|NCT00551083|Active Comparator|UC|Usual Care (UC) - This group of physicians treated their patients suffering from Major Depressive Disorder with their standard treatment as usual, and received no algorithm support with regard to treatment decisions
9886973|NCT00551096|Experimental|Gemcitabine, capecitabine and ZD6474|"Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.~Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off .~ZD6474 administered orally at 300 mg/day once daily. One cycle will consist of 28 days."
9886974|NCT00551109|Placebo Comparator|P|Placebo
9886975|NCT00551109|Experimental|A1|SA4503
9886976|NCT00551109|Experimental|A2|SA4503
9886977|NCT00551122|Experimental|Paclitaxel, gemcitabine, cisplatin, ifosfamide|"Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.~If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.~Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.~MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF."
9886978|NCT00551187|Experimental|1|V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
9886979|NCT00551187|Placebo Comparator|2|Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
9886980|NCT00551226||1|Patients with tuberculosis
9886981|NCT00551226||2|Healthy controls
9886982|NCT00551239|Active Comparator|Arm I (control)|Patients receive rituximab IV on day 1 and fludarabine phosphate IV on days 2-4. Treatment repeats every 28 days for up to 6 courses.
9886983|NCT00551239|Experimental|Arm II|Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
9886984|NCT00551252|Experimental|I|
9886985|NCT00551265|Experimental|Arm I|Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.
9886986|NCT00551265|Active Comparator|Arm II|Patients undergo DTH skin testing and receive oregovomab as in arm I.
9886987|NCT00551278||1|Patients with previous diagnosis of breast cancer scheduled for sentinel lymph node dissection.
9886988|NCT00551330|Experimental|1|Vicriviroc 30 mg QD
9886989|NCT00551330|Placebo Comparator|2|Placebo
9886990|NCT00551343|Other|PWS|
9886991|NCT00551343|Other|Controls|
9886992|NCT00551356|Active Comparator|2|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
9886993|NCT00551356|Active Comparator|1|Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.
9886994|NCT00551382|Experimental|A|
9886995|NCT00551382|Placebo Comparator|B|
9886996|NCT00551395|Experimental|SLT Early Completion (Arm 1)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degree on Day 2
9886997|NCT00551395|Active Comparator|SLT Late Completion (Arm 2)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degrees at 1 month follow up appointment.
9886998|NCT00551408||A|20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization able to walk >50 m during a standardized 6-min walk test.
9886999|NCT00551434|Experimental|1|
9887000|NCT00551434|Experimental|2|
9887001|NCT00551434|Experimental|3|
9887002|NCT00551434|Placebo Comparator|4|
9887003|NCT00551486||1|Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy
9887004|NCT00551499|No Intervention|CRT for patients with CSA|Patients suffering from HF with central Sleep Apnea (CSA) programmed to DDD/45 (CRT) for 12 weeks. Intervention is CRT.
9887005|NCT00551499|Active Comparator|CRT + AOP for patients with CSA|Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
9887006|NCT00551512|Experimental|CBP501 and Cisplatin|Dose escalation study
9887007|NCT00551538|Active Comparator|1|Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
9887008|NCT00551538|Active Comparator|2|Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.
9887009|NCT00551551|Experimental|Rééducation|Standardized pelvic floor muscle training program with a physiotherapist in 8 sessions (20-30 minutes each) between 24 and 36 weeks of gestation AND Written instructions about personal (Kegel) pelvic floor exercises
9887010|NCT00551551|Active Comparator|Control|Written instructions about personal (Kegel) pelvic floor exercises
9887011|NCT00551564|Experimental|Subjects in healthy normal and overweight control arm|Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
9887012|NCT00551564|Experimental|Subjects in healthy obese with T2DM arm|Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
9887013|NCT00551577|Active Comparator|A1|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
9887014|NCT00551577|Experimental|A2|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
9887015|NCT00551590|Placebo Comparator|1|placebo PO (placebo control for sitagliptin) for three days. Saline IV (placebo control for exendin(9-39) on two consecutive study days.
9887016|NCT00551590|Experimental|2|Sitagliptin 100 mg PO for three days. Saline IV (placebo control for exendin(9-39)) on two consecutive study days
9887017|NCT00551590|Experimental|3|Sitagliptin 100 mg PO for three days. Exendin(9-39) IV on two consecutive study days.
9887018|NCT00551590|Placebo Comparator|4|placebo PO (placebo control for sitagliptin) for three days. Exendin(9-39)IV on two consecutive study days.
9887019|NCT00551603|Experimental|1|Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
9887020|NCT00551603|Active Comparator|2|Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
9887021|NCT00551629|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
9887022|NCT00551629|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
9887023|NCT00551629|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
9887024|NCT00551629|Experimental|PR51 (6, 15)|Participants were vaccinated with 0.5 ml of PR51 (6, 15) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
9887025|NCT00551668|Experimental|1|Operative
9887026|NCT00551668|Experimental|2|Nonoperative
9887027|NCT00551681|Active Comparator|1|Epicardial left ventricular lead placement
9887028|NCT00551681|Active Comparator|2|transvenous left ventricular lead
9887029|NCT00551720|Experimental|Standard Care|
9887030|NCT00551720|Experimental|Motivational Enhancement|
9887031|NCT00551733|Experimental|Arm I|Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9887032|NCT00551733|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9887033|NCT00551785||1|Women prescribed Intrinsa and estrogen therapy
9887034|NCT00551785||2|Women prescribed estrogen therapy
9887035|NCT00551811|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive single doses of placebo in period 1, SB-656933-AAA with a dose of 50 milligrams in period 2 and 150 milligrams in period 3.
9887036|NCT00551811|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, placebo in period 2 and SB-656933-AAA 150 milligrams in period 3.
9931739|NCT00941382|Experimental|Sibutramin-Metformin|Sibutramine-metformin therapy in a single tablet
9667066|NCT03999710|Experimental|Non-Small Cell Lung Cancer|All participants have locally-advanced non-small cell lung cancer, Stage II-III. Treatment will consist of durvalumab administered concurrently with thoracic radiation consisting of 60 Gy in 30 fractions. Patients will be monitored weekly during on-treatment visits. Durvalumab will then be continued up to 1 year as maintenance or until disease progression or unacceptable toxicity. Optional Research MRIs (Does not apply to the Alliance Sites. Research MRIs will only be done at MSKCC)
9887037|NCT00551811|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, 150 milligrams in period 2 and placebo in period 3.
9887038|NCT00551824|Experimental|1|"First dilation session with topical mitomycin applied over esophageal mucosa after dilation.~Second dilation session (after 14 days): standard dilation without topical mitomycin."
9887039|NCT00551824|Experimental|2|"First dilation session: standard dilation without topical mitomycin.~Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation."
9887040|NCT00551850|Experimental|1|
9887041|NCT00551863|Active Comparator|IVPT|Intervention based on Motivational Interviewing and CBT
9887042|NCT00551902|Experimental|1|Trabeculectomy with anterior chamber infusion system
9887043|NCT00551902|Active Comparator|2|Trabeculectomy without anterior chamber infusion system
9887044|NCT00551915|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
9887045|NCT00551915|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
9887046|NCT00551915|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
9887047|NCT00551915|Active Comparator|PENTACEL™ + RECOMBIVAX HB™|Participants were vaccinated with 0.5 ml each of PENTACEL™ + RECOMBIVAX HB™ via intramuscular injection as a primary series at 2, 4, and 6 months of age, and with 0.5 ml PENTACEL™ as a booster at 12 to 14 months of age.
9887048|NCT00551941|Active Comparator|2|non-union of diaphysary tibial fractures will be treated with allograft together with DBM
9887049|NCT00551941|Experimental|1|non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft
9887050|NCT00551954|Experimental|1|20 weeks of treatment with acarbose (100 mg t.i.d.)
9887051|NCT00551954|Placebo Comparator|2|20 weeks of treatment with placebo (one tablet t.i.d.)
9887052|NCT00551967|Active Comparator|E1 polyethylene|All patients received an E1 polyethylene liner which is the material being monitored in this study.
9887053|NCT00551980|Experimental|Cognitive and physical program|Randomized group of workers of the same institution ( City of Turin, Italy).
9887054|NCT00551980|No Intervention|Control group|Randomized group of workers of the same institution ( City of Turin, Italy).
9887055|NCT00551993|Active Comparator|2|Robotic Sacral Colpopexy
9887056|NCT00551993|Active Comparator|1|Laparoscopic Sacral Colpopexy
9887057|NCT00552006|Experimental|NET|
9887058|NCT00552006|Active Comparator|AC|
9887059|NCT00552006|No Intervention|WL|Waiting list
9887060|NCT00552045||subject|individuals with epilepsy
9887061|NCT00552149|Active Comparator|1|GEMOX
9887062|NCT00552149|Experimental|2|GEMOX + CETUXIMAB
9887063|NCT00552162|Active Comparator|1|NOTES Transvaginal cholecystectomy The gallbladder will be dissected free and will be removed through an incision in the vagina.
9887064|NCT00552162|Active Comparator|2|NOTES Transvaginal Appendectomy. The appendix will be dissected free and will be removed through an incision in the vagina.
9887065|NCT00552214|Other|Human Blood Donor Plasma Specimens|
9887066|NCT00552227|Experimental|1|
9887067|NCT00552227|Placebo Comparator|2|
9887068|NCT00552253|Experimental|1|under eltroxin
9887069|NCT00552331|Active Comparator|LISS|Treatment of distal femur fracture with less invasive stabilization system
9887070|NCT00552331|Active Comparator|Standard Treatment|Treatment of distal femoral fractures using locking condylar plates or dynamic condylar screws
9990247|NCT01441583|Active Comparator|RYTHMIQ Off at Pre-discharge, On at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ Off at Pre-Discharge will have RYTHMIQ programmed Off until their 1-month follow up, when they will be crossed over to RYTHMIQ On until their 3-month follow up.
9990248|NCT01441583|Active Comparator|RYTHMIQ On at Pre-Discharge, Off at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ On at Pre-Discharge will have RYTHMIQ programmed On until their 1-month follow up, when they will be crossed over to RYTHMIQ Off until their 3-month follow up.
9990249|NCT01441609||the value of anti-HBs =0 mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
9990250|NCT01441609||the value of anti-HBs≤5mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
9990251|NCT01441609||5mIU≤anti-HBs≤10mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
9990252|NCT01441609||anti-HBs≥1000mIU|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
9990253|NCT01441622|Experimental|AL539|Device AL539
9990254|NCT01441648||experimental group|(1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3) previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria includes: (1) subjects with previous Rigid Gas Permeable (RGP) wear (2) any ocular inflammation or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.
9990255|NCT01441661||Sunitinib Renal Cell Carcinoma|Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
9990256|NCT01441674|Experimental|Animal Assisted Therapy Visit 1|Standard OT Therapy with Animal Assisted Therapy at Visit 1 and Not at Visit 2
9990257|NCT01441674|Experimental|Animal Assisted Therapy at Visit 2|Standard OT Therapy with Animal Assisted Therapy at Visit 2 and not Visit 1
9990258|NCT01441700|Active Comparator|Prone position|
9990259|NCT01441700|Active Comparator|Supine position|
9990260|NCT01441713||Pharmaceutical group|Patients in pharmaceutical castration treatment for advanced prostate cancer
9667067|NCT03998839||Intervention|Children tested will live within an area targeted for community IPTp distribution for pregnant women.
9887071|NCT00552435|Experimental|1|Micropulse 810nm diode laser
9887072|NCT00552435|Active Comparator|2|Argon laser photocoagulation
9887073|NCT00552461|Experimental|1|
9887074|NCT00552487|Other|1|healthy people without Hashimoto disease receive a 1µg ACTH stimulation test
9887075|NCT00552487|Other|2|patients with Hashimoto disease with well being receive a 1 µg ACTH stimulation test
9887076|NCT00552487|Other|3|patients with Hashimoto disease an impaired well-being receive a 1 µg ACTH stimulation test
9887077|NCT00552487|Other|4|patients with Hashimoto disease and negative TPO antibodies receive a 1µg ACTH stimulation test
9887078|NCT00552500|Active Comparator|Schizophrenics|i) meets DSM-IV criteria for schizophrenia, any type, treated with atypical or high potency typical neuroleptics for at least 3 months; ii) aged 18 to 60 years; iii) able to give informed consent; iv) no antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.
9887079|NCT00552526|Active Comparator|Ketogenic diet|
9887080|NCT00552526|Active Comparator|AED|Most appropriate antiepileptic drug
9887081|NCT00552539|Experimental|1|pre test survey, educational video, post test survey
9887082|NCT00552539|No Intervention|2|no intervention
9887083|NCT00552539|Experimental|3|educational video and post test survey
9887084|NCT00552539|No Intervention|4|post test survey
9887085|NCT00552552|Experimental|1|
9887086|NCT00552552|Other|2|waiting control group
9887087|NCT00552565|Placebo Comparator|1|
9887088|NCT00552565|Experimental|2|
9887089|NCT00552565|Experimental|Rezular 37.5mg|
9887090|NCT00552565|Experimental|Rezular - 75mg|
9887091|NCT00552604|Experimental|1|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
9887092|NCT00552604|Placebo Comparator|2|matching placebo capsules, twice daily
9887093|NCT00552630|Experimental|1|This group will receive d-penicillamine for 6 weeks
9887094|NCT00552630|Placebo Comparator|2|This group will receive placebo for 6 weeks
9887095|NCT00552643|Experimental|1|Treatment with Polyheal 1
9887096|NCT00552643|Active Comparator|2|Saline
9887097|NCT00552656||1|the group of patients with angiographic results of complex coronary lesions(refer to the definition of protocol)are enrolled and given a clinical follow up and angiographic follow up during the following one year.
9887098|NCT00552682|Experimental|A|Duloxetine 60 mg, 1 tablet/day
9887099|NCT00552682|No Intervention|B|To continue with the antidepressive treatment if exist
9887100|NCT00552721|Experimental|A|Physical therapy with strength training.
9887101|NCT00552721|Active Comparator|B|Physical therapy without strength training.
9887102|NCT00552734||Control|The other half of the patients were randomized to the control group who were followed for their routine diabetes care and had to visit the clinic on the same schedule as the experimental group.
9887103|NCT00552734||Experimental|Half of the subjects were randomized to this group using insulin guidance software on a PDA to adjust their insulin dose at home based on the prescription provided by the provider.
9887104|NCT00552747|Active Comparator|1|fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day
9887105|NCT00552747|Placebo Comparator|2|placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day
9887106|NCT00552773|Experimental|Cyclamen Europaeum|
9887107|NCT00552773|Placebo Comparator|Placebo|
9887108|NCT00552799|Experimental|1|Penicillin VK 250 mg b.d.
9887109|NCT00552799|Placebo Comparator|2|placebo tablet b.d.
9887110|NCT00552825||1|all were in a single group
9931740|NCT00941382|Active Comparator|Sibutramine|Sibutramine monotherapy
9887111|NCT00552838|No Intervention|A|Physicians in this arm did not have any intervention with the AUT. Antimicrobial prescriptions were based on hospital guidelines or on the physician's medical knowledge.
9887112|NCT00552851|Other|Pegvisomant|patients with active acromegaly and impaired cardiac function
9887113|NCT00552864|Active Comparator|R|
9887114|NCT00552864|Active Comparator|L|
9887115|NCT00552877|Active Comparator|1|Cypher Select plus stent
9887116|NCT00552877|Active Comparator|2|Xience V stent
9887117|NCT00552890|Experimental|ATK|modified Atkins diet
9887118|NCT00552890|Experimental|ADA|subjects assigned to follow ADA recommended diet for 1 year
9887119|NCT00552903|Experimental|1|Active intervention - personal health coaching provided
9887120|NCT00552903|No Intervention|2|Control arm - no intervention, data on health outcomes collected at baseline (entry to the study) and during the 12 month follow-up
9887121|NCT00552916|Other|1|Participants will be randomized to either an intervention arm where they will receive 'true' FES and the other control arm where they will receive 'false' FES. The sham group will receive 'false' FES.
9887122|NCT00552916|Other|2|The intervention group will receive 'true' FES
9887123|NCT00552942|Experimental|1|surgery plus omentectomy
9887124|NCT00552942|No Intervention|2|standard gastric bypass
9887125|NCT00552981|Active Comparator|1|
9887126|NCT00552981|Sham Comparator|2|
9887127|NCT00552994|Active Comparator|1|Cypher Select plus stent
9887128|NCT00552994|Active Comparator|2|Xience V stent
9931741|NCT00941382|Active Comparator|Metformin|Metformin monotherapy
9931742|NCT00941395|Experimental|Arm I (smoker, survey)|Participants who currently smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2. Participants also complete 3 internet surveys over 20 minutes.
9931743|NCT00941395|Experimental|Arm II (non-smoker, survey)|Participants who currently do not smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2.
10211892|NCT03740334|Experimental|RIBO + Everolimus (EVE) + DEX|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days"
10211893|NCT03740334|Experimental|RIBO + EVE+ DEX (dose expansion)|"Ribociclib administered daily for 21 consecutive days. Dosing at RDE~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days. Dosing at RDE"
10211894|NCT03738332|Other|Low-level laser therapy|Single arm
10211895|NCT03734653|Experimental|Square Wave Testosterone Therapy + SOC|All patients will receive transdermal testosterone. All patients will also receive standard of care enzalutamide. Patients will alternate between the two therapies.
10211896|NCT03720795|Other|Stepped Care CBT|Stepped Care CBT consists of two main steps. Step One involves 4 parent-led, therapist-assisted treatment sessions, up to 45 minutes each, over an 8-week period. Participants who do not show significant improvement in symptom severity at the end of Step One, are then 'stepped up' to receive Step Two, which involves 12 weekly, therapist-led, parent-assisted treatment sessions, up to 60 minutes each.
9990261|NCT01441713||Surgical group|Patients having undergone surgical castration treatment for advanced prostate cancer
9990262|NCT01441726||Training of staff|
10211897|NCT03695406|Experimental|Mind-Body Group Intervention|
10211898|NCT03692312|Experimental|Tideglusib|Weight adjusted tideglusib, orally, once daily
10211899|NCT03692312|Placebo Comparator|Placebo|Matching placebo, orally, once daily
10211900|NCT03684343|Other|Atopic Dermatitis patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
10211901|NCT03684343|Other|Healthy patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
10211902|NCT03637556|Experimental|DST-0509|DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets. DST-0509 is taken once daily with food; the first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
10211903|NCT03637556|Active Comparator|Jadenu|Jadenu is commercially available as tablets and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. Jadenu is taken once daily with or without a light meal. However, Jadenu can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
9931744|NCT00941408||Diagnostic tumor core biopsy|
9931745|NCT00941421|Other|videocapsul and OGDFE|Each patient have a Fiberoptic endoscopy by videocapsul, followed by one traditional oeso-gastro-duodenal fiberoptic endoscopy
9931746|NCT00941434|Experimental|RUTF|Children with Severe malnutrition will be treated with Ready to use therapeutic food (RUTF) till their weight for age z scores are no longer in severe malnutrition group
9931747|NCT00941447|Experimental|Self-Regulation|Self Regulation Arm focuses on increasing participants self-monitoring blood glucose (SMBG) AND awareness of self-regulatory approaches to managing diabetes.
9931748|NCT00941447|Experimental|Self-Monitoring|Self-Monitoring Arm focuses on increasing participants self-monitoring blood glucose (SMBG) and providing nutrition education ONLY.
9931749|NCT00941460|Experimental|one week on one week off|One week on temozolomide is followed by a week without temozolomide.
9931750|NCT00941460|Experimental|three weeks on, one week off|Temozolomide is given over 3 weeks, followed by a week without temozolomide.
9931751|NCT00941473|Active Comparator|Epidural Steriod Injection|This study focuses on the changes in bone mineral density over time of the cohort previously described in the inclusion criteria (post-menopausal white women)
9931752|NCT00941499|Experimental|Group 1|HAI oxaliplatin in combination with HAI 5-fluorouracil and IV bevacizumab
9931753|NCT00941499|Experimental|Group 2|HAI oxaliplatin in combination with IV 5-fluorouracil, leucovorin, bevacizumab, and cetuximab
9931754|NCT00941499|Experimental|Group 3|HAI oxaliplatin in combination with IV bevacizumab.
9931755|NCT00941499|Experimental|Group 4|HAI oxaliplatin in combination with IV bevacizumab and cetuximab.
9667068|NCT03998839||Control|Children tested will live within an area NOT targeted for C-IPTp, but will live in an area nearby.
9887129|NCT00553033||A|
9887130|NCT00553046||family burden|chronich respiratory failure home ventilated patients
9887131|NCT00553072|Active Comparator|Magnesium sulphate, neurological outcome|Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
9887132|NCT00553072|Placebo Comparator|Placebo|Placebo every 24 hours for 3 doses starting from 6 hours after birth
9887133|NCT00553085||Anx group|
9887134|NCT00553085||ADHD group|
9887135|NCT00553085||Nonanx/nonadhd group|
9887136|NCT00553111|Experimental|1|pre survey, intervention, post test survey
9887137|NCT00553111|No Intervention|2|pre test survey and post test survey
9887138|NCT00553111|Experimental|3|video intervention and post test survey
9887139|NCT00553111|No Intervention|4|post test survey
9887140|NCT00553137|Active Comparator|1|single dose fluconazole (750 mg) and placebos 150 mg tablets once daily for 14 days
9887141|NCT00553137|Active Comparator|2|150 mg fluconazole once daily for 14 days and placebos (5 placebos tablets) 750 mg once
9887142|NCT00553176||Patients with Crohn's disease|The Registry is an observational research program featuring clinical, economic, and humanistic measures characterizing the treatment of Crohn's disease
9887143|NCT00553228|Experimental|group I|Tdap
9887144|NCT00553228|Active Comparator|group 2|Td
9887145|NCT00553241||1|"Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China~Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour."
9887146|NCT00553293|Active Comparator|A,1|rFSH + rLH arm
9887147|NCT00553293|Placebo Comparator|A,2|rFSH alone
9887148|NCT00553397||Live Lung Donors|Participants had a living donor lobectomy at one of the two participating study centers, the University of Southern California and the Washington University Medical Center between 1993 and 2006.
9887149|NCT00553423|Experimental|1|Lactulose 30 ml q6h for 48 hrs
9887150|NCT00553423|Placebo Comparator|2|Placebo 30 ml q6 hrly for 48hrs
9887151|NCT00553488|Active Comparator|1|Regular insulin SC at -17 mins
9887152|NCT00553488|Active Comparator|2|Regular insulin ID at -17 mins
9887153|NCT00553488|Active Comparator|3|Regular insulin ID at -2 mins
9887154|NCT00553488|Active Comparator|4|Insulin lispro given SC at -2 mins
9887155|NCT00553488|Experimental|5|Insulin lispro given ID at -2 mins
9887156|NCT00553527|Other|1|Patient will receive standard of care humeral stem replacement. Only a data collection study. There will be no changes in standard of care for diagnosis.
9887157|NCT00553553|Active Comparator|1|IV morphine group
9887158|NCT00553553|Experimental|2|Remifentanil-intrathecal morphine group
9887159|NCT00553579||DE|All subjects will have clinically significant dry eye.
9887160|NCT00553592|Experimental|Drug|Bicifadine
9887161|NCT00553592|Experimental|Drug: 2|Bicifadine
9887162|NCT00553592|Placebo Comparator|Control|Placebo of Bicifadine
9887163|NCT00553618|Experimental|Proleukin/DTIC Arm|Adjucant proleukin and DTIC
9887164|NCT00553670||1|Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement
9887165|NCT00553683|Experimental|poly ICLC|
9887166|NCT00553709|Experimental|Nicotine patch|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
9887167|NCT00553709|Placebo Comparator|Placebo patch|Placebo patch 10 cm2
9887168|NCT00553722|Experimental|Eplerenone|Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
9887169|NCT00553722|Placebo Comparator|placebo|Administer a placebo tablet orally twice daily for 4 weeks
9887170|NCT00553748|Experimental|I|
9887171|NCT00553774|Experimental|Flavanol|Cocoa Flavanol
9990263|NCT01441726||No training of staff|
9887172|NCT00553774|Placebo Comparator|Placebo|
9887173|NCT00553800|Experimental|Bevacizumab & Erlotinib|bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
9990264|NCT01441739||NEC suspected - Final diagnosis NEC|
9990265|NCT01441739||NEC suspected - Final diagnosis no NEC|
9990266|NCT01441739||Controls|
9990267|NCT01441752|Experimental|Chemotherapy + TCM group|"The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.~Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number."
9990268|NCT01441752|Placebo Comparator|Chemotherapy + placebo group|The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
9990269|NCT01441778|Active Comparator|NSS irrigation salt|
9990270|NCT01441778|Experimental|BHS nasal irrigaiton salt|
9990271|NCT01441791|Experimental|Lung protective strategy ventilation|Lung protective strategy ventilation: PEEP at 12 cmH2O, Recruitment maneuvers (after intubation, after any disconnection from the mechanical ventilator, directly before detubation)
9990272|NCT01441791|No Intervention|Conventional Strategy|"PEEP at maximum 2 cmH2O, if possible 0 cmH2O~No recruitment maneuvers Patients are randomized and intra-operatively ventilated with conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers)."
9990273|NCT01441804|Experimental|24-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
9990274|NCT01441804|Active Comparator|48-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
9990275|NCT01441817|Other|Surgery|
9990276|NCT01441830|Sham Comparator|sham rESWT|
9990277|NCT01441830|Active Comparator|rESWT|
9990278|NCT01441856|Active Comparator|Open or Laparocopic Left|Open or Laparoscopic left hemihepatectomy
9990279|NCT01441856|Active Comparator|Open or Laparoscopic Right|Open or Laparoscopic right hemihepatectomy
9990280|NCT01441856|Active Comparator|Prospective registry|Prospective registry of patients that cannot be randomized (both open and laparoscopic left + right hemihepatectomy)
9990281|NCT01441869|Experimental|A|5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet
9990282|NCT01441869|Experimental|B|5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet
9990283|NCT01441869|Experimental|C|5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet
9990284|NCT01441869|Experimental|D|5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet
9990285|NCT01441908|No Intervention|Control Group|Control Group
9990286|NCT01441908|Active Comparator|Statin|Receiving Statin
9990287|NCT01441921|Active Comparator|Control diet|Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)
9990288|NCT01441921|Experimental|Pistachio diet|Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)
9990289|NCT01441934|Active Comparator|Sildenafil citrate|20 mg t.i.d.
9990290|NCT01441934|Placebo Comparator|Sugar pill|
9990291|NCT01441947|Experimental|Cabozantinib plus fulvestrant|Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)
9990292|NCT01441999|Active Comparator|Less rigid rods|Titanium rods that have a soft, plastic end
9990293|NCT01441999|Active Comparator|Rigid Rods|Titanium rods
9990294|NCT01442012|Active Comparator|Group A|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Pericardium 6, Heart 7 and Stomach 25
9990295|NCT01442012|Sham Comparator|Group B|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Gall Bladder 34, Kidney 6 and Liver 3
9990296|NCT01442025|Placebo Comparator|Cohort 1 =Control Group|the dose of IFX will be increased by 5 mg/kg (maximally 1 time) based on symptom relapse (usual clinical practice) Dose will be kept stable ofr the rest of the trial Dose decreases will not be allowed.
9990297|NCT01442025|Active Comparator|Cohort 2|Dose of IFX will be increased by 2.5 mg/kg (maximally 2 times) if the following criteria are met A dose increase is maintained for the following infusions
9667069|NCT03995641|No Intervention|Surgery Alone|Patient will receive sacrospinous ligament suspension surgery without any additional interventions
9887174|NCT00553852|Experimental|1|The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
9887175|NCT00553852|Placebo Comparator|2|PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).
9887176|NCT00553865|Experimental|Group 1|OJP-2028 1mg/day
9887177|NCT00553865|Experimental|Group 2|OJP-2028 2mg/day
9887178|NCT00553865|Experimental|Group 3|OJP-2028 4mg/day
9887179|NCT00553865|Placebo Comparator|Group 4|Placebo
9887180|NCT00553865|Other|Group 5|Reference drug
9887181|NCT00553878|Placebo Comparator|dutasteride|
9887182|NCT00553917||1|Pregnant women currently taking Prozac for the treatment of depression
9887183|NCT00553917||2|Pregnant women currently taking Zoloft for the treatment of depression
9887184|NCT00553917||3|Pregnant women not currently using medication for the treatment of depression
9887185|NCT00553917||4|Pregnant women with no history of, symptoms of, or treatment for depression
9887186|NCT00553930|Experimental|G 2/3|Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.
9887187|NCT00553943|Experimental|Rituximab + Cytarabine|
9887188|NCT00553956|Experimental|1|Intervention group A treatment combination of Narrative Exposure Therapy and Interpersonal Psychotherapy (5 individual sessions NET in addition to 3 individual sessions IPT)
9887189|NCT00553956|No Intervention|2|Waiting list control
9887190|NCT00553982|Experimental|1|Patellar resurfacing
9887191|NCT00553982|Active Comparator|2|Patellar retention
9887192|NCT00553995|Experimental|Salsalate|Salsalate
9887193|NCT00553995|Placebo Comparator|Placebo|Placebo
9887194|NCT00554008|Active Comparator|1|children randomized to open appendectomy
9887195|NCT00554008|Active Comparator|2|children randomized to laparoscopic appendectomy
9887196|NCT00554021||1|Department of Traumatology and Critical Care Medicine, National Defense Medical College
9887197|NCT00554047|Experimental|1|Multidisciplinary Memory Clinic
9887198|NCT00554047|Active Comparator|2|General practitioner
9887199|NCT00554112|Active Comparator|1|Exercise
9887200|NCT00554112|Active Comparator|2|Exercise
9887201|NCT00554112|No Intervention|3|Control
9887202|NCT00554125|Active Comparator|2, III ,intervention|
9887203|NCT00554138|Placebo Comparator|1|
9887204|NCT00554138|Experimental|2|
9887205|NCT00554164|Active Comparator|B1|Six cycles of the (R-)CHOP regimen.
9887206|NCT00554164|Experimental|B2|Six blocks of the B-ALL protocol.
9887207|NCT00554164|Active Comparator|A1|Four cycles of the (R-)CHOP regimen.
9887208|NCT00554164|Active Comparator|A2|Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.
9887209|NCT00554177|Experimental|1|Medicane (mifepristone)
10211904|NCT03637556|Active Comparator|Exjade|Exjade is commercially available as tablets and Exjade as tablets for oral suspension and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. If converting from Exjade, the dose will be scaled for each treatment by 28 mg/40 mg (treatment/Exjade). Jadenu and Exjade are taken once daily, Jadenu is taken with or without a light meal, and Exjade is recommended to be taken without food. However, either Jadenu or Exjade can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
10211905|NCT03633786|Other|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
10211906|NCT03633786|Other|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
10211907|NCT03627897|Experimental|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
10211908|NCT03627897|Other|Control group|
10211909|NCT03618186|Experimental|Normal control|Cognitively normal volunteers
10211910|NCT03618186|Experimental|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
10211911|NCT03618186|Experimental|Demented|Patient's that meet dementia criteria
10211912|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
10211913|NCT03610815|Experimental|mSBIRT|Mobile Screening, Brief Intervention, Referral to Treatment (mSBIRT)
9887210|NCT00554177|Placebo Comparator|2|Placebo
9887211|NCT00554268|Experimental|PBI-05204|PBI-05204 starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle.
9887212|NCT00554281|No Intervention|A|Run in period
9887213|NCT00554281|Experimental|B|
9887214|NCT00554307||Indo|Infants that are treated with indomethacin
9887215|NCT00554307||Neo|Infants treated with neoprofen
9887216|NCT00554307||Control|Infants without PDA
9990298|NCT01442025|Active Comparator|Cohort 3|Dose of IFX will be increased by 5 mg/kg (maximally 1 time) if the following criteria are met A dose increase is maintained for the following infusions
9667070|NCT03995641|Experimental|Surgery Plus Trigger Point Injection|Patient will have sacrospinous ligament suspension procedure with addition of a trigger point injection (9cc of 0.5% marcaine and 1 cc kenalog) over area of suture placement
9667071|NCT03992235|Experimental|Study Group|Chest physiotherapy + educational material
9667072|NCT03992235|Other|Control group|Chest physiotherapy
9887217|NCT00554320|Active Comparator|A|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
9887218|NCT00554320|Placebo Comparator|C|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
9887219|NCT00554333|Experimental|1|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
9887220|NCT00554333|Active Comparator|2|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
9887221|NCT00554346|Active Comparator|1|Etoricoxib 90mg
9887222|NCT00554346|Placebo Comparator|2|placebo
9887223|NCT00554359|Experimental|I5NP drug|
9887224|NCT00554359|Placebo Comparator|Placebo|
9887225|NCT00554398|Experimental|A|MK-0518 400mg twice a day
9887226|NCT00554398|No Intervention|B|No intervention
9887227|NCT00554424|Active Comparator|LA|Intravaginal and pre-peritoneal injection of 1% lignocaine into each side of the upper vagina under ultrasound guidance immediately prior to ultrasound guided transvaginal oocyte retrieval
9887228|NCT00554424|Placebo Comparator|P|Intravaginal saline placebo injection into each side of upper vagina under ultrasound guidance immediately prior to transvaginal oocyte retrieval
9887229|NCT00554437|Experimental|1|Intermediate-intensity, community-based, multifactorial falls intervention
9887230|NCT00554437|Active Comparator|2|Occupational therapist home safety evaluation
9887231|NCT00554450|Experimental|Arm 1|50 mg single dose
9887232|NCT00554450|Experimental|Arm 2|20 mg up to 7 days
9887233|NCT00554502|Active Comparator|A|
9887234|NCT00554502|Active Comparator|B|
9887235|NCT00554528|Other|A|patient receiving cervical disc prosthesis with a mobile insert named Mobi-C and product by LDR médical
9887236|NCT00554528|Other|B|patient receiving intersomatic cage
9887237|NCT00554541||Normal Body-Mass|BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
9887238|NCT00554541||Obese Body-Mass|BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
9887239|NCT00554541||Morbidly Obese Body-Mass|BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study
9887240|NCT00554567|Experimental|Intervention Arm|Fully Decentralized HIV Testing and Care Services
9887241|NCT00554580|Active Comparator|A|Usual care of pulmonary acute oedema
9887242|NCT00554580|Experimental|B|CPAP + usual care of pulmonary acute oedema
9887243|NCT00554606|Experimental|Canakinumab|Participants received one single dose of 600 mg canakinumab via intravenous infusion on Day 1 and thereafter every 6 weeks until completion of the 54-week treatment period.
9887244|NCT00554632|Active Comparator|1|Use of transdermal hormonal contraceptive
9887245|NCT00554632|Active Comparator|2|Use of oral hormonal contraceptive
9887246|NCT00554645|Experimental|1|Multi-disciplinary group intervention
9887247|NCT00554645|Active Comparator|2|traditional information
9887248|NCT00554658|Active Comparator|A|Patients will be taken quetiapine for the treatment of first episode schizophrenia.
9887249|NCT00554697||1|
9887250|NCT00554697||2|
9887251|NCT00554710|Experimental|1|Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
9931756|NCT00941525|Other|Ocular hypertensives|"This study includes two groups.~Subjects with ocular hypertension and~Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment."
9931757|NCT00941538||Screening, Control|
9931758|NCT00941551||Group A|receiving levothyroxine postoperatively
9931759|NCT00941551||Group B|not-receiving levothyroxine postoperatively
9887252|NCT00554710|Active Comparator|2|Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
9887253|NCT00554723|Experimental|A|NeuroAid
9887254|NCT00554723|Placebo Comparator|B|NeuroAid matched Placebo
9887255|NCT00554736|Experimental|1|In the first phase, subjects with a history of grass pollinosis, with positive skin tests to grass, will be studied out of season and will be randomized to active treatment for 4 months.
9887256|NCT00554775|Experimental|erlotinib hydrochloride|WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
9887257|NCT00554775|Placebo Comparator|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm
9887258|NCT00554814|Experimental|3|Blédilait Biofer® milk (1,1mg/100kcal)
9887259|NCT00554814|Experimental|1|Blédilait Biofer® milk (2mg/100kcal)
9887260|NCT00554814|Active Comparator|2|Milk supplemented with ferrous sulphate (2mg/100kcal)
9887261|NCT00554827|Experimental|Pralatrexate Injection (FOLOTYN,PDX,Pralatrexate(R|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
9887262|NCT00554866|Experimental|VLBW between 6 and12 hours after birth|"Blood sample and buccal swab sample. One blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
9887263|NCT00554879|Experimental|1|Acupuncture
9887264|NCT00554879|Sham Comparator|2|Sham Acupuncture
9887265|NCT00554892|Active Comparator|1|Bowel preparation
9887266|NCT00554892|Experimental|2|without bowel preparation
9887267|NCT00554905|Experimental|1|TACE first, then RFA within 2 weeks
9887268|NCT00554905|Active Comparator|2|RFA alone
9887269|NCT00554957||NBC|All dancers with the National Ballet of Canada will be given the opportunity to participate in the study.
9887270|NCT00554957||TDT|All dancers with the Toronto Dance Theatre will be given the opportunity to participate.
9887271|NCT00554957||KDC|All members of the Kibbutz Contemporary Dance company will be given the opportunity to participate.
9887272|NCT00554957||BDC|All dancers with the Batsheva Dance Company or Ensemble will be given the opportunity to participate.
9887273|NCT00554957||RSB|All dancers with the Royal Swedish Ballet will be given the opportunity to participate.
9887274|NCT00554957||RDB|All dancers with the Royal Danish Ballet will be given the opportunity to participate.
9887275|NCT00554983|Placebo Comparator|2|
9887276|NCT00554983|Experimental|1|
9931760|NCT00941564|Experimental|Commercially available infant formula A|Varying fat blend from comparator product
9931761|NCT00941564|Active Comparator|Commercially available infant formula B|
9931762|NCT00941577|Experimental|AIR645|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
9931763|NCT00941577|Placebo Comparator|Physiologic saline solution|Physiologic saline solution
9931764|NCT00941590||Patients with tick borne encephalitis.|
9931765|NCT00941616|Experimental|PK|Includes subjects participating in the pharmacokinetic component of the study.
9931766|NCT00941616|Experimental|Prophylaxis|Includes subjects receiving 12 months of prophylactic therapy.
9931767|NCT00941616|Experimental|On-demand|Includes subjects receiving 12 months of on-demand treatment.
9931768|NCT00941616|Experimental|Cross-over to prophylaxis|"Includes subjects completing 12 months of on-demand treatment (the On-demand arm) who cross-over to prophylactic therapy for an additional 12-month period."
9887277|NCT00555009|Experimental|Genotropin treatment arm|
9887278|NCT00555009|Placebo Comparator|Placebo|
9887279|NCT00555022|Experimental|All subjects|Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide
9887280|NCT00555074|Experimental|1|Sodium Tungstate
9887281|NCT00555074|Placebo Comparator|2|
9887282|NCT00555087|Experimental|A= Nebido|It is and intervention study with 1 arm
9887283|NCT00555113||1|pseudoxanthoma elasticum
9887284|NCT00555126|Active Comparator|Warming with Forced Air|Forced Air Warming
9887285|NCT00555126|Experimental|Endovascular Warming|Warming with Endovascular Catheter
9887286|NCT00555139|Experimental|GW876008|The subjects will be randomized to one of the six sequences A/B/D A/D/B B/A/D B/D/A D/A/B D/B/A across three treatment periods where A represents placebo, B represents GW876008 and D represents alprazolam.
9887287|NCT00555139|Experimental|GSK561679|The subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
9887288|NCT00555165|Experimental|I|
9887289|NCT00555178||1|Patients with polymorphic light eruption without medical photohardening treatment
9887290|NCT00555178||2|Patients with polymorphic light eruption treated with medical photohardening
9887291|NCT00555178||3|Patients with other disorders (including psoriasis) treated with phototherapy
9887292|NCT00555178||4|Normal healthy subjects
9887293|NCT00555191|Active Comparator|1|PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSE REDUCED DIET FOR A PERIOD OF 3 MONTHS
9887294|NCT00555191|No Intervention|2|these patients use their usual diet
9667073|NCT03991949|Experimental|Experimental Infant Formula|Ready-to-feed, milk-based formula
9887295|NCT00555230|Experimental|1|Rosuvastatin
9887296|NCT00555230|Placebo Comparator|2|Placebo
9887297|NCT00555243|Experimental|1|Laparoscopic Simulation Education
9887298|NCT00555243|Placebo Comparator|2|
9887299|NCT00555256|Experimental|1|Patients will be instructed to take sunitinib and rapamycin every morning for 4 weeks, then to take 2 weeks off. The sunitinib dose will be 25mg in the first cohort and the rapamycin dose will be 2 mg.
9887300|NCT00555269||MB|
9887301|NCT00555269||IFCG|
9887302|NCT00555282|Experimental|1|coated central venous catheter
9887303|NCT00555282|Active Comparator|2|standard central venous catheter
9887304|NCT00555308|Experimental|one|undergo EDTU
9887305|NCT00555334|Experimental|1|nucleoid antiviral therapy after RFA
9887306|NCT00555334|Active Comparator|2|RFA only
9887307|NCT00555347|Active Comparator|Armnodafinil|Armodafinil
9887308|NCT00555347|Placebo Comparator|Placebo|
9887309|NCT00555373|Other|Sirolimus|Single arm
9887310|NCT00555386|Active Comparator|1|6g of chocolate (supplemented with selenium and isoflavones) per day for the duration of one menstrual cycle (25-35 days)
9887311|NCT00555386|Placebo Comparator|2|6g of chocolate (control) per day for the duration of one menstrual cycle (25-35 days)
10211914|NCT03610815|Active Comparator|SBIRT-CTS),|Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision strategy
9887312|NCT00555399|Experimental|Ph I: Arm 1|Vorinostat plus isotretinoin
9887313|NCT00555399|Experimental|Ph I: Arm 2|Temozolomide plus isotretinoin
9887314|NCT00555399|Experimental|Ph I: Arm 3|Vorinostat plus isotretinoin plus temozolomide
9887315|NCT00555399|No Intervention|Ph II: Arm 1|Non-Surgical
9887316|NCT00555399|Other|Ph II: Arm 2|Surgical Arm
9887317|NCT00555412|Experimental|A - 10 mg loxapine q 4 h x 3 (30 mg total)|
9887318|NCT00555412|Experimental|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|
9887319|NCT00555412|Experimental|C - 5 mg loxapine q 4 h x 3 (15 mg total)|
9887320|NCT00555412|Placebo Comparator|D - inhaled placebo q 4 h x 3|
9887321|NCT00555490|Experimental|1|
9887322|NCT00555503||1|Patients who have risk-reduction mastectomy of any type, per protocol inclusion and exclusion criteria.
9887323|NCT00555516|Active Comparator|1|"The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle~Group 1 will receive EW02 for 15 consecutive days during the second cycle~will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle."
9887324|NCT00555516|Placebo Comparator|2|"The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle~Group 2 will receive 15 consecutive days of Placebo~Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle"
9887325|NCT00555529||1|
9887326|NCT00555529||2|
9887327|NCT00555542|Experimental|1|Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15.
9887328|NCT00555555|Experimental|Coagulation FVIII/VWF|Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT
9887329|NCT00555594|Active Comparator|A|Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
9887330|NCT00555594|Active Comparator|B|Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.
9887331|NCT00555607|Active Comparator|steroid|Group receiving oral prednisolone (0.5 mg/kg bodyweight per day) during 14 days.
9931769|NCT00941629|Active Comparator|Cognitive Processing Therapy FTF|Cognitive Processing Therapy delivered in traditional face-to-face sessions (FTF)
10211915|NCT03603184|Experimental|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
9800231|NCT01682837|Experimental|KMgCit, Placebo, KCit, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9887332|NCT00555607|Placebo Comparator|placebo|Group receiving placebo tablets during 14 days, followed by an open prednisolone treatment (0.5 mg/kg bodyweight per day) during a following 14 days.
9887333|NCT00555685|Active Comparator|A|Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
9800232|NCT01682837|Experimental|KMgCit, Placebo, KCl, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9887334|NCT00555685|Placebo Comparator|B|Group of patients that will receive placebo
9887335|NCT00555698|Experimental|DBS|DBS
9887336|NCT00555711||Modulated Imaging|Modulated Imaging
9887337|NCT00555724|Experimental|BIIB022|
9887338|NCT00555763|Active Comparator|1|
9887339|NCT00555776|Active Comparator|1|Randomly,half of the subjects are given Gabapentin.
9887340|NCT00555776|Placebo Comparator|2|Randomly,half of the subjects receive placebo.
9887341|NCT00555815||1|Extended hygiene measures
9887342|NCT00555815||2|Standard hygiene measures
9887343|NCT00555828|Experimental|A1|5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
9887344|NCT00555828|Other|A2|5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
9887345|NCT00555828|Experimental|B1|5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
9887346|NCT00555828|Other|B2|3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
9887347|NCT00555828|Experimental|C1|5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
9887348|NCT00555828|Other|C2|2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
9887349|NCT00555841|Experimental|ALC|I g three times daily
9887350|NCT00555841|Placebo Comparator|Placebo|1 g three times daily
9887351|NCT00555867||1|Standard routine care for breast cancer
9887352|NCT00555867||2|Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
9887353|NCT00555919|Experimental|Arm 1|
9887354|NCT00555919|Experimental|Arm 2|
9887355|NCT00555932|Active Comparator|1|The research head ultrasound (HUS) will be performed at the bedside in the Neonatal Unit. The ultrasound examination will be performed within 10 hours time window of the MR and or CT study.
9887356|NCT00555945|Active Comparator|1|Gamma3 intramedullary nail
9887357|NCT00555945|Active Comparator|2|Sliding hip screw
9887358|NCT00555958|Experimental|A|All study subjects will be implanted with the Maestro System, and all will receive VBLOC therapy.
9887359|NCT00555984|Active Comparator|Total Intravenous anesthetic|Intravenous anesthetics (propofol + remifentanil) for maintenance of General Anesthesia
9887360|NCT00555984|Active Comparator|Volatile Anesthetic|Inhalational anesthetics (sevoflurane+remifentanil) for maintenance of General Anesthesia. Patients receive Sevoflurane as a volatile anesthetic and remifentanil as an IV agent for maintenance of general anesthesia.
9887361|NCT00556023|Experimental|CP-675,206 and gemcitabine|
9887362|NCT00556036||1|lean healthy women, age 18-45
9887363|NCT00556036||2|overweight healthy women, age 18-45
9887364|NCT00556036||3|women with hypothalamic amenorrhea (have not had a period in three months), age 18-45
9887365|NCT00556036||4|women with anorexia nervosa, age 18-45
9887366|NCT00556062|Experimental|1: Lot 1|
9887367|NCT00556062|Experimental|2: Lot 2|
9887368|NCT00556062|Experimental|3: Lot 3|
9887369|NCT00556062|Active Comparator|4: control vaccine|
9887370|NCT00556088|Experimental|Part 1|"Part I Phase I dose escalation trial. LBH589 will be administered orally on Monday and Thursday or Tuesday and Friday each week (twice weekly). Paclitaxel and carboplatin will be administered intravenously every 21 days.~Part II LBH589, paclitaxel, and carboplatin dosing will be determined in the first phase of this study (Phase I). The drug dosages to be administered will be reduced one level from the determined Maximum Tolerated Dose (MTD). In addition, bevacizumab 15 mg/kg will be added to the second portion of this trial."
9887371|NCT00556114||Optical Coherence Tomography|Optical Coherence Tomography
9887372|NCT00556127|Experimental|1|
9887373|NCT00556153||Phase I|Children, ages 5-15 years with brain tumors
9887374|NCT00556179|Experimental|1|
9887375|NCT00556192|Active Comparator|1|Rituximab
9887376|NCT00556192|Active Comparator|2|Rituximab + Cyclophosphamide
9887377|NCT00556192|Active Comparator|3|Cyclophosphamide
9887378|NCT00556205|Active Comparator|1|Bevacizumab monotherapy 10 mg/kg IV q2 weeks
9887379|NCT00556205|Active Comparator|2|Combination Sunitinib & Bevacizumab Bevacizumab 10 mg/kg IV q2 weeks Sunitinib 50 mg PO QD on 4/2 schedule
9887380|NCT00556218|Other|Tibetan Meditation|
9887381|NCT00556218|Other|No Meditation|
9887382|NCT00556231||1|Children with congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
9887383|NCT00556231||2|Children without congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
9887384|NCT00556231||3|
9887385|NCT00556231||4|
9887386|NCT00556231||5|
9887387|NCT00556231||6|
9887388|NCT00556244|Active Comparator|2|
9887389|NCT00556257|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications.
9887390|NCT00556257|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive select standard of care medications.
9887391|NCT00556270||Matrix II|
9887392|NCT00556283|Experimental|1|STARR
9887393|NCT00556283|Active Comparator|2|Biofeedback
9887394|NCT00556296|Experimental|1|
9887395|NCT00556296|Experimental|2|
9887396|NCT00556296|Experimental|3|
9887397|NCT00556296|Placebo Comparator|4|
9887398|NCT00556309||Diagnostic Tool|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
9887399|NCT00556335|Experimental|manual aspiration|manual aspiration
9887400|NCT00556335|Active Comparator|conventional drainage|conventional drainage
9887401|NCT00556348|Experimental|1|
9887402|NCT00556361|Placebo Comparator|1|
9887403|NCT00556361|Experimental|2|
9887404|NCT00556387|Placebo Comparator|1|Placebo Group receiving Saline Infusion.
9887405|NCT00556387|Experimental|2|Case Group receiving Ketamine infusion.
9887406|NCT00556413|Experimental|ERBIRINOX|5FU + Irinotecan + Oxaliplatine + Cetuximab
9887407|NCT00556465|Experimental|A, 1,III|in this arm patients took 1200 mg N-acetylcysteine
9887408|NCT00556465|No Intervention|B,2, III|
9887409|NCT00556569|Experimental|Intervention|2 Intervention schools are cluster randomized to receive CHAM JAM (previously known as the Moving Smart Program) in Year 1
9887410|NCT00556569|No Intervention|Wait-Listed Control|2 Wait-Listed Control Schools will receive CHAM JAM (previously known as the Moving Smart Program) in Year 2 of the study
9887411|NCT00556595|Experimental|1|primary electrophysiological approach
9887412|NCT00556595|Active Comparator|2|primary anatomical approach
9887413|NCT00556608|Experimental|Sinovial|3 intra-articular injections of Sinovial®
9887414|NCT00556608|Active Comparator|Sinvisc|
9887415|NCT00556621|Other|gemcitabine, cisplatine, radiotherapy|
9887416|NCT00556634|Active Comparator|B|
9887417|NCT00556634|Experimental|A|
9887418|NCT00556647||A|Fast-track diagnosis
9887419|NCT00556660|Experimental|1|SPECT imaging
9887420|NCT00556686||1|Individuals with a history of canker sores.
9887421|NCT00556686||2|Individuals with no history of canker sores.
9887422|NCT00556699|Experimental|1|
9887423|NCT00556738|Experimental|nHFPV|Intrapulmonary Percussive Ventilation
9887424|NCT00556738|Active Comparator|nCPAP|Nasal Continuous Positive Airway Pressure ventilation
9887425|NCT00556764|Experimental|2 cohorts|"In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers.~A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the [123I] IBVM and SPECT imaging portion of this study"
9887426|NCT00556790|Other|1|Standard Care
9887427|NCT00556790|Other|2|Fast Track Care
9887428|NCT00556803|Experimental|1|TACE after RFA within one month as an adjuvant therapy
9887429|NCT00556803|Active Comparator|2|RFA alone
9887430|NCT00556816|Active Comparator|Conventional outpatient clinic|Conventional outpatient clinic
9887431|NCT00556816|Experimental|On demand outpatient clinic|On demand outpatient clinic
9887432|NCT00556855|Experimental|A|applied on one hand
9887433|NCT00556855|Placebo Comparator|B|applied on the other hand
9887434|NCT00556868|Experimental|A|Breakfast on the first day of intervention, fasting (no breakfast) on the second day of intervention
9887435|NCT00556868|Experimental|B|Fasting (no breakfast) on the first day of intervention, breakfast on the second day of intervention
9887436|NCT00556907|Other|1|Patients will receive IORT
9931770|NCT00941629|Experimental|Cognitive Processing Therapy TMH|Cognitive Processing Therapy delivered over videoconferencing equipment to a distant location (or telemental health; TMH)
9931771|NCT00941642|Active Comparator|Lovaza|Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
9990299|NCT01442051|Experimental|Acute Normovolemic Hemodilution|A pilot study will be performed. Intraoperative data including vital signs, procedures performed, and transfusions of allogenic blood will be collected prospectively. Postoperative outcomes, including transfusions of allogenic blood, perioperative complications, and 30-day mortality will be collected prospectively. These outcomes will be compared to historical controls to assess for the safety and efficacy of ANH in ovarian cancer cytoreductive surgery.
9990300|NCT01442077|Active Comparator|arm 1|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments.
9990301|NCT01442077|Active Comparator|arm 2|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
9990302|NCT01442077|Active Comparator|arm 3|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
9990303|NCT01442077|Active Comparator|arm 4|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
9990304|NCT01442116|Experimental|Hypertensives|
9990305|NCT01442142|Experimental|Appetitie Awareness|"Parents and kids assigned to this group with learn about appetite awareness and to appropriately respond to their hunger meter."
9990306|NCT01442142|Experimental|Cue Reactivity and Sensitivity Training|Parents and kids in this group learn about how external cues can lead to overeating and how to better respond to these cues.
9990307|NCT01442142|Experimental|Combined CAAT/CRST|In this 14 week intervention combining Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST), parents and kids learn about both internal hunger cues and external cues that can cause one to overeat. Skills to learn the internal hunger cues and better responses to external cues are taught.
9990308|NCT01442142|No Intervention|Control|Between baseline and the post-intervention data collection point, no intervention is given. Participants are given a take home binder of intervention materials at that second data collection point; they have the option of reviewing the material prior to the final follow-up data collection point.
9990309|NCT01442168|Experimental|Sevuparin/DF02|Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
9990310|NCT01442168|Active Comparator|Control|Anti-malarial regimen (Malanil®) alone
9990311|NCT01442207|Active Comparator|Placement of Cervical Cerclage|Cervical Cerclage is to be placed in an inpatient hospital setting within 24 to 72 hours of being assigned to this treatment group
9990312|NCT01442207|Placebo Comparator|Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, Premature rupture of the membranes (PROM) > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
9990313|NCT01442233|Experimental|plasma exchange|6 plasma exchanges during 2 weeks after randomization
9990314|NCT01442233|Sham Comparator|sham exchange|6 sham plasma exchanges during 2 weeks after randomization
9990315|NCT01442246|Experimental|Adjuvant treatment|Leuproreline acetate
9990316|NCT01442246|No Intervention|Surveillance|Surveillance
9990317|NCT01442259|Experimental|All study subjects|
9990318|NCT01442272|No Intervention|Habitual medication withuot additional|
9990319|NCT01442272|Active Comparator|Habitual medication plus Hidroferol®|
9990320|NCT01442272|Active Comparator|Habitual medication plus Zemplar®|
9990321|NCT01442285|Experimental|personalized, motivational messages|A Healthcare Provider Report will be reviewed by oncologist. If mental health functioning scores are elevated or high range,treatment plan is constructed. Subjects receive personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
9990322|NCT01442285|No Intervention|Control Group|Control subjects will receive a resource packet upon initial diagnosis consisting of brochures and printed material describing local resources and support groups as part of their routine care. At 12 months, subjects will receive the full assessment with reports and referrals.
9990323|NCT01442298|Active Comparator|conventional treatment|the Standard method;tourniquet pressure based on systolic blood pressure, plus a safety margin.
9990324|NCT01442298|Experimental|limb occlusion pressure(LOP)|cuff pressure is based on limb occlusion pressure measurement
9990325|NCT01442311|Experimental|enhanced DOT (PEG/RBV-DOT)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
9990326|NCT01442311|Active Comparator|standard DOT (PEG-DOT)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
9990327|NCT01442324|Experimental|IRE|Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.
9990328|NCT01442363|Experimental|BLI-1300 (low dose)|Low dose BLI-1300
9990329|NCT01442363|Experimental|BLI-1300 (high dose)|High dose BLI-1300
9990330|NCT01442363|Placebo Comparator|placebo|placebo (vehicle)
9990331|NCT01442402||2 APOL1 genotypes|African American transplant recipients with homozygous APOL1 gene variants
9990332|NCT01442402||0 or 1 APOL1 genotypes|African American transplant recipients without homozygous APOL1 gene variants
9990333|NCT01442415|Other|Lifestyle Modification|Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling
9990334|NCT01442428|Experimental|Steroid+Statin|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
9990335|NCT01442428|Active Comparator|NSAID+Statin|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
9990336|NCT01442428|Active Comparator|Steroid+Placebo|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
9990337|NCT01442428|Active Comparator|NSAID+Placebo|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
9990338|NCT01442441||chronic pancreatitis|
9990339|NCT01442454||Chronic Pancreatitis|
9990340|NCT01442467||Mild to Severe MAC|
9990341|NCT01442467||No to mild MAC|
9990342|NCT01442480|Experimental|Fish oil|
9517135|NCT03309176|Experimental|Stair Step group|Intervention: Stair step protocol without medroxyprogesterone acetate 10 mg prior to ovulation induction with clomiphene citrate (CC), nor in between anovulatory cycles. After performing an ultrasound to check for the presence of cysts or any other abnormalities and a negative pregnancy test, patients will receive CC 50 mg daily for 5 days. Ultrasounds will be performed on CD11-14. If there is no response on CD14 (no follicle ≥ 14 mm), the dose of CC is immediately increased to 100 mg CC daily for 5 days and an ultrasound is performed 1 week following the last ultrasound. If there is no response, 150 mg CC daily is initiated immediately for 5 days and the ultrasound is repeated 1 week after the previous ultrasound.
9887437|NCT00556959|Experimental|1|CLONICEL High Dose
9990343|NCT01442480|Experimental|Olive oil|
9990344|NCT01442506||Barrett|
9990345|NCT01442519|Active Comparator|Intravesical BCG alone|
9990346|NCT01442519|Experimental|Intravesical sequential BCG and EMDA MMC|
9990347|NCT01442532|Experimental|1|
9990348|NCT01442532|Experimental|2|
9990349|NCT01442532|Experimental|3|
9990350|NCT01442532|Placebo Comparator|4|
9990351|NCT01442532|Experimental|5|
9990352|NCT01442545|Experimental|001|
9990353|NCT01442558|Active Comparator|SCL|Supraclavicular ultrasound-guided brachial plexus block
9990354|NCT01442558|Active Comparator|ICL|Infraclavicular ultrasound-guided brachial plexus block
9990355|NCT01442558|Active Comparator|AX|Axillary ultrasound-guided brachial plexus block
9990356|NCT01442571|Experimental|Hyaluronic Acid Injection, pain, function|
9990357|NCT01442571|Placebo Comparator|Saline Injection|
9990358|NCT01442584|Experimental|fertility restoration by transplantation|fertility restoration by transplantation of ovarian cortex slivers that were cryopreserved prior to chemotherapy
9990359|NCT01442597|Active Comparator|Individual clinician-provided CBT|Individual treatment provided by a trained Cognitive Behavioral Therapy (CBT)clinician who will cover the same skills provided by the CBT4CBT computer program.
9990360|NCT01442597|Experimental|CBT4CBT|A computerized program that teaches skills for stopping drug use and increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc.
9990361|NCT01442597|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
9990362|NCT01442610|Experimental|Rasagiline|Effect of Rasagiline on sleep parameters in PD Patients
9990363|NCT01442610|Placebo Comparator|Placebo|Effect of placebo on sleep parameters in PD Patients
9990364|NCT01442623|Active Comparator|Conventional Vestibular Rehabilitation|Six week program of conventional vestibular rehabilitation.
9990365|NCT01442623|Experimental|Nintendo Wii Vestibular Rehabilitation|Six week program of vestibular rehabilitation using the Nintendo Wii Fit Plus.
9990366|NCT01442636|Experimental|Xience Prime stent|Patients with critical limb ischemia due to below the knee arterial lesion between 30 and 100mm in length, treated with the XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
9990367|NCT01442662|Experimental|pazopanib, gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
9887438|NCT00556959|Experimental|2|CLONICEL Low Dose
9887439|NCT00556959|Placebo Comparator|3|Placebo
9887440|NCT00557011|Experimental|1|NRP104
9887441|NCT00557011|Active Comparator|2|Adderall XR
9887442|NCT00557011|Placebo Comparator|3|Placebo
9887443|NCT00557024|Experimental|1|radiotherapy after RFA
9887444|NCT00557024|Active Comparator|2|RFA alone
9887445|NCT00557037|Experimental|A|Patients with chemotherapy naïve androgen independent disease
9887446|NCT00557037|Experimental|B|Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent
9887447|NCT00557089|Other|1|This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
9887448|NCT00557089|Other|2|This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.
9887449|NCT00557102|Other|cetuximab, FOLFIRI|
9887450|NCT00557115|No Intervention|Usual Care|Usual Care (UC): usual follow up care post acute COPD exacerbation
9887451|NCT00557115|Experimental|EPR|Early pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
9887452|NCT00557141||1|Age > 18 years, Asthma with irregular or regular use of short acting beta-agonists and / or: Asthma treatment with inhaled steroids, Ability to understand the questionnaire
9517136|NCT03309163|Active Comparator|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
9517137|NCT03309163|Placebo Comparator|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
9887453|NCT00557154|Experimental|1|Ultrasound used to visualize peripheral venous anatomy. This guides subsequent attempts at venipuncture.
9887454|NCT00557154|Active Comparator|2|Routine venipuncture using standard methods.
9887455|NCT00557180||BASALT|Participants in the ACRN BASALT study
9887456|NCT00557180||TALC|Participants in the ACRN TALC study
9887457|NCT00557206|Experimental|1|This is a single arm trial.
9887458|NCT00557219|Placebo Comparator|Placebo|Control group receiving placebo
9887459|NCT00557219|Experimental|Ketanserin|patients receiving ketanserin infusion
9887460|NCT00557219|Experimental|Fenoldopam|patients receiving fenoldopam infusion
9887461|NCT00557388|Experimental|1|Young men 18-30 years, BMI < 27 kg/m2
9887462|NCT00557388|Experimental|2|Young men 18-30 years, BMI < 27 kg/m2
9887463|NCT00557388|Experimental|3|Old men 70-85 years, BMI < 27 kg/m2
9887464|NCT00557388|Experimental|4|Old men 70-85 years, BMI < 27 kg/m2
9887465|NCT00557388|Experimental|5|Old men 70-85 years, BMI < 27 kg/m2
9887466|NCT00557388|Experimental|6|Old men 70-85 years, BMI < 27 kg/m2
9887467|NCT00557388|Experimental|7|Old men 70-85 years, BMI < 27 kg/m2
9887468|NCT00557388|Experimental|8|Old men 70-85 years, BMI < 27 kg/m2
9887469|NCT00557388|Experimental|9|Old men 70-85 years, BMI < 27 kg/m2
9887470|NCT00557388|Experimental|10|Old men 70-85 years, BMI < 27 kg/m2
9887471|NCT00557427|Experimental|A|hypericum 250mg tablets twice daily for 8 weeks
9887472|NCT00557427|Active Comparator|B|fluoxetine 20mg - 40mg daily for 8 weeks
9887473|NCT00557453||A|Antibiotic treatment
9887474|NCT00557453||B|Non antibiotic treatment
9887475|NCT00557518|Active Comparator|1|
9887476|NCT00557518|Placebo Comparator|2|
9887477|NCT00557531|Experimental|BL-1040|
9887478|NCT00557544|Experimental|1|metoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
9887479|NCT00557544|Active Comparator|2|metoclopramide 0,15 mg/Kg + placebo per os
9887480|NCT00557544|Active Comparator|3|ketoprofen 1 mg/Kg and placebo in single dose
9887481|NCT00557557|Experimental|IHP with Oxaliplatin and 5-Fluorouracil (5-FU)|Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)
9887482|NCT00557648|Experimental|1|CBT for children only
9887483|NCT00557648|Experimental|2|CBT for children with parental involvement
9887484|NCT00557648|No Intervention|3|No intervention control group: families free to seek treatment on their own
10211916|NCT03603184|Placebo Comparator|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
9887485|NCT00557700|Placebo Comparator|2|Administration of placebo
9887486|NCT00557700|Experimental|1|Administration of inhaled tiotropium bromide
9887487|NCT00557713|Experimental|A|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
9887488|NCT00557739|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
9887489|NCT00557739|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
9887490|NCT00557739|Active Comparator|3|0.1% mometasone furoate
9887491|NCT00557739|Active Comparator|4|0.05% nortriptyline HCl
9887492|NCT00557739|Active Comparator|5|0.1% nortriptyline HCl
10211917|NCT03594305|Experimental|Educational Intervention Arm|Villages randomized to this arm will receive a one-day educational seminar, which their religious leaders of all denominations will be invited to attend. The seminar will address religious, cultural, and medical aspects of family planning. Leaders who attend will also have the opportunity to participate in mentorship group discussions after the intervention. In addition, both villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
10211918|NCT03594305|No Intervention|Control arm|Villages randomized to this arm will not receive the educational seminar. These villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
9887493|NCT00557739|Placebo Comparator|6|Vehicle (placebo)
9887494|NCT00557752|Active Comparator|1|Addition to the standard therapy of non-invasive mechanical ventilation. Continuously for the first 24 hours, then trials to discontinuation every 24 hours. Interface adjusted for the associated injuries.
9887495|NCT00557752|No Intervention|2|Standard therapy for severe post-traumatic hypoxia: pain control with epidural anesthesia and oxygen.
9887496|NCT00557778||1|Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
9887497|NCT00557778||Group 2|Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
9887498|NCT00557791|Active Comparator|A|Lucentis® (0.5 mg) every 4 weeks.
10211919|NCT03594123|Experimental|Brexpiprazole Arm 1|Oral tablet; taken once daily. Total daily dose of 2 mg/day
10211920|NCT03594123|Experimental|Brexpiprazole Arm 2|Oral tablet; taken once daily. Total daily dose of 3 mg/day
10211921|NCT03578731||Consilium-APP|Patients with oncological, medical treatment for breast cancer, colon cancer, prostate cancer, lung cancer or hematological malignancies.
10211922|NCT03551938|No Intervention|Control|Receive only the standard HIV Counseling, Testing, and Referral or Couples HIV Testing and Counseling (CHTC) Session.
10211923|NCT03551938|Experimental|Intervention|Receive one 45-minute Relationship skills session for YMSM individuals and couples (the intervention) as an addition to the standard HIV Counseling, Testing, and Referral (CTR) or Couples HIV Testing and Counseling (CHTC) Session.
10211924|NCT03548584|Experimental|Low Dose Brexpiprazole Arm|Tablet
10211925|NCT03548584|Experimental|High Dose Brexpiprazole Arm|Tablet
10211926|NCT03548584|Placebo Comparator|Placebo|Tablet
10211927|NCT03547726|Active Comparator|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
10211928|NCT03547726|Experimental|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
10211929|NCT03528031|Experimental|Intervention Daily Avocado|Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
10211930|NCT03528031|No Intervention|Control Usual Diet and Lifestyle|Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
9887499|NCT00557791|Experimental|B|Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
9887500|NCT00557791|Experimental|C|Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
9887501|NCT00557791|Experimental|D|Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
9887502|NCT00557817|No Intervention|1|No medication given
9887503|NCT00557817|Active Comparator|2|Aranesp 300 µg/15 days
9887504|NCT00557817|Active Comparator|3|Aranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.
9887505|NCT00557843|Active Comparator|bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
9887506|NCT00557843|Placebo Comparator|Placebo|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
9887507|NCT00557908||VWF/FVIII product infusions|One to three infusions of factor replacement as needed to control bleeding.
9887508|NCT00557921|Experimental|1|
9887509|NCT00557921|Active Comparator|2|
9887510|NCT00557934|Experimental|1|
9887511|NCT00557986|No Intervention|A|Standard Systemic Therapy only group (no primary surgery)
9887512|NCT00557986|Other|B|Surgery group
9887513|NCT00557999|Other|Experimental group|Application of a weaning mechanical ventilation protocol
9887514|NCT00557999|No Intervention|Control group|
9887515|NCT00558051|Active Comparator|Intradermal administration|Intradermal administration
9887516|NCT00558051|Active Comparator|Intranodal administration|Intranodal administration
9887517|NCT00558051|Active Comparator|Intralymphatic infusion|Intralymphatic infusion
9887518|NCT00558077|Experimental|A|Metformin plus clomiphene citrate
9887519|NCT00558077|Active Comparator|B|Laparoscopic ovarian drilling
9887520|NCT00558090|Active Comparator|A|patients receive 2,5 mg morphine iv, before the first intervention on the day after admission in the ICU
9887521|NCT00558116|Experimental|1|Treatment with Dynasplint device
9887522|NCT00558116|No Intervention|2|Control group; does not receive conservative or surgical treatment.
9887523|NCT00558129|Experimental|Investigational|X-STOP® PEEK IPD
9887524|NCT00558129|Active Comparator|Control|Laminectomy
9887525|NCT00558142|Active Comparator|1|Healthy volunteers will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
9887526|NCT00558142|Active Comparator|2|Volunteers with CKD III will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
9990368|NCT01442701||No triclosan / Triclosan|Participants are randomized to receive household and personal cleaning products from one of 2 arms: products that either do not contain triclosan or that may contain triclosan. Participants select products from an arm-specific list of commercially available items.
9990369|NCT01442727|Placebo Comparator|Placebo|Patients who receive control (placebo)
9990370|NCT01442727|Active Comparator|Selenium|Patients who receive treatment (selenium)
9990371|NCT01442740|Experimental|15-degree Reverse Trendelenburg Position|Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
9990372|NCT01442740|No Intervention|0-degree Supine Position|Patients will be placed on the operating table in the standard, 0-degree supine position.
9990373|NCT01442753|Active Comparator|Intervention Group|Families will be randomized to either receive the intervention (family-skills training) immediately. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
9990374|NCT01442753|Active Comparator|Control Group|Control group will receive the intervention (family-skills training) in approximately ten months. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
9990375|NCT01442766|Experimental|Donepezil|
9990376|NCT01442766|Placebo Comparator|Placebo|
9990377|NCT01442792|Active Comparator|Arm 1|
9990378|NCT01442792|Experimental|Arm 2|
9990379|NCT01442792|Experimental|Arm 3|
9990380|NCT01442792|Experimental|Arm 4|
9990381|NCT01442805|Experimental|RV|Cognitive Behavioral Therapy with Virtual Reality Exposures
9990382|NCT01442805|Experimental|IMAGO|Cognitive Behavioral Therapy with Exposure Therapy through Imagination
9990383|NCT01442818|Experimental|Scheduled IV post op|Patient's will receive scheduled nurse administered IV pain medications post operatively.
9990384|NCT01442818|Experimental|PCA post op|Patients will receive PCA for pain control post operatively.
9990385|NCT01442831|Experimental|Human ADME|
9990386|NCT01442857|Experimental|Block technique|"Active Comparator: Arm 1: catheter injection 40 ml of LA through the catheter~Active Comparator: Arm 2: catheter and transarterial injection 20 + 10 ml transarterial block and 10 ml through the catheter"
9990387|NCT01442870|Experimental|Metformin|Metformin
9990388|NCT01442870|No Intervention|No metformin|No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
9990389|NCT01442883||treatment resistant hypertensives with CKD 3-5|
9990390|NCT01442896||Primary Open Angle Glaucoma|"• Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past and high IOP (IOP above target), disc hemorrhage, family history of glaucoma-related vision loss or thin central cornea (<510um),~Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy~For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery~Best corrected visual acuity of 20/40 or better at enrollment"
9990391|NCT01442896||Healthy Individuals|"• Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP < 22mmHg~o Normal appearing optic disc and no evidence of optic disc damage"
9990392|NCT01442909|Active Comparator|D followed by P|Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).
10211931|NCT03515317|Experimental|LoRETA Z-score NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both LoRETA Z-score NF. A total treatment dosage of 600 minutes is needed.
10211932|NCT03515317|Experimental|theta/beta NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both theta/beta NF. A total treatment dosage of 600 minutes is needed.
9990393|NCT01442909|Active Comparator|P followed by D|"Pemetrexed treatment followed by docetael (in reverse sequence of Arm D followed by P"
9990394|NCT01442922||Human Meniscus Allograft (HMA)|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo surgery for (HMA) implantation to replace the nucleus pulposus.
9990395|NCT01442935|Active Comparator|Arm A1 : Folfiri + targeted therapy|"Every 2 weeks :~irinotecan 180 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
9990396|NCT01442935|Active Comparator|Arm A2 : Folfox 4 + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
9990397|NCT01442935|Experimental|Arm B : Folfirinox + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~irinotecan 150 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
9990398|NCT01442948||Acute coronary syndrome|
9990399|NCT01442948||Stable Angina|
9990400|NCT01442961|Active Comparator|laparoscopy|Intervention: Procedure: laparoscopy
9990401|NCT01442961|Active Comparator|vaginal|Intervention: Procedure: vaginal
9887527|NCT00558142|Active Comparator|3|Healthy volunteers will receive a single IV dose of 100mls Visipaque 320 (iodixanol, equivalent to 320 mg iodine/ml). They will then be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
9887528|NCT00558142|Active Comparator|4|Volunteers with CKD III will receive Visipaque 320 during coronary angiography. They will have been randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
9887529|NCT00558155|Experimental|SEN|standard enteral nutrition
9887530|NCT00558155|Experimental|IMEN|immunostimulating enteral nutrition
9887531|NCT00558155|Experimental|SPN|standard parenteral nutrition
9887532|NCT00558155|Experimental|IMPN|immunostimulating parenteral nutrition
9887533|NCT00558181|Experimental|Rituximab, Methylprednisolone|
9887534|NCT00558194|Experimental|1|Standard behavioral weight loss treatment with cognitive and affective skills training
9887535|NCT00558194|Active Comparator|2|Standard behavioral weight loss treatment
9887536|NCT00558220|Experimental|A|Intensive induction followed by high-dose consolidation with stem cell support ± radiotherapy
9887537|NCT00558233|Experimental|Intervention group|
9887538|NCT00558233|Placebo Comparator|Placebo group|
9887539|NCT00558324|Experimental|I|Corneal flaps were created with mechanical microkeratome (Hansatome 160μm (Chiron Vision Corp, Claremont, Calif)
9887540|NCT00558324|Experimental|II|Corneal flaps were created with mechanical microkeratome K3000 130μm ( BD Ophthalmic Systems, Waltham, Mass) .
9887541|NCT00558324|Experimental|III|Corneal flaps were created with microkeratome femtoseconds laser (Intralase Corp, Irvine, Calif.)
9887542|NCT00558337|Active Comparator|A|
9887543|NCT00558337|Active Comparator|B|
9887544|NCT00558350||1|lobectomy / segmentectomy in patients with lung cancer
9887545|NCT00558376|Active Comparator|1|Ingestion of 3L polyethylene Glycol
9887546|NCT00558376|Active Comparator|2|Ingestion of 2 doses of sodium phosphate 45 cc
9887547|NCT00558402|Experimental|1|Meditation class, 90min/week for 8 weeks, with home assignments, adapted from MBCT program
9887548|NCT00558402|Active Comparator|2|Education
9887549|NCT00558402|Active Comparator|3|Respite care only, 90 mins per week for 8 weeks
9887550|NCT00558441|Experimental|1|
9887551|NCT00558454|Placebo Comparator|1|Placebo
9887552|NCT00558454|Experimental|2|1 mg/kg/day from age 6 weeks to 6 months
9887553|NCT00558454|Experimental|3|2 mg/kg/day from age 6 weeks to 6 months
9887554|NCT00558480|Active Comparator|1|Vitamin A
9887555|NCT00558480|Placebo Comparator|2|Vitamin A placebo
9887556|NCT00558493|Experimental|1|switching treatment from lamivudine to clevudine
9887557|NCT00558506|Experimental|A|Abatacept
9887558|NCT00558532||Surgical|Those subjects undergoing bariatric surgery or abdominal surgery following a previous bariatric surgery.
9887559|NCT00558532||Control|Volunteers who have dietary habits similar to the subjects.
9887560|NCT00558584|Active Comparator|IA/IgG group|immunoadsorption using IA columns and subsequent IgG substitution
9887561|NCT00558584|Placebo Comparator|control group|pseudo-immunoadsorption followed by an intravenous infusion without IgG
9887562|NCT00558597||1|30 patients with stable graft function
9887563|NCT00558597||2|30 patients with acute rejection after lung transplantation
9887564|NCT00558623|Placebo Comparator|1|Placebo
9887565|NCT00558649|Experimental|1|Low dose flu vaccine delivered intradermally using microneedles
9887566|NCT00558649|Experimental|2|Medium dose flu vaccine delivered intradermally using microneedles
9887567|NCT00558649|Active Comparator|3|Standard dose flu vaccine delivered intramuscularly with a regular needle
9887568|NCT00558662|Active Comparator|1|Coban 2 Layer Compression System
9887569|NCT00558662|Active Comparator|2|Short-Stretch Bandage
9887570|NCT00558675|Experimental|1|Single intravenous infusion of AlloStim
9887571|NCT00558675|Experimental|2|Intravenous AlloStim infusion on day 1 and day 7
9887572|NCT00558675|Experimental|3|Intravenous AlloStim infusion on day 1, day 7 and day 14
9887573|NCT00558675|Experimental|4|Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
9887574|NCT00558740||healthy volunteers|
9887575|NCT00558779|Experimental|1|
9887576|NCT00558779|Active Comparator|2|
9887577|NCT00558805|Active Comparator|1|Usual Care + Family Intervention for Suicide Prevention (FISP)
9887578|NCT00558805|Other|2|Usual Care
9887579|NCT00558857|Active Comparator|DSM|Treatment using DSM to guide ablation
9887580|NCT00558883|Active Comparator|1|treatment with Acarbose: 2 weeks 1 x 50mg; 2 weeks 3 x 50mg; 16 weeks 3 x 100mg
9887581|NCT00558883|Placebo Comparator|2|treatment with placebo: 2 weeks 1 x 50mg 2 weeks 3 x 50mg 16 weeks 3 x 100mg
9887582|NCT00558961|Experimental|I|Gleevec Chlorambucil
9887583|NCT00558987|Experimental|1|
9887584|NCT00558987|Sham Comparator|2|
9887585|NCT00559000|No Intervention|Waitinglist Control|
9887586|NCT00559000|Experimental|KIDNET|
9887587|NCT00559026|Active Comparator|1|
9887588|NCT00559026|Experimental|2|
9887589|NCT00559052|No Intervention|1|Baseline measurement. No drug with the liquid meal during perfusion procedure to establish baseline secretion.
9887590|NCT00559052|Experimental|2|The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.
9887591|NCT00559065||Benzene Cohort|Benzene exposed and unexposed workers.
9931772|NCT00941642|Placebo Comparator|Placebo|Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.
9931773|NCT00941694|Experimental|Self-Management Intervention|Will receive 6 asthma self-management group or individual session over a 7 week period
9931774|NCT00941694|Placebo Comparator|Control|Group will receive 3 phone calls not related to asthma self management over a 7 week period
9931775|NCT00941707|Experimental|JNJ-38518168|
9931776|NCT00941707|Placebo Comparator|Placebo|
9931777|NCT00941746|Experimental|Lowest dose of PG110|single, slow intravenous infusion
9931778|NCT00941746|Experimental|Second dose of PG110|single, slow intravenous infusion
9931779|NCT00941746|Experimental|Third dose of PG110|single, slow intravenous infusion
9931780|NCT00941746|Experimental|Fourth dose of PG110|single, slow intravenous infusion
9931781|NCT00941746|Experimental|Fifth dose of PG110|single, slow intravenous infusion
9931782|NCT00941746|Experimental|Top dose of PG110|single, slow intravenous infusion
9931783|NCT00941746|Experimental|Placebo|single, slow intravenous infusion that matches PG110 in appearance
9931784|NCT00941746|Experimental|Seventh Dose of PG110|single, slow intravenous infusion
9931785|NCT00941746|Experimental|Eight Dose of PG110|single, slow intravenous infusion
9990402|NCT01442974|Experimental|Gemcitabine plus nab-paclitaxel|This is a single arm study.
9887592|NCT00559078||CAH|Women diagnosed with CAH (either simple virilizing or salt-losing)
9887593|NCT00559091|Experimental|I|Ribavirin
9887594|NCT00559117|Experimental|Cohort|
9887595|NCT00559143|Active Comparator|1|DDD(R)-RV pacing
9887596|NCT00559143|Experimental|2|DDD(R)- BIV pacing
9887597|NCT00559182|Experimental|Parts A and B: MK-8033|Dose Escalation Study
9887598|NCT00559182|Experimental|Part C: MK-8033 +/- omeprazole|Crossover Study
9887599|NCT00559208||Children's Aid Societies|Comparing differential response (Wraparound) with usual care
9887600|NCT00559221|No Intervention|1|
9887601|NCT00559286|Experimental|A|treatment with 80 mg Telmisartan per day for 30 days
9887602|NCT00559286|Active Comparator|B|treatment with 20mg Telmisartan per day for 30 days
9887603|NCT00559312|Experimental|FSC 250/50|fluticasone 250μg/salmeterol 50μg combination
9887604|NCT00559312|Placebo Comparator|Placebo|matched placebo inhaler
9887605|NCT00559338|Active Comparator|1|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
9887606|NCT00559338|Placebo Comparator|2|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
9887607|NCT00559351|Active Comparator|S|esophagectomy
9887608|NCT00559351|Experimental|CHTS|neoadjuvant chemotherapy followed by esophagectomy
9887609|NCT00559351|Experimental|CHRTS|neoadjuvant chemoradiotherapy followed by esophagectomy
9887610|NCT00559390||Pre-PCOS|First degree relatives, either sisters or daughters, of women with Polycystic Ovary Syndrome.
9887611|NCT00559390||Controls|Sisters and daughters of women who do not have PCOS
9887612|NCT00559403|Experimental|HIV/STD Sessions|The HIV/STD Risk-Reduction Intervention arm focuses on reducing the risk of STDs, including HIV.
9887613|NCT00559403|Active Comparator|Health Promotion Control Sessions|The Health Promotion Intervention arm focuses on physical activity, diet, and other behaviors linked to risk of heart disease, high blood pressure, stroke, diabetes, and certain cancers, which are all leading causes of morbidity and mortality among South Africans.
9887614|NCT00559429|Active Comparator|C1|
9887615|NCT00559429|Active Comparator|C2|
9887616|NCT00559429|Active Comparator|C3|
9887617|NCT00559429|Active Comparator|C4|
9887618|NCT00559442|Experimental|1|high altitude exposure without prior acclimatization
9887619|NCT00559455|Experimental|1|
9887620|NCT00559494|Experimental|Minocycline|
9887621|NCT00559494|Placebo Comparator|Placebo|
9887622|NCT00559494|Experimental|SCPP augmentation|
9887623|NCT00559494|Sham Comparator|SCPP control|
9887624|NCT00559520|Active Comparator|Impact|"patient receiving 3 drinks Impact a day during 5 days before surgery"
9887625|NCT00559520|Experimental|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
9887626|NCT00559533|Experimental|1|
9887627|NCT00559546|Active Comparator|1|3 weeks of Montelukast and 3 weeks of placebo treatment
9887628|NCT00559546|Active Comparator|2|3 weeks of placebo and 3 weeks of montelukast treatment
9887629|NCT00559559|Other|Control Group|Patient Notifier turned OFF
9887630|NCT00559559|Experimental|Treatment group|Patient Notifier turned ON
9887631|NCT00559572|Experimental|1|Exercise information group
9517138|NCT03309163|Placebo Comparator|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
9887632|NCT00559572|Active Comparator|2|General health information group
9887633|NCT00559611|Experimental|Endobronchial Ultrasound vs. Mediastinoscopy|"Endobronchial Ultrasound - A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.~Mediastinoscopy - Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS."
9887634|NCT00559663|Active Comparator|GT|The green tea group is given initially green tea treatment and then after a washout period of four weeks switched to the dark chocolate treatment.
9887635|NCT00559663|Active Comparator|DC|The dark chocolate group is given initially dark chocolate treatment and then after a washout period of four weeks switched to the green tea treatment.
9887636|NCT00559689||1|receive once-daily administration of inhaled glucocorticosteroids at bedtime
9887637|NCT00559689||2|receive twice-daily administration of inhaled glucocorticosteroids
9887638|NCT00559702|Experimental|1|Natalizumab IV (Participants with secondary progressive multiple sclerosis)
9887639|NCT00559702|Experimental|2|Natalizumab IM (Participants with secondary progressive multiple sclerosis)
9887640|NCT00559702|Experimental|3|Natalizumab SC (Participants with secondary progressive multiple sclerosis)
9887641|NCT00559702|Other|4|Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
9887642|NCT00559702|Experimental|5|Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
9887643|NCT00559702|Experimental|6|Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
9887644|NCT00559715|Experimental|A|
9887645|NCT00559715|Active Comparator|B|
9887646|NCT00559780|Experimental|1|12 weeks of resistance training
9887647|NCT00559780|Experimental|2|12 weeks of neuromuscular electrical stimulation
9887648|NCT00559780|Other|3|12 weeks of standard rehabilitation
9887649|NCT00559806|Experimental|1|9 healthy elderly males
9887650|NCT00559806|Experimental|2|11 healthy young males
9887651|NCT00559819|Active Comparator|Alcohol|Alcohol
9887652|NCT00559819|Placebo Comparator|Placebo|Orange juice
9887653|NCT00559832|No Intervention|Normoxia|Sleeping in normoxia for 14 nights prior to one night at 4500 m
9887654|NCT00559832|Experimental|Hypoxia|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
9887655|NCT00559871|Placebo Comparator|1|One placebo tablet administered tid from Day 1 to 28
9887656|NCT00559871|Active Comparator|2|One 30-mg tablet of Fipamezole tid from Day 1 to 28
9887657|NCT00559871|Active Comparator|3|One 30-mg tablet of Fipamezole tid from Day 1 to 7; and one 60-mg tablet of Fipamezole tid from Day 8 to 28
9887658|NCT00559871|Active Comparator|4|One 30-mg tablet of Fipamezole tid from Day 1 to 7; one 60-mg tablet of Fipamezole tid from Day 8 to 14; and one 90-mg tablet of Fipamezole tid from Day 15 to 28
9887659|NCT00559910|Experimental|PH-797804|PH-797804 at four dose levels
9887660|NCT00559910|Placebo Comparator|Placebo|Placebo
9887661|NCT00559975|Active Comparator|1|
9887662|NCT00559975|Active Comparator|2|
9887663|NCT00559975|Experimental|3|
9887664|NCT00559975|Experimental|4|
9887665|NCT00559975|Experimental|5|
9887666|NCT00560001|Experimental|A|Those subjects that receive an MD.2 Medication Dispenser
9887667|NCT00560001|No Intervention|B|Control subjects that do not receive an MD.2 Medication Dispenser, but continue to take their medications utilizing standard care, such as pill boxes, etc.
9887668|NCT00560014|Experimental|1|Arginine and Canola oil supplemented group
9887669|NCT00560014|Experimental|2|Arginine and Coromega
9887670|NCT00560014|No Intervention|3|Control
9887671|NCT00560079|Experimental|1|Lithium 900mg/day plus allopurinol 600mg/day
9887672|NCT00560079|Active Comparator|2|
9887673|NCT00560079|Placebo Comparator|3|
9887674|NCT00560092|Experimental|intrathecal magnesium sulfate|
9887675|NCT00560144|Experimental|1|
9887676|NCT00560144|Experimental|2|
9887677|NCT00560144|Experimental|3|
9887678|NCT00560157|Active Comparator|I|Sondalis HP
9887679|NCT00560157|Experimental|II|Crucial
9887680|NCT00560170|Experimental|high dose statin|40mg of Simvastatin (n=20)
9887681|NCT00560170|Active Comparator|combination arm|10mg/10mg of Ezetimibe/Simvastatin (n=20)
9887682|NCT00560196||1|Patients with panic anxiety disorder without pain
9887683|NCT00560196||2|Patients with depression without pain
9887684|NCT00560196||3|Healthy controls
9887685|NCT00560209|Placebo Comparator|P|
9887686|NCT00560209|Experimental|E2|
9887687|NCT00560209|Experimental|E1|
9887688|NCT00560222|Active Comparator|A|This group will receive daily lactoferrin supplementation
9887689|NCT00560222|Placebo Comparator|B|placebo
9887690|NCT00560248||I|Patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin.
9887691|NCT00560261|Experimental|1:Children with sickle cell disease|"NO-CO inhalation and expiration:~Children with sickle cell disease"
9887692|NCT00560261|Active Comparator|2: Healthy volunteers|"NO-CO inhalation and expiration:~Healthy volunteers"
9887693|NCT00560274|Experimental|1|
9887694|NCT00560287|Active Comparator|1|Volume assist non-invasive ventilation
9887695|NCT00560287|Active Comparator|2|Pressure Assist mode
9887696|NCT00560300|Experimental|1|Doxercalciferol + Calcium Carbonate
9887697|NCT00560300|Experimental|2|Doxercalciferol + Sevelamer
9887698|NCT00560300|Experimental|3|Calcitriol + Calcium Carbonate
9887699|NCT00560300|Experimental|4|Calcitriol + Sevelamer
9887700|NCT00560326|Experimental|1|
9887701|NCT00560378|Experimental|Tacrolimus Ointment 0.1%|
9887702|NCT00560430|Active Comparator|T1|Telmisartan 80 mg/d
9887703|NCT00560430|Active Comparator|T2|Telmisartan 160 mg/d
9887704|NCT00560430|Placebo Comparator|P|placebo
9887705|NCT00560443|Active Comparator|1|children 4-17 y. old with not compound bone fracture treated with ketorolac
9887706|NCT00560443|Experimental|2|children 4-17 y. old with not compound bone fracture treated with tramadol
9887707|NCT00560456|Experimental|1|snorers
9887708|NCT00560456|Other|2|healthy volonters (control)
9887709|NCT00560456|Experimental|3|young subjects
9887710|NCT00560456|Experimental|4|mature subjects
9887711|NCT00560469||1|Men and Women over age 40 who are obese (BMI>30) and insulin-resistant.
9887712|NCT00560469||2|Men and women over age 40 who are obese (BMI>30) and insulin-sensitive.
9887713|NCT00560521|Active Comparator|1|
9887714|NCT00560547|Experimental|1|
9887715|NCT00560586|Experimental|Budesonide|Budesonide for 6 weeks followed by crossover to placebo
9887716|NCT00560586|Placebo Comparator|Placebo|Placebo for 6 weeks followed by crossover to treatment.
9887717|NCT00560599|No Intervention|1: Standard of care|Standard of care (no body decolonization regimen) and Standard of care (no environmental decolonization regimen)
9887718|NCT00560599|Experimental|2: Body decolonization regimen|Body decolonization regimen and Standard of care (no environmental decolonization regimen)
9887719|NCT00560599|Experimental|3 Environmental decolonization regimen|Standard of care (no body decolonization regimen) and Environmental decolonization regimen
9887720|NCT00560599|Experimental|4 Body and Environmental decolonization regimens|Body decolonization regimen and Environmental decolonization regimen
9887721|NCT00560638|Experimental|Loteprednol Etabonate TID|loteprednol etabonate ophthalmic suspension, 0.5%, TID
9887722|NCT00560638|Experimental|Loteprednol Etabonate QID|loteprednol etabonate ophthalmic suspension, 0.5%, QID
9887723|NCT00560638|Placebo Comparator|Vehicle|vehicle of loteprednol etabonate
9887724|NCT00560651||1|Cross linked eyes
9887725|NCT00560664|Experimental|1|Autologous chondrocytes transplantation
9887726|NCT00560664|Active Comparator|2|Mosaicoplasty
9887727|NCT00560690|Placebo Comparator|Placebo|standard treatment with pegylated interferon and ribavirin + placebo
9887728|NCT00560690|Experimental|Metformin|standard treatment with pegylated interferon and ribavirin + metformin
9887729|NCT00560729|No Intervention|I|
9887730|NCT00560729|Active Comparator|II|oral nutrition
9887731|NCT00560729|Experimental|III|oral nutrition
9887732|NCT00560729|Experimental|IV|oral nutrition
9887733|NCT00560742|Active Comparator|Control|
9887734|NCT00560742|Experimental|Intramuscular|
9887735|NCT00560742|Experimental|Intracoronary|
9887736|NCT00560768|Experimental|1|
9887737|NCT00560781|Active Comparator|1|Pregnenolone
9887738|NCT00560781|Placebo Comparator|2|Placebo
9887739|NCT00560807|No Intervention|A|Zero treatment/3 weeks
9887740|NCT00560807|Active Comparator|B|Frequency of Mobilization:1/week Duration of Mobilization Treatment: 3 weeks
9887741|NCT00560807|Active Comparator|C|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 6 weeks
9887742|NCT00560807|Active Comparator|D|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 12 weeks
9887743|NCT00560807|Active Comparator|F|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 3 weeks
9887744|NCT00560807|Active Comparator|G|Frequency of Mobilization: 2/week Duration of Mobilization Treatment:6 weeks
9887745|NCT00560807|Active Comparator|H|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 12 weeks
9887746|NCT00560807|Active Comparator|J|Frequency of Mobilization: 3/week Duration of Mobilization Treatment: 3 weeks
9887747|NCT00560807|Active Comparator|K|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:6 weeks
9887748|NCT00560807|Active Comparator|L|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:12 weeks
9887749|NCT00560807|No Intervention|E|Zero treatment/6 weeks
9887750|NCT00560807|No Intervention|I|Zero treatment/12 weeks
9887751|NCT00560820|Experimental|Deferasirox|30 mg/kg/day
9887752|NCT00560846|Experimental|Nutrition|Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
9887753|NCT00560846|No Intervention|Control|No immunonutrition, no glucose load, no early enteral immunonutrition
9887754|NCT00560872|Other|1|conventional ablation with manual catheter navigation
9887755|NCT00560872|Active Comparator|2|ablation with remote magnetic catheter navigation
9887756|NCT00560898|Experimental|2|contact lenses disinfected in multipurpose solution
9887757|NCT00560898|Experimental|3|contact lenses disinfected in multipurpose solution
9887758|NCT00560898|Experimental|4|contact lenses disinfected in multipurpose solution
9887759|NCT00560898|Experimental|1|contact lenses disinfected in multipurpose solution
9931786|NCT00941785|Experimental|DHA-PQ|Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.
9931787|NCT00941785|Active Comparator|SP-AQ|Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine
9931788|NCT00941837|Experimental|Olive Oil|
9931789|NCT00941837|Experimental|Coconut oil|
9931790|NCT00941837|Experimental|Palm Olein|
9931791|NCT00941850|Experimental|Triple site CRT|These patients will continue to receive CRT via existing device but will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced
9931792|NCT00941850|No Intervention|Optimised medical and device therapy|These patients will receive optimised medical and device therapy.
9931793|NCT00941876|Experimental|A. Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
9931794|NCT00941902||Patients scheduled to bariatric surgery|
9931795|NCT00941941|Experimental|Non-mesh Hernia Repair|Reinforcement with a strip of external oblique aponeurosis
9931796|NCT00941941|Active Comparator|Mesh Hernia Repair|Polypropylene mesh placement
9931797|NCT00941954|Experimental|Lifestyle counseling|A group-based structured educational programme.
9931798|NCT00941954|Active Comparator|Control|Written Information (booklet).
9931799|NCT00941967|Experimental|Arm I|Patients receive oral sorafenib tosylate as in arm I. Patients also receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment with gemcitabine hydrochloride and oxaliplatin repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
9931800|NCT00941967|Experimental|Arm II|Patients receive oral sorafenib tosylate twice daily on days 1-14.
9931801|NCT00942006|Active Comparator|LNB-doxycycline|
9931802|NCT00942006|Active Comparator|LNB-ceftriaxone|
9931803|NCT00942019||obese smokers|BMI > 30 kg/m2 CO ≥ 15 ppm
9931804|NCT00942019||non-obese smokers|BMI < 25 kg/m2 CO ≥ 15 ppm
9931805|NCT00942019||obese non-smokers|BMI > 30 kg/m2 CO ≤ 6 ppm
9931806|NCT00942019||non-obese non-smokers|BMI < 25 kg/m2 CO ≤ 6 ppm
9517139|NCT03309137|Experimental|Antiseptic device|Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place
9931807|NCT00942058||CA9 level|Serum and urinary CA9 level
9931808|NCT00942071|Experimental|1. MVA-NP+M1 ID|12 volunteers to receive MVA-NP+M1 via ID route
9931809|NCT00942071|Experimental|2. MVA-NP+M1 IM|16 volunteers to receive MVA-NP+M1 via IM route
9931810|NCT00942071|Experimental|3. MVA-NP+M1 IM upper age group|30 volunteers to receive MVA-NP+M1 via IM route
9931811|NCT00942097|Placebo Comparator|Nutritional plus Placebo (homeopathy)|Nutritional oriented diet for pregnancy period add homeopathic preparation from inert substance.
9931812|NCT00942097|Active Comparator|Nutr and Homeop Sulph Puls Lyc Lackt Con Sep Nuxv Calcc Phos|Nutrition oriented diet for pregnancy period add active homeopathic medication (Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos)
9931813|NCT00942110|Experimental|CPAP|
9931814|NCT00942136|Experimental|Cohort 1, Sequence 1|Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
9931815|NCT00942136|Experimental|Cohort 2|Subjects will receive a single dose of either GSK1349572 250 mg or placebo as a suspension. Subjects will have a screening visit within 30 days prior to the dose of study medication and a follow up visit 7-14 days after the dose of study medication.
9931816|NCT00942136|Experimental|Cohort 1, Sequence 2|Subjects in Cohort 1, Sequence 2 will receive a single dose of GSK134972 50 mg after a a high fat meal in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after fast of 10 hours in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
9931817|NCT00942201|Active Comparator|Single dose dexamethasone|Single dose dexamethasone 0.6 mg/kg, rounded to nearest 2 mg, max 16 mg administered in ED
9931818|NCT00942201|Active Comparator|Two dose dexamethasone|First dose in ED, a prescription for second dose to be administered on Day 3 after discharge
9931819|NCT00942227|Active Comparator|Extension oriented treatment approach|Extension exercises. Subjects are instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to further increase extension movement and/or reduction of symptoms.
9931820|NCT00942227|Experimental|Mechanical traction plus extension-oriented treatment|Mechanical lumbar traction will be utilized in addition to extension oriented exercises. Subjects are also instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to increase extension movement and/or reduce radicular symptoms.
9931821|NCT00942240|Experimental|ACU-4429 tablet|
9931822|NCT00942240|Placebo Comparator|matching placebo tablet|
9931823|NCT00942253|Experimental|Dopamine Agonist Group|"Dialysis patients will receive dopamine agonist for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist and aerobic intradialytic exercise.~Patients will be given evening doses of dopamine agonists, 2 hours before bedtime. The dopamine agonists' dose will be 0.25 mg/dose and remain constant until the end of the study."
9990403|NCT01442987|Experimental|Irbesartan/Atorvastatin A|
9990404|NCT01442987|Active Comparator|Irbesartan|
9887760|NCT00560911|Other|1Self-management|
9887761|NCT00560911|Other|2 Routine control|
9887762|NCT00560963|Experimental|1 RAD001|
9887763|NCT00560976|Experimental|Iron Saccharate (Venofer)|IV Iron Saccharate (Venofer)100 mg
9887764|NCT00560989||1|CBD cases
9887765|NCT00560989||2|Beryllium-exposed, non-diseased control subjects
9887766|NCT00560989||3|Sarcoidosis cases
9887767|NCT00560989||4|Sarcoidosis control subjects
9887768|NCT00561028||1|ST-elevation acute myocardial infarction.
9887769|NCT00561028||2|high-risk unstable angina or non-ST-elevation myocardial infarction.
9887770|NCT00561028||3|known coronary artery disease, either asymptomatic or with stable angina.
9887771|NCT00561028||4|blood donors without known coronary artery disease.
9887772|NCT00561041|Experimental|1|Brief phone aftercare intervention composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
9887773|NCT00561041|Experimental|2|Individual aftercare therapy - composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
9887774|NCT00561041|No Intervention|3|No intervention
9887775|NCT00561054|No Intervention|1|CISPLATIN gENCITABINE cETUXIMAB
9887776|NCT00561067|Active Comparator|1|Methylprednisolone
9887777|NCT00561067|Experimental|2|Erythropoietin
9887778|NCT00561093|Experimental|A|Group A (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
9887779|NCT00561093|Experimental|B|Group B (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline while undergoing hemodialysis and the following non-dialysis day (6 days per week)
9887780|NCT00561093|Experimental|C|Group C (n=25) Placebo dietary supplement to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
9887781|NCT00561093|Placebo Comparator|D|Group D (n=25) Placebo to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
9887782|NCT00561106|Active Comparator|1|
9887783|NCT00561106|Placebo Comparator|2|
9887784|NCT00561119|No Intervention|Arm 1|Observation after 6 cycles of gemcitabine plus paclitaxel till progression
9887785|NCT00561119|Experimental|Arm 2|Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression
9887786|NCT00561132|Experimental|1|
9887787|NCT00561132|Placebo Comparator|2|
9887788|NCT00561158|Experimental|A|
9887789|NCT00561158|No Intervention|2|
9887790|NCT00561171|Experimental|1|high dose
9887791|NCT00561171|Experimental|2|lower dose
9887792|NCT00561184|Experimental|1|
9887793|NCT00561184|Experimental|2|
9887794|NCT00561210|Experimental|I|Total enteral tube feeding
9887795|NCT00561210|Active Comparator|II|Total enteral tube feeding
9887796|NCT00561223|Experimental|1|"This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.~It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD."
9887797|NCT00561249|Experimental|1|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo.
9887798|NCT00561249|No Intervention|2|No intervention
9887799|NCT00561288|Experimental|1|2000 mg acetaminophen per day
9887800|NCT00561288|Placebo Comparator|2|2000 mg cornstarch per day
9887801|NCT00561301|No Intervention|1|
9887802|NCT00561327||A|Patients chronically treated with drug losartan
9887803|NCT00561327||B|Patients not chronically treated with losartan
9887804|NCT00561366|Placebo Comparator|1|
9887805|NCT00561366|Experimental|2|
9887806|NCT00561379|Active Comparator|1|
9887807|NCT00561379|Active Comparator|2|
9887808|NCT00561405|Experimental|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner.
9887809|NCT00561405|Active Comparator|Body weight supported treadmill training|Body Weight Supported Treadmill Training. Participants walk on a treadmill while partially supported with an overhead harness system. Mass repetition of the normal gait cycle is encouraged through the support of the harness, the movement of the treadmill, and the assistance of one or two trainers to position limbs and trunk.
9887810|NCT00561444||Quality of Life Study|Prostate cancer patients
9887811|NCT00561483||Observation|Patients admitted to the hospital with decompensated heart failure
9887812|NCT00561496|Other|Twice daily|Tenofovir gel intravaginal twice daily for 14 days
9887813|NCT00561496|Other|Once daily|Tenofovir gel intravaginal once daily for 14 days
9887814|NCT00561509||A|SSRIs
9887815|NCT00561509||B|Dual antidepressants
9887816|NCT00561522|Experimental|Intervention treatment|Capecitabine
9887817|NCT00561522|No Intervention|No intervention treatment|No other preventive treatment
9887818|NCT00561535|Experimental|A|Lactobacillus FARCIMINIS
9887819|NCT00561535|Placebo Comparator|B|Placebo
9887820|NCT00561548|Other|A|Patients with active Crohn disease and with azathioprine treatment
9887821|NCT00561548|Other|B|Patient with active crohn disease and without azathioprine disease
9887822|NCT00561561|Experimental|1|Subjects with schizophrenia
9887823|NCT00561561|Active Comparator|2|Health controls
9887824|NCT00561561|Active Comparator|3|Family members of subjects with schizophrenia
9887825|NCT00561561|Active Comparator|4|Family members of healthy controls
9887826|NCT00561587|Active Comparator|1|
9887827|NCT00561587|No Intervention|2|
9887828|NCT00561613|Placebo Comparator|1|SILCS with K-Y Jelly
9887829|NCT00561613|Active Comparator|2|SILCS with N-9
9887830|NCT00561626|Experimental|A|
9887831|NCT00561626|Experimental|B|
9887832|NCT00561717|Experimental|Arm 1|
9887833|NCT00561717|Active Comparator|Arm 2|
9887834|NCT00561717|Active Comparator|Arm 3|
9887835|NCT00561717|Placebo Comparator|Arm 4|
9887836|NCT00561756|Experimental|Vaccine Therapy|This single arm, open-label, phase I clinical trial of xenogeneic CD20 DNA vaccination is designed to evaluate its safety in patients with B cell lymphoma. The study is a dose escalation study at three test doses, 0.5 mg, 2 mg and 4 mg of purified plasmid DNA per injection. There will be an initial cohort of three patients receiving a pre-level 1 dose of 0.1 mg/vaccination before proceeding to the three test doses.
9887837|NCT00561769||A|poor responder
9887838|NCT00561782||Group 1|Spinal cord injured with chronic central neuropathic pain.
9887839|NCT00561782||Group 2|Spinal cord injured without chronic central neuropathic pain.
9990405|NCT01442987|Active Comparator|Atorvastatin A|
9990406|NCT01442987|Placebo Comparator|Placebo|
9990407|NCT01442987|Experimental|Irbesartan/Atorvastatin B|
9990408|NCT01442987|Active Comparator|Atorvastatin B|
9990409|NCT01443013||Cohort of Renal Transplant recipients|
9990410|NCT01443039|Experimental|phenotypical approach|phenotypical approach
9990411|NCT01443052||post-stroke patients|Stroke patients who had only one cerebrovascular accident, at least one year before inclusion and Able to walk without using assisting devices or ambulatory aids
9990412|NCT01443052||healthy subjects|Aged 65 to 80 years
9990413|NCT01443052||fallers|Reported 2 or more falls within 6 months prior to the beginning of the study and Able to walk without using assisting devices or ambulatory aids
9990414|NCT01443065|Active Comparator|Arm A : simplified Folfox 4|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :~5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h"
9990415|NCT01443065|Experimental|Arm B : simplified FOLFOX 4 + panitumumab|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :~5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h~Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn."
9990416|NCT01443065|Experimental|Arm C : simplified FOLFOX 4 + AMG 102|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h~AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn."
9990417|NCT01443091|Experimental|Colostrum|
9990418|NCT01443091|Placebo Comparator|Sterile water|
9990419|NCT01443104|Active Comparator|Orsiro Stent|Sirolimus-eluting Stent with a Biodegradable Polymer
9990420|NCT01443104|Active Comparator|Xience Prime Stent|Everolimus-eluting Stent with a Durable Polymer
9990421|NCT01443117|Experimental|Step 1: PPV-23 Vaccine (Arm 1a)|Participants will receive one intramuscular (IM) injection of 0.5 mL of the PPV-23 vaccine at baseline.
9990422|NCT01443117|Experimental|Step 1: PCV-13 Vaccine (Arm 1b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine at baseline.
9990423|NCT01443117|Placebo Comparator|Step 1: Placebo Vaccine (Arm 1c)|Participants will receive one IM injection of 0.5 mL of the placebo vaccine at baseline.
9990424|NCT01443117|Experimental|Step 2: PPV-23 Vaccine (Arm 2a)|Participants will receive one IM injection of 0.5 mL of the PPV-23 vaccine 6 months after delivery.
9990425|NCT01443117|Experimental|Step 2: PCV-13 Vaccine (Arm 2b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine 6 months after delivery.
9990426|NCT01443143|Experimental|Commercial diet|Commercially available diet program (i.e., Nutrisystem D) that includes pre-packaged low-glycemic index portion-controlled entrees and snacks that are supplemented with grocery items in accordance with a structured meal plan.
9990427|NCT01443143|No Intervention|Usual Diet|Participants' usual consumption of food and beverages.
9990428|NCT01443156||Caregivers|Employees at a local medical facility, including (but not limited to): nurses, laboratory technicians, non-clinical hospital staff
9990429|NCT01443169|Experimental|Sequence 1|
9990430|NCT01443169|Experimental|Sequence 2|
9990431|NCT01443169|Experimental|Sequence 3|
9990432|NCT01443169|Experimental|Sequence 4|
9990433|NCT01443182|Experimental|STAIR + MPE|A two-phased treatment with Skills Training in Affective and Interpersonal Regulation (STAIR) in Phase 1 en modified prolonged exposure (MPE) in Phase 2
9990434|NCT01443182|Active Comparator|STAIR + EMDR|a two-phase treatment Phase 1: Skills Training in Affective and Interpersonal Regulation (STAIR) Phase 2: Eye Movement Desensitization and Reprocessing (EMDR)
9997414|NCT01508715|Active Comparator|Concentric exercise group|The participants in this group will perform the intervention exercises by actively completing the lifting portion of the resistive shoulder exercises. The physical therapist will then perform the lowering portion of the exercise for the participant.
9997415|NCT01508715|Experimental|Eccentric exercise group|The participants in this group will actively perform the lowering portion of the resistive shoulder exercises in the intervention. The physical therapist will perform the lifting portion of the exercise for the participant.
9997416|NCT01508728|Experimental|Active vibration|
9997417|NCT01508728|Placebo Comparator|Placebo Vibration|
9997418|NCT01508741|Active Comparator|5-Aminolevulinic Acid (5-ALA)|Active component 50 mg. capsules of 5-Aminolevulinic Acid (5-ALA)
9997419|NCT01508741|Placebo Comparator|Placebo capsule|Non-active component capsules
9997420|NCT01508754|Active Comparator|CPAP|Treatment with Continuous Positive Airway Pressure
9997421|NCT01508754|No Intervention|Control|Usual anti-hypertensive treatment without CPAP treatment
9997422|NCT01508767|Experimental|Study group 1|Early removal of urethral catheter 48 hours post-operatively.
9997423|NCT01508767|Other|Study group 2|Removal of urethral catheter once epidural analgesia has been withdrawn.
9997424|NCT01508780|Experimental|Pulmonary Arterial Hypertension, bosentan|Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
9997425|NCT01508793|No Intervention|Control|
9997426|NCT01508793|Experimental|Optimize Sleep|
9887840|NCT00561782||Group 3|Able-bodied without history of chronic pain of any type
9887841|NCT00561782||Group 4|Traumatically Brain Injured with a history of pain that onset after their TBI
9887842|NCT00561808|Experimental|Observational|
9887843|NCT00561860|No Intervention|1|This pathway represents our standard clinical protocol when a patient has been diagnosed with sleep apnea and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise.
9517140|NCT03309137|No Intervention|Routine Care|Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.
9887844|NCT00561860|Experimental|2|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
9887845|NCT00561886|Experimental|1|Patients with COPD receiving once 24 µg formoterol
9887846|NCT00561899|Experimental|1|SP+AQ
9887847|NCT00561899|Experimental|2|Piperaquine plus SP arm
9887848|NCT00561899|Experimental|3|Du-Cotecxin
9887849|NCT00561964|Experimental|1|
9887850|NCT00561964|Placebo Comparator|2|
9887851|NCT00561990|Active Comparator|Nimotuzumab|Nimotuzumab
9887852|NCT00561990|Placebo Comparator|Placebo|Placebo
9887853|NCT00562016|Experimental|IMPELLA LP 2.5|
9887854|NCT00562016|Active Comparator|IABP Intra-aortic balloon pump|
9887855|NCT00562029|Experimental|DJB patient|Patient has undergone a duodeno-jejunal bypass
9887856|NCT00562042||1|Patients diagnosed with acute pulmonary embolism were enrolled in this study.
9887857|NCT00562055|Experimental|Arm A|
9887858|NCT00562055|Active Comparator|Arm B|
9887859|NCT00562081|Placebo Comparator|1|Patient does not have 24/7 access to a Certified Asthma Educator.
9887860|NCT00562081|Active Comparator|2|Patient has 24/7 access to a Certified Asthma Educator.
9887861|NCT00562107|Experimental|1|AAIsafeR /SafeR Patient randomized with the SafeR switched ON
9887862|NCT00562107|Experimental|2|DDD(R) mode. Patients randomized with the SafeR mode switched OFF
9887863|NCT00562133|Experimental|1|One Day Treatment with Insulin Glulisine
9887864|NCT00562133|Active Comparator|2|One day Treatment with Human insulin
9887865|NCT00562146||1|Successful progression of spiral tube to duodenum within 3 days
9887866|NCT00562146||2|Failure of progression to duodenum within 3 days
9887867|NCT00562172|Experimental|1|
9887868|NCT00562172|Active Comparator|2|
9887869|NCT00562198|Experimental|1|Investigational drug Stalevo 200
9887870|NCT00562211|Experimental|1|
9887871|NCT00562211|Active Comparator|2|
9887872|NCT00562224|Experimental|Arm 1|All study subjects will receive PCI-24781 (study drug).
9887873|NCT00562237|Placebo Comparator|1|
9887874|NCT00562237|Experimental|2|
9887875|NCT00562237|Experimental|3|
9887876|NCT00562237|Experimental|4|
9887877|NCT00562237|Experimental|5|
9887878|NCT00562237|Experimental|6|
9887879|NCT00562237|Experimental|7|
9887880|NCT00562250|Experimental|Arm 1|
9887881|NCT00562250|Active Comparator|Arm 2|
9887882|NCT00562250|Active Comparator|Arm 3|
9887883|NCT00562263|Experimental|Lifestyle Modification|Parents are randomized to attend 12 educational sessions covering strategies to manage children's health behaviors.
9887884|NCT00562263|No Intervention|Control|Teen participates in lifestyle intervention, but parent does not attend parent education sessions
9887885|NCT00562276|Experimental|1|Immediate IUD insertion following suction aspiration between 5 and 12 weeks gestation
9887886|NCT00562276|No Intervention|2|Delayed IUD insertion 2-6 weeks following suction aspiration between 5 and 12 weeks gestation
9887887|NCT00562289|Active Comparator|aspirin|aspirin use like antiplatelet
9887888|NCT00562289|Experimental|anticoagulant|Antivitamins K or rivaroxaban or dabigatran or apixaban
9887889|NCT00562289|Experimental|Devices for PFO closure|Devices for PFO closure
9887890|NCT00562341||bariatric surgery|description of enrollees
9887891|NCT00562393|Experimental|Overfeeding|4 weeks of 1250 kcal added daily
9887892|NCT00562406|Active Comparator|1|laser photocoagulation to the retina at the area of edema
9887893|NCT00562406|Experimental|2|intravitreal injection of ranibizumab
9887894|NCT00562406|Experimental|3|laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
9887895|NCT00562419|Experimental|1|CT-322
9887896|NCT00562419|Experimental|2|CT-322 and irinotecan hydrochloride
9887897|NCT00562432|Experimental|Plexisyl-AF|Plexisyl-AF implants
9887898|NCT00562432|Sham Comparator|No Treatment|Surgery without experimental treatment
9887899|NCT00562445||1|Peptic bleeding
9887900|NCT00562445||2|Portal hypertension bleeding
9887901|NCT00562445||3|Severe acute pancreatitis
9887902|NCT00562471|Experimental|1|Adhesion Prevention Gel Arm
9887903|NCT00562471|Other|2|Standard of Care Comparator Arm (standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure)
9887904|NCT00562510|Experimental|Raltegravir|
9887905|NCT00562510|Placebo Comparator|Raltegravir matching placebo|
9887906|NCT00562523|Experimental|Arm 1|
9887907|NCT00562536|Experimental|A 1|Delayed umbilical cord clamping 30-45 seconds.
9887908|NCT00562536|No Intervention|A 2|Immediate umbilibcal cord clamping
9887909|NCT00562549|Experimental|1|SLx-2101
9887910|NCT00562549|Placebo Comparator|2|Matching Placebo Dose
9887911|NCT00562562|Other|MOT|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
9887912|NCT00562614|Experimental|1|SLx-2101
9887913|NCT00562614|Placebo Comparator|2|Comparative Placebo Dose
9887914|NCT00562640|Experimental|WT1-Specific T Cells|This is a phase I dose escalating trial designed to identify tolerable, clinically active doses of Wilms' tumor gene (WT1) peptide sensitized T cells when administered alone or with nonmyelosuppressive chemotherapy in patients with recurrent or persistent, evaluable WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas.
9887915|NCT00562653||1|infective endocarditis patients before treatment
9887916|NCT00562653||2|infective endocarditis treatment after treatment
9887917|NCT00562653||3|control
9887918|NCT00562666|Experimental|1|Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes
9887919|NCT00562666|Experimental|2|Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes
9887920|NCT00562666|Experimental|3|Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes
9887921|NCT00562666|Experimental|4|Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes
9887922|NCT00562679||2 groups|The cohort is grouped according to one group with sleep apnea and one group without sleep apnea
9887923|NCT00562692|Experimental|A|Nesiritide
9887924|NCT00562692|Placebo Comparator|B|Placebo
9887925|NCT00562705|Experimental|1|Growth hormone and nutritional intervention
9887926|NCT00562705|Active Comparator|2|growth hormone
9931824|NCT00942253|Placebo Comparator|Placebo Group|"Dialysis patients will receive placebo for 24 weeks following a 24 weeks period of combined treatment with placebo and aerobic intradialytic exercise.~Patients will be given evening doses of placebo, 2 hours before bedtime."
9931825|NCT00942292|Active Comparator|Lipidem (fish oil)|Lipidem (TPN containing fish oil)
9931826|NCT00942292|Active Comparator|Lipofundin (TPN)|Control arm (no fish oil)
9931827|NCT00942318|Experimental|PPE|PPE : CSII +/- Metformin.
9931828|NCT00942318|Active Comparator|injections|INJ: basal/bolus MDI +/- Metformin
9931829|NCT00942370||accelerometric device|
9931830|NCT00942383||IOUS-USEI|Receive intraoperative ultrasound (IOUS) using the Siemens Anteras to acquire ultrasound elasticity imaging (USEI) during standard of care surgical radiofrequency ablation and microwave ablation
9931831|NCT00942396|Experimental|mammography|Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography
9931832|NCT00942435|Experimental|YM150 group|
9931833|NCT00942435|Active Comparator|mechanical prophylaxis group|
9931834|NCT00942461|Active Comparator|Laparoscopic Surgery group|Group of patients that are operated with laparoscopic approach
9931835|NCT00942461|Active Comparator|Open surgery Group|Group of patients operated with open approach
9931836|NCT00942474|Experimental|Research Arm|Facilitate nerve stimulation lead placement with the nerve access tool
9931837|NCT00942487|Experimental|Nebivolol|
9931838|NCT00942487|Active Comparator|Metoprolol|
9931839|NCT00942500|Experimental|Post-conditioning|
9931840|NCT00942500|No Intervention|Conventional primary PCI|
9931841|NCT00942526|No Intervention|1|no intervention with perioperative oral anti-infective agent or water for gargling
9931842|NCT00942526|Sham Comparator|2|perioperative gargling with water
9931843|NCT00942526|Experimental|3|perioperative oral gargling with oral anti-infective agent for seven days
9931844|NCT00942539|Experimental|Midazolam|Administration of Midazolam prior Lumbar Puncture
9931845|NCT00942565|Active Comparator|Tramadol/acetaminophen|The tramadol and acetaminophen combination was given to patients at the same day after surgery.
9931846|NCT00942565|Active Comparator|acetaminophen|Acetaminophen was used as active control.
9931847|NCT00942591|Experimental|1|Interferon beta-1b AND atorvastatin
9931848|NCT00942591|Active Comparator|2|Interferon beta-1b
9931849|NCT00942617|Experimental|40 mg non-enteric coated aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
9931850|NCT00942643|No Intervention|no treatment|being observed at 4 weeks and 12 weeks
9931851|NCT00942643|Active Comparator|CPAP treatment|a machine delivers positive airway pressure into the upper airway via nasal mask
9931852|NCT00942669|Experimental|SleepStrip OTC(TM)|Participants will receive the SleepStrip OTC(TM) for a night (or two) test at home, before or after undergoing an independent PSG test at the Sleep lab. The reading of both methods will be analyzed.
9931853|NCT00942682|Experimental|Sorafenib and RAD001|"Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have neuroendocrine tumors, not everyone who participates in this research study will receive the same dose of the study drug. The dose the participant will be given will depend on the number of participants who have been enrolled in the study.~Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in the morning. Participants will take sorafenib orally twice daily.~Participants will remain on this research study as long as they continue to benefit from the study medications."
9931854|NCT00942695|Other|base|average American diet without pistachios
9887927|NCT00562744|Experimental|SIM|Participants complete training and assessment of performance in PALS scenarios using high-fidelity simulator
9887928|NCT00562744|No Intervention|MAN|Participants complete training and assessment of performance in PALS scenarios using mannequin
9887929|NCT00562757||A|Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups
9887930|NCT00562770|Active Comparator|1|Valacyclovir
9887931|NCT00562770|Active Comparator|2|Valganciclovir
9887932|NCT00562796||1|Participants with abdominal obesity without growth hormone deficiency
9887933|NCT00562796||2|Participants with abdominal obesity with growth hormone deficiency
9887934|NCT00562796||3|Participants who are lean controls
9887935|NCT00562822|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery optimized with physical and medical therapy
9887936|NCT00562822|Active Comparator|Physical and medical therapy|treatment with physical and medical therapy alone
9887937|NCT00562835|Active Comparator|1|Methylprednisolone
9887938|NCT00562835|Placebo Comparator|2|
9887939|NCT00562848|Experimental|Subjects enrolled in single dose escalation cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
9887940|NCT00562848|Experimental|Subjects enrolled in gastric emptying cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
9887941|NCT00562848|Experimental|Subjects enrolled in gastro-enteral contractility cohort|Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.
9887942|NCT00562874|Experimental|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months.
9887943|NCT00562874|Active Comparator|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy flour as an ingredient for 5 days each week for 12 months.
9887944|NCT00562874|Sham Comparator|Wheat Biscuit|75 women and one of their children will receive a biscuit containing pm;u wheat flour as a source of protein as an ingredient for 5 days each week for 12 months.
9887945|NCT00562900|Active Comparator|A, robotic|
9887946|NCT00562900|Active Comparator|B, laparoscopic|
9887947|NCT00562913|Experimental|Arm 1|
9887948|NCT00562939|Experimental|A|1 mg CpG 7909 + pneumococcal vaccines
9887949|NCT00562939|Placebo Comparator|B|Pneumococcal vaccines
9887950|NCT00562952|Active Comparator|1|Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
9887951|NCT00562952|Placebo Comparator|2|Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.
9887952|NCT00562991||FeNO group|asthma patients, exhaled NO is used to monitor asthma
9887953|NCT00562991||Symptom group|asthma patients, exhaled NO is not used to monitor asthma
9887954|NCT00563004|Active Comparator|A|Patients receive the herbal medication DBCARE for 3 months
9887955|NCT00563004|Placebo Comparator|B|PATIENTS RECEIVE PLACEBO PILLS
9887956|NCT00563030||1|Patients undergoing CABG with CPB
9887957|NCT00563030||2|Patients undergoing off-pump CABG
9887958|NCT00563056|Experimental|Flutiform|2 puffs 50/5 or 125/5 mcg
9887959|NCT00563056|Active Comparator|Flixotide plus Foradil|Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg
9887960|NCT00563082||1|SLE participants positive for both APA and CHD
9887961|NCT00563082||2|Normal participants with a high titer of APA
9887962|NCT00563147|Experimental|A|tivozanib (AV-951) plus temsirolimus
9887963|NCT00563173|Other|1|Low dose
9887964|NCT00563173|Other|2|Medium dose
9887965|NCT00563173|Other|3|High dose
9887966|NCT00563212|Experimental|A1|
9887967|NCT00563238|No Intervention|Control|
9887968|NCT00563238|Active Comparator|Metoprolol|
9887969|NCT00563264|Active Comparator|1|Participants receive monthly newsletter (for 10 months) including general health and reading information for child and mother and incentives for completing the baseline and 2 follow-up assessments
9931855|NCT00942695|Active Comparator|1.5PD|average American diet plus 1.5 oz per day pistachios
9887970|NCT00563264|Experimental|2|Mothers and preschoolers in the intervention group will receive monthly mailed family kits that encourage interactive mother/child exercises for healthy lifestyle change. Mailings are supported by counseling calls and two in-person motivational/informational group sessions. The content of the intervention addresses parenting skills, healthy eating, and physical activity. Families can earn $40 for returning postcards describing their activities in the past month.
9887971|NCT00563303|Experimental|H|Hydrocortisone
9887972|NCT00563303|Placebo Comparator|P|Treatment by NaCl (placebo)
9887973|NCT00563394|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
9887974|NCT00563394|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
9887975|NCT00563433|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
9887976|NCT00563433|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
9887977|NCT00563472|Active Comparator|1|10 mg estetrol
9887978|NCT00563472|Active Comparator|2|20 mg estetrol
9887979|NCT00563472|Active Comparator|3|20 mg estetrol and 150 microg desogestrel
9887980|NCT00563472|Active Comparator|4|20 mg E4 and 200 mg progesterone
9887981|NCT00563524|Placebo Comparator|1|
9887982|NCT00563537|Experimental|1|18F-X PET Scan imaging
9887983|NCT00563602|Active Comparator|2|Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)
9887984|NCT00563602|Experimental|1|"Hemodynamic guided therapy:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
9887985|NCT00563641|Experimental|1|Early NCPAP plus very early surfactant
9887986|NCT00563641|Active Comparator|2|NCPAP alone
9887987|NCT00563693|Experimental|A|The patients use ASV
9887988|NCT00563693|Active Comparator|B|Patients without ASV
9887989|NCT00563745|Experimental|Telemedicine|Patients were submitted to a Telemedicine program for 1 year
9887990|NCT00563745|No Intervention|Control group|Patients were submitted to usual care (i.e: educational plan and outpatient visits every 3 months)
9887991|NCT00563836|Experimental|1|
9887992|NCT00563888|Experimental|A|Narrative Exposure Therapy (NET)
9887993|NCT00563888|No Intervention|B|Waitinglist Control Group
9887994|NCT00563901||1|Adults with a high risk for high blood pressure from the ALLHAT study
9887995|NCT00563914|Experimental|1|
9887996|NCT00563914|Active Comparator|2|
9887997|NCT00563940||1|
9887998|NCT00563940||2|
9887999|NCT00563953|Experimental|1|Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
9888000|NCT00563979|Active Comparator|1|VitaluxPlus®
9888001|NCT00563979|Active Comparator|2|Omega 3
9888002|NCT00563992|Experimental|1|Participants will take lithium for 12 months
9888003|NCT00563992|Experimental|2|Participants will take valproate for 12 months
9888004|NCT00564005|Experimental|1|constraint-induced therapy
9888005|NCT00564005|Experimental|2|bilateral arm training
9888006|NCT00564005|Experimental|3|combined therapy
9888007|NCT00564005|Active Comparator|Control intervention|
9888008|NCT00564031|Placebo Comparator|1|
9888009|NCT00564031|Experimental|2|
9888010|NCT00564031|Experimental|3|
9888011|NCT00564031|Experimental|4|
9888012|NCT00564044|Active Comparator|2|
9888013|NCT00564057|Experimental|1|candesartan 8-16 mg once daily
9888014|NCT00564057|Active Comparator|2|lercanidipine 10-20 mg once daily
9888015|NCT00564096|Active Comparator|Real TMS|10 patients will be given 20 minutes stimulation with real deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 20 consecutive working days.
9888016|NCT00564096|Placebo Comparator|Sham & real TMS|10 patients will be given 20 minutes stimulation with sham deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 10 consecutive working days, and thereafter 20 sessions of real TMS with the same parameters (=Left Tempor-oparietal Cortex in frequency of 1 Hz with 120% motor threshold).
9888017|NCT00564122||All subjects|
9888018|NCT00564135|Experimental|A B C|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
9888019|NCT00564148|Experimental|A,1, II|
9888020|NCT00564161||1|
9888021|NCT00564161||2|
9888022|NCT00564174|Experimental|a|
9888023|NCT00564174|Active Comparator|b|Low dose aspirin only
9888024|NCT00564187|Active Comparator|1|"Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
9888025|NCT00564187|Active Comparator|2|• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
9888026|NCT00564213|Experimental|1|A single intraoperative topical application of mitomycin C 0.02% for 15 seconds
9888027|NCT00564213|Experimental|2|A single intraoperative topical application of mitomycin C 0.02% for 30 seconds
9888028|NCT00564239|Experimental|A|
9888029|NCT00564239|Active Comparator|B|
9888030|NCT00564239|No Intervention|C|
9888031|NCT00564291||1|Healthy volunteers
9888032|NCT00564291||2|CSME secondary to diabetic retinopathy
9888033|NCT00564291||3|ARMD with CNV before and after therapy
9888034|NCT00564291||4|ARMD atrophic
9888035|NCT00564291||5|Retinal vein occlusion
9888036|NCT00564291||6|retinitis pigmentosa
9888037|NCT00564291||7|vitreoretinal proliferation
9888038|NCT00564317|Experimental|1 KIDNET|Narrative Exposure Therapy for Children
9888039|NCT00564317|Experimental|2 Meditation/Relaxation|mixed Meditation/Relaxation Protocol
9888040|NCT00564317|Experimental|3 KIDNET + Meditation/Relaxation|KIDNET according to protocol, waiting time of 5 months, then Meditation/Relaxation according to protocol
9888041|NCT00564317|Experimental|4 Meditation/Relaxation + KIDNET|Med/Relax according to protocol, 5 months waiting time, KIDNET according to protocol
9931856|NCT00942695|Active Comparator|3.0PD|average American diet plus 3.0 oz per day pistachios
9931857|NCT00942721|Experimental|Web-based CBT for PPD|Participants will receive Web-based CBT for PPD.
9931858|NCT00942747|Experimental|Temsirolimus|Weekly IV temsirolimus
9931859|NCT00942760||Research MRI|High Grade Glioma patients who show progression based on MRI
9931860|NCT00942773|Active Comparator|CYP2C19 extensive metabolizer|
9931861|NCT00942773|Active Comparator|CYP2C19 heterozygous extensive metabolizer|
9931862|NCT00942773|Active Comparator|CYP2C19 poor metabolizer|
9931863|NCT00942799|Experimental|Study Drug: Genz-644282 (28-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
9931864|NCT00942799|Experimental|Study Drug: Genz-644282 (21-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
9931865|NCT00942812|Experimental|Intervention|A diarrhea Pack comprising of low osmolality ORS, Zinc, water purification sachets and pictorial chart.
9931866|NCT00942812|Other|Control|Standard Care through National LHW (Lady Health Workers)program
9931867|NCT00942916||Patients with confirmed diagnosis of NTM pulmonary disease|Those with sputum mycobacterial culture yielded the same NTM species for at least two sets within one year.
9931868|NCT00942916||Patients with not definite NTM pulmonary disease|Those who had sputum culture yielded NTM but did not satisfy the criteria for diagnosis with NTM pulmonary disease.
9931869|NCT00942929||Adolescents hospitalized for anorexia nervosa|Adolescent 12-18 years old, fulfilling the DSM IV criteria for anorexia nervosa, hospitalized for medical stabilization and/ or initiation of refeeding
9931870|NCT00942929||Controls|Adolescents 12-18 years old without anorexia nervosa hospitalized for reasons other than those involving the respiratory system and with no underlying lung disease
9931871|NCT00942955||CLT|The patients whose blood are analyzed by conventional central laboratory.
9931872|NCT00942955||POCT|the patients group whose lab analyze by POCT device.
9931873|NCT00943007|Active Comparator|Conventional Neuronavigation|Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift
9931874|NCT00943007|Experimental|Intraoperative MRI|Standard neuronavigation plus intraoperative MRI to correct for brain shift
9931875|NCT00943020|Active Comparator|Nutricia PreOp + Lipid|Nutricia PreOp + Lipid
9931876|NCT00943020|Active Comparator|Nutrica PreOP + Glutamine|Nutrica PreOP + Glutamine
9931877|NCT00943020|Experimental|Nutricia PreOP|Nutricia PreOP: carbohydrate only drink
9931878|NCT00943033|Experimental|Mindfulness-Based Cognitive Therapy plus treatment as usual|
9931879|NCT00943033|No Intervention|MBCT Waitlist plus Treatment as Usual|
9931880|NCT00943046|Experimental|Siello pacemaker lead|Patients with Siello Pacemaker lead
9931881|NCT00943059|Experimental|Acipimox|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
9931882|NCT00943059|Placebo Comparator|Cellulosum mycrocryst capsula|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
9931883|NCT00943085|Experimental|Family-focused therapy|Participants will receive family-focused therapy.
9931884|NCT00943085|Active Comparator|Brief educational treatment|Participants will receive one session of diagnostic feedback, recommendations for continued treatment, and crisis intervention as needed.
9931885|NCT00943137|Experimental|5-FU dosage adjustments|The dose of continuous infusion 5-FU will be adjusted every cycle until patients reached the therapeutic plasma range (450 to 550 microgram/L).
9931886|NCT00943176|Placebo Comparator|Sugar Pill|
9931887|NCT00943176|Experimental|Modafinil|
9931888|NCT00943228|Experimental|mycophenolate mofetil|mycophenolate mofetil 2000mg BID (4g/day) for 14 days, followed by mycophenolate 1000mg BID (2g/day) thereafter
9931889|NCT00943254|Experimental|Arm 1|"Patients randomized to this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based and DVD materials"
9931890|NCT00943254|Experimental|Arm 2|"Patients in this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based material"
9888042|NCT00564330|Active Comparator|esomeprazole|Esomeprazole 20mg twice daily
9888043|NCT00564330|Placebo Comparator|placebo|Placebo tablet twice daily
9888044|NCT00564343||ChSt, water training, Observation|Subjects suffer from chronic hemiplegia (a year or more post stroke) that upon questioning was judged to meet the following inclusion criteria: (a) able to stand independently 90 seconds; (b) able to walk 10 meters (with cane if necessary); (c) able to understand verbal instructions. The exclusion criteria will be: (a) Serious visual impairment; (b) Inability to ambulate independently (cane acceptable, walker not). (c) Severely impaired cognitive status (score less then 24 in Mini Mental State Examination). (d) Persons with impaired communication capabilities.
9888045|NCT00564356|Other|A|patients under coumadin and antiaggregants operated by phacoemulsification
9888046|NCT00564369|Experimental|1|2006 CDC recommendations
9888047|NCT00564369|Active Comparator|2|Prior CDC recommendations
9888048|NCT00564382|Other|1|Patients with ACS in the emergency department and primary tests (ECG, TNT) negative for myocardial ischemia
9888049|NCT00564408|Experimental|I|
9888050|NCT00564460|Active Comparator|1|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
9888051|NCT00564460|Placebo Comparator|2|Placebo
9888052|NCT00564473||A|patients hospitalized in the Department of Internal Medicine of the Shaare Zedek Medical Center, Jerusalem, Israel.
9888053|NCT00564512|Experimental|FCCAM|Fludarabine-Cyclophosphamide-Campath (FCCam) Oral Fludarabine: 40 mg/m2 per os, D1 to D3 Oral Cyclophosphamide: 250 mg/m2/day as one dose at noon, D1 to D3 Campath®: 30 mg sc, D1 to D3 without dose escalation
9888054|NCT00564512|Active Comparator|FCR|"Fludarabine-Cyclophosphamide-Rituximab (FCR)~First course:~Rituximab 375 mg/m2 on D1.~D2 to D4:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon~Subsequent courses (2 to 6)~Rituximab 500 mg/m2 on D1~D1 to D3:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon"
9888055|NCT00564525|Placebo Comparator|1|
9888056|NCT00564525|Experimental|2|Amitriptyline given
9888057|NCT00564538|Experimental|1|Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
9888058|NCT00564538|Active Comparator|2|patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
9888059|NCT00564551|Active Comparator|2|High dairy intake and calcium supplement. High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
9888060|NCT00564551|Placebo Comparator|1|Usual diet of low dairy and calcium intake. Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet.
9888061|NCT00564564|Experimental|Quetiapine augmentation|Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage
9888062|NCT00564564|Active Comparator|Clomipramine augmentation|Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage
9888063|NCT00564577|Other|CFA/I and CS17 challenge strain|Colonization factor antigen (CFA/I) and CS17 challenge strainAscending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
9888064|NCT00564590|Experimental|A|Melatonin treatment group
9888065|NCT00564590|Active Comparator|B|Omeprazole 20 mg once a day for 3 months
9888066|NCT00564590|Experimental|C|Placebo once a day for 3 months
9888067|NCT00564603|Placebo Comparator|1|Saline with same volume added to tramadol infusion combined with morphine PCA.
9888068|NCT00564603|Active Comparator|2|Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
9888069|NCT00564616|Placebo Comparator|voice group|"the voice group received voice CPR instruction via a voice-only cell phone"
9888070|NCT00564616|Experimental|video group|"the video group received interactive voice and video instruction via a video cell phone"
9888071|NCT00564655|Active Comparator|1|Patients in the control group will receive localized infiltration of local anesthesia at the beginning of the procedure as is current standard practice.
9888072|NCT00564655|Experimental|2|Patients in the experimental group will receive a regional anesthetic blockade of the anterior abdominal wall via the transversus abdominis plane.
9888073|NCT00564707|Active Comparator|1|Standard biofeedback therapy will be given for painful levator ani syndrome over a course of eight weeks.
9888074|NCT00564707|Active Comparator|2|Botulinum toxin type A will be injected under EMG guidance into spastic and painful levator ani muscles. This may be repeated only twice on separate visits.
9888075|NCT00564720|Experimental|1|GEM/TAR
9888076|NCT00564720|Experimental|2|GEM/OX/TAR
9888077|NCT00564746|Experimental|6 subjects in a single cohort|Each subject will be administered a single 10 milligrams (50 microcurie) oral dose of [14C]SB-681323.
9888078|NCT00564772|Experimental|single arm|all subjects dosed the same
9888079|NCT00564785|Placebo Comparator|Placebo|
9888080|NCT00564785|Experimental|Synera(TM)|
9888081|NCT00564798||1|Study Group
9888082|NCT00564798||2|Control Group
9888083|NCT00564811|No Intervention|G1|
9888084|NCT00564811|Experimental|G2|
9931891|NCT00943254|No Intervention|Arm 3|Patients randomized to control receive the diagnosis of individual cardiovascular risk factors with paper-based educational material
9931892|NCT00943267|Experimental|Activated protein C|
9931893|NCT00943267|Placebo Comparator|Saline|
9888085|NCT00564824|Experimental|CAD patients|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
9888086|NCT00564824|Experimental|Placebo|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
9888087|NCT00564837|Experimental|Home-based|Home-based post-operative rehabilitation program with 4 scheduled physiotherapy sessions over the first 3 post-op months
9888088|NCT00564837|Active Comparator|Physiotherapy supervised|Physiotherapy-supervised rehabilitation program including 17 scheduled physiotherapy sessions in the first 3 post-op months
9888089|NCT00564863|Other|CS19 expressing ETEC strain|Ascending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
9888090|NCT00564941|Experimental|Deferasirox|
9888091|NCT00564967|Experimental|1|CBT via the Internet
9888092|NCT00564967|Experimental|2|15 weeks, CBT group therapy, 1 session/week (2.5 hours).
9888093|NCT00564980|Active Comparator|1|Wafer Procedure
9888094|NCT00564980|Active Comparator|2|Ulnar shortening osteotomy
9888095|NCT00564993|Active Comparator|A|"necessary re-intervention (pulmonary valve replacement) after repair of Fallot:~2 Visits with cardiac imaging under rest and stress (Dobutamin) before and after pulmonary valve replacement"
9888096|NCT00564993|Active Comparator|B|"comparison group: with a good result of repair of tetralogy of fallot and good ventricular function:~1 Visit with cardiac imaging under rest and stress (Dobutamin)"
9888097|NCT00565019|No Intervention|Control|
9888098|NCT00565019|Experimental|Steroid|
9888099|NCT00565071|Other|Field microscopy|Field microscopy is the main method of malaria diagnosis
9888100|NCT00565071|Other|Paracheck Pf® device|Paracheck Pf® device (Rapid Diagnostic Test) is the main method for malaria diagnosis
9888101|NCT00565071|No Intervention|Presumptive diagnostic method|
9888102|NCT00565097|Placebo Comparator|2|Placebo
9888103|NCT00565097|Experimental|1|Lanreotide
9888104|NCT00565123|Experimental|Group A|Experimental dosage
9888105|NCT00565123|Active Comparator|Group B|Classical dosage
9888106|NCT00565149|Experimental|1|Normal Protein (15%) diet
9888107|NCT00565149|Experimental|2|Low Protein (5%) diet
9888108|NCT00565149|Experimental|3|High Protein (25%) diet
9888109|NCT00565175|Experimental|famotidine|
9888110|NCT00565175|Placebo Comparator|Placebo|
9888111|NCT00565188|Experimental|I|
9888112|NCT00565188|No Intervention|C|
9888113|NCT00565201|Experimental|Botox and Rehab|"Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site).~Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs."
9888114|NCT00565201|Placebo Comparator|Placebo and Rehab|Patients will placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
9888115|NCT00565214|Active Comparator|Group 1|On Day 1, Group 1 will initiate in a double-blinded fashion, a once daily vitamin combination of selenomethionine(400 μg), vitamin E(400 IU), and vitamin C (1000 mg) orally for 30 days at home. After 30 days of treatment with Vitamin supplements, the gene expression of the airway epithelium will be compared to that of the Placebo group.
9888116|NCT00565214|Placebo Comparator|Group 2|On Day 1, Group 2 will initiate the placebo in a double-blinded fashion.
9888117|NCT00565227|Experimental|docetaxel plus vorinostat|
9888118|NCT00565240|Experimental|Oral Contraceptive|
9888119|NCT00565240|Experimental|Contraceptive Ring|
9888120|NCT00565240|Experimental|Aromatase Inhibitors|
9888121|NCT00565240|No Intervention|Control|
9888122|NCT00565279|Experimental|ASF1057|
9888123|NCT00565279|Placebo Comparator|ASF1057 placebo|
9888124|NCT00565279|Placebo Comparator|ASF1057 Vehicle|
9888125|NCT00565305|Experimental|Healing Touch|Healing Touch + Standard Treatment Healing Touch treatments daily following standard Radiation Therapy. Standard radiation therapy is part of their medical care and is not administered as part of this study. Protocol of 4 HT techniques will be used including Pain Drain, Chakra connection, Magnetic Unruffling, and Mind Clearing. Treatments will be approximately 20-30 minutes.
9888126|NCT00565305|Active Comparator|Usual Care|Standard Treatment. These patients receive usual medical care but no additional intervention. Standard treatment is not administered as part of this study but as part of their medical treatment.
9888127|NCT00565318|Active Comparator|A|
9888128|NCT00565318|Placebo Comparator|B|
9888129|NCT00565331|Active Comparator|1|Rituximab
9888130|NCT00565331|Placebo Comparator|2|Placebo
9888131|NCT00565357|Experimental|E|
9888132|NCT00565357|No Intervention|C|
9888133|NCT00565383|Active Comparator|Intravenous fentanyl analgesia|Intravenous fentanyl (50 mcg) analgesia
9888134|NCT00565383|Experimental|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia (intrathecal fentanyl 2.5 mg plus bupivacaine 2.5 mg) single administration
9888135|NCT00565396|Active Comparator|1|Fosinopril 10mg/day(oral)
9888136|NCT00565396|Active Comparator|2|Fosinopril 20mg/day(oral)
9888137|NCT00565396|Active Comparator|3|Losartan 50mg/day(oral)
9888138|NCT00565396|Active Comparator|4|Losartan 100mg/day(oral)
9888139|NCT00565422|Experimental|Single Arm|Escitalopram
9888140|NCT00565461|Experimental|Group 1|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
9888141|NCT00565461|Experimental|Group 2|40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
9888142|NCT00565461|Experimental|Group 3|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
9888143|NCT00565461|Experimental|Group 4|40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
9888144|NCT00565474|Active Comparator|1|fluvastatin 40mg b.i.d.
9888145|NCT00565474|Placebo Comparator|2|Placebo b.i.d.
9888146|NCT00565487|Experimental|Single arm|This is a single arm dose escalation study with a cohort expansion.
9888147|NCT00565500|Experimental|1|
9888148|NCT00565500|Experimental|2|
9888149|NCT00565500|Placebo Comparator|3|
9888150|NCT00565513|Other|A|cord blood and maternal milk tests
9888151|NCT00565552|Active Comparator|1|Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
9888152|NCT00565565|Experimental|BAY60-4552, 1 mg|Subjects were planned to receive 1 mg of BAY60-4552 as solution
9888153|NCT00565565|Experimental|BAY60-4552, 2.5 mg|Subjects were planned to receive 2.5 mg of BAY60-4552 as tablet
9888154|NCT00565565|Experimental|BAY60-4552, 5 mg|Subjects were planned to receive 5.0 mg of BAY60-4552 as tablet
9888155|NCT00565565|Experimental|BAY60-4552, 7.5 mg|Subjects were planned to receive 7.5 mg of BAY60-4552 as tablet
9888156|NCT00565565|Experimental|BAY60-4552, 10 mg|Subjects were planned to receive 10 mg of BAY60-4552 as tablet
9888157|NCT00565591|Placebo Comparator|Dose escalation|
9888158|NCT00565630|Experimental|1|Vigamox via the experiemntal device
9888159|NCT00565630|Active Comparator|2|Vigamox drops from the commercially available bottles
9888160|NCT00565656|Experimental|A|Bevacizumab
9888161|NCT00565682|Experimental|A|Etoricoxib 120 mg
9888162|NCT00565708|Experimental|acetylsalicylic acid|200mg OD for 3 years
9888163|NCT00565708|Placebo Comparator|Placebo|200mg OD for 3 years
9888164|NCT00565734||Posterior surgical approaches|Posterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM)
9888165|NCT00565734||Anterior surgical approaches|Anterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM).
9888166|NCT00565786||ArCom® Polyethylene|ArCom® Polyethylene
9888167|NCT00565786||ArComXL® Polyethylene|ArComXL® Polyethylene
9888168|NCT00565799|Active Comparator|1. Omentectomy|LAGB & Omentectomy
9888169|NCT00565799|Placebo Comparator|2 No Omentectomy|LAGB Only
9888170|NCT00565838||2|G1 - Autologous Fascial Sling G2 - TVT
9888171|NCT00565877|Experimental|1 - Neck Ultrasound|post-PICC insertion ultrasound inspection of the ipsilateral neck
9888172|NCT00565877|No Intervention|2 - Control|No post-PICC insertion ultrasound inspection of the ipsilateral neck
9888173|NCT00565890|No Intervention|2|No replacement therapy
9888174|NCT00565929|Experimental|Group A: MVA-BN 1 X 10^7 TCID 50|10 participants to receive vaccine dose 1X10^7 TCID 50; 2 participants to receive placebo.
9888175|NCT00565929|Experimental|Group B: MVA-BN 1 X 10^8 TCID 50|10 participants to receive vaccine dose 1X10^8 TCID 50; 2 participants to receive placebo.
9888176|NCT00565942|Active Comparator|Usual care|Treatment as usual coordinated by general practitioners in primary care.
9888177|NCT00565942|Active Comparator|Integrative care|Selected complementary therapies (Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong) added to usual care.
9888178|NCT00565955|Active Comparator|A1|Children Between 5-15 Years of Age Receiving Montelukast
9888179|NCT00565955|Placebo Comparator|A2|Children Between 5-15 Years of Age Receiving Placebo
9888180|NCT00565968|Experimental|Sorafenib dose escalation|
9888181|NCT00565981|Experimental|Overall study|The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting
9888182|NCT00565994||Hemodialysis patients|Male and female patients undergoing hemodialysis therapy as outpatients
9888183|NCT00565994||Control|Male and female healthy volunteers
9888184|NCT00565994||Pre-dialysis patients|Male and female patients with Stage 3, 4, or 5 chronic kidney disease, but not yet on dialysis
9888185|NCT00566007|Active Comparator|1|Discectomy/micro discectomy
9888186|NCT00566007|Active Comparator|2|Intradiscal ozone infiltration
9888187|NCT00566007|Active Comparator|3|Intradiscal oxygen infiltration (control arm)
9888188|NCT00566033|Experimental|1|
9888189|NCT00566033|No Intervention|2|Patients in this arm (arm 2) will undergo to standard care.
9888190|NCT00566046|Experimental|Levetiracetam|
9888191|NCT00566046|Placebo Comparator|Placebo|
9888192|NCT00566072|Experimental|1|instructions and coaching on the use and intake of ganciclovir
9888193|NCT00566072|No Intervention|2|
9888194|NCT00566085|Other|Molecular Breast Imaging|
9888195|NCT00566124|Active Comparator|1|Insulin detemir
9888196|NCT00566124|Active Comparator|2|Insulin glargine
9888197|NCT00566124|Active Comparator|3|NPH insulin
9931894|NCT00943280||1 EGD|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to EGD.
9931895|NCT00943280||2 Transnasal|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to Transnasal endoscopy.
9931896|NCT00943280||3 PillCam|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to PillCam.
9935530|NCT03549715|Experimental|ARM B: durvalumab + tremelimumab+ ddMVAC|"durvalumab + tremelimumab + ddMVAC Tremelimumab 75 mg IV D1 every 28 days Tremelimumab will be administered first, with durvalumab infusion starting approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion.~Infusion of ddMVAC will start approximately 1 hour after completion of durvalumab."
9935531|NCT03539341|Experimental|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
9935532|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
9935533|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy for endometrial cancer or precursors
9935534|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
9935535|NCT03538652|Placebo Comparator|EMA only|Randomized control group undergoing mobile assessment without JITAI
9935536|NCT03538652|No Intervention|Formative Interviews|First stage, before content of mobile intervention is finalized
9935537|NCT03538652|Active Comparator|JITAI|Group receiving microrandomized active intervention: JITAI with both CBT and ACT
9935538|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
9935539|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
9935540|NCT03538639||3|Healthy adult volunteers
9935541|NCT03538626|Experimental|1|5 mg/kg IV
9935542|NCT03538626|Experimental|2|5 mg/kg SC
9935543|NCT03538626|Experimental|3|20 mg/kg IV
9935544|NCT03538626|Experimental|4|40 mg/kg IV
9935545|NCT03538626|Experimental|5|5mg/kg SC
9935546|NCT03538626|Experimental|6|20 mg/kg IV
9935547|NCT03538626|Experimental|7|5mg/kg SC + 2000 U/ml rHuPH20
9935548|NCT03538626|Experimental|8|20 mg/kg SC+ 2000 U/ml rHuPH20
9935549|NCT03538600||Healthy Volunteers|healthy volunteers
9935550|NCT03538587|Active Comparator|1/EMI Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions.
9935551|NCT03538587|Active Comparator|2/Control Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
9935552|NCT03535129|No Intervention|Stage 1|Pilot portion to optimize intervention and achievecorrelational research aims
9935553|NCT03535129|Experimental|Stage 2|Main Clinical Trial with random assignment
9935554|NCT03534245||1|Healthy children aged 2 - 9 years
9935555|NCT03531814|Experimental|1/Intervention|Questionnaires and use of the medication event monitoring system (MEMS)
9935556|NCT03529019|Experimental|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
9935557|NCT03523442|Experimental|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days. After final analysis (FA), participants who are receiving apalutamide in the open-label treatment phase may continue receiving single oral dose apalutamide 240 mg once daily in a long-term extension (LTE) phase if they continue to derive benefit from treatment (based on investigator assessment).
9935558|NCT03520660|Experimental|Phase I|Phase I treatment
9888198|NCT00566189|Experimental|1|Roux-en-Y bypass gastroplasty
9888199|NCT00566215|Experimental|1|Duodenal exclusion plus total omentectomy
9888200|NCT00566215|Active Comparator|2|Duodenal exclusion without omentectomy
9888201|NCT00566241|Experimental|IGF-1|Recombinant human IGF-1
9888202|NCT00566241|Placebo Comparator|Placebo|Placebo
9888203|NCT00566267|Experimental|2|Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg
9888204|NCT00566280|Other|Molecular Breast Imaging|
9888205|NCT00566306|Experimental|A|PHMG will be introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets will be coated with biocide coating (PHMG) as well as bed frames in investigational wards.
9888206|NCT00566306|No Intervention|B|Three wards will be control wards and continue using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines.
9888207|NCT00566319|Experimental|1|
9888208|NCT00566319|Active Comparator|2|
9888209|NCT00566332|Active Comparator|1|Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
9888210|NCT00566332|Active Comparator|2|Fludarabine
9888211|NCT00566358|Experimental|1|Duodenal exclusion
9888212|NCT00566371|Experimental|1|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
9888213|NCT00566371|Placebo Comparator|2|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
9888214|NCT00566384|Active Comparator|Arm 1|
9888215|NCT00566384|Placebo Comparator|Arm 2|
9888216|NCT00566423|Experimental|1|Patients with Pulmonary Arterial Hypertension
9888217|NCT00566436|Active Comparator|REA|Patients presenting with a long occlusion of the superficial femoral artery enrolled in REA arm will undergo remote endarterectomy of the occluded superficial femoral artery
9888218|NCT00566436|Active Comparator|Bypass|Patients presenting with a long occlusion of the superficial femoral artery enrolled in Bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery
9888219|NCT00566475|No Intervention|1|Usual care of type 1 diabetes at the diabetes center
9888220|NCT00566475|Experimental|2|Usual care at the diabetes center supplemented by a telemedicine intervention in the school involving school personnel, the child with diabetes and at least 1 parent of the child. The diabetes center NP conducts videovisits with the school nurse, patient (child) +/- parent monthly.
9888221|NCT00566514|Active Comparator|1|D-ribose 5 grams TID orally
9888222|NCT00566514|Placebo Comparator|2|Dextrose 5 grams TID
9888223|NCT00566553|Active Comparator|Grape Seed Extract # 1|200 mg [1 pill]
9888224|NCT00566553|Active Comparator|Grape Seed Extract # 2|200 mg [2 pills]
9888225|NCT00566553|Active Comparator|Grape Seed Extract # 3|200 mg [3 pills]
9888226|NCT00566553|Active Comparator|Grape Seed Extract # 4|200 mg [4 pills]
9888227|NCT00566566||1|ALL survivors 5 years after completion of treatment, during routine medical follow up
9888228|NCT00566592|Experimental|1|Oral ethanol, overnight
9888229|NCT00566592|Experimental|2|IV ethanol, overnight
9888230|NCT00566592|Placebo Comparator|3|Placebo, overnight
9888231|NCT00566592|Placebo Comparator|4|Placebo, daytime
9888232|NCT00566605|Active Comparator|Group 1|
9888233|NCT00566605|Active Comparator|Group 2|
9888234|NCT00566670||Observation (all participants)|Stage 5 Chronic Kidney Disease and hemodialysis patients
9888235|NCT00566683|Active Comparator|1|Diazemuls-Pethidine
9888236|NCT00566683|Active Comparator|2|Propofol- Alfentanil
9888237|NCT00566774|Experimental|1|
9888238|NCT00566774|Active Comparator|2|
9888239|NCT00566826|Experimental|1|Patient support treatment sessions
9888240|NCT00566826|Active Comparator|2|Treatment as usual
9888241|NCT00566839|Experimental|1|
9888242|NCT00566839|Active Comparator|2|
9888243|NCT00566865|Experimental|2|mitiglinide + gemfibrozil
9888244|NCT00566865|Placebo Comparator|1|mitiglinide + placebo for gemfibrozil
9888245|NCT00566891|Active Comparator|A|Tirofiban
9888246|NCT00566891|Placebo Comparator|B|Clopidogrel
9888247|NCT00566904|Experimental|1|Participants will receive one of three different topical treatments on Days 8, 15, or 22.
9888248|NCT00566917|Active Comparator|1|Anterior colporrhaphy (standardised)
9888249|NCT00566917|Experimental|2|Anterior PROLIFT
9888250|NCT00566956|Experimental|1|For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
9888251|NCT00566956|No Intervention|2|Patients assigned to group 2 will not have the hydrosalpinx aspirated
9931897|NCT00943293|Experimental|Vaccine|
9888252|NCT00566995|Experimental|Vandetanib in Participants with Kidney Cancer|300 mg/day (starting dose) oral dose of vandetanib once a day for 28 days
9888253|NCT00567021||1|patients with GERD or NSAID-related ulcers
9517141|NCT03309124|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
9888254|NCT00567034|Active Comparator|1|taking naltrexone
9888255|NCT00567034|Placebo Comparator|2|taking placebo
9888256|NCT00567047|Experimental|1|Vildagliptin
9888257|NCT00567073||Pregnant women with confirmed diagnosis of pompe Disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Pompe disease that are participating in the Pompe Registry (NCT00231400) and consented to participate in the Pompe Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglusidase alfa) and irrespective of the commercial product with which she may be treated.
9888258|NCT00567073||Pregnant women receiving no treatment for pompe disease|Pregnant women with pompe disease enrolled in the pompe disease registry (NCT00231400) who are not receiving treatment
9888259|NCT00567073||Infants born to mothers receiving treatment for pompe disease|The infants of mothers with pompe disease enrolled in the pompe disease registry (NCT00231400) where the mothers are receiving treatment of alglucosidase alpha (Myozyme)
9888260|NCT00567073||Infants born to mothers receiving no treatment for pompe disease|The infants of mothers with pompe disease enrolled in the Pompe Disease Registry (NCT00231400) where the mothers are not receiving Treatment
9888261|NCT00567086|Placebo Comparator|A|
9888262|NCT00567086|Experimental|B|
9888263|NCT00567086|Experimental|C|
9888264|NCT00567086|Experimental|D|
9888265|NCT00567125||I|Patients with cholelithiasis operated on using standard laparoscopy method
9888266|NCT00567125||II|Patients with cholelithiasis operated on using low-pressure CO2 pneumoperitoneum laparoscopy
9888267|NCT00567177|Active Comparator|1|
9888268|NCT00567177|Placebo Comparator|2|
9888269|NCT00567203|Experimental|1|
9888270|NCT00567203|Experimental|2|
9888271|NCT00567203|Placebo Comparator|3|
9888272|NCT00567216|No Intervention|G|Endoscopic injection of cyanoacrylate alone
9888273|NCT00567216|Active Comparator|C|Combination of GVO and nadolol
9888274|NCT00567281|Experimental|1|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
9888275|NCT00567281|Active Comparator|2|Active rTMS to left/right Wernicke's region plus sham rTMS to opposite hemisphere middle temporal cortex
9888276|NCT00567294|Active Comparator|A|Participants will receive mailed education materials on osteoporosis and medication use.
9888277|NCT00567294|Experimental|B|Participants will receive a telephone coaching program.
9888278|NCT00567294|Experimental|C|Participants will receive a telephone coaching program, and doctors of these participants will receive medication adherence alert notifications.
9888279|NCT00567333|Other|1|
9888280|NCT00567333|Other|2|
9888281|NCT00567346|Active Comparator|grass pollen extract twice weekly|Current standard dose regimen of grass pollen immunotherapy (9,500 BU), given twice weekly. Note: patients in twice weekly dosing regimen will also receive placebo on days no active treatment is given.
9888282|NCT00567346|Active Comparator|Grass pollen extract, daily|Grass pollen immunotherapy, 9,500 BU, given daily
9888283|NCT00567346|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen immunotherapy, 19,000 BU, given daily
9888284|NCT00567346|Placebo Comparator|Placebo control|Patients randomized to placebo will receive placebo daily.
9888285|NCT00567411|Active Comparator|I|Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
9888286|NCT00567411|Active Comparator|A|Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
9888287|NCT00567437|Other|A|10 patients with no aortic stenosis
9888288|NCT00567437|Other|B|100 patients with asymptomatic AS
9888289|NCT00567450|Active Comparator|B|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
9517142|NCT03309124|Experimental|Baked potato with skin|Baked russet potato
9888290|NCT00567450|Experimental|A|30 ml of ropivacaine 0.75%
9888291|NCT00567463|Placebo Comparator|Placebo|Placebo inhalator will be used by subjects in the placebo group(same course as patients in the treated group)
9888292|NCT00567515|Experimental|LAA Clip|AtriCure LAA Exclusion System
9888293|NCT00567528|Other|1|Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
9888294|NCT00567528|Other|2|Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules
9888295|NCT00567554|Experimental|1|EC-T
9888296|NCT00567554|Experimental|2|EC-T +/- B
9888297|NCT00567554|Experimental|3|Pw
9888298|NCT00567554|Experimental|4|Pw + RAD001
9888299|NCT00567554|Experimental|5|EC-T + H
9888300|NCT00567554|Experimental|6|EC-T + L
9888301|NCT00567606|Experimental|1|Subjects in the G1 group receive 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
9888302|NCT00567606|Experimental|2|Subjects in the G2 group receive the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
9888303|NCT00567658|Placebo Comparator|A 1|Arm I: placebo group receives BID placebo
9888304|NCT00567658|Experimental|A2|subjects receive active drug, esomeprazole 40 mg BID
9888305|NCT00567671|Experimental|Treatment|Corneal collagen cross-linking
9888306|NCT00567671|Sham Comparator|Control|Sham Treatment
9888307|NCT00567697|Active Comparator|A|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
9888308|NCT00567697|Sham Comparator|B|
9888309|NCT00567710|Experimental|I|BL - 1020 lowdose
9888310|NCT00567710|Experimental|II|BL 1020 high dose
9888311|NCT00567710|Placebo Comparator|III|
9888312|NCT00567710|Active Comparator|IV|Risperidone
9888313|NCT00567723||1|Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol
9888314|NCT00567723||2|Historical control group: Patients with no lanthanum exposure
9888315|NCT00567723||3|Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product
9888316|NCT00567736|Active Comparator|1|Disci/Rhus toxicodendron comp.®
9888317|NCT00567736|Placebo Comparator|2|placebo solution
9888318|NCT00567736|No Intervention|3|waiting list group
9888319|NCT00567749||A, Observational|
9888320|NCT00567762|Experimental|1|FK506 ophthalmic suspension
9888321|NCT00567762|Placebo Comparator|2|Base of eye drops
9888322|NCT00567788|Active Comparator|1|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
9888323|NCT00567788|Active Comparator|2|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
9888324|NCT00567801|Active Comparator|1|conventional embolectomy/thrombectomy
9888325|NCT00567801|Experimental|2|embolectomy/thrombectomy with controlled reperfusion
9888326|NCT00567814|Active Comparator|1|Lower dose combination of metyrapone with oxazepam
9888327|NCT00567814|Active Comparator|2|Higher dose combination of metyrapone with oxazepam
9888328|NCT00567814|Placebo Comparator|3|
9888329|NCT00567853|Other|MEMO 3D ring|All patients in the study will be implanted with the MEMO 3D ring
9888330|NCT00567866|Experimental|1|placebo -50 mg quetiapine- 100 mg quetiapine
9888331|NCT00567866|Experimental|2|50 mg quetiapine -100 mg quetiapine- placebo
9888332|NCT00567866|Experimental|3|50 mg quetiapine -placebo- 100 mg quetiapine
9888333|NCT00567905|Experimental|A|Green tea extract
9888334|NCT00567905|Placebo Comparator|B|
9888335|NCT00567918|Experimental|1|FK506 ophthalmic suspension
9888336|NCT00567931|Experimental|Treatment (Immunomodulating therapy)|Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9888337|NCT00567957|Placebo Comparator|C|Saline starting before induction till entry to abdominal cavity
9888338|NCT00567957|Active Comparator|R|Remifentanil starting before induction till entry to abdominal cavity
9888339|NCT00567983|Active Comparator|1.|
9888340|NCT00567983|Placebo Comparator|2.|
9888341|NCT00568035|Active Comparator|QR-333|
9888342|NCT00568035|Placebo Comparator|Placebo|
9888343|NCT00568048|Experimental|Combination Therapy Temozolomide & Bevacizumab|"Combination therapy~Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days~Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days"
9888344|NCT00568100|Experimental|1|COPD patients
9888345|NCT00568113|Experimental|NAC group|NAC given plus 17Oh progesterone caproate
9888346|NCT00568113|Active Comparator|Progesterone group|17 OH progesterone caproate
9888347|NCT00568139||Mitotane|Patients with adrenocortical carcinoma treated with mitotane
9888348|NCT00568139||Control|Patients with adrenocortical carcinoma not treated with mitotane
9888349|NCT00568152|Experimental|Low PA apple puree|230grams of low PA apple puree (Golden Delicious) consumed daily for 14 days.
9888350|NCT00568152|Experimental|High PA apple puree|High PA apple puree (Mitchalin) 230grams consumed daily for 14 days
9888351|NCT00568152|Placebo Comparator|Aspirin|75mg dispersable aspirin taken daily for 14 days
9888352|NCT00568165|Experimental|1|Mobile Team
9888353|NCT00568165|Active Comparator|2|Standard care
9888354|NCT00568191||1|retinal thickness program Stratus OCT software 4.0
9888355|NCT00568191||2|retinal cube 200x200 program of Cirrus OCT
9888356|NCT00568204|Experimental|1|Mexyn-A
9888357|NCT00568217|Active Comparator|1 drug|diclofenac 15 mg/kg suppository once
9888358|NCT00568217|Placebo Comparator|2 drug|Placebo suppository once
9888359|NCT00568217|Active Comparator|3 drug|acetaminophen mixture 15 mg/kg up to four times a day
9888360|NCT00568217|Active Comparator|4 drug|ibuprofen mixture 10 mg/kg up to four times a day
9888361|NCT00568217|Placebo Comparator|5 drug|oral placebo mixture up to four times a day
9931898|NCT00943332||spica casting|
9931899|NCT00943332||intramedullary nailing|
9931900|NCT00943332||submuscualr plating|
9931901|NCT00943345|Active Comparator|GS dual sugar permeability test|"Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
9931902|NCT00943345|Other|Multi sugar test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
9931903|NCT00943345|Other|Protein test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
9931904|NCT00943345|Other|PEG test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
9931905|NCT00943358|Active Comparator|Vaccine|adjuvanted influenza vaccine
9931906|NCT00943358|Active Comparator|Vaccine 2|non-adjuvanted vaccine
9931907|NCT00943371|Experimental|1|MK6349
9931908|NCT00943371|Placebo Comparator|2|Placebo to MK6349
9931909|NCT00943410|Active Comparator|Surgical Candidate|After 5 consecutive weeks of treatment with Radiation and Herceptin, these subjects will receive mastectomy excision
9931910|NCT00943410|Active Comparator|Non-Surgical Candidate|After 5 weeks of consecutive treatment with radiation and herceptin, these subjects will not be eligible for surgery. They will continue with radiation and herceptin for an additional 2 weeks.
9931911|NCT00943423|Active Comparator|Arm I|Within 6 weeks after completion of course 3 of chemotherapy, patients undergo involved field radiotherapy to disease areas.
9931912|NCT00943423|Experimental|Arm II|Patients receive no further treatment.
9931913|NCT00943449|Experimental|4SC-201|
9931914|NCT00943449|Experimental|4SC-201 + Sorafenib|
9931915|NCT00943462||Glioblastoma Multiforme (GBM)|We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre-Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
9931916|NCT00943475|Active Comparator|anaesthesia, circumcision|
9931917|NCT00943501|Experimental|I.a|
9931918|NCT00943501|Placebo Comparator|I.b|
9931919|NCT00943501|Experimental|II.a|
9931920|NCT00943501|Placebo Comparator|II.b|
9931921|NCT00943527||1|Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.
9931922|NCT00943527||2|Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.
9931923|NCT00943527||3|Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.
9935559|NCT03520660|No Intervention|Phase II after Phase I|Participants who achieved SVR12 in Phase I
9888362|NCT00568230|Experimental|1|Patient is screened for study, and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
9888363|NCT00568256|Experimental|Experimental|Mind/Body Course
9888364|NCT00568256|Other|Other|Mind/Body Course
9888365|NCT00568269|Active Comparator|Lichtenstein|
9888366|NCT00568269|Experimental|TEP|
9888367|NCT00568295|Experimental|Acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP
9888368|NCT00568295|Active Comparator|Refecoxib 12.5 mg|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A
9888369|NCT00568295|Active Comparator|Rofecoxib 12.5 x 2|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A
9888370|NCT00568308|Placebo Comparator|1|
9888371|NCT00568308|Experimental|2|
9888372|NCT00568347||long acting bronchodilator|salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
9888373|NCT00568347||bronchodilator/ inhaled corticosteroid|fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
9888374|NCT00568347||C|Fluticasone 100mcg/salmeterol 50mcg
9888375|NCT00568373|Experimental|Treatement|All subjects that meet the requirement for gastric stimulator placement
9888376|NCT00568412|Active Comparator|1|Zarzenda applied topically twice daily for three weeks
9888377|NCT00568412|Active Comparator|2|Elidel 1% cream, applied topically twice daily for three weeks
9888378|NCT00568464|Experimental|A|
9888379|NCT00568477|Experimental|Arm 1|Treatment with rituximab
9888380|NCT00568477|No Intervention|Arm 2|Treatment without rituximab
9888381|NCT00568503|Active Comparator|1|QAX028 high dose
9888382|NCT00568503|Placebo Comparator|2|Placebo
9888383|NCT00568503|Active Comparator|3|Tiotropium bromide
9888384|NCT00568503|Active Comparator|4|QAX028 medium dose
9888385|NCT00568503|Active Comparator|5|QAX028 low dose
9888386|NCT00568516|Experimental|1.Low dose group|
9888387|NCT00568516|Experimental|2.High dose group|
9888388|NCT00568529|Experimental|Combine Chemotherapy|XELOX(Xeloda and oxaliplatin combination)
9888389|NCT00568542|Active Comparator|1|35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
9888390|NCT00568542|Placebo Comparator|2|Placebo to erythropoetin beta.
9888391|NCT00568568|Experimental|Growth hormone|
9888392|NCT00568607|Experimental|IFO, VP-16, DDP, DXM|
9888393|NCT00568620|Experimental|1: Nasogastric feeding tube|
9888394|NCT00568620|Experimental|2: Placement of nasojejunal feeding tube|
9888395|NCT00568646|Experimental|1|
9888396|NCT00568659|Experimental|1|
9888397|NCT00568672|Active Comparator|1|Olanzapine 5 mg / day
9888398|NCT00568672|Placebo Comparator|2|Placebo
9888399|NCT00568711|Active Comparator|1|a 5-day course of daily 200-mg doses of doxycycline
9888400|NCT00568711|Active Comparator|2|a 5-day course of daily 600-mg doses of rifampin
9888401|NCT00568724||1|Children referred to surgical treatment of congenital hydronephrosis
9888402|NCT00568724||2|15 age- and sex-matched controls
9888403|NCT00568724||Children with healthy pelvic tissue|Children referred to nephrectomy due to nephrotic syndrome
9888404|NCT00568724||Adults with healthy pelvic tissue|Adults referred to nephrectomy due to another cause than hydronephrosis
9888405|NCT00568737|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
9888406|NCT00568737|Placebo Comparator|2|0.9% sodium chloride
9888407|NCT00568750|Experimental|Dasatinib|
9888408|NCT00568789|Experimental|Ramelteon 8 mg, zolpidem 10 mg and placebo|
9888409|NCT00568815|Experimental|Chemo|
9888410|NCT00568841|Experimental|1|
9888411|NCT00568880|Experimental|Hydroxychloroquine Added to Bortezomib|Dose escalated by cohorts Hydroxychloroquine 200-600 mg pill every other day. Bortezomib 1.0-1.3mg/m2 IV, days 1, 4, 8, and 11 of each 21 day cycle.
9888412|NCT00568893|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
9888413|NCT00568945|Experimental|Arm 1|
9888414|NCT00568971|Experimental|weekly chemo|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
9888415|NCT00569023|Experimental|A,1,I|
9888416|NCT00569036|Experimental|BMS-754807|Single arm, multiple-ascending dose escalation study
9888417|NCT00569075||High Risk|High risk disease prone population
9888418|NCT00569075||Low Risk|Low risk disease population
9888419|NCT00569088|Experimental|B|A combined treatment would be used in the arm.That means Chinese herb formula would be used with the current Modern Medicine therapy for stroke in this arm.
9888420|NCT00569088|Active Comparator|A|just the current Modern Medicine therapy for stroke would be available in the arm.
9888421|NCT00569101|Experimental|single|single arm study (tacrolimus trial group)
9888422|NCT00569114|Other|1|
9888423|NCT00569140|No Intervention|1|E10030
9517143|NCT03309124|Experimental|Mashed potatoes|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
9888424|NCT00569179|Experimental|Alloreactive NK cell infusion|Escalating doses of alloreactive NK cells.
9888425|NCT00569244|Experimental|Arm 1|
9888426|NCT00569244|Active Comparator|Arm 2|
9888427|NCT00569296|Experimental|T-cells|EGFRBi-armed autologous activated T cells
9888428|NCT00569335|Experimental|1|S-1, Irinotecan, Bevacizumab
9888429|NCT00569361|Other|A|Collection of nasal epithelial cells by brushing
9888430|NCT00569413||1|Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
9888431|NCT00569413||2|20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
9888432|NCT00569439|Experimental|D5|5% Dextrose Solution in Normal Saline
9888433|NCT00569439|Experimental|D10|
9888434|NCT00569439|Placebo Comparator|NS|
9888435|NCT00569452|Experimental|A|
9888436|NCT00569452|Experimental|B|
9888437|NCT00569465|Placebo Comparator|A|
9888438|NCT00569465|Experimental|B|
9888439|NCT00569478|Active Comparator|1|rehabilitation
9888440|NCT00569478|No Intervention|2|controls
9888441|NCT00569504||A, observatoin|inpatients and outpatients in Seoul National Hospital
9888442|NCT00569517|Experimental|1|6-CBT-sessions for weight loss
9888443|NCT00569517|Experimental|2|Single educational intervention for weight
9888444|NCT00569556|No Intervention|Usual Care|Patients receive care through primary care provider
9888445|NCT00569556|Experimental|Case Management|Specially trained nurse case managers contact patients by telephone; monitor blood pressure, LDL, and HgbA1C;, and recommend lifestyle and medication changes as needed
9888446|NCT00569569|Experimental|1|Patients treated with Retaane
9888447|NCT00569595|Experimental|1|Multi-Level, Patient-Directed, Lifestyle Change, Health Promotion Program
9888448|NCT00569595|Sham Comparator|2|"Patient health counseling program by lay health educators Entitled Fighting Cancer with Advice."
9888449|NCT00569608|Experimental|EDA|Neonates submitted to the protocol of early discharge.
9888450|NCT00569608|No Intervention|SDP|Discharge following the standard protocol of the neonatal intensive care unit.
9888451|NCT00569621|Experimental|1|
9888452|NCT00569621|Placebo Comparator|2|
9888453|NCT00569634|Other|1|
9888454|NCT00569647|Experimental|v|Use of VRH headset
9888455|NCT00569647|Placebo Comparator|c|
9888456|NCT00569686|Active Comparator|1|treatment with lovaza
9888457|NCT00569686|Placebo Comparator|2|
9888458|NCT00569699|Experimental|1|S-1, Bevacizumab
9888459|NCT00569738||A|patients with neuroendocrine tumors
9888460|NCT00569764||observational|patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
9888461|NCT00569790|Experimental|1|S-1, Irinotecan, Bevacizumab
9888462|NCT00569816|Active Comparator|Group 1|Propofol as the primary anesthetic
9888463|NCT00569816|Experimental|Group 2|Sevoflurane administered continuously after induction of anesthesia until initiation of cardiopulmonary bypass.
9888464|NCT00569816|Experimental|Group 3|Sevoflurane administered repetitive up to 1 MAC from induction of anesthesia until initiation of cardiopulmonary bypass. Wash in and wash out performed twice.
9888465|NCT00569829|Experimental|1|Cognitive behavioral therapy
9888466|NCT00569829|No Intervention|2|Waitlist
9888467|NCT00569842||observational|
9888468|NCT00569881||1|Corneal epithelial wound healing with moxifloxacin
9888469|NCT00569881||2|Corneal epithelial wound healing with gatifloxacin
9888470|NCT00569894||2|TIV
9888471|NCT00569894||1|FluMist
9888472|NCT00569894||3|Unvaccinated
9888473|NCT00569920|Placebo Comparator|1|Placebo
9888474|NCT00569920|Active Comparator|2|"dexamethasone low-dose"
9888475|NCT00569920|Active Comparator|3|"Dexamethasone high-dose"
9888476|NCT00569933|Other|A/B/C|Patients are randomized to voice/music/ or no CD
9888477|NCT00569959|Other|Fasting|
9888478|NCT00569959|Other|Non-fasting|
9888479|NCT00569985|Experimental|Treatment (autologous HCT)|CONDITIONING: Patients receive carmustine IV over 1-2 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANTATION: Patients undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells IV on day 0.
9888480|NCT00570011|Experimental|1|
9888481|NCT00570011|Experimental|2|
9888482|NCT00570024|Active Comparator|TA|Active TA
9888483|NCT00570024|Other|AA|
9888484|NCT00570024|No Intervention|Waiting Group|
9888485|NCT00570050|Experimental|Intranasal Insulin nasal spray|
9888486|NCT00570050|Experimental|Placebo nasal spray (i.e., no active treatment)|
9888487|NCT00570102|Active Comparator|A highly hydrolyzed casein formula|
9888488|NCT00570102|Placebo Comparator|A conventiona cow's milk based formula|
9888489|NCT00570115||A|The subjects for this group are matched for age, gender, body mass index. The presence of obstructive sleep apnea will divide the cohort in 02 subgroups: non-Obstructive Sleep Apnea and Obstructive Sleep Apnea
9888490|NCT00570167|Active Comparator|2|Total cementless hip arthroplasty with metal-on-metal bearings
9888491|NCT00570167|Active Comparator|1|Hip resurfacing
9888492|NCT00570180|Experimental|Single Arm|Please see intervention description for Bortezomib (Velcade)
9931924|NCT00943540|Experimental|Raltegravir BID-QD|"Week 1-4~600 mg of atazanavir to be taken once daily~400 mg of raltegravir to be taken twice daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily~Week 5-8~600 mg of atazanavir to be taken once daily~800 mg of raltegravir to be taken once daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily"
9931925|NCT00943553|Experimental|1|
9931926|NCT00943553|Experimental|2|
9931927|NCT00943566|Experimental|Sufentanil Transdermal Delivery System|Experimental drug
9931928|NCT00943566|Active Comparator|Control|Sustained release morphine sulfate
9931929|NCT00943709|Experimental|Arm I|Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.
9931930|NCT00943709|Active Comparator|Arm II|Patients with goal blood glucose < 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.
9931931|NCT00943748|Active Comparator|deferiprone|deferiprone 30 mg/kg/day
9931932|NCT00943748|Placebo Comparator|placebo|placebo : 30 mg/kg/day, in 2 liquid doses
9931933|NCT00943774||All subjects|All subject participants
9931934|NCT00943813||Patients in clinic waiting room|When patients are approached in the clinic, they will be given the permission form and asked to participate in the assessment through allowing video-recording and completing the survey. Procedures will be similar to our current operations, with the RSA starting the video-recording equipment before the fellow enters the room and stopping it when the fellow leaves the room. One additional step will be added: When the RSA goes into the room to turn off and remove the video-recording equipment, she will also give the patient the survey, to complete. We expect this survey to take no longer than 5 minutes. In our experience, it is usually at least 10 minutes from when the fellow leaves the room until the attending comes back into the room. Thus, we believe there will be sufficient time for the patient to complete the survey.
9931935|NCT00943839|Experimental|SUVEGIL|
9931936|NCT00943865|Active Comparator|hypocaloric diet + exercise advice|Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
9931937|NCT00943865|Experimental|pragmatic diet+ pedometer 10000 steps|Group 2 (pragmatic diet + step counter) - Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control. Subjects were provided with pedometers and were instructed to perform at least 10.000 steps daily, diary recorded.
9931938|NCT00943865|Experimental|pragmatic diet + fitness|Group 3 (pragmatic diet + fitness) - They received the same diet intervention (low carbohydrates, high protein and vegetables style diet and favoring daily brazilian cook habits colored handbook) and hand sized portion control instructions of group 2. They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions.
9888493|NCT00570193|Experimental|I|Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
9888494|NCT00570193|Experimental|II|Treatment with ranibizumab (Lucentis)
9888495|NCT00570206|Experimental|1|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
9888496|NCT00570206|No Intervention|2|Probation officers who are interested in Motivational Interviewing, but have not yet been trained to use it while conducting meetings with probationers.
9888497|NCT00570206|No Intervention|3|Treatment as usual. Regular probation officers conduct standard meetings with probationers.
9888498|NCT00570219|Experimental|B|Gradual benzodiazepine discontinuation and valproate treatment
9888499|NCT00570219|No Intervention|A|Gradual benzodiazepine discontinuation
9888500|NCT00570245|No Intervention|A|Neither donors or recipients will receive NO
9888501|NCT00570245|Active Comparator|B|Donor will not receive NO, recipient will receive up to 48 hours of NO
9888502|NCT00570245|Active Comparator|C|The donor will receive NO for 3 hours and the recipient will receive NO for up to 48 hours
9888503|NCT00570271|Experimental|1|
9888504|NCT00570271|Experimental|2|
9888505|NCT00570271|Experimental|3|
9888506|NCT00570271|Experimental|4|
9888507|NCT00570271|No Intervention|5|
9888508|NCT00570271|No Intervention|6|
9517144|NCT03309124|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
9517145|NCT03309124|Experimental|Meal skipping|No food given
9888509|NCT00570284|Experimental|LBH589|
9888510|NCT00570375|Experimental|Single Arm|All patients will receive 150 mg of Erlotinib
9888511|NCT00570388|Active Comparator|2|Subjects in the active Prometa group will receive flumazenil, gabapentin, and hydroxyzine per the Prometa Protocol.
9888512|NCT00570388|Placebo Comparator|1|"Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine"
9888513|NCT00570414|Active Comparator|1|Laryngeal mask airway (LMA)
9888514|NCT00570414|Active Comparator|2|Endotracheal tube (ETT)
9888515|NCT00570427|Experimental|1.|All participants
9888516|NCT00570440|Experimental|A|
9888517|NCT00570440|Active Comparator|B|
9888518|NCT00570466|Experimental|Video games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.
9888519|NCT00570466|Placebo Comparator|Web and DVD knowledge|Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.
9888520|NCT00570479|Active Comparator|1|50 mgs of anecortave acetate (0.5 ml of a 10% suspension)
9888521|NCT00570479|Active Comparator|2|Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension)
9888522|NCT00570479|Active Comparator|3|Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension)
9888523|NCT00570479|Active Comparator|4|Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension)
9888524|NCT00570518||1|randomly stopped drivers of motorised vehicles and bicycles
9888525|NCT00570518||2|drivers of motorised vehicles and bicycles injured or killed in road traffic accidents
9888526|NCT00570544||1|patients with moderate to severe copd with varying extent of emphysema
9888527|NCT00570557|No Intervention|Group A Nurses|Participants receive neither web-based refresher courses nor periodic feedback by SLP
9888528|NCT00570557|Experimental|Group B Nurses|Participants receive web-based skill refresher courses but no periodic feedback by SLP
9888529|NCT00570570|Other|group 1|Muscular Strengthening for paretic knee flexor and extensor
9888530|NCT00570570|Active Comparator|group 2|conventional physiotherapy
9888531|NCT00570583||Depressed|Older individuals with major depression
9888532|NCT00570583||Non-depressed|Older individuals without psychiatric disorder
9888533|NCT00570609|Experimental|CPR Anytime|Participants will be asked to complete the program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
9888534|NCT00570622|Active Comparator|1|Patients receive 60mg of pioglitazone once a day orally for 9 days
9888535|NCT00570622|Placebo Comparator|2|Patients receive Placebo orally once a day for 9 days
9888536|NCT00570648|Experimental|1|1% sodium hyaluronate (Healoon) applied at the end of surgery to the surface of the corneal transplant
9888537|NCT00570648|No Intervention|2|Nothing applied at the end of surgery
9888538|NCT00570791||Effect of age on intraocular pressure|Correlation between age and IOP with GAT compared to other tonometers.
9931939|NCT00943891||Tumor biopsies|
9888539|NCT00570791||Effect of CCT and IOP|Correlation between CCT and IOP among all tonometers
9888540|NCT00570804|Other|MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
9888541|NCT00570804|Other|MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
9888542|NCT00570817|Other|1|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 4 hours prehydration. At the 2nd methotrexate infusion the child will receive 12 hours prehydration. At the 3rd methotrexate infusion the child will receive 4 hours prehydration. At the 4th methotrexate infusion the child will receive 12 hours prehydration. At the 5th methotrexate infusion the child will receive 4 hours prehydration. At the 6th methotrexate infusion the child will receive 12 hours prehydration. At the 7th methotrexate infusion the child will receive 4 hours prehydration. At the 8th methotrexate infusion the child will receive 12 hours prehydration."
9888543|NCT00570817|Other|2|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 12 hours prehydration. At the 2nd methotrexate infusion the child will receive 4 hours prehydration. At the 3rd methotrexate infusion the child will receive 12 hours prehydration. At the 4th methotrexate infusion the child will receive 4 hours prehydration. At the 5th methotrexate infusion the child will receive 12 hours prehydration. At the 6th methotrexate infusion the child will receive 4 hours prehydration. At the 7th methotrexate infusion the child will receive 12 hours prehydration. At the 8th methotrexate infusion the child will receive 4 hours prehydration."
9888544|NCT00570830|Other|1|single armed case series in which all patients underwent the same treatment.
9888545|NCT00570843|Active Comparator|1.|
9888546|NCT00570843|Placebo Comparator|2.|
9888547|NCT00570856|Experimental|1|Folic acid supplementation
9888548|NCT00570856|Placebo Comparator|2|
9888549|NCT00570869|Active Comparator|CPR Class|mothers who are currently certified in CPR (i.e., have taken the traditional CPR class, or have been recertified in CPR by classroom instruction, within the past two years).
9888550|NCT00570882|Active Comparator|Sunitinib 4/2|Sunitinib 50 mg PO 4-week on and 2-week off
9888551|NCT00570882|Experimental|Sunitinib 2/1|Sunitinib 50 mg PO 2-week on 1-week off
9888552|NCT00570895|Active Comparator|A|Subjects in Arm A will receive the juice without ascorbic acid in addition to the muffin with ferrous fumarate.
9888553|NCT00570895|Active Comparator|B|Subjects in Arm A will receive the juice with 25mg ascorbic acid in addition to the muffin with ferrous fumarate
9888554|NCT00570934|Experimental|Placebo|order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol
9888555|NCT00570934|Experimental|Calcium|order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol
9888556|NCT00570934|Experimental|Cholecalciferol|order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium
9888557|NCT00570934|Experimental|Calcium and cholecalciferol|order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo
9888558|NCT00570947|Active Comparator|Class|The control group will be advised to take a traditional CPR class and be offered a list of local classes.
9888559|NCT00570973|Active Comparator|1|Endoscopic Band ligation combined with medical therapy (orally, daily administered propranolol and mononitrate)
9888560|NCT00570973|Active Comparator|2|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent
9888561|NCT00570999|Experimental|Arm A|Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
9888562|NCT00570999|Placebo Comparator|Arm B|Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
9888563|NCT00571012||Only one group- A|Healthy young subjects aged 18-45.
9888564|NCT00571025|Experimental|1|AD risk assessment based on family history and APOE genotype
9888565|NCT00571025|Active Comparator|2|AD risk assessment based on family history alone
9888566|NCT00571051|Experimental|1|MBSR 8 week course
9888567|NCT00571051|No Intervention|2|8 weeks of natural history
9888568|NCT00571077||A|"This is a a single arm study evaluating the efficacy and accuracy of EIS in detecting malignant thyroid nodules.~PAtients with thyroid nodules scheduled for surgery will undergo EIS examination."
9888569|NCT00571090||Thyroid nodule|Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled.
9931940|NCT00943930||Marijuana-dependent volunteers|
9935560|NCT03520660|No Intervention|Phase II without Phase I|Participants who achieved SVR 24 previously
9935561|NCT03520647|Experimental|Treatment Arm|G-CSF mobilized peripheral stem cells and post haplo-identical transplantation cyclophosphamide
9888570|NCT00571116|Experimental|Disulfiram and arsenic trioxide|"Patients receive disulfiram 250 mg PO twice daily and arsenic trioxide IV over 1-2 hours on Monday through Friday, alternating two weeks on treatment followed by two weeks off treatment. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~The Arsenic trioxide dose will be escalated or reduced until a tolerable dose is reached. Arsenic trioxide will be administered at a starting dose of 0.05 mg/kg. If the initial dose is tolerated, the patient will be dose escalated to 0.10 mg/kg/day. If the first dose escalation is tolerated, then a second dose escalation will be attempted to 0.15 mg/kg/day, the current dose recommended for leukemia. Dosing will be continued for two weeks on alternating with two weeks off as long as tolerated to a maximum of 60 doses."
9888571|NCT00571129|Active Comparator|with tubes or mitomycin|After DCR bicanalicular tubes were inserted After re-DCR mitomycin in cottonpads were placed into rhinostoma for 5 minutes
9888572|NCT00571129|Active Comparator|without tubes or mitomycin|After DCR no tubes were inserted After re-DCR no mitomycin was used
9888573|NCT00571142|Active Comparator|1|Renal disease
9888574|NCT00571142|Active Comparator|2|Without renal disease
9888575|NCT00571155|Other|1|
9888576|NCT00571168|Experimental|A|Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
9888577|NCT00571168|Placebo Comparator|B|Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
9888578|NCT00571181|Experimental|1|
9888579|NCT00571181|Active Comparator|2|
9888580|NCT00571207||I|Drivers suspected of driving under the influence of drugs
9888581|NCT00571207||II|Drivers not suspected of driving under the influence of drugs
9888582|NCT00571220||Gastric bypass surgery|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
9888583|NCT00571220||Diet induced weight loss|Diet group of obese patient with type 2 diabetes, matched with the surgical group for diabetes duration, diabetes control (HbA1C), BMI, age.
9888584|NCT00571233||1|Group one consists of children 1 month - 6 years old who have structurally normal hearts, no heart failure, and a patent ductus arteriosus (PDA).
9888585|NCT00571233||2|Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
9888586|NCT00571246|Experimental|Topiramate|Participants will be randomized to topiramate (250mg)
9888587|NCT00571246|Experimental|Lamotrigine|Participants will be randomized to lamotrigine (250mg)
9888588|NCT00571246|Placebo Comparator|Placebo|Participants will be randomized placebo
9888589|NCT00571285|Placebo Comparator|Placebo|Placebo capsule once a week and 600 IU vitamin D daily for 26 weeks
9888590|NCT00571285|Experimental|Vitamin D|50K IU vitamin D3 (high dose) weekly plus 600 IU Vitamin D3 capsule daily for 26 weeks
9888591|NCT00571298|Experimental|Extrapleural pneumonectomy (EPP)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
9888592|NCT00571298|Experimental|Pleurectomy/Decortication (P/DC)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
9888593|NCT00571298|Experimental|Tumor Debulking (TD)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
9888594|NCT00571350|Active Comparator|A|women with vaginal prolapse who underwent TVT O
9888595|NCT00571363|Active Comparator|standard surgery|basal cell carcinomas were excised with 4 mm margins
9888596|NCT00571363|Active Comparator|Mohs|Basal cell carcinoma were removed via Mohs Micrographic surgery
9888597|NCT00571376||1|Those exposed to health information technology or health information exchange
9888598|NCT00571376||2|Those not exposed to health information technology or health information exchange
9888599|NCT00571402|Experimental|FFT|Family-focused therapy (FFT) and pharmacotherapy for adolescents, a 21 session family psychoeducational interventio0n administered with best practice medication treatment
9888600|NCT00571402|Active Comparator|Echanced Care|Enhanced care (EC) and pharmacotherapy for adolescents
9888601|NCT00571415||cervix cancer patients|
9888602|NCT00571441||Primary|All subjects are included in this group, non-randomized observational study.
9888603|NCT00571454|Experimental|1|Telephone depression care management + treatment as usual
9888604|NCT00571454|No Intervention|2|Treatment as usual
9888605|NCT00571467|Experimental|PRTX-100 (Staphylococcal protein A)|"Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
9935562|NCT03519464|Other|ICL and Healthy Volunteers|Biological/Vaccine
9888606|NCT00571480|Experimental|1 true acupuncture|acupuncture needles are inserted into three preselected ear acupuncture points which are thought to be specific for low back pain
9888607|NCT00571480|Sham Comparator|2|three acupuncture needles are inserted to three ear acupuncture points which are not specific for low back pain during pregnancy
9888608|NCT00571480|Other|3|standard of care
9888609|NCT00571506|Experimental|1|Rosiglitazone 4 mg by mouth daily
9888610|NCT00571506|Active Comparator|2|Pioglitazone 30 mg by mouth daily
9888611|NCT00571545|Experimental|1|Subjects recruited from the community with a history of traumatic brain injury were enrolled into a 10 week supervised exercise program and encouraged to exercise at home as well.
9888612|NCT00571545|Other|2|Controls were wait-listed for the supervised exercise program but were not treated during the 10 week wait period.
9888613|NCT00571558|Experimental|Treatment (aminolevulinin acid and photodynamic therapy)|Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.
9888614|NCT00571571|Experimental|TFP-A|Specific aspects of TFP-A involve the setting up of a treatment contract/collaboration between patient and therapist to deal with the likely threats both to the treatment and to the patient's well being that may occur in the course of the treatment. After the behavioral symptoms of identity pathology are contained through structure and limit setting, the psychological structure that is believed to be the core of identity pathology are analyzed. In particular, treatment would involve the family in setting up the contract parameters, provide a psychoeducational component to the family and patient, inclusion of school personnel as appropriate to reinforce contract parameters, place an emphasis on the technique of clarification to understand specific emotional states.
9888615|NCT00571571|Active Comparator|Control|The Control Group is treatment as usual in the outpatient clinic. Treatment in this arm will be carried out by therapists in the Outpatient Department. Treatment will be determined by the therapist(s) and carried out according to their particular orientation and their assessment of patient's needs. It is expected based on clinic data that the majority of patients will be seen at least one time per week.
9888616|NCT00571610|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
9888617|NCT00571623||1|All subjects act as their own contral
9888618|NCT00571636|Active Comparator|fentanyl|Patients assigned to this arm will receive continuous infusion of fentanyl + open label boluses of Fentanyl if necessary.
9888619|NCT00571636|Placebo Comparator|placebo|Patients assigned to this arm will receive continuous infusion of placebo+ open label boluses of Fentanyl if necessary.
9888620|NCT00571675|Experimental|1|AT-101, prednisone and docetaxel
9888621|NCT00571675|Placebo Comparator|2|Placebo, prednisone and docetaxel
9888622|NCT00571714|Active Comparator|1|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
9888623|NCT00571714|Active Comparator|2|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
9888624|NCT00571727|Experimental|mecasermin, injections BID of rhIGF-1|
9888625|NCT00571740|Active Comparator|Arm I (second-line therapy)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
9888626|NCT00571740|Experimental|Arm II (second-line therapy)|Patients receive bevacizumab and modified FOLFOX7 as in arm I. Patients also receive cetuximab IV over 2 hours on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
9888627|NCT00571753|Experimental|Test|Isoniazid dose adapted according to NAT2 status i.e. appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
9888628|NCT00571753|Active Comparator|Control|Treatment with standard isoniazid dose (appr. 5 mg/kg b.w.)
9888629|NCT00571766|Experimental|1|Oral L-Arginine 2 g twice a day for 14 weeks
9888630|NCT00571766|Placebo Comparator|2|Placebo 2 g, twice a day for 14 weeks
9888631|NCT00571792||1|Individuals with normal lung function who do not smoke
9888632|NCT00571792||2|Individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
9888633|NCT00571792||3|Individuals who smoke that demonstrate symptoms of COPD
9888634|NCT00571805|Active Comparator|1|Varenicline
9888635|NCT00571805|Placebo Comparator|2|placebo
9888636|NCT00571818|Active Comparator|EP|
9888637|NCT00571818|Active Comparator|HP|
9888638|NCT00571818|Active Comparator|EK|
9888639|NCT00571818|Active Comparator|HC|
9888640|NCT00571831|No Intervention|letter|a blue-filtering IOL an UV-filtering IOL
9888641|NCT00571844|Experimental|DASH diet|
9888642|NCT00571844|Experimental|DASH diet plus Weight loss|
9888643|NCT00571844|No Intervention|Usual Care|Usual Care Control Group: Patients in the Usual Care control group will be asked to maintain their usual dietary and exercise habits for 4 months until they are re-evaluated. At biweekly intervals we will ask patients to describe any spontaneous changes in their eating habits or food preferences. To ensure patient safety, BPs will also be monitored biweekly by our staff.
9888644|NCT00571870|Active Comparator|A|Stimulated as conventional protocol
9888645|NCT00571870|Experimental|B|GnRH antagonist stopped one day earlier than conventional protocol
9888646|NCT00571896|Experimental|SennaS|This group of participants will receive SennaS to use after surgery.
9888647|NCT00571896|Placebo Comparator|Placebo|This group of participants will receive placebo pills to use after surgery.
9888648|NCT00571909|Experimental|video thoracoscopic splanchnicectomy (VSPL)|
9888649|NCT00572013|Experimental|Arm I|
9888650|NCT00572026|Experimental|1|Daytrana
9888651|NCT00572026|No Intervention|2|No treatment for ADHD
9888652|NCT00572065|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12.
9888653|NCT00572078|Experimental|Sorafenib, Bevacizumab & Paclitaxel|Paclitaxel is given as i.v infusion over 60 min on days 1, 8, 15 every 28 days. Sorafenib is given orally starting with cycle 1 day 2. Bevacizumab is given as i.v infusion on days 1 and 15 every 28 days.
9888654|NCT00572091|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
9888655|NCT00572104|Experimental|resistance exercise|12 month resistance exercise training
9888656|NCT00572104|Experimental|plyometric exercise|12 month plyometric exercise training
9888657|NCT00572130|Experimental|Rexin-G Dose 1|
9888658|NCT00572130|Experimental|Rexin-G Dose 2|
9888659|NCT00572143|Active Comparator|1|Postoperative follow-up of ca coli patients at the surgical outpatient dpt
9888660|NCT00572143|Active Comparator|2|Postoperative follow-up of ca coli patients by GP's
9931941|NCT00943943|Experimental|G-CSF and Plerixafor with Sorafenib|G-CSF 10 mcg/kg adjusted body weight subcutaneous injection. Plerixafor fixed dose of 240 mcg/kg adjusted body weight subcutaneous injection in abdomen. Patients will receive the 1st doses of G-CSF and Plerixafor on day 1. G-CSF and Plerixafor every other day for 7 total doses, repeated every 28 days. Sorafenib starting dose 400 mg twice daily orally after G-CSF/Plerixafor injections.
9931942|NCT00943956|Experimental|Everolimus|Everolimus + radiation
9931943|NCT00943969|Other|obemo|
9931944|NCT00943995|Other|Treatment Arm|Getting Growth Hormone therapy TIW instead of nightly in the Pediatric Tanner 1 Hemodialysis population.
9931945|NCT00944008|Experimental|Depocyte|
9931946|NCT00944060|Experimental|lifestyle intervention|Control group: usual WIC care
9931947|NCT00944086||Recruitment Manoeuvre ,Laparoscopy|
9931948|NCT00944099|Experimental|Grazing|participants will be given an eating frequency prescription to eat every 2 to 3 hours
9931949|NCT00944099|Experimental|Three Meals|participants will be given an eating frequency prescription of eating 3 meals per day
9931950|NCT00944112|Experimental|Restrictive RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70g/L with a target Hb concentration of 71-90g/L during the intervention period.
9931951|NCT00944112|Experimental|Liberal RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90g/L with a target Hb concentration of 91-110g/L during the intervention period.
9931952|NCT00944138|Experimental|Mindful meditation|Participants assigned to the mindful meditation plus standard care arm will receive individualized instruction on mindful meditation at the time they are randomized to this arm. The participants will be led through a 20 minute relaxation exercise. They will then be led through a brief eating exercise where they will be instructed to eat the food very slowly and pay attention to how the food tastes and the sensations of swallowing the food. This is done to enhance the person's awareness of what and how they are eating and enhance their intuitive sense of satiety. Finally, they will receive an MP3-player with several relaxation instructional audios loaded on the MP3 player.
9935563|NCT03518190|Experimental|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
9935564|NCT03510468|Experimental|1|(1) TAF once daily alone (days 1-14) and (2) TAFonce daily + weight-based RPT + INH (withpyridoxine) once weekly (days 15-31)
9997427|NCT01508806|Experimental|Normal renal function|
9990435|NCT01443195|Experimental|Iron suplementation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal
9990436|NCT01443208|Experimental|50 mg|
9990437|NCT01443208|Experimental|100 mg|
9990438|NCT01443208|Experimental|200 mg|
9990439|NCT01443221|Active Comparator|Free combination|Free combination of Mitiglinide 10mg and Metformin 500mg
9990440|NCT01443221|Experimental|Fixed-dose combination|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
9990441|NCT01443234|Experimental|OxIGen program|Internet based intervention taking place over 4 weeks
9990442|NCT01443234|Placebo Comparator|OxIGen: control version|A control version of the internet-based OxIGen intervention
9990443|NCT01443247|Experimental|platelet support + anti-d|
9990444|NCT01443247|No Intervention|platelet support|
9990445|NCT01443273||Infants with thrombotic events|All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
9990446|NCT01443312||Thalassemia Intermedia Patients|Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
9990447|NCT01443325|Experimental|lidocaine patch|
9990448|NCT01443338|Active Comparator|Triptergium Wilfordii|a kind of traditional chinese medicine
9990449|NCT01443338|Active Comparator|Acitretin|
9990450|NCT01443351||ITP patients|Patients with refractory ITP eligible for treatment with TPO-ra
9990451|NCT01443416|Experimental|13-valent pneumococcal conjugate vaccine|12 month booster dose of Prevenar
9990452|NCT01443416|Experimental|10-valent pneumococcal conjugate vaccine|12 month booster dose of Synflorix
9990453|NCT01443429|Experimental|subjects with normal renal function|
10211933|NCT03515317|No Intervention|control group|The control group involves no NF training. The control group will be designed to parallel the cognitive tasks to control for practice effects due to repeated testing (pre- and post- assessments) and the time effect on cognitive function recovery (spontaneous recovery of cognition).
10211934|NCT03511352|No Intervention|Control Condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
9990454|NCT01443429|Experimental|patients with mild renal impairment|
9990455|NCT01443429|Experimental|patients with moderate renal impairment|
9990456|NCT01443429|Experimental|patients with severe renal impairment|
10211935|NCT03511352|Experimental|Frequent Sit-to-Stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
10211936|NCT03511352|Experimental|Stand More (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
10211937|NCT03507855|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
10211938|NCT03507855|Active Comparator|Control|Normal operating room environment.
10211939|NCT03502031|Active Comparator|RAAS alone|RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)
10211940|NCT03502031|Active Comparator|RAAS in Combination with Spironolactone|RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject); Spironolactone taken each day at 25mg
10211941|NCT03497481||Neopterin Dosage|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
10211942|NCT03490500||S100B protein dosage|Biological
10211943|NCT03490357|Active Comparator|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
10211944|NCT03490357|Experimental|Quadratus Lumborum Block|Quadratus lumborum nerve block
9990457|NCT01443455|Experimental|VideoDance|
9990458|NCT01443455|Active Comparator|Brisk Walking|
9990459|NCT01443455|Other|Delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
9990460|NCT01443481|Experimental|TKI258 normal hepatic function|TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off
9990461|NCT01443481|Experimental|TKI258 mild hepatic impairment|TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off
9990462|NCT01443481|Experimental|TKI258 moderate hepatic impairment|TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off
9990463|NCT01443481|Experimental|TKI258 severe hepatic impairment|TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
9990464|NCT01443507|Experimental|high intensity long interval|A group training four by four minutes interval at 90-95% of maximal heart rate dispersed by three minutes active pauses at 70% of maximal heart rate.
9990465|NCT01443507|Experimental|long duration at moderate training|a continuous training group exercising at 70% of maximal heart rate for 90 minutes.
9990466|NCT01443520|Placebo Comparator|Placebo|
9990467|NCT01443520|Active Comparator|Duloxetine|
9990468|NCT01443520|Active Comparator|Venlafaxine|
9990469|NCT01443533|Experimental|LARC script|Received routine postpartum counseling and LARC script.
9990470|NCT01443533|No Intervention|No LARC script|Received only routine postpartum counseling
9990471|NCT01443559|Experimental|Xenogenic cornea|
9990472|NCT01443559|Active Comparator|human cornea|
9990473|NCT01443572|Experimental|desflurane group|
9990474|NCT01443572|Active Comparator|sevoflurane group|
9990475|NCT01443611||Infants with first episode of Febrile Convlusions|
9997428|NCT01508806|Experimental|Mild renal impairment|
9517146|NCT03309111|Experimental|ISB 1342|Part 1: Cohorts of multiple ISB 1342 dose levels; Part 2: One dose regimen until disease progression or other discontinuation criterion is met
9888661|NCT00572169|Experimental|VDTPACE|Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide
9888662|NCT00572208|Active Comparator|1|Gabapentin group
9888663|NCT00572208|No Intervention|2|placebo
9888664|NCT00572221|Other|CQI Program Only|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. (The SAVE+ intervention, the CQI system with facility responsible for identifying or designing care protocols for the identified problem condition.)
9888665|NCT00572221|Other|CQI Program and Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions. (The SAVE+ intervention, a CQI system plus best-practice protocols designed by study team to address identified problem condition.)
9888666|NCT00572247|Experimental|1|Behavioral
9888667|NCT00572247|No Intervention|2|
9888668|NCT00572286||1|heart transplant patient ( pre or post)
9888669|NCT00572299||glucocorticoids|patients receiving glucocorticoid treatment
9888670|NCT00572299||glucocorticoids and bisphosphonates|patients receiving both glucocorticoids and bisphosphonates
9888671|NCT00572325||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
9888672|NCT00572338||patients with myeloma/related diseases|
9888673|NCT00572351|Active Comparator|Red Wine|
9888674|NCT00572351|Active Comparator|White Wine|
9888675|NCT00572377|Active Comparator|FemLife Gel|
9888676|NCT00572377|Placebo Comparator|Placebo|
9888677|NCT00572390|Placebo Comparator|1|No oestrogen treatment
9888678|NCT00572390|Experimental|2|Oestrogen treatment
9888679|NCT00572416|Experimental|1|Four component behavioral sleep intervention comprised of activity-rest, sleep-wake, phychological distress and symptom management. Four components of the Individual Sleep Promotion Plan are: stimulus control, sleep restruction, relaxation, and sleep hygiene.
9888680|NCT00572416|Placebo Comparator|2|Equal time and attention, information about healthy eating and general conversation
9888681|NCT00572429|Placebo Comparator|A|
9888682|NCT00572442||1|"Subjects without any cardiovascular risk factors:~Age ≥ 45 in men; Age ≥ 55 in women.~Hypertension: BP > 140/90 mmHg or on BP meds.~Diabetes Mellitus: Known fasting blood sugar >126 mg/dl or on DM meds.~Dyslipidemia: On lipid lowering medication or LDL ≥ 160 mg/dl in absence of other risk factors; ≥ 130 mg/dl if other non-diabetic risk factors; ≥ 100 mg/dl if diabetic. Known HDL < 40 mg/dl.~Cigarette smoking (past or present).~Family history of premature CAD in first degree relatives: Age < 55 in men; Age < 65 in women."
9888683|NCT00572442||2|Subjects with 1 cardiovascular risk factor (listed above)
9888684|NCT00572442||3|Subjects with 2 cardiovascular risk factors (listed above)
9888685|NCT00572442||4|Subjects with more than 2 cardiovascular risk factors (listed above)
9888686|NCT00572494|Experimental|1|Stenting with AMS
9888687|NCT00572494|Active Comparator|2|PTA alone
9888688|NCT00572507|Experimental|MonoMax|MonoMax is used for abdominal wall closure
9888689|NCT00572520|Active Comparator|1|Evidence-based behavioral weight loss treatment with health education counseling
9888690|NCT00572520|Experimental|2|Evidence-based behavioral weight loss treatment with brief behavior therapy for depression
9888691|NCT00572559|Experimental|1|
9888692|NCT00572559|Experimental|2|
9888693|NCT00572611|Experimental|I|Single oral dose of 20 mg [14C]-bilastine
9888694|NCT00572650|Active Comparator|1|
9888695|NCT00572689|Experimental|A|Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
9888696|NCT00572689|No Intervention|B|Patients given mixed meal test and blood samples drawn for laboratory testing
9888697|NCT00572702|Active Comparator|A|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with Amreich-Richter procedure; it will be set randomly
9888698|NCT00572702|Active Comparator|B|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with total Prolift procedure; it will be set randomly
9888699|NCT00572715||Observation|"Inclusion criteria - Families of infants (birthweight >1500g) be asked to participate in the study.~Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded"
9888700|NCT00572741|Experimental|1|Nutritional supplementation
9888701|NCT00572741|Placebo Comparator|2|Placebo
9888702|NCT00572767|Experimental|1|
9888703|NCT00572767|Placebo Comparator|2|
9888704|NCT00572780||CTE with CD|Crohn's disease patients who underwent a CT enteroclysis as part of their clinical evaluation for symptomatic Crohn's disease.
9888705|NCT00572819|Active Comparator|Misoprostol|
9888706|NCT00572819|Placebo Comparator|Placebo|
9888707|NCT00572845|Experimental|1|Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.
9888708|NCT00572858||Premenopausal women|Female patients who have undergone coronary angiography and are under the age of 55
9888709|NCT00572871||Exercise after fasting|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions after a 10-hour fast
9888710|NCT00572871||No exercise|Will complete a ten-hour fast but do no exercise
9888711|NCT00572871||Exercise after snack|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions 2 hours following a 500 calorie nutritional supplement
9888712|NCT00572923||1|"Inclusion criteria~Histological or cytological proven SCLC~UICC stage I-III, limited disease~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
9888713|NCT00572949||1|Patients with chest pain syndrome
10211945|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
10211946|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
9888714|NCT00572962|Experimental|1|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
9517147|NCT03309098||Ankle Injury|Person who injures their ankle
9888715|NCT00572975|Experimental|1|
9888716|NCT00573001|Experimental|1|
9888717|NCT00573001|Experimental|2|
9888718|NCT00573001|Experimental|3|
9888719|NCT00573001|Active Comparator|4|
9888720|NCT00573014||OBTP|Obtunded blunt trauma patients with normal CT C-spine
9931953|NCT00944138|Active Comparator|Music for relaxation|Participants assigned to the control arm will receive the dietary counseling and will be told that relaxation can help reduce appetite. However, techniques to relax will not be taught. Instead, participants will be encouraged to sit quietly listening to music (of their choice) every day for 20 minutes. Participants assigned to the standard care arm will receive an MP3-player and will be given a choice of selection of music that they can load on their MP3 player (classical music, country music, jazz, etc.).
10211947|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
10211948|NCT03489187||VTTS as standard of care|VTTS as standard of care.
10211949|NCT03464630|Experimental|Mom & Baby Net|CBT skills based M-health intervention targeting maternal depression and and sensitive responsive parenting practices for optimizing infant social-communication promotion
10211950|NCT03464630|Active Comparator|Depression & Developmental Awareness System|Supportive, person-centered M-health intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and community resources (active control condition)
10211951|NCT03457792||Abatacept for Rheumatoid Arthritis (RA)|Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept
10211952|NCT03452111|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day). This daily gel volume will contain approximately 62 mg of T that will deliver 6 mg T to the body per day and will also contain 8 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/day + T 62 mg/day (NES-8/T-62) gel).
10211953|NCT03451786|Experimental|Treatment group|
10211954|NCT03441555|Experimental|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
10211955|NCT03439293|Experimental|Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg|Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), have an unacceptable toxicity, or withdraw consent, or until the sponsor terminates the study when the study has completed (approximately up to 4 years).
10211956|NCT03438526|Experimental|Melatonin (Circadin ®)|
10211957|NCT03438526|Placebo Comparator|Placebo|
10211958|NCT03426826|Placebo Comparator|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
10211959|NCT03426826|Active Comparator|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
10211960|NCT03421392||Idiopathic thrombocytopenic purpura|
10211961|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
10211962|NCT03421392||without thrombocytopenia|
10211963|NCT03416179|Experimental|Arm A (Intensive Study)|Glasdegib + '7+3' Induction(s)
9997429|NCT01508806|Experimental|Moderate renal impairment|
9517148|NCT03309085|Experimental|Single arm|Repeated CT scan
9888721|NCT00573027|Other|Single Arm|"fill out baseline demographic and health/medical history questionnaires, CV risk factors, reasons of diagnosis of ischemia, information of coronary artery, and medication use~undergo clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory (Appendix);~undergo noninvasive Peripheral Artery Tonometry (PAT) testing (Appendix);~undergo clinically indicated Cardiac Magnetic Resonance (CMR) imaging (Appendix) to detect subendocardial ischemia (if indicated and referred by the treating physician). The three tests (heart catheterization with adenosine coronary flow reserve testing, acetylcholine provocative vasomotor testing during heart catheterization, cardiac MRI) are performed for standard care.~have blood and urine testing.~fill out health questionnaires~be followed prospectively 6-week, 6-month, and annually for clinical status"
9888722|NCT00573040||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~Stage IV~Performance status 3 or more~FeV 1 or DLCO < 30% of the age-predicted value"
9888723|NCT00573053|Active Comparator|High|Arterial oxygen saturations in the range of 91-95%
9888724|NCT00573053|Experimental|Low|Arterial oxygen saturations in the range of 85-89%
9888725|NCT00573079||Observation|Premature infants in the NICU; 500-1500g birthweight, >=25 weeks gestation
9888726|NCT00573092||1|Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs
9888727|NCT00573105|Experimental|1|Laparoscopic Ventral hernia repair by heavy weight mesh
9888728|NCT00573105|Experimental|2|Laparoscopic Ventral hernia repair by lighter weight mesh
9888729|NCT00573118||1|The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
9888730|NCT00573118||2|The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
9888731|NCT00573196|Experimental|1|
9888732|NCT00573209|Other|1|
9888733|NCT00573274||1|Elective cesarean section patients
9888734|NCT00573300||Schizophrenia|Schizophrenia Patients
9888735|NCT00573300||Healthy Controls|Healthy Controls
9888736|NCT00573326|Experimental|1|Imatinib 200 mg p.o. once a day for 6 months
9888737|NCT00573339||Normal Controls|
9888738|NCT00573352|Other|1|Far infrared radiation
9888739|NCT00573365|Experimental|Treatment|LED treatment with Gentlewaves Select™ handheld high energy LED array 5 to 10 minutes before each radiation treatment and again 5-10 minutes after each radiation treatment
9888740|NCT00573365|Other|Control|Radiation only
9888741|NCT00573378|Experimental|1|
9888742|NCT00573404|Experimental|Therapeutic Intervention|
9888743|NCT00573417|Experimental|modafinil|modafinil 100mg, 200mg, or 300mg (dose escalation)
9888744|NCT00573417|Placebo Comparator|placebo|placebo
9888745|NCT00573456|Other|1|
9888746|NCT00573482|Active Comparator|control group|Control (only exposure to the food labels and the new lower ED foods).
9888747|NCT00573482|Experimental|intervention group|Education in REDE techniques plus exposure to the food labels and the new lower ED foods.
9888748|NCT00573495|Experimental|hTERT/Survivin Multi-Peptide Vaccine|
9888749|NCT00573573|Other|1|
9888750|NCT00573586|Other|HIFU|"Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to <0.5ng/ml.~Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir)~Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects"
9888751|NCT00573599|Experimental|1|prochlorperazine and benadryl IV, saline subQ
9888752|NCT00573599|Active Comparator|2|imitrex SubQ, saline IV
9888753|NCT00573612|Placebo Comparator|1|Telephone Call for the Attention Control Group Each AC call will follow the same format as the MI call. During the AC call, study subjects will receive health information on important topics relevant to their illness. Specifically, there will be one topic during each phone call that includes the following: (a) overview of FMS, (b) pain, (c) fatigue (d) sleep, (e) stress, and (f) living well with FMS. The AC calls will be an avenue to transfer relevant health information from the RA to the study subject. The scheduled topics during each contact will give the call face validity (i.e., establish a credible pretense for the contact) while being neutral with respect to encouragement of exercise.
9888754|NCT00573612|Active Comparator|2|Telephone-delivered Motivational Interviewing Participants will receive 6 telephone calls throughout the study. Harland et al reported that the most effective intervention for promoting exercise in the primary care setting was the most intensive treatment arm that included six MI sessions (208). Importantly, in our pilot study, participants who completed 5 to 6 phone calls achieved greater symptomatic benefits than participants who had ≤ 4 phone calls. The phone calls will be scheduled at week 3, 4, 6, 8, 10 and 12 of the study. Telephone sessions may run for 30 minutes on the average
9935565|NCT03510442||adult-onset Still's disease (AOSD)|Composed of patients with known or suspected AOSD as defined by Yamaguchi criteria.
9888755|NCT00573651|Other|Group A pauciarticular JIA|Females age 9-26 with pauciarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for serum titres taken to measure antibody and RNA titers.
9888756|NCT00573651|Other|Group B polyarticular JIA|Females age 9-26 with polyarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for Serum Titers taken to measure antibody and RNA titers.
9888757|NCT00573651|Other|Group C seronegative arthritis|Females age 9-26 with seronegative arthritis (including ankylosing spondylitis and psoriatic arthritis). All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers.
9888758|NCT00573664|Active Comparator|1|Gabapentin
9888759|NCT00573664|Placebo Comparator|2|Placebo
9888760|NCT00573690|Experimental|Group 1|Patients receive cisplatin IV over 1 hour on day 2 of courses 1 and 2 and on day 1 of all subsequent courses; etoposide IV over 30 minutes on days 1-3; and oral sorafenib tosylate once or twice daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
9888761|NCT00573690|Experimental|Group 2|Patients receive carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Patients also receive sorafenib tosylate as in group 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
9888762|NCT00573703|Active Comparator|Group A|
9888763|NCT00573703|Experimental|Group B|
9888764|NCT00573716||1|15 subjects who are taking aripiprazole monotherapy
9888765|NCT00573716||2|15 subjects who are taking Risperidone therapy
9888766|NCT00573716||3|30 healthy volunteers with an ethnicity, sex, and pubertal stage match of subjects taking aripiprazole monotherapy and Risperidone therapy
9888767|NCT00573729|Experimental|Pulsed Dye Laser 577 nm|Pulsed Dye Laser Treatment 577 nm treatment of Port Wine Stain Birthmarks
9888768|NCT00573729|Experimental|Pulsed Dye Laser 595 nm|Pulsed Dye Laser Treatment 595 nm treatment of Port Wine Stain Birthmarks
9888769|NCT00573781|Experimental|A|Diet with increased intake of rye bread, berries and fish
9888770|NCT00573781|Experimental|B|Increased intake of whole grain and rye bread
9888771|NCT00573781|Active Comparator|C|Control diet with decreased intake of rye bread, berries and fish
9888772|NCT00573807|Other|1|
9888773|NCT00573820|Other|1|
9888774|NCT00573885|Experimental|Arm I|Patients receive oral defined green tea catechin extract twice daily for 6 months.
9888775|NCT00573885|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
10211964|NCT03416179|Placebo Comparator|Arm B (Intensive Study)|Placebo + '7+3' Induction(s)
9888776|NCT00573924|Active Comparator|1|Oral PPI
9888777|NCT00573924|Active Comparator|2|Intravenous PPI
9888778|NCT00573950|Experimental|Cilostazol|cilostazol group
9888779|NCT00573950|Placebo Comparator|Placebo|placebo group
9888780|NCT00573963|Active Comparator|1|Ropivacaine
9888781|NCT00573963|Placebo Comparator|2|Placebo
9888782|NCT00574002||Group A|Patients that have their chest tube removed when drainage is 400mL or less in 24 hours.
9888783|NCT00574002||Group B.|Patients that have their chest tube removed when drainage is 200mL or less in 24 hours.
9888784|NCT00574015|Active Comparator|oral|administration of oral analgesia
9888785|NCT00574015|Experimental|Dental Block|Administration of supraperiosteal nerve block to effected tooth
10211965|NCT03416179|Experimental|Arm A (Non-intensive study)|Glasdegib + azacitidine
10211966|NCT03416179|Placebo Comparator|Arm B (Non-intensive study)|Placebo + azacitidine
10211967|NCT03409198|Active Comparator|Arm A|Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
10211968|NCT03409198|Experimental|Arm B|Chemo + ipilimumab + nivolumab
10211969|NCT03384875|Experimental|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
10211970|NCT03384875|Placebo Comparator|Control|Standard of care
10211971|NCT03377179|Experimental|ABC294640 +/- HCQ treatment|Part 1: All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles Part 2: All participants will be receiving ABC294640, 500 mg twice a day (BID) and HCQ at a determined level, continuously in 28 day cycles
10211972|NCT03373032|Experimental|Stiper - A|Stiper, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
10211973|NCT03373032|Experimental|Acupuncture - B|Acupuncture with needles, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
10211974|NCT03373032|Experimental|Exercise - C|Exercise, breast cancer patients during chemotherapy cycles, once a week, during 10 weeks
10211975|NCT03373032|Experimental|Follow Up - D|Selected patients from the 3 groups Stiper / Acupuncture / Exercise. One session with a Peridell Massager
9931954|NCT00944151|Placebo Comparator|Single injection with Saline infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
9931955|NCT00944151|Active Comparator|Single injection with Ropivicaine infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter
9931956|NCT00944164|Experimental|Healthy eating/physical activity|
9931957|NCT00944164|Active Comparator|Safety/Injury prevention|
10211976|NCT03373032|Other|Observation - S|Group patients who were unable to participate in the intervention group A / B and C. In this group, only the evaluation will be performed.
10211977|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
10211978|NCT03353922|Experimental|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
9888786|NCT00574041|Experimental|1|titrated dose of Avonex
9888787|NCT00574041|Active Comparator|2|full dose Avonex
9888788|NCT00574054|Other|1|
9888789|NCT00574093|Experimental|A|A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
9888790|NCT00574106|Other|1|Infrared Radiation
9888791|NCT00574210|Experimental|1|Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
9888792|NCT00574210|Experimental|2|Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
9888793|NCT00574210|Experimental|3|Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
9888794|NCT00574210|Experimental|4|Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
9888795|NCT00574210|Placebo Comparator|5|Placebo oral twice per day (2 placebo tablets)
9888796|NCT00574223|Experimental|Arm 1|
9888797|NCT00574223|Placebo Comparator|Arm 2|
9888798|NCT00574301|Experimental|1|
9888799|NCT00574314||Women|Women with varying backgrounds
9888800|NCT00574327||A- Barrett's Esophagus subjects|Patients with documented Barrett's Esophagus with or without dysplasia (LGD or HGD) that will undergo surveillance endoscopies dictated by the grade of dysplasia.
9888801|NCT00574327||B- gastroesophageal reflux subjects|Patients undergoing endoscopy for evaluation of GERD symptoms.
9888802|NCT00574327||C-subjects without BE or GERD|The control group would include patients undergoing upper endoscopy for reasons other than stated above, such as evaluation of iron deficiency anemia, weight loss, positive fecal occult blood, etc.
9888803|NCT00574353|Experimental|1|FMISO PET study.
9888804|NCT00574366|Experimental|Erlotinib/RAD001 Ph I|"Tarceva (OSI-774; erlotinib) Everolimus (RAD001)~Study did not progress to Phase II:~Experimental: Erlotinib/RAD001 Phase II Maximum tolerated dose of erlotinib (Tarceva,OSI-774) and RAD001 (Everolimus)"
9888805|NCT00574379|Experimental|1|Bilastine 20mg once per day
9888806|NCT00574379|Experimental|2|Bilastine 20mg twice per day
9888807|NCT00574379|Experimental|3|Bilastine 10mg once per day
9888808|NCT00574379|Experimental|4|Bilastine 10mg twice per day
9888809|NCT00574379|Placebo Comparator|5|
9888810|NCT00574392||1|Multiwavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented lesions on skin in vivo
9888811|NCT00574418|Other|1|
9888812|NCT00574431|Other|Observation|Observation
9888813|NCT00574431|Active Comparator|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
9888814|NCT00574444|Experimental|Procedure|Procedure/Surgery: transvaginal diagnostic peritoneoscopy For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
9888815|NCT00574457|Other|All subjects that meet the inclusion criteria invited|
9888816|NCT00574470|Experimental|1|Treatment with daclizumab/infliximab
9888817|NCT00574483|Experimental|1|Unblinded treatment arm
9888818|NCT00574509|Experimental|131I-Anti-B1|BEAM + 131Iodine-Anti-B1 radioimmunotherapy and autologous HSCT
9888819|NCT00574522|Other|1|Infrared Radiation, wavelength between 5 and 20 microns
9888820|NCT00574574|Experimental|1|500mg/d of anthocyanin, contained in 4 X 250mg capsules (125mg anthocyanin/ capsule). 2 capsules to be taken with food, twice per day (n=4 in total).
9888821|NCT00574574|Placebo Comparator|2|500mg/d of placebo control containing no anthocyanin, 2 X 250mg capsules to be taken with food, twice per day (n=4, 250mg capsules in total / d).
9888822|NCT00574600|Experimental|Vaccine|SAAVI DNA-C2 administered as 1 ml intramuscularly in either deltoid at study entry and Months 1 and 2; SAAVI MVA-C administered as 0.5 ml intramuscularly in either deltoid at Months 4 and 5
9888823|NCT00574600|Placebo Comparator|Placebo|Placebo administered at Months 0, 1, 2, 4 and 5
9888824|NCT00574613|Experimental|1|
9888825|NCT00574613|Placebo Comparator|2|
9888826|NCT00574626|Experimental|PBSCT|Peripheral Blood Stem Cell Transplant
9888827|NCT00574626|Active Comparator|BMT|Bone Marrow Transplantation
9888828|NCT00574639|Experimental|Arm 1|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
9997430|NCT01508806|Experimental|Severe renal impairment|
9888829|NCT00574639|Experimental|Arm 2|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
9888830|NCT00574639|Experimental|Arm 3|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
9888831|NCT00574639|Experimental|Arm 4|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
9888832|NCT00574652|Other|1|it is a single arm study
9888833|NCT00574665|Experimental|1|
9888834|NCT00574678|No Intervention|1|
9888835|NCT00574691|Other|1|Vascular Closure Device
9888836|NCT00574717|Experimental|A|Infants will receive spectacle under-correction of their hyperopia.
9888837|NCT00574730|Experimental|Arm 1|
9888838|NCT00574743|No Intervention|2|
9888839|NCT00574743|Active Comparator|1|
9888840|NCT00574756|Other|1|Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
9888841|NCT00574756|Other|2|Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
9888842|NCT00574769|Experimental|1|
9888843|NCT00574808|Experimental|intervention|Outreach Facilitation implementing elements of the Chronic Care Model. The facilitators will provide hands on support to practices and help to implement tools and processes designed to incorporate evidence-based practice into the routine delivery of cardiovascular care. Specifically, they will a) assist with practice performance assessment, feedback, and consensus building towards goal setting, b) offer clinical, technical, organizational resources and practical advice, and c) provide encouragement to face and overcome the challenges of implementing system change.
9888844|NCT00574808|No Intervention|control|Baseline data before implementation of the program will serve as the control. Comparisons will be made between baseline and post-intervention within each divisions of primary care practices as well as between divisions (ie. baseline information from one division will serve as the control for another).
9888845|NCT00574886|Experimental|1|
9888846|NCT00574899||1|patients scheduled to receive standard of care with a Radical prostatectomy
9888847|NCT00574899||2|patients scheduled to receive standard of care with radiation therapy
9888848|NCT00574964|Experimental|1|
9888849|NCT00574977|Experimental|A|Subjects who have been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection
9888850|NCT00574977|Experimental|B|Subjects will include those who have not been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection.
9888851|NCT00574977|Experimental|C|Subjects will be those who have been vaccinated with vaccinia virus (small pox)and will be receiving the vvCD-CDSR via intravenous infusion
9888852|NCT00575003|Experimental|1|
9888853|NCT00575003|Placebo Comparator|2|
9888854|NCT00575068|Experimental|1|
9888855|NCT00575081||Stereotactic Brain Procedures|Patients who have consented to undergo or have undergone a stereotactic brain procedure for any reason including those who need Deep Brain Stimulation, SEEG or other brain neurmodulation device implant.
9888856|NCT00575107|Experimental|VSC-VLC|velocity-controlled variable resistance, lengthening contraction
9888857|NCT00575107|Active Comparator|SC|Constant weight shortening contraction
9888858|NCT00575120|No Intervention|A|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI before 15 min. ischemia reperfusion of forearm
9888859|NCT00575120|Active Comparator|B|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI after 15 min. ischemia reperfusion
9888860|NCT00575172||U|Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
9888861|NCT00575172||R|Intensified insulin therapy with human regular insulin
9888862|NCT00575198|Experimental|1|No drainage threshold
9888863|NCT00575198|Active Comparator|2|Drainage <2 mL/kg
9888864|NCT00575211||Cardiomyopathy|
9888865|NCT00575224|Other|A|Pegylated interferon and ribavirin for 24 weeks
9888866|NCT00575224|Other|B|Pegylated interferon and ribavirin for 48 weeks
9888867|NCT00575237|No Intervention|Control|In the control group, CO2 was removed by passive deflation of the abdominal cavity through the holes of the trocar.
9888868|NCT00575237|Experimental|Intervention|
9888869|NCT00575250|Active Comparator|1|Osteoporosis Prevention and Self-Management Course (4 x 2 1/2 hours)
9888870|NCT00575250|Active Comparator|2|"One introductory osteoporosis education session (1 x 2 1/2 hours)"
9888871|NCT00575263||Normal Teeth|Normal molar teeth
9888872|NCT00575263||painful teeth|Painful molar teeth
9888873|NCT00575276||1|Females with acute cholecystitis
9888874|NCT00575276||2|Females with Chronic Cholecystitis
9888875|NCT00575276||3|Males with acute cholecystitis
9888876|NCT00575276||4|Males with Chronic Cholecystitis
9888877|NCT00575302|Active Comparator|300|administration of 300 IU Gonal-f® in a short agonist protocol.
9888878|NCT00575302|Experimental|450|administration of 450 IU Gonal-f® in a short agonist protocol.
9888879|NCT00575341|Active Comparator|1|substitution of DHEA-hormone, oral, once daily
9888880|NCT00575341|Placebo Comparator|2|substitution of placebo, oral, once daily
9888881|NCT00575354|Active Comparator|1|Sevoflurane: induction 3-6%, maintenance 2-3%
9888882|NCT00575354|Active Comparator|2|Isoflurane: induction 3-6%, maintenance 2-3%
9888883|NCT00575406|Active Comparator|R-CHOP|Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone
9888884|NCT00575406|Experimental|R-COMP|Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone
9888885|NCT00575419|Experimental|1, IV NAC|N-acetylcysteine administered intravenously
9888886|NCT00575419|Experimental|2, IA NAC|N-acetylcysteine administered intra-arterial
9888887|NCT00575432||1|
9888888|NCT00575445||1|Pediatric patients with previously diagnosed asthma
9888889|NCT00575458||1|Static Splint
9888890|NCT00575458||2|Dynamic Splint
9888891|NCT00575471|Experimental|1|rivoglitazone HCl 0.5 mg tablets once daily for 12 weeks
9888892|NCT00575471|Experimental|2|rivoglitazone HCl 1 mg tablets once daily for 12 weeks
9888893|NCT00575471|Experimental|3|rivoglitazone HCl 1.5 mg tablets once daily for 12 weeks
9888894|NCT00575471|Placebo Comparator|4|Matching placebo tablets once daily for 12 weeks
9888895|NCT00575484|Placebo Comparator|1|
9888896|NCT00575484|Active Comparator|2|
9888897|NCT00575497|Experimental|A|Six Day per week short daily hemodialysis
9888898|NCT00575497|Experimental|B|Six nights per week nocturnal hemodialysis
9888899|NCT00575497|Experimental|C|Every other day short daily hemodialysis
9888900|NCT00575497|Experimental|D|Every other night hemodialysis
9888901|NCT00575497|Experimental|E|5 days per week short daily hemodialysis
9888902|NCT00575497|Experimental|F|5 nights per week hemodialysis
9888903|NCT00575497|Active Comparator|G|Conventional three time per week short daily hemodialysis
9888904|NCT00575523|Active Comparator|1: Atropine|Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.
9888905|NCT00575523|Placebo Comparator|2: Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
9888906|NCT00575536||Rhizotomy for children with spasticity|Children with spasticity needing Rhizotomy surgery
9888907|NCT00575575|Experimental|A,2|
9888908|NCT00575601|Active Comparator|A|
9888909|NCT00575601|Placebo Comparator|B|
9888910|NCT00575614|Active Comparator|1|
9888911|NCT00575614|Placebo Comparator|2|
9888912|NCT00575627|No Intervention|2|
9888913|NCT00575627|Experimental|1|Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks
9888914|NCT00575640|Active Comparator|1|"The objective of this study is to determine the MTD for Hydralazine added to standard neoadjuvant chemotherapy for operable recta cancer. Four dose levels of hydralazine are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
9888915|NCT00575653||11-18 (Primary)|Enrolled members of one of the participating health plans who are ages 11-18 at any time during the study period, March 1, 2005 through August 31, 2008.
9888916|NCT00575653||19-21 (Secondary)|Enrolled members of one of the participating health plans who are ages 19-21 at any time during the study period, March 1, 2005 through August 31, 2008.
9888917|NCT00575679|Experimental|1|Brief motivational interview
9888918|NCT00575679|No Intervention|2|No discussion
9888919|NCT00575692||PulmoHypertension|Patients with suspected, latent or manifest pulmonary hypertension
9888920|NCT00575692||Controls|Controls without history of cardiac or pulmonary diseases
9888921|NCT00575718|Active Comparator|1|Hospital Counseling + Nicotine Replacement Therapy (HC+NRT)
9888922|NCT00575718|Experimental|2|Hospital Counseling + Nicotine Replacement Therapy + Pre-surgical Schedule Reduced Smoking (HC+NRT+PS/SRS)
9888923|NCT00575731|Experimental|Fine-Tuning|2-month intervention (8 lifestyle counseling classes)
9888924|NCT00575731|Active Comparator|Record-Keeping|2-month intervention (8 lifestyle counseling classes)
9888925|NCT00575744|No Intervention|1|
9888926|NCT00575757||Primary|HIV infected with abnormal liver enzymes in the absence of HCV or HBV coinfections.
9888927|NCT00575783||1A, 1B|"Type 1 diabetic subjects with a history of severe hypoglycemia and hypoglycemia unawareness who:~1A) meet criteria for islet cell transplantation and are referred by a participating islet cell transplantation center~1B) meet similar criteria but are not currently planning islet cell transplantation"
9888928|NCT00575783||2|Type 1 diabetics who are not optimally controlled (>8% HbA1c) and rarely experience hypoglycemia
9888929|NCT00575783||3|Healthy non-diabetics
9931958|NCT00944190|Experimental|Self-management Intervention|Telephone based self management intervention targeted at pain, fatigue, depression, and cognitive difficulties.
9888930|NCT00575796|Experimental|1|"Children will be treated with Vinblastine Sulphate chemotherapy via intravenous administration once a week over a period of 26 weeks. MRI disease evaluation should be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 > stable (i.e. stable disease, objective or partial or complete response compared to the baseline MRI exam), continue weekly Vinblastine to the total duration of treatment (i.e. 70 weeks).~All children will be followed until they demonstrate clear signs tumour progression."
9888931|NCT00575809||Obsevational|
9888932|NCT00575822|Active Comparator|1|NDO Endoscopic Full-thickness Plicator procedure
9888933|NCT00575822|Sham Comparator|2|Sham control procedure
9888934|NCT00575835|Active Comparator|1|
9888935|NCT00575835|Experimental|2|
9888936|NCT00575848|Active Comparator|1|
9888937|NCT00575848|Placebo Comparator|2|
9888938|NCT00575861|Active Comparator|1|Advair 250/50 (baseline) fluticasone/salmeterol 250/50
9888939|NCT00575874|Experimental|1|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
9888940|NCT00575874|Experimental|2|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
9888941|NCT00575874|Experimental|3|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
9888942|NCT00575874|Active Comparator|4|30 mg pioglitazone HCl capsules once daily for 12 weeks
9888943|NCT00575874|Placebo Comparator|5|Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
9888944|NCT00575900|Experimental|1|Low carbohydrate and low fat.
9888945|NCT00575900|Experimental|2|Low carbohydrate fat rich diet
9888946|NCT00575900|Active Comparator|3|A balanced low fat diet
9931959|NCT00944190|Active Comparator|Education|Education about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
9931960|NCT00944203|Experimental|Test Area|Test Area = Standard Treatment plus Ipomea pes-caprae oinment
9931961|NCT00944203|No Intervention|Control Area|Control = Standard Treatment
9931962|NCT00944255||RA with drug|
9931963|NCT00944255||RA without drug|
9931964|NCT00944268|Experimental|Liquid and solid|
9931965|NCT00944281|Experimental|LNS-Zn5|Daily intake of 20 g LNS containing 5 mg of zinc and a daily placebo supplement
9931966|NCT00944281|Experimental|LNS-Zn10|Daily intake of 20 g LNS containing 10 mg of zinc and a daily placebo supplement
9931967|NCT00944281|Placebo Comparator|LNS-Zn0|Daily intake of 20 g LNS containing 0 mg of zinc and a daily placebo supplement
9931968|NCT00944281|Experimental|Suppl-Zn5|Daily intake of zinc supplement containing 5 mg of zinc and 20 g LNS containing 0 mg of zinc
9931969|NCT00944281|No Intervention|Delayed intervention group|Standard care from age 8 to 18 months. Daily consumption of LNS from age 18 to 28 months.
9931970|NCT00944307|Active Comparator|raltegravir alone|Subjects will receive a single dose of 400 mg raltegravir orally
9931971|NCT00944307|Experimental|raltegravir plus antacid|Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
9931972|NCT00944333|Experimental|Clopidogrel 6|6 month dual antiplatelet therapies in patients after second generation DES implantation
9931973|NCT00944333|Experimental|Clopidogrel 12|12 month dual antiplatelet therapies in patients after second generation DES implantation
9931974|NCT00944359|Experimental|Daily preventive Zn; placebo treatment|7 mg zinc per day for 12 months and placebo supplement during diarrhea episode
9931975|NCT00944359|Experimental|Therapeutic Zn; daily placebo|20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement
9931976|NCT00944359|Experimental|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode
9931977|NCT00944359|Active Comparator|Surveillance control group|Surveillance control group will be randomly assigned to intervention groups every 3 months
9931978|NCT00944359|No Intervention|Non-intervention|Standard care provided by health system
9931979|NCT00944372|Experimental|Group 1|Control, age greater than or equal to 18 with normal renal function
9931980|NCT00944372|Experimental|Group 2|Age 18 to less than 65 with mild renal impairment
9931981|NCT00944372|Experimental|Group 3|Age 18 to less than 65 with moderate to severe renal impairment
9931982|NCT00944372|Experimental|Group 4|Age 18 to less than 65 with end stage renal impairment
9931983|NCT00944372|Experimental|Group 5|Age 65 to less than 75 with mild renal impairment
9931984|NCT00944372|Experimental|Group 6|Age 65 to less than 75 with moderate to severe renal impairment
9931985|NCT00944372|Experimental|Group 7|Age 65 to less than 75 with end stage renal impairment
9931986|NCT00944372|Experimental|Group 8|Age greater than or equal to 75 with mild renal impairment
9931987|NCT00944372|Experimental|Group 9|Age greater than or equal to 75 with moderate to severe renal impairment
9931988|NCT00944372|Experimental|Group 10|Age greater than or equal to 75 with end stage renal impairment
9931989|NCT00944385|Experimental|ulinastatin|Administer with 30,000U /ulinastatin
9931990|NCT00944385|Placebo Comparator|C group|administer normal saline
9931991|NCT00944398|Experimental|Zinc fortified group|Daily consumption of zinc-fortified complementary food
9888947|NCT00575926|Active Comparator|A: Lingzhi extract|Oral 300mg capsules containing Lingzhi extract (4 to 6 capsules per day as dosed by patients' age)
9888948|NCT00575926|Placebo Comparator|B: Placebo|Starch with same appearance and taste as LingZhi
9888949|NCT00575939||HIV positive|HIV infected treatment naive with CD4 cell count of at least 400
9888950|NCT00575939||Healthy controls|Healthy controls
9888951|NCT00575952|Experimental|Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)|"Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
9888952|NCT00575978|Experimental|Hydralazine|"The objective of this study is to determine the MTD for hydrazaline added to standard neoadjuvant chemotherapy for operable breast cancer. Four dose levels of hydrazalline are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
9888953|NCT00575991|Experimental|A|
9888954|NCT00575991|Placebo Comparator|B|
9888955|NCT00576004|Active Comparator|group A|Pelvic organ prolapse repair plus concomitant Burch Colposuspension
9888956|NCT00576004|Active Comparator|group B|Pelvic organ prolapse without Burch colposuspension
9888957|NCT00576030|Other|H|habitual coffee drinkers
9888958|NCT00576030|Other|N|non-habitual coffee drinkers
9888959|NCT00576043|Active Comparator|1: Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator
9888960|NCT00576043|No Intervention|2: No Training|No simulator training before starting endoscopy training on real patients
9888961|NCT00576069||asthma, quality of life, lung function|All Asthmatics will be treated with 1 of 3 long acting beta 2 agonist + corticosteroid using low or medium dose of inhaled (Advair) fluticasone or equivalent corticosteroid 200-500mcg/day plus salmeterol 100 mcg/day or (Symbicort) budesonide 320-640 mcg +formoterol 18 mcg/day or (Dulera) mometasone 400-800mcg + formoterol 20 mcg/day. In addition tiotropium 18ucg/day will be used. Additionally, albuterol 0.083%/ipratropium 0.02% solution or MDI HFA for acute exacerbation.Will measure lung function and asthma quality of life questionaire
9888962|NCT00576095||PMD|Patients diagnosed with major depression with psychotic features
9888963|NCT00576095||NPMD|Patients diagnosed with major depression without psychotic features
9888964|NCT00576095||Controls|Participants with no psychiatric or depression history
9888965|NCT00576108|Experimental|KD7040 topical gel|
9888966|NCT00576108|Placebo Comparator|Placebo gel|
9888967|NCT00576121||1|Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
9888968|NCT00576121||2|End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
9888969|NCT00576121||3|End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
9888970|NCT00576160|No Intervention|A|"Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians."
9888971|NCT00576160|Experimental|B|Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
9888972|NCT00576186||1|Patients being referred for the routine Equilibrium Radionuclide Angiocardiography (ERNA) for assessment of their left ventricular function will be asked to participate in the study. All patients will be asked to sign the consent form. Patients will be given a choice to participate in either or both studies (i.e. ERNA plus ACGBS or ERNA plus ACGBS and 3 DE).
9990476|NCT01443624|Experimental|critical care patients venofer|Critically ill patients are injected with Venofer (ferric hydroxide sucrose) 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
10211979|NCT03353922|Placebo Comparator|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
10211980|NCT03353922|Active Comparator|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
9990477|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 1)|A single subcutaneous injection of Formulation A
9990478|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation B x 1)|A single subcutaneous injection of Formulation B
9990479|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 2)|2 single subcutaneous injections of Formulation A
9990480|NCT01443663|Experimental|Group 1 (Previously Received H5N1 VN 04 ca Vaccine)|Participants will have previously received two doses of 10^7.5 tissue culture infectious dose (TCID)50 of H5N1 A/VN/1203/04 x A/AA/6/60 ca LAIV (H5N1 VN 04 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
9990481|NCT01443663|Experimental|Group 2 (Previously Received H5N1 HK 03 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H5N1 A/HK/213/03 x A/AA/6/60 ca LAIV (H5N1 HK 03 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
9990482|NCT01443663|Experimental|Group 3 (Previously Received H7N3 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H7N3 A/ck/BC/CN-6/04 x A/AA/6/60 ca LAIV (H7N3 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
9990483|NCT01443663|Experimental|Group 4 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive one dose of the H5N1 vaccine at baseline.
9990484|NCT01443663|Experimental|Group 5 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive two doses of the H5N1 vaccine at baseline and Day 28.
9990485|NCT01443676|Active Comparator|Radiotherapy|Radiotherapy
9990486|NCT01443676|Experimental|Radiotherapy plus Bevacizumab|Radiotherapy plus Bevacizumab
9990487|NCT01443689|Experimental|Group1 :Conventional plus hUCMSCs treatment|Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.
9990488|NCT01443689|Experimental|Group 2: Conventional plus hCBMNCs and hUCMSCs therapy|Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.
9990489|NCT01443689|Active Comparator|Group 3:Conventional therapy|Participants will be given conventional therapy only with a 6 months follow-up.
9990490|NCT01443702|Placebo Comparator|Placebo|
9990491|NCT01443702|Active Comparator|Lapis judaicus|
9990492|NCT01443715|Experimental|Stepped Care IPT-A - Interpersonal Psychotherapy|IPT-A focuses on communication and problem-solving skills.
9990493|NCT01443715|Active Comparator|Treatment as Usual|Treatment as Usual is the standard treatment received in the community
9990494|NCT01443741|Active Comparator|FIT Therapy|Patient with functional insulin therapy
9990495|NCT01443741|Active Comparator|Traditional way|Patient with traditional way
9990496|NCT01443754||Hybrid group|Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)
9990497|NCT01443767||Partial liver resection|Adult patients scheduled for elective partial liver resection
9990498|NCT01443780|Experimental|sellenium + Q10|Active dietary supplement that is compared against a placebo arm
9990499|NCT01443780|Placebo Comparator|Sugar pills|Placebo arm that is compared against active intervention with a dietary supplement with selenium + Q10
9990500|NCT01443806|Experimental|Oseltamivir, genetic testing|
9990501|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|
9990502|NCT01443819|Other|Physical Therapy|
10211981|NCT03346239|Experimental|Gaze Contingent Music Reward Therapy|Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
10211982|NCT03346239|Active Comparator|Selective Serotonin Reuptake Inhibitors|Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
10211983|NCT03346239|Placebo Comparator|Waitlist Control|Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
10211984|NCT03322384|Experimental|Experimental|All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.
10211985|NCT03281720|Experimental|Targeted Axillary Dissection|"After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes.~The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an axillary dissection."
10211986|NCT03275740|Experimental|PF-06755347 intravenous healthy participant|intravenous administration
10211987|NCT03275740|Placebo Comparator|Placebo intravenous healthy participant|intravenous administration
9990503|NCT01443819|Other|Cohort observational|
9990504|NCT01443832||iron absorption|
9990505|NCT01443871|Experimental|Aromatherapy|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the odor for 10 minutes as during inhalation. The last part, the odor was dispersed and assessed EEG activity for 10 minutes as after inhalation.
9997431|NCT01508806|Experimental|End-stage renal disease|
9997432|NCT01508819||1|Guidelines for ICU admission of elderly patients arriving in Emergency Departments with a life threatening conditions
9888973|NCT00576212|Experimental|A|Subjects in the intervention group will receive supportive telephone calls biweekly for 6 months.
9888974|NCT00576212|No Intervention|B|Subjects in the control group will receive no intervention.
9888975|NCT00576225|Experimental|Experimental|
9888976|NCT00576225|Active Comparator|Control|
9888977|NCT00576238|Experimental|1:1|Part 1 - eczema treatment
9888978|NCT00576238|Active Comparator|1:2|Part 1 - eczema treatment
9888979|NCT00576238|Experimental|2:1|Part 2 - maintenance treatment
9888980|NCT00576238|No Intervention|2:2|Part 2 - maintenance treatment
9888981|NCT00576329|Placebo Comparator|A|
9888982|NCT00576329|Experimental|B|
9888983|NCT00576355|Active Comparator|2|Participants will receive treatment as usual
9888984|NCT00576355|Experimental|1|Participants will receive interpersonal and social rhythm therapy for adolescents
9888985|NCT00576368|Experimental|1|
9888986|NCT00576394|Active Comparator|1Moderate Glycemic Control|Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl
9888987|NCT00576394|Active Comparator|2Aggressive Glycemic Control|Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl
9888988|NCT00576433|Experimental|1|
10211988|NCT03275740|Experimental|PF-06755347 subcutaneous healthy participant|subcutaneous administration
9888989|NCT00576446|Experimental|1|
9888990|NCT00576459|Experimental|Fluocinolone acetonide 0.59 mg|0.59 mg fluocinolone acetonide intravitreal implant
9888991|NCT00576459|Experimental|Fluocinolone acetonide 2.1 mg|2.1 mg fluocinolone acetonide intravitreal implant
9888992|NCT00576459|Active Comparator|Laser photocoagulation|standard of care laser photocoagulation
9888993|NCT00576485|Experimental|1|Cataract surgery and implantation of a spherical intraocular lens
9888994|NCT00576485|Experimental|2|Cataract surgery and implantation of a spherical intraocular lens
9888995|NCT00576498|Experimental|1- Narrow Band Imaging|"NBI-AFI imaging - Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.~Autofluorescence Imaging (AFI)- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm)"
9888996|NCT00576498|Other|2-Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars
9888997|NCT00576511|Active Comparator|1|Prucalopride
9888998|NCT00576511|Placebo Comparator|2|
9888999|NCT00576550|Experimental|1:1|Part 1 of the study (maintenance part)
9889000|NCT00576550|No Intervention|1:2|Part 1 of the study (maintenance part)
9889001|NCT00576550|Experimental|2:1|Part 2 of the study (eczema part)
9889002|NCT00576550|Active Comparator|2:2|Part 2 of the study (eczema part)
9889003|NCT00576563|Other|FDG PET CT|To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy.
9889004|NCT00576589|Experimental|CE-326,597|
9889005|NCT00576589|Placebo Comparator|Placebo|
9889006|NCT00576602|Experimental|1|
9889007|NCT00576602|Active Comparator|2|
9889008|NCT00576615||1: placebo|placebo solution
9889009|NCT00576615||2: propofol|propofol
9889010|NCT00576641|Experimental|Vaccine|
9889011|NCT00576706|Experimental|1|
9889012|NCT00576706|Active Comparator|2|
9889013|NCT00576719|Experimental|1|Participants will receive intensive cognitive behavioral therapy treatment without parent involvement
9889014|NCT00576719|Experimental|2|Participants will receive intensive cognitive behavioral therapy treatment with parent involvement
9889015|NCT00576719|Placebo Comparator|3|Waitlist control group
9889016|NCT00576745|Active Comparator|1 Vicryl Suture|Patients will have their incision closed with vicryl suture
9889017|NCT00576745|Experimental|2 Steri-Strips|Patients will have their incisions closed with 3M Surgical-Strips
9889018|NCT00576771|Experimental|1|"ALI/ARDS patients~evaluated the effect of PSV, NAVA and assisted controlled mechanical ventilation by patient through a button"
9889019|NCT00576784|Active Comparator|A|pioglitazone/glimepiride
9889020|NCT00576849|Experimental|A|Total balanced volume replacement regimen consisting of a balanced HES 130/0.42 plus a balanced crystalloid
9889021|NCT00576849|Active Comparator|B|Conventional volume replacement strategy consisting of 6% HES 130/0.4 prepared in saline solution plus Ringer's lactate
9889022|NCT00576862|Experimental|1|
10211989|NCT03275740|Placebo Comparator|Placebo subcutaneous healthy participant|subcutaneous administration
10211990|NCT03275740|Experimental|PF-06755347 subcutaneous ITP|subcutaneous
10211991|NCT03263325||AKI Group|Patients developing AKI after surgery
10211992|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
10213816|NCT03085680|Experimental|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
9889023|NCT00576875||Depressed|Older individuals with major depression
9889024|NCT00576875||Non-depressed|Older individuals without major depression
9889025|NCT00576888||Vascular Anomaly with Coagulopathy|All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) or with a vascular anomaly with coagulopathy
9889026|NCT00576914|Active Comparator|A|vinorelbine plus cisplatin plus recombinant human endostatin
9889027|NCT00576914|No Intervention|B|vinorelbine plus cisplatin
9889028|NCT00576940|Experimental|IMEN: 1|Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
9889029|NCT00576940|Active Comparator|SEN|postoperative enteral nutrition - standard oligopeptic diet
9889030|NCT00576992||GI observation|Patients presenting for an upper endoscopy procedure with gastrointestinal symptoms or complaints.
9889031|NCT00577018|Active Comparator|1|
9889032|NCT00577018|Active Comparator|2|
9889033|NCT00577018|Placebo Comparator|3|
9889034|NCT00577070|Active Comparator|H1|"Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS,20 minutes each session, to the left prefrontal cortex using H1 coil, in frequency of 20 HZ, with intensity of 120 % of motor threshold. H1-coil is an extracorporeal device positioned on the patient's scalp, designed to stimulate deep prefrontal brain regions, preferentially in the left hemisphere. The effective part of the coil, which has contact with the patient's scalp, includes 14 strips of 7-12 cm length. These strips are oriented in an anterior-posterior axis.This coil stimulates neuronal fibers in anterior-posterior orientation.~During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas."
9889035|NCT00577070|Experimental|H2|Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS, 20 minutes each session, to the prefrontal cortex bilateraly using H2 coil, in frequency of 0.1 HZ, with intensity of 120 % of motor threshold. H2-coil is designed to stimulate deep prefrontal brain regions bilaterally (without any preferencefor either hemisphere). The effective part of the coil, which has contact with the patient's scalp, includes 10 strips of 14-22 cm length.These strips are oriented in a right-left direction (lateral-medial axis).This coil is destined to stimulate lateral-medial neuronal fibers. During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas.
9889036|NCT00577109|Experimental|1|
9889037|NCT00577161|Active Comparator|Comparator|fludarabine and rituximab
9889038|NCT00577161|Experimental|Experimental|fludarabine, rituximab, pixantrone
9889039|NCT00577174||1. Controls|Healthy children ages 8 to 18 years
9889040|NCT00577174||2. Obese childrens|Obese children, ages 8 to 18 years
9889041|NCT00577200|No Intervention|Control|Control group subjects are not undergoing any surgical procedures and will not be randomized to any anesthetic drug group.
9889042|NCT00577200|Experimental|Midazolam + Sufentanil + Propofol|"Midazolam 0.03 mg/kg + Sufentanil 0.1 µg/kg + Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.~For subjects who are chronic pain patients undergoing minor surgical procedures."
9889043|NCT00577200|Experimental|Midazolam and Sufenatnil|"Midazolam 1-5 mg in holding area + Sufentanil 5-10 mcg.~For subjects who are chronic pain patients undergoing minor surgical procedures."
9889044|NCT00577226||1 Shilla Technique|The patients whose data is observed are those who have undergone the shilla surgical technique.
9889045|NCT00577252||1|Adolescents with CF.
9889046|NCT00577304|Other|2|Placebo - Topical AmphiMatrix
9889047|NCT00577304|Active Comparator|1|Topical AmphiMatrix with Nitroglycerin
9889048|NCT00577330|Experimental|Myalgesin|Subjects receive Myalgesin twice daily
9889049|NCT00577330|Active Comparator|Acetaminophen|Subjects receive acetaminophen 1000 mg three times a day
9889050|NCT00577369|Active Comparator|1|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
9889051|NCT00577421|Experimental|1|5 mg/day risedronate
9889052|NCT00577447|Active Comparator|1|DHA supplemented group
9889053|NCT00577447|Placebo Comparator|2|Placebo group
9889054|NCT00577499||Only group|adult cystic fibrosis patients who are not at goal body mass index and have started lubiprostone therapy within one month of study enrollment
9889055|NCT00577525||1|Case : Patients with steroid sensitive nephrotic syndrome
9889056|NCT00577525||2|Controls (matched for age and sexe with the first group)
9889057|NCT00577538||1|
9889058|NCT00577538||2|
9889059|NCT00577603|Active Comparator|2|mesh reinforcement at stoma
9889060|NCT00577603|Active Comparator|Arm 1|standard stoma
9889061|NCT00577616|Other|1|Endovascular repair
9889062|NCT00577616|Other|2|conventional surgery repair
9889063|NCT00577668|Experimental|VDT and Melphalan|To find out if three drugs, bortezomib, thalidomide, and dexamethasone in addition to high doses of melphalan (M-VTD) and autologous transplant can be given safely and effectively to subjects who have failed previous regimens with transplant(s).
9889064|NCT00577681||1|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who have no history of CVD
9889065|NCT00577681||2|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who experienced a major CVD event during the study, analyzed along with 2 matched controls
9889066|NCT00577681||3|Participants from the SMART study who have no previous use of ART or have taken ART but not done so within 6 months prior to study entry; allows for a comparison of immediate ART versus deferred ART
9889067|NCT00577694|Other|single arm study|1
9889068|NCT00577733||obese|obese
9889069|NCT00577733||healthy volunteers|healthy volunteers
9889070|NCT00577746||surgery|Those subjects who went to surgery for treatment for their lung cancer.
9889071|NCT00577746||no surgery|The subjects who did not go to surgery for treatment of their lung cancer.
9889072|NCT00577759|Experimental|Active Intervention|Direct referral to community organizations, with support for practices to do so. These include the North Carolina Tobacco Quitline, public health department dietitians, and the YMCA.
9889073|NCT00577759|Experimental|Passive Intervention|Provision of information about community organizations to patients as above.
9889074|NCT00577759|Placebo Comparator|Usual Care|Usual care
9889075|NCT00577785||cystectomy group|Subjects undergoing planned cystectomy who agree to provide bladder tissue from removed bladder post cystectomy and/or cystoscopic biopsy tissue prior to cystectomy
9889076|NCT00577798|No Intervention|Observational|Only had observational arm
9889077|NCT00577811||1|Patients from 6 different Special Need Plans
9889078|NCT00577811||2|
9889079|NCT00577837|Active Comparator|1|5 mg risedronate, once daily for 6 months
9889080|NCT00577837|Experimental|2|100 mg risedronate, once a month for 6 months
9889081|NCT00577837|Experimental|3|150 mg risedronate, once a month for 6 months
9889082|NCT00577837|Experimental|4|200 mg risedronate, once a month for 6 months
9889083|NCT00577850|Experimental|1|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks
9889084|NCT00577850|Active Comparator|2|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 70 mg of alendronate once a week for 52 weeks
9889085|NCT00577876|Experimental|1|Day of Surgery:Patient is admitted through the Preoperative Surgical Center (PSC). If a large APA is identified, then subject will continue on study Dissect APA (without any changes from what is routinely done) with a penile injection of Trimix. Once the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
9889086|NCT00577902||Observational|This is an observational study
9889087|NCT00577915|Experimental|Breast MR Spectroscopy|Conventional images will be taken with standard pulse sequences. These images will be used for the diagnostic examination for which the patient will have been scheduled. Following the diagnostic study, a pulse sequence designed to obtain spectroscopy data will be used.This will be used on the existing magnets 1.5T and 3T. Memorial Sloan-Kettering Cancer Center has 1.5T and 3T magnets. The patient will have only one injection of contrast (gadolinium-DTPA) for the initial diagnostic study. No additional contrast will be administered. The additional sequence should take about 10 minutes, depending on breast size.
9889088|NCT00577928||1|
9889089|NCT00577928||2|
9889090|NCT00577954||1|Patients in a coma condition after a traumatic brain injury (250), stroke, cerebral anoxia or subarachnoid hemorrhage (150), for at least 7 days.
9889091|NCT00577980|Experimental|Testosterone|Testosterone 200 mg administered parenterally by intramuscular (IM) injection every 2 weeks
9889092|NCT00578006|Experimental|A|If you are in group A, the investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
9889093|NCT00578006|Experimental|B|If you are in group B, the investigators will provide you with access to the STAR website using a computer in the waiting area, into which you can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy. The investigators may also provide you with a website address so that you can access STAR from home (or any other location) to report your symptoms at any time.
9889094|NCT00578019|Active Comparator|1, A|
9889095|NCT00578019|Experimental|2, B|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
9931992|NCT00944398|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified complementary food and placebo supplement.
9931993|NCT00944398|Experimental|Zinc supplement group|Daily consumption of zinc supplement and non-fortified complementary food.
9931994|NCT00944424|Experimental|Arm A|Arm A = Docetaxel + High dose Vitamin D2
9931995|NCT00944424|Active Comparator|Arm B|Docetaxel + Standard dose Vitamin D2
9931996|NCT00944437|Active Comparator|Helmet|Patients in this group will receive continuous positive airway pressure delivered through a helmet connected to a high-flow reservoir system.
9931997|NCT00944437|Experimental|Mask|Patients in this group will receive continuous positive-airway pressure delivered through a novel full-face mask connected to a high-flow system. Expiratory pressure will be maintained using an expiratory valve connected to a T-tube.
9931998|NCT00944463|Experimental|Gemcitabine+simvastatin|Gemcitabine and simvastatin
9931999|NCT00944463|Placebo Comparator|Gemcitabine+Placebo|Gemcitabine plus Placebo
9932000|NCT00944476||Pts/volunteers getting regular MRI exam|Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
9932001|NCT00944489||1|Patients with diagnosis of essential hypertension under the criteria established by the Joint National Committee VII (9) and those patients under pharmacological treatment with the same therapeutic regime during at least the last 6 months.
9932002|NCT00944502|Experimental|Dexamethasone and complex vitamins|"Group A: Vitatonus dexa injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablet:~1 tablet orally every 8 hours for 10 days."
9997433|NCT01508819||2|no intervention
9889096|NCT00578032||1|Patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.
9889097|NCT00578045|Experimental|1|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
9889098|NCT00578058|Other|1|Counseling plus everyday noise type 1
9889099|NCT00578058|Other|2|Counseling plus static noise type 2
9889100|NCT00578058|Other|3|Counseling plus static noise type 3
9889101|NCT00578058|Other|4|Hearing aid and counseling plus everyday noise type 1
9889102|NCT00578058|Other|5|Hearing aid and counseling plus static noise type 2
9889103|NCT00578058|Other|6|Hearing aid and counseling plus static noise type 3
9889104|NCT00578084||surgery|those subjects who went to surgery to treat their lung cancer
9889105|NCT00578084||no surgery|those subjects who did not go to surgery for their lung cancer
9889106|NCT00578084||NSCLC|subjects with NSCLC
9889107|NCT00578084||Small cell lung cancer|those with small cell lung cancer
9889108|NCT00578097|Experimental|A - 125 units|
9889109|NCT00578097|Experimental|B - 250 units|
9889110|NCT00578097|Experimental|C - 500 units|
9889111|NCT00578097|Placebo Comparator|D|
9889112|NCT00578110|Experimental|Group 1|Glaucoma Patients
9889113|NCT00578110|Experimental|Group 2|Glaucoma suspects
9889114|NCT00578110|Active Comparator|Group 3|Controls
9889115|NCT00578123|Other|1 Questionnaire|Quality of Life Questionnaires
9889116|NCT00578162||1|Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory.
9889117|NCT00578188||RP100-400|Subjects with Chlamydia. The control group will also be identified with these numbers.
9889118|NCT00578201|Experimental|1|radiochemotherapy,combination Cetuximab-FOLFOX
9889119|NCT00578266|Other|No Arms|
9889120|NCT00578357|Experimental|1|immediate intervention
9889121|NCT00578357|No Intervention|2|note: participants in this arm will receive the intervention after the 6-month follow-up (serving as control during the trial)
9889122|NCT00578370|Experimental|1|
9889123|NCT00578370|Experimental|2|
9889124|NCT00578370|Active Comparator|3|
9889125|NCT00578370|Active Comparator|4|
9889126|NCT00578370|Placebo Comparator|5|
9889127|NCT00578396|Active Comparator|Dose Level 1|1 lb/day fresh red grapes
9889128|NCT00578396|Active Comparator|Dose Level 2|2/3 lb/day fresh red grapes
9889129|NCT00578396|Active Comparator|Dose Level 3|1/3 lb/day fresh red grapes
9889130|NCT00578422||Arm I: In Vitro IVUS Plaque studies|IVUS of Amputation Specimens
9889131|NCT00578422||Arm 2: Obserational Study|IVUS for patients undergoing standard lower extremity angiography for PAD.
9889132|NCT00578500|Active Comparator|OCCT|Patients referred to ovarian cryopreservation.
9889133|NCT00578526|Active Comparator|Arm 1|SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks
9889134|NCT00578526|Placebo Comparator|Arm 2|1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment.
9889135|NCT00578578|Active Comparator|1|"Active Arm:~1000 mg Lemon flavored Capsules. Three capsules every morning."
9889136|NCT00578578|Placebo Comparator|2|"Placebo Arm:~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning."
9889137|NCT00578591|Experimental|Patient|Four Rituximab doses administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT)
9889138|NCT00578604||Patients with a diabetic wound|Patients with a diabetic wound
9889139|NCT00578604||Control|Patients without a diabetic wound
9889140|NCT00578630||1|All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
9889141|NCT00578656|Experimental|1|Baked milk and at least 4 oral food challenges as clinically indicated
9889142|NCT00578682|Experimental|1|Single IV dose of 0.3 mg/kg MEDI-557
9889143|NCT00578682|Experimental|2|Single IV dose of 3 mg/kg MEDI-557
9889144|NCT00578682|Experimental|3|Single IV dose of 15 mg/kg MEDI-557
9889145|NCT00578682|Experimental|4|Single IV dose of 30 mg/kg MEDI-557
9889146|NCT00578708|Experimental|1|
9889147|NCT00578721|Experimental|325 mg Aspirin|325 mg aspirin po qd with arginine-restricted diet
9889148|NCT00578760|Placebo Comparator|2|placebo OD during course of chemotherapy
9889149|NCT00578760|Experimental|1|325mg ASA OD during course of chemotherapy
9889150|NCT00578799|Active Comparator|Kyo-Dophilus|Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)
9889151|NCT00578799|Placebo Comparator|Placebo|placebo capsules (potato starch)
9889152|NCT00578838||1|25 patients with metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
9889153|NCT00578838||2|25 patients with non-metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
9889154|NCT00578838||3|11 healthy volunteers, who will also undergo two scans 2-3 weeks apart.
9889155|NCT00578851||C2a Taper recipients|Patients who receive a THA with the C2a - Taper™ Acetabular System
9889156|NCT00578890|Experimental|1|
9889157|NCT00578916|Experimental|1|
9889158|NCT00578981|Experimental|Arm 1|
9889159|NCT00578981|No Intervention|Arm 2|
9889160|NCT00578994||Oxford® Meniscal Unicompartmental Knee|Patients with PKA using the Oxford® Meniscal Unicompartmental Knee System
9889161|NCT00579007||1|Women with a strong family history of breast cancer.
9889162|NCT00579033|Sham Comparator|1|
9889163|NCT00579033|Active Comparator|2|
9889164|NCT00579046|Experimental|1|
9889165|NCT00579085|Placebo Comparator|1|
9889166|NCT00579085|Experimental|2|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline with or without ketamine for four hours (25 ml/hr) daily for 10 days. The maximum intravenous ketamine infusion dose for this study will be 0.35 mg/kg/hr, not to exceed 25 mg/hr (100 mg of ketamine over a 4 hour period). On the first day, the intravenous ketamine infusion will be set to 50% of the maximum rate. On the second day, the intravenous ketamine infusion will be increased to 75% of the maximum rate. On the third day, the intravenous ketamine infusion will be increased to the maximum rate. The daily ketamine infusion rate is maintained at this level for the duration of the ten day study."
9889167|NCT00579150||Exenatide|Exposure to any form of exenatide during pregnancy for treatment of type 2 diabetes. Patients also taking Insulin may be included, though only as part of a combination treatment.
9889168|NCT00579150||Non-exenatide group|Exposure to non-insulin antidiabetic medication not including exenatide for treatment of pre-existing type 2 diabetes during pregnancy. Patients also taking Insulin may be included, though only as part of a combination treatment.
9889169|NCT00579215|Experimental|1|Enhance Care (EC) will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits.
9889170|NCT00579215|Other|2|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
9889171|NCT00579228||1|Normal controls both men and women
9889172|NCT00579228||2|Individuals with type 2 Diabetes with good control
9889173|NCT00579228||3|Individuals with type 1 diabetes with good control
9889174|NCT00579241|Experimental|1|Transcranial imaging using Doppler ultrasound
9889175|NCT00579306||SPS3 patient cohort|All SPS3 patients who participate in Baseline and 1-Year F/U blood draw
9889176|NCT00579332|Placebo Comparator|1|one a day placebo
9889177|NCT00579332|Experimental|2|Brassica intake
9889178|NCT00579332|Experimental|3|indole-3-carbinol supplement
9889179|NCT00579371|Experimental|1|
9889180|NCT00579397||1|"For Objective #1:~Healthy adult volunteers"
9889181|NCT00579397||2|"For Objectives #2 & #3:~Recipients undergoing an allogeneic stem cell transplant"
9889182|NCT00579410||A|Patients with Barrett's Esophagus
9889183|NCT00579410||B|Patients with reflux symptoms but no Barrett's Esophagus
9889184|NCT00579410||C|Patients without reflux symptoms and a normal endoscopy
9889185|NCT00579423|Experimental|vaccine|Patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administrated at the standard dose of 100ug.
9889186|NCT00579449|Active Comparator|HF 36|For those randomly assigned to the 3-year HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, when possible, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. The 3-year HFD group will receive services to the child's third birthday.
9932003|NCT00944502|Active Comparator|Dexamethasone|"Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablet:~1 tablet orally every 8 hours for 10 days."
9932004|NCT00944515|Active Comparator|azithromycin|azithrimycin 3 days/week
9932005|NCT00944515|Placebo Comparator|placebo|placebo 3 days/week
9932006|NCT00944580|Experimental|Vaccine Intervention|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
9889187|NCT00579449|Active Comparator|HF 18|For those randomly assigned to the 18-month HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. Services for this group are terminated when the child is 18 months old, with clinically necessary referrals made for ongoing psychosocial and health needs.
9889188|NCT00579449|Active Comparator|YC|For those assigned to the Yearly Checkup group, a clinically-trained member of the HFD team will make yearly home visits to conduct the evaluation assessment. Information about community services and assistance with referrals are provided based on needs identified.
9889189|NCT00579449|No Intervention|MCC|Women placed in the community services as usual (Maternity Care Coordination only) group will receive no additional services or assessments as a part of this study.
9889190|NCT00579462||1|Patients with advanced lung cancer.
9889191|NCT00579475|Placebo Comparator|Placebo|
9889192|NCT00579475|Active Comparator|I|Mifepristone (Mifegyne) 50 mg every other day for 3 months
9889193|NCT00579540|Active Comparator|1|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
9889194|NCT00579540|Active Comparator|2|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
9889195|NCT00579540|Active Comparator|3|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
9889196|NCT00579592|Experimental|1|Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine
9889197|NCT00579605|Experimental|1|1 intervention group 1 attention intervention group Behavioral: Motivational Interviewing Client-centered strategy that may decrease ambivalence in behavior performance
9889198|NCT00579631||1|Questionnaire or Interview
9889199|NCT00579644|Active Comparator|1 Methotrexate* & minocycline|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
9889200|NCT00579644|Active Comparator|2|"Methotrexate Dosing:~Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month~12 month evaluation: End of the blinded portion of the study."
9889201|NCT00579657|Placebo Comparator|1|"Intervention: 'control diet, supported by dietary supplement twice daily'~control diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement daily)]"
9889202|NCT00579657|Experimental|2|"Intervention: 'high cereal fiber diet, supported by dietary supplement twice daily'.~high cereal fiber diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber > 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber daily)]"
9889203|NCT00579657|Experimental|3|"Intervention: 'high protein diet, supported by dietary supplement twice daily'~high protein diet [carbohydrates 40 - 45% , protein > 25 - 30%; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 25 g whey and plant protein daily)]"
9889204|NCT00579657|Experimental|4|"Intervention: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily.~high cereal fiber/high protein (MIX) moderately high cereal fiber/high protein diet (carbohydrates 45- 50)% , protein 20 - 25%; fat ca. 30% of energy content; dietary fiber 15 - 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber and 2 x 25 g whey and plant protein daily)"
9889205|NCT00579683||1|This is a protocol to study tissue specimens to identify changes in tumor DNA in NSCLC patients who have previously responded to therapy and who have subsequently experienced disease progression.
9889206|NCT00579748||1|
9889207|NCT00579774|Experimental|1 - Low AGE Diet|Low Age Diet
9889208|NCT00579774|Active Comparator|2 - Regular Diet|Regular Diet
9889209|NCT00579787||1|Women with early stage cervical cancer undergoing radical trachelectomy
9889210|NCT00579787||2|Women with early stage cervical cancer undergoing radical hysterectomy
9889211|NCT00579800|Experimental|women undergoing routine breast MRI|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
9889212|NCT00579839|Experimental|A|Delayed Cord Clamping
9889213|NCT00579839|Active Comparator|B|Immediate cord clamping
9889214|NCT00579852||1|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day.
9889215|NCT00579865||Group A|Patients scheduled for percutaneous drainage
9889216|NCT00579865||Group B|Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
9889217|NCT00579904|Active Comparator|walnuts|Patients will be randomized to receive walnuts
9889218|NCT00579904|Active Comparator|almonds|Patients will be randomized to receive almonds
9889219|NCT00579917||1 Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT) involves one-on-one counseling
9889220|NCT00579917||2 Usual Care|Usual Care
9889221|NCT00579943||premature infants|Inpatient very low birth weight infants who are ventilated and have an umbilical arterial catheter in place
9889222|NCT00579956|Experimental|Meropenem|Meropenem
9889223|NCT00579956|Active Comparator|Ceftazidime|Ceftazidime
9889224|NCT00579969|Experimental|1|prostaglandin analogue
9889225|NCT00579969|Experimental|2|prostaglandin analogue
9889226|NCT00579995|No Intervention|1, oral N-Acetylcysteine|
9889227|NCT00579995|No Intervention|2, Intravenous Sodium Bicarbonate|
9889228|NCT00580021||1|Patients with breast and pancreas cancer.
9889229|NCT00580086||1|
9889230|NCT00580099|Experimental|1|4 weeks of assisted exercise using passive range of motion on all major joints
9889231|NCT00580099|Active Comparator|2|cuddle for 20 minutes
9889232|NCT00580112|Experimental|Group A|Participants with triple negative phenotype: estrogen receptor, progesterone receptor and human estrogen receptor-2 (HER-2) negative status for breast cancer (abnormal tissue that grows and spreads in the body until it kills) will receive trabectedin 1.3 milligram per meter square (mg/m^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hours (hrs) every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72hrs after the start of study drug infusion from Day 1 to 3.
9889233|NCT00580112|Experimental|Group B|Participants with overexpressing HER-2 breast cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
9889234|NCT00580112|Experimental|Group C|Participants with familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carriers cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 mg orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
9889235|NCT00580164||1|Splint
9889236|NCT00580164||2|No Splint
9889237|NCT00580177|Active Comparator|L|The Lichtenstein procedure for repair of inguinal hernia (Single On-lay patch)
9889238|NCT00580177|Active Comparator|P|The well-konown PerFixPlug technique for inguinal hernia repair.
9889239|NCT00580177|Active Comparator|PHS|The well-known Prolene Hernia System method for inguinal hernia repair.
9889240|NCT00580190|Active Comparator|1|
9889241|NCT00580190|Placebo Comparator|2|
9889242|NCT00580190|Experimental|3|
9889243|NCT00580242|Experimental|1|This is a Phase I dose escalation trial with three cohorts of 3-6 patients each plus 10 additional patients (up to a maximum total of 28 patients) treated at the candidate maximum tolerated dose.Cohorts will receive increasing doses of bortezomib at 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 in combination with lenalidomide at 10 mg a day for Days 1-21. Each cycle will be 28 days. Patients will receive up to 9 cycles of treatment, with efficacy assessed after 3, 6, and 9 cycles.
9889244|NCT00580268||H|Pregnant women with bipolar disorder
9889245|NCT00580281|Experimental|blood, urine, and dexa scan|This study will involve venipuncture for obtaining blood samples; a spot second void (whenever possible) urine sample will be obtained at the same time. A Dexa scan to evaluate bone density will be obtained at the beginning, middle and end of the study.
9889246|NCT00580307|Placebo Comparator|Septoplasty|Septoplasty only
9889247|NCT00580307|Experimental|Septoplasty and correction|Septoplasty and endoscopic contact point correction
9889248|NCT00580320|Experimental|A|dacarbazine + bortezomib
9889249|NCT00580346|Experimental|2|
9889250|NCT00580359|Active Comparator|A|S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
9889251|NCT00580359|Active Comparator|B|Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
9889252|NCT00580385|Experimental|1|
9889253|NCT00580411||Alcohol Problem First|Alcohol Problem precedes Insomnia
9889254|NCT00580411||Insomnia First|Insomnia Precedes Alcohol Problem
9889255|NCT00580437|Experimental|Arm 1|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
9889256|NCT00580450|No Intervention|2|
9889257|NCT00580450|Experimental|1|
9889258|NCT00580476||1|150 patients will be women with breast cancer (75 early stage and 75 late stage)
9889259|NCT00580476||2|150 will be men with prostate cancer (75 early stage and 75 late stage)
9889260|NCT00580489|Active Comparator|C|either fentanyl or morphine
9889261|NCT00580489|Active Comparator|D|either fentanyl or morphine
9889262|NCT00580528|Experimental|1|
9889263|NCT00580528|Experimental|2|
9889264|NCT00580528|No Intervention|3|
9889265|NCT00580567||1|Pathological Gamblers
9889266|NCT00580567||2|Non-Pathological Gamblers
9889267|NCT00580580|Active Comparator|1|"Administration of Optison (0.1-0.4 mL) intravenously followed by Contrast Pulse Sequencing to image both the coronary and carotid arteries.~Use will depend on availability of the contrast for the given study Optison will not be used on patients with blood allergies or Jehovah Witnesses"
9889268|NCT00580580|Active Comparator|2|Intravenous injection of Definity (0.05-0.20 mL) followed by Contrast Pulse Sequencing to image both coronary and carotid arteries
9889269|NCT00580580|Active Comparator|3|intravenous Injection of PESDA at a rate of 0.05-0.20 mL followed by image of coronary and carotid arteries PESDA will be used exclusively in patients who are eligible for other IRB studies
9889270|NCT00580593|Active Comparator|1|
9889271|NCT00580593|Sham Comparator|2|
9889272|NCT00580619|Experimental|1 (markers of sympathetic activity)|To evaluate if the various indices of sympathetic activity (Autonomic Function Testing) differ between patients with chronic fatigue syndrome and postural tachycardia syndrome (CFS-P), and CFS without POTS.
9889273|NCT00580619|Experimental|2 (saline)|To test the null hypothesis that there is no difference between two saline therapies (pulse saline vs. sham saline) in improving both the fatigue score and postural tachycardia syndrome.Saline infusions
9889274|NCT00580619|Experimental|3 (NO inhibition/ autonomic blockade)|Response to nitric oxide inhibition in the presence and absence of an intact autonomic nervous system will be evaluated. L-NMMA trimethaphan will be used for NO inhibition and autonomic blockade, respectively.
9889275|NCT00580619|Active Comparator|4 (methyldopa)|The effects of chronic autonomic withdrawal on improving symptoms of chronic fatigue and postural tachycardia syndrome will be evaluated
9889276|NCT00580684|Active Comparator|G1|G1: prevenar
9889277|NCT00580684|Active Comparator|G2|G2: pneumo 23
9889278|NCT00580736|Experimental|Optical Clearing|Optical Clearing
9889279|NCT00580749|Active Comparator|DJ|Naso disal jejunal(DJ) feedings randomized to 50% of subjects meeting criteria.
9889280|NCT00580749|Active Comparator|NG|Placement of naso gastric feeding tube through nare into stomach for enteral feeding.
9889281|NCT00580762|Experimental|ESRD|End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
9889282|NCT00580762|Active Comparator|Non-ESRD|Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
9889283|NCT00580775||Placebo|Observing heart rate variability in placebo and active estrogen preparations
9889284|NCT00580775||Active estogen|Observing heart rate variability in placebo and active estrogen preparations
9889285|NCT00580827|Placebo Comparator|placebo disulfiram|placebo disulfiram (0 mg/day)
9889286|NCT00580827|Experimental|disulfiram 62.5|disulfiram at 62.5 mg/day
9889287|NCT00580827|Experimental|disulfiram 125|disulfiram at 125 mg/day
9889288|NCT00580827|Experimental|disulfiram 250|disulfiram at 250 mg/day
9889289|NCT00580892||Airway and Pleural Disorders|Optical Coherence Tomography imaging
9889290|NCT00580905|Active Comparator|1|To compare the effects of adenosine at a dose of 80 mcg/kg/min for 30 minutes, Sodium nitroprusside will be used at a dose that produce similar systemic effects (5 mcg/kg/.min)
9889291|NCT00580905|Active Comparator|2|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
9889292|NCT00580918||1|Mild Traumatic Brain Injury group
9889293|NCT00580918||2|Normal healthy control group
9889294|NCT00580931|Experimental|1|Subjects will receive experimental drug in a blinded fashion.
9889295|NCT00580931|Placebo Comparator|2|Identical in size, shape and color to experimental drug.
9889296|NCT00580944|Experimental|Port Wien Stain Birthmark|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
9889297|NCT00580996|Experimental|1|16 oz water in AM
9889298|NCT00580996|Active Comparator|2|water 1 oz in AM
9889299|NCT00581009|Experimental|1|chronobiological augmentation group
9889300|NCT00581009|Experimental|2|medication only group
9889301|NCT00581009|Experimental|MDD Mechanism|
9889302|NCT00581022||1|Patients with Chronic Orthostatic Intolerance
9889303|NCT00581035|Experimental|1|Prevenar and Meningitec
9889304|NCT00581035|Experimental|2|Prevenar
9889305|NCT00581035|Experimental|3|Meningitec
9889306|NCT00581074|Active Comparator|G|grapefruit
9889307|NCT00581074|Active Comparator|J|Juice
9889308|NCT00581074|Placebo Comparator|W|placebo
9889309|NCT00581087|Experimental|1|DHEA
9889310|NCT00581087|Placebo Comparator|2|Placebo
9889311|NCT00581126|Experimental|1|Patients will receive Benefix IV according to blood amount
9889312|NCT00581139|Active Comparator|1|
9889313|NCT00581139|Active Comparator|2|
9889314|NCT00581139|Active Comparator|3|
9889315|NCT00581139|Active Comparator|4|
9889316|NCT00581191|Experimental|1|0.5 mg SLV-351 (fasted)
9889317|NCT00581191|Experimental|2|1 mg SLV-351 (fasted)
9889318|NCT00581191|Experimental|3|2.5 mg SLV-351 (fasted)
9889319|NCT00581191|Experimental|4|5 mg SLV-351 (fasted)
9889320|NCT00581191|Experimental|5|10 mg SLV-351 (fasted)
9889321|NCT00581191|Experimental|6|15 mg SLV-351 (fasted)
9889322|NCT00581191|Experimental|7|20 mg SLV-351 (fasted)
9889323|NCT00581191|Experimental|8|30 mg SLV-351 (fasted)
9889324|NCT00581191|Experimental|9|xx mg SLV-351 (fasted and fed)
9889325|NCT00581204||Diagnostic Tool|Near-Infrared Diffuse Optical Spectroscopy Imaging
9889326|NCT00581217||Single arm study|Burn patients or patients with skin loss requiring split-thickness skin graft
9889327|NCT00581243|Experimental|1|2 mg SLV-313 SR (fixed dose)
9889328|NCT00581243|Experimental|2|5 mg SLV-313 SR (fixed dose)
9889329|NCT00581243|Experimental|3|10 mg SLV-313 SR (fixed dose)
9889330|NCT00581243|Experimental|4|xx mg SLV-313 SR (titration)
9889331|NCT00581269|Active Comparator|1|low-impact aerobic exercise group
9889332|NCT00581269|Active Comparator|2|dietary restriction group
9889333|NCT00581269|No Intervention|3|control group
9889334|NCT00581282||1|Cocaine abstinent group
9889335|NCT00581282||2|Normal healthy control group
9889336|NCT00581295||trauma|Diffuse optical spectroscopy measurment
9889337|NCT00581321|Experimental|1|water ingestion
9889338|NCT00581373|Experimental|1|water 16 oz
9889339|NCT00581425|Experimental|Treated|
9889340|NCT00581438||1|
9889341|NCT00581451|Experimental|A|bifeprunox 25 day
9889342|NCT00581451|Experimental|B|bifeprunox 14 day
9889343|NCT00581451|Experimental|C|bifeprunox 14 day
9889344|NCT00581451|Experimental|D|bifeprunox 9 day
9889345|NCT00581464|Active Comparator|1|
9889346|NCT00581464|Active Comparator|2|
9889347|NCT00581490||Idiopathic premature pubarche|Children with premature pubarche without precious puberty, adrenal hyperplasia or androgen secreting tumors
9889348|NCT00581503||diagnostic|oct imaging
9889349|NCT00581568|Experimental|Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
9889350|NCT00581594|Other|1|Posterior repair with graft augmentation.
9889351|NCT00581594|Other|2|Posterior repair without graft augmentation.
9889352|NCT00581607|Active Comparator|Bosentan for 16 weeks|Active drug
9889353|NCT00581607|Placebo Comparator|Placebo|Placebo for 16 weeks
9889354|NCT00581620|Active Comparator|G1|G1: HIV+
9889355|NCT00581620|Active Comparator|G2|G2: Sicle Cell disease
9889356|NCT00581620|Active Comparator|G3|G3: neprotic symdrome
9889357|NCT00581620|Active Comparator|G4|G4: Chronic pulmonary disease
9889358|NCT00581633|Experimental|1|saline infusion for sodium loading
9889359|NCT00581646||1|gynecologic cancer survivors
9889360|NCT00581646||2|survivors of any type of malignancy with history of BMT/SCT
9889361|NCT00581646||3|non-cancer infertile women awaiting third party reproduction
9889362|NCT00581659||Lens A, Lens B|The first independent variable is the contact lens. Each subject will wear both PureVision (TM0 aspheric contact lenses and conventional spherical contact lenses on separate visits. The second independent variable is visibility condition. Subjects will complete the study drive both in clear nighttime conditions and at night under glare conditions. In both cases, the driver will experience oncoming traffic; however, in the glare condition, the simulator will be equipped with a point light source sufficient to provide glare similar to that provided by oncoming traffic in the real world.
9889363|NCT00581685|Placebo Comparator|2|Prospective, single center, randomized, double-blinded, placebo controlled study
9889364|NCT00581698||Surgical|Patients with primary melanomas Clark III and Breslow thickness > 1 mm, or Clark IV-V and any Breslow thickness, and clinically negative regional nodes
9889365|NCT00581711|No Intervention|Control|Usual Care
9889366|NCT00581711|Experimental|HIT Intervention without feedback|3-Part Intervention: Training, Otitis Media Episode Grouper, Clinical Decision Support
9889367|NCT00581711|Experimental|HIT Intervention with feedback|4-Part Intervention: Training, Episode Grouper, Clinical Decision Support, and Physician Feedback.
9889368|NCT00581711|Experimental|Feedback only|1 part intervention: Physician Feedback
9889369|NCT00581724||1|"First 50 breast cancer survivors and then after demonstrating feasibility of the study design in the first 50 participants, recruitment will be opened to the other services Colorectal, Genitourinary, Head and Neck, and Thoracic.~Participants will be recruited in allotments of 50 patients from each service."
9889370|NCT00581750||LCIS diagnosis|Patient with LCIS diagnosis
9889371|NCT00581763||Observation|Those with a condition
9889372|NCT00581789|Experimental|1|Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
9889373|NCT00581802||1|Intensively studied participants initiating potentially suppressive drug therapy. Group 1 participants may undergo optional leukapheresis. Group 1 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 1 participants will default to either Group 3 or Group 4.
9889374|NCT00581802||2|Intensively studied, well-suppressed participants on HAART. Participants in Group 2 may undergo optional leukapheresis. Group 2 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 2 participants will default to either Group 3 or Group 4.
9889375|NCT00581802||3|Nonintensively studied participants initiating potentially suppressive drug therapy
9889376|NCT00581802||4|Nonintensively studied well-suppressed participants on HAART
9932007|NCT00944593|Experimental|300kcal liquid Nutrient|300kcal liquid nutrient delivered by NJ tube over 60 minutes before ingestion of a standard oral liquid nutrient test meal
9932008|NCT00944593|Placebo Comparator|Normal Saline|Normal Saline delivered via NJ tube over 60 minutes ahead of a standard liquid nutrient test meal
9990506|NCT01443871|Placebo Comparator|Pure water|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the water for 10 minutes as during inhalation. The last part, the water was dispersed and assessed EEG activity for 10 minutes as after inhalation.
9990507|NCT01443884|Experimental|Group 1|After a 1 week baseline, volunteers will consume two packets of grape powder stirred into water for three weeks. Each packet will contain the equivalent of approximately 2 servings of fresh grapes (46 grams of powder). Following a two week washout period, volunteers will cross-over to a placebo powder.
9990508|NCT01443884|Experimental|Group 2|After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
10211993|NCT03259074|Experimental|Secukinumab 150 mg s.c.|Secukinumab 150 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
10211994|NCT03259074|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
9990509|NCT01443897|Placebo Comparator|Group 1|Untreated mushrooms plus placebo capsule.
9990510|NCT01443897|Experimental|Group 2|UVB-treated mushrooms (400 IU vitamin D2 per serving) plus placebo capsule.
9990511|NCT01443897|Experimental|Group 3|UVB-treated mushrooms (1,000 IU vitamin D2 per serving) plus placebo capsule.
9990512|NCT01443897|Experimental|Group 4|Untreated mushrooms plus 1,000 IU Vitamin D2 in capsule
9990513|NCT01443962|Experimental|Zero positive end expiratory pressure|Number: 30, apply no PEEP during the pneumoperitoneum during the laparoscopic cholecystectomy PEEP was not applied whole investigation period
9990514|NCT01443962|Active Comparator|positive end expiratory pressure|applying PEEP 10 cmH2O during pneumoperitoneum continuously
9990515|NCT01443975||All patients|Measurement with x-pander in acetabulum prior to inserting the artificial hip socket.
9990516|NCT01443988|Active Comparator|iStent|Implantation of two iStent devices
9990517|NCT01443988|Active Comparator|Drug|Travoprost drops
9990518|NCT01444001|Experimental|Pneumococcal Vaccine Dose 1 (Low dose)|Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.
9990519|NCT01444001|Experimental|Pneumococcal Vaccine Dose 2 (Middle dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.
9990520|NCT01444001|Experimental|Pneumococcal Vaccine Dose 3 (High dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.
9990521|NCT01444014|Experimental|YF476|
9990522|NCT01444040|Active Comparator|iStent inject|Implantation of two iStent inject devices
9990523|NCT01444040|Active Comparator|Drug|Travoprost drops
9990524|NCT01444053||Wearers of contact lenses without UV Protection|Subjects who have worn a soft contact lens without UV protection for the past five years or more.
9990525|NCT01444053||Wearers of contact lenses with UV Protection|Subjects who have worn a soft contact lens with UV protection for the last 5 years or more.
9990526|NCT01444066|Placebo Comparator|dilation to 27 French|
9990527|NCT01444066|Experimental|Dilation of the esophagus to 54 French|Esophagus will be dilated with a Savory dilator
9990528|NCT01444079||Liver transplant recipients|Recipients who will undergo liver transplantation during study period
9990529|NCT01444105|Active Comparator|iStent|implantation of two iStent devices
9990530|NCT01444105|Active Comparator|SLT|Laser treatment
9990531|NCT01444118|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
9990532|NCT01444118|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
9990533|NCT01444131|Placebo Comparator|Varenicline and Placebo Patch|Varenicline and Nicotine Patch (placebo)
10211995|NCT03259074|Experimental|GP2017 (adalimumab biosimilar) 40mg s.c.|GP2017 (adalimumab biosimilar) 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 102
10211996|NCT03243071|Experimental|Intervention Group|The intervention group will have access to culturally tailored website.
10211997|NCT03243071|Active Comparator|Control Group|Participants in the control group will have access to NYU 's standard trial participation website.
9990534|NCT01444131|Active Comparator|Varenicline and Nicotine Patch|Varenicline and Nicotine Patch 15mg
9990535|NCT01444144||Ankle Fracture|Patients aged 55 years at time of surgery undergoing treatment for ankle fractures.
9990536|NCT01444157|Experimental|Palliative homecare nursing group|In addition to the standard homecare nursing the families will receive six home visits from a research nurse with at least 1 year specialised palliative care experience. During the first 2 hour visit a family assessment is obtained containing identification of family roles, resources and coping strategies. The first home visit takes place no later than one week after randomization. The visits continues every third week up to 16 weeks, each visit with a duration of 1,5 hours. At every visit the EORTC-QLQ-C30 patient administered questionnaire is used to identify the nature, frequency and intensity of the patients physical and psychosocial problems.
9997434|NCT01508845|Active Comparator|High MUFA/PUFA, 1600 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
10211998|NCT03236857|Experimental|Venetoclax with or without chemotherapy|Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
10211999|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
9889377|NCT00581802||5|Intensively studied participants who are currently participating in the Merck Expanded Access Program and receiving raltegravir. Participants in Group 5 may undergo optional leukapheresis. Group 5 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 5 participants will default to either Group 3 or Group 4.
9889378|NCT00581815|Experimental|1|
9889379|NCT00581841||1|Healthy adult participants with no history of knee injury or osteoarthritis.
9889380|NCT00581880||1|Terminally Ill patients
9889381|NCT00581932||A|One group, all subjects with DSM-IV diagnosis of Schizophrenia, age 18-65 who are initiating clozapine therapy.
9889382|NCT00581958||Patients undergoing HSCT|Research subjects will have blood and/or urine sampled at three time points in the Department of Radiation Oncology. Participating patients will have at least a total two samples collected at each time point. The first sampling will occur before the first TBI treatment is given. The second sampling will occur before the second TBI treatment, usually 3 to 8 hours after the first treatment (in the case of multifraction TBI). If a patient is being treated with single fraction TBI, then the second sampling will occur approximately 3-8 hours after the first TBI treatment. The third and final sampling will occur at the next morning blood draw, prior to the fourth TBI treatment (in the case of multifraction TBI), 24 hours after the first TBI treatment.
9889383|NCT00582049||1|Cases: retinoblastoma patients
9889384|NCT00582049||2|Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).
9889385|NCT00582062||1|Positive controls will include patients who have positive cytology or positive biopsy of peritoneal metastases. Cell lines which over-express these tumor markers will also be used as positive controls. Sensitivity will be defined using serial dilutions of several established gastric and pancreatic tumor cell lines. The mRNA of the tumor markers will be normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA expression.
9889386|NCT00582062||2|Patients who are scheduled to undergo laparoscopy for benign disease (e.g., laparoscopic cholecystectomy, hernia repair, or prophylactic BSO) will be recruited as negative controls. A leukemia cell line which does not express epithelial cell markers will also be used as a negative control for the RT-PCR reactions.
9889387|NCT00582088|Experimental|Vaccine|VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205
9889388|NCT00582101|Experimental|Family-based HIV|
9889389|NCT00582101|Active Comparator|Family-based HP|
9889390|NCT00582127||1|Mild-moderate Alzheimer's Disease
9889391|NCT00582127||2|Age-matched Controls
9889392|NCT00582140|Experimental|Cohort Level 1|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
9889393|NCT00582140|Experimental|Cohort Level 2|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
9889394|NCT00582140|Experimental|Cohort Level 3|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
9889395|NCT00582179|Active Comparator|1, A|Group A patients will be treated with a pressure dressing and observation.
9889396|NCT00582179|Active Comparator|2, B|Group B patients will be treated with a Vacuum Assisted Closure device (VAC).
9889397|NCT00582192||1|Participants with certain types of cancers that are eligible for studies at Memorial Sloan-Kettering Cancer Center.
9932009|NCT00944606|Active Comparator|Vitamin D|
9932010|NCT00944606|Placebo Comparator|Placebo|
9932011|NCT00944619|Experimental|Closed loop (algorithm)|Subcutaneous delivery of Novorapid insulin, dose calculated by computer-driven control algorithm, based on continuous glucose sensor readings
9932012|NCT00944619|Placebo Comparator|Open loop|Subcutaneous delivery of Novorapid insulin according to usual pump regime
9932013|NCT00944632|Active Comparator|Zk 245186 0.01% ointment|Active treatment, lowest dose
9932014|NCT00944632|Active Comparator|ZK 245186 0.03% ointment|Active comparator middle dose
9932015|NCT00944632|Active Comparator|ZK 245186 0.1% ointment|Active comparator highest dose
9932016|NCT00944632|Placebo Comparator|Vehicle ointment|Placebo comparator
9889398|NCT00582244|Experimental|1|CBT and relaxation.
9889399|NCT00582244|Experimental|2|Physical activity
9889400|NCT00582244|Experimental|3|CBT and physical activity
9889401|NCT00582244|No Intervention|4|Control group
9889402|NCT00582270||1|Follicular Lymphoma
9889403|NCT00582270||2|Non-follicular Lymphoma
9889404|NCT00582283|Other|Diagnostic: iodine I-124 NM404 CT/PET scan|Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
9889405|NCT00582374||A|Pregnant Women
9889406|NCT00582387||nonmuscle invasive bladder cancer|This is a hospital-based cohort study in which subjects with non-muscle invasive bladder cancer diagnosed within the previous 12 months will be evaluated to determine whether candidate genetic variants in patients with superficial bladder cancer can predict the risk of disease recurrence and/or progression, with the goal of modifying surveillance schedules as a function of predicted risk of recurrence or progression. All patients will be treated according to the treatment plan as outlined by their attending physician. The study will not require any deviation from the planned usual treatment.
9889407|NCT00582413||1|Patients who have been diagnosed with Carcinoma of the oral cavity
9889408|NCT00582439|Other|1|Repair of Orthopaedic Trauma Fractures and Non-Unions
9889409|NCT00582452||2|Affected patients who are at high risk for metachronous colorectal tumors due to mutation status.
9889410|NCT00582452||1|Unaffected patients who are at high risk for developing colon cancer based on family history and/or mutation status.
9889411|NCT00582465||Observation|Lupus
9889412|NCT00582478||1|women with breast cancer
9889413|NCT00582504|Experimental|Vaccination|VEE TC-83
9889414|NCT00582530||1 men with prostate cancer|Patients who have opted for radical prostatectomy as treatment for prostate cancer.
9889415|NCT00582543|Experimental|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position.
9889416|NCT00582582|Experimental|A|Docetaxel plus doxercalciferol
9889417|NCT00582582|Placebo Comparator|B|Docetaxel plus placebo
9889418|NCT00582634|Experimental|Docetaxel followed by cisplatin|Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
9889419|NCT00582673|Experimental|1|
9889420|NCT00582673|Placebo Comparator|2|
9889421|NCT00582686|Active Comparator|ORIF with Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group A will be made up of patients that undergo ORIF and Tricortical iliac crest bone grafting.
9889422|NCT00582686|Active Comparator|ORIF without Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group B will consist of patients that undergo open reduction with internal fixation without bone grafting
9889423|NCT00582699||1|Patients with pancreatic cancer who meet DSMIV criteria for a current diagnosis of a Major Depressive Episode (N=25).
9889424|NCT00582699||2|Patients with pancreatic cancer who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25)
9889425|NCT00582699||3|Healthy controls who meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
9889426|NCT00582699||4|Healthy controls who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
9889427|NCT00582725|Experimental|R-CHOP + GM-CSF|R-CHOP therapy (6-8 cycles) with GM-CSF
9889428|NCT00582764||1|Any patient undergoing MRI guided preoperative needle localization or MRI guided biopsy of the breast.
9889429|NCT00582777|Active Comparator|USUAL|USUAL treatment - The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
9889430|NCT00582777|Experimental|HS Dosing|"HS DOSING - In this period, the patient's antihypertensive regimen at the baseline visit will be standardized for the once/day medications to be given at bedtime.~For those on monotherapy with a once/day antihypertensive regimen, the time of administration will be changed to bed time.~For those on multi-drug therapy, the time of administration of all once a day antihypertensive drugs will be changed to bed time."
9889431|NCT00582777|Experimental|ADD-ON DOSING|ADD-ON DOSING - This regimen will start with the USUAL regimen to which an additional agent will be added at bed time. An additional dose of ramipril, diltiazem, or hydralazine are three possible options for the add on medication. The intent of the ADD ON therapy is to lower nocturnal BP with minimal impact on daytime BP. Thus, agents with < 24 hr duration of action are preferred. The specific choice and dose of add-on therapy (of the three agents) will be up to the site investigator considering the clinical situation of each participant based on the guidelines below.
9889432|NCT00582829||1|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
9889433|NCT00582829||2|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
9932017|NCT00944684|Experimental|A|PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
9889434|NCT00582829||3|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
9889435|NCT00582855|Experimental|1|
9889436|NCT00582855|Placebo Comparator|2|
9889437|NCT00582868||Hemorrhage|Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy
9889438|NCT00582959|Other|1|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
9889439|NCT00583024|Experimental|Arm A|
9889440|NCT00583037|Experimental|NAVA|Implementation of NAVA for 24 hours
9889441|NCT00583063|Experimental|A|Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
9889442|NCT00583063|Experimental|B|Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
9889443|NCT00583089||1|Algorithm Test Set
9889444|NCT00583089||2|Algorithm Development Set
9889445|NCT00583167||A1|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count >200 cells/mm3. Group A1 will undergo continuous CSF ( cerebrospinal fluid) sampling via intrathecal catheter.
9889446|NCT00583167||A2|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count <200 cells/mm3. Group A2 will undergo continuous CSF sampling via intrathecal catheter.
9889447|NCT00583167||B|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. Group B will not undergo continuous CSF sampling, but will undergo sparse CSF sampling by lumbar punctures.
9889448|NCT00583180||A|Capsaicin treated patients
9889449|NCT00583180||P|Placebo treated patients
9889450|NCT00583193|Other|1|Open-label Study
9889451|NCT00583232|Active Comparator|Corticosteroid|Subjects receiving corticosteroid therapy (1-2 mg/kg/day up to 60mg/day) with taper.
9889452|NCT00583232|Active Comparator|infliximab|Subjects receiving infliximab therapy (5 mg/kg at 0, 2 and 6 weeks, followed by every 8 week therapy)
9889453|NCT00583245|Experimental|1|Gait training
9889454|NCT00583258|Experimental|A|
9889455|NCT00583258|Placebo Comparator|B|
9889456|NCT00583271||1|subjects who are getting a celiac block for chronic pancreatitis
9889457|NCT00583271||2|subjects who are getting a celiac block for pancreatic cancer
9889458|NCT00583297||ABCD Subjects|The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study
9889459|NCT00583310|No Intervention|Control|Subjects receive standard written educational information at baseline, but do not receive the telephone-based intervention. Subjects may participate in the intervention following completion of the study.
9889460|NCT00583310|Experimental|Intervention|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
9889461|NCT00583323|Experimental|1|Lomotil given
9889462|NCT00583323|Placebo Comparator|2|Normal Saline given
9889463|NCT00583336|Experimental|Diagnostic|
9889464|NCT00583349|Experimental|Abraxane administration|Patients will restrict their fluid intakes the morning of treatments and will have emptied their bladders at each of their visits and have up to 100ml of Abraxane solution administered to their bladder via urinary catheter once weekly for six weeks.
9889465|NCT00583388||A|42 healthy subjects aged 18 to 60 will be be randomly assigned to 6 different treatment sequences.
9889466|NCT00583427|Experimental|Sulodexide|
9889467|NCT00583440|Experimental|1|
9889468|NCT00583440|Active Comparator|2|
9889469|NCT00583479|Other|A|subjects who get one medication injection into the celiac ganglion during the EUS
9889470|NCT00583479|Other|B|subjects who get divided dose of the medication injected into two locations within the celiac ganglion during the EUS
9889471|NCT00583544|Placebo Comparator|1|
9889472|NCT00583544|Experimental|2|
9889473|NCT00583570|Experimental|A|
9889474|NCT00583635||1|Low Risk Pregnancy, Placebo
9889475|NCT00583635||2|Low Risk Pregnancy, Active Food Supplement
9889476|NCT00583635||3|High Risk Pregnancy, Placebo
9889477|NCT00583635||4|High Risk Pregnancy, Active Food Supplement
9889478|NCT00583648|Experimental|1|Recieves urinalysis by nurse per set protocol based off of inclusion criteria
9889479|NCT00583648|No Intervention|2|ordering of test will be up to the treating physician
9889480|NCT00583726|Active Comparator|1|The control arm receives written information and pedometers
9889481|NCT00583726|Experimental|2|This arm also receives telephone counseling.
9889482|NCT00583739|Active Comparator|1|Yoga intervention
9889483|NCT00583739|No Intervention|2|Control. No Yoga for 8 weeks.
9889484|NCT00583752|Experimental|Arm B|On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
9889485|NCT00583752|Experimental|Arm A|On Arm A, subjects can begin the three vaccinations immediately.
9889486|NCT00583765||A|Critically ill patients with acute renal failure requiring continuous renal replacement therapy
9889487|NCT00583778|Active Comparator|1|levalbuterol 1.25 mg every 20 minutes for 3 doses plus placebo (saline)
9889488|NCT00583778|Experimental|2|ipratropium 0.5 mg nebulized every 20 minutes for 3 doses added to levalbuterol 1.25 mg every 20 minutes for 3 doses
9889489|NCT00583843||Ultrasound|The group of women who are being followed by Ultrasound.
9889490|NCT00583869|Placebo Comparator|1|Patient to receive placebo beginning on the day of surgery until discharge.
9889491|NCT00583869|Experimental|2|Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.
9889492|NCT00583869|Experimental|3|Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.
9889493|NCT00583882|Other|1|Change every 6 days, rewire every 6 days
9889494|NCT00583882|Other|2|New site every 6 days
9889495|NCT00583882|Other|3|New site every 12 days
9889496|NCT00583895|Active Comparator|1|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
9889497|NCT00583895|Placebo Comparator|2|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
9889498|NCT00583934||A|Those six months post treatment for head and neck cancer.
9889499|NCT00583973||1|Chronic hemodialysis patients
9889500|NCT00583986|Experimental|1|Levalbuterol HFA MDI with top mounted actuation indicator
9889501|NCT00583999||A|bariatric surgery
9889502|NCT00584038|No Intervention|1 Standard Care (SC)|Participants receive usual contraceptive care administered by clinic provider.
9889503|NCT00584038|Other|2 Standard Care + Educational (SCE)|Participants receive standard contraceptive care from clinic provider, followed by 45-minute educational intervention.
9889504|NCT00584038|Other|3 Standard Care + Educational + Phone Calls (SCEP)|Participants receive standard contraceptive care from clinic provider, followed by phone calls weekly until onset of menses and monthly thereafter for six consecutive months.
9889505|NCT00584051||1|
9889506|NCT00584051||2|
9889507|NCT00584051||3|
9889508|NCT00584090|Experimental|1|
9889509|NCT00584090|Placebo Comparator|2|
9889510|NCT00584103|Experimental|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
9889511|NCT00584103|Other|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
9889512|NCT00584129|Experimental|1|Patients will receive pre-treatment swallowing exercises.
9889513|NCT00584129|Active Comparator|2|Post-treatment swallowing exercises.
9889514|NCT00584142|Experimental|1|
9889515|NCT00584142|No Intervention|2|
9889516|NCT00584155|Placebo Comparator|1|Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.
9889517|NCT00584155|Experimental|2|Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.
9889518|NCT00584168|Placebo Comparator|2|Patient will receive a placebo.
9889519|NCT00584168|Experimental|1|Patient will receive dexamethasone.
9889520|NCT00584181||Lung transplant recipients|Lung transplant recpients enrolled as study subjects will undergo pulmonary function tests (spirometry and lung volume measurements) and initial HRCT of chest. These subjects will receive nebulized ipratropium followed by pulmonary function tests (spirometry and lung volume measurements) and repeat HRCT.
9889521|NCT00584298|Experimental|1|
9889522|NCT00584298|Placebo Comparator|2|
9889523|NCT00584311|Experimental|1|All patients (with no structural damage on the plain x-ray) will receive a MRI and Ultrasound (US) of their most involved joint and an asymptomatic joint.
9889524|NCT00584324|Experimental|Bispectral Index (BIS) 40|Target BIS 40
9889525|NCT00584324|Experimental|Bispectral Index (BIS) 60|Target BIS 60
9889526|NCT00584337||1|
9889527|NCT00584337||2|
9889528|NCT00584350|Experimental|A: Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
9889529|NCT00584350|Active Comparator|B: Standard hydratation|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
9889530|NCT00584350|Experimental|C: Hydratation with sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
9932018|NCT00944684|Active Comparator|B|PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
9932019|NCT00944723|Experimental|Zinc-fortified bread (10 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month
9932020|NCT00944723|Experimental|Zinc fortified bread (20 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month.
9932021|NCT00944723|Experimental|Zinc supplemented group|Daily consumption of non-fortified bread and daily intake of zinc supplement (10 mg zinc/d)
9932022|NCT00944723|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified bread and a placebo supplement for 1 month.
9932023|NCT00944736|Active Comparator|VSL#3|
9932024|NCT00944736|Placebo Comparator|Placebo|
9932025|NCT00944762|Experimental|Ecosystem Focused Therapy (EFT)|Participants will receive EFT.
9932026|NCT00944762|Active Comparator|Education in stroke and depression|Participants will receive education in stroke and depression.
9932027|NCT00944775|Experimental|exercise training|10-month exercise training program
9932028|NCT00944775|No Intervention|controls|usual care sedentary lifestyle
9932029|NCT00944788|Experimental|qi-gong|
9932030|NCT00944788|No Intervention|Usual care|
9932031|NCT00944801|Experimental|Pegylated Liposomal Doxorubicin|Radiotherapy is planned with dedicated computed tomography and three-dimensional planning systems and delivered to the gross tumor volume with a 2 to 3 cm margin for the clinical target volume. After a 4-week break, patients receive adjuvant TMZ 150 to 200 mg/m2 day 1 to 5 in 28 days until tumor progression or up to at least 12 cycles. In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
9932032|NCT00944814|Experimental|LNS with zinc|LNS containing 10 mg zinc per 20 g dose of LNS
9932033|NCT00944814|Placebo Comparator|LNS without zinc|LNS containing no zinc
9932034|NCT00944827|Experimental|GTE|The experimental group will receive 20 mg atorvastatin (Lipitor) daily and 600 mg. of pure catechin in capsules
9932035|NCT00944827|Placebo Comparator|CON|The control group will receive 20 mg atorvastatin (Lipitor) and Placebo in identical capsules containing 600 mg placebo for 12 weeks
9932036|NCT00944840|Active Comparator|SP and amodiaquine|Study subjects received intermittent preventive treatment with SP plus amodiaquine.
9932037|NCT00944840|Placebo Comparator|SP placebo plus amodiaquine placebo|Intermittent preventive treatment with SP placebo and amodiaquine placebo
9932038|NCT00944853|Experimental|Zinc syrup|Liquid Zinc Syrup (ZnSO4) solution provided daily
9932039|NCT00944853|Experimental|Zinc tablet|Dispersible zinc tablets provided daily
9932040|NCT00944853|Placebo Comparator|Placebo|Liquid placebo supplement provided daily
9932041|NCT00944866||RA with drug|
9932042|NCT00944866||RA without drug|
9932043|NCT00944879||HPV vaccine|Those choosing to receive the HPV vaccine
9932044|NCT00944879||no HPV vaccine|Those choosing not to receive the HPV vaccine
9932045|NCT00944905|Experimental|MDX-1203|Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study
9932046|NCT00944918|Experimental|1|fulvestrant and anastrozole
9932047|NCT00944918|Experimental|2|fulvestrant and placebo
9932048|NCT00944918|Active Comparator|3|exemestane alone
9932049|NCT00944944||Gyn Pts with lymphedema|
9932050|NCT00944944||Gyn Pts without Lymphedema|
9889531|NCT00584376|Active Comparator|1|Pregabalin
9889532|NCT00584376|Placebo Comparator|2|Placebo
9889533|NCT00584389|Experimental|1|Rimonabant treatment (20mg/d) for 12 weeks
9889534|NCT00584389|Other|2|Dietary intervention
9889535|NCT00584428|Experimental|1|
9889536|NCT00584441||1|Women with pre-menstrual asthma (PMA): As defined by a 20% or more fall in PEFR and / or change by 20% or more of daily symptom score.
9889537|NCT00584441||2|Women without pre-menstrual asthma
9889538|NCT00584441||3|Women on oral contraceptives
9889539|NCT00584519||500 patients|Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
9889540|NCT00584532|Placebo Comparator|A|A=Placebo ARM of Study
9889541|NCT00584532|Active Comparator|B|B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.
9889542|NCT00584571|Active Comparator|Sensory Adaptation training|a large compliant balloon is placed in the rectum attached to a barostat. The balloon is distended in 1 mm increments until patient reports moderate discomfort and then increased in 1 mm increments until maximum tolerable pressure. Gradually over 6 training sessions, administered biweekly, the maximum tolerable pressure is increased over 3 months, if treatment is successful.
9889543|NCT00584571|Experimental|Escitalopram Therapy|Patients randomized to this arm will receive daily 10 mg escitalopram for 3 months. If the medication is effective their bowel symptoms and pain thersholds will improve.
9889544|NCT00584584|Experimental|1|
9889545|NCT00584584|Placebo Comparator|2|
9889546|NCT00584597|Placebo Comparator|1|Saline
9889547|NCT00584597|Experimental|2|Traumeel S 1 mL
9889548|NCT00584597|Experimental|3|Traumeel S 2 mL
9889549|NCT00584597|Experimental|4|Traumeel S 3 mL
9889550|NCT00584610|Experimental|1|Levonorgestrel-containing intrauterine device insertion
9889551|NCT00584610|Active Comparator|2|Copper containing intrauterine device
9889552|NCT00584636|Experimental|Pulmicort Respules|using pulmicort respules
9889553|NCT00584649|Other|Single Group Assignment|electrophysiology study and radiofrequency ablation
9889554|NCT00584662|Active Comparator|1|Oxymetazoline Hydrochloride
9889555|NCT00584753|Other|1|Normal volunteers
9889556|NCT00584753|Active Comparator|2|Breast PET/CT scan
9889557|NCT00584753|Active Comparator|3|Whole body and breast PET/CT
9889558|NCT00584766|Experimental|1|
9889559|NCT00584779|Experimental|1|
9889560|NCT00584779|Experimental|2|
9889561|NCT00584779|Experimental|3|
9889562|NCT00584779|Experimental|4|
9889563|NCT00584792||1|Controls (No prostate cancer)
9889564|NCT00584792||2|Cases (Prostate Cancer Diagnosed)
9889565|NCT00584883|Experimental|ABT 510|The only arm will receive the ABT 510 following standard therapy with radiation and temozolomide chemotherapy concurrent.
9889566|NCT00584961||600 patients|Patients with diagnosis of Bipolar Disorder (DSM-IV TR)
9889567|NCT00585000|Experimental|1|
9889568|NCT00585065||1|
9889569|NCT00585091|Other|A|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
9889570|NCT00585117|Experimental|1 CNS|imaging with CuATSM
9889571|NCT00585117|Experimental|2. Head and Neck|Imaging with CuATSM
9889572|NCT00585117|Experimental|3. Lung|imaging with CuATSM
9889573|NCT00585117|Experimental|4. Prostate|PET imaging with CuATSM
9889574|NCT00585117|Experimental|5. Esophagus|PET imaging with CuATSM
9889575|NCT00585143|Experimental|1|
9889576|NCT00585156|Experimental|Arm #1|Celebrex treatment group
9889577|NCT00585208|Active Comparator|Active drug|Ramelteon - this group receives active drug at a fixed dose of 8mg daily throughout study
9889578|NCT00585208|Placebo Comparator|Placebo (sugar pill)|placebo (sugar pill) - this arm receive the fake pill, also know as placebo or the sugar pill
9889579|NCT00585234||1|We intend to photograph male and female subjects from age 1 through skeletal maturity. Healthy children will be photographed to determine the normative characteristics of thoracic function using this technique. We will also enroll patients with thoracic pathology to determine how digital imaging can document thoracic dysfunction. There are no specific disease related exclusion criteria. Participation is voluntary.
9889580|NCT00585260|Experimental|Exploratory Mannitol|This is an exploratory / ancillary study open to all participants in the BASALT trial [NCT00495157] who consented to undergo mannitol bronchoprovocation procedures during the 36 week treatment period
9889581|NCT00585273||1|Incident users of antipsychotics.
9889582|NCT00585273||2|Non-users of antipsychotics
9889583|NCT00585299|Experimental|Low-fat diet|20% kcals from fat diet followed for 8 weeks then 8 weeks of maintenance diet with visits to dietitian every other week
9889584|NCT00585299|Active Comparator|Traditional|Traditional low-fat diet given and dietitian follows up in 16 weeks
9889585|NCT00585338|Experimental|Tandem 532/1064 nm Laser|Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser
9889586|NCT00585364||CF (non-ABPA)|cystic fibrosis and culture positive for A. fumigatus in airway cultures.
9889587|NCT00585364||CF and ABPA|cystic fibrosis and diagnosis of ABPA
9889588|NCT00585364||healthy control|healthy non-CF
9889589|NCT00585390|Experimental|Essential omega-3 fatty acid replacement|
9889590|NCT00585390|Placebo Comparator|Placebo|
9889591|NCT00585403||Children|Early and late pubertal girls and boys
9889592|NCT00585416|Experimental|1|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
9889593|NCT00585429||1|ESLD subjects on active liver transplant waiting list
9889594|NCT00585429||2|Subjects post-liver transplant with good liver function
9889595|NCT00585429||3|Subjects without liver disease undergoing kidney biopsy for diagnostic purposes
9889596|NCT00585442|Experimental|Calcitriol|
9889597|NCT00585442|Placebo Comparator|Placebo|
9889598|NCT00585455||A|Chronic heart failure patients with concomitant depression
9889599|NCT00585481||1|All subjects will perform samples collection for RSV analysis. Subject's enrolled in Porto Alegre's site will perform lung function tests.
9889600|NCT00585507|Experimental|single|fulvestrant 500mg
9889601|NCT00585520|Active Comparator|PG|
9889602|NCT00585520|Placebo Comparator|PLA|
9889603|NCT00585559|Placebo Comparator|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
9889604|NCT00585559|Active Comparator|Acetaminophen and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
9889605|NCT00585559|Active Comparator|N-acetylcysteine and acetaminophen|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
9889606|NCT00585559|Active Comparator|Acetaminophen 1 Gram and N-acetylcysteine|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
9889607|NCT00585559|Active Comparator|Acetaminophen 1.5 Gram and N-acetylcysteine|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
9889608|NCT00585598||1|all patients that are admitted to the trauma bay with a supralaryngeal airway
9889609|NCT00585624|Experimental|1|Supplement: 3 servings/day of Impact Advanced Recovery in addition to regular food or any other supplements recommended or desired by patient or primary care/surgical team.
9889610|NCT00585624|Placebo Comparator|2|Standard Care: Food, beverages, or supplements as recommended or desired by patient or primary care/surgical team.
9889611|NCT00585676||Diabetic|Patients with Diabetes
9889612|NCT00585676||Abnormal glucose level|Patients who were screened and had abnormal blood glucose levels
9889613|NCT00585676||Control|Non-diabetic (normal glucose screening)
9889614|NCT00585702||1|Pregnant women with bipolar disorder
9889615|NCT00585702||2|Pregnant women without bipolar disorder
9889616|NCT00585728|Other|1|CT virtual proctoscopy
9889617|NCT00585741|Experimental|2. Head and neck|Imaging with 18F-FLT PET
9889618|NCT00585741|Experimental|3. Lung|Imaging with 18F-FLT PET
9889619|NCT00585741|Experimental|4. prostate|Imaging with 18F-FLT PET
9889620|NCT00585741|Experimental|5. esophagus|Imaging with 18F-FLT PET
9889621|NCT00585741|Experimental|1.CNS|Imaging with 18F-FLT PET
9889622|NCT00585754|Active Comparator|Guanfacine|
9889623|NCT00585754|Placebo Comparator|PLA|
9889624|NCT00585767||1|Patients with two kidneys
9889625|NCT00585767||2|Patients with solitary kidney
9889626|NCT00585793||PEPFAR 1|
9889627|NCT00585806||1|Subjects with Heart Failure and ejection fraction greater than or equal to 45%
9889628|NCT00585806||2|Healthy Volunteers
9889629|NCT00585819|Experimental|2. Free breathing|Freebreathing in Body fix mold
9889630|NCT00585819|Experimental|1. breathing cycle|reproducing breathing cycles
9889631|NCT00585832|Experimental|A|DASH-4-Teens Intervention
9889632|NCT00585832|Other|B|Routine Care
9889633|NCT00585845|Experimental|CRS-207|
9889634|NCT00585858||1|Subjects on mimimal or no immunosuppression and no rejection history
9889635|NCT00585858||2|Subjects who have had rejection on conventional immunosuppression
9889636|NCT00585858||3|Subjects who have not had acute or chronic rejection who are on conventional immunosuppression
9889637|NCT00585871|Experimental|Clonidine therapy group|clonidine 0.1 TID
9889638|NCT00585871|Active Comparator|Metoprolol control group|metoprolol 25 TID
9889639|NCT00585897|Experimental|Behavioral counseling|Individual sessions which utilize motivational interviewing to assist participants to discontinue sugar sweetened beverages from their diet.
9889640|NCT00585936||1|Normal controls without evidence of diabetes or islet specific autoimmunity
9889641|NCT00585936||2|Individuals within 6 months of diagnosis with type 1 diabetes
9889642|NCT00585936||3|Individuals at high risk for the development of type 1 diabetes
9889643|NCT00585936||4|Individuals with longstanding autoimmune diabetes
9889644|NCT00585949||Angiography|Patients undergoing coronary angiography without percutaneous coronary angioplasty
9889645|NCT00585949||Percutaneous Coronary Angioplasty|Patients with stable coronary artery disease undergoing angioplasty
9889646|NCT00585988|Other|1|
9889647|NCT00585988|Other|2|
9889648|NCT00586014|Experimental|I|High-dose sequential cyclophosphamide and VP-16 followed by myeloablation with high-dose BCNU and melphalan with autologous stem cell transplant
9889649|NCT00586027||NT-proBNP|150 consecutive patients undergoing cardiac surgery with an intraoperative measured cardiac output <2L/min/m².
9889650|NCT00586040|Experimental|1|superficial closure with PTB
9889651|NCT00586040|Active Comparator|2|superficial sutures
9889652|NCT00586053||1|485 patients,who have an average risk (asymptomatic and without colon screening in the last 5 years) or those who have a high risk for colon cancer (strong family history of colon cancer or polyps and/or personal history of colon cancer or polyps).
9889653|NCT00586053||2|160 patients, with a known colorectal lesion at or greater than 1 cm.
9889654|NCT00586053||3|610 patients, who are of average risk for colon cancer (asymptomatic and no colon cancer screening in the last 5 years).
9889655|NCT00586079|Experimental|A|Ten patients who have had deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
9889656|NCT00586079|Experimental|B|Ten patients who are scheduled to have deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
9889657|NCT00586092|Other|1|This trial employs a phase I design with a dose escalation stage (stage I) and an expansion stage (stage 2) to better describe the tolerability of this combination and the effect of this combination on several biomarkers. In this second stage there will be two groups, each with ten patients, to better describe the tolerability of the bevacizumab/ABT-510 combination and the effect of this combination on several biomarkers. The primary objective of this study is to estimate the MTD/recommended phase II dose regimen. All other objectives are exploratory in nature.
9889658|NCT00586118||1-Sevo|Sevoflurane/ACD group (n=60)
9889659|NCT00586118||2-Propofol|Propofol group (n=60)
9889660|NCT00586131|Active Comparator|Low normal pH (arterial pH 7.36-7.38)|Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
9889661|NCT00586131|Active Comparator|High Normal pH (arterial pH 7.44-7.46)|High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved
9889662|NCT00586183|Experimental|1|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
9889663|NCT00586222|Placebo Comparator|2|
9889664|NCT00586222|No Intervention|Healthy Comparsions|We will compare the BP group with 32 age-, gender-, and handedness-matched healthy adolescents. Subjects who have a first or second degree relative with a psychiatric history will be excluded from the healthy comparison group. Subjects must be safe to undergo MRI scanning as per Mayo MRI safety screening which is explained in detail elsewhere in this protocol. We will exclude the subjects with cardiac pacemakers, metallic clips, other bodily metallic implants and dental braces because of the MRS procedure. Subjects who cannot complete clinical assessments or the MRI scan and subjects who are not fluent in English will be excluded from the study.
9889665|NCT00586222|Experimental|1|
9889666|NCT00586235||1|patients with indeterminate kidney or liver lesions
9889667|NCT00586274|Experimental|CD34 selected haploidentical PBSCT|CD34 selected haploidentical PBSCT
9889668|NCT00586287|Experimental|A|Algorithm which uses serum albumin and weight to determine the loading dose of phenprocoumon within the first 5 days
9889669|NCT00586287|Experimental|B|Algorithm which uses serum age and weight to determine the loading dose of phenprocoumon within the first 5 days
9889670|NCT00586287|Active Comparator|C|The physician chooses the loading dose of phenprocoumon according to his/her experience
9889671|NCT00586300|Active Comparator|1|Physical training program
9889672|NCT00586300|Active Comparator|2|Self-management training program
9889673|NCT00586300|Active Comparator|3|Physical and self-management training programs
9889674|NCT00586352|Active Comparator|Normal|Subjects who have normal endoscopic findings
9889675|NCT00586352|Active Comparator|Newly diagnosed Crohn's disease|Subjects who are newly diagnosed with Crohn's disease after endoscopy.
9889676|NCT00586352|Active Comparator|Newly diagnosed Ulcerative Colitis|Subjects diagnosed with Ulcerative Colitis after endoscopy
9889677|NCT00586365|Experimental|1|Will receive 500 mg Naproxen twice a day for two weeks
9889678|NCT00586365|No Intervention|2|Will not receive naproxen
9889679|NCT00586404||A|Patients with confirmed Barrett's Esophagus
9889680|NCT00586417|Experimental|1|This is a basic research study. There are no treatments with drugs or devices. Wound healing is being studied in healthy volunteers.
9889681|NCT00586430|Active Comparator|1|single 2 mg dose of lorazepam
9889682|NCT00586430|Placebo Comparator|2|single dose of placebo
9889683|NCT00586443|Other|I|This is a Phase I safety study. There is only one arm.
9889684|NCT00586534|Active Comparator|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
9932051|NCT00944957|Experimental|Raltegravir first|Patients treated with Raltegravir for first 2 weeks
9932052|NCT00944957|Experimental|Efavirenz first|Patients treated with Efavirenz for first 2 weeks
9889685|NCT00586534|Experimental|I/GDC + VR/CER|Second Arm:NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
9889686|NCT00586547|Experimental|Treatment|After patients have completed preparation to receive cells, they will be treated at one of five dose levels.
9932053|NCT00944996|Active Comparator|antidepressant|
9932054|NCT00944996|No Intervention|Healthy volunteers|
9932055|NCT00945022|Experimental|Lipsus|
9932056|NCT00945074|Experimental|Condition 1|"Condition 1:~Subjects receive Standard Acu/Moxa (fixed protocol)"
9932057|NCT00945074|Experimental|Condition 2: Individualized Acupuncture/Moxibustion|"Condition 2:~Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis)."
9932058|NCT00945074|Sham Comparator|Condition 3: Control|"Condition 3:~Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)"
9932059|NCT00945113|Experimental|Treatment group|attendance at one-week speech therapy group
9932060|NCT00945152|Experimental|Drug Vancogel,Treatment,Kill MRSA,Heal|Treatment of open wounds with Vancogel(R) 1.25-1.50% to eliminate MRSA. End point is: a negative culture report after 1-3 topical applications. The infected wounds with MRSA will be treated with the Vancomycin 1.25 to 1.50% complex gel formulation and will have conventional management in order to heal the wound. Vancogel is anticipated to accelerate wound healing by eliminating MRSA. A randomized, double blind study protocol approved by FDA.
9932061|NCT00945152|Placebo Comparator|Placebo|Half of the patients in the study will be given a placebo consisting of all ingredients in Vancogel except the active principal Vancomycin in order to compare their clinical efficacy in rate of wound healingafter 1-3 applications
9932062|NCT00945165|Experimental|Exercise|
9932063|NCT00945165|Experimental|No exercise|
9932064|NCT00945178|Experimental|Part A: A|AZD1386
9932065|NCT00945178|Experimental|Part A: B|Placebo for AZD1386
9932066|NCT00945178|Experimental|Part B: A|Naproxen
9932067|NCT00945178|Experimental|Part B: B|Placebo for Naproxen
9932068|NCT00945204|Experimental|access to intermediate care clinics|
9932069|NCT00945204|No Intervention|usual care|
9932070|NCT00945217||Postmenopausal women|women with natural menopause
9935566|NCT03510442||family members|Composed of family members of patients with systemic juvenile idiopathic arthritis, adultonset Still's disease and related conditions.
9935567|NCT03510442||healthy volunteers|Composed of healthy adults and children (above the age of 6 years) who volunteer to participate in this protocol.
9935568|NCT03510442||related inflammatory conditions|Composed of patients with suspected inflammatory disease as indicated by thepresence of episodic fever and/ or arthritis.
9935569|NCT03510442||systemic juvenile idiopathic arthritis (sJIA)|Composed of patients with known or suspected sJIA as defined by the international league of Associations for Rheumatology (ILAR) criteria
9935570|NCT03507790|Active Comparator|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=40 group
9935571|NCT03507790|Active Comparator|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=40 group
9935572|NCT03507790|Placebo Comparator|Placebo Comparator - Placebo|Placebo, n=40 group
9935573|NCT03504020|Experimental|ECG Belt|The ECG Belt arm will utilize the ECG Belt Research System at implant and all follow up visits.
9935574|NCT03504020|No Intervention|Control Arm|Standard CRT through 6 months follow-up.
9935575|NCT03493958|Other|Control|Control group: education/monitor only (insomnia education web-based program that participants access and read at their own pace - contains no customization of program based on sleep diary responses). Participants in the control group are given educational information (like they might see on WebMD or National Sleep Foundation websites), but are left to apply it themselves.
9935576|NCT03493958|Experimental|SHUTI|Intervention group: 6 sessions ( modules ) of SHUTi intervention (at least one module completed while inpatient, the rest while outpatient): In SHUTi, customization is based on multiple variables, including sleep diary responses. The SHUTi program tailors specific recommendations based on sleep diary responses or other input within the program (e.g., responses on the Dysfunctional Beliefs and Attitude Scale trigger recommendations for specific cognitive restructuring strategies).
9935577|NCT03493945|Experimental|Arm 1.1|M7824 + N-803
9935578|NCT03493945|Experimental|Arm 2.1A|M7824 + BN-Brachyury
9935579|NCT03493945|Experimental|Arm 2.1B|M7824 + BN-Brachyury
9935580|NCT03493945|Experimental|Arm 2.2A|M7824 + BN-Brachyury + N-803
9935581|NCT03493945|Experimental|Arm 2.2B|M7824 + BN-Brachyury + N-803
9935582|NCT03493945|Experimental|Arm 2.3A|M7824 + BN-Brachyury + N-803 + Epacadostat
9935583|NCT03493945|Experimental|Arm 2.3B|M7824 + BN-Brachyury + N-803 + Epacadostat
9935584|NCT03492216|No Intervention|Control|All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
9935585|NCT03492216|Experimental|Escalating incentives (EtG tests)|Escalating incentives for EtG negative urine test (Intervention: Incentives for negative EtG test).
9935586|NCT03492216|Experimental|Escalating incentives (IsoScreen tests)|Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test).
9935587|NCT03492216|Experimental|Escalating incentives (EtG + IsoScreen)|Escalating incentives for EtG negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test).
9935588|NCT03486067|Experimental|Administration of CC-93269|
9935589|NCT03481829||Children|Children of mothers enrolled in the study
9935590|NCT03481829||Pregnant women and mothers|Pregnant women/mothers
9935591|NCT03480139||Pregnant Women|Pregnant women aged 18 years and older
9935592|NCT03478917||Arm 1|Subjects previously enrolled onto protocol 05-H-0019 who were hospitalized with vasoocclusivecrisis.
9935593|NCT03478878|Experimental|Participants|Participants with reticular pseudodrusen
9935594|NCT03478865|Experimental|Participants|Participants with age-related macular degeneration
9935595|NCT03478852||Single Arm|Single arm open enrollment of patients with standard of care treatment and evaluation
9889687|NCT00586560|Experimental|1|Stratum 1 (~ 25 patients) will include patients with known bone marrow metastases or those who have had prior intensive myelosuppression therapy (including autologous or allogeneic stem cell rescue [SCR], total body irradiation [TBI], craniospinal irradiation [CSI], or hemipelvic radiation).
9889688|NCT00586560|Experimental|2|Stratum 2 (~ 25 patients) will include patients without previous intensive myelosuppressive therapy and bone marrow metastases.
9889689|NCT00586586|Experimental|Group CBT|The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered in groups of 4 to 8. 10 weekly sessions plus 2 booster sessions.
9667074|NCT03991377|Experimental|EMDR therapy|Patients in the psychotherapy intervention will receive up to 20 individual sessions of EMDR, weekly sessions, of 60 minutes each, using the standard EMDR therapy protocol developed by Shapiro to treat both current and past trauma-related symptom.
9889690|NCT00586586|Experimental|Individual CBT|"The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered individually.~10 weekly sessions plus 2 booster sessions."
9889691|NCT00586586|No Intervention|Wait-list control|Wait-list control condition for 5 weeks after last child has been included.
9889692|NCT00586599|Other|Control|Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
9889693|NCT00586599|Other|IBD and infliximab|Subjects who have IBD and will be receiving infliximab for the first time.
9889694|NCT00586599|Other|Newly Diagnosed IBD|Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
9889695|NCT00586638|Experimental|1|Video Game play with training strategy
9889696|NCT00586638|Active Comparator|2|Video game play without training strategy
9889697|NCT00586638|No Intervention|3|Minimal contact control
9889698|NCT00586677|Active Comparator|RF|Relationship focused where the primary goals are to strengthen the relationship between the parent and the child and to give the parent additional skills that can be used to manage the behavior of the child.
9889699|NCT00586677|Active Comparator|HS|The physical health and safety are the primary components of this parenting program where the parent is taught about basic healthcare and safety in the home.
9889700|NCT00586742|Active Comparator|1|Labral repair with suture anchors
9889701|NCT00586742|Active Comparator|2|Biceps tenodesis with suture anchor
9889702|NCT00586742|Sham Comparator|3|only a diagnostic arthroscopy performed
9889703|NCT00586755|Experimental|Intensive Induction-BMT|Patients will undergo induction regimen and stem cell mobilization with cyclophosphamide for bone marrow transplant (BMT). This will be immediately followed by high dose therapy with stem cell support.
9889704|NCT00586781|Experimental|3|The S.T.A.R. ankle system is the study device. The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants. Both ankles of every subject will be treated with the STAR ankle.
9889705|NCT00586794|Active Comparator|A|
9889706|NCT00586794|Placebo Comparator|B|from the 26th weeks on open-label, all patients were treated with Sildenafil
9889707|NCT00586807|Other|Infliximab|Subjects on infliximab
9889708|NCT00586833||1|No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
9889709|NCT00586833||2|CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
9889710|NCT00586833||3 Healthy normal adults|No identifiable cardiac issues at time of exercise.
9889711|NCT00586859|Experimental|A|NDO Full-thickness Plicator Procedure
9889712|NCT00586885|Experimental|1|Single arm, active treatment
9889713|NCT00586911|Active Comparator|Cystadane|
9889714|NCT00586911|Placebo Comparator|Identical Placebo|
9889715|NCT00586924|Experimental|5 mcg/kg|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
9889716|NCT00586924|Experimental|10 mcg/kg|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
9889717|NCT00586924|Experimental|20 mcg/kg|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
9889718|NCT00586924|Experimental|30 mcg/kg|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
9889719|NCT00586924|Experimental|40 mcg/kg|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
9889720|NCT00586924|Experimental|50 mcg/kg|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
9889721|NCT00586937||1|Lung Cancer Survivors
9889722|NCT00586976|Experimental|1|Ropivicaine infusion into the sternal wound
9889723|NCT00586976|Placebo Comparator|2|Normal saline infusion into the sternal wound
9667075|NCT03991377|Active Comparator|Treatment as usual|Multidisciplinary approach that includes pharmacological treatment and psychological support.
9889724|NCT00586989||1|Patient with Barrett's Esophagus with a history of High grade dysplasia or early esophageal adenocarcinoma
9889725|NCT00587002|Active Comparator|1|Gender comparison
9889726|NCT00587015|Active Comparator|1|CAT-8015
9889727|NCT00587028||Oral Omnipaque MCA|Ten participant minimum: for stool tagging two days preceding the CT colonography, if applicable, with oral Omnipaque. This cohort at Scottsdale Mayo Clinic only.
9889728|NCT00587028||IV Iodine MCR|Ten participant minimum: for intravenous iodine contrast dye. This cohort at Rochester Mayo Clinic only.
9889729|NCT00587028||NO oral and no IV MCR|Five participant minimum for no oral or IV contrast.
9889730|NCT00587028||Replacement Group|Five participant minimum for either cohorts 1, 2, or 3 as above should there be poor imaging results. A like prepped participant will replace that who had poor quality imaging to meet 25 imaging data sets.
9889731|NCT00587093|Other|1|CT scan and CA-125
9889732|NCT00587106||1|One cohort group of patient with PNDS or suspected PNDS
9889733|NCT00587119|Experimental|1|Single arm, active treatment
9889734|NCT00587184||1|patients who were seen clinically indicated endoscopic surveillance and biopsies of BE and confocal microscopy was performed.
9889735|NCT00587210||Suspected or known Crohn Disease|Suspected or known Crohn Disease
9889736|NCT00587236||1|Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
9889737|NCT00587236||2|Patients with chronic ulcerative colitis and known dysplasia or cancer.
9889738|NCT00587249|Experimental|3|50 mcg of ICC-1132 with alhydrogel adjuvant.
9889739|NCT00587249|Experimental|2|20 mcg of ICC-1132 with alhydrogel adjuvant.
9889740|NCT00587249|Experimental|1|10 mcg of ICC-1132 with alhydrogel adjuvant.
9889741|NCT00587262||1|Two pediatric participants with high frequency hearing loss post cochlear implant with either long or short electrode array.
9889742|NCT00587262||2|Eight participants with high frequency hearing loss post cochlear implant with either short or long electrode array.
9889743|NCT00587262||3|Fifteen participants from the existing Cochlear Implant data base.
9889744|NCT00587327|Experimental|Barusiban|
9889745|NCT00587327|Experimental|Atosiban|
9889746|NCT00587327|Placebo Comparator|Placebo|
9889747|NCT00587340||1|15 subjects with subjective sleep disturbance based on the Pittsburgh Sleep Quality Index
9889748|NCT00587340||2|mild/moderate subjective sleep disturbance (insomnia) based on the Pittsburgh Sleep Quality Index
9889749|NCT00587340||3|severe subjective sleep disturbance (insomnia)based on the Pittsburgh Sleep Quality Index
9889750|NCT00587379|Active Comparator|1|Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period
9889751|NCT00587379|Placebo Comparator|2|Patients randomized to 1 40mg placebo pill per day for 6 week study
9889752|NCT00587392||A|Active NDO Endoscopic Full-thickness Plicator Procedure
9889753|NCT00587405|Active Comparator|1|Cryotherapy
9889754|NCT00587405|Active Comparator|2|Argon Plasma Coagulation
9889755|NCT00587418|Experimental|Arginine|
9889756|NCT00587418|Placebo Comparator|Placebo|
9889757|NCT00587444|Other|1|control standard dose heparin dose
9889758|NCT00587444|Active Comparator|2|high dose heparin dose
9889759|NCT00587444|Active Comparator|3|hepcon guided therapy
9889760|NCT00587470|Experimental|1|Atacand treatment.
9889761|NCT00587470|Placebo Comparator|2|Placebo
9889762|NCT00587496|Experimental|1|placebo, 6 capsules per day for 30 days
9889763|NCT00587496|Experimental|2|500 mg Valtrex one capsule per day plus 5 capsules of placebo per day for 30 days
9889764|NCT00587496|Experimental|3|500 mg Valtrex capsule one per day, Acetylsalicylic acid (aspirin) 325 mg capsules three per day, plus 2 placebo capsules per day for 30 days
9889765|NCT00587522|Experimental|A|NDO Full-thickness Plicator Procedure
9889766|NCT00587535||Hemochromatosis|Hemochromatosis
9889767|NCT00587535||Living-related liver donation|Living-related liver donation
9889768|NCT00587561|Experimental|1 Social Cognition Interaction Training|Will receive 20-26 sessions of a manualized group treatment called Social Cognition Interaction Training
9889769|NCT00587561|Other|2 Wait List Control|Wait list control; 6 months of treatment as usual followed by Social Cognition Interaction Training group
9889770|NCT00587574||I|Chronic graft-versus-host disease
9889771|NCT00587574||II|No chronic graft-versus-host disease
9889772|NCT00587600|Active Comparator|Photodynamic therapy|will have photodynamic therapy
9889773|NCT00587600|Active Comparator|radiofrequency ablation of barretts esophagus|radiofrequency ablation of barretts esophagus
9889774|NCT00587626|Active Comparator|1|InterX treatment plus rehabilitation exercises
9889775|NCT00587626|Placebo Comparator|2|Inactive InterX treatment plus rehabilitation exercises
9889776|NCT00587652||1|Intermediate Segment Barrett's (2-4cm)
9889777|NCT00587652||2|Long segment Barrett's (>4 cm)
9889778|NCT00587665|Experimental|1|Low dose ketamine given
9889779|NCT00587665|Placebo Comparator|2|Saline given as control
9889780|NCT00587691|Experimental|Dose Level 1|6-9 million MRTC
9889781|NCT00587691|Experimental|Dose Level 2|30-45 million MRTC
9889782|NCT00587691|Experimental|Dose Level 3|60-90 million MRTC
9889783|NCT00587704|Other|Nerve Stimulation|Use of nerve stimulator for placement of PVB nerve block
9889784|NCT00587704|Other|Anatomic landmarks|Use of anatomic landmarks for placement of PVB block
9889785|NCT00587717|Active Comparator|1|Two 80 mg pills simvastatin taken 24 hours prior to surgery
9889786|NCT00587717|Placebo Comparator|2|Two 80 mg pills placebo are taken 24 hours prior to surgery
9889787|NCT00587730|Active Comparator|Clinical SPECT|GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.
9889788|NCT00587756||1|Prospective cohort of consecutive patients who undergo surgery for colorectal cancer liver metastases
9889789|NCT00587808||HFpEF|Patients with a history of HFpEF
9889790|NCT00587808||control|Patients with a without a history of CHF
9889791|NCT00587821||1|The first 250 samples will be used as a training set and results of these breast biopsies (benign or malignant) will be used to determine the peptide profile characteristic of a diagnosis of breast cancer on biopsy.
9889792|NCT00587821||2|The predictive capacity of this profile will then be prospectively assessed using the next 250 samples, which will serve as a validation set. Subjects who are candidates for enrollment on cohort B of this study (metastatic disease)
9889793|NCT00587873|Experimental|1|MTX, 6-TG, and Leucovorin combination
9889794|NCT00587899|Other|1|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
9889795|NCT00587899|No Intervention|2|The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation
9889796|NCT00587925|Experimental|1|Bone Mineral Density
9889797|NCT00587938||A|BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
9889798|NCT00587938||B|BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
9889799|NCT00587951||A|Candidates for epilepsy surgery, undergoing pre-surgical evaluation at Mayo Clinic, and in whom SISCOM was ordered by the treating physician as part of that evaluation
9889800|NCT00587977||1|Aortic aneurysm repair
9889801|NCT00587977||2|Aortic aneurysm growth
9889802|NCT00587977||3|Aortic aneurysm growth stable.
9889803|NCT00588003|Experimental|1|This is an exploratory study utilizing micro-array technology and immunohistochemistry to test the hypothesis that changes in gene expression occur as an early event in response to endocrine therapy and that these changes can be correlated with changes in surrogate biological markers.
9889804|NCT00588003|Placebo Comparator|2|no medication before surgery
9889805|NCT00588016|Experimental|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
9889806|NCT00588029||1|breast cancer patients
9889807|NCT00588029||2|control subjects without breast cancer
9889808|NCT00588042|Active Comparator|1|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
9889809|NCT00588042|Sham Comparator|2|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
9889810|NCT00588068||1|Tumor and Marrow Markers
9889811|NCT00588081|Other|1|Participants will receive a cover letter, questionnaire and invitation to participate in a post-operative interview.
9889812|NCT00588107|Experimental|Web site access|Web intervention- and access to pharmacotherapy
9889813|NCT00588107|Active Comparator|print materials|Receives tailored print materials and access to pharmacotherapy (Materials condition)
9889814|NCT00588120|Experimental|C-13 labeled oxalate|Hyperoxaluric patients
9889815|NCT00588133|Experimental|1|New drug dosing schedule
9889816|NCT00588133|Active Comparator|2|Standard drug dosing schedule
9889817|NCT00588172|Sham Comparator|1|Individuals with no nsSNPs or mutations known to alter oct1 function
9889818|NCT00588172|Active Comparator|2|Individuals with nsSNPs or mutations known to alter oct1 function
9889819|NCT00588198||1|Melanoma patients
9889820|NCT00588211||1|We will recruit fifteen New York University College of Dentistry (NYUCD) clinic patients who report current tobacco use.
9889821|NCT00588211||2|Second, we will recruit thirty dental clinic smokers (10 per day for 3 days) from the NYUCD waiting room.
9889822|NCT00588211||3|Third, we will survey 200 student participants from Adelphi University.
9889823|NCT00588211||4|Queens Hospital Center with 800 patients.
9889824|NCT00588224||1|adults
9889825|NCT00588224||2|adolescents
9889826|NCT00588250|Experimental|A|
9889827|NCT00588250|No Intervention|B|
9889828|NCT00588276|Experimental|1|Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).
9889829|NCT00588302|Experimental|A, 1|All patients received an open-label moexipril during the study period.
9889830|NCT00588328|Experimental|1|
9889831|NCT00588367||1|Suspected pancreatic ductal adenocarcinoma.
9889832|NCT00588367||2|Chronic pancreatitis and slated for decompression treatment.
9889833|NCT00588367||3|Autoimmune pancreatitis.
9889834|NCT00588419||1|Patients who have undergone mastectomy Patients who have undergone immediate, twostage expander/implant breast reconstruction; Patients who have undergone immediate, autogenous tissue flap reconstruction including: pedicled and/or free TRAM flap or DIEP flap reconstruction
9889835|NCT00588432||1|Hemiparesis as the result of an ischemic hemispheric stroke.
9889836|NCT00588432||2|Immobilization following severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain.
9889837|NCT00588432||3|Myofascial trigger points in trapezius muscle.
9889838|NCT00588432||4|Hyperthyroid Myopathy
9889839|NCT00588458|Experimental|single arm|All patients with PSC in will have CT cholangiography.
9889840|NCT00588484||1|Men, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
9889841|NCT00588484||2|Women, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
9889842|NCT00588497||Study Group|Twenty-five subjects for this study will be recruited from patients who have requested a form of permanent sterilization, and who, after considering all the options, choose the trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert system, Conceptus Incorporated, Mountain View, California) placement will be offered the opportunity to participate in the study.
9889843|NCT00588510||Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible.
9889844|NCT00588523|Experimental|1|temozolomide followed by high dose busulfan and thiotepa
9889845|NCT00588562||Primary Hyperoxaluria patients|Registry will include data on patients with confirmed diagnosis of Primary Hyperoxaluria.
9889846|NCT00588562||Dent Disease Patients|Registry will include data on patients with confirmed diagnosis of Dent Disease.
9889847|NCT00588562||Cystinuria Patients|Registry will include data on patients with confirmed diagnosis of Cystinuria.
9889848|NCT00588562||APRT deficiency Patients|Registry will include data on patients with confirmed diagnosis of APRT deficiency.
9932071|NCT00945230|Experimental|Actigraphic Neurosurgical Outcomes|Actigraphic measurements that will be obtained by attaching the actigraphic watch device to the individual's non-dominant wrist and operationally defined repeated observational measurements. All measurements will continue through a baseline period and continue through the identified post surgical period. Actigraphic measurements will occur every 30 seconds with brief periods of non-measurement during the actual neurosurgical procedure and periods when the actigraphic device has reached storage capacity (approximately every 22 days) when data is retrieved and the device prepared resume measurements.
9932072|NCT00945308|Active Comparator|Eptifibatide (intracoronary)|
9932073|NCT00945308|Active Comparator|Eptifibatide (intravenous)|
9932074|NCT00945347|No Intervention|Baseline|Visit 1
9932075|NCT00945347|Active Comparator|Miglustat|Nasal instillation of Miglustat (visit 2 or 3)
9932076|NCT00945347|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
9932077|NCT00945360|Experimental|aromatase inhibitors: Letrozole|All consenting patients will be started on Letrozole at a dose of 2.5 mg/day for 8 weeks.
9932078|NCT00945373|Experimental|Erythematotelangiectatic Rosacea|2.5% gel calcium dobesilate and pulsed dye laser
9932079|NCT00945399|Experimental|Autologous Chondrocytes Implantation|
9932080|NCT00945399|Active Comparator|Microfracture|
9932081|NCT00945412|Experimental|Micropolysaccharide Hemospheres (MPH)|
9932082|NCT00945412|Active Comparator|Electrocautery|
9932083|NCT00945425|Experimental|1|Low dose or placebo, twice daily
9932084|NCT00945425|Experimental|2|Low dose or placebo, once daily
9932085|NCT00945425|Experimental|3|Middle dose or placebo, twice daily
9932086|NCT00945425|Experimental|4|High dose or placebo, once daily
9932087|NCT00945438|Experimental|Group 1|Participants aged 18 to 59 years at enrollment.
9932088|NCT00945438|Experimental|Group 2|Participants aged 60 years or older at enrollment.
9932089|NCT00945451|Experimental|CyberKnife irradiation|
9932090|NCT00945464||No treatment|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care Center.
9932091|NCT00945503|Experimental|GSK1018921|All subjects will received a dose of GSK1018921 and will peforme three PET scans using the ligand [11C]GSK931145, but in order to obtain adequate sampling of the exposure-time-occupancy curves, a range of doses will be evaluated, and the timing of the post-dose scans will differ between subjects.
9932092|NCT00945516|Active Comparator|Flared end FCSEMS|Flared end FCSEMS will be inserted for the benign bile duct stricture.
9932093|NCT00945516|Active Comparator|Anchoring FCSEMS|Anchoring FCSEMS will be inserted for benign bile duct stricture
9935596|NCT03478839||CRF completion|Individuals with a diagnosis of GACI or ARHR2 with sufficient chart data to be included in the study will be eligible for enrollment, as well as all their siblings and parents.
9935597|NCT03477708||Study group|TCCO2 monitoring
9889849|NCT00588588|Active Comparator|1|Bronchoscopy
9889850|NCT00588588|Active Comparator|2|CPIS
9889851|NCT00588627||1|Post Nasal Drip and chronic cough
9889852|NCT00588627||2|Post nasal drip and no cough
9889853|NCT00588653|Active Comparator|1|All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.
9889854|NCT00588679|Experimental|1|Patients taking part in this study will have one MRI and one MRSI scan acquired in succession during a single MR examination. For those patients who have undergone prostate biopsy it is recommended that this should be done at least eight weeks after the prostate biopsy and should take one hour to one hour and ten minutes total to complete.
9889855|NCT00588705||focus group & questionaire|The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
9889856|NCT00588718||Cases|Infants who meet the entry criteria
9889857|NCT00588718||Controls|Banked blood samples from newborns who do not meet inclusion criteria for this study will be held at Stanford University Core Laboratory and will constitute controls. Proteomic and genomic profiles in blood samples of cases will be compared with blood samples of controls.
9889858|NCT00588757|Active Comparator|1|Optease filter
9889859|NCT00588757|Active Comparator|2|Tulip filter
9889860|NCT00588783||1|
9889861|NCT00588783||2|
9889862|NCT00588796||Healthy Volunteers|Healthy Volunteers
9889863|NCT00588796||Burn patients|Patients who have sustained burn injury greater than or equal to 20% of total body surface area
9889864|NCT00588796||Trauma patients|Patients who have undergone trauma
9889865|NCT00588835|Experimental|A|Aprepitant 125mg oral on day 1 and 80mg on day 2 and 3 during CE treatment.
9889866|NCT00588835|Active Comparator|B|CE cycle with standard anti-emetic regimen.
9889867|NCT00588861|Active Comparator|Answer® hip stem with Simplex Cement|Femoral stem replacement with Answer® hip stem & Simplex Bone Cement
9889868|NCT00588861|Active Comparator|Answer® hip stem with Palacos Cement|Femoral stem replacement with Answer® hip stem & Palacos Bone Cement
9889869|NCT00588874||1|men 50 yrs of age or older
9889870|NCT00588887||1|
9889871|NCT00588887||2|
9889872|NCT00588926|Experimental|A|The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.
9889873|NCT00588939||I|participants with symptoms of acid reflux disease (heartburn)
9889874|NCT00588978|Active Comparator|1|Diet alone
9889875|NCT00588978|Active Comparator|2|Exercise alone
9667076|NCT03990766|Experimental|Theophylline saline irrigation|Theophylline 12 mg capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
9889876|NCT00588978|Active Comparator|3|Diet and exercise (combined)
9889877|NCT00589082|Active Comparator|1|standard 3+7
9889878|NCT00589082|Experimental|2|DNX 3+7
9889879|NCT00589095||1|
9889880|NCT00589134|Experimental|1|type of beverage
9889881|NCT00589147|Active Comparator|1|One study group will consist of patients treated with the modular cemented tibia.
9889882|NCT00589147|Active Comparator|2|Study arm will consist of patients that are treated with non-modular cemented tibia.
9889883|NCT00589147|Active Comparator|3|Study arm will consist of patients that are treated with non-modular uncemented tibia.
9889884|NCT00589173|Experimental|Intervention|Patients referred to the IPHR
9889885|NCT00589173|Active Comparator|Control|"Patients receiving standard preventive care"
9889886|NCT00589199|Experimental|1|Functional Electrical Stimulation for Production of Artificial Cough
9889887|NCT00589212|Experimental|1|Patients with 1-3 brain metastases
9889888|NCT00589225||1|Genetic Analysis
9889889|NCT00589238|Other|Arm 1 (Standard Arm)|Arm 1 (Standard Arm) Preoperative (primary/ neoadjuvant) intravenous weekly paclitaxel 80 mg/m2 for 12 weeks followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
9889890|NCT00589238|Experimental|Arm 2 (Experimental Arm)|Arm 2 (Experimental Arm) Preoperative intravenous weekly paclitaxel 80 mg/m2 in combination with carboplatin AUC 2 on D1, D8 and D15 every 28 days for 4 cycles followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
9889891|NCT00589251|Other|penicillin skin test|Patients will have the skin test placed
9889892|NCT00589264|Experimental|1|iron + copper + zinc
9889893|NCT00589264|Active Comparator|2|iron + copper only
9889894|NCT00589316|Experimental|Treatment (chemo, TBI, transplant, immunosuppression)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.~NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.~POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84."
9935598|NCT03477708||Control group|Routine monitoring
9889895|NCT00589355||1|postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
9889896|NCT00589355||2|postmenopausal women with normal glucose tolerance
9889897|NCT00589368||1|stroke group
9889898|NCT00589368||2|control group
9889899|NCT00589394|Other|pneumococcal vaccination (Pneumovax)|"Intervention:~Patients receive one dose of the Pneumovax vaccine. The 23 pneumococcal serotypes are measured before and after vaccination in order to measure response in a healthy population."
9889900|NCT00589433||1|
9889901|NCT00589446|Experimental|1|Embryoscopy will be evaluated in women with at least two previous miscarriages, after confirmation of missed abortion by ultrasound. Embryoscopy will only be performed in patients in whom curettage is clinically indicated, and will only be added to the D&C if there is a possibility of visualizing embryonic tissue, i:e. from approximately 5½ weeks onwards when there is an embryonic pole detected on ultrasound.
9889902|NCT00589459||1|non-diabetic women with acute coronary syndrome (ACS)
9889903|NCT00589459||2|non-diabetic men with acute coronary syndrome (ACS)
9889904|NCT00589485||1|
9889905|NCT00589485||2|
9889906|NCT00589498|Experimental|1|Subjects who are randomized to overfeed will visit with the General Clinical Research Center dieticians as often as necessary to gain 2 kg of fat (about 4 kg overall) over a period of 8 weeks.
9889907|NCT00589498|No Intervention|2|Subjects who are randomized to non-overfeeding will continue with their normal diet and activity levels for a period of 8 weeks.
9889908|NCT00589589|Active Comparator|A|
9889909|NCT00589615|Active Comparator|1|The multidisciplinary osteoporosis prevention study started with a five-day program at a rehabilitation centre and will be followed by one-day group appointments twice.
9889910|NCT00589615|No Intervention|2|The control group will get information about osteoporosis through media and health care system.
9889911|NCT00589641|Experimental|CBT-RP + Enhanced TAU|CBT-RP augmenting relapse prevention intervention, in addition to enhanced treatment as usual, monthly check-ins, and monitoring
9889912|NCT00589641|Active Comparator|Enhanced TAU (Treatment as Usual)|Treatment as usual in the community, monthly monitoring regarding service use and needs, monitoring
9889913|NCT00589680||2|Patients treated for DKA under DKA protocol implemented by hospital
9889914|NCT00589680||1|To establish a baseline on how patients are being treating with DKA in general and without a standardized DKA protocol
9889915|NCT00589706|Experimental|A|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).
9889916|NCT00589719||2000,3000,4000|Children at risk for asthma were identified using a cross-sectional asthma screening survey.
9889917|NCT00589732|Experimental|Valsartan treatment gorup|Valsartan 160mg per day group
9889918|NCT00589732|No Intervention|No Valsartan treatment group|No valsartan treatment
9889919|NCT00589745|Other|Subjects being evaluated for CF|Subjects will be referred from physicians who are clinically concerned about the possibility of Cystic Fibrosis. Nasal potential difference measurement will be obtained to potentially help aid in diagnosis.
9889920|NCT00589758||Acute Decompensated Heart Failure|"Admitted to Heart Failure ICU for acute decompensated heart failure. 2D and 3D echocardiography will be obtained at baseline, 24 -48 hours and 1-2 weeks post discharge.~Blood and urine will be collected for biomarker evaluation at each timepoint"
9889921|NCT00589771|Experimental|A|"Capsule Saccharomyces boulardii 250 mg TDS for six weeks.~Ispahgula husk 1 Tsf daily after dinner for six weeks."
9889922|NCT00589771|Placebo Comparator|B|"Capsule Placebo TDS for six weeks.~Ispaghula husk 1 Tsf daily after dinner for six weeks"
9990537|NCT01444157|No Intervention|Standard homecare nursing group|Patients continue to receive the standard homecare nursing. They can contact municipality services for visitation to homecare nursing if they feel that additional homecare is needed or if they do not yet receive this service and feel they need homecare nursing.
9889923|NCT00589810||Controls|Controls = Patients in Genebank that had BMS placed that did not go on to have ISR within 1 year of BMS placement and have not had prior ISR in any vessel ever. If testing is available, the Control status will be further verified by angiographic documentation of <50% luminal loss with the stent or negative stress test six or more months after stenting.
9889924|NCT00589810||Cases|Cases = Patients in Genebank that had BMS placed that went on to have ISR which is defined as PCI or CABG to the Target Vessel within 1 year of the BMS placement.
9889925|NCT00589862|Experimental|1|
9889926|NCT00589901|Experimental|A|phase II trial of capecitabine and cyclophosphamide in the management of metastatic breast cancer
9889927|NCT00589927|Experimental|cilostazol|Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
9889928|NCT00589927|Placebo Comparator|placebo|Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
9889929|NCT00589953|Placebo Comparator|EPO###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
9889930|NCT00589953|Experimental|EPO ###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
9889931|NCT00589966|Experimental|Coping Skills Training|
9889932|NCT00589966|Active Comparator|Prostate Cancer Education|
9889933|NCT00590070|Active Comparator|1|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
9889934|NCT00590070|Active Comparator|2|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
9889935|NCT00590070|Placebo Comparator|3|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered
9889936|NCT00590083|Experimental|Virus Specific Cytoxic T lymphocytes|Virus Specific Cytoxic T lymphocytes
9889937|NCT00590122|Experimental|b|Parcopa at equivalent dosage to subjects surrent stable dose
9889938|NCT00590122|Active Comparator|a|carbidopa-levodopa at subjects current stable dose
9889939|NCT00590174|Experimental|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
9889940|NCT00590174|Active Comparator|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
9889941|NCT00590252||Scheduled for an MRI|Clinically Indicated Adults
9889942|NCT00590265|Experimental|1|
9889943|NCT00590265|Placebo Comparator|2|
9889944|NCT00590291||Cases|premature CAD and MI, AVM
9889945|NCT00590291||Controls|No CAD, MI, AVM
9889946|NCT00590304||EU, LV, MA, EL, DU|The population will consist of 120 English-speaking participants ages 4-17 years from four rural schools with physician-diagnosed asthma or symptoms of asthma in the previous 12 months. As of June 2008, an additional rural school has been added to the population criteria, making a total of five rural schools.
9889947|NCT00590343|Experimental|1|Intervention=Patients will receive treatment with PTK787/ZK222584 daily. A treatment cycle will be defined as a 28-day period. Subjects will continue on their present treatment regimen of receiving Sandostatin LAR 30mg IM every 4 weeks.
9889948|NCT00590356|Active Comparator|A2|AngioSeal®
9889949|NCT00590356|Experimental|A1|StarClose®
9889950|NCT00590408|Active Comparator|1|
9889951|NCT00590408|Placebo Comparator|2|
9889952|NCT00590421||1|145 individuals treated by irradiation in their childhood
9889953|NCT00590421||2|150 matched control subjects with no history of irradiation
9889954|NCT00590434||1|Patients older than 80 years presenting for average risk screening or surveillance colonoscopy
9889955|NCT00590434||2|Patients younger than 80 years presenting for average risk screening or surveillance colonoscopy
9889956|NCT00590447|Experimental|A|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
9889957|NCT00590447|Experimental|B|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.
9889958|NCT00590473|Active Comparator|1|Unilateral Placement of Interstim IPG
9889959|NCT00590473|Active Comparator|2|Bilateral Placement of Interstim IPG
9990538|NCT01444170|Placebo Comparator|Sugar pill|"Placebo sugar pill was used as a sham control"
9990539|NCT01444170|Experimental|dicreatinol sulfate|
9990540|NCT01444183|Active Comparator|Progressive muscle relaxation|Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
9990541|NCT01444183|Sham Comparator|Sham exercise|Subjects practice a sham exercise consisting of focused attention activities
9990542|NCT01444196|Other|Desloratadine dose|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
9990543|NCT01444196|Other|Dose of Desloratadine|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
9990544|NCT01444222||Pulmonary Hypertension|
9990545|NCT01444222||pulmonic valve stenosis|
9990546|NCT01444222||pulmonic valve homograft|
9990547|NCT01444222||pulmonic valve insufficiency|
9990548|NCT01444222||atrial septum defect|
9990549|NCT01444222||Ebstein's anomaly|
9990550|NCT01444222||transvalvular right ventricular lead|
9990551|NCT01444222||control|
9990552|NCT01444235|Active Comparator|Custodiol|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
9990553|NCT01444235|Experimental|Custodiol-N|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
9889960|NCT00590499||agitation group|The Riker sedation-agitated scale (SAS) levels 5-7.
9889961|NCT00590499||non-agitation group|The Riker sedation-agitated scale (SAS) levels 1-4.
9889962|NCT00590512|Active Comparator|High Sodium|High sodium
9889963|NCT00590512|Active Comparator|Low sodium|Low sodium
9889964|NCT00590525||1|
9889965|NCT00590551|Experimental|1-6|
9889966|NCT00590603|Experimental|1|Dose escalation study with two cohorts. A standard dose of Arsenic Trioxide will be given with escalating dose of Bortezomib.
9889967|NCT00590616||1|
9889968|NCT00590642||1|
9889969|NCT00590655|Active Comparator|2|Treatment B includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). Treatment lasts 17 weeks and after that there will be one and two year control visits including weighing and questionnaires for eating behavior and quality of life.
9889970|NCT00590655|Experimental|1|Treatment includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). After that a maintenance programme starts with monthly sessions for one year. Weight loss, quality of life, and eating behavior will be assessed at the end of the maintenance program and one year later.
9889971|NCT00590694|Active Comparator|Group1|Will receive ranibizumab treatments until resolution of macular edema only and as macular edema recurs.
9889972|NCT00590694|Active Comparator|Group 2|Will receive ranibizumab treatments until resolution of both macular edema and PED, and as macular edema or PED recur.
9889973|NCT00590785|Experimental|1|
9889974|NCT00590785|Experimental|2|
9990554|NCT01444248|Experimental|Amaryl MEX|
9990555|NCT01444248|Active Comparator|Amaryl M|
9990556|NCT01444261|Active Comparator|Intervention|Fer-in-Sol drops and iron-fortified cereal
9990557|NCT01444261|Other|Control|No intervention
9990558|NCT01444274||Obalon Gastric Balloon|One or two balloons administered to each patient
9990559|NCT01444313|Other|nelfilcon A OD / narafilcon A OS|Soft contact lens without UV protection worn on the right eye (OD) and soft contact lens with UV protection worn on the left eye (OS).
9990560|NCT01444313|Other|narafilcon A OD / nelfilcon A OS|Soft contact lens with UV protection worn on the right eye (OD) and soft contact lens without UV protection worn on the left eye (OS).
9990561|NCT01444326|Experimental|Dairy diet|
9990562|NCT01444326|Placebo Comparator|Control diet|
9990563|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 1|Participants will receive an injection of pneumococcal vaccine (Formulation 1, 1 middle dose) on Day 0 and Day 30, respectively.
9990564|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 2|Participants will receive an injection of Pneumococcal vaccine (Formulation 2, 2 low doses) on Day 0 and Day 30, respectively.
9990565|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 3|Participants will receive an injection of pneumococcal vaccine (Formulation 3, 2 middle doses) on Day 0 and Day 30, respectively.
9990566|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 4|Participants will receive an injection of pneumococcal vaccine (Formulation 4, 2 middle doses) on Day 0 and Day 30, respectively.
9889975|NCT00590798|Experimental|1|Patients are asked to walk within 30 minutes after implantation of the Star- Close vascular closure system.
9889976|NCT00590811||adolescents|3rd year high school girls (14-16 years old)
9889977|NCT00590811||young adults|1st year university young females (18 - 20 years old)
9889978|NCT00590837|Experimental|1|Patients will be treated by adding lomustine to chemotherapy
9889979|NCT00590837|No Intervention|2|Patients will be treated without adding lomustine to chemotherapy
9889980|NCT00590876||1|T1DM patients with a history of severe hypoglycemia and/or hypoglycemia unawareness who have been selected based upon this history to undergo islet cell transplantation at the University of Minnesota.
9889981|NCT00590876||2|T1DM patients (C-peptide negative) who are matched for age, gender, and duration of diabetes, who also have a history of severe hypoglycemia and/or hypoglycemia unawareness meeting the criteria for islet cell transplantation. The hemoglobin A1c for each of these subjects will fall within 1% of the islet transplant recipient to whom they are matched.
9889982|NCT00590876||3|Nondiabetic subjects (fasting plasma glucose < 110 mg/dl) who are matched for age and gender to the islet transplant recipient to whom they are matched.
9889983|NCT00590928|Active Comparator|1|patients with indication for stress ulcer prophylaxis and gastric pH < 4
9889984|NCT00590928|Active Comparator|2|patients with indication for stress ulcer prophylaxis and gastric pH < 4
9889985|NCT00590941|No Intervention|R-CHOP|Patients receiving R-CHOP via standard of care which consists of cyclophosphamide 750 mg/m2 IV day 1 of each 21 day cycle, doxorubicin 50 mg/m2 IV day 1 of each 21 day cycle, vincristine 1.4 mg/m2 IV day 1 of each 21 day cycle, prednisone 100 mg PO days 1-5 of each 21 day cycle, and rituximab 375 mg/m2 IV day 1 of each 21 day cycle.
9889986|NCT00590993||1 - MRSI / MRI|
9889987|NCT00591045|Experimental|1|The patients will undergo neoadjuvant chemotherapy with mFOLFOX and then an operation and then individualized adjuvant chemotherapy.
9889988|NCT00591045|No Intervention|2|No neoadjuvant chemotherapy and surgery and then adjuvant chemotherapy.
9889989|NCT00591058|Experimental|Cohort 1|0.04 mg/kg TM-601 dose per administration
9889990|NCT00591058|Experimental|Cohort 2|0.08 mg/kg TM-601 dose per administration
9889991|NCT00591058|Experimental|Cohort 3|0.16 mg/kg TM-601 dose per administration
9889992|NCT00591058|Experimental|Cohort 4|0.3 mg/kg TM-601 dose per administration
9889993|NCT00591058|Experimental|Cohort 5|0.6 mg/kg TM-601 dose per administration
9889994|NCT00591058|Experimental|Cohort 6|1.2 mg/kg TM-601 dose per administration
9889995|NCT00591071|Active Comparator|B|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
9889996|NCT00591071|Experimental|A|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
9889997|NCT00591084|Experimental|ginsenoside-Rd 10mg|both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
9889998|NCT00591084|Placebo Comparator|placebo|2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
9889999|NCT00591084|Experimental|ginsenoside-Rd 20mg|2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
9890000|NCT00591097||pediatric|
9890001|NCT00591110|Active Comparator|1|Educational intervention communicating practical information about vision, eye conditions and eye care.
9890002|NCT00591110|Sham Comparator|2|
9890003|NCT00591136|Experimental|Single Arm|
9890004|NCT00591162|Active Comparator|1|Compare bone density of severly burned children to normal non-burned population
9890005|NCT00591175||1|Standard Care
9890006|NCT00591175||2|Standard Care with Hygienist Counseling
9890007|NCT00591175||3|Standard Care with Hygienist Counseling & Personalized Risk Communication
9890008|NCT00591188|Experimental|1|All patients will receive capecitabine and interferon-alpha.
9890009|NCT00591201|Experimental|A|Infliximab
9890010|NCT00591201|Placebo Comparator|B|Placebo
9890011|NCT00591279||A|Barium enema and colonoscopy at one and three years after entry.
9890012|NCT00591279||B|Barium enema and colonoscopy at three years only after entry.
9890013|NCT00591292|Experimental|Single Arm|
9890014|NCT00591331|Experimental|1|NatrOVA Creme Rinse - 1%
9890015|NCT00591331|Experimental|2|NatrOVA Creme Rinse Vehicle Only
9890016|NCT00591331|Placebo Comparator|3|Blank patch
9890017|NCT00591357|Active Comparator|A|Loperamide
9890018|NCT00591357|Placebo Comparator|B|Placebo
9890019|NCT00591383|Experimental|Single Arm|Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
9890020|NCT00591396|Experimental|Single Arm|
9890021|NCT00591422|Experimental|Single Arm|
9890022|NCT00591435||1|200 laparoscopic cholecystectomies will be included, consultant cases will be compared to resident cases
9890023|NCT00591435||2|200 laparoscopic pelviscopies will be included, consultant cases will be compared to resident cases
9890024|NCT00591435||3|200 transurethral resection of urinary bladder or prostate gland will be included, consultant cases will be compared to resident cases
9890025|NCT00591448|Experimental|Virtual Reality|Patients with burns participate in VR during occupational therapy (OT) or physical therapy (PT) sessions ranging from 2 to 9 min in length
9890026|NCT00591461||1|Study participants must be older than 18 years of age who are having an endoscopy performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth, dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.
9890027|NCT00591474|Experimental|1|VRE positive patients
9890028|NCT00591474|Placebo Comparator|2|VRE positive patients
9890029|NCT00591487|Active Comparator|I|Infiltration with 0.9% saline+1:1,000,000 epinephrine+0.06% Lidocaine
9890030|NCT00591487|Placebo Comparator|II|Infiltration with 0.9% saline+1:1,000,000 epinephrine
9890031|NCT00591526|No Intervention|A|"Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days AraC 200 mg/m2/d during 7 days~2) Consolidation treatment~First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection) 3) Maintenance treatment~Consists of the combination of continuous low dose chemotherapy and intermittent ATRA, during 2 years~Continuous low dose chemotherapy~Intermittent ATRA"
9890032|NCT00591526|Experimental|B|Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 (Group B) Same treatment as Group A but without AraC.
9890033|NCT00591526|No Intervention|C|"First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection)~CNS prophylaxis : consists of 5 intrathecal (IT) injections of MTX 15mg and AraC 50 mg (12 mg/m2 maximum 15 mg, and 30mg/m2, maximum 50 mg, respectively, in children) + depomedrol IT. I~3) Maintenance treatment"
9890034|NCT00591526|No Intervention|D|"Patients aged >60 years and initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days (intravenous bolus injection) NO ARA C DURING THIS FIRST COURSE~2) Consolidation treatment~First consolidation course DNR 60 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~Second consolidation course DNR45 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~3) maintenance treatment: similar to other groups"
9890035|NCT00591539||Carotid Ultrasound|Carotid Ultrasound: Irradiated and non-irradiated sides of the neck in long-term survivors of pediatric cancers who received unilateral radiation therapy involving the carotid artery as part of their treatment
9890036|NCT00591552|Active Comparator|Group A|Electrocautery used for dissection.
9890037|NCT00591552|Active Comparator|Group B|Harmonic Scalpel used for dissection
9890038|NCT00591604|Experimental|1|Vitamin D administration
9890039|NCT00591617|Active Comparator|1: MM|Medical Management: group receives medical management from study physician and Suboxone pharmacotherapy
9890040|NCT00591617|Active Comparator|2: CBT|Cognitive Behavioral Therapy (CBT) group receives CBT, medical management and Suboxone pharmacotherapy
9890041|NCT00591617|Active Comparator|3: CM|Contingency Management (CM) group receives CM, medical management, and Suboxone pharmacotherapy
9890042|NCT00591617|Active Comparator|4: CBT + CM|Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) group receives CBT, CM, medical management, and Suboxone pharmacotherapy
9890043|NCT00591643|Experimental|Imaging, Adrenal acans & Radiation|
9890044|NCT00591669|Experimental|1|IBD patients
9890045|NCT00591669|Other|2|Control subjects
9890046|NCT00591682|Experimental|1|MSX-122
9890047|NCT00591695|Active Comparator|A|positioning in emergency of a prosthetic metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
9890048|NCT00591695|Active Comparator|B|emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
9890049|NCT00591708|Experimental|B|Supplementation of a higher level of calcium (500-1300 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
9890050|NCT00591708|Experimental|A|Supplementation of a lower level of calcium (0-400 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
9890051|NCT00591747|Experimental|1|Progressive resistance training program 3 times a week for 12 months
9890052|NCT00591747|Active Comparator|2|Flexibility training 3 times a week for 12 months
9890053|NCT00591812|Experimental|1 - ComPreSs system|
9890054|NCT00591877|Active Comparator|AC|"Acupuncture:~The patients will receive acupuncture by a trained doctor with acupuncture expertise, at 3 points relevant to reflux symptoms. Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation."
9890055|NCT00591877|Sham Comparator|SAC|The patients randomized to this arm will receive acupuncture for a similar duration and number of sessions. The sham acupoints are at least 2 cm away from the actual acupoints to prevent acupressure effects
9890056|NCT00591877|Active Comparator|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
9890057|NCT00591890|Experimental|Single Arm|
9890058|NCT00591916|Experimental|1|Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
9890059|NCT00591916|Experimental|2|fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
9890060|NCT00591916|Active Comparator|3|Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
9890061|NCT00591929|No Intervention|1|No Continuous passive motion following ORIF of fractures around the knee
9890062|NCT00591929|Active Comparator|2|Continuous Passive Motion following ORIF of fractures around the knee
9890063|NCT00591968|No Intervention|1|The control group will receive traditional ultrasound consults (i.e. travel to nearest tertiary center for intraabdominal sonographic evaluation and return with radiologist's report).
9890064|NCT00591968|Experimental|2|The experimental group will receive the teleultrasound service. Participants are randomly assigned to this group. All patients will receive a traditional clinical work-up. An ultrasound examination will be offered if, based on initial clinical evaluation by an attending physician, the patient is found to have symptoms consistent with any the following abnormalities: ascites, blunt abdominal trauma, cholelithiasis, cholecystitis, cholangitis, pancreatitis, hydronephrosis, abdominal aortic aneurysm, hepatitis, portal hypertension, urolithiasis, abnormal uterine bleeding, ovarian mass or torsion.
9890065|NCT00591981||Primary|All patients 70 years old and above scheduled for a thoracic oncologic surgery (typically esophageal or lung cancer) will be approached for entry into this study
9890066|NCT00592020|Active Comparator|1|Short Transverse Incision
9890067|NCT00592020|Active Comparator|2|Hockey Stick Incision
9890068|NCT00592033|No Intervention|2|Rehabilitation, no supplemental oxygen
9890069|NCT00592033|Experimental|1|Rehabilitation plus supplemental oxygen
9890070|NCT00592046|Experimental|Single Arm|
9890071|NCT00592085|Active Comparator|Relapse Prevention Counseling|Motivational Relapse Counseling: 6 counseling calls over two weeks accompanied by questionnaires
9890072|NCT00592085|Active Comparator|Relapse Prevention + Alcohol Counseling|Motivational Relapse Prevention Plus Alcohol Risk Reduction Counseling: 6 counseling calls over two weeks for both smoking cessation and at-risk alcohol use accompanied by questionnaires
9890073|NCT00592098|Experimental|1|2PX
9890074|NCT00592098|Placebo Comparator|2|Placebo
9890075|NCT00592111|Experimental|1|
9890076|NCT00592111|Experimental|2|
9890077|NCT00592111|Experimental|3|
9890078|NCT00592137|Placebo Comparator|C|During one three week session of a controlled diet subjects will receive a smoothie based on soy protein two times per day that does not contain any additional calcium
9890079|NCT00592137|Active Comparator|B|During one three week period half of the participants will receive two smoothies per day based on soy protein that contain 650 mg Ca as calcium carbonate
9890080|NCT00592137|Active Comparator|A|During one three week session subjects will receive two smoothies per day based on dairy protein containing 650 mg calcium
9890081|NCT00592150|Experimental|1|Fenoldopam infusion
9890082|NCT00592150|Placebo Comparator|2|Placebo infusion
9890083|NCT00592163|Experimental|Single Arm|
9890084|NCT00592189|Experimental|1|Amnion tissue and blood collection
9890085|NCT00592202|Experimental|1|Adolescents between the ages 14 through 17 with a BMI of 40 or more or with a BMI of 35 or more and with an obesity related comorbidity will undergo placement of an adjustable gastric band
9890086|NCT00592215|Experimental|A|Mifepristone followed by labor induction with misoprostol after 6-8 hours
9890087|NCT00592228|Other|1|Fractional flow guided drug-eluting stent implantation arm
9890088|NCT00592228|Other|2|Routine drug-eluting stent implantation
9890089|NCT00592241|No Intervention|A|Subject is diagnosed as a diabetic, or subject is parent/guardian of a diabetic child age under 18 years.
9890090|NCT00592280|Experimental|1|
9890091|NCT00592293|Experimental|Proton Beam Radiation|Proton Beam Radiation
9890092|NCT00592306|Active Comparator|thymoglobulin (intraoperative)|we plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)
9890093|NCT00592306|Placebo Comparator|thymoglobulin (postoperative dosing)|We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)
9890094|NCT00592332|Experimental|2|Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.
9890095|NCT00592332|Experimental|1|Hyperinsulinemic glucose clamp in group with no drug.
9890096|NCT00592397|Experimental|1|All participants underwent the same dietary intervention
9890097|NCT00592410|Experimental|1|
9890098|NCT00592423|Other|1|"A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study."
9890099|NCT00592436||1|
9890100|NCT00592449|No Intervention|1|Participants with knee OA who meet research diagnostic criteria for insomnia will partake in Phase 1
9890101|NCT00592449|No Intervention|2|Participants with knee OA who meet research diagnostic criteria for normal sleep will partake in Phase 1
9890102|NCT00592449|No Intervention|3|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for primary insomnia will partake in Phase 1
9890103|NCT00592449|No Intervention|4|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for normal sleep will enroll in Phase I
9890104|NCT00592449|Experimental|5|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive behavioral desensitization treatment for insomnia
9890105|NCT00592449|Experimental|6|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive cognitive behavior therapy for insomnia
9890106|NCT00592462||Whole Body MRI|
9890107|NCT00592540|Experimental|Unrelated Donor BMT|
9890108|NCT00592566|No Intervention|1|Standard supportive care
9890109|NCT00592566|Experimental|2|Dexamethasone treatment
9890110|NCT00592566|Experimental|3|Desmopressin treatment
9890111|NCT00592579|Experimental|1|Open label, oral administration of 2ME2
9890112|NCT00592592|Experimental|Proton Beam Radiation|Proton Beam Radiation
9890113|NCT00592644|Experimental|1|Pulse Dye Laser
9890114|NCT00592644|Active Comparator|2|Traditional surgeries
9890115|NCT00592657||1|Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
9890116|NCT00592657||2|Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion
9890117|NCT00592670|Experimental|1|Baseline measures followed by a randomized 6 weeks treatment of Prozac.
9890118|NCT00592670|Placebo Comparator|2|Baseline followed by a 6 week randomized treatment of placebo.
9890119|NCT00592696||Observation|
9890120|NCT00592735||1|
9890121|NCT00592748|Active Comparator|Group 1|40-44 Treatments
9890122|NCT00592748|Active Comparator|Group 2|37-40 Treatments
9890123|NCT00592800||1|children between 11 and 13 years of age
9890124|NCT00592800||2|children between 14 to 15 years of age
9890125|NCT00592800||3|children between 16 and 18 years of age
9890126|NCT00592813|Experimental|1|
9890127|NCT00592813|Placebo Comparator|cardiovascular education (attention control)|
9932094|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
9932095|NCT00945542|Experimental|Preemptive transfusion|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. This corresponds to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
9932096|NCT00945568|Experimental|Aminolaban EN|Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
9932097|NCT00945568|No Intervention|Control|The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.
9932098|NCT00945581|Experimental|AN777|Powder twice a day
9932099|NCT00945581|Placebo Comparator|Placebo powder|Powder twice a day
9932100|NCT00945607|Experimental|Guided Relaxation Training|"Eligible subjects who have been randomized to the intervention arm will be scheduled for GRT introduction and training with a research staff member. The GRT sessions will consist of six weekly on-site sessions in which the subject is provided instructions and then allowed to listen to the GRT CD. Subjects will be instructed to conduct independent GRT sessions at home, twice daily, at least four hours apart, for the duration of the study. Subjects will also be instructed that on the days of one-on-one sessions with a research staff member at TCCC, that they will only be required to perform the independent session once at home.~Subjects will be provided with a diary to record the date and time of each independent GRT session performed at home. Subjects will be instructed to bring their completed diary with them at each subsequent visit."
9932101|NCT00945607|No Intervention|Standard of Care(SOC)|Eligible subjects who are randomized to the SOC arm will not receive the GRT sessions. During the six week treatment phase, these subjects will only receive SOC provided to all subjects newly diagnosed with breast cancer at TCCC. This consists of an education session with the nurse or nurse practitioner. In addition, they will also be provided with supportive care and symptom management as needed. This arm will also be provided with a diary to record their stress level at least twice daily.
9932102|NCT00945620|Placebo Comparator|right side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
9932103|NCT00945620|Placebo Comparator|Left side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
9890128|NCT00592891|Experimental|Hyperbaric oxygen therapy|Patients undergoing low pressure HBOT for chronic brain injury
9890129|NCT00592917|Active Comparator|Ia|1718 subjects randomised for active calcium and vitamin-D -intervention, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except Ib (every four months)
9890130|NCT00592917|Active Comparator|Ib|random sample of 292 of 1718 (Ia), data collection by questionnaires mentioned in Ia, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
9890131|NCT00592917|No Intervention|IIa|1714 subjects randomised to no intervention group, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except IIb (every four months)
9890132|NCT00592917|No Intervention|IIb|random sample of 314 of 1714 (IIa), data collection by questionnaires mentioned in IIa, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
9890133|NCT00592930|Experimental|1|olanzapine
9890134|NCT00592930|Placebo Comparator|2|matching placebo
9890135|NCT00593034||1|"Participants in this study will be 12-21 year old patients who have been referred to the Adolescent Substance Abuse Program for evaluation of drug or alcohol use and are participating in the parent study, Medical Office Intervention for Adolescent Drug Abuse."
9890136|NCT00593047|Placebo Comparator|1|Statin + placebo
9890137|NCT00593047|Experimental|2|Statin + KB2115 dose 1
9890138|NCT00593047|Experimental|3|Statin + KB2115 dose 2
9890139|NCT00593047|Experimental|4|Statin + KB2115 dose 3
9890140|NCT00593073|Experimental|1|Tailored Reminder Message
9890141|NCT00593073|Experimental|2|General Reminder Message
9890142|NCT00593086|Active Comparator|A|Standard of care pain management
9890143|NCT00593086|Experimental|B|SnoWorld Virtual Reality Game
9890144|NCT00593099|Experimental|1|Buproprion
9890145|NCT00593099|Placebo Comparator|2|Placebo
9890146|NCT00593125|Experimental|1|levetiracetam
9890147|NCT00593138|Experimental|1|
9890148|NCT00593151|Experimental|A, C, 320 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
9890149|NCT00593151|Experimental|B, C, 640 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
9890150|NCT00593151|Active Comparator|A, B, C PEG|Weekly subcutaneous injections of 1.5 ug/kg PegIntron (12 kDalton pegylated interferon alpha 2b) with oral ribavirin.
9890151|NCT00593164|Experimental|1|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous magnesium sulfate (30 mg per kg IV over 15 min).
9890152|NCT00593164|Active Comparator|2|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous normal saline.
9890153|NCT00593177|Experimental|Treatment Group 1|0.05% PTH (1-34) Gel
9890154|NCT00593177|Experimental|Treatment Group 2|0.10% PTH (1-34) Gel
9890155|NCT00593177|Placebo Comparator|Treatment Group 3|Placebo (Vehicle) Gel
9890156|NCT00593190|Experimental|1|
9890157|NCT00593216||Healthy|Healthy volunteers devoid of any ear problems
9890158|NCT00593216||Vertigo|Patients with the symptoms of vertigo
9890159|NCT00593229||3|Familial atypical HUS
9890160|NCT00593229||4|Thrombotic thrombocytopenic purpura (TTP)
9890161|NCT00593229||1|Severe diarrhea-associated hemolytic uremic syndrome (D+HUS)
9890162|NCT00593229||2|Non-familial atypical HUS
9890163|NCT00593242|Experimental|infusions|infants who arrive at the study site within the first 14 postnatal days and had a history of moderate to severe hypoxic ischemic encephalopathy, and have cells available for infusion that pass Carolinas Cord Blood Bank Quality checks Outcomes will be measured at 22-26 months fby neurodevelopment assessment
9990567|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 5|Participants will receive an injection of pneumococcal vaccine (Formulation 5, 2 high doses) on Day 0 and Day 30, respectively.
9990568|NCT01444339|Placebo Comparator|Pooled placebo Group|Participants will receive an injection of a placebo on Day 0 and Day 30, respectively.
9990569|NCT01444352|Experimental|Vaccine Formulation 1 (Low dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
9990570|NCT01444352|Experimental|Vaccine Formulation 2 (Middle dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
9990571|NCT01444352|Experimental|Vaccine Formulation 3 (High dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
9990572|NCT01444352|Placebo Comparator|Placebo Pooled|Participants who receive 2 injections of tris buffered saline
9990573|NCT01444404|Experimental|Dose Expansion|The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
9990574|NCT01444404|Experimental|Dose Escalation|The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.
9990575|NCT01444443|Experimental|Closed-loop glucose control|Blood glucose controlled by control algorithm.
9990576|NCT01444443|Active Comparator|Open-loop glucose control|Blood glucose controlled by patient
9990577|NCT01444469|Experimental|Azithromycin (Zithromax)|500 mg of azithromycin (2×250mg capsules)
9990578|NCT01444469|Placebo Comparator|Placebo|Placebo
9990579|NCT01444482|Experimental|Matrix M adjuvanted influenza vaccine|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M
9990580|NCT01444482|Active Comparator|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
9990581|NCT01444495|Active Comparator|Short time interval|Patients operated on 7-10 days after completing preoperative radiotherapy 5x5Gy.
9990582|NCT01444495|Experimental|Long time interval|Patients operated on 4-5 weeks after completing preoperative radiotherapy 5x5Gy.
9990583|NCT01444508|Active Comparator|crystalloid|
9990584|NCT01444508|Placebo Comparator|colloid|
9990585|NCT01444521|Experimental|single-arm Irinotecan-Cisplatin|
9990586|NCT01444534|Experimental|use of the diabetes application|
9990587|NCT01444534|Active Comparator|Control arm without app (usual care)|
9990588|NCT01444547|Experimental|single-arm Paclitaxel-Cisplatin|
9990589|NCT01444560||Cutaneous Melanoma|
9990590|NCT01444560||Cutaneous Melanoma Metastases|
9990591|NCT01444560||Benign Melanocytic Nevi|
9990592|NCT01444573|Active Comparator|Group 2 (Lenient control <120bpm)|
9990593|NCT01444573|Active Comparator|Group 1 (Strict control <80 bpm)|
9990594|NCT01444586||Group 1|
9990595|NCT01444599||low FFR group (<0.8)|the patient with FFR values less than 0.8
9990596|NCT01444599||high FFR group (>0.8)|the patient with FFR values greater than 0.8
9990597|NCT01444612||Cancer-related surgery patient records|Healthcare claims records from patients aged 18 years or older with at least one primary inpatient discharge diagnosis of cancer and a cancer-related surgery during the hospitalization
9990598|NCT01444625|Experimental|Dark chocolate|Flavanol-rich chocolate
9990599|NCT01444625|Placebo Comparator|Placebo chocolate|Flavanol-free chocolate
9990600|NCT01444638|Experimental|Ultrasound|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
9990601|NCT01444638|No Intervention|Control|Control group. (Standard practice) Trainees will NOT receive pre-procedure U/S guided examination.
9990602|NCT01444664|Experimental|Aneurysm|
9990603|NCT01444677|Experimental|MB12066 300mg|single dose
9990604|NCT01444677|Active Comparator|MB12066 400mg|single dose
9990605|NCT01444677|Active Comparator|MB12066 100mg|multiple dose
9890164|NCT00593242|Other|historical control|Infants who had moderate to severe hypoxic ischemic encephalopathy in the neonatal period but did not receive autologous cord blood cells.
9890165|NCT00593281|No Intervention|1|IV Morphine
9890166|NCT00593281|Experimental|2|SC Morphine with Hylenex
9890167|NCT00593281|Active Comparator|3|SC Morphine with Saline
9890168|NCT00593294|Experimental|A,1,I|
9890169|NCT00593294|Active Comparator|B, 2, II|
9890170|NCT00593294|Placebo Comparator|C,3,III|
9890171|NCT00593307|Experimental|Low GI|low GI breakfast
9890172|NCT00593307|Experimental|Low GI -low carb|Low GI and Low carb breakfast
9890173|NCT00593307|Experimental|High GI|High GI breakfast
9890174|NCT00593307|Experimental|High GI Low Carb|high GI low carb breakfast
9890175|NCT00593359||A|Lactated Ringer's replacement for blood loss and placebo eye drops
9890176|NCT00593359||B|Lactated Ringer's replacement for blood loss and brimonidine eye drops
9890177|NCT00593359||C|Albumin replacement for blood loss and placebo eye drops;
9890178|NCT00593359||D|Albumin replacement for blood loss and brimonidine eye drops
9890179|NCT00593424|Active Comparator|1|Low Fat/High Carbohydrate
9890180|NCT00593424|Active Comparator|2|High Monounsaturated Fat/Low Carbohydrate
9890181|NCT00593437||1|diagnosed with normal bone density by Norland Excel
9890182|NCT00593437||2|diagnosed with osteopenia by Norland Excel densitometer
9890183|NCT00593437||3|diagnosed with osteoporosis by Norland Excel densitometer
9890184|NCT00593463|Experimental|1|Receives 2-4 of the interventions listed
9890185|NCT00593476|Active Comparator|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
9890186|NCT00593476|Active Comparator|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
9890187|NCT00593502|Active Comparator|1|Oseltamivir
9890188|NCT00593502|Placebo Comparator|2|Placebo
9890189|NCT00593515|Experimental|1|Family CBT
9890190|NCT00593515|Active Comparator|2|Child-focused CBT
9890191|NCT00593528|Active Comparator|A|Naked Stents
9890192|NCT00593528|Experimental|B|PTFE Covered Stents
9890193|NCT00593567|Experimental|A|Daily topical gentamicin sponge and standard daily wound care
9890194|NCT00593567|Active Comparator|B|Daily oral levofloxacin 750 mg and standard daily wound care
9890195|NCT00593580|Active Comparator|1|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
9890196|NCT00593580|Placebo Comparator|2|
9890197|NCT00593619|Active Comparator|Iron Dextran|
9890198|NCT00593619|Active Comparator|Iron Sucrose|
9890199|NCT00593632|Experimental|High Fiber Intake|Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
9890200|NCT00593658|Experimental|single|
9890201|NCT00593671|Active Comparator|PGS group|
9890202|NCT00593671|No Intervention|control group|
9890203|NCT00593697|Active Comparator|A|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 -> FE75C x3)
9890204|NCT00593697|Active Comparator|B|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
9890205|NCT00593710|Experimental|1|Losartan
9890206|NCT00593710|Active Comparator|2|Atenolol
9890207|NCT00593723|Experimental|IMRT + Concurrent chemotherapy|"180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks.~Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist."
9890208|NCT00593749|Active Comparator|HCS|Intervention group
9890209|NCT00593749|Placebo Comparator|Control|Control
9890210|NCT00593775|No Intervention|control|control group without intervention
9890211|NCT00593775|Active Comparator|AH group|assisted hatching performed on the embryo
9890212|NCT00593788||1|Normal-hearing adults between 18 and 31 years of age.
9890213|NCT00593801|Active Comparator|2: late rhEPO|late EPO treatment from the fourth week for 6 weeks
9890214|NCT00593801|No Intervention|3: no EPO|control group, no EPO treatment
9890215|NCT00593801|Active Comparator|1: early rhEPO|early rhEPO treatment from the first week until 9 weeks
9890216|NCT00593853|Active Comparator|1|
9890217|NCT00593853|Placebo Comparator|2|
9890218|NCT00593879|Placebo Comparator|1|Placebo
9890219|NCT00593879|Experimental|2|
9890220|NCT00593892||Observation|All patients who are admitted to UAB for trauma, are 19 years of age and older, and whose Injury Severity Score (ISS) is greater than 9.
9890221|NCT00593931|Experimental|A|Normal Subjects
9890222|NCT00593944|Experimental|1|Patients will receive active MDX-1342.
9890223|NCT00593970||1|All women presenting to our prenatal clinic and postpartum floor during the study period.
9890224|NCT00593983|Experimental|1|
9890225|NCT00593983|Placebo Comparator|2|Control
9890226|NCT00593996|Placebo Comparator|1|oral placebo 3 times weekly
9890227|NCT00594048|Experimental|1|15 hypertensive patients use the Resperate for 9 weeks and measure their blood pressure before and after using this device
9890228|NCT00594048|Active Comparator|2|15 patients use a discman with freely chosen music for 9 weeks and measure their blood pressure before and after use of this device
9890229|NCT00594074|Experimental|1|This group will receive 3.25 ounces of white wine with lunch and dinner
9890230|NCT00594074|No Intervention|2|This group receives the same amount of calories as the experimental group
9890231|NCT00594087|Active Comparator|1|Lunesta 2 or 3 mg
9890232|NCT00594087|Placebo Comparator|2|Placebo 2mg or 3 mg
9890233|NCT00594113|Experimental|1|Multimedia Colorectal Cancer Screening
9890234|NCT00594126|Other|1|3+3 cohort dose escalation
9890235|NCT00594139|Experimental|1|Receipt of autologous neo-bladder construct
9890236|NCT00594152|No Intervention|1Control|Standard treatment of type 1 diabetes mellitus with 3-4 subcutaneous injections of insulin daily
9890237|NCT00594152|Experimental|Treatment|Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.
9890238|NCT00594191|Placebo Comparator|A|Placebo treatment
9890239|NCT00594191|Experimental|B|
9890240|NCT00594217|Experimental|Progesterone|oral micronized progesterone suspension, single 100 mg oral dose
9890241|NCT00594217|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
9890242|NCT00594243|Experimental|Intervention|8-week mindfulness based stress reduction program
9890243|NCT00594243|Active Comparator|Wait-list control|Wait-list received no intervention during the time the treatment group received the 8-week program
9890244|NCT00594269|Placebo Comparator|A|Discontinuation of antipsychotic or antidepressants
9890245|NCT00594282|Experimental|1|Enhanced Mammography (EM) - Women who are randomized to the Enhanced Mammography (EM) condition will receive a mammogram in which a MammoPad radiolucent breast plate cushion is used.
9890246|NCT00594282|No Intervention|2|Routine Mammography (RM) - Women who are randomized to the Routine Mammography (RM) condition will obtain a routine, un-altered mammogram during which typical exam protocol will be followed and no radiolucent cushion is used.
9890247|NCT00594321|Active Comparator|2|Subjects randomized to the control arm of the study will have a standard vertebroplasty with any FDA-approved bone cement done in accordance with the usual method employed by the treating physician.
9890248|NCT00594321|Experimental|1|Subjects randomized to the experimental arm of the study will have a vertebroplasty with the SPACE CpsXL Bone cement (FDA-approved) and SPACE 360 Delivery System (FDA-approved).
9890249|NCT00594334|Experimental|E, I|
9890250|NCT00594347|Experimental|Group A|Pneumo 23
9890251|NCT00594347|Active Comparator|Group B|Prevnar
9890252|NCT00594360|Active Comparator|1|
9890253|NCT00594373|Experimental|1|Application of 1% tenofovir gel for 14 consecutive days between menses
9890254|NCT00594373|Placebo Comparator|2|Application of 1% tenofovir placebo gel for 14 consecutive days between menses
9890255|NCT00594438|Experimental|1, A|Femoral reaming with the Synthes Reamer-Irrigator-Aspirator (RIA)
9890256|NCT00594438|Active Comparator|2 B|Femoral reaming with a Zimmer Sentinel Reamer.
9890257|NCT00594451||I|multicenter Veteran Affairs Rheumatoid Arthritis (VARA) registry
9890258|NCT00594451||II|NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)
9890259|NCT00594477|Experimental|IMRT|The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
9890260|NCT00594490||Silicone|patients undergoing placement of silicone breast prosthetics
9890261|NCT00594503|Experimental|Hyperbaric oxygen therapy-TBI|Low pressure hyperbaric oxygen therapy
9890262|NCT00594529|Other|1|
9890263|NCT00594542|Experimental|0.5% lidocaine group|Group that receives 0.5% lidocaine with 1:200,000 epinephrine
9890264|NCT00594542|Experimental|1.0% lidocaine group|Group that receives 1.0% lidocaine with 1:100,000 epinephrine
9890265|NCT00594555|Experimental|Single Arm - treatment period|"Drug Name/Days Administered~Neupogen/Days 1-6~CLAG/Days 2-6~Gleevec/Days 2-15"
9890266|NCT00594581|Active Comparator|1|Juvista (avotermin) 50ng/100μl/linear cm wound margin
9890267|NCT00594581|Active Comparator|2|Juvista (avotermin) at 200ng/100μl/linear cm
9890268|NCT00594594|Experimental|1|Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
9890269|NCT00594607|Active Comparator|1: AN69ST|Hemodialysis sessions with use of the dialysis filter AN69ST.
9890270|NCT00594607|Active Comparator|2:Fx8|Hemodialysis sessions with use of the dialysis filter Fx8
9890271|NCT00594633|Experimental|1|donepezil and questionaires
9890272|NCT00594711||1|Case-group
9890273|NCT00594711||2|Control-group
9890274|NCT00594724|Experimental|1|
9890275|NCT00594763||TS|Women with Turner syndrome
9890276|NCT00594776||1|Patients who have received a structrual allograft or vascularized fibular autograft surgery to reconstruct their tibia, femur, ulna/radius or humerus for treatment of a bone tumor.
9890277|NCT00594789|Experimental|1 (physician-only)|Physician(s) connected with a fracture that meets study inclusion criteria.
9890278|NCT00594789|Experimental|2 (physician/patient)|Physician(s) and patient connected with a fracture that meets study inclusion criteria.
9890279|NCT00594789|No Intervention|Control|Usual care.
9932104|NCT00945685|Experimental|Endymion study group|
9932105|NCT00945698|Other|ST-DI (Delayed intervention)|"1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
9932106|NCT00945698|Experimental|LNS-10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
9932107|NCT00945698|Experimental|LNS-20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
9890280|NCT00594802||CHART REVIEW ONLY|CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
9890281|NCT00594828|Experimental|1|6 months of supervised patient self testing using an expert system
9890282|NCT00594828|Active Comparator|2|6 months of routine medical care by the anticoagulation management service
9890283|NCT00594841|Active Comparator|1|Conservative (nonoperative) management of the AC joint dislocation.
9890284|NCT00594841|Experimental|2|Operative fixation (i.e., ORIF) of the dislocation with a hook plate and screws.
9890285|NCT00594867|Active Comparator|1|Acetaminophen - 4 grams per day + Placebo
9890286|NCT00594867|Active Comparator|2|Aspirin - 325 mg per day + Placebo
9890287|NCT00594867|Experimental|3|Acetaminophen 4 gram per day + Aspirin 325 mg per day
9890288|NCT00594893|Active Comparator|1|Mini Incision Approach
9890289|NCT00594893|Active Comparator|2|2 Incision Approach
9890290|NCT00594919||AKI group|Acute kidney injury group after cardiac surgery.
9890291|NCT00594919||NKF group|Normal kidney function group after cardiac surgery
9890292|NCT00594971|Other|B|90 terminally ill cancer patients will be referred to a specialist palliative care team at time of discharge.
9890293|NCT00594971|Other|C|90 terminally ill cancer patients will be discharged from hospital with extra effort put into improving the communication between the hospital and the primary sector.
9890294|NCT00594971|No Intervention|A|90 terminally ill cancer patients will be discharged from hospital, receiving usual care.
9890295|NCT00595010|Experimental|Managing Child Behavior|Families with a high risk for or a history of child abuse and are enrolled in Comprehensive Home-Based Services and receive services as usual, which includes SafeCare, plus Managing Child Behavior module if they report significant behavior problems with their child between the ages of 2-12.
9890296|NCT00595023||1|All eligible subjects
9890297|NCT00595049|Experimental|bosentan|
9890298|NCT00595062|Experimental|1|
9890299|NCT00595140|No Intervention|1|patients with acromegaly on stable pegvisomant therapy
9890300|NCT00595140|Active Comparator|2|Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
9890301|NCT00595140|Active Comparator|3|Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
9890302|NCT00595166||B|Speculum Sheath group. Participants all received the speculum sheath.
9890303|NCT00595205||Group IS|Subjects <1 year of age with definite intussusception cases who had received Rotarix™.
9890304|NCT00595218|No Intervention|1|Patients whose radiation oncologist are blinded to their patient preference survey results
9890305|NCT00595218|Active Comparator|2|Patients whose radiation oncologist are not blinded to their patient preference survey results
9890306|NCT00595257|Experimental|1|injection of BMAC into ischemic limb
9890307|NCT00595257|Active Comparator|2|Injection and Infusion of BMAC into ischemic lower limb
9890308|NCT00595283|Experimental|1|Participants assigned to Parent-Child Interaction Therapy-Emotional Development
9890309|NCT00595283|Active Comparator|2|Participants assigned to Developmental Education Parenting Intervention
9890310|NCT00595296||1|All eligible patients.
9890311|NCT00595322|Experimental|1|bevacizumab and radiation (IMRT)
9890312|NCT00595387|Active Comparator|1|Participants receiving supportive psychotherapy
9890313|NCT00595387|Experimental|2|Participants receiving cognitive behavioral therapy
9890314|NCT00595543|Active Comparator|1|
9890315|NCT00595543|Active Comparator|2|
9890316|NCT00595543|Active Comparator|3|
9890317|NCT00595569||Type 1 diabetes|
9890318|NCT00595608|Active Comparator|1|Nasal Sterimar spray
9890319|NCT00595608|Active Comparator|2|Nasal saline spray
9890320|NCT00595647|Active Comparator|1|Percutaneous coronary intervention
9890321|NCT00595647|Placebo Comparator|2|Percutaneous coronary intervention
9890322|NCT00595660|Active Comparator|1|Needle 21 for FNA
9890323|NCT00595660|Active Comparator|2|22 needle for FNA
9890324|NCT00595660|Active Comparator|3|23 needle for FNA
9890325|NCT00595660|Active Comparator|4|24 needle for FNA
9890326|NCT00595686|Experimental|Single Arm|
9890327|NCT00595712|Active Comparator|A|Using Iliac crest allograft in high tibial osteotomy
9890328|NCT00595712|Active Comparator|B|Using iliac crest autograft in high tibial osteotomy
9890329|NCT00595725|Experimental|1|
9890330|NCT00595738||Heart Failure Patients|Patients admitted with advanced heart failure for tailoring of heart failure therapy via placement of a pulmonary artery (PA) catheter. In our study, the patients will already have a PA catheter placed for clinical/treatment reasons when we approach them for the study.
9890331|NCT00595777|No Intervention|1. Comparison|The centres allocated to the comparison group will continue to provide usual care only.
9890332|NCT00595777|Experimental|2. Experimental|The EPAT package consists of an educational programme, which deals with the common barriers to effective cancer pain control and the bedside pain tool.
9890333|NCT00595816|Experimental|1|Active treatment: physical training and counselling
9890334|NCT00595829|Experimental|1|
9890335|NCT00595842||Group one|Subjects are drawn from a search of all patients treated with MTA between ages 5-40
9890336|NCT00595855|Active Comparator|TE|trabeculectomy
9890337|NCT00595855|Experimental|DS|deep sclerectomy
9890338|NCT00595894||1|CLEAR enrollees include African American patients with early rheumatoid arthritis, as defined using ACR criteria
9890339|NCT00595894||2|VARA enrollees will include male veterans with established RA diagnosed using ACR criteria
9890340|NCT00595933|Experimental|1|Each participant will receive an unidentified product to use for a one week period. This will continue until all 7 dry-mouth products have been evaluated.
9890341|NCT00595972|Experimental|A|patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar
9890342|NCT00595985|Experimental|A|administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent
9890343|NCT00595998||1|newly onset CNV secondary to AMD
9890344|NCT00595998||2|Intermediate AMD
9890345|NCT00596024|Experimental|1|Daily Lutein/zeaxanthin supplementation with a meal
9890346|NCT00596024|Placebo Comparator|2|
9890347|NCT00596037|Experimental|LB03002 throughout|administered LB03002 for preceding 26 weeks
9890348|NCT00596037|Experimental|Switched to LB03002|administered placebo for preceding 26 weeks
9890349|NCT00596050|Active Comparator|ketamine and midazolam|ketamine and midazolam
9890350|NCT00596050|Active Comparator|etomidate and fentanyl and lidocaine|etomidate and fentanyl and lidocaine
9890351|NCT00596063|Experimental|Wosulin R|Regular insulin for subcutaneous injection (recombinant human insulin), 600nmol, 100 IU
9890352|NCT00596063|Active Comparator|Novolin R|Regular insulin for injection (recombinant human insulin)
9890353|NCT00596076|Experimental|1|Workers with low back pain
9890354|NCT00596089||1|Men and women 60 years and older
9890355|NCT00596089||2|Men and women 20-30 years of age
9890356|NCT00596128|No Intervention|1|Blood sugar monitoring and intervention as clinical routine, no SOP defined and implemented
9890357|NCT00596128|Experimental|2|Blood sugar monitoring after implementation of SOP
9890358|NCT00596141|Experimental|1|Conventional postoperative care and instructions on dental hygiene will be provided along with the TOWE treatment which consists of the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site 3 times daily for a period of 7 days. At three (3) days and seven (7) days postoperatively, photographs will be taken of all vertical releasing incisions (before suture removal).
9890359|NCT00596141|No Intervention|2|Conventional postoperative care and instructions on dental hygiene.
9890360|NCT00596154|Experimental|1|Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.
9890361|NCT00596180||1|HBOT
9890362|NCT00596193||Group I|patients with normal or irreversible pulpitis teeth with capsaicin administered at increasing volumes.
9890363|NCT00596193||Group II|Patients with normal teeth only with capsaicin added at a specific volume only
9890364|NCT00596206|Experimental|1|100 mg of leflunomide
9890365|NCT00596206|Active Comparator|2|20 mg of leflunomide
9890366|NCT00596219|Experimental|1|
9890367|NCT00596232||Asthma|People who have been diagnosed with Asthma
9890368|NCT00596232||Cystic Fibrosis|People who have been diagnosed with Cystic Fibrosis
9890369|NCT00596232||Healthy|People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
9890370|NCT00596245|Experimental|1|MT 400, naproxen sodium 550mg
9890371|NCT00596258|Experimental|A-007|Single arm open label
9890372|NCT00596284|Experimental|CBT-AD|Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
9890373|NCT00596284|Active Comparator|EUC|EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop.
9890374|NCT00596297|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
9890375|NCT00596297|Active Comparator|B|Pars plana vitrectomy only
9890376|NCT00596310|Experimental|1|Screening CT
9890377|NCT00596336|Active Comparator|Group A CLL patients|Vaccination with current trispecific influenza vaccine Day 1
9890378|NCT00596336|Experimental|Group B CLL patients|Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
9890379|NCT00596336|Active Comparator|Group C volunteers|Vaccination with current trispecific influenza vaccine Day 1
9890380|NCT00596349||A|epithelial ovarian cancer survivors (women disease-free at 5 to 10 years from diagnosis of ovarian cancer)
9890381|NCT00596349||B|women in second- or greater remission (women who have had one or more relapses from ovarian cancer but are considered to be currently clinically disease-free 5 to 10 years from original diagnosis of ovarian cancer).
9890382|NCT00596349||C|women surviving with epithelial ovarian cancer (women alive with disease 5 to 10 years from original diagnosis of ovarian cancer)
9890383|NCT00596375|No Intervention|Routine Care Group|The routine care group will help us to quantify the routine amount of distress associated with catheterization.
9890384|NCT00596375|Experimental|Lidocaine Group|A experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention.
9890385|NCT00596375|Experimental|Instillation|This group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress.
9890386|NCT00596388||1|Subjects diagnosed as intermediate AMD
9890387|NCT00596414|Placebo Comparator|1|
9890388|NCT00596414|Experimental|2|midazolam
9890389|NCT00596414|Experimental|3|midazolam + pethidine
9890390|NCT00596492|Active Comparator|High Dose|
9890391|NCT00596492|Active Comparator|Low Dose|
9890392|NCT00596505||1|Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
9890393|NCT00596505||2|Group 2 will not receive bevacizumab pretreatment
9890394|NCT00596518|Experimental|PF-00734200|
9890395|NCT00596531|Active Comparator|A|"Subjects will take acamprosate (Campral) at a dose of 666 mg. three times daily (morning, lunch time, bed time) for 28 days. Only responders will be included in the subsequent double-blind cross over arms after a minimum washout period of 4 weeks.~Subjects will randomly be assigned to Group 1 (A/B) or Group 2 (B/A) after completion of Phase I and its subsequent washout period (Figure 1, periods 1 and 2). Group 1 will receive acamprosate (Campral) at a dose of 666 mg. three times daily for 24 weeks followed by a 4-week washout period"
9890396|NCT00596531|Placebo Comparator|B|Group 2 will be assigned to the placebo group and take matched placebos for next 24 weeks followed by a 4-week washout period. After the washout period each group will be assigned to the other intervention (acamprosate or placebo) and complete another trial for 24 weeks.
9890397|NCT00596544||1|FSFI score <= 26
9890398|NCT00596544||2|FSFI score >26
9890399|NCT00596557|Experimental|Everolimus, Immunosupression|everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
9890400|NCT00596570||1|Patient with atrial fibrillation who underwent PCI
9890401|NCT00596583|Active Comparator|High Dose|
9890402|NCT00596583|Active Comparator|Low Dose|
9890403|NCT00596596|Active Comparator|1|0,5 mg prucalopride
9890404|NCT00596596|Active Comparator|2|1 mg prucalopride
9890405|NCT00596596|Active Comparator|3|2 mg prucalopride
9890406|NCT00596596|Placebo Comparator|5|Placebo arm
9890407|NCT00596596|Active Comparator|4|4 mg prucalopride
9890408|NCT00596609||1|Group 1 will be subjects who receive Intrathecal Morphine.
9890409|NCT00596609||2|Group 2 will be subjects who do not receive Intrathecal Morphine.
9890410|NCT00596648|Experimental|Phase 1 Arm|Escalating doses of XL184 + erlotinib
9890411|NCT00596648|Experimental|Phase 2 Arm 1|XL184 + erlotinib (dose determined from Phase 1 portion of study)
9890412|NCT00596648|Experimental|Phase 2 Arm 2|XL184 administered as a single agent
9890413|NCT00596661|Experimental|TRIMAXX|TRIMAXX Coronary Stent
9890414|NCT00596674|Experimental|Lifestyle Counts Intervention|A wellness intervention that includes 8 weeks of behavior change classes focused on acquiring the skills and knowledge to improve health behaviors (e.g., exercise, stress management), followed by 3 months of phone support.
9890415|NCT00596674|Placebo Comparator|Attention Countrol|8 weeks of general health classes followed by phone calls for 3 months
9890416|NCT00596700|Experimental|Device|"Patient preparation procedure will be done according to chapter 4 in the Given Diagnostic System user manual. In brief: to drink only clear liquids beginning 12:00 noon the day before.at least 8 hours (since 12:00 PM) fast prior to the procedure. Patient will undergo a standard capsule endoscopy. Patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion.~Eight hours post ingestion, data recorder will be removed and the patient will be dismissed.~A local experienced reader will review the RAPID video to determine the diagnosis blinded to the results of the standard workup procedures, and to each other results. Results will be recorded in the case report forms. A decoded video will be transferred to the principal investigator for reevaluation"
9890417|NCT00596713||1|Both genders aged 20 to 80 years and living in private households in the city of São Paulo. Pregnant or lactating women, people with physical or mental impairment and workers in night shifts are not part of the population of interest.
9890418|NCT00596765|Experimental|1|Neuropsychological cognitive behavioral psychotherapy for patients with acquired brain injury consists of 25 weekly 1-hr sessions of individualized outpatient treatment. The therapeutical intervention is modularised, patients are assigned to specific interventional modules according to the results of cognitive testing and interviews. Modules concern on the one hand the treatment of deficits in attention, memory, and executive functions. On the other hand psychosocial adjustment to chronic illness is addressed through modules that concern the development of a positive self-concept, the adjustment of life-goals and coping with negative affect (e.g. depressive symptoms, irritability, guilt).
9990606|NCT01444677|Active Comparator|MB12066 200mg|multiple dose
9990607|NCT01444677|Placebo Comparator|Placebo|Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
9890419|NCT00596765|Other|2|"Waiting list: Patients are randomly assigned to one of two existing groups after completion of the first session of various neuropsychological tests and interviews.~Patients assigned to the experimental group receive therapy immediately after completing the first session of various neuropsychological tests and interviews. Patients randomized to the waiting list receive the treatment as specified above after waiting for 5 month."
9890420|NCT00596778|Other|C, CP|Thirty-one adults were randomly assigned to control (C) and chest physiotherapy (CP) groups. Chest physiotherapy group received treatment at the post-anesthesia unit care and control group did not.
9890421|NCT00596791|Other|1 arm|Open-lable study with one arm.
9890422|NCT00596843|Experimental|1|Motivational intervention
9890423|NCT00596843|Active Comparator|2|Educational intervention
9890424|NCT00596856|Active Comparator|1|25 randomly selected pediatric practices that have never participated in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to non-participating practices)
9890425|NCT00596856|Experimental|2|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to participating practices)
9890426|NCT00596856|Experimental|3|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through an intense in-office intervention. (Intense intervention with participating practices)
9890427|NCT00596882|Other|1|Threat only message. Participants hear information about the negative health consequences of smoking
9890428|NCT00596882|Other|2|Genetic threat + threat. Participants will bear infomration about genetic influences of smoking in additon to the negative health consequences of smoking.
9932108|NCT00945698|Experimental|LNS-20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
9932109|NCT00945698|Experimental|LNS-40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
9932110|NCT00945698|Experimental|LNS-40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
9932111|NCT00945711||1|Eating Disorder Diabetes Mellitus T1 patients
9932112|NCT00945711||2|Eating Disorder only patients
9932113|NCT00945724|Experimental|R-CHOP, Depocyte, Methotrexate|
9932114|NCT00945737|Active Comparator|Soy protein|
9932115|NCT00945737|Placebo Comparator|Milk protein|
9932116|NCT00945776|Active Comparator|Weekly phone calls|Will be called weekly to answer questions regarding usage.
9932117|NCT00945776|Active Comparator|Frequently asked questions|Providing written general answers to commonly asked questions.
9932118|NCT00945776|Active Comparator|Usual care|
9932119|NCT00945789|Experimental|EPO HIE Group|Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
9932120|NCT00945789|No Intervention|Control HIE|Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
9932121|NCT00945789|Other|Healthy Controls|Healthy newborn without hypoxic ischemic encephalopathy
9932122|NCT00945828|Experimental|Annual Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
9932123|NCT00945828|Experimental|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
9932124|NCT00945841|Other|1|
9932125|NCT00945880|Experimental|Experimental Group|clemizole hydrochloride, 100mg, BID
9932126|NCT00945932|Experimental|28 day repeat dose|
9932127|NCT00945971|Experimental|Physical activity|The intervention group will participate in an exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be performed at the start and in the end of this study.
9932128|NCT00945984||LESS|Patients who underwent LESS radical nephrectomy
9932129|NCT00945984||Conventional laparoscopy|Patients who underwent conventional laparoscopic radical nephrectomy
9932130|NCT00945997|Active Comparator|A|
9932131|NCT00945997|Active Comparator|B|
9932132|NCT00946010||1|Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan
9932133|NCT00946049|Experimental|Vicryl Plus|
9932134|NCT00946049|Active Comparator|Vicryl|
9932135|NCT00946062|Active Comparator|regular O&M-training|orientation and mobility training in use of the identification cane as provided by mobility trainers
9932136|NCT00946062|Experimental|standardised O&M-training|standardised orientation and mobility training in use of the identification cane as provided by mobility trainers who received instruction in using the standardised protocol
9932137|NCT00946127||Shunt Arm|Ventriculoperitoneal Shunt
9932138|NCT00946127||ETV arm|Endoscopic Third Ventriculostomy
9932139|NCT00946140||Patients with ovarian cancer currently undergoing treatment|All of the patients will be treated per their treatment protocols by their physicians and they will be referred to this study for the DCE-MRI scans at baseline, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
9932140|NCT00946166|Placebo Comparator|Placebo Control|Subjects receive standard treatment for pneumonia and a simvastatin-like placebo
9932141|NCT00946166|Experimental|Simvastatin|Subjects receive simvastatin in addition to standard pneumonia treatment
9932142|NCT00946179|Experimental|Group 1|Participants aged 18 to 60 years at enrollment
9932143|NCT00946179|Experimental|Group 2|Participants aged 61 years or older at enrollment
9890429|NCT00596895|Experimental|1|Isoflavone treatment
9890430|NCT00596908||1|Subjects with Parkinsonian Tremor (PT)
9890431|NCT00596908||2|Subjects with non Parkinsonian Tremor (nPT)
9890432|NCT00596973|Experimental|Ileal transposition with SG|Procedure: Surgical Treatment
9890433|NCT00596986|Active Comparator|AD|Antidepressant Duloxetine
9890434|NCT00596986|Active Comparator|PT|Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
9890435|NCT00596999||1|all subjects will be treated with UCB and HPDSC
9890436|NCT00597025|Active Comparator|Group A|Center Hemodialysis patients
9890437|NCT00597025|Active Comparator|Group B|Center hemodialysis patients
9890438|NCT00597025|No Intervention|Group C|Center Hemodialysis Patients
9890439|NCT00597025|Active Comparator|Group D|Peritoneal dialysis patients
9890440|NCT00597025|No Intervention|Group E|Peritoneal dialysis patients
9890441|NCT00597077|Active Comparator|Rate control|
9890442|NCT00597077|Active Comparator|Rhythm control|
9890443|NCT00597090||1|
9890444|NCT00597103||1|Prevalent patients who have been receiving more frequent dialysis.
9890445|NCT00597103||2|Incident patients new to more frequent dialysis
9890446|NCT00597103||3|Patients who switch from one more frequent hemodialysis treatment regimen to another more frequent dialysis regimen.
9890447|NCT00597129|Experimental|Multi Dose levels|different doses of 90YhPAM4 will be given only once.
9890448|NCT00597142|Experimental|1|
9890449|NCT00597181|Active Comparator|1|Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
9890450|NCT00597181|Active Comparator|2|Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes
9890451|NCT00597194|Active Comparator|OH|Inguinal hernia operated using a classic open herniotomy(OH)
9890452|NCT00597194|Active Comparator|LH|Laparoscopic herniorraphy (LH) for inguinal hernia
9890453|NCT00597220|Experimental|1|Omega 3
9890454|NCT00597220|Placebo Comparator|2|
9890455|NCT00597259|Experimental|A|
9890456|NCT00597259|Active Comparator|B|Entecavir Alone
9890457|NCT00597298|Active Comparator|1|inspiratory muscle training program using a pressure threshold device
9890458|NCT00597298|Sham Comparator|2|
9890459|NCT00597311|Experimental|1|preoperative short term radiation group 5x5 Gy and surgery after 6 weeks
9890460|NCT00597311|Experimental|2|preoperative chemoradiotherapy group 50Gy + 5FU/Lv and surgery after 6 weeks.
9890461|NCT00597324|Active Comparator|1|Patients with normal Allen's test
9890462|NCT00597324|Experimental|2|Patients with intermediate Allen's test
9890463|NCT00597324|Experimental|3|Patients with abnormal Allen's test
9890464|NCT00597337|Experimental|1|Receiving FearNot
9890465|NCT00597337|No Intervention|2|Control: Treatment as usual (normal curriculum)
9890466|NCT00597350||1|Group with diabetes mellitus
9890467|NCT00597363|Experimental|1|Neptune PAD utilization to accelerate closure of the vascular access site
9890468|NCT00597363|Active Comparator|2|manual compression for closure of the vascular access site
9890469|NCT00597389|Active Comparator|1|oral solution of propranolol (propranolol HCL 20 mg/5 ml solution) or a liquid placebo twice daily for 10 days (and taper for 5 days; based on Pitman et al, 2002). Dose was calculated as determined by Famularo et al. (1988) to be 2.5 mg/kg/d with a maximum dose of 40 mg bid (Green, 2001).
9890470|NCT00597389|Placebo Comparator|2|A 25/5ml solution of placebo (a sugar solution that looks and tastes like the propranolol solution)
9890471|NCT00597415|Placebo Comparator|A 1|A 1=placebo
9890472|NCT00597415|Active Comparator|A 2|A 2=celecoxib
9890473|NCT00597454|Experimental|1|
9890474|NCT00597467|Experimental|Test Contact Lenses|VISA (comfilcon A) Silicone Hydrogel Soft contact lens
9890475|NCT00597467|Active Comparator|Control Contact Lenses|Acuvue 2 Soft Contact Lens
9890476|NCT00597480|Active Comparator|1|the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
9890477|NCT00597480|Active Comparator|2|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
9890478|NCT00597532|Experimental|1|soy (soy protein supplementation 50 grams/day)
9890479|NCT00597532|Placebo Comparator|2|milk protein supplementation 50 grams/day
9890480|NCT00597597|Experimental|A|Open label; all subjects receive active drug, Erlotinib
9890481|NCT00597610|Experimental|1|
9890482|NCT00597623|Experimental|1|2 injections of Adalimumab (Humira®)
9890483|NCT00597623|Placebo Comparator|2|2 injection of Placebo
9890484|NCT00597636||1|NEVER SMOKERS WITH LUNG CANCER
9890485|NCT00597636||2|NEVER SMOKERS WITHOUT ANY CANCER
9890486|NCT00597649|Experimental|1|Bicifadine 800 mg/day for a year
9890487|NCT00597649|Experimental|2|Bicifadine 1200 mg/day for a year
9890488|NCT00597662|Experimental|1|
9890489|NCT00597662|Active Comparator|2|
9890490|NCT00597688|Active Comparator|1|Chlorhexidine gel
9890491|NCT00597688|Placebo Comparator|2|Placebo gel
9890492|NCT00597779|Active Comparator|EM device|Extramedullary Device (EM)
9890493|NCT00597779|Active Comparator|IM device|Intramedullary Device (IM)
9890494|NCT00597792|Active Comparator|A|Active Plicator Treatment
9890495|NCT00597831||A|All patients in the Rijnstate Hospital with an indication for unilateral ECT treatment and a major depression or psychotic depression according to DSM IV-TR criteria.
9890496|NCT00597844|Experimental|1|voice evaluation and fMRI prior to surgical rehabilitation of UVCP
9890497|NCT00597844|Other|2|Healthy volunteers-voice evaluation and fMRI
9890498|NCT00597857|Placebo Comparator|1|receipt of a placebo pill for 16 days
9890499|NCT00597857|Active Comparator|2|oral pill of hydrocortisone (ranging from 20mg - 2.5mg) taken for 10 days with a taper for 6 days (based on Pitman et al, 2002).
9890500|NCT00597870|Experimental|Treatment of Thoracic Lesions|Endoluminal treatment of thoracic lesions
9890501|NCT00597922||1|2,000 women between the ages of 18 and 55 years who are hospitalized with a heart attack
9890502|NCT00597922||2|1,000 men between the ages of 18 and 55 years who are hospitalized with a heart attack
9890503|NCT00597948|Experimental|1|Workshop Group: Receives Healthy Lifestyles curriculum and subsequent support.
9890504|NCT00597948|No Intervention|2|Comparison Group: Does not receive Healthy Lifestyles curriculum and subsequent support.
9890505|NCT00597974||Patients having angioplasty (case)|Patients undergoing carotid artery angioplasty and/or stent-supported angioplasty for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
9890506|NCT00597974||Patients having angiography (control)|Patients undergoing coronary angiography for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
9890507|NCT00597987||1|RNA samples
9890508|NCT00598000||1|Determine the impact, in terms of quality of life (QOL), of minimally invasive, video-assisted thoracic surgery (VATS)
9890509|NCT00598000||2|Determine the impact, in terms of quality of life (QOL), in traditional thoracotomy and anatomic lung resection in early stage lung cancer.
9890510|NCT00598013|Experimental|1|
9890511|NCT00598013|No Intervention|2|
9890512|NCT00598026|Experimental|1|Tele- follow-up: remote transmission to the implantation centre every 3 months
9890513|NCT00598026|Active Comparator|2|Conventional follow-up: visits at the implantation centre every 3 months
9890514|NCT00598052|Active Comparator|A|Escitalopram + cognitive-behavior treatment
9890515|NCT00598052|Placebo Comparator|B|Placebo + cognitive-behavior therapy
9890516|NCT00598091|Active Comparator|A|
9890517|NCT00598091|Active Comparator|B|
9890518|NCT00598104|Experimental|1|
9890519|NCT00598104|Placebo Comparator|2|
9890520|NCT00598117||1|Group 1 (newly diagnosed patients) Initial assessment → first post op visit → 6 and 12 months post surgery
9890521|NCT00598117||2|Group 2 (post-treatment patients) A one-time assessment will be conducted at least 18 months following treatment
9890522|NCT00598130|Experimental|I|patients who will be treated in accordance with standard of care
9890523|NCT00598130|Active Comparator|II|patients for which the Fibrin Fleece will be applied directly on the active bleeding site.
9890524|NCT00598143||Group A|Ten healthy smokers will provide a saliva sample used to genotype UGT1A7 and complete a questionnaire to assess understanding of and willingness to participate in molecular risk assessments.
9890525|NCT00598143||Group B|Thirty smokers will receive standard smoking cessation therapy and provide urine specimens for PGE-M analysis at approximate 3-monthly intervals over one year. Self-reported smoking status and expired-air carbon monoxide (CO) will also be recorded at 3-monthly clinic visits.
9890526|NCT00598156|Experimental|1|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
9890527|NCT00598156|Experimental|2|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
9890528|NCT00598169|Experimental|CD20+ Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, rituximab 375mg/m2 on Day 1 of a 21-day cycle."
9890529|NCT00598169|Experimental|CD20- Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, 21-day cycle."
9890530|NCT00598195|No Intervention|Ketamine Pharmacokinetics|The pharmacokinetic action of Ketamine used in Children having heart surgery.
9890531|NCT00598234|Active Comparator|1|Celecoxib (Celebrex)
9890532|NCT00598234|Placebo Comparator|2|Placebo
9890533|NCT00598247|Experimental|A|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks. A
9890534|NCT00598260|Experimental|1- study group|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
9890535|NCT00598260|No Intervention|2 - control group|control group
9890536|NCT00598299||A|Healthy adult serum
9890537|NCT00598299||B|cord blood serum
9890538|NCT00598325|Experimental|NicVAX|
9932144|NCT00946205|Experimental|Laparoscopic anterior mesh rectopexy|
9890539|NCT00598325|Experimental|NicVAX Lot 2|2nd cohort receives a different lot of vaccine from the 1st cohort
9890540|NCT00598338|Active Comparator|1|Prucalopride
9890541|NCT00598338|Placebo Comparator|2|Placebo
9890542|NCT00598364||Thyroidectomy or neck dissection|Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent thyroidectomy and/or neck dissection as standard of care.
9890543|NCT00598377|Active Comparator|1|Patients with autosomal dominant polycystic kidney disease
9890544|NCT00598377|Active Comparator|2|Healthy subjects
9890545|NCT00598403|Experimental|1|Cefditoren pivoxil
9890546|NCT00598403|Active Comparator|2|Ciprofloxacin
9890547|NCT00598416|Experimental|Psychoeducation|
9890548|NCT00598429|Active Comparator|High dose|PGE1 300 ng/kg/min via nebulizer over a 72-hour period
9890549|NCT00598429|Active Comparator|Low dose|PGE1 150 ng/kg/min via nebulizer over a 72-hour period
9890550|NCT00598429|Placebo Comparator|Placebo|Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
9890551|NCT00598533|Experimental|Dual-DES|Rapamycin + Probucol-eluting stent
9890552|NCT00598533|Active Comparator|ZES|Polymer based Zotarolimus-eluting stent
9890553|NCT00598546||1|
9890554|NCT00598572|Experimental|1|All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
9890555|NCT00598611|Active Comparator|1|desloratadine 20 mg
9890556|NCT00598611|Active Comparator|2|desloratadine 20 mg
9890557|NCT00598624|Experimental|A|
9890558|NCT00598637|Active Comparator|EES|Everolimus-eluting stent (Xience)
9890559|NCT00598637|Experimental|ZES|Zotarolimus-eluting stent (Endeavor Resolute)
9890560|NCT00598676|Experimental|BPRES|biodegradable polymer rapamycin-eluting stent
9890561|NCT00598676|Active Comparator|PPRES|permanent polymer rapamycin-eluting stent
9890562|NCT00598676|Active Comparator|PPEES|permanent polymer everolimus-eluting stent
9890563|NCT00598715|Experimental|Same drug|sirolimus-eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
9890564|NCT00598715|Active Comparator|Different drug|paclitaxel eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
9890565|NCT00598728||1|Hodgkin lymphoma Survivors
9890566|NCT00598741|Experimental|1|
9890567|NCT00598780||1|Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
9890568|NCT00598845||Consecutive numbers|Patients with endometrial cancer
9890569|NCT00598858|Experimental|Treatment (docetaxel and prednisone)|Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9932145|NCT00946205|Active Comparator|Laparoscopic posterior rectopexy|
9932146|NCT00946218||Part A|Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
9932147|NCT00946218||Part B|Children with definitive dengue infection enrolled for gene expression analysis.
9932148|NCT00946231||Heart Failure|Subjects admitted to the hospital with decompensated heart failure.
9932149|NCT00946244||Term infants|Healthy term infants
9990608|NCT01444690|Experimental|Active|Dimiracetam 400 mg capsules
9890570|NCT00598884|Experimental|6-week delay start|This group begins treatment 6 weeks after recruitment and baseline.
9890571|NCT00598884|Experimental|No delay start|This group begins treatment after enrollment and assessment with no wait period.
9890572|NCT00598897|Experimental|clarithromycin and rifabutin/rifampin|Clarithromycin and rifabutin/rifampin with ethambutol given three times weekly.
9890573|NCT00598910|Experimental|A|
9890574|NCT00598910|Placebo Comparator|B|
9890575|NCT00598923|Experimental|1|Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
9890576|NCT00598923|Experimental|2|topiramate for 3 months after loading dose of phenytoin
9890577|NCT00598923|Placebo Comparator|3|Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
9890578|NCT00598936||Cardiac Surgery or Hospitalization|"Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours."
9890579|NCT00598962|Experimental|azithromycin and rifabutin/rifampin|Azithromycin and rifabutin/rifampin administered three times weekly.
9890580|NCT00598988|Experimental|A|Traditional Chinese acupuncture in conjunction with standard medical care
9890581|NCT00598988|Active Comparator|B|standard medical care
9890582|NCT00599001|Experimental|Escalating Dose of SD-101|
9890583|NCT00599001|Placebo Comparator|Placebo|
9890584|NCT00599040|Active Comparator|Weight loss|Weight loss diet focused on the DASH diet
9890585|NCT00599040|Active Comparator|DASH diet|The DASH diet without weight loss
9890586|NCT00599040|Active Comparator|Diary|Dairy Intervention
9890587|NCT00599066||Study cases|Application of a second M-Entropy probe on the forehead of the patient; at the end the patient will have 2 probes on the forehead, one in the right and one in the left.
9890588|NCT00599079|Experimental|Azithromycin|Azithromycin combined with 2 other drugs given 3 times weekly for MAc lung disease
9890589|NCT00599118||atrial fibrillation|Atrial fibrillation
9890590|NCT00599118||Control|Control subjects with no atrial fibrillation
9890591|NCT00599144|Experimental|1|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
9890592|NCT00599144|Experimental|2|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
9890593|NCT00599144|No Intervention|3|Group3: control group without any local anesthetic use.
9890594|NCT00599183|Other|1|Participants will receive baseline conventional MRI of the cervical spine as part of their clinical care with an additional diffusion tensor imaging (DTI)sequence as part of the research; they will complete an anonymized questionnaire about their condition. Participants will receive an MRI with DTI and tractography as part of the research and will complete an anonymized questionnaire about their condition. The baseline and follow up data will be compared.
9890595|NCT00599209|Experimental|A - coded unit ID|Nursing home units provided the CDS intervention
9890596|NCT00599209|No Intervention|B - coded unit ID|Nursing home units not provided the CDS intervention
9890597|NCT00599222|Active Comparator|TTT|TTT is given every three months
9890598|NCT00599222|Sham Comparator|Sham TTT|Sham TTT is given every three months
9890599|NCT00599235|Experimental|1|
9890600|NCT00599235|Active Comparator|2|
9890601|NCT00599261|Experimental|1|Removal of the fibrotic pocket surrounding the generator and leads
9890602|NCT00599261|Experimental|2|Tissue is not removed
9890603|NCT00599274||A|This group was treated with Avonex once a week
9890604|NCT00599274||B|This group was treated with Rebif three times a week
9890605|NCT00599287|No Intervention|1|No intervention
9890606|NCT00599287|Experimental|2|Methylphenidate
9890607|NCT00599287|Experimental|3|Rivastigmine
10212000|NCT03208855|Experimental|CBT-I|Participants will receive 8 1-hour sessions of group Cognitive Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
10212001|NCT03208855|No Intervention|Treatment as Usual|Participants will receive treatment as usual for substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
10212002|NCT03194269|Experimental|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
9890608|NCT00599287|Experimental|4|Haloperidol
9890609|NCT00599352|Experimental|1|Magnesium infusion
9932150|NCT00946244||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth
9932151|NCT00946244||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in previous study)
9932152|NCT00946244||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in previous study)
9932153|NCT00946257|Experimental|Cohort 1|0.3 mg dose
10212003|NCT03188705|Experimental|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
10212004|NCT03179436|Experimental|Escalation: Dose Level (DL) 1 Quavonlimab + Pembro: Cohort 1|On Cycle 1, Day 1 of the Dose Escalation Phase, advanced solid tumor participants receive a single monotherapy dose lead-in with quavonlimab at dose level 1 (DL1). On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL1 in combination with pembrolizumab (pembro) at pembrolizumab dose level 1 (PDL1) according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
9890610|NCT00599365|Experimental|Pharmacy Care arm|"The pharmacist:~will take all the patient's medication bottles, and give medication boxes filled with medications in the order the patient should take them in.~will need to obtain a complete list of medications.~will teach the patient about the medications.~will provide a medication schedule, and other papers about the medications.~will count the pills in the medication boxes.~will review all the medications with the patient and answer any question.~will check to see if the medication is working for the patient.~will work with the patient's kidney doctor to adjust medications if needed.~will give the medication boxes filled with medications to take home."
9890611|NCT00599365|No Intervention|Control|"The pharmacist:~will obtain a complete list of medications.~will count the pills in the patients' medication bottles.~will inform patients to take their medications from these bottles."
9890612|NCT00599378|Experimental|1|Implementation Intentions-based telephone counseling. Partnership intervention between rural Primary Care Physicians, their patients, and CRC Information Specialists using an implementation intentions based approach.
9890613|NCT00599378|No Intervention|2|Healthy Living information on Physical Activity and Nutrition
9890614|NCT00599391|Other|1|Far Infrared Radiation
9890615|NCT00599417|Experimental|1|
9890616|NCT00599417|Placebo Comparator|2|
9890617|NCT00599430|Placebo Comparator|1|Placebo
9890618|NCT00599430|Active Comparator|Active 1|One probiotic strain
9890619|NCT00599430|Active Comparator|Active 2|Blend of two strains
9890620|NCT00599443|Experimental|1|
9890621|NCT00599443|Placebo Comparator|2|
9890622|NCT00599456|Experimental|1|Omega 3 vitamin supplements
9890623|NCT00599456|Placebo Comparator|2|Placebo capsule
9890624|NCT00599469|Other|1|Far Infrared Radiation
9890625|NCT00599482|Other|1|Far Infrared Radiation
9890626|NCT00599508|Active Comparator|grape juice active intervention|Concord grape juice administered daily for 12 or 16 weeks
9890627|NCT00599508|Placebo Comparator|juice placebo|berry placebo juice administered daily for 12 or 16 weeks
9890628|NCT00599508|Active Comparator|blueberry juice active intervention|wild blueberry juice administered daily for 12 weeks
9890629|NCT00599508|Active Comparator|blueberry powder intervention|whole fruit blueberry powder administered daily for 16 weeks
9890630|NCT00599508|Placebo Comparator|powder placebo|placebo powder administered daily for 16 weeks
9890631|NCT00599534|Active Comparator|1|4 mg tablet for 16 weeks
9890632|NCT00599534|Placebo Comparator|2|5 mg for 16 weeks
9890633|NCT00599547|Experimental|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
9890634|NCT00599560|Experimental|1. Meniere's disease|Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
9890635|NCT00599560|No Intervention|2. Acoustic neurinoma|Diagnosed by CT and/or MRI
9890636|NCT00599573|Experimental|1|Ondansetron
9890637|NCT00599586|Experimental|group 1|specific acupoints of Shaoyang meridians
9890638|NCT00599586|Experimental|Group 2|Non-specific acupoints of Shaoyang meridians
9890639|NCT00599586|Experimental|group 3|Acupoints of other meridians
9890640|NCT00599586|Sham Comparator|group 4|Non-acupoints
9890641|NCT00599599|Experimental|1|Prolonged Exposure Therapy.
9890642|NCT00599599|No Intervention|2|Weekly monitoring/Waitlist Control Group.
9890643|NCT00599612|Experimental|Healthy male volunteers|Six healthy male volunteers aged between 30-60 years old will be recruited for this study,
9890644|NCT00599625|Experimental|1|Patients with active Crohn's Disease
9890645|NCT00599651|Experimental|1|Surfactant by LMA
9890646|NCT00599651|Other|2|Standard of care
9890647|NCT00599664|Experimental|1|Drug
9890648|NCT00599664|Placebo Comparator|2|Vehicle
9890649|NCT00599677|Experimental|group 1|specific acupoints of Stomach meridians
9890650|NCT00599677|Experimental|group 2|Non-specific acupoints of Stomach meridians
9890651|NCT00599677|Experimental|group 3|alarm and transport points
9890652|NCT00599677|Experimental|group 4|acupoints of the other meridian
9890653|NCT00599677|Sham Comparator|group 5|non-acupoints
9890654|NCT00599677|Active Comparator|group 6|Itopride
9932154|NCT00946257|Experimental|Cohort 2|0.6 mg dose
9797394|NCT01594749|Active Comparator|Control Regimen|On Day 1, participants received fosaprepitant placebo, 150 mL IV infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 20 mg, PO ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy; followed by 8 mg PO, 8 hours after the first dose. On Days 2-3, participants received ondansetron 8 mg, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
9797395|NCT01594762|Placebo Comparator|Topical placebo control|Drug: Topical placebo cream
9797396|NCT01594762|Experimental|Topical pexiganan cream 0.8%|Drug: Topical pexiganan cream 0.8%
9797397|NCT01594827|Experimental|Inhaled Vanc and Oral Abx|In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
9797398|NCT01594827|Active Comparator|Inhaled Placebo and Oral Abx|In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
9797399|NCT01594853|Experimental|exercise|Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
9797400|NCT01594931|Experimental|pyronaridine/artesunate (6:2 mg/kg)|pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg
9797401|NCT01594931|Experimental|pyronaridine/artesunate (9:3 mg/kg)|pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg
9797402|NCT01594931|Experimental|pyronaridine/artesunate (12:4 mg/kg)|pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg
9797403|NCT01594970|Experimental|Bimatoprost 0.01% (Naive Monotherapy)|1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
9797404|NCT01594970|Experimental|Bimatoprost 0.01% (Switched Monotherapy)|1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
9797405|NCT01594970|Experimental|Bimatoprost 0.01% (with Adjunctive Therapy)|1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.
9797406|NCT01595282|Experimental|Ketorolac|Intramuscular injection of ketorolac 60 mg in 2cc -plus- placebo tablet (calcium carbonate 600 mg tablet). For subjects who are 50 kg or less, intramuscular injection of ketorolac 30 mg in 1cc -plus- placebo tablet (calcium carbonate 600 mg tablet)
9797407|NCT01595282|Active Comparator|Ibuprofen|Ibuprofen 800 mg tablet -plus- intramuscular injection of 2cc saline placebo. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet -plus- intramuscular injection of 2cc saline placebo
9797408|NCT01595386|Placebo Comparator|Normal Saline|The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
9797409|NCT01595386|Experimental|Hydrocortisone|Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
9797410|NCT01595438|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
9797411|NCT01595438|Active Comparator|Doripenem|IV treatment
9797412|NCT01595516|Active Comparator|Nebivolol|
9797413|NCT01595516|Active Comparator|Metoprolol|
9797414|NCT01595516|Placebo Comparator|Placebo|
9797415|NCT01595516|Other|Bradykinin|
9797416|NCT01595516|Other|Saline|
9797417|NCT01595516|Other|Vitamin C|
9797418|NCT01595529|Experimental|Active treatment|5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)
9932155|NCT00946257|Experimental|Cohort 3|1.2 mg dose
9932156|NCT00946257|Experimental|Cohort 4|1.8 mg dose
9932157|NCT00946257|Experimental|Cohort 5|2.4 mg dose
9932158|NCT00946257|Experimental|Cohort 6|3.0 mg dose
9932159|NCT00946283|Experimental|Lactobacillus GG|Open label trial of Culturelle (Lactobacillus GG) administered to patients after engraftment, post allogeneic stem cell transplantation.
9932160|NCT00946335|Experimental|Treatment (veliparib, temozolomide)|"Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected for pharmacokinetics and further laboratory analysis."
9932161|NCT00946361||Diagnostic|
9932162|NCT00946387|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
9932163|NCT00946387|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
9797419|NCT01595529|Placebo Comparator|Placebo treatment|5 days of placebo treatment to match physician-initiated therapy
9797420|NCT01595646|Placebo Comparator|Saline|Saline placebo taken twice per day via intranasal route.
9797421|NCT01595646|Experimental|Insulin Detemir|20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
9797422|NCT01595646|Experimental|Insulin|20IU Insulin, administered twice per day (40IU total per day) via intranasal route
9797423|NCT01595854|Experimental|Test 2 (part 3)|low dose dabigatran + high dose ticagrelor
9932164|NCT00946400||Suspected HIT|Those who are clinically suspected of having HIT will be enrolled in this study.
9932165|NCT00946413|Experimental|CBT plus parent education|
9797424|NCT01595854|Active Comparator|Test 1 (part 1 + 2)|high dose ticagrelor
9797425|NCT01595854|Experimental|Reference 1 (part 1 + 2)|medium dose dabigatran
9797426|NCT01595854|Experimental|Reference 2 (part 3)|low dose dabigatran
9797427|NCT01596062|Active Comparator|Simulect 40mg + Neoral + Myfortic + steroids|A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
9797428|NCT01596062|Experimental|Simulect 80mg + Neoral + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
9797429|NCT01596062|Experimental|Simulect 80mg + Certican + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
9797430|NCT01596088|Experimental|Drug: Dexrazoxane|"Dexrazoxane should be given once daily for 3 consecutive days. The dose is:~Day 1: 1000 mg/m2, Day 2: 1000 mg/m2, Day 3: 500 mg/m2 (body surface area)"
9797431|NCT01596127|Experimental|Intrathecal Rituximab|"Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I."
9797432|NCT01596231|Placebo Comparator|Placebo|This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
9797433|NCT01596231|Active Comparator|Kudzu|Kudzu 2mg
9797434|NCT01596283|Active Comparator|Standard fluid management|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
9797435|NCT01596283|Active Comparator|Goal directed fluid therapy|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
9797436|NCT01596335|Experimental|TA-650|
9797437|NCT01596335|Active Comparator|VGIH|
9797438|NCT01596504|Experimental|Lixisenatide 20 μg|Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
9797439|NCT01596504|Active Comparator|Liraglutide 1.2 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
9797440|NCT01596504|Active Comparator|Liraglutide 1.8 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
9797441|NCT01596582|No Intervention|Standard Care|Subjects randomized to the control arm will review the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled visit with their provider.
9797442|NCT01596582|Experimental|Risk Assessment|Subjects randomized to the experimental arm will complete the ACNI risk assessment tool after reviewing the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled office visit with their provider.
9797443|NCT01596595||Medically Indicated for ICD or CRT-D|Medically Indicated for ICD or CRT-D implantation per guidelines
9797444|NCT01596699|Experimental|Patients with Myeloid Malignancies|
9797445|NCT01596699|Experimental|Patients with Non-Malignancies|
9797446|NCT01596751|Experimental|Phase Ib: 600 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 600 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8."
9797447|NCT01596751|Experimental|Phase Ib: 800 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 800 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
9797448|NCT01596751|Experimental|Phase Ib: 1000 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 1000 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
9800233|NCT01682837|Experimental|KCit, KMgCit, KCl, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9890655|NCT00599690|Experimental|A|Epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
9890656|NCT00599703||1|neurosurgical patients
9890657|NCT00599716|Experimental|1|study drug
9890658|NCT00599716|Placebo Comparator|2|vehicle control
9890659|NCT00599729||1|patient demonstrating degenerative changes in the knee joint (osteoarthritis)
9890660|NCT00599742|Active Comparator|A|Balance training group
9890661|NCT00599742|Active Comparator|B|Motor Training
9890662|NCT00599781|Experimental|PBL/HSC|
9890663|NCT00599794||1|Healty volunteers who are euvolemic.
9890664|NCT00599794||2|Critically ill patients who will be having a central venous catheter with a monitor to measure central venous pressure placed as part of their planned care independent of this study.
9890665|NCT00599807|Active Comparator|1: 2000 IU D3/day|2000 IU vitamin D3 taken orally each day for 2 years
9890666|NCT00599807|Active Comparator|2: 800 IU D3 / day|800 IU vitamin D3 taken orally each day for 2 years
9890667|NCT00599859|Active Comparator|1|Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
9890668|NCT00599859|Active Comparator|2|Arm 2 are lactose maldigesters: 2 interventions are a. withdrawal from lactose for 2 weeks and b. consumption of 50g lactose in divided doses mixed in water for a 2 week period.
9890669|NCT00599885|Active Comparator|1|
9890670|NCT00599885|Active Comparator|2|
9890671|NCT00599898|Experimental|1|
9890672|NCT00599898|Experimental|2|
9890673|NCT00599911|Experimental|Lu AA24530: 5 mg|
9890674|NCT00599911|Experimental|Lu AA24530: 10 mg|
9890675|NCT00599911|Experimental|Lu AA24530: 20 mg|
9890676|NCT00599911|Active Comparator|Duloxetine: 60 mg|
9890677|NCT00599911|Placebo Comparator|Placebo|
9890678|NCT00599937|No Intervention|ATRA ->Chemo|Patients 65 years of age with a WBC count less than 5,000 were randomized to receive the reference ATRA treatment of our previous trial (APL91 trial), ie, 45 mg/m2/d ATRA followed by CT or ATRA plus CT (ATRA+CT). In the ATRA followed byCT group, patients received 45 mg/m2/d ATRA orally until CR, with a maximum of 90 days. After CR achievement, they received a course of 60 mg/m2/d daunorubicin (DNR) for 3 days and 200 mg/m2/d AraC for 7 days (course I). However, course I was added to ATRA if the WBC count was increased to greater than 6,000, 10,000, or 15,000 by day 5, 10, and 15 of ATRA treatment, respectively, because, from our experience, patients were at risk of ATRA syndrome above those thresholds.
9890679|NCT00599937|Experimental|ATRA+CT|Patients randomized to the ATRA+CT group received the same combination of ATRA and CT, with course I of CT starting on day 3 of ATRA treatment. This 48-hour interval before onset of CT was based on our previous report, because it allowed correction of coagulopathy.
9890680|NCT00599937|No Intervention|High WBC|Patients with a WBC count greater than 5,000 at presentation (irrespective of their age) and patients 66 to 75 years of age with a WBC count 5,000 were not randomized but received ATRA plus CT course I from day 1 (high WBC group) and the same schedule as in the ATRA->CT group (elderly group), respectively.
9890681|NCT00599937|No Intervention|no maintenance|No maintenance
9890682|NCT00599937|Experimental|maintenance ATRA|Intermitent ATRA as maintenance
9890683|NCT00599937|Experimental|maintenance Cxt|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) as maintenance
9890684|NCT00599937|Experimental|maintenance both|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) AND ATRA as maintenance
9890685|NCT00599950|Experimental|1|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
9890686|NCT00599950|Placebo Comparator|2|Photorefractive keratectomy (PRK)without mitomycin C.
9890687|NCT00599963|Experimental|1|paricalcitol 1 mg/day for 12 weeks, followed by a washout period of 4 weeks, then crossed over to no treatment for another 12 weeks
9890688|NCT00599963|Active Comparator|2|no treatment for 12 weeks, followed by a washout period of 4 weeks, then crossed over to paricalcitol for another 12 weeks
9890689|NCT00600002|Experimental|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
9890690|NCT00600041|Experimental|A|Pantoprazole IV
9890691|NCT00600041|Placebo Comparator|B|NaCl 0.9% IV
9890692|NCT00600054|Experimental|Single arm|
9890693|NCT00600093|Experimental|A|
9890694|NCT00600145|Experimental|1|Mirtazapine
9890695|NCT00600145|Placebo Comparator|2|Placebo
9890696|NCT00600158|Experimental|2|lidocaine intravenously
9890697|NCT00600158|Active Comparator|1|epidural local anesthetic
9890698|NCT00600197|Experimental|Back school|a kind of educational program for low back pain
9890699|NCT00600197|Experimental|back school|
9890700|NCT00600210|Experimental|I|
9890701|NCT00600223||1|Patients undergoing laryngectomy and pharyngeal reconstruction
9890702|NCT00600314||High risk|Patients who are at high risk of developing acute or chronic GVHD
9890703|NCT00600314||GVHD|Patients who currently have either grade II or greater acute GVHD, or clinically extensive chronic GVHD
9890704|NCT00600327|Experimental|1|
9890705|NCT00600379|Experimental|A,|Virtual Reality training for an overall of 18 sessions 2/week + usual care.
9890706|NCT00600379|No Intervention|B,|Usual care
9890707|NCT00600392||1|patients who meet criteria for CRT-D implantation
9890708|NCT00600405|Experimental|I|Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.
9890709|NCT00600405|Other|II|Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.
9890710|NCT00600431||1|Study group: 16 children under 18 years undergoing systemic chemotherapy
9890711|NCT00600431||2|Control group: 16 age and sex matched healthy children under 18 years
9890712|NCT00600444|Active Comparator|A|Venae Sectio technique will be used to insert totally implantable access port (TIAP) by a surgeon
9890713|NCT00600444|Experimental|B|Punction of Vena Subclavia will be used to insert totally implantable access port (TIAP) by a radiologist.
9890714|NCT00600457||A,1|
9890715|NCT00600470|Experimental|1|Doctor-office collaborative care management
9890716|NCT00600470|Active Comparator|2|"Treatment as usual: psychoeducation and outside referral to treatment (PORT). In papers, this arm is referred to as Enhanced Usual Care (EUC)."
9890717|NCT00600483|Experimental|1|Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy
9890718|NCT00600483|No Intervention|2|Standard of care, ie, insertion of no gentamicin-collagen sponge.
9890719|NCT00600522||1|Patients selected for hepatectomy because carriers of hepatocellular carcinoma or colorectal cancer liver metastases invading the middle hepatic vein at caval confluence (last 4 cm).
9890720|NCT00600535|Experimental|Abiraterone acetate (non-fasting)|
9890721|NCT00600535|Experimental|Abiraterone acetate (fasting)|
9890722|NCT00600548|Experimental|1.1|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.
9890723|NCT00600548|Active Comparator|1.2|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).
9890724|NCT00600548|Experimental|2.1|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.
9890725|NCT00600548|Active Comparator|2.2|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).
9890726|NCT00600561|Active Comparator|1-Day MBSR|One-day condensed MBSR class
9890727|NCT00600561|Experimental|8-week MBSR|8-week Mindfulness-Based Stress Reduction Intervention
9890728|NCT00600574|Active Comparator|S|physiotherapy in warm pool by means of stretching
9890729|NCT00600574|Experimental|AI|physiotherapy in warm pool by means of Ai Chi
9890730|NCT00600587|Experimental|A|Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
9890731|NCT00600587|Active Comparator|B|Non-erlotinib targeted NSCLC population based on EGFR gene analysis
9890732|NCT00600600|Experimental|Tigecycline|tigecycline titrated dose according to patient age and clinical status
9932166|NCT00946413|Experimental|CBT alone|
9932167|NCT00946426||Diagnostic|Hyperinsulinemic euglycemic clamp
9890733|NCT00600639|Experimental|1|non-invasive ventilation with BiPAP Vision or another ICU ventilator with NIV option
9890734|NCT00600639|Active Comparator|2|standard therapy + oxygen
9890735|NCT00600652||1|glucocorticoid-resistant patients
9890736|NCT00600652||2|glucocorticoid-sensitive patients
9890737|NCT00600652||3|normal controls
9890738|NCT00600665|Active Comparator|Usual Care|In Part 1 of the study, participants will access PAINReportIt and computer games. PAINReportIt helps the patient describe the pain experienced. In Part 2 of the study, participants will continue to access PAINReportIt when they are seen in the clinic, emergency department (ED), acute care center (ACCA), and hospital. They will gain access to the PAINUCope computer-based programs, which provides multimedia education tailored to the patient's misconceptions about pain management. They will receive medial usual care at the outpatient clinic, ED, ACC, and hospital.
9890739|NCT00600665|Experimental|PAINUCope/PAINConsultN|In Part 1 of the study, participants will access PAINReportIt and PAINUCope computer-based programs. PAINReportIt helps the patients describe the pain experiences and PAINUCope provides multimedia education tailored to the patient's misconceptions about pain management. In Part 2 of the study, participants will continue to access PAINReportIt and PAINUCope programs when they are seen in the clinic, emergency department (ED), acute care center (ACC), and hospital. Their doctors will have access to PAINConsultN when seen at the ED, ACC, and hospital. PAINConsultN is just-in-time decision support for the physicians with the pain data summarized and suggestions for analgesics that may be useful to help manage the patient's pain.
9890740|NCT00600678|Experimental|1|
9890741|NCT00600691|Experimental|1|5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.
9890742|NCT00600717||Pediatric Patients and Healthy Children|Healthy children without dental works. Pediatric patients with epilepsy and migraine (headache).
9890743|NCT00600730|Experimental|1|Hyperinsulinemic euglycemic clamp with fMRi
9890744|NCT00600730|Experimental|2|Hyperinsulinemic hypoglycemic clamp with fMRI
9890745|NCT00600769|Other|treatment of MAC and other NTM|Clarithromycin drug given twice daily.
9890746|NCT00600795||A|Patients diagnosed with Normal Pressure Hydrocephalus
9890747|NCT00600834||1|patients with moderate CKD (stage 3, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
9890748|NCT00600834||2|patients with severe CKD or kidney failure (stages 4 and 5, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2).
9890749|NCT00600847|Active Comparator|1|desloratadine 20 mg
9890750|NCT00600847|Active Comparator|2|desloratadine 5 mg
9890751|NCT00600847|Placebo Comparator|3|
9890752|NCT00600860||MDS patients|Patients with MDS according to current WHO criteria and International Prognostic Scoring System (IPSS) classification
9890753|NCT00600873|Experimental|1|patients with early ALS
9890754|NCT00600899|Experimental|A|Group A patients will receive perisciatic continuous infusion of ropivacaine 2 mg/ml through an elastomeric pump (Baxter, Deerfield, IL, USA)) 8 ml/h (reservoir of 500 ml)as postoperative analgesia.
9890755|NCT00600899|Active Comparator|B|Group B patients will receive standard treatment: continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/t (Baxter infusor with 275 ml reservoir)
9932168|NCT00946465|Experimental|1|Ramipril 10 Capsule (Sandoz)
9890756|NCT00600912|Experimental|1-SMOFlipid®|lipid emulsion based on soybean oil, medium-chain triglycerides, olive oil and fish oil SMOFlipid®-Group (n = 21)
9890757|NCT00600912|Active Comparator|2-ClinOleic 20%®|olive and soybean oil-group (n=21)
9890758|NCT00600951||1|Patients with moderate chronic kidney disease (stage 3, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
9890759|NCT00600951||2|Patients with severe chronic kidney disease or kidney failure (stages 4 and 5, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2)
9890760|NCT00600964|Experimental|GX15-070MS|GX15-070MS at various doses and schedules
9890761|NCT00600977|Active Comparator|doxorubicine|VAD
9890762|NCT00600977|Experimental|Doxorubicine pegylated|Doxorubicine pegylated 40 MG/M² J1
9890763|NCT00601029||1|Winter Phase - Observational
9890764|NCT00601029||2|Summer Phase - Observational
9890765|NCT00601042|Experimental|1|Swedish snus ad libitum as a substitute for cigarettes
9890766|NCT00601042|Placebo Comparator|2|Tobacco-free, nicotine-free placebo snus ad libitum as a substitute for cigarettes
9890767|NCT00601055|Experimental|Problem Solving-Rx Adherence (PSA)|Participants will receive problem-solving therapy integrated with adherence-enhanced procedures (PSA).
9890768|NCT00601055|Active Comparator|PID-C|Participants will receive adherence-enhanced (PID-C) procedures, a treatment mobilizing patients to participate in their care.
9890769|NCT00601068||Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
9890770|NCT00601081||1|Very low birth weight and preterm infants who will likely receive fortification of breast milk with HMF
9890771|NCT00601094|Experimental|experimental arm|
9890772|NCT00601133||Patient Postural Instability|Participants having difficulty walking and with balance after cancer treatment that are leaving the M.D. Anderson rehabilitation hospital or after treatment through the rehabilitation mobile team.
9890773|NCT00601159|Experimental|gemcitabine and cisplatin|cisplatin and gemcitabine in the management of triple negative metastatic breast cancer
9890774|NCT00601185||1|Patients undergoing a shave biopsy and confocal microscopy.
9890775|NCT00601198|Experimental|Treatment Period|The chemotherapy regimen will be given for 2 consecutive days. On day #1, pt. will be premedicated with drugs to prevent nausea and vomiting in addition to intravenous fluids. Then they will receive amifostine intravenously followed by oxaliplatin, 5FU and leucovorin. This will be followed by an infusion of 5FU given in a pump over 22 hours. If the doctor decides on giving the pt. Avastin, this will be given on day #1. On day #2, they will receive the same treatment except for oxaliplatin.
9890776|NCT00601224|Experimental|1|Participants will receive social cognition and interaction training plus treatment as usual
9890777|NCT00601224|Active Comparator|2|Participants will receive treatment as usual
9890778|NCT00601237|Experimental|A|Participants will receive HIV-related text messages
9890779|NCT00601237|Active Comparator|B|Participants will receive nutrition-related text messages
9890780|NCT00601237|No Intervention|C|Participants will attend a 90-minute focus group to develop messages for the cell-phone program
9890781|NCT00601263|Active Comparator|1a|Low dose ASHMI (2 caps bid).
9890782|NCT00601263|Placebo Comparator|1b|Placebo 2 caps bid.
9890783|NCT00601263|Active Comparator|2a|Medium dose ASHMI (4 caps bid).
9890784|NCT00601263|Placebo Comparator|2b|Placebo 4 caps bid.
9890785|NCT00601263|Active Comparator|3a|High dose ASHMI (6 caps bid).
9890786|NCT00601263|Placebo Comparator|3b|Placebo 6 caps bid.
9890787|NCT00601276|Experimental|1|
9890788|NCT00601276|Active Comparator|2|
9890789|NCT00601341|Experimental|1|lumbosacral joint manipulation
9890790|NCT00601341|Experimental|2|lumbar passive range of motion
9890791|NCT00601341|Other|3|lie on exam table for 3 minutes
9890792|NCT00601393|Active Comparator|1|Participants will receive treatment as usual followed by 8 weeks of Internet-based cognitive behavioral therapy treatment
9890793|NCT00601393|Experimental|2|Participants will receive 8 weeks of Internet-based cognitive behavioral therapy treatment
9890794|NCT00601471|Experimental|1|proximal tibiofibular manipulation
9890795|NCT00601471|Experimental|2|distal tibiofibular manipulation
9890796|NCT00601471|No Intervention|3|no treatment
9890797|NCT00601497|Experimental|1|
9890798|NCT00601497|Placebo Comparator|2|
9890799|NCT00601510|Experimental|Imatinib mesylate|Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2
9890800|NCT00601549|Experimental|1|Patients with low rectal cancer after CCRT undergoing laparoscopic surgery
9890801|NCT00601549|Active Comparator|2|Patients with low rectal cancer after CCRT undergoing traditional open surgery
9890802|NCT00601653|Active Comparator|1|Cognitive behavioral therapy plus general nutrition counseling
9890803|NCT00601653|Experimental|2|Cognitive behavioral therapy plus low energy density diet counseling
9890804|NCT00601679|Experimental|NT-proBNP|Surveillance NT-proBNP levels disclosed to physicians. Intervention (e.g. Diuretic management) based on NT-proBNP results.
9890805|NCT00601679|No Intervention|Usual Care|Surveillance NT-proBNP levels blinded. Intervention (e.g. Diuretic management) based on clinical judgments.
9890806|NCT00601692|Experimental|Regimen 1|Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
9890807|NCT00601692|Experimental|Regimen 2|Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
9890808|NCT00601744||Patient|Diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
9890809|NCT00601744||Family Member/Friend|Family member or close friend of a patient with a diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
9890810|NCT00601757|Other|1|Participants assigned to the Postpartum Prevention Program
9890811|NCT00601757|Other|2|Participants assigned to enhanced care as usual
9990609|NCT01444690|Placebo Comparator|Pseudo-placebo|Dimiracetam 25 mg capsules
9990610|NCT01444703|Placebo Comparator|sugar solution|Gargle 5 minutes before induction of general anesthesia with sugar solution.
9990611|NCT01444703|Active Comparator|licorice|Gargle 5 minutes before induction of general anesthesia with licorice solution.
9990612|NCT01444729||xiapex|Subject treated with Xiapex
9990613|NCT01444729||Surgery|Fasciotomy or fasciectomy
9990614|NCT01444755||1-Neoadjuvant Chemotherapy|This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
9990615|NCT01444755||2 Surgery|Surgery will be performed in patients of this arm.
9990616|NCT01444807|Experimental|Sorafenib|Active Arm
9990617|NCT01444807|No Intervention|Best Supportive Care|Comparator
9990618|NCT01444820|Experimental|Hypofractionation|One phase technique (IMRT or 3D-CRT): radiotherapy to the prostate + pelvic lymphnodes
9990619|NCT01444820|Other|Conventional|two-phase technique (IMRT or 3D-CRT): 1) whole pelvis including the prostate and regional lymph nodes; 2) boost to the prostate
9997435|NCT01508845|Active Comparator|High MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
9997436|NCT01508845|Active Comparator|Low MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
9997437|NCT01508845|Active Comparator|Fat free meal, 50,800 IU vitamin D3|Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
9997438|NCT01508858|Experimental|Treatment period 1|
9997439|NCT01508858|Placebo Comparator|Treatment period 2|
9997440|NCT01508871||Cardiomyopathy|
9997441|NCT01508884|Active Comparator|IM vaccine and placebo cream|A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
9997442|NCT01508884|Active Comparator|ID vaccine and placebo cream|A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
9997443|NCT01508884|Experimental|ID vaccine and imiquimod cream|A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
9997444|NCT01508897|Experimental|Phase 2 formulation|
9997445|NCT01508897|Experimental|Phase 3 formulation|
9997446|NCT01508923|Experimental|Treatment period 1|
9997447|NCT01508923|Placebo Comparator|Treatment period 2|
9997448|NCT01508949|Experimental|NNC 90-1170|
9997449|NCT01508949|Placebo Comparator|Placebo|
9997450|NCT01508975|Experimental|white rice|White rice
9997451|NCT01508975|Experimental|Brown rice|Brown Rice
9997452|NCT01508975|Experimental|Glucose|Glucose
9997453|NCT01508988|Experimental|Eye drops 0.3 µg/mL|
9997454|NCT01508988|Experimental|Eye drops 1 µg/mL|
9997455|NCT01508988|Experimental|Eye drops 3 µg/mL|
9997456|NCT01508988|Experimental|Eye drops 10 µg/mL|
9997457|NCT01508988|Experimental|Eye drops 20 µg/mL|
9997458|NCT01508988|Experimental|Eye drops 30 µg/mL|
9997459|NCT01508988|Experimental|Eye drops placebo|
9997460|NCT01509001|Active Comparator|metformin|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
9997461|NCT01509001|Active Comparator|glimepiride|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
9997462|NCT01509014|Experimental|Pharmacy Intervention Arm|All patients receiving statins from pharmacies allocated to the pharmacist intervention arm of the study
9997463|NCT01509014|No Intervention|Usual Care|Pharmacies not allocated to the intervention arm will serve as the control. They received no training on the CPATCH intervention and provide usual care to patients at their pharmacy.
9997464|NCT01509027|Active Comparator|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
9997465|NCT01509027|Active Comparator|Education by unpersonalised DVD|Information on detrimental consequences of hyperphosphatemia is presented on DVD
9997466|NCT01509027|Placebo Comparator|Standard Care|standard care
9890812|NCT00601770|Experimental|IC41|8 injections of 4 x 0.125mL
9890813|NCT00601809|Experimental|GG|
9890814|NCT00601809|Other|TT|
9890815|NCT00601822|Experimental|1|Group receiving cognitive behavioral therapy for anorexia nervosa (CBT-AN)
9890816|NCT00601822|Experimental|2|Group receiving cognitive behavioral therapy for anorexia nervosa, plus cognitive remediation therapy (CBT-AN+CRT)
9890817|NCT00601861|Experimental|A|
9890818|NCT00601913|Experimental|Erlotinib|Erlotinib
9890819|NCT00601939|Experimental|Psychoeducational intervention (PEI)|Culturally competent group empowerment psychoeducational treatment (group intervention that is culturally informed and educational in nature)
9890820|NCT00601939|Active Comparator|Enhanced Treatment as Usual|Enhanced treatment as usual that includes an adherence protocol (regular care at the hospital plus an adherence protocol)
9890821|NCT00601978|Active Comparator|1|Immediate-Release Carbidopa/Levodopa
9890822|NCT00601978|Active Comparator|2|Carbidopa/Levodopa/Entacapone
9890823|NCT00602030|Experimental|1|Lead in Open Label Phase 1 dose-finding study to identify a safe dose of entinostat in combination with erlotinib for further evaluation
9890824|NCT00602030|Experimental|2|erlotinib (Tarceva) and entinostat
9890825|NCT00602030|Placebo Comparator|3|"erlotinib (Tarceva) and matched Placebo~patients in this arm who progress will be offered the opportunity to receive SNDX-275 with erlotinib for up to 6 28-day treatment cycles"
9890826|NCT00602056|Experimental|1|Redesigned immunization card
9890827|NCT00602056|Experimental|2|Center based education to mothers/caregivers
9890828|NCT00602056|Experimental|3|Redesigned immunization card with center based education to mothers/caregivers
9890829|NCT00602056|No Intervention|4|Standard care only
9890830|NCT00602069|Experimental|1|Participants will receive cognitive behavioral therapy through the Helping to Overcome PTSD through Empowerment program
9890831|NCT00602069|Active Comparator|2|Participants will receive standard shelter services
9890832|NCT00602095|Experimental|1|Labour induction with misoprostol
9890833|NCT00602095|Active Comparator|2|Labour induction with dinoprostone
9890834|NCT00602095|Experimental|3|Labour induction with bard
9890835|NCT00602147||Retrospective sample|People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
9890836|NCT00602147||Prospective sample|People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
9890837|NCT00602160|Active Comparator|1|2 different dosages
9890838|NCT00602160|Placebo Comparator|2|
9890839|NCT00602186|Experimental|1|taking Tamsulosin
9890840|NCT00602186|Active Comparator|2|taking prasosin
9890841|NCT00602212|Active Comparator|VR + Mobile Phone without Biofeedback|In this experimental condition patients received an eight-session VR-based treatment including relaxation and exposure
9890842|NCT00602212|Experimental|VR + Mobile Phone with biofeedback|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
9890843|NCT00602264||1|Treatment-naïve patients with a recent diagnosis of anorexia nervosa
9890844|NCT00602264||2|The weight recovered subgroup of group 1
9890845|NCT00602264||3|Recovered patients with a previous history of anorexia nervosa but normal menstrual cycles and body weight at the present time
9890846|NCT00602264||4|Control group
9890847|NCT00602277|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5 in course 1, followed by insertion of an IP access port. Beginning in course 2, patients receive wild-type reovirus IV over 60 minutes on days 1-5 and wild-type reovirus IP over 10 minutes on days 1 and 2*. Treatment with IV and IP wild-type reovirus repeats every 28 days in the absence of disease progression or unacceptable toxicity. (phase II closed as of 1/7/2011). NOTE: *Patients receive IP wild-type reovirus on days 2 and 3 in course 3.
9890848|NCT00602433||questionnaire and laboratory biomarker analysis|Subjects with advanced non-small cell lung cancer and take erlotinib as part of their anticancer therapy for at least 3 months. Subjects have had some changes in hair growth, acne or menses (periods) that might be a side effect of erlotinib. Subjects will complete a questionnaire and blood collected for biomarker analysis.
9932169|NCT00946465|Active Comparator|2|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
9932170|NCT00946491|Experimental|1|Haloperidol 10 mg Tablets (Cord Laboratories)
9932171|NCT00946491|Active Comparator|2|Haldol 10 mg Tablets (McNeil Pharmaceuticals)
9932172|NCT00946504|Experimental|1|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
9932173|NCT00946504|Active Comparator|2|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
9932174|NCT00946517||Parents|Parents or caregivers of type 1 diabetics
9932175|NCT00946517||Child|Type 1 diabetics
9932176|NCT00946556|Placebo Comparator|Placebo|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
9932177|NCT00946556|Experimental|Valacyclovir|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
9932178|NCT00946595|Active Comparator|efavirenz/emtricitabin/tenofovir|
9932179|NCT00946595|Experimental|lopinavir/ritonavir|
9890849|NCT00602511|Active Comparator|1|Bortezomib - dexamethasone
9890850|NCT00602511|Experimental|2|Thalidomide - dexamethasone
9890851|NCT00602563|Experimental|1 Attention Modification Program (AMP)|The AMP is a computer-delivered attention modification
9890852|NCT00602563|Active Comparator|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
9890853|NCT00602563|Placebo Comparator|Clinical monitoring control|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions ; however, they will not be randomized to treatment until after the 3-month follow-up assessment. To control for the effects of psychoeducation, symptom monitoring, contact by project staff, and maturation effects, participants will be asked to complete pre-, mid- and post-assessments, and will be informed that they will receive treatment.
9890854|NCT00602563|Experimental|Combining the AMP and AR|Both AMP and AR
9890855|NCT00602680|Experimental|1|dose 1
9890856|NCT00602680|Experimental|2|dose 2
9890857|NCT00602680|Experimental|3|dose 3
9890858|NCT00602680|Placebo Comparator|4|
9890859|NCT00602680|Active Comparator|5|
9890860|NCT00602693|Experimental|UCB post-transplant Treg Cell Infusion|Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.
9890861|NCT00602732|Experimental|1|Participants assigned to the ROSE program
9890862|NCT00602732|Active Comparator|2|Participants assigned to enhanced care as usual
9890863|NCT00602758|Experimental|Enhanced Counseling|Participants meet with a counselor trained in motivational interviewing and cognitive behavioral techniques
9890864|NCT00602758|No Intervention|Standard Care|Participants receive usual clinical care provided by health care providers and they participate only in evaluation components of the study
9890865|NCT00602758|Experimental|Enhanced Counseling/Modified Directly Observed Therapy|Participants receive their ART medications delivered to them by study staff and they receive the enhanced counseling
9890866|NCT00602784|Experimental|IC41-B-01/02|peptide dose 0.00 mg, polyarginine dose 2.00 mg
9890867|NCT00602784|Experimental|IC41-C-01/02|peptide dose: 5.00 mg, polyarginine dose: 0.00 mg
9890868|NCT00602784|Experimental|IC41-G-01/02|peptide dose: 2.50 mg, polyarginine dose: 1.25 mg
9890869|NCT00602784|Experimental|IC41-H-01/02|peptide dose: 2.50 mg, polyarginine dose: 2.00 mg
9890870|NCT00602784|Experimental|IC41-K-01/02|peptide dose: 5.00 mg, polyarginine dose: 2.00 mg
9890871|NCT00602862|Experimental|1|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
9890872|NCT00602862|Experimental|2|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/10mg 111In-cG250. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
9890873|NCT00602862|Active Comparator|3|5 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Whole-body scintigraphic images are recorded 1 week after the injection to calculate tumor uptake. Hereafter, patients will undergo surgery.
9890874|NCT00602901|Experimental|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
9890875|NCT00602901|Experimental|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
9890876|NCT00602901|Active Comparator|Usual Medical Care|Usual medical care - (Celebrex, Aleve, Bextra, Naproxen)
9890877|NCT00602914|Experimental|1|10 healthy volunteers will receive 0.1 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
9890878|NCT00602914|Experimental|2|10 Type II DM subject will receive 0.2 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
9890879|NCT00602940|Experimental|1|Active acupuncture treatment
9890880|NCT00602940|Sham Comparator|2|Sham acupuncture treatment
9890881|NCT00602966||Slow Freeze|
9890882|NCT00602966||Vitrification|
9890883|NCT00603005|Experimental|1|
9890884|NCT00603005|Experimental|2|
9890885|NCT00603005|Experimental|3|
9890886|NCT00603005|Experimental|4|
9890887|NCT00603031|Experimental|GLP-1|time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
9932180|NCT00946608|Experimental|1|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
9890888|NCT00603031|Placebo Comparator|NaCl|time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
9890889|NCT00603031|Experimental|GIP|time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
9890890|NCT00603057||Lung Cancer Imaging Patients|Adult patients (>18 years of age)with histologically confirmed or clinically diagnosed lung cancer who require radiation therapy, with or without surgery and with or without chemotherapy.
9890891|NCT00603070||1|All physicians and nurse practitioners at 1 ambulatory care clinics
9890892|NCT00603070||2|All physicians and nurse practitioners at 1 ambulatory care clinics
9890893|NCT00603083|Active Comparator|A|This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
9890894|NCT00603083|Placebo Comparator|B|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.
9890895|NCT00603096|Experimental|1|patients will benefit from a complete polysomnography under NIV
9890896|NCT00603096|Active Comparator|2|settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas
9890897|NCT00603109|Experimental|I|Subjects receive rimonabant 20 mg per day PO
9890898|NCT00603109|Placebo Comparator|II|Subjects take placebo capsule one a day PO
9890899|NCT00603122|Experimental|1|fast ascent
9890900|NCT00603122|Active Comparator|2|slow ascent
9890901|NCT00603135|Experimental|A|
9890902|NCT00603174|Experimental|A|Intubated and mechanically ventilated infants with respiratory failure (age < 1 year old). see inclusion-exclusion criteria.
9890903|NCT00603200||Group 1|Patients with cirrhosis, who have refractory ascites requiring large volume paracentesis
9890904|NCT00603226||1|Patients diagnosed with slow coronary artery flow during coronary angiography
9890905|NCT00603226||2|Patients with normal coronary artery flow observed during coronary angiography
9890906|NCT00603317|Experimental|1|Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo
9890907|NCT00603317|Experimental|2|Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic
9890908|NCT00603343|Active Comparator|1|
9890909|NCT00603343|Placebo Comparator|2|
9890910|NCT00603356|Experimental|1|Dose Escalation
9890911|NCT00603369|Experimental|1|13 session group intervention including sexual health information, affect management skills, cognitive monitoring, and communication skills training.
9890912|NCT00603369|Active Comparator|2|2 session group intervention including sexual health information training.
9890913|NCT00603395|Other|ReCap|ReCap Total Hip Resurfacing System
9890914|NCT00603421|Experimental|1|Patient benefits from treatment as usual plus access to a crisis 24 hour phone line.
9890915|NCT00603421|Active Comparator|2|Patient benefits from treatment as usual
9890916|NCT00603434|Experimental|1|Osmotic-Release Methylphenidate
9890917|NCT00603434|Experimental|2|Osmotic-Release Methylphenidate
9890918|NCT00603434|Experimental|3|Osmotic-Release Methylphenidate
9890919|NCT00603460|Active Comparator|A|
9890920|NCT00603460|Active Comparator|B|
9890921|NCT00603499|Active Comparator|1|Magnesium chloride
9890922|NCT00603499|Placebo Comparator|2|Placebo
9890923|NCT00603551||Chemotherapy|Postmenopausal women who have been diagnosed with a breast or gynecological cancer and who have undergone chemotherapy as a result of that diagnosis
9890924|NCT00603603|Experimental|80% inhaled oxygen-non-rebreather|10 liters of oxygen via non re-breather mask during cesarean section and up to two hours post-operatively
9890925|NCT00603603|Active Comparator|30% inhaled oxygen-nasal cannula|2 liters of oxygen via nasal cannula (standard of care) during cesarean section only
9890926|NCT00603629||I|People with acute asthma in the Emergency department or inpatient settings
9890927|NCT00603655|Experimental|A|This group will receive a low glycemic load
9890928|NCT00603655|Active Comparator|B|This group will receive a high glycemic load
9890929|NCT00603681|Experimental|T|Test product
9890930|NCT00603681|Active Comparator|C|Reference product
9890931|NCT00603694||1|(Experimental group): Receiving > 2 Gy SRS to left hippocampus (n=10)
9890932|NCT00603694||2|(Low-dose control group): Receiving < 0.5 Gy SRS to left hippocampus (n=10)
9890933|NCT00603694||3|(High-dose control group): Receiving whole brain PCI (n=10)
9890934|NCT00603707||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
9890935|NCT00603707||Constipated|Adult subjects with functional constipation as define by Rome II criteria
9890936|NCT00603759|Active Comparator|1|
9890937|NCT00603759|Placebo Comparator|2|
9890938|NCT00603772|Experimental|1|Safety when exposed to sunlight
9890939|NCT00603785|Placebo Comparator|A|Subjects to receive placebo treatment for 6 months
9890940|NCT00603785|Experimental|B|Subjects to receive Xolair treatment for 6 months
9890941|NCT00603811|Experimental|1|VAX102, a recombinant fusion protein that links the influenza A virus M2e antigen to S. typhimurium flagellin, a TLR5 ligand.
9890942|NCT00603811|Placebo Comparator|2|Vaccine buffer
9890943|NCT00603824|Experimental|A|Fondaparinux
9890944|NCT00603824|Active Comparator|B|Direct thrombin inhibitor
9890945|NCT00603850||1|Intermediate AMD Patients
9890946|NCT00603876|Experimental|2|Step 1 dietary counseling plus 100-110 grams of almonds daily
9890947|NCT00603876|No Intervention|1|Step 1 dietary counseling
9890948|NCT00603967|Other|Aromatase inhibitor|
9890949|NCT00604006|Experimental|Group A|
9890950|NCT00604006|Placebo Comparator|Group B|
9990620|NCT01444846|Active Comparator|SPI-1005 Low dose|200mg SPI-1005, capsule, bid, po, x4d
9990621|NCT01444846|Active Comparator|SPI-1005 Middle Dose|400mg SPI-1005, capsule, bid, po, x4d
9990622|NCT01444846|Active Comparator|SPI-1005 High Dose|600mg SPI-1005, capsule, bid, po, x4d
9990623|NCT01444846|Placebo Comparator|Placebo|0mg SPI-1005, capsule, bid, po, x4d
9990624|NCT01444859|Placebo Comparator|Placebo capsule|40 subjects allocated to daily placebo capsule for 10 weeks
9990625|NCT01444859|Experimental|Trenev Trio®/Healthy Trinity®|80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
9990626|NCT01444872|Experimental|TRV120027|TRV120027 administered as an IV infusion
9990627|NCT01444872|Placebo Comparator|Normal Saline|Normal Saline administered as an IV infusion
9990628|NCT01444885|Experimental|Cilostazol|To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
9990629|NCT01444976|Active Comparator|topical pharyngeal anesthesia|There were 26 patients who had the procedure under topical pharyngeal anesthesia.
9990630|NCT01444976|Active Comparator|midazolam|There were 25 patients who received midazolam.
9990631|NCT01444976|No Intervention|hypnosis|There were 27 patients receiving hypnosis.
9990632|NCT01444989|Experimental|Patients without actinic keratosis|Patients with out the diagnosis of actinic keratosis will receive the experimental questionnaire.
9990633|NCT01444989|Experimental|Patients with Actinic Keratosis|Patients with the diagnosis of actinic keratosis will receive the experimental questionnaire.
9990634|NCT01445002|Experimental|BM32 low dose|3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
9990635|NCT01445002|Experimental|BM32 medium dose|3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
9990636|NCT01445002|Experimental|BM32 high dose|3 subcutaneous injections of BM32 over a time span of 8 weeks
9990637|NCT01445002|Placebo Comparator|Placebo|3 subcutaneous injections over a time span of 8 weeks
9990638|NCT01445015|Experimental|Stress management program|
9990639|NCT01445015|Active Comparator|peer viewed movies|
9990640|NCT01445041|Experimental|Single infusion of UCB|(autologous red blood cell and volume reduced cord blood cells)
9990641|NCT01445041|Experimental|Three infusions of UCB|(autologous red blood cell and volume reduced cord blood cells)
9990642|NCT01445054|Experimental|1-Arm 1|Subjects with primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
9990643|NCT01445067|Active Comparator|Arm 1: BMS-927711 (300 mg)|
9990644|NCT01445067|Active Comparator|Arm 2: BMS-927711 (600 mg)|
9990645|NCT01445158||1|bone marrow or stem cell donors ages 10 to 15
9990646|NCT01445158||2|bone marrow or stem cell donors ages 16 to 26
9990647|NCT01445197|Experimental|Biostate|
9990648|NCT01445210|Active Comparator|0,2% Ropivacaine|"Patients randomized to the experimental group receive a continuous infusion of 0,2 % Ropivacaine by elastomeric infusion pump at 5 ml/h in the saphenous catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
9990649|NCT01445210|Placebo Comparator|Control|"Patients randomized to the control group receive a continuous infusion of isoton saline by elastomeric infusion pump at 5 ml/h in their catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
9990650|NCT01445223|Active Comparator|lopinavir/ritonavir|400/100 mg BID + 2 NRTIs BID
9990651|NCT01445223|Active Comparator|atazanavir/ritonavir|300mg+100mg QD+ 2 NRTI QD
9990652|NCT01445223|Active Comparator|efavirenz|600mg QD + 2NRTI QD
9990653|NCT01445236|Experimental|Weaning patients|
9990654|NCT01445249|Active Comparator|Landmark guided ankle block|This group will receive a landmark guided ankle block.
9990655|NCT01445249|Active Comparator|This group will be given a PNS guided ankle block|Peripheral nerve stimulation will be used in this group to guide local anaesthetic infiltration. The technique is termed medial forefoot block.
9990656|NCT01445262||Subjects prescribed levocetirizine tablets|Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
9990657|NCT01445275||Ancillary-Correlative (Health Services Research)|Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
9990658|NCT01445366|Experimental|Patients with end-stage renal disease|
9990659|NCT01445379|Experimental|1|Ipilumumab (DSE) given on day 1 of 21 day cycle for 4 cycles, from cycle 5+ ipilumumab will be given ~every 12wks
9990660|NCT01445392|Experimental|1|Multi-cycle cohort
9990661|NCT01445392|Experimental|2|Single cycle cohort
9990662|NCT01445418|Experimental|Arm 1|Standard dose escalation
9990663|NCT01445418|Experimental|Arm 2|Expanded cohort
9990664|NCT01445431|Experimental|Virgin Coconut Oil|
9990665|NCT01445431|Active Comparator|Mineral Oil|
9990666|NCT01445444|Experimental|HRT group|This group receives habit reversal training immediately.
9990667|NCT01445444|Active Comparator|TAU group|This group receives treatment as usual for 8 weeks.
9990668|NCT01445561|Experimental|1|100,000 international units/m2 SQ daily for 5 days
9990669|NCT01445561|Experimental|2|200,000 international units/m2 SQ daily for 5 days
9990670|NCT01445587|Experimental|GSK2110183|The oral dose of GSK2110183 the subjects received will be dependent on when the subject is enrolled to the study. GSK2110183 will be provided in 25mg and 50mg capsules containing the hydrochloride salt form of the API, microcrystalline cellulose, magnesium stearate, and microcrystalline cellulose (optional). They are filled into hard gelatin capsules. The 25mg tablets are opaque, swedish orange, size 2 capsules with no external markings, filled with a white powder. The 50mg tablets are opaque, white, size 1 capsules with no external markings, filled with a white powder.
9990671|NCT01445587|Other|Bortezomib|Bortezomib salvage therapy will be administered as a 3 to 5 second intravenous (IV) push at 1.3 mg/m2 on Days 1, 8, and 15 in each 21-day cycle until one of the Treatment Discontinuation Criteria is met.
10212005|NCT03179436|Experimental|Escalation: DL 2 Quavonlimab + Pembro: Cohort 2|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL2. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
9990672|NCT01445600||ALTARGO(retapamulin)|The subjects with bacterial skin and skin structure infections (SSSI)
9990673|NCT01445639|Experimental|Dexmedetomidine group|
9990674|NCT01445639|Placebo Comparator|Placebo group|
9990675|NCT01445691|Experimental|5-ALA (Gliolan)|Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
9990676|NCT01445704|Experimental|Probiotics|Patients treated with a probiotic (in capsule form) once daily for 12 weeks
9990677|NCT01445704|Placebo Comparator|Placebo|Patients treated with a placebo (in capsule form) identical to that of the probiotic capsule once daily for 12 weeks
9990678|NCT01445743|Experimental|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention women will receive a blinded dose of Tdap vaccine (ADACEL)
9990679|NCT01445743|Placebo Comparator|Placebo Comparator: Physiologic Saline solution|Administration of Tdap vaccine or placebo as a single 0.5 mL of Saline (0.9% NaCl) solution
9990680|NCT01445756|Active Comparator|Topical Lidocaine|Topical Lidocaine
9990681|NCT01445756|Placebo Comparator|Placebo|Placebo
9990682|NCT01445782|Experimental|1|AZD2115
9990683|NCT01445782|Placebo Comparator|2|Placebo to AZD2115
9990684|NCT01445808|Experimental|Psychodynamic Motivation and Training Program (PMT)|
9990685|NCT01445808|Active Comparator|Advice in Exercise Training|One session of advice in exercise training based on the results of spiroergometry
9990686|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor and cardiologist
9990687|NCT01445834||Incontinent women|
9990688|NCT01445860|Experimental|Treatment|
9990689|NCT01445925|Active Comparator|Pulmonary vein isolation|Patients will undergo pulmonary venous isolation plus pharmacological substrate modification
9990690|NCT01445925|Experimental|Pulmonary vein isolation + Linear Lesions|Patients will undergo pulmonary venous isolation plus both pharmacological and interventional substrate modification
9990691|NCT01445938|Experimental|Step 1 (SAR97276A od)|1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
9990692|NCT01445938|Experimental|Step 1 (SAR97276A bid)|1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
9990693|NCT01445938|Active Comparator|Step 1 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
9990694|NCT01445938|Experimental|Step 2 (SAR97276A)|1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
9890951|NCT00604032|Placebo Comparator|1|
9890952|NCT00604058|Experimental|Group A|
9890953|NCT00604058|Active Comparator|Group B|
9890954|NCT00604071||1|subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
9890955|NCT00604084|Experimental|Ivermectin|Non-pregnant, non-breastfeeding, taller than 90cm and 5 years or older
9890956|NCT00604084|Experimental|Permethrin|Pregnant, breastfeeding, children under 90cm or under 5 years old
9890957|NCT00604097|Experimental|1|Attachment-Based Family Therapy
9890958|NCT00604097|Active Comparator|2|Enhanced Usual Care
9890959|NCT00604149||1|case of out-of-hospital cardiac arrest
9890960|NCT00604149||2|cases of MI
9890961|NCT00604149||3|controls without coronary disease
9890962|NCT00604227|Experimental|1|high altitude exposure
9890963|NCT00604240||1|Parents / caregivers of any infant who has a length of stay of at least 1 week in the NICU at Christiana Hospital or Thomas Jefferson University Hospital.
9890964|NCT00604266||1|10-15 patients with potentially resectable hiilar cholangiocarcinoma
9890965|NCT00604292||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases
9890966|NCT00604305|Active Comparator|Acrysof|Routine monofocal IOL
9890967|NCT00604305|Active Comparator|Acuity's AIOL|Accomodaing IOL
9890968|NCT00604318|Placebo Comparator|placebo|To receive the placebo treatment in connection with the primary RI therapy and the T3 tablets and rh-TSH injections prior to second RI uptake measurement
9990695|NCT01445938|Active Comparator|Step 2 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
9890969|NCT00604318|Active Comparator|rh-TSH|To continue with L-T3 and to receive rh-TSH stimulation with 0,9 mg Thyrogen® (Genzyme) x 2 days minus 1 and 2 prior to RI therapy, and following this to have placebo tablets and placebo injections with isotone NaCl prior to the RI uptake measurement 4-6 months later
9890970|NCT00604331|Active Comparator|A|Pyruvate
9890971|NCT00604357|Experimental|1|Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.
9890972|NCT00604370||1|Acutely ill medical and surgical patients who were hospitalized at BWH, and at-risk for VTE, but were not treated with prophylaxis at hospital discharge.
9890973|NCT00604370||2|Acutely ill medical and surgical patients who were at risk for VTE at time of hospital discharge and prescribed a prophylaxis strategy.
9890974|NCT00604409|Experimental|Treatment (SIRT and capecitabine)|Patients receive capecitabine PO twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo SIRT on day 2 and may undergo a second course of SIRT on day 58.
9890975|NCT00604422||A|Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
9890976|NCT00604435|Active Comparator|chemotherapy|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
9890977|NCT00604435|Experimental|chemotherapy plus endostatin|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin
9890978|NCT00604448|Experimental|Pulse group|a group receiving a meal with pulses (5 cups/week) for 8 weeks
9890979|NCT00604448|Experimental|Energy-restricted group|a group with a diet restriction of 500 kcal/day for 8 weeks
9890980|NCT00604474|Active Comparator|1|
9890981|NCT00604487|Active Comparator|1|Insertion of the Atad double balloon ripener device (100 ml NS in each balloon).
9890982|NCT00604487|Active Comparator|2|Insertion of the double balloon instillation device (100 ml NS in each balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
9890983|NCT00604487|Active Comparator|3|Insertion of the folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
9890984|NCT00604513|Experimental|1|
9890985|NCT00604513|Sham Comparator|2|
9890986|NCT00604526|Experimental|1|Questionnaires, Iridium 192 radioactive seeds
9890987|NCT00604539|Experimental|1|Chondroitin sulphate
9890988|NCT00604539|Placebo Comparator|2|
9890989|NCT00604591|Placebo Comparator|Placebo then Tolcapone|"Participants take placebo during study week 1 and then tolcapone during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
9890990|NCT00604591|Experimental|Tolcapone then Placebo|"Participants take tolcapone during study week 1 and then placebo during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
9890991|NCT00604604|No Intervention|1|Control group (usual postpartum care)
9890992|NCT00604604|Experimental|2|Experimental group (usual postpartum care plus telephone-based support from an experienced mother who has participated in a 4-hour training session)
9890993|NCT00604630|Placebo Comparator|placebo|50ml 0.9% NaCL
9890994|NCT00604630|Active Comparator|verum|erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl
9932181|NCT00946608|Experimental|2|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
9932182|NCT00946608|Active Comparator|3|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
9932183|NCT00946621|Experimental|1|Ramipril 10 mg Capsule (Sandoz)
9932184|NCT00946621|Active Comparator|2|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
9932185|NCT00946634|Experimental|Ozone Gas|Endodontic protocol preconized by University of Sao Paulo associated to ozone gas 40 mg/L
9932186|NCT00946634|Active Comparator|Control|Regular endodontic protocol preconized by University of Sao Paulo
9932187|NCT00946634|Experimental|Aqueous Ozone|Endodontic protocol preconized by University of Sao Paulo associated to Aqueous ozone 40mg/L
9932188|NCT00946673|Experimental|vorinostat & stereotactic radiosurgery|
9932189|NCT00946686|Experimental|1|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
9932190|NCT00946686|Active Comparator|2|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
9932191|NCT00946699|Experimental|1|MEDI-551
9932192|NCT00946699|Experimental|2|MEDI-551
9932193|NCT00946699|Experimental|3|MEWDI-551
9932194|NCT00946699|Experimental|4|MEDI-551
9932195|NCT00946699|Experimental|5|MEDI-551
9932196|NCT00946699|Placebo Comparator|6|Placebo
9932197|NCT00946725|Experimental|1|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
9932198|NCT00946725|Active Comparator|2|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
9932199|NCT00946738|Active Comparator|physical therapy|
9932200|NCT00946738|No Intervention|control|
9932201|NCT00946751|Experimental|1|Levetiracetam Tablets, 750 mg (Sandoz Inc.)
9932202|NCT00946751|Active Comparator|2|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
9932203|NCT00946764|Experimental|1|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
9932204|NCT00946764|Active Comparator|2|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
9932205|NCT00946777|Experimental|Systane® Ultra|
9932206|NCT00946790|Experimental|1|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
9932207|NCT00946790|Active Comparator|2|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
9932208|NCT00946803|Experimental|PC-CB Intervention|Patient-Controlled Cognitive-Behavioral Intervention
9797449|NCT01596751|Experimental|Phase II: 800 mg/Day PLX3397 Lead in +Combined with Eribulin|"Treatment begins with a 7 day Lead-in phase of PLX3397 alone, followed by 21 day cycles of PLX3397 in combination with eribulin.~Lead-in phase treatment:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest.~Treatment given in each 21 day cycle:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest, repeated weekly~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
9797450|NCT01596842|Active Comparator|Omega-3 fatty acid|
9797451|NCT01596842|Placebo Comparator|Olive oil|
9797452|NCT01596972|Experimental|Serum quantitative urine pregnancy test|uterine evacuation follow-up consisting of an at-home, self-administered SQ-UPT and standardized pregnancy symptom questionnaire in 1 week
9797453|NCT01596972|No Intervention|serum hCG|follow-up consisting of a 1 week return visit and serum hCG plus standardized pregnancy symptom questionnaire
9797454|NCT01597050|Active Comparator|Drug: R932333|R333 6% (60 mg/g), bid
9797455|NCT01597050|Placebo Comparator|Placebo|Placebo, bid
9797456|NCT01597128|Active Comparator|Flex HD|Mesh Type
9797457|NCT01597128|Active Comparator|Strattice|Use of a second mesh type
9797458|NCT01597141|Experimental|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
9797459|NCT01597141|Active Comparator|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.
9797460|NCT01597193|Experimental|enzalutamide (80-mg with increase to 160 mg)|enzalutamide be provided as two or four 40-mg capsules by mouth daily
9797461|NCT01597193|Experimental|enzalutamide and anastrozole|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
9797462|NCT01597193|Experimental|enzalutamide and exemestane 25 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
9797463|NCT01597193|Experimental|enzalutamide and exemestane 50 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
9797464|NCT01597193|Experimental|enzalutamide and fulvestrant|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
9797465|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
9797466|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
9797467|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 3|Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
9797468|NCT01597245|Active Comparator|50 mg etanercept|Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
9797469|NCT01597245|Placebo Comparator|Placebo for ixekizumab|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
9797470|NCT01597258||Crizotinib (Xalkori)|
9797471|NCT01597375|Experimental|Placebo then Prasugrel|"Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] and returned for the second aspirin challenge.~Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined."
9797472|NCT01597375|Experimental|Prasugrel then Placebo|"Subjects with AERD first received prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.~Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined."
9797473|NCT01597440|Experimental|N-Carbamylglutamate|Active NCG & Standard of Care
9797474|NCT01597440|Placebo Comparator|Placebo|Standard of Care therapy
9797475|NCT01597479|No Intervention|No dPNBs group|Patients in this group didn't receive any intervention in the postoperative period.
9800234|NCT01682837|Experimental|KCit, KMgCit, Placebo, KCl|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9890995|NCT00604682|Experimental|Administration of CC10004|
9890996|NCT00604734|Other|ReCap|ReCap Total Hip Resurfacing System
9890997|NCT00604747|Other|1, 2|
9890998|NCT00604760|Experimental|A|
9890999|NCT00604760|Experimental|B|
9891000|NCT00604760|Experimental|C|
9891001|NCT00604760|Placebo Comparator|D|
9891002|NCT00604773||delirious patients|minimal one positive CAM-ICU score during ICU admission
9891003|NCT00604773||non-delirious patients|without any positive CAM-ICU scores during ICU admission
9891004|NCT00604799|Active Comparator|Test (Enrollment Completed)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair whom are low to moderate risk (0, 1, & 2) per the modified SVS/AAVS criteria who meet inclusion/exclusion criteria. The aneurysm must be at least 20 mm distal to the left common carotid artery & 20 mm proximal to the origin of the celiac artery.
9891005|NCT00604799|Other|Registry (Enrollment Completed)|Surgical candidates of low to moderate risk (SVS 0, 1, 2) that meet the Registry Inclusion/Exclusion criteria.
9891006|NCT00604799|Other|High Risk (Enrollment Completed)|"Patients that meet one or more of the following:~High Risk (SVS 3)~Non-surgical candidates not associated with SVS scoring~Traumatic thoracic injuries"
9891007|NCT00604799|Other|Talent Captivia (Recruiting)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair who meet inclusion/exclusion criteria.
9891008|NCT00604838|Experimental|I|
9891009|NCT00604864|Experimental|1|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
9891010|NCT00604864|Placebo Comparator|2|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
9891011|NCT00604877|Experimental|1|
9891012|NCT00604877|Active Comparator|2|
9891013|NCT00604903|Experimental|Patients implanted with Pressure Sensor|Implant of Pressure sensor. These are patients, who were implanted with the Remon CHF Implantable Pressure Sensor utilizing the corresponding delivering system.
9891014|NCT00604916|Experimental|E|received a 7 day standardized oral care protocol
9891015|NCT00604916|Placebo Comparator|C|received a 7 day mimic protocol
9891016|NCT00604929|Experimental|1|
9891017|NCT00604942|Experimental|Achalasia|Long vs Short Myotomy repair of Achalasia
9891018|NCT00604942|Experimental|Dysphagia control|Conservative Management
9891019|NCT00604942|Experimental|GORD for surgery|Partial vs Full Fundoplication repair
9891020|NCT00604942|Experimental|GORD not for surgery|esomeprazole 40 mg vs no esomeprazole
9891021|NCT00604955|Experimental|A|Paromomycin IM Injection (approved product in India)
9891022|NCT00604981|Experimental|1|Multisystemic Therapy (MST)
9891023|NCT00604981|Active Comparator|2|Shapedown
9891024|NCT00604994||Malignant|Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina
9891025|NCT00604994||Benign|Patients without malignant gynaecological cancers
9891026|NCT00605046|Experimental|Asses [123I] AV151 and SPECT imaging|
9891027|NCT00605059|Experimental|Assess [123I] AV94 and SPECT imaging|
9891028|NCT00605098|Active Comparator|1|
9891029|NCT00605098|Experimental|2|
9891030|NCT00605124|Experimental|exercise|progressive exercise, home-based exercise program, tree exercise sessions weekly, chec-up visits every third month
9891031|NCT00605124|Active Comparator|Conventional treatment|Normal treatment, single guidance to home exercise
9891032|NCT00605228|Experimental|1|
9891033|NCT00605228|Active Comparator|2|
9891034|NCT00605241|Other|GSK598809|Drug
9891035|NCT00605332|Experimental|1|Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
9891036|NCT00605371|Experimental|Subjects receiving regimen A|Eligible subjects will receive regimen A containing lamotrigine extended release tablet of 200 milligrams plus 50 milligrams in fasted state
9891037|NCT00605371|Experimental|Subjects receiving regimen B|Eligible subjects will receive regimen B containing lamotrigine extended release caplet of 250 milligrams in fasted state.
9891038|NCT00605371|Experimental|Subjects receiving regimen C|Eligible subjects will receive regimen C containing lamotrigine extended release caplet of 250 milligrams in fed state.
9891039|NCT00605397|Experimental|1|breast cancer pt receiving trastuzumab therapy will undergo two complete PET studies.
9891040|NCT00605397|Experimental|2|breast cancer pt receiving trastuzumab therapy will undergo one complete PET studies
9891041|NCT00605410|Active Comparator|1|
9891042|NCT00605410|Placebo Comparator|2|
9891043|NCT00605436|Experimental|A|Restorative yoga therapy group: one orientation workshop for 3 hours, then twice-weekly group yoga therapy classes for first 5 weeks followed by once-weekly group yoga classes for another 5 weeks. The group will also be asked to practice their yoga postures at home for 30 minutes three times per week.
9891044|NCT00605436|No Intervention|B|The control group is a wait-list control group with no active intervention.
9891045|NCT00605488|Experimental|1|Pet Scan
9891046|NCT00605592|Experimental|1|Islet cell transplant
9891047|NCT00605605|Experimental|1|
9891048|NCT00605618|Experimental|Single Arm|
9891049|NCT00605631|Experimental|1|
9891050|NCT00605631|Active Comparator|2|
9891051|NCT00605631|Other|3|
9891052|NCT00605670||1|Postoperative Breast Surgery Patients
9891053|NCT00605670||2|Preoperative Breast Surgery Patients
9891054|NCT00605683|Active Comparator|1|50 mg/day Safinamide
9891055|NCT00605683|Active Comparator|2|Safinamide 100mg/day
9891056|NCT00605683|Placebo Comparator|3|Placebo 0mg/Safinamide
9891057|NCT00605709|Experimental|1|Active Cream 3% ; AM & PM
9891058|NCT00605709|Active Comparator|2|Placebo Cream AM; 3% Active Cream PM
9891059|NCT00605709|Active Comparator|3|Placebo Cream AM; 1.5% Active Cream PM
9891060|NCT00605709|Placebo Comparator|4|Placebo Cream AM & PM
9891061|NCT00605748|Active Comparator|1|Segmental PV-Isolation of the arrhythmogenic vein(s)
9891062|NCT00605748|Active Comparator|2|Segmental PV-Isolation of all veins
9891063|NCT00605761|Experimental|Cohort 1|50 mg treatment
9891064|NCT00605761|Experimental|Cohort 2|150 mg treatment
9891065|NCT00605774|Experimental|1|Hyperinsulinemic euglycemic glucose clamps x 2 on Day 1 Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion on Day 2
9891066|NCT00605774|Experimental|2|Day 1 euglycemic exercise period x 2 Day 2 hyperinsulinemic euglycemic glucose clamp with epinephrine infusion
9891067|NCT00605787|Active Comparator|Single group|Single group all treated similarly, outcome evaluated as changes within individuals during intervention
9891068|NCT00605800||1|normal healthy volunteers
9891069|NCT00605800||2|Patients undergoing major liver resections
9891070|NCT00605852|Experimental|Subjects receiving treatment in cohort I|Eligible subjects will receive three single doses of GSK835726 and one single dose of placebo in cohort I.
9891071|NCT00605852|Experimental|Subjects receiving GSK835726 in cohort II|Eligible subjects will receive repeat doses of GSK835726 once daily for 7 days.
9891072|NCT00605852|Placebo Comparator|Subjects receiving placebo in cohort II|Eligible subjects will receive repeat doses of placebo once daily for 7 days.
9891073|NCT00605852|Experimental|Subjects receiving treatment in cohort III|Eligible subjects will receive two single doses of GSK835726 and one single dose of placebo in cohort III.
9891074|NCT00605891|Experimental|A|carmoterol (CHF 4226) 1.0 μg once a day, in the morning
9891075|NCT00605891|Experimental|B|carmoterol (CHF 4226) 2.0 μg once a day, in the morning
9891076|NCT00605891|Experimental|C|carmoterol (CHF 4226) 4.0 μg once a day, in the morning
9891077|NCT00605891|Placebo Comparator|D|Placebo once a day, in the morning
9891078|NCT00605891|Active Comparator|E|Salmeterol 50 μg BID, in the morning and in the evening
9891079|NCT00605930|Active Comparator|Pyruvate, creatine, niacinamide|Pyruvate, creatine, niacinamide administered
9891080|NCT00605930|Placebo Comparator|Placebo|placebo
9891081|NCT00605956|Experimental|1|NatrOVA Creme Rinse - 1% Spinosad
9891082|NCT00605956|Experimental|2|NatrOVA Vehicle - no Spinosad
9891083|NCT00605956|Placebo Comparator|3|Blank Patch
9891084|NCT00605969|Active Comparator|FAI patients|This group consists of participants diagnosed with femoroacetabular impingement that are undergoing surgical correction.
9891085|NCT00605969|Placebo Comparator|Control|This group consists of healthy control participants with no hip problems.
9891086|NCT00605995|Experimental|Simvastatin|Simvastatin, 20 mg Tablet, given once daily. Dosage increased to 40 mg/day at the end of week 4 until endpoint.
9891087|NCT00605995|Placebo Comparator|Placebo|Placebo pill, similar in its appearance to Simvastatin, taken once daily for the duration of the trial.
9891088|NCT00606060|Experimental|Arm 1|
9891089|NCT00606073|Active Comparator|I|IVF Procedure-IVF Medium
9891090|NCT00606073|Active Comparator|II|IVF Procedure - ISM1 Medium
9891091|NCT00606073|Active Comparator|III|ICSI Procedure - IVF Medium
9891092|NCT00606073|Active Comparator|IV|ICSI Procedure - ISM1 Medium
9891093|NCT00606099|Experimental|1|telbivudine
9891094|NCT00606099|Active Comparator|2|adefovir dipivoxil
9891095|NCT00606112|Placebo Comparator|1|
9891096|NCT00606112|Placebo Comparator|2|
9891097|NCT00606112|Placebo Comparator|3|
9891098|NCT00606112|Placebo Comparator|4|
9891099|NCT00606125|Experimental|Arm 1|
9891100|NCT00606164|Placebo Comparator|Placebo|
9891101|NCT00606164|Experimental|10 ug/m2 Bryostatin|
9891102|NCT00606164|Experimental|15 ug/m2 Bryostatin|
9891103|NCT00606190|Active Comparator|Retrograde brain perfusion|Pt may be randomized to retrograde brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
9891104|NCT00606190|Active Comparator|Antegrade brain perfusion|Pt may be randomized to antegrade brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
9891105|NCT00606203|Experimental|A|The aims of this study are to investigate the prophylactic effect of milnacipran in post stroke depression.
9891106|NCT00606203|Placebo Comparator|B|Placebo
9891107|NCT00606216||A|TBI and Chemotherapy Conditioning Regimen. Twenty (20) patients will undergo conditioning treatment with TBI and chemotherapy prior to receiving a myeloablative allogeneic or an autologous HSCT.
9891108|NCT00606216||B|Chemotherapy Alone Conditioning Regimen Twenty (20) patients will undergo conditioning treatment with an all chemotherapy regimen prior to receiving an allogeneic or an autologous HSCT.
9891109|NCT00606216||C|A cohort of twenty (20) healthy controls, frequency matched on age, gender, and education, will be recruited at WCMC to participate in the study.
9891110|NCT00606242|Active Comparator|Low dose steroid|Fluticasone, 100 mcg per day
9891111|NCT00606242|Active Comparator|High dose steroid|Fluticasone, 1000 mcg per day
9891112|NCT00606255||A|Active training group: Electronic Pill-Boxes with SMS service 1/week, training material provided
9891113|NCT00606255||B|Passive training group: Electronic Pill-Boxes ,Training material provided
9891114|NCT00606255||C|Usual treatment group: Electronic Pill-Boxes, maintain current treatment method
9891115|NCT00606268|Experimental|1|1.0 mg/kg
9891116|NCT00606268|Experimental|2|1.5 mg/kg
9891117|NCT00606333|Experimental|Investigational arm|Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
9891118|NCT00606333|Active Comparator|Control Arm|Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
9891119|NCT00606359|Experimental|Study Group 1|
9891120|NCT00606359|Active Comparator|Study Group 2|
9891121|NCT00606372||1|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated with use of the cardio-pulmonary bypass
9891122|NCT00606372||2|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated without use of the cardio-pulmonary bypass
9891123|NCT00606385|Experimental|laparoscopic liver resection|Patients who underwent laparoscopic liver resection for HCC
9891124|NCT00606385|Active Comparator|open liver resection|Patients who underwent open liver resection for HCC
9891125|NCT00606411|Active Comparator|Topiramate|Study medication arm, 25-300mg of Topiramate
9891126|NCT00606411|Placebo Comparator|Placebo|Placebo arm of study, 25-300mg of sugar pill
9891127|NCT00606437|Experimental|I|Total Body Irradiation (TBI)/Flu Conditioning followed by combined UCB
9891128|NCT00606450|Experimental|20 mg Apremilast daily|20 mg of CC-10004 daily
9891129|NCT00606450|Experimental|20mg Apremilast twice daily|CC-10004 twice daily
9891130|NCT00606450|Placebo Comparator|Placebo|Placebo arm
9891131|NCT00606463|Experimental|(Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
9891132|NCT00606515|Experimental|A|Liposomal paclitaxel
9891133|NCT00606515|Active Comparator|B|Paclitaxel
9891134|NCT00606528||Group A|patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy
9891135|NCT00606528||Group B|Healthy volunteers willing to donate blood on 2 separate occasions
9891136|NCT00606541|Experimental|1|Quetiapine XR 50mg-400mg per day
9891137|NCT00606541|Placebo Comparator|2|Placebo
9891138|NCT00606567|Active Comparator|1-treatment|remote monitoring with carelink every 3 months
9891139|NCT00606567|No Intervention|2- control|device interrogations in clinic every 3 months
9891140|NCT00606606|Experimental|I - Intervention units|nursing home units, provided HIT CDS intervention
9891141|NCT00606606|No Intervention|C - control units|nursing home units, not provided the HIT CDS intervention
9891142|NCT00606619|No Intervention|1|Conventional feeding : They begin ingesting sips of water on third postoperative day and continued with a liquid diet for the next two days. Patients were given a soft diet on sixth postoperative day.
9932209|NCT00946803|No Intervention|Wait list|Wait list control group. Offered PC-CB Intervention after the study.
9891143|NCT00606619|Experimental|2|Early oral feeding : The patients begin ingesting sips of water on the first postoperative day. If they are tolerable, they continued with a clear liquid diet the next day and a soft diet on the third post operative day.
9891144|NCT00606645|Experimental|1|XmAb2513
9891145|NCT00606658|Other|Oil dripping therapy|Single Arm
9891146|NCT00606671||1|lean control women without PCOS
9891147|NCT00606671||2|lean women with PCOS
9891148|NCT00606671||3|Obese control women without PCOS
9891149|NCT00606671||4|Obese women with PCOS
9891150|NCT00606671||1xx - 04 LC|lean control women
9891151|NCT00606671||1xx-04 LP|lean women with PCOS
9891152|NCT00606671||1xx-04 OC|obese control women
9891153|NCT00606671||1xx-04 OP|obese women with PCOS
9891154|NCT00606723|Experimental|1|"Group I: Relapsed AML-patients with blast cell reduction to <20% before the second course of induction therapy. These patients will receive conventional SCT.~Group II: Patients with non response to frontline treatment of AML, patients with blast cells <20% before the second course of induction therapy who do not achieve a second remission and relapsed AML-patients with blast cells >=20% before the second course of induction therapy. If these patients have a matched donor (MSD/MD) they will receive SCT with FLAMSA.~Group III: Patients who are eligible for Group II but have no matched donor. These patients will receive SCT from a haploidentical donor."
9891155|NCT00606736||patients|subjects with right ventricular outflow tract arrhythmia
9891156|NCT00606736||control|subjects ,age match,healthy
9891157|NCT00606762|Active Comparator|LPLC, HPLC|LPLC: Low pressure pneumoperitoneum is defined as intraabdominal pressure kept at8 mm Hg after initial trocar insertion at 12 mm Hg HPLC: High pressure pneumoperitoneum is defined as intra abdominal pressure kept at 12 mm Hg throughout the procedure
9891158|NCT00606775|Experimental|Carvedilol|
9891159|NCT00606775|No Intervention|Control|
9891160|NCT00606788|Active Comparator|AW|Patients received computer-driven protocolized weaning (= Automated Weaning)
9891161|NCT00606788|Active Comparator|CW|Patients received physician-directed non-protocolized weaning (= Conventional Weaning)
9891162|NCT00606827|Experimental|A|Bicarbonate
9891163|NCT00606827|Active Comparator|B|Saline
9891164|NCT00606840|Experimental|1|One arm is a large changes group in which participants will be asked to make periodic large changes in their eating and activity, aimed at producing initial weight loss, in order to prevent weight gain over time.
9891165|NCT00606840|Experimental|2|The second arm is a small changes group in which participants will be asked to make small changes to their eating and activity and maintain these changes forever in order to prevent weight gain.
9891166|NCT00606853|Experimental|1|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
9891167|NCT00606853|Experimental|2|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $560 in prizes and twice-weekly breath and urine samples.
9891168|NCT00606853|Experimental|3|Standard Treatment plus prize contingency management for attendance with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
9891169|NCT00606853|No Intervention|4|Standard Treatment
9891170|NCT00606866|Placebo Comparator|I|placebo pill
9891171|NCT00606866|Active Comparator|II|Sorafenib, 200 mg bid
9891172|NCT00606866|Active Comparator|III|Sorafenib, 400 mg bid
9891173|NCT00606879|Experimental|Single arm|
9932210|NCT00946816|Active Comparator|Anorexia Nervosa|
9932211|NCT00946816|Active Comparator|Obesity|
9932212|NCT00946816|Active Comparator|Healthy volunteers|
9932213|NCT00946842|Experimental|Panel A: Treatment Sequence ABC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ABC with food and subsequent treatments will be separated by 4 weeks.
9932214|NCT00946842|Experimental|Panel A: Treatment Sequence ACB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ACB with food and subsequent treatments will be separated by 4 weeks.
9932215|NCT00946842|Experimental|Panel A: Treatment Sequence BAC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BAC with food and subsequent treatments will be separated by 4 weeks.
9932216|NCT00946842|Experimental|Panel A: Treatment Sequence BCA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BCA with food and subsequent treatments will be separated by 4 weeks.
9932217|NCT00946842|Experimental|Panel A: Treatment Sequence CBA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CBA with food and subsequent treatments will be separated by 4 weeks.
9932218|NCT00946842|Experimental|Panel A: Treatment Sequence CAB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CAB with food and subsequent treatments will be separated by 4 weeks.
9932219|NCT00946842|Experimental|Panel B: Treatment Sequence DEF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DEF with food and subsequent treatments will be separated by 4 weeks.
9932220|NCT00946842|Experimental|Panel B: Treatment Sequence DFE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DFE with food and subsequent treatments will be separated by 4 weeks..
9932221|NCT00946842|Experimental|Panel B: Treatment Sequence EDF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EDF with food and subsequent treatments will be separated by 4 weeks.
9932222|NCT00946842|Experimental|Panel B: Treatment Sequence EFD|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EFD with food and subsequent treatments will be separated by 4 weeks.
9932223|NCT00946842|Experimental|Panel B: Treatment Sequence FDE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FDE with food and subsequent treatments will be separated by 4 weeks.
9932224|NCT00946842|Experimental|Panel B: Treatment Sequence FED|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FED with food and subsequent treatments will be separated by 4 weeks.
9932225|NCT00946855||soccer players|players of the first two German soccer leagues
9891174|NCT00606918||1|Individuals with ALS
9891175|NCT00606918||2|Healthy Adults
9891176|NCT00606970|Experimental|Intervention group|Seigen Alpha EV Treatment
9891177|NCT00606970|Placebo Comparator|2|Identically packaged placebo packets taken 3x daily for 3 months maximum
9891178|NCT00606983|No Intervention|1|
9891179|NCT00606983|Experimental|2|oral administration of Tamsulosin
9891180|NCT00606996|Experimental|IPT-G|Group Interpersonal Psychotherapy
9891181|NCT00606996|Active Comparator|PSYCHOED|Psychoeducation
9891182|NCT00607009|Experimental|Intervention|ALIVE - received emails about chosen behavioral intervention path - physical activity, fruits/vegetables or fats/sugars
9891183|NCT00607009|No Intervention|Control|no intervention
9891184|NCT00607035|Experimental|A|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
9891185|NCT00607035|Experimental|H|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
9891186|NCT00607061|Other|1|Full term newborn babies with gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile.
9891187|NCT00607061|Other|2|Low birth weight newborn babies (gestational age < 32 weeks of amenorrhea and/or weight of birth < 1500 g and/or weight of birth < third percentile for their gestational age.
9891188|NCT00607061|Other|3|Full term newborn babies (gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile).
9891189|NCT00607074|Experimental|1|
9891190|NCT00607100||1|Patients with Band atrophy of the optic nerve
9891191|NCT00607100||2|Normal Controls
9891192|NCT00607152|Experimental|1|IV infusion at a dose level of 0.20mg/kg per day
9891193|NCT00607152|Active Comparator|2|100mg tablets, administered orally, according to standard medical practice
9891194|NCT00607178|Experimental|Influenza vaccine|Enrolled patients who are randomly assigned to receive influenza vaccine
9891195|NCT00607178|Placebo Comparator|Placebo|Enrolled patients who are randomly assigned to receive placebo of influenza vaccine
9891196|NCT00607217|Experimental|CAD-Exp|Enrolled coronary artery disease patients who are randomly assigned to receive influenza vaccine
9891197|NCT00607217|Placebo Comparator|CAD-Control|Enrolled coronary artery disease patients who are randomly assigned to receive placebo of influenza vaccine
9891198|NCT00607217|Experimental|Healthy-Control|Enrolled healthy subjects serve as control for CAD-Exp
9891199|NCT00607230|Experimental|E|BCG vaccination
9891200|NCT00607230|Placebo Comparator|P|Saline vaccination
9891201|NCT00607282|Placebo Comparator|Placebo|normal control group
9891202|NCT00607282|Experimental|Udenafil|oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
9891203|NCT00607295|Experimental|1|Clino-san 2ml vaginal application 3 times per week for 12 weeks
9891204|NCT00607295|Placebo Comparator|2|placebo 2ml vaginal application 3 times per week for 12 weeks
9891205|NCT00607308|Experimental|0.1 mg/kg|
9891206|NCT00607308|Experimental|0.5 mg/kg|
9891207|NCT00607308|Experimental|1 mg/kg|
9891208|NCT00607308|Experimental|5 mg/kg|
9891209|NCT00607308|Placebo Comparator|Placebo|
9891210|NCT00607308|Experimental|10 mg/kg|
9891211|NCT00607334|Experimental|GP|Children with Developmental Language Impairments were enrolled in this group.
9891212|NCT00607334|Experimental|GC|Children with normal language development were enrolled in this group.
9891213|NCT00607347|Experimental|A|The subjects will be undergoing a oral glucose tolerance test.
9891214|NCT00607360|No Intervention|Standard Drug Court|Participants received standard services from drug court
9891215|NCT00607360|Experimental|Drug Court plus Therapeutic Workplace|Participants receive standard drug court services plus therapeutic workplace intervention
9891216|NCT00607399|Experimental|Single arm|
9891217|NCT00607412|Experimental|1|Present focused, integrated psychotherapy for PTSD and substance use disorders
9891218|NCT00607412|Active Comparator|2|Supportive therapy using 12-step model
9891219|NCT00607425||1|Non-small cell lung cancer patients
9891220|NCT00607425||2|Healthy control subjects
9891221|NCT00607451|Experimental|1|
9891222|NCT00607451|Experimental|2|
9891223|NCT00607451|Experimental|3|
9891224|NCT00607451|Experimental|4|
9891225|NCT00607464|Experimental|1|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
9891226|NCT00607464|No Intervention|2|Standard care
9891227|NCT00607490|Experimental|Cognitive-behavioral Therapy|10 weekly individual 60-minute sessions
9891228|NCT00607490|Active Comparator|Supportive Psychotherapy|10 weekly individual 60-minute sessions
9891229|NCT00607503|Experimental|1|
9891230|NCT00607516|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
9891231|NCT00607516|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
9891232|NCT00607529||1|Patients having a creatinine drawn
9891233|NCT00607542|Active Comparator|1|starting dose of baclofen 2.5 mg PO TID with dose escalation as tolerated
9891234|NCT00607555||Observation|Premature infants over 23 weeks of gestation and less than 1.25 kilograms at birth, who are tolerating feedings, and are clinically stable
9891235|NCT00607568|Experimental|1|atomoxetine 40mg per day
9891236|NCT00607568|Placebo Comparator|2|second arm is placebo, sugar pill
9891237|NCT00607581|Experimental|1|"The participants receive up to 9 28-day cycles of~cyclophosphamide: 500 mg orally on days 1, 8, 15;~lenalidomide: 15 mg orally on days 1-21;~dexamethasone: 40 mg orally on days on days 1, 8, 15, 22."
9891238|NCT00607607|Experimental|A|Ovarian Cancer Patients
9891239|NCT00607607|Experimental|B|Endometrial Cancer Patients
9891240|NCT00607633||1|Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT
9891241|NCT00607646|Experimental|1|Hyperinsulinemic (high dose insulin) hypoglycemic clamp studies with oral administration of DHEA or placebo prior to each clamp x 2 on day 1. Day 2 hyperinsulinemic hypoglycemia. Participant randomized to either DHEA or placebo for baseline trial (arm 1) and 6 weeks treatment.
9891242|NCT00607646|Experimental|2|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
9891243|NCT00607646|Experimental|Arm 3 (optional)|Individuals will be asked to return after at least 2 months and repeat the trial they did not complete (for example, placebo if they were in the DHEA trial before). Again Day 1 would consist of two hyperinsulinemic clamps with placebo or DHEA given orally. Day 2 hyperinsulinemic hypoglycemic clamp with oral administration of placebo or DHEA.
9891244|NCT00607646|Experimental|Arm 4|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
9891245|NCT00607659||Chlamydia Positive|Adolescent females, 11-21 years old, evaluated for pelvic examinations or STI screening will be asked to participate in this study. Participants are being asked to give us permission to collect:additional cervical or vaginal swabs, rectal swabs, blood draws where three tablespoons of blood, a urine pregnancy test, and a comprehensive health history. You may be asked to provide a urine specimen at the initial visit instead of having a cervical swab. The study team will obtain a cervical swab when you come back for your follow-up appointments. If your culture is positive for Chlamydia, you will be asked attend 3 additional follow-up appointments after 3 months, 6 months, 1 year, 2 years, and 3 years .
9891246|NCT00607659||Control/Chlamydia Negative|Some participants with negative cultures will be included in this study as a control group. The same specimens, exams and blood draws will apply for those subjects with visits at 3 months, 6 months, 1 year, 2 years, and 3 years
9891247|NCT00607685|Experimental|1|The participants will receive a subconjunctival injection of a mixture of 5FU with hyaluronic acid.
9891248|NCT00607685|Active Comparator|2|Participants will receive a subconjunctival injection of 5 Fluorouracil only.
9891249|NCT00607711|Experimental|Single arm|
9891250|NCT00607737|Experimental|1|insulin detemir
9891251|NCT00607737|Placebo Comparator|2|saline
9891252|NCT00607750|Placebo Comparator|1|
9891253|NCT00607750|Experimental|ATG003|
9891254|NCT00607763|Experimental|1. Micafungin|
9891255|NCT00607776|Active Comparator|1|Systane
9891256|NCT00607776|Experimental|2|Blink tears
9891257|NCT00607841|Experimental|Dose Escalation Cohort 1|Ispinesib given on days 1 and 15 of a 28 day cycle.
9891258|NCT00607841|Experimental|Dose Escalation Cohort 2|Ispinesib given on days 1 and 15 of a 28 day cycle.
9891259|NCT00607841|Experimental|Dose Escalation Cohort 3|Ispinesib given on days 1 and 15 of a 28 day cycle.
9891260|NCT00607854|Experimental|Zevalin|Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen
9891261|NCT00607906|Experimental|Subjects receiving treatment in cohort A1|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 5 milligrams, 15 milligrams, 50 milligrams, or 100 milligrams.
9891262|NCT00607906|Experimental|Subjects receiving treatment in cohort A2|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 100 milligrams, 200 milligrams, 300 milligrams, or 400 milligrams.
9891263|NCT00607906|Experimental|Subjects receiving treatment in cohort A3|Eligible subjects will receive oral immediate release capsules of SB-756050 with a dose of 150 milligrams. Subjects will also receive oral modified release capsules of SB-756050 with doses of 150 milligrams, 300 milligrams, or 400 milligrams.
9891264|NCT00607906|Experimental|Subjects receiving treatment in cohort A4|Eligible subjects will receive SB-756050 in this additional cohort.
9891265|NCT00607906|Experimental|Subjects receiving treatment in cohort B1|Eligible subjects will receive oral modified release capsules of SB-756050 with doses of 50 milligrams, 150 milligrams or 400 milligrams. Subjects will also receive immediate release oral capsules of SB-756050 with a dose of 150 milligrams.
9891266|NCT00607932|Experimental|Brassica Vegetables Diet Intervention|
9891267|NCT00607932|Experimental|Pill|
9891268|NCT00607945|Placebo Comparator|0 g CLA|Avandia (Rosiglitazone) 4-8mg/day OR other diabetes medication currently prescribed to participant, 0 g CLA, 8 g Placebo oil (based on typical American diet)
9891269|NCT00607945|Experimental|3.2 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 3.2 g CLA, 4.8 g placebo oil (based on typical American diet)
9891270|NCT00607945|Experimental|6.4 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 6.4 g CLA, 1.6 g placebo oil (based on typical American diet)
9891271|NCT00607958|Experimental|1|dose reduction
9891272|NCT00607971|Experimental|1|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
9891273|NCT00607984|Experimental|single|
9891274|NCT00608010|Experimental|1|Vitrification
9891275|NCT00608010|Active Comparator|2|Slow freezing
9891276|NCT00608049|Experimental|1|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/high GI, and low carbohydrate/low GI
9891277|NCT00608049|Experimental|2|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/low GI, and low carbohydrate/high GI
9891278|NCT00608049|Experimental|3|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/high GI, and low carbohydrate/low GI
9891279|NCT00608049|Experimental|4|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/low GI, and low carbohydrate/high GI
9891280|NCT00608049|Experimental|5|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/high GI, and high carbohydrate/low GI
9891281|NCT00608049|Experimental|6|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/low GI, and high carbohydrate/high GI
9891282|NCT00608049|Experimental|7|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/high GI, and high carbohydrate/low GI
9891283|NCT00608049|Experimental|8|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/low GI, and high carbohydrate/high GI
9891284|NCT00608075|Other|1|Manic Patients
9891285|NCT00608075|Other|2|Depressed Patients
9891286|NCT00608088|Active Comparator|1|Usual Care
9891287|NCT00608088|Active Comparator|2|Health Nurse/Peer Councelor Intervention
9891288|NCT00608101|Experimental|1|Day 1 hyperinsulinemic euglycemic clamps with either 0.2 mg fludrocortisone, 0.75 mg Dexamethasone, or both given orally before each morning and afternoon clamp. Day 2 hyperinsulinemic hypoglycemic glucose clamp.
9891289|NCT00608101|Experimental|2|Fludrocortisone will be administered in doses of 0.05mg, 0.1mg and 0.2 mg form at the start of each clamp period on day 1. Dexamethasone will be administered orally in the doses of 0.18 mg, 0.375mg and 0.75mg doses. The combination of the 0.05mg fludrocortisone and 0.18mg dexamethasone and 0.1mg of fludrocortisone and 0.375 mg doses will be administered at the start of each day 1 clamp period. Day 2 90 minutes of moderate exercise.
9891290|NCT00608127|Experimental|1|Single arm open label
9891291|NCT00608153||1|Patient with essential hypertension under treatment with candesartan or candesartan HCT
9891292|NCT00608179|Experimental|1|
9891293|NCT00608179|Experimental|2|
9891294|NCT00608179|Experimental|3|control-euglycemia
9891295|NCT00608179|Experimental|4|control-hypoglycemia
9891296|NCT00608192|Active Comparator|Testing, Education, & Counseling (TEC)|HIV and hepatitis screening is done on-site, but vaccination and medical care will be provided by off-site referral. HIV and Hepatitis, Testing, Education, & Counseling (TEC) participants will receive standard HIV and hepatitis education & counseling. TEC participants will not receive case management services.
9932226|NCT00946868||Intermittent claudication patients|Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
9667077|NCT03990766|Placebo Comparator|Placebo saline irrigation|Identical-appearing lactose monohydrate capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
9891297|NCT00608192|Experimental|Hepatitis Care Coordination (HCC)|Participants will receive on-site HIV and viral hepatitis screening. Hepatitis A and B combination vaccination will be provided on-site. Participants will receive on-site theory-based HIV and hepatitis education, counseling, and 6 months of case management to promote adherence to HIV and HCV evaluation.
9891298|NCT00608218||Artist|
9891299|NCT00608231|Experimental|PD-STN|Parkinson's Disease -- STN target
9891300|NCT00608231|Experimental|PD - GPi|Parkinson's Disease -- GPi target
9891301|NCT00608231|Experimental|ET - VIM|Essential Tremor -- VIM target
9891302|NCT00608231|Experimental|Dystonia - GPi|Dystonia -- GPi target
9891303|NCT00608231|Placebo Comparator|PD - STN Control|Parkinson's Disease -- STN target
9891304|NCT00608231|Placebo Comparator|PD - GPi Control|Parkinson's Disease -- GPi target
9891305|NCT00608231|Placebo Comparator|ET - VIM Control|Essential Tremor -- VIM target
9891306|NCT00608231|Placebo Comparator|Dystonia - GPi Control|Dystonia -- GPi target
9891307|NCT00608283||Live Kidney Donors|People who are going to donate a kidney at one of the three transplant centers from August 2007 until June 2011
9891308|NCT00608296||1|Study subjects on lithium
9891309|NCT00608296||2|study subjects on quetiapine
9891310|NCT00608335|Experimental|1. Micafungin 3.0 mg|IV
9891311|NCT00608335|Experimental|2. Micafungin 4.5 mg|IV
9891312|NCT00608348|Experimental|1|Hyperinsulinemic euglycemic or hypoglycemic clamp with Muscle and skin sympathetic nerve activity recording in arm and/or leg
9891313|NCT00608348|Experimental|2|Exercise with insulin or no insulin infused with muscle and skin sympathetic nerve activity measurements
9891314|NCT00608361|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9891315|NCT00608387|Experimental|A|Participants will receive usual care from their healthcare providers and have access to a Web-based CVD risk-factor management program.
9891316|NCT00608387|No Intervention|B|Participants will receive usual care from their healthcare providers.
9891317|NCT00608400|Experimental|1|CLA 1.5 g/d
9891318|NCT00608400|Experimental|2|CLA 3.0 g/d
9891319|NCT00608400|Placebo Comparator|3|
9891320|NCT00608439|Placebo Comparator|Placebo|Placebo CAST
9891321|NCT00608439|Active Comparator|Centella asiatica selected triterpenes|Active CAST
9891322|NCT00608452||1|
9891323|NCT00608595|Experimental|Therapeutic Intervention/Celecoxib|Celecoxib
9891324|NCT00608621||1-physostigmine|"Physostigmine 4 mg in 50 ml NaCl 0.9% per 24 h as syringe pump continuously for 48 hours, plus physostigmine 2mg (in NaCl 0.9% 50 ml)at termination of sedation~PCA: Patient-controlled analgesia with piritramide 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
9891325|NCT00608621||2-placebo|"NaCl 0.9% 50 ml per 24 h continuously over 48 hours, plus 50 ml NaCl 0.9% at termination of sedation~PCA: Patient-controlled analgesia with piritramid 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
9891326|NCT00608660|Experimental|A|staging acupuncture for treating Bell's Palsy
9891327|NCT00608660|Experimental|B|staging acupuncture and moxibustion for treating Bell's Palsy
9891328|NCT00608660|Experimental|C|staging electroacupuncture for treating Bell's Palsy
9891329|NCT00608660|Experimental|D|staging acupuncture along Yangming musculature for treating Bell's Palsy
9891330|NCT00608660|Experimental|E|non-staging acupuncture for treating Bell's Palsy
9891331|NCT00608673|Experimental|1|Patients in arm one used twice daily pimecrolimus 1% cream on their facial discoid lupus erythematosus lesions for 8 weeks.
9891332|NCT00608673|Active Comparator|2|Twice daily betamethasone valerate 0.1% cream to facial lesions of discoid lupus erythematosus for 8 weeks
9891333|NCT00608725|Other|Patients|Patients with orthostatic intolerance
9891334|NCT00608725|Other|Healthy Control Subjects|"Healthy subjects to determine normal response"
9891335|NCT00608751|Experimental|IMRT|External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
9891336|NCT00608790|Experimental|1|
9891337|NCT00608803|Experimental|Single arm|Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy.
9891338|NCT00608816|Experimental|1|Hyperinsulinemic euglycemic glucose clamp study on day 1 Hyperinsulinemic euglycemic clamp study on day 2 with epinephrine infusion
9891339|NCT00608816|Experimental|2|Hyperinsulinemic hypoglycemic glucose clamp x 2 on day 1 Hyperinsulinemic euglycemic clamp with epinephrine infusion on Day 2
9891340|NCT00608920|Experimental|SPECT lymph node mapping|"Diagnostic pelvic CT~Nuclear tracer injection (Tc-99m) - same time as the ACCULOC seed implantation~CT simulation (2 hours after prostate markers are placed)~SPECT lymphoscintigraphy (first set of images 3-6 hours after injection and second set may be obtained 18-24 hours after injection)"
9891341|NCT00608933|Active Comparator|Arm I (intervention)|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
9891342|NCT00608933|Other|Arm II (wait-list)|Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I (educational intervention) are made available to the wait-list health providers.
9891343|NCT00608946|Experimental|1|efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear
9891344|NCT00608946|Placebo Comparator|2|placebo
9667078|NCT03990662||TMD|Patients (aged ≥18 years) with a diagnosis of Temporomandibular Disorders
9891345|NCT00608972|Experimental|Doxil, Carboplatin and Bevacizumab|
9932227|NCT00946894|Experimental|Total thyroidectomy|Patients who underwent total thyroidectomy
9932228|NCT00946894|Experimental|Dunhill operation|Patients who underwent unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
9932229|NCT00946894|Active Comparator|Bilateral subtotal thyroidectomy|Patients who underwent bilateral subtotal thyroidectomy
9667079|NCT03982186|Experimental|Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA|Participants will receive medium dose of JNJ-73763989 along with JNJ-56136379 and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) up to 48 weeks.
9667080|NCT03982186|Experimental|Arm 2: JNJ-73763989 (high dose) + Placebo + NA|Participants will receive high dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
9667081|NCT03982186|Experimental|Arm 3: JNJ-73763989 (medium dose) + Placebo + NA|Participants will receive medium dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
9667082|NCT03982186|Experimental|Arm 4: JNJ-73763989 (low dose) + Placebo + NA|Participants will receive low dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
9667083|NCT03982186|Experimental|Arm 5: Placebo + JNJ-56136379 + NA|Participants will receive placebo for JNJ-73763989 and a fixed dose of JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
9667084|NCT03982186|Placebo Comparator|Arm 6 (Control): Placebo + Placebo + NA|Participants will receive placebo for JNJ-73763989 and placebo for JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
9990696|NCT01445938|Experimental|Step 3 (SAR97276A)|1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)
9990697|NCT01445964|Experimental|1|SLCO2B1 wild type allele
9667087|NCT03981211|Experimental|Cohort A: 8 weeks G/P standard therapy|8 weeks treatment of a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (standard duration therapy).
9667088|NCT03981211|Experimental|Cohort B: 4 weeks SOF/G/P shortened therapy|4 weeks treatment of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (shortened duration therapy).
9990698|NCT01445964|Experimental|2|SLCO2B1 variant allele
9667090|NCT03973814|Active Comparator|Prior to Thermax Warming|Baseline temperature
9667091|NCT03973814|Active Comparator|During warming|Temperature during Thermax warming
9667092|NCT03973814|Active Comparator|Post warming|Temperature after cessation of Thermax warming
9667093|NCT03973281|Active Comparator|Materna Prep Device|Materna Prep Device
9667094|NCT03973281|Other|Standard of Care (SOC)|Standard of Care (SOC)
9667095|NCT03971838|Experimental|Intervention Arm|Women with a history of gestational diabetes will be offered 4-6 months of a diabetes prevention program.
9667096|NCT03967704|Experimental|Life quality evaluation|"Patients consulting the Emergency Department (SAU) or the rheumatology department of the GHPSJ (referred by a colleague orthopaedic surgeon, rheumatologist, radiologist or other) for a recent symptomatic osteoporotic dorsal or lumbar vertebral fracture, are called for a rheumatology consultation, vertebral fracture consultation.~Patients consulting in the rheumatology department during a spinal fracture consultation at the GHPSJ as well as patients hospitalized in the rheumatology department at the GHPSJ are selected consecutively.~- Arm 1 (intervention): two additional consultations with the rheumatology"
9667097|NCT03965468|Experimental|Immunotherapy, chemotherapy, radiotherapy and surgery|"Durvalumab 1500 mg administered intravenously every 3 weeks for the first 4-6 cycles (during chemotherapy);~4-6 cycles of chemotherapy, carboplatin AUC5 every 3 weeks plus paclitaxel 175 mg/m2, every 3 weeks;~Stereotactic body radiotherapy (SBRT) of all oligo-metastatic lesions, in a maximum of 10 treatment fractions over 2 weeks, starting after week one of chemotherapy cycle 1 and completed within four weeks after start of durvalumab treatment;~Restaging at 3 months; if no disease progression, proceed to definitive local treatment (surgical resection of primary tumour or radiotherapy at a minimum dose of 60-66Gy to the primary tumour). Durvalumab continues at 1500 mg intravenously every 4 weeks until progression of disease or for a maximum of 1 year from start of treatment."
9667098|NCT03965273|Experimental|Full TP|Full TP intervention including emphasized social norms change
9667099|NCT03965273|Experimental|Light TP|Light TP intervention without emphasized social norms change
9667100|NCT03965273|No Intervention|Pure control|Pure control
9667101|NCT03963739||Race: Non-Hispanic African American|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
9667102|NCT03963739||Race: Non-Hispanic White|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
9667103|NCT03963739||Income: Lower Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
9932230|NCT00946907|Active Comparator|aspirin|
9932231|NCT00946907|Placebo Comparator|placebo|
9990699|NCT01446029|No Intervention|Usual Care|
9990700|NCT01446029|Active Comparator|Intervention Device|
9990701|NCT01446055|Experimental|ResQ process group|Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
9990702|NCT01446055|Active Comparator|Ficoll-based conventional method|A conventional method based on Ficoll cell separation is used to process bone marrow.
9990703|NCT01446068|Experimental|Lean Subjects|
9797476|NCT01597479|Experimental|dPNBs group|"Patients in this group received ultrasound guided dPNBs on radial and median nerves (target nerves of TRA) in the postoperative period, before discharge.~The procedural objective of dPNBs was to place local anesthetic around the target nerves to achieve a long lasting, sensitive and selective block in the surgical area. dPNBs were performed with 5 ml/nerve of levobupivacaine 0,125%.~Ultrasound guidance allowed us to verify the correct distribution of LA around the target nerves target and optimize needle position if it was necessary, always avoiding the intraneural injection."
9797477|NCT01597492|Experimental|Belimumab plus Early Vaccination|Belimumab plus Early Vaccination
9797478|NCT01597492|Experimental|Belimumab plus Late Vaccination|Belimumab plus Late Vaccination
9797479|NCT01597505|Experimental|Surotomycin|250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
9797480|NCT01597505|Active Comparator|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
9797481|NCT01597557|Active Comparator|Magnesium Sulfate|Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure
9797482|NCT01597557|Placebo Comparator|Placebo|Patients in this arm receive normal saline drip intravenously before the cardioversion procedure
9797483|NCT01597596|Experimental|Alglucosidase Alfa 4000 L material (Non-US participants)|Alglucosidase alfa 4000 L material for 52 weeks.
9797484|NCT01597596|Active Comparator|Alglucosidase Alfa 160 L material (US participants)|Alglucosidase alfa 160 L material for 52 weeks.
9797485|NCT01597622|Experimental|Open-label Belimumab|Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
9797486|NCT01597635|Experimental|Part A|4 increasing doses of GSK2586881 given over 2 days
9797487|NCT01597635|Experimental|Part B|Repeat Medium-High dose of GSK2586881 (or placebo) over 3 days
9797488|NCT01597687|Experimental|Malaysia Group|Malaysian adults aged >19 years with prolonged cough of 2 weeks or more.
9797489|NCT01597687|Experimental|Taiwan Group|Taiwanese adults aged >19 years with prolonged cough of 2 weeks or more.
9797490|NCT01597687|Experimental|Thailand Group|Thailandese adults aged >19 years with prolonged cough of 2 weeks or more.
9797491|NCT01597791|Placebo Comparator|Foley catheter|Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
9797492|NCT01597791|Experimental|No Foley Catheter|Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
9797493|NCT01597843|Experimental|First educational intervention group|Group that receives intervention first. The intervention is a series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
9797494|NCT01597843|Experimental|Second intervention group|This arm receives a series of training sessions over study months 6-9. The training sessions are in person and on line and are directed at post superusers who will in turn educate post members on the utility and mechanics of use of MHV. They complete survey rounds 1 and 2 before the training and survey round 3 after the training.
9797495|NCT01597843|No Intervention|Education after data collection complete|This group received a similar intervention, but after all quantitative data collection complete.
9797496|NCT01597856|Experimental|SBIRT|"The SBIRT-VA manual codifies basic substance abuse screening, treatment, Motivational Interviewing and referral procedures. It is designed for providers with minimal substance abuse expertise and is easy for experienced substance abuse providers to deliver.~Study sessions include identifying the Veterans' values through a card sort, the change ruler, on which the Veteran rates his/her willingness to change current behavior, listing the pros and cons of changing."
9797497|NCT01597856|No Intervention|No additional treatment|Veterans assigned to the control condition will not receive any study-related therapy. A Veteran who completes a Compensation examination ordinarily has no further treatment, referral, or debriefing as part of the Compensation examination.
9797498|NCT01597908|Experimental|Dabrafenib plus Trametinib|BRAF inhibitor plus MEK inhibitor
9797499|NCT01597908|Active Comparator|Vemurafenib|BRAF inhibitor
9797500|NCT01597973|Active Comparator|colistin and meropenem|
9797501|NCT01597973|Active Comparator|colistin and placebo|
9797502|NCT01598064|Experimental|GK#10|GK#10 1 pk tid for 8 weeks
9797503|NCT01598064|Placebo Comparator|Placebo|Placebo 1 pack tid for 8 weeks
9797504|NCT01598090|Experimental|Part A: Peginterferon Lambda-1a + RBV + TVR|
9797505|NCT01598090|Experimental|Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR|
9797506|NCT01598090|Experimental|Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR|
9797507|NCT01598129|Experimental|CGTG-102|CGTG-102 dose escalation
9797508|NCT01598194|Experimental|Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle|The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
9797509|NCT01598207|Experimental|Marinol|
9797510|NCT01598207|Placebo Comparator|Placebo|
9797511|NCT01598298|Experimental|Arm I|Patients receive duloxetine hydrochloride orally (PO) once daily (QD) on days 1-7, twice daily (BID) on days 8-84, and then QD on days 85-91.
9932232|NCT00946933|Placebo Comparator|Placebo|0.025 g/kg/day of NaCl (sodium chloride)
9990704|NCT01446068|Experimental|Obese subjects|
9990705|NCT01446081|Experimental|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
9990706|NCT01446081|No Intervention|Control|Participants assigned to this arm will receive usual care.
9990707|NCT01446094|Other|single-arm|Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
9990708|NCT01446107|Experimental|fissure sealant|single placement of resin fissure sealant on tooth surface
9990709|NCT01446107|Experimental|fluoride varnish|application of a 5% sodium fluoride varnish every 6 months
9990710|NCT01446107|Experimental|SDF solution|application of a 38% silver diamine fluoride solution onto tooth surface every year
9990711|NCT01446107|Placebo Comparator|control|application of water onto tooth surface every year
9990712|NCT01446120|Experimental|Insulin loaded Orally Dissolved Films (insulin-ODF)|
9990713|NCT01446120|Active Comparator|Human Insulin Specific RIA Kit <5uCi|
9990714|NCT01446146|Experimental|IDM intervention|Will receive a 40 minute intervention session with a clinician, learning about PTSD treatment options and choosing a preferred treatment.
9990715|NCT01446146|Placebo Comparator|Treatment as usual plus placebo session|Will work with provider to select a treatment plan and will receive a 40 minute session without IDM intervention.
9990716|NCT01446172||cognitive, schema focused, guided mastery, exposure|
9990717|NCT01446185|Other|a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population|
9990718|NCT01446198||AHPV positive and negative subjects|
9990719|NCT01446211|Experimental|Test group - gusperimus|Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
9990720|NCT01446211|Active Comparator|Control group|"The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.~The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
9990721|NCT01446224||Subjects who experience cardiac ischemia|Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident
9990722|NCT01446224||Subjects who do not experience cardiac ischemia|Subjects who do not experience cardiac ischemia
9990723|NCT01446224||Subjects who experience Torsades de Pointes|Subjects who experience Torsades de Pointes
9990724|NCT01446224||Subjects who do not experience Torsades de Pointes|Subjects who do not experience Torsades de Pointes
9990725|NCT01446263|Active Comparator|Radial access|
9990726|NCT01446263|Active Comparator|Femoral access|
9990727|NCT01446276|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for six month
9990728|NCT01446276|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for six month
9990729|NCT01446276|No Intervention|Control group|Men without non-alcoholic fatty liver disease
9990730|NCT01446302|Active Comparator|Double meal on a HD day|A standardized meal is served 1 h after start of HD and 1 h after end of HD
9990731|NCT01446302|No Intervention|Single meal on a HD day|A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
9990732|NCT01446302|No Intervention|Single meal on a non-HD day|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
9990733|NCT01446302|No Intervention|Single meal (healthy controls)|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
9990734|NCT01446315|Experimental|Asthma APGAR|Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
9990735|NCT01446315|Placebo Comparator|Usual care|Usual asthma care as provided by the sites.
9990736|NCT01446328|Active Comparator|Amisulpride|
9990737|NCT01446328|Active Comparator|Aripiprazole|
9990738|NCT01446328|Active Comparator|Olanzapine|
9990739|NCT01446341|Active Comparator|Immobilization|50 patients will be randomly assigned to have their lateral ankle sprain immobilized in a below knee cast
9990740|NCT01446341|Active Comparator|Functional Rehabilitation|50 patients will be randomly assigned to a functional rehabilitation program for their lateral ankle sprain
9990741|NCT01446354||Cardiac surgery with HCA|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
9990742|NCT01446380||Pseudoxanthoma elasticum|
9990743|NCT01446406|Active Comparator|MONARCA|MONARCA self-monitoring application on a cell phone to monitor affective symptoms every day.
9990744|NCT01446406|Placebo Comparator|NON-MONARCA|This is the same mobile phone as the MONARCA mobile phone. Yet the MONARCA application has not been installed. The mobile phone can only be used as a normal mobile phone for communication purposes.
9990745|NCT01446445|Active Comparator|1.A (Prophylaxis-SPC)|Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
9990746|NCT01446445|Experimental|1.B (Prophylaxis- PK model)|Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
9990747|NCT01446445|Active Comparator|2.A (Treatment-SPC)|Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
9990748|NCT01446445|Experimental|2.B (Treatment-PK model)|Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model
9990749|NCT01446458|Experimental|5-Fluorouracil, Oxaliplatin, Irinotecan|5-Fluorouracil, Oxaliplatin, Irinotecan are administered as a modified FOLFIRINOX regimen every 15 days. Subjects receive bi-weekly cycles of therapy on the 1st week, the 3rd week, the 5th week and finally the 7th week for a total of 4 cycles. Assessments include history and physical, laboratory tests on a weekly basis throughout the treatment period prior to and including week 8 assessment for stereotactic body radiotherapy (SBRT).
9990750|NCT01446471||Cardiac Arrest|Patients in Cardiac Arrest will be enrolled
9891346|NCT00609037||1|Individuals who has had a weight reduction procedure such as gastric bypass and have body contouring surgery to remove the excessive skin due to the weight loss
9891347|NCT00609037||2|Normal controls include individuals who schecule to have an abdominoplasty and are within normal for height and weight
9891348|NCT00609050|Active Comparator|1|Self-Regulated Exercise with Telephone Reinforcement
9891349|NCT00609050|Active Comparator|2|Attention Control
9891350|NCT00609063|Experimental|1|Participants will receive atorvastatin for 6 months.
9891351|NCT00609063|Placebo Comparator|2|Participants will receive matching placebo for 6 months.
9891352|NCT00609089|Experimental|I|Community Reinforcement and Family Training for Retention in Treatment and Recovery and Reduction of HIV Risk Behavior (CRAFT-T)
9891353|NCT00609089|Active Comparator|II|Treatment As Usual
9891354|NCT00609102|Placebo Comparator|Placebo|
9891355|NCT00609102|Active Comparator|antioxidant drug|n-acetylcysteine
9891356|NCT00609115|Experimental|T|The Test Group will have 18 half hour AMES (Assisted Movement with Enhanced Sensation) treatments per qualified subject limb with the AMES device. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
9891357|NCT00609115|Sham Comparator|C-1|Eighteen treatment sessions for each qualifying subject limb using the AMES device programed to provide placebo therapy. Each treatment session consisting of 30 minutes of placebo therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
9891358|NCT00609115|Active Comparator|C-2|Crossover treatment of subjects who received placebo treatment during Phase 1 of the study to provide 18 regular (i.e., non-placebo) AMES (Assisted Movement with Enhanced Sensation) treatment sessions. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.
9891359|NCT00609141|Experimental|Treatment (monoclonal antibody therapy)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.
9891360|NCT00609154|Experimental|Diabetic Group|Participants with Type 2 diabetes
9891361|NCT00609154|Active Comparator|Non-diabetic Group|Participants who are non-diabetic will serve as control. treatment is matched to experimental group
9891362|NCT00609180|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
9891363|NCT00609180|Experimental|2|Participants will receive initial full-calorie enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
9891364|NCT00609180|Experimental|3|Participants will receive initial minimal (trophic) enteral feeding and the placebo supplement
9891365|NCT00609180|Placebo Comparator|4|Participants will receive initial full-calorie enteral feeding and the placebo supplement
9891366|NCT00609193||1|Study subjects receiving lithium
9891367|NCT00609193||2|Study subjects receiving quetiapine
9891368|NCT00609219|Experimental|EBV specific CTL|autologous EBV specific CTLs
9891369|NCT00609284|Experimental|1|Radiotherapy 70Gy, Erbitux, Carboplatin-5FU
9891370|NCT00609284|Active Comparator|2|Radiotherapy 70Gy, Erbitux
9891371|NCT00609297||Supportive Care|Alive Hospice Patients with Pain
9891372|NCT00609310|Experimental|I|Flavonoid treatment
9891373|NCT00609349|Other|connective tissue disease|all patients suffer from a connective tissue disease representing a risk for the development of pulmonary hypertension
9891374|NCT00609375|Experimental|I|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
9891375|NCT00609375|Active Comparator|II|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
9891376|NCT00609388|Active Comparator|A|Group A receives an intraportal Tacrolimus-infusion, ATG Induction, Tacrolimus and Steroids.
9891377|NCT00609388|Placebo Comparator|B|Group B receives a placebo-Saline solution (0.9%)-Infusion, ATG induction, Tacrolimus and Steroids.
9891378|NCT00609401|Experimental|1|Sorafenib 400 bid + IL-2 3 MU per 5 day/week for 2 weeks every 4
9891379|NCT00609401|Experimental|2|Sorafenib 400 mg bid
9891380|NCT00609427|Experimental|EA|Training in external memory aids
9891381|NCT00609427|Experimental|MT|Mnemonic training intervention
9891382|NCT00609427|No Intervention|WL|Wait-list control
9891383|NCT00609440|Other|A|A single case study, of a patient that was submitted to a physiotherapeutic treatment.
9891384|NCT00609453|Experimental|1|Individuals with major depressive disorder receiving therapy
9891385|NCT00609479|Experimental|1|Internal fixation with Micronail. 41 patients.
9891386|NCT00609479|Experimental|2|External fixation with Hoffmann-II-non-bridging. 41 patients.
9891387|NCT00609505|Other|TM|Telemedicine genetic counseling group
9891388|NCT00609505|Other|FTF|Face-to-face genetic counseling group
9891389|NCT00609531|Experimental|Active|Individuals with an Autism Spectrum Disorder receiving citalopram
9891390|NCT00609531|Placebo Comparator|Placebo|Individuals with an Autistic Spectrum Disorder receiving placebo
9891391|NCT00609544|Experimental|1|
9891392|NCT00609544|Placebo Comparator|2|
9891393|NCT00609557|Experimental|A|All subjects receive placebo for the first two weeks and then duloxetine for the next 10 weeks, but they are blind to what they are receiving.
9891394|NCT00609570|Experimental|Fruit and vegetables|Fruits and vegetables
9891395|NCT00609570|Active Comparator|Whey protein|Whey protein
9891396|NCT00609570|Active Comparator|Ca|Calcium pills
9891397|NCT00609596|Other|Arm 1|
9891398|NCT00609648|Experimental|CARL|CARL computer program
9891399|NCT00609648|Active Comparator|Pamphlet|Reassuring pamphlet about dental injections
9891400|NCT00609661||1|Patients presenting to the Ohio State University Emergency Department or directly admitted to the Ohio State University Burn Unit following thermal burn.
9891401|NCT00609661||2|Healthy volunteers
9891402|NCT00609687|Other|A|Patients with suspected sarcoid-related posterior segment inflammation with inconclusive clinical exam findings, ancillary testing, and laboratory results
9891403|NCT00609700||1|Historical group: patients treated with Ringer's Lactate solution after severe burn injury
9891404|NCT00609700||2|Actual group: patients treated with Ringer's Acetate solution after severe burn injury
9891405|NCT00609713|Experimental|1|Comprehensive 12-month family-based obesity treatment with separate adolescents and parents group sessions
9891406|NCT00609713|Active Comparator|2|Individual 12-month nutrition education program
9891407|NCT00609752|Active Comparator|1|
9891408|NCT00609752|Active Comparator|2|
9891409|NCT00609778|Experimental|1:Mechanical CPR with LUCAS|A Mechanical device that provides chest compressions
9891410|NCT00609778|Active Comparator|2 Manual CPR|Manual chest compressions
9891411|NCT00609817|Experimental|GCS-100|
9891412|NCT00609830|Experimental|Tailored Materials|
9891413|NCT00609830|Experimental|Physician Feedback|
9891414|NCT00609830|Active Comparator|Generic Materials|
9891415|NCT00609830|Placebo Comparator|Placebo Comparator|Participants receive no information
9891416|NCT00609843|Experimental|1|
9891417|NCT00609856|Active Comparator|1|Pioglitazone
9891418|NCT00609856|Active Comparator|2|Insulin glargine
9891419|NCT00609882|Active Comparator|HHFNC|Infants randomized to the Humidified High Flow Nasal Cannula (HHFNC) treatment group post extubation
9891420|NCT00609882|Active Comparator|nCPAP|Infants randomized to the nasal Continuous Positive Airway Pressure (nCPAP) treatment group
9891421|NCT00609908|Active Comparator|A1|Acute Burn Wounds: Wound debridement and split skin grafting
9891422|NCT00609908|Experimental|A2|Acute Burn Wounds: excision of the burn wound and primary closure, using a skin stretching device
9891423|NCT00609908|Active Comparator|B1|Scar reconstruction: serial excision
9891424|NCT00609908|Experimental|B2|Scar reconstruction: primary closure, using skin stretching device
9891425|NCT00609921|Active Comparator|1|ARQ197
9891426|NCT00609934|Experimental|Sorafenib and palliative radiotherapy|
9891427|NCT00609960|No Intervention|1|no medication or clowns present during the preopertaive phase
9891428|NCT00609960|Active Comparator|2|midazolam a anxiolytic drug was given in the preoperative phase
9891429|NCT00609960|Active Comparator|3|clowns where present during the preoperative phase
9891430|NCT00609999|Experimental|Stratum A|Pts not on EIAEDs
9891431|NCT00609999|Experimental|Stratum B|Pts on EIAEDs
9891432|NCT00610025|Active Comparator|1|10 patients with no previous abdominal surgeries, pre-insufflation of the abdomen using a veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
9891433|NCT00610025|Active Comparator|2|10 patients with history of previous abdominal surgeries, pre-insufflation of the abdomen using veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
9891434|NCT00610025|Active Comparator|3|10 patients with no previous history of abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
9891435|NCT00610025|Active Comparator|4|10 patients with history of previous abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
9891436|NCT00610025|Active Comparator|5|10 patients, all with no previous mid to upper abdominal surgeries, no Veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
9891437|NCT00610025|Active Comparator|6|10 patients, all with previous mid-to-upper abdominal surgeries, no Veress needle pre-insufflation, endoscopic take-down of intra-abdominal adhesions (if identified)
9891438|NCT00610038|Experimental|1|Glibenclamide
9891439|NCT00610051|Placebo Comparator|trial arm|6 months central continuous infusion with Papeilin by infusion pump.
9891440|NCT00610051|Active Comparator|Placebo arm|6 months central infusion with NS by infusion pump with exact infusion rat as trial arm.
9891441|NCT00610064|Other|A|Baseline neuroimaging
9891442|NCT00610064|Other|B|Neuroimaging during sacral neuromodulation
9891443|NCT00610077|Experimental|1|Letrozole
9891444|NCT00610077|Active Comparator|2|Clomiphene citrate
9891445|NCT00610090|Experimental|Treatment - UniFit AAA Stent Graft|
9891446|NCT00610103|Active Comparator|KW-6500|Drug: KW-6500 (apomorphine hydrochloride (USAN))
9891447|NCT00610103|Placebo Comparator|Placebo|Placebo
9891448|NCT00610142|Active Comparator|1|
9891449|NCT00610142|Active Comparator|2|
9891450|NCT00610181||Breast MRI|Magnetic resonance imaging (MRI) of breast for patients with invasive lobular carcinoma of the breast.
9891451|NCT00610194|Experimental|Arm 1|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
9891452|NCT00610220|Active Comparator|1|
10212006|NCT03179436|Experimental|Escalation: DL 3 Quavonlimab + Pembro: Cohort 3|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL3. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL3 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
9891453|NCT00610220|Experimental|2|
9891454|NCT00610233|Active Comparator|A|Urodynamic investigation with deep brain stimulation ON
9891455|NCT00610233|Experimental|B|Urodynamics with deep brain stimulation OFF
9891456|NCT00610246|Experimental|Sorafenib and Radiation|Eligible patients (not candidates for curative treatment) will have measurable lesions in the anatomic thorax, abdomen or pelvis (any histology) amenable to palliative radiation treatment (30 Gy in 10 fractions). Patients receive sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. If full oral dose (400 mg po bid) is reached in a given cohort (dose level three) then an additional dose level will open where sorafenib treatment (400 mg bid) is extended following radiation for a total of eight weeks.
9891457|NCT00610259|Experimental|1|brief behavioral therapy for insomnia (bBT-I) in addition to treatment as usual (TAU)
9891458|NCT00610259|Active Comparator|2|Treatment as usual (TAU)
9891459|NCT00610272|Experimental|Single Site Radiation 4Gy Fraction|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
9891460|NCT00610272|Active Comparator|Single Site Radiation 8Gy Fraction|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
9891461|NCT00610272|Active Comparator|Multiple Sites Radiation 8Gy Fraction|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
9891462|NCT00610272|Experimental|Multiple Sites Radiation 12Gy Fraction|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
9891463|NCT00610285||non-invasive immobilization system|This is a feasibility study to evaluate the accuracy of an alternative, non-invasive immobilization system in combination with image guided patient setup for SRS treatments. The aim is to determine whether or not the non-invasive system can provide comparable accuracy as the conventional invasive head ring system. If successful, patient discomfort can be significantly reduced for such treatments.
9891464|NCT00610298|Experimental|I|Subjects who receive whole body vibration
9891465|NCT00610298|No Intervention|N|Subjects do not receive whole body vibration intervention
9891466|NCT00610324|Experimental|1|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
10212007|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm A|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
10212008|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm B|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL1 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
9797512|NCT01598298|Placebo Comparator|Arm II|Patients receive placebo PO QD on days 1-7, BID on days 8-84, and then QD on days 85-91.
9797513|NCT01598311|Experimental|CB-183,315|Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
9797514|NCT01598311|Active Comparator|Vancomycin|Participants took vancomycin 125 mg four times daily (q.i.d.) by mouth for 10 days.
9797515|NCT01598350|Experimental|Orthotic|Orthotic Use
9797516|NCT01598428|Other|cataract|
9797517|NCT01598506|Experimental|Hydromorphone|Laboring patients receive ED50 of hydromorphone one time intrathecally
9797518|NCT01598532|Experimental|Transcranial LED Treatment|All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.
9797519|NCT01598545|Experimental|Hydromorphone|Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
9797520|NCT01598610|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.
9797521|NCT01598662|Active Comparator|1: IUD insertion 6 Weeks after delivery|"Device:Levonorgestrel-releasing intrauterine device marketed as Mirena.~Subjects randomized to interval placement will have their IUD placed in the office at six weeks postpartum or later. They must return for one visit within a month for a string check."
9797522|NCT01598662|Experimental|2: Immediate Post-placental insertion|"Device: Levonorgestrel-releasing intrauterine device marketed as Mirena~Subjects randomized to immediate post-placental placement within 10 minutes of delivery will have an IUD placed manually under sterile technique and with ultrasound guidance. An ultrasound will be performed within two days postpartum to verify proper placement and again at approximately six weeks postpartum."
9797523|NCT01598701|Experimental|Intravenous Acetaminophen|Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
9797524|NCT01598701|Placebo Comparator|Placebo|Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
9797525|NCT01598740|Experimental|CLP with spironolactone|
9797526|NCT01598740|Experimental|CLP without spironolactone|
9797527|NCT01598753|Active Comparator|Tramadol|
9797528|NCT01598753|Placebo Comparator|Placebo|
9797529|NCT01598753|Active Comparator|Cognitive Behavior Therapy for FM|
9797530|NCT01598753|Sham Comparator|Health Education|
9797531|NCT01598831|Active Comparator|ART-123|
9797532|NCT01598831|Placebo Comparator|Placebo|
9797533|NCT01598896|Experimental|Dronabinol + Clonidine|Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
9797534|NCT01598896|Placebo Comparator|Placebo|Placebo
9797535|NCT01598922|Experimental|Internet Cognitive Behavioral Therapy|Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
9797536|NCT01598922|No Intervention|Monitored Attention Control|Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
9797537|NCT01598987|Experimental|Everolimus based regimen|"Conversion at Baseline from an immunosuppressive regimen which contains either cyclosporine (CsA) or tacrolimus (TAC) with or without mycophenolic acid (MPA), with or without corticosteroids in a regimen which contains everolimus combined reduced dose of either cyclosporine (CsA) or tacrolimus (TAC).~The dosing schedule was twice daily, 12 hours apart."
9797538|NCT01599104|Experimental|LCZ696 200 mg|LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
9797539|NCT01599104|Experimental|LCZ696 400 mg|LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
9797540|NCT01599104|Active Comparator|Olmesartan 20 mg|Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks
9797541|NCT01599234|Experimental|Sativex|Active treatment
9797542|NCT01599234|Placebo Comparator|Placebo|Control
9797543|NCT01599286|Experimental|Active Comparator|Parallel Trial Comparing NCG + Standard of Care Treatment
9797544|NCT01599286|Active Comparator|Placebo Comparator|Placebo and Standard of Care Therapy
9797545|NCT01599325|Experimental|Azacitidine|Azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
9800235|NCT01682837|Experimental|KCit, KCl, KMgCit, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9891467|NCT00610324|Active Comparator|2|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
9891468|NCT00610337|Placebo Comparator|1|
9891469|NCT00610337|Experimental|2|1mg Cethrin®
9891470|NCT00610337|Experimental|3|3mg Cethrin®
9891471|NCT00610337|Experimental|4|6mg Cethrin®
9891472|NCT00610337|Experimental|5|12mg Cethrin®. Administration of this dose is dependent on data from lower doses.
9891473|NCT00610337|Experimental|6|18mg Cethrin®. Administration of this dose is dependent on data from lower doses.
9891474|NCT00610350|Experimental|L|
9891475|NCT00610350|Experimental|P|
9891476|NCT00610376|Experimental|1A|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home intervention component.
9891477|NCT00610376|Active Comparator|2|This group did not receive any special treatment during the study, but did receive the intervention at the close of the study
9891478|NCT00610376|Experimental|1B|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home control component.
9891479|NCT00610389|Experimental|1|
9891480|NCT00610402||blood sample tear drop sample|blood sample tear drop sample
9891481|NCT00610493|Experimental|Bevacizumab + Temsirolimus|Bevacizumab 5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle. Temsirolimus 5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle. First tumor biopsy during screening visit and Second at the end of Cycle 1. DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1.
9891482|NCT00610506|Experimental|A|Lexapro
9891483|NCT00610519|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
9891484|NCT00610519|Placebo Comparator|2|spray containing placebo.
9891485|NCT00610545|Active Comparator|1|Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60
9891486|NCT00610545|Active Comparator|2|Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60
9891487|NCT00610571|Experimental|Oral Topotecan and Temodar|Two separate strata to accrue independently. Stratum 1: Patients taking receiving Dilantin, Tegretol, Trileptal or Phenobarbital. Stratum 2: Patients on anti-convulsants other than Dilantin, Tegretol, Trileptal or Phenobarbital or patients not on any anti-convulsants
9891488|NCT00610584|Experimental|1|verum acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
9891489|NCT00610584|Placebo Comparator|2|minimal (sham) acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
9891490|NCT00610584|Active Comparator|3|rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))alone
9891491|NCT00610597||1|alcoholic liver disease
9891492|NCT00610597||2|chronic hepatitis C virus infection
9891493|NCT00610610|Experimental|A|Paroxetine - Controlled Release
9891494|NCT00610610|Placebo Comparator|B|Same colour, shape placebo
9891495|NCT00610623|Experimental|1|azithromycin iv 300 mg/day
9891496|NCT00610623|Placebo Comparator|2|Placebo
9891497|NCT00610636|Experimental|1|The patients with secondary resectable colorectal hepatic metastasis undergoing surgery
9891498|NCT00610636|Active Comparator|2|The patients with secondary resectable colorectal hepatic metastasis who underwent continuous chemotherapy
9891499|NCT00610753|Experimental|Family Behavioral Therapy|This intervention focuses on counseling the parents (and other family members) on refeeding their child. When weight is being steadily regained the focus of therapy shifts to allow the child more independence.
9891500|NCT00610753|Active Comparator|Systems Family Therapy|This therapy focuses primarily on clarifying psychological processes within the family.
9891501|NCT00610766||1|
9891502|NCT00610779|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
9891503|NCT00610779|Placebo Comparator|2|spray containing placebo.
9891504|NCT00610792|Experimental|1|
9891505|NCT00610805|Experimental|1|Participants randomized to this arm (n=15) will be followed by Preventive Cardiology and will have appropriate goal oriented interventions on their risk factor levels for 2 years.
9891506|NCT00610805|Other|2|Participants randomized to this arm (n=15) will receive usual care. The PI will send a letter of all testing results to their primary care physician. No standard care will be withheld.
9891507|NCT00610818||A|Patients receiving palifermin to prevent mucositis from bone marrow transplant.
9891508|NCT00610831|Experimental|DirectView CR Mammography|Each subject will have routine clinical care imaging obtained and 4 standard mammogram views (RMLO, RCC, LMLO, LCC) using CR mammography. If routine mammograms were obtained on a day previous to enrollment in the study, those images (4 views; 2 views for mastectomy patients) will not be repeated for this study; only the CR images will be obtained.
9891509|NCT00610844|Experimental|1|pulmonary radiofrequency ablation
9891510|NCT00610870|Experimental|1|Atorvastatin group
9891511|NCT00610870|No Intervention|2|Control group
9891512|NCT00610896||Observation|30 Patients with dualchamber pacemakers or implantable cardioverter-defibrillators (ICDs)
9891513|NCT00610909|Experimental|1|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
9667104|NCT03963739||Income: Higher Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
9891514|NCT00610909|Placebo Comparator|2|Same shape placebo
9891515|NCT00610922|No Intervention|1|
9891516|NCT00610922|Experimental|2|
9932233|NCT00946933|Active Comparator|High salt diet|0.2 g/kg/day of NH4Cl (ammonium chloride)
9932234|NCT00946946|Experimental|Azathioprine|2.0-2.5 mg/kg/BW azathioprine tablets/day AND mesalazine placebo tablets
9932235|NCT00946946|Active Comparator|Mesalazine|4g mesalazine tablets/day AND azathioprine placebo tablets
9932236|NCT00946959|Experimental|cardiac surgery|This arm will include patients older than 18 years and candidate to cardiac surgery.
9932237|NCT00946959|No Intervention|cardiac angiography|Patients older than 18 years who undergo coronary angiogram. This arm will include patients with coronary revascularization and patients without coronary revascularization.
9932238|NCT00947024|Experimental|1|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
9932239|NCT00947024|Active Comparator|3|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
9932240|NCT00947024|Experimental|2|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
9932241|NCT00947037|Experimental|Extension|Open label extension, 1 arm
9797546|NCT01599585|Experimental|In Home|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week). The sessions will be conducted in their homes using an Army approved secure web-based video conferencing system. BA has been successfully delivered in this time frame, and it has been delivered via in-home video conferencing technology.
9797547|NCT01599585|Active Comparator|In-Person|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week with allowance for rescheduled sessions). The sessions will be conducted in a clinic setting at The National Center for Telehealth & Technology.
9797548|NCT01599637|Experimental|IGE025|Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
9797549|NCT01599637|Placebo Comparator|Placebo to IGE025|Placebo administered subcutaneously every 4 weeks at the study center.
9797550|NCT01599650|Experimental|1-ranibizumab monotherapy|Ranibizumab 0.5 mg
9797551|NCT01599650|Experimental|2-ranibizumab with laser|Ranibizumab 0.5 mg + laser
9797552|NCT01599650|Active Comparator|3-laser monotherapy|Laser monotherapy with Ranibizumab 0.5 mg from Month 6
9797553|NCT01599754|Experimental|Axitinib|
9797554|NCT01599754|Placebo Comparator|Placebo|
9797555|NCT01599793|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
9797556|NCT01599806|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
9797557|NCT01599806|Active Comparator|Doripenem|IV treatment
9797558|NCT01599832|Experimental|Treatment (pazopanib hydrochloride, DCE-MRI)|Patients receive pazopanib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7.
9797559|NCT01600014|Active Comparator|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days on the face or scalp
9797560|NCT01600014|Placebo Comparator|Vehicle gel|Topical field treatment once daily for 3 consecutive days on the face or scalp
9797561|NCT01600053|Experimental|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles
9797562|NCT01600092|Experimental|RotaTeq™ Experimental Formulation|Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
9797563|NCT01600092|Active Comparator|RotaTeq™ Existing Formulation|Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).
9797564|NCT01600105|Experimental|Perfusion MRI|chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.
9797565|NCT01600170|Active Comparator|Atorvastatin|Participants were given atorvastatin for 12 weeks at various doses based on their specific HAART treatment.
9797566|NCT01600170|Placebo Comparator|Placebo|Participants were given Placebo tablets for 12 weeks.
9797567|NCT01600222|Experimental|LEO 90100|
9797568|NCT01600287|Experimental|IAADS group|dosage of propofol adjusted automatically by IAADS
9797569|NCT01600287|Active Comparator|Manual group|dosage of propofol adjusted manually
9800236|NCT01682837|Experimental|KCit, KCl, Placebo, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800237|NCT01682837|Experimental|KCit, Placebo, KMgCit, KCl|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800238|NCT01682837|Experimental|KCit, Placebo, KCl, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9932242|NCT00947050|Active Comparator|rest first|rest first, cfi, exercise, cfi
9932243|NCT00947050|Active Comparator|exercise first|ex first
9932244|NCT00947063|Experimental|1|Promethazine HCl 50 mg Tablets (Sandoz, Inc)
9891517|NCT00610948|Experimental|Group 1|Patients receive oral everolimus once daily on days 1-28. Patients also receive leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9891518|NCT00610948|Experimental|Group 2|Patients receive oral everolimus once daily on days 1-28 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9891519|NCT00610948|Experimental|Group 3|Patients receive oral everolimus once daily on days 1-28, leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1, and oxaliplatin IV over 2-4 hours on day 1. Some patients may also receive panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9891520|NCT00610961||Basiliximab (Simulect) Induction|Prospective group: patients are scheduled to receive a kidney transplant; and will receive Simulect®, Myfortic® and Prograf® with or without steroids according to routine care (Standard of Care).
9891521|NCT00610961||Thymoglobulin Induction|Retrospective (historical or control) group: patients have already received a kidney transplant and were treated with Thymoglobulin®, Myfortic®, and Prograf® with or without steroids. This treatment was Standard of Care at a time of transplant.
9891522|NCT00610974|Active Comparator|1|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
9891523|NCT00610974|Experimental|2|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
9891524|NCT00611039|Experimental|1|Darunavir 900mg + ritonavir 100 mg once a day
9891525|NCT00611039|Active Comparator|2|Darunavir 600mg + ritonavir 100mg twice day
9891526|NCT00611052|Experimental|1|Group cognitive intervention (the Adolescent Coping with Stress)
9891527|NCT00611052|Active Comparator|2|Treatment as usual
9891528|NCT00611052|Active Comparator|3|Healthy controls, receive usual health education in school health care
9891529|NCT05331664|Active Comparator|Group 1|"Subconjunctival antibiotic (cefazolin 50 mg/0.5 mL, moxifloxacin 0.5 mg/0.1 mL, or vancomycin 1 mg/0.1 mL) and subconjunctival dexamethasone (4 mg/mL) at the time of surgery~Topical atropine 1% and antibiotic-steroid ointment (neomycin-polymyxin B-dexamethasone) at the time of surgery~Topical moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin; 4 times per day for 1 week after surgery.~Topical prednisolone 1% 1 drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper)~Topical atropine 1% daily for 1 week"
9891530|NCT05331664|Active Comparator|Group 2|"Subtenon triamcinolone acetonide (40 mg/1mLl) at the time of surgery~Subconjunctival antibiotic (cefazolin 50 mg/0.5 mL, moxifloxacin 0.5 mg/0.1 mL, or vancomycin 1 mg/0.1 mL) and subconjunctival dexamethasone (4 mg/mL) at the time of surgery~Topical atropine 1% and antibiotic-steroid ointment (neomycin-polymyxin B-dexamethasone) at the time of surgery~No postoperative eye drops"
9891531|NCT05331651|Experimental|Glycopyrronium in Combination With Tropisetron|
9891532|NCT05331651|Placebo Comparator|Normal Saline in Combination With Tropisetron|
9891533|NCT05331638|Experimental|Prostate Cancer Genius app|The Prostate Cancer Genius app includes the following components: (1) educational content that is consistent with existing evidence and recommendations for prostate cancer and prostate cancer screening but has been adapted for the African American male population and for adults who read at or below the 8th-grade level; (2) real-time messages about the risks of prostate cancer and the benefits of completing a PSA test, placing a special emphasis on screening considerations for individuals with a family history of prostate cancer and/or lower urinary tract symptoms (measured via the American Urological Association Symptom Score); (3) general trivia that also incorporates quiz questions about prostate cancer and the PSA test; (4) African American-specific testimonials and educational videos; (5) optional counseling by African American prostate cancer survivors; and (6) on-demand, automated ordering of a home-based PSA test.
9891534|NCT05331638|Active Comparator|Prevention Taskforce app|The Prevention Taskforce app provides on-demand access to evidence-based recommendations for prostate cancer for men between 55 and 69 (i.e., it can be accessed as needed).
9891535|NCT05331625|Experimental|Intervention|Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic at which time they will be offered additional resources to promote symptom management. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
9932245|NCT00947063|Active Comparator|2|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
9932246|NCT00947076|Experimental|1|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
9891536|NCT05331625|No Intervention|Usual Care|Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic where they will receive symptom management and supportive care. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
9891537|NCT05331612|Experimental|Blended group intervention|"Blended intervention group, consisting of 4 face-to-face group sessions lasting 2 hours every 2 weeks, alternated with the online treatment protocol carried out by the participants in a self-applied. The intervention has a period of duration of 12 weeks and it is composed by 8 modules (Motivation for change, Psychoeducation, Stimulus control, Cognitive restructuring, Urge surfing and emotion regulation, Planning of significant activities, Coping skills and exposure with response prevention, and Relapse prevention). These modules is based in the online platform and manualized protocol treatment Sin jugar, ganas (Díaz-Sanahuja et al., 2021)."
9891538|NCT05331612|No Intervention|Waiting list control group|Waiting list control group receives the blended treatment when the intervention has finished in the experimental group (blended group intervention).
9891539|NCT05331599||Currently Depressed Participants|Individuals who are currently depressed and receive treatment through an antidepressant treatment
9891540|NCT05331599||Remitted Depressed Participants|Individuals who have achieved remission from depression within 4 months
9891541|NCT05331599||Remitted Depressed Elders|Individuals who no lifetime history of depression
9891542|NCT05331586|No Intervention|control intervention|The control group will receive the standard prenatal care in Hospital Center of São Joao (CHUSJ). The standard prenatal care will be regular appointments with obstetrician and midwife nurses, ultrasounds and nutritional appointments. The pregnant women in control group will also receive a pamphlet with the benefits of physical exercise during pregnancy and recommendations for adequate gestational weight gain. Pregnant women in control group will not be discouraged from exercising on their own.
9891543|NCT05331586|Experimental|Exercise intervention|The exercise group intervention will perform home-based remotely monitored exercise
9891544|NCT05331560|Experimental|Treatment Group|A 2-week intervention TPS intervention will result in a significant improvement in the Montreal Cognitive Assessment (HK-MoCA; Hong Kong Chinese version), which will be maintained for 12 weeks.
9891545|NCT05331547||BioFreedom BA9 (SS) Ultra DCS|STEMI patients treated with one or several BioFreedom stent(s)
9891546|NCT05331534|Experimental|patients with a PTSD receiving ACTo and prolonged exposure therapy.|
9891547|NCT05331534|Sham Comparator|patients with PTSD receiving ACT and prolonged exposure therapy.|
9891548|NCT05331521|Active Comparator|RT PCV|"Radiotherapy (RT) for over approximately 5-6 weeks:~at 50.4/54 Gy in 1.8 Gy fractions for grade II and~at 59.4 Gy in 1.8 Gy fractions for grade III gliomas~PCV cycles are 6 weeks long and given as:~Day 1: Lomustine (CCNU) at 110 mg/m2 body surface orally,~Days 8/29: Vincristine 1.4 mg/m2 i.v. (capped at 2 mg),~Days 8-21: Procarbazine 60 mg/m2 orally (capped at 100 mg)."
9891549|NCT05331521|Experimental|CETEG|"Six 42-day cycles of lomustine plus temozolomide according to the commonly used regimen:~Day 1: Lomustine (CCNU) at 100 mg/m2~Days 2-6: Temozolomide at 100 mg/m2 (cycles 1) and in 50 mg/m2 steps to 200 mg/m2 from cycle 2 on dependent on hematological toxicity"
9891550|NCT05331495|Experimental|Hemoperfusion and CPB and DHCA surgery|The experimental group was treated with hemoperfusion simultaneously with CPB and DHCA.
9891551|NCT05331495|No Intervention|traditional CPB and DHCA surgery|The control group was treated with intraoperative CPB and DHCA surgery.
9932247|NCT00947076|Active Comparator|2|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
9932248|NCT00947089|Experimental|group A-the treatment group|Group A-patients have their wound, the site of the previous stoma, wad with ORC
9891552|NCT05331469|Active Comparator|Daily basal insulin titration|Participants in this intervention arm will be started with basal insulin of 10 units or 0.2 unit/kg (whichever lower) at pre-bed time. They will then check their morning fasting CBG the following day. If they have no hypoglycemia symptoms or documented hypoglycemic CBG (<3.9mmol/L), and their fasting CBG is more than 7mmol/L, they will then self-titrate their basal insulin by 1 unit (ie 10+1) the following night. This same process is going to be repeated until their fasting CBG achieve 7mmol/L or lower. Then, they will continue and maintain on the desired basal insulin dosage till their appointment. The maximum basal insulin that is allowed to be titrated by the participants is up to 0.5unit/kg. Participants are required to document down their CBG and any hypoglycemia symptoms in a simple table method provided to them
9891553|NCT05331469|Active Comparator|3 daily basal insulin titration|Participants in this intervention arm will be started with basal insulin of 10 units or 0.2 unit/kg (whichever lower) at pre-bed time. They will then check their morning fasting CBG the following 3 days. If they have no hypoglycemia symptoms or documented hypoglycemic CBG (<3.9mmol/L), and their fasting CBG is more than 7mmol/L (for 2 out of 3 days), they will then self-titrate their basal insulin by 2 units (ie 10+2) on the 3rd night. This same process is going to be repeated until their fasting CBG achieved 7mmol/L or lower. Then, they will continue and maintain on the desired basal insulin dosage till their appointment. The maximum basal insulin that is allowed to be titrated by the participants is up to 0.5unit/kg. Participants are required to document down their CBG and any hypoglycemia symptoms in a simple table method provided to them.
9891556|NCT05331391|Experimental|Brief mobile SMART Exercise Support Program|Patients will receive a brief SMART Exercise individual session with instant messages and telephone coaching for exercise habit formation and maintenance.
9891557|NCT05331391|Placebo Comparator|General Hygiene Information (GHI)|Patients will receive an individual session, instant messages and telephone coaching regarding general hygiene information.
9891558|NCT05331352|Experimental|Subjects following a psychotherapy|Domestic violence victims following a psychotherapy 15 subjets Aged from 20 to 55
9891559|NCT05331352|Experimental|Subjects unfollowing a psychotherapy|Domestic violence victims unfollowing a psychotherapy 15 subjects Aged from 20 to 55
9891560|NCT05331326|Experimental|HER2 Positive|Drug: RC48-ADC 2.0 mg/kg (HER2 Positive) 32 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
9891561|NCT05331326|Experimental|HER2 Low Expression|Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression) 32 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
9891562|NCT05331313||patients with a diagnosis of multiple myeloma|This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing.
9891563|NCT05331300|Experimental|LASN01|Part A (SAD in healthy subjects) Part B (MAD in healthy subjects)
9891564|NCT05331300|Placebo Comparator|Placebo|Part A (SAD in healthy subjects) Part B (MAD in healthy subjects)
9891565|NCT05331287|Experimental|snifing Position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The snifing position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
9891566|NCT05331287|Experimental|neutral position|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The Head Extension was obtained by the occiput of the patient close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
9891567|NCT05331287|Experimental|Head Extension|Nasotracheal intubation via fiberoptic bronchoscope under snifing position.The extension position with a 7-cm pillow underneath the shoulder and the occiput close to the operating table. When the FOB was inserted into Nasal cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB.
9891568|NCT05331274|Experimental|exercise group|Only DYMK exercise training will be applied to the exercise group.
9891569|NCT05331274|Experimental|pain training group|In the pain training group, pain training will be applied in addition to the DYMK exercise training.
9891570|NCT05331261|Experimental|Patients who have had knee replacement surgery|
9891571|NCT05331248|Experimental|LIA Household Training|This treatment arm is an 8-session training with a tailored schedule at the household level that targets couples at risk of domestic violence. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of GBV and social norms around domestic violence and is delivered at the household level in a private environment. Additionally, the intervention includes sessions on soft skills and conflict resolution. The session topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women's agency.
9891572|NCT05331248|Experimental|LIA Group Training|This treatment arm is an 8-session training delivered in gender-segregated groups at the village level that targets couples at risk of domestic violence in separate spaces. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of GBV and social norms around domestic violence and is delivered at the household in a private environment. The sessions topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women agency.
9891573|NCT05331248|Experimental|LIA Household and Group Training|This treatment arm combines LIA Household and Group training. Villages in this arm will first receive the 8-sessions household-level intervention, then the 8-sessions of village-level gender-segregated group intervention will follow. The sessions topics for both interventions are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) Assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women agency.
9891574|NCT05331248|No Intervention|Control group|Villages in the control group will not receive any intervention.
9891575|NCT05331222|Experimental|Jantar-1 (JT-1), 7% (w/w) aqueous solution|Dosing regimen: ad libitum between at least 2 doses, in the morning and in the evening, and at most 10 doses per day. A dose corresponds to two strokes of 100ul each per nostril.
9891576|NCT05331209|Active Comparator|Acupuncture only|Acupuncture treatments will take place at a frequency of once per week, with each session lasting between 30 to 45 minutes. At each session patients will be re-assessed by the study acupuncturist, with acupuncture points individualized in accordance with the principles of traditional Chinese medicine. At the same time, acupuncturists will include a set group of acupuncture points which have been used in the research of hot flashes: HT-6, Kid-3, Liv-3, SP-6.
9891577|NCT05331209|Active Comparator|Acupuncture-Acupressure|Patients randomly allocated to the acupuncture-acupressure arm of the study will first be treated by the study acupuncturist in accordance with the protocol described in the Acupuncture arm of the study. At the end of the first session, patients in this group will be taught by the study acupuncturist to self-treat at home with acupressure, on the acupressure points PC-7, ST-36, SP-9. Self-acupressure sessions will last between 3-5 minutes each, and will take place 3-4 times each day. At subsequent acupuncture treatments patients will receive reinforcement and guidance to ensure the fidelity of the self-acupuncture treatments
9891578|NCT05331196||Patients with colorectal cancer|Patients with colorectal cancer who underwent elective surgery.
9891579|NCT05331183|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
9891580|NCT05331157|No Intervention|palpation group|"In lateral decubitus position, the conventional palpation technique will be used to detect the epidural space. The midline will be identified by palpation of the spinous processes. Through the Tuffier's line, L5 spine then, the two intervertebral spaces (L3-4 and L2-3) will be detected and the middle of each intervertebral space will be marked with selection of the widest space.~After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline"
9932249|NCT00947089|Active Comparator|group B-the control group|control group-patients have their wound wad with iodoform gauze
9935973|NCT02911142|Experimental|1|Lenalidomide, Rituximab, Prednisone, Etopiside, Doxorubicin, Vincristine and Cyclophosphamide
9935974|NCT02911129||Healthy Volunteer|Inclusion Criteria for Healthy Volunteers/Age-matched Controls
9891581|NCT05331157|Experimental|Ultrasonography group|In lateral decubitus position, a curved array probe will be utilized to scan the sacrum in the longitudinal paramedian plane, then the probe will be moved upwards to detect the L5-S1, L4-5, L3-4 and L2-3 intervertebral spaces then turned 90º to the transverse plane and used to scan L3-4 and L2-3 spaces inside the 2 spaces, midline will be detected by noting the site of spinous processes with selection of the space with the best sonographic image quality. Then skin surface at the middle of the long and short axis of the probe will be marked horizontally. If the 2 spaces have the same image quality, L2-3 space will be chosen for the entrance of epidural needle. After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline
9891582|NCT05331144|Experimental|Intensive Treatment (IT)|Lowering SBP < 120 mmHG
9891583|NCT05331144|Active Comparator|Usual Care (UC)|Lowering SBP < 140 mmHg
9891584|NCT05331131|Experimental|Ketamine Mouthwash|"Enrolled patients with histologically confirmed squamous cell carcinoma of the head and neck undergoing definitive radiation therapy to 70Gy with concurrent cisplatin chemotherapy who develop grade 3+ toxicity will be prescribed ketamine mouthwash at a strength of 20mg/5mL in NovaFilm suspension with OraSweet flavoring agent via swish and spit route of administration. They will take the investigational drug four times daily."
9891585|NCT05331105|Experimental|HL-085|HL-085 9mg BID
9891586|NCT05331092|Experimental|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
9891587|NCT05331092|No Intervention|Control|20 minutes of rest
9891588|NCT05331079|Experimental|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
9891589|NCT05331079|No Intervention|Control|20 minutes of rest
9891590|NCT05331053|Experimental|Atorvastatin|"Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.~Atorvastatin acts as a systemic LOX inhibitor."
9891591|NCT05331014|Experimental|JW0101+C2101|LivaloVA
9891592|NCT05331014|Active Comparator|JW0101+C2102|LivaloV
9891593|NCT05331014|Active Comparator|C2101|VA
9891594|NCT05330988|Experimental|Real|Randomly selected participants will receive 20 min. of anodal transcranial direct current stimulation to the the top of their heads. The current will slowly be ramped up over 30 secs.
9891595|NCT05330988|Sham Comparator|Sham|Randomly selected participants will receive 20 min. of sham transcranial direct current stimulation to the top of their heads. Sham stimulation is accomplished by turning on the device and slowly increasing and subsequently decreasing the amount of current to zero. This occurs over 30 secs.
9891596|NCT05330975|Experimental|mRNA-1345 + Placebo|Single injection of mRNA-1345 and placebo matching to mRNA-1345, administered intramuscularly (IM), one in each arm on Day 1.
9891597|NCT05330975|Experimental|mRNA-1345 + Afluria® Quadrivalent|Single injection of mRNA-1345 and Afluria® quadrivalent, administered IM, one in each arm on Day 1.
9891598|NCT05330975|Active Comparator|Afluria® Quadrivalent + Placebo|Single injection of Afluria® quadrivalent and placebo matching to mRNA-1345, administered IM, one in each arm on Day 1.
9891599|NCT05330949||case group|
9891600|NCT05330949||control|
9891601|NCT05330936|Active Comparator|Group A|Steroid combination ointment in the treatment of chronic Plaque Psoriasis
9891602|NCT05330936|Active Comparator|Group B|Cyanocobalamin in Avocado Oil cream in the treatment of chronic Plaque
9891603|NCT05330910|Active Comparator|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
9891604|NCT05330910|Experimental|Laparoscopic sleeve gastrectomy with hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
9891605|NCT05330897|Experimental|Treatment arm|Implantation of an eCLIPs™ device
9891606|NCT05330871|Experimental|1. Adolescent booster sentinel group|1 dose of 0.1ml Ad5-nCoV-IH
9891607|NCT05330871|Experimental|2. Adolescent booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
9891608|NCT05330871|Experimental|3. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
9891609|NCT05330871|Experimental|4. Adolescent booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
9891610|NCT05330871|Experimental|5. Adolescent booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
9891611|NCT05330871|Experimental|6. Adolescent booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
9891612|NCT05330871|Experimental|7. Adolescent booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
9891613|NCT05330871|Active Comparator|8. Adolesent booster safety group to receive ICV|1 dose of 0.5ml ICV
9891614|NCT05330871|Active Comparator|9. Adolescent booster immunopersistency group to receive ICV|1 dose of 0.5ml ICV
9891615|NCT05330871|Active Comparator|10. Adolescent booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
9891616|NCT05330871|Experimental|11. Children booster sentinel group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
9891617|NCT05330871|Experimental|12. Children booster safety group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
9891618|NCT05330871|Experimental|13. Children booster immuno-persistency group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
9891619|NCT05330871|Experimental|14. Children booster cellular immunity group to receive Ad5-nCoV-IH|1 dose of 0.1ml Ad5-nCoV-IH
9891620|NCT05330871|Experimental|15. Children booster safety group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
9891621|NCT05330871|Experimental|16. Children booster immuno-persistency group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
9891622|NCT05330871|Experimental|17. Children booster cellular immunity group to receive Ad5-nCoV-IM|1 dose of 0.3ml Ad5-nCoV-IM
9891623|NCT05330871|Active Comparator|18. Children booster safety group to receive ICV|1 dose of 0.5ml ICV
9891624|NCT05330871|Active Comparator|19. Children booster immuno-persistency group to receive ICV|1 dose of 0.5ml ICV
9891625|NCT05330871|Active Comparator|20. Children booster cellular immunity group to receive ICV|1 dose of 0.5ml ICV
9891626|NCT05330871|Experimental|21. Adolescent primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
9891627|NCT05330871|Experimental|22. Adolescent primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
9891628|NCT05330871|Experimental|23. Children primary sentinel group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
9891629|NCT05330871|Experimental|24. Children primary group|2 doses of 0.1ml Ad5-nCoV-IH, 56 days interval
9891630|NCT05330858|Experimental|ESK-001 Liquid|ESK-001 administered as an oral liquid
9891631|NCT05330858|Experimental|ESK-001 Tablet Fasted|ESK-001 administered as an oral tablet in the fasted state
9891632|NCT05330858|Experimental|ESK-001 Tablet Fed|ESK-001 administered as an oral tablet in the fed state
9891633|NCT05330858|Experimental|ESK-001 and Rabeprazole|ESK-001 administered as an oral tablet with rabeprazole
9891634|NCT05330845|Other|Patients with COVID-19 acute respiratory distress syndrome|Patients with acute respiratory distress syndrome due to COVID-19 and requiring mechanical ventilation
9891635|NCT05330832||Patients with confirmed SARS-Cov-2 infection|Hospitalized patients with modern or critical condition with confirmed COVID-19 infection. Patients received standard therapy for COVID-19 infection and anticoagulant prophylaxis if needed according to current temporary clinical recommendations.
9891636|NCT05330819||Group and Interventions|Participants: Adult patients with stable coronary artery disease and previous history of myocardial infarction currently receiving aspirin monotherapy.
9891637|NCT05330819||Groups and interventions|Interventions: Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.
9891638|NCT05330806|Experimental|Collagenase|The patient lies on the surgical operation bed facing down with a cushion under the lower abdomen. The treatment level was localized and local anesthesia was applied to the skin 8-10 cm lateral to the midline. The needle was directed toward the center of the disc under X ray guidance, and the annulus was punctured. Make the needlepoint through small articular process edge into the intervertebral foramen to vertebral body near the trailing edge of the disc. 600UI collagenase was dissolved in 2ml normal saline and injected slowly (1ml/min) into the disc.
9891639|NCT05330806|Active Comparator|Percutaneous transforaminal endoscopic discectomy (PTED)|PTED will be performed using a standardised transforaminal approach and surgical technique using the TESS. A skin incision measuring 0.8-1.0cm in length will be made above the dorsolateral side of the pelvis and 10-14cm from the midline.The puncture needle will be inserted from the incision to the superior articular process of the lower involved vertebrae. After checking the position of the puncture needle under fluoroscopic control, a guidewire will be set. Next, the sequential straight guide rods and a drill/reamer will be placed along the guidewire or rods. After enlarging the intervertebral foramen, the working cannula and the endoscope will be introduced. Removal the herniated disc that compress the nerve root.
9891640|NCT05330793|Other|: Oral probiotic lozenges + placebo toothpaste (toothpaste without ADP-1)|1 active oral probiotic with placebo toothpaste
9891641|NCT05330793|Active Comparator|Oral probiotic lozenges + toothpaste with ADP-1|Oral probiotic and ADP1 toothpaste
9891642|NCT05330793|Placebo Comparator|Placebo lozenges (lozenges without oral probiotics) + placebo toothpaste (toothpaste without ADP-1)|Placebo without oral probiotics or ADP1 toothpaste
9891643|NCT05330780|Experimental|All participants|The study will be single arm with intervention provided to all participants
9891644|NCT05330767||Wound on either the upper or lower extremity with DermaClose and/or DermaClose XL|Non-fasciotomy
9891645|NCT05330767||Wound undergoing fasciotomy with DermaClose and/or DermaClose XL|
9891646|NCT05330767||Wound undergoing fasciotomy with conventional wound dressings|
9891647|NCT05330741|Experimental|Designed Physical Therapy Program|Designed Physical Therapy Program Down syndrome children will receive the designed physical therapy program for 1 hour. The duration of treatment will be 3 times/week for 12 weeks.
9891648|NCT05330741|Experimental|Whole-Body Vibration|Designed physical therapy program in addition to whole-body vibration. Down syndrome children will receive the designed physical therapy program for 1 hour in addition to whole-body vibration with an amplitude of 2 mm, vibration frequency ranged from 25 to 30 Hz and, vibration time ranged from 5 to10 minutes. The duration of treatment will be 3 times/week for 12 weeks.
9891649|NCT05330741|Experimental|Gravity Force Stimulation|Designed physical therapy program in addition to gravity force stimulation. Down syndrome children will receive the designed physical therapy program for 1 hour in addition to gravity force stimulation with 10 repetitions for each position. The duration of treatment will be 3 times/week for 12 weeks.
9891650|NCT05330728|Experimental|Massage group|Suggestions for lifestyle changes + abdominal massage will be performed.
9891651|NCT05330728|Active Comparator|Taping group|Suggestions for Lifestyle Changes + Kinesio taping will be performed.
9891652|NCT05330728|Other|Control group|Suggestions for lifestyle changes will be performed.
9891653|NCT05330715|Other|Advanced Mobile Stroke Unit|Prehospital treatment of patients with an advanced Mobile Stroke Unit. The advanced Mobile Stroke Unit is an ambulance equipped with a computed tomography scanner, and additional diagnostic devices, such as point-of-care-laboratory and telemedicine to enable the team to diagnose and initiated specialised treatment of emergency patients at the emergency site.
9891654|NCT05330715|Other|Conventional ambulance|Prehospital emergency care with conventional ambulances.
9891655|NCT05330702|Experimental|Tuberosity Connective Tissue Graft (CTG)|Subjects in this arm will have a tuberosity connective tissue graft at the time of immediate implant placement.
9891656|NCT05330702|Experimental|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft|Subjects in this arm will have Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft at the time of immediate implant placement.
9891657|NCT05330702|No Intervention|No Soft Tissue Augmentation|Subjects in this arm will have no soft tissue augmentation at the time of immediate implant placement.
9891658|NCT05330689|Active Comparator|Sample group 1|Sample of subjects with primary osteoarthritis of the knee
9891659|NCT05330689|Active Comparator|Sample group 2|Sample of subjects with primary osteoarthritis of the knee
9891660|NCT05330689|Active Comparator|Sample group 3|Sample of subjects with primary osteoarthritis of the knee
9891661|NCT05330689|Active Comparator|Sample group 4|Sample of subjects with primary osteoarthritis of the knee
9891662|NCT05330689|Placebo Comparator|Sample group 5|Sample of subjects with primary osteoarthritis of the knee
9891663|NCT05330676||No shock|Patients who have no evidence of clinical malperfusion or require vasoactive agents after cardiac surgery.
9891664|NCT05330676||Shock|Patients who have evidence of clinical malperfusion or require vasoactive agents after cardiac surgery.
9891665|NCT05330663|Experimental|Intervention group|Low protein diet with Fresubin® renal
9891666|NCT05330663|Other|Standard of care|Low protein diet with normal food
9891667|NCT05330650|Active Comparator|Triclosan coated suture|
9891668|NCT05330650|Active Comparator|Non coated suture|
9891669|NCT05330637||Migratory old people with asthma from northern China in Sanya|Migratory old people with asthma from northern China in Sanya have being expousured to two different climate and environment from northern China to Sanya for months.
9891670|NCT05330637||Migratory old people with allergic rhinitis from northern China in Sanya|Migratory old people with allergic rhinitis from northern China in Sanya have being expousured to two different climate and environment from northern China to Sanya for months.
9891671|NCT05330637||Migratory old people with Chronic Obstructive Pulmonary Disease (COPD) from northern China in Sanya|Migratory old people with Chronic Obstructive Pulmonary Disease (COPD) from northern China in Sanya have being expousured to two different climate and environment from northern China to Sanya for months.
9891672|NCT05330637||Migratory old people with atopic dermatitis from northern China in Sanya|Migratory old people with atopic dermatitis from northern China in Sanya have being expousured to two different climate and environment from northern China to Sanya for months.
9891673|NCT05330637||Children with asthma in Sanya|Children with asthma have being expousured to tropical climate and environment in Sanya for years.
9891674|NCT05330637||Children with allergic rhinitis in Sanya|Children with allergic rhinitis have being expousured to tropical climate and environment in Sanya for years.
9891675|NCT05330637||Children with atopic dermatitis in Sanya|Children with atopic dermatitis have being expousured to tropical climate and environment in Sanya for years.
9891676|NCT05330637||Children with eczema in Sanya|Children with eczema have being expousured to tropical climate and environment in Sanya for years.
9891677|NCT05330637||Children with urticaria in Sanya|Children with urticaria have being expousured to tropical climate and environment in Sanya for years.
9891678|NCT05330637||Migratory old people with eczema from northern China in Sanya|Migratory old people with eczema from northern China in Sanya have being expousured to two different climate and environment from northern China to Sanya for months.
9891679|NCT05330637||Migratory old people with urticaria from northern China in Sanya|Migratory old people with urticaria from northern China in Sanya have being expousured to two different climate and environment from northern China to Sanya for months.
9891680|NCT05330624|Experimental|the D0- M1-M6 regimen|Adults receive three doses of 1.0 ml plague vaccine at day 0, month 1, and month 6 (referred as the D0-M1-M6 regimen).
9891681|NCT05330624|Experimental|the D0- M2-M6 regimen|Adults receive three doses of 1.0 ml plague vaccine at day 0, month 2, and month 6 (referred as the D0-M2-M6 regimen).
9891682|NCT05330611|Experimental|Ultrasound-guided Cryoneurolysis: Group A|"Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be18-64 years of age and will be randomized (1:1) to the ultrasound-guided cryoneurolysis group within 72 hours of admission to the ED.~Intervention is ultrasound guided cryoneurolysis of intercostal nerves creating lost lasting pain relief. Device used for cryoneurolysis is Iovera Smart tip 190"
9891683|NCT05330611|Active Comparator|Standard-of-Care : Group B|Patients who are admitted to the Emergency Department after a traumatic injury. Patients will have rib fractures in any of ribs 3-9. Patients will be18-64 years of age and will be randomized (1:1) to Standard of Care which typically includes multi-modal pain therapy and pulmonary toilet.
9891684|NCT05330598|Experimental|Connected Catheter Users|Device: Connected Urinary Catheter Patients will use the Connected Catheter to empty the bladder during the course of treatment.
9891685|NCT05330585|Experimental|Unaided|Participants with hearing loss.
9891686|NCT05330585|Experimental|Hearing aids|Participants with hearing loss wearing hearing aids.
9891687|NCT05330572||Oral lichen planus|No interventions were administered to this group of patients as a part of the study.
9891688|NCT05330572||Oro-vulvovaginal lichen planus|No interventions were administered to this group of patients as a part of the study.
9891689|NCT05330546|Experimental|Osseodensification technique group|10 patients will be randomly assigned to the osseodensification group so the implant osteotomy will be prepared using densah burs
9891690|NCT05330546|Active Comparator|Ridge expansion screw group|10 patients will be randomly assigned to the ridge expansion screw group so the implant osteotomy will be prepared using ridge expansion screws
9891691|NCT05330520|Experimental|Patients Who Completed 12 Months of Follow-Up Post Butterfly Implantation|Continuation study for Study BM-011-IL
9891692|NCT05330507||Wellinks Intervention|Following inpatient hospitalization for COPD exacerbation, participants will receive 16 weeks of access to Wellinks (i.e., connected spirometer and pulse oximeter, virtual respiratory therapist sessions with pulmonary rehabilitation, virtual health coaching sessions, mobile app access, COPD-related education). The 16-week period is comprised of a 30-day post-discharge program followed by a 12-week intensive period, which vary by frequency of contact with respiratory therapists/health coaches.
9891693|NCT05330507||Matched Controls|A matched control dataset will be extracted from electronic medical records of the participating healthcare system. Participants will be matched on an index COPD-related hospitalization and other key factors, utilizing propensity score matching (i.e., number of COPD-related hospitalizations in prior year, severity of COPD, age).
9891694|NCT05330494|Experimental|S1|TEAS treatment initiated at 30 minutes before induction and lasted for 30min,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
9891695|NCT05330494|Experimental|S2|TEAS treatment initiated immediately after induction and stopped at the end of surgery,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
9891696|NCT05330494|Experimental|S3|TEAS treatment initiated immediately after extubating and lasted for 30 minutes,TEAS treatment(disperse-dense waves; frequency, 2/100 Hz)on acupoints Hegu(LI4) , Neiguan(PC6) and Zusanli（ST 36）of both sides, and the present intensity(8～12 mA) was the maximum current that could be tolerated.Then, the TEAS treatment was administered twice a day (once in the morning and once in the afternoon) on the first and second postoperative day, which lasted for 30 minutes each time.
9891697|NCT05330494|Sham Comparator|control|the control group was given all manipulations without electrical stimulation, electrodes were placed on the same acupoints, but no current was given
9891698|NCT05330481||<70 kg body mass|Cyclists or triathletes with a body mass of less than 70 kg
9891699|NCT05330481||>80 kg body mass|Cyclists or triathletes with a body mass of less than 80 kg
9891700|NCT05330468||Abbott Regent MHV|Subjects implanted with an Abbott Regent MHV replacement of the aortic valve.
9891701|NCT05330455|Experimental|Part 1 Cohort 1: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 1) + Placebo; in period 2: GSK3965193 (Dose 2) + Placebo; in period 3: GSK3965193 (Dose 3) + Placebo and in period 4: GSK3965193 (Dose 4) + Placebo. There will be a minimum of 7 days washout between dosing in each treatment period.
9891702|NCT05330455|Experimental|Part 1 Cohort 2: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 5) + Placebo; in period 2: GSK3965193 (Dose 6) + Placebo; in period 3: GSK3965193 (Dose 7) + Placebo and in period 4: GSK3965193 (Dose 8) + Placebo. There will be a minimum of 7 days washout between dosing in each period.
9891703|NCT05330455|Experimental|Part 2A Cohort 3: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses of either GSK3965193 (Dose X) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
9891704|NCT05330455|Experimental|Part 2A Cohort 4: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses either GSK3965193 (Dose Y) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
9891705|NCT05330455|Experimental|Part 2A Cohort 5: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses either GSK3965193 (Dose Z) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
9891706|NCT05330455|Experimental|Part 2B Cohort 6: GSK3965193|Healthy Participants will be randomized 1:1 to receive single doses of GSK3965193 (Dose A) under fasted and fed conditions in treatment period 1. In period 2, the participants who received GSK3965193 (Dose A) under fasted conditions in treatment period 1 will receive the same dose under fed conditions, and vice versa. In the third period, all participants will receive a single dose of GSK3965193 (Dose B) different strength under fasted conditions. The dose level for the third period will be selected based on the results of the first two periods. There will be a minimum of 7 days washout between dosing in each treatment period.
9891707|NCT05330455|Experimental|Part 3 Cohort 7: GSK3965193 or placebo|PLWCHB on stable nucleos(t)ide analog (NA) therapy will be randomized 3:1 to receive repeat dose of either GSK3965193 (Dose E) or placebo. This part will commence after completion of both Part 1 and Part 2.
9891708|NCT05330455|Experimental|Part 4 Cohort 8: GSK3965193 and bepirovirsen or placebo and bepirovirsen|PLWCHB participants on stable NA therapy who have not participated in Part 3 of the study will be randomized 3:1 to receive repeat dose either GSK3965193 or placebo. In addition, all participants in this cohort will also receive bepirovirsen. This part will commence after completion of Part 3, contingent on the clinical safety and efficacy data from Part 3.
9891709|NCT05330429|Experimental|Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI|Participants will receive magrolimab in de-escalating doses to establish recommended Phase 2 dose (RP2D) in combination with + bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
9891710|NCT05330429|Experimental|Randomized Cohort: Magrolimab + Bevacizumab + FOLFIRI|"Participants will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).~Additional dose expansion cohorts of magrolimab in combination with bevacizumab and FOLFIRI may be opened at the sponsor's discretion."
9891711|NCT05330429|Active Comparator|Randomized Cohort: Bevacizumab + FOLFIRI|Participants will receive bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 +leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
9891712|NCT05330377|Experimental|Gilteritinib (Dose Level -1: 40 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 40 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
9891713|NCT05330377|Experimental|Gilteritinib (Dose Level 1: 80 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 80 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
9891714|NCT05330377|Experimental|Gilteritinib (Dose Level 2: 120 mg/day)|"Dose escalation for gilteritinib will be conducted according to a BOIN design. Gilteritinib 120 mg/day will be given orally starting day 6 until day 19. CLAG-M chemotherapy will be administered at a fixed dose and schedule as following:~Cladribine (CL) 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5, given first.~Cytarabine (A) 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.~Filgrastim (GCSF) 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is > 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.~Mitoxantrone (M) 10 mg/m2 I.V. once per day on days 1 to 3"
9891716|NCT05330351||Pediatric Trauma Patients|Pediatric patients (<18 years old) who have suffered a traumatic event requiring surgical fixation within 48 hours prior to time to arrival in the operating room.
9891717|NCT05330338|Other|Congenital heart disease|
9891718|NCT05330325|Experimental|Somapacitan|Participants will receive Somapacitan for 156 weeks
9891719|NCT05330325|Active Comparator|Norditropin®|Participants will receive Norditropin® for 52 weeks (main phase) and Somapacitan for 104 weeks (extension phase)
9932250|NCT00947102||Pancreatic tubular adenocarcinoma|Patients with pancreatic tubular adenocarcinoma
9891720|NCT05330312|Experimental|Digital cognitive behavioral therapy|Part 1: 4 weeks digital cognitive behavioral therapy Part 2 9 weeks digital cognitive behavioral therapy
9891721|NCT05330312|No Intervention|Control group|Waitlist control group in part 2 of the study
9891722|NCT05330299|Experimental|COMPASS (single arm)|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of IBD.
9891723|NCT05330286|Experimental|Pediatric Formulation|Part 1 - healthy participants receiving pediatric formulation
9891724|NCT05330286|Experimental|Adult Formulation|Part 1 - healthy participants receiving adult formulation
9891725|NCT05330286|Experimental|Adult formulation fasted state|Part 2- healthy participants receiving adult formulation in fasted conditions
9891726|NCT05330286|Experimental|Adult formulation Fed state|Part 2- Part 2- healthy participants receiving adult formulation in fed conditions
9891727|NCT05330273|Experimental|Period 1: KAF156 + LUM566 / Period 2: KAF156 + LUM566 + Efavirenz|"Participants enrolled will receive a single oral dose of ganaplacide and lumefantrine combination on Day 1 of Period 1.~In Period 2, participants will receive an oral dose of efavirenz q.d. in the evening on Days 1 through 24 and a single dose of ganaplacide and lumefantrine combination on the morning of Day 11."
9891728|NCT05330260||Endo-CABG|Group that underwent retrograde arterial cardiopulmonary bypass flow.
9891729|NCT05330260||PCI|Surgical control group
9891730|NCT05330260||Healthy controls|Non-surgical control group
9932251|NCT00947128|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
9932252|NCT00947128|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
9932253|NCT00947141|Experimental|Group A|"Group A: (low level infection) has 2 arms:~Start treatment when 2 consecutive levels CMV PCR >200copies / ml~Monitor (Treatment starts when CMV PCR >3,000 copies / ml (current site clinical protocol))"
9932254|NCT00947141|Experimental|Group B|"Group B: (patients receiving pre-emptive therapy) has 2 arms:~Stop treatment when 2 levels CMV PCR <3,000 copies / ml~Monitor (Treatment stops when there are 2 consecutive levels of CMV PCR <200 copies / ml (current site clinical protocol))"
9932255|NCT00947180|Active Comparator|Electrogalvanic stimulation|High voltage electrical stimulation was delivered through an anal plug to induce relaxation of pelvic floor muscles.
9932256|NCT00947180|Active Comparator|Digital massage|The therapist massaged the levator ani muscles by applying firm pressure with a gloved finger and rotating from left to right.
9932257|NCT00947180|Experimental|Biofeedback|Electromyographic (EMG) activity was recorded from a probe in the anal canal, averaged and displayed to patients to help them learn to relax pelvic floor muscles during straining.
9932258|NCT00947206|Experimental|LHWO about CRC|The intervention group participants will be exposed to 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
9932259|NCT00947206|Active Comparator|Nutrition education + CRC brochure|The comparison group will receive a bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
9932260|NCT00947232|Experimental|Motivational interviewing|Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
9932261|NCT00947232|Active Comparator|Education|Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
9932262|NCT00947245|Experimental|BMS-791325 - Part A, Dose 1|
9932263|NCT00947245|Experimental|BMS-791325 - Part A, Dose 2|
9932264|NCT00947245|Experimental|BMS-791325 - Part A, Dose 3|
9932265|NCT00947245|Experimental|BMS-791325 - Part B, Dose 1|
9932266|NCT00947245|Experimental|BMS-791325 - Part B, Dose 2|
9932267|NCT00947245|Experimental|BMS-791325 - Part B, Dose 3|
9932268|NCT00947323|Placebo Comparator|placebo|
9932269|NCT00947323|Experimental|Simvastatin|Treatment arm.
9932270|NCT00947336|Active Comparator|Norfloxacin + Synbiotic|
9932271|NCT00947336|Placebo Comparator|Norfloxacin + Placebo|
9932272|NCT00947362|Experimental|ETC + DAC N-055|
9932273|NCT00947362|Active Comparator|ETC + physiological saline|
9932274|NCT00947375|Experimental|Starch|In these study participants are randomly (by chance) assigned for two treatment arms of a clinical trial.
9935975|NCT02911129||Patients|Patients with neglect after a right hemisphere brain lesion
9891731|NCT05330247|Experimental|Therapeutic Diet: CRHP Diet|Carbohydrate-reduced high-protein (CRHP) dietary intervention. Intervention: Therapeutic Diet: CRHP Diet.
9891732|NCT05330247|Active Comparator|Therapeutic Diet: CD Diet|Conventional diabetes (CD) dietary intervention. Intervention: Therapeutic Diet: CD Diet.
9891733|NCT05330234|Other|Therapists|Single arm study. Participants are members of the therapy team at Imperial College Healthcare NHS Trust's stroke wards.
9891734|NCT05330221|Experimental|Intervention Group|"PAL2 Intervention~Drug Therapy"
9891735|NCT05330221|No Intervention|Usual Care Group|Participants that are randomized into usual care will be assisted with arrangement of follow-up, either with existing primary care provider (PCP) or a Wayne Health provider. All subsequent medical treatment will be at the discretion of the PCP.
9891736|NCT05330208|Experimental|Group A|
9891737|NCT05330208|Placebo Comparator|Group B|
9891738|NCT05330195|Experimental|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group
9891739|NCT05330195|Active Comparator|Control Group|Home Based Exercise Group Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 3-5 days a week.
9891740|NCT05330182|Experimental|Sentinel Cohort|
9891741|NCT05330182|Active Comparator|LMN-201|
9891742|NCT05330182|Placebo Comparator|Placebo|
9891743|NCT05330156|Active Comparator|Transurethral resection of the prostate group (TURP).|the 1st group of patients will undergone Transurethral resection of the prostate for treatment of BPH
9891744|NCT05330156|Active Comparator|transurethral enucleation of prostate group (TUEP)|the 2nd group of patients will undergone Transurethral enucleation of the prostate for treatment of BPH
9891745|NCT05330143|Experimental|ASC22 1mg/kg|ASC22 Injection of 1mg/kg and anti-retroviral therapy for 12 weeks
9891746|NCT05330143|Experimental|ASC22 2.5mg/kg|ASC22 Injection of 2.5mg/kg and anti-retroviral therapy for 12 weeks
9891747|NCT05330143|Placebo Comparator|Placebo|0.9% Saline and anti-retroviral therapy for 12 weeks
9891748|NCT05330130|Active Comparator|Daily 150 IU recFSH|Follitropin beta injection 150 IU daily
9891749|NCT05330130|Active Comparator|Daily 300 IU recFSH|Follitropin beta injection 300 IU daily
9891750|NCT05330117|Experimental|Active TENS|In the active treatment group, the TENS unit will remain on up to 30 minutes (10 minutes pre-procedure, during the procedure and during the questionnaires).
9891751|NCT05330117|Sham Comparator|Control TENS|The sham stimulation group will undergo the same procedure; however, the TENS stimulation current will be reduced to a minimal detectable level and turned off after 20 seconds.
9891752|NCT05330104|Experimental|mEMA Arm|In this arm, participants will be using a mobile survey system to track the emergence of Chemotherapy-Induced Peripheral Neuropathy symptoms and fall risk over the course of the participant's chemotherapy.
9891753|NCT05330091||Healthy Women|Once Daily Women's Probiotic Placebo
9891754|NCT05330078|Experimental|Keloid treatment with botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
9891755|NCT05330078|Placebo Comparator|Keloid treatment with vehicle control (saline)|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
9891756|NCT05330065|Experimental|Bevacizumab and Camrelizumab for Malignant Pleural Effusion|
9891757|NCT05330039||Patients with IEM|Collection of biological samples (stool and urine) and health-related data at two timepoints, three to six months apart.
9891758|NCT05330039||Healthy Siblings|Collection of biological samples (stool) and health-related data at two timepoints, three to six months apart.
9891759|NCT05330000|Active Comparator|Voriconazole (R)|
9891760|NCT05330000|Experimental|Voriconazole (T)|
9891761|NCT05329987||Parkinson Disease|Rehabilitation according to Physiotherapy and Occupational Therapy European Guidelines for Parkinson Disease.
9891762|NCT05329974|Experimental|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
9891763|NCT05329961|Experimental|Single Arm|HPV 9-valent human papillomavirus vaccine (Gardasil 9) - 0.5mL intramuscular dose - 2 doses (Month 0, 12)
9891764|NCT05329948|Experimental|haptonomy application|The data will be obtained by applying a pre-test to the pregnant women and their spouses included in the experimental group before the application. After the pre-test data are collected, 5 sessions of haptonomy will be applied to the couples in the experimental group. Each session (Breath awareness and diaphragm breathing 5 minutes, Feminine energy attunement and heart-looking energy work 5 minutes, Physical communication with the baby in the womb with touches 10 minutes, meditation from the heart to the uterus 15 minutes, awareness of the environment, closing breath and feedback 5 minutes) It will be 40 minutes. For the effectiveness and continuity between each session, planning will be made for 3 days to 7 days. The final test will be applied 1 week after the hapatonomy application (after 5 sessions are completed).
9891765|NCT05329948|No Intervention|Control|no application will be made
9891766|NCT05329922|Experimental|ALICE|Clients participating in this arm are asked to train their listening and communication skills using the ALICE app on their personal smart device for 8 weeks.
9891767|NCT05329922|No Intervention|Control|This arm will receive the standard of care given to the client. Persons with a moderate to profound hearing loss are provided with a hearing aid. Persons with a profound to severe HI are provided with a cochlear implant and concomitant rehabilitation. Most persons with a cochlear implant receive intensive rehabilitation during the first 6 months after their implantation. Afterwards, they mainly return for mapping of the device but not for listening training therapy.
9891768|NCT05329870||Normal Colonoscopy and Normal qFIT|Normal colonoscopy and qFIT <10 micrograms haemoglobin
9891769|NCT05329870||Normal Colonoscopy and Raised qFIT|Normal colonoscopy and qFIT >=10 micrograms haemoglobin
9891770|NCT05329857|Experimental|Metformin and Vildagliptin 1000/50 mg Tablet|1 tablet of Metformin and Vildagliptin 1000/50 mg as single-dose administration
9891771|NCT05329857|Active Comparator|EUCREAS® 50/1000 mg Tablet|1 tablet of EUCREAS® 50/1000 mg (each film-coated tablet contains Vildagliptin 50 mg and Metformin hydrochloride 1000 mg) as single-dose administration
9891772|NCT05329844|Experimental|Vildagliptin 50 mg Tablet|1 tablet of Vildagliptin 50 mg as single-dose administration
9891773|NCT05329844|Active Comparator|Galvus 50 mg Tablet|1 tablet of Galvus 50 mg (each tablet contains 50 mg Vildagliptin) as single-dose administration
9891774|NCT05329831|Experimental|Experimental|"Patients will be asked to fill out the Introductory Information Form, the Numerical Rating Scale, the Oxford Happiness Scale Short Form, and the Life Activities Scale scales. Then, the educational needs of the patients in the experimental group will be determined. Trainings will be planned individually for each patient according to the needs of the patients.~After the patients go to their homes, telehealth will be implemented. Patients included in the experimental group will continue their routine physician appointments and prescriptions. In addition, telehealth education initiative will be made for the patients. Structured training will be applied to the patients once a week for 12 weeks, each training will be 20-40 minutes. The researcher will develop a trusting relationship with the patient and evaluate the patient's compliance with treatment, obstacles to happiness, information needs related to pain management, and difficulties in life activities."
9891775|NCT05329831|No Intervention|Control|No application will be made by the researcher to the patients in the control group. Patients will continue with their prescriptions and physician visit routines. The scales will be administered to the patients in this group at the beginning of the study and at the 4th, 8th, and 12th weeks.
9891776|NCT05329818|Experimental|Prefrontal stimulation.|Participants receive anodal tDCS on the ipsilesional dlPFC for 5days/week for 2 weeks.
9891777|NCT05329818|Experimental|Cerebellar stimulation.|Participants receive anodal tDCS on the contralesional cerebellum for 5days/week for 2 weeks. min of HD-tDCS with 2.0mA.
9891778|NCT05329818|Experimental|Fronto-cerebellar stimulation.|Participants receive simultaneous anodal tDCS on the ipsilesional dlPFC and in contralesional cerebellum for 5days/week for 2 weeks.
9891779|NCT05329818|Sham Comparator|Sham stimulation.|Participants receive sham tDCS for 5days/week for 2 weeks.
9891780|NCT05329805|Experimental|interventional group|Job crafting intervention
9891781|NCT05329805|No Intervention|control group|Regarding the control group, the participants will receive a simple educational booklet with one-session
9891782|NCT05329792|Experimental|Treatment arm with L19IL2 /L19TNF|70 patients will be enrolled and treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks. The total dose/volume will be distributed among the target lesions defined at screening via single or multiple intralesional injections, according to lesions' size and number.
9891783|NCT05329766|Experimental|Cohort A: First Line - Treatment Naïve Participants|Domvanalimab and zimberelimab in addition to FOLFOX chemotherapy by intravenous (IV) infusion
9891784|NCT05329766|Experimental|Cohort B: Second Line or greater Checkpoint Inhibitor Naïve Participants|Domvanalimab and zimberelimab will be administered by IV infusion
9891785|NCT05329766|Experimental|Cohort C: Second Line or greater - Checkpoint Inhibitor Experienced Participants|Domvanalimab and zimberelimab will be administered by IV infusion
9891786|NCT05329753|Experimental|Intervention group|Mobile application
9891787|NCT05329753|No Intervention|Control group|Usual education
9891788|NCT05329740|Experimental|Glucocorticoid group|
9891789|NCT05329740|No Intervention|Control Group|
9891790|NCT05329714||Patients with Pulmonary Hypertension|Patients with a diagnosis of pulmonary hypertension typically diagnosed via right heart catheterization.
9891791|NCT05329714||Control Group|Participating PH centers can optionally provide data about patients with exclusion of pulmonary hypertension
9891792|NCT05329701|Experimental|Individualized treatment duration|"Antibiotic treatment will be discontinued when both of the following two criteria are fulfilled:~The infant has had 24 hours without clinical symptoms of infection, after systematic clinical evaluation by a neonatologist. Clinical symptoms specified in Table 1.~CRP is < 30 mg/l. If CRP is > 30 at the time when the infant has been symptom-free for 24 hours, CRP will be assessed once every 24 -48 hours and antibiotics will be stopped when CRP < 30."
9891793|NCT05329701|No Intervention|Standard treatment duration|Standard treatment duration is seven days.
9891794|NCT05329688|Experimental|Arm A|"Novel nutrition program :~Give nutrition health education every week and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease."
9932275|NCT00947375|No Intervention|Lifestyle councelling|May be required to comply with US Public Law 110-85, Section 801
9797570|NCT01600326|Active Comparator|Tenotomy Group|Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
9797571|NCT01600326|Active Comparator|Plasma Injection Group|Treatment is Ultrasound guided platelet rich plasma injection.
9797572|NCT01600482|Experimental|CELT ACD device|The CELT ACD device is a vascular closure device.
9797573|NCT01600482|No Intervention|Manual Compression|Manual Compression
9797574|NCT01600495|Experimental|Experimental TENS|TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
9797575|NCT01600495|No Intervention|control Group|Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.
9797576|NCT01600586|Experimental|Pacifier-Activated-Lullaby system (PAL)|Pacifier-Activated-Lullaby system (PAL) group.
9797577|NCT01600586|No Intervention|No PAL group|No PAL. Standard of care procedures.
9797578|NCT01600638|Experimental|Zeltiq System Treatment Group|Individuals with sharp flank curvatures were treated on one (1) flank with the Zeltiq CoolSculpting System and the CoolCurve+ applicator at protocol-defined temperatures and durations.
9797579|NCT01600677|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with an EMMA MDU for use in their homes for the 90-day period immediately following discharge.
9797580|NCT01600677|Active Comparator|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
9797581|NCT01600703|Experimental|Sitagliptin|sitagliptin, 100mg, oral, single dose
9797582|NCT01600703|Placebo Comparator|Placebo|Placebo, oral, single dose
9797583|NCT01600716|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
9797584|NCT01600716|Other|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.
9797585|NCT01600729||All Participants|Participants with facial lines. There was no intervention in this study.
9891795|NCT05329688|Active Comparator|Arm B|Routine nutrition education Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
9891796|NCT05329675|Sham Comparator|Arm A|one capsule /day
9891797|NCT05329675|Experimental|Arm B|two capsule/day
9891798|NCT05329675|Experimental|Arm C|Three capsule /day
9891799|NCT05329662|Active Comparator|AD-MSCs infusions, then Placebo|Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 ± 7
9891800|NCT05329662|Placebo Comparator|Placebo, then AD-MSCs infusions|Patients in group B will receive two autologous AD-MSC administrations on day 180 ± 14 and day 270 ± 14
9891801|NCT05329649|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.
9891802|NCT05329636|Placebo Comparator|Placebo FMT capsules|Glycerol and saline solution will be pipetted into commercially available acid-resistant hypromellose capsules (DRCaps, Capsugel) (650 μL), which will be closed and then secondarily sealed. Capsules will be stored frozen at -80°C (-112°F). Patients will swallow 30 frozen capsules on two consecutive days. Capsules look exactly the same as FMT capsules
9891803|NCT05329636|Experimental|FMT capsules|Fecal matter solution (feces, glycerol and saline solution) will be pipetted into commercially available acid-resistant hypromellose capsules (DRCaps, Capsugel) (650 μL), which will be closed and then secondarily sealed. Capsules will be stored frozen at -80°C (-112°F). Patients will swallow 30 frozen capsules on two consecutive days.
9891804|NCT05329636|Experimental|FMT enemas|patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema/ Fecal matter solution (feces(25 gr of stool , glycerol and saline solution) will be stored at 50 ml tubes frozen at -80°C (-112°F).
9891805|NCT05329610|Experimental|Beta-alanine|Slow-release beta-alanine (Natural Alternatives International, Carlsbad, CA, USA). Dose: 4.8 grams per day for 3-months (potential total intake of 432 g beta-alanine). The daily intake will be split into four doses of 2 x 600 mg. Participants will be instructed to consume each dose alongside their main daily meals (e.g., breakfast, lunch, and dinner) and before bed.
9891806|NCT05329610|Placebo Comparator|Placebo|Taste and appearance-matched placebo (tapioca starch) (Natural Alternatives International, Carlsbad, CA, USA). Doses equivalent to the experimental arm.
9891807|NCT05329597||100mg|After 15 consecutive days of takeing 100mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
9891808|NCT05329597||200mg|After 15 consecutive days of takeing 200mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
9891809|NCT05329597||400mg|After 15 consecutive days of takeing 400mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
9891810|NCT05329597||600mg|After 15 consecutive days of takeing 600mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
9891811|NCT05329584|Experimental|Group I|InSpace device + accelerated rehabilitation in a formalized program (FP)
9891812|NCT05329584|Experimental|Group II|InSpace device + accelerated rehabilitation in an at-home program (AHP)
9891813|NCT05329571|Experimental|Low-FODMAP Diet|Participants will be instructed to maintain their usual diet, while eliminating FODMAPs (A subgroup of carbohydrates are considered fermentable, given the lack of suitable hydrolase enzymes in the colon, required for their digestion and absorption, thus making them available for fermentation).
9891814|NCT05329571|Experimental|Gluten-Free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
9891815|NCT05329571|Other|Control|Patients of this group will be asked to adhere to their regular, daily diet.
9891816|NCT05329558||Healthy Controls|
9891817|NCT05329558||Patients with ART without MRONJ|
9891818|NCT05329558||Patients with oral ART with MRONJ|
9891819|NCT05329558||Patients with intravenous ART with MRONJ|
9891820|NCT05329532|Experimental|Patients with TNBC, advanced/unresectable SCCHN, high grade serous ovarian carcinoma, or RCC|
9891821|NCT05329532|Experimental|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; monotherapy)|
9891822|NCT05329532|Experimental|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; combination)|
9891823|NCT05329519|Experimental|Music group|Patients in this groups underwent VATS with wedge recession, performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player and head phones on postoperative three days.
9891824|NCT05329519|No Intervention|Controlled group|Patients in this groups underwent VATS with wedge recession, performed deep breathing and coughing exercises for postoperative three days without music
9891825|NCT05329506||Supportive care patient population|Attitudes and Believes About Vaccinations, questionnaires
9891826|NCT05329493|Experimental|Cooling digit device application|Device: Cooling digit device. The cooling finger device will be applied in the subjects on their right hand. Subjects will serve as their own control.
9891827|NCT05329480|Experimental|Creatine Monohydrate Supplementation|Blinded subjects are instructed to ingest 20g of creatine monohydrate for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).
9932276|NCT00947388|Experimental|Bendamustine plus Alemtuzumab|
9891828|NCT05329480|Placebo Comparator|Maltodextrin Supplementation|Blinded subjects are instructed to ingest 20g of maltodextrin for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).
9891829|NCT05329480|No Intervention|Control|Participants in the control group do not receive a supplement (creatine or placebo) to ingest over the 7 day period.
9891830|NCT05329467|Other|Validation|
9891831|NCT05329454|Experimental|Treatment ABC|Receive the investigational product and active comparator in a sequence of treatment A, treatment B and treatment C.
9891832|NCT05329454|Experimental|Treatment ACB|Receive the investigational product and active comparator in a sequence of treatment A, treatment C and treatment B.
9891833|NCT05329454|Experimental|Treatment BAC|Receive the investigational product and active comparator in a sequence of treatment B, treatment A and treatment C.
9891834|NCT05329454|Experimental|Treatment BCA|Receive the investigational product and active comparator in a sequence of treatment B, treatment C and treatment A.
9891835|NCT05329454|Experimental|Treatment CAB|Receive the investigational product and active comparator in a sequence of treatment C, treatment A and treatment B.
9891836|NCT05329454|Experimental|Treatment CBA|Receive the investigational product and active comparator in a sequence of treatment C, treatment B and treatment A.
9891837|NCT05329441||Study Participants|All depressed participants will undergo the same study procedures
9891838|NCT05329428|Experimental|Vitamin D Supplementation 20 µg/day|Dietary supplements containing 20 µg of vitamin D per day will be provided to study subjects.
9891839|NCT05329428|Experimental|Vitamin D Supplementation 40 µg/day|Dietary supplements containing 40 µg of vitamin D per day will be provided to study subjects.
9891840|NCT05329428|Active Comparator|Usual Antenatal Care|Women randomized to usual antenatal care will receive advise about vitamin D supplementation according to usual antenatal care routines.
9891841|NCT05329415||Diabetic Group (Cases)|"Subject aged 18 years of age or over~Written, informed consent obtained.~New diagnosis of tuberculosis and starting on anti-tuberculosis treatment~Known diagnosis of diabetes or a raised IFCC HbA1c level (>= 48 mmol/mol) at the time of TB diagnosis"
9891842|NCT05329415||Non-Diabetic Group (Controls)|"Subject aged 18 years of age or over~Written, informed consent obtained.~New diagnosis of tuberculosis and starting on anti-tuberculosis treatment~IFCC HbA1c level < 48mmol/mol and no known diagnosis of diabetes"
9891843|NCT05329402|Active Comparator|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|The Disposable Powered Articulating Endoscopic Linear Cutter Stapler is intended for transection, resection, and/or creation of anastomoses. The instrument has application in multiple open or minimally invasive general, gynecologic, urologic, thoracic, and pediatric surgical procedures. It can be used with staple line or tissue buttressing materials. The instrument may also be used for transection and resection of liver parenchyma (hepatic vasculature and biliary structures), pancreas, kidney and spleen.
9891844|NCT05329402|Experimental|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|ECHELON Flex Powered Articulating Endoscopic Linear Cutters has application in multiple open or minimally invasive general, gynecologic, urologic, thoracic, and pediatric surgical procedures.
9891845|NCT05329376|Experimental|Group A|Three months of daily interactions with a voice command virtual interaction system followed by three months of usual care maintenance;
9891846|NCT05329376|Experimental|Group B|Three months of maintenance of usual care followed by three months of daily interactions with a voice command virtual interaction system;
9891847|NCT05329363|Experimental|PEPITS programme|
9891848|NCT05329363|Active Comparator|Usual care|
9891849|NCT05329350||muscular ventricular septal defects|patients with muscular ventricular septal defects
9891850|NCT05329337|Experimental|10 patients with high insulin levels (13.3 ± 9.2 microU/mL) and markers of metabolic syndrome|These are individuals who were isolated from the previous MetACTIV study due to their specific immune profile (Profile 2) defined by 43 immune activation markers and characterized by a high percentage of differentiated T cells and activated T cells.
9891851|NCT05329337|Active Comparator|20 patients with other immune profiles|
9891852|NCT05329311||ERATS protocol applied|Inflammatory parameters of the operated patients by applying the ERATS protocol will be investigated.
9891853|NCT05329311||ERATS protocol not applied|Inflammatory parameters of patients who were operated without the ERATS protocol will be investigated.
9891854|NCT05329298|Experimental|Phase I|"Patients will receive a single dose on Day 1, then after an 7-day wash-out period, repeated dosing, once daily will be initiated(Ia).~Patients receive BPI-361175 PO. Cycles repeat every 28 days(Ib)."
9891855|NCT05329298|Experimental|Phase II|Patients receive BPI-361175 based on RP2D.
9891856|NCT05329285|Experimental|Percutaneous Coronary Intervention (PCI)|Patients will be revascularized by PCI
9891857|NCT05329285|No Intervention|Coronary artery bypass grafting (CABG)|Patients will be revascularized by CABG
9891858|NCT05327348|Experimental|Parenteral Ascorbic Acid|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) for 7 days
9891859|NCT05327348|Placebo Comparator|0.9% Normal Saline|Intravenous 0.9% normal saline 10 mL 8 hourly for 7 days
9891860|NCT05327153|Experimental|intervention group|Breast cancer patients from the IPPT Breast Clinic who meet the inclusion criteria will be contacted and informed about the study and procedure. Informed consent will be obtained once the respondent agrees to participate. In the case of group psychological intervention, 8 breast cancer patients form one group, and group psychological intervention is given once a week for four weeks as part of the treatment process. The batteries of assessment were carried out at 3-time points; pre-intervention, post-intervention, and 3 months after the intervention.
9891861|NCT05327153|Other|waitlist group|After the intervention of the intervention group, the waitlist group was interfered again. The batteries of assessment was same as the intervention group.
9891862|NCT05324176|Active Comparator|Gillian-Barre|Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration.
9891863|NCT05324176|Active Comparator|Myasthenia Gravis|Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration.
9932277|NCT00947401||elective post surgery patients|
9891864|NCT05324176|Active Comparator|control|Patients hospitalized with neurological disorders without affection of the respiratory system.
9891865|NCT05323734|Experimental|GNX|GNX oral suspension, TID
9891866|NCT05323734|Placebo Comparator|Placebo|Placebo oral suspension, TID
9891867|NCT05323123|Experimental|Intervention|Participants will receive PrEP
9891868|NCT05322512|Experimental|124I-EV|Imaging cohort All enrolled participants will be allocated to undergo three 124I-EV PET/CT scans.
9891869|NCT05321251|Experimental|Topical insulin|Topical insulin (Humulin R) will be compounded under sterile conditions at a local pharmacy at a concentration of 25 IU / ml in sterile balanced saline solution (0.9%). Topical insulin will be administered four times per day to the affected eye. A bottle of topical insulin can be used for 14 days. Any remaining topical insulin will be discarded as waste after 14 days.
9891870|NCT05321251|Active Comparator|Tarsorrhaphy|Patients in this group will receive a temporary, central tarsorrhaphy and will not use additional eye drops.
9891871|NCT05321199|Experimental|Control patients|Closed Envelope for group A (control); patients receiving no tranexamic acid. With Double-Blind Study in which the participants and observers are unaware of who receives tranexamic acid. The total blood loss (TBL), intraoperative blood loss (IBL), postoperative blood loss (PBL), hemoglobin (HGB) levels and Hematocrit value (Hct) on preoperatively (pre-op) and postoperatively, and amount of allogenic blood transfusion were recorded. Furthermore, the general information was also compared between groups.
9891872|NCT05321199|Experimental|Case patients|Closed Envelope for group B (case); patients receiving tranexamic acid intravenously and topically. With Double-Blind Study in which the participants and observers are unaware of who receives tranexamic acid. The total blood loss (TBL), intraoperative blood loss (IBL), postoperative blood loss (PBL), hemoglobin (HGB) levels and Hematocrit value (Hct) on preoperatively (pre-op) and postoperatively, and amount of allogenic blood transfusion were recorded. Furthermore, the general information was also compared between groups.
9891873|NCT05320731|Active Comparator|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
9891874|NCT05320731|Active Comparator|Atomization with lidocaine|A 20-gauge cannula will be attached to oxygen bubble tubing via a three-way tap. The other end of bubble tubing will be then attached to an oxygen source, which will turned on to deliver a flow of 8 L/min. a 10-mL syringe filled with 2% lidocaine will be attached to the top port of the cannula. As LA is slowly atomized as a jet-like spray, the cannula will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen to anaesthetize the pharynx, glottis and subglottic structures. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
9891875|NCT05320705|Active Comparator|dexmedetomidine|dexmedetomidine will be administered as a bolus dose, before the surgical incision, followed by infusion and stopped at the end of operation
9891876|NCT05320705|Placebo Comparator|normal saline placebo|similar bolus and infusion volumes of normal saline will be administered
9891877|NCT05320679||Study Group|Patients who have musculoskeletal pain
9891878|NCT05320497|Experimental|Transparent cap-assisted SpyGlass|Add a transparent cap to the end of the SpyGlass choledochoscopy
9891879|NCT05320146||CORT118335-860 Participants|This group will include patients who participated in CORT118335-860 study and received at least one dose of miricorilant.
9891880|NCT05320146||CORT118335-861 Participants|This group will include patients who participated in CORT118335-861 study and received at least one dose of miricorilant.
9891881|NCT05320042|Experimental|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
9891882|NCT05320042|Active Comparator|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
9891883|NCT05319977|Experimental|Mobile incentive-based intervention|Contingent incentives on abstinence from alcohol; Text-based health promotion support
9891884|NCT05316571|Active Comparator|One 5-Minute Walking Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
9932278|NCT00947414|Active Comparator|Shockwave plus strength training|6 sessions of extracorporeal shock wave plus daily gluteal strength exercises
9932279|NCT00947414|Sham Comparator|Sham extracorporeal shock wave plus gluteal strength exercise|SHAM extracorporeal shock wave plus gluteal strength exercise
9891885|NCT05316571|Active Comparator|One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
9891886|NCT05316571|Active Comparator|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~The interruption strategy includes breaking up the 4-hour sitting bout with one 5-minute light intensity walking bout and one 15-minute standing bout each hour. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
9891887|NCT05316571|Active Comparator|Uninterrupted Sitting|"A 4-hour sedentary behavior bout, during which the participant remains seated while watching a non-stimulatory documentary.~This uninterrupted sedentary bout will serve as a control. Each participant will be re-randomized to any of the non-completed arms after completion of the initial 4-hour sitting bout and interruption strategy until all arms have been completed."
9891888|NCT05316506|Other|Anticipated Discomfort Group|Participants will be prompted using anticipated discomfort language during the standard of care hysteroscopy.
9891889|NCT05316506|Other|Objective Description Group|Participants will be prompted using objective description language during the standard of care hysteroscopy.
9891890|NCT05316103|Experimental|Endoscopic biopsy and probe-based confocal laser endomicroscopy biopsy|In this study , endoscopic biopsy and pCLE-targeted optical biopsy will be successively performed for local rectal scars in rectal cancer patients after neoadjuvant chemoradiotherapy.
9891891|NCT05313074|Placebo Comparator|Healthy volunteers|Healthcare workers at National Cancer Institute
9891892|NCT05313074|Active Comparator|Cancer patients|"Cancer patients were divided into 3 groups based on treatment status including~active cancer on treatment~Planned to start treatment~Post-treatment (<6 months)"
9891893|NCT05312060|Experimental|Pneumatic Compression (PC)|The PC will undergo two daily 30-minute sessions of sequential pneumatic compression.
9891894|NCT05312060|Active Comparator|Antithromboembolic exercises (AE)|AE will perform two supervised antithromboembolic exercises sessions daily lasting 30 minutes.
9891895|NCT05311098|Experimental|Vestibule Group|Cryoablation
9891896|NCT05310968|Experimental|Tirofiban group|"This group will receive tirofiban and aspirin. Day 1: Tirofiban injected intravenously for 24 hours and aspirin of 100-300 mg. Tirofiban will be injected at 4 ug/kg/ min for the first 30 minutes and 0.1 ug/kg/min for the next 24 hours.~Day 2-90: Aspirin 100mg per day."
9891897|NCT05310968|Placebo Comparator|Tirofiban placebo group|"This group will receive tirofiban placebo and aspirin. Day 1: Tirofiban placebo injected intravenously for 24 hours and aspirin of 100-300 mg. The placebo will be injected at the same rate with Tirofiban group.~Day 2-90: Aspirin 100mg per day."
9891898|NCT05310253|Experimental|Fludrocortisone & TSST - BPD patients|intake of 0.4mg fludrocortisone (orally) before stress
9891899|NCT05310253|Experimental|Fludrocortisone & TSST - Healthy controls|intake of 0.4mg fludrocortisone (orally) before stress
9891900|NCT05310253|Experimental|Placebo pills & TSST - BPD patients|intake of placebo pill before stress
9891901|NCT05310253|Experimental|Placebo pills & TSST - Healthy controls|intake of placebo pill before stress
9891902|NCT05310253|Experimental|Fludrocortisone & Placebo-TSST- BPD patients|"intake of 0.4mg fludrocortisone (orally) before no stress"
9891903|NCT05310253|Experimental|Fludrocortisone & Placebo-TSST - Healthy controls|"intake of 0.4mg fludrocortisone (orally) before no stress"
9891904|NCT05310253|Experimental|Placebo pills & Placebo-TSST - BPD patients|"intake of placebo pill before no stress"
9891905|NCT05310253|Experimental|Placebo pills & Placebo-TSST - Healthy controls|"intake of placebo pill before no stress"
9891906|NCT05309993|Active Comparator|Posterior Tibial Nerve Stimulation (PTNS)|Women randomized to the PTNS will be scheduled for sessions once weekly for 30 minutes, for 12 weeks total. The patient sits reclined with their legs elevated on a foot rest. After alcohol swab, a 34 gauge needle is inserted percutaneously 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice) at a 60 degree angle. A surface electrode is placed on the medial ipsilateral heel. The needle and electrode are connected to a low voltage (9V) electrical stimulator. Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 μsec is increased until flexion of the big toe or fanning of all toes visualized, or until the woman reports a tingling sensation across the heel or sole of the foot. The current is then set to the highest level of tolerable to the patient (0-10 mA) and then she undergoes therapy for 30 minutes.
9891907|NCT05309993|Experimental|Home transcutaneous electrical nerve stimulation (TENS)|"Women randomized to the TENS group will be asked to purchase a TENS 7000 device (estimated cost $30) and will administer self-treatment at home, daily for 20 minutes, for 12 weeks total.~TENS treatment will be performed as follows (adapted from the most common setting from a s systematic review of TENS for OAB):~- Surface electrodes, 2 x 2 in diameter, will be placed 5 cm cephalad to the medial malleolus of the right or left ankle (patient's choice). The second surface electrode is placed on the medial aspect of the ipsilateral calcaneus. The electrodes are connected to the TENS device with pre-set settings.~Women will complete 20-minute daily TENS treatment for 12 weeks total."
9891908|NCT05309486|Experimental|Online pilates group|Online pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates trainings.
9932280|NCT00947440|Active Comparator|Tablet 1 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.
9935976|NCT02911103|Experimental|Active|single arm study
9891909|NCT05309486|Active Comparator|Face-to-face pilates group|Face-to-face pilates training, which lasts for a total of 8 weeks, 3 days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Face-to-face pilates training will be held at Ankara Medipol University. To make the exercises more effective, the individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates exercises, 15 minutes of cool-down and stretching exercises, and the exercises will be performed as 10 repetitions. The same exercises will be applied in online pilates and face-to-face pilates trainings.
9891910|NCT05309434|Experimental|Study group with standing coach|The team performs the simulated CPR with the coach standing next to the defibrillator
9891911|NCT05309434|Experimental|study group with mobile coach|The team performs the simulated CPR with the coach free to move around the simulation room
9891912|NCT05309434|No Intervention|control group without coach|The team performs the simulated CPR without the coach
9891913|NCT05308901|Experimental|Pembrolizumab + Lenvatinib|Lenvatinib 20 mg daily plus pembrolizumab 200 mg IV every 3 weeks.
9891914|NCT05308394||Control group|The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent < 25% (male) or < 35% (female), and up to 1 other risk factor among the following: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
9891915|NCT05308394||Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent > 25% (male) or > 35% (female).
9891916|NCT05308394||Metabolically Healthy Obesity|Metabolically healthy obesity will be defined as having an obese BMI (> 30 kg/m2), body fat percent < 25% (male) or < 35% (female), and up to 1 other risk factor among the following: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
9891917|NCT05308394||Metabolic Syndrome|Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( > 30 kg/m2) and 2 or more of the following risk factors: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
9891918|NCT05307887|Experimental|Virtual Reality Technology|Group receiving virtual reality technology in addition to standard therapy
9891919|NCT05307887|No Intervention|Standard Therapy Control Group|
9891920|NCT05305482|Experimental|DCS group|Drug-coated stent group
9891921|NCT05305482|Active Comparator|DES group|Drug-eluting stent group
9891922|NCT05304104|Experimental|Telehealth Cognitive Behavioral Therapy (teleCBT)|About one-half of participants will be randomly assigned to Telehealth Cognitive Behavioral Therapy (teleCBT), a virtual Cognitive Behavioral Therapy (CBT) for binge eating disorders delivered via an Office of Information and Technology (OI&T)-approved video platform, by a master's-level research clinician. TeleCBT will be administered in 8 to 10 hourly individual sessions over a three-month treatment period.
9891923|NCT05304104|Active Comparator|Self-Help Cognitive Behavioral Therapy (shCBT)|About one-half of participants will be randomly assigned to Self-Help Cognitive Behavioral Therapy (shCBT), a Self-Help CBT for binge eating disorders initiated by a research assistant via telephone and then continued by the participant at home. These materials are the same exact ones provided to participants in TeleCBT (i.e., treatments are matched for materials), and will be mailed to participants. They will be instructed to work independently through one chapter per week for the following 12 weeks (i.e., treatment length is matched to TeleCBT).
9891924|NCT05302063|Experimental|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
9891925|NCT05301322|Experimental|Coadministration Group|RSVpreF and SIIV followed by placebo a month later
9891926|NCT05301322|Experimental|Sequential Administration Group|Placebo and SIIV followed by RSVpreF a month later
9932281|NCT00947440|Active Comparator|Tablet 2 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.
9932282|NCT00947453|Experimental|montelukast group|Identified patients with asthma to recieve Montelukast 10 mg (Merck Sharp & Dohme Ltd, Herts, UK) at 0800 am once daily for 8 weeks.
9932283|NCT00947466|Experimental|Patch|
9932284|NCT00947479|Other|continuous positive airway pressure (CPAP)|CPAP will be applied in all patients
9932285|NCT00947570|Experimental|Cognitive behavioral therapy|Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
9932286|NCT00947596|Experimental|Atropine Dry Powder Inhaler|
9932287|NCT00947596|Active Comparator|Atropen Autoinjector|
9932288|NCT00947609||HIV-infected and HIV-uninfected children|HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
9932289|NCT00947622|Placebo Comparator|Placebo stimulation|Placebo stimulation at the occipital head area for 1800 seconds at 0 mA, three times a week, during one week (with seconds of stimulation to get onset tingling sensation)
9891927|NCT05300893|No Intervention|Treatment with night splint after percutaneous needle fasciotomy|
9891928|NCT05300893|Experimental|No treatment with night splint after percutaneous needle fasciotomy|
9891929|NCT05298748|Other|ambient noise followed by Womb sound|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support >1.5 lpm, will be exposed to alternating 6-hour periods of a recording of ambient noise followed by commercially available womb sounds over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
9891930|NCT05298748|Other|Womb sound recordings followed by ambient noise|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support >1.5 lpm, will be exposed to alternating 6-hour periods of a recording of commercially available womb sounds followed by ambient noise over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
9891931|NCT05298501||AMYWEB-Normative|This cohort assessed over six recruitment and test phases, will be sampled to be as closely representative of the demographic population as possible.
9891932|NCT05298501||AMYWEB-Diversity|This cohort assessed over two recruitment and test phases will oversample participants from minority and mixed ethnic and racial backgrounds as well as participants from lower educational backgrounds.
9891933|NCT05298501||AMYWEB-MCI|This cohort assessed and recruited over one test phase, will include participants with a reported diagnosis of mild cognitive impairment or dementia.
9891934|NCT05298397|Experimental|Intervention - EAT|This study has one arm (it is an open trial). All participants will receive the intervention (EAT-PTSD adapted for youth).
9891935|NCT05296226|Experimental|dry needling group|dry needling is probably the most popular, trigger-point dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Goniometry will be used to assess range ofmotion. Ischemic compression is one of the least invasive trigger point therapies.
9891936|NCT05296226|Experimental|ischemic compression group|compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points. Pressure is sustained for 10 to 20 second
9891937|NCT05292131|Experimental|Test|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-2mL presentation (test).
9891938|NCT05292131|Other|Reference|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-1x2mL presentation (reference).
9891939|NCT05291403|Experimental|Experimental group (medical thoracoscopic cryotherapy)|
9891940|NCT05291403|Active Comparator|Cisplatin/erythromycin control group (sequential intrathoracic injection of cisplatin/erythromycin)|
9891941|NCT05291403|Other|Blank control group|Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.
9891942|NCT05288439|Experimental|patients|A full neurocognitive battery with quality-of-life assessment will be conducted and an rs-fcMRI sequence will be added to the brain MRI performed as standard of care follow-up between 3-5 months post-PBRT.
9891943|NCT05288439|Experimental|healthy matched controls|Healthy participants will be asked to complete the MRI scan and undergo neurocognitive assessment.
9891944|NCT05286164|Experimental|Eltrombopag|Patients with bone marrow aplasia for more than 30 days after CART treatment
9891945|NCT05285514||Brain-damaged patients under anesthesia and requiring the administration of a vasoactive agent|Patients with severe brain injuries over 18 years of age are eligible to participate in this protocol: head trauma, subarachnoid hemorrhage, ischemic or hemorrhagic stroke and requiring the administration of a vasoactive agent as part of routine medical care to restore Cerebral Perfusion pressure (CPP).
9891946|NCT05282849|Active Comparator|Group F: ultrasound guided fascia iliaca block group|
9891947|NCT05282849|Active Comparator|Group Q: ultrasound guided quadratus lumborum block group|
9891948|NCT05281510|Experimental|VRC07523LS + CAP256V2LS + Vesatolimod (VES)|Participants will receive VES 6 mg (or up to 8 mg) every 2 weeks, for a total of 10 doses + VRC07-523LS and CAP256V2LS 20 mg/kg each on Day 7.
9891949|NCT05275751|Placebo Comparator|Hot injection without TRP-channel inhibition|Pain induced by an increasingly hot intradermal injection up to 52°C over 2 minutes.
9891950|NCT05275751|Experimental|Hot injection with TRPA1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891951|NCT05275751|Experimental|Hot injection with TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891952|NCT05275751|Experimental|Hot injection with TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891953|NCT05275751|Experimental|Hot injection with TRPA1- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891954|NCT05275751|Experimental|Hot injection with TRPA1- and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891955|NCT05275751|Experimental|Hot injection with TRPM3- and TRPV1-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and TRPV1 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891956|NCT05275751|Experimental|Hot injection with TRPA1-, TRPV1 and TRPM3-inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPV1 and TRPM3 are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891957|NCT05275751|Experimental|Hot injection with TRPA1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891958|NCT05275751|Experimental|Hot injection with TRPV1-, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891959|NCT05275751|Experimental|Hot injection with TRPA1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPA1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891960|NCT05275751|Experimental|Hot injection with TRPV1- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891961|NCT05275751|Experimental|Hot injection with TRPV1-, TRPA1, TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891962|NCT05275751|Experimental|Hot injection with TRPM3- and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPM3 and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891963|NCT05275751|Experimental|Hot injection with TRPV1-, TRPA1, and chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while TRPV1, TRPA1, and a chloride channel are blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9932290|NCT00947622|Experimental|Effective transcranial stimulation|Effective stimulation at the occipital head are for 1800 seconds at 2 mA, 3 times a week for 1 week
9932291|NCT00947635|Experimental|Islet transplant|People with Type 1 diabetes undergoing islet transplantation
9891964|NCT05275751|Experimental|Hot injection with chloride channel inhibition|Pain is induced by an increasingly hot intradermal injection up to 52°C over 2 minutes, while a chloride channel is blocked pharmacologically by an antagonist dissolved in the hot fluid (synthetic interstitial fluid). The antagonist(s) have sufficient concentration to reliably block the channel. The total dose is in the range of a microdose trial.
9891965|NCT05273151|Other|KOS treatment|Treatment with intranasal kinetic oscillation stimulation (KOS)
9891966|NCT05269901||Seizures group|20 newly diagnosed untreated school-aged children from Jan 20, 2021 to Jan 1, 2022 in affiliated Hospital of Jiangnan University, department of pediatrics.
9891967|NCT05269901||Healthy control group|20 age-matched healthy school-aged children from Jan 20, 2021 to Jan 1, 2022 in affiliated Hospital of Jiangnan University, department of pediatrics.
9891968|NCT05268991||AGE Participants|Participants aged 65 and older with diagnosis of solid tumor malignancy or lymphoma and planned to start a new chemotherapy regimen in the outpatient setting
9891969|NCT05267470|Experimental|Part 1: Combination Dose Escalation|Participants with SqNSCLC will receive escalating doses of bemarituzumab in combination with docetaxel.
9891970|NCT05267470|Experimental|Part 2: Combination Dose Expansion|Participants with SqNSCLC and FGFR2b overexpression will receive the dose of bemarituzumab in combination with docetaxel identified as safe during Part 1.
9891971|NCT05267470|Experimental|Part 3: Bemarituzumab Monotherapy|Participants with SqNSCLC and FGFR2b overexpression will receive bemarituzumab monotherapy.
9891972|NCT05263154|Experimental|Goal directed low oxygen|Oxygen given at low concentrations following goals of oxygen saturation during and after anesthesia
9891973|NCT05263154|Active Comparator|High oxygen|Oxygen given as traditionally including high concentrations
9891974|NCT05263076|Experimental|Uterine Transplant|uterus transplantation from living or deceased donor.
9891975|NCT05262426|Experimental|Standard PrEP Counseling, MES-PrEP and Enhanced YaCool|Participants in this arm will receive standard PrEP counseling, followed by two mHealth interventions (MES-PrEP and Enhanced YaCool) to improve PrEP uptake and support PrEP adherence.
9891976|NCT05262426|Experimental|Standard PrEP Counseling and MES-PrEP|Participants in this arm will receive standard PrEP counseling, followed by one mHealth intervention (MES-PrEP) to improve PrEP uptake and support PrEP adherence.
9891977|NCT05262426|Experimental|Standard PrEP Counseling and Enhanced YaCool|Participants in this arm will receive standard PrEP counseling, followed by one mHealth intervention (Enhanced YaCool) to improve PrEP uptake and support PrEP adherence.
9891978|NCT05262426|Active Comparator|Standard PrEP Counseling|Participants in this arm will receive the standard PrEP counseling.
9891979|NCT05256381|Experimental|SOT101 and Pembrolizumab|Participants will be treated with 12 μg/kg of SOT101 on Day 1, Day 2, Day 8, and Day 9 of each 3-week cycle in combination with 200 mg pembrolizumab on Day 1 of each 3-week cycle.
9891980|NCT05253820|Experimental|distal radial approach group|subjects randomized to experimental group were underwent coronary diagnosis and intervention via distal radial approach
9891981|NCT05253820|Active Comparator|conventional radial access group|subjects randomized to active comparator group were underwent coronary diagnosis and intervention via conventional radial approach
9891982|NCT05253755|Active Comparator|DBI-001 Gel|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
9891983|NCT05253755|Placebo Comparator|Aqueous Gel|Topical product of aqueous gel on skin affected with atopic dermatitis.
9891984|NCT05253404|No Intervention|Anesthesia remove endotracheal tube|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at MAC 2-3%, at the same time we perform suction secretions in endotracheal tube and oral cavity and give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when spontaneously generating tidal volume of >4ml/kg, EtCO2<45mmHg, Train of four ratio >70-90%.
9932292|NCT00947635|Experimental|Liver transplant|People with liver failure undergoing liver transplantation
9932293|NCT00947635|Experimental|Control|Healthy normal people which serve as control group
9932294|NCT00947648|Other|"Raw Group"|Participants will eat cooked food and the addition of raw fruits and vegetables.
9932295|NCT00947648|Other|"Cooked Group"|Participants will eat only cooked foods.
9932296|NCT00947674|Experimental|Cellsorba EX|
9932297|NCT00947674|Sham Comparator|Sham treatment|
9932298|NCT00947687|Experimental|PUR003|
9932299|NCT00947687|Placebo Comparator|Placebo|
9932300|NCT00947700|No Intervention|Assessment & Monitoring|No Intervention. Parent-Child participants in assessment and monitoring visits but does not receive any study provided treatment.
9932301|NCT00947700|Experimental|Assessment, Monitoring + Intervention|Parent-Child participants in assessment and monitoring visits but also the Promoting First Relationships PFR intervention (http://pfrprogram. Org). PFR is a 10 weekly 60-85 minute in-home visits by a masters level mental health provider trained in the PFR curriculum. The PFR curriculum focuses on increasing parenting sensitivity using attachment theory-informed, strength-based consultation strategies. The curriculum is fully manualized and fidelity was assessed according to the manual.
9932302|NCT00947713|Experimental|Low dose hCG group|
9932303|NCT00947713|Active Comparator|Clomiphen citrate plus HMG|
9932304|NCT00947739|Experimental|Cohort 1|80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY
9932305|NCT00947739|Experimental|Cohort 2|160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
9932306|NCT00947739|Experimental|Cohort 3|320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
9932307|NCT00947739|Experimental|Cohort 4|640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
9932308|NCT00947739|Experimental|Cohort 5a|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
9932309|NCT00947739|Experimental|Cohort 6|2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932310|NCT00947739|Experimental|Cohort 7|18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932311|NCT00947739|Experimental|Cohort 8|36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932312|NCT00947739|Experimental|Cohort 9|72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932313|NCT00947739|Experimental|Cohort 10|144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932314|NCT00947739|Experimental|Cohort 11|288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932315|NCT00947739|Experimental|Cohort 12|576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932316|NCT00947739|Experimental|Cohort 13|750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932317|NCT00947739|Experimental|Cohort 14|1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932318|NCT00947739|Experimental|Cohort 5b|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
9932319|NCT00947778|Active Comparator|session of training 1|Arm from which members will perform their training session after the first session of evaluation
9932320|NCT00947778|Active Comparator|Session of training 2|Arm from which members will perform their training session after the second session of evaluation
9932321|NCT00947804||1. Patients with symptoms of ACS|Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG).
9932322|NCT00947804||2. Patients without symptoms of ACS|Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization.
9932323|NCT00947817|Experimental|patient|
9932324|NCT00947817|Other|control|
9932325|NCT00947843|Placebo Comparator|aspirin+placebo|aspirin protect (Bayer) 100mg + placebo clopidogrel 75mg for 1mo
9932326|NCT00947843|Active Comparator|aspirin+pregrel|pregrel is a generic brand name of clopidogrel
9932327|NCT00947843|Active Comparator|Aspirin+Plavix|plavix is a original brand name of clopidogrel
9932328|NCT00947895|Active Comparator|Methylprednisolone|Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
9932329|NCT00947895|Active Comparator|ACTH|Intramuscular (IM) ACTH 80 mg/day for 5 days.
9932330|NCT00947908|Experimental|A|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
9932331|NCT00947921|Active Comparator|Plasty|Patients treated with restrictive Annuloplasty
9932332|NCT00947921|Active Comparator|Prosthesis|Patients treated with valve replacement
9932333|NCT00947934|Experimental|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation.
9932334|NCT00947947|Experimental|intervention media condition|Received a stage tailored DVD-based intervention
9932335|NCT00947947|Placebo Comparator|standard of care|received only clinical standard of care
9932336|NCT00947960|Other|Active/Placebo|Subjects receive 1-2 grams/kilogram body weight triheptanoin divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive placebo vegetable oil at the same dose and frequency for the next 6 months during the randomization phase.
9891985|NCT05253404|Experimental|Switching endotracheal tube to laryngeal mask|When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at 2.63%-2.97%, we perform suction secretions in endotracheal tube and oral cavity, then switching endotracheal tube to laryngeal mask. Then we discontinue inhalation anesthestic sevoflurane and support oxygen at the rate of 6L/min. At the same time, give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when sevofulrane at MAC 0.4, spontaneously generating tidal volume of >4ml/kg, EtCO2<45mmHg, Train of four ratio >70-90%.
9891986|NCT05252507|Experimental|Paint Night|
9891987|NCT05247229|Experimental|Middle school after-school education program|"The education intervention centers around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices, including those for shellfish.~The education program is divided into three units, following other tribal education programs. Primary data collection will be conducted by unit to assess student learning for each unit. The first unit will cover an introduction to shellfish, harmful algal blooms (HAB), and paralytic shellfish poisoning (PSP). The second unit will cover herring and how herring relates to Tlingit culture. The third unit will focus on intertidal zones as zones relate to Tlingit culture."
9891988|NCT05246930||Subjects with a diagnosis of vocal cord dysfunction|Subjects with a confirmed or suspected diagnosis of vocal cord dysfunction (also called inducible laryngeal obstruction). Some subjects will have concomitant diagnosis of asthma.
9891989|NCT05246930||Subjects with diagnosis of asthma|Subjects with physician-diagnosed asthma. Some subjects will have concomitant diagnosis of vocal cord dysfunction.
9891990|NCT05244993|Experimental|AK105+Anlotinib Hydrochloride+Albumin Paclitaxel|AK105 200mg IV Day 1 Anlotinib Hydrochloride 12mg PO once daily on Days 1-14 Albumin paclitaxel 125mg/m2 IV Days 1, 8 Cycled every 21 days until disease progression, death or toxicity is intolerable (for subjects who can continue to tolerate the treatment, albumin paclitaxel lasts for at least 6 cycles)
9891991|NCT05244018|Active Comparator|Group 1(Treatment group)|
9891992|NCT05244018|Active Comparator|Group 2(Control group)|
9891993|NCT05243836|Active Comparator|MiSight®|MiSight® Contact Lens (Omafilcon A, 60% water)
9891994|NCT05243836|Experimental|S.T.O.P® F2|S.T.O.P® F2 Contact Lens (Ocufilcon D, 55% water)
9891995|NCT05243836|Experimental|S.T.O.P® DT|S.T.O.P® DT Contact Lens (Ocufilcon D, 55% water)
9891996|NCT05242445|Experimental|Cohort 1: Cetrelimab or Placebo (Dose 1)|Participants will receive cetrelimab Dose 1 or placebo via subcutaneous (SC) injection on Day 1.
9891997|NCT05242445|Experimental|Cohort 2: Cetrelimab or Placebo (Dose 2)|Participants will receive cetrelimab Dose 2 or placebo administered via an Intravenous (IV) infusion on Day 1.
9891998|NCT05242445|Experimental|Cohort 3 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on data review from Cohorts 1 and 2.
9891999|NCT05242445|Experimental|Cohort 4 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on data review from Cohort 3.
9892000|NCT05232929|Experimental|Risdiplam|Participants will receive risdiplam prescribed based on clinician judgment, as per the Evrysdi® USPI.
9892001|NCT05228899|Experimental|Group 1: Zofin|Group 1 (15 subjects) Fifteen subjects will receive 1 mL of Zofin diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing 2-5 x 10^11 particles/ml intravenously.
9892002|NCT05228899|Placebo Comparator|Group 2: Placebo|Group 2 (15 subjects) Fifteen subjects will receive 1mL of placebo diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing sterile saline intravenously.
9892003|NCT05228275||Ancillary-Correlative (Specimen collection)|Patients are expected to receive one of the FDA or FDA-EUA approved COVID-19 vaccines based on preference, availability, or provider discretion. Study data and peripheral blood specimens will be collected at specified time points from Baseline (pre-vaccination) through 24 ±2 months post first vaccine dose.
9892004|NCT05224843|Experimental|Older adults in Primary Care setting|Elder mistreatment in the Primary Care setting.
9892005|NCT05223673|Experimental|Futuximab/modotuximab combined with trifluridine/tipiracil (Safety Lead-In and Phase III parts)|
9892006|NCT05223673|Active Comparator|Trifluridine/tipiracil (Phase III part)|
9892007|NCT05221606|Experimental|Nurse AMIE Supportive Care Intervention|Participants in the intervention arm will receive the computer tablet with the Nurse AMIE program. Nurse AMIE will assess their symptoms daily and provide an intervention to help manage their symptoms.
9892008|NCT05221606|Active Comparator|Usual Care|Participants in the usual care arm will receive a book with some supportive care educational materials and recommendations.
9892009|NCT05218798|Active Comparator|Continous Treadmill Running Test|One of the four testing conditions the subject will be allocated to is a Continous Treadmill Running Test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration ([LA-]).
9935977|NCT02911077||AUD population|The participants/group were treatment-seeking AUD individuals admitted to the NIH CC 1SE Addictions Unit.
9892010|NCT05218798|Active Comparator|Continous 2-mile run test|One of the four testing conditions the subject will be allocated to is a Continous 2-mile run test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration ([LA-]).
9892011|NCT05218798|Active Comparator|30-15 Intermittent Fitness Test - first trial|"Aerobic capacity will be measured using the field-based 30-15IFT test. This intermittent, incremental test consists of 30-second shuttle runs interspersed with 15-second active recovery periods. Running speed will be set at 8 km/h for the first 30-second run and increased by 0.5 km/h in each 30-second phase thereafter. The speed of the last successfully completed stage will be recorded as the test result, i.e. the maximum running speed (V) during IFT. Vo2max will be estimated by the following equation:~Vo2max IFT (ml/min/kg) = 28.3 - 2.15G - 0.741A - 0.0357BM + 0.058A X VIFT + 1.03VIFT where G stands for subjects gender, A for age and BM for body mass, respectively."
9892012|NCT05218798|Active Comparator|30-15 Intermittent Fitness Test - second trial|The procedures will be the same as previously described
9892013|NCT05216250|Experimental|BOTOX/BOTOX Unilateral|Participants will receive BOTOX dose A in Cycle 1, BOTOX dose B in Cycle 2 and unilateral BOTOX in Cycle 3.
9892014|NCT05216250|Experimental|BOTOX/BOTOX Bilateral|Participants will receive BOTOX dose A in Cycle 1, BOTOX dose B in Cycle 2 and bilateral BOTOX in Cycle 3.
9892015|NCT05216250|Experimental|Placebo/BOTOX Unilateral|Participants will receive placebo in Cycle 1 and Cycle 2 followed by unilateral BOTOX in Cycle 3.
9892016|NCT05216250|Experimental|Placebo/BOTOX Bilateral|Participants will receive placebo in Cycle 1 and Cycle 2 followed by bilateral BOTOX in Cycle 3.
9892017|NCT05216146|Experimental|Experimental|Specially designed program for physical fitness enhancement
9892018|NCT05216146|Active Comparator|Control|A regular program of physical exercise
9892019|NCT05216081|Experimental|Elder adults in emergency department setting with cognitive impairment|Elder mistreatment in an Emergency Department setting with cognitive impairment.
9892020|NCT05214807|Active Comparator|Control group receiving Synvisc-One®|
9892021|NCT05214807|Experimental|IMD group receiving KiOmedine® CM-Chitosan|
9892022|NCT05212571|Experimental|Outpatient|The experimental intervention group visits the outpatient clinic to receive intravenous esketamine in day-care setting every 2 weeks for 3 months.
9892023|NCT05212571|Active Comparator|Inpatient|The standard treatment group receives intravenous esketamine for 6 consecutive days in hospital.
9892024|NCT05210179|Active Comparator|TURKOVAC-Koçak|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
9892025|NCT05210179|Active Comparator|TURKOVAC-Dollvet|The dose of the TURKOVAC vaccine will be 3 μg/0.5 mL and will be administered by injection into the deltoid muscle.
9892026|NCT05208840|Experimental|LMCE-positive|LMCE-positive participants enrolled in the study will receive therapy with ocrelizumab for 2 years.
9892027|NCT05208840|Experimental|LMCE-negative|LMCE-negative participants enrolled in the study will receive therapy with ocrelizumab for 2 years.
9892028|NCT05207098||Neurocognitive Tests and Questionnaires|The performance-based measures will be administered with a total completion time estimated to be 90 minutes. The neurocognitive battery is similar in content and duration to multiple previous and ongoing studies being conducted by the Neurocognitive Research Lab.
9892029|NCT05205005|Experimental|Dietary supplementation of glycocalyx precursors (DSGP)|Participants will daily ingest 3,712mg (i.e., six capsules) of DSGP for eight weeks. DSGP, commercially available as Endocalyx (Microvascular Health Solutions LLC, Alpine, UT), include glucosamine sulfate, fucoidan, superoxide dismutase, and high molecular weight hyaluronan.
9892030|NCT05205005|Placebo Comparator|Placebo|Participants will daily ingest 6 capsules daily of placebo
9892031|NCT05201469|Experimental|VIB4920|"Participants will receive VIB4920 1500 mg intravenously at Weeks 10, 12, 14, 18, 22, 26, 30, and 34.~Participants will receive induction therapy with Mycophenolate Mofetil (MMF) beginning at Week 0. The target dose is 2 to 3 g/d and must be reached by Week 4. MMF administration will continue at the target dose through Week 60.~Participants will also receive prednisone 25 mg per day beginning at day 0 or on the day after completion of methylprednisolone"
9892032|NCT05201469|Placebo Comparator|VIB4920 Placebo|"Participants will receive VIB4920 placebo intravenously at Weeks 10, 12, 14, 18, 22, 26, 30, and 34.~Participants will receive induction therapy with MMF beginning at Week 0. The target dose is 2 to 3 g/d and must be reached by Week 4. MMF administration will continue at the target dose through Week 60. Participants will receive a total of 1000 mg of methylprednisolone at Day 0 or Day 1~Participants will also receive prednisone 25 mg per day beginning at day 0 or on the day after completion of methylprednisolone."
9892033|NCT05196035|Experimental|Finerenone (Kerendia, BAY94-8862)|Participants will receive finerenone treatment.
9892034|NCT05196035|Placebo Comparator|Placebo|Participants will receive placebo to finerenone.
9935978|NCT02897778|Active Comparator|Entinostat|Participants received a single oral supratherapeutic dose of 15 mg entinostat under fasted conditions.
9892035|NCT05195840|Experimental|Personalized Treatment for Eating Disorders|Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of personalized treatment for eating disorders.
9892036|NCT05195840|Active Comparator|Cognitive Behavioral Therapy for Eating Disorders|Participants will complete 3 sessions of education about the treatment while completing 2 weeks of mobile application questions. After completion of treatment education and mobile application questions, participants will complete 17 sessions of Cognitive Behavioral Therapy for Eating Disorders.
9892037|NCT05194839|Experimental|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
9892038|NCT05194839|Experimental|RIST4721 200 mg|RIST4721 200 mg: 2 active (100 mg) tablets + 2 placebo tablets once daily for 12 weeks
9892039|NCT05194839|Placebo Comparator|Placebo|Placebo: 4 placebo tablets once daily for 12 weeks
9892040|NCT05190653|Experimental|Palliative and Supportive Care Intervention|Participants randomized to the intervention arm will meet virtually (either by phone or Zoom contingent upon participant preference) with a palliative care nurse practitioner or palliative care physician, both part of the study team. During the first meeting, pre-transplant, content will focus on the provision of information and education, including: a description of palliative and supportive care, symptom management, advance care planning, prognostic and illness understanding and treatment expectations, and coping strategies. All subsequent visits will include, at minimum, these topics. All meetings will be audio-recorded using a handheld audio-recorder; the record feature of Zoom will not be utilized. Participants in the intervention arm will meet with a member of the study team (palliative care nurse practitioner or palliative care physician) one to two times weekly, or more frequently if requested by the patient and/or family caregiver, until 3 months post-transplant.
9892041|NCT05190653|No Intervention|Standard Care|Standard care will involve the usual care that patients undergoing hematopoietic stem cell transplantation would be expected to receive, including palliative care consultation as needed or upon request. Palliative care interventions beyond what are provided in the study will be tracked in both the intervention and the standard care arms.
9892042|NCT05188508|Experimental|Recurrent enhancing grade II and III IDH-mutated gliomas that have failed previous therapy|All patients will receive pembrolizumab for two cycles prior to the addition of olaparib and temozolomide. Combination olaparib and temozolomide will be added in cycle 3. Combination therapy will continue through cycle 11 (cycles 3-11 = 27 weeks or approximately 6 months). Patients will then continue on pembrolizumab maintenance for a maximum of 35 cycles (two years) or until progression of disease or unacceptable toxicity.
9892043|NCT05188508|Experimental|Recurrent IDH-wildtype gliomas and homologous recombination deficiency (HRD).|Five patients will receive pembrolizumab for two cycles prior to the addition of olaparib and temozolomide. Combination olaparib and temozolomide will be added in cycle 3. Combination therapy will continue through cycle 11 (cycles 3-11 = 27 weeks or approximately 6 months). Patients will then continue on pembrolizumab maintenance for a maximum of 35 cycles (two years) or until progression of disease or unacceptable toxicity. This cohort will be analyzed descriptively.
9892044|NCT05187624|Experimental|Part I: Dose Escalation|Participants with newly diagnosed GBM will receive RO7428731, intravenously (IV), up to one year or until disease progression, withdrawal of consent, unacceptable toxicity, or death, whichever occurs first.
9892045|NCT05187624|Experimental|Part II: Dose-Expansion(s)|Participants with newly diagnosed GBM will receive RO7428731, IV, in maximum of two dose expansion cohorts at a dose(s) not exceeding the maximum tolerated dose (MTD) established in Part I.
9892046|NCT05187624|Experimental|Part III: Safety Run-in|Participants with recurrent GBM will receive RO7428731, IV in a dosing schedule determined in Part I. At the end of the Safety Run-in period, a decision will be made as to whether to open the Dose-Expansion Cohort Part IVA or open a second Safety Run-in Cohort at a lower dose.
9892047|NCT05187624|Experimental|Part IV A: Dose-Expansions Cohort|Participants with recurrent GBM will receive RO7428731, IV at specified doses and dosing schedules.
9892048|NCT05185934|Active Comparator|Food supplement Endocalyx|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the food supplement Endocalyx for 4 months.
9892049|NCT05185934|Placebo Comparator|Placebo|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the placebo for 4 months.
9935979|NCT02897778|Placebo Comparator|Placebo|Participants received a single dose of placebo-matching entinostat under fasted conditions.
9935980|NCT02890342||Affected Patients with Propionic Acidemia|Patients with Propionic Acidemia, standard adult, parental permission
9990751|NCT01446484|Experimental|T reg therapy|Kidney transplantation, followed by immunotherapy given along with autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells infusions
9990752|NCT01446484|Active Comparator|Immunosuppression|Patients will undergo immunosuppressive therapy followed by living related kidney transplantation
9990753|NCT01446497|Active Comparator|Timolol|non selective beta blocker, aqueous humor suppressant ophthalmic solution
9990754|NCT01446497|Active Comparator|Combigan (Timolol/Brimonidine) combination drug|Brimonidine: alpha-2 agonist
9990755|NCT01446510||Hospitalized Medical Patients|All hospitalized medical adult patients
9990756|NCT01446523|Placebo Comparator|Lactulose|Group L receives lactulose Group NL receives placebo
9990757|NCT01446523|Placebo Comparator|Placebo|Group NL receives placebo
9990758|NCT01446536|No Intervention|Control group|This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
9990759|NCT01446536|Active Comparator|Checklist (intervention) cohort|checklist was used in this group arbitrarily by their treating physician
9990760|NCT01446549|Experimental|Deep Brain Stimulation|
9990761|NCT01446549|Experimental|Locomotor Exercise|
9990762|NCT01446562|Experimental|Y90 Ibritumomab Tiuxetan|Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan
9990763|NCT01446588|Experimental|Yoga|Yoga group
9990764|NCT01446601|Experimental|Treatment|The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
9990765|NCT01446601|Other|Control|The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
9990766|NCT01446614|Experimental|MSC|Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.
9990767|NCT01446627||metal staples|
9990768|NCT01446627||Insorb vicryl staples|
9990769|NCT01446640|Experimental|MSC|Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.
9990770|NCT01446653|Experimental|EARLY|Motivational Interviewing plus feedback counseling with information via video and brochures
9797586|NCT01600885|Active Comparator|Guanfacine then Placebo|During the first study session, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive a placebo before undergoing a ketamine-infusion fMRI.
9797587|NCT01600885|Active Comparator|Placebo then Guanfacine|During the first study session, the participant will receive a placebo before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI.
9990771|NCT01446653|Active Comparator|Video Information|Providing FASD information via documentary video clips
9990772|NCT01446653|Active Comparator|Informational Brochure|Participants will receive informational brochures on contraception, women and drinking, and cutting down your drinking.
9990773|NCT01446679||atrovastatin group|Who receive atrovastatin
9990774|NCT01446692||Patients with suboptimal response|
9990775|NCT01446692||Patients with symptomatic remission|
9990776|NCT01446718||Gardasil Vaccine|"This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya study."
9990777|NCT01446731|Experimental|Arm A|DC vaccine (mRNA transfected dendritic cell) + Docetaxel
9990778|NCT01446731|Active Comparator|Arm B|Docetaxel alone
9990779|NCT01446757|Experimental|The intervention group|The intervention group will receive Comprehensive Geriatric Assessment and follow up as a complement to the same standard health care services as the control group. The Comprehensive Geriatric Assessment and follow up will be provides through an outpatient facility that tailors care from a holistic perspective and, based on each patient's individual needs in line with the policy program that Sweden's pensioners' organizations have presented in 2010 together with the Swedish Association of Geriatric Medicine. The team includes, among other things. a. geriatricians, nurses, physiotherapists, assistance officer, dietician, pharmacist and co-operation with the dental hygienist.
9990780|NCT01446757|Placebo Comparator|Control group|The control group will receive care in the same way as usual meaning access to primary care, hospital in- and outpatient care and care received by the municipality. The only difference between the two groups are that the control group will not have access to the geriatric care team.
9990781|NCT01446783|Active Comparator|mecasermin + Ehlers-Danlos|
9990782|NCT01446783|Placebo Comparator|Saline + Ehlers-Danlos|
9990783|NCT01446783|Active Comparator|Mecasamin + healthy control|
9990784|NCT01446783|Placebo Comparator|Saline + healthy control|
9990785|NCT01446822|Experimental|Bipolar transurethral resection|
9990786|NCT01446822|Active Comparator|Monopolar transurethral resection|
9990787|NCT01446835|Experimental|nelfilcon A|Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
9990788|NCT01446835|Active Comparator|etafilcon A|Etafilcon A printed contact lens randomly assigned to one eye, with nelfilcon A printed contact lens assigned to the fellow eye for contralateral wear.
9997467|NCT01509066|Experimental|Vegan diet|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask participants to keep foods low in fat and low in glycemic index.
9997468|NCT01509066|Active Comparator|Low-calorie|A low-calorie diet contains all food groups. However, participants will be provided with a calorie goal which should promote weight loss.
9997469|NCT01509092|No Intervention|obervation|patients in this arm received 6-months observation alone after injury
9997470|NCT01509092|Active Comparator|Surgical intervention|patients in this arm received vitrectomy surgery as soon as possible after injury
9997471|NCT01509131|Experimental|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)
9997472|NCT01509131|Active Comparator|2L PEG-ASC|Patients will be asked to take PEG-ASC according to labeling instructions
9997473|NCT01509144|Active Comparator|nasal active low dose + IM active|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
9997474|NCT01509144|Active Comparator|nasal active mid dose + IM active|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
9997475|NCT01509144|Active Comparator|nasal active full dose + IM active|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
9997476|NCT01509144|Active Comparator|nasal placebo + IM active|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
9997477|NCT01509144|Placebo Comparator|nasal placebo + IM placebo|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
9997478|NCT01509157|Experimental|MDRS system|Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
9997479|NCT01509157|Active Comparator|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
9997480|NCT01509196|Experimental|HIP0901|Fenofibric acid
9997481|NCT01509196|Active Comparator|Lipidilsupra|Fenofibrate
9997482|NCT01509209|Placebo Comparator|Placebo|placebo
9997483|NCT01509209|Experimental|Cossac L|Pseudoephedrine 120mg + Levocetirizine 2.5mg
9997484|NCT01509222|Other|Personalized nurition counseling|Personalized nutrition counseling based on dietary intake and motivation to change.
9997485|NCT01509222|No Intervention|Control|No intervention, control group.
9997486|NCT01509235|Experimental|1. Exercise testing and self drainage session|
9997487|NCT01509235|Active Comparator|2. Chest physiotherapy (CP) session|
9997488|NCT01509261|Experimental|Ilaprazole|Ilaprazole 20mg
9997489|NCT01509261|Active Comparator|lansoprazole|lansoprazole 30mg
9997490|NCT01509274|Experimental|Plasma|
9997491|NCT01509274|Sham Comparator|Saline|
9997492|NCT01509274|Active Comparator|Physiotherapy + heel cap|
9997493|NCT01509287||Donnai-Barrow Syndrome (DBS)|Individuals affected with Donnai-Barrow Syndrome (DBS)
9997494|NCT01509287||Unaffected|Healthy family members of individuals affected with Donnai-Barrow Syndrome (DBS)
9997495|NCT01509300|Experimental|HAPLO|
9998205|NCT01516099|Experimental|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
9998206|NCT01516099|Experimental|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
9998207|NCT01516138|Active Comparator|GIK|glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).
9998208|NCT01516138|Placebo Comparator|Control|6.12 g/L sodium acetate, 5.85 g/L sodium chloride, 0.3 g/L potassium chloride and 0.33 g/L calcium chloride
9998209|NCT01516151|Active Comparator|Group A|0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8
10212009|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm C|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and at DL2 quavonlimab according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
10212010|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (SCLC): Arm D|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with SCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
9892052|NCT05182359|Other|CVD-T2D Informed Medical Management (Informed)|The SomaSignal Metabolic Factors test results will be provided in the Open Label Extension; results will not be provided to provider and participant until study conclusion.
9892053|NCT05182359|Other|Standard of Care (Uninformed)|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) and Metabolic Factors test results will be provided in the Open Label Extension; results will not be provided to provider and participant until study conclusion.
9892054|NCT05182060|Experimental|Transition Intervention|"We will implement a bundle of care transition safety resources with the assistance of home health coordinators at the study site.~These resources include a link to a video about home health services, a caregiver assessment, a care task role assignment sheet, and a shopping list."
9892055|NCT05182060|No Intervention|Control|"We will select other home health provider teams that provide care to similar populations to serve as concurrent controls.~No interventions will be administered."
9892056|NCT05181618|Experimental|Cohort 1, Hemophilia A and Without Arthropathy: Emicizumab|Cohort 1 comprises participants with severe or moderate hemophilia A and with no synovitis and no osteochondral damage (Haemophilia Early Arthropathy Detection with Ultrasound [HEAD-US] score of 0) in all index joints.
9892057|NCT05181618|Experimental|Cohort 2, Hemophilia A and with Synovitis Only: Emicizumab|Cohort 2 comprises participants with severe or moderate hemophilia A and with synovitis (HEAD-US synovitis score of ≥1) in at least one joint and no osteochondral damage (HEAD-US bone and cartilage score of 0).
9892058|NCT05181618|Experimental|Cohort 3, Hemophilia A and with Osteochondral Damage: Emicizumab|Cohort 3 comprises participants with severe or moderate hemophilia A and with osteochondral damage (HEAD-US bone and cartilage score of ≥1) in at least one joint with any synovitis score.
9892059|NCT05180812|Experimental|Experimental Group: Gravity Compensation|The participants will be wearing the ExoNet device tuned to gravity support.
9892060|NCT05180812|Sham Comparator|Control Group: No Gravity Compensation|The participants will be wearing the ExoNet device, but it will not be tuned to gravity support.
9892061|NCT05180669|Experimental|OARSCM|OARSCM (n = 51) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
9892062|NCT05180669|Sham Comparator|TAU with MyMAT|TAU (n = 51) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
9892063|NCT05176951|Experimental|Treprostinil Palmitil|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be titrated up to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
9892064|NCT05176951|Placebo Comparator|Placebo|Participants will be administered a placebo matching treprostinil palmitil (TPIP) once daily.
9892065|NCT05176314|Experimental|Rosuvastatin + Pirtobrutinib|Rosuvastatin administered orally on day 1 followed by rosuvastatin administered with pirtobrutinib on day 6 orally. Pirtobrutinib alone administered orally from days 7 to 12 followed by rosuvastatin administered with a single dose of pirtobrutinib on day 13. Pirtobrutinib alone administered from days 14 to17.
9892066|NCT05174091||With Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
9892067|NCT05174091||Without Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
9892068|NCT05162755|Experimental|Dose escalation 1a: S95029|
9892069|NCT05162755|Experimental|Dose escalation 1b: S95029 and Sym021|
9892070|NCT05162755|Experimental|Dose expansion 2a: S095029 and Sym021 and anti-HER2 therapy|
9892071|NCT05162755|Experimental|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|
9892072|NCT05158088|Active Comparator|Borescope group|Using an Endotracheal tube mounted over Borescope with the aid of conventional laryngoscope for intubation
9892073|NCT05158088|Active Comparator|Videolaryngoscope group|Using videolaryngoscope for intubation
9892074|NCT05153967||Pediatric Myeloablative allo-HSCT|Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT.
9797588|NCT01600950|Experimental|LY2963016|A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
9797589|NCT01600950|Active Comparator|Lantus|A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
9797590|NCT01601067|Experimental|Arm 1: Integrated Prolonged Exposure Therapy|Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
9797591|NCT01601067|Active Comparator|Arm 2: Seeking Safety|Seeking Safety
9797592|NCT01601132|Experimental|theophylline|300mg (80mg/15ml elixir) theophylline
9797593|NCT01601132|Experimental|Colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
9797594|NCT01601236|Experimental|Acthar 8 U (0.1 mL) daily|Repository Corticotropin Injection
9797595|NCT01601236|Placebo Comparator|Placebo (0.1 mL) daily|Placebo
9797596|NCT01601236|Experimental|Acthar 16 U (0.2 mL) daily|Repository Corticotropin Injection
9797597|NCT01601236|Placebo Comparator|Placebo (0.2 mL) daily|Placebo
9797598|NCT01601236|Experimental|Acthar 32 U (0.4 mL) daily|Repository Corticotropin Injection
9797599|NCT01601236|Placebo Comparator|Placebo (0.4 mL) daily|Placebo
9797600|NCT01601431|Experimental|Cap Assisted Colonoscopy|Cap Assisted Colonoscopy uses a Cap which is a transparent hood which is attached to the distal end of the colonscope and allows depressing the colon folds in order to visualize hidden polyps behind the folds.
9797601|NCT01601431|Active Comparator|Conventional colonoscopy|A conventional colonoscopy does not use a Cap in order to perform the procedure
9797602|NCT01601470|Experimental|Period 1:Sildenafil;Period 2:LCZ696;Period 3:LCZ696+Sildenafil|During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
9797603|NCT01601496|Experimental|FUSION Vascular Graft|All subjects who received a FUSION Vascular Graft at the baseline implant procedure.
9797604|NCT01601535|Experimental|Treatment|"Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.~Irinotecan will be administered intravenously during each course on study day 1 through day 5.~Temozolomide will be administered orally during each course on study day 1 through day 5."
9797605|NCT01601626|Experimental|A: Standard-dose LPV/r w/RBT|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
9797606|NCT01601626|Active Comparator|B: Double-dose LPV/r w/RIF|"ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
9797607|NCT01601626|Experimental|C: Standard-Dose LPV/r w/RBT + RAL|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
9797608|NCT01601652|Experimental|Omeagven|
9797609|NCT01601691|Experimental|Spacer|Subjects with spacer injection
9797610|NCT01601704|Experimental|NB32|
9797611|NCT01601704|Placebo Comparator|PBO|
9797612|NCT01601782|Experimental|Volume Imaging scan|New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.
9797613|NCT01601821|Active Comparator|Arm A (CsA+Rapamune+CS)|
9797614|NCT01601821|Experimental|Arm B (CsA+MMF+CS)|
9797615|NCT01601847|Active Comparator|Sustained|Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
9892075|NCT05153967||Pediatric Standard Disease-Modifying Therapy|Participants ages 4 to 17 years old with SCD who receive standard therapy.
9892076|NCT05153967||Adult Non-Myeloablative allo-HSCT|Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT.
9892077|NCT05153967||Adult Standard Disease-Modifying Therapy|Participants ages 18 to 65 years old with SCD who receive standard therapy.
9892078|NCT05150938||Cancer patients with VTE|Cancer patients who received anticoagulation treatment.
9892079|NCT05150886||Patients at low risk of intubation|Patients with a ROX index of 4.88 and above measured at the 12th hour of hospitalization in the intensive care unit.
9892080|NCT05150886||Patients at hihg risk of intubation|Patients with a ROX index of less than 4.88, measured at the 12th hour of admission to the intensive care unit.
9892081|NCT05150340|Experimental|Epoch 1: TAK-771 Ramp up Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI will be increased from 1/3 of full dose to full dose in 3 weeks for participants who will receive TAK-771 once every 3 week, or from 1/4 of full dose to full dose in 6 weeks for participants who will receive TAK-771 once every 4 week.
9892082|NCT05150340|Experimental|Epoch 2: TAK-771 Treatment Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 24.
9892083|NCT05147350|Experimental|Phase 1: RP-6306 in combination with FOLFIRI Dose Escalation|RP-6306 will be administered as oral capsules Multiple dose levels of RP-6306 (oral) and FOLFIRI (IV)
9892084|NCT05147272|Experimental|Phase 1 Dose Escalation|Multiple dose levels of RP-6306 and gemcitabine
9892085|NCT05143021||Pregnant Women with Sickle Cell Disease|Pregnant women with sickle cell disease from the 3 centers in Ghana
9892086|NCT05142254|Experimental|Tadalafil and Hydroxyurea|Tadalafil 2.5-5 mg/day and Hydroxyurea 20 mg/kg/day
9892087|NCT05142254|Placebo Comparator|Placebo and Hydroxyurea|Placebo and Hydroxyurea 20 mg/kg/day
9892088|NCT05137717|Experimental|Maribavir|Maribavir 400 milligrams (mg), tablets, orally twice a day (BID) for up to 8 weeks.
9892089|NCT05137314|Experimental|3 mg/mL PLG0206|administered intraoperatively by local irrigation
9892090|NCT05137314|Experimental|10 mg/mL PLG0206|administered intraoperatively by local irrigation
9892091|NCT05136404|Experimental|Selpercatinib (Formulation 1)|Selpercatinib (formulation 1) given orally on days 1, 8 or 15.
9892092|NCT05136404|Experimental|Selpercatinib (Formulation 2)|Selpercatinib (formulation 2) given orally on days 1, 8 or 15.
9892093|NCT05136404|Experimental|Selpercatinib (Formulation 3)|Selpercatinib (formulation 3) given orally on days 1, 8 or 15.
9892094|NCT05132595|Placebo Comparator|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
9892095|NCT05132595|Active Comparator|Esketamine in patients|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
9892096|NCT05132595|Active Comparator|Ketorolac in patients|After the induction of anesthesia, ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h ketorolac until starting skin suture.
9892097|NCT05132595|Active Comparator|Esketamine and Ketorolac in patients|After the induction of anesthesia, 0.2mg/kg esketamine and 0.2mg/kg ketorolac are intravenously injected, and then a continuous infusion of 0.2mg/kg/h esketamine and 0.2mg/kg/h ketorolac until starting skin suture.
9892098|NCT05130346|Experimental|Mindfulness Based Stress Reduction (MBSR)|
9892099|NCT05130346|No Intervention|Standard of Care (SOC)|
9892100|NCT05126303|Experimental|RMC-035|"RMC-035 is a concentrate (6.0 mg/mL) for solution for infusion for IV administration.~Dosing will be based on renal function at Day -1: Subjects with eGFR ≥60 mL/min/1.73m2 will receive 1.3 mg/kg (per dose) for the first and second dose, followed by 0.65 mg/kg (per dose) for the third, fourth and fifth dose, while subjects with eGFR >30 and <60 mL/min/1.73m2 will receive 0.65 mg/kg (per dose) for all five doses Dosing occurs at time 0 and then after 6, 12, 24 and 48 hours."
9892101|NCT05126303|Placebo Comparator|Placebo|Identical to RMC-035 arm except that the placebo contains no active ingredient.
9990789|NCT01446848|Experimental|iron supplement|open-label iron supplement intervention group
9990790|NCT01446861||Cystic fibrosis patients|Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
9990791|NCT01446861||Healthy controls|Age and gender matchet healthy Controls recruited by Board notice and advertising.
9990792|NCT01446887|No Intervention|non-prophylactic anticoagulation|without prophylactic anticoagulation
9990793|NCT01446887|Experimental|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
9990794|NCT01446900|Experimental|Rituximab cladribine|
9990795|NCT01446926|Experimental|Group 1: Adults High Dose (Formulation 1)|Adults who will receive a single injection of high dose investigational Pneumococcal vaccine
9990796|NCT01446926|Placebo Comparator|Group 2: Adults Placebo|Adult participants who will receive an injection of placebo
9990797|NCT01446926|Experimental|Group 3: Toddlers High Dose (Formulation 1)|Toddlers who will receive a single injection of high dose Pneumococcal vaccine
9990798|NCT01446926|Placebo Comparator|Group 4: Toddlers Placebo|Toddlers who will receive a single injection of placebo
9990799|NCT01446926|Experimental|Group 5: Infants Low Dose (Formulation 2)|Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine
9990800|NCT01446926|Placebo Comparator|Group 6: Infants Placebo|Infants who will receive 3 injections of placebo
9990801|NCT01446926|Experimental|Group 7: Infants Middle Dose (Formulation 3)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
9990802|NCT01446926|Experimental|Group 8: Infants Middle Dose (Formulation 4)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
9990803|NCT01446926|Placebo Comparator|Group 9: Infants Placebo|Infants who will receive 3 injections of placebo
9990804|NCT01446926|Experimental|Group 10: Infants High Dose (Formulation 1)|Infants who will receive 3 injections of high dose Pneumococcal vaccine
9990805|NCT01446926|Placebo Comparator|Group 11: Infants Placebo|Infants who will receive 3 injections of placebo
9990806|NCT01446939||Parkinson's disease|Patients with primary Parkinson's disease
9990807|NCT01446939||Essential tremor|Patients with essential tremor
9990808|NCT01446939||Healthy volunteers|Healthy volunteers
9990809|NCT01446952|Experimental|Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent once. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
9990810|NCT01446978|Active Comparator|initial single dose of hep A vaccine|The participants will receive a single dose of hepatitis A vaccine at 0+1+6 months
9990811|NCT01446978|Active Comparator|initial double dose|Participants will receive one dose of hepatitis A vaccine in each M. deltoids and an additional dose at 6 months later
9990812|NCT01446991|Experimental|Favorable prostate cancer with pubic arch interference|Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
9990813|NCT01446991|Experimental|Intermediate risk prostate cancer, 6 months Degarelix|Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network [NCCN] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be > 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
9990814|NCT01447043||Group 1|
9990815|NCT01447056|Experimental|LMP Specific T cells|LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
9892102|NCT05123937|Experimental|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
9892103|NCT05123937|Experimental|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
9892104|NCT05123703|Experimental|Ocrelizumab|Participants will receive Ocrelizumab by IV infusion every 24 weeks. The first dose is given as dual infusions of half the dose of ocrelizumab on Days 1 and 15 and subsequent doses are given as single infusions of ocrelizumab every 24 weeks. Participants will also receive a placebo of fingolimod (administered as QD capsule).
9892105|NCT05123703|Active Comparator|Fingolimod|Participants will receive Fingolimod PO QD as per the prescribing information provided with fingolimod. Patients will also receive a placebo of ocrelizumab (administered as IV infusions on Days 1 and 15, and every 24 weeks thereafter).
9892106|NCT05123222|Experimental|ZIKV-SJRP/2016-184 Strain|Dose of 10ˆ2 PFU Dose escalation of 10ˆ3 PFU Dose escalation of 10ˆ4 PFU
9892107|NCT05123222|Experimental|ZIKV-Nicaragua/2016 Strain|Dose of 10ˆ2 PFU Dose escalation of Dose of 10ˆ3 PFU Dose escalation of 10ˆ4 PFU
9892108|NCT05123222|Placebo Comparator|Placebo|
9892109|NCT05121896|Active Comparator|Patients with facial synkinesis|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
9892110|NCT05121896|Active Comparator|Control participants|Functional MRI scan of the primary and secondary somatosensory cortexes, the primary motor cortex, the supplementary motor cortex, and the ventral lateral premotor cortex while the participant performs motor and sensory tasks.
9892111|NCT05119751|Active Comparator|Birch allergy|"randomised (1:1) to receive vestibular or sublingual birch pollen~once daily tree 12 SQ-Bet AIT tablet"
9892112|NCT05119751|Active Comparator|Grass allergy|"randomised (1:1) to receive vestibular or sublingual grass pollen~grass 2800 BAU AIT tablet"
9892113|NCT05119751|Active Comparator|ragweed allergy|randomised (1:1) to receive vestibular or sublingual ragweed pollen ragweed 12 Amb a 1-U AIT Tablet
9892114|NCT05119751|Active Comparator|House dust mite allergy|"randomised (1:1) to receive vestibular or sublingual HDM~HDM 12 SQ-HDM"
9892115|NCT05115370||Patients with an inflammatory disease taking immune-suppressing medication|
9892116|NCT05112666||Cancer patients with VTE|Adults diagnosed with active (primary or metastatic) cancer experiencing a hospitalization or emergency department admission or a primary care visit with an incident venous thromboembolism (VTE), being administered rivaroxaban or other direct-acting oral anticoagulants (DOACs) or a low molecular weight heparin (LMWH) will be included.
9892117|NCT05110053|Active Comparator|Active|All patients will receive surgery with implantation of a SCS device. Patients randomized to the active arm, will receive active stimulation. However, for the purposes of this study, the stimulation paradigm and intensity is designed to be below perceptional thresholds so as to assure appropriate blinding. Blinding will continue for 6 months, followed by a 6 month voluntary open-phase, active extension.
9892118|NCT05110053|Placebo Comparator|Placebo|All patients will receive surgery with implantation of a SCS device. Patients randomized to the placebo-arm of the trial will have the device switched of or set to a stimulation intensity of zero. Blinding will continue for 6 months, followed by a 6 month voluntary open-phase, active extension.
9892119|NCT05106413|Experimental|Speech Intelligibility with CROS device|"The focus of this study is on Speech Intelligibility (SI), evaluated by the Oldenburg Sentence test (OLSA), which measures a speech recognition threshold (SRT) in dB SNR (signal to noise ratio).~Therefore each participant will perform the tests with the experimental rechargeable CROS transmitter (CROS) in different interventions, like comparison to monaural fitting and unaided condition.~All participants will perform the same tests. The order of the intervention in the speech test is randomized, but will be performed in the same visit by each participant."
9892120|NCT05104242|No Intervention|Standard diet - Control group|The standard diet will include energy intake of 30-35 kcal/kg of ideal body weight (IBW)/day and protein intake of 0.75 g/kg of IBW/day for females and 0.84 g/kg of IBW/day for males
9797616|NCT01601847|Placebo Comparator|Diet-Limited|Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
9797617|NCT01601860|Active Comparator|Control|Active Comparator: Control Group Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
9797618|NCT01601860|Experimental|Intervention Group|Experimental: Intervention Group Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: Walking (with cervical dilation between 4 and 5 cm) Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm) Shower (with dilation> 7 cm);
9797619|NCT01601873|Experimental|PROPATEN|patients with heparin-bonded graft implantation
9797620|NCT01601873|Active Comparator|Standard Graft|patients undergoing ePTFE hemodialysis graft implantation
9797621|NCT01601977|Experimental|Intervention|AVAPS-AE
9797622|NCT01601977|Active Comparator|Usual care|Non-invasive ventilation
9797623|NCT01602068|Experimental|Dexamethasone Phosphate Ophthalmic|Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
9797624|NCT01602068|Placebo Comparator|100 mM Sodium Citrate Buffer|Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
9797625|NCT01602120|Experimental|CFD4870g Sham|Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), will receive lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
9797626|NCT01602120|Experimental|CFD4870g Lampalizumab|Participants will receive lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
9797627|NCT01602120|Experimental|GX29455 Sham|Participants who were administered sham comparator in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
9797628|NCT01602120|Experimental|GX29455 Lampalizumab|Participants who were administered lampalizumab in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
9797629|NCT01602172|Experimental|Brief Alcohol Intervention (BI)|The 3-part Brief Intervention (BI) consists of . Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
9797630|NCT01602172|Active Comparator|Attention Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity. Two weeks later, the Research Assistant calls subjects in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. This intervention is designed to provide all the information and assessments that that Brief Intervention participants as well as all the alcohol consumption and motivation to change measures-- it is designed to control for the attention that the BI participants receive w/o the motivational interventions
9797631|NCT01602172|Active Comparator|Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. Subjects complete only drinking quantity measures at baseline and 6 months post baseline. The inclusion of this group tests whether completing more extensive questionnaires (in comparison the Attention Control group) decreases alcohol consumption.
9797632|NCT01602224|Experimental|100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)|"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.~Bortezomib 1.3 milligram per square meter (mg/m^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles.~All treatment may continue past 8 cycles."
9797633|NCT01602224|Experimental|300 mg Tabalumab+Dexamethasone+Bortezomib|"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
9797634|NCT01602224|Placebo Comparator|Placebo Comparator: Placebo + Dexamethasone + Bortezomib|"Placebo administered once IV on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
9797635|NCT01602315|Experimental|Phase Ib: A-BYL719 FC whole tab+cetux|Oral film-coated tablets without swallowing dysfunction.
9797636|NCT01602315|Experimental|Phase II: 2-Cetuximab|Cetuximab in patients naive to cetuximab (phase ll)
9797637|NCT01602315|Experimental|Phase Ib: B-BYL719 FC drink sus+cetux|Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
9797638|NCT01602315|Experimental|Phase II: 3-BYL719 + Cetuximab|BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
9797639|NCT01602315|Experimental|Phase II: 1-BYL719 + Cetuximab|BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
9797640|NCT01602315|Experimental|Phase Ib: C-BYL719 DT+cetux|Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
9797641|NCT01602315|Experimental|Phase II: Cross over|patients received BYL719 at RP2D in combination with cetuximab.
9797642|NCT01602341|Experimental|AN2728 Topical Ointment, 2% QD vs 0.5% QD|"AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied once daily for 29 days to a target lesion~Treatments will be randomly assigned to target lesions A and B."
9797643|NCT01602341|Experimental|AN2728 Topical Ointment, 2% BID vs 0.5% BID|"AN2728 Topical Ointment, 2% applied twice daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied twice daily for 29 days to a target lesion.~Treatments will be randomly assigned to target lesions A and B."
9797644|NCT01602419||Patients using Wilate as standard of care treatment|This patient population is being treated with Wilate as standard of care treatment
9797645|NCT01602484|Experimental|Splint Pack|Group of post-op patients who have splint applied from prepared Plaster-of-Paris splint pack
9797646|NCT01602484|Active Comparator|Bulk Supplies|Group of post-op patients who have splint applied from bulk supplies
9797647|NCT01602510|Experimental|Lamotrigine CD|lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
9797648|NCT01602510|Placebo Comparator|Placebo|Placebo
9797649|NCT01602549|Experimental|Cohort|1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days
9797650|NCT01602562|Experimental|VACV (256U87; valaciclovir hydrochloride)|Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily.
9797651|NCT01602614||Group 1|≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
9797652|NCT01602614||Group 2|≤ 27 weeks 6 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
9797653|NCT01602614||Group 3|≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
9797654|NCT01602614||Group 4|≥ 28 weeks 0 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
9797655|NCT01602679|Experimental|micronized progesterone, then placebo|Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo (matching oral micronized progesterone suspension).
9797656|NCT01602679|Placebo Comparator|Placebo, then micronized progesterone|Participants first received placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone syrup (100 mg p.o.)Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
9797657|NCT01602692|Active Comparator|Tumescent solution with dilute epinephrine|Subjects in this arm of the study will be randomized to receive tumescent solution containing dilute epinephrine (1:1,000,000) during their breast reduction.
9797658|NCT01602692|Active Comparator|Tumescent solution with dilute lidocaine and epinephrine|Subjects in this arm of the study will receive tumescent solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000).
9797659|NCT01602731|Experimental|Automated Medication Dispensing Device|Subjects with <88% medication adherence, determined by 30-day pillcount, and with cognitive impairment (determined by Saint Louis University Mental Status score) proceeded to AMDD portion of study.
9797660|NCT01602744|No Intervention|Controll|The medications in this arm will not be screened.
9797661|NCT01602744|Active Comparator|Intervention screening medication group|STOPP/START screening tools are used for medication intervention
9797662|NCT01602965|Experimental|counseling monthly phone calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviours that need to be changed, problem-solving as to how to make the changes and physical activity levels.
9797663|NCT01602965|Active Comparator|self help informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies.
9797664|NCT01603056|Experimental|PANGRAMIN SLIT HDM MIX|PANGRAMIN SLIT HDM MIX Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
9797665|NCT01603056|Placebo Comparator|Placebo|Placebo Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
9892121|NCT05104242|Experimental|Low AGE diet - Intervention group|"The low AGE diet will be the same as the standard diet in terms of calories (i.e. 30-35 kcal/kg/day) and protein (0.75-0.84 g/kg/day). However, it will reduce the dietary AGE content by changing cooking methods in food preparation to avoid exposure to dry heat such as frying, broiling, grilling and roasting, and to favour cooking with lower temperatures and high-water content as in stewing, steaming, boiling and poaching. In addition, the low-AGE group will be instructed to choose foods with low content of AGEs based on a food choice list that will contain examples of foods commonly available in the UK to be chosen as allowed, moderate intake, or occasional. The goal will be to reduce dietary AGE intake to less than 8000 kU/day."
9892122|NCT05103436|No Intervention|Control Group|Participants will not receive intervention for the first 2 months. This period will be used for comparison with the intervention group. At the end of the 2-month delay, they will receive TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit).
9892123|NCT05103436|Experimental|Intervention Group|Participants will receive 2 months of TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit) immediately upon entry to the study.
9892124|NCT05092477|Experimental|Integrated Intervention|4 intervention sessions over 6 months using an educational and counseling intervention developed by the study team.
9892125|NCT05092477|Active Comparator|Control|Attention Control group - Supportive counseling for DM management
9892126|NCT05090904|Experimental|Brensocatib 10 mg|Participants will be administered brensocatib at a dose of 10 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered cystic fibrosis transmembrane conductance regulators (CFTRs) during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
9892127|NCT05090904|Experimental|Brensocatib 25 mg|Participants will be administered brensocatib at a dose of 25 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
9892128|NCT05090904|Experimental|Brensocatib 40 mg|Participants will be administered brensocatib at a dose of 40 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
9892129|NCT05090904|Experimental|Brensocatib 65 mg|Following review of safety and pharmacokinetic data by the safety review committee, an additional cohort of participants may be administered brensocatib at a dose of 65 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
9892130|NCT05090904|Placebo Comparator|Placebo|Participants will be administered a placebo matching brensocatib once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
9892131|NCT05086679|Active Comparator|Compression stockings with 25-30 mm Hg pressure|Compression stockings with 25-30 mm Hg pressure, as long as they could (ideal would be the majority of the time they are upright)
9892132|NCT05086679|Sham Comparator|Compression stockings with up to 10 mm Hg pressure|Compression stockings with up to <=10 mm Hg pressure, as long as they could (ideal would be the majority of the time they are upright)
9932337|NCT00947960|Other|Placebo/Active|Subjects receive 1-2 grams/kilogram body weight placebo vegetable oil divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive triheptanoin at the same dose and frequency for the next 6 months during the randomization phase.
9932338|NCT00947973|Experimental|Challenging Horizons Program after-school model|Participants will receive the CHP after-school model.
9892133|NCT05084053|Experimental|Cohort 1: TAK-771 for CIDP Participants|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
9892134|NCT05084053|Experimental|Cohort 2: TAK-771 for MMN Participants|TAK-771 includes IGI 10% and rHuPH20. Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
9892135|NCT05082909|Active Comparator|Penicillin alone|Penicillin orally at dose of either 250mg, 500mg, 750mg QDS for 36 hours.
9892136|NCT05082909|Experimental|Penicillin plus probenecid|"Penicillin orally at dose of either 250mg, 500mg, 750mg QDS for 36 hours.~PLUS~Probenecid 500mg QDS for 36 hours."
9892137|NCT05079035|Experimental|Experimental: TTAX03|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is suspended in a volume of 2.0mL of sterile, preservative free 0.9% NaCl.
9892138|NCT05079035|Placebo Comparator|Control: Saline|2.0mL of sterile, preservative free 0.9% NaCl alone
10212011|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm E|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
9892142|NCT05073315|Active Comparator|Continued-use Group (Adalimumab)|Randomized participants will receive continuous injection of adalimumab Q2W until last dose at Week 28.
9892143|NCT05073315|Experimental|Switching Group (Adalimumab - ABP 501)|Participants will initially receive adalimumab until Week 10 during the lead-in period. Thereafter, starting from Week 12, participants will switch between ABP 501 and adalimumab Q2W with last dose of ABP 501 at Week 28.
9892144|NCT05070429|Other|Conventional hearing healthcare group|The conventional hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. During Year 1, this group will receive clinic-based audiological rehabilitative service delivery and be able to use conventional options to address any unanticipated needs that arise, and then during Year 2, this group will also receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise.
9892145|NCT05070429|Other|Telehealth hearing healthcare group|The telehealth hearing healthcare group will have clinic-based visits every 6 months for the duration of the 2-year study. This group will receive telehealth audiological rehabilitative service delivery and be able to utilize telehealth options, in addition to conventional options, to address any unanticipated needs that arise during both years of the study.
9892146|NCT05069935|Experimental|Dose Escalation|"Cohort A: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved~Cohort B: FT538 plus trastuzumab in subjects with advanced documented HER2+ tumors~Cohort C: FT538 plus cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell carcinoma (HNSCC)"
9892147|NCT05069935|Experimental|Dose Expansion|"Cohort A, Arm 1: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved (except urothelial carcinoma (UC))~Cohort A, Arm 2: FT538 plus an anti-PD-1 antibody (nivolumab or pembrolizumab) in subjects with solid tumor malignancies where anti-PD-1/PD-L1 antibodies are approved (except UC)~Cohort B, Arm 1: FT538 plus trastuzumab in subjects with HER2+ tumors~Cohort C, Arm 1: FT538 plus cetuximab in subjects with advanced CRC or HNSCC~Subjects with UC may be enrolled in the randomized expansion cohorts as follows:~Cohort A, Arm R1: FT538 plus avelumab~Cohort A, Arm R2: FT538 plus atezolizumab"
9892148|NCT05069740|Experimental|Salsalate|3000 mg/day salsalate (1500 mg twice daily) for 5 days
9892149|NCT05069740|Placebo Comparator|Placebo|1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days
9892150|NCT05065502|Active Comparator|Academic Detailing (AD) Only|One-on-one educational outreach to employees and providers.
9892151|NCT05065502|Experimental|AD + LEAP Combined|This arm combines use of AD plus the Learn. Engage. Act. Process (LEAP) program. LEAP is a 6-month quality improvement coaching program plus a 6-month monthly follow-up.
9892152|NCT05063331|Active Comparator|Sacrocolpopexy|Minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP)
9892153|NCT05063331|Active Comparator|Uterosacral Ligament Suspension|Total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
9892154|NCT05059626|Experimental|Simvastatin|30 days of Simvastatin (10mg/day)
9892155|NCT05059626|Experimental|bazedoxifene + conjugated estrogen|30 days of bazedoxifene + conjugated estrogen (0.45mg/20mg/day)
9892156|NCT05059626|Placebo Comparator|Placebo|30 days of placebo (microcrystalline cellulose filler capsule; 1 pill/day)
9892157|NCT05054816|Experimental|Investigational adaptive directional microphone strategy|Receiver-in-canal hearing aid with an investigational adaptive directional microphone strategy.
9892158|NCT05054816|Active Comparator|Comparator omnidirectional microphone strategy|Receiver-in-canal hearing aid with a comparator omnidirectional microphone strategy.
9892159|NCT05054816|Active Comparator|Comparator fixed directional microphone strategy|Receiver-in-canal hearing aid with a comparator fixed directional microphone strategy.
9892160|NCT05054075|Experimental|Vaccinated|Subjects that received a vaccine against COVID-19 lineage virus
9892161|NCT05054075|Experimental|Non-vaccinated|Subjects that did not receive a vaccine against COVID-19 lineage virus
9892162|NCT05054075|Experimental|Infected|Subjects that are infected with a COVID-19 lineage virus
9892163|NCT05053035|Experimental|AL001|AL001 every 4 weeks
9892164|NCT05053035|Placebo Comparator|Placebo|Placebo every 4 weeks
9892165|NCT05051449|Experimental|Ketamine|
9892166|NCT05048641|Experimental|WhatsApp Reminder group|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
9892167|NCT05048641|No Intervention|No Reminder (NR) group|Subjects who are allocated to the NR group received standard-of-care service which is no reminder text messages via WhatsApp Messenger prior to their scheduled repeat mammography and no follow up phone reminder until the completion of the outcome measurement period.
9892168|NCT05047042|Experimental|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The intervention will take place in participants' homes, at times convenient for the participant. Programming will be administered virtually through the University of Alberta's Cancer Rehabilitation Clinic, which is fully equipped for virtual delivery of services. The study intervention will be tailored to the individual with respect to their baseline strength, symptom profile and prior experience with exercise. Pre- and post-testing will be done virtually. The mode, intensity and duration of each exercise session will be based on the participant's baseline fitness and status that day. Variations on each exercise will be provided to ensure an appropriate movement and intensity and to allow for individual prescription. Resistance bands will be used to provide resistance during strengthening and balance retraining exercises. The interactive group class will be led virtually by an exercise or rehabilitation specialist.
9892169|NCT05044793||Number of Subjects Enrolled|
9892170|NCT05037929|Experimental|Astegolimab Q2W|Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).
9892171|NCT05037929|Experimental|Astegolimab Q4W|Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).
9892172|NCT05037929|Placebo Comparator|Placebo|Participants will receive SC placebo Q2W.
9892173|NCT05036148||Patients indicated for MH screening|Patients referred to MH center for MH diagnostic
9892174|NCT05027867|Experimental|Arm 1|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
9892175|NCT05027867|Experimental|Arm 2|KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
9892176|NCT05023967|Experimental|Arm I (fasting, glucose monitoring, counseling, metformin)|Patients fast for >= 16 hours every night and use the continuous glucose monitoring system for 4-6 weeks. Patients also receive nutritional counseling sessions on days 0 and 10. Beginning During week 2, patients also receive metformin hydrochloride ER 750 mg orally once daily; week 3 until the day of surgery the dose is 1500 mg daily. Treatment continues for 4-6 weeks (until surgery) in the absence of disease progression or unacceptable toxicity.
9892177|NCT05023967|Active Comparator|Arm II (glucose monitoring)|Patients continue their usual dietary pattern and use the continuous glucose monitoring system for 4-6 weeks (until surgery).
9892178|NCT05022758||Participants treated with rivaroxaban|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on rivaroxaban (defined as the index date) during the enrollment period from January 2015 to December 2017.
9892179|NCT05022758||Participants treated with warfarin|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on warfarin (defined as the index date) during the enrollment period from January 2015 to December 2017.
9892180|NCT05020496|No Intervention|Group 1 (Negative Control, 20 participants)|"At the first visit, various doses of diphenylcyclopropenone (DPCP) are applied in acetone to give the required dose range, increasing by 60% increments. Elicitation patch is applied on the upper inner arm skin and removed by patients themselves exactly 6 hours after the application.~The second visit will be 48 hours after the DPCP treatment. At this visit, the bi-fold skin thickness will be measured using a Medical Skinfold Caliper.~The group1 will have only one treatment with DPCP and serve as negative controls for DPCP induced cutaneous immune responses in comparison to Group 2 and 3, which require two treatments with DPCP (sensitization and challenge) as described in the following group 2 and 3. The first reading of skin thickness prior to DPCP application serves as the baseline and the second reading after DPCP indicates an increase in skin thickness, which represents a quantitative parameter of DPCP induced immune responses."
9932339|NCT00947973|Experimental|Challenging Horizons Program consultation model|Participants will receive the CHP consultation model.
9932340|NCT00947973|No Intervention|Community care|Participants will have access to standard community care.
9932341|NCT00947986|Experimental|Johnson's Baby Shampoo|1% diluted solution
9935981|NCT02890342||Healthy Volunteers|Healthy Volunteers, standard adult, parental permission
9935982|NCT02890342||Unaffected Family Members|Unaffected family members
9892181|NCT05020496|Other|Group 2 (Positive Control, 20 participants)|"This group of the study will take approximately 5 weeks and requires 3 visits. At the first visit, skin sites on the right upper buttock will be topically treated with a patch of the contact sensitizer (DPCP) for sensitization on the upper buttock for 48 hours. The skin patches will be removed by patients themselves after the application.~The second visit will be four weeks after the DPCP sensitization, participants will have a DPCP treatment again on the right upper inner arm with the same agent. At the visit, the bi-fold skin thickness will be measured prior to the application of DPCP skin patch by using a Medical Skinfold Caliper. Various DPCP doses are applied increasing by 60% increments. The patches are applied on the upper inner arm skin and removed by patients themselves exactly 6 hours after application.~The third and final visit will be 48 hours after the second DPCP treatment. At this visit, bi-fold skin thickness will be measured using a Caliper."
9892182|NCT05020496|Experimental|Group 3 (UVB & Biopsy 30 participants)|"This group of the study will take approximately 10 weeks and requires 10 visits.~At the first visit, blood will be collected and MED will be determined. The second visit will be 24h after UV when MED will be measured. Blood will be collected from patients at this time. The third visit will be on the 8th day. The two marked skin sites will be UV exposed at 2MED on 4 consecutive days.~Days 9-11 make up the fourth, fifth, and sixth visits. Following the last UV exposure blood will be collected. A single dose of DPCP will be placed on the upper buttock for 48 hours. The seventh visit will be on the 12th day when two skin biopsies will be taken. The ninth visit will be four weeks after the sensitization with DPCP, when the upper inner arm will be treated with DPCP. Bi-fold skin thickness will be measured prior to the application of DPCP. Various DPCP doses are applied. The tenth visit will be 48 hours after the DPCP treatment. At this visit, bi-fold skin thickness will be measured."
9892183|NCT05018585|Experimental|Diamyd|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
9892184|NCT05018585|Placebo Comparator|Placebo|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (rhGAD) on Days 0, 30, and 60 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day -30 through Day 90)
9892185|NCT05009069|Experimental|Atezolizumab + Tiragolumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab plus tiragolumab (Day 1 of each 21-day cycle for 3 cycles)."
9892186|NCT05009069|Other|Atezolizumab|"Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.~Day 1 of Weeks 8, 11 and 14: Atezolizumab (Day 1 of each 21-day cycle for 3 cycles)."
9892187|NCT05005273|Experimental|Part 1|
9892188|NCT05005273|Experimental|Part 2: Arm A|
9892189|NCT05005273|Experimental|Part 2: Arm B|
9892190|NCT05004727|Experimental|Guselkumab + Topicals (GUS)|
9892191|NCT05004727|Placebo Comparator|Placebo + Topicals (PBO)|
9892192|NCT05004727|No Intervention|Standard-of-Care Therapy (SOC)|"In this third, non-randomized arm, patients would continue treatment with topical therapy or UVB, as part of our ongoing natural history of disease registries. This arm will include participants fulfilling RM-PsASon criteria but also those that do not (to serve as negative controls)."
9892193|NCT05000125||Slides from the German Co-Screening program|From 32506 LBC slides (ThinPrep, Hologic Inc., USA) from the German Co-screening program measured in 2020 with the TIS all abnormal findings according to Munich III groups (II-p - V) and 3% of normal slides (Munich III groups (I+II-a)) will be selected for the additional measurement with the Genius Digital cytology system.
9892194|NCT04998851|Experimental|Women with CIS or MS|Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.
9932342|NCT00947999||Healthy Control Group|Subjects in particular group will not have a diagnosis of SCI and do not experience chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
9892195|NCT04998812|Experimental|Women with CIS or MS|Women with CIS or MS (in line with the locally approved indications) receiving commercial ocrelizumab up to 6 months before the LMP or during the first trimester of pregnancy (up to gestational week 13), due to accidental exposure, or in whom a decision to treat with ocrelizumab was taken as part of routine clinical practice.
9892196|NCT04998617|Experimental|Toothpaste Containing Curcumin|After screening, participants will be randomly assigned to receive toothpaste that contains 0.5% curcumin.
9892197|NCT04998617|Placebo Comparator|Toothpaste Without Curcumin|After screening, participants will be randomly assigned to receive toothpaste that does not contain curcumin.
9892198|NCT04993313|Experimental|Arm I (counseling, photo guide)|Patients undergo verbal counseling and view a photo guide. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
9892199|NCT04993313|Active Comparator|Arm II (counseling)|Patients undergo verbal counseling. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
9892200|NCT04992273|Experimental|≥20 kg to <40 kg|SC administration
9892201|NCT04992273|Experimental|≥10 kg to <20 kg|SC administration
9892202|NCT04992273|Experimental|≥5 kg to <10 kg|SC administration
9892203|NCT04992273|Experimental|≥3 kg to <5 kg|SC administration
9892204|NCT04992195||Vaccination Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and received COVID-19 vaccination (SinoVac or BioNTech).
9892205|NCT04992195||Control Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and have not received any COVID-19 vaccines nor clinically/serologically evident SARS-CoV-2 infection.
9892206|NCT04988308|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Week 0 through Week 15. At Week 16, participants will cross over to receive bermekimab dose 3 SC every week thereafter through Week 31.
9892207|NCT04988308|Active Comparator|Group 2: Adalimumab|Participants will receive adalimumab 40 milligrams (mg) SC at Week 0, placebo SC at Week 1 followed by adalimumab 40 mg SC and placebo SC at Week 2 and placebo SC at Week 3. Participants will then receive Adalimumab 40 mg SC and placebo SC at Week 4 and every week thereafter through Week 31.
9892208|NCT04988308|Experimental|Group 3: Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC and placebo SC at Week 0 followed by bermekimab dose 1 SC at week 1 and every week thereafter through Week 31.
9892209|NCT04988308|Experimental|Group 4: Bermekimab Dose 2|Participants will receive bermekimab dose 2 SC and placebo SC at Week 0 and every Week thereafter through Week 31.
9892210|NCT04988308|Experimental|Group 5: Bermekimab Dose 3|Participants will receive bermekimab dose 3 SC and placebo SC at Week 0 and every week thereafter through Week 31.
9892211|NCT04985903|Experimental|Intervention|Clinicians in the intervention arm will receive a tailored communication training on smoking cessation skills and a general lecture on smoking cessation.
9892212|NCT04985903|Active Comparator|Control|Clinicians in the control arm will be asked to attend a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
9892213|NCT04981041|Experimental|Potent P2Y12-Inhibition|Prasugrel 10mg (5 mg in patients ≥ 75 years old or weighing < 60 kg) q.d. per os or Ticagrelor 90mg bid per os
9892214|NCT04981041|Active Comparator|Clopidogrel|Clopidogrel 75mg q.d. per os
9892215|NCT04975815||Non-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores0 will place the participants in Non-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
9892216|NCT04975815||Pre-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores1-2 will place the participants in Pre-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
9892217|NCT04975815||Frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores3-5 will place the participants in Frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
9892218|NCT04975191|Other|Resources Program (RP)|
9892219|NCT04975191|Active Comparator|Personalized Feedback Program (PFP)|
9892220|NCT04975191|Active Comparator|Brief motivational intervention (BMI)|
9892221|NCT04975191|Active Comparator|Combined PFP+BMI|
9932343|NCT00947999||Subjects with SCI and Chronic Pain|Individuals recruited into this particular group will have a diagnosis of a spinal cord injury and experience pain on a daily basis with an average intensity of 4 out of 10 on a 0-10 scale.
9990816|NCT01447069|Active Comparator|Salbutamol|The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.
9990817|NCT01447069|No Intervention|control|The patients in the control group will continue with their regular optimal medical therapy without any intervention.
9990818|NCT01447082||Quetiapine XR group|
9990819|NCT01447082||Non-quetiapine comparison group|
9990820|NCT01447095|Active Comparator|Low dose prostacyclin|
9990821|NCT01447095|Active Comparator|High dose prostacyclin|
9990822|NCT01447095|Placebo Comparator|Placebo|
9990823|NCT01447108|Experimental|TN patients|Patients suffering from Trigeminal neuralgia
9990824|NCT01447134||Surgical|Group (a) [Those to undergo surgical excision or biopsy] patients will receive RGD-K5 scan within two weeks of conventional image evaluations. The image result will be confirmed with histopathological results.
9990825|NCT01447134||Chemotherapy concurrent Radiation|Group (b) patients [Those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy] will receive RGD-K5 scan prior to beginning of the therapy, after induction chemotherapy, within two weeks after concurrent chemoradiotherapy and two months after completion of concurrent chemoradiotherpy; all within two weeks of conventional image evaluations.
9990826|NCT01447134||RGD-K5 scan|Group (c) patients [Those with M1 disease to receive biotherapy or chemotherapy] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
9990827|NCT01447147|Placebo Comparator|Placebo (Group A)|
9990828|NCT01447147|Experimental|CCX140-B (Group B)|
9990829|NCT01447147|Experimental|CCX140-B (Group C)|
9990830|NCT01447160|Experimental|facet joint infiltration|The experimental group will be submitted to intra-articular infiltration of six facet joints (L3/L4;L4/L5;L5/S1 bilaterally) with triamcinolone hexacetonide
9990831|NCT01447160|Active Comparator|intramuscular injection|The control group which were submitted to triamcinolone acetonide intramuscular injection of six lumbar paravertebral points
9990832|NCT01447173|Experimental|2000 IU vitamin D Daily|
9797666|NCT01603082|Experimental|Ticagrelor|Ticagrelor - 180 mg loading dose
9990833|NCT01447173|Placebo Comparator|400 IU Vitamin D pill|
9990834|NCT01447186||Patient Decision Aid for Spanish Speaking Men|Spanish-Language Slide Set
9990835|NCT01447199||Gene Mutation|Group with increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset.
9990836|NCT01447199||No Cancer History|Group with little/no personal or family history of cancer.
9797667|NCT01603082|Active Comparator|Clopidogrel|Clopidogrel - 600 mg loading dose
9990837|NCT01447199||Spouses|Spouses of those who may have an increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset, or little/no personal or family history of cancer.
9990838|NCT01447212|Experimental|Hydromorphone|Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
9990839|NCT01447212|Active Comparator|Diacetylmorphine|Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.
9990840|NCT01447251|Experimental|A: Newly Diagnosed/CPAP/NO DM/PreDx DRS|patients who have newly-diagnosed obstructive sleep apnea (OSA) requiring continuous positive airway pressure (CPAP) therapy without diabetes and are given the result of the diabetes risk score
9990841|NCT01447251|Experimental|B: Newly Diagnosed/CPAP/NO DM/NO PreDx DRS|patients who have newly-diagnosed OSA requiring CPAP therapy without diabetes and are not given the result of the diabetes risk score
9990842|NCT01447251|Active Comparator|C: Controls|age, sex, and BMI-matched controls without OSA or diabetes
9990843|NCT01447251|Active Comparator|D: Controls on CPAP|age, sex, BMI, and OSA severity matched patients on CPAP therapy for OSA
9990844|NCT01447264|Placebo Comparator|Land exercises|The patients of this group will perform the same exercises from water exercises
9990845|NCT01447264|Active Comparator|Water exercises|The patients of this group will perform the same exercises from land exercises
9990846|NCT01447264|No Intervention|Control group|No intervention will be recommended
9990847|NCT01447277|Experimental|Femoral and Sciatic Block|Administration of preoperative femoral and sciatic nerve blocks
9990848|NCT01447277|Other|Femoral Block Only|Administration of a femoral nerve block prior to surgery
9990849|NCT01447290||Women being evaluated for preeclampsia|
9990850|NCT01447303||Outcomes following viscosupplemantation|Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
9990851|NCT01447316||Bariatric surgery|Patients undergoing bariatric surgery for weight loss.
9990852|NCT01447329|Experimental|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
9990853|NCT01447329|Placebo Comparator|standard|placebo
9990854|NCT01447355|Experimental|Prevention (cholecalciferol)|Participants receive cholecalciferol PO twice weekly for up to 8-9 weeks.
9990855|NCT01447368|Experimental|Cinacalcet treatment|Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
9990856|NCT01447368|Active Comparator|Surgical total parathyroidectomy|Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
9990857|NCT01447381||mycophenolate mofetil|Moderate to severe atopic dermatitis being treated with systemic mycophenolate mofetil
9990858|NCT01447381||cyclosporine|Moderate to severe atopic dermatitis being treated with systemic cyclosporine
9990859|NCT01447381||azathioprine|Moderate to severe atopic dermatitis being treated with systemic azathioprine
9990860|NCT01447381||methotrexate|Moderate to severe atopic dermatitis being treated with systemic methotrexate
9990861|NCT01447394|Experimental|Arm 1: Pegylated Interferon Lambda + Ribavirin|
9990862|NCT01447394|Active Comparator|Arm 2: Pegylated Interferon Alfa-2a + Ribavirin|
9990863|NCT01447459|Experimental|Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 months (t2), and 3 months (t3) after enrollment.~This group will also receive reinforced asthma education via telephone at 2 weeks, 1 month, and 3 months after enrollment."
9990864|NCT01447459|No Intervention|No Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 month (t2), and 3 months (t3) after enrollment.~This group will not receive reinforcing of the asthma education at 2 weeks, 1 month, and 3 months after enrollment."
9990865|NCT01447472|Experimental|MDMA|One single dose of MDMA (1.5 mg/kg; range 75-100 mg)
9990866|NCT01447485|Experimental|Valsartan 20 mg or 40 mg|
9990867|NCT01447498|No Intervention|Control group|
9892222|NCT04967885|Experimental|Immediate Intervention|Participants in the Immediate Intervention condition will create their Implementation Intention (II) messages before the two-week EMA + EMI-II period begins. During the EMA + EMI-II period, participants will complete five daily EMAs, and they will also complete weekly assessments reporting their past week cigarette smoking as a distal outcome and rating intervention acceptability. Following the EMA + EMI-II period, participants will enter a two-week follow-up period. During this time, participants will not receive any messages, but will report past week smoking on a weekly basis.
9892223|NCT04967885|Active Comparator|Waitlist|Participants randomized to the Waitlist control condition will begin with a two-week no intervention condition during which they will report past week smoking on a weekly basis but will not receive any other intervention components. At the end of the two-week waitlist control period, participants will begin the two-week EMA plus EMI-II period. During the EMA plus EMI-II active study period, participants will complete five daily EMAs and weekly assessments to report their past week cigarette smoking and rate intervention acceptability. No follow-up is planned for the wait list control condition.
9892224|NCT04967508|Experimental|SB17 (Proposed Ustekinumab Biosimilar)|
9892225|NCT04967508|Active Comparator|Stelara® (Ustekinumab)|
9892226|NCT04966923||Breast Cancer and documented pathogenic variant TP53|Documented pathogenic or likely pathogenic variants of TP53 were identified using blood DNA colection and breast cancer diagnosis by histological confirmation. All patients met Revised Chompret criteria or Li Fraumeni like syndrome or family member of carrier TP53
9892227|NCT04966923||Breast Cancer and no documented pathogenic variants in genetic test|Control with patients breast cancer and no pathogenic variants documented in a genetic test
9892228|NCT04966013|Active Comparator|RD-X19 Device, Dose A|RD-X19. Investigational device that uses safe electromagnetic energy to target the oropharynx.
9892229|NCT04966013|Active Comparator|RD-X19 Device, Dose B|RD-X19. Investigational device that uses safe electromagnetic energy to target the oropharynx.
9892230|NCT04966013|Sham Comparator|Sham Device|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
9892231|NCT04965857||Slides from the German Co-Screening program|From 25,000 LBC slides (ThisPrep, Hologic Inc., USA) from the German Co-screening program evaluated using the Genius Digital cytology system all abnormal findings according to Munich III groups (II-p - V) and each 10th normal slide (Munich III group I and II) will be selected for the prospective evaluation by manual microscopy.
9892232|NCT04965714|Experimental|Treatment (nivolumab, pegargiminase)|Patients receive nivolumab IV over 30 minutes on day 1 and pegargiminase IM at 2 days before day 1 of cycle 1, day 8 of cycle 1, days 1 and 8 of cycle 2, and day 1 of cycle 3. Treatments repeat every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection at week 7. A cycle is 14 days.
9892233|NCT04963036|Experimental|Entropy and NOL-Guided Goal Directed Anesthesia|
9892234|NCT04963036|Active Comparator|Standard of Care Group (Entropy and blinded NOL)|
9892235|NCT04960579|Experimental|P-BCMA-ALLO1 CAR-T cells (single dose)|Dose escalation cohorts, administered intravenously as a single dose following a conditioning chemotherapy regimen. Rimiducid may be administered as indicated.
9892236|NCT04958798|Experimental|Culturally Centered MOUD Implementation|Culturally centered program-level implementation intervention to increase the use of medications for opioid use disorder in healthcare and treatment settings serving AI/AN communities
9892237|NCT04954859|Experimental|Nucleos(t)ide analogue (NA) naïve participants|Participants who have not received NA therapy during the parent study. No study treatment will be administered in this study.
9892238|NCT04954859|Experimental|NA controlled participants|Participants who entered the parent study on stable NA therapy and remained on NA therapy for the duration of the treatment and follow-up periods. NA cessation at 3 months. No study treatment will be administered in this study.
9892239|NCT04951089|Experimental|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation i-gel supraglottic device insertion for oxygenation and ventilation
9892240|NCT04951089|Experimental|Air-Q SP 3G supraglottic insertion for oxygenation|Air-Q SP 3G supraglottic device insertion for oxygenation Air-Q SP 3G supraglottic device insertion for oxygenation and ventilation
9892241|NCT04943731|Other|Provox Life™|"Phase 1: Provox Life™. Like-for-like transition from Provox (or other brand) to Provox Life™ under guidance from Speech Pathologist who will assess when the participant is ready to commence the 6 week study observation period.~Phase 2: Provox Life™ with Day/Night regimen. Establishment of optimal day/night routine under guidance of Speech Pathologist who will assess when the participant is ready to commence the 6 week observation period."
9892242|NCT04940780|Active Comparator|Patient Preference Arm|patients who specify their preference for either acupuncture or touch therapy
9892243|NCT04940780|Active Comparator|Randomized Treatment Arm|with no preference, to be randomly allocated to either the acupuncture or touch-therapy subgroup
9892244|NCT04940624|Experimental|Soticlestat|"Participants weighing <45 kg: Soticlestat, mini-tablets, at the dose of 40 mg to 200 mg, orally or via gastrostomy tube (G-tube) or percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) based on the body weight up to 4 weeks in Titration Period. Participants will continue to receive the dose that they are on at the end of the Titration Period, for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). The dose will be tapered down if participants decide to discontinue the treatment.~Participants weighing ≥45 kg: Soticlestat mini-tablets or tablets with a starting dose of 100 mg BID followed by 200 mg BID and, then 300 mg BID, up to 4 weeks in Titration Period. Participants will continue to receive 300 mg BID for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). The dose will be tapered down if participants decide to discontinue the treatment."
9990868|NCT01447498|Active Comparator|Screening and risk assessment|
9990869|NCT01447537|Active Comparator|Exercise, relaxation|Active comparator: Exercise + relaxation Patients will perform exercise + relaxation for 3 months
9990870|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
9990871|NCT01447550||Bosentan|Bosentan
9990872|NCT01447563|Experimental|Clopidogrel tablets 75mg|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
9990873|NCT01447563|Experimental|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
9990874|NCT01447589|Experimental|Nelfinavir plus radical radiotherapy|Nelfinavir given in combination with radical RT
9990875|NCT01447602|Experimental|Interpersonal psychotherapy (IPT-A)|Interpersonal psychotherapy for depressed adolescents which focuses on identifying problematic relationships connected to onset or maintenance of depression and suicidal behavior. The treatment teaches skills such as communication and problem-solving to the adolescent and parents.
9990876|NCT01447615|Experimental|Bridges|
9990877|NCT01447615|Experimental|Bridges PLUS|
9990878|NCT01447615|Other|Usual Care|
9990879|NCT01447641||Cluster headache|Cluster headache sufferers (both chronic and episodic)
9990880|NCT01447654|Active Comparator|Losartan|
9990881|NCT01447654|Placebo Comparator|Placebo|
9990882|NCT01447667|Experimental|Magnetic resonance elastography|Magnetic resonance elastography before radiofrequency ablation therapy will be performed.
9990883|NCT01447680||Blood samples, low risk population|
9990884|NCT01447680||Blood samples, high risk population|
9990885|NCT01447680||Blood samples, known HIV positive|
9990886|NCT01447732|Experimental|Part 1|Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
9990887|NCT01447732|Experimental|Part 2|Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
9990888|NCT01447745||Observational, longitudinal study|Adult men and women representative of the population of asymptomatic adult men and women aged from 35-65 years living in the Québec City metropolitan area
9990889|NCT01447758|Experimental|LEO 29102 2,5 mg/g cream|
9990890|NCT01447758|Placebo Comparator|LEO 29102 Cream Vehicle|
9990891|NCT01447771|Experimental|Lifestyle counseling|Decision control preference intervention
9990892|NCT01447784|Placebo Comparator|Placebo|
9990893|NCT01447784|Experimental|ToleroMune HDM Dose 1|
9990894|NCT01447784|Experimental|ToleroMune HDM Dose 2|
9990895|NCT01447784|Experimental|ToleroMune HDM Dose 3|
9797668|NCT01603277|Experimental|Anti-GM-CSF Monoclonal Antibody 400mg|
9797669|NCT01603277|Placebo Comparator|Normal Saline|
9797670|NCT01603355|Experimental|Tocilizumab|
9990896|NCT01447797|Experimental|HCP0912|Irbesartan/Atorvastatin combination tablet
9990897|NCT01447797|Active Comparator|Irbesartan and Atorvastatin|coadministration of irbesartan and atorvastatin
9990898|NCT01447810|Experimental|Treatment|
9990899|NCT01447836||Sepsis|Sepsis patients who are admitted to SICU of our clinical center.
9990900|NCT01447836||Control|Postoperative patients who underwent abdominal surgery and then was directly transferred to SICU of our clinical center.
9990901|NCT01447862|Active Comparator|Vernakalant|Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
9990902|NCT01447862|Active Comparator|Ibutilide|Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
9990903|NCT01447901||previously treated LPLD Cohort|Subjects in Cohort 1 (previously treated LPLD Cohort) must have received AMT-011 during Studies CT-AMT-011-01 or -02
9990904|NCT01447901||untreated LPLD control Cohort|Subjects in Cohort 2 (untreated LPLD control Cohort)) may have completed study PREPARATION-02 or known patients with genetically confirmed LPLD
9990905|NCT01447901||normal healthy control Cohort|Volunteers in Cohort 3 (normal healthy control Cohort) must not have LPLD
9990906|NCT01447940|Placebo Comparator|Conventional Care|Patients will have conventional care with 2 standard visits (inclusion and 12 months) + HbA1c measure at 6 months. Patients won't use Meos ePortal
9990907|NCT01447940|Experimental|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
9990908|NCT01447953|Experimental|Activity targeted pain rehabilitation|A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
9990909|NCT01447953|Active Comparator|Treatment as usual|Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.
9998210|NCT01516151|Active Comparator|Group B|1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week
9998211|NCT01516151|Active Comparator|Group C|2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8
9998212|NCT01516151|Other|Group D|Standard of care
9892245|NCT04940624|Placebo Comparator|Placebo|Soticlestat placebo-matching mini-tablets or tablets, orally or via G-tube or PEG tube, BID, up to 4 weeks in the Titration Period. Participants will continue to receive the soticlestat placebo-matching mini-tablets or tablets for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks. Soticlestat matching tapering will be done to maintain the blind if participants decide to discontinue the treatment.
9892246|NCT04939467|Experimental|Pirfenidone & BLD-0409|Following an overnight fast, subjects will be administered IP in a fixed sequence.
9892247|NCT04939467|Experimental|Nintedanib & BLD-0409|Following an overnight fast, subjects will be administered IP in a fixed sequence.
9892248|NCT04938960||Biological Heart Valve|Participants receiving a biological heart valve
9892249|NCT04938960||Mechanical Heart Valve|Participants receiving a mechanical heart valve
9892250|NCT04938427|Experimental|Soticlestat|"Participants weighing <45 kg: Soticlestat, mini-tablets, at the dose of 40 mg to 200 mg, orally or via gastrostomy tube (G-tube) or percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) based on body weight up to 4 weeks in Titration Period. Participants will continue to receive the dose that they are on at the end of the titration period, for 12 weeks in the Maintenance Period. Total duration of the treatment will be up to 16 weeks (Treatment Period). Dose will be tapered down if participants decide to discontinue the treatment.~Participants weighing ≥45 kg: Soticlestat mini-tablets or tablets with a starting dose of 100 mg BID followed by 200 mg BID and, then 300 mg BID, up to 4 weeks in Titration Period. Participants will continue to receive 300 mg BID for 12 weeks in the Maintenance Period. Total duration of the treatment will be up to 16 weeks (Treatment Period). Dose will be tapered down if participants decide to discontinue the treatment."
9892251|NCT04938427|Placebo Comparator|Placebo|Soticlestat placebo-matching mini-tablets or tablets, orally or via G-tube or PEG tube, BID, up to 4 weeks in the Titration Period. Participants will continue to receive the soticlestat placebo-matching mini-tablets or tablets for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). Soticlestat matching tapering will be done to maintain the blind if participants decide to discontinue the treatment.
9892252|NCT04938232|Experimental|Stable disease after previous therapy (Cohort 1)|"Participants will receive a combination of Ipilimumab and Nivolumab, followed by a maintenance regimen of Nivolumab.~Combination: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles~Maintenance: Nivolumab every 4 weeks for up to 15 study cycles"
9892253|NCT04938232|Experimental|Disease Progression after previous therapy (Cohort 2)|"Participants will receive Ipilimumab alone and depending on response will receive either a maintenance course of Ipilimumab or a course of Nivolumab and Ipilimumab in combination followed by a maintenance course of Ipilimumab~Ipilimumab Monotherapy: Every 3 weeks for 4 study cycles~Complete Response/Partial Response: Maintenance Ipilimumab every 12 weeks for 8 cycles~Stable or Progressive Disease Response: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles, followed by Maintenance Ipilimumab every 12 weeks for 7 cycles"
9892254|NCT04932447|Experimental|Training Group A|Participants will perform their respiratory training (high-intensity, low-volume IMST) on a hand-held respiratory training device.
9892255|NCT04932447|Sham Comparator|Training Group B|Participants will perform their respiratory training (low-intensity, low-volume IMST) on a hand-held respiratory training device.
9892256|NCT04931563|Placebo Comparator|placebo|Placebo will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
9892257|NCT04931563|Active Comparator|anifrolumab|Anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
9892258|NCT04929938|Experimental|Inmediate UP plus Treatment As Usual|Treatment As Usual Plus Inmediate Virtual group Therapy applying the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. The treatment consists in 15 weekly sessions of 120 minutes that combines cognitive-behavioural techniques to improve emotional self-regulation skills.
9892259|NCT04929938|Active Comparator|Waiting list plus Treatment As Usual|A waiting list for treatment with delayed UP after 7 months while receiving the treatment as usual (WL + TAU).
9892260|NCT04928222|Placebo Comparator|Placebo-containing MNA|A placebo-containing array will be applied to subjects.
9892261|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 50 µg|A doxorubicin-containing array of 50 µg will be applied to subjects.
9892262|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 100 µg|A doxorubicin-containing array of 100 µg will be applied to subjects.
9892263|NCT04928222|Active Comparator|Doxorubicin-containing MNA - 200 µg|A doxorubicin-containing array of 200 µg will be applied to subjects.
9892264|NCT04928222|Experimental|Placebo MNA for Training|Training phase for application of arrays
9892265|NCT04926831|Experimental|Cohort A|Participants with NSCLC with MET exon 14 skipping mutations, irrespective of MET gene copy number (GCN) will take 400 mg tablet orally twice per day
9892266|NCT04926831|Experimental|Cohort B|Participants with NSCLC with high level MET amplification will take 400 mg tablet orally twice per day
9892267|NCT04925700|Experimental|Probiotic Lozenge|
9892268|NCT04925700|Placebo Comparator|Placebo Lozenge|
9892269|NCT04921449|Experimental|Embedded ED Physical Therapy (NEED-PT)|An ED physical therapist will be embedded with the primary treatment team to evaluate patients presenting with low back pain at the beginning of the overall treatment course. The physical therapist will utilize a clinical protocol (NEED-PT) that matches the patient's history and exam findings to an appropriate treatment classification consisting of directional preference exercises, manual traction, stabilization exercises, non-thrust manipulation/mobilization, and/or psychologically informed rehabilitation. The NEED-PT intervention will supplement any usual care performed by the treating physician.
9892270|NCT04921449|Other|Usual Care|Usual care consists of any ED testing or treatment not involving an ED physical therapist in accordance with the treating physician's usual and customary practice. This could include diagnostic imaging, patient education and reassurance, and administration and/or prescribing of analgesic medications.
9892271|NCT04920578|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts (Double-blind)|Healthy male participants will receive JNJ-69095897 or matching placebo orally in Cohorts 1-8.
9892272|NCT04920578|Experimental|Part 2: Single Dose Cohort (Open-label)|Healthy male participants will receive JNJ-69095897 orally in Cohort 9.
9892273|NCT04920578|Experimental|Part 3: Single or Divided Dose Cohort (Double-blind)|Healthy male participants and women of non-childbearing potential (WONCBP) will receive JNJ-69095897 or matching placebo orally in Cohort 10.
9892274|NCT04917796|Experimental|Electroacupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
9892275|NCT04917796|Placebo Comparator|Sham Acupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
9892276|NCT04912804||COVID-19 Patient|Patient discharged from a conventional short-stay hospitalization unit.
9892277|NCT04908605|Active Comparator|Mirtazapine group (Group I) (n=55)|
9892278|NCT04908605|Active Comparator|Melatonin group (Group II) (n=55)|
9892279|NCT04908605|Placebo Comparator|Placebo group (Group III) (n=55)|
9892280|NCT04901689|Experimental|Leronlimab (700 mg)|Leronlimab 700 mg intravenously once a week (up to 4 doses) until hospital discharge
9892281|NCT04901689|Placebo Comparator|Placebo|Placebo intravenously once a week (up to 4 doses) until hospital discharge
9892282|NCT04901676|Experimental|Leronlimab|Leronlimab subcutaneously once a week (up to 4 doses) until hospital discharge. The first dose will be of 700 mg, followed by weekly doses of 350 mg.
9892283|NCT04901676|Placebo Comparator|Placebo|Placebo subcutaneously once a week (up to 4 doses) until hospital discharge
9892284|NCT04898686|Active Comparator|Probiotic group|daily use of a probiotic chewable for 8 weeks
9892285|NCT04898686|Placebo Comparator|Placebo group|daily use of the placebo chewable for 8 weeks
9892286|NCT04897074|Experimental|AKL-T01|Digital Treatment
9892287|NCT04895046|Experimental|Investigational Group|"Cycle 1-4 (cycle length 4 weeks): Niraparib 300 mg taken orally on days 1-21 and Dostarlimab 500 mg intravenously on day 1~Cycle 5 and above (cycle length 3 weeks): Niraparib 300 mg taken orally on days 1-21 and 1000 mg intravenously on day 1 of every other cycle"
9892288|NCT04894903|Experimental|Intervention|"Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention.~."
9892289|NCT04894903|No Intervention|Usual Care|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care).
9892290|NCT04888481|Experimental|68Ga-HA-DOTATATE PET/CT scan|2.64 MBq/kg (minimum 37 MBq, maximum 250 MBq) 68Ga-HA-DOTATATE intravenous single-dose administration for PET/CT imaging
9932344|NCT00947999||Subjects with SCI and No Chronic Pain|Subjects in particular group will have a diagnosis of SCI and not have chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
9932345|NCT00948012||Patients without pulmonary hypertension|Patients with sickle cell with normal response of pulmonary artery pressure to exercise
9932346|NCT00948012||Exercise-induced pulmonary hypertension|Patients with sickle-cell anemia with exercise-induced pulmonary hypertension.
9932347|NCT00948038|Active Comparator|Soy|Soy-based supplement to normal diet
9892291|NCT04887688|Experimental|Group A: Wound treated using exciflex|Intervention treated wounds in Group A participants will be covered using the exciflex bandage which will be activated to deliver ES using a 10% duty cycle, i.e. ES will be active for 1 minute out of every 10 minutes. ES will be delivered for up to 10 weeks or until the wound is healed for 3 days. The exciflex bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. The exciflex power/control module will then be transferred to a new sterile flexible substrate and the exciflex bandage reapplied to the wound.
9892292|NCT04887688|No Intervention|Group B: Wound treated using standard of care|Control treated wounds in Group B participants will be covered with a standard of care hydrogel dressing such as Restore (Hollister Inc) together with Tegaderm . The SoC dressing will be used for up to 10 weeks or until the wound is healed for 3 days. The SoC bandage will be changed when indicated clinically or every 5 days, whichever is sooner. At each bandage change, wound status monitored as described above, specifically a 3D digital image and wound swabs will be obtained. A fresh sterile SoC bandage will then be reapplied to the wound.
9892293|NCT04885998|Experimental|Phase 1: Dose Exploration|The recommended phase 2 target dose (RP2D) of AMG 757 in combination with AMG 404 will be estimated using a modified toxicity probability interval (mTPI-2) design. A combination RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an maximum tolerated dose (MTD).
9892294|NCT04885998|Experimental|Phase 2: Dose Expansion|Participants will receive the RP2D of AMG 757 in combination with AMG 404 identified in Phase 1 (dose exploration) of the study.
9892295|NCT04884295|Experimental|XVR011|Single Ascending Dose with 3 dose cohorts: low dose - medium dose - high dose (Phase 1)
9892296|NCT04883424|Experimental|Diabetes Education Program Based on Health Belief Model|Experimental group After the diabetic patients were determined according to the research criteria, they were randomly divided into intervention and control groups. First, pre-tests were applied to diabetics and family members in the experimental group. Diabetes Education Program Based on Health Belief Model It will be administered in two sessions to people with diabetes and their family members. This program; definition of diabetes, the importance of healthy nutrition in diabetes, the importance of exercise, the importance of regular medication, fingertip blood glucose measurement, acute and chronic problems that may develop in diabetic patients, diabetic foot care, personal self-care and family support. A reminder text message will be sent twice a week to diabetics and family members in the intervention group to manage their diabetes well. Once a month, both the diabetic patient and their family member will be called by phone for counseling.
9892297|NCT04883424|No Intervention|Control Group|First of all, pre-tests will be applied to diabetic patients in the control group. Diabetics in this group will not be intervened and their final tests will be made 3 months after the pre-test.
9892298|NCT04879225|Experimental|E-liquid Availability|Flavor availability is manipulated
10212012|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2+PDL2 Pembro Schedule 2: Arm F|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 in combination with pembrolizumab at pembrolizumab dose level 2 (PDL2). Both quavonlimab and pembrolizumab will be administered according to Schedule 2 for up to 24 months on study.
10212013|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2 Monotherapy: Arm G|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 according to Schedule 2 for up to 24 months on study. Participants who demonstrate radiographically confirmed progressive disease in Arm G will be eligible to receive combination therapy with pembrolizumab (crossover).
9892301|NCT04874857|Experimental|Intervention group (Aromatherapy group)|With a mixture of Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L. essential oils, the foot and lower leg will be massaged for three sessions a week for 30 minutes in each session for four weeks.
9892302|NCT04874857|Experimental|Placebo group|The foot and lower leg will be massaged with baby oil for four weeks, three sessions a week, 30 minutes in each session.
9892303|NCT04874857|No Intervention|Control group|No application will be made in addition to standard HD treatment.
9892304|NCT04873765|Experimental|Pegfilgrastim Megalabs|Pegfilgrastim injectable 6 mg in a single subcutaneous application.
9892305|NCT04873765|Active Comparator|Pegfilgastrim Neulastim|Neulastim injectable 6 mg in a single subcutaneous application.
9892306|NCT04871594|Experimental|Cohort A1: domatinostat + nivolumab|Day 1-56: domatinostat 200 mg BID Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg
9892307|NCT04871594|Active Comparator|Cohort A 2: nivolumab|Day 1: nivolumab 240 mg Day 22: nivolumab 240 mg Day 43: nivolumab 240 mg
9892308|NCT04871594|Experimental|Cohort B1: domatinostat + ipilimumab + nivolumab|Day 1-56: domatinostat 200 mg QD Day 1: ipilimumab 240 mg Day 22: ipilimumab 240mg + nivolumab 80 mg Day 43: nivolumab 240 mg
9892309|NCT04871594|Active Comparator|Cohort B2: ipilimumab + nivolumab|Day 1: ipilimumab 240 mg Day 22: ipilimumab 240mg + nivolumab 80 mg Day 43: nivolumab 240 mg
9892310|NCT04871412|Experimental|Integrative Care (Treatment)|Participants in the Integrative arm will receive standard surgical and oncologic care at The Ottawa Hospital plus complementary care guided by a naturopathic doctor at The Centre for Health Innovation
9892311|NCT04871412|No Intervention|Standard Care (Control)|Participants in the control arm will receive standard surgical and oncologic care at The Ottawa Hospital
10212014|NCT03179436|Experimental|Coformulation: Pembrolizumab/Quavonlimab Schedule 2: Arm I|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants with advanced/metastatic solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
10212015|NCT03179436|Experimental|Coformulation Phase in China: Pembrolizumab/Quavonlimab Schedule 2: Arm K|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants in mainland China with advanced solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
9892315|NCT04865536|Active Comparator|Cohort 1 TBI-223 1800 mg, fasting|1800 mg, fasting
9892316|NCT04865536|Active Comparator|Cohort 1 TBI-23 1800, fed|TBI-23 1800, fed
9892317|NCT04865536|Placebo Comparator|Cohort 1 Placebo, fed|Placebo, fed
9892318|NCT04865536|Placebo Comparator|Cohort 1 Placebo fasting|Placebo fasting
9892319|NCT04865536|Active Comparator|Cohort 2 TBI-223, 2400mg,fed|2400mg,fed
9892320|NCT04865536|Active Comparator|Cohort 2 TBI-223, 2400 mg fasting|2400 mg fasting
9892321|NCT04865536|Placebo Comparator|Cohort 2 Placebo, fed|Placebo, fed
9892322|NCT04865536|Placebo Comparator|Cohort 2 Placebo, fasting|Placebo, fasting
9892323|NCT04865536|Active Comparator|Cohort 3 3000mg, fed|3000mg, fed
9892324|NCT04865536|Placebo Comparator|Cohort 3 placebo, fed|placebo, fed
9892325|NCT04855201|Experimental|ASP0367|Participants will receive ASP0367 once daily in the morning for 6 weeks.
9892326|NCT04855201|Placebo Comparator|Placebo|Participants will receive placebo once daily in the morning for 6 weeks.
9892327|NCT04852601|Experimental|ToolboxDetect Strategy|"All practices randomized to the intervention arm will implement the ToolboxDetect battery as the standard of care routine cognitive assessment to fulfill the Medicare Annual Wellness Visit (AWV) requirement. The 7-8 minute ToolboxDetect battery contains self-administered versions of the NIH ToolBox Picture Sequence Memory Test (PSM) and the NIH ToolBox Dimensional Change Card Sorting (DCCS). PSM measures episodic memory and DCCS tests executive functioning.~The validated ToolboxDetect application will be imparted either as an application on an iPad or on a PC desktop/laptop computer commonly found in a clinical exam room for EHR access."
9892328|NCT04852601|No Intervention|Enhanced Usual Care|"At Northwestern Medicine, cognitive assessments included in Annual Wellness Visits or other routine or sick/problem-based visits vary by practice and also by clinician. However, the choice of test was limited to either a Mini-Cog©, Montreal Cognitive Assessment (MoCA), or Mini Mental Status Exam (MMSE).~While we will not make any explicit recommendations to these practices with regard to their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to an Epic SmartData element, which will allow the clinician to record the results of the test as discrete data (which can then be queried), and that 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will also be provided to each clinic's medical leadership."
9892329|NCT04839952|Experimental|Healthy Lifestyles Intervention Arm|Participants will receive the healthy lifestyles intervention.
9892330|NCT04839952|Active Comparator|Education-Only Control Arm|Participants will receive the education-only intervention.
9892331|NCT04837820|Experimental|Acupuncture|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
9892332|NCT04837820|Placebo Comparator|Sham Acupuncture (SA)|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
9892333|NCT04837820|Experimental|Wait-List Control|During the 26-week waiting period, the CRC will contact patients in the WLC group at the same frequency as the acupuncture groups with respect to data collection. Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians. WLC patients will be compensated with real acupuncture treatments after Week 26 (end of study).
9932348|NCT00948038|Experimental|Milk|Milk-based supplement to normal diet
9932349|NCT00948051|Experimental|Fructo-oligosaccharides|
9932350|NCT00948051|Placebo Comparator|Placebo|
9932351|NCT00948077|Active Comparator|Treatment A|"Study agents (Rifater+EMB) will be given approximately 45 minutes prior to the breakfast."
9932352|NCT00948077|Experimental|Treatment B|"Study agents (Rifater+EMB) will be given approximately 45 minutes after the breakfast is finished."
9932353|NCT00948103|Placebo Comparator|Oxygen|
9932354|NCT00948103|Active Comparator|Nitrous Oxide|
9932355|NCT00948116||Diabetes mellitus, renal impairment|Patients with both diabetes mellitus and eGFR <60 ml/min
9932356|NCT00948129|Active Comparator|Group I (standard care)|Participants undergo standard of care smoking cessation intervention consisting of brief advice to quit smoking, NRT, and self-help written materials.
9932357|NCT00948129|Experimental|Group II (enhanced care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number and supportive text messages daily for 12 weeks.
9932358|NCT00948129|Experimental|Group III (intensive care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number, supportive text messages daily for 12 weeks, and a smoking cessation telephone call over 15 minutes weekly for 12 weeks.
9932359|NCT00948181||Surgeon|To detect the degree of intraoperative stress, venous blod will be drawn from one surgeon during 8 pheochromocytoma resections.
10212016|NCT03173456|Active Comparator|oxycodone/acetaminophen (APAP)|5 mg oxycodone + 325 mg acetaminophen
10212017|NCT03173456|Active Comparator|hydrocodone/APAP|5 mg hydrocodone + 300 mg acetaminophen
10212018|NCT03173456|Active Comparator|codeine/APAP|30 mg codeine + 300 mg acetaminophen
10212019|NCT03173456|Active Comparator|400 ibuprofen/APAP|400 mg ibuprofen + 1000 mg acetaminophen
10212020|NCT03173456|Active Comparator|800 ibuprofen/APAP|800 mg ibuprofen + 1000 mg acetaminophen
10212021|NCT03167281|No Intervention|tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.
9892334|NCT04836494|Experimental|BBP-671 for SAD|The SAD portion of the study will consist of up to 8 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
9892335|NCT04836494|Placebo Comparator|Placebo for SAD|The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
9892336|NCT04836494|Experimental|BBP-671 for MAD|The MAD portion of the study will consist of up to 6 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
9892337|NCT04836494|Placebo Comparator|Placebo for MAD|The MAD portion of the study will consist of up to 6 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
9892338|NCT04836494|Experimental|BBP-671 for SAD Food Effect|Eight (8) healthy male or female adult subjects will be randomized to receive BBP-671.
9892339|NCT04836494|Experimental|BBP-671 for PA and MMA Patients|Up to eight (8) PA patients and eight (8) MMA patients will receive BBP-671.
9892340|NCT04834414|Active Comparator|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
9892341|NCT04834414|Experimental|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
9892342|NCT04833192||experimental group|patients diagnosed with subclinical hypercortisolism as assessed by an endocrinologist.
9892343|NCT04833192||control grpup|patients diagnosed with nonfunctional adrenal adenoma as assessed by an endocrinologist.
9892344|NCT04833140|Active Comparator|Estradiol|"Estradiol in the form of a transdermal patch 100 mcg daily (Vivelle-Dot generic).~Women with an intact uterus will also receive progesterone (100 mg) in the form of a vaginal tablet (Endometrin, Ferring Pharmaceuticals, Inc.) inserted daily for endometrial protection"
9892345|NCT04833140|Placebo Comparator|Placebo|Placebo patch (containing no estradiol) Women with an intact uterus will also receive vaginal placebo capsules (containing no progesterone)
9892346|NCT04826003|Experimental|Part I: Dose-escalation of RO7122290|The dose-escalation of RO7122290 will use a QW dosing schedule of RO7122290 in combination with a Q3W dosing interval for cibisatamab with obinutuzumab pre-treatment. The starting dose for RO7122290 will be 35 mg, which represents the human equivalent dose for the minimal pharmacologically active dose (1 mg/kg) in mice.
9892347|NCT04826003|Experimental|Part II: Dose-expansion of RO7122290|Part II of this study will evaluate selected dose levels of RO7122290 from Part I (a QW RO712290 administration in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment) in a Q3W regimen in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment.
9892348|NCT04819841|Experimental|GPH101 Drug Product|GPH101 Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.
9892349|NCT04819659|No Intervention|Group Control|Without pharyngeal pack insertion
9892350|NCT04819659|Experimental|Group Pharyngeal packing (Group PP)|Pharyngeal pack insertion after endotracheal intubation
9892351|NCT04815291|Experimental|Device|Receives SCOUT at biopsy
9892352|NCT04814082|Active Comparator|Medial-Pivot Knee System|Total Knee Arthroplasty will be done by implanting the MicroPort Medial Pivot Knee System into subjects.
9892353|NCT04814082|Active Comparator|Single Radius Design Total Knee System|Total Knee Arthroplasty will be done by implanting the Stryker Triathlon Tritanium Knee System into subjects.
9892354|NCT04810078|Experimental|Arm A: Subcutaneous Nivolumab|
9892355|NCT04810078|Active Comparator|Arm B: Intravenous Nivolumab|
9892356|NCT04808934||Non-Valvular Atrial Fibrillation (NVAF) Adults|Adult patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban or VKAs between June 16, 2014 and December 31, 2018.
9892357|NCT04806035|Experimental|TG-1801|TG-1801 Single Agent
9892358|NCT04806035|Experimental|TG-1801 + Ublituximab|TG-1801 in combination with ublituximab
9892359|NCT04805411|Experimental|High-dose arm|600mg for 1st dose, and then 300 mg for 2-8nd doses, every 2 weeks, SC
9892360|NCT04805411|Experimental|low-dose arm|300mg for 1st dose, and then 150 mg for 2-8nd doses, every 2 weeks, SC
9892361|NCT04805411|Placebo Comparator|placebo|placebo for 1-8 doses, every 2 weeks, SC
9892362|NCT04805398|Experimental|CM310|CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
9892363|NCT04805398|Placebo Comparator|Placebo|Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.
9892364|NCT04804553|Experimental|Apremilast|Participants will receive apremilast in the double-blind 16 week treatment phase. Then the participants will continue to receive apremilast in the active 36 weeks treatment phase.
9892365|NCT04804553|Placebo Comparator|Placebo to Apremilast|Participants will receive the matching placebo in the double-blind 16 week treatment phase. Then the participants will receive apremilast in the active 36 weeks treatment phase.
9892366|NCT04801771|Experimental|Subjects implanted with Inspire UAS System|Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.
9892367|NCT04800809||Children and young adults with SCD and stroke|"Participants with SCD confirmed with hemoglobin electrophoresis or high pressure liquid chromatography (HPLC)~Age 5 to 26 years old~Present within three months of stroke event that is diagnosed as a stroke by the local health care provider~Medical records are available for review for the stroke event that occurred within 3 months"
9935983|NCT02882282|Active Comparator|Arm A (observation)|Patients undergo observation.
9892368|NCT04800809||The participants in SPIN and SPRING and SPRINT Trials|The participants enrolled in our previous primary and secondary stroke prevention trials in northern Nigeria; SPIN and SPRING (children with SCD with normal and abnormal TCD measurements; NCT02560935 and NCT01801423), SPRINT (children with SCD and strokes; NCT02675790) Trials for ascertainment of incidences rates of strokes in children and young adults receiving standard care after completion of primary stroke prevention trials. For this purpose, we will enroll these participants to follow their progress after completion of the trials. No intervention is planned, only to follow the participants with and without abnormal TCD measurements and with and without strokes.
9892369|NCT04799249|Experimental|Trilaciclib + gemcitabine + carboplatin|Trilaciclib (240mg/m2) + gemcitabine (1000 mg/m2) and carboplatin (AUC 2)
9892370|NCT04799249|Placebo Comparator|Placebo + gemcitabine + carboplatin|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib.
9892371|NCT04795596|Experimental|surgery + chemotherapy|surgical resection for recurrent platinum resistant ovarian cancer followed by second line chemotherapy as per the investigator's choice
9892372|NCT04795596|Active Comparator|chemotherapy alone|second line chemotherapy according to investigator's choice
9892373|NCT04795466|Experimental|Canakinumab|increasing doses of sub-cutaneous injections
9892374|NCT04795466|Placebo Comparator|Placebo|Matching placebo sub-cutaneous injections
9892375|NCT04787614||Home-based providers|Individuals who provided paid care for children under the age of 13 in a residential setting as of 2019
9892376|NCT04787614||Center-based providers|Providers who cared to children ages 0 through 5 years of age (not yet in kindergarten) in a non-residential setting as of 2019
9892377|NCT04787614||Center-based workforce|Individuals employed in center-based child care programs working directly with children in classrooms as of 2019
9892378|NCT04786548|Experimental|Celecoxib Treatment|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment
9892379|NCT04786275||Tetanic stimulation|Single arm study
9892380|NCT04785820|Experimental|RO7121661|
9892381|NCT04785820|Experimental|RO7247669|
9892382|NCT04785820|Active Comparator|Nivolumab|
9892383|NCT04785651|Experimental|Tranexamic arm|Patients in this arm will undergo to a tibial osteotomy in combination with the anti-fibrinolytic agent Tranexamic acid.
9892384|NCT04785651|Other|control arm|Patients in this arm will undergo to a tibial osteotomy without the use of Tranexamic acid
9892385|NCT04785092|Experimental|Treatment - All Autologous Cartilage Regeneration|
9892386|NCT04777617||WU/Barnes cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
9892387|NCT04777617||UT Southwestern cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
9892388|NCT04777201|Experimental|Faricimab|
9892389|NCT04776317|Experimental|Stage 1 (Naïve) Group 1|5 x 10^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
9892390|NCT04776317|Experimental|Stage 1 (Naïve) Group 3A|30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
9517149|NCT03309059|Placebo Comparator|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
9998213|NCT01516151|Active Comparator|Group E|4.0g total CaPre™ from baseline to week 8
9998214|NCT01516164|Active Comparator|MacIntosh|
9998215|NCT01516164|Active Comparator|McGrath MAC direct|
9892391|NCT04776317|Experimental|Stage 1 (Naïve) Group 3B|30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
9892392|NCT04776317|Experimental|Stage 1 (Naïve) Group 4|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
9892393|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 13|5 x 10^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and on or after Day 113 in participants older than 60 years of age. N=7-10
9892394|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 14|1 x 10^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
9892395|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 15|5 x 10^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
9892396|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 10A|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=5-7
9892397|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 10B|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=5-7
9892398|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 11A|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=5-7
9892399|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 11B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=5-7
9892400|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 12A|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=5-7
9892401|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 12B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=5-7
9892402|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 9|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8
9892403|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 5|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
9892404|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 6|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
9892405|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 7A|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=5-7
9892406|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 7B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=5-7
9892407|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 8A|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=5-7
9998216|NCT01516164|Active Comparator|McGrath MAC indirect|
9892408|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 8B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=5-7
9892409|NCT04770311|No Intervention|Control|In a typical Healthy Lifestyless Nutrition visit, dietitians provide medical nutrition therapy to patients and their families. This includes addressing abnormal, nutrition-related lab values and providing targeted nutrition advice (foods to include, foods to limit) in order to resolve said labs. Motivational interviewing techniques will be used to help families identify barriers to Lifestyles change and provide strategies to help overcome these barriers. Families will receive compensation per each nutritional visit.
9892410|NCT04770311|Other|Intervention|Besides the usual standard of care during the nutrition visits, participants will have guidance on a microbiome-friendly diet and will receive groceries 1 time per week for 4 weeks.
9892411|NCT04747925|Active Comparator|mulligan two leg rotation , core muscle strengthening exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
9892412|NCT04747925|Experimental|Mulligan bent leg raise technique core muscle strengthning exercises.|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
9892413|NCT04747509|Experimental|Blackburn exercises|Blackburn exercises and hot pack
9892414|NCT04747509|Active Comparator|Conventional physical therapy|Conventional physical therapy and hot pack
9892415|NCT04745832|Experimental|Rituximab plus Zandelisib|Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
9892416|NCT04745832|Experimental|Rituximab plus chemotherapy|Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles
9892417|NCT04741256|Experimental|Tracheostomy discharge protocol|"All head and neck cancer patients regardless of participation in the study will receive the standard of care: A copy of a tracheostomy education booklet and standardized discharge training for patients and their caregivers by nursing staff during their inpatient stay.~Research personnel will provide protocol training to the inpatient nurses who are to provide training to caregivers.~Pre-implementation phase: Eligible patient participants identified & healthcare utilization recorded. Nursing staff participants complete nursing survey to capture volume of tracheostomy-related questions received.~Protocol-phase: Caregiver participants will complete a survey prior to patient tracheostomy, on day of patient discharge, and one week following discharge~Post-implementation phase: Nursing staff participants will complete an additional survey similar to the one in the pre-implementation phase. EMR will be reviewed for implementation fidelity."
9892418|NCT04739696|No Intervention|Caregiver Control|biomarker analysis; questionnaire administration; survey administration; treatment as usual
9892419|NCT04739696|Experimental|Caregiver Intervention|biomarker analysis; questionnaire administration; survey administration; PsychoEducation Paced Respiration and Relaxation (PEPRR), which includes virtual one-on-one psychoeducation and stress management intervention.
9892420|NCT04739696|Experimental|Caregiver Self-Directed|biomarker analysis; questionnaire administration; survey administration; Pep-Pal web-accessible video modules of the psychoeducation and stress management intervention.
9998217|NCT01516177||Renal Transplant Recipients|Subjects who received a kidney transplant within the past 1 to 5 years
9998218|NCT01516229||Somatropin|
9892421|NCT04738942|Experimental|Vedolizumab 300 mg in UC cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
9892422|NCT04738942|Experimental|Vedolizumab 300 mg in CD cohort|Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
9892423|NCT04734145||Participants with an Undiagnosed Pulmonary Nodule|One hundred evaluable individuals aged 21 to 85 years with a single undiagnosed pulmonary nodule measuring <3 cm, clinically staged as cT1N0M0 (eighth edition of the TNM staging manual) by CT and PET scans, will be enrolled in this diagnostic study and will undergo e-nose testing. These patients must have a risk assessment profile that, according to institutional guidelines, identifies them as candidates for subsequent surgical resection of the pulmonary nodule, which will confirm the results of the breathprinting analysis.
9892424|NCT04733768|Experimental|18F-PSMA-1007 PET/CT scan|Single Arm study - all enrolled patients will undergo an experimental 18F-PSMA-1007 PET/CT scan
9892425|NCT04727281|Experimental|dialysis patients|Patients included in the study will be recruited from the dialysis units in Alexandria University Hospitals.
9892426|NCT04725071|Experimental|Immunonutrition|Participants will consume a 6oz immunonutrition drink 2 times daily for 7 days and then once a day for remaining hospital stay.
9892427|NCT04725071|Active Comparator|Conventional Supplement|Participants will consume a 6oz conventional supplement drink 3 times daily for 7 days and then once a day for remaining hospital stay.
9892428|NCT04723641|Experimental|STUDY GROUP|they received progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
9892429|NCT04723641|No Intervention|control group|received a designed physical therapy program
9892430|NCT04723576|Experimental|Stress First Aid|"The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. SFA sites will implement SFA through a train-the-trainer model."
9932360|NCT00948181||Anesthesiologist|To detect the degree of intraoperative stress, venous blood will be drawn from one anesthesiologist during 8 pheochromocytoma resections.
9932361|NCT00948181||Patients with pheochromocytoma|Venous blood will be drawn from 8 patients with pheochromocytoma during tumor resection.
9998219|NCT01516242||NovoPen® 4|
9998220|NCT01516255|Experimental|Double-blind / liraglutide|
9892431|NCT04723576|No Intervention|Usual Care|The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. UC sites will not implement SFA during the study period but will be given full access to all implementation materials following the conclusion of their participation.
9892432|NCT04721548|Placebo Comparator|Minoxidil´s Placebo|The recommended dosage is 1 ml of the solution twice a day.
9892433|NCT04721548|Experimental|Topical Minoxidil 5%|The recommended dosage is 1 ml of the solution twice a day.
9892434|NCT04719338|Experimental|participants|"Immediately after confirmation of 24 weeks SVR after the end of treatment, we will collect samples of peripheral blood from each patient into EDTA tube and test for HCV RNA in peripheral blood mononuclear cells (PBMCs) .~All patients included in this study will be subjected to full history taking and thorough clinical examination. The initial pre treatment data of the patients will be revised including body mass index (BMI), pre treatment status (naïve,experienced), pretreatment viral load by sensitive real-time HCV PCR technique, liver function tests, complete blood count, prothrombin time, international normalized ratio , Child-Pugh score, MELD score and FIB-4 score ."
9892435|NCT04708418|Experimental|Arm A (pembrolizumab)|"NEOADJUVANT PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity."
9892436|NCT04708418|Experimental|Arm B (CMP-001, pembrolizumab)|"NEOADJUVANT PHASE: Patients receive CMP-001 SC on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity."
9892437|NCT04704037|Active Comparator|Arm 1: Minimally enhanced usual care|See intervention/treatment description
9892438|NCT04704037|Experimental|Arm 2: Guideline implementation tool|See intervention/treatment description
9892439|NCT04703725|Experimental|Experimental Group|Infertile women recruited to the experimental group by randomization will be given a counseling program including psychosocial care in addition to routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care). IVF treatment
9892440|NCT04703725|No Intervention|Control Group|Routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care) IVF treatment will be applied to infertile women who are randomized to the control group.
9892441|NCT04700163|Experimental|S1 - low dose|100 mg of C144-LS and 100 mg of C135-LS, subcutaneously
9892442|NCT04700163|Experimental|S2 - mid dose|200 mg of C144-LS and 200 mg of C135-LS, subcutaneously
9892443|NCT04700163|Experimental|V1 - low dose|1.5 mg/kg of C144-LS and 1.5 mg/kg of C135-LS, intravenously
9892444|NCT04700163|Experimental|V2 - mid dose|5 mg/kg of C144-LS and 5 mg/kg of C135-LS, intravenously
9892445|NCT04700163|Experimental|V3 - high dose|15 mg/kg of C144-LS and 15 mg/kg of C135-LS, intravenously
9892446|NCT04699877|Experimental|Part 1: Participants with Severe Renal Impairment|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1
9892447|NCT04699877|Experimental|Part 1: Participants with Normal Renal Function|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1
9892448|NCT04699877|Experimental|Part 2: Participants with Mild Renal Impairment|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1.
9892449|NCT04699877|Experimental|Part 2: Participants with Moderate Renal Impairment|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1.
9892450|NCT04699877|Experimental|Part 2: Participants with Normal Renal Function|Participants will receive a single oral dose of gilteritinib under fasting conditions on Day 1.
9892451|NCT04687540|Placebo Comparator|Study day 1 (study visit 1)|Baseline measurements (pre-intervention) are obtained on study visit 1.
9892452|NCT04687540|Active Comparator|Study day 21 (study visit 2)|Post-intervention measurements: Participants will be under the influence of tocilizumab, which was injected at the end of study visit 1.
9892453|NCT04680637|Placebo Comparator|Placebo + Standard of Care|
9892454|NCT04680637|Experimental|Efavaleukin Alfa Dose Level One + Standard of Care|
9892455|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Two + Standard of Care|
9892456|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Three + Standard of Care|
9892457|NCT04676022|Experimental|Spinal Cord Stimulation|To receive Spinal Cord Stimulation programming
9892458|NCT04676022|Other|Conventional Medical Management|To receive conventional medical management
9892459|NCT04675866|Experimental|camrelizumab+albumin-bound paclitaxel+S-1|camrelizumab+albumin-bound paclitaxel+S-1
9892460|NCT04673630|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
9998221|NCT01516255|Placebo Comparator|Double-blind / placebo|
9998222|NCT01516255|Active Comparator|Open-label / moxifloxacin|
9990910|NCT01447966|No Intervention|Treatment as Usual|Participants randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
9990911|NCT01447966|Experimental|Immediate CBT|Therapists will work with families for 12 twice weekly sessions, each lasting up to 60 minutes implementing a developmentally appropriate modulated cognitive behavioral therapy approach. A manualized CBT protocol will be followed.
9990912|NCT01447979|Experimental|All patients|this is the only arm of the study, and concerns all patients.
9990913|NCT01447992|Experimental|Portable artificial pancreas system with Control-To-Range|
9797671|NCT01603368|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938, 125 million bacteria/day
9990914|NCT01448005||wearable defibrillator use|subjects will use a wearable defibrillator
9990915|NCT01448018|Active Comparator|ranibizumab|patients in this arm receive 3 monthly injection of ranibizumab
9990916|NCT01448018|Active Comparator|Hemodilution|hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)
9990917|NCT01448018|Active Comparator|ranibizumab and hemodilution|patients receive both treatments
9990918|NCT01448031|Experimental|1|Capsule ASA 81mg/esomeprazole 20mg
9990919|NCT01448031|Active Comparator|2|ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg
9990920|NCT01448070|Experimental|NN729 manufacturing process|
9990921|NCT01448070|Active Comparator|Current manufacturing process|
9990922|NCT01448083||Neuroendocrine tumor patients|
9990923|NCT01448096|Experimental|primary breast DLBCL|isolated breast involvement with or without nodal disease
9990924|NCT01448109|Active Comparator|Hydrocortisone|
9990925|NCT01448109|Placebo Comparator|Sterile air filled vial|
9990926|NCT01448122|Active Comparator|Avene Compact Honey SPF 50|Study product will be scraped from compact case and weighed. Product will be applied to half the area to be exposed with visible light at a concentration of 2 mg/mL.
9990927|NCT01448122|No Intervention|No intervention|Half of the area to be exposed to visible light will have no study product applied.
9990928|NCT01448135|Experimental|Vital AF|
9990929|NCT01448135|Active Comparator|Osmolite 1.2|
9990930|NCT01448148|Experimental|Cognitive intervention|Use of Memo protocol for 8 weeks
9990931|NCT01448148|Experimental|Psychosocial intervention|"Use of Programme d'intervention psychosociale axé sur le bien-être psychologique for 8 weeks"
9990932|NCT01448148|No Intervention|no contact control group|waiting list
9990933|NCT01448161||Pediatric and Adult ICU patients|Pediatric and Adult ICU patients
9990934|NCT01448174|Active Comparator|atorvastatin|"The prospective, randomized, double-blind, placebo-controlled study:~will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)~130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.~Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).~The prospective, observational study:~- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia"
9990935|NCT01448174|No Intervention|Lifestyle counseling|"Protocol of the prospective study in obese persons:~after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity~follow-up for 30 weeks (measurement of body weight every week)."
9990936|NCT01448174|No Intervention|The controls (healthy volunteers)|
9990937|NCT01448200|Experimental|Part I: single dose escalation in healthy volunteers|"There will be three sequential single dose cohorts:~Cohort A: PPI-668 dose D1 or placebo~Cohort B: PPI-668 dose D2 or placebo~Cohort C: PPI-668 dose D3 or placebo"
9990938|NCT01448200|Experimental|Part I: multiple dose administration to healthy volunteers|"Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:~Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days"
9990939|NCT01448200|Experimental|Part II: multiple dose escalation in HCV subjects|"Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:~Cohort E (genotype-1): PPI-668 dose E1 or placebo~Cohort F (genotype-1): PPI-668 dose E2 or placebo~Cohort G (genotype-1): PPI-668 dose E3 or placebo~Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined~Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo"
9990940|NCT01448226||proven or probable aspergillosis|
9990941|NCT01448226||possible aspergillosis|
9990942|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
9990943|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
9990944|NCT01448252|Active Comparator|TCV|multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
9990945|NCT01448252|Sham Comparator|Placebo|saline injections subcutaneously at the same 4 time points with active treatment
9990946|NCT01448265|Experimental|Paroxysmal atrial fibrillation.|
9990947|NCT01448278|Experimental|All-inside technique|
9990948|NCT01448278|Active Comparator|Classical technique|
9990949|NCT01448291|Experimental|Nuvaring|This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.
9990950|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
9990951|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
9990952|NCT01448317|Experimental|Cohort 1|Alirocumab dose 1 versus placebo
9990953|NCT01448317|Experimental|Cohort 2|Alirocumab dose 2 versus placebo
9990954|NCT01448317|Experimental|Cohort 3|Alirocumab dose 3 versus placebo
9892461|NCT04666740|Experimental|Cohort A: Core HRD|Patients with either pathogenic germline or somatic alterations of 3 core homologous recombination-genes (HR-genes) - (BRCA1/2, or PALB2) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort A.
9892462|NCT04666740|Experimental|Cohort B: Non core HRD|Patients with either pathogenic somatic or germline non-core 14 HR-gene alterations (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort B.
9892463|NCT04666740|Experimental|Cohort C: Platinum sensitive|Patients without any of the above HR-gene alterations included in Cohort A and B who have platinum-sensitivity, which is defined as a partial response (PR) or complete response (CR) for the best overall response (BOR) during at least 4 months on platinumbased therapy. Variants of unknown significance of candidate HR-genes from Cohort A or B will be eligible for Cohort C if they meet the partial response to platinum criterion.
9892464|NCT04659122|Experimental|AT-100 75 mg|Once daily AT-100 via intratracheal administration for up to 7 doses.
9892465|NCT04659122|Experimental|AT-100 150 mg|Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe & tolerated.
9892466|NCT04659122|Experimental|AT-100 75 mg or 150 mg|Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe & tolerated dose as determined by the prior 2 dosing levels.
10212022|NCT03167281|Experimental|Early tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.
10212023|NCT03161678|Active Comparator|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
10212024|NCT03161678|Experimental|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
9892470|NCT04657302|Experimental|R/R DLBCL|Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).
9892471|NCT04657289|Experimental|Arm A [Q36W] 36-weeks between refill-exchange procedures|Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.
9892472|NCT04657289|Active Comparator|Arm B [Q24W] 24-weeks between refill-exchange procedures|Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.
9892473|NCT04657081|Experimental|Oral administration of ASTX727 and venetoclax combination|"Cycle 1: ASTX727 according to a prescribed dosing regimen and venetoclax on day 1 (100 mg daily), day 2 (200 mg daily), and days 3-28 (400 mg daily) of a 28-day cycle.~Cycle 2 and beyond: ASTX727 according to a prescribed dosing regimen and venetoclax on days 1-28 (400 mg daily) of a 28-day cycle."
9892474|NCT04648683|Experimental|Individual telehealth mindfulness|Telehealth mindfulness sessions delivered one-on-one with mindfulness therapist
9892475|NCT04639219|Experimental|T-DXd|T-DXd monotherapy
9892476|NCT04635930|Experimental|Taping plus Traditional exercises|"kinesio tape for improving the alignment of the scapula by inhibiting the hyperactive upper trapezius and facilitating the weak serratus anterior muscleStretching of the tight muscles of upper limb.~Reaching forward sidewise and backward.~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).~Prone lying weight bearing on elbows (four point kneeling)~side sitting with weight bearing on the effected side, for 5 minutes.~Wall pushups.~Catching and throwing of ball"
9935984|NCT02882282|Experimental|Arm B (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10212025|NCT03161678|Experimental|Carriers of CES1 Functional Mutation|Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
10212026|NCT03149380|Experimental|Intervention|Subjects will be given access to educational content on AD using interactive learning strategies
10212027|NCT03149380|Sham Comparator|Time-neutral control|Subjects will be given access to time-neutral general educational content on AD
10212028|NCT03136055|Experimental|Part A: Pembrolizumab only|Participants will receive 200 mg of pembrolizumab will be given every three weeks via IV infusion.
10212029|NCT03136055|Experimental|Part B: Pembrolizumab + Chemotherapy|Participants will receive 200 mg of pembrolizumab will be given every three weeks via IV infusion and, either 125 mg/m2 of irinotecan given via IV infusion in a two week (on for one week, off for one week format in 3 week cycles) or 80 mg/m2 of paclitaxel given every week via IV infusion depending on physician assessment
10212030|NCT03115840||Adults (≥18 years old) with critical illness|
10212031|NCT03101566|Experimental|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV on days 1,8 every 3 weeks~Drug: Cisplatin 25 mg/m2 IV on days 1,8 every 3 weeks~Drug: Nivolumab 360 mg IV on day 1 every 3 weeks~If there is continued benefit after 6 months, then:~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
10212032|NCT03101566|Experimental|Nivolumab + Ipilimumab|"Drug: Ipilimumab~1 mg/kg IV on day 1 every 6 weeks~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
10212033|NCT03098082|Other|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
10212034|NCT03059355|Experimental|Pilot Phase: Group 1 (UCMSCs)|Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
10212035|NCT03059355|Experimental|Pilot Phase: Group 2 (UCMSCs - 100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
9990955|NCT01448317|Experimental|Cohort 4|Alirocumab dose 4 versus placebo
9990956|NCT01448330|Experimental|HCP0911|clopidogrel/aspirin combination tablet
9990957|NCT01448330|Active Comparator|clopidorel and aspirin|coadministration of clopidogrel and aspirin
9990958|NCT01448343|Experimental|FMS|Patients who received blood transfusion using FMS
9990959|NCT01448369|Active Comparator|EyeGiene|EyeGiene (Eyedetec Medical Inc., US) is a self-contained, convenient warm compress system for the eyes. The system is composed of a reusable eye mask and one time use warmers that are inserted into the eye mask. The warming units are activated by squeezing just prior use and deliver 40°C heat for up to 5 minutes within 30-60 seconds.
9990960|NCT01448369|Active Comparator|Blephasteam|Blephasteam (Spectrum Théa, France) is an eyelid warming device that can be conveniently used at home. The goggles provide standardised heat of about 38 degrees to liquefy lipids and also humidify the chambers with mineral water to ensure optimal moisture levels.
9990961|NCT01448369|Placebo Comparator|Control- Hot Compress|The participants in this group will be using warm compresses with a hot towel.
9990962|NCT01448382|Experimental|Healthy volunteers|healthy volunteers
9990963|NCT01448382|Experimental|GI bleeding subjcets|Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care
9990964|NCT01448395|Experimental|1|
9990965|NCT01448408||Forme Fruste Keratoconus group (FFKG)|FFK eyes had to present a) no apparent signs of KC in clinical examination b) stage 0 in the Amsler-Krumeich scale, and c) demonstrate a KISA index value between 60-100%
9990966|NCT01448408||Normal Group (CG)|Eligibility for participation in the CG was confirmed by consecutive topographies, while all CG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography and KISA index value less than 60%, as well.
9990967|NCT01448434|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs
9990968|NCT01448434|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
9990969|NCT01448460||Fertility Patients|IVF patients with extra eggs or other subjects who desire egg vitrification for fertility preservation
9797672|NCT01603368|Placebo Comparator|Placebo|The same oil drops as the active study product but without Lactobacillus reuteri
9997496|NCT01509313|Experimental|Uterine polypectomy using morcellator|A new instrument using a mechanical cutting edge has come to market for uterine polypectomy. In patients having a general anaesthesia the mechanical cutting instrument has been shown to be easier to learn, more effective at completely removing polyps and quicker than current techniques. However, the instrument is slightly larger, which could potentially cause more discomfort and prolong the procedure in the outpatient setting.
9997497|NCT01509313|Active Comparator|Electical Resection|At present the most commonly used device for removing the uterine polyps in the outpatient setting is by electrical resection. This will provide comparison for the morcellator device being tested
9997498|NCT01509326|Active Comparator|Chiropractic|spinal manipulation, mobilization, massage, advice, exercises
9997499|NCT01509326|Experimental|Chiropractic PLUS pillow|spinal manipulation, mobilization, massage, advice, exercises, pillow
9997500|NCT01509352|Active Comparator|with esophageal stitches|fundoplication with crural stitches
9997501|NCT01509352|Experimental|without esophageal stitches|fundoplication without crural stitches.
9997502|NCT01509365|No Intervention|sensible|Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
9997503|NCT01509365|Active Comparator|simple dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
9997504|NCT01509365|Experimental|double dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
9997505|NCT01509391|Experimental|Keyhole-limpet hemocyanine|
9997506|NCT01509417|Experimental|Ad lib feeding|ad lib feedings following pyloromyotomy
9997507|NCT01509417|Active Comparator|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
9997508|NCT01509430|Experimental|Early training patient|12 weeks of Progressive Resistance Training followed by 12 weeks of a self chosen level of physical activity
9997509|NCT01509430|Experimental|Late training patients|12 weeks of a self chosen level of physical activity followed by 12 weeks of progressive resistance training
9997510|NCT01509443|Experimental|Interventional|Participants will receive standard asthmatic treatment and breathing/mild physical exercise
9997511|NCT01509443|No Intervention|Control Arm|The control arm will receive standard medical care for asthma
9997512|NCT01509456|Active Comparator|Potassium Bicarbonate|
9997513|NCT01509456|No Intervention|Control|
9997514|NCT01509469|Experimental|Low dose casein|Ileal infusion of low dose casein
9997515|NCT01509469|Experimental|High dose casein|Ileal infusion of high dose casein
9997516|NCT01509469|Experimental|Low dose sucrose|Ileal infusion of low dose sucrose
9997517|NCT01509469|Experimental|High dose sucrose|Ileal infusion of high dose sucrose
9997518|NCT01509469|Placebo Comparator|Placebo|Ileal infusion saline
9997519|NCT01509469|Active Comparator|Safflower oil|Ileal infusion safflower oil
9892477|NCT04635930|Active Comparator|Traditional exercises|"Stretching of the tight muscles of upper limb.~Reaching forward sidewise and backward.~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).~Prone lying weight bearing on elbows (four point kneeling)~side sitting with weight bearing on the effected side, for 5 minutes.~Wall pushups.~Catching and throwing of ball"
9892478|NCT04623944|Experimental|NKX101 - CAR NK cell therapy|"All subjects in Part 1 will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 or 2 (Regimen A or B, respectively) weekly doses of NKX101.~Subjects in Part 2 will receive either fludarabine/cyclophosphamide lymphodepletion or, if an AML combination arm is opened, fludarabine/cytarabine (ara-C), followed by 3 or 2 weekly doses of NKX101 depending on specific expansion cohort.~Regimen A will have 3 doses of NKX101 on Day 0, 7, and 14 of a 28-day cycle. Regimen B will have 2 doses of NKX101 on Day 0 and 7 of a 28-day cycle.~Part 1 and 2: either haplo-matched related donor derived or unrelated off-the-shelf donor derived NKX101 will be used."
9892479|NCT04620759|Experimental|Psilocybin Treatment|Participants will be administered 25mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.
9892480|NCT04620759|Placebo Comparator|Placebo|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.
9892481|NCT04614935|No Intervention|Standard of Care|Pediatric patients with functional constipation who are treated with medications and/or behavioral therapies as they would be if they were not enrolled in the study. In addition to standard of care treatment, these families will fill out a brief quality of life survey.
9892482|NCT04614935|Experimental|Action Plan|Pediatric patients with functional constipation who are treated with standard of care medications and/or behavioral therapies and are also provided with a medication adherence log along with a constipation action plan. These families will also fill out a brief quality of life survey.
9892483|NCT04614662|Experimental|Intervention|"Participants enrolled at intervention sites will be prompted to complete symptom screening three times weekly via SPARK with corresponding feedback and links to symptom management care pathways sent to their healthcare providers.~Symptom screening using SPARK can be performed at any time and as often as desired, but screening will be prompted three times weekly for eight weeks.~Each day the participant completes symptom screening and has at least one severely bothersome symptom, the primary healthcare team will receive an email summarizing the symptom report and highlighting symptoms that are a lot or extremely bothersome.~Upon study activation, we will work with each of the 10 intervention sites to develop site-specific, adapted care pathways that consider relevant work flows, institutional culture and available resources."
9892484|NCT04614662|No Intervention|Control|At control sites, usual care will be provided, which may or may not include symptom screening, access to CPGs or care pathways. Participants will complete SSPedi to obtain the primary outcome at weeks 0, 4 and 8 but the scores will not be revealed to providers and will not be linked to care pathways.
9892485|NCT04614454|Experimental|Experimental arm|Devices will be programmed by our study coordinator to provide a sham signal or the experimental signal. The location of the TENS electrodes will be determined by the location of the pain with the goal of placing the unit at the top of the dermatological level corresponding to the pain. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
9892486|NCT04614454|Sham Comparator|Sham arm|The sham unit looks identical to the experimental unit. There may be a sensation experienced by subjects with the sham device but it does not deliver an electric current as the experimental units. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
9892487|NCT04613375||All participants|
9892488|NCT04612790|Experimental|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
9892489|NCT04612790|Experimental|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
9892490|NCT04609696|Experimental|Part 1: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 1 formulation under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
9892491|NCT04609696|Experimental|Part 1: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 1 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
9892492|NCT04609696|Experimental|Part 1: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fasted conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
9892493|NCT04609696|Experimental|Part 2: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 2 formulation under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
9990970|NCT01448473|Experimental|4 views radiograph serie|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
9998223|NCT01516255|Placebo Comparator|Open-label / placebo|
9990971|NCT01448473|Active Comparator|2-view radiography serie|The 2-film series will include the following views: anterior-posterior and one lateral.
9990972|NCT01448499|Experimental|Clozapine|Clozapine monotherapy
9990973|NCT01448499|Experimental|Amisulpride|Amisulpride monotherapy
9990974|NCT01448499|Experimental|Augmentation|Augmentation of clozapine with amisulpride
9990975|NCT01448512|Other|Usual Care|Participation in 4 time matched sessions on health education topics
9990976|NCT01448512|Experimental|PartnerPlus intervention|Four group counseling sessions focused on prevention of mother to child transmission (PMTCT) sexual risk reduction & adherence.
9990977|NCT01448538||Group 1|
9990978|NCT01448551|Experimental|Text Messaging|
9990979|NCT01448551|No Intervention|Control|Participation in the MPOWER program without receiving tailored text messages
9990980|NCT01448564|Active Comparator|Laser therapy|Recently has been using the LED, known by its acronym in English LED (Light Emitting Diode), devices that are light-emitting non-coherent and monochromatic, having a longer wavelength (± 10 - 30 nm) compared to lasers. The difference between the fundamental radiation emitted by a laser and an LED is the coherence of the beam.
9990981|NCT01448564|Placebo Comparator|Placebo Laser therapy|
9990982|NCT01448577||Dose 3 x 1011 gc/kg|Subjects received AMT-011 at dose 3 x 1011 gc/kg
9990983|NCT01448577||Dose 1 x 1012 gc/kg|Subjects received AMT-011 at dose 1 x 1012 gc/kg
9990984|NCT01448590||Epidural Resite|After ADP, those patients who receive an epidural resite.
9990985|NCT01448590||Spinal catheter|After ADP, those who receive the epidural catheter into the spinal space
9990986|NCT01448603||Placebo|Subjects previously randomised to placebo in TR002
9990987|NCT01448603||ToleroMune Ragweed Regimen 1|Subjects previously randomised to receive ToleroMune Ragweed regimen 1 in study TR002
9990988|NCT01448603||ToleroMune Ragweed Regimen 2|Subject previously randomised to receive ToleroMune Ragweed regimen 2 in study TR002
9990989|NCT01448603||ToleroMune Ragweed regimen 3|Subject previously randomised to receive ToleroMune Ragweed regimen 3 in study TR002
9990990|NCT01448603||ToleroMune Ragweed regimen 4|Subjects previously randomised to receive ToleroMune Ragweed regimen 4 in study TR002
9990991|NCT01448629|Experimental|River|
9990992|NCT01448629|Active Comparator|Standard Care|Standard Care can have several manufacture and brand names. Standard Care is defined af the participants currently used stoma care product.
9990993|NCT01448642|Active Comparator|Atorvastatin|
9990994|NCT01448642|Placebo Comparator|Placebo|
9990995|NCT01448655||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
9990996|NCT01448655||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
9990997|NCT01448668||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
9990998|NCT01448668||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
9990999|NCT01448681||SICU patients with ICP|Surgical intensive care unit patients with elevated intracranial pressure
9991000|NCT01448694||Blood donors|Healthy volunteers who are donating a pint of whole blood
9991001|NCT01448720|Experimental|Paliperidone palmitate|
9991002|NCT01448733|Experimental|Acanya Plus Atralin|A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.
9991003|NCT01448746|Experimental|intermittent pneumatic compression|another arm include intermittent pneumatic compression plus low molecular weight heparin
9991004|NCT01448772|Active Comparator|Marinol|
9991005|NCT01448772|Experimental|oral solution|
9991006|NCT01448785|Active Comparator|abiliti Group|Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
9991007|NCT01448785|Active Comparator|Gastric Band Group|Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
9991008|NCT01448798|Experimental|gelatine-thrombin matrix|Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix.
9991009|NCT01448798|Sham Comparator|Control|Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping.
9991010|NCT01448811|Experimental|AEP monitoring|
9991011|NCT01448811|Active Comparator|RSS monitoring|
9991012|NCT01448837|Active Comparator|Bimatoprost/Timolol drops|The patients will be treated with bimatoprost/timolol fixed combination therapy
9991013|NCT01448837|Active Comparator|Latanoprost drops|The patients will be crossed over to therapy with latanoprost
9991014|NCT01448863||CONTROL|Fertile women (egg-donors)
9991015|NCT01448863||WITH PCO|Obese women with Polycystic Ovarian Syndrome
9991016|NCT01448863||NO PCO|Obese women without Polycystic Ovarian Syndrome
9991017|NCT01448876||chlamydia care as usual|
9991018|NCT01448889|Active Comparator|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
9991019|NCT01448889|Placebo Comparator|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
9991020|NCT01448902|Experimental|OC000459|
9991021|NCT01448902|Placebo Comparator|Placebo|
9892494|NCT04609696|Experimental|Part 2: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 2 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
9892495|NCT04609696|Experimental|Part 2: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fasted conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
9892496|NCT04607460|Experimental|EMG-Biofeedback for Lower Back Pain|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 8 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
9892497|NCT04607460|No Intervention|Treatment as usual (Lower Back Pain)|Participants in this group will receive no active treatment.
9892498|NCT04607460|Experimental|EMG-Biofeedback for Persistent Post-Mastectomy Pain|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 4 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor ahead of their mastectomy.
9892499|NCT04607460|No Intervention|Treatment as usual (Persistent Post-Mastectomy Pain)|Participants in this group will receive no active treatment.
9892500|NCT04607460|Experimental|EMG-Biofeedback for Migraine|Participants will receive a JOGO Digital Therapeutics EMG Biofeedback device and a software installed on a tablet or smart phone. During the 6 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
9892501|NCT04607460|No Intervention|Treatment as usual (Migraine)|Participants in this group will receive no active treatment.
9892502|NCT04605978|Experimental|S95011 concentrate for solution for infusion|S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
9892503|NCT04605978|Placebo Comparator|S95011 Placebo concentrate for solution for infusion|S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
9892504|NCT04604925||Remote patient monitoring for hypertension|RPM Integration: All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
9892505|NCT04604925||Usual care|Matching patients from control practices will be selected from remaining Northwestern Medical Group primary care sites and be chosen to provide as sufficiently large number of eligible patients for comparison. These groups will contribute EHR data through the NM EDW but will not have any new procedures put in place
9892506|NCT04599309||PRE-MERIDIAN|Patients with a histological or cytological diagnosis of LA-HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx (stage III HPV positive or stage III-IV HPV negative). Patients who are candidates for standard definitive treatment such as surgery followed by radiotherapy +/- chemotherapy, or definite radiotherapy, or definite chemoradiotherapy.
9892507|NCT04594213|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection
9892508|NCT04594213|Experimental|MP: NT201 (incobotulinumtoxinA): GFL/HFL; Placebo: LCL|Intramuscular injection
9892509|NCT04594213|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection
9892510|NCT04594213|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection
9892511|NCT04592991|Active Comparator|AAA Group|"Participants with AAA will undergo routine clinical evaluation of AAA including ultrasound and CT and scheduling of open surgical repair as directed by the treating physician. We will record age and tobacco use of participant. If participant has not had a renal function blood test performed within the past 90 days, we will draw approximately 2 teaspoons of blood for a creatinine test. We will also ask the participant's permission to use a contrast dye for the CT portion of the PET-CT scan. If the participant agrees we will additional questions to gauge eligibility to receive the contrast dye.~If available, we would like to collect any discarded AAA tissue from the surgical procedure. This discarded tissue will be kept as part of a Washington University vascular research repository. If the participant agrees to this there will be a separate consent form to sign allowing the collection of the leftover tissue along with some information about medical history."
9667105|NCT03958565||Actionable driver oncogene|One group will have an actionable driver oncogene and initiate treatment in any line with a TKI as standard of care and concurrent to participation to this study; expected to have an objective response rate in ≥40% who have not previously seen anti-bone resorptive therapy.
9991022|NCT01448928||Group 1|
9892512|NCT04592991|Active Comparator|Aortoiliac Occlusive Disease Group|Participants with non-aneurysmal aortoiliac occlusive disease, will be eligible for the study based on lifestyle limiting claudication (lack of blood flow to muscles causing cramping), pain in the feet or toes at rest, and/or tissue loss (leg or foot ulcers that don't heal or gangrene) that requires aortofemoral bypass. The aortofemoral bypass is not part of this research study.
9892513|NCT04592341|Experimental|Gantenerumab|Participants will receive gantenerumab by subcutaneous (SC) injection at a dose of 120 mg every 4 weeks (Q4W) for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg every 2 weeks (Q2W) for another 12 weeks, followed by the target dose 255 mg once weekly (Q1W) for up to Week 103.
9892514|NCT04583982||Prospective Study Arm SARS-CoV-2 negative and positive samples|
9892515|NCT04580940||Subjects with complex pancreaticobiliary disease|All subjects will undergo the percutaneous transhepatic cholangiopancreatoscopy with the SpyGlass Discover System.
9892516|NCT04567888|Active Comparator|Happify Teens|Happify Teens is a digital well-being intervention that can be accessed via mobile application or web browser
9892517|NCT04567888|No Intervention|Waitlist Control|Waitlist Control Condition
9892518|NCT04567303|Experimental|Part 1: Intravitreal Injections|RO7250284 administered in ascending dose levels through IVT injections.
9892519|NCT04567303|Experimental|Part 2: Port Delivery System with High Dose|RO7250284 administered at a high dose through the PDS implant.
9892520|NCT04567303|Experimental|Part 2: Port Delivery System with Low Dose|RO7250284 administered at a low dose through the PDS implant.
9892521|NCT04567303|Experimental|Part 3: Port Delivery System with High Dose|RO7250284 administered at a high dose through the PDS implant.
9892522|NCT04567303|Active Comparator|Part 3: Port Delivery System with Ranibizumab|100 mg/mL of ranibizumab administered through the PDS implant.
9892523|NCT04562090|Experimental|Mirabegron 25 mg|Participants will receive 25 mg of mirabegron, once daily orally in the morning around the same time of day and around time of food intake (i.e., within 1 hour after breakfast).
9892524|NCT04562090|Experimental|Mirabegron 50 mg|Participants will receive 50 mg of mirabegron, once daily orally in the morning around the same time of day and around time of food intake (i.e., within 1 hour after breakfast).
9892525|NCT04560361|Experimental|Electroacupuncture group|Choose the appropriate position according to the patient's herpes site, and routinely disinfect the skin. Paste the fixed insulating pad on the acupoint, and use a 0.30×40mm acupuncture needle to penetrate the skin 10mm obliquely through the fixed insulating gasket at Ashi point; According to the above operation, the SJ6 and GB34 point of the affected side are directly penetrated into the skin 15-20mm. The local Ashi point connects the two poles of the electroacupuncture device according to the first and last points of the long axis of the painful part, and the SJ6 and GB34 point on the affected side are connected to the poles of the electroacupuncture device. Electroacupuncture waveform is continuous wave, frequency is 2Hz, and current intensity is 1-5mA (causing slight tremor of the skin around the acupuncture point without pain). Continue the electroacupuncture treatment for 30 minutes.
9892526|NCT04560361|Sham Comparator|Sham electroacupuncture group|Participants randomly assigned to the sham electroacupuncture (SA) group received sham electroacupuncture by using placebo blunt needles at the same acupoints. After disinfecting the skin and placing the sterile insulating adhesive pads on unilateral Zhigou, Yanglingquan and Ashi points, placebo blunt needles are inserted through the pads and reach the insulating adhesive layer, causing the participants to feel the needle resistance (a sensation of needle insertion). Other procedures, electrode placements, parameter of electroacupuncture apparatus and treatment settings are the same as in the EA group, but with no skin penetration or electricity output.
9892527|NCT04559906|Experimental|Group A|Spray and Stretch technique Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
9892528|NCT04559906|Active Comparator|Group B|Sustain pressure release Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
9892529|NCT04558164|Experimental|Active TBS|Theta burst stimulation (TBS) will be delivered at 100% of motor threshold (MT).
9892530|NCT04558164|Sham Comparator|Sham TBS|Sham stimulation will be delivered at 0% of motor threshold (MT), with all other parameters matching the active TBS condition.
9892531|NCT04557150|Experimental|Part I: Dose Escalation|Participants will receive RO7425781 as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.
9892532|NCT04557150|Experimental|Part II: Dose Expansion|Dose Expansion cohorts with IV and/or SC administration will be initiated at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) determined from Part I: Dose Escalation.
9892533|NCT04554485|Experimental|Blinatumomab followed by high-dose chemotherapy|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
9892534|NCT04554459|Experimental|ponatinib plus reduced-intensity chemotherapy|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
9892535|NCT04551092|Experimental|Single|Single group to receive intervention
9892536|NCT04550962||Participants with asthma|Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country
9892537|NCT04536298|Active Comparator|Vitamin D|Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
9892538|NCT04536298|Placebo Comparator|Placebo|Placebo
9892539|NCT04533750|Experimental|Treatment (peposertib, IMRT)|Patients receive peposertib PO QD and undergo IMRT daily Monday-Friday for 7 weeks in the absence of disease progression or unacceptable toxicity.
9892540|NCT04531046|Experimental|axicabtagene ciloleucel|Single infusion administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg
9892541|NCT04528446||BoneGN participants|Participants who have already been recruited into the CureGN study, or meet its criteria.
9892542|NCT04528446||Healthy subjects|A reference population of healthy subjects who are age- sex- BMI-matched to the CureGN study participants.
9892543|NCT04526223|Experimental|treatment group|MF patients exposure to ruxolitinib during transplantation
9892544|NCT04524130|Experimental|Lidocaine and Ketamine|Participants in this arm will receive intra-operative lidocaine and ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
9892545|NCT04524130|Active Comparator|Lidocaine|Participants in this arm will receive only intra-operative ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
9892546|NCT04524130|Placebo Comparator|Placebo|Participants in this arm will receive normal saline, same volume as lidocaine and ketamine.
9892547|NCT04521361|Experimental|Patients with Low extent of disease|Adult men with bone mCRPC having < 6 bone metastases
9892548|NCT04521361|Experimental|Patients with High extent of disease|Adult men with bone mCRPC having ≥ 6 bone metastases
9932362|NCT00948207|Experimental|My Living Story|"My Living Story elicits a dignity-enhancing life story via a telephone interview, and delivers the edited transcript on the patient's personal miLivingStory social network. miLivingStory also provides a direct link to miStory, a life review education website with links to high quality websites that provide cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.~miLivingStory and miStory are both password protected."
9932363|NCT00948207|Active Comparator|My Own Resources|"My Own Resources offers usual care access to high quality websites that provide cancer information, databases to do your own research, social support, and interactive planning tools. Participants will receive access to the website miOwnResources."
9932364|NCT00948220|Experimental|Treatment|Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
9932365|NCT00948220|No Intervention|Control|Chronic hepatitis C patients without standard antiviral therapy
9932366|NCT00948233||Intervention|Educational video game
9932367|NCT00948233||Standard Care|Pamphlets on stopping tobacco use
9932368|NCT00948259|Experimental|NP031112|Patients will receive 400 mg of NP031112 for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this dose will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for dose escalation will remain on the tolerated dose for the remainder of the study.
9932369|NCT00948259|Placebo Comparator|Placebo|Patients will receive 400 mg for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for escalation will remain on the tolerated dose for the remainder of the study.
9932370|NCT00948272|Experimental|VRVg Group|
9932371|NCT00948272|Active Comparator|Verorab Group|
9932372|NCT00948285|Experimental|MRI|Preoperative staging with mammogram, ultrasound, and MRI, followed by surgery (n=200)
9932373|NCT00948285|No Intervention|Non-MRI|Preoperative staging with mammogram and ultrasound alone, followed by surgery (n=200)
9932374|NCT00948324|Active Comparator|CSII|CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.
9932375|NCT00948324|Active Comparator|ALA|ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.
9932376|NCT00948324|Active Comparator|RSG|RSG:CSII combined with three months rosiglitazoneor 4mg QD.
9797673|NCT01603420|Active Comparator|Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)|Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
9932377|NCT00948324|Active Comparator|MET|MET:CSII combined with metformin 500mg BID-TID.
9932378|NCT00948337|Experimental|Photonovella of Secondary Cancer Screening|
9932379|NCT00948337|Active Comparator|Photonovella of Dietary Suppelment of Cancer survivor|
9932380|NCT00948350|Active Comparator|translaryngeal injection|translaryngeal injection of local anesthetics before the awake intubation
9932381|NCT00948350|Active Comparator|spray as you go|local anesthetics are given through the fiberoptic during awake intubation
9932382|NCT00948363|Active Comparator|Kiwi fruits|
9932383|NCT00948363|Placebo Comparator|Apple|
9932384|NCT00948376||Patients|All ages
9932385|NCT00948376||Fetuses|
9932386|NCT00948402|Experimental|metformin|
9932387|NCT00948402|Active Comparator|oral contraceptive|
9932388|NCT00948415|Experimental|SURI Enhanced|
9932389|NCT00948415|Active Comparator|SURI Standard|
9932390|NCT00948454||Light smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
9932391|NCT00948454||Heavy Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
9932392|NCT00948454||Non Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Female subjects will also have a pregnancy test done on the test day.
9932393|NCT00948467|Experimental|TAK-733|
9932394|NCT00948519|Experimental|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
9932395|NCT00948519|Active Comparator|Laser only|same as above, without ICG
9932396|NCT00948545||No treatment|Observing individuals pre and post bariatric surgery
9932397|NCT00948571||head down, laparoscopic|20 patients with laparoscopic surgery (radical robotic prostatectomy) in head down position
9932398|NCT00948571||head down, open|"20 patients undergoing opensurgery (open radical prostatectomy) in head down position."
9932399|NCT00948571||horizontal, open|"20 patients undergoing open surgery in horizontal position (open hemicolectomy)"
9932400|NCT00948584|Experimental|insulin titration by specialized system|Insulin dose titration system by using a SMS automatically produced by a knowledge matrix
9932401|NCT00948623|Experimental|1|
9932402|NCT00948623|Sham Comparator|2|
9932403|NCT00948636||Related Donors|Related Hematopoietic Stem Cell Donors
9932404|NCT00948649|Active Comparator|Varenicline|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
9932405|NCT00948649|Placebo Comparator|Placebo|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
9892549|NCT04521231|Experimental|Blinatumomab: Dose escalation|Cohorts of at least 3 participants each will be treated with escalating doses of blinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.
9892550|NCT04521231|Experimental|Blinatumomab: Dose expansion|Participants will be administered the recommend phase 2 dose (RP2D) determined from dose escalation stage to further assess safety, pharmacokinetics (PK), pharmacodynamic (PD), and efficacy.
9892551|NCT04518657|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and oneonone video chats with a behavioral coach.The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory.Each course consists of an introduction,the primary content,and a take home message.The interactive courses include embedded,supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps,and these steps will be entered into the website so progress can be monitored.The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries.The chats are conducted facetoface through an online videoconferencing platform.The chats occur 7 times during the first 2 months,4 times during the second 2 months,and twice during the final 2 months of the intervention.
9892552|NCT04518657|Sham Comparator|Wellness for MS (WellMS)|Provides an internet website and oneonone video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity.The materials are transformations of brochures provided by the National MS Society,including Gait or Walking Problems:The Basic Facts;MS and Your Emotions;Pain:The Basic Facts; Solving Cognitive Problems;Taming Stress in MS;Food for Thought:MS and Nutrition;and Vitamins,Minerals,and Herbs:An Introduction.The delivery of the internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition,and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
9892553|NCT04516967|Active Comparator|Experimental: Avatrombopag|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
9892554|NCT04516967|Placebo Comparator|Placebo Comparator:Placebo|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
9932406|NCT00948662|Experimental|1|active arm/healthy young
9932407|NCT00948662|Placebo Comparator|2|placebo arm
9892555|NCT04507061|Experimental|runcaciguat|Participant randomized to this arm will be up-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
9892556|NCT04507061|Placebo Comparator|Placebo|Participant randomized to this arm will be sham-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
9892557|NCT04505722|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S at a dose level of 5*10^10 virus particles (vp) as single dose vaccine on Day 1. At Year 1 (booster visit), participants who previously received any coronavirus disease-2019 (COVID-19) vaccination (as primary regimen or additional dose) will be offered a single booster dose of Ad26.COV2.S at the 5*10^10 vp dose level.
9892558|NCT04505722|Experimental|Placebo|Participants will receive IM injection of placebo on Day 1. At Month 6/unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine IM at a dose level of 5*10^10 vp. At Year 1 (booster visit), participants who previously received any COVID-19 vaccination (as primary regimen or additional dose) will be offered a single booster dose of Ad26.COV2.S at the 5*10^10 vp dose level.
9892559|NCT04503174||Pump Naiive|New to insulin pump use
9892560|NCT04503174||6-13 YO|Subjects between the age of 6-13 years old.
9892561|NCT04503174||14-17 YO|Subjects between the age of 14-17 years old.
9892562|NCT04503174||Adults (18+)|Subjects are 18 years old and older.
9892563|NCT04503174||CGM Naiive|Subjects have not used CGM in the 30 days prior to enrollment.
9892564|NCT04503174||HbA1c more than or equal to 8.5%|Subjects have an HbA1c of more than or equal to 8.5% in the 3 months prior to enrollment.
9892565|NCT04503174||HbA1c less than or equal to 8.5%|Subjects have an HbA1c of less than or equal to 8.5% in the 3 months prior to enrollment.
9892566|NCT04489199||Stroke patient|Patient included in the Dijon Stroke Registry.
9892567|NCT04484532|Experimental|Supportive Care (trivalent influenza vaccine)|Within 14 days of baseline influenza titer, patients receive trivalent influenza vaccine IM on day 0 (patients in cohorts 1 and 5 receive the vaccine at any time, patients in cohorts 2 and 3 receive the vaccine between days 14-25 of hypomethylating agent therapy course, and patients in cohort 4 receive the vaccine between days 21-365 from onset of cytotoxic chemotherapy). Patients then undergo titer assessment at days 25-90 and days 115-185.
9892568|NCT04482309|Experimental|Arm 1|Cohort 1: Biliary tract cancer
9892569|NCT04482309|Experimental|Arm 2|Cohort 2: Bladder cancer
9892570|NCT04482309|Experimental|Arm 3|Cohort 3: Cervical cancer
9892571|NCT04482309|Experimental|Arm 4|Cohort 4: Endometrial cancer
9892572|NCT04482309|Experimental|Arm 5|Cohort 5: Ovarian cancer
9892573|NCT04482309|Experimental|Arm 6|Cohort 6: Pancreatic cancer
9892574|NCT04482309|Experimental|Arm 7|Cohort 7: Rare tumors
9892575|NCT04479436|Experimental|Cohort 1: HER3 High (IHC 3+, 2+)|Cohort 1 participants will have high tumor expression levels of human epidermal receptor 3 (HER3) in a pre-treatment biopsy specimen.
9892576|NCT04479436|Experimental|Cohort 2: HER3 Low/Negative (IHC 1+, 0)|Cohort 2 participants will have low or negative tumor expression levels of human epidermal receptor 3 (HER3) expression levels in a pre-treatment biopsy specimen.
9667106|NCT03958565||No Actionable Mutations|The other group will not have actionable mutations and initiate treatment with chemotherapy/immunotherapy along with new onset therapy with IV zoledronic acid 4mg Q4 weeks or subcutaneous denosumab 120 mg Q12 weeks for bone disease, which is standard of care and would be concurrent to participation in this study.
9892577|NCT04475432|Experimental|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
9892578|NCT04475432|Placebo Comparator|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
9892579|NCT04472637|Experimental|Atorvastatin|They will receive atorvastatin 10 mg, as one tablet /day for 24 weeks.
9892580|NCT04472637|Placebo Comparator|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 24 weeks.
9892581|NCT04467879|Experimental|"Zona Plus - Active - Normal Grip"|Using the Zona Plus Device, the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day . After an initial handgrip strength assessment (the session calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
9892582|NCT04467879|Sham Comparator|"Control Device - Sham - Weaker Grip"|Using the Zona Sham Control Device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day. After an initial handgrip strength assessment (the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip, or rest session between each isometric routine.
9892583|NCT04466865|Experimental|Best Case/Worst Case communication tool|The participant's enrolled nephrologist will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the participant.
9892584|NCT04466865|No Intervention|Usual Care|"Usual care conversations are typically focused on mode and timing of dialysis, management of electrolytes and scheduling of laboratory testing. Conservative management or a treatment option of no dialysis is rarely mentioned."
9932408|NCT00948662|Other|3|ketoconazole interaction evaluation
9991023|NCT01448941|Active Comparator|Primary arthrodesis TMT 1|Arthrodesis TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
9991024|NCT01448941|Experimental|Temporary extraarticular plate fixation|Temporary extraarticular plate fixation of TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
9991025|NCT01448954|Experimental|ADC3680B oral|
9991026|NCT01448954|Placebo Comparator|Placebo oral|
9991027|NCT01448980|Active Comparator|Physical therapy|The control group will receive physical therapy 2 time per week for 6 weeks
9991028|NCT01448980|Experimental|Thai Traditional Massage|The experimental group will receive Thai traditional massage program 2 times per week for 6 weeks.
9991029|NCT01448993|Placebo Comparator|Placebo|Taking placebo 3 times per week for four weeks
9991030|NCT01448993|Active Comparator|AZI|
9991031|NCT01449019|Active Comparator|intravenous infusion|
9991032|NCT01449019|Experimental|intraduodenal perfusion|
9991033|NCT01449032|Active Comparator|MSC|Adipose derived stem cells
9991034|NCT01449032|Placebo Comparator|Saline|
9991035|NCT01449045|Placebo Comparator|Community Case Management|Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
9991036|NCT01449045|Experimental|Community Case Management plus IPTc|Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management
9991037|NCT01449058|Experimental|BYL719 + MEK162|BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162
9991038|NCT01449084|Active Comparator|early removal of pancreatic duct stent|immediate removal of the pancreatic duct stent at the end of the ERCP procedure
9991039|NCT01449084|No Intervention|leaving the stent in place|the pancreatic duct stent is left in place
9991040|NCT01449097|Experimental|Adductor-Canal-Blockade|
9991041|NCT01449097|Active Comparator|The femoral nerve block|
9991042|NCT01449097|Placebo Comparator|Placebo|
9991043|NCT01449110|Placebo Comparator|Placebo in PP|Placebo arm in primary cardiovascular prevention (PP)
9991044|NCT01449110|Placebo Comparator|Placebo in SP|Placebo arm in secondary cardiovascular prevention (SP)
9667107|NCT03954327|Experimental|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir|one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
9991045|NCT01449110|Active Comparator|Grape extract in PP|Grape extract obtained without resveratrol in primary cardiovascular prevention
9991046|NCT01449110|Active Comparator|Grape extract in SP|Grape extract without resveratrol in secondary cardiovascular prevention
9991047|NCT01449110|Experimental|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention
9991048|NCT01449110|Experimental|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention
9991049|NCT01449123|Experimental|Inhaler|Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
9991050|NCT01449136|Experimental|antibacterial cement|
9991051|NCT01449149|Experimental|Proton group|Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
9991052|NCT01449188|Active Comparator|ondansetron, 8 mg IV over 15 minutes|the lower ondansetron IV dose will be used in one of the four treatment periods
9991053|NCT01449188|Active Comparator|ondansetron, 32 mg IV over 15 minutes|the higher ondansetron IV dose will be used in one of the four treatment periods
9991054|NCT01449188|Placebo Comparator|placebo for ondansetron, IV over 15 minutes|placebo for ondansetron IV dose will be used in one of the four treatment periods
9991055|NCT01449188|Active Comparator|moxifloxacin, 400mg tablet (oral)|moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods
9991056|NCT01449201|Experimental|PF-00299804|
9991057|NCT01449214|Experimental|Ultrasound|Use of ultrasound to identify interlaminar spaces for needle insertion. Intervention/Procedure: ultrasound-guided technique.
9991058|NCT01449214|Active Comparator|Landmarking|Use of manual palpation to identify anatomic landmarks for needle insertion. Procedure/Intervention: landmark-guided technique.
9991059|NCT01449253|Active Comparator|Monotherapy|Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months
9991060|NCT01449253|Active Comparator|Sequential Therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started be added after 3 months. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. Bosentan and sildenafil will be in combination in the last 3 months. No fixed dose combination will be used.
9997520|NCT01509482|Experimental|insulin resistance|unexplained oligospermia and azoospermia. Blood samples will be taken for hormonal and blood lipids analysis.
9892585|NCT04457349|Experimental|Therapeutic Plasma Exchange (TPE)|Each patient will undergo two sessions. TPE will be done through filtration technique using a plasma filter at a dose of (1-1.5) plasma volume/session. Fresh frozen plasma or albumin 5% will be used to replace plasma.
9892586|NCT04457154||Registry Population|Pediatric subjects (age 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation System for the treatment of moderate to severe obstructive sleep apnea (OSA)
9892587|NCT04450329|Experimental|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
9892588|NCT04450329|Active Comparator|Eylea (Aflibercept)|"Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.~At Week 32, subjects in Eylea group will re-randomized into SB15 or Eylea group. After re-randomization, subjects transited to SB15 group will receive SB15 2 mg (0.05 mL) once every 8 weeks until Week 48 and subjects remaining in Eylea group will continue to receive Eylea 2 mg (0.05 mL) once every 8 weeks until Week 48."
9892589|NCT04445714|Other|dapagliflozin and saxagliptin|Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
9892590|NCT04445701|Experimental|AO-176 Dose Escalation Monotherapy|The dose escalation monotherapy cohorts will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
9892591|NCT04445701|Experimental|AO-176 + DEX Expansion Cohort|Once the monotherapy RP2D has been established, an expansion cohort of AO-176 + dexamethasone will be enrolled.
9892592|NCT04445701|Experimental|AO-176 + DEX + BORT Dose Escalation|Following evaluation of AO-176 + dexamethasone, dose escalation cohorts of AO-176 + dexamethasone + bortezomib will be enrolled. Each dose escalation cohort will initially recruit 3 patients in a standard 3+3 design; cohorts will be expanded in the event of a DLT. The Phase 2 portion of the study will further evaluate the RP2D of AO-176 + DEX + BORT.
9892593|NCT04444050|Experimental|Part 1 Single Ascending Dose (SAD): Panel 1|
9892594|NCT04444050|Experimental|Part 1 SAD: Panel 2|
9892595|NCT04444050|Experimental|Part 1 SAD: Panel 3|
9892596|NCT04444050|Experimental|Part 1 SAD: Panel 4|
9892597|NCT04444050|Experimental|Part 1 SAD: Panel 5|
9892598|NCT04444050|Experimental|Part 1 SAD: Panel 6|
9892599|NCT04444050|Experimental|Part 1 SAD: Optional Split-dose Panel|
9892600|NCT04444050|Experimental|Part 2 Multiple Ascending Dose (MAD): Panel 1|
9892601|NCT04444050|Experimental|Part 2 MAD: Panel 2|
9892602|NCT04444050|Experimental|Part 2 MAD: Panel 3|
9892603|NCT04444050|Experimental|Part 2 MAD: Panel 4|
9892604|NCT04444050|Experimental|Part 2 MAD: Optional (to be determined) Panel|
9892605|NCT04444050|Experimental|Part 3 MAD in Japanese Participants (J-MAD): Panel 1|
9892606|NCT04444050|Experimental|Part 3 J-MAD: Panel 2|
9892607|NCT04444050|Experimental|Part 3 J-MAD: Panel 3|
9892608|NCT04444050|Experimental|Part 3 J-MAD: Optional (to be determined) Panel|
9892609|NCT04441008|Experimental|aiTBS arm|aiTBS treatment as lead-in phase to ECT standard of care treatment.
9892610|NCT04441008|Active Comparator|ECT arm|ECT as clinically indicated.
9892611|NCT04439045|Experimental|VPM1002|A single dose of 0.1 mL of the reconstituted vaccine containing VPM1002 (Mycobacterium bovis rBCGΔureC::hly, live 2-8 × 105 CFU), administered via intradermal injection.
9892612|NCT04439045|Placebo Comparator|Placebo|A single dose of 0.1 mL of the 0.9% sodium chloride injection, administered via intradermal injection.
9892613|NCT04432623|Experimental|Low dose|A low dose, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks
9892614|NCT04432623|Experimental|Middle dose|A middle dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 weeks
9892615|NCT04432623|Experimental|High dose 3 days per week|Highest dose, by mouth, once per day, on Monday, Wednesday, and Friday, for 12 to 24 weeks
9892616|NCT04432623|Experimental|High dose 5 days per week|The highest dose, by mouth once per day on 5 days per week for 24 weeks
9892617|NCT04432623|Experimental|Sickle Cell Disease Arm|The most active dose given once per day on the most active regimen for up 24 weeks
9892618|NCT04431778|Experimental|Ethosuximide|Patients with chronic peripheral neuropathic pain
9892619|NCT04431778|Placebo Comparator|Placebo|Patients with chronic peripheral neuropathic pain
9892620|NCT04431726|Experimental|Emicizumab|
9892621|NCT04428281|Experimental|Cohort A1 RO7248824|Participants 5-12 Years
9892622|NCT04428281|Experimental|Cohort A2 RO7248824|Participants 5-12 Years
9892623|NCT04428281|Experimental|Cohort A3 RO7248824|Participants 5-12 Years
9892624|NCT04428281|Experimental|Cohort A4 RO7248824|Participants 5-12 Years
9892625|NCT04428281|Experimental|Cohort A5 RO7248824|Participants 5-12 Years
9892626|NCT04428281|Experimental|Cohort B1 RO7248824|Participants 1-4 Years
9892627|NCT04428281|Experimental|Cohort B2 RO7248824|Participants 1-4 Years
9892628|NCT04428281|Experimental|Cohort B3 RO7248824|Participants 1-4 Years
9892629|NCT04428281|Experimental|Cohort B4 RO7248824|Participants 1-4 Years
9892630|NCT04428281|Experimental|Cohort B5 RO7248824|Participants 1-4 Years
9892631|NCT04428281|Experimental|Cohort EA1 RO7248824|New participants (age 5-12) enrolling directly in the LTE part
9892632|NCT04428281|Experimental|Cohort EA2 RO7248824|Participants continuing from MAD cohorts A1 and A2
9892633|NCT04428281|Experimental|Cohort EA3 RO7248824|Participants continuing from MAD cohorts A3 and A4
9892634|NCT04428281|Experimental|Cohort EA4 RO7248824|Participants continuing from MAD Cohort A5
9892635|NCT04428281|Experimental|Cohort EB1 RO7248824|New participants (age 1-4) enrolling directly into the LTE
9892636|NCT04428281|Experimental|Cohort EB2 RO7248824|Participants continuing from MAD cohorts B1 and B2
9892637|NCT04428281|Experimental|Cohort EB3 RO7248824|Participants continuing from MAD cohorts B3 and B4
9892638|NCT04428281|Experimental|Cohort EB4 RO7248824|Participants continuing from MAD Cohort B5
9892639|NCT04423718|Active Comparator|Aflibercept 2q8|Aflibercept 2 mg administered every 8 weeks after a loading phase.
9892640|NCT04423718|Experimental|Aflibercept high dose (HD)q Interval A|Aflibercept high dose administered at a treatment interval A after a loading phase.
9892641|NCT04423718|Experimental|Aflibercept (HD)q Interval B|Aflibercept high dose administered at a treatment interval B after a loading phase.
9892642|NCT04423029|Experimental|Monotherapy Dose Escalation|
10212036|NCT03059355|Experimental|Pilot Phase: Group 3 (BMMSCs - 20 million)|Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
10212037|NCT03059355|Experimental|Pilot Phase: Group 4 (BMMSCs -100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
10212038|NCT03059355|Experimental|Group A (UCMSCs - 20 Million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
10212039|NCT03059355|Experimental|Group B (UCMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
9667108|NCT03954327|Placebo Comparator|Placebo|Identical tablets resembling one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
9892643|NCT04423029|Experimental|Monotherapy Dose Expansion (Melanoma)|
9892644|NCT04423029|Experimental|Monotherapy Dose Expansion (NSCLC)|
9892645|NCT04423029|Experimental|Combination Dose Escalation|
9892646|NCT04423029|Experimental|Combination Dose Expansion (Melanoma)|
9892647|NCT04423029|Experimental|Combination Dose Expansion (NSCLC)|
9892648|NCT04422314||Cohort 1|Lyme disease testing cohort
9892649|NCT04422314||Cohort 2|Endemic, asymptomatic controls
9892650|NCT04422314||Cohort 3|Non-endemic, asymptomatic controls
9892651|NCT04422314||Cohort 4|Potential cross-reactive disease states
9892652|NCT04422314||Cohort 5|Lyme disease testing cohort
9892653|NCT04417049|Experimental|Pentoxifylline|
9892654|NCT04414384|Experimental|Abdominal Binder|During this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
9892655|NCT04414384|Other|Control|This group of patients will not wear abdominal binders, but during this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
9892656|NCT04401748|Experimental|Arm 1: Venetoclax + Azacitidine (AZA)|Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
9892657|NCT04401748|Active Comparator|Arm 2: Placebo + Azacitidine|Participants will receive placebo once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
9892658|NCT04372927|Experimental|Treatment (chemotherapy, durvalumab, radiation therapy)|Patients with squamous cell cancer receive standard of care chemotherapy consisting of cisplatin on days 1, 8, 29, and 36, and etoposide on days 1-5 and 29-33. Cycles repeat every 4 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell cancer receive standard of care chemotherapy consisting of cisplatin and pemetrexed on days 1, 21, and 42. Cycles repeat every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. All patients receive durvalumab IV over 1 hour Q4W. Radiation to the primary tumor will be given over 8-15 fractions during weeks 1-3 of chemotherapy. For patients who have residual disease in the mediastinal lymph nodes at week 9, radiation will be given to the lymph nodes starting week 11. Durvalumab is given for 2 years after completion of radiationin the absence of disease progression or unacceptable toxicity.
9892659|NCT04372602|Experimental|Duvelisib|-Duvelisib 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.
9892660|NCT04372602|Sham Comparator|Placebo|-Placebo 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.
9892661|NCT04363606|Experimental|"Non-fatigued patients who have been in intensive care units"|
9892662|NCT04363606|Experimental|"Fatigued patients who have been in intensive care units"|
9892663|NCT04363606|Experimental|patients who have not been in intensive care units|
9892664|NCT04363112|Other|study with just one arm|"All of participants are in this arm. Mini Kid II and CBCL score are administered between day 3 and 7. Moreover, salivary test will be remove to evaluate cortisol secretion, 4 time per day during 2 consecutive days.~Psychologic aftercare will be propose if children have psychologic troubles (results of Mini Kid II)"
9892665|NCT04356599|Experimental|Intervention Group|All participants will receive study intervention
9892666|NCT04353661|Experimental|Arm A Open-label: azithromycin + SOC therapy|Participants will receive azithromycin and SOC theraphy for 52 weeks.
9892667|NCT04353661|Active Comparator|Arm A Open-label: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
9892668|NCT04353661|Active Comparator|Arm B Observational: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
9892669|NCT04350866||Pre-Implementation (0-, 6-, 12-, or 18-months)|Following training in BBTI, all sites (except site 1) will enter the pre-implementation phase for 6-, 12-, or 18-months. During this phase, sites will not receive any access to or support for the implementation strategies. They will deliver and implement BBTI as they see fit. Qualitative interviews will be conducted at the end of this phase.
9517150|NCT03309059|Active Comparator|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
9892670|NCT04350866||Implementation (12-months)|After the pre-implementation phase, all sites will enter a 12-month implementation phase (except site 1, which will begin implementation following BBTI training). During this phase, sites will receive access to and support for the bundle of implementation strategies, both from the hub site and their local champion/internal facilitator. During this phase, PCMHI clinicians trained in BBTI will receive feedback as necessary regarding their BBTI skills from their local champion/internal facilitator. During this phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
9892671|NCT04350866||Post-Implementation (6-months)|Following the 12-month implementation phase, each site will have access to and support for the implementation strategies removed and similar to the pre-implementation phase, will deliver and implement BBTI as they see fit. During this 6-month phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
9892672|NCT04349267|Experimental|BMS-986315|
9892673|NCT04349267|Experimental|BMS-986315 + nivolumab|
9892674|NCT04349267|Experimental|BMS-986315 + cetuximab|
9892675|NCT04336410|Experimental|Group 1: INO-4800|Participants will receive one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
9892676|NCT04336410|Experimental|Group 2: INO-4800|Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
9892677|NCT04336410|Experimental|Group 3: INO-4800|Participants will receive one ID injection of 0.5 mg of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
9892678|NCT04335656|Experimental|Treatment Group|Subjects will be randomized to the treatment or placebo group. The treatment is a capsule taken by mouth once a day for 6 months.
9892679|NCT04335656|Placebo Comparator|Placebo Group|Subjects will be randomized to the treatment or placebo group. The placebo is a capsule taken by mouth once a day for 6 months.
9892680|NCT04322006|Experimental|TJ004309 Injection|2mg/kg~20mg/kg TJ004309 Injection is administered once a week for a treatment cycle every 28 days
9892681|NCT04317781|Experimental|Treatment (tagraxofusp-erzs)|Within day 45 and 180 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9892682|NCT04316117|Experimental|Diagnostic (FDG-PET/CT)|Patients receive FDG IV and undergo PET/CT scan over 15-30 minutes at baseline (within 21 days before start of standard systemic treatment) and at 12 weeks after start of standard systemic treatment in the absence of unacceptable toxicity.
9892683|NCT04303702|Other|Discontinue Oxytocin|
9892684|NCT04303702|Active Comparator|Continue Oxytocin|
9892685|NCT04298827|Active Comparator|Unimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment.
9892686|NCT04298827|Active Comparator|Trimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation, nutritional counseling and group therapy, prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment. Patient nutritional assessments will be obtained with Patient Generated Subjective Global Assessment questionnaires as well as targeted questioning by the dietician.
9892687|NCT04293341|Experimental|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
9892688|NCT04293341|Active Comparator|Disorder Specific Therapies|To provide an evidence-based comparison for the TBT condition, DSTs will be used that are matched to the participant's most severe diagnosis, based upon the average of the ADIS interference and distress scores. If the scores are equivalent for two or more diagnoses, participants will be asked to list which diagnosis/symptoms that they find most impairing. DSTs will be included for each of the three targeted diagnoses, including PTSD (CPT for PTSD), PD/AG (CBT for PD/AG), and MDD (CBT for MDD). Each of these DSTs have published manuals for administration and have received extensive support in the literature (Barlow, 2014).
9892689|NCT04291703|Experimental|Antithymocyte globulin (ATG)|Antithymocyte globulin (ATG) will be intravenously administered over two days, with a total of 2 infusion periods. The first infusion is given at baseline visit (day 1), the second is given the next day at baseline visit (day 2). Body weight at baseline (Day 0- admission for the ATG/placebo infusion) will be used in calculating the doses for all infusions. The first dose (0.5mg/kg) will be infused over a minimum of 4 hours, and the second dose (2mg/kg) over a minimum of 4 hours with a maximum infusion time for each infusion of 10 hours. The second dose should be given no less than 12 and no more than 24 hours after completion of the previous dose. The final prepared product is to be labeled to protect the blind. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion.
9892690|NCT04291703|Placebo Comparator|Placebo|"0.9% Sodium Chloride Injection USP (Normal saline) is to be dispensed as the placebo for this study. The placebo is to be prepared dispensing an infusion bag of 0.9% Sodium Chloride Injection USP (Normal saline) with no additives (no ATG, no premedications) and label the product to protect the blind. The placebo will also be administered over a minimum of 4 hours for the first and second doses with a maximum infusion time of 10 hours. The second dose of the placebo arm should be given no less than 12 and no more than 24 hours after completion of the previous dose. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion."
9892691|NCT04289753|Active Comparator|Brief clinician education|Clinicians attributed to clinics in the brief clinician education arm will receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
9892692|NCT04289753|Experimental|Clinical decision support nudges and brief clinician education|Clinicians attributed to clinics randomized to the clinical decision support nudges and brief clinician decision support arm will receive clinical decision support within the EHR when conditions meet alert triggering criteria. These clinicians will also receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
9892693|NCT04285567|Experimental|VEN + G|Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
9892694|NCT04285567|Active Comparator|FCR/BR|Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
9892695|NCT04279613|Experimental|NNC0361-0041|Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s) in cohort 1: 1mg Additional doses in cohorts 2, 3, and 4: 5mg, 12.5mg and 25mg Dosing instructions: Once weekly on site
9892696|NCT04279613|Placebo Comparator|Placebo|Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site
9892697|NCT04266015|No Intervention|Control group|Patients assigned to control group will not receive feeding via the nasogastric tube during operation
9892698|NCT04266015|Experimental|Intraoperative feeding group|Patients assigned to intraoperative feeding group will receive enteral nutrition formula via the nasogastric tube during operation
9892699|NCT04262856|Experimental|Arm 1 (zimberelimab monotherapy)|Participants will receive zimberelimab as an intravenous (IV) infusion.
9892700|NCT04262856|Experimental|Arm 2 (domvanalimab and zimberelimab combination therapy)|Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.
9892701|NCT04262856|Experimental|Arm 3 (domvanalimab, zimberelimab, and etrumadenant combination therapy)|Participants will receive oral etrumadenant in combination with zimberelimab IV and domvanalimab IV infusion
9892702|NCT04259450|Experimental|AFM24|"Phase 1: Treatment of escalating doses of AFM24.~Phase 2a: Treatment of AFM24 at maximum tolerated dose/recommended phase 2 dose, stratified into cohorts by tumor type."
9892703|NCT04259411|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.
9892704|NCT04255212|Experimental|Soft tissue treatment|Participants will be treated with 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms.
9892705|NCT04255212|Placebo Comparator|Mechaninsms explanation|Participants will be instructed with a 10 minute lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
9892706|NCT04255212|Other|Control group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
9892707|NCT04255212|Experimental|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
9892708|NCT04251130|Experimental|Cognitively Normal Older Adults|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
9892709|NCT04251130|Experimental|Mild Cognitively Impaired Older Adults or Older Adults with Alzheimer's Disease|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
9892710|NCT04250155|Experimental|Phase 1a Dose Escalation|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
9892711|NCT04250155|Experimental|Phase 1a Dose Expansion|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
9892712|NCT04250155|Experimental|Phase 1b Dose Escalation|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
10212040|NCT03059355|Experimental|Group C (BMMSCs - 20 million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
10212041|NCT03059355|Experimental|Group D (BMMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
9892713|NCT04250155|Experimental|Phase 1b Dose Expansion|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
9892714|NCT04247542|Experimental|Ibezapolstat|Active investigational antibacterial agent: ibezapolstat 450 mg po Q12H x 10 days
9892715|NCT04247542|Active Comparator|Vancomycin|Standard of care: Vancomycin 125 mg po Q6H x 10 days
9892716|NCT04246437|Experimental|[18F]F-DOPA|All patients will receive [18F]F-DOPA for PET imaging to measure pre-synaptic dopamine in the brain.
9892717|NCT04243720||Immune Resistance Interrogation Study (IRIS)|Patients with a histological or cytological diagnosis of solid malignancies. Patients must have progressed on immunotherapy as their most recent line of therapy.
9892718|NCT04240002|Experimental|Dose Escalation - 2 years to less than 21 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
9892719|NCT04240002|Experimental|Dose Escalation - 1 year to less than 2 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
9892720|NCT04240002|Experimental|Dose Escalation - 6 months to less than 1 year of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
9892721|NCT04240002|Experimental|Dose Expansion|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the dose determined in dose escalation portion. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
9892722|NCT04236297|Other|Modified Bite Block|Patients undergoing transesophageal echocardiogram under sedation or general anesthesia during which a modified bite block is used
9892723|NCT04234113|Experimental|Experimental: Part A (SO-C101 Monotherapy)|Drug: SO-C101
9892724|NCT04234113|Experimental|Experimental: Part B (SO-C101 combined with pembrolizumab)|Drug: SO-C101 Drug: pembrolizumab
9892725|NCT04234113|Experimental|Experimental: Part A1 (SO-C101 divided dosing, Monotherapy)|Drug: SO-C101, twice a day as 2 divided doses (50%:50%)
9892726|NCT04234113|Experimental|Experimental: Part B1 (SO-C101 divided dosing, combined with pembrolizumab)|Drug: SO-C101, twice a day as 2 divided doses (50%:50%) Drug: pembrolizumab
9892727|NCT04234113|Experimental|Experimental: Part D (SO-C101 Monotherapy, dose expansion at the RP2D identified in Part A)|Drug: SO-C101 Indications: Relapsed/refractory advanced/metastatic renal cell carcinoma, relapsed/refractory advanced/metastatic skin squamous-cell carcinoma, and relapsed/refractory advanced/metastatic melanoma.
9892728|NCT04234113|Experimental|Part D1 (SO-C101 divided dosing, Monotherapy, dose expansion at RP2D identified in Part A1)|Drug: SO-C101, twice a day as 2 divided doses (50%:50%) Indications: Relapsed/refractory advanced/metastatic renal cell carcinoma, relapsed/refractory advanced/metastatic skin squamous-cell carcinoma, and relapsed/refractory advanced/metastatic melanoma.
9892729|NCT04231734|Experimental|All Subjects|Low tumor burden, treatment-naïve MCL
9892730|NCT04225416||Hemodialysis patients|Patients undergoing hemodialysis
9892731|NCT04225416||Peritoneal dialysis patients|Patients undergoing peritoneal dialysis
9892732|NCT04222972|Experimental|Pralsetinib|Participants randomized to the Experimental Arm will receive Pralsetinib
9892733|NCT04222972|Active Comparator|Platinum-based chemotherapy with or without pembrolizumab|"Participants randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology)~Nonsquamous histology~Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance.~Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance.~Squamous histology~Carboplatin or cisplatin / gemcitabine~Carboplatin with paclitaxel/nab-paclitaxel and pembrolizumab"
9892734|NCT04222569|Experimental|T-piece and PSV 7 PEEP 0 and PSV 0 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
10212042|NCT03059355|Placebo Comparator|Group E (Placebo)|Five (5) subjects will be treated with a single administration of placebo delivered via peripheral intravenous infusion.
10212043|NCT03020199|Experimental|A1|80 patients (65 in Arm A1a and 15 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive.
9892735|NCT04222569|Experimental|T-piece and PSV 0 PEEP 0 and PSV 7 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
9892736|NCT04222569|Experimental|PSV 0 PEEP 0 and PSV 7 PEEP 0 and T-piece|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
9892737|NCT04222569|Experimental|PSV 0 PEEP 0 and T-piece and PSV 7 PEEP 0|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
9892738|NCT04222569|Experimental|PSV 7 PEEP 0 and T-piece and PSV 0 PEEP 0|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
9892739|NCT04222569|Experimental|PSV 7 PEEP 0 and PSV 0 PEEP 0 and T-piece|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
9892740|NCT04205396|Experimental|Written emotional disclosure|
9892741|NCT04205396|Experimental|Resilience training|
9892742|NCT04205396|Other|Control arm|
9892743|NCT04200508|Experimental|Intervention|Targeted gown and glove use for high risk care activities in high risk residents
9892744|NCT04200508|No Intervention|Baseline|Standard of Care
9892745|NCT04196413|Experimental|GD2-CAR T|"Dose escalation in subjects with DIPG:~A standard 3+3 dose escalation design will test GD2-CAR T cells in subjects with H3K27M-mutant DIPG, starting with Dose~Level 1:~Dose Level 1: 1x10^6 CAR+ T cells/kg body weight (+/- 20%)~Dose Level 2: 3x10^6 CAR+ T cells/kg body weight (+/- 20%)~Dose Level 3: 10x10^6 CAR+ T cells/kg body weight (+/- 20%)~Dose Level -1 will be explored if the first subject treated experiences dose limiting toxicity (DLT) or if >2 of 6 subjects treated at Dose Level 1 experiences DLT.~Dose expansion in subjects with DIPG and spinal DMG: Once the MTD or RP2D is determined, up to 20 evaluable subjects with H3K27M-mutant DIPG and 10 evaluable subjects with H3K27M-mutant spinal DMG will be treated at the RP2D (including subjects treated during dose escalation)."
9892746|NCT04186442|Experimental|Botulinum toxin type A (Botulax®)|
9892747|NCT04186442|Active Comparator|Botulinum toxin type A (Botox®)|
9892748|NCT04184882|Experimental|ASP0367 group|Participants will be dosed investigational product (IP) at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks in the DB part and OLE part, respectively.
9892749|NCT04184882|Placebo Comparator|Placebo to ASP0367 group|Participants will be dosed matching placebo in the DB part. In OLE part, participants will dosed IP at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks.
9892750|NCT04177953|Active Comparator|Carboplatin or Cisplatin and Pemetrexed|"Four cycles (q4w) platinum-based adjuvant chemotherapy i.v.:~carboplatin AUC5 or cisplatin 75 mg/m2~pemetrexed 500 mg/m2"
9892751|NCT04177953|Experimental|Carboplatin or Cisplatin and Pemetrexed + Nivolumab|"Four cycles (q4w) of a combination of platinum-based adjuvant chemotherapy and immunotherapy i.v.:~carboplatin AUC5 or cisplatin 75 mg/m2~pemetrexed 500 mg/m2~nivolumab 480 mg flat-dose.~Followed by up to 12 cycles (q4w) maintenance immunotherapy:~- nivolumab 480 mg flat-dose i.v."
9892752|NCT04176081|Active Comparator|Group 1: Radiation Therapy Only|Participants randomized to Group 1 will receive radiation therapy only.
9892753|NCT04176081|Experimental|Group 2: Radiation Therapy + darolutamide + degarelix|Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix.
9892754|NCT04171895||Enhanced Usual Care (EUC)|
9892755|NCT04171895||Communication Training|
9997521|NCT01509482|Active Comparator|Fertile males|Healthy Men with proven fertility. Blood samples will be taken for hormonal and blood lipids analysis
9892756|NCT04170361|Active Comparator|Control Group|Patients will be admitted to chest physiotherapy program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization.
9892757|NCT04170361|Experimental|Training Group|In addition to conventional chest physiotherapy program, patients in this group will also be taught to use Triflo ® and apply at two-hour intervals.
9892758|NCT04168684|Experimental|Attachment and Biobehavioral Catch-up (ABC)|10 sessions that focused on parental nurturance, and sensitivity
9892759|NCT04168684|Active Comparator|Developmental Education for Families (DEF)|10 sessions that focused on cognitive development
9892760|NCT04163003|Experimental|TAPAS|Participants will participate in the TAPAS intervention, which will consist of one in-person engagement session with a therapist and 8 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week.
9892761|NCT04163003|Experimental|Sleep monitoring only, then TAPAS|Participants will participate in sleep monitoring only first, then participate in the TAPAS intervention. First, participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.TAPAS will consist of one engagement session with a therapist and 4 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week. Sleep monitoring is proposed to last the same duration as the targeted intervention in this arm.
9892762|NCT04159220|No Intervention|Control group|The transport will be released without a clamping of endotracheal tube before each disconnection from ventilator.
9892763|NCT04159220|Experimental|Clamping group|The transport will be released with a clamping of endotracheal tube before each disconnection from ventilator.
9892764|NCT04158583|Experimental|Part A|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682. RO7296682 will be administered by intravenous (IV) infusion in a three-weekly schedule (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
9892765|NCT04158583|Experimental|Part B|Dose-Expansion: Will start once MTD/RP2D dose is defined in Part A. Participants will receive a fixed dose of RO7296682 at the dosing regimen established in part A (Q3W schedule).
9892766|NCT04153422|Experimental|Treatment (IVIG)|Patients in the treatment arm will receive 2g/kg Gammagard IVIG initially (1g/kg dose on Day 1 and 1g/kg dose on Day 2) and then 1g/kg maintenance infusions for 5 additional months (six months total).
9892767|NCT04153422|Placebo Comparator|Placebo|Patients in the placebo arm will receive 0.9% NaCl during the initial infusion and at maintenance infusions for 5 additional months (six months total).
9892768|NCT04151082|Experimental|Supportive care (steroid therapy)|Patients receive prednisone PO (or by feeding tube) QD on days 1-5 and then taper off over 2 weeks or methylprednisolone IV over 1 hour on days 1-5 in the absence of disease progression or unacceptable toxicity.
9892769|NCT04149574|Experimental|Arm A: nivolumab + Bacillus Calmette-Guérin (BCG)|
9892770|NCT04149574|Placebo Comparator|Arm B: placebo +BCG|
9892771|NCT04145076|Experimental|Placebo, Citalopram, Tianeptine|Dose order: Placebo, Citalopram, Tianeptine
9892772|NCT04145076|Experimental|Placebo, Tianeptine, Citalopram|Dose order: Placebo, Tianeptine, Citalopram
9892773|NCT04145076|Experimental|Citalopram, Placebo, Tianeptine|Dose order: Citalopram, Placebo, Tianeptine
9892774|NCT04145076|Experimental|Citalopram, Tianeptine, Placebo|Dose order: Citalopram, Tianeptine, Placebo
9892775|NCT04145076|Experimental|Tianeptine, Placebo, Citalopram|Dose order: Tianeptine, Placebo, Citalopram
9892776|NCT04145076|Experimental|Tianeptine, Citalopram, Placebo|Dose order: Tianeptine, Citalopram, Placebo
9892777|NCT04140708|Experimental|Exercise--Rock Steady Boxing class|Participants will be going twice a week to a Rock Steady Boxing class for an hour/class. Participants will be going to this class for a total of three months.
9892778|NCT04133948|Experimental|A|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks)
9892779|NCT04133948|Experimental|B|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
9892780|NCT04133948|Experimental|C|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
9892781|NCT04133948|Experimental|D|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + ipilimumab 80 mg (q3weeks) + domatinostat. Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200 mg, on days 1-14 (q3weeks). Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200 mg BID, days 1-14, q3weeks), a lower dosing scheme (100 mg OD, days 1-14, q3weeks), or the same dosing scheme (200 mg OD, days 1-14, q3weeks).
9892782|NCT04131413|Other|Vaccination Arm Level 1|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; Level 1 dose of 0.3 mg
9892783|NCT04131413|Other|Vaccination Arm Level 2|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 2 at dose 1.0 mg
9892784|NCT04131413|Other|Vaccination Arm Level 3|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 3 dose of 3.0 mg
9892785|NCT04130997|Experimental|Ublituximab Infusions|"RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 168.~RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 168.~For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 168 weeks, or until physician or participant decision to withdraw from the study"
9892786|NCT04123795|Experimental|Cohort A - certolizumab pegol|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent Open-Label Extension Period.
9892787|NCT04123795|Placebo Comparator|Cohort A - placebo|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of placebo from Week 1 to 16 and certolizumab pegol to Week 52 and through the subsequent Open-Label Extension Period.
9892788|NCT04123795|Experimental|Cohort B - certolizumab pegol|Enrolling study participants aged 6 to 11 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent Open-Label Extension Period.
9892789|NCT04117672|Placebo Comparator|Placebo|Egg yolk powder not enriched for antisecretory powder
9892790|NCT04117672|Experimental|Salovum|Egg yolk powder enriched for antisecretory powder
9892791|NCT04099628|Experimental|Diagnostic tests|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
9892792|NCT04094961|Experimental|ixazomib plus pomalidomide and dexamethasone|"The study drugs will be administered within a 21-day cycle~Phase I will follow a standard 3 +3 dose escalation design: Starting with the first cohort, 3 to 6 patients will be treated at this and each subsequent dose level.~The Phase II portion of the study will be a single-arm open-label enrollment with dosing based on the MTD determination in the Phase I portion of the study"
9892793|NCT04089358|Active Comparator|Control Group (educational materials, Fitbit)|Participants receive educational materials about physical activity and wear a Fitbit daily for 48 weeks.
9892794|NCT04089358|Experimental|Intervention group (educational materials, goal set, Fitbit)|See outline
9932409|NCT00948701|Experimental|Phone-based PA program (RTR Plus)|"The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials. RTR volunteers or coaches will be asked to contact participants by telephone once a week for 12 weeks. The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers."
9932410|NCT00948701|Active Comparator|Standard RTR services (RTR)|RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
9932411|NCT00948714|Experimental|Case|
9932412|NCT00948714|Active Comparator|Control|
9932413|NCT00948727|Experimental|Dose adjustment according CN activity|
9997522|NCT01509508|Experimental|Immediate ARV treatment initiation|Initiation of ARV treatment regardless of participants's immunological and clinical staging
9892795|NCT04083456|Experimental|Walking Biobehavioral Intervention (EXP)|The EXP group will receive biobehavioral training that is integrated into the conventional outpatient training component and is delivered over 5 months. There will be 10 biobehavioral sessions, 1 of which will be a combined biobehavioral/conventional outpatient session and the other 9 being telehealth sessions.
9892796|NCT04083456|Active Comparator|Attention Control (CTL)|The CTL group intervention will include the same conventional outpatient training (10 sessions) as the EXP group and receive the same computer tablets with telehealth software as the EXP group (week 3 of prosthetic training).
9892797|NCT04072289|Experimental|Low cylinder (treatment)|0.25D and 0.50D cylinder treatments will be measured and treated by the laser.
9892798|NCT04072289|No Intervention|Low cylinder (no treatment)|0.25D and 0.50D cylinder treatments will be measured but not treated by the laser. No spherical equivalent will be used.
9892799|NCT04067752|Experimental|High Dialysate Na|high dialysate sodium concentration (138 mEq/L)
9892800|NCT04067752|Active Comparator|Low Dialysate Na|Low dialysate sodium concentration (132 mEq/L)
9892801|NCT04062630|Active Comparator|Standard care|Multilevel Lumbar Fusion Surgery
9892802|NCT04062630|Experimental|Standard Care + iFuse 3-D|Multilevel Lumbar Fusion Surgery with additional placement of iFuse 3-D in a trajectory parallel to the S2AI screws
9892803|NCT04054674|Experimental|flat occlusal scheme restored by lithium disilicate crown|flat occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
9892804|NCT04054674|No Intervention|planar occlusal scheme restored by lithium disilcate crown|planar occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
9892805|NCT04053881||Certolizumab pegol|Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).
9892806|NCT04052490|Experimental|flat occlusal reduction with feather edge finish|
9892807|NCT04052490|Experimental|flat occlusal reduction with shoulder finish line|
9892808|NCT04052490|No Intervention|planar occlusal reduction with shoulder finish line|
9892809|NCT04041258|Experimental|evaluation of clinical and radiographic findings after surgical treatment|Evaluation of clinical and radiographic findings at least 1 year after surgical treatment for pseudoarthrosis of clavicle
9892810|NCT04032470||Essential Tremor|Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems
9892811|NCT04031690||patient-caregiver dyads|
9892812|NCT04030676|Experimental|QuantiFERON Test|Patient with CytoMegaloVirus (CMV) infection will be included. They will have biopsies and blood samples, composite of QuantiFERON-CytoMegaloVirus (QF-CMV) assay.
9892813|NCT04029922|Experimental|Arm 1- Dose Escalation|"The dose escalation part of the study is aimed at determining the Recommended Phase 2 Dose (RP2D) of MT-5111.~The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
9892814|NCT04029922|Experimental|Arm 1- Dose Expansion|"The dose expansion part of the study will begin after completion of the dose escalation phase to confirm the safety and tolerability of the RP2D.~The RP2D dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
9892815|NCT04026412|Experimental|Arm A: nivolumab + CCRT + ipilimumab|Concurrent chemoradiotherapy (CCRT)
9892816|NCT04026412|Experimental|Arm B: nivolumab + CCRT|Concurrent chemoradiotherapy (CCRT)
9892817|NCT04026412|Experimental|Arm C: CCRT + durvalumab|Concurrent chemoradiotherapy (CCRT)
9892818|NCT04016805|Experimental|ublituximab + umbralisib + ibrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~ibrutinib: dose tolerated by subject; to be administered daily"
9892819|NCT04016805|Experimental|ublituximab + umbralisib + venetoclax|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~venetoclax: dose tolerated by subject; to be administered daily"
9892820|NCT04016805|Experimental|ublituximab + umbralisib + acalabrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~acalabrutinib: previously tolerated dose; to be administered every 12 hours"
9892821|NCT04012099|Experimental|BMT101|BMT101 injection (treatment)
9892822|NCT04012099|No Intervention|control|Un-treated control
9667109|NCT03954314|Active Comparator|Topical Tranexamic Acid/Placebo|Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
9667110|NCT03954314|Active Comparator|Intravenous Tranexamic Acid/Placebo|Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.
9892823|NCT04002674|Placebo Comparator|Placebo|"Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
9892824|NCT04002674|Active Comparator|200 mg Nilotinib|Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
9892825|NCT03996473|Experimental|Phase 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
9892826|NCT03996473|Experimental|Phase 2 Cohort 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
9892827|NCT03996473|Active Comparator|Phase 2 Cohort 1: Pembrolizumab alone|Participants will receive pembrolizumab every 3 weeks
9892828|NCT03996473|Experimental|Phase 2 Cohort 2: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
9892829|NCT03993054|Active Comparator|Standard CBSM|Participants will receive standard web-based cognitive behavioral stress management (CBSM) over 4 weeks.
9892830|NCT03993054|Experimental|Culturally-tailored CBSM|Participants will receive web-based CBSM that is culturally-tailored for Latino men specifically over 4 weeks.
9892831|NCT03992443|Experimental|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 milligrams (mg) per 2 milliliter (mL) directly into the catheter lumen. Participants received the first dose at minute (min) 0, and the second dose, if needed, at min 90. Assessments were performed at min 30, 60, 90, 120, 150, and 180.
9892832|NCT03986593|Other|Cryoablation +- cementoplasty treated patients|cone beam computed tomography guided cryoablation +- cementoplasty
9892833|NCT03970590|Experimental|CTC|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
9892834|NCT03970590|Active Comparator|Control|6-month HTN management assessment text messages without narrative component
9892835|NCT03967600||Hidradenitis Suppurativa Patients|Patients with physician diagnosed Hidradenitis Suppurativa
9892836|NCT03967600||Healthy Volunteers|Healthy volunteers without any skin conditions or recent history of antibiotic use.
9892837|NCT03965728|Experimental|BAY1830839 arm|Period 1: Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, single dose. Period 2: Dose 1, Dose 2 and Dose 3, once daily over 10 days. Dose 4 and Dose 5, twice daily over 10 days. Dose 6, single dose on Day 1, three times daily (TID) for 9 days (Days 2-10).
9892838|NCT03965728|Placebo Comparator|Placebo arm|Placebo tablets matching BAY1830839
9892839|NCT03962335|Experimental|VD group|Group that starts with Vegetarian diet (VD)
9892840|NCT03962335|Experimental|MD+Bt group|Group that starts with Mediterranean diet with oral supplementation with butyrate (MD+Bt)
9892841|NCT03962335|Active Comparator|MD group|Group that starts with Mediterranean diet (MD)
9892842|NCT03960554|Active Comparator|Active drug|Denosumab 60 mg subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
9892843|NCT03960554|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
9892844|NCT03959085|Experimental|Arm I (HR-FAV B-ALL)|See detailed description for Arm I
9892845|NCT03959085|Active Comparator|Arm II (HR B-ALL CONTROL)|See detailed description for Arm II.
9892846|NCT03959085|Experimental|Arm III (HR B-ALL EXPERIMENTAL)|See detailed description for Arm III.
9892847|NCT03959085|Experimental|Arm IV (MPAL)|See detailed description for Arm IV.
9892848|NCT03959085|Experimental|ARM V (B-LLY)|See detailed description for Arm V.
9892849|NCT03950739|Experimental|Tyvaso to TreT|Each subject will receive a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.
9892850|NCT03946800|Experimental|MEDI1191 escalation in combination with durvalumab|MEDI1191 escalation in sequential and concurrent combination with durvalumab
9892851|NCT03946800|Experimental|MEDI1191 expansion in combination with durvalumab|MEDI1191 expansion in concurrent combination with durvalumab
9892852|NCT03943446|Experimental|TAK-018 0.30 g Low Dose|TAK-018 3*0.10 gram (g), tablets, orally, twice daily (BID) for up to 26 weeks.
9892853|NCT03943446|Experimental|TAK-018 1.5 g High Dose|TAK-018 3*0.50 g, tablets, orally, BID for up to 26 weeks.
9892854|NCT03943446|Placebo Comparator|Placebo|TAK-018 placebo-matching 3*0 g tablets, orally, BID for up to 26 weeks.
9892855|NCT03939767||wAMD patients|Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.
9892856|NCT03934775||Patients with acute illness|Patients admitted to the acute medical/emergency department and/or Cardiology department at Bispebjerg Hospital.
9892857|NCT03934619|Experimental|Intervention|Convenient cohort, non-randomized group will be enrolled to examine the effects of the Dolores One on improving the ease of communication and intelligibility
9892858|NCT03932201||Previously treated patient (PTPs) with hemophilia A|Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
9892859|NCT03929601|Experimental|Rituximab followed by Abatacept|"Rituximab will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 1 of the study.~Abatacept will be given by a subcutaneous formulation weekly for 2 years, beginning at Week 16 (Month 4) of the study. Dosing will be determined by weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL)."
9892860|NCT03926689|Experimental|Suaahara II Standard + SMS|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.) Suaahara II monthly SMS campaign targeting all adult household members of households in the 1000-day period between conception and a child's second birthday
9892861|NCT03926689|Active Comparator|Suaahara II Standard|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.)
10212044|NCT03020199|Active Comparator|B1|80 patients (65 in Arm B1a and 15 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb-UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle).Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 μg/g and betamethasone 0.5 mg/g.
9892863|NCT03915535|Active Comparator|MaxSimil|Subjects of group A will receive a constant daily dose of 4.3g of MaxSimil, a combination of EPA + DHA in proportions of 500/200, for a period of 90 days.
10212045|NCT03020199|Experimental|A2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
10212046|NCT03020199|Experimental|C1|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 48 inclusive (last dose administered at Week 48)
10212047|NCT03020199|Experimental|C2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
10212048|NCT03020160|Experimental|Emicizumab: Expansion Part|Participants will received SC emicizumab at a loading dose of 3 mg/kg every week for initial 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
10212049|NCT03020160|Experimental|Emicizumab: PK Run-in Part|Participants will received SC emicizumab at a dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
10212050|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A or Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.
10212051|NCT03006068|Experimental|Participants receiving Placebo|The participants in this arm will receive placebo until study is unblinded.
10212052|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose C|The participants in this arm will receive Upadacitinib (ABT-494) dose C.
10212053|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose B.
10212054|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A|The participants in this arm will receive Upadacitinib (ABT-494) dose A.
10212055|NCT03003520|Experimental|DUR + R-CHOP|"On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months."
10212056|NCT03003520|Experimental|DUR + R2-CHOP|"Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.~Enrollment into Arm B was discontinued."
10212057|NCT02995551|Experimental|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
9892864|NCT03915535|Experimental|MAG-EPA|Subjects of group B will receive a constant daily dose of 4.4g of MAG-EPA, a purified formulation of EPA with traces of DHA (730/050), for a period of 90 days.
10212058|NCT02995551|Active Comparator|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
10212059|NCT02992015|Experimental|Gemcitabine|The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.
10212060|NCT02991495|Active Comparator|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
9892872|NCT03910660|Other|Phase 1b|"Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO:~If there are no DLTs, the dose of BXCL701 will be escalated to 0.6 mg in the next cohort.~If ≥1/3 of patients has a DLT in Cycle 1, either 3 patients (if 1 experience a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg dose.~At the 0.4mg dose:~If <1/3 of the patients experience a DLT, consideration will be given to dose to 0.6 mg BXCL701 plus PEMBRO.~If 1/3 of the patients experience a DLT, the Phase 2a can commence. If >1/3 of the patients experience a DLT, a discussion will be held as to how to proceed.~Following 0.6 mg dose. If there are no DLTs, the Phase 2a can commence. If ≥1/3 patients have a DLT in Cycle 1, after a discussion, 6 to 9 patients will be added at the 0.6 mg dose.~For this cohort of 6 to 9 patients:~If </=1/3 of the patients experience a DLT, the Phase 2a can commence"
9892873|NCT03910660|Other|Phase 2a|After assessment of the safety and confirmation of the BXCL701/+PEMBRO dose schedule to be used in the subsequent stage, the Phase 2a will begin. Eligible patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
9892874|NCT03910660|Other|Phase 2b combination|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~• Combination therapy of BXCL701 on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 of every 21 days."
9892875|NCT03910660|Other|Phase 2b monotherapy|"Upon completion of the Phase 2a and achievement of the protocol required composite responses for a given histologic subtype, the Phase 2b enrollment will begin for that subtype. Eligible patients will be randomized to receive:~Monotherapy BXCL701 on Days 1 to 14 of a 21-day cycle. Upon radiographic disease progression with monotherapy, crossover to combination treatment is allowed."
9892876|NCT03907917|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
9892877|NCT03907917|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
9892878|NCT03902704|Experimental|Cleverscope|Cleverscope is a new videolaryngoscope used for tracheal intubation. in this group we use this device to intubate participants.
9892879|NCT03902704|Active Comparator|Laryngoscope / Videolaryngoscope C-MAC® Storz|in this group we use a standart comercial device for intubation (laryngoscope or C-MAC) to intubate participants
9892880|NCT03899649||IRE Cohort|Patients who received SOC and received IRE
9892881|NCT03899649||SOC Cohort|Patients who received SOC and did not receive IRE
9892882|NCT03899636|Experimental|IRE|
9892883|NCT03899636|Active Comparator|Control|
9892884|NCT03889756|Experimental|Ketamine|Ketamine is an FDA-approved anesthetic agent that is commonly used to induce surgical anesthesia due to its low incidence of significant respiratory depression and hypotension. It as a N-methyl-D-aspartate (NMDA) receptor antagonist and glutamatergic modulator, and has been demonstrated in multiple controlled clinical trials to have rapidly acting antidepressant and anti-suicidal effects in adults.
9892885|NCT03889756|Placebo Comparator|Midazolam|Midazolam, the active control in this study, is a medication that is approved by the Food and Drug Administration as a sedative for both children and adults.It is a benzodiazepine with a short half-life that was chosen so as to blind the psychotomimetic effects of Ketamine.
9892886|NCT03880292|Other|Intraoperative Maneuvers|To document intraoperative maneuvers performed in repsonse to alerts
9892887|NCT03877055|Experimental|Copanlisib and Ibrutinib|Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles. Ibrutinib is given orally every day on 28 days cycles. The maximum duration of treatment is 36 cycles not exceeding 36 months. In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation. In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
9892888|NCT03870750|Experimental|Arm I (SPC)|Patients undergo SPC on days -15 before to +56 after transplant. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
9892889|NCT03870750|Experimental|Arm II (CMC)|Patients undergo a CMC program on days -15 to 56. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT..
9892890|NCT03870750|Experimental|Arm III (SPC and CMC)|Patients undergo interventions as outlined in Arm I and Arm II. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
9991061|NCT01449253|Active Comparator|Combination therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. No fixed dose combination will be used.
9991062|NCT01449292|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System and Optimal Medical Therapy
9991063|NCT01449292|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
9991064|NCT01449318|No Intervention|Patients undergoing hysterectomy|
9991065|NCT01449344|Experimental|R-HAD + Bortezomib|
9991066|NCT01449344|Active Comparator|R-HAD|
9991067|NCT01449357|Experimental|zalutumumab|
9991068|NCT01449383|Active Comparator|low meat high fibre (lmhf)|consumption of less than 30g red meat per day and at least 40g dietary fibre per day
9991069|NCT01449383|Active Comparator|high meat low fibre (hmlf)|consumption of 200g red meat and not more than 20g dietary fibre per day
9991070|NCT01449396|Sham Comparator|SHAM ACUPUNCTURE|Sham intervention: acupuncture needle without puncture nor stimulation
9991071|NCT01449396|Experimental|REAL ACUPUNCTURE|Experimental: acupuncture in selected points of the protocol designed
9991072|NCT01449396|Other|Control|Bed Rest
9991073|NCT01449422|Experimental|URGO 310 3082|
9991074|NCT01449422|Active Comparator|Aquacel|
9991075|NCT01449448|Experimental|NSAID|Test Group: This group was given subacromial injections of Ketorolac.
9991076|NCT01449448|Active Comparator|Steroid|This group was given a subacromial injection triamcinolone.
9991077|NCT01449474|Experimental|Group 1|Patient matched instruments
9991078|NCT01449474|Experimental|Group 2|Jig based instruments
9991079|NCT01449487|Active Comparator|PPC-5650|
9991080|NCT01449487|Placebo Comparator|Placebo|
9991081|NCT01449500|Placebo Comparator|Placebo|Placebo
9991082|NCT01449500|Active Comparator|L. reuteri|"L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.~Intervention: Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475"
9991083|NCT01449552|Experimental|Group A|No clamp and placebo
9991084|NCT01449552|Experimental|Group B|Tranexamic acid
9991085|NCT01449552|Experimental|Group C|Drain clamping
9991086|NCT01449552|Experimental|Group D|Drain clamping and tranexamic acid
9991087|NCT01449565|Active Comparator|Naltrexone|
9991088|NCT01449565|Placebo Comparator|Placebo|
9991089|NCT01449578|Experimental|Part A, Treatment 1|Dexpramipexole single dose (SAD Dose 1)
9991090|NCT01449578|Placebo Comparator|Part A, Treatment 1 placebo|Dexpramipexole single dose placebo (SAD Dose 1)
9991091|NCT01449578|Experimental|Part A, Treatment 2|Dexpramipexole single dose (SAD Dose 2)
9991092|NCT01449578|Placebo Comparator|Part A, Treatment 2 placebo|Dexpramipexole single dose placebo (SAD Dose 2)
9991093|NCT01449578|Experimental|Part A, Treatment 3|Dexpramipexole single dose (SAD Dose 3)
9991094|NCT01449578|Placebo Comparator|Part A, Treatment 3 placebo|Dexpramipexole single dose placebo (SAD Dose 3)
9991095|NCT01449578|Experimental|Part B, Treatment 1|Dexpramipexole multiple dose (MAD Dose 1)
9991096|NCT01449578|Placebo Comparator|Part B, Treatment 1 placebo|Dexpramipexole multiple dose placebo (MAD Dose 1)
9991097|NCT01449578|Experimental|Part B, Treatment 2|Dexpramipexole multiple dose (MAD Dose 2)
9991098|NCT01449578|Placebo Comparator|Part B, Treatment 2 placebo|Dexpramipexole multiple dose placebo (MAD Dose 2)
9991099|NCT01449604|Active Comparator|stereotactic radiosurgery|Radio surgery single fraction 12 Gy
9991100|NCT01449604|Active Comparator|stereotactic radiotherapy|Stereotactic radiotherapy hypo fraction 18 Gy in 3 fraction
9991101|NCT01449617||Aspirin plus clopidogrel|Patients undergoing stenting for critical carotid stenosis, either symptomatic (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.
9991102|NCT01449643|Active Comparator|IMT Group|Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
9991103|NCT01449643|Sham Comparator|Sham Group|Non-training protocol
9991104|NCT01449656||LMA proseal|
9991105|NCT01449656||LMA Supreme|
9991106|NCT01449695|Experimental|Lifestyle counseling|Group consultation and individual nurse consultation
9991107|NCT01449695|Experimental|e health|An individual web based entry
9991108|NCT01449695|No Intervention|usual care|Usual care
9991109|NCT01449760|No Intervention|No treatment|
9991110|NCT01449760|Active Comparator|Physical Therapy|
9991111|NCT01449760|Experimental|Wii Balance group|
9991112|NCT01449773|Experimental|n-3 PUFAs|
9991113|NCT01449773|Placebo Comparator|Corn and soybean oil pill|
9991114|NCT01449786|Experimental|treatment with rMal d 1|these apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major apple allergen, Mal d 1 during 4 months
9991115|NCT01449786|Active Comparator|treatment with rBet v 1|These apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major birch pollen allergen,Bet v 1 during 4 months
9991116|NCT01449786|Placebo Comparator|treatment with placebo drops|These apple and birch pollen allergic patients are treated daily with placebo applied sublingually during 4 months
9991117|NCT01449799|Experimental|Sequence 1|In period 1, subjects will be administered GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers in period 2. In period 3 and period 4, the subjects will receive fluticasone propionate and GSK961081 respectively.
9997523|NCT01509508|Other|South African recommendation guided ARV initiation|HIV-infected individuals will be assessed clinically and immunologically and when eligible for treatment as per South African guidelines will be offered ART
9892891|NCT03870750|Active Comparator|Arm IV (standard of care)|Patients receive standard of care. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
9892892|NCT03869905|Experimental|Aquamin®|To be taken for 180 days
9892893|NCT03869905|Placebo Comparator|Placebo first then Aquamin®|Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)
9892894|NCT03869892|Experimental|S95005 + Bevacizumab|
9892895|NCT03869892|Active Comparator|Capecitabine + Bevacizumab|
9892896|NCT03869853|Experimental|intervention|Entrepreneurial stimulation and integrated education
9892897|NCT03869853|Experimental|control|no intervention
9892898|NCT03865498|Experimental|Hispanic dementia caregivers|De-identified followers of our Hispanic dementia caregiver Twitter network will receive messages from the network (Twitter for Hispanic caregivers' intervention).
9892899|NCT03865498|Experimental|African American dementia caregivers|De-identified followers of our African American dementia caregiver Twitter network will receive messages from the network (Twitter for African American caregivers' intervention).
9892900|NCT03858283|Experimental|Mindfulness Based Health Care Program|
9892901|NCT03858283|No Intervention|Control|
9892902|NCT03851627|Active Comparator|Testosterone undecanoate|intramuscular Testosterone undecanoate 1000mg/4ml
9892903|NCT03851627|Placebo Comparator|Testosterone like Placebo|intramuscular Testosterone undecanoate like Placebo
9892904|NCT03850522|Experimental|Vaccination|Vaccination with PD-L1 peptide
9892905|NCT03834948|Experimental|AO-176 Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
9892906|NCT03834948|Experimental|AO-176 Dose Expansion|Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
9892907|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
9892908|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + paclitaxel.
9892909|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
9892910|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + pembrolizumab.
9892911|NCT03828448|Experimental|ublituximab + umbralisib|"Ublituximab: 900 mg administered through Cycle 12, via IV infusion~Umbralisib: 800 mg administered through Cycle 24, via daily oral tablet"
9892912|NCT03825692|Experimental|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule Arm is Zhizhu Kuanzhong Capsule, Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd. ; Approval number: NMPA approval number: GUOYAOZHUNZI Z20020003; Dosage and administration: 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals
9892913|NCT03825692|Placebo Comparator|Zhizhu Kuanzhong Placebo Capsule|Zhizhu Kuanzhong Placebo Capsule Arm is Zhizhu Kuanzhong Capsule Mimics composed of microcrystalline cellulose, mannitol and magnesium stearate, which used for filling agent and lubricant respectively; Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd.; Dosage and administration: Be identical with the investigational drug.
9892914|NCT03816228||Experimental Flortaucipir|
9892915|NCT03804996|Experimental|TG-1801|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. Subjects who experience disease progression after completing 6 months of single agent TG-1801 will be eligible for TG-1801 single-agent re-treatment at the discretion of the investigator.
9892916|NCT03804996|Experimental|TG-1101|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. To explore the safety of TG-1801 in combination with ublituximab will be explored at doses below and up to the RP2D. TG-1801 intrapatient dose escalation will not be permitted in combination therapy.
9892917|NCT03803774|Experimental|Treatment (IMRRT, birinapant)|Beginning on day 1, patients undergo IMRRT 5 days a week (Monday-Friday). Patients also receive birinapant IV over 30 minutes on days 2 and 9 of each cycle. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
9892918|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Not Refractory)|
9892919|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Refractory)|
9892920|NCT03801525|Experimental|Phase 2: Treatment Naïve CLL|
9892921|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
9892922|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib (U2)|
9892923|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
9892924|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib (U2)|
9892925|NCT03790657|Experimental|tDCS Dosage A|"mild electrical stimulation (Dosage level A) delivered to the frontal region of the brain during practice of a complex walking task"
9892926|NCT03790657|Experimental|tDCS Dosage B|"mild electrical stimulation (Dosage level B) delivered to the frontal region of the brain during practice of a complex walking task"
9892927|NCT03786549|No Intervention|Control|Patients included in this arm wil have usual follow-up.
9892928|NCT03786549|Experimental|Care transitional program|"Patients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~Educative, family (patient and parent), at home~Psychological, with the patient individually~Medico-social orientation, group of patients"
9892929|NCT03785678|Experimental|Tenecteplase|Patients in this arm will receive Tenecteplase (0.25 mg/kg, maximum 25 mg) administered as a single bolus injection over 5 seconds.
9892930|NCT03785678|Placebo Comparator|Placebo|Patients in this arm will receive placebo administered as a single bolus injection over 5 seconds.
9892931|NCT03778073|Experimental|Cohort A|Cosibelimab (TG-1501) single-agent
9892932|NCT03778073|Experimental|Cohort B|Cosibelimab + Ublituximab + Bendamustine combination
9892933|NCT03778073|Experimental|Cohort C|Cosibelimab + Ublituximab + Bendamustine combination
9892934|NCT03769311|Experimental|Pre-Operative Cetuximab Therapy|Two weekly doses of pre-operative cetuximab during the interval between diagnostic HNSCC biopsy and surgery (~14 days), ensuring that no delay in standard of care (SOC) will occur. For dose #1, participants will receive cetuximab 400 mg/m2 via intravenous infusion over 2 hours (maximum infusion rate 10 mg/min) as per the standard of care loading regimen for cetuximab monotherapy. For dose #2, participants will receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
9892935|NCT03766035||Consented, enrolled PSC patients undergoing ERCP + SpyGlass|Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.
9892936|NCT03765073|Experimental|Stage 1 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
9892937|NCT03765073|Experimental|Stage 1 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
9892938|NCT03765073|Experimental|Stage 2 - Lowest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
9892939|NCT03765073|Experimental|Stage 2 - Lowest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
9892940|NCT03765073|Experimental|Stage 2 - Middle dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
9892941|NCT03765073|Experimental|Stage 2 - Middle dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
9892942|NCT03765073|Experimental|Stage 2 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
9892943|NCT03765073|Experimental|Stage 2 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
9892944|NCT03765073|Experimental|Stage 3 - Selected dose and formulation|Multivalent group B streptococcus vaccine - Stage 3 Pregnant women
9892945|NCT03765073|Placebo Comparator|Stage 1 Placebo|Saline control
9892946|NCT03765073|Placebo Comparator|Stage 2 Placebo|Saline control
9892947|NCT03765073|Placebo Comparator|Stage 3 Placebo|Saline control
9892948|NCT03760211|Experimental|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Battle Viro on their mobile phones, an electronic pill monitoring device, and, for 24 weeks, game-related text messages guided by medication adherence data (collected from an electronic pill monitoring device).
9892949|NCT03760211|Active Comparator|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game and an electronic pill monitoring device.
9892950|NCT03739931|Experimental|Arm A: mRNA-2752|Participants will be administered mRNA-2752 at an applicable dose as monotherapy.
9892951|NCT03739931|Experimental|Arm B: mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose in combination with durvalumab.
9892952|NCT03739931|Experimental|Arm C: mRNA-2752 Alone or mRNA-2752 + Durvalumab|Participants will be administered mRNA-2752 at an applicable dose as monotherapy or in combination with durvalumab.
9892953|NCT03735667|Experimental|ACURATE Valve - Randomized|"Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.~*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy."
9892954|NCT03735667|Experimental|ACURATE Valve - Single-arm Roll-in|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
9932414|NCT00948740|Experimental|ergocalciferol|After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
9997524|NCT01509521|Active Comparator|Ephedrine|
9997525|NCT01509521|Active Comparator|Phenylephrine|
9892955|NCT03735667|Active Comparator|Commercial Valve - Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.~*A minimum of 200 subjects will also be enrolled in the 4D CT Imaging Substudy."
9892956|NCT03729453||Intraoperative Pancreatoscopy|All subjects will undergo the intraoperative pancreatoscopy with SpyGlass procedure.
9892957|NCT03724747|Experimental|BAY2315497 dose escalation|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
9892958|NCT03724747|Experimental|BAY2315497 dose escalation in combination with darolutamide|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. In addition, Darolutamide oral dosing at the approved dose of twice daily 600 mg will be initiated 14 days prior to the first BAY2315497 Injection dose on Day 1 of the first cycle. Daily darolutamide dosing will continue throughout the entire BAY2315497 Injection treatment period until withdrawal criteria from study treatment period are met.
9892959|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 1|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
9892960|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 2|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
9932415|NCT00948779|Other|antibiotics|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the use of antibiotics at home.
9932416|NCT00948779|Experimental|the antipyretic therapy|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the antipyretic therapy at home.
9991118|NCT01449799|Experimental|Sequence 2|In period 1, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by administration of GSK961081 in period 2. In period 3 and period 4, the subjects will receive GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of fluticasone propionate respectively.
9892961|NCT03710772|Experimental|Group I (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as described in part I.~COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone PO or IV on days 1-4, cyclophosphamide IV over 3 hours BID on days 2-4, and doxorubicin hydrochloride IV over 24 hours and vincristine sulfate IV over 15-30 minutes on day 5 of odd-numbered cycles (1 and 3). Patients also receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4 of even-numbered cycles (2 and 4). Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and rituximab IV over 4-8 hours on day 1 of every other month. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
9892962|NCT03710772|Experimental|Group II (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as in part I.~Patients receive combination chemotherapy as in group I. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive maintenance therapy as in group I."
9892963|NCT03710772|Experimental|Group III (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib, rituximab, venetoclax as in part I. Patients then receive maintenance therapy as in group I.
9892964|NCT03699501||Patients|
9892965|NCT03699501||Voluntary patients|
9892966|NCT03690089|Experimental|Intervention Group (Atropine 0.01%)|The intervention group will receive 0.01% atropine sulfate eye drops, administered once daily for two years.
9892967|NCT03690089|Placebo Comparator|Placebo Group|The control group will receive placebo eye drops, administered once daily for two years.
9892968|NCT03690050|Experimental|Diode Subthreshold Micropulse Laser|"DSML is a relatively new laser technology aimed at minimising damage (tissue-sparing) to choroid and retina but maintaining treatment efficacy by its selective effect on the retinal pigment epithelium (RPE). It is performed using laser that, instead of delivering a continuous-wave laser beam, as the standard laser, it provides very small, repetitive, low energy pulses of laser separated by a brief rest period. This rest period allows the tissue to cool down between laser pulses avoiding the increased tissue heat that would be produced by continuous laser and allowing the use of lower laser energy power to achieve an effect. The reduced heat produced in the tissue and the reduced energy power required for the treatment may reduce side effects."
9892969|NCT03690050|Active Comparator|Standard threshold laser (532 nm laser)|Green-yellow argon laser photocoagulation at threshold levels has been used for many years as the standard laser for the treatment of many retinal disorders including DMO. The ETDRS demonstrated the efficacy of laser in preventing visual loss in patients with DMO.
9892970|NCT03690037|Experimental|Intervention Group 1|Intervention Group 1: 1g intravenous Tranexamic Acid 100 milligrams (MG)/ML peri-operatively plus 1g oral Tranexamic Acid 500mg Tablets every 8hrs for up to 24hrs
9892971|NCT03690037|Experimental|Intervention Group 2|Intervention Group 2: 1g intravenous Tranexamic Acid 100 MG/ML peri-operatively
9892972|NCT03690037|No Intervention|Control Group 3|Standard care - no TXA
9892973|NCT03687957|Experimental|Phase I: rhIL-7-hyFc|"Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 7 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned~The phase I part will begin with an Accelerated Phase with 1 patient per cohort at the first 2 doses (60 mcg/kg and 120 mcg/kg) followed by a standard 3+3 design on the remaining 4 dose levels"
9935985|NCT02879409|Experimental|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >140mg/dl~Intervention: intensify treatment until their FBG is <90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to >140mg/dl again."
9997526|NCT01509560|Experimental|Everolimus|All patients will be given everolimus and the magnitude of the side effects will be measured
9892974|NCT03687957|Experimental|Randomized Phase II: Placebo|-Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. Placebo will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of placebo injections are planned.
9892975|NCT03687957|Experimental|Randomized Phase II: rhIL-7-hyFc|Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned.
9892976|NCT03687957|Experimental|Phase II Expansion Arm: rhIL-7-hyFc|Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 14 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned.
9892977|NCT03686332|Other|Arm A: Atezolizumab and Radiotherapy|"Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.~Drug: Arm A: Atezolizumab and Radiotherapy~Atezolizumab, 1200 mg, every 3 weeks, by IV infusion and receive 33 fractions of 1.5 or 1.8 Gy irradiation."
9892978|NCT03686332|Other|Arm B: Atezolizumab|Atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
9892979|NCT03682068|Experimental|Durvalumab in Combination with SoC Chemotherapy|"Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
9892980|NCT03682068|Experimental|Durvalumab in Combination with Tremelimumab+SoC Chemotherapy|"Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks~Tremelimumab will be provided for 4 cycles.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
9892981|NCT03682068|Active Comparator|SoC Chemotherapy|"Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
9892982|NCT03678129|Experimental|Placebo, AZD7325_10, AZD7325_20|Dose order: Placebo, AZD7325 10mg, AZD7325 20mg
9892983|NCT03678129|Experimental|Placebo, AZD7325_20, AZD7325_10|Dose order: Placebo, AZD7325 20mg, AZD7325 10 mg
9892984|NCT03678129|Experimental|AZD7325_20, Placebo, AZD7325_10|Dose order: AZD7325 20mg, Placebo, AZD7325 10mg
9892985|NCT03678129|Experimental|AZD7325_10, Placebo, AZD7325_20|Dose order: AZD7325 10mg, Placebo, AZD7325 20mg
9892986|NCT03678129|Experimental|AZD7325_10, AZD7325_20, Placebo|Dose order: AZD7325 10mg, AZD7325 20mg, Placebo
9892987|NCT03678129|Experimental|AZD7325_20, AZD7325_10, Placebo|Dose order: AZD7325 20mg, AZD7325 10mg, Placebo
9892988|NCT03671590|Experimental|Arm 1|TG-1701 oral daily dose
9892989|NCT03671590|Experimental|Arm 2|TG-1701 + Ublituximab + Umbralisib
9892990|NCT03671018|Experimental|Dose Finding|Participants will receive mosunetuzumab in combination with polatuzumab vedotin. Dose finding will be guided by the observed incidence of dose-limiting toxicities (DLTs) at each dose level.
9997527|NCT01509573|Experimental|FSI-R (Intervention group)|The intervention group will participate in the mental health assessments and FSI-R, and will participate in post-intervention assessments and follow-up assessments.
9797674|NCT01603420|Experimental|Radiation + Chemo + 6mo luteinizing hormone-releasing hormone|Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
9797675|NCT01603459|Experimental|IncobotulinumtoxinA (Xeomin) (up to 800 Units)|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection"
9797676|NCT01603602|Experimental|BOTOX® 3 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
9797677|NCT01603602|Experimental|BOTOX® 6 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
9797678|NCT01603602|Placebo Comparator|Placebo|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
9797679|NCT01603615|Experimental|BOTOX®|Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
9797680|NCT01603628|Experimental|BOTOX® 4 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
9797681|NCT01603628|Experimental|BOTOX® 8 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
9797682|NCT01603628|Placebo Comparator|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
9797683|NCT01603641|Experimental|BOTOX®|Participants received maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into a single lower limb muscles or divided between both lower limb muscles or into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment not to exceed a maximum of 8 unit per kilogram (U/kg) of body weight (not to exceed 300 U) in treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 or 8 U/kg into the lower limb in the previous study or were de novo participants who were not enrolled in the previous study.
9797684|NCT01603875|Active Comparator|PrEP and Simulated PEP with PVRV by intramuscular route|
9797685|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intramuscular route|
9797686|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intradermal route|
9797687|NCT01603940|Active Comparator|Losartan|This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
9797688|NCT01603940|Active Comparator|Benazepril|This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
9797689|NCT01604109|Active Comparator|Tooth Mousse|10% w/v Calcium Phosphopeptide Amorphous Calcium Phosphate paste
9797690|NCT01604109|Placebo Comparator|placebo control paste|the paste without Calcium phosphopeptide - Amorphous Calcium Phosphate
9797691|NCT01604122||Patients|Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
9797692|NCT01604122||Caregivers|Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
9797693|NCT01604265|Placebo Comparator|Placebo|Placebo control.
9797694|NCT01604265|Experimental|Sativex|Active treatment.
9797695|NCT01604278|Active Comparator|NVA237 + indacaterol|
9797696|NCT01604278|Placebo Comparator|Placebo to NVA237 + indacaterol|
9797697|NCT01604291||Cohort|
9797698|NCT01604343|Experimental|Placebo then Sirukumab 50 mg or Sirukumab 100 mg|
9797699|NCT01604343|Experimental|Sirukumab 100 mg|
9797700|NCT01604343|Experimental|Sirukumab 50 mg + Placebo|
9797701|NCT01604408|Experimental|LY2495655|Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
9797702|NCT01604408|Placebo Comparator|Placebo|Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
9797703|NCT01604772|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9797704|NCT01604785|Experimental|Experimental Treatment Group|Propofol at subanesthetic dose via IV push
9797705|NCT01604785|Active Comparator|Standard Treatment Group|Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
9797706|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 1|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
9797707|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
9797708|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 1|Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
9797709|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
9797710|NCT01604850|Experimental|SOF+RBV+placebo|Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
9797711|NCT01604850|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 16 weeks.
9797712|NCT01604941|Experimental|SPD602|50 mg/kg/day orally twice daily for 24 weeks
9797713|NCT01605032|Experimental|Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.~TRANSPLANT: Patients undergo autologous PBSCT on day 0."
9797714|NCT01605071|Active Comparator|Early Postmenopausal|Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy
9797715|NCT01605071|Active Comparator|Late Postmenopausal|Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy
9797716|NCT01605097|Experimental|HDR interstitial brachytherapy|HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion
9797717|NCT01605136|Experimental|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
9797718|NCT01605136|Placebo Comparator|Placebo|One placebo subcutaneous implant every 2 months for 6 months.
9797719|NCT01605227|Experimental|cabozantinib|Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
9797720|NCT01605227|Active Comparator|prednisone|Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
9797721|NCT01605292|Active Comparator|Palpation|Manual palpation of radial pulse, as sole guide to needle cannulation.
9797722|NCT01605292|Experimental|Ultrasound|Real-time ultrasound guidance to facilitate needle cannulation of artery.
9797723|NCT01605396|Experimental|Ridaforolimus + Dalotuzumab + Exemestane|Participants receive ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.
9797724|NCT01605396|Active Comparator|Ridaforolimus + Exemestane|Participants receive ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.
9797725|NCT01605435|Experimental|Ghrelin Group 1|Dose finding with each of the first two participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 2ug/kg (second visit) , 5 ug/kg (third visit), and 10 ug/kg (fourth visit).
9797726|NCT01605435|Experimental|Ghrelin Group 2|Dose finding with each of the final three participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 5ug/kg (second visit) , 7.5 ug/kg (third visit), and 10 ug/kg (fourth visit).
9892991|NCT03671018|Experimental|Mosunetuzumab + Polatuzumab Vedotin 2L+ R/R FL|Participants with at least one line of prior therapy (2L+) and that have relapsed or refractory (R/R) follicular lymphoma (FL) will receive mosunetuzumab + polatuzumab vedotin.
9892992|NCT03671018|Experimental|Mosunetuzumab + Polatuzumab Vedotin 2L+R/R DLBCL|2L+ participants with R/R diffuse large B-cell lymphoma will receive mosunetuzumab + polatuzumab vedotin.
9892993|NCT03671018|Experimental|Mosunetuzumab SC + Polatuzumab Vedotin 3L+R/R MCL|Participants with at least 2 lines of prior therapy (3L+) will receive subcutaneous (SC) mosunetuzumab + polatuzumab vedotin.
9892994|NCT03667573|Experimental|tsDCS Dosage A and textured insoles|"tsDCS dosage A and textured shoe insoles"
9892995|NCT03667573|Experimental|tsDCS Dosage B and textured insoles|"tsDCS dosage B and textured shoe insoles"
9892996|NCT03667573|Experimental|tsDCS Dosage A and smooth insoles|"tsDCS dosage A and smooth shoe insoles"
9892997|NCT03667573|Experimental|tsDCS Dosage B and smooth insoles|"tsDCS dosage B and smooth shoe insoles"
9892998|NCT03665077|Experimental|Participants|Patients with breast cancer who have completed all their primary treatments (surgery±radiation therapy) and are scheduled to start their adjuvant hormonal therapy.
9892999|NCT03659955|Experimental|Autologous blood|"Patients with severe dry eye and ocular surface disease who attend the corneal service within NHS Lanarkshire and who are unresponsive to conservative treatment measures will be considered for treatment of their condition with autologous blood.~Intervention is application of autologous blood."
9893000|NCT03652272|Experimental|EMC2|"Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications:~Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~Patients will receive a Medication Guide + Summary with their After Visit Summary~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
9893001|NCT03652272|No Intervention|Usual Care|Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
9893002|NCT03648073|Experimental|Untreated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
9893003|NCT03648073|Experimental|Previously treated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
9893004|NCT03643562|Experimental|Adrabetadex|Participants receive prescribed adrabetadex by intra-thecal injection
9893005|NCT03627208||1|Retrospective chart review of children and young adults with ALL/LBL enrolled on treatment protocols in the POB
9893006|NCT03603730|Experimental|taVNS|Active or inactive taVNS
9893007|NCT03599245|Experimental|Ocrelizumab|Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.
9893008|NCT03594552|Experimental|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
9893009|NCT03594552|Experimental|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
9893010|NCT03594552|Experimental|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
9893011|NCT03594552|Experimental|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
9893012|NCT03594552|Experimental|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
9893013|NCT03594552|Experimental|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
9932417|NCT00948805|Experimental|GnRH agonist|3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
9932418|NCT00948805|Active Comparator|Control|250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
9932419|NCT00948870|Experimental|Shugan Decoction|
9932420|NCT00948870|Placebo Comparator|low does of Shugan decoction|
9932421|NCT00948883||Patient-Case|Transplanted patient with cancer
9932422|NCT00948883||Patient-Control|Transplanted patient without cancer
9932423|NCT00948987|Experimental|Aspirin|single dose of aspirin 325 mg p.o.
9932424|NCT00949000|Other|ICD Implant|Implantation of a commercially available AnalyST or AnalyST Accel ICD
9935986|NCT02879409|Experimental|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >115mg/dl~Intervention: intensify treatment until FBG is <=115 mg/dl and intensify further if >115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
9893014|NCT03587116|Other|Standard of Care FIX replacement therapy|
9893015|NCT03587116|Other|Standard of Care FVIII replacement therapy|
9893016|NCT03582956|Other|Adolescent Overweight|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
9893017|NCT03582956|Other|Adolescent Typical|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
9893018|NCT03582956|Other|Young Adult|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
9893019|NCT03579121|Experimental|Pharmacogenomic (PGx) guided|Subjects will have Pharmacogenomic (PGx) testing preoperatively. The pharmacists will review results and make recommendations to the anesthesia and orthopedic teams for perioperative anesthesia and analgesia. The teams will use this information to drive clinical decisions as they see fit.
9893020|NCT03579121|Active Comparator|Control|Subjects will undergo Pharmacogenomic (PGx) preoperatively but the results will be sealed until completion of treatment and clinicians will not have access to this information. These patients will undergo standard treatment dosing and medication selection.
9893021|NCT03564691|Experimental|Dose Escalation, Part A: MK-4830 Monotherapy|MK-4830 monotherapy (with MK-4830 doses determined by an accelerated titration design [ATD]) will be administered intravenously (IV), every 3 weeks (Q3W), starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pancreatic adenocarcinoma.
9893022|NCT03564691|Experimental|Dose Escalation, Part B: MK-4830 Monotherapy|MK-4830 monotherapy (with MK 4830 doses determined by a modified toxicity probability interval [mTPI] method) will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes,
9893023|NCT03564691|Experimental|Dose Escalation, Part C: MK-4830 and Pembrolizumab|Combination therapy with MK-4830 and pembrolizumab (with MK-4830 doses determined by an mTPI design). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9893024|NCT03564691|Experimental|Dose Expansion, Arm A: Pancreatic Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed pancreatic adenocarcinoma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9893025|NCT03564691|Experimental|Dose Expansion, Arm B: Glioblastoma (GBM)|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed GBM. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9893026|NCT03564691|Experimental|Dose Expansion, Arm C: R/M HNSCC|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease progressed on an anti-programmed cell death 1/programmed cell death ligand 1 (PD1/L1) therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9893027|NCT03564691|Experimental|Dose Expansion, Arm D: PD-L1 positive HNSCC, Dose A|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed advanced programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma (HNSCC). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9932425|NCT00949026|Experimental|A|
9932426|NCT00949039|Experimental|Chemotherapy|Isolated pelvis perfusion
9932427|NCT00949039|Active Comparator|Control|Standard treatment
9932428|NCT00949065|Active Comparator|Intravenous immunoglobulins (IvIg)|3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks
9893028|NCT03564691|Experimental|Dose Expansion, Arm E: First-Line Advanced NSCLC, Dose A|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9893029|NCT03564691|Experimental|Dose Expansion, Arm F: First-Line Advanced NSCLC, Dose B|Combination therapy with the preliminary recommended phase 2 dose (RP2D) B of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9893030|NCT03564691|Experimental|Dose Expansion, Arm G: NSCLC, +Carboplatin/Pemetrexed|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, pembrolizumab, and carboplatin/pemetrexed in participants with advanced non-squamous non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Carboplatin and pemetrexed will be administered IV Q3W, starting with Cycle 1, Day 1, for 4 cycles, followed by pemetrexed Q3W continuous with MK-4830 and pembrolizumab, up to 35 cycles. Each cycle is 21 days.
9893031|NCT03564691|Experimental|Dose Expansion, Arm H: RCC, +Lenvatinib|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, pembrolizumab, and lenvatinib in participants with advanced renal cell carcinoma (RCC). MK-4830 will be administered IV, Q3W, starting with Cycle 1 following pembrolizumab infusion, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Lenvatinib will be administered orally once daily for up to 35 cycles of 21 days.
9893032|NCT03564691|Experimental|Dose Expansion, Arm I: R/M Gastric/GE Junction Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic (R/M) gastric or gastroesophageal (GE) junction adenocarcinoma and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
9893033|NCT03564691|Experimental|Dose Expansion, Arm J: Ovarian Cancer|Triple combination therapy with pembrolizumab plus preliminary recommended phase 2 dose (RP2D) A of MK-4830 plus paclitaxel in participants who have histologically confirmed, ovarian cancer. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles. Each cycle is 21 days. Paclitaxel will be administered by IV, once every week (QW) on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity.
9893034|NCT03564691|Experimental|Dose Expansion, Arm K: Triple negative Breast Cancer (TNBC)|Triple combination therapy with pembrolizumab plus preliminary recommended phase 2 dose (RP2D) A of MK-4830 plus paclitaxel in participants who have histologically confirmed TNBC. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles. Each cycle is 21 days. Paclitaxel will be administered by IV on Days 1, 8, and 15 every 4 weeks (Q4W) until disease progression or prohibitive toxicity.
9893035|NCT03564691|Experimental|Dose Expansion, Arm L: Mesothelioma|Triple combination therapy with pembrolizumab plus preliminary recommended phase 2 dose (RP2D) A of MK-4830 plus pemetrexed plus cisplatin in participants who have histologically confirmed advanced mesothelioma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles. Each cycle is 21 days. Pemetrexed will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days. Cisplatin will be administered by IV, on Day 1 of each Q3W cycle for a maximum of 6 cycles. Each cycle is 21 days.
9893036|NCT03539952|Experimental|TETA 4HCL|Active Treatment
9893037|NCT03539952|Experimental|Penicillamine|Comparator: Penicillamine
9893038|NCT03532295|Experimental|Regimen A: Retifanlimab+RT+bevacizumab|"Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~Treatment may continue for up to two years."
9893039|NCT03532295|Experimental|Regimen B: Retifanlimab+RT+bevacizumab+epacadostat|"Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~Epacadostat will be administered orally at 600 mg BID.~Treatment may continue for up to two years."
10212061|NCT02991495|Experimental|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
9893041|NCT03523858|Experimental|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion.
9893042|NCT03513562|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO daily on days 1-28 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 or 24 courses in the absence of disease progression or unacceptable toxicity. Participants with MRD negativity after 12 or 24 courses discontinue treatment, while participants with MRD positivity continue treatment with venetoclax in the absence of disease progression or unacceptable toxicity.
9893043|NCT03497637|Active Comparator|Pd/Pa guided Therapy|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
9893044|NCT03497637|Active Comparator|FFR guided therapy|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
9893045|NCT03457142|Experimental|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9893046|NCT03456076|Experimental|Alectinib|
9893047|NCT03456076|Active Comparator|Platinum-Based Chemotherapy|
9893048|NCT03454451|Experimental|Cohort 1a|CPI-006
9893049|NCT03454451|Experimental|Cohort1b|CPI-006 + ciforadenant
9893050|NCT03454451|Experimental|Cohort 1c|CPI-006 + pembrolizumab
9893051|NCT03454451|Experimental|Cohort 2a|CPI-006
9893052|NCT03454451|Experimental|Cohort 2b|CPI-006 + ciforadenant
9893053|NCT03454451|Experimental|Cohort 2c|CPI-006 + pembrolizumab
9893054|NCT03441893|Active Comparator|Patients with ulcerative colitis|Patients with ulcerative colitis in this group will take nitazoxanide per os
9893055|NCT03441893|No Intervention|Participants (control group)|only parasitological diagnostics will be performed in this group to compare the prevalence of some representatives of the microbiota
9893056|NCT03441893|Active Comparator|UC patients (cohort 1)|Patients with ulcerative colitis in this group will take standart therapy (mesalazin)
9893057|NCT03441893|Placebo Comparator|UC patients (cohort 2)|Patients with ulcerative colitis in this group will take placebo tabletes
9893058|NCT03441893|Active Comparator|UC patients (cohort 3)|Patients with ulcerative colitis in this group will take combination standart therapy with nitazoxanide
9893059|NCT03439514|Experimental|Part 1 Double-blind Treatment|ARRY-371797 (PF-07265803) tablet orally OR matching placebo tablet orally
9893060|NCT03439514|Experimental|Part 2 Open-label Treatment|ARRY-371797 (PF-07265803) tablet orally
9893061|NCT03432949|No Intervention|Standard of Care Radium-223|Radium-223 treatment will be administered as per standard of care.
9893062|NCT03432949|Experimental|Radium-223 with oral Dexamethasone 0.5 mg|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
9893063|NCT03423628|Experimental|AZD1390 + Radiation Therapy|AZD1390 + Radiation Therapy
9893064|NCT03421340|Other|ERC Arm|After screening examination and confirmed presence of non-complex bile duct stone by image, patients will be randomly assigned by stratified randomization to Electroscopic Retrograde Cholangioscopy (ERC) treatment.
9893065|NCT03421340|Other|DSC Arm|After screening examination and confirmed presence of non-complex bile duct stone by imagine, patients will be randomly assigned by stratified randomization to fluoroscopy/radiation-free direct solitary cholangioscopy (DSC).
9893066|NCT03421288|Experimental|Arm A: FLOT with Atezolizumab|Patients randomized to treatment Arm A will receive atezolizumab (840 mg IV over 1 hour) + FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of atezolizumab + FLOT followed by 8 additional 3-week treatment cycles with atezolizumab alone (maintenance setting: 1,200 mg q3w). FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
9893067|NCT03421288|Active Comparator|Arm B: FLOT alone|Patients randomized to Arm B will receive FLOT alone for four 2-week treatment cycles prior to surgery. Following surgery, patients will receive four further 2-week cycles of chemotherapy alone. FLOT can be deescalated to FLO, FLT or FL in case of chemo-related toxicity at any time and at the discretion of investigator. Docetaxel 50 mg/m², d1 Oxaliplatin 85 mg/m², d1 Calciumfolinat 200 mg/m², d1 5-Fluorouracil 2600 mg/m², d1
9893068|NCT03408236|Experimental|Botulax|Single dose
9893069|NCT03408236|Active Comparator|Botox|Single dose
9893070|NCT03400943|Experimental|Vilaprisan (A1)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
9893071|NCT03400943|Experimental|Vilaprisan (A2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks without a break.
9893072|NCT03400943|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan (2 mg) in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
9893073|NCT03400943|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
10212062|NCT02991495|Active Comparator|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
9893074|NCT03381170|Experimental|Ublituximab|Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
9893075|NCT03379051|Experimental|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
10212063|NCT02991495|Experimental|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
10212064|NCT02991495|Active Comparator|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
9893076|NCT03379051|Experimental|Ublituximab + Umbralisib + Lenalidomide|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions; Umbralisib and Lenalidomide both administered days 1 - 21 of every 28 days
9893077|NCT03378570|Active Comparator|5.5cm Rule Group|rTMS will be targeted at a left prefrontal target 5.5cm anterior to the primary motor strip identified on the scalp during motor threshold testing.
9893078|NCT03378570|Active Comparator|F3 Group|rTMS will be targeted at the left prefrontal scalp target identified as F3 according to the 10-20 EEG system.
9893079|NCT03377491|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with gemcitabine and nab-Paclitaxel
9893080|NCT03377491|Active Comparator|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
9893081|NCT03376893||SCA with overt stroke|Participants have sickle cell disease and a history of overt stroke.
9893082|NCT03376893||SCA with silent stroke|Participants have sickle cell disease and a history of silent stroke.
9893083|NCT03376893||SCA with no stroke|Participants have sickle cell disease and no history of stroke.
9893084|NCT03368625|Other|Arm 1|Neoadjuvant SRS
9893085|NCT03364231|Experimental|Umbralisib|Umbralisib oral daily dose
9893086|NCT03348631|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9893087|NCT03319368|Experimental|Intervention: Targeted gown and glove use|Additional gowns and gloves used for high risk care activities
9893088|NCT03301883|Experimental|Tocilizumab|Participants weighing greater than or equal to (>/=) 30 kilograms (kg) will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W), and participants weighing less than (<) 30 kg will receive tocilizumab 12 mg/kg IV infusion Q2W for 52 weeks. After Week 12, the dose of tocilizumab can be adjusted for non-transient changes in body weight (shifting from <30 to >/=30 kg) over a minimum of three consecutive dosing visits. MTX, NSAIDs, and oral corticosteroids (CSs) are permitted but not required during the study.
9893089|NCT03300141|Active Comparator|Healthy|Healthy participants will participate in reaching activity using the Looking Glass and Leap motion tracking system
9893090|NCT03300141|Experimental|Chronic Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
9893091|NCT03300141|Experimental|Chronic Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
9893092|NCT03300141|Experimental|Acute Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
9893093|NCT03300141|Experimental|Acute Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
9893094|NCT03295565|Active Comparator|A: Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
9893095|NCT03295565|Active Comparator|B: Abiraterone OR Enzalutamide|"At physician's discretion:~Abiraterone 1000mg oral, taken daily Prednisone 5mg oral, 2 times a day OR Enzalutamide 160mg oral taken daily"
9932429|NCT00949065|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks
9932430|NCT00949091|Experimental|1|
9932431|NCT00949104|Active Comparator|Sucrose|1 ml of 24% sucrose was administered 2 minutes before the procedure
9932432|NCT00949104|Placebo Comparator|Placebo|Double distilled water
9932433|NCT00949130|Experimental|NXL103|BID for 7-14 days orally
9932434|NCT00949130|Active Comparator|Linezolid|BID for 7-14 days orally
9932435|NCT00949143|Experimental|forward position|
9932436|NCT00949143|Experimental|rear position|
9935987|NCT02858336|Active Comparator|Control|All participants will receive the NEA availability to act as their own control to the experimental DEA intervention.
9893096|NCT03288142|Experimental|Intervention: Hypertension Coaching Application and Home Monitor:|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
9893097|NCT03288142|Active Comparator|Control:Tracking Application and Home Monitor:|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
9893098|NCT03253978|Experimental|SABR to prostate / seminal vesicles with pelvic ENI|36.25Gy / 5 fractions to prostate and seminal vesicles with additional SABR (25Gy /5 fractions) delivered to the pelvic nodes.
9893099|NCT03253978|Active Comparator|SABR to prostate and seminal vesicles only|36.25Gy / 5 fractions to prostate and seminal vesicles.
9893100|NCT03245892|Experimental|Carboplatin and Paclitaxel Chemotherapy With Nivolumab (Closed)|Patients will be treated with nivolumab plus standard of care dose dense paclitaxel and carboplatin for three cycles, where each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen administered as adjuvant treatment. Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle. Carboplatin dose calculation instructions can be found in Appendix 4. Nivolumab 360mg will be infused IV over approximately 30min on Day 1 of Cycles 1-6. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks.
9893101|NCT03245892|Experimental|Nivolumab plus Ipilimumab plus Paclitaxel & Carboplatin|Patients will be treated with nivolumab plus ipilimumab plus standard of care dose dense paclitaxel & carboplatin chemotherapy for 3 cycles (up to a maximum of six), each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen. Paclitaxel 80mg/m2 IV will be administered over approx 1 hour on Days 1,8, & 15 of each 21 day cycle. Carboplatin AUC6 will be administered as an approx 30 minute IV infusion, following paclitaxel admin on Day 1 of each 21 day cycle. Nivolumab 360mg will be infused IV over approx 30 min on Day 1 of Cycles 1-6 (to 9) of each 21 day cycle. Ipilimumab 1mg/kg will be infused IV over approx 30 min on Day 1 of Cycles 1 & 3, as well as Cycle 4 & Cycle 6. Of note, if patients receive more than 3 cycles in the pre-operative setting, then ipilimumab will be administered with the first & third cycle in the post-operative setting. Nivolumab will then be infused Day 1 of each 28 day maintenance phase cycle.
9893102|NCT03234114|Experimental|1-month TT|Randomized experimental group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg q.d. and aspirin 100 mg q.d.) for 1 month (30 days) then quit aspirin till 12 months after PCI
9893103|NCT03234114|Experimental|6-month TT|Randomized control group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg q.d. and aspirin 100 mg q.d.) for 6 months (180 days）then quit aspirin till 12 months after PCI
9893104|NCT03234114|Experimental|12-month DT-1|Randomized experimental group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg q.d. for 12 months after PCI
9893105|NCT03234114|Experimental|12-month DT-2|Randomized control group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI
9893106|NCT03217110|Experimental|patient active rTMS|Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
9893107|NCT03217110|Sham Comparator|patient sham rTMS|Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
9893108|NCT03217110|Active Comparator|Control active rTMS|
9893109|NCT03217110|Sham Comparator|Control sham rTMS|
10212065|NCT02991495|Experimental|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
9893111|NCT03213678|Experimental|Treatment (samotolisib)|Patients receive samotolisib PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unexpected toxicity.
10212066|NCT02991495|Active Comparator|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
9893113|NCT03207256|Experimental|TGR-1202|Oral TGR-1202 Daily
9893114|NCT03207256|Experimental|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
9893115|NCT03206905|Experimental|Endoscopic Sleeve Gastroplasty|
9893116|NCT03206905|Active Comparator|Diet and exercise only.|
9893117|NCT03206450||Observational (questionnaire, biospecimen collection)|Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
10212067|NCT02991495|Experimental|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
9893118|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
9893119|NCT03190915|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9893120|NCT03150810|Experimental|Arm A (Dose Escalation) TMZ Pulse Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.
9893121|NCT03150810|Experimental|Arm B (Dose Escalation) TMZ Continuous Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.
9893122|NCT03150810|Experimental|Dose Expansion, 6 cohorts|Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles
9893123|NCT03144700||Compensated Cirrhosis|
9893124|NCT03133377|Experimental|Early activity and Mobilisation intervention|Patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
9893125|NCT03133377|No Intervention|Standard of care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
9893126|NCT03132805|No Intervention|Control|Schools which receive no intervention
9893127|NCT03132805|Experimental|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
9893128|NCT03132805|Experimental|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
9893129|NCT03112603|Experimental|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
9893130|NCT03112603|Active Comparator|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
9893131|NCT03107897|No Intervention|Pre-procedure standard of care|No prehab prior to TAVR.
9893132|NCT03107897|Active Comparator|Prehab prior to TAVR procedure.|Individuals participate in prehabilitation prior to TAVR.
9893133|NCT03104868|No Intervention|Usual Care|Patients in this group will receive the usual standard of care.
9893134|NCT03104868|Experimental|Intervention|Patients in this group will receive the TAKE IT strategy components.
10212068|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in Children|Subcutaneous administration of 1 dose of the yellow fever vaccine
10212069|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in Children|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
10212070|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in HIV+ adults|Subcutaneous administration of 1 dose of the yellow fever vaccine
9893138|NCT03078023|Experimental|swallowed sponge device|Swallowing a sponge prior to a clinical upper endoscopy. Patients diagnosed with Eosinophilic Esophagitis (EoE) > than 15 Eosinophils per high power field (phf) and failed to respond to Proton Pump Inhibitors (PPI) therapy. Will be asked to swallow a sponge, this is a 10 minute procedure done in the office prior to their clinical upper endoscopy. This will be sent for histology, >15 Eos phf would be considered active disease. We will compare the results of the sponge using the EPO staining technique compared to histologic response.
9893139|NCT03069937|Experimental|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
9893140|NCT03038984|Experimental|Every 3 months|screening every 3rd month: (home monitoring: FC and DA)
10212071|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in HIV+ adults|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
10212072|NCT02977624|Experimental|Tele-CO-OP|The intervention included weekly videoconferencing sessions using the Cognitive Orientation to Daily Occupational Performance approach (tele-CO-OP) over a period of three months. Participant identified five functional goals, of which three were directly addressed.
10212073|NCT02977624|No Intervention|Waitlist control|The waitlist control group did not receive the intervention during the same time period
10212074|NCT02928406|Experimental|Atezolizumab|Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
10212075|NCT02918370|Experimental|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
10212076|NCT02918370|Placebo Comparator|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
10212077|NCT02891824|Placebo Comparator|Arm A: Placebo + Avastin + platinum-based chemotherapy|"The placebo arm:~Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression"
10212078|NCT02891824|Experimental|Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy|"The atezolizumab arm:~Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression~."
9797727|NCT01605461|Experimental|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
9893141|NCT03038984|Active Comparator|On demand|screening On demand: (home monitoring: FC and DA)
9893142|NCT03031730|Experimental|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 Inhibitor KRT-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of cycles 1-12 and on days 1-2 and 15-16 of cycles 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or dexamethasone sodium phosphate IV on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
9893143|NCT03007329|Active Comparator|Dapagliflozin & Exenatide|Dapagliflozin 10mg orally once daily & Exenatide 2mg subcutaneous once weekly
9893144|NCT03007329|Placebo Comparator|Dapagliflozin & Placebo|Dapagliflozin 10mg orally once daily & Exenatide matching Placebo 2mg subcutaneous once weekly
9893145|NCT02987257|Placebo Comparator|Harmonized supportive care|Harmonized supportive care with placebo cyclosporine days 0-14 and etanercept placebo days 0 and 3
9893146|NCT02987257|Active Comparator|Cyclosporine 5mg/kg bid days 0-14|Harmonized supportive care with placebo etanercept days 0 and 3
9893147|NCT02987257|Active Comparator|Etanercept 50mg sc day 0 and day 3|Harmonized supportive care with placebo cyclosporine days 0-14
9893148|NCT02977052|Experimental|Arm A: 2 courses ipi 3 + nivo 1|Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
9893149|NCT02977052|Experimental|Arm B: 2 courses ipi 1 + nivo 3|Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
9893150|NCT02977052|Experimental|Arm C: 2 courses ipi 3 + 2 courses nivo 3|Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (> 2 hours and < 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
9893151|NCT02977052|Experimental|PRADO extension cohort|"Patients will be treated with 2 courses ipilimumab and nivolumab at the dose level defined as the winner dosing scheme from OpACIN-neo, which is the dosing schedule of arm B.~Surgery and adjuvant therapy~Patients achieving a pCR or pnCR will not undergo CLND and will not receive any adjuvant treatment. Structural follow-up will be perfomed every 12 weeks by CT, ultrasound of regional lymph nodes.~Patients achieving a pPR will undergo CLND and start structural follow-up (including CT and physical examination) every 12 weeks thereafter without any adjuvant treatment.~Patients achieving no response (pNR) will undergo CLND and start at week 12 with adjuvant nivolumab 480mg q4wks for 52 weeks + radiotherapy (according to patient's and physicians' decision). In patients that are BRAF V600E/K mutation positive, adjuvant BRAF+MEK"
9893152|NCT02973542|Experimental|ethosuximide|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
9893153|NCT02973542|Placebo Comparator|placebo|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
9893154|NCT02973386|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
9893155|NCT02973386|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
9893156|NCT02965469|No Intervention|Usual care|Participants randomized to this arm will have no change to their usual care
9893157|NCT02965469|Experimental|Cell phone app|"Participants randomized to this arm will use a stress reduction cell phone app called Breathe2Relax to assess feasibility and acceptability"
9893158|NCT02949934|Placebo Comparator|Placebo/rs4680 val/val|"Placebo three times per day for eight days~Individuals with the rs4680 val/val genotype"
9935988|NCT02858336|Experimental|Experimental|All participants will be in the experimental arm and received the DEA intervention.
9893159|NCT02949934|Active Comparator|Tolcapone/rs4680 val/val|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/val genotype"
9893160|NCT02949934|Placebo Comparator|Placebo/rs4680 val/met|"Placebo three times per day for eight days~Individuals with the rs4680 val/met genotype"
9893161|NCT02949934|Active Comparator|Tolcapone/rs4680 val/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 val/met genotype"
9893162|NCT02949934|Placebo Comparator|Placebo/rs4680 met/met|"Placebo three times per day for eight days~Individuals with the rs4680 met/met genotype"
9893163|NCT02949934|Active Comparator|Tolcapone/rs4680 met/met|"Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days~Individuals with the rs4680 met/met genotype"
9893164|NCT02935634|Active Comparator|Nivolumab + Ipilimumab|
9893165|NCT02935634|Experimental|Nivolumab + Relatlimab|
9893166|NCT02935634|Experimental|Nivolumab + BMS-986205|
9893167|NCT02935634|Experimental|Nivolumab + Rucaparib|
9893168|NCT02935634|Experimental|Ipilimumab + Rucaparib|
9893169|NCT02935634|Experimental|Nivolumab + Ipilimumab + Rucaparib|
9893170|NCT02932150|Experimental|TAF (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive TAF 25 mg tablet for 24 weeks
9893171|NCT02932150|Placebo Comparator|Placebo (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive placebo tablet for 24 weeks
9893172|NCT02932150|Experimental|TAF (Cohort 2 Group 1)|Participants (6 to < 12 years) weighing ≥ 25 kg will receive TAF 25 mg tablet for 24 weeks
9893173|NCT02932150|Experimental|TAF (Cohort 2 Group 2)|Participants (6 to < 12 years) weighing ≥ 14 kg to < 25 kg will receive TAF 15 mg oral granules for 24 weeks
9893174|NCT02932150|Experimental|TAF (Cohort 2 Group 3)|"Participants (2 to < 6 years) will receive TAF for 24 weeks as follows:~weight ≥ 10 kg to < 14 kg (7.5 mg oral granules)~weight ≥ 14 kg to < 25 kg (15 mg oral granules)"
9893175|NCT02932150|Placebo Comparator|Cohort 2 Placebo|Participants will receive matching placebo of TAF (tablet or oral granules) for 24 weeks.
9893176|NCT02932150|Experimental|Open-Label TAF|Following 24 weeks of blinded randomized treatment, participants will be eligible to participate in an open-label extension phase to receive TAF for an additional 216 weeks.
9893177|NCT02908672|Experimental|Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo|Run-In Period (Cycle 1=28 days): Participants will receive vemurafenib 960 mg (four, 240 mg tablets) PO BID along with cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21 followed by vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 22 to 28 and vemurafenib placebo (1 tablet) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive atezolizumab 840 mg IV infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
9893178|NCT02908672|Experimental|Atezolizumab Placebo + Cobimetinib + Vemurafenib|Run-In Period (Cycle1=28 days): Participants will receive vemurafenib 960 milligrams (mg) (four, 240 mg tablets) orally (PO) twice a day (BID) along with cobimetinib 60 mg (three, 20 mg tablets) PO once a day (QD) on Days 1 to 21 followed by vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive ATZ placebo by intravenous (IV) infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, and vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
9893179|NCT02879617|Experimental|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
9893180|NCT02869399|Experimental|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
9935989|NCT02858323||1|Previously selected HLA-alloimmunized platelet refractory, clinical, patients.
9935990|NCT02858310|Experimental|Arm 1: Phase I|Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR Cells at escalating doses, followed by aldesleukin
9935991|NCT02858310|Experimental|Arm 2: Phase II|1 x 10 e11 E7 Cells that was determined in Phase I + aldesleukin
9991119|NCT01449799|Experimental|Sequence 3|In period 1, subjects will be administered GSK961081 followed by administration of fluticasone propionate in period 2. In period 3, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by GSK961081/fluticasone propionate blend via Diskus inhaler in period 4.
9991120|NCT01449799|Experimental|Sequence 4|In period 1, subjects will be administered fluticasone propionate followed by the administration of GSK961081/fluticasone propionate blend via Diskus inhaler in period 2. The subjects will receive GSK961081 in period 3 and concurrent administration of GSK961081 and fluticasone propionate in period 4.
9991121|NCT01449825||Prescriber compliance group|Adult (18+ years) new users of pazopanib with an indication of RCC evaluated for prescriber compliance
9991122|NCT01449825||Incidence of liver chemistry test (LCT) elevation group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib in monotherapy who have a baseline LCT evaluated for LCT elevations
9991123|NCT01449825||Incidence of drug induced liver injury (DILI) cases group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of LCT elevations consistent with Hy's Law to evaluate for drug-induced liver injury
9991124|NCT01449825||Incidence of cases of ALF group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of ICD-9 codes indicative of possible ALF to evaluate for drug-induced liver injury
9991125|NCT01449838|Placebo Comparator|Saline|Subjects were administered single dose or twice daily for 2.5 days repeat dose of placebo by the intravenous route.
9991126|NCT01449838|Experimental|Colistimethate sodium|2.5 milligrams (mg)/kilogram (kg) of CMS-NA (as colistin activity or 75,000 International Unit/kg) was administered as single dose or twice daily for 2.5 days repeat dose by the intravenous route.
9991127|NCT01449877|Active Comparator|Trimethoprim-Sulfamethoxazole|1 tablet every other day, morning.
9991128|NCT01449877|Placebo Comparator|Starch tablet|1 starch tablet every other day, morning.
9991129|NCT01449890|Experimental|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises they have learned during the initial treatment phase in order to cope with depression, e.g. integrating positive activities in their all day life or monitoring the interdependence of cognition, emotion and behaviour.
9991130|NCT01449890|No Intervention|Treatment as usual|After having terminated inpatient CBT patients receive treatment as usual within routine care.
9991131|NCT01449903||Rebilda DC|
9991132|NCT01449903||Clearfil Core DC / Plus|
9991133|NCT01449903||Multicore Flow|
9991134|NCT01449916|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
9991135|NCT01449916|Active Comparator|Usual care|Early blood cultures and antibiotics. Monitoring by study nurses as in experimental arm. Other interventions are according to admitting (non-study) doctors' orders.
9991136|NCT01449942|Experimental|DZ1|DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
9991137|NCT01449942|Placebo Comparator|Saline|Placebo group receives saline injection in combination with radiation therapy.
9991138|NCT01449968||home visit of UMG|home visit with evaluation and management of the situation (control over in-home telephone)
9991139|NCT01449968||telephone management|geriatric mobile unit provides a telephone advice only to the general practitioner with guidance and recommendations (call control)
9991140|NCT01449981|Experimental|Integrated Twelve-Step Facilitation|
9991141|NCT01449981|Experimental|Cognitive Behavioral Therapy|
9991142|NCT01449994|Placebo Comparator|Placebo-Activator|Treatment with Placebo Activator IV
9991143|NCT01449994|Active Comparator|Activator|Treatment with Activator IV adjusting instrument
9991144|NCT01450020|Experimental|Arm I (PN and ACS material)|Participants receive 4 PN sessions tailored to their needs followed by a 6 month booster session and ACS materials.
9991145|NCT01450020|Active Comparator|Arm II (ACS material)|Participants receive ACS materials only.
9991146|NCT01450033|No Intervention|Control group|Standard of care
9991147|NCT01450033|Experimental|Mentoring group|Subjects in this group will participate in the following intervention activities: medical record review; questionnaires including the Hollingshead Socioeconomic Status Survey, modified Medication Adherence Module, Peds QL Transplant Module, Medical Outcomes Study Social Support Scale, and self-efficacy scale; in-person meetings with mentor; e-communication with mentor (i.e. texts, Facebook, phone calls, etc); and collection of pharmacy refill data and clinical data.
9991148|NCT01450046|Experimental|Phase I Dose Escalation|Each investigator will be provided with adequate supplies of Vitamin E δ -Tocotrienol, which will be supplied as 100-mg, 200-mg, and 400-mg capsules. Vitamin E δ-Tocotrienol will be administered orally once. The dose administered to each subject will be fixed and based on cohort assignment. Doses will be administered at the clinical site during each protocol-defined visit.
9991149|NCT01450059||Spontaneous delivery|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via spontaneous delivery.
9991150|NCT01450059||Cesarean section|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via cesarean section.
9797728|NCT01605539|Placebo Comparator|Control|Subjects will receive pills that resemble the Cannabidiol capsule but do not have have its properties.
9991151|NCT01450072|Sham Comparator|Control arm|Venography and sham angioplasty
9991152|NCT01450072|Active Comparator|Active arm|therapeutic balloon angioplasty
9797729|NCT01605539|Experimental|Cannabidiol 400|Subjects in Arm Cannabidiol 400 will receive 400 mg of cannabidiol
9797730|NCT01605539|Experimental|Cannabidiol 800|Subjects in Arm Cannabidiol 800 will receive 800mg of cannabidiol
9797731|NCT01605552|Experimental|Beating the Blues (BtB)|An 8-session, empirically supported, computerized, cognitive-behavioral intervention for depression (www.beatingthebluesus.com)
9797732|NCT01605552|Other|Usual Care|Patients and their primary care providers were informed of the positive depression screen, and follow-up was encouraged.
9797733|NCT01605669||Aortic stenosis patients|Patients with varying degrees of aortic stenosis without significant additional valvular disease will be considered eligible for this study. All participants will recieve a transthoracic echocardiogram and recorded cardiac auscultation.
9797734|NCT01605799|Active Comparator|IOK Treatment|Six to eight week treatment lasting one to 1.5 hours addressing maladaptive cognitions related to killing in war.
9797735|NCT01605799|Placebo Comparator|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
9797736|NCT01605825|Placebo Comparator|placebo/dalfampridine-ER|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
9797737|NCT01605825|Placebo Comparator|dalfampridine-ER/placebo|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
9797738|NCT01605877|Experimental|SN6AD2|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
9797739|NCT01605890|Experimental|raltegravir / emtricitabine / tenofovir disoproxil fumarate|
9797740|NCT01605903|Experimental|Treatment with Ibuprofen|Children in the experimental group will receive grape-flavored ibuprofen 100mg/5 mL. Ibuprofen will be dispensed at 10mg/kg (max dose 600 mg) will be dispensed Q6 hours x 9 days.
9797741|NCT01605903|Active Comparator|Treatment with Acetaminophen|Children in the active comparator group will receive grape flavored acetaminophen 160 mg/5 ml. Acetaminophen will be dispensed at 15 mg/kg (max dose 650/mg) Q6 hours x 9 days.
9797742|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg|monotherapy
9797743|NCT01605916|Experimental|Selumetinib (AZD6244) 50 mg|monotherapy
9797744|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg|monotherapy
9797745|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg + Doce|Combination
9797746|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg + Doce|combination
9797747|NCT01605942|Experimental|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
9797748|NCT01605942|Placebo Comparator|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
9797749|NCT01606007|Active Comparator|Arm 1: Saxagliptin+Metformin XR+Placebo|
9797750|NCT01606007|Active Comparator|Arm 2: Dapagliflozin+Metformin XR+Placebo|
9797751|NCT01606007|Experimental|Arm 3: Saxagliptin+Dapagliflozin+Metformin XR|
9797752|NCT01606124|Experimental|Arm I (Green Tea Catechin Extract)|Patients receive Polyphenon E PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
9797753|NCT01606124|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
9797754|NCT01606137|Experimental|GW-1000-02|Active treatment
9797755|NCT01606176|Experimental|GW-1000-02|Each 100 μl actuation contains 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose was 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
9797756|NCT01606176|Placebo Comparator|Placebo|Each 100 μl actuation contains the excipients only. The maximum permitted dose was 48 actuations in any 24 hour period
9797757|NCT01606189|Experimental|GW-1000-02|Active treatment.
9797758|NCT01606189|Experimental|GW-2000-02|Active treatment.
9797759|NCT01606189|Placebo Comparator|Placebo|Placebo control.
9797760|NCT01606202|Experimental|GW-1000-02|Active treatment.
9797761|NCT01606202|Placebo Comparator|Placebo|Placebo control.
9797762|NCT01606228|Experimental|Paliperidone ER|
9797763|NCT01606254|Experimental|Paliperidone palmitate 50 mg|Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
9797764|NCT01606254|Experimental|Paliperidone palmitate 100 mg|Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
9991153|NCT01450085|Active Comparator|GeneXpert|Point of care GeneXpert
9991154|NCT01450085|Active Comparator|LED Microscopy|Point of care LED Microscopy
9991155|NCT01450111|Experimental|Lacosamide 50 mg group|Lacosamide 50 mg tablet, once a day per os (po)
9991156|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 50 mg|Placebo matched with lacosamide 50 mg tablet, po
9991157|NCT01450111|Experimental|Lacosamide 100 mg group|Lacosamide 100 mg tablet, po
9991158|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 100 mg|Placebo matched with lacosamide 100 mg tablet, po
9991159|NCT01450111|Experimental|Lacosamide 200 mg group|Lacosamide 200 mg tablet, po
9991160|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 200 mg|Placebo matched with lacosamide 200 mg tablet, po
9991161|NCT01450124|Experimental|Boswellic acids (BOSWELAN)|Baseline to treatment single arm - 4 months baseline and 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg of BOSWELAN.
9991162|NCT01450150|Experimental|Active tDCS|
9991163|NCT01450150|Sham Comparator|Sham tDCS|
9991164|NCT01450163|Active Comparator|Pregabalin|
9991165|NCT01450163|Placebo Comparator|Placebo|
9991166|NCT01450176|Active Comparator|Pataday once daily|15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.
9991167|NCT01450176|Active Comparator|Bepreve twice daily|Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks
9991168|NCT01450202|Placebo Comparator|Air insufflation, colonoscopy, esophagogastroduodenoscopy|
9991169|NCT01450202|Active Comparator|CO2 insufflation, colonoscopy, esophagogastroduodenoscopy|
9991170|NCT01450215|Experimental|Revlimid|
9991171|NCT01450215|No Intervention|Revlimid and dexamethasone|
9991172|NCT01450228|Placebo Comparator|Placebo KI1001|
9991173|NCT01450228|Experimental|KI1001|
9991174|NCT01450241|Experimental|Early antibiotic discontinuation|Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
9991175|NCT01450241|Other|Usual practice|Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
9997528|NCT01509573|No Intervention|TAU (Treatment as Usual)|The TAU control group will not receive any intervention, but will participate in treatment as usual as provided by Partners In Health. They will complete assessments at all three time points.
9997529|NCT01509599|Experimental|Cryotherapy|"Cryotherapy is delivered via a cooling gel wrap applied to the affected lower leg using a dosing regimen, starting with daily cooling in month one to PRN in the last 3 months over the 9 month study."
9997530|NCT01509599|Sham Comparator|Usual care|"The sham wrap, filled with cotton, is applied to the affected lower leg using a dosing regimen, starting with daily application in month one to PRN in the last 3 months over the 9 month study."
9997531|NCT01509651|Experimental|Sugammadex|
9997532|NCT01509703|Experimental|High flow therapy|
9997533|NCT01509729|Placebo Comparator|Sham operation|
9997534|NCT01509729|Active Comparator|Knee arthroscopic surgery|
9997535|NCT01509742|Experimental|NNC 90-1170|
9893181|NCT02869399|No Intervention|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
9893182|NCT02867735|Experimental|LKA651|
9893183|NCT02867735|Sham Comparator|Sham Comparator|
9893184|NCT02862275|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30- 60 minutes on day 1. Cycles repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity.
9893185|NCT02802553|Experimental|Integrated Imaging Goggles|Cardio-GreenTM (indocyanine green) peritumorally injected to breast tumor with 1 cycle. Viewed by Smart Googles and compare lesions detected by commercial FDA approved near infrared camera device (SPY Elite/Quest/PDE) in addition to those detected by gamma probe and blue dyes.
9893186|NCT02801084|Experimental|Float|One arm only: restricted environmental stimulation
9893187|NCT02793583|Experimental|Umbralisib + Ublituximab|Umbralisib oral daily dose in combination with Ublituximab intravenous administration
9893188|NCT02793583|Experimental|Umbralisib|Umbralisib oral daily dose
9893189|NCT02793583|Experimental|Umbralisib + Ublituximab + Bendamustine|Umbralisib oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration
9893190|NCT02790723|Experimental|Low Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{11} viral genomes.
9893191|NCT02790723|Experimental|Medium Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{12} viral genomes.
9893192|NCT02790723|Experimental|High Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{13} viral genomes.
9893193|NCT02788955|Active Comparator|Normal Protein Diet|In the normal protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
9893194|NCT02788955|Experimental|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
9893195|NCT02767570|Experimental|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback. The goal of the training is to encourage participants to adopt an altered foot progression angle in an attempt to alter the distribution of forces crossing the knee joint. Training will occur once a week for six weeks. This will be followed by a 46-week home and community-based walking program to practice and internalize the new personalized, gait pattern and to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to enhance internalization of the new foot progression angle.
9893196|NCT02767570|Experimental|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback. The goal of the training is to encourage participants to maintain a consistent foot progression angle in an attempt to minimize the variability in the forces crossing the knee joint. Training will occur once a week, for 6 weeks. This will be followed by a 46-week home and community-based walking program to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to maintain foot progression angle consistency.
9893197|NCT02743494|Experimental|Nivolumab|
9893198|NCT02743494|Placebo Comparator|Placebo|
9893199|NCT02742090|Experimental|TGR-1202|Oral daily dose of TGR-1202
9893200|NCT02735083|Experimental|UCART19 follow-up|
9893201|NCT02727972|Other|Cognitive Testing|Cognitive assessments
9893202|NCT02727972|Active Comparator|Magnetic Resonance Imaging|All subjects will have one MRI with a possibility of one functional MRI (fmri).
9893203|NCT02727972|Active Comparator|Positron Emission Tomography|All subjects will have PET scan using FPEB or ABP688.
9893204|NCT02713386|Active Comparator|Arm I (paclitaxel and carboplatin)|See Detailed Description.
9893205|NCT02713386|Experimental|Arm II (ruxolitinib, paclitaxel, and carboplatin)|See Detailed Description.
9893206|NCT02702180|Experimental|Double-blind molgramostim once daily|Inhalation of molgramostim nebuliser solution 300 mcg once daily for 24 weeks
9893207|NCT02702180|Experimental|Double-blind molgramostim intermittent|Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 weeks (12 cycles)
9893208|NCT02702180|Placebo Comparator|Double-blind placebo|Inhalation of placebo nebuliser solution once daily for 24 weeks
9997536|NCT01509742|Placebo Comparator|Placebo|
9997537|NCT01509755|Placebo Comparator|Placebo|
9991176|NCT01450254|Experimental|Experimental|These patients will carry out a therapy program with the study intervention device.
9893209|NCT02702180|Experimental|Open-label molgramostim intermittent|Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 or 48 weeks from completion of the double-blind period
9893210|NCT02683824|Experimental|pancreatic cancer patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
9893211|NCT02683824|Experimental|healthy patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
9893212|NCT02668653|Experimental|Chemotherapy plus quizartinib|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with the experimental drug quizartinib"
9893213|NCT02668653|Active Comparator|Chemotherapy plus placebo|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with placebo"
9893214|NCT02656303|Experimental|Ublituximab + TGR-1202|Ublituximab IV treatment + TGR-1202 oral daily dose
9893215|NCT02652052|Other|Group 1: Observational|Observational only
9893216|NCT02652052|Experimental|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
9893217|NCT02612311|Experimental|Ublituximab + TGR-1202|"Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions~TGR-1202: Fixed oral daily dose"
9893218|NCT02612311|Active Comparator|Obinutuzumab + Chlorambucil|"Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6~Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6"
9893219|NCT02612311|Experimental|Ublituximab|- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
9893220|NCT02612311|Experimental|TGR-1202|- TGR-1202: Fixed oral daily dose
9893221|NCT02602769||Cases of ROHHAD syndrome|"Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians.~The investigators will perform transcriptome profiling in this group."
9893222|NCT02602769||Control cohort|Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.
9893223|NCT02597426||Patient|Nasopharyngeal carcinoma (NPC) patients who are disease free more than four years after definitive management with radiotherapy +/- chemotherapy who were treated with Intensity-Modulated Radiotherapy (IMRT), study will involve Collection of demographic data, endocrine assessment (Pituitary and Thyroid), Patient reported outcomes (Quality of Life Questionnaire), neurocognitive assessment (Behavioral rating scale) and audiology assessment (Assessment of hearing)
9893224|NCT02597426||Caregiver/Family member|Caregivers for patients who consent to participate. Study will involve Frontal Systems Behavior Scale- FrSBe (behavioral rating scale)
9893225|NCT02595931|Experimental|Treatment (irinotecan, M6620)|Patients receive irinotecan hydrochloride IV over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
9893226|NCT02591654|Experimental|Pembrolizumab and FLT|Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.
9893227|NCT02590120|Active Comparator|Enteral nutrition product : product A|Administration during 16 hours.
9893228|NCT02590120|Active Comparator|Enteral nutrition product : product B|Administration during 16 hours.
9893229|NCT02568189|Experimental|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
9893230|NCT02568189|Active Comparator|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
9893231|NCT02568189|Experimental|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
9893232|NCT02568189|Active Comparator|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
10212079|NCT02875561|Active Comparator|Sonopet Ultrasonic Aspirator|Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
9932437|NCT00949156||Retrospective cohort|The 198 cases of CP with primary surgery in our hospital (since July, 1997 until now) were divided into three topographical groups based on the pre-operative MRI, intraoperative findings and the tumor-membrane relationship. The presurgical manifestation, the different surgical approach, intraoperative techniques, and postoperative complication were described and analyzed to establish a normalized surgical treatment of individual CP patient, which has the highest rate of the totally tumoral resection and the lowest rate of the hypothalamic injury.
9991177|NCT01450254|Active Comparator|Control|The patients in this group will not carry out a therapy program with the study intervention device.
9991178|NCT01450267|Placebo Comparator|Physiological solution|
9991179|NCT01450267|Experimental|Reduced Inhaled Glutathione|
9997538|NCT01509755|Experimental|0.045 mg|
10212080|NCT02875561|Experimental|CO2 Laser Ablation|Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
10212081|NCT02862457|Experimental|Part A Cohort 1: epacadostat 25 mg|Participants received 25 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years).
10212082|NCT02862457|Experimental|Part A Cohort 1: epacadostat 100 mg|Participants received 100 mg of epacadostat orally BID alone on Days 1-5 of Cycle 1 (28-day cycle) with a washout on Days 6 and 7. On Day 8 participants received a one-time IV infusion of 200 mg pembrolizumab while continuing to receive 100 mg of epacadostat BID on Days 8-28. For each 21-day cycle thereafter, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat BID on Days 1-21 for up to 35 cycles (approximately 2 years).
10212083|NCT02862457|Experimental|Part A Cohort 2: epacadostat 25 mg+pembrolizumab|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 25 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years).
9893236|NCT02549664||LQT/HCM sedentary patients|LQT/HCM sedentary lifestyle
9893237|NCT02549664||LQT/HCM moderate/vigorous exercise|LQT/HCM participate in moderate or vigorous exercise
9893238|NCT02545049|Experimental|BAY94-8862|Finerenone tablet
9893239|NCT02545049|Placebo Comparator|Placebo|Matching placebo
9932438|NCT00949156||Prospective cohort|The anticipated 40 cases of CP were surgical treated by our standard procedure, which is recruited in the prospective cohort. With the long-term follow up, QOL including the cognition, circadian rhythm, endocrine, Water-Electrolyte, and body weight et al were evaluated to assess the rationality of the treatment. Then according to the results, the surgical treatment was modified, and the endocrinic substitution therapy was also been developed.
9932439|NCT00949169||Carrotid IMT group according to maximal IMT|We defined increased IMT group as whom had maximal IMT ≥ 1.0 mm.
9932440|NCT00949182|Experimental|Sorafenib Tosylate, Doxorubicin, Mytomicin C|Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
9932441|NCT00949195||COPD patients|COPD patients with severe obstruction performed the tests.
9932442|NCT00949195||Healthy subjects|Age-matched healthy subjects performed the same test also.
9932443|NCT00949208||A|The study population will consist of healthy volunteers who fulfill all the inclusion criteria and do not meet any of the exclusion criteria.
9932444|NCT00949221|Other|Group 1|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months
9932445|NCT00949221|Other|Group 2|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intensive strategy using continuous glucose monitoring for 12 months
9932446|NCT00949221|Other|Group 3|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
9932447|NCT00949247|Experimental|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab|
9932448|NCT00949260||Normal, Non-Pregnant|Normal, non-pregnant patients will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
9932449|NCT00949260||Normal, Pregnant|Normal, pregnant patients in their 3rd trimester will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
9932450|NCT00949260||Pregnant, PIH|Pregnant patients in their 3rd trimester with pregnancy-induced hypertension that has not been treated will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
9932451|NCT00949273||cylindrical abdominoperineal resection|patients underwent cylindrical abdominoperineal resection for advanced very low rectal cancer
9932452|NCT00949273||abdominoperineal resection|patients underwent conventional abdominoperineal resection for advanced very low rectal cancer
9932453|NCT00949338|Active Comparator|Arm I|Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
9932454|NCT00949338|Experimental|Arm II|Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
9932455|NCT00949351|Placebo Comparator|Aliskiren|
9932456|NCT00949364|Experimental|Pomalidomide|Every patient will remain on treatment until disease progression for at least 12 cycles, withdrawal of patient's informed consent or the occurrence of unacceptable toxicity. If a patient may benefit from treatment with pomalidomide the investigator together with the principle investigator will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision. This additional treatment will be performed within the follow-up period of the study, data will be collected and duration will be maximally 12 cycles.
9932457|NCT00949377|Experimental|Methylnaltrexone Bromide|
9932458|NCT00949377|Placebo Comparator|Normal Saline|
9932459|NCT00949390||Phase I and CAM Survey|Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
10212084|NCT02862457|Experimental|Part A Cohort 2: epacadostat 100 mg+pembrolizumab|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and received 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years).
9797765|NCT01606254|Experimental|Paliperidone palmitate 150 mg|Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
9797766|NCT01606254|Experimental|Paliperidone palmitate 150/ 50 mg|Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
9797767|NCT01606306|Experimental|Crossover sequence 1|daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
9797768|NCT01606306|Experimental|Crossover sequence 2|daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
9893240|NCT02543255|Experimental|Abiraterone acetate + prednisone + leuprolide + cabazitaxel|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day), prednisone (5 mg twice daily), leuprolide (22.5 mg every 3 months), and cabazitaxel (20 mg/m2, with 6 mg pegfilgrastim administered 24 h following cabazitaxel) prior to radical prostatectomy.
9991180|NCT01450280|Experimental|Group 1A|AdCh63 CS 5x10^9 vp
9797769|NCT01606306|Experimental|Crossover sequence 3|daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
9797770|NCT01606306|Experimental|Crossover sequence 4|daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
9797771|NCT01606306|Experimental|Crossover sequence 5|as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
9797772|NCT01606306|Experimental|Crossover sequence 6|as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
9797773|NCT01606319|Experimental|acetaminophen|acetaminophen given as needed for pain or fever
9797774|NCT01606319|Experimental|ibuprofen|ibuprofen given as needed for pain or fever
9797775|NCT01606670||Neupro® Treatment|Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.
9800239|NCT01682837|Experimental|KCl, KMgCit, KCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800240|NCT01682837|Experimental|KCl, KMgCit, Placebo, KCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800241|NCT01682837|Experimental|KCl, KCit, KMgCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800242|NCT01682837|Experimental|KCl, KCit, Placebo, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800243|NCT01682837|Experimental|KCl, Placebo, KMgCit, KCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800244|NCT01682837|Experimental|KCl, Placebo, KCit, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800245|NCT01682837|Experimental|Placebo, KMgCit, KCit, KCl|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9800246|NCT01682837|Experimental|Placebo, KMgCit, KCl, KCit|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9893241|NCT02543255|Active Comparator|Abiraterone acetate + prednisone + leuprolide|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day) , prednisone (5 mg twice daily), and leuprolide (22.5 mg every 3 months) prior to radical prostatectomy.
9893242|NCT02512913|Experimental|Adapted/enhanced MAPS|Counseling sessions delivered by phone to the pregnant/postpartum women and to the husbands/partners
9893243|NCT02512913|No Intervention|Usual Care|Couples in the control condition will receive usual care
9893244|NCT02500407|Experimental|Dose Escalation|Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
9893245|NCT02500407|Experimental|Dose Expansion|Participants will receive BTCT4465A (Mosunetuzumab) as a single-agent or in combination with atezolizumab.
9893246|NCT02488759|Experimental|Neoadjuvant Cohort|"Nivolumab intravenous infusion as specified~**Not participating: Japan, Korea, and Taiwan"
9893247|NCT02488759|Experimental|Metastatic Monotherapy Cohort|Nivolumab intravenous infusion as specified
9893248|NCT02488759|Experimental|Nivolumab plus Ipilimumab Cohort|"Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified~**Not participating: Belgium, France and Germany~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico~**Not participating in cohort expansion: France, Germany, Korea and Taiwan"
9893249|NCT02488759|Experimental|Nivolumab plus Relatlimab Cohort|"Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified~** Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
9893250|NCT02488759|Experimental|Nivolumab plus Daratumumab Cohort|"Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified~**Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands~Enrollment is closed for this cohort"
9893251|NCT02448381|Active Comparator|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
9893252|NCT02448381|Placebo Comparator|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
9893253|NCT02437279|Active Comparator|Arm A|Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
9893254|NCT02437279|Active Comparator|Arm B|A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
9893255|NCT02419846|Experimental|Men over 40: Screening with intervention|Participants over the age of 40 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences. Participants may undergo a screening exam comprising a prostate specific antigen level and digital rectal exam.
9893256|NCT02419846|Experimental|Men 18-39: Educational intervention|Participants between 18 and 39 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences.
9893257|NCT02278887|Active Comparator|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
9893258|NCT02278887|Experimental|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
9893260|NCT02235792|Experimental|Deep Brain Stimulation 37604 Activa PC+S|All subjects will undergo DBS using the 37604 Activa PC+S device (single arm study).
9893261|NCT02224144|Experimental|Vitamin D3 plus Calcitriol|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months~1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months"
9893262|NCT02224144|Placebo Comparator|Vitamin D3 plus Placebo|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months~1 pill of placebo (sugar pill) per day for 12 months"
9893263|NCT02158858|Experimental|Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm|"Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi.(CPI-0610 alone)~Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)"
9893264|NCT02158858|Experimental|Arm 2: Prior JAKi Combination Arm|"Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)~Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)"
9893265|NCT02158858|Experimental|Arm 3: JAKi Naïve Combination Arm|Open to patients with MF who have not previously received a JAKi. (CPI-0610 + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
9893266|NCT02158858|Experimental|Arm 4: Essential Thrombocythemia (ET) Monotherapy Arm|Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)
9893267|NCT02151981|Experimental|Osimertinib|Osimertinib 80 mg, orally, once daily
9893268|NCT02151981|Active Comparator|Platinum-based doublet chemotherapy|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2
9893269|NCT02071134||Parkinson's disease|Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
9991181|NCT01450280|Experimental|Group 1B|ChAd63 CS 5x10^9 vp Day 0; MVA CS 2x10^8 pfu Day 56
9997539|NCT01509755|Experimental|0.225 mg|
9797776|NCT01606735|Experimental|Dose 1|
9797777|NCT01606735|Experimental|Dose 2|
9797778|NCT01606735|Experimental|Dose 3|
9893270|NCT02067052||Advanced vulvar cancer|Patients with advanced-stage tumors.
9893271|NCT02067052||Early-stage vulvar cancer|Patients with early-stage tumors
9893272|NCT02030990|Experimental|Mitomycin-C; 3 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 3 week fluorometholone 1% topical steroid taper.
9893273|NCT02030990|Experimental|Mitomycin-C; 1 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 1 week of fluorometholone 1% topical steroid.
9893274|NCT02030990|Active Comparator|No mitomycin-C; 8 week FML steroid taper|No mitomycin-C will be administered during the procedure. Instead a sham application of salt solution will be given for 15 seconds. The patient will take 8 weeks of topical fluorometholone 1% topical steroid drop taper.
9893275|NCT02025257|Experimental|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
9893276|NCT02025257|No Intervention|Control|Patients are asked to live as usual.
9893277|NCT01977560|Other|Standard Care|Participants randomized to this arm will receive dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines.
9893278|NCT01977560|Experimental|Intensive Lifestyle intervention|Participants randomized to this arm will be participate in weekly dietary and behavioral education session in addition to four 60-min supervised exercise training sessions per week for 8 months. All dietary and- behavioral education and exercise training sessions will be conducted at the worksite.
9893279|NCT01972217|Active Comparator|Olaparib|200 mg or 300 mg bid
9893280|NCT01972217|Placebo Comparator|Placebo|placebo to match olaparib bid
9893281|NCT01965912|Experimental|Kuvan®|
9893282|NCT01907412|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
9893283|NCT01907412|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
9893284|NCT01898793|Experimental|Phase I: 0.5 x 10^6/kg CIML NK cells (Dose Levels 1-3)|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
9893285|NCT01898793|Experimental|Lead-in Cohort & Phase II (ALT-803): Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.~Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5)."
9893286|NCT01898793|Experimental|Pediatric Cohort: Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0~Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses"
9893287|NCT01898793|Experimental|Phase II (IL-2): Maximum NK cell/number kg|The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
9893288|NCT01849874|Experimental|MEK162|
9893289|NCT01849874|Active Comparator|Physician's choice chemotherapy|
9893290|NCT01791920|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
9893291|NCT01791920|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A
9893292|NCT01773707|Experimental|abatacept IV infusion|CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)
9893293|NCT01773707|Placebo Comparator|Placebo|The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.
9893294|NCT01724866|Experimental|Arm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 milligram/ square metre (mg/m^2) intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
9991182|NCT01450280|Experimental|Group 2A|AdCh63 CS 5 x 10^10 vp
9991183|NCT01450280|Experimental|Group 2B|ChAd63 CS 5x10^10 vp Day 0; MVA CS 2x10^8 pfu Day 56
9991184|NCT01450293|Experimental|Group A|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
9991185|NCT01450293|Experimental|Group B|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
9991186|NCT01450293|No Intervention|Group C|5 to 12 months old infants; no vaccination
9991187|NCT01450293|Experimental|Group D|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
9991188|NCT01450293|Experimental|Group E|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
9991189|NCT01450293|No Intervention|Group F|10 week old babies; no vaccination
9991190|NCT01450332|Experimental|study|
9991191|NCT01450345|Experimental|Pregabalin Group|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
9991192|NCT01450358|Active Comparator|Pathogen detection by Multiplex PCR|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. Multiplex PCR will be immediately undertaken and its results will be reported to prompt medical researcher (6-12 hours).The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR.
9991193|NCT01450358|No Intervention|Pathogen detection by blood culture|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. The results of multiplex PCR will be not informed to the medical researcher, being focused care as a result of blood culture (at least after 72 hours).
9991194|NCT01450371||Interferential|The individuals are treated acutely with interferential electrical stimulation (IES) during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
9991195|NCT01450371||Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
9991196|NCT01450384|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis)|Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9991197|NCT01450410|Active Comparator|Nicotinic Acid|
9991198|NCT01450410|Placebo Comparator|Placebo|
9991199|NCT01450423|Experimental|Physical activity|
9991200|NCT01450423|No Intervention|Control|
9991201|NCT01450436||preterm infants (<35 weeks gestation)|
9991202|NCT01450449|Experimental|Arm 1 - Short Course Radiotherapy|Short Course
9991203|NCT01450449|Active Comparator|Arm 2 - Standard Course Radiotherapy|Standard Course
9991204|NCT01450462|Experimental|Vitamin D (cholecalciferol)|
9991205|NCT01450462|Placebo Comparator|Placebo|
9991206|NCT01450475|Experimental|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
9991207|NCT01450475|No Intervention|control|A blood cuff was around leg without inflation or deflation.
9991208|NCT01450488|Experimental|masitinib 3 mg/kg/day|
9991209|NCT01450488|Experimental|masitinib 6 mg/kg/day|
9991210|NCT01450501||Patients with vascular chronic Q-fever|All patients with chronic Q-fever and an aneurysm or vascular reconstruction
9991211|NCT01450514|Placebo Comparator|Placebo|Sugar pill
9991212|NCT01450514|Experimental|Pipamperone|15 mg once daily
9991213|NCT01450527||Patient fulfilling the criteria of ARDS|
9991214|NCT01450566|Experimental|Lidocaine|Use of lidocaine
9991215|NCT01450566|Placebo Comparator|No lidocaine|No lidocaine/standard of care
9991216|NCT01450579|Placebo Comparator|Placebo|Saline
9991217|NCT01450579|Experimental|Dose -1|ASP7373
9991218|NCT01450579|Experimental|Dose -2|ASP7373
9991219|NCT01450579|Experimental|Dose -3|ASP7373
9991220|NCT01450592||Group 1|
9991221|NCT01450592||Group 2|
9991222|NCT01450605||Patients ≥ 13 years of age with HIV-1|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
9991223|NCT01450618||Atazanavir|HIV patients on antiretroviral therapy using Atazanavir
9991224|NCT01450618||Darunavir|HIV patients on antiretroviral therapy using Darunavir
9991225|NCT01450618||Fosamprenavir|HIV patients on antiretroviral therapy using Fosamprenavir
9991226|NCT01450618||Lopinavir|HIV patients on antiretroviral therapy using Lopinavir
9991227|NCT01450644|Other|Fast track|If patients are randomised to fast-track, their information will be passed to the H2H nurse to organise a case conference within one week of discharge.
9991228|NCT01450644|Other|Waiting list|If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
9991229|NCT01450657||Chronic Kidney Failure 3/4|
9991230|NCT01450670||Dialysis patients|
9991231|NCT01450709||Dialysis patients|
9991232|NCT01450722|Active Comparator|drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction
9997540|NCT01509755|Experimental|0.45 mg|
9991233|NCT01450722|Active Comparator|bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft
9991234|NCT01450748|Experimental|Sodium alginate|oral suspension, 50 mg/ml
9991235|NCT01450748|Placebo Comparator|Placebo|oral suspension without active ingredient
9991236|NCT01450774|Experimental|CHF 1535 50/6µg|
9991237|NCT01450774|Active Comparator|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|
9991238|NCT01450839|Experimental|E2020 5 mg tablet and tape|
9991239|NCT01450839|Placebo Comparator|2|
9991240|NCT01450852|Experimental|Strength Training|The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
9991241|NCT01450852|No Intervention|Active Control Group|The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.
9991242|NCT01450865|Experimental|Placebo first|Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
9991243|NCT01450865|Experimental|Flupirtine first|Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
9991244|NCT01450878|Experimental|Graft with EPO|intravenous 1000 000UI beta-epoietin one hour before organe retrieval.
9991245|NCT01450878|No Intervention|graft without EPO|no injection befoe organ retrieval
9991246|NCT01450891||total patient group|all new consecutive patients of the participating memory clinics who are suspected of having a primary neurodegenerative disease, meaning that all patients with subjective as well as objective memory complaints are included
9991247|NCT01450904|Experimental|Group A|The length of Quadriceps incision was less than 2 cm.
9991248|NCT01450904|Experimental|Group B|The length of Quadriceps incision was 2 to 4 cm.
9991249|NCT01450904|Experimental|Group C|The length of Quadriceps incision was more than 4 cm.
9991250|NCT01450917||Group A|Brachial plexus injured patients with phrenic nerve dysfunction
9991251|NCT01450917||Group B|Brachial plexus injured patients without phrenic nerve dysfunction
9991252|NCT01450917||Group C|Non brachial plexus injured patients
9991253|NCT01450930|Active Comparator|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
9991254|NCT01450930|Active Comparator|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
9991255|NCT01450956|Experimental|Sevoflurane|Patients will receive 2% sevoflurane via oxygenator during CPB
9991256|NCT01450956|No Intervention|Control|Patients will receive only oxygen and air through oxygenator
9991257|NCT01450969||Interventional Radiologists|All operators are Interventional Radiologists and co-investigators. Prior to start of the study, all operators are asked to provide written informed consent to participate in the study.
9991258|NCT01450982|Experimental|001|JNJ-38518168 / MTX Day 1: MTX: Route=oral use single dose of participant's weekly MTX dose Days 2-15: MTX: Route=oral use single dose of participant's weekly MTX dose and of JNJ-38518168 Type=exact unit=mg number=100 form=capsule route=oral use administered daily.
9991259|NCT01450995|Active Comparator|Treximet|
9991260|NCT01450995|Active Comparator|Imitrex and Aleve|
9991261|NCT01451034|Active Comparator|WHYX cancer group|WHYX cancer diagnosed by pathologic report
9991262|NCT01451034|Placebo Comparator|non-WHYX cancer group|all cancer except WHYX cancer diagnosed by pathologic report
9991263|NCT01451086|Experimental|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
9991264|NCT01451086|Active Comparator|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
9991265|NCT01451112|Experimental|Treated|
9991266|NCT01451125|Experimental|Treated|
9991267|NCT01451138|Experimental|Treated|
9991268|NCT01451151|Experimental|Treated|
9991269|NCT01451177|Experimental|Treated|
9991270|NCT01451190|Experimental|Treated|
9991271|NCT01451216||ABI 50-70 y|patients suffering from acquired brain injury aged 50-70 years old
9991272|NCT01451216||ABI 25-50y|Patients suffering from acquired brain injury aged 25-50 years oled
9991273|NCT01451242||brain injury|
9991274|NCT01451268|Experimental|Panobinostat Arm A|
9991275|NCT01451268|Experimental|Panobinostat Arm B|
9991276|NCT01451294|Active Comparator|Ephedrine|
9991277|NCT01451294|Active Comparator|Phenylephrine|
9991278|NCT01451307||Gastrointestinal malformations|Children who underwent standardized neonatal pediatric surgery due to gastrointestinal malformations
9991279|NCT01451307||No gastrointestinal malformations|Control group of healthy children matched concerning gestational age, weight class and gender
9991280|NCT01451320|Active Comparator|rapid streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
9997541|NCT01509755|Experimental|0.60 mg|
9997542|NCT01509755|Experimental|0.75 mg|
9893295|NCT01724866|Experimental|Arm 2: SPI-2012 135 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 135 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
9893296|NCT01724866|Experimental|Arm 3: SPI-2012 270 µg/kg and Docetaxel + Cyclophosphamide (TC)|"Participants received SPI-2012 270 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
9893297|NCT01724866|Experimental|Arm 4: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)|"Participants received Pegfilgrastim 6 milligram (mg), SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m^2 IV infusion over 30-60 minutes."
9893298|NCT01711021|Active Comparator|d-Amphetamine Transdermal System|d-Amphetamine Transdermal System
9893299|NCT01711021|Placebo Comparator|Placebo patch|Placebo patch
9893300|NCT01670877|Experimental|Part I: Neratinib Only|-Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9893301|NCT01670877|Experimental|Part II: Neratinib Only (ER-)|-Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9893302|NCT01670877|Experimental|Part II: Neratinib + Fulvestrant (ER+, fulvestrant-naive)|-Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9893303|NCT01670877|Experimental|Part II: Neratinib + Fulvestrant (ER+. prior fulvestrant-tx)|-Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9893304|NCT01670877|Experimental|Crossover: Neratinib + Trastuzumab|-If a participant experiences disease progression during Part I or Part II following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days. Patients will continue to receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks.
9893305|NCT01670877|Experimental|Crossover: Neratinib + Fulvestrant + Trastuzumab|-If a participant experiences disease progression during Part I or Part II following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days. Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks.
9893306|NCT01653899|Experimental|IDN-6556|Drug
9893307|NCT01602380|Experimental|faslodex+placebo|Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
9893308|NCT01602380|Active Comparator|arimidex +placebo|Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
9893309|NCT01550003|Experimental|Certolizumab Pegol|Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
9893310|NCT01530659|Experimental|NT-501|Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina
9893311|NCT01530659|Sham Comparator|Sham|Sham surgery
9893312|NCT01518556|Experimental|Idarubicin|Idarubicin dose intensification for remission induction in acute myeloid leukemia
9893313|NCT01494324|Experimental|CT guided percutaneous ablation|The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.
9893314|NCT01428895|Active Comparator|Surgery Alone|
9893315|NCT01428895|Active Comparator|Surgery + Radiation Therapy|
9893316|NCT01412333|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
9893317|NCT01412333|Experimental|Ocrelizumab|Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
9893318|NCT01389050|No Intervention|Follow-up|Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
9893319|NCT01389050|Experimental|Prospective|
9893320|NCT01247324|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
9893321|NCT01247324|Experimental|Ocrelizumab|Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
9893322|NCT01213732|Experimental|L19TNFα plus melphalan|Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).
9893323|NCT01208662|Active Comparator|High Dose Treatment|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Maintenance Lenalidomide.
9893324|NCT01208662|Experimental|High Dose Treatment with SCT|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Autologous Stem Cell Transplant. Maintenance Lenalidomide.
9893325|NCT01198522|Other|Therapy of L19IL2 and Gemcitabine|Dose escalation study. Part A) Gemcitabine dose escalation. Part B) L19IL2 dose escalation.
9893326|NCT01134250|Experimental|F16IL2 in combination with paclitaxel|
9893327|NCT01094691|Experimental|Renal Allograft Biopsy|Urine left over from clinic visits is analyzed for 'Haufen' by negative staining electron microscopy as a marker of intra-renal polyomavirus nephropathy. Correlate Haufen, urine, and plasma data with the clinical presentation and with renal biopsy findings. Patients with PVN will be approached for study participation in which their routine samples will be monitored until urine is negative for 'Haufen', and a study protocol biopsy will be obtained for confirmation.
9893328|NCT00984672||Bone morphogenetic protein within an interbody cage|Transforaminal Lumbar Interbody Fusion with the use of BMP
9893329|NCT00984672||Other bone grafting techniques within cage (non-BMP)|Use of iliac crest autograft, allograft, or local autogenous bone grafting within the cage during Transforaminal Lumbar Interbody Fusion.
9893330|NCT00979238|Other|Group 1|"All participants who meet the eligibility requirements.~Intervention: Gene Transfer and drug (scAAV2/8-LP1-hFIXco)."
9893331|NCT00937248|Experimental|Interventional|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device with a CVID.
9893332|NCT00937248|Active Comparator|Standard Arm|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device without a CVID
9893333|NCT00778206||1. PKUDOS Registry|Patients with a confirmed diagnosis of Phenylketonuria (PKU) with hyperphenylalaninemia who have either received Kuvan therapy, or currently receive Kuvan therapy, or intend to begin receiving Kuvan therapy within 90 days of entering the registry.
9893334|NCT00778206||2. PKU MOMS Subregistry|Patients with PKU who are pregnant at enrollment in the registry or who become pregnant while participating in the registry.
9893335|NCT00667628|Placebo Comparator|Placebo|Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period. Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
9893336|NCT00667628|Experimental|TAC-101|Participants were administered with TAC-101 tablets, 20 milligram per day (mg/day) orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.
9893337|NCT00588185|Experimental|1|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
9893338|NCT05333315|Experimental|Investigation Product 1 (IP1) in softchews form|0,5 g of glucomannan per softchew
9893339|NCT05333315|Experimental|Investigation Product 2 (IP2) in powder form|Fiber of light Indian plantain, 7 g; glucomannan, 4,3 g; Inulin 2,5 g; Apple fiber, 1g; Choline, bitartrate 90 mg; Apple pectin,50 mg; Inositol, 40 mg
9893340|NCT05333315|Experimental|Investigation Product 3 (IP3) in powder form and capsules form|POWDER: Plantain fibre 10 g; Inulin, 2 g; Apple fibre, 1,5 g; Root of pellitory, 500 mg; Apple pectin, 450 mg CAPSULE: Pumpkin seed extract, 300 mg; Garlic extract odourless, 300 mg; Artichoke leaf extract, 150 mg; Cumin seed extract, 150 mg; Peppermint leaf extract, 150 mg; Anise seed extract, 150 mg; Curcuma rhizome extract, 150 mg; Vitamin C, 42 mg; Zinc (in gluconate),10 mg; Vitamin B6, 1,5 mg
9893341|NCT05333315|Experimental|Investigation Product 4 (IP4) in liquid form|LIQUID: Arabinogalactan, 700 mg; Inulin, 700 mg; Beta-glucans, 30 mg
9893342|NCT05333315|Experimental|Investigation Product 5 (IP5) in two capsules form|CAPSULE 1:L-arginine, 100 mg; Choline bitartrate, 100 mg; L-carnosine, 100 mg; L-taurine, 100 mg; Soy lecithin, 50 mg; R-alfa lipoic acid,10 mg; Vitamin B6,2 mg; Folic acid, 200 µg; Vitamin D3, 5 µg; Vitamin B12, 2 µg CAPSULE 2: Schisandra fruit extract, 400 mg; Milk thistle fruit extract associated with phospholipids, 200 mg; Grape seed extract associated with phospholipids, 50 mg; Grape seed extract (Vitis vinifera),50 mg
9893343|NCT05333302|Experimental|CD19 CAR-T cells immunotherapy|After a cycle of lymphodepleting chemotherapy a patient receive locally produced autologous CD19 CAR-T cells
9893344|NCT05333289|Experimental|mRNA-1030 Dose Level A|Participants will receive mRNA-1030 at Dose Level A by intramuscular (IM) injection on Day 1.
9893345|NCT05333289|Experimental|mRNA-1020 Dose Level A|Participants will receive mRNA-1020 at Dose Level A by IM injection on Day 1.
9893346|NCT05333289|Experimental|mRNA-1030 Dese Level B|Participants will receive mRNA-1030 at Dose Level B by IM injection on Day 1.
9893347|NCT05333289|Experimental|mRNA-1020 Dose Level B|Participants will receive mRNA-1020 at Dose Level B by IM injection on Day 1.
9893348|NCT05333289|Experimental|mRNA-1030 Dose Level C|Participants will receive mRNA-1030 at Dose Level C by IM injection on Day 1.
9893349|NCT05333289|Experimental|mRNA-1020 Dose Level C|Participants will receive mRNA-1020 at Dose Level C by IM injection on Day 1.
9893350|NCT05333289|Active Comparator|mRNA-1010|Participants will receive mRNA-1010 by IM injection on Day 1.
9893351|NCT05333289|Active Comparator|Active Comparator|Participants will receive an active comparator by IM injection on Day 1.
9893352|NCT05333276|Experimental|TQB3602 Capsule + AK105 Injection|TQB3602 capsule administered orally on day 1, 8 in 21-day cycle; every three weeks intravenous (IV) for one times of AK105 injection.
9893353|NCT05333250|Experimental|Modafinil|One 200mg modafinil capsule once daily for one week
9893354|NCT05333250|Placebo Comparator|Placebo|One placebo capsule once daily for one week
9893355|NCT05333237|Experimental|Sequence 123|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
9893356|NCT05333237|Experimental|Sequence 132|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
9893357|NCT05333237|Experimental|Sequence 213|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution)."
9893358|NCT05333237|Experimental|Sequence 231|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon second study session, intervention #3 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
9893359|NCT05333237|Experimental|Sequence 312|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink).~upon third study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink)."
9893360|NCT05333237|Experimental|Sequence 321|"In this study arm the following sequence of interventions will be administered:~upon first study session, intervention #3 will be administered (Dietary Supplement: Generic Glucose Solution).~upon second study session, intervention #2 will be administered (Dietary Supplement: Fresubin Energy Drink).~upon third study session, intervention #1 will be administered (Dietary Supplement: ProvideXtra Drink)."
9893361|NCT05333224|Experimental|Telerehabilitation|A telerehabilitation-based exercise group where the therapist coaches the family, performs one-on-one exercises with families with a doll in his hand, and can perform the necessary interventions such as promoting good practices and preventing bad practices, and the other 2 days where the families show their exercises by sending videos to the therapist, and again provide the therapist's intervention and follow-up via videos
9893362|NCT05333224|Other|Control|The control group that will be given exercise training in 1., 4., 8., and 12. week.
9893363|NCT05333198|Other|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
9893364|NCT05333198|Active Comparator|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
9893365|NCT05333185|Experimental|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
9893366|NCT05333185|No Intervention|Control group|The control group will recieve standard diabetes treatment without any training intervention
9893367|NCT05333159||Experimental|Subjects will be treated with SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) with or without conventional hypoglycemic drugs .
9893368|NCT05333159||Control|Subjects will be only treated with conventional hypoglycemic drugs.
9932460|NCT00949442|Experimental|1|"Before randomization (common with arm 2):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose"
9991281|NCT01451320|Active Comparator|high dose tpa|5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
9893369|NCT05333133|Experimental|High calorie formula on IGF-1, TNF-alpha and total lymphocyte counts|Interventional study with pre-, post design after the subjects are diagnosed with TB and UTI, they will receive 400 ml (equal with 400 kcal) of high calorie formula per day, prescribed by the researcher (a pediatrician) for 90 days consumption. Body weight and body height will be monitored by the researcher group every 30 days to record the tolerance, acceptance and complaints (and the side effects) the blood will be withdraw at day 0 (before intervention) and day 90 (after intervention) to investigate the IGF-1, TNF-alpha and total lymphocyte counts
9893370|NCT05333107|Experimental|Sequence 1|Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2).
9893371|NCT05333107|Experimental|Sequence 2|Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2).
9893372|NCT05333107|Experimental|Sequence 3|Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2).
9893373|NCT05333107|Experimental|Sequence 4|Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2).
9893374|NCT05333107|Experimental|Sequence 5|Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2).
9893375|NCT05333107|Experimental|Sequence 6|Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2).
9893376|NCT05333094|Active Comparator|American orthodontics brackets|"Roth prescription, 0.022 slot size"
9893377|NCT05333094|Active Comparator|FANTA brackets|"Roth prescription, 0.022 slot size"
9893378|NCT05333094|Active Comparator|MATT brackets|"Roth prescription, 0.022 slot size"
9893379|NCT05333081|Other|Evaluation of the glycemic index|
9893380|NCT05333068|Experimental|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment
9893381|NCT05333068|Sham Comparator|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)
9893382|NCT05333055||Group 1|Eyes with treatment naive DR with or without DME
9893383|NCT05333055||Group 2|Eyes with DME that are incompletely responsive to anti-VEGF therapy
9893384|NCT05333055||Group 3|Eyes with various retinal conditions including eyes with DR and DME that is anti-VEGF responsive as well as non-exudative retinal pathologies such as epiretinal membrane and macular hole
9893385|NCT05333029|Experimental|MSCs + ECP|"The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.~Participants will be followed for up to 1 year for assessment of endpoints."
9893386|NCT05333003|Experimental|Semaglutide|Semaglutide medication will be taken by participants on a weekly schedule, and adherence tracked
9893387|NCT05333003|Placebo Comparator|Placebo|Placebo will be taken by participants on a weekly schedule, and adherence tracked
9893388|NCT05332977|Experimental|CAD-CAM fabricated provisional prothesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
9997543|NCT01509755|Active Comparator|Glim|
9517151|NCT03309059|Experimental|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
9667164|NCT03875820|Experimental|Dose Escalation Phase|"Escalating doses of VS-6766 (RO5126766) and Defactinib (VS-6063) were evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation followed a 3+3 design with a maximum of four patient cohorts.~This arm is now complete."
9991282|NCT01451320|Active Comparator|slow streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
9991283|NCT01451320|Active Comparator|half-dose slow infusion tpa|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
9991284|NCT01451320|Active Comparator|low dose slow infusion tpa|6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
9991285|NCT01451333|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
9991286|NCT01451333|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
9991287|NCT01451346|Placebo Comparator|Placebo|Placebo sachets contained 5 grams of Maltodextrin only.
9991288|NCT01451346|Experimental|B Infantis 35624|Each 5gram freeze-dried powder contained ≥1*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
9991289|NCT01451359|Experimental|endobronchial valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
9991290|NCT01451450|Experimental|QGE031 A|
9991291|NCT01451450|Experimental|QGE031 B|
9991292|NCT01451450|Experimental|QGE031 C|
9991293|NCT01451450|Experimental|QGE031 D|
9991294|NCT01451450|Placebo Comparator|Placebo A|
9991295|NCT01451450|Placebo Comparator|Placebo B|
9991296|NCT01451450|Placebo Comparator|Placebo C|
9991297|NCT01451450|Placebo Comparator|Placebo D|
9991298|NCT01451476||Healthy females aged >=18|Healthy female volunteers of skin type I or II
9991299|NCT01451489|Active Comparator|Cyclophosphamide|CTX
9991300|NCT01451489|Experimental|FK506|0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.
9991301|NCT01451515|Experimental|Treatment|"Patients will undergo treatment as described in the intervention section. Interventions include:~Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine~Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine~Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine, methotrexate~Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide~All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22."
9797779|NCT01606748|Experimental|Necitumumab, Gemcitabine and Cisplatin|The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
9991302|NCT01451528|Experimental|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation
9991303|NCT01451593|Experimental|phenytoin|active arm of trial 1:1 allocation active versus placebo
9991304|NCT01451593|Placebo Comparator|placebo|1:1 allocation active versus placebo
9991305|NCT01451619|Experimental|Laropiprant|
9991306|NCT01451619|Placebo Comparator|Placebo|
9991307|NCT01451658|No Intervention|EVL or GVS treatment|"Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)"
9991308|NCT01451658|Experimental|Endoscopic treatment combined propranolol|Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
9991309|NCT01451697|Experimental|Experimental: Cognitive Remediation|The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, & Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
9991310|NCT01451697|Placebo Comparator|Control (Placebo)|The placebo control condition will consist of structured relaxation training, which will involve viewing and participating with meditation and stress-reduction DVDs, and listening to and following a CD of Progressive Muscle Relaxation. Participants will benefit from learning stress reduction techniques in this condition, but will not exercise any of the cognitive domains of interest targeted in the treatment group.
9991311|NCT01451710|Experimental|Prednisone or Prednisolone|
9991312|NCT01451788|No Intervention|Conventional group|conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)
9991313|NCT01451788|Experimental|Floseal|Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)
9991314|NCT01451801|Other|HBsAg|
9991315|NCT01451840|Active Comparator|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of intravenous remifentanil before emergence of a desflurane-based anesthesia
9991316|NCT01451840|Experimental|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
9991317|NCT01451853|Active Comparator|SPI-1005 Low Dose|200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
9991318|NCT01451853|Active Comparator|SPI-1005 Middle Dose|400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
9991319|NCT01451853|Active Comparator|SPI-1005 High Dose|600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
9991320|NCT01451853|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
9517504|NCT03305718|Experimental|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
9991321|NCT01451866|Active Comparator|classic leg-press training|Classic resistance training on the dynamic leg press. 6 x 8 repetitions at 60% 1 RM
9991322|NCT01451866|Experimental|Complex leg-press training|Complex leg-press training with visual feed-back on a dynamic leg-press.
9991323|NCT01451879||Age 0 months to 65 years|Confirmed diagnosis of Pompe Disease, and clinically prescribed immune modulation regimen with agents such as rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone Miglustat, N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their primary/specialist caregiver.
9991324|NCT01451892|Experimental|Dance therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
9991325|NCT01451892|Active Comparator|Education|overweight individuals participating in a patient education ambulatory program for obese people
9991326|NCT01451905|Active Comparator|Psoriasis|
9991327|NCT01451905|Placebo Comparator|Placebo|
9991328|NCT01451918|Active Comparator|Resveratrol|
9991329|NCT01451918|Placebo Comparator|Placebo|
9991330|NCT01451944|Experimental|asthma education and case management|asthma education and case management
9991331|NCT01451957|Experimental|Exercise|90 min exercise on Day 1
9991332|NCT01451957|Experimental|Sedentary Control|Subjects remain sedentary on Day 1 and will either consume a hyper-caloric or a caloric balanced diet
9991333|NCT01452009|Experimental|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|
9991334|NCT01452009|Active Comparator|TRAVATAN®|TRAVATAN® administered one drop once daily
9991335|NCT01452022|Experimental|Inductigraft|open label non randomised to assess performance of synthetic bone graft using the product, Inductigraft, in posterolateral lumbar fusion
9991336|NCT01452035|Experimental|Exercise|
9991337|NCT01452035|No Intervention|Sedentary Control|
9991338|NCT01452061||ASD|Participants with autism spectrum disorder.
9991339|NCT01452061||ADHD/DD|Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
9991340|NCT01452061||Siblings|Siblings without a developmental or psychiatric disorder.
9991341|NCT01452061||Control|Unrelated individuals without a developmental or psychiatric disorder.
9997544|NCT01509768||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIB to identify endpoints that may be used for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures
9997545|NCT01509781|Active Comparator|Suction drain|Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
9997546|NCT01509781|Experimental|Adaptive suture|Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.
9997547|NCT01509794|Active Comparator|Low Valence|Participants in the low valence condition will participate in photo-based simulations. They will see a photo of the patient and hear affectively flattened audio. The script and clinical information remain the same as the high valence condition.
9997548|NCT01509794|Experimental|High Valence|Participants in the high valence condition will participate in video-based simulations. They will see a rich multimedia presentation of the clinical encounter, with affectively enhanced audio. The script and clinical information remain the same as the low valence condition.
9997549|NCT01509833|Experimental|rFSH|Administration of recombinant FSH for ovarian stimulation.
9997550|NCT01509833|Experimental|hCG(100IU)|Administration of late follicular low dose hCG(100U) for ovarian stimulation.
9997551|NCT01509833|Experimental|hCG(200IU)|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
9997552|NCT01509859|Active Comparator|PFNA|"these patients will be treated with synthes PFNA device"
9997553|NCT01509859|Active Comparator|INTERTAN|"these patients will be treated with Smith&Nephew INTERTAN device"
9997554|NCT01509885||Complete Spinal Cord Injured Subjects|Patients with no motor scores in their legs and suffering a complete spinal cord injury.
9997555|NCT01509885||Incomplete Spinal Cord Injured Subjects|Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
9997556|NCT01509898|Experimental|water-Jet|use of water jet for 1 month
9997557|NCT01509911|Experimental|TL-118 with standard of care Gemcitabine|
9997558|NCT01509911|Active Comparator|Gemcitabine with out TL-118|
9997559|NCT01509924|Experimental|Physical activity on Prescription (PaP)|Intervention group receives a PaP for 12 month.
9997560|NCT01509924|No Intervention|Control Group|The control group has the same monitoring as the experimental group but receives no PaP.
9997561|NCT01509924|No Intervention|Cognitiv function in patients with TIA|"Before discharged from hospital cognitive function is assessed. At the first visit the patients fill in a self assessment questionnaire for mental fatigue.~If impaired at the previous assessment cognitive function will be assessed at 3, 6 and 12 month."
9997562|NCT01509924|No Intervention|Controlgroup Cognitive function|In order to determine whether hospitalization in itself is associated with transient impaired cognition, a comparison group will be included. The comparison group will consist of patients with angina pectoris consecutively admitted to the Norrtälje Hospital. The patients with angina pectoris will be age and sex matched with the patients with TIA and assessed for cognitive function when their angina symptoms have subsided.
9997563|NCT01509937|Experimental|BCM Arm|BCM measured every 2 months
9997564|NCT01509937|Sham Comparator|Control arm|patients care according to standard of care
9797780|NCT01606761|Experimental|Group 1|Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.
9797781|NCT01606761|Experimental|Group 2|Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
9797782|NCT01606761|Experimental|Group 3|Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.
9797783|NCT01606787|Experimental|mannitol arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
9797784|NCT01606787|Placebo Comparator|placebo arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
9797785|NCT01606800|Experimental|44 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.
9797786|NCT01606800|Experimental|20 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.
9797787|NCT01606852|No Intervention|usual sedative practice|"Subjects will have usual care sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration."
9797788|NCT01606852|Experimental|Patient controlled sedation|Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
9797789|NCT01607073|Other|open label adjunctive add on|open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)
9797790|NCT01607112|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
9797791|NCT01607112|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
9797792|NCT01607203|Active Comparator|hCG|5000 IU Pregnyl SC
9797793|NCT01607203|Active Comparator|hCG and GnRH agonist|5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
9797794|NCT01607255|Experimental|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
9797795|NCT01607255|Experimental|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
9800247|NCT01682837|Experimental|Placebo, KCit, KMgCit, KCl|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9997565|NCT01509963||patients candidates for the SN procedure|The study will focus on patients candidates for the SN procedure as recommended by Saint-Paul de VENCE initially in 2005 but modified in 2009.
9893389|NCT05332977|Active Comparator|Insertion of denture conversion (DC)|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
9893390|NCT05332964||stroke (right)|stroke patient with lesions at right hemisphere
9893391|NCT05332964||stroke (left)|stroke patient with lesions at left hemisphere
9893392|NCT05332964||control|age-matched group for the stroke patients
9893393|NCT05332951||Adult patients followed for multiple sclerosis|
9893394|NCT05332912|Experimental|Immediate|Participants will receive 16 weeks of spatial ability experience.
9893395|NCT05332912|Placebo Comparator|Delayed|Participants will receive 8 weeks of verbal ability experience prior to receiving 8 weeks of spatial ability experience.
9893396|NCT05332899|Experimental|Influenza Challenge Model with Influenza A H3N2 Strain|Participants receiving a previously validated influenza challenge model with influenza A H3N2 strain (A/Perth/16/2009 H3N2).
9893397|NCT05332886|Experimental|MetaHealth Group|It is intervention group that aims to provide youth with healthy lifestyle behaviors by using metaverse technology.
9893398|NCT05332886|Active Comparator|MobileHealth Group|It is comparator group that aims to provide youth with healthy lifestyle behaviors by using mobile application materials with digital health education will be given to the MobileHealth Group.
9893399|NCT05332873|Experimental|Rivet Shunt Therapy|
9893400|NCT05332860||Immediate Extubation or IE|patients were extubated in the operating room (OR) or in 6 hours after surgery
9893401|NCT05332860||Early Extubation or EE|patients were extubated within 6-48 hours of admission to the ICU
9893402|NCT05332860||Delayed Extubation or DE|patients were extubated sometime after 48 hours or not extubated
9893403|NCT05332847|Active Comparator|intervention group|The intervention group underwent clinical evaluation and a bedside-focused sonographic assessment
9893404|NCT05332847|No Intervention|control group.|The control group underwent clinical evaluation without POC-US
9893405|NCT05332821||Study group: TACE+PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|TACE was performed up to 3 months after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or within 1 month before treatment. The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
9893406|NCT05332821||Control group: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
9893407|NCT05332795|Active Comparator|group 1: gouty patients on metformin.|metformin users: include gouty patients, who will receive metformin tablets (1000 mg) once daily for about 3 months.
9893408|NCT05332795|Placebo Comparator|gouty patients on placebo.|placebo users: include gouty patients, who were on placebo tablets once daily for about 3 months.
9893409|NCT05332782||M-TEER|Patients with primary mitral regurgitation undergoing mitral valve transcatheter edge-to-edge repair.
9893410|NCT05332756||Moyamoya disease patients|
9893411|NCT05332756||First-degree relatives of patients with Moyamoya Disease|
9893412|NCT05332743|Experimental|Nutraceutical Dietary Supplement|Nutraceutical Dietary Supplement capsules are comprised of primary and secondary ingredients, designed to restore hair health from the inside out. In addition to the necessary vitamins, minerals, proteins to support the nutritional needs of hair.
9893413|NCT05332730|Experimental|BAT2506|BAT2506 injection, 50 mg, subcutaneous administration. Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
9893414|NCT05332730|Active Comparator|Simponi® (EU commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
9893415|NCT05332730|Active Comparator|Simponi® (US commercially available product)|50 mg, subcutaneous administration Dose regimen: 50 mg/0.5 mL/syringe, subcutaneously injected at the lower abdomen, except for the 5 cm area around the navel. Do not inject into skin that is tender, bruised, red, scaly, or hard. Avoid areas with scars or stretch mark.
9893416|NCT05332717|Experimental|Melatonin Group (Experimental)|Patients who will take one (1) 5mg Melatonin tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
9893417|NCT05332717|Sham Comparator|Placebo Group (Control)|Patients who will take one (1) placebo (Vitamin C) tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
9893418|NCT05332704|Experimental|Part A, Active|
9893419|NCT05332704|Placebo Comparator|Part A, Placebo|
9893420|NCT05332704|Experimental|Part B, Active|
9893421|NCT05332704|Placebo Comparator|Part B, Placebo|
9893422|NCT05332704|Experimental|Part C, Active|
9893423|NCT05332704|Placebo Comparator|Part C, Placebo|
9893424|NCT05332691|Experimental|Hypertrophic Obstructive Cardiomyopathy|Minimally invasive transapical septal myectomy for Hypertrophic Obstructive Cardiomyopathy.
9893425|NCT05332678|Experimental|SLS-005|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week over 60 ± 5 minutes for volumes <600 mL or 90 minutes +5 min for volumes >600 mL.~For 52 weeks."
9893426|NCT05332678|Placebo Comparator|Placebo|"Placebo (sodium chloride injection, 0.9%, USP) will be administered as a weight-based volume equivalent to a SLS-005 0.75 g/kg dose calculation by IV infusion once a week over 60 ± 5 minutes for volumes <600 mL or 90 minutes +5 min for volumes >600 mL.~For 52 weeks."
9893427|NCT05332665||Angle opening distance (AOD)|The AOD measured as perpendicular distance between anterior iris surface and point at trabecular meshwork at 500 μm anterior to the scleral spur
9893428|NCT05332665||Trabecular iris space area (TISA) 500|TISA 500 was measured as an area bounded anteriorly by the AOD 500, posteriorly by a line drawn from the scleral spur perpendicular to the plane of the inner scleral wall to the opposing iris, superiorly by the inner corneoscleral wall, and inferiorly by the iris surface
9893429|NCT05332665||Anterior chamber depth (ACD)|The ACD was measured as the perpendicular distance from the corneal endothelium at the corneal apex to the anterior lens surface
9893430|NCT05332652|Experimental|Anodal tDCS stimulation to the ipsilesional M1|"Participant will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
9893431|NCT05332652|Experimental|Anodal tDCS to the contralesional premotor cortex|Participant will receive 1mA anodal tDCS to the contralesional premotor cortex. Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.
9893432|NCT05332652|Sham Comparator|Sham tDCS|"Participant will receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
9893433|NCT05332652|No Intervention|Control group|Subjects who fulfill the inclusion criteria of Study 2 but refuse tDCS stimulation.
9893434|NCT05332639|Experimental|Intervention Arm|Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool
9893435|NCT05332639|Active Comparator|Comparator arm|Standard Crohn's Disease Education
9893436|NCT05332626|Experimental|Probiotic group|The probiotic group will receive a supplement diet capsule consisting of Lactobacillus acidophilus with a dose of 1x109 CFU for 12 weeks
9893437|NCT05332626|Placebo Comparator|Placebo group|The placebo group will receive a capsule that consists of the excipient (maize starch and maltodextrins) for 12 weeks
9893438|NCT05332613|Experimental|TRE plus SOC|Participants will be required to fast each day for 12 weeks and will be given lifestyle recommendations with respect to diet and exercise. The registered dietitian (RD) will obtain a baseline dietary record and provide counseling on the time-restricted eating regimen. The RD will collect the participant's normal diet and exercise routine. Counseling will involve instructing the participant to choose an eight-hour eating window (e.g., 10:00am - 6:00pm) during which the participant will be able to eat. During the 16-house fasting window (e.g., 6:00pm - 10:00 am), the participant is able to drink regular water and black coffee or tea. The RD will be available to answer any questions the participants may have pertaining to the regimen and will instruct the participants regarding standard of care lifestyle recommendations. This includes education of a low-calorie diet (500-1000 kcal) and moderate-intensity exercise.
9893439|NCT05332613|Active Comparator|SOC|lifestyle modifications and weight management. Participants will be given lifestyle recommendations with respect to diet and exercise. The registered dietitian (RD) will obtain a baseline dietary record and provide counseling on the time-restricted eating regimen. A baseline dietary record will be assessed prior to fasting initiation with the RD in person. The RD will also collect the subject's normal diet and exercise routine. The RD will instruct the participants regarding standard of care lifestyle recommendations. This includes education of a low-calorie diet (500-1000 kcal) and moderate-intensity exercise.
9932461|NCT00949442|Active Comparator|2|"Before randomization (common with arm 1):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: NPH + OAD(s) at stable dose"
9932462|NCT00949455|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
9932463|NCT00949455|Placebo Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
9932464|NCT00949468||Keratitis group|37 patients with keratitis
9932465|NCT00949468||Control Study Group|37 control volunteers
9932466|NCT00949481|Experimental|Supply|In each country, this arm will be comprised of women attending family planning clinics within the 5 facilities randomized to this group.
9932467|NCT00949481|Experimental|Demand|In each country, this arm will be comprised of women attending immunization clinics within the 5 facilities randomized to this group.
9932468|NCT00949481|No Intervention|Control|In each country, this arm will be comprised of women attending family planning and immunization clinics in 5 facilities randomized to this group.
9932469|NCT00949494|Active Comparator|Synvisc|
9932470|NCT00949494|Placebo Comparator|Placebo|
9932471|NCT00949507||anaesthesia using propofol|the children are anaesthetized using intravenous anaesthesia with propofol and remifentanil; a binasal catheter is used for administration of oxygen during the anaesthesia
9932472|NCT00949507||anaesthesia using sevoflurane|the patients are anaesthetized using sevoflurane 1 MAC; a laryngeal mask is used
9932473|NCT00949546||placebo controlled|A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.
9893440|NCT05332600|Experimental|pre and post fatigue assessment|assessment pre and post fatigue protocol
9893441|NCT05332587|Experimental|Rituximab Treated|rituximab
9893442|NCT05332574|Experimental|GB263T|Experimental: GB263T
9893443|NCT05332561|Experimental|Arm 1 Atezolizumab (Immune Evasion)|Atezolizumab Dosage: 1200 mg, intravenous, on d1, q21d
9893444|NCT05332561|Experimental|Arm 2 Inavolisib (PI3K)|Inavolisib Dosage: 9 mg, oral, on d1-d28, q28d
9893445|NCT05332561|Experimental|Arm 3 Ipatasertib (AKT)|Ipatasertib Dosage: 400 mg, oral, on d1-d21, q28d
9893446|NCT05332561|Experimental|Arm 4 Olaparib (PARP, DNA-Repair)|Olaparib Dosage: 300 mg, oral, bid d1-d28, q28d
9893447|NCT05332561|Experimental|Arm 5 Sacituzumab Govitecan (TROP-2)|Sacituzumab Govitecan Dosage: 10 mg/kg BW, intravenous, on d1 and d8, q21d
9893448|NCT05332561|Experimental|Arm 6 Trastuzumab/Pertuzumab (ERBBB)|Trastuzumab/Pertuzumab Administration: subcutaneous; Initial dose: Trastuzumab 600 mg, Pertuzumab 1200 mg, 30 000 units hyaluronidase; Maintainance dose: Trastuzumab 600 mg, Pertuzumab 600 mg, 20 000 units hyaluronidase; Frequency: on d1, q21d
9893449|NCT05332561|No Intervention|Arm 7 Observation|Observation
9893450|NCT05332535|Experimental|Serious game web aplication|Nursing students played the serious game for two weeks.
9893451|NCT05332535|No Intervention|Control grup|
9893452|NCT05332522|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation
9893453|NCT05332496||Study group: TACE+PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|TACE was performed up to 3 months after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or within 1 month before treatment. The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
9893454|NCT05332496||Control group: TACE|TACE monotherapy
9893455|NCT05332483|Experimental|Arm 1 - Megestrol|All study participants will receive Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
9893456|NCT05332431||Patients with Migraine|Patients diagnosed with migraine based on prespecified criteria according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) established by established by the International Headache Society, for migraine with aura and migraine without aura, attending the neurology outpatient clinic, Assiut University.
9893457|NCT05332431||Control|Age and sex matched healthy control group (with the absence of any pathological headache and eye problems), will be recruited from the outpatient clinic for comparison.
9893458|NCT05332418|Experimental|study group|the study group received the same exercise training program in addition to electromagnetic field therapy, three times per week for four weeks
9893459|NCT05332418|Experimental|control group|the control group which received the selected exercise program
9893460|NCT05332405|Experimental|Study Group|Participants will have planned surgical procedure to repair the median or ulnar nerve compression. During the procedure, the doctor will administer a small injection of indocyanine green (ICG) and laser angiography using the SPY Elite device will be used to evaluate blood flow and extent of nerve decompression at the surgical site. Participation will also involve filling out two questionnaires on pain and function level and an examination of hand strength and range of motion.
9893461|NCT05332353||BCG responders|Non-muscle invasive bladder cancer patients who do not have T1/Ta HG recurrence within 6 months of adequate BCG therapy.
9893462|NCT05332353||BCG non-responders|Non-muscle invasive bladder cancer patients who have T1/Ta HG recurrence within 6 months of adequate BCG therapy or CIS within 12 months of BCG therapy
9893463|NCT05332314|Experimental|NSAIDs|This arm is given NSAIDs perioperatively and after discharge
9893464|NCT05332314|No Intervention|Opioids|This arm will be given the standard opioids treatment to control pain perioperatively and at discharge.
9893465|NCT05332301|Experimental|High-fat test meal|All participants will consume a high-fat breakfast after an overnight fast. This meal will consist of a flour tortilla, eggs, bacon, cheddar cheese, mayonnaise, and hashbrowns. After the initial blood sample (0 min) is drawn during Visit 2, we will ask participants to consume this breakfast within 10 minutes. This meal has been designed to mimic the amount of energy (calories) and fat contained in a typical fast-food breakfast (e.g., from Tim Hortons or McDonalds). Each meal will provide 846 kcal, derived from 54 g fat (58% energy), 61 g carbohydrate (29% energy), and 29 g protein (13% energy).
9893466|NCT05332249||Lumbar|Patients undergo lumbar spinal surgery for degenerative lumbar spinal disease.
9893467|NCT05332249||Cervical|Patients undergo cervical spinal surgery for degenerative cervical spinal disease.
9893468|NCT05332236||Community sample|Adolescents (10-18 years) and their parents, recruited via schools or online sampling, from the general population
9893469|NCT05332236||At-risk sample|Parents seeking parenting advice in information centres/helplines.
9893470|NCT05332236||Clinical sample|Children and parents are recruited among in- and outpatients at the Clinic for Child and Adolescent Psychiatry of the University Medical Center Hamburg-Eppendorf
9893471|NCT05332223||Chronic Heart Failure Patients|All patients in our specialised heart failure clinic will be screened by the investigator/s.
9932474|NCT00949572|Experimental|Intramuscular administration|Intramuscular injection of HPV vaccine proteins
9893472|NCT05332210|Experimental|HBM9161 Drug Product (680mg)|HBM9161 680mg: subcutaneous injection, 6 times in total per treatment cycle, once a week; the second cycle of treatment should be launched 4 weeks after the last dose in the previous treatment cycle; if the disease state is still stable 4 weeks after the last dose, the observation can be continued until the disease activity is aggravated (improvement of MG-ADL < 3 points compared with the previous treatment cycle), and the next treatment cycle and the observation period can be started.
9893473|NCT05332210|Experimental|HBM9161 Drug Product (340mg)(Enter low dose if required due to investigator assessment)|HBM9161 340 mg: subcutaneous injection, 6 times in total per treatment cycle, once a week; the second cycle of treatment should be launched 4 weeks after the last dose in the previous treatment cycle; if the disease state is still stable 4 weeks after the last dose, the observation can be continued until the disease activity is aggravated (improvement of MG-ADL < 3 points compared with the previous treatment cycle), and the next treatment cycle and the observation period can be started.
9893474|NCT05332197|Experimental|17D Yellow fever vaccine|"All children will receive a single shot of the 17D Yellow fever vaccine. This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. This vaccine is presented as a 10 dose vial with freeze-dried content which is reconstituted with a diluent, provided with the vaccine by the manufacturer. Reconstituted vaccines have to be kept in a vaccine carrier at 2-8°C as per WHO and manufacturer requirements. Any remaining reconstituted vaccine not used has to be discarded after 6 h. The standard dose is 0·5 ml and is administered subcutaneously in the deltoid region using standard vaccination syringes (needle size 25G × 3/4) with a 45° injection angle"
9893475|NCT05332184||Patients prior to aortic valve surgery|
9893476|NCT05332171|No Intervention|physical activity counseling|Home exercises will be taught to the physical activity counseling group and will be followed up under the supervision of a physiotherapist with weekly controls. Evaluation will be done before and after treatment.
9893477|NCT05332171|Active Comparator|training group|Breathing exercises and calisthenic exercises will be taught to the training group, and they will be followed under the supervision of a physiotherapist for 8 weeks, 3 days a week. Evaluations will be made before and after treatment. Individuals in the calisthenic exercise group will be given exercise training at the level of 65%-80% of the maximal heart rate for 30-40 minutes, 3 days a week for 8 weeks.
9893478|NCT05332158|Experimental|Intervention arm|A single arm to administer questionnaires for patients barriers to adherence.
9893479|NCT05332145|Experimental|Intervention development and testing|"Phase 1 participants (N=12) will complete the MAP to Health online interview and rate the ease of use, usefulness, intention to use, and theoretical fidelity of the intervention.~Phase 2 participants (N=35) will participate in a proof-of-concept pilot trial via a double-pretest single group design. Participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 week period."
9893480|NCT05332132|Experimental|Intrauterine Morcellation of Uteri Post-Surgery|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
9932475|NCT00949572|Experimental|Sublingual administration|Sublingual administration of HPV vaccine proteins
9932476|NCT00949585|Other|Dietary potassium intake: 100 mmol/day|Participants will be given one of two diets: one contains 100 mmol of potassium per day, and the other contains 40 mmol of potassium per day
9893481|NCT05332119|Experimental|Virtual reality|The intervention will consist of the use of VR glasses during the removal of chest drains. The VR content has been developed by VR Pharma Immersive Technologies (LtD). Its main objective is to improve patient experience and have better management of pain and anxiety. Chest drains are removed following the usual protocol.
9893482|NCT05332119|Sham Comparator|Control group|Patients in the control group will be cared for with the usual care protocol.
9893483|NCT05332106|Experimental|Estradiol Valerate and Dienogest Test Product.|Participants will receive one tablet of the test formulation containing Estradiol Valerate and Dienogest 2 mg/ 2 mg.The tablet will be taken with water and in a fasting condition.
9893484|NCT05332106|Active Comparator|Estradiol Valerate and Dienogest Referent Product|Participants will receive one tablet of the marketed reference containing Estradiol Valerate and Dienogest 2 mg/ 2 mg. The tablet will be taken with water and in a fasting condition.
9893485|NCT05332093||Local cutaneous leishmaniasis patients group (LCL)|local cutaneous leishmaniasis patients
9893486|NCT05332093||Mucocutaneous leishmaniasis patients group (MCL)|mucocutaneous leishmaniasis patients
9893487|NCT05332093||Diffuse cutaneous leishmaniasis patients group (DCL)|diffuse cutaneous leishmaniasis patients
9893488|NCT05332093||Healthy control patients group Ethiopia (HC - Ethiopia)|healthy control patients undergoing elective surgery in Northern Ethiopia
9893489|NCT05332093||Healthy control patients group Belgium (HC - Belgium)|healthy control patients undergoing plastic surgery in Belgium
9893490|NCT05332080|Experimental|Telerehabilitation via application on cell phone|The patients in this group had application installed on their cell phones to access the online content, where they received advice on self-care and the type of exercises to be performed. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned 4-week objectives. Participants in both groups were provided with written exercise material, training, and advice on how to return to work and leisure activities. Each patient made a weekly record of the therapy he/she performed, including the day, type, and time of development of his/her exercises
9893491|NCT05332080|No Intervention|In-person rehabilitation|The patients in this group received an in-person rehabilitation program and was considered the control group, this group received for two weeks a 10-session program for two weeks that included external heat application, stretching, mobilization, strengthening, and occupational therapy. Moreover, it was complemented with occupational therapy focused on improving essential functions and strengthening extrinsic and intrinsic hand musculature, effectiveness in wrist mobility, and simulation of specific activities for reincorporation to work
9893492|NCT05332067|Experimental|Omalizumab|Single dose of omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
9893493|NCT05332067|Placebo Comparator|Placebo for omalizumab|Single dose of placebo for omalizumab at the start of a viral upper respiratory infection as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) during the fall outcome season (defined as the 90-day period beginning on each child's return to school)
9893494|NCT05332054||Patients who received a Caribou-sponsored allogeneic CAR-T therapy|in a Caribou-sponsored clinical study or special access program
9893495|NCT05332041|Experimental|Predicta Bioactive bulk fil composite restoration|Bioactive bulk fil resin composite dental restoration material
9893496|NCT05332041|Active Comparator|High viscosity glass ionomer (Equia Fil)|High viscosity dental restoration material
9932477|NCT00949585|Other|Dietary potassium intake: 40 mmol/day|Diet containing 40 mmol/day of potassium
9932478|NCT00949598|Experimental|Arm I|Patients receive oral letrozole once daily for 16 weeks.
9932479|NCT00949598|Experimental|Arm II|Patients receive oral tamoxifen citrate once daily for 16 weeks.
9932480|NCT00949611|Experimental|FRAX + Decision Aid|
9893497|NCT05332028|Experimental|Group 1: Patients undergoing paravertebral block|After cleaning the area with antiseptic solution, the sterilized linear USG probe (Esaote MyLab30®, CA631 high-frequency probe, United Kingdom) was covered. The flat probe was placed between two transverse processes on the paramedian plane; transverse processes, superior costotransverse ligament and pleura were consecutively visualized. The linear ultrasound probe was fixed to the T3-T4 vertebra level. The skin and subcutaneous tissue were anaesthetized with 2% lidocaine, then 22 gauge 100 mm needle (Stimuplex ®; B Braun, Melsungen, Germany) was led in a cranial-cephalic direction to the paravertebral gap. Trapezius, rhomboid, erector spinae muscles were crossed by seeing the tip of the needle. Transverse processes were reached and the intercostal muscles were passed. When the needle reached the paravertebral level, a 20 mL of 0.25% bupivacaine was applied as a single administration.
9893498|NCT05332028|Active Comparator|Group 2: Patients undergoing Mid-Point Transverse Process Pleura (MTP) block|After cleaning the area with antiseptic solution, the sterilized linear USG probe (Esaote MyLab30®, CA631 high-frequency probe, United Kingdom) was covered. The flat probe was placed between two transverse processes on the paramedian plane; transverse processes, superior costotransverse ligament and pleura were consecutively visualized. The linear ultrasound probe was fixed to the T3-T4 vertebra level. The skin and subcutaneous tissue were anaesthetized with 2% lidocaine, then 22 gauge 100 mm needle (Stimuplex ®; B Braun, Melsungen, Germany) was led in a cranial-cephalic direction to the paravertebral gap. Trapezius, rhomboid, erector spinae muscles were crossed by seeing the tip of the needle. Transverse processes were reached and the intercostal muscles were passed. When the needle reached the midpoint level between the transverse process and pleura, a 20 mL of 0.25% bupivacaine was applied as a single administration.
9893499|NCT05332015|Active Comparator|Oral hydration with normal water|Oral hydration with drinkable normal water daily additional 2 liters for 5 days
9667165|NCT03875820|Experimental|Dose Expansion KRAS mutant NSCLC Cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).~This arm is now complete."
9893500|NCT05332015|Active Comparator|Oral hydration with distilled water|Oral hydration with distilled water daily 2 liters for 5 days
9893501|NCT05332002|Other|4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),|"A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:~Odd Cycles (e.g. 1, 3, 5, etc…) - mFOLFOX6 initiated on days 1 & 15: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~Even Cycles (e.g. 2,4,6, etc…) - FOLFIRI initiated on days 1 & 15: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~Nivolumab (optional, in-line with labelled approval) - 240 mg every 2 weeks"
9893502|NCT05331989||patient group,healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
9893503|NCT05331963|Experimental|Kinesio taping with rehabilitation program group|Rehabilitation program will be given to this group in addition to Kinesio taping on skin for 72 hour.
9893504|NCT05331963|No Intervention|Rehabilitation plan group|The rehabilitation program will be provided individually to all participants (twice weekly during the first 4 weeks, then once weekly)
9893505|NCT05331950||Office workers|
9893506|NCT05331937|Experimental|real rTMS|verum rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
9893507|NCT05331937|Sham Comparator|sham rTMS|sham rTMS condition, 1500 continuous 1-Hz pulses to the pre-SMA
9893508|NCT05331924|Active Comparator|IPL therapy|Fifteen patients with severe to moderate evaporative dry eye disease were treated with 3 sessions of IPL therapy.
9893509|NCT05331924|Active Comparator|Punctal plugs|Fifteen patients with severe to moderate evaporative dry eye disease were treated with silicone punctal plug insertion.
9893510|NCT05331898|Experimental|Education Group|increase the rational drug use of the parents.
9893511|NCT05331898|No Intervention|control|PARENTS CANNOT USE RATIONAL MEDICATION ON THEIR CHILDREN
9893512|NCT05331872|Experimental|human umbilical cord-derived mesenchymal stem cell transplantation for patients with liver cirrhosis|"Umbilical cords from healthy donor are processed with 24 hours after vaginal delivery.~The cords are delivered in a sterilized jar the laboratory to process. After washing in PBS to remove any contaminating blood, the cord is cut into small pieces. The pieces are minced and digested by enzyme. The UC-MSCs is cultured and expanded using commercially available serum-free and xeno-free medium at 37°C in a humidified atmosphere with 5% CO2. The UC-MSCs is suspended in 15 ml of saline buffer"
9893513|NCT05331846|Experimental|SMELL OF BREAST MILK|the smell of breast milk will reduce pain and stress
9893514|NCT05331846|No Intervention|control|pain and stress will not decrease
9893515|NCT05331833||study group|CTV-omitted IMRT under PET-CT guidance
9893516|NCT05331833||control group|CTV-delineated IMRT under PET-CT guidance
9932481|NCT00949611|No Intervention|Usual care|
9932482|NCT00949611|Experimental|FRAX estimated fracture risk|
9932483|NCT00949624|Experimental|Cohort 1|60 mg BID/ 75 mg/m2
9667166|NCT03875820|Experimental|Dose Expansion biopsy cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).~This arm is now complete."
9893517|NCT05331820|No Intervention|standard care group|this group of participants will be used to compare to the intervention group. normal and professional instructions and motivation will be given to them but they will not receive weekly reminders about the importance of adherence to instructions
9893518|NCT05331820|Experimental|weekly reminder group|this group of participants will receive a weekly reminder about the importance of oral hygiene, appliance care, and adherence to recommendations from the dentist.
9893519|NCT05331807|Experimental|Group (A)|Participants will be received daily omega-3 fatty acid (two capsules of 1000mg fish oil daily). Each soft gel capsule contains 300 mg of omega-3 fatty acids in the bioactive triglyceride (TG) and 180mg EPA and 120 mg DHA. (Omega3 complex, Jamieson Laboratories, Canada)
9893520|NCT05331807|Experimental|Group (B)|Participants will be received only vitamin D (one capsule of 50,000IU weekly). Each film coated tablet of vitamin D contains 50,000 IU Vitamin D3 (Cholecalciferol). (J-Dee, Jerusalem Pharmaceutical Company, West bank, Palestine).
9893521|NCT05331807|Experimental|Group (C)|Participants will be received both omega-3 fatty acids capsules and vitamin D3 capsule. (one capsule of D3 50,000 IU weekly + two omega-3 fatty acids capsules daily (each capsule contains 300 mg of omega-3 fatty acids)
9893522|NCT05331807|No Intervention|Group (D)|Participants will not be received any supplements and just receive oncology treatment as an usual oncology patient.
9893523|NCT05331794|Experimental|"Experimental: BIOFIT-Park outdoor fitness equipment"|"Refers to an arm that trains on the BIOFIT-Park line of outdoor fitness equipment that is currently under development and testing."
9893524|NCT05331794|Experimental|Experimental: Gym park equipment|Refers to an arm that trains on gym park equipment
9893525|NCT05331781|Experimental|transversus abdominis plain block group|post-cesarean section tap block will be given by ultrasound guidance using 20 ml bupivacaine local anesthetic 0.25% concentration for each side as an adjuvant to spinal anesthesia
9893526|NCT05331781|Experimental|intrathecal morphia group|intrathecal 150 microgram morphine in a 0.5 ml volume as an adjuvant to spinal anesthesia
9893527|NCT05331768|Experimental|24-h group|The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
9893528|NCT05331768|Active Comparator|72-h group|The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe
9893529|NCT05331742||vaccinated|patient between age 18 and above who have received a complete dose of coronavirus disease vaccine patient who has been admitted to critical care unit due to corona virus disease infection
9893530|NCT05331742||unvaccinated|patients between age 18 and above who has been admitted to critical care unit due to coronavirus disease infection and admitted to critical care unit
9893531|NCT05331729|Experimental|Patients with idiopathic pulmonary fibrosis|
9893532|NCT05331729|Active Comparator|Healthy volunteers|
9893533|NCT05331703|Experimental|group A|will receive a designed physical therapy program in addition to program of virtual reality
9893534|NCT05331703|Experimental|group B|will receive a designed physical therapy program in addition to program of mirror therapy.
9893535|NCT05331690|Active Comparator|Group 1 NSAIDs pre|Topical nepafenac (Nevanac) 3 mg/ml started 1 day before surgery
9893536|NCT05331690|Active Comparator|Group 2 NSAIDs post|Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
9893537|NCT05331690|Active Comparator|Group 3 NSAIDs and steroids|Topical nepafenac (Nevanac) 3 mg/ml + topical dexamethasone (Spersadex) started the day after surgery
9893538|NCT05331677|Experimental|study group|
9893539|NCT05331365|Experimental|The construction of the composite score and internal validations|50 patients for the construction of the composite score and internal validations. These tests and questionnaires are part of the standard post-operative management of a patient undergoing ankle ligamentoplasty. For the study, these tests and questionnaires will be performed.
9893540|NCT05331365|Experimental|The external validation stage of the composite score|50 additional patients for the external validation stage of the composite score. These tests and questionnaires are part of the standard post-operative management of a patient undergoing ankle ligamentoplasty. For the study, these tests and questionnaires will be performed.
9893541|NCT05331365|No Intervention|To analyze the ability of composite score discrimination|30 healthy volunteers will be included in the study to analyze the ability of composite score discrimination. The healthy population will perform the same physical and psychological tests as the population of the group, without having undergone ankle ligamentoplasty and without a history of ankle trauma ankle.
9893542|NCT05331001||Medical doctors|Medical doctors who are employed as permanent staff in a cardiac arrest center which provides extracorporeal membrane oxygenation.
9893543|NCT05331001||Nurses|Nurses who are employed as permanent staff in a cardiac arrest center which provides extracorporeal membrane oxygenation.
9893544|NCT05330403|Experimental|the lung meridian intervention group|moxibustion intervention was performed over Site 1 (LU5) of the lung meridian
9893545|NCT05330403|Experimental|the heart meridian intervention group|moxibustion intervention was applied over Site 4 (HT3) of the heart meridian
9893546|NCT05324215|Active Comparator|Transversalis Fascia Plane Block and Rectus Sheath Block Group|Transversalis Fascia Plane Block and Rectus Sheath Block will be administered to this group.
9893547|NCT05324215|Sham Comparator|Control Group|No regional anesthesia technique will be applied to the control group.
9893548|NCT05323903|No Intervention|Control Group|Postpartum Hemorrhage and Its Management course
9893549|NCT05323903|Experimental|Intervention Group 1- Telesimulation|Postpartum Hemorrhage and Its Management course, Telesimulation application
9893550|NCT05323903|Experimental|Intervention Group 2- Kahoot|Postpartum Hemorrhage and Its Management course, Kahoot game
9893551|NCT05323903|Experimental|Intervention Group 3-Telesimulation and Kahoot|Postpartum Hemorrhage and Its Management course, Telesimulation application and Kahoot game
9893552|NCT05322551||Obese only|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Non Diabetes: Fasting Plasma Glucose (FPG) < FPG 100 mg/dL (5.6 mmol/L)"
9893553|NCT05322551||Obese with prediabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Prediabetes: FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG) OR A1C 5.7-6.4% (39-47 mmol/mol)"
9893554|NCT05322551||Obese with diabetes|"Definition of Obese:~Body Mass Index ≥ 30kg/m^2 (WHO classification)~Definition of Diabetes: (American Diabetes Association, 2020) FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.* OR A1C ≥6.5% (48 mmol/mol)."
9893555|NCT05322382|Experimental|Single|Subjects undergo an interventional procedure and non-invasive measurements of SpO2.
9893556|NCT05321472||group for training the algorithm|This group of images is used for training the algorithm of the artificial intelligence
9893557|NCT05321472||group for testing the algorithm|This group of images is used for testing the algorithm of the artificial intelligence
9893558|NCT05321433||The Swedish Cohort|Swedish data comes from a historical cohort of 424,386 clients of public dental clinics aged 23 and older in the Stockholm region with inception between October 2015 and January 2020, with follow-up from February 2020 to December 2020. In Sweden, the public dental clinics (Folktandvården, FTV) provide routine preventive visits (oral check-ups) to all residents who choose to receive care in these clinics. At each health check-up smoking and snus use are ascertained as past use, current use, and amount of current use. The national personal numbers assigned to every resident in Sweden at birth or at immigration will be used to obtain information on diagnoses of COVID-19 and of other diseases through record-linkage with regional health care registers. Demographic information will be extracted through record-linkage with the register of the total population of the Stockholm region held by Statistics Sweden.
9893559|NCT05321433||The Finnish Cohort|The Finnish data will come from three pooled cross-sectional national health surveys in Finland (FinSote 2018-2020) of 44,199 participants aged 20 and older. The study samples included permanent residents in Finland from the FinSote surveys 2018, 2019, and 2020. The unique personal identifier assigned to all Finnish residents will be linked to the Communicable Diseases Registry to obtain information on diagnoses of COVID-19, to the Care Register for Health Care (HILMO) to obtain information on hospital admissions due to COVID-19, and to Statistics Finland Mortality Data to obtain information on deaths. Data on some sociodemographic characteristics will be also obtained from the Digital and Population Data Services Agency.
9932484|NCT00949624|Experimental|Cohort 2|100 mg BID/75 mg/m2
9932485|NCT00949624|Experimental|Cohort 3|100 mg BID/100 mg/m2
9932486|NCT00949624|Experimental|Cohort 4b|CP-868,596 + AG-013736 + TXT 75
9935992|NCT02851706||1/Patients with CNS Tumors|Patients with CNS tumors (or a history) including those with undiagnosed imaging abnormalities in the CNS; and patients with known genetic syndromes at high risk of developing CNS Cancers.
9991342|NCT01452087|Other|Exercise Session|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
9893560|NCT05321433||The Norwegian Cohort|The Norwegian data will be based on the Norwegian Mother, Father and Child Cohort Study (MoBa) (Magnus et al., 2016), and the Norwegian Influenza Pregnancy Cohort (NorFlu) (Laake, 2018), with linkages to the Norwegian Surveillance System for Communicable Diseases (MSIS), the Norwegian Immunisation Registry (SYSVAK), and the Norwegian Population Registry. MoBa is a nation-wide population-based cohort consisting of 280 000 participants, where parents were recruited during pregnancy from 1999 to 2008, while NorFlu is a pregnancy cohort consisting of 9 000 participants recruited in Oslo and Bergen during the swine flu pandemic in 2009-2010. Demographic information is extracted from the registries via linkage to the existing cohort databases. For the purpose of this study, all subjects who died before the onset of the pandemic (February 2020) in the three countries will be excluded from the analysis.
9893561|NCT05320991|Placebo Comparator|Placebo|Participants receive a saline-solution intravenously
9893562|NCT05320991|Experimental|Ketamine|Participants receive ketamine (Plasma-level 100 ng/ml with an initial bolus administered as a 2 mg/ml solution)
9893563|NCT05319184|Experimental|Myofascial Release Group|The application will be made with the patient in the prone position. By applying a few grams of constant force to the lumbar paravertebral muscles bilaterally with the hand of the physiotherapist in the direction of restriction for 3-5 minutes, the fascia will be stretched and allow the tissue to relax on its own. Thus, it is aimed to decrease the tone and stiffness of the paravertebral muscles.
9893564|NCT05319184|Experimental|Kinesiology Taping Group|During the application, the participants will be positioned standing and facing backwards due to the ease of application. While taping the lumbar region, the kinesiology tape cut as a long strip (I tape) will be applied paravertebrally to the right and left sides of the spine. Rounded corners will be created to prevent premature loosening and unwanted bends in the belt. The patient will be asked to perform maximum trunk flexion and 2 I-shaped pieces will be taped with 10-15% tension from the lumbar region to the thoracic region. The tape will remain on the patient's skin for 30 minutes.
9893565|NCT05319184|No Intervention|Control Group|No intervention.
9893566|NCT05319158|Experimental|Intervention group|The group intervention will receive MIT-PB.
9893567|NCT05319158|No Intervention|control group|The control group will receive standard care
9893568|NCT05318001||Group: Pregnant women (first-timed pregnant)|This group will consist of women in first trimester of pregnancy
9893569|NCT05317884|No Intervention|No Contact|No reminder sent
9893570|NCT05317884|Experimental|Reminder|Reminder email with contact information to set an appointment will be sent 12 weeks before the appointment.
9893571|NCT05317819|Experimental|Drug: ADI-PEG 20|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
9893572|NCT05317819|Placebo Comparator|Drug: Placebo|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
9893573|NCT05315024|Experimental|Repeat 0.5ml IM Quadrivalent IIV (IIV-IM)|Repeat 0.5ml IM Quadrivalent IIV (IIV-IM) (15micrograms haemagglutinin per vaccine strain)
9893574|NCT05315024|Experimental|0.1ml ID Quadrivalent IIV (IIV-ID)|0.1ml ID Quadrivalent IIV (IIV-ID) (3micrograms haemagglutinin per vaccine strain)
9893575|NCT05315024|Experimental|0.1ml ID Quadrivalent IIV|0.1ml ID Quadrivalent IIV (3micrograms haemagglutinin antigen per vaccine strain) + 5% imiquimod cream (IIV-Q-ID)
9893576|NCT05314114|Experimental|No Axillary Surgery|No axillary surgery including SLNB
9893577|NCT05313100|Active Comparator|Smokers|The patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking were included in the smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.
9667167|NCT03875820|Experimental|Dose Expansion LGSOC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with LGSOC (20 patients).
9893578|NCT05313100|Sham Comparator|Nonsmokers|The patients who never smoked were included in the non-smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.
9893581|NCT05312554|Experimental|Intervention arm|Patients with cryptogenic stroke complicated with patent foramen ovale,and passed the screening and signed the informed consent form
9893582|NCT05311735|Other|Freeze-Dried Bone Allograft Control|-Control group (FDBA): extracted teeth will be discarded and sites will be grafted with FDBA.
9893583|NCT05311735|Experimental|Mineralized Dentin Graft|-Test group I (mineralized tooth graft): extracted teeth will undergo the mineralization process according to the manufacture's guidelines. Procedure will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines)
9893584|NCT05311735|Experimental|Partial-Demineralized Dentin Graft|-Test group II (partial-demineralized tooth graft): extracted teeth will be undergone to partial-demineralized process, according to the manufacture's guidelines. Procedures will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines).
9893585|NCT05308407|Other|Aim 1. Focus Groups|"Healthcare providers (n=16-24 participants in 4 focus groups) from MD Anderson Cancer Center (MDACC).~AYAs with primary benign or malignant central nervous system tumors (n=16-24 participants in 4 focus groups) treated at MDACC."
9893586|NCT05308407|Other|Aim 2. Pilot randomized controlled trial:|AYAs with primary benign or malignant central nervous system tumors (n=80 patients approached, with n= 40 participants consented and randomized to the intervention (n=20) or usual care control group (n=20)) treated at MDACC, any gender and race, who are ≤1-year post-surgery for a central nervous system tumor.
9893587|NCT05308290|Experimental|Blood pressure managed by cerebral autoregulation|In this arm cerebral autoregulation monitoring will be used to determine the lower and upper limits of cerebral autoregulation. Monitoring will continue throughout the surgery. Blood pressure management will be maintained to be within the limits of cerebral autoregulation.
9893588|NCT05308290|Active Comparator|Standard of care blood pressure management|In this arm cerebral autoregulation monitoring will be used for observation. The anesthesia provider will use usual care guidelines for blood pressure management.
9893589|NCT05307159|Experimental|bean protein supplement|The supplement will be consumed daily for 21 days in the athletes' snack, the supplement contains 7 g of bean protein mixed in 60 mL of milk and 60 mL of strawberry drinkable yogurt
9893590|NCT05303337||Patients switching towards a long-aging injectable treatment|
9893591|NCT05303337||Patients maintaining oral ART 2-drug regimens|
9893592|NCT05303337||Patients maintaining oral ART 3 drug regimens|
9893593|NCT05296603|Experimental|Cohort A|Duration of response time more than 6 months
9893594|NCT05296603|Experimental|Cohort B|Duration of response time between 3 and 6 months
9893595|NCT05296603|Experimental|Cohort C|Duration of response time less than 3 months
9893596|NCT05295602||Group|A CT scan of both legs will be made in patient scheduled for a primary knee arthroplasty. No other additional intervention will be made apart from those already routinely used for the operation.
9893597|NCT05295225|Active Comparator|Green Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a green light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
9997566|NCT01509976|Other|Red|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
9667168|NCT03875820|Experimental|Dose Expansion CRC cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with CRC (10 patients).~This arm is now complete."
9893598|NCT05295225|Placebo Comparator|White Light Exposure|Subjects will complete thermal and mechanical pain threshold detection tests and Electroencephalography (EEG). After completion, subjects will be exposed to a white light-emitting diode for two hours. After exposure, thermal and mechanical pain threshold assessments and Electroencephalography (EEG) will be conducted.
9893599|NCT05290363|Experimental|Patients with axial spondyloarthritis participating in the study|People with axial spondylarthritis (60 participants),
9893600|NCT05290363|Experimental|Patients with peripheral spondyloarthritis participating in the study|People with peripheral spondylarthritis (30 participants).
10212085|NCT02862457|Experimental|Part B Cohort 1: pembrolizumab+cisplatin+pemetrexed|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of 75 mg/m^2 cisplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
10212086|NCT02862457|Experimental|Part B Cohort 2: pembrolizumab+carboplatin+pemetrexed|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of Area Under the Curve (AUC) 5 carboplatin and 500 mg/m^2 pemetrexed on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
10212087|NCT02862457|Experimental|Part B Cohort 3: pembrolizumab+carboplatin+paclitaxel|For each 21-day cycle, participants received a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for up to 35 cycles (approximately 2 years). For the first 4 cycles, participants also received a one-time IV infusion of AUC 6 carboplatin and 200 mg/m^2 paclitaxel on Day 1. Treatment with epacadostat was stopped with protocol amendment 02.
10212088|NCT02845323|Experimental|Nivolumab in combination with Urelumab|"Nivolumab and Urelumab combination:~Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles~Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles"
10212089|NCT02845323|Active Comparator|Nivolumab monotherapy|Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
10212090|NCT02836093||evaluations/assessments|
9893607|NCT05287711|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy for alcohol use problems, which includes empathic support, feedback and advice, strategies for enhancing self-efficacy, techniques for eliciting self-motivational statements from the participant, strategies for addressing participant ambivalence about change and participant resistance to change, and methods for eliciting and affirming commitment to a specific change plan (active intervention).
9893608|NCT05287711|Experimental|Alcohol Education Control|Psychoeducational intervention intended to: (1) dispel myths about the effects of alcohol, (2) provide information about the general risks of drinking and process of recovery from alcohol problems, (3) provide information about the specific risks related to family relationships and IPV, (4) offer self-help program information and related strategies to address drinking problems, (5) promote and encourage healthy decision-making, and (6) reinforce the benefits of abstinence or controlled drinking.
9893609|NCT05287711|Other|Telephone Monitoring|Brief supportive telephone monitoring sessions that are commonly delivered while Veterans wait to begin their groups (treatment as usual).
9893610|NCT05287360|Experimental|Treatment Sequence 1|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 1; Period 2: Formulation 2; Period 3: Formulation 3; Period 4: Formulation 4~There will be a washout period of 5 days between each dosing."
9893611|NCT05287360|Experimental|Treatment Sequence 2|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 2; Period 2: Formulation 4; Period 3: Formulation 1; Period 4: Formulation 3~There will be a washout period of 5 days between each dosing."
10212091|NCT02820753|No Intervention|Enhanced Usual Care|"Patients who have not received the initial 6 weeks of text message reminders telling them to take their medicines; or did not complete at least 1 portal survey that asks them if they filled their medications, if they had any side effects or concerns; or did not receive either intervention will be considered as enhanced usual care.~Patients will only receive EHR tools (patient-friendly med-sheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles)."
10212092|NCT02820753|Active Comparator|Text or Portal|Participants who received EHR strategies as well as, the initial 6 weeks of SMS messaging continuously that remind them to take their medicines; or logged on to the patient portal and completed at least one survey will be considered as receiving the intervention.
10212093|NCT02816658|Active Comparator|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
10212094|NCT02816658|Active Comparator|Robotic Surgery|Robotic Inguinal Hernia Repair
10212095|NCT02790515|Experimental|Treatment|"Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.~Cells for infusion are prepared using the CliniMACS System."
10212096|NCT02733042|Experimental|Arm A: Durvalumab + Lenalidomide ± Rituximab|"Participants assigned to Arm A will receive:~Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and~Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of:~Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or~All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL~Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5.~All treatment cycles were 28 days."
9893612|NCT05287360|Experimental|Treatment Sequence 3|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 3; Period 2: Formulation 1; Period 3: Formulation 4; Period 4: Formulation 2~There will be a washout period of 5 days between each dosing."
9893613|NCT05287360|Experimental|Treatment Sequence 4|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 4; Period 2: Formulation 3; Period 3: Formulation 2; Period 4: Formulation 1~There will be a washout period of 5 days between each dosing."
9893614|NCT05281666|Active Comparator|Absorbable Surgical Gut Suture|Ethicon Chromic Surgical Gut Suture Is an absorbable, sterile surgical suture composed of purified connective tissue (mostly collagen) derived from either the serosal layer of beef (bovine) or the submucosal fibrous layer of sheep (ovine) Intestines. Surgical Gut Suture is Indicated for use In general soft tissue approximation and/or ligation, including use In ophthalmic procedures, but not for use in cardiovascular and neurologic tissues.
9893615|NCT05281666|Active Comparator|Non-absorbable Nylon Suture|Ethicon ETHILON* nylon suture is a nonabsorbab\e, sterile surgical monofi\ament suture composed of the long-chain aliphatic polymers Nylon 6 and Nylon 6,6. ETHILON sutures are dyed black or green to enhance visibility in tissue. The suture is also available undyed (clear). ETHILON suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
9893616|NCT05281471|Experimental|Olvi-Vec + Platinum-doublet & bevacizumab|"Olvi-Vec: A total of 2 consecutive days of intraperitoneal catheter infusions in Week 0~Platinum-doublet & bevacizumab (or biosimilar) administered beginning in Week 4 (preferred), but no later than Week 5"
9893617|NCT05281471|Active Comparator|Platinum-doublet & bevacizumab|Platinum-doublet & bevacizumab (or biosimilar) administered beginning in Week 0
9893618|NCT05280743||MATERNAL cohort|Nursing mothers who underwent Cesarean Delivery and who are receiving oxycodone to treat post-operative pain
9893619|NCT05280743||NEONATE-INFANT cohort|"Neonate encompasses a newborn from the age of birth until <28 days of life. Infant refers to the period of 28 days of life until 1 year of life."
9893620|NCT05273541|Experimental|Prime-boost vaccination|Patients in the experimental group need to accept the prime-boost vaccination regimen
9893621|NCT05267600|Experimental|EFG PH20 SC|participants receiving efgartigimod PH20 SC on top of Prednisone
9893622|NCT05267600|Placebo Comparator|PBO PH20 SC|participants receiving placebo PH20 SC on top of Prednisone
9893623|NCT05263453|Experimental|HL-085+Vemurafenib|HL-085 12mg BID+Vemurafenib 720mg BID combination therapy
9932487|NCT00949637|Experimental|Scouting curricular implementation|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
9932488|NCT00949637|Active Comparator|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
9932489|NCT00949663|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
9932490|NCT00949663|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
9893624|NCT05261958|Experimental|Interventional Group|"Warm up and cool down (10 minutes before physical activity)~Players will be given the SAQ training which includes~High Knees with Mini Hurdles.~30 Yard Sprint.~Agility Ring Hops.~Ladder 2 in 2 out.~Depth Jumps.~Overhead Ball Drop Reaction Drill"
9893625|NCT05261958|No Intervention|Control Group|"Players in this group did not undergo any interventional Programme rather than their daily routine work which includes:~Dumbbell squat~Dumbbell bicep arm curl~Burpee pull up~Medicine ball pushups~Sprints~HIIT on treadmill"
9893626|NCT05254990|Experimental|Reparixin + standard of care|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care. Administered up to 21 days (or until IMV/ECMO, if any)
9893627|NCT05254990|Placebo Comparator|Placebo + standard of care|Placebo tablets. Administered orally with the same schedule as reparixin.
9893628|NCT05253443|Experimental|Mentalizing Imagery Therapy and caregiver skills mobile application|
9893629|NCT05253443|Active Comparator|Caregiver skills mobile application|
9893630|NCT05253339|Active Comparator|Standard administration method|"Drug: Cefoxitin, Device: not applicable (standard method)~Two grams of cefoxitin (JW Pharmaceutical Co., Ltd., Seoul, South Korea) was dissolved in 50 mL of normal saline and administered for about 10 min before skin incision."
9893631|NCT05253339|Experimental|Target controlled infusion (TCI)|"Drug: Cefoxitin, Device: TCI Syringe pump~Two grams of cefoxitin were dissolved in 50 mL of normal saline to give a concentration of 40 mg/mL. Before skin incision, cefoxitin was infused with a TCI syringe pump (Pilot Anesthesia 2, Fresenius vial, France), which was connected to a personal computer by an RS232c cable and controlled with TCI software (Asan pump, version 2.1.3; Bionet Co. Ltd., Seoul, Korea, http://www.fit4nm.org/download, last accessed: 27 August, 2012). Target concentrations of total concentrations were set to 80 μg/mL."
9893632|NCT05249829|Experimental|Part 1: mRNA-1273.529|Participants will receive 1 intramuscular (IM) dose of mRNA-1273.529 on Day 1.
9893633|NCT05249829|Active Comparator|Part 1: mRNA-1273|Participants will receive 1 IM dose of mRNA-1273 on Day 1.
9893634|NCT05249829|Experimental|Part 2: mRNA-1273.214|Participants will receive 1 IM dose of mRNA-1273.214 on Day 1.
9893635|NCT05249829|Active Comparator|Part 2: mRNA-1273|Participants will receive 1 IM dose of mRNA-1273 on Day 1.
9893636|NCT05247866|Experimental|Study Group|"30 patients will be given dupilumab (dose based on current approved doses or used in current EoE clinical trial, q weekly dosing) and monitored for clinical response after 12 weeks of therapy)~Dosing:~>12 years of age > 40 kg 300 SQ weekly~6-11 years of age 5-15 kg 100 mg SQ Q2W 15-30 kg 200 mg SQ Q2W >30-60 kg 300 mg SQ Q2W"
9893637|NCT05246839||Arm 1 - Usual Care (No Video)|Subjects will receive the usual care pertaining to colorectal cancer (CRC) screening according to their respective clinical site and will not view either of the study videos.
9893638|NCT05246839||Arm 2 - Brief Video|Subjects will watch a video pertaining to the importance of CRC screening.
9893639|NCT05246839||Arm 3 - Brief Video Plus|Subjects will watch the same video as described in Arm 2, immediately followed by a second video pertaining to 3 CRC screening modalities: colonoscopy, FIT, and Cologuard.
9893640|NCT05242874|Experimental|Standard antiemetic therapy without dexamethasone|Olanzapine in combination with fosaprepitant and tropisetron
9893641|NCT05242874|Active Comparator|Standard antiemetic therapy|Olanzapine in combination with fosaprepitant, tropisetron and dexamethasone
9893642|NCT05240144|Experimental|IHG group|Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% Maximal Voluntary Contraction (MVC) on both hands with the frequency of 3 days per week for a period of 6 weeks.
9893643|NCT05240144|Active Comparator|Aerobic training group|Aerobic Exercises include walk for 50 min with the frequency of 3 days per week. This exercise will be done for a 6-week period.
9893644|NCT05240144|Sham Comparator|IHG + Aerobic exercises group|"Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% MVC on both hands with the frequency of 3 days per week for a period of 6 weeks.~Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% MVC on both hands with the frequency of 3 days per week for a period of 6 weeks."
9893645|NCT05240144|Sham Comparator|Sham IHG group|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period.
9893646|NCT05239247|Experimental|Mckenzie extension exercise|
9893647|NCT05239247|Experimental|Eldoa stretch technique|
9893648|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)|"Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 1.~Rimiducid may be administered as indicated."
9893649|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)|"Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 1.~Rimiducid may be administered as indicated."
9893650|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)|"Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 2.~Rimiducid may be administered as indicated."
9893651|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)|"Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 2.~Rimiducid may be administered as indicated."
9893652|NCT05238766|No Intervention|Treatment as Usual|This arm does not receive any intervention. It will serve as a comparison for the experimental arm.
9667169|NCT03875820|Experimental|Dose Expansion KRAS G12V mutant NSCLC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS G12V mutant NSCLC (10 patients).
9893653|NCT05238766|Experimental|Treatment + DEAL|Parents in the Treatment plus Defuse Experience Accept Live (T+DEAL) arm will attend five 45-min DEAL sessions with a therapist. Across the five sessions, the therapist will 1) introduce caregivers to behavior change strategies that maximize contact with positive-maintaining contingencies related to adherence, while undermining the contingencies that maintain accommodation, and 2) provide caregivers with new treatment-related committed actions that are sensitive to positive changes in parent-child interactions.
9893654|NCT05235295|Experimental|Fluoroscopic-guided sacroiliac joint injection|
9893655|NCT05235295|Active Comparator|Ultrasound-guided sacroiliac joint injection|
9893656|NCT05234320|Experimental|stage I- Healty|The first 2 patients in this stage will receive the vehicle treatment and will not undergo the first 24 hour hospitalization. The 3rd and 4th patients will receive a lower dose of 12.5 mg of the DP once daily for 7 days, and the first 24 hours will be hospitalized for the first 24 hours. The 5th patient will receive the 25 mg from the DP once daily for 7 days and will be hospitalized for the first 24 hours. The next 2 patients will receive the 25 mg dose and will not undergo the first 24 hour hospitalization. The next 3 patients will receive the optimal dose of 50 mg and will not undergo the first 24 hour hospitalization
9893657|NCT05234320|Active Comparator|Stage II- Placebo + SOC|This arm will be include 20 This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Placebo + standard of care
9893658|NCT05234320|Active Comparator|Stage II- DP low dose (25 mg) + SOC|This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Drug product low does(25 mg) + standard of care
9893659|NCT05234320|Active Comparator|Stage II- DP planned dose (50 mg) + SOC|This arm will be include 20 This arm will be include 20 symptomatic non-hospitalized COVID-19 patients and will be conducted at patients' homes during their self-isolation, and they will be received Drug product planned does(50 mg) + standard of care
9893660|NCT05234073|Experimental|Experimental: A (first group to receive the intervention)|The class will be instructed in the social emotional and ethical learning (SEELearning) for 4 weeks.
9893661|NCT05234073|Experimental|Experimental: B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive SEE Learning after this period.
9893662|NCT05232344|Experimental|Estradiol / Progesterone treatment|Estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) Vaginal progesterone (400 mg, Progestan®, evening and morning, ie 800 mg per day).
9893663|NCT05232318|Active Comparator|leveling and alignment using fixed orthodontic appliance|leveling and alignment using fixed orthodontic appliance
9893664|NCT05232318|Experimental|leveling and alignment using clear aligner|leveling and alignment using clear aligner
9893665|NCT05232318|Experimental|leveling and alignment using clear aligner with low level laser therapy|leveling and alignment using clear aligner with low level laser therapy
9893666|NCT05229679|Experimental|HPV-based screening|Women 23-29 invited to cervical screening will have their samples analyzed for HPV.
9893667|NCT05223322|Active Comparator|Taking Charge during Treatment (TCT) Intervention|"Taking Charge during Treatment (TCT) Intervention. TCT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Participants will receive Take Charge program binder, 2-4 x weekly text messaging, activity tracker and resistance bands."
9893668|NCT05223322|No Intervention|Control Group|"To ensure scientific rigor allowing us to test causal pathways associated with exercise, women will be randomized to the TCT intervention or control group arm. The control group will not receive the TCT intervention The investigators experience teaches us that to increase the likelihood of retaining control group participants, the investigators must offer some resources. Thus, the investigators will provide the control group with a one-page summary of the American College of Sports Medicine exercise recommendations, and the Take Charge program binder at the completion of the study. Participants will also receive resistance bands and activity tracker at the end of the study. 95 The investigators will also send weekly text messages with supportive content not related to exercise or lifestyle (i.e., a riddle, take a moment to smile today, a picture of a baby animal)."
9893669|NCT05222321|Experimental|SenPlay Intervention Group|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through activities such as pushing, pulling, climbing, jumping, and crashing. These activities are designed to facilitate changes in the child's arousal by providing sensory input and are used at random during the 15 minute window and are facilitated and monitored to ensure the child is reaching a threshold of moderate to vigorous physical activity. All participants will wear the ActiGraph accelerometer to measure the intensity of physical activity during the SenPlay intervention. Intervention sessions will occur at three time points, one per week for three weeks. Following the SenPlay intervention, participants will engage in 10 minutes of developmentally appropriate tasks (DAT) lead by the same investigator. DAT will be videotaped and coded for off task behaviors using Momentary Time Sampling (MTS).
9932491|NCT00949663|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
9932492|NCT00949676||Heart Failure|
9932493|NCT00949689|Experimental|Cognitive Behavioral Therapy for insomnia and depression|cognitive behavioral therapy for insomnia followed by cognitive behavioral therapy for depression
9932494|NCT00949689|Active Comparator|contol|participants will receive sleep hygiene, time management techniques and cognitive therapy for depression
9893670|NCT05222321|Placebo Comparator|Free play Control Group|The control group will engage in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes, prior to the assessment of off-task behaviors during 10 minutes of developmentally appropriate tasks (DAT). All participants will wear the ActiGraph accelerometer to measure the intensity of physical activity reached during spontaneous, free play. Participants in the control group will participate in three sessions, one per week for three weeks. Intervention sessions will occur at three time points, one per week for three weeks. Following the spontaneous play, participants will engage in 10 minutes of developmentally appropriate tasks (DAT) lead by the same investigator. DAT will be videotaped and coded for off task behaviors using Momentary Time Sampling (MTS).
9893671|NCT05214794|Experimental|nemolizumab|
9893672|NCT05213156|Active Comparator|Patients without Dry Eye Disease|Control Group
9893673|NCT05213156|Experimental|Patients with Dry Eye Disease, except the severe Dry Eye Disease|non severe Dry Eye Disease
9893674|NCT05213156|Experimental|Patients with severe Dry Eye Disease|severe Dry Eye Disease
9893675|NCT05208736||5-year nonsurvival or transplantation|Patients who died or underwent liver transplantation within 5 years since admission.
9893676|NCT05208736||5-year transplantation-free survival|Patients who survival without liver transplantation at 5 years since admission.
9893677|NCT05205408|Experimental|Oncolytic Virus Injection(RT-01)|Intratumoral administration of RT-01 as single agent for patients with advanced solid tumors. Dose cohorts: 1×10^8 TCID50/mL and 7×10^8 TCID50/ mL
9893678|NCT05198557|Experimental|MT-0551 group|Participants will receive intravenous (IV) inebilizumab on Day 1 and Day 15 of randomized controlled period (RCP). The participants who entered open label period (OLP) will receive IV inebilizumab on Day 1 and IV placebo on Day 15 of OLP and will be followed by IV inebilizumab every 26 weeks.
9893679|NCT05198557|Placebo Comparator|Placebo group|Participants will receive IV placebo on Day 1 and Day 15 of the RCP. The participants who entered OLP will receive IV inebilizumab on both Day 1 and Day 15 in OLP and will be followed by IV inebilizumab every 26 weeks.
9893680|NCT05195034|Active Comparator|Awake-DEX group|The DEX group patients will be received dexmedetomidine intraoperatively.
9893681|NCT05195034|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively.
9893682|NCT05194631|Experimental|Regeneration Capacity of Satellite Cells|In vitro Regeneration Capacity of Satellite Cells from the Quadriceps Compared to That of the Diaphragm isolated From one patient
9893683|NCT05190549|Experimental|CVA Regimen Bridging to HSCT|
9893684|NCT05186753|Experimental|(Part 1) CGT9486 Dose 1 + BSC|
9893685|NCT05186753|Experimental|(Part 1) CGT9486 Dose 2 + BSC|
9893686|NCT05186753|Experimental|(Part 1) CGT9486 Dose 3 + BSC|
9893687|NCT05186753|Placebo Comparator|(Part 1) Placebo + BSC|
9893688|NCT05186753|Experimental|(Part 2) CGT9486 Selected Dose + BSC|
9893689|NCT05186753|Placebo Comparator|(Part 2) Placebo + BSC|
9893690|NCT05186753|Experimental|(Part 3) CGT9486 + BSC|
9893691|NCT05186584|Experimental|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|Patients in this group will receive Maitland's Antero-Posterior Mobilization.
9893692|NCT05186584|Experimental|MAITLAND'S LATERAL MOBILIZATION|Patients in this group will receive Maitland's Lateral Mobilization.
9893693|NCT05185843|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 49 weeks.
9893694|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
9893695|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds + GLS-5310 IN|GLS-5310 ID + GeneDerm + GLS-5310 IN administered at Visit 1
9893696|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 15 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
9893697|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 80 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
9893698|NCT05177614|Experimental|Upper-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
9893699|NCT05177614|Experimental|Lower-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
9932495|NCT00949728|Other|Fibrin glue|
9893700|NCT05177614|Placebo Comparator|Control (iodine-fortified bouillon cube)|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with one micronutrient
9893701|NCT05176171|Experimental|Photorefractive Keratectomy with Corneal Cross-Linking|For correction of refractive error
9893702|NCT05173649|Experimental|Calisthenic Training|Calisthenic Training Group
9893703|NCT05173649|Experimental|Neuromuscular Training Group|Neuromuscular Training Group
9893704|NCT05168943|Active Comparator|Group N (n=30)|Continuous Epidural Anesthesia using Nylon (Polyamide) Epidural Catheter
9893705|NCT05168943|Active Comparator|Group P (n=30)|Continuous Epidural Anesthesia using Polyurethane Epidural Catheter
9893706|NCT05168020|Experimental|Safety Behavior Fading|"Participants will be asked to identify their five most common SBs from the SAFE. Participants will then be shown a sample checklist with instructions to fill it out. For the next 14 days, participants will receive the following text message Please remember to avoid using SBs you selected. As you drop them, you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each SB over the past 24 hours"
9893707|NCT05168020|Active Comparator|Unhealthy Behavior Fading|"Participants will be asked to pick five unhealthy behaviors they engage in most often to decrease. Participants will then be shown the same sample checklist as the Safety Behavior Fading Group. For the next 14 days participants will receive the following text message Please try to remember to decrease your unhealthy behaviors. As you decrease them you will feel better, and you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each Unhealthy Behavior over the past 24 hours."
9893708|NCT05165186|Experimental|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video
9893709|NCT05165186|No Intervention|Control Arm|For participants randomized to the control group arm, participants will review an informational sheet, which covers the same information as the videos shown to the intervention arm.
9893710|NCT05160064||Patients Treated with Loncastuximab Tesirine|Patients with B-cell lymphomas and other diagnoses who have been treated with loncastuximab tesirine will have their medical chart data entered into the registry.
9893711|NCT05159934|Active Comparator|Nicotine|Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
9893712|NCT05159934|Placebo Comparator|saline|Saline will compared to different nicotine doses. Nicotine doses: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
9893713|NCT05158023|Placebo Comparator|Placebo every two weeks (q2w)|Placebo q2w - placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14.
9893714|NCT05158023|Experimental|ASLAN004 300 mg q2w|ASLAN004 300 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 300mg q2w from Week 2 to Week 14.
9893715|NCT05158023|Experimental|ASLAN004 400 mg q2w|ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
9893716|NCT05158023|Experimental|ASLAN004 400 mg every four weeks (q4w)|ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14.
9893717|NCT05158023|Experimental|ASLAN004 600 mg q4w|ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
9893718|NCT05151471|Experimental|MT-1186 - Group 1|Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.
9893719|NCT05151471|Experimental|MT-1186 - Group 2|Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.
9893720|NCT05147831|Experimental|Remote Ischemic Preconditioning Protocol|
9893721|NCT05147831|No Intervention|Sham Preconditioning Protocol|
9893722|NCT05145374||Stressful Stimuli|Participation in meal, exercise, sleep activities alone or in combination with stressful stimuli.
9893724|NCT05140382|Experimental|Cohort 1: non-natural killer (NK) PTCL (Non-NK PTCL)|Eligible participants with PTCL, all comers (excluding NKTCL) will receive AZD4573 monotherapy
9893725|NCT05140382|Experimental|Cohort 2: NK PTCL|Eligible participants with PTCL (NKTCL only) will receive AZD4573 monotherapy
9893726|NCT05140382|Experimental|Cohort 3: cHL|Eligible participants with cHL will receive AZD4573 monotherapy
9932496|NCT00949754|Active Comparator|histamine|histamine in saline administered ID as active control for Apitox
9932497|NCT00949754|Experimental|Apitox pure honeybee venom|ID study drug
9932498|NCT00949767|Experimental|BMS-866949 (Panel 1)|
9932499|NCT00949767|Experimental|BMS-866949 (Panel 2)|
9932500|NCT00949767|Experimental|BMS-866949 (Panel 3)|
9932501|NCT00949767|Experimental|BMS-866949 (Panel 4)|
9893727|NCT05139550|Experimental|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities Lift can, Lift pencil, Lift paper clip, Stack checkers, Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
9893728|NCT05134428|Experimental|ADAM System|All subjects who consent and meet inclusion and none of the exclusion will be enrolled and receive the ADAM System, which is a hydrogel device implanted into the vas deferens.
9893729|NCT05132374|Experimental|Treatment Group|Those receiving standard practice early childhood mental health consultation but enhanced with the I-T CHILD as a framework for consultation
9893730|NCT05132374|No Intervention|Waitlist-control group|Those who receive no intervention until the end of the evaluation period)
9893731|NCT05131165|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices. At recruitment participant will be explained the importance of pill-taking. All participants (including in the control group) will receive a leaflet containing detailed information on how to establish healthy pill-taking routines. Finally, clinic staff will counsel participants on how to select an already regularly routine behavior that occurs at roughly the same time each day that forms the basis of their implementation plan.
9893732|NCT05131165|Experimental|Intervention group receiving messages (Messages Group)|"Participants will receive the same information as those in the Control Group, but in addition, receive the Daily Text Message Intervention."
9893733|NCT05131165|Experimental|Intervention group receiving messages and incentives (Incentives Group)|"Participants will receive the same information as the Control group. Additionally, they will receive the Daily Text Message Intervention and will be eligible for prize drawings."
9893734|NCT05130177|Experimental|Zimberelimab plus Domvanalimab|"Treatment Phase 1: Zimberelimab, 360mg, IV, every 3 weeks for 3 cycles. Domvanalimab, 15mg/kg, IV, every 3 weeks for 3 cycles. After 3 cycles, scans will be performed. If it is determined that the cancer is stable or responding patients will continue with Treatment Phase 2.~Treatment Phase 2: Zimberelimab, 360mg, IV, every 3 weeks for 3 cycles. Domvanalimab, 15mg/kg, IV, every 3 weeks, for up to 24 months."
9893735|NCT05118295|Experimental|SAVI Scout®|marker is accurately placed in the breast tumor
9893736|NCT05113069|Experimental|Treatment group|SHR-A1912
9893737|NCT05108961|Experimental|Acupuncture arm|One session of acupuncture with precise acupuncture points
9893738|NCT05108961|Sham Comparator|Sham acupuncture arm|One session of sham acupunture (needles inserted 1 mm, outside the acupuncture points)
9893739|NCT05108961|Placebo Comparator|Control arm|One session where no needles are inserted, the subject lies down under the same conditions as group 1 and 2
9893740|NCT05103332|Experimental|Zilebesiran (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
9893741|NCT05103332|Experimental|Placebo (Add-on to Olmesartan)|Following a run-in on olmesartan, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
9893742|NCT05103332|Experimental|Zilebesiran (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
9893743|NCT05103332|Placebo Comparator|Placebo (Add-on to Amlodipine)|Following a run-in on amlodipine, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
9893744|NCT05103332|Placebo Comparator|Zilebesiran (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
9893745|NCT05103332|Placebo Comparator|Placebo (Add-on to Indapamide)|Following a run-in on indapamide, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.
9932502|NCT00949767|Experimental|BMS-866949 (Panel 5)|
9893746|NCT05101616|Experimental|camrelizumab+chemotherapy|neoadjuvant treatment with camrelizumab+chemotherapy
9893747|NCT05101616|Active Comparator|chemotherapy|neoadjuvant treatment with chemotherapy
9893748|NCT05099497|Experimental|Intervention group: Practice facilitation and additional support|Ontario Health will send out letters to physicians in the intervention group that will explain to them that they have a large group of eligible and unvaccinated patients and that an initiative is planned to support them in reaching out to those patients, with an embedded evaluation. It will ask them to reach out to the research team to plan a time to access the supports to gather more information, or to opt-out from the evaluation. Specifically, physicians will receive invitations to receive practice facilitation via mail letter and fax, followed by up to five weekly phone calls from a team member at Ontario Health.
9893749|NCT05099497|No Intervention|Control group- No intervention|We choose to include a control group as we do not have the resources to deliver the intervention to the entire physician group. Cluster randomization by primary practice address will limit contamination.
9893750|NCT05091866|Experimental|Treatment (progesterone)|Patients receive progesterone SC QD for up to 24 weeks in the absence of disease progression or unacceptable toxicity.
9893751|NCT05091424|Experimental|R/R CLL|Participants will receive weekly step-up dosing of mosunetuzumab until the target dose is reached, after which mosunetuzumab will be administered once every 21 days for up to 17 cycles (cycle = 21 days) or until objective disease progression or unacceptable toxicity, whichever occurs first.
9893752|NCT05090332|Experimental|Facial Gun|Vibrations through Facial gun along with conventional Therapy
9893753|NCT05090332|Experimental|Dry needling|Dry needling along with conventional treatment.
9893754|NCT05085197|Experimental|Cohort 1:1mg/kg|All participants (fasted) received either 1mg/kg of STSA-1005 as a single dose or dose-matched placebo.
9893755|NCT05085197|Experimental|Cohort 2:2.5mg/kg|All participants (fasted) received either 2.5mg/kg of STSA-1005 as a single dose or dose-matched placebo.
9893756|NCT05085197|Experimental|Cohort 3:5mg/kg|All participants (fasted) received either 5 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
9893757|NCT05085197|Experimental|Cohort 4:10mg/kg|All participants (fasted) received either 10 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
9893758|NCT05079919|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
9893759|NCT05079919|Placebo Comparator|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
9893760|NCT05076370|Active Comparator|CBD 400mg|CBD 400mg
9893761|NCT05076370|Active Comparator|CBD 800mg|CBD 800mg
9893762|NCT05076370|Active Comparator|CBD 1200mg|CBD 1200mg
9893763|NCT05076006|Placebo Comparator|Placebo|Tablets without active ingredients
9893764|NCT05076006|Experimental|PF-06700841|tablets containing active drug (a combined TYK/JAK inhibitor)
9893765|NCT05070559|Experimental|Active Release Technique Group|Patients in this group will receive Active Release Technique along with conventional therapy
9893766|NCT05070559|Experimental|Graston Technique Group|Patients in this group will receive Instrumental Assisted Soft Tissue Mobilization along with conventional therapy
9893767|NCT05066165|Experimental|Arm 1: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count <5%, administered by IV infusion following lymphodepleting chemotherapy.
9893768|NCT05066165|Experimental|Arm 2: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count ≥5%, administered by IV infusion following lymphodepleting chemotherapy.
9893769|NCT05061199||ECA group|TCC with extracorporeal anastomosis (ECA)
9893770|NCT05061199||ICA group|TCC with intracorporeal anastomosis (ICA).
9893771|NCT05061095||Pilot Testing: Aggressive Lymphoma|20 patients diagnosed with aggressive lymphomas (e.g. diffuse large B-cell, advanced Hodgkin's) participating in the questionnaire portion of the study.
9893772|NCT05061095||Pilot Testing: Acute Leukemia|20 patients diagnosed with acute leukemias participating in the questionnaire portion of the study.
9667170|NCT03875820|Experimental|Dose Expansion RAS/RAF mutant endometrioid cancer cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with RAS/RAF mutant endometrioid subtype of gynaecological cancers (ovarian, endometrial, endometriosis-related) (10 patients).
9893773|NCT05061095||Pilot Testing: Myeloma/CLL/CML|10 patients diagnosed with either myelomas, chronic lymphocytic leukemia, or chronic myeloid leukemia that are participating in the questionnaire portion of the study.
9893774|NCT05061095||Qualitative Interviews: Living Longer|"10 participants (subset of the three pilot testing cohorts) that designate in their questionnaires that living longer is the most important outcome for them."
9893775|NCT05061095||Qualitative Interviews: Other|"10 participants (subset of the three pilot testing cohorts) that designate in their questionnaires that any other outcome besides living longer is the most important."
9893776|NCT05059080||Participants Diagnosed with COVID-19|Participants were previously enrolled in a RO7496998 (AT-527) study
9893777|NCT05056883|Experimental|Treatment A|K-237 0.3-0.4mg/kg (once daily)
9893778|NCT05056883|Placebo Comparator|Control A|Placebo (once daily)
9893779|NCT05055362|Experimental|Honey Spice Group|The dietary intervention will be a 10-day feasibility trial, using a honey, spice infused baked good. The participants will receive the baked good on day 1 and will be asked to consume a 50-gram baked good daily for 10 days with or without their meals. The honey, spice infused baked good will contain 15g honey and 3g of spice blend (turmeric and cinnamon). A saliva sample will be taken at the start of the intervention (day 1) before consumption of the baked good and after the intervention ends (day 10), 2 hours after consuming the final baked good. Additionally, participants will provide a urine sample to determine microalbuminuria level, complete a spice-consumption survey and a semi-quantitative food frequency questionnaire (day 1). At day 10, participants will indicate if their spice consumption and dietary intake has changed over the past 10 days. Each day, they will tick off the amount of baked good consumed (100%, 75%, 50%, 25%, 0%).
9893780|NCT05054894|Experimental|Experimental Group (Plasmapheresis for Age-Related Frailty)|Participants will receive plasmapheresis once a month for six months. All participants will be in this arm.
9893781|NCT05053672|No Intervention|Conventional therapy back pain treatment|Participants randomized to сonventional therapy group will receive complex rehabilitation program including physical exercise, phonophoresis with hydrocortisone, lumbar region massage, acupuncture within 2 weeks.
9893782|NCT05053672|Active Comparator|Conventional physiotherapy therapy back pain treatment + ReOxy-therapy|Participants randomized to Active Comparator group will receive complex rehabilitation program and 10 ReOxy-therapy sessions within 2 weeks (5 sessions per week).
9893783|NCT05053672|Placebo Comparator|Conventional physiotherapy therapy + Sham ReOxy-therapy|Participants randomized to Placebo Comparator group will receive complex rehabilitation program and 10 sham ReOxy-therapy sessions within 2 weeks (5 sessions per week).
9893784|NCT05032820|Experimental|Lenalidomide and bb2121|Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m2 and fludarabine 30mg/m2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x106 cells. Maintenance lenalidomide, starting at 10mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.
9893785|NCT05018650|Experimental|Route 92 Medical Reperfusion System|Aspiration thrombectomy with the Route 92 Reperfusion System to treat acute ischemic stroke
9893786|NCT05018650|Active Comparator|Aspiration Predicate|Aspiration thrombectomy with a predicate aspiration device to treat acute ischemic stroke
9893787|NCT05017935|Experimental|Renal Denervation|
9893788|NCT05013528|Experimental|Bal-A-Vis-X training Group|Bal-A-Vis-X training Group
9893789|NCT05013528|Active Comparator|Aerobic Training Group|Aerobic Training Group
9893790|NCT05007691|Experimental|Occlusal splints|"In a clinical setting, participants test the closure of the occlusal splint with the antagonistic dentition.~Only one of the two occlusal splints (mandibular splint and maxillary splint) is used at a time. Occlusal splints are applied separately and alternately."
9893791|NCT05006716|Experimental|Part 1 Monotherapy Dose Finding|BGB-16673
9893792|NCT05006716|Experimental|Part 2 Expansion Cohorts|BGB-11673 for two expansion cohorts
9893793|NCT05002998|Other|Teprotumumab 4 Infusions|"• 4 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 3 infusions) (Cohort 1) followed by 4 infusions of:~Placebo if a participant is a treatment responder at Week 12 or~Teprotumumab 20 mg/kg if a participant is a treatment non-responder at Week 12"
9893794|NCT05002998|Other|Teprotumumab 8 Infusions|8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) (Cohort 2)
9893795|NCT05002998|Other|Teprotumumab 16 Infusions|16 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 15 infusions) (Cohort 3)
9893796|NCT04988022|Experimental|Dupilumab|dupilumab 600mg loading dose at Baseline (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
9893797|NCT04988022|Placebo Comparator|Placebo|matching placebo loading dose at Baseline (given as two injections) followed by one weekly subcutaneous injection through Week 24. Starting at Week 24, dupilumab 600mg loading dose (given as two 300 mg injections) followed by one 300mg weekly subcutaneous injection through Week 52.
9893798|NCT04986605|Experimental|Administration of Extracorporeal Photopheresis Treatment|"Duration of treatment: 48 weeks. Treatments occur on 2 consecutive days every 4 weeks.~Dose of UVADEX: Treatment Volume x 0.017 = mL of UVADEX for each treatment Treatment Volume (TV) is defined as: The total volume of Buffy Coat plus prime solution that will undergo photoactivation.~Route of administration: Extracorporeal"
9893799|NCT04985773|Experimental|Lacrosse NSE ALPHA percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) in which at least one Lacrosse NSE ALPHA device is used.
9893800|NCT04982029|Experimental|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
9893801|NCT04982029|Placebo Comparator|Placebo|All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.
9893802|NCT04978428|Experimental|Epidiolex|Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)
9893804|NCT04974528|Experimental|Afrezza (Technosphere Insulin) + Basal Insulin|"Individualized dose of Afrezza (Technosphere Insulin) for each patient before each meal (breakfast, lunch, and dinner) for 26 weeks.~Individualized basal insulin (insulin degludec or glargine) for each patient as 1 dose in the evening."
9893805|NCT04974528|Active Comparator|RAA Injection + Basal Insulin|"Individualized dose of RAA injection (insulin aspart or lispro) for each patient for 26 weeks.~Individualized basal insulin (insulin degludec or glargine) for each patient as 1 dose in the evening."
9893806|NCT04968652||IBS-C Group|Result of ROME VI marked as 'IBS-C'.
9893807|NCT04968652||Non IBS-C Group|Result of ROME VI marked as 'Non IBS-C'
9893808|NCT04968340|Other|• Group 1(conventional c s)|this arm will be exposed to the conventional method of cesserian section which entail introduction of the operator hand below the fetal head during its extraction
9893809|NCT04968340|Other|• Group2(EPO technique)|this group will be exposed to external pop out teqnique which entails support of lower uterine segment without introduction of the obstetrician hand into uterine incision
9893810|NCT04967599|No Intervention|Control (CONTROL)|Participants do not receive PHEN or GENE.
9893811|NCT04967599|Experimental|Phenotype Feedback (PHEN)|Participants receive the PHEN intervention.
9893812|NCT04967599|Experimental|Phenotype and Genotype Feedback (PHEN+GENE)|Participants receive the PHEN and GENE interventions.
9893813|NCT04962971||Cranberry extract X|373 mg per Day
9893814|NCT04962971||Cranberry extract Y|404 mg per Day
9893815|NCT04962971||Cranberry extract Z|2090 mg per Day
9893816|NCT04958291|Experimental|Administration of Dose A of CC-99677 or Placebo|Administration of Dose A of CC-99677 or Placebo
9893817|NCT04958291|Experimental|Administration of Dose B of CC-99677 or Placebo|Administration of Dose B of CC-99677 or Placebo
9893818|NCT04958291|Experimental|Administration of Dose C of CC-99677 or Placebo|Administration of Dose C of CC-99677 or Placebo
9893819|NCT04955821||VAP group|Children with respiratory tract infection by mechanical ventilation
9893820|NCT04946708|Experimental|Small group zoom meeting|Group one: will be asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants e.g. questions, perceptions, etc.).
9893821|NCT04946708|Experimental|YouTube pre-recorded video|Group two: will be asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
9893822|NCT04944784|Experimental|300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Day 1 until Week 24|Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Day 1 until Week 24.
9893823|NCT04944784|Placebo Comparator|Placebo twice daily, from Day 1 until Week 24|Patients in this arm take 2 placebo oral tablets twice a day from Day 1 until Week 24.
9893824|NCT04944784|Experimental|300 mg reldesemtiv twice daily for a 600 mg total daily dose, from Week 24 until Week 48|Patients in this arm take 2 reldesemtiv 150 mg oral tablets twice a day for a 600 mg total daily dose from Week 24 until Week 48 for patients who were not down titrated during the 24 weeks of blinded dosing.
9893825|NCT04944784|Experimental|150 mg reldesemtiv twice daily for a 300 mg total daily dose, from Week 24 until Week 48|Patients in this arm take 1 reldesemtiv 150 mg oral tablet twice a day for a 300 mg total daily dose from Week 24 until Week 48 for patients who were down titrated for any reason during the 24 weeks of blinded dosing.
9893826|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 1|Multiple doses of ALN-AGT01 administered by subcutaneous (SC) injection during the 12-month DB treatment period.
9893827|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 2|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
9893828|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 3|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
9893829|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 4|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
9893830|NCT04936035|Placebo Comparator|Placebo + ALN-AGT01|Multiple doses of placebo administered by SC injection during the first 6 months of 12-month DB treatment period, followed by multiple doses of ALN-AGT01 administered by SC injection during the last 6 months of the 12-month DB treatment period.
9932503|NCT00949767|Experimental|BMS-866949 (Panel 6)|
9932504|NCT00949767|Experimental|BMS-866949 (Panel 7)|
9932505|NCT00949780|Active Comparator|chloral hydrate , sedative|
9932506|NCT00949793|Experimental|All patients|
9932507|NCT00949806|Experimental|Administrated|All patients included will receive an intradermal administration of BNT
9932508|NCT00949832|Active Comparator|Vitamin D + Calcium|Vitamin D and calcium supplementation
9932509|NCT00949832|Placebo Comparator|Calcium|Calcium supplementation
9932510|NCT00949832|Active Comparator|Vitamin D2|Vitamin D2 response
9932511|NCT00949832|Active Comparator|Vitamin D3|Vitamin D3 response
9932512|NCT00949897|Active Comparator|Biofoam|
9932513|NCT00949897|Active Comparator|Iliac Crest Allograft with locked plate|
9932514|NCT00949923|Active Comparator|tea capsules|3 tea capsules daily for 3 weeks
9932515|NCT00949923|No Intervention|Control|No tea capsules
9932516|NCT00949949|Experimental|Cohort I (everolimus and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and everolimus PO once daily or 3 times weekly.
9932517|NCT00949949|Experimental|Cohort II (everolimus, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8 and everolimus PO once daily or 3 times weekly.
9932518|NCT00949949|Experimental|Cohort III (MTD)|Patients receive treatment as in cohort II.
9932519|NCT00949962|Active Comparator|Arm I|Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
9932520|NCT00949962|Experimental|Arm II|Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.
9932521|NCT00950001|Experimental|Arm I (SRS)|Patients undergo stereotactic radiosurgery to the surgical cavity within 30 days of the craniotomy.
9932522|NCT00950001|No Intervention|Arm II (observation)|Patients undergo clinical observation after craniotomy.
9932523|NCT00950014|Experimental|Percentage format only|Numbers are presented in percentage format (e.g., 35%, 0.2%) only.
9932524|NCT00950014|Experimental|Fixed frequency format only|Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
9932525|NCT00950014|Experimental|Variable frequency format|Frequency denominators are adjusted to keep the numerator greater than 1, so they may change throughout the survey (e.g., 6 out of 1000, 42 out of 100)
9932526|NCT00950014|Active Comparator|Fixed combination format|Numbers are presented with both percentages and frequencies, and frequency denominators remain fixed (e.g., _ out of 1000).
9932527|NCT00950014|Experimental|Variable combination format|Numbers are presented with both percentages and frequencies, but frequency denominators may vary (e.g., _ out of 1000, _ out of 100).
9932528|NCT00950027|Experimental|povidone iodine|Povidone iodine
9932529|NCT00950027|Placebo Comparator|placebo|
9932530|NCT00950040|Experimental|Brief alcohol intervention|Brief alcohol intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
9932531|NCT00950040|Active Comparator|General Health Education|General health education intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
9932532|NCT00950053|Active Comparator|Achilles decompression & debridement|
9932533|NCT00950053|Active Comparator|Achilles decompression,debride&FHLtransf|Achilles tendon decompression and debridement augmented with FHL transfer. The preferred skin incision will be followed by central-splitting Achilles debridement, resection of a Haglund's lesion if present and pathologic, followed by FHL harvest for patients in group 2. The fixation technique in group 2 will utilize an interference screw for the FHL. For all patients, the Achilles will be reattached with lateral and medial suture anchors (just distal to interference screw in FHL patients).
9932534|NCT00950066|Placebo Comparator|Placebo|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with placebo once a day."
9932535|NCT00950066|Active Comparator|Irbesartan 150mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg once a day."
9932536|NCT00950066|Active Comparator|Irbesartan 150 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day."
9667171|NCT03875820|Experimental|Dose Expansion pancreatic cancer|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with pancreatic cancer (10 patients).
9893831|NCT04932512|Experimental|ION224|Multiple doses of ION224 will be administered by SC injection once every 4 weeks for up to 49 weeks.
9893832|NCT04932512|Placebo Comparator|Placebo|Multiple doses of matching placebo will be administered by SC injection once every 4 weeks for up to 49 weeks.
9893833|NCT04930172||Steerable introducers|
9893834|NCT04928599||Health Services Research (survey, interview, chart review)|Parents complete surveys over 15-30 minutes at the beginning of their child's induction chemotherapy, at the beginning of maintenance chemotherapy, and at the end of last chemotherapy. Parents may also participate in one-time individual interview over 30-45 minutes. Additionally, children's medical records are reviewed during the study
9893835|NCT04924660|Experimental|TXA127|An investigational peptide agonist of Mas receptors.
9893836|NCT04924660|Experimental|TRV027|An investigational peptide biased agonist of the AT1 receptor.
9893837|NCT04924660|Placebo Comparator|Placebo|"NaCl 0.9% infused to match the duration of the agent for TXA127, TRV027, and APN01.~Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
9893838|NCT04924660|Experimental|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
9893839|NCT04920162|Other|Skin deseases biospecimens collection|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
9893840|NCT04916002|Experimental|CMP-001 and cemiplimab-rwlc for cutaneous squamous cell carcinoma (CSCC) (A1)|Subjects who have not received prior systemic therapy for CSCC will receive CMP-001 IT and cemiplimab-rwlc IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9893841|NCT04916002|Experimental|CMP-001 and cemiplimab-rwlc for CSCC (A2)|Subjects who have progressed while receiving PD-1-blocking antibody(ies) or are within 3 months of discontinuation of treatment for CSCC will receive CMP-001 IT and cemiplimab-rwlc IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9893842|NCT04916002|Experimental|CMP-001 and cemiplimab-rwlc for Merkel cell carcinoma (MCC) (B1)|Subjects who have not received prior systemic therapy for MCC will receive CMP-001 IT and cemiplimab-rwlc IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9893843|NCT04916002|Experimental|CMP-001 and cemiplimab-rwlc for MCC (B2)|Subjects who have progressed while receiving PD-1-blocking antibody(ies) or are within 3 months of discontinuation of treatment for MCC will receive CMP-001 IT and cemiplimab-rwlc IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9893844|NCT04916002|Experimental|CMP-001 and cemiplimab-rwlc for triple negative breast cancer (TNBC) (C1)|Subjects who have not received prior therapy with immune checkpoint inhibitors (iCPIs) for TNBC will receive CMP-001 IT and cemiplimab-rwlc IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9893845|NCT04916002|Experimental|CMP-001 and cemiplimab-rwlc for TNBC (C2)|Subjects who have received prior treatment for PD-1-blocking antibody(ies) for TNBC will receive CMP-001 IT and cemiplimab-rwlc IV according to the treatment schedule until a reason for treatment discontinuation is reached.
9893846|NCT04914234|Active Comparator|Group A (n=30)|Atenolol group
9893847|NCT04914234|Active Comparator|Group M (n=30)|Metoprolol group
9893848|NCT04907370|Experimental|Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of toripalimab are administrated concurrently with IC and IMRT, respectively. After 3 weeks of the completion of IMRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
9893849|NCT04907370|Active Comparator|Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by concurrent chemoradiotherapy (CCRT; every 3 weeks × 2 cycles of cisplatin + IMRT 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day). PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of CCRT, involving the whole-course of IC + CCRT. The first and last 3 cycles of toripalimab are administrated concurrently with IC and CCRT, respectively. After 3 weeks of the completion of CCRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.
9893850|NCT04904588|Experimental|Regimen A (MAC: busulfan and fludarabine, PBSC HCT)|"Patients receive:~Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0."
9893851|NCT04904588|Experimental|Regimen B (MAC: Fludarabine and TBI; PBSC HCT)|"Patients receive:~Fludarabine (90 mg/m2 total dose) IV on days -7 to -5~Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
9893852|NCT04904588|Experimental|Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -6 to -2~Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
9893853|NCT04904588|Experimental|Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -7 to -3~Melphalan (100-140 mg/m2) IV on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
9893854|NCT04904588|Experimental|Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)|"Patients receive:~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Cyclophosphamide (29-50 mg/kg) IV on days -6 and -5~TBI (200 cGy) on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
9893855|NCT04904588|Experimental|Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)|"Patients receive:~Busulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3~Cyclophosphamide (100 mg/kg total dose) IV on days -2 and -1~Patients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0."
9893856|NCT04904588|Experimental|Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)|"Patients receive:~Cyclophosphamide (100 mg/kg total dose) IV on days -5 and -4~TBI (1200 cGy total dose) on days -3, -2 and -1~Patients receive a BM graft infusion from a mismatched unrelated donor on Day 0."
9893857|NCT04899661||Molidustat|Participants diagnosed with renal anemia treated with Molidustat at the discretion of investigators
9893858|NCT04896502|Experimental|Telemedicine Arm|For the proposed study, participants will randomized to receive TM home assessments/interventions performed by a trained home visitor (HV) or standard of care asthma trigger education by the HV. Those who are randomized to TM home assessments/interventions will complete a baseline home assessment and two follow-up visits, 2 months apart. Visits will assess the presence of potential asthma triggers in the home and frequency of asthma symptoms/exacerbations. TM participants will be provided education and materials necessary to reduce asthma triggers in the home. Follow-up visits will assess the interval change in presence of asthma triggers, change in daily asthma symptoms/exacerbations, and participant/family retention of education.
9893859|NCT04896502|Active Comparator|Standard of Care Education|For subjects randomized to receive standard of care asthma education, written and verbal information will be provided regarding identification and removal of potential asthma triggers in the home but no formal assessment of the home will be performed, nor will participants in this arm receive trigger reduction materials.
9893860|NCT04892706|Experimental|IDP-126 Gel|
9893861|NCT04892706|Placebo Comparator|IDP-126 Vehicle Gel|
9893862|NCT04892706|Active Comparator|Epiduo® Forte Gel|
9893863|NCT04887350|Experimental|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership is a phone administered talk therapy.
9893864|NCT04887350|Active Comparator|Problem Solving Therapy (PST)|Problem Solving Therapy is a phone administered talk therapy.
9893865|NCT04887350|Other|Wait List Control (WLC)|Participants in the WLC will continue with their regular treatments for the 12 week study period but not receive any study related intervention during this 12 weeks. Following completion of all study assessments WLC participants will self-select either SSIPP or PST. Participants in WLC will not complete study assessments after week 12.
9893866|NCT04886505|Experimental|Treatment|Single arm study - treatment with Electrolytic eCLIPs Bifurcation System
9893867|NCT04884568|Experimental|Exufiber|This is an open, non-randomised , single arm study
9893868|NCT04868604|Experimental|67Cu-SAR-bisPSMA|"In the dosimetry phase patients will receive a single 200 MBq administration of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the cohort expansion phase patients will receive up to 3 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 67Cu-SAR-bisPSMA (dose will be determined based on cohort allocation).~In the cohort expansion phase patients will receive 2 administrations of 67Cu-SAR-bisPSMA at the recommended dose level determined through dose escalation."
9893869|NCT04855747|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
9893870|NCT04855747|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
9893871|NCT04850469||trial group|Mesenchymal Stem Cell-Derived Exosomes
9893872|NCT04850469||control group|conventional treatment
9893873|NCT04849676|Experimental|Upper limb subacute spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Grip strength - measure of hand and forearm muscle strength using dynamometer~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
9667172|NCT03875183|Experimental|INL1 50mg BID|INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
9893874|NCT04849676|Experimental|Upper limb chronic spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Grip strength - measure of hand and forearm muscle strength using dynamometer~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
9893875|NCT04849676|Experimental|Lower limb subacute spinal cord injury (sLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
9893876|NCT04849676|Experimental|Lower limb chronic spinal cord injury (cLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
9893877|NCT04843761|Experimental|Aviptadil + Remdesivir + SOC|
9893878|NCT04843761|Placebo Comparator|Aviptadil + Remdesivir Placebo + SOC|
9893879|NCT04843761|Experimental|Aviptadil Placebo + Remdesivir + SOC|
9893880|NCT04843761|Experimental|Aviptadil Placebo + Remdesivir Placebo + SOC|
9893881|NCT04835597||Observational (movement assessment, medical data collection)|Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.
9893882|NCT04835493|Experimental|Intervention|Intervention individuals will receive the 12-month diabetes TIME program
9893883|NCT04835493|Other|Enhanced Usual Care (EUC)|We will define EUC as usual clinical care, which consists of diabetes management provider encounters (mean quarterly) plus monthly individual appointments with a pharm-Ds or nutritionists as clinically indicated. In addition, clinics offer multiple other individual and group opportunities. In addition for the EUC arm, we will provide three quarterly, 1-hour classes (nutrition medications, exercise). The classes will be led by a research-staff trained, bilingual healthcare professional e.g., nurse. EUC individuals will not have contact with CHWs.
9893884|NCT04835038|Experimental|Sodium Bicarbonate Ringer's Injection group|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
9893885|NCT04835038|Active Comparator|Sodium Lactated Ringer's Injection group|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
9893886|NCT04834661||inside group|laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
9893887|NCT04834661||outside group|laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
9893888|NCT04830306|Active Comparator|6MST|Six minute step test
9893889|NCT04830306|Active Comparator|6MWT|Six minute walk test
9893890|NCT04830306|Active Comparator|CPET|Cardiopulmonary exercise test
9893891|NCT04823039|Other|Vaccination in patient with sepsis|
9893892|NCT04822597|Active Comparator|Ice Pack|Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)
9893893|NCT04822597|Experimental|Lidocaine Patch|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection
9893894|NCT04822597|Experimental|Buzzy(R)|A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.
9932537|NCT00950066|Active Comparator|Amlodipine|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Amlodipine 5 mg once a day."
9667173|NCT03875183|Experimental|INL1 150 mg BID|INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
9893895|NCT04822597|Experimental|Lidocaine Patch and Buzzy(R)|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.
9893896|NCT04821414||trial group|anakinra canakinumab
9893897|NCT04821414||control group|conventional treatment
9893898|NCT04821089|Experimental|IPN10200 group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
9893899|NCT04821089|Placebo Comparator|Placebo group|Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee recommendation.
9893900|NCT04816643|Experimental|Low/Mid-Dose, ≥5 to <12 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
9893901|NCT04816643|Experimental|Mid-Dose, ≥5 to <12 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
9893902|NCT04816643|Experimental|High-Dose, ≥5 to <12 Years|High-Dose (30mcg), 2 doses 21 days apart
9893903|NCT04816643|Experimental|Low/Mid-Dose, ≥2 to < 5 Years|Low/Mid-Dose (10mcg), 2 doses 21 days apart
9893904|NCT04816643|Experimental|Mid-Dose, ≥2 to <5 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
9893905|NCT04816643|Experimental|High-Dose, ≥2 to <5 Years|High-Dose, (30mcg), 2 doses 21 days apart
9893906|NCT04816643|Experimental|Low/Mid-Dose, ≥6 Months to <2 Years|Low/Mid-Dose, (10mcg), 2 doses 21 days apart
9893907|NCT04816643|Experimental|Mid-Dose, ≥6 Months to <2 Years|Mid-Dose, (20mcg), 2 doses 21 days apart
9893908|NCT04816643|Experimental|High-Dose, ≥6 Months to <2 Years|High-Dose, (30mcg), 2 doses 21 days apart
9893909|NCT04816643|Experimental|Low/Mid-Dose, 16 to <18 Years (21 day schedule)|Low/Mid-Dose (10mcg), 2 doses 21 days apart
9893910|NCT04816643|Placebo Comparator|Placebo, ≥6 Months to <2 Years|
9893911|NCT04816643|Placebo Comparator|Placebo, ≥2 to <5 Years|
9893912|NCT04816643|Placebo Comparator|Placebo, ≥5 to <12 Years|
9893913|NCT04816643|Experimental|Low-Dose, ≥6 Months to <2 Years|Low-Dose (3mcg), 2 doses 21 doses apart
9893914|NCT04816643|Experimental|Low-Dose, ≥2 to <5 Years|Low-Dose (3mcg), 2 doses 21 days apart
9893915|NCT04816643|Experimental|Low/Mid-Dose, 12 to <16 Years (21 day schedule)|Low/Mid-Dose (10mcg), 2 doses 21 days apart
9893916|NCT04816643|Experimental|High-Dose, 12 to <16 Years (Troponin I Testing)|High-Dose (30mcg), 2 doses 21 days apart
9893917|NCT04816643|Experimental|Low/Mid-Dose, ≥5 to <12 Years (Troponin I Testing)|Low/Mid-Dose (10mcg), 2 doses 21 days apart. A separate cohort of participants to collect serum samples for potential troponin I testing
9893918|NCT04816643|Experimental|Placebo, ≥5 to <12 Years (Troponin I Testing)|A separate cohort of participants to collect serum samples for potential troponin I testing
9893919|NCT04816643|Experimental|Low/Mid-Dose, 12 to <16 Years (8 week schedule)|Low/Mid-Dose (10mcg), 2 doses 8 weeks apart
9893920|NCT04816643|Experimental|Low/Mid-Dose, 16 to <18 Years (8 week schedule)|Low/Mid-Dose (10mcg), 2 doses 8 weeks apart
9893921|NCT04816643|Experimental|Low-Dose, ≥6 Months to <2 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
9893922|NCT04816643|Experimental|Low-Dose, ≥2 to <5 Years (3-dose regimen)|Low-Dose (3mcg), 3 doses
9893923|NCT04816643|Placebo Comparator|Placebo, ≥6 Months to <2 Years (3-dose regimen)|
9893924|NCT04816643|Placebo Comparator|Placebo, ≥2 to <5 Years (3-dose regimen)|
9893925|NCT04802200||Patients operated from minimally invasive cardiac surgery|Patients operated between December 16, 2019 and june 30, 2021 from minimally invasive cardiac surgery with femoral cannulation for cardiopulmonary bypass in Dijon University hospital and in whom the MANTA device has been used for femoral artery closure
9893926|NCT04801030|Experimental|Culturally-appropriate social marketing campaign|Participants will receive a multi-layered, social marketing campaign which is deemed culturally appropriate. This will occur over a 6 month -time period. Rates will be observed at 0, 6, and 12 months.
9893927|NCT04801030|No Intervention|Control Arm 1|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
9893928|NCT04801030|No Intervention|Control Arm 2|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
9893929|NCT04794699|Experimental|Dose Escalation Monotherapy|IDE397 dosed orally, once daily (QD) for each 21-day cycle
9893930|NCT04793204|Experimental|fezolinetant|A single oral dose of fezolinetant will be administered with water under fasting conditions on day 1 (low dose), day 4 (medium dose) and day 7 (high dose). From day 10 to day 15, the medium dose of fezolinetant will be administered with water after breakfast once daily. On day 16, the medium dose of fezolinetant will be administered with water under fasting conditions.
9893931|NCT04790409|Experimental|Sintilimab with anlotinib|Patients received sintilimab (anti-PD-1) combined with anlotinib (multi-target anti-angiogenesis).
9893932|NCT04778644|Experimental|Patients with psychosis|People who are part of a dimensionally-organized psychosis sample spanning several serious mental illness diagnoses including schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
9893933|NCT04778644|Experimental|Healthy controls|People who do not have a diagnosis of schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
9893934|NCT04776720|Experimental|Yoga Program|The 3-month yoga intervention provides instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
9893935|NCT04776720|Active Comparator|Physical Conditioning Program|The 3-month physical conditioning program provides instruction and practice in a variety of exercises and stretches that have been designed by the study physical therapist.
9893936|NCT04773158|Experimental|Intervention Arm|The intervention clinic sites will be provided access to both the Functional gastrointestinal disorders (FGIDs) Screening Module and the Treatment Module
9893937|NCT04773158|No Intervention|Control Arm|The control clinics will have the Functional gastrointestinal disorders (FGIDs) Screening Module. However, control clinics will not have access to the FGIDs Treatment Module. These clinic sites will be given access to the pre-screener form section of the module, so that providers are made aware of a positive screen for a FGID.
9893938|NCT04772911||Strata A: One-time OCT Measurements|The indication for Strata A is that some participants will elect not to undergo laser treatment, particularly if they have been extensively treated with laser previously, or have a light pink vascular stain that has been stable.
9893939|NCT04772911||Strata B: Serial OCT Measurements|Participants will have serial OCT measurements of their vascular stain performed prior to the start of standard of care laser treatment. OCT will be performed prior to each standard of care laser treatment if the participant has elected to have standard of care laser treatment as treatment of their vascular stain at the time of enrollment.
9893940|NCT04755452|Experimental|Low Intra-abdominal pressure|Intra-abdominal pressure will be set at 7 mm Hg during the procedure.
9893941|NCT04755452|Active Comparator|High (standard) intra-abdominal pressure|Intra-abdominal pressure will be set at 12 mm Hg during the procedure.
9893942|NCT04740008|Experimental|Control message on low nicotine cigarettes|
9893943|NCT04740008|Experimental|Test message on low nicotine cigarettes|
9893944|NCT04736745|Experimental|Dose escalation|"One single injection of study medication (IPN59011 or Placebo) will be injected locally. IPN59011 is injected in a dose-escalation manner.~In total for this stage at least 40 subjects."
9893945|NCT04736745|Experimental|Dose ranging|"Up to two IPN59011dose(s) groups will be included in parallel groups versus Azzalure group and placebo group. One single injection of study medication will be injected locally into several sites.~In total for this stage at least 70 subjects."
9893946|NCT04736745|Experimental|Additional dose ranging|"Dose-ranging for three additional placebo-controlled parallel groups. One single injection of study medication will be injected locally into several sites, concomitantly and non-concomitantly.~In total for this stage at least 110 subjects."
9893947|NCT04736745|Experimental|Total dose for Upper Facial Lines|"One single injection of study medication will be injected locally into Upper Facial Lines.~In total for this stage approximately 48 subjects."
9893948|NCT04735653|Experimental|Personalized Glaucoma Coaching|
9893949|NCT04735653|Active Comparator|Enhanced standard care|
9893950|NCT04729686|Active Comparator|Pericapsular Nerve Block Group|Pericapsular Nerve Block targets the anterior hip capsule by blocking the articular branches of the femoral nerve and accessory obturator nerve.
9893951|NCT04729686|Active Comparator|Fascia Iliaca Nerve Block Group|Fascia Iliaca Nerve Block targets the space between the iliacus muscle and the fascia that overlies it (fascia iliaca), within which the femoral nerve and lateral femoral cutaneous nerve (LFCN) course.
9893952|NCT04724369|Experimental|Study Cohort: Subjects with known or presumed neuroblastoma|"Drug: 18F-mFBG Positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for identification of neuroblastoma.~Other Names:~meta-fluorobenzylguanidine~IRP101"
9893953|NCT04724265|Experimental|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation
9893954|NCT04721067|Experimental|CBT-I|This arm will receive internet CBT-I using SHUTi, a validated and proven therapy provided via internet in the general population.
9893955|NCT04721067|Active Comparator|Sleep Education/Hygiene|This arm will receive best practices education on sleep hygiene.
9893956|NCT04713813|Active Comparator|Exercise group 1(Exercise via mechanical horse-riding simulator)|Exercise via mechanical horse-riding simulator; Subjects remained in sitting position for 30 minutes on the simulator during these sessions, with extension of the trunk and stabilization of the pelvis. Feet were placed on the footplates as the simulator produced a rhythmic and repetitive movement similar to a walking horse. The simulator can produce several modes of rhythmic and repetitive motions.
9893957|NCT04713813|Active Comparator|Exercise group 2 (Home exercises)|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
9893958|NCT04703231||Natural menopause(Control group)|Female patients between 45-60 years of age diagnosed with menopause without any intervention
9893959|NCT04703231||Surgical Menopause (Case group)|Female patients aged 45-60 years included in the study 3 months after bilateral oophorectomy and hysterectomy
9667174|NCT03875183|Experimental|INL1 300 mg BID|INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
9893960|NCT04702620||healthy children without symptoms|healthy children without symptoms
9893961|NCT04702620||sick children without wheezing|sick children without respiratory wheezing
9893962|NCT04702620||sick children with respiratory wheezing|
9893963|NCT04688164|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT).
9893964|NCT04688164|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
9893965|NCT04677829|Experimental|PNT001 1000mg|PNT001 diluted in 5% dextrose for infusion
9893966|NCT04677829|Experimental|PNT001 4000mg|PNT001 diluted in 5% dextrose for infusion
9893967|NCT04677829|Placebo Comparator|Placebo|5% dextrose for infusion
9893968|NCT04676412|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
9893969|NCT04676412|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
9893970|NCT04657991|Experimental|Triplet Arm|Encorafenib and Binimetinib in combination with Pembrolizumab
9893971|NCT04657991|Active Comparator|Control Arm|Pembrolizumab
9893972|NCT04654468|Experimental|Crovalimab|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
9893973|NCT04651725|Active Comparator|Exercise group 1: Exercise via mechanical horse-riding simulator|All patients in both groups were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
9893974|NCT04651725|Active Comparator|Exercise group 2: Home exercises|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
9893975|NCT04649359|Experimental|Elranatamab (cohort A)|BCMA-CD3 bispecific antibody
9893976|NCT04649359|Experimental|Elranatamab (cohort B)|BCMA-CD3 bispecific antibody
9893977|NCT04644289|Other|cohort A - olaparib monotherapy|Olaparib tablets 2 × 300 mg per day for 3 weeks prior to surgery until one day prior to surgery or withdrawal of informed consent and as long as the patient has received all possible licensed treatment regimens according to national guideline or for whom further licensed treatment options are contraindicated, offered as investigational maintenance therapy for 24 months after completion of primary therapy (chemotherapy).
9893978|NCT04644289|Other|cohort B - olaparib + durvalumab combination|Olaparib tablets 2 × 300mg per day for 4 weeks plus durvalumab 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle).
9893979|NCT04642365|Experimental|Part I|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
9893980|NCT04642365|Experimental|Part II|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.
9893981|NCT04642365|Experimental|Part III (Exploratory)|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.
9893982|NCT04642079|Experimental|Cohort 1: =>15 through 23 months of age|20vPnC
9893983|NCT04642079|Experimental|Cohort 2: 2 through 4 years of age|20vPnC
9893984|NCT04642079|Experimental|Cohort 3: 5 through 9 years of age|20vPnC
9893985|NCT04642079|Experimental|Cohort 4: 10 through 17 years of age|20vPnC
9893986|NCT04639206|Experimental|HOBSCOTCH group|Participants in this study arm will receive the HOBSCOTCH intervention immediately.
9893987|NCT04639206|No Intervention|Wait-listed control|Participants in this study arm will be wait-listed for 6 months and will then receive the HOBSCOTCH intervention.
9893988|NCT04639050|Experimental|Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
9893989|NCT04639050|Placebo Comparator|Cohort 1: Placebo|Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.
9893990|NCT04639050|Experimental|Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
9893991|NCT04639050|Placebo Comparator|Cohort 2: Placebo|Participants will receive matching placebo to dose level 2 Q4W for 28 weeks followed by a 28-week safety follow-up period.
9893992|NCT04639050|Experimental|Cohort 3: Dose Level 3 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 3 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
9893993|NCT04639050|Placebo Comparator|Cohort 3: Placebo|Participants will receive matching placebo to dose level 3 Q4W for 28 weeks followed by a 28-week safety follow-up period.
9893994|NCT04639050|Experimental|Cohort : Dose Level 4 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 4 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
9893995|NCT04639050|Placebo Comparator|Cohort 4: Placebo|Participants will receive matching placebo to dose level 4 Q4W for 28 weeks followed by a 28-week safety follow-up period.
9893996|NCT04637776||Patients with Heart Failure|Patients with heart failure who were discharged within the past month after hospitalization for any reason.
9893997|NCT04634825|Experimental|Retifanlimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
9893998|NCT04634825|Experimental|Tebotelimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles
9893999|NCT04632771||Pilot survey: non-pregnant, non-lactating women|Survey of non-pregnant, non-lactating women 15-49 years of age (n=250)
9894000|NCT04632771||Pilot survey: lactating women|Survey of lactating women 15-49 years of age who are currently breastfeeding a child 4-18 months of age (n=250)
9894001|NCT04632771||Pilot survey: children|Survey of children 2-5 years of age (n=250)
9894002|NCT04632771||RID Pilot 1|Two-week study to assess total body vitamin A stores in a sample of non-pregnant, non-lactating women 15-49 years of age (n=30)
9894003|NCT04632771||RID Pilot 2|"Kinetic study with Super-woman design to develop a prediction equation to assess total body vitamin A stores among non-pregnant, non-lactating women 15-49 years of age (n=123)"
9894004|NCT04632771||Focus group discussions|Focus group discussions conducted among women of reproductive age, older women, and men (n=120 total)
9894005|NCT04632771||Market assessment|Survey of retail outlets selling fortified staple foods and/or bouillon (n=50 shop owners or operators)
9894006|NCT04632771||Recipe observations|Observations of cooking of local dishes by selected participants (n=50) enrolled in the pilot survey.
9894007|NCT04631445|Experimental|Ketogenic (KD) + Triplet|Ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
9894008|NCT04631445|No Intervention|Non-ketogenic + Triplet|Non-ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
9894009|NCT04629443|Experimental|S64315 (also referred as MIK665) with azacitidine|
9894010|NCT04626596|Experimental|ENG implant|Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
9894011|NCT04612725|Experimental|Benralizumab Arm 1|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
9894012|NCT04612725|Experimental|Benralizumab Arm 2|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
9894013|NCT04612725|Experimental|Benralizumab Arm 3|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
9517753|NCT03303352|Experimental|Slow Pass First - Fast Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as slow pass first, fast pass second."
9800248|NCT01682837|Experimental|Placebo, KCit, KCl, KMgCit|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9894014|NCT04612725|Experimental|Benralizumab Arm 4|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
9894015|NCT04612725|Experimental|Placebo and Benralizumab|Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
9894016|NCT04607954|Experimental|Group 1 (durvalumab, topotecan hydrochloride)|Patients receive durvalumab IV over 60 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9894017|NCT04607954|Experimental|Group 2 (durvalumab, lurbinectedin)|Patients receive durvalumab IV over 60 minutes on day 1 and lurbinectedin IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9894018|NCT04587791|Active Comparator|CBD 400mg|CBD 400 mg
9894019|NCT04587791|Active Comparator|CBD 800mg|CBD 800mg
9894020|NCT04587791|Active Comparator|CBD 1200mg|CBD 1200mg
9894021|NCT04587791|Placebo Comparator|Saline|saline
9894022|NCT04583748|Experimental|Sahaj Samadhi Meditation|Participants randomized to the Sahaj Samadhi Meditation (SSM) arm will undergo SSM training in groups of 10. SSM will be delivered virtually using the Cisco WebEx platform by trained, certified non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
9894023|NCT04583748|Active Comparator|Health Enhancement Program|Participants randomized to the Health Enhancement Program (HEP) arm will undergo HEP training in groups of 10. HEP will be delivered virtually using the Cisco WebEx platform by trained non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
9894024|NCT04583748|No Intervention|Treatment as Usual|Participants randomized to the Treatment as Usual (TAU) arm will continue to receive their treatment as usual. The usual standard of care for irreversible age-related vision patients includes no active treatment since eye surgeons have done all that could possibly be done to restore vision.
9894025|NCT04583280|Experimental|Rilematovir|Participants will receive rilematovir orally based on body weight and age group.
9894026|NCT04583280|Experimental|Placebo|Participants will receive matching placebo of rilematovir based on body weight and age group.
9894027|NCT04571827|Experimental|Placebo Effect|"Group with positive expectation: it is a very effective technique that achieves excellent results in the improvement of the cervical musculature~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
9894028|NCT04571827|Experimental|Nocebo Effect|"Group with negative expectation: this is a technique that will cause discomfort in the area of intervention of the cervical muscles after applying it .~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
9894029|NCT04571827|Experimental|Neutral Effect|"Group with neutral expectations: It's a physical therapy technique used to treat neck pain and we're investigating its effects~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
9894030|NCT04569942|Active Comparator|Vasopressor|a restricted fluids and early vasopressor strategy
9894031|NCT04569942|Active Comparator|Fluids|a larger intravenous (IV) fluid volume and later vasopressor strategy
9894032|NCT04568122|Experimental|Saliva test|Participants perform each test assay, noting the results for comparison by technician, and completing survey questionnaires.
9894033|NCT04564027|Experimental|Cohort A|Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.
9894034|NCT04564027|Experimental|Cohort B|Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.
9894035|NCT04553367|Placebo Comparator|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
9894036|NCT04553367|Active Comparator|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
9800249|NCT01682837|Experimental|Placebo, KCl, KMgCit, KCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9894037|NCT04542278|Active Comparator|Steroids|Participants randomized to the steroid arm will be given a prescription for prednisone 20mg daily for 7 days prior to surgery, otherwise, pre-operative standard of care
9894038|NCT04542278|No Intervention|No Steroids|Pre-operative Standard of Care
9894039|NCT04539704|Experimental|Healthy Adults-magnet|Healthy adults with magnet and/or sham
9894040|NCT04539704|Sham Comparator|Healthy Adults-sham|Healthy adults with magnet and/or sham
9894041|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (subcutaneous)|20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
9894042|NCT04530838|Active Comparator|13-valent pneumococcal conjugate vaccine (subcutaneous)|13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
9894043|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (intramuscular)|20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)
9894044|NCT04521686|Experimental|LY3410738|Phase 1 dose escalation - Multiple doses of LY3410738 Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
9894045|NCT04520425|Experimental|Intervention|Participants will receive 5 standardized osteopathic manipulative treatments, two weeks apart. (To be considered a study completer, a participant must complete at least 3 of these treatments.) In addition to assessments at intake and during treatments, 1 and 3 months after their last treatment patients will be asked to provide follow-up data. Assessments include the HIT-6, MIDAS, and MSQ surveys, treatment satisfaction assessments, and a headache diary. Participants will also consent to an electronic medical record extraction of medication and healthcare services utilization.
9894046|NCT04518449||SMA group|the medial border along the left side of superior mesenteric artery (SMA)
9894047|NCT04518449||SMV group|the medial border along the left side of superior mesenteric vein (SMV)
9894048|NCT04505553|Experimental|Arm I (acupuncture, acupressure, cryotherapy)|Patients undergo acupuncture during chemotherapy infusion on day 1 and fluorouracil pump disconnect on day 3 of each biweekly chemotherapy infusion over 12 weeks. Patients also undergo self-administered acupressure over 11 minutes daily for 12 weeks and undergo standard of care oral cryotherapy.
9894049|NCT04505553|Active Comparator|Arm II (cryotherapy)|Patients undergo standard of care oral cryotherapy.
9894050|NCT04502082|Experimental|ET140203 TCells|ET140203 T Cells
9894051|NCT04500665|Experimental|Colchicine|Colchicine 0.3 mg once daily
9894052|NCT04500665|Placebo Comparator|Placebo|Placebo once daily
9894053|NCT04493853|Experimental|Capivasertib + Abiraterone|Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
9894054|NCT04493853|Placebo Comparator|Placebo + Abiraterone|Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
9894055|NCT04492722|Experimental|AZD5718 Dose 1 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 1 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
9894056|NCT04492722|Experimental|AZD5718 Dose 2 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 2 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
9894057|NCT04492722|Experimental|AZD5718 Dose 3 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 3 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
9894058|NCT04492722|Placebo Comparator|Placebo + Dapagliflozin 10 mg|Participants will receive once daily oral dose of placebo matched to AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
9894059|NCT04475926||LGMD2E/R4 Cohort|Patients with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
9894060|NCT04475926||LGMD2D/R3 Cohort|Patients with LGMD2D/R3 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
9894061|NCT04475926||LGMD2C/R5 Cohort|Patients with LGMD2C/R5 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
9894062|NCT04466072||High Ventricular Arrhythmia burden group|"Inclusion criteria for all groups:~age >18 years-old~competent and willing to provide consent~presence of implantable cardioverter-defibrillator~diagnosis of cardiomyopathy~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment~Inclusion criteria for high ventricular arrhythmia burden group:~• at least one episode of sustained VT/VF or VT/VF requiring ICD therapies within the preceding 3 months as assessed on device interrogation at the time of study enrollment~Both groups will have stool sample collected for microbial analysis. This is anticipated twice for the high ventricular arrhythmia (VA) burden group. Once at the time of diagnosis of VA and later after the clinically indicated treatment for the VA."
9894063|NCT04466072||Control group|"Inclusion criteria for all groups:~age >18 years-old~competent and willing to provide consent~presence of implantable cardioverter-defibrillator~diagnosis of cardiomyopathy~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment~Inclusion criteria for control group:~• no VT/VF on device interrogation for a period of at least 3 months preceding study enrollment~Both groups will have stool sample collected for microbial analysis. This is anticipated only once for the control group."
9894064|NCT04457700||Triple-negative and HER2 Positive breast cancer|Patients with triple-negative or HER2 Positive breast cancer, axillary lymph node metastasis who underwent NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis. CT-based radiomics will be uesd in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.
9894065|NCT04452149|Placebo Comparator|Observation Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed per standard of care for heart failure management without visibility to the heart failure sensor data. Subjects will transition to the intervention arm after 13 months.
9894066|NCT04452149|Experimental|Intervention Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed using an integrated device diagnostic-based risk stratification algorithm combined with a clinical medication plan.
9932538|NCT00950066|Active Comparator|Irbesartan 300 mg|"Active Comparator: Irbesartan~Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg once a day."
9932539|NCT00950066|Active Comparator|Irbesartan 300 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day."
9932540|NCT00950079|Experimental|Sodium bicarbonate|sodium bicarbonate
9932541|NCT00950079|Active Comparator|Saline|saline infusion
9932542|NCT00950092|Other|Treatment|
9932543|NCT00950105|Experimental|CPSI-2364 1 mg p.o.|Single dose
9932544|NCT00950105|Experimental|CPSI-2364 10 mg p.o.|single dose
9932545|NCT00950105|Experimental|CPSI-2364 30 mg p.o.|single dose
9932546|NCT00950105|Experimental|CPSI-2364 90 mg|single dose
9932547|NCT00950105|Experimental|CPSI-2364 270 mg p.o.|single dose
9932548|NCT00950118||Congenital Diaphragmatic Hernia (CDH)|Humans affected with congenital diaphragmatic hernia (CDH)
9932549|NCT00950118||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
9932550|NCT00950131|Experimental|Directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs.~This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record."
9932551|NCT00950131|Experimental|Non-directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs.~This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market."
9932552|NCT00950131|Experimental|No new drug warning|Survey contains information about when the drug was approved by the FDA (2009) only.
9932553|NCT00950157|Experimental|"Directive open question statement"|"Survey describes the surrogate outcome of the drug along with a directive warning (i.e., stating the issue and why it matters) for drugs shown to improve surrogate outcomes.~This directive warning mentions that it is not known whether the drug will help patients feel better, and that readers should ask their doctor if there is an available drug shown to improve patient outcomes."
9932554|NCT00950157|Experimental|Non-directive open question statement|"Survey describes the surrogate outcome of the drug along with a non-directive warning (i.e., stating the issue only) for drugs shown to improve surrogate outcomes.~This non-directive warning mentions only that it is not known whether the drug will help patients feel better."
9932555|NCT00950157|Experimental|No open question statement|Survey only describes the surrogate outcome of the drug.
9932556|NCT00950196|Experimental|amantadine (PKMERZ)|
9932557|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l."
9932558|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp with Endolipide and heparin|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l but will be also infused with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids."
9932559|NCT00950209|Active Comparator|hyperglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose."
9932560|NCT00950222|Experimental|1:Imipenem/Amikacin|"patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.~Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours~Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment"
9932561|NCT00950261|Experimental|tri-weekly cisplatin|Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
9894067|NCT04446351|Experimental|Participants receiving GSK6097608 monotherapy (Arm A)|Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
9894068|NCT04446351|Experimental|Participants receiving GSK6097608 plus dostarlimab (Arm B)|Participants will be administered an IV infusion of GSK6097608 every 3 weeks in escalating doses followed by an IV infusion of dostarlimab (every 3 weeks for 4 doses and every 6 weeks thereafter).
9894069|NCT04446351|Experimental|Participants receiving dostarlimab monotherapy (Arm D)|Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).
9894070|NCT04446351|Experimental|Participants receiving dostarlimab plus GSK4428859A (EOS884448) (Arm E)|Participants will be administered an IV infusion of dostarlimab every 3 weeks followed by an IV infusion of GSK4428859A (EOS884448) every 3 weeks.
9894071|NCT04446351|Experimental|Participants receiving dostarlimab plus GSK4428859A (EOS884448) plus GSK6097608 (Arm F)|Participants will be administered an IV infusion of dostarlimab every 3 weeks followed by an IV infusion of GSK4428859A (EOS884448) every 3 weeks followed by an IV infusion of GSK6097608 every 3 weeks.
9894072|NCT04434092|Experimental|Arm A (Crovalimab)|Adult Participants will receive an initial intravenous (IV) loading dose on Week 1 Day 1, followed by 4 weekly crovalimab subcutaneous (SC) doses on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter, for a total of at least 24 weeks of study treatment.
9894073|NCT04434092|Active Comparator|Arm B (Eculizumab)|Adult Participants will receive initial IV weekly doses for 4 weeks which will be followed by Q2W (every 2 weeks) IV administrations starting on Week 5.
9894074|NCT04434092|Experimental|Arm C (Crovalimab) (Exploratory)|Paediatric participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
9894075|NCT04432584|Experimental|Arm A (Crovalimab)|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
9894076|NCT04432584|Active Comparator|Arm B (Eculizumab)|Participants will receive an approved maintenance dose of eculizumab starting on Day 1 and Q2W (every 2 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of study eculizumab treatment, participants will have the option to switch to crovalimab or to discontinue from the study after completion of 10 weeks of safety follow-up.
9894077|NCT04432584|Experimental|Arm C (Crovalimab) (Exploratory)|Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
9894078|NCT04429022|Experimental|Prospective cohort|"Pre-Op:~Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op)~Acetaminophen 1000mg PO x1 prior to surgery (in pre-op)~Intra-Op:~Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point) for total of 20mL~Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL~Will operate at <15mmHg intra-abdominal pressure, with goal of <12mmHg~At end of procedure during closure of fascia, give 30mg ketorolac IV x 1~Post-Op:~Gabapentin 300mg PO BID for 7 days~Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN~Celecoxib 200mg PO q 12h x 7d~Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 x 5mg upon discharge (90MME) if patient did not use any opioids postoperatively while inpatient, will not prescribe opioid medication upon discharge"
9894079|NCT04429022|Active Comparator|Historical Control|Traditional post-operative opioid medication regimen: Dilaudid 1mg IV PRN q3h while inpatient; Perocets 12 x 5mg/325 (90MME) upon discharge
9894080|NCT04413279|Active Comparator|Lipiflow Only Group|Patients with dry eye disease Lipiflow only
9894081|NCT04413279|Experimental|Lipiflow + Dextenza Group|Patients with dry eye disease Lipiflow + Dextenza
9517754|NCT03303326|Experimental|Immediate Interview|A 60-minute interview about women's health conducted immediately after baseline questionnaires.
9517755|NCT03303326|No Intervention|Delayed Interview|The interview is conducted after the follow-up questionnaires are completed, rather than after baseline.
9894082|NCT04413253|Active Comparator|Xiidra Only Group|Patients with dry eye disease Xiidra only
9894083|NCT04413253|Experimental|Xiidra + Dextenza Group|Patients with dry eye disease Xiidra + Dextenza
9894084|NCT04391322||Group 1|Healthy participants without lung disease
9894085|NCT04391322||Group 2|Participants with stable cystic fibrosis
9894086|NCT04391322||Group 3|Participants with cystic fibrosis, anticipated to receive treatment with CFTR-modulator therapy. Please note: treatment is determined by your physician as part of your normal therapy plan.
9894087|NCT04383873|Experimental|Intervention|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
9894088|NCT04383873|Active Comparator|Control|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
9894089|NCT04380649|Experimental|ALS people with severe disability|
9894090|NCT04368676|Experimental|Sudarshan Kroya Yoga (SKY)|Sudarshan Kriya Yoga (SKY) will be delivered using the Hospital approved Cisco WebEx platform. The online version of SKY will be delivered by at least one certified Canadian SKY teacher, with at least one back up teacher, under the supervision of Ms. Ronnie Newman, Director of Research and Health Promotion, Art of Living Foundation, USA. The online version of SKY for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered.
9894091|NCT04368676|Active Comparator|Health Enhancement Program (HEP)|The Health Enhancement Program (HEP) will be delivered using the Hospital approved Cisco WebEx platform. The online version of HEP for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered. HEP will be taught by Dr. Paris Lai, co-investigator and senior psychiatry resident.
9894092|NCT04362072|Experimental|Lorlatinib|Participants will take 100 mg (four, 25 mg tablets) once daily.
9894093|NCT04351113|Experimental|MITO-AO|Healthy older adult subjects ages 65-75 will take the supplement MITO-AO during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (31P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
9894094|NCT04351113|Experimental|PB-125|Healthy older adult subjects ages 65-75 will take the supplement PB-125 during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
9894095|NCT04351113|Placebo Comparator|Placebo|Healthy older adult subjects ages 65-75 will take placebo during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
9894096|NCT04344028|Experimental|True Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program improves performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
9894097|NCT04344028|Active Comparator|True Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
9894098|NCT04344028|Placebo Comparator|Control Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program increases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
9894099|NCT04344028|Sham Comparator|Control Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
9894100|NCT04333407|Experimental|Active Arm|
9894101|NCT04333407|No Intervention|Control Arm|
9894102|NCT04317482|Other|Standard social stress task|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three standard scenarios presented in counterbalanced order. This will involve approximately 30 minutes of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
9932562|NCT00950274|Active Comparator|CD133+ autologous bone marrow stem cells|
9517756|NCT03303313|Experimental|Cemdisiran|
9932563|NCT00950274|Placebo Comparator|Placebo|
9932564|NCT00950287||cohort|One group of preterm infants
9894103|NCT04317482|Other|Stressful experience in the ED|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three experiences surrounding their most stressful ED visit. These experiences are presented in counterbalanced order. This will involve approximately 30 of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
10212097|NCT02733042|Experimental|Arm B: Durvalumab + Ibrutinib|"Participants assigned to Arm B will receive:~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason.~All treatment cycles were 28 days."
9894106|NCT04290546|Experimental|Cohort I without Ipilimumab Lead in|"Haploidentical donor derived CIML NK cell infusion with subcutaneous N-803 for eligible patients with platinum-refractory and immune checkpoint blockade-refractory, advanced head and neck squamous cell carcinoma (Cohort 1)~CIML NK cell infusion (Dose 0 or -1) infused on Day 0.~Interleukin-15 Superagonist dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles)."
9894107|NCT04290546|Experimental|Cohort 2 with Ipilimumab Lead In|"Cohort 2 treated with an ipilimumab lead-in prior to CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone.~Participants in the ipilimumab subgroup (Cohort 2) will receive a single dose of lead-in ipilimumab via iv per protocol determined dose followed by lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.~CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0~Interleukin-15 Superagonist (N-803) Administration~-- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~Cohort 2 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
9894108|NCT04286529|Active Comparator|Men-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
9894109|NCT04286529|Active Comparator|Premenopausal Women-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
9894110|NCT04286529|Placebo Comparator|Men-Placebo|0.25mcg capsule daily for eight weeks
9894111|NCT04286529|Placebo Comparator|Premenopausal Women-Placebo|0.25mcg capsule daily for eight weeks
9894112|NCT04286373|Experimental|Active stimulation then placebo stimulation|"VNS active for 12 weeks, then VNS placebo for 12 weeks.~The VNS placebo stimulation period being the control one."
9894113|NCT04286373|Experimental|Placebo stimulation then active stimulation|"VNS placebo for 12 weeks, then VNS active for 12 weeks.~The VNS placebo stimulation period being the control one."
9894114|NCT04269200|Active Comparator|Arm A (control)|Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
9894115|NCT04269200|Experimental|Arm B (durvalumab+placebo)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
9894116|NCT04269200|Experimental|Arm C (durvalumab+olaparib)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
9894117|NCT04268264|Experimental|Treatment arm|Will receive trial intervention, Incremental haemodialysis (n=20)
9894118|NCT04268264|Other|Control arm|Historical controls. Matched controls from database of historical patients receiving conventional, three times weekly haemodialysis treatment (n=40)
9894119|NCT04260958|Experimental|Intervention center|Patients at intervention centers will be offered remote video exCR (first-hand option) or usual care centre-based exCR. The exercise program (remote/centre-based) will be standardized and performed for totally 60 minutes, 2 times a week for 3 months. Exercise will be individually prescribed and progressed by physiotherapists in accordance with guidelines. Patients will also be asked to perform one additional session of at least 30 min aerobic exercise per week, at intensity level 13-15 according to Borg RPE-scale.
9894120|NCT04260958|No Intervention|Control|At control centers, patients will be offered usual care centre-based exCR only.
9894121|NCT04258917|Experimental|Total Knee Arthroplasty|
9894122|NCT04258917|Experimental|Anterior Cruciate Ligament Reconstruction|
9894123|NCT04254978|Experimental|IMG-7289|IMG-7289 administered daily for 169 consecutive days
9894124|NCT04254783|Experimental|Cytochrome P450 (CYP) + Risankizumab|In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
9894125|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1a)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
9894126|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)|Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
9894127|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1c)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
9894128|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)|Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
9932565|NCT00950313|Active Comparator|Self Assessment|Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
9894129|NCT04248725|Experimental|E-TIPS|The E-TIPS intervention is based upon a cognitive-behavioral intervention for pain that was developed for and shown to be effective in people with chronic pain and a physical disability such as the conditions of interest in this study. Eight, 45-minute telephone sessions will be delivered by a clinician. A patient workbook will be used to facilitate skill acquisition and rehearsal in and outside of sessions. The intervention includes education about the role of unhelpful thoughts, particularly pain catastrophizing, and unhelpful pain coping behaviors; instruction in how to identify and change unhelpful or negative thinking about pain; utilization of helpful coping strategies; relaxation techniques; behavioral activation including setting goals for physical activation, activity pacing and scheduling; and coping with pain flare-ups. Each session includes a brief relaxation exercise. Participants receive digital audio recordings of relaxation exercises to practice at home.
9894130|NCT04248725|No Intervention|Usual care|Participants assigned to the control intervention will continue to pursue standard care (a waitlist). Waitlist control subjects will be offered the opportunity to receive the intervention following completion of the final 6-month follow up outcome assessment.
9894131|NCT04241809||A: Notified TB with sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
9894132|NCT04241809||B: Notified TB without sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
9894133|NCT04241809||C: Not Notified for TB|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
9894134|NCT04235062|Experimental|Fluid Expansion and Diuretic Challenge|Subject receive intravenous infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution, followed by diuretic challenge with 40mg Furosemide intravenous bolus.
9894135|NCT04218071|Experimental|9-ING-41|9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.
9894136|NCT04218071|Experimental|9-ING-41 plus Ruxolitinib|9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.
9894137|NCT04192929|Placebo Comparator|High definition white light endoscopy|colonoscopy performed using high definition equipment
9894138|NCT04192929|Active Comparator|Chromoendoscopy|indigo carmine is sprayed on the colon mucosa during withdrawal phase
9894139|NCT04192929|Experimental|Narrow band imaging|Narrow band imaging is used during withdrawal phase
9894140|NCT04180176|Experimental|All-Comer Cohort|Participants with mNSCLC or ES-SCLC will give blood samples at three separate timepoints for ctDNA profiling.
9894141|NCT04180176|Experimental|Front-line Immunotherapy Re-enrollment Cohort|Participants with mNSCLC or ES-SCLC that have received front-line treatment as defined by the protocol will give blood samples at three separate timepoints for ctDNA profiling.
9894142|NCT04166513|Experimental|Targeted tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions before.
9894143|NCT04166513|Active Comparator|Active Control tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with active control tDCS for 10 therapy sessions.
9894144|NCT04166513|Experimental|Targeted tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with targeted anodal-tDCS for 10 therapy sessions.
9894145|NCT04166513|Active Comparator|Active Control tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with active control tDCS for 10 therapy sessions.
9894146|NCT04156997||Patients with extreme lipid phenotypes|Adult patients (age 18 years or older) diagnosed with any lipid or metabolic disorder including hyperlipidemia, dyslipidemia, hyperlipoproteinemia, low HDL levels and deranged lipoprotein metabolism
9894147|NCT04156997||Healthy volunteers|Healthy adult volunteers with normal lipid metabolism will be recruited for the purpose of comparison
9894148|NCT04153149|Experimental|Vutrisiran 25 mg|Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period.
9894149|NCT04153149|Placebo Comparator|Placebo|Participants will receive placebo during the double-blind period.
9894150|NCT04146467|Experimental|Arm 1|Subjects will be treated with the Renuvion APR device.
9894151|NCT04141748|Active Comparator|Hand Casting|hand cast will be taken using a circumferential plaster of Paris or fiber glass wrap of the residual limb with the subject in a seated position
9517757|NCT03303287|Experimental|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
9894152|NCT04141748|Active Comparator|standing hydrostatic pressure casting with a water cylinder|hand cast will be taken using a circumferential plaster of Paris wrap of the residual limb with the subject in a seated position. The residual limb is then placed into the Symphonie Aqua System while in a weight bearing standing position.
9894153|NCT04139967|Experimental|Elderly rectal cancer patients|
9894154|NCT04099511|Active Comparator|Usual Care Occupational Therapy-Outpatient|
9894155|NCT04099511|Experimental|Cognitive Orientation to daily Occupational Performance|
9894156|NCT04092686|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
9894157|NCT04092686|Experimental|SEP-363856 100mg|SEP-363856 100mg dosed once daily
9894158|NCT04092686|Placebo Comparator|Placebo|Placebo dosed once daily
9894159|NCT04089046|Experimental|TEAM-UP for Teens Intervention|TEAM-UP for Teens pairs school-based and video-supported directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
9894160|NCT04089046|Active Comparator|Enhanced Care Comparison|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
9894161|NCT04088864|Experimental|R/R B-ALL|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
9894162|NCT04088864|Experimental|Lymphoma|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
9894163|NCT04071847||Deep brain stimulation|Subjects implanted with an Abbott DBS system
9894164|NCT04070183|Other|Attention Control (Home Safety Evaluation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family member (if they've designated one), in which he or she will provide suggestions on how to improve the safety of the patient's home.
9894165|NCT04070183|Experimental|Intervention (POST Facilitation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family (if they've designated one), in which he or she will provide education about the POST form. The POST facilitators will be nurses trained using the Respecting Choices Advanced Steps model.
9894166|NCT04068155|Experimental|DaRT Seeds Intratumoral Diffusing alpha-emitters|An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.
9894167|NCT04067674||Septic shock patients|Patients included in this cohort will have blood sampling for measurement of immune related biomarkers (immunophenotyping, functional tests, messenger ribonucleic acid (mRNA), circulating markers) in circulating blood and their associations with relevant clinical outcomes
9894168|NCT04066361|Experimental|Chatbot|"Participant is given a pamphlet introducing genetic testing~Participant is given information utilized for clinical, standard of care testing.~Will receive genetic information with a virtual interactive Chatbot prior to genetic testing. After the Chatbot education, participant is asked if they would like to proceed with genetic testing.~Participant is asked to complete an electronic family history tool"
9894169|NCT04066361|Experimental|Video Education|"Participant is given a pamphlet introducing genetic testing~Participant is given information utilized for clinical, standard of care testing.~Participant will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing. After the video education, participant is asked if they would like to proceed with genetic testing.~Participant is asked to complete an electronic family history tool"
9517758|NCT03303287|No Intervention|control|usual
9894170|NCT04061577|Experimental|Stimulation arm|"Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers:~Tier 1 - 1 mA, and Tier 2- 2 mA: Consist of a single stimulation cycle (20min) after the endovascular procedure (EVT) in patients with TICI<2c,3 and negative immediate post-EVT CT scan for definitive evidence of ICH.~Tier 3 - 1 mA and Tier 4- 2mA consist of 2 treatment cycles after the EVT in patients with TICI<2c and 3, and negative immediate post-EVT CT scan for definitive evidence of ICH.~Tier 5 - 1 mA and tier 6- 2 mA consist of 3 treatment cycles. The first cycle will be up to 20 min cycle, after initial imaging and prior to arterial puncture, the second and third cycles after EVT in patients with TICI<2c and 3 and negative immediate post-EVT CT scan for definitive evidence of ICH."
9894171|NCT04061577|Sham Comparator|Sham arm|Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without delivery of electrical stimulation.
9894172|NCT04061018||High Cholesterol Efflux|Dallas Heart Study participants who are above the sex and ethnicity specific 90th % of cholesterol efflux
9894173|NCT04061018||Low Cholesterol Efflux|Dallas Heart Study participants who are below the sex and ethnicity specific 10th % of cholesterol efflux
9894174|NCT04041921||Chronic coronary occlusion patients|≥3 months chronic total occlusion on coronary angiography
9894175|NCT04038138|Experimental|Patient with muscular dystrophy|
9894176|NCT04035486|Active Comparator|Osimertinib 80mg QD|"Osimertinib (AZD9291) 80mg QD.~All patients randomized into this will only receive Osimertinib 80mg.~Dose may be reduced to allow for the management of IP related toxicity."
9894177|NCT04035486|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|"Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.~Dose may be reduced to allow for the management of IP related toxicity."
9894178|NCT04029116|Experimental|Ibrexafungerp|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
9894179|NCT04029116|Placebo Comparator|Placebo|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days
9894180|NCT04020185|Experimental|Ph I Monotherapy|"Dose escalation design in which administered dose levels of IMSA101 as monotherapy will be escalated stepwise in successive cohorts of 3 to 6 patients per dose group (using a standard 3+3 study design) of IMSA101 until the RP2D or maximum tolerated dose (MTD) level is identified.~The first patient enrolled in each dose level must complete the first two weeks of Cycle 1 prior to enrolling the second and third patients.~Dose levels to be evaluated include (although not necessarily limited to) 100 µg (representing 1/60th of the pre-clinical Highest Non-Severely Toxic Dose [HNSTD] dose), 200 µg, 400 µg, 800 µg, and 1,200 µg."
9894181|NCT04020185|Experimental|Ph I Combination Therapy|"Ph I combination dosing of IMSA101 shall be evaluated upon satisfaction of the following criteria:~A given dose level (combo dose level 1) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).~The next higher dose level (combo dose level 2) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).~The dose level (combo dose level 1) is found to demonstrate adequate IMSA101 pharmacodynamic (PD) activity based on exploratory endpoints.~Eligible patients shall have demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1/PD-L1-targeted ICI with no Grade ≥ 3 CTCAE events considered to be drug-related.~Safety evaluations and dose escalation of IMSA101 administered in combination with current therapy shall proceed in a manner consistent with monotherapy escalation and shall proceed independently of monotherapy dose escalation."
9894182|NCT04020185|Experimental|Ph II Monotherapy (Arm A)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as monotherapy~Tumor type to be evaluated will be identified prior to Phase IIA commencement and will be documented in a protocol amendment."
9894183|NCT04020185|Experimental|Ph II Combination Therapy (Arm B)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with PD-1/PD-L1 targeted immune checkpoint inhibitors.~This arm shall include a safety run-in of 5-10 patients.~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment."
9932566|NCT00950313|Active Comparator|Electronic risk score|Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
9932567|NCT00950326|Active Comparator|B1-Physio|In Group B1, patients will be given physiotherapy of the hip or knee joint three times a week
9517759|NCT03303274|Experimental|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally before subclavian venous catheterization.
9517760|NCT03303274|No Intervention|Supine|Catheterization of right subclavian vein in supine position.
9894184|NCT04020185|Experimental|Ph II Combination Therapy (Arm C)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with non-PD-1/PD-L1-targeted immuno-oncology (IO) drugs approved by the FDA.~This arm shall include a safety run-in of 5-10 patients.~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment.."
9667175|NCT03875183|Placebo Comparator|Placebo|Placebo dose to be given twice daily using 3 placebo capsules at each dose
9894185|NCT04019964|Experimental|Nivolumab in biochemically recurrent prostate cancer|"Participants with previous prostatectomy or radiation therapy who subsequently developed detectable prostate specific antigen (PSA) levels (biochemically recurrent prostate cancer)."
9894186|NCT04019015|Experimental|Kcentra|"A single dose of Kcentra based on estimated body weight~2000 U for patients with an estimated body weight ≤ 75kg~3000 U for patients with an estimated body weight > 75kg"
9894187|NCT04019015|Placebo Comparator|Placebo|A single infusion of volume matched placebo solution (Normal Saline)
9894188|NCT04002505|Experimental|Head Injury Subject|Subjects that present to the Emergency Department with a blunt head injury within the past 24 hours, determined to be low risk by the Canadian CT Head Rules (CCHR), and are being considered for a head CT by the treating provider will use the shared decision making tool Concussion and Brain Bleed app (CBC) with their clinician
9894189|NCT03990428||Caregivers of Patients|This is an observational study of informal caregivers (ICs) of patients with Erdheim-Chester Disease (ECD) and other histiocytic diseases. That will collect data cross-sectionally, at a single time point. Caregiver-reported data will be completed in the form of online surveys by the participants themselves using the Research Electronic Data Capture Platform [RedCAP] platform.
9894190|NCT03980769|Experimental|Treatment (chemotherapy, transplant)|Patients receive thiotepa IV BID on days -7, treosulfan IV on days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.
9894191|NCT03970278||All Participants|All participants enrolled in study 401GSDIA02 will have received a single IV dose of DTX401 during their participation in study 401GSDIA01 (NCT03517085).
9894192|NCT03936192|Experimental|glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)|glucosamine sulfate 1500mg plus meloxicam 15mg combination, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
9894193|NCT03936192|Active Comparator|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg plus Chondroitin Sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.
9894194|NCT03936192|Placebo Comparator|Placebo|Placebo administered once daily for 12 weeks
9894195|NCT03929627||Group 1 - Medical personnell|Group 1 consists of 70 participants belonging to medical staff of the Medical University of Vienna/University Hospital of Vienna and is divided into subgroups consisting of medical technical assistants, nurses, assistant physicians and physicians.
9894196|NCT03929627||Group 2 - Control|Group 2 consists of 70 participants and is recruited from the General non-medical staff of the Austrian Federal Ministry of Defence and Sports, Austrian Armed Forces.
9894197|NCT03915652|Experimental|Rheum iCMP Wave 1|20 patients enrolled immediately in Rheum iCMP
9894198|NCT03915652|Experimental|Rheum iCMP Wave 2|20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months
9894199|NCT03915652|Experimental|BWH iCMP to Rheum iCMP|100 lupus patients within the Partners system who are already enrolled in BWH iCMP will have their iCMP nurse trained in lupus-specific care
9894200|NCT03915223|Experimental|"Arm Injection corticosteroids"|Single dose of Solumedrol 2 mg/kg
9894201|NCT03915223|Placebo Comparator|"Arm  injection physiological serum"|Single dose of physilogical serum
9894202|NCT03901729|Experimental|Arm 1|BAY1753011 30mg in addition to standard of care (SoC) for part A and part B
9894203|NCT03901729|Placebo Comparator|Arm 2|Placebo of BAY1753011 in addition to SoC for part A and part B
9894204|NCT03901729|Experimental|Arm 1-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
9894205|NCT03901729|Active Comparator|Arm 1-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
9894206|NCT03901729|Experimental|Arm 2-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
9894207|NCT03901729|Active Comparator|Arm 2-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
9894208|NCT03897335|Active Comparator|Aminophylline pre CPB & immediately post CPB|
9894209|NCT03897335|Placebo Comparator|Placebo|
9894210|NCT03896230|Active Comparator|Arm 1: 0.1 mg/kg ketamine|0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
9932568|NCT00950326|Experimental|A1 Hydro|In this group patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region.
9991343|NCT01452100|Experimental|prednisone|• Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
9991344|NCT01452100|Placebo Comparator|placebo|Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
9991345|NCT01452113|Other|neuropathy|patients with autonomic neuropathy
9991346|NCT01452113|Other|control|patients without autonomic neuropathy (ewing score <= 0.5)
9991347|NCT01452139|Experimental|At-Risk Genetics Arm: Prasugrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.
9991348|NCT01452139|Active Comparator|At-Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.
9991349|NCT01452139|Active Comparator|Low Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.
9991350|NCT01452204|Experimental|Pulsed Electromagnetical Field|
9991351|NCT01452204|Placebo Comparator|Placebo|
9991352|NCT01452217|Experimental|Secretin|
9991353|NCT01452230|Experimental|Supervised physical activity|
9991354|NCT01452230|No Intervention|Usual care|
9991355|NCT01452243|Experimental|Calcium and vitamin D|The pharmacological intervention will be the daily administration of chewable tablets containing vitamin D and calcium.
9991356|NCT01452256|Experimental|Desflurane|Desflurane for pharmacological conditioning
9991357|NCT01452256|Experimental|Propofol|
9991358|NCT01452282||Ankle Brachial Index|
9991359|NCT01452295|Experimental|AOCH patients|Patients with acute on chronic hepatitis
9991360|NCT01452295|Experimental|AAH patients|Patients with acute alcoholic hepatitis
9991361|NCT01452321|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
9991362|NCT01452321|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of active rTMS delivered to the left dorsolateral prefrontal cortex.
9991363|NCT01452334|Experimental|Arm 1: BMS-936559|
9991364|NCT01452360||Collection of CKD patient group|
9991365|NCT01452360||Collection of CKD high-risk group|
9667176|NCT03874858|Experimental|Nilotinib|Oral 300 mg hard capsules taken once a day
9991366|NCT01452360||Collection of healthy control group|
9991367|NCT01452373|Placebo Comparator|Control (placebo)|
9991368|NCT01452373|Experimental|DHEA + Acolbifene|
9991369|NCT01452386||Experimental Group|
9991370|NCT01452386||Control Group|
9991371|NCT01452399|Experimental|Shave Margins|
9991372|NCT01452399|Active Comparator|No shave margins|
9991373|NCT01452438||MenACYW-CRM vaccinated children|All children between the age of 2 to 10 years old who have received of MenACYW-CRM vaccine during the study period.
9991374|NCT01452464||MenACYW-CRM vaccinated adolescents|All adolescent recipients of MenACYW-CRM vaccines during the study period. Among these, adolescents who have additionally experienced an event of interest within the 1-year observation period following vaccination will be included in the self-controlled case series.
9991375|NCT01452477|Active Comparator|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
9991376|NCT01452477|Placebo Comparator|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
9991377|NCT01452490|Experimental|Diode Laser Treatment|
9991378|NCT01452503|Active Comparator|PATH Women's Condom|PATH Women's Condom
9991379|NCT01452503|Active Comparator|FC2 female condom|Female Health Company's FC2 female condom
9991380|NCT01452503|Active Comparator|Reddy 6 female condom (V-Amour)|Reddy 6 female condom (Commercially known as the V-Amour female condom)
9991381|NCT01452542|Experimental|Sequence 1|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: TRTR, with a 7-day washout between dosing in each period.
9997567|NCT01509976|Other|Blue|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
9894211|NCT03896230|Active Comparator|Arm 1: 0.2 mg/kg ketamine|0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
9894212|NCT03896230|Active Comparator|Arm 1: 0.3 mg/kg ketamine|0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
9894213|NCT03890718|Experimental|Photorefractive keratectomy in mile keratoconus|Photorefractive keratectomy in mile keratoconus type of corneal surface ablation in for correct refractive error
9894214|NCT03879577|Experimental|Docetaxel|Investigators will give patients docetaxel through drip every 3 weeks for four doses for 12 weeks before a repeat breast ultrasound. After breast ultrasound, if the investigator feels the injection is good, surgery will be done.
9894215|NCT03879577|Other|Herceptin|Herceptin will be given to patients under the skin of the thigh every 3 weeks for 18 times if they are HER2-positive
9894216|NCT03879577|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with a poor response to docetaxal will receive FEC injection by drip every 3 weeks.
9894217|NCT03879577|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years every 3 months for contraception and fertility preservation.
9894218|NCT03879577|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
9894219|NCT03864926|Active Comparator|Standard of Care|Standard of Care Tacrolimus
9894220|NCT03864926|Experimental|Experimental|Envarsus XR
9894221|NCT03861676|Experimental|Focal brachytherapy|"Drug: 18F-DCFPyl Other names: PET, PSMA~Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy"
9894222|NCT03856918|Experimental|PEEP 3 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 3 cm of water during thoracic surgery.
9894223|NCT03856918|Experimental|PEEP 6 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 6 cm of water during thoracic surgery.
9894224|NCT03856918|Experimental|PEEP 9 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 9 cm of water during thoracic surgery.
9894225|NCT03830866|Experimental|Durvalumab (intravenous infusion)|durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization
9894226|NCT03830866|Placebo Comparator|Placebo (matching placebo for intravenous infusion)|placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)
9894227|NCT03822871|Experimental|Cohort A-J|Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled.
9997568|NCT01510002|Active Comparator|TT|Extracapsular total thyroidectomy
9894228|NCT03822871|Experimental|Cohort K - at Recommended Phase 2 Dose|Cohort F: Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled at the recommended phase 2 dose.
9894229|NCT03782246|No Intervention|Usual Care|No intervention, participant will continue their usual care for pain and MS. We will collect information about what treatments are used by the usual care participants. They will be offered the opportunity to participate in one of the two active study treatments (MBCT or CBT) after completion of the 6-month followup.
9894230|NCT03782246|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Participants will attend eight, 2-hour group treatment MBCT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. MBCT integrates mindfulness meditation practices within a CBT-oriented framework to address not only unhelpful pain cognitions and behaviors but also attentional control, decoupling of attention from emotion, mindful cognitions, and meditative behavior.
9894231|NCT03782246|Experimental|Cognitive Behavioral Therapy (CBT)|Participants will attend eight, 2-hour group treatment CBT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. CBT focuses on increasing adaptive pain coping strategies and reducing unhelpful thoughts and behaviors related to pain. Strategies include relaxation techniques, goal-setting, activity pacing, and changing unhelpful thinking patterns.
9894232|NCT03759379|Experimental|Vutrisiran (ALN-TTRSC02)|Participants will receive vutrisiran during the Treatment and Treatment Extension Periods.
9894233|NCT03759379|Active Comparator|Patisiran|Participants will receive patisiran during the Treatment Period and will switch to vutrisiran during the Treatment Extension Period.
9894234|NCT03736863|Experimental|Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）
9894235|NCT03711305|Experimental|SHR-1316 + carboplatin + etoposide|Participants will receive SHR-1316 intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) SHR-1316 until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
9894236|NCT03711305|Active Comparator|Placebo + carboplatin + etoposide|Participants will receive placebo intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
10212098|NCT02733042|Experimental|Arm C: Durvalumab + Rituximab ± Bendamustine|"Participants assigned to Arm C will receive:~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose)~Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6.~All treatment cycles were 28 days."
10212099|NCT02733042|Experimental|Arm D: Durvalumab Monotherapy|Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.
9894239|NCT03678766|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experimental learning.
9894240|NCT03678766|Experimental|Cognitive Behavior Therapy (CBT)|CBT provides coping skills, self-monitoring, and goal setting.
9894241|NCT03674528||Control Group|Subjects with a BMI of 35 or more will be asked to undergo a single MRE imaging session.
9894242|NCT03674528||Patient Group|Adults that are candidates for weight loss surgery will be asked to participate in four study visits that include MRE imaging and 1 - 2 liver biopsy procedures.
9894243|NCT03672695|Experimental|S64315 and venetoclax administered in combination|
9894244|NCT03664427||Group 1: Patients with VOD|paediatric patients with Veno-Occlusive Disease (VOD) complicating haematological stem cell transplantation
9894245|NCT03664427||Group 2: matched controls|Paediatric patients defined as matched controls without veno-occlusive disease complicating haematological stem cell transplantation
9894246|NCT03661528|Experimental|andexanet alfa|Patients will receive one of two dosing regimens of andexanet alfa based on which FXa inhibitor they received and the amount and timing of the most recent dose.
9894247|NCT03661528|Other|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
9894248|NCT03638128|Experimental|Denosumab 3-Month Dosing Regimen|
9894249|NCT03638128|Active Comparator|Alternative Treatment|Alternative osteoporosis medication/s at the discretion of the investigator, including the commercially available denosumab on a 6-month dosing regimen.
9894250|NCT03638128|Active Comparator|No Intervention|Subjects who discontinue any osteoporosis medication when joining Study 20170534 for off-treatment observation.
9894251|NCT03636789|Experimental|Neurological consultation group|
9894252|NCT03630562|Other|Patients with exudative AMD|
9894253|NCT03608657||Psoriatic Arthritis patients treated with Apremilast|Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
9894254|NCT03604198|Experimental|relacorilant (CORT125134)|
10212100|NCT02668874|Other|Isolite System|The Isolite technique utilizes a flexible plastic dental adapter to separate the cheek and tongue prior to sealant placement.
10212101|NCT02668874|Other|Cotton Roll technique|A cotton roll is placed between the cheek and tongue prior to sealant placement.
10212102|NCT02663518|Experimental|TTI-621 Escalation Phase|The Escalation Phase will include multiple doses of TTI-621
10212103|NCT02663518|Experimental|Indolent B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
10212104|NCT02663518|Experimental|Aggressive B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
10212105|NCT02663518|Experimental|T-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
10212106|NCT02663518|Experimental|Hodgkin Lymphoma|Monotherapy expansion cohort with TTI-621
10212107|NCT02663518|Experimental|Chronic Lymphocytic Leukemia|Monotherapy expansion cohort with TTI-621
10212108|NCT02663518|Experimental|Acute Lymphoblastic Leukemia|Monotherapy expansion cohort with TTI-621
10212109|NCT02663518|Experimental|Multiple Myeloma|Monotherapy expansion cohort with TTI-621
10212110|NCT02663518|Experimental|Acute Myeloid Leukemia|Monotherapy expansion cohort with TTI-621
9894258|NCT03581786|Placebo Comparator|placebo combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 & 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years
9894259|NCT03581786|Experimental|TORIPALIMAB INJECTION(JS001 )combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 & 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years
9894260|NCT03576885|Active Comparator|Treatment group - active|inhaled nitric oxide treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
9894261|NCT03576885|Placebo Comparator|Treatment group - placebo|Placebo treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
9894262|NCT03576885|No Intervention|Control group|Enrolled infants with no evidence of pulmonary hypertension will serve as the control group for incidence of death or bronchopulmonary hypertension
9894263|NCT03574038|Active Comparator|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
9894264|NCT03574038|Sham Comparator|Sham Stimulation|Sham Stimulation
9932569|NCT00950326|Active Comparator|C- Hydro & Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
9932570|NCT00950339|Experimental|4 weeks of omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
9932571|NCT00950339|Experimental|4 weeks of famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
9932572|NCT00950339|Experimental|4 weeks of pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
9932573|NCT00950378||CVI|Varicose veins, varicose veins with leg swelling, venous stasis skin color changes, no open ulcers
9932574|NCT00950378||No treatment|Subjects with no venous disease CEAP (clinical etiology antomy pathophysiology)Class 0
9932575|NCT00950391|Experimental|Tacrolimus|Treatment with tacrolimus following nerve repair/reconstruction
9932576|NCT00950404|Active Comparator|Viagra 50 mg tablet, administered with water.|
9932577|NCT00950404|Experimental|Formulation B ODT tablet 50 mg, administered without water.|
9932578|NCT00950404|Experimental|Formulation C ODT tablet 50 mg, administered without water.|
9932579|NCT00950404|Experimental|Formulation D ODT tablet 50 mg, administered without water.|
9932580|NCT00950417|Experimental|Esophageal Cancer|
9932581|NCT00950430|Experimental|PiB PET, FDG PET, Tau PET|
9932582|NCT00950443|Experimental|1|Children with upper airway obstruction
9932583|NCT00950443|Active Comparator|2|Children without upper airway obstruction
9932584|NCT00950456||H1N1 Pandemic Influenza Vaccine|Subjects will be enrolled and vaccinated according to national policy and standard practice.
9935993|NCT02850939|Experimental|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.
10212111|NCT02663518|Experimental|Myelodysplastic Syndrome|Monotherapy expansion cohort with TTI-621
10212112|NCT02663518|Experimental|Myeloproliferative Neoplasms|Monotherapy expansion cohort with TTI-621
10212113|NCT02663518|Experimental|Small Cell Lung Cancer|Monotherapy expansion cohort with TTI-621
10212114|NCT02663518|Experimental|Rituximab Combination|Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies
9894265|NCT03573648|Active Comparator|Endocrine Therapy|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
9894266|NCT03573648|Active Comparator|Endocrine Therapy with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
9894267|NCT03573518|Experimental|BTX 1503 5% BID|BTX 1503 5% CBD (w/w) solution twice daily
9894268|NCT03573518|Experimental|BTX 1503 5% QD|BTX 1503 5% CBD (w/w) solution once daily
9894269|NCT03573518|Experimental|BTX 1503 2.5% QD|BTX 1503 2.5% CBD (w/w) solution once daily
9894270|NCT03573518|Placebo Comparator|Vehicle BID|Vehicle twice daily
9894271|NCT03573518|Placebo Comparator|Vehicle QD|Vehicle once daily
9894272|NCT03570814|Active Comparator|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
9894273|NCT03570814|Experimental|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
9894274|NCT03568084|Experimental|MEFAP|MEFAP (multicomponent physical activity program) for 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
9894275|NCT03568084|Active Comparator|Control: usual practice|No intervention. Individuals allocated to this arm, will be look after as usual in their health Centers.
9894276|NCT03561376|Other|Single arm - split scar study|Surgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half
9894277|NCT03557697|Active Comparator|wait-list control|3 measurement visits, baseline, 3, and 6 months
9894278|NCT03557697|Active Comparator|SMS intervention|3 measurement visits, baseline, 3, and 6 months
9894279|NCT03554616|Experimental|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
9894280|NCT03554616|Experimental|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
9894281|NCT03554616|Experimental|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
9894282|NCT03554616|Active Comparator|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
9894283|NCT03505554|Experimental|Lorlatinib|100 mg QD
9894284|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
9894285|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
9894286|NCT03486314|Experimental|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.
9894287|NCT03486314|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 intravenously in combination with docetaxel 75 mg/m^2 or at 20 mg/m^2 in combination with carboplatin +paclitaxel 175 mg/m^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
9894288|NCT03460236||PRP|Symptomatic early knee osteoarthritis subjects who have elected to receive PRP treatment.
9894289|NCT03454334|Active Comparator|AMO Tecnis Symfony|"Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic~-0.20~Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity."
9894290|NCT03454334|Active Comparator|AcrySof ReSTOR (Alcon Laboratories)|"Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).~6.0mm Silicone~-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision"
9894291|NCT03454334|Active Comparator|AT Lisa tri (CarlZeiss Meditec AG)|Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32
9894292|NCT03454334|Active Comparator|PanOptix(Alcon Laboratories)|"Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic~-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)"
9894293|NCT03429166|Experimental|STAIR|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
9894294|NCT03429166|Active Comparator|PCT|PCT stands for Present Centered Therapy, a non-trauma-focused treatment
9894295|NCT03425812|Experimental|Non- NSAIDS group|To withdraw NSAIDS therapy
9894296|NCT03425812|Active Comparator|NSAIDS group|To continue NSAIDS therapy
9894297|NCT03413995|Experimental|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
10212115|NCT02663518|Experimental|Nivolumab Combination|Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma
9894299|NCT03377387|Experimental|capecitabine 7/7 with neratinib|"In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days).~The MD has been determined as 240mg of neratinib and 1000mg BID of capecitabine."
9894300|NCT03337906||Participants infected with HIV-1|Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
9894301|NCT03335488|Experimental|Arm 1, RAVICTI|Used for Baseline, Treatment, Transition, Maintenance, and Safety. Dosing will be based on participants disease and treatment status at entry to the study. RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose.
9894302|NCT03335488|Active Comparator|Arm 2, NaPBA (sodium phenylbutyrate)|"Used for Baseline and Treatment. Sodium Phenylbutyrate (NaPBA). Dosing will be based on participants disease and treatment status at entry to the study.~NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
9894303|NCT03325452|Experimental|cardio-respiratory arrest|
9894304|NCT03318549|Other|Glaucoma|Patients with diagnosed glaucoma
9894305|NCT03318549|Other|Suspicious of having glaucoma|Patients with suspicious of having glaucoma based on intra-ocular pressure or optic nerve photographs with glaucoma appearance
9894306|NCT03318549|Other|Non-glaucomatous optic neuropathies;|Patients with optic neuropathies that do not look glaucomatous-like
9894307|NCT03318549|Other|Age-related macular degeneration (AMD)|Patients with diagnosed age-related macular degeneration
9894308|NCT03318549|Other|Retinal degenerations|Patients with other retinal degenerations excluding AMD
10212116|NCT02663518|Experimental|Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion cohort with TTI-621
10212117|NCT02663518|Experimental|Peripheral T-Cell Lymphoma (PTCL)|Monotherapy expansion cohort with TTI-621
10212118|NCT02663518|Experimental|Part 4: Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion Part 4 (Dose Optimization) cohort with TTI-621
10213817|NCT03085680|Placebo Comparator|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
10213818|NCT03067077|Active Comparator|SMILE|SMILE surgery
10213819|NCT03067077|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
10213820|NCT03064217|Active Comparator|CLP and 12 weeks waiting|After core build-up and initial tooth preparation, a clinical crown lengthening procedure (CLP) will be performed. Restorative treatments will be initiated 12 weeks after CLPs.
10213821|NCT03064217|Experimental|Digital impression taken at surgery|The final impression will be taken at surgery. The final crown will be delivered at suture removal.
10213822|NCT03059446|Experimental|Cenicriviroc (CVC) 150 mg|Cenicriviroc 150 mg tablet once daily in the morning with food until the study was terminated (up to approximately 4 years).
10213823|NCT03051282|Active Comparator|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
10213824|NCT03051282|Active Comparator|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
10213825|NCT03039673|Experimental|low dose interleukin-2|"Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: IL-2"
10213826|NCT03039673|Placebo Comparator|Placebo|"Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: 5% glucose water solution"
10213827|NCT03035565|Experimental|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
10213828|NCT03035565|Active Comparator|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
10213829|NCT03035565|No Intervention|Usual Care|No computerized cognitive intervention
9894309|NCT03318549|Other|Other diseases of visual pathways|Other diseases of the visual pathway not included in the previous groups
9894310|NCT03318549|Other|Healthy control group|Patients labeled as healthy controls for not having any other eye diseases that would be included on the other groups
9894311|NCT03265314|Experimental|LeadHer|The LeadHer curriculum is presented to the target population over a total of 30 hours. The program addresses the following adult preparation subjects: Healthy relationships, Adolescent development, Healthy life skills, Educational and career success. The LeadHer curriculum is also accompanied by a mobile application.
9894312|NCT03265314|Placebo Comparator|Sassy Science|The Sassy Science curriculum is presented to the target population over a total of 30 hours. The program addresses the following subjects: States of Matter, Math, Engineering, Chemistry, Arts and Crafts, Sweet Treats and Celebrations. The curriculum does not have a mobile application.
9894313|NCT03260127|Experimental|CEFT-CPT|Computerized executive function training plus Cognitive Processing Therapy for PTSD
9894314|NCT03260127|Active Comparator|WT-CPT|Word game training plus Cognitive Processing Therapy for PTSD
9894315|NCT03219268|Experimental|Dose level 1|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894316|NCT03219268|Experimental|Dose level 2|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894317|NCT03219268|Experimental|Dose level 3|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894318|NCT03219268|Experimental|Dose level 4|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894319|NCT03219268|Experimental|Dose level 5|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894320|NCT03219268|Experimental|Dose level 6|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894321|NCT03219268|Experimental|Dose level 7|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894322|NCT03219268|Experimental|Dose level 8|Tebotelimab administered IV once every 2 weeks for up to 96 weeks
9894323|NCT03219268|Experimental|Dose level 9|Tebotelimab administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles
9894324|NCT03219268|Experimental|Dose level 10|Tebotelimab administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles
9894326|NCT03203460|Experimental|Exercise Group|Supervised high-intensity aerobic interval training (HIIT) during active surveillance
9894327|NCT03203460|No Intervention|Usual Care Group|The usual care group will be provided with standard active surveillance medical care.
9894328|NCT03194893|Experimental|Alectinib|Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
9894329|NCT03194893|Experimental|Crizotinib|Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
9894330|NCT03186456|Experimental|Group 1|Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg
9894331|NCT03186456|Placebo Comparator|Group 2|Aspirin Tablet, 100mg/d; Placebo
9894332|NCT03184935|Experimental|Experimental group|Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
9517761|NCT03303248|Experimental|Web-based Educational Intervention|This group of participants will be given access to a web-based educational resource in addition to the standard of care.
9517762|NCT03303248|No Intervention|Standard of Care|This group will be given only the standard of care during their clinic visit.
9517763|NCT03303235|Experimental|IV Methergine|"IV methylergonovine group~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
9894333|NCT03184935|Placebo Comparator|Control group|Basic medication: Decitabine; placebo: saline.
9894334|NCT03180450|Experimental|Treatment group|conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.
9894335|NCT03180450|Placebo Comparator|Control group|Conventional treatment
9894336|NCT03167892|Experimental|Intervention|Oral screen
9894337|NCT03167892|No Intervention|Control|No intervention
9894338|NCT03167489|Experimental|Lifestyle Plus Emotional Regulation|The core intervention will last 5 months. Nutrition content: Mediterranean diet education, social support, self-regulation techniques, and environmental support. Physical activity content: education, guidance in starting a routine, and a walking program with pedometers, weekly physical activity tips and step goals. Emotion regulation content: based on Dialectical Behavior Therapy adapted to binge eating disorders and other ER sources, emphasizing identifying emotions, recognizing the causes of emotions, accepting and tolerating negative emotions, effective self-support and self-compassion, and the ability to manage situations that elicit negative emotions, as well as re-appraisal skills, which are identified as particularly influential on eating behaviors.
9894339|NCT03163511|Experimental|Cohort 1|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants
9894340|NCT03163511|Experimental|Cohort 2|VC-02 Combination Product; Up to twelve units implanted of which up to ten (10) are VC-02-300 implants and the rest are VC-02-20 implants.
9894341|NCT03097276|Other|Patients who underwent open decompression surgery|
9894342|NCT03096418|Experimental|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
9894343|NCT03085004|Active Comparator|Control Group|Cyst will be lavaged for 3 to 5 minutes with >/=99% ethanol. Following lavage with >/=99% ethanol, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
9894344|NCT03085004|Experimental|Study group|Cyst will be lavaged for 3 to 5 minutes with normal saline. Following lavage with normal saline, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
9894345|NCT03059485|Experimental|DC/AML Vaccine|- Patients will be vaccinated with DC/AML Fusion Vaccine
9894346|NCT03059485|Experimental|Observation|- Patients will be monitored with routine labs and bone marrow biopsies
9894347|NCT02993198|Experimental|Prophylactic Carvedilol|Carvedilol 3.125 mg by mouth every 12 hours, titrated to a max dose of 25 mg by mouth every 12 hours, depending on blood pressure and heart rate, until completion of study.
9894348|NCT02993198|No Intervention|No Therapy|Standard of care monitoring without prophylactic treatment.
9894349|NCT02988713|Experimental|Spinal cord stimulation|Spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
9894350|NCT02942823|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). Additionally, the intervention group will take the game home on a tablet computer to play it with their parents in between session 1 and 2. The game equips the children and their parents with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
9894351|NCT02942823|No Intervention|Control|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors. The parents are not involved.
9894352|NCT02916550|Experimental|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
9894353|NCT02907242|No Intervention|Concealment|Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight <p10
9894354|NCT02907242|Other|Revealment|Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio <p5
9894355|NCT02879448|Experimental|Amulet|Amulet left atrial appendage occluder
9894356|NCT02879448|Active Comparator|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
9894357|NCT02875223|Experimental|CC-90011 and Rifampicin|
9894358|NCT02875223|Experimental|CC-90011 and Itraconazole|
9894359|NCT02845453|Experimental|Quetiapine|Quetiapine
9894360|NCT02845453|Placebo Comparator|Placebo|Placebo
9894361|NCT02811744|Experimental|Amnestic MCI cohort|Patients with Mild Cognitive Impairment (MCI) (up to 14) will be recruited primarily from the Penn Memory Center (PMC). Clinical diagnostic criteria (described in further detail in Study Procedures section) will be used to identify subjects who are meet criteria for amnestic MCI. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
9894362|NCT02811744|Other|Control cohort|Normal control subjects in the same age range (up to 6) will be recruited from a current ongoing study investigating neuroinflammation in late life depression and healthy controls, from the control group in which all subjects receive MRI and LP and from the PMC research cohort. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
9894363|NCT02795858|Experimental|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with Ramucirumab at a pre-determined dose intravenously every 14 days of a 28-day treatment cycle.~Patients will receive treatment with a Somatostatin Analog at a pre-determined dose.~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
9894364|NCT02794883|Active Comparator|Treatment (durvalumab)|Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
9894365|NCT02794883|Active Comparator|Treatment (tremelimumab and durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
9894366|NCT02794883|Experimental|Treatment (tremelimumab)|Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9894367|NCT02771249|Experimental|Arm B|Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + RPT and INH once weekly (days 5-19).
9517764|NCT03303235|Active Comparator|Conventional|"IM methylergonovine group~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
9894368|NCT02754375|Experimental|Patient|Patient with resistant depression treated with rTMS
9894369|NCT02677987|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
9894370|NCT02677987|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
9894371|NCT02659059|Experimental|Nivolumab+Ipilimumab|"Part 1~Specified Dose on Specified Days"
9894372|NCT02659059|Experimental|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2~Specified Dose on Specified Days"
9894373|NCT02629692|Experimental|Vodobatinib (K0706) capsules|
9894374|NCT02520908||HSCT|Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor
9894375|NCT02520908||Standard care|Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group
9894376|NCT02419287|Experimental|crizotinib|250mg BID
9894377|NCT02384265|Experimental|IM/SMS + Incentive Condition|"Participants in the intervention condition will consist of the PWD and their two STMs. The PWD and STM will receive the same protocols that the Usual Care participants receive, including an introductory educational session, written materials on diabetes, a blood glucose log, and a physical activity monitoring log. The PWDs in this condition will also receive training in action planning with their STMs. They will also receive SMS messages supporting diabetes self-care from the study team. The study team will also encourage the STMs to interaction in person and via text messages with the PWD."
9894378|NCT02384265|No Intervention|Control|Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
9894379|NCT02347618|Experimental|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
9894380|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 30 mg BID|Subjects are randomized to receive 30 mg twice daily of enoxaparin.
9894381|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 40 mg QD|Subjects are randomized to receive 40 mg once daily of enoxaparin.
9894382|NCT02339922|Experimental|Treatment (ixazomib citrate, rituximab)|Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.
9894383|NCT02337829|Experimental|Arm A|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
9894384|NCT02337829|Experimental|Arm B|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
9894385|NCT02329470|Experimental|No device, n=50|Withdrawal of device, continuous positive airway pressure treatment during 5 nights
9894386|NCT02329470|No Intervention|Continue using device, continuous positive airway pressure treatment n=50|Control group, Continue with device, continuous positive airway pressure treatment
9894387|NCT02269592||Specimen Collection|Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol
9894388|NCT02258451|Experimental|Radium-223 dichloride + exemestane/everolimus|Up to 6 cycles of radium-223 dichloride 50kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) (randomized). Participants will also receive exemestane, 25-mg tablet once daily (after a meal), and everolimus, 10 mg once daily (with or without food), and supportive care as per the local or institutional standard of practice.
9894389|NCT02258451|Placebo Comparator|Placebo + exemestane/everolimus|Up to 6 cycles of saline injection (placebo) (randomized). Participants will also receive exemestane, 25-mg tablet once daily (after a meal), and everolimus, 10 mg once daily (with or without food), and supportive care as per the local or institutional standard of practice.
9894390|NCT02074631|Active Comparator|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
9894391|NCT02074631|Experimental|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
9935994|NCT02850939|No Intervention|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.
9517765|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
9894392|NCT02020707|Experimental|Treatment (AB-complex)|Patients receive nab-paclitaxel/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may receive paclitaxel if supply of nab-paclitaxel is exhausted.
9894393|NCT01928394|Experimental|Arm N - Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9894394|NCT01928394|Experimental|Arm N-I, Level 1: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 1 mg/kg solution every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9894395|NCT01928394|Experimental|Arm N-I, Level 2: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9894396|NCT01928394|Experimental|Arm N-I, Level 2b: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously plus Ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9894397|NCT01928394|Experimental|Arm N-I, Level 2c: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9894398|NCT01928394|Experimental|Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks and cobimetinib 60mg once daily 21days on/7 days off until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9894399|NCT01894802|Experimental|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
9894400|NCT01657500|Active Comparator|Life 4°C media for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
9894401|NCT01657500|Active Comparator|Optisol GS|Donor cornea is stored in the Optisol GS media prior to implantation.
9894402|NCT01630785||IONM patients|all patients where surgery requires IONM
9894403|NCT01628406||Patients treated at the neurosurgery department|Patients treated at the neurosurgery department
9894404|NCT01497509|Experimental|Patients electing to receive intrapartum epidural analgesia|
9894405|NCT01497509|No Intervention|Patients electing not to receive epidural analgesia|
9894406|NCT01488149||Recipients of intrapartum epidural analgesia|
9894407|NCT01488149||Non-recipients of intrapartum epidural analgesia|
9894410|NCT01260051||Epidural Recipients|
9894411|NCT01260051||Non-Epidural Recipients|
9894412|NCT01255748||Treatment with Radiation Therapy|Includes 16 different arms to capture patient data by disease site
9894413|NCT01179932||Anesthesia Record|The nursing and anesthesia records will be examined for accuracy and completeness
9894414|NCT01013649|Active Comparator|Arm I (gemcitabine hydrochloride or combination chemotherapy)|Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months.
9894415|NCT01013649|Experimental|Arm II (gemcitabine hydrochloride, erlotinib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 4/2/14)
9894416|NCT01013649|Experimental|Arm III (chemotherapy)|Patients receive the same treatment as in arm I for 1 month.
9894417|NCT01013649|Experimental|Arm IV (chemotherapy, chemoradiotherapy)|Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.
9894418|NCT00831571||All Participants|Patients receiving Oxaliplatin
9894419|NCT00831571||Desensitization|Patients that have experienced a moderate to severe hypersensitivity reaction to oxaliplatin
9894420|NCT00669734|Experimental|Treatment (vaccine therapy, sargramostim)|Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine SC on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity. Beginning on day 71, patients with no irreversible or dose limiting toxicity, receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity.
9894421|NCT00630565|Experimental|Bone Marrow Transplant (2-70 Years old)|Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
9894422|NCT00630565|Experimental|Bone Marrow Transplant (less and 2 years old)|Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
9894423|NCT00580710||conventionally treated|conventionally treated, relatively poorly controlled patients with type 1 diabetes
9517152|NCT03309046|Experimental|REACH Individual Session|The individual sessions intervention focuses on education, skills building, and support. It will be delivered in six sessions by telephone over three months. A Caregiver Notebook will include comprehensive materials for all sessions and topics. Treatment fidelity will be monitored and ensured through assessment of intervention delivery, receipt, and enactment. The intervention is targeted and individualized to the concerns of the specific caregiver and care recipient through a risk assessment. The Risk Assessment (RA) assesses the main caregiving risk areas for the specific caregiving dyad. The RA is used to tailor the intervention for care recipient behaviors or safety issues and/or caregiver centered issues/concerns related to health, physical and emotional well being, and/or social support.
9894424|NCT00580710||intensively treated|intensively treated, well controlled patients with type 1 diabetes
9894425|NCT00580710||lean healthy|age- and sex- matched non-diabetic, normal weight (BMI > or = 18.5 but < or = 25 kg/m2) control subjects
9894426|NCT00580710||obese subjects|obese individuals defined as BMI > or = 30kg/m2
9894427|NCT00580710||type 2 diabetics|Type 2 diabetics on diet only or diet and Metformin
9894428|NCT00580710||type 1 diabetes unaware|Type 1 diabetics unaware of hypoglycemic symptoms
9894429|NCT00580710||type 1 diabetes aware|Type 1 diabetics aware of hypoglycemic symptoms
9894430|NCT00178932|Active Comparator|1 Outcome in schizophrenia with certain antipsychotic|clozapine
9894431|NCT00178932|Active Comparator|2 Outcome in schizophrenia with other Antipsychotics|Other Antipsychotics
9894432|NCT05338125|Experimental|Intervention arm|Patients undergoing the extra intra-operative electrophysiological measurement
10212119|NCT02609737|Experimental|68Ga-DOTA-JR11 and 177Lu-DOTA-JR11|Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging & therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
10212120|NCT02575144|Experimental|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:~Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated creatinine clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
9894435|NCT05338086|Experimental|MB09-MB09|Subjects randomised into MB09-MB09 group will receive MB09 (60 mg in 1 mL) SC injection every 6 months.
9894436|NCT05338086|Active Comparator|Prolia-MB09|Subjects randomised into Prolia- MB09 group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
9894437|NCT05338086|Active Comparator|Prolia-Prolia|Subjects randomised into Prolia-Prolia group will receive Prolia® (60 mg in 1 mL) SC injection every 6 months.
9894438|NCT05338073||Cancer patients|Patients who have primary solid cancer that is being surgically resected, biopsied, or drained (via malignant pleural effusion) and are 18 years of age or older.
9894439|NCT05338047|Placebo Comparator|Generic pegfilgrastim|One 6mg subcutaneous dose of generic pegfilgrastim in day+1 after autotransplant
9894440|NCT05338047|Active Comparator|Brand name pegfilgrastim|One 6mg subcutaneous dose of brand name pegfilgrastim in day+1 after autotransplant
9894441|NCT05338034|Experimental|HPG1860 3 mg|20 subjects will be treated with HPG1860 3 mg once daily at a similar time with or without food.
9894442|NCT05338034|Experimental|HPG1860 5 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
9894443|NCT05338034|Experimental|HPG1860 8 mg|20 subjects will be treated with HPG1860 5 mg once daily at a similar time with or without food.
9894444|NCT05338034|Placebo Comparator|Placebo|20 subjects will be treated with Placebo once daily at a similar time with or without food.
9894445|NCT05338021|Experimental|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 25ml of normal saline was injected directly into the joint with an 18-gauge needle.
9894446|NCT05338008|Experimental|Intrawound Administration of Vancomycin|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 25ml of normal saline was injected directly into the joint with an 18-gauge needle.
9894447|NCT05337995||Non-Specific Low Back Pain patients|Participants must have pain located between the thoracolumbar hinge and the lower gluteal fold, with or without pain in either leg, present for more than 12 weeks, on a daily or almost daily basis (at least 4 days out of 7).
9894448|NCT05337995||Control group|Participant with no current or past chronic pain
9894449|NCT05337982|Experimental|SCI Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate low levels of inflammation will start immediately.
9894450|NCT05337982|Experimental|SCI No Go|Participants with SCI randomized to the experimental group that have biomarkers that indicate high levels of inflammation will have a delayed start of 3 months.
9894451|NCT05337982|No Intervention|SCI SOC|Participants with SCI randomized to the standard of care (SOC) group will continue with regular therapy.
10212121|NCT02575144|Active Comparator|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.Patients with renal failure will recived an ajusted dose.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously. In patients over 75 years old, dexametasona oral will be given at dose of 20mg on days 1, 8, 15, 22 ."
9991382|NCT01452542|Experimental|Sequence 2|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: RTRT, with a 7-day washout between dosing in each period.
9991383|NCT01452555|Active Comparator|In Person Counseling|Participants will receive an in person HIV and HIV testing counseling session
9991384|NCT01452555|Experimental|Video Presentation|Participants will watch an HIV and HIV testing video
9991385|NCT01452568|Experimental|Aspirin|Aspirin 150mg daily, starting day 1 after surgery, for three months.
9991386|NCT01452568|Active Comparator|Warfarin|Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.
9991387|NCT01452581|Active Comparator|RBC transfusion|"Administration of up to 2 RBC units on the first postoperative day.~(1 unit at a time followed by evaluation of the primary outcome measure)"
9991388|NCT01452581|Placebo Comparator|Restrictive: Colloid infusion|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
9991389|NCT01452594||Diphenylcyclopropenone|topical gel administration to skin
9991390|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x1|Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
9991391|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x2|2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
9991392|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x4|4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
9991393|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x8|8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
9991394|NCT01452607|Placebo Comparator|SPI-1000 Capsule 0 mg Ebselen Placebo|Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
9991395|NCT01452620||EVAR cohort|All consecutive patients undergoing endovascular AAA repair (EVAR) in our community setting were followed for outcomes.
9991396|NCT01452633|Placebo Comparator|Preincision Placebo|This group of patients will receive saline injection at study port site before incision
9991397|NCT01452633|Active Comparator|Preincision Marcaine|This group will receive marcaine injection at the study port site prior to incision
9991398|NCT01452633|Placebo Comparator|Postincision Placebo|This group of patients will receive preincisional marcaine and then saline injection at study port site prior to closure
9991399|NCT01452633|Active Comparator|Postincision marcaine|This group will receive preincisional marcaine and then marcaine injection at study port site prior to closure
9991400|NCT01452646|Experimental|MRD-directed therapy|
9991401|NCT01452659|Experimental|TAK-385 10 mg QD|
9991402|NCT01452659|Experimental|TAK-385 20 mg QD|
9991403|NCT01452659|Experimental|TAK-385 40 mg QD|
9991404|NCT01452659|Placebo Comparator|Placebo|
9991405|NCT01452672|Active Comparator|RT to chest wall and S/C|Irradiation of the chest-wall and supraclavicular fossa
9991406|NCT01452672|Experimental|RT to chest wall|Irradiation of the chest-wall alone
9991407|NCT01452685|Placebo Comparator|Placebo|
9991408|NCT01452685|Experimental|TAK-385 10 mg QD|
9991409|NCT01452685|Experimental|TAK-385 20 mg QD|
9991410|NCT01452685|Experimental|TAK-385 40 mg QD|
9991411|NCT01452685|Other|Leuplin|
9991412|NCT01452698|Experimental|TAK-438 20 mg QD|
9991413|NCT01452698|Active Comparator|AG-1749 30 mg QD|
9991414|NCT01452711|Experimental|TAK-438 20 mg QD|
9991415|NCT01452711|Active Comparator|Lansoprazole 30 mg QD|
9991416|NCT01452724|Experimental|TAK-438 20 mg QD|
9991417|NCT01452724|Active Comparator|Lansoprazole 30 mg QD|
9991418|NCT01452737|Experimental|2L Golytely/15mg bisacodyl|Subjects will be asked to take 2L Golytely + 15mg bisacodyl for bowel prep the day before colonoscopy.
9991419|NCT01452737|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep (4L Golytely) prior to colonoscopy.
9991420|NCT01452750|Experimental|TAK-438 10 mg QD|
9991421|NCT01452750|Experimental|TAK-438 20 mg QD|
9991422|NCT01452750|Active Comparator|Lansoprazole 15 mg QD|
9991423|NCT01452763|Experimental|TAK-438 10 mg QD|
9991424|NCT01452763|Experimental|TAK-438 20 mg QD|
9991425|NCT01452763|Active Comparator|Lansoprazole 15 mg QD|
9991426|NCT01452776|Experimental|TAK-438 10 mg QD|
9991427|NCT01452776|Experimental|TAK-438 20 mg QD|
9991428|NCT01452802||HM II (HeartMate II LVAD)|Subjects who elect to, and receive HM II LVAD therapy at baseline
9991429|NCT01452802||OMM (Optimal Medical Management)|Subjects who elect to remain on optimal medical management
9991430|NCT01452815|Placebo Comparator|1|Drug: placebo
9991431|NCT01452815|Experimental|2|10mg TZP-102
9991432|NCT01452815|Experimental|3|20mg TZP-102
9991433|NCT01452828|Experimental|Renal Impairment Nondialyzed|
9991434|NCT01452828|Experimental|Renal Impairment Dialyzed|
9991435|NCT01452828|Experimental|Matched Control|
9991436|NCT01452841|Experimental|Grapefruit Consumption|
9991437|NCT01452841|Active Comparator|Control|
9991438|NCT01452867|Active Comparator|Bag-Mask-Ventilation|Bag-Valve Mask-Ventilation in 50 patients in general anesthesia
9991439|NCT01452867|Active Comparator|Laryngeal Mask Ventilation|Laryngeal Mask Ventilation in 50 patients in general anesthesia
9991440|NCT01452867|Active Comparator|Laryngeal Tube Ventilation|Laryngeal Tube Ventilation in 50 patients in general anesthesia
9991441|NCT01452893||Type I diabetes|Adult patients with diabetes mellitus type I but normal adrenal function
9991442|NCT01452893||Addison's disease|Adult patients with Addison's disease
9991443|NCT01452893||Type I diabetes and Addison's disease|Patients suffering from both, diabetes mellitus type I and Addison's disease
9991444|NCT01452893||healthy controls|healthy controls with normal adrenal function and normal glucose regulation
9991445|NCT01452906|Experimental|PA21 and Omeprazole with food|
9991446|NCT01452906|Experimental|No PA21; Omeprazole with food|
9991447|NCT01452906|Experimental|PA21 with food, Omeprazole 2 hrs later|
9517766|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
9894452|NCT05337982|No Intervention|Healthy Control|Healthy controls will provide biomarker and/or myelin (MRI) data
9894453|NCT05337969|Experimental|Metformin and Vildagliptin 850/50 mg Tablet|1 tablet of Metformin and Vildagliptin 850/50 mg as single-dose administration
9894454|NCT05337969|Active Comparator|EUCREAS® 50/850mg Tablet|1 tablet of EUCREAS® 50/850mg (each film-coated tablet contains Vildagliptin 50mg and Metformin hydrochloride 850mg) as single-dose administration
9894455|NCT05337956|Active Comparator|ESPB catheter group|Patient in this group will receive ESP block
9894456|NCT05337956|No Intervention|Control group|Patient in this group will not receive any block
9932585|NCT00950469||patients with acute coronary syndrome|"94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of the University of Heidelberg were enrolled with symptoms suggestive of ACS.~Unstable angina and non-ST-segment elevation myocardial infarction were diagnosed using the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of myocardial infarction guidelines. Patients with ST-segment elevation were excluded."
9932586|NCT00950482|Active Comparator|TA|Active TA
9932587|NCT00950482|Active Comparator|AA|Alternative Acupuncture
9932588|NCT00950482|Active Comparator|WC|Waiting Group
9932589|NCT00950495|Active Comparator|Mandibular advancement device (MAD)|an MAD is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
9932590|NCT00950495|Active Comparator|nasal CPAP|The device is turned on, and the nasal mask is placed on the nose prior to sleep. After waking up in the morning, the device is turned off and the mask is removed
9932591|NCT00950495|Placebo Comparator|placebo|the placebo appliance is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
9932592|NCT00950508|Active Comparator|High volume plasma exchange|3 successive plasma exchanges over 3 days
9932593|NCT00950508|Placebo Comparator|Standard medical treatment|
9932594|NCT00950521|Active Comparator|PBSC Treatment|Patients in PBSC treatment will receive brain implant of autologous peripheral blood stem cell(CD34+) plus convention stroke treatment that include rehabilitation and antiplatelet medication
9932595|NCT00950521|Active Comparator|Control|Control group receive conventional stroke treatment that include rehabilitation and antiplatelet medication
9932596|NCT00950534|Experimental|General Practitioner initiation with insulin glargine|Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.
9932597|NCT00950534|Active Comparator|Usual standard of care|Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)
9932598|NCT00950547|Active Comparator|Control|Traditional Chest drains
9932599|NCT00950547|Experimental|CARDIOPAT|CARDIOPAT Cell Saver after Surgery
9932600|NCT00950560||inpatient|
9932601|NCT00950560||outpatient|
9932602|NCT00950560||emergency patient|
9932603|NCT00950573||hemodialysis|patients treated with conventional hemodialysis
9932604|NCT00950573||peritoneal dialysis|patients treated with peritoneal dialysis
9932605|NCT00950573||nocturnal hemodialysis|patients treated with frequent nocturnal hemodialysis
9932606|NCT00950573||kidney transplantation|patients treated with renal transplantation
9932607|NCT00950586|Experimental|Cohort 1|14 days dosing
9932608|NCT00950586|Experimental|Cohort 2|Single dose followed by 14 days repeat dosing
9932609|NCT00950586|Experimental|Cohort 3|Up to 28 days repeat dosing with drug interaction
9932610|NCT00950625|Active Comparator|intraperitoneal lignocaine|Intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine for pain control after laparoscopic cholecystectomy
9932611|NCT00950625|Active Comparator|intraperitoneal bupevacaine|intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine after laparoscopic cholecystectomy
9935599|NCT03467373|Experimental|Part 1: Dose Escalation r/r NHL|"Dose finding in participants with r/r NHL: the study will explore different doses of glofitamab in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP every 3 weeks (Q3W). Participants with r/r NHL will receive 6 cycles of induction treatment (G/R-CHOP). Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) may optionally receive post-induction treatment (referred to as maintenance) with glofitamab alone.~The use of G versus R in Cycle 1 will be compared in parallel dose escalation cohorts."
9935600|NCT03467373|Experimental|Part 2: DLBCL G/R-CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by G/R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
9935601|NCT03467373|Experimental|Part 2: DLBCL Pola-R-CHP|Participants with untreated DLBCL will receive Pola-R-CHP + glofitamab on Day 1 of each 21-day cycle for a maximum of 6 cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
9935602|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
9935995|NCT02843425|Experimental|Regular Diet + Beans, Then Regular Diet - Beans|
9935996|NCT02843425|Active Comparator|Regular Diet - Beans, Then Regular Diet + Beans|
9517767|NCT03303183|Active Comparator|Direct Ear Scanner|Digitale impression via direct ear scanner
9517768|NCT03303183|Active Comparator|Silicone Ear impression|Impression via silicone
9991448|NCT01452932|Experimental|Physiotherapy|Group of participants who recive physiotherapy treatment using Kabat technique for the upper limbs resistance training during 12 weeks
9991449|NCT01452932|Other|Yoga|Group of participants who recive Yoga sessions during 12 weeks
9517505|NCT03305718|Experimental|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
9991450|NCT01452958|Experimental|TNF-α|Beromun, Boehringer-Ingelheim, Germany
9991451|NCT01452958|Experimental|Endotoxin|
9991452|NCT01452984||Single Retrospective Interviews|Each retrospective interview will be conducted by the Principal Investigator and/or Project Manager to collect denmographic information and experiential narratives from the patient, using open-ended questions and structured probes based on individual responses. Retrospective interviews will be recorded and scheduled at the patients' convenience either in the clinic, at the home, or at a place that is convenient to them.
9991453|NCT01452984||Prospective Observations|Prospective Observations of clinic visits will be combined with informal interview to document conversations with their treating physicians about concerns emerging from appearance, function, and other factors that may impinge on clinical decision making and experience including quality of life. The Project Manager will be present for the clinical visit during which the Mohs surgery takes place and record field observations as well as informal interview notes in a notebook.
9991454|NCT01452997|Active Comparator|Ibuprofen Gel|Ibuprofen 5% gel
9991455|NCT01452997|Placebo Comparator|Ibuprofen placebo|K-Y jelly
9991456|NCT01452997|Active Comparator|Eumovate|0.05% w/w clobetasone butyrate
9991457|NCT01452997|Placebo Comparator|Cream Placebo|Aqueous Cream B.P.
9991458|NCT01453010|Experimental|8 individual case reviews|SaeboFlex Self-directed training
9991459|NCT01453062||Patients with a diagnosis of CLL|Patients with a diagnosis of CLL
9991460|NCT01453088|Active Comparator|Treatment A|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
9991461|NCT01453088|Experimental|Treatment Arm B|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
9991462|NCT01453101|Other|Fludarabine, Melphalan, Bortezomib|
9991463|NCT01453114|Experimental|Psychotherapy|Cognitive Behavioral Therapy
9991464|NCT01453127|Experimental|Alzheimer's Disease|Alzheimer's Disease
9991465|NCT01453127|Experimental|Dementia with Lewy Bodies|Dementia with Lewy Bodies
9991466|NCT01453127|Experimental|Frontotemporal Dementia|Frontotemporal Dementia
9991467|NCT01453127|Experimental|Parkinson's Disease|Parkinson's Disease
9991468|NCT01453127|Experimental|Corticobasal Degeneration|Corticobasal Degeneration
9991469|NCT01453127|Experimental|Essential Tremor|Essential Tremor
9991470|NCT01453127|Experimental|Mild Cognitive Impairment|Mild Cognitive Impairment
9991471|NCT01453127|Experimental|REM sleep behavior disorder|REM sleep behavior disorder
9991472|NCT01453192|Experimental|Raltegravir|Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
9991473|NCT01453218|No Intervention|Basiliximab|Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
9991474|NCT01453218|Active Comparator|ATeGe-Fresenius|
9991475|NCT01453231|No Intervention|Control|No surgery
9991476|NCT01453231|Experimental|thighplasty|
9991477|NCT01453244||SVR group|A patients who achieved SVR (sustained virologic response)
9991478|NCT01453244||non-SVR group|A patients who not achieved SVR (sustained virologic response)
9991479|NCT01453257|Experimental|Chemotherapy treatment|Tailored chemotherapy by Therapeutic Targets
9991480|NCT01453270|Experimental|NICOM and PLR|A systematic approach to resuscitation started in the ED and using a step-wise approach to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues will be applied to the intervention group using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg-raising (PLR) maneuver.
9991481|NCT01453270|Active Comparator|Usual care|
9991482|NCT01453309|Active Comparator|Cell Saver|Patients will have the use of a cell-saver during surgery
9991483|NCT01453309|Placebo Comparator|No Cell saver|Patient will not have cell saver available during surgery.
9991484|NCT01453400|Experimental|Arm 1|
9991485|NCT01453400|Active Comparator|Arm 2|
9991486|NCT01453400|Placebo Comparator|Arm 3|
9991487|NCT01453426|Experimental|Chinese Subjects - Dose 1 BG00012|
9991488|NCT01453426|Experimental|Chinese Subjects - Dose 2 BG00012|
9991489|NCT01453426|Experimental|Japanese Subjects - Dose 1 BG00012|
9991490|NCT01453426|Experimental|Japanese Subjects - Dose 2 BG00012|
9991491|NCT01453426|Experimental|Caucasian Subjects - Dose 1 BG00012|
9991492|NCT01453426|Experimental|Caucasian Subjects - Dose 2 BG00012|
9991493|NCT01453452|Experimental|Exercise and Lifestyle counseling|Patients will receive behavioral dietary intervention & counseling intervention by phone, exercise intervention at Curves(R) facility, and take a quality-of-life assessment online.
9517769|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
9894457|NCT05337943|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|CBT-I treatment will receive 1 session every week, for 8 weeks (8 total sessions). The CBT-I sessions will be provided by a pool of clinical PhD psychology students by a trained professional. Each visit will be conducted via telehealth. Sessions will include discussions regarding such topics as sleep restriction, stimulus control and sleep hygiene. Review of sleep diaries will occur during the sessions.
9894458|NCT05337943|Experimental|Bright Light Therapy|Bright Light treatment will consist of 8 weeks of daily use of the Re-timer device. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of ~500 lux lm/m2. Subjects will be instructed to use the device for 30 minutes within two hours of waking, in the morning on the full brightness setting.
9894459|NCT05337943|No Intervention|Standard Care|Subjects will continue the care they routinely receive.
9894460|NCT05337930|Other|Intervention arm|Study participants will use the Happyr Health app, a mobile application to support CYP with primary headaches in coping with chronic pain, for eight weeks. For this study, a research version of the app will be provided via Google Play Store Testing Tracks and Apple TestFlight. In the app, a storyline and gamification elements engage CYP in filling out their headache diary and a regular mood diary.
9894461|NCT05337904|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
9894462|NCT05337904|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
9894463|NCT05337891||Patients with suspected or diagnosed myasthenia gravis|Patients with suspected or diagnosed myasthenia gravis (ocular and generalized form), aged 18-80, both sexes, with performed or planned determination of anti-AChrR and anti-MUSK antibodies
9894464|NCT05337878|Placebo Comparator|SAD: Placebo|Single dose of Pelacarsen-matching placebo administered by SC injection on Day 1 of single-dose treatment period.
9894465|NCT05337878|Experimental|SAD: Pelacarsen 20 milligrams (mg)|Single dose of Pelacarsen, 20 mg, administered by SC injection on Day 1 of single-dose treatment period.
9894466|NCT05337878|Experimental|SAD: Pelacarsen 40 mg|Single dose of Pelacarsen, 40 mg, administered by SC injection on Day 1 of single-dose treatment period.
9894467|NCT05337878|Experimental|SAD: Pelacarsen 80 mg|Single dose of Pelacarsen, 80 mg, administered by SC injection on Day 1 of single-dose treatment period.
9894468|NCT05337878|Placebo Comparator|MD: Placebo|Multiple doses of Pelacarsen-matching placebo administered by SC injection every 4 weeks, on Days 1, 29, 57 and 85 of multiple-dose treatment period.
9894469|NCT05337878|Experimental|MD: Pelacarsen 80 mg|Multiple doses of Pelacarsen, 80 mg, administered by SC injection every 4 weeks, on Days 1, 29, 57 and 85 of multiple-dose treatment period.
9894470|NCT05337865||Transgender women|Well-trained transgender women.
9894471|NCT05337865||Cisgender Women|Well-trained cisgender women.
9894472|NCT05337865||Cisgender Men|Well-trained cisgender men.
9894473|NCT05337852|Experimental|Experimental group|"To the pregnant women in the experimental group;~Emotional freedom technique will be applied online with the researcher, 3 sessions every other day for 1 week,~PUQE, PRAQ-2 tests will be applied before the intervention,~SUE and PUQE will be applied before and after each session,~After 3 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
9894474|NCT05337852|No Intervention|Control group|"After each intervention applied to the experimental group, SUE and PUQE will be applied to the control group over the phone, simultaneously.~After 1 week, post-test data will be obtained with PUQE, SUE, PRAQ-2."
9894475|NCT05337839|Experimental|Community-dwelling older adults receiving supervision|Group I; supervised home exercise group
9894476|NCT05337839|Active Comparator|Community-dwelling older adults not supervised|Group II; unsupervised home exercise group
9894477|NCT05337826|Experimental|Single Arm|
9894478|NCT05337813|Experimental|A. Overactive bladder|Overactive bladder (LiESWT therapy once a week, duration 8 weeks)
9894479|NCT05337813|Experimental|B. Stress incontinence|Stress incontinence (LiESWT therapy once a week, duration 8 weeks + PRP therapy once a month, duration 3 months)
9894480|NCT05337813|Experimental|C. Interstitial cystitis|Interstitial cystitis (LiESWT therapy once a week, duration 8 weeks + PRP therapy once a month, duration 3 months)
9932612|NCT00950638|Active Comparator|dose comparison|
9894481|NCT05337813|Experimental|D. Female sexual dysfunction|Female sexual dysfunction (LiESWT therapy once a week, duration 8 weeks)
9894482|NCT05337800|Experimental|stress management program|
9894483|NCT05337800|No Intervention|Control|
9894484|NCT05337787|Experimental|Experimental|All students in the experimental group were trained with only according to the Flipped Classroom Model
9894485|NCT05337787|No Intervention|Control|All students in the control group were trained only with the traditional education method.
9894486|NCT05337774|Experimental|Blast-related mTBI group|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
9894487|NCT05337774|Experimental|mTBI not blast-related (control group 1)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
9894488|NCT05337774|Experimental|no history of TBI (control group 2)|Assessments will include:(i) neuropsychological and neurobehavioral testing, (ii) MRI, with a special emphasis on (iii) PET, using emerging tracers for tauopathy ([18F]PI-2620), and amyloid ([18F]florbetaben).
9894489|NCT05337761|Experimental|Intervention|The peers will be trained to train their colleagues (fellow boaters) on proper lifejacket use. A training manual has been developed for this.
9894490|NCT05337761|Placebo Comparator|Control|The Marine Police will be encouraged to continue conducting their community policing on water safety and emphasize lifejacket wear.
9894491|NCT05337748|Experimental|Experimental : Lexie Self Test and Fit Group (Lexie STF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
9894492|NCT05337748|Active Comparator|Control: Lexie Professional Test and Fit Group (Lexie PTF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
9894493|NCT05337722|Experimental|App+fixed MI|The participants will use the SFT2.0 app and receive a fixed number of 4 counseling video sessions during pregnancy up to 1-month postpartum.
9894494|NCT05337722|Experimental|Adaptive app + as-needed MI|The participants will use the SFT2.0 app and receive as-needed prenatal and postnatal video counseling sessions (between 1 and 10 sessions) during pregnancy up to 1-month postpartum.
9894495|NCT05337722|Active Comparator|Control|Participants will receive low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session.
9894496|NCT05337709|Experimental|treatment group|Patients from the pharmacies assigned as treatment group will receive intervention. Intervention are education (aid with leaflet and video) and medication review with counselling.
9894497|NCT05337709|No Intervention|control group|Patients from the pharmacies assigned as control group will receive as usual care they have been provided regularly.
9894498|NCT05337696|Experimental|Participants with vertebral compression fractures|Participants with vertebral compression fractures who have failed conservative care strategies.
9894499|NCT05337657|Experimental|GB491+Letrozole|
9894500|NCT05337618|Experimental|SD-Guided Care|In this arm, ECoG data will be reviewed for SDs in real-time using the bedside clinical CNS monitor. As a secondary measure, recognition of SDs will be facilitated by custom software on a laptop that receives data from the CNS monitor. Data on SD occurrence will be used to guide treatment in a tier-based therapeutic escalation and de-escalation protocol with the goal of SD suppression. Therapies to be used among the tiers include adjusted targets for MAP, CPP, PaCO2, plasma glucose, temperature, as well as ketamine pharmacotherapy. Changes between tiers are determined by the success or failure of SD suppression at the given treatment level.
9894501|NCT05337618|No Intervention|Standard ICU Care|"Management in the Standard ICU Care arm will follow published national guidelines consisting of common ICU-based targets for physiologic intervention that are thought to mitigate the development of secondary brain injuries.~Continuous ECoG monitoring will be performed for seizure monitoring, but information on the course of SDs in these patients will not be used to guide care. To enforce blinding to SD-related ECoG data, the ECoG bedside software will be locked with password protection to prevent displays with frequency filtering and time/amplitude scales that are necessary to identify SDs."
9894502|NCT05337605||Hand driven tissue removal system|Endometrial polyp removed by hysteroscopic hand-driven tissue removal system in a previous study.
9894503|NCT05337605||Motor driven tissue removal system|Endometrial polyp removed by hysteroscopic motor-driven tissue removal system in a previous study.
9894504|NCT05337592|Experimental|SRD part: BI 1815368|
9894505|NCT05337592|Placebo Comparator|SRD part: Placebo|
9894506|NCT05337592|Experimental|BA part: T1-R-T2|R: BI 1815368 formulation 1, fasted condition T1: BI 1815368 formulation 2, fasted condition T2: BI 1815368 formulation 2, fed condition
9894507|NCT05337592|Experimental|BA part: R-T2-T1|
9894508|NCT05337592|Experimental|BA part: T2-T1-R|
9894509|NCT05337579|Active Comparator|Supplemental Rest Breaks|
9991494|NCT01453465||Ancillary-Correlative (gene expression profile, miRNA profile)|Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
9991495|NCT01453478|Experimental|GSK1325756 Immediate Release 50 mg|Administered to volunteers in the fasted and fed states
9991496|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 1 50 mg|Administered to volunteers in the fasted and/or fed states
9991497|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 2 50 mg|Administered to volunteers in the fasted and/or fed states
9991498|NCT01453491|Experimental|50mg SRT2104|Single oral administration of 50mg SRT2104 study drug will be supplied as 25 mg and 250 mg capsules and will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
9991499|NCT01453491|Experimental|500mg SRT2104|Single oral administration of 500mg SRT2104 will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
9991500|NCT01453504|Active Comparator|Ever-DHAP|Combination of Everolimus and DHAP
9991501|NCT01453504|Placebo Comparator|Placebo-DHAP|
9991502|NCT01453530|Active Comparator|Sugammadex|A single dose of sugammadex 2 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed
9991503|NCT01453530|Active Comparator|Neostigmine/glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed.
9991504|NCT01453530|Placebo Comparator|No reversal agent|No treatment
9991505|NCT01453543|Experimental|Deep transverse friction massage|Massage technique will be used.
9991506|NCT01453556|Experimental|Intracorpopreal anastomosis|Intracorporeal mechanical anastomosis
9991507|NCT01453556|Active Comparator|Extracorporeal anastomosis|Extracorporeal mechanical anastomosis
9991508|NCT01453582|Experimental|Propolis|Total Flavonoids of Propolis dropping pill
9991509|NCT01453582|Placebo Comparator|Placebo|Simulant of total Flavonoids of Propolis dropping pill
9991510|NCT01453608|Experimental|Ferinject (ferric carboxymaltose)|
9991511|NCT01453608|Placebo Comparator|Placebo (saline)|
9991512|NCT01453621|Experimental|Clinical decision support (post-intervention phase)|Clinicians will receive computerized clinical decision support regarding the risk of clinically important traumatic brain injury (TBI) based on the prediction rules
9991513|NCT01453621|No Intervention|Standard care (pre-intervention phase)|Prior to implementation of the computerized clinical decision support, we will collect data to determine the baseline rate of CT use for children with minor blunt head trauma at very low risk of clinically-important traumatic brain injuries.
9991514|NCT01453634|Experimental|Lunacalcipol 180|180 µg (n=4)Lunacalcipol Injection
9991515|NCT01453634|Experimental|Lunacalcipol 270|270 µg (n=8)Lunacalcipol Injection
9991516|NCT01453647|Experimental|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
9991517|NCT01453647|No Intervention|control|Participants in the control group will be instructed to maintain their FM treatment regimens as reported at baseline.
9991518|NCT01453660||Cisplatin-Based Chemotherapy Group|GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.
9894510|NCT05337579|Active Comparator|Exercise Breaks|
9894511|NCT05337579|Experimental|Supplemental Rest and Exercise Breaks|
9517770|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
10212122|NCT02574286|Experimental|Velaglucerase alfa 60 U/kg|Participants will receive 60-minute intravenous infusion of 60 units per kilogram (U/kg) velaglucerase alfa every other week (EOW) and an oral daily dose of 800 IU vitamin D for 24 months (101 weeks).
10212123|NCT02542956|Active Comparator|Exparel|Injection of Exparel
9894514|NCT05337540|Experimental|EVI-01 - low dose|4 mL, one single intra-articular injection
9894515|NCT05337540|Experimental|EVI-01 - high dose|6 mL, one single intra-articular injection
9894516|NCT05337540|Active Comparator|Synvisc-One|6 mL, one single intra-articular injection
9894517|NCT05337527|Experimental|Beetroot supplementation|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
9894518|NCT05337527|Placebo Comparator|Placebo supplementation|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
9894519|NCT05337514|Experimental|EngAGE|Older adult subjects will receive an Alexa Echo Show or Amazon Fire tablet that runs an exercise app called EngAGE.
9894520|NCT05337514|Active Comparator|Physical Exercise Handouts|Older adults subjects will receive a paper booklet containing exercise instructions.
9894521|NCT05337501|Experimental|Patients group|
9894522|NCT05337488||Subject with solitary drinking behaviour|A convenience sample of 40 solitary drinkers aged between 10 and 24 will be invited to undergo complete a questionnaire and an individual semi-structured interviews.
9894523|NCT05337449|Active Comparator|silver diamine fluoride|
9894524|NCT05337449|Active Comparator|conventional composite resin restoration|
9894525|NCT05337423|Experimental|Group 1|Moisturizing cream indicated and provided by the hospital (with urea) + LED treatment.
9894526|NCT05337423|Sham Comparator|Group 2|Moisturizing cream indicated and provided by the hospital (with urea) + LED sham treatment.
9894527|NCT05337410|Experimental|YES-ERACE|Students participate in the YES-ERACE program.
9894528|NCT05337410|No Intervention|Control|Students participate in the regular after-school programming.
9894529|NCT05337397||Prior pTa low grade Non-Muscle invasive bladder cancer|Patient with recurrent Pta low grade Non-Muscle invasive bladder cancer, with negative urine cytology, and tumor size between 1 and 3 cm.
9894530|NCT05337371||Philips ePatch® 2.0|Patients who are discharged from the hospital with ECG patch (Philips ePatch® 2.0).
9894531|NCT05337358|Active Comparator|Lithium disilicate|The intervention will be: Prosthetic endocrown
9894532|NCT05337358|Active Comparator|Fiber reinforced composite|The intervention will be: Prosthetic endocrown
9894533|NCT05337345|Experimental|Part 1|
9894534|NCT05337345|Experimental|Part 2|
9894535|NCT05337332|Experimental|Central serous chorioretinopathy group|Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide.
9894536|NCT05337332|Experimental|Irvine-Gass Syndrome group|Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide
9894537|NCT05337306|Experimental|GogyUp|"Participants in the GogyUp arm will have the GogyUp Reader app preloaded on a cellular-enabled tablet with the same patient education documents as the Control arm. Patients will be able to use on-demand / in-the-moment assistive-reading technologies to understand any word or phrase:~Speech-to-Text~Word-by-Word Translation~Alternative Formatting~Simplified and Contextualized Definitions~No-Fail Comprehension Questions~Personalized Training in Phonemic Awareness"
9894538|NCT05337306|No Intervention|Control|Participants in the Standard Care arm will receive the standard after-visit patient education documents the clinics current provide for type 2 diabetes education and self-management.
9894539|NCT05337267|Experimental|sintilimab (after the change)|
9894540|NCT05337267|Active Comparator|sintilimab (before the change)|
9894541|NCT05337254|Experimental|STS101 5.2 mg|STS101 (dihydroergotamine nasal powder), 5.2 mg
9894542|NCT05337254|Experimental|STS101 7.0 mg|STS101 (dihydroergotamine nasal powder), 7.0 mg
9894543|NCT05337254|Experimental|STS101 8.6 mg|STS101 (dihydroergotamine nasal powder), 8.6 mg
9894544|NCT05337254|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
9894545|NCT05337254|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
10212124|NCT02542956|Active Comparator|Marcaine|Receive Marcaine in a pain pump or by injection
10212125|NCT02471144|Experimental|Secukinumab low dose|Secukinumab
10212126|NCT02471144|Experimental|Secukinumab high dose|Secukinumab
10212127|NCT02471144|Placebo Comparator|Placebo|Placebo
10212128|NCT02471144|Active Comparator|Etanercept Comparator|Etanercept
10212129|NCT02440464|Experimental|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
10212130|NCT02440464|Placebo Comparator|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo maintenance.
10212131|NCT02434705||Antigen (wheat base soy sauce) spray|"Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.~During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.~After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
10212132|NCT02384421|Experimental|Activa PC+S Neurostimulator|"Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool~PC+S: Primary Cell+Sensing"
9894546|NCT05337215|Active Comparator|Control group|While the IIF was applied to control group at the first meeting in the postpartum ward, FIAS was administered by phone or home visit in the third month after the face-to-face interview.There was any intervention for this group
9894547|NCT05337215|Experimental|kangaroo father care|While the IIF was applied to control group at the first meeting in the postpartum ward, FIAS was administered by phone or home visit in the third month after the face-to-face interview.. the first KC was applied within the first 4-6 hours after birth, and the second KC was applied in the postpartum ward under the supervision of the researcher on the first day after birth. The third KC was performed by the fathers themselves at home on the third postpartum day after discharge. Immediately afterwards, the researcher observed the father and baby from an appropriate distance, and the father and the baby had skin-to-skin contact for mean 15-20 minutes.
9894548|NCT05337189||Bladder cancer group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting urine specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) test, eligible subjects also need to undergo the examination of standard method.
9894549|NCT05337189||The normal group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting urine specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) test, eligible subjects also need to undergo the examination of standard method.
9894550|NCT05337163||Lung cancer group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting sputum specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) , eligible subjects also need to undergo the chest CT or pathological examination.
9894551|NCT05337163||The normal group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting sputum specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) , eligible subjects also need to undergo the chest CT or pathological examination.
9517771|NCT03303118|Other|Left|No product administration will be done in this study.
9894552|NCT05337150|Experimental|Lifestyle Modification with a Balanced Calorie Deficit Diet|Lifestyle modification intervention with a balanced calorie deficit diet (i.e., participants will be prescribed a calorie goal and will track their dietary intake in order to meet this goal).
9894553|NCT05337150|Experimental|Lifestyle Modification with an Ad Libitum Whole Food Plant-Based Eating Plan|Lifestyle modification intervention with an ad libitum whole food plant-based diet (i.e., participants will eat, ad libitum, fruits, vegetables, starches, legumes, and whole grains, and will avoid eating processed foods, refined oils, and animal products)
9894554|NCT05337137|Experimental|Arm A: Relatlimab + Nivolumab + Bevacizumab|
9894555|NCT05337137|Experimental|Arm B: Placebo + Nivolumab + Bevacizumab|
9894556|NCT05337124||Lupkynis Treatment Group|
9894557|NCT05337111||Chinese men|Chinese men based on self-identity for three generations (parents and grandparents), age 25 - <45 years, who are physically inactive (< 150 minutes moderate or < 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (>23-<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
9932613|NCT00950638|Active Comparator|Dose comparison|
9991519|NCT01453660||Surgery-Only Group|GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.
9991520|NCT01453686|Experimental|Hydrocortisone 1%|
9991521|NCT01453686|Experimental|Clobetasol Propionate 0.05%|
9991522|NCT01453712|No Intervention|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
9991523|NCT01453712|Experimental|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
9991524|NCT01453738|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
9991525|NCT01453738|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
9991526|NCT01453751|Experimental|Intravenous Injection of AD-SVF|Intravenous administration of AD-SVF.
9991527|NCT01453764|Experimental|Adipose SVF IV Infusion|IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
9991528|NCT01453790|Experimental|Parent-Specific Depression Education-Motivation|Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.
9991529|NCT01453790|Active Comparator|General Depression Education|Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.
9991530|NCT01453803|Experimental|Intravenous Injection and Intanasal infusion of AD-SVF|AD-SVF
9997569|NCT01510002|Experimental|TT+CND|Extracapsular total thyroidectomy puls prophylactic central neck dissection
9997570|NCT01510015|Active Comparator|Anti-psychotic medication|Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
9997571|NCT01510015|Active Comparator|Counseling|Participants will receive individual and group therapy
9997572|NCT01510041|Experimental|Inspiratory muscle training group|
9997573|NCT01510041|Experimental|Respiratory exercise group|
9997574|NCT01510054||steroid support|Endometrial biopsies from subjects of with or without luteal phase steroid support will be compared for miRNA expression
9997575|NCT01510080|Experimental|Computer-assisted live supervision|"Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as bug-in-the-eye (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to."
9997576|NCT01510080|Experimental|Delayed video-based supervision|Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
9997577|NCT01510093|Other|Insulin Aspart without glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
9997578|NCT01510093|Other|Insulin Aspart with glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
9997579|NCT01510132|Experimental|Travacom|Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.
9997580|NCT01510171|Active Comparator|Prasugrel loading dose|
9997581|NCT01510171|Active Comparator|Ticagrelor Loading dose|
9997582|NCT01510223|Experimental|Dietary supplementation macademia oil|emia oil
9997583|NCT01510223|Experimental|Dietary supplementation olive oil|Olive oil
9997584|NCT01510223|Experimental|Dietary Supplementation fish oil|fish oil
9997585|NCT01510236|Experimental|Early self-help program|The early self-help program starts directly after randomization i.e. 4 weeks after diagnosis.
9997586|NCT01510236|Experimental|Later self-help program|The later self-help program starts sixty-two weeks after diagnosis.
9997587|NCT01510262|Experimental|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
9998224|NCT01516281||mTBI|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI+ subjects are randomly selected for clinical assessment and DaTscan.
9894558|NCT05337111||Indian men|Indian men based on self-identity for three generations (parents and grandparents), age 25 - <45 years, who are physically inactive (< 150 minutes moderate or < 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (>23-<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
9894559|NCT05337111||Malay men|Malay men based on self-identity for three generations (parents and grandparents), age 25 - <45 years, who are physically inactive (< 150 minutes moderate or < 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (>23-<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
9894560|NCT05337098|Active Comparator|Aspartame|Controlled feeding study. Dosage of aspartame will follow 50% of the acceptable daily intake (equivalent to 25 mg/kg for aspartame). This amount represents 1,500 mg/day of aspartame for a 60 kg adult.
9894561|NCT05337098|Active Comparator|Sucralose|Controlled feeding study. Dosage of sucralose will follow 50% of the acceptable daily intake (equivalent to 2.5 mg/kg for sucralose). This amount represents 150 mg/day of sucralose for a 60 kg adult.
9894562|NCT05337098|Sham Comparator|No NNS|Controlled feeding study with no non-nutritive sweeteners.
9894563|NCT05337085|Active Comparator|Dexmedetomidine|Inj. Dexmedetomidine (precidex) 200/mcg/2ml given to participants in infusion form for 10 mins of surgery and maintenance dose given till the end of surgery
9894564|NCT05337085|Active Comparator|Midazolam|Inj midazolam 0.5 mg/kg stat dose will be given to participants during surgery
9894565|NCT05337059|Experimental|Transpulmonary based ventilation strategy|PEEP and tidal volume will be set to target expiratory and inspiratory transpulmonary pressures of 0 and 20 cmH2O, respectively.
9894566|NCT05337046||Tissue removal system|Endometrial polyp removed by hysteroscopic tissue removal system in a previous study.
9894567|NCT05337046||Bipolar resectoscopy|Endometrial polyp removed by hysteroscopic bipolar resectoscopy in a previous study.
9894568|NCT05337033|Experimental|Cannabidiol-enriched Cannabis Herbal Extract|LGP Classic 1:20
9894569|NCT05337020|Experimental|Intervention group|240 patients will receive the questionnaire to assess patients vision on telemedicine.
9894570|NCT05337007|Experimental|dietary intervention, high protein diet|commercially available high protein ultraprocessed food items (30% protein content), cross-over design, all subjects receive all interventions
9894571|NCT05337007|Active Comparator|dietary intervention, moderate protein diet|commercially available moderate protein ultraprocessed food items (13% protein content), cross-over design, all subjects receive all interventions
9894572|NCT05336994|Experimental|Multivitamin/mineral supplement A to B|Participants will be randomly assigned to receive Supplement A and after 5-7 days of follow-up, they will receive Supplement B.
9894573|NCT05336994|Experimental|Multivitamin/mineral supplement B to A|Participants will be randomly assigned to receive Supplement B and after 5-7 days of follow-up, they will receive Supplement A.
9894574|NCT05336981|Experimental|Low-Level Light Therapy ACTIVE|Patients will receive applications of photobiomodulation directly in the region extraoral of the salivary glands ( parotid and submaxilar) will be given once a week for another 6 weeks.
9894575|NCT05336981|Sham Comparator|Low-Level Light Therapy sham|Patients will receive applications of photobiomodulation sham directly in the region extraoral of the salivary glands ( parotid and submaxilar) will be given once a week for another 6 weeks
9894576|NCT05336968|Active Comparator|Triamcinolone acetonide - Ropivacaine - Normal Saline|"Subject would receive:~Triamcinolone acetonide, 40 mg/mL. 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
9894577|NCT05336968|Experimental|Ketorolac - Ropivacaine - Normal Saline|"Subject would receive:~Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
9894578|NCT05336968|Experimental|Triamcinolone acetonide - Ketorolac - Ropivacaine|"Subject would receive:~Triamcinolone acetonide, 40 mg/mL Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
9894579|NCT05336955|Experimental|Telemental health START|Telemental health START will deliver two components via telephonic or other communication technology (e.g., Zoom). This includes component #2 (consultation and coping skills coaching) and component #4 (service linkages, referrals, outreach, & training). START components #1 (intake and quarterly assessment) and #3 (24-hour urgent crisis response and intervention) will continue to be provided in-person.
9894580|NCT05336955|Active Comparator|In-person START|In-person START will deliver all model components in-person. This is the established model.
9894581|NCT05336942||MCI-HI group|Mild cognitive impairment and hearing impairment group
9894582|NCT05336942||MCI-nHI group|Mild cognitive impairment and no hearing impairment group
9894583|NCT05336942||Control group|Control group
9894584|NCT05336929|Experimental|education arm (n=30)|Roy adaptation model-based training was given to the training arm.
9894585|NCT05336929|No Intervention|control arm (n=30)|Roy adaptation model-based training not given to the training arm
9894586|NCT05336916|Experimental|Blended MBCT|"The blended MBCT consists of four 2,5 hour group sessions through videoconference (session 1, 3, 5 and 8), taught by experienced mindfulness trainers. The other sessions (2, 4, 6 and 7) are delivered online and are individual. Mindfulness trainers will provide online feedback to participants for these sessions. The sessions include meditation exercises, psycho-education, and group discussion. In addition to the sessions, participants are instructed to do daily home practice 45 minutes a day. The regular MBCT program was adapted to fit the needs of the target group and, for instance includes psycho-education about grief and cancer-related fatigue.~Online sessions were built around a specific theme. Participants are provided with information, audio files of meditations, and recording assignments around the theme of the session through a personal, secure webpage. The sessions look appealing and persuasive technologies such as reminders and videos are used."
9991531|NCT01453842|Experimental|Diet oil|
9894587|NCT05336916|Experimental|Unguided online MBCT|"Participants in the unguided online arm receive access to the 8 online mindfulness sessions (same intervention as blended MBCT arm), but no mindfulness trainer will be involved.~Each online session was built around a specific theme, for instance automatic pilot, communication or self-care. Participants are provided with information, audio files of meditations, and recording assignments around the theme of the session through a personal, secure webpage. Participants are encouraged to read the information and do the assigned meditations and recording assignments within one week. The sessions will look appealing and persuasive technologies such as reminders and video's will be used."
9894588|NCT05336916|No Intervention|Treatment As Usual|Not offered the mindfulness program, treatment as usual
9894589|NCT05336851||Viral infection|Viral infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree
9894590|NCT05336851||Bacterial infection|Bacterial infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
9894591|NCT05336851||Viral-Viral co-infection|Viral-viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
9894592|NCT05336851||Bacterial-Viral co-infection|Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
9894593|NCT05336851||Fungal-Mycobacterium co-infection|Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
9894594|NCT05336851||Infection of uncertain origin|Infection of uncertain origin subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
9894595|NCT05336851||Control Subjects|Control group subjects, if they agree, will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms (if applicable); and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if applicable); and c) 48 hours +/- 6 hours from symptom onset (if applicable).
9894596|NCT05336825|Experimental|CO2 laser|Mona Lisa CO2 laser will be applied externally to the vulvar vestibule in three sessions over a three month period.
9894597|NCT05336825|Active Comparator|Lidocaine|5% topical lidocaine will be applied nightly via a cotton square in participants
9894598|NCT05336812|Experimental|Arm I (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 13 and day 1 of cycles 14-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
9894599|NCT05336812|Experimental|Arm II (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive venetoclax PO QD on days 1-28 days of cycles 13-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
9894600|NCT05336786|Experimental|Diagnostic (perflutren lipid microspheres, ultrasound)|Patients receive perflutren lipid microspheres IV over 5-6 minutes and undergo ultrasound over 30 minutes. Patients may receive up to 2 additional doses of perflutren lipid microspheres
9894601|NCT05336760||ALS Patients|Patients with confirmed amyotrophic lateral sclerosis.
9894602|NCT05336760||Relatives|Close relatives of the patients included in the study.
9894603|NCT05336747|Experimental|Voice Lessons|Voice Lessons
9894604|NCT05336734|Experimental|Main group|The group underwent a psychotherapy course combining CBT and imagery work. (For full protocol see Prinz et al., 2019)
9894605|NCT05336721|Experimental|Experimental: Chiauranib + capecitabine|Patients receive the combined treatment of Chiauranib plus capecitabine, 21 days as a cycle until objective disease progression.
9894606|NCT05336708|Experimental|Acupressure group|The acupressure (experimental) group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
9894607|NCT05336708|Sham Comparator|Sham Acupressure Group|The sham acupressure group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
9894608|NCT05336695|Experimental|Cognitively Normal Subjects|Healthy volunteers with no history of ADRD
9894609|NCT05336695|Experimental|ADRD Subjects|Volunteers with a clinical diagnosis of ADRD
9932614|NCT00950677|Active Comparator|exenatide|exenatide one dose
9894610|NCT05336695|Experimental|BAnD Subjects|Volunteers referred through the Brain Aging and Dementia (BAnD) research registry
9894611|NCT05336682|Experimental|LSTR with radicular instrumentation.|
9894612|NCT05336682|Experimental|LSTR with no radicular instrumentation.|
9894613|NCT05336682|Active Comparator|Conventional pulpectomy.|
9894614|NCT05336669||Non-smoking|Non-smoking patients undergoing coronary angiography or percutaneous coronary intervention
9894615|NCT05336669||Smoking|Smoking patients undergoing coronary angiography or percutaneous coronary intervention
9894616|NCT05336643|Experimental|Radioisotope and fluorescence guidance|Patients undergoing curative resection for rectal cancer will receive a peritumoural, submucosal administration of indocyanine green and technetium-99m nanocolloid. Intraoperatively the SENSEI gamma probe and Da Vinci Firefly will be used to identify pelvic side wall lymph nodes.
9894617|NCT05336630|Experimental|Forceps Assisted Cannulation|Patients will have a forceps assisted cannulation during their ERCPs.
9894618|NCT05336630|No Intervention|No Forceps Assisted Cannulation|Patients will not have a forceps assisted cannulation during their ERCPs.
9894619|NCT05336604||General population, aged 15 years or more, living in France|Population-based ohort of general population, aged 15 years or more, living in France in May 2020, selected at random from national administrative sample frame
9894620|NCT05336591||Medical doctor|
9894621|NCT05336591||Nurses (Pediatric department and youth healthcare)|
9894622|NCT05336591||Other professionals in treatment (e.g. dieticians, physiotherapists)|
9894623|NCT05336591||Other (such as policy makers)|
9894624|NCT05336578|Experimental|1- PRF|After wisdom tooth extraction PRF located to the extraction socket
9894625|NCT05336578|No Intervention|PRF free|Only surgical procedure of the wisdom tooth extraction is performed
9894626|NCT05336526|Experimental|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Participants who meet the requirements for bilateral breast augmentation in primary intention and have been implanted with ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants
9894627|NCT05336513|Other|Diet Control|"Diet Control (DC): nutritional education and adherence monitoring. DC will be based on the Portuguese Nova Roda dos Alimentos following the principles of the Mediterranean diet."
9894628|NCT05336513|Experimental|Diet Anti-inflammatory|Diet Anti-inflammatory (DAI): nutritional education and adherence monitoring. The DAI dietary intervention will be based on combining individual food items described as potential anti-inflammatory mitigators.
9894629|NCT05336500|Experimental|Pilates method exercises associated with education to keep the abdomen relaxed|The group will receive guidance to perform the exercises in a relaxed and smooth way
9894630|NCT05336500|Active Comparator|Pilates method exercises associated with education to keep the abdomen contracted|The group will receive guidance on the specific activation of the center of strength (the powerhouse)
9894631|NCT05336487|Experimental|Physical Activity group (PA-group)|The intervention group. Participants with intellectual disabilities is recruited from a local daily activity center, where the participants participate in teacher-organized physical activity ~2 hours/day, 5 days/week.
9894632|NCT05336487|No Intervention|Control Group (CON-group)|The control group. The participants with intellectual disabilities is recruited from daily activity centers, which does not use physical activity in their daily work with the participants.
9932615|NCT00950677|Active Comparator|pramlintide|pramlintide one dose
9932616|NCT00950716|Active Comparator|Usual care|The 'control arm' will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
9932617|NCT00950716|Active Comparator|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
9932618|NCT00950768|Active Comparator|Mel100|
9932619|NCT00950768|Experimental|Mel200|
9932620|NCT00950781||Group|Group
9932621|NCT00950794|Active Comparator|Hokunalin(tulobuterol) tape|Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
9932622|NCT00950794|Experimental|Salmeterol(408DP-02)|Salmeterol(408DP-02)：long-acting Beta2-agonist
9932623|NCT00950820|Experimental|Panitumumab + XELOX|KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
9932624|NCT00950820|Other|XELOX (KRAS mutational status wt)|KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
9932625|NCT00950820|Other|XELOX (KRAS mutational status mutant)|KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
9894633|NCT05336435|No Intervention|Control Arm - Current sex-uniform manufacturer provided 99th percentile URL of troponin|Standard use of the current sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women
9894634|NCT05336435|Active Comparator|Intervention Arm - New population and sex-specific 99th percentile URLs of troponin|Implementation of the new population and sex-specific 99th percentile URLs of troponin for the specific assay utilized at the enrolled centers.
9894635|NCT05336422|Experimental|training on the risks associated with sun exposure|power point on the risks associated with sun exposure
9894636|NCT05336409|Experimental|Dose Escalation: Schedule A|Lymphodepleting chemotherapy (LDC) will be followed by single dose administration of CNTY-101, alone or with supplemental human recombinant interleukin 2 (IL-2).
9894637|NCT05336409|Experimental|Dose Escalation: Schedule B|LDC will be followed by administration of CNTY-101, 3 times over 3 weeks, alone or with supplemental IL-2.
9894638|NCT05336396|Experimental|BMI|
9894639|NCT05336396|No Intervention|Traditional Oral Hygiene Instruction|
9894640|NCT05336370|Experimental|Hypnosis|A brief hypnosis session will be provided to participants in this arm prior to immersion in the cold water.
9894641|NCT05336370|Experimental|Active tVNS|Participants in the active tVNS condition will receive electronic stimulation of the vagus nerve prior to immersion in the cold water.
9894642|NCT05336370|Sham Comparator|Sham tVNS|Participants in the sham tVNS will receive the electrode similar to the active treatment, but no stimulation will be performed.
9894643|NCT05336357|Experimental|Goal-Directed Therapy Group|Patients allocated to the Goal-Directed Therapy group will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours after randomization, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously.
9894644|NCT05336357|No Intervention|Conventional Therapy Group|Patients allocated to the Conventional Therapy Group will be treated according to the assistant team of the Emergency Unit, where will be measured the following parameters: invasive or non-invasive blood pressure (decided by the assistant team), peripheral oximetry, heart and respiratory rate, urinary output, in association with clinical history, complete physical examination and laboratory and imaging tests.
9894645|NCT05336344|Experimental|ENCODE Group|The intervention consists of three weekly video-conferencing sessions scheduled at the caregiver's convenience. Each session is scheduled to last approximately 40 minutes. The ENCODE intervention is manualized and has related curriculum designed specifically for caregivers of patients with ADRD. The agenda for the first session (week 1) includes an assessment of caregivers' pain management challenges and concerns. Once the barriers or challenges are identified, the interventionist works specific problem solving therapy steps covered over the three sessions.
9894646|NCT05336344|No Intervention|Attention Control Group|"Caregivers in the attention control group will receive standard hospice services and complete the same measures and receive the same number of contacts as participants in the intervention group. Three video-conferencing calls will be scheduled based on the caregiver's availability following, if possible, a timeline between days 5 and 30 of the hospice admission. During these calls, the interventionist will allow caregivers in the attention control group to discuss their feelings, thoughts, and relationships. This friendly call intervention controls for the nonspecific aspects of treatment, i.e., the passage of time, amount of contact with a researcher, and the general support of an empathic, concerned and skilled professional and is based on the principles of nondirective supportive therapy."
9894647|NCT05336331||laparoscopic sleeve gastrectomy (SG)|Patients operated on with a SG
9894648|NCT05336331||laparoscopic Roux-en-Y gastric bypass (RYGB)|patients operated on with aRYGB
9894649|NCT05336318|Experimental|Intervention group|
9894650|NCT05336318|No Intervention|Control group|
9894651|NCT05336305|Placebo Comparator|Placebo Group|Administration of corn starch daily for 2 months
9894652|NCT05336305|Experimental|polydextrose|Administration of 12g polydextrose daily for 2 months
9894653|NCT05336292|Active Comparator|Meaningful life intervention|We will work with psychological skills, meaningful life model, mindfulness skills ,personal values, the Wellbeing Model (Ryff, 1989) . The strengths of character (Park et al., 2004) and sources meaningful life. We will identify ways to use strengths and enhance meaningful life and develop an action plan to improve strengths. ). To identify the Meaning at the work. Link our strengths and values to our goals and purposes. Apply the SMART Method to achieve meaningful goals. Visualizing Our Best Future Self (Burton & King, 2004).
9894654|NCT05336292|Active Comparator|Meaningful life and emotional regulation|Program Based on meaningful life and Emotional Regulation (MLI+ER) Session 1 Emotional regulation as a path towards the meaningful life Mindfulness training (emotional mindfulness) Generate knowledge of emotions and their functioning Session 2 Emotional Psychoeducation Emotional care To Know the well-being model Carol Ryff and Vital Sense To Understand the process of emotional regulation Session 3 Strengths and Personal Values Cultivate introspection and self-knowledge (Mindfulness, Carlson, 2013; Klussman, 2020) To Know the strengths of character (Park et al., 2004) and sources of vital meaning Identify ways to use strengths and enhance the sense of life Making Core Values Real (My 80th Birthday Speech; Harris, 2009) Note: Sessions 4, 5 and 6 are the same as the intervention based on meaningful life
9894655|NCT05336292|Active Comparator|Control group|The waiting list will be the control group. Participants will not be part of the program. They will participate in a day of positive psychology
9894656|NCT05336279|Experimental|Treatment group TR|T - R
9894657|NCT05336279|Experimental|Treatment group RT|R -T
9894658|NCT05336266|Experimental|Ketorolac (open label)|Pancreatic patients receiving Ketorolac four times a day for up to five days
9991532|NCT01453842|Active Comparator|Olive oil|
9894659|NCT05336253|Experimental|EVERYbody Project-Connect Online Program|"Three weekly 90-minute online group sessions facilitated by expert peer leaders. Retains key dissonance activities and the inclusivity focus of the original EVERYbody Project (e.g., expanded gender focus, critically discussing the impact of limited diversity representation in cultural appearance norms). Additional activities were added, including an increased focus on body compassion (self-acceptance) and weight neutrality content to target weight bias.~College students with body image interest and lived or academic diversity and advocacy experience will complete 16 hours of training to become expert peer leaders. Training includes observation, practice, and feedback on using the program manual and managing groups. Students will self-assess and be evaluated by the primary trainer on facilitation readiness. Only peer leaders with sufficient expertise will be invited to facilitate groups."
9894660|NCT05336253|Active Comparator|Self-Help Workbook|In this time-matched comparison intervention, participants will be provided with an online copy of The Body Is Not An Apology Workbook by author and activist Sonya Renee Taylor (2021). Weekly emails will assign workbook activities to complete on their own (90 minutes per week for three weeks). This low-dissonance comparison intervention covers many of the same topics within the EVERYbody Project-Connect (body acceptance and scrutinizing the diversity within body ideals) and its activities include reflective writing and drawing exercises to challenge media messages around bodies, identify systems of oppression underpinning body messages, challenge body stereotypes, and make peace with your own body. Activities within the workbook are considered low-dissonance since they will be done privately and not shared.
9894661|NCT05336240|Active Comparator|PCOM Standard Arm|"Providers in participating in the PCOM-standard intervention will be trained on optimizing an in-person provider communication technique about HPV vaccination by training primary care providers in a 2-step verbal communication process: 1) to start the HPV vaccine discussion using a presumptive format, and 2) to use motivational interviewing (MI) techniques to address parental vaccine hesitancy."
9894662|NCT05336240|Experimental|PCOM2 Virtual Arm|"Providers participating in the PCOM2-virtual arm will receive training on this communication method through an adapted virtual model of PCOM-standard.~PCOM2-Virtual intervention will result in a shelf ready intervention and associated User Manual that can be easily incorporated into practices broadly to improve the practice's adolescent HPV vaccination rates. PCOM-Virtual arm will then be compared to that of the original PCOM-standard intervention in its efficacy for increasing HPV vaccination among adolescents."
9894663|NCT05336214|Experimental|Refer|Practice referral of patients to a virtual CGM initiation service
9894664|NCT05336214|Experimental|Learn|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care
9894665|NCT05336214|Experimental|Learn + Practice Facilitation|Practice completion of online educational module, American Academy of Family Physicians (AAFP) Transformation in Practice Series (TIPS) on continuous glucose monitoring in primary care plus practice facilitation
9894666|NCT05336201|Experimental|C-READY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Self-management and goal-setting cognitive remediation
9894667|NCT05336201|Other|Wait-List Control Group|Will receive the same C-READY intervention after a 4-week wait period
9894668|NCT05336188|Experimental|Smartphone|Participants randomized into the Smartphone app arm would use the smartphone app OptiMAT in conjunction with treatment as usual (TAU). Participants would use OptiMAT to complete daily self-assessments of opiate misuse, opiate craving, opiate withdrawal, and mood. The app will personalized feedback for maintaining abstinence goals. The app would also use geographic ecological momentary assessment (GEMA) to intervene via push notification when participants enter areas previously identified as high-risk for opiate use.
9894669|NCT05336188|No Intervention|Monitoring Only|Participants randomized into the Monitoring Only arm would undergo treatment as usual (TAU) but without the smartphone app.
9894670|NCT05336175|Experimental|Ang-(1-7)|30 participants will take 100 micrograms of Ang-(1-7) a day via subcutaneous injection for 90 days
9894671|NCT05336175|Placebo Comparator|Saline Placebo|10 participants will take 100 micrograms of saline placebo a day via subcutaneous injection for 90 days
9894672|NCT05336162|Experimental|Patients with non-cavitated pits and fissures in permanent molars will be treated with BeautiSealant|Young adults (16-22 y) who have existing pits and fissures that are anatomically deep and caries susceptible or with Stained pits and fissures with minimum decalcification of opacification and no softness at the base of the fissure (ICDAS 1 and 2).
9894673|NCT05336162|Active Comparator|Patients with non-cavitated pits and fissures in permanent molars will be treated with UltraSeal XT|Young adults (16-22 y) who have existing pits and fissures that are anatomically deep and caries susceptible or with Stained pits and fissures with minimum decalcification of opacification and no softness at the base of the fissure (ICDAS 1 and 2).
9894674|NCT05336149|Experimental|Whole-tooth dentin graft|The extracted tooth will be prepared as whole-tooth dentin graft and inserted in the extraction socket.
9894675|NCT05336149|Active Comparator|Particulate dentin graft|The extracted tooth will be prepared as particulate dentin graft and inserted in the extraction socket.
9894676|NCT05336136|Experimental|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
9894677|NCT05336136|Active Comparator|Current commercial mask|Current commercial mask used by the participant for administration of non-invasive ventilation
9932626|NCT00950924|Experimental|Bifocal Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
9991533|NCT01453842|Placebo Comparator|Carrot|
9894678|NCT05336123|Experimental|Hatha Yoga|Participants will be invited to attend one 60-75 minute yoga class for 10 weeks in the prison facility where they reside. Each class will consist of: breathing exercises, brief guided centering meditation, warm-ups, standing postures, floor postures, an inversion, relaxation, and between-class practice assignments. Classes will emphasize mindfulness, including noticing emotions, thoughts, and physical sensations related to anger, and moderate physical activity. Classes will include some teaching of a relevant yoga theme, such as nonviolence (ahimsa).
9894679|NCT05336123|Active Comparator|Health Education|To match for attention, the control condition will be a 10-week program that consists of weekly 60-75 minute group classes. In classes, instructors will provide information about general health topics through a variety of means such as slides and handouts. There will be an emphasis on group discussion of relevant topics; instructors do not just lecture. The core rationale for this course is that good physical health is important for good mental health. Instructors will provide information and encourage questions but avoid psychotherapeutic techniques or personalized goal-setting. Instructors will give participants readings to explore on their own.
9894680|NCT05336110||Patient with a positive preoperative SARS-CoV-2 test|Patient with a positive preoperative SARS-CoV-2 test
9894681|NCT05336097|Experimental|Intervention group|"Participants in this group will receive support from professionals trained in Pathways to Empowerment (PTE).~These professionals received a four-day training program with two weeks in between each training day, allowing them to immediately implement their acquired set of knowledge and skills. At the end of the training program, professionals had to successfully pass an end assignment to become PTE-certified.~In order to ensure the implementation of PTE, the training will be supplemented with a learning cycle. This cycle consists of several workshops and on-the-job coaching. A part of this cycle is predetermined (e.g., a workshop on the lived experiences of poverty); the other part is tailored to the wishes and needs of each team."
9894682|NCT05336097|No Intervention|Control group|Participants in this group receive support as usual (i.e., social domain professionals are not trained in Pathways to Empowerment). This pretest-posttest control group design is used in the area of Nieuwegein only. In the municipality of Nijmegen, a one-group pretest-posttest design is used (i.e., no control group).
9894683|NCT05336084|Experimental|Ultradian Sleep/Wake protocol|This study uses an ultradian sleep/wake protocol to examine circadian and homeostatic sleep systems and their contributions to reward and cognitive control function. All participants will undergo the ultradian sleep/wake protocol following a night of sleep in the lab (measured with polysomnography) for 36 hours. The ultradian sleep/wake protocol will last for 36 h, during which every 120-minutes, there will be an 80-minute period of waking, followed by a 40-minute sleep opportunity. A repeat night of sleep will occur at the end of the 36-hour ultradian sleep/wake protocol.
9894684|NCT05336071|Experimental|Treatment group A|T - R(T: new formulation, R: old formulation)
9894685|NCT05336071|Experimental|Treatment group B|R -T(T: new formulation, R: old formulation)
9894686|NCT05336058||Gastric cancer group|A total of about 500 cases are expected to be enrolled, including 150 cases in stage I and 100 cases in II-IV. Pathological diagnosis is required.
9894687|NCT05336058||Negative group|A total of about 740 cases were included, including 400 cases without abnormal gastroscopy, 100 cases with other cancers, and 240 cases with precancerous gastric cancer and other lesions.
9894688|NCT05336032|Active Comparator|Oral glucose tolerance test|The volunteer will be performing the standardized oral glucose tolerance test with 75 gm of glucose. After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
9894689|NCT05336032|Experimental|Post prandial response to Rice|The participants will be served cooked basmati rice (70-gram available glucose). After an overnight fast of 10 hours the venous blood will be collected at fasting, 30, 60 and 120 minutes post-prandial and hunger-satiety scale recorded at the same interval.
9894690|NCT05336019|Experimental|"Diabetes self-management Coaching"|Participate in a 12-week Diabetes self-management Coaching program and the usual care
9894691|NCT05336019|Active Comparator|"Usual Care"|The control group will be assigned to 12 weeks usual care or routine diabetes service
9894692|NCT05335993|Experimental|Combination of Oregovomab and Niraparib|"Niraparib (300/200 mg) will be administered orally once daily.~Oregovomab (2 mg) will be administered via IV infusion on Day 1 of Week 1, Week 4, Week 7, Week 12, and Week 20."
9894693|NCT05335980|Experimental|Nu-V3 Device|Treatment with the Nu-V3 Device.
9894694|NCT05335967|Experimental|Self-management group|The experimental group will receive the self-management program for 12 weeks.
9894695|NCT05335967|Other|Information group|The control group will receive an information package on a healthy diet.
10212133|NCT02366728|Experimental|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
10212134|NCT02366728|Experimental|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td) (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.
9894698|NCT05335941|Experimental|Pemetrexed Plus AB928 (Etrumadenant) Plus AB122 (Zimberelimab)|All patients will receive combination therapy of pemetrexed and ZIMBERELIMAB (AB122) intravenously every 3 weeks as well as ETRUMADENANT (AB928) orally daily.
9894699|NCT05335928|Experimental|Abatacept plus standard of care|Abatacept (10 mg/kg) will be administered IV after randomization, again at 24 hours after first study drug treatment, at 14 days after first study drug treatment and an optional 4th dose at 28 days.
9894700|NCT05335928|Placebo Comparator|Placebo plus standard of care|Placebo will be administered at the same intervals.
9894701|NCT05335915|Experimental|Original/Tobacco Flavored Pouch (low nicotine dose)|participants will use a tobacco flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
9894702|NCT05335915|Experimental|Original/Tobacco Flavored Pouch (high nicotine dose)|participants will use a tobacco flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
9894703|NCT05335915|Experimental|Mint/Menthol Flavored Pouch (low nicotine dose)|participants will use a mint/menthol flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
9894704|NCT05335915|Experimental|Mint/Menthol Flavored Pouch (high nicotine dose)|participants will use a mint/menthol flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
9894705|NCT05335915|Experimental|Fruit Flavored Pouch (low nicotine dose)|participants will use a fruit flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
9894706|NCT05335915|Experimental|Fruit Flavored Pouch (high nicotine dose)|participants will use a fruit flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
9894707|NCT05335915|Active Comparator|Own brand cigarettes|participants will smoke participants' own brand of cigarettes under both controlled (experimenter-directed) and ad libitum use conditions
9894708|NCT05335902||standard cardiopulmonary bypass|patients 18 year or older undergoing heart surgery with standard cardiopulmonary bypass
9894709|NCT05335902||mini-cardiopulmonary bypass|patients 18 year or older undergoing heart surgery with standard mini-cardiopulmonary bypass
9894710|NCT05335889||Type 2 Diabetes group|Participants with Type 2 Diabetes will wear eButton and Continuous Glucose Monitoring (CGM) for 2 weeks and complete food diaries to record carb grams.
9894711|NCT05335876|Experimental|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec|Patients who received OAV101 IT or OAV101 IV in AveXis/ Novartis or Novartis Gene Therapies Phase I to IIIb clinical trials
9894712|NCT05335863|Experimental|Experimental|Ingestion of FontActiv® DiaBest high protein/hypercaloric
9894713|NCT05335863|Placebo Comparator|Control|Ingestion of glucose standard solution
9894714|NCT05335850|Experimental|Intervention Group|Breathing and Wellness Webinar: a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
9894715|NCT05335850|Active Comparator|Waitlisted Control Group|This group will be asked to wait for 6 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
9894716|NCT05335837||General Anesthesia|patients received general anesthesia for inguinal hernia repair
9894717|NCT05335837||Regional Anesthesia and Sedation|patients received ilioinguinal/iliohypogastric nerve blocks and sedation for inguinal hernia repair
9894718|NCT05335824|Experimental|The platelet-rich plasma (PRP) group:|The patients in this group received PRP injections immediately before the canine retraction, and after 8 weeks of the onset of retraction
9894719|NCT05335824|Experimental|The injectable platelet-rich fibrin (I-PRF) group|The patients in this group received I-PRF injections immediately before the canine retraction, and after 8 weeks of the onset of retraction
9894720|NCT05335824|Active Comparator|The control group|The patients in this group did not receive any injections
9894721|NCT05335811|Experimental|4-[18F]Fluoro-1-Naphthol|Participants will receive 1 injection of [18F]4FN
9894722|NCT05335798|Experimental|Adults with Cerebral Palsy|Adults with Cerebral Palsy who are able to be self-ambulatory for minimum 100 feet
9894723|NCT05335785|Active Comparator|5 session lazer therapy|30 patients will be included to 5 session lazer therapy group. They will take totally 5 sessions of high-intensity laser every other day.
9894724|NCT05335785|Active Comparator|10 session lazer therapy|30 patients will be included to 10 session lazer therapy group. They will take totally 10 sessions of high-intensity laser every other day.
9894725|NCT05335785|Other|control group|30 patients will be included to control group. They will take only exercise program three times in a week.
9894726|NCT05335772|Experimental|VR-AOT|Experimental group, observing actions in virtual reality
9894727|NCT05335772|Other|VR-LO|Control group, observing a matched dose of videos depicting landscapes in virtual reality
9894728|NCT05335746||Vitiligo patients on therapy|Patients diagnosed as vitiligo and on systemic and local therapy.
9894729|NCT05335746||Control group|Normal subjects recruited from ophthalmology clinic and visit the clinic for regular check-up.
9894730|NCT05335733||Postmenopausal women|
9894731|NCT05335733||Premenopausal women|
9894732|NCT05335720|Active Comparator|Cohort 1|"EASYEF® + moist gauze EASYEF® is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
9894733|NCT05335720|Active Comparator|Cohort 2|"EASYEF® + tulle gauze + moist gauze EASYEF® is applied directly on the wound surface then tulle gauze and moist gauze is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
9894734|NCT05335694||1. General Use/Healthy Control Subjects|Subjects between 18-75 who are willing and able to perform testing procedures may be included in this cohort of the study.
9894735|NCT05335694||2. ESKD Subjects|Non-invasive device worn over vasculature.
9894736|NCT05335681|Experimental|Experimental group;|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen, and groin areas will be applied
9894737|NCT05335681|No Intervention|Control group|No intervention will be made in the control group. In stages where the dilatation gap is 4 and 7 cm, the pain will be evaluated with the VAS scale at 0, 10, and 20 minutes.
9894738|NCT05335668|Experimental|Patients with central poststroke pain|Patients with central poststroke pain
9894739|NCT05335668|Experimental|Patients without central poststroke pain|Patients without central poststroke pain
9894740|NCT05335668|Active Comparator|healthy controls|healthy volunteers
9894741|NCT05335655|Active Comparator|Group A|IV bolus of dexmedetomidine, blindly administered and tittered to 0.5mcg per kilogram (real weight), diluted in 10 ml of 0.9% saline solution during 15 minutes before the spinal block. Once the anesthetic effect is confirmed, the maintenance IV infusion, based on dexmedetomidine 100 mcg diluted in 100 ml of 0.9% saline solution tittered at 0.5 mcg per kilogram per hour (real weight), begins.
9894742|NCT05335655|Placebo Comparator|Group B|IV 10 ml initial bolus of 0.9% saline solution during the 15 minutes before the spinal block. Once de anesthetic effect is confirmed, the maintenance infusion of IV 0.9% saline solution (100 ml in equivalent dosage per hour) begins.
9894743|NCT05335642||Patients that had secondary interventions after EVAR|
9894744|NCT05335642||Patients without secondary interventions after EVAR|
9894745|NCT05335629|Active Comparator|Intervention arm|"30 patients will receive standard of care in addition to the SGLT2 Dapagliflozin 10 mg daily for 4 Weeks~Interventions:~Drug: Dapagliflozin 10 mg oral tablets Standard of care: Dual antiplatelet therapy, Statin, anticoagulation therapy"
9894746|NCT05335629|No Intervention|Control arm|30 patients will receive standard of care (Dual antiplatelet therapy, Statin, anticoagulation therapy) for 4 weeks
9894747|NCT05335577||Preterm neonates with NEC|Preterm neonates with gestational age of 28-32 weeks and diagnosed with Necrotizing Enterocolitis based on Bell's modification criteria.
9894748|NCT05335577||Preterm neonates without NEC|Preterm neonates with gestational age of 28-32 weeks and without Necrotizing Enterocolitis based on Bell's modification criteria.
9894749|NCT05335577||Healthy term neonates|Term neonates with gestational age of 37-42 weeks without any comorbidities.
9894750|NCT05335564|Experimental|General information about depression|Exposure to general information about depression
9894751|NCT05335551||Patients monitored with TruGraf/TRAC Liver testing|"Subjects in the biomarker arm will have TruGraf Liver and TRAC Liver testing at study enrollment (1-2 months post-liver transplant) and thereafter every month for 6 months. Subjects will also have Trugraf Liver and TRAC Liver testing at months 9 and 12 following transplantation (7-8 and 10-11 months postbaseline)~The TruGraf and TRAC Liver results will be used in the biomarker arm in conjunction with all other clinical parameters available to guide decisions of the Principal Investigator and Sub-Investigators related to immunosuppression management.~changes."
9894752|NCT05335551||Patients not monitored with TruGraf/TRAC Liver testing|Patients in control/ stamdard of care arm will have immusuppresion reduction based on the clinical judgement and management of the Principal Investigator and Sub-Investigators.
9894753|NCT05335512||Patients underwent TURBT|Patients undergoing complete TURBT for evaluation of a newly diagnosed bladder lesion in TMH and found to have NMIBC (either low risk or high risk)
9894754|NCT05335499|Experimental|TAS5315 Dose 1|
9894755|NCT05335499|Experimental|TAS5315 Dose 2|
9894756|NCT05335499|Experimental|TAS5315 Dose 3|
9894757|NCT05335499|Experimental|AS5315 Dose 4|
9894758|NCT05335499|Experimental|TAS5315 Dose 5|
9894759|NCT05335499|Placebo Comparator|Placebo|
9894760|NCT05335473|Experimental|Eribulin plus Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
9894761|NCT05335460|Experimental|Envafolimab combined with XELOX regimen|Envafolimab:300mg,sc,d1,Q3W XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w)
9894762|NCT05335447|Experimental|Period 1 - Absolute Bioavailability|
9894763|NCT05335447|Experimental|Period 2 - Mass Balance|
9894764|NCT05335434|Experimental|INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT|"The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations. Participants will receive the study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first~-THOR LX2.3 with LED Lollipop"
9894765|NCT05335421|Experimental|Mindfulness Intervention plus Standard of Care|The Foundations and Awareness modules of the HMP app require a minimum of 133 and 253 minutes, equating to less than 5 and less than 10 minutes per day on average, respectively. Date, duration, and content of usage will be recorded for each participant through the app. Participants will have access to the entire contents of the app for the full duration of the study.
9894766|NCT05335421|No Intervention|Standard of Care|Control group receives standard of care only
9894767|NCT05335395|Experimental|SUNRISE clusters|SUNRISE campaign broadcast through local radio stations plus broadcasting as usual
9894768|NCT05335395|No Intervention|Control clusters|Local radio stations broadcast as usual
9894769|NCT05335382|Experimental|Implementing PCBH directly|PCCs randomized to this arm will immediately start the implementation of PCBH.
9894770|NCT05335382|Active Comparator|Delayed implementation of PCBH|PCCs randomized to this arm will have a delayed start of their PCBH implementation, waiting between 5-9 months. During this time, the same patient-level and organizational-level data will be collected from these centers while they continue to use traditional primary care / Care As Usual (CAU) .
9894771|NCT05335356|Experimental|Bmab1200|Bmab 1200 45 mg Bmab 1200 90 mg
9894772|NCT05335356|Active Comparator|Stelara|Stelara 45 mg Stelara 90 mg
9894773|NCT05335330||Group: Pregnant women (first pregnancy)|This group will consist of women in the first trimester of pregnancy. Pregnant women will be evaluated 3 times in total, each measurement being in a different trimester.
9894774|NCT05335317|Experimental|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks.~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
9894775|NCT05335317|Active Comparator|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy, when the suppository will be used of 2 times a week for 1.5-2 months to prevent symptoms.
9894776|NCT05335317|Other|No treatment|Participants without vaginal atrophy (no complaints of vaginal health and a vaginal health index greater than 20) and not receiving any treatment.
9894777|NCT05335304|Active Comparator|intervention group 1|Kinesio taping and standard treatment program
9894778|NCT05335304|Active Comparator|intervention group 2|Rigid taping and standard treatment program
9894779|NCT05335304|Active Comparator|intervention group 3|Thoracic Mobilization and standard treatment program
9894780|NCT05335304|Active Comparator|intervention group 4|Core Stabilization and standard treatment program
9894781|NCT05335304|Other|Control group|No intervention, only standard treatment program
9894782|NCT05335291||Group I|
9894783|NCT05335278|Experimental|Nintedanib treatment|Single arm treatment with nintedanib
9894784|NCT05335265|Active Comparator|FIT (face-to-face inhaler training)|"Face-to-face inhaler training.~o The trainers watched the Turkish Thoracic Society (TTS) MDI training video before giving the training.~Training given 3 times on the first day, 2 times on the 2nd day, and once on the 3rd day.~During discharge, inhaler technic was checked according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by TTS.~The trainer and the inhaler technical controller are different."
9991534|NCT01453868|Active Comparator|Active non impact aerobics|This group will be performing a 12 week non impact aerobics program twice a week.
9991535|NCT01453868|Active Comparator|Control group: Passive lecture series|The control group will also be measured for balance and then attend a 12 week lecture series with no exercise. They will then also be remeasured post lectures series
9991536|NCT01453881|Experimental|Spacer|Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
9991537|NCT01453881|Active Comparator|Comparator|Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
9991538|NCT01453907|Experimental|ETI-204|ETI-204, Anthim
9991539|NCT01453907|Sham Comparator|placebo|
9991540|NCT01453920|Active Comparator|Treat-and-extend|Ranibizumab injection every 3 months, with follow-up assessments at each visit (every 3 months)
9991541|NCT01453920|Experimental|Treat-and-observe'|No injection, follow-up assessments every month
9991542|NCT01453933|Active Comparator|Raltegravir|At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).
9991543|NCT01453933|No Intervention|Lopinavir/ritonavir|Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)
9991544|NCT01453959|Other|Diet cycles|The patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days). After 4 weeks without any intervention, the patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days.
9991545|NCT01453959|Other|Fludrocortisone|The patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days. After 4 weeks without any intervention, the patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days).
9991546|NCT01453972|Experimental|Long distanse moderate training|40 minutes moderate treadmill running
9991547|NCT01453972|Experimental|Long interval training|4x4min interval treadmill running
9991548|NCT01453972|Experimental|Short interval training|10x1min interval treadmill running
9991549|NCT01453985|Experimental|Full-Thickness-Gastroplication|
9991550|NCT01454011|Active Comparator|Testosterone 250mg injection,|
9991551|NCT01454011|Active Comparator|Testosterone transdermal application|
9991552|NCT01454024||Total study population|
9991553|NCT01454037||Prostate cryoablation|Subjects receiving cryotherapy for prostate cancer
9991554|NCT01454037||Radical prostatectomy|Subjects receiving radical prostatectomy
9991555|NCT01454037||Radiation|Subjects receiving radiation for prostate cancer
9991556|NCT01454115|Experimental|Panel 1: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
9991557|NCT01454115|Experimental|Panel 2: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
9991558|NCT01454115|Experimental|Panel 3: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
9991559|NCT01454115|Experimental|Panel 4: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
9991560|NCT01454115|Experimental|Panel 5: BMS-708163 or Placebo|"Healthy male subjects (age: 18 to 45 years).~In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.~In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1"
9991561|NCT01454115|Experimental|Panel 6: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
9991562|NCT01454115|Experimental|Panel 7: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
9991563|NCT01454115|Experimental|Panel 8: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
9991564|NCT01454115|Experimental|Panel 9: BMS-708163 or Placebo|Healthy, elderly male subjects (age: 60 years and greater)
9991565|NCT01454115|Experimental|Panel 10: BMS-708163 or Placebo|Healthy, elderly female subjects (age: 60 years and greater)
9991566|NCT01454115|Experimental|Panel 11: BMS-708163 or Placebo|Healthy male subjects (age: between 46 to 59 years)
9991567|NCT01454115|Experimental|Panel 12: BMS-708163 or Placebo|Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
9991568|NCT01454115|Experimental|Panel 13: BMS-708163 or Placebo|Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
9894785|NCT05335265|Experimental|VIT (virtual inhaler training)|"Virtual Training was gave 3 times on the first day, 2 times on the 2nd day, and once on the 3rd day (discharge) by the TTS Virtual training video.~During discharge, inhaler technics of the patient's were controlled according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by the TTS.~o The inhaler technique controller and the trainer are different."
9894786|NCT05335252|Experimental|Dronabinol|Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
9894787|NCT05335252|Placebo Comparator|Placebo|Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
9894788|NCT05335239|Experimental|Intervention group|Every third month, a dental nurse will visit at home and deliver professional dental cleaning and delivery of one new toothbrush and fluoride toothpaste (>4000ppm) (n:3) for the next three months. The visit is expected to take at the most 30 minutes.
9894789|NCT05335239|No Intervention|Controll group|Continuous with oral care as usual, either by themselves or nursing assisted (help with oral hygiene procedure) during the whole study period. Home care aides working with the control study participants deliver a toothbrush and fluoride toothpaste (> 4000 ppm) (n:3) every third month during the study period.
9894790|NCT05335226|Experimental|Haplo-HSCT group|58 patients will be involved in this group
9894791|NCT05335226|Experimental|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation group|58 patients will be involved in this group
9894792|NCT05335213||Participants with cirrhosis and urinary tract infections|"Participants collect urine and fecal specimens at first two days when they admit to hospital, after 7-10 days and last two days hospital treatment and during episodes of complications (variceal bleeding, hepatic coma, hepatorenal syndrome).~Urine samples take from patients via clean catch if the patient not have a catheter placed, otherwise take from urinary catheters if present. Straight catheterization utilize if the patient unable to void and doesn't have a catheter placed.~Fecal specimens collect using a toilet specimen collection kit. Clinical, standart laboratory and cultural test, molecular genetic methods, using 16S rRNA gene sequencing of the V4-V5 hypervariable region be administered."
9894793|NCT05335213||Participants with cirrhosis without urinary tract infections|"Participants ask to collect urine and fecal specimens at first two days when they admit to hospital, after 7-10 days and last two days hospital treatment and during episodes of complications (variceal bleeding, hepatic coma, hepatorenal syndrome).~Urine samples take from patients via clean catch if the patient not have a catheter placed, otherwise take from urinary catheters if present. Straight catheterization utilize if the patient unable to void and doesn't have a catheter placed.~Fecal specimens collect using a toilet specimen collection kit. Clinical, standart laboratory and cultural test, molecular genetic methods, using 16S rRNA gene sequencing of the V4-V5 hypervariable region be administered."
9894794|NCT05335200|Experimental|(S)-[18F]FBFP injection and PET/CT scan|Patients will be intravenously injected with(S)-[18F]FBFP and undergo PET/CT scan.
9894795|NCT05335187|Experimental|micro-macro electrode|In this single-arm, open-label study, all patients receive one or a handful of micro-macro electrode (MME) in place of conventional intracranial EEG electrodes.
9894796|NCT05335174||HPI monitor|
9894797|NCT05335161|Experimental|Home-based leg heat therapy|Patients will be provided with the Aquilo heat therapy device and will be instructed on how to operate the equipment. The device will be used in accordance to the manufacturers recommendations. Patients will be asked to apply the therapy daily in the home setting for 12 week (90 min/day, 7 days/week).
9991569|NCT01454115|Experimental|Panel 15: BMS-708163 or Placebo|Healthy young male subjects
9894798|NCT05335148|No Intervention|Standard of care arm - placebo colchicine pill|The standard of care arm will receive a placebo colchicine pill once a day
9894799|NCT05335148|Experimental|Experimental arm - oral colchicine once a day|The experimental arm will receive 0.6 mg of oral colchicine once a day
9894800|NCT05335135||Pre-Implementation|Usual care will be provided during all ED patient encounters.
9894801|NCT05335135||Post-Implementation|TriageGo-MDW CDS will be made available during all ED patient encounters at two points in the ED care continuum: (1) shortly after arrival during initial ED triage (First Triage) and (2) after initial laboratory results have been populated within the EHR. General illness severity estimates will be provided to nurses at ED triage in the form of recommended triage acuity scores (CDS for First Triage). General illness severity estimates along with estimated risk for specific outcomes including sepsis and septic shock will be presented to clinicians after laboratory results have populated (CDS for Early Assessment). TriageGO-MDW risk estimates will be generated by machine learning algorithms using routinely available clinical data as predictor inputs. Nurses and clinicians will receive risk estimates within existing EHR workflows, along with brief and rapidly interpretable explanations of the logic driving each risk estimate.
9894802|NCT05335122|Experimental|OTX-TIC Low Dose|Travoprost Intracameral Implant low dose
9894803|NCT05335122|Experimental|OTX-TIC High Dose|Travoprost Intracameral Implant high dose
9894804|NCT05335122|Active Comparator|Durysta|Bimatoprost Intracameral Implant 10 µg
9894805|NCT05335096|Experimental|Intervention group|
9894806|NCT05335096|Active Comparator|TAU group|
9894807|NCT05335083|Experimental|CPAP on condition|Participants in this arm will begin by using their CPAP as per usual for 2 weeks. Then they will undergo 2 weeks of CPAP withdrawal and stop using their CPAP machine.
9894808|NCT05335083|Experimental|CPAP off condition|Participants in this arm will withdraw from their regular CPAP use for 2 weeks. They will then resume their CPAP use for 2 weeks as usual.
9894809|NCT05335057|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
9894810|NCT05335057|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
9894811|NCT05335057|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
9894812|NCT05335057|Experimental|Time 4|Participant will be randomly assigned to the remainingintervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
9894813|NCT05335044|Experimental|Sequence A|"Period 1: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 3: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-331 - A single oral dose of 2 tablets under fasting condition"
9894814|NCT05335044|Experimental|Sequence B|"Period 1: CKD-331 - A single oral dose of 2 tablets under fasting condition~Period 2: EX5619 - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-331 - A single oral dose of 2 tablets under fasting condition~Peirod 4: EX5619 - A single oral dose of 1 tablet under fasting condition"
9894815|NCT05335031||Participants with relapsing-remitting multiple sclerosis (RRMS) treated with Ozanimod|
9932627|NCT00950924|Placebo Comparator|Single Vision Soft Contact Lenses|Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.
9932628|NCT00950976|Experimental|Citrulline|
9932629|NCT00950976|Placebo Comparator|lemonade|Equal volume and flavor to citrulline.
9932630|NCT00951002||acellualr dermal matrix|patients treated with acellular dermal matrix plug
9932631|NCT00951028|Active Comparator|Enhanced treatment as usual|Participants will receive the life-steps intervention and treatment as usual.
9932632|NCT00951028|Experimental|CBT for adherence and depression (CBT-AD)|Participants will receive the life-steps and CBT-AD interventions.
9932633|NCT00951028|Active Comparator|ISP for adherence and depression (ISP-AD)|Participants will receive the life-steps and ISP-AD interventions.
9932634|NCT00951067|Active Comparator|Group A|Exercise, Elevation, and Garment Compression
9932635|NCT00951067|Active Comparator|Group B|Pneumatic Compression Device (B)
9932636|NCT00951067|Active Comparator|Group C|Pneumatic Compression Device (C)
9932637|NCT00951067|Active Comparator|Group D|Pneumatic Compression Device (D)
9932638|NCT00951067|Active Comparator|Group E|Pneumatic Compression Device (E)
9932639|NCT00951106|Experimental|Pyrimethamine/sulfdoxine (Fansidar)|Pyrimethamine/sulfdoxine (Fansidar)
9932640|NCT00951119|Experimental|resperate device|"Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim<10 breathings per minute)."
9932641|NCT00951119|Sham Comparator|control device|Resperate device without slowing of breathing
9932642|NCT00951132|Experimental|2|Rosuvastatin
9932643|NCT00951132|Placebo Comparator|1|Placebo
9991570|NCT01454128|Active Comparator|Non-EPB|with exercise
9894816|NCT05335018|Experimental|Treatment|"total 2years. Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
9894817|NCT05334992|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) combines the ideas of cognitive therapy with meditative practices and attitudes based on the cultivation of mindfulness. The heart of this work lies in becoming acquainted with the modes of mind that often characterize mood disorders while simultaneously learning to develop a new relationship to them.
9894818|NCT05334992|Experimental|Behavior Activation|BA Increase reinforcing behaviors in order to influence emotions and cognitions.
9894819|NCT05334966|No Intervention|Historical LHH Controls|Previous women with a dx of fetal LHH and whose care was continued at Texas Children's Hospital.
9894820|NCT05334966|Placebo Comparator|Healthy Fetal Controls|Healthy mothers with healthy fetuses that will come in monthly for fetal echcos starting at 20 wks.
9894821|NCT05334966|Experimental|Chonic Maternal Hyperoxygenation w/ LHH|Mothers who have a fetus diagnosed with LHH and elect daily maternal hyperoxygenation therapy.
9894822|NCT05334966|Experimental|Acute Maternal Hyperoxygenation with LHH|Mothers who have a fetus diagnosed with LHH and elect acute maternal hyperoxygenation challenge testing.
9894823|NCT05334953|Experimental|Experimental: ESWT(Extracorporeal Shock Wave Therapy)|Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program
9894824|NCT05334953|Experimental|Phonophoresis|Group 2 ( n=17) will be given five times a week, total 10 sessions of diclofenac phonophoresis + home exercise program
9894825|NCT05334953|Experimental|Ultrasound therapy|Group 2 (n=17) will be given five times a week, total 10 sessions of ultrasound therapy+ home exercise program
9894826|NCT05334953|Other|Control goup|Group 4 ( n=17) will be given home exercise program
9894827|NCT05334940||Atopic disorders|Patients with at least 2 atopic disorders who are eligible for systemic therapy with biologics
9894828|NCT05334927||Medicine Overuse Headache/New Daily Persistent Headache|The first 18 months were followed up once a month,then followed up once at the 24th month,follow-up visits were made annually after 24 months
9894829|NCT05334927||Chronic Migraine|The patients were followed up at 1, 2, 3, 6, 9, 12, 18 and 24 months,then follow-up visits were made annually
9894830|NCT05334927||Patients with other types of primary headache|The patients were followed up at 3, 6, 9months
9894831|NCT05334914|Other|Intervention Arm|Participants will complete the baseline session, a 1:1 motivation building session, and 8 weeks of ACT group therapy. They will then complete a final study visit and a follow-up study visit to occur 1 month after the end of therapy.
9894832|NCT05334901|Experimental|High intensity light cure|High intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
9894833|NCT05334901|Active Comparator|Low intensity light cure|Conventional light curing (1200 mw/cm2) for long exposure time (20 seconds) to achieve the slower rate of conversion allowing for a better flow of the material, which decreases contraction stress in the filling material
9894834|NCT05334875|Active Comparator|Electroretinogram test (ERG)|ERG test will be done for each subject twice and compare the results to assess repeatability of the test.
9894835|NCT05334875|Active Comparator|Visual evoked potential test (VEP)|VEP test will be done for each subject twice and compare the results to assess repeatability of the test.
9894836|NCT05334836|Active Comparator|Pancreatic cystic lesion subjects|Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm
9894837|NCT05334836|Active Comparator|Healthy subjects|Healthy subjects
9894838|NCT05334823|Experimental|pCAR-19B cells|Infusion of pCAR-19B cells by dose of 0.6-2 x106 cells/kg
9894839|NCT05334810|Experimental|DP303c|Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
9894840|NCT05334797|Experimental|Hot application|After the patients come to the service after the surgery, a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes. Pain assessment will be done before and after the application. However, 0-2-4-8-12-24. Routine pain assessment will be done at In addition, the type, route, effect and amount of analgesic done in this process will also be recorded. Response evaluation will follow. Response evaluation will follow. Hot application will be applied to every shoulder pain reported by the patients.
9932644|NCT00951158|Experimental|CLA|Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. oral dose 7.5 g/day 28 day cycle
9991571|NCT01454128|Experimental|EPB with exercise|with exercise
9991572|NCT01454141|Experimental|Peripheral Vision Task|During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
9991573|NCT01454141|Experimental|Cognitive Control Training|Cognitive Control Training (CCT) A modified version of the Paced Auditory Serial Addition Task (PASAT) and the Attention Control Intervention were used to train participants' attentional control in accordance with procedures used by Siegle and colleagues.
9991574|NCT01454154|Experimental|Glyburide|Glyburide delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
9991575|NCT01454154|Placebo Comparator|Placebo|Matching placebo delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
9991576|NCT01454180|Active Comparator|Arm A|Control treatment arm will be treated with any of the schemes used in the study according to the discretion of the physician responsible
9991577|NCT01454180|Experimental|Arm B|treatment guided by the therapeutic targets
9991578|NCT01454206|No Intervention|Treatment as Usual|
9991579|NCT01454206|Experimental|iSBIRT|Participants will receive the internet-facilitated screening, brief intervention and referral to treatment (iSBIRT intervention)
9991580|NCT01454232|Other|gastric surgery|obese patients addressed for gastric surgery
9991581|NCT01454232|Active Comparator|lean healthy subjects evaluated once|lean healthy subjects evaluated once
9991582|NCT01454245|Experimental|001|"JNJ-39439335 Part 1:Type=1 unit=mg number=25 form=capsule route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.,JNJ-39439335 Part 2:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods."
9991583|NCT01454271|Experimental|Total Hip Arthroplasty CERAFIT® grafted|
9991584|NCT01454297||Newly diagnosed Multiple Myeloma|This is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease.
9991585|NCT01454310|Experimental|Acellular skin substitute|
9991586|NCT01454310|Active Comparator|Autologous skin graft|
9991587|NCT01454323|Experimental|Intervention|Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
9991588|NCT01454336|Experimental|Cirrhotic Patients|3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy
9991589|NCT01454349|Experimental|PRX302|
9991590|NCT01454349|Placebo Comparator|Inactive substance|
9991591|NCT01454375|No Intervention|Control Arm|No change in current practice
9991592|NCT01454375|Experimental|Referral fo QuitNow Services|Behavioural - referral to QuitNow Services, smoking cessation counseling telephone line supported by the Ministry of Healthy Living and Sport
9991593|NCT01454388|Active Comparator|PEG plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
9991594|NCT01454388|No Intervention|PEG without breakfast|
9991595|NCT01454388|Active Comparator|picosalax plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
9991596|NCT01454388|No Intervention|picosalax without breakfast|
9991597|NCT01454427||healthy volunteers|
9991598|NCT01454440|Experimental|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure).
9991599|NCT01454440|Placebo Comparator|Placebo|
9991600|NCT01454453|Experimental|Patients - dose titration|Amisulpride 50-200mg, 4-12 weeks, with brain imaging
9991601|NCT01454479|Experimental|Lapatinib (Tykerb) Plus Ixabepilone|
9991602|NCT01454492||Allergy rhinitis|Allergy rhinitis patients group
9991603|NCT01454492||Non- Allergy rhinitis|Non- Allergy rhinitis patients group
9991604|NCT01454518|Experimental|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
9991605|NCT01454518|Placebo Comparator|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
9991606|NCT01454544|Experimental|ALK house dust mite tablet 6 DU|
9991607|NCT01454544|Experimental|ALK house dust mite tablet 12 DU|
9991608|NCT01454544|Placebo Comparator|Placebo|
9991609|NCT01454557|Experimental|Acquired Brain Injury|auditory stimuli for ABI group
9991610|NCT01454557|Experimental|Controls|Auditory stimuli for control group
9991611|NCT01454609|Placebo Comparator|Saline|0.9% normal saline
9991612|NCT01454609|Experimental|Bupivacaine|0.25% bupivacaine
9991613|NCT01454609|Experimental|Bupivacaine with clonidine|0.25% bupivacaine with 1 microgram/kg of clonidine
9991614|NCT01454622|Experimental|Treatment Sequence AB|
9991615|NCT01454622|Experimental|Treatment Sequence BA|
9991616|NCT01454635|Other|Sertraline, Treatment response|dosage, frequency and duration
9991617|NCT01454648||Physician-staffed|Patients treated by physician-staffed emergency medical service (EMS) unit
9991618|NCT01454648||Paramedic-staffed|Patients treated by paramedic-staffed emergency medical service (EMS) unit
9991619|NCT01454661|Active Comparator|placebo mother - LGG infant|Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
9991620|NCT01454661|Placebo Comparator|placebo mother - placebo infant|Placebo is administered to both the lactating mother and her infant.
9932645|NCT00951197||elderly subjects retired from agriculture|
9932646|NCT00951210|Experimental|PLX-PAD low dose|IM injection Single treatment; multiple injections
9932647|NCT00951210|Experimental|PLX-PAD high dose|IM injection Double treatment; multiple injections
9932648|NCT00951223||Patients with Chronic Hepatitis C|HCV positive patients who have failed previous HCV therapy This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patientadministered therapy with Infergen® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV. The primary endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends. Safety will be assessed by monitoring AEs, reduction/discontinuation of therapy because of AEs, routine laboratory results and by other means determined by the Investigator
9932649|NCT00951236|Active Comparator|One injection|
9932650|NCT00951236|Active Comparator|Two Injections|
9932651|NCT00951249|Experimental|A|HIV-infected and uninfected black MSM
9932652|NCT00951262|Experimental|life review|a life review program includes 3-session life review and formulation of a life review book as a gift for advanced cancer patients.
9932653|NCT00951262|No Intervention|controlled group|the subjects in the controlled group do not receive the life review program
9932654|NCT00951288|Active Comparator|Saffron|Crocus Sativus extract
9932655|NCT00951288|Placebo Comparator|Placebo|Placebo comparator
9932656|NCT00951301|Active Comparator|mangosteen juice|subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient
9932657|NCT00951301|Placebo Comparator|placebo juice|subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient
9932658|NCT00951340|Active Comparator|CBT with listening therapy|Participants will receive CBT with listening therapy.
9932659|NCT00951340|Experimental|CBT with emotional processing and interpersonal therapy|Participants will receive CBT with emotional processing and interpersonal therapy.
9932660|NCT00951353||Pediatric Renal Transplant Recipients|
9932661|NCT00951366||Bronchopulmonary Dysplasia (BPD)|
9932662|NCT00951392|Experimental|Problematic aging|
9932663|NCT00951392|Experimental|successful aging|
9932664|NCT00951431|Experimental|PPI|
9932665|NCT00951431|Placebo Comparator|Control|
9932666|NCT00951444|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9932667|NCT00951444|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride and carboplatin as in arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients may crossover to arm upon disease progression.
9932668|NCT00951470|Other|No CDT|CDT=complete decongestive therapy
9932669|NCT00951470|Other|Modified CDT Program|CDT=complete decongestive therapy
9932670|NCT00951470|Other|Full CDT Program|CDT=complete decongestive therapy
9932671|NCT00951522|Experimental|1|GS-9411 2.4 mg
9932672|NCT00951522|Experimental|2|GS-9411 4.8 mg
9932673|NCT00951522|Experimental|3|GS-9411 7.2 mg
9932674|NCT00951522|Experimental|4|GS-9411 9.6 mg
9932675|NCT00951522|Placebo Comparator|5|Placebo
9932676|NCT00951535|Other|Arm A|Treatment will be delivered in 1.8 Gy fractions; dose escalation will be in 1.8 Gy increments from 75.6 Gy to a maximum 81 Gy.
9932677|NCT00951548|Experimental|VSL#3|Probiotic preparation VSL#3
9932678|NCT00951548|Placebo Comparator|placebo|Corn Starch
9932679|NCT00951574|Placebo Comparator|saline solution|Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
9932680|NCT00951574|Experimental|nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
9932681|NCT00951587|Experimental|1|Patients that are indicated for colonoscopy or who are suspected or known to suffer from colonic diseases.
9932682|NCT00951600|Experimental|1|Oxcarbazepine oral suspension 300 mg/5mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
9932683|NCT00951600|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5mL of Novartis
9932684|NCT00951678||ER patients|"Subjects must be 18 yrs or older, male or female, and must have the anatomy that we will be examining. Patients will be given the option of enrolling in the study whilst being cared for in Tampa General Hospital Emergency Room.~We anticipate enrolling normal, healthy volunteers, elderly persons (>65) not cognitively impaired, persons with social, economic or educational disadvantages , and persons who do not understand English fluently."
9991621|NCT01454661|Active Comparator|LGG mother - placebo infant|The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
9991622|NCT01454661|Active Comparator|LGG+Bb-12 mother - Placebo infant|A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
9991623|NCT01454661|Active Comparator|Pacebo mother - LGG+Bb-12 infant|Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
9991624|NCT01454700|Experimental|CSII plus CGM|Patients who has never been treated with insulin pump are randomized to 12 months with insulin pump therapy plus continuous glucose monitoring.
9991625|NCT01454700|Active Comparator|Multiple daily insulin injections|randomized to 12 months standard/usual insulin regimen (multiple daily injections). (stays on insulin pen).
9991626|NCT01454713||Veritas|Breast reconstruction with Veritas
9991627|NCT01454752|Active Comparator|Intermittent parasite clearance|Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
9991628|NCT01454752|Placebo Comparator|Control|Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo
9991629|NCT01454765||Sperm sample from healthy volunteers|
9991630|NCT01454804|Experimental|Arm A: Pazopanib + Lapatinib|Oral Pazopanib 200 mg every other day starting on day 1 and oral Lapatinib 500 mg daily starting day 1, both for 28 days.
9991631|NCT01454804|Experimental|Arm B: Pazopanib + Trastuzumab|Oral Pazopanib 200 mg daily for 28 day cycle and Trastuzumab (Herceptin®) 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1, with a maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
9991632|NCT01454817|Other|Patients with ICDs|
9991633|NCT01454817|Other|Caregivers of Patients with ICDs|
9991634|NCT01454856||Surgical cancer patients|No modification of the treatment
9991635|NCT01454856||Non-surgical cancer patients|No modification of the treatment
9517536|NCT03305471|Experimental|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.
9991636|NCT01454856||Surgical non-cancer patients|No modification of the treatment
9991637|NCT01454856||Non-surgical non-cancer patients|No modification of the treatment
9991638|NCT01454869|Active Comparator|Standard care|nac + salotamul
9991639|NCT01454869|Experimental|heparin group|heparin group
9991640|NCT01454882||Behavioral effects of clothing and temperature|In this first study, we will determine how variations in clothing and ambient temperature influence the accuracy of EE determined from measurements of total heat production. 65 individuals will be studied. This will be a randomized cross-over trial with two within subject factors: 1) ambient temperature and 2) amount of clothing. There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
9991641|NCT01454882||Behavioral effects of age, sex, and adiposity|THe aim of this study is to Determine how age, sex, and adiposity influence the accuracy of EE determined from measurements of total heat production . This will be a randomized study with two within subject conditions(high and low physical activity levels). A heterogenous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age range (≥ 18 yrs).
9991642|NCT01454882||Effects of free living energy expenditure|The primary aim of this study is to compare the accuracy of measuring free-living energy expenditure in humans measured using portable direct calorimetry. This will be a comparison study; TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age (>18 yrs).
9991643|NCT01454895|Experimental|Interactive Web-based Info (IWI) & HPDs|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
9991644|NCT01454895|Experimental|Interactive Web-based Information (IWI)|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
9991645|NCT01454895|Experimental|Static Web information (SWI) & HPDs|Subjects will receive static Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
9991646|NCT01454895|Active Comparator|Static Web information only|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing.
9991647|NCT01454895|Experimental|Hearing protection Devices only|Subjects will receive a mailed sample of various types of hearing protection devices.
9991648|NCT01454895|Other|Interactive Web-based information only|used for cases enrolling after achievement of study enrollment goal
9991649|NCT01454908|Other|Partial Knee Arthroplasty|Oxford Mobile Bearing Unicompartmental Knee Arthroplasties
9991650|NCT01454921|Experimental|Intervention I|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
9991651|NCT01454921|Experimental|Intervention II|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
9991652|NCT01454960|Experimental|SA, AJ, PC|"Participants are given all 3 interventions:~Suggested Alternatives, Accountable Justification, and Peer Comparison."
9991653|NCT01454960|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
9991654|NCT01454960|Experimental|SA, PC|Participants receive the Suggested Alternatives and Peer Comparison interventions, but not the Accountable Justification intervention.
9991655|NCT01454960|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternatives intervention.
9991656|NCT01454960|Experimental|Peer Comparison|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
9991657|NCT01454960|Experimental|Suggested Alternatives|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
9991658|NCT01454960|Experimental|Accountable Justification|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
9991659|NCT01454960|No Intervention|Control|Participants do not receive any of the 3 interventions.
9991660|NCT01454973||Healthy obese individuals|
9991661|NCT01454986|Active Comparator|Cohort 1|0.06 mg/kg ALXN1007
9991662|NCT01454986|Active Comparator|Cohort 2|0.1 mg/kg ALXN1007
9991663|NCT01454986|Active Comparator|Cohort 3|0.3 mg/kg ALXN1007
9991664|NCT01454986|Active Comparator|Cohort 4|1.0 mg/kg ALXN1007
9991665|NCT01454986|Active Comparator|Cohort 5|3.0 mg/kg ALXN1007
9991666|NCT01454986|Active Comparator|Cohort 6|6.0 mg/kg ALXN1007
9991667|NCT01454986|Active Comparator|Cohort 7|10.0 mg/kg ALXN1007
9991668|NCT01454999|Experimental|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
9991669|NCT01454999|Experimental|CTI + text|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change. Tailored feedback messages based on stage of change will also be sent by cell phone.
9991670|NCT01455025|Experimental|Plerixafor granulocyte-colony stimulating factor|4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.
9991671|NCT01455038||Control group|Healthy controls had no history of psychiatric disorder and had no psychiatric symptom when interviewed by a board-certified psychiatrist.
9991672|NCT01455038||Bipolar group|individual patient as being in subsyndromal depressive phase when the patient had a Montgomery-Åsberg depression rating scale score of 10 or less and Clinical Global Impression severity of 3 or less for last one month.
9991673|NCT01455051|Experimental|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
9991674|NCT01455077||Obese patients|BMI > 35
9991675|NCT01455103|Experimental|Arm 1: BMS-936559 (1mg/kg)|
9894841|NCT05334797|No Intervention|control group|First, an individual information form will be filled in for the control group patients who meet the sampling criteria. 0-2-4-8-12-24 after the patients come to the service after the surgery. Routine pain assessment will be done at In addition, the type, route, effect and amount of analgesic done in this process will also be recorded. Response evaluation will follow.
9894842|NCT05334784|Experimental|Impella ECP Device|Subjects receiving the Impella ECP.
9894843|NCT05334758|Experimental|At least 30 children between 2 - 13 years of age|Subjects less than 14 years of age, where the Parent or legal guardian collects a sample from their child (e.g., ages 2-13) and performs the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.
9894844|NCT05334758|Experimental|Subjects 14 - 90 years of age|The subject will self collect and test using the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.
9894845|NCT05334745|Experimental|application of Alvogyl in the palatal wound with stent|
9894846|NCT05334745|Other|application of 0.2% Hyaluronic acid is placed in the palatal wound with stent .|
9894847|NCT05334719||Cohort 1|Participants with previously untreated advanced/recurrent gastric cancer (GC)
9894848|NCT05334693|Experimental|Expanded haploidentical NK cell immunotherapy|After a lymphodepleting chemotherapy a patient receive two intravenous infusions of expanded haploidentical NK cells.
9894849|NCT05334667|Placebo Comparator|Control group|Patients will receive routine management only.
9894850|NCT05334667|Active Comparator|CRRT group|Patients will receive CRRT and routine management.
9894851|NCT05334667|Active Comparator|PPH group|Patients will receive plasmapheresis and routine management.
9894852|NCT05334654|Active Comparator|Enoxaparin sodium|Enoxaparin sodium once or twice daily, according to the renal function and clinical indication (thromboprophylaxis versus treatment)
9894853|NCT05334654|Experimental|Bivalirudin|Bivalirudin will be administered by continuous infusion, until day 7. Bivalirudin will be administered at dosage of 0,25 mg/kg in first 30 minutes, followed by continuous infusion of 0,2 mg/kg/h until 7 days. The infusion rate will be adjusted targeting a prothrombin time ratio of about 1.5.
9894854|NCT05334641|Experimental|Experimental Group|
9894855|NCT05334641|Active Comparator|Control Group|
9894856|NCT05334602|Experimental|study group|Dermal fat graft is added over the grafted bone in the alveolar cleft to protect the bone from resorption
9894857|NCT05334602|No Intervention|control group|Conventional procedure of alveolar cleft grafting
9894858|NCT05334589|Experimental|Experimental: Intervention group|Patients in the intervention group will be prewarming with a hot air blowing system for 30 minutes before the operation. The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
9894859|NCT05334589|No Intervention|Control group|The patients will continue to be warmed with a carbon fiber heating bed, which is a resistive system, during the surgery.
9894860|NCT05334576|Other|Single Arm: Crizanlizumab|Single-arm: Patients with sickle cell disease and increased risk of silent cerebral infarcts
9894861|NCT05334550|Experimental|Intervention group|Allocated to intervention group through randomization process.
9894862|NCT05334550|No Intervention|Control group|Allocated to control group through randomization process.
9894863|NCT05334537|Experimental|the aromatherapy group|"After the birth of the baby, two drops of 100% pure medical lavender oil (Lavandula angustifolia) was inhaled for 5 min through an oxygen mask by groups A and C, respectively. After 5 min, 2 mg intravenous midazolam for sedation was administred to the patients who gained 1 point from the Ramsey Sedation Scale (RSS). Complications, such as nausea, vomiting, hypotension (mean arterial pressure<60 mmHg), and allergies that developed after aromatherapy, were recorded. At the end of the operation, the dose added to the initial midazolam dose for all patients and the total surgical time were recorded. VAS pain and STAI-I scores were re-evaluated at the third postoperative hour, and the satisfaction levels of each patient after aromatherapy were recorded according to the Likert scale as very satisfied, satisfied, moderate, and not at all satisfied."
9894864|NCT05334537|Placebo Comparator|the control group|"Then, after the birth of the baby two drops of odorless baby oil (jojoba and almond oil) was inhaled for 5 min through an oxygen mask by groups A and C, respectively. After 5 min, 2 mg intravenous midazolam for sedation was administred to the patients who gained 1 point from the Ramsey Sedation Scale (RSS). Complications, such as nausea, vomiting, hypotension (mean arterial pressure<60 mmHg), and allergies that developed after aromatherapy, were recorded. At the end of the operation, the dose added to the initial midazolam dose for all patients and the total surgical time were recorded. VAS pain and STAI-I scores were re-evaluated at the third postoperative hour, and the satisfaction levels of each patient after aromatherapy were recorded according to the Likert scale as very satisfied, satisfied, moderate, and not at all satisfied."
9894865|NCT05334511|Experimental|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
9894866|NCT05334498|Experimental|Motor dual-task gait training|Motor dual task gait training was the protocol which performed by the patients after the measurement of the balance and gait ability
9991676|NCT01455103|Experimental|Arm 2: BMS-936559 (3mg/kg)|
9991677|NCT01455103|Experimental|Arm 3: BMS-936559 (10mg/kg)|
9991678|NCT01455116|Experimental|Mild induced hypothermia|Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
9991679|NCT01455116|No Intervention|Fever Respect|Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
9991680|NCT01455129|Active Comparator|tiotropium group|18 mcg tiotropium, once daily, inhaled by HandiHaler
9991681|NCT01455129|Placebo Comparator|placebo group|matching placebo, once daily, inhaled by HandiHaler
9991682|NCT01455142|Experimental|Formulation 1|
9991683|NCT01455142|Experimental|Formulation 2|
9991684|NCT01455155|Experimental|Creative therapy|Conventional physical therapy program (5 times/week) plus creative therapy (Art and Music) 2 times/week for 4 weeks
9991685|NCT01455155|Active Comparator|Control|Conventional physical therapy (5 times/week) for 4 weeks
9991686|NCT01455168||No treatment|Capsular tension ring is not used in the group.
9991687|NCT01455168||CTR simply implanted|Capsular tension ring is simply implanted in the group.
9991688|NCT01455168||CTR with the eyelets closed|Capsular tension ring is implanted and closed by tying both eyelets in the group.
9991689|NCT01455207|Other|alcoholic patients|
9991690|NCT01455207|Other|korsakoff patients|
9991691|NCT01455207|Other|healthy controls|
9991692|NCT01455233|Active Comparator|besivance|ocular antibiotic
9991693|NCT01455233|Active Comparator|vigamox|ocular antibiotic
9991694|NCT01455246|Experimental|Daptomycin + Meropenem|30 patients with cirrhosis and nosocomial SBP
9991695|NCT01455246|Active Comparator|Ceftazidime|30 patients with cirrhosis and nosocomial SBP
9991696|NCT01455259|Experimental|AdCD40L|Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.
9991697|NCT01455272|Experimental|high-risk leukemia|
9991698|NCT01455298|Other|Transient elastography and fibrotest|
10212135|NCT02366728|Experimental|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccines #1 and #2 with Td pre-conditioning (1 flocculation unit) will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the 4th human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine.
9991699|NCT01455311||Cystic Pancreatic Tumor Specimens|Specimen collection via EUS Guided Fine Needle Aspiration EchoBrush Sampling
9991700|NCT01455324||Lower Limb Amputees|Those with lower limb amputations
9991701|NCT01455337|Active Comparator|prednisolone|
9991702|NCT01455337|Experimental|pentoxifylline|
9991703|NCT01455350|Active Comparator|Lidocaine|10 week treatment of daily application of topical lidocaine
9991704|NCT01455350|Experimental|Multimodal physiotherapy|10 weeks of weekly multimodal physiotherapy treatments
9991705|NCT01455376|No Intervention|Hyperosmolar sodium chloride|Patients in this group received intravenous infusion of hyperosmolar Sodium Chloride 3% at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
9991706|NCT01455376|Experimental|Hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
9991707|NCT01455441|Active Comparator|Training and liraglutide|Treatment with both training and liraglutide for 16 weeks
9991708|NCT01455441|Placebo Comparator|Training and placebo|Treatment wiht both training and placebo for 16 weeks
9991709|NCT01455454||coronary artery disease|patients undergoing coronary artery bypass grafting using cardiopulmonary bypass
9991710|NCT01455467|Active Comparator|One iStent|Implantation of one iStent in conjunction with cataract surgery
9991711|NCT01455467|Active Comparator|Two iStent|Implantation of two iStent devices in conjunction with cataract surgery
9991712|NCT01455480|Experimental|RPh201|
9991713|NCT01455506|Experimental|Decitabine with fludarabine and busulfan|decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation
9991714|NCT01455532|Experimental|Iniparib, single agent|Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
9991715|NCT01455532|Experimental|Iniparib/Gemcitibine/Carboplatin|Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
9991716|NCT01455532|Experimental|Iniparib/Paclitaxel|Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
9991717|NCT01455532|Experimental|Iniparib/Pegylated liposomal doxorubicin/Carboplatin|Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
9991718|NCT01455558|Experimental|Cilostazol|
9991719|NCT01455571|Experimental|HM781-36B|Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
9991720|NCT01455584|Experimental|HM781-36B|HM781-36B
10212136|NCT02344355|Experimental|ascorbate, radiation, temozolomide|"Concomitant therapy:~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions~Adjuvant therapy:~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
10212137|NCT02340884|Experimental|PRISM|Promoting Resilience In Stress Management Intervention (skills-based intervention designed to teach stress-management, goal-setting, cognitive reframing, and meaning-making skills)
9894867|NCT05334498|Experimental|Cognitive dual-task gait training|Cognitive dual task gait training was the protocol which performed by the patients after the measurement of the balance and gait ability
9894868|NCT05334485|Experimental|Pyridostigmine|Patients randomized to this group will be given 60mg of pyridostigmine bromide orally, every 12 hours. Pyridostigmine will be administered from the time of diagnosis of postoperative ileus until the return of bowel function, or for a maximum of 48 hours.
9894869|NCT05334485|Placebo Comparator|Placebo|Patients randomized to this group will be given starch orally, every 12 hours for a maximum of 48 hours.
9894870|NCT05334472||Kesimpta|Patients or caregivers of patients administered Kesimpta
9894871|NCT05334446|Experimental|The Effect ''of Follow-up with the Mobile Application'' in Patients with Hypertension|Intervention Group:mobile application for 4 weeks; This is the training group in which individual motivational messages will be sent to the mobile phones every week for compliance with the diet, exercise and drug therapy of the patients, and the weekly average of blood pressure follow-ups is monitored over the system.
9894872|NCT05334446|No Intervention|The Effect ''of Follow-up with the Mobile Application'' in Hypertension control group|It is the control group whose routine outpatient follow-up will continue and no training is given
9894873|NCT05334420|Experimental|Healthy Dads Healthy Kids|A group-based lifestyle behavioral program for Hispanic fathers and children
9894874|NCT05334420|Other|Standard of care control|National guidelines and recommendations for healthy eating, physical activity and weight loss.
9894875|NCT05334407|Experimental|GroupA（DE+/DI+）|The treatment includes the combination of implant-supported full-arch fixed prostheses (dental intervention, DE) and dietary intervention tailored to the dental status (dietary intervention, DI) without waiting period
9894876|NCT05334407|Active Comparator|GroupB（DE+/DI-）|The treatment includes implant-supported full-arch fixed prostheses (dental intervention, DE) without waiting period and dietary intervention tailored to the dental status (dietary intervention, DI) 4-month later
9894877|NCT05334407|Active Comparator|GroupC（DE-/DI+）|The treatment includes dietary intervention tailored to the dental status (dietary intervention, DI) without waiting period and implant-supported full-arch fixed prostheses (dental intervention, DE) 4-month later
9894878|NCT05334407|Placebo Comparator|GroupD（DE-/DI-）|The treatment included implant-supported full-arch fixed prostheses (dental intervention, DE) and dietary intervention tailored to the dental status (dietary intervention, DI) with 4-month waiting period. Only general dietary information is provided at baseline.
9894879|NCT05334394|Experimental|Mulligan Group|
9894880|NCT05334394|Experimental|Control Group|
9894881|NCT05334381|Experimental|Adapted STAT-ED|The intervention will assist the family in following up with mental health referral recommendations provided by ED staff and eliciting families' preferences in regards to race and gender of providers, convenience of provider, and type of treatment. This assistance could involve help with the initial telephone contact, getting to appointments, and preparing for the appointments. The patient navigator will communicate with the family in person, by telephone, and/or by text messaging as per family's preference. This once to twice a week communication with both the youth and their parent will promote mental health care initiation and identify barriers and problem-solving solutions.
9894882|NCT05334381|Active Comparator|Standard Enhanced Treatment|After discharge from the Children's Hospital of Philadelphia emergency department, the participant will be given a list of resources and referrals for mental health treatment by the hospital social work team. Phone call contact will be made to follow up on the initiation of treatment from the referral recommendations given at discharge.
9894883|NCT05334368|Experimental|Depemokimab|All participants in this arm will receive depemokimab.
9894884|NCT05334368|Placebo Comparator|Placebo|All participants in this arm will receive placebo.
9894885|NCT05334355||Positive Family History of Hypertension|Young normotensive generally healthy adult with one or more biological parents with diagnosed hypertension.
9894886|NCT05334355||Negative Family History of Hypertension|Young normotensive generally healthy adult with no biological parent with diagnosed hypertension.
9894887|NCT05334342|Experimental|Low-GI Diet|Low Glycemic Index Diet
9894888|NCT05334342|Active Comparator|High-GI Diet|High Glycemic Index Diet
9894889|NCT05334329|Experimental|Treatment (fludarabine, cyclophosphamide, COH06, atezolizumab)|Patients receive fludarabine IV on days -5 to -3, cyclophosphamide IV on days -5 to -3, and COH06 IV on days 0, 7, 14, and 21 in the absence of disease progression or unacceptable toxicity. Patients assigned to dose level 4 also receive atezolizumab IV over 60 minutes on days 0, 14, 28, and 42 in the absence of disease progression or unacceptable toxicity.
9894890|NCT05334316|No Intervention|Usual Care Group|Usual care as determined by the patient's primary team. Initiation and daily dosing of corticosteroid treatment will be based on clinicians' preference and clinicians.
9894891|NCT05334316|Experimental|Individualized dosing strategy|Biomarker guided corticosteroid use. Initiation of corticosteroid will be recommended based on the an individual treatment rule (ITR) and subsequent dosing of corticosteroid will be recommended based on daily CRP values till CRP <50 mg/L.
9894892|NCT05334303||epigenetic MMR deficiency|Tumors with MMR abnormalities by IHC and MLH1 methylation
9894893|NCT05334303||probable MMR mutations|Tumors with MMR abnormalities by IHC and without MLH1 methylation
9894894|NCT05334303||MMR proficient|without MMR abnormalities by IHC
9894895|NCT05334277|Experimental|Group A: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
9894896|NCT05334277|Experimental|Group B1: Furmonertinib 80mg QD|Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
9894897|NCT05334277|Experimental|Group B2: Furmonertinib plus chemotherapy|Furmonertinib 80 mg QD and platinum-based chemotherapy All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
9932685|NCT00951691|Experimental|Enhanced acute medical rehabilitation|Participants will receive enhanced acute medical rehabilitation.
9932686|NCT00951691|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
9932687|NCT00951704||Cardiac arrest|
9894898|NCT05334277|Experimental|Group B3: Furmonertinib plus chemotherapy and bevacizumab|Furmonertinib 80 mg QD plus platinum-based chemotherapy and bevacizumab All patients enrolled into this group will receive furmonertinib 80 mg daily, in combination with Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
9894899|NCT05334264|Experimental|Group A|cervical cerclage between 14 and 20 weeks will be done by one of the three authors. McDonald cervical cerclage.
9894900|NCT05334264|No Intervention|Group B|Routine antenatal care without cerclage
9894901|NCT05334251||general anesthesia group|Patients in this group will undergo open colon cancer surgery under general anesthesia. Epidural catheterization will be applied for postoperative analgesia.
9894902|NCT05334251||combined spinal-epidural anesthesia group|Patients in this group will undergo open colon cancer surgery under combined spinal-epidural anesthesia with ketofol sedation. Epidural catheterization will be applied for postoperative analgesia.
9894903|NCT05334238|Experimental|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
9894904|NCT05334238|No Intervention|No Orelabrutinib|no treatment after autologous transplantation
9894905|NCT05334225||Health Workers|Doctors, nurses, paramedics, midwifes
9894906|NCT05334212|Experimental|Evaluation of usefulness|To evaluate usefulness of Surgical Theater's Patient Engagement 360VR platform in helping align patient expectations and improve patient satisfaction and understanding in spinal surgery consults.
9894907|NCT05334186|Experimental|Telehealth Reasoning Training|Telehealth-delivered inductive reasoning training will focus on improving the ability to solve problems that require linear thinking and that follow a serial pattern or sequence. Participants will be taught strategies to identify patterns to solve problems. These problems involve identifying the pattern in series of numbers and letters, or recognizing patterns in everyday activities, like dosing for medications. Training will consist of ten training sessions, over 5 weeks, and will be conducted over Zoom. Each training session is 60-75 minutes long and typically consists of (a) 10 minutes of introductory training exercises for basic mental abilities, such as finding patterns in schedules, (b) training exercises for everyday tasks, such as filling out medication charts, recycling charts, and understanding medicine bottle labels, and (c) a 20-question practice assessment.
9894908|NCT05334173|Active Comparator|RYGB TYPE 1 - LONGER ALIMENTARY LIMB (LAL-GB)|150 cm alimentary limb and 70 cm biliopancreatic limb
9894909|NCT05334173|Active Comparator|RYGB TYPE 2 - LONGER BILIOPANCREATIC LIMB (LBPL-GB)|70 cm alimentary limb and 150 cm biliopancreatic limb
9894910|NCT05334147||Anlotinib in combination with chemotherapy|anlotinib12mg qd p.o. d1-14/21day/cycle；eribulin 1.4 mg/m2，d1&d8/21day/cycle；capecitabine 1000 mg/m2，bid，d1-14/21day/cycle.
9894911|NCT05334147||chemotherapy|eribulin 1.4 mg/m2，d1&d8/21day/cycle；capecitabine 1000 mg/m2，bid，d1-14/21day/cycle.
9894912|NCT05334108|Other|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Substrate Cocktail given on 2 separate days:~midazolam: 1 µg infused IV~caffeine: 200 mg oral tablet~omeprazole: two 20 mg oral tablets~dextromethorphan: 1.6mL (containing ~10 mg) oral solution"
9894913|NCT05334108|Other|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Substrate given on 2 separate days:~- bupropion: 100mg oral tablet"
9894914|NCT05334108|Other|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Substrate Cocktail given on 3 separate days:~midazolam: 10 µg/mL given as 1mL oral solution.~dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
9894915|NCT05334095|Active Comparator|Perclose ProGlide|Perclose ProGlide 6F Suture-Mediated Closure (SMC) System
9894916|NCT05334095|Placebo Comparator|Angio-seal VIP|Angio-seal VIP Vascular Closure Device
9894917|NCT05334082|Experimental|FIFA 11+ Group|Teams will replace regular warm-up with the intervention protocol - FIFA11+ injury prevention program - during training sessions
9894918|NCT05334082|No Intervention|Control Group|Teams will maintain regular warm-up during training sessions
9894919|NCT05334069||Screening (questionnaire, biospecimen collection)|Participants complete a questionnaire at baseline. Participants undergo collection of blood samples at registration and at 12 months after registration. Patients with a cancer diagnosis may undergo collection of tissue samples at registration and 12 months after registration.
9894920|NCT05334043|Experimental|CuminUP30,then Curcumin capsules|Participants first received CuminUP30 3500mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 2250mg on the eighth day in a fasting state.
9991721|NCT01455623||Health Care Provider|A person working within the field of CMT.
9894921|NCT05334043|Experimental|Curcumin capsules,then CuminUP30|Participants first received curcumin capsules 2250mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP30 3500mg on the eighth day in a fasting state.
9894922|NCT05334030|Experimental|Stroke|
9894923|NCT05334030|Experimental|Healthy|
9894924|NCT05334004|Experimental|Cohort 1: Lopinavir/Ritonavir 200mg/50mg|Cohort 1 will receive two 5-day cycles of the low dose of the suppository (Lopinavir/Ritonavir (200mg/50mg)) in Weeks 0 and 2
9894925|NCT05334004|Experimental|Cohort 2: Lopinavir/Ritonavir 200mg/50mg|Cohort 2 will receive three 5-day cycle of the same low dose of the suppository (Lopinavir/Ritonavir (200mg/50mg)) in Weeks 0, 2 and 4 if Cohort 1 dose is safe.
9894926|NCT05334004|Experimental|Cohort 3: Lopinavir/Ritonavir 400mg/100mg|Cohort 3 will receive two 5-day cycles of the higher dose of the suppository (Lopinavir/Ritonavir (400mg/100mg)) in Weeks 0 and 2, if the Cohort 2 dose is safe.
9894927|NCT05334004|Experimental|Cohort 4: Lopinavir/Ritonavir 400mg/100mg|Cohort 4 will receive three 5-day cycles of the higher dose of the suppository (Lopinavir/Ritonavir (400mg/100mg)) in Weeks 0, 2, and 4, if the Cohort 3 dose is safe.
9894928|NCT05334004|Experimental|Cohort 5: Lopinavir/Ritonavir 600mg/150mg|Cohort 5 will receive two 5-day cycles of the highest dose of the suppository (Lopinavir/Ritonavir (600mg/150mg)) in Weeks 0 and 2, if the Cohort 4 dose is safe.
9894929|NCT05334004|Experimental|Cohort 6: Lopinavir/Ritonavir 600mg/150mg|Cohort 6 will receive three 5-day cycles of the highest dose of the suppository (Lopinavir/Ritonavir (600mg/150mg)) in Weeks 0, 2, and 4, if the Cohort 5 dose is safe.
9894930|NCT05333978|Experimental|Imaging of Inflammatory region|"Inflammatory regions of patients scheduled for standard of care clinical visits will be imaged using the MSOT device before and after 4 weeks of treatment.~The temperature of their skin prior to and after MSOT imaging will also be measured."
10212138|NCT02340884|No Intervention|Control|Standard psychosocial supportive care
10212139|NCT02332850|Experimental|Arm I (20 mg dexamethasone, isatuximab, carfilzomib)|"20 mg dexamethasone IV given on days 1, 8, 15, 22 (pre- SAR650984 and carfilzomib), then dexamethasone 4 IV or PO mg Day 2, 9, 16.~All patients will receive a fixed dose of Isatuximab (SAR650984) according to their assigned dose cohort. Patients receive isatuximab IV over 4-6 hours on days 1 and 15 of every cycle for the starting cohort, and days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Carfilzomib IV will be administered over 10 minutes on days 1, 2, 8, 9, 15, and 16 . Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment after 8 courses if clinical benefit is present at the investigator's discretion (carfilzomib may be switched to days 1, 2, 15, and 16 after 8 cycles per investigator discretion)."
9894933|NCT05333952|Experimental|Pulmonary vein isolation + Waveform Periodicity Group|Pulmonary vein isolation + Substrate ablation
9894934|NCT05333952|Other|Pulmonary vein isolation group|Pulmonary vein isolation (Conventional treatment)
9894935|NCT05333939|Experimental|Moringa|4 g moringa leaf powder in green capsules divided into 4 capsules twice daily x 28 days
9894936|NCT05333939|Placebo Comparator|Control|comparable weight green capsules with cornstarch divided into 4 capsules twice daily x 28 days
9894937|NCT05333926|Experimental|MHNA-001|
9894938|NCT05333900|Active Comparator|Plant-based|A diet low in sulfur-containing amino acids (Low-S diet), emphasizing plant-based foods and fat sources
9894939|NCT05333900|Active Comparator|Animal-based|A diet high in sulfur-containing amino acids (High-S diet), emphasizing animal protein and fat sources
9894940|NCT05333887|Experimental|PFC+|In this condition, therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support.
9894941|NCT05333887|No Intervention|Waitlist|In this condition, parents are placed on a waitlist where they continue life as usual. After the waitlist they participate in the PFC+ program.
9894942|NCT05333874|Active Comparator|Neoadjuvant chemotherapy|"If Circulating tumor DNA (ctDNA) blood test is positive, change in treatment can be made. Participants will be monitored with ctDNA at 60days, 3 months, 6 months, 9 months, 12 months, 18months and 24months from surgery.~The participant's core biopsy specimens will be sent to NateraTM to sequence the primary tumor. The baseline blood work for ctDNA will be collected prior to the initiation of systemic therapy. Subsequently, ctDNA will be collected prior to each cycle of neoadjuvant chemotherapy. Participants will undergo surgery and ctDNA needs to be collected fourteen days post-surgery The treating oncologist will complete a questionnaire to determine how ctDNA impacts treatment decisions in the adjuvant setting once the results from the fourteen day ctDNA is available and at the time of ctDNA re-emergence. Participants will complete participant questionnaire at 3 months, 6months, 12months and 24 months post-operatively."
9894943|NCT05333874|Other|Observational|Observation for triple negative breast cancer (TNBC): No adjuvant chemotherapy. Patients may complete checkpoint inhibitor from neoadjuvant setting. human epidermal growth factor receptor 2 (HER2) positive breast cancer: complete twelve months of anti-HER2 therapy, which was initiated in neoadjuvant setting), participants in the observation arm, will be monitored for Circulating tumor DNA (ct-DNA) re-emergence and systemic therapy can be added at the time of ctDNA re-emergence.
9894944|NCT05333861||Full-analysis set (FAS)|The FAS includes all enrolled patients. The FAS will be used for all analyses.
9894945|NCT05333848|Experimental|COMBO condition|An interactive stigma content website.
9894946|NCT05333848|Experimental|STIGMA condition|A non-interactive stigma content website.
9894947|NCT05333848|Experimental|INTERACT condition|An interactive non-stigma content website.
9894948|NCT05333848|Placebo Comparator|CONTROL condition|A non-interactive non-stigma content website.
9894949|NCT05333835|Experimental|HR17031 injection|
9894950|NCT05333835|Active Comparator|INS068 injection|
9894951|NCT05333835|Active Comparator|SHR20004 injection|
9894952|NCT05333822|Experimental|Bashan|a vegetable plant based compound drink add after three meals for 14 days
9894953|NCT05333822|Placebo Comparator|Water|water as placebo
9894954|NCT05333809|Experimental|1|Pembrolizumab plus Disitamab vedotin
9894955|NCT05333796|Experimental|Healthy children (5 to 12 years old)|
9894956|NCT05333783|Experimental|Augmented Reality Exposure Therapy Based on ExposXR software|The intervention arm will receive the assigned intervention in one session. Participants will be called for 2 times for post-assessment.
9894957|NCT05333783|No Intervention|Treatment as Usual|The control arm has no intervention. However, the participants are not given any instruction limiting their encounters with the phobic stimuli. The participants in the control arm will receive the intervention after the post-assessments are completed.
9932688|NCT00951717|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
9932689|NCT00951717|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
9932690|NCT00951730||Down syndrome|Adult and children with Down syndrome.
9894958|NCT05333770|Experimental|SCI Group|"Complete testing at Baseline, Post, and 6 month follow up. Intervention includes 15 treatment sessions (3-5 times per week) with HF-rTMS & 6 month follow-up. Following HF-rTMS, there will be 30 minutes of arm and hand training. Each session will last for approximately 60 mins.~At baseline, post and 6 months, the following evaluations to evaluate safety and other related measures. These measures include a safety and pain questionnaire, spasticity measurement, a physician or clinician evaluation to determine motor and sensory neurological level of injury, hand and arm function measurement, evaluation of ability to perform everyday tasks, and measures to determine level of brain function."
9894959|NCT05333757||Quality of life|"Adult patients treated conservatively for idiopathic scoliosis or undergoing clinical monitoring who have completed both questionnaires at least once and simultaneously and who meet the following inclusion criteria:~Age ≥ 18 years~Diagnosis of idiopathic or degenerative scoliosis with curve ≥30 ° Cobb"
9894960|NCT05333744|Experimental|Prednisone plus rhTPO|Prednisone 20mg per day, 2 weeks and rhTPO 300U/kg per day, 2 weeks
9894961|NCT05333744|Active Comparator|Prednisone|Prednisone 20mg per day, 2 weeks
9894962|NCT05333731||Cesarean section group|In the cesarean section group, all the pregnant women had only one prior cesarean section.
9894963|NCT05333731||Non-cesarean section group|In the non-cesarean section group, all the pregnant women are primipara, and never had a cesarean section.
9894964|NCT05333718||Newly diagnosed T2DM|"To assess and characterize the relevant subgroups (clusters) of type 2 diabetes at diagnosis in our population.~This objective will be addressed using the 6 main variables that have been used so far in previous studies in other populations to develop disease groupings, that is, age, GAD antibodies, body mass index, glycosylated hemoglobin (HbA1c), and estimates of the evaluation of the homeostatic model 2 of β-cell function and insulin resistance."
9894965|NCT05333705|Experimental|immune cell arm|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were cultured. NK cell production will be infused after chemotherapy.
9894966|NCT05333692|Active Comparator|NEPRO®|
9894967|NCT05333692|Experimental|Fresubin® Protein Energy DRINK|
9894968|NCT05333679|Experimental|Intervention|POC adherence testing by a urine TFV assay with feedback
9894969|NCT05333679|No Intervention|Standard of Care|Standard enhanced adherence counselling, SA Department of Health, March 2020
9894970|NCT05333666||Age over 20 years and under non-vitamin K antagonist oral anticoagulant therapy|
9894971|NCT05333653|Experimental|Continous Supportive Care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.
9894972|NCT05333653|Experimental|Control|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
9894973|NCT05333640||AVFs treated with Sirolimus Drug Coated Balloon|Dysfunctional matured AVF that have underwent thrombolysis or balloon angioplasty with SDCB within 6 months witll be considered for the registry.
9894974|NCT05333640||AVFs treated with Paclitaxel Drug Coated Balloon|Dysfunctional matured AVF that have underwent thrombolysis or balloon angioplasty with PDCB within 6 months witll be considered for the registry.
9894975|NCT05333627|Experimental|Fast-Track Course|Clients who select the Fast-Track Course option will receive access to a single ICBT core lesson and Do-It-Yourself guide, followed by three additional Do-It-Yourself guides that they can access in any order. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive up to five weeks of optional therapist support.
9894976|NCT05333627|Experimental|5-Week Course|Clients who select the 5-week course will receive access to an ICBT course which consists of four lessons spread across the span of five weeks. The content includes examples that are tailored to students' experiences. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive five weeks of optional therapist support.
9894977|NCT05333627|Experimental|8-Week Course|Clients who select the 8-week course will receive access to an ICBT course which consists of five lessons spread across the span of eight weeks. The content in this course is not student-specific. Clients have access to diverse additional resources (e.g., managing panic, assertive communication) throughout the course. Clients will receive eight weeks of optional therapist support.
9932691|NCT00951743|Experimental|Adaptavir Treatment|MDAPTA (Adaptavir) will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
9894978|NCT05333601|Experimental|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
9894979|NCT05333588|Experimental|Tumor infiltrating lymphocyte|1x10^9-5x10^10 of autologous TILs will be adoptive transfer to patients.
9894980|NCT05333575|Experimental|Experimental Group: Lullaby|The mothers in this group sang lullabies to their babies next to the incubator during feeding.
9894981|NCT05333575|Experimental|Experimental Group: Classic Music|Babies in this group were listened to classical music during feeding.
9894982|NCT05333575|No Intervention|Control Group|Premature newborns in the control group were fed according to the routine of the clinic and no intervention was performed other than routine practice.
9894983|NCT05333562|Other|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
9894984|NCT05333562|Active Comparator|Motor control exercise with neural mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
9894985|NCT05333536|Experimental|Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of UL and LL with theraband ,10 reps each.Upper limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower Limb: Flexors of hip, Extensors of hip,Plantar flexors.
9894986|NCT05333536|Active Comparator|Control group|control only participates in their yearly swimming trainings.
9894987|NCT05333523|Experimental|Sentinel lymph node biopsy guided selective elective neck irradiation|"FDG-PET-scan in treatment mask for radiotherapy planning~Sentinel lymph node biopsy~Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with selective elective neck irradiation guided by histopathologic status of the sentinel lymph node(s)"
9894988|NCT05333523|Active Comparator|Standard elective neck irradiation|"FDG-PET-scan in treatment mask for radiotherapy planning~Radiotherapy (IMRT/VMAT with SIB) to the primary tumor with standard elective neck irradiation"
9932692|NCT00951743|Placebo Comparator|Placebo|Placebo will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
9932693|NCT00951756|Other|High Fat Low Fiber Diet|
9932694|NCT00951756|Other|Low Fat High Fiber Diet|
9932695|NCT00951769||Control,|Control
9932696|NCT00951769||DAS: Difficult Airway Society, UK|DAS difficult airway algorithm
9932697|NCT00951769||Australian|Australian difficult airway algorithm
9932698|NCT00951782|Active Comparator|High frequency TMS + smoking cue|
9932699|NCT00951782|Sham Comparator|Sham TMS + smoking cue|
9932700|NCT00951782|Active Comparator|Low frequency TMS +smoking cue|
9932701|NCT00951782|Sham Comparator|Sham TMS - no cue|
9932702|NCT00951782|Active Comparator|High frequency TMS - no cue|
9932703|NCT00951782|Active Comparator|Low frequency - no cue|
9932704|NCT00951795||Adults|Adult men and women over age of 18
9932705|NCT00951795||Pediatrics|Pediatric boys and girls ages 12-18
9932706|NCT00951834|Experimental|Epigallocatechin-Gallate|"Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)~add-on to Donepezil."
9932707|NCT00951834|Placebo Comparator|Placebo|add-on to Donepezil.
9932708|NCT00951847|Experimental|1|Oxcarbazepine oral suspension 300 mg/5 mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
9932709|NCT00951847|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5 mL of Novartis
9991722|NCT01455623||Patient with CMT|Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.
9991723|NCT01455636|Experimental|Hand hygiene with Hand Sanitizer (HS)|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
9991724|NCT01455636|Experimental|Hand hygiene with no Hand Sanitizer|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
9991725|NCT01455636|Experimental|Micronutrient Powder|"From 6 months of age, children in randomized clusters will be assigned to receive one sachet of Improved Micronutrient Powder, I-MNP per day for six months with or without hand sanitizer.~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
9991726|NCT01455636|Placebo Comparator|Control|"From 6 months of age, children in randomized clusters will be assigned to receive no hand sanitizer or no micronutrient powder~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
9991727|NCT01455649|Experimental|Everolimus|
9991728|NCT01455649|Active Comparator|calcineurin inhibitor|
9991729|NCT01455662||all patients after cardiac arrest|
9991730|NCT01455675|Experimental|IgY, gargling solution|Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
9991731|NCT01455675|Placebo Comparator|Placebo, gargling solution|70 ml gargling solution without antibodies, once daily
9991732|NCT01455688|Experimental|Early antiviral therapy|
9991733|NCT01455688|Active Comparator|Conventional therapy|
9991734|NCT01455701|Experimental|Tocilizumab|Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.
9991735|NCT01455714||A, B, C|Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
9991736|NCT01455727|Experimental|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
9517537|NCT03305471|Experimental|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.
9517538|NCT03305471|Placebo Comparator|Part B: Placebo|Participants are given placebo three times daily [Treatment B1]
9991737|NCT01455727|Active Comparator|Usual care|Patients received usual care directed by their physician.
9991738|NCT01455740|Experimental|Provider Visit Incentive (PVI)|"Participants were told that they would receive $30 after attending each scheduled provider visit (a CCT).~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 21 individuals to the PVI arm."
9991739|NCT01455740|Experimental|Incentive Choice (IC)|"Participants were given a choice between the CCT described in the PVI arm and a commitment contract, which made the $30 payment conditional on the patient attending the provider visit AND meeting an ART adherence threshold.~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 19 individuals to the IC arm."
9991740|NCT01455740|No Intervention|Passive Control (PC)|The study also included 70 individuals in a PC arm, who did not receive financial incentives. Individuals in the PC arm were not enrolled in the randomized trial but met basic study eligibility criteria during the same time period.
9894989|NCT05333510||TEG group|Thromboelastography guided blood product administration in patients of liver cirrhosis with non variceal bleed
9894990|NCT05333510||ROTEM group|Throboelastometry guided blood product administration in patients of liver cirrhosis with non variceal bleed
9894991|NCT05333497|Experimental|Programmed acupiont stimulation group|"On the basis of routine treatment in the Department of Acupuncture, the fourth generation of low-frequency acupoint electric stimulation therapy instrument (patent No. : ZL201610793646.9) jointly developed by our research group and the Robotics Institute of Harbin Institute of Technology is used to improve the program. The output of the improved instrument program is: the patient should complete the program of reaching and retrieving, namely shoulder joint forward flexion - elbow extension - wrist dorsal extension - finger extension ( reaching for objects ), then grasping - wrist flexion - elbow flexion - shoulder joint backward extension ( retrieve objects ). All patients were in a sitting position, the wrist of the affected limb is suspended, and the other parts do not touch any plane."
9894992|NCT05333497|Active Comparator|Conventional acupiont stimulation group|On the basis of the basic treatment in the Department of Acupuncture, the output mode of the fourth generation of low-frequency acupoint electric stimulation instrument of the original program is adopted to synchronously stimulate the flexor and extensor acupoints respectively. The selection of acupoints, treatment time and course of treatment were the same as those of the programmed acupoint electric stimulation group.
9894993|NCT05333497|No Intervention|Healthy controls|"No treatment. Ask them to do the reaching and retrieving gross motor and record the resting brain electrical and motion state of electrical parameters. Brain electric power spectrum analysis and electromyography synergy - coherence analysis are made to evaluate the brain energy state and degree of muscle coordination, for better interpreting the movement of the central nervous system control strategy and providing a reference for the prognosis of patients and the curative effect evaluation."
9894994|NCT05333484|Experimental|Pilates Intervention Group|12-week programed Pilates intervention
9894995|NCT05333484|No Intervention|Control Group|maintenance of normal lifestyle in control group
9894996|NCT05333445|Experimental|Nursing intervention|The NI will be performed at 3 times: face to face between 21 and 7 days before admission, between 7 and 15 days after the date of ablation, and 6 months after the ablation procedure.
9894997|NCT05333445|Active Comparator|control group|"After hospital discharge, all patients will be referred to their primary care physician or cardiologist for follow-up.~Patients will receive standard follow-up checks by the medical team will not receive structured education from the nurse."
9894998|NCT05333432|Other|Men at high genetic risk of prostate cancer|Cohort of unaffected men from 40 to 70 years olds with high risk of prostate cancer (PC) defined as being a member from a family that meets hereditary PC criteria or by carrying a mutation of a DNA repair gene or a gene specific to PC.
9894999|NCT05333419|Experimental|Single Dose 100ng/day PA5346 Latanoprost FA SR Ocular Implant|After washout, eligible subjects will be dosed with a single 100ng/day PA5346 Latanoprost FA SR Ocular Implant at study Day 0.
9895002|NCT05333393|Experimental|Experimental group|Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months.
9895003|NCT05333393|No Intervention|Control group|The control group will recieve standard diabetes treatment without any training intervention
9895004|NCT05333367|Other|Patients undergoing extracorporeal photochemotherapy|
9895005|NCT05333354|Experimental|Experimental(simulation education group)|The experimental group (simulation teaching group), the content of simulation teaching is based on the simulation model, and includes five important elements: Instructor, student, educational practice, simulation situation design and characteristics, and result that design covering the four stages of learning, concrete experience, reflective observation, abstract conceptualization and action experience, and design lesson plans, which include delirium assessment and delirium risk factor detection. Delirium prevention and management (PADIS guidelines). The main objectives of the teaching plan design of the experimental group are: to be able to confirm delirium by assessment of the Delirium Assessment Scale; to confirm the risk factors by the history taking; to propose treatment and measures according to the assessment results. Secondary goals: Be able to perform handovers.
9895006|NCT05333354|No Intervention|Control(traditional group)|Nurses in the control group did not receive simulated situational teaching, but received classroom teaching 3 times (once every other week) (delirium assessment, risk factor assessment; PADIS treatment), each session of about 2 hours. In order to avoid inconsistent teaching content, the control group and the experimental group are not to be together in classroom.
9895007|NCT05333341|Active Comparator|TCM|TCM uses clinical pharmacists leading LTOT reassessment and, when indicated for underlying OUD, buprenorphine (BUP) initiation in consultation with a BUP-prescribing physician. Clinical pharmacists will lead LTOT reassessment and, when indicated for underlying OUD, buprenorphine (BUP) initiation in consultation with a BUP-prescribing physician.
9895008|NCT05333341|Experimental|TCM plus COPES|Participants in this arm will use TCM plus COPES that will augment the effectiveness of TCM alone.
9895009|NCT05329623|Experimental|Normal hepatic function|Matched healthy participants with normal hepatic function
9895010|NCT05329623|Experimental|Mild hepatic impairment|Mild hepatic impaired participants with Child-Pugh A (score of 5 to 6)
9895011|NCT05329623|Experimental|Moderate hepatic impairment|Moderate hepatic impairment with Child Pugh B (score from 7 to 9)
9895012|NCT05329623|Experimental|Severe hepatic impairment|Severe hepatic impairment with Child Pugh C (score from 10 to 15)
9895013|NCT05329389|Experimental|StoneMD|"Patients will receive standard recommendations of keeping diuresis at the level of 2.5 l/day and to use the StoneMD application on their smartphones after the surgery. Patients will use the section Water balance and follow the instructions during the 12 month after the surgery."
9895014|NCT05329389|Experimental|StoneMD & Schools of Patients|"Patients will receive standard recommendations of keeping diuresis at the level of 2.5 l/day and and recommendations to use the StoneMD application on their smartphones after the surgery. Patients will use the section Water balance and follow the instructions during the 12 month after the surgery. Additionally, patients will visit schools during a following year. Patients receive 4 consultations (one per 3 month)."
9895015|NCT05329389|Active Comparator|Recommendations only|Only fluid balance recommendations given at the day of discharge. Patients will receive recommendations of keeping diuresis at the level of 2.5 l/day after the surgery
9895016|NCT05327647|Experimental|Bicalutamide|Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral bicalutamide for 90 days
9895017|NCT05327647|Active Comparator|Control Arm|Induction intravesical Bacille Calmette-Guérin treatment
9895018|NCT05327595|Experimental|LY3549492 (Part A)|LY3549492 administered orally as multiple ascending doses.
9895019|NCT05327595|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
9895020|NCT05327595|Experimental|LY3549492 + Midazolam + Atorvastatin (Part B)|LY3549492 coadministered orally with midazolam and atorvastatin.
9895021|NCT05327595|Placebo Comparator|Placebo + Midazolam + Atorvastatin (Part B)|Placebo coadministered orally with midazolam and atorvastatin.
9895023|NCT05326958|Experimental|Normal Eyes of Subjects without DM|Study Part 1 conducted at only site 1 . Single measurement made on 3 separate visits at site 1 (total 3 images acquired) with HRT RCM and HRT RCM-E functional module (investigational).
9895024|NCT05326958|Experimental|Eyes of DM Type 2 subjects without coexisting DPN|"Study part 2 conducted at site 2.~1 image acquired with HRT RCM-E functional module (investigational)."
9895025|NCT05326958|Experimental|Eyes of DM Type 2 subjects with coexisting early to moderate DPN|"Study part 2 conducted at site 2.~1 image acquired with HRT RCM-E functional module (investigational)."
9895026|NCT05326620||localized RCC|all patients with localized RCC
9895027|NCT05326620||metastatic RCC|all patients with metastatic RCC, synchronous or metachronous
9895028|NCT05326568|Experimental|Experimental|Sesame oil was applied by the researcher to the patients assigned to the intervention group. Sesame oil was applied to the 10 cm circumference of the cannula, in the form of 10 drops and 10 minutes.
9895029|NCT05326568|No Intervention|Control|No treatment was applied to the patients assigned to the control group and only standard care was applied.
9895030|NCT05326425|Experimental|lazertinib(YH25448)|lazertinib 240mg, once a day, oral, before disease progression
9895031|NCT05326360|No Intervention|group C|receive ramosetron i.v. 0.3mg at the end of surgery without additional ramosetron
9895032|NCT05326360|Experimental|group B|receive ramosetron i.v. 0.3mg at the end of surgery with two additional doses of ramosetron at 12- and 24- hour postoperative time points
9895033|NCT05326360|Experimental|group M|receive ramosetron i.v. 0.3mg at the end of surgery followed ramosetron 0.6 mg mix with the patient-controlled analgesia (PCA) regimen
9895034|NCT05326165|Experimental|Compression therapy|"Participants will receive a ready to wear compression sleeve and glove with embedded sensor.~Compression sleeve will be set to 20-30mm Hg pressure with instructions to wear for 12 hours a day for four consecutive weeks.~Participants will also receive a journal to record usage and standard of care post-operative lymphedema monitoring and education and asked to fill out questionnaires."
9895035|NCT05325853|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
9895036|NCT05325853|Active Comparator|Proparacaine|0.5% Proparacaine Hydrochloride
9895037|NCT05325814||Device: Continuous monitoring system|Continuous monitoring system Recruited patients will be continuously monitored with Isansys Lifetouch patch, Nonin WristOx 3150, Isansys wireless blood pressure monitor (Meditech Blue BP-05) and standard monitoring at the post anesthesia care unit
9895038|NCT05325164|Experimental|Methadone|"DESCRIPTION:~Blinded methadone 1mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 0.5mg Q4H x 4 doses + 1.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.0 mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Second increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~Third increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Fourth increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 1.0mg Q4H x 4 doses + 2.0mg QHS + 0.5mg Q2H PRN (max 4 doses)~First increase: 1.5mg Q4H x 4 doses + 3.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Second increase: 2.0mg Q4H x 4 doses + 4.0mg QHS + 1.0mg Q2H PRN (max 4 doses)~Third increase: 2.5mg Q4H x 4 doses + 5.0mg QHS + 1.5mg Q2H PRN (max 4 doses)~Fourth increase: 3.0mg Q4H x 4 doses + 6.0mg QHS + 1.5mg Q2H PRN (max 4 doses)"
9895039|NCT05325164|Active Comparator|Morphine|"DESCRIPTION:~Blinded morphine 5mg tablets PO~--~DOSAGE:~A) For patients initially taking 0-30 mg MEDD:~Starting dose: 2.5mg Q4H x 4 doses + 5.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 5.0 mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Second increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~Third increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Fourth increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~B) For patients initially taking 31-60 mg MEDD:~Starting dose: 5.0mg Q4H x 4 doses + 10.0mg QHS + 2.5mg Q2H PRN (max 4 doses)~First increase: 7.5mg Q4H x 4 doses + 15.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Second increase: 10.0mg Q4H x 4 doses + 20.0mg QHS + 5.0mg Q2H PRN (max 4 doses)~Third increase: 12.5mg Q4H x 4 doses + 25.0mg QHS + 12.5mg Q2H PRN (max 4 doses)~Fourth increase: 15.0mg Q4H x 4 doses + 30.0mg QHS + 12.5mg Q2H PRN (max 4 doses)"
9895040|NCT05325060|Experimental|Electromagentically navigated Total knee arthroplasty|"Patients underwent total knee arthroplasty using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA). The system employs small reference frames attached to the femur and tibia which are incorporated within the primary surgical incision. A standard process of joint registration maps the surface anatomy of the joint. Alignment targets were similar in both groups with a neutral Hip-Knee-Ankle-Axis and the aim to implant both femur and tibial components perpendicular to this in the coronal plane.~All patients received a cemented posterior stabilized NexGen LPS Flex TKA (Zimmer, Warsaw, Indiana, USA)."
9895041|NCT05325060|Active Comparator|Conventional mechanically alligned Total knee arthroplasty|"Participants randomized to the conventional group received a TKA implanted using standard instrumentation.~All patients received a cemented posterior stabilized NexGen LPS Flex TKA (Zimmer, Warsaw, Indiana, USA).~Alignment targets were similar in both groups with a neutral Hip-Knee-Ankle-Axis and the aim to implant both femur and tibial components perpendicular to this in the coronal plane."
9895042|NCT05325047|Experimental|Speech rehabilitation|
9895043|NCT05325034|Active Comparator|Early intervention|Participants randomised to 'early' will receive the intervention at baseline through 6 months. while those randomised to 'late' will receive standard-of-care and represent a control arm over this period.
9895044|NCT05325034|Other|Late intervention|Those randomised to 'late' will receive standard-of-care and represent a control arm to the early intervention group.
9895045|NCT05324397|Experimental|Experimental: Treatment|Subjects will undergo treatment with the NEUROMARK System
9895046|NCT05324319|Active Comparator|homologous 3rd vaccination (mRNA vaccine)|Participants will receive a third SARS-CoV-2 vaccination with the same mRNA vaccine they received for the initial prime-boost vaccination (BNT162b2 or mRNA-1273 )
9895047|NCT05324319|Experimental|heterologous 3rd vaccination (vector vaccine)|participants will receive a third SARS-CoV-2 vaccination with a vector vaccine (Ad26COVS1 or ChAdOx1-S)
9895048|NCT05324124|Experimental|Selpercatinib (Period 1)|Selpercatinib will be administered orally on Day 1 either in fast or fed state.
9895049|NCT05324124|Experimental|Selpercatinib (Period 2)|Selpercatinib will be administered orally on Day 8 either in fast or fed state.
9895050|NCT05324059|Experimental|Group A: Pregabalin/Tramadol|Fixed dose combination tablet of 75 mg Pregabalin and 50 mg of Tramadol, orally, every 12 hours.
9895051|NCT05324059|Active Comparator|Group B: Pregabalin|Monotherapy with 75 mg of Pregabalin, orally, every 12 hours.
9895052|NCT05324046||Liver metastasis|Patients with suspicion of liver metastasis and scheduled for CT
9895053|NCT05323968|Other|Acute diverticulitis|Patients with clinical suspicion of acute diverticulitis
9895054|NCT05323708|Experimental|Bmab 1000, A single 60 mg dose of Bmab 1000 administered by subcutaneous injection.|
9895055|NCT05323708|Active Comparator|Prolia®, A single 60 mg dose of Prolia® administered by subcutaneous injection.|
9895056|NCT05323682|Experimental|Experimental|Individualized physical exercise program
9895057|NCT05323682|Active Comparator|Control|No individualized physical exercise program
9517539|NCT03305471|Experimental|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]
9991741|NCT01455753||Employees|A total of 1,801 employees of a health benefits administrator that held a free workplace influenza vaccination clinic.
9895058|NCT05323630|Other|Procedure with the Renuvion APR System in the labia|The labia procedure utilizing the Renuvion APR system will be performed per the investigator's standard clinical practice.
9895059|NCT05323591||Filgotinib|Participants will receive treatment for moderate to severe active RA with at least one dose of filgotinib in accordance with the product label.
9895060|NCT05323526||Study Group|100 patients who will undergo cataract surgery
9895061|NCT05323331|Experimental|Circuit Training|"This group preformed interval training alternating between aerobic and resistance training, varying between moderate to high intensity. Each set started with 3 minutes of aerobic training on cycle or treadmill followed by resistance training and a rest interval. Eight circuits were formed; horizontal rowing, chest press, leg press, shoulder press, leg extension, lateral pull down, leg flexion and partial squat. Weight was calculated through 1 RM calculation.~This training is to be carried out for 12 weeks, in three phases, the intensity progressing from light to moderate (30% of RM to 50%). Sessions will be carried out thrice a week."
9895062|NCT05323331|Active Comparator|Aerobic Training|The control group consists of aerobic exercise training, with 20 minutes on the cycle, 15 minutes of treadmill and 10 minutes of walking
9895063|NCT05323266|Experimental|Nasal Continuous Positive Airway Pressure (nCPAP)|Nasal Continuous Positive Airway Pressure is the main mode of oxygen supply observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
9895064|NCT05323266|Experimental|High-Flow Nasal Cannula (HFNC)|NasalContinuousPositiveAirwayPressure is another oxygen supply mode mainly observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
9895065|NCT05323136|Experimental|Renal impairment|moderate and severe Renal impairment subjects
9895066|NCT05323136|Experimental|Healthy control|Healthy control subjects with normal renal function
9895067|NCT05322902|Experimental|Remimazolam group|Total intravenous anesthesia with remimazolam and remifentanil
9895068|NCT05322902|Active Comparator|Propofol group|Total intravenous anesthesia with propofol and remifentanil
9895069|NCT05322733|Experimental|Treatment (oFCG)|See Detailed Description.
9895070|NCT05322655||infants living in low-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
9895071|NCT05322655||infants living in middle-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
9895072|NCT05322655||infants living in low-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
9895073|NCT05322655||infants living in middle-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
9895075|NCT05322408|Experimental|Administer HCW9218|"Administer HCW9218 as monotherapy at assigned dose by SC injection once every 3 weeks. Dose Level~-1 - 0.1 mg/kg~- (start) 0.25 mg/kg~- 0.5 mg/kg~- 0.8 mg/kg~- 1.2 mg/kg"
9895076|NCT05322291|Experimental|Experimental Group|The developed mobile application will be installed on the phones of hemodialysis patients in the experimental group. Online consultancy and training will be provided with the application.
9895077|NCT05322291|No Intervention|Control Group|No intervention will be made. They will continue to receive routine care.
9895078|NCT05321875|Experimental|Candesartan|Candesartan, 16 mg oral tablets. Target dose 32 mg or maximum tolerated dose after dose escalation from 16 mg
9895079|NCT05321875|Placebo Comparator|Placebo|Matching placebo. Target dose 2 tablets or maximum tolerated dose after dose escalation from 1 tablet
9895080|NCT05321173||Extubation ≤ 8 hour|Patients who mechanically ventilated less than 8 hours postoperatively
9895081|NCT05321173||Extubation > 8 hour|Patients who mechanically ventilated more than 8 hours postoperatively
9895082|NCT05321043|Other|Vitamin B2 labeled group|A liquid of vitamin B2 and hand sanitizer (0.12mg/mL) is marked on the patients' hands outside the endoscopy center.
9895083|NCT05319561|Experimental|VAST+|Sites that implement the VAST augmented by quarterly facility-level Antibiotic Use Reports (VAST+).
9895084|NCT05319561|No Intervention|VAST -|to sites that implement the VAST and do NOT receive a quarterly facility-level Antibiotic Use Reports (VAST-).
9895085|NCT05318612|Other|Control group (biopsy group)|Standard of care: biopsy + adjuvant treatment
9895086|NCT05318612|Experimental|Intervention group (LITT group)|Biopsy + LITT + adjuvant treatment
9895087|NCT05318586|Experimental|Individualized rTMS based on fNIRS|Low-frequency rTMS will be given to the most active brain regions assessed by fNIRS.
9895088|NCT05318586|Active Comparator|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1
9895089|NCT05318326|Placebo Comparator|Placebo control group|Placebo control group
9895090|NCT05318326|Experimental|Yogliptin 200mg group|Yogliptin 200mg group
9895091|NCT05318326|Experimental|Yogliptin 400mg group|Yogliptin 400mg group
9895092|NCT05317247||Discovery Cohort|An anticipated number of 473 participants will be recruited in Cape Town, South Africa. Data (cough audio) will be collected and used to train a machine learning algorithm. The cough audio signal specific for TB will be refined. During the discovery phase, the ground truth obtained through biological testing of sputum specimens will be used to inform the machine learning.
9895093|NCT05317247||Validation Cohort|In the validation phase, the cough audio signature will have its sensitivity and specificity measured in new patients in Cape Town, South Africa (n=511) and Kampala, Uganda (n=767). The data will be used to evaluate the performance of the algorithm.
9895094|NCT05317065|Experimental|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
9895095|NCT05317065|No Intervention|Control|Control
9895096|NCT05316311|Experimental|CERENOVUS ENTERPRISE 2 Intracranial Stent|Participants with severe symptomatic intracranial artery stenosis will be treated with CERENOVUS ENTERPRISE 2 Intracranial Stent.
9895097|NCT05316259|Experimental|Group A（Dosing in the fasted state followed by fed dosing）|Dosing in the fasted state followed by fed dosing.A washout period of 14 days will be maintained between the 2 treatment periods.
9895098|NCT05316259|Experimental|Group B（Dosing in the fed state followed by fasted dosing）|Dosing in the fed state followed by fasted dosing.A washout period of 14 days will be maintained between the 2 treatment periods.
9895099|NCT05315700|Experimental|Dose Escalation|ORIC-114 dosed orally on a continuous daily dosing regimen in 28-day cycles.
9895100|NCT05315570|Experimental|Intervention arm|Study participants will be followed up as per clinical practice and will receive the investigational electronic platform, including an Android-based app. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
9895101|NCT05315570|No Intervention|Control arm|No specific mobile apps will be provided to study participants, who will be followed as per clinical practice. Study subjects will be asked to fill in questionnaires at study entry and during follow-up.
9895102|NCT05315011|Experimental|Whole-body cryotherapy|
9895103|NCT05315011|Placebo Comparator|Placebo cryotherapy|
9895104|NCT05313802|Experimental|LY3502970 (Dose Level 1)|LY3502970 administered orally.
9895105|NCT05313802|Experimental|LY3502970 (Dose Level 2)|LY3502970 administered orally.
9895106|NCT05313802|Experimental|LY3502970 (Dose Level 3)|LY3502970 administered orally.
9895107|NCT05313633|Experimental|Wii group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a Wii training program for 45 minutes The treatment will be implemented three sessions a week for three months period.
9895108|NCT05313633|Experimental|plyometric group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a plyometric training program for 45 minutes The treatment will be implemented three sessions a week for three months period.
9895109|NCT05313607|Experimental|conventional group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a conventional physical therapy program for 45 minutes The treatment will be implemented three sessions a week for three months period.
9895110|NCT05313607|Experimental|plyometric group|Children in this group will receive a designed physical therapy and occupational therapy programs prescribed individually for each child based on the functional capacity of each child (each program lasted for 30 minutes). Additionally, a 30- minute rest period will be implemented before receiving the allocated intervention. This group will receive a plyometric physical therapy program for 45 minutes The treatment will be implemented three sessions a week for three months period.
9895111|NCT05313035|Experimental|Vaccine Candidate Formula 1|2 doses of vaccine candidate formula 1 administered with 28 days interval (0.5 mL per dose)
9895112|NCT05313035|Experimental|Vaccine Candidate Formula 2|2 doses of vaccine candidate formula 2 administered with 28 days interval (0.5 mL per dose)
9895113|NCT05313035|Placebo Comparator|Control|2 doses of placebo administered with 28 days interval (0.5 mL per dose)
9895114|NCT05312606|Experimental|Trial Group|Home treatment with hyaluronic acid.
9895115|NCT05312606|Active Comparator|Control Group|Home treatment with chlorhexidine.
9895116|NCT05312593|Experimental|Trial Group|A group of 20 patients will be randomly assigned to Hyaluronic Acid domiciliary treatment, applied into Peri-implant mucositis sites.
9895117|NCT05312593|Active Comparator|Control Group|A group of 20 patients will be randomly assigned to Chlorhexidine mouthwash domiciliary treatment, applied into Peri-implant mucositis sites.
9895118|NCT05312411|Experimental|UB-TT170 following SCRI-E2CAR_EGFrtv1|Following CAR T cell administration, subjects will receive a first Course of 3 escalating doses of UB-TT170 over 2 weeks followed by fixed weekly dosing for 2 weeks. If eligible, subjects may proceed to Courses 2 - 4 consisting of 7 weekly doses of UB-TT170.
9895119|NCT05311176|Experimental|Arm 1: HER-Vaxx in combination with chemotherapy (irinotecan or paclitaxel)|Patients who have received an immune checkpoint inhibitor (ICI) previously will exclusively be enrolled in Arm 1 treated with HER-Vaxx (IM) in combination with chemotherapy (irinotecan or paclitaxel)
9895120|NCT05311176|Experimental|Arm 2: HER-Vaxx in combination with pembrolizumab|Arm 2 will investigate the combination of HER-Vaxx plus pembrolizumab in patients who are naïve to ICI treatment including patients who have had chemotherapy only treatment after progression on trastuzumab. As the combination treatment has not been investigated, Arm 2 is planned to initiate with a safety run-in phase.
9932710|NCT00951860||Newborn|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the hospital neonatal unit at the time of registration (after 37 weeks corrected for prematurity) or in the maternity
9932711|NCT00951873|Experimental|A|
9895121|NCT05310942||A|The fluid management of patients in this group will be assessed by IVC collapsibility index (IVC CI) calculated by ultrasound through maximum IVC diameter - minimum IVC diameter divided by maximum diameter then multiplied by 100. If it is less than 50% means that the patient is volume non- depleted while if it is more than 50% means the reverse.
9895122|NCT05310942||B|All patients in this group with sepsis will be evaluated by the electrical cardiometry monitor.
9895123|NCT05310747|Experimental|Artwork present + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with artwork for 10 minutes
9895124|NCT05310747|Experimental|Artwork present + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with artwork for 10 minutes
9895125|NCT05310747|Experimental|Artwork absent + social connection high|Individuals participate in an exercise to prime a feeling of high social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
9895126|NCT05310747|Active Comparator|Artwork absent + social connection low|Individuals participate in an exercise to prime a feeling of low social connection and then explore a virtual museum exhibit with no artwork for 10 minutes
9895127|NCT05310747|No Intervention|Hanging control group|Individuals will receive no exposure to any independent variables (i.e. artwork: present or absent; social connection prime: high or low) for 10 minutes before completing their final survey.
9895128|NCT05309902|Experimental|Sequence 1: (Regimen A + Regimen B + Regimen C + Regimen D)|Regimen A (soticlestat 300 milligram [mg] tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
9895129|NCT05309902|Experimental|Sequence 2: (Regimen B + Regimen D + Regimen A + Regimen C)|Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen C (soticlestat -matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 4.
9895130|NCT05309902|Experimental|Sequence 3: (Regimen C + Regimen A + Regimen D + Regimen B)|Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
9895131|NCT05309902|Experimental|Sequence 4: (Regimen D + Regimen C + Regimen B + Regimen A)|Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.
9895132|NCT05308511|Experimental|Swallowing order I|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
9895133|NCT05308511|Experimental|Swallowing order II|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
9895134|NCT05308433|Experimental|Experimental|
9895135|NCT05307198|Experimental|Rectal Artery Infusion Chemotherapy|Patients receive 2 cycles of Capecitabine and Oxaliplatin (CapeOx) chemotherapy and evaluated with rectum Magnetic Resonance Imaging (MRI). Patients with more than 20% regression of maximum diameter of rectal tumor in MRI image will entry into next step of rectal artery infusion of Oxaliplatin（85mg/㎡）and oral Capecitabine（1000mg/㎡）with anti-PD1 antibody（200mg）every 3 weeks for 2 cycles.Then those patients will receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME.
9932712|NCT00951873|Placebo Comparator|B|
9932713|NCT00951873|Experimental|C|
9932714|NCT00951925||No Treatment|
9517540|NCT03305471|Experimental|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]
9517541|NCT03305471|Experimental|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]
9517542|NCT03305471|Experimental|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]
9895136|NCT05306379|Experimental|Voclosporin/Simvastatin|"Subjects will receive a single oral dose of 40 mg simvastatin (given as two 20 mg tablets) in the morning of Day 1 and Day 8.~Subjects will receive voclosporin administered as an oral 23.7 mg dose (three 7.9 mg capsules) twice-daily for 7 days from the morning of Day 2 until the evening of Day 8."
9895137|NCT05305092||chemotherapy|Premenopausal breast cancer patients receiving chemotherapy (including preoperative neoadjuvant chemotherapy) and endocrine therapy after surgery
9895138|NCT05305092||Endocrine therapy|Premenopausal breast cancer patients receiving endocrine therapy alone after surgery
9895139|NCT05305092||Healthy control|Healthy non-cancer controls
9895140|NCT05304962|Experimental|Arm A|RGT-419B given alone as monotherapy
9895141|NCT05304962|Experimental|Arm B|RGT-419B in combination with Hormonal Therapy
9895142|NCT05304715|Placebo Comparator|Placebo|Patients will be treated with 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
9895143|NCT05304715|Active Comparator|Bezlotoxumab|Patients will be treated with bezlotoxumab at a dose of 10mg per kg of body weight (up to maximum of 1000mg) dissolved in 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
9895144|NCT05304663|Experimental|ARM 1: Fractionating Lomustine|"Patients will be treated in escalating cohorts of 6 patients with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and lomustine at different doses on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Cohort 1: 10 µg/kg L19TNF and 60 mg/m2 lomustine~Cohort 2: 10 µg/kg L19TNF and 75 mg/m2 lomustine"
9895145|NCT05304663|Experimental|ARM 2: Priming with L19TNF|"Patients will be treated in escalating cohorts of 6 patients with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and lomustine at different doses on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles.~Cohort 1: 10 µg/kg L19TNF and 90 mg/m2 lomustine~Cohort 2: 10 µg/kg L19TNF and 110 mg/m2 lomustine In each arm, patients will be enrolled sequentially and no more than 2 patients will be treated in Cycle 1 in the same arm in parallel.~Recruitment to an arm will be stopped should ≥ 2 DLTs occur in a cohort."
9895146|NCT05304143|Experimental|Virtual Reality intervention group|The exploration in the intervention group will be carried out with virtual reality glasses compatible with the magnetic resonance imaging equipment.
9895147|NCT05304143|Active Comparator|Conventional nurse support|The exploration in the control group will be carried out with the standard procedure for claustrophobic patients that includes close nursing support.
9895148|NCT05303805|Experimental|Topical sevoflurane|The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment,
9895149|NCT05303805|Active Comparator|Cyteal|the control group will only have a standard rinse solution with Cyteal PIERRE FABRE MEDICAMENT, France (100 ml of skin fluid contains hexamidine diisetione 100 mg, chlorohexidine digluconate (solutio 20 %) 100 mg and chlorocresol 300 mg), with sevoflurane used to soak the absorbent material held under the distal pole of the wound.
9895150|NCT05303402|Experimental|Experimental: COVID-19 Vaccine HIPRA 40 ug/dose|Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 ug/dose.
9895151|NCT05303038|Experimental|cryoablation combined with tirelizumab + Bevacizumab|
9895152|NCT05301153||Myasthenia Gravis cases|"Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by Ficoll-Paque gradient centrifugation according to the manufacturer's protocol.~Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using SYBR Green using the following primers Interleukin-37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39.~Autoantibodies detection:~Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA according to the manufacturer's protocol."
9895153|NCT05301153||Healthy Control|"Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by Ficoll-Paque gradient centrifugation according to the manufacturer's protocol.~Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using SYBR Green using the following primers IL-37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39."
9895154|NCT05299268|Experimental|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 1x3 min Seated Isometric Knee Extension
9895155|NCT05299268|Placebo Comparator|No pain (isotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 1x3 min Seated Isometric Knee Extension
9895156|NCT05298254|Experimental|Non-adjuvanted HSV formulation 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 1 vaccine, one at Day 1 and one at Day 29.
9895157|NCT05298254|Experimental|Non-adjuvanted HSV formulation 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 2 vaccine, one at Day 1 and one at Day 29.
9895158|NCT05298254|Experimental|Non-adjuvanted HSV formulation 3 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 3 vaccine, one at Day 1 and one at Day 29.
9895159|NCT05298254|Experimental|HSV formulation 1 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
9895160|NCT05298254|Experimental|HSV formulation 2 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
9932715|NCT00951951|Active Comparator|Anterior Surgical Approach|(AMIS)
9895161|NCT05298254|Experimental|HSV formulation 3 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
9895162|NCT05298254|Experimental|HSV formulation 1 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
9895163|NCT05298254|Experimental|HSV formulation 2 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
9895164|NCT05298254|Experimental|HSV formulation 3 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
9895165|NCT05298254|Placebo Comparator|Placebo - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
9895166|NCT05298254|Experimental|Selected formulation - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of the formulation of the HSV vaccine selected from Part I of the study, one at Day 1 and one at Day 29.
9895167|NCT05298254|Placebo Comparator|Placebo - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
9895168|NCT05297526|Experimental|Intervention Group|The intervention group will receive a culturally adapted children's book that contains the same oral health educational information as the control brochure, but celebrates Tribe-specific culture and utilizes entertainment education. The children's book includes vibrant illustrations by a Tribal artist, and has eBook and audio narration options for multi-media use and/or those with limited literacy.
9895169|NCT05297526|Active Comparator|Control Group|The control group will receive a standard educational brochure about children's oral health designed by the the National Institutes for Health (NIH) for American Indian/Alaska Native parents.
9895170|NCT05297045|Experimental|Dose Group A|
9895171|NCT05297045|Experimental|Dose Group B|
9895172|NCT05297045|Experimental|Dose Group C|
9895173|NCT05297045|Experimental|Dose Group D|
9895174|NCT05297045|Experimental|Dose Group E|
9895175|NCT05297045|Experimental|Dose Group F|
9895176|NCT05297045|Placebo Comparator|Placebo Group|
9895177|NCT05296798|Other|Induction Therapy: Phesgo plus Taxane-Based Chemotherapy|
9895178|NCT05296798|Active Comparator|Arm A, Maintenance Therapy: Phesgo|
9895179|NCT05296798|Experimental|Arm B, Maintenance Therapy: Giredestrant plus Phesgo|
9895180|NCT05296577|Experimental|anlotinib and vinorelbine|anlotinib combined with vinorelbine
9895181|NCT05296577|Placebo Comparator|vinorelbine|placebo and vinorelbine
9895182|NCT05295212|Experimental|Cohort A|MRD revealed negative
9895183|NCT05295212|Experimental|Cohort B|MRD revealed positive
9895184|NCT05294367|Experimental|Cycle 1|Participants consume magnesium rich foods PO daily for 28 days.
9895185|NCT05294367|Experimental|Cycle 2, Arm I|Participants continue consuming magnesium rich foods PO daily and apply Ancient Minerals Magnesium Lotion topically daily for 28 days.
9895186|NCT05294367|Experimental|Cycle 2, Arm II|Participants continue consuming magnesium rich foods PO daily for 28 days.
9895187|NCT05293470||Piqray|Patients prescribed with Piqray
9895188|NCT05291936|Experimental|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
9895189|NCT05291936|Experimental|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
9895190|NCT05291923||Post whipple's procedure patients|
9932716|NCT00951951|Active Comparator|Posterior Approach Group|Posterior surgical approach for total hip replacement.
9932717|NCT00951964|Other|1|patients receive the treatment in first and placebo in second part of study
9932718|NCT00951964|Other|2|patients receive placebo in first and treatment in second part of study
9932719|NCT00951977||Subjects who have formerly donated a kidney|
9895191|NCT05289869|Experimental|High-dose oxytocin regimen|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
9895192|NCT05289869|Experimental|Low-dose oxytocin regimen|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
10213830|NCT03035409|Experimental|Supportive Care (anamorelin, physical activity, counseling)|Patients receive anamorelin hydrochloride PO QD and undergo physical activity consisting of resistance exercises and a home walking program. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo nutritional counseling on day 21.
10213831|NCT03033225|Experimental|Treatment (verteporfin, EUS-guided PDT)|Patients receive verteporfin IV and after 60 minutes undergo EUS-guided PDT.
9895195|NCT05288777|Other|Her2/neu positive and lymph node positive|T-DM1/ trastuzumab emtansine infusion along with radiation to the breast or chest wall and lymph nodes
9895196|NCT05288777|Other|Her2/neu positive and lymph node negative|T-DM1/trastuzumab emtansine infusion along with radiation to the whole breast or chest wall
9895197|NCT05288777|Other|Her2/neu negative and lymph node positive|oral capecitabine twice per day along with radiation to the breast or chest wall and lymph nodes
9895198|NCT05288777|Other|Her2/neu negative and lymph node negative|oral capecitabine twice per day along with radiation to the whole breast or chest wall
9895199|NCT05286281|Experimental|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
9895200|NCT05285982|Experimental|Patients rolling over from the InPedILD™ study|
9895201|NCT05285982|Experimental|Patients newly enrolled in this study|
9895202|NCT05285592|Experimental|Fecal Transplantation|"Donors will be supplied clean, sealable containers for collection and transport of stool. Containers will be labeled with the name, UHID and date/time of stool collection.~Collected stool will be immediately transferred to the laboratory facility for processing and used within 6 hours collection~Stool sample from Healthy donor will be processed~Patient preparation~Patient was kept NPO for 4 hours prior to stool instillation~Iv antibiotics were continued as per treating doctor in the event of sepsis~The patient was allowed to consume the prescribed diet 2 hours after the procedure instillation~Methods of FMT infusion.~Seven doses (30gm one dose) of FMT will be given via jejunal port of NJ/NG tube"
9895203|NCT05285592|Active Comparator|Standard Medical Treatment|Standard Medical Treatment
9895204|NCT05284435|Experimental|iCBT-Email (iCBT-E)|Parents will receive a weekly email from a therapist over the 12 weeks of treatment.
9895205|NCT05284435|Active Comparator|iCBT-Email and Videoconferencing (iCBT-EV)|Parents will receive a weekly email and six 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
9895206|NCT05284214|Experimental|Sargramostim daily: 14 of 21 days|Sargramostim administered by subcutaneous (SC) injection for 14 consecutive days every 3 weeks, for up to 12 weeks, given in combination with an ipilimumab-containing regimen.
9895207|NCT05284214|Experimental|Sargramostim daily: 5 of 7 days|Sargramostim given by SC injection for 5 consecutive days every week, for up to 12 weeks, given in combination with an ipilimumab-containing regimen for a total of 12 weeks.
9895208|NCT05283512|Other|IV-hydration group (standard of care)|The total IV-hydration volume is 500-1000 mL of isotonic NaCl with an infusion rate of 1-3 mL/kg/hour. The IV-hydration spans 3-4 hours prior to cardiac CT and 4-6 hours after. Patients with heart failure are prescribed an individual hydration protocol of a total volume of 500 mL, while other patients are prescribed a total volume of 500-1000 mL.
9895209|NCT05283512|Active Comparator|Oral hydration group|The total hydration volume is 500-1000 mL tap water. The oral hydration spans from 1-2 hours prior to cardiac CT and until 3 hours after. Patients with heart failure are prescribed an individual hydration protocol of a total volume of 500 mL (250 mL within 1-2 hours before and 250 mL within 3 hours after), while other patients are prescribed the standard amount of fluid with a total volume of 1000 mL (500 mL within 1-2 hours before and 500 mL within 3 hours after).
9895210|NCT05283187|Experimental|MBCT|Mindfulness Based Cognitive Therapy
9895211|NCT05283187|No Intervention|Control Group|No intervention
9895212|NCT05283135|Experimental|risankizumab subcutaneous injection 600 mg (4x dosing) at Weeks 0, 4, and 16|
9895213|NCT05283135|Experimental|risankizumab subcutaneous injection 300 mg (2x dosing) at Weeks 0, 4, and 16|
9895214|NCT05282927|Active Comparator|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
9895215|NCT05282927|Experimental|Enhanced REP|EnREP begins with the same activities as foundational REP. Sites that do not meet EBP-specific a priori benchmarks reflecting adoption within 6 months will continue with foundational REP and will receive higher intensity support for a period of 6 months (enREP). Additionally, sites randomized to enREP that met adoption benchmarks but did do not meet the sustainment benchmark, will also receive intensified implementation support for the remainder of the study period (3 months). The higher intensity support will consist of 3 to 4 tailored modules including a barrier/needs assessment and facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship. Facilitators will follow a table specifying identified barriers to implementation, along with potential aligned strategies to overcome the barriers, and examples in the context of the EBP. Facilitation will be provided by Function QUERI team members.
9895216|NCT05281757||Ennovate® Complex|All patients who are treated with the Ennovate® Complex system in accordance with indications given in the instructions for use (IFU)
9932720|NCT00951977||Matched community control Subjects|
9932721|NCT00952003|Experimental|interventional arm|Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination therapy cycles Bevacizumab will be continued until progression.
9932722|NCT00952029|Experimental|Maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab
9932723|NCT00952029|Active Comparator|No maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval NO maintenance
9895217|NCT05281731|Experimental|Sonobiopsy|"Once enrolled, participants would be prepared for surgery following the standard procedure.~The sonobiopsy involves the standard procedure for a biopsy, but the biopsy needle is replaced with a customized ultrasound probe, a standard ultrasound contrast agent (microbubbles) is injected intravenously, and the probe is turned on for 3 minutes for the sonobiopsy. Then the planned surgery to remove the tumor will occur.~Blood will be collected before the sonobiopsy, immediately after the sonobiopsy, and then optional blood draws at 30 minutes after sonobiopsy, 60 minutes after sonobiopsy, and during the planned surgery.~A small skin biopsy or another blood draw will be drawn for comparison against the genetic mutations shown in the tumor.~The blood, tumor, and skin (if applicable) will undergo genetic analysis."
9895218|NCT05279963|Active Comparator|medication group|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of participants will be recorded on diary cards.
9895219|NCT05279963|Experimental|EA group|Patients allocated to this group will receive treatment with electroacupuncture. The location of acupoints will be determined based on the National Standard Nomenclature and Location of Acupoints. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks.
9895220|NCT05279963|Sham Comparator|SA group|Patients allocated to this group will receive acupuncture in non-meridian and non-acupoints regions. The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the EA group.
9895221|NCT05279846|Experimental|MOB015B|Applied at bedtime daily for 8 weeks and then reduced to once weekly for 40 weeks
9895222|NCT05279846|Placebo Comparator|Control Arm|Applied at bedtime daily for 8 weeks and then reduced to once weekly for 40 weeks
9895223|NCT05279300|Experimental|Dose escalation|
9895224|NCT05279300|Experimental|Dose expansion|
9895225|NCT05277714|Experimental|NF|
9895226|NCT05277714|Sham Comparator|Sham|
9895227|NCT05277233||Early-onset preeclampsia|Defined as preeclampsia that develops before 34 weeks of gestation
9895228|NCT05277233||Late-onset preeclampsia|Defined as preeclampsia that develops after 34 weeks of gestation
9895229|NCT05277233||Control|Healthy pregnancies, matched to early and late-onset cases
9895230|NCT05276505|No Intervention|Control Group - Standardized care|"Standardized nursing care applications~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
9895231|NCT05276505|Experimental|Experimental Group- Lavender Aromatherapy Tablet|"Before 20 minutes from breast biopsy. Lavender aromatherapy tablets. A small (approximately 1x 0.5 inch), rectangular, absorbent tablet containing 2 ml of lavender essential oil (10) was adhered to the patient's shoulder level in the waiting room.~Patients were asked to inhale the aromatherapy tablet for 20 minutes before the procedure.~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
9895232|NCT05276505|Experimental|Experimental Group- Lavender-Mint Aromatherapy Tablet|"Before 20 minutes from breast biopsy. Lavender-Mint aromatherapy tablets. A small (approximately 1x 0.5 inch), rectangular, absorbent tablet containing 2 ml of lavender essential oil (10) was adhered to the patient's shoulder level in the waiting room.~Patients were asked to inhale the aromatherapy tablet for 20 minutes before the procedure.~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
9895233|NCT05276401|Experimental|Active|Dosage Form: Topical Antimicrobial Gel; Dosage: 5% Gel, 10% Gel; Frequency: BID for 28 days
9895234|NCT05276401|Placebo Comparator|Placebo|Dosage Form: Topical Gel; Dosage: Placebo; Frequency: BID for 28 days
9895235|NCT05275868|Experimental|Dose escalation|Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status
9895236|NCT05275868|Experimental|Dose expansion group 1|Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status
9895237|NCT05275868|Experimental|Dose expansion group 2|Patients with advanced NSCLC irrespective of prior knowledge of NFE2L2/KEAP1/CUL3 mutational status.
9895238|NCT05275400|Experimental|LY3209590|Participants will be given LY3209590 subcutaneously (SC).
9895239|NCT05275400|Active Comparator|Insulin Degludec|Participants with be given insulin degludec SC.
9932724|NCT00952042|Experimental|Heavy slow resistance training|12 wks of heavy slow resistance training. training three times per week. each session: 3 heel-raise exercises. 12-6RM. Slow contractions.
9517543|NCT03305458|Active Comparator|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
9895240|NCT05275231|Experimental|Dyads|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. The intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this dyad-based group, participant's social partner must commit to attend all in-person sessions.
9895241|NCT05275231|Active Comparator|Men Only|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. the intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this group just the participant will receive the intervention.
9895242|NCT05274711|Active Comparator|Conventional treatment|will receive conventional physical therapy prograM
9895243|NCT05274711|Experimental|Experimental treatment|will receive conventional physical therapy program and whole body vibration training
9895244|NCT05273749|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
9895245|NCT05273749|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
9895246|NCT05272748|Experimental|Conventional Exercise|Conventional exercises used in the treatment of knee and hip osteoarthritis will be performed by the telerehabilitation method for 8 weeks. Patients will be contacted via laptop, ipad and phones with cameras, microphones and internet connection. Exercise by telerehabilitation will be implemented with a live connection for the first 4 weeks. In the second 4 week periods, exercise videos will be given to the patients and it will be checked by phone. Strengthening and flexibility exercises will be done to the conventional exercise group. Hip and knee isometric and isotonic exercises, terminal knee extension, mini squat, lunge, range of motion exercises for lower extremities, hamstring, quadriceps, gastrocnemius stretching exercises will be performed by the patients. Exercises will be applied 3 times a week.
9895247|NCT05272748|Experimental|Conventional Exercise + Core Stabilization Exercise|Conventional exercises and core stabilization exercises will be performed with the telerehabilitation method for 8 weeks. Patients will be contacted via laptop, ipad and phones with cameras, microphones and internet connection. Exercise by telerehabilitation will be implemented with a live connection for the first 4 weeks. In the second 4 week periods, exercise videos will be given to the patients and it will be checked by phone. In addition to the exercises in the conventional exercise group, patients will perform bridging, lateral bridging, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, clam exercise. Exercises will be applied 3 times a week.
9895248|NCT05269147|Placebo Comparator|SBGB with normal saline|patients will receive standardized general anesthesia + SBGB with normal saline.
9895249|NCT05269147|Active Comparator|SBGB with lidocaine 2%|patients will receive standardized general anesthesia + SBGB with lidocaine 2%
9895250|NCT05269147|Active Comparator|SBGB with bupivacaine 0.5%|patients will receive standardized general anesthesia+ SBGB with bupivacaine 0.5%
9895251|NCT05268796|Active Comparator|In-person treatment|
9895252|NCT05268796|Active Comparator|Telehealth-enabled treatment|
9895253|NCT05268796|Placebo Comparator|Psychoeducation|
9895254|NCT05268666|Experimental|JBI-802|10 mg JBI-802 once daily as the starting dose with 4 days on/3 days off cycle
9895255|NCT05268016|Experimental|ME3183 Dose 1, BID|Specified dose of ME3183 capsule for 16 weeks
9895256|NCT05268016|Experimental|ME3183 Dose 2, QD|Specified dose of ME3183 capsule for 16 weeks
9895257|NCT05268016|Experimental|ME3183 Dose 3, BID|Specified dose of ME3183 capsule for 16 weeks
9895258|NCT05268016|Experimental|ME3183 Dose 4, QD|Specified dose of ME3183 capsule for 16 weeks
9895259|NCT05268016|Placebo Comparator|Placebo|Placebo capsule of ME3183 for 16 weeks
9895260|NCT05267626|Experimental|AU-007 Monotherapy|AU-007 (Q2w) will be administered as a monotherapy sequential ascending doses with each Dose Escalation Cohort
9895261|NCT05267626|Experimental|AU-007 combined with an aldesleukin loading dose|AU-007 (Q2w) will be administered at a fixed dose in combination with a single dose of aldesleukin with the initial AU-007 dose. The aldesleukin dose will be escalated with each Dose Escalation Cohort
9895262|NCT05267626|Experimental|AU-007 combined with aldesleukin given concomitantly|AU-007 will be administered at a fixed dose in combination with a aldesleukin, both administered Q2w. The aldesleukin dose will be escalated with each Dose Escalation Cohort
9895263|NCT05266456|Experimental|Group 1|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
10213832|NCT03030066|Experimental|Experimental Drug DS-1001b|Oral administration
10213833|NCT03025698|Experimental|Cohort A (Option 1)|
10213834|NCT03025698|Experimental|Cohort A (option 2)|
10213835|NCT03025698|Experimental|Cohort B|
10213836|NCT03019575|Experimental|Corifollitropin alfa (CFA)+human Chorionic Gonadotropin (hCG)|Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was >60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.
10213837|NCT03011034|Experimental|Talacotuzumab|Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
9517544|NCT03305458|Experimental|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
9895264|NCT05266456|Experimental|Group 2|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
9895265|NCT05266456|Experimental|Group 3|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
9895266|NCT05266456|Active Comparator|Group 4|Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
9895267|NCT05265754|Experimental|Experimental group|In the hand area, firstly, the points will be determined by means of the diagnostic stick and massage will be applied with buckwheat seeds. This massage will be 3 sessions a week, and a total of 6 sessions in 2 weeks.
9895268|NCT05265754|No Intervention|control group|A questionnaire will be applied to the patients by the researcher. Questionnaires will be made as pre-test and post-test.
9895269|NCT05265000|Experimental|tSpinalStim|Individuals in this arm will receive spinal cord stimulation
9895270|NCT05265000|Sham Comparator|sham_tSpinalStim|Individuals in this arm will receive placebo or sham spinal cord stimualtion
9895271|NCT05263518|Experimental|AcrySof IQ toric IOL|patients who had cataract surgery with AcrySof IQ toric IOL implantation. The patients diagnosed age related cataract The patients' ages are over 50.
9895272|NCT05263518|Experimental|TECNIS toric IOL|patients who had cataract surgery with TECNIS toric IOL implantation. The patients are diagnosed age related cataract. The patients' ages are over 50.
9895273|NCT05263440|Experimental|Experimental: Female participants with Depression|Female participants with mild to severe depression to determine if a single-session of tDCS can alter negative attention bias. The primary objective is to study if single-session tDCS will affect attention bias in depression and is not meant to treat depression.
9895274|NCT05263141|Experimental|RASSET group|Patients in the retro-auricular single-site endoscopic thyroidectomy (RASSET) group will receive endoscopic thyroid lobectomy and central lymph node dissection.
9895275|NCT05263141|Active Comparator|traditional open thyroid lobectomy group|Patients in the traditional open thyroid lobectomy group will receive thyroid lobectomy and central lymph node dissection.
9895276|NCT05262777|Experimental|GP0112|GP0112 Single injection and optional touch up injection and re-treatment with GP0112
9895277|NCT05262777|Active Comparator|Restylane Lyft Lidocaine|Restylane Lyft Lidocaine Single injection and optional touch up injection and re-treatment with Restylane Lyft Lidocaine
9895278|NCT05260437|Experimental|CV2CoV dose Cohort 1 (2µg or 4µg)|"Group 1a will receive CV2CoV dose level 2 µg~Group 1b will receive CV2CoV dose level 4 µg"
9895279|NCT05260437|Experimental|CV2CoV cohort (8 µg)|"Cohort 2 will receive CV2CoV dose level 8 µg~Enrollment into Cohort 2 will begin after the Safety Review Team (SRT) has reviewed safety data from 2 sentinel participants from the previous dose cohort."
9895280|NCT05260437|Experimental|CV2CoV cohort (12 µg)|"Cohort 3 will receive CV2CoV dose level 12 µg~Enrollment into Cohort 3 will begin after the SRT has reviewed safety data from 2 sentinel participants from the previous dose cohort."
9895281|NCT05260437|Experimental|CV2CoV cohort (16 µg)|"Cohort 4 will receive CV2CoV dose level 16 µg~Enrollment into Cohort 4 will begin after the SRT has reviewed safety data from all participants in the previous dose cohort."
9895282|NCT05260437|Experimental|CV2CoV cohort (20 µg)|"Cohort 5 will receive CV2CoV dose level 20 µg~Enrollment into Cohort 5 will begin after the SRT has reviewed safety data from all participants in the previous dose cohort."
9895283|NCT05260021|Experimental|Tirzepatide Dose 1|"Double-Blind:~Participants receive Tirzepatide by weekly subcutaneous (SC) injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached.~Open-Label:~Participants will continue to receive Tirzepatide at the last dose level"
9895284|NCT05260021|Experimental|Tirzepatide Dose 2|"Double-Blind:~Participants receive Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 2 is reached.~Open-Label:~Participants will continue to receive Tirzepatide at the last dose level"
9895285|NCT05260021|Placebo Comparator|Placebo|"Double-Blind:~Participants receive placebo during the 30-week double-blind period.~Open-Label:~Participants will switch to Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached."
9895286|NCT05258747|Experimental|Olaparib tablets, 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
9895287|NCT05258747|Active Comparator|Lynparza® (olaparib) tablets 150 mg|participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
9895288|NCT05258149|Experimental|TEST/CONTROL/CONTROL|Eligible subjects will be randomized into the sequence TEST/CONTROL/CONTROL.
9895289|NCT05258149|Experimental|CONTROL/TEST/TEST|Eligible subjects will be randomized into the sequence CONTROL/TEST/TEST
9895290|NCT05256654|Experimental|LY3561774 Dose 1|Participants will receive LY3561774 subcutaneously (SC)
9895291|NCT05256654|Experimental|LY3561774 Dose 2|Participants will receive LY3561774 SC
9895292|NCT05256654|Experimental|LY3561774 Dose 3|Participants will receive LY3561774 SC
9895293|NCT05256654|Experimental|LY3561774 Dose 4|Participants will receive LY3561774 SC
9895294|NCT05256654|Placebo Comparator|Placebo|Participants will receive placebo
9895295|NCT05255380|Experimental|Mindful Activity group|Participants complete mindfulness and compassion-based practices via the study app.
9895296|NCT05255380|Sham Comparator|Mindful Awareness group|Participants monitor and report their thoughts and feelings via the study app.
9895297|NCT05255354||Diffuse Large B Cell Lymphoma|For DLBCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, and potentially at relapse following CAR infusion. For DLBCL, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
9895298|NCT05255354||Follicular Lymphoma|For FL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For FL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
9895299|NCT05255354||Mantle Cell Lymphoma|For MCL patients, prospective blood samples will be collected, in provided collection kits, at: pre-lymphodepletion chemotherapy, Day+14, Day+28, Day+90, Day+180, Day+365, and potentially D+547 and at relapse following CAR infusion. For MCL patients, PET/CT scan images done prior to CAR19 therapy, Day 28 post-infusion, 3 months post-infusion, and 6 months post-infusion of CAR19 cells
9895300|NCT05254639|Experimental|Donepezil|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
9895301|NCT05254639|Placebo Comparator|Placebo|5 mg/day for 4 weeks then 10 mg/day for 12 weeks
9895302|NCT05254509|Active Comparator|Occupational Therapy (OT)|Subjects in this treatment group will receive outpatient occupational therapy geared towards people with chronic pain conditions. After obtaining consent, an occupational therapist will meet with the participant to begin their occupational therapy sessions targeted for those who have chronic pain. Additionally, subjects will complete online surveys administered by the therapist before and after each therapy session. There is a total of six 1-hour visits during the 3-month study duration involving occupational therapy. They will also receive online surveys every two weeks and will be asked to complete them at home.
9895303|NCT05254509|Experimental|Occupational Therapy + Virtual Reality (OT+VR)|Subjects in this treatment group will receive outpatient occupational therapy intervention geared towards people with chronic pain conditions followed by active, immersive virtual reality sessions. Participants in this treatment group will have 10-30minutes of usual care while receiving 10-30 minutes of virtual reality (e.g. exercises, games, and activities in the virtual world) during each study visit. Subjects will complete online surveys before and after each virtual reality session, along with debriefing from a therapist after each VR session to review what happened and why. Debriefing will include questions to obtain thoughts and narrative information about the participant's experience, as well as overall take-aways from the session. The therapist and subject will also watch a video recording of the subject's VR experience as a method to provide them feedback on their performance. Subjects will receive online surveys every two weeks and will be asked to complete them at home.
9895304|NCT05254288|Experimental|Split-mouth Group A|Half of patients will be assigned to this group. Quadrants Q1/Q4 will receive ozone administration. Quadrants Q2/Q3 will receive chlorhexidine administration.
9895305|NCT05254288|Experimental|Split-mouth Group B|Half of patients will be assigned to this group Quadrants Q2/Q3 will receive ozone administration. Quadrants Q1/Q4 will receive chlorhexidine administration.
9895306|NCT05253326|Experimental|Exercises Group|Patients will be taught Progressive Muscle Relaxation Exercises before the surgery and will be applied twice a week for 2 months after the surgery.
9895307|NCT05253326|No Intervention|Control Group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital.
9932725|NCT00952042|Active Comparator|Eccentric resistance training|12 wks of eccentric resistance training. 3 x 15 Eccentric heel-raises performed twice daily.
9932726|NCT00952055||Patients diagnosed with acute coronary syndrome (ACS)|
9932727|NCT00952094|Active Comparator|KRN1493 50mg group|KRN1493 50mg single oral administration
9895308|NCT05252988|Experimental|Arm A|"Neratinib 240 mg (six 40mg tablets) orally once daily for 13 cycles (C) (1 C = 28 days), unless patient discontinues earlier.~Mandatory loperamide 4 mg (2 tablets/capsules) orally, 3 times a day (total 12 mg a day) starting Day (D) 1 of neratinib and for the first 14 days. Then, 4 mg (2 tablets/capsules) orally, 2 times a day (total 8 mg a day) until the end of C2 (D56); thereafter, loperamide will be administered PRN (without exceeding 16 mg per day)."
9895309|NCT05252988|Experimental|Arm B|"Neratinib 120 mg for Week 1 (C1D1 - C1D7), followed by 160 mg neratinib for Week 2 (C1D8 - C1D14), followed by 240 mg neratinib for Week 3 and thereafter for 13 cycles inclusive, until cycle 13 day 28 (unless patient discontinues earlier).~Loperamide to be administered PRN only (without exceeding 16 mg per day)."
9895310|NCT05252988|Experimental|Arm C|"Neratinib 240 mg (six 40-mg tablets) orally once daily for 13 C, unless patient discontinues earlier.~Mandatory loperamide 4 mg (2 tablets/capsules) orally, 3 times a day (total 12 mg a day) for the first 14 days. After the first 14 days, 4 mg (2 tablets/capsules) orally, 2 times a day (total 8 mg a day) to complete a total of 28 days.~Mandatory colesevelam 1,875 mg (three 625-mg capsules orally), 2 times a day for the first month (28 days). After day 28, any prophylaxis or treatment for diarrhoea could be administered PRN, if loperamide not to exceed 16 mg per day."
9895311|NCT05251181|Active Comparator|Normal saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
9895312|NCT05251181|Experimental|Centhaquine|Hypovolemic shock patients will be provided the standard of care. Following randomization centhaquine (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
9895313|NCT05249283|Experimental|Patients|Patients with acute or chronic otoneurological disorders, presenting or having experienced dizziness and / or balance disorders
9895314|NCT05249283|Other|Control subjects|
9895315|NCT05248984||Ketorolac 30 mg|Participants will receive single dose of intravenous (IV) Ketorolac 30mg
9895316|NCT05248984||Ketorolac 60 mg|Participants will receive single dose of intravenous (IV) Ketorolac 60mg
10213838|NCT03011034|Experimental|Daratumumab|Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
10213839|NCT03007758|Active Comparator|robotic ventral hernia repair (VHR)|Robotic VHR
9895319|NCT05247892|Active Comparator|Fluoroscopic-guided S1 Radiofrequency stimulation|
9895320|NCT05247892|Experimental|Ultrasound-guided S1 Radiofrequency stimulation|
9895321|NCT05247489|Experimental|Group A: Ruxolitinib + Narrow-Band Ultraviolet B Phototherapy (NB-UVB)|Participants will initially apply ruxolitinib 1.5%mg cream as a monotherapy. At week 12, those who have < 25% improvement in total body Vitiligo Area Scoring Index (T-VASI25) will have NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen. NB-UVB will be given 3 times per week starting at Week 12 through Week 48 (36 weeks). For participants who receive combination therapy, NB-UVB machines will be supplied by the sponsor for at home use during the study.
9895322|NCT05247489|Experimental|Group B: Ruxolitinib Monotherapy|Participants will apply ruxolitinib 1.5% cream BID as monotherapy. Participants who have ≥ T-VASI25 at Week 12 will continue on ruxolitinib 1.5% cream BID alone.
9895323|NCT05246007|Experimental|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
9895324|NCT05246007|Placebo Comparator|Placebo group|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
9895325|NCT05245617||JPS treated patients|This grup will include all patients with regular indication for JPS: system is intended in pediatric (excluding newborns) and small stature adult patients. Pediatric patients include infants (greater than 1 month to 1 years of age), children (greater than 1 to 12 years of age), adolescents (greater than 12 to 18 years of age) and appropriate adults (where according to investigator assessment, the JPS plates fit the treated bone anatomy).
9895326|NCT05245292|Experimental|3BNC117-LS + 10-1074-LS + N-803|3BNC117-LS dosed at 30 mg/kg IV, day 0 10-1074-LS dosed at 10 mg/kg IV, day 0 N-803 dosed at 6 mcg/kg, SC, 8 doses every 3 weeks (week 1 through week 22)
9895327|NCT05243940|Active Comparator|dexmedetomidine-ketamine-lidocaine (DKL) group|combination of dexmedetomidine-ketamine-lidocaine in one syringe
9895328|NCT05243940|Active Comparator|remifentanil (control) group|remifentanil infusion (TCI Minto protocol)
9895329|NCT05240937|Experimental|mindfulness-based self-compassion will be applied|The group in which mindfulness-based self-compassion program will be implemented.
9895330|NCT05240937|No Intervention|Control Group|The group in which mindfulness-based self-compassion program will not be implemented
9895331|NCT05240612|Experimental|MT-3921|Intravenous (IV)
9895332|NCT05240612|Placebo Comparator|Placebo|Intravenous (IV)
9895333|NCT05238922|Experimental|Phase 1a Dose Escalation|"INCB123667 will be administered at a protocol defined starting regimen once daily (QD) orally in 28-day cycles.~Subsequent dose regimens will be determined during study conduct."
9895334|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 1 Gynecological Tumors|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants in this group will have gynecologic tumors (epithelial ovarian/fallopian/primary peritoneal carcinoma or clear cell ovarian cancer, or endometrial adenocarcinoma, uterine carcinosarcoma, or uterine papillary serous carcinoma).
10213840|NCT03007758|Active Comparator|open ventral hernia repair (VHR)|Open VHR
10213841|NCT02999477|Experimental|Nab-Paclitaxel|"2 weeks Nab-Paclitaxel Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 15 weeks"
10213842|NCT02999477|Experimental|Pembrolizumab|"2 weeks Pembrolizumab Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 14 weeks"
10213843|NCT02988245|Experimental|Genetically-Guided Treatment for HTN|Using a patient's genetic composition to guide BP prescribing for patients with hypertension, post diagnosis.
9991742|NCT01455779|Other|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
9991743|NCT01455792|Experimental|MRI and soft image fusion biopsy|Preoperative MRI and soft image ultrasound guided biopsy.
9991744|NCT01455792|Active Comparator|Gold standard biopsy|Gold standard TRUS biopsy
9991745|NCT01455805|Active Comparator|Minuteman Fusion Implant|Minuteman™ interspinous interlaminar fusion Implant (interspinous interlaminar fusion device) which gained CE Mark approval in May 2011
9991746|NCT01455805|Other|Surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis.
9991747|NCT01455831|Experimental|Extended peri-operative thromboprophylaxis|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
9991748|NCT01455831|Active Comparator|Standard thromboprophylaxis|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
9991749|NCT01455844|Experimental|CaPre 1.0g|
9991750|NCT01455844|Experimental|CaPre 2.0g|
9991751|NCT01455844|Placebo Comparator|Placebo|
9991752|NCT01455883|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
9991753|NCT01455883|Active Comparator|glimepiride|glimepiride up-titrated to 8 mg/day over first 13 weeks
9991754|NCT01455909|Experimental|ITCA 650 60 mcg/day|
9991755|NCT01455909|Active Comparator|sitagliptin|sitagliptin 100 mg/day
9991756|NCT01455922|Experimental|ITCA 650 60 mcg/day|
9991757|NCT01455922|Active Comparator|glimepiride|
9991758|NCT01455935|Active Comparator|Medical Therapy|"Current standard of care per the latest stroke guidelines~Permissive Hypertension up to 220~Antipletelets therapy:~ASA 81 mg PO daily or~Plavix 75 mg PO daily or~Aggrenox 225mg PO twice daily~Anti-inflammatory therapy:~Lipitor 80 mg PO daily or~Crestor 20 mg PO daily"
9991759|NCT01455935|Experimental|Intravenous Thrombolysis|"Full dose Intravenous thrombolysis~0.9 mg/kg~Maximum dose is 90 mg~10% of the dose will be given over one minute~90% of the dose will be infused over 1 hour~Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~Neuro checks every 5 minutes during the infusion~Neuro checks every hour after the infusion for 24 hours"
9991760|NCT01455935|Experimental|Intra-Arterial Therapy|"-Choice of therapy per experienced Endovascular surgeon and includes:~Intra arterial Activase (Maximum dose of 22 mg)~MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~PENUMBRA device (no standard time frame for how long the procedure takes)"
9991761|NCT01455948|Active Comparator|Balloon Sinuplasty™ System|
9991762|NCT01455948|Active Comparator|Functional Endoscopic Sinus Surgery|
9991763|NCT01455974|Experimental|Dialysate sodium set at 136 mmol/L|
9991764|NCT01456013|Active Comparator|Standard Therapy|Standard of care for patients at risk of CIN
9991765|NCT01456013|Experimental|RenalGuard Therapy|Induced Diuresis with Matched Replacement
9991766|NCT01456026|Experimental|Glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
9991767|NCT01456026|Active Comparator|Non-glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
9991768|NCT01456065|Other|Vaccine weekly administration|
9991769|NCT01456065|Other|Vaccine biweekly administration|
9991770|NCT01456078|Experimental|177Lu-DOTA-TATE|
9895335|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 2 GI Tumors|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants in this group will have gastrointestinal tumors (gastric, GEJ, and esophageal adenocarcinomas).
9895336|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 3 Breast Cancer|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants in this group will have breast cancer (participants with HR-positive/HER2-negative breast cancer who have had disease progression on or been intolerant of therapies known to confer clinical benefit, including a CDK4/6 inhibitor).
9895337|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 4 Tumor Agnostic|at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. This group will include participants who have had disease progression on prior standard treatment or are intolerant to or ineligible for standard treatment or there is no available treatment to improve the participant's disease outcome.
9895338|NCT05238116|Experimental|PC945|PC945 dose, administered via nebulizer, twice daily
9895339|NCT05238116|Placebo Comparator|Placebo|PC945-placebo administered via nebulizer, twice daily
9895340|NCT05237505|No Intervention|Obstructive Sleep Apnea|
9895341|NCT05237505|No Intervention|Chronic Obstructive Pulmonary Disease|
9895342|NCT05237505|Experimental|Overlap Syndrome|OSA + COPD
9895343|NCT05237141|Experimental|Main cohort|Insertion of etonogestrel contraceptive implant prior to LH surge
9895344|NCT05236894|Experimental|Arm I (lower dose nicotine pouch)|Patients receive lower dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
9895345|NCT05236894|Experimental|Arm II (higher dose nicotine pouches)|Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
9895346|NCT05236894|Active Comparator|Arm III (cigarette smoking)|Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3.
9895347|NCT05234593|Other|Lightning Stick|Feasibility and acceptability
9895348|NCT05233800|Experimental|Voice-Activated Smart Speaker Program|Faster Asleep
9895349|NCT05233800|Active Comparator|Website|Faster Asleep Website
9895350|NCT05232981|Experimental|Study group|Conservative management of PAS with Ligation of the bilateral internal iliac arteries
9895351|NCT05232981|Active Comparator|Control group|Conservative treatment with Shehata's technique and no internal iliac ligation
9895352|NCT05231278|Experimental|nCLE aided RANB biopsy|Single arm study
9895353|NCT05230095||Parkinson's disease patients|30 parkinsonian patients scheduled for deep brain stimulation implantation surgery will be recruited
9895354|NCT05230095||Controls|15 healthy volunteers matched in age and sex will be recruited
9895355|NCT05229731||Case group|Patients with visual snow syndrome according to international criteria
9895356|NCT05229731||Control group|Patients without visual snow syndrome according to international criteria
9895357|NCT05229562|Experimental|Cohort 1: Low-Dose|Participants will receive Dose 1 of BIIB122, orally, once on Day 1.
9895358|NCT05229562|Experimental|Cohort 2: Mid-Dose|Participants will receive Dose 2 of BIIB122, orally, once on Day 1.
9895359|NCT05229562|Experimental|Cohort 3: High-Dose|Participants will receive Dose 3 of BIIB122, orally, once on Day 1.
9895360|NCT05229562|Experimental|Cohort 4: High-Multi-Dose|Participants will receive Dose 3 of BIIB122, orally, once daily (QD), for 10 days.
9895361|NCT05228288|Active Comparator|CDL|Conventional direct laryngoscopy using a Macintosh blade
9895362|NCT05228288|Experimental|M-VAL|Video assisted laryngoscopy with a Macintosh-shaped blade
9895363|NCT05228288|Experimental|H-VAL|Video assisted laryngoscopy with a hyper-angulated blade
9895364|NCT05226494|Experimental|Treatment (fb-PMT)|Daily subcutaneous injection of fb-PMT in three escalating cohorts to determine maximum tolerated dose, followed by treatment of up to 10 additional patients at maximum tolerated dose.
9895365|NCT05226143|Experimental|Gel Cream|Participants will be provided with the Gel Cream to apply on clean, dry face (facial skin) once per day and on the target lesion on the face or body at least 2 times per day or more as needed, in the morning and at night for 14 days.
9895366|NCT05225610|Experimental|VALSALVA Group|40 Patients will perform the Valsalva manoeuvre before starting propofol injection by blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds and 5 ml saline will be administered in 5 seconds.
9895367|NCT05225610|Experimental|DEXMED Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group, patients will receive 0.5 µg/kg Dexmedetomidine diluted in 5 ml saline in 5 seconds as a sedating dose prior to injection of propofol.
9895368|NCT05225610|Placebo Comparator|CONTROL Group|40 patients will receive the tube between the lips, however, the manoeuvre will not be performed in this group and only 5 ml saline will be administered over 5 seconds.
9895369|NCT05225506|Experimental|Exercise|In this single group design, all participants will be provided with 6 months of twice weekly supervised group exercise.
9895370|NCT05224973|Experimental|speech therapy combined with digital fine motor stimulation|At the beginning of the swallowing rehabilitation session, a fine manual motor training is practiced during the first ten minutes of the session. Training consists of activities requiring increasing precision and different types of grips
9895371|NCT05224973|Active Comparator|speech therapy only|standard swallowing rehabilitation session
9895372|NCT05224544|Experimental|Test Catheter|Healthy volunteers to test the investigational intermittent catheter.
9895373|NCT05224544|Active Comparator|Comparator Catheter|Healthy volunteers to test the comparator.
9895374|NCT05222529|Experimental|Glycopyrronium 25μg|Glycopyrronium 25μg for two weeks
9895375|NCT05222529|Experimental|Glycopyrronium 12.5μg|Glycopyrronium 12.5μg for two weeks
9895376|NCT05222529|Placebo Comparator|Placebo|Placebo for two weeks
9991771|NCT01456091|Experimental|AIM 4 Teen Moms|
9991772|NCT01456091|No Intervention|Control|
9991773|NCT01456117|Experimental|Pioglitazone (Dose 1) QD|
9991774|NCT01456117|Experimental|Pioglitazone (Dose 2) QD|
9991775|NCT01456117|Experimental|Pioglitazone (Dose 3) QD|
9991776|NCT01456117|Placebo Comparator|Placebo QD|
9991777|NCT01456156|Experimental|hepatectomy plus radiotherapy|
9991778|NCT01456182|Other|Dose arm 1|
9991779|NCT01456182|Other|Dose arm 2|
9991780|NCT01456182|Other|Dose arm 3|
9991781|NCT01456182|Other|Dose arm 4|
9991782|NCT01456182|Other|Dose arm 5|
9991783|NCT01456234|Active Comparator|Patients with Oseltamivir Prescription|Patients arriving at the pharmacy with a prescription for Oseltamivir
9991784|NCT01456234|Experimental|Patients with signs, symptoms of flu|Patients arriving at the pharmacy with signs, symptoms of flu that the pharmacist diagnoses as having flu and being suitable for pharmacist prescribing of Oseltamivir according to an algorithm.
9991785|NCT01456247|Experimental|TAK-438 10 mg QD|
9991786|NCT01456247|Experimental|TAK-438 20 mg QD|
9991787|NCT01456247|Active Comparator|AG-1749 15 mg QD|
9991788|NCT01456260|Experimental|TAK-438 10 mg QD|
9991789|NCT01456260|Experimental|TAK-438 20 mg QD|
9991790|NCT01456260|Active Comparator|Lansoprazole 15 mg QD|
9991791|NCT01456273|Placebo Comparator|A2- Medical consultation + placebo|Traditional medical interview + placebo
9991792|NCT01456273|Active Comparator|B1 - Therapeutic Encounter / Omeprazol|
9991793|NCT01456273|Placebo Comparator|B2 - Therapeutic Encounter / Placebo|
9991794|NCT01456273|Active Comparator|A1- Medical consultation + omeprazole|Traditional medical interview + omeprazole
9991795|NCT01456286|Experimental|Sapropterin|5 mg/kg daily first week; 10 mg/kg daily second week of treatment
9991796|NCT01456286|Placebo Comparator|placebo|
9991797|NCT01456312|Sham Comparator|HBsAg quantification>20,000 IU/ml|stop peginterferon alfa 2a if patients reach HBsAg quantification>20,000 Iu/ml at 12w
9991798|NCT01456312|Sham Comparator|HBsAg<=1500IU/ml|extend peginterferon alfa 2a until 48weeks
9991799|NCT01456312|Sham Comparator|HBsAg >1500 <=20,000 IU/ML|add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w
9991800|NCT01456325|Experimental|Onartuzumab+Erlotinib|Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
9991801|NCT01456325|Placebo Comparator|Placebo+Erlotinib|Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
9991802|NCT01456338|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based, manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
9991803|NCT01456338|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
9991804|NCT01456351|Experimental|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
9895377|NCT05222269|Experimental|68Ga-PTF|150 (+/-50) Megabecquerel (MBq) 68Ga-PTF will be injected intravenously at three timepoints during the course of the standard of care treatment.
9895378|NCT05221723|Experimental|Exercise Group|In this single group design, all participants will be provided with 6 months of twice weekly supervised group exercise.
9895379|NCT05220709|Other|Bio impedance spectroscopy in children scheduled for elective surgery under general anesthesia|All subjects receive bio impedance monitor measurements pre operatively and post operatively.
9895380|NCT05220358|Experimental|FTR+suppressive regimen|addition of fostemsavir 600 mg PO BID to the stable suppressive HIV regimen in immunologic non responders
9895381|NCT05220241|Other|Case : patient with 1st episode of COVID-19 and persistence of neurocognitive complaint|Patient with a 1st episode of COVID-19 in the 12 months preceding inclusion and presenting persistence of neurocognitive complaint beyond 4 weeks
9517480|NCT03305952|Experimental|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
9895382|NCT05220241|Other|Control : Patient with a 1st episode of COVID-19 cured and without neurocognitive complaint|Patient with a cured 1st episode of COVID-19 (without persisting symptoms beyond 4 weeks) in the 12 months preceding inclusion and without neurocognitive complaint
9895383|NCT05220202|No Intervention|Waitlist Control Group|The waitlist control group will continue with usual care management of musculoskeletal pain and depression. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, midpoint, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the intervention once they have completed the end outcomes assessment.
9895384|NCT05220202|Experimental|Behavior Intervention Group (MOTIVATE)|For participants assigned to the intervention arm, trained health coaches will deliver the 8 session intervention via telephone. MOTIVATE users motivational interviewing techniques, values elicitation and physical activity based goal setting. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, midpoint, final assessments) conducted by a blinded research assistant.
9895385|NCT05219864|Experimental|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
9895386|NCT05219864|Placebo Comparator|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
9895387|NCT05218499|Experimental|BI 907828 low dose|Phase II
9895388|NCT05218499|Experimental|BI 907828 high dose|Phase II
9895389|NCT05218499|Experimental|BI 907828 arm|Phase III
9895390|NCT05218499|Active Comparator|Doxorubicin arm|Phase II/III
9895391|NCT05217797|Experimental|Glasses|Participants in the experimental arm are asked to wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.).
9895392|NCT05217797|No Intervention|Not glasses|Participants in no interventions arm are asked to not wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.).
9895393|NCT05217615|Experimental|ezParent+ coach|"ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation. Coaches will be trained in active and empathic listening and problem solving techniques to facilitate learning and support of parents."
9932728|NCT00952094|Active Comparator|KRN1493 75mg group|KRN1493 75mg single oral administration
9932729|NCT00952094|Active Comparator|KRN1493 100mg group|KRN1493 100mg single oral administration
9932730|NCT00952107|Experimental|Imaging system operation|
9932731|NCT00952146|Experimental|Transgastric peritoneoscopy|Only one arm, feasibility study
9517481|NCT03305952|Active Comparator|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
9895394|NCT05217615|Experimental|ezParent|ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.
9895395|NCT05217615|Active Comparator|Active Control+coach|"Active Control - The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation."
9895396|NCT05217615|Placebo Comparator|Active Control|The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks (~1 topic every 1.5 weeks) to match the dose and timing of contact that the intervention groups will receive.
9895397|NCT05217589|Experimental|Funny/Amusing Video Clips|Participants will watch 5-7-min video clips that are meant to be funny/amusing
9895398|NCT05217589|Experimental|Horror/Scary Video Clips|Participants will watch 5-7-min video clips that are meant to be scary
9895399|NCT05217589|Experimental|Thrilling/Suspenseful Video Clips|Participants will watch 5-7-min video clips that are meant to be thrilling/suspenseful
9895400|NCT05217173|Experimental|Intervention group|"Rehabilitation service that will be provided remotely through information and communication technologies. It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks.~The content of the rehabilitation program will consist of e modules: 1) Information module on the disease and self-care, 2) Exercise module (Stretching, strengthening and proprioception)."
9895401|NCT05217173|No Intervention|Control group|Care service that is carried out by the Family Physician. The medical care that the patient with an ankle sprain will carry out with the Family Physician of the assigned office; Medical care will consist of the approach that the Doctor considers appropriate for the patient. The follow-up and time of disability will be the responsibility of the Physician in question
9932732|NCT00952159||Not Poor metabolizer|
9932733|NCT00952159||Poor metabolizer|
9932734|NCT00952198|Experimental|ARRY-403|
9932735|NCT00952198|Placebo Comparator|Placebo|
9932736|NCT00952224||Acute myocardial infarction patients|Patients undergoing primary percutaneous coronary intervention in ST-elevation myocardial infarction plus magnetic resonance imaging
9932737|NCT00952237|Experimental|IL-2 and GM-CSF for Mobilization|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
9932738|NCT00952250|Active Comparator|Targeted Feedback Reports|Conventional feedback reports
9932739|NCT00952250|Experimental|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement.
9932740|NCT00952263|Experimental|MBL-HCV1|
9932741|NCT00952302|Placebo Comparator|CMS - placebo first|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
9932742|NCT00952302|Experimental|CMS - iron|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
9932743|NCT00952302|Placebo Comparator|SLR - placebo|Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
9991805|NCT01456351|Active Comparator|Fludarabine plus Rituximab|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
9991806|NCT01456364|Active Comparator|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
9991807|NCT01456364|Active Comparator|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
9991808|NCT01456377|Active Comparator|corticosteroids, analgesics oral pill|Oral Corticosteroids and oral analgesics
9991809|NCT01456377|Placebo Comparator|placebo|oral placebo and oral analgesics
9991810|NCT01456390|Other|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
9991811|NCT01456403||Carotid endarterectomy patients|Patients scheduled for clinically indicated carotid endarterectomy
9991812|NCT01456416||Glatiramer Acetate|GA administered SQ daily in MS patients who met all Inclusion-Exclusion Criteria and were approved by their Health Care Plans for GA treatment.
9991813|NCT01456429|Experimental|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
9991814|NCT01456468|Experimental|UDCA + ATRA|This is a single-arm study. All subjects will take UDCA and ATRA.
9991815|NCT01456481|Active Comparator|midodrine hydrochloride pills|
9991816|NCT01456481|Placebo Comparator|oral placebo or sugar pill|
9991817|NCT01456507|Experimental|A|1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.
9991818|NCT01456507|Experimental|B|1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).
9991819|NCT01456507|Experimental|C|1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.
9517482|NCT03305939|Experimental|Intervention|Participants randomized in to the intervention group will receive group sessions, monthly phone calls, and telephonic prompts (text/voice recording).
9991820|NCT01456520|Experimental|A: single dose Vycavert (Test)|
9991821|NCT01456520|Active Comparator|B: single dose Norco (Reference)|
9991822|NCT01456533||hospitalized patients|hospitalized patients with hyponatremia
9991823|NCT01456546|Active Comparator|Period A: proguanil|Proguanil pharmacokinetics
9991824|NCT01456546|Active Comparator|Period B: clopidogrel|Clopidogrel pharmacokinetics
9991825|NCT01456572|Active Comparator|satiation_obese weight|Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
9991826|NCT01456572|Active Comparator|gastric emptying_obese weight|Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
9991827|NCT01456572|Placebo Comparator|gastric emptying_normal weight|Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
9991828|NCT01456572|Placebo Comparator|satiation_normal weight|Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
9895402|NCT05216692|Experimental|Experimental group|The foot strengthening protocol will last 4 weeks with 2 sessions per week and is composed of 3 exercises targeting forefoot and midfoot region strength as well as enhancing plyometric capabilities of the foot complex.
9895403|NCT05216692|Active Comparator|Control group|The standard literature foot strengthening protocol will last 4 weeks with 3 sessions per week and is composed of one exercise targeting the strength of the foot medial arch.
9895404|NCT05215184||Chronic Pain Patients|
9895405|NCT05215184||Healthy Controls|
9895406|NCT05214326||Participants with moderate to severe atopic dermatitis|Participants initiating dupilumab therapy within 30 days of enrollment, according to the treating physician's decision independently of study participation.
9895407|NCT05213468|Experimental|Self management app as add on to standard care|PainDrainerTM App as add on to standard treatment at the physiotherapy program at the clinic PainDrainer software application: PainDrainerTM app (version 1.1.19c). ' The PainDrainer app is an investigational device, intended as a digital aid for the self-management of chronic pain for use by adults without supervision by healthcare professionals in a home setting.
9895408|NCT05213468|No Intervention|Standard of care|Treatment as usual, standard treatment of care at the physiotherapy program at the clinic
9895409|NCT05212311|Active Comparator|Group A (Control group)|Group A (n=27) will receive a conventional physical therapy program only for 5 weeks in the form of Splinting, Ultrasound and Exercises.
9895410|NCT05212311|Experimental|Group B (Chitosan phonophoresis group)|Patients in group B (n=27) will receive phonophoresis with chitosan nanoparticles. Patients will also receive the conventional physical therapy program: in the form of Splinting, Ultrasound and Exercises. Session will be applied 3 times per week for a total of 5 weeks.
9895411|NCT05211947|Experimental|Patients with cognitive impairment due to schizophrenia|
9895412|NCT05210764||propofol|General anesthesia is induced and maintained mainly with propofol.
9895413|NCT05210764||sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
9895414|NCT05210764||ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
9895415|NCT05210725|Experimental|Stable coronary artery disease|Patients with stable coronary artery disease with an indication for single antiplatelet therapy according to international (ESC) guidelines, with a high cardiovascular risk.
9895416|NCT05210374|Experimental|DSF/Cu|"A 3+3 dose escalation design will be used to determine the recommended phase 2 dose (RP2D) of DSF/Cu in combination with liposomal doxorubicin. There will be a 7 day lead-in week of Disulfiram (DSF)/Copper Gluconate (Cu). The disulfiram and the copper gluconate will be dosed once a day. Disulfiram in the morning and copper gluconate in the evening. Same total daily dose every 4 week (28 days) administration of liposomal doxorubicin (Doxil) 30mg/m2/dose IV~Cycle length: 28 days Maximum 12 cycles"
9895417|NCT05208333|Other|Albendazole treatment|"Treatment drugs: Albendazole (Zentel) tablets 200mg, Glaxo Wellcome Production France manufacturer .~Dose: 15 mg/kg divided into 2 times/day x 5 days, orally after meals. Procedure: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection Advice on preventing re-infection according to Vietnam Ministry of Health disease prevention guidelines"
9895418|NCT05208164|Experimental|Mindfulness Meditation Classes|"8 mindfulness classes: Participants will engage in 8 two-hour mind and body practice classes over 8 weeks in-person or online (during the pandemic). You will receive compensation for your participation and a yoga mat. You will need to wear comfortable clothing. These sessions can be done sitting in chair, sitting on the floor, or standing.~Text messaging., in between classes you will receive text messages to encourage mind and body practices at home. Text messaging may appear as the following:~1.Do you have time to meditate right now? Yes or No. 2.Did you practice your mindfulness today? Yes or no. 3.Remember to wind down this evening and do not drink any caffeinated beverages 4 hours before bed."
9895419|NCT05208164|No Intervention|Usual Care|
9895420|NCT05208047|Experimental|Part 1a|CGT9486 plus sunitinib 37.5 mg QD
9895421|NCT05208047|Experimental|Part 2 - Experimental Group|CGT9486 plus sunitinib 37.5 mg QD
9517772|NCT03303066|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
9895422|NCT05208047|Active Comparator|Part 2 - Control Group|sunitinib 37.5 mg QD
9895423|NCT05208047|Experimental|DDI Cohort 1|CGT9486 plus sunitinib 37.5 mg QD
9895424|NCT05208047|Experimental|DDI Cohort 2|sunitinib 37.5 mg QD plus CGT9486
9895425|NCT05207137|Experimental|Telephone call from family physician|Individuals allocated to the experimental arm will receive a phone call from the their family physician, where they are offered the opportunity to raise questions they might have about the COVID-19 vaccine.
9895426|NCT05207137|No Intervention|Usual care|
9895427|NCT05205265|Experimental|Rivet Shunt Therapy|
9895428|NCT05203419|Experimental|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
9895429|NCT05203419|Placebo Comparator|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
9895430|NCT05203419|Experimental|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
9895431|NCT05203419|Experimental|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
9895432|NCT05203419|Experimental|Part B: MHS552|Participants will receive MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
9895433|NCT05203419|Placebo Comparator|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
9895434|NCT05201001|Active Comparator|Standard of Care|"Carboplatin AUC = 5, IV day 1 and pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks~Total:6 cycles or until progressive disease or unacceptable toxicity."
9895435|NCT05201001|Experimental|APX005M|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy~Total:6 cycles or until progressive disease or unacceptable toxicity."
9895436|NCT05201001|Experimental|APX005M+RT|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy External beam radiation therapy; a dose of 0.5 Gy per fraction, administered as single fractions prior to APX005M administration; days 1 & 15 q4 wks x 6 cycles. Maximum 24 wks of therapy; total dose 6 Gy.~Total:6 cycles or until progressive disease or unacceptable toxicity."
9895437|NCT05199961|Experimental|Single Arm Cohort Receiving Digital Health Coaching|A single cohort of up to 100 individuals receiving chimeric antigen receptor T cell therapy will be enrolled in the study, all of whom will be enrolled in a 6-month digital health coaching program. Individuals will be enrolled at The Ohio State University Comprehensive Cancer Center.
9895438|NCT05199948|Experimental|Soybean Oil|Consumption of study foods each day made with soybean oil
9895439|NCT05199948|Placebo Comparator|Palm Oil|Consumption of study foods each day made with palm oil
9895440|NCT05199662|Placebo Comparator|Control group|Placebo administered as a single bolus injection over 5 seconds
9895441|NCT05199662|Experimental|Intravenous tenecteplase (TNK)|Intravenous thrombolysis with Tenecteplase (TNK) at a dose of 0.25 mg/Kg (maximum 25mg, administered as a bolus over 5 seconds)
9517483|NCT03305939|No Intervention|Control|Control group participants will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if any exists). Any abnormal OGTT results during the follow-up visits will be provided to the patient and their doctor. This is entirely consistent with current usual care.
9517484|NCT03305926|Active Comparator|Conventional CVR|
9895442|NCT05199194|Experimental|Mechanical Thrombectomy preceded by TNK|Subjects assigned to this arm will receive an intravenous bolus of tenecteplase (0.25mg/kg) before the mechanical thrombectomy.
9895443|NCT05199194|Placebo Comparator|Mechanical Thrombectomy preceded by Placebo|Subjects assigned to this arm will receive an intravenous bolus of matching placebo (with the same volume of infusion as of 0.25mg/kg of tenecteplase) before the mechanical thrombectomy.
9895444|NCT05198726|Active Comparator|Active tACS plus active SoP|Active alpha range tACS plus Speed of Processing Training
9895445|NCT05198726|Active Comparator|Active tACS plus sham SoP|Active alpha range tACS plus sham Speed of Processing Training
9895446|NCT05198726|Active Comparator|Sham tACS plus active SoP|Sham alpha range tACS plus Speed of Processing Training
9895447|NCT05198596|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
9895448|NCT05198596|Active Comparator|AZD1222|ChAdOx1 nCoV-19 vaccine
9895449|NCT05196763|Experimental|Supplemental Nutrition Assistance Program-Education|"This group will receive the core content of the Supplemental Nutrition Assistance Program-Education over the 10-week intervention period."
9895450|NCT05196763|No Intervention|Control|"This group will not receive the Supplemental Nutrition Assistance Program-Education during the intervention period nor throughout the study (1 year)."
9895451|NCT05195151|Experimental|Probiotics|taking a capsule containing the probiotics 15 d before and 15 d after booster shot.
9895452|NCT05195151|Placebo Comparator|Control|taking a capsule containing a placebo 15 d before and 15 d after booster shot.
9895453|NCT05194514|Other|SherpaPak™ Cardiac Transport System|When a matching donor heart from a non-local donor offer (from Northern California, Arizona, Nevada or farther geographies) becomes available the recipient will be assigned a subject identification number and randomized 1:1 to receive a heart transported using either standard of care cold storage or the SherpaPak™ Cardiac Transport System.
9895454|NCT05194514|Other|Cold Storage|When a matching donor heart from a non-local donor offer (from Northern California, Arizona, Nevada or farther geographies) becomes available the recipient will be assigned a subject identification number and randomized 1:1 to receive a heart transported using either standard of care cold storage or the SherpaPak™ Cardiac Transport System.
9895455|NCT05192642||Larotrectinib clinical trial cohort|
9895456|NCT05192642||RW external comparator cohort|
9895457|NCT05192473|Experimental|Lithotripsy Treatment|"Pulse Intravascular Lithotripsy System~Device: Pulse Intravascular Lithotripsy Catheter"
9895458|NCT05190744|Experimental|Polyuric subjects with Hereditary Nephrogenic Diabetes Insipidus|Polyuric subjects with hereditary nephrogenic diabetes insipidus with loss of function of AVPR2 or AQP2 will be treated with PB
9895459|NCT05190744|Experimental|Polyuric subjects with Autosomal Dominant Polycystic Kidney Disease treated with Tolvaptan|Polyuric subjects with autosomal dominant polycystic kidney disease on chronic tolvaptan treatment will be treated with PB
9895460|NCT05190744|Experimental|Polyuric subject secondary to lithium administration|Polyuric subject post lithium administration will receive PB
9932744|NCT00952302|Experimental|SLR - iron|Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.
9895461|NCT05190666|Experimental|PACE Weight Loss Program|Participants randomized to this arm will receive personalized diet, activity, and weight loss goals as well as tools to self-monitor behaviors and weight. To facilitate changes, participants will receive coaching calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
9895462|NCT05190666|Sham Comparator|Chronic Disease Self-Management Program|Participants randomized to this arm will receive a chronic disease self-management program including a self-management book. Participants will receive regular calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
9895463|NCT05189340|No Intervention|Standard of Care|Patients in the Standard of Care arm will receive pharmacist discharge education via fully in-person education as is currently being done.
9895464|NCT05189340|Experimental|Intervention|Patients in the Intervention arm will have access to pre-recorded educational videos covering key educational points. Patients will also have in-person interaction with pharmacists to address additional questions not covered in the videos.
9895465|NCT05188664|Experimental|LM-302 monotherapy dose escalation|LM-302 monotherapy dose escalation (part Ia). Accelerated titration combined with traditional 3+3 design will be used for monotherapy dose escalation (part Ia).
9895466|NCT05188664|Experimental|LM-302 in combination therapy dose escalation|LM-302 in combination therapy dose escalation (part Ib).Accelerated titration combined with traditional 3+3 design will be used for LM-302 in combination with fixed dose Toripalimab dose escalation (part Ib).
9895467|NCT05188664|Experimental|LM-302 Dose Expansion|SMC will select appropriate dose(s) and/or tumor types for dose expansion study.
9895468|NCT05188638|Experimental|Single dose of up to 5 mL nebulised SIS @ 25 ppm/placebo|
9895469|NCT05188638|Experimental|Single dose of up to 5 mL nebulised SIS @ 50 ppm/placebo|
9895470|NCT05188638|Experimental|Single dose of up to 5 mL nebulised SIS @ 100 ppm/placebo|
9895471|NCT05188638|Experimental|OD dosing of up to 5 mL nebulised SIS @ x ppm/placebo for 5 days|The dose to be administered in the multiple dose groups will depend on the results obtained in the single dose groups and will be decided by the SMC. The dose tested in the first multiple dose group will be the second highest well-tolerated single dose or lower.
9895472|NCT05188638|Experimental|OD dosing of up to 5 mL nebulised SIS @ y ppm/placebo for 5 days|
9895473|NCT05188638|Experimental|BID dosing of up to 5 mL nebulised SIS @ y ppm/placebo, for 4 days + morning dose on Day 5|
9895474|NCT05188638|Experimental|QID dosing of up to 5 mL nebulised SIS @ y ppm/placebo for 4 days + morning dose on Day 5|
9895475|NCT05183464||Children with primary hypersomnia|Children with primary hypersomnia, i.e. narcolepsy or idiopathic hypersomnia
9895476|NCT05183464||Children with secondary hypersomnia|Children with a secondary hypersomnia, i.e. caused by sleep deprivation, a psychiatric disorder, sleep fragmentation, circadian delay.
9895477|NCT05182411||Patients with spasticity|adult neurological patients with spasticities in their lower extremities
9895478|NCT05182398||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform Modified Four Square Step Test.
9895479|NCT05182073|Experimental|Regimen A|FT576 single dose monotherapy in subjects with r/r MM
9895480|NCT05182073|Experimental|Regimen A1|FT576 fractionated dose monotherapy in subjects with r/r MM
9895481|NCT05182073|Experimental|Regimen B|FT576 single dose in combination with daratumumab in subjects with r/r MM
9895482|NCT05182073|Experimental|Regimen B1|FT576 fractionated dose in combination with daratumumab in subjects with r/r MM
9895483|NCT05179993||Study Group|Proof of principle Study group: detection of microplastics in human granulosa cells and in the follicular fluid of women undergoing intracytoplasmic sperm injection (ICSI) treatment
9895484|NCT05178901|Experimental|PHV02 2x10^5 pfu|
9895485|NCT05178901|Experimental|PHV02 2x10^6 pfu|
9895486|NCT05178901|Experimental|PHV02 2x10^7 pfu|
9895487|NCT05178901|Placebo Comparator|Placebo|
9895488|NCT05178537||AAS users|current og previous use of AAS
9895489|NCT05177094|Experimental|LY3526318|Participants will be administered LY3526318 orally.
9895490|NCT05177094|Placebo Comparator|Placebo|Participants will be administered placebo orally.
9895491|NCT05176847|Experimental|Gamified mLIFE app group|Participants allocated to this group will be provided with elements of social gaming and healthy competition within the mLIFE app.
9895492|NCT05176847|Active Comparator|standard mLIFE app|Participants in this group will receive the same intervention as the experimental group, but some features of the App will not facilitate gaming or competition.
9895493|NCT05176665|Experimental|Phase Ib and Phase II|"In phase 1b part of the study, the study will recruit approximate 6 patients to each of the 4 GI cancer groups (gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer) to characterize PK profile of EMB-01 at the RP2D (1600 mg QW) in GI cancers and evaluate the safety and tolerability of EMB-01 at the RP2D.~In the Phase 2part of the study, additional patients will be enrolled into each of the 4 GI cancer groups (gastric cancer, hepatocellular cancer, cholangiocarcinoma, and colorectal cancer) until a total of 24 patients are treated at the RP2D."
9895494|NCT05176197|Experimental|Almond Group|Participants will consume almonds every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
9895495|NCT05176197|Experimental|Control Group|Participants will consume pretzels every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
9895496|NCT05176145|Other|single arm|Only one arm. The urine collection from each patient will be used for VisioCyt® test and conventional cytology
9895497|NCT05175690||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
9895498|NCT05174832|Active Comparator|Cisplatin+ Nab-paclitaxel + Pembrolizumab followed by Pembrolizumab monotherapy|4~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab monotherapy as maintenance therapy
9895499|NCT05174832|Experimental|Cisplatin+Nab-paclitaxel+Pembrolizumab followed by Pembrolizumab+Olaparib|4~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab plus Olaparib as maintenance therapy
9895500|NCT05174767|Experimental|Acute DeBakey Type I Dissection|In eligible patients, the ascending aorta is transected and removed in a routine standard of care manner utilizing hypothermic circulatory arrest; the operator will leave at least 10 mm (1.0 cm) aortic tissue proximal to the innominate artery. AMDS is pre-loaded onto the delivery system and is delivered into the true lumen through the open distal aorta and implanted according to the instructions for use.
9895501|NCT05174507|Other|Group 1 (anakinra; placebo; empagliflozin)|"Group 1:~study day 1: anakinra; study day2: placebo; study day 3: empagliflozin"
9895502|NCT05174507|Other|Group 2 (placebo; anakinra; empagliflozin)|study day 1: placebo; study day2: anakinra; study day 3: empagliflozin
9895503|NCT05174507|Other|Group 3 (empagliflozin; placebo; anakinra)|study day 1: empagliflozin; study day2: placebo; study day 3: anakinra
9895504|NCT05174507|Other|Group 4 (empagliflozin; anakinra; placebo)|study day 1: empagliflozin; study day2: anakinra; study day 3: placebo
9895505|NCT05174507|Other|Group 5 (placebo; empagliflozin; anakinra)|study day 1: placebo; study day2: empagliflozin; study day 3: anakinra
9895506|NCT05174507|Other|Group 6 (anakinra; empagliflozin; placebo)|study day 1:anakinra; study day2: empagliflozin; study day 3: placebo
9895507|NCT05174000|Experimental|Sequence 1:Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®|Participants will receive single oral dose of Test Euthyrox® on in treatment period 1, followed by single oral dose of Reference Euthyrox® in treatment period 2, followed by single oral dose of Test Euthyrox® in treatment period 3, followed by single oral dose of Reference Euthyrox in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period.
9895508|NCT05174000|Experimental|Sequence 2:Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® in treatment period 1, followed by single oral dose of Test Euthyrox® in treatment period 2, followed by single oral dose of Reference Euthyrox® in treatment period 3, followed by single oral dose of Test Euthyrox® in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period.
9895509|NCT05173974|No Intervention|Negative Control|Denture adhesive will not be used.
9895510|NCT05173974|Active Comparator|Positive Control|A single application of 1 gram of Super Poligrip Free denture adhesive will be applied topically to oral tissues via the upper denture.
9895511|NCT05173974|Experimental|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
9895512|NCT05173974|Experimental|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
9895513|NCT05173207||Cardiothoracic surgical patients|Subjects will undergo one simultaneous instrumental examination of swallowing and concurrent monitoring of metrics of respiratory-swallow physiology. Research exam will be performed at bedside within Cardiac & Thoracic Intensive Care Units during their early postoperative recovery.
9895514|NCT05172596|Experimental|PHE885|Patients will receive PHE885
9895515|NCT05172557|Experimental|Healthy Living Program|In addition to usual clinical Inflammatory Bowel Disease medical care, subjects will participate in a Wellness Program.
9895516|NCT05170074||SRS implant|Surgical reconstruction of the anterior and apical compartment of the pelvic floor with an SRS implant
9895517|NCT05169684|Experimental|Arm 1A: Docetaxel + BMS-986218|
9895518|NCT05169684|Experimental|Arm 1B: Docetaxel + BMS-986218 + Nivolumab|
9895519|NCT05169684|Experimental|Arm 2A: Docetaxel|
9895520|NCT05169684|Experimental|Arm 2B: Docetaxel + BMS-986218|
9895521|NCT05169684|Experimental|Arm 2C: Docetaxel + BMS-986218 + Nivolumab|
9895522|NCT05169684|Experimental|Arm 2D (Optional Crossover): BMS-986218 + Nivolumab|
9895523|NCT05169567|Experimental|Arm A: Abemaciclib plus Fulvestrant|Abemaciclib administered orally in combination with fulvestrant administered intramuscularly (IM).
9895524|NCT05169567|Active Comparator|Arm B: Placebo plus Fulvestrant|Placebo administered orally in combination with fulvestrant administered IM.
9895525|NCT05168657|Active Comparator|EN-IP-UC|Random-order cross-over participants on USUAL CARE managed by ENDOCRINOLOGY with IN-PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9895526|NCT05168657|Experimental|EN-TH-UC|Random-order cross-over participants on USUAL CARE managed by ENDOCRINOLOGY with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9895527|NCT05168657|Experimental|EN-IP-BP|Random-order cross-over participants on BIONIC PANCREAS managed by ENDOCRINOLOGY with IN PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9932745|NCT00952328|Experimental|Limited Formula|Participants will supplement feedings with early limited formula following nursing
9895528|NCT05168657|Experimental|EN-TH-BP|Random-order cross-over participants on BIONIC PANCREAS managed by ENDOCRINOLOGY with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9517485|NCT03305926|Experimental|eCVR|
9895529|NCT05168657|Active Comparator|PC-IP-UC|Random-order cross-over participants on USUAL CARE intervention managed by PRIMARY CARE with IN-PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9895530|NCT05168657|Experimental|PC-TH-UC|Random-order cross-over participants on USUAL CARE managed by PRIMARY CARE with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9895531|NCT05168657|Experimental|PC-IP-BP|Random-order cross-over participants on BIONIC PANCREAS managed by PRIMARY CARE with IN PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9895532|NCT05168657|Experimental|PC-TH-BP|Random-order cross-over participants on BIONIC PANCREAS managed by PRIMARY CARE with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
9895533|NCT05168605|Experimental|Home Visit|Participants will receive home visit During the course of the first home visit, patients will receive routine care for diabetes and hypertension management (outcome variables are listed below) and data will be recorded in the EHR for primary outcomes. The resident physician will also assist the patient in completing enrollment in MyChart (if interested), utilizing either the resident's computer or smartphone and an internet hotspot. MyChart is a patient health platform that allows patients to contact their healthcare doctors, log health reminders, see test results, and a list of medications. The resident physician will also review a social determinants of health (SDH) screener (included in the EHR). The research faculty (licensed medical clinician) will collect blood pressure readings during this visit.
9895534|NCT05168605|No Intervention|Standard of care|Participants will receive a standard of care
9895535|NCT05163548|Experimental|Subjects that receive PerQseal Plus Device|Subjects undergoing large hole endovascular percutaneous procedures with a femoral arteriotomy created with 14 to 22 F sheaths (arteriotomy up to 26 F)
9895536|NCT05163327||Healthy Volunteer|10 Volunteers (Male or Female), aged18 or over, with no known history of Coronary Artery Disease
9895537|NCT05163327||Known Coronary Artery Disease|10 Volunteers (Male orFemale), aged 18 or over,with a known significant (defined as => 70% stenosis) single or 2 vessel Coronary Artery Disease
9895538|NCT05163119|No Intervention|Control Group|Commercial cell-phone blocking app installed on smartphone, but app will be inactive.
9895539|NCT05163119|Experimental|Commercial Cellphone-Blocking App|Commercial cellphone-blocking app that blocks handheld cellphone use while driving, but allows emergency calls and phone use after pressing the passenger button will be installed on smartphone.
9895540|NCT05163119|Experimental|Driving Mode|Driving mode blocks handheld phone use while driving or facilitates hands free use (exact functionality dependent on smartphone type and service provider).This group will also have the commercial cell-phone blocking app installed on smartphone, but app will be inactive.
9895541|NCT05162729|Experimental|Working memory intervention group|Receive game-like working memory online training for 5 weeks, 3 times per week, each lasting for15 minutes.
9895542|NCT05162729|Active Comparator|Social emotional intervention group|Receive game-like social-emotional online training for 5 weeks, 3 times per week, each lasting for 15 minutes.
9895543|NCT05162729|No Intervention|Control group|Receive no training
9932746|NCT00952328|No Intervention|Control|Participants are instructed to continue exclusively breastfeeding; no use of formula
9895544|NCT05162404|Experimental|Video Intervention|The intervention in this study is a TED-talk style video series designed to provide patient education on cancer, care coordination, and self-advocacy. The content is designed to provide both a background about cancer disease and to address each of the specific domains in care coordination (CCI). The development of video contents was informed by our prior/current research in rural care coordination and components of evidence-based interventions including the patient navigator training by the George Washington University Cancer Institute, Imi Hale (the Native Hawaiian Cancer Network), and a supportive care intervention by Mokuau et al. As the target population of this intervention is rural patients, videos include some rural-specific considerations related to care coordination.
9895545|NCT05162261|Experimental|Tixel Group|Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
9895546|NCT05162261|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits,Treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
9895547|NCT05161208|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
9895548|NCT05161208|Placebo Comparator|Placebo (vehicle) nasal spray|Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
9895549|NCT05155449|Active Comparator|Probiotics|Two capsules per day for 8 weeks
9895550|NCT05155449|Placebo Comparator|Placebo|Two capsules per day for 8 weeks
9895551|NCT05155163|No Intervention|Treatment as Usual|Treatment as usual for opioid use disorder
9895552|NCT05155163|Experimental|SC-POWR|Treatment as usual for opioid use disorder with the addition of CBT with possible stepped care to exercise and stress reduction
9895553|NCT05151965||Bankart Repair and Remplissage|Patients will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
9895554|NCT05151965||Latarjet Coracoid Transfer|Patients will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
9895555|NCT05149911|Experimental|Coaching|Participants randomized to the coaching group will receive a 1-hour initial professional coaching session followed by five 30-minute professional coaching sessions occurring at a goal frequency of every 2 to 3 weeks within 5 months (total of 3.5 coaching hours). All coaching sessions will be conducted individually (i.e. between one coach and one participant). Participants will be able to request coaching on any topic to individualize the intervention, but the general structure of the sessions will be standardized across participants. All coaching sessions will be performed over the phone or virtual web meeting as standard in coaching practices.
9895556|NCT05149911|No Intervention|Control|"Participants randomized to the control group will receive no intervention but will be asked to complete the distress and wellness survey at the same time points as participants in the intervention group. Participants in the control group will receive the life coaching intervention after the statistical analysis is completed."
9895557|NCT05149196|Experimental|Targeted blood pressure management|"During anesthesia, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~For patients admitted to intensive care unit after surgery, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~In the general ward, systolic blood pressure is maintained ≥110 mmHg or within 10% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or norepinephrine infusion."
9895558|NCT05149196|Active Comparator|Routine care|"During anesthesia, mean blood pressure is maintained ≥65 mmHg or within 20% of baseline according to routine practice;~For patients admitted to intensive care unit, mean blood pressure is maintained ≥65 mmHg or within 20% of baseline according to routine practice;~In the general ward, management is performed according to routine practice."
9895559|NCT05147922|Experimental|Booster Training Group|Participants randomized to intervention will undergo booster training sessions with the RQI cart (including audiovisual feedback) at 3, 6 and 9 months post instructor-led training session. Following each of these booster sessions, the participants will undergo 1 minute assessments, without feedback.
9895560|NCT05147922|No Intervention|No Booster Training Group|Participants randomized to the control group will undergo 1 minute assessments, without feedback, at 6 and 9 months. Participants will not be able to access the RQI cart outside of their assessment.
9895561|NCT05147207|Experimental|Superpath|This is a minimally invasive surgical approach.
9895562|NCT05147207|No Intervention|Posterior Approach|This is the traditional THA surgical approach used.
9895563|NCT05146193||All subjects are diagnosed of having a spinal deformity|Routine care of patients with spinal deformities
9895564|NCT05144347|Experimental|XL114 Dose-Escalation Cohorts|Subjects (Cohort A1-An) will accrue in cohorts of 3-12 subjects in a i3+3 design.
9895565|NCT05144347|Experimental|XL114 Expansion Cohorts|The recommended dose from the Dose-Escalation stage, will be used in subjects with activated B-cell-like diffuse large B-cell lymphoma [ABC-DLBCL] (Cohort B), mantle cell lymphoma [MCL] (Cohort C), chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL] (Cohort D). Subjects will also be enrolled in a Biomarker cohort (Cohort E).
9895566|NCT05144334|Experimental|BTX-1188 Dose Cohort 1|Starting dose of BTX-1188 administered orally per dosing schedule
9895567|NCT05144334|Experimental|BTX-1188 Dose Cohort 2|First dose escalation of BTX-1188 administered orally per dosing schedule
9895568|NCT05144334|Experimental|BTX-1188 Dose Cohort 3|Second dose escalation of BTX-1188 administered orally per dosing schedule
9895569|NCT05144334|Experimental|BTX-1188 Dose Cohort 4|Third dose escalation of BTX-1188 administered orally per dosing schedule
9895570|NCT05144334|Experimental|BTX-1188 Dose Cohort 5|Fourth dose escalation of BTX-1188 administered orally per dosing schedule
9895571|NCT05144334|Experimental|BTX-1188 Dose Cohort 6|Fifth dose escalation of BTX-1188 administered orally per dosing schedule
9895572|NCT05144334|Experimental|BTX-1188 Dose Cohort 7|Sixth dose escalation of BTX-1188 administered orally per dosing schedule
9895573|NCT05143099|Experimental|1|tislelizumab combined with cetuximab and irinotecan
9895574|NCT05142618|Active Comparator|Standard Post-operative Instructions|Participants in the control group will be told upon post-operative discharge that they should follow the post-operative instructions.
9895575|NCT05142618|Experimental|Supervised Physical Therapy|Participants in the physical therapy group will be scheduled for visits to the physical therapy clinic beginning two weeks after surgery, and will undergo supervised physical therapy treatments approximately twice per week for eight weeks according to a standardized evidence-based post-operative abdominal core surgery rehabilitation program.
9895576|NCT05142189|Experimental|Cohort 1 - BNT116 monotherapy|
9895577|NCT05142189|Experimental|Cohort 2 - BNT116 + cemiplimab|
9895578|NCT05142189|Experimental|Cohort 3 - BNT116 + docetaxel|
9895579|NCT05142189|Experimental|Cohort 4 - BNT116 + cemiplimab|
9895580|NCT05142150||Patient|Patient satisfaction with end of life care. Questionnaire to be completed at baseline and every 8 week.
9895581|NCT05142150||Carer|Carer satisfaction with care leading up to the time of death and the quality of the patient's death. Questionnaire to be completed at baseline and every 8 weeks,and 5-7 weeks after patient deceased.
9895582|NCT05138341|Experimental|Mechanical Minimal Invasive Surgical (MIS) management|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
9895583|NCT05138341|No Intervention|Best Medical Management (MM)|Best medical management per standard of care
9895584|NCT05137353|Experimental|Music Training (RitMoZ Training)|12 sessions spread in the course of 1.5 months: each session has a duration of 90 minutes; each week will have 2 sessions
9895585|NCT05137353|Active Comparator|Spelling Training|12 sessions spread in the course of 1.5 months: each session has a duration of 90 minutes; each week will have 2 sessions
9895586|NCT05135923|Active Comparator|Benchmark gluten-free products|Products containing less than 6g fibre per 100g product.
9895587|NCT05135923|Experimental|Optimised gluten-free products|Products containing less than 6g fibre per 100g product.
9895588|NCT05135377||Children with Anaphylaxis|Patients under 18 years of age presenting to the Emergency Department (ED) with an allergic reaction that matches diagnostic criteria for anaphylaxis.
9895589|NCT05135000|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 24 weeks
9895590|NCT05135000|Placebo Comparator|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks
9895591|NCT05133895|Experimental|Tocilizumab treatment|
9895592|NCT05133895|Active Comparator|Glucocorticoids monotherapy|
9895593|NCT05133440|Experimental|Experimental Arm|Participants will receive two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease.
9517486|NCT03305913|Experimental|Dose Level 1|TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
9895594|NCT05133440|Active Comparator|Control Arm:|Participants will receive SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice.
9895595|NCT05133141||Echelon Contour|This prospective study will include the participants who plan to have an elective colorectal surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the Echelon Contour instruction for use (IFU).
9932747|NCT00952354||research group|60 children aged from 3 to 10 years, both genders, observed in a symbolic play situation with their language therapists
9932748|NCT00952406||Survey of Women PFDs|Women with PFDs
9932749|NCT00952432|Active Comparator|ACUPUNCTURE|ACUPUNCTURE
9932750|NCT00952432|Active Comparator|MEDICATION|Carbamazepine
9895596|NCT05132686|Experimental|Intermittent energy restriction (IER) + Mediterranean diet (MED) or IER+MED|The IER+MED group intervention will be to restrict 70% energy (25%, 45% and 30% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow a MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. This would be equivalent to an over-all 20% daily energy restriction. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
9895597|NCT05132686|Experimental|Mediterranean diet (MED) + daily energy restriction (DER) or MED/DER|The MED/DER group intervention will restrict 20% energy (25%, 45% and 30% distribution of protein, carbohydrate, and fat, respectively) continuously. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
9895598|NCT05131828|Experimental|Research arm: metformin and clemastine|
9895599|NCT05131828|Placebo Comparator|Control arm: placebos for both metformin + clemastine|
9895600|NCT05131490|Experimental|Experimental|Experimental group intervention consists two months a mobile application intervention developed for gynecological cancer patients receiving chemotherapy
9895601|NCT05131490|No Intervention|No intervention|Control group receive routine care.
9895602|NCT05130827|Experimental|Plinabulin|In this pilot study, 15 patients age 18-75 with multiple myeloma will be admitted to the hospital and treated with a single dose of high dose melphalan. Stem cell infusion will occur per institutional standard of care. Patients will then receive plinabulin 40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0. Pegfilgrastim 6mg will be administered as per standard of care on day +1.
9895603|NCT05127642||Postpartum hemorrhage patients|
9895604|NCT05127642||Controls (non postpartum hemorrhage patients)|
9932751|NCT00952445|Experimental|T0903131 Besylate|1.0 mg
9932752|NCT00952445|Experimental|T0903131 Besylate|10.0 mg
9932753|NCT00952445|Placebo Comparator|Placebo|Once daily, oral
9932754|NCT00952458|Experimental|BIS monitoring|Dosing of sedatives with BIS monitoring
9932755|NCT00952458|No Intervention|Standard monitoring|Dosing of sedatives without BIS monitoring
9932756|NCT00952471|No Intervention|Baseline Period|Patients in the baseline period were cared for using the standard historical electronic order set.
9932757|NCT00952471|Active Comparator|Post Intervention Period|Patients in the Post intervention period were cared for with evidence-bsed modified order set changes
9932758|NCT00952497|Experimental|Cisplatin, Capecitabine, Telatinib|
9932759|NCT00952510||Whiplash patients|The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.
9932760|NCT00952536|Active Comparator|Triple therapy|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule (test group 1)
9932761|NCT00952536|Active Comparator|Dual Therapy|Juice Plus+ with 2 vegetable & 2 fruit & 2 placebo capsule (test group 2)
9932762|NCT00952536|Placebo Comparator|Control|Daily Placebo in the form of 6 capsules (control group)
9932763|NCT00952549|Experimental|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
9932764|NCT00952562|Active Comparator|cholecalciferol|3000 IU cholecalciferol per day for 16 weeks
9932765|NCT00952562|Placebo Comparator|placebo|
9932766|NCT00952575|Active Comparator|polyclonal anti-D immunoglobulin|
9932767|NCT00952575|Experimental|Monoclonal anti-D immunoglobulin|
9932768|NCT00952601|Experimental|Modified Atkins Diet|Patients are started on the modified Atkins diet at 15 grams per day.
9932769|NCT00952627|Experimental|Pycnogenol|200 mg/day
9932770|NCT00952627|Placebo Comparator|Control|placebo
9935603|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
9935604|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
9935605|NCT03466411|Active Comparator|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
9935606|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
9935607|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
9895605|NCT05127122|Placebo Comparator|Placebo Saline|Saline
9895606|NCT05127122|Experimental|10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
9895607|NCT05127122|Experimental|15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
9895608|NCT05127044||Qualified Preterm Infants|Preterm infants will receive non-invasive optical spectroscopy and transcutaneous bilirubin testing for baseline comparison
9895609|NCT05126407||Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray|Participants who have personally used or administered the Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray to a child at least once within the past 6 months will provide feedback via electronic survey on the prior use of the Drop/Spray.
9895610|NCT05124886|Active Comparator|Healthy Controls|
9895611|NCT05124886|Experimental|Enteric Hyperoxaluria|
9895612|NCT05123911|Experimental|Product Kit: Shampoo, Conditioner and Combining Cream (Investigational Products [IPs])|The parents/legally acceptable representative (LAR) of the participants will receive a product kit containing the 3 investigational products (shampoo, conditioner and combining cream) and will bathe the child participant with shampoo followed by conditioner and then apply combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
9895613|NCT05123664|Experimental|Bacillus coagulans|2 billion CFU Bacillus coagulans Unique IS2 per capsule
9895614|NCT05123664|Placebo Comparator|Placebo|Appearance-matched capsule
9895615|NCT05123586|Experimental|LY3361237|Participants are administered LY3361237 subcutaneously (SC) and standard of care (SOC)
9895616|NCT05123586|Placebo Comparator|Placebo|Placebo administered SC and SOC given at matching intervals
9895617|NCT05123313|No Intervention|Control group|The control group will not receive a series of consultations with their general practitioner. Controls will receive baseline measurements and follow-up measurements 3 months and 6 months following baseline measurements.
9895618|NCT05123313|Experimental|Intervention group|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences. Interventions will receive baseline measurements and follow-up measurements 3 months and 6 months following baseline measurements.
9895619|NCT05122208||Famotidine Group|Patients who were administered Famotidine 160 mg/day PO or nasogastric.
9895620|NCT05122208||Control Group|Patients who were not administered Famotidine
9517487|NCT03305913|Experimental|Dose Level 2|TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
9895621|NCT05121948|Experimental|Phase 1a Cohort 1 - 10 mg|10 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895622|NCT05121948|Experimental|Phase 1a Cohort 2 - 20 mg|20 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895623|NCT05121948|Experimental|Phase 1a Cohort 3 - 40 mg|40 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895624|NCT05121948|Experimental|Phase 1a Cohort 4 - 75 mg|75 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895625|NCT05121948|Experimental|Phase 1a Cohort 5 - 125 mg|125 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895626|NCT05121948|Experimental|Phase 1a Cohort 6 - 150 mg|150 mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895627|NCT05121948|Experimental|Phase 1b Cohort 7 - Dose 1 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895628|NCT05121948|Experimental|Phase 1b Cohort 8 - Dose 2 Chosen for Expansion|XX mg capsules of HC-7366 administered orally once a day in the fasting state with water at least 1 hour before food or at least 2 hours after food of each 3-week treatment cycle
9895629|NCT05121909|Experimental|Prototype 1 Mouthwash|Participants will brush their teeth using Colgate (registered [R]) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Prototype 1 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
9895630|NCT05121909|Experimental|Prototype 2 Mouthwash|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 2 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
9895631|NCT05121909|Experimental|Prototype 3 Mouthwash|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 3 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
9895632|NCT05121909|Active Comparator|Listerine (R) Cool Mint (R) Antiseptic Mouthwash (Positive Control)|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Antiseptic Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
9895633|NCT05121909|Active Comparator|5 Percent (%) Hydroalcohol Mouthwash (Negative Control)|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the 5% Hydroalcohol Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
9895634|NCT05121792|Experimental|Therapist online training in Prolonged Grief Disorder Therapy|Participants will be given access to an online 10-module interactive tutorial about Prolonged Grief Disorder Therapy.
9895635|NCT05120570|Experimental|PTCy/sirolimus plus VIC-1911|Patients enrolled and treated with PTCy/sirolimus plus VIC-1911
9895636|NCT05120128|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will enter wearing their own lens, then given the TEST Lens for the remainder of the study.
9895637|NCT05119582|Experimental|TOOsonix System ONE-M|Cutaneous neurofibromas will be treated by high intensity focused ultrasound.
10212140|NCT02332850|Experimental|Arm II (40 mg dexamethasone, isatuximab, carfilzomib)|"40 mg dexamethasone IV given on Days 1, 8, 15 and 22 (use as premed to isatuximab).~All patients will receive a fixed dose of Isatuximab (SAR650984) according to the assigned dose. Patients receive isatuximab IV over 4-6 hours on day 1, 3-4 hours on Day 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycle (patients may be eligible for rapid siatuximab given over 75 minutes), and carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
10212141|NCT02313870|Experimental|A|Superpotent topical steroids/methotrexate
10212142|NCT02313870|Other|B|Superpotent topical steroids (clobetasol propionate)
10212143|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
9895644|NCT05117840||Lung Cancer Screening Cohort|Individuals at high-risk of lung cancer undergoing standard of care screening as per USPSTF guidelines. All subjects will undergo low-dose CT scanning as per guidelines and an investigational blood-draw will be taken from all enrolled subjects.
9895645|NCT05117112|Experimental|10g of nutritional product|All subjects will ingest 10g of a commercially available nutritional supplement one time during a study visit.
9895646|NCT05116826|Experimental|Healthy Control Match (Normal hepatic function)|NTZ 500 mg twice a day for 7 days
9895647|NCT05116826|Experimental|Moderate Child-Pugh B (Moderate hepatic impairment)|NTZ 500 mg twice a day for 7 days
9895648|NCT05116826|Experimental|Severe Child-Pugh C (Severe hepatic impairment)|NTZ 500 mg twice a day for 7 days
9895649|NCT05116761|Placebo Comparator|Treatment Arm 1|Normal Saline 100 mL
9895650|NCT05116761|Experimental|Treatment Arm 2|Normal saline 85 mL and ExoFlo 15 mL, which is 10.5 x 10^8 EV
9895651|NCT05115864|Experimental|PFMT with device (intervention) group|The patients in PFMT with device (intervention) group followed the practice program three months. During three months, the intervention group is commanded to complete the PFMT program with the vaginal device and assess the grade of type I and II pelvic floor muscle fiber strength once three weeks.
9895652|NCT05115864|No Intervention|PFMT alone （control） group|The patients in PFMT alone (control) group are commanded to follow the same practice program three months without using the device.
9895653|NCT05115474||Participants with TNBC (triple negative breast cancer)|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
9895654|NCT05115474||Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
9895655|NCT05115474||Participants with Hormone Receptor (HR) +Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
9895656|NCT05113368|Experimental|Oral Regorafenib combined with intra-muscular injection of Fulvestrant|Oral regorafenib in a ReDOS plan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) [3 weeks on/1 week off] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
9895657|NCT05112263|Active Comparator|Group A|Group A: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks
9895658|NCT05112263|Experimental|Group B|Oral Tofacitinib 10 mg TDS for 3 days, and then 10 mg BD to complete 8 weeks followed by 5 mg BD till follow-up (14 weeks)
9895659|NCT05112081|Experimental|Botox injections|Patients randomised to the intervention arm will be treated with injection of 100 units of botox in 10 ml sterile saline close to superficial inguinal ring.
9895660|NCT05112081|Placebo Comparator|Sterile saline injections|Patients randomised to the control arm will be treated with injection of 10 ml sterile saline close to superficial inguinal ring.
9895661|NCT05110586|Experimental|1st group: TENS|Tens will be applied.
9895662|NCT05110586|Experimental|2nd group: Interferential current|Interferential current will be applied.
9895663|NCT05109637|Experimental|Participants with SMA (PwSMA)|Participants with SMA will have their motor functions assessed using the Konectom NMD smartphone-based application up to Day 28.
9895664|NCT05109637|Experimental|Participants with ALS (PwALS)|Participants with ALS will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application up to Day 28.
9895665|NCT05109637|Experimental|Healthy Participants|Healthy participants will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application for 28 days.
9895666|NCT05108935|Experimental|Medication and telemedicine follow up|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
9895667|NCT05108922|Experimental|Donanemab|Donanemab is administered intravenously (IV) every 4 weeks (Q4W)
9895668|NCT05108922|Active Comparator|Aducanumab|Aducanumab administered IV per label
9895669|NCT05107154|Experimental|Dialectical Behavioural Therapy|Participants randomized to the Dialectical Behavioural Therapy (DBT) skills training intervention will receive a 90-minute DBT skills training session every week for 16 weeks total. The sessions will be facilitated by a health practitioner supervised by a clinical health psychologist with expertise in program development and DBT-adaptations for a variety of populations. Sessions for Pilot 1 will be delivered via Zoom HealthCare and in person if allowable. In-person sessions would be delivered at the Children's Hospital Research Institute of Manitoba. Pilot 2 will be adapted to address any additional needs uncovered through he qualitative assessment of Pilot 1. Traditional medicine components will be developed within the first 2 years of the grant by Indigenous researchers, patient and parent advisors, elders, and community advisory groups. These elements will be offered as an encouraged, yet optional component (additional modules) within the 16-week DBT intervention in Pilot 2.
9895670|NCT05107154|No Intervention|Control|Participants randomized to the control arm will receive standard medical care and clinical follow-up. Controls will be offered DBT after completion of Pilot 1 and 2. Participation will be optional.
9895671|NCT05105841|Experimental|Venetoclax + Obinutuzumab (V+G)|Participants will receive venetoclax + obinutuzumab for twelve 28-day cycles.
9895672|NCT05105841|Experimental|Venetoclax + Ibrutinib (V+I)|Participants will receive venetoclax + ibrutinib for fifteen 28-day cycles.
9895673|NCT05104983|Experimental|Sirolimus|Sirolimus
9895674|NCT05104983|Placebo Comparator|Placebo|Placebo
9895675|NCT05104554|Experimental|Weekly IFA|Receive weekly IFA
9895676|NCT05104554|Experimental|Daily MMS|Receive daily MMS (including iron and folic acid as components)
9895677|NCT05104554|No Intervention|Control|
9895678|NCT05102370|Experimental|Participants with CCUS with mutations in IDH2|Participants will have CCUS with mutations in IDH2
9895679|NCT05101096|Experimental|Sacituzumab Govitecan-hziy (SG) 6 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive sacituzumab govitecan-hziy (SG) 6 mg/kg by intravenous (IV) injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9895680|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 8 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 8 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9895681|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 10 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9895682|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 6 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 6 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9895683|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 8 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 8 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9895684|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 10 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9895685|NCT05101096|Experimental|Sacituzumab Govitecan-hziy, Triple-negative Breast Cancer (TNBC)|(Phase 2: dose expansion) Japanese participants with TNBC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
9895686|NCT05100199|Placebo Comparator|Placebo|Placebo will be injected into the Glabellar Complex on Day 1.
9895687|NCT05100199|Experimental|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X Dose A will be injected into the Glabellar Complex on Day 1.
9895688|NCT05100199|Experimental|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X Dose B will be injected into the Glabellar Complex on Day 1.
9895689|NCT05100199|Experimental|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X Dose C will be injected into the Glabellar Complex on Day 1.
9895690|NCT05099159|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
9895691|NCT05099159|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
9895692|NCT05097989|Experimental|LN Cohort: ALXN2050 180 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
9895693|NCT05097989|Experimental|LN Cohort: ALXN2050 120 mg|Participants diagnosed with LN with an active flare will receive ALXN2050 in addition to standard-of-care background therapy.
9895694|NCT05097989|Placebo Comparator|LN Cohort: Placebo|Participants diagnosed with LN with an active flare will receive matched placebo in addition to standard-of-care background therapy.
9895695|NCT05097989|Experimental|IgAN Cohort: ALXN2050 180 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
9895696|NCT05097989|Experimental|IgAN Cohort: ALXN2050 120 mg|Participants diagnosed with IgAN will receive ALXN2050 in addition to standard-of-care background therapy.
9895697|NCT05097989|Placebo Comparator|IgAN Cohort: Placebo|Participants diagnosed with IgAN will receive matched placebo in addition to standard-of-care background therapy.
9895698|NCT05097469|Active Comparator|Laser treatment|Carbon dioxide laser treatment
9895699|NCT05097469|Sham Comparator|Sham treatment|Sham laser treatment
9895700|NCT05097183||Control|Transcatheter aortic valve replacement (TAVR) with standard procedure
9895701|NCT05097183||ACA|Transcatheter aortic valve replacement (TAVR) with Accurate Commissural Alignment (ACA) technique
9895702|NCT05094089||SYNECOR IP Device|Hernia mesh repair with GORE® SYNECOR Intraperitoneal Biomaterial
9895703|NCT05094089||SYNECOR PRE Device|Hernia mesh repair with GORE® SYNECOR Preperitoneal Biomaterial
9895704|NCT05092659|Other|patient interviews|Patient enrolled in a carcinological (group 1), bariatric (group 2) or non-bariatric non-carcinological (group 3) surgical pathway scheduled for visceral surgery.
9895705|NCT05091957|Experimental|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
9895706|NCT05091957|Active Comparator|Usual Care|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. Based on the ethical imperative to provide some support to families who identify unmet social needs, the comparator group will receive Usual Care, defined as: Participants in both groups will receive a written summary of available resources.
9895707|NCT05091567|Experimental|Arm A: Atezolizumab+Lurbinectedin|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle in combination with lurbinectedin on Day 1 of each 21-day cycle."
9895708|NCT05091567|Active Comparator|Arm B: Atezolizumab|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle."
9895709|NCT05090826|Experimental|TECNIS Synergy IOL|Model ZFR00V
9895710|NCT05090813|Experimental|TECNIS Eyhance IOL|Model ICB00
9895711|NCT05090787|Experimental|Investigational Device|Investigational mDCB00
9895712|NCT05090787|Active Comparator|Control Device|Control DCB00
9895713|NCT05090488|Experimental|Received Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
9895714|NCT05090488|Active Comparator|Received Diabetes Education in Group|Diabetes education in group, with trained educator team from primary health care
9895715|NCT05089903|Experimental|No Order|
9895716|NCT05089903|Experimental|No Order + Text (NO+T)|
9895717|NCT05089903|Experimental|Bulk Order (BO)|
9895718|NCT05089903|Experimental|Bulk Order + Text (BO+T)|
9895719|NCT05089903|Experimental|Clinician Endorsement (CE)|
9895720|NCT05089903|Experimental|Clinician Endorsement + Text (CE+T)|
9895721|NCT05089903|Experimental|Standard Messaging (SM)|
9895722|NCT05089903|Experimental|Standard Messaging (SM+T)|
9895723|NCT05088980|Experimental|VOLBELLA with Lidocaine|Participants will receive VOLBELLA with Lidocaine on Day 1 and followed for 12 months.
9895724|NCT05088980|Placebo Comparator|Control Group|Participants will be followed for 3 months. Participants can opt to receive VOLBELLA with Lidocaine after 3 months and followed for 9 months.
9895725|NCT05088629|Other|One group|3-meter Walk Back Test, Proprioception, Trunk Control and Muscle Strength test
9895726|NCT05087641|Experimental|IAB System|Patients will be treated with IAB(s)
9895727|NCT05087082|Other|App and Case Management system with algorithms|Feasibility study of hospital at home model including telemedicine and specifically developed app and case management system
9895728|NCT05086809|Active Comparator|AAB|Starts with Device A in first and second trial period and change to Device B in third trial period.
9895729|NCT05086809|Active Comparator|ABA|Starts with Device A in first trial period, wears Device B in second trial period and change to Device A in third trial period.
9895730|NCT05086497|No Intervention|Conventional Array Mapping Layout|Participants in this study arm will still receive Optune array layout mapping based on standard MR imaging sequences.
9895731|NCT05086497|Experimental|Advanced MR Imaging Array Mapping Layout|Participants in this study arm will receive Optune array layout mapping created from advanced MR imaging sequences obtained through trial enrollment.
9895732|NCT05086289|Experimental|LY3526318|LY3526318 administered orally
9895733|NCT05086289|Placebo Comparator|Placebo|Placebo administered orally
9895734|NCT05086276|Active Comparator|FX-322|FX-322, 1 dose (N=62)
9895735|NCT05086276|Placebo Comparator|Placebo|Placebo, 1 dose (N=62)
9895736|NCT05085405|Experimental|Clinician Notification only|
9895737|NCT05085405|Experimental|Clinician Notification with Nurse Facilitation only|
9895738|NCT05085405|Experimental|Clinician Notification / Patient Activation|
9895739|NCT05085405|Experimental|Clinician Notification with Nurse Facilitation / Patient Activation|
9895740|NCT05082428||Patients treated with Tofacitinib|Patients treated with tofacitinib for ulcerative colitis in Finland.
9932771|NCT00952640|Active Comparator|vitamin A directly post-partum|200.000 IU of vitamin A within 3 days of delivery
9932772|NCT00952640|Experimental|vitamin A delayed|200.000 IU vitamin A 6 weeks post-partum
9895741|NCT05081024||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood samples at baseline (before any neoadjuvant therapy), every 2 months while undergoing TNT, and then every 3 months for up to 3 years after completion of TNT. Patients' medical records are also reviewed. Patients may undergo collection of tissue sample if an archival tissue sample is not available.
9895742|NCT05080660|Experimental|LY3526318|LY3526318 administered orally.
9895743|NCT05080660|Placebo Comparator|Placebo|Placebo administered orally.
9895744|NCT05076448||Group 1 (Gonadal veins resection)|This group includes patients who underwent open retroperitoneal resection of the gonadal veins, endoscopic transperitoneal and retroperitoneal resection of the gonadal veins.
9895745|NCT05076448||Group 2 (Gonadal veins embolozation)|This group includes patients who underwent embolization of the gonadal veins with coils.
9895746|NCT05076448||Group 3 (Stenting of the common iliac vein with or without gonadal veins embolization)|This group includes patients who underwent isolated iliac vein stenting or iliac vein stenting combined with gonadal vein embolization.
9895747|NCT05074537||MRI Participants|
9895748|NCT05074537||PET/CT Participants|
9895749|NCT05074537||CT Participants|
9895750|NCT05074420|Experimental|Baricitinib|Baricitinib given orally to participants daily
9895751|NCT05074355|Experimental|Azacitidine and Venetoclax|"A treatment cycle is 28 days long.~Azacitidine will be given by injection under the skin, once a day, for the first 6 days of every cycle.~Venetoclax will be given orally, once a day, as follows at the discretion of their study doctors:~Cycle 1:~Day 1 - 100 mg~Day 2 - 200 mg~Days 3 to 28 - 400 mg~Cycle 2:~Participants with a response to the study drugs will continue taking 400 mg from Days 1 to 21, with no study drug from Days 22 to 28 during Cycle 2.~Participants who have not yet responded to the study drugs will continue taking 400 mg from Days 1 to 28 during Cycle 2.~Cycle 3 and subsequent cycles:~Participants with a response to the study drugs will continue to take 400 mg from Days 1 to 21, with no study drug from Days 22 to 28.~Participants whose disease has not worsened will continue taking 400 mg from Days 1 to 28.~Participants have not responded to the study drugs will be withdrawn from the study."
9895752|NCT05073887|Experimental|3 nerve|3 genicular nerve blockade and radio frequency ablation
9895753|NCT05073887|Active Comparator|5 nerve|3 genicular nerve blockade and radio frequency ablation 2 genicular nerve blockade and pulse radio frequency
9895754|NCT05073679|Experimental|Intervention|Oral naltrexone, to start as 25mg for three days then 50mg a day thereafter for up to nine weeks or completion of higher level of care, whichever haver happens first. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler
9895755|NCT05073679|Placebo Comparator|Control|Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for nine weeks or until completion of higher level of care, whichever happens first
9895756|NCT05071729|Experimental|Moderate renal impairment|Participants with estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m^2
9895757|NCT05071729|Experimental|Severe renal impairment|Participants with eGFR < 30 mL/min/ 1.73 m^2
9895758|NCT05071729|Experimental|Normal renal function|Participants with ≥ 90 mL/min/1.73 m^2
9895759|NCT05069844|Experimental|Gum chewing for 2 minutes|Patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
9895760|NCT05069844|Experimental|Gum chewing for 4 minutes|Patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
9895761|NCT05069844|No Intervention|Control group|Patients will be asked to swallow 2 times only.
9895762|NCT05068193|Other|Sequence 1|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.~*Sequence 1~[Period I] Administration of BR2008-1 (single dose)~- Wash out for 2 weeks~[Period II] Administration of BR2008 (single dose)"
9895763|NCT05068193|Other|Sequence 2|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.~*Sequence 2~[Period I] Administration of BR2008 (single dose)~Wash out for 2 weeks~[Period II] Administration of BR2008-1 (single dose)"
9895764|NCT05068102|Experimental|Tumor patients|
9895765|NCT05067647|Experimental|Thoracic, Urologic, Ear, Nose and Throat (ENT) Procedures|Any thoracic, urologic, or ENT procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use. Participants will be considered enrolled when the ENSEAL X1 device has been attempted to be used for a vessel transection during thoracic, urologic, or ENT procedures.
9517488|NCT03305913|Experimental|Dose Level 3|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
9895766|NCT05065736|Experimental|18F-Clofarabine|18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy
9895767|NCT05065190|Experimental|nintedanib|
9895768|NCT05065190|Placebo Comparator|Placebo|
9895769|NCT05064553||Ultrasound Surveillance Group|Subjects will undergo standard of care ultrasound surveillance imaging. Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up with CT or MRI as well as other procedures as needed. Subjects with negative ultrasound will be sent for a study CT/MRI.
9895770|NCT05064553||CT/MRI Surveillance Group|Subjects will undergo standard of care CT/MRI surveillance imaging.
9895771|NCT05064514|Experimental|Transcatheter Tricuspid Valved Stent Graft intervention|Participants who have carcinoid heart disease with severe symptomatic tricuspid regurgitation and with a significant backflow in the caval and hepatic veins will be treated with the implantation of the Transcatheter Tricuspid Valved Stent Graft
9895772|NCT05063565|Active Comparator|TheraSphere alone|Treatment with TheraSphere
9895773|NCT05063565|Experimental|TheraSphere followed by Durvalumab and Tremelimumab|TheraSphere followed by Tremelimumab plus Durvalumab administered once, then repeated administration of Durvalumab monthly up 18 months post randomization
9895774|NCT05063539|Experimental|LY3372689 High Dose|LY3372689 given orally
9895775|NCT05063539|Experimental|LY3372689 Low Dose|LY3372689 given orally
9895776|NCT05063539|Placebo Comparator|Placebo|Placebo given orally
9895777|NCT05062213|Experimental|Moisturizer Body Lotion|All participants will receive the product and use it at home.
9895778|NCT05062200|Experimental|Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])|Japanese participants will receive single oral dose 1 of JNJ-77242113 or matching placebo on Day 1 in Cohort 1 of Part 1.
9895779|NCT05062200|Experimental|Cohort 2: JNJ-77242113 or Placebo (SAD)|Japanese participants will receive single oral dose 2 of JNJ-77242113 or matching placebo on Day 1 in Cohort 2 of Part 1.
9895780|NCT05062200|Experimental|Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])|Chinese participants will receive single oral dose 2 of JNJ-77242113 or matching placebo on Day 1 in Cohort 3 of Part 2.
9895781|NCT05061979|Experimental|Mild renal impairment|Participants with mild renal impairment will receive a single dose of BAY1747846.
9895782|NCT05061979|Experimental|Moderate renal impairment|Participants with moderate renal impairment will receive a single dose of BAY1747846.
9895783|NCT05061979|Experimental|Normal renal function|Participants with normal renal function will receive a single dose of BAY1747846.
9895784|NCT05059041|Experimental|Dilated first, non-dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained after dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained before dilation.
9895785|NCT05059041|Experimental|Non-dilated first, dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained before dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained after dilation.
9895786|NCT05058898||Risk factors transmission cases|Human cases of monkeypox confirmed by PCR
9895787|NCT05058898||Risk factors transmission contacts and co-exposures|Human contact of confirmed monkeypox cases
9895788|NCT05058898||Serological follow up cases|Human cases of monkeypox confirmed by PCR from Lobaye region
9895789|NCT05058898||Serological follow up contacts and co-exposures|Human contact of confirmed monkeypox cases from Lobaye region adjusted for age, month of the year and village of origin
9895790|NCT05057494|Experimental|Arm A: Acalabrutinib plus Venetoclax (AV)|Participants will receive acalabrutinib and venetoclax orally.
9517489|NCT03305913|Experimental|Dose Level -1a|TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
9895791|NCT05057494|Experimental|Arm B: Venetoclax plus Obinutuzumab (VO)|Participants will receive Venetoclax orally and Obinutuzumab via IV infusion.
9895792|NCT05055401||Anesthesiology providers|Group will contain anesthesiologists, CRNA and AAs. The type of healthcare professional participating will be recorded along with the years of experience the participant has. Each participants experience will be categorized into three ranges, 0-3 years, 3-10 years, and 10+ years of experience. For further clarification and analysis, the healthcare professional's normal practice setting will also be recorded including inpatient, outpatient, or hybrid (inpatient and outpatient) settings. All providers will be analyzed together.
9895793|NCT05054088||Cohort 1|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.
9895794|NCT05054088||Cohort 2|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.
10213844|NCT02988245|Active Comparator|JNC-8-Guided Treatment|Using traditional (JNC-8) guidelines for BP prescribing for patients with hypertension, post diagnosis.
10213845|NCT02980666|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
10213846|NCT02971748|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
10213847|NCT02962102|Experimental|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
10213848|NCT02962102|Experimental|Calcitriol|Calcitriol 4mcg orally daily x 5 days
10213849|NCT02962102|Placebo Comparator|Placebo|Equal volume of medium chain triglyceride (MCT) oil orally daily x 5 days
10213850|NCT02956473|Experimental|Supine MRI|"Standard MRI will be performed~Supine MRI will be performed~Participant will receive mammography and ultrasound~Breast Radiologist will take a brief survey.~Patients will undergo upfront surgery or receive Neoadjuvant Therapy per standard of care~Standard of care will be performed"
9895795|NCT05053971|Experimental|Treatment (entinostat, ZEN003694)|"RUN-IN PHASE: Patients receive ZEN003694 PO QD or entinostat PO QW during days -14 to 1. Patients also undergo core needle biopsy within 30 days prior to starting therapy.~PHASE 2: Patients receive entinostat PO QW on days 1, 8, 15, and 22, and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo core needle biopsy on day 1 of cycle 1, and on day 1 of cycle 14."
9895796|NCT05053399|Experimental|TECNIS Symfony Toric IOL|Model Series ZXT
9895797|NCT05053334|Experimental|BP11 (Proposed biosimilar)|Subcutaneous injection of Omalizumab developed by CuraTeQ.
9895798|NCT05053334|Active Comparator|US-Xolair|Subcutaneous injection of Omalizumab licensed for use in USA
9895799|NCT05053334|Active Comparator|EU-Xolair|Subcutaneous injection of Omalizumab approved for use in Europe.
9895800|NCT05053230|Experimental|IM@Home|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, or breast cancer
9895801|NCT05053230|Placebo Comparator|Enhanced usual care|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, or breast cancer
9895802|NCT05051995|Placebo Comparator|Open-label placebo ABAB Sequence|The N-of-1 trial will, on the level of the individual patient, test whether open-label placebo reduces negative side effects caused by discontinuation of antidepressants compared to no treatment. After antidepressant discontinuation, subjects will be randomized to 2 arms differing in the treatment order (ABAB; BABA). Subjects in this arm (ABAB) will start with open-label placebo (A) for 2 weeks; they will then crossover to no treatment (B) for 2 weeks and repeat this sequence once again.
9895803|NCT05051995|Placebo Comparator|Open-label placebo BABA Sequence|The N-of-1 trial will, on the level of the individual patient, test whether open-label placebo reduces negative side effects caused by discontinuation of antidepressants compared to no treatment. After antidepressant discontinuation, subjects will be randomized to 2 arms differing in the treatment order (ABAB; BABA). Subjects in this arm (BABA) will start with no treatment (B) for 2 weeks; they will then crossover to open-label placebo (A) for 2 weeks and repeat this sequence once again.
9895804|NCT05051579|Experimental|LY3502970 Dose 1|Participants will receive LY3502970 administered orally
9895805|NCT05051579|Experimental|LY3502970 Dose 2|Participants will receive LY3502970 administered orally
9895806|NCT05051579|Experimental|LY3502970 Dose 3|Participants will receive LY3502970 administered orally
9895807|NCT05051579|Experimental|LY3502970 Dose 4|Participants will receive LY3502970 administered orally
9895808|NCT05051579|Placebo Comparator|Placebo|Placebo administered orally
9895809|NCT05048719|Experimental|LY3502970 Dose 1|Participants will receive escalated doses of LY3502970 administered orally
9895810|NCT05048719|Experimental|LY3502970 Dose 2|Participants will receive escalated doses of LY3502970 administered orally
9895811|NCT05048719|Experimental|LY3502970 Dose 3|Participants will receive escalated doses of LY3502970 administered orally
9895812|NCT05048719|Experimental|LY3502970 Dose 4|Participants will receive escalated doses of LY3502970 administered orally
9895813|NCT05048719|Experimental|LY3502970 Dose 5|Participants will receive escalated doses of LY3502970 administered orally
9895814|NCT05048719|Active Comparator|Dulaglutide|Participants will receive Dulaglutide subcutaneously (SC)
9895815|NCT05048719|Placebo Comparator|Placebo Matching LY3502970|Participants will receive placebo matching LY3502970 orally
9895816|NCT05048719|Placebo Comparator|Placebo Matching Dulaglutide|Participants will receive placebo matching Dulaglutide subcutaneously
9932773|NCT00952666|Experimental|Device|Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.
9932774|NCT00952679|Experimental|experimental arm|
9932775|NCT00952757||1.|Patients diagnosed of schizophrenia or bipolar disorder with APS-related hyperprolactinaemia who have been switched to quetiapine based on the clinician's judgement
9932776|NCT00952770|Experimental|Atorvastatin|Group receiving atorvastatin 20mg/day
9932777|NCT00952770|Active Comparator|Simvastatin/Ezetimibe|Group receiving simvastatin/ezetimibe 10/10mg
9932778|NCT00952783||1|
9932779|NCT00952796|Experimental|1|patients with intra-abdominal infection treated with moxifloxacin 400mg once daily
9932780|NCT00952796|Active Comparator|2|patients with intra-abdominal infection treated with ampicillin/sulbactam 1.5g 4 times daily
9932781|NCT00952835||asthma and rhinitis control|
9932782|NCT00952861|Active Comparator|Doxycycline|Doxycycline 200 mg QD in 5 days
9517490|NCT03305913|Experimental|Dose Level -1b|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
9932783|NCT00952861|Placebo Comparator|Placebo|Matching placebo QD i 5 days
9932784|NCT00952887|Experimental|ACE-031|8 dosing groups
9932785|NCT00952887|Placebo Comparator|Placebo|
9932786|NCT00952900|Experimental|Early Biobehavioral Intervention|This intervention involves the use of non-invasive treatment modalities such as relaxation/biofeedback, stress management, and cognitive coping skills. It is based upon previous clinical research studies demonstrating the efficacy of this intervention in allowing acute TMD patients to better cope with stress and lifestyle issues that produce the TMD pain/discomfort.
10212144|NCT02291523|Sham Comparator|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
10212145|NCT02291523|Active Comparator|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
10212146|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
10212147|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
10212148|NCT02243709|Active Comparator|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
9895817|NCT05048212|Experimental|Nivolumab|by vein every 3 weeks for 4 doses
9895818|NCT05048212|Experimental|Ipilimumab|by vein over 30 minutes every 3 weeks for 4 doses
9895819|NCT05048212|Experimental|Cabozantinib|tablets by mouth 1 time every day.
9895820|NCT05048095||Screened women in Region Östergötland Linkoping|
9895821|NCT05046093|Experimental|Single intervention arm - transbronchial cryobiopsy|Patients enrolled in this single arm will have lung nodules biopsied by transbronchial cryobiopsy.
9895822|NCT05044234|Experimental|Arm 1: Cedirogant|Participants will receive cedirogant Dose A once daily.
9895823|NCT05044234|Experimental|Arm 2: Cedirogant|Participants will receive cedirogant Dose B once daily.
9895824|NCT05044234|Experimental|Arm 3: Cedirogant|Participants will receive cedirogant Dose C once daily.
9895825|NCT05044234|Placebo Comparator|Arm 4: Placebo|Participants will receive placebo once daily.
9895826|NCT05043090|Experimental|Arm A|savolitinib 600mg plus durvalumab 1500mg
9895827|NCT05043090|Active Comparator|Arm B|sunitinib 50mg
9895828|NCT05043090|Experimental|Arm C|durvalumab 1500mg
9895829|NCT05042986|Experimental|Single Dose Capsule|Single oral dose of 200 mg (100 μCi in 200 mg salt [0.5 μCi/mg as salt], equivalent to 100 μCi in 142 mg active [0.7 μCi/mg as active]) of [14C]-SKI-O-703 containing approximately 100 μCi of [14C]-SKI-O-703 per capsule after an overnight fast.
9895830|NCT05042362|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
9895831|NCT05042362|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
9895832|NCT05041621|Experimental|Sensor augmented MDI therapy plus mobile application with reinforcement learning algorithm|Participants with type 1 diabetes will undergo sensor-augmented MDI therapy for 4 months using a freestyle libre glucose sensor (Abbott Diabetes Care) and a mobile application integrated with the reinforcement learning algorithm.
9895833|NCT05041543|Experimental|NTX-101 Group A|Day 1: One time administration, single drop. 4 subjects randomized 3:1 to NTX-101 or placebo.
9895834|NCT05041543|Experimental|NTX-101 Group B|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
9895835|NCT05041543|Experimental|NTX-101 Group C|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
9895836|NCT05041543|Experimental|NTX-101 Group D|Day 1: One time administration, two drops. Day 3-7: Two time administration, two drops each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
9895837|NCT05041543|Experimental|NTX-101 Group E|Day 1: One time administration, four drops. Day 3-7: Two time administration, four drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
9895838|NCT05040009|Active Comparator|moderate and high risk patient with integrated foot care program|"Integrated foot care program will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months~Regular foot care and examination by an adequately trained professional: -~Structured education~Adequate footwear~Foot-related exercises and weight-bearing activity.~Foot examination and screening every 4 months in moderate risk and 2 months in high-risk patient for diabetic foot.~Instructions about foot self-management"
9895839|NCT05040009|No Intervention|moderate and high risk patient with conventional treatment|conventional treatment will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months.
9895840|NCT05039021|Experimental|Pediatric; adult (HPB, lower gastrointestinal, gastric, gynecological, urological, thoracic)|Any pediatric or adult (hepato-pancreato-biliary, lower gastrointestinal, gastric, gynecological, urological, thoracic) procedures where the HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
9895841|NCT05037409|Experimental|PF-06823859 low|Participants will receive single intravenous infusion.
9895842|NCT05037409|Experimental|PF-06823859 high|Participants will receive single intravenous infusion.
9895843|NCT05037409|Placebo Comparator|Placebo|Participants will receive single intravenous infusion.
9895844|NCT05037045|Experimental|GLP-1 RA therapy|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months.
9895845|NCT05036070|Experimental|Study Lens|Model C0001
9895846|NCT05036070|Active Comparator|Control Lens|Model ZCB00
9895847|NCT05032807|Experimental|Novel lipid formulation cannabidiol|
9895848|NCT05032807|Active Comparator|Standard formulation cannabidiol|
9895849|NCT05031468||Group 1: Individuals vaccinated during pregnancy|Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine during pregnancy (up to 200 individuals per vaccine type)
9895850|NCT05031468||Group 2: Individuals vaccinated postpartum|Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 65 individuals per vaccine type)
9895851|NCT05031468||Group 3: Infants of individuals vaccinated during pregnancy|Infants of individuals who receive a SARS-CoV-2 vaccine during pregnancy (approximately 200 infants per vaccine type)
9895852|NCT05031468||Group 4: Infants of individuals vaccinated postpartum|Infants of individuals who receive a SARS-CoV-2 vaccine postpartum (approximately 65 infants per vaccine type)
10212149|NCT02243709|Placebo Comparator|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
10212150|NCT02236806|Experimental|Arm 1|bisoprolol plus ramipril
10212151|NCT02236806|Active Comparator|Arm 2|Bisoprolol plus placebo
10212152|NCT02236806|Active Comparator|Arm 3|Ramipril plus placebo
10212153|NCT02236806|Placebo Comparator|Arm 4|Placebo
10212154|NCT02236572|Experimental|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
10212155|NCT02220452|Experimental|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
10212156|NCT02220452|Active Comparator|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
9797796|NCT01607255|Active Comparator|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
9797797|NCT01607346|Experimental|ezogabine/retigabine|Open-label
9797798|NCT01607398|Experimental|ADOAIR250|ADOAIR 250mcg inhalations, twice daily, from week0 - 12
9797799|NCT01607398|Placebo Comparator|Placebo|Placebo inhalation, twice daily, from week0 -12
9797800|NCT01607411|Placebo Comparator|Fluoride free toothpaste|toothpaste with no fluoride
9797801|NCT01607411|Experimental|1426ppm Fluoride Toothpaste|Experimental toothpaste containing 1426 ppm Fluoride
9797802|NCT01607411|Experimental|1000 ppm Fluoride Toothpaste|Experimental toothpaste containing 1000 ppm Fluoride
9797803|NCT01607411|Experimental|500 ppm Toothpaste|Experimental toothpaste containing 500 ppm Fluoride
9797804|NCT01607450|Other|Saline|12 hour saline (control) infusion prior to PET study
9797805|NCT01607450|Experimental|GLP-1 Low dose|GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
9797806|NCT01607450|Experimental|GLP-1 Mid-Range Dose|GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
9797807|NCT01607450|Experimental|GLP-1 High Dose|GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
9797808|NCT01607476|Experimental|Alzheimer's Disease|"Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first."
9797809|NCT01607476|Active Comparator|Cognitive Normal Elderly|Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
9797810|NCT01607476|Active Comparator|Cognitive Normal Young|Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
9797811|NCT01607554|Experimental|Irinotecan|The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
9797812|NCT01607593||sertraline (Zoloft)|
9797813|NCT01607645|Experimental|Arm1: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
9797814|NCT01607645|Experimental|Arm2: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
9797815|NCT01607658|Placebo Comparator|Placebo|Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
9797816|NCT01607658|Experimental|Experimental 1|Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
9797817|NCT01607658|Experimental|Experimental 2|Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
9797818|NCT01607658|Experimental|Experimental 3|High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
9797819|NCT01607853|Experimental|Daivobet® gel|
9797820|NCT01607892|Experimental|selinexor|
9797821|NCT01607905|Experimental|Arm A (Colorectal Cancer)|Participants with colorectal cancer and liver metastasis received oral selinexor as single agent in 8 schedules, Schedule1: ≤12milligrams per meter square(mg/m^2) 3 times weekly(TIW) during Weeks 1 and 3, twice weekly(BIW) during Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule2: >12mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule3: ≥30mg/m^2 BIW(Days 1 and 3) up to 8 doses/cycle(28 days/cycle); Schedule4: ≥20mg/m^2 BIW(Days 1 and 2) up to 8 doses/cycle(28 days/cycle); Schedule5: ≥35mg/m^2 BIW(Days 1 and 4) up to 8 doses(28 days/cycle); Schedule6: ≥20mg/m^2 BIW(Days 1 and 4) after 500 mg(Week 1) to 1000 mg(Week 2 onwards) acetaminophen(given 1 hour prior to each selinexor dose) up to 8 doses/cycle (28 days/cycle); Schedule7: ≥50mg/m^2 once weekly(QW) up to 4 doses/cycle(28 days per cycle); Schedule8: ≥45mg/m^2 BIW(Days 1 and 3) up to 4 doses/cycle(21 days/cycle), until disease progression, death, or unacceptable toxicity.
9797822|NCT01607905|Experimental|Arm B (Gynecological Cancer)|Participants with gynecological cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
9797823|NCT01607905|Experimental|Arm C (Squamous Cell Cancer)|Participants with squamous cell cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
9895853|NCT05031468||Group 5: Individuals receiving additional vaccines during pregnancy|Individuals who receive additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (up to 200 individuals).
9895854|NCT05031468||Group 6: Infants of individuals receiving additional vaccines during pregnancy|Infants of individuals who received additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (approximately 200 infants).
9895855|NCT05030506|Experimental|Belzutifan + Lenvatinib|Participants will receive a daily oral dose of 120 mg of belzutifan monotherapy for 3 weeks, followed by a combination of a daily oral dose of 120 mg of belzutifan with a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
9895856|NCT05030506|Experimental|Belzutifan + Lenvatinib + Pembrolizumab|Participants will receive an intravenous dose of 400 mg of pembrolizumab once every six weeks for up to 18 infusions (up to 2 years) in combination with a daily oral dose of 120 mg of belzutifan and a daily oral dose of 20 mg of lenvatinib until progressive disease or discontinuation.
9895857|NCT05029661||No intervention|No intervention
9895858|NCT05027971||Lithotripsy Cohort|Subjects in this cohort will undergo lithotripsy procedure for the treatment of urinary calculi.
9895859|NCT05027971||Benign Prostatic Hyperplasia (BPH) Cohort|Subjects in this cohort will undergo Holmium Laser Enucleation of the Prostate (HoLEP) procedure for the treatment of BPH.
9895860|NCT05026866|Experimental|Donanemab|Donanemab administered intravenously (IV)
9895861|NCT05026866|Placebo Comparator|Placebo|Placebo is administered intravenously
9895862|NCT05026671|Active Comparator|Group DL|The control group consists of intubating the trachea with an endotracheal tube alone (without stylet).
9895863|NCT05026671|Experimental|Group DLS|The Experimental group consists of intubating the trachea with an endotracheal tube + stylet.
9895864|NCT05026671|Experimental|Group VL|The Experimental consists of intubating the trachea with an endotracheal tube + Video-laryngoscope
9895865|NCT05026671|Experimental|Group VLS|The Experimental consists of intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
9895866|NCT05025722||Confirmed PXE participants|Participants who have index PXE/proband with established PXE and ABCC6 mutations identified.
9895867|NCT05025722||PXE carrier participants|Participants who are biological siblings of the PXE index case and confirmed as PXE carrier.
9895868|NCT05025722||Non-PXE normal participants|Participants who are biological siblings of PXE index case and confirmed as non-PXE normal.
9895869|NCT05025345|Experimental|Study Lens|Tecnis Eyhance
9895870|NCT05025345|Active Comparator|Control Lens|Tecnis 1 piece IOL (Intraocular lens)
9895871|NCT05024708|Experimental|ARVC patients|
9895872|NCT05024708|Active Comparator|Endurance athletes with a dilated RV|
9895873|NCT05024708|Active Comparator|Endurance athletes with normal RV|
9895874|NCT05024708|Experimental|Untrained subject with normal RV|
9895875|NCT05024032|Experimental|Tirzepatide Dose 1|tirzepatide administered subcutaneously (SC) once a week.
9895876|NCT05024032|Experimental|Tirzepatide Dose 2|tirzepatide administered SC once a week.
9895877|NCT05024032|Placebo Comparator|Placebo|placebo administered SC once a week.
9895878|NCT05023551|Experimental|Single arm DSP-0390|Arm Description [*] DSP-0390 by oral administration
9895879|NCT05022589|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, ~30 minutes per session.
9895880|NCT05022264||Participants|All participants will have their vital signs measured with conventional techniques as well as with the new experimental medical device (labelled RIA-VS)
9895881|NCT05018520|Experimental|4RCHOP+4R|Four Courses of R-CHOP Plus Four Courses of Rituximab
9895882|NCT05018520|Experimental|6RCHOP+2R|Six Courses of R-CHOP Plus Two Courses of Rituximab
9895883|NCT05016778|Experimental|Treatment Group|This is a open label, single arm clinical trial.
9895884|NCT05014672|Experimental|Setanaxib 1200 mg/day|"Participants will be administered setanaxib at a dose of 1200 mg/day for the 52-week double-blind treatment period and the 52-week extension period.~The interim analysis outcome will determine if the setanaxib dose level for participants receiving 1200 mg/day will be escalated to 1600 mg/day for the continued extension period."
9895885|NCT05014672|Experimental|Setanaxib 1600 mg/day|"Participants will be administered setanaxib at a dose of 1600 mg/day for the 52-week double-blind treatment period and the 52-week extension period.~The interim analysis outcome will determine if the setanaxib dose level for participants receiving 1600 mg/day will be reduced to 1200 mg/day for the continued extension period."
9895886|NCT05014672|Placebo Comparator|Placebo|"Participants will be administered a placebo for the 52-week double-blind treatment period.~During the 52-week extension period, participants will switch from placebo to setanaxib at a dose of either 1200 or 1600 mg/day depending on interim analysis outcome."
9895887|NCT05013632||Exposed pregnant women|Pregnant or recently pregnant women 18 years of age and older treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 at any time during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
9895888|NCT05013632||Active comparator pregnant women|Pregnant women treated with another therapy for mild, moderate, or severe COVID-19
9895889|NCT05013632||Unexposed pregnant women|Pregnant women hospitalized but not treated with a medication specifically indicated for the treatment of mild, moderate, or severe COVID-19
9895890|NCT05013385|Experimental|Spesolimab|
9895891|NCT05013385|Placebo Comparator|Placebo|
10212157|NCT02187848|Experimental|SAR408701 Main Dose Escalation Cohort|Dose escalation administered intravenously, once every two weeks
10212158|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC)|Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer
9895892|NCT05012982|Experimental|AirBand followed by uninflated AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
9895893|NCT05012982|Experimental|Uninflated Airbnd followed by AirBand|The order of study days will be randomized. participants will wear an uninflated AirBand as the control intervention during the session in which BFR is not performed,
9895894|NCT05011266|Experimental|Buprenorphine-naloxone|Buprenorphine/naloxone 5.7 mg /1.4 mg/day sub-lingual tablets
9895895|NCT05011266|Placebo Comparator|Placebo|placebo sub-lingual tablet
9895896|NCT05010460|Experimental|Roxadustat|Roxadustat
9895897|NCT05010460|Placebo Comparator|placebo|Placebo has the same appearance with the experimental drug (Roxadustat).
9895898|NCT05010005|Experimental|Ruxolitinib and Duvelisib|Ruxolitinib 20mg BID plus Duvelisib 25mg, 50mg, or 75mg BID. Patients will be instructed to take duvelisib and ruxolitinib by mouth every 12 hours, the same time each day, +/- 2 hours. Duvelisib and ruxolitinib will be provided via the institutional investigational pharmacy. The researchers will utilize a dose-escalation standard 3+3 design in which we evaluate 3 doses of duvelisib (25mg BID, 50mg BID, and 75mg BID) in combination with ruxolitinib 20mg BID. A minus-1 dose level of duvelisib (15mg BID) can be used if de-escalation is needed. The cohort expansion phase will have two treatment groups JAK/STAT activation or mutation present or JAK/STAT activation or mutation absent or unknown.
9895899|NCT05008887|Experimental|Fractional CO2 laser and topical methotrexate solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of methotrexate solution (2.5% concentration vial 50mg/2ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
9895900|NCT05008887|Active Comparator|Fractional CO2 laser and topical 5-fluorouracil solution|"In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals.~In each patient, two patches or their duplicates (if small sized) will be subjected first to fractional CO2 laser treatment at two different energies (half the number of selected patches will be treated with 50 mJ-energy with the aim to use laser more as a delivery system to drug solution, and the other half will be treated with 100mJ-energy with the aim to use laser as both therapeutic and delivery system , followed by topical application of 5-fluorouracil solution 5% concentration vial 250mg/5ml using insulin syringe as 0.1 ml at 1 cm-intervals with a maximum volume of 2 ml per session). Then gentle massage will be done and after about 10 minutes, an occlusive dressing will be applied for 24 hours after the session.~In all patients, the selected patches of vitiligo will be treated with fractional CO2 laser for 3 sessions at one-month intervals."
9895901|NCT05008848|Experimental|Group I (SGR program, text messages)|Patients participate in schedule gradual reduction program over 8 weeks to reduce the frequency of cigarette use. Patients also receive cessation support messages via text messages for 12 weeks.
9895902|NCT05008848|Active Comparator|Group II (booklet)|Patients receive NCI's Clearing the Air booklet to help plan to gradually quit smoking.
9895903|NCT05008835|Experimental|Drug - ACP-044 Dose A|ACP-044 Dose A
9895904|NCT05008835|Experimental|Drug - ACP-044 Dose B|ACP-044 Dose B
9895905|NCT05008835|Placebo Comparator|Placebo|Placebo
9895906|NCT05007704||Anesthesiologists for preliminary survey|Anesthesiologists who have completed their training within the last three years to identify preliminary competencies for Delphi round one survey.
9895907|NCT05007704||Global Experts in Anesthesiology and Critical Care Medicine|Anesthesiologist (a medical graduate who has completed a nationally recognized Anesthesiology training programme) involved in the management of critically ill patients in ICU and have more than ten years of experience in teaching and training in Critical Care. They will be involved in the Delphi process to generate expert consensus on the additional competencies (mandatory desirable and optional) required for Anesthesiologists to practice Critical Care in the Intensive Care Unit (ICU).
9895908|NCT05003986|Experimental|Population 1: FSGS and/or MCD|Subjects with selected proteinuric glomerular diseases associated with FSGS and MCD histological patterns
9895909|NCT05003986|Experimental|Population 2: IgAN, IgAV, or AS|Subjects with biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or subjects with Alport syndrome (AS)
9895910|NCT05001828|Experimental|Previously Treated AML|Previously treated AML based on the revised 2017 European LeukemiaNet (ELN) criteria with age at least 18 years, and having ≥10% blasts in bone marrow or peripheral blood
9895911|NCT05001828|Experimental|Untreated AML With High Risk Features|Untreated AML per ELN criteria with high risk features, or age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75 years, cardiac disease or prior anthracycline use or high probability of treatment-related mortality
9895912|NCT05000957|Experimental|"Magic Max Laser Treatment + Colporrhaphy"|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~st Stage - vaginal processing with a conical mirror handpiece,~nd Stage - vaginal processing with a corner mirror handpiece,~d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.~A/R colporrhaphy will be performed 1 month after last laser treatment."
9895913|NCT05000957|Active Comparator|Colporrhaphy (control group 1)|A/R colporrhaphy only will be performed.
9895914|NCT05000957|Other|No Treatment (control group 2)|Any surgery which do not affect condition of vagina, vulva and paraurethral region will be performed.
9895915|NCT04998058|Placebo Comparator|Control (conventional graft procedure), bone substitute and saline solution.|one randomly assigned maxillary sinus grafted internally defined as control (bone substitute + saline solution) per subject.
9895916|NCT04998058|Experimental|Test (modified graft), bone substitute and concentrated culture medium (CM)|one randomly assigned maxillary sinus grafted internally defined as test (bone substitute + concentrated culture medium) per subject.
9895917|NCT04997993|Experimental|Leflunomide|Leflunomide, 20-50mg PO daily
9895918|NCT04995055|Experimental|Period 1|Eligible subjects will be randomly assigned to contact lens wear sequence TEST/CONTROL in a bilateral fashion.
9895919|NCT04995055|Experimental|Period 2|Eligible subjects will be randomly assigned to contact lens wear sequence CONTROL/ TEST in a bilateral fashion.
9895920|NCT04992520|Experimental|Group 1A: S. sonnei 53G|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
9895921|NCT04992520|Experimental|Group 1B: S. flexneri 2a 2457T|"At least 3 months after challenging Group 1A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
9895922|NCT04992520|Experimental|Group 2A: S. flexneri 2a 2457T (1500 cfu)|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
9895923|NCT04992520|Experimental|Group 2B: S. sonnei 53G|"At least 3 months after challenging Group 2A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
10212159|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity
10212160|NCT02187848|Experimental|SAR408701 Expansion Cohort gastric adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma
10212161|NCT02187848|Experimental|SAR408701 Loading Dose Escalation cohorts (Escalation bis)|Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
9895927|NCT04991493|Placebo Comparator|Placebo group|5ml normal saline was injected intravenously 15 minutes before anesthesia and 5ml normal saline was injected intravenously when the incision was washed and sutured.
9895928|NCT04991493|Experimental|pre-tramadol group|5ml of tramadol containing 1mg / kg was injected intravenously 15 minutes before anesthesia and 5ml of normal saline was injected intravenously when the incision was washed and sutured.
9895929|NCT04991493|Active Comparator|post-tramadol group|5ml of normal saline was injected intravenously 15 minutes before anesthesia and 5ml of tramadol containing 1mg / kg was injected intravenously when the incision was washed and sutured.
9895930|NCT04989283|Experimental|Arm I (atezolizumab, chemotherapy, RT, surgery)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive one of the chemotherapy combinations below depending on their previous therapy and disease. Beginning on the first day of chemotherapy and the first day of cycle 2 of chemotherapy, patients undergo external beam radiation therapy 5 days per week. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 21 and 90 days after treatment, patients undergo surgery. Within 42 days after completion of surgery, patients then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
9895931|NCT04989283|Active Comparator|Arm II (chemotherapy, RT, surgery)|Patients receive one of the chemotherapy combinations below depending on their previous therapy and disease. Beginning on the first day of chemotherapy and the first day of cycle 2 of chemotherapy, patients also undergo external beam radiation therapy 5 days per week. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 21 and 90 days after treatment, patients undergo surgery.
9895932|NCT04989231||Experimental Group|723 subjects who have received 4 doses of the experimental vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
9895933|NCT04989231||Control Group|362 subjects who have received 4 doses of control vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
9895934|NCT04985812|Experimental|JNJ-67484703|Participants will receive multiple doses of JNJ-67484703.
9895935|NCT04985812|Placebo Comparator|Placebo|Participants will receive multiple doses of placebo.
9895936|NCT04984876|Experimental|ligelizumab 240 mg|ligelizumab 240 mg subcutaneous injection for 52 weeks
9895937|NCT04984876|Experimental|ligelizumab 120 mg|ligelizumab 120 mg subcutaneous injection for 52 weeks
9895938|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 120 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks
9895939|NCT04984876|Experimental|Placebo 16 weeks and ligelizumab 120 mg/240 mg|Placebo subcutaneous injection for first 16 weeks and ligelizumab 120 mg OR 240 mg subcutaneous injection for 36 weeks
9895940|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 240 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks
9895941|NCT04984291|Experimental|Zimmer Biomet Total Shoulder Arthroplasty System|Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.
9797824|NCT01607905|Experimental|Arm D (Castrate-resistant Prostate Cancer)|Participants with castrate-resistant prostate cancer (CRPC) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
9797825|NCT01607905|Experimental|Arm E (Glioblastoma Multiforme)|Participants with glioblastoma multiforme (GBM) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
9797826|NCT01607905|Experimental|Arm F (Melanoma)|Participants with Melanoma received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
9797827|NCT01607905|Experimental|Arm G (Other Solid Tumors)|Participants with other solid tumors received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
9797828|NCT01607957|Experimental|TAS-102|
9797829|NCT01607957|Placebo Comparator|Placebo|
9797830|NCT01608061|Experimental|DBS-f on|DBS-f on
9797831|NCT01608061|Sham Comparator|DBS-f off|DBS-f off
9797832|NCT01608087|Experimental|BI 695502|Subject to receive one intravenous (i.v.) infusion of BI 695502
9797833|NCT01608087|Active Comparator|bevacizumab A|Subject to receive one i.v. infusion of bevacizumab
9797834|NCT01608087|Active Comparator|bevacizumab B|Subject to receive one i.v. infusion of bevacizumab
9797835|NCT01608100|Experimental|ARCHITECT STAT High Sensitive Troponin I Assay testing|All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.
9797836|NCT01608295|Experimental|Vilazodone; Viibryd|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
9797837|NCT01608295|Experimental|Paroxetine; Paxil|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
9797838|NCT01608308|Experimental|IV Acetaminophen|The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
9895942|NCT04981639|Active Comparator|I (IVPCA)|Intravenous patient controlled analgesia will be performed.
9895943|NCT04981639|Active Comparator|II (IVPCA+TAP)|Intravenous patient controlled analgesia and transversus abdominis plane block will be performed.
9895944|NCT04981639|Active Comparator|III (IVPCA, IMS, and TAP)|Intravenous patient controlled analgesia, transversus abdominis plane block, and intramuscular muscular stimulation will be performed.
9895945|NCT04980781|Experimental|Participants receiving PED-t|"Participants, i.e. females with bulimia nervosa or binge eating disorder, are recruited for therapy in the trained ERC. The treatment program consists of 20 behavioral therapy sessions covering 16 weeks, and with single follow-up sessions at 2-, and 4- months post-therapy.~Participants are interviewed on the expectations to- and experiences from having therapy in the ECR, and monitored and evaluated on therapy effectiveness (i.e. diagnostic outcomes)."
9895946|NCT04980781|Experimental|Therapists and management in ERC offering PED-t|"Employees in the ECR and the management will be trained in giving PED-t in their facility, and will then perform therapy with a single group of participants recruited.~Therapists/employees trained in PED-t will be interviewed about their expectations to- and experiences from giving the PED-t, and also being monitored according to therapy manual fidelity.~The management at the facility offering PED-t will be interviewed about their experiences on administration and implementation of the PED-t in their facility."
9895947|NCT04980495|Experimental|efgartigimod IV - I|Patients receiving efgartigimod IV treatment (Continuous regimen: efgartigimod 10 mg/kg q2w)
9895948|NCT04980495|Experimental|efgartigimod IV - II|Patients receiving efgartigimod IV treatment (Cyclic regimen: efgartigimod 10 mg/kg q7d for a total of 4 infusions per TP for 2 TPs with a fixed 4-week IP between each TP)
9895949|NCT04980469|Experimental|Vitex negundo + Zingiber officinale|Dosage: 200 mg/ Capsule;1 capsule twice daily Route: Oral
9895950|NCT04980469|Placebo Comparator|Placebo (MCC)|Dosage: 200 mg/ Capsule; 1 capsule twice daily Route: Oral
9895951|NCT04975308|Experimental|Imlunestrant|Imlunestrant administered orally.
9895952|NCT04975308|Active Comparator|Investigator's Choice of Endocrine Therapy|Investigator's choice of exemestane administered orally or fulvestrant administered intramuscularly (IM).
9895953|NCT04975308|Experimental|Imlunestrant plus Abemaciclib|Imlunestrant plus abemaciclib administered orally.
9895954|NCT04974515|Experimental|Low intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at low intensity application for 20 minutes per day for 6 consecutive weeks.
9895955|NCT04974515|Active Comparator|High intensity application of eXciteOSA|Participants will receive the eXciteOSA device intervention at high intensity application for 20 minutes per day for 6 consecutive weeks.
9895956|NCT04971200|Experimental|Vitiligo Patients on Tildrakizumab|
9895957|NCT04969367||Observational (activity monitor)|Patients wear an activity monitor (Fitbit) for 90 days. Patients also undergo collection of blood samples and complete questionnaires twice weekly for up to 90 days.
9895958|NCT04968197|Experimental|Stochastic Vestibular Stimulation (SVS) Condition|Subjects will perform standard clinical testing for balance and gait while wearing the Vestibular Intervention via Portable Electrical Stimulator (VIPES) system. The SVS device will be active throughout the testing at the respective current levels (i.e., 0.2mA to 1 mA at 0.2 mA increments).
9895959|NCT04968197|No Intervention|Control Condition|Subjects will perform standard clinical testing for balance and gait without SVS
9895960|NCT04965636|Experimental|Participants receiving mepolizumab|
9895961|NCT04964986|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
9895962|NCT04964206||Neuraxial analgesia exposure|For mothers who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided according to routine practice of each study center.
9895963|NCT04964206||No neuraxial analgesia exposure|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
9895964|NCT04964063|Other|Sensodyne Fresh Mint Toothpaste|"Participants will be asked to follow commercial tube instructions as recommended for sensitivity relief: Apply at least a 1-inch strip of the product onto a soft bristle toothbrush. Brush teeth thoroughly for at least 1 minute twice a day (morning and evening), and not more than 3 times a day, or as recommended by a dentist or doctor. Make sure to brush all sensitive areas of the teeth. Minimize swallowing, Spit out after brushing."
9895965|NCT04960644|Experimental|MTX and corticosteroid|perimental: MTX and corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response MTX (5-6mg/m^2/day,Maximum dose 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
9895966|NCT04960644|Active Comparator|corticosteroid|perimental: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response
9895967|NCT04959474|Active Comparator|Arm I (standard dietary recommendations, SABR, surgery)|Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
9895968|NCT04959474|Experimental|Arm II (caloric restriction diet, SABR, surgery)|Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
9895969|NCT04958538|Experimental|MTX and corticosteroid|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
9895970|NCT04957914|Active Comparator|Insulin Glargine (Period 1)|Insulin glargine administered subcutaneously (SC).
9895971|NCT04957914|Experimental|LY3209590 (Period 2)|LY3209590 administered SC.
9895972|NCT04954898|Experimental|Study Lens|TECNIS Multifocal Toric 1-piece lens, Model ZMT
9895973|NCT04951388|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
9895974|NCT04951388|Placebo Comparator|MVC-COV1901(Saline)|Saline/0.5 mL
9895975|NCT04949295||the hemodialysis group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
9797839|NCT01608308|Placebo Comparator|Control|The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
9797840|NCT01608321|Experimental|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
9797841|NCT01608321|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
9797842|NCT01608490|Experimental|RePneu Lung Volume Reduction Coil System|The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
9797843|NCT01608490|No Intervention|Control arm is standard medical care|The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.
9797844|NCT01608659||botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
9797845|NCT01608672||All participants|Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
9797846|NCT01608724|Experimental|Open label|Saxagliptin, oral 5mg once a day(Q. D.)
9797847|NCT01608815|Experimental|Study Group|All participants will receive single dose of typhoid Vi polysaccharide vaccine on Day 0.
9797848|NCT01608971||Weight based protamine group|In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)
9797849|NCT01608971||Heparin level based protamine group|In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.
9797850|NCT01609010|Active Comparator|Rituximab Monotherapy|Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.
9797851|NCT01609010|Experimental|Rituximab, Interferon|Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
9797852|NCT01609023||Rituximab|Participants with chronic lymphocytic leukemia treated with rituximab in combination with chemotherapy according to SPC and routine clinical practice will be observed for 24 months.
9797853|NCT01609062|Experimental|BMN 110 Weekly at 2.0 mg/kg/week|
9797854|NCT01609062|Experimental|BMN 110 Weekly at 4.0 mg/kg/week|
9797855|NCT01609218|Experimental|80 mg LY2140023|Single oral dose of 80 milligrams (mg) LY2140023 administered alone
9797856|NCT01609218|Experimental|80 mg LY2140023 + 75 g aqueous activated charcoal|Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 grams (g) aqueous activated charcoal.
9797857|NCT01609257|Experimental|Norovirus Bivalent VLP Vaccine|Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.
9797858|NCT01609257|Placebo Comparator|Placebo|Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.
9797859|NCT01609296|Experimental|IN.PACT Admiral DEB|"The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as IN.PACT Admiral™ DEB)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial."
9797860|NCT01609348|Active Comparator|Venlafaxine|225 mg daily over 12 weeks
9797861|NCT01609348|Placebo Comparator|Sugar pill|
9797862|NCT01609478|Experimental|indacaterol acetate 75 µg|"indacaterol acetate 75 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
9797863|NCT01609478|Experimental|indacaterol acetate 150 µg|"indacaterol acetate 150 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
9797864|NCT01609478|Placebo Comparator|placebo|"placebo delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
9797865|NCT01609543|Experimental|Single Arm|
9797866|NCT01609556|Experimental|Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)|Participants will receive mirvetuximab soravtansine intravenous (IV) infusion on Day 1 of every 21-day (every 3 weeks [Q3W]) cycle. Dose escalation for this group schedule will start at 0.15 milligrams per kilogram (mg/kg) and proceed through 7.0 mg/kg. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
9895976|NCT04949295||the normal group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
9895977|NCT04948905||Patients diagnosed as having Borderline Personality Disorder|These patients have been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
9895978|NCT04948905||Healthy Controls (Patients not diagnosed as having Borderline Personality Disorder )|These patients have NOT been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
9895979|NCT04948047||Malignant pulmonary nodules|Patients with pulmonary nodule diagnosed as malignant cancer by pathological examinations after surgical resection.
9895980|NCT04948047||Benign pulmonary nodules|Patients with pulmonary nodule diagnosed as benign disease by pathological examinations after surgical resection.
9895981|NCT04945330||Gastrointestinal (GI)|Participants with GI cancer.
9895982|NCT04945330||Head and neck (H&N)|Participants with H&N cancer.
9895983|NCT04945330||Lung|Participants with lung cancer.
9895984|NCT04945330||Soft tissue sarcoma (STS)|Participants with STS cancer.
9895985|NCT04945330||Primary central nervous system (CNS)|Participants with CNS cancer.
9895986|NCT04945330||Melanoma|Participants with Melanoma cancer.
9895987|NCT04945330||Pediatrics|
9895988|NCT04945330||Others|
9895989|NCT04944316|Active Comparator|Low-fat, vegan diet|For a 12-week period, participants will be asked to follow a low-fat, vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
9895990|NCT04944316|Active Comparator|Portion-controlled diet|For a 12-week period, participants will be asked to follow a portion-controlled diet that is compliant with American Diabetes Association (ADA) guidelines. This diet will include individualized diet plans that reduce daily energy intake by 500-1,000 kcal for overweight (body mass index > 25 kg/m2) participants and keep carbohydrate intake reasonably stable over time. It will derive 15-20% from protein, <7% saturated fat, 60-70% carbohydrate and monounsaturated fats and ≤200 mg/day of cholesterol/day.
10212162|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity
10212163|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC-L)|Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
9895993|NCT04940364|Experimental|Cohort 1|Pozelimab: Single-dose SC on day 1
9895994|NCT04940364|Experimental|Cohort 2|Pozelimab: Single-dose IV on day 1
9895995|NCT04940364|Experimental|Cohort 3|Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1
9895996|NCT04940364|Experimental|Cohort 4|Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1
9895997|NCT04940364|Experimental|Cohort 5|Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1
9895998|NCT04940364|Experimental|Cohort 6|Pozelimab: Single-dose IV on day 1
9895999|NCT04940065||Kesimpta|Patients treated with Kesimpta
9896000|NCT04939844|Experimental|NDMM ineligible for transplant|"All participants will receive isatuximab in combination with bortezomib, lenalidomide and dexamethasone for 2 cycles, followed by isatuximab in combination with bortezomib and lenalidomide for 6 cycles, followed by isatuximab in combination with lenalidomide for 10 cycles, followed by continuous lenalidomide until disease progression. The cycle duration is 28 days.~Isatuximab will be administered IV at a dose of 10 mg/kg~on D1, D8, D15 and D22 during Cycle 1~on D1 and D15 during Cycles 2-18~Bortezomib will be administered SC at a dose of 1,3mg/m2~-on D1, D8 and D15 during Cycles 1-8~Lenalidomide will be administered PO at a dose of 25mg/day (15 mg/day in participants with GFR <30mL/minute/1.73m2)~-on D1 to D21 during all Cycles.~Dexamethasone will be administered PO at a dose of 20 mg -on D1, D8, D15 and D22 during Cycles 1 and 2"
9896001|NCT04939246|Other|Single-fraction SABR|Patients will receive SABR in a single-fraction regiment treatment with one single dose of radiation therapy per lesion. Patients may be treated for up to a total of ten lesions. Each lesion will be treated in one fraction.
9896002|NCT04939051|Experimental|Arm I (OCA)|Patients receive OCA PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
10212164|NCT02187848|Experimental|SAR408701 Expansion Cohort small cell lung cancer (SCLC)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC
10212165|NCT02187848|Experimental|SAR408701 Dose Escalation every 3 weeks cohort|Dose escalation administered intravenously, once every three weeks
10212166|NCT02164019|Active Comparator|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
9896003|NCT04939051|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
9896004|NCT04938141||Acalabrutinib|CLL patients initiating acalabrutinib alone or in combination with an anti-CD20 mAb
9896005|NCT04938141||Ibrutinib|CLL patients receiving ibrutinib alone or in combination with an anti-CD20 mAb
9896006|NCT04937556|Active Comparator|Probiotic: Lactobacillus salivarius + Vit D + Zinc|Lactobacillus strain during 28 days, approximately 1*10E9 colony forming unit (CFU) of L. salivarius in 1 capsule per day.
9896007|NCT04937556|Placebo Comparator|Placebo|Placebo supplement in 1 capsule per day during 28 days.
9896008|NCT04934553|Experimental|Amplification of Positivity for Alcohol Use Disorders (AMP-A; 12 sessions)|
9896009|NCT04934553|Active Comparator|Cognitive-behavioral Therapy (CBT; 12 sessions)|
9896010|NCT04933968|Placebo Comparator|Placebo|Placebo, visually identical to ALVR106
9896011|NCT04933968|Active Comparator|ALVR106|ALVR106, visually identical to placebo
9896012|NCT04931602||Model A|"Patients will be followed-up at bone, endocrine and rheumatology clinic after discharge depending upon availability of the consultant. Multifaceted risk-factor assessment for identifying patients at risk will be conducted including formal future fracture risk assessment/life style/medication review and fall risk assessment.~Comprehensive laboratory designed package including calcium (Ca), albumin (ALB), phosphate (P), bone alkaline phosphatase (BAP), C terminal peptide of type 1 collagen (CTx), vitamin D (25OHD) and intact parathyroid hormone (iPTH) will be performed at first clinic visit for all patients between 6-8 weeks post fracture. Screening for secondary causes of osteoporosis will be conducted for those identified in need. BMD testing as per guidelines for patients with fragility fractures will be conducted at clinic visit and recorded with risk assessment form (12)."
9896013|NCT04931602||Model B|All routine intervention except treatment initiation-the responsibility of patient's general practitioner for prevention of secondary fracture. Those included in this intervention arm, will be identified and risk assessment will be performed at hospital admission. Recommendations for the treatment will be made to be initiated by the patient's general physician. Patients will be followed at 6 months on telephone, and a questionnaire related to treatment compliance &/or non-compliance will be filled by the coordinator.
9896014|NCT04931602||Model C|Health education only provided at the time of admission with handover to family physician for follow-up. Patients will be given an appointment to follow-up at community health center of Aga Khan University
9896015|NCT04931602||Model D|Health Education provided. There is no physician contact with the person's general practitioner for prevention of secondary fracture. Education material for the patient have been prepared and will be provided to patient along with counselling by the nurse at the time of discharge
9896016|NCT04931082|Active Comparator|Probiotics|One capsule per day for 12 weeks
9896017|NCT04931082|Placebo Comparator|Placebo|One capsule per day for 12 weeks
9896018|NCT04928846|Experimental|Telisotuzumab Vedotin|Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
9896019|NCT04928846|Active Comparator|Docetaxel|Participants will receive docetaxel every 3 weeks until meeting study drug discontinuation criteria.
9896020|NCT04925609|Other|Phase 1|"Phase 1:~To estimate the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~To characterize the PK of brigatinib administered as monotherapy in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~Note that:~If the MTD is not reached at the highest proposed test dose, no further dose-escalation will be performed.~Pediatric PK data, compared to exposure in adults, and cumulative toxicity, will be taken into consideration to determine the RP2D regimen."
9896021|NCT04925609|Other|Phase 2|"Phase 2:~• B1, ALK+ IMT: To establish the activity (ORR by RECIST 1.1) of single agent brigatinib when administered to children with ALK+ IMT.~• B2, ALK+ ALCL: To establish the efficacy (EFS) of single agent brigatinib when administered to children with ALK+ ALCL for a duration of 2 years, without SCT in consolidation."
9896022|NCT04922554|Experimental|Omadacycline 300 mg PO|omadacycline 150 mg tablets (x 2) administered orally, once daily, q24h
9896023|NCT04922554|Placebo Comparator|Placebo PO|Placebo tablets resembling omadacycline (x 2) administered once daily, q24h
9896024|NCT04921943|Experimental|Hypertonic saline|Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.
9896025|NCT04921943|Active Comparator|Standard of Care|Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.
9896026|NCT04921358|Experimental|Arm A: Tislelizumab in combination with Sitravatinib|tislelizumab 200 mg intravenously once every 3 weeks in combination with sitravatinib 100 mg orally once a day
9896027|NCT04921358|Active Comparator|Arm B: Docetaxel|docetaxel 75 mg/m2 intravenously once every 3 weeks
9517491|NCT03305913|Experimental|Dose Level -2a|TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
9517773|NCT03303066|Placebo Comparator|Placebo (Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
9517774|NCT03303053|Experimental|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
9896028|NCT04919499|Experimental|Part A: BI 765128 low dose|
9896029|NCT04919499|Experimental|Part A: BI 765128 medium dose|
9896030|NCT04919499|Experimental|Part A: BI 765128 high dose|
9896031|NCT04919499|Experimental|Part B: BI 765128|Highest safe dose from Part A
9896032|NCT04919499|Sham Comparator|Part B: Sham comparator|
9896033|NCT04919343|Experimental|BBC Tiny Happy People intervention|Parents will be sent links each month directing them to BBC Tiny Happy People content via SMS text message using the secure service FireText. This content will be aimed at supporting language development. Parents will be asked to watch the video content and incorporate it into their parenting practices. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits.
9896034|NCT04919343|Active Comparator|Physical health control|Similar to the experimental condition, parents will be sent links each month via SMS text message using FireText. These links will direct them to publicly available web content with tips to promote the healthy development of their baby, focusing on things such as healthy eating, physical activities, and dental care. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits
9896035|NCT04919122||Patients with metastatic renal cell cancer (mRCC) with no prior systemic therapy for mRCC|This is an observational cohort.
9896036|NCT04919096|Experimental|SCB-420|Subjects randomized to SCB-420 will receive SCB-420 2mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
9896037|NCT04919096|Active Comparator|Aflibercept|Subjects randomized into Aflibercept (Eylea) group will receive Aflibercept (Eylea) 2 mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
9896038|NCT04915755|Experimental|Cohort1:Participants with tBRCAmut HER2-breast cancer(Independent of HR status,including HR+andTNBC)|Eligible participants will receive either Niraparib or Placebo.
9896039|NCT04915755|Experimental|Cohort 2: Participants with tBRCAwt TNBC|Eligible participants will receive either Niraparib or Placebo.
9896040|NCT04915729|Experimental|tenecteplase|Treatment Group
9896041|NCT04915729|Active Comparator|alteplase|Active control group
9896042|NCT04915027|Experimental|Intervention i.e. with Rehabkompassen®|The participants will use the digital graphic Rehabkompassen® at follow-up.
9896043|NCT04915027|Active Comparator|Control exposure i.e. without Rehabkompassen®|"The participants will use Post-Stroke Checklist at follow-up as recommended by Socialstyrelsen."
9896044|NCT04914780|Experimental|Intervention group|4 weeks training with mobile application
9896045|NCT04914780|No Intervention|Control group|No intervention will be made for 4 weeks
9896046|NCT04914208|Active Comparator|Wearing a face mask for 4 hours|Participants are wearing different kinds of face masks for 4 hours each. Masks are worn on different days and the order is randomly assigned.
9896047|NCT04914208|Other|4 hours without wearing a face mask|Participants do not wear any face mask for 4 hours.
9896048|NCT04914000|Experimental|Self Help Materials|Participants will receive a smoking cessation booklet/pamphlet corresponding to their cancer type.
9896049|NCT04913584|Experimental|Immediate Intervention|Online Group CBT for PPD. Women in the treatment group will attend an online 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by eight lay-peers.
9896050|NCT04913584|Experimental|Wait-List Controls|Online Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however, they will begin the CBT group 9 weeks after enrolling in the study.
9896051|NCT04909697|Sham Comparator|Saline|
9896052|NCT04909697|Experimental|Sivelestat Sodium|
9896053|NCT04906707|Experimental|EaseVRx Group|Participants will be asked to complete the 8-week program with assigned modules each week. Each week, participants will be asked to complete 7 modules, averaging 5 minutes in duration and ranging from 2 to 16 minutes in duration, for a total of 56 modules across the program. Participants will be instructed not to use the device while ambulating, and that they should use the headset a maximum of 3 times per 24-hour period (morning, noon, and evening) for not more than 30 minutes consecutively.
9517492|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
9896054|NCT04906707|Active Comparator|Active control Group|Participants in the control group will be asked to use the audio-only version of EaseVRx that excludes references to visual content. They will receive an electronic link to the audio recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer. Each week, participants will be asked to complete 7 audio sessions.
9896055|NCT04906239|Active Comparator|Group ESP|While the patient is in a sitting position, A ultrasound probe covered with a sterile sheath will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After the T 4-5 transverse process and the erector spinae muscle above it are shown, a quincke-type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal with the entrance made using the in-plane technique. When the transverse process is touched, the needle will be pulled out and a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.The same procedure will be repeated on the contralateral side of the T5 spinous process and half of the remaining bupivacaine dose will be injected. The total volume of bupivacaine injected on both sides will be 20 mL.
9896056|NCT04906239|No Intervention|Group Control|"No block will be made to the control group.~After extubation, 1mg / kg tramadol will be applied routinely to both groups, and PCA (Patient Control Analgesia) and morphine consumption and VAS (visual analog scale) pain scores of both groups will be evaluated and recorded at the 1st, 4th, 12th and 24th hour. When VAS is 3, patients will be advised to press the PCA device."
9896057|NCT04904471|Experimental|Experimental|Three doses of recombinant SARS-CoV-2 vaccine (Sf9 Cell) on Day 0, Day 21and Day 42.
9896058|NCT04904471|Placebo Comparator|Placebo Comparator|Three doses of placebo on Day 0, Day 21and Day 42.
9896059|NCT04900935|Experimental|POISE|"The intervention will be a structured palliative care intervention in which patients will meet with a palliative care clinician who has been trained on a manual with specific topics to be covered in each of the four visits:~Three surveys: baseline, 12-week, and 24-week post-enrollment~Four 60-minute visits with a trained palliative care clinician~Semi-structured exit interview~Chart review"
9896060|NCT04900376||vaccinated group|
9896061|NCT04900376||unvaccinated group|
9896062|NCT04898894|Experimental|Treatment|"Dose Escalation Phase:~Venetoclax plus selinexor will initially be given at dose level 1 in combination with intravenous (IV) cytarabine and fludarabine. Dosing of venetoclax and selinexor will be based on tolerability.~Intrathecal (IT) chemotherapy (IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are all acceptable) will be given.~G-CSF SC may be given.~Dose Expansion Phase:~Two expansion cohorts will be treated at the recommended phase 2 dose (RP2D). Cohort A will include venetoclax-naïve patients, whereas Cohort B will include patients with prior exposure to venetoclax."
9896063|NCT04895436|Experimental|Cohort 1 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.
9896064|NCT04895436|Experimental|Cohort 2 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.
9896065|NCT04894006|Experimental|Home visit intervention by community health workers|The caregiver-centered, culturally and language specific home visit intervention with wearable devices (smartwatch/ring) will be delivered by trained bilingual community health workers (CHW) for Latino, Vietnamese, Korean, non-Hispanic White caregivers of PWD. The home visit intervention components will include (1) stress reduction techniques; mindful breathing and compassionate support/listening and (2) weekly education on dementia caregiving skills to handle difficult behaviors of PWD and knowledge of resources available for dementia care. The duration of the intervention will be 12 weeks that include 6 home visits (4 times for the first month and then once a month for two months) carried out in the participant's home. The on-site home visit intervention delivered by CHWs will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions.
9896066|NCT04894006|Active Comparator|Attention Control with wearable smartwatch/ring|The caregivers randomly assigned to the Attention Control (AC) group will be asked to wear smartwatch during the day time and smart ring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months asking about the WIoT technology and answering general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
9896067|NCT04894006|Placebo Comparator|Usual Care Group|The caregivers randomly assigned to Usual Care (UC) group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. At recruitment, the participants will be told that at the end of the 6 months they will receive a smartwatch and a smartring for their participation. CHWs will contact them monthly for 6 months by phone answering only general questions from participants. CHW will also visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
10213851|NCT02950259|Experimental|IRX-2 Regimen -Early Stage Breast Cancer|Enrolled subjects with early stage breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
9896070|NCT04893083||LRRK2 Mutant PD|Patients with a G2019S mutation
9896071|NCT04893083||LRRK2 Wild Type PD Low burden|Patients with a low burden of genetic modifiers
9896072|NCT04893083||LRRK2 Wild Type High burden|Patients with a high burden of genetic modifiers
9896073|NCT04893018|Experimental|Treatment (efineptakin alfa)|Patients receive efineptakin alfa IM on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9896074|NCT04892524|Experimental|Virtual multidisciplinary review|Participants in this arm will be reviewed in a virtual clinic by a multidisciplinary team
9896075|NCT04892524|No Intervention|Face-to-face review|Participants in this group will be reviewed in a face-to-face clinic
9896076|NCT04892043|Experimental|Part 1 Monotherapy Dose Escalation Phase|"In Part 1, SQZ-AAC-HPV as a monotherapy is administered every 3 weeks for up to a year.~There are 3 groups (Cohorts) in this Phase as follows:~Cohort 1a: low dose SQZ-AAC-HPV~Cohort 1b: intermediate dose SQZ-AAC-HPV~Cohort 1c: high dose SQZ-AAC-HPV"
9896077|NCT04892043|Experimental|Part 2 Combination Safety Phase|"In Part 2, SQZ-AAC-HPV in combination with immune checkpoint inhibitors (1) ipilimumab, (2) nivolumab, or (3) nivolumab plus ipilimumab is administered every 3 weeks up to a year, but the immune checkpoint inhibitors may be administered up to 2 years. There are 3 groups (Cohorts) in this Phase as follows:~Cohort 2a: SQZ-AAC-HPV RP2D (Recommended Phase 2 Dose) plus ipilimumab~Cohort 2b: SQZ-AAC-HPV RP2D plus nivolumab~Cohort 2c: SQZ-AAC-HPV RP2D plus nivolumab and ipilimumab"
9896078|NCT04890249|Experimental|Investigational Lens Device #1|Investigational IOL Model C1V000
9896079|NCT04890249|Experimental|Investigational Lens Device #2|Investigational IOL Model C2V000
9896080|NCT04890249|Active Comparator|Control Lens|Control IOL Model ICB00
9896081|NCT04889989|Other|Microwave Ablation of Lung Tumor|Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors who plan to receive percutaneous microwave ablation.
9896082|NCT04888832|No Intervention|Control Group|No change to work requirements or recertification period
9896083|NCT04888832|Active Comparator|Intervention Group 1|Standard 6-month recertification period, additional 6-month work requirement exemption
9896084|NCT04888832|Active Comparator|Intervention Group 2|Standard 6-month recertification period, additional 12-month work requirement exemption
9896085|NCT04888832|Active Comparator|Intervention Group 3|Standard 6-month recertification period, additional 12-month work requirement exemption
9896086|NCT04888832|Active Comparator|Intervention Group 4|12-month recertification period (6-month extension), additional 6-month work requirement exemption
9896087|NCT04888195||Questionnaire|This study aims to examine the cancer patient's symptom clusters and their changes over chemotherapy among pediatric patients with blood cancer in Hong Kong
9896088|NCT04887298|Experimental|Liposomal Annamycin (L-Annamycin)|
9896089|NCT04887038|Active Comparator|Drug :SRT-015|Experimental, Single and Multiple Oral escalating dose and Food Effect Cohort
9896090|NCT04887038|Placebo Comparator|Matching Placebo for SRT-015|
9896091|NCT04886804|Experimental|Phase Ia - Dose escalation part|Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.
9896092|NCT04886804|Experimental|Phase Ib - Dose expansion part|
9896093|NCT04882449|Experimental|Bodyport Scale|All subjects will be given the Bodyport scale to use
9896094|NCT04882124|Experimental|CSJ117 8mg|Intervention: Drug: CSJ117
9896095|NCT04882124|Experimental|CSJ117 4mg|Intervention: Drug: CSJ117
9896096|NCT04882124|Placebo Comparator|CSJ117 Placebo|Intervention: Drug: Placebo
9896097|NCT04881760|Experimental|LY3437943 Dose 1|LY3437943 administered subcutaneously (SC)
9896098|NCT04881760|Experimental|LY3437943 Dose 2|LY3437943 administered SC
9896099|NCT04881760|Experimental|LY3437943 Dose 3|LY3437943 administered SC
9896100|NCT04881760|Experimental|LY3437943 Dose 4|LY3437943 administered SC
9896101|NCT04881760|Placebo Comparator|Placebo|Placebo administered SC
9896102|NCT04879979|Experimental|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) designed for the treatment of Cancer-Related Cognitive Impairment (CRCI)
9896103|NCT04877847|Experimental|Low-Frequency Therapeutic Ultrasound|LOTUS system will be operated per operated per normal instructions
9896104|NCT04877847|Sham Comparator|Sham Control|LOTUS system will be set to Control setting
9896105|NCT04877782||Healthy older participants|Healthy older participants receiving both stimulation conditions (experimental and placebo) randomized across scanning sessions.
9896106|NCT04876937|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1-0.2 ug/kg/h during mechanical ventilation, for a maximum of 7 days.
9896107|NCT04876937|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 7 days.
9896108|NCT04875533|Experimental|20vPnC/Saline|20vPnC and saline
9896109|NCT04875533|Active Comparator|13vPnC/PPSV23|13vPnC and PPSV23
9896110|NCT04875507|Active Comparator|Positive psychology|The experimental group(n=60), who will receive a 1.5-hour workshop covering positive psychology techniques delivered by a qualified research assistant, in groups of less than 5 people.
9896111|NCT04875507|No Intervention|Control|The control group will receive no intervention.
9896112|NCT04875234||Legally Blind Dry AMD Patients|Legally Blind Dry AMD Patients with either unilateral or bilateral blindness
9896113|NCT04871919||Filgotinib|Individuals will receive treatment for moderate to severe active rheumatoid arthritis with at least one dose of filgotinib in accordance with the product label
9896114|NCT04870658||Complication|Any patients with biological or mechanical complication in dental implant treatment.
9896115|NCT04869189|Experimental|High Sphere-Game/Video/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively.
9896116|NCT04869189|Experimental|High Sphere-VA/Video/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
9896117|NCT04869189|Experimental|High Sphere-VA/Game/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
9896118|NCT04869189|Experimental|High Sphere-Game/VA/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
9896119|NCT04869189|Experimental|High Sphere-Video/VA/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
9896120|NCT04869189|Experimental|High Sphere-Video/Game/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
9896121|NCT04869189|Experimental|Low Sphere-Game/Video/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video, or continuous VA test).
9896122|NCT04869189|Experimental|Low Sphere-VA/Video/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game).
9896123|NCT04869189|Experimental|Low Sphere-VA/Game/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video).
9896124|NCT04869189|Experimental|Low Sphere-Game/VA/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video).
9896125|NCT04869189|Experimental|Low Sphere-Video/VA/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game).
9896126|NCT04869189|Experimental|Low Sphere-Video/Game/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test).
9896127|NCT04864834|Experimental|SOK583A1 (40 mg/mL)|Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
9991829|NCT01456572|Active Comparator|hormone profiles_obese weight|Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
9991830|NCT01456572|Placebo Comparator|hormone profiles_normal weight|Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
9991831|NCT01456598|Experimental|Laparoscopic gastrectomy|Laparoscopic subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
9991832|NCT01456598|Active Comparator|Open gastrectomy|Open subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
9991833|NCT01456611|Experimental|Diclofenac Sodium Gel|Diclofenac sodium Topical Gel 1%
9991834|NCT01456611|Active Comparator|Voltaren (R) Gel|Voltaren (R) Gel 1%
9991835|NCT01456611|Placebo Comparator|Placebo|Placebo Topical Gel
9991836|NCT01456624|Active Comparator|Megace / Fasting condition|800mg
9991837|NCT01456624|Experimental|DW-ES(B) / Fasting condition|625mg
9991838|NCT01456624|Active Comparator|Megace / Fed condition|800mg
9991839|NCT01456624|Experimental|DW-ES(B) / Fed condition|625mg
9991840|NCT01456637|Experimental|CBT for insomnia with feedback|In this arm participants received internet based self-help CBT for insomnia with e-mail feedback form a therapist.
9991841|NCT01456637|Experimental|CBT for insomnia without feedback|In this arm participants receive internet based self-help CBT for insomnia without feedback from a therapist.
9991842|NCT01456650|Experimental|Glyburide|Patients in which the fasting glucose persisted above the treatment goal (fasting glucose <126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
9991843|NCT01456663|Experimental|AFQ056|
9991844|NCT01456676|Experimental|Nilotinib + LDE225|The planned dose of nilotinib 400 mg b.i.d (twice a day) was selected for the combination as this is the dose approved for the treatment of the patient population that will be included in the present study. The starting dose for LDE225 chosen for the current study is 400 mg once daily(q.d.). The maximum dose of LDE225 that will be tested in combination with nilotinib is 800 mg once dail.y
9991845|NCT01456689|Experimental|LGH447|Eligible patients will be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
9991846|NCT01456689|Experimental|LGH447 and midazolam|Eligible patients will receive midazolam on two separate days, the first dose will be administered prior to the start of LGH447 and the second will be co-administered with LGH447. After that, the patients will continue to be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
9991847|NCT01456702|No Intervention|control arm|volume therapy via standard operating procedure
9991848|NCT01456702|Experimental|intervention arm|goal-directed volume therapy due to svv in dependence of preoperative risk stratefication
9991849|NCT01456715|Active Comparator|Gardasil, Immunogenicity, Booster dose.|
9991850|NCT01456715|Experimental|Cervarix, Immunogenicity, Booster dose.|
9991851|NCT01456728|Experimental|Progastria|One chewable tablet of the study product is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day together with omeprazole 2x20mg. The study product and omeprazole will be taken daily for 28 consecutive days.
9991852|NCT01456728|Placebo Comparator|Placebo|The placebo will have identical appearance and taste with the study product only lacking the bacteria. All subjects from this group will receive 2 x 20 mg omeprazole per day and Placebo 1 chewable tablet per day for 28 days.
9991853|NCT01456741|Experimental|1-EBNA with ROSE|
9991854|NCT01456741|Experimental|1-EBNA without ROSE|
9991855|NCT01456754|Experimental|High feeding frequency (14x)|
9991856|NCT01456754|Experimental|low feeding frequency (3x)|
9991857|NCT01456767|Active Comparator|Lactobacillus plantarum WCFS1|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum WCFS1).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
9991858|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104448|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104448).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
9991859|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104450|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104450).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
9998225|NCT01516281||mTBI-|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of disorders other than mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI- subjects are randomly selected for clinical assessment and DaTscan.
9896128|NCT04864834|Active Comparator|Eylea EU (40 mg/mL)|"IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.~EU: European"
9896129|NCT04862156|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions for Use.
9896130|NCT04861805|Other|Vienna Aortic Valve|transcatheter aortic valve implantation (TAVI)
9896131|NCT04861181|Experimental|Pharmacokinetics, Dosage of Niraparib|Patients received 3 cycles of Niraparib (200 mg or 300 mg/day). Each cycle lasts 28 days. Serum niraparib assays will be performed for all patients over 3 courses immediately prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
9896132|NCT04856982|No Intervention|Part A: Natural History Run-in|Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess neurofilament light chain (NfL) levels.
9896133|NCT04856982|Experimental|Part B: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive BIIB067 100 milligram (mg) or placebo via intrathecal (IT) injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
9896134|NCT04856982|Experimental|Part C: Open-Label Extension|Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive BIIB067 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years. Participants who received BIIB067 during Part B will receive BIIB067 100 mg on Days 1, 29, and every 28 days thereafter for up to 2 years, with a dose of placebo on Day 15 to maintain the study blind.
9896135|NCT04856982|Experimental|Part D: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will be randomized to receive BIIB067 100 mg or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
9896136|NCT04856631|Experimental|Experimental group|Toripalimab Injection (JS001) + Cetuximab
9896137|NCT04856085|Experimental|Cohort 1a (VIR-2218 + VIR-3434)|Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
9896138|NCT04856085|Experimental|Cohort 2a (VIR-2218 + VIR-3434)|Subjects will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
9896139|NCT04856085|Experimental|Cohort 3a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
9896140|NCT04856085|Experimental|Cohort 4a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
9896141|NCT04856085|Experimental|Cohort 5a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
9896142|NCT04856085|Experimental|Cohort 6a (VIR-2218 + VIR-3434)|Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
9896143|NCT04856085|Experimental|Cohort 7a (VIR-2218 + VIR-3434)|Subjects will be randomized 3:2:2 to Cohort 7a, 8a, or 1c respectively. Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks
9896144|NCT04856085|Experimental|Cohort 8a (VIR-2218 + VIR-3434)|Subjects will be randomized 3:2:2 to Cohort 7a, 8a, or 1c respectively. Subjects will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks
9896145|NCT04856085|Experimental|Cohort 1b (VIR-3434)|Subjects will receive multiple doses of VIR-3434 for 44 weeks
9896146|NCT04856085|Experimental|Cohort 2b (VIR-3434)|Subjects will receive multiple doses of VIR-3434 for 20 weeks
9896147|NCT04856085|Experimental|Cohort 1c (VIR-2218 + VIR-3434)|Subjects will be randomized 3:2:2 to Cohort 7a, 8a, or 1c respectively. Subjects will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks
9797867|NCT01609556|Experimental|Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)|Participants will receive mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation for this group schedule will start at 1.1 mg/kg (calculated based on AIBW) and proceed through 2.5 mg/kg. Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
9797868|NCT01609556|Experimental|Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)|Participants with epithelial ovarian cancer (EOC) will receive mirvetuximab soravtansine 6.0 mg/kg (maximum tolerated dose [MTD]) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminated the study.
9797869|NCT01609556|Experimental|Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)|Participants with endometrial cancer (EC) will receive mirvetuximab soravtansine 6.0 mg/kg (MTD) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
9797870|NCT01609582|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 6 years.
9797871|NCT01609582|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 6 years.
9797872|NCT01609933|Experimental|2-DAA + PegIFN/RBV|2-direct-acting antiviral (2-DAA: ABT-450 [paritaprevir] 200 mg once daily [QD], ritonavir 100 mg QD, ABT-267 [ombitasvir] 25 mg QD) plus pegylated interferon alpha-2a (pegIFN) 180 mcg once weekly and Ribavirin (RBV) weight-based dosing, 1000 to 1200 mg divided twice daily (BID) for 24 weeks (Substudy 1) and followed by pegIFN and RBV alone for an additional 24 weeks (Substudy 2).
9797873|NCT01610011|Experimental|Glycine administration|Glycine will be administered once orally to all subjects to determine brain and plasma pharmacodynamics.
9797874|NCT01610037|Experimental|QVA149|
9797875|NCT01610037|Active Comparator|Tiotropium|
9797876|NCT01610037|Placebo Comparator|placebo|
9797877|NCT01610063|Experimental|Guided|A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
9797878|NCT01610063|No Intervention|Unguided|Treatment as usual
9797879|NCT01610076|No Intervention|No Video - Control|"This group does not watch the 10 minute code status video before having the knowledge base video administered."
9797880|NCT01610076|Experimental|Code Status Video|"This group views a 10 minute video about code status prior to knowledge base survey administration"
9797881|NCT01610154|Experimental|Sitagliptin treatment|
9797882|NCT01610167|Active Comparator|NUPRO(r) Classic Prophy Paste|
9797883|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.|
9797884|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin|
9797885|NCT01610206|Active Comparator|gemcitabine|
9797886|NCT01610206|Experimental|Gemcitabine + pazopanib|
9797887|NCT01610271|Experimental|Air Barrier System|The Air Barrier System will be employed throughout the surgical procedure for this group of patients.
9797888|NCT01610271|No Intervention|Control|The Air Barrier System will not be used during the surgical procedure for this group of patients.
9797889|NCT01610284|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
9797890|NCT01610284|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
9797891|NCT01610297|Experimental|ICL670|Oral dose of ICL670 at 10 mg/kg daily
9797892|NCT01610336|Experimental|INC280 100 mg Cap QD Phase Ib|cap=capsule; QD=once daily
9797893|NCT01610336|Experimental|INC280 200 mg Cap QD Phase Ib|cap=capsule; QD=once daily
9797894|NCT01610336|Experimental|INC280 400 mg Cap QD Phase Ib|cap=capsule; QD=once daily
9797895|NCT01610336|Experimental|INC280 800 mg Cap QD Phase Ib|cap=capsule; QD=once daily
9797896|NCT01610336|Experimental|INC280 200 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
9797897|NCT01610336|Experimental|INC280 400 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
9797898|NCT01610336|Experimental|INC280 600 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
9797899|NCT01610336|Experimental|INC280 200 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
9797900|NCT01610336|Experimental|INC280 400 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
9797901|NCT01610336|Experimental|INC280 400 mg Cap BID Phase II|cap=capsule; BID=twice daily
9797902|NCT01610336|Experimental|INC280 400 mg Tab BID Phase II|tab=tablet; BID=twice daily
9797903|NCT01610414|Experimental|GSK1437173A Group|Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
9797904|NCT01610414|Placebo Comparator|Placebo Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
9797905|NCT01610427|Experimental|HIV-1 Group|Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected. No investigational vaccine was administered.
9797906|NCT01610453||ultrasound|primiparous women with prolonged labours will be eligible for examination
9896148|NCT04854499|Experimental|Safety Run-in Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum|"Participants with untreated metastatic or unresectable, locally recurrent head and neck squamous cell carcinoma (HNSCC) regardless of programmed cell death ligand 1 (PD-L1) status will receive the following:~magrolimab~pembrolizumab 200 mg on Day 1 of each cycle~5-fluorouracil (5-FU) 1000 mg/m^2/day Days 1-4 of each cycle (for up to 6 cycles)~platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin area under the concentration versus time curve (AUC) 5 per investigator choice (for up to 6 cycles))~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the recommended Phase 2 dose (RP2D) is determined. Each cycle is 21 days."
9896149|NCT04854499|Experimental|Safety Run-in Cohort 2, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive the following:~magrolimab~docetaxel 75 mg/m^2 on Day 1 of each cycle~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
9896150|NCT04854499|Experimental|Pre-expansion Safety Run-in Cohort, Magrolimab + Pembrolizumab|"The pre-expansion safety run-in cohort may be conducted at the sponsor's discretion prior to the initiation of Phase 2 Cohort 2.~Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.~Participants will continue treatment until unacceptable toxicity or disease progression, whichever occurs first, and will not change their magrolimab dose level after the RP2D is determined. Each cycle is 21 days."
9896151|NCT04854499|Experimental|Phase 2 Cohort 1, Magrolimab + Pembrolizumab + 5-FU + Platinum (Arm A)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
9896152|NCT04854499|Active Comparator|Phase 2 Cohort 1, Pembrolizumab + 5-FU + Platinum (Arm B)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive pembrolizumab 200 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
9896153|NCT04854499|Experimental|Phase 2 Cohort 1, Magrolimab + Zimberelimab + 5-FU + Platinum (Arm C)|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC regardless of PD-L1 status will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, zimberelimab 360 mg on Day 1 of each cycle, 5-FU 1000 mg/m^2/day Days 1-4 of each cycle, and platinum chemotherapy (cisplatin 100 mg/m^2 or carboplatin AUC 5 per investigator choice). Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Zimberelimab therapy will be administered until loss of clinical benefit or unacceptable toxicity, whichever occurs first. 5-FU and platinum chemotherapy will be administered for up to 6 cycles or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
9896154|NCT04854499|Experimental|Phase 2 Cohort 2, Magrolimab + Pembrolizumab|"Participants with untreated metastatic or unresectable, locally recurrent HNSCC with a PD-L1 combined positive score (CPS) ≥ 1 will receive magrolimab at the RP2D determined in the Safety run-in cohort 1 and pembrolizumab 200 mg on Day 1 of each cycle. Each cycle is 21 days.~Magrolimab will be continued until loss of clinical benefit, unacceptable toxicity, or death. Pembrolizumab therapy will be administered for up to 24 months or until loss of clinical benefit or unacceptable toxicity, whichever occurs first."
9896155|NCT04854499|Experimental|Phase 2 Cohort 3, Magrolimab + Docetaxel|"Participants with locally advanced/metastatic HNSCC regardless of PD-L1 status who were previously treated with at least 1 and no more than 2 lines of prior systemic therapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and docetaxel 75 mg/m^2 on Day 1 of each cycle. Each cycle is 21 days.~Magrolimab and docetaxel will be continued until loss of clinical benefit, unacceptable toxicity, or death."
9896156|NCT04848597|Experimental|Single Arm|Recombinant humanized anti-PD-1 monoclonal antibody injection:200mg once every 3 weeks
9896157|NCT04847557|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
9896158|NCT04847557|Placebo Comparator|Placebo|Placebo administered SC
9896159|NCT04847232|Experimental|Sodium Zirconium Cyclosilicate|
9896160|NCT04847232|Placebo Comparator|Placebo|
9896161|NCT04846881|Experimental|BI 425809|
9896162|NCT04846881|Placebo Comparator|Placebo|
9896163|NCT04846803|Experimental|Patients prophylatic treated with ABU|Patients with prophylactic bladder flushing with an ABU strain.
9896164|NCT04846803|Placebo Comparator|Patients control group|The control group with bladder flushing with saline solution.
9896165|NCT04844606|Experimental|Mirikizumab Dose 1 for UC|"Dose 1 of Mirikizumab is administered subcutaneously (SC)~Dosing is based on the participant's weight."
9896166|NCT04844606|Experimental|Mirikizumab Dose 2 for UC|"Dose 2 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
9896167|NCT04844606|Experimental|Mirikizumab Dose 3 for UC|"Dose 3 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
9896168|NCT04844606|Experimental|Mirikizumab Dose 4 for CD|"Dose 4 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
9896169|NCT04844606|Experimental|Mirikizumab Dose 5 for CD|"Dose 5 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
9896170|NCT04844606|Experimental|Mirikizumab Dose 6 for CD|"Dose 6 of Mirikizumab is administered SC~Dosing is based on the participant's weight."
9896171|NCT04844463|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive a single ascending oral dose of JNJ-68179280 or placebo capsules under fasted condition (Cohort 1, 2 and 5) and under fasted-fed condition (either Cohort 3 or 4) on Day 1. In 1 of the study cohorts 3 or 4, participants will also receive study intervention on Day 8 under fed condition. One additional optional Cohort 6 may be dosed to assess the safety and pharmacokinetics (PK) of an alternate dose of formulation A under fasted condition.
9896172|NCT04844463|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive multiple ascending oral doses of JNJ-68179280 or placebo capsules once daily in Cohort 1 through 4 or twice daily in Cohort 5 (optional) on Days 1 through 14 under fasted or fed condition.
9896173|NCT04844463|Experimental|Part 3: Multiple Dose Alternative Formulation (Optional)|Participants will receive multiple oral doses of an alternative JNJ-68179280 formulation once daily in Cohort 1 and Cohort 2 (optional) on Days 1 through 14 under fasted or fed condition. Doses in Part 3 will depend on the safety, tolerability, PK and pharmacodynamics data from Part 1 and Part 2.
9896175|NCT04841902|Experimental|Life Style Intervention Manual (Supervised)|Supervised Exercises with Life Style Intervention Manual (Dietary & Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of alternating light to moderate intensity aerobic exercises including warm up and rest interval
9896176|NCT04841902|Experimental|Life Style Intervention Manual (Home Based)|Home Based- Life Style Intervention Manual (Exercise, Dietary & Educational Component for 16 weeks. Subject will be asked to maintain a regular exercise and dietary diary to ensure adherence to the program
9896177|NCT04841902|Placebo Comparator|Control|Age matched Control Group followed for 16 weeks with General Advise to stay healthy and active
9896178|NCT04840914|Experimental|LY3461767|LY3461767 administered subcutaneously (SC).
9896179|NCT04840914|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC).
9896180|NCT04840602|Active Comparator|Arm I (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24 and rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm I may receive ibrutinib, rituximab, and venetoclax as in Arm II for up to an additional 24 cycles.
9896181|NCT04840602|Experimental|Arm II (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24, rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5, and venetoclax PO QD on days 1-28 of cycles 2-24. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9896182|NCT04838639|Experimental|NO-13065, oral tablet|
9896183|NCT04838639|Placebo Comparator|Placebo matched to NO-13065, oral tablet|
9896184|NCT04836988||Digitally delivered osteoarthritis treatment|Participants enrolled in the digitally delivered osteoarthritis managament program (Joint Academy register)
9896185|NCT04836988||Face-to-face delivered osteoarthritis treatment|Participants enrolled in the face-to-face delivered osteoarthritis managament program (BOA-register)
9896186|NCT04836416||Young Adult/Normal|Age 18-35, BMI 18.5-24.9
9896187|NCT04836416||Young Adult/Overweight and Obese|Age18-35, BMI greater than 25.0
9896188|NCT04836416||Adult/Normal|Age 36-50, BMI 18.5-24.9
9896189|NCT04836416||Adult/Overweight and Obese|Age 36-50, BMI greater than 25.0
9896190|NCT04836416||Older Adult/Nornal|Age 51-65, BMI 18.5-24.9
9896191|NCT04836416||Older Adult/Overweight and Obese|Age 51-65, BMI greater than 25.0
9896192|NCT04835766||Symptomatic group|These patients had bladder injury during PAS surgery and had Lower urinary tract symptoms
9896193|NCT04835766||Asymptomatic group|These patients had bladder injury during PAS surgery and had no Lower urinary tract symptoms
9896194|NCT04835714|Experimental|Part A with Monotherapy dose escalation|
9896195|NCT04835714|Experimental|Part B with Combination therapy dose escalation|
9896196|NCT04835714|Experimental|Part C with Combination therapy dose confirmation|
9896197|NCT04835714|Experimental|Part D with Combination therapy dose expansion|
9896198|NCT04834778|Experimental|Cohort 1 - 25 mg|25 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
9896199|NCT04834778|Experimental|Cohort 2 - 50 mg|50 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
9896200|NCT04834778|Experimental|Cohort 3 - 100 mg|100 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
9896201|NCT04834778|Experimental|Cohort 4 - 200 mg|200 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
9896202|NCT04834778|Experimental|Cohort 5 - 400 mg|400 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
9896203|NCT04834778|Experimental|Cohort 6 - 600 mg|600 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
9896204|NCT04834778|Experimental|Cohort 7 - 900 mg|900 mg capsules of HC-5404-FU administered orally twice a day with food or within 30 minutes of completing a meal of each 3-week treatment cycle
9896205|NCT04833894|Experimental|Efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
9896206|NCT04831411|Active Comparator|Whole Body Vibration|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive whole-body vibration training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
9896207|NCT04831411|Active Comparator|Progressive Resistance Training|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive resistance training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
9896208|NCT04830553|Experimental|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
9896209|NCT04830553|No Intervention|Waiting list.|Each couple will go through an initial waiting period before the treatment phase. Duration of the waiting period: five weeks.
9896210|NCT04824118||Group 1: Gestation less than 10 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
9896211|NCT04824118||Group 2: Gestation 10-14 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
9896212|NCT04824118||Group 3: Gestation 14-20 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
9896213|NCT04824118||Group 4: Non-pregnant controls|Blood tests at baseline only.
9896214|NCT04824079|Experimental|Keynatinib treatment group|All subjects shall be treated with Keynatinib twice a day (once every 12±3 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. Every 21 days is a treatment cycle .
9896215|NCT04823650||Ages 3-5|
9896216|NCT04823650||Ages 6-11|
9896217|NCT04823650||Ages 12-17|
9896218|NCT04822298|Experimental|Part 1: Dose Exploration|The dose exploration part of the study will estimate the MTD and/or the RP2D.
9896219|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC|Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.
9896220|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 2 Squamous NSCLC|Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.
9896221|NCT04820556||Arterial hypertension|
9896222|NCT04820556||Atherosclerosis occlusive disease|
9896223|NCT04820556||Heart failure with preserved ejection fraction|
9896224|NCT04820556||Heart failure with reduced ejection fraction|
9896225|NCT04820556||Diabetes mellitus, type 2|
9896226|NCT04820556||Chronic obstructive pulmonary disease and asthma|
9896227|NCT04820556||Nonalcoholic fatty liver disease|
9896228|NCT04820556||Control group|
9896229|NCT04819100|Experimental|Selpercatinib|Selpercatinib administered orally.
9896230|NCT04819100|Placebo Comparator|Placebo|Placebo administered orally.
9896231|NCT04818892||IBD and Non-Immunosuppressive Group|Clinical diagnosis of IBD, non-systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
9896232|NCT04818892||IBD and Immunosuppressive Group|Clinical diagnosis of IBD, treated with systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
9998226|NCT01516294|Experimental|Iray plus Lucentis|open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
9896233|NCT04818541|Experimental|Protected Percutaneous Coronary Intervention|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for PPCI. Duration of Impella use ≤ 6 hours if used for PPCI.
9896234|NCT04818541|Experimental|Cardiogenic shock|Subjects with a femoral arteriotomy created with 13 to 14 F sheaths (arteriotomy up to approximately 18 F) and in whom an Impella device was used for cardiogenic shock. Duration of Impella use > 8 hours and ≤ 4 days.
9896235|NCT04816591|Experimental|Experimental: Interventional Cohort: Treatment Arm|Standard of Care Surgery + Embolization
9896236|NCT04816591|Active Comparator|Active Comparator: Interventional Cohort: Control Arm|Standard of Care Surgery Only
9896237|NCT04816591|Experimental|Experimental: Observational Cohort: Treatment Arm|Standard of Care Medical Management + Embolization
9896238|NCT04816591|Active Comparator|Active Comparator: Observational Cohort: Control Arm|Medical Management Only
9896239|NCT04815226|Other|Using Peristeen Transanal Irrigation|All participants in the trial will use Peristeen Transanal Irrigation. Eligible volunteers will be those patients who have failed conventional supportive bowel care, have neurogenic bladder, and use CIC (ClC: Clean Intermittent Catheterization) daily.
9896240|NCT04815044||Women from the PED-t study|Women who participated in the PED-t study in 2016-2018 who report previous (or in future time) pregnancy.
9896241|NCT04811287|Active Comparator|CTR with PRP|Carpal tunnel release with adjuvant platelet-rich plasma.
9896242|NCT04811287|Placebo Comparator|CTR without PRP|Carpal tunnel release without adjuvant platelet-rich plasma.
9896243|NCT04811079|Experimental|Spectacle Filter Sequence 1|(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.
9896244|NCT04811079|Experimental|Spectacle Filter Sequence 2|(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.
9896245|NCT04811079|Experimental|Spectacle Filter Sequence 3|(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.
9896246|NCT04811079|Experimental|Spectacle Filter Sequence 4|(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.
9896247|NCT04811079|Experimental|Spectacle Filter Sequence 5|(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.
9896248|NCT04811079|Experimental|Spectacle Filter Sequence 6|(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.
9896249|NCT04811079|Experimental|Spectacle Filter Sequence 7|(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.
9896250|NCT04811079|Experimental|Spectacle Filter Sequence 8|(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.
9896251|NCT04811079|Experimental|Spectacle Filter Sequence 9|(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.
9896252|NCT04811079|Experimental|Spectacle Filter Sequence 10|(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.
9896253|NCT04810221|Experimental|Experimental|Measure of SpO2 and HR obtained in enrolled subjects using BrOxy M and a reference pulse oximeter in paired observations
9896254|NCT04809766|Experimental|Cohorts I, II, and III (FH-TCR Tᴍsʟɴ)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days 39-41.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
9896255|NCT04809766|Experimental|Cohort IV (FH-TCR Tᴍsʟɴ)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -3 to -1.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
9896256|NCT04809220|Experimental|1.5 mg Dulaglutide|"1.5 mg Dulaglutide given subcutaneously (SC).~Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medications (OAM).~Participants taking DPP-4 inhibitors (DPP-4i) to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period."
9896257|NCT04809220|Active Comparator|0.75 mg Dulaglutide|"0.75 mg Dulaglutide given SC.~Dulaglutide will be given alone or in combination with 1 OAM.~Participants taking DPP-4i to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period."
9932787|NCT00952900|Active Comparator|Attention Control Group|This intervention involves the presentation of helpful information to patients that explains etiology and potential treatment modalities used to modify/reduce TMD pain/discomfort.
9932788|NCT00952900|No Intervention|No Active Treatment Comparison Group|Unlike the other two treatment groups, that involve high-risk acute TMD patients, this group includes low-risk acute TMD patients. Past studies have shown that these low risk patients do not need any early intervention in order to prevent chronicity.
9932789|NCT00952913|Experimental|1|Bosutinib
9932790|NCT00952913|Experimental|2|bosutinib + lansoprazole
9932791|NCT00952965||blood pressure monitor|wrist circumference: 14cm-25cm
9932792|NCT00952965||stethoscopy|wrist circumference: 14cm-25cm
9932793|NCT00952978|Experimental|10 mg ilaprazole|
9932794|NCT00952978|Active Comparator|20 mg omeprazole|
9932795|NCT00953004|Experimental|fiber drink|
9932796|NCT00953004|Experimental|fiber bread|
9932797|NCT00953004|Experimental|placebo|
9932798|NCT00953030|Experimental|COACH|"web-based risk assessments with an action plan that is negotiated with a Coach who provides personalized follow-up reinforcement"
9932799|NCT00953030|Experimental|RealAge|a web-based health risk assessment and risk profile with disease-specific follow-up reinforcement modules
9932800|NCT00953030|No Intervention|light health education control|
9896258|NCT04808544|Placebo Comparator|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
9896259|NCT04808544|Active Comparator|Naldebain group|Patients assigned to Naldebain group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
9896260|NCT04808011|Experimental|Treatment|Each subjects will be treated with his prescribed dialysis device for 14 days, followed by a treatment period of 30 days with the investigational IDA system, and concluding with additional 14 days of treatment with the prescribed dialysis device.
9896261|NCT04807972|Experimental|Phase 1b Dose Escalation|Participants will receive escalating doses of ABBV-927 in combination with modified FOLFIRINOX (mFFX) and Budigalimab.
9896262|NCT04807972|Experimental|Phase 2 Cohort A|Participants will receive modified FOLFIRINOX on Day 1 and Day 15 of each 28 day cycle.
9896263|NCT04807972|Experimental|Phase 2 Cohort B|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV-927 in each 28 day cycle.
9896264|NCT04807972|Experimental|Phase 2 Cohort C Expansion|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV 927 and Budigalimab as Intravenous (IV) Infusion in each 28 day cycle.
9896265|NCT04807881|Experimental|Keynatinib treatment group|Keynatinib, 20 mg，BID
9896266|NCT04806607|Active Comparator|19Gauge Fine Needle Biopsy|19Gauge Fine Needle
9896267|NCT04806607|Active Comparator|22 Gauge Fine Needle Biopsy|22Gauge Fine Needle
9896268|NCT04803669|Active Comparator|Conventional Treatment Group|Includes Hotpack, TENS, Ultrasound and Exercise programs.
9896269|NCT04803669|Experimental|IASTM Group|Inludes Hotpack, TENS, Ultrasound, Exercise program and Instrument-assisted Soft Tissue Mobilization Technique
9896270|NCT04803383|Experimental|Tele-Yoga Group|Patients in the tele-yoga group will participate in tele-yoga sessions with a maximum of 5 people in each group by video-conference method for 8 weeks, 3 days a week. Assessments will perform just before starting to study and after the 8-week tele-yoga program
9896271|NCT04803383|No Intervention|Control group|Patients in the waiting list control group will be asked to continue their normal physical activities during the 8-week study, not to start a new exercise program, and to report any changes in the drug or dosage used. Control group's assessments will be performed when they are included in the study and at the end of 8 weeks. After these assessments, patients who wish will participate in the tele-yoga program.
9896272|NCT04803201|Experimental|Arm A (duvelisib, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive duvelisib PO BID on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9896273|NCT04803201|Experimental|Arm B (CC-486, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive CC-486 PO QD on days -6 to 0 of cycle -1 and days 8-21 of cycles 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9896274|NCT04803201|Active Comparator|Arm C (CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9896275|NCT04801693|Experimental|BI 1819479|single rising doses (SRD) part
9896276|NCT04801693|Placebo Comparator|Placebo|Single rising doses (SRD) part
9896277|NCT04801693|Experimental|BI 1819479 fed - fasted arm|Food effect part
9896278|NCT04801693|Experimental|BI 1819479 fasted - fed arm|Food effect part
9896279|NCT04800055|Experimental|ATSB + VC intervention|Arm 1 will receive ATSBs for up to two years.
9896280|NCT04800055|No Intervention|VC only|Arm 2 will receive the standard of care of universal vector control coverage.
9896281|NCT04799912|Experimental|Elective labor induction|Elective labor induction via oxytocin between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days for women with favorable cervix. Those with an unfavorable cervix (Bishop score < 6) will first undergo cervical ripening (method left to the discretion of the practitioner) in conjunction with or followed by oxytocin stimulation unless a contraindication arises. Except for elective induction of labor between 39 weeks of gestation and 0 day and 39 weeks of gestation and 4 days, the obstetrical management will not be modified compared to routine obstetrical management.
9896282|NCT04799912|No Intervention|Expectant management|Standard follow-up visits until at least 41 weeks of gestation and 0 day without elective labor induction unless a medical indication is present. Antepartum fetal testing will be initiated no later than 41 weeks of gestation and 1 day according to policies at each center (according to the French guidelines). If still pregnant, women will undergo induction at 41 weeks of gestation and 6 days (according to the French guidelines)
9896283|NCT04796610|Experimental|Intervention|Unsuppressed HIV patients at the intervention clinic will receive guidance from their health care provider on the selection of a treatment partner. The patient and treatment partner will receive education on HIV treatment and how treatment partners can support patients in treatment adherence.
9896284|NCT04796610|No Intervention|Control|Patients at the control clinic will receive standard of care at the clinic during the intervention assessment period.
9896285|NCT04792502|Experimental|Planned Therapy|
9896286|NCT04791059|Experimental|Combined analgesia group|Patient-controlled analgesia is established with S-ketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
9896287|NCT04791059|Placebo Comparator|Control group|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
9896288|NCT04791033||Adenomyosis|Patients with adenomyosis
9896289|NCT04791033||Other benign gynecological conditions|Patients with other benign gynecological conditions (i.e: myomas, endometriosis).
9896290|NCT04790903|Experimental|Venetoclax (Schedule A)|"Participants enrolled in dosing Schedule A will receive a total of six 21-day cycles of venetoclax treatment for 5 days in combination with Polatuzumab Vedotin + R-CHP (Rituximab, Cyclophosphamide, Doxorubicin and Prednisone) as described below:~Schedule A: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 5 consecutive days as follows:~Cycle 1: 5 consecutive days of dosing on Days 4-8. Cycles 2-6: 5 consecutive days of dosing on Days 1-5."
9896291|NCT04790903|Experimental|Venetoclax (Schedule B)|"Participants enrolled in dosing Schedule B will receive a total of six 21-day cycles of venetoclax treatment for 10 days in combination with Polatuzumab Vedotin + R-CHP as described below:~Schedule B: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 10 consecutive days as follows:~Cycle 1: 10 consecutive days of dosing on Days 4-10. Cycles 2-6: 10 consecutive days of dosing on Days 1-10."
9896292|NCT04790370|Active Comparator|Anticoagulation|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
9896293|NCT04790370|Active Comparator|Anticoagulation and EkoSonicTM Endovascular System|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
9896295|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 1_B Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03B adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
9896296|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 1_A Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 1 vaccine and AS03A adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
9896297|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 2_B Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03B adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
9896298|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 2_A Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 2 vaccine and AS03A adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
9896299|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 3_B Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03B adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
9896300|NCT04789577|Active Comparator|FLU-Q-PAN H7N9 Formulation 3_A Group|Healthy male and female participants who will receive two doses of FLU-Q-PAN H7N9 Formulation 3 vaccine and AS03A adjuvant. Participants will receive the first dose at Day 1 and the second dose at Day 22
9896301|NCT04789577|Placebo Comparator|Placebo Group|Healthy male and female participants who will receive two doses of placebo, the first dose at Day 1 and the second dose at Day 22
9896302|NCT04787666|Experimental|the first group: non-invasive mask ventilation|Dinamika of the indicator p/F Ratio
9896303|NCT04787666|Experimental|the second group:high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation)|Dinamika of the indicator p/F Ratio
9896304|NCT04787666|Experimental|the third group:non-invasive ventilation with a helmet|Dinamika of the indicator p/F Ratio
9896305|NCT04783077|Experimental|WhatsApp|
9896306|NCT04783077|Active Comparator|Control|
9896307|NCT04780087||Weight lifting women|Experienced resistance exercise trained and pregnant women
9896308|NCT04780087||Reference women|Physically active pregnant women (not experienced with free weight lifting)
9896309|NCT04777084|Experimental|Cohort A|Cohort A is evaluating the efficacy and safety of IBI318 in combined with lenvatinib in advanced NSCLC patients who had failed first-line PD-1/PD-L1 inhibitor therapy.
9896310|NCT04777084|Experimental|Cohort B|Cohort B is the efficacy and safety of advanced NSCLC with EGFR-sensitive mutation /ALK fusion after EGFR-TKI /ALK-TKI treatment resistance.
9896311|NCT04777084|Experimental|Cohort C|Cohort C is the efficacy and safety of first-line treatment of advanced NSCLC with negative PD-L1 expression and EGFR, ALK, and ROS1 wild-type.
9896312|NCT04776746|Experimental|Drug - trofinetide|trofinetide oral solution
9896313|NCT04771273|Experimental|BI 456906 low dose|low dose
9896314|NCT04771273|Experimental|BI 456906 medium dose|medium dose
9896315|NCT04771273|Experimental|BI 456906 high dose|high dose
9896316|NCT04771273|Placebo Comparator|Placebo|Placebo
9896317|NCT04770896|Experimental|Atezolizumab + Lenvatinib or Sorafenib|Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
9896318|NCT04770896|Active Comparator|Lenvatinib or Sorafenib|Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
9896319|NCT04770766||Staff observation|Doctor-in-training and non-medical practitioner volunteers
9896320|NCT04770766||Patient questionnaires|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study
9896321|NCT04770766||Case study NHS Trusts|NHS organisations with an Emergency Department participating as a case study site
9896322|NCT04770766||All England NHS Trusts|NHS Trusts whose Emergency Department (n=183) records data is held by NHS Digital and will be provided anonymously/without individual patient consent (these anticipated hundreds of thousands of records are not included in the enrolled patient numbers)
9896323|NCT04770766||Patient interviews|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview following completion of the patient questionnaire
9896324|NCT04770766||Staff interviews|Staff working in the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview
9896325|NCT04770766||Stakeholder interviews|Senior NHS clinicians, managers, commissioners and lay representatives with roles and interests in the non-medical practitioner workforce
9896326|NCT04769050||First-line patients|First-line treatment of HER2-positive metastatic breast cancer patients
9896327|NCT04769050||Second-line patients|Second-line treatment of HER2-positive metastatic breast cancer patients
9896328|NCT04768855|Experimental|LY3540378 (Part A)|Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC).
9896329|NCT04768855|Experimental|LY3540378 (Part B)|Multiple ascending doses of LY3540378 administered SC.
9896330|NCT04768855|Experimental|LY3540378 (Part C)|Multiple ascending doses of LY3540378 administered SC in Japanese Participants.
9896331|NCT04768855|Experimental|LY3540378 (Part D)|Multiple ascending doses of LY3540378 administered SC in Chinese Participants.
9896332|NCT04768855|Placebo Comparator|Placebo (Part A, B, C & D)|Placebo administered either IV or SC.
9896333|NCT04765072|Experimental|Survivorship care|Participants in rural areas will receive a telehealth (providing health-related services through electronic communication technologies) survivorship care plan in combination with assistance from a patient navigator.
9896334|NCT04763278|Experimental|Prosthesis|Patient is temporarily fit with Point Digit partial hand prosthetic system
9896335|NCT04763135|Experimental|Oral mirtazapine|Arm 1 patients will be treated using a daily mirtazapine treatment. Treatment will be taken on the evening. Treatment will be initiated at 15 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for old patients and those with liver failure.
9896336|NCT04763135|Active Comparator|Oral escitalopram|Arm 2 patients will be treated using a daily escitalopram treatment. Treatment will be taken in the morning. Treatment will be initiated at 10 mg daily and gradually increased depending on symptom control and side effects. Treatment doses will be adapted for 5 mg for old patients.
9896337|NCT04762875|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days
9896338|NCT04759456|Experimental|Intervention group|Participants will undergo 12-week comprehensive remotely-supervised rehabilitation program along with individually titrated CPAP therapy.
9896339|NCT04759456|No Intervention|Control group|Participants will undergo individually titrated CPAP therapy.
9896340|NCT04759170|Other|Mother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
9896341|NCT04759170|Other|Fother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
9896342|NCT04759170|Other|Music therapist Recorded Receptive Music therapy intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
9896343|NCT04759170|Other|No singing|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
9896344|NCT04758416||Metastatic breast cancer patients|50 metastatic breast cancer patients
9896345|NCT04756726|Experimental|Phase 1: Arm A - CFT7455|Participants with r/r NHL or r/r MM will be treated with oral CFT7455 as a single agent administered according to different dosing schedules
9896346|NCT04756726|Experimental|Phase 1: Arm B1 - CFT7455|Participants with r/r MM will be treated with escalating doses of single agent CFT7455 administered according to different dosing schedules until the determination of maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
9896347|NCT04756726|Experimental|Phase 1: Arm B2 - CFT7455 in combination with dexamethasone|Participants with r/r MM will be treated with oral CFT7455 in combination with a fixed dose of oral dexamethasone in each cohort
9896348|NCT04756726|Experimental|Phase 1: Arm C - CFT7455|Participants with r/r NHL will be treated with escalating doses of single agent CFT7455 administered according to different dosing schedules in each cohort until determination of MTD/RP2D
9896349|NCT04756726|Experimental|Phase 2: Arm 1 - CFT7455|Participants with r/r MM will be treated with oral CFT7455
9896350|NCT04756726|Experimental|Phase 2: Arm 2 - CFT7455 in combination with dexamethasone|Participants with r/r MM treated with oral CFT7455 in combination with oral dexamethasone
9896351|NCT04756726|Experimental|Phase 2: Arm 3 - CFT7455|Participants with r/r mantle cell lymphoma (MCL) treated with oral CFT7455
9896352|NCT04756726|Experimental|Phase 2: Arm 4 - CFT7455|Participants with r/r peripheral T-cell lymphoma (PTCL) treated with oral CFT7455
9896353|NCT04755790|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
9896354|NCT04755790|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
9896355|NCT04755153|Experimental|Kaiser Blood Pressure Control Bundle|
9896356|NCT04754243|Experimental|Study group|Will receive ANTIUI protocol
9896357|NCT04754243|Active Comparator|Control group|Will receive standard protocol in IUI and unexplained infertility
9896358|NCT04753359|Experimental|Med-A|"Med-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of group sessions. For subjects randomized to Med-A the study RD will instruct on adoption of an eating pattern consistent with a MedDiet using an individualized MedDiet exchange list and companion guide. Recommended daily exchanges are based on individual caloric needs to maintain weight. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial in-person session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 7.5 months.~The Med-A group will be asked to maintain their usual physical activity pattern."
9896359|NCT04753359|Experimental|WL-A|"WL-A will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of group sessions. For subjects randomized to WL-A, the focus will be on daily calorie restriction (-500-750 kcal/day) to achieve a 1-2 lb. per week WL and 5% WL from baseline at 8 months in the context of the subject's typical diet pattern. We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial in-person session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 7.5 months.~The WL-A group will be prescribed an activity program with an initial recommendation of 100 min/week progressing to 150 min/week within 6 weeks. Subjects will also participate in 30 minutes of supervised physical activity during the group sessions"
9896360|NCT04753359|Experimental|WL-Med|"WL-Med will attend a one-hour, in-person individual session with a registered dietitian (RD) during the two weeks prior to the start of group sessions. The study RD will instruct on adoption of an eating pattern consistent with a MedDiet using an individualized exchange list and companion guide. Recommended daily exchanges are based on individual caloric needs to lose weight (WL-Med, calorie restriction to achieve a 1-2 lb. per week WL and 5% WL from baseline at 8 months). We will not ask subjects to abstain from alcohol during the trial despite its known effects on BA metabolism, but we will recommend that only 5% of calories come from alcohol taken with meals. Following the initial in-person session, subjects will meet for 26 group sessions (1-hour, held approximately weekly) over the remaining 7.5 months.~Physical activity. Participants will be prescribed an activity program and will also participate in 30 minutes of supervised physical activity during the group sessions"
9932801|NCT00953095|Experimental|Caregiver Mediated Model (CMM)|focuses on joint attention/engagement intervention using an established evidence based treatment (Kasari et al., 2006). It involves meeting the parent and child in their home for one hour, twice a week for 12 weeks. In this intervention, the parent-child pair meet with the interventionist (as opposed to the group training in the CEM condition). Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input and coaching from the interventionist) as they implement these techniques with their child.
9896361|NCT04753359|No Intervention|Control|The study RD will meet individually with the Control group subjects for 1-hour at the start of the 8-month intervention. Control participants will be instructed to maintain current eating and activity patterns and weight over the next 8 months. No dietary recommendations are provided, and they will receive weekly health newsletters that include non-diet related health topics (e.g., flu prevention). Contact will be made again at month-4 and post-intervention (month-8) research visits and during monthly phone calls to collect data pertaining to recent diet intake. At the month-4 assessment, weight will be checked and those with >2.5% WL from baseline will receive additional instruction from the RD to maintain lifestyle patterns. All WL-Med materials are offered to the group in a self-guided format following the 8-month intervention.
9896362|NCT04753047||Children practicing football|Children in late childhood (age 10-12 years) practicing sport, which is high dynamic (> 75%), and low static (<10&) and in the same time it is open skill exercise sport (football)
9896363|NCT04753047||Children practicing gymnastics|Children in late childhood (age 10-12 years) practicing sport, which is low dynamic (<50%), high static (>30%) and in the same time it is closed skill exercise sport (sport gymnastics)
9896364|NCT04753047||Comparative group|A comparative group of children that do not attend sport classes or sports clubs, but carrying out sports activity and / or in other areas
9896365|NCT04752332|Experimental|Abemaciclib Plus (+) Endocrine Therapy (ET)|Abemaciclib administered orally and standard adjuvant ET (physician's choice) administered according to package label.
9896366|NCT04752332|Active Comparator|Placebo + ET|Placebo administered orally and standard adjuvant ET (physician's choice) administered according to package label.
9896367|NCT04751942|Experimental|Non-compressive Bioactive Garment|The non-compressive bioactive garment is a commercially available garment that is designed to reflect infrared waves generated by the wearer back into the soft tissue surrounded by the garment. The reflection of the infrared waves is intended to improve pain and swelling at the site. Patients following Total knee replacement are intended to wear morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
9896368|NCT04751942|Active Comparator|Thrombo-Embolic Deterrent|a gradient compression stocking that is currently the gold standard for deterring thromboembolic events and assisting with post-operative swelling after total knee replacements. Patients following Total knee replacement are intended to wear the TED hose morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
9896369|NCT04751435||Breast,Ovarian, Prostate & Pancreatic Cancer|"There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview.~This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2."
9896370|NCT04751266||Patients with MIRPE|first minimally invasive repair of pectus excavatum
9896371|NCT04750798||Participants Diagnosed with Cardiac Arrhythmias|Patients diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure in routine clinical practice for management of their arrhythmia with a BWI therapeutic catheter will be observed.
9896372|NCT04750577|Experimental|Dose group 1: BI 685509|Low dose.
9896373|NCT04750577|Placebo Comparator|Dose group 1: Matching placebo|Matching placebo for low dose.
9896374|NCT04750577|Experimental|Dose group 2: BI 685509|Low dose followed by up-titration to medium dose.
9896375|NCT04750577|Placebo Comparator|Dose group 2: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose.
9896376|NCT04750577|Experimental|Dose group 3: BI 685509|Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.
9896377|NCT04750577|Placebo Comparator|Dose group 3: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose, followed by up-titration to high dose.
9896378|NCT04750447||Open Angle Glaucoma|Patients aged 30-90 Primary open angle glaucoma on maximum tolerated medical therapy Going to receive XEN63 ab interno gelatin stent with or without MMC in study eye ± cataract surgery
9896379|NCT04747522||Kidney Transplanted patients|Kidney transplanted patients transplanted at least 6 months prior to SARS-CoV-2 vaccination. Vaccination according to national plan with messenger Ribonucleic acid (mRNA) vaccine
9896380|NCT04747522||Healthy controls|Healthy hospital staff receiving SARS-CoV-2 mRNA vaccine as being front line Healthcare workers.
9896381|NCT04747353|Experimental|Catheter ablation procedure with heart 3D model|Experimental: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
9896382|NCT04745975|Experimental|Personalized treatment guided by Mini-PDX|The tumor tissue is used for drug sensitivity test by Mini-PDX, and acquiring the genetic information by RNA-sequence. Patients with mTNBC will receive personalized treatment guided by the experimental results of mini-PDX and RNA sequencing.
9998227|NCT01516320|Experimental|Gastric Bypass (GBP) Subjects|Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.
9896383|NCT04745975|Active Comparator|Treatment of Physician's Choice (TPC)|TPC will be administered per standard of care. Patients randomized to TPC will receive chemotherapy, including but not limited to the following agents: nab-paclitaxel, eribulin, vinorelbine, gemcitabine, capecitabine.
9896384|NCT04745728|Active Comparator|cyclophosphamide and prednisone|"Prednisone will be given at 1mg/kg/d p.o. and will be tapered after 2 months and discontinued over a 6-12 month period.~Cyclophosphamide will be given at 1-2mg/kg/d p.o. with a target accumulated dose of 12g.~Azathioprine or mycophenolate mofetil are optional which could be given for a short period of time (<6 months）after discontinuation of cyclophosphamide if patients do not remit at 6 month."
9896385|NCT04745728|Active Comparator|Rituximab|"Rituximab 1000mg I.V. on Day1 and at 6 month. After 6 months, in patients with response but without complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be given on the 15th day after each Rituximab infusion if CD19+ B cell count>5/ul on the 15th day.~Calcineurin inhibitors (CNI) are optional but should be tapered after 6 months and discontinued after 9 months."
9896386|NCT04743583||Endosonography group|Patients with known or suspected lung cancer or intrathoracic malignancy with indication to endosonography for diagnosis or staging of intrathoracic lymph nodes according to currently accepted international guidelines
9896387|NCT04742075|Active Comparator|Olaparib|Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.
9896388|NCT04742075|Experimental|Olaparib + durvalumab|"Olaparib 300 mg tablets twice daily until progressive disease or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity."
9896389|NCT04742075|Experimental|Olaparib + durvalumab + UV1|"Olaparib 300 mg tablets twice daily until disease progression or unacceptable toxicity.~Durvalumab 1500 mg IV every 4 weeks for 24 months or until disease progression or unacceptable toxicity.~Eight UV1 vaccinations during the first 5 month: Four UV1 vaccinations 300 μg (+ 75 μg of sargramostim) during the first 10 days with a minimum of 2 days apart. From cycle 2-5 subjects will receive one UV1 (+ sargramostim) vaccination every 4th week."
9896390|NCT04740892|Experimental|Wash and Cream Investigational Product (IP)|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks. Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
9896391|NCT04736628|Experimental|Dose group 1: BI 685509|Low dose.
9896392|NCT04736628|Placebo Comparator|Dose group 1: Matching placebo|Matching placebo for low dose.
9896393|NCT04736628|Experimental|Dose group 2: BI 685509|Low dose followed by up-titration to medium dose.
9896394|NCT04736628|Placebo Comparator|Dose group 2: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose.
9896395|NCT04736628|Experimental|Dose group 3: BI 685509|Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.
9896396|NCT04736628|Placebo Comparator|Dose group 3: Matching placebo|Matching placebo for low dose followed by up-titration to medium dose, followed by up-titration to high dose.
9896397|NCT04736134|Experimental|Active Treatment (BMS 986326) IV|Intravenous (IV)
9896398|NCT04736134|Experimental|Active Treatment (BMS 986326) SC|Subcutaneous (SC)
9896399|NCT04736134|Placebo Comparator|Placebo IV|
9896400|NCT04736134|Placebo Comparator|Placebo SC|
9896401|NCT04735731||EBV-patients|Patients who are scheduled for a bronchoscopic lung volume reduction treatment using endobronchial valves
9896402|NCT04735406||Multiple Sclerosis (MS)|Data from the participants with diagnosed MS treated and untreated will be part of this study. Medical records of participants will be used to collect demographics and data pertaining to Multiple Sclerosis (MS) management.
9896403|NCT04730271|Active Comparator|Manual Arm|Subjects enrolled into this arm of the study will receive an ATTUNE primary total knee replacement that has been implanted using manual instrumentation which is the current standard of care at the participating sites.
9896404|NCT04730271|Experimental|Robotic-Assisted Arm|Subjects enrolled into this arm will receive an ATTUNE primary total knee replacement that has been implanted with the use of the VELYS Robotic-Assisted Solution device.
9896405|NCT04725565|Experimental|Genetics ADviSER Decision Aid Plus Standard Genetic Counselling|Participants in the intervention arm will use the Genetics ADviSER to learn about genomic sequencing and to select which results they would like to receive from genomics sequencing results. After using the Genetics ADviSER decision aid they will speak with genetic counselor to discuss their choices and to finalized their selection.
9896406|NCT04725565|Active Comparator|Standard Genetic Counselling Only|Participants will speak with a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
9896407|NCT04723303|Experimental|Treatment Arm|A single IV infusion of ULSC's in patients with DM or PM
9896408|NCT04722939||Critical illness with acute kidney injury|See below for detailed inclusion/exclusion criteria
9896409|NCT04720404|Experimental|Mindfulness Based Stress Reduction program|Healthcare workers in the MBSR arm will be invited to participate in an adapted online MBSR program added to support as usual
9896410|NCT04720404|Active Comparator|Daily self-help mindfulness exercises via YouTube-channel|Healthcare workers in the self-help arm will be invited to follow a self-help program with mindfulness/compassion exercises of 30 minutes per day via YouTube channel
9896411|NCT04710368|Experimental|Treatment|Evolocumab subcutaneously administered 140 mg every 2 weeks for 26 weeks
9896412|NCT04709783|Experimental|Implementation Arm|Participants will receive the 3-Step Workout for Life program and other rehabilitation services based on the plan of care.
9896413|NCT04708704|Experimental|Erythrosine, prepared in drinking water|One point-of-use technology in development that has demonstrated potential for inactivating viruses in drinking water is the application of an edible photosensitizing dye to the water for disinfection. When exposed to sunlight, the photosensitizing dye produces singlet oxygen, a reactive oxygen species capable of inactivating a wide range of viruses. Erythrosine, an FDA-approved dye, has proven its ability to disinfect drinking water, achieving 4-log inactivation of bacteriophage MS2 in under 10 minutes of sunlight exposure. Furthermore, the dye photobleaches upon exposure to light, and the accompanying distinct color change (e.g., red to transparent) occurs at a rate comparable to the disinfection, providing a safety indication that disinfection has completed, a much-needed function lacking in other point-of-use technologies.
9896414|NCT04707157|Experimental|LY3556050|LY3556050 given orally
9896415|NCT04707157|Placebo Comparator|Placebo|Placebo given orally
9896416|NCT04705116||Vaccinated pregnant women|Pregnant women who received at least one dose of a COVID-19 vaccine from 30 days prior to the first day of the LMP to end of pregnancy.
9896417|NCT04705116||Non-vaccinated pregnant women|Pregnant women who have not received a COVID-19 vaccine during pregnancy.
9896418|NCT04704934|Experimental|Trastuzumab deruxtecan|Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle.
9896419|NCT04704934|Active Comparator|Ramucirumab + paclitaxel|Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
9896420|NCT04702893||Chronic fibrosing interstitial lung disease (ILD) patients with a progressive phenotype|
9896421|NCT04700969|Experimental|A support program to facilitate implementation of EBP for postoperative urinary retention|12- month support program. Multi-professional facilitator-teams will be supported by a 12-month support program including seminars and monthly supervision (e-discussion forum and group teleconferences) to develop an awareness of, and skills in facilitating implementation of evidence/EBP in clinical everyday care.
9896422|NCT04700969|No Intervention|Control-No support program|No support program
9896423|NCT04695210|Experimental|Virtual Peer-to-Peer Support|"Those participants randomised to the intervention arm will have access to a 12-week virtual peer-to-peer support programme which entails:~weekly audio, video, or text private messaging with a peer supporter;~synchronous weekly discussion forum attended by peer supporters and family caregiver participants moderated by the research team. These forums will discuss specific topics (e.g. caregiver self-care, the emotional impact of caregiving). Ask the expert forums will be moderated by clinical experts every 6 weeks (meaning all participants will have access to 2 ask the expert sessions);~asynchronous discussion forums in which participants can post questions; and~access to informational resources."
9896424|NCT04695210|No Intervention|Control|Those participants randomised to the control arm will receive usual care which comprises self-directed access to the MND Association Visitors programme and MND Association educational resources via their website.
9896425|NCT04693702||Age-related Macular Degeneration|
9896426|NCT04693702||Diabetic Macular Edema|
9896427|NCT04692467|Experimental|Intervention (Early hypertension)|Participants randomized to the early HTN treatment arm will initiate 5mg daily of amlodipine immediately, increasing to 10 mg if SBP >130 mmHg after 1 month.
9896428|NCT04692467|No Intervention|Standard of Care|Participants randomized to the SOC arm will not be initiated on any medications initially. They may be initiated on amlodipine only if they develop HTN (SBP ≥140 or DBP ≥90 mm Hg).
9896429|NCT04692298|Other|Pulse|Participants will consume kidney beans, lentil, pinto beans, black-eyed pea, chickpea
9896430|NCT04690582|Active Comparator|Treatment As Usual|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a self-guided safety plan. As a recommended standard care practice with suicidal patients, the combination of CPT and safety plan represents treatment as usual. The safety plan will be assigned during the first therapy session.
9896431|NCT04690582|Experimental|Crisis Response Plan (CPT+CRP)|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a collaborative crisis response plan (CRP). The CRP includes many of the same elements as the safety plan (i.e., warning signs, self-management strategies, sources of social support, crisis services), but is created collaboratively by the patient with active input of their clinician rather than being self-guided. The CRP also includes a section focused on the participant's reasons for living, an addition that has been shown to increase positive emotional states (e.g., hope, optimism) and lead to faster reductions in suicidal intent. The CRP will be collaboratively created during the first therapy session.
9517775|NCT03303053|Experimental|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
9935608|NCT03466411|Active Comparator|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
9896432|NCT04690322|Active Comparator|Extended half-life factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
9896433|NCT04690322|Active Comparator|Non-Factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
9896434|NCT04689828|Experimental|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used.
9896435|NCT04689828|Active Comparator|Androgen receptor-directed therapy (ARDT)|For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used.
9896436|NCT04687371|Experimental|Grup I|Proprioceptive vestibular rehabilitation exercises, Cawthorne Cooksey Exercises and Gaze Stabilization exercises,
9896437|NCT04687371|Experimental|Grup II|Cawthorne Cooksey Exercises and Gaze Stabilization exercises
9896438|NCT04687371|Other|Grup III|No intervention will be made, patients will be asked to continue their daily life
9896439|NCT04686838|Experimental|READyR II A|Continuous monitoring will be conducted and analyzed for anomaly detection. Participants in this arm will receive contact phone call when a potential change in care needs is indicated by an anomaly.
9896440|NCT04686838|Active Comparator|READyR II B (comparison)|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content. Standard educational content will instead be shared over the phone.
9896441|NCT04686331||Suspected CAP|All patients admitted to the emergency department with suspected community-acquired pneumonia (CAP) assessed by the receiving physician
9896442|NCT04686318||suspected acute pyelonephritis|All patients admitted to the emergency department with suspected acute pyelonephritis assessed by the receiving physician
9896443|NCT04686292||Suspected infection|All patients admitted to the emergency department with suspected infections assessed by the receiving physician
9896444|NCT04681963||Suspected pneumonia diagnosis|Acutely admitted patients suspected having pneumonia.
9896445|NCT04681651|Experimental|NBO group|Normobaric Hyperoxia combined with endovascular mechanical thrombectomy
9896446|NCT04681651|Placebo Comparator|Control group|Inhale air placebo plus endovascular mechanical thrombectomy
9896447|NCT04678271|Experimental|AFIX-OB Intervention Arm|Practices randomized to this arm will choose from a suite of quality improvement interventions that address patient, provider, and practice-level factors relating to maternal vaccination.
9896448|NCT04678271|No Intervention|Control Arm|Practices randomized to this arm will continue to provide their normal standard of care to pregnant patients at their practice.
9896449|NCT04677946|Experimental|Healthy Cookie Group|All participants in the study
9896450|NCT04677179|Experimental|LY3471851 (High Dose)|"Stage 1 LY3471851 given subcutaneously (SC)~Stage 2 LY3471851 multiple doses to be confirmed"
9517493|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
9517494|NCT03305861|Experimental|ThuLEP|Thulium laser enucleation of prostate
9517495|NCT03305861|Experimental|Green LEP|Greenlight laser enucleation of prostate
9517776|NCT03303053|Active Comparator|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
9517496|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
9896451|NCT04677179|Experimental|LY3471851 (Low Dose)|"Stage 1 LY3471851 given subcutaneously (SC)~Stage 2 LY3471851 multiple doses to be confirmed"
9896452|NCT04677179|Placebo Comparator|Placebo|"Stage 1 Placebo given SC~Stage 2 Placebo given SC"
9896453|NCT04676633|Experimental|Cohort 1: STP705 20 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
9896454|NCT04676633|Experimental|Cohort 2: STP705 40 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
9896455|NCT04676633|Experimental|Cohort 3: STP705 80 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
9896456|NCT04676633|Experimental|Cohort 4: STP705 160 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
9896457|NCT04676633|Experimental|Cohort 5: STP705 320 μg dose|Intratumoral injection, administered as a single agent on Day 1,8 and 15 of a 28-day cycle. If the patient is deriving clinical benefit from the agent it may be continued and will be administered on Day 1 of each successive cycle.
9896458|NCT04675931|Experimental|IV KAE609 Dose regimen 1|Intravenous KAE609 (cipargamin) 20 mg
9896459|NCT04675931|Experimental|IV KAE609 Dose regimen 2|Intravenous KAE609 (cipargamin) 40 mg
9896460|NCT04675931|Experimental|IV KAE609 Dose regimen 3|Intravenous KAE609 (cipargamin) Dose regimen 3 (dose will be evaluated post Interim analysis from Cohort 1 and Cohort 2.
9896461|NCT04675931|Active Comparator|IV Artesunate|IV Artesunate 2.4 mg/kg (for participants weighing at least 20 kg) IV Artesunate 3 mg/kg (for participants weighing less than 20 kg)
9896462|NCT04675931|Other|Coartem|Standard of care (Coartem) will be given to all participants for 3 days as part of treatment.
9896463|NCT04675346||Questionnaire|The EUNASS Study Questionnaire is an electronic questionnaire (using the Qualtrics programme) designed to assess management after diagnosis of melanoma and during follow-up, health status, fear of melanoma recurrence, melanoma-specific supportive care needs, sun protection behaviour, views and habits about SSE and standard socio-demographic details.
9896464|NCT04675346||Interviews|A qualitative researcher will undertake 25-30 semi-structured interviews with participants who have volunteered their contact details in the final section of the EUNASS Study Questionnaire. A purposive sampling approach will be taken for participant recruitment to this part of the study.
9896465|NCT04673422|Experimental|Montelukast|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
9896466|NCT04673422|Placebo Comparator|Placebo|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
9896467|NCT04673032||Boston Scientific Radiofrequency Ablation Systems|Subjects with pain or other disorders treated with a commercially approved Boston Scientific RF system
9896468|NCT04672486|Experimental|Intervention Arm|Participants will be offered an online problem-solving intervention that is delivered through a smartphone app (called POD Adventures) with telephone-based guidance from a lay counsellor. The app teaches problem-solving skills through interactive animated vignettes and personalized action plans, with encouraging prompts and feedback offered through an in-app guide character. In addition, methods of gamification are used to model and practice complementary coping strategies (e.g., relaxation) and enhance engagement. Participants will use the app remotely (i.e., from their home) in their own time.
9896469|NCT04672486|No Intervention|Usual Care|Participants randomized to the control arm will be provided with usual care. This will consist of information and contact details about local mental health service providers and two recently established government provided/affiliated helplines: (i) Manodarpan, a student mental health helpline supported by the Ministry of Human Resource Development; and (ii) a 24/7 mental health helpline (KIRAN) supported by the Social Justice and Empowerment Ministry. The same information will be provided to participants in the intervention arm.
9932802|NCT00953095|Experimental|Caregiver Education Model (CEM)|focuses on teaching parents information about autism, behavior modification, and community services using a manualized approach (Brereton & Tonge, 2005). Parents will receive information on child development each week, and will be able to ask questions and discuss the information vis-à-vis their own child. This intervention is manualized (Brereton & Tonge 2005). In the CEM condition, parents meet in a group (without their children) in a community-based setting to receive the intervention. Intervention sessions occur once a week for 2 hours.
9932803|NCT00953108|Experimental|quetiapine|
9932804|NCT00953108|Active Comparator|escitalopram|
9932805|NCT00953134|Experimental|1|IFA - Iron and Folic Acid (60 mg of ferrous fumarate and 400 mcg folic acid)
9932806|NCT00953134|Active Comparator|2|FA - Folic Acid (400 mcg folic acid)
9932807|NCT00953186|Active Comparator|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
9932808|NCT00953186|Placebo Comparator|Placebo|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
9932809|NCT00953251||patients with acute coronary syndrome|patients with acute coronary syndrome
9932810|NCT00953251||Non-STEMI and unstable angina|
9932811|NCT00953264|Experimental|life style intervention|
9932812|NCT00953277|Experimental|Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
9932813|NCT00953303|Experimental|glucocorticoid|
9932814|NCT00953303|Active Comparator|Standard care|
9932815|NCT00953316||at-risk infants|Includes all children born at less than 37 weeks gestation and other high risk newborns such as those with a history of breathing problems and/or low tone.
9932816|NCT00953342|Experimental|Aerobic exercise|12 weeks of supervised aerobic exercise and standard care
9896470|NCT04669886||endotoxin study group|Patients scheduled for Percutaneous Nephrolithotomy (PCNL) as surgical treatment for their kidney stones will be evaluated for postoperative endotoxin levels as a risk marker for sepsis.
9896471|NCT04669860||calcium oxalate urolithiasis group|Participants with CO urolithiasis scheduled for definitive endoscopic stone removal will be evaluated to identify bacterial and fungal microbiome in mid-stream voided urine sample, urine sample collected from the bladder, kidney stone fragment, and a renal papillae biopsy specimen.
9896472|NCT04669860||renal cell carcinoma group|Participants with RCC scheduled for definitive kidney removal surgery will be evaluated to identify bacterial and fungal microbiome in a catheterized urine specimen from the bladder, a biopsy of the tumor, and a biopsy of normal-appearing renal papillae specimen.
9896473|NCT04669860||healthy control group|The participants will provide a clean-catch voided midstream urine sample to identify bacterial and fungal microbiome.
9896474|NCT04669041|Experimental|Single pill combination (SPC)|Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks
9896475|NCT04669041|Active Comparator|Rosuvastatin|Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks
9896476|NCT04668066|Experimental|Single ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive a single intravenous dose of either PF-07242813 or placebo
9896477|NCT04668066|Experimental|Multiple ascending doses of PF-07242813 or placebo in healthy participants|Participants will receive multiple subcutaneous doses PF-07242813 or placebo
9896478|NCT04668066|Experimental|Single dose of PF-07242813 or placebo in participants with moderate to severe atopic dermatitis|Participants will receive a single intravenous dose of either PF-07242813 or placebo
9896479|NCT04667195||Suspected acute pyelonephritis|Diagnosis of APN suspected at the initial clinical assessment by the receiving emergency department physician
9896482|NCT04662632|Experimental|Experimental|Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per SOC.
9896483|NCT04662632|Active Comparator|Control|SOC for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer.
9896484|NCT04662619|Experimental|B. infantis|A once-daily feeding of activated B. infantis EVC001 (8.0 *10^9 colony forming units [CFU]) will be provided to infants for 12 weeks.
9896485|NCT04662619|Placebo Comparator|Placebo|A once-daily oral feeding of lactose placebo will be provided to infants for 12 weeks.
9896486|NCT04661930|Experimental|Fenofibrate + Usual Care|Participants in this arm will receive the study drug, Fenofibrate, in combination with usual care.
9896487|NCT04661930|Placebo Comparator|Placebo + Usual Care|Participants in this arm will receive placebo treatment, in combination with usual care.
9896488|NCT04661930|No Intervention|Usual Care (Observetional)|Participants in this arm will receive the usual care and be compared by their medical records and laboratory results
9896489|NCT04657068|Experimental|Part A1|Part A1 will evaluate intermittent and continuous dosing of ART0380 monotherapy. Treatment will be given in 21-day cycles. Up to 50 participants will participate in this dose-escalation arm.
9896490|NCT04657068|Experimental|Part A2|Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 21 participants will participate in this dose escalation arm.
9896491|NCT04657068|Experimental|Part A3|Part A3 will evaluate intermittent dosing of ART0380 in combination with irinotecan in 21-day cycles. Up to approximately 12 participants will participate in this dose escalation arm.
9932817|NCT00953342|Placebo Comparator|Usual care|12 weeks of standard care
9932818|NCT00953355|Experimental|Folate|Folate plus metformin
9896492|NCT04657068|Experimental|Part B1|Part B1 will evaluate ART0380 monotherapy in up to 80 participants with solid cancers with alterations in the ATM(ataxia-telangiectasia mutated) gene likely to predict for loss of ATM protein.
9896493|NCT04657068|Experimental|Part B2|In Part B2, up to 60 participants with high grade serous ovarian, primary peritoneal, or fallopian tube carcinoma will be randomized (open-label) 1:1 to either ART0380 in combination with gemcitabine or gemcitabine alone.
9896494|NCT04657003|Experimental|10 mg Tirzepatide|10 mg Tirzepatide administered subcutaneously (SC)
9896495|NCT04657003|Experimental|15 mg Tirzepatide|15 mg Tirzepatide administered SC
9896496|NCT04657003|Placebo Comparator|Placebo|Placebo administered SC
9896497|NCT04655976|Experimental|Participants receiving cobolimab+dostarlimab+docetaxel|
9896498|NCT04655976|Experimental|Participants receiving dostarlimab+docetaxel|
9896499|NCT04655976|Active Comparator|Participants receiving docetaxel|
9896500|NCT04654845|Experimental|Pulpotomy|Only the tissue in the pulp chamber will be removed.
9896501|NCT04654845|Active Comparator|Pulpectomy|Both the chamber´s and root´s pulp tissue will be removed up to a 25 gauge.
9896502|NCT04653142|Experimental|BI 765063 (Part A) and BI 765063 + BI 754091 (Part B)|
9896503|NCT04653038|Experimental|Unresectable, recurrent or metastatic melanoma|Cohort1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune checkpoint inhibitor therapy
9896504|NCT04653038|Experimental|Untreated mucosal or acral lentiginous melanoma|Cohort2: patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous melanoma
9896505|NCT04652167||Patients suspected of community-acquired pneumonia|All patients admitted to the emergency department with suspected community- acquired pneumonia by the attending physician
9896506|NCT04651712|No Intervention|Standard care|A treating physician must perform a clinical assessment within half an hour of patient arrival. This assessment includes the decision whether the patient is suspected of having pneumonia and if this is the case, a sputum specimen and chest x-ray will be ordered. Patients with suspected pneumonia who can deliver a sputum specimen will be randomly allocated with a 1:1 computer-generated randomization schedule with permuting blocks in relation to optimal therapeutical intervention strategy. All standard care sputum samples will be cultured and analysed according to the sites' standard procedures. Under standard care, the treating physician alone decides on the optimal therapeutical intervention.
9896507|NCT04651712|Active Comparator|POC-PCR analysis supplied with a recommended action list developed by a microbiologist|Along with standard analyses, the specimens will be analysed with POC-PCR and the treating physician will receive an action-list with the results from POC-PCR.
9896508|NCT04651660|Experimental|Manual Insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole MANUAL insertion (by the surgeon).
9896509|NCT04651660|Experimental|Robotic insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole ROBOTIC insertion.
9896510|NCT04647435|Experimental|APSCTC|Oral tablets every 6h for 3 days
9896511|NCT04647435|Active Comparator|Toragesic®|Oral tablets every 6h for 3 days
9896512|NCT04647435|Active Comparator|Tramal®|Oral tablets every 6h for 3 days
9896513|NCT04645966|Experimental|MenABCWY with PLP - 6 months of age|Group 1 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.
9896514|NCT04645966|Experimental|MenABCWY - 6 months of age|Group 2 - Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule
9896515|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimerix, with PLP or SLP - 2 months of age|Group 3 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP or Scheduled Liquid Pracetamol (SLP) during primary vaccinations.
9896516|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age|Group 4 - Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule
9896517|NCT04645966|Experimental|Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age|Group 5 - Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.
9896518|NCT04645966|Experimental|MenABCWY with SLP - 2 months of age|Group 7 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given SLP during primary vaccinations.
9896519|NCT04645966|Experimental|Bexsero and Nimenrix with PLP - 2 months of age|Group 8 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations
9896520|NCT04645966|Experimental|Bexsero and Nimenrix - 2 months of age|Group 10 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule
9896521|NCT04645966|Experimental|MenABCWY with TLP - 2 months of age|Group 11 - Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with Therapeutic Liquid Paracetamol (TLP) during primary vaccinations.
9517497|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
9517777|NCT03303040|Experimental|Stimulation|Electrical stimulation of hemidiaphragm
9896522|NCT04645966|Experimental|Blinded: MenABCWY and placebo with SLP or TLP - 2 months of age|Group 13 - Participants 2 months of age vaccinated with MenABCWY and placebo on a 2+1 schedule, with a determined ratio of participants given SLP or TLP during primary vaccinations.
9896523|NCT04645966|Experimental|Blinded: Bexsero and Nimenrix with PLP or TLP - 2 months of age|Group 14 - Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule with a determined ratio of participants given PLP or TLP during primary vaccinations.
9896524|NCT04645030||Patients suspected of pneumonia|Patients suspected for pneumonia after initial evaluation by the treating physician.
9896525|NCT04644029|Experimental|ISL QM|ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil) once daily during Part 1.
9896526|NCT04644029|Active Comparator|FTC/TDF QD|FTC/TDF (TRUVADA™ or generic product emtricitabine/tenofovir disoproxil) once daily AND placebo to ISL (islatravir) once monthly in Parts 1 and 2 (placebo was not administered in Part 2).
9896527|NCT04642651|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
9896528|NCT04642651|Placebo Comparator|Control group|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
9896529|NCT04640194|Other|Control group|Standard of care alone
9896530|NCT04640194|Experimental|Treatment group A|Alteplase (low dose) on top of standard of care
9896531|NCT04640194|Experimental|Treatment group B|Alteplase (high dose) on top of standard of care
9896532|NCT04637945|Placebo Comparator|placebo|The placebo will be delivered in softgels consisting of colorant, olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, glycerin and water.
9896533|NCT04637945|Experimental|ACRB|The ACRB product will be delivered in softgels consisting of anthocyanin-rich blend. Each softgel will contain: i) 49 mg bilberry extract; ii) 101 mg black currant extract; and iii) 303 mg black rice extract. The high ACRB will deliver at least 108 mg anthocyanins. The product will also contain olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, and water.
9896534|NCT04637594|Active Comparator|Arm A (immune checkpoint inhibitor)|"CONTINUATION OF ICI TREATMENT:~Patients receive either pembrolizumab intravenously (IV) over 30 minutes on day 1, nivolumab IV over 30 minutes on days 1 and 15, atezolizumab IV over 30-60 minutes on day 1, durvalumab IV over 60 minutes on days 1 and 15, or avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 21 or 42 days for pembrolizumab, every 21 days for atezolizumab, and 28 days for nivolumab, durvalumab, and avelumab in the absence of disease progression or unacceptable toxicity."
9896535|NCT04637594|Experimental|Arm B (immune checkpoint inhibitor)|"DISCONTINUATION OF ICI TREATMENT:~Patients receiving ICI treatment will discontinue ICI treatment within 1 cycle length after randomization. Cycle length is determined by the ICI regimen the patient is receiving at randomization. At disease progression patients may restart the same ICI treatment they were receiving upon randomization at physician discretion."
9896536|NCT04637529|Experimental|S (+) - Ibuprofen|S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.
9896537|NCT04637529|Active Comparator|Ibuvix® - ibuprofen|Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.
9896538|NCT04636073|Experimental|Leaflex™ Performer|
9896539|NCT04635605|Experimental|Methylene Blue|Methylene Blue 100 mg capsules. Patients will receive Methylene blue (MB) capsules of 100mg every 12 hours for a total of 5 days.
9896540|NCT04635605|Active Comparator|control group|The control intervention would be the group receiving 100 mg placebo capsules twice a day for five consecutive days
9896541|NCT04635111||Symptomatic TGCT Participants|Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).
9896542|NCT04634747|Experimental|PVX-410/pembrolizumab/chemotherapy|
9896543|NCT04631809|Active Comparator|invasive Coronary Angiography alone|
9896544|NCT04631809|Experimental|CT-Coronary Angiography + invasive Coronary Angiography|
9896545|NCT04631016|Experimental|MEDI3506|Approximately 72 participants will be randomized to receive MEDI3506
9896546|NCT04631016|Placebo Comparator|Placebo|Approximately 72 participants will be randomized to receive placebo
9896547|NCT04630262|Active Comparator|ATTUNE Cementless CR Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Cruciate Retaining Configuration.
9896548|NCT04630262|Active Comparator|ATTUNE Cementless PS Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Posterior Stabilizing Configuration.
9896549|NCT04629534|Experimental|Group A|
9896550|NCT04629534|Placebo Comparator|Group B|
9896551|NCT04629248|Experimental|Open Label Treatment: Obinutuzumab|Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).
9517778|NCT03303040|No Intervention|Control|No stimulation of hemidiaphragm
9896552|NCT04629248|Active Comparator|Open Label Treatment: Tacrolimus|Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).
9896553|NCT04627558||stroke patients, balance assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
9896554|NCT04627142|Experimental|Expansion dose 1|Part C: Combination therapy expansion part
9896555|NCT04627142|Experimental|Expansion dose 2|Part C: Combination therapy expansion part
9896556|NCT04626297|Experimental|Lebrikizumab|Lebrikizumab given by subcutaneous (SC) injection.
9896557|NCT04626297|Placebo Comparator|Placebo|Placebo given by SC injection.
9896558|NCT04622904|Active Comparator|lidocaine-magnesium group|combination of lidocaine and magnesium infusions
9896559|NCT04622904|Active Comparator|lidocaine-ketamine group|combination of lidocaine and ketamine infusions
9896560|NCT04622904|Active Comparator|lidocaine group|lidocaine infusion alone
9896561|NCT04619927|Experimental|Intervention group|The intervention includes testing of patients for carriage of the CYP2C19*2 and *3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
9896562|NCT04619927|Active Comparator|Comparison group|The comparison group will not be prescribed clopidogrel 75mg without preceding testing for carriage of the CYP2C19*2 and *3 loss-of-function alleles. CYP2C19 genotyping will be performed at the end of the study.
9896563|NCT04616326|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
9896564|NCT04616326|Placebo Comparator|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
9896565|NCT04610736|Experimental|Single arm|Temozolomide 40 mg/ml, Oral suspension
9896566|NCT04610047|Experimental|Norketotifen|Norketotifen oral capsules, twice daily for 7 days
9896567|NCT04610047|Placebo Comparator|Placebo|Placebo oral capsules, twice daily for 7 days
9896568|NCT04609215|Experimental|ALECSAT|"This is an exploratory single arm study. 20 patients will be included with the objective to investigate the safety, tolerability and trends of efficacy of ALECSAT for the treatment of recurrent TNBC.~ALECSAT is a form of adoptive cell therapy medicinal product. ALECSAT is an abbreviation for Autologous Lymphoid Effector Cells Specific Against Tumor. ALECSAT is an autologous product that induces an immune response against a broad repertoire of CTAs expressed on cancer cells (including TNBC) leading to killing of these cells.~Patients will receive standard treatment with carboplatin and gemcitabine along with ALECSAT."
9896569|NCT04608331|Experimental|Dexmedetomidine group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
9896570|NCT04608331|Placebo Comparator|Placebo group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
9896571|NCT04605861|Experimental|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on abdomen, thigh or upper arm.
9896572|NCT04605861|Placebo Comparator|Placebo|Placebo (Liraglutide Injection simulator), once a day, injected subcutaneously on abdomen, thigh or upper arm.
9896573|NCT04603326||Non-manifesting LRRK2 mutation carriers|Patients must have confirmed LRRK2 G2019S mutation Age 30 years or older at date of informed consent.
9932819|NCT00953355|Placebo Comparator|Placebo|Placebo plus metformin
9517779|NCT03303027|Experimental|6-0 fast absorbing gut suture|6-0 fast absorbing gut used to suture wound
9896574|NCT04603326||LRRK2 Parkinson Disease (PD) Participants:|Patients must have confirmed LRRK2 G2019S mutation Patients must meet the MDS criteria for Parkinson's disease Disease duration: any Age 30 years or older at time of PD diagnosis.
9896575|NCT04603326||Idiopathic PD (iPD) Particpants:|Patients must meet the MDS criteria for Parkinson's disease. Disease duration: any Age 30 years or older at time of PD diagnosis.
9896576|NCT04603326||Control (C) Participants:|Age 30 years or older at date of informed consent.
9896577|NCT04602611|No Intervention|Standard of Care|Standard of Care
9896578|NCT04602611|Experimental|Oncology Nurse Navigation|Standard of Care + Oncology Nurse Navigation
9896579|NCT04602390|Experimental|ANK-700 SAD Cohort 1, Dose A|All enrolled patients will receive one dose of ANK-700 Dose A
9896580|NCT04602390|Experimental|ANK-700 SAD Cohort 2, Dose B|All enrolled patients will receive one dose of ANK-700 Dose B
9896581|NCT04602390|Experimental|ANK-700 SAD Cohort 3 Dose C|All enrolled patients will receive one dose of ANK-700 Dose C
9896582|NCT04602390|Experimental|MAD Cohort 4 ANK-700 Dose A or Placebo|All enrolled patients will receive three doses of ANK-700 Dose A or placebo
9896583|NCT04602390|Experimental|MAD Cohort 5 ANK-700 Dose B or placebo|All enrolled patients will receive three doses of ANK-700 Dose B or placebo
9896584|NCT04600336|Experimental|Arm A (low-dose oxybutynin)|Patients receive low-dose oxybutynin chloride (2.5 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
9896585|NCT04600336|Experimental|Arm B (high-dose oxybutynin chloride)|Patients receive high-dose oxybutynin chloride (5.0 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
9896586|NCT04600336|Placebo Comparator|Arm C (low-dose placebo)|Patients receive a low-dose placebo (2.5 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm A per physician discretion.
9896587|NCT04600336|Placebo Comparator|Arm D (high-dose placebo)|Patients receive a high-dose placebo (5.0 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm C per physician discretion.
9896588|NCT04597632|Experimental|brolucizumab 6 mg|Participants will receive brolucizumab 6 mg/0.05 mL solution by intravitreal injection in a Treat-to-Control regimen with injection intervals from 4 up to 20 weeks. Intervals may be changed in steps of 4 weeks at a time per investigators' decisions determined by the disease activity.
9896589|NCT04597333|Active Comparator|2nd Dinoprostone.|Women induced with a second dinoprostone insert.
9896590|NCT04597333|Active Comparator|Cervical ripening balloon.|Women induced with a cervical ripening balloon.
9896591|NCT04596579||Participants age 18-34|Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.
9896592|NCT04596579||Participants age 35-54|Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
9896593|NCT04596579||Participants age 55-64|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
9896594|NCT04596579||Participants 65 and over|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
9896595|NCT04595721|No Intervention|Standard of care|Participants will receive standard injection procedures
9896596|NCT04595721|Active Comparator|Visual distraction|Participants engage in visual distraction during the injection procedures
9896597|NCT04595721|Active Comparator|Physical distraction|Participants engage in physical distraction during the injection procedures
9896598|NCT04595565|Experimental|Sacituzumab govitecan|Sacituzumab govitecan is administered intravenously 10 mg/kg body weight on days 1, 8 q3w for eight cycles.
9896599|NCT04595565|Other|Treatment of physician´s choice|TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or Observation.
9896600|NCT04594707|Experimental|PRM-151|"Corhort A: Participants entering, following participation in study PRM-151-202.~Cohort B: Participants entering, following participation in study WA42293."
9896601|NCT04593927||Mayzent|Patients administered Mayzent by prescription
9896602|NCT04593121|Experimental|Cohort 1A|Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.
9896603|NCT04593121|Experimental|Cohort 2A|Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1.
9896604|NCT04593121|Experimental|Cohort 3A|Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1.
9896605|NCT04593121|Experimental|Cohort 4A|Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1.
9896606|NCT04593121|Experimental|Cohort 5A|Participants will receive Dose 2 of BIIB107 or placebo intravenous (IV) on Day 1.
9896607|NCT04593121|Experimental|Cohort 6A|Participants will receive Dose 5 of BIIB107 or placebo IV on Day 1.
9896608|NCT04593121|Experimental|Cohort 1B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
9896609|NCT04593121|Experimental|Cohort 2B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
9896610|NCT04593121|Experimental|Cohort 3B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
9896611|NCT04591860|Active Comparator|Sutures only|"Patients with a large hiatal hernia undergo the cruroplasty with sutures only.~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
9896612|NCT04591860|Active Comparator|Absorbable Mesh|"Patients with a large hiatal hernia undergo the cruroplasty with mesh implantation.~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
9896613|NCT04591860|Active Comparator|Pledgeted sutures|"Patients with a large hiatal hernia undergo the cruroplasty with pledgeted sutures.~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
9896614|NCT04588428|Experimental|Part 1: INO-4700 Group A|Participants will receive one ID injection of 0.6 milligram (mg) of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
9896615|NCT04588428|Experimental|Part 1: INO-4700 Group B|Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
9896616|NCT04588428|Experimental|Part 1: INO-4700 Group C|Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
9896617|NCT04588428|Experimental|Part 1: INO-4700 Group D|Participants will receive two ID injections (in an acceptable location on two different limbs) of 0.5 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
9896618|NCT04588428|Experimental|Part 1: INO-4700 Group E|Participants will receive two ID injections (in an acceptable location on two different limbs) of 1.0 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
9896619|NCT04588428|Placebo Comparator|Part 1: Placebo Group F|Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
9896620|NCT04588428|Placebo Comparator|Part 1: Placebo Group G|Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
9896621|NCT04588428|Placebo Comparator|Part 1: Placebo Group H|Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
9896622|NCT04588428|Placebo Comparator|Part 1: Placebo Group I|Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
9896623|NCT04588428|Experimental|Part 2: Parts 2A and 2B|Participants will receive ID injection of INO-4700 based on optimal dose and regimen selection in Part 1 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4 or Week 8 and a booster dose at Week 48 (only for Part 2B participants receiving a third dose).
9896624|NCT04587869|Experimental|Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
9896625|NCT04587869|No Intervention|No-treatment control|Participants who are assigned to the control group will not receive the intervention.
9932820|NCT00953368|Active Comparator|Remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
9896626|NCT04587830|Experimental|ADI-PEG 20 plus Radiotherapy and Temozolomide|"ADI-PEG 20 Dose: 18 and 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)~Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 5 weeks of surgery (diagnostic and/or resection)~Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous"
9896627|NCT04587154|Experimental|Intervention Group|This arm will follow a low-fat vegan diet in addition to 1/2 a cup of cooked soybeans each day for the duration of the study. They will also weigh themselves each week, and report weight and hot flash frequency/severity weekly.
9896628|NCT04587154|No Intervention|Control Group|This arm will not change their diet for the duration of the study. They will also weigh themselves each week and report weight and hot flash frequency/severity weekly.
9896629|NCT04585815|Experimental|Sub-Study A|Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
9896630|NCT04585815|Experimental|Sub-Study B|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.
9896631|NCT04582149|Experimental|EyeControl Eye-tracking Device|Ventilated ICU patients using the EyeControl wearable, eye-tracking device.
9896632|NCT04579432|Experimental|Training Group|
9896633|NCT04579432|No Intervention|Control Group|
9896634|NCT04579406||non-diabetic group|The non-diabetic patients undergoing non-cardiac surgery.
9896635|NCT04579406||Diabetic group|The diabetic patients without peripheral neuropathy undergoing non-cardiac surgery.
9896636|NCT04579406||Diabetic neuropathic group|The diabetic patients with peripheral neuropathy undergoing non-cardiac surgery.
9896637|NCT04578873|Experimental|QPX7831 SAD Cohorts|oral, single ascending dose (or placebo)
9896638|NCT04578873|Experimental|QPX7831 MAD Cohorts|oral, multiple ascending dose (or placebo)
9896639|NCT04576585|Experimental|Appetite lexicon training group|They will get appetite lexicon training in week three.
9896640|NCT04576585|Active Comparator|taste Lexicon training|They will get taste lexicon training In week three.
9896641|NCT04576455|Experimental|Giredestrant|
9896642|NCT04576455|Active Comparator|Physician's Choice of Endocrine Monotherapy|The physician's choice of endocrine monotherapy will be limited to fulvestrant or an aromatase inhibitor.
9896643|NCT04576156|Experimental|Imetelstat|Participants will receive imetelstat at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
9896644|NCT04576156|Active Comparator|Best Available Therapy (BAT)|Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
9896645|NCT04576104|Active Comparator|Arm I (megestrol acetate)|Prior to standard of care surgery, patients receive megestrol acetate PO BID for 4 weeks in the absence of disease progression or unacceptable toxicity.
9896646|NCT04576104|Experimental|Arm II (megestrol acetate, metformin hydrochloride)|Prior to standard of care surgery, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 4 weeks in the absence of disease progression or unacceptable toxicity.
9896647|NCT04575038|Experimental|Brequinar 100 mg|Brequinar oral capsules 100 mg x 5 days
9896648|NCT04575038|Placebo Comparator|Placebo|Placebo for Brequinar capsules x 5 days
9932821|NCT00953368|Placebo Comparator|control|sham placement of a blood-pressure cuff around the upper limb without inflation
9932822|NCT00953381|Experimental|5 mg ilaprazole|
9932823|NCT00953381|Experimental|10 mg ilaprazole|
9896649|NCT04574518|Experimental|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
9896650|NCT04574518|Other|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
9896651|NCT04574492||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
9896652|NCT04574115|Experimental|Study Eye|study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.
9896653|NCT04574115|Active Comparator|Control Eye|Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).
9896654|NCT04574102|Experimental|Study Eye|Omega Refractive capsule, model V, with an FDA approved intraocular lens.
9896655|NCT04574102|Active Comparator|Control Eye|FDA approved Intraocular Lens
9896656|NCT04573738|Experimental|Robotic transanal surgery|Robotic assisted transanal total mesorectal excision for rectal cancer patients
9896657|NCT04573738|Active Comparator|Laparoscopic transanal surgery|Laparoscopic transanal total mesorectal excision for rectal cancer patients
9896658|NCT04572802||control group|Coronary heart disease population: after coronary angiography, Gensini score was used to evaluate the severity of coronary artery occlusion, and then compared with the population of type 2 diabetes complicated with coronary heart disease
9896659|NCT04572802||experimental group (course of disease <5 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).Retrospective examination of patients' data, recording patients' laboratory tests and drug use, taking blood to measure orphanin, and evaluating the severity of coronary artery occlusion with Gensini score.
9896660|NCT04572802||experimental group(course of disease 5-10 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).
9896661|NCT04572802||experimental group(course of disease10-20 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 10 -20years).Finally, the data were obtained to evaluate the relationship between the course of diabetes and the severity of coronary heart disease, as well as the relationship between the course of diabetes and OFQ in patients' blood.
9896662|NCT04565834||Suicidal patients|Patients who have made at least one attempt to commit suicide.
9896663|NCT04565834||Control group|"This group will consist of two types of people:~75 healthy subjects (i.e. those who have no mental disorders and have never attempted to commit suicide) and~150 patients suffering from depression but have never attempted to commit suicide."
9896664|NCT04563520|Experimental|Experimental treatment|"Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI. If there is less than a good' response in bleed event response efficacy as stated above at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with max dose no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days without further discussion with the PI."
9896665|NCT04559945|Experimental|Aveir Leadless Pacemaker|VVIR pacing
9896666|NCT04558918|Experimental|LNP023 monotherapy|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
9896667|NCT04558918|Active Comparator|anti-C5 antibody treatment|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
9896668|NCT04556435||LC Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.
9896669|NCT04556435||Control Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).
9896670|NCT04554966|Experimental|Part A: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.
9896671|NCT04554966|Experimental|Part A: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.
9896672|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.
9896673|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A|Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.
9896674|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.
9896675|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B|Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.
9932824|NCT00953381|Experimental|20 mg ilaprazole|
9896676|NCT04554966|Experimental|Part B: Subcutaneous Cohort: ABBV-382|Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.
9896677|NCT04553536|Active Comparator|Opioid analgesics|Mu-opioid receptor agonists (remifentanil, sulfentanil) will be used as the only analgesic(s) in the surgery.
9896678|NCT04553536|Experimental|Ketamine|Esketamine will be used as the only anagesic in the surgey.
9896679|NCT04551547|Experimental|Experimental Vaccine-low dosage|low dosage inactivated SARS-CoV-2 vaccine
9896680|NCT04551547|Experimental|Experimental Vaccine-medium dosage|medium dosage inactivated SARS-CoV-2 vaccine
9896681|NCT04551547|Placebo Comparator|Placebo|No active ingredient in the placebo
9932825|NCT00953381|Active Comparator|20 mg omeprazole|
9932826|NCT00953394|Experimental|treatment arm|continuous 5 fluouracil infusion plus long-acting octreotide
9932827|NCT00953433|Experimental|Endoflex tube|Use of Endoflex tube for intubation.
9932828|NCT00953433|Active Comparator|Endotracheal tube with stylet|Use of conventional endotracheal tube with a stylet for intubation.
9932829|NCT00953446|Experimental|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|"ASL MRI~Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment"
9932830|NCT00953498|Active Comparator|pioglitazone|treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)
9932831|NCT00953498|Active Comparator|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
9932832|NCT00953511|Other|genetic|
9932833|NCT00953537|Other|capecitabine|
9932834|NCT00953550|Experimental|Rocuronium-Sugammadex|
9932835|NCT00953550|Active Comparator|Succinylcholine|
9932836|NCT00953563|No Intervention|compression therapy|
9932837|NCT00953563|Active Comparator|Biologic with compression therapy|
9932838|NCT00953589|Experimental|Locteron ® PANEL A|PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)
9932839|NCT00953589|Experimental|Locteron ® PANEL B|PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections
9932840|NCT00953589|Active Comparator|PEG-Intron® PANEL A|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
9932841|NCT00953589|Active Comparator|PEG-Intron® PANEL B|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
9932842|NCT00953628|Active Comparator|o Group A=uHCG ovul trig|HCG for triggering
9932843|NCT00953628|Experimental|o Group B=recHCG ovul trig|recombinant HCG for triggering
9932844|NCT00953641|Active Comparator|Pre-Menopausal 1|Pre-Menopausal group, receiving Misoprostol
9932845|NCT00953641|Placebo Comparator|Pre-Menopausal 2|Patients will insert a placebo vaginal suppository 12h or more prior to the endometrial biopsy
9932846|NCT00953641|Active Comparator|Post-Menopausal 1|Post-Menopausal patients will insert a Misoprostol vaginal suppository 12h or more prior to the endometrial biopsy
9932847|NCT00953641|Placebo Comparator|Post-Menopausal 2|Placebo vaginal suppository prior to the endometrial biopsy
9932848|NCT00953732||1|
9932849|NCT00953758|Experimental|1|
9932850|NCT00953771|Experimental|Danazol, Plex, Steroids|Everyone will receive Danazol with plasma exchange and corticosteroids
9932851|NCT00953784|No Intervention|1|Standard management
9932852|NCT00953784|Active Comparator|2|Extended management: with no bowel prep except enema,restricted fluids, increased O2,body warming and use of skin protectors during surgery as previously described
9932853|NCT00953810|No Intervention|control|General heart failure population staying under regular care of their primary care physician
9932854|NCT00953810|Active Comparator|Intervention|Like control plus one education training regarding heart failure aspects and management
9932855|NCT00953888|Experimental|Active|AZD5069 oral solution
9932856|NCT00953888|Placebo Comparator|Placebo|Placebo oral solution
9932857|NCT00953914|Experimental|Pyridostigmine|
9932858|NCT00953914|Placebo Comparator|Placebo|If a subject is randomized to placebo, he will receive placebo pills 3 times daily for 1 day.
9932859|NCT00953940|Experimental|Isotonic saline|Isotonic saline
9932860|NCT00953940|No Intervention|No treatment|Habitual therapy
9932861|NCT00953953||Acutely Decompensated Systolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
9932862|NCT00953953||Chronic HF Patients on Dialysis|Patients who have heart failure (defined as NYHA class II, III, or IV) and are on dialysis.
9932863|NCT00953953||Ambulary Chronic HF|Patients with diagnosis of chronic heart failure (NYHA class II and III) who are on optimal medical therapy.
9932864|NCT00953953||Acutely Decompensated Diastolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
9896682|NCT04549792|Experimental|Open Label|
9896683|NCT04547140|Experimental|Liquid Alpha1-Proteinase Inhibitor+Standard Medical Treatment|Participants will receive the first Intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) (120 milligram per kilogram [mg/kg]), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
9896684|NCT04547140|Placebo Comparator|Placebo+Standard Medical Treatment|Participants will receive IV infusions of 0.9% Normal Saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
9896685|NCT04546009|Experimental|Giredestrant + Letrozole-matched Placebo + Palbociclib|
9896686|NCT04546009|Active Comparator|Letrozole + Giredestrant-matched Placebo + Palbociclib|
9896687|NCT04545619|Experimental|Paroxysmal and Early Persistent AFIB|
9896688|NCT04545567|Experimental|RocketAP|Adolescents will be assessed for a 48-70 hour period on the Rocket AP. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the USS Virginia system under the same conditions.
9896689|NCT04545567|Active Comparator|USS Virginia|Adolescents will be assessed for a 48-70 hour period on the USS Virginia system. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the Rocket AP system under the same conditions.
9896690|NCT04544865|Experimental|Gastric and thoracic staple line reinforcement|ECHELON ENDOPATH Staple Line Reinforcement is used during a gastric or thoracic procedure.
9896691|NCT04544852|Placebo Comparator|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge."
9896692|NCT04544852|Active Comparator|Targeted intervention programme|"Intervention B involves a targeted intervention programme tackling issues relating to a lack of education, inconvenience and cost would improve screening rates amongst the spouses."
9896693|NCT04543617|Experimental|Arm A: Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab.
9896694|NCT04543617|Experimental|Arm B: Tiragolumab Placebo + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab matching placebo.
9896695|NCT04543617|Placebo Comparator|Arm C: Tiragolumab Placebo + Atezolizumab Placebo|Participants will receive matching placebos to tiragolumab and atezolizumab.
9896696|NCT04542057|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
9896697|NCT04542057|Placebo Comparator|Arm 2|Placebo Nebulized BID
9896698|NCT04540211|Experimental|Atezolizumab + Tiragolumab + PC|Participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
9896699|NCT04540211|Placebo Comparator|Placebo + PC|Participants will receive atezolizumab matching placebo and tiragolumab matching placebo on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
9896700|NCT04535986|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
9896701|NCT04535986|Placebo Comparator|Arm 2|Placebo Nebulized BID
9896702|NCT04533997|Active Comparator|Intravenous furosemide|
9896703|NCT04533997|Experimental|Hypertonic saline solution plus intravenous furosemide|
9896704|NCT04533451|Experimental|Group A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9896705|NCT04533451|Experimental|Group B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV per institutional guidelines on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9896706|NCT04530110|Experimental|Fremanezumab|The dose of Fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
9896707|NCT04529304|Experimental|Visual EEG|Individual dosing of anesthetic medications based on EEG AND other standardized clinical observations (BP, HR)
9896708|NCT04529304|Experimental|Blinded EEG|Individual dosing of anesthetic medications based on standardized clinical observations (BP, HR).
9896709|NCT04527419|Active Comparator|Systematically mediastinal lymph node dissection group|Systematically mediastinal lymph node dissection will be performed.
9896710|NCT04527419|Experimental|No mediastinal lymph node dissection group|Mediastinal lymph node dissection will not be performed.
9896711|NCT04525547||Patients treated with Nintedanib|
9896712|NCT04524364|Other|Participants with Paroxysmal Atrial Fibrillation (PAF)|Participants with PAF and who are candidates for catheter ablation will be enrolled.
9896713|NCT04522375|Experimental|FP-045|FP-045 at one of 3 dose levels to sequential cohorts of adolescent, followed by pediatric subjects
9896714|NCT04521478|Experimental|Treatment group 1|BI 1358894
9896715|NCT04521478|Placebo Comparator|Placebo group|Placebo
9896716|NCT04521478|Experimental|Treatment group 2|Quetiapine
9896717|NCT04519476|Experimental|Selinexor/Lenalidomide/Steroids|All subjects enrolled will receive: 1) selinexor, PO, at 60 mg once weekly on days 1-28 of a 28-day cycle, 2) lenalidomide, PO, 10 mg daily on days 1-21 of 28-days cycle and 3) methylprednisolone at the same dose and schedule as the last lenalidomide-containing regimen if it contained steroids. If patient's qualifying lenalidomide-containing regimen contained different type of steroid (e.g. prednisone, dexamethasone, etc.) then patient on this study will receive methylprednisolone at the equivalent dose and schedule.
9896718|NCT04506619||SHP607 250 mcg/kg/24 hours|Participants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
9896719|NCT04506619||SHP607 400 mcg/kg/24 hours|Participants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
9896720|NCT04506619||Standard Neonatal Care|Participants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
9896721|NCT04500158|Experimental|Local anesthesia|Participants will receive local anesthesia in addition to the standard care general anesthesia
9896722|NCT04500158|No Intervention|Standard care|Participants will receive standard care general anesthesia
9896723|NCT04499482|Experimental|Foods containing 10 g soy flour|Participants will receive foods containing 10 g of soy flour to be consumed everyday for one week.
9896724|NCT04499482|Experimental|Foods containing 20 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week.
9896725|NCT04499482|Experimental|Foods containing 30 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week.
9896726|NCT04496947|Experimental|Stress Reduction|8 week stress reduction course
9896727|NCT04496947|No Intervention|Control|No intervention
9896728|NCT04494412|Experimental|Hospitalized neonates and infants with influenza infection|Preterm neonates and infants who have reached Post-Menstrual Age (PMA) of at least 28 weeks and have a confirmed complicated influenza infection will be included. Participants will receive daily IV infusion of zanamivir for up to 5 days. This initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests warrant further treatment. The initial dose of IV zanamivir will be determined by PMA/corrected age and body weight. The maintenance dose and interval between the initial dose and subsequent twice-daily maintenance dose will be further determined by Principal Investigator based on renal function.
9896729|NCT04493203|Experimental|Nivolumab plus Axitinib|"Nivolumab 480mg, IV, every 4 weeks, for up to two years.~Axitinib 5mg, PO, BID, for up to two years."
9896730|NCT04485559|Experimental|Treatment (trametinib, everolimus)|Patients receive dosing per their assigned dose level. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
9896731|NCT04480190|Experimental|Research Treatment|Gemcitabine/Cisplatin/ChemoRT
9896732|NCT04480125|Experimental|Aza+Chida|Azacitidine ivgtt D1-7 Chindamide 30mg,PO,twice a week Every 21 days for total 6 courses
9896733|NCT04480099|Active Comparator|CHOP|Patients in this arm will receive conventional CHOP regimen for 6 cycles
9896734|NCT04480099|Experimental|CHOP+X|Patients in this arm will receive targeted drug in combination with conventional CHOP regimen for 6 cycles, based on NGS results
9896735|NCT04472897|Experimental|Part A: Participants receiving GSK2556286|Participants will be randomized to receive GSK2556286 in any of the 11 cohorts. In each dosing cohort, 6 participants will receive a single dose of GSK2556286. Following initial dosing of cohorts in the fasted state, one cohort will investigate the effect of food administration (high fat meal) on safety, tolerability and PK data of GSK2556286. One cohort may also investigate the effects of a moderate fat meal.
9896736|NCT04472897|Placebo Comparator|Part A: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 11 cohorts. In each dosing cohort, 2 participants will receive a single dose of matching placebo.
9932865|NCT00953966|Other|Starch 1|Starch 1
9932866|NCT00953966|Other|Starch 2|Starch 2
9932867|NCT00953966|Other|Starch 3|Starch 3
9932868|NCT00953966|Other|Starch 4|Starch 4
9932869|NCT00953966|Other|Starch 5|Starch 5
9932870|NCT00953966|Other|Starch 6|Starch 6
9932871|NCT00953966|Other|Starch 7|Starch 7
9896737|NCT04472897|Experimental|Part B: Participants receiving GSK2556286|"Participants will be randomized to receive GSK2556286 in any of the 4 cohorts. In each dosing cohort, 6 participants will receive repeat doses of GSK2556286 under either fasting or fed conditions, dependent on the results from Part A.~Appropriate doses and dose regimens for Part B will be selected by the Dose Escalation Committee based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B."
9896738|NCT04472897|Placebo Comparator|Part B: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 4 cohorts. In each dosing cohort, 2 participants will receive repeat doses of matching placebo under either fasting or fed conditions, dependent on the results from Part A.
9896739|NCT04472143|Experimental|Granisetron Transdermal Delivery System|The patch will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days
9896740|NCT04471987|Experimental|Treatment|"The study will take place in two stages:~In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached.~Following successful identification of the RD, the study will proceed with a dose expansion part and 40 patients will be treated at the RD dose level."
9896741|NCT04464980|Experimental|Retention: SL-BUP standard dose + MM|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896742|NCT04464980|Experimental|Retention: SL-BUP high dose + MM|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896743|NCT04464980|Experimental|Retention: XR-BUP + MM|Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896744|NCT04464980|Experimental|Retention: XR-NTX + MM|Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896745|NCT04464980|Experimental|Retention: SL-BUP standard dose + MMR|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
9896746|NCT04464980|Experimental|Retention: SL-BUP high dose + MMR|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
9896747|NCT04464980|Experimental|Retention: XR-BUP + MMR|Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
9896748|NCT04464980|Experimental|Retention: XR-NTX + MMR|Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus Pear-002a, a technology-based behavioral component, to support retention and abstinence.
9896749|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with SL-BUP + MM|Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896750|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with XR-BUP + MM|Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896751|NCT04464980|Experimental|Discontinuation: Discontinue XR-BUP with XR-BUP + MM|Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896752|NCT04464980|Experimental|Discontinuation: Discontinue XR-NTX with XR-NTX + MM|Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
9896753|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with SL-BUP + MMD|Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
9896754|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with XR-BUP + MMD|Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
9896755|NCT04464980|Experimental|Discontinuation: Discontinue XR-BUP with XR-BUP + MMD|Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
9896756|NCT04464980|Experimental|Discontinuation: Discontinue XR-NTX with XR-NTX + MMD|Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
9896757|NCT04464707|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
9896758|NCT04464707|Placebo Comparator|Placebo|Matching placebo
9932872|NCT00953979|Active Comparator|Sulfasalazine|Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
9896759|NCT04464200|Experimental|19(T2)28z1xx CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of 19(T2)28z1XX CAR T cells to establish the RP2D. There are 4 planned flat-dose levels: 25x10^6, 50 x 10^6, 100 x 10^6 and 200 x 10^6 CAR T cells and one de-escalation dose: 12.5 x 10^6 CAR T cells. A standard 3+3 dose escalation design will be implemented starting from dose 1.
9896760|NCT04463654|Experimental|Zero Self-Harm|When randomized to the Zero Self-Harm app the participants will receive an introduction to the app through videos in the app, which explains, amongst others, how to review previous crisis situations and possible strategies for future crisis. This will ensure the navigation and knowledge of the technicalities of the app, in addition to ensure the app can be used privately without personal guidance from e.g a therapist.
9896761|NCT04463654|No Intervention|Treatment as usual|The control group will continue their present course of treatment and/or counseling at non-profit organizations, service centers in the municipalities, at outpatient treatment services for psychiatric disorders and/or care, attention at emergency departments. They will receive no treatment on the nature of NSSI. Participants in the control group will be offered a possibility to download the Zero Self-Harm app after they have completed the last questionnaire at six months, which will be stressed at the initial appointment as well as after collection of all data.
9896762|NCT04462536|Placebo Comparator|Placebo|Vehicle only
9896763|NCT04462536|Experimental|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
9896764|NCT04460248|Experimental|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|
9896765|NCT04458857|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
9896766|NCT04458857|Placebo Comparator|Placebo|Matching placebo
9896767|NCT04455750|Experimental|Arm I (enzalutamide, rucaparib)|Patients receive enzalutamide PO QD and rucaparib PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9896768|NCT04455750|Active Comparator|Arm II (enzalutamide, placebo)|Patients receive enzalutamide PO QD and placebo PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9896769|NCT04452526|Experimental|ARM I (EARLY INTERVENTION) (educational material, reminders)|Health systems receive educational materials consisting of posters, brochures and handouts. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination
9896770|NCT04452526|Experimental|ARM II (DELAYED INTERVENTION)(education, reminder, usual care)|Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.
9896771|NCT04451772|Experimental|Part 1: Elsubrutinib Dose A and Upadacitinib Dose A|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose A once daily (QD).
9896772|NCT04451772|Experimental|Part 2: Elsubrutinib Dose A and Upadacitinib Dose B|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose B QD.
9896773|NCT04451772|Experimental|Part 3: Elsubrutinib Dose A and Upadacitinib Placebo|Participants will receive Elsubrutinib Dose A and Upadacitinib placebo QD.
9896774|NCT04451772|Experimental|Part 4: Elsubrutinib Placebo and Upadacitinib Dose A|Participants will receive Elsubrutinib placebo and Upadacitinib Dose A QD.
9896775|NCT04451408|Experimental|LY3372993 (Part A)|LY3372993 administered as multiple doses intravenously (IV).
9896776|NCT04451408|Experimental|LY3372993 (Part B)|LY3372993 administered as single dose IV.
9896777|NCT04451408|Placebo Comparator|Placebo (Part A)|Placebo administered as multiple doses IV.
9896778|NCT04451408|Placebo Comparator|Placebo (Part B)|Placebo administered as single dose IV.
9896779|NCT04445896||Study Participants|Patients with a diagnosis of a life-limiting illness who have previosuly had a discussion with a healthcare professional about the care they would want at the end of life
9896780|NCT04442269|Experimental|dupilumab|Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
9896781|NCT04442269|Experimental|Placebo|Matching dupilumab without active substance
9896782|NCT04437511|Experimental|Donanemab|Donanemab given intravenously (IV).
9896783|NCT04437511|Placebo Comparator|Placebo|Placebo given IV.
9896784|NCT04433585|Experimental|LY3471851 High Dose|LY3471851 administered subcutaneously (SC).
9896785|NCT04433585|Experimental|LY3471851 Mid Dose|LY3471851 administered SC.
9896786|NCT04433585|Experimental|LY3471851 Low Dose|LY3471851 administered SC
9896787|NCT04433585|Placebo Comparator|Placebo|Placebo administered SC.
9896788|NCT04432935|Experimental|Bovine Lactoferrin|Intervention group will receive bovine lactoferrin supplementation daily once a day from day 0 of birth to 6 weeks of life.
9896789|NCT04432935|Placebo Comparator|Glucon D|Control group will receive Glucon-D supplementation daily once a day from day 0 of birth to 6 weeks of life.
9896790|NCT04430842|Experimental|Dose escalation of QBS10072S|Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.
9896791|NCT04429087|Experimental|BI 764532|
9991860|NCT01456767|Placebo Comparator|Placebo|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of a placebo).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
9991861|NCT01456793|Experimental|Teen Options to Prevent Pregnancy|
9991862|NCT01456793|No Intervention|Usual care services|
9991863|NCT01456806|No Intervention|Patients and provider non educated|In this arm neither the patients nor the providers have attended the groupal education courses
9991864|NCT01456806|Active Comparator|Provider educated|Provider attend the interactive group education, while patients do not.
9991865|NCT01456806|Active Comparator|Patients Educated|Patients attend the interactive group education, while providers do not.
9991866|NCT01456806|Active Comparator|Providers/Patients Educated|Provider and Patients both attend the interactive group education.
9991867|NCT01456819|Experimental|Mononuclear and mesenchymal stem cells|Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells
9991868|NCT01456819|Active Comparator|Mononuclear cells only|Autologous bone marrow-derived mononuclear cells
9991869|NCT01456832||Renal Transplant Patients with Post-operative Hypoatremia|All renal transplant recipients at the Mayo Clinic of Florida from 1/1/2010 through 8/19/2011 who received a kidney from either a living or cadaveric donor.
9991870|NCT01456845||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
9991871|NCT01456858|Placebo Comparator|Child UPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Untreated plastic sheeting (interior wall and ceiling lining)
9991872|NCT01456858|Experimental|Child ITPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Insecticide treated plastic sheeting (interior wall and ceiling lining)
9991873|NCT01456858|Placebo Comparator|Child UPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Untreated plastic sheeting (ceiling and interior roof lining)
9991874|NCT01456858|Experimental|Child ITPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Insecticide treated plastic sheeting (ceiling and interior roof lining)
9991875|NCT01456871||Healthy adult females|Females, aged 20 to 30 with no history of upper extremity injury or disorder in the non-dominant arm, no history of neurologic or bleeding disorder, and no evidence of Linburg-Comstock syndrome.
9991876|NCT01456884|Experimental|Live - Vibroacoustic|Treatment order A: live guitar and vocal music therapy on day one, vibroacoustic music therapy on day two.
9991877|NCT01456884|Experimental|Vibroacoustic - Live|Treatment order B: vibroacoustic music therapy live guitar on day one, and vocal music therapy on day two.
9991878|NCT01456910|Experimental|Working group|G1 intervention group of 20 participants aged 14-36 years old and mild to severe intellectual disability of both gender.
9991879|NCT01456910|Active Comparator|Daily Living|G2 control group continue usual routine
9991880|NCT01456923|Active Comparator|Control (chemotherapy and surgery)|Patients treated with chemotherapy + surgery
9991881|NCT01456923|Active Comparator|Study|Patients treated only with chemotherapy
9991882|NCT01456975|Experimental|Valsalva|Reimplantation procedure using Valsalva prosthesis
9991883|NCT01457001|Experimental|25-OH-D vitamin|
9991884|NCT01457001|No Intervention|control|
9991885|NCT01457027|Experimental|All subjects|
9991886|NCT01457040|Experimental|Complete Remission (CR)|CR Cohort: high-risk ALL in CR and standard-risk ALL in the status of ≥CR2
9991887|NCT01457040|Experimental|Non-Remission (NR)|NR Cohort: ALL in non-remission
9991888|NCT01457066|Experimental|Intervention|This group will receive the peer navigator intervention.
9896792|NCT04426058|Experimental|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
9896793|NCT04426058|Active Comparator|Fascia iliaca|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
9896794|NCT04425538|Experimental|Infliximab|All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.
9896795|NCT04421456|Experimental|GWP42003-P 300 mg|GWP42003-P 300 milligrams (mg) per day
9896796|NCT04421456|Placebo Comparator|Placebo|Matching placebo
9896797|NCT04421456|Experimental|GWP42003-P 1000 mg|GWP42003-P 1000 mg per day
9896798|NCT04420156||i-ROP cohort|Premature infants who are at risk of retinopathy of prematurity(ROP) at participating study sites. As standard of care, babies who are born less than 31 weeks gestational age or less than 1500 grams are routinely screened for ROP. Families are approached to participate in this study where finding from babies' eye exams and associated retinal images along with demographic and other health data are collected and coded with unique identifier. No intervention is administered. The ROP exams and images obtained are done as a standard of care and would be performed even if there is no consent provided.
9896799|NCT04419649|Experimental|KER-050 Cohort 1|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles.
9896800|NCT04419649|Experimental|KER-050 Cohort 2|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles.
9896801|NCT04419649|Experimental|KER-050 Cohort 3|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 24 cycles.
9896802|NCT04419649|Experimental|KER-050 Cohort 4|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 24 cycles.
9896803|NCT04419649|Experimental|KER-050 Cohort 5|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 24 cycles.
9896804|NCT04419649|Experimental|KER-050 Dose Confirmation Cohort|Participants to receive KER-050 administered subcutaneously (SC) every 4 weeks for up to 24 cycles.
9896805|NCT04419207||Patients with Surbery|Patients who with pulmonary nodules in computed tomography and planned to receive thoracic surgery will be included. And those who have other types of cancer, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
9896806|NCT04419207||Healthy Controls|Adult participants (>18 yr) who plan to receive annual physical examination and low-dose computed tomography will be included. And those who have history cancers, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
9896807|NCT04412096|Experimental|Timolol 0.5%|To compare the variation in response to timolol between individuals
9896808|NCT04412096|Experimental|Latanoprost 0.005%|To compare the variation in response to latanoprost between individuals
9896809|NCT04406974||Patients with local recurrence|
9896810|NCT04406974||Patients with advanced colorectal cancer|
9896811|NCT04403763|Experimental|AGN-241622 Dose 1|Administered as single drop in one eye or a single drop in each eye
9896812|NCT04403763|Placebo Comparator|Placebo Dose|Administered as single drop in one eye or a single drop in each eye
9896813|NCT04403763|Experimental|AGN-241622 Dose 2|Administered as single drop in one eye or a single drop in each eye
9896814|NCT04403763|Experimental|AGN-241622 Dose 3|Administered as single drop in one eye or a single drop in each eye
9896815|NCT04403763|Active Comparator|AGN-190584|Administered as single drop in each eye
9896816|NCT04403308|Experimental|ONO-7913 as a Single Agent|
9896817|NCT04401332|Experimental|Intervention|
9896818|NCT04401332|No Intervention|Usual Care|
9896819|NCT04399551|Experimental|Participants with HIV infection|HIV-infected participants will receive CAB LA + RPV LA regimen for a month of oral lead in (OLI) at Day 1 followed by CAB LA + RPV LA injections at Months 1 and 2 and every 2 months (Q2M) thereafter.
9896820|NCT04399551|Other|Staff study participants (SSP)|Staff study participants will be randomized to receive standard implementation support (Arm-S; through visit(s) with the medication lead in their country, education on the medication, and patient and staff education/support materials) or through enhanced implementation support (Arm-E; through the addition of continuous quality improvement during the study).
9896821|NCT04397939||Patients with Cardiac Injury|Patients with cardiac injury
9896822|NCT04397939||Patients without cardiac injury|Patients without cardiac injury
9896823|NCT04397757|Experimental|COVID-19 Convalescent plasma|COVID-19 Convalescent plasma on Study Day 1 in addition to standard care
9896824|NCT04397757|No Intervention|Standard care|Standard care alone
9896825|NCT04396574|Experimental|Lasmiditan Dose 1|Lasmiditan administered orally.
9896826|NCT04396574|Experimental|Lasmiditan Dose 2|Lasmiditan administered orally.
9896827|NCT04396236|Experimental|Lasmiditan High Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
9896828|NCT04396236|Experimental|Lasmiditan Mid Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
9896829|NCT04396236|Experimental|Lasmiditan Low Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
9896830|NCT04396236|Placebo Comparator|Placebo|Placebo administered orally.
9896831|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label) from Parent Study|Participants assigned to lebrikizumab Q2W (once every 2 weeks) arm will receive investigational product Q2W by subcutaneous (SC) injection.
9896832|NCT04392154|Experimental|Lebrikizumab Q2W (Blinded) from Parent Study|Participants assigned to lebrikizumab Q2W arm will receive investigational product Q2W by SC injection. Some participants will receive loading doses.
9896833|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label Addendum)|Participants enrolling in Open-Label Addendum will receive lebrikizumab Q2W by SC injection after loading doses.
9896834|NCT04392154|Experimental|Lebrikizumab Q4W|"Participants assigned to lebrikizumab Q4W (once every 4 weeks) arm will receive investigational product Q4W by SC injection.~Intervention assigned: Lebrikizumab balanced with Placebo to maintain the blind between treatment arms."
9896835|NCT04392011|Experimental|Arm 1|"Six non-naive* subjects (3 men, 3 women) will be administered a single low dose of a well-characterized kratom product (2 g) by mouth as a tea. These subjects may or may not choose to participate in Arms 2a and 2b. For subjects who will participate in Arms 2a and 2b, a washout period of 7 days will separate Arm 1 and Arm 2. Plasma will be collected from 0-120 hours and during the washout period. Urine will be collected from 0-120 hours.~*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks."
9896836|NCT04392011|Experimental|Arm 2|"Arm 2 is divided into Arms 2a and 2b. Twelve non-naive subjects (6 men and 6 women) will participate in Arm 2a. Subjects who participate in this study arm will be administered an oral probe drug cocktail of dextromethorphan HBr (2 x 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-24 hours. Urine will be collected from 0-24 hours. A washout period of 7 days will separate Arms 2a and 2b.~For Arm 2b, the same 12 subjects will be administered a combination of a well-characterized kratom product (2 g) by mouth as a tea with an oral probe drug cocktail consisting of dextromethorphan HBr (2, 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-12 hours and during a midpoint collection within 5 days of the 24-hour blood collection. Urine will be collected from 0-24 hours."
9896837|NCT04390763|Experimental|Safety Run-in|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
9896838|NCT04390763|Experimental|Randomized Arm 1|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
9896839|NCT04390763|Experimental|Randomized Arm 2|Combination of NIS793 + gemcitabine + nab-paclitaxel
9896840|NCT04390763|Active Comparator|Randomized Arm 3|gemcitabine + nab-paclitaxel
9896841|NCT04388878|Experimental|PF-07054894|Participants will receive single or multiple ascending doses of oral PF-07054894
9896842|NCT04388878|Placebo Comparator|Placebo|Participants will receive matching placebo
9896843|NCT04388683|Experimental|Intervention|Will receive study drug treatment.
9896844|NCT04388683|No Intervention|Control|Will receive standard of care.
9896845|NCT04385680|Experimental|Chlorhexidine vaginal prep.arm|"Women in labor who will receive vaginal cleaning immediately before cesarean section using 50 ml of chlorhexidine gluconate 0.05% solution and standard abdominal scrub with chlorhexidine gluconate 4%. This concentration is indicated within the British National Formulary for swabbing in obstetrics. A swab soaked in the antiseptic will be used to clean the vagina for 30 seconds prior to CS at the time of urinary catheter insertion by long forceps.~After the CS procedure, the vagina is always cleaned of excess blood as with a dry swab."
9896846|NCT04385680|No Intervention|No vaginal antiseptic arm|Women in labor who will receive abdominal scrub with chlorhexidine gluconate 4% only. Vaginal preparation is not including antiseptic or using normal saline only.
9991889|NCT01457066|No Intervention|Control|This group will receive usual care.
9896847|NCT04385667|Active Comparator|levonorgestrel intrauterine system (LNG-IUD)|"levonorgestrel intrauterine system (LNG-IUD) applied.~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
9896848|NCT04385667|Active Comparator|Megestrol acetate (MA)|"Megesterol arm will receive 160 mg daily~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
9896849|NCT04383574|Experimental|Experimental Vaccine-medium dosage|24 participants in medium-dosage group in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants in medium-dosage group in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 ,1 dose of booster immunization 6 months after primary immunization(the third dose ) and the second booster dose (the fourth dose) 1 year after the second dose.
9896850|NCT04383574|Experimental|Experimental Vaccine-high dosage|24 participants in high-dosage group in phase Ⅰ will receive two doses of primary immunization according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 100 participants in high-dosage group in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 ,1 dose of booster immunization 6 months after primary immunization(the third dose) and the second booster dose (fourth dose) 1 year after the second dose .
9896851|NCT04383574|Placebo Comparator|Placebo|24 participants including 12 at medium dosage stage and 12 at high dosage in phase Ⅰ will receive two doses of placebo according to the immunization schedule of day 0, 28 and will receive 1 dose of booster immunization 1 year after primary immunization; 50 participants in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
9896852|NCT04383574|Experimental|Experimental Vaccine-low dosage|100 participants at low dosage stage in phase Ⅱ will receive two doses of primary immunization according to the immunization schedule of day 0,28 and will receive 1 dose of booster immunization 6 months after primary immunization.
9896853|NCT04383210|Experimental|Cohort 1|"A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
9896854|NCT04383210|Experimental|Cohort 2|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
9896855|NCT04383210|Experimental|Cohort 3|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
9896856|NCT04382651|Experimental|MAS825 + SoC|Single dose of MAS825 by intravenous infusion in addition to SoC
9896857|NCT04382651|Placebo Comparator|Placebo + SoC|Single dose of matching Placebo by intravenous infusion in addition to SoC
9896858|NCT04382326|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
9896859|NCT04382326|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
9896860|NCT04380207|Experimental|QPX7728|antibiotic
9896861|NCT04380207|Placebo Comparator|Placebo|Matched placebo
9896862|NCT04380207|Experimental|QPX2014|antibiotic
9896863|NCT04379570|Experimental|Arm I (TMR)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
9896864|NCT04379570|Experimental|Arm II (MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
9896865|NCT04379570|Experimental|Arm III (TMR + MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
9932873|NCT00953979|Placebo Comparator|placebo|The placebo capsule was used to be a comparator of kunxian capsule
9991890|NCT01457092|Experimental|FC Nitinol SEMS|FC Nitinol SEMS
9991891|NCT01457105|Experimental|ComVi biliary stent|
9896866|NCT04379570|Active Comparator|Arm IV (enhanced usual care)|Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
9896867|NCT04377932|Experimental|AGAR T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 (AGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
9896868|NCT04376502|Other|radiation therapy (RT)|RT for all subjects will consist of treating one tumor of the treating physician's preference (40 Gy in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor (ICI) is continued alone, RT will be given to a second and separate tumor (30 Gy in 5 fractions).
9896869|NCT04376112|Active Comparator|Standard of Care|
9896870|NCT04376112|Experimental|Pharmacist Intervention|
9896871|NCT04375462|Experimental|AspireAssist|"Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days, and the AspireAssist group will have a clinic visit at 7 days to have the skin-port placed.~All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube"
9896872|NCT04375462|Active Comparator|Standard PEG|Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube
9896873|NCT04372706|Experimental|Part 1: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors
9896874|NCT04372706|Experimental|Part 2: RTX-240 Solid Tumor Expansion|Phase 2: RTX-240 monotherapy dose expansion in Non-small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), and anal cancers
9896875|NCT04372706|Experimental|Part 3: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in AML
9896876|NCT04372706|Experimental|Part 4: RTX-240 Plus Pembrolizumab Dose Escalation|Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors
9896877|NCT04371952|Experimental|Doxycycline 100mg|Doxycycline capsule containing 2 tablets doxycycline 100mg over-encapsulated. Doxycycline is given at 200 mg once a day and administered per os during 2 weeks
9896878|NCT04371952|Placebo Comparator|Doxycycline placebo|Doxycycline Placebo capsule 200 mg, containing 1 capsule of a marketed placebo = RODAEL placebo ( lactose, 380 mg / capsule). Doxycycline placebo is given once a day and administered per os during 2 weeks
9896879|NCT04369677||First-Episode Psychosis|Twenty individuals with FEP will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
9896880|NCT04369677||Healthy|Twenty age-matched individuals with no psychotic disorder will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
9896881|NCT04368039|Experimental|Normobaric Oxygen Therapy (40% FiO2)|4 weeks of nightly normobaric oxygen therapy (40% FiO2)
9896882|NCT04368039|Placebo Comparator|Placebo Condition|4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)
9896883|NCT04365257|Experimental|Prazosin|"Prazosin 1mg given to observe if medication is tolerated or if signs or symptoms of hypotension develop (e.g. dizziness, lightheadedness).~If the patient remains asymptomatic and BP >110/60 mmHg, prazosin is continued at 1mg every 8 hours (q8h).~Day 3: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 2mg q8h.~Day 6: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 5mg q8h.~If the BP is <100/60 mmHg at any time, the next dose should be held, and patient continues with the highest previously tolerated dose 8 hours later.~If the patient did not tolerate dose escalation to 5mg q8h, one attempt is made to increase dose to 3mg q8h. If this is not tolerated, the patient continues with the highest previously tolerated dose 8 hours later.~If BP monitoring is not available, repeated occurrences of postural dizziness should trigger drug dose reduction or BP monitoring."
9896884|NCT04365257|Active Comparator|Standard of care|Subjects randomized to this arm will receive standard of care.
9896885|NCT04364633||Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
9896886|NCT04364633||Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
9896887|NCT04364126|Active Comparator|Standard of care|Clinical blood pressure measured at regular visits
9896888|NCT04364126|Experimental|Home blood pressure monitoring|Home blood pressure measured daily for 1 week before regular clinical visits
9896889|NCT04362722|Experimental|Single arm|"40 patients will be enrolled and treated with a mixture of 6.5 Mio IU (~1.08 mg) L19IL2 and 200 µg L19TNF once weekly for 4 consecutive weeks. The dose will be distributed among the lesions via multiple intralesional injections.~New lesions occurring during the treatment phase will also be treated as described but the treatment period for new lesions will not be extended beyond the previously defined 4 weeks treatment period with clock-start at the time of the first intralesional L19IL2/L19TNF injection.~After the Tumor Assessment/Safety visit, patients may receive surgery in a curative intention within 6 weeks, in order to assess the pathological response with estimation of percent of residual viable tumor cells."
9896890|NCT04362228|Experimental|Whole-body exercise|
9932874|NCT00954005|Experimental|Rituximab, Gemcitabine and Oxaliplatin|Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
9932875|NCT00954018||Cystic Fibrosis patient during outpatient clinic visit|
9932876|NCT00954018||Cystic Fibrosis patients during hospitalization|
9932877|NCT00954018||CF patients about to have sinus surgery and bronchoscopy|
9932878|NCT00954031||case|hospitalized patients, adult or child, including the diagnosis of APA was made, after consulting their physician.
9932879|NCT00954031||The control group|"Two patients witnesses will be matched to each case:~Chronological criterion: consultation for a sore throat 10 days (± 3 days) before the date of hospitalization of cases, between 13 and J-J-7.~Age criteria: year of birth ± 5 years Geographical criteria: living in the same department, failing in an adjacent Department Social criteria: beneficiary or otherwise of the CMU, to avoid a selection bias leading social most frequently at the onset of the APA"
9932880|NCT00954044|Experimental|Exercising Together|Partnered progressive resistance exercise
9932881|NCT00954044|Placebo Comparator|Usual Care|Usual Care Control
9932882|NCT00954070||Case (subjects with NERD)|The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
9932883|NCT00954070||Control|Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases
9932884|NCT00954083|Experimental|DIR/Floortime intervention|1=DIR/Floortime intervention
9932885|NCT00954083|Active Comparator|routine care|2=routine care
9932886|NCT00954096|Experimental|Transdermal nicotine patch or placebo|A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
9932887|NCT00954135|Active Comparator|letrozolo+cyclophosphamide|
9932888|NCT00954135|Experimental|letrozolo+sorafenib+cyclophosphamide|
9932889|NCT00954148|Active Comparator|PET/CT follow-up|PET/CT with history and physical exams at 3,9,18,36,60 months only
9932890|NCT00954148|Other|conventional follow-up|NCCN recommendations
9932891|NCT00954161|Experimental|first aid and helping behaviour|The helping behaviour training is given after 24 hours first aid training and aims to sensitise participants towards a helping reaction and teach participants how to deal with barriers to helping
9896891|NCT04357951|Experimental|Behavior Therapy + DCS|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the d-cycloserine pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
9896892|NCT04357951|Active Comparator|Behavior Therapy + Placebo|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the placebo pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
9896893|NCT04352270|Active Comparator|Group 1- Printed educational materials|Parent-child dyads randomized to this group will receive printed educational materials in English or Spanish about atopic dermatitis.
9896894|NCT04352270|Experimental|Group 2- Educational videos|Parent-child dyads randomized to this group will receive an investigator developed educational video in English or Spanish about atopic dermatitis.
9896895|NCT04350593|Active Comparator|Dapagliflozin 10mg|Dapagliflozin 10 mg daily
9896896|NCT04350593|Placebo Comparator|Placebo|Dapagliflozin matching placebo 10 mg daily
9896897|NCT04349475|Experimental|Omega 3 Supplementation|Supplementation of 4g of DHA/EPA daily
9896898|NCT04349475|Placebo Comparator|Safflower Oil Supplement|Supplementation of Safflower Oil daily
9896899|NCT04340882|Experimental|Treatment (docetaxel, ramucirumab, pembrolizumab)|Patients receive docetaxel IV over 60 minutes, ramucirumab IV over 60 minutes, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9896900|NCT04338984|Active Comparator|General anesthesia alone (AG)|"Opioid based analgesia:~Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
9896901|NCT04338984|Experimental|Erector Spinae Plane Block and General Anaesthesia (ESPAG)|"Bilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision.~Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
9896902|NCT04337476|Experimental|mother's song|At the suggestion of the music therapist, the mothers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
9896903|NCT04337476|Experimental|father's song|At the suggestion of the music therapist, the fathers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
9896904|NCT04337476|Experimental|singing of the music therapist|Music therapist will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
9896905|NCT04337476|No Intervention|No singing|Control group (not subjected to musical stimulation- no singing). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
10213852|NCT02950259|Experimental|IRX-2 Regimen -Triple Negative Breast Cancer|Enrolled subjects with triple negative breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
10213853|NCT02947750|Experimental|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
9896908|NCT04333576|Experimental|Elagolix + Combined Oral Contraceptive (COC)|Participants will receive elagolix in combination with COC for 18 months.
9896909|NCT04333576|Experimental|Elagolix + Placebo for COC|Participants will receive elagolix in combination with placebo for COC for 3 months followed by elagolix in combination with COC for 15 months.
9896910|NCT04333576|Placebo Comparator|Placebo for Elagolix + Placebo for COC|Participants will receive placebo for elagolix in combination with placebo for COC for 3 months followed by elagolix in combination with COC for 15 months.
9896911|NCT04329832|Experimental|Hydroxychloroquine|
9896912|NCT04329832|Active Comparator|Azithromycin|
9896913|NCT04326192|Experimental|All subjects|All subjects will have two PET/CT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET/CT) or with SCS during PET/CT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.
9896914|NCT04323436|Experimental|Run-in part|capmatinib in combination with spartalizumab
9896915|NCT04323436|Experimental|Randomized part - Arm 1 spartalizumab|capmatinib in combination with spartalizumab
9896916|NCT04323436|Experimental|Randomized part - Arm 2 placebo|capmatinib in combination with placebo
9896917|NCT04323046|Experimental|Group A (neoadjuvant nivolumab and placebo)|"NEOADJUVANT: Patients receive nivolumab IV over 30 minutes and placebo IV over 30 minutes 14 days before undergoing standard of care surgical resection.~ADJUVANT COMBINATION INFUSION: After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9896918|NCT04323046|Experimental|Group B (neoadjuvant nivolumab and ipilimumab)|"NEOADJUVANT: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes 14 days before undergoing standard of care surgical resection.~ADJUVANT COMBINATION INFUSION: After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9896919|NCT04323046|Experimental|Group C (neoadjuvant placebo and ipilimumab)|"NEOADJUVANT: Patients receive placebo IV over 30 minutes and ipilimumab IV over 30 minutes 14 days before undergoing standard of care surgical resection.~ADJUVANT COMBINATION INFUSION: After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9896920|NCT04321395|Experimental|Vigabatrin|
9896921|NCT04321395|Placebo Comparator|Placebo|
9896922|NCT04321330|Experimental|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
10213854|NCT02947750|Active Comparator|Exercise training + 6R-BH4 placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the study drug 6R-BH4.
10213855|NCT02947750|Active Comparator|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
9896926|NCT04318548|Experimental|MenB+MenACWY Group|Subjects will receive 1 dose rMenB+OMV NZ given concomitantly with MenACWY at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of placebo at Day 91.
9896927|NCT04318548|Experimental|MenB Group|Subjects will receive 1 dose of rMenB+OMV NZ and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of MenACWY at Day 91.
9896928|NCT04318548|Experimental|MenACWY Group|Subjects will receive 1 dose of MenACWY and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ each at Day 61 and at Day 91.
9896929|NCT04315415|Other|6 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 6 months.
9896930|NCT04315415|Other|12 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 12 months.
9896931|NCT04315415|Other|24 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 24 months.
9896932|NCT04314401||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 10 years.
9896933|NCT04311411|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
9896934|NCT04311411|Placebo Comparator|Placebo|Placebo administered SC.
9896935|NCT04311411|Active Comparator|Liraglutide|Liraglutide administered SC.
9896936|NCT04307212|Active Comparator|Trained|Participants who have been CrossFit training at least 3 times per week for the previous 3 months. These individuals will be invited in person to participate in the study.
9896937|NCT04307212|Active Comparator|Untrained|Nonactive/non--exercise trained participants who have participated in any type of exercise no more than 2 times per week for the past 3 months. These individuals will be recruited from the general public.
9896938|NCT04306341|Experimental|Experimental|Neurofeedback in conjunction with Dialectical Behavior Therapy
9896939|NCT04306341|No Intervention|Control|Dialectical Behavior Therapy (treatment as usual)
9932892|NCT00954161|Active Comparator|first aid only|This group receives training in first aid only without training in helping behaviour.
9932893|NCT00954200|Placebo Comparator|Placebo|
9517498|NCT03305757|Active Comparator|conventional wound closure|The skin flaps will not undergo further treatment in this group.
9932894|NCT00954200|Active Comparator|ibuprofen|
9896940|NCT04305496|Experimental|Capivasertib + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
9896941|NCT04305496|Placebo Comparator|Placebo + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
9896942|NCT04305470|Experimental|Single Arm|Open-label, single-arm
9896943|NCT04298190|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
9896944|NCT04298190|Active Comparator|Enhanced Usual Care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
9896945|NCT04295538|Experimental|Elezanumab|Participants will receive elezanumab dose A
9896946|NCT04295538|Placebo Comparator|Placebo|Participants will receive placebo for elezanumab
9896947|NCT04295382|Experimental|Software Application|
9896948|NCT04294563|Experimental|Immediate Intervention Group|Participants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
9896949|NCT04294563|Active Comparator|Wait-llist Control Group|Participants will complete baseline measures 7 days prior to total knee arthroplasty and will receive a 7 week supply after completion of 12 week post-surgery visit.
9896950|NCT04293016|Active Comparator|Support as usual|
9896951|NCT04293016|Experimental|Problem Solving therapy|
9896952|NCT04293016|Experimental|ICU diary|
9896953|NCT04292600||UMMC|Cohort recruited at University of Mississippi Medical Center
9896954|NCT04292600||UAB|Cohort recruited at University of Alabama in Birmingham
9896955|NCT04292600||BRH|Cohort recruited at Brandon Regional Hospital by Bay Area Consulting Telemedicine
9896956|NCT04289480||ENTERPRISE 2 group|"The study population enrolled for this clinical study is aneurysm patients who need stent-assisted coiling treatment, using ENTERPRISE 2 device."
9896957|NCT04289376|Other|Gaze tracking|No intervention. Monitor gaze as subjects watch a video
9896958|NCT04287413|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
9896959|NCT04287413|Active Comparator|Usual care|The physician-led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, order diagnostic imaging, prescribe medications and/or refer based on their assessment findings and patient preferences.
9896960|NCT04285398|Other|Study Group 1|Four years follow up of patients with ophthalmic examination.
9896961|NCT04285398|Other|Study Group 2|Four years follow-up of patients with ophthalmic examination and mobility testing.
10213856|NCT02947750|Placebo Comparator|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
9932895|NCT00954213|Experimental|DIR/Floortime parent intervention|
9932896|NCT00954252|Experimental|Test Article|
10213857|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
9896963|NCT04279236||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and an additional follow-up visit after surgery.
9896964|NCT04278924|Placebo Comparator|Part A: Double Blind, Placebo|TAK-079 placebo-matching injection subcutaneously (SC) once weekly (QW) for 8 weeks.
9896965|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 1|TAK-079 Dose 1, SC injection QW for 8 weeks.
9896966|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 2|TAK-079 Dose 2, SC injection QW for 8 weeks.
9896967|NCT04278924|Experimental|Part A: Open-label Extension (OLE) Phase, TAK-079 Dose 1|Participants who received placebo in double-blind Part A and opt to receive further treatment who have been randomized to receive TAK-079 Dose 1, SC injection QW for 8 weeks in OLE phase of Part A.
9896968|NCT04278924|Experimental|Part A: OLE Phase, TAK-079 Dose 2|Participants who received placebo in double-blind Part A and opt to receive further treatment who have been randomized to receive TAK-079 Dose 2, SC injection QW for 8 weeks in OLE phase of Part A.
9896969|NCT04278924|Placebo Comparator|Part B: Double Blind, Placebo|TAK-079 placebo-matching injection SC, QW for 8 weeks.
9896970|NCT04278924|Experimental|Part B: Double Blind, TAK-079 Dose 3|TAK-079 Dose 3, SC injection QW for 8 weeks.
9896971|NCT04278924|Experimental|Part B: OLE Phase, TAK-079 Dose 3|Participants who received placebo in double-blind Part B and opt to receive further treatment will receive TAK-079 Dose 3, SC injection QW for 8 weeks in OLE phase of Part B.
9896972|NCT04278417|Experimental|Brolucizumab Arm|Intra-vitreal injection
9896973|NCT04278417|Active Comparator|Panretinal photocoagulation laser Arm|laser
9896974|NCT04278157|Experimental|SCBT-SB|A culturally centered CBT treatment protocol called Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)
9896975|NCT04278157|Active Comparator|Treatment as Usual|Treatment as usual is base on the standard care for teens and their parents under a community mental health center.
9896976|NCT04276233|Experimental|Subject severe eosinophilic asthma|Subjects with severe eosinophilic asthma will receive Mepolizumab 100 mg subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with oral corticosteroid (OCS) as part of their standard of care. Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
9896977|NCT04275661|Placebo Comparator|Group (C) (control group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7.
9896978|NCT04275661|Experimental|Group (K) (Ketamine group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg ketamine at each level with total dose 2mg/kg
9896979|NCT04275661|Experimental|Group (M) (magnesium sulphate group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg MgSo4 at each level with total dose 2mg/kg
9896980|NCT04271280||High Risk and Very High Risk Dyslipidemic Participants|Participants are stratified as High and Very High Risk (as assessed by the Framingham risk score for High Risk participants and the SMART score for Very High Risk participants and ) as well as if previously or newly diagnosed.
9896981|NCT04268836|Experimental|Treatment arm|Patients will be treated by the Optimal Acuity Clear-K Low Vision Aid System.
9896982|NCT04266730|Experimental|PANDA-VAC combined with pembrolizumab|The final primary therapeutic neoantigen vaccine product will comprise 6 peptides at a dose of 300 μg per peptide and Poly-ICLC at a dose of 500 μg formulated in an aqueous solution containing <5% DMSO in isotonic dextrose for a total volume of 750 μL. The vaccine will be administered subcutaneously via 3 equal volume (250 μL) injections, one in an arm and one in each leg. The product will be administered on the following schedule: Days 1 and 4 of Week 1, Day 1 of Week 2, Day 1 of Week 3, Day 1 of Week 4, Day 1 of Week 11, and Day 1 of Week 21.
9896983|NCT04264819|Experimental|RTH258/Brolucizumab|This is a single arm study in which all patients will be treated with brolucizumab 6mg; 3 loading injections (at Screening/Baseline, week 4 and week 8) followed by treat-to-control phase with adjustable treatment frequency based on disease activity from every 8 to up to 16 weeks; last treatment at week 44/46 based on the treatment regimen.
9896984|NCT04263025|Experimental|CLARIX CORD 1K|They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP).
9896985|NCT04263025|Active Comparator|Controls|They will undergo RARP without adjunctive CLARIX® CORD 1K.
9896986|NCT04260802|Experimental|Drug: Dose Escalation|Escalating doses of OC-001 administered intravenously (IV)
9896987|NCT04260802|Experimental|Drug: Combination: Tumor Type 1|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
9896988|NCT04260802|Experimental|Drug: Combination: Tumor Type 2|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
9896989|NCT04257123|Experimental|Controlled-Feeding|For two weeks (separated by a wash-out week), participants will consume all meals in the Nutrition Science facility.
9896990|NCT04257123|Experimental|Free-Feeding|For two weeks (separated by a wash-out week), participants will receive no dietary guidance and will be allowed to consume whatever they desire.
9896991|NCT04256317|Experimental|Phase 1, Stage A (Dose Escalation)|In Cycle 1 (28 days per cycle), single dose oral azacitidine will be administered, followed by subcutaneous (SC) azacitidine, ASTX030 and oral cedazuridine on a specific dosing schedule; in Cycle 2, oral ASTX030 (cedazuridine + azacitidine) will be administered
9896992|NCT04256317|Experimental|Phase 1, Stage B (Dose Expansion)|Oral cedazuridine + azacitidine will be administered separately at the recommended dose for expansion (RDE)
9517499|NCT03305757|Experimental|flap fixation with vicryl sutures|The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
9517500|NCT03305757|Experimental|Artiss tissue glue|ARTISS tissue glue will be applied to the skin flaps after mastectomy
9797907|NCT01610492|Experimental|Cohort 1|10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
9797908|NCT01610557|Experimental|Group 1 - Ranibizumab-Ranibizumab-Bevacizumab Injection Series|"Group 1 eyes were assigned to Ranibizumab-Ranibizumab-Bevacizumab (RRB) treatment sequence and received intravitreal injections of ranibizumab at baseline, Weeks 4, and 8 (period 1), and Weeks 12, 16 and 20 (period 2), then crossed over to receive intravitreal injections of bevacizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
9797909|NCT01610557|Experimental|Group 2 - Ranibizumab-Bevacizumab-Bevacizumab Injection Series|"Group 2 eyes were assigned to Ranibizumab-Bevacizumab-Bevacizumab (RBB) treatment sequence and received intravitreal injections of ranibizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of bevacizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
9797910|NCT01610557|Experimental|Group 3 - Bevacizumab-Bevacizumab-Ranibizumab Injection Series|"Group 3 eyes were assigned to Bevacizumab-Bevacizumab-Ranibizumab (BBR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4, 8, 12, 16 and 20 (periods 1 and 2), then crossed over to receive intravitreal injections of ranibizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
9797911|NCT01610557|Experimental|Group 4 - Bevacizumab-Ranibizumab-Ranibizumab Injection Series|"Group 4 eyes were assigned to Bevacizumab-Ranibizumab-Ranibizumab (BRR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of ranibizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
9797912|NCT01610570|Experimental|Phase I Dose Level -1|Dose Escalation Phase 9.0 mcg/kg.dose
9797913|NCT01610570|Experimental|Phase I Dose Level 1|Dose Escalation Phase 13.0 mcg/kg.dose
9797914|NCT01610570|Experimental|Phase I Dose Level 2|Dose Escalation Phase 17.5 mcg/kg.dose
9517501|NCT03305744||Endurance Athlete with Atrial Fibrillation|These are middle-aged athletes who are diagnosed with paroxysmal Atrial Fibrillation in the last 4 years, but are otherwise free of disease.
9517780|NCT03303027|Experimental|5-0 fast absorbing gut suture|5-0 fast absorbing gut used to suture wound
9797915|NCT01610570|Experimental|Phase II - Expansion Phase|Expansion phase 17.5 mcg/kg.dose
9797916|NCT01610596|Experimental|Halobetasol Propionate Lotion 0.05%|Topical lotion, applied twice daily
9797917|NCT01610596|Placebo Comparator|Vehicle Lotion|Topical lotion, applied twice daily
9797918|NCT01610687|Experimental|GW-1000-02|Active treatment
9797919|NCT01610700|Experimental|GW-1000-02|Active treatment
9797920|NCT01610700|Placebo Comparator|Placebo|Control
9797921|NCT01610713|Experimental|GW-1000-02|Active treatment.
9797922|NCT01610752|Experimental|SmartMoms-Clinic|If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
9797923|NCT01610752|Experimental|SmartMoms-Phone|If picked for this group, you will have two individual sessions with a weight management counselor. At the first session, you will receive a scale and other technology to help manage your weight during pregnancy. Each week you will receive information from a weight management counselor via a Smartphone (you can use your own Smartphone or one will be provided to you). The information will cover topics to help manage your weight during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to measure your body weight (using a scale we will provide) as well as monitor your food intake and exercise habits with the Smartphone.
9797924|NCT01610752|No Intervention|Physician Directed|If picked for this group, you will receive weight management advice from your physician's office.
9797925|NCT01610791|Experimental|Single Arm|
9932897|NCT00954252|Placebo Comparator|Placebo|
9991892|NCT01457144|Experimental|RiBVD|Rituximab Bendamustine Velcade® Dexamethasone 6 cycles every 28 days
9991893|NCT01457170|Experimental|Apelin/Saline|Apelin infusion then crossover to Saline infusion
9991894|NCT01457170|Experimental|Saline/Apelin|Saline infusion then crossover to Apelin infusion
9991895|NCT01457183|Experimental|Lavage group|Healthy subjects with intact skin will be lavaged within the device in 3 locations on their bodies.
9991896|NCT01457222|Active Comparator|Mindfulness|Mindfulness intervention 10 minutes daily
9991897|NCT01457222|Active Comparator|Music relaxation|Music intervention 10 minutes daily
9991898|NCT01457222|No Intervention|Business as usual|No intervention - control group.
9991899|NCT01457235|Active Comparator|Active Group|This group receives cognitive remediation in groups (each group consisting of 6-8 subjects)
9991900|NCT01457235|No Intervention|Waiting List|Patients randomized to the waiting list group continues standard treatment and will be offered a course of cognitive remediation upon completion of participation provided that they still meet the inclusion criteria.
9997588|NCT01510262|Active Comparator|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
9997589|NCT01510275|Experimental|Intervention|Combined use of RESPIVOL® and RESPILIFT® (with resistive load)
9997590|NCT01510275|Sham Comparator|Control|Combined use of RESPIVOL® and RESPILIFT® (without resistive load)
9997591|NCT01510288|Experimental|Ipilimumab and GVAX|
9997592|NCT01510301|Other|Self-report|
9997593|NCT01510340|No Intervention|Web sites|Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
9997594|NCT01510340|Experimental|VIH-TAVIE|Patients assigned to this arm must follow the four interactive computer sessions
9997595|NCT01510353|Experimental|Use of a radiation monitoring device|Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
9997596|NCT01510353|No Intervention|No use of radiation monitoring device|No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
9997597|NCT01510366|Experimental|Cohort 1|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
9517502|NCT03305744||Endurance Athlete without Atrial Fibrillation|These are middle-aged athletes who will serve as our control group- they have not been diagnosed with AF or any other disease.
9997598|NCT01510366|Experimental|Cohort 2:|Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.
9997599|NCT01510405||40 Participants|Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
9997600|NCT01510418||Person with congenital bleeding disorder|Adult men with congenital hemophilia A or B
9997601|NCT01510418||Spouse/Significant Other|Spouse/significant other of person with congenital bleeding disorder participating in this study.
9997602|NCT01510483|Experimental|Obesity prevention|Orthodontist promotion of physical activity and healthy diet
9997603|NCT01510483|Active Comparator|Tobacco prevention|Orthodontist promotion of tobacco and second hand smoke avoidance
9997604|NCT01510496||Patients who had inguinal herniorraphy.|
9997605|NCT01510496||Patients who had hysterectomy.|
9997606|NCT01510496||Patients who had thoracotomy.|
9997607|NCT01510509|Experimental|Titanium bare metal stent|Titanium bare metal stent (Titan2®, Hexacath, Paris, France)
9991901|NCT01457248|Experimental|endotracheal tube with taper-shaped cuff|
9991902|NCT01457248|Active Comparator|Endotracheal tube with cylindrical-shaped cuff|
9991903|NCT01457261|Experimental|Partical size 1|Monodisperse particle delivered with radiolabel
9991904|NCT01457261|Experimental|Particle size 2|Monodisperse particle delivered with radiolabel
9991905|NCT01457261|Experimental|Nebulised salbutamol|Polydisperse particle via a nebuliser
9991906|NCT01457261|Experimental|Salbutamol MDI|Unlabelled salbutamol via a metered dose inhaler
9991907|NCT01457274|Experimental|"light sedation"|"In this study the depth of sedation will be guided by the Bispectral Index monitor (BIS monitor). A BIS value of 70-80 will be targeted in the light sedation arm."
9991908|NCT01457274|Active Comparator|"deep sedation"|"In this study the deep sedation arm will have a BIS value of less than 60 targeted."
9991909|NCT01457300||District Rehabilitation Centre (Model 1)|Patients admitted to Primary Health Care Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited continuously at Entrance to the Rehabilitation Centre.
9991910|NCT01457300||Standard PHC Rehabilitation (Model 2)|Patients admitted to Standard Primary Health Care (PHC) Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited Continuously at Entrance to the Short Term Rehabilitation Beds in Nursing Homes or at the Beginning of Rehabilitation in their Own Homes.
9991911|NCT01457313||BTKA|patients undergoing bilateral staged total knee arthroplasty
9991912|NCT01457326||Immersion Therapy- Study|1. Patients who participate in the immersion therapy post-operative protocol and begin progressive weight bearing at 4 weeks (study)
9991913|NCT01457326||Control Group|2. Patients who undergo the traditional 10-week non-weight bearing post-operative care protocol (control)
9991914|NCT01457365||subjects|it is a cross-sectional research and there is only one group.
9991915|NCT01457378||Healthy volunteers|100 healthy volunteers
9991916|NCT01457378||IBS Subjects|100 IBS Subjects
9991917|NCT01457391|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
9991918|NCT01457391|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
9991919|NCT01457391|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical intensive outpatient (IOP) treatment that the patient would receive ordinarily at the identified addiction treatment program. Each TAU service operates using the American Society of Addiction Medicine criteria for Level II Intensive Outpatient services: 9-12 hours per week; group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
9991920|NCT01457404|Experimental|Integrated Cognitive Behavioral Therapy|Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
9991921|NCT01457404|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical outpatient treatment that patients would receive ordinarily at the PVAMC Substance Abuse Treatment Program (SATP) or PTSD Clinic.
9991922|NCT01457443||Observation|Patients with Pompe disease
9991923|NCT01457456||Observation|Patients with Morquio disease
9932898|NCT00954265|Active Comparator|Urinary-HCG group|These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
9991924|NCT01457469|Active Comparator|Arm I (usual care plus) (closed to accrual as of 3/6/2012)|"Patients receive a personalized letter from their physician with advice to quit smoking and a copy of the National Cancer Institute's Cleaning the Air smoking cessation booklet."
9991925|NCT01457469|Experimental|Arm II (enhanced quitline)|Patients receive a personalized letter and a smoking cessation booklet. Patients also receive an 8-week supply of nicotine replacement patches and undergo a counseling session over 30-45 minutes with a trained nurse or midlevel provider that focuses on the benefits of quitting smoking for cancer patients and addresses cancer-specific concerns about smoking cessation. Patients also undergo a quitline-based smoking cessation intervention comprising 5 individual 25- to 30-minute telephone counseling sessions and unlimited inbound phone-based access to Quit Coaches over 8-11 weeks, mailed written materials, and an interactive online program.
9991926|NCT01457482|Experimental|Art therapy group|Treatment in this arm consists of five Art Therapy sessions and therapeutic conversations.
9991927|NCT01457482|Active Comparator|Therapeutic conversation group|Treatment by therapeutic conversations only
9991928|NCT01457495|Experimental|DTPa 1 Group|
9991929|NCT01457495|Active Comparator|DTPa 2 Group|
9991930|NCT01457508|Experimental|Group A|Subjects will receive one single injection of DTPa-HBV-IPV vaccine mixed with Hib vaccine.
9991931|NCT01457508|Active Comparator|Group B|Subjects will receive two separate injections of DTPa-HBV-IPV and Hib vaccine.
9991932|NCT01457534||liver transplantation|
9991933|NCT01457547|Experimental|DTPa 1 Group|
9991934|NCT01457547|Active Comparator|DTPa 2 Group|
9991935|NCT01457560|Experimental|Group A|
9896993|NCT04256317|Experimental|Phase 2, Sequence A|Oral ASTX030 (cedazuridine + azacitidine) will be administered in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
9896994|NCT04256317|Experimental|Phase 2, Sequence B|SC azacitidine will be administered in Cycle 1, followed by oral cedazuridine + azacitidine tablets/capsules in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
9896995|NCT04256317|Experimental|Phase 3, Sequence A|Participants will receive ASTX030 in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
9896996|NCT04256317|Experimental|Phase 3, Sequence B|Participants will receive SC azacitidine in Cycle 1 followed by ASTX030 in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
9896997|NCT04256304|Experimental|Intervention group|"Personalized Health Engagement Plan group~First face-to-face session (Motivational interviewing) + Pre-tests~Patient Health Engagement Scale~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus~Phone call coaching~A set of personalized home-based exercises~Second face-to-face session (Motivational interviewing) + Post-tests"
9896998|NCT04256304|No Intervention|Control group|"First meeting (Pre-tests)~Patient Health Engagement Scale~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus~Second meeting (Post-tests)~Patient Health Engagement Scale~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus"
9896999|NCT04255433|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
9897000|NCT04255433|Active Comparator|Dulaglutide|Dulaglutide administered SC once a week.
9897001|NCT04254094||Early onset dementias (EOD)|Prospective multicenter cohort of EOD patients with a three-year follow-up in tertiary Reference Memory centers
9897002|NCT04251507|Experimental|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
9897003|NCT04251507|No Intervention|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
9897004|NCT04249362|Experimental|Cohort A|Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.
9897005|NCT04249362|Experimental|Cohort B|Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.
9897006|NCT04243785|Experimental|Phase 1a (Dose Escalation Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). The BTX-A51 starting dose for Cohort 1 is 1 mg, to be given 5 days per week (maximum weekly dose of 5 mg). Beginning with Cohort 2, doses are intended to be administered 3 days per week. Barring dose-limiting toxicity (DLT), sequential dose escalation of BTX-A51 is planned with up to a total of eight dose levels to a maximum of 20 mg (60 mg/week); on the basis of these an MTD will be identified. The numbers of participants and actual doses administered will be determined using a Bayesian optimal interval (BOIN) design to determine the DLTs and MTD of BTX-A51.
9897007|NCT04243785|Experimental|Phase 1b (Cohort Expansion Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). Phase 1b will continue at the MTD or the highest dose achieved in Phase 1a.
9897008|NCT04243785|Experimental|Continued Treatment Phase|Participants who complete one cycle of BTX-A51 treatment in either Phase 1a or Phase 1b will be offered continued access to treatment for up to eight 28-day cycles if the Investigator determines that the benefit outweighs the risk. Dosing will continue at the assigned dose or may be increased (not to exceed a level already tolerated by at least one participant if Phase 1a is ongoing or the MTD/recommended Phase 2 dose if already established).
9897009|NCT04242095||Observational (biospecimen collection, medical record review)|Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.
9897010|NCT04241510|Active Comparator|Facilitation Tape|Diaphragm and Intercostal muscles will be taped with facilitation technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
9897011|NCT04241510|Active Comparator|Mechanical Correction Tape|Thorax will be taped with mechanical correction technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
9897012|NCT04241510|No Intervention|No Tape|Patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea with no tape.
9897013|NCT04238676|Experimental|PP353|
9897014|NCT04238676|Placebo Comparator|Sham injection|
9897015|NCT04235517||Axial deviations in children|Children with axial deviations in the lower extremity treated with guided growth
9897016|NCT04235517||Limb length discrepancy in children|Children with limb length discrepancy treated with temporary epiphysiodesis
9897017|NCT04234646|Active Comparator|Group 1: One-on-One Patient Navigation|One-on-one Patient Navigation will be based on a Case Management Model where patients navigators perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources.
9897018|NCT04234646|Experimental|Group 2: Patient Navigation 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
9932899|NCT00954265|Experimental|Recombinant HCG group|These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
9897019|NCT04233242|Experimental|Intervention|The viral load ≥400 c/mL before enrolment triggers genotypic resistance testing (GRT), followed by GRT-informed patient management and counselling. Onward treatment is informed by the resistance profile determined through GRT, with a GRT Expert Committee issuing a treatment recommendation.
9897020|NCT04233242|No Intervention|Control|Standard of care according to national guidelines and recommendations of the World Health Organization: The viral load ≥400 c/mL before enrolment is followed by 3 sessions of enhanced adherence counselling and a follow-up viral load test. Onward treatment is informed by viral load testing.
9897021|NCT04232553|Experimental|Mirikizumab SC|Mirikizumab given subcutaneously (SC).
9897022|NCT04232553|Experimental|Mirikizumab IV and SC|Mirikizumab given intravenously (IV) and SC.
9897023|NCT04230148|Experimental|Egaten|All subjects will receive Egaten as two 10 mg/kg doses given 12 hours apart.
9897024|NCT04229017|Active Comparator|Anterior Cervical Discectomy and Fusion (ACDF)|ACDF is a a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate. The plate is intended to stabilize the treated levels until fusion occurs.
9897025|NCT04229017|Experimental|Circumferential Cervical Fusion (CCF)|Circumferential Cervical Fusion (CCF) is a combination of ACDF and Posterior Cervical Fusion (PCF) procedures. The PCF is completed with Posterior Cervical Stabilization System (PCSS).
9897026|NCT04228042|Experimental|Treatment (infigratinib, surgery)|Patients receive infigratinib PO QD on days 1-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. During weeks 8-9 (at least 48 hours after last dose of infigratinib), patients undergo surgery.
9897027|NCT04225832|Experimental|CBT Coping Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP among Latinx sexual minority men (SMM). The intervention sessions will address topics such as: understanding and coping with intersectional stigma, multiple identities (e.g., race/ethnicity, sexual orientation), medical mistrust, social support, and structural stigma. Intervention groups will be led by a trained facilitator (with expertise in group therapy with Latinx SMM) and a trained peer co-facilitator matched in identities with participants (Latinx SMM).
9897028|NCT04225832|No Intervention|Control|Participants who are randomized to the control condition will be referred to the standard of care program at Bienestar, which includes an ongoing weekly open wellness-oriented support group available to all clients.
9897029|NCT04224987|Active Comparator|Azithro 1-11|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-11 months old and oral placebo or no intervention to children 12-59 months old
9897030|NCT04224987|Active Comparator|Azithro 1-59|Biannual age, weight- or height-based dose of oral azithromycin suspension to children 1-59 months old
9897031|NCT04224987|Placebo Comparator|Placebo|Biannual weight- or height-based dose of oral placebo to children 1-59 months old
9897032|NCT04223804|Placebo Comparator|Stage 1: Arm A|Participants will receive placebo.
9897033|NCT04223804|Experimental|Stage 1: Arm B|Participants will receive ABBV-181 dose A.
9897034|NCT04223804|Experimental|Stage 1: Arm C|Participants will receive ABBV-181 dose B.
9897035|NCT04223804|Placebo Comparator|Stage 2: Arm D|Participants will receive Placebo.
9897036|NCT04223804|Experimental|Stage 2: Arm E|Participants will receive ABBV-181 dose C.
9897037|NCT04223752|Experimental|Group 1: Ceftolozane/Tazobactam 12 to <18 Years of Age|Participants 12 to <18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.
9897038|NCT04223752|Experimental|Group 2: Ceftolozane/Tazobactam 7 to <12 Years of Age|Participants 7 to <12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
9897039|NCT04223752|Experimental|Group 3: Ceftolozane/Tazobactam 2 to <7 Years of Age|Participants 2 to <7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
9897040|NCT04223752|Experimental|Group 4: Ceftolozane/Tazobactam 3 Months to <2 Years of Age|Participants 3 months to <2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
9897041|NCT04223752|Experimental|Group 5: Ceftolozane/Tazobactam Birth to <3 Months of Age|Participants from birth to <3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
9897042|NCT04223284|Active Comparator|Experimental1|"During the Cross-Over study, patients will be randomly assigned to one of the arms:~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with D-Limonene at visit 2 and olfactory Stimulation with lavender oil (SLVO) at visit 3"
9897043|NCT04223284|Active Comparator|Experimental2|"During the Cross-Over study, patients will be randomly assigned to one of the arms:~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with SLVO at visit 2 and olfactory Stimulation with D-Limonene at visit 3"
9897044|NCT04222894|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 12 weeks
9897045|NCT04222894|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 12-week study period.
9932900|NCT00954278|Experimental|sorafenib|
9932901|NCT00954291||Granisetron|14 mg Granisetron
9932902|NCT00954304|Experimental|1mg group|Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
9897046|NCT04221373|Experimental|Exoskeletal-assisted walking training group|Participants will receive locomotor training provided with an Ekso™ powered exoskeleton according to the standard of care of AIR at Mount Sinai Hospital with the exception that the EAW training will be incorporated into the designated therapy times (3 hours of physical therapy (PT) and/or occupational therapy (OT)) which will be provided as determined by the clinical team from the earliest time they are identified to be able to safely stand, through discharge. The goal of EAW intervention is to complete three or more sessions of EAW training a week during the AIR period (after enrolling into the study until discharge).
9897047|NCT04221373|Active Comparator|Standard of care group|Participants will receive standard of care of acute inpatient rehabilitation which includes three hours of physical therapy and/or occupational therapy per day until they are discharged.
9897048|NCT04221009|Experimental|Intervention (single arm)|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
9897049|NCT04220320||Classic BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation, effacement, texture, station and position.
9897050|NCT04220320||Modified BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation and effacement alone.
9897051|NCT04220320||Cervical Length|Gynecological evaluation based on cervical length measured by transvaginal sonography.
9897052|NCT04219839|No Intervention|SOC only patient education post- kidney transplant|Participants in this group will receive only SOC patient education following kidney transplant
9897053|NCT04219839|Experimental|SOC + Videos for patient education post-kidney transplant|Participants in this group receive SOC patient education following kidney transplant and access to educational videos designed specifically for post-kidney transplant patients.
9897054|NCT04219475||GBM patients|Newly diagnosed patients above 18 years of age with GBM receiving standard of care, i.e., maximal surgical resection possible followed by radiation therapy (RT) plus temozolomide (TMZ) therapy and maintenance TMZ.
9897055|NCT04211337|Experimental|Selpercatinib|Selpercatinib given orally.
9897056|NCT04211337|Active Comparator|Cabozantinib or Vandetanib|Cabozantinib or vandetanib given orally.
9897057|NCT04208802||Smokers|Volunteers smoking at least 10 cigarettes per day
9897058|NCT04208802||Non-smokers|Non-smoking volunteers
9897059|NCT04207619|Experimental|Arm 1|Participants will have their glial acetate metabolism measured by carbon-13 magnetic resonance spectroscopy as well as their neuroendocrine response to hypoglycemia 3 days later.
9897060|NCT04207177|Active Comparator|Mycophenolate mofetil|In the subgroup of living donor recipients included before transplantation this group will be treated with mycophenolate mofetil (750 mg BID) for one week
9897061|NCT04207177|Active Comparator|Tacrolimus|In the subgroup of living donor recipients included before transplantation this group will be treated with tacrolimus (BID, dose by weight) for one week
9897062|NCT04205136|Experimental|Spironolactone|Dose of 25 mg daily that may be titrated up to 50 mg daily, if tolerated and will receive treatment as usual for obstructive sleep apnea.
9897063|NCT04205136|Placebo Comparator|Placebo|Placebo and will receive treatment as usual for obstructive sleep apnea.
9897064|NCT04204447|Experimental|Brochure intervention|Subjects will be asked to read an educational brochure about Hepatitis C
9897065|NCT04204447|Experimental|Video intervention|Subjects will be asked to watch an educational video about Hepatitis C
9897066|NCT04200937||BSC Penile Prothesis Recipients|Men for whom BSC Penile Prothesis is recommended.
9897067|NCT04200898|Experimental|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
9897068|NCT04198818|Experimental|Dose escalaltion study of HH2710|to determin the MTD of HH2710 and/or Recommended Phase II dose (RP2D).
9897069|NCT04196218|Other|Driving assessment|All subjects will undergo a driving assessment(s) following shoulder surgery.
9897071|NCT04195347|Experimental|CM4620 Treatment|"Phase I:~Cohort 1 patients receive CM4620 IV at dose level 1 on days 1-4. Cohort 2 patients receive CM4620 IV at dose level 2 on days 1-4. Cohort 3 patients receive CM4620 IV at either dose level 1 or 2 on days 1-4~Phase II:~Patients will receive CM4620 IV on days 1-4 at the recommended Phase II dose (RP2D) as determined in Phase I."
9897072|NCT04194944|Experimental|Selpercatinib|Selpercatinib administered orally.
9897073|NCT04194944|Active Comparator|Pemetrexed with or without Pembrolizumab|Pemetrexed administered intravenously (IV) plus the investigator's discretion of carboplatin IV or cisplatin IV with or without pembrolizumab IV.
9897074|NCT04194944|Active Comparator|Pemetrexed with Pembrolizumab|Pemetrexed administered IV plus the investigator's discretion of carboplatin IV or cisplatin IV with pembrolizumab IV.
9897075|NCT04192903|Experimental|Chidamide combined with Cisplatin|"Chidamide: 30mg,PO,biw one week before cycle 1 treatment~Combined treatment period:~Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off Patients whose efficacy was evaluated as Complete Response (CR) / Partial Response (PR) / Stable Disease (SD) after the end of the combined treatment period received maintenance treatment with chidamide combined with cisplatin reduction.~Maintenance treatment period:~Cisplatin 25mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off"
9897076|NCT04191733|Experimental|Anterior Approach with KINCISE|Anterior Approach THA using KINCISE(TM) Surgical Automated System
9897077|NCT04191733|Active Comparator|Anterior Approach without KINCISE|Anterior Approach THA with a mallet (without KINCISE)
9932903|NCT00954304|Experimental|5mg group|Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15
9932904|NCT00954304|Experimental|10mg group|Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
9991936|NCT01457586|Active Comparator|Transfusion|Patient who received blood transfusion in the perioperative period
9897078|NCT04190550|Experimental|Treatment (navtemadlin, cytarabine, idarubicin)|Patients receive navtemadlin PO QD on days 1-7, cytarabine IV BID over 3 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease may receive cytarabine IV BID over 3 hours for 5 days and idarubicin IV over 10-15 minutes for 2 days starting between days 14-21 of cycle 1 or the second cycle of navtemadlin, cytarabine, and idarubicin. Patients who achieve a CR or a CRi in either cycle 1 or 2 may receive cytarabine IV BID over 3 hours on days 1, 3, and 5 for 3-4 additional 28 to 35-day cycles in the absence of disease progression or unacceptable toxicity.
9897079|NCT04190225|Experimental|Multi-technology physical activity intervention|Digital/social media
9897080|NCT04190225|No Intervention|Control|Control group receives a Fitbit but none of the intervention components.
9932905|NCT00954304|Experimental|15mg group|Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
9932906|NCT00954304|Experimental|60mg group|Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
9932907|NCT00954317|Active Comparator|Low epidural|epidural placed in the lower lumbar vertebral column
9932908|NCT00954317|Experimental|high epidural|high epidural
9932909|NCT00954330|Experimental|surgery|All twenty-five patients underwent ligament repair, where the ruptured ends of the FTA (in 11 cases) or FTA and FC (in 14 cases) ligaments were rejoined by using absorbable sutures. A supine position and a tourniquet were used. A curvilinear skin incision of 5-10 cm was made; the retinacular structures were incised and the hematoma was removed.
9932910|NCT00954330|Active Comparator|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle
9932911|NCT00954343|Experimental|Group I|
9932912|NCT00954343|Experimental|Group II|
9932913|NCT00954343|Experimental|Group III|
9932914|NCT00954343|Experimental|Group IV|
9932915|NCT00954343|No Intervention|Group V|
9932916|NCT00954369|Experimental|[F-18]W372|Approximately twenty (20) adult subjects including ten (10) healthy volunteers and ten (10) high probability AD subjects, as defined by protocol criteria
9932917|NCT00954382||IQ trend|all subjects
9932918|NCT00954395||1. anticoagulation suspension|eligible patients undergo measurement of residual venous obstruction (RVO) with compression ultrasound (CUS) in case of a previous deep vein thrombosis (DVT) and/or of pulmonary artery pressure (PAP) with echocardiography in case of previous pulmonary embolism (PE). In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is below age and gender cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If all the D-dimer measurements are below the cut-offs, anticoagulation is definitely interrupted and patients are followed-up for two years.
9932919|NCT00954395||2. anticoagulation prolongation|If RVO is greater than 4 mm at CUS of the lower limbs and/or PAP is increased (> 35 mmHg, > 40 mmHg in the elderly or obese), anticoagulation is prolonged for additional 6 months and the measures of RVO and/oR PAP are repeated. In those in whom PAP is altered also after 6 months of additional therapy, anticoagulation is prolonged. In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is above age and gender cut-offs , anticoagulation is prolonged. If D-dimer is below the cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If one of these D-dimer measurement is above the cut-off , anticoagulation is resumed for at least 6 months and patients are re-evaluated.
9932920|NCT00954408||Patients with dystonia|Patients with dystonia, 21-100 years of age.
9932921|NCT00954434|Experimental|red wine|intervention: dietary supplement intake of red wine on a daily basis, 1 glass/day for women, 2 for men
9932922|NCT00954434|No Intervention|total abstention from alcohol|
9517781|NCT03303014|Experimental|5-0 Prolene|Half of the wound will be treated with 5-0 prolene
9517782|NCT03303014|Experimental|5-0 Fast Absorbing Gut|Half of the wound will be treated with 5-0 fast absorbing gut
9897081|NCT04188548|Experimental|Dose Escalation LY3484356|LY3484356 given orally.
9897082|NCT04188548|Experimental|Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI|LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
9897083|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E3: LY3484356|LY3484356 given orally.
9897084|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus|LY3484356 and everolimus given orally.
9897085|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib|LY3484356 and alpelisib given orally.
9897086|NCT04188548|Experimental|Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib|LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
9897087|NCT04188548|Experimental|Part D: Dose Expansion: LY3484356 +/- Abemaciclib|LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
9897088|NCT04188548|Experimental|Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab|LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
9897089|NCT04187729||Diseased|Subjects with a known disease.
9897090|NCT04187729||Non-diseased|Subjects without a known disease and reportedly healthy.
9897091|NCT04187365|No Intervention|GROUP 1 (NonSevere PUR and women without PUR)|Women in GROUP 1 will be prospectively observed to characterize their clinical outcomes.
9897092|NCT04187365|Experimental|GROUP 2 (Severe PUR)|Women in GROUP 2 will be a randomized to either 3 or 7 days of indwelling catheterization.
9897093|NCT04182815||Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
9897094|NCT04181151||Stroke patients|
9897095|NCT04181151||Healthy Subjects|
9897096|NCT04175847|Experimental|RC88|
9897097|NCT04170907|Other|Nicotine salt 20 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 20 mg/mL.
9897098|NCT04170907|Other|Nicotine salt 40 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 40 mg/mL.
9897099|NCT04170907|Other|Free-base nicotine 20 mg/mL|Vaping of free-base nicotine e-liquids with a nicotine concentration of 20 mg/mL.
9897100|NCT04170283|Experimental|Zanubrutinib (BGB-3111)|All participants to receive open-label zanubrutinib
9897101|NCT04170283|Experimental|Zanubrutinib in combination with Tislelizumab|Participants to receive the combination as in the parent study (Australia Only)
9897102|NCT04166773|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
9897103|NCT04166773|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
9897104|NCT04166773|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
9897105|NCT04166773|Placebo Comparator|Placebo|Placebo administered SC once a week.
9897106|NCT04162548||cardio-relay|"Cardio-relay is a novel collaboration model between hospital-based specialists and primary care, to provide high-quality care to frail patients, relieving their burden to attend multiple hospital specialist visits.~Using telemedicine, it is possible to make measurements where the patient is (at the family clinic at the patient's home). Data are available for all the involved. That is, primary the patient, the relatives and caregivers that the patient wishes help from and health professionals from the family clinics and the hospital. Thereby, the hospital-based specialist supports the family clinic with expert knowledge, the need for attending the hospital facilities reduced to focus on what is strictly needed as specialized provider. Ultimately, the patient can be reached for high-quality care, relieving the patient's burden to attend multiple hospital specialist visits."
9897107|NCT04160468|Experimental|Exebacase|
9897108|NCT04160468|Placebo Comparator|Placebo|
9897109|NCT04158440|Experimental|4cycles Toripalimab+platinum doublet chemotherapy,13 cycles Toripalimab Neoadjuvant Chemotherapy|Participants receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during peioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
9897110|NCT04158440|Experimental|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo ); Neoadjuvant Chemotherapy|Participants receive totally 4 cycles of Placebo combined with platinum doublet chemotherapy during peioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
9897111|NCT04158258||Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
9897112|NCT04158258||Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
9897113|NCT04158258||Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
9897114|NCT04158258||Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
9897115|NCT04158258||Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
9897116|NCT04158258||Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
9991937|NCT01457586|No Intervention|No Transfusion|Patients who did not receive blood transfusion in the perioperative period
9897117|NCT04157465|Other|Early Empiric group|Participants will receive standard medical therapy along with the empiric strategy of treatment of invasive fungal infection (based on both risk factors and clinical suspicion of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
9897118|NCT04157465|Active Comparator|Pre-emptive group|Participants will receive standard medical therapy along with the pre-emptive strategy of treatment of invasive fungal infection (based on risk factors, clinical suspicion and radiological or mycological evidence of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
9897119|NCT04157348|Experimental|Benralizumab arm|1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
9897120|NCT04157348|Active Comparator|Mepolizumab arm|3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
9897121|NCT04149028|Experimental|PRP injection|injection of PRP inside ovary by the assistance of laparoscopy
9897122|NCT04147195|Experimental|Cohort 1, Arm 1|LYS006
9897123|NCT04147195|Experimental|Cohort 1, Arm 2|LYS006 + Tropifexor (LJN452)
9897124|NCT04144751||Subjects Enrolled in 2019-01 BLUE-C|Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.
9897125|NCT04144738||Individuals eligible for CRC Screening|Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy.
9897126|NCT04142073||Children under 18 years of age|
9897127|NCT04141137|Experimental|TricValve® System Single-Arm|Two self-expanding biological valves for implantation into the inferior and superior vena cava.
9897128|NCT04139876|Active Comparator|Minimal open hemorrhoidectomy|Patients randomized to Minimal open hemorrhoidectomy
9897129|NCT04139876|Active Comparator|LigaSure hemorrhoidectomy|Patients randomized to LigaSure hemorrhoidectomy
9897130|NCT04137120||Patients_Ocular disease|Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)
9897131|NCT04136912|Experimental|Breast Imaging Cohort|A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy
9897132|NCT04136912|Experimental|Thyroid Imaging Cohort|A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy
9897133|NCT04136912|Experimental|Healthy Volunteers Cohort|A total of 5 participants will be included to optimize imaging parameters.
9897134|NCT04136457|Experimental|Endurance|Endurance training
9897135|NCT04136457|Experimental|Resistance|Resistance training
9897136|NCT04136457|Experimental|Sprint|Sprint training
9897137|NCT04133168|Experimental|Cryoablation|Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System
9897138|NCT04126525|Experimental|neoadjuvant pyrotinib|pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m^2, d1, 8, 15, 22 cisplatin 25mg/m^2, d1, 8, 15 every 28 days
9897139|NCT04123626|Experimental|QR-1123 Single dose - dose level 1|Open label Single dose cohort: dose level 1
9897140|NCT04123626|Experimental|QR-1123 Single dose - dose level 2|Open label Single dose cohort: dose level
9897141|NCT04123626|Experimental|QR-1123 Single dose - dose level 3|Open label Single dose cohort: dose level 3
9897142|NCT04123626|Experimental|QR-1123 Single dose - dose level 4|Open label Single dose cohort: dose level 4
9897143|NCT04123626|Experimental|QR-1123 Single dose - dose level 5|Open label Single dose cohort: dose level 5
9897144|NCT04123626|Experimental|Repeat dose cohort 1|Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.
9897145|NCT04123262|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
9897146|NCT04122976||Men with nmCRPC|Men with nmCRPC for whom a decision to treat with darolutamide has been made before enrollment, and who have signed informed consent, will be eligible for the study.
9897147|NCT04119986|Experimental|drug coated balloon|A total of 110 patients with ISR are assigned to drug coated balloon treated group after randomization schedule.
9897148|NCT04119986|Other|drug eluted stent implantation|A total of 110 patients with ISR are assigned to drug eluted stent treated group after randomization schedule.
9991938|NCT01457599||Marking Liver|
9897149|NCT04119115||Interstitial Lung Disease (ILD)|CT-V and metabolite analysis of breath and serum at baseline
9897150|NCT04119115||COPD/Emphysema: Age-matched control|CT-V and metabolite analysis of breath and serum at baseline
9897151|NCT04119115||Healthy Volunteers: Age-matched + /- 10 yrs controls|Metabolite analysis of breath and serum at baseline
9897152|NCT04117126|Experimental|urinary incontinence|Recruitment, 3-day voiding record, initiate a individualized prompted voiding schedule based on the client's toileting needs until discharge, 1, 3 and 6 month follow-up post-discharge.
9897153|NCT04116736||TEST Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with the ACUVUE® OASYS with Transitions™ will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
9897154|NCT04116736||CONTROL Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with spherical non-photochromic reusable marketed silicone hydrogel contact lenses (of any brand) will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
9897155|NCT04115293|Experimental|0.3 mg/kg zilucoplan (RA101495)|
9897156|NCT04115293|Placebo Comparator|Placebo|
9897157|NCT04114981|Active Comparator|Arm I (SSRS)|Patients undergo SSRS over 1 session.
9897158|NCT04114981|Experimental|Arm II (FSRS)|Patients undergo FSRS over 3 or 5 daily sessions.
9897159|NCT04112303|Experimental|SOF/VEL|Participants received SOF/VEL (400/100 mg) orally once daily for up to 12 weeks.
9897160|NCT04111952|Experimental|Additional laser treatment|Women receiving a single laser treatment.
9897161|NCT04111952|Sham Comparator|Sham laser treatment|Women receiving sham laser treatment.
9897162|NCT04111926|Experimental|Intervention group|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
9897163|NCT04111926|Placebo Comparator|Control group|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
9897164|NCT04111705|Experimental|Lorlatinib|100 mg once daily
9897165|NCT04107766||Population|Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.
9897166|NCT04106219|Experimental|LY3295668 Erbumine Escalation|LY3295668 Erbumine given orally.
9897167|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).
9897168|NCT04106219|Experimental|LY3295668 Erbumine Expansion|LY3295668 Erbumine given orally.
9897169|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.
9897170|NCT04106115|Experimental|Durvalumab + S-488210/S-488211|Trial treatment for up to 24 weeks of Durvalumab (1500 mg IV infusion every 4 weeks for up to 7 doses) in combination with S-488210/S-488211 vaccine (given as 2 subcutaneous injections of S-488210/Montanide and S-488211/Montanide starting day after first durvalumab dose, then weekly for the first 6 weeks, and then every 2 weeks for a further 9 doses).
9897171|NCT04104854|Experimental|drug coated balloon|A total of 110 patients are assigned to drug coated balloon treated group after randomization schedule.
9897172|NCT04104854|No Intervention|drug eluted stent implantation|A total of 110 patients are assigned to drug eluted stent treated group after randomization schedule.
9897173|NCT04104776|Experimental|Phase 2 Cohort M1|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M1: Open to patients with urothelial carcinoma (with known ARID1A mutation)"
9897174|NCT04104776|Experimental|Phase 2 Cohort M2|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M2: Open to patients with ovarian clear cell carcinoma (with known ARID1A mutation)"
9897175|NCT04104776|Experimental|Phase 2 Cohort M3|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M3: Open to patients with endometrial carcinoma (with known ARID1A mutation)"
9897176|NCT04104776|Experimental|Phase 2 Cohort M4|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M4: Open to patients with peripheral T-cell lymphoma (PTCL) and patients with diffuse large B-cell lymphoma (DLBCL), including patients with documented germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) with at least 1 EZH2 hotspot mutation"
9897177|NCT04104776|Experimental|Phase 2 Cohort M5|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M5: Open to patients with relapsed or refractory malignant pleural or peritoneal mesothelioma with known BAP1 loss"
9897178|NCT04104776|Experimental|Phase 2 Cohort M6|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M6: Open to patients with castration-resistant prostate cancer(mCRPC) with measurable soft tissue disease"
9897179|NCT04103177|Experimental|Intervention group|20 participants to receive physical activity educational booklet with instructions on chair based exercises, Instructor-led training on how to perform the chair based exercises, two times a week, over a 6 week period, and motivational interviewing and prompts.
9897180|NCT04102020|Experimental|Part 1: Dose Confirmation|Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 24 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.
9897181|NCT04102020|Experimental|Part 3 (Dose Finding): Dose Escalation|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).
9897182|NCT04102020|Experimental|Part 3 (Dose Finding): Safety Expansion|Participants will receive venetoclax QD for up to 24 cycles, CC-486 QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.
9897183|NCT04102020|Experimental|Part 3 (Randomization): Venetoclax + CC-486|Participants will receive venetoclax QD, CC-486 QD on Days 1-14 of each 28-day cycle for 24 cycles.
9897184|NCT04102020|Experimental|Part 3 (Randomization): Placebo + CC-486|Participants will receive Placebo for venetoclax QD, CC-486 QD on Days 1-14 of each 28-day cycle for 24 cycles.
9897185|NCT04101045|Active Comparator|Poorly-controlled T1D|Patients in this group will have poorly-controlled T1D (HbA1c >8.5%).
9897186|NCT04101045|Active Comparator|Controlled T1D|Patients in this group will have T1D and achieve targeted glycemic control (HbA1c <7.5%).
9897187|NCT04101045|Active Comparator|Lean controls|Patients in this group will not have T1D.
9897188|NCT04094688|Experimental|Arm I (bevacizumab, chemotherapy, high-dose vitamin D3)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV on days 1-3 or irinotecan hydrochloride IV on day 1, leucovorin calcium IV over 90 minutes on day 1, and fluorouracil IV on days 1-3. Patients also receive high-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
9897189|NCT04094688|Active Comparator|Arm II (bevacizumab, chemotherapy, standard-dose vitamin D3)|Patients receive bevacizumab and chemotherapy as in Arm I. Patients also receive standard-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
9897190|NCT04093492|Experimental|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention in its current form sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
9897191|NCT04093492|Active Comparator|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
9897192|NCT04093076|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device.
9897193|NCT04093076|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit.
9897194|NCT04093076|Placebo Comparator|Placebo Group C|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device.
9897195|NCT04093076|Placebo Comparator|Placebo Group D|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit..
9897196|NCT04092452|Experimental|Cohort 1|PF-06650833
9897197|NCT04092452|Experimental|Cohort 2|PF-6700841
9897198|NCT04092452|Experimental|Cohort 3|PF-06826647
9897199|NCT04092452|Placebo Comparator|Cohort placebo|placebo
9897200|NCT04089566|Experimental|28/28 Milligram (mg) Safety Group|Part A: Participants with later-onset SMA will receive loading doses of 28 mg of nusinersen intrathecally on Days 1, 15 and 29 followed by maintenance doses of 28 mg on Days 149 and 269.
9897201|NCT04089566|Active Comparator|12/12 mg Randomized Control Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 12 mg of nusinersen intrathecally on Days 1, 15, 29, and 64 followed by maintenance doses of 12 mg on Days 183 and 279. Sham procedure will be administered on Day 135.
9897202|NCT04089566|Experimental|50/28 mg Randomized Treatment Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 50 mg of nusinersen intrathecally on Days 1 and 15 followed by maintenance doses of 28 mg on Days 135 and 279. Sham procedure will be administered on Days 29, 64 and 183.
9897203|NCT04089566|Experimental|12/50/28 mg Titration Group|Part C: Participants who have been receiving the approved dose of 12 mg for at least 1 year prior to entry, will receive a single bolus dose of 50 mg of nusinersen intrathecally on Day 1 (4 months after their most recent maintenance dose of 12 mg) followed by maintenance doses of 28 mg on Days 121 and 241.
9897204|NCT04088409|Experimental|Baricitinib|Baricitinib given orally.
9897205|NCT04088409|Active Comparator|Adalimumab|Adalimumab given subcutaneously (SC).
9897206|NCT04086745|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
9897207|NCT04086745|Experimental|Baricitinib High Dose|Baricitinib administered orally.
9897208|NCT04086745|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
9897209|NCT04081831||New-users of Low-dose aspirin (exposed group)|New-users of low-dose aspirin is defined as patients who did not receive any prescriptions of low-dose aspirin one year prior to the index date.
9897210|NCT04081831||Users of Paracetamol (non-exposed group)|Users of Paracetamol is defined as patients who receive first prescription of paracetamol during the study period. Since the patients receiving low-dose aspirin are potentially less healthy compared to non-users of aspirin, patients receiving paracetamol as the control group can minimise healthy user bias.
9897211|NCT04081649||Cardiac surgery|Patients undergoing non-emergent cardiac surgery for coronary bypass graft and/or valvular replacement
9897212|NCT04077073|Experimental|ReIn-hand and robot|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand and of robot to reduce the shoulder load."
9897213|NCT04077073|Active Comparator|ReIn-Hand|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand."
9897214|NCT04075591|Experimental|Wavefront-guided Lasik Monovision Treatment|Wavefront-guided LASIK monovision treatment of myopic subjects with presbyopia using the STAR S4 IR® Excimer laser System with the iDesign Refractive Studio.
9897215|NCT04074109|Experimental|Teleyoga|group will receive instruction via computer tablet
9897216|NCT04074109|Active Comparator|In-person yoga|group will receive instruction in-person
9897217|NCT04071808||Coronary angiography group|In diabetic patients without symptoms of myocardial ischemia, coronary angiography showed no stenosis or stenosis less than 75%.
9897218|NCT04071808||Coronary angiographic stent implantation group|Coronary angiographic stenosis was more than 75% in diabetic patients without myocardial ischemia symptoms, and coronary stents were implanted.
9897219|NCT04071236|Active Comparator|Arm A (radium-223 dichloride)|Patients receive radium-223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9897220|NCT04071236|Active Comparator|Arm B (radium-223 dichloride, nedisertib)|Patients receive radium-223 dichloride as in Arm A and peposertib PO or BID on days 3-26. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9897221|NCT04071236|Experimental|Arm C (radium-223 dichloride, nedisertib, avelumab)|Patients receive radium-223 dichloride IV as in Arm A and peposertib PO QD or BID as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 15 of cycles 2-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9897222|NCT04070989|Experimental|Posterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the posterior approach
9897223|NCT04070989|Experimental|Lateral Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the lateral approach
9897224|NCT04070989|Experimental|Anterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the anterior approach
9897225|NCT04070352||clostridium difficile infection (CDI)|This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled
9897226|NCT04068727|No Intervention|Control|Control Patients will be provided with educational materials. Control patients will receive no additional guidance.
9932923|NCT00954473||Ancillary-correlative (osteosarcoma genetic risk)|Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
9932924|NCT00954486|Experimental|Epoetin alfa, 10,000 units/week|Epoetin alfa is a recombinant erythropoietin.
9897227|NCT04068727|Experimental|Clinical Pharmacist Intervention|Two intervention pharmacists will deliver the intervention. First, a pharmacy technician will call the patient to ensure access and affordability. Next the clinical pharmacist will call to conduct an initial consultation and educational session, documenting the findings and recommendations related to this consultation in the Electronic Medical Record (EMR). Finally, the intervention staff will send educational materials customized to the patient preference - short video clips, print materials, or an email with links to print materials. Over the remaining weeks of the study, the intervention pharmacists will field questions from patients, perform two follow up monthly phone calls, order and follow up on renal and hepatic function lab work, and write an off-service note.
9897228|NCT04056377||Black boys|240 black boys were included in the study (mean age 7.5 years)
9897229|NCT04056377||Black girls|339 black girls were included in the study (mean age 7.5 years)
9897230|NCT04056377||White boys|239 white boys were included in the study (mean age 7.4 years)
9897231|NCT04056377||White girls|224 white girls were included in the study (mean age 7.4 years)
9897232|NCT04056247||Newly diagnosed NSCLC stage IV|Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
9897233|NCT04056247||NSCLC stage IV 2nd line and further of immunotherapy|Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.
9897234|NCT04056247||Malignant melanoma stage IV|Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.
9897235|NCT04056247||Malignant melanoma stage IIIb-d|Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.
9897236|NCT04056247||SCLC stage IV|Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
9897237|NCT04047251|Experimental|Cohort 1: Treatment at Dose Level 1|FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
9897238|NCT04047251|Experimental|Cohort 2: Treatment at Dose Level 2|FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
9897239|NCT04047251|Experimental|Cohort 3: Treatment at Dose Level 3|FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
9897240|NCT04047251|Experimental|Cohort E1: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced ovarian cancer: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
9897241|NCT04047251|Experimental|Cohort E5: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced Merkel cell carcinoma: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
9897242|NCT04046224|Experimental|Sequential dose escalation|ST-920 is administered as a single infusion
9897243|NCT04039061||ADPKD patients|Patients with a diagnosis, or suspected diagnosis, of ADPKD
9897244|NCT04037917|Experimental|Synthetic Tissue Substitute|Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
9897245|NCT04036773|Experimental|Intervention Group|
9897246|NCT04036773|No Intervention|Control Group|
9897247|NCT04033718|Experimental|Inpatient lab bundling plus navigation|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach. Additional inpatient support from a patient navigator
9897248|NCT04033718|Experimental|Inpatient lab bundling alone|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach.
9897249|NCT04032964|Experimental|Arm L19TNF + DOXO|"Patients will be treated with:~doxorubicin 75 mg/m2 i.v. on day 1 of each 21-day cycle;~L19TNF 13 µg/kg i.v. on day 1, 3 and 5 of each 21-day cycle"
9897250|NCT04029454|Experimental|Intervention period|Intervention : birth dose vaccination against hepatitis B strategy Birth dose of vaccine against hepatitis B + routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
9897251|NCT04029454|No Intervention|Control period|Routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
9897252|NCT04026048|Experimental|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
9897253|NCT04026048|Experimental|Waitlist Control Group|Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
9897254|NCT04025359|Active Comparator|Dronabinol 2.5mg|Dronabinol 2.5mg
9897255|NCT04025359|Active Comparator|Dronabinol 5mg|Dronabinol 5mg
9897256|NCT04025359|Placebo Comparator|Placebo|Placebo
9897257|NCT04022356|Experimental|Connected soles|Number of steps recorded by the soles (activation per smartphone)
9897258|NCT04022356|Active Comparator|Gold Standard|Number of steps counted by two observers viewing the film
9897259|NCT04020913||Short Stature Boys|Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency (defined as peak GH responses to pharmacologic stimuli <10ng/ml) or idiopathic short stature (i.e., no identifiable pathology) will be studied pre and post 12 months of GH therapy.
9897260|NCT04020913||Normally Statured Boys|A group of 15 healthy, normally statured (between 10th- 90th %), age-matched boys not on Growth Hormone replacement, preferably siblings (although not exclusively), will be recruited to serve as healthy controls.
9932925|NCT00954499|Active Comparator|Standard care|
9991939|NCT01457612|Placebo Comparator|Placebo1|Placebo Beverage 1 without fiber
9991940|NCT01457612|Active Comparator|Strawberry|Strawberry Beverage 20g/BID
9991941|NCT01457612|Placebo Comparator|Placebo2|Placebo Beverage 2 with Fiber
9991942|NCT01457625||liver fat contents|
9991943|NCT01457638|Sham Comparator|No inferior turbinate surgery|During rhinoseptoplasty there is no intervention on inferior turbinates
9991944|NCT01457638|Experimental|Inferior Turbinate surgery|During rhinoseptoplasty, inferior turbinate submucosal cauterization is performed.
9991945|NCT01457651|Active Comparator|Recruitment 40x40|The group where recruitment is performed by increase in airway pressure up to 40 cm H2O for 40 seconds
9991946|NCT01457651|Active Comparator|Recruitment PEAK40|Increase in peak airway pressure up to 40 cm H2O during tidal ventilation
9991947|NCT01457651|Active Comparator|Recruitment 15x300|Recruitment by increase in airway PEEP up to 15 cm H2O for 300 sec
9991948|NCT01457651|Active Comparator|No recruitment|No recruitment is performed: standard respiratory support.
9991949|NCT01457664|Placebo Comparator|Placebo|
9991950|NCT01457664|Experimental|RO4995819|
9991951|NCT01457690|Experimental|Tocofersolan: Vitamin E water-soluble|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
9991952|NCT01457690|Active Comparator|Tocopherol alpha: Vitamin E conventional fat-soluble form|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
9991953|NCT01457690|Active Comparator|volunteers|
9991954|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler A|
9991955|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler B|
9991956|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler C|
9991957|NCT01457716|Active Comparator|Budesonide/Formoterol Turbohaler Forte|
9991958|NCT01457729|No Intervention|No Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes per day, no more intervention is done.
9991959|NCT01457729|Other|Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes every day. If training time declines to less than 20 minutes per day for one week, a motivation phone call will take place once a week.
9897261|NCT04017247|Active Comparator|Intermittent treatment|Infusion of oxytocin for 6 hours at a time until patient delivers.
9991960|NCT01457742|Active Comparator|Pulsed Radio Frequency (PRF)|
9991961|NCT01457742|Sham Comparator|Sham|Use of Sham device for 15 minutes simulated treatment twice per day
9991962|NCT01457794|Other|NewNordicDiet first|Intervention with NND for 3 mo then no intervention for 3 mo
9991963|NCT01457794|Other|NewNordicDiet last|No intervention for 3 mo and then intervention with NND for 3 mo
9991964|NCT01457807|Experimental|1|AZD3241 300mg extended release formulation 1
9991965|NCT01457807|Experimental|2|AZD3241 300mg extended release formulation 2
9991966|NCT01457807|Placebo Comparator|3|Placebo
9991967|NCT01457820|Experimental|Allopurinol High dose|
9991968|NCT01457820|Experimental|Allopurinol Low dose|
9991969|NCT01457820|Placebo Comparator|Placebo|
9991970|NCT01457833|Active Comparator|Endobronchial valves (EBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves
9991971|NCT01457833|Active Comparator|Intrabronchial valves (IBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves
9991972|NCT01457859|Active Comparator|Conventional sutures|
9991973|NCT01457859|Experimental|Antiseptic sutures|
9991974|NCT01457872|Experimental|Strength-based case management|Case management plus referral (vs referral-only)
9991975|NCT01457872|Active Comparator|Referral only|Referral only (no case management intervention)
9991976|NCT01457898|Experimental|VPAP II®|VPAP II® Group
9991977|NCT01457911|Experimental|AMARYL M (Glimepiride and Metformin hydrochloride combination)|AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal
9991978|NCT01457911|Active Comparator|AMARYL (Glimepiride)|AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal
9991979|NCT01457937|Active Comparator|PEG IFN/Ribavirin|Standard of care for HCV-positive CAH
9991980|NCT01457937|Experimental|PEG IFN/Ribavirin/Boceprevir|Combination to be tested for possible higher efficacy
9991981|NCT01457963||pulmonary embolism, deep venous thrombosis|
9991982|NCT01457976||Members of the US public, non-probability sample|
9991983|NCT01457976||Members of the German public, non-probability sample|
9991984|NCT01457976||Members of the US public, probability sample|
9991985|NCT01457989||retigabine/ezogabine|retigabine/ezogabine; dose range up to 1200 mg/day
9991986|NCT01458002|No Intervention|Control|Assessment only
9991987|NCT01458002|Other|Tailored Internet Communications|TTM expert system only
9897262|NCT04017247|Active Comparator|Continous treatment|Infusion of oxytocin continuously from patient admission until patient delivers.
9897263|NCT04013828||Patients|Patients with recurrent high-grade glioma
9897264|NCT04013828||Relatives|Close relatives of patients with recurrent high-grade glioma
9897267|NCT04009148||Successful Cascade Testing|Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.
9897268|NCT04009148||Relative Declines Genetic Testing|Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.
9897269|NCT04009070|Active Comparator|Acupuncture|"Group A: Acupuncture group:Group A: Acupunctur will be applied to the Acupunctur group 24 hours prior to bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally on the tibia) . The tape (Needle Press) will stay for 24 hours.~Needle Press: Pres Needle: 0.22x1.5 mm needle"
9897270|NCT04009070|No Intervention|Control Group|Group C: Control group
9897271|NCT04008602|Active Comparator|Experimental: Quick Icing|Group receiving the application of cold on the ventral side of the thigh (bilaterally) for 30 seconds, using the technique of ice beakers dynamically.
9897272|NCT04008602|Active Comparator|Experimental: Prolonged Cold|"Group receiving the intervention of ice bag for a period of eight minutes n the ventral side of the thigh (bilaterally)."
9897273|NCT04008602|No Intervention|Control:|Group that does not receive intervention and that will rest for ten minutes.
9897274|NCT04008537|Experimental|Halcyon kV CBCT imaging|-Each patient will undergo five Halcyon kV CBCT imaging sessions that will then be utilized to simulate the CBCT-guided online ART workflow. Halcyon imaging will be scheduled as per the patient's schedule and availability, with intent but not mandate for imaging on the same days as clinical treatments, preceding clinical treatment. Multiple images may be acquired in one session but no more than 6 Halcyon kV CBCT images will be acquired per day. No more than 6 additional Halcyon kV CBCT images will be acquired in one imaging session and no more than 10 total additional Halcyon kV CBCT images for the duration of the study
9897275|NCT04007536||Part 1|Participants from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
9897276|NCT04007536||Part 2|Participants from 2 through 30 years of age who have MPS II; Part 2 will entail a single collection of cerebrospinal fluid (CSF), urine, and blood. Clinical assessments are optional in Part 2.
9897277|NCT04007536||Part 3|Participants <8 years of age who have the neuronopathic form of mucopolysaccharidosis type II (nMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
9897278|NCT04007536||Part 4|Participants 6 to 17 years of age with the non-neuronopathic form of mucopolysaccharidosis type II (nnMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
9897279|NCT04005183||All patients|Patients undergoing nephrectomy at the University Health Network are eligible for enrolment. All histological subtypes and stages are eligible. Tumor, blood and urine samples are acquired at the time of nephrectomy.
9897280|NCT04004819|Experimental|Rituximab group|Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
9897281|NCT04004819|No Intervention|Control group|Patients will receive usual care and drug use.
9897282|NCT04004078||Group A|Non-gene directed group：Voriconazole was intravenously administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 4mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 400mg or 200mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）. Voriconazole was sequential therapy administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）.
9897283|NCT04004078||Group B|Gene directed group（UMs and EMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with UMs，EMs.
9897284|NCT04004078||Group C|Gene directed group（IMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with IMs.
9897285|NCT04004078||Group D|Gene directed group（PMs）： Voriconazole was intravenously administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 3mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 200mg or 100mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 100mg . Voriconazole was sequential therapy administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 100mg.
9897286|NCT04001621|Experimental|Pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
9897287|NCT04000217|Active Comparator|Written Exposure Therapy|Written exposure therapy (Sloan et al., 2012) is a brief evidence-based treatment for PTSD (US Dept. of VA & DoD, 2017), wherein patients are asked to write about their trauma memories for 30 minutes, with therapist instruction and feedback before and after each writing exercise.
9897288|NCT04000217|Active Comparator|Imaginal Exposure Therapy|Imaginal exposure therapy will involve verbal recounting of trauma memories for 30 minutes with therapist instruction and feedback before and after each recounting exercise.
9897289|NCT03995225|Experimental|Smokers|This study involves wearing a smartband to monitor, record and notify smokers of smoking events and deliver real-time brief mindfulness exercises by smartphone app.
9897290|NCT03994796|Experimental|Arm I (CDK gene mutation)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9897291|NCT03994796|Experimental|Arm II (PI3K gene mutation)|Patients receive PI3K inhibitor paxalisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9897292|NCT03994796|Experimental|Arm III (NTRK/ROS1 gene mutation)|Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9932926|NCT00954499|Experimental|Tactile stimulation|
9932927|NCT00954525|Experimental|Intravenous Vitamin C|
9932928|NCT00954551||All adult patients with SAH in ICU|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively evaluated.
9935609|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
9935610|NCT03449758|Experimental|Sarilumab|Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.
9935611|NCT03448393|Experimental|Dose escalation|CD19/CD22-CAR-transduced T cells at escalating doses
9935612|NCT03448393|Experimental|Dose expansion|CD19/CD22-CAR-transduced T cells at MTD or highest dose administered
9935613|NCT03440047|Experimental|Fuji Flim Processor VP-7000|Screening or surveillance colonoscopy using Fuji Flim Processor VP-7000, Light Source BL-7000
9935614|NCT03436745|Active Comparator|Female|Single 5 mg oral dose of zolpidem
9935615|NCT03436745|Experimental|Zolpidem pre and post castration|5 mg oral dose of zolpidem prior to undergoing ADT followed by 5 mg oral dose of zolpidem after ADT and testosterone reaches castrate levels
9935616|NCT03434080||Autism Spectrum Disorder|The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD)
9935617|NCT03434080||Cerebral Palsy|The group with CP (including all infants less than 18 months who are identified as being athigh-risk for CP)
9935618|NCT03434080||Typical Development toddlers infants|The control group will consist of 50 healthy volunteers with TD
9935619|NCT03429036||1|Subjects must be diagnosed with a disorder of the head and neck region
9935620|NCT03427424||AUD-E|Early-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP within 2 months of starting treatment (AUD-E)
9935621|NCT03427424||AUD-L|Long-term-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (AUD-L)
9935622|NCT03427424||Characterization|substance use disorder participants currently enrolled in PHP, not eligible for main imaging study
9935623|NCT03427424||CON|healthy, non-drug using control participants (CON)
9935624|NCT03427424||POAUD-E|Early-in-treatment, healthy dual prescription opioid and alcohol and use disorder participants currently enrolled in PHP within 2 months of starting treatment (POAUD-E)
9935625|NCT03427424||POAUD-L|Long-term-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POAUD-L)
9935626|NCT03427424||POUD-E|Early-in-treatment, healthy prescription opioid use disorder participants currently enrolled in physician health program (PHP) within 2 months of starting treatment (POUD-E)
9935627|NCT03427424||POUD-L|Long-term-in-treatment, healthy prescription opioid use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POUD-L)
9935628|NCT03416738|Active Comparator|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
9935629|NCT03416738|Active Comparator|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
9897293|NCT03990402||Malawi group|500 young people with asthma symptoms in Malawi
9897294|NCT03990402||South Africa group|500 young people with asthma symptoms in South Africa
9897295|NCT03990402||Uganda group|500 young people with asthma symptoms in Uganda
9897296|NCT03990402||Nigeria|500 young people with asthma symptoms in Nigeria
9897297|NCT03990402||Zimbabwe group|500 young people with asthma symptoms in Zimbabwe
9897298|NCT03990402||Ghana group|500 young people with asthma symptoms in Ghana
9897299|NCT03989869|Experimental|VEMA|Immediate medical abortion treatment
9897300|NCT03989869|No Intervention|Standard of Care|Delayed care until an intrauterine pregnancy has been confirmed with ultrasound.
9897301|NCT03988309|Active Comparator|"Test, subjects categorised as low risk or Not low risk"|"A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either low risk or not low risk categories. Low risk subjects satisfy all conditions and not low risk satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as not low risk will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects."
9897302|NCT03988309|No Intervention|Control|Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.
9897303|NCT03987451|Experimental|Semaglutide|Dose escalation to 2.4 mg of semaglutide once-weekly
9897304|NCT03987451|Placebo Comparator|Placebo|Semaglutide placebo once-weekly
9897305|NCT03979495|No Intervention|Standard of care|standard of care
9897306|NCT03979495|Active Comparator|IT platform|Access to an IT platform for visit-based reminders about overdue abnormal cancer screening test results
9897307|NCT03979495|Active Comparator|IT platform with reminders|Access to an IT platform that will deliver both visit based and between visit reminders about abnormal cancer screening test results.
9897308|NCT03979495|Active Comparator|IT platform and patient navigation|the IT platform available in Arm 3 and navigation to help with scheduling and to address social barriers to care.
9897309|NCT03974594|Experimental|Trifluridine and Tipiracil Tablets|
9897310|NCT03974594|Active Comparator|TAS-102|
9897311|NCT03972709|Experimental|FHTR2163 Q4W|Participants will receive FHTR2163 every 4 weeks (Q4W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label FHTR2163 injections.
9897312|NCT03972709|Sham Comparator|Sham Control Q4W|Participants will receive Sham-control Q4W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label FHTR2163 injections.
9897313|NCT03972709|Experimental|FHTR2163 Q8W|Participants will receive FHTR2163 every 8 weeks (Q8W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label FHTR2163 injections.
9897314|NCT03972709|Sham Comparator|Sham Control Q8W|Participants will receive Sham-control Q8W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label FHTR2163 injections.
9897315|NCT03965221|Experimental|LYNX|LYNX is developed using IMB model and engages youth through entering sexual diary data, earning badges, and calculating a personalized sexual protection (Sex Pro) score, which informs and motivates youth around HIV/STI testing and PrEP uptake. Behavioral skills are built through HIV/STI testing reminders, presenting options for home HIV testing and/or linkage to nearby testing services, and access to an online chat with support for HIV/STI testing and PrEP referral.
9897316|NCT03965221|Experimental|MyChoices|"MyChoices is adapted from an app for adult MSM, HealthMindr, developed using SCT. The app aims to increase HIV testing and PrEP uptake by increasing self- regulation, self-reflection, and self-efficacy around HIV testing and PrEP uptake. Brief surveys about sexual risk and protective health behaviors within the app are used to assist users in tracking and self-monitoring their behaviors and creating a personalized HIV testing plan. Quizzes, videos and infographics as well as Help me Choose, Ordering, and geofencing functions are used to maximize self-efficacy around HIV prevention and uptake of PrEP."
9897317|NCT03965221|No Intervention|Standard of Care|Provision of referrals to local HIV/STI testing and PrEP resources.
9932929|NCT00954603|Experimental|quetiapine|atypical antipsychotic drug
9991988|NCT01458002|Experimental|Tailored Internet Communication with Relational Agent|TTM expert system plus relational agent
9991989|NCT01458015|Active Comparator|oxycodone|
9991990|NCT01458015|Active Comparator|tapentadol|
9991991|NCT01458028|Experimental|Arm 1|
9991992|NCT01458028|Placebo Comparator|Arm 2|
9991993|NCT01458041||Group 1|
9991994|NCT01458054|Experimental|Treatment A|GSK2336805 60mg x 1 dose (fasted) [Reference Treatment]
9991995|NCT01458054|Experimental|Treatment B|Omeprazole 40 mg q24h x 4 days (fed)
9991996|NCT01458054|Experimental|Treatment C|GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) [Test Treatment]
9991997|NCT01458054|Experimental|Treatment D|GSK2336805 30mg x 1 dose (fasted) [Reference Treatment]
9991998|NCT01458054|Experimental|Treatment E|Ritonavir 100mg q12h x 4 days (fed)
9991999|NCT01458054|Experimental|Treatment F|GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) [Test Treatment]
9992000|NCT01458054|Experimental|Treatment G|Ritonavir 100mg q12h x 1 day
9992001|NCT01458067|Experimental|Part 1|GSK2636771 single dose and then daily dosing after approximately 1 week
9992002|NCT01458067|Experimental|Part 2|GSK2636771 single dose and then daily dosing starting on Day 4
9992003|NCT01458067|Experimental|Part 3|GSK2636771 daily dosing
9992004|NCT01458080||Patients w/secondary thrombocytopenia related to hepatitis C|Patients w/secondary thrombocytopenia related to hepatitis C
9517783|NCT03303001|Experimental|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
9992005|NCT01458093||Colonoscopy patients|Consecutive colonoscopy outpatients referred to one of 29 endoscopy units in Italy
9992006|NCT01458145|Experimental|Home visits|
9992007|NCT01458145|No Intervention|routine primary care at community health center|
9992008|NCT01458158||Diabetic nephropathy|Diabetic nephropathy in patients with type 2 diabetes
9992009|NCT01458158||chronic glomerulonephritis|chronic glomerulonephritis in patients without diabetes mellitus
9992010|NCT01458158||controls|participants without diabetic nephropathy and chronic glomerulonephritis
9992011|NCT01458184|Experimental|PhoneCare system|This arm is evaluating whether utilizing the PhoneCare system aids participants with their complex health care needs.
9992012|NCT01458184|No Intervention|Control Group: without PhoneCare System|Subjects in this arm will receive the usual care. Usual care is defined as receiving regular care from their physicians and no additional care or intervention from the study.
9992013|NCT01458197|Experimental|Tarafenacin 0.2 mg|Group 1
9992014|NCT01458197|Experimental|Tarafenacin 0.4 mg|Group 2
9992015|NCT01458197|Placebo Comparator|Placebo|Group 3
9992016|NCT01458223|Active Comparator|Control|24 hours post-operative antibiotics
9992017|NCT01458223|Experimental|experimental|72 hours of post-operative antibiotics
9992018|NCT01458236|Experimental|BPS-314d-MR|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration.
9992019|NCT01458236|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group.
9992020|NCT01458301|Placebo Comparator|Placebo|
9992021|NCT01458301|Experimental|TAK-385 10 mg QD|
9992022|NCT01458301|Experimental|TAK-385 20 mg QD|
9992023|NCT01458301|Experimental|TAK-385 40 mg QD|
9992024|NCT01458301|Other|Leuplin|
9992025|NCT01458314|Active Comparator|Rehabilitation without NIV|A usual rehabilitative training will be performed in patients using nocturnal NIV, without adoption of daily NIV
9992026|NCT01458314|Experimental|Daily NIV during rehabilitation|Daily NIV will be adopted during the rehabilitation program in patients already using nocturnal NIV
9897318|NCT03964688|Experimental|Vitamin C|vitamin C intravenous during hospitalization, followed with vitamin C oral
9897319|NCT03964688|Experimental|Placebo|placebo intravenous during hospitalization, followed with placebo oral
9897320|NCT03962166||Cohort|consecutive adult patients undergoing first-time elective open-heart surgery
9897321|NCT03961165|Experimental|Treatment arm|1mL 20 mg/mL butylscopolamine bromide i.v.
9897322|NCT03961165|Placebo Comparator|Placebo|1mL 9mg/mL NaCl
9897323|NCT03960073|Experimental|MitoQ|20mg daily oral dose of MitoQ
9897324|NCT03960073|Placebo Comparator|Placebo|Oral TTP placebo
9897325|NCT03958877|Experimental|BIIB017 (peginterferon beta-1a)|Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
9897326|NCT03958877|Active Comparator|Avonex|Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
9897327|NCT03957876|Experimental|intravenous CPX-351 with potential maintenance therapy|Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.
9897328|NCT03956979|Experimental|JM-010 group A|As JM-010 4/0.8mg dose fixed combination drug(tablet) +Placebo 2
9897329|NCT03956979|Experimental|JM-010 group B|As JM-010 8/0.8mg dose fixed combination drug(tablet) + Placebo 1
9897330|NCT03956979|Placebo Comparator|Placebo|Double-dummy - 2 tablets = Placebo 1 +Placebo 2
9897331|NCT03956810|Experimental|On-demand transportation|Women randomized to the intervention group will be able to contact the transportation broker via telephone, web portal, or the broker's mobile application. In addition to the current trips provided by their Medicaid managed care organization , women assigned to the intervention group will be provided with extra trips to the pharmacy and grocery store or food bank.
9897332|NCT03956810|Active Comparator|Usual transportation|Women assigned to the usual care group will receive the usual transportation services from their Medicaid managed care organization.
9897333|NCT03954067|Experimental|Dose Escalation - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9897334|NCT03954067|Experimental|Dose Escalation - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9897335|NCT03954067|Experimental|Dose Expansion (Monotherapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9897336|NCT03954067|Experimental|Dose Expansion (Monotherapy) - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9897337|NCT03954067|Experimental|Dose Expansion (Monotherapy Induction) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1, 8, 15 and 22 of the first 28 day cycle. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9897338|NCT03954067|Experimental|Dose Expansion (Combination Therapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9932930|NCT00954603|Active Comparator|haloperidol|typical antipsychotic drug
9932931|NCT00954629|Experimental|2PX|Pain medication
9932932|NCT00954629|Placebo Comparator|Placebo|
9932933|NCT00954642|Experimental|A|
9932934|NCT00954642|Experimental|B|
9992027|NCT01458353|Experimental|Handsewn ileocolonic anastomosis|Swabs obtained from patients undergoing handsewn ileocolonic anastomosis
9992028|NCT01458353|Experimental|Stapled ileocolonic anastomosis|Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis
9992029|NCT01458431|Experimental|Levobupivacaine|Continuous levobupivacaine subfascial infusion
9992030|NCT01458431|Placebo Comparator|NaCl|Continuous NaCl subfascial infusion
9992031|NCT01458444|Active Comparator|BIPAP|Non invasive ventilation (VNI) by BIPAP® vision
9992032|NCT01458444|Experimental|OPTIFLOW|OPTIFLOW system
9992033|NCT01458457|Active Comparator|Usual care|
9992034|NCT01458457|Active Comparator|Usual Care + Complementary Medicine|
9992035|NCT01458470|Active Comparator|Memantine|NMDA Receptor Antagonist
9992036|NCT01458470|Placebo Comparator|Sugar pill|
9992037|NCT01458483|Experimental|Baroreceptor Stimulation|
9992038|NCT01458496|Experimental|Health Coaching|
9992039|NCT01458496|No Intervention|Usual Care -Control|Patients assigned to the control (usual care) group will be advised to seek standard lifestyle counselling from their primary care physician.
9992040|NCT01458509||IVRS ( interactive voice response system) EASP|Telephone Group with Nurse Intervention
9992041|NCT01458509||Web EASP|Web Group with Nurse Intervention
9517784|NCT03303001|Active Comparator|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
9992042|NCT01458509||IVRS ( interactive voice response system) No EASP|Telephone Group without nurse intervention
9992043|NCT01458509||Web No EASP|Web Group without nurse intervention
9992044|NCT01458600|Active Comparator|diclofenac|12 months treatment with diclofenac 50 mg 1x2 in addition to regular treatment for thyrotoxicosis.
9992045|NCT01458600|Other|without diclofenac|12 months treatment without diclofenac in addition to regular treatment for thyrotoxicosis.
9992046|NCT01458613||Observation|Patients with Maroteaux-Lamy disease
9992047|NCT01458626|Active Comparator|Add-on therapy|mirtazapine 30mg QD and paroxetine 20mg QD
9992048|NCT01458626|Active Comparator|mirtazapine monotherapy|mirtazapine 30mg QD
9992049|NCT01458626|Active Comparator|paroxetine monotherapy|paroxetine 20mg QD
9992050|NCT01458652|Experimental|Lifestyle counseling|"Drug:Kremezin~Other Names:AST-120~Kremezin is an oral adsorbent, 9g/day in treatment arm"
9992051|NCT01458665|Experimental|PRP group|
9992052|NCT01458665|Placebo Comparator|Conventional group|
9992053|NCT01458678|Active Comparator|Oesophageal Doppler (OD)|Goal directed volume therapy is most often guided by stroke volume measurements by OD.
9992054|NCT01458678|Active Comparator|Pleth Variability Index (PVI)|The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.
9992055|NCT01458691|Active Comparator|Steroid group|Triamcinolone injection group
9992056|NCT01458691|Experimental|PRP group|Allogeneic PRP injection group
9992057|NCT01458704||fresh frozen tumor tissue|patients providing fresh frozen tumor tissue
9992058|NCT01458717|Experimental|Neoadjuvant|Neoadjuvant - operation - maintenance chemotherapy
9992059|NCT01458717|Active Comparator|Upfront surgery|Operation - adjuvant chemoradiation - maintenance chemotherapy
9992060|NCT01458743|Experimental|Ceftaroline q12h|Ceftaroline 600mg q12h
9992061|NCT01458743|Experimental|Ceftaroline q8h|ceftaroline 600mg q8h
9997608|NCT01510509|Experimental|Everolimus Drug Eluting Stent|Xience-V®, Abbott Vascular, Santa Clara, California, USA
9992062|NCT01458756||liver transplant patients|Population of adult patients awaiting liver transplant, status on the waiting list in the transplant center of University Hospital of Lille.
9992063|NCT01458769|Active Comparator|Part A1|"Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz.~C-10276 200 mg -> C-10276 400 mg -> Reyataz 400 mg~C-10276 200 mg -> Reyataz 400 mg -> C-10276 400 mg"
9992064|NCT01458769|Active Comparator|Part A2|"Part A2 will evaluate the single agent C-10276, co-administration of CTP-518 and C-10276, and a dose of Reyataz.~C-10276 300 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)-> C-10276 400 mg~C-10276 300 mg -> C-10276 400 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)"
9992065|NCT01458769|Active Comparator|Part B Group 1|"Group B1 will evaluate single doses of an ATV isotopolog, C-10297.~C-10297 200 mg"
9992066|NCT01458769|Active Comparator|Part B Group 2|"Group B2 will evaluate single doses of an ATV isotopolog, C-10299.~C-10299 200 mg"
9992067|NCT01458769|Active Comparator|Part B Group 3|"Group B3 will evaluate two single ascending doses of isotopologs C-10297 and 400 mg dose of Reyataz in a 3-way crossover design.~C-10297 400 mg -> Reyataz 400 mg -> C-10297 600 mg"
9992068|NCT01458769|Active Comparator|Part B Group 4|"Group B4 will evaluate two single ascending doses of isotopolog C-10299 and a 400 mg dose of Reyataz in a 3-way crossover design.~C-10299 400 mg -> Reyataz 400 mg -> C-10299 600 mg"
9992069|NCT01458769|Active Comparator|Part B Group 5|"Group B5 will evaluate a single dose of C-10276 and a 400 and 600 mg dose of Reyataz in a 3-way crossover design.~C-10276 600 mg -> Reyataz 400 mg -> Reyataz 600 mg"
9992070|NCT01458782|Active Comparator|ACI-C|Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
9992071|NCT01458782|Active Comparator|AMIC|"Autologous matrix induced chondrogenesis. Microfracture of the defect and covering using the collagen membrane (ChondroGide).~Please see reference 3 for details regarding AMIC"
9992072|NCT01458808|Experimental|Group A|Composed by 21 patients treated with reduction of 2 grams of sodium reduction in their habitual diet.
9992073|NCT01458808|Experimental|Group B|Composed by 20 patients treated by reduction of dialysate concentration from 138 to 135 mEq/L
9992074|NCT01458808|No Intervention|Group C|Composed by 18 patients followed without changes in dialysate sodium concentration or diet sodium amount.
9992075|NCT01458821|Experimental|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
9992076|NCT01458821|No Intervention|No treatment|Subject will make no changes in their usual daily routine. No intervention. Will repeat all study procedures at end of 8 weeks.
9992077|NCT01458834|Experimental|Active attention training condition|
9992078|NCT01458834|Placebo Comparator|Control condition|
9992079|NCT01458847|Experimental|Cohort I: 2% cis-UCA solution (50 ml)|
9992080|NCT01458847|Experimental|Cohort II: 4% cis-UCA solution (50 ml)|
9992081|NCT01458847|Experimental|Cohort III: 6% cis-UCA solution (50 ml)|
9992082|NCT01458860||GROUP A|patients had a CT
9992083|NCT01458860||GROUP B|patients with severe carotid artery stenosis
9992084|NCT01458873|Experimental|sodium bicarbonate 4.2%|"sodium bicarbonate 4.2% 50 ml"
9992085|NCT01458873|Experimental|sodium bicarbonate 2.1%|"sodium bicarbonate 2.1% 1 50 ml"
9992086|NCT01458873|Placebo Comparator|normal saline|"50 ml normal saline"
9992087|NCT01458886|Experimental|BI 54903 LD b.i.d.|Patients receive 2 puffs b.i.d. via Respimat inhaler
9992088|NCT01458886|Experimental|BI 54903 MD q.d.|Patients receive 2 puffs q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
9992089|NCT01458886|Placebo Comparator|Placebo|Patients receive 2 puffs b.i.d. via Respimat inhaler
9517785|NCT03302988|Experimental|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
9992090|NCT01458899|Experimental|A - first fed then fasted treatment|TC-5214
9992091|NCT01458899|Experimental|B - first fasted then fed treatment|TC-5214
9992092|NCT01458912|Experimental|BI 54903 HD q.d.|Patients receive 2 puffs BI 54903 HD q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
9992093|NCT01458912|Placebo Comparator|Placebo|Patients receive 2 puffs Placebo b.i.d. via Respimat inhaler
9992094|NCT01458912|Experimental|BI 54903 MD b.i.d.|Patients receive 2 puffs BI 54903 MD b.i.d.via Respimat inhaler
9997609|NCT01510522|Experimental|Glucophage sachets|Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
9932935|NCT00954655||Group 1|Tumor samples are used for polymorphism and mutation analysis.
9932936|NCT00954668|Experimental|immediate angiography|Immediate invasive angiography < 2 h after randomization
9932937|NCT00954668|Active Comparator|early invasive angiography|early invasive angiography 12-72 h after randomization
9932938|NCT00954694|Experimental|introductory exercise regimen|sedentary adults will be introduced to an introductory fitness regimen using the NuStep
9932939|NCT00954720||Patient undergoing transplant|Patients with acute leukemia or MDS undergoing ablative stem cell transplantation. No intervention.
9932940|NCT00954746||Follow-up|Subjects Previously Treated with AA4500
9932941|NCT00954759|Experimental|Chiropractic treatment|Manipulation and/or mobilisation
9932942|NCT00954759|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
9932943|NCT00954772||Staged Bilateral STN DBS|
9932944|NCT00954772||Simultaneous Bilateral STN DBS|
9932945|NCT00954785|Placebo Comparator|Placebo drug|
9932946|NCT00954785|Experimental|Etoricoxib|
9932947|NCT00954785|Active Comparator|Diclofenac|
9932948|NCT00954798|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
9932949|NCT00954798|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
9932950|NCT00954798|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
9932951|NCT00954811|Active Comparator|HCG for ovulation triggering and luteal progesterone|conventional triggering with HCG and conventional luteal support with progesterone
9932952|NCT00954811|Experimental|Agonist triggering and rec-LH luteal support plus progesterone|new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
9932953|NCT00954837|Other|Fine needle aspiration|Patient with solid nodules more than 10 mm in diameter will be biopsied by ultrasound-guided fine-needle aspiration(FNA)after consultation with an endocrinologist or ENT specialist.
9932954|NCT00954850||Severe asthmatics|Main study group
9932955|NCT00954850||Mild-moderate asthmatics|Control group
9932956|NCT00954889|Experimental|Tamsulosin|
9932957|NCT00954889|Placebo Comparator|placebo|
9932958|NCT00954902|Sham Comparator|No spice, no stress|Subject are given placebo capsules and told they contain an antioxidant concentrate
9932959|NCT00954902|Sham Comparator|No Spice, Stress|Subjects are given placebo capsules and told they are receiving an equivalent amount of an antioxidant concentrate.
9932960|NCT00954902|Experimental|Spice, no stress|
9932961|NCT00954902|Experimental|Spice and Stress|
9932962|NCT00954928||Anticoagulated patients|Those patients taking Coumadin, Plavix, Aspirin, Lovenox.
9932963|NCT00954928||Control patients|Those patients having hand or wrist surgery who do not take any anticoagulant medication.
9932964|NCT00954954|Active Comparator|Standard|Knees that will be implanted with standard posterior stabilized RP-MB knee prostheses
9932965|NCT00954954|Active Comparator|High-flexion|Knees that will be implanted with high-flexion posterior stabilized RP-MB knee prostheses
9932966|NCT00954967|No Intervention|Usual care|The subjects in the control group will receive the usual care for smoking cessation in diabetic smokers.
9932967|NCT00954967|Experimental|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
9932968|NCT00954980||Endovenous Sclerotherapy|For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure
9932969|NCT00955006|Experimental|Group 1|Participants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
9932970|NCT00955045|Experimental|istradefylline|
9932971|NCT00955058|Active Comparator|cyproterone compound|Before and after treatment
9932972|NCT00955058|Experimental|oral contraceptive pill|Treatment
9932973|NCT00955071|No Intervention|Control|
9932974|NCT00955071|Active Comparator|Exercise: LVLI|low volume, low intensity
9932975|NCT00955071|Active Comparator|Exercise: HVLI|high volume, low intensity
9932976|NCT00955071|Active Comparator|Exercise: LVHI|low volume, high intensity
9932977|NCT00955097|Experimental|Definity Contrast Dye|During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors
9897339|NCT03954067|Experimental|Dose Expansion (Combination Induction Therapy) - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1, 8, 15 and 22 of first 28 day cycle at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9897340|NCT03954067|Experimental|Dose Expansion (Combination Therapy) - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
9897341|NCT03952559|Experimental|Baricitinib Open Label High Dose|Baricitinib administered orally.
9897342|NCT03952559|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9897343|NCT03952559|Experimental|Baricitinib Mid Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9897344|NCT03952559|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9897345|NCT03952559|Placebo Comparator|Placebo|Placebo administered orally. Matching placebo administered orally to maintain the blind.
9897346|NCT03952234|Other|Dose finding safety study|In this study, the highest acceptable dose of an amino acid called citrulline will be established in people who have a mitochondrial disorder. Previous research conducted by several groups including our center at Baylor College of Medicine has determined that there is a deficiency of a compound called nitric oxide in people affected with MELAS.
9897347|NCT03946670|Experimental|MBG453 + hypomethylating agents|Patients will take MBG453 plus hypomethylating agents
9897348|NCT03946670|Placebo Comparator|Placebo + hypomethylating agents|Patients will take placebo plus hypomethylating agents
9897349|NCT03940703|Experimental|Tepotinib and Osimertinib|Participants will receive a combination of tepotinib and osimertinib. The combination will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
9897350|NCT03940703|Experimental|Tepotinib Mono-therapy|Participants will receive once daily dose of tepotinib. The mono therapy will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
9897351|NCT03940196|Experimental|NovoTTF-100L(O)|Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel
9897352|NCT03940196|Active Comparator|Best Standard of Care|Patients receive best standard of care with weekly Paclitaxel
9897353|NCT03938792|Experimental|PF-06741086|Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
9897354|NCT03937011||Stratafix Arm|The single study arm would comprise of two different specialties in Robotic surgical procedures: Bariatric Sleeve gastrectomy (Staple line reinforcement) and Hysterectomy (Vaginal cuff closure).
9897355|NCT03935607||Normal amniotic fluid index|Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.
9897356|NCT03935607||Oligohydramnios|Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.
9897357|NCT03933202||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any oral or infusion DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
9897358|NCT03932656||Females with borderline personality disorder|
9897359|NCT03931941|Experimental|Active|RBX2660 is an enema of a microbiota suspension
9897360|NCT03930277||Pregnant women in labor.|Pregnant women in labor during the 2nd stage of labor.
9897361|NCT03929120|Experimental|Interstitial Lung Disease with Connective Tissue Disorder|Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
9897362|NCT03927651|Experimental|Administration of ICG|ICG will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. Near infrared fluorescence imaging will be used to illuminate the ICG. The extent of perfusion will be determined using digital imaging software. ICG will be stored at the NM Investigational Pharmacy and administered intravenously by the anesthesiologist at the direction of the surgeon during surgical procedure.
9897363|NCT03927378|Experimental|S-katamine group|Low-dose s-ketamine (0.2 mg/kg in 20 ml normal saline) is intravenously infused in 40 minutes after childbirth.
9897364|NCT03927378|Placebo Comparator|Placebo group|Placebo (20 ml normal saline) is intravenously infused in 40 minutes after childbirth.
9897365|NCT03925402||Ertapenem|Patients who received ertapenem as an empirical antibiotic
9897366|NCT03925402||Other carbapenems|Patients who received carbapenems other than ertapenem as an empirical antibiotic
9932978|NCT00955123||Active inflammatory bowel disease|Patients with moderate to severe active inflammatory bowel disease (ulcerative colitis and Crohn's disease)
9897367|NCT03923686|Experimental|LAMS plus DPS|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
9897368|NCT03923686|Active Comparator|LAMS alone|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
9897369|NCT03920410|Experimental|stimulated serotonergic activity|
9897370|NCT03920410|Experimental|unstimulated serotonergic activity|
9897371|NCT03918447|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
9897372|NCT03918447|Experimental|Maximum bardoxolone methyl dose 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6.~Patients will continue to receive study drug through Week 100, and will not receive study drug during a 12-week off-treatment period between Weeks 100 and 112."
9897373|NCT03918447|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.~Patients will continue to receive placebo capsules through Week 100, and will not receive capsules during a 12-week off-treatment period between Weeks 100 and 112."
10212167|NCT02164019|Active Comparator|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
10212168|NCT02117817|Experimental|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
10212169|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
9897377|NCT03915951|Experimental|Treatment Period|"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.~Patients will receive the following per 28-day (± 3 days) cycle:~Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)~Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)"
9897378|NCT03913208|Experimental|Study group|Will be subjected to priority to freeze
9897379|NCT03913208|Active Comparator|Control group|Will receive fresh embryo transfere
9897380|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 0.3mg dose|Low dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
9897381|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 1 mg dose|Intermediate dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
9897382|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 3 mg dose|High dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
9897383|NCT03913117|Experimental|PVX-6|Selected dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0 and 4, and the TA-CIN protein is administered by intramuscular injection at week 8.
9897384|NCT03911076|Experimental|PVX-2|Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein
9897385|NCT03911076|Placebo Comparator|Placebo|Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)
9897386|NCT03903744|Experimental|Treatment arm|Patients treated with cardioneuroablation.
9897387|NCT03903744|Active Comparator|Control arm|Patients treated with standard non-pharmacological methods.
9897388|NCT03898960||Mechanical Thrombectomy|NIMBUS Device
9897389|NCT03898531||hip prosthesis metal/polyethylene in simple mobility|
9897390|NCT03898531||hip prosthesis metal/polyethylene in double mobility|
9897391|NCT03898531||hip prosthesis ceramic/polyethylene in simple mobility|
9897392|NCT03898531||hip prosthesis ceramic/polyethylene in double mobility|
9897393|NCT03898531||Primary implanted hip prosthesis|
9897394|NCT03898531||metal / metal prosthesis removed|
9897395|NCT03898531||ceramic / ceramic prosthesis removed|
9897396|NCT03896568|Experimental|Part I (oncolytic adenovirus Ad5-DNX-2401)|Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.
9897397|NCT03896568|Experimental|Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)|Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.
9897398|NCT03896503|Active Comparator|Arm I (topotecan hydrochloride )|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II at disease progression.
9897399|NCT03896503|Experimental|Arm II (topotecan hydrochloride, M6620)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and M6620 IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9897400|NCT03896477|Experimental|Pneumosil|Infants received two primary vaccinations with Pneumosil, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
10213858|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the histidine and beta-alanine supplementation.
9897401|NCT03896477|Active Comparator|Synflorix|Infants received two primary vaccinations with Synflorix, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
9897402|NCT03896477|Active Comparator|Prevenar 13|Infants received two primary vaccinations with Prevenar 13, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
9897403|NCT03894059||Retrospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period preceding the implementation of the educational intervention for ambulance telecommunicators.
9897404|NCT03894059||Prospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period following the implementation of the educational intervention for ambulance telecommunicators.
9897405|NCT03893370|Active Comparator|Treatment|RJA MCS
9897406|NCT03893370|Sham Comparator|Sham Control|Sham
9897407|NCT03893175|Experimental|Ibuprofen|"During the double-blind stage, subjects will receive blinded ibuprofen (400 mg by mouth) when pain is at least 4/10 following third molar extraction.~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
9897408|NCT03893175|Placebo Comparator|Placebo|"During the double-blind stage, subjects will receive blinded placebo when pain is at least 4/10 following third molar extraction.~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
9897409|NCT03887559|Experimental|Intervention group|Group-based stabilization and skill-training combined with individual treatment.
9897410|NCT03887559|Active Comparator|controls|Individual treatment as usual only.
9897411|NCT03886246|Experimental|Spesolimab (every 6 weeks)|
9897412|NCT03886246|Experimental|Spesolimab (every 12 weeks)|
9897413|NCT03886246|Experimental|Spesolimab (every 4 weeks)|
9897414|NCT03886025|Experimental|Combined anodal tDCS and cognitive training|Combined anodal tDCS and cognitive training. Anodal tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). Anodal tDCS will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration of each tDCS session will be 20 minutes.
9897415|NCT03886025|Sham Comparator|Combined sham tDCS and cognitive training|Combined sham tDCS and cognitive training. Sham tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). For sham tDCS, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each tDCS session will be 20 minutes.
9517786|NCT03302988|Active Comparator|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
9897416|NCT03878147|Other|HIV infected|HIV infected children
9897417|NCT03878147|Other|HIV exposed uninfected|HIV exposed, uninfected children
9897418|NCT03878147|Active Comparator|HIV unexposed uninfected|HIV unexposed uninfected children (community controls)
9897419|NCT03875235|Experimental|Treatment Arm|Durvalumab + Gemcitabine + Cisplatin
9897420|NCT03875235|Placebo Comparator|Placebo Arm|Placebo + Gemcitabine + Cisplatin
9897421|NCT03874039||Healthy Adults|Healthy adults with no prior diagnosis of atopic dermatitis
9897422|NCT03874039||Atopic Dermatitis|Adults with prior diagnosis of Atopic Dermatitis from board certified dermatologist
9897423|NCT03872479|Experimental|Adults Low Dose|Single dose of EDIT-101 administered by subretinal injection surgery
9897424|NCT03872479|Experimental|Adults Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
9897425|NCT03872479|Experimental|Adults High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
9897426|NCT03872479|Experimental|Pediatric Middle Dose|Single dose of EDIT-101 administered by subretinal injection surgery
9897427|NCT03872479|Experimental|Pediatric High Dose|Single dose of EDIT-101 administered by subretinal injection surgery
9897428|NCT03868709|Experimental|Penehyclidine group|Penehyclidine inhalation is administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
9897429|NCT03868709|Placebo Comparator|Placebo group|Placebo inhalation is administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
9897430|NCT03868605|Experimental|EMR/ESD|Standard EMR or ESD technique
9897431|NCT03868605|Experimental|Over- the- scope full- thickness resection device|Endoscopic full thickness resection
9897432|NCT03865238|Experimental|EV71vac|
9897433|NCT03865238|Placebo Comparator|Placebo|
9897434|NCT03862157|Experimental|Treatment (venetoclax, azacitidine, pevonedistat)|Patients receive venetoclax PO QD on days 1-28, azacitidine IV or SC on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9897435|NCT03861273|Experimental|PF-06838435/ fidanacogene elaparvovec|
9897436|NCT03859973|Experimental|BI 425809|Active drug treatment arm
9897437|NCT03859973|Experimental|Placebo|Placebo drug arm
9897438|NCT03858686|Active Comparator|400 mg FP-025 capsules|Based on a double-blind randomized schedule, 16 subjects will receive FP-025 capsules in Period 1 and matching placebo FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
9897439|NCT03858686|Placebo Comparator|FP-025 Placebo Capsules|Based on a double-blind randomized schedule, 16 subjects will receive matching placebo FP-025 capsules in Period 1 and FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
9897440|NCT03857620|Active Comparator|Arm I (usual care)|Healthcare providers/institutions perform usual care.
9897441|NCT03857620|Experimental|Arm II (OPTI-Surg training and materials)|Healthcare providers/institutions receive OPTI-Surg training and informational materials.
9897442|NCT03857620|Experimental|Arm III (OPTI-Surg training and materials, coach)|Healthcare providers/institutions receive OPTI-Surg training and informational materials and meet with a coach.
9897443|NCT03854474|Experimental|Treatment (tazemetostat, pembrolizumab)|Patients receive tazemetostat PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9897444|NCT03853044|Experimental|Chidamide plus CHOP|Participants received six 21-day cycles of chidamide, combined with six cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (21-day cycles).
9897445|NCT03847857|Experimental|Surgery+PFS|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal anastomosis during McKeown esophagectomy.
9897446|NCT03847857|Placebo Comparator|Surgery|Arm B underwent conventional anastomosis during McKeown esophagectomy.
9897447|NCT03843645|Active Comparator|general anesthesia group|patients allocated to the general anesthesia group will be subjected to general anesthesia with sevoflurane (inhalational agent) used for maintenance
9897448|NCT03843645|Active Comparator|regional anesthesia group|patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with ropivacaine and fentanyl
9897449|NCT03842995|Placebo Comparator|Genetic Counselor|Standard of Care. Parents/caregivers of neonates enrolled in SouthSeq will receive counseling on their child's Whole Genome Sequencing (WGS) results from Genetic Counselors
9897450|NCT03842995|Experimental|Trained Healthcare Provider|Healthcare providers (e.g., neonatologists and neonatology nurse practitioners) will receive training to competently deliver Whole Genome Sequencing results to parents/caregivers of neonates enrolled in SouthSeq
9897451|NCT03841253|Experimental|Observation Phase|A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
9897452|NCT03841253|Experimental|Treatment Phase|If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.
9897453|NCT03839472|Experimental|Continuous Bladder Irrigation (CBI)|"Each subject will have a TURBT procedure performed per standard of care procedure, which will be followed by the study intervention - Continuous Bladder Irrigation (CBI) for up to two hours after procedure.~Six samples of discarded bladder irrigation will be collected from each participant (N=20) immediately after TURBT and after the completion of each liter of normal saline 0.9% irrigation (1 to 5 L) for a total of 120 samples."
9897454|NCT03837899|Experimental|Durvalumab / Tremelimumab Combination Therapy|"Part 1 (dose finding) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are initially administered at dose level 1 and dose escalated based on results from PK modeling and tolerance to determine the RP2D. Both drugs are administered every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvavalumab for 4 doses, from cycles 2-5. (sarcoma, NB and NHL)~Part 2 (dose expansion phase) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are administered at the RP2D, every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvalumab for 4 doses, from cycles 1-4. Tremelimumab may be added for 4 doses at time of progressive disease. Cohorts: solid tumors, sarcomas, NHL restricted to PMBCL and ALCL subtypes)"
9897455|NCT03834714|Active Comparator|Noise Stimulus and Infrared Light|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive infrared light therapy for 2 out of the 4 visits and sham infrared light therapy for the other 2 visits.
9897456|NCT03834714|Sham Comparator|Noise Stimulus and Sham|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive sham infrared light therapy for 2 out of the 4 visits and infrared light therapy for the other 2 visits.
9897457|NCT03833804|Experimental|NLP (natural language processing) pre-screen|Automated processing of clinical notes collected during routine care in first 24 hours of hospital admission to identify individuals at-risk for substance misuse to receive standard-of-care full screening and assessment, brief intervention, or referral to treatment (SBIRT) intervention.
9897458|NCT03831516||Non Invasive Electroanatomical Mapping|Patients will undergo non invasive electroanatomical mapping (CardioInsight by Medtronic) prior and during an invasive electrophysiology study and ablation of ventricular Arrhythmias.
9897459|NCT03828513|Active Comparator|High flow nasal cannula oxygen applied|High flow nasal cannula oxygen is start at a flow rate of 80 L/min with 100% oxygen in the preoperative period.
9897460|NCT03828513|Active Comparator|High flow nasal cannula oxygen is not applied|Preoxygenation will be applied with an oxygen supplement of 5 l/min to an endtidal O2> 90%.
9897461|NCT03826303|Experimental|E-cigarette with ethanol, 1 puff|
9897462|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 1 puff|
9897463|NCT03826303|Experimental|E-cigarette with ethanol, 10 puffs|
9897464|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 10 puffs|
9897465|NCT03820726|Experimental|All subjects|
9897466|NCT03819686|Experimental|Living ACTS website|In addition to the provision of standard transplant education procedures, a patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching the 20-minute video).
9897467|NCT03819686|Other|Standard transplant education procedures|Usual Care, which involves the provision of standard transplant education procedures at each transplant center, which entail reviewing a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two 10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
9897468|NCT03810404|Experimental|Sodium bicarbonate supplementation|Group taking oral SB supplementation in a different-dose regimen.
9897469|NCT03810404|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (NaCl).
9897470|NCT03807713|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
9897471|NCT03806608|Experimental|Crestal|Implants were placed with the implant-abutment interface(IAI) at the level of the the alveolar ridge
9897472|NCT03806608|Experimental|Subcrestal|Implants were placed with the implant-abutment interface(IAI) 1 mm below the level of the alveolar ridge
9897473|NCT03805594|Experimental|Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
9897474|NCT03805594|Experimental|Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
9897475|NCT03805594|Experimental|Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)|Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
9897476|NCT03803761|Experimental|Treatment (copanlisib, fulvestrant)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and fulvestrant IM over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9897477|NCT03802812|No Intervention|Conventional arm|"Perform bronchial washing using conventional methods.~CT-guided thick bronchoscope"
9897478|NCT03802812|Active Comparator|Investigational arm|"Perform bronchial washing using investigational methods.~virtual bronchoscopic navigation (VBN)-guided thin bronchoscope (4.0mm of outer diameter)"
9897479|NCT03799003|Experimental|ASP1951 Monotherapy Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1951.Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
9897480|NCT03799003|Experimental|ASP1951 Monotherapy Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in a monotherapy or combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.
9897481|NCT03799003|Experimental|ASP1951 Optional Monotherapy Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
9897482|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Escalation|The combination escalation cohort will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
9897483|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in the combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable. Once the high dose RP2D and schedule of ASP1951 in combination with pembrolizumab has been determined, expansion cohorts may be opened to enroll participants with NSCLC (all PD-L1 status), NSCLC PD-L1 high, SCCHN and cervical cancer (if any of these tumor specific expansion cohorts are not already opened). Also, low dose cohorts of ASP1951 in combination will be opened in NSCLC (all PD-L1 status), SCCHN and cervical cancer for further evaluation of response and safety and establishing a possible low dose RP2D based on clinical and biomarker activity.
9897484|NCT03799003|Experimental|ASP1951 plus pembrolizumab Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
9897485|NCT03798015||mitral valve surgery|outcome of mitral valve surgery (stroke yes or no)
9897486|NCT03791619|Active Comparator|Higher Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
9897487|NCT03791619|Active Comparator|Lower Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
10212170|NCT02103348||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to inhaled, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past."
10212171|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
10212172|NCT02083354|Experimental|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
10212173|NCT02067819|Experimental|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
10212174|NCT02067819|Placebo Comparator|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
10212175|NCT02066285|Experimental|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
10212176|NCT02065635|Experimental|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
10212177|NCT02065635|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
10212178|NCT02061514|Experimental|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
10212179|NCT02061514|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
10212180|NCT01937468|Experimental|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
10212181|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
9935630|NCT03412877|Experimental|1/iTCR|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin
9935631|NCT03412877|Experimental|2/iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCRTransduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeksfollowing cell infusion
9935632|NCT03407079|Experimental|Study Arm 1|Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
9935633|NCT03407079|Placebo Comparator|Study Arm 2|Participants will receive placebo capsules by mouth for 28 days.
9935634|NCT03407066||In-person|200 in-person healthy volunteers
9935635|NCT03407066||On-line|10,000 on-line healthy volunteers
9935651|NCT03394066|Experimental|TMS|All participants will receive TMS to investigate acute modulations of brain activity by TMS
9935652|NCT03394053||Affected Patient|Person with a clinical diagnosis of a PID; either known or unknown as defined by lab and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity
9935653|NCT03394053||Normal Volunteer|Persons (age 18-75 years) who are not related to another study subject, who do not have a PID, weight >110lbs, no history of viral hepatitis B or C, have a negative HIV screening test
9935654|NCT03394053||Relative of Patient|Biological relatives (age 0-75 years) of a subject who meets affected patient criteria, but who do not have a PID themselves
9935655|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
9935656|NCT03389347|Experimental|Device feasibility (high-throughput assay, sequencing)|Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.
9935657|NCT03388632|Experimental|lead-in doublet A|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + ipilimumab (anti- CTLA-4) given IV on day 8 (IL-15 doses are limited to first 4 cycles only)
9935658|NCT03388632|Experimental|lead-in doublet B|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + nivolumab (anti-PD1) given IV on days 8, 22, and 36 (IL-15 doses are limited to first 4 cycles only)
9935659|NCT03388632|Experimental|triplet|triplet combination
9935660|NCT03388619|Experimental|1/Prostate bed with integrated boost|Dose to prostate bed with integrated boost
9935661|NCT03388619|Experimental|2/Prostate bed irradiation only|Dose to prostate bed irradiation only
9935662|NCT03388606||Adolescents with Major Depression|Adolescents with a current or past history of meeting full critieria for major depressive disorder
9935663|NCT03388606||Adolescents with sub-threshold Major Depression|Adolescents with no past or current history of major depression who meet criteria at initialenrollment of sub-threshold major depression as defined in the protocol
9935664|NCT03388606||Health volunteer adolescents|Adolescents with no history of significant psychiatric or medical disorders (as defined in the protocol) currently or in the past.
9997610|NCT01510522|Active Comparator|Glucophage tablets|Patients received Glucophage tablets.
9797926|NCT01611090|Experimental|Ibrutinib + BR|Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
9797927|NCT01611090|Placebo Comparator|Placebo + BR|Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
10212182|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
9797928|NCT01611155|Experimental|Arm I (management of therapy complications)|Patients receive venlafaxine PO BID beginning on day 1 of and continuing through completion of FOLFOX.
9797929|NCT01611155|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.
9797930|NCT01611194|Experimental|HBO2 at 1.5 Atomspheres Absolute (ATA)|Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization.
9797931|NCT01611194|Sham Comparator|Sham Control (1.2 Atomspheres)|Sham control 1.2 atms. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
9797932|NCT01611259|Experimental|Rituximab and Lenalidomide|Single arm: 6 cycles for patients with complete response, 8 cycles for subjects with stable disease or partial remission; cycles duration: 28 days Rituximab (Mabthera®): 375 mg/m² i.v. day 1 Lenalidomide (Revlimid®): 20 mg p.o. daily for 21 days
9797933|NCT01611298|Experimental|Single arm: Tetanus Toxoid|SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest
9797934|NCT01611454|Experimental|XPF thyroid collar|Administration of the XPF Thyroid Collar during the same type of interventional radiology procedures as Comparator arm above
9797935|NCT01611454|Active Comparator|Equivalent collar|Administration of the Standard 0.5mm lead-equivalent thyroid collar during the same type of interventional radiology procedures as Comparator arm above.
9797936|NCT01611558|Experimental|Arm: Ipilimumab, 10 mg/kg|Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
9797937|NCT01611571|Active Comparator|Active Risedronate Placebo Teriparatide|Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months
9797938|NCT01611571|Active Comparator|Active Risedronate Active Teriparatide|Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months
9797939|NCT01611571|Active Comparator|Placebo Risedronate Active Teriparatide|Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months
9797940|NCT01611662|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, surgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.
9797941|NCT01611779|Experimental|Tongue suspension|Tongue-based suspension
9797942|NCT01611792|Experimental|Stabilization|
9797943|NCT01611792|Active Comparator|Strengthening and Conditioning|
9797944|NCT01611857|Experimental|Maximum Tolerated Dose|Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer.
9797945|NCT01611935|Active Comparator|Vasopressin|Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
9797946|NCT01611935|Placebo Comparator|Normal Saline|An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.
9797947|NCT01611948|Active Comparator|Active Drug|125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
9897488|NCT03789669|Experimental|Investigational|In phase I the investigators will use the investigational Cheetah femtosecond laser and Cheetah patient interface (PI) on one eye to create a LASIK flap (worst seeing eye should be preferred). Refractive correction via corneal ablation with a commercial excimer laser will be performed at the discretion of the investigator.If refractive correction is performed on the study eye, the fellow eye may receive standard LASIK treatment, otherwise, fellow eye will remain untreated.
9897489|NCT03789669|Active Comparator|Investigational/Control|"In phase II, both eyes of each subject will be treated. The investigators will use the investigational Cheetah femtosecond laser and Cheetah PI on one eye, and commercial iFS femtosecond laser and PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
9897490|NCT03789669|Active Comparator|Control/Investigational|"In phase II, both eyes of each subject will be treated. The investigators will use the investigational Cheetah femtosecond laser and Cheetah PI on one eye, and commercial iFS femtosecond laser and PI on the other eye to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The eye to receive Cheetah flap will be randomized (ratio of 1:1 for right eye and left eye).~Subjects in phase II will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system will be used on both eyes)."
9932979|NCT00955136|Experimental|High MI impulses, myocardial infarction, echocardiography|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
9932980|NCT00955149|Experimental|Arm A|Erlotinib (Tarceva) 25 mg by mouth once daily.
9932981|NCT00955149|Experimental|Arm B|Erlotinib (Tarceva) 50 mg by mouth once daily for 6 months
9932982|NCT00955162|Active Comparator|Subutex|
9932983|NCT00955162|Experimental|Suboxone|
9932984|NCT00955175|Experimental|Group 1|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 24 fractions (total of 72 Gy).
9932985|NCT00955175|Experimental|Group 2|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 22 fractions (total of 66 Gy).
9932986|NCT00955175|Experimental|Group 3|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 20 fractions (total of 60 Gy).
9932987|NCT00955214|Experimental|2.5mm Paclitaxel-eluting stent|
9932988|NCT00955227|No Intervention|Statins only|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. Patients in this arm will be excluded if they are on ezetimibe.
9932989|NCT00955227|Active Comparator|Statins and ezetimibe|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. In addition, these patients will be on ezetimibe.
9932990|NCT00955227|Experimental|Statins and flax oil only|In this arm- 15 Patients receiving standard statin treatment as determined by their cardiologist will also receive two flaxseed oil capsules/day each containing 500 mg of ALA.
9932991|NCT00955227|Experimental|Statins and ezetimibe and flax oil|In this arm- 15 Patients with heart disease and hypercholesterolemia that are on standard statin treatment as determined by their cardiologist, will also receive (as an intervention) ezetimibe and flaxseed oil capsules containing 500mg of ALA.
9932992|NCT00955292|Experimental|Quarfloxin|
9932993|NCT00955318|Experimental|KW-6500|
9932994|NCT00955344|Experimental|Web-based intervention (eToolbox)|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module that will embed a link to the web-based intervention (eToolbox).
9932995|NCT00955344|Active Comparator|Practice Improvement Module|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module without any link to the Web-based eToolbox.
9932996|NCT00955383|Active Comparator|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
9932997|NCT00955383|Placebo Comparator|Placebo|Matching placebo
9932998|NCT00955396|Other|Period 1|
9932999|NCT00955396|Other|Period 2|
9933000|NCT00955448|Experimental|SIS Mesh (Cook Medical)|Anterior prolapse repair will be reinforced using SIS mesh
9933001|NCT00955448|Active Comparator|No-mesh|Anterior prolapse repair with no mesh reinforcement
9933002|NCT00955461|Experimental|Laser treatment|Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
9933003|NCT00955500|Active Comparator|Normal-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).
9933004|NCT00955500|Active Comparator|Low-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine
9933005|NCT00955526|Experimental|Istradefylline 20mg|
9933006|NCT00955526|Experimental|Istradefylline 40mg|
9933007|NCT00955526|Placebo Comparator|Placebo|
9933008|NCT00955539|Active Comparator|CRT group 1|
9933009|NCT00955539|Active Comparator|CRT group 2|
9933010|NCT00955552|Active Comparator|Condroflex|
9933011|NCT00955552|Experimental|Glucosamine/chondroitin sulphate|Glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal
9933012|NCT00955565|Experimental|Navigated|
9933013|NCT00955565|Active Comparator|Conventional|
9933014|NCT00955578||Segmental Dysplastic Nevi|One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
9933015|NCT00955591|Other|swab test|
9933016|NCT00955604||Group R+AD|Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
9933017|NCT00955604||Group R|At least 2 months of rasagiline
9992095|NCT01458925|Other|P1 capsule and screening Cscopy|"Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study"
9992096|NCT01458938||Healthy volunteers|
9992097|NCT01458938||surgery for spinal radiculopathy|
9992098|NCT01458938||surgery for axial spine pain|
9992099|NCT01458938||myelography for spinal pain|
9992100|NCT01458964|Active Comparator|Quetiapine|Quetiapine will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
9992101|NCT01458964|Placebo Comparator|Sugar pill|Sugar pill will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
9992102|NCT01458977|Experimental|TDF/FTC (3 months) + Placebo (6 months)|TDF/FTC (3 months) + Placebo (6 months)
9992103|NCT01458977|Placebo Comparator|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)
9992104|NCT01459003|Experimental|experimental|
9992105|NCT01459003|No Intervention|control|
9997611|NCT01510535|Experimental|Placebo and then LBSA0103|The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
9997612|NCT01510535|Active Comparator|Hyruan Plus|The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
9997613|NCT01510548|Active Comparator|Adalimumab 20 mg per week|Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections
9997614|NCT01510548|Active Comparator|Adalimumab 40 mg per week|Patient will get at double blind situation adalimumab 40 mg per week injections
9997615|NCT01510548|Placebo Comparator|placebo arm|Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms
9797948|NCT01611948|Placebo Comparator|Placebo pill|Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
9797949|NCT01611974|Experimental|Maribavir 400 mg twice daily|
9997616|NCT01510561|Experimental|90Y-hPAM4|90Y-hPAM4 is administered weekly for 3 weeks
9997617|NCT01510561|Experimental|90Y-hPAM4 + gemcitabine|90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
9997618|NCT01510574|Active Comparator|misoprostol|3 tablets of 200mcg misoprostol self-administered following home birth, taken orally immediately after delivery of baby
9997619|NCT01510574|Placebo Comparator|placebo|3 tablets of placebo resembling misoprostol self-administered following home birth, taken orally immediately after delivery of baby
9997620|NCT01510587|Experimental|4-Health Educational curriculum|Parents participate in 10 face-to-face educational sessions delivered by Extension Agents at individual county locations over a 8-month period (fall to spring).
9997621|NCT01510587|Active Comparator|Healthy Living Information|Participants receive 10 mailed packets of written information derived from USDA's MyPlate website on approximately the same schedule as meetings of the experimental group.
9997622|NCT01510613|Experimental|Pomalidomide and Dexamethasone|
9997623|NCT01510626|Experimental|One|
9997624|NCT01510639|Experimental|Cuff repair PRP|Cuff repair Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the cuff repair group
9997625|NCT01510639|No Intervention|Cuff repair Control|No intervention
9997626|NCT01510639|Experimental|NEER PRP|Neer Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the NEER surgery group
9997627|NCT01510639|No Intervention|NEER Control|No intervention
9997628|NCT01510665|Experimental|Magnesium Supplement|Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
9997629|NCT01510665|Placebo Comparator|Placebo|Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
9997630|NCT01510665|Active Comparator|Diet|Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
9997631|NCT01510691||Epiretinal membrane|
9997632|NCT01510691||diabetic macular edema|
9997633|NCT01510691||vein occlusion|
9997634|NCT01510730|No Intervention|control group|no treatment for Helicobacter pylori infection
9997635|NCT01510730|Active Comparator|treatment group|treatment group receive eradication treatment for helicobacter pylori infection
9997636|NCT01510743|Active Comparator|Group SC|US guided subclavian vein catheterization
9997637|NCT01510743|Active Comparator|Group IJ|US-guided internal jugular vein catheterization
9997638|NCT01510782|Experimental|BI 655064 subcutaneous|Escalating single dose as solution for subcutaneous injection
9997639|NCT01510782|Placebo Comparator|Placebo to BI 655064 subcutaneous|Escalation single dose as solution for subcutaneous injection (Placebo)
9997640|NCT01510782|Experimental|BI 655064 intravenous|Escalating single dose as solution for intravenous infusion
9997641|NCT01510782|Placebo Comparator|Placebo to BI 655064 intravenous|Escalating single dose as solution for intravenous infusion (Placebo)
9997642|NCT01510795|No Intervention|retrospective control|
9997643|NCT01510795|Active Comparator|spironolactone|
9997644|NCT01510808||aggressive Periodontitis|Aggressive Periodontitis during maintenance
9997645|NCT01510808||aggressive periodontitis|aggressive periodontitis patients during maintenance
9992106|NCT01459029|Active Comparator|D-serine|D-serine up to 6000 mg/day subject to tolerability
9992107|NCT01459029|Placebo Comparator|Control|Treatment with inert capsules (placebo)
9992108|NCT01459042||primary aldosteronism|
9992109|NCT01459042||essential hypertension|
9992110|NCT01459081|Experimental|Zanamivir|
9992111|NCT01459081|Placebo Comparator|Placebo|
9992112|NCT01459094|Experimental|Treatment Sequence AB|
9992113|NCT01459094|Experimental|Treatment Sequence BA|
9992114|NCT01459107|Experimental|Treatment (Transplantation)|Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
9992115|NCT01459120|Experimental|Door-to-Door|Health care workers propose the integrated service package including VCT at the peoples' homes.
9992116|NCT01459120|Active Comparator|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (pitso)."
9992117|NCT01459120|No Intervention|control|Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level. These villages get no particular intervention (VCT-campaign). However, routine services continue to be provided. These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
9992118|NCT01459133|Experimental|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
9992119|NCT01459146|Experimental|AL plus ABZ; Arm 1|Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral
9992120|NCT01459146|Active Comparator|AL plus PZQ plus ABZ; Arm 2|artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral
9992121|NCT01459146|Active Comparator|ABZ plus PZQ; Arm 3|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
9667207|NCT03843255||Part 1: Dilated Cardiomyopathy patients|Approximately 1200 patients recruited prospectively from participating sites with a diagnosis of Dilated Cardiomyopathy (DCM). Will also include approximately 800 retrospective patients diagnosed with DCM currently biobanked by the lead site.
9992122|NCT01459172|Experimental|Limonene intervention|
9992123|NCT01459185|Experimental|S-1|Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
9992124|NCT01459198|Experimental|Adults: Vaccine (Group 1)|Adult participants will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
9992125|NCT01459198|Experimental|Seropositive Children: Vaccine (Group 2)|Seropositive children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
9992126|NCT01459198|Placebo Comparator|Seropositive Children: Placebo Vaccine (Group 2)|Seropositive children will receive one dose of the placebo vaccine intranasally.
9992127|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 3)|Seronegative infants and children will receive one dose of the 10^5 RSV MEDI ΔM2-2 vaccine intranasally.
9992128|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 3)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
9992129|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 4)|Seronegative infants and children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
9992130|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 4)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
9992131|NCT01459211|Other|Lenalidomide & Dexamethasone|Lenalidomide, 5mg daily, increased to 10mg after 1st cycle. Dexamethasone, 20mg days 1-4 each cycle
9992132|NCT01459250|Experimental|AGO178C|
9992133|NCT01459263||GSV insufficiency|Patients with insufficiency of the greater saphenous vein (GSV) will be included.
9992134|NCT01459276|Experimental|FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
9992135|NCT01459276|Active Comparator|FLUVALAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
9992136|NCT01459289|Active Comparator|leaflet|
9992137|NCT01459289|Active Comparator|counseling|
9992138|NCT01459302||Familial and Sporadic ALS|Individuals with ALS and families with a history of two or more people in the family who have had ALS or other forms of motor neuron disease.
9992139|NCT01459315|Experimental|GSK1349572|
9992140|NCT01459328|Active Comparator|Arm A: Conventional Long Course Chemo-Radiation|Conventional long course chemo-radiation
9992141|NCT01459328|Experimental|Arm B: Short Course Radiation Followed by Chemotherapy|Experimental short course radiation followed by chemotherapy.
9992142|NCT01459354||post, bimanual laryngoscopy, POGO score|one control, one study group
9992143|NCT01459367|Experimental|TAK-438 10 mg QD|
9992144|NCT01459367|Experimental|TAK-438 20 mg QD|
9992145|NCT01459367|Active Comparator|Lansoprazole 15 mg QD|
9992146|NCT01459380|Experimental|Regimen I (intermittent veliparib)|Patients receive veliparib PO BID on days 1-7, and pegylated liposomal doxorubicin hydrochloride IV over 1 hour and carboplatin IV over 30 minutes on day 1.
9897491|NCT03789617|Experimental|EBViNT Cell|
9897492|NCT03787251|Experimental|experimental group|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
9897493|NCT03787251|Active Comparator|Control group|"The chemotherapeutic drug chosen by the investigator (if not used in the previous treatment regimen, it cannot be selected).~The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient decease. If the adverse event grade 3 and above Or non-hematologic toxicity of grade II and above appeared, allowing the dose to be lowered twice."
9897494|NCT03784846|Experimental|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
9897495|NCT03784846|Active Comparator|Stress Management Education|SME was designed as an active control condition for other mindfulness-based intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
9897496|NCT03784846|No Intervention|No Intervention Control|No contact control condition (other than baseline, post, and follow-up assessments)
9897497|NCT03783871|Experimental|Single-arm|Subjects will be treated with microwave ablation.
9897498|NCT03780257|Experimental|QR-421a|Single dose administration
9897499|NCT03780257|Sham Comparator|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
9897500|NCT03775512|Experimental|Main Arm|Subjects will be ablated with the QDOT Micro Catheter for Pulmonary Vein Isolation with nMARQ RF Generator
9897501|NCT03775512|Experimental|Second Arm (variable flow)|subjects will be treated with QDOT Micro catheter with variable flow nMARQ RF generator
9897502|NCT03771508||PillCam SB3 procedure|Subjects with normal/abnormal PillCam SB3 procedure
9897503|NCT03768284||Psoriasis patients|Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
9897504|NCT03768284||Parents of psoriasis patients|Parents of patients who developed psoriasis before 12 years of age
9897505|NCT03768284||Up to third-degree family members with or without psoriasis|Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
9897506|NCT03765749||Community onset 3rd generation cephalosporin resistant entero|Patient with Community onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received inappropriate Antibiotic
9897507|NCT03765749||Nosocomial onset 3rd generation cephalosporin resistant ente|Patient with Nosocomial onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received appropriate Antibiotic
9897508|NCT03761823||Healthy subjects|Healthy subjects
9897509|NCT03761823||Patients|Patients extubated after > 5 days of mechanical ventilation.
9897510|NCT03761173||FlowTriever|Mechanical thrombectomy for pulmonary embolism
9897511|NCT03761173||Conservative Therapy Sub-Study|Anticoagulation medication for pulmonary embolism (as directed by treating physician)
9897512|NCT03760185|Experimental|Brimonidine Tartrate 0.2%|One eye was treated with Brimonidine Tartrate 0.2% after a 20-day washout period. Patients will treat right eye 3 times per day for 7 days of treatment.
9897513|NCT03760185|No Intervention|Control - untreated|The left eye will serve as the control for the study and will not receive the Brimonidine Tartrate 0.2% treatment
9897514|NCT03755063|Experimental|Treatment arm|Tablet with speech therapy apps
9897515|NCT03755063|No Intervention|Standard of Care|The standard care provided by speech language therapists.
9897516|NCT03753789|Experimental|Microwave Ablation|NEUWAVE Microwave Ablation System with AC software for patients undergoing a percutaneous ablation of a soft tissue liver lesion by an interventional radiologist.
9897517|NCT03753243|Experimental|Intervention|Treatment will be planned for a total of 14 to 16 weeks. Pembrolizumab will be administered every 3 weeks via IV infusion with a dose of 200 mg per infusion. Enzalutamide will be given orally and dispensed to the patient on the date of their first infusion. The dosage of Enzalutamide will be 160 mg, administered once daily for approx. 16 weeks. GNRH agonist therapy will be administered as a standard of care therapy and will follow a standard dosage to maintain castrate levels.
9797950|NCT01611974|Experimental|Maribavir 800 mg twice daily|
9797951|NCT01611974|Experimental|Maribavir 1200 mg twice daily|
9933018|NCT00955604||Group AD|At least 2 months of Anti-PD and Rasagiline
9933019|NCT00955630|Active Comparator|Monthly injections|3 monthly injections of ranibizumab followed by prn injections
9933020|NCT00955630|Active Comparator|PRN injections|injections of ranibizumab on a prn basis from the start of the study
9933021|NCT00955643|Experimental|hyperbaric therapy|Hyperbaric therapy by oxygen
9933022|NCT00955643|Experimental|dental scaling and root planing|dental scaling and cleaning
9933023|NCT00955656||primary care providers|"Primary care providers who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors (ARIA#53054)"
9933024|NCT00955669|Active Comparator|Symptoms and Objective Examination|
9933025|NCT00955734|Experimental|Early motion|This group of patients will begin wrist motion 1 week after surgery.
9933026|NCT00955734|Active Comparator|Immobilization|This group will be casted for 6 weeks after surgery
9933027|NCT00955773|Experimental|Group I|20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.
9933028|NCT00955773|Experimental|Group II|20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
9933029|NCT00955773|Experimental|Group III|Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
9933030|NCT00955786|Experimental|CX-3543|
9933031|NCT00955812|Experimental|OPB-31121|OPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
9933032|NCT00955838|Experimental|Manus|
9933033|NCT00955838|Experimental|BCI_Manus|
9933034|NCT00955851||Pneumonia patients|The study group will consist of individuals diagnosed with pneumonia and admitted to the Medicine ward under the Pneumonia Core Measure Protocol.
9933035|NCT00955890|No Intervention|control arm|anthracycline chemotherapy only
9933036|NCT00955890|Experimental|low dose dexrazoxane group|anthracycline chemotherapy plus low dose dexrazoxane(10:1)
9933037|NCT00955890|Experimental|middle dose dexrazoxane group|anthracycline chemotherapy plus middle dose dexrazoxane(15:1)
9933038|NCT00955942|Experimental|Arm I|Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
9933039|NCT00955942|Placebo Comparator|Arm II|Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
9933040|NCT00956007|Active Comparator|Arm I: Intensity-Modulated Radiotherapy|Patients undergo intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
9933041|NCT00956007|Experimental|Arm II: IMRT plus cetuximab|Patients undergo IMRT as in arm I. Patients also receive cetuximab IV over 1-2 hours once weekly beginning at least 5 days prior to the start of IMRT and continuing for 4 weeks after the completion of IMRT (for a total of 11 doses) in the absence of disease progression or unacceptable toxicity.
9933042|NCT00956033||Patients with multiple myeloma|
9933043|NCT00956046|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
9933044|NCT00956046|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
9933045|NCT00956046|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
9933046|NCT00956059|Experimental|prednisone, MMF and FK506|
9933047|NCT00956059|Active Comparator|prednisone|
9933048|NCT00956072|Experimental|Arm I|Patients undergo surgery of residual disease.
9933049|NCT00956072|Active Comparator|Arm II|Patients receive imatinib mesylate therapy according to standard of care.
9933050|NCT00956098|Placebo Comparator|placebo|
9933051|NCT00956098|Experimental|oltipraz|
9897518|NCT03750006|Experimental|HIIT intervention|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
9897519|NCT03749070|Active Comparator|Silymarin|Patients will receive 2 capsules containing a total of 700mg of silymarin, 8mg of vitamin E and 50mg of phosphatidylcholine, in addition to the excipient, which should be ingested daily for 12 weeks.
9897520|NCT03749070|Placebo Comparator|Placebo|Patients will also receive similarly 2 capsules per day, but without the bioactive principle tested (silymarin). Therefore, the capsules in the control group will contain only 700 mg of maltodextrin, a neutral food component derived from starch, in addition to the excipient and the same amount of vitamin E and phosphatidylcholine to balance the two groups.
9897521|NCT03747419|Experimental|Avelumab and Bladder-Directed Radiation|"Avelumab will be administered every 2 weeks intravenously for 6 doses unless there is unacceptable toxicity~Two radiation dose regimens are allowed, and the regimen selected is at the discretion of the treating radiation oncologist"
9897522|NCT03745820|Experimental|BIIB104 0.5 mg|Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
9897523|NCT03745820|Experimental|BIIB104 0.15 mg|Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
9897524|NCT03745820|Placebo Comparator|Matching Placebo|Participants will receive matching placebo twice a day, orally, for 12 weeks.
9897525|NCT03735199|Experimental|PCL-TCP scaffold|During the surgery, the PCL-TCP scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A Geistlich Bio-Gide collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
9897526|NCT03735199|Active Comparator|Geistlich Bio-Gide collagen membrane|"No space filler will be inserted in the extraction socket but similar to the test group, a Geistlich Bio-Gide collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.~denture overlying the extraction site will be completely relieved."
9897527|NCT03732677|Experimental|Arm 1|Chemotherapy + Durvalumab
9897528|NCT03732677|Active Comparator|Arm 2|Chemotherapy alone
9897529|NCT03732534|Experimental|NBI-98854|NBI-98854 administered once daily for up to 96 weeks
9897530|NCT03723239|Experimental|TricValve® System Single-Arm|Minimally invasive catheter-supported, bicaval tricuspid valve (self-expanding) replacement
9897531|NCT03721705|Experimental|Treatment Arm|The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
9897532|NCT03721705|Sham Comparator|Sham Arm|The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.
9897533|NCT03708731||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study.
9897534|NCT03707782||Individuals with immune deficiencies|aged 18 years or older and have an immune deficiency
9897535|NCT03707782||Family members|aged 18 years or older and are related to a person who has an immune deficiency
9897536|NCT03706365|Experimental|A1. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
9897537|NCT03706365|Experimental|A2. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
9897538|NCT03706365|Active Comparator|B1. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
9897539|NCT03706365|Active Comparator|B2. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
9897540|NCT03706365|Experimental|A. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
9897541|NCT03706365|Active Comparator|B. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
9897542|NCT03701828|Experimental|Weight loss|Participants will undergo weight loss surgery
9897543|NCT03701230|Experimental|low temperature rota-flush solution|A total of 55 patients are assigned to low temperature rota-flush solution group after randomization schedule.
9897544|NCT03701230|No Intervention|room temperature rota-flush solution|A total of 55 patients are assigned to room temperature rota-flush solution group after randomization schedule.
9797952|NCT01612000|Experimental|PanBlok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
9897545|NCT03700567|Experimental|low temperature contrast|A total of 150 patients are assigned to low temperature contrast group after randomization schedule.
9897546|NCT03700567|No Intervention|room temperature contrast|A total of 150 patients are assigned to room temperature contrast group after randomization schedule.
9897547|NCT03699748|Experimental|Intervention Group Arm|"Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice).~The intervention arm will also receive usual care as provided by Unite Here Health and their local oncologists."
9897548|NCT03699748|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by Unite Here Health and their local oncologists.
9897549|NCT03692910|Experimental|Part A (Open-label): SAGE-217|Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD), in the evening, from Day 1 to Day 14.
9897550|NCT03692910|Experimental|Part B (Double-blind): SAGE-217|Participants were to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
9897551|NCT03692910|Placebo Comparator|Part B (Double-blind): Placebo|Participants were to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
9897552|NCT03688867|Experimental|At-home prehabilitation regimen|"Grip strength: Squeeze a stress ball in your hand, holding it squeezed for 5 seconds. Perform this at least thirty times with each hand over the course of a day.~Lower body strength: Perform at least one hundred chair sit-stands in a day.~Endurance: Walking at least 7,500 steps in a day."
9897553|NCT03685578||Mechanical Thrombectomy|EmboTrap® Revascularization Device
9897554|NCT03683394|Active Comparator|SMARRT Intervention|The SMARRT intervention team will use a standardized procedure to develop an individualized Alzheimer's risk profile for each participant randomized to the SMARRT intervention arm. Participants will then meet in-person with an interventionist to review their risk profile and develop an initial personalized risk reduction action plan. For the few participants enrolled during COVID, initial interventionist visits were conducted by phone. Targeted areas will include: increasing physical, mental and social activities; quitting smoking; healthy diet; controlling cardiovascular risk factors (diabetes, hypertension), including avoiding hypoglycemia in people with diabetes; reducing depressive symptoms; improving sleep; and decreasing use of potentially harmful medications.
9897555|NCT03683394|Active Comparator|Health Education Intervention|Participants in the Health Education arm will be mailed general information that will address factors that will be targeted in the SMARRT intervention, including physical, mental and social engagement; management of cardiovascular risk factors; quitting smoking, healthy diet; depression; sleep; and contraindicated medications. HE participants will not be provided with personalized information about their risk of Alzheimer's and dementia.
9897556|NCT03683030|Experimental|Treatment Group|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
9897557|NCT03679078|Experimental|IDDSI nutritional supplement drink|Single arm designed, 28day on IDDSI nutritional supplement drink
9897558|NCT03677713|Active Comparator|Nasal Packing|Nasal packing will be placed at the end of surgery.
9897559|NCT03677713|Experimental|No Nasal Packing|No nasal packing will be placed during or after the surgery.
9897560|NCT03674021|Experimental|Intervention Arm|Patients in the intervention arm will receive the Chest Pain Choice visual aid prior to discussion with their primary physician regarding disposition.
9897561|NCT03674021|No Intervention|Control Arm|Patients in the control arm will not receive the Chest Pain Choice visual aid and will receive standard care.
9897562|NCT03673956|Experimental|Mupirocin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Mupirocin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
9897563|NCT03673956|Experimental|Tobramycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Tobramycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
9897564|NCT03673956|Experimental|Levofloxacin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Levofloxacin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
9933052|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
9997646|NCT01510821|Experimental|Maquet Vasoshield Arm|Pressure limiting syringe
9897565|NCT03673956|Experimental|Vancomycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Vancomycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
9897566|NCT03672630|Active Comparator|2-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
9897567|NCT03672630|Active Comparator|3-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
9897568|NCT03669614|Experimental|AR-501 inhaled|Three doses (low, medium, high) of inhaled AR-501 will be used.
9897569|NCT03669614|Placebo Comparator|inhaled AR-501 Placebo|Three doses (low, medium, high) of inhaled placebo will be used
9897570|NCT03668236|Experimental|Fluid restriction group|"No IV fluids unless one of the extenuating circumstances occur; then, IV fluid may be given in measured amounts:~In case of severe hypoperfusion or severe circulatory impairment defined by either:~Lactate≥4 mmol/L~MAP<50 mmHg (with or without vasopressor/inotrope)~Mottling beyond the kneecap (mottling score >2) OR~Urinary output<0.1 mL/kg bodyweight/h, but only in the first 2hrs after randomisation~A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation~In case of overt fluid losses (e.g. vomiting, large aspirates,…) IV fluid may be given to correct for the loss, but not above the volume lost.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~Correct dehydration or electrolyte deficiencies~Ensure a total fluid input of 1L per 24hrs~IV fluids may be given as carrier for medication, but the volume should be reduced to the lowest possible"
9897571|NCT03668236|Active Comparator|Standard-care|"There will be no upper limit for the use of either IV or oral/enteral fluids. In particular:~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
9897572|NCT03667482|Experimental|Cabozantinib in Combination With Cetuximab|Cetuximab will be administered at 500 mg/m^2 intravenously every other week. Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
9897573|NCT03664466|Experimental|Astaxanthin|Astaxanthin 12mg twice daily by mouth
9897574|NCT03664466|Placebo Comparator|Placebo|Placebo twice daily by mouth
9897575|NCT03661411|Experimental|Aspirin+ clopidogrel|aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
9897576|NCT03661411|Active Comparator|Alteplase|intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.
9897577|NCT03651011|Active Comparator|Aflibercept + Navigated laser|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
9897578|NCT03651011|Active Comparator|Aflibercept only|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase). Patients will receive aflibercept according to pro re nata regimen from M3-M12.
9897579|NCT03649347|Experimental|AR Therapy Intervention for Spider Phobia|AR Therapy Intervention participants first complete a behavioral approach test (BAT). They approach a live spider to get as close as they comfortably can. This BAT provides a baseline measure of the degree of fear of spiders; the BAT is not a form of exposure therapy. Participants then complete exposure therapy using an augmented reality (AR) headset. A therapist controls the AR paradigm, placing virtual spiders in a participant's real environment as a method of exposure therapy. Once a participant's anxiety is reduced to low, stable levels (as measured by the participant's subjective units of distress assessed at intervals during session), the participant then completes a second BAT to measure their degree of fear immediately following AR therapy. The difference between the first and second BAT are used to assess the efficacy of the AR exposure therapy treatment. One month later, the AR Therapy Intervention participants complete a third BAT to assess for treatment efficacy over time.
9933053|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
9517545|NCT03305445|Experimental|Pts with Diffuse Large B Cell Lymphoma|"Patients with DLBCL not eligible for autologous stem cell transplant. All patients will receive dual checkpoint blocking antibody (DCBA) therapy of ipilimumab and nivolumab given at three week intervals, two times before, and two times following immunotransplant in which T cells (in whole PBMCs) are cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting chemotherapy regimen, currently being employed in adoptive T cell therapies."
9517546|NCT03305432|Experimental|PPI group|take preoperative PPI for 10 days
9897580|NCT03649347|No Intervention|No Treatment Control Group for Spider Phobia|The No Treatment Control group participants do not receive any AR exposure therapy for the duration of the study. These participants complete a behavioral approach test (BAT) at their first study visit, during which they approach a live spider as close as they comfortably can. This BAT provides a baseline measure of the degree of fear of spiders; the BAT is not a form of exposure therapy. One month later, the No Treatment Control group participants return for a second BAT to assess the degree to which their fear has changed as a function of time, in the context of NOT receiving any exposure therapy. After completion of the second BAT at this one-month follow-up visit, these participants are offered the opportunity for some form of exposure therapy following the conclusion of the study.
9897581|NCT03649347|Experimental|AR Therapy Intervention for Snake Phobia|Augmented reality (AR) exposure therapy involves placing virtual objects in the participant's real environment as a method of exposure therapy. The AR therapy intervention group will complete an exposure therapy session using an augmented reality headset. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The exposure therapy session will be as long as needed to reduce anxiety to low and stable levels, as measured by the participant's subjective units of distress.
9897582|NCT03649347|No Intervention|No Treatment Control Group for Snake Phobia|This will be a waitlist control group that will receive no treatment for the duration of the study, however they will be offered the opportunity for some form of exposure therapy following the conclusion of the study (1 month).
9897583|NCT03648632|Experimental|Stereotactic Radiotherapy|50 Gy in 5 fractions within a total of 7 - 8 days
9897584|NCT03648372|Experimental|Phase 1, Dose Escalation Cohort: TAK-981|TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1, 4, 8, and 11 in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study. If clinical safety, pharmacokinetics, and pharmacodynamics are supportive, the dosing schedule may be modified to evaluate a less intensive administration of TAK-981 on Day 1, or Days 1 and 8, or Day 1, Day 8, and Day 15 in 21-day cycles in participants with advanced or metastatic solid tumors or lymphomas. Dose levels will be escalated based on the Bayesian logistic regression modeling (BLRM). The dose escalation phase will determine the RP2D of TAK-981.
9897585|NCT03648372|Experimental|Phase 2, Cohort A: Nonsquamous NSCLC|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with nonsquamous non-small cell lung cancer (NSCLC).
9897586|NCT03648372|Experimental|Phase 2, Cohort B: Cervical Cancer|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with cervical cancer.
9897587|NCT03648372|Experimental|Phase 2, Cohort C: MSS-CRC|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with microsatellite-stable colorectal cancer (MSS-CRC).
9897588|NCT03648372|Experimental|Phase 2, Cohort D: r/r DLBCL after CAR T-cells therapy|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after prior chimeric antigen receptor (CAR) T-cells therapy.
9897589|NCT03648372|Experimental|Phase 2, Cohort E: r/r DLBCL without prior cellular therapy|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory DLBCL that have not received prior cellular therapy.
9897590|NCT03648372|Experimental|Phase 2, Cohort F: r/r Follicular Lymphoma|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory follicular lymphoma (FL).
9897591|NCT03646604|Experimental|Part 1; Cohort 1|Participants, 6 to <12 years of age, will receive low dose of upadacitinib.
9897592|NCT03646604|Experimental|Part 1; Cohort 2|Participants, 6 to <12 years of age, will receive high dose of upadacitinib.
9897593|NCT03646604|Experimental|Part 1; Cohort 3|Participants, 2 to <6 years of age, will receive low dose of upadacitinib.
9897594|NCT03646604|Experimental|Part 1; Cohort 4|Participants, 2 to <6 years of age, will receive high dose of upadacitinib.
9897595|NCT03646604|Experimental|Part 2|Eligible participants who completed Part 1 will receive weight-dependant low dose of upadacitinib.
9897596|NCT03642639|Other|Coils|MICRUSFRAME and GALAXY coils
9897597|NCT03641326|Experimental|Participants With Primary Gliosarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
9897598|NCT03641326|Experimental|Participants With Secondary Gliosarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
9797953|NCT01612000|Experimental|PanBlok 3.8µg in 2% SE|3.8µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
9517547|NCT03305432|Active Comparator|Control group|take placebo for for 10 days preoperative
9797954|NCT01612000|Experimental|PanBlok 7.5µg No Adjuvant|7.5µg recombinant hemagglutinin, no adjuvant. 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
9797955|NCT01612000|Experimental|PanBlok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
9797956|NCT01612156|Active Comparator|2% lidocaine gel|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.
9797957|NCT01612156|Active Comparator|water based lubricant|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared wtih water based lubricant before use in the pelvic floor examination.
9797958|NCT01612221|Experimental|Patients receiving N-acetylcysteine|Patients receiving NAC (N-acetylcysteine)
9797959|NCT01612221|Placebo Comparator|Placebo Group|Participants not receiving NAC (N-acetylcysteine)
9797960|NCT01612494|Placebo Comparator|Normal Saline|
9797961|NCT01612494|Experimental|Hypertonic Saline|
9797962|NCT01612546|Experimental|Treatment (cyclodextrin-based polymer-camptothecin CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX101 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the completion of 6 courses, patients achieving stable disease or better may receive treatment for an additional 6 months.
9797963|NCT01612676|Experimental|Drug|FE 202158
9797964|NCT01612702|Experimental|Dexamethasone|dexamethasone 10 mg administration 1 hour before surgery
9797965|NCT01612702|No Intervention|Control|No dexamethasone
9797966|NCT01612767|Experimental|Pro-Kinetic Energy Stent|
9797967|NCT01612780|Experimental|XprESS Multi-Sinus Dilation Tool|Balloon sinus dilation
9797968|NCT01612793||AlphaCore device|AlphaCore device group will consist of subjects enrolled into the study with chronic obstructive pulmonary disease and receive an electrical stimulation to the vagus nerve to help open the subjects airways during the subjects stay in the hospital.
9797969|NCT01612858|Experimental|Metformin|
9797970|NCT01612858|Experimental|Pioglitazone|
9797971|NCT01612884|Other|TEG|Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA<69
9797972|NCT01612884|Other|Light transmittance aggregometry|Clopidogrel non-response defined as MPA ADP >42.9% Clopidogrel response defined as MPA ADP <42.9%
9797973|NCT01613014|Placebo Comparator|Sugar Pill|Matched Placebo sugar pill - target dose 2 pills BID
9797974|NCT01613014|Active Comparator|ABT-436|ABT-436 Target dose of 400 mg BID
9797975|NCT01613027||Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
9797976|NCT01613118|Experimental|RE-021 (Sparsentan) 200 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
9797977|NCT01613118|Experimental|RE-021 (Sparsentan) 400 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
9797978|NCT01613118|Experimental|RE-021 (Sparsentan) 800 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
9797979|NCT01613118|Active Comparator|Irbesartan 300 mg|"The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks.~Patients at </= 50kg will receive 150mg irbesartan for the 8 week duration."
9800250|NCT01682837|Experimental|Placebo, KCl, KCit, KMgCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
9992147|NCT01459380|Experimental|Regimen II (continuous veliparib)|Patients receive veliparib PO BID on days 1-28, and pegylated liposomal doxorubicin hydrochloride and carboplatin as in Regimen I.
9992148|NCT01459393|Experimental|5-ALA Photodynamic Therapy|Topical application of a 2mm of thickness layer of 20% 5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion, over the actinic keratosis lesion and over a 0,5 cm margin around it. After a 4 hours interval under light protection with plastic film and aluminum foil, the light protection and the emulsion is removed. Then the lesion is lightened with a red (630 nm) incoherent LED lamp AKTILITE CL 128 (PhotoCure ASA, Oslo, Norway) with a total light dose of 37J/cm2.After that dressings are done and kept for 24H, and removed at patient home.
9992149|NCT01459393|Active Comparator|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
9992150|NCT01459406|Experimental|Glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g glucose
9992151|NCT01459406|Experimental|Fructose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose
9992152|NCT01459406|Experimental|Fructan drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructan
9992153|NCT01459406|Experimental|Fructose and glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose and 40 g glucose
9992154|NCT01459419|Experimental|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up to 9 subjects will be treated at each dosage level
9992155|NCT01459419|Placebo Comparator|Sodium chloride|Up to 9 subjects will receive placebo. Subjects will receive the drug in a similar manner as as the treatment group
9992156|NCT01459432||Follow-on blood sample from previous study|
9992157|NCT01459445|Other|Metformin+Drospirenone / EE 30µg|
9992158|NCT01459458|Experimental|Clinics trained in brief intervention|Female clients ages 16-29 seeking care in 11 reproductive health clinics in Western Pennsylvania where clinic providers are trained to implement the brief partner violence/reproductive coercion intervention.
9992159|NCT01459458|No Intervention|Control sites providing standard of care|Female clients ages 16-29 seeking care in 14 reproductive health clinics in Western Pennsylvania where clinic providers are providing standard domestic violence screening per usual standard of care.
9992160|NCT01459471|Experimental|bleeding, leak, operative time|
9992161|NCT01459484|Experimental|Mifamurtide arm|Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
9992162|NCT01459484|Other|3 drugs arm|High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein
9992163|NCT01459510|Experimental|multi media intervention|Play Nicely Program
9992164|NCT01459510|No Intervention|Routine primary care|Routine primary care
9517548|NCT03305406||Focus Group Participants|Semi-structured focus groups
9517549|NCT03305406||Interview Participants|One-on-one interviews
9517550|NCT03305393|Other|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
9992165|NCT01459523|Active Comparator|Imaging technique|In one substudy, subjects will be randomly assigned to either short axis or long axis target ultrasound imaging for perineural catheter insertion. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
9992166|NCT01459523|Active Comparator|Catheter location|In another substudy, subjects will be randomly assigned to receive their perineural catheters either proximally or distally along the same target nerve or plexus.
9992167|NCT01459536||Rotator Cuff Tear-surgical|
9992168|NCT01459536||Health Older Adult Control|
9992169|NCT01459536||Rotator cuff tear - non surgical|
9992170|NCT01459549|No Intervention|Control Group|Just clear the stone without choledochojejunostomy
9992171|NCT01459549|Experimental|Experimental Group|Clear the stone combined with Roux-en-y choledochojejunostomy
9992172|NCT01459562|Experimental|NI-0501|
9797980|NCT01613131|Active Comparator|Mirena + Estradiol Gel|Subjects will be assigned to use of Estradiol gel for use with Mirena.
9517551|NCT03305380||Patients with a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the first group of the retrospective part of the study.
9797981|NCT01613131|Placebo Comparator|Mirena + Placebo Gel|Subjects will be assigned to use of placebo gel for use with Mirena.
9797982|NCT01613222|Experimental|Pulse oximetry monitoring|The U-TruSignal with different sensors is feasible for noninvasive and continuous SpO2 monitoring and meets the specified measurement accuracy when compared to a co-oximetry gold reference.
9797983|NCT01613248|Experimental|MK-1602 1 mg|MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
9797984|NCT01613248|Experimental|MK-1602 10 mg|MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
9797985|NCT01613248|Experimental|MK-1602 25 mg|MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
9797986|NCT01613248|Experimental|MK-1602 50 mg|MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
9797987|NCT01613248|Experimental|MK-1602 100 mg|MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
9797988|NCT01613248|Placebo Comparator|Placebo|Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
9797989|NCT01613313|Experimental|Dose #1|single injection 0.058 mg Collagenase Clostridium Histolyticum
9797990|NCT01613313|Experimental|Dose #2|single injection 0.15 mg Collagenase Clostridium Histolyticum
9797991|NCT01613313|Experimental|Dose #3|single injection 0.29 mg Collagenase Clostridium Histolyticum
9797992|NCT01613313|Experimental|Dose #4|single injection 0.44 mg Collagenase Clostridium Histolyticum
9797993|NCT01613326|Experimental|NVA237|NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
9797994|NCT01613326|Active Comparator|Tiotropium|Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
9797995|NCT01613339|Experimental|Body awareness therapy|
9797996|NCT01613339|No Intervention|Control|
9797997|NCT01613378||Rheumatoid Arthritis Cohort|The cohort included participants with moderate to severe rheumatoid arthritis (RA) in whom the treating physician made the decision to initiate tocilizumab treatment.
9797998|NCT01613417|Active Comparator|MRI with Gadoteridol|MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.
9797999|NCT01613417|Active Comparator|MRI with Gadobutrol|MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.
9798000|NCT01613599||Rituximab|Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4 years.
9798001|NCT01613716|Experimental|Ozurdex|Subjects will receive Ozurdex injections and will be monitored for macular edema.
9798002|NCT01613768|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9798003|NCT01614093|Active Comparator|Oxytocin/Placebo|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
9798004|NCT01614093|Active Comparator|Placebo/Oxytocin|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
9798005|NCT01614210|Experimental|All patients|All patients enrolled in the study.
9798006|NCT01614249|Placebo Comparator|Soybean oil soft gels|Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
9798007|NCT01614249|Experimental|Fish oil omega-3 EPA-rich soft gels|Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
9798008|NCT01614392|Experimental|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
9798009|NCT01614392|Experimental|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
9798010|NCT01614457|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
9798011|NCT01614457|Placebo Comparator|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
9798012|NCT01614470|Experimental|Part 1: Ivacaftor First, Then Placebo|Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
9798013|NCT01614470|Experimental|Part 1: Placebo First, Then Ivacaftor|Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
9798014|NCT01614470|Experimental|Part 2: Ivacaftor|Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
9798015|NCT01614509|Experimental|Monotherapy group|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
9798016|NCT01614509|Experimental|Combined group|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
9798017|NCT01614574|Experimental|Investigational|velaglucerase alfa
9798018|NCT01614600|Experimental|DAILIES® AquaComfort Plus®|Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
9798019|NCT01614613|Experimental|Intended BGM Users|Subjects were assigned to subgroups according to their initial glucose levels. SUBGROUP 1 goal: safely decrease subject glucose levels during the visit. SUBGROUP 2 goal: safely raise subject glucose levels. Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety. Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems. Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
9798020|NCT01614743|Experimental|IncobotulinumtoxinA|
9798021|NCT01614743|Placebo Comparator|Placebo|
9798022|NCT01614769|Experimental|Placebo → Glimepiride 2 mg → Glimepiride 4 mg|Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
9798023|NCT01614769|Experimental|Glimepiride 2 mg → Glimepiride 4 mg → Placebo|Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
9798024|NCT01614769|Experimental|Glimepiride 4 mg → Placebo → Glimepiride 2 mg|Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
9798025|NCT01614769|Experimental|Placebo → Glimepiride 4 mg → Glimepiride 2 mg|Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
9798026|NCT01614769|Experimental|Glimepiride 2 mg → Placebo → Glimepiride 4 mg|Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
9798027|NCT01614769|Experimental|Glimepiride 4 mg → Glimepiride 2 mg → Placebo|Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
9798028|NCT01614795|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
9798029|NCT01614821|Experimental|Treatment Arm|PCI-32765; ibrutinib
9798030|NCT01614847|Experimental|Isotonic hyaluronate artificial tear|At random, subjects will receive isotonic hyaluronate artificial tear or a control (normal saline).
9798031|NCT01614847|Placebo Comparator|Normal saline|
9798032|NCT01614886|Experimental|1 step|
9798033|NCT01614886|Active Comparator|3 step|
9798034|NCT01614925|Experimental|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
9798035|NCT01614925|Active Comparator|Periodontal Surgery|Periodontal surgery alone
9798036|NCT01615120|Experimental|GTx-758 125mg|one GTx-758 tablet orally administered daily
9798037|NCT01615120|Experimental|GTx-758 250 mg|two GTx-758 tablets orally administered daily
9798038|NCT01615198|Experimental|LCZ696|Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd.
9798039|NCT01615198|Active Comparator|Olmesartan|Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd.
9992173|NCT01459562|Placebo Comparator|Placebo|
9997647|NCT01510821|Active Comparator|Non-regulated Arm|standard non-regulated syringe
9798040|NCT01615263|Active Comparator|Double lumen tube|Lung isolation with a left double lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland.
9798041|NCT01615263|Active Comparator|Bronchial blocker|Lung isolation with a bronchial blocker with the inner channel closed (Fuji Uniblocker 9F, Fuji System Corporation, Tokyo, 113-0033, Japan) inserted via a 8.0 mm simple lumen endotracheal tube.
9798042|NCT01615328|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
9798043|NCT01615328|Experimental|Bonion|The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.
9798044|NCT01615367|Experimental|NEW Tx|25 people will be randomized to NEW Tx, a weekly individualized psychotherapy. Therapy is 20 weeks long.
9800251|NCT01682863|Experimental|QVA149 dose 1|QVA149 27.5/12.5 μg capsules
9517552|NCT03305380||Patients without a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the second group of the retrospective part of the study.
9897599|NCT03641326|Experimental|Participants With Primary Central Nervous System (CNS) Sarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
9897600|NCT03637062|Experimental|pessary|the test group is pessary.The pregnant woman is assigned to the pessary group and after having excluded a vaginal infection the pessary will be inserted directly.
9897601|NCT03637062|Active Comparator|Progesterone|the control group is progesterone. Pregnant women in the control group were treated by 200 mg QN, it is used for 34 gestational weeks.
9897602|NCT03633110|Experimental|Part A|"Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).~Part A will consist of approximately 9 participants."
9897603|NCT03633110|Experimental|Part B|"Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).~Part B will consist of up to 90 participants."
9897604|NCT03631771|Experimental|Iodixanol, iohexol, iopromide, or ioversol|Investigational medicinal product administered intravascularly per usual clinical practice at each participating institution. Doses will be per usual practice. The dose of ICM, timing of ICM administration in relation to the diagnostic procedure, rate of ICM administration, and route of ICM administration will be determined by the physician performing the enhanced radiologic procedure per medical need and local clinical practice.
9897605|NCT03628066|Experimental|Arm 1|"Oncotype DX Breast recurrence score on diagnostic tissue~Daily Letrozole for 24 weeks + Palbociclib daily for 24 weeks + Goserelin weekly for 24 weeks"
9897606|NCT03618420|Other|Clinical Investigation|All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.
9897607|NCT03609216|Experimental|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
9897608|NCT03609216|Experimental|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
9897609|NCT03608202|Experimental|POCUS protocol group|"POCUS protocol group~It will be submitted to an ultrasound protocol which consists in performing the following ultrasound studies in each patient:~Measurement of the diameter of the optic nerve. Neck. Pulmonary ultrasound (LUS score). Echocardiogram (function and volemia). Abdomen. Femoral vascular package. Eco-guided interventionism. Central venous accesses (controlling positioning with saline injection under ultrasound), arterial, pleural or abdominal drainage and percutaneous tracheotomy will be performed under ultrasound."
9897610|NCT03608202|Active Comparator|Control group|The usual handling will be followed. The studies will only be performed if the medical team-treating team considers it, requesting a radiologist specialist the same, as is done routinely.
9897611|NCT03604406|Experimental|Varicella Zoster Vaccine (Zostavax)|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
9897612|NCT03604406|Placebo Comparator|Placebo Injection (Zostavax Comparator)|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
9897613|NCT03604406|Experimental|Varicella Zoster Vaccine (Shingrix)|Non-live zoster vaccine injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
9897614|NCT03604406|Placebo Comparator|Placebo Injection (Shingrix Comparator)|Saline injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
9897615|NCT03603600|Experimental|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
9897616|NCT03603600|Sham Comparator|enVista MX60E|enVista MX60E monofocal IOL
9897617|NCT03591887|Experimental|ABY-035 2 mg|2 mg ABY-035 SC
9897618|NCT03591887|Experimental|ABY-035 20 mg|20 mg ABY-035 SC
9897619|NCT03591887|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
9897620|NCT03591887|Experimental|ABY-035 160 mg|160 mg ABY-035 SC
9897621|NCT03591887|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 12 weeks
9897622|NCT03586050|Experimental|Microwave Ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
9897623|NCT03585153||T1D|Individuals with type 1 diabetes
9897624|NCT03585153||Control|Individuals without type 1 diabetes
9897625|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
9897626|NCT03585153||MODY|Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)
9897627|NCT03573609|No Intervention|Control|Usual respiratory care
9897628|NCT03573609|Active Comparator|Supranav|"Respiratory care with supranav which is a continuous supraglottic suction device"
9933054|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
9517553|NCT03305367|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
9517554|NCT03305367|Experimental|Hydrolyzed pine nut oil low dose|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
9517555|NCT03305367|Experimental|Hydrolyzed pine nut oil high dose|Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil
9517556|NCT03305354|Experimental|CBTI app intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide
9798045|NCT01615367|Active Comparator|Treatment as usual (TAU)|25 people will be randomized to TAU and will meet with their psychiatrist as often as clinically needed over the 20 week study duration.
9798046|NCT01615484|Experimental|Ex-vivo lung perfusion (EVLP) with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.
9798047|NCT01615484|No Intervention|Lung transplant from conventional brain-dead organ donor|No experimental procedures will be carried out.
9798048|NCT01615731|Active Comparator|Two sets of dilators|Two sets of osmotic dilators inserted 1 and 2 days pre-op
9798049|NCT01615731|Experimental|Mifepristone plus one set of dilators|One set of dilators plus mifepristone
9798050|NCT01615809|Experimental|Amphotericin B (ABELCET®)|"Drug: AMPHOTERICIN B Dosage form: Abelcet® 5mg/ml administered by inhalation. Dosage: 10 ml (50 mg) for the first week with a frequency twice a week. Dosage: from the second week onwards 5 ml (25 mg) with a frequency of a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.~Duration: 4-5 prophylaxis courses defined as each administration period during a neutropenia period, with a 4-6 weeks length considering the duration of neutropenia."
9798051|NCT01615822|Experimental|OZ439 100mg single dose|OZ439 100mg single dose oral suspension
9798052|NCT01615822|Experimental|OZ439 100mg plus MQ 250mg single doses|Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
9798053|NCT01615822|Experimental|OZ439 400mg single dose|OZ439 400mg single dose oral suspension
9798054|NCT01615822|Experimental|OZ439 400mg plus MQ 750mg single doses|Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
9798055|NCT01615822|Placebo Comparator|Placebo|Placebo
9798056|NCT01615939|Active Comparator|Single Shot Sciatic Nerve Block|Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
9798057|NCT01615939|Active Comparator|Continuous Sciatic Nerve Block|Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
9798058|NCT01616056|Experimental|Bandage Contact Lenses|Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.
9798059|NCT01616082|Active Comparator|Overwight/Obese with no drug|After screening, overweight/obese subjects (BMI >27 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved.
9798060|NCT01616082|Active Comparator|Overweight/obese with Phentermine|After screening, overweight/obese (BMI >27.0 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
9798061|NCT01616160|Experimental|Nasal polyps subjects|24 subjects with nasal polyps. Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.
9798062|NCT01616173|Active Comparator|Perineural Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL, and 50mL IV normal saline infusion
9798063|NCT01616173|Active Comparator|Intravenous Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and IV dexamethsone 8mg in 50mL infusion
9798064|NCT01616173|Placebo Comparator|No Perioperative Steroids|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and 50mL infusion
9798065|NCT01616459|Experimental|11Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830929A, or 11Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 11Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 11Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
9800252|NCT01682863|Experimental|QVA149 dose 2|QVA149 27.5/25 μg capsules
9800253|NCT01682863|Active Comparator|QAB149|QAB149 75 μg capsules
9800254|NCT01682876|Placebo Comparator|2 through 5 years (1 Vac) MenACWY-CRM 1|Subjects 2 through 5 years received one vaccination of MenACWY-CRM
9800255|NCT01682876|Active Comparator|2 through 5 years (2 Vac) MenACWY-CRM 2|Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
9800256|NCT01682876|Placebo Comparator|6 through 10 years (1 Vac) MenACWY-CRM 3|Subjects 6 through 10 years received one vaccination of MenACWY-CRM
9517557|NCT03305354|Active Comparator|CBTI app+Physical Activity Intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide plus self-management guidance on increased step counts
9897629|NCT03571971|Experimental|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
9897630|NCT03571971|Active Comparator|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
9897631|NCT03568097|Experimental|Avelumab + Standard 1st line Chemotherapy|Administration of cisplatin or carboplatin + etoposide every 3 weeks with phased avelumab administered every 2 weeks until disease progression.
9897632|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab (Cohort enrollment completed)
9897633|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab with chemotherapy|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab and nab-paclitaxel chemotherapy
9897634|NCT03567018|Experimental|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
9897635|NCT03567018|Experimental|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
9897636|NCT03564041|Experimental|Sahaj Samadhi Meditation (SSM)|SSM will be taught to participants over 4 consecutive days, for 2 hours each day. Participants will initially learn about the nature of meditation and will be taken through a guided meditation. Afterwards, participants will undergo training which includes understanding the nature of the mind and the thoughts arising from it, guided meditation by the instructor, and a discussion of what is correct and incorrect meditation. Follow-ups will be conducted once every week for the following 11 weeks, each including guided meditation. Participants will be encouraged to practice the meditation at home for 20 minutes per session and will be given weekly practice logs to complete.
9897637|NCT03564041|Other|Health Enhancement Program (HEP)|"Arm type: Active control group~HEP controls for several non-specific factors found in a meditation group such as Sahaj Samadhi, including: group support and morale, behavioral activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP has been tailored to be structurally equivalent to a SSM intervention, with similar-sized groups, meeting for 4 days for 2 hours, and then a one-hour follow up session weekly for the subsequent 11 weeks, and completing the same amount of home practice (20 minutes twice daily, every day), and will be asked to complete weekly practice logs."
9897638|NCT03560635|Active Comparator|Control|Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
9897639|NCT03560635|Experimental|Reverse Diet|Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
9897640|NCT03557788|Experimental|Rifaximin|Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
9897641|NCT03557385|Other|aFFR vs cFFR|All subjects will receive Fractional Flow Reserve Measurements with both adenosine (aFFR) and contrast (Iopamidol) (cFFR) using the Navvus® Catheter and CVi® Contrast Delivery System
9897642|NCT03557216|Experimental|Complicated diverticulitis|Patients with complicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
9897643|NCT03557216|Experimental|Uncomplicated diverticulitis|Patients with uncomplicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
9897644|NCT03557008|Active Comparator|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
9897645|NCT03557008|Active Comparator|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
9897646|NCT03550885|Experimental|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
9897647|NCT03550885|Experimental|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
9933055|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
9997648|NCT01510847|Other|Oral Testosterone Therapy|90 day oral testosterone therapy
9897648|NCT03550404||Navigators|"AIE Navigators will use the Seasons of Care app in the context of their everyday outreach work with AIEs over two four-month intervention periods (P1 and P2). Their goal will be to facilitate health literacy to shift attitudes, beliefs, and behaviors to create a Culture of Coverage for AIEs at individual, organizational/community, and policy levels. Separated by distance, the AIE Navigators will receive coaching as necessary, using virtual meeting space, to help refine their implementation skills from a member of the research team with experience in AIE health outreach."
9897649|NCT03550404||American Indian Elders (AIEs)|Elders will be exposed to the Seasons of Care app when they reach out to navigators for assistance navigating the healthcare system.
9897650|NCT03550404||Healthcare providers/staff|This cohort will be exposed to the Seasons of Care app via navigators and their patients.
9897651|NCT03536416|Experimental|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
9897652|NCT03536416|Active Comparator|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
9897653|NCT03536416|No Intervention|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
9897654|NCT03530163|Experimental|Respiratory Muscle Training|
9897655|NCT03530163|Sham Comparator|Sham Breathing Training|
9897656|NCT03524092|Experimental|Mirikizumab Dose #1|Mirikizumab Dose #1 administered subcutaneously (SC)
9897657|NCT03524092|Experimental|Mirikizumab Dose #2|Mirikizumab Dose #2 administered intravenously (IV)
9897658|NCT03524092|Placebo Comparator|Placebo|Placebo administered SC
9897659|NCT03519945|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC).
9897660|NCT03519659|Experimental|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
9897661|NCT03519659|Experimental|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
9897662|NCT03519659|Experimental|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
9897663|NCT03519659|Experimental|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
9897664|NCT03519659|Experimental|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
9897665|NCT03519659|Experimental|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
9897666|NCT03504683|Experimental|Early Time-Restricted Feeding|
9897667|NCT03504683|Experimental|Mid-day Time-Restricted Feeding|
9897668|NCT03504683|Placebo Comparator|Control Schedule|
9897669|NCT03499678||Lung Cancer|Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
9897670|NCT03499678||Control|Age and sex matched control individuals
9897671|NCT03494881|Experimental|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
9517787|NCT03302962|Experimental|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
9897672|NCT03494803||Control|
9897673|NCT03494803||Prostate Cancer|
9897674|NCT03494335||Volunteer participants|Volunteer participants will participate in surveys assessing their perception of various imaging aspects.
9897675|NCT03491059|Experimental|Full Study - Radiation|
9897676|NCT03491059|No Intervention|Dress Rehearsal Only - No Radiation|
9897677|NCT03491046|Experimental|Patient population with ACL injury or reconstruction|
9897678|NCT03491046|Experimental|Patient population without ACL injury or reconstruction|
9897679|NCT03490812|Experimental|Prospective population|
9897680|NCT03490812|Experimental|Retrospective population|
9897681|NCT03490656|Experimental|Healthy volunteer population|
9897682|NCT03490656|Experimental|Patient population|
9897683|NCT03489174|Experimental|Monthly Pregnancy Screening|Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
9517788|NCT03302962|No Intervention|Routine Asthma Education Literature|"The remaining 54 cases were randomized to the control arm and received written materials related to patient-centered asthma control."
9800257|NCT01682876|Active Comparator|6 through 10 years (2 Vac) MenACWY-CRM 4|Subjects 6 through 10 years received two vaccinations of MenACWY-CRM
9800258|NCT01682954|Experimental|Lifestyle counseling|Diabetes Prevention Program lifestyle intervention
9800259|NCT01682954|No Intervention|Usual Care|Usual care from primary care physician
9800260|NCT01683019|Active Comparator|Active Fixed Alpha Frequency Magnetic Stimulation|Sinusoidal magnetic field set to the subject's intrinsic alpha frequency (IAF).
9800261|NCT01683019|Active Comparator|Active Random Frequency Magnetic Stimulation|Magnetic field hops to random frequencies in the alpha band (8-13Hz), once per second.
9800262|NCT01683019|Sham Comparator|Inactive Sham Treatment|Generate sound similar to active treatment, except that no magnetic field is generated.
9800263|NCT01683058|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
9800264|NCT01683071|Experimental|(Part 1) EXPAREL 67 mg|5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
9800265|NCT01683071|Experimental|(Part 1) EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
9800266|NCT01683071|Experimental|(Part 1) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
9800267|NCT01683071|Placebo Comparator|(Part 1) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
9800268|NCT01683071|Experimental|(Part 2) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
9800269|NCT01683071|Placebo Comparator|(Part 2) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
9800270|NCT01683266|Experimental|HOE901-U300|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
9800271|NCT01683266|Active Comparator|Lantus|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
9800272|NCT01683331|Active Comparator|Insulin treatment for hyperglycemia|Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen, based on pre-dinner capillary blood glucose measurements (CPG) expressed in mg/dl; All NPH initiation doses and dose adjustments are presented in IU/day For pts. with CPG > 240, NPH initiation: 14, dose increases by 4; For pts. with CPG > 180 mg/dl, NPH initiation: 12, dose increases by 4; For pts. with CPG > 140 mg/dl, NPH initiation: 10, dose increases by 4; For pts. with CPG > 120 mg/dl, NPH initiation: 0, dose increases by 2; For pts. with CPG 100-119 mg/dl, NPH initiation: 0, maintain dose; For pts. with CPG 80-<100 mg/dl, NPH initiation: 0, dose decrease by 4; For pts. with CPG 60-<80 mg/dl, NPH initiation: 0, decrease by 8; For pts. with CPG <60 mg/dl, NPH initiation: 0, ½ of previous dose.
9800273|NCT01683331|No Intervention|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation.
9800274|NCT01683383|Active Comparator|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
9800275|NCT01683383|Experimental|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
9800276|NCT01683409|Placebo Comparator|Placebo|Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
9800277|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg QD|Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
9800278|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg BID|Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
9897684|NCT03489174|Active Comparator|Usual Care|Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.
9897685|NCT03487640||Transanal rectal mucosa resection|TARMR: Transanal resection of rectal mucosa for at least 5cm in length.
9897686|NCT03487640||Laparoscopic rectal suspension and colectomy|LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
9933056|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 5 μg|100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
9933057|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 10 μg|"200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21.~100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only."
9933058|NCT00956111|Placebo Comparator|Placebo control|100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
9933059|NCT00956124||uveitic patients|
9933060|NCT00956124||patients with diabetes|
9933061|NCT00956137|Experimental|Ultrasound|Use of ultrasound to identify vertebral interspaces for needle insertion.
9933062|NCT00956137|Active Comparator|Palpation|Use of manual palpation to identify vertebral landmarks and vertebral interspaces for needle insertion.
9933063|NCT00956150|Active Comparator|60 GWS Rifaximin|
9933064|NCT00956150|Placebo Comparator|60 GWS Placebo|
9933065|NCT00956150|Experimental|Healthy Control|Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.
9933066|NCT00956163|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET)|Patients undergo technetium Tc 99m methylene diphosphonate bone scan, fluorine F 18 sodium fluoride PET/CT scan, and whole-body MRI for the detection of bone metastases. Patients with discordant imaging results (negative bone scan and positive PET/CT scan and/or MRI) undergo additional imaging at 6, 12, 18, and 24 months.
9933067|NCT00956176|Experimental|Cidofovir|
10212183|NCT01834625||Florbetapir +ve NPH patients|Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
10212184|NCT01834625||Florbetapir -ve patients|Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
9933068|NCT00956189|Experimental|Amisulpride|A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
9997649|NCT01510860|Active Comparator|Ursodeoxycholic acid (UDCA)250 mg|UDCA 250 mg capsule
10212185|NCT01775813|Experimental|Obese metformin arm|Double-blinded placebo-controlled trial of metformin during puberty, treatment arm Dosage form: Metformin 1000 mg tablets Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years
10212186|NCT01775813|Placebo Comparator|Obese placebo arm|Double-blinded placebo-controlled trial of metformin during puberty, placebo arm Dosage form: Placebo stamped to match 1000 mg metformin tablets Placebo comparator: Stamped placebo pill matching metformin dose Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years
10212187|NCT01775813|No Intervention|Obese - NT|"Comparator group for the observational comparison of metabolic changes in youth with normal weight and obesity as they progress through puberty.~Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years"
10212188|NCT01775813|No Intervention|Normal weight|"Comparator group for the observational comparison of metabolic changes in youth with normal weight and obesity as they progress through puberty.~Duration: From early puberty (Tanner 2-3) until puberty completion (Tanner 5), approximately 3 years"
10212189|NCT01694069|Active Comparator|Intermittent Infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
10212190|NCT01694069|Experimental|Continuous infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
10212191|NCT01619553||affected|individuals with keloids
10212192|NCT01619553||unaffected|unrelated unaffected controls or unaffected family members
10212193|NCT01606826||Asthmatics|Subjects with active asthma.
10212194|NCT01606826||Healthy Controls|Subjects without any known pulmonary disease.
10212195|NCT01533636||Healthy Control|This group will be comprised of healthy individuals without evidence of lung disease.
10212196|NCT01533636||Cystic Fibrosis|This group will be comprised of individuals who have been diagnosed with cystic fibrosis.
10212197|NCT01508078||Asthmatics|Otherwise healthy asthmatic subjects
10212198|NCT01508078||Healthy controls|Healthy individuals without evidence of pulmonary disease.
10212199|NCT01473199|Experimental|BioPoly RS Implant|BioPoly RS Implant
10212200|NCT01446016|Experimental|Chloroquine with Taxane or Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) Chemotherapy|Chloroquine (250 mg) was given daily orally with either Paclitaxel or Docetaxel or Abraxane or Ixabepilone chemotherapy every 3 weeks (1 cycle) fro a maximum of 6 cycles.
10212201|NCT01445327||Markers of Tumor Burden and Radiation Toxicity|Serum, plasma, urine, and stool samples will be collected prior to radiotherapy for participants with gastrointestinal malignancies.
10212202|NCT01434602|Experimental|1/Phase I|Daily everolimus (days 1- 28) in combination with sorafenib as per the Phase I dosing table. Maximum tolerated dose. Dose Escalation.
10212203|NCT01434602|Experimental|2/Phase II|Combination of sorafenib and everolimus. Sorafenib 400mg twice daily will be taken for 7 days on, then 7 days off. Everolimus 5mg will be taken daily. Determined from dose escalation in phase I, maximum tolerated dose -1.
10212204|NCT01417286|Experimental|Radiation Therapy|Patients undergo hypofractionated accelerated radiation therapy over 11 weekdays (for 15 elapsed days) within 21-63 days after last surgery or last course of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
10212205|NCT01411332|Active Comparator|Arm I: SIMRT|'Participants in this group will receive the Standard Fractionated Intensity Modulated Radiotherapy (SIMRT) consisting 40 fractions over 8 weeks.
9897687|NCT03486444|Experimental|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
9897688|NCT03486444|Experimental|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
9897689|NCT03486444|Experimental|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
9897690|NCT03485209|Experimental|Part A: Tisotumab Vedotin - Q3W Schedule|Tisotumab Vedotin every 3 weeks
9897691|NCT03485209|Experimental|Part B: Tisotumab Vedotin - 3Q4W Schedule|Tisotumab Vedotin on Days 1, 8, and 15 of 28-day cycle
9897692|NCT03485209|Experimental|Part C: Tisotumab Vedotin - 3Q4W/2Q4W Schedule|Tisotumab Vedotin on Days 1, 8, and 15 of a 28-day cycle and Tisotumab Vedotin on Days 1 and 15 of every 28-day cycle
9897693|NCT03485209|Experimental|Part D: Tisotumab Vedotin Combination Therapy - Q3W Schedule|Tisotumab vedotin + pembrolizumab + (carboplatin or cisplatin). Given on Day 1 of every 21-day cycle.
9897694|NCT03482986|Experimental|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
9897695|NCT03482986|Experimental|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
10212206|NCT01411332|Active Comparator|Arm II: HTIMRT|Participants in this group will receive the Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT) consisting of 38 fractions over 7.5 weeks.
10212207|NCT01399918|Experimental|everolimus and bevacizumab|This is a single-institution, single-arm phase II trial of everolimus in combination with bevacizumab in patients with advanced non-clear cell RCC, who have not received prior VEGF-.or mTOR-targeted therapy. A separate cohort of patients with non-clear cell RCC with papillary features will be enrolled in order to gather information regarding the efficacy given the rarity of these entities.
10212208|NCT01377753|Experimental|Arm 1/Magnetic Resonance (MR) Thermal Image Guided Laser Ablation|Eligible subjects will undergo MR thermal image guided laser ablation of all biopsy proven areas of prostate cancer using one or multiple laser probes during a single procedure lasting approximately two hours in duration.
9897696|NCT03480659||Breast Cancer|Early stage luminal A and triple negative breast cancer [TNBC] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
9897697|NCT03480659||Control|Age matched control females
9897698|NCT03476876|Experimental|Dermacell|Subject will receive treatment for deep diabetic foot ulcer using Dermacell acellular matrix. Subject will be followed for 16 weeks post treatment.
9897699|NCT03476876|Active Comparator|Integra|Subject will receive treatment for deep diabetic foot ulcer using Integra acellular matrix. Subject will be followed for 16 weeks post treatment.
9897700|NCT03474107|Experimental|Arm A: Enfortumab Vedotin 1.25 mg/kg|Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
9897701|NCT03474107|Active Comparator|Arm B: Chemotherapy|Participants received either 75 milligrams per square meter (mg/m^2) docetaxel by IV infusion over approximately 1 hour or 320 mg/m^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m^2 paclitaxel by IV infusion over approximately 1 hour on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
9897702|NCT03470558||Sleeve gastrectomy patients|Patients electing to undergo sleeve gastrectomy will monitor their dietary habits.
9897703|NCT03466697|Other|Healthy subjects|All subjects will be injected twice for each visit (normal saline or glucose)
9897704|NCT03463993|Experimental|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
9897705|NCT03463993|Active Comparator|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
9897706|NCT03456895|Experimental|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:~completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)~completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
9897707|NCT03456895|Experimental|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
10212209|NCT01147653|Active Comparator|Autologous UCB Reinfusion First,Then Placebo|Subjects receive their autologous umbilical cord blood cells at Baseline, than placebo at Year 1.
10212210|NCT01147653|Placebo Comparator|Placebo First, Then Autologous UCB Reinfusion|Subjects receive placebo at Baseline, then autologous umbilical cord blood cell reinfusion at Year 1.
9517789|NCT03302949|No Intervention|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
9897708|NCT03456895|Experimental|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
9897709|NCT03454893|Experimental|Single Assignment AVR-RD-01|AVR-RD-01 Drug Product (autologous CD34+ cell-enriched fraction that contains cells transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence
9897710|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
9897711|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
9897712|NCT03436290|Experimental|Palliative Care Intervention|
9897713|NCT03436290|No Intervention|Standard of Care|
9897714|NCT03432286|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
9897715|NCT03432286|Placebo Comparator|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
9897716|NCT03429829|Experimental|Flairesse varnish|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as fluoridated toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. In addition, fluoride varnish (22.600 ppm, DMG, Hamburg, Germany) was applied in 3-monthly intervals by the local non-professional assistants who had been trained beforehand and supervised at the first application.
9897717|NCT03429829|No Intervention|Control|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. Beyond that, the children in this arm were left untreated.
9897718|NCT03427827|Experimental|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation
9897719|NCT03427827|No Intervention|Best supportive care|Patients randomized to this arm will receive best supportive care after chemoradiation
9897720|NCT03427255|Active Comparator|CBT group treatment|CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
9897721|NCT03427255|Other|Waiting list|Six months waiting-list control condition.
9897722|NCT03423940|Experimental|Evaluation of Treatment Dosage|The goal of intervention for arm 1 is to examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each subject's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across subjects, but each subject will receive treatment at each duration. Resurgence will be tested following each treatment duration.
9897723|NCT03423940|Active Comparator|Empirically Derived Schedule Thinning|The goal of the intervention for arm 2 is to develop the optimal progression for reinforcement schedule thinning during functional communication training. The investigators will use measurements of destructive behavior, appropriate behavior, and reinforcer deliveries during each treatment session to inform the frequency of reinforcers that will be available during upcoming treatment sessions. The investigators will develop the schedule thinning progression by plugging these measurements into the quantitative model to describe the proper steps to schedule thinning to decrease the probability of a relapse of destructive behavior. The investigators will compare these results to those in the extant literature.
9897724|NCT03422822|Experimental|Abrocitinib 100 mg|Abrocitinib 100 mg QD PO
9897725|NCT03422822|Experimental|Abrocitinib 200 mg|Abrocitinib 200 mg QD PO
9897726|NCT03421756|Experimental|Non Myeloablative regimen (Alemtuzumab)|Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
9897727|NCT03417531|Active Comparator|Protein Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)
9897728|NCT03417531|Active Comparator|Protein-free Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)
9897729|NCT03417531|Active Comparator|Protein Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)
9897730|NCT03417531|Sham Comparator|Protein-free Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)
9897731|NCT03414229|Experimental|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
9897732|NCT03414229|Experimental|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
9897733|NCT03414229|Experimental|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
9897734|NCT03414229|Experimental|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
9933069|NCT00956189|Experimental|Aripiprazole|A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.
9798066|NCT01616459|Experimental|12Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 12Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 12Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
9897735|NCT03412266|Other|RIC regimen|"Low- and intermediate MDS patients without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
9897736|NCT03411031|Active Comparator|A: Elotuzumab + Lenalidomide at 25 mg|"Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule."
9897737|NCT03411031|Active Comparator|B: Elotuzumab + Lenalidomide at 10 mg|"Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule."
9897738|NCT03405480|Experimental|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
9897739|NCT03405480|No Intervention|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
9897740|NCT03404193|Experimental|Treatment (decitabine, venetoclax)|Participants receive decitabine IV over 1 hour on days 1-10 and may also receive decitabine on days 1-5 after achieving complete remission/complete remission with incomplete count recovery during consolidation/maintenance. Participants also receive venetoclax PO daily on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles. Treatment repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9897741|NCT03401203|Experimental|rotational atherectomy followed by balloon angioplasty|
9897742|NCT03401203|Active Comparator|balloon angioplasty|
9897743|NCT03400410|Experimental|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
9897744|NCT03400410|No Intervention|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
9897745|NCT03398395|Active Comparator|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
9897746|NCT03398395|Active Comparator|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
9897747|NCT03383081|Experimental|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
9897748|NCT03383081|Experimental|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
9897749|NCT03383081|No Intervention|Control groups|No intervention
9897750|NCT03376880||Obese Boys|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
9897751|NCT03376880||Obese Girls|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
9897752|NCT03376880||Normal Weight Boys|Normal weight boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
9897753|NCT03376880||Normal Weight Girls|Normal weight girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
9933070|NCT00956202|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
9935665|NCT03387761|Experimental|Cohort 1: Ipi + Nivo|"Day 1: Ipilimumab 3 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v."
9897754|NCT03376880||Obese Boys Misdiagnosed with Asthma|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
9897755|NCT03376880||Obese Girls Misdiagnosed with Asthma|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
9897756|NCT03366844|Experimental|Pembrolizumab with RT Boost|"Study drug plus tumor boost before standard of care treatment"
9897757|NCT03365752|Experimental|Chloroprocaine|
9897758|NCT03365752|Active Comparator|Mepivacaine|
9897759|NCT03365752|Active Comparator|General Anesthesia|
9897760|NCT03364036|Experimental|Mavenclad®|
9897761|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
9897762|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
9897763|NCT03363464||patients with T2DM initiating a GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist treated patients
9897764|NCT03362541|Experimental|MS INFoRm group|Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
9897765|NCT03362541|Active Comparator|Usual care control group|Participants in the usual care group will be given a login and password that will take them to a usual care webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
9897766|NCT03331978|Experimental|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
9897767|NCT03331978|No Intervention|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
9897768|NCT03328741|Experimental|Joint Academy|Online osteoarthritis treatment
9897769|NCT03328741|Active Comparator|The BOA program|Face-to-face osteoarthritis treatment
9897770|NCT03312803|Active Comparator|Mini autogenous skin grafts|we take the autogenous skin graft from the same patient then cut it into small pieces then we spread it over the burn wound on one limb then cover these small pieces with homogenous skin graft taken from another person.
9897771|NCT03312803|Active Comparator|Autogenous skin graft|we take the regular autogenous one piece skin graft from the same patient and cover the burn wound on the other limb then we make a comparison between both limbs
9897772|NCT03310957|Experimental|LV + pembrolizumab|LV + pembrolizumab
9897773|NCT03302494|Experimental|WaveCrest|WaveCrest left atrial appendage occluder
9897774|NCT03302494|Active Comparator|Watchman (control)|Watchman left atrial appendage closure device
9897775|NCT03292198|Active Comparator|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
9933071|NCT00956202|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
9933072|NCT00956202|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
9933073|NCT00956215|Active Comparator|80mg of Aprepitant|Patients will be randomized to receive 80mg of Aprepitant with 50 ml of water no later than 30 minutes before induction of anesthesia.
9897776|NCT03292198|Experimental|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
9897777|NCT03291470|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
9897778|NCT03291470|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
9897779|NCT03290287||New users of aclidinium bromide|This nested cohort will be composed of patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of aclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and aclidinium/formoterol)
9897780|NCT03290287||New users of other COPD medication|This nested cohort will include patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of other COPD medication: tiotropium, other LAMAs, LABA, LABA/ICS and LAMA/LABA.
9897781|NCT03289962|Experimental|Phase 1a Flat Dose Escalation: Autogene Cevumeran|Participants will receive autogene cevumeran at escalated dosages.
9897782|NCT03289962|Experimental|Phase 1b Flat Dose Escalation: Autogene Cevumeran + Atezolizumab|Participants will receive autogene cevumeran at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg)
9897783|NCT03289962|Experimental|Phase Ib: Dose Exploration: Autogene Cevumeran + Atezolizumab|Non-small cell lung cancer (NSCLC) or melanoma cancer immunotherapy (CIT)-treated participants will receive autogene cevumeran (at dosage lower than maximum tolerated dose [MTD] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
9897784|NCT03289962|Experimental|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab|Participants with different indications as per inclusion criteria will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
9897785|NCT03289962|Experimental|Phase 1b Expansion: Autogene Cevumeran + Atezolizumab (Serial Biopsy)|CIT-naive patients with selected tumor types who consent to optional serial biopsies will receive autogene cevumeran (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a dixed dose of 1200 mg.
9897786|NCT03288493|Experimental|Phase 1: P-BCMA-101 CAR-T cells|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
9897787|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort A)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
9897788|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort B)|Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
9897789|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort C)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
9897790|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
9897791|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
9897792|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
9897793|NCT03288493|Experimental|Phase 2: P-BCMA-101 CAR-T Cells|CAR-T cells administered via intravenous infusion as a total dose
9897794|NCT03286725|No Intervention|Control Group|The Control Group will be asked to continue with their normal PE lessons.
9897795|NCT03286725|Experimental|Intervention Group|'Physical Education (PE) Programme'
9897796|NCT03285152|Experimental|Ketogenic Diet (KD)|The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
9897797|NCT03285152|Active Comparator|Standard Diet (SD)|Patients randomized to the SD group will consume their normal diet plan. They will meet with the dietitian from the CTSC at WCMC weekly and receive standard nutritional counseling from the CTSC. Average intake will be documented through analyzing a 3 day intake pre and post the 4 week period.
9897798|NCT03283540||TaTME|Trans-anal Total Mesorectal Excision (TaTME) is the visualization and dissection of the rectum located deep in the pelvis. In it, a trans-anal port is inserted for the duration of the surgery. Multiple surgical tools are then introduced through the port and the rectum is resected from down-to-up under direct visualization.
9897799|NCT03283540||abdominal TME|"Total Mesorectal Excision involves resecting the rectum along with its surrounding Mesorectal plane. If the anal sphincter is spared, this surgery is named Low Anterior resection (LAR) for rectal cancer. Traditionally, TME dissection in LAR is performed through open or laparoscopic incisions(s) made in the abdominal wall. Mobilization of the splenic flexure along with sigmoid dissection follows. Lastly, the rectum is dissected in accordance with TME principles from above. This up-to-down approach is known as abdominal TME."
9897800|NCT03283449|Experimental|AV-1451 Recipients|Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
9897801|NCT03279874||German dentists|Dentists who are working in dental offices in Germany
9897802|NCT03275129|Experimental|Ultrasound assessment of heart and lungs|Patients (over the age of 18) who will be undergoing surgery for hip fracture repair. These patients will receive an ultrasound of the heart and lungs to determine whether or not information gained from this ultrasound assessment is significant enough to influence their anesthetic care plan.
9897803|NCT03266900|Experimental|re-TURBT|Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
9897804|NCT03266900|Active Comparator|6 BCG instillations|Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.
9897805|NCT03260491|Experimental|Dose Escalation: Cohort 1, 3.2 mg/kg|Participants in the Dose Escalation Cohort 1 will receive U3-1402 intravenously (IV) once every three weeks at 3.2 mg/kg.
9897806|NCT03260491|Experimental|Dose Escalation: Cohort 2, 4.8 mg/kg|Participants in Dose Escalation Cohort 2 will receive U3-1402 intravenously (IV) once every three weeks at 4.8 mg/kg.
9897807|NCT03260491|Experimental|Dose Escalation: Cohort 3, 5.6 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 5.6 mg/kg.
9897808|NCT03260491|Experimental|Dose Escalation: Cohort 4, 6.4 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 6.4 mg/kg.
9897809|NCT03260491|Experimental|Dose Expansion: Cohort 1, EGFR mutant|Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
9897810|NCT03260491|Experimental|Dose Expansion: Cohort 2, EGFR wild-type|Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
9897811|NCT03260491|Experimental|Dose Expansion: Cohort 3a, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).
10212211|NCT01078454|Experimental|ARM A (Mel-Dex)|Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
10212212|NCT01078454|Experimental|ARM B (B-Mel-Dex)|Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m^2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9897812|NCT03260491|Experimental|Dose Expansion: Cohort 3b, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive U3-1402 IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).
9897813|NCT03260491|Experimental|Dose Expansion: Cohort 4, EGFR mutant|Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive U3-1402 IV at 5.6 mg/kg every 3 weeks.
9897814|NCT03256097|Experimental|XDP - VG - XDP|
10212213|NCT01073410||Healthy, non-asthmatic controls|People who are non-asthmatic and non-smokers.
10212214|NCT01073410||Asthmatics|People who have been diagnosed with asthma.
10212215|NCT01034254|Experimental|influenza vaccine|Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
10212216|NCT01034254|Placebo Comparator|saline placebo|Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
10212217|NCT00937001|Experimental|Biopsy/Ultrasound|
10212218|NCT00881920|Experimental|Kappa CD28 T cells for B-CLL|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
10212219|NCT00881920|Experimental|Kappa CD28 T cells for B-cell lymphoma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
10212220|NCT00881920|Experimental|Kappa CD28 T cells for myeloma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
10213859|NCT02947035|Experimental|Low Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
9800279|NCT01683409|Experimental|Baricitinib 1.5 mg/1 mg|Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
9897815|NCT03256097|Experimental|VG - XDP - VG|
9933074|NCT00956215|Placebo Comparator|80 mg of placebo|. Patients will be randomized to placebo with 50 ml of water no later than 30 minutes before induction of anesthesia.
9517558|NCT03305328|Experimental|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
9800280|NCT01683409|Experimental|Baricitinib 4 mg/2.75 mg|Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
9800281|NCT01683422|Experimental|Proton Radiation|"Pre-Proton-chemotherapy (PCT) Patients will receive a combination of the agents (Gemcitabine plus Erlotinib) for 8 weeks prior to PCT Gemcitabine 1000 mg/m2 IV, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43~PCT to be started in 4 to 8 weeks after completion of Pre-PCT Proton therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day for 5 ½ weeks.~Chemotherapy: Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed~Post-PCT to be started in 4 to 6 weeks after completion of PCT Oxaliplatin 130 mg/m2, day 1 Capecitabine 1000 mg/m2 po bid on days 2 to 15 for 14 days The CapOx regimen (Capecitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles"
9800282|NCT01683526|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy
9800283|NCT01683526|Active Comparator|Video laryngoscopy|Intubation will be done using video laryngoscopy
9800284|NCT01683565|Experimental|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement
9800285|NCT01683565|Placebo Comparator|Canola Oil Placebo|
9800286|NCT01683604||Rheumatoid Arthritis (RA) Participants (All Groups)|Participants with severe RA were prescribed with tocilizumab in accordance with routine clinic practice, and were observed for 6 months.
9800287|NCT01683630||Confirmed influenza A and B cases|Cases of influenza A and B as diagnosed by PCR, viral culture or florescence microscopy
9800288|NCT01683812|Experimental|Cranial Cup Arm|Single arm
9800289|NCT01683838|Active Comparator|fampridine-SR 50mg/day|
9800290|NCT01683838|Placebo Comparator|Placebo|
9800291|NCT01683994|Experimental|combination of cabozantinib, docetaxel and prednisone|combination of cabozantinib, docetaxel and prednisone
9800292|NCT01683994|Active Comparator|PII/ Arm 1-docetaxel + prednisone only|docetaxel + prednisone only
9800293|NCT01683994|Active Comparator|PII/Arm 2 -docetaxel+ prednisone + cabozantinib|docetaxel+ prednisone + cabozantinib
9800294|NCT01684007|Experimental|Bilateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
9800295|NCT01684007|Active Comparator|Contralateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] and AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, contralateral implantation
9800296|NCT01684020|Experimental|ARTISS Human Fibrin Sealant|Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
9800297|NCT01684020|No Intervention|Standard of Care|Fixation of the skin flap created during external rhinoplasty will use the standard of care
9800298|NCT01684033|Other|PureMoist - Biotrue|Opti-Free® PureMoist® MPDS used first, followed by Biotrue™ MPS. Each product used as indicated for 30 days with participant's habitual contact lenses.
9800299|NCT01684033|Other|Biotrue - PureMoist|Biotrue™ MPS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
9800300|NCT01684046|Other|PureMoist - RevitaLens|Opti-Free® PureMoist® MPDS used first, followed by RevitaLens MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
9800301|NCT01684046|Other|RevitaLens - PureMoist|RevitaLens MPDS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
9800302|NCT01684202|Experimental|OPC-41061|
9800303|NCT01684215|Experimental|Single-agent PD-0332991|Phase 1 Part 1
9800304|NCT01684215|Experimental|PD-0332991 in combination with letrozole|Phase 1 Part 2
9800305|NCT01684215|Experimental|PD-0332991 with letrozole|Phase 2
9800306|NCT01684410|Experimental|Alpha-1 HC 100 mg|100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
9800307|NCT01684410|Experimental|Alpha-1 HC 200 mg|200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
9800308|NCT01684410|Placebo Comparator|Placebo|Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
9897816|NCT03255174|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
9897817|NCT03254654|Experimental|Vinorelbine Plus Apatinib|"Vinorelbine: 20 mg/m2, D6, D13, D20~Apatinib: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2."
9897818|NCT03254654|Active Comparator|Vinorelbine|Vinorelbine: 25 mg/m2, D1, D8, D15
9897819|NCT03253263|Experimental|SHP607 250 mcg/kg/24 hours|Participants will receive continuous intravenous (IV) infusion of SHP607 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) from birth up to postmenstrual age (PMA) 29 weeks +6 days.
9897820|NCT03253263|Experimental|SHP607 400 mcg/kg/24 hours|Participants will receive continuous IV infusion of SHP607 400 mcg/kg/24 hours through from birth up to PMA 29 weeks +6 days.
9897821|NCT03253263|No Intervention|Standard Neonatal Care|Standard neonatal care alone will be provided.
9897822|NCT03251313|Experimental|JS001 120mg+GP|Level 1: JS001 120mg +GP q3w,*6 cycles, then JS001 120mg q3w for maintenance therapy for up to approximately 2 years.
9897823|NCT03251313|Experimental|JS001 240mg+GP|Level 2: JS001 240mg +GP q3w,*6 cycles, then JS001 240mg q3w for maintenance therapy for up to approximately 2 years.
9897824|NCT03251313|Experimental|JS001 480mg +GP|Level 3: JS001 480mg+GP q3w,*6 cycles, then JS001 480mg q3w for maintenance therapy for up to approximately 2 years.
9897825|NCT03251313|Experimental|GP followed by JS001|sequential treatment: Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
9897826|NCT03233191|Experimental|Arm A (digital mammography)|Patients undergo bilateral screening DM with standard CC and MLO views at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
9897827|NCT03233191|Experimental|Arm B (digital tomosynthesis mammography)|Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
9897828|NCT03225287|Experimental|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
9897829|NCT03220893||Women with Dense Breast Tissue|"Subjects will have had heterogeneously dense or extremely dense breasts on most recent prior mammographic examination (Breast Imaging Reporting and Data System (BI-RADS) c or d) and be asymptomatic for breast disease.~Subjects will receive Molecular Breast Imaging (MBI) and Digital Breast Tomosynthesis (DBT) at Year 0 screening within a 24-hour period. All patients who did not receive a diagnosis of breast cancer during the Year 0 screening will undergo DBT and MBI at approximately one year (Year 1 screening), again within a 24-hour period."
9897830|NCT03217006|Experimental|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
9897831|NCT03217006|Experimental|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
9897833|NCT03213418|Experimental|Contingency management|
9897834|NCT03207191|Experimental|F16IL2 + BI 836858|"Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.~Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months."
9997650|NCT01510860|Experimental|Ursodeoxycholic acid (UDCA)500 mg|UDCA 500 mg tablet
9897835|NCT03205163|Experimental|Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg|Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
9897836|NCT03205163|Experimental|High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg|Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
9897837|NCT03204695|Experimental|LAA Occlusion|
9897838|NCT03203330|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
9897839|NCT03203330|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
9897840|NCT03195777|Experimental|Single Arm: Observation after Imaging|This is a single-arm study, where subjects will be monitored for development of PTS after baseline non-invasive imaging with FDG PET/CT. The experimental interventIon is the PET/CT imaging.
9897841|NCT03182907|Experimental|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
9897842|NCT03182907|Placebo Comparator|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose
9897843|NCT03181750|No Intervention|Control|Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
9897844|NCT03181750|Experimental|Patient Navigator Intervention Group|Patient and caregivers randomized to this arm will receive the same packet of educational materials. They will also receive at least 5 visits from a bicultural bilingual patient navigator. The navigator will utilize a annualized visit guide manual to lead discussions on advance care planning, pain and symptom management, and hospice care.
9897845|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
9897846|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
9897847|NCT03173729||Phase 1 Cohort 1|CRC (n = 150)
9897848|NCT03173729||Phase 1 Cohort 2|Precancerous polyps (n = 150)
9897849|NCT03173729||Phase 1 Cohort 3|Normal controls (n = 150)
9897850|NCT03173729||Phase 2 Field Test|75 patients who are high risk for CRC as described in the eligibility
9897851|NCT03173729||Phase 2 Validation Study Cohort 1|Family history of CRC (n = 330)
9897852|NCT03173729||Phase 2 Validation Study Cohort 2|LGI bleeding (n = 240)
9897853|NCT03173729||Phase 2 Validation Study Cohort 3|Patients with history of CRC (n = 75)
9897854|NCT03168672|Other|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
9897855|NCT03166332|Active Comparator|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts.
9897856|NCT03166332|Active Comparator|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
9897857|NCT03166332|No Intervention|No intervention|No intervention strategy
9897858|NCT03161249|Experimental|Experimental group|Mobile psychotherapy (5 modules) plus treatment as usual
9897859|NCT03161249|Other|Control group|"Control group: Treatment as usual~The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention"
9897860|NCT03153475|Other|ATTUNE Revision Knee System|The ATTUNE Revision system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in revision knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
9897861|NCT03153449|Other|ATTUNE Revision knee system|The ATTUNE Revision knees system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in complex primary knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
9897862|NCT03150693|Active Comparator|Arm I (frontline chemotherapy)|See detailed description.
9897863|NCT03150693|Experimental|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
9897864|NCT03145766|Experimental|Group 1: VRVg-2 Formulation 1|VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.
9897865|NCT03145766|Experimental|Group 2: VRVg-2 Formulation 2|VRVg-2 formulation 2, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
9897866|NCT03145766|Experimental|Group 3: VRVg-2 Formulation 3|VRVg-2 formulation 3, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
9897867|NCT03145766|Experimental|Group 4: VRVg-1|VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
9992174|NCT01459627|Active Comparator|6 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.
9992175|NCT01459627|Active Comparator|12 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study
9992176|NCT01459640|Active Comparator|Hyaluronic acid|
9992177|NCT01459640|Experimental|Bone marrow mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells
9992178|NCT01459666|Experimental|Dysport (abobotulinumtoxinA)|Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry.
9992179|NCT01459666|Placebo Comparator|Placebo|
9992180|NCT01459692|No Intervention|Control group - No Music Exposure|Subjects that were assigned to the control group of the study were not exposed to music.
9992181|NCT01459692|Experimental|Music Exposure|The treatment subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
9992182|NCT01459731||Age 18-29|
9992183|NCT01459731||Age 30-39|
9992184|NCT01459731||Age 40-49|
9992185|NCT01459731||Age 50-59|
9992186|NCT01459731||Age 60-69|
9992187|NCT01459731||Age 70+|
9992188|NCT01459744|Experimental|Communication training for cardiologists|The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
9992189|NCT01459744|Placebo Comparator|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
9992190|NCT01459757||Data generated from the past sunitinib A6181036 GIST study|
9992191|NCT01459770|Active Comparator|control|"usual care for hospital discharge:~CKD group~ESRD group"
10212221|NCT00687596|Experimental|TAC-101|Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 milligram per day (mg/day) of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.
9992192|NCT01459770|Active Comparator|intervention|"pharmacist administered medication information transfer intervention~CKD group~ESRD group"
9992193|NCT01459809|Experimental|ARM 1: glimepiride alone|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline < 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
9997651|NCT01510873||Newly Diagnosed pITP|Patients within 3 months from diagnosis.
10212222|NCT00687596|Placebo Comparator|Placebo|Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.
10212223|NCT00594750||Asthma|People who have been diagnosed with Asthma
10212224|NCT00503438|Other|Salto Talaris Ankle|This is an Implant Registry of the approved Salto Talaris Ankle replacement device
10212225|NCT00473031|Experimental|1|High Protein
10212226|NCT00473031|Active Comparator|2|Normal Protein
10212227|NCT00472680|Experimental|1|High Dietary Protein
10212228|NCT00472680|Active Comparator|2|Normal Dietary Protein
10212229|NCT00472654|Placebo Comparator|WL|
10212230|NCT00472654|Experimental|WL + D|
10212231|NCT00472654|Placebo Comparator|WM|
10212232|NCT00472654|Active Comparator|WM + D|
10213860|NCT02947035|Experimental|High Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
10213861|NCT02921893|Experimental|Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
10213862|NCT02921893|Experimental|Group II (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
10213863|NCT02890641||drug resistant epilepsy|Sequencing of paired blood-brain DNA samples
10213864|NCT02880020|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10213865|NCT02880020|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes every 6 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10213866|NCT02879825|Experimental|Group A|Mitral valve prolapse without mitral regurgitation
10213867|NCT02879825|Experimental|Group B|Mitral valve prolapse with trivial mitral regurgitation
10213868|NCT02879825|Experimental|Group C|Mitral valve prolapse with moderate or mild mitral regurgitation and asymptomatic
10213869|NCT02879825|Experimental|Group D|Mitral valve prolapse with severe mitral regurgitation or symptomatic
9992194|NCT01459809|Experimental|ARM 2: metformin alone|24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
9992195|NCT01459809|Experimental|ARM3: Glimepiride/metformin free combination|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline < 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.
9992196|NCT01459822||Survival Group|
9992197|NCT01459822||Death Group|
9992198|NCT01459835|Experimental|media diet|advice tips and tools to reduce exposure to violent programming
9992199|NCT01459835|Active Comparator|Nutrition intervention|diet advice
9992200|NCT01459848|Active Comparator|block play|30 minutes of block play with parent
9992201|NCT01459848|Experimental|baby dvd|watch baby dvd with parent
9992202|NCT01459861|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
9992203|NCT01459861|Active Comparator|Femoral with Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa.
9992204|NCT01459874||Cardiac Implantable Device recipients|
9992205|NCT01459887|Experimental|combination group|
9992206|NCT01459887|Experimental|sequential group|
9992207|NCT01459900|Active Comparator|Renal artery ablation|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
9992208|NCT01459900|Sham Comparator|Sham|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
9992209|NCT01459939|Placebo Comparator|Placebo|Daily treatment with placebo
9992210|NCT01459939|Active Comparator|Rose-hip powder|Daily treatment with Rose-hip powder
9992211|NCT01459952|Experimental|Rose hip Liquid|20 ml Rose hip Liquid BID
9992212|NCT01459952|Placebo Comparator|Placebo|20 ml placebo liquid BID
9992213|NCT01459965|Active Comparator|10 French Stent|10 French biliary plastic stent
9992214|NCT01459965|Active Comparator|11.5 French stent|11.5 French biliary plastic stent
9992215|NCT01459978||Early CUSUM result group|"Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity.~Phase 2: results of the CUmulative SUM (CUSUM) will be provided for a period of 12 months (Early CUSUM result group), Phase 3: maternity will continue to receive the results of the CUmulative SUM (CUSUM) for a period of 12 months,"
9992216|NCT01459978||CUSUM result Delayed group|Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity Phase 2: the results of CUmulative SUM (CUSUM) will not be shared. Phase 3: group receive CUmulative SUM (CUSUM) result (CUSUM result Delayed group) during the same period 12 months
9992217|NCT01459991|Experimental|Mediterranean|Participants in this arm will follow a Mediterranean style diet, rich in olive oil and fruits and vegetables, and also consume 1 ounce of walnuts daily.
9992218|NCT01459991|Active Comparator|MyPyramid|
9992219|NCT01460004|No Intervention|patella knee strap|infra patella knee strap- cotton, applied in straight leg
9992220|NCT01460017|Active Comparator|DS arm|Deep sclerectomy surgery will be conduct in this arm
9992221|NCT01460017|Active Comparator|Trab arm|combined Trabeculectomy and Trabeculotomy surgery will be conducted in this arm
9992222|NCT01460030|Experimental|KRN1493|
9992223|NCT01460043|Placebo Comparator|placebo|
9992224|NCT01460043|Experimental|Homeopathy|Individualized symptom based therapy
9992225|NCT01460056||Peritoneal dialysis|
10212233|NCT00458536|Experimental|Cohort 1|Patients treated with DC/RCC vaccine to evaluate for treatment-limiting toxicity
10212234|NCT00458536|Experimental|Cohort 2|Patients treated with DC/RCC vaccine to evaluate response
10212235|NCT00112840|Experimental|CCI-779 and bevacizumab|Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
10212236|NCT05223361|Active Comparator|Hydroxy ethyl starch (HES)|Six percent hydroxy ethyl starch 130/0.4 additive to ringer lactate as priming solution during CPB
10212237|NCT05223361|Active Comparator|Ringer lactate (RL)|Ringer lactate as priming solution during CPB
9992226|NCT01460069|Active Comparator|Victoza treatment|
9992227|NCT01460069|Placebo Comparator|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
9992228|NCT01460082||Exacerbation|The study sample will consist of patients admitted to the hospital because of an acute exacerbation of COPD
9992229|NCT01460095|Experimental|HbA1c measurement and education|3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
9992230|NCT01460108|Experimental|AeriSeal System Treatment|Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.
9992231|NCT01460121|Experimental|SpotOn's corrective elements|
9992232|NCT01460121|Placebo Comparator|Placebo corrective elements|
9992233|NCT01460134|Experimental|Hematologic Malignancies (Dose Escalation)|B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
9992234|NCT01460134|Experimental|Solid tumors (Dose Escalation; COMPLETED)|
9992235|NCT01460134|Experimental|Solid Tumors (Expansion Phase; COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
9992236|NCT01460134|Experimental|Hematologic Malignancies (COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
9992237|NCT01460147|Other|DXA scan + MRI|
9992238|NCT01460173|Other|Normal subjects|
9992239|NCT01460173|Other|OSA Patients|
9992240|NCT01460186|Experimental|Blood samples|
9992241|NCT01460199|Placebo Comparator|Placebo|Matching Placebo
9992242|NCT01460199|Experimental|CTP-499|
9992243|NCT01460212|Experimental|Cognitive-Behavior Therapy group|treatment with Cognitive-Behavior Therapy
9992244|NCT01460212|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
9992245|NCT01460238||No treatment|No intervention. Each patient will have blood drawn at a standard of care venipuncture.
9992246|NCT01460251|Experimental|Drug:Diapep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
9992247|NCT01460277|Experimental|Hydrokinesiotherapy|A 6-week water-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
9992248|NCT01460277|Active Comparator|Conventional exercise intervention|A 6-week land-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
9992249|NCT01460316||Conotruncal cardiac defects patients|
9992250|NCT01460316||Mothers of patients|
9992251|NCT01460329||USCOM Cardiac index|
9992252|NCT01460355|Active Comparator|Botulinum toxin plus surgery|Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery
9992253|NCT01460355|Placebo Comparator|Saline solution plus surgery|Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure
9992254|NCT01460394||Healthy adolescents and young adults|
9992255|NCT01460420|Experimental|Bortezomib + Lenalidomide|After conditioning treatment and graft versus host disease prophylaxis with Bz 1.3 mg/m2 on days +1, +4 and +7 plus sirolimus/rapamycin at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL, a maintenance therapy with Bz 1.3 mg/m2 on days 1, 8 and 15 in cycles of 56 days up to 6 cycles post-transplant and on day +180 Len will be started at a dose of 5 mg and will be maintained until relapse.
9992256|NCT01460459|Experimental|high frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day weekly in group A.
9992257|NCT01460459|Experimental|middle frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day per two weeks in group B.
9992258|NCT01460459|Experimental|low frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) Group C: one day monthly
9992259|NCT01460472|Experimental|Racotumomab plus Best Support Treatment|Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.
9992260|NCT01460472|Active Comparator|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC including onco-specific therapies when disease progresses.
9992261|NCT01460498|Experimental|Dose Escalation Group (AZA)|Azacitidine (AZA) starting dose 50 mg/m2 a day for 3 days subcutaneous or intravenous of 28 day cycle. TKI at dose received during last 6 months.
9992262|NCT01460498|Experimental|Expansion Group (AZA MTD)|Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.
9997652|NCT01510873||Persistent pITP|Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.
10212238|NCT05223348|Experimental|Body Scan Meditation|The experimental condition involves participants listening to a 16-minute recording of a body scan meditation. The body scan condition guides participants to focus on their bodily sensations separately, then together as a whole.
9798067|NCT01616459|Active Comparator|Synflorix Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Synflorix™ at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Synflorix™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Synflorix™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
9897868|NCT03145766|Active Comparator|Group 5: Imovax Rabies|Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
9897869|NCT03139318|Experimental|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
9897870|NCT03127592|Experimental|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
9897871|NCT03127592|Active Comparator|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
9897872|NCT03127592|Active Comparator|Group 3|1 active treatment (Etodolac) + 2 placebos
9897873|NCT03116425|Experimental|Verum 1 - Premotor|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the premotor region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
9897874|NCT03116425|Experimental|Verum 2 - Prefrontal|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the prefrontal region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
9897875|NCT03116425|Active Comparator|Placebo|Stimulation of a region with normal rCBF and putatively unrelated to catatonic symptoms (parietal cortex).
9897876|NCT03114033|Experimental|Targeted therapeutic mild hypercapnia|Target arterial carbon dioxide range of 50-55 mmHg for 24 hours following randomisation
9897877|NCT03114033|Active Comparator|Targeted normocapnia (Standard care)|Target arterial carbon dioxide range of 35-45 mmHg for 24 hours following randomisation
9897878|NCT03110822|Experimental|Rux Len and Steroid|Ruxolitinib Oral Tablet [Jakafi] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
9897879|NCT03110822|Experimental|Rux and Steroid until progression, then add Len|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
9897880|NCT03110822|Experimental|Expanded Eligibility Criteria|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, Lenalidomide at 10mg QD, and Methylprednisolone at 40mg QOD until disease progression.
9897881|NCT03110822|Experimental|High-dose Ruxolitinib|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 20mg BID and Methylprednisolone at 40mg QOD until disease progression.
9897882|NCT03106987|Experimental|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
9897883|NCT03106987|Placebo Comparator|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
9897884|NCT03105843|Experimental|Cough Variant Asthma|Individuals diagnosed with Cough variant asthma
9897885|NCT03105843|Experimental|Methacholine-induced cough|Individuals with chronic cough and negative methacholine challenge
9897886|NCT03105843|Experimental|Control|Individuals with no history of asthma or chronic cough
9897887|NCT03103750|Experimental|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
9997653|NCT01510873||Chronic pITP|Patients with ITP lasting for more than 12 months.
9997654|NCT01510886||1|
10212239|NCT05223348|Active Comparator|Listening Task|The active comparer condition involves participants listening to a 16-minute recording of text that describes the human musculoskeletal system. The text will be narrated by a female voice to match the body scan meditation. In addition, the focus on the body in the text of the active condition matches the focus on the body in the body scan meditation and, as such, controls for demand characteristics.
10212240|NCT05223296|Active Comparator|Group I LigaSure (n=100)|100 patients subjected to LigaSure pile excision
10212241|NCT05223296|Active Comparator|Group II Conventional diathermy (n=108)|108 patients subjected to conventional diathermy for grade IV pile excision
10212242|NCT05223270|Experimental|intervention group-1|Hydrocolloid wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
10212243|NCT05223270|Experimental|intervention group-2|Hydrocelluler wound dressings were placed on the pressure areas under the NIMV mask of the patients in this group.
10212244|NCT05223270|No Intervention|control group|Patients in this group were treated without placing an additional dressing under the NIMV mask.
10212245|NCT05223244|Active Comparator|dimethyl sulfoxide (DMSO)|Six weekly bladder instillations with 50mL of DMSO and 1mL of triamcinolone (10mg/mL)
10212246|NCT05223244|Experimental|bupivacaine, triamcinolone, and heparin (BTH)|Six weekly bladder instillations with 30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
10213870|NCT02853448|Experimental|Novel Device|Every Subject will be assigned to the same arm. This arm calls for blood to be drawn using an original blood drawing apparatus as well as using the novel blood drawing apparatus.
10213871|NCT02853331|Experimental|Pembrolizumab+Axitinib Combination Therapy|Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
9897888|NCT03103750|Experimental|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
9897889|NCT03103087|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
9897890|NCT03103087|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
9897891|NCT03103087|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
9897892|NCT03102580|Experimental|OA Care Plan Intervention|For intervention sites, the patient and surgeon will receive the OA Care Plan (currently under development). The OA Care plan with have Patient Reported Outcomes, feedback reports, and risk factors for shared decision making.
9897893|NCT03102580|No Intervention|Usual care|As collection of Patient Reported Outcomes (PROs) is considered standard of care in orthopedics (CMS mandate, Bundled Payment requirements, and reporting for Qualified Clinical Data Registry requirement for example), usual care patients and surgeons will have the ability to see PRO scores.
9897894|NCT03102047|Experimental|durvalumab|IV infusion once every 2 weeks for 4 total doses
9897895|NCT03100110|Experimental|NeuroCognitive Communicator|
9933075|NCT00956228|Experimental|Radioimmunoguided IMRT|All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
9933076|NCT00956241|Other|j-pouch coloanal anastomosis|although a j-pouch coloanal anastomosis is a common type of anastomosis, a comparison with the side-to-end has not been made.
9933077|NCT00956241|Other|side-to-end coloanal anastomosis|in the Netherlands, the side-to-end anastomosis is the standard procedure to perform an anastomosis in case of rectal resection. therefore, the side-to-end group was our control group
9933078|NCT00956267|Experimental|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
9933079|NCT00956267|Active Comparator|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
9933080|NCT00956306|Experimental|Child-Pugh A|
9933081|NCT00956306|Experimental|Child-Pugh B|
9933082|NCT00956306|Experimental|Healthy Volunteers|
9933083|NCT00956319|Experimental|Zolpidem group|
9933084|NCT00956319|Active Comparator|Estazolam group|
9933085|NCT00956332|Experimental|MGA - Low therapeutic dose|
9933086|NCT00956332|Experimental|MGA - Intermediate therapeutic dose|
9933087|NCT00956345|Experimental|25U/kg|
9933088|NCT00956345|Experimental|50U/kg|
9933089|NCT00956345|Experimental|100U/kg|
9933090|NCT00956358||Pre-HSCT|Haematological conditions requiring haemopoietic stem cell transplantation
9933091|NCT00956358||Post-HSCT with BOS|Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
9933092|NCT00956358||Control|Healthy HSCT donors
9933093|NCT00956371|Placebo Comparator|P|
9933094|NCT00956371|Experimental|E|
9933095|NCT00956384|Experimental|One-stage dermal matrix/implant|One-stage breast reconstruction with dermal matrix and implant
9933096|NCT00956384|Active Comparator|Two-stage tissue expander/implant|Two-stage breast reconstruction with tissue expander and implant
9935666|NCT03387761|Experimental|Cohort 2a: high-Ipi + low-Nivo|"Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
9935667|NCT03387761|Experimental|Cohort 2b: low-Ipi + high-Nivo|"Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
9935668|NCT03377296|Experimental|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
9935669|NCT03374215||Adult AA with primary aldosteronism|Adult individuals (age 18 or older) with HTN and discrete adrenal masses or bilateral hyperplasia of the adrenal glands, with outpatient positive ARR or string clinical suspicion for PA
9935670|NCT03374215||Family members age >= 7 of participants|DNA from relatives of patients (age 7 or older)
9935671|NCT03374202|Experimental|Group 1|5 x 10 (10) vg/kg IM
9935672|NCT03374202|Experimental|Group 2|5 x 10 (11) vg/kg IM
9935673|NCT03374202|Experimental|Group 3|2.5 x 10 (12) vg/kg IM
9997655|NCT01510899|Experimental|Healthy Subjects Arm|
9897896|NCT03097796|Experimental|PUL-042|PUL-042 Inhalation Solution
9897897|NCT03093818|Experimental|Pharmacogenomic testing arm|"4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a Safety-Code card containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions."
9897898|NCT03093818|No Intervention|Standard of care arm|"4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock Safety-Code card, which does not contain personal pharmacogenomics results."
9897899|NCT03089996|Experimental|Piezocision|Piezocision-assisted canine retraction x Control (split mouth design)
9897900|NCT03089996|Experimental|Corticotomy|Corticotomy-assisted canine retraction x Control (split mouth design)
9897901|NCT03089996|Experimental|Piezocision x Corticotomy|Piezocision-assisted retraction x Corticotomy-assisted retraction (split mouth design)
9897902|NCT03085212|Experimental|Online stress management program|Participants will receive free access to Stress Free Now, which is an online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavior therapy to help individuals learn to manage their stress.
9897903|NCT03085212|Active Comparator|Wait list control|Participants in this arm will receive free access to the Stress Free Now program at the end of the study.
9897904|NCT03083678|Experimental|Afatinib|Afatinib active treatment.
9897905|NCT03073980|Experimental|Group 1: Intravenous (IV) acetaminophen/oral (PO) placebo|In the pre-operative suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.
9897906|NCT03073980|Active Comparator|Group 2: Intravenous (IV) placebo/oral (PO) acetaminophen|In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.
9897907|NCT03073980|Placebo Comparator|Group 3: Oral and intravenous Placebo / Standard of care|In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.
9897908|NCT03071926|Experimental|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
9897909|NCT03061552|Experimental|IVCD arm|IVCD-assisted determination of target post-dialysis weight
9897910|NCT03061552|No Intervention|conventional arm|conventional determination of target post-dialysis weight
9897911|NCT03058952|Experimental|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
9897912|NCT03058952|Active Comparator|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
9897913|NCT03057119|Experimental|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
9897914|NCT03057119|No Intervention|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
9897915|NCT03049735|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
9897916|NCT03049735|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
9897917|NCT03049735|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
9897918|NCT03044613|Experimental|Arm A|Nivolumab 240mg administered IV over 30 minutes every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation
9897919|NCT03044613|Experimental|Arm B|Nivolumab 240mg administered IV over 30 minutes followed by relatlimab 80mg administered IV over 60 minutes on Day 1 every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation).
9897920|NCT03028519|Experimental|Treatment|Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
9897921|NCT03021551|Experimental|Rainbow sensor|
9897922|NCT03021135|Active Comparator|Conventional Mucosal Resection|C-EMR will be made with saline injection with the indigo carmine.
9897923|NCT03021135|Experimental|Underwater Mucosal Resection|UW-EMR will be made after the complete filling of lumen with water.
9897924|NCT03016156|Experimental|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
9897925|NCT03016156|Experimental|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
9897926|NCT03016156|Experimental|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
9897927|NCT03012971|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
9897928|NCT03012971|Placebo Comparator|Control group|Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
9897929|NCT03008122|Experimental|Group 1|5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29 , n=45 (2 sentinels, 43 non-sentinels) or placebo, n=5
9897930|NCT03008122|Experimental|Group 2|2.5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29, n=35 or placebo, n=5
9897931|NCT03006172|Experimental|Stage I Arm A: Inavolisib Single Agent|Participants will receive inavolisib in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of inavolisib on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
10212247|NCT05223218||Breast Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Mammogram, ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
9897932|NCT03006172|Experimental|Stage I Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9897933|NCT03006172|Experimental|Stage I Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of inavolisib will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9897934|NCT03006172|Experimental|Stage II Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9933097|NCT00956397|Active Comparator|Control Participants|
9933098|NCT00956397|Active Comparator|FD Participants|
9933099|NCT00956397|Placebo Comparator|FD (Placebo) Participants|
10212248|NCT05223218||Pancreatic Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
10212249|NCT05223218||Colon Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
10212250|NCT05223218||Prostate Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
10213872|NCT02853331|Active Comparator|Sunitinib Monotherapy|Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
9933100|NCT00956410|Experimental|CAD106|
9897935|NCT03006172|Experimental|Stage II Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9897936|NCT03006172|Experimental|Stage II Arm D: Inavolisib + Fulvestrant|Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9897937|NCT03006172|Experimental|Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9897938|NCT03006172|Experimental|Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9897939|NCT03006172|Experimental|Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab|Participants will receive inavolisib in combination with trastuzumab and pertuzumab (Days 1-21). Dose of inavolisib will be determined from the results of Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
9897940|NCT02992522|Experimental|Treatment (lenalidomide, venetoclax, obinutuzumab)|Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9897941|NCT02990338|Active Comparator|Pd (pomalidomide + dexamethasone)|Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).
9897942|NCT02990338|Experimental|IPd (isatuximab + pomalidomide + dexamethasone)|Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants >= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).
9897943|NCT02978612|Experimental|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
9897944|NCT02978612|No Intervention|Arm No treatment|no chemotherapy, observation
9897945|NCT02977884|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
9897946|NCT02975882|Experimental|Treatment (nab-rapamycin, temozolomide, irinotecan)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8 beginning on cycle 1. Patients also receive temozolomide PO and irinotecan hydrochloride PO on days 1-5 beginning on cycle 2. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
9897947|NCT02975310|Experimental|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
9897948|NCT02975310|Active Comparator|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
9897949|NCT02972996|Experimental|Blueberry|22 g freeze-dried blueberries
9897950|NCT02972996|Placebo Comparator|Placebo|22 g placebo
9897951|NCT02968212|Experimental|clofazimine|Participants receive lamprene
9897952|NCT02968212|Placebo Comparator|sugar pill|Participants receive placebo
9897953|NCT02960230|Experimental|Stratum A: Newly Diagnosed DIPG|Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
9897954|NCT02960230|Experimental|Stratum B: Newly Diagnosed Glioma (non-DIPG)|Newly diagnosed children with gliomas other than DIPG who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
9933101|NCT00956423|Experimental|moderate-intensity exercise training|
9933102|NCT00956423|Active Comparator|low-intensity stretching|
9933103|NCT00956436|Experimental|Sorafenib Monotherapy|Sorafenib Monotherapy
9933104|NCT00956436|Experimental|Sorafenib with BIIB022|Sorafenib with BIIB022
9933105|NCT00956449|Experimental|1|
9933106|NCT00956462|Experimental|NSAID|
9933107|NCT00956462|Active Comparator|Steroids|
9933108|NCT00956514|Experimental|Transcranial Magenetic Stimulation|All subjects will be assigned to active, open-label treatment with the NeuroStar TMS System for 6 weeks (30 treatment sessions).
9517559|NCT03305328|Sham Comparator|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
9517560|NCT03305315||Cases|Diseases of the temporomandibular joint
9897955|NCT02960230|Experimental|Stratum C: Newly Diagnosed DIPG or other Midline Glioma|Newly diagnosed children with DIPG or other midline gliomas (excluding primary spinal cord tumors) who are positive for HLA-A2 (02:01) and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Nivolumab will also be given via IV. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks. Nivolumab will continue to be given every 3 weeks throughout all of treatment.
9517561|NCT03305315||Controls|Asymptomatic subjects
9897956|NCT02957032|Experimental|F16IL2 + cytarabine|Patients will be enrolled sequentially in cohorts and treated at different dose levels of F16IL2 and a fixed dose of cytarabine.
9897957|NCT02956798|Experimental|Stereotactic ablative body radiation (SABR)|Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.
9897958|NCT02954991|Experimental|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks
9897959|NCT02954991|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks
9897960|NCT02954991|Experimental|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks
9897961|NCT02947516|Active Comparator|Percutaneous liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol.
9897962|NCT02947516|Experimental|EUS-guided liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication.
9897963|NCT02933970|No Intervention|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
9897964|NCT02933970|Other|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
9897965|NCT02932956|Experimental|GAP T cells + Fludarabine and Cytoxan|GPC3-Car (GAP T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
9897966|NCT02932332|Active Comparator|High-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
9897967|NCT02932332|Active Comparator|Low-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
9897968|NCT02932332|Sham Comparator|High-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
9897969|NCT02932332|Sham Comparator|Low-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
9897970|NCT02919592|Experimental|Primary Breast Augmentation|Participants who meet the requirements for primary breast augmentation (have not had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
9897971|NCT02919592|Experimental|Revision Breast Augmentation|Participants who meet the requirements for revision breast augmentation (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast implants
9897972|NCT02919592|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
9897973|NCT02919592|Experimental|Revision Breast Reconstruction|Participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
9897974|NCT02919592|Active Comparator|Other Aesthetic Surgery|Participants who meet the requirements for other aesthetic surgery procedures, which may not include silicone implants (breast or otherwise)
9897975|NCT02909361||Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
9897976|NCT02905422|No Intervention|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
9897977|NCT02905422|Active Comparator|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
9897978|NCT02901717|Active Comparator|Standard of Care|Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.
9897979|NCT02901717|Experimental|Mino-Lok Therapy (MLT)|Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
9897980|NCT02897908||liver fibrosis and steatosis|measurements of liver fibrosis and steatosis will be obtained using Vibration controlled transient elastography FDA approved device- FibroScan for the purpose of building a data base of potential subjects for future research.
9897981|NCT02897050|Experimental|T+mCX followed by FEC|Docetaxel 75mg/m2, iv, d1 + CTX 50 mg/d, po, d1-d21 + capecitabine 1200mg/m2/d, po, d1-d21 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
9897982|NCT02897050|Active Comparator|T followed by FEC|Docetaxel 100mg/m2, iv, d1 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
9897983|NCT02878850|Experimental|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
9897984|NCT02878850|No Intervention|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
9897985|NCT02877498|Experimental|Adaptive support ventilation|adaptive support ventilation mode during invasive mechanical ventilation
9897986|NCT02877498|Active Comparator|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
9897987|NCT02871297|Experimental|Vortioxetine tablets|Vortioxetine tablets for 26 weeks
9897988|NCT02871297|Experimental|Vortioxetine|Single dose of vortioxetine oral drops (only a subset of patients)
9897989|NCT02865551|Experimental|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
9897990|NCT02865551|Experimental|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
9897991|NCT02864953|Experimental|BIIB093|BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
9897992|NCT02864953|Placebo Comparator|Placebo|Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
9897993|NCT02864576|Experimental|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program, performed 3 days per week, lasting 40 minutes."
9997656|NCT01510899|Experimental|Renal Impaired Subjects Arm|
9897994|NCT02864576|Active Comparator|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Health Promotion:~12 weeks of health promotion sessions, performed 3 days per week, lasting 40 minutes each."
9897995|NCT02863796|Experimental|Single arm|This prospective, multi-center, single arm study is designed to evaluate the safety and feasibility of the WhiteSwell System in the reduction of interstitial fluid overload in patients with acutely decompensated heart failure (ADHF)
9897996|NCT02848092|Experimental|FOCAL+Training|
9897997|NCT02848092|Sham Comparator|Rules of the Road Training|
9897998|NCT02845635||Relapsing Remitting Multiple Sclerosis|Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis.
9897999|NCT02845635||Primary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis.
9898000|NCT02845635||Secondary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis.
9898001|NCT02845635||Control|This who document during the on-boarding process that they do not suffer from multiple sclerosis.
9898002|NCT02845440|Active Comparator|Treatment as Usual (TAU) - Cohort 1|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.Cohort 1 (AD-eligible) comprised participants seen in primary care clinics serving ≥3 enrolled participants.
9898003|NCT02845440|Experimental|AD + CHW - Cohort 1|"Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers."
9898004|NCT02845440|Experimental|AD - Cohort 1|Participant in this arm will have Academic Detailing offered to their primary care clinical staff as described above. Participants who are randomized to this condition will not be offered Community Health Worker support.
10212251|NCT05223218||Melanoma|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
9898005|NCT02845440|Experimental|CHW - Cohort 2|Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers.
9898006|NCT02845440|Active Comparator|Treatment as Usual (TAU) - Cohort 2|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention. Cohort 2 (AD-ineligible) comprised participants whose primary care clinic served ≤2 enrolled participants
9898007|NCT02839850|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty
9898008|NCT02827617||TP53 mutated CLL|
9898009|NCT02821507|Experimental|sirolimus and cyclophosphamide|combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
9898010|NCT02803333||Data Capture Participants|This is a prospective observational cohort study of advanced non-small cell lung cancer patients (stage 3b/4) receiving treatment at the Moffitt Cancer Center (MCC) or The Ohio State Comprehensive Cancer Center (OSUCCC) to assess treatment impact at monthly intervals from baseline to 6 months post-enrollment.
10212252|NCT05223218||Healthy Control|"Individuals aged between 18-100 years who do not currently have a previous diagnosis of any cancer for which they are currently being treated.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
10212253|NCT05223192|Experimental|Intervention group|Participants in this group will receive the ocean disc music therapy entrainment intervention
10212254|NCT05223192|No Intervention|Control group|Participants in this group will not receive any intervention
10212255|NCT05223140||Cases|Admission to NICU or early perinatal death
10212256|NCT05223140||Controls|No admission to NICU or early perinatal death
10212257|NCT05223127|Experimental|Experimental group|The gel will be applied directly to the cesarean section wound sewn by the investigator and dressed with dry gauze. In the control group, dressings of stitched wounds will be done using only dry gauze. Twenty-four hours after the operation, the dressing will be removed by the midwives and the wound healing will be evaluated by the researcher who does not know the experimental and control groups using the REEDA scale. Afterwards, participants will be asked to use the gel once a day for 14 days. The experimental group will be evaluated using the REEDA scale, the McGill Pain Scale, and the SF-36 quality of life scale at the 48th hour, 7th and 14th days after the operation.
10212258|NCT05223127|No Intervention|Control group|It will be evaluated using the REEDA scale, the McGill Pain Scale, and the SF-36 quality of life scale at the 48th hour, 7th, 14th days after the operation.
10212259|NCT05223114||HIV+COPD+|40 male and female adults > 35 years with COPD and HIV
10212260|NCT05223114||HIV+COPD-|40 male and female adults > 35 years with HIV but no COPD
10212261|NCT05223114||HIV-COPD+|40 male and female adults > 35 years with COPD not HIV
10212262|NCT05223114||HIV-COPD-|40 male and female adults > 35 years with no COPD and no HIV
10212263|NCT05223088|Experimental|Tislelizumab combined with apatinib and oxaliplatin plus S1|Neoadjuvant immunotherapy, PD-1, plus apatinib and oxaliplatin plus S1 will be applied to patients with Borrmann IV、large Borrmann III type and Bulky N positive advanced gastric cancer before surgery.
9898011|NCT02786394|Experimental|REACH Participant Course|This study will run twice a week over 6 weeks with 6 REACH sessions optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
9898012|NCT02783274|Other|Actis Total Hip System|The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
9898013|NCT02771353|Active Comparator|WT_vDIBH|Wide tangent radiotherapy in voluntary deep inspiratory breath hold
9898014|NCT02771353|Active Comparator|VMAT_FB|Volumetric modulated arc therapy in free breathing.
9898015|NCT02726763|Experimental|tDCS with cognitive training|We will collect: 1) self-reported demographic information (~5 min) 2) cognitive functioning data (PAOFI) at session 1 and session 4 (~10min) [60]; 3) behavioral data and EEG data from the tDCS stimulation task for each session (downloaded by investigators); 4) patient feedback on their experience with tDCS (tDCS Patient Experience Questionnaire (tPEQ)) for each session (~5 min); 5) tDCS accrual and session completion rates at the completion of treatment and 6) Brunoni Adverse Events Questionnaire (~5 min)
9898016|NCT02726061|Experimental|Internet Based psychological support|The internet-based psychological support intervention (PATH) is an internet based Problem Solving Therapy, stress management training and conflict management training program.
9898017|NCT02724371|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
9898018|NCT02724371|Experimental|Revision Breast Reconstruction|participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
9898019|NCT02720653||Appropriate Medical Therapy|Patients will self-select continued, non-standardized, appropriate medical management of symptoms associated with chronic sinusitis.
9898020|NCT02720653||Endoscopic Sinus Surgery|Patients will self-select endoscopic sinus surgery for symptoms associated with chronic sinusitis.
10212264|NCT05223075|Experimental|articaine group|
10212265|NCT05223075|Experimental|lidocaine group|
10212266|NCT05223049||Psoriatic Arthritis patients with neuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≥4 or PainDETECT score of ≥13.
10212267|NCT05223049||Psoriatic Arthritis patients with nonneuropathic pain|Patients diagnosed with Psa according to The Classification Criteria for Psoriatic Arthritis (CASPAR) psoriatic arthritis criteria. Who has a DN4 score of ≤4 or PainDETECT score of ≤13.
10212268|NCT05223010|Active Comparator|1|39 participant will receive melatonin 0.05 mg/kg
10212269|NCT05223010|Active Comparator|2|39 participant will receive melatonin 0.2 mg/kg
10212270|NCT05223010|Active Comparator|3|39 participant will receive melatonin 0.4 mg/kg
10212271|NCT05222958|Experimental|Experimental:|The intervention consists of using a smoking cessation app. Patients assigned to the intervention group will be given the access code to the Gestobb App and advice on how to use it.
10212272|NCT05222958|No Intervention|No intervention|Patients in the control group will continue their follow-up visits at ASSIR and will be offered smoking cessation treatment following standard practice protocols.
10212273|NCT05222945|Other|Single arm composed by 34 HIV-1 infected male subjects|
10212274|NCT05222932|Experimental|TILT-123 and avelumab|"Patients will receive multiple administrations of TILT-123 and avelumab.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
10212275|NCT05222919|Active Comparator|Bare performance supplement|Dietary supplement
10212276|NCT05222919|Placebo Comparator|Placebo|Placebo
10212277|NCT05222893|Active Comparator|PEEP Pes|PEEP adjustment according to the pressure indicators in the lower third of the esophagus Pes (intervention group)
10212278|NCT05222893|Active Comparator|PEEP 5|PEEP constantly set at 5 cmH2O (control group)
10212279|NCT05222867|Experimental|Intervention|pregnant women undergoing lower back massage
10212280|NCT05222867|No Intervention|control group|pregnant women given routine care
10212281|NCT05222841|Experimental|Spermotrend|
10212282|NCT05222828|Experimental|Mepivacaine arm|mepivacaine injection
10212283|NCT05222815|Experimental|CGM (continuous glucose monitoring)|"Use CGM, with availability of Ambulatory Glucose Profile (AGP) data, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
10212284|NCT05222815|Active Comparator|SMBG (Self-monitoring of blood glucose)|"Use SMBG, as currently used in primary care, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
10212285|NCT05222711|Active Comparator|Monitor used|The device is applied and the GP provides usual care.
10212286|NCT05222711|No Intervention|Usual care|Usual care is provided by the GP.
10212287|NCT05222698|Active Comparator|Group A|Segmental free latissimus muscle trasfer to the face.
10212288|NCT05222698|Active Comparator|Group B|Free gracillis muscle trasfer to the face.
10212289|NCT05222685|Experimental|Intervention Group|Will receive the 6 month online group coaching program from 9/1/2022-3/1/23
10212290|NCT05222685|No Intervention|Control Group|"Control group - no coaching intervention from 9/1/2022-3/1/23.~(They will receive the coaching intervention after study completion from 3/1/23-9/1/23)"
10212291|NCT05222659||Urologic surgery patients|
10212292|NCT05222646|Active Comparator|Metoclopramide group|They will be receiving10mg of Metoclopramide intramuscularly
10212293|NCT05222646|Active Comparator|Hyoscine bromide group|They will be receiving 20 mg of Hyoscine bromide
9898021|NCT02718170|Experimental|Buried Intramedullary K-wire Fixation|Patients randomized to buried intramedullary k-wire fixation will undergo a standardized antegrade open reduction and fixation procedure with an intramedullary k-wire.
9898022|NCT02718170|Active Comparator|Plate and Screw Fixation|Patients randomized to Plate and Screw Fixation will undergo a standardized open reduction and internal fixation with plate and screws. Brand of plate will be left to the operating surgeon's discretion.
9898023|NCT02703922|Other|GCA suspicion|A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.
9898024|NCT02643667|Experimental|Safety Run-In: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
9898025|NCT02643667|Experimental|Phase II: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
9898026|NCT02640664|Experimental|Ranibizumab 0.1 mg|Ranibizumab 0.1 mg
9898027|NCT02640664|Experimental|Ranibizumab 0.2 mg|Ranibizumab 0.2 mg
9898028|NCT02640664|No Intervention|Laser therapy|Laser therapy
9898029|NCT02610179|Active Comparator|Standard Glucola GCT|A prospective cohort of 617 women who will undergo screening for gestational diabetes with the standard glucola GCT between 24 and 28 weeks gestational age.
9898030|NCT02610179|Experimental|Twizzlers challenge|At a later date, the same prospective cohort of 617 women Participants will receive their Twizzlers challenge between 24 and 28 weeks gestational age.
9898031|NCT02607215|Experimental|Vinorelbine Plus DDP|"Vinorelbine:25 mg/m2, D1, D8 every 21 days~DDP:75 mg/m2, D1 every 21 days"
10212294|NCT05222633||Neovascular age-related macular edema|Patients with new-onset and recurrent Neovascular age-related macular edema.
10212295|NCT05222633||Diabetic macula edema|Patients with new-onset and recurrent diabetic macula edema
10212296|NCT05222633||Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy|Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
10212297|NCT05222633||Retinal vein occlusions|Patients with new-onset and recurrent retinal vein occlusions
10212298|NCT05222633||Choroidal neovascularization|Patients with new-onset and recurrent choroidal neovascularization
10212299|NCT05222607||Facial treatment with incobotulinumtoxinA in treatment naïve participants|
10212300|NCT05222594|Other|Epileptic participants undergoing intracranial monitoring|Patients with pharmaco-resistant epilepsy undergoing intracranial monitoring involving the left cerebral hemisphere.
10212301|NCT05222581|Experimental|Prototypes of Breast Shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump
10212302|NCT05222568||BCVmin=0|This study was a prospective observational study, and the patients was divided into two groups with BCVmin=0 or BCVmin >0, according to the BCVmin which was naturally determined during anesthesia in each patient.
10212303|NCT05222568||BCVmin>0|The patients was divided into two groups with BCVmin=0 or BCVmin >0, according to the BCVmin which was naturally determined during anesthesia in each patient.
10212304|NCT05222503|Active Comparator|Control group: Medial off-loader brace and home exercise program|The subject will receive a traditional medial off-loader brace and a take-home, self-guided exercise program. The subject will be instructed how to wear the brace. The subject will be instructed to incrementally increase wear time of the brace in the first week to get accustomed to the brace to reach a minimum of 6 hours per day after the first week.
10212305|NCT05222503|Experimental|2. Intervention group: Medial off-loader brace with OPUM Digital Knee and Remote Patient Monitoring|"The same off-loader brace as above but with the ODK sensor will be provided. The subject will be instructed how to wear the brace and sensor. The patient will be instructed to incrementally increase wear time in the first week to get accustomed to the brace to reach a minimum of 6 hours per day after the first week. Using the sensor they will be able to keep track of their exercise frequency, range of motion (ROM), and kinematics in the OPUM app on their mobile phone. Education/resources will also be provided to the subjects via modules in the mobile app. The subjects will be instructed how to use the app as well.~Patients data will be monitored remotely for 20mins per patient per month in the sensor group. Programs will be updated as necessary based on data."
10212306|NCT05222490|Experimental|Diabetic with Ulcers|Patient with diabetic foot and ulceration diagnosed/confirmed by the study physician on the day of enrollment
10212307|NCT05222490|Experimental|Diabetic without Ulcers|Patient without ulcers diagnosed/confirmed by the study physician on the day of enrollment
10212308|NCT05222490|Active Comparator|Control|Generally Healthy Non-diabetic Subjects
10212309|NCT05222477|Active Comparator|Pelvic floor group|pelvic floor exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
10212310|NCT05222477|Active Comparator|Abdominal group|Abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
10212311|NCT05222451|Experimental|Dietary Guidelines for Americans|7 days of a diet consistent with the Dietary Guidelines for Americans (DGA).
10212312|NCT05222451|Experimental|Medium Chain Triglyceride Supplemented DGA|7 days of a diet consistent with the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
10212313|NCT05222451|Experimental|Ketogenic Diet|7 days of a ketogenic diet (KETO).
10212314|NCT05222438|Experimental|Loncastuximab tesirine|Patients will start loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles). Patients will receive IV infusion of loncastuximab tesirine 150 μg/kg at Q3W for the first 2 cycles followed by 75 μg/kg at Q3W for the remaining 6 cycles.
10212315|NCT05222347||Comparison of biochemical parameters of OLT drinkers|Compared biochemical parameters of OLT smokers and nonsmokers
10212316|NCT05222347||Comparison of biochemical parameters of OLT nondrinkers|Compared biochemical parameters of OLT smokers and nonsmokers
9898032|NCT02607215|Active Comparator|Vinorelbine|Vinorelbine:30 mg/m2, D1, D8 every 21 days
9898033|NCT02605759|Experimental|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation for the treatment of esophageal squamous cell dysplasia
9898034|NCT02604563||Arm A: Clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
9898035|NCT02604563||Arm B: No clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
9898036|NCT02604563||Arm C: No clonal hematopoiesis & no follow-up|"Complete several self-administered health assessments at baseline with no further follow-up~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up~Peripheral blood draw will occur at baseline with no further follow-up~Buccal swabs will occur at baseline with no further follow-up"
9898037|NCT02604563||Arm D: Hip replacement|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Participants with or without clonal hematopoiesis who are undergoing hip replacement~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
9898038|NCT02604563||Arm E: Trauma|-Blood sample at the time of admission with initial bloodwork. For inpatient participants, weekly follow-up samples will be drawn with morning phlebotomy. A follow-up sample collection will occur 4-7 weeks after discharge.
9898039|NCT02589353|Experimental|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
9898040|NCT02588248|Experimental|Peppermint Oil|"Solution A) Peppermint oil solution (1.6% peppermint oil, which is 0.8% L-menthol)~Ingredients:~16mL of peppermint oil (provided by the NowFoods® company)~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~1L prepackage sterile water~2.6mL of undyed simethicone"
9898041|NCT02588248|Placebo Comparator|Placebo|"Solution B) Placebo solution~Ingredients:~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~1L prepackage sterile water~2.6mL of undyed simethicone~Instructions to prepare:~Add tween and simethicone to sterile water. Then, shake vigorously.~Once solution has settled, and patient has been randomized, draw 20mL of solution into a plastic syringe"
10212317|NCT05222334|Experimental|Intrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for intrafascial interscalene brachial plexus block group
10212318|NCT05222334|Experimental|Extrafascial interscalene brachial plexus block group|The patients will receive 10 ml of 0.5% bupivacaine for extrafascial interscalene brachial plexus block group
10212319|NCT05222308|Other|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
10212320|NCT05222295|Experimental|Supervised Pulmonary Telerehabilitation Group|Three times a week for 8 weeks, a supervised and standardized pulmonary rehabilitation program will be applied in the form of telerehabilitation with simultaneous video conference method, accompanied by a specialist physiotherapist, while the patients are at home.
9898042|NCT02584309|Experimental|Arm 1: dexrazoxane & standard of care doxorubicin|"Dexrazoxane will be given intravenously on an outpatient basis over 15 minutes on each day that doxorubicin is given.~Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.~Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.~In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin.."
9898043|NCT02584309|Active Comparator|Arm 2: control (standard of care doxorubicin)|"Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.~The last 10 patients enrolled after completion of enrollment to Arm 1 (dexrazoxane & standard of care doxorubicin) will be enrolled to Arm 2 (control arm - standard of care doxorubicin only)"
10212321|NCT05222295|Experimental|Cognitive Telerehabilitation Group|Motor imagery + action observation methods will be applied. In therapy, a video recording of each exercise in the supervised telerehabilitation group will be sent to the patients by the physiotherapist in accordance with the number of repetitions. At the end of the session, the cognitive telerehabilitation group will be asked to actively do the breathing exercises and active breathing techniques cycle in the supervised telerehabilitation group as well as to imagine with the instructions in the video recording, and commands will be given accordingly.
10212322|NCT05222282|Experimental|Intervention|"Intervention with~nurseled sexual consultations with screening questionnaire prior to consultation~genital examintaion with doctor"
10212323|NCT05222282|Other|Kontrol|Usual care
10212324|NCT05222243|Active Comparator|Calcium Hydroxide (CH)|Calcium Hydroxide is the gold standard for direct pulp capping depends on regeneration
10212325|NCT05222243|Experimental|MTA|Mineral trioxide aggregate used for pulp regeneration
9898044|NCT02576496|Experimental|Tinostamustine (EDO-S101)|EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2
9898045|NCT02572284|Experimental|Dose Escalation of SBRT|Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
9898046|NCT02538861||ARM-A|Arm-A patients will receive the standard of care diagnostic test at Baptist Hospital, which includes SPECT imaging
9898047|NCT02538861||ARM-B (Group-1)|Group-1 will receive CT Angiography and CT myocardial perfusion with new Revolution CT scanner.
9898048|NCT02538861||ARM-B (Group-2)|The Group-2 of arm B will receive SPECT imaging test.
9898049|NCT02535065|Experimental|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
9898050|NCT02523014|Experimental|Arm A (vismodegib)|Patients receive vismodegib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018)
9898051|NCT02523014|Experimental|Arm B (FAK inhibitor GSK2256098)|Patients receive FAK inhibitor GSK2256098 PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017)
9898052|NCT02523014|Experimental|Arm C (capivasertib)|Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity.
9898053|NCT02523014|Experimental|Arm D (abemaciclib)|Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9935674|NCT03372733|Experimental|Group 1|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2weeks and cross-over to the palmitoleate-rich oil
10212326|NCT05222243|Experimental|Formocresol (FC)|composed of formaldehyde, cresol, glycerin and water used for fixation of pulp tissue
10212327|NCT05222230|Experimental|FFP3 Respirator|Participants will wear FFP3 respirators during the study.
10212328|NCT05222204|Experimental|IP|intravenous AG+ IP cisplatin
10212329|NCT05222191|Active Comparator|Spironolactone + Placebo|Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.
10212330|NCT05222191|Experimental|Spironolactone + Chlorthalidone|Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.
10212331|NCT05222178|Experimental|Low Dose Cohort|Low dose of HMI-103 delivered intravenously one time
10212332|NCT05222178|Experimental|Intermediate Dose Cohort|Intermediate dose of HMI-103 delivered intravenously one time
10212333|NCT05222178|Experimental|High Dose Cohort|High Dose of HMI-103 delivered intravenously one time
10212334|NCT05222165|Experimental|Infigratinib (BGJ398)|"Generic name: infigratinib. Dosage forms: 18mg and 25mg sprinkle capsules and 25mg, 75mg, 100mg capsules.~Phase 1b Three dose levels escalation until RP2D is determined.~Phase 2~Pediatric patients: dose defined in the phase 1b (RP2D);~Adults: 125 mg.~Frequency: once daily for 21 days in each 28-day treatment cycle.~Duration: Treatment duration will last up to 26 cycles unless progression, death or unacceptable toxicity occur."
10212335|NCT05222152|Experimental|Chronocort|Chronocort (hydrocortisone modified-release hard capsule) supplied as 5 mg and 10 mg strengths will be administered orally. Chronocort 10 mg will be taken on waking (typically between 06:00 and 08:00 hours) and Chronocort 15 mg will be taken just prior to going to bed (typically between 22:00 hours and midnight).
10212336|NCT05222152|Active Comparator|Plenadren|Plenadren (hydrocortisone modified-release tablet) supplied as 5 mg and 20 mg strengths and administered orally. Plenadren 25 mg will be taken on waking (typically between 06:00 and 08:00 hours).
10212337|NCT05222126|Experimental|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve using 5 cc of 5% dextrose.
10212338|NCT05222126|Active Comparator|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 5 cc normal saline.
10212339|NCT05222126|Experimental|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 10 cc 5% dextrose.
10212340|NCT05222126|Active Comparator|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve from , using 10 cc normal saline.
10212341|NCT05222100||Women without breast implants|Women without breast implants participating in the mammography screening program.
10212342|NCT05222100||Women with breast implants|Women with breast implants participating in the mammography screening program.
10212343|NCT05222087|Active Comparator|Arm 1: SoC systemic therapy|
10212344|NCT05222087|Experimental|Arm 2: radiotherapy to lung primary, delivered before cycle one or cycle two of SoC systemic therapy|
10212345|NCT05222074||CVP ≥ 12|central venous pressure ≥12 mmHg
10212346|NCT05222074||CVP ≥ 16|central venous pressure ≥16 mmHg
10212347|NCT05222074||CVP ≥ 20|central venous pressure ≥20 mmHg
10212348|NCT05222074||MAP ≤ 55 mmHg|mean arterial pressure ≤55 mmHg
10212349|NCT05222074||MAP ≤ 65 mmHg|mean arterial pressure ≤65 mmHg
10212350|NCT05222074||MAP ≤ 75 mmHg|mean arterial pressure ≤75 mmHg
9992263|NCT01460537|Experimental|Treatment A: Gemcitabine-Copanlisib|The treatment consists of repetitive cycles, each over 28 days. Treatment continues until disease progression or dose limiting toxicity. If gemcitabine is discontinued for toxicity, Copanlisib may be continued at the discretion of the Investigator if a clinical benefit (response or stable disease for 3 months) is noted. - Hour 0 to 0.5: Gemcitabine (1000 mg/m2 as 30-minute IV infusion) on Days 1, 8 and 15 every 28 days - Hour 1.5 to 2.5: BAY80-6946 (starting dose = 0.6 mg/kg as 60-minute IV infusion, starting 1 hour post completion of gemcitabine infusion) on Days 1, 8 and 15 every 28 days
9992264|NCT01460537|Experimental|Treatment B: Cisplatin-Gemcitabine-Copanlisib|Treatment consists of repetitive 21 day cycles for a maximum of 8 cycles. Treatment continues until disease progression, DLT or completion of 8 cycles. After 8 cycles, gemcitabine and Copanlisib, without cisplatin, may continue at the discretion of the Investigator until disease progression or DLT if a clinical benefit is noted (response or stable disease for 3 months). Treatment is administered on Days 1 and 8 every 21 days as follows: - Hour 0 to 1: Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 mmol of magnesium sulfate) - Hour 1 to 1.5: IV infusion of 500 ml of 0.9% NaCl over 30 min - Hour 1.5 to 2: Gemcitabine (1000 mg/m2 as 30 min IV infusion) - Hour 3 to 4: Copanlisib IV infusion at the MTD determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one Copanlisib Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
9992265|NCT01460550|Experimental|gastrointestinal reconstruction|
9992266|NCT01460563|Experimental|Mg_orfil|patients preloaded with sodium valproate receives MgSO4 during the craniotomy.
9992267|NCT01460563|Placebo Comparator|control_orfil|patients preloaded with sodium valproate receives 0.9% saline as placebo.
9992268|NCT01460563|Placebo Comparator|control_no orfil|patients not preloaded with sodium valproate receives 0.9% saline as placebo.
9992269|NCT01460589|Experimental|early commencement|Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery
9992270|NCT01460589|Active Comparator|conventional commencement|Individuals who initiate the adjuvant chemotherapy after 14 days after surgery
9992271|NCT01460602|Experimental|Part 1: establish MTD|Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
9992272|NCT01460602|Experimental|Part 2: The MTD from Part 1|During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
9992273|NCT01460641||CT perfusion|
9997657|NCT01510938|Placebo Comparator|Placebo|1 g of rice maltodextrin will be reconstituted in 25-50 ml of tepid water or juice and immediately fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
9997658|NCT01510938|Experimental|Probiotic|"powder of L. acidophilus DDS-1, B. lactis UABLA-12, 50 mg of fructooligosaccharide~1 g of probiotic will be reconstituted in 25-50 ml tepid water or juice and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer."
9997659|NCT01510951|Placebo Comparator|PLACEBO|
9997660|NCT01510951|Experimental|AMG 811|
9997661|NCT01510964|Experimental|prompt-sheet|"Patients and companions of intervention group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and the prompt sheet. An introduction explains the importance of asking questions during the consultations. The patient (companion) is invited to select among a written list of about 50 possible questions those, if any, s/he would like to ask today to the oncology."
9997662|NCT01510964|Other|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
9997663|NCT01510977|Active Comparator|PEG|2L of polyethylene glycol addition immediately after first colonoscopy failure
9997664|NCT01510977|Experimental|PEG + bisacodyl|One week after initial colonoscopy failure, conventional amount (5L) of polyethylene glycol together with bisacodyl administration
9997665|NCT01510990|Experimental|Gefitinib|"After a baseline 18F FDG-PET, patients are treated with gefitinib 250mg/d as 1st line treatment for 7 days. And follow up 18F-FDG PET image is acquired after 1 week's treatment of gefitinib (with window period +/- 2 days).~If % decrease of peak SUV of main lesion is 20% or more, gefitinib treatment is continued till progression, unacceptable toxicities or patient's refusal. But if % decrease of peak SUV of main lesion less than 20% or peak SUV increase, gefitinib treatment is stopped, and changed to Pemetrexed/Cisplatin chemotherapy."
9997666|NCT01511003|Experimental|Tacrolimus group|oral
9997667|NCT01511029|Experimental|Dexpramipexole|
9997668|NCT01511029|Placebo Comparator|Dexpramipexole (placebo)|
10212351|NCT05222061|Active Comparator|provisional-stenting group|Provisional stenting will be performed according to european bifurcation club consensus. MB and SB predilatation will be at the operator's discretion. A stent is delivered in the main vessel and positioned across the bifurcation. POT is mandatotary. In case of dissection impeding the flow in the SB or acute coronary closure after MB atenting a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus.
10212352|NCT05222061|Experimental|DCB group|"Coronary guidewires should be passed to the MB and SB, respectively. Lesion preparation of the main branch should be undertaken as considered necessary. Lesion preparation of the side branch is mandatorary. If the angiographic result will be good after predilatation (residual stenosis < 30%), drug-eluting stent will implanted in the main branch of the bifurcation site (the stent diameter should be choosen based on the diameter of the distal MB). A kissing with conventional balloons should be performed in the MB and SB. Reapet kissing with drug-coated balloonin the SB and conventional balloon in MB (30 seconds at low pressure (8-10 bar) should be performed. The DCB diameter was again 0.8-1.0 of the vessel diameter.~In case of dissection impeding the flow in the SB or acute coronary closure after DCB application a SB stenting using a DES was allowed. Dual-stent techniques will be performed according to the recommendation of the EBC consensus."
10212353|NCT05222035|Experimental|G-CSF+Camrelizumab|
10212354|NCT05222035|Active Comparator|Camrelizumab|
9997669|NCT01511029|Active Comparator|Moxifloxacin|
9997670|NCT01511094|Experimental|Eye Surgery|Goniocurettage was used to treat open angle glaucoma patients
9992274|NCT01460654|Placebo Comparator|Testosterone and Placebo Alendronate|
9992275|NCT01460654|Placebo Comparator|Alendronate and Placebo Testosterone|
9992276|NCT01460654|Experimental|Testosterone and Alendronate|
9992277|NCT01460667|Active Comparator|IV acetaminophen|
9992278|NCT01460667|Placebo Comparator|IV 0.9% normal saline|
9992279|NCT01460680||Fibromyalgia patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR 1990 criteria
9992280|NCT01460680||SLE patients|Patients diagnosed as suffering from Systemic Lupus Erythematosus by the ACR criteria
9992281|NCT01460680||Healthy controls|Healthy controls
9992282|NCT01460693|Active Comparator|Arm A - Imatinib|Imatinib 400mg daily
9992283|NCT01460693|Experimental|Arm B - Dasatinib|Dasatinib 100mg daily
9992284|NCT01460706|Experimental|68Ga-DOTATOC|
9992285|NCT01460758|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
9992286|NCT01460758|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
9992287|NCT01460758|Sham Comparator|Placebo Stimulation|Sham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
9992288|NCT01460771|Experimental|Treatment|Active Transcranial Direct Current Stimulation (TDCS) at 1mA or highest tolerated current
9992289|NCT01460771|Sham Comparator|sham|inactive Transcranial Direct current stimulation (TDCS) at 0mA
9992290|NCT01460784||N=60|Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
9992291|NCT01460784||N=600|Cross-sectional study of patients undergoing clinical PET/CT to identify active brown fat. No intervention. Enrolled 405 participants.
9992292|NCT01460784||N=220|Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
9992293|NCT01460797|Other|High Glycemic Index|Hypocaloric diet with predominating high glycemic index foods
9992294|NCT01460797|Other|Low Glycemic Index|Hypocaloric diet with predominant low glycemic index foods
9992295|NCT01460797|Other|Low Glycemic Index plus Metformin|Hypocaloric diet with predominant low glycemic index foods plus Metformin (1g/d)
9992296|NCT01460823|Experimental|Use of image guided surgery|
9992297|NCT01460836||Tobramycin Solution|
9992298|NCT01460836||Aztreonam lysine|
9992299|NCT01460888|Experimental|OLA-0 (de-escalation dose)|25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
9992300|NCT01460888|Experimental|OLA-1|50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
9992301|NCT01460888|Experimental|OLA-2|100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
9992302|NCT01460888|Experimental|OLA-3|200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
9992303|NCT01460888|Active Comparator|RT alone|
9992304|NCT01460953|Experimental|training intervention|Students participating in didactic training
9992305|NCT01460966|Active Comparator|Filtrap™+ Thrombus aspiration catheter|
9992306|NCT01460966|Active Comparator|Thrombus aspiration catheter|
9992307|NCT01460979|Experimental|Temsirolimus|
9992308|NCT01460992||Pacemaker therapy|Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.
9992309|NCT01461018|Experimental|IgPro20|
9992310|NCT01461070||Breast Cancer Cases|Breast Cancer Cases
9992311|NCT01461070||Controls|Controls
9992312|NCT01461083|Experimental|Assess [18F]MPPF and PET imaging|To assess [18F]MPPF and PET imaging
9992313|NCT01461109|Experimental|Assess [18F] CFPyPB and PET imaging|To assess [18F]CFPyPB and PET imaging
9992314|NCT01461148|Experimental|FSP peptides|Vaccination with three FSP peptides
9992315|NCT01461161|Experimental|20 mg bardoxolone methyl|
9992316|NCT01461161|Experimental|60 mg bardoxolone methyl|
9992317|NCT01461161|Experimental|80 mg bardoxolone methyl|
9992318|NCT01461174|Experimental|Modafinil|200 mg tablet, single dose
9992319|NCT01461174|Experimental|Donepezil|5 mg tablet one per day, 15 days
9992320|NCT01461174|Experimental|Memantine|10 mg tablet one per day, 15 days
9992321|NCT01461187|Experimental|exercise in pregnancy|37 pregnant women who performed supervised aerobic physical exercises twice a week
9992322|NCT01461187|No Intervention|Control group|29 pregnant women who had not performed any kind of physical activity during pregnancy
9992323|NCT01461200||Non allergics|
9992324|NCT01461200||allergics|
9992325|NCT01461213|Experimental|Dose 1|Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
9992326|NCT01461213|Experimental|Dose 2|Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
9992327|NCT01461226|Experimental|Exercise training|
9992328|NCT01461226|Other|Usual Care|
9992329|NCT01461239|Active Comparator|cast post and core|
9992330|NCT01461239|Experimental|fiber post - self-adhesive cement|
9992331|NCT01461239|Experimental|fiber post - conventional cement|
9992332|NCT01461252|Other|Cryoablation combined with radiation|All subjects will have cryoablation combined with radiation on one or two painful metastatic bone tumors.
9992333|NCT01461265|Other|Cryoablation|All subjects will have cryoablation on one or two painful metastatic bone tumors.
9992334|NCT01461278|Experimental|Cataract surgery plus iStent supra|
9992335|NCT01461278|Active Comparator|Cataract surgery|
9992336|NCT01461291|Experimental|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
9992337|NCT01461291|Active Comparator|Cataract surgery|Cataract surgery alone
9992338|NCT01461330|Experimental|DASH diet|DASH DIET + EXERCISE
9992339|NCT01461330|Active Comparator|ADA DIET|DIET ACCORDING AMERICAN DIABETES ASSOCIATION DIETARY RECOMMENDATIONS FOR DIABETES
9992340|NCT01461343|Experimental|pulmonary hypertension|Patients with Group I pulmonary arterial hypertension and exercise-induced pulmonary hypertension to undergo CT imaging, functional PET imaging
9992341|NCT01461343|Active Comparator|healthy controls|healthy adults to serve as controls and to undergo the same study procedures: CT imaging, functional PET imaging
9992342|NCT01461356|Experimental|Minimally Invasive Surgical approach|Minimally invasive surgical approach for total knee replacement.
9992343|NCT01461356|Active Comparator|Medial Parapatellar surgical approach|Standard medial parapateller surgical approach for total knee replacement.
9992344|NCT01461382|Experimental|Phase I|Entered Study May 2008.
9992345|NCT01461382|Experimental|Phase II|Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
9992346|NCT01461408|Experimental|Beauty Salon #1b|Females ages 18-26
9992347|NCT01461408|Experimental|Beauty Salon #1a|Mothers of 9-18 year old females
9992348|NCT01461408|Experimental|Beauty Salon #2b|Females ages 18-26
9992349|NCT01461408|Experimental|Beauty Salon #3a|Mothers of 9-18 year old females
9992350|NCT01461408|Experimental|Beauty Salon #3b|Females ages 18-26
9992351|NCT01461408|Experimental|Beauty Salon #4a|Mothers of 9-18 year old females
9992352|NCT01461408|Experimental|Beauty Salon #4b|Females ages 18-26
9992353|NCT01461408|Experimental|Beauty Salon #2a|Mothers of 9-18 year old females
9992354|NCT01461408|Experimental|Beauty Salon #5a|Mothers of 9-18 year old females
9992355|NCT01461408|Experimental|Beauty Salon #5b|Females ages 9-26
9992356|NCT01461408|Experimental|Beauty Salon #6a|Mothers of 9-18 year old females
9992357|NCT01461408|Experimental|Beauty Salon #6b|Females ages 18-26
9992358|NCT01461408|Experimental|Beauty Salon #7a|Mothers of 9-18 year old females
9992359|NCT01461408|Experimental|Beauty Salon #7b|Females ages 18-26
9992360|NCT01461408|Experimental|Beauty Salon #8a|Mothers of 9-18 year old females
9992361|NCT01461408|Experimental|Beauty Salon #8b|Females ages 9-18
9992362|NCT01461421|Active Comparator|Standard Behavioral Treatment|Nutrition education, behavioral weight loss techniques, and standard cognitive strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
9992363|NCT01461421|Experimental|Acceptance Based Behavioral Intervention|Nutrition education, behavioral weight loss techniques, and acceptance based strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
9992364|NCT01461434|Experimental|loop recorder|patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
9992365|NCT01461434|No Intervention|regular follow-up|patients will receive regular follow-ups with standard ECG
9992366|NCT01461447|Experimental|MVA|Volunteers who were primed with 3 HIVIS DNA and further boosted with 2 MVA vaccine will receive a third MVA there shall not be an comparator for this study.
9992367|NCT01461460|Active Comparator|Moxifloxacin 400 mg|
9992368|NCT01461460|Experimental|TR-701 FA 1200 mg|
9992369|NCT01461460|Experimental|TR-701 FA 200 mg plus Placebo|
9992370|NCT01461460|Placebo Comparator|Placebo|
9992371|NCT01461486|Active Comparator|Continuous Positive Airway Pressure|Intervention group
9992372|NCT01461486|Active Comparator|Oral Appliance (BRD)|Intervention group
9992373|NCT01461486|No Intervention|Hygiene sleep care|Control group
9992374|NCT01461512|Placebo Comparator|Placebo|
9992375|NCT01461512|Experimental|Heme arginate treatment|
9992376|NCT01461525|Experimental|Sphincter preservation surgery|Temporary ileostomy with anal sphincter preservation
9992377|NCT01461525|Experimental|Abdominoperineal Resection|Permanent colostomy with total anal sphincter sacrifice
9992378|NCT01461564|Experimental|Carbon dioxide|Patients insufflated with carbon dioxide during screening colonoscopy
9992379|NCT01461564|Active Comparator|Air|Patients insufflated with air during screening colonoscopy
9992380|NCT01461577|Experimental|insulin glargine|Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day. Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
9992381|NCT01461590|Active Comparator|20ml/kg of whole blood transfusion|Standard care recommended by WHO
9992382|NCT01461590|Experimental|30ml/kg of whole blood|Higher volume than currently recommended
9992383|NCT01461603|Active Comparator|Amino acids|Amino acids compared to saline
9992384|NCT01461603|Active Comparator|3hydroxybutyrat (3OHB)|Ketone body, 3OHB compared to saline
9992385|NCT01461616|Experimental|NPH insulin injection|NPH insulin will be injected in random order in one of three seperated visit days.
9992386|NCT01461616|Experimental|detemir insulin injection|insulin detemir will be injected in random order in one of three seperated visit days.
9992387|NCT01461616|Experimental|glargine insulin injection|insulin glargine will be injected in random order in one of three seperated visit days.
9992388|NCT01461629||heart failure|left systolic heart failure (EF </= 40%)
9992389|NCT01461642|Experimental|Asthma - ICT support.|
9992390|NCT01461642|No Intervention|Asthma, comparator - no ICT support|
9992391|NCT01461681|Experimental|Symptom Management Service for heart failure|Subjects randomized to the SMS-HF group will receive a comprehensive PC consultation by the interdisciplinary PC team at each site consisting of a nurse practitioner, physician, social worker and chaplain with 6 months of follow up. All members of the PC team are experienced PC clinicians. The SMS-HF intervention is based on National Quality Forum preferred practices and the National Consensus Project guidelines for quality PC. The SMS-HF will include assessment and management of symptoms, particularly focused on depression, pain and dyspnea, and a discussion of goals of care.
9992392|NCT01461681|No Intervention|Usual cardiology care|The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
9992393|NCT01461694|Active Comparator|IPL|Half face treated with IPL
9992394|NCT01461694|Active Comparator|Alexandrite Laser|Half face treated with Alexandrite Laser
9992395|NCT01461720|Other|Standard medical care|This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
9992396|NCT01461720|Experimental|BM-MSCs|Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
9992397|NCT01461746|Experimental|Chemotherpay and radiation therapy|Docetaxel plus cisplatin followed by radiation therapy
9992398|NCT01461759|Experimental|Chemotherapy|Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
9992399|NCT01461772|Experimental|CCRT weekly carboplatin|Concurrent chemoradiation therapy with weekly carboplatin
9992400|NCT01461772|Active Comparator|CCRT weekly cisplatin|Concurrent chemoradiation therapy with weekly cisplatin
9992401|NCT01461785|Experimental|GROUP A: PRP +|Group A (16 subjects) will receive lipofilling enriched with 3 ml of autologous PRP ( Platelet rich plasma) with lipofilling
9992402|NCT01461785|Placebo Comparator|GROUP B: PRP -|Group B ( 16 subjects) will receive lipofilling without addition PRP. 27 ml blood will be drawn from the patient, but will be discarded, and not turned into PRP.
9992403|NCT01461798|Experimental|Benecol|In 2009, the dairy Cooperative Colanta Launches Benecol ® yogurt, a product with optimal daily dose of plant stanol, each portion of 100 g containing 3.4 g of Benecol ®, corresponding to 2 g of plant stanol esters . Skim yogurt with Benecol ® is a product made from pasteurized skim milk, sweetened with sucralose homogenized and fermented by the action of specific lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32).
9992404|NCT01461798|Placebo Comparator|yogurt|Yogurt without plant stanols
9992405|NCT01461837|Experimental|Haplo Stem Cell Transplantation|CD34 selected T-cell depleted allogeneic SCT
9992406|NCT01461850|Active Comparator|Primary debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted to an attempt of primary debulking surgery in order to obtain RT < 1 cm, followed by adjuvant chemotherapy.
9992407|NCT01461850|Experimental|Interval debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted only to diagnostic laparoscopy followed by neoadjuvant chemotherapy and subsequent Interval Debulking Surgery, followed by further cycles of chemotherapy.
9992408|NCT01461876||HIV-infected cohort|
9992409|NCT01461876||HIV-uninfected control group|
9992410|NCT01461889|Experimental|High INR|Transfuse plasma to High INR target. Plasma will be transfused to reach a target INR=2.5 for 48 hours while patient is actively bleeding.
9992411|NCT01461889|Active Comparator|Low INR|Transfuse plasma to Low INR target. Plasma will be transfused to reach a target INR=1.8 for 48 hours while patient is actively bleeding.
9992412|NCT01461902||Pediatric Traumatic Brain Injury|Children from 5 days to 15 years of age who have been admitted to the hospital with a traumatic brain injury.
9992413|NCT01461941|Experimental|Drug: 0.2% E6005 ointment|
9992414|NCT01461941|Placebo Comparator|Drug: 0.0% E6005 ointment (vehicle)|
9992415|NCT01461967|Experimental|Part 1a|
9992416|NCT01461967|Placebo Comparator|Part 1b|
9992417|NCT01461967|Experimental|Part 2|
9992418|NCT01462006|Experimental|Sirolimus|
9992419|NCT01462006|Placebo Comparator|Placebo|
9992420|NCT01462019|No Intervention|Control|
9992421|NCT01462019|Experimental|Photobiomodulation|
9992422|NCT01462032|Experimental|Cognitive enhancing games|Children will be introduced to specific games believed to enhance cognitive functioning. Parent will be encouraged to play these games with their children.
9992423|NCT01462032|Active Comparator|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
9992424|NCT01462058|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 12 weeks.
9992425|NCT01462058|Placebo Comparator|placebo|one tablet of sugar pill per day for 12 weeks.
9992426|NCT01462071||Chronic kidney disease|
10212355|NCT05222009|Experimental|G-CSF arm1|PD-1 inhibitor resistance regimen+ G-CSF 3mg
10212356|NCT05222009|Experimental|G-CSF arm2|PD-1 inhibitor resistance regimen+ G-CSF 6mg
10212357|NCT05221970|Other|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|MBCT uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
10212358|NCT05221970|Other|Positive Psychology - online|Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
10212359|NCT05221970|Other|Autogenic Training - online|Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
9992427|NCT01462123||small polyps patients|Patients with one small polyps at colonoscopy
9992428|NCT01462136|Experimental|ACHN-490 Injection|
9992429|NCT01462149|Experimental|Chemotherapy|Neoadjuvant chemotherapy with docetaxel plus carboplatin
9992430|NCT01462175|Experimental|Schedule A: RO5503781 QW|Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.
9992431|NCT01462175|Experimental|Schedule B: RO5503781 QD|Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.
9992432|NCT01462188|Active Comparator|Immediate stenting|Patients being randomized to the immediate stenting arm will be managed according to the guidelines. Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting. In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
9992433|NCT01462188|Experimental|Delayed stenting|"Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion.~In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy."
10212360|NCT05221970|No Intervention|Waiting list|No intervention.
10212361|NCT05221957|Experimental|Iron(III)isomaltoside 1000|Anemic patients receiving treatment with iron(III)isomaltoside
10212362|NCT05221957|No Intervention|Historical comparison|Anemic patients without receiving treatment prior to surgery. Historical comparison.
10212363|NCT05221957|No Intervention|Concurrent comparison|Non-anemic patients not receiving treatment with iron(III)isomaltoside prior to surgery
10212364|NCT05221905|Active Comparator|Acute High-Intensity Exercise|Subjects will exercise at an intensity of 75% of the difference between the lactate threshold and VO2peak until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
10212365|NCT05221905|Active Comparator|Acute Moderate-Intensity Exercise|Subjects will exercise at an intensity at the lactate threshold until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
9992434|NCT01462201|Experimental|Group 1 - Non Invasive Ultrasound|Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
9997671|NCT01511120|Active Comparator|Tetraspan|
9997672|NCT01511133||HRV Group|Subjects received two or three doses of HRV in previous studies.
10212366|NCT05221905|Placebo Comparator|Non-Exercise Control|Measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, without exercise taking place during time points 0-60 min.
10212367|NCT05221892|Experimental|Test combination|Gamma-aminobutyric acid tartrate 100mg, glutamic acid 100mg, dibasic calcium phosphate 50mg, thiamine nitrate 25mg, pyridoxine hydrochloride 10mg and cyanocobalamin 5mcg
10212368|NCT05221892|Active Comparator|Comparative medication|Ginger extract 160mg (8mg gingerols)
10212369|NCT05221879|No Intervention|Patients with target factor 10a levels|Patients with target factor 10a levels continued to recieve the standard Enoxaparin dose of 40 mg SC daily.
9898054|NCT02521493|Experimental|Arm A (standard risk)|"INDUCTION II: Patients receive cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV over 1-15 minutes, and thioguanine PO BID on days 1-4. Induction II continues for a minimum of 28 days.~INDUCTION III: Patients receive cytarabine, daunorubicin hydrochloride, and thioguanine as in Induction II. Induction III continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 60-120 minutes on days 1-3. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive cytarabine and etoposide as in Intensification I. Intensification II continues for a minimum of 28 days.~(This arm is closed to accrual and treatment with amendment #4A 01/07/2019)"
9898055|NCT02521493|Experimental|Arm B (high risk)|"INDUCTION II: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours on days 1-4 and mitoxantrone hydrochloride IV over 15-30 minutes on days 3-6. Induction II continues for a minimum of 28 days.~INTENSIFICATION I: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours and etoposide IV over 90-120 minutes on days 1-5. Intensification I continues for a minimum of 28 days.~INTENSIFICATION II: Patients receive high dose cytarabine IV over 3 hours Q12 hours on days 1, 2, 8, and 9. Patients also receive asparaginase or asparaginase Erwinia chrysanthemi IM or IV over 30 minutes on days 2 and 9. Intensification II continues for a minimum of 28 days."
9898056|NCT02512926|Experimental|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide
9898057|NCT02512497|Experimental|Romidepsin + Busulfan + Fludarabine + Stem Cell Transplant|"Part 1:~Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the optimal dose. Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1. Stem cell infusion on Day 0.~Romidepsin Maintenance Therapy - Part 2:~Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
9898058|NCT02510885|Experimental|SD-OCT Angiography|Study participants will undergo imaging of both eyes with the AngioVue unit (approximately 60 seconds/eye), per standard operating protocol. Imaging is noncontact, and pharmacologic dilation will not be used for the purposes of this study. In most instances, study participants will undergo only a single imaging session on a single day. However, potential participants will be asked to consent for additional imaging sessions (up to 12) that may occur over the course of subsequent future visits to the clinic. Additionally, study participants will be asked to consent to prospective collection of clinical and demographic data, to correlate findings of OCT-A imaging to subsequent clinical course.
9898059|NCT02500316|Experimental|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
9898060|NCT02462239|Experimental|Whole-body FDG PET-CT|Whole-body FDG PET-CT (Experimental arm)
9898061|NCT02462239|No Intervention|No PET-CT|No PET-CT (Control arm)
10212370|NCT05221879|Other|Patients with sub-therapuetic factor 10a levels|In patients with sub-therapuetic factor 10a levels we increased the Enoxaparin dose to 60 mg SC daily.
10212371|NCT05221827||MIBC|Patients with clinically and pathologically confirmed diagnosis of MIBC stage II-IIIA, planned to undergo RC.
10212372|NCT05221801|Active Comparator|angle 5 + 1ml water|The measurement would be done in seat inclination angles of 5 degrees with 1 ml water intake.
10212373|NCT05221801|Active Comparator|angle 5 + 5 ml water|The measurement would be done in seat inclination angles of 5 degrees with 5 ml water intake.
10212374|NCT05221801|Active Comparator|angle 5 + 5 ml pudding|The measurement would be done in seat inclination angles of 5 degrees with 5 ml pudding intake.
10212375|NCT05221801|Active Comparator|angle 15 + 1ml water|The measurement would be done in seat inclination angles of 15 degrees with 1 ml water intake.
10212376|NCT05221801|Active Comparator|angle 15 + 5 ml water|The measurement would be done in seat inclination angles of 15 degrees with 5 ml water intake.
10212377|NCT05221801|Active Comparator|angle 15 + 5 ml pudding|The measurement would be done in seat inclination angles of 15 degrees with 5 ml pudding intake.
10212378|NCT05221801|Active Comparator|angle 30 + 1ml water|The measurement would be done in seat inclination angles of 30 degrees with 1 ml water intake.
10212379|NCT05221801|Active Comparator|angle 30 + 5 ml water|The measurement would be done in seat inclination angles of 30 degrees with 5 ml water intake.
10212380|NCT05221801|Active Comparator|angle 30 + 5 ml pudding|The measurement would be done in seat inclination angles of 30 degrees with 5 ml pudding intake.
10212381|NCT05221801|Active Comparator|angle 45 + 1ml water|The measurement would be done in seat inclination angles of 45 degrees with 1 ml water intake.
10212382|NCT05221801|Active Comparator|angle 45 + 5 ml water|The measurement would be done in seat inclination angles of 45 degrees with 5 ml water intake.
10212383|NCT05221801|Active Comparator|angle 45 + 5 ml pudding|The measurement would be done in seat inclination angles of 45 degrees with 5 ml pudding intake.
10212384|NCT05221788|Experimental|GDHT(goal-directed hemodynamic therapy)|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If stroke volume (SV) increased >10%, 200 ml of electrolyte solution was continued until SV increased <10%. After fluid shock, if SV increases <10% but MAP <65 mmHg and/or cardiac index (CI) <2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output <0.5 ml /kg/h and/or heart rate (HR) more than 20% above baseline), plasma was administered until urine output and/or heart rate returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
10212385|NCT05221788|No Intervention|control|Continuous infusion of compounded sodium lactate 5-7 ml/kg/h was allowed to receive colloidal solution, norepinephrine and dobutamine at the discretion of the anesthesiologist.
10212386|NCT05221775|Experimental|experimental arm|
9898062|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months|Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.
9898063|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years|Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.
9898064|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years|Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.
9898065|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 4: >=18 Years|Participants aged >=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.
9898066|NCT02441322|Experimental|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
9898067|NCT02421276|Other|Persons without Down syndrome|White blood cell analysis from persons without Down syndrome assessed by absence of trisomy 21.
9898068|NCT02421276|Other|Persons with Down syndrome|White blood cell analysis from persons with Down syndrome assessed by presence of trisomy 21.
9898069|NCT02414269|Experimental|modified T cells alone (without chemotherapy)|Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
9898070|NCT02414269|Experimental|modified T cells with cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2) , 2 - 7 (Day (-7) -(-2) days before T cell infusion. On Day 1 , patients will be admitted to the MSKCC Inpatient Service (if not already inpatients) for intravenous hydration, clinical monitoring, and blood work for immune monitoring. Standard MSKCC antiemetic therapy will be administered prior to chemotherapy to prevent nausea/vomiting. Administration of corticosteroids will be avoided as steroids may impede the efficacy of CAR T cells.
9898071|NCT02414269|Experimental|CAR T cell and pembrolizumab|Pembrolizumab 4 weeks (+3/-1 week window) after completing CAR T cell administration. Patients will receive 3 doses of pembrolizumab given on a recurring schedule followed by reassessment. Those responding or deriving clinical benefit, without unacceptable toxicity, will continue pembrolizumab. Patients will be followed weekly for the first four weeks. Patients in cohorts 9 and in Phase II will receive pembrolizumab 4 weeks(+3/- 1 week window) following CAR T cell administration.
9898072|NCT02403310|Experimental|Dose Escalation - Selinexor|"Dose escalation of selinexor with fixed doses of daunorubicin and cytarabine.~Induction Therapy may be followed by Consolidation Phase and Maintenance Phase as outlined in the Detailed Description and Intervention Descriptions."
9933109|NCT00956527|Experimental|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
9933110|NCT00956553|Active Comparator|Cervarix|Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
9933111|NCT00956553|Active Comparator|Gardasil|Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
9933112|NCT00956566|Active Comparator|low fat hypocaloric diet|
9933113|NCT00956566|Active Comparator|Low carbohydrate hypocaloric diet|
9933114|NCT00956579||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study"
9933115|NCT00956579||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
9933116|NCT00956605|Experimental|EEG biofeedback intervention|
9933117|NCT00956605|Active Comparator|Non EEG biofeedback computerized attention training|
9933118|NCT00956605|No Intervention|waitlist control|
9933119|NCT00956644|Experimental|irbesartan/amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks
9997673|NCT01511133||Placebo Group|Subjects received two or three doses of placebo in previous studies.
9898073|NCT02398734|Experimental|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
9898074|NCT02398734|Sham Comparator|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
9898075|NCT02389036|No Intervention|Control group- standard care|Standard care- In Australia there are no national guidelines so local policy is determined by each ICU. We are recommending (but not mandating) that control and SDD group management be in line with these national guidelines. We will recommend control and SDD group management is in line with current national standards of practice that may or may not include a VAP bundle. We will monitor record data regarding the nature and delivery of the control and SDD group co-interventions.
9898076|NCT02389036|Experimental|SDD intervention group|"The intervention will entail:~A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx~A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube~A four-day course of an IV antibiotic. Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ dysfunction. Ciprofloxacin (400mg 12-hourly) may be used as an alternative if there is a contraindication to cephalosporins (e.g. allergy). Patients already receiving an alternative IV antibiotic to treat infection will not receive this additional IV antibiotic, but will continue the prescribed antibiotic for the usual duration of therapy."
9898077|NCT02375204|Other|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.~Cycles 1-4 (1 cycle = 21 days)~paclitaxel 250 mg/m^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 1500 mg/m^2 IV daily on Days 2-5 with mesna protection as defined in the protocol~cisplatin 25 mg/m^2 IV daily on Days 2-5~pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
9898078|NCT02375204|Other|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.~Cycles 1-2 (1 cycle = 14 days)~paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 2000 mg/m^2 IV daily on Days 1-3 with mesna protection as defined in the protocol~G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)~leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1~Cycles 3-5 (1 cycle = 21 days)~carboplatin daily on Days 1-3~etoposide 400 mg/m^2 daily on Days 1-3~stem cell reinfusion on day 5~pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
9898079|NCT02359565|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 34 cycles in the absence of disease progression or unacceptable toxicity.
9898080|NCT02349906|Experimental|Treosulfan|"One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.~The dose has to be calculated as follows:~If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.~If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.~If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day."
9898081|NCT02349906|Active Comparator|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
9898082|NCT02341911|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
9898083|NCT02341911|Active Comparator|Gemcitabine,carboplatin|GC (gemcitabine and carboplatin combination)
9898084|NCT02336750|Experimental|treatment group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4
9898085|NCT02336750|Experimental|control group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3
9898086|NCT02319291||Participants|P.F.C. Sigma PS150 RP Total Knee System
10212387|NCT05221749|Active Comparator|Silver diamine fluoride|These active caries lesions will receive silver diamine fluoride treatment
10212388|NCT05221749|Experimental|Nanosilver fluoride|These active caries lesions will receive nanosilver fluoride treatment
10212389|NCT05221736|Experimental|Warthin tumor in parotid tumor|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) & surgical excision in management of warthin tumor of parotid gland.
10212390|NCT05221710|No Intervention|Acupuncture Group|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling)"
10212391|NCT05221710|Experimental|Electroacupuncture Group|On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation
10212392|NCT05221710|No Intervention|Neuromuscular Electrical Stimulation Group|Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points
9898087|NCT02310217||1|Hypertensive
9898088|NCT02310217||2|Normotensive
9898089|NCT02268175|Experimental|ARM 1|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle~Enzalutamide- Once daily at prespecified dose, orally~Abiraterone Acetate- Once daily at prespecified dose, orally~Prednisone-Once daily at prespecified dose, orally~Leuprolide Acetate-Intermuscular injection at prespecified dose and duration"
9898090|NCT02268175|Experimental|ARM 2|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle.~Enzalutamide- once daily at prespecified dose, orally~Leuprolide Acetate- Intermuscular injection at prespecified dose and duration"
9898091|NCT02221427|Active Comparator|Static labour progression curve (F)|Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
9898092|NCT02221427|Experimental|Dynamic progression curve (Z)|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
9898093|NCT02207647||Patients with syndromes requiring lumbar puncture|
9898094|NCT02204072|Experimental|BI 836845 & Enzalutamide|
9898095|NCT02204072|Active Comparator|Enzalutamide|
9898096|NCT02192502|Experimental|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
9898097|NCT02192502|Active Comparator|human albumin 5%|human albumin 5% during surgery
10212393|NCT05221671|No Intervention|not received information leaflet|"During the preoperative anesthesia clinic examination, demographic data will be recorded and routine information about anesthesia will be provided. However, the information leaflet will not be handed to the patient and parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
10212394|NCT05221671|Active Comparator|received information leaflet|"During the preoperative anesthesia evaluation, the children and their parents, who are included in the group who will receive information leaflets according to randomization, will be given information leaflets and both the child and their parents will be asked to read them before the procedure day. Age-appropriate brochures will be provided for children, and parent information leaflets will be provided for parents.~The m-YPAS scale for pediatric patients will be evaluated and filled by the investigators before the anesthesia induction. Parents will be asked to fill out questionnaires for anxiety assessment and anesthesia knowledge level in the waiting room before the procedure."
10212395|NCT05221645|Active Comparator|Control Arm A|"Patients will receive three cycles of R-ICE. Each cycle is 21 days +/- 3 days Rituximab 375mg/m2 Ifosfamide 5,000mg/m2 Carboplatin AUC = 5 (max dose 800mg) Etoposide 100mg/m2~All patients who are deemed to be in CR or PR on the post treatment PET-CT scan will undergo autologous stem cell transplant (ASCT) within 4 weeks of completing R-ICE treatment. BEAM (carmustine, etoposide, cytarabine and melphalan) conditioning will be employed according to institutional protocol."
10212396|NCT05221645|Experimental|Experimental Arm B|"Pembrolizumab 200mg Rituximab 375mg/m2 Ifosfamide 5,000mg/m2 Carboplatin AUC = 5 (max dose 800mg) Etoposide 100mg/m2 Patients will receive up to 3 cycles of: P+R-ICE, where each cycle is 21 days long +/-_3 days.~All patients who are deemed to be in CR or PR on the post treatment PET-CT scan will undergo autologous stem cell transplant (ASCT) within 4 weeks of completing P+R-ICE treatment. BEAM (carmustine, etoposide, cytarabine and melphalan) conditioning will be employed according to institutional protocol.~These patients will then be offered maintenance pembrolizumab every 3 weeks for one year."
10212397|NCT05221632|Experimental|accelerated continue theta-burst stimulation|Fifty intermittent TBS sessions (1800 pulses per session, 50 minute inter-session interval ) were delivered as ten daily sessions over five consecutive days at 80% resting motor threshold (RMT). The MRI data set should be collected before the first rTMS session and after the last rTMS session.
10212398|NCT05221632|Active Comparator|1-HZ repetition transcranial magnetic stimulation Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 80% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
10212399|NCT05221593|No Intervention|control group|will receive chemotherapy regimen with placebo
10212400|NCT05221593|Experimental|study group|"will receive chemotherapy regimen with Lithium Carbonate in controlled release formula (400mg b.i.d).~In order to avoid the potential for bone marrow stimulation at the time chemotherapy was administered, the administration of lithium was started 24 hours after the administration of chemotherapy and continued for 18 days of every 21.the lithium serum level will be measured at specific times to ensure lithium serum level between 0.4-0.8 mmol\L along the treatment course."
10212401|NCT05221580||Real-world adult population of Chinese patients with T2DM|Ryzodec as per local clinical practise
9898100|NCT02183987|Experimental|Active Knowledge Translation Group|CKD clinics receiving the active knowledge translation intervention.
9898101|NCT02183987|No Intervention|Passive Knowledge Translation Group|Clinics will have access to the Canadian Society of Nephrology (CSN) guidelines on the optimal timing of dialysis initiation (current practice). These guidelines have been published in the Canadian Medical Association Journal (CMAJ) and have been recently presented at the annual meeting of the Canadian Society of Nephrology.
9933120|NCT00956644|Active Comparator|amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks
9997674|NCT01511146|Experimental|Mitomycin+Gemcitabine|Intrahepatic treatment, where all standard treatments have been used
9898102|NCT02178709|Experimental|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle~5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
9898103|NCT02176278|No Intervention|Usual Care Group|"Usual care (UC) group:~After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment."
10212402|NCT05221567|Active Comparator|High intensity high dosage inpatient short-term psychodynamic psychotherapy (affect phobia therapy)|APT and VITA psychotherapy was carried out in accordance with treatment manuals. In addition to weekly individual sessions the inpatient program at both groups contained two 75 min group sessions each week. In addition, VITA had shorter group meetings each morning (15 minutes). Patients in both treatments participated in two physical exercise sessions per week, weekly psycho-educational lectures and art-therapy groups, and both groups finish each week with end of the week status groups. On average, patients in both treatments received seven sessions of therapeutic activity each week. All treatment components, with the exception of the physical exercises, adhered to the APT or VITA treatments, and thus the two intensive treatments were similar in dose but different in content. Medication was managed by psychiatrists, aiming to optimize the psychotropic medication regime, typically by reducing medication use.
10212403|NCT05221567|Other|Treatment-as-usual|TAU through public services locally, either outpatient treatment from a psychologist/psychiatrist and/or treatment/support from their local general practitioner.
10212404|NCT05221567|Active Comparator|High intensity high dosage inpatient short-term psychodynamic psychotherapy (VITA)|APT and VITA psychotherapy was carried out in accordance with treatment manuals. In addition to weekly individual sessions the inpatient program at both groups contained two 75 min group sessions each week. In addition, VITA had shorter group meetings each morning (15 minutes). Patients in both treatments participated in two physical exercise sessions per week, weekly psycho-educational lectures and art-therapy groups, and both groups finish each week with end of the week status groups. On average, patients in both treatments received seven sessions of therapeutic activity each week. All treatment components, with the exception of the physical exercises, adhered to the APT or VITA treatments, and thus the two intensive treatments were similar in dose but different in content. Medication was managed by psychiatrists, aiming to optimize the psychotropic medication regime, typically by reducing medication use.
9898104|NCT02176278|Experimental|Empowered Care Group|"Empowered care (EC) group:~After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment."
9898105|NCT02176278|Experimental|Team-based, Empowered Care Group|"Team-based, empowered care (TEC) group:~After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment."
9898106|NCT02163681|Experimental|Hyperpolarized Helium 3 MRI of the chest|Using hyperpolarized helium-3 as an inhaled contrast agent for MRI, we will assess the lung ventilation.
9898107|NCT02131805|Experimental|Electronic Skin Surface Brachytherapy|The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
9898108|NCT02117791||Group 1|Riociguat treatment group
9898109|NCT02096211||CERAMAX COC 36mm Acetabular Cup|The CERAMAX 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic.The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
9898110|NCT02066220|Experimental|PNET 5 MB-LR (low-risk)|Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.
9898111|NCT02066220|Experimental|PNET 5 MB-SR (standard-risk)|"Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.~Total treatment duration is 48 weeks."
9898112|NCT02066220|Experimental|PNET 5 MB WNT-HR|"Radiotherapy adapted to age and metastatic Status and maintenance chemotherapy adapted to age.~Total treatment duration is 39 to 48 weeks."
9898113|NCT02066220|Experimental|PNET 5 MB SHH-TP53|"Reduced chemotherapy with Doxorubicin, VCR, HD-MTX, Carboplatin, and MTX intraventricularly Stratification of radiotherapy according to~presence of metastasis~germline mutation in TP53 (including mosaicism) Maintenance chemotherapy with VBL Total treatment duration is 1 year"
9898114|NCT02060227|Active Comparator|Arthroscopic Bankart repair|After the diagnostic arthroscopy is completed, any other pathology is documented. At least 3 anchors will be used for the bankart repair for repair of the labrum with an inferior to superior capsular shift. The suture anchors used will be at the discretion of the surgeon but will be of the screw-in variety. The sutures are passed through the labrum, and the labrum is tied to the glenoid rim after the bone is prepared in the standard fashion. The surgical times will be recorded on standardized forms.
9935997|NCT02841995|Experimental|belumosudil 200 mg QD|Two 100 mg capsules or one 200 mg tablet (200 mg) of belumosudil once daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal.
9798068|NCT01616459|Active Comparator|Prevnar13 Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Prevnar13™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Prevnar13™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Prevnar13™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate ).
9798069|NCT01616563|Experimental|Diet and exercise|A combined diet and exercise program tailored to individuals incorporating behavioural modification support
9798070|NCT01616576|Experimental|Control first, then Experimental (Group A)|Initial subject use of Control Sound Processing Strategy for the first week, followed by subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the HiResolution™ Bionic Ear System for the second week.
9798071|NCT01616576|Experimental|Experimental first, then Control (Group B)|Initial subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the first week for the HiResolution™ Bionic Ear System, followed by subject use of the Control Sound Processing Strategy for the second week.
10212405|NCT05221554|Experimental|Prospective Computer-Navigated Cohort|Patients in this arm will receive standard patient of care implants but navigation software will be used to plan optimal acetabular cup placement.
10212406|NCT05221554|Active Comparator|Cross-sectional Standard of Care Cohort|Patients in this arm will receive standard of care implants and undergo standard of care procedure for total hip arthroplasty.
10212407|NCT05221541|Experimental|Vibration|Vibration (WBV and Tendon vibration) will be applied to participants
10212408|NCT05221515|Experimental|Intervention condition|Participants received both parent training and child-focussed treatment
10212409|NCT05221515|Active Comparator|Control condition|Participants received only parent training
9798072|NCT01616654|Experimental|CD5789 25 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
9798073|NCT01616654|Experimental|CD5789 50 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
9798074|NCT01616654|Active Comparator|CD5789 100 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
9798075|NCT01616654|Placebo Comparator|Tazarotene 0.1% Gel|Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
9798076|NCT01616654|Experimental|Vehicle Cream|Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.
9798077|NCT01616693|Experimental|Zinc and probiotic|Received daily zinc and probiotic supplements, in addition to rotavirus vaccine and trivalent oral polio vaccines.
9798078|NCT01616693|Active Comparator|Zinc alone|Received daily zinc and probiotic placebo supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
9798079|NCT01616693|Active Comparator|Probiotic alone|Received daily zinc placebo and probiotic supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
9798080|NCT01616693|Placebo Comparator|Placebo|Received daily zinc placebo and probiotic placebo, in addition to rotavirus vaccine and trivalent oral polio vaccine.
9798081|NCT01616771|Other|glottis view assessment|Glottis view assessment using Macintosh laryngoscope & GVL selected by weight & smaller sized GVL in single patient
9798082|NCT01616953|Experimental|Ixmyelocel-T|iliac bone marrow aspirates are expanded ex vivo to enrich for adult multipotent cells (ixmyelocel-T) capable of regenerating bone and blood vessels and reducing inflammation. Following cell expansion, autologous ixmyelocel-T is then packaged and can be used as an autologous graft for treatment of bone defects.
9798083|NCT01616953|Active Comparator|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
9798084|NCT01617005||Tocilizumab in Moderate to Severe Active RA|Moderate to severe active RA participants, receiving tocilizumab treatment according to effective official Summary of Product Characteristics (SPC), will be observed. The choice of therapy will be based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
9798085|NCT01617070|Experimental|LNAA, washout, Kuvan, and LNAA+Kuvan|One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)
9798086|NCT01617083|Active Comparator|Azithromycin|Antibiotic used to treat infections.
9798087|NCT01617083|Placebo Comparator|Placebo|Compound thickening agent with sugar and flavor additives.
9798088|NCT01617148|Experimental|Treatment with Aflibercept|Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
9798089|NCT01617369|Experimental|Acute Hypertonic Saline Effect|2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
9798090|NCT01617369|Active Comparator|Sustained Hypertonic Saline Effect|2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
9798091|NCT01617421|Experimental|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation [9]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
9798092|NCT01617434|Experimental|Liraglutide|
9798093|NCT01617434|Placebo Comparator|Placebo|
9898115|NCT02060227|Active Comparator|Open Latarjet procedure|A deltopectoral approach is used. The coracoacromial ligament (CAL) is exposed and incised 1 cm from its coracoid attachment. Harvesting of a 2.5- to 3-cm coracoid graft allows use of 2 screws for fixation to the glenoid neck through a subscapularis-splitting approach. The stump of the CAL is repaired to the capsule with the arm positioned in neutral. The graft is placed in a extra-articular fashion with capsular closure to the native glenoid rim.
9898116|NCT02007226||Spinal Cord Injury|Chronic SCI (Duration of Injury >5 years)
10212410|NCT05221502|Experimental|Arm 1|Delamanid + Bedaquiline + OPC-167832 10 mg
9898117|NCT01991457|Other|Treatment|Fludarabine, Total Body Irradiation (TBI)
9898118|NCT01980017|No Intervention|Wait-Listed Control Group|Usual care for smoking cessation
9898119|NCT01980017|Experimental|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
9898120|NCT01969643|Experimental|LV Dose Escalation|
9898121|NCT01969643|Experimental|LV + Trastuzumab|
9898122|NCT01969643|Experimental|LV Monotherapy|LV will be given at the recommended dose (at or below the monotherapy MTD determined in the LV dose escalation arm).
9898123|NCT01961375||Group 1|BAY 86-5028; Levonorgestrel- Intra Uterine System
9898124|NCT01940185||LINX device|Patients implanted with the LINX® Reflux Management System.
9898125|NCT01917929|Other|Secur-Fit Advanced|Secur-Fit Advanced Hip Stem
9898126|NCT01905046|Experimental|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
9898127|NCT01905046|Placebo Comparator|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
9898128|NCT01901770|Experimental|Arm I-HPV vaccine education|"The educational intervention is that parents and providers receive materials about HPV by mail including HPV/ cervical cancer videos and brochures, fact sheets, HPV/cervical cancer resource lists. Clinics receive posters, brochures, tabletop/reminder cards, resource lists, newsletters, and invitation to be vaccinated letters for parents."
9898129|NCT01901770|Active Comparator|Arm II- Flu vaccine education|The educational intervention is that parents and providers receive materials about Flu by mail including Flu brochures, fact sheets, Flu resource lists. Clinics receive posters and brochures.
9898130|NCT01901094|Other|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
9898131|NCT01901094|Other|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
9898132|NCT01893307|Experimental|Arm I (IMRT)|Patients undergo IMRT QD five days a week for approximately 6.5 weeks.
9898133|NCT01893307|Experimental|Arm II (IMPT)|Patients undergo IMPT QD five days a week for approximately 6.5 weeks.
9898134|NCT01890759|Experimental|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
9898135|NCT01890590|Experimental|Cyberknife|You will receive a series of Cyberknife Radiosurgery treatments, with the amount of radiation dosing adjusted for the size of your tumor. The treatment will ideally take place over the course of 3-4 days, but not more than 14 days overall. (3 or 4 fractions of radiation therapy delivered by cyberknife)
9898136|NCT01877772|Active Comparator|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
9898137|NCT01877772|Active Comparator|Control|The control group will undergo standard rotator cuff repair.
9898138|NCT01855867|Other|Stribild|Single dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV
9898139|NCT01855464|Experimental|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
9898140|NCT01855464|Active Comparator|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
9898141|NCT01837225||Control|Patients in the control arm will not receive the fluorescent contrast agent (5-ALA); however, intraoperative fluorescence imaging will still be performed. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
9997675|NCT01511159|Experimental|NNC 90-1170, initial dose|
9997676|NCT01511159|Experimental|NNC 90-1170|
9997677|NCT01511159|Active Comparator|Insulin|
10212411|NCT05221502|Experimental|Arm 2|Delamanid + Bedaquiline + OPC-167832 30 mg
10212412|NCT05221502|Experimental|Arm 3|Delamanid + Bedaquiline + OPC-167832 90 mg
10212413|NCT05221502|Active Comparator|Arm 4|RHEZ
10212414|NCT05221489|Experimental|lullaby group|For two weeks and 30 minutes every day at home, the lullaby group (LG) only listened to the lullaby record selected by the researcher.
10212415|NCT05221489|Experimental|mix music group|For two weeks and 30 minutes every day at home, the multi-music group (MG) listened to self-selected music from different records presented to them by the researcher.
10212416|NCT05221489|No Intervention|control group|The control group (CG) only received routine care.
10212417|NCT05221476||polytraumatized patients|Patients with an ISS >16 points, an AIS >3 in one body region and at least 2 different body regions affected were included.
10212418|NCT05221411|Experimental|Mycofenolate Mofetil|Patients in the mycophenolate mofetil (MMF) arm will receive MMF for a total of 12 months (if tolerated)
9898142|NCT01837225||Low Dose Contrast Agent|Patients in the low dose arm will receive 15 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
9898143|NCT01837225||High Dose Contrast Agent|Patients in the high dose arm will receive 30 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
9898144|NCT01837225||Intermediate Dose Contrast Agent|Patients in the intermediate dose arm will receive 20 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
9898145|NCT01770249|Other|POEM procedure|An endoscopic surgical procedure for achalasia; Per-oral Endoscopic Esophagomyotomy (POEM)will be performed. The POEM procedure will be performed in the operating room under general anesthesia and a scope will then be inserted into your mouth and down your throat and measurements will be taken. With the use of this lighted flexible scope the surgeon will make a small incision in the inner lining of your esophagus (throat), create a tunnel and then cut the muscle between the esophagus (throat) and the stomach. The initial little opening will be closed with a small clip. This procedure will allow easier passage of food into the stomach.
9898146|NCT01754857|Experimental|Bendamustine, rituximab, lenalidomide|"INDUCTION: Bendamustine 90mg/m2 IV D1&2 and rituximab IV D1 (up to day 5 of course 1) every 28 days for 6 cycles. Patients with objective response move to maintenance therapy. Patients with objective response after 4 courses are eligible to for maintenance therapy if ongoing induction therapy is associated w/unacceptable toxicity.~MAINTENANCE: At 6-12 wks post induction therapy, patients receive rituximab IV on day 1 of odd-numbered cycles for 24 cycles; lenalidomide 5mg PO daily on days 1-21 of each cycle (28 day cycles). Dose escalation to 10mg daily on days 1-21 allowed at start of cycle 2 or at start of subsequent cycles in subjects w/acceptable toxicities. Lenalidomide dose escalation only allowed at start of a new cycle up to a max dose of 10 mg/day on days 1- 21. Subjects entering maintenance with CrCl ≥40 & <60mL/min will begin dosing at 5mg every other day on days 1-21. Patients with excessive toxicity from lenalidomide may continue maintenance therapy with rituximab alone."
9898147|NCT01754363|Experimental|Attune Primary Total Knee Replacement|"Subjects will receive one of the following Attune total knee implants:~Cruciate retaining fixed bearing (CR FB) Cruciate retaining rotating platform (CR RP) Posterior stabilized fixed bearing (PS FB) Posterior stabilized rotating platform (PS RP)"
9898148|NCT01721746|Experimental|BMS-936558 3 mg/kg (IV)|BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
9898149|NCT01721746|Active Comparator|Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)|"Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
9898150|NCT01716312|Placebo Comparator|1|Subjects who were randomized to the placebo arm originally will receive 600 mg omalizumab by subcutaneous injection
9898151|NCT01716312|Active Comparator|2|Subjects in the omalizumab arm will receive 300 mg omalizumab by subcutaneous injection in a doubleblinded fashion
9898152|NCT01705977|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
9898153|NCT01705977|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
9898154|NCT01662609||Endoscopic Ultrasound (EUS) Participants|High-risk for Pancreatic Cancer: Patients with 2 or more relatives with pancreatic cancer and a first degree relationship with at least one of the relatives with pancreatic cancer.
9898155|NCT01661491||Cystic Fibrosis|Infants and toddlers with Cystic Fibrosis
9898156|NCT01661491||Non-cystic fibrosis controls|Infants and toddlers without Cystic Fibrosis
9898157|NCT01661400|No Intervention|Control|No intervention
9898158|NCT01661400|Experimental|Metronomic Cyclophosphamide|Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children < 40kg or 100 mg daily for children > 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
9898159|NCT01661400|Experimental|Thalidomide|Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
9898160|NCT01656603|Experimental|unlicensed CBU|The Principal Investigators will be the transplant physicians at participating US transplant centers
9898161|NCT01633268||Healthy Volunteers|Healthy men and women aged 18-65
9997678|NCT01511159|Experimental|NNC 90-1170, final dose|
9992435|NCT01462201|Experimental|Group 2 - Non Invasive Ultrasound|Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
9798094|NCT01617447|Placebo Comparator|Placebo|administered orally once daily
9798095|NCT01617447|Experimental|Aripiprazole|administered orally once daily
9798096|NCT01617460|Experimental|Aripiprazole|administered orally once daily
9798097|NCT01617577|Experimental|G-CSF (filgrastim) first phase|Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
9798098|NCT01617577|Placebo Comparator|Placebo first phase|Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.
9798099|NCT01617603|Experimental|High polyphenol milk chocolate|High polyphenol milk chocolate containing approximately 1 mg/g of epicatechin
9798100|NCT01617603|Active Comparator|Nestle Noir 70 % chocolate|Nestle Noir 70 % chocolate containing approximately 1 mg/g of epicatechin
9798101|NCT01617603|Placebo Comparator|Low polyphenol milk|Low polyphenol milk control (matched to product 1 as closely as possible for milk content, carbohydrate, fat and calories, made from cocoa butter, sugar, milk powder and small amount of cocoa liquor to improve taste, giving approximately 0.05mg/g epicatechin.
9798102|NCT01617629|Experimental|Cvac Treatment Group|Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment.
9798103|NCT01617655|Placebo Comparator|Placebo Q2W|Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
9798104|NCT01617655|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.
9798105|NCT01617668|Experimental|Paclitaxel with LCL161|Patients randomized to the experimental arm received paclitaxel 80 mg/m2 weekly + LECL161 1800 mg once weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
9798106|NCT01617668|Active Comparator|Paclitaxel without LCL161|Patients randomized to the control arm received paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
9798107|NCT01617681|Experimental|Valsartan 0.25 mg/kg|Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
9798108|NCT01617681|Experimental|Valsartan 4 mg/kg|Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
9798109|NCT01617681|Experimental|Valsartan 1 mg/kg|Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
9798110|NCT01617967|Experimental|Patisiran (ALN-TTR02)|Two administrations of patisiran will be administered once every 4 weeks [Q4W]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks [Q3W]), and an alternative premedication regimen.
9798111|NCT01618019|Experimental|N-3 PUFA|5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
9798112|NCT01618019|Placebo Comparator|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
9798113|NCT01618162|Experimental|Insulin degludec/liraglutide|
9798114|NCT01618162|Placebo Comparator|Placebo|
9798115|NCT01618214|Experimental|Subject-driven titration|
9798116|NCT01618214|Active Comparator|Investigator-driven titration|
9798117|NCT01618227|Experimental|Rehabilitation with static progressive splinting|Static progressive splinting is a well-established adjunct for restoring motion in stiff joints. Such splints apply a static stress relaxation force to the wrist and forearm tissues, which is sequentially increased as motion is achieved.
9798118|NCT01618227|Experimental|Rehabilitation without splinting|
9798119|NCT01618240||Long term ventilated subjects|Muscle Strength Measurement, ventilator
9798120|NCT01618266||Ozurdex® (dexamethasone intravitreal implant)|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
9798121|NCT01618305|Experimental|Arm A (Women)|Pregnant women received ZDV/3TC + EFV
9798122|NCT01618305|Experimental|Arm B (Women)|Pregnant women received ZDV/3TC + RAL
9798123|NCT01618305|No Intervention|Arm A (Infants)|Infants born to women in Arm A; infants received no study intervention.
9798124|NCT01618305|No Intervention|Arm B (Infants)|Infants born to women in Arm B; infants received no study intervention.
9898162|NCT01631084|Experimental|JADE|Patients randomized to the JADE group will be followed according to protocol-driven diabetes care based on their individual risk levels, using a web-based disease management program. In addition to their annual comprehensive assessments at baseline, year 1 and year 2, all subsequent follow-up visits will be documented and entered into the JADE portal, which will then issue reports to both patients and doctor to promote sharing of information and informed decisions.
9898163|NCT01631084|Active Comparator|DIAMOND|Patients will receive a comprehensive assessment at baseline, year 1 and year 2. In the interim between these time points patients will be managed according to 'usual care' procedures.
9898164|NCT01593202|Experimental|Dialectical behavior therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
9898165|NCT01593202|Active Comparator|Enhanced usual care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
9898166|NCT01587040|Experimental|SAR245408: Monotherapy|Participants received SAR245408 400 milligrams (mg) once daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days).
9898167|NCT01587040|Experimental|SAR245408: Combination Regimen|Participants received SAR245408 400 mg once daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days). Commercially available drugs were used as combination medications with SAR245408 (depending on the parental study, the following drugs were used in combination with SAR245408: paclitaxel and carboplatin, letrozole, trastuzumab, paclitaxel and trastuzumab).
9898168|NCT01587040|Experimental|SAR245409: Monotherapy|Participants received SAR245409 50 mg twice daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days).
9898169|NCT01587040|Experimental|SAR245409: Combination Regimen|Participants received SAR245409 50 mg twice daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days). Commercially available drugs were used as combination medications with SAR245409 (depending on the parental study, the following drugs were used in combination with SAR245409: letrozole, temozolomide, rituximab, bendamustine and rituximab).
9898170|NCT01558804||Rapid Strep Positive|Children will be eligible for this study if they are ages 5 to 15 years and have been diagnosed to have acute pharyngitis caused by GAS with a positive Rapid Antigen Detection Test (RADT) and have not been treated with antibiotics in the last 30 days.
9898171|NCT01556490|No Intervention|Control group|Standard-of-care sorafenib, with no added therapy
9898172|NCT01556490|Experimental|Treatment group|Standard-of-care sorafenib plus TheraSphere
9898173|NCT01521039||Allogeneic SCT recipients|Patients who are receiving allogeneic stem cell transplantation at the Ohio State University are eligible and will be consented for the study.
9898174|NCT01503606|Active Comparator|one-week treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week
9898175|NCT01503606|Active Comparator|until-delivery treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery
9898176|NCT01406184|Experimental|Durham Connects Eligible Group|From July 1, 2009 - December 31, 2010, all even-birth-date residential births in Durham County, North Carolina were randomly assigned to receive the Durham Connects nurse home visiting program.
9898177|NCT01406184|No Intervention|Control Group|From July 1, 2009 - December 31, 2010, all odd-birth-date residential births in Durham County, North Carolina were randomly assigned to a control group condition. These families were assigned to receive services as usual and served as the randomized comparison group for evaluating Durham Connects program impact.
9898178|NCT01324531|Active Comparator|Bankart repair|
9898179|NCT01324531|Active Comparator|Bankart repair and remplissage|
9898180|NCT01293682|Experimental|Calcitriol|Calcitriol 45mcg/week
9898181|NCT01254409|Experimental|PRM-151|PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.
9898182|NCT01254409|Placebo Comparator|Placebo|0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.
9898183|NCT01253161|Experimental|Pasireotide LAR Treatment|The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.
9898184|NCT01192568|Experimental|Oxybutynin Chloride|
9898185|NCT01134172||Breast cancer survivors|Women being treated for stage I-III breast cancer who were employed prior to this diagnosis will be recruited in their physicians' offices.
9898186|NCT01134172||Comparison group|Peer controls will be nominated by participants in the breast cancer survivor group or recruited by community outreach and matched for age, language, and ethnicity. This cohort is no longer recruiting.
9898187|NCT01084252|Experimental|Phase 1:Isatuximab <=1 mg/kg Q2W|Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (<=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9992436|NCT01462240||1 - LPS Flex Pororus Femoral Components|Patients suffering from severe knee pain and disability.
9898188|NCT01084252|Experimental|Phase 1: Isatuximab 3mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9898189|NCT01084252|Experimental|Phase 1: Isatuximab 5 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9898190|NCT01084252|Experimental|Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9898191|NCT01084252|Experimental|Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9898192|NCT01084252|Experimental|Phase 1: Isatuximab 10 mg/kg QW|Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9898193|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9898194|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg QW|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
9898195|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
9898196|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
9898197|NCT01084252|Experimental|Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
9898198|NCT01084252|Experimental|Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W|Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).
9898199|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab Alone|Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision maximum exposure: 97 weeks).
9898200|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab + Dexamethasone|Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than [<] 75 years of age; 20 mg/day [greater than or equal to [>=] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 97 weeks).
9898201|NCT00949819||no treatment|Men with previously untreated, early stage prostate cancer.
9898202|NCT00887536|Active Comparator|Group 1: TAC then pegfilgrastim|docetaxel, doxorubicin, cyclophosphamide, and pegfilgrastim/filgrastim
9898203|NCT00887536|Active Comparator|Group 2: TC|docetaxel and cyclophosphamide
9898204|NCT00887536|Experimental|Group 3: TC + bevacizumab|docetaxel, cyclophosphamide, and bevacizumab
9898205|NCT00867321|Experimental|Arm I (Phase II)|Patients receive oral sorafenib tosylate on days 1-28 twice daily and bevacizumab IV on days 1 and 15.
9898206|NCT00867321|Experimental|Arm II (Phase II)|Patients receive oral sorafenib tosylate twice daily on days 1-28.
9898207|NCT00728754|Experimental|Dental implant Osseotite Prevail|Dental implant with lateralized design
9898208|NCT00728754|Active Comparator|Dental implant Osseotite|Dental implant without the lateralized design
9898209|NCT00723944|Active Comparator|Osseotite Certain Prevail|Dental implant with lateralized design
9898210|NCT00723944|Placebo Comparator|Osseotite Certain|Dental implant without the lateralized design
9898211|NCT00639301||1|Long term survivors of retinoblastoma
9898212|NCT00614211|Active Comparator|1|Total Abdominal Radical Hysterectomy
9898213|NCT00614211|Experimental|2|Total Laparoscopic or Robotic Radical Hysterectomy
9898214|NCT00565851|Active Comparator|Arm I (paclitaxel, docetaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days.
9898215|NCT00565851|Experimental|Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab)|Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days.
9898216|NCT00565851|Experimental|Arm III (gemcitabine hydrochloride, carboplatin)|Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.
9898217|NCT00565851|Experimental|Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)|Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.
9898218|NCT00491842||At-risk|Individuals at-risk for HD
9898219|NCT00491842||Presymptomatic|Presymptomatic carriers of HD
9898220|NCT00467142|Experimental|Folfiri and Bevacizumab|"Premedication = Dexchlorpheniramine, 5 mg in slow Direct IntraVeinous (DIV) on D1.~FOLFIRI (simplified LV5FU2 + irinotecan):~Irinotecan (Campto®): 180 mg/m² on D1 by IV infusion in 250 mL of 0.9% saline over 90 minutes.~LV5FU2, in its so-called simplified version, will be administered as follows L-folinic acid, as a 2-hour intravenous infusion, at a dose of 200 mg/m², on Day 1, in 500 mL of 5% glucose solution, concomitantly with the irinotecan infusion via a Y-tube, followed by 5 Fluorouracil (5 FU), intravenous bolus, at a dose of 400 mg/m² on D1, followed by 5 Fluorouracil (5 FU) as a 46-hour continuous infusion at a dose of 2400 mg/m² from D1 to D3, either in 1000 mL of 5% glucose solution, or in an electric syringe or pump dispenser~Bevacizumab (Avastin®): 5 mg/kg IV infusion in 100 mL of 0.9% saline over 90 minutes for the first infusion, then 60 minutes for the second infusion if tolerated, and 30 minutes for subsequent infusions if tolerated."
9898221|NCT05342649|Experimental|Main treatment group|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
9898222|NCT05342649|Active Comparator|Control group|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
9898223|NCT05342636|Experimental|Pembrolizumab plus chemotherapy|Participants will receive pembrolizumab intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
9898224|NCT05342636|Experimental|Coformulation Favezelimab/Pembrolizumab plus Chemotherapy|Participants will receive coformulation of favezelimab/pembrolizumab administered intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
10212419|NCT05221411|Experimental|Tacrolimus (Envarsus)|Patients in the tacrolimus (TAC) arm will receive treatment with meltdose TAC for a total of 12 months (if tolerated)
9898225|NCT05342636|Experimental|Pembrolizumab plus MK-4380 plus Chemotherapy|Participants will receive pembrolizumab intravenously plus MK-4380 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
9898226|NCT05342636|Experimental|Pembrolizumab plus MK-4380 plus lenvatinib|Participants will receive pembrolizumab intravenously plus MK-4380 plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
9898227|NCT05342623|Experimental|Difelikefalin 1 mg Oral Tablet|Patients receive oral difelikefalin 1 mg once daily
9898228|NCT05342623|Placebo Comparator|Placebo Oral Tablet|Patients receive oral placebo once daily
9992437|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-1|A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
10212420|NCT05221385|Experimental|Experimental cohort|Gentulizumab monotherapy 0.1, 0.3, 1, 3, 10, 30, 45 mg/kg administered intravenously once every week.
10213873|NCT02847637|Experimental|A: Emicizumab 1.5 mg/kg/week|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
10213874|NCT02847637|Experimental|B: Emicizumab 3 mg/kg/2 weeks|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 3 mg/kg/2 weeks emicizumab subcutaneously until the end of study (maximum up to 6 years).
10213875|NCT02847637|Active Comparator|C: No Prophylaxis|Participants who received episodic treatment with FVIII prior to study entry will be randomized to continue episodic FVIII treatment when they start the trial; they will have the opportunity to switch to emicizumab prophylaxis after 24 weeks on-study.
10213876|NCT02847637|Experimental|D: Emicizumab 1.5 mg/kg/week (Pre-study FVIII Prophylaxis)|Participants who received FVIII prophylaxis prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
10213877|NCT02841644||Traumatic Arthrotomy- Treated Nonoperatively|Patient diagnosed with traumatic arthrotomy treated nonoperatively.
9898229|NCT05342610|Experimental|Experimental (distant reiki) group|Reiki (complementary and integrative medicine method) was applied individually to the experimental group for 30 minutes three times a week for four weeks. Data collection forms was applied 3 times in total, before the intervention, in the fourth and the eighth week.
9898230|NCT05342610|No Intervention|Control group|No intervention was made to women in the control group. However, data collection forms was applied 3 times in total, before the intervention, in the fourth and the eighth week.
9898231|NCT05342597|Experimental|Group A|A single oral dose of MT-1186 with fasted condition in period 1, meal 1 condition in period 2, meal 2 condition in period 3, meal 3 condition in period 4, and meal 4 condition in period 5.
9898232|NCT05342597|Experimental|Group B|A single oral dose of MT-1186 with meal 1 condition in period 1, meal 2 condition in period 2, meal 3 condition in period 3, fasted condition in period 4, and meal 4 condition in periond 5.
9898233|NCT05342597|Experimental|Group C|A single oral dose of MT-1186 with meal 2 condition in period 1, meal 3 condition in period 2, fasted condition in period 3, meal 1 condition in period 4, and meal 4 condition in period 5.
9898234|NCT05342597|Experimental|Group D|A single oral dose of MT-1186 with meal 3 condition in period 1, fasted condition in period 2, meal 1 condition in period 3, meal 2 in period 4, and meal 4 condition in period 5.
9898235|NCT05342584|Experimental|Venetoclax plus 7+3|see detailed description
9898236|NCT05342571|Experimental|Supportive care (ABC session, surveys, biospecimen collection)|Phase 1 of the intervention (10 weeks) will follow the following agenda: 1) Overview and progressive muscle relaxation, 2) Seeking and asking for disease-related and treatment-related information, 3) Problem solving skills, 4) Breathing techniques and sleep hygiene, 5) Assertive communication skills, 6) Identifying social network, 7) Asking for support, 8) Further information on social support, 9) Physical activity, and 10) Review of major topics, transition. Phase 2 of the intervention (4 weeks) which will be completed only by patients who do not experience remission in depressive symptoms by the end of phase 1, will follow the following agenda: 1) Identifying negative thoughts and problematic thinking patterns, 2) Generating alternative thoughts, 3) Behavioral activation, and 4) Review and wrap-up, transition to optional maintenance. Each session in Phase 1 and Phase 2 occurs once per week, for 60 minutes each. Maintenance sessions occur monthly, 60 minutes each.
9898237|NCT05342558|Active Comparator|Biomass Smoke COPD|"Fluticasone Furoate/Vilanterol 100/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks.~Umeclidinium/Vilanterol 62.5/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks."
9898238|NCT05342558|Active Comparator|Tobacco Smoke COPD|"Fluticasone Furoate/Vilanterol 100/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks.~Umeclidinium/Vilanterol 62.5/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks."
9898239|NCT05342545|Experimental|Alert|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
9898240|NCT05342545|No Intervention|No Alert|"Providers in the No Alert group will not receive any on-screen notification"
9898241|NCT05342532|Active Comparator|High Dose Dual Therapy|This regimen includes a 14-day course of amoxicillin 1 g three times daily and omeprazole 40 mg three times daily.
9898242|NCT05342532|Active Comparator|Standard triple therapy|This regimen includes a 14-day course of clarithromycin 500 mg twice daily, omeprazole 40 mg twice daily, and amoxicillin 1g twice daily.
9997679|NCT01511172|Experimental|NNC 90-1170 + Met|
9898243|NCT05342519|Experimental|Topical rapamycin 0.001%|Patients randomized to this arm of the study will apply 2 finger tip units (FTU) or 0.5 cc topical rapamycin 0.001% cream daily for 6 months
9898244|NCT05342519|Active Comparator|Topical rapamycin 0.1%|Patients randomized to this arm of the study will apply 2 FTU (0.5 cc) topical rapamycin 0.1% cream daily for 6 months
9898245|NCT05342519|Placebo Comparator|Placebo|All patients will apply 2 FTU (0.5 cc) topical placebo cream daily for 6 months to the corresponding anatomic location on the opposite side of the body where the experimental drug is not being applied
9898246|NCT05342506|Experimental|Cohort 1|Study subjects: Patient with cervical carcinoma
9898247|NCT05342506|Experimental|Cohort 2|Study subjects: Patient with ovarian cancer
9898248|NCT05342506|Experimental|Cohort 3|Study subjects: Patient with malignant trophoblastic tumor
9898249|NCT05342493||Drug|Ajovy syringe for SC injection 225 mg.
9933121|NCT00956670|Experimental|Supportive care (lymphedema assessment)|"Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)~Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.~Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.~Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months."
9933122|NCT00956683|Experimental|Ultrasound|Ultrasound guided infraclavicular block
9933123|NCT00956683|Active Comparator|Dual Endpoint Nerve Stimulator|Nerve stimulator guided dual endpoint infraclavicular block
9933124|NCT00956696||Topiramte|single arm, flexible dosing
9933125|NCT00956722|Experimental|Treatment|Active treatment with Bovine colostrum
9933126|NCT00956735|Experimental|Pistachio Diet|Incorporates 3.0 oz (2 servings) of pistachios into a daily diet
9933127|NCT00956735|No Intervention|Non-Pistachio|Does not incorporate pistachios into a daily diet
9933128|NCT00956748|Active Comparator|Ciprodex otic solution|ciprofloxacin 0.3% / dexamethasone 0.1% otic solution
9898250|NCT05342467|Active Comparator|Gemeprost|Gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours.
9898251|NCT05342467|Active Comparator|Dinoprostone|Dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours.
9898252|NCT05342441|Experimental|QT-graft|Quadriceps tendon autograft (n=50)
9898253|NCT05342441|Experimental|St/Gr-graft|Semitendinosus/gracilis autograft (n=50)
9898254|NCT05342441|Experimental|BPTB-graft|Patella tendon autograft (n=50)
10212421|NCT05221359|Experimental|test arm|All patients will be enrolled in same arm which contains the two interventions (device + drug) and follow mandatory phases of trial: screening, implantation, treatment with ExOlin, explantation.
10212422|NCT05221346|Experimental|Plant food supplement|"Dietary supplements in capsule form~1 capsule per day at breakfast"
10212423|NCT05221346|Placebo Comparator|Maltodextrin|"Dietary supplements in capsule form~1 capsule per day at breakfast"
10212424|NCT05221333|Other|Healthy participants|Up to 25ml of saline administered through OBI
9898259|NCT05342415|Active Comparator|Internally Focused|Focusing on the muscles that reveal the movement.
9898260|NCT05342415|Experimental|Externally Focused|Focusing on the result of the movement.
9898261|NCT05342402|Experimental|Somatosensory Rehabilitation Program|Includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
9898262|NCT05342402|Active Comparator|Educational Pain Management Program (PMP)|Includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
9898263|NCT05342389|Experimental|Experimental group|A fixed dose of Camrelizumab 200mg will be administered intravenously (without preventive medication), and each infusion lasts 45min (no less than 30min, no more than 60min), once every two weeks; During the treatment period, 250 mg of Apatinib mesylate tablets will be taken orally daily continuously, and every 2 weeks is a treatment cycle. The treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurred.
9898264|NCT05342389|Active Comparator|Control group|Apatinib mesylate tablets 500 mg will be taken orally daily continuously, every 2 weeks as a treatment cycle. Treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurs.
9898265|NCT05342376|Active Comparator|Dexmedetomidine|This is group D, which will receive 10 micro-gram Dexmeditomidine diluted in 02 ml normal saline to be administered intravenously in 10 minutes after umbilical cord is clamped..
9898266|NCT05342376|Active Comparator|Saline|This group S will receive 02 ml normal saline intravenously as placebo in 10 minutes after umbilical cord is clamped..
9898267|NCT05342363||cardiopulmonary resuscitation during treatment with extracorporeal membrane oxygenation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) during the retrospective observation period who required mechanical cardiovascular resuscitation (CPR) during their treatment.
9898268|NCT05342363||Treatment with extracorporeal membrane oxygenation without resuscitation|Patients treated with venovenous extracorporeal membrane oxygenation (vv-ECMO) for acute respiratory distress syndrome (ARDS) without the need for cardiovascular resuscitation during the retrospective observation period.
9898269|NCT05342337|Experimental|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management."
9898270|NCT05342337|Active Comparator|Control Group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
9898271|NCT05342285||normal FMD|SLE femals patientd with normal flow mediated whose ages from 18 to 45yrs
9898272|NCT05342285||abnormal FMD|SLE femals with abnormal flow mediated dikation ages between 18 to 45yrs old
10212425|NCT05221294|Experimental|MDN group|will receive modified Del Nido cardioplegia solution
10212426|NCT05221294|Experimental|C group|will receive Custodiol cardioplegia
10212427|NCT05221268|Experimental|downhill|Received downhill walking training.
10212428|NCT05221268|Experimental|Level -walking|Received level walking training.
10212429|NCT05221255|Sham Comparator|Sham Therapy|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation plus non-real magnetic stimulation.
10212430|NCT05221255|Experimental|Spinal magnetic stimulation|Patients will receive 12 sessions of biofeedback-assisted pelvic floor muscle relaxation followed by real spinal magnetic stimulation.
10212431|NCT05221242|Experimental|Patients with PLV|All patients will receive ceramic partial laminate veneers as treatment. As this is a split mouth design, one side of the mouth will receive partial laminate veneers bonded with a conventional light-curing resin cement and the other side of the mouth with a pre-heated resin composite.
10212432|NCT05221216||patients in Intensive Care unit|patients in Intensive Care unit with infection treated with cotrimoxazole will be included. Data will be collected of medical record.
10212433|NCT05221190|Experimental|Single buccal infiltration of articaine anesthesia|The local anesthetic solution will be administered using single buccal infiltration with articaine anesthesia.
10212434|NCT05221190|Active Comparator|Inferior alveolar nerve block of lidocaine anesthesia|The anesthetic solution will be administered using inferior alveolar nerve block with lidocaine anesthesia.
10212435|NCT05221164|Experimental|Intervention with 162 mg aspirin|Aspirin 162 mg daily for prevention of preeclampsia in pregnant patients at Family Medicine Clinic
10212436|NCT05221138|Experimental|VV116 after High-fat meal intake|a single oral after High-fat meal intake
10212437|NCT05221138|Experimental|VV116 after Fasting+Standard diet|a single oral after Fasting
10212438|NCT05221138|Experimental|VV116 after Standard meal intake|a single oral after Standard meal intake
10212439|NCT05221008|Experimental|group A|Experimental: SHR6508 Placebo Comparator: normal saline
10212440|NCT05221008|Experimental|group B|Experimental: SHR6508 Placebo Comparator: normal saline
10212441|NCT05221008|Experimental|group C|Experimental: SHR6508 Placebo Comparator: normal saline
9898273|NCT05342285||Normal female|normal femals whise ages from 18 to 45yrs old
9898274|NCT05342272|Experimental|GUM Hydral Moisturizing Gel|One group of 20 patients receiving GUM® Hydral® Moisturizing Gel (test group): they were be instructed to apply during a 28 days treatment period 1 to 2 cm of gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary.
9898275|NCT05342272|Active Comparator|Biotene Oral Balance Gel|One group of 20 patients receiving Biotene® Oral Balance Gel (control group): they were be instructed to apply during a 28 days treatment period 1 to 2 cm of gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary.
9898276|NCT05342259|Active Comparator|dorsal penile block patients|
9898277|NCT05342259|Active Comparator|caudal block patients|
9898278|NCT05342259|Active Comparator|combined block patients|
9898279|NCT05342246|Experimental|conservative treatment|The patent canal is retreated, no attempt to deal with the separated instrument
9898280|NCT05342246|Active Comparator|traditional|All canals are retreated with attempts to retrieve the broken file
9898281|NCT05342233||Endovascular treatment Group|Patients receiving endovascular treatments
9898282|NCT05342233||Conservative treatment Group|Patients receiving conservative treatments, including blood pressure control, bowel rest, antithrombotic therapy, nutrition treatment and pain management.
9898283|NCT05342220|Active Comparator|Remote Ischemic Preconditioning|Remote ischemic preconditioining
9898284|NCT05342220|Sham Comparator|Control|Sham preconditioning
9898285|NCT05342207|Experimental|cases|
9898286|NCT05342194|Experimental|Toripalimab, lenvatinib, and gemcitabine-based chemotherapy-Arm A|Toripalimab plus lenvatinib and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
9898287|NCT05342194|Experimental|Toripalimab, oral placebo, and gemcitabine-based chemotherapy -Arm B|Toripalimab plus lenvatinib placebo and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
9898288|NCT05342194|Active Comparator|Intravenous placebo, oral placebo, and gemcitabine-based chemotherapy-Arm C|Toripalimab placebo plus lenvatinib placebo and GEMOX (Gemcitabine hydrochloride and Oxaliplatin for injection ) or GC (Gemcitabine hydrochloride and Cisplatin)
9898289|NCT05342181|Experimental|Static exercises|static exercises i.e traditional exercises along with base line treatment of TENS and hot pack
9898290|NCT05342181|Experimental|Dynamic exercises|dynamic (Swiss ball) exercises along with base line treatment of TENS and hot pack
9898291|NCT05342168|Experimental|Histology|Specimen samples from the tradition pinch esophageal biopsy and the supernatant sample obtained from the mesh sponge (Cytosponge TM) will each be fixed and stained. The eosinophil count per high power field for the mesh sponge sample and the traditional biopsy sample will be compared for each subject.
9898292|NCT05342155||Focus Group|For the focus group, the participant will be asked to review the potential platform the investigators are developing to better describe risks of health are developing to better describe risks of health issues in childhood cancer survivors. The focus group session will last approximately 2 hours.
9898293|NCT05342155||Campus and Home Assessments|"For the campus and home assessments, the participant will be engaged in the research activities over 108 weeks (approximately 2 years).~DatStat Connect app-Throughout participation in this research study, the participant will use a personal compatible device, such as smartphone or tablet, to report information about their health and respond to questionnaires using a website app called DatStat Connect.~The wrist monitor (Actigraph) and heart monitor (CorSense) will also transmit information to DatStat Connect. The wrist monitor and heart monitor will connect to a compatible personal device via Bluetooth.~The wrist monitor and heart CorSense device and St Jude Life study visit St Jude LIFE study visit: the participant will be asked to complete a St Jude LIFE research study assessment on the St Jude campus at three timepoints: initial visit (Week 0),approximately end of Year 1 (Week 60), and approximately end of Year 2 (Week 108)."
9898294|NCT05342142|Active Comparator|Exercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
9898295|NCT05342142|No Intervention|Control|No intervention will be made
9898296|NCT05342129|Experimental|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
9898297|NCT05342129|No Intervention|regular rehabilitation exercises|walking exercise
9898298|NCT05342116|No Intervention|Fasting Arm|Patient will fast at least 6 hours prior to endoscopy
9898299|NCT05342116|Active Comparator|Water Arm|Patient will drink 400 ml of water 2 to 4 hours prior to endoscopy
9898300|NCT05342116|Experimental|CHO Arm|Patient will drink 400 ml of Preload 2 to 4 hours prior to endoscopy
9898301|NCT05342103|Active Comparator|High flow nasal cannula (HFNC) group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. The flow rate will be set at 60 L/min
9898302|NCT05342103|Active Comparator|Continuous positive airway pressure (CPAP) group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. Pressure will be set to 3 cm H2O for 5 minutes, then titrated according to patient comfort and tolerance, as well as clinical observation
9898303|NCT05342103|Placebo Comparator|Venturi mask (MV) group|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%. Patients will receive oxygen at a rate of 10L/min.
9898304|NCT05342090|Active Comparator|Standardized Counselling Tool|If randomized to the treatment group, patients will be counselled using the structured counselling tool, and given a bulleted list of the counseling instrument to take home with them.
9898305|NCT05342090|No Intervention|Control|Routine postoperative counselling and care will be administered with no specific standardized counselling for return to sexual activity after surgery.
9898306|NCT05342077|Experimental|Virtual Reality-Reward Training (VR-RT)|13 sessions of positive VR immersion and positive memory specificity training exercises designed to savor rewarding features of immersion followed by memory specificity training exercises to savor rewarding features of autobiographical memory.
9898307|NCT05342077|Active Comparator|Virtual Reality-Memory Training (VR-MT)|13 sessions of neutral VR immersion and neutral memory specificity training exercises, designed to train memory of objective non-emotional stimuli followed by memory exercises to neutral autobiographical memories.
9898308|NCT05342064|No Intervention|Standard of care|No intervention will be administered. Observational data regarding TPT uptake and adherence will be captured on all participants presenting for care
9898309|NCT05342064|Experimental|TB screening and evaluation followed by TPT via a decentralized delivery system|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
9898310|NCT05342051|Experimental|balneotherapy group|balneotherapy plus usual care
9898311|NCT05342051|No Intervention|control group|usual care
9898312|NCT05342038|Experimental|Single Arm|T-02
9898313|NCT05342025|Experimental|PNF group|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases. The physiotherapist will apply patterns over the 2nd and 3rd ribs in a bilateral anterior manner including intercostal stretches.
9898314|NCT05342025|Active Comparator|Control Group|"Individuals in this group will be taught breathing exercises (diaphragmatic breathing, thoracic expansion, pursed-lip breathing, and respiratory control) after the assessments, and they will be informed about performing breathing exercises for 15 minutes a day, every day of the week. Patients will be asked to keep a treatment diary to control regular breathing exercises. Individuals will be re-evaluated after 2 months."
9898315|NCT05342012|Experimental|Experimental: Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 140ml a day for 2 weeks, and finally visit the investigators once more following another 140ml drink.
9898316|NCT05342012|Experimental|Experimental: Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 140ml a day for 2 weeks, and finally visit the investigators once more following another 140ml drink.
9898317|NCT05341999|Experimental|Final irrigation with cold saline (cryotherapy).|20ml of 2.5°C cold saline for 5 min
9898318|NCT05341999|Experimental|Ibuprofen post-operative medication.|a single dose of Ibuprofen 400 mg immediately after completion of root canal treatment
9898319|NCT05341999|Active Comparator|Final irrigation with normal saline, and no post-operative medication|final irrigation will be done using normal saline at room temperature.
9898320|NCT05341986|Other|Link-Out|Clinicians will be trained on the web-based portal of the CDS tool and shown where the Link to the tool will be available in the EHR.
9898321|NCT05341986|Other|BPA + Link-out|Clinicians will be trained on how a BPA is triggered when a patient is diagnosed with AF. The alert will pop up within the EHR with the Link-out to the web portal.
9933129|NCT00956748|Experimental|Ciprodex with 2% NAC|Ciprodex otic solution (ciprofloxacin 0.3% / dexamethasone 0.1%) augmented with 2% N-acetylcysteine
10212442|NCT05221008|Experimental|group D|Experimental: SHR6508 Placebo Comparator: normal saline
10212443|NCT05220995||100 patients with minimal|In advancing maternal age (AMA) women, minimal stimulation protocol (MSP) with the new combination of human menopausal gonadotrophin (hMG) and clomiphene citrate (CC) were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
10212444|NCT05220995||100 patients with recombinant FSH antagonist protocol|In advancing maternal age (AMA) women, flexible antagonist protocol with recombinant FSH were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
10212445|NCT05220982|Experimental|Conversation Training Therapy|
10212446|NCT05220982|Experimental|Global Voice Prevention and Therapy Model|
10212447|NCT05220982|Experimental|Modified Conversation Training Therapy|
10212448|NCT05220982|Experimental|Modified Global Voice Prevention and Therapy Model|
10212449|NCT05220969||Elite male youth footballers|Elite male youth footballers at an English championship / premier league football club
10212450|NCT05220943|Other|Video|All participants are invited to complete a pre survey, watch a five minute video, and then complete a post survey.
10212451|NCT05220891||Crystalloid group|"Group( 1)Patients will be randomly assigned to be treated with crystalloid (n=30). They will receive an intravenous infusion of saline at a constant rate utilizing a pump infusion device (170 mL of 3.5% saline solution per liter of ascites removed at 999 mL/h). The amount of liquid infused and rate of infusion was selected based on previous studies (Sola-vera et al.,2003) Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
10212452|NCT05220891||Colloid group|"Group (2)Patients will be randomly assigned to be treated with colloid (n=30). Albumin will be given at a dose of 8 g/L of ascitic fluid removed and will be infused immediately during the process of paracentesis.~After paracentesis, diuretics and plasma expanders will be withheld until hospital discharge."
10213878|NCT02841644||Traumatic Arthrotomy- Treated Operatively|Patient diagnosed with traumatic arthrotomy treated operatively.
9898322|NCT05341986|Other|BPA + FHIR|Instead of a link to the web-based portal, the BPA will contain a link to the FHIR-integrated CDS tool portal. FHIR will automatically pull EHR data about the patient into the CDS tool portal. Data include demographic information, comorbidities in the active problem list, past medical and surgical history, and social history. Clinicians will also receive training before the implementation of this step.
9898323|NCT05341973|Experimental|Education|The Self- Management Program Developed will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
9898324|NCT05341973|No Intervention|Control|It will not change the Self-Efficacy, Self-Care Management in Hypertension Patients of the Self-Management Program.
9898325|NCT05341960|Experimental|Food Delivery|Food box delivered to participant home every 2 weeks until 6 weeks post delivery
9898326|NCT05341960|Experimental|Financial Support and Navigation|$30 provide on gift card every two weeks until 6 weeks post delivery + neighborhood food retail navigation support.
9898327|NCT05341960|No Intervention|Control Group|Selected from claims data, matched.
9898328|NCT05341947|Experimental|Activated T cells|
9898329|NCT05341934|Active Comparator|Conditionning|
9898330|NCT05341934|Placebo Comparator|Placebo|
9898331|NCT05341921|Active Comparator|Alternate Nostril Breathing Phase I|Alternate nostril breathing for normotensive women in 3rd trimester of pregnancy
9898332|NCT05341921|Active Comparator|Bhramari Breathing Phase I|Bhramari breathing for normotensive women in 3rd trimester of pregnancy
9898333|NCT05341921|Active Comparator|Sheetali Breathing Phase I|Sheetali breathing for normotensive women in 3rd trimester of pregnancy
9898334|NCT05341921|Active Comparator|Alternate Nostril Breathing Phase II|Alternate nostril breathing for hypertensive women in 3rd trimester of pregnancy
9898335|NCT05341921|Active Comparator|Bhramari Breathing Phase II|Bhramari breathing for hypertensive women in 3rd trimester of pregnancy
9898336|NCT05341921|Active Comparator|Sheetali Breathing Phase II|Sheetali breathing for hypertensive women in 3rd trimester of pregnancy
9898337|NCT05341895|Other|kinesiotape|Kinesiotape applied to the paraspinal muscles
9898338|NCT05341895|No Intervention|Placebo|No intervention
9898339|NCT05341869|Placebo Comparator|Control|Prior to starting surgery after general anesthesia, the 10 mL of normal saline was performed by the primary surgeon. The syringe was injected with 5 mL on each side into the cervical stroma at 3 and 9 o'clock with a depth of 2 to 3 cm.
9898340|NCT05341869|Experimental|Study|Prior to starting surgery after general anesthesia, thE 10 mL of 0.5% bupivacaine with epinephrine was performed by the primary surgeon. The syringe was injected with 5 mL on each side into the cervical stroma at 3 and 9 o'clock with a depth of 2 to 3 cm.
9898341|NCT05341856|Active Comparator|Uterine artery Doppler Changes After IMN In Patients with URPL|compare uterine artery blood flow before and after the administration of Isosorbide mononitrate as a nitric oxide donor during mid secretory phase of menstrual cycle for patients with unexplained recurrent pregnancy loss.
9898342|NCT05341856|Placebo Comparator|Uterine artery Doppler Changes After placebo In Patients with URPL|compare uterine artery blood flow before and after the administration of placebo during mid secretory phase of menstrual cycle for patients with unexplained recurrent pregnancy loss.
9898343|NCT05341843|Experimental|sertraline|they will receive sertraline at the intended dose of 50 mg twice daily for 8 weeks.
9898344|NCT05341843|Placebo Comparator|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 8 weeks
9898345|NCT05341830|Experimental|Recovery Housing|Individuals in this arm will have access to a placement in recovery housing and the associated services. Recovery housing organizations provide individuals recovering from substance use disorders with housing and a variety of services, including transportation, rental assistance, life skills, family services, and educational and employment opportunities.
9898346|NCT05341830|No Intervention|No Recovery Housing|Individuals in this arm will not receive a placement in recovery housing. When possible, they will be informed about other available services in their community.
9933130|NCT00956787|Experimental|Treatment with AR-67|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days.
9933131|NCT00956800|Experimental|telemedicine/study group|
9898347|NCT05341817|Experimental|Letrozole|Day 1: Oral letrozole 10mg under direct observation therapy (DOT) in the clinic Day 2: Oral letrozole 10mg to self-administer at home Day 3: Oral letrozole 10mg to self-administer at home or at the hospital. Vaginal misoprostol 800mcg given in the ward, followed by vaginal misoprostol 400mcg, approximately 4 hours later, if subject showed no signs of abortion
9898348|NCT05341817|Active Comparator|Control|Day 1: Oral mifepristone 200mg (control) under direct observation therapy (DOT) in clinic Day 2: NIL medication to be self-administered at home Day 3: NIL medication to be self-administered at home. Vaginal misoprostol 800mcg given in the ward, followed by vaginal misoprostol 400mcg, approximately 4 hours later, if subject showed no signs of abortion
10212453|NCT05220852|Experimental|Dry needling and exercise|subjects in this group will have 1 session of dry needling in their upper trapezius muscle overactive trigger points will be applied at the first session, then they are going to continue to have neck exercise for 2 weeks minimum 3 times a week.
10212454|NCT05220852|Active Comparator|Exercise|subjects in this group will have neck exercise only for 2 weeks minimum 3 times a week.
10212455|NCT05220787|Experimental|Cold stored platelets in 100% plasma stored for 10-14 days|Cold stored apheresis platelets in 100% plasma stored for 10-14 days, maximum of up to three units (3x10^11/unit) from the start of surgery until 24 hours after the end of surgery
10212456|NCT05220787|Active Comparator|Room temperature stored platelets in 100% plasma stored for up to 7 days|Room temperature stored platelets in 100% plasma stored for up to 7 days, maximum of up to three units (3x10^11/unit) from the start of surgery until 24 hours after the end of surgery
10212457|NCT05220774||anesthetist-administered sedation (AAS)|Patients undergoing ERCP and receiving AAS
9898354|NCT05341778|Experimental|Pilates exercises|The Pilates method's exercises emphasize breathing and the activation of the deep stabilizing muscles of the trunk in coordination with the PFM. The pilates method consists of exercises that emphasize pelvic stability, mobility, and body alignment. PMFE are performed in tandem with breathing, with concurrent trunk muscle recruitment in various positions.
9898355|NCT05341778|Active Comparator|Pelvic floor exercise|These exercises are intended to strengthen weak perineal and pelvic floor muscles.
9898356|NCT05341765||End-Stage Kidney Disease Subjects|Non-invasive device worn over vasculature.
9898357|NCT05341752||End-Stage Kidney Disease Subjects|Non-invasive device worn over vasculature.
9898358|NCT05341739|Experimental|Pre-Operative Stereotactic Radiosurgery (SRS)|Subjects are treated using the standard of care SRS to a total dose of 24-27 Gray (Gy) in 3 fractions with a once daily fractionation or every other day at treating physician discretion. The preferred dose will be 27 Gy, with ability to drop dose down to 24 Gy if normal tissue constraints cannot be met. It should be noted, that while the dosing remains within standard of care, the timing of the radiation (pre-operative) is still not considered standard of care but is supported by emerging data as described in the study background. Additional metastatic lesions may be treated using SRS according to institutional practices. The radiation dose prescribed to the non-index lesions is at the discretion of the treating physicians. Surgical resection will be performed within 2 weeks of completion of SRS.
10212458|NCT05220774||endoscopist-directed conscious sedation (EDCS)|Patients undergoing ERCP and receiving EDCS
10212459|NCT05220696||Critically ill patients with shock|Critically ill patients with shock
9898361|NCT05341700|Experimental|Endurance and Jumping Exercises|5 days of endurance treadmill running and 5 sets of 10 jumping exercises
9898362|NCT05341700|Active Comparator|Endurance Exercise Only|5 days of endurance treadmill running
9898363|NCT05341674||Model of the stump scanned with a 3d scanner|For the artificial intelligence-based software planned to be created, the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner. The scanned patterns were saved as point clouds
9898364|NCT05341674||Socket matched to stump|The socket parts of the prostheses used by the same patients (with other group) were also scanned with the same scanner device and recorded.
10212460|NCT05220683|Experimental|Verion and Callisto|Alignment axis will be analysed with both, the Verion and the Callisto, digital marking system in the same eye of the same patient
10212461|NCT05220657||Low active subjects|No intervention
10212462|NCT05220657||Moderately active subjects|No intervention
10212463|NCT05220657||Elite soccer players|No intervention
10212464|NCT05220657||Elite cyclists|No intervention
10212465|NCT05220631|Experimental|Cohort 1|Cohort 1 will start the intervention directly after randomization.
10212466|NCT05220631|Active Comparator|Cohort 2|Cohort 2 will serve as the control while cohort 1 is in the intervention stage. Cohort 2 will start the intervention after cohort 1 concludes the intervention.
10212467|NCT05220618|Experimental|Memory Training Group|This group will receive an online two-week intervention to train the specificity of autobiographical memories. During the two-week intervention and the following two weeks, participants will complete ecological-momentary assessments (EMA) to monitor the amount of positive and specific memories recalled during the day. EMA is an Experience Sampling Method assessment system that allows data to be collected from participants in their natural environment at various points in time (McDevitt-Murphy et al., 2018). For this study, we designed an EMA to monitor essential project variables throughout the intervention (2 weeks; from Day 0 to Day 15) and then as a follow-up (2 weeks after; from Day 16 to Day 30).
10212468|NCT05220618|No Intervention|Control Group|This group will receive no intervention to train the specificity of autobiographical memories. During four weeks (from Day 0 to Day 30), participants will complete ecological-momentary assessments (EMA) to monitor the amount of positive and specific memories recalled during the day.
10212469|NCT05220592|Experimental|Internet-based recovery training program (n=35)|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week.
10212470|NCT05220592|No Intervention|Wait-list control group (n=34)|Wait-list control group received equal and parallell assessment and eligibility procedure as the experimental conditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
10213879|NCT02835261|No Intervention|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
9898365|NCT05341648|Experimental|Experimental Group|Aerobic Training for 3 days/week with 40-70% Intensity for 6 Weeks
9898366|NCT05341648|Placebo Comparator|Control group|Home plan: Positioning, Breathing Exercises, Muscle Relaxation, and Flexibility exercises for 6 weeks
9898367|NCT05341635||COVID-19 Symptomatic inpatients|Patients admitted to the Unit of Infectious Diseases of the ASST Monza for COVID-19 will run the collection of a nasopharyngeal swab, performed as part of the normal diagnostic routine; will take up to two samples collected in parallel to the development and optimization of the new method/process preanalitico and for the clinical validation of the performance of the pre-analytic method. The subjects will be adequately informed, both verbally and by means of a summary document of the study before signing a consent for participation in the study.
9898368|NCT05341635||COVID-19 Suspected subjects|To the subjects who present at the Emergency department of the ASST Monza for symptomatology referable to the COVID-19 and to patients on discharge from the Unit of Infectious Diseases of the ASST Monza for complete healing from COVID-19 will run the collection of a nasopharyngeal swab, performed as part of the normal diagnostic routine; will take up to two samples collected in parallel to the development and optimization of the new method/process preanalitico and for the clinical validation of the performance of the pre-analytic method. The subjects will be adequately informed, both verbally and by means of a summary document of the study before signing a consent for participation in the study.
9898369|NCT05341622|Experimental|Arm 1|Box + Text + Reminder
9898370|NCT05341622|Experimental|Arm 2|Box + Text + No Reminder
9898371|NCT05341622|Experimental|Arm 3|Box + No Text + Reminder
9898372|NCT05341622|Experimental|Arm 4|Box + No Text + No Reminder
9898373|NCT05341622|Experimental|Arm 5|Standard Mail + Text + Reminder
9898374|NCT05341622|Experimental|Arm 6|Standard Mail + Text + No Reminder
9898375|NCT05341622|Experimental|Arm 7|Standard Mail + No Text + Reminder
9898376|NCT05341622|Experimental|Arm 8|Standard Mail + No Text + No Reminder
9898379|NCT05341596||Reintubation after planned extubation|Reintubation after planned extubation(RAP) was defined as repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room.
9898380|NCT05341596||matched group|Patients without RAP during the PACU stay were designated as the matched group
9800309|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18|Subjects aged from 12 - <18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram [mg] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
9800310|NCT01684423|Active Comparator|Comparator, Age: 12 - <18 years|Subjects aged from 12 - <18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
9800311|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
9898381|NCT05341583|Experimental|Ensatinib|Ensatinib ( 225 mg, once daily), in accordance with the randomization schedule
9898382|NCT05341583|Placebo Comparator|Placebo|Placebo ( 225 mg, once daily), in accordance with the randomization schedule
9898383|NCT05341570|Experimental|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BPI-21668 administered, once daily (QD).
9898384|NCT05341570|Experimental|Dose Expansion|Oral tablets administered at MTD/RP2D. Each treatment cycle will be 28 days in duration with BPI-21668 administered, once daily (QD).
9898385|NCT05341557|Experimental|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).
9898386|NCT05341557|Experimental|Dose Expansion|"Oral capsules administered at recommended doses. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).~Cohort 1: Advanced NSCLC Cohort 2: Relapsed/refractory lymphoma Cohort 3: Advanced HCC Cohort 4: Other Advanced Solid Tumors"
9898387|NCT05341544|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 10 days.
9898388|NCT05341544|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 10 days.
9898389|NCT05341518|Experimental|Subscapularis repair|Patients will undergo standard of care reverse total shoulder arthroplasty with subscapularis repair
9898390|NCT05341518|No Intervention|No repair|Patients will undergo standard of care reverse total shoulder arthroplasty. The subscapularis will not be repaired.
9898391|NCT05341505|Experimental|ER intervention|Cognitive-behavioral emotion regulation intervention administered twice weekly for 8 weeks.
9898392|NCT05341492|Experimental|Treatment|Patients will receive 2*10e6/kgCAR-T cells.
9898393|NCT05341479||Surgical treatment for early-stage OPC|Early-stage OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).
9898394|NCT05341479||RT treatment for early-stage OPC|Early-stage OPC patients treated with radiotherapy (RT) according to proper indications (CSCO 2021 and NCCN 2021).
9898395|NCT05341479||CRT treatment for advanced OPC|Advanced OPC patients treated with chemoradiotherapy (CRT) according to proper indications (CSCO 2021 and NCCN 2021).
9898396|NCT05341479||Surgical treatment for advanced OPC|Advanced OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).
9898397|NCT05341479||Neoadjuvant treatment for advanced OPC|Advanced OPC patients treated with neoadjuvant treatment according to proper indications (CSCO 2021 and NCCN 2021).
9898398|NCT05341466|Experimental|Repetitive Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
9898399|NCT05341466|Sham Comparator|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
9898400|NCT05341453|Active Comparator|Individual physiotherapy (SMA-SOC)|Individual physiotherapy will be performed according to the recommended SMA-SOC guidelines.
9898401|NCT05341453|Experimental|Hippotherapy by the children with cerebral palsy|Hippotherapy by the children with cerebral palsy is an accredited form of hipotherapy, whose methodology is based on the clinical picture of cereberal palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, we assume its effect for children with SMA.
9898402|NCT05341453|Other|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA.
9898403|NCT05341427|Experimental|burn wound receiving electromagnetic therapy|There will be only one intervention group. The duration of the study will be 6 weeks divided to 18 sessions (three sessions per week). Sixty patients (male and female) will be recruited from the burn units of Cairo university hospitals
9898404|NCT05341401|Active Comparator|Budesonide MMX|this study aims to detect the safety and side effects of budesonide MMX in the management of mild to moderate cases of ulcerative colitis in comparison to prednisolone. Budesonide MMX will be given after randomization to patients with mild to moderate cases who failed to respond to mesalazine. The dose will be 9mg as a single dose given for 8 weeks.
9898405|NCT05341401|Active Comparator|prednisolone|this study aims to detect the safety and side effects of budesonide MMX in the management of mild to moderate cases of ulcerative colitis in comparison to prednisolone. prdinisolone MMX will be given after randomization to patients with mild to moderate cases who failed to respond to mesalazine. The starting dose will be 40 mg and reduced by 5 mg each weak for 8 weeks .
9898406|NCT05341388||Patients with type 2 diabetes-SGLT2 inh|patients with type 2 diabetes who were recently prescribed an SGLT2 inhibitor
9898407|NCT05341388||Patients with type 2 diabetes-control|patients with type 2 diabetes who were recently prescribed a pre-defined antidiabetic medication other than SGLT2 inhibitors
9898408|NCT05341375|Other|Group C|The general anesthesia was used.In this group, cognitive function was evaluated by MMSE scale on one day before surgery, one day after surgery, and three months after surgery
9898409|NCT05341375|Experimental|Group TA|Group TA received 0.375% ropivacaine 20ml thoracic paravertebral nerve block combined with general anesthesia under ultrasound guidance after anesthesia induction
9898410|NCT05341375|Experimental|Group TE|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
9898411|NCT05341375|Other|Non-surgical controls|Age and sex-matched community people are included for three sessions of MMSE test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCD incidence to rule out learning effect
9898412|NCT05341362|No Intervention|Blank Group|In this group, the anesthesia management is conducted according to the anesthetists' experience, based on the regular monitor.
9898413|NCT05341362|Experimental|LiDCO Group|In this group, the anesthesia management is conducted based on both the regular monitor and the hemodynamic figures on the Lidco.
9898414|NCT05341349|Experimental|Arm I (SRS, pembrolizumab, TTFields)|Patients receive standard of care pembrolizumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
9933132|NCT00956800|Active Comparator|control group|
9933133|NCT00956826|Experimental|Electrode added to device|With an electrode and a regular vacuum device
9997680|NCT01511172|Experimental|NNC 90-1170 + Met placebo|
9992438|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-2|A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
9992439|NCT01462331|Placebo Comparator|Placebo|A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
9992440|NCT01462396|Experimental|Single Arm|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
9992441|NCT01462409|Experimental|heated humidification|
9992442|NCT01462409|Experimental|No Humidification|
9992443|NCT01462409|Experimental|Controlled heated Humidification with heated tube|
9992444|NCT01462422|Other|Primary prevention|
9992445|NCT01462422|Other|Secondary Prevention|
9992446|NCT01462448||Phantom Limb Pain|Subjects will have lower or upper extremity amputation(s) that have resulted in the presence of phantom limb pain.
9992447|NCT01462448||No Phantom Limb Pain|Subjects in the group will have a lower or upper extremity amputation(s) without the presence of phantom limb sensation.
9992448|NCT01462474|Experimental|Drug: Famitinib|
9992449|NCT01462487||Pregnancy outcomes analysis group|Pregnant women evaluated for the following pregnancy outcomes: elective termination, spontaneous abortion (defined as spontaneous fetal loss at < 20 weeks' gestation), fetal death (defined as death of a fetus at > 20 weeks' gestation), premature birth (defined as a birth occurring at < 37 weeks' gestation), and live birth at term
9992450|NCT01462487||Congenital anomalies analysis group|Infants evaluated for congenital anomalies
9992451|NCT01462487||Treatment-emergent diagnoses analysis group|Pregnant women evaluated for treatment-emergent diagnoses
9992452|NCT01462500|Experimental|Miltefosine|Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days
9992453|NCT01462513|Experimental|L-BLP25|L-BLP25 treatment
9992454|NCT01462513|Placebo Comparator|Placebo|Placebo
9992455|NCT01462526||Control|Participants who do not have glaucoma in either eye
9992456|NCT01462526||Glaucoma|Participants who have glaucoma in one or both eyes
9992457|NCT01462539||OSAS group|
9992458|NCT01462539||Non-OSAS group|
9992459|NCT01462552||Metastatic breast cancer pre-label group|Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
9992460|NCT01462552||Metastatic breast cancer post-label group|Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
9992461|NCT01462591|Experimental|L-citrulline|L-citrulline (100mg/kg of body weight per day for 2 weeks)
9992462|NCT01462591|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
9992463|NCT01462604||HER2 overexpressing metastatic or advanced breast cancer pts|
9992464|NCT01462617|Experimental|Pi3K|Experimental
9992465|NCT01462617|Placebo Comparator|Placebo|Placebo Comparator
9997681|NCT01511172|Placebo Comparator|Met + NNC 90-1170 placebo|
9997682|NCT01511172|Active Comparator|Met + Glim|
9997683|NCT01511185|Experimental|NNC 90-1170|
9997684|NCT01511185|Placebo Comparator|Placebo|
9997685|NCT01511185|No Intervention|Healthy|
9997686|NCT01511198|Experimental|0.045 mg|
9997687|NCT01511198|Experimental|0.225 mg|
9997688|NCT01511198|Experimental|0.45 mg|
9997689|NCT01511198|Experimental|0.60 mg|
9997690|NCT01511198|Experimental|0.75 mg|
9997691|NCT01511198|Active Comparator|Met|
9997692|NCT01511211|Experimental|Ropivacaine + Dexamethasone Combination|
9997693|NCT01511211|Active Comparator|Ropivacaine-Only Block|
9997694|NCT01511224||Colistin monotherapy|
9997695|NCT01511224||Colistin based combination therapy|Colistin-Tigecycline, Colistin-Carbapenem, Colistin-Rifampin, Colistin-HD Unasyn
9997696|NCT01511224||Non-colistin containing regime|
9997697|NCT01511224||Glycopeptide with colistin combination|
9997698|NCT01511224||Colistin with loading dose|
9997699|NCT01511237|Experimental|Perinatal intensification|"Perinatal antiretroviral intensification (study treatment):~Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks~The standard of care in Thailand is defined as:~Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor~Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants)."
9997700|NCT01511263|Active Comparator|Arm A|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).
9997701|NCT01511263|Experimental|Arm B|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)
9997702|NCT01511276|Experimental|Diet-induced weight loss|The diet-induced weight loss group will follow a calorie restricted diet. They are asked to keep their habitual sedentary lifestyle. The aim of this group is to loose 5-6 kg of body weight in 14 weeks time.
9933134|NCT00956852||Lung cancer|Non-small cell lung cancer patients undergoing surgical lung resections
9933135|NCT00956865|Active Comparator|Voucher|Voucher for transportation reimbursement
9933136|NCT00956865|Active Comparator|Voucher and call|Voucher for transportation and telephone calls
9933137|NCT00956865|Active Comparator|Voucher and call and contact|Voucher for transportation, telephone calls, and a contact at the senior center
9933138|NCT00956878||Cancer Pain Patients|
9933139|NCT00956891||group A|autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)
9933140|NCT00956891||group B|only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation.
9933141|NCT00956904|Experimental|3-D TRUS navigation software during T-RALP|
9933142|NCT00956917|Active Comparator|Akern EFG|
9933143|NCT00956917|Active Comparator|RJL device|
9933144|NCT00956956|Experimental|PF-04455242 treatment|
9933145|NCT00956956|Placebo Comparator|Placebo|
9933146|NCT00956969|Experimental|Anger awareness and expression|Training for anger awareness and expression
9933147|NCT00956969|Active Comparator|Relaxation Training|Teach patients relaxation training
9933148|NCT00956969|No Intervention|No-treatment control|Assessment only control condition
9933149|NCT00957060|Experimental|glimepiride|The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.
9933150|NCT00957060|Active Comparator|sitagliptin|100 mg once a day. The dose will not be titrated.
9933151|NCT00957073|Experimental|Device|Rheos® system
9933152|NCT00957073|No Intervention|Medical Management|Medical Management Therapy
9933153|NCT00957099||Imaging|Women diagnosed with breast cancer having pre-treatment MRI for spread of disease
9933154|NCT00957112|Experimental|Arm I|Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
9933155|NCT00957112|No Intervention|Arm II|Patients receive standard care. They also receive written information about fatigue as in arm I.
9933156|NCT00957112|Experimental|Arm A|Patients receive treatment as in arm I for 4 more weeks.
9933157|NCT00957112|No Intervention|Arm B|Patients receive standard care as in arm II for 4 more weeks.
9933158|NCT00957112|Experimental|Arm C|Patients learn to self-acupuncture and do so weekly for 4 more weeks.
9933159|NCT00957125|Experimental|Epirubicin Docetaxel Bevacizumab|"Epirubicin and docetaxel i.v. infusion q 3 weeks for 2 cycles.~If complete response this treatment continues for 4 cycles, totally 6 cycles.~If partial response or stable disease, epirubicin and docetaxel and bevacizumab i.v. infusion q 3 weeks for 4 cycles.~If progressive disease after the first 2 cycles individualized treatment."
9933160|NCT00957164|Active Comparator|Pain Treatment Only|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
9898415|NCT05341349|Experimental|Arm II (nivolumab, ipilimumab, SRS, TTFields)|Patients receive standard of care nivolumab and ipilimumab and undergo 3-5 fractions SRS. Patients also undergo TTFields over 8 hours daily using NovoTTF-100M device until intra-cranial progression or until end of immunotherapy treatments at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
9898416|NCT05341336|Experimental|Surgical excision|complete surgical excision of the scalp AVMs after identifying feeding arteries, vein and high flew shunts to perform a complete devascularization of the AVM.
9898417|NCT05341323|Active Comparator|Group K1 Ketamine|pre-incisional submucosal infiltration of ketamine .5 mg/kg in the Peritonsillar area
9898418|NCT05341323|Active Comparator|Group B1 Bupivacaine|pre-incisional submucosal infiltration of Bupivacaine .25 % in the Peritonsillar area
9898419|NCT05341310|Experimental|ADHDCoach|Participants in the experimental group will have access to an individually-tailored Internet intervention developed for the present study. The intervention in clinician-guided and it consists of nine modules delivered for four weeks. The Internet Intervention, called ADHDCoach, is based on an existent Behavioral Parent training protocol, an intervention that was previously tested in a randomized controlled trial with Romanian children (David et al., 2021). The contents for parent modules were developed according to Rational Emotive and Behavioral Therapy (REBT; Ellis, 1994).
9898420|NCT05341310|Active Comparator|Treatment as usual|Treatment as usual at the outpatient clinic
9898421|NCT05341297|Experimental|ParentKIT|Transdiagnostic parent-led Internet-delivered intervention Participants in the experimental group will have access to the ParentKIT intervention. The intervention was developed based on existing Cognitive Behavioral Therapy/ Rational Emotive Behavior Therapy protocols for parents of children with internalizing problems. It consists of nine modules delivered over three weeks.
9898422|NCT05341297|No Intervention|Waitlist|Participants in the waitlist condition will have access to the program after 3 weeks.
10213880|NCT02835261|Experimental|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
10213881|NCT02819882||Luminal A-like subtype|Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
9898425|NCT05341271|Other|digital reminiscence group (DRG)|Experiment group A accepted the planned digital nostalgic group activities using the official account platform of line as a medium, one class per week, 45-50 minutes each time, lasting 8 times.
9898426|NCT05341271|Other|general reminiscence group (GRG)|Experiment group B participated in a general traditional nostalgic group, using actual nostalgic objects or utensils to carry out nostalgic activities, one class per week, 45-50 minutes each time, lasting 8 times
9898427|NCT05341258|Other|Critical Care Patients whom intubated last 24 hours|Critical Care Patients whom intubated last 24 hours
9898428|NCT05341245|Experimental|Graphene oxide group|The surgical defect will be managed by open flap debridement and application of Graphene oxide
9898429|NCT05341245|Other|Open flap group|The surgical defect will be managed by open flap debridement
9898430|NCT05341232|Experimental|Problem-Solving Training|Participants will learn to program LEGO robots and will be encouraged to actively solve problems.
9898431|NCT05341232|Active Comparator|Step-By-Step Training|Participants will learn to program LEGO robots and will be instructed step by step.
9898432|NCT05341232|Placebo Comparator|Board Games|Participants will play boards games under a schedule matching the Experimental and Active Comparator arms.
9898433|NCT05341219|Experimental|light needle therapy|The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
9898434|NCT05341219|Sham Comparator|sham light needle therapy|The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
9898435|NCT05341206|Experimental|Treatment group|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
10213882|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
10213883|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
10213884|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
10213885|NCT02819882||Triple Negative (TN) subtype|Patients who are negative for the expression of ER, PgR and HER2.
10213886|NCT02818517||Heart failure|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
10213887|NCT02814526|Experimental|Aerobic|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
10213888|NCT02814526|Active Comparator|Stretching/balance/range of motion|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
10213889|NCT02812524|Experimental|Intratumoral Ipilimumab|Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.
10213890|NCT02809521|Other|Activity Liking|Subjects will look at images of people doing different types of activities (e.g., walking, skiing, watching television) and rate their liking of the activity.
9898436|NCT05341206|Sham Comparator|Control group|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
9898437|NCT05341193|Experimental|low risk|Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab every 3 weeks for a maximum of 1 year after radiotherapy.
9898438|NCT05341193|Experimental|high risk|Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab and bevacizumab every 3 weeks for a maximum of 1 year after radiotherapy.
10212471|NCT05220579|Experimental|"Exposure to TOR device"|"Patients undergo standard therapy + exposure to the TOR device~Modes of patients' treatment with the TOR device:~The exposure is carried out for at least 5 (five) days in a row for at least 4 hours daily in the 15 + 15 mode (15 minutes exposure + 15 minutes break).~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
10212472|NCT05220579|No Intervention|Control|"Patients received standard therapy~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
9933161|NCT00957164|Active Comparator|PTSD Treatment Only|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
9933162|NCT00957164|Active Comparator|Combined Pain and PTSD Treatment|This treatment arm will involve 5 sessions each of the Pain-Only and PTSD-Only treatments described above.
9933163|NCT00957164|No Intervention|Treatment as Usual|The treatment as usual group will complete the assessments given in each of the other study arms, but will not participate in treatment through the study. Instead, participants randomized to this group will be encouraged to seek treatment for pain and/or PTSD through existing channels. Referrals for treatment will be made for those with clinically significant symptoms for pain and/or PTSD at intake.
9933164|NCT00957177|Placebo Comparator|Placebo|Placebo
10212473|NCT05220579|Placebo Comparator|"Placebo (exposure to switched off TOR device)"|"Patients undergo standard therapy + a switched off TOR device was installed in the wards~Standard therapy was prescribed in accordance with the recommended treatment regimens presented in the guidelines of the the Ministry of Health of Russia Prevention, diagnosis and treatment of coronavirus infection (COVID-19) No. 9 dated 26.10. 2020)."
9933165|NCT00957177|Active Comparator|Pregabalin group|Receiving 300mg pregabalin preoperative
9933166|NCT00957190|Experimental|Cosopt|Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
9933167|NCT00957203|Experimental|Istradefylline|
9933168|NCT00957216|Placebo Comparator|sugar pill|
9933169|NCT00957216|Active Comparator|Coenzyme Q10|The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias
9933170|NCT00957255|Active Comparator|RCR without augmentation|Rotator cuff repair without OrthoADAPT augmentation
9933171|NCT00957255|Experimental|RCR with augmentation|Rotator cuff repair with OrthoADAPT augmentation
9933172|NCT00957281||Asthma|Asthma patients on inhaled corticosteroids
9933173|NCT00957294||Schizophrenia|Patients with first-episode schizophrenia age 18-45 years
9933174|NCT00957294||Depression|First-time hospitalized patients with depression age 18-45 years
9933175|NCT00957294||healthy controls|Healthy controls matched on age and gender (18-45 years)
9935998|NCT02841995|Experimental|belumosudil 200 mg BID|Two 100 mg capsules or one 200 mg tablet (200 mg) of belumosudil twice daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal and 2 capsules or 1 tablet with their evening meal or within 5 minutes of completing a meal.
10212474|NCT05220566|Experimental|'Reserved Therapeutic Space'|Participants will receive 'Reserved Therapeutic Space' Nursing Intervention
10212475|NCT05220566|No Intervention|Control|Participants will receive usual care
10212476|NCT05220553|Experimental|Prosthesis|Participants will be given the PROLIMB II prosthesis to trial in our lab and in their daily lives
10212477|NCT05220527|Experimental|Study group|triamcinolone plus hyruan injection
10212478|NCT05220527|Active Comparator|Experimental|vitagen plus hyruan injection
10212479|NCT05220527|Placebo Comparator|Placebo|normal saline plus hyruan injection
10212480|NCT05220501|Active Comparator|Micro-US Only|Subjects will undergo biopsy using micro-ultrasound only.
10212481|NCT05220501|Active Comparator|mpMRI + Micro-US|Subjects will undergo fusion biopsy using mpMRI and micro-ultrasound
10212482|NCT05220501|Active Comparator|mpMRI Only|Subjects will undergo biopsy using mpMRI fused with regular ultrasound
10212483|NCT05220475|Experimental|fc-SEMS with anchoring plastic stent|fully covered self-expanable metal stent with an external anchoring plastic stent
10212484|NCT05220475|Active Comparator|uc-SEMS|uncovered self-expandable metal stent
10212485|NCT05220449|Active Comparator|Cf-tACS (V1-Alpha_V5-Gamma)|
10212486|NCT05220449|Experimental|Cf-tACS (V1-Gamma_V5-Alpha)|
10213891|NCT02777424|Experimental|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
10213892|NCT02777424|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
9898441|NCT05341167|Active Comparator|Intervention group:|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
9898442|NCT05341167|Other|Control group:|Hypotensive episodes will be treated with vasoactive agents and fluids according to the standard clinical practice. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
9898443|NCT05341154|Active Comparator|Ketamine group|"An anesthesiologist who is not involved in the study will prepare the intervention, ketamine1 mg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
9898444|NCT05341154|Active Comparator|Dexmedetomidine group|"An anesthesiologist who is not involved in the study will prepare the intervention, Dexmedetomidine 1 μg/kg BW, in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
9898445|NCT05341154|Placebo Comparator|Placebo group|"An anesthesiologist who is not involved in the study will prepare the intervention, normal saline 0.9% in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.~All patients will be received standardized GA protocol as follows:~Induction with propofol (1-2 mg/kg body weight).~Esmeron (1 mg/kg body weight).~Isoflurane is a volatile anesthetic agent in 50% O2 and air.~Fentanyl (1 microgram/kg body weight) during induction of anesthesia and the total doses of fentanyl used during the operation will be recorded.~All patients received a combination of intravenous paracetamol 1 g and ketorolac 30 mg at the conclusion of surgery. This regimen will be repeated regularly every 8 h."
9898446|NCT05341141|Experimental|ddEC-ddT and cryotherapy combined with compression|Cryotherapy will be applied using a frozen glove and sock for 15 minutes before, during and 15 minutes after each albumin-paclitaxel infusion. Compression therapy will be applied using a surgical glove for 30 minutes before, during and 30 minutes after each albumin-paclitaxel infusion.
9898447|NCT05341141|Other|ddEC-ddT|ddEC-ddT will be administered without cryotherapy combined with compression.
9898448|NCT05341128||Pediatric Participants With CPP|Pediatric participants who have been diagnosed with CPP per criteria set in the 2015 version of The Consensus on the Diagnosis and Treatment of Central Precocious Puberty and have received treatment or medical services in China between 07 August 2015 and 31 December 2024 will be assessed retrospectively using the Chinese CPP Big Data Platform database.
9935999|NCT02841995|Experimental|belumosudil 400 mg QD|Four 100 mg capsules or two 200 mg tablets (400 mg) of belumosudil once daily. Subjects should take 4 capsules or 2 tablets with their morning meal or within 5 minutes of completing a meal.
9936000|NCT02840448||Case|Subjects with WS/SVAS/WS gene region variation
9992466|NCT01462630|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9992467|NCT01462643|Experimental|variant1|topical ointment, once daily application
9992468|NCT01462643|Experimental|variant 2|topical ointment, once daily application
9992469|NCT01462643|Experimental|variant 3|topical ointment, once daily application
9992470|NCT01462643|Experimental|variant4|topical ointment, once daily application
9992471|NCT01462643|Experimental|variant 5|topical ointment, once daily application
9992472|NCT01462643|Placebo Comparator|variant 6|topical ointment, once daily application
9992473|NCT01462643|Active Comparator|control positive|topical ointment,once daily application
9992474|NCT01462656||Patients with urinary retention|Patients with urinary retention
9992475|NCT01462669|Other|Treatment Period 1|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
9992476|NCT01462669|Other|Treatment Period 2|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
9992477|NCT01462669|Other|Treatment Period 3|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
9992478|NCT01462669|Other|Treatment Period 4|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
9992479|NCT01462708|Experimental|Assess [18F]MK-9470 and PET imaging|To Assess [18F]MK-9470 and PET imaging
9992480|NCT01462721|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery (Cx) or the Right Coronary Artery (RCA) will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
9992481|NCT01462734||human vitreous, human blood serum, PCR|Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease
9992482|NCT01462747|Experimental|KULIST|Medical Device, Activated carbon
9992483|NCT01462760|Other|First assessment: inclinometer|First assessment: inclinometer Second assessment: actigraph and inclinometer
9992484|NCT01462760|Other|first: Inclinometer and actigraph|first: Inclinometer and actigraph second: inclinometer
9992485|NCT01462786|Experimental|ATX-101 in abdomen area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
9992486|NCT01462786|Experimental|ATX-101 in submental area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
9992487|NCT01462799|Experimental|PBL- patient education|Patients will be randomised to PBL in patient education (experiment group)
9992488|NCT01462799|Experimental|Mailed patient information|Patients will be randomised to controlgroup receiving mailed patient information during the year
9992489|NCT01462825|Experimental|tomato ketchup meal|
9992490|NCT01462825|Placebo Comparator|Placebo meal|
9936001|NCT02840448||Controls|Healthy volunteers
9992491|NCT01462838|Experimental|Immunization|P16_37-63 peptide plus Montanide ISA-51 VG
9992492|NCT01462851|Experimental|Dose Escalation|Ascending doses in healthy volunteers
9992493|NCT01462851|Experimental|Part 2: CSF PKPD|Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment
9992494|NCT01462864|Active Comparator|Intervention|Lifestyle education intervention
9992495|NCT01462864|No Intervention|Control|The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
9992496|NCT01462890|Other|Control Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
9992497|NCT01462890|Experimental|Research Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
9992498|NCT01462903|Experimental|Drug, T cell immunoterhapy|
9936002|NCT02839733||Cerebral Palsy|Children and young adults with Cerebral Palsy.
9992499|NCT01462916||honey, no honey|
9936003|NCT02839733||Healthy Volunteer|Children and young adults healthy volunteer
9936004|NCT02835222|Experimental|Arm 2 (Selinexor) cytarabine, daunorubicin and selinexor|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2, and selinexor PO twice weekly. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3, and selinexor PO twice weekly from day 1. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
9992500|NCT01462968|Active Comparator|Activated clotting time (ACT) group|heparinization measured as activated clotting time during surgery
9992501|NCT01462968|Experimental|Hepcon group|heparinization measured as heparin concentration in the blood during surgery
9992502|NCT01462994|No Intervention|Single arm|
9992503|NCT01463020|Experimental|Smartphone delivered BA|
9992504|NCT01463020|Active Comparator|Smartphone delivered mindfulness|
9992505|NCT01463046|Experimental|Panobinostat|
9992506|NCT01463072|Experimental|Treatment (nab-paclitaxel)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9992507|NCT01463085|Placebo Comparator|Control foods|3 servings per day of control foods
9992508|NCT01463085|Experimental|Low-fat dairy|3 servings per day of low-fat dairy products
9992509|NCT01463124|Experimental|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
9992510|NCT01463124|Active Comparator|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
9992511|NCT01463137|Sham Comparator|Control training with words|Computerized, internet-based control training program. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency.
9992512|NCT01463137|Sham Comparator|Control training with words + pictures|Computerized, internet-based control training program. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
9517562|NCT03305289|Active Comparator|pulsed radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
9992513|NCT01463137|Active Comparator|Positive bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
9517790|NCT03302949|Experimental|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
9992514|NCT01463137|Active Comparator|Positive bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
9997703|NCT01511276|Experimental|Mainly exercise induced weight loss|"Participants in the exercise- plus diet-induced weight loss group are enrolled in an exercise programme. Next to the exercise programme, they will follow a calorie restricted diet.~The aim of this group is to loose 5-6 kg of body weight in 14 weeks time."
9898449|NCT05341115|Experimental|Leuprorelin Acetate Depot 3M 11.25 mg|Participants with CPP having body weight ≥20 kg will receive the recommended dose of leuprorelin acetate depot 11.25 mg subcutaneous administration (SC) every 12 weeks based on the standard of 30～180ug/kg/4weeks for the 24-week Treatment Period. It is not recommended to exceed the dose above 180 μg/kg.
9898450|NCT05341102|Experimental|LY3556050 (Part 1)|Participants will receive single ascending doses of LY3556050 orally.
9898451|NCT05341102|Experimental|Placebo (Part 1)|Participants will receive placebo orally.
9898452|NCT05341102|Experimental|LY3556050 (Part 2)|Participants will receive multiple ascending doses of LY3556050 orally.
9898453|NCT05341102|Experimental|Placebo (Part 2)|Participants will receive placebo orally.
9898454|NCT05341089|Experimental|LY3502970 (Formulation 1)|LY3502970 administered orally.
9898455|NCT05341089|Experimental|LY3502970 (Formulation 2)|LY3502970 administered orally.
9898456|NCT05341076|Experimental|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
9898457|NCT05341076|Active Comparator|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
9898458|NCT05341063|Experimental|Intervention Group|Following the first meeting after the pre-tests, a weekly training was created via Zoom. Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.
9898459|NCT05341063|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
9898460|NCT05341050||patients with Ph+ CML-CP|
9898461|NCT05341037||Postoperative complications +|Patients who have postoperative complications during hospital stay after cardiac surgery
9898462|NCT05341037||Postoperative complications -|Patients who have not postoperative complications during hospital stay after cardiac surgery
9898463|NCT05341024|Experimental|Intervention Group|16 weeks home-based PFM training program with weekly follow-up by a physiotherapist
9898464|NCT05341024|No Intervention|Control Group|No intervention
9898465|NCT05341011|Experimental|Treatment (TX) Group|The TX group received 14 weeks of the PEERS® intervention immediately following a baseline assessment,
9898466|NCT05341011|Experimental|Delayed Treatment Control (DTC) Group|The DTC group received the same intervention after a 14-week waiting period. Parents and teens attended concurrent sessions held in separate rooms.
9898467|NCT05340998||Crossover Group|Patients with Transradial access failure for percutaneous coronary procedures necessitating vascular crossover
9898468|NCT05340998||Non Crossover Group|Patients with successful transradial access for percutaneous coronary procedures
9898469|NCT05340985|Experimental|25(OH)D3 (Calcifediol)|50 micrograms per day 25(OH)D3 or vitamin D hydroxylated for 24 weeks
9898470|NCT05340985|Experimental|Cholecalciferol|50 micrograms (2000IU) per day Cholecalciferol for 24 Weeks
9898471|NCT05340959||Adult patient with single or multiple missing tooth or teeth requiring dental implants|"Adult patient with single or multiple missing tooth or teeth requiring dental implants, 40 dental implants will be placed in osteotomy sites based on radiographic findings (CBCT), the primary stability will be measured immediately after implant installation and secondary stability will be measured after 12 weeks .~Both primary and secondary stability will be measured by three devices:~Osstell®: based on Resonance Frequency Analysis (RFA).~Periotest®: based on damping effect.~AnyCheck®: based on tapping-motion."
9898472|NCT05340946|Experimental|Group (G)|received general anaesthesia followed by IV patient-controlled analgesia (IV PCA).
9898473|NCT05340946|Experimental|Group (F)|received spinal anaesthesia followed by continuous ultrasound guided femoral never block once the anaesthesia-induced motor block resolved.
9898474|NCT05340933|Experimental|Arm 1|intervention correspond to the voice registration
9997704|NCT01511276|No Intervention|Control, stable weight|The control group is asked to follow a baseline isocaloric diet and to not change their habitual sedentary lifestyle.
9997705|NCT01511289|Active Comparator|Imatinib|Imatinib 400mg QD
10212487|NCT05220436|Experimental|DISCOVER workshop programme|"As this is a case series study, all participants will receive the intervention (i.e. no other arms to the study design).~The DISCOVER workshop programme includes: 1:1 mental health and emotional well-being assessment session with a Clinical Psychologist, a group workshop day, follow-up supportive phone calls and a closing follow-up 1:1 mental health and emotional well-being session with a Clinical Psychologist."
10212488|NCT05220423|Other|Reminders Group|This group will receive 6 reminders (sms/emails) on top of the National annual communication campaign organized by the French Health System authorities
10212489|NCT05220423|Other|No reminders group|This group will receive no reminders on top of the National annual communication campaign organized by the French Health System authorities
10212490|NCT05220384|Other|Personalized In-person therapy|
10212491|NCT05220384|Other|Generalized, Video-based therapy|
10212492|NCT05220345|Other|colonoscopy with a combined BFT and CADe assisted approach|This multicenter single-arm colonoscopy trial will compare colonoscopy assisted by both balloon-BFT visualizing and CADe to CADe-only assisted colonoscopy in diagnostic, screening (non-iFOBT based)), or surveillance colonoscopy. The latter group will be selected from the interventional arm from the Discovery II trial, using corresponding participating centers. All subjects in this trial will undergo the same treatment, i.e., combined balloon and CADe-assisted colonoscopy.
10212493|NCT05220332|Experimental|Heart to Heart|
10212494|NCT05220332|Active Comparator|Money Smart|
10212495|NCT05220306|Experimental|Device Arm|Participants will use the MouthLab device for monitoring their vital signs
10212496|NCT05220280|No Intervention|Local standard of care|
10212497|NCT05220280|Experimental|Imatinib + local standard of care|
10212498|NCT05220280|Experimental|Infliximab + local standard of care|
10212499|NCT05220267|Other|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle) .Sintilimab was administered intravenously (200mg once every 3weeks).
10212500|NCT05220254|Experimental|MindCotine mobile app program|
10212501|NCT05220228|Experimental|Prucalopride|Prucalopride - 1mg for 2 days, and then increased to 2mg for a further 5-8 days. Testing will occur on day 7 ideally, but may take place up to and including day 10.
9898475|NCT05340907|No Intervention|Patient undergoing Bronchoscopy without use of VR device|patients undergoing flexible bronchoscopy without the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
9898476|NCT05340907|Experimental|Patient Undergoing Bronchoscopy with the use of VR device|patients undergoing flexible bronchoscopy with the VR device on, they will be shown a video consisting of calming nature scene together with soothing instrumental music. Sedation will be given as per standard practice.
9898477|NCT05340894|Active Comparator|Mckenzie group|"adolescents will receive 4 weeks Mckenzie exercise program~Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
9898478|NCT05340894|Active Comparator|William's group|"adolescents will receive 4 weeks William's exercise program~Follow-up:pre-test (Baseline), 2 weeks post-test and 4 weeks post-test."
9898479|NCT05340881|Active Comparator|Bright Light Exposure|Participants are exposed to bright light (1,000 lux at eye level) using light glasses (Luminette Version 3) for a maximum duration of 30 minutes upon awakening each day from Monday to Friday for 6 weeks while wearing an actigraph and periodic completion of questionnaires, cognitive assessments, and lab work.
9898480|NCT05340881|Placebo Comparator|Dim Light Exposure|Participants are exposed to exposed to dim light (equivalent intensity of <25 lux) using light glasses (Luminette) for a maximum duration of 30 minutes upon awakening each day from Monday to Friday for 6 weeks while wearing an actigraph and periodic completion of questionnaires, cognitive assessments, and lab work.
9898481|NCT05340868|Experimental|Semaglutide (oral)|In the project, each participant will receive oral semaglutide for three months. 3 mg a day for the first two weeks, then 7 mg a day for the next two weeks, until reaching a dose of 14 mg a day, which will be taken for the next eight weeks.
10212502|NCT05220228|Placebo Comparator|Placebo|Placebo (sucrose / lactose) for 7-10 days
9898483|NCT05340842|Experimental|Simulation training experiment group|"In this training, the researcher firstly explained breastfeeding by wearing the Lactation Simulation Model on himself and showing it practically on himself.~Afterwards, the model was dressed on the pregnant woman and the pregnant woman was given one-on-one breastfeeding practice.~In this process, all questions of the pregnant woman were answered by the researcher."
10212503|NCT05220215|Experimental|Group A: Nordic Hamstring Exercise|"This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stretching.~Number of sets and repetitions progressively increase i-e: Week 1 - 2 sessions with 2 sets of 5 repetitions each. Week 2 - 2 sessions with 3 set of 5 repetitions each. Week 3 - 2 sessions with 4 set of 6 repetitions each. Week 4 - 2 sessions with 4 set of 8 repetitions each."
10212504|NCT05220215|Experimental|Group B: Hamstring Curl with Resistance Band|"This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stretching.~Number of sets progressively increase i-e: Week 1 - 2 sessions with 2 sets of 15 repetitions each. Week 2 - 2 sessions with 3 set of 15 repetitions each. Week 3 - 2 sessions with 4 set of 15 repetitions each. Week 4 - 2 sessions with 4 set of 15 repetitions each."
9898484|NCT05340842|No Intervention|Control group|At this stage, the standard video screening prepared for breastfeeding education within the scope of the hospital protocol was shown to the pregnant woman by the researcher with a tablet.
9898485|NCT05340829|Experimental|ThisCART19A 2×10^6 cells/kg for dose level 1|Patients will receive 2×10^6 cells/kg of ThisCART19A
9898486|NCT05340829|Experimental|ThisCART19A 3×10^6 cells/kg as dose level 2|Patients will receive 3×10^6 cells/kg of ThisCART19A
9898487|NCT05340829|Experimental|Patients will receive 4×10^6 cells/kg as dose level 3|Patients will receive 4×10^6 cells/kg of ThisCART19A
9898488|NCT05340816|Experimental|Manual Lymphatic Drainage|5 days, 30 minutes, Manual Lymphatic Drainage
9898489|NCT05340816|Experimental|Transcutaneous Electrical Nerve Stimulation|5 days, 20 minutes, Transcutaneous Electrical Nerve Stimulation
9898490|NCT05340816|No Intervention|Control|no any intervention
9898491|NCT05340803|Active Comparator|Group A|Sedation by midazolam alone
9898492|NCT05340803|Active Comparator|Group B|Sedation by midazolam and dexmedetomidine during the first 24 hours
9898493|NCT05340803|Active Comparator|Group C|Sedation by midazolam and magnesium sulfate during the first 24 hours
9898494|NCT05340790|Experimental|Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
9898495|NCT05340790|Placebo Comparator|Placebo dose|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
9898496|NCT05340764|Active Comparator|2-hour infusion of infliximab|Standard of care 2 hour infusion of infliximab
9898497|NCT05340764|Experimental|1-hour infusion of infliximab|Reduced 1 hour infusion of infliximab
9898498|NCT05340751||Anesthesia|hemoglobin
9898499|NCT05340738|Active Comparator|LyssnCBT|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. Therapists and supervisors will also have access to LyssnCBT features like speech-to-text transcription, annotation tools, and AI-generated metrics.
9898500|NCT05340738|No Intervention|SAU (services-as-usual)|Therapists will use the LyssnCBT tool with clients for recording and session-sharing functionalities. No other LyssnCBT features will be available for therapist or supervisor review.
9898501|NCT05340725|Active Comparator|DEX-IV|Patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. and rectal placebo 30 min. before induction of anesthesia.
10212505|NCT05220189||Hematuria patients aged ≥40|Device: EarlyTect Bladder Cancer test, PENK methylation assay by LTE (Linear Target Enrichment)-qMSP (quantitative methylation-specific real time PCR)
10212506|NCT05220150|Experimental|Alzheimer's patients|Patient diagnosed with early onset Alzheimer's disease.
10212507|NCT05220150|Active Comparator|Control|Healthy volunteers that do not have Alzheimer's disease.
9898502|NCT05340725|Active Comparator|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg an iv. saline placebo. at 30 min. before induction of anesthesia.
9898503|NCT05340725|Active Comparator|DEX Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg an iv. saline placebo at 30 min. before induction of anesthesia
9992515|NCT01463137|Active Comparator|Negative bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
9992516|NCT01463137|Active Comparator|Negative bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
9992517|NCT01463150|Active Comparator|Clopidogrel|Clopidogrel 150mg per day for 15 days
9992518|NCT01463150|Experimental|Prasugrel|Prasugrel 5mg for 15 days
9992519|NCT01463163|Active Comparator|Prasugrel|Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
9992520|NCT01463163|Experimental|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
9992521|NCT01463176|No Intervention|Standard Care|Children in the Standard Care Control group will receive standard care and will be videotaped by the music therapist but will not receive music therapy during their immunization
9992522|NCT01463176|Experimental|Music Therapy|Children in this group will receive live music therapy during their immunization.
9992523|NCT01463189|Experimental|painACTION: Arthritis|
9992524|NCT01463189|No Intervention|treatment as usual|
9992525|NCT01463215|Experimental|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
9992526|NCT01463228|Experimental|Treatment Sequence AB|
9992527|NCT01463228|Experimental|Treatment Sequence BA|
9992528|NCT01463241|Other|BASIC treatment|As an open trial, all participants in this study will receive the BASIC treatment.
9992529|NCT01463254||Surveillance|- a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant
9997706|NCT01511289|Experimental|Radotinib 600mg|Radotinib 300mg BID
10213893|NCT02769806||GBM patients undergoing MRI|GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.
9898506|NCT05340699|Experimental|experimental group|A group of children wearing Xingyouxue Defocus Distributed Multi-point lens
9898507|NCT05340699|Active Comparator|control group|A group of children wearing single vision lens
9898508|NCT05340686|Experimental|Braining high intensity|Moderate to vigorous physical exercise, supervised by psychiatric staff 3 times per week
9898509|NCT05340686|Active Comparator|Braining relaxing exercise|Relaxation, light yoga or stretching exercise, supervised by psychiatric staff 3 times per week
9898510|NCT05340686|Active Comparator|Information about physical exercise|Written and oral information about health benefits from physical exercise, provided by researcher on one occasion.
9898511|NCT05340673|Experimental|Arm I (Aquaphor)|Beginning on day 1 of radiation therapy, patients apply Aquaphor BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
9898512|NCT05340673|Experimental|Arm II (Miaderm)|Beginning on day 1 of radiation therapy, patients apply Miaderm BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
9898513|NCT05340660|Experimental|ALS Patient|
9898514|NCT05340647||Group 1 Preserflo microshunt|
9898515|NCT05340647||Group 2 Trabeculectomy|
9898516|NCT05340647||Group 3 Other MIGS|Other micro-invasive glaucoma surgery (MIGS) than Preserflo microshunt (e.g., Xen gel stent, iStent inject)
9898517|NCT05340634|Active Comparator|Oral Contraceptive|Drospirenone 4 mg once a day for 6 months
9898518|NCT05340634|Experimental|Oral Contraceptive + Food supplement Metionac|Drospirenone 4 mg once a day and Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
9898519|NCT05340634|Other|Food supplement MetioNac|Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
9898520|NCT05340621|Experimental|OKI-179 + binimetinib|
9898521|NCT05340608||Observation Group One|Twenty subjects with high functioning autism spectrum disorder, aged between 20 and 40 years, residing at home.
9898522|NCT05340608||Control Group|Twenty typically-developed subjects matched for sex and age distribution with participants in the Observation Group One.
9898523|NCT05340608||Observation Group Two|This group will include ten people with autism spectrum disorders, aged between 20 and 40 years, residing at home and presenting aggressive or disruptive challenging behaviors, and their caregivers.
9898524|NCT05340608||Proof of Concept|One participant with autism spectrum disorder, aged between 20 and 40 years attending a special school and living at home and exhibiting aggressive or disruptive challenging behavior, and healthcare professionals and teachers who care for him in the school setting, will participate in the proof-of-concept phase of the present study.
9898525|NCT05340595|Other|Control group|The primer (Transbond XT Primer; 3M Unitek, California) was applied in a thin and uniform coat. Then the adhesive resin (Transbond LR Light Cure Adhesive Paste; 3M Unitek, California) was administered to the lingual surface of the anterior teeth and the lingual retainer was placed in position. The adhesive resin was polymerized from two directions for a total of 20 s using a visible-light curing unit (Hilux 200, Benlioglu Dental Inc., Ankara, Turkey) with an output power of 600 mW/cm2.
9898526|NCT05340595|Active Comparator|Study group|In the study group, the SEP (3M Unitek, Monrovia, California) was used according to the manufacturer's instructions, namely it was administered to the lingual surfaces of the teeth and rubbed for 3 s. Then a gentle burst of dry air was delivered to thin the primer. In the control group, the lingual surfaces of the teeth were etched using 37% phosphoric etchant liquid gel (3M Espe, St Paul, Minnesota, USA) for 30 s, followed by rinsing and drying.
9898527|NCT05340582|Experimental|Combination Therapy|Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates < 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And study drug (intravenous acetaminophen 15 mg/kg/dose IV q6h for 3 days).
9898528|NCT05340582|Placebo Comparator|Standard Clinical Practice - Monotherapy|Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates < 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And Placebo [(0.9% saline IV q6h for 3 days).
9898529|NCT05340569|Experimental|DWI-MRI|Patients to undergo DWI-MRI (patients include in the study.
9898530|NCT05340556|Experimental|sRPL patient|sRPL with an older brother and at least one child prior to diagnosis
9898531|NCT05340556|Experimental|Brother or child to the sRPL patient|An older brother (with at least same biological mother) og child to the sRPL patient
9898532|NCT05340543||Patient with basal cell carcinoma|"- CBC: Presence of lobule of basal cells with palisading on the edges, stromal reaction and dilated horizontal vessels."
9898533|NCT05340543||Patient with squamous cell carcinoma|- CSC: Proliferation of keratinocytes presenting cellular atypia, crossing the JDE (invasive CSC versus in situ), glomerular vessels
9898534|NCT05340543||Patient with melanoma|Melanoma: Destructured dermal-epidermal junction (DEJ), presence of pagetoid cells, clusters of atypical melanocytes, dendritic cells
9898535|NCT05340530|Experimental|The injectable TQD3606|received a single dose of 0.75g TQD3606 for injection
9898536|NCT05340530|Active Comparator|The injectable TQD3606+ meropenem|First, a single dose of 0.5g of meropenem for injection was administered for 0.5h intravenous infusion; after washout for at least 2 days, 0.75g of TQD3606 for injection was administered for 1h intravenous infusion; for at least 2 days of washout, 0.75g was administered A single dose of TQD3606 for injection was administered for 2 hours, and the elution time was at least 2 days. Finally, a single dose of 0.75 g of TQD3606 for injection was administered, and the duration of intravenous infusion was 3 hours.
9992530|NCT01463254||Prospective|a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment
9992531|NCT01463280|Experimental|tumescent lidocaine infiltration|Assess Platelet function with respect to dosage of tumescent lidocaine There is only one arm.
9898537|NCT05340530|Active Comparator|The injectable TQD3606+ meropenem+ Avibactam Sodium|According to the random table, they were divided into two groups, A and B, Group A was given 1.0g meropenem for injection (Mepin) in the first cycle, and 0.5g avibactam sodium for injection in the second cycle. The third cycle was given 1.5g TQD3606 for injection; group B was given 0.5g avibactam sodium for injection in the first cycle, 1.0g meropenem (Mepin) for injection in the second cycle, and 1.5g for injection in the third cycle TQD3606.
9898538|NCT05340530|Experimental|The injectable TQD3606-1|First, 0.75g TQD3606 for injection was administered multiple times (Dosing every 8 hours, 3 consecutive doses), and at least 2 days were washed out after the last dose; then 1.125g TQD3606 for injection was administered multiple times (Dosing every 12 hours, 2 consecutive doses) times), wash out at least 2 days after the last administration; finally, a single administration of 2.25 g of TQD3606 for injection (Dosing every 12 hours, once administered). Intravenous infusion for 3 hours.
9898539|NCT05340530|Placebo Comparator|The injectable TQD3606/ Placebo|First, a single dose of 3.0g TQD3606 for injection/placebo was administered, intravenous infusion for 3hours, and washout for at least 3 days; then multiple doses of 3.0g TQD3606 for injection/placebo were administered (Dosing every 8 hours, 10 consecutive doses) , the intravenous infusion duration is 3hours.
9898540|NCT05340517|Experimental|video-assisted rib planting|
9898541|NCT05340504|Experimental|Group A: NAC, then Placebo Oral Capsule|Group A will receive NAC 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive Placebo Oral Capsule 2 times a day for 14 days and have another MRI exam on day 14.
9898542|NCT05340504|Experimental|Group B: Placebo Oral Capsule, then NAC|Group A will receive Placebo Oral Capsule 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive NAC 2 times a day for 14 days and have another MRI exam on day 14.
9898543|NCT05340491|Experimental|Chemoradiotherapy+anti-PD-1|Patients in this arm will receive three cycles of GP chemotherapy plus PD-1 antibody, then receive IMRT and PD-1 antibody maintenance for eight cycles.
9898544|NCT05340491|Active Comparator|Chemoradiotherapy|Patients in this arm will receive three cycles of GP chemotherapy, then receive IMRT.
9898545|NCT05340478||1|Veterans with anxiety
9898546|NCT05340465|Active Comparator|Group 1. Oral iron|Oral iron is started on day 7 of life if baby is feeding 100 mL/kg/day. Iron supplements of up to 12 mg/kg/day are given based on CBC, retic, ret-hgb, serum ferritin and zinc protoporphyrin to heme ratio (ZnPP/H). Iron supplements are adjusted every 2 weeks following iron studies.
9898547|NCT05340465|Experimental|Group 2|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive LMW-ID: 10 mg/kg x 1, retreat if ferritin < 76 mcg/L
9898548|NCT05340465|Experimental|Group 3|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive LMW-ID: 20 mg/kg x 1, retreat if ferritin < 76 mcg/L
9898549|NCT05340465|Experimental|Group 4|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive FMX: 10 mg/kg x 1, retreat if ferritin < 76 mcg/L
9898550|NCT05340465|Experimental|Group 5|Infants randomized to this arm will receive Darbe 10 mcg/kg q week started on day 3 of life. In addition, beginning on day 7, they will receive FMX: 20 mg/kg x 1, retreat if ferritin < 76 mcg/L
10212508|NCT05220124|Experimental|Immunotherapy with Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 3-4 treatment cycles,21 days per cycle.
10212509|NCT05220124|No Intervention|Immunotherapy without Probiotics|control group, Immunotherapy without Probiotics
9898553|NCT05340439|Experimental|Incobotulinumtoxin A treatment|The study will consist of three injection cycles. In each, an injection visit is followed by an observation period of 12 to 20 weeks.
9898554|NCT05340426|Experimental|Porcine Kidney (UKidney) transplant|In this phase I single arm study patients with acute renal failure will be transplanted with a porcine xenograft versus a human allograft-after transplantation the best practice standard of care will be followed for monitoring and immunosuppression with the exception of additional monitoring for potential porcine transmitted infections
9898555|NCT05340413|Experimental|Cohort 1|"HER2-negative ABC with documented germline or somatic mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Patients with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations that are considered to be non-detrimental (e.g., Variants of uncertain clinical significance or Variant of unknown significance or Variant, favor polymorphism or benign polymorphism, etc.) will not be eligible for this cohort."
9992532|NCT01463319|Experimental|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
9992533|NCT01463319|Experimental|air insufflation|air insufflation during insertion phase of colonoscopy
10212510|NCT05220098|Experimental|TAK-280|Participants will receive TAK-280 for up to 14 treatment cycles (Each treatment Cycle = 28 days) until disease progression, unacceptable toxicity, or withdrawal from study occurs.
10212511|NCT05220072|Experimental|Carbon-14 BIA 28-6156|Healthy volunteers receive a single dose of Carbon-14 BIA 28-6156
10212512|NCT05220033|Experimental|Journey Ahead|Experimental: Journey Ahead intervention focusing on coping and communication skill development during the course of 8 sessions and 6 phone calls.
10212513|NCT05220020|Experimental|Experimental group|Synchronous treatment group: the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.
10212514|NCT05220020|Active Comparator|Control group|Sequential treatment group: patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
10212515|NCT05220007|Experimental|Glaucomatous arm|Mild stage glaucomatous patients age more than 18 years old, a history of uneventful phacoemulsification with MIOL implantation at least 1 month before participation, distant best-corrected visual acuity (BCVA) equal to or better than 20/30, near BCVA at least Jaeger 2.
9997707|NCT01511289|Experimental|Radotinib 800mg|Radotinib 400mg BID
9517791|NCT03302923|Experimental|Brisk walking 1|1 time a week of 9 months brisk walking
9898556|NCT05340413|Active Comparator|Cohort 2|HER2-negative ABC with RAD51-foci low score in the most recent locally recurrence or biopsy from the metastatic context and without known or with negative germline or somatic mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Mutation status will be assessed in, at least, olaparib responding patients in this subgroup.
9898557|NCT05340400||Patients diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
9898558|NCT05340400||Patients not diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
10212516|NCT05220007|Active Comparator|Non-glaucomatous arm|Pseudophakic participants without glaucoma, age more than 18 years old, a history of uneventful phacoemulsification with MIOL implantation at least 1 month before participation, distant best-corrected visual acuity (BCVA) equal to or better than 20/30, near BCVA at least Jaeger 2.
10212517|NCT05219916|Experimental|Adult patients infected by HIV, controlled under treatment.|Blood sample collection from HIV controlled patients during their scheduled consultation, after obtaining their non-opposition by an investigator.
9898561|NCT05340374|Experimental|Treatment Arm|In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-617 on Day 1 of every 6 week Cycle. Cabazitaxel will be administered concurrently on Day 2 and Day 23 of each Cycle (every 3 weeks). The dose of cabazitaxel will vary in dose-escalation. Up to 6 Cycles will be given.
9898562|NCT05340361||In vivo|OCT examination is performed using a frequency-domain OCT system (C7 DragonflyTM OPTISTM Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
9898563|NCT05340361||In vitro|In vitro study with phantom tube model regarding tapered vessel type
9898564|NCT05340348|Other|Patient library|All the patients are included in one arm. They will undergo various type of samples.
9898565|NCT05340335|Experimental|Remimazolam|A loading dose of remimazolam is administered for sedation
9898566|NCT05340322|Experimental|HPV+ Pap smear|Visualization of cervix and if abnormalities are present treat with SOC thermocoagulation.
9898567|NCT05340309|Experimental|Treatment (atezolizumab and recombinant human hyaluronidase)|Patients receive atezolizumab and recombinant human hyaluronidase SC over 3-8 minutes on day 1. Cycles repeat every 3 weeks for 1 year (early-stage lung cancer) or up to 2 years (late-stage lung cancer) in the absence of disease progression or unacceptable toxicity.
9898568|NCT05340296|Experimental|Acute Youth Connect + TAU|Subjects will receive 12 weeks of post-discharge Acute Youth Connect intervention, in addition to regular post-discharge treatment as usual.
9898569|NCT05340283||Observational group|Patients with Parkinson's disease who were referred to a Home Rehabilitation Service in Gijón, Asturias region, Spain, during the years 2015 to 2021.
9898570|NCT05340270|Experimental|PD-1 inhibitor + GP Group|PD-1 inhibitor plus GP chemotherapy as Neoadjuvant Therapy followed by IMRT combined with cisplatin concurrent chemotherapy
9898571|NCT05340270|Active Comparator|GP Group|GP chemotherapy as Neoadjuvant Therapy chemotherapy followed by IMRT combined with cisplatin concurrent chemotherapy
9898572|NCT05340257|Experimental|Participants with CAP and ABRS|
9898573|NCT05340231|Experimental|Study group|sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy
9898574|NCT05340231|Active Comparator|Control group|neoadjuvant chemotherapy alone
9898575|NCT05340205|Active Comparator|Tranexamic acid group|Patients will receive 1 gm (10 ml) tranexamic acid diluted in 20 ml of Glucose 5% (administered as IV infusion over 5 minutes, at least 15 minutes prior to skin incision). Following the delivery of the baby, patients will additionally receive a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).
9898576|NCT05340205|Active Comparator|Misoprostol group|Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and swabbing the uterine cavity. Patients will additionally receive a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).
9898577|NCT05340205|Active Comparator|Oxytocin only (control) group|Patients will receive only an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
9898578|NCT05340192|Other|Healthy Volunteer|Octreotide, 100 mcg (1 ml) s.c.
9898579|NCT05340179|Active Comparator|Interlaminar cervical epidural steroid injection|
9898580|NCT05340179|Experimental|Cervical selective nerve root block|
9898581|NCT05340166|Active Comparator|Radiofrequency Neurolysis|Radiofrequency Neurolysis of genicular nerves
9898582|NCT05340166|Experimental|Chemical Neurolysis|Chemical Neurolysis of genicular nerves
10212518|NCT05219838|Experimental|Lu AG06466 Low Dose|Participants will receive Lu AG06466 low dose capsule orally once daily for 6 days approximately 30 minutes following a light meal.
10212519|NCT05219838|Experimental|Lu AG06466 High Dose|Participants will receive Lu AG06466 high dose capsule orally once daily for 6 days approximately 30 minutes following a light meal.
10212520|NCT05219786|Experimental|Decision Support Tool|In this arm study participants saw a decision support tool consisting of a video and a interactive decision aid (www.appyornot.org).
10212521|NCT05219786|Active Comparator|Infographic|Participant saw a static infographic providing information about the two treatments for appendicitis.
9898583|NCT05340153|Active Comparator|Artemether-lumefantrine|Drug: Artemether-lumefantrine drug combination Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains a blister of 12 tablets. It will be administered each day as one, two or three tablets depending on the weight of the child.
9898584|NCT05340153|Experimental|Dihydroartemisinin-piperaquine|Drug: Dihydroartemisinin-piperaquine drug combination Dihydroartemisinin-piperaquine is formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains a blister of 6 tablets and given each day as half, one, two or three tablets depending on the weight of the child.
9898585|NCT05340140||CBCT Images of Maxillary 1st molars|
9898586|NCT05340127|Experimental|Subjects examined by the study participants using CEREBO®|"CEREBO® - A non-invasive intracranial haemorrhage detector~Scan Duration - 40 seconds per subject~Frequency - Every operator will perform CEREBO® scan on at least 10 different subjects~Adverse Effect: None"
9898587|NCT05340114|Experimental|Subjects examined by the operations with CEREBO®|CEREBO® - A portable non-invasive device to detect intracranial haemorrhage Frequency - The operator will scan at least 10 patients Duration - 40 seconds per subject No adverse effect or contraindications
9898588|NCT05340101|Experimental|experimental group|This group will practiced progressive muscle relaxation exercise
9898589|NCT05340101|No Intervention|control group|This group will not practiced progressive muscle relaxation exercise
9898590|NCT05340088||Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
9898591|NCT05340088||Patients who underwent RIRC for 4-6 weeks after DJ stent placement for passive dilatation|Patients who underwent RIRC for 4-6 weeks after DJ stent placement for passive dilatation
9898592|NCT05340075||Staged percutaneous nephrolithotomy group 1|Those who underwent percutaneous nephrolithotomy 2-4 weeks after percutaneous nephrolithotomy for stones in the other kidney
9898593|NCT05340075||Staged percutaneous nephrolithotomy group 2|Those who underwent percutaneous nephrolithotomy 4-6 weeks after percutaneous nephrolithotomy for stones in the other kidney
9898594|NCT05340062||pediatric patients with ICP device|"In children requiring ICP, TCD and ONSD will be measured:~within 30 minutes before to the placement of the ICP (if possiblel)~at least twice a day after placement of the invasive ICP for the first 48 hours~Each measurement will include:~The measure of the invasive ICP~Calculation of invasive CPP (invasive MAP-invasive ICP)~TCD: FVs, FVd, FVm, from which the nCPP will be obtained with the formula FVdICP. The nICP will be obtained from invasive MAP minus nCPP.~The measurement of the nICP ONSD (2) for a total of 2 measurements preferably from the side where the invasive ICP device is positioned.~Measurements (TCD and ONSD) will be done by two operators blinded by each other in order to evaluate the inter-operator variability"
9898595|NCT05340049|Placebo Comparator|"Primary Group Control"|41 patients of the total sample are part of the placebo group, being these patients without active primitive reflexes and/or cranial blocks, or in smaller quantities than the other participants of the study
9898596|NCT05340049|Active Comparator|"Secondary group Rhythmic Movement Therapy"|40 patients of the total sample are part of the rhythmic movement therapy group, having 1 or all of the primitive reflexes active and/or cranial blocks studied.
9898597|NCT05340049|Experimental|"Tertiary group Craniosacral Therapy"|39 patients of the total sample are part of the rhythmic movement therapy group, having 1 or all of the primitive reflexes active and/or cranial blocks studied.
10212522|NCT05219773|Other|Clinic vs Home spirometry|The collection of medical history and demographic data Spirometry testing in both the clinic and home setting. The measurement of height and weight. The evaluation of the perception of home spirometry via a survey.
10212523|NCT05219747|Experimental|A.Oleracea group|Mucoadhesive film containing Acmella oleracea extract
9997708|NCT01511302|Experimental|RNS60-BD 0.25|RNS60 in combination with Budesonide 0.25mg/2ml concentration
10212524|NCT05219747|Placebo Comparator|Placebo group|Mucoadhesive film without Acmella oleracea extract
10212525|NCT05219721|Experimental|CAR-GPRC5D cells|"The tolerability and safety of CAR-GPRC5D cells will be assessed according to the 3+3 dose-escalation design. There will be three dose levels, 0.5×10^6, 1.0×10^6, and 2.0×10^6, CAR+T cells/kg. For each level, 3-6 subjects will be enrolled."
10212526|NCT05219669|Experimental|Intranasal Nalmefene 1 spray in 1 nostril|Nalmefene Hydrochloride nasal spray, 3mg, 1 spray in 1 nostril
10212527|NCT05219669|Experimental|Intranasal Nalmefene 2 sprays in 1 nostril|Nalmefene Hydrochloride nasal spray, 6mg, 2 sprays in 1 nostril
10212528|NCT05219669|Experimental|Intranasal Nalmefene 1 spray in each nostril|Nalmefene Hydrochloride nasal spray, 6mg, 1 spray in each nostril
10212529|NCT05219643|Experimental|NAVA|Received NAVA.
10212530|NCT05219643|Active Comparator|PSV|Received PSV.
10212531|NCT05219565|Experimental|Attractive Targeted Sugar Bait (ATSB)|Clusters within the ATSB arm will have 2 to 3 ATSBs hung on all eligible structures in the cluster where consent from the corresponding compound has been given.
10212532|NCT05219565|No Intervention|Control|Clusters within the control arm will not receive ATSBs.
10212533|NCT05219526|Experimental|Subject BGMS measurement|Blood glucose measurement using BGMS
10212534|NCT05219500|Experimental|Ac225-PSMA I&T|All patients will receive 225Ac-PSMA-I&T, administered at 8 ± 1-week interval, with the initial activity of 100 kBq/kg (±10%), then de-escalation to 87 kBq/kg (±10%), 75 kBq/kg (±10%) or 50 kBq/kg (±10%) in cases of good response (PSA decline >50%), at the discretion of the principal investigator.
10212535|NCT05219474|Experimental|Cochlear implant subjects|Participates in 7 visits over a six-month duration. Subjects will be given several tests that require them to listen to sounds presented to their cochlear implant and answer questions about those sounds.
10212536|NCT05219474|No Intervention|Normal hearing subjects|Participates in 1 visit lasting 3 hours. Will be given several tests that require you to listen to sounds and answer questions about those sounds. The sounds will be distorted in ways that approximate how a cochlear implant sounds.
9898600|NCT05340023||Patient with suspicion of Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH)|"right cardiac catheterization (usual practice)~a blood sample (inclusion for all patients with suspicion)~if diagnosis of Chronic thromboembolic pulmonary hypertension confirmed a another bood sample at 6 months"
9898601|NCT05340010|Experimental|HCG group|n Group 1 (hCG): participants will receive endometrial preparation with estrogen and an intramuscular hCG injection will before progesterone supplementation
9898602|NCT05340010|No Intervention|control group|Group 2 (control): participants will receive the conventional endometrial preparation with estrogen followed by progesterone supplementation
9898603|NCT05339984|Experimental|Hepatectomy|Liver resection group
9898604|NCT05339984|Experimental|Liver Transplantation|Liver Transplantation group
9898605|NCT05339984|Experimental|Portal vein embolization|Portal vein embolization group
9898606|NCT05339971|Experimental|block perforation|
9898607|NCT05339958|Experimental|Nutraceutical Dietary Supplement Capsule|The nutraceutical capsules are comprised of standardized, natural, medical-grade ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
9898608|NCT05339958|Placebo Comparator|Placebo Capsule|The placebo capsules contain no active ingredients. Subject will be instructed to take four (4) capsules by mouth once daily with a substantial meal.
9898609|NCT05339932|Experimental|Manual wheelchair skills training|
9898610|NCT05339906|Experimental|ZOV.ai digital therapy candidate|"The arm will use a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms.~The total length of the audio stimuli is 5 minutes."
9898611|NCT05339893|Sham Comparator|Affected Limb|"Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.~Within subject. Sham controlled. Double blind, the patient will not know whether they are receiving taVNS, all patients feel a ramp up current but only the active group will receive timed stimulation bursts during the robotic protocol that engages the affected limb. '"
9898612|NCT05339893|No Intervention|Unaffected limb|Patients will engage the robot first with their unaffected limb. This practice will ensure understanding and serve to activate the hemisphere ipsilateral to the impaired limb. Patients are likely to perform this activity quickly, there will not be any taVNS during this part of the procedure.
9933176|NCT00957320|Experimental|1|"Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL. The dose of sirolimus will be dose escalated following standard phase 1 statistical methods.~For patients with active CNS leukemia, intrathecal methotrexate, hydrocortisone and cytarabine (triple IT) will be administered weekly, with leucovorin rescue at the treating physician's discretion."
9933177|NCT00957346|Experimental|Mifepristone + Misoprostol|200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
9933178|NCT00957346|Placebo Comparator|Misoprostol|Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses
9933179|NCT00957385|Active Comparator|A|Arm A will receive Revlimid.
9933180|NCT00957385|No Intervention|B|Arm B will not receive Revlimid but an observational arm
9933181|NCT00957398||IBS-D|12 IBS-D patients who will all undergo MTS.
9933182|NCT00957398||IBS-C|12 IBS-C patients who will all undergo MTS.
9933183|NCT00957411|Active Comparator|Arm I|Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
9933184|NCT00957411|Experimental|Arm II|Patients receive cisplatin and undergo radiotherapy as in arm I. Patients also receive cetuximab IV over 1 hour once weekly during weeks 1-6.
9933185|NCT00957437|Experimental|Part A: 3 way crossover|AZD1305: ER test formulation 1 (w/wo food) and reference formulation
9933186|NCT00957437|Experimental|Part B1: single arm|AZD1305: ER test formulation 1
9933187|NCT00957437|Experimental|Part B2: 3 way crossover|AZD1305: ER test formulation 2 (w/wo food) and reference formulation
9997709|NCT01511302|Experimental|RNS60-BD 0.5|RNS60 in combination with Budesonide 0.5mg/2ml concentration
9997710|NCT01511302|Placebo Comparator|NS-BD 0.5|Normal Saline control (NS) in combination with Budesonide 0.5mg/2ml concentration
9898613|NCT05339867|No Intervention|Mothers following Standard of Care|Participants randomized to this group will receive standard of Care for Postpartum. The standard of care control condition will be what women would typically get at hospital discharge (typically an Electronic Medical Record (EMR) generated document; a non-standardized, generalized brief review of how to care for self and the baby).
9517503|NCT03305718|Experimental|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
9898614|NCT05339867|Experimental|Mother Using PM3 Intervention|Participants in this group will be using the PM3 intervention. PM3 is a maternal mortality prevention and optimal reproductive health promotion mobile app created based on formative work with Black women to ultimately increase postpartum comorbidity self-management, promote timely provider notification of postpartum-related complications, and ensure access to social support and community resources.
9898615|NCT05339854||ECPR survivor|Adult patient who survived therapy-refractory cardiac arrest with extracorporeal cardiopulmonary resuscitation (ECPR).
9898616|NCT05339841|No Intervention|Control group|Subjects monitored following usual-care.
9898617|NCT05339841|Experimental|Intervention group|Subjects in the intervention group, in addition to usual-care, will download a mHealth App that contains educational information promoting healthy lifestyle behaviours. The participant will be also able to self-monitor his/her clinical status regarding hypertension, diabetes or hypercholesterolemia.
9898618|NCT05339828||unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. Next, a local anesthetic agent comprising a solution of lidocaine (20 mg/mL) and adrenaline (0.0125 mg/mL) was diluted with distilled water in a 1:2 ratio and applied. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing.
9898619|NCT05339815||36 mm CoCrMo glenospheres|
9898620|NCT05339815||40 mm cross-linked UHMWPE glenospheres|
9898621|NCT05339802|Experimental|Cohort 1|9MW1411 injection , single administration, intravenous infusion, infusion time 2H (120 ± 15min);
9898622|NCT05339802|Experimental|Cohort 2|9MW1411 injection , single administration, intravenous infusion, infusion time 2H (120 ± 15min);
9898623|NCT05339802|Placebo Comparator|Placebo|9MW1411 injection placebo, single administration, intravenous infusion, infusion time: 2h (120 ± 15min)
9898624|NCT05339776|Active Comparator|One of groups: amputees group|"We planned to enroll two groups to the study. One group is named amputees the other one is control. Both groups will enroll hand lateralization for at least 10 days. Before and after comparisons will be analyzed."
9898625|NCT05339776|Active Comparator|One of groups: control group|Control group will be matched in terms of age and gender with the amputees group.
9898626|NCT05339763|Active Comparator|radiation group|Those are patient with rectal cancer who underwent preoperative neoadjuvant chemo radiotherapy before surgery.
9898627|NCT05339763|Active Comparator|non radiation group|Those are patient with rectal cancer who did not receive preoperative neoadjuvant chemo radiotherapy before surgery.
9898628|NCT05339750|Experimental|Allergy Skin Patch Testing|On day 1, subjects will have a allergy skin patch test applied and a routine skin examination. On day 3, the patch test will be removed and documentation of the test sites using iPhone app. On day 5, the final assessment for allergic contact dermatitis will be conducted by a medical professional.
9898629|NCT05339724||Group 1. Total cystic fibrosis patients with pulmonary exacerbation|Platelet count (PC) and mean platelet volume (MPV) during pulmonary exacerbation.
9898630|NCT05339724||Group 2. Total cystic fibrosis patients with no pulmonary exacerbation|PC and MPV during no pulmonary exacerbation
9898631|NCT05339724||Group 3. Cystic fibrosis patients with chronic colonization in acute pulmonary exacerbation|PC and MPV during chronic colonization in acute pulmonary exacerbation
9898632|NCT05339724||Group 4. Cystic fibrosis patients with chronic colonization without pulmonary exacerbation|PC and MPV during chronic colonization without pulmonary exacerbation
9898633|NCT05339724||Group 5. Cystic fibrosis patients with chronic colonization without pulmonary exacerbation|PC and MPV during chronic colonization without pulmonary exacerbation
9898634|NCT05339724||Group 6. Cystic fibrosis patients with no chronic colonization without pulmonary exacerbation|PC and MPV during no chronic colonization without pulmonary exacerbation
9898635|NCT05339711|Experimental|Robotic Pet Therapy/Robot Cat Group|"In the robot cat group, the patients were given face-to-face personal information about the robot cat for about 15 minutes in the waiting room by the researcher, and the Robot Cat Information Brochure was given. Therefore, in this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher. After eight weeks of robotic pet therapy in the hemodialysis unit, this group of patients was followed up by the researcher with the same applications, without robotic pet therapy for eight more weeks. Data collection tools were applied to this group of patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
9898636|NCT05339711|Experimental|Pet Therapy/Betta Fish Group|"In the Betta fish group, the patients were given a 15-minute hands-on, face-to-face, individual information about Betta fish care in the waiting room by the researcher, and a Betta Fish Information Brochure was given to the patients. Then, the patients were asked to take care of the fish given to them at home for two months.This group of patients was given pet therapy for eight weeks, and then followed by the researcher with the same practices for another eight weeks without pet therapy. In order to observe or measure the positive effects of fish on patients, patients should spend at least 10 minutes with fish during the day (52). Data collection tools were applied to this group of patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
9898637|NCT05339711|No Intervention|Control Group|"This group of patients was only informed about the study and received routine hemodialysis treatment. The patients were followed for four months. Data collection tools were applied to the patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
9898638|NCT05339685|Experimental|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
9898639|NCT05339672||Morphine|The participating patients are treated with morphine before start of enzalutamide (according to label).
9898640|NCT05339672||Edoxaban|The participating patients are treated with edoxaban before start of enzalutamide (according to label).
9898641|NCT05339659|Active Comparator|Control|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking.
9898642|NCT05339659|Experimental|Experimental|mHealth app consisting of standard, best-practice information and guidance to help people stop smoking + additional experimental content targeted to smokers living with HIV who are ambivalent about quitting smoking.
9898643|NCT05339646|Experimental|SSD8432 dose 1~7|Dose level 1 ~7 of SSD8432
9898644|NCT05339646|Experimental|SSD8432 dose 8~9|Dose level 8 ~9 of SSD8432
9898645|NCT05339646|Experimental|SSD8432 dose 10~12|Dose level 10 ~12 of SSD8432
9898646|NCT05339646|Experimental|SSD8432 dose 13|Dose level 13 of SSD8432
9898647|NCT05339646|Experimental|SSD8432 dose 14|Dose level 14 of SSD8432
9898648|NCT05339633|Other|Single Dose|All study subjects will receive a a single oral dose of radiolabeled microtracer of D-0502 following an overnight fast
9898649|NCT05339620|Experimental|mop group|a group of patients with a class 2 divsion 1 dental malocclusion, overjet greater than 9 mm, extraction of upper first premolars planned, and it has been 3 months post extraction and before canine retraction is commenced.
9898650|NCT05339620|Active Comparator|mop group ( same)|a group of patients with a class 2 divsion 1 dental malocclusion, overjet greater than 9 mm, extraction of upper first premolars planned, and it has been 3 months post extraction and before canine retraction is commenced.
9898651|NCT05339607|Experimental|Intervention|
9898652|NCT05339594||NeuraGen Nerve Guide|Integra NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
9898653|NCT05339594||NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
9898654|NCT05339568||Platform follow-up cohort|This cohort will be managed and follow-up by patients' whole process follow-up platform. The patients can report the symptoms, get the reminder of the hospital visit, get the reminder of medicine taking, get the information of patients education.
9517792|NCT03302923|Experimental|Brisk walking 3|3 times a week of 9 months brisk walking
9898655|NCT05339568||Routine follow-up cohort|This cohort will be managed and follow-up by the investigators or nurses. This cohort will take the routine follow-up and management way by the hospital.
9898657|NCT05339542|Experimental|Platelet rich plasma group|"platelet rich plasma (PRP) will be produced through whole blood centrifuge using a specific methodology in a strict aseptic setting. Then, blood will be collected and mixed with anticoagulant and Citrate-phosphate-dextrose adenine in a 10 volume blood to 1 volume anticoagulant ratio. The blood will be centrifuged for 10 minutes at 1000 rpm. Afterward, the plasma will be transferred to a new glass tube and centrifuged for 15 minutes at 3000 rpm. At the bottom of the tube, platelets will form a pellet. Finally, pure platelet-rich plasma will be obtained at a concentration of up to four times higher than baseline. Prior to the injection, calcium gluconate will be combined with PRP (at a ratio of 0.3 ml ca gluconate/ml PRP).~The injection will be done once."
9933188|NCT00957463||smoker, with high apnea-hypopnea index|subjects who smoke either in the past or currently, with confirmed moderate-severe OSA
9898658|NCT05339542|Active Comparator|Methylprednisolone group|"2 ml methylprednisolone acetate 40mg/ml (total 80mg methylprednisolone acetate) together with 1 ml lidocaine 2% (total 3 ml solution) will be directly injected under ultrasound guidance to the plantar fascia.This group serves as active comparative group.~The injection will be done once."
9898659|NCT05339529|Experimental|Thymosin alpha 1|
9898660|NCT05339529|Placebo Comparator|Normal saline|
9898661|NCT05339516||Healthy group|
9898662|NCT05339516||Women with low back pain|
9898663|NCT05339503|Experimental|GROUP A (HYDROCHLORIC ACID)|Total 30 teeth in each group were included. Preoperatively shade was checked. The mixture (hydrochloric acid pumice compound) was applied 10 times or more during the same session. Total treatment time was around 30 minutes. Every patient received entire microabrasion treatment. At the end of the treatment, neutral sodium fluoride gel was applied. Then changes in shade were checked.
9898664|NCT05339503|Experimental|GROUP B ( SODIUM HYPOCHLORITE)|Total 30 teeth in each group were included. Preoperatively shade was checked. The mixture (sodium hypochlorite pumice compound) was applied 10 times or more during the same session. Total treatment time was around 30 minutes. Every patient received entire microabrasion treatment. At the end of the treatment, neutral sodium fluoride gel was applied. Then changes in shade were checked.
9898665|NCT05339490|Experimental|Progenitor Biological Bandages|"Donor Site Wound (DSW) is created with a dermatome. PBB are placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days.~Dressing's changes are performed at Day 5 ± 1 and Day 10 ± 1."
9898666|NCT05339490|Active Comparator|Jelonet|"Donor Site Wound is created with a dermatome. Jelonet® are placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days.~Dressing's changes are performed at Day 5 ± 1 and Day 10 ± 1."
10212537|NCT05219461|Experimental|Group A rhEGF 10mcg/mL|"single dose of rhEGF 10mcg/mL eye drop or single dose of placebo~*single dose means daily dose (administration twice daily)"
9898668|NCT05339464|Experimental|Group 1|This group will begin the family wellness program first; approximately, 5 weeks before group 2.
9898669|NCT05339464|Experimental|Group 2|This group will begin the family wellness program approximately 5 weeks after group 1.
9898670|NCT05339451||Severe/Deep infiltrating endometriosis|Endometriosis stage III/IV according to rASRM.
9898671|NCT05339451||Minimal/mild endometriosis|Endometriosis stage I/II according to rASRM
9898672|NCT05339451||Controls|Women operated for other benign gynecological diseases and have no signs of endometriosis perioperatively.
9898673|NCT05339438|Experimental|Epileptic patients|Epileptic patients with anterior temporal lobe epilepsy
9517793|NCT03302923|No Intervention|Control group|No brisk walking session
9898674|NCT05339438|Experimental|Healthy volonteers|Healthy volonteers
9898675|NCT05339425||Osteoporotic fracture|No additional intervention will be administered.
9898676|NCT05339412|Experimental|Technology Based Training Tool Only|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
9933189|NCT00957463||smoker, mild OSA or without OSA|subjects who smoke either in the past or currently, with mild OSA or without OSA
9933190|NCT00957463||nonsmoker, with high apnea-hypopnea index|subjects who never smoke, with confirmed moderate-severe OSA
9933191|NCT00957463||nonsmoker, with mild OSA or without OSA|subjects who never smoke, with mild OSA or without OSA
9933192|NCT00957476|Active Comparator|Omega-3 Fish Oil|800mg DHA & 1200mg EPA
9933193|NCT00957476|Placebo Comparator|Placebo|Wheat germ oil
10212538|NCT05219461|Experimental|Group B rhEGF 50mcg/mL|"single dose of rhEGF 50mcg/mL eye drop or single dose of placebo~*single dose means daily dose (administration twice daily)"
10212539|NCT05219461|Experimental|Group C rhEGF 100mcg/mL|"single dose of rhEGF 100mcg/mL eye drop or single dose of placebo~*single dose means daily dose (administration twice daily)"
10212540|NCT05219461|Experimental|Group D rhEGF 10mcg/mL|multiple dose of rhEGF 10mcg/mL eye drop or multiple dose of placebo
9898677|NCT05339412|Experimental|Technology Based Training Tool plus Live Supervision|Participants randomized to this condition will receive (in addition to the training tool described above) access to live supervision delivered remotely via commercially available video conferencing software (Zoom). Facilitators-in-training will complete two mock roleplays of curriculum activities, which can be conducted live via Zoom with PHAT Life trainers (either Dr. Floyd or Dr. Snow-Hill) or can be recorded and submitted via the app. Trainers will review for fidelity and provide feedback. During the supervision sessions, participants will have the opportunity to clarify content, ask questions, roleplay group sessions to practice difficult parts of the group sessions, and review feedback on role plays.
10212541|NCT05219461|Experimental|Group E rhEGF 50mcg/mL|multiple dose of rhEGF 50mcg/mL eye drop or multiple dose of placebo
10212542|NCT05219461|Experimental|Group F rhEGF 100mcg/mL|multiple dose of rhEGF 100mcg/mL eye drop or multiple dose of placebo
9898680|NCT05339386||Initiating Therapy|PAH patients who are newly initiating background therapy to treat pulmonary arterial hypertension.
9898681|NCT05339386||Stable|PAH patients who are stable on therapy (On stable doses of background PAH therapy and diuretics for at least 90 days prior to screening).
9898682|NCT05339373|Other|Sequence TR|18 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9898683|NCT05339373|Other|Sequence RT|18 subjects assigned to the sequence RT will receive a single 100 mg dose of the test product Airtal ® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of thetest product Aceclofenac (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
9898684|NCT05339360||ZNN Bactiguard Antegrade Femoral Nail|Subjects that have received or will receive the ZNN Bacitugard Antegrade Femoral Nail to treat femoral fractures or osteotomies according to the cleared/approved indications.
9898685|NCT05339347|Active Comparator|Active Comparator: Active Photoneuromodulation|Active stimulation with light fields as described in the intervention
9898686|NCT05339347|Sham Comparator|Sham Comparator: Sham Photoneuromodulation|The blinding will be done with sham light, which consists of fields that do not reproduce light, but which have the same size and thickness as the true one.
9898687|NCT05339334|Experimental|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days to adult Chinese healthy volunteers
9898688|NCT05339321|Experimental|SCG101|SCG101 will be given via Intravenous (IV) infusion.
9898689|NCT05339321|Experimental|SCG101 + PD1/PD-L1 checkpoint inhibitor|SCG101 will be given via Intravenous (IV) infusion. The PD-1/PD-L1 checkpoint inhibitor will be given per product label.
9898690|NCT05339295|Experimental|Test Group|Levomerc (Levofloxacin) tablets 500 mg
9898691|NCT05339295|Active Comparator|Reference Group|Tavanic (Levofloxacin) tablets 500 mg
9898692|NCT05339282|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) was used before surgery."
9898693|NCT05339282|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used before surgery."
9898694|NCT05339269|Experimental|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
9898695|NCT05339256|Experimental|Telehealth buprenorphine induction and maintenance|Sublingual (SL) Buprenorphine and a medical management protocol adapted to the unique needs of home-based telehealth for MOUD using SL buprenorphine
9898696|NCT05339256|Active Comparator|Standard in-person SL buprenorphine induction and maintenance|In-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
9898697|NCT05339243|Active Comparator|ES 1|Two capsules orally once daily after breakfast for 84 days
9898698|NCT05339243|Active Comparator|HT ES1|Two capsules orally once daily after breakfast for 84 days
9898699|NCT05339243|Placebo Comparator|Placebo|Two capsules orally once daily after breakfast for 84 days
9898700|NCT05339230|Experimental|Active|Salovum egg powder high in antisecretory factor, 4 g/sachet. Four sachets, ie 16 g q 8 h for 6 days starting 6 days before 1st cycle of chemotherapy. SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started in parallel with Salovum to be continued during the first 8 weeks of chemotherapy.
9898701|NCT05339230|Placebo Comparator|Control|Salovum placebo powder without antisecretory factor, 4 g/sachet. Four sachets, ie 16 g q 8 h for 6 days starting 6 days before 1st cycle of chemotherapy. SPC placebo flakes flat dose of 75 g/d divided in 2 - 4 doses started in parallel with Salovum placebo to be continued during the first 8 weeks of chemotherapy.
9898702|NCT05339217|Experimental|Telitacicept and low dose IL2|"160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.~Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL2 was injected once a week for 12 weeks subcutaneously."
9898703|NCT05339217|Active Comparator|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
9933194|NCT00957489|Experimental|Functional appliance|
9898704|NCT05339217|Active Comparator|low dose IL2|Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL2 was injected once a week for 12 weeks subcutaneously.
9898705|NCT05339204|Experimental|allo-HSCT|Patients with AML in CR1, MRD-negative after first course recieve allo-HSCT
9898706|NCT05339204|Active Comparator|Chemo|Patients with AML in CR1, MRD-negative after first course continue chemotherapy
9898707|NCT05339191|Experimental|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
9898708|NCT05339152|Experimental|FETO Group|Participants undergoing fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
9898709|NCT05339126|Active Comparator|Condition A|high-frequency short bursts (HFSB: 100 Hz, 160 µs pulse width, 200 msec burst)
9898710|NCT05339126|Active Comparator|Condition B|low-frequency long bursts (LFLB: 5 Hz, 160 µs pulse width, 5 sec burst)
9898711|NCT05339113|Experimental|68Ga-FAPI-46 PET/CT + 18-FDG PET/CT|18FDG PET/CT scan is followed by [68Ga]FAPI-46 PET/CT within 2-3 days.
9898712|NCT05339100|Experimental|Anifrolumab administered using AI|Randomized participants will receive a single SC dose of anifrolumab via AI.
9898713|NCT05339100|Active Comparator|Anifrolumab administered using APFS|Randomized participants will receive a single SC dose of anifrolumab via APFS.
9898714|NCT05339087|Experimental|Riociguat|patients will undergo a titration phase starting with 1mg riociguat oral tablets tid (three times daily) up to a maximum dosage of 2.5mg tid that will be continued for the remainder of the study.
9898715|NCT05339087|Placebo Comparator|Placebo|Placebo tablets with the same treatment regimen (tid) as the verum therapy will be provided. Patients will undergo a sham titration phase with sham doses individually adjusted as in the experimental arm
9898716|NCT05339074|Experimental|Ketamine|Open-label ketamine infusions will be provided on a flexible schedule (every 2-4 weeks) with flexible dosing (0.5-1.0mg/kg over 40 minutes) titrated to optimize benefits, while minimizing the dosage and frequency over a 12-week extension period
9898717|NCT05339061|Experimental|Physician-Modified Endograft|Physician-Modified Endograft will be used in this single-arm of the study to evaluate the safety and effectiveness of this technique for the treatment of patients with a complex, juxtarenal, pararenal or thoracoabdominal abdominal aortic aneurysm (Extent I-V).
9898718|NCT05339048||General group|18-80 years old adults from the Colombian Caribbean Coast.
9898719|NCT05339035|Experimental|experimental group|In the first stage, the participants will be trained according to the IMB model. In the second stage, 6 sessions of individual motivational interviews will be held for a total of 7 weeks. Finally, participants will be given hippotherapy 1 hour a week for 8 weeks.
9898720|NCT05339035|No Intervention|control group|attempt will not be implemented.
9898721|NCT05339022|Experimental|Arm I (ROAR-LCT intervention)|Patients receive ROAR-LCT intervention weekly for 12 weeks consisting of physical therapy visits and an exercise intervention. Patients also undergo progressive muscles relaxation exercises over 20 minutes for 12 weeks.
9898722|NCT05339022|Active Comparator|Arm II (standard of care)|Patients receive standard of care for 12 weeks.
9898723|NCT05339009||All patients receive conventional dialysis treatment at inclusion|All patients receive conventional dialysis treatment at inclusion
9898724|NCT05338996|Experimental|iENGAGE for PrEP|We will conduct an exploratory pilot of the PrEP intervention, using a quasi-experimental design, among 80 multi-ethnic WOC in Miami-Dade, Broward, and Palm Beach counties to evaluate feasibility, acceptability, and fidelity. PrEP uptake, adherence, and retention in care will be measured over a 4-month period, including biomarkers of adherence.
10212543|NCT05219422|Active Comparator|Project ALERT only|Some schools will be randomized to receive Project ALERT only for 3 years starting fall 2022.
10212544|NCT05219422|Active Comparator|Project ALERT plus GTO|Some schools will be randomized to receive Project ALERT plus Getting to Outcomes for 3 years starting fall 2022.
9933195|NCT00957502|Experimental|One year aged staples|Subjects implanted with sterile staples aged to approximately one year.
9997711|NCT01511341|Experimental|Telenursing|
10212545|NCT05219422|No Intervention|Status quo|Some schools not receive either Project ALERT or Project ALERT plus GTO until year 3 of the study.
10212546|NCT05219409|Active Comparator|Treatment group|Sitagliptin
10212547|NCT05219409|Placebo Comparator|Control group|Placebo
10212548|NCT05219357|Active Comparator|Usual Care Group (UCG)|The usual care control group received care only on hospital wards during episodes
10212549|NCT05219357|Other|Ayu Care Group (ACG)|Multidisciplinary Ayurveda based treatment team aimed to manage acute crises of patients in the community settings or at their home if feasible.
10212550|NCT05219344|Experimental|One set of muscle flossing|This group will receive one set of muscle flossing around the thigh with low pressure. Pressure will be individualized based on thigh circumferences.
10212551|NCT05219344|Active Comparator|Two sets of muscle flossing|This group will receive two sets of muscle flossing around the thigh with low pressure. Pressure will be individualized based on thigh circumferences.
10212552|NCT05219318|Experimental|Treatment pause|Treatment pause for 12 months
10212553|NCT05219318|Active Comparator|Treatment continuation|Treatment continuation regimens with PD-1/PD-L1 ICI + VEGFR-TKI until disease progression or unacceptable toxicity
10212554|NCT05219292||Adult patients followed for a recent lung transplant.|Patients will be recruited during the pre-transplant assessment by the physiotherapist, the pneumologist and/or the transplant nurse coordinator. The patient has the hospital stay of the pre-transplantation to give his answer. The protocol starts on arrival in the rehabilitation department.
10212555|NCT05219279||HIV+ participants|"HIV-infected between age of 20 and 65 years~Consistently have plasma HIV RNA levels <200 copies/mL for at least the last 12 months on a stable antiretroviral regimen with any changes made only for convenience, safety or simplicity."
10212556|NCT05219279||HIV- participants|25 age- and sex- matched HIV- subjects (healthy) will be recruited also at the UCLA Medical center who will undergo the neuroimaging examination.
10212557|NCT05218187|Active Comparator|Conventional Physical Therapy (CPT) Group|CPT sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be provided using traditional over-ground walking. Additional strategies for home exercises, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided. Training will be administered 2 times per week for 40-60 minutes for six weeks.
10212558|NCT05218187|Experimental|Conventional Physical Therapy (CPT) Group with G-EO Training (CPT-GEO)|CPT-GEO sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be administered using end-effector gait training protocols (G-EO trainer). Training will be administered 2 times per week for 40-60 minutes for six weeks.
9898729|NCT05338970|Experimental|Patritumab deruxtecan|Participants who will be randomized to receive patritumab deruxtecan (HER3-DXd) 5.6 mg/kg q3W.
9898730|NCT05338970|Active Comparator|Platinum-based chemotherapy|Participants who will be randomized to receive platinum-based chemotherapy for 4 cycles: pemetrexed plus either cisplatin or carboplatin. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy may continue treatment with maintenance pemetrexed with no restriction on the number of cycles.
9898731|NCT05338957|Experimental|MRG002+HX008|"MRG002 will be administrated via intravenous infusion at 1.8，,2.2, or 2.6 mg/kg , (if appropriate) once on Day 1 of every 3 weeks (21-day cycle), up to 24 months.~HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day- cycle), up to 24 months."
9898732|NCT05338944|Experimental|DBT + lifestyle|Participants will receive 90 minutes of dialectical behavioral therapy and 60 minutes of lifestyle sessions each week for 16 weeks.
9898733|NCT05338944|Experimental|Lifestyle alone|Participants will receive 2 lifestyle sessions per week, one 90 minutes in length and the other 60 minutes for 16 weeks.
9898734|NCT05338944|No Intervention|Control|Participants will be included in baseline, endpoint and follow up measurements, but will receive no form of intervention.
10212559|NCT05216874|Experimental|Occlusal stabilization splint|Skeletal class III laterognathia surgery patients who has occlusal stabilization splint thearapy for at least 2 mounths before surgery
9898736|NCT05338918|Experimental|Mental Imagery with Virtual Reality Group|Mental Imagery with Virtual Reality
9898737|NCT05338918|Active Comparator|Virtual Reality Alone Group|Virtual Reality Alone
9898738|NCT05338905|Experimental|Group A (quality of life questionnaire)|Patients complete a quality of life questionnaires over 10-15 minutes BIW during standard of care radiation therapy and QW for the first month after completing standard of care radiation therapy course, and then once monthly for 6 months.
9898739|NCT05338905|Active Comparator|Group B (standard symptom management)|Patients receive standard symptom management QW during standard of care radiation therapy and at 1, 3, and 6 months after completing radiation therapy course.
9898740|NCT05338892||Cohort 1|Participants with r/r DLBCL who were treated with at least 2 prior systemic therapies in the real-world setting
9898741|NCT05338879||Cohort 1|Participants with r/r FL grade 1-3a who were treated with at least 2 prior systemic therapies in the real-world setting.
9898742|NCT05338866||Cohort 1. Cohort 2|"A total of 6 courses of oxaliplatin plus capecitabine chemotherapy and 2 courses of capecitabine single drug chemotherapy were performed. Concurrent chemoradiotherapy starts at the second cycle.~Cohort 1: For patients with low rectal cancer who refused surgery before the initial diagnosis and treatment, the first stage of radiotherapy used conventional linear accelerated radiotherapy, with doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. Subsequently, the second stage of radiotherapy boost was continued with MR linear accelerator, and the dose was GTV 16~20Gy/8~10f for 2 weeks.~Cohort 2: For locally advanced low rectal cancer patients who did not achieve clinical complete remission 6-8 weeks after neoadjuvant radiochemotherapy and refused surgery, radiotherapy was given in the first stage at the doses of GTV 50Gy/25f and CTV 45Gy/25f for 5-6 weeks. In the second stage, MR linear accelerator was used for radiotherapy boosting, and the dose was GTV 30Gy/15f for 3 weeks."
9898743|NCT05338853|Experimental|Gongs Mmobilization|to deal adhesive capsulitis
9898744|NCT05338853|Experimental|scapular mobilization|to deal adhesive capsulitis
9898745|NCT05338840|Experimental|MULLIGAN|ROTATIONAL MOVEMENT
9898746|NCT05338840|Experimental|Medial gapping technique|Medial gapping technique
9933196|NCT00957502|Experimental|18 month aged staples|Subjects implanted with sterile staples aged to approximately 18 months.
9933197|NCT00957541|Experimental|CRT Therapy|All patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
10212560|NCT05216874|No Intervention|Control|Skeletal class III laterognathia surgery patients did not have occlusal stabilization splint thearapy
10212561|NCT05214846|Experimental|Education and Counseling|"After obtaining written informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. Women were counseled for 6 weeks.~Anxiety-depression levels (post-test) were applied by phone call 6 weeks later.This education consisted of the definition and the purpose of pregnancy and pregnancy problems and nutrition during pregnancy, sexuality during pregnancy, number of fetal movements, preparation of the delivery bag, breast care, etc."
10212562|NCT05214846|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed.The control group was called by phone at the end of 6 weeks and told that they would be retested and 6 weeks later, they were called by phone and their anxiety and depression levels (posttest) were applied. directed to continue
10212563|NCT05214118|No Intervention|Brochure|
10212564|NCT05214118|Experimental|Technology-based program|
10212565|NCT05205681||Pandemic Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2020 and February 2021
10212566|NCT05205681||Control Group|All patients who underwent emergency appendicectomy for suspected acute appendicitis between March 2019 and February 2020
9517794|NCT03302897|Experimental|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
9898747|NCT05338827|Experimental|Polyvinyl Chloride Tube group|Polyvinyl Chloride tube is made of hard material and has a certain radian.After anesthesia induction,the SaCo laryngeal mask is successfully inserted then through the laryngeal mask visual screen for EVGS grade. If the grade is 1 or 2, the tracheal tube with the curvature of the tube facing upwards would be inserted through the SaCo laryngeal mask under the guidance of the visual screen. Intubation is considered successful if the endotracheal tube slid through the LMA without any resistance and tracheal intubation would be confirmed by the laryngeal mask visual screen and the detection of end-tidal CO2. If tracheal intubation is unsuccessful after the first attempt, the tube would be pulled 2 cm, rotated tube, and then advanced. If this attempt is unsuccessful, the tube would be pulled again 2 cm, adjust the laryngeal mask by up-down maneuver and assist in rotating tube, and then advanced.
9898748|NCT05338827|Experimental|Wire-Reinforced Tube group|Wire-Reinforced tube is made of softer material and has no certain radian.After anesthesia induction,the SaCo laryngeal mask is successfully inserted then through the laryngeal mask visual screen for EVGS grade. If the grade is 1 or 2, the tracheal tube with the curvature of the tube facing upwards would be inserted through the SaCo laryngeal mask under the guidance of the visual screen. Intubation is considered successful if the endotracheal tube slid through the LMA without any resistance and tracheal intubation would be confirmed by the laryngeal mask visual screen and the detection of end-tidal CO2. If tracheal intubation is unsuccessful after the first attempt, the tube would be pulled 2 cm, rotated tube, and then advanced. If this attempt is unsuccessful, the tube would be pulled again 2 cm, adjust the laryngeal mask by up-down maneuver and assist in rotating tube, and then advanced.
9898749|NCT05338814|Experimental|conventional neck exercises & scapular corrective exercise|isometric & stretching exercises of neck plus scapular corrective exercise
9898750|NCT05338814|Active Comparator|conventional neck exercises|isometric & stretching exercises of neck
9898751|NCT05338801|Experimental|Menthol-flavored e-cigarette|All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
9898752|NCT05338801|Experimental|Tobacco-flavored e-cigarette|All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
9898753|NCT05338788||Patient Group|"Thirty-two 32 patients with cervical disk herniation related chronic neck pain participated in this cross-sectional controlled study. Patients who aged 18-64 years, had neck pain for at least 12 weeks, no tumor, trauma, fracture pathology in the spinal region and no history of spine surgery were included.~The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control. The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI) was assessed."
9898754|NCT05338788||Control Group|"Twenty-three 23 age and sex-matched asymptomatic controls participated in this cross-sectional controlled study.~The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control.The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI)was assessed."
9898755|NCT05338775|Experimental|Part 1: Dose Escalation|Participants will receive either talquetamab (treatment regimen A) or teclistamab (treatment regimen B) with a PD-1 inhibitor biweekly.
9898756|NCT05338775|Experimental|Part 2: Dose Expansion|Participants will receive either treatment regimen A or treatment regimen B with a PD-1 inhibitor at the dose levels identified in Part 1.
9898757|NCT05338762||Current COVID-19 symptoms or SARS-CoV-2 in the last 30 days with a positive RT-PCR test|"75 subjects will be enrolled who were diagnosed as SARS-CoV-2 with a positive RT-PCR nasal pharangeal test or are suspected of having a COVID-19 infection with symptom onset in the last 30 days. (Symptom onset 0-30 days)~This group of subjects will receive:~a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test~a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)~a nasal-pharangeal RT-PCR test"
9898758|NCT05338762||Diagnosed with SARS-CoV-2 (COVID-19) in the past 3 months with a positive RT-PCR test|"30 subjects will be enrolled who have been diagnosed with COVID-19 in the past 3 months and had a prior positive RT-PCR nasal pharangeal test. (Symptom onsent 31-90 days)~This group of subjects will receive:~a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test~a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)"
9898759|NCT05338749|Experimental|Cognitive Training|Participants in this condition will received game-based cognitive training.
9898760|NCT05338736||Control group|Control patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, and with a nasopharyngeal swab negative for SARS-CoV-2 isolation.
9898761|NCT05338736||Asymptomatic group|Patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, with a nasopharyngeal swab positive for SARS-CoV-2 isolation, in absence of any symptoms of COVID-19
9997712|NCT01511341|No Intervention|Standard practice|Group receive the standard practice, without telephone nursing intervention.
9997713|NCT01511354||Standard clinical care|Standard nutritional therapy and treatment
9898762|NCT05338736||Symptomatic group|Patients with a complete first-cycle vaccination against SARS-CoV-2, received between 4 to 7 months before the inclusion, with a nasopharyngeal swab positive for SARS-CoV-2 isolation, with moderate to severe symptoms of COVID-19
9898763|NCT05338723|No Intervention|control-group|This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy.
9898764|NCT05338723|Active Comparator|rosuvastatin-group|This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy in addition to 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
9898765|NCT05338697||Ischemic & Hemorrhagic stroke patients|557 ischemic stroke patients and 100 hemorrhagic stroke patients
9898766|NCT05338684|Experimental|diagnostic catheter intervention then therapeutic if indicated|
9898767|NCT05338671|Active Comparator|2% Lidocaine 1:100,000 epinephrine|Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 2% Lidocaine 1:100,000 epinephrine following endodontic treatment.
9898768|NCT05338671|Active Comparator|0.5% bupivicaine 1:200,000 epinephrine|Participants in this arm will receive an inferior alveolar nerve block with 1 cartridge (1.8 mL) of 0.5% bupivicaine 1:200,000 epinephrine following endodontic treatment.
9898769|NCT05338658|Experimental|Peptide Alarm Therapy + Pembrolizumab|"Participants receive pembrolizumab 200 mg every 3 weeks (Dose Finding Component) or a disease appropriate PD1/PD-L1 inhibitor (Dose Expansion Component) for 2 treatment courses per standard of care.~The first dose of PAT is given on Day 1 and on Day 3 (36 to 48 hours after the 1st PAT dose)~A second course of the PD1/PD-L1 inhibitor is given per standard of care on Day 22 (Cycle 2 Day 1)."
9898770|NCT05338632|Experimental|Intravenous fentanyl year 1|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
9898771|NCT05338632|Experimental|Intravenous sufentanil year 1|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
9898772|NCT05338632|Experimental|Intravenous sufentanil year 2|continuous intravenous infusion of sufentanil to induce 40-60% respiratory depression.
9898773|NCT05338632|Experimental|Intravenous fentanyl year 2|continuous intravenous infusion of fentanyl to induce 40-60% respiratory depression.
9898774|NCT05338619|Experimental|Lazertinib|Lazertinib 240mg, oral, QD
9898775|NCT05338580|Experimental|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
9898776|NCT05338567||Open/laparoscopic surgery|Small bowel length measurement by laparoscopy or laparotomy
9898777|NCT05338567||3D reconstruction|Small bowel length measurement by 3D digital model
9898778|NCT05338554|Experimental|pcTBS|The protocol is same as the previous study: pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz using repetitive transcranial magnetic stimulation device . A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
9898779|NCT05338554|Experimental|10HZ rTMS|The protocol is same as the previous study: 10HZ rTMS included 15 trains of 10-second stimulation given at 10 Hz to the left M1 at 80% resting motor threshold (RMT) using repetitive transcranial magnetic stimulation device , with the inter-train interval being set to 50 seconds (1500 pulses)
9898780|NCT05338541|Experimental|Tucidinostat and etoposide|
9933198|NCT00957554|Experimental|irbesartan/amlodipine|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks
9933199|NCT00957554|Active Comparator|irbesartan|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks
9933200|NCT00957619|Active Comparator|pentoxyfilline group|pentoxyfilline group
9933201|NCT00957619|Placebo Comparator|placebo group|placebo group
9933202|NCT00957710|Other|langauge therapy|Naming therapy
9933203|NCT00957736||Allogeneic stem cell transplant|Stem cells from a genetically non-identical donor transplanted into a patient.
9933204|NCT00957749|Experimental|cPMP|
9933205|NCT00957762||Body Composition|120 subjects will help create the regression models. The remaining 50 subjects will be recruited to determine if the equations work for the population.
9933206|NCT00957775|Active Comparator|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, self-help groups) provided at the treatment site.
9933207|NCT00957775|Experimental|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
9933208|NCT00957788|Experimental|Cohort 0|
9933209|NCT00957788|Experimental|Cohort 1|
9933210|NCT00957788|Experimental|Cohort 2|
9933211|NCT00957788|Experimental|Cohort 3|
9933212|NCT00957814|Experimental|Control|Usual care with medical and nursing staff
9933213|NCT00957814|Experimental|Intervention|Usual care with medical and nursing staff and additional nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats. Enforcement of the nutritional guidance was performed after 4 weeks.
9935675|NCT03372733|Experimental|Group 2|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil arm will take the equivalent to3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the control olive oil
10213894|NCT02749045|Other|Image acquisition arm|Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.
10213895|NCT02748369|No Intervention|Control Group|No somatostatin and glucagon infusions
9898783|NCT05338515|Experimental|Selpercatinib Cohort 1|Selpercatinib administered orally.
9898784|NCT05338515|Experimental|Selpercatinib Cohort 2|Selpercatinib administered orally.
9898785|NCT05338515|Experimental|Selpercatinib Cohort 3|Selpercatinib administered orally.
9898786|NCT05338502|Experimental|Selpercatinib|Selpercatinib administered orally.
9898787|NCT05338502|Experimental|Ranitidine|Ranitidine administered orally.
9898788|NCT05338502|Experimental|Selpercatinib + Ranitidine|Selpercatinib and ranitidine administered orally.
9898789|NCT05338502|Experimental|Omeprazole|Omeprazole administered orally.
9898790|NCT05338502|Experimental|Selpercatinib + Omeprazole|Selpercatinib and omeprazole administered orally.
9898791|NCT05338489|Experimental|Selpercatinib - Part 1 Period 1|Selpercatinib administered orally.
9898792|NCT05338489|Experimental|Selpercatinib and Itraconazole - Part 1 Period 2|Selpercatinib and itraconazole administered orally.
9898793|NCT05338489|Experimental|Selpercatinib - Part 2 Period 1|Selpercatinib administered orally.
9898794|NCT05338489|Experimental|Selpercatinib and Rifampin - Part 2 Period 2|Selpercatinib and rifampin administered orally.
9898795|NCT05338476|Experimental|Midazolam|Midazolam administered orally.
9898796|NCT05338476|Experimental|Selpercatinib and Midazolam|Selpercatinib and midazolam administered orally.
9898797|NCT05338463|Experimental|Fespixon Cream|"A single arm of Fespixon Cream for DFU (TEXAS 1A, 2A) in dialysis patients~Test drug :~Name : Fespixon Cream~Dosage form: Topical cream, 15 g ointment per tube~Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~Dose(s): Apply 1 cc per 5 cm^2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply twice a day~Duration: up to 20 weeks"
9898798|NCT05338450|Experimental|Clemastine Fumarate|
9898799|NCT05338450|Placebo Comparator|Placebo|
9898800|NCT05338437|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the quadriceps. 45 minutes, 5 days per week
9898801|NCT05338437|No Intervention|Control|No treatment control
9898802|NCT05338424||Sprint Interval Training (SIT)|"The 1-session SIT protocol will include Work bouts performed at maximal intensity targets. Three Work bouts will be performed at 20-second intervals separated by 2 recovery bouts consisting of 2 minutes of low-intensity cycling. The SIT session will employ a standardized warm up and cool down of 3 minutes at a self-selected light intensity, per current guidelines. SIT sessions will take 15 minutes to complete."
9898803|NCT05338424||Stretching|Stretching will include a low-intensity range of motion and stretching exercises with session duration (15 minutes) being matched to SIT.
9898804|NCT05338411||Early or precocious puberty who receive GH|Children with early or precocious puberty who receive exogenous growth hormone
9898805|NCT05338411||Early or precocious puberty who does not receive GH|Children with early or precocious puberty who does not receive exogenous growth hormone
9898806|NCT05338411||Healthy|Healthy children without any past medical history
9898807|NCT05338398|Placebo Comparator|Control Group (Group 1): Standard Therapy|"Group 1 will receive standard therapy with conventional oral care to prevent oral mucositis consisting of oral hygiene and rinses/mouthwashes with baking soda or saline solutions 3-5 times daily.~Half of the subjects in Group 1 will also receive Bocaliner™ devices"
9898808|NCT05338398|Experimental|Intervention Group (Group 2): Benzydamine mouthwash|Group 2 will receive benzydamine mouthwashes 3-5 times daily. Half of the subjects in Group 1 will also receive Bocaliner™ devices.
9898809|NCT05338385|Experimental|Intervention|Participants will receive mental skills training in addition to receiving standard-of-care ACL reconstruction and follow-up care. The goal of mental skills training is to help athletes maximize performance, reach self-determined goals, and build confidence in their fields of play. Many of the same tools that benefit athletes in sport performance also translate to their injury experience. Mental conditioning helps athletes navigate the many ups and downs that accompany ACL injury and recovery. Athletes are taught techniques to maintain their sport mindset by capitalizing on motivation, consistency, and resilience. One-on-one sessions are athlete-centered, and are designed to encourage exploration and growth through tangible mental skills strategies.
9898810|NCT05338372|Experimental|Two days forest therapy|
9898811|NCT05338372|Experimental|Three days forest therapy|
9935676|NCT03367754|Experimental|1|single dose of 200 mg (IV) infusion
9935677|NCT03367754|Placebo Comparator|2|single dose (IV infusion)
9517795|NCT03302897|Experimental|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
9935678|NCT03366168||Group 1|Ages 18-39 years
9935679|NCT03366168||Group 2|Ages 40-59 years
9935680|NCT03366168||Group 3|Ages 60 years and older
10213896|NCT02748369|Active Comparator|Intervention Group|Somatostatin and glucagon infusions
10213897|NCT02744001|Experimental|Low Added Sugar Diet|Menu containing <10% of total daily energy intake from added sugars.
10213898|NCT02738216|Experimental|Prenatal Yoga|A 9-week prenatal yoga program
10213899|NCT02738216|Active Comparator|Mother Baby Wellness Workshop|A 9-week workshop on mother and baby wellness in the first postpartum year
10213900|NCT02737293|Experimental|Control Diet|Menu based on the average American diet.
10213901|NCT02737293|Experimental|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
10213902|NCT02737293|Experimental|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
10213903|NCT02734290|Experimental|Arm A|pembrolizumab + weekly paclitaxel
10213904|NCT02734290|Experimental|Arm B|pembrolizumab + capecitabine
9898812|NCT05338346|Experimental|ATG-018|"Dose Escalation Phase:~For Solid Tumors Group: A maximum of 44 subjects with solid tumors will be enrolled during the Dose Escalation Phase.~For Hematological Malignancies Group: Subjects with hematological malignancy will be enrolled.~Dose Expansion Phase:~The tumor types in Dose Expansion Phase may involve other tumor types based on the signals from the Dose Escalation Phase. Each tumor type is planned to enroll at least 12 subjects, and a further expansion (up to 40 subjects in each tumor type) may be triggered if 2 or more confirmed responses are observed in this cohort."
9898813|NCT05338333|Other|LID210464, then AOHG MF|Lehfilcon A multifocal contact lenses (LID210464) worn in Period 1, with lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
9898814|NCT05338333|Other|AOHG MF, then LID210464|Lotrafilcon B multifocal contact lenses (AOHG MF) worn in Period 1, with lehfilcon A multifocal contact lenses (LID210464) worn in Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 30 days. CLEAR CARE® will be used for nightly contact lens cleaning and disinfecting.
9898815|NCT05338320|Active Comparator|General anesthesia and Ultrasound Guided Erector Spinae Plane Block|
9898816|NCT05338320|Active Comparator|General anesthesia and intrathecal morphine|
9898817|NCT05338320|Other|General anesthesia using intravenous fentanyl (1µg/kg)|
9898818|NCT05338307|Experimental|BHB supplementation|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol, for a total of 4 weeks.
9898819|NCT05338294|Experimental|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
9898820|NCT05338281|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of the abdominal donor wound following DIEP flap-based breast reconstruction surgery, AND the negative pressure wound therapy. The Prevena™ Incision Management System will be placed at the abdominal flap donor site after incision is closed. The Prevena™ will remain for up to 5 days, or until patient is discharged from the hospital.
9898821|NCT05338281|Active Comparator|Standard Dressing|This group will receive the usual care of the abdominal donor wound following DIEP flap-based breast reconstruction surgery, and standard dressing which will be composed of gauze, secured with paper tape.
9898822|NCT05338268|Experimental|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth.
9898823|NCT05338268|Active Comparator|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
9898824|NCT05338255||Patients who have undergone surgery at the MAZ hospital for knee/hip replacement.|
9898825|NCT05338242|Experimental|Real-Time Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
9898826|NCT05338242|No Intervention|No Feedback|Participants will have exposure levels monitored by the same device, but it will only display the date/time and will not provide real-time feedback.
9898827|NCT05338229|Experimental|video game in CP children (pilot study)|The cerebral palsy children will play the engineer-built system, video-game based Kinect sensor 3 times/week for 5 weeks. Each session will last for 40 minutes. The video-game Kinect sensor was developed by the researcher team.
9898828|NCT05338216|Experimental|Traditional Ecological Momentary Assessment (Traditional EMA)|People with aphasia (PWA) in the traditional EMA arm will receive four prompts per day to complete a set of nine picture naming trials per prompt for a total of n = 36 prompts/day for three weeks.
9898829|NCT05338216|Experimental|Micro-Interaction Ecological Momentary Assessment (µEMA)|People with aphasia (PWA) in the µEMA condition will complete a single naming trial at a time, 36 times per day for three weeks.
9898830|NCT05338203|Experimental|experimental group (tandem breastfeeding)|mother mılk wıll collected from these mother and they wıll be analyzed
9898831|NCT05338203|No Intervention|control group ( non-tandem breastfeeding)|mother mılk wıll collected from these mother and they wıll be analyzed
9898832|NCT05338190|Experimental|ARM A|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
9898833|NCT05338190|Placebo Comparator|ARM B|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
9517796|NCT03302884|Experimental|Biological sampling in ovarian carcinoma|Blood and tumor samples
9898834|NCT05338177|Experimental|Immunosuppression reduction|Participants stop mycophenolate or azathioprine for two weeks peri-vaccination. Treatment is stopped on week before vaccination and only restarted one week after vaccination
9898835|NCT05338177|Active Comparator|No immunosuppression reduction|no alterations to immunosuppression
9898836|NCT05338164|Experimental|Cerclage group|cervical cerclage between 14 and 20 weeks will be done by one of the three authors.
9898837|NCT05338164|No Intervention|No Cerclage group|Routine follow up without cerclage
9898838|NCT05338151|Other|Brief Negotiated Interview (with referral and telephone booster) alone|All participants will receive BNI with referral and a 15-20 minute telephone booster delivered by a trained Health Promotion Advocate (HPA) at 2 weeks. The purpose of the BNI is to assist patients in recognizing and changing levels of alcohol consumption that pose health risks. The main goals of the BNI are to: 1) lessen ambivalence about reducing alcohol use; and 2) negotiate strategies for change. During BNI, the HPA will: 1) Raise the subject of alcohol; 2) Provide feedback: review the patient's alcohol consumption, make a connection to the patient's medical condition and reason for hospitalization; review guidelines for lower risk alcohol use; 3) Enhance motivation: have the patient identify on a readiness change ruler and develop discrepancy; and 4) Negotiate and Advise: negotiate goal, give advice, have patient complete drinking agreement; summarize and arrange follow-up.
9898839|NCT05338151|Active Comparator|BNI+MAUD|For either BNI+facilitated provision of MAUD or BNI+facilitated provision of MAUD+CBT4CBT, the HPA will provide education and counseling regarding MAUD as part of the BNI to the participant and communicate to the primary medical team that MAUD is indicated. The specific MAUD chosen will be made at the discretion of the patient and the primary medical team with recommendations from the study physicians, with a goal of prioritizing FDA approved medications. Participants will be encouraged to initiate (or receive as in the case of injectable naltrexone) MAUD prior to discharge and will be provided a prescription for a 30-day supply. Medications will be obtained through regular means and not provided directly through the study. During the BNI telephone booster, the HPA will inquire about and address any barriers to MAUD and encourage continued adherence.
9898840|NCT05338151|Experimental|BNI+MAUD+CBT4CBT|Participants randomized to BNI+facilitated provision of MAUD+CBT4CBT will be given a username and password to access the web-based program and be encouraged to begin accessing the program during their hospitalization. The HPA will assist each participant with login during the first session and be available to answer any questions. Participants will be asked to complete no more than two modules per week, with an expectation of completing all seven modules by the end of the 34-day post-discharge. The program tracks, for each participant, time logged onto the program, modules accessed, progress through the program from session to session, completion of homework assignments, and learning of CBT principles through brief quizzes. Participants will be allowed to repeat modules as desired. During the BNI telephone booster, the HPA will inquire about engagement with CBT4CBT, address any questions and problems with the program, and encourage practice of coping activities (i.e., homework).
9898841|NCT05338138||the standard blind technique for Central venous catheter insertion into the internal jugular vein.|using the blind experience based technique without imaging guidance
9898842|NCT05338138||ultrasound guided technique for Central venous catheter insertion into the internal jugular vein.|using real time ulrasound guidance
9898843|NCT05338112||Patients with active pemphigus lesions|
9898844|NCT05337735|Experimental|XmAb20717|Participants will receive XmAb20717 by vein over 1 hour on Days 1 and 15 of each cycle.
9898845|NCT05337293|Experimental|COPE-HF Partnership Intervention|Working with a trained registered nurse interventionist, participants in this arm were trained to use a 4-step problem-solving process to manage identified problems related to heart failure. Heart failure self-care education and materials were provided as indicated based on specific identified problems.
9898846|NCT05337293|Sham Comparator|Attention|Participants in this arm received telephone calls from a trained research assistant on the same schedule as the intervention group. During these calls basic data were collected on several key areas of heart failure self-care. No intervention or patient education took place during these calls.
9898847|NCT05337293|No Intervention|Usual Care|Participants in this arm received usual care from their healthcare providers and facility designated heart failure discharge education only.
9898848|NCT05334524|Active Comparator|kinesiotaping with combined chain exercises|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises."
9898849|NCT05334524|Active Comparator|kinesiotaping|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension."
9898850|NCT05333172|Active Comparator|balance exercise group|The balance program was performed on soft and hard surface. Firstly the participants started the exercises on hard ground while standing. Postural balance program consisted of static and dynamic functional balance exercises (hıp flexion, hıp abduciton, semitandem stance, one leg stance, toe tips lifting). Afterwards exercises were performed on soft surface. Three sets of eight to ten repetitions of each exercise in a slow, controlled manner were performed. This section was completed 30 minitues.
9935681|NCT03366155|Experimental|1/ Arm 1|HAIP chemotherapy + Systemic chemotherapy
9935682|NCT03366142|Experimental|Single Arm|treatment with ustekinumab based on weight
9898851|NCT05333172|Experimental|Dual task exercises|"Dual task exercises are in two forms as motor dual task and cognitive dual task. In this study we used cognitive secondary task exercises. In addition to the exercises applied by the balance exercise group, a cognitive task was added. Participants in this group tried to count 4, 5 and 7 back from 100 while practicing balance exercises.~The balance program was performed on soft and hard surface. Firstly the participants started the exercises on hard ground while standing. Postural balance program consisted of static and dynamic functional balance exercises (hıp flexion, hıp abduciton, semitandem stance, one leg stance, toe tips lifting). Afterwards exercises were performed on soft surface. Three sets of eight to ten repetitions of each exercise in a slow, controlled manner were performed. This section was completed 30 minitues."
9898852|NCT05333016|Experimental|Multimodal Exercise Intervention|12-week, twice weekly partner-based multimodal exercise program
9898853|NCT05332366|Experimental|Delgocitinib - Delgocitinib|Participants will be blinded and randomised to delgocitinib cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
9898854|NCT05332366|Placebo Comparator|Placebo - Delgocitinib|Participants will be blinded and randomised to placebo cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.
9898855|NCT05332366|No Intervention|No treatment|Participants will not receive any treatment. They will only provide a molecular signature of healthy skin to act as a control.
9898856|NCT05332275|Experimental|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
9898857|NCT05332275|Active Comparator|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and follow up to address potential contamination effects across study arms.
9898858|NCT05331885|Experimental|AR-320 (Suvratoxumab)|Participants will receive a single intravenous (IV) dose of suvratoxumab on Day 0 of the study.
9898859|NCT05331885|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo to survatoxumab on Day 0 of the study.
9898860|NCT05331859|Placebo Comparator|conventional|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated only with conventional postoperative eye drops.
9898861|NCT05331859|Active Comparator|Insulin|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated with topical insulin and conventional postoperative eye drops.
9992534|NCT01463332|Placebo Comparator|Group NS|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
9517563|NCT03305289|Active Comparator|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
9517564|NCT03305276||general population|the study is open to all population, (14-90 years, male/female) to verify the impact of lifestyles (mediterranean style) on intermediate and hard endpoint.
9935683|NCT03366129||Cohort|Stroke patients with white matter hyperintensities (WMH)
9935684|NCT03366116|Experimental|1|Aza-TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
9935685|NCT03354416||1/ Cohort 1|Subjects with an increased risk of prostate cancer or a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
9935686|NCT03354390|Experimental|1|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT).
9935687|NCT03351764|Other|arm 1|these are within subject repeated measures studies across a number of conditions
9935688|NCT03351764|Placebo Comparator|arm 2|
9935689|NCT03331380|Other|Group A|Group A includes 600 healthy adult volunteers of both sexes with-out known cardiovascular disease
9935690|NCT03331380|Other|Group B|Group B includes 500 adult subjects of both sexes with known sta-ble cardiovascular disease including adults with stable coronary artery disease after myocardial infarction; adults with heart failure and reduced left ventricular systolic function; adults with pulmonary artery hypertension; adults with congenital heart disease including cardiac shunts; adults with valvular heart disease including aortic stenosis, mitral regurgitation, and tricuspid regurgitation; and adults with metallic cardiovascular implants (such as coronary and peripheral artery stents) known to be safe for CMR at 1.5T
9935691|NCT03331380|Other|Group C|Group C includes 500 adult subjects of both sexes with known non-cardiovascular disease
9935692|NCT03326245|Active Comparator|1:Oral MP- IV PL|Oral Methylphenidate /IV Placebo
9935693|NCT03326245|Active Comparator|2 Oral PL/IV MP|Oral Placebo/IV Methylphenidate
9935694|NCT03326245|Placebo Comparator|3: Oral PL/IV PL|Oral Placebo/IV Placebo
9935695|NCT03324646||controls|healthy subjects
9935696|NCT03319732|Experimental|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
9935697|NCT03315871|Experimental|1/combination therapy [close December 2018]|Combination immunotherapy
9935698|NCT03315871|Experimental|2/combination therapy + surveillance [closed]|Surveillance followed by Prostvac + CV301 then Prostvac + CV301 + MSB0011359C
9935699|NCT03315871|Experimental|3/combination vaccine therapy + surveillance|Surveillance followed by Prostvac + CV301 then Prostvac + CV301
9935700|NCT03312400|Active Comparator|200 mg Arm|100 mg twice a day
9935701|NCT03312400|Active Comparator|400 mg Arm|200 mg twice a day
9935702|NCT03307317||Adult pilots|Healthy adults between the ages of 18-65 years
9935703|NCT03307317||AR infants|Infants with 12 months of age (+/- 2 weeks) with one of the following: observed developmental delay, sibling of a child with autism, premature birth, small for gestational age.
9935704|NCT03307317||TD infants|Healthy infants with 9 months of age (+/- 2 weeks)
9935705|NCT03307304||Family members|Unaffected family members of individuals diagnosed with CLN3-Batten
9935706|NCT03307304||Proband/Affected Individuals|Individuals diagnosed with CLN3-Batten
9935707|NCT03304704||DSF Cohort|Accrual/Screening up to 1800 will include volunteers between the ages of 5 and 17 years and will be enrolled for genotyping and monthly blood sampling
9935708|NCT03304704||Genotype Cohort|Accrual/Screening up to 1500 will complete a single visit with blood draw for genotyping for future fidelity assessments with blood-fed, spray wild-caught mosquitoes.
9935709|NCT03304704||Parasite Surveillance Cohort|Accrual/Screening up to 1500 will be enrolled for genotyping and a minimum of six monthly blood sampling and mosquito wild catches wild-caught mosquitoes within their compound
9935710|NCT03304691||Bandiagara, Mali|Children of both sexes between 6 months and 10 years of age.
9935711|NCT03304691||Yirimadio, Bamako, Mali|Children and adults of both sexes 6 months and older.
9935712|NCT03304678||taking sirolimus|Subjects will come to the NIH and begin taking sirolimus 2mg
9935713|NCT03304665||Healthy Volunteers|Healthy Volunteers
9935714|NCT03300830||group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease
9935715|NCT03294460|Experimental|1|Alcohol self-administration (IV ethanol for sessions 1 and 3, oral for session 2)
9935716|NCT03289923|Experimental|Active TMS+Cognitive Therapy|active
9935717|NCT03289923|Sham Comparator|Sham TMS + Cognitive Therapy|inactive
9935718|NCT03289273||uHCC patients treated with regorafenib|Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)
9935719|NCT03288220||Healthy volunteers|Healthy volunteers age 50 and older
9935720|NCT03288220||Stroke patients|Stroke patients aged 18 and older
9935721|NCT03288207||Mobile Health|African-American female;age of 25-75 years old - Must be overweight or obese (Body Mass Index (BMI) >= 25 kg/m^2) - Must live in Washington DC Wards (5, 7, or 8)
9898862|NCT05331859|Active Comparator|Autologous serum eye drops|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated with Autologous serum eye and conventional postoperative eye drops.
9898863|NCT05331755||Severe T2 high asthma|"Included patients will have severe type 2 high asthma, are eligible for dupilumab conform EU label, minimally treated with high dose ICS and LABA and have:~blood eosinophils 150 - 1500/mm2 OR~FeNO >20 ppb OR~clinical significant inhalation allergy (+ sIgE positive) OR~OCS dependency"
9898864|NCT05331482|Experimental|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
9898865|NCT05331482|Active Comparator|Conventional training protocol-|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
9898866|NCT05331482|No Intervention|Control Group|Subject continues with activities of daily living. Does not receive deep cervical muscle training.
9898867|NCT05331430|Experimental|Experimental group 1: Dry needling on cervical trigger point|Dry needling of the trigger point of the upper fibres of the trapezius muscle. Using the Hong technique.
9898868|NCT05331430|Experimental|Experimental group 2: Trapezius muscle stretch|Manual passive stretching of the upper trapezius muscle fibres.
9898869|NCT05331430|No Intervention|Control group: Informative talks|Informative talks on breathing techniques, relaxation techniques and posture hygiene.
9898870|NCT05331378|Experimental|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
9898871|NCT05331378|Other|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
9898872|NCT05331170|Active Comparator|Healthy|Subjects without asthma, COPD, rhinitis and with negative allergen test
9898873|NCT05331170|Active Comparator|Allergic Rhinitis|Subjects without asthma, COPD and with positive allergen test
9898874|NCT05331170|Active Comparator|Allergic Ashthma|Subjects with asthma and positive allergen test
9898875|NCT05330754||Control group|No caffeine intake
9898876|NCT05330754||Safe level Group|Caffeine daily intake ≤200 mg/day
9898877|NCT05330754||Unsafe level group:|Caffeine daily intake >200 mg/day
9898878|NCT05330052|Experimental|Agilik|The participant will be provided custom knee orthoses (the Agilik) to trial in this study
9898879|NCT05329545|Experimental|XMT-1536 (upifitamab rilsodotin)|XMT-1536 (upifitamab rilsodotin)
9898880|NCT05329545|Placebo Comparator|Placebo|Saline placebo will be administered with same schedule and stopping rules as for the assigned interventions in the Experimental Arm.
9898881|NCT05329233||minimal flow|For minimal-flow anesthesia, oxygen 0.3 L/min and medical air 0.2 L/min (FGF 0.5 L/min, FiO2 68%) were administered to patients in group M.
9898882|NCT05329233||low flow|For low-flow anesthesia, oxygen 0.37 L/min and medical air 0.63 L/min (FGF 1 L/min, FiO2 50%) were administered to patients in group L.
9898883|NCT05329233||high flow|For high-flow anesthesia, oxygen 1 L/min and medical air 3 L/min (FGF 4 L/min, FiO2 40%) were administered to patients in group H.
9898884|NCT05329077|Other|Home Ultrasound users|Single Arm home ultrasound in pregnant women users
9898885|NCT05328908|Experimental|Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC)|
9898886|NCT05328908|Active Comparator|Arm B: Investigator's Choice|Treatment with Regorafenib or TAS-102
9898887|NCT05328830|Experimental|Instrument assisted soft tissue mobilization group|Instrument assisted soft tissue mobilization will be applied after 30 minutes of DOMS creation
9898888|NCT05328830|Experimental|Foam roller|Foam roller will be applied after 30 minutes of DOMS creation
9898889|NCT05328830|No Intervention|control group|no intervention
9898890|NCT05328791|Experimental|Mindfulness+Diet intervention|Diet and mindfulness intervention
9898891|NCT05328791|Experimental|Diet intervention|Diet intervention
9992535|NCT01463332|Active Comparator|Group D25|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
9997714|NCT01511367|Active Comparator|Flutiform|
9898892|NCT05328648|Experimental|Community Score Card|In the Community Score Card approach, community members come together to document challenges they encounter when seeking services and develop a corresponding set of indicators that can be used to produce a validated facility score. The score is shared with the community and a collaborative process between key community members and facility staff takes place to develop feasible solutions and a strategic action plan.
9898893|NCT05328648|Experimental|Citizen Report Card|In the Citizen Report Card approach, individual-level feedback is collected from actual clients of target facilities, via a structured questionnaire, to assess facility performance and generate a public record of service quality. In addition to sharing the final report card with communities, engaged policymakers are invited to use the citizen feedback to improve service delivery.
9898894|NCT05328648|No Intervention|Control|Communities in the control arm will not receive an intervention.
9898895|NCT05328570|Experimental|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
9898896|NCT05328505|Experimental|Molecular Imaging Informed Radiation Dose Escalation and De-escalation|Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas.
9898897|NCT05328349||Education Program|All participants will have to present shoulder symptoms related to rotator cuff related shoulder pain, which is defined as pain over the deltoid and/or upper arm region, pain associated with arm movement, and familiar pain reproduced with loading or resisted testing during abduction and/or external rotation of the arm.
9898898|NCT05328076||Surgical group|Patients who undergo thyroid surgery and receive indocyanine green angiography
9898899|NCT05328024||Recurrent and/or metastatic head and neck carcinoma|Patients with indication of anti-PD1 immunotherapy according to recommendations
9898900|NCT05327673||patients who accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)|
9898901|NCT05327673||patients who did not accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)|
9898902|NCT05327543|Experimental|Iyengar yoga|Intervention group 1 receives an Iyengar yoga intervention in a group setting, based on the internationally renowned yoga school of B.K.S. Iyengar, which in the context of this study primarily includes physical and relaxation exercises.
9898903|NCT05327543|Experimental|Meditative yoga|Intervention group 2 receives an Integrative yoga intervention including physical and meditation exercises as well as ideologically neutral explanations of the ethical aspects of Yoga.
9898904|NCT05327543|No Intervention|Waitlist Control Group|Group 3 consists of a waitlist control group. Participants will be offered the opportunity to attend a yoga intervention after 4 months. The patients in this waiting list control group are allowed to choose the yoga course after 4 months.
9898905|NCT05327413||Group 1|
9898906|NCT05326490|Experimental|Test arm|"Double-blinded treatment period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage~Open-label extended period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage"
9898907|NCT05326490|Placebo Comparator|Placebo arm|"Double-blinded treatment period:~PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;Basic treatment with stable dose of Glucophage~Open-label extended period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage"
9898908|NCT05326477|Other|Standard-of-care behavioral weight loss treatment|6-months of group-based behavioral weight loss treatment following the Centers for Disease Control and Prevention Prevent T2 curriculum.
9898909|NCT05326204||1 hour|Blood glucose monitoring comprises of 1 hour post meal
9898910|NCT05326204||2 hours|Blood glucose monitoring comprises of 2 hours post meal
9898911|NCT05325970||Cohorts Interventions Patients receiving head and neck RT|
9898912|NCT05325840|Experimental|music therapy|"Experimental Group: Pre-test will be applied to pregnant women before the intervention. Since ST will be applied later, Nki will be applied to pregnant women, and their props will then be right lateral or lateral. NST registration form will be filled.~After the pregnancy is given, the type of music (Classical Turkish Music, Turkish Classical Music, Lullaby) is asked according to the preferences of the pregnant women and their music is given for 20 minutes. The NST process will be implemented from start to finish. In the application, music from pregnant women will be played on MP3 players. After the NST procedure is applied, the pregnant women will have a son."
9997715|NCT01511367|Active Comparator|Seretide|
9997716|NCT01511367|Active Comparator|Flixotide|
9898913|NCT05325840|No Intervention|standard of care|"Control group: First of all, Personal Information Form, State Anxiety Scale and blood pressure measurement will be made to the pregnant women in the control group. In order to perform the NST procedure, the pregnant women will be given the left side or right side position to fix the probes. NST registration form will be filled.~20 minutes after positioning the pregnant women. During the routine NST procedure will be applied and no intervention will be made. After the NST procedure is completed, the State Anxiety Scale and blood pressure measurement will be repeated as the last test of the pregnant women."
9898914|NCT05325775|Experimental|ACER-801 50 mg BID|ACER-801 (osanetant) 50 mg BID (1 x 50 mg and 3 x placebo, twice daily)
9898915|NCT05325775|Experimental|ACER-801 100 mg BID|ACER-801 (osanetant) 100 mg BID (2 x 50 mg and 2 x placebo, twice daily)
9898916|NCT05325775|Experimental|ACER-801 200 mg BID|ACER-801 (osanetant) 200 mg BID (3 x 50 mg and 1 x placebo, twice daily)
9898917|NCT05325775|Placebo Comparator|Placebo|Placebo (4 x Placebo of ACER-801 twice daily)
9898918|NCT05325489|Experimental|Nebulized Budesonide|Drug: budesonide 0.5mg/2ml Pulmicort Respules budesonide inhalation suspension(BIS) once a day (QD) oral montelukast sodium chewable tablets 4mg QD
9898919|NCT05325489|Active Comparator|Intranasal Budesonide Spray|Drug: budesonide nasal spray 100μg QD oral montelukast sodium chewable tablets 4mg QD
9898920|NCT05324670|Experimental|Experimental condition|Didactic intervention based on religious teachings and cultural milieu, the experimental group will receive 12 sessions for three months, 4 sessions per month including focused group discussion.
9898921|NCT05324670|Other|Control condition|They will have sessions like the experimental group but the control group will get the knowledge in the form of written material without any explanation (Information Leaflet).
9898922|NCT05323539|Active Comparator|Patients with endometrioma|Patients having a prediagnosis of surgically planned endometrioma occured this group.
9898923|NCT05323539|Active Comparator|Control group|Patients who had planned gynecological surgery for a reason (ovarian cycts) other than endometrioma
9898924|NCT05323110|Experimental|Part A - Cohort 1A|Single dose cohort
9898925|NCT05323110|Experimental|Part A - Cohort 2A|Single dose cohort
9898926|NCT05323110|Experimental|Part A - Cohort 3A|Single dose cohort
9898927|NCT05323110|Experimental|Part A - Cohort 4A|Single dose cohort
9898928|NCT05323110|Experimental|Part A - Cohort 5A|Single dose cohort
9898929|NCT05323110|Experimental|Part A - Cohort 6A|Single dose cohort
9898930|NCT05323110|Experimental|Part A - Cohort 7A|Single dose cohort
9898931|NCT05323110|Experimental|Part A - Cohort 8A|Single dose cohort
9898932|NCT05323110|Experimental|Part B - Cohort 1B|Multiple dose cohort
9898933|NCT05323110|Experimental|Part B - Cohort 2B|Multiple dose cohort
9898934|NCT05323110|Experimental|Part A - Cohort 3B|Multiple dose cohort
9898935|NCT05322694||Acute respiratory infections|"Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.~Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient."
9898936|NCT05322694||Acute infectious diarrhea|"Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.~Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient."
9898937|NCT05322031|Experimental|Onset of depression|15 participants with onset of schizophrenia who, after a period of stabilization with aripiprazole in oral formulation, would begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole since no more than two weeks.
9898938|NCT05321901|Active Comparator|Experimental Group: Telerehabilitation assisted exercise program|"The telerehabilitation-assisted exercise program included a Biopsychosocial Exercise Therapy approach (BETY).~The approaches that make up the BETY innovation are grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.~Tele-rehabilitation group participated in the sessions that lasted for one and a half hours, 3 days a week for 8 weeks, over the Whatsapp group.~The investigators, who provided supervision during the sessions, also participated in the exercises simultaneously."
9898939|NCT05321901|Other|Control Group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
9992536|NCT01463332|Active Comparator|Group D50|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
9898940|NCT05321758|Active Comparator|FMT group|Repeated and multiple FMTs plus PEN(80%) in the treatment of pediatric CD. Patients received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) and FMT intervention. In the induction stage of CD, FMT was given 3 courses, 3 times per course. In the maintaining stage, FMT was performed every 3 months, with the same 3 times of FMT treatment for each course.
9898941|NCT05321758|Sham Comparator|PEN group|Patients received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention
9898942|NCT05321745|Experimental|Repeated and multiple FMTs plus PEN|repeated and multiple FMTs plus PEN(50% of total calories as polymeric diet, Peptamen, Nestle, Vevey, Switzerland) in refractory pediatric CD
9898943|NCT05321537|Experimental|Somatosensory training|It consists of head relocation exercises, eye tracking, gaze stability and eye-head coordination. It requires the use of special material, the pupillary glasses allow the gaze to be fixed by restricting peripheral vision and the laser pointer provides visual feedback on the positioning of the head.
9898944|NCT05321537|Experimental|Endurance-strength training|It consists of low-load training of the craniocervical flexor muscles. This exercise is specific for the deep cervical flexor muscles, while seeking minimal activation of the superficial flexor muscles. This training consists of 5 phases, starting with a pressure of 20 mmHg, progressively increasing 2 mmHg in each phase.
9898945|NCT05321238|Experimental|High agency and immediate threat|Participants were asked to make decisions within the interactive digital narrative and were presented with acute alcohol poisoning of the main character in the story.
9898946|NCT05321238|Experimental|High agency and distant threat|Participants were asked to make decisions within the interactive digital narrative and were presented with multiple organ failure after years of alcohol consumption of the main character in the story.
9898947|NCT05321238|Experimental|Low agency and immediate threat|Participants were presented with a fixed (passive) narrative without decisions and were presented with acute alcohol poisoning of the main character in the story.
9898948|NCT05321238|Experimental|Low agency and distant threat|Participants were presented with a fixed (passive) narrative without decisions and were presented with multiple organ failure after years of alcohol consumption of the main character in the story.
9898949|NCT05321082|Experimental|BI 1015550 - Treatment|
9898950|NCT05321082|Placebo Comparator|Placebo|
9898951|NCT05320978||patients undergoing minimally invasive pylor-preserving pancreaticoduodenectomy|Adult patients aged 20 years or older and who underg minimally invasive pylor-preserving pancreaticoduodenectomy
9898952|NCT05320627|Experimental|Edoxaban treatment|
9898953|NCT05320510|Experimental|Se-yeast|Selenium-enriched yeast tablet (Se, 50 μg/d)
9898954|NCT05320510|Placebo Comparator|Placebo|placebo-yeast tablet
9992537|NCT01463345|Experimental|Conservative Transfusion Arm|Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
9898955|NCT05320445|Experimental|Supportive-expressive group therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
9898956|NCT05320445|No Intervention|Treatment as usual|The treatment as usual group will receive standard care only (which may include an individual psychiatric consultation).
9898957|NCT05319860|Active Comparator|Standard of Care With No Study Intervention|Participants will receive standard medical care, consisting of antiemetic medicine at the first sign of Chemotherapy-Induced Nausea and Vomiting (CINV) on a schedule as prescribed by the healthcare provider.
9898958|NCT05319860|Experimental|Standard of Care With Study Intervention|Participants will receive an aromatherapy inhaler for complementary in addition to their standard of care antiemetic medication for Chemotherapy-Induced Nausea and Vomiting (CINV).
9898959|NCT05319093||Early Ozanimod treatment|"In this group the effect of Ozanimod will be assessed in patients who initiated on Ozanimod treatment at study baseline (n=10).~Treatment schedule and dosage of Ozanimod and the other disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital."
9898960|NCT05319093||Medium-term Ozanimod treatment|"In this group, the effect of Ozanimod will be assessed in patients treated with Ozanimod for ≥6 months at study baseline (n=10).~Treatment schedule and dosage of Ozanimod and the other disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital."
9898961|NCT05319093||Non-Ozanimod treatment|"In this group, investigators will involve patients initiated on any disease-modifying drug (other than Ozanimod) at study initiation (n=10).~Treatment schedule and dosage of the disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital. The proposed study is purely observational and will not influence the selection, schedule or dosage of patient treatments."
9898962|NCT05319093||Untreated|In this group, MS patient will be involved who did not receive any disease-modifying drug for at least 3 months before study initiation (i.e., untreated patients, n=10)
9898963|NCT05318079|Experimental|Group virtual reality gaming|The intervention will include home-based exercise using the Oculus Quest 2. Participants will be prescribed two gaming goals to achieve across the 8-week intervention. The first goal will be to play with the Quest for at least ≥60 minutes, 5 days per week (Monday - Friday) across the 8-week intervention: a total of 300 minutes. Participants can achieve these goals through either single- or multiplayer gaming but will be prescribed to engage in online multiplayer or peer-to-peer gaming at least 2 days per week.
9898964|NCT05318079|No Intervention|Wait-list Control|People who are randomized to the waitlist group will undergo 4-weeks of wait (habitual daily activities), followed by 8-weeks of VR intervention. People in the wait-group will be in the study for a total of 12 weeks.
9898965|NCT05316441|Experimental|Intervention Group|A total of 5 sessions of 1.5 hours of group therapy will be applied to the Intervention Group. Group therapies will be carried out over the internet once a week, after appropriate days and times are determined.
9898966|NCT05316441|No Intervention|Control Group|The control group will not be interfered with.
9898967|NCT05316155|Experimental|Part 1: Dose Escalation|Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D[s]) for Part 2.
9898968|NCT05316155|Experimental|Part 2: Dose Expansion|Participants in each of 4 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1.
9898969|NCT05315362|Experimental|Intervention group - intradermal vaccination with patch|Participants will receive 20 µg of mRNA-1273 vaccine through the intradermal route using a solid micro needle delivery system
9898970|NCT05315362|Active Comparator|Control group - intramuscular vaccination with standard needle|Participants will receive 20 µg of mRNA-1273 vaccine through the intramuscular route
9898971|NCT05315271|Active Comparator|Group 1|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
9898972|NCT05315271|Active Comparator|Group 2|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
9898973|NCT05315037|Other|Resistance Training|Bench press, Deadlift, Seated overhead press machine
9898974|NCT05314660|Experimental|Silver diamine fluoride group|Application of 38% SDF.
9898975|NCT05314660|Experimental|Atrumatic restorative technique|
9898976|NCT05314660|Experimental|Ultra conservative treatment (UCT)|
9898977|NCT05314036|Experimental|Acute Postprandial Blood Sampling|Two-hour postprandial blood sampling following administration of a standardized test meal
9933214|NCT00957840|Other|Omaya reservoir group- observational|These infants have been identified with severe enough post hemorrhagic ventricular dilation (PHVD) that they require a reservoir placed for serial cerebro-spinal fluid (CSF) removal. There is no randomization, and infants are compared to a baseline. Observational data will be collected to include NIRS and aEEg which will be done twice weekly, and CSF will be analyzed with each reservoir tap for protein biomarkers.
9933215|NCT00957879|Active Comparator|ergocalciferol|Weekly ergocalciferol for 12 weeks
9992538|NCT01463345|Active Comparator|Liberal Transfusion Arm|Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
9992539|NCT01463371|No Intervention|Control|without azithromycin
9992540|NCT01463371|Active Comparator|azithromycin|treatment with azithromycin during three months
9992541|NCT01463436|Experimental|soy isoflavone 100 mg|the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
9992542|NCT01463436|Placebo Comparator|calcium carbonate 500 mg|The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
9992543|NCT01463449||Obese|Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
9992544|NCT01463462||Electronic Catheter Stethoscope|
9992545|NCT01463475|Other|Bone Marrow Aspirate|A qualified enrolled donor will have an aspirate bone marrow draw.
9992546|NCT01463488|Experimental|SAR113945 - Dose 1|
9992547|NCT01463488|Experimental|SAR113945 - Dose 2|
9992548|NCT01463488|Experimental|SAR113945 - Dose 3|
9992549|NCT01463488|Placebo Comparator|Placebo|
9992550|NCT01463501|Experimental|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy
9992551|NCT01463501|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy
9992552|NCT01463514|Experimental|AIR|"Randomization sequences according to modified catheter protocol.~1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen"
9992553|NCT01463514|Experimental|NO|"Randomization sequences according to modified catheter protocol.~1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen"
9992554|NCT01463514|Experimental|Oxygen|"Randomization sequences according to modified catheter protocol.~1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)"
9992555|NCT01463514|Experimental|Target Oxygen|"Randomization sequences according to modified catheter protocol.~1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR"
9992556|NCT01463540|Active Comparator|Push/pull endoscopic gastrostomy|
9992557|NCT01463540|Experimental|Gastrostomy after gastropexy|
9992558|NCT01463553|No Intervention|wedge resection|
9992559|NCT01463553|Experimental|Wedge resection and pleurodosis|
9992560|NCT01463566||1 - Gender Natural Knee|Patients suffering from severe knee pain and disability.
9992561|NCT01463579|Experimental|Exercise programme|
9992562|NCT01463579|Other|Standard Care|
9992563|NCT01463592|Experimental|Group II a|TRIPPLE THERAPY
9898978|NCT05313373|Experimental|Virtual Reality Group|
9898979|NCT05313373|No Intervention|Control Group|
9898980|NCT05311917|Experimental|home vision therapy|near glasses will be prescribed along with a complete training of the exercises and with a eye exercise form of information about how and how long to do the exercise, by optometrist No 2 (Saeid Abdi).training includes: Voluntary convergence, Bug on string, Eccentric Circles, Jumping vergence , Barrel card, chiastopic fusion, Brock string, push-up These exercises will be done 3 days a week for 20 minutes ( 10 minutes at noon and 10 minutes at night ) for 2 month. Home exercises include eight vision therapy exercises and patients will do two exercises each day at noon and two exercises at night.
9898981|NCT05311917|Experimental|base in prism prescription|base in prism prescription using sheards criterion near prismatic glasses will be prescribed and the amount of prism will be divided between two eyes; and random and aimless eye movements, without convergence and accommodation effects will be prescribed by optometrist No. 2 (Saeid Abdi). patients should complete their checking form for eye exercises.
9898982|NCT05311917|Placebo Comparator|conventional|new near glasses as a conventional treatment with the practice of random and aimless eye movements, without convergence and accommodation effects will be prescribed by optometrist No. 2 (Saeid Abdi). patients should complete the form of their eye training.
9898983|NCT05311462||Weight-loss success with history of weight cycling|High-protein diet for three months
9898984|NCT05311462||Weight-loss failure with history of weight cycling|High-protein diet for three months
9898985|NCT05311358|Experimental|Normal children|Normal children aged 10-15 years play the game and comment on the satisfaction form
9898986|NCT05310435||Pregnant women with lower leg edema|Pregnant women with clinical lower leg edema measured two times with Edema Stocking device, two times with water displacement volumetry and two with tape measure each day for three days.
9898987|NCT05310422|Experimental|Tivanisiran sodium ophthalmic solution|
9898988|NCT05310422|Placebo Comparator|Vehicle ophthalmic solution|
9898991|NCT05309733||Observational Cohort 1|All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
9898992|NCT05309083|Experimental|Mindfulness Based Walking Therapy (MBWT)|Participants will participate in the MWBT developed during Aim 1 and Aim 2.
9898993|NCT05309083|No Intervention|Usual care|Participants will receive their usual care.
9898994|NCT05308225|Experimental|STI-6129|Seven dosing cohorts will be evaluated: 0.67 mg/kg, 0.88 mg/kg, 1.18 mg/kg, 1.56 mg/kg, 2.08 mg/kg, 2.77 mg/kg, 3.68 mg/kg where STI-6129 will be intravenously administered once as part of a 4-week treatment cycle.
9898995|NCT05307640|Experimental|CG-Well|CG-Well is a web & phone based psychosocial intervention that teaches caregivers how to obtain information, education & support
9898996|NCT05307640|Placebo Comparator|Information Support and Referral|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
9933216|NCT00957879|Active Comparator|calcitriol|Daily calcitriol for 12 weeks
9933217|NCT00957957||1|Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)
9933218|NCT00957957||2|Participants having elective gastric banding surgery (GB)
9933219|NCT00957970|Active Comparator|Stemless femoral component|Stemless PROXIMA femoral component
9933220|NCT00957970|Active Comparator|Stemmed femoral component|IPS, proximal anatomical fit stemmed femoral component
9933221|NCT00957983|Active Comparator|BGC20-1531 200mg|
9933222|NCT00957983|Placebo Comparator|sugar pill|
9933223|NCT00957983|Active Comparator|BGC20-1531 400mg|
9992564|NCT01463592|Active Comparator|Group II b|DUAL THERAPY
9992565|NCT01463592|Experimental|Group I|ORAL RENESSANS
9898997|NCT05307237|Experimental|Continuous Glucose Monitoring|Research Assistants (RAs) will verbally administer baseline survey and insert Dexcom G6 CGM, before unveiling the group assignment. CGM data will be transmitted from bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by remote monitoring team) and (2) Clinical Optimization (via CLARITY, a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub). A post-CGM satisfaction survey will be administered and compensation provided when CGM is removed prior to discharge or within 2 weeks following discharge. The CGM readings will be used to make recommendations for insulin adjustment and glucose management. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in Excel. The Data Analyst, blinded to condition, will routinely screen CGM data and merge individual spreadsheets for analysis.
9898998|NCT05307237|Active Comparator|Usual Care|RAs will verbally administer a baseline survey and insert the Dexcom G6 CGM. before unveiling the group assignment. CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring, A post-CGM satisfaction survey will be administered and compensation provided when the CGM is removed prior to discharge or within 2 weeks following discharge. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in individual Excel spreadsheets. The study Data Analyst, blinded to study condition, will routinely screen CGM data and merge individual spreadsheets for analysis.
9898999|NCT05307003||Quetiapine|"Patients diagnosed with delirium who received quetiapine for treatment.~Start study medication at 25 mg daily PO ; may increase to BID (twice a day) or TID (three times a day) if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE (adverse effects) likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
9899000|NCT05307003||Trazodone|"Patients diagnosed with delirium who received trazodone for treatment.~Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
9899001|NCT05306340|Experimental|Giredestrant plus Everolimus|
9899002|NCT05306340|Active Comparator|Exemestane plus Everolimus|
9899003|NCT05305014||Patient with conversive motor disorder|Patients with paralysis, motor weakness or abnormal movements meeting the DSM-IV criteria of conversive motor disorder consulting the SAU or the Neurology departments of the CHU of Nîmes and Montpellier included in the HYCORE parent study (RCB ID 2014-A01159-38, NCT02329626)
9899004|NCT05304702||NEGBAL|"Negative Fluid Balance (NEGBAL) Approach:~COVID-19 patients with tomographic detection of pulmonary edema (dilated superior vena cava, large pulmonary arteries, diffuse interstitial infiltrates with Kerley lines, and dilated right ventricle or dilated cardiac axis) treated with NEGBAL approach. This consisted of oral hydric restriction and use of diuretics (20 mg of furosemide, intravenous bolus, followed by furosemide in endovenous continuous infusion, starting at 60 mg/day).~The objective of this approach was to achieve negative fluid balance, between 600 to 1400 mL/day adjusted to body surface area, with a final target of 8-10% of body weight in up to 8 days. The furosemide dose was titrated considering heart rate and blood pressure, target fluid balance, hematocrit, and serum creatinine."
9899005|NCT05304702||NO-NEGBAL|"Treatment for COVID-19 pneumonia in this series were based on standard recommendations.~All patients in this group received dexamethasone 6 mg/day and thromboembolic prevention with enoxaparin 40 mg/day.~Participants in the NO-NEGBAL group, did not received a NEGBAL approach as treatment."
9899006|NCT05304416||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or a Simultaneous FEES and Videofluoroscopy instrumental swallowing exam before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
9899007|NCT05304416||Cardiovascular Surgical Patients Postoperative Exam|Participants without preoperative dysphagia will be seen for a postop exam within 72 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy (or a FEES or VFSS exam in isolation) will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow-up clinic visit.
9899008|NCT05304377|Experimental|phase 1b expansion arm at recommended dose level 1|ELVN-001 administered orally once daily at RDE-1 in CML without T315I mutations
9899009|NCT05304377|Experimental|Phase 1b expansion arm at recommended dose level 2|ELVN-001 administered orally once daily at RDE-2 in CML without T315I mutations
9899010|NCT05304377|Experimental|Phase 1b expansion arm in T315I mutated CML|ELVN-001 administered orally once daily at RDE-3
9899011|NCT05304377|Experimental|Phase 1a dose escalation in CML|ELVN-001 administered orally once daily in 3+3 dose escalation
9899012|NCT05303558||Participants With High-risk Localized Prostate Cancer|Adult participants from Japan, South Korea, and Taiwan with high-risk localized prostate cancer (HR LPC) who received radical prostatectomy (RP) and perioperative (neoadjuvant and/ or adjuvant) hormonal therapy will be observed from the date of confirmed HR LPC diagnosis until death, lost to follow-up (last known visit), or end of study period, whichever comes first. This study will utilize data from electronic medical records (EMR) in South Korea and Taiwan, and data from chart reviews in Japan. Data will be analyzed retrospectively from 1 January 2015 to 30 June 2017, with a follow-up till 30 June 2022.
9899013|NCT05301998|Other|Study Group|"Measurements of elasticity and thickness will be performed for each of the 200 patients.~Among the 200 patients, 10 will have a breast MRI in 3 different positions"
9899014|NCT05299905|Experimental|Semi-CAVE|
9899015|NCT05299905|Experimental|Head-mounted display system|
9899018|NCT05298059|Placebo Comparator|CPP-ACPF PASTE APLICATION|Apply the cpp-acpf paste, at four different times (one each week of whitening treatment), for five minutes in each application and evaluate if it was able to reduce the sensitivity after home whitening with 22% carbamide peroxide.
9899019|NCT05298059|No Intervention|Evaluate the effectiviness at home bleaching|To evaluate the effectiveness of at-home bleaching with 22% carbamide peroxide, with the help of the VITA Easyshade 4.0 spectrophotometer
9899020|NCT05298059|Placebo Comparator|LASER APLICATION|Apply the laser at four different times (one every week of whitening treatment), using the spectrum of infrared light with a wavelength of 808 nm with its active medium of Arsento Gallium and Aluminum (AsGaAl), at three points, one in the center of the crown of the tooth, another in the center of the cervical region and the last one in the incisal region, with the light beam directed apically, from all teeth to the second premolar of each upper and lower hemi-arch, with energy of of 1 Joule per point for 10 seconds. and evaluate if it was able to reduce the sensitivity after home whitening with 22% carbamide peroxide.
9899021|NCT05298059|Placebo Comparator|Associate the CPP-ACPF paste with the LASER|Associate the CPP-ACPF paste with the LASER, following the same clinical protocol mentioned above and assess whether the association is more efficient than both treatments alone.
9899022|NCT05297500||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
9899023|NCT05296915|Experimental|tVNS + CBT-E group|N=10 Interventional group with transcutaneous stimulation of the auricular branch of the vagus nerve associated with targeted cognitive-behavioral therapy (following the CBT-E protocol, CG Fairburn - 2010.
9899024|NCT05296915|Experimental|rTMS + CBT-E group|N=10 Interventional group with repetitive transcranial magnetic stimulation associated with targeted cognitive-behavioral therapy (following the CBT-E protocol, CG Fairburn - 2010.).
9899025|NCT05296915|Experimental|Only CBT-E group|N=10 Group with only cognitive-behavioral therapy of eating disorders.
9899026|NCT05296733|Experimental|Part A: BI 456906: Cohort 1|Healthy subjects
9899027|NCT05296733|Experimental|Part A: BI 456906: Cohort 2|Patients with cirrhosis + Child-Turcotte-Pugh (CTP) Class A
9899028|NCT05296733|Experimental|Part A: BI 456906: Cohort 3|Patients with cirrhosis + CTP Class B
9899029|NCT05296733|Experimental|Part A: BI 456906: Cohort 4|Patients with cirrhosis + CTP Class C
9899030|NCT05296733|Experimental|Part B: BI456906: Cohort 1|Patients with overweight/obesity without cirrhosis/hepatic impairment
9899031|NCT05296733|Experimental|Part B: BI456906: Cohort 2|Patients with overweight/obesity with cirrhosis + CTP Class A
9899032|NCT05296733|Experimental|Part B: BI456906: Cohort 3|Patients with overweight/obesity with cirrhosis + CTP Class B
9899033|NCT05296681|Experimental|NM108 Drinks|"NBT-NM108 Drinks four times daily before meals and 2 hours after dinner for 56 days.~Beginning 5 days before starting chemotherapy, patients receive NBT-NM108 PO QID for 56 days. Patients receive irinotecan-based chemotherapy per standard of care."
9899034|NCT05296681|No Intervention|No Microbiome Support|"No microbiome~Patients receive irinotecan-based chemotherapy per standard of care."
9899035|NCT05296525|Other|GDA-201|"Phase 1 dose escalation with up to 4 dose levels to reach MTD and determine recommended phase 2 dose (RP2D).~Phase 2 RP2D will be administered to all patients."
9899036|NCT05295927|Experimental|Group A: EPI-7386 + Abiraterone Acetate Plus Prednisone (AAP)|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive EPI-7386 + AAP to determine the recommended phase 2 dose (RP2D) dose of EPI-7386 in combination with AAP in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with AAP.
9899037|NCT05295927|Experimental|Group B: EPI-3786 + Apalutamide|Participants with mCRPC will receive EPI-7386 + apalutamide to determine RP2D dose of EPI-7386 in combination with apalutamide in dose finding portion of the study. In dose expansion portion of the study, participants will receive EPI-7386 RP2D in combination with apalutamide.
9933224|NCT00958022|Experimental|LBH589 and carboplatin with etoposide|"The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how lung cancer responds to the LBH589 in combination with carboplatin and etoposide.~This study will also investigate how the body processes the combination of LBH589 and carboplatin with etoposide."
9933225|NCT00958048|Experimental|2|ALS with non-invasive ventilation
9899038|NCT05295901|Experimental|experimental group|"In the pre-test phase (first interview) - Patient Diagnosis Form, COPD Self-efficacy Scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) Dyspnea Scale average 15-20 min. will be implemented.~After the pre-test, the mCOPD mobile application will be installed on the phones of the patients and it will be checked whether the mobile application is working. mobile application content will be explained. In addition, a pulse oximeter device will be given to the patients by the researcher to record their pulse and saturation values and its use will be explained.~In the final test phase (final interview); The COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (mMRC) Dyspnea Scale and the Satisfaction Questionnaire will be applied to determine the degree of satisfaction"
9899039|NCT05295901|No Intervention|control group|"In the pre-test phase (first interview); Patient Diagnosis Form, COPD self-efficacy scale, Chronic Disease Care Assessment Scale-Patient Form, COPD Assessment Test (CAT), Modified Medical Research Council (MRC) Dyspnea Scale will be applied. No action will be taken after the interview.~In the final testing phase (final interview); After applying the COPD Self-Efficacy Scale, the Chronic Disease Care Assessment Scale-Patient Form, the COPD Assessment Test (CAT), the Modified Medical Research Council (MRC) Dyspnea Scale, the mCOPD application will be installed on their phones and training"
9899040|NCT05295147|Experimental|Palmar Grasp Reflex Stimulation|
9899041|NCT05295147|No Intervention|Control Group|
9899042|NCT05293041|Experimental|OR-Argipressin|Open hepatic resection. Patients will be treated with Empressin® 0.8 U/ml, 0.056 ml/kg/h during surgery.
9899043|NCT05293041|Placebo Comparator|OR-Placebo|Open hepatic resection. Patients will receive normal saline 0.056 ml/kg/h during surgery.
9899044|NCT05293041|Experimental|Lap-Argipressin|Laparoscopic resection. Patients will be treated with Empressin® 0.8 U/ml, 0.056 ml/kg/h during surgery.
9899045|NCT05293041|Placebo Comparator|Lap-Placebo|Laparoscopic resection. Patients will receive normal saline 0.056 ml/kg/h during surgery.
9899046|NCT05292898|Experimental|LCAR-AIO Cells|Each subject will be treated with LCAR-AIO Cells
9899047|NCT05291325|Experimental|3L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 3L polyethylene glycol solution combined with 3-day linaclotide.
9899048|NCT05291325|Active Comparator|3L PEG alone|Bowel preparation for colonoscopy was performed with 3L polyethylene glycol solution without linaclotide.
9899049|NCT05291325|Experimental|2L PEG + Linaclotide|Bowel preparation for colonoscopy was performed with 2L polyethylene glycol solution combined with 3-day linaclotide.
9899050|NCT05287906|Experimental|Normal Weight Group|The normal weight group incudes men and women with BMI 18.5 - 24.9 kg/m2, and will receive all interventions.
9899051|NCT05287906|Experimental|Overweight Group|The overweight group includes men and women with BMI 25.0 - 29.9 kg/m2, and will receive all interventions.
9899052|NCT05287906|Experimental|Type 2 Diabetes Mellitis Group|The T2DM group includes men and women with BMI 25.0 - 34.9 kg/m2, HbA1c <8%, and will receive all interventions.
9899053|NCT05286697|Other|effect of increase intracranial pressure on postoperatve cognitive function|All patient will be given a mini mental test before and after the surgery and the optic nerve diameter will be measured 5 times during the surgery.
9899054|NCT05286229|Experimental|Cohort 1 (ABBV-383 Dose A)|Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive ABBV-383 dose A in 21-day cycles.
9899055|NCT05286229|Experimental|Cohort 2 (ABBV-383 Dose B)|Participants with R/R MM who meet the criteria outline in the protocol will receive ABBV-383 dose B in 21-day cycles.
9899056|NCT05284292|Experimental|experimental arm|The Guardian platform consists of the robot Misty II, the Senior App and the Caregiver App will be tested by the elderly subjects together with their caregivers
9899057|NCT05283577|Experimental|Treatment Arm|Each participant will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Each EA session will be approximately 1 hour. Participants in the treatment arm will receive EA at 13 standardized acu-points that were chosen for their therapeutic effects.
9933226|NCT00958048|No Intervention|1|ALS without non-invasive ventilation
9992566|NCT01463605|Other|radiotherapy|It is just a single group assignment
9992567|NCT01463644|Active Comparator|mepolizumab|
9899058|NCT05283577|Sham Comparator|Control Arm|Each participant in the control arm will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Participants in the control arm will receive electrical stimulation at non-disease related acu-points for approximately 1 hour per session.
9899059|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + absent-to-mild psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
9899060|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + absent-to-mild psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
9899061|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + moderate psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
9899062|NCT05282277|Experimental|Perimenopausal women with mild-to-moderate anhedonia + moderate psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
9899063|NCT05282277|Experimental|Perimenopausal women with high anhedonia + absent-to-mild psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
9899064|NCT05282277|Experimental|Perimenopausal women with high anhedonia + absent-to-mild psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
9899065|NCT05282277|Experimental|Perimenopausal women with high anhedonia + moderate psychosis, active group|Participants will be randomly assigned to take 100 μg/day of transdermal estradiol for 3 weeks followed by 1 week of combined 100 μg/day of transdermal estradiol and 200 mg/day progesterone.
9899066|NCT05282277|Experimental|Perimenopausal women with high anhedonia + moderate psychosis, placebo group|Participants will be randomly assigned to receive a matching placebo patch for 3 weeks.
9899067|NCT05282069|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
9899068|NCT05282069|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
9899069|NCT05282069|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
9899070|NCT05282069|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
9899071|NCT05281211|Experimental|Preoperative Nutrition+Exercise|Preoperative nutrition and exercise pre-habilitation followed by major liver resection.
9899072|NCT05281211|No Intervention|Upfront Surgery|Upfront major liver resection.
9899073|NCT05279651|Active Comparator|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
9899074|NCT05279651|Placebo Comparator|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
9899075|NCT05278091||Patients with CANVAS with genetic confirmation|Patients with CANVAS with genetic confirmation (RFC1 gene mutation)
9899076|NCT05278091||others patients|Patients with axonal neuropathy, autoimmune neuronopathy and anti-MAG neuropathy
9899077|NCT05278091||Healthy controls|Patients without CANVAS or other neuropathy
9899078|NCT05278039|Experimental|Respiratory-Swallow Phase Training|Participants will be trained to initiate swallowing during expiration.
9992568|NCT01463644|Placebo Comparator|placebo|
9992569|NCT01463657|Experimental|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
9992570|NCT01463657|Active Comparator|Juvéderm® Ultra Plus|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
9992571|NCT01463670|Experimental|lenalidomide|The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.
9992572|NCT01463709|Experimental|nanopulse|Administer nano pulse to lesion for varying time intervals.
9992573|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|
9992574|NCT01463748|Experimental|Placebo|starch
9992575|NCT01463748|Experimental|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
9992576|NCT01463761||high-level athletes|High-level athlete, enrolled in a Ministry-recognized Pôle
9992577|NCT01463774|Experimental|Treatment Sequence AB|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
9992578|NCT01463774|Experimental|Treatment Sequence BA|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
9992579|NCT01463787|Experimental|inguinal group|
9992580|NCT01463787|Active Comparator|sub-inguinal group|
9992581|NCT01463800|Active Comparator|Structured Exercise training|12 weeks ambulatory low level exercise training
9992582|NCT01463800|No Intervention|Control group|No structured exercise training
9992583|NCT01463813|Placebo Comparator|Placebo|Placebo, no Vitamin D3
9992584|NCT01463813|Experimental|Vitamin D3 80|Vitamin D3 80 micrograms (3200 IU) per day
9992585|NCT01463813|Experimental|Vitamin D3 40|Vitamin D3 40 micrograms (1600 IU) per day
9992586|NCT01463826||Children with bruxism|14 children with bruxism
9992587|NCT01463826||children without bruxism|19 children without bruxism
9992588|NCT01463839||Children 3 to 6|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo
9992589|NCT01463852|Experimental|Vincrisitne 2mg|Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.
9992590|NCT01463865|Placebo Comparator|Placebo|Sodium chloride
9992591|NCT01463865|Active Comparator|ropivacaine|Naropin
9992592|NCT01463891||Eribulin Mesylate|
9992593|NCT01463904||Morbid obese, diabetics|Patients with morbid obesity or severe metabolic disease
9992594|NCT01463917|Active Comparator|Hypertonic|Use of Hypertonic solution during left marginal branch CABG surgery.
9992595|NCT01463917|Placebo Comparator|Isotonic|Use of Isotonic solution during left marginal branch CABG surgery.
9992596|NCT01463930|Experimental|Audiovisual videodisc and medical verbal information|
9992597|NCT01463930|Active Comparator|Medical verbal information|
9992598|NCT01463943|Experimental|Saccharomyces boulardii capsules (200 mg).|
9992599|NCT01463943|Active Comparator|Floratil®|
9992600|NCT01463943|Experimental|Saccharomyces boulardii powder (200 mg).|
9992601|NCT01463956|Experimental|Boceprevir, Pegylated interferon and Ribavirin|"Lead-in phase (4 week): Pegylated interferon + Ribavirin~Triple therapy regimen for 44 weeks :Boceprevir + Pegylated interferon + Ribavirin~Pegylated interferon + Ribavirin therapy until transplantation (less or equal to 24 weeks)"
9992602|NCT01463969||PCOS patients|
9992603|NCT01463969||Control group|
9992604|NCT01463995||severe neurological diseases|Patients with severe neurological diseases treated on the neurological intensive care unit
9992605|NCT01464008||chronic hepatitis C|
9992606|NCT01464034|Experimental|Carfilzomib, Pomalidomide, Dexamethasone|All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
9992607|NCT01464047||Patients with CML or Ph+ ALL|
9992608|NCT01464060|Active Comparator|"Hybrid therapy"|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
9992609|NCT01464060|Experimental|"Concomitant therapy"|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
9992610|NCT01464073|Active Comparator|arm 3 : Good Medical Practices|physical exercise at home monitored by telephone (achieving a minimum of 30 minutes per day)
9899079|NCT05278039|Sham Comparator|Swallow Practice|Participants will practice swallowing, but will not learn the key therapeutic element (i.e., initiating swallowing during expiration).
9899080|NCT05277116|Experimental|Participants receiving a Genome Informed Risk Assessment (GIRA)|All participants and their health care providers will receive a Genome Informed Risk Assessment (GIRA) report.
9899081|NCT05275439|Experimental|SL-172154|Patients will receive intravenous administration
9899082|NCT05275439|Experimental|SL-172154 + Azacitidine|Patients will receive intravenous administration of SL-172154 and Azacitidine.
9899083|NCT05275439|Experimental|SL-172154 + Azacitidine + Venetoclax|Patients will receive intravenous administration of SL-172154 and Azacitidine plus oral venetoclax.
9899084|NCT05272150|Experimental|Cohort A: Moderate-to-severe Plaque Psoriasis|Participants will receive either guselkumab subcutaneously (SC) or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
9899085|NCT05272150|Experimental|Cohort B: Moderate-to-severe Scalp Psoriasis|Participants will receive either guselkumab SC or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
9899086|NCT05271708|Experimental|Fespixon cream|Fespixon cream contains 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%) with appearance in yellow-green to light green color. Fespixon cream will be applied twice daily for up to 12 weeks to the linear wound.
9899087|NCT05271708|Placebo Comparator|Placebo Cream|Placebo cream will be applied twice daily for up to 12 weeks to the linear wound.
9899088|NCT05269862|Experimental|In-Clinic Cohort|Subjects who are implanted with Abbott Infinity DBS systems with the Neuosphere Virtual Clinic feature, and receive programming for their DBS system in-clinic only.
9899089|NCT05269862|Active Comparator|Virtual Clinic Cohort|Subjects who are implanted with Abbott Infinity DBS systems with the Neuosphere Virtual Clinic feature, and receive programming for their DBS system with Virtual Clinic and in-clinic sessions.
9899090|NCT05269498|Experimental|CORTEXPLORER MED|Mixed-reality assisted planning of aneurysm clipping with the optical navigation system CORTEXPLORER MED.
9899091|NCT05268575|Experimental|endoscopic sclerotherapy|Patients with hemorrhoids will be treated with endoscopic sclerotherapy. Injection site is submucosa of hemorrhoid nucleus. Sclerosing agent makes the submucosal tissue fibrotic, and then fixes the hemorrhoidal tissue.
9899092|NCT05268575|Experimental|endoscopic rubber band ligation|Patients with hemorrhoids will be treated with endoscopic rubber band ligation. The ligature position is above the mucosa of the hemorrhoid nucleus. Ligation of hemorrhoidal tissue can lead to ischemic necrosis of the prolapsed mucosa, which in turn leads to scar fixation. At the same time, the ligature also has the effect of lifting the tissue upward.
9899093|NCT05268575|Experimental|endoscopic sclerotherapy combined with rubber band ligation|Patients with hemorrhoids will be treated with endoscopic sclerotherapy combined with rubber band ligation. Sclerotherapy first, followed by rubber band ligation. Sclerotherapy injection reduces the likelihood of ligature dislodgement.
9899094|NCT05267925|Experimental|Intervention|All participants will be asked to take the dietary herbal supplement CuraLin for the duration of the study. All participants will take 2 capsules orally, three times per day following meals for 12 weeks.
9899095|NCT05266417|Experimental|Active|Insulin (Novolin R) and Glutathione (INS-GSH)
9899096|NCT05266417|Placebo Comparator|Control|Placebo
9899097|NCT05266326|Other|Test group|conventional Western medical treatment + bloodletting puncture
9899098|NCT05266326|Other|Control group|conventional Western medical treatment.
9899099|NCT05265650|Experimental|Single Treatment Arm|"Treatment will consist of IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent with systemic administration of nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.~In the initial cohort A, BO-112 will be IT injected on a weekly basis during the first cycle on the accessible lesions, and every 2 weeks thereafter. The minimum dose to be injected per visit is 1 mg (unless injected lesion in case of response, if solitary, becomes smaller than 1.5 cm) and the maximum dose is 2 mg (3.4 mL), distributed in the different lesions.~Stereotactic ablative radiotherapy (SABR) will be initiated on week 3.~In the cohort B, BO-112 and SABR will be administered as described previously.~Nivolumab will be administered at the dose of 240 mg every 2 weeks in both cohorts, starting at cycle 4 (week 7) in cohort A and at cycle 3 (week 5) in cohort B."
9899100|NCT05265208|Experimental|Capecitabine combined with SIRT|Patients in the experimental arm will be treated with capecitabine combined with Selective Internal Radiotherapy (SIRT) before surgery.
9899101|NCT05265208|Other|Surgery only|Patients in the control group will receive surgery only.
9899102|NCT05261763|Active Comparator|Group A|Group A will receive trigger point dry needling in quadricep muscles
9899103|NCT05261763|Sham Comparator|Group B|Group B will get Sham needling in quadriceps muscles
9992611|NCT01464073|Active Comparator|arm 2 : 60% VO2peak|physical exercise at the intensity of 60% of VO2 peak. 4 times a week. duration will be adjusted for arm 1 and arm 2 have the same total energy expenditure by session.
9992612|NCT01464073|Experimental|arm 1 : LIPOXmax|physical exercise at the LIPOXmax intensity during 60 minutes. 4 times a week
9899104|NCT05261399|Active Comparator|Chemotherapy|Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W
9899105|NCT05261399|Experimental|Savolitinib + Osimertinib|300 mg savolitinib BID plus 80 mg osimertinib QD
9899106|NCT05259254|Placebo Comparator|Standard Direct Observed Therapy (DOT)|After a patient was diagnosed with TB, they will be provided TB therapy which is consist of health education and anti-TB medication. Patient that is not in life-threatening condition typically will be treated as outpatient. Patient will receive medication that will be monitored closely through DOT, which is either by health facilities (by healthcare staff), or community (by family members or community members). Observation of medication will be conducted daily, and the health care staff will sign the DOT diary provided to the patient to verify the medication consumption.
9992613|NCT01464086|No Intervention|Standard arm|standard follow-up
9992614|NCT01464086|Experimental|Intensive follow-up|Standard follow-up plus whole body MRI at inclusion, one and two years
9899107|NCT05259254|Active Comparator|Mobile application DOT|The mobile application will be consisting of four basic modules which are: 1) reminder system, 2) visual observed therapy, 3) feedback, and 4) health education. Researcher will teach patient on how to record, and send video of every dose of medication ingested every day. Participants also required to show their mouth is empty by opening their mouth and sticking out their tongue. The participants also are required to record and send the self-recorded video of ingesting the medication daily. Researcher will subsequently view the video through a password protected website. The observation of taking medication will be completed until the end of study period.
9899108|NCT05258825|Experimental|Intravenous Iron Infusion Arm|If the patient is found to have iron deficiency anemia, the patient will receive IV iron preoperatively. Patients that agree to be enrolled in the study will be scheduled for the IV iron dose approximately 3-4 weeks prior to surgery. A single IV dose of 1000 mg of Monoferric will be administered. This will be administered at the Brigham and Women's Hospital infusion center and coordinated with the Hematology team.
9899109|NCT05258539|Experimental|Women aged 18 to 85 years who come to the CRMP for a breast cancer risk assessment.|
9899110|NCT05258500|Experimental|Ghostly|The first arm consists of a strength training program incorporated in the Ghostly game that will be given to the patient to be completed without supervision of the therapist as an added exercise program to their conventional therapy.
9899111|NCT05258500|Experimental|Blood flow restriction and Ghoslty|The second intervention arm incorporates blood flow restriction into the conventional therapy using the Smart Cuffs PRO system (Smart Tools, USA). Additionally, these participants will receive additional exercises added to their conventional therapy using the Ghostly game
9899112|NCT05258500|Active Comparator|Control|The control group will not be given the Ghostly game as additional exercises to complete after their conventional therapy, but will receive instructions for a strength training program targeting the same muscles as both intervention groups.
9899113|NCT05258201|Experimental|Muscle Energy Technique|Muscle energy Technique will be applied on the subjects, when they will be lying supine and on the effect side therapist will stabilize shoulder by one hand, while the ear / mastoid area of the affected side will be hold by opposite hand. The head and neck will be bend to contralateral side, then bends on the same side. Subject will raise his shoulder with the shoulder fixed to the ear with less effort than the maximum. Isometric contraction will be maintain for 7-10 seconds. This position will be held for 30 seconds and repeat three to five times per on treatment session
9899114|NCT05258201|Experimental|Strain-counterstrain|Strain And Counter Strain will be applied on subject in normal position and will be produced by placing the muscle in a short / relaxed position, the point where the pain will reduce of at least 70% will be produce will easily define. The patient will be in a supine position while the doctor will place the labial arm in flexion, abduction and external rotation to reduce the reported Trp pain. Once the position is easy to find, the pressure will be apply to the Trp and will be hold for 20-30 seconds and repeat this process for up to five times
9899115|NCT05257733||CIDP associated with systemic diseases|Patients with CIDP associated with systemic diseases
9899116|NCT05257733||CIDP without systemic diseases|Patients with CIDP without other systemic diseases
9899117|NCT05256134|Experimental|Gantenerumab|Gantenerumab will be administered as subcutaneous (SC) injection with gradual uptitration.
9899118|NCT05256134|Placebo Comparator|Placebo|Placebo will be administered as SC injection with gradual uptitration.
9899119|NCT05255003|Experimental|Modified dose LMWH|"Patients will be given modified dose LMWH as below based on the first platelet count of the day (daily in admitted patients or at least 3 times a week in outpatients), without empiric platelet transfusion:~I. Platelet count 25-50,000/µL: 50% dose LMWH~II. Platelet count < 25,000/µL: hold anticoagulation"
9899120|NCT05255003|Active Comparator|Full dose LMWH with platelet transfusion support|"Patients assigned to full dose LMWH will be empirically transfused when the first platelet count of the day falls below 50,000/uL (daily inpatient or at least 3 times a week in outpatients). Post-transfusion counts will not be routinely obtained unless there are clinical indications, such as prior to a procedure or reasonable expectation that a single transfusion will be insufficient to achieve the target (50,000/uL).~LMWH will be prescribed as standard of care and can include enoxaparin, dalteparin, or tinzaparin. Full dose LMWH is listed as the following:~Enoxaparin - 1mg/kg subcutaneously twice daily~Dalteparin - 200 IU/kg subcutaneously daily for the first month of an acute VTE then 150 U/kg subcutaneously daily thereafter~Tinzaparin - 175 units/kg subcutaneously daily"
9899121|NCT05252923|Experimental|Sulodexide|Standard treatment plus oral sulodexide
9899122|NCT05252923|No Intervention|Control|Standard treatment only
9899123|NCT05250973|Experimental|Cohort1 (Arm A): Immediate Daratumumab + Cyclophosphamide, Bortezomib and Dexamethasone (VCd)|Participants with newly diagnosed systemic amyloid light chain (AL) amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive daratumumab 1800 milligrams (mg) subcutaneously (SC) starting on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square [mg/m^2] either orally or intravenously [IV], bortezomib 1.3 mg/m^2 SC, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
9899124|NCT05250973|Experimental|Cohort1 (Arm B): Daratumumab + Deferred VCd|Participants with newly diagnosed systemic AL amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive SC daratumumab 1800mg on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (Cyclophosphamide 300 mg/m^2 either orally or IV, Bortezomib 1.3 mg/m^2 SC, Dexamethasone 40 mg weekly either orally or IV) starting at Cycle 4 Day 1, weekly (Days 1, 8, 15, 22) in every 28-day cycle for a maximum of 6 cycles (Cycle 9 Day 22).
9933227|NCT00958061||Vietnam-Era Women Veterans|For this study we will use a cohort of women who are on a roster of Vietnam Era women veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and characterized by a review of their military personnel records and link it to a list of 8,061 women who presumably served in Southeast Asia. This final cohort could potentially contain approximately 14,000 women. After deceased individuals are removed from the active cohort and contact information is updated, we estimate that there could be approximately 10,000 women to whom the informed consent and mailed survey will be initially mailed.
9899125|NCT05250973|Experimental|Cohort 2: Daratumumab + VCd|Participants with racial and ethnic minorities, including Black or African American participants, with newly diagnosed AL amyloidosis will receive SC injection of daratumumab 1800 mg SC on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square [mg/m^2] either orally or intravenously [IV], bortezomib 1.3 mg/m^2 SC, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
9899126|NCT05248997|Active Comparator|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
9899127|NCT05248997|Active Comparator|Matching Placebo|One dose of matching placebo
10212567|NCT05202392|Experimental|Myofascial release with Isometric Exercises|Myofascial release technique combined with isometric exercises will be given to first group. Patients in this group will be given muscle stretching along with trigger point release for following muscles. For the trapezius muscle as the patient will be in sitting and restrained friction for 30 seconds will be applied to a primary trigger point along with passive trapezius stretching on the alternative side. A chin tuck will be applied to stretch the sub-occipital muscles. Flexion and slight rotation of head will stretch the posterior rotator muscles. The extension of neck and its rotation will stretch sternocleidomastoid muscle. Combining lateral bend to alternative medial head will stretch the scalene muscles. Isometrics for this group will be neck flexion, isometric neck extension, isometric neck side flexion, Isometric neck rotation, neck extensors stretch, neck flexors and side flexors stretch, stretch for right side and lateral rotation stretch
9899129|NCT05248867|Experimental|AGN-151586|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
9899130|NCT05248867|Placebo Comparator|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
9899131|NCT05246761||Cesarean section group|In the cesarean section group, all the pregnant women had only one prior cesarean section.
9899132|NCT05246761||Non-cesarean section group|In the non-cesarean section group, all the pregnant women are primipara，and never had a cesarean section.
9899133|NCT05246670|Experimental|Arm I (lower-dose PEA)|Patients receive PEA PO QD for 8 weeks as long as there is not any unacceptable toxicity.
9899134|NCT05246670|Experimental|Arm II (higher-dose PEA)|Patients receive PEA PO BID for 8 weeks as long as there is not any unacceptable toxicity.
9899135|NCT05246670|Placebo Comparator|Arm III (QD placebo)|Patients receive placebo PO QD for 8 weeks.
9899136|NCT05246670|Placebo Comparator|Arm IV (BID placebo)|Patients receive placebo PO BID for 8 weeks.
9899137|NCT05246280|Experimental|Candidates for initiation of anti-TNFα bDMARD therapy|All subjects will be candidates for initiation of, or change to, a new anti-TNFα bDMARD for RA treatment.
9899138|NCT05244473|Experimental|Brentuximab vedotin + ART|Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.
9899139|NCT05244473|Placebo Comparator|Placebo + ART|Placebo given on Day 1 and Day 15. ART will be given throughout the study.
9899140|NCT05242965|Experimental|Arm I (STEMVAC, sargramostim)|Patients receive STEMVAC ID and sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.
9899141|NCT05242965|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on day 14 of the 21-day maintenance therapy cycle for a series of 3 vaccines doses and a booster vaccine 9 weeks after third vaccine dose.
9899142|NCT05240534|Placebo Comparator|Control group (ET-Text)|Participants will receive ElderTree on a laptop.
9899143|NCT05240534|Experimental|Experimental group (ET-Voice)|Participants will receive ElderTree on a smart system.
9899144|NCT05239910|Experimental|Tenalisib 400 mg BID and CHOP|
9899145|NCT05239910|Experimental|Tenalisib 800 mg BID and CHOP|
10213905|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
10213906|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
10213907|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
10213908|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
9899150|NCT05239039|Experimental|Patients with Generalized Pustular Psoriasis (GPP) presenting with a flare|
9899151|NCT05239026|Experimental|Advanced Training Group|This arm will receive a single session treadmill training session in which both cadence and treadmill speed are controlled.
9899152|NCT05239026|Experimental|Traditional Training Group|This arm will receive a single session treadmill training session in which only treadmill speed is controlled.
9899153|NCT05238675|Experimental|BI 1291583: Low dose group|
9899154|NCT05238675|Experimental|BI 1291583: Medium dose group|
9899155|NCT05238675|Experimental|BI 1291583: High dose group|
9899156|NCT05238675|Placebo Comparator|Placebo|
9899157|NCT05237687|Active Comparator|Intervention|Patients randomized to the intervention will initially take 0.5 mg sirolimus. The dose will be adjusted weekly to obtain a sirolimus levels of 5-7 ng/ml whole blood in the first months. After the first month, the patient will have monthly blood work and will be followed in clinic every 3 months. Functional assessment and aging biomarkers will be obtained at baseline and 1 year follow up. Completion of the 1-year treatment period will be followed by a follow-up visit 4 weeks later.
9899158|NCT05237687|No Intervention|Control|Interventions: standard of care Patients are not going to receive any additional intervention.
9899159|NCT05237388|Experimental|Baricitinib|Participants will take one pill of Baricitinib daily with their regular medications.
9899160|NCT05237388|Placebo Comparator|Placebo|Participants will take a Baricitinib placebo pill matching Baricitinib daily with their regular medications.
9899161|NCT05237284|Experimental|SAR443820|twice daily (BID) oral SAR443820
9899162|NCT05237284|Placebo Comparator|Placebo|twice daily (BID) oral placebo
9899163|NCT05236985|Active Comparator|Bolus arm|Patients will receive 3 IU oxytocin IV bolus over 15 seconds after delivery of the baby/uterine cord clamping and a maintenance infusion of 0.9% Saline will be started at 225ml/hr. If uterine tone is inadequate after 3 minutes, a second bolus of 3 IU oxytocin will be given. If uterine tone is inadequate after an additional 3 minutes, a third bolus of 3 IU Oxytocin IV is given over 15 seconds. If after an additional 3 mins uterine tone is still inadequate, a second infusion consisting of oxytocin 3 IU/hr is started at 100ml/hrs and continued for a total of 4 hours, second line uterotonic agents (Methergine, Hemabate and/ or Cytotec) will be given, and the maintenance 0.9% Saline infusion will be changed to 450 ml/hr for a total of 1 hour, then changed to 38 ml/ hour for the following 3 hours. If uterine tone is considered adequate at 3, 6 or 9 minutes, a second infusion of oxytocin 3 IU/hr (100ml/hr) is started and maintained for 4 hours.
9899164|NCT05236985|Active Comparator|Infusion arm|Patients will receive a bolus of IV 0.9% Saline over 15 seconds after delivery of the baby/uterine cord clamping and a maintenance infusion of 18 IU/hr Oxytocin IV (225ml/hr). If uterine tone is inadequate after 3 minutes, a second bolus of 0.9% Saline will be given. If uterine tone is inadequate after another 3 minutes, a third bolus of 0.9% Saline will be given. If after another 3 mins uterine tone is inadequate, a second infusion of 0.9% Saline will be started for 4 hours, second line uterotonic agents (Methergine, Hemabate and/or Cytotec) will be given, and the Oxytocin infusion will be changed to 36 IU/hour (450 ml/hr) for a total of 1 hour, and then changed to 38 ml/hr for the following 3 hours. If uterine tone is considered adequate at 3, 6 or 9 minutes, a second infusion of 0.9% Saline at 100 ml/hr will be started and maintained for 4 hours, along with the maintenance infusion of 18 IU/hr (225 ml/ hr) for a total of 1 hour, then changed to 38 ml/hr for an additional 3 hours.
9899165|NCT05236881|Experimental|ANíMATE mobile application|Standard care protocol (3 face-to-face visits: basal, 2 and 4 months) + ANíMATE mobile application
9899166|NCT05236881|No Intervention|Standard care|Standard care protocol (3 face-to-face visits: basal, 2 and 4 months)
9899167|NCT05235451|Experimental|Intervention group|The 2 HAI intervention reading groups will receive visits from a registered canine team during children's small group reading sessions twice a week over 12 weeks.
9899168|NCT05235451|No Intervention|Control group|The 2 control reading groups will receive care as usual and offered a 1-time visit from the dog at the end of the study (after T3 completed).
9933228|NCT00958087||Sarcoidosis with cardiac involvement|
9933229|NCT00958087||Dilated cardiomyopathy|
9933230|NCT00958087||Sarcoidosis without cardiac involvement|
9933231|NCT00958087||Healthy controls|
9933232|NCT00958100|Experimental|Tenofovir Emtricitabine Raltegravir|Patients switching to raltegravir with tenofovir+emtricitabine as backbone
9933233|NCT00958100|Experimental|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
9933234|NCT00958100|Experimental|Abacavir free|Patients switched to raltegravir whose backbone therapy should not be randomized in order to avoid the use of abacavir (HLA-B*5701 positive patients,Framingham score 20% or higher)
9933235|NCT00958113||Autoimmune Thyroid Disease|Patients with Hashimoto's disease or Graves' disease
9933236|NCT00958113||Unaffected Population|Population not known to be affected by Hashimoto's Disease or Graves' Disease
9933237|NCT00958139|Experimental|Permethrin treatment of clothing|0.5% permethrin sprayed one time on uniform shorts, pants, and socks
9933238|NCT00958139|Sham Comparator|Placebo|Water sprayed on uniform shorts, pants, and socks
9933239|NCT00958152|Experimental|Cohort 1|
9933240|NCT00958152|Experimental|Cohort 2|
9933241|NCT00958152|Experimental|Cohort 3|
9933242|NCT00958178|Experimental|Rebreathing method of preoxygenation|Subjects will breathe Oxygen through a close fitting mask, but the flow will be low so that they rebreathe some of their expired air. After 30 seconds, the flow will be turned up so that they will breathe 100% Oxygen.
9933243|NCT00958178|Active Comparator|T method of preoxygenation|Tidal breathing of 100% oxygen through a well fitting facemask, for 4 minutes.
9933244|NCT00958204|Experimental|1|Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
9933245|NCT00958204|Experimental|2|Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
9933246|NCT00958204|Active Comparator|3|Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
9899169|NCT05233826|Experimental|COVI-VAC|COVI-VAC Nose Drops
9899170|NCT05233085|Experimental|AZD4041|Daily oral dose given by syringe directly into the mouth
9899171|NCT05233085|Placebo Comparator|Placebo|Daily oral dose given by syringe directly into the mouth
9899172|NCT05232032|Experimental|Participants with MDD or an anxiety disorder receiving the nociceptin receptor antagonist|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. Functional magnetic resonance imagining (fMRI) will begin 2 hours after the nociceptin receptor antagonist is administered.
9899173|NCT05232032|Placebo Comparator|Participants with MDD or an anxiety disorder receiving the placebo|After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
9899174|NCT05232032|Experimental|Healthy controls receiving the nociceptin receptor antagonist|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive a nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the nociceptin receptor antagonist is administered.
9899175|NCT05232032|Placebo Comparator|Healthy controls receiving the placebo|After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered.
9899176|NCT05230134|Experimental|Cervical sympathetic block|"Patients hospitalized in the ICU and developing clinical manifestations of cerebral vasospasm will undergo a computerized tomography (CT) angiography and a CT perfusion scan. If the vasospasm will be confirmed by the CT imaging, a cervical sympathetic nerve block under ultrasound guidance will be performed. The block consists in the deposition of local anesthetic at the cervical sympathetic ganglion that will be visualized with an ultrasound device. A periganglionar catheter will be left in place. A CT angiography and CT perfusion will be repeated to check the effect of the block on the brain vasculature after the block is done.~Patients will have a daily monitoring of their neurological function and of their cerebral blood flow with transcranial doppler in the ICU."
9899177|NCT05227391|Experimental|Letrozole-stimulated group|
9899178|NCT05227391|Active Comparator|Hormone replacement treatment group|
9899179|NCT05224505|Experimental|GNT0006 - Stage 1|6 patients treated with GNT0006 in Stage 1 (open label) 2 dose cohorts : Cohort 1: single intravenous injection 9.0E+12 vg/Kg Cohort 2: single intravenous injection 2.7E+13 vg/Kg
9899180|NCT05224505|Experimental|GNT0006 - Stage 2|"22 patients randomized in single intravenous GNT0006 arm at selected dose in Stage 2 (double blind).~The patients will receive placebo one year after to maintain the blind"
9899181|NCT05224505|Placebo Comparator|Placebo - Stage 2|11 patients randomized in placebo arm in Stage 2 (double blind). The patients will receive single intravenous GNT0006 at selected dose one year after to maintain the blind
9899182|NCT05224271||Observational (surveys, medical records & Fitbit collection)|Patients complete surveys via the Hugo Platform at baseline (before treatment), after treatment, and at 3 and 6 months after treatment. Patients' medical records and Fitbit information are also collected into the Hugo Platform.
9899183|NCT05224258|Experimental|MiniMed 780G System Utilizing Insulin Fiasp|Subjects with insulin-requiring type 1 diabetes age 2-80 using the MiniMed 780G system with Insulin Fiasp® for a period of three months.
10213909|NCT02731521||3 Tesla Scanning and 7 Tesla Scanning|Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.
9899185|NCT05224011|Experimental|Experimental|The Boppli device will be applied to the patients' arm or foot on either side of the body and is intended for single use of up to 72 hours and is discarded following use. The device will only be used in patients requiring continuous blood pressure monitoring, through the use of an invasive arterial line (IAL), to compare the data obtained by the Boppli to that obtained by the IAL.
9899186|NCT05222906|Experimental|Venglustat|Venglustat
9899187|NCT05222906|Active Comparator|Cerezyme|Cerezyme
9899188|NCT05222386|Other|Usual Care|Community neurologists provide their usual care to enrolled participants. The clinicians may utilize other community resources to support patients and families as per their usual practice.
9899189|NCT05222386|Other|Online Community-Supported Palliative Care Intervention|Community neurologists get training in palliative care via teleconferences (ECHO model), in addition to other support from our team. Patients and carepartners will also have access to additional support services when their providers enter the intervention (Online support groups, tailored education)
9899190|NCT05217667|Experimental|ARO-ANG3 Dose 1|ARO-ANG3 Dose 1 subcutaneous (SC)
9899191|NCT05217667|Experimental|ARO-ANG3 Dose 2|ARO-ANG3 Dose 2 SC
9899192|NCT05217641|Experimental|Part A, Group 1: Low dose BG505 MD39.3 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 mRNA formulated administered at months 0, 2, and 6
9899193|NCT05217641|Experimental|Part A, Group 2: Low dose BG505 MD39.3 gp151 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
10213910|NCT02728557|Experimental|Supportive psychotherapy|Participants will receive supportive therapy.
10213911|NCT02728557|Experimental|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy.
10213912|NCT02699957||Atrial Fibrillation|Those patients with the condition of atrial fibrillation.
10213913|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
9899194|NCT05217641|Experimental|Part A, Group 3: Low dose BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
9899195|NCT05217641|Experimental|Part B, Group 1: BG505 MD39.3 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 mRNA administered at months 0, 2, and 6
9899196|NCT05217641|Experimental|Part B, Group 2: BG505 MD39.3 gp151 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
9899197|NCT05217641|Experimental|Part B, Group 3: BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
9899198|NCT05216952|Experimental|UPA 90mg|Participants receive ulipristal acetate 90mg PO followed by self-administration of misoprostol 800mcg vaginally 6 to 18 hours following ulipristal acetate administration.
9899199|NCT05215756|Experimental|Healthy Subjects|Cold pressor test will be performed 3 times. transcutaneous Vagal nerve stimulation will be administered in the 2nd and 3rd cold pressor tests.
9899200|NCT05215314|Experimental|Healthy Mind Program|fully remote, 4-week meditation intervention
9899201|NCT05215314|No Intervention|Waitlist Control|will not complete the Healthy Minds Program during the study, but can use it after participant has completed the study
9899202|NCT05214937|Experimental|Intervention|Participants will be provided with a FitBit Inspire 2 and assigned a movement specialist. They will be asked to monitor their daily steps over the 12-week intervention period. Participants will attend 6 remotely-delivered behaviour change sessions (4 one-on-one sessions with their movement specialist, 2 group-based webinars). Sessions will be delivered bi-weekly and last ~30 minutes.
9899203|NCT05214937|Active Comparator|Fitbit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living (e.g., 24-hour movement guidelines).
9899204|NCT05214105||Patients with sickle cell anemia|Prospective longitudinal study of patients with sickle cell anemia
9899205|NCT05213936|Experimental|Scalp cooling with hairstyle|Scalp cooling with hairstyle (braids, twists, cornrows) to minimize hair volume and increase scalp cooling cap to scalp contact
9899206|NCT05213936|Experimental|Scalp Cooling with conditioner and water emulsion|Scalp cooling after coating hair with conditioner and water emulsion to minimize hair volume and increase scalp cooling cap to scalp contact
9899207|NCT05213936|No Intervention|No Scalp Cooling|Control with no scalp cooling
9899208|NCT05212116|Experimental|SDI-118 low dose|SDI-118 (low dose) orally once daily (QD) for 17±1 day.
9899209|NCT05212116|Experimental|SDI-118 high dose|SDI-118 (high dose) orally once daily (QD) for 17±1 day.
9899210|NCT05212116|Placebo Comparator|Placebo|Placebo orally once daily (QD) for 17±1 day.
9899211|NCT05209126|Experimental|Beetroot supplementation|One serving 140 mL of beetroot juice (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
9992615|NCT01464099|Active Comparator|Insulin aspart 100U/mL|
9899212|NCT05209126|Placebo Comparator|Placebo supplementation|One serving 140 mL of beetroot juice placebo (0.08 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
9899213|NCT05208905|Experimental|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
9899214|NCT05208216|Experimental|Intervention arm|Application of the Geko device for mechanical VTE prophylaxis up until day 10 / discharge form critical care (whichever comes sooner).
9899215|NCT05208216|Active Comparator|Usual care arm|Application of our usual intermittent pneumatic compression devices for mechanical VTE prophylaxis up until day 10 / discharge form critical care (whichever comes sooner).
9899216|NCT05207722|Experimental|Phase I Dose Escalation|Up to two dosing cohorts of CYNK-101 in combination with rhIL2 will be evaluated following an initial induction and lymphodepletion regimen.
9899217|NCT05207722|Experimental|Phase IIa Expansion|Once the Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is determined in Phase I, the Phase IIa portion of the study will commence.
9899218|NCT05207423||Participants With Advanced NSCLC|Participants diagnosed with advanced NSCLC with EGFR exon 20 insertions (ex20ins) mutations who were treated according to routine clinical practice will be observed retrospectively up to 1 year or until the end of follow-up.
9899219|NCT05206110|Experimental|Peri- and postoperative 10 mg Ketolorac|Patients undergoing LAVH, RARP or TLH will receive dosages of 10 mg ketolorac (IV).
9899220|NCT05206110|Active Comparator|Peri- and postoperative standard-dose 30 mg Ketolorac|Patients undergoing LAVH, RARP or TLH will receive standard dosages of 30 mg ketolorac (IV).
9899221|NCT05205759|Experimental|Bamlanivimab Etesevimab|Bamlanivimab 700 mg + Etesevimab 1400 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
9899222|NCT05205759|Experimental|Sotrovimab|Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
9899223|NCT05205759|Active Comparator|Casirivimab Imdevimab|Casirivimab 600 mg + Imdevimab 600 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
9899224|NCT05202262|Experimental|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
9899225|NCT05202262|Experimental|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
9899226|NCT05202262|Experimental|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
9899227|NCT05202262|Active Comparator|Open-label Symbicort TBH 320/9 μg|Open-Label Comparator Symbicort Turbuhaler 320/9 μg
9899228|NCT05201781|Experimental|Cilta-cel|Participants who had previously received treatment with cilta-cel in a Janssen-sponsored clinical study (example, NCT04923893, NCT04181827, NCT04133636, and NCT03548207) in the global development program will be enrolled into this study once the individual's participation in the particular interventional study has ended. Participants will not receive any treatment in this study and will be followed-up at least once per year on delayed adverse events for up to 15 years after receiving the last dose of cilta-cel.
9899229|NCT05200988|Experimental|Induction with heckpoint inhibition followed by consolidative chemoradiation|Checkpoint inhibition and chemoradiation
9899230|NCT05200247|Experimental|Patients with Generalized Pustular Psoriasis (GPP) presenting with a flare|
9899231|NCT05200208|Experimental|Citicoline Supplement|Participants with AD will receive dietary citicoline supplements in addition to their standard of care donepezil.
9899232|NCT05200208|Placebo Comparator|Placebo|Participants with AD will receive a placebo supplement in addition to their standard of care donepezil.
9899233|NCT05199272|Experimental|Part A|Patients will receive escalating doses of 23ME-00610
9899234|NCT05199272|Experimental|Part B|Patients will receive the recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD) of 23ME-00610
9899235|NCT05199142|Experimental|SDI-118|SDI-118 capsule self-administered orally once daily (QD) for 17 days.
9899236|NCT05199142|Placebo Comparator|Placebo|Placebo capsule self-administered orally once daily (QD) for 17 days.
9899237|NCT05198375|Active Comparator|Control group (CG)|decision to administer exogenous surfactant when FiO2 >0.30 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%.
9899238|NCT05198375|Experimental|LUS group (LUSG)|"decision to administer surfactant when LUS > 8 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%.~The LUS group will receive surfactant administration as rescue therapy in case of LUS < or = 8 but FiO2 > 0.30 on nCPAP (pressure 6-8 cmH20) to maintain preductal SpO2 between 90 and 95%."
9992616|NCT01464099|Experimental|Insulin aspart 200U/mL|
9899239|NCT05191797|Experimental|Treatment (bomedemstat, atezolizumab)|Patients receive bomedemstat PO QD on days 1-21 and atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9899240|NCT05190731|Sham Comparator|Contact touch at occipital region, but no actual cranial manipulation|Each subject was treated with Sham by CSPOMM and NMM board-certified osteopathic physicians. The physician's finger pads of both hands were placed underneath the supine subject's head in contact on the occipital squama medial to the lambdoidal and occipitomastoid sutures. The subject's head rested passively on the finger pads for 3 minutes. No cranial manipulative forces were applied.
9899241|NCT05190731|Active Comparator|Osteopathic cranial manipulative medicine|Each subject was treated with CV4 technique by CSPOMM and NMM board-certified osteopathic physicians. All CV4 treatments were performed by one individual according to standardized protocol. The physician's hands were placed underneath the occiput with the thenar eminences in contact on the occipital squama medial to the lambdoidal and occipitomastoid sutures. Inherent cranial rhythmic motion was identified and thenar eminences followed occipital motion anteriorly during the extension phase until a still point was attained. This position was held until the still point released (usually about 3 minutes) and normal cranial motion ensued.
9899242|NCT05190679||Cardiomyopathy Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in cardiomyopathy (CM) gene which include inherited CM syndromes.
9899243|NCT05190679||Arrhythmia Rare Variant Cases|Identified Pathogenic/Likely pathogenic rare variant in arrhythmia genes.
9899244|NCT05190679||Controls|No rare variant in CM, arrhythmia, or other atrial fibrillation gene.
9899245|NCT05190523|Experimental|ASC42 tablets of 5mg|ASC42 tablets 5mg for 12 weeks
9899246|NCT05190523|Experimental|ASC42 tablets of 10mg|ASC42 tablets 10mg for 12 weeks
9899247|NCT05190523|Experimental|ASC42 tablets of 15mg|ASC42 tablets 15mg for 12 weeks
9899248|NCT05190523|Placebo Comparator|Placebo|Placebo for 12 weeks
9899249|NCT05184452|Experimental|PGDM1400LS 5 mg/kg IV|Participants will receive PGDM1400LS 5 mg/kg by intravenous (IV) infusion at Month 0
9899250|NCT05184452|Experimental|PGDM1400LS 20 mg/kg IV|Participants will receive PGDM1400LS 20 mg/kg by IV infusion at Month 0
9899251|NCT05184452|Experimental|PGDM1400LS 20 mg/kg SC|Participants will receive PGDM1400LS 20 mg/kg by subcutaneous (SC) infusion at Month 0
9899252|NCT05184452|Experimental|PGDM1400LS 40 mg/kg IV|Participants will receive PGDM1400LS 40 mg/kg by IV infusion at Month 0
9899253|NCT05184452|Experimental|PGDM1400LS 40 mg/kg SC|Participants will receive PGDM1400LS 40 mg/kg by SC infusion at Month 0
9899254|NCT05184452|Experimental|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg IV|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
9899255|NCT05184452|Experimental|PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg SC|Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by SC infusion sequentially in this order at Month 0 and Month 4
9899256|NCT05184452|Experimental|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram IV|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by IV infusion sequentially in this order at Month 0 and Month 4
9899257|NCT05184452|Experimental|PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram SC|Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by SC infusion sequentially in this order at Month 0 and Month 4
9899258|NCT05184452|Experimental|PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg IV|Participants will receive PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
9899259|NCT05182840|Experimental|Treatment period: Empagliflozin + BI 690517|
9899260|NCT05182840|Experimental|Treatment period: Empagliflozin + Placebo to BI 690517|
9899261|NCT05182840|Experimental|Treatment period: Placebo to Empagliflozin + BI 690517|
9899262|NCT05182840|Placebo Comparator|Treatment period: Placebo to Empagliflozin + Placebo to BI 690517|
9899263|NCT05181540|Experimental|AB-205 plus standard-of-care preventive and supportive therapies.|
9899264|NCT05181540|Placebo Comparator|Placebo plus standard-of-care preventive and supportive therapies.|
9899265|NCT05181384|Experimental|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
9899266|NCT05181384|Active Comparator|Exercise group|pelvic floor muscle training
9899267|NCT05181384|Placebo Comparator|Control group|pelvic girdle education
9899268|NCT05178069|Placebo Comparator|Placebo Comparator: Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
9899269|NCT05178069|Active Comparator|Active Comparator: Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
9899270|NCT05177822|Experimental|anakinra|
9899271|NCT05177822|Placebo Comparator|placebo|
9933247|NCT00958204|Placebo Comparator|4|Negative ion generator (30 minutes daily) plus placebo pill every day
9933248|NCT00958230|Experimental|dCell Vascular Patch|This Xenograft device is manufactured from Porcine Pericardium Tissue which has been decellularised leaving a scaffold style structure for ingrowth of human endothelial cells after placement into the operative site.
9992617|NCT01464112|Experimental|001|
9899272|NCT05177458|Experimental|Moderate Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of moderate intensity (70-75% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
9899273|NCT05177458|Active Comparator|Control - Low Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of light intensity (40-50% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
9899274|NCT05177055|Experimental|n=17, sleep-school 6 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep-school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
9899275|NCT05177055|Experimental|n=18, sleep-school 6 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
9899276|NCT05177055|Active Comparator|n=35 Six-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
10213914|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
10213915|NCT02687646|Experimental|Allogeneic Mesenchymal Cells|All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.
9899279|NCT05173233|Experimental|K-clipTM transcatheter annuloplasty system|
9899280|NCT05171153||IBD group|Subjects over 21 years old, with inflammatory bowel disease (both ulcerative colitis and Crohn's disease), diagnosed by clinical, biochemical, endoscopic and anatomo-pathological criteria.
9899281|NCT05171153||Control group|Subjects over 21 years old, without IBD or known metabolic bone disease, recruited voluntarily in the Endocrinology and Nutrition, Digestive System and Rheumatology departments of the Ruber Juan Bravo Hospital, during routine health control visits
9899282|NCT05170204|Experimental|Cohort A1: ALK-Positive (alectinib arm)|Participants will receive alectinib 600 mg orally twice daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
9899283|NCT05170204|Active Comparator|Cohort A1: ALK-positive (durvalumab arm)|Participants will receive 1500 mg of intravenous (IV) durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
9899284|NCT05170204|Experimental|Cohort A2: ROS 1-positive (entrectinib arm)|Participants will receive entrectinib 600 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first.
9899285|NCT05170204|Active Comparator|Cohort A2: ROS 1-positive (durvalumab arm)|Participants will receive 1500 mg of IV durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
9899286|NCT05170204|Experimental|Cohort A3: RET fusion-positive (pralsetinib arm)|Participants will receive pralsetinib 400 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first.
9899287|NCT05170204|Active Comparator|Cohort A3: RET fusion-positive (durvalumab arm)|Participants will receive 1500 mg of IV durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
9899288|NCT05168280|Active Comparator|DEX group|The DEX group patients will be received dexmedetomidine intraoperatively.
9899289|NCT05168280|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively.
9899290|NCT05167318|Experimental|every 3-4 hour oral care|Infants will receive standardized oral care every 3-4 hours for 4 weeks
9899291|NCT05167318|No Intervention|every 12 hour oral care|Infants will receive standardized oral care every 12 hours for 4 weeks
9899292|NCT05166161|Experimental|PTC923|Participants will receive PTC923 7.5 milligrams (mg)/kilogram (kg (participants 0 to <6 months of age), 15 mg/kg (participants 6 to <12 months of age), 30 mg/kg (participants 12 months to <2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for a minimum of 12 months or until participant experiences lack of efficacy.
10213916|NCT02678091|Experimental|Patients|Patients with an orbital mass
10213917|NCT02667587|Experimental|Nivolumab + Temozolomide + Radiotherapy|Nivolumab: specified dose on specified days; IV (intravenous) infusion Temozolomide: 75 mg (milligram)/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units (joule of radiation energy per kilogram) 5 times per week for 6 weeks
9899293|NCT05161481|Experimental|BI 685509, dose group 1|
9899294|NCT05161481|Experimental|BI 685509, dose group 2|
9899295|NCT05161481|Placebo Comparator|Placebo|Placebo
9899296|NCT05160584||Participants with Relapsed/Refractory Multiple Myeloma|Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant.
9899297|NCT05159778|Experimental|Experimental|
9899298|NCT05158686||Paclitaxel-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with paclitaxel coated balloon immediately proximal to the CTO during the index procedure
9899299|NCT05158686||Non-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with non-coated balloon immediately proximal to the CTO during the index procedure
9899300|NCT05157997|Experimental|Casirivimab and Imdevimab Antibody Cocktail|Patients receiving a Covid-19 positive liver, kidney, or heart transplant.
9899301|NCT05156112|Experimental|PAP Treatment on SARRTP Unit|Veterans will receive Positive Airway Pressure device while on the 28-day SARRTP Unit.
9899302|NCT05156112|No Intervention|Waitlist Control|Veterans will not receive PAP device until after 3-month Follow Up.
9899303|NCT05155605|Experimental|Participants 50 years of age or older|The study will aim to enroll a diverse participant population generally representative of the US population with respect to race, ethnicity, and sex. The target age categories of 60-69 years and 70-79 years will be enriched to increase the number of cancer events that are observed during the study.
9899304|NCT05154162|Experimental|Experimental|Pelvic PSMA PET ± transperineal targeted prostate biopsy
9899305|NCT05154162|Other|Control|No pelvic PSMA PET + transperineal template prostate biopsy
9899306|NCT05153317|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
9899307|NCT05151640||Nintedanib treatment group|
9899308|NCT05150171|Experimental|e-self-management intervention|Patients will receive the HAPPY Hands e-self-management intervention delivered through a smartphone app.
9899309|NCT05150015|Experimental|Number of consented patients who complete the antibiotics through an elastomeric pump|Flucloxacillin, piperacillin/taozbactam and benzylpenicillin will be use
9899310|NCT05149898|Experimental|Open-label|Open-label
9899311|NCT05147805|Experimental|Treprostinil Palmitil Inhalation Powder|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
9899312|NCT05147805|Placebo Comparator|Placebo|Participants will be administered a placebo matching TPIP once per day for 16 weeks.
9899313|NCT05146362|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
9899314|NCT05146362|No Intervention|Control|This arm receives information about American Job Center services and assistance with opening a JobLink account if an individual doesn't have one. Medical providers at all practices will receive training on how to identify early and then manage the risk of work disability to help prevent long-term unemployment
9899315|NCT05144243|Experimental|Venetoclax in Combination with Azacitidine|Participants will receive oral tablet venetoclax dose ramp-up only in Cycle 1 Days 1-3 until target dose is reached. Particpants will then receive oral tablet venetoclax at the target dose every day (QD) on Cycle Days 1 - 28 plus Azacitidine through subcutaneous injection (SC) QD on Cycle Days 1 - 7 (28-day cycle).
9899316|NCT05141149|Experimental|Cohort 1M|1 mg/kg of PBP1510 as monotherapy will be administered
9899317|NCT05141149|Experimental|Cohort 1C|1 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
9899318|NCT05141149|Experimental|Cohort 2M|3 mg/kg of PBP1510 as monotherapy will be administered
9899319|NCT05141149|Experimental|Cohort 2C|3 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
9899320|NCT05141149|Experimental|Cohort 3M|6 mg/kg of PBP1510 as monotherapy will be administered
9899321|NCT05141149|Experimental|Cohort 3C|6 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
9899322|NCT05141149|Experimental|Cohort 4M|10 mg/kg of PBP1510 as monotherapy will be administered
9899323|NCT05141149|Experimental|Cohort 4C|10 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
9899324|NCT05141149|Experimental|Cohort 5M|15 mg/kg of PBP1510 as monotherapy will be administered
9899325|NCT05141149|Experimental|Cohort 5C|15 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
9899326|NCT05141006|Experimental|BOTOX|Participants will receive BOTOX on Day 1 and followed for at least 12 weeks in treatment period 1. An optional dose of BOTOX in Treatment 2 can be requested between Weeks 12 and 24.
9899327|NCT05141006|Placebo Comparator|Placebo|Participants will receive placebo on Day 1 and followed for at least 12 weeks in treatment period 1. An optional dose of BOTOX in Treatment 2 can be requested between Weeks 12 and 24.
9899328|NCT05140070|Experimental|Intervention|Mousse with prebiotic
9899329|NCT05140070|Active Comparator|Control|Mousse without prebiotic
9899330|NCT05137730|Experimental|Part I: Sequence AB|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation A) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation B) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
9933249|NCT00958269|Experimental|dutogliptin (double-blind, placebo-controlled period)|weeks 1-26
9899331|NCT05137730|Experimental|Part I: Sequence BA|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation B) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation A) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
9899332|NCT05137730|Experimental|Part II: Sequence cdef|Participants will receive a single SC injection of 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 1 followed by 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 2 followed by 75 mcg (dose e ) rhPTH(1-84) on Day 1 of treatment period 3 followed 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
9899333|NCT05137730|Experimental|Part II: Sequence dfce|Participants will receive a single SC injection of 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 1 followed by 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 2 followed by 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 3 followed by 75 mcg (dose e) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
9899334|NCT05137730|Experimental|Part II: Sequence ecfd|Participants will receive a single SC injection of 75 mcg (dose e) rhPTH(1-84) on Day 1 of treatment period 1 followed by 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 2 followed by 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 3 followed by 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
9899335|NCT05137730|Experimental|Part II: Sequence fedc|Participants will receive a single SC injection of 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 1 followed by 75 mcg (dose e) rhPTH(1-84) on Day 1 of treatment period 2 followed by 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 3 followed by 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
9899336|NCT05137262|Experimental|Arm A: Standard of Care with dose-dense MVAC|The patient will receive treatment every 14 days for up to 6 cycles in the neoadjuvant setting.
9899337|NCT05137262|Experimental|Arm B: Intervention with dose-dense MVAC plus Durvalumab|Durvalumab will be administered one week prior to the initial cycle of dose-dense MVAC and then with each additional cycle of dose-dense MVAC on Arm B
9899338|NCT05135611|Experimental|4-channel Sequential NMES|"After diagnosis of sleep apnea, the registered patient group receives sufficient explanations from the researcher and uses sequential 4-channel electrical stimulation therapy at home, 5 times a week, 60 minutes each, for 8±2 weeks.~During 4-channel electrical stimulation treatment, study participants kept a treatment log including the number of applications, intensity (mA), and treatment time at home."
9899339|NCT05135351|Experimental|Treatment|resistant starch
9899340|NCT05135351|Placebo Comparator|Placebo|maltodextrin
9899341|NCT05135260|Experimental|Virtual Reality Therapy|Participants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.
9899342|NCT05135260|Active Comparator|Control Group|This group will not watch videos, but will continue with their normal routine as if nothing has changed.
9899343|NCT05133232|Experimental|SynPhNe physio-neuro platform|Subjects will receive 15 to18 sessions of training at 60 minutes each on the use of the SynPhNe physio-neuro platform, for over the course of 4 weeks, outside of their conventional occupational therapy in accordance to a study protocol.
9899344|NCT05133232|No Intervention|Conventional occupational therapy|Subjects will receive conventional occupational therapy (OT) only.
9899345|NCT05130086|Experimental|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
9899346|NCT05128071|Active Comparator|Progesterone Arm|Randomized to receive progesterone
9899347|NCT05128071|Placebo Comparator|Placebo Arm|Randomized to receive placebo
9899348|NCT05121545|Other|Pro-GRID treatment Arm|Patients enrolled in this study will receive spatially-fractionated radiotherapy or GRID-therapy, which involves delivering a one-time treatment of high dose radiation to small amounts of tumor in a manner that creates alternating regions of high and low dose radiation within the tumor. Patients will receive 2 (lowest dose) to 18 Gy (highest dose) in a single fraction.
9899349|NCT05121480|Experimental|Cohort 1|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 2 capsules (1.6 x 10^11 total cells) once daily for 16 weeks
9899350|NCT05121480|Experimental|Cohort 2|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 2 capsules (6.4 x 10^11 total cells) once daily for 16 weeks
9899351|NCT05121480|Experimental|Cohort 3|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 1 capsule (3.2 x 10^11 cells) twice daily (6.4 x 10^11 total cells) for 16 weeks
9899352|NCT05119855|Experimental|Concomitant Group|Participants will receive the first dose of 9vHPV vaccine and first dose of mRNA-1273 vaccine on Day 1; participants will then receive the second dose of mRNA-1273 vaccine at Month 1 and the second dose of 9vHPV vaccine at Month 6.
9899353|NCT05119855|Experimental|Non-concomitant Group|Participants will receive the first and second doses of mRNA-1273 vaccine on Day 1 and at Month 1, respectively; participants will then receive the first and second doses of 9vHPV vaccine at Months 2 and 8, respectively.
9899354|NCT05117853|Experimental|Autofluorescent detection and injection of indocyanine green|"Drug: indocyanine green (ICG)~Autofluorescence detection of the parathyroid glands and injection of indocyanine green at two predefined timepoints will be performed to evaluate the vascularization of the parathyroid glands."
9933250|NCT00958269|Experimental|dutogliptin (single-blind, active-controlled period)|weeks 27-52
9899355|NCT05117853|Placebo Comparator|Control group|Gold standard of visual identification and evaluation of viability.
9899356|NCT05117242|Experimental|Arm A|Treatment with GEN1046 once every 21 days for the first 2 cycles and then every 42 days in subsequent cycles
9899357|NCT05117242|Experimental|Arm B|Treatment with GEN1046 + Pembrolizumab once every 21 days
9899358|NCT05117242|Experimental|Arm C|Treatment with GEN1046 + Pembrolizumab once every 42 days
9899359|NCT05117099|Experimental|FCU Online + Coach|Parents in this arm will receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include videos, animated videos, parenting tips, and interactives to help practice parenting skills.Telehealth coaching sessions will focus on Healthy Behaviors, Positive Parenting, Rules and Consequences, School Support, and Communication.
9899360|NCT05117099|No Intervention|Waitlist Control|Parents in this arm will initially serve as the control group but will receive access to the FCU Online website and telehealth coaching after completing three waves of data collection (baseline, 2-mo, and 4-mo follow-up).
9899361|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 1|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
9899362|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 2|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
9899363|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 3|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
9899364|NCT05117060|Placebo Comparator|LEO 152020 placebo tablet|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
9899365|NCT05116189|Experimental|Pembrolizumab + paclitaxel ± bevacizumab|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 every 3 weeks [Q3W]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
9899366|NCT05116189|Placebo Comparator|Placebo + paclitaxel ± bevacizumab|Participants receive placebo via IV infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 every 3 weeks [Q3W]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
9899367|NCT05115110|Experimental|RO7204239 + Risdiplam|"Participants who have not previously been treated with risplidam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive RO7204239 + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive treatment with RO7204239 + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
9899368|NCT05115110|Active Comparator|Risdiplam + Placebo|"Participants who have not previously been treated with risplidam will receive risdiplam for at least 8 weeks prior to randomization into a treatment group (Part 1 only). Participants that have been treated with risdiplam for at least 8 continuous weeks immediately prior to joining the study may be immediately randomized to combination therapy, or join the study run-in period (the period between screening and randomization to a treatment group) where they will continue to receive risdiplam monotherapy until randomization.~Participants enrolled in Part 1 will receive placebo + risdiplam for 24 weeks, followed by RO7204239 + risdiplam for 72 weeks.~Participants enrolled in Part 2 will receive treatment with placebo + risdiplam for 72 weeks.~Once the treatment period has completed (Part 1 or Part 2), participants will have the option of treatment with RO7204239 + risdiplam for 2 additional years."
9899369|NCT05113381|Experimental|Intraventricular Hemorrhage Subjects|Intervention: Cerebrospinal Fluid (CSF) reduction Extra Ventricular Drainage (EVD) catheters will be used for cerebrospinal fluid drainage
9899370|NCT05112952|Experimental|Part A: Group 1: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of lazertinib.
9899371|NCT05112952|Active Comparator|Part A: Group 2: Normal Hepatic Function|Participants with normal hepatic function who qualify for the control group will receive a single oral dose of lazertinib.
9899372|NCT05112952|Experimental|Part B: Group 3 (Optional): Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of lazertinib.
9899373|NCT05112952|Experimental|Part B: Group 4 (Optional): Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of lazertinib.
9899374|NCT05111626|Experimental|Part 1 Safety Lead-in: Bemarituzumab with mFOLFOX6 and Nivolumab|Participants will be administered bemarituzumab at different doses with mFOLFOX6 and nivolumab to determine the recommended phase 3 dose (RP3D) based on occurence of dose-limiting toxicities (DLTs), and on an evaluation of the overall safety, tolerability, and pharmacokinetics (PK).
9899375|NCT05111626|Experimental|Part 2: Bemarituzumab with mFOLFOX6 and Nivolumab|Participants will be administered bemarituzumab at the RP3D determined from Part 1 in combination with mFOLFOX6 and nivolumab.
9899376|NCT05111626|Placebo Comparator|Part 2: Placebo with mFOLFOX6 and Nivolumab|Participants will be administered placebo comparator in combination with mFOLFOX6 and nivolumab.
9933251|NCT00958269|Placebo Comparator|placebo (double-blind, placebo-controlled period)|weeks 1-26
9933252|NCT00958269|Placebo Comparator|placebo (single-blind, active-controlled period)|weeks 27-52
9899377|NCT05111574|Experimental|Arm 1 (nivolumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
9899378|NCT05111574|Active Comparator|Arm 2 (nivolumab, placebo)|Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
9899379|NCT05111574|Experimental|Arm 3 (nivolumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycle in the absence of disease progression or unacceptable toxicity.
9933253|NCT00958269|Active Comparator|sitagliptin (single-blind, active-controlled period)|weeks 27-52
9933254|NCT00958321|Experimental|3-DCRT|Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT
9933255|NCT00958386|Experimental|1|Panitumumab+irinotecan
9933256|NCT00958399|Placebo Comparator|No fiber|No fiber added to study products
9933257|NCT00958399|Experimental|Resistant Starch|Muffins, cereal, and bars made with a resistant starch
9933258|NCT00958399|Experimental|Resistant starch + soluble fiber|Muffins, cereal, and bars made with a mixture of resistant starch and a soluble fiber
9933259|NCT00958399|Experimental|Fiber made from corn starch|Muffins, cereal, and bars made with novel corn fiber
9933260|NCT00958399|Experimental|Fiber made from corn starch + soluble fiber|Muffins, cereal, and bars made with a mixture of novel corn fiber and a soluble fiber
9933261|NCT00958425|Experimental|Hyaluronic acid gel|
9933262|NCT00958425|Active Comparator|Saline|
9933263|NCT00958451|Active Comparator|Paricalcitol|Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
9992618|NCT01464125|Experimental|Fos-Azi|Open label single arm concurrent administration of fosmidomycin and azithromycin.
9992619|NCT01464138|Experimental|Fosmidomycin-Clindamycin|Single arm study. Co-administration of Fosmidomycin and Clindamycin.
9992620|NCT01464151||Patients with inflammatory bowel disease|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
9992621|NCT01464203|Experimental|CT coronary angiography|Patients in this arm will undergo CT coronary angiography to assess the patency of coronary arteries and their clinical management will be decided by the results of CT coronary angiography.
9992622|NCT01464203|Active Comparator|Control Arm|"Patients in this arm will receive the standard of care (SoC). They will undergo either coronary angiography, myocardial perfusion scan or stress echocardiography as decided by the physician in charge, depending on the local availability of individual investigations and the patient's clinical scenario."
9992623|NCT01464242|Experimental|Glucantime® + pentoxifylline|Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
9992624|NCT01464242|Placebo Comparator|Glucantime® + placebo|Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
9992625|NCT01464281|Experimental|48-week standard treatment|48-week standard treatment by Peginterferon alfa 2a 180µg/week
9992626|NCT01464281|Active Comparator|96-week prolonged treatment|96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
9992627|NCT01464294||nano-composite|crowns and onlays
9992628|NCT01464294||ceramic|crowns & onlays
9992629|NCT01464320|Experimental|ABT-614|
9992630|NCT01464320|Placebo Comparator|Placebo Comparator|
9992631|NCT01464372|Experimental|Investigational Device|Treatment using electrical field stimulation of peripheral nerves
9992632|NCT01464372|Sham Comparator|Sham Device|Control group using sham device to mimic sound and sensation of investigational device
9992633|NCT01464385|Experimental|Nutritional Beverage #2|Nutritional Beverage with an amino acid Oral 237 ml
9992634|NCT01464385|Experimental|Nutritional Beverage #3|Nutritional Beverage with an amino acid Oral 237 ml
9992635|NCT01464385|Placebo Comparator|Nutritional Beverage #1|Nutritional Beverage Oral 237 ml
9997717|NCT01511380|Experimental|Risk Reduction Therapy for Adolescents|Youth randomly assigned to RRTA will complete a family focused treatment program that will work with the youth and his or her caregiver to help reduce youth substance use and risky sexual behavior using principals of behavior modification and contingency management.
9997718|NCT01511380|Active Comparator|Usual services|For youth randomly assigned to usual treatment services, the youth will receive the treatment services recommended by the drug court.
9997719|NCT01511393||Questionnaire|None. Non-interventional study.
9997720|NCT01511406|Experimental|cognitive behavioral therapy|Cognitive behavioral therapy up to 26 sessions
9997721|NCT01511432|Experimental|Part A|Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.
9997722|NCT01511432|Experimental|Part B|Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state
9997723|NCT01511458||Case|Patient with a trisomy 21 pregnancy confirmed by genetic testing.
9997724|NCT01511458||Control|Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.
9997725|NCT01511471|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
9997726|NCT01511484|Experimental|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
9997727|NCT01511484|Experimental|Generic-appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
9997728|NCT01511484|Experimental|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
9997729|NCT01511497|Experimental|PF-04427429|
9997730|NCT01511497|Placebo Comparator|Placebo|Normal saline
9997731|NCT01511510|Experimental|PF-04958242|
9997732|NCT01511510|Placebo Comparator|Placebo|
9992636|NCT01464398|Active Comparator|Stress reduction|Mindfulness-based stress reduction
9992637|NCT01464398|Active Comparator|Stress reduction with Health education|General stress management and health education
9992638|NCT01464450|Active Comparator|Sequence 1: Treatment A - B - C|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
9992639|NCT01464450|Active Comparator|Sequence 2: Treatment A - C - B|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
9992640|NCT01464450|Active Comparator|Sequence 3: Treatment B - C - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
9992641|NCT01464450|Active Comparator|Sequence 4: Treatment B - A - C|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
9997733|NCT01511523|Active Comparator|RGMA001|Proprietary blend of Vitamin E, Silymarin, and Carnitine.
9997734|NCT01511523|Placebo Comparator|Sugar Pill|No treatment.
9997735|NCT01511549|Experimental|Dose 1|SAR113945 low dose
9997736|NCT01511549|Experimental|Dose 2|SAR113945 medium dose
9997737|NCT01511549|Experimental|Dose 3|SAR113945 high dose
9997738|NCT01511549|Placebo Comparator|Placebo|Placebo
9992642|NCT01464450|Active Comparator|Sequence 5: Treatment C - A - B|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
9992643|NCT01464450|Active Comparator|Sequence 6: Treatment C - B - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
9992644|NCT01464463|Experimental|CBT-active|Patients with Major Depression (N = 50) get a common CBT treatment in combination with physical exercise.
9997739|NCT01511562|Other|Arm I|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
9899380|NCT05111197|Experimental|A. (Immunotherapy + SRT)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy, started at least 6 months ago, associated with Stereotactic Radiation Therapy (SRT)
9899381|NCT05111197|Active Comparator|B (Immunotherapy alone)|Continuation of anti-PD-1 or anti-PD-L1 immunotherapy alone (started at least 6 months ago)
9899382|NCT05109793||Cohort|Late infantile or juvenile onset for GM1 or GM2 Gangliosidosis. This study will enrol a minimum of 75 patients in total, including at least 25 patients with GM1 Gangliosidosis and 25 patients with GM2 Gangliosidosis
9899383|NCT05109416|Active Comparator|Group A|Children will receive bupivacaine 0.5% ( 1 mg / kg ) ,divided in each side , by infiltration through anterior and posterior approaches to block glossopharyngeal nerve
9899384|NCT05109416|Placebo Comparator|Group B|Children will receive sterile saline 0.9 , 5 cm in each side , by infiltration through anterior and posterior approaches
9899385|NCT05104866|Experimental|Dato-DXd|Arm 1: Dato-DXd
9899386|NCT05104866|Active Comparator|Investigators Choice of Chemotherapy (ICC)|"Arm 2: ICC~Capecitabine~Gemcitabine~Eribulin mesylate~Vinorelbine"
9899387|NCT05103475|Experimental|Rage Against the Pain (RAP)|The RAP program curriculum will mirror that of the Hatha Yoga classes, but will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the poses/movements (rather, poses will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the typical relaxation/meditation exercise used in yoga, referred to as savasana).
9899388|NCT05103475|Active Comparator|Treatment as Usual (i.e., yoga)|The 'treatment as usual' class will be conducted in the style of the yoga classes currently being offered to Veterans at the Hines VA Hospital, which is a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
9899389|NCT05100290||HVS+|Subjects without documented respiratory or cardiac disease, with a spirometry and metacholine tests within expected values AND with complaints documented by a Nijmegen questionnaire score of ≥23/64 (suspected of idiopathic hyperventilation)
9899390|NCT05100290||HVS-|Healthy controls without documented respiratory or cardiac disease, with a spirometry and metacholine tests within expected values AND without complaints documented by a Nijmegen questionnaire score of <23/64
9899391|NCT05100056||HL Participants: BV Salvage Pre-ASCT|Participants diagnosed with HL who undergone or undergoing pre-ASCT BV salvage and continue with post-ASCT treatment will be observed prospectively over 24-month period after treatment cessation.
9899392|NCT05100056||HL Participants: BV Consolidation Treatment Post-ASCT|Participants diagnosed with HL who undergone or undergoing post-ASCT BV consolidation treatment will be observed prospectively over 24-month period after treatment cessation.
9899393|NCT05099978||NGS analysis of ctDNA|"This study consists of 6 cohorts; cervical cancer(n=100), ovarian clear cell cancer(n=50), nasopharyngeal cancer(n=96), ovarian cancer(n=100), breast cancer(n=100), endometrial cancer(n=60).~In each cohort, the blood samples will be collected within 2weeks after registration. ctDNA will be extracted from blood samples and somatic gene abnormalities will be analyzed using NGS, PCR, and Sanger sequencing. In addition, the analysis of DNA methylation and RNA sequencing may be performed to obtain information related to gene expression."
9899394|NCT05099965|Active Comparator|Vaccine Group|60 participants will receive CMV-MVA Triplex® containing 5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine Encoding CMV Antigens by intramuscular (IM) deltoid injections.
9899395|NCT05099965|Placebo Comparator|Placebo Group|30 participants will receive a volume of placebo (7.5% Lactose in phosphate-buffered saline [PBS]) that matches the volume of the active vaccine injection by IM deltoid injections.
9899396|NCT05099770|Sham Comparator|Cohort 1|Participants randomized to Cohort 1 will receive 2 sham injections of REACT®. Second injection to occur 3 months (+30 days) after the first REACT® injection. Sham procedures simulate real procedure. No tissue is taken during biopsy and nothing is injected into kidney for injection.
9899397|NCT05099770|Experimental|Cohort 2|Participants randomized to Cohort 2 will receive 2 injections of REACT®. The second injection to occur 3 months (+30 days) after the first REACT® injection.
9899398|NCT05097599|Other|Lorbrena® (Lorlatinib)|
9899399|NCT05097599|Other|Braftovi® (Encorafenib) + Mektovi® (Binimetinib)|
9899400|NCT05097599|Other|Talzenna® (Talazoparib)|
9899401|NCT05097599|Other|Enhertu® (fam-trastuzumab deruxtecan-nxki)|
9899402|NCT05097599|Other|Padcev® (Enfortumab-vedotin)|
9899403|NCT05094271|Active Comparator|Supplemental Oxygen during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
9899404|NCT05094271|Placebo Comparator|Room Air during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min of pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
9899405|NCT05094271|Experimental|Supplemental Oxygen for 3 Months|Over a 12-week period, participants randomized to receive supplemental Oxygen for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
9899406|NCT05094271|Experimental|PAP Therapy for 3 Months|Over a 12-week period, participants randomized to receive supplemental PAP therapy for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
9899407|NCT05093699|Active Comparator|Control Group|Arterial line placement via standard mechanism; utilization of a single-plane ultrasound probe
9899408|NCT05093699|Experimental|Butterfly iQ+ ultrasound probe|Arterial line placement utilizing dual-plane, Butterfly iQ+ ultrasound probe
9899409|NCT05092958|Active Comparator|Arm A (avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.
9899410|NCT05092958|Experimental|Arm B (avelumab, cabozantinib)|Patients receive avelumab IV over 60 minutes on days 1 and 15 of each cycle and cabozantinib PO daily. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.
9899411|NCT05092607|Experimental|Venous and Capillary blood sampling|Venous and Capillary blood sampling
9899412|NCT05091905|Active Comparator|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout).
9899413|NCT05091905|Experimental|Titratable Automated Boluses|Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
9899414|NCT05087758|Experimental|Matrion decellularized placental membrane|Matrion placental membrane graft will be use to treat subjects diagnosed with a diabetic foot ulcer.
9899415|NCT05087758|Active Comparator|Conventional Care Wound Management|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diabetic foot ulcer diagnosis.
9899416|NCT05086744|Experimental|Iptacopan 200 mg BID|Iptacopan 200 mg BID
9899417|NCT05086692|Experimental|MDNA11|"MDNA11 is a long-acting beta-only recombinant interleukin-2 (rIL-2) albumin fusion"
9899418|NCT05083169|Experimental|Arm A: Teclistamab-daratumumab (Tec-Dara)|Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose.
9899419|NCT05083169|Experimental|Arm B:Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Bortezomib, Dexamethasone (DVd)|In DPd treatment (28-day cycle), participants will receive daratumumab SC 1800mg weekly on Cycles 1 and 2, every 2 weeks on Cycles 3 to 6, every 4 weeks on Cycle 7 and beyond; oral pomalidomide 4 mg on Days 1 to 21 of every 28-day cycle, dexamethasone 40 mg (less than or equal to [<=] 75 years) or 20 mg (greater than [>] 75 years) orally or intravenously (IV) weekly on every cycle. In DVd treatment (21-day cycle from Cycles 1 to 8 and 28-day cycle from Cycle 9 and beyond), daratumumab SC injection 1800 mg weekly on Cycles 1 to 3 and on Day 1 (Cycle 4 and beyond); bortezomib 1.3 milligrams per meter square (mg/m^2) on Days 1, 4, 8 and 11 (Cycles 1 to 8), and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8).
9899420|NCT05081596|Experimental|Problem Adaptation Therapy for Pain (PATH-Pain)|Problem Adaptation Therapy-PAIN (PATH-PAIN) is an emotion regulation intervention aimes to reduce stress and decrease depression and disability.
9899421|NCT05081596|No Intervention|Attention Control Usual Care|Usual Care involves the continued medical attention and treatment provided by the subject's physician and other medical professionals in primary care. This may include medical intervention or referrals to specialists to address issues of depression, pain or memory difficulties. Subjects will also be asked to meet with a study research assistant for structured interviews and educational sessions consisting of general questions regarding health habits and other non-medical topics unrelated to cognitive impairment, pain, and depression. Additionally, subjects will receive an educational booklet on pain and depression.
9899422|NCT05075759|Experimental|Arm 1 (personalized clinician-led self-management telehealth)|Patients receive a personalized clinician-led self-management telehealth session at baseline and 2 months. Patients with poor response at 3 months are randomized to Arm 2 or 4, otherwise patients receive the same telehealth session at months 4 and 6. Patients may receive 2 additional telehealth sessions after 12 months.
9899423|NCT05075759|Experimental|Arm 2 (personalized goal setting)|Patients receive personalized goal setting for daily steps and activity (updated weekly) and 3 dietary goals (updated monthly) with social media peer support for 6 months. Patients with poor response at 3 months are randomized to Arms 1 or 4. Patients may receive personalized goal setting for daily steps and activity (updated monthly) and dietary goals (updated every 2 months) after 12 months.
9997740|NCT01511562|Other|Arm II|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
9997741|NCT01511627|Active Comparator|General Anesthesia|
9997742|NCT01511627|Experimental|General Anesthesia + Spinal Anesthesia|
9899424|NCT05075759|Active Comparator|Arm 3 (waitlist)|Patients receive no intervention for 12 months, and then receive their choice of intervention for up to 6 months.
9899425|NCT05075759|Experimental|Arm 4 (remote sessions with a health coach)|Patients receive remote sessions with a health coach every 1-2 weeks for 6 months. Patients may continue to receive remote sessions once a month after 12 months.
9899426|NCT05074888|Experimental|Prospekta|Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15 minutes before eating or drinking), keep the tablets in the mouth, without swallowing, until completely dissolved.
10212568|NCT05202392|Experimental|Myofascial Release with Scapular Stabilization Exercise|These individuals will only receive same myofascial release therapy as 1st group combined with stabilization exercises. The stabilization exercises will include total 5 stages. The patient will be instructed to get into a supine position and to relax their body and will be instructed to place their feet flat on floor while bending their knees and holding this posture without and involvement of neck movements. After this, the subjects will be taught to raise their shoulder arm up to 90° combined with full scapular protraction and elbow extension and to hold this position for 10 seconds before returning to the prior positions doing this for 3 laps and 10 repetitions and with a minute break in between. For a quadruped position the individuals will alternatively lift their arms along with 120° flexion and shoulder abduction and hold this for ten seconds for ten repetitions for 3 laps and a 30 second break in between
10212569|NCT05202340||Prostate Cancer|Patients diagnosed with prostate cancer
10212570|NCT05202106|No Intervention|Control|Families in the control group will not receive any interventions and will simply complete baseline and endline surveys.
10212571|NCT05202106|Experimental|Home visits|Families in the home visiting arm will receive visits by trained child development agents every two weeks between enrollment and 2 years of age.
10212572|NCT05202106|Experimental|Afini|Families in the Afini arm will be introduced to the Afini app on Messenger and encouraged to use this platform throughout the study.
10212573|NCT05202067|Experimental|pharmaceutical education|The patients assigned to the intervention group will receive from the research pharmacist, a didactic talk (of at least 10 and up to 20 minutes), where they will be provided information about type 2 diabetes mellitus and Systemic Arterial Hypertension, causes of the disease and consequences of poor control, on its pharmacological treatments, changes in lifestyle and diet. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
10212574|NCT05202067|No Intervention|control|Patients assigned to the control group will receive only standard care, represented by regular consultation with their prescribing physician.
9899427|NCT05074888|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Prospekta scheme.
9899428|NCT05074823|Active Comparator|Ketamine 0.1|Group I: will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
9899429|NCT05074823|Active Comparator|Ketamine 0.2|Group II will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
9899430|NCT05074823|Active Comparator|Ketamine 0.3|Group III will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
9899431|NCT05071664|Experimental|Group 1: Guselkumab and Golimumab|Participants will receive subcutaneous (SC) guselkumab and golimumab.
9899432|NCT05071664|Active Comparator|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab and placebo.
9899433|NCT05071014|Experimental|pembrolizumab followed by cryoablation|The treatment will consist of 1 cycle of pembrolizumab (200mg/flat dose) intravenously followed by cryoablation of an ablation index lesion 1-7 days prior to the start of cycle 2. Pembrolizumab will be continued for up to 24 months, until disease progression, or intolerable toxicity.
9899434|NCT05070858|Experimental|Group 1|Placebo in DBTP; Re-randomized to Combination or Cemdisiran in ETP and OLTP
9899435|NCT05070858|Experimental|Group 2|Combination regimen throughout the study
9899436|NCT05070858|Experimental|Group 3|Cemdisiran throughout the study
9899437|NCT05070858|Experimental|Group 4|Pozelimab monotherapy in DBTP followed by combination in ETP and OLTP
9899438|NCT05069649|Experimental|Ergoferon|Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15-30 minutes before meals), keep the tablets in the mouth, without swallowing, until completely dissolved.
9899439|NCT05069649|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Ergoferon scheme.
9899440|NCT05069597|Experimental|Run-in Period: Creon|Participants will receive Creon daily for 112 days.
9899441|NCT05069597|Experimental|Treatment Period: Creon|Participants will receive Creon daily for 112 days.
9899442|NCT05067894|Experimental|Adult - Vaccine candidate|50 µg dose, adult group (18-59 years)
9899443|NCT05067894|Active Comparator|Adult - Control|SARS-CoV-2 inactivated vaccine, adult group (18-59 years)
9899444|NCT05067894|Experimental|Elderly - Vaccine candidate|50 µg dose, elderly group (> 60 years)
9899445|NCT05067894|Active Comparator|Elderly - Control|SARS-CoV-2 inactivated vaccine, elderly group (> 60 years)
9899446|NCT05067829|Active Comparator|Ideal Body weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR IDEAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR IDEAL BODY WEIGHT WILL BE GIVEN."
9899447|NCT05067829|Active Comparator|Total Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR TOTAL BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR TOTAL BODY WEIGHT WILL BE GIVEN."
9899448|NCT05067829|Active Comparator|Corrected Body Weight|"ROCURONIUM PRIMING DOSE 0,06 MG/KG FOR CORRECTED BODY WEIGHT BEFORE 3 MINUTES BEFORE INDUCTION.~AFTER INDUCTION, ROCURONIUM 0,94 MG/KG FOR CORRECTED BODY WEIGHT WILL BE GIVEN."
9899449|NCT05067634|Experimental|12 to < 18 year olds|
9899450|NCT05067634|Experimental|6 to <12 years old|
9899451|NCT05067634|Experimental|4 to <6 years old|
9899452|NCT05067634|Experimental|2 to <4 years old|
9899455|NCT05064761|Experimental|Treatment group|PLLA new dilution for treatment to improve appearance of cellulite.
9992645|NCT01464463|Active Comparator|CBT-euthymic|"Patients with Major Depression (N = 50) get the same common CBT treatment as the CBT-active-group, but instead of physical exercise they receive an enjoyment training, which is based on exercises from the Kleine Schule des Genießens (Koppenhöfer, 2004)"
9992646|NCT01464463|Active Comparator|CBASP|Patients with Major Depression (N=50) get a cognitive therapy according to the Cognitive Behavioral Analysis System of Psychotherapy (CBASP).
9992647|NCT01464463|No Intervention|Waiting List|Patients randomized to the waiting list receive psychological treatment after waiting for 4 month.
9992648|NCT01464476|Experimental|Azimilide|Azimilide 75 mg film coated tablets
9992649|NCT01464476|Placebo Comparator|Placebo|
9992650|NCT01464489|Experimental|Control group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.And receive normal saline for control group
9992651|NCT01464489|Active Comparator|Atropine group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.
9992652|NCT01464502|Active Comparator|Standard CRT Implant|
9992653|NCT01464502|Active Comparator|Pressure-wire guided CRT Implant|
9992654|NCT01464515|Active Comparator|Real TMS|this group will receive high frequency deep TMS treatment of 10HZ
9992655|NCT01464515|Sham Comparator|SHAM TMS|this group will receive SHAM treatment of deep TMS
9992656|NCT01464528|Active Comparator|Hyaluronan|Use of hyaluronic acid gel
9992657|NCT01464528|No Intervention|control|
9992658|NCT01464541|Experimental|orbital fractures size|patients who undergo surgical repair of orbital fracture with measuring the fracture size intraoperatively and had available orbital Ct scan preoperatively.
9992659|NCT01464554|Active Comparator|Usual Care|Teens will receive six sessions of an alcohol and drug education group
9992660|NCT01464554|Experimental|Project Free Talk|Teens will receive six sessions of and evidenced based motivational interviewing alcohol and drug program
9992661|NCT01464567|Active Comparator|"T Tube Spontaneous Breathing Trial"|"Spontaneous Breathing Trial wuth T Tube for 30 minutes."
9992662|NCT01464567|Experimental|Pressure Support Ventilation|Spontaneous Breathing Trial wuth Ventilation on Pressure-Support mode set at 10cmH2O for 30 minutes
10212575|NCT05202054|Experimental|The Effect of mindfulness stress reduction program on slepness and quality of life|Groups of 20 will be formed for the implementation of the mindfulness stress reduction program in the experimental group. The BFSAP day and time will be determined by taking into account the time zones where women are available. 150 minutes of BFSAP will be applied to the women in the experimental group once a week, lasting 8 weeks and consisting of 8 times in total. The women will then be given a midterm test. After the midterm, women will be asked to individually repeat the BFSAP application in their own home for 8 weeks (weeks 8-16).
10213918|NCT02667587|Placebo Comparator|Nivolumab placebo + Temozolomide + Radiotherapy|Nivolumab Placebo: specified dose on specified days; IV infusion Temozolomide: 75 mg/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units 5x/week x 6 weeks
10213919|NCT02664740|Experimental|Phage therapy|"Patients randomized to this arm will have phage therapy.~Intervention: Topical anti-Staphylococcus bacteriophage therapy"
10213920|NCT02664740|Placebo Comparator|Placebo|"Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm.~Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy"
9992663|NCT01464593|Experimental|Thermodox|Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.
9992664|NCT01464606|Experimental|Type I PPB therapy|PPB Type I therapy: All patients will be treated with surgery. Chemotherapy after surgery is per the treating physician(s) discretion. If chemotherapy is used the Registry will suggest that it be combination chemotherapy with Vincristine, Dactinomycin, Cyclophosphamide (VAC).
9992665|NCT01464606|Experimental|Types II and III PPB therapy|"Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin (IVADo). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery."
9992666|NCT01464632||Primary|Post Market Study
9992667|NCT01464645||Primary|Post Market Study
9992668|NCT01464658|Other|panniculectomy|surgical intervention
9992669|NCT01464671|Active Comparator|Bivalirudin|Anticoagulation during percutaneous coronary intervention
9992670|NCT01464671|Active Comparator|Unfractionated Heparin|Anticoagulation during percutaneous coronary intervention
9992671|NCT01464736|Experimental|Physical Training Group|This group performed aerobic physical training in treadmill.
9992672|NCT01464736|Experimental|NIV Trained|"This group performed aerobic physical training associated with ventilation in the bilevel modality (BiPAP®), using a nasal mask as an interface.~On evaluation day, the levels of inspiratory positive airway pressure (IPAP) (between 10 and 15cmH2O) and expiratory positive airway pressure (EPAP) (between 4 and 6cmH2O) were defined, varying according to the comfort level of each patient."
9992673|NCT01464749|Experimental|Task-oriented circuit class training|"Functional Circuit include 6 different work-stations in which patients exercise for 5 minutes in each one : 3 minutes exercises and 2 minutes rest. Total training takes about 30 minutes (2 laps/session over 60 minutes).~Walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary.~It is a progressive circuit and subjects, while exercising, receives feedback (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One task oriented session may include up to 3 patients and lasts 120 minutes. At the end of the 2 weeks an exercises brochure will be given to patients so that they can independently train for 3 month. Independent home training takes about 90 minutes."
9998228|NCT01516320|Active Comparator|Laparoscopic adjustable gastric banding (LAGB) Subjects|Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.
9998229|NCT01516320|Active Comparator|Vertical Sleeve Gastrectomy (VSG) Subjects|Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.
10212576|NCT05201898|Placebo Comparator|usual medical management|with regular doctor visits every 3 months
10212577|NCT05201898|Experimental|usual medical management+individual dietary consultation|with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit
10212578|NCT05201898|Experimental|usual medical management+individual dietary consultation+ daily tea drinking|with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking
10212579|NCT05201885||laparoscopic surgery|Different surgical methods for rectal cancer resection
9899461|NCT05063162|Experimental|Rozanolixizumab Arm|Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints.
9899462|NCT05063162|Placebo Comparator|Placebo Arm|Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding.
9899463|NCT05061693|Experimental|INCB054707 Dose A|Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
9899464|NCT05061693|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
9899465|NCT05061693|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
9899466|NCT05061693|Placebo Comparator|Placebo followed by INCB054707 Dose B or C|Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
9899467|NCT05059652|Experimental|Ischemic Preconditioning (n= 22)|"The IPC protocol will be applied in the proximal region of the thigh of the limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain.~Participants will be relaxed and comfortably seated. The same cuff used to determine the total occlusion pressure (TOP) will be used and the protocol will consist of four cycles of total ischemia (according to the TOP value determined individually) of five minutes, followed immediately by four cycles of five minutes of vascular reperfusion (0 mmHg ), totaling 40 minutes."
9899468|NCT05059652|Placebo Comparator|Placebo (n= 22)|The placebo protocol will be performed on the lower limb with knee osteoarthritis and if both knees are affected, it will be applied to the knee with the greatest complaint of pain. Participants will perform a protocol similar to the IPC, but during the four cycles of five minutes of occlusion, the cuffs will only be inflated with 10mmHg so as not to cause arterial or venous occlusion, alternating with four cycles of five minutes of reperfusion (0 mmHg).
9899469|NCT05058508|Experimental|EXER|"Just Move exercises"
9899470|NCT05058508|Experimental|SOC EXER|Standard of Care Exercise
9899471|NCT05058131|Active Comparator|Dietary fibre|Butyrate-promoting dietary fibre
10212580|NCT05201885||Transanal endoscopic surgery|Different surgical methods for rectal cancer resection
10212581|NCT05199883|Experimental|TI.VA group|The titration of Propofol and Remifentanil levels will be guided by TI.VA algorithm in the time between skin incision and completion of surgical resection.
10212582|NCT05199844||Group A|cardiac patients with regular heart rate
10212583|NCT05199844||Group B|cardiac patients with irregular heart rate
10212584|NCT05198453||vaccinated patients with COVID-19|
10212585|NCT05198453||unvaccinated patients with COVID-19|
10212586|NCT05197790|Other|Assess device prototype functionality|Everyone will be in the same arm
10212587|NCT05197660||- cataract surgery|
10212588|NCT05197660||- hip arthoplasty|
10212589|NCT05197660||- knee arthoplasty|
10212590|NCT05197660||- coronary angioplasty|
10212591|NCT05197660||- definitive cardiac stimulation (pacemaker)|
10212592|NCT05197374|Experimental|Group 1|Cases who received estradiol pretreatment then underwent ICSI.
10212593|NCT05197374|No Intervention|group 2|Cases who underwent ICSI directly without receiving any pretreatment
10212594|NCT05197231|Experimental|IV amino acids + standardized physiotherapy with lower limb resistance exercise.|Research subjects randomized to the intervention group will receive an infusion of IV amino acids during a session of protocolized physiotherapy that includes a knee extension resistance exercise targeting the thigh muscles. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
10212595|NCT05197231|Active Comparator|IV amino acids + standardized physiotherapy.|Research subjects randomized to the control group will receive an infusion of IV amino acids during a session of protocolized physiotherapy NOT including lower limb resistance exercise. The supplemental amino acid infusion will continue up until 90 minutes after the subject has returned to bed rest.
10212596|NCT05195125|Experimental|Direct Peritoneal Resuscitation (DPR) Group|At the time of abdominal closure and determination that the patient will either go to extended stay or the intensive care unit, three drains will be placed per standard of care. An additional 19 French drain will be placed at the ligament of Treitz at the base of the mesentery. Following abdominal closure DPR will be initiated with commercially available 2.5% glucose-based peritoneal dialysis solution at a rate of 1.5 cc/kg/hr based on previously reported therapy in trauma. Drains will be connected to continuous wall suction. This infusion will continue for the duration the patients stay in extended stay (8 hours) if they are deemed eligible for hospital ward admission, or for 24 hours if requiring ICU care. These patients will then be observed for their hospital course and monitored for outcomes listed above.
10212597|NCT05195099|Active Comparator|control group|
10212598|NCT05195099|Experimental|respiratory treatment|
10212599|NCT05195073|Active Comparator|3 D laparoscopy group|salpingectomy will be performed by using Storz image 1 S 3D laparoscopy system (Karl Storz, Tuttlingen, Germany) which is comprised of a 10 mm scope with 2 full HD sensors at the tip of the scope and a 3 D control unit plus a 3 D display
10212600|NCT05195073|Active Comparator|2 D laparoscopy group|salpingectomy will be performed by using a conventional 2 D laparoscopy system.
10212601|NCT05194709|Experimental|Anti-5T4 CAR-NK Cells|
10213921|NCT02659605|Experimental|Delayed cord clamping above the perineum|
10213922|NCT02659605|Active Comparator|Delayed cord clamping below the perineum|
9899472|NCT05058131|Placebo Comparator|Placebo compound|Placebo compound
9899473|NCT05056727|Experimental|Sodium Zirconium Cyclosilicate (SZC)|SZC 5 g every other day to 15 g once daily + Lisinopril/Valsartan
9899474|NCT05056727|Placebo Comparator|Placebo|Placebo + Lisinopril/Valsartan
9899475|NCT05052229|Placebo Comparator|Placebo|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquide Healthcare, Montreal, Quebec, Canada).
9899476|NCT05052229|Active Comparator|Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; DIN 02451328).
9899477|NCT05052060|Experimental|Group A|19 patients will be treated with pelvic tilt exercises
9899478|NCT05052060|Active Comparator|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
9899479|NCT05050500|Experimental|Intervention Group|Dapagliflozin 10 mg every 24 hours for 6 months
9899480|NCT05050500|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 6 months
9899481|NCT05050097|Experimental|Treatment Regimen A: Talquetamab + Carfilzomib|Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.
9899482|NCT05050097|Experimental|Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib|Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.
9899483|NCT05050097|Experimental|Treatment Regimen C: Talquetamab + Lenalidomide|Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.
9899484|NCT05050097|Experimental|Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide|Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.
9899485|NCT05050097|Experimental|Treatment Regimen E: Talquetamab + Pomalidomide|Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.
9899486|NCT05049525|Active Comparator|Itraconazole and Terbinafine|During the first 4 weeks itraconazole will be administered alone at 200 mg twice daily, followed by itraconazole 200 mg twice daily and terbinafine 250 mg twice daily for the remaining 16 weeks. Both drugs will be administered orally.
9899487|NCT05049525|Placebo Comparator|Placebo|During the first 4 weeks a placebo will be administered alone at 200 mg twice daily, followed by placebo 200 mg twice daily and another placebo 250 mg twice daily for the remaining 16 weeks. Both placebos will be administered orally.
9899488|NCT05048992|Active Comparator|ELDOA method|Twenty (20) patients will be treated with ELDOA method
9899489|NCT05048992|Active Comparator|Post-facilitation stretching|Twenty (20) patients will be treated with Post-facilitation stretching technique.
9899490|NCT05045833|Experimental|5 mg SYN-020|1 x 5 mg oral capsule, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
9899491|NCT05045833|Experimental|15 mg SYN-020|1 x 15 mg oral capsule, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
9899492|NCT05045833|Experimental|45 mg SYN-020|3 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
9899493|NCT05045833|Experimental|75 mg SYN-020|5 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
9899494|NCT05045833|Experimental|≤ 75 mg SYN-020 (new formulation)|≤ 5 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
9899495|NCT05042128|Experimental|Standard Care + CEND1|Participants will receive nab-paclitaxel 125mg/m2; CEND1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
9899496|NCT05042128|Placebo Comparator|Standard Care + Placebo|Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
9998230|NCT01516333|Experimental|Diet 1|High GI; High Carb; High GL
9998231|NCT01516333|Experimental|Diet 2|High GI, Low Carb, Med GL
9992674|NCT01464749|Active Comparator|Usual Care|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement (usual care). At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) or do physical rehabilitation in rehabilitative gyms not directly addressed to gait, mobility or balance training such as stretching exercises, active and passive mobilization and Bobath neurorehabilitation or similar.
9992675|NCT01464801|Experimental|Resveratrol|Subjects are given resveratrol 500 mg 3 times daily for 6 months.
9992676|NCT01464801|Placebo Comparator|Placebo|Subjects are given Placebo tablets 3 times daily for 6 months.
9992677|NCT01464814|Experimental|Probiotic|Lactobacillus casei in fish oil capsule
9992678|NCT01464814|Placebo Comparator|Placebo|Fish oil capsule
9992679|NCT01464853|Experimental|Specialized Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
9992680|NCT01464853|Active Comparator|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
9992681|NCT01464866|Active Comparator|Hospital Feed|Standard hospital food
9992682|NCT01464866|Experimental|Hospital Feed plus nutritional supplement|Standard hospital food plus nutritional supplement
9992683|NCT01464905|Experimental|NU100|
9992684|NCT01464905|Placebo Comparator|Placebo|
9992685|NCT01464905|Active Comparator|recombinant human interferon beta- 1b|
9992686|NCT01464918|Experimental|ESD using the MASTER device|Endoscopic submucosal dissection of gastric/colon cancer using the device, MASTER
9992687|NCT01464944|Experimental|Arm 2|
9992688|NCT01464944|Active Comparator|Arm 3|
9992689|NCT01464944|Active Comparator|Arm 4|
9992690|NCT01464944|Placebo Comparator|Arm 5|
9992691|NCT01464944|Experimental|Arm 1|
9992692|NCT01464957|Experimental|Newsletter intervention|Semi-tailored newsletter intervention for parents and children
9992693|NCT01464957|No Intervention|Usual care|No newsletter intervention
9992694|NCT01464970|Active Comparator|SIE Vessels Both Clamped|
9992695|NCT01464970|Active Comparator|SIE Vessels both Unclamped|
9992696|NCT01464970|Active Comparator|SIE Artery Unclamped; Vein Clamped|
9992697|NCT01464970|Active Comparator|SIE Artery Clamped, SIE Vein Unclamped|Superficial Inferior Epigastric Artery Clamped; Vein Unclamped
9992698|NCT01464983|Active Comparator|Arm 1|
9992699|NCT01464983|Experimental|Arm 2|
9992700|NCT01464983|Active Comparator|Arm 3|
9992701|NCT01464983|Active Comparator|Arm 4|
9992702|NCT01464983|Placebo Comparator|Arm 5|
9992703|NCT01465009|Experimental|Arm 1|
9992704|NCT01465009|Active Comparator|Arm 2|
9992705|NCT01465009|Placebo Comparator|Arm 3|
9992706|NCT01465035|Experimental|TIV and MVA-NP+M1|"Co-administration group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of 1.5 x108pfu MVA-NP+M1"
9992707|NCT01465035|Placebo Comparator|Saline placebo and seasonal influenza vaccine TIV|"Control group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of a saline placebo"
9992708|NCT01465061||Online support user|
9992709|NCT01465074|Active Comparator|Nicotine gum (4 mg)|Nicotine gum will be given once on one of the two test days in a randomized, double-blinded fashion. Gum will be chewed for 30 min before the plasticity induction occurs.
9998232|NCT01516333|Experimental|Diet 3|Low GI, High Carb, Med GL
9899497|NCT05038241||Active VKC|All females and males of pubertal age with active VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
9899498|NCT05038241||Previous active VKC|All females and males of pubertal age who suffered of VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
9899499|NCT05035459||Conventional heart failure management group|Patients with ≥ 3 B-lines will be divided into the conventional heart failure management group and the LUS-BL-guided intensive heart failure management group at 1:1 ratio. Patients in the conventional heart failure management group will receive conventional guideline recommended HF therapy post discharge and be followed up at 2-month interval post discharge by clinical visit. LUS-BL will be assessed at 2-month interval post discharge also in this group, but results will be enveloped.
9899500|NCT05035459||LU-BL guided intensive heart failure management group|The group with ≥ 3 B-lines will be divided into the conventional heart failure management group and the LUS-BL-guided intensive heart failure management group at 1:1 ratio. Patients in the LUS-BL-guided intensive heart failure management group will receive optimized HF medication and medication will be adjusted according the status of LUS-BL during the follow-up at 2-month interval.
9899501|NCT05032066|Experimental|HZN-825 300 mg once daily (QD)|Two 150 mg oral tablets given in the morning with a meal and two matching placebo tablets given in the evening with a meal, total daily dose 300 mg HZN-825
9899502|NCT05032066|Experimental|HZN-825-300 mg twice daily (BID)|Two 150 mg oral tablets given in the morning with a meal and two 150 mg oral tablets given in the evening with a meal, total daily dose 600 mg HZN-825
9899503|NCT05032066|Placebo Comparator|Placebo BID|Matching placebo tablets (2) given in the morning with a meal and matching placebo tablets (2) given in the evening with a meal, total daily dose 4 placebo tablets
9899504|NCT05031780|Experimental|Phase 2: Mitapivat 50 mg BID|Double-blind Period: Mitapivat 50 milligrams (mg) twice daily (BID) for 12 weeks.
9899505|NCT05031780|Experimental|Phase 2: Mitapivat 100 mg BID|Double-blind Period: Mitapivat 100 mg BID for 12 weeks.
9899506|NCT05031780|Placebo Comparator|Phase 2: Placebo|Double-blind Period: Mitapivat-matching placebo for 12 weeks.
9899507|NCT05031780|Experimental|Phase 2: Open-Label Extension Period|"Participants who received mitapivat 50mg BID in the double-blind period may choose to receive mitapivat 50mg BID for 216 weeks after.~Participants who received mitapivat 100mg BID in the double-blind period may choose to receive mitapivat 100 mg BID for 216 weeks after.~Participants who received mitapivat-matching placebo in the double-blind period, may be randomized to receive either mitapivat 50 mg or 100 mg BID for 216 weeks after."
9899508|NCT05031780|Experimental|Phase 3: Mitapivat selected Phase 3 dose|Double-blind Period: Mitapivat selected Phase 3 dose (50 mg or 100 mg BID) for 52 weeks.
9899509|NCT05031780|Placebo Comparator|Phase 3: Placebo|Double-blind Period: Mitapivat-matching placebo selected Phase 3 dose (which can be either 50 mg or 100 mg BID based on the phase 2 results) for 52 weeks.
9899510|NCT05031780|Experimental|Phase 3: Open-Label Extension Period|Participants may choose to receive the selected Phase 3 mitapivat dose (which can be either 50 mg or 100 mg BID based on the phase 2 results) for 216 weeks after the Double-blind Period.
9899511|NCT05030428|Experimental|Inclisiran sodium|Subcutaneous injection
9899512|NCT05030428|Placebo Comparator|Placebo|Subcutaneous injection
9899513|NCT05030103|Active Comparator|Glasses|The participants are asked to wear reading glasses during near-work. The reading glasses have a lenspower of +2.0 diopters.
9899514|NCT05030103|No Intervention|Control|Age matched children and adolescents, no intervention.
9899515|NCT05028634|Experimental|Cohort 1 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine.
9899516|NCT05028634|Experimental|Cohort 1 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), Pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine.
9899517|NCT05028634|Experimental|Cohort 2 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), and pneumococcal polysaccharide vaccine (PPSV23).
9899518|NCT05028634|Experimental|Cohort 2 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap) and Pneumococcal polysaccharide vaccine (PPSV23).
9935722|NCT03284957|Experimental|Amcenestrant Monotherapy: Arm #1 Part A Dose Escalation, Part B Dose Expansion|"Part A: Amcenestrant will be administered orally once daily (QD). Treatment will begin with an identified starting dose. Administration of higher doses to subsequent participants is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug will be administered in a 28-day cycle.~Part B: When the dose escalation phase ends, the recommended dose will be administered for the expansion cohort. Drug will be administered in a 28-day cycle."
9517565|NCT03305263|Experimental|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
9899519|NCT05027464|Experimental|Intervention Arm|The VAMC Internal Facilitator will partner with the trial External Facilitators (research team and designated External Facilitators in VISNS 16 and 21) to adapt and implement the study intervention to best meet the needs and preferences of their VAMC site. In addition, each CBOC and clinic affiliated with a VAMC in the Intervention arm will need to identify a Site Champion to provide clinic-specific information to facilitate implementation of the Vaccine Acceptance Intervention at their clinic or CBOC. In addition, for clinics and CBOCs assigned to the Vaccine Acceptance Intervention, VAMC, clinic and CBOC leadership will need to agree to release PACT staff for an initial two-hour Motivational Interviewing (MI) training, and at least one 60-minute post-training consultation session over the one-year trial period. There will be additional consultation sessions offered to intervention clinics and CBOC staff, but these will be optional.
9899520|NCT05027464|No Intervention|Usual Care Arm|"A VAMC assigned to Usual Care will have no specific trial intervention requirements beyond their usual level of participation in national and local initiatives to improve COVID-19 vaccine acceptance. At both Intervention and Usual Care sites, the study team will perform quarterly environmental scans. The environmental scan survey will include questions about site specific barriers to COVID-19 vaccination (first dose and second dose if needed), current programs/initiatives in the clinic or local community that are improving or have had no impact on vaccination rates, and the perceived importance that the VAMC/CBOC clinic staff is placing on vaccination (Environmental Scan Survey, in preparation). At Usual Care sites, a point of contact will be chosen from each clinic and CBOC to complete the environmental scan, and at Intervention sites, the Site Champion (see below) will perform the quarterly scan."
9899521|NCT05026086|Experimental|biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
9899522|NCT05026086|Active Comparator|isometric exercises|10 patients will be treated with isometric exercises without pressure biofeedback.
9899523|NCT05025423|Experimental|venetoclax and rituximab in patients over 60 yrs old with previously untreated mantle cell lymphoma|Venetoclax dose escalation for Cycles 1-4. If Complete response (CR) at Cycle 4, continue with cycles 5-12 at fixed venetoclax 400mg dose. If partial response (PR) at Cycle 4, continue with cycles 5-8 at fixed venetoclax 800mg dose. If CR at Cycle 8 after PR, continue with cycles 9-12 at fixed venetoclax 800mg dose. If continued PR at Cycle 8, reduce venetoclax to 400mg and add bendamustine 90 mg/m2.
9899524|NCT05025332|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
9899525|NCT05025241|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
9899526|NCT05024552|Experimental|Dose Escalation Arm|"Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy. The induction and reinduction dose of Vyxeos is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion.~Dose level 1: Vyxeos + 120 mg Gilertinib~In the event of a dose-limiting toxicity (DLT) at the initial dose level, a dose level minus (-) 1 is permitted Dose Level -1: Vyxeos + 80 mg Gilertinib"
9899527|NCT05024552|Experimental|Dose Expansion Arm|Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy in the dose determined in the dose escalation arm.
9899528|NCT05023083||diseased individuals|post CABG patients will be included in the study to fill the tool
9899529|NCT05023083||healthy individuals|20 healthy individual will be included to solve questionnaire
9899530|NCT05022849|Experimental|Part 1: Dose Escalation|Participants will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by JNJ-75229414 IV infusion escalated sequentially with a targeted dose consistent with the dose required by the cohort being enrolled to determine recommended Phase 2 dose (RP2D) regimen(s). Additional, intermediate dose levels may be implemented based on the review of all available data including, but not limited to, safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) by the study evaluation team (SET). Participants may receive bridging therapy (anti-androgen receptor agents [example, abiraterone, enzalutamide] and radiotherapy, or chemotherapy [example, docetaxel]) if clinically indicated to maintain disease stability.
9899531|NCT05022849|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-75229414 for each RP2D regimen determined in Part 1.
9899532|NCT05021835|Experimental|ziltivekimab 15 mg|Participants will receive ziltivekimab 15 mg for up to 4 years.
9899533|NCT05021835|Placebo Comparator|Placebo (ziltivekimab)|Participants will receive placebo (ziltivekimab) for up to 4 years.
9899534|NCT05021471|Experimental|Group A|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
9899535|NCT05021471|Active Comparator|Group B|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
9899536|NCT05021458|Experimental|Group A|Ten patients will be treated with Gong's mobilization.
9899537|NCT05021458|Active Comparator|Group B|Ten patients will be treated with SNAGs
9899538|NCT05021133|Other|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.
9899539|NCT05021107|Experimental|Group A|Fascial Distortion Model with neck isometrics
9899540|NCT05021107|Active Comparator|Group B|Fascial Distortion Model with neck isometrics
9899541|NCT05021003|Experimental|Group A|: Core stabilization training with pressure biofeedback unit
9899542|NCT05021003|Active Comparator|Group B|: Core stabilization training without pressure biofeedback unit
9899543|NCT05018416|Experimental|2 REACT® injections|Cohort 1 subjects will receive 2 REACT® injections in the biopsied and non-biopsied contralateral kidneys 3 months apart (+60 days).
9899544|NCT05018416|Experimental|1 REACT® Injection|Cohort 2 subjects will receive 1 REACT® injection into the biopsied kidney and if a pre-defined trigger is met, will undergo a second REACT® injection into the contralateral kidney.
9899545|NCT05017805|Experimental|3 doses of vaccine|Covid-19 vaccination on day 0, day 25±3, and 6 months after the second dose , respectively，and follow up one and half a year
9899546|NCT05017805|Experimental|1 dose of the third vaccination|One dose of COVID-19 vaccine and 1 year of follow-up
9899547|NCT05016596|Placebo Comparator|placebo|Acacia gum
9899548|NCT05016596|Experimental|turmeric|Turmeric supplement
9899549|NCT05016245|Experimental|TheraSphere™ Yttrium-90 Glass Microspheres|
9899550|NCT05016245|Active Comparator|conventional Transarterial Chemoembolization(cTACE)|
9899551|NCT05014360|Experimental|JNJ-64251330|Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
9899552|NCT05014204|Experimental|Interventional|All eligible patients will receive the endoscopic Endogenex procedure.
9899553|NCT05013437|Experimental|Evomela (Melphalan)|Participants will receive Evomela 16 mg/m2 on day 1 of the study only. Evomela will be given as IV infusion over 30 minutes after administration of 500 cc normal saline as pre-hydration and pre-medications Prochlorperazine, Acetaminophen, and Diphenhydramine.
9899554|NCT05012124|Experimental|Arm I (t-CoCM)|Patients use the t-CoCM digital app platform and clinic care managers use the t-CoCM web-based registry platform to support delivery of collaborative care. Patient's complete surveys at baseline, 3, 6 and 9 months. Some patients also participate in an interview about their user experience with the t-CoCM digital platform. Care managers also participate in interviews regarding their experience with CoCM and the newly developed web-based platform.
9899555|NCT05012124|Active Comparator|Arm II (u-CoCM)|Patients receive usual care and clinic care managers deliver usual CoCM. Patients complete surveys at baseline, 3, 6 and 9 months.
9899556|NCT05009862|Placebo Comparator|Control|Participants will receive 81mg daily of aspirin + placebo for 30 days.
9899557|NCT05009862|Experimental|Intervention|Participants will receive 81mg of aspirin + rivaroxaban 2.5mg twice daily for 30 days.
9899558|NCT05009264||OMT Group|This group will receive OMT muscle energy as treatment for myofascial pain syndrome
9899559|NCT05009264||Injection Group|This group will receive lidocaine injections for myofascial pain syndrome
10212602|NCT05194618|Experimental|Valerian/Lavender arm|Participants in this arm will receive actives products : 420 mg per tablet of Valerian root extract and 40 mg per tablet of essential oil of Lavender
9899561|NCT05007782|Experimental|Phase 1a, Part A - GS-1811 Dose Escalation|Participants will receive escalating dose levels of GS-1811 for up to 12 months to determine maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of GS-1811.
9899562|NCT05007782|Experimental|Phase 1a, Part B - Mandatory Paired Tumor Biopsy|Participants with select tumor types will receive GS-1811 at the dose deemed safe in Part A for up to 12 months.
9899563|NCT05007782|Experimental|Phase 1b, Part C: GS-1811 + Pembrolizumab|Participants will receive GS-1811 at dose levels deemed safe in Part A in combination with pembrolizumab for up to 24 months.
9899564|NCT05007236|Experimental|RP7214 + Standard of care (SOC)|
9899565|NCT05007236|Placebo Comparator|Placebo + Standard of care (SOC)|
9899566|NCT05004935|Experimental|beetroot juice|single intake of beetroot juice containing 800mg nitrates
9899567|NCT05004935|Active Comparator|nitrates|single intake of 800mg nitrates (NaNO3)
9899568|NCT05004181|Experimental|Part A - Cohort 1: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
9899569|NCT05004181|Experimental|Part A - Cohort 2: 18 to 55 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
9899570|NCT05004181|Experimental|Part A - Cohort 3: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7) of 30 µg.
9899571|NCT05004181|Experimental|Part A - Cohort 4: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
9899572|NCT05004181|Experimental|Part A - Cohort 5: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 of 30 µg.
9899573|NCT05004181|Experimental|Part A - Cohort 6: 18 to 55 years of age|Participants will receive 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
9899574|NCT05004181|Experimental|Part B - Cohort 1: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
9899575|NCT05004181|Experimental|Part B - Cohort 4: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
9899576|NCT05004181|Experimental|Part B - Cohort 6: 18 to 85 years of age|Participants will receive 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
9899577|NCT05004181|Experimental|Part C - Cohort 7: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.529) of 30 µg.
9899578|NCT05004181|Experimental|Part C - Cohort 8: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 of 30 µg.
9899579|NCT05004181|Other|Part C - Cohort 9: 18 to 85 years of age|Participants will receive no vaccination within 3 months after Visit 1.
9899580|NCT05003271|Experimental|Small group zoom meeting|Group one: will be asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants e.g. questions, perceptions, etc.).
9899581|NCT05003271|Experimental|YouTube pre-recorded video|Group two: will be asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
9899582|NCT05002088||Primary Analysis Population|The primary analysis population will include patients who have signed an Informed Consent Form, and at minimum, the Portico delivery system entered his/her vasculature for an attempted Portico ViV implant. Patients must have met the sizing requirements of the PorticoTM transthoracic aortic valve sizing specification (≥19 mm and ≤27 mm).
10212603|NCT05194618|Placebo Comparator|Placebo arm|Participants in this arm will receive placebo (no active product)
10212604|NCT05192239|Placebo Comparator|Placebo|Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout.
10212605|NCT05192239|Active Comparator|10 mg THC|Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout.
10212606|NCT05192187|Experimental|LBP|This group will be asked to complete self-reported questionnaires on a single occasion (cross-sectional)
10212607|NCT05191290|Active Comparator|heparin anticoagulation|standard heparin anticoagulation during plasmapheresis
9899583|NCT05002088||Exploratory Registry Arm|The exploratory registry arm will collect data for patients that were treated for a failed surgical bioprosthetic aortic valve true inner diameter size of <19 mm or >27 mm.
9899584|NCT05000437|Experimental|High Intensity Interval Training|single arm intervention, with high intensity interval training
9899585|NCT04994717|Experimental|Safety Run-in: Blinatumomab alternating with low-intensity chemotherapy|"The safety run-in will be performed prior to initiating the phase 3 randomized part of the study. This safety run-in is to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.~The safety run-in also evaluates a shorter dose step interval from (4 days instead of 7 days) and a 1-week (instead of 2-week) drug free interval between blinatumomab cycles. Blinatumomab will be infused at a lower dose for 4 days and increase to a higher dose on Day 5 of the infusion for the remainder of the infusion."
9899586|NCT04994717|Experimental|Phase 3: Blinatumomab alternating with low-intensity chemotherapy|Participants will receive blinatumomab alternating with low-intensity chemotherapy.
9899587|NCT04994717|Active Comparator|Phase 3: Standard of care (SOC) chemotherapy|Participants will receive 1 of 2 SOC chemotherapy regimens (GMALL or HyperCVAD) per investigator's choice.
9899588|NCT04994535|Experimental|BOTOX|BOTOX will be injected into the platysma muscle on Day 1
9899589|NCT04994535|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1
9899590|NCT04993755|Experimental|TPN-101, 400 mg/day|
9899591|NCT04993755|Placebo Comparator|Placebo|
9899592|NCT04991740|Experimental|Part 1: Dose Escalation|Participants with renal cell carcinoma (RCC), ovarian cancer, colorectal cancer (CRC), and other tumor types with sponsor approval will receive JNJ-78306358. The dose will be escalated sequentially based on the decisions of the study evaluation team until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
9899593|NCT04991740|Experimental|Part 2: Dose Expansion|Participants with RCC, ovarian cancer, CRC and other types of tumors will receive JNJ-78306358 at the RP2D regimen(s) determined in Part 1.
9899594|NCT04990492|Experimental|Paper Baseline|Half of the participants will complete the GAD 7 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 on the Mirror device equipped with Amazon Alexa.
9899595|NCT04990492|Experimental|Alexa Baseline|The other half of the participants will complete the GAD 7 on the Mirror device equipped with Amazon in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 in the traditional paper format.
9899596|NCT04989218|Experimental|Novel combination of chemotherapy and immunotherapy|"This study has one arm. All enrolled patients will receive a combination of a platinum based chemotherapy regimen (gemcitabine and cisplatin) and a combination of two immune check point inhibitors, anti- CTLA4 (Tremelimumab) and anti PDL-1 (durvalumab).~Gemcitabine will be administered (gemzar) intravenously, 1000mg/m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles. Cisplatin (Platinol) will be administered intravenously, 25mg//m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles.~Tremelimumab will be administered intravenously, 300mg flat dose, on Day 1 of cycle 1 only. Durvalumab will be administered intravenously 1500mg on Day 1 of a 21 day cycle for 4 cycles."
9899597|NCT04986904|Experimental|SHUTi (Sleep Healthy Using the Internet)|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
9899598|NCT04985916|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
9899599|NCT04985916|Experimental|ET-01, Dose 1|Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline
9899600|NCT04985916|Experimental|ET-01, Dose 2|Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline
9899601|NCT04985643||Participants With MM|Participants diagnosed with MM (complete response [CR], very good partial response [VGPR] and partial response [PR]) and who have received one prior first line treatment within 3 months preceding the enrollment, will be observed retrospectively and medical data will be monitored and collected prospectively every 3 months until the second biochemical and symptomatic relapse is identified.
9899602|NCT04984798|Experimental|Vitamin E Dose-Escalation|Subjects will take an oral Vitamin E (dl-alpha-tocopherol) supplement twice daily with a fat-containing meal for 6-9 weeks. The dose will be increased every 2-3 weeks over the course of the study (initial dose 600 IU twice daily, next dose 1,200 IU twice daily, final dose 2,400 IU twice daily). Formulations include softgel capsules in 200, 400, and 1,000 IU doses.
9992710|NCT01465074|Placebo Comparator|Regular Mint Gum|Regular, taste-, texture- and color matched with the Nicotine Gum will be ingested once on one of the two testing days, 30 min before plasticity induction.
9992711|NCT01465087|Experimental|Diagnosis|Diagnosis, breath and confounding factor
9992712|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
9992713|NCT01465113|Experimental|high grade dysplasia|Barrett's esophagus with high grade dysplasia
9992714|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm:Vitamin D/Metformin Subarm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
9992715|NCT01465139|Experimental|CDX-301|CDX-301 (rhuFlt3L), administered to healthy patients.
9992716|NCT01465152|Experimental|Met|
9992717|NCT01465152|Active Comparator|Rep|
9992718|NCT01465152|Active Comparator|Met+Rep|
9992719|NCT01465165||Depressed, unmedicated|Participants with MDD who are not treated with any antidepressant medication
9992720|NCT01465165||Depressed, on antidepressant|Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
9992721|NCT01465165||Healthy control|Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants
9992722|NCT01465204|No Intervention|Control|
9992723|NCT01465204|Experimental|Handwashing Intervention|scaling up handwashing with soap
9992724|NCT01465204|Experimental|Sanitation Intervention|total sanitation and sanitation marketing
9992725|NCT01465204|Experimental|Combined|combined scaling up handwashing with soap and total sanitation and sanitation marketing interventions
9992726|NCT01465217|Experimental|text message medication reminders|
9992727|NCT01465217|No Intervention|control|
9992728|NCT01465243|Experimental|Icotinib|This is a single arm study.
9992729|NCT01465256|No Intervention|Aspirin holding group|Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy. The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
9992730|NCT01465256|Experimental|Aspirin continuing group|Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
9992731|NCT01465269|Experimental|GIST Intervention|
9992732|NCT01465269|Active Comparator|Alternative Intervention|
9992733|NCT01465282|Experimental|0.05% (w/w) CT327 ointment|0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
9992734|NCT01465282|Experimental|0.1% (w/w) CT327 ointment|0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
9992735|NCT01465282|Experimental|0.5% (w/w) CT327 ointment|0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
9992736|NCT01465282|Placebo Comparator|Placebo ointment|Placebo ointment
9992737|NCT01465295|Experimental|HemiBridge|Patients meeting eligibility criteria will be treated with the HemiBridge System.
9992738|NCT01465308|Experimental|receiving Honey|The patients will receive honey mouthwash rinses
9992739|NCT01465308|Active Comparator|Saline mouthwash|The patients in this group will receive saline rinses
9992740|NCT01465360||Study patients|Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
9992741|NCT01465373|Active Comparator|Progesterone in Oil|"Donor egg recipients will begin progesterone 50 mg IM injection starting the day after donor egg fertilization, and continue daily until pregnancy results can be determined.~If pregnant, donor egg recipient will continue progesterone 50 mg IM injections daily until approximately 9 weeks of pregnancy."
9992742|NCT01465373|Active Comparator|Endometrin|"Donor egg recipients will begin Endometrin 100 mg per vagina three times daily starting the day after donor egg fertilization and continue until pregnancy result can be determined.~If pregnant, donor egg recipients will continue Endometrin 100 mg TID until approximately 9 weeks of pregnancy."
9992743|NCT01465399|Experimental|PRGF-Endoret|
9992744|NCT01465399|Active Comparator|Conventional treatment|
9992745|NCT01465425||E3/E4 Case Group|The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules.
9992746|NCT01465425||Pulmonary Nodules Case Group|The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules.
9992747|NCT01465425||E1 Control Group|The E1 Control Group will be drawn from the 866 E1 ECF cases from ACRIN 6664 to create a cohort of 260 E1 ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible.
9992748|NCT01465438|Experimental|Adalimumab|Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
9992749|NCT01465451|Active Comparator|ARM A- surgery alone|all cases will receive standard surgical procedures of curative resection for colorectal cancer, without intra-operative chemotherapy.
9998233|NCT01516333|Experimental|Diet 4|Low GI, Low Carb, Low GL
9992750|NCT01465451|Experimental|ARM B surgery plus chemotherapy|all cases will receive standard surgical procedures described as arm A. In addition, all cases will receive 5-FU chemotherapy during operation.
9992751|NCT01465477|Experimental|Fibromyalgia arm|Patients fulfilling ACR 1990 Criteria for classification of Fibromyalgia, receiving the vaccination.
9992752|NCT01465477|Experimental|Heathy controls|Healthy controls receiving Influenza vaccination
9992753|NCT01465490|Experimental|Monitoring and Feedback Intervention|
9992754|NCT01465490|No Intervention|Treatment as usual|
9992755|NCT01465503|Placebo Comparator|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparin (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
9992756|NCT01465503|Active Comparator|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
9992757|NCT01465516||Hispanic, HCV genotype 1|Historical group will be a continuous group of Hispanic patients with genotype 1 who were naive to treatment and completed or initiated 48 weeks of pegylated interferon and ribavirin. Patients, who discontinued the treatment due to side effects, adherence issues, or treatment failure, will be included and analyzed based on intention to treat analysis. All patients will be stratified according to their SVR, relapse and no response rate. RVR, EVR, and ETR will be also collated and compared to the study group.
9992758|NCT01465529|Experimental|Active|
9992759|NCT01465529|Placebo Comparator|Placebo|
9992760|NCT01465542||Oral NAC|Patients receiving oral NAC treatment after an acute acetaminophen ingestion.
9517566|NCT03305263|Placebo Comparator|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
9992761|NCT01465542||IV NAC|Patients receiving IV NAC after an acute Acetaminophen ingestion.
9992762|NCT01465555|Experimental|Clinical Alert|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
9992763|NCT01465555|No Intervention|Treatment As Usual|Counselors in this condition will work with the original RecoveryTrack which has not been altered to provide automated Clinical Alerts for High Risk patients. Supervisors will receive no automated help in identifying these clients in the counselors' caseloads. The Clinical Alert feature will not be discussed in the training these counselors receive. Rather, the counselors will receive an attention-control training, a one-day training on assessment and treatment planning, with monthly tips and reminders for six months.
9992764|NCT01465568|Active Comparator|Denosumab|denosumab
9992765|NCT01465568|Active Comparator|bisphosphonates|continuation of bisphosphonates
9992766|NCT01465581||Neurogenic incontinence|The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.
9992767|NCT01465594|Active Comparator|transurethral catheter after EERPE/ RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
9992768|NCT01465594|Active Comparator|suprapubic catheter after EERPE /RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
9992769|NCT01465607|Experimental|Theory-based counseling (Mujer Segura)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
9992770|NCT01465607|Active Comparator|CENSIDA counseling program (didactic)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
9992771|NCT01465620|Experimental|Coaching|active hygienic-dietetic coaching
9992772|NCT01465620|Active Comparator|control|reference hygienic-dietetic recommendations
9517797|NCT03302871|Experimental|İntensive Therapy Group|Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT
9992773|NCT01465633|Active Comparator|with iodine|
9992774|NCT01465633|Experimental|without iodine|
9992775|NCT01465646|Active Comparator|with idodine|
9992776|NCT01465646|Experimental|without iodine|
9992777|NCT01465672||neurosurgical patients|Patients undergoing transphenoidal pituitary adenoma resection and patients with transcranial surgery of tumors close to the pituitary gland and hypothalamus.
9992778|NCT01465685|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9992779|NCT01465698|Experimental|Exercise|
9992780|NCT01465698|Experimental|Counseling|
9992781|NCT01465698|Experimental|Exercise and counseling|
9992782|NCT01465698|Other|Control group|Participants in the control group only participate in study measurements.
9992783|NCT01465711||Control|Admission to the Intensive Care Unit (ICU) after abdominal surgery without suspicion / evidence of peritonitis.
9899603|NCT04983680|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training to treat emotional problems.
9899604|NCT04982471||First relapsed/refractory diffuse large B-cell lymphoma|First relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants who have initiated second-line (2L) systemic treatment within 60 days prior to enrollment (date of informed consent)
9899605|NCT04982471||Second relapsed/refractory diffuse large B-cell lymphoma|Second relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants who have initiated third-line (3L) systemic treatment within 60 days prior to enrollment
9899606|NCT04982471||First relapsed/refractory follicular lymphoma|First relapsed/refractory follicular lymphoma (FL) participants who have initiated 2L systemic treatment within 60 days prior to enrollment
9899607|NCT04982471||First relapsed/refractory primary mediastinal B-cell lymphoma|First relapsed/refractory primary mediastinal B-cell lymphoma (PMBCL) participants who initiated 2L systemic treatment within 60 days prior to enrollment
9933264|NCT00958451|Active Comparator|Ergocalciferol|Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
9935723|NCT03284957|Experimental|Amcenestrant/Palbociclib: Arm #2 Part C Dose Escalation, Part D Dose Expansion|"Part C: Amcenestrant will be administered in combination with palbociclib: amcenestrant starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of amcenestrant (with standard palbociclib dose) to subsequent participants will be based on occurrence of DLTs at initial and subsequent doses, until MAD of amcenestrant is reached. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle).~Part D: Based on the results in Part C, participants will be administered either: 1) a determined amcenestrant dose (RD) with standard dose of palbociclib in combination therapy, or 2) one of two randomized dose levels of amcenestrant with standard dose of palbociclib in combination therapy. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle)."
9935724|NCT03284957|Experimental|Amcenestrant/Alpelisib: Arm #3 Part F Safety Run-In, Part G Dose Expansion|"Part F: Amcenestrant will be administered in combination with alpelisib at a fixed standard dose. Additional dose levels of amcenestrant with alpelisib could be explored if needed based on the safety and PK results. Lower dose of alpelisib could be explored based on the PK results and safety profile from the initial combination administration. Both amcenestrant and alpelisib will be administered in a 28-day cycle.~Part G: Based on the conclusion in Part F, participants will be administered the determined RD of amcenestrant and alpelisib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
9935725|NCT03284957|Experimental|Amcenestrant/Everolimus: Arm #4 Part H Dose Escalation, Part I Dose Expansion|"Part H: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of everolimus. Additional dose levels of amcenestrant with everolimus could be explored if needed based on the safety and PK results. Both amcenestrant and everolimus will be administered in a 28-day cycle.~Part I: Based on the conclusion in Part H, participants will be administered the determined RD of amcenestrant and RD of everolimus given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
9935726|NCT03284957|Experimental|Amcenestrant/Abemaciclib: Arm #5 Part J Dose Escalation, Part K Dose Expansion|"Part J: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of abemaciclib. Additional dose levels of amcenestrant with abemaciclib could be explored if needed based on the safety and PK results. Both amcenestrant and abemaciclib will be administered in a 28-day cycle.~Part K: Based on the conclusion in Part J, participants will be administered the determined RD of amcenestrant and RD of abemaciclib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
9935727|NCT03284502|Experimental|Stage 1|Dose-escalation
9935728|NCT03284502|Experimental|Stage 1b|Dose-escalation
9935729|NCT03284502|Experimental|Stage 2 (Cohort I and II)|Dose-expansion
9935730|NCT03284502|Experimental|Stage 2 (Cohort III)|Dose-expansion
9935731|NCT03282799|Active Comparator|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
9935732|NCT03282799|Experimental|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
9935733|NCT03280030|Experimental|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
9935734|NCT03280030|Placebo Comparator|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
9935735|NCT03278912||IBD|-Patients with IBD without a diagnosed PIDD.-First- or second-degree relatives of patients with a PIDD of interest who do not have a PIDD themselves, but have diagnosed or suspected IBD.
9935736|NCT03278912||Non-PIDD/non-IBD (healthy volunteers)|healthy volunteers
9935737|NCT03278912||PIDD|CGD cohort; IPEX syndrome cohort; CTLA4 haploinsufficiency cohort; LRBA deficiency and hypomorphic RAG deficiency cohorts
9935738|NCT03269578||1|Patients with advanced, refractory cancers being treated on NCI/DTC studies
9935739|NCT03267277|Experimental|Treatment|Patient will be assessed for 10 weeks off treatment and then will receive 10 weeks of treatment. They will return at weeks 24 and 52 for safety and sustainability of efficacy assessments.
9935740|NCT03258593|Experimental|1/ Run In|Durvalumab + Vicineum, escalating doses. Up to 2 dose levels will be evaluated in the first 6 - 12 subjects
9935741|NCT03258593|Experimental|2/ Expansion|Durvalumab + Vicineum, at the MTD. Up to 24 subjects
9992784|NCT01465711||Peritonitis|Admission to the Intensive Care Unit (ICU) after abdominal surgery with suspicion / evidence of peritonitis
9992785|NCT01465724|Experimental|Renal denervation|
9992786|NCT01465737||Patients with uterine cancer|All patients diagnosed with uterine cancer in Taiwan between 1979-2008
9992787|NCT01465750||Ovarian Cancer|
9992788|NCT01465776|Experimental|Treatment (chemoprevention)|
9992789|NCT01465815|Experimental|Treatment (adjuvant enzyme inhibitor and radiation therapy)|"Optional non-therapeutic (biomarker) portion: Patients are randomized to 1 of 3 treatment arms.~Arm A: Patients receive erlotinib hydrochloride PO QD and linsitinib PO BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
9992790|NCT01465815|Experimental|Erlotinib and Placebo (Sugar Pill)|"Arm B: Patients receive erlotinib hydrochloride PO QD and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
9992791|NCT01465815|Experimental|OSI-906 and Placebo (Sugar Pill)|"Arm C: Patients receive linsitinib PO BID and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
9992792|NCT01465828|Active Comparator|high clopidogrel dose|Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
9992793|NCT01465828|No Intervention|prasugrel standard dose|Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.
9992794|NCT01465854||LCINS|Never smokers with newly diagnosed lung cancer
9992795|NCT01465867|Experimental|Selenium|
9992796|NCT01465867|Placebo Comparator|Sugar Pill Placebo|
9992797|NCT01465867|Experimental|Selenium + L-Thyroxine (LT4)|
9992798|NCT01465867|Experimental|Sugar Pill Placebo + L-Thyroxine (LT4)|
9992799|NCT01465880|No Intervention|Part B. Healthy Caucasian adult non-smokers|Non-smokers
9992800|NCT01465880|Experimental|Part A.Healthy Caucasian adult smokers|No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
9992801|NCT01465893|Active Comparator|vitamin D|vitamin d 50000/w
9992802|NCT01465893|Sham Comparator|control|follow up
9992803|NCT01465906|Experimental|tulobuterol combined with tiotropium bromide|
9992804|NCT01465906|Active Comparator|Tiotropium bromide|
9992805|NCT01465919|Experimental|mirtazapine|mirtazapine
9992806|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be given by a specialized psychiatrist.
9992807|NCT01465932|Active Comparator|No proprioception|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, in addition to cryotherapy reduction of pain.
9992808|NCT01465932|Experimental|Proprioceptive exercises|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, proprioception exercises to improve motor control, besides cryotherapy for reduction of pain.
9992809|NCT01465945|Other|Rectal Defect Sutured|The subject will have his/her defect sutured after the rectal tumors have been removed.
9992810|NCT01465945|Other|Rectal Defect Unsutured|The defect will be left open and let naturally close after the rectal tumor has been removed by TEM.
9992811|NCT01465971||not acclimatized|no stay in an altitude above 2500 m within the last 3 Months
9992812|NCT01465971||acclimatized|stay above 2500 m with the last 14 days
9992813|NCT01465984|Experimental|IV Paracetamol|
9992814|NCT01465984|Active Comparator|IV Morphine Sulfate|
9992815|NCT01466010||osteoid osteoma|patients with osteoid osteoma at any location
9992816|NCT01466036|Experimental|Metastatic or Unresectable PNET|35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
9992817|NCT01466036|Experimental|Metastatic or Unresectable Carcinoid|35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib
9992818|NCT01466101|Active Comparator|Pregabalin administration|Administration of pregabalin
9899608|NCT04978493|Experimental|BI 706321 + ustekinumab|
9899609|NCT04978493|Placebo Comparator|Placebo + ustekinumab|
9899610|NCT04978454|Experimental|Cohort 1A|10^4 TCID50of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 80% of subjects meet the case definition for influenza in Cohort 1A, the dose will escalate to include Cohort 2A. N = 13
10212608|NCT05191290|Experimental|citrate anticoagulation|sodium citrate anticoagulation during plasmapheresis
10212609|NCT05189028|Experimental|Locally advanced bulk cervical cancer neoadjuvant chemotherapy group(NACT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:A Point dose 6Gy*4-6F~Drug: gemcitabine plus cisplatin,cisplatin Neoadjuvant chemotherapy:gemcitabine and cisplatin (GP) regimen*2 cycles Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
9899611|NCT04978454|Experimental|Cohort 1B|10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A and 1B meet the case definition for influenza, proceed to Cohort 1C. Cumulatively, if fewer than 80% of subjects in Cohorts 1A and 1B meet the case definition for influenza, the dose will escalate to include Cohort 2A. N = 13
9899612|NCT04978454|Experimental|Cohort 1C|10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and sham sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 80% or more of the subjects in Cohorts 1A, 1B, and 1C combined meet the case definition for influenza then the optimal dose of 104 TCID50 will be selected. Cumulatively, if fewer than 80% of subjects in Cohorts 1A, 1B, and 1C meet the case definition for influenza the dose will escalate to include Cohort 2A. N = 13
9899613|NCT04978454|Experimental|Cohort 2A|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more subjects in Cohort 2A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 70% of subjects meet the case definition for influenza in Cohort 2A, the dose will escalate to include Cohort 3A. N = 13
9899614|NCT04978454|Experimental|Cohort 2B|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1.If 70% or more subjects in Cohort 2A and 2B meet the case definition for influenza, proceed to Cohort 2C. Cumulatively, if fewer than 70% of subjects in Cohorts 2A and 2B meet the case definition for influenza, the dose will escalate to include Cohort 3A N = 13
9899615|NCT04978454|Experimental|Cohort 2C|10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If 70% or more of the subjects in Cohorts 2A, 2B, and 2C combined meet the case definition for influenza then the optimal dose of 10^4 TCID50 will be selected. Cumulatively, if fewer than 70% of subjects in Cohorts 2A, 2B, and 2C meet the case definition for influenza the dose will escalate to include Cohort 3A. N = 13
9899616|NCT04978454|Experimental|Cohort 3A|10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. If no safety threshold is met (halting conditions) proceed to Cohort 3B. N = 18
9933265|NCT05352516|Experimental|Treatment group|60 mg, once every 6 months
9933266|NCT05352516|Active Comparator|Control group|60 mg, once every 6 months
9899617|NCT04978454|Experimental|Cohort 3B|10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (0.5 mL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (0.5 mL per nostril) (n=1) administered intranasally on Day 1. N = 18
9899618|NCT04977453|Experimental|GI-101|"Dose escalation: GI-101, multiple ascending doses~Dose expansion:"
9899619|NCT04977453|Experimental|GI-101 + Pembrolizumab|"Dose escalation: GI-101, multiple ascending doses~Dose expansion:"
9899620|NCT04977453|Experimental|GI-101 + Lenvatinib|"Dose optimization:~Dose expansion:"
9899621|NCT04977453|Experimental|GI-101 + Local Radiotherapy|"Dose optimization:~Dose expansion:"
9899622|NCT04974840|Experimental|Treadmill training combined with thera-band|Participants will receive walking training on treadmill with thera-band at the waist. The direction of the thera-band resistance will be straight backward, backward-toward-right, and backward-toward-left. For each direction, the level of resistance and treadmill speed will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'.
9899623|NCT04974840|Active Comparator|Treadmill training alone|Participants will receive treadmill walking training at a speed that will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'. For each session, there will be three 10-min treadmill walking bouts.
9899624|NCT04973891|Experimental|Experimental: Canagliflozin/metformin group|Intervention with canagliflozin combined with metformin for three months
9899625|NCT04973891|Active Comparator|Active Comparator: Metformin group|Intervention with metformin for three months
9899626|NCT04973163|Experimental|Monotherapy Arm|Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
9899627|NCT04973163|Experimental|Combination Therapy Arm|Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C).
9899628|NCT04971785|Experimental|SEMA + CILO/FIR FDC|Participants will receive semaglutide (SEMA) 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and fixed-dose combination (FDC) of cilofexor and firsocostat (CILO/FIR 30 mg/20 mg) once daily for 72 weeks
9899629|NCT04971785|Experimental|SEMA + Placebo-To-Match (PTM) CILO/FIR|Participants will receive SEMA 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and PTM CILO/FIR administered once daily for 72 weeks
9899630|NCT04971785|Experimental|PTM SEMA + CILO/FIR FDC|PTM Semaglutide once weekly and CILO/FIR 30 mg/20 mg FDC administered once daily for 72 weeks
9899631|NCT04971785|Placebo Comparator|PTM SEMA + PTM CILO/FIR|PTM Semaglutide once weekly and PTM CILO/FIR once daily for 72 weeks
9899632|NCT04971564||Case|Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage
9899633|NCT04971564||Control|Patients without cerebral hypoxia
9899634|NCT04970290|Experimental|Definisse threads free floating and Definisse threads double needle|"Definisse™ free floating threads will be used with the Soft Tissue Reshaping-2 (STR-2) Technique, to reposition the tissue of the malar area.~It is to be used for the face and neck. The thread presents a central area, free of barbs, and two distal areas with barbs. The 12 cm thread will be used in this study.~Definisse™ double needle thread (12 cm) that is equipped with barbs in the intermediate section, while the side and the central sections are smooth. The thread ends with two straight cut edge needles 10 cm long Definisse™ double needle threads will be used with the Jawline Reshaping (JR) Technique, to reshape the frame of the jawline, lifting the lower face. This is to be used for the face and the neck. The thread ends with two straight cut edge needles The 12 cm thread will be used in this study."
9899635|NCT04970277|Experimental|drinking water group|Patients in this group drink colorless water after capsule ingestion.
9899636|NCT04970277|Other|control group|Patients in this group don't drink colorless water after capsule ingestion.
9899637|NCT04968847|Experimental|FemaSeed|Investigational device and procedure
9899638|NCT04967664|Experimental|Qutenza (capsaicin) 8% topical system|Qutenza (capsaicin 8% topical system, containing capsaicin 179 mg or capsaicin 640 µg/cm2 of topical system)
9899639|NCT04967664|Active Comparator|Low-dose capsaicin control|capsaicin 0.04% topical system
9899640|NCT04967313|Experimental|Behavioral Change Techniques to Increase Walking|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps five days per week. Participants will be enrolled for a baseline period lasting two weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will receive daily text messages of behavior change techniques (BCTs) for eight weeks. The four BCTs utilized in this study are: goal setting, action planning, self-monitoring of behavior, and feedback on behavior. Each BCT will be delivered to participants daily for a two-week block. Four blocks (one BCT per block) will be delivered to the participant. The order in which the BCT interventions are presented to participants will be randomized by the study statistician. The goal of the BCT text messages will be to encourage walking behavior.
9899641|NCT04966546|Experimental|Memantine|Subjects will be given memantine 10mg PO/ NG BID for 7 days
9899642|NCT04966546|Placebo Comparator|Placebo|Subjects will be given identical placebo syrup PO/NG BID for 7 days
9899643|NCT04965597|Experimental|Treatment (conditioning regimen; transplant; GVHD prophylaxis)|"CONDITIONING REGIMEN: Patients receive treosulfan IV over 120 minutes on days -6 to -4, fludarabine phosphate IV over 60 minutes on days -6 to -2, and rATG IV over 4-6 hours on days -4 to -2.~TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -2 and a taper beginning on day 180. Patients may also receive tacrolimus PO. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
9517798|NCT03302871|Active Comparator|Control Group|Children who received Botulinum toxin type A to plegic upper limb would continue their usual care
9899644|NCT04961944||Hypersensitivity pneumonitis|see elegibility criteria
9899645|NCT04958642|Experimental|Adrabetadex|All participants receive their prescribed dose of adrabetadex. Dose is allowed to be adjusted down or up to a maximum of 900 mg, at the investigator's discretion.
9899646|NCT04955691|Experimental|low carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the low carbohydrate group will limit carbohydrate intake to 15% of total daily calories.
9899647|NCT04955691|Active Comparator|standard carbohydrate diet|In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the standard carbohydrate group will follow an ad libitum diet with standard carbohydrate intake.
9899648|NCT04954742|Other|Riociguat|Riociguat (1 mg, 1.5 mg, 2 mg and 2.5 mg three times daily) starting at 1.0 mg three times daily at the beginning of the study. Dosage will be individually up-titrated up to a maximum dosage of 2.5 mg three times daily after 8 weeks. Study medication will be provided orally with or without food. Tablets should be taken three times daily approximately 6 to 8 hours apart.
9899649|NCT04954027||Patients with a use-related disorder weaning for a substance|
9899650|NCT04952753|Experimental|Safety run-in: NIS793+SOC (Investigational arm 1)|In the safety run-in part for investigational arm 1, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of the NIS793
9899651|NCT04952753|Experimental|Expansion: NIS793+SOC (Investigational arm 1)|In the expansion part, participants in the investigational arm 1 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in
9899652|NCT04952753|Active Comparator|Expansion: SOC (control arm)|In the expansion part, participants in the control arm will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)
9899653|NCT04952753|Experimental|Safety run-in: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the safety run-in part for investigational arm 2, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793 and tislelizumab to confirm the RP2D of NIS793.
9899654|NCT04952753|Experimental|Expansion: NIS793+Tislelizumab+SOC (Investigational arm 2)|In the expansion part, participants in the investigational arm 2 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FLOFOX6 or FOLFIRI) with NIS793 and tislelizumab at the RP2D for NIS793 defined in the safety run-in
9899655|NCT04952402|Experimental|mRNA-based COVID-19 vaccine|To be administered intramuscularly (IM) at Day 0 and Day 28.
9899656|NCT04951362|Active Comparator|intranasal Ivermectin group|49 pateints with anosmia received ivermectin nanosuspension nasal spray
9899657|NCT04951362|Placebo Comparator|saline nasal spray|47 pateints with anosmia received saline nasal spray
9899658|NCT04950166|Experimental|Fluorescence imaging with pegsitacianine|1 mg/kg of pegsitacianine administered IV 24-72 hours prior to surgery.
9899659|NCT04949256|Experimental|Pembrolizumab + Lenvatinib + Chemotherapy|Participants receive pembrolizumab intravenously (IV) plus lenvatinib orally in combination with FP or TP in Part 1, or in combination with investigator's choice of chemotherapy with FP IV or TP IV or oxaliplatin, 5-FU and leucovorin (mFOLFOX6) IV in Part 2. Induction consists of pembrolizumab 400 mg once every 6-weeks (Q6W) for up to ~12 weeks plus lenvatinib 8 mg once daily (QD) for up to ~12 weeks plus chemotherapy with FP (cisplatin 80 mg/m^2 and 5-FU 4000 mg/m^2) or TP (paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2) once every 3 weeks (Q3W) for up to ~12 weeks or mFOLFOX6 (oxaliplatin 85 mg/m^2, 5-FU 400 mg/m^2 followed by 2400 mg/m^2, and leucovorin 400 mg/m^2 [or levoleucovorin 200 mg/m^2] once every 2 weeks [Q2W] for up to ~12 weeks). This is followed by consolidation with pembrolizumab 400 mg Q6W for up to 16 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is ~2 years) plus lenvatinib 20 mg QD until progressive disease or discontinuation.
9899660|NCT04949256|Active Comparator|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 400 mg IV Q6W for up to 18 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is ~2 years) in combination with investigator's choice of chemotherapy with FP (cisplatin 80 mg/m^2 IV Q3W for up to 6 administrations [up to ~18 weeks] and 5-FU 4000 mg/m^2 IV Q3W for up to 35 administrations [up to ~2 years]) or TP (paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 Q3W for up 6 administrations [up to ~18 weeks]) or in combination with mFOLFOX6 (oxaliplatin 85 mg/m^2, 5-FU 400 mg/m^2 followed by 2400 mg/m^2, and leucovorin 400 mg/m^2 [or levoleucovorin 200 mg/m^2] IV Q2W for up to 12 administrations [up to ~24 weeks, based on local guidance]), during Part 2.
9933267|NCT05352503|Experimental|watching video with virtual reality glasses|
9933268|NCT05352503|No Intervention|routine maintenance, no intervention|
9517567|NCT03305250|Active Comparator|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
9517568|NCT03305250|No Intervention|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
9899661|NCT04948333|Experimental|ABL001|Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
9899662|NCT04948099|Experimental|VIB1116|"Single dose of VIB1116, SC or IV administration.~Multiple doses of VIB1116, SC administration."
9899663|NCT04948099|Placebo Comparator|Placebo|"Single dose of Placebo, SC or IV administration.~Multiple doses of Placebo, SC administration."
9899664|NCT04948073|Experimental|Experimental Group|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment. DNS group's protocol will involve 5 min warm-up, 40 min DNS movements (4 different parts, each part lasts for 10 min) accompanied with breathing exercises, and 5 min cool-down. DNS exercises will include diaphragmatic breathing, Baby Rock, Rolling, Side Lying, Oblique Sit, Tripod, Kneeling, Squat, Prone, and Czech Get Up (CGU). Week one specifically will involve training and practicing basic DNS exercises. The complexity of the exercises will increase gradually by adding a new task to an already practiced task every week. An increase in the complexity of a task will help the performer to automate performance. We will use the dual-task paradigm to examine if the task is automated or not (e.g. no new task should disturb the diaphragmatic breathing).
9899665|NCT04948073|Active Comparator|Control Group|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration). All patients will also continue their usual activities and receive advices related to the daily living activites in the form of a leaflet. Participants will be asked to refrain from seeking any other types of rehabilitation treatments during the trial. The conventional physical therapy program for both groups includes: TENS therapy for the low back (15 min 3 days/week), with a frequency of 100 Hz and fixed pulse; ultrasound for 5 minutes, 1 Hz, continuous mode of application 1.5 w/cm2. The exercise programs will consist strengthening, stretching exercises for the abdominal, back, pelvic, and lower limb muscles.
9899666|NCT04943393||Individuals with PKU|Adults with early-treated PKU
9899667|NCT04943393||Individuals without PKU|Adults without PKU who are otherwise healthy
9899668|NCT04940390|Experimental|STS101|STS101 (dihydroergotamine nasal powder)
9899669|NCT04940390|Experimental|STS101 Placebo|STS101 Placebo
9899670|NCT04940052|Experimental|Dabrafenib plus trametinib|Participants will be treated with dabrafenib twice daily and trametinib once daily
9899671|NCT04940052|Placebo Comparator|Placebo dabrafenib plus placebo trametinib|Participants will receive placebo dabrafenib twice daily and placebo trametinib once daily
9899672|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
9899673|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
9899674|NCT04938817|Experimental|Coformulation Pembrolizumab/Quavonlimab + MK-4830|Participants receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS MK-4830 800 mg. Pembrolizumab/quavonlimab will be administered by intravenous (IV) infusion once every 6 weeks (Q6W) for up to 18 infusions (up to approximately 2 years) or until progressive disease or discontinuation. MK-4830 will be administered by IV infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
9899675|NCT04938817|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) administered by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 36 infusions (up to approximately 2 years) or until progressive disease or discontinuation.
9899676|NCT04936308|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
9899677|NCT04936308|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
9899678|NCT04936308|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive guselkumab SC.
9899679|NCT04934111|Experimental|LNP-nCOV saRNA-02 Vaccine arm|Participants that have evidence of previous infection with SARS-CoV-2 and those with no evidence of previous infection will all receive receive LNP-nCOV saRNA-02 Vaccine. Both groups will be given a dose of 5.0ug at 0 weeks and 4 weeks.
9899680|NCT04933851|Experimental|ACT1VATE|Participants assigned to the intervention group will be offered a psychological intervention specifically designed to address diabetes-related emotional distress.
9933269|NCT05352490||HF-group|patients with AECOPD and acute heart failure
9933270|NCT05352490||non HF-group|patients with AECOPD without acute heart failure
9933271|NCT05352477|Experimental|Balneotherapy with thermal water|Daily balneotherapy with Acquabios thermal water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
9933272|NCT05352477|Placebo Comparator|Balneotherapy with tap water|Daily balneotherapy with tap water at 33°C for 20 minutes each, for a total of 12 applications carried out over a period of 2 weeks
9933273|NCT05352464|Experimental|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
9933274|NCT05352464|Active Comparator|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.
9933275|NCT05352451|Experimental|Intervention Arm - coaching sessions|Intervention group, will be asked to complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member
9933276|NCT05352451|Active Comparator|Control Arm - interview|"Will be asked to complete the same surveys at appropriate time after meeting with the research assistant. Be asked to complete brief questionnaire about the understanding of the illness.~All individual interviews, patient and caregiver coaching, and caregiver support sessions will be audio recorded. The recorders are password protected and the audio files will be saved securely. Only authorized study team members can access the recordings to evaluate how well the answers to survey questions are logged and how well the coaching/support content is delivered by the study team member."
9933277|NCT05352438|Experimental|Manual Therapy Group|Manual Therapy combined with education and home exercises
9933278|NCT05352438|Experimental|Splint Therapy Group|Splint Therapy combined with education and home exercises
9933279|NCT05352425|Experimental|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD® device
9933280|NCT05352412|Active Comparator|Baseline Counseling As Usual|Patients randomized to the baseline counseling as usual arm will receive provision of one of 3 MAT options, prescription and referral to community providers; overdose prevention education and access to naloxone kits; harm reduction counseling (e.g safe injection practices, referral to PrEP); lab testing for HIV, HBV, HCV infection, and routine vaccinations (e.g. Hepatitis A). That includes wrap-around services modeled on the Ryan White Program, with access to social worker, case manager, and mental health counselor who follow up with patients, enroll them in insurance as eligible, and provide ongoing support. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.
9933281|NCT05352412|Active Comparator|Shared Decision Making Aid|Patients randomized to the decision aid arm will receive all of the above as well as a shared decision making aid. This will be a 10-minute tablet- or web-based intervention administered by one of our wraparound care service team members in-person or via telehealth (or possibly in person depending on pandemic procedures). IT will be a 10-minute procedure with summary of decision considerations and patient value assessment.The provider will have access to then have access to this summary in making final care decisions with the patient.
9933282|NCT05352399|Experimental|Intervention (NeuViCare AI)|An anticipated 55 participants will be part of the Intervention arm participants and will engage with NeuViCare AI, including all variations of its 5 components described further below.
9933283|NCT05352386|Other|Patients with familial hypercholesterolemia, early treated|
9933284|NCT05352386|Other|Patients without familial hypercholesterolemia, late treated|
9933285|NCT05352386|Other|Healthy individuals|
9933286|NCT05352373|Active Comparator|Rett Active Supplement|Females with clinical diagnosis of Rett syndrome treated orally daily with calcium carbonate, dose based on Dietary Reference Intake for age, for one year
9933287|NCT05352373|Placebo Comparator|Rett Placebo Supplement|Females with clinical diagnosis of Rett syndrome treated orally daily with sodium bicarbonate, dose based on equivalent weight for active supplement for age, for one year
9933288|NCT05352360|Experimental|Pilates Exercises with kinesiotaping|
9933289|NCT05352360|Experimental|Muscle energy technique with kinesiotaping|
9933290|NCT05352347|Active Comparator|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
9933291|NCT05352347|Active Comparator|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
9933292|NCT05352347|Placebo Comparator|Placebo|Normal saline (NS) 100mL bid
9933293|NCT05352334|Experimental|High Intensity Interval Training|
9933294|NCT05352334|Experimental|Aerobic Exercise|
9935742|NCT03258567|Experimental|Nivolumab (A)|Nivolumab, 3mg/kg IV every 2 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment (closed effective with activation of Amendment C)
9992819|NCT01466101|Placebo Comparator|Placebo|Administration of placebo
9992820|NCT01466114|Experimental|Group A: Estriol|Standard MS Treatment + Estriol
9992821|NCT01466114|Placebo Comparator|Group B: Placebo|Standard MS Treatment + Placebo
9992822|NCT01466140|No Intervention|Control group|Patients in the control group were asked to participate in a patient satisfaction study. They were asked to fill in a questionnaire with respect to patient satisfaction.
9992823|NCT01466140|Experimental|Use of request card|Patients in the intervention group were told that the practice was participating in a patient satisfaction study, and they were given an envelope with information about the 'doorknob phenomenon' and a request card. The envelope for the control group only consisted of information about a patient satisfaction study, without any information on the 'doorknob phenomenon', and without a request card. Both groups received the same letter with patient information about the study.
9997743|NCT01511666|Experimental|Hyperinvasive arm|Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
9997744|NCT01511666|Active Comparator|Standard arm|Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.
9997745|NCT01511679||Alcohol-naive adolescents|A general population longitudinal cohort of alcohol-naïve (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o).
9997746|NCT01511679||Treatment sample|A sample of adolescents who have a >1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan
9997747|NCT01511679||High risk sample|High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)
9997748|NCT01511692|Experimental|Lira --> placebo|
9997749|NCT01511692|Placebo Comparator|Placebo --> glim|
9997750|NCT01511692|Active Comparator|Glim --> lira|
9997751|NCT01511705|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
9997752|NCT01511705|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
9997753|NCT01511718|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
9997754|NCT01511718|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
9997755|NCT01511731|Experimental|Famotidine|Famotidine tablets 40 mg of Dr. Reddy's
9997756|NCT01511731|Active Comparator|Pepcid|Pepcid 40 mg Tablets of Merck & Co.,
9997757|NCT01511744|Experimental|Inactivated influenza split vaccine|Biological: Experimental: influenza split vaccine of 15 μg HA, one dose regime
9997758|NCT01511744|No Intervention|Blank control|
9997759|NCT01511757|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
9997760|NCT01511757|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
9997761|NCT01511770|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
9997762|NCT01511770|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
9997763|NCT01511783|Experimental|E2609|E2609 at ascending doses
9997764|NCT01511783|Placebo Comparator|Placebo|
9997765|NCT01511796|Experimental|upper limb rehabilitation for total of 6 months|upper limb rehabiliation
9997766|NCT01511822|Active Comparator|Drospirenone + Ethinyl estradiol|
9997767|NCT01511822|Experimental|Drospirenone + Ethinyl estradiol + Myo-inositol|
9997768|NCT01511822|Placebo Comparator|Placebo|
9997769|NCT01511835|Experimental|Myo-inositol powder|
9997770|NCT01511835|Experimental|Myo-inositol soft gel capsules|
9997771|NCT01511835|Placebo Comparator|Folic acid|
9997772|NCT01511848|Active Comparator|arm 1|30 Patients will be treated with combined DFP and deferasirox.
9997773|NCT01511848|Active Comparator|arm 2|Patients will be treated for 6 days with a combination of deferoxamine and DFP
9997774|NCT01511874|Experimental|ELIGRAD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
9997775|NCT01511887|Experimental|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
9997776|NCT01511887|No Intervention|No treatment|No treatment
9997777|NCT01511900|Experimental|Cohort 1: Dose level 1|Multiple dose orally: CAT-1004 Dose level 1 or placebo
9997778|NCT01511900|Experimental|Cohort 2: Dose level 2|Multiple dose orally: CAT-1004 Dose level 2 or placebo
9997779|NCT01511900|Experimental|Cohort 3: Dose level 3|Multiple dose orally: CAT-1004 Dose level 3 or placebo
9997780|NCT01511900|Experimental|Cohort 4: Dose level 4|Multiple dose orally: CAT-1004 Dose level 4 or placebo
9997781|NCT01511900|Experimental|Cohort 5: Dose level TBD|Multiple dose orally: CAT-1004 Dose level TBD or placebo
9997782|NCT01511926||1|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid arthritis (RA) or ankylosing spondylitis
9997783|NCT01511952|Active Comparator|Music intervention- SGA|Infants will be randomly assigned to receive one of three music interventions randomized for the AM or PM
9997784|NCT01511952|Active Comparator|Music Intervention- RDS|Infants will be randomly assigned to receive music-one of 3 randomized interventions in the AM or PM
9997785|NCT01511952|Active Comparator|Music Intervention- Sepsis|Infants randomly assigned to receive one of three interventions-randomized for the AM or PM
9997786|NCT01511965|Other|traitement A|Lesion 1= graft and lesion 2 = UltraViolet B
9899681|NCT04933851|Active Comparator|DSME/S (usual care)|Participants randomized to the usual care group will be offered standard diabetes self-management education and support (DSME/S).
9899682|NCT04932291|Experimental|vafidemstat 1.2mg|Vafidemstat is administered as capsules.
9899683|NCT04932291|Placebo Comparator|placebo|Placebo is administered as capsules.
9899684|NCT04931407|Experimental|Interdisciplinary complex intervention|The intervention includes patient education, physical exercise, a group-based cognitive behavioral program and individual nutritional counseling
9899685|NCT04931134|Experimental|Active stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.~Trigeminal nerve stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Active stimulation will occur at 120 Hz with a 250 µs pulse width and with a duty cycle of 30 seconds on to 30 seconds off."
9899686|NCT04931134|Sham Comparator|Sham stimulation|"Active or sham TNS treatment will be performed at the patients' home for approximately 8 hours per night 7 days a week for 8 consecutive weeks.~Sham stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, NY, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 mA. Sham stimulation will use the same parameters of active stimulation, but after 60 seconds the stimulator will turn off."
9899687|NCT04929210|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.
9899688|NCT04929210|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
9899689|NCT04929210|Experimental|Group 3: Placebo followed by Guselkumab|Participants will receive matching placebo and will cross over to receive guselkumab SC.
9899690|NCT04929184|Experimental|Adults who stutter (AWS)|Participants will have 2 visits.
9899691|NCT04929184|Other|Healthy Adults|Participants will have 2 visits.
9899692|NCT04929184|Experimental|Children who Stutter|Participants will have 1 visit.
9899693|NCT04929184|Other|Healthy Children|Participants will have 1 visit.
9899694|NCT04924075|Experimental|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
9899695|NCT04923893|Experimental|Arm A: VRd+Rd (Standard Therapy)|Participants will receive bortezomib, lenalidomide, and dexamethasone (VRd) regimen for 6 cycles before randomization. Following randomization, participants in Arm A will receive 2 more cycles of VRd. In VRd treatment, participants will receive bortezomib 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each cycle (Cycles 1 to 8), oral lenalidomide 25 mg on Days 1 to 14 of each cycle (Cycles 1 to 8) and oral dexamethasone 25 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle (Cycles 1 to 8). Each cycle will consist of 21 days. After 8 cycles of VRd, treatment will continue with lenalidomide and dexamethasone (Rd) maintenance therapy. In Rd treatment, participants will receive oral lenalidomide 25 mg on Days 1 to 21 of each cycle and oral dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle. Each cycle will consist of 28 days. Participants will continue to receive Rd until confirmed progressive disease or unacceptable toxicity.
9899696|NCT04923893|Experimental|Arm B: VRd+Ciltacabtagene Autoleucel (Cilta-cel)|Participants will receive VRd regimen for 6 cycles before randomization. Following randomization, participants in Arm B will undergo apheresis and receive two more cycles of VRd as bridging therapy. In VRd treatment, participants will receive bortezomib 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each cycle for Cycles 1 to 8; oral lenalidomide 25 mg on days 1 to 14 of each cycle for Cycles 1 to 8 and oral dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle for Cycles 1 to 8. Each cycle will consist of 21 days. After 8 cycles of VRd, participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg).
9899697|NCT04922424|Experimental|atorvastatin|We are testing that the lipid sensitive statin, atorvastatin treatment will reduce low density lipoprotein cholesterone, sympathetic nerve activity, increase endothelium-dependent vasodilation and improve autonomic function in trans men, while having little impact on cis women.
9899698|NCT04922424|Placebo Comparator|Placebo|We are testing that the placebo will have little effect on low density lipoprotein cholesterone, sympathetic nerve activity, endothelium-dependent vasodilation, autonomic function in trans men or cis women.
9899699|NCT04920110||Phase 1: Qualitative Interviews|Approximately 20 parents/caregivers will discuss typical communication abilities of their loved one and complete the ORCA measure for determination of its content validity through a hybrid approach of concept elicitation and cognitive testing.
9899700|NCT04920110||Phase 2: Cross-Sectional Assessment of Psychometric Properties|Approximately 250 parents/caregivers will complete the ORCA measure and additional measures to determine its psychometric properties including reliability, floor/ceiling effects and construct validity.
9899701|NCT04919993|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Group intervention; topics include psychoeducation about sleep, sleep restriction, stimulus control, relaxation strategies, and cognitive restructuring.
9899702|NCT04919512|Experimental|Cohort 1: TAR-200 + Cetrelimab|Participants will receive TAR-200 in combination with cetrelimab.
9899703|NCT04919512|Experimental|Cohort 2: Cetrelimab|Participants will receive cetrelimab.
9899704|NCT04917419|Experimental|Luminotherapy and Psychoeducation Program|
9899705|NCT04917419|Active Comparator|Psychoeducation Program|
9899706|NCT04914741|Experimental|Glofitamab plus R-CHOP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by R-CHOP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
9899707|NCT04914741|Experimental|Glofitamab plus polatuzumab vedotin-RCHP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by polatuzumab vedotin-RCHP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
9899708|NCT04914429|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous (SC) injection at Weeks 0, 4, and then every 8 weeks (q8w) through Week 44. Participants will receive matching placebo at Week 16.
9899709|NCT04914429|Placebo Comparator|Group 2: Placebo|Participants will receive placebo SC injection for guselkumab at Weeks 0, 4, and 12, and then cross over at Week 16 to receive guselkumab 100 mg SC injection at Weeks 16 and 20 and q8w thereafter through Week 44.
9899710|NCT04912050||Tablo Hemodialysis System|Hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy > 12 hours on the Tablo Hemodialysis System
9899711|NCT04909450|Experimental|CSB-001 Investigational Treatment Arm|One drop CSB-001 four times daily for 8 weeks in the study eye
9899712|NCT04909450|Placebo Comparator|Vehicle Control Arm|One drop matching vehicle four times daily for 8 weeks in the study eye
9899713|NCT04905069|No Intervention|No-Spacer Control|Subjects will receive radiotherapy without the use of the SpaceOAR Vue.
9899714|NCT04905069|Experimental|SpaceOAR Vue|Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel.
9899715|NCT04903951|Experimental|ASV therapy + best medical treatment for stroke, including rehabilitation|Adaptive Servoventilation (ASV) therapy plus best medical treatment for stroke, including rehabilitation.
9899716|NCT04903951|Active Comparator|Best medical treatment for stroke, including rehabilitation|Best medical treatment for stroke, including rehabilitation.
9899717|NCT04903314|Experimental|Cohort I|Xcopri to be administered to ages 12 to < 18 years not to exceed 400 mg/day.
9899718|NCT04903314|Experimental|Cohort IIa|Xcopri to be administered to ages 6 to < 12 years not to exceed 400 mg/day.
9899719|NCT04903314|Experimental|Cohort IIb|Xcopri to be administered to ages 4 to < 6 years not to exceed 400 mg/day.
9899720|NCT04903314|Experimental|Cohort III|Xcopri to be administered to ages 2 to < 4 years not to exceed 400 mg/day.
9899721|NCT04902768||Adults with congenital heart disease|
9899722|NCT04902508|Experimental|Explicit Master Plus No Additional Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
9899723|NCT04902508|Experimental|Explicit Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of explicit treatment."
9899724|NCT04902508|Experimental|Explicit Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of implicit treatment."
9899725|NCT04902508|Experimental|Explicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of explicit treatment."
9899726|NCT04902508|Experimental|Explicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of implicit treatment."
9899727|NCT04902508|Experimental|Implicit Master Plus No Additional Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
9899728|NCT04902508|Experimental|Implicit Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of implicit treatment."
9899729|NCT04902508|Experimental|Implicit Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of explicit treatment."
9899730|NCT04902508|Experimental|Implicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of implicit treatment."
9899731|NCT04902508|Experimental|Implicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of explicit treatment."
9899732|NCT04901195|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period.
9899733|NCT04901195|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period.
9899734|NCT04899349|Experimental|Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR|Alpelisib 300mg orally once daily starting at Cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants will receive a combination treatment of dapagliflozin+metformin XR (as a single tablet or as two separate tablets, at the discretion of the investigator) at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily which can be titrated to a maximum dose of 10 mg dapagliflozin + 2000 mg metformin XR once daily.
9899735|NCT04899349|Active Comparator|Alpelisib + Fulvestrant + Metformin XR|Alpelisib 300mg orally once daily starting at cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants will receive metformin XR 500mg orally once daily which can be titrated to a maximum dose of 2000 mg once daily.
9899736|NCT04899193|Experimental|Sequence 1: First Reference, Then Test 1, Then Test 2|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
9899737|NCT04899193|Experimental|Sequence 2: First Test 1, Then Test 2, Then Reference|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
9899738|NCT04899193|Experimental|Sequence 3: First Test 2, Then Reference, Then Test 1|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
9899739|NCT04899193|Experimental|Sequence 4: First Reference, Then Test 2, Then Test 1|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
9899740|NCT04899193|Experimental|Sequence 5: First Test 1, Then Reference, Then Test 2|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
9899741|NCT04899193|Experimental|Sequence 6: First Test 2, Then Test 1, Then Reference|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
9899742|NCT04898634|Experimental|JNJ-78278343|Participants will receive JNJ-78278343 subcutaneously (SC). The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 SC at recommended phase 2 dose (RP2D) as determined in Part 1.
9899743|NCT04898621|Experimental|Group A|Subjects in Group A will drink 75g fructose solution daily for 4 weeks.
9899744|NCT04898621|Experimental|Group B|Subjects in Group B will drink 150g fructose solution daily for 4 weeks.
9899745|NCT04897711|Experimental|Perceptual training with a speaker with dysarthria|To examine the effect of perceptual training with speakers with dysarthria, we use a standard three-phase perceptual training protocol involving pretest, training, and posttest phases, in which speech samples from a single speaker with dysarthria are utilized for all three phases.
9899746|NCT04895748|Experimental|Arm 1 Dose Escalation DFF332|DFF332 Single Agent
9899747|NCT04895748|Experimental|Arm 2 Dose Escalation DFF332 + Everolimus|Combination treatment DFF332 + Everolimus
9899748|NCT04895748|Experimental|Arm 3 Dose Escalation DFF332 + Spartalizumab + Taminadenant|Combination treatment DFF332 + Spartalizumab + Taminadenant
9899749|NCT04895748|Experimental|Arm 1a Dose Expansion DFF332 in ccRCC|DFF332 Single Agent in patients with ccRCC (age 18 years old and above)
9899750|NCT04895748|Experimental|Arm 1b Dose Expansion DFF332 in HIF stabilizing malignancies|DFF332 Single Agent in patients with HIF stabilizing malignancies (age 12 years old and above)
9899751|NCT04895748|Experimental|Arm 2a Dose Expansion DFF332 + Everolimus in ccRCC|Combination treatment DFF332 + Everolimus in patients with ccRCC (age 18 years old and above)
9899752|NCT04895748|Experimental|Arm 3a Dose Expansion DFF332 + Spartalizumab + Taminadenant in ccRCC|Combination treatment DFF332 + Spartalizumab + Taminadenant in patients with ccRCC (age 18 years old and above)
9899753|NCT04895709|Experimental|Part 1A: BMS-986340 Dose Escalation|
9899754|NCT04895709|Experimental|Part 2A: BMS-986340 Dose Expansion|
9899755|NCT04895709|Experimental|Part 1B: BMS-986340 + Nivolumab Dose Escalation|
9899756|NCT04895709|Experimental|Part 2B: BMS-986340 + Nivolumab Dose Expansion|
9935743|NCT03258567|Experimental|Nivolumab (B)|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
9899757|NCT04895358|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg administered by intravenous infusion (IV) on Day 1 of each 21-day cycle (Q3W) PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle (Q4W), 2) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m^2 by oral administration (PO) twice a day (BID) on Days 1-14 Q3W for up to 35 administrations.
9899758|NCT04895358|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline or dextrose) IV on Day 1 Q3W PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 Q4W, 2) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m^2 PO BID on Days 1-14 Q3W for up to 35 administrations.
9899759|NCT04891133|Experimental|Active arm|4mg Baricitinib up to 14 days + SoC
9899760|NCT04891133|Placebo Comparator|Comparator|Matching placebo up to 14 days + SoC
9899761|NCT04889950|Experimental|Tixel Group|Tixel C Group: Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
9899762|NCT04889950|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits, Treatment- 1 single treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
9899763|NCT04889352|Experimental|Access to colonoscopy web app|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the intervention group where they are provided access to an application which indicates recommended timing of follow-up colonoscopy given values for various entered factors. In the intervention group, the application can be downloaded to smart phones for portability which will allow access in an endoscopy suite or in clinic or used as a reference at other times. It can also be accessed online (all endoscopy rooms in Winnipeg have computers with internet access for the endoscopy physicians' use). Access to the application will be password-protected, thereby avoiding exposure of the non-intervention group to the application. The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.
9899764|NCT04889352|No Intervention|Control|Approximately half of the consenting individual endoscopy physicians in the city (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to the group where they are not provided access to the application (control group).
10212610|NCT05189028|Active Comparator|Locally advanced bulk cervical cancer chemoradiotherapy group(CCRT)|"Radiation: Radiotherapy with IMRT/VMAT+192Ir-HDR brachytherapy Radiotherapy: 46Gy/23F to external pelvic radiotherapy and 14Gy/7F boost to imaging diagnosis of positive lymph nodes 192Ir-HDR brachytherapy:APoint A dose 6Gy*4-6F~Drug: cisplatin Concurrent Chemotherapy: Weekly cisplatin chemotherapy ≥5 cycles"
10212611|NCT05188391|Other|Positive Group (Rupture and Gap Sign are both positive)|Rupture and Gap Sign are both positive
10212612|NCT05188391|Other|Rupture Positive Group (Rupture positive but Gap Sign is negative)|Rupture positive but Gap Sign is negative
10212613|NCT05188391|Other|Gap Sign Positive Group (No rupture exists but Gap Sign is positive)|No rupture exists but Gap Sign is positive
10212614|NCT05188391|Other|Negative Group (Rupture and Gap sign are both negative)|Rupture and Gap sign are both negative
10212615|NCT05187377|Experimental|Growth Hormone then Saline|12 weeks in each treatment phase (rhGH then placebo) and a four week wash-out period between phases.
10212616|NCT05187377|Placebo Comparator|Placebo (saline) then Growth Hormone|12 weeks in each treatment phase (placebo then rhGH) and a four week wash-out period between phases.
10212617|NCT05185674||COVID-19 survivors subjects|"All patients discharged from the National University Hospital of Colombia (Bogotá, Colombia) who required admission to the Intensive Care Unit of the same institution with a confirmed diagnosis of SARS-CoV-2 disease (COVID-19 disease) between April 1, 2020 and March 31, 2021~Severe Acute Respiratory Syndrome (SARS)~Coronavirus (CoV)"
10212618|NCT05185609||Healthy volunteers|Healthy volunteers aged 18-to 65
10212619|NCT05185609||Asymptomatic patients with quiescent IBD|Asymptomatic patients with IBD in remission.
10212620|NCT05185609||Symptomatic patients with quiescent UC|Symptomatic patients with UC in remission
10212621|NCT05185609||Symptomatic patients with quiescent CD with anorectal involvement|Symptomatic patients with CD with distal involvement of the colon or perianal disease
10212622|NCT05184868|Experimental|AT247|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
10212623|NCT05184868|Active Comparator|NovoLog®|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
10212624|NCT05184868|Active Comparator|Fiasp®|0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
10212625|NCT05183607|Experimental|Virtual nutritional Intervention|This arm will receive the virtual nutritional intervention consisting of 4 - 30 minute sessions to educate cardiac surgery patients before their date of surgery. Each session will provide a different theme such as: 1) nutritional assessment, 2) protein intake education, 3) nutritional adequacy prior to surgery, and 4) protein and nutrition intake post surgery
10212626|NCT05182723|Active Comparator|oXiris|Monotoring of extracorporeal Method for Removing Mediators of Systemic Inflammation of oXiris will be performed for 24 hours
10212627|NCT05182723|Experimental|oXiris in combination with Jafron HA330|"Extracorporeal Method for Removing Mediators of Systemic Inflammation oXiris in combination with Jafron HA330 will be performed for 4 hours.~If SOFA is more or equally 4 , CRP is more than 100 ng/ml;, the IL6 value is increased by 5 or more times after 12 hours of procedure Jafron HA330 will be reconnected and performed for 4 hours.~Monitoring of whole procedure will be performed for 24 hours."
10212628|NCT05181124|Experimental|JP-1366 and aceclofenac|
10212629|NCT05181124|Experimental|JP-1366 and meloxicam|
10212630|NCT05181124|Experimental|JP-1366 and naproxen|
10212631|NCT05181124|Experimental|JP-1366|
10212632|NCT05180422|Experimental|Dose Expansion|AMG 510/MVASI
10212633|NCT05180383|Experimental|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
10212634|NCT05179499|Active Comparator|Peripheral Vasopressor Infusion Arm|Participants will receive peripheral vasopressor infusion of norepinepherine (16 micrograms/ml) All other care will be as per local protocol
10212635|NCT05179499|Placebo Comparator|Standard care|Participants will receive standard care as per UK national guidelines on Sepsis. All other care will be as per local protocol
10212636|NCT05174806|Experimental|MBN-101 topical|MBN-101 at a dose of 2.5 mg/mL will be applied directly to the infected wound and covered with an appropriate non-antimicrobial dressing. Dosing will be daily for the first week followed by 3 times per week for an additional 11 weeks.
10212637|NCT05174806|Other|Standard of Care|Standard of care treatment without administration of any topical drugs.
10212638|NCT05173636|Experimental|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
10212639|NCT05173636|Experimental|thoracic mobilization|A posteroanterior unilateral pressure will be applied over the transverse processes at T2-T5 on the ipsilateral side of pain in prone position.
10212640|NCT05169606|Experimental|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
10212641|NCT05169606|Experimental|Active Isolated Stretch|Active Isolated Stretch is a specific stretching program developed by Aaron Mattes over 30 years ago. Active isolated stretch is also found to be effective to increase flexibility and improve ROM.
10212642|NCT05169606|Experimental|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients.
10212643|NCT05169541||Recurrent pregnancy loss after spontaneous conception|Minimum three consecutive losses from pregnancies achieved after spontaneous conception
9899783|NCT04888507|Experimental|Pozelimab+Cemdisiran|
9899784|NCT04888312|Experimental|Intravenously administered mitazalimab given in combination with chemotherapy|Mitazalimab, a human monoclonal antibody targeting CD40, administered intravenously every 14 days, in combination with standard of care chemotherapy modified FOLFIRINOX.
9899785|NCT04882098|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.
9899786|NCT04882098|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
9899787|NCT04882098|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
9899788|NCT04881448|Experimental|patients with chronic kidney disease|
9935744|NCT03258177|Experimental|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
9997787|NCT01511965|Other|traitement B|Lesion 1 = UltraViolet B and lesion 2 = graft
10212644|NCT05169541||Recurrent pregnancy loss after assisted reproductive treatment|Minimum three consecutive losses from pregnancies achieved after assisted reproductive treatment (ART), which includes in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FER).
10212645|NCT05169541||Recurrent implantation failure|Minimum three consecutive embryo transfers (ET) of good quality embryos with no hCG production. The patient must not have experienced any clinical pregnancies (i.e. evidence of pregnancy on an US or by histopathological examination) after IVF or spontaneous conception. Biochemical pregnancies after spontaneous conception, which terminated before evidence of a gestational sac on an ultrasonic scan (US) could be visualized and before the series of RIF occurred, are accepted.
9899789|NCT04878328|Experimental|onsite Point-of-care (o-POC)|CHWs will reach out to participants to schedule O-PoC visits. At O-PoC visits, CHWs will provide: 1. COVID-19 education; 2. PoC Cepheid XpertXpressSARS-CoV-2PCR tests; 3. Needs assessments and facilitated access to masks and hygiene supplies; 4. Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5. Supportive counseling. Due to SCT's emphasis on social influence, external and internal social reinforcement, we propose our O-PoC intervention delivered by CHWs onsite at Fortune locations over a 12-month period will lead to increased uptake of mitigation behaviors.
9899790|NCT04878328|No Intervention|Standard of Care (SOC)|The current standard of care (SoC) for SARS-CoV-2 testing for Fortune clients is referral to offsite community testing sites and informal, unstructured education. In the SoC arm, Fortune staff will provide clients with a list of offsite SARS-CoV-2 testing locations, which are published online and available to all NYC residents. Those without insurance are not subject to a copay. Participants in SoC will continue to receive Fortune's suite of services as they are delivered (remote and/or in-person) at the time of study participation.
9899791|NCT04878172|Experimental|TempSure Firm Day 0 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 0 (within 24 hours after treatment).
9899792|NCT04878172|Experimental|TempSure Firm Day 10 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 10 (+/- 3 days) after treatment.
9899793|NCT04878172|Experimental|TempSure Firm Day 20 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 20 (+/- 3 days) after treatment.
9899794|NCT04878172|Experimental|TempSure Firm Day 30 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 30 (+/- 7 days) after treatment.
9899795|NCT04876391|Experimental|Participants from parent trial (1368-0052) who were on placebo or active medication|
9899796|NCT04876092|Experimental|JNJ-67856633 and Ibrutinib|Participants in Part A (dose escalation) will receive JNJ-67856633 together with Ibrutinib orally on a 21-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in Part B (cohort expansion) will receive JNJ-67856633 together with Ibrutinib orally at one of the RP2D(s) determined in Part A.
9899797|NCT04869644|Experimental|Intervention: Behavioral Change Techniques to encourage Habit Formation|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps 5 days per week. Participants will be enrolled for a baseline period lasting 2 weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will be asked to generate a walking plan with the goal of walking an additional 2,000 steps above their baseline activity level on 5 days per week. This walking plan will include details about day of the week, time of day, and location of walking. Once participants have completed their walking plan, they will receive daily texts based on the 5 identified BCTs for the duration of the 10-week intervention. All BCTs will be delivered daily. The goal of the text messages will be to encourage habit formation for walking behavior.
9899798|NCT04869540|Active Comparator|Usual care|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources.
9899799|NCT04869540|Experimental|Usual care + PSE|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources and will also receive a family-based problem solving eduction (PSE) intervention.
9899800|NCT04865289|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
9899801|NCT04865289|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
9899802|NCT04865237|Experimental|Healthy Volunteers|SARS-CoV-2, intranasally, (1x10^1 TCID50, 1x10^2 TCID50 and 1x10^3 TCID50 or higher, as necessary)
9899803|NCT04864405|Active Comparator|Morning administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient wake up time
9899804|NCT04864405|Active Comparator|Evening administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient bed time
9899805|NCT04862910|Experimental|Kinect Based Virtual Reality Training|Kinect-Based Virtual Reality Training. Routine Medication and routine diet will be continued.
9899806|NCT04862910|Other|Control Group|Moderate-level regular physical activity with a routine diet and routine Medication
9899807|NCT04862650|Experimental|Treatment (cemiplimab, paclitaxel, carboplatin)|Patients receive cemiplimab IV over 30 minutes every 3 weeks (Q3W) for up to 104 weeks, and paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes once weekly (QW) for up to 24 weeks. Treatment continuous in the absence of disease progression or unacceptable toxicity.
9899808|NCT04862195|Active Comparator|Attune™|Attune™ is a completely digital, 10-session, cognitive behavioral therapeutic intervention.
9899809|NCT04862195|Active Comparator|Cerena™|Cerena™ is a completely digital, 10-session, health education and wellness intervention.
9899810|NCT04860830|Experimental|BI 425809 treatment group|
9899811|NCT04860830|Placebo Comparator|Placebo group|
9899812|NCT04857190|Active Comparator|Group DS (n=40)|Parker Flex-it Directional Stylet group
9899813|NCT04857190|Active Comparator|Group MS (n=40)|Conventional Malleable Stylet group
9899814|NCT04853576|Experimental|EDIT-301|EDIT-301 (autologous gene edited (CD)34+ hematopoietic stem cells) will be administered as a one-time intravenous infusion.
9899815|NCT04851613|Experimental|Afuresertib and Fulvestrant Safety Run In|Safety run-in Cycle 1 (a cycle is 28 days) will be performed in the first 6 patients of the phase Ib. Combination regimens during the safety run-in period are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
9899816|NCT04851613|Experimental|Afuresertib and Fulvestrant|Combination regimens are: afuresertib 125 mg QD (once daily) or 125 mg Day1-21 Q4W + fulvestrant 500 mg or 250 mg Intra Muscular (IM) on Day 1, 15 of Cycle 1, and on Day 1 of the subsequent 28-day cycles.
9899817|NCT04849910|Experimental|Cohort 1|VOR33 infusion followed by Mylotarg Dose Level 1
9899818|NCT04849910|Experimental|Cohort 2|VOR33 infusion followed by Mylotarg Dose Level 2
9899819|NCT04849910|Experimental|Cohort 3|VOR33 infusion followed by Mylotarg Dose Level 3
9899820|NCT04847739|Experimental|Standard of Care Treatment + AVB-114|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.
9899821|NCT04847739|Active Comparator|Standard of Care Treatment|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.
9899822|NCT04847531||Stage 3 chronic kidney disease patients|Patients with two consecutive eGFR measurements indicating stage 3 CKD (≥30 and <60 mL/min/1.73m2) during the observation period
9899823|NCT04846868|Experimental|BI 425809|
9899824|NCT04846868|Placebo Comparator|Placebo|
9899825|NCT04846244||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for radiographic axial spondyloarthritis (r-axSpA).
9899826|NCT04845945||PCV13 only|Draw blood for ELISA and OPA, then administer PCV13
9899827|NCT04845945||PPS23 only|Draw blood for ELISA and OPA, then administer PPS23
9899828|NCT04845945||PCV13 and PPS23|Draw blood for Administer PPS23 then draw blood again ELISA and OPA, then administer PCV13
9933295|NCT05352321|Experimental|Nasopharyngectomy Plus Target-reduction Chemoradiotherapy|"Nasopharyngectomy:~Endoscopic nasopharyngectomy will be performed under general anesthesia through both sides of nasal cavities to ensure the complete resection of primary lesion as well as adequate safe margin.~Induction Chemotherapy:~Gemcitabine, 1000 mg/m2, intravenously within 30min, Day 1 and Day 8, Q3W, 3 cycles Cisplatin, 80 mg/m2, intravenously, Day 1, Q3W, 3 cycles~Intensity-modulated Radiotherapy:~GTVrnd (retropharyngeal lymph nodes): 69.96Gy/33Fr/2.12Gy GTVnd: 69.96Gy/33Fr/2.12Gy CTV2 : 54.12Gy/33Fr/1.64Gy~Concurrent Chemotherapy:~Cisplatin, 100 mg/m2, intravenously, Day 1, Q3W during radiotherapy"
9933296|NCT05352321|Active Comparator|Regular Chemoradiotherapy|"Induction Chemotherapy:~Gemcitabine, 1000 mg/m2, intravenously within 30min, Day 1 and Day 8, Q3W, 3 cycles Cisplatin, 80 mg/m2, intravenously, Day 1, Q3W, 3 cycles~Intensity-modulated Radiotherapy:~GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy GTVrnd (retropharyngeal lymph nodes): 69.96Gy/33Fr/2.12Gy GTVnd: 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy~Concurrent Chemotherapy:~Cisplatin, 100 mg/m2, intravenously, Day 1, Q3W during radiotherapy"
9935745|NCT03258177|No Intervention|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
9899829|NCT04841226|Active Comparator|Silq ClearTract™ 100% Silicone 2-Way Foley Catheter|Up to 82 subjects
9899830|NCT04841226|Active Comparator|Silver-coated Latex 2-Way Foley Catheter|Up to 82 subjects
9899831|NCT04841226|Active Comparator|Silicone-coated Latex 2-Way Foley catheter|Up to 82 subjects
9899832|NCT04839887||Validation study|Three hundred patients with ischemic stroke (18-65 years) will be enrolled for the validation of the Czech version of the the Stroke Impact Scale 3.0. The reliability and validity study will have a cross-sectional design.
9899833|NCT04839887||Prospective quantitative study|Two hundred enrolled IS patients (100 young IS patients < 50 years and 100 IS patients of 50-65 years) will undergo a serial of structured and standardized questionnaires during scheduled outpatients' controls three, six and 12 months after IS. In all enrolled patients, the functional outcome, neuropsychological status and quality of life will be assessed using standardized scales and tools.
9899834|NCT04839887||In-depth interview qualitative study|twenty young IS patients < 50 years will undergo an in-depth, semi-structured interview with explanatory questions that will allow a detailed understanding of the patient's experience. Interpretative phenomenological analysis (IPA) study design will be used.
9899835|NCT04836884|Experimental|Vascular anomaly/malformation biopsy|Subjects with a vascular anomaly will have a research percutaneous vascular anomaly/malformation biopsy completed at the time of the clinically indicated percutaneous sclerotherapy, embolization and/or ablation.
9899836|NCT04836858|Experimental|CMK389 high dose|Active
9899837|NCT04836858|Placebo Comparator|Placebo high dose|Placebo
9899838|NCT04836858|Experimental|CMK389 low dose|Active
9899839|NCT04836858|Placebo Comparator|Placebo low dose|Placebo
9899840|NCT04835805|Experimental|Belvarafenib Monotherapy|Twice daily (BID), continuous dosing.
9899841|NCT04835805|Experimental|Belvarafenib Plus cobimetinib|Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.
9899842|NCT04835805|Experimental|Belvarafenib Plus Cobimetinib Plus Atezolizumab|Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus atezolizumab IV infusion every 4 weeks (Q4W) followed by an expansion phase
9899843|NCT04833855|Active Comparator|Group 1: Omalizumab|Participants naive to anti-IgE therapies will receive omalizumab.
9899844|NCT04833855|Placebo Comparator|Group 2: Placebo|Participants naive to anti-IgE therapies will receive a placebo.
9899845|NCT04833855|Experimental|Group 3: Tezepelumab Dose 1|Participants naive to anti-IgE therapies will receive tezepelumab.
9899846|NCT04833855|Experimental|Group 4: Tezepelumab Dose 2|Participants naive to anti-IgE therapies will receive tezepelumab.
9899847|NCT04833855|Placebo Comparator|Group 5: Placebo|Participants previously treated with anti-IgE therapies will receive a placebo.
9899848|NCT04833855|Experimental|Group 6: Tezepelumab Dose 1|Participants previously treated with anti-IgE therapies will receive tezepelumab.
9899849|NCT04833855|Experimental|Group 7: Tezepelumab Dose 2|Participants previously treated with anti-IgE therapies will receive tezepelumab.
9899850|NCT04832152|Other|Feasibility trial group|One group (arm) trial where all will receive treatment.
9899851|NCT04831281|Experimental|40mg Dose|Daily subcutaneous injection of 40mg ATH-1017
9899852|NCT04831281|Experimental|70mg Dose|Daily subcutaneous injection of 70mg ATH-1017
9899853|NCT04831281|Placebo Comparator|Placebo|Daily subcutaneous injection of Placebo
9899854|NCT04830917|Experimental|Treatment with Kinesiotape and Oval 8|
9899855|NCT04830917|Experimental|Treatment with quick cast|
9899856|NCT04829136|Experimental|Arm I (enteral nutrition)|Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
9899857|NCT04829136|Active Comparator|Arm II (standard of care)|Patients receive standard of care nutritional support.
9997788|NCT01511991|Experimental|sevoflurane|10 min exposure to sevoflurane 1.0, 2.0 and 3.0 inspiratory vol% at sevoflurane dosage titration
9997789|NCT01512004|Active Comparator|Propiverine Hydrochloride Extended-Release Capsule|30 mg/capsule; oral; once per day
9899858|NCT04828590||Patients with suspected CAD containing at least one 30%-90% coronary CTA stenosis|Patients' datasets with suspected CAD containing at least one 30%-90% coronary CTA stenosis; and ICA-FFR was measured on vessels with diameters greater than 2 mm will be analyzed. Diagnostic performance based on CT-derived FFR using DVFFR software will be compared with the diagnostic performance from ICA-FFR measurements.
9899859|NCT04827914|Experimental|Enhanced Care Condition|
9899860|NCT04827914|Active Comparator|Basic Care Condition|
9899861|NCT04827576|Experimental|Safety Run-in Cohort 1, mNSCLC, mUC, mSCLC (Magrolimab + Docetaxel)|Participants with solid tumors (metastatic non-small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), metastatic small cell lung cancer (mSCLC)) will receive an escalating dose of magrolimab and docetaxel.
9899862|NCT04827576|Experimental|Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)|Participants with mNSCLC will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety Run-in Cohort 1 and docetaxel.
9899863|NCT04827576|Experimental|Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)|Participants with mUC will receive magrolimab at the RP2D determined in the Safety Run-in Cohort 1 and docetaxel.
9899864|NCT04827576|Experimental|Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)|Participants with mSCLC will receive magrolimab at the RP2D determined in the Safety Run-in Cohort 1 and docetaxel.
9899865|NCT04823611|Placebo Comparator|Part A:Placebo|Placebo solution for subcutaneous injection.
9899866|NCT04823611|Experimental|Part A:AZD8233|AZD8233 for subcutaneous injection.
9899867|NCT04823611|Placebo Comparator|Part B:Placebo|Placebo solution for subcutaneous injection.
9899868|NCT04823611|Experimental|Part B:AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
9899869|NCT04823611|Experimental|Part B:AZD8233 low dose|AZD8233 low dose for subcutaneous injection.
9899870|NCT04823611|Placebo Comparator|Part C: Placebo|Placebo solution for subcutaneous injection.
9899871|NCT04823611|Experimental|Part C: AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
9899872|NCT04822337|Experimental|Phase I|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
9899873|NCT04822337|Experimental|Phase II|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
9899874|NCT04818853||COVID Patients with Aspergillosis and Other fungal Infections|All patients have been diagnosed with COVID-19. The purpose of this study is to look at this group of patients in the potential to develop Aspergillosis and other fungal infections.
9899875|NCT04818229|Experimental|Investigational Group 1|Therapeutic and supratherapeutic multiple oral doses of CBP-307.
9899876|NCT04818229|Placebo Comparator|Investigational Group 2A|Moxifloxacin (positive control for method validation) and Placebo oral administration.
9899877|NCT04818229|Placebo Comparator|Investigational Group 2B|Moxifloxacin (positive control for method validation) and Placebo oral administration.
9899878|NCT04818073|Experimental|Group A|Participants with undergo new FINGER robotic training with no physical assistance 3 times a week for a period of 3 weeks.
9899879|NCT04818073|Experimental|Group B|Participants will undergo new FINGER robotic training with physical assistance 3 times a week for a period of 3 weeks.
9899880|NCT04818073|Experimental|Group C|Participants will undergo new FINGER robotic training with physical assistance and proprioceptive exercises 3 times a week for a period of 3 weeks.
9899881|NCT04816214|Experimental|Combination of capmatinib + osimertinib (run-in part)|For run-in part: Up to 2 dose levels of capmatinib in combination with osimertinib may be investigated. The starting dose of combination is capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation is required, a lower dose level is defined as capmatinib 400 mg orally twice a day (b.i.d) and osimertinib 40 mg orally once per day (q.d.)
9899882|NCT04816214|Experimental|Combination of capmatinib + osimertinib (randomized part)|For randomized part: capmatinib in combination with osimertinib administered at the recommended Phase III regimen (defined in the safety run-in part).
9899883|NCT04816214|Active Comparator|platinum + pemetrexed based doublet chemotherapy|For randomized part: following local guidelines as per standard of care and products labels
9899885|NCT04811560|Experimental|JNJ-75276617|Participants in Part 1 (dose escalation) will receive JNJ-75276617 orally on a 28-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Food effect cohort participants in Part 1 will receive JNJ-75276617 orally on Cycle 2 Day 1 under fasted condition and on Cycle 2 Day 2 under fed condition. Participants in Part 2 (dose expansion) will receive JNJ-75276617 orally at one of the RP2D(s) determined in Part 1.
9899886|NCT04810143|Experimental|Aim 1|"All patients presenting for routine post-transplant care including, but not limited to: cardiac catheterization, cardiac biopsy, inpatient admission, or outpatient visits. A convenience sample of 25 inpatient samples will be collected for Aim 1. Although the assay developed by the MSCF will be validated for accuracy, the purpose of Aim 1 is to test real world application of the Mitra Microsampler tubes against the gold standard of blood collected by venipuncture in a controlled setting. To accomplish this, consecutive inpatient heart transplant patients will be enrolled. That sample will be collected at the same time (+/- 15 minutes) as a clinically-indicated, appropriately-timed venipuncture for measurement of a tacrolimus trough and prior to the subject taking tacrolimus so as to represent a trough."
9899887|NCT04810143|Experimental|Aim 2|Outpatient. A convenience sample of 25 outpatients collecting 1-2 samples will be collected for Aim 2. For those who agree to participate, the parent/patient will be taught by a member of the team on how to use the Microsampler to collect blood from a finger stick. They will be provided with a kit for collection of up to 2 samples and will also be provided with appropriate shipping materials to return samples to CCHMC. Participants will then be instructed to collect a sample in the Mitra Microsampler via fingerstick. In addition to the process of collecting the sample in Aim 2, appropriately-aged participants and/or families will be asked to fill out a brief survey regarding sample collection. This will include questions about the ease or difficulty of performing the steps and tolerability of the procedure relative to past experiences with values obtained by venipuncture.
9899888|NCT04807348|Experimental|Chiglitazar sodium 32mg QD+metformin|Chiglitazar 32mg qd+metformin
9899889|NCT04807348|Experimental|Chiglitazar sodium 48 mg QD+metformin|Chiglitazar 48 mg qd+metformin
9899890|NCT04807348|Placebo Comparator|placebo+metformin|placebo+metformin
9899891|NCT04799886||Child and adolescent psychiatrist|
9899892|NCT04798768|Experimental|Patients implanted with S-ICD and leadless cardiac pacemaker|Patients implanted with an S-ICD and leadless cardiac pacemaker that complete intended testing based on the study protocol
9899893|NCT04797000|Experimental|Eltrombopag Arm|Participants randomized to a 1: 1 ratio will take eltrombopag.
9899894|NCT04797000|Placebo Comparator|Placebo Arm|Participants randomized to a 1: 1 ratio will take Placebo.
9899895|NCT04796896|Experimental|mRNA-1273|"Part 1: Participants will receive 2 intramuscular (IM) injections of mRNA-1273 at doses pre-specified for this study, 28 days apart, on Days 1 and 29. Part 1 participants will be offered an optional booster dose of mRNA-1273 lower than the dose chosen for primary series for each age group, at least 6 months after Dose 2.~Part 2: Participants will receive 2 IM injections of mRNA-1273 at dose selected from Part 1, 28 days apart, on Days 1 and 29. Part 2 participants (6 to <12 year old) will be offered an optional booster dose of mRNA-1273 lower than the dose chosen for primary series for this age group, at least 6 months after Dose 2.~Part 3: Participants will receive 2 IM injections of mRNA-1273 approximately 28 days apart (on Days 1 and 29) as the primary series followed by 1 IM injection as a third dose (on Day 149) at least 3 months after receipt of the second dose of the primary series. All 3 injections will be administered at the low dose that participants received during Part 1."
9899896|NCT04796896|Placebo Comparator|Placebo|Part 2 only: Participants will receive 2 IM injections of mRNA-1273-matching placebo 28 days apart, on Day 1 and Day 29. Part 2 participants (6 to <12 year old) will be offered an optional booster dose of mRNA-1273 at a dose lower than the dose that was chosen for the primary series for this age group, at least 6 months post-cross-over Dose 2.
9899897|NCT04796779|Experimental|CLC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the intervention group will use the Tandem t:slim X2 with Control-IQ Technology v1.0 during the first 13 weeks of the study (RCT phase, weeks 1-13) and then use Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 for the remaining 13 weeks of the study (extension phase, weeks 14-26).
9899898|NCT04796779|Active Comparator|SC Group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Standard of Care (SC group) for 3 weeks. Participants randomized to the SC group will use their existing insulin therapy in conjunction with study Dexcom G6 CGM during the first 13 weeks of the study (RCT phase, weeks 1-13). The SC group will then transition to using the Tandem t:slim X2 insulin pump with Control-IQ Technology v1.5 and study Dexcom G6 CGM for the remaining 13 weeks of the study (weeks 14-26).
9899899|NCT04795427|Experimental|asciminb arm|Patients will receive asciminib (40 mg BID continuous)
9899900|NCT04795427|Experimental|best available treatment arm|Patients will receive best available therapy chosen by investigator
9899901|NCT04793035|Experimental|Enrolled patients|Single-arm study for enrolled GERD patients to be treated with an Omega-Cuff device
9899902|NCT04792190|Active Comparator|Intervention Management Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
9899903|NCT04792190|Placebo Comparator|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
9899904|NCT04791514|Experimental|Treprostinil Palmitil Inhalation Powder|"Participants will be administered a single dose of trepreostinil palmitil inhalation powder (TPIP). The first participant will be administered TPIP 112.5 μg. Dose levels for subsequent participants will be determined based on information collected for the previous participant(s) by a Safety Review Committee.~An optional extended-use period for 16 weeks will be available to participants who have completed the core, single-dose period."
9899905|NCT04791488|Experimental|Healthy individuals|
9899906|NCT04791488|Experimental|Decompression sickness patients|
9899907|NCT04790786|Experimental|Lilly Bamlanivimab|The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset.
9899908|NCT04790786|Experimental|Regeneron Casirivimab + Imdevimab|The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset.
9899909|NCT04790786|Experimental|Lilly Bamlanivimab + Etesevimab|The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset.
9899910|NCT04790786|Experimental|Sotrovimab|The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
9899911|NCT04790786|Experimental|Bebtelovimab|The monoclonal antibody of bebtelovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
9899912|NCT04788524|Experimental|Computer Task Manipulation|Participants will complete computer tasks while undergoing an fMRI brain scan
9899913|NCT04785066|Experimental|Study treatment|Administration of dornase alfa during intervention of thrombectomy
9899914|NCT04784663|Experimental|Message Exposure|Participants exposed to 4 study videos over a one-month period and complete telephone-based assessments at baseline, 1- and 2-month follow up. Study videos are delivered by study's mobile app downloaded to participants' own Smartphone.
9899915|NCT04784663|Placebo Comparator|Wait List Control|While wait-listed, participants will receive one push notification each week thanking them for participation, informing them that they will receive messages in the near future or reminding them of the length of the study. Telephone-based assessments are completed at baseline, 1- and 2-month follow up. Push notifications are delivered by study's mobile app downloaded to participants' own Smartphone.
9899916|NCT04784559|Experimental|Plitidepsin 1.5 mg arm|"Patients will receive plitidepsin 1.5 mg/day intravenous (IV) combined with dexamethasone phosphate 8 mg/day (equivalent to 6.6 mg dexamethasone base) IV on Days 1 to 3, followed by dexamethasone phosphate 7.2 mg (equivalent to 6 mg/day dexamethasone base) oral administration (PO)/IV from Day 4 and up to a total cumulative dose of 60 mg of dexamethasone base (as per physician judgement according to patient clinical condition and evolution).~The study allows up to a total cumulative dose of 60 mg of dexamethasone base (calculation of the total dose will also include corticosteroids administered within 72 hours before the start of the study treatment and dexamethasone administered as premedication)."
9899917|NCT04784559|Experimental|Plitidepsin 2.5 mg arm|"Patients will receive plitidepsin 2.5 mg/day intravenous (IV) combined with dexamethasone phosphate 8 mg/day (equivalent to 6.6 mg dexamethasone base) IV on Days 1 to 3, followed by dexamethasone phosphate 7.2 mg (equivalent to 6 mg/day dexamethasone base) from Day 4 and up to a total cumulative dose of 60 mg of dexamethasone base (as per physician judgement according to patient clinical condition and evolution).~The study allows up to a total cumulative dose of 60 mg of dexamethasone base (calculation of the total dose will also include corticosteroids administered within 72 hours before the start of the study treatment and dexamethasone administered as premedication)."
9899918|NCT04784559|Active Comparator|Control arm|"Dexamethasone phosphate 8 mg/day (equivalent to 6.6 mg dexamethasone base) IV on Days 1 to 3, followed by dexamethasone phosphate 7.2 mg (equivalent to 6 mg/day dexamethasone base) from Day 4 and up to a total cumulative dose of 60 mg of dexamethasone base (as per physician judgement according to patient clinical condition and evolution). Per local treatment guidelines, patients may receive a regulatory approved antiviral treatment, such as remdesivir (200 mg IV on Day 1 followed by 100 mg/day IV on Days 2 to 5) or favipiravir (1600 mg twice daily [BID] PO on Day 1, followed by 600 mg BID PO daily for 2 to 5 days). Antiviral to be used per approved product information in each country, different dosages could be used.~The study allows up to a total cumulative dose of 60 mg of dexamethasone base (calculation of the total dose will also include corticosteroids administered within 72 hours before the start of the study treatment and dexamethasone administered as premedication)."
9899919|NCT04777357|Placebo Comparator|Placebo|Participants will receive Placebo over a 6 week treatment period.
9899920|NCT04777357|Experimental|Cariprazine|Participants will receive flexible dose Cariprazine over a 6 week treatment period.
9899921|NCT04776252|Experimental|MK-8591A|Fixed dose combination (FDC) tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for 48 weeks.
9899922|NCT04775953|Experimental|Arm 1 (Dalbavancin)|Dalbavancin 1500 mg will be administrated intravenously (IV) over 30 (-/+10) minutes on Day 1 and 1500 mg IV over 30 (-/+10) minutes on Day 8, renally dose-adjusted to 1125 mg for subjects with Creatinine Clearance (CrCl) <30 and not on dialysis. N=100
9899923|NCT04775953|Active Comparator|Arm 2 (Standard of Care)|For Methicillin-sensitive Staphylococcus aureus (MSSA): nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks) OR oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks OR cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks) For Methicillin-resistant Staphylococcus aureus (MRSA): vancomycin (dose per local standard of care × 4-6 weeks) OR daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks). N=100
9899924|NCT04775316||Patients with fragile skin|Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.
9899925|NCT04774198||Occurrence of persistent postoperative hypotension|Patients with need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
9899926|NCT04774198||No occurrence of persistent postoperative hypotension|Patients without need for noradrenaline the morning after surgery to maintain middle arterial blood-pressure (MAP)>65 mmHg, after pancreaticoduodenectomy.
9899927|NCT04772196|No Intervention|Control Group|Patients enrolled in the control group will receive standard of care.
9899928|NCT04772196|Experimental|Vitamin D Supplementation Group|Patients enrolled in the Vitamin D Supplementation Group will receive 50,000 IU Vitamin D3 weekly for 8 weeks.
9899929|NCT04771741||Multimodal Pain Pathway|"This group will receive the multimodal pain pathway cocktail of medications. This cocktail includes:~Tylenol (acetominophen), 1000 mg, every 6 hours as needed for pain~Ketorolac (Toradol), 10 mg, every 6 hours as needed for pain until post-op day 3~Mobic (Meloxicam), 15 mg once daily, beginning on post-op day 4~Flexeril (Cyclobenzaprine), 10 mg every 8 hours as needed for pain~Pregabalin (Lyrica), 75 mg every 12 hours as needed for pain"
9899930|NCT04770831||Single Arm|QOL following MIBG
9899931|NCT04770246|Experimental|TAS-117 Dose Escalation Daily Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
9899932|NCT04770246|Experimental|TAS-117 Dose Escalation Intermittent Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
9992824|NCT01466205|Experimental|DAR 0-100A|The examination of SPD subjects, who are more likely than schizophrenia patients to show significant cognitive improvement after the use of single doses of dopamine agonists, such as DAR-0100A provides an excellent opportunity to demonstrate the effectiveness of D1 agonists on cognition in the schizophrenia spectrum.
9992825|NCT01466205|Placebo Comparator|Placebo|Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
9992826|NCT01466218||WTC Volunteers and Workers|Any current participant of the World Trade Center Health Program-Clinical Center of Excellence, formerly known as World Trade Center Medical Monitoring and Treatment Program
9992827|NCT01466231|Experimental|everolimus 10 mg po daily|everolimus 10 mg po daily
9992828|NCT01466296|Experimental|Re-Step|"Mechatronic shoe with a sole made to change slopes in the swing phase of walking.~This unpredictable change will introduce a situation of necessary adaptation to keep balance"
9992829|NCT01466296|Experimental|Dummy shoes|The shoes are in the same shape and weight of the Re-Step without the perturbations.
9992830|NCT01466296|Active Comparator|treadmill|A treadmill with safety adaptation and all the usual characteristics of speed and slopes of fitness treadmills.
9992831|NCT01466309|Experimental|treatment|patients treated with Somnoguard
9992832|NCT01466322|Experimental|Oral formulations of GSK2018682|Three oral formulations of GSK2018682. A: CD2 Capsule; B: CD3 non-micronised Tablet; C: CD3 micronised Tablet; D: CD3 non-micronised Tablet in fed state
9992833|NCT01466335|Experimental|Ronacaleret 100mg once daily|1 x 100mg oral tablet
9992834|NCT01466335|Experimental|Ronacaleret 100mg twice daily|1 x 100mg oral tablet twice daily
9992835|NCT01466335|Experimental|Ronacaleret 200mg once daily|2 x 100mg oral tablet
9992836|NCT01466335|Experimental|Ronacaleret 200mg twice daily|2 x 100mg tablets twice daily
9992837|NCT01466335|Experimental|Ronacaleret 400mg once daily|4 x 100mg tablets
9992838|NCT01466335|Placebo Comparator|Placebo|Matching number of identical placebo tablets
9992839|NCT01466400||infants two to six months of age|
9992840|NCT01466413|Experimental|Restylane|"Patients with an even subject identification number (SIN) (02, 04, 06, 08, 10, 12, 14, 16) will have ELAPR to the right arm and the control to the left, where patients with an odd subject identification number (01, 03, 05, 07, 09, 11, 13, 15) will have the ELAPR to the left arm and the control to the right.~Patients will receive either device ELAPR002c or ELAPR002e. This will alternate to minimise bias between the right and left arms.~The first group of eight patients (01 - 08) will have their biopsy performed at day 169. The second group of eight patients (09 - 16) will have their biopsy at day 85."
9992841|NCT01466426||DVT confirmed|
9992842|NCT01466426||DVT ruled out|
9992843|NCT01466426||PE confirmed|
9992844|NCT01466426||PE ruled out|
9992845|NCT01466439|Other|high frequency rTMS|
9992846|NCT01466439|Other|low frequency rTMS|
9992847|NCT01466452|Active Comparator|Aspirin 100|
9992848|NCT01466452|Active Comparator|Aspirin 200|
9992849|NCT01466452|Active Comparator|Aspirin 100 x 2|
9992850|NCT01466465|Experimental|Vigantol|
9992851|NCT01466465|Placebo Comparator|neutral oil (vigantol carrier)|
9992852|NCT01466478|Experimental|LEO 29102 plus calcipotriol|
9992853|NCT01466517|Active Comparator|Reference Drug|
9992854|NCT01466517|Active Comparator|Test Drug|
9992855|NCT01466530|Placebo Comparator|Placebo|sublingual two moistened white coated placebo tablets
9992856|NCT01466530|Active Comparator|Misoprostol|sublingual misoprostol (400 µg)
9992857|NCT01466543|Active Comparator|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, once
9992858|NCT01466543|Placebo Comparator|Placebo|placebo medication
9992859|NCT01466556||Obese children|
9992860|NCT01466569|Experimental|AbGn-7 phase 1a cohort 1|
9992861|NCT01466569|Experimental|AbGn-7 phase 1a cohort 2|
9992862|NCT01466569|Experimental|AbGn-7 phase 1a cohort 3|
9992863|NCT01466569|Experimental|AbGn-7 phase 1b cohort 1|
9992864|NCT01466569|Experimental|AbGn-7 phase 1b cohort 2|
9997790|NCT01512004|Placebo Comparator|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
9899933|NCT04770246|Experimental|TAS-117 Dose and Regimen Confirmation (Part A: safety lead-in)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
9899934|NCT04770246|Experimental|TAS-117 Phase 2 (Part B)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
9899935|NCT04770090|Experimental|Early stage cervical cancer|Patients with cervical cancer eligible for surgery, stage IA1 to IB2
9899936|NCT04767373|Experimental|MK-1654|Participants receive a single intramuscular (IM) administration of MK-1654 on Day 1.
9899937|NCT04767373|Placebo Comparator|Placebo|Participants receive a single IM administration of placebo on Day 1.
9899938|NCT04766723|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limbs."
9899939|NCT04766723|Placebo Comparator|Placebo|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of the upper limbs."
9899940|NCT04765384|Experimental|Groups 1-4: Ad26.COV2.S (One Dose)|Participants who are previously vaccinated (Group 1-3) and participants who are vaccine naïve (Group 4) will receive single dose of Ad26.COV2.S vaccine at standard dose level on Day 1. Participants from group 4 who are no longer pregnant may receive single booster dose of Ad26.COV2.S vaccine at standard dose level.
9899941|NCT04765202|Experimental|All participants|"Each participant will receive both treatments.~On each participant, similar wounds will be identified as treatment sites.~Treatment sites will be randomized to receive either AG Tx (control) or SOMA Tx (experimental)."
9899942|NCT04765059|Experimental|Treatment Arm A|All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin ([AUC] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
9899943|NCT04765059|Placebo Comparator|Treatment Arm B|All randomized patients will receive placebo QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
9899944|NCT04763759|Experimental|Dose Level 1- 6mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
9899945|NCT04763759|Experimental|Dose Level 2- 15mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
9899946|NCT04763759|Experimental|Dose Level 3- 30 mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
9899947|NCT04763421|Experimental|Upper Gastrointestinal/Lower Gastrointestinal/Gynecological|Any upper gastrointestinal/lower gastrointestinal/gynecological procedure where the ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
9997791|NCT01512017|Active Comparator|Veloderm|
9899948|NCT04763161||Experimental group|"Patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy.~Intervention is decompressive hemicraniectomy in the context of a malignant sylvian ischaemic cerebral"
9899949|NCT04763161||Control group|"Patients not suffering from AIC, hospitalised in neurosurgery for another reason,~Patients to be opered on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach."
9899950|NCT04758767|Experimental|Dose escalation cohort|Monotherapy CID-103. Priming dose will be given for first dose. Dose and duration of infusion dependent on dose cohort and tolerability.
9899951|NCT04758767|Experimental|Dose expansion cohort - pretreated|CID-103 monotherapy at the recommended phase 2 dose
9899952|NCT04758767|Experimental|Dose expansion cohort - Naïve|CID-103 monotherapy at the recommended phase 2 dose
9899953|NCT04758117||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for psoriatic arthritis (PsA).
9899954|NCT04757298|Other|Navigation/tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who complete the COVID-19 testing will again be randomized and some will continue receiving NS.
9899955|NCT04757298|Other|Navigation/tested/brief counseling|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC)
9899956|NCT04757298|Other|Navigation/not tested/navigation services|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who do not complete the COVID-19 testing will again be randomized and some will continue receiving NS.
9899957|NCT04757298|Other|Navigation/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive navigation services(NS). Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD)
9899958|NCT04757298|Other|Referral/tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
9899959|NCT04757298|Other|Referral/tested/brief counseling|After initial randomization, some participants will be assigned to receive standard referral services. Those who complete the COVID-19 testing will again be randomized and some will be assigned to receive Brief Counseling (BC).
9899960|NCT04757298|Other|Referral/not tested/brochure|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will receive a digital brochure.
9899961|NCT04757298|Other|Referral/not tested/critical dialogue|After initial randomization, some participants will be assigned to receive standard referral services. Those who do not complete the COVID-19 testing will again be randomized and some will be assigned to Critical Dialogue (CD).
9899962|NCT04751396||Part A (Interview)|Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.
9899963|NCT04751396||Part B Group I (standard information)|Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
9899964|NCT04751396||Part B Group II (educational tool)|Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
9899965|NCT04750954|Experimental|Treatment (peposertib, lutetium Lu 177 dotatate)|Patients receive peposertib PO QD or BID on days 1-21 and lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9899966|NCT04750213||Participants Receiving Humira (Adalimumab)|Participants receiving Adalimumab for Pyoderma Gangrenosum (PG).
9899967|NCT04749628|Placebo Comparator|Ora-sweet SF|
9899968|NCT04749628|Experimental|400mg cannabidiol|
9899969|NCT04749628|Experimental|800mg cannabidiol|
9899970|NCT04747704|Experimental|Intervention|Participants receiving Three-Principles Counseling
9899971|NCT04744350|Active Comparator|Surgical|Surgical treatment using a minimal invasive surgical method. At our hospital we perform a percutaneous sacroiliac osteosynthesis using cannulated, perforated and fenestrated screws. This procedure is preferably performed in our hybrid operation theatre, which allows for correct placement using an intraoperative CT-scan.
9899972|NCT04744350|Active Comparator|Conservative|Patients will receive individually tailored physiotherapy and analgesics if necessary.
9899973|NCT04742725|Placebo Comparator|Placebo|
9899974|NCT04742725|Experimental|Prothione ™|
9899975|NCT04740801|Other|PVI procedure|Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form. For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 4.0.1 or greater (commercially approved version) with DIRECTSENSE™ and Force Computation Software Module; the IntellaMap Orion mapping catheter and the IntellaNav StablePoint ablation catheter.
10213923|NCT02646384|Experimental|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
9899977|NCT04739592|Experimental|alendronate sodium vitamin D3 tablets|participants will receive alendronate sodium vitamin D3 tablets once per week for one year.
9899978|NCT04739592|Placebo Comparator|placebo|participants will receive a placebo tablet once per week for one year.
9997792|NCT01512017|Placebo Comparator|Vaseline|
10212646|NCT05168644|Experimental|Drug: Niclosamide Inhalation Powder|"PART A (SAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 0.5 mg, Cohort 2: 2 mg, Cohort 3: 6 mg.~PART B (MAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects will receive Niclosamide Inhalation Powder BID for a total of 9 doses. Subjects in Cohort 4 will receive 3 mg BID, Cohort 5: 6 mg BID."
9899982|NCT04736199|Experimental|Darolutamide+ADT|Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy
9899983|NCT04736199|Placebo Comparator|Placebo+ADT|Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy
9899984|NCT04736121|Experimental|Open-label Single Arm|Open-label single arm study evaluating treatment with hepatic arterial injection of SIR-Spheres.
9899985|NCT04735458|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
9899986|NCT04735458|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
9899987|NCT04732780||Questionnaire group|Individuals who attend the type 1 diabetes clinic will complete a number of self-report questionnaires and a survey.
9899988|NCT04732780||Questionnaire and interview group|"Individuals who attend the type 1 diabetes clinic will complete a number of self-report questionnaires and a survey.~Approximately 16 individuals who experience avoidance of hyperglycaemia will then take part in a semi-structured interview."
9899989|NCT04732013||Study cohort|Single observational cohort of patients who meet study criteria
9899990|NCT04729387|Experimental|Alpelisib+olaparib|Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule.
9899991|NCT04729387|Active Comparator|Paclitaxel or PLD|Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days.
9899992|NCT04728893|Experimental|Nemtabrutinib|Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.
9899993|NCT04727827|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
9899994|NCT04727632|Experimental|Treatment: all patients|One session of [18F]FES PET/CT Imaging
9899995|NCT04727567||Multiple Visit Patient (MVP) Program|"The MVP program aims to manage health and lower hospital utilization among patients with a history of high inpatient hospital stays at Atrium Health. Patients eligible for the program have four or more inpatient visits over the 12-month period prior to enrollment. Once enrolled, each MVP program participant receives on-going support from an assigned MVP care manager and larger care management team, including the following core program components:~customized care plan developed for each patient at the time of enrollment routine, virtual health monitoring and collaborative care management team-based review personalized navigation and coordination across multidisciplinary Atrium Health services, as needed.~Education, health coaching, and support via telephonic and in-person interactions, as needed."
9899996|NCT04727567||Usual Care|Atrium Health standard of care. Patient's post-discharge usual care depends on the inpatient care management assessment at last hospital admission. Patients can be discharged to home and receive no further care, or home with home health, or to a skilled nursing facility (SNF) or another type of Continuing Care facility. Patients can be referred to advanced illness management, hospice, and Community Care Partners by the inpatient care manager. Patient can be referred to Ambulatory Care Management for care management also via telehealth, by a primary care physician or the Transitions Clinic.
9899997|NCT04726852||Patients|Patients having elective cardiac surgery
9899998|NCT04722250|Experimental|Medtronic Self-Expanding TAV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
9899999|NCT04722250|Experimental|Edwards Balloon-Expandable THV|Subjects will be randomized on a 1:1 basis to receive TAVR with either a Medtronic SE TAV or an Edwards BE THV.
9900000|NCT04722146|Experimental|Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide|Participants will receive teclistamab plus daratumumab plus pomalidomide.
9900001|NCT04722146|Experimental|Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 21-day cycles.
9900002|NCT04722146|Experimental|Treatment Regimen C: Teclistamab + Nirogacestat|Participants will receive teclistamab plus nirogacestat.
9900003|NCT04722146|Experimental|Treatment Regimen D: Teclistamab + Lenalidomide|Participants will receive teclistamab plus lenalidomide.
9900004|NCT04722146|Experimental|Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide|Participants will receive teclistamab plus daratumumab plus lenalidomide.
9900005|NCT04722146|Experimental|Treatment Regimen F: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 28-day cycles.
9900006|NCT04722003|Experimental|4CMenB|Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=40
9900007|NCT04722003|Placebo Comparator|Placebo|Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=10
9997793|NCT01512043|Experimental|1. Breathing control|Description ...
9992865|NCT01466582||HIV-negative controls|A group of HIV-negative controls, aged 45 years and above, that is recruited at the STD-clinic of the Public Health Service Amsterdam or at the existing Amsterdam Cohort Studies.
9992866|NCT01466582||HIV-positive patients|A group of HIV-1-infected patients, aged 45 years and above, that is recruited at the HIV outpatient clinic of the Academic Medical Center.
9992867|NCT01466608|Experimental|Rosuvastatin|Rosuvastatin 20 mg will be administered once a day for 8 weeks (open-label, one-arm, single-sequence design)
9992868|NCT01466621||Previously RV Paced|Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
9992869|NCT01466621||Non-Previously RV Paced|Patients who received a CRT device without being previously RV paced.
9992870|NCT01466634||permanent polymer DES|
9992871|NCT01466634||bioabsorbable polymer DES|
9992872|NCT01466647|Other|AXL1717 in combination with Gemcitabine HCL and Carboplatin|AXL1717 in combination with Gemcitabine HCL and Carboplatin
9992873|NCT01466686|Experimental|Temozolomide with Low Dose Fractionated Radiation Therapy|"All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.~All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide."
9992874|NCT01466712|Experimental|Tiotropium+formoterol/beclomethasone|run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks
9992875|NCT01466712|Sham Comparator|tiotropium+placebo|cross-over cfr arm1
9992876|NCT01466738|Experimental|HRV-16 (100 TCID50)|
9992877|NCT01466738|Experimental|HRV-16 (1000 TCID50)|
9992878|NCT01466777|Active Comparator|traditional laparoscopic surgery type|
9992879|NCT01466777|Experimental|Robotic assisted operation type|
9992880|NCT01466803|Active Comparator|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
9992881|NCT01466803|Placebo Comparator|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
9992882|NCT01466816|Experimental|Saturated fatty acid test meal|
9992883|NCT01466816|Experimental|Monounsaturated fatty acid meal|
9992884|NCT01466816|Experimental|Polyunsaturated fatty acid meal|
9992885|NCT01466829|Placebo Comparator|Control|Control patients treated with placebo.
9992886|NCT01466829|Active Comparator|Intervention|Daily injection with Parathyroid hormone
9992887|NCT01466842|Other|Catheter ablation|
9992888|NCT01466842|No Intervention|Antiarrhythmic drugs|Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
9992889|NCT01466855|Experimental|Treatment of Retinoblastoma|Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
9992890|NCT01466868|Experimental|MK2206|Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
9992891|NCT01466894|Experimental|IMM 124-E high dose|IMM 124-E 3600 mg per day
9992892|NCT01466894|Experimental|IMM 124-E low dose|IMM 124-E 1800 mg per day
9992893|NCT01466894|Placebo Comparator|Placebo|Placebo tablets
9992894|NCT01466907|Active Comparator|Intervention group|Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.
9992895|NCT01466907|Other|Control group|Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.
9992896|NCT01466933|Experimental|Community-based|Community trained peer educator delivers parenting sessions to mothers in the village on a monthly basis
9992897|NCT01466933|Active Comparator|Government-based|Government community health workers, trained, deliver the intervention to mothers in the village
9992898|NCT01466933|No Intervention|Control|Mothers receive the standard care which is a visit from the health worker
9900009|NCT04717414|Experimental|Experimental Arm: Luspatercept (ACE-536)|Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)
9900010|NCT04717414|Placebo Comparator|Control Arm: Placebo|Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
9900011|NCT04710277|Experimental|Novel multimodal protocol group|They will receive scheduled topical ice therapy for 24 hours after surgery. It will be applied over abdominal incisions for 20 minutes every 2-3 hours. Acetaminophen and an NSAID will be scheduled for 96 hours. While inpatient, they will receive acetaminophen 975 mg every 8 hours and IV Toradol 15-30 mg every 6 hours with change to ibuprofen 800 mg every 8 hours when tolerating oral intake. They may take oxycodone 5 mg every 4-6 hours as needed (PRN) for breakthrough pain and pain score >6. They may use ice PRN after 24 hours. They will be prescribed acetaminophen 1000 mg every 8 hours and ibuprofen 800 mg every 8 hours for 96 hours postoperative. They may take them as needed after. If the participant used 0 narcotics in the first 24 hours, they will not be prescribed a narcotic. If up to 5 tablets were used, they will be prescribed 5 tablets of oxycodone 5 mg every 6 hours PRN. If more than 5 tablets were used, they will be prescribed 10 tablets of oxycodone 5 mg every 6 hours PRN.
9900012|NCT04710277|Active Comparator|Usual care protocol group|Participants randomly assigned to the usual care protocol will receive current standard of care: scheduled acetaminophen and an NSAID for 24 hours. They will take acetaminophen 975 mg every 8 hours. They will also receive IV toradol 15 to 30 mg every 6 hours then switch to ibuprofen 800 mg every 8 hours when tolerating oral intake. They can also take oxycodone 5 mg every 4 to 6 hours on an as needed (PRN) basis for breakthrough pain with a pain score >6. Per our current standard of care, usual care participants will be allowed to use either topical heat or ice on an as needed basis during their recovery. On discharge home, they will be prescribed acetaminophen 1000 mg every 8 hours PRN and ibuprofen 800 mg every 8 hours PRN. They will also be prescribed 15 tablets of oxycodone 5 mg every 6 hours PRN.
9900013|NCT04708782|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
9900014|NCT04708782|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
9900015|NCT04705376|Active Comparator|Breg Polarcare|Patients within the Breg Polarcare treatment arm will use the Breg Polarcare device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Thermazone device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
9900016|NCT04705376|Experimental|Thermazone|Patients within the Thermazone treatment arm will use the Thermazone device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Breg Polarcare device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
9900017|NCT04703075|Experimental|Rifapentine 600 mg and Isoniazid 300 mg|Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.
9900018|NCT04703075|Active Comparator|Rifapentine 900 mg and Isoniazid 900 mg|Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.
9900019|NCT04702880|Experimental|Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012|
9900020|NCT04702880|Experimental|Arm B: Carboplatin + Etoposide + Nivolumab|
9900021|NCT04701619|Other|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
9900022|NCT04701476|Experimental|colorectal cancer|metastatic colorectal cancer progressed on at least two lines of chemotherapy
9900023|NCT04701476|Experimental|NSCLC|Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
9900024|NCT04700124|Experimental|Arm A: Perioperative EV+ Pembrolizumab and RC + PLND|Participants receive 4 cycles (each cycle length = 21 days) of EV intravenous (IV) infusion plus pembrolizumab IV infusion preoperatively, followed by RC + PLND, followed by 5 cycles of adjuvant EV IV infusion plus 13 cycles of adjuvant pembrolizumab IV infusion postoperatively. The total treatment duration is up to approximately 1 year.
9900025|NCT04700124|Experimental|Arm B: Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND|Participants receive 4 cycles (each cycle length = 21 days) of standard of care (SOC) chemotherapy (gemcitabine IV infusion plus cisplatin IV infusion) preoperatively, followed by RC + PLND. The total treatment duration is up to approximately 3 months.
9933297|NCT05352308|Experimental|Common Sense Model Guided Narrative Video Group|The narrative videos is guided by the CSM and designed to provide a comprehensive resource for college students. The narrative video addresses illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers. The format of the narrative video includes (1) a direct testimonial of a college woman (in her dorm room) telling a story to her roommates about what motivated her to get vaccinated, and (2) a conversation among the roommates where information about the HPV vaccine is discussed.
9933298|NCT05352308|No Intervention|Standard of Care Group|"Participants in the standard of care group will receive the Centers for Disease Control and Prevention's Vaccine Information Statement (VIS; https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv.pdf). The VIS contains information about HPV, the HPV vaccine, and the benefits and risks of the vaccine.~The VIS will be utilized because healthcare providers are required to distribute the VIS to patients before receiving each dose of the HPV vaccine, it is easy to understand, and it is publicly available information."
9933299|NCT05352308|No Intervention|Time & Attention Group|Participants in the time and attention video group will receive a Centers for Disease Control and Prevention video on binge drinking (https://youtu.be/I9hdkDTaQWU; 4:22 minutes). The video contains information on the health risks of binge drinking including unintended pregnancy, sexually transmitted diseases, injury, car accidents, violence, and HIV/AIDS
9933300|NCT05352295||infected|40 patients admitted to the IRCCS Galeazzi Orthopedic Institute for fracture with Covid 19 infection ascertained by nasal pharyngeal swab during the patients' clinical routine
9933301|NCT05352295||not infected ( control)|40 patients admitted to the IRCCS Galeazzi Orthopedic Institute for fracture without Covid 19 infection ascertained by nasal pharyngeal swab during the patients' clinical routine
9933302|NCT05352282|Active Comparator|Group A|
9933303|NCT05352282|Active Comparator|Group B|
9933304|NCT05352269|Experimental|Cohort 1 XBI-302|40 XBI-302 capsules in 1 day
9933305|NCT05352269|Placebo Comparator|Cohort 1 Placebo|40 placebo capsules in 1 day
9933306|NCT05352269|Experimental|Cohort 2 XBI-302|80 XBI-302 capsules over 2 days
9933307|NCT05352269|Placebo Comparator|Cohort 2 Placebo|80 placebo capsules over 2 days
9933308|NCT05352269|Experimental|Cohort 3 XBI-302|40 XBI-302 capsules per day, once a week for 4 weeks.
9933309|NCT05352269|Placebo Comparator|Cohort 3 Placebo|40 placebo capsules per day, once a week for 4 weeks.
9933310|NCT05352269|Experimental|Cohort 4 XBI-302|80 XBI-302 capsules over 2 days, once a week for 4 weeks.
9933311|NCT05352269|Placebo Comparator|Cohort 4 Placebo|80 placebo capsules over 2 days, once a week for 4 weeks.
9933312|NCT05352243|Active Comparator|Expressive Disclosure|Participants will be instructed to write about their deepest thoughts and feelings surrounding their bereavement experience.
9933313|NCT05352243|Experimental|Expressive Helping|Participants will be instructed to write about their deepest thoughts and feeling surrounding their bereavement experience in their first two essays and to provide advice and support for someone who recently experienced a loss in their final essay.
9933314|NCT05352243|Sham Comparator|Fact-Writing|Participants will be instructed to write objectively about different time frames (e.g., routine for getting up in the morning, routine for going to sleep at night).
9933315|NCT05352230|Active Comparator|Continue Glucose Monitoring (CGM)|External diabetes device glucose sensor that measures interstitial glucose levels every minute
9933316|NCT05352230|Other|Glucometer|Device that measures capillary blood glucose levels
9933317|NCT05352204||micronecrosis(+) group|
9933318|NCT05352204||micronecrosis(-) group|
9933319|NCT05352191|Active Comparator|Beclomethasone|800 ug inhaled once aday for 8 days
9933320|NCT05352191|Placebo Comparator|Placebo|one pill once aday for 8 days
9933321|NCT05352178|Active Comparator|MDT alone|Metastasis-directed therapy alone
9933322|NCT05352178|Experimental|MDT + 1 month of ADT|Metastasis-directed therapy plus one month of androgen deprivation therapy (gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im)
9997794|NCT01512043|Active Comparator|2. Listening to music|Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
9992899|NCT01466946||semi-structured interviews|A qualitative study of MSKCC lung cancer patients of Hispanic/Latino descent by collecting retrospective patient narratives to understand the processes that led them to seek medical help when they did, their experiences in seeking and receiving medical guidance, as well as their decisions regarding lung cancer treatment. In addition, we will explore how these patients' representations of lung cancer with its associated risk factors and symptoms affected their treatment decisions.
9992900|NCT01466959|Active Comparator|AD- acetic acid dialysate|AD is a standard bicarbonate based dialysate with a small amount of acetic acid which is the standard of care for dialysis.
9992901|NCT01466959|Experimental|CD - citrasate dialysate|Dialysis with a citric acid based dialyasate.
9992902|NCT01466998|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
9992903|NCT01466998|Active Comparator|Music Therapy|Participant will use an identical appearing device, programmed to play quiet, relaxing non-rhythmic music while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
9992904|NCT01467011||Cases|de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium
9992905|NCT01467024||EIA Negative|Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.
9992906|NCT01467024||EIA Repeat Reactive|Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.
9992907|NCT01467024||Known Positive|Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.
9992908|NCT01467050|Active Comparator|Application of STOPP/START criteria|
9992909|NCT01467050|No Intervention|Control|
9992910|NCT01467089||schizophrenia|"Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.~Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures."
9992911|NCT01467102||Patients|> 18 years of age
9992912|NCT01467115|Experimental|Treatment|Treatment with induction chemotherapy followed by radiation and cetuximab.
9992913|NCT01467128|Active Comparator|Structured expert pharmacist review|
9992914|NCT01467128|No Intervention|Normal pharmaceutical care in hospital|
9992915|NCT01467141|Experimental|IAsp|
9992916|NCT01467141|Active Comparator|HI|
9992917|NCT01467154||Control group|
9992918|NCT01467154||NAC group|
9992919|NCT01467167||Baseline|Baseline group in which patients are anesthetized without the use of Smart Pilot View, according to common practice.
9992920|NCT01467167||Smart Pilot View Group|Study group in which patients are anesthetized with the use of Smart Pilot View.
9992921|NCT01467180|Experimental|HCO CVVHD|treatment of rhabdomyolysis pts with septeX dialyzer
9992922|NCT01467180|Active Comparator|HF CVVH|treatment of rhabdomyolysis pts with standard high flux dialyzer
9992923|NCT01467193||1|Endurance trained athletes: minimal >50 mlO2/KG body weight
9992924|NCT01467193||2|Sedentary healthy control subjects: age, BMI, Gender and waist matched (to the growth hormone deficient patients)
9992925|NCT01467193||3|GHD patients without a GH substitution therapy in the last 6 months
9992926|NCT01467206|Experimental|Long term follow up program|
9992927|NCT01467206|Active Comparator|Standard care|
9900026|NCT04699838|Experimental|Cisplatin or Carboplatin + Etoposide + Durvalumab + Ceralasertib|"Initial Phase: Cycles 1-4 Cisplatin or Carboplatin: Day 1 Etoposide: Days 1-3 Durvalumab, 1500 mg: Day 1 q 3 weeks~Maintenance Phase, Cycles 5+ Durvalumab, 1500 mg: Day 8 q 4 wks. Ceralasertib at 240mg po BID twice a day: Days 1-7"
9900027|NCT04696471|Experimental|Left ventrolateral prefrontal cortex (vlPFC)/Left SS/Left vlPFC sham|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
9900028|NCT04696471|Experimental|Left vlPFC/Left vlPFC sham/Left SS|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
9900029|NCT04696471|Experimental|Left SS/Left vlPFC sham/Left vlPFC|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
9900030|NCT04696471|Experimental|Left SS/Left vlPFC/Left vlPFC sham|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
9900031|NCT04696471|Experimental|Left vlPFC sham/Left SS/Left vlPFC|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
9900032|NCT04696471|Experimental|Left vlPFC sham/Left vlPFC/Left SS|"A random number sequence will be generated for randomization of the 3 cTBS scan session order to which each participant is assigned:~left vlPFC cTBS (cTBS applied to the left ventrolateral prefrontal cortex)~left SS cTBS (cTBS applied to the left somatosensory area)~left vlPFC sham TBS (go through the motions of applying cTBS to the left ventrolateral prefrontal cortex but very low current is administered so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells) Participants will know that one session will be a sham, but they will be blinded to which session is the sham."
9900033|NCT04692181|Placebo Comparator|Placebo + IV Meropenem|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
9900034|NCT04692181|Active Comparator|SYN-004 + IV Meropenem|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
9900035|NCT04692181|Placebo Comparator|Placebo + IV Piperacillin/Tazobactam|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
9900036|NCT04692181|Active Comparator|SYN-004 + IV Piperacillin/Tazobactam|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
9900037|NCT04692181|Placebo Comparator|Placebo + IV Cefepime|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
9900038|NCT04692181|Active Comparator|SYN-004 + Cefepime|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
9900039|NCT04688658|Experimental|Duvelisib plus Nivolumab|"Phase 1: Duvelisib will be taken orally in doses from 15mg once a day, 25mg once a day or 25mg twice a day, 12 hours a part, to determine the recommended dose for the Phase II study when combined with nivolumab.~Nivolumab, 240mg, IV, every 2 weeks for the first four cycles; thereafter it may be switched to 480mg, IV, once every 4 weeks if deemed appropriate by the study doctor.~Phase II: The Recommended Phase II dosage of duvelisib administered will not be determined until Phase I is completed.~Nivolumab, 480mg, IV, every 4 weeks, for up to 1 year."
9992928|NCT01467219|Experimental|PET Probe|"Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify hot lymph nodes."
9900040|NCT04685616|Active Comparator|ABVD +/- ISRT|"2 x 28 day cycles of ABVD: Doxorubicin 25mg/m^2 IV days 1 & 15 Bleomycin 10000 IU/m^2 days 1 & 15 Vinblastine 6mg/m^2 days 1 & 15 Dacarbazine 375mg/m^2 days 1 & 15~PET-CT after 2 cycles will determine subsequent treatment:~Deauville score 1-3 (PET CMR): 1 further cycle of ABVD then follow up Deauville score 4 (PET positive): 2 further cycles of ABVD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
9900041|NCT04685616|Experimental|A2VD +/- ISRT|"2 x 28 day cycles of A2VD: Doxorubicin 25mg/m^2 IV days 1 & 15 Brentuximab vedotin 1.2mg/kg (max 120mg) days 1 & 15 Vinblastine 6mg/m^2 days 1 & 15 Dacarbazine 375mg/m^2 days 1 & 15 Filgrastim (or equivalent haematopoietic growth factor) for 5-7 days from day 2 and day 16 (or single dose of peg-filgrastim on days 2 & 16)~PET-CT after 2 cycles will determine subsequent treatment:~Deauville score 1-3 (PET CMR): 1 further cycle of A2VD then follow up Deauville score 4 (PET positive): 2 further cycles of A2VD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
9900042|NCT04685408|Experimental|TargEted MAnageMent Intervention (TEAM)|This arm will receive the experimental intervention, TargEted MAnageMent Intervention (TEAM)
9900043|NCT04685408|Active Comparator|Enhanced treatment as usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
9900044|NCT04683939|Experimental|Part 1A - BNT141 monotherapy escalation|Administration once every three weeks (Q3W)
9900045|NCT04683939|Experimental|Part 1B - BNT141 in combination with nab-paclitaxel and gemcitabine|BNT141 will be administered once every three weeks (Q3W). Nab-paclitaxel and gemcitabine will be administered on three days of each 28-day cycle.
9900046|NCT04681729|Experimental|Dupilumab|Dose regimens, on top of regular or as needed non-sedating H1-antihistamine
9900047|NCT04681729|Placebo Comparator|Matched Placebo|Placebo,on top of regular/as needed non-sedating H1-antihistamine
9900048|NCT04677166|Experimental|NPWT with Instillation|"NPWT coupled with instillation will be employed via use of V.A.C. VeraFlo device. The protocol to be used is as follows:~Instillation Solution: normal saline Dwell/Soak Time: 30 seconds Cycle Time: 4 hours Pressure: 125mmHg"
9900049|NCT04677166|Active Comparator|Standard NPWT|Standard NPWT with use of V.A.C. Ulta device employed at 125mmHg continuous suction.
9900050|NCT04671017|Experimental|Low Dose: VLA2001|
9900051|NCT04671017|Experimental|Medium Dose: VLA2001|
9900052|NCT04671017|Experimental|High Dose: VLA2001|
9900053|NCT04671017|Experimental|Booster: High Dose: VLA2001|
9900054|NCT04668768|Experimental|Glucarpidase|Prophylactic glucarpidase treatment
9900055|NCT04666961|Experimental|Extended ductal carcinoma in situ with mastectomy indication|"Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation.~Tamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 :~Tamoxifen: box of tablets dosed at 20 mg~Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg/day as a single dose for 6 months.~Anastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg/day in a single dose for 6 months."
9900056|NCT04665388||EBV-related cancer cohort|up to N=30
9900057|NCT04665388||HPV-related cancer cohort|up to N=45
9900058|NCT04665388||HCC cohort|up to N=30
9900059|NCT04662970|Experimental|Device programming|according to different settings from the SyncAV algorithm
9900060|NCT04662710|Experimental|Lenvatinib + Pembrolizumab + Chemotherapy|Participants receive lenvatinib administered orally (PO) every day (QD) in combination with pembrolizumab intravenously (IV) every 6 weeks (Q6W) plus chemotherapy with either capecitabine and oxaliplatin (CAPOX) or chemotherapy with 5-FU, leucovorin, and oxaliplatin (mFOLFOX6). Induction with lenvatinib 8 mg QD plus pembrolizumab (400 mg Q6W) plus chemotherapy (CAPOX or mFOLFOX6) will be administered for 2 cycles (approximately 12 weeks), followed by consolidation with lenvatinib 20 mg QD plus pembrolizumab (400 mg Q6W) for 16 cycles. A cycle is 6 weeks (42 days).
9900061|NCT04662710|Experimental|Chemotherapy|Participants receive chemotherapy with either CAPOX Q3W or mFOLFOX6 Q2W. A cycle is 6 weeks (42 days).
9900062|NCT04658862|Experimental|TAR-200 + Cetrelimab|Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with Cetrelimab.
9900063|NCT04658862|Active Comparator|Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy|Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 6 treatment weeks or gemcitabine intravenously twice weekly for 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray [Gy], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.
9900064|NCT04658654|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 24 weeks
9900065|NCT04658654|Experimental|Roflumilast 50ug|Roflumilast (50 microgram) oral capsule, once daily for 24 weeks
9992929|NCT01467232|Experimental|Autologous CD133+ Stem Cells|Autologous CD133+ stem cells
9900066|NCT04658654|Experimental|Roflumilast 100ug|Roflumilast (100 microgram) oral capsule, once daily for 24 weeks
9900067|NCT04657562||De novo renal/liver transplant recipients|The group of 40 consecutive adult (age > 18 years) male and female recipients of deceased kidney or liver transplant from the Regional Qualification Center (Warsaw, Poland).
9900068|NCT04657562||Random renal transplant recipients|The group of 300 random adult (age > 18 years) male and female recipients of deceased kidney attending the local outpatient clinic.
9900069|NCT04657562||Renal transplant recipients experiencing graft rejection|The group of 40 consecutive adult (age > 18 years) male and female recipients of deceased kidney experiencing acute rejection of the renal allograft.
9900070|NCT04657224|Experimental|Part A: Dose escalation: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 will be administered together until disease progression, intolerable toxicity, withdrawal of consent, or the investigator.
9900071|NCT04657224|Experimental|Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
9900072|NCT04651075|Experimental|music theraphy|One of the 4 music genres (Turkish Folk, Classical, Turkish Art and Sufi Music), which was determined by the researcher by scanning the literature 30 minutes before the CAG procedure, and the expert opinion was taken to the participants in this group was played with a 5-minute headset. The musical genres were arranged in instrumental, nonverbal, 70 decibels in terms of rhythm and duration and played according to the individual's choice.
9900073|NCT04651075|Experimental|information education|Participants in this group were trained to inform them about CAG in visual, audio and written form. Information training was provided by the researcher 30 minutes before the CAG procedure after the outpatient clinic controls of the patient. Information education prepared by the researcher by scanning the literature and getting expert opinion; It includes 7 minutes of video explanation about the CAG process, discussion after video watching, question and answer, and the delivery of a training book prepared in written form.
9900074|NCT04651075|No Intervention|nursing care|Individuals in this group received routine nursing care and no intervention was made by the researcher. In routine nursing care for individuals who will receive CAG procedure in the clinic; Preparation for the CAG procedure, which involves opening the vascular access and dressing the surgical gown, is included in the pre-and post-procedure routine once and more frequently when there are deviations from normal, and if the patient asks questions about the procedure, measurement of blood pressure, heart rate and oxygen saturation.
9900075|NCT04650854|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized/assigned to dosage regimen 1 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
9900076|NCT04650854|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized/assigned to dosage regimen 2 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
9900077|NCT04649775|Active Comparator|Device intervention|Intervention participants will receive the AirFLO2 device and training via video with reinforcement from the coordinator how to use and to self-apply it. Clinical data will be recorded before and after intervention. Questionnaires will be completed at baseline and at serial time points after intervention starts.
9900078|NCT04649775|No Intervention|Standard of Care- Control|Participants will receive standard of care, clinical data will be recorded. Baseline and end of study questionnaires will be performed.
9900079|NCT04649580||Online Survey|
9900080|NCT04649580||One-to-one interviews|
9900081|NCT04649073|Experimental|OPC-415 (up to 1×10^7cells/kg)|
9900082|NCT04649047|Experimental|Intervention|All participants will be assigned to the experimental group and receive a 3-weekly intervention via web and individual health coaching. The educational topics cover stress management, healthy eating, and physical activity
9900083|NCT04647474||Radical Prostatectomy|Participants undergoing any curative surgical treatment option for prostate cancer irregardless of approach (open, laparoscopic or robotic)
9900084|NCT04647474||Active Surveillance|Participants undergoing active surveillance as the management option for prostate cancer as defined by regular surveillance attendance at the primary treating site.
9992930|NCT01467232|Placebo Comparator|Saline solution containing autologous plasma|Saline solution containing autologous plasma without CD133+ (indistinguishable from the autologous CD133+ stem cells)
9517799|NCT03302845|Experimental|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
9900085|NCT04647474||Hormone Monotherapy|Participants undergoing medical hormone therapy (Antiandrogens and Gonadotropin-releasing hormone (GnRH) agonists or antagonists) or surgical castration (e.g. orchidectomy) options as the primary treatment for prostate cancer.
9900086|NCT04647474||Radical Radiotherapy|Participants undergoing primary radiotherapy treatment for prostate cancer irregardless of delivery methods (e.g. External beam radiation therapy or brachytherapy).
9900087|NCT04646837|Experimental|Experimental Arm|Durvalumab 1000 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IB-IIIA NSCLC adult patients followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 15000mg Q4W for 8 months
9900088|NCT04643470|Experimental|Zanubrutinib Low Dose|Participants will receive zanubrutinib 40 mg twice daily (BID) for 72 weeks
9900089|NCT04643470|Experimental|Zanubrutinib High Dose|Participants will receive zanubrutinib 160 mg twice daily (BID) for 72 weeks
9900090|NCT04643470|Experimental|Zanubrutinib Medium Dose|Participants will receive zanubrutinib 160 mg once daily (QD) for 72 weeks
9900091|NCT04643470|Experimental|Placebo|Participants will receive placebo to match zanubrutinib for 72 weeks
9900092|NCT04642469|Experimental|Durvalumab|Intravenous administration of Durvalumab
9900093|NCT04642469|Placebo Comparator|Placebo|Intravenous administration of placebo
9900094|NCT04640948|Experimental|High flow nasal therapy (HFNT)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
9900095|NCT04640948|Active Comparator|Low flow oxygen (LFO)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
9900096|NCT04640623|Experimental|Cohort 1: TAR-200 and Cetrelimab|TAR-200 is placed into the bladder through a urinary placement catheter on Day 0 and will be dosed every 3 weeks (Q3W) for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2). In addition, Cetrelimab will be dosed Q3W through Week 78 (18 months).
9900097|NCT04640623|Experimental|Cohort 2: TAR-200|TAR-200 is placed into the bladder through a urinary placement catheter on Day 0 and will be dosed Q3W for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2).
9900098|NCT04640623|Experimental|Cohort 3: Cetrelimab|Participants will receive Cetrelimab which will be dosed Q3W through Week 78 (18 months).
9900099|NCT04639986|Experimental|Arm A|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle.
9900100|NCT04639986|Active Comparator|Arm B|"Recommended doses and schedules as per package insert depending on region.~Eribulin (1.4 mg/m2 of eribulin mesylate or 1.23 mg/m2 of eribulin IV on Days 1 and 8 of a 21-day cycle)~Capecitabine (1000 to 1250 mg/m2 PO twice daily on Days 1 to 14 of a 21-day cycle)~Gemcitabine (800 to 1200 mg/m2 IV on Days 1, 8, and 15 of a 28-day cycle)~Vinorelbine (25 mg/m2 IV on Day 1 weekly)"
9992931|NCT01467258|Experimental|Amantadine|Single dose
9900101|NCT04634877|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
9900102|NCT04634877|Placebo Comparator|Placebo + Chemotherapy|Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
9900103|NCT04634552|Experimental|Part 3: Cohort A (Talquetamab)|Cohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
9900104|NCT04634552|Experimental|Part 3: Cohort B (Talquetamab)|Cohort B will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
9900105|NCT04634552|Experimental|Part 3: Cohort C (Talquetamab)|Cohort C will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
9900106|NCT04633460|Experimental|Ketone ester|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a ketone ester
9900107|NCT04633460|Placebo Comparator|Placebo|KE-free solution
9900108|NCT04633421|Experimental|PRECISe protocol EN (8g protein/100kcal)|Enteral (EN) feed with 8 grams protein per 100 kcal (2.0 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
9900109|NCT04633421|Active Comparator|PRECISe protocol EN (5g protein/100kcal)|Enteral (EN) feed with 5 grams protein per 100 kcal (1.2 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
9900110|NCT04632992|Experimental|Arm A: Entrectinib|Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.
9900111|NCT04632992|Experimental|Arm B: Inavolisib|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
9900112|NCT04632992|Experimental|Arm C: Alectinib|Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.
9900113|NCT04632992|Experimental|Arm D: Ipatasertib|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
9900114|NCT04632992|Experimental|Arm E: Atezolizumab + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
9900115|NCT04632992|Experimental|Arm F: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutations or amplification without known TMB high or MSI high/dMMR.
9900116|NCT04632992|Experimental|Arm G: PH FDC SC|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
9900117|NCT04632992|Experimental|Arm H: PH FDC SC + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
9900118|NCT04632992|Experimental|Arm I: Trastuzumab Emtansine + Tucatinib|Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
9900119|NCT04632992|Experimental|Arm J: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have positive tumor biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.
9900120|NCT04632992|Experimental|Arm K: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
9900121|NCT04632992|Experimental|Arm L: Ipatasertib + Atezolizumab|Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
9900122|NCT04632992|Experimental|Arm M: Ipatasertib + Paclitaxel|Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.
9900123|NCT04632992|Experimental|Arm N: Atezolizumab + Tiragolumab|Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.
9900124|NCT04632992|Experimental|Arm O: Pralsetinib|Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.
9900125|NCT04631211|Experimental|Thrombosomes Low Dose|
9900126|NCT04631211|Experimental|Thrombosomes Medium Dose|
9900127|NCT04631211|Experimental|Thrombosomes High Dose|
9900128|NCT04631211|Active Comparator|Liquid Stored Platelets (Control)|
9933323|NCT05352178|Experimental|MDT + 6 months of ADT + anzalutamide|Metastasis-directed therapy plus 6 months of androgen deprivation therapy (gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im) and enzalutamide (4 x 40 mg each day during 6 months )
9933324|NCT05352165|Experimental|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
9997795|NCT01512043|Sham Comparator|3. Silence|Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
9900129|NCT04631003|Other|Dynamic testing|"There are only one arm in this study. All patients get the same diagnostics and therapy. The preoperative assessments consist of an arthroCT of the wrist as well as the collection of demographic data, accident mechanism, medication intake, etc. within the scope of the usual medical history on the emergency ward. With the arthro-CT, in addition to the fracture balance, the proof of a possible rupture of the scapholunary tape apparatus takes place.~The dynamic determination of the scapholunary instability takes place during the osteosynthesis of the radius fracture.~With the dynamic functional test, the change of the scapholunary distance is assessed by illumination by movement of the wrist from the radial abduction into the ulnar abduction, before and after the execution of the osteosynthesis of the distal radius fracture.~Subsequently, the results of the scapholunary dissociation of the arthro-CT are checked with the results of the intraoperative dynamic test for correlation."
9900130|NCT04629547|Experimental|Poor sleep treatment group|100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
9900131|NCT04629547|Placebo Comparator|Poor sleep control grop|100 participants will be randomized to take placebo daily at h.s. for two years.
9900132|NCT04628767|Experimental|Arm A (durvalumab, chemotherapy)|Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
9900133|NCT04628767|Active Comparator|Arm B (chemotherapy)|Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
9900134|NCT04628767|Experimental|Arm C (durvalumab, gemcitabine hydrochloride)|Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
9900135|NCT04626583|Active Comparator|Low dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 µL at the low dose level.
9900136|NCT04626583|Active Comparator|Medium dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL at the medium dose level.
9900137|NCT04626583|Active Comparator|High dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 µL each at the high dose level.
9900138|NCT04626518|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg). Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years).
9900139|NCT04626518|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg). Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
9900140|NCT04626518|Experimental|Pembrolizumab + MK-4830|Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to ~2 years).
9900141|NCT04626518|Experimental|Pembrolizumab + Belzutifan|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Belzutifan will be administered orally once-daily (QD) until progressive disease or discontinuation.
9900142|NCT04626518|Experimental|Belzutifan + Lenvatinib|Participants will receive Belzutifan 120 mg PLUS lenvatinib 20 mg. Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
9900143|NCT04626518|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
9900144|NCT04626479|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
9900145|NCT04626479|Experimental|Coformulation Favezelimab/Pembrolizumab+ Lenvatinib|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
9900146|NCT04626479|Experimental|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
9900147|NCT04626479|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
9900148|NCT04624204|Experimental|Group A - Pembrolizumab 200 mg|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg every 6 weeks (Q6W) plus olaparib matching placebo twice daily (BID) for 12 months or until specific discontinuation criteria are met.
9900149|NCT04624204|Experimental|Group B - Pembrolizumab 200 mg plus Olaparib 300 mg BID|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg Q6W plus olaparib 300 mg BID for 12 months or until specific discontinuation criteria are met.
9900150|NCT04624204|Placebo Comparator|Group C (Pembrolizumab and Olaparib Matching Placebos)|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab placebo (saline) Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab placebo (saline) Q6W plus olaparib matching placebo for 12 months or until specific discontinuation criteria are met.
9900151|NCT04623008|Experimental|Goal-Oriented Episodic Future Thinking (GOEFT) Intervention|In addition to usual prenatal care, intervention participants will receive a 20-week intervention via web and individual health counseling. The intervention topics focus on stress management, healthy eating, and physical activity.
9900152|NCT04623008|No Intervention|Usual Prenatal Care|The usual prenatal care group will receive usual care from their providers
9900153|NCT04619420|Experimental|JNJ-63733657|Participants will receive single dose of JNJ-63733657 low dose or high dose administered by intravenous (IV) infusion every 4 weeks.
9900154|NCT04619420|Placebo Comparator|Placebo|Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks.
10213924|NCT02630368|Experimental|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 14"
10213925|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 1.~Experimental phase II soft-tissue sarcoma :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 48"
9900157|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Moderate Liver Impairment|Participants with advanced solid tumor and moderate hepatic impairment will receive an escalating dose of sacituzumab govitecan-hziy on Days 1 and 8. The dose-escalation plan will start at 5 mg/kg and escalate to 7.5 mg/kg, and finally 10 mg/kg, if deemed to be safe. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
9900158|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Normal Liver function|Participants with advanced or metastatic solid tumor and normal hepatic function will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
9517800|NCT03302845|Experimental|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
9900159|NCT04615104||Pelvic Ring Fracture|Patients with pelvic ring fractures.
9900160|NCT04615104||Acetabular Fracture|Patients with acetabular fractures.
9900161|NCT04613518|Experimental|BMS-986165|
9900162|NCT04613518|Placebo Comparator|Placebo|
9900163|NCT04613518|Experimental|Open label Extension, BMS-986165|
9900164|NCT04613440|Other|Standard of care - Proband-mediated cascade testing|Probands randomized to the standard of care group will be instructed to share a family letter (providing information on the familial mutation) with their FDRs and encourage FDRs to complete genetic testing.
9900165|NCT04613440|Other|Intervention - Facilitated cascade testing|In the intervention group, a patient navigator will provide facilitated support, including an initial genetic counseling call, an email with a link to an educational video, and, for individuals who are interested in completing testing - a link to create an account for a free saliva kit and a follow-up call to discuss the results and ensure participants are connected with their primary care provider or other clinician, as appropriate.
9900166|NCT04609826|Experimental|Arm A: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until a recommended Phase 2 dose (RP2D) has been identified.
9900167|NCT04609826|Experimental|Arm B: JNJ-74856665 + Azacitidine (AZA)|Participants will receive JNJ-74856665 orally in combination with AZA administered intravenously (IV) or subcutaneously (SC) in a 28-day cycle.
9900168|NCT04609826|Experimental|Arm C: JNJ-74856665 + Venetoclax (VEN)|Participants will receive JNJ-74856665 orally in combination with VEN in a 28-day cycle.
9900169|NCT04609826|Experimental|Arm D: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. Participants with transfusion dependent relapsed/refractory Myelodysplastic Syndrome (MDS) will be included.
9900170|NCT04607941||Cases|Subjects diagnosed as positive for SARS-CoV-2 infection
9900171|NCT04607941||Close Subjects|"Subjects living within the same household as cases:~close cases if tested positive for SARS-CoV-2 following contact tracing recommendations~close controls if tested negative for SARS-CoV-2 following contact tracing recommendations"
9900172|NCT04607941||Control Subjects|Controls selected within the population to allow for an age, gender and location of residence-matched analysis with cases
9900173|NCT04606381|Experimental|Part 1: Ami-LC-MD and Ami-LC|Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.
9900174|NCT04606381|Experimental|Part 2: Ami-HC and Ami-HC-CF|Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).
9900175|NCT04606381|Experimental|Part 3: Ami-HC-CF + Lazertinib and Ami-HC+ Lazertinib|Participants will receive SC infusion of either Ami-HC-CF or Ami-HC in combination with lazertinib tablet.
9900176|NCT04596995|Experimental|Rozanolixizumab Treatment Arm|All study participants will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
9900177|NCT04592289|Experimental|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery~Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
9900178|NCT04592289|Active Comparator|Mechanical bowel preparation only|"Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
9900179|NCT04590001|Experimental|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD device.
9900180|NCT04589650|Experimental|Adult cohort (group 1)- Alpelisib|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
9900181|NCT04589650|Placebo Comparator|Adult cohort (group 1)- Placebo|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo (125 mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
9900182|NCT04589650|Experimental|Pediatric cohort (group 2: 6 to 17 years old) -Alpelisib|During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
9900183|NCT04589650|Placebo Comparator|Pediatric cohort (group 2: 6 to 17 years old)-Placebo|During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo (50mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
9900184|NCT04589650|Experimental|Pediatric cohort (group 3: 2 to 5 years old)- Alpelisib granules|Pediatric participants (2 to 5 years old) will receive alpelisib with the alpelisib granules formulation at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2 in addition to the data from Group 4 as available. An extrapolation approach will be used for dose selection for this group.
9900185|NCT04589650|Experimental|Pediatric cohort (group 4: 2 to 5 years old)- Alpelisib FCT|Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.
9900186|NCT04587882|Experimental|Telehealth|Participants will be provided with a smartwatch, have access to activity tracking and goal setting through the VALENTINE app, receive micro-randomized, contextually tailored notifications, and receive weekly activity summaries via email, which will be provided to participants and to their exercise physiologist while enrolled in cardiac rehabilitation.
9900187|NCT04587882|Active Comparator|Control|Participants will continue to receive usual care and a smartwatch but without access to the micro-randomized notifications or weekly activity summaries.
9900188|NCT04586426|Experimental|Part 1: Dose Escalation|Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
9900189|NCT04586426|Experimental|Part 2: Dose Expansion|Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the RP2R(s) of the study treatment identified in Part 1.
9900192|NCT04579224|Active Comparator|Arm I (standard of care chemotherapy)|Patients receive 1 of the 3 standard of care chemotherapy regimens based on treating investigator's choice: Choice A: Patients receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Choice B: Patients receive gemcitabine IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Choice C: Patients receive paclitaxel IV on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9900193|NCT04579224|Experimental|Arm II (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9900194|NCT04579224|Experimental|Arm III (eribulin, gemcitabine)|Patients receive eribulin IV over 2-5 minutes and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9900195|NCT04578756|Experimental|Cariprazine Dose 1|Participants with Schizophrenia 13 to 17 years will receive cariprazine.
9900196|NCT04578756|Experimental|Cariprazine Dose 2|Participants with Bipolar I Disorder, 10 to 12 years (weighing <=40 kg) will receive cariprazine.
9900197|NCT04578756|Experimental|Cariprazine Dose 3|Participants with Bipolar I Disorder, 10 to 12 years (weighing >40 kg) will receive cariprazine.
9900198|NCT04578756|Experimental|Cariprazine Dose 4|Participants with Bipolar I Disorder, 13 to 17 years will receive cariprazine.
9900199|NCT04577833|Experimental|Treatment Sequence ABD|Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
9900200|NCT04577833|Experimental|Treatment Sequence ADB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
9900201|NCT04577833|Experimental|Treatment Sequence CBD|Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
9900202|NCT04577833|Experimental|Treatment Sequence CDB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
9900203|NCT04573660||Coronary and peripheral stents|Participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
9900204|NCT04573660||Pacing catheters|Participants in the Pacing catheters arm will receive Pacing catheters
9900205|NCT04573660||Vascular plugs|Participants in the Vascular plugs arm will receive Vascular plugs
9900206|NCT04573660||Measurement and imaging (FFR and OCT)|Participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
9900207|NCT04573660||Peripheral dilatation catheters|Participants in the Peripheral dilatation catheters arm will receive Peripheral dilatation catheters
9900208|NCT04573660||Coronary dilatation catheters|Participants in the Coronary dilatation catheters arm will receive Coronary dilatation catheters
9900209|NCT04573660||Coronary and peripheral guidewires|Participants in the Coronary and peripheral guidewires arm will receive Coronary and peripheral guidewires
9900210|NCT04573660||Vessel closure/compression devices|Participants in the Vessel closure/compression devices arm will receive Vessel closure/compression devices
9900211|NCT04573660||Vascular access introducers|Participants in the Vascular access introducers devices arm will receive Vascular access introducers
9900212|NCT04572893|Experimental|MYK-491|Primary DCM due to MYH7 or TTN Variant
9900213|NCT04572750|Experimental|EMPOWER-ED|Individuals will be given access on their preferred platform to an electronic self-help app focused on reducing benzodiazepine use
9900214|NCT04572750|No Intervention|Control|Individuals will be provided care as usual
9900215|NCT04572451|Experimental|Nivolumab (Anti-PD-1) + BMS-986253 (Anti-IL-8) + SBRT|480 mg intravenous nivolumab (BMS-936558-01) every 4 weeks + 2,400 mg intravenous BMS-986253 (Anti-IL-8) every 2 weeks + Stereotactic Body Radiotherapy (SBRT)
9900216|NCT04569357|Experimental|Prospecta|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
9900217|NCT04569357|Placebo Comparator|Placebo|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
9900218|NCT04569084|Experimental|MT-1186|
9900219|NCT04569084|Experimental|MT-1186 and Placebo|
9900220|NCT04567615|Experimental|Arm A : Nivolumab|
9900221|NCT04567615|Experimental|Arm B : Nivolumab + Relatlimab Dose 1|
9900222|NCT04567615|Experimental|Arm C : Nivolumab + Relatlimab Dose 2|
9900223|NCT04566601|Experimental|BI 1358894 dose group 1|
9900224|NCT04566601|Placebo Comparator|Placebo|
9900225|NCT04566601|Experimental|BI 1358894 dose group 2|
9900226|NCT04566601|Experimental|BI 1358894 dose group 3|
9900227|NCT04566601|Experimental|BI 1358894 dose group 4|
9900228|NCT04564742|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo
9900229|NCT04564742|Placebo Comparator|Placebo|Placebo matching dapagliflozin
9900230|NCT04562233|Experimental|Intervention arm|Participants will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer. Once a week, the exercise trainer and participant will each onto Zoom from their locations to begin the supervised exercise session. The exercise trainer will record all sessions. Sessions will be 30-45-minutes long and be structured as follows: review of previous session and an opportunity to ask questions; 5-minute warm-up; 20-25-minute workout; 5-10-minute cool down and reminder of next session and/or data collection time period. Supervised sessions will be scheduled once a week over the 12-week intervention. Participants will be expected to complete their resistance-based physical activity program for an additional 1-2 days a week as per the intervention schedule to meet as physical activity guidelines. The exercise trainer will track participant attendance. During the session, participants must have another person in the same location incase of an emergency.
9900231|NCT04562233|Other|Control Arm|"The attention control arm will include a printed, individualized resistance-based physical activity program.~Participants randomized to the control arm will also be given a printed or digital individualized, resistance-based physical activity program and told to aim to for three exercise sessions per week. Control participants will follow the same measurement schedule as intervention participants."
9900232|NCT04561388|Other|Cochlear implant candidates with measurable residual hearing|"Electrocochleography responses to acoustic will be recorded during the cochlear implantation and the 6 first months of use of the cochlear implant.~A pure tone audiometry will be done prior and after the implantation. Speech audiometry will be done twice after the cochlear implantation."
9900233|NCT04560504|Placebo Comparator|Control Group|Receive 10 sessions of 45-minute (3 sessions per week) in-office leisure activities e.g. simple non-action computer games or board games (e.g. card and chess games) and 10-20 minutes of video watching at home
9900234|NCT04560504|Active Comparator|Intervention Group|Receive 10 sessions of 45-minute office training (3 sessions per week) and 10-20 minute home training (3 sessions per week) of eye movement training
9900235|NCT04559802|Experimental|Transmucosal (Non-Submerged)|Flaps will be adapted to the healing abutments for a trans-mucosal healing up on closure
9900236|NCT04559802|Active Comparator|Submerged|Flaps will be advanced to achieve primary wound closure.
9900237|NCT04559633|Experimental|Anxious school refusal|Adolescents with anxious shool refusal will beneficiate of cognitive and behavioral therapy (CBT) in order to help them to return back to school
9900238|NCT04557371|Experimental|Developmental Serum|The participants will apply a developmental serum topically to the face twice daily (morning and evening) to freshly cleansed with normal moisturizing routine for 21 days.
9900239|NCT04557371|Experimental|Developmental Lotion|The participants will apply a developmental lotion topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
9900240|NCT04557371|Experimental|Developmental Cream|The participants will apply a developmental cream topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
9900241|NCT04557228|Placebo Comparator|Placebo|Study participants will receive 4 weeks of supplementation with 400mg placebo supplements
9900242|NCT04557228|Experimental|Phosphatidylserine Supplementation|Study participants will receive 4 weeks of supplementation with 400mg phosphatidylserine supplements.
9900243|NCT04557098|Experimental|Part 3: Teclistamab|Participants in all cohorts will receive teclistamab SC at an RP2D.
9900244|NCT04555720|Experimental|Interdisciplinary Care|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participant's doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
9900245|NCT04555720|No Intervention|Standard of Care|If assigned to standard of care, group participants will have a normally scheduled visit with neurologist.
9900246|NCT04552041|Experimental|Prospecta|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
9900247|NCT04552041|Placebo Comparator|Placebo|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
9900248|NCT04549207|Active Comparator|Standard BMA frequency|Continue standard BMA frequency (every 4 or 12 weeks) as administered previously. If a change in BMA frequency (every 4 weeks to every 12 weeks OR every 12 weeks to every 4 weeks) was prescribed by the physician, this would still be considered on protocol treatment.
9900249|NCT04549207|Active Comparator|De-escalate BMA to once every 24 weeks|Bone modifying agent once every 24 weeks.
9900250|NCT04547283|Active Comparator|Usual Care|Participants randomized to this arm will remain in their clinician's team standard practice and their natural choice of position, which is anticipated to favor a supine (rather than prone) position.
9900251|NCT04547283|Experimental|Awake-Prone Positioning Strategy|Participants randomized to this arm will receive guidance from their Inpatient treatment team to assume the prone position for as much time as is tolerable during hospitalization.
9900252|NCT04545385|Experimental|TEV-48574|The patients will receive the investigational medicinal product (IMP) loading dose on the day of randomization and the subsequent corresponding IMP maintenance dose every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
9900253|NCT04545385|Placebo Comparator|Placebo|Matching Placebo
9900254|NCT04543591|Experimental|Ravulizumab|"In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC).~In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC)."
9900255|NCT04543591|Placebo Comparator|Placebo|In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.
9900256|NCT04540952|Experimental|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
9900257|NCT04540952|Active Comparator|Control|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
9900258|NCT04540796|Experimental|Part A: Dose Escalation|Participants will receive once weekly dose or may receive every 2 weeks (Q2W) administration of JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
9900259|NCT04540796|Experimental|Part B: Cohort Expansion|Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
9900260|NCT04540341|Experimental|Mulligan mobilization group|Painless movement
9900261|NCT04540341|Experimental|Core stabilization group|Abdominal drawing-in maneuver
9900262|NCT04540341|Active Comparator|conventional therapy group|Ultrasound TENS Hotpack
9900263|NCT04536792|Experimental|Part 1: Single Ascending Dose (SAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once on Day 1. AG-946 will be given under fasted or fed conditions.
9900264|NCT04536792|Experimental|Part 2: Multiple Ascending Dose (MAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once daily (QD) for 14 days or using an alternative dosing regimen for 28 days under fasted conditions.
9900265|NCT04536792|Experimental|Part 3: Sickle Cell Disease (SCD) Phase|Participants will receive a range of selected ascending doses of AG-946, orally, QD or using an alternative dosing regimen for 28 days.
9900266|NCT04536701|Experimental|Dementia/Caregiver Dyad|All dementia/caregiver dyads will have in-home acoustic monitoring to classify mood and will be provided mindfulness-based stress reduction recommendations via a smart phone.
9900267|NCT04532463||Amphotericin B,Flucytosine, Fluconazole|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
9900268|NCT04531462|Experimental|Empagliflozin|
9900269|NCT04531462|Placebo Comparator|Placebo|
9900270|NCT04529564||EAP patients|The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in South Korea and Taiwan during 2018 to 2019.
9933325|NCT05352165|Active Comparator|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
9933326|NCT05352165|Active Comparator|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
9933327|NCT05352165|Active Comparator|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
9933328|NCT05352165|Active Comparator|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
9933329|NCT05352165|Active Comparator|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
9933330|NCT05352152||Patients with ascites infection|Patients who is confirmed with ascites infection or clinically diagnosed as ascites infection will be enrolled in this cohort.
9933331|NCT05352139||Elbow Calcific Tendinosis (Recalcitrant Epicondylitis)|Treatment of participants who present with either lateral or medial epicondylitis
9933332|NCT05352139||Hip Calcific Tendinosis (Recalcitrant Gluteal Tendinopathy)|Treatment of participants diagnosed with Recalcitrant Gluteal Tendinopathy
9933333|NCT05352139||Shoulder Calcific Tendinosis (Calcific Shoulder Tendinopathy)|Treatment of participants diagnosed with Calcific Shoulder Tendinopathy
9933334|NCT05352126|Experimental|Puressentiel Purifying spray|"Puressentiel Air Purifying Spray with 41 essential oils~Capacity: 200 ml~BIOCIDE Product type 2: Disinfectants used in the private and public health sector~Composition: Ethanol (CAS no. 64-17-5) 75% m/m and 41 essential oils"
9933335|NCT05352126|Placebo Comparator|Placebo|Saline spray in the similar device as Puressentiel Purifying spray
9933336|NCT05352113|Experimental|acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
9992932|NCT01467284|Experimental|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
9933337|NCT05352113|Experimental|acupuncture + placebo group|This group will include 40 patients with MDD who will be treated with acupuncture and a placebo. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
9992933|NCT01467284|Active Comparator|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
9992934|NCT01467297|Experimental|ceftidoren|ceftidoren 200 mg bid for 5 days
9992935|NCT01467297|Active Comparator|levofloxacin|levofloxacin 500 mg once daily for 7 days
9992936|NCT01467310|Experimental|GSK1120212|
9900271|NCT04526509|Experimental|Substudy 1: Cohort 1 - GSK3901961 in previously treated metastatic NSCLC|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as intravenous (IV) infusion after completing lymphodepleting chemotherapy.
9900272|NCT04526509|Experimental|Substudy 1: Cohort 2 - GSK3901961 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as IV infusion after completing lymphodepleting chemotherapy.
9900273|NCT04526509|Experimental|Substudy 2: GSK3845097 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as IV infusion after completing lymphodepleting chemotherapy.
9900274|NCT04526509|Experimental|Substudy 3: GSK4427296 in previously treated advanced SS or MRCLS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK4427296, as IV infusion after completing lymphodepleting chemotherapy.
9900275|NCT04526301||Tablo Hemodialysis System|Home dialysis treatment with the Tablo Hemodialysis System
9900276|NCT04524390|Experimental|Maralixibat|"Maralixibat chloride oral solution administered twice daily, up to 600* microgram per kilogram, for 26 weeks and in the OLE for all patients.~*equivalent to 570 mcg/kg/day maralixibat free base"
9900277|NCT04524390|Placebo Comparator|Placebo|Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and continue in the open label extension (OLE) will receive maralixibat after Week 26.
9900278|NCT04524286||Public - Childbearing Women|Childbearing women living in three deprived areas in a city in the South of England.
9900279|NCT04524286||Staff - Midwives|Midwives working in caseloading teams providing continuity of care to women living in three deprived areas in a city in the South of England.
9900280|NCT04524000|Experimental|Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)|Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular).
9900281|NCT04524000|Experimental|Cohort 2: CDK4/6 inhibitor naive (Part 2)|Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
9900282|NCT04524000|Experimental|Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)|Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
9900283|NCT04523207|Experimental|Apalutamide + Androgen Deprivation Therapy (ADT)|In the main study, participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days). Participants who enrolled in the sub-study will receive apalutamide 240 mg once daily along with relugolix (a type of ADT) 120 mg once daily following a loading dose of 360 mg relugolix orally. Sub-study participants will be receiving relugolix up to Day 28 after which they will be transitioned into the main study from Cycle 2 Day 1 and will continue to receive conventional or oral ADT.
9900284|NCT04521803|No Intervention|Arm 1: Standard of care (RIF10)|Dosing of the daily oral RHZE fixed dose combination (FDC) will be according to WHO weight bands
9900285|NCT04521803|Experimental|Arm 2: High-dose RIF (RIF35)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used39
9900286|NCT04520607|Experimental|Arm 1|Subjects assigned to this arm will receive one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study); performed on Day 1, at Week 48 and every 52 weeks thereafter.
9900287|NCT04520607|Experimental|Arm 2|Subjects assigned to this arm will receive one intra-articular injection of 0 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study) into their target knee (the same target knee injected in the parent study) on Day 1, followed by one intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle at Week 48 and every 52 weeks thereafter.
9900288|NCT04518228|Experimental|Component 1: Arm 1.1: Bictegravir (BIC) 50 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving bictegravir (BIC) 50 mg once daily (q.d.), and their infants
9900289|NCT04518228|Experimental|Component 1: Arm 1.2: Doravirine (DOR) 100 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving doravirine (DOR) 100 mg q.d., and their infants
9900290|NCT04518228|Experimental|Component 1: Arm 1.3: Tenofovir alafenamide (TAF) 10 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving tenofovir alafenamide (TAF) 10 mg q.d. boosted with cobicistat, and their infants
9900291|NCT04518228|Experimental|Component 1: Arm 1.4: TAF 25 mg q.d. without boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. without boosting, and their infants
9900292|NCT04518228|Experimental|Component 1: Arm 1.5: TAF 25 mg q.d. with boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. boosted with cobicistat or ritonavir, and their infants
9900293|NCT04518228|Experimental|Component 2: Arm 2.1: CAB LA|Women ≥ 24 weeks gestation who received at least one dose of long-acting injectable formulation of cabotegravir (CAB LA) any dose during pregnancy, and their infants
9900294|NCT04518228|Experimental|Component 3: Arm 3.1: Dolutegravir (DTG) 50 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving dolutegravir (DTG) 50 mg twice daily (b.i.d.) when combined with RIF or 50 mg q.d. if RIF is not part of the TB regimen, and their infants
9900295|NCT04518228|Experimental|Component 3: Arm 3.2: ATV/r or DRV/r|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving atazanavir/ritonavir (ATV/r) ≥ 300/100 mg q.d. or darunavir/ritonavir (DRV/r) ≥ 600/100 mg b.i.d., and their infants
9900296|NCT04518228|Experimental|Component 3: Arm 3.3: Lopinavir/ritonavir (LPV/r) 800/200 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving lopinavir/ritonavir (LPV/r) 800/200 mg b.i.d., and their infants
9900297|NCT04518228|Experimental|Component 4: Arm 4.1: Second-line TB treatment drugs|"Women ≥ 20 weeks gestation receiving at least one of the following second-line TB treatment drugs, and their infants:~Levofloxacin (LFX) 750mg - 1000mg q.d.~Clofazimine (CFZ) 100mg q.d.~Linezolid (LZD) 300mg - 600mg q.d.~Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~Delamanid (DLM) 100mg b.i.d.~Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study"
9900298|NCT04518228|Experimental|Component 5: Arm 5.1: ATV/r|Women post-delivery receiving ATV/r, and their infants
9900299|NCT04518228|Experimental|Component 5: Arm 5.2: DRV/r|Women post-delivery receiving DRV/r, and their infants
9900300|NCT04518228|Experimental|Component 5: Arm 5.3: LPV/r|Women post-delivery receiving LPV/r, and their infants
9900301|NCT04515771|Experimental|Active PARTNER-MH|The Active PARTNER-MH arm will test the intervention program starting immediately after enrollment in the study. Participants enrolled into this arm will continue to receive normal mental health services in addition to the peer-administered intervention.
9900302|NCT04515771|Other|Waitlist Control|The Waitlist Control arm will test the intervention program after a waiting period of 6-months following enrollment into the study. During the 6-month waiting period, participants in this arm will continue to receive normal mental health services.
9900303|NCT04514549||Cohort 1|will enroll approximately 5 patients with pronounced respiratory dysfunction. Patients may be enrolled with tremors and or seizures. All patients will be observed via Emerald to capture sleep staging, movement and breathing for up to approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. MC10 nPoint data will be captured for at least two 24-hour periods in each of the 4 weeks to assess patch placements for breathing detection. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 1 progresses.Preliminary results from Cohort 1 will determine if Emerald will continue to be evaluated and will inform on MC10 nPoint optimizations for Cohort 2. If preliminary results indicate Emerald is not an effective device, then Emerald will be discontinued
9900304|NCT04514549||Cohort 2|will enroll approximately 15 patients. Patients with pronounced respiratory dysfunction, tremors, seizures, and/or other expanded features of Rett syndrome deemed appropriate may be enrolled. If Emerald is continued, all patients are observed via Emerald to capture sleep staging, movement and breathing up to for approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 2 progresses.
9900305|NCT04514497|Experimental|Cohort I (elimusertib, irinotecan)|Patients receive elimusertib PO BID on days 1 and 2 and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9900306|NCT04514497|Experimental|Cohort II (elimusertib, topotecan)|Patients receive topotecan IV over 30 minutes on days 1-5 and elimusertib PO BID on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9992937|NCT01467323|Experimental|A|
9992938|NCT01467323|Active Comparator|B|
9900307|NCT04512911|Active Comparator|Patients who didn't fail AAD|This group of patients will be randomized to 3 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation; 3) Antiarrhythmic medications
9900308|NCT04512911|Active Comparator|Patients who failed AAD|This group of patients will be randomized to 2 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation
9900309|NCT04512287|Experimental|Experimental: Autologous PRP followed by Placebo Group|Participants in this group will receive the autologous intervention first, followed by the placebo intervention 3 months later.
9900310|NCT04512287|Experimental|Experimental: Placebo followed by Autologous PRP Group|Participants in this group will receive the placebo intervention first, followed by the Autologous PRP intervention 3 months later.
9900311|NCT04509674|Experimental|Empagliflozin|
9900312|NCT04509674|Placebo Comparator|Placebo|
9900313|NCT04506892|Experimental|Adept Meditators|Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness.
9900314|NCT04505878|Experimental|Vitamin C Arm|Ascorbic Acid will be administered at a dose of 1500 mg in 100 mL of saline over 30 minutes intravenously once every 6 hours for a total of 72 hours
9900315|NCT04504734|Active Comparator|Bucillamine low dose|Bucillamine 100 mg 3 times a day (TID)
9900316|NCT04504734|Active Comparator|Bucillamine high dose|Bucillamine 200 mg 3 times a day (TID)
9900317|NCT04504734|Placebo Comparator|Placebo|Placebo, 3 times a day (TID)
9900318|NCT04502173||Training|Study participants trained on how to use the Ellavi intra-uterine balloon tamponade via virtual webinar training. Feedback on training course elements will be obtained for future improvements prior to scaling.
9900319|NCT04502173||Managing PPH|Study participants who provided refractory PPH care using an Ellavi UBT device will give feedback on the barriers and facilitators to use of the newly registered, low-cost medical device.
9900320|NCT04501679|Experimental|Nemolizumab|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W). Participants weighing greater than or equal to (>=) 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
9900321|NCT04501679|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing >= 90 kg will receive two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
9900322|NCT04501666|Experimental|Nemolizumab 30 milligram (mg)|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W) and participants >= 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W up to 24 weeks.
9900323|NCT04501666|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive matching placebo of two SC injections at baseline, then one SC injection Q4W and participants weighing >= 90 kg will receive matching placebo of two SC injections at baseline, then two SC injections Q4W up to 24 weeks.
9900324|NCT04500301|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
9900325|NCT04500236|Active Comparator|General Anesthesia (GA)|Patients undergoing thyroid or breast cancer surgery under general anesthesia
9900326|NCT04500236|Placebo Comparator|Hypno-analgesia (Hyp)|Patients undergoing thyroid or breast cancer surgery under Hypno-analgesia; i.e.hypnosis combined with the use of analgesics.
9900327|NCT04498156||CKD-Patients|Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD)
9900328|NCT04498156||Physicians treating CKD|Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
9900329|NCT04498117|Experimental|Cohort 1- Surgery Active|Six (6) 21-day cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
9900330|NCT04498117|Placebo Comparator|Cohort 1 - Primary Surgery Control|Six (6) 21-day cycles of chemotherapy with placebo comparator given with chemotherapy at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
9900331|NCT04498117|Experimental|Cohort 2 - NACT + Interval Surgery Active|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
9900332|NCT04498117|Placebo Comparator|Cohort 2 - NACT + Interval Surgery Control|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with placebo comparator given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
9900333|NCT04497597||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
9900334|NCT04495946|Experimental|Sepsis Transition and Recovery (STAR) Program|Virtual sepsis navigation delivered across the peri-hospital discharge interval
9900335|NCT04495946|Active Comparator|Usual Care|Standard of care received through Atrium Health facilities for patients hospitalized with sepsis. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
9900336|NCT04495855||Visanne treatment|Patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis, who have been prescribed Visanne
9900337|NCT04495296|Experimental|TST001 Injection|TST001 Injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
9992939|NCT01467336|Other|Passive group|Rehabilitation program is immediate. Active range of motion rehabilitation is started at the sixth week.
9798125|NCT01618422|Sham Comparator|Directly Observed Therapy (DOTS)|The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
9798126|NCT01618422|Active Comparator|Directly Observed Therapy (DOTS) plus|The DOTS-Plus strategy (the strategy to be tested) includes additional measures including continuous drug resistance surveillance, culture, drug susceptibility testing for TB patients, and tailoring of individual drug regimen through the use of first and second-line drugs.
9798127|NCT01618669|Experimental|Regadenoson After Peak Exercise|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
9798128|NCT01618669|Active Comparator|Regadenoson Alone|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
9798129|NCT01618695|Experimental|Perampanel|
9798130|NCT01618695|Placebo Comparator|Placebo|
9798131|NCT01618708|Experimental|Synvisc-One|Single intraarticular (IA) injection of Synvisc-One (48 mg of Hylan G-F 20 polymer) at Day 1. Participants were observed for 26 weeks in follow up period.
9798132|NCT01618708|Placebo Comparator|Placebo|Single IA injection of placebo matched to Synvisc-One at Day 1. Participants were observed for 26 weeks in follow up period.
9798133|NCT01618838|Other|CyberKnife Radiosurgery, Colonoscopy|CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).
9798134|NCT01618864|Other|Luxe|
9798135|NCT01618916|Experimental|1.0 milligrams per kilogram (mg/kg) LY3015014 Every 2 Weeks|1.0 mg/kg LY3015014 given subcutaneously (SC) once every 2 weeks for 29 days.
9798136|NCT01618916|Experimental|1.0 mg/kg LY3015014 Every 4 Weeks|1.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
9798137|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 2 Weeks|3.0 mg/kg LY3015014 given SC once every 2 weeks for 29 days.
9798138|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 4 Weeks|3.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
9798139|NCT01618916|Placebo Comparator|Placebo Every 2 Weeks|Saline injection (to match LY3015014) given SC once every 2 weeks for 29 days.
9798140|NCT01618916|Placebo Comparator|Placebo Every 4 Weeks|Saline injection (to match LY3015014) given SC once every 4 weeks for 29 days.
9798141|NCT01618942|Experimental|male subjects|grouped by gender and applied pressure pain test
9798142|NCT01618942|Experimental|female subjects|grouped by gender and applied pressure pain test
9798143|NCT01618955|Active Comparator|VIBEX MTX|VIBEX MTX dose based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status
9798144|NCT01618968|Experimental|10 mg Methotrexate (MTX)|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
9798145|NCT01618968|Experimental|15 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
9798146|NCT01618968|Experimental|20 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
9798147|NCT01618968|Experimental|25 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
9798148|NCT01619059|Experimental|Arm 1: Saxagliptin+Dapagliflozin+Metformin IR|
9798149|NCT01619059|Experimental|Arm 2: Placebo+Dapagliflozin+Metformin IR|
9798150|NCT01619410|Active Comparator|linezolid|
9798151|NCT01619410|Active Comparator|Clindamycin|
9798152|NCT01619423|Active Comparator|FOLFOX6 + PledOx 2 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
9798153|NCT01619423|Active Comparator|FOLFOX6 + PledOx 5 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
9798154|NCT01619423|Active Comparator|FOLFOX6 + PledOx 10 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
9798155|NCT01619423|Placebo Comparator|FOLFOX6 + 0,9% NaCl|Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
9798156|NCT01619579|Experimental|Treatment|Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
9798157|NCT01619774|Experimental|GSK2118436 + GSK1120212|GSK1120212 2 mg by mouth once a day, and GSK2118436 150 mg by mouth 2 times every day (1 time in the morning and 1 time in the evening, about 12 hours apart).
9798158|NCT01619839|Experimental|100 mg NKTR-181|100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
9798159|NCT01619839|Experimental|200 mg NKTR-181|200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
9900338|NCT04494425|Experimental|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
9900339|NCT04494425|Active Comparator|Standard of Care|Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm
9900340|NCT04491292||Observational (questionnaire)|Participants complete 2 online questionnaires over 10 minutes each at baseline and at 3 months after the pandemic ends.
9900341|NCT04486833|Experimental|Phase 1|"Up to 3 sequential dose escalation cohorts will be treated with Reqorsa intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet during 21-day treatment cycles until disease progression or unacceptable toxicity.~The first group will receive Reqorsa IV infusion at 0.06 mg/kg, the next group 0.09 mg/kg and the third will receive 0.12 mg/kg. Additional Reqorsa dose levels may be evaluated until RP2D is identified."
9900342|NCT04486833|Experimental|Phase 2 Combination|Patients will receive the RP2D of Reqorsa intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet during 21-day treatment cycles until disease progression or unacceptable toxicity.
9900343|NCT04486833|Active Comparator|Phase 2 Active Comparator|Patients will continue on monotherapy osimertinib 80 mg fixed dose oral daily tablet until disease progression.
9900344|NCT04484519||Cognitively unimpaired|
9900345|NCT04484077|Experimental|hCT-MSC infusion|A single, intravenous infusion of hCT-MSCs. Targeted dose is 2x10^6 cells/kg with a maximum dose of 10 x 10^7 cells/kg.
9900346|NCT04483921|Experimental|Exercise|Participants will complete a prescribed exercise bout.
9900347|NCT04483921|No Intervention|Sedentary|Participants will rest quietly in a seated position for the equivalent amount of time prescribed for the exercise condition.
9900348|NCT04480918||Major Depressive Episode|After referral to the University of Iowa's Interventional Psychiatry Clinic, the patient will be clinically evaluated and, if appropriate, commence the procedural-based treatment course.
9900349|NCT04479579|Experimental|Apixaban|apixaban for extended prophylaxis against VTE after discharge
9900350|NCT04477772|Experimental|1mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects
9900351|NCT04477772|Experimental|3mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 9 subjects
9900352|NCT04477772|Experimental|10mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects
9900353|NCT04477772|Experimental|200mg, Q3W until to 2 years|Dose expansion, enrolled 9 subjects and indication expansion if RP2D is 200mg
9900354|NCT04477772|Experimental|240mg JS004+100mg JS001, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 6-9 subjects and indication expansion if RP2D is confirmed this arm
9900355|NCT04477772|Experimental|240mg JS004+200mg JS001, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 6-9 subjects and indication expansion if RP2D is confirmed this arm
9900356|NCT04472377|Experimental|study population|"We enroll a total of 1,200 women, as follows,~120 cases with no history or current cervical intraepithelial lesion or malignancy.~180 cases with a history of abnormal Pap test including ASCUS, CIN1, or atypical glandular cell.~240 cases with a history of atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.~240 cases with current ASCUS, CIN1, or atypical glandular cell.~420 cases with current abnormal Pap test as atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma."
9900357|NCT04471207|Experimental|Intelligent Biometrics - Prolonged Exposure (Therapist Guided).|In the therapist-guided group, Study Therapists will virtually accompany patients during IVEs and use actionable biometric and subjective data during IVEs (e.g., HR, GSR, SUDS) to modify the assignments in real-time.
9900358|NCT04471207|Active Comparator|Intelligent Biometrics - Prolonged Exposure (Record Only).|In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.
9900359|NCT04468984|Experimental|Arm A: Navitoclax + Ruxolitinib|Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.
9900360|NCT04468984|Active Comparator|Arm B: Best Available Therapy (BAT)|Participants will receive one of the BAT options, per the investigator's discretion.
9900361|NCT04466891|Experimental|ZW25 (Zanidatamab) Monotherapy|
9900362|NCT04465409|Experimental|Presbyopic adults|"Presbyopic adults, male or female between 40-65 years of age who need from +1.25 D to +3.50 D of reading addition in the non-dominant eye to improve near visual acuity by at least one line or more.~In this investigation, CorVision® will be implanted in the non-dominant eye to improve near vision and the dominant eye is left intact or corrected by a standard refractive surgery to emmetropia. In brief, subjects will undergo laser corneal surgery on their non-dominant eye to create an anterior stromal pocket into which the investigational device will be implanted."
9900363|NCT04462770|Active Comparator|Active arm with EPX-100 (Clemizole HCl)|EPX-100 oral solution 5 mg/mL starting at 2.0 mg/kg/day increasing 2 mg/kg/day every 7 days until the maximum tolerated dose is found. Those intolerant of the 2.0 mg/kg/day starting dose will drop to a dose of 1.0 mg/kg/day and increasing by 0.5 mg/kg every 7 days or to MTD. The titration period can extend beyond 4 weeks for participants who do not reach their MTD. This will be determined per Primary Investigator discretion.
9900364|NCT04462770|Placebo Comparator|Placebo arm|Color- and taste-matched placebo oral solution dosed to match the active arm.
9900365|NCT04460612|Placebo Comparator|Placebo Sock|Placebo Socks will be placed on participants feet either first or second for 60 minutes
9900366|NCT04460612|Active Comparator|Active IR Sock|Active IR socks will be placed on participants feet either first or second
9900367|NCT04456699|Experimental|Olaparib + bevacizumab|Participants will receive olaparib (300 mg twice daily [BID] oral) + Bevacizumab (5 mg/kg intravenous [IV] once every 2 weeks [Q2W]) until progressive disease or end of study.
9900368|NCT04456699|Experimental|Olaparib|Participants will receive olaparib (300 mg BID) oral, until progressive disease or end of study.
9900369|NCT04456699|Active Comparator|Bevacizumab + 5-FU|Participants will receive bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W; bolus 5FU (400mg/m2) can be added prior to infusional 5FU, per local standards and at the investigator's discretion) until progressive disease or end of study. Leucovorin or levoleucovorin 400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) Q2W IV infusion may be added per investigator's discretion.
9900370|NCT04456699|Active Comparator|Bevacizumab + capecitabine|Participants will receive bevacizumab (7.5mg/kg IV once every three weeks (Q3W)) + capecitabine (1000mg/m^2 BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study.
9900371|NCT04454437|Other|Arm A|
9900372|NCT04452591|Experimental|Single Arm|"Patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease.~CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 49then every 24 weeks thereafter."
9900373|NCT04451525||Cohort I|Cohort I will focus on data collection on the SOFIA® Flow Plus 6F Aspiration Catheter used with the direct aspiration as first line treatment technique with the intent to evaluate per prespecified endpoints.
9900374|NCT04451525||Cohort II|Cohort II will focus on data collection on MicroVention devices used for acute ischemic stroke treatment with the intent to evaluate standard outcomes while also generating additional research questions for analysis based on data collected.
9900375|NCT04446962|Active Comparator|Arm A: R-MPV with Lenalidomide|Lenalidomide in association with R-MPV as a targeted induction treatment
9900376|NCT04446962|Active Comparator|Arm B: R-MPV with Ibrutinib|Ibrutinib in association with R-MPV as a targeted induction treatment
9900377|NCT04445545|Experimental|Experimental group 1 (HILT + stretching exercise)|The group will receive treatment of high-intensity laser therapy (HILT) with a total energy delivery of 1,060J divided into 3 phases will be achieved: phase 1, 500J; phase 2, 60J; phase 3, 500J. It will work with an average power of 3W and an energy density of 50J/cm2. At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
9900378|NCT04445545|Sham Comparator|Experimental group 2 (Sham HILT + stretching exercise)|The group will receive a sham treatment of high-intensity laser therapy (HILT). At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
9992940|NCT01467336|Other|Immobilization group|No passive Rehabilitation program is started. An active protocol is started after the sixth week
9900379|NCT04445545|Active Comparator|Experimental group 3 (US + stretching exercise)|The group will receive treatment of therapeutic ultrasound. The US parameters will be programmed with a frequency of 1MHz, the intensity of 1.5 W/cm2, the Duty cycle of 100%, an ERA of 5cm2, and a time of 6 minutes. At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
9900380|NCT04443907|Experimental|OTQ923 or HIX763|Single intravenous infusion of either OTQ923 or HIX763, Part A - Adults treated with OTQ923; Part B - Adults treated with HIX763 Part C - Children age 2-17 - either OTQ923 or HIX763 based on review of data from Part A and/or Part B by Health agency after a formal interim analysis.
9900381|NCT04441905|Experimental|Cohort 1|0.3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
9900382|NCT04441905|Experimental|Cohort 2|1 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
9900383|NCT04441905|Experimental|Cohort 3|3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
9900384|NCT04441905|Experimental|Cohort 4|10 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
9900385|NCT04441905|Experimental|Cohort 5|20 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
9900386|NCT04436640|Experimental|Bimekizumab|Subjects will receive bimekizumab throughout the Treatment Period.
9900387|NCT04435782|Experimental|JNJ-67896049|Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
9900388|NCT04435678|Other|birch pollen allergy|"106 patients with suspicion of birch pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
9900389|NCT04435678|Other|grass pollen allergy|"106 patients with suspicion of grass pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
9900390|NCT04435678|Other|house dust mite allergy|"148 patients with suspicion of house dust mite allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)"
9900391|NCT04435678|Other|cat allergy|"106 patients with suspicion of cat allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
9900392|NCT04435678|Other|bee venom allergy|"106 patients with suspicion of bee venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
9900393|NCT04435678|Other|vespid venom allergy|"106 patients with suspicion of vespid venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
9900394|NCT04435678|Other|non-allergic individuals|"148 non-allergic individuals will be included in the study. They should have no symptoms that could be related to inhalant allergy or Hymenoptera venom allergy, negative skin test results and undetectable IgE levels.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
9900395|NCT04434040|Experimental|Atezolizumab and Sacituzumab govitecan|"Patients will receive the following treatment:~Atezolizumab and Sacituzumab govitecan treatment will continue for 6 cycles (18 total weeks).~Atezolizumab intravenously (IV) at a pre-determined dose on day 1 in a 21-day cycle~Sacituzumab govitecan: intravenously (IV) at a pre-determined dose on days 1 and 8 in a 21-day cycle"
9900396|NCT04432311|Experimental|Binge Focused Therapy (BFT)|Guided self-help - Three online group sessions, homework, and self-guided check-ins to monitor continued progress and/or signs of relapse.
9900397|NCT04432311|Active Comparator|CBT Unguided Self Help (CBT USH)|Pure self-help - The use of the book Overcoming Binge Eating and its associated homework.
9900398|NCT04431453|Experimental|Remdesivir (RDV)|"Participants will receive RDV up to 10 days. The RDV dose administered in each cohort is as follows:~Cohort 1: intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg daily~Cohorts 2-5: IV RDV 5 mg/kg on Day 1 followed by IV RDV 2.5 mg/kg daily~Cohort 6-7: IV RDV 2.5 mg/kg on Day 1 followed by IV RDV 1.25 mg/kg daily for up to 10 days~Cohort 8: IV RDV 200 mg on Day 1 followed by IV RDV 100 mg daily"
9900399|NCT04428151|Experimental|Lenvatinib + Pembrolizumab|Participants will be treated with the combination of lenvatinib (once daily 20 mg oral dose) plus pembrolizumab (200 mg 30-minute intravenous (IV) infusion on Day 1 of each 21-day cycle for 35 cycles), until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. Participants may receive up to an additional 17 cycles of pembrolizumab as Second Course treatment, with or without lenvatinib.
9900400|NCT04428151|Active Comparator|SOC Chemotherapy|Participants will be treated with investigator's choice of standard of care (SOC) chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
9900401|NCT04428151|Active Comparator|Lenvatinib Monotherapy|Participants will be treated with lenvatinib monotherapy (once daily 24 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
9900402|NCT04422730||pancreatectomy in cancer patients|
9900403|NCT04422730||pancreatectomy in non-cancer patients|
9900404|NCT04422730||mastectomy|
9900405|NCT04422730||Acute leukaemia|
9900406|NCT04419558|Experimental|Pamrevlumab|"Treatment phase: Pamrevlumab 30 mg/kg administered by intravenous infusion, every 3 weeks, for a total of 17 infusions over 48 weeks.~Open-label extension phase: Pamrevlumab 30 mg/kg administered by intravenous infusion, every 3 weeks for up to 48 weeks"
9900407|NCT04419558|Experimental|Placebo|Pamrevlumab-matching placebo administered by intravenous infusion every 3 weeks for a total of 17 infusions over 48 weeks
9900408|NCT04411836|No Intervention|Control|Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)
9900409|NCT04411836|Experimental|PQ Intervention|Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
9900410|NCT04411836|Experimental|TQ Intervention|Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)
9900411|NCT04406857|Experimental|Treatment (ropidoxuridine, capecitabine, radiation therapy)|Patients receive ropidoxuridine PO QD over 7 days per week and capecitabine PO BID over 6 days per week for 6 weeks. Patients also undergo radiation therapy over 1 fraction per day for 5 days per week (Monday-Friday) during weeks 1-5 and for 3 days during week 6 in the absence of disease progression or unacceptable toxicity. Approximately 8-12 weeks after completion of treatment with ropidoxuridine, capecitabine, and radiation therapy, patients undergo standard of care surgery.
9900412|NCT04406792|Experimental|DPP+doula divas|Enrolled participants will have access to an online DPP with other Black post-partum mothers who have had GDM. The teams will be led by doula divas trained in aspects of motivational interviewing and trained on the Healthiby platform.
9900413|NCT04406792|Active Comparator|DPP only|Online DPP only support without doula as team lead. The participants will be in groups with a diverse group of patients that are non-mothers but who are at risk of type 2 diabetes.
9900414|NCT04403698|Experimental|24 weeks|Subject receiving alendronate treatment for 24 weeks (n = 20)
9900415|NCT04403698|Experimental|48 weeks|Subject receiving alendronate treatment for 48 weeks (n = 20)
9900416|NCT04400487|Experimental|Voxelotor|Participants will receive voxelotor at 1500 mg
9900417|NCT04399837|Experimental|Spesolimab, treatment arm 1|
9900418|NCT04399837|Experimental|Spesolimab, treatment arm 2|
9900419|NCT04399837|Experimental|Spesolimab, treatment arm 3|
9900420|NCT04399837|Placebo Comparator|Placebo|
9900421|NCT04399772|Experimental|Cognitive Functional Therapy+ pathway|Treatment is performed by a CFT trained physiotherapists and a psychologist in the Pain Center. Patients receive max 10 consultations over 3 months. The first two sessions is combined with the physiotherapist and psychologist who investigates potential maintaining factors for pain and disability in the patient's everyday life. Remaining sessions are run by the physiotherapist, and the treatment is individually tailored to the needs of the individual patient, aiming to provide the patient with skills in dealing with his / her own situation via information, reflection, change of movement and training of functions and physical level. The psychologist provide extra support for 2-3 sessions to reinforce the physiotherapist work.The ethical committee made blinding conditional on a possibility of usual care after CFT+ if: the patient does not feel ready to stop treatment AND analgesic treatment is inappropriate OR the social situation is problematic OR significant psychological distress.
9900422|NCT04399772|Active Comparator|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Treatment can be diverse, but based on an individual assessment it consists of a combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects) AND (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs. On average patients in the pain center receives 9-10 sessions."
9900423|NCT04397419|Experimental|Intervention group|This group is administered a total of 750 ml Red Bull® Energy Drink at defined time-intervals.
9900424|NCT04397419|Placebo Comparator|Placebo group|This group is administered a total of 750 ml still water at defined time-intervals.
9900425|NCT04392999|Experimental|Platelet Rich Plasma|One time injection of 1.5-6cc of platelet rich plasma prepared from a blood sample into cervical facet joints. There is no trade/generic name
9900426|NCT04392999|Active Comparator|Dexamethasone Sodium Phosphate|Corticosteroid: 0.5 cc saline and 0.5cc of 10 mg/mL dexamethasone per facet joint (up to 6 mL total volume for 4 facet injections)
9900427|NCT04392401||Cohort|Patients over 18 years with a confirmed diagnosis of COVID 19 hospitalized in intensive care unit
9900428|NCT04387461|Experimental|Single Arm|"CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 12, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 12 (e.g., complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 24, patients will receive weekly x 3 treatments every 3 months through Week 48 then every 24 weeks thereafter.~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 3 weeks for up to 2 years."
9900429|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo|Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.
9900430|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib|Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.
9900431|NCT04380636|Active Comparator|chemoradiation→durvalumab|Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.
9900432|NCT04379596|Experimental|Arm 1A|T-DXd and 5-fluorouracil (5-FU)
9900433|NCT04379596|Experimental|Arm 1B|T-DXd and capecitabine
9900434|NCT04379596|Experimental|Arm 1C|T-DXd and durvalumab
9900435|NCT04379596|Experimental|Arm 1D(a)|T-DXd, 5-FU, and oxaliplatin
9900436|NCT04379596|Experimental|Arm 1D(b)|T-DXd, capecitabine, and oxaliplatin
9900437|NCT04379596|Experimental|Arm 1E(a)|T-DXd, 5-FU, and durvalumab
9900438|NCT04379596|Experimental|Arm 1E(b)|T-DXd, capecitabine, and durvalumab
9900439|NCT04379596|Active Comparator|Arm 2A|Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin
9900440|NCT04379596|Experimental|Arm 2B|T-DXd monotherapy
9900441|NCT04379596|Experimental|Arm 2C|T-DXd, 5-FU or capecitabine, and oxaliplatin
9900442|NCT04379596|Experimental|Arm 2D|T-DXd, 5-FU or capecitabine, and pembrolizumab
9900443|NCT04379596|Experimental|Arm 2E|T-DXd and pembrolizumab
9900444|NCT04377204|Active Comparator|Lidocaine Group|Local injection of 1% lidocaine with 1:100,000 epinephrine one time pre-operatively prior to general anesthesia
9900445|NCT04377204|Active Comparator|Lidocaine with Bupivacaine|Local injection of 1% lidocaine with 1:100,000 epinephrine mixed 1:1 with 0.5% marcaine bupivacaine with 1:200,000 epinephrine, one time pre-operatively prior to general anesthesia
9900446|NCT04374253|Experimental|Group 1|Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 104 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
9900447|NCT04374253|Experimental|Group 2|Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
9900448|NCT04369742|Experimental|Hydroxychloroquine|
9900449|NCT04369742|Placebo Comparator|Placebo|
9900450|NCT04365868|Experimental|belapectin 2 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
9900451|NCT04365868|Experimental|belapectin 4 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3: The patient will be switched to the optimal dose"
9900452|NCT04365868|Placebo Comparator|Placebo|"Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)~Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)"
9900453|NCT04365855|Other|Subjects at risk for NAFLD|Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.
9900454|NCT04365660|Experimental|18-F-FTC 146 PET/CT|For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).
9900455|NCT04365218|Experimental|Cohort 1 (Dose A)|6 subjects will be randomized to receive MEDI8367 Dose A and 2 subjects will be randomized to receive placebo.
9900456|NCT04365218|Experimental|Cohort 2 (Dose B)|6 subjects will be randomized to receive MEDI8367 Dose B and 2 subjects will be randomized to receive placebo.
9900457|NCT04365218|Experimental|Cohort 3 (Dose C)|6 subjects will be randomized to receive MEDI8367 Dose C and 2 subjects will be randomized to receive placebo.
9900458|NCT04365218|Experimental|Cohort 4 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D and 2 subjects will be randomized to receive placebo.
9900459|NCT04365218|Experimental|Cohort 5 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 2 subjects will be randomized to receive placebo.
9900460|NCT04365218|Experimental|Cohort 6 (Dose D)|15 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 15 subjects will be randomized to receive placebo.
9900461|NCT04362826|Experimental|Novel probiotic|Investigational novel probiotic plus normal standard of care for breast cancer.
9900462|NCT04362826|Placebo Comparator|Placebo|Placebo plus normal standard of care for breast cancer.
9900463|NCT04361617|Active Comparator|Epigenetic age knowledge arm|Half of the intervention participants will be randomly selected to be informed of their epigenetic age before the intervention.
9900464|NCT04361617|Active Comparator|No epigenetic age knowledge arm|The other half of intervention participants will not be informed of their epigenetic age before the intervention.
9900465|NCT04358289|No Intervention|Arm 1: Control group|For commune health center and community
9900466|NCT04358289|Other|Arm 2: Basic antimicrobial stewardship education|For commune health center and community
9900467|NCT04358289|Other|Arm 3: 3. Basic AS education + community education|For commune health center and community
9900468|NCT04358289|Other|Arm 4: Education + participatory action research|For commune health center and community
9900469|NCT04358289|Other|Hospital intervention|For hospital: The hospital interventions will use quality improvement using a participatory action research approach to improve antibiotic stewardship. These activities will be evaluated through a before and after knowledge, attitudes and practice (KAP) survey, to assess whether or not the engagement activities had a measurable impact on knowledge and behaviour. There are not sufficient hospitals in the area to conduct a cluster randomized evaluation, so we will conduct a before and after survey, patient record review, and overall antibiotic use data from the Pharmacy Department
9900470|NCT04350138|Experimental|Group 1|Bexsero vaccine will be administered as an intramuscular injection in 1 mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
9900471|NCT04350138|Placebo Comparator|Group 2|Placebo will be administered as an intramuscular injection in single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
9900472|NCT04349072|Experimental|Drug: Mavacamten|"Mavacamten Capsules~Other names:~MYK-461"
9900473|NCT04349072|Placebo Comparator|Drug: Placebo|Matching Placebo Capsules
9900474|NCT04348955||women with adjuvant breast cancer|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
9900475|NCT04346654|Experimental|Eltrombopag + Dexamethasone|Patients will be treated with eltrombopag in combination with a standard high-dose dexamethasone (1 cycle: 40 mg QD from day 1-4) to induce sustained response off treatment.
9900476|NCT04346654|Active Comparator|Dexamethasone|Patients will be treated with a standard high-dose dexamethasone (1-3 cycles: 40 mg QD day 1-4 every 14-28 days) to induce sustained response off treatment
9900477|NCT04346628|Experimental|Favipiravir|In addition to SOC, participants will receive favipiravir for 10 days, and be evaluated for health outcomes through day 28.
9900478|NCT04346628|Active Comparator|Placebo|In addition to SOC, participants will receive placebo to match favipiravir for 10 days, and be evaluated for health outcomes through day 28.
9900479|NCT04343560||patients with MACS|Patients with adrenal adenoma and dexamethasone suppression test >1.8 mcg/dl
9900480|NCT04343560||healthy controls|no history of adrenal and pituitary disease, no exogenous steroids
9900481|NCT04340843|Experimental|Treatment (belinostat, guadecitabine, ASTX727)|Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline (within 21 days of the first cycle) and during cycle 2 (on day 3, 4, or 5). In addition, patients undergo MRI or CT scans every 2 cycles (8 weeks) while receiving guadecitabine or ASTX727 and belinostat.
9900482|NCT04340596|Experimental|Arm A: N-803 only|Participants will receive N-803 6 mcg/kg 1 week after Step 2 entry and then every 3 weeks for a total of eight doses.
9900483|NCT04340596|Experimental|Arm B: N-803 in combination with 10-1074 and VRC07-523LS|"Participants will receive N-803 in combination with 10-1074 and VRC07-523LS as follows:~At Step 2 entry:~VRC07-523LS 20 mg/kg~10-1074 30 mg/kg~At Step 2, week 1: N-803 6 mcg/kg every 3 weeks for eight doses~At Step 2, week 9: 10-1074 30 mg/kg"
9900484|NCT04335682|Active Comparator|Darolutamide (DARO)|Patients will take DARO at a dose of 600 mg (300 mg ×2 tablets) by mouth twice daily beginning on Day 1, of Week 1. Patients will take DARO throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
9900485|NCT04335682|Active Comparator|Enzalutamide (ENZ)|Patients will take ENZ at a dose of 160 mg PO once daily (QD), beginning on Day 1, of Week 1. Patients will take ENZ throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
9900486|NCT04333472|Experimental|Piclidenoson|Piclidenoson 2 mg every 12 hours orally added to standard of care
9900487|NCT04333472|Placebo Comparator|Placebo|Placebo every 12 hours orally added to standard of care
9900488|NCT04333420|Experimental|Arm A: SOC + IFX-1|
9900489|NCT04333420|Experimental|Arm B : SOC + Placebo|
9933338|NCT05352113|Experimental|sham acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with sham acupuncture and SSRIs antidepressants. The sham acupuncture will be needled on the points 1cm lateral to acupoints. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
9935746|NCT03255031|Active Comparator|Diet Randomization-Active Comparator|Ketogenic diet (KD) liquid diet consists of snacks and shakes 3x p/day (high in fat). SA will receive the same KD solid snacks, in order to keep the diets blind to participants. KD will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
9900490|NCT04329039|Active Comparator|Group 1|Active somatostatin analogue combined with perioperative antibiotics
9900491|NCT04329039|Placebo Comparator|Group 2|Placebo combined with perioperative antibiotics
9900492|NCT04327141|Experimental|Protein pacing and intermittent fasting|During the 8-week weight loss (WL) phase, participants assigned to the P-IF will consist of P days, whereby female participants will consume four and male participants will consume five meals/snacks total, two of which (breakfast and lunch) will include a protein powder meal replacement mixed with water (240-400 kcals per meal) along with an evening dinner meal (~500 kcals), an afternoon snack (men only), and an evening snack (250 kcals). Subjects will be calorie restricted to ~1500 and ~1800 calories per day, women and men, respectively during P days. For each IF day, subjects will be provided a variety of supplements/snacks made by Isagenix International LLC. The P-IF group will be further divided into two subgroups for weeks 1-4. One subgroup will consist of five days of P and two days of IF, and the second subgroup will consist of six days of P and one day of IF. For weeks 5-8 both subgroups will follow 6 days of a P diet and 1 day IF.
9900493|NCT04327141|Experimental|Heart Healthy|The HH group will observe the dietary guidelines in compliance with the National Cholesterol Education Program Therapeutic Lifestyle Changes (TLC) diet. This diet consists of consuming <35% of kcal as fat; 50%-60% of kcal as carbohydrates; <200 mg/dL of dietary cholesterol; and 20-30 g/day of fiber. The total calorie intake will be 1200 and 1500 calories per day, women and men, respectively during the weight loss phase (weeks 0-8).
9900494|NCT04325828|Experimental|Apalutamide plus GnRH Agonist|Participants will receive apalutamide 240 milligram (mg) in combination with a gonadotropin-releasing hormone (GnRH) agonist until disease progression, unacceptable toxicity, death, or the end of the study and each treatment cycle will be of 28 days.
9900495|NCT04324814|Experimental|Dose level 1|Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle
9900496|NCT04324814|Experimental|Dose level 2|Subjects will receive a single dose of SHR-1701 at Dose level 2 on Day 1 of each cycle
9900497|NCT04324814|Experimental|Dose level 3|Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 of each cycle
9900498|NCT04324814|Experimental|Dose level 4|Subjects will receive a single dose of SHR-1701 at Dose level 2 1 on Day 1 and Day 15 of each cycle
9900499|NCT04324814|Experimental|Dose level 5|Subjects will receive a single dose of SHR-1701 at Dose level 3 on Day 1 and Day 15 of each cycle
9900500|NCT04324814|Experimental|Dose expansion 1|Subjects will receive a single dose of SHR-1701 on a selected dose level Day 1 of each cycle
9900501|NCT04324814|Experimental|Dose expansion 2|Subjects will receive a single dose of SHR-1701 on a selected dose level on Day 1 of each cycle
9900502|NCT04321915|Other|Children with Autism spectrum disorder|"Patients will realised quesstionnaires, a blood sample will be collected, the feces will be collected too.~The analysis of intestinal microbiota and neuroinflammation markers will be processed."
9900503|NCT04321668|Other|Injection of SYNVISC-ONE|Patients suffering from symptomatic knee osteoarthritis (OA), receiving intra-articular (IA) injection of SYNVISC-ONE® (Hylan G-F 20; 10 mL single-injection viscosupplement)
9900504|NCT04318691||acute respiratory failure group|60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure
9900505|NCT04318691||vascular surgery control group|10 control patients admitted to the ICU after a planned vascular surgery
9900506|NCT04318691||Healthy volunteers group|10 healthy subjects.
9900507|NCT04312191|No Intervention|Control Group|The Control Group participants (Group A) will be initiating radiation therapy and receiving only standard of care therapy per their Radiation Oncologist.
9900508|NCT04312191|Experimental|Test Group|The Test Group participants (Group B) will be initiating radiation therapy and receiving standard of care therapy per their Radiation Oncologist. This group will also be taught mantra-based meditation to use during each radiation treatment session and encouraged to practice MM ad libitum outside of the treatment setting.
9900509|NCT04311502|Experimental|Arm 1: Experimental 3-month, with CFZ loading dose|Participants will receive rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks.
9900510|NCT04311502|Active Comparator|Arm 2: Standard of care for drug-susceptible (DS) TB|Participants will receive rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks.
9900511|NCT04311502|Experimental|Arm C: PK only subgroup|Participants will receive PHZE + CFZ 100 mg once daily for 4 weeks; then on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks).
9900512|NCT04308304|Experimental|MK-1942|Dose Level 1: 8-mg MK-1942 twice daily (BID) x 7 days (7D), Day 1 to Day 7; Dose Level 2: 15-mg MK-1942 BID x 7D, Day 8 to Day 14; Dose Level 3: 30-mg MK-1942 BID x 7D, Day 15 to Day 21; Dose Level 4: ≤50-mg MK-1942 BID x 7D (Provisional Dose Level), Day 22 to Day 28 All participants to receive Donepezil once daily.
9900513|NCT04308304|Placebo Comparator|Placebo|Placebo to MK-1942 BID x 21 [28] D All participants to receive Donepezil once daily.
9900514|NCT04308122|Active Comparator|Cervical Orthosis (CO)|Cervical orthosis will be worn at all times for 6 weeks according the standard of care after posterior cervical fusion
9900515|NCT04308122|Experimental|No Orthosis (NO)|No cervical orthosis will be worn after posterior cervical fusion
9900516|NCT04307251|Experimental|Navio™ Robotics-assisted Surgical System|
9900517|NCT04307251|Experimental|Conventional, non-robotics-assisted total knee surgical system|
9900518|NCT04305054|Experimental|Pembrolizumab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
9900519|NCT04305054|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
9900520|NCT04305054|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants will receive coformulation of pembrolizumab and quavonlimab (MK-1308A) IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
9900521|NCT04305054|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive coformulation of pembrolizumab and quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
9900522|NCT04296890|Experimental|Treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
9900523|NCT04295915||Specimens that meet inclusion criteria|
9900524|NCT04295759|Experimental|Dose-finding|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
9900525|NCT04295681|Experimental|MMH-MAP|Oral administration. 2 tablets twice daily (approximately at the same time). The drug is taken outside a meal (between the meals or 15 min prior to meal or fluid intake). Tablets should be held in the mouth until completely dissolved. The overall duration of treatment is 90 months.
9900526|NCT04295681|Placebo Comparator|Placebo|Oral administration. For 90 days according to MMH-MAP dosing regimen.
9900527|NCT04294355|Experimental|Artificial intelligence-Assisted colonoscopy|Tandem colonoscopy of proximal colon assisted with artificial intelligence followed by conventional colonoscopy
9900528|NCT04294355|Active Comparator|Conventional colonoscopy|Tandem conventional colonoscopy of proximal colon followed by usual conventional colonoscopy
9900529|NCT04293185|Experimental|bb1111|"Subjects will receive treatment with a single dose of Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis, transduced with BB305 lentiviral vector (LVV) encoding the human beta-A-T87Q globin gene.~Plerixafor mobilization and apheresis will also be used for collection of rescue cells."
9900530|NCT04289740|Experimental|cognitive-bahavioral therapy|Trasdiagnotic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period.
9900531|NCT04289740|Active Comparator|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
9900532|NCT04278352|Experimental|Mindfulness Based Relapse Prevention|MBRP is a group aftercare program that integrates mindfulness skills training with cognitive-behavioral relapse prevention strategies. The intervention consists of eight weekly two-hour group therapy sessions, delivered by two facilitators with 6-12 people. The experimental group will complete the intervention in weeks 1-8. They will continue treatment as usual for weeks 9-16.
9900533|NCT04278352|No Intervention|Control|The waitlist control group will not receive the MBRP program during weeks 1-8 and will continue treatment as usual. During weeks 9-16, the control group will receive MBRP.
9900534|NCT04276259|Experimental|Buprenorphine Injection + Oral Placebo Pill|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~6 hours) and an oral placebo tablet.
9900535|NCT04276259|Experimental|Naltrexone Oral Tablet + Intramuscular Saline Injection|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours) and a saline IM injection.
9900536|NCT04276259|Experimental|Oral Placebo Pill + Intramuscular Saline Injection|Inert pill and saline injection that have no inherent power to produce an effect. In the inert pill condition, participants will receive one IM arm injection of saline (1ML) and an oral placebo tablet.
9900537|NCT04272242|Experimental|Arm 1: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally twice daily (~12 hours apart). Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. Participants will take non-study supply of DTG for morning doses, and will take study-supplied DTG for evening doses."
9900538|NCT04272242|Experimental|Arm 2: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally each morning. Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on once-daily DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. DTG will be from non-study ARV supply.~NOTE: Arm 2 will only open based on assessment of DTG pharmacokinetics (PK) data from participants in Arm 1."
9900539|NCT04272073|Active Comparator|Standard Care|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
9900540|NCT04272073|Experimental|High-Protein Mediterranean Diet|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet~eating more fruit and vegetables,~reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),~replacing butter and margarine by olive oil as the main culinary fat,~reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 high-protein yoghurts to eat each day)."
9900541|NCT04272073|Experimental|Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
9900542|NCT04272073|Experimental|High-Protein mediterranean Diet and Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet~eating more fruit and vegetables,~reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),~replacing butter and margarine by olive oil as the main culinary fat,~reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 high-protein yoghurts to eat each day)."
9900543|NCT04268173|Experimental|Immediate Intervention|Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention.
9900544|NCT04268173|Experimental|Delayed Intervention|"Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention after being put on a wait-list for three months.~Per the protocol amendment approved on 9/3/2021, no additional participants will be recruited into the delayed intervention arm."
9900545|NCT04268173|No Intervention|Nonintervention|Participants enrolled in this arm will receive services as usual from Vivent Health and will not engage in the intervention.
9900546|NCT04267926|Placebo Comparator|Placebo|Placebo
9900547|NCT04267926|Active Comparator|20mg of MitoQ|20mg of oral mitoquinol
9900548|NCT04267926|Active Comparator|40mg of MitoQ|40mg of Oral Mitoquinol
9900549|NCT04255147|Experimental|Mesenchymal Stromal Cell Therapy|Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee.
9900550|NCT04254315|Experimental|Cardiac rehabilitation+cognitive therapy|"The intervention group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively.~In addition, the intervention group follows a standardized group based cognitive therapy program with participation of maximum four patients, consisting of 5 sessions (each 2 hours) performed by a trained cardiac rehabilitation nurse."
9900551|NCT04254315|No Intervention|Cardiac rehabilitation|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
9900552|NCT04254315|No Intervention|Control group without psychological distress|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
9900553|NCT04253444|Active Comparator|slow deep breathing|Patients are instructed to do deep breathing at full inspiratory capacity for 4 seconds followed by forced expiration in 6 seconds (forced vital capacity) for 10 minutes.
9900554|NCT04253444|Sham Comparator|sham breathing|Patients are instructed to count 10 breaths and tick a box every time they count ten breaths. The counting distracts the patient reducing the effect of focussing of breathing on their autonomic nervous system.
9900555|NCT04251533|Experimental|alpelisib + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Single arm Open label in Study Part B1
9900556|NCT04251533|Placebo Comparator|placebo + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Not applicable in Study Part B1
9900557|NCT04248283|Experimental|Adjustable Continence Therapy for Women|Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
9900558|NCT04246281|Active Comparator|Group 1: Peripheral Nerve Stimulation (PNS)|Subjects in Group 1 will have leads placed in their lower back. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
9900559|NCT04246281|Active Comparator|Group 2: Standard Interventional Management (Standard of Care)|Subjects in Group 2 will receive the standard of care. Group 2 subjects may be able to crossover to receive PNS after 12 months from start of treatment (Visit 16).
9900560|NCT04246177|Experimental|Lenvatinib plus Pembrolizumab plus TACE|Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
9900561|NCT04246177|Active Comparator|Oral Placebo plus IV Placebo plus TACE|Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
9900562|NCT04243278|Experimental|PO LD-ASA|Study participants who are assigned to the oral aspirin arm of the study will receive 81mg oral aspirin. Over-encapsulated 81mg aspirin tablets will be used. Study participants in this arm will take 81mg aspirin daily for 6 months.
9900563|NCT04243278|Placebo Comparator|PO Placebo|A standard placebo pill, the same size, shape and color of the oral aspirin will be used. The placebo pills will be over-encapsulated in the same manner as the aspirin tablets. The placebo will be administered to the participants randomized to placebo group in the same manner the oral aspirin would be administered - they will take the pill daily for 6 months.
9900564|NCT04243122|Active Comparator|Aspirin and cytoreductive therapy (if applicable)|Patients who are randomized to this group will take a low-dose aspirin 81mg pill once per day (standard-of-care) for at least 6 months along with cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of his or her treating physician after the completion of the study.
9900565|NCT04243122|Experimental|Apixaban and cytoreductive therapy (if applicable)|Patients who are randomized to this group will receive apixaban 2.5mg twice daily for at least 6 months along with standard intervention, cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of their treating physician after the completion of the study.
9900566|NCT04242446|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
9900567|NCT04242446|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
9900568|NCT04242446|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
9900569|NCT04242446|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
9900570|NCT04242264|Experimental|Group 1|Vaccine: 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
9992941|NCT01467336|Other|Delayed group|Rehabilitation program is delayed to the third week. Active range of motion rehabilitation is started at the sixth week.
9992942|NCT01467349||Raltegravir group|"This study will include subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.~A control group will be used for the evaluation of the primary and secondary objectives in comparison to patients treated with raltegravir (study patients). The control group will be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV co-infection status yes/no). For control patients, the last antiretroviral regimen prescribed will be considered."
9992943|NCT01467362|Experimental|V0034CR01B|
9992944|NCT01467362|Placebo Comparator|Vehicle cream|
9992945|NCT01467375|Experimental|A|
9992946|NCT01467388||phacic|Study patients who still have their own ocular lens
9992947|NCT01467388||pseudophacic|Study patients who have an intraocular lens after cataract surgery
9992948|NCT01467401|Experimental|A|
9992949|NCT01467401|Active Comparator|B|
9992950|NCT01467414|Experimental|NN1250|
9992951|NCT01467440||PGA|Patients under glaucoma treatment with prostaglandines
9992952|NCT01467440||NON-PGA|Patient not recieving prostaglandines to treat their glaucoma
9992953|NCT01467518|Other|Period 1|Subjects will be on individualize stable dose of methdaone for 8 days.
9992954|NCT01467518|Other|Period 2|Subjects will be on individualize stable dose of methadone and open label doses of 50mg Dolutegravir (DTG) every 12 hours for 5 days.
9992955|NCT01467531|Experimental|Cohort 1|Period 1 Treatment A = Dolutegravir 50mg q24h x 5 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 11; Period 3 Dolutegravir 50mg q24h + Rilpivirine q24h x 5 days
9992956|NCT01467531|Experimental|Cohort 2|Period 1 Treatment A = GSK1265744 30mg q24h x 12 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 12; Period 3 GSK1265744 30mg q24h + Rilpivirine q24h x 12 days
9992957|NCT01467544|No Intervention|wait list control group|After completing time three data collection, wait-listed participants will be provided with the complete tai chi intervention (8 weeks).
9992958|NCT01467544|Experimental|Tai Chi intervention group|This participant group completes the 8-week tai chi group intervention.
9992959|NCT01467596|Experimental|Elderly population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
9992960|NCT01467596|Active Comparator|Middle aged population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
9992961|NCT01467622||Study population|Patients undergoing elective pulmonary wedge resection, anatomic segmentectomy, or lobectomy.
9992962|NCT01467635|Active Comparator|EBUS-TBNA|Sampling using endobronchial ultrasound guided transbronchial needle aspiration
9992963|NCT01467635|Experimental|EBUS-TBNB|Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.
9992964|NCT01467648|Experimental|0.5 g by 4 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 4 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
9992965|NCT01467648|Experimental|0.5 g by 1 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 1 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
9992966|NCT01467674||Healthy|
9992967|NCT01467674||Chronic Periodontitis|
9992968|NCT01467674||Better Controlled T2DM|
9992969|NCT01467674||Poor Controlled T2DM|
9992970|NCT01467687|Active Comparator|1|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
9900571|NCT04242264|Experimental|Group 2|Placebo+Vaccine: 30 ml of Placebo administered orally on Day 1 and 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
9900572|NCT04242264|Placebo Comparator|Group 3|Placebo: 30 ml of Placebo administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
9900573|NCT04241185|Experimental|Pembrolizumab + Chemotherapy + Radiotherapy|Participants receive pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
9900574|NCT04241185|Placebo Comparator|Placebo + Chemotherapy + Radiotherapy|Participants receive placebo to pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
9900575|NCT04234217|No Intervention|Untreated|Untreated condition (obstructive sleep apnea)
9900576|NCT04234217|Active Comparator|Continuous positive airway pressure (CPAP) treatment|Continuous positive airway pressure (CPAP) treatment
9900577|NCT04234217|Active Comparator|Niacin|Untreated, pharmacological suppression of lipolysis by Niacin
9900578|NCT04232631||patients with diabetic foot ulcers|"Patient of the investigators~Diagnosis of diabetes mellitus~One or more moderate to severe diabetic foot ulcers/infections~18-89 years of age"
9900579|NCT04231981|Experimental|Interventional arm|Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.
9900580|NCT04231266|Active Comparator|ManNAc|Oral ManNAc will be administered at a dose of 4 grams three times daily (total of 12 grams daily).
9900581|NCT04231266|Placebo Comparator|Placebo|Oral Placebo will be administered three times daily.
9900582|NCT04230668|Experimental|CPT + SRM|Participants will be randomized to teletherapy sessions of Cognitive Processing Therapy + Suicide Risk Management for PTSD-BPD which will be administered twice weekly over 6 weeks, for a total of 12 sessions.
9900583|NCT04230668|Experimental|SRM|Participants will be randomized to teletherapy sessions with only Suicide Risk Management for PTSD-BPD which will be administered once a week for 6 weeks, for a total of 6 sessions.
9900584|NCT04230252|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
9900585|NCT04230252|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8 hour ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
9900586|NCT04230031|Experimental|1: Daratumumab|Pre-ASCT and Post-ASCT: Daratumumab
9900587|NCT04227600|Experimental|Part1 JR-171|Drug: JR-171 IV infusion, dose escalation
9900588|NCT04227600|Experimental|Part2 JR-171|Drug: JR-171 IV infusion, dose escalation, low dose, high dose
9900589|NCT04226690|Experimental|Active Dose 1|Participants will receive the most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
9900590|NCT04226690|Placebo Comparator|Matching Placebo|Participants will receive a placebo with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
9900591|NCT04226690|Experimental|Active Dose 2|Participants will receive the second most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1 and 7 of the 7-day dosing, subjects will complete laboratory sessions
9900592|NCT04225507|Other|Lifestyle Intervention|Diet and exercise.
9900593|NCT04225507|Experimental|Lifestyle Plus CPAP Intervention|CPAP treatment, diet and exercise.
9900594|NCT04221945|Experimental|chemoradiotherapy + pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).
9900595|NCT04221945|Experimental|chemoradiotherapy + placebo for pembrolizumab|Participants receive placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays).
9900596|NCT04213404|Experimental|Ribociclib-spartalizumab|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
9933339|NCT05352100|Experimental|Hospitalized patients|This phase will recruit hospitalized bedridden patients who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. They may receive multiple 5 minute episodes of various vibration frequencies.
9900597|NCT04210115|Experimental|Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy|"Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)] 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray [Gy] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year."
9900598|NCT04210115|Placebo Comparator|Placebo+FP or FOLFOX Therapy+Radiotherapy|"Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year."
9900599|NCT04204616|Experimental|Nemolizumab|Participants weighing less than (<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
9900600|NCT04200417|Experimental|Lung, Endobronchial, Mediastinal or Pleural Metastases|Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy
9900601|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9900602|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900603|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9933340|NCT05352087|Active Comparator|early cholecystectomy|In early cholecystectomy group after antibiotherapy was started with ceftriaxone and metronidazole, laparoscopic cholecystectomy was performed in the first 7 days following the hospitalization.
9933341|NCT05352087|Active Comparator|delayed cholecystectomy|Patients who accepted delayed surgery were also given the same antibiotherapy and operated after 6 weeks following their discharge
9900604|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900605|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9900606|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900607|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9900608|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900609|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have not access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9900610|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900611|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9900612|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900613|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9992971|NCT01467687|Active Comparator|2|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
9992972|NCT01467726|Experimental|Dose regimen 1|Varied doses
9900614|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900615|NCT04199117|Experimental|No Incentive,Untailored,No Care Manage,IntensiveTreatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
9900616|NCT04199117|Active Comparator|No Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
9900617|NCT04199104|Experimental|Pembrolizumab with Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
9900618|NCT04199104|Active Comparator|Pembrolizumab with Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months).
9900619|NCT04199065|Experimental|Good Practice Guidelines group|Implementation of Good Practice Guidelines
9900620|NCT04199065|No Intervention|usual practices group|Not Implementation of Good Practice Guidelines, so working as the usual way
9900621|NCT04198714|Experimental|Pudendal block|9cc of 0.25% Marcaine + 1cc of 40mg/mL triamcinolone. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
9900622|NCT04198714|Sham Comparator|Sham injection|10cc normal saline. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
9900623|NCT04197297|Other|CT and MRI Scans|Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
9900624|NCT04196257|Experimental|BP1001-A monotherapy|Dose escalation of BP1001-A monotherapy
9900625|NCT04196257|Experimental|BP1001-A and Paclitaxel|Dose expansion of selected dose of BP1001-A with paclitaxel
9900626|NCT04192799|Experimental|Direct Admission|Referring providers contact the hospital to arrange for a child to be admitted directly into the pediatric hospital medicine unit.
9900627|NCT04192799|Active Comparator|ED Admission|Children initially present at the Emergency Department and are then admitted to the pediatric hospital medicine unit.
9900628|NCT04188873|Active Comparator|12-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9992973|NCT01467726|Experimental|Dose regimen 2|Varied doses
9992974|NCT01467726|Experimental|Placebo|Matching placebo
9992975|NCT01467739|Active Comparator|Ambu ® aScope®|
9992976|NCT01467739|Active Comparator|a conventional reusable fiberscope.|
9900629|NCT04188873|Active Comparator|12-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 12 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9900630|NCT04188873|Active Comparator|24-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9900631|NCT04188873|Active Comparator|24-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9900632|NCT04188873|Active Comparator|12-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9900633|NCT04188873|Active Comparator|12-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9900634|NCT04188873|Active Comparator|24-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9900635|NCT04188873|Active Comparator|24-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9900636|NCT04188873|Active Comparator|12-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9900637|NCT04188873|Active Comparator|12-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief 15-30 minute phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9900638|NCT04188873|Active Comparator|24-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9900639|NCT04188873|Active Comparator|24-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
9900640|NCT04188873|Active Comparator|12-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9900641|NCT04188873|Active Comparator|12-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9900642|NCT04188873|Active Comparator|24-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9933342|NCT05352074|Active Comparator|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
9992977|NCT01467752|Experimental|MCP joint|reconstruction of metacarpophalangeal (MCP) joint
9992978|NCT01467765|Active Comparator|Elemental diet|
9992979|NCT01467765|Placebo Comparator|Liquid nutrient|
9992980|NCT01467778|Active Comparator|ELAPR001|Tropoelastin 0.1ml SC implant
9992981|NCT01467778|Active Comparator|ELAPR002|Tropoelastin 0.1ml SC implant
9992982|NCT01467778|Active Comparator|ELAPR003|Tropoelastin 0.1ml SC implant
9992983|NCT01467778|Placebo Comparator|Saline|Normal Saline 0.9%
9992984|NCT01467791||Patients|All patients with sarcoidosis associated pulmonary hypertension
9992985|NCT01467804|Experimental|Chinese medicine|There are 90 patients with mild to moderate depress in JWXY group, who take the JWXY capsule, and placebo of Sertraline, for 2 months
9992986|NCT01467804|Active Comparator|westen medicine|There are 90 patients with mild to moderate depress in westen medicine group, who take Sertraline, and placebo of the JWXY capsule, for 2 months
9992987|NCT01467817|Experimental|Lifestyle Intervention|This arm will test the combination of 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
9992988|NCT01467817|Placebo Comparator|Exercise Control|This arm will test the benefits of exercise alone while controlling for investigator contact.
9992989|NCT01467830|Experimental|absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using absorbable sutures.
9992990|NCT01467830|Other|non absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using non absorbable sutures,this is the method being considered the standard of care thus far.
9992991|NCT01467843|Active Comparator|Cognitive Behavioral Therapy|Participants randomized to the CBT intervention will attend eight weekly 2 hour sessions.
9992992|NCT01467843|Active Comparator|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR arm will attend eight weekly 2 hour MBSR sessions.
9992993|NCT01467843|No Intervention|Usual Care|Participants randomized to Usual Care will continue to receive care for their low back pain as prescribed by his/her Primary Care Physician.
9992994|NCT01467856||chronic tetraplegia|
9992995|NCT01467908|Experimental|Vegetative state|Patients with the diagnosis of the vegetative state
9992996|NCT01467921|Active Comparator|LV5FU2|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2
9992997|NCT01467921|Experimental|FOLFOX|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2 oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
9992998|NCT01467986|Active Comparator|Irinotecan, Temozolomide|Patients randomized to the control arm receive irinotecan (I) and temozolomide (T) alone.
9992999|NCT01467986|Experimental|Rapamycin, Dasatinib, Temozolomide, Irinotecan|Patients with rNB receive on the study arm the experimental combination of rapamycin (R)- mTOR Inhibitor, dasatinib (D)- protein kinase inhibitor irinotecan (I)- cytostatic topoisomerase-I-inhibitor and temozolomide (T)- Antineoplastic agent
9997796|NCT01512056|Experimental|the immunogenicity profiles of the AdimFlu-S|"Experimental group: to receive either only one dose of influenza vaccine at day 0 or one more booster vaccination 3 weeks later.~Negative control group: dialysis patients who refused to receive influenza vaccination."
9997797|NCT01512056|No Intervention|The safety outcome of the vaccine|Any adverse effect, including systemic or local site, will be recorded during the study period.
9997798|NCT01512069|Experimental|Web-based, Stage-matched Exercise and Diet Planning program|The experimental arm is a group that assigned to use web-based, stage-matched exercise and diet planning program.
9997799|NCT01512069|Active Comparator|Non-tailored booklet on exercise and diet|The control group is provided a booklet containing same information on exercise and diet as in the experimental group's web-based program, but the information on a booklet is not tailored to participants' stage of motivational readiness for exercise and diet based on the TTM.
9997800|NCT01512082|Experimental|Active pulsed electromagnetic field|
9997801|NCT01512082|Sham Comparator|Non-active pulsed electromagnetic field|
9997802|NCT01512095|Experimental|Norditropin®|
9997803|NCT01512095|Active Comparator|Nutropin AQ®|
9997804|NCT01512121||functional MRI testing|"fMRI scanning with SCS on and off at different settings."
9997805|NCT01512134|Experimental|DBS Surgery|All patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.
9997806|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|Our trial will examine the changes in latency and amplitude of SSEP and changes in amplitude and morphology of MEP while using different anesthetic combinations including isoflurane, proposal and dexmedetomidine. Monitoring teams will document any changes throughout the surgery and communicate with the team about those changes. The design of the study will be a prospective AB design.
9997807|NCT01512173|Experimental|propranolol gel|
9997808|NCT01512173|Placebo Comparator|Placebo|
9900643|NCT04188873|Active Comparator|24-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
9900644|NCT04185272|Experimental|non-metastatic colon cancer|
9900645|NCT04185272|Experimental|metastatic colon cancer|
9900646|NCT04181827|Experimental|Arm A: PVd or DPd (Standard Therapy)|Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
9900647|NCT04181827|Experimental|Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])|Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 (cilta-cel) along with conditioning regimen (cyclophosphamide 300 milligram [mg]/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days), and JNJ-68284528 (cilta-cel) infusion 0.75 * 10^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
9900648|NCT04176783|Active Comparator|Opioid|The opioid-based arm utilizes traditional, standard-of-care treatment for each applicable surgery. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.
9900649|NCT04176783|Active Comparator|Opioid-Free|The opioid-free arm utilizes medications that do not belong to the opioid family of medications. All medications used are FDA-approved and no experimental medications are being used. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.
9900650|NCT04176172|Active Comparator|Varenicline & Standard Cessation Counseling|varenicline plus standard behavioral smoking cessation treatment
9900651|NCT04176172|Active Comparator|NMR-Tailored Medication & Standard Cessation Counseling|varenicline or nicotine patch plus standard behavioral smoking cessation treatment
9900652|NCT04176172|Experimental|Varenicline & Standard Cessation Counseling + MAPS|varenicline plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
9900653|NCT04176172|Experimental|NMR-Tailored Medication & Standard Cessation Counseling + MAPS|varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
9900654|NCT04174989|Experimental|Plasminogen-Depleted Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
9900655|NCT04174989|Other|Fresh-Frozen Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of FFP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
9900656|NCT04174742||A|Subjects 45 years of age or younger
9900657|NCT04174742||B|Subjects over 45 years of age
9900658|NCT04174677|Experimental|Inebilzumab Treatment|Infusion of Inebilizumab
9993000|NCT01468025|Active Comparator|Theramine and naproxen|Patients in this group were randomly given active Theramine and active naproxen.
9993001|NCT01468025|Active Comparator|Theramine and placebo|Patients in this group were randomly given active Theramine with placebo representing naproxen.
10212647|NCT05168644|Placebo Comparator|Drug: Placebo|"PART A (SAD): Placebo will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects (Part A) will receive a single dose of Placebo.~PART B (MAD): Placebo inhalation powder will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects (Part B) will receive Placebo inhalation powder BID for a total of 9 doses."
10212648|NCT05166044||Safety group|All of the participants(N=12500) received one dose of EV71 vaccine and one of other vaccines(such as MMR vaccine,encephalitis vaccine,mumps vaccine,inactivated poliomyelitis vaccine,influenza vaccine and so on ) at the same time.
10212649|NCT05165979||Hospitalized COVID-19 patients|Hospitalized COVID-19 patients
9900659|NCT04174677|Experimental|VIB4920 Treatment|Infusion of VIB4920
9900660|NCT04174677|Experimental|Inebilzumab+VIB4920 Treatment|Infusion of Inebilizumab and VIB4920
9900661|NCT04171258|Experimental|Botulax®|
9900662|NCT04171258|Active Comparator|Botox®|
9900663|NCT04169542||Observational (questionnaire)|Patients complete up to 4 electronic questionnaires over 15 minutes before surgery and at 6, 12, and 24 months after surgery.
9900664|NCT04168060|Experimental|Crura Dissection|Participants with a visually detectable hiatal hernia at the time of sleeve gastrectomy procedure will undergo a crura dissection and hiatal hernia repair.
9900665|NCT04168060|Experimental|National Practice|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 2 participants will be treated to the national practice patterns of complete dissection of the curvature of the stomach without dissection of the crura.
9900666|NCT04168060|Experimental|Standard of Care|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 3 participants will undergo the institutional standard of care with the dissection of the crura.
9900667|NCT04166162|Experimental|Focus Group|The Focus Group consists of the participating parents who are BTC employees with child/children in the range of 8 to 16 years old. The Focus Group will receive a total of 6 weekly sessions of the TBD Intervention.
9900668|NCT04166162|Experimental|Social Development Strategy (SDS) Group|All participating BTC workers will be receiving SDS intervention for a minimum of 1 session.
9900669|NCT04166162|Experimental|Brief Intervention Motivational Interviewing (BIMI) Group|Participating 11 to 16 year old children of BTC employees will be receiving the BIMI intervention.
9900670|NCT04166162|Experimental|Business that Care (BTC) Coalition Group|Participating BTC employees who are selected by the respective directors of the participating companies to be part of the BTC Coalition will receive a total of 8 BTC training sessions in the space of 6 months.
10212650|NCT05165836|Placebo Comparator|Erector Spinae Plane block without Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL saline
10212651|NCT05165836|Experimental|Erector Spinae Plane block with Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg
10212652|NCT05163600|Experimental|COPD|Diagnosed COPD according to GOLD-guidelines
9900672|NCT04165564||Group 1 - Screening|Participants in this group will be 55-77 years old and currently smoke or were former smokers with 30 pack-years or more (and quit less than 15 years ago)
9900673|NCT04165564||Group 2 - Incidental|Participants in this group will be > 45 years old and currently smoke or were former smokers with 10 pack-years or more (and quit less than 15 years ago)
10212653|NCT05163600|Experimental|Healthy|Age ≥ 18 years Clinically healthy
10212654|NCT05159115|Active Comparator|Low-FODMAP diet|Patients with IBS on a 4-week low-FODMAP diet.
10212655|NCT05159115|Experimental|Starch- and Sucrose Reduced Diet|Patients with IBS on a s 4-week Starch- and Sucrose Reduced Diet (SSRD).
10212656|NCT05158244|Experimental|PF-07081532|multiple dosing, once-daily for 42 days
10212657|NCT05158244|Placebo Comparator|Placebo|multiple dosing, once-daily for 42 days
10212658|NCT05156957|Experimental|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including three exercises for daily self-guided therapy.
10212659|NCT05156957|No Intervention|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
10212660|NCT05145907|Experimental|TJ107+Pembrolizumab|TJ107 1200ug/Kg,Q12W + Pembrolizumab 200mg Q3W
10212661|NCT05145478||Shockwave Intravascular Lithotripsy (IVL)|Patients with calcified common-femoral artery disease, who are eligible to receive IVL per the FDA indications.
10212662|NCT05141357|Experimental|HBI-8000 in combination with pembrolizumab|
10212663|NCT05141175|Experimental|Hypertension patients|Patients with documented diagnosis of hypertension and their most recent office systolic BP average measured using automated office BP is ≥140 mmHg systolic or ≥90 mmHg diastolic and they are currently prescribed at least one BP-lowering medication will be recruited.
10212664|NCT05140889||Group 1|Children with severe asthma
10212665|NCT05140889||Group 2|Children who undergo chest CT scan for other reasons than asthma
10212666|NCT05139862|Experimental|Active iTBS|Active intermittent theta-burst stimulation (iTBS) rTMS session on the left dorsolateral prefrontal cortex (L-DLPFC)
10212667|NCT05139225|Experimental|TTI-621 + Daratumumab Hyaluronidase-fihj|
10212668|NCT05139225|Experimental|TTI-622 + Daratumumab Hyaluronidase-fihj|
10212669|NCT05138497|Experimental|HILIT group|An experimental group (EG) that after an initial evaluation and with their consent, will be subjected to a directed physical training program, based on Beat Fit exercises for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 50 min per session. The exercises to be carried out will be divided into three different phases: warm-up during the first 10 minutes; the main part with a duration of 30 minutes (where each exercise should be performed for 20 to 30 seconds as intense or fast as possible without generating joint impact, and then take a break for 10 to 15 seconds, before repeating it); and the return to calm, based mainly on stretching exercises with a total duration of 10 minutes.
10212670|NCT05138497|No Intervention|Control group|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study. The participants assigned to this group will receive general advice on the positive effects of the regular practice of physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
10212671|NCT05133830|Experimental|Treatment Arm 1|Participants will receive OCA at dose level 1, 4 hours after the linerixibat administration
10212672|NCT05133830|Experimental|Treatment Arm 2|Participants will receive OCA at dose level 2 along with linerixibat
10212673|NCT05133830|Experimental|Treatment Arm 3|Participants will receive OCA at dose level 1 along with linerixibat
9900685|NCT04161885|Experimental|Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care|Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)
9900686|NCT04161885|Experimental|Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC|Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
9900687|NCT04161885|Experimental|Part 2: Arm B - Best Supportive Care (BSC)|Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)
9900688|NCT04150887|Experimental|Experimental: Cohort 2: Cusatuzumab + Venetoclax|Participants enrolled in this cohort will receive venetoclax ramp-up to 400 mg orally (as background therapy) starting on Cycle 1 Day 1 and followed by 400 mg daily dosing starting on Cycle 1 Day 4 plus cusatuzumab IV on Day 3 and Day 17 of each 28-day cycle. Cohort 2 will not be enrolled in the US.
9900689|NCT04150887|Experimental|Cohort 3: Cusatuzumab + Venetoclax + Azacitidine (CVA)|Participants enrolled at US sites will receive cusatuzumab 10 mg/kg and potentially escalate to 20 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies). Participants enrolled from ex-US sites will receive cusatuzumab 20 mg/kg and potentially de-escalate to 10 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies).
9900690|NCT04149210|Experimental|fluorometholone|Fluorometholone 0.1% eyedrops, one drop twice daily for four weeks
9900691|NCT04149210|Placebo Comparator|Artificial Tears|one drop two times daily for four weeks
9900692|NCT04148534|Active Comparator|muscle relaxant|Facial motor evoked potential monitoring in patient who will receive muscle relaxant, patients will receive rocronium infusion by (5 mcg/kg/min) , twenty minutes after induction. maintain partial NMB TOF count 2 and targeting BIS = (30-40)
9900693|NCT04148534|Placebo Comparator|without muscle relaxant|Facial motor evoked potential monitoring in patient who will not receive muscle relaxant, will recieve normal saline targeting BIS = 30-40 after ending of monitoring of neurophysiology propofol dose will be adjusted to 4-6 mg\kg\hr. targeting Bispecteral index 40-60.
9900694|NCT04148391|Placebo Comparator|Placebo|Matching placebo Capsules
9900695|NCT04148391|Experimental|NYX-458 30 mg|Single oral dose taken daily for 12 weeks.
9900696|NCT04147884|Experimental|Mitral Valve Repair|All subjects will receive mitral valve repair using the Millipede System
9993002|NCT01468025|Active Comparator|Naproxen and placebo|Patients in this group were randomly given active naproxen and placebo to represent Theramine.
9993003|NCT01468038|Active Comparator|Active trazodone and placebo|trazodone 50mg with Sentra PM-like placebo
9993004|NCT01468038|Active Comparator|placebo and active Sentra PM|Trazodone-like placebo and Sentra PM
10212674|NCT05133830|Experimental|Treatment Arm 4|Participants will receive OCA at dose level 2, 4 hours after the linerixibat administration
10212675|NCT05129657|Experimental|Product usage order ABCDN|Subjects will use each of the 5 products sequentially (ABCDN) during an evaluation period, followed by a 4 hour Test Session.
10212676|NCT05129657|Experimental|Product usage order ACBND|Subjects will use each of the 5 products sequentially (ACBND) during an evaluation period, followed by a 4 hour Test Session.
10212677|NCT05129657|Experimental|Product usage order BADCN|Subjects will use each of the 5 products sequentially (BADCN) during an evaluation period, followed by a 4 hour Test Session.
10212678|NCT05129657|Experimental|Product usage order BDANC|Subjects will use each of the 5 products sequentially (BDANC) during an evaluation period, followed by a 4 hour Test Session.
10212679|NCT05129657|Experimental|Product usage order CANBD|Subjects will use each of the 5 products sequentially (CANBD) during an evaluation period, followed by a 4 hour Test Session.
10212680|NCT05129657|Experimental|Product usage order CNADB|Subjects will use each of the 5 products sequentially (CNADB) during an evaluation period, followed by a 4 hour Test Session.
10212681|NCT05129657|Experimental|Product usage order DBNAC|Subjects will use each of the 5 products sequentially (DBNAC) during an evaluation period, followed by a 4 hour Test Session.
10212682|NCT05129657|Experimental|Product usage order DNBCA|Subjects will use each of the 5 products sequentially (DNBCA) during an evaluation period, followed by a 4 hour Test Session.
10212683|NCT05129657|Experimental|Product usage order NCDAB|Subjects will use each of the 5 products sequentially (NCDAB) during an evaluation period, followed by a 4 hour Test Session.
10212684|NCT05129657|Experimental|Product usage order NDCBA|Subjects will use each of the 5 products sequentially (NDCBA) during an evaluation period, followed by a 4 hour Test Session.
9900697|NCT04141644|Experimental|Treatment: all patients|Patients entering trial should be on stable dose of osi for ≥4 weeks. Patients will self-administer osi by mouth regardless of food once daily. Doses should be taken at about the same time every day (±6hrs) and recorded on the patient dosing diary. Doses missed outside of the dosing window should not be made up but patients should be instructed to take their next dose at their regularly scheduled time. Ipi will be administered at the assigned dose level every 21 days (±3days) for a max of 4 doses. Ipi must be infused using a volumetric pump over 90min (±10min) through an IV line. Upon completion of the ipilimumab regimen, patients will continue osimertinib daily until disease progression, initiation of new anti-cancer therapy, or death by any cause.
9900698|NCT04140266|Experimental|Group A: Dapivirine (DPV) Vaginal Ring (VR)-004|Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
9900699|NCT04140266|Experimental|Group B: Truvada Tablet|Mothers will take one Truvada oral tablet daily for approximately three months.
9900700|NCT04130854|Experimental|APX005M on day 3 of RT & day 3 of cycles 1-5 of mFOLFOX|On Day 3 of Cycles 1-5 of each mFOLFOX treatment, participants will receive another dose of APX005M. The sequence of administration of APX005M in combination with mFOLFOX. In Cycle 6, participants will receive only mFOLFOX. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
9900701|NCT04130854|Active Comparator|Radiation Therapy 5Gy x 5 days, mFOLFOX|Participants randomized to Arm 2 will receive short-course RT and mFOLFOX regimen, except that participants will not receive any of the study drug. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
10212685|NCT05127564|Experimental|DRF: Chinese Participants|Chinese participants will receive DRF Dose 1, oral capsules, twice daily (BID), from Day 1 to Day 4 and DRF Dose 1, oral capsules, once daily (QD), on Day 5.
9900703|NCT04128579|Experimental|EQ001 Type A cohort|EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg).
9900704|NCT04128579|Experimental|EQ001 for Type B cohort|EQ001 administered in an unblinded single dose cohort by subcutaneous injection every two weeks for a total of 13 doses (1.6 mg/kg).
9900705|NCT04123366|Experimental|Olaparib+Pembrolizumab|Participants receive olaparib 300 mg via oral tablet 2 times each day PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 21-day cycle. Participants may receive olaparib+pembrolizumab for up to approximately 2 years.
9900706|NCT04121260|Experimental|Daratumumab|Participants will receive daratumumab dose 1 subcutaneously (SC) with recombinant human hyaluronidase [rHuPH20] 30,000 units [U] that is 2,000 U/milliliter (U/mL) SC injection once weekly for the first 8 weeks Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks Cycles 3 to 6 (Days 1 and 15) or the following 16 weeks and then every 4 weeks from Cycle 7 [Day 1] in subsequent cycles, until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
9900707|NCT04118738||ZIKV-Exposed|Children born to women with documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery or the children's laboratory documentation of confirmed or presumptive in-utero ZIKV exposure within five days of birth.
9900708|NCT04118738||ZIKV-Unexposed|Children born to women without documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery and the children have no laboratory documentation of confirmed or presumptive in-utero ZIKV exposure at any time prior to ZIP 2.0 enrollment, if testing was performed prior to enrollment.
9900709|NCT04116437|Experimental|Zanubrutinib|"Cohort 1: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with ibrutinib~Cohort 2: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with acalabrutinib alone/with ibrutinib"
9900710|NCT04115644|Placebo Comparator|Group 1 (control)|will receive an injection of 5 cc 0.25% Marcaine without epinephrine
9900711|NCT04115644|Experimental|Group 2 (ketorolac)|will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
9900712|NCT04115644|Other|Group 3 (kenalog)|Pt will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone. Group 3 is standard of care
10212686|NCT05127564|Experimental|DRF: Caucasian Participants|Caucasian participants will receive DRF Dose 1, oral capsules, BID, from Day 1 to Day 4 and DRF Dose 1, oral capsules, QD, on Day 5.
10212687|NCT05126563|Active Comparator|Treatment|HB-ad MSC's allogeneic
10212688|NCT05126563|Placebo Comparator|Placebo|Sterile Normal Saline
10212689|NCT05126355|Experimental|On the Move|On the Move group exercise program to improve walking. Delivered twice per week for 12 weeks.
10212690|NCT05126355|Other|On the Move - Delayed|Individuals in this arm will be placed on a wait-list for 12 weeks and will receive no intervention during this time. At the end of the 12 weeks they will receive the On the Move group exercise program. This is a wait-list control group.
10212691|NCT05126264|Experimental|Modified dosage|Ibuprofen pill at morning and afternoon; Placebo at night
10212692|NCT05126264|Active Comparator|Normal dosage|Ibuprofen three times a day: morning, afternoon and night
10212693|NCT05125731|Experimental|Parental absence|The parent will not be present in the dental clinic during the treatment. Parents will be instructed to wait in a waiting room outside the clinic, out of sight of the child.
10212694|NCT05125731|Active Comparator|Parental visual support|The parent will watch and wait behind a transparent barrier without disrupting the interaction between the dentist and the child. This type of separation differs from the total absence of the parent because the parent is within the child's sight.
9667208|NCT03843255||Part 2: Heritable Cardiovascular Disease|Patients may be recruited with other diagnosed heritable cardiovascular disorders. Family members of patients may be invited to take part in the study. Children may also be approached to take part in the study.
9900713|NCT04113161|Active Comparator|Standard Care|Standard care will consist of 1) community-based screening and referral and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
9900714|NCT04113161|Experimental|Child Behavioral Health Navigators (cbhN)|CbhNs will engage in a series of face to face and phone contacts with families to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
9900715|NCT04113018|Experimental|1|Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
9900716|NCT04111458|Experimental|BI 1701963 monotherapy|
9900717|NCT04111458|Experimental|BI 1701963 + Trametinib|
9900718|NCT04109729|Experimental|Treatment: all patients|
9933343|NCT05352074|Experimental|subtotal colectomy with cecal-rectal anastomosis|After a complete mobilization of the colon, a resection 2-3cm distal to the ileocecal junction and at the upper part of the rectal ampulla are conducted; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
9933344|NCT05352061|Experimental|Cognitive Behavioral Therapy (CBT) for Syndemic and Adherence Factors Group|Participants in this group will receive the CBT for Syndemics and Adherence Factors intervention for a total of 14 sessions over 4 months.
9933345|NCT05352048|Experimental|Intraoperative MMG vs EMG for cortical breach detection|Participants in this arm will be assessed with both MMG and EMG during their lower spine fusion surgery.
9933346|NCT05352035||Prospective cohort|This cohort will enroll a total of 300 patients prospectively
9900719|NCT04106583||Single Arm|Single Arm - Patients with intracranial aneurysms treated with WAVE, as part of the Penumbra SMART COIL System
9900720|NCT04105543|Experimental|CLR 131 Dose Escalation|"Enrollment will start at dose level 1 (first 4 participants). Participants will receive 2 doses of CLR 131 intravenously with the first dose on day 1 followed by the second dose on day 8.~Dose Level -1 (de-escalation dose, if toxicities warrant) = 12.5 mCi/m^2 Dose Level 1 (beginning dose) = 15.6 mCi/m^2 Dose Level 2 (escalation dose) = 18.75 mCi/m^2~Dose escalation will proceed with no limiting toxicities at each level (maximum of 8 participants at each dose level). With maximum tolerated dose confirmed, an expansion phase will proceed."
9900721|NCT04103749|Experimental|Exalt DScope 02|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
9900722|NCT04100902|Active Comparator|Odactra 12-sq HDM sublingual tablet|House Dust Mite, sublingual tablet
9900723|NCT04100902|Placebo Comparator|Placebo sublingual tablet|Placebo, sublingual tablet
9900724|NCT04096963||The WATCHMAN FLX Delivery System|Patients who are eligible for a WATCHMAN FLX device according to current international and local guidelines (and future revisions) and per physician discretion;
9900725|NCT04096170|Experimental|IV Lidocaine|100 mg Lidocaine bolus on induction, then an infusion of 1.5 mg/kg/hr to begin prior to incision, run throughout the operation and continues into PACU for 1 hour OR until one 2gm/250mL D5W bag has been infused, whichever occurs first. The Patient will be monitored by nursing staff with the aid of continuous cardiac monitoring in the PACU for at least 30 minutes after the discontinuation of the lidocaine drip.
9900726|NCT04096170|Placebo Comparator|Placebo|Patients will receive D5W solution at the same volume and rate as the IV lidocaine.
9900727|NCT04093024|Experimental|Nintedanib (Ofev®)|
9900728|NCT04093024|Placebo Comparator|Placebo|
9900729|NCT04090528|Experimental|Arm 1: One DNA vaccine|"100 µg pTVG-HP administered intradermally (i.d.) days 1, 8 plus 200 mg Pembrolizumab, administered intravenously on day 1 of 21-day cycles (for 8 cycles)~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 of 21-day cycles x 4 cycles"
9900730|NCT04090528|Experimental|Arm 2: Two DNA vaccines|"100 µg pTVG-AR administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 1, 2, 5, and 6 alternating with 100 µg pTVG-HP administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 3, 4, 7, and 8.~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-AR i.d days 1, 8 + 200 mg pembrolizumab IV day 1 of q 21-day cycles, for cycles 1 and 2 followed by 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 in 21-day cycles, for cycles 3 and 4"
9900731|NCT04090125|Experimental|Physical Activity and Symmetry (PAS) Intervention|Participants assigned to the PAS intervention will receive 4 sessions on balance training and physical activity coaching delivered by a physical therapist, in addition to their usual post-TKA physical therapy (PT) care.
9667209|NCT03841201|Experimental|Treatment|"Lenvatinib peroral qd (8 mg for patients with body weight <60kg and 12 mg for patients with body weight ≥ 60kg)~Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles"
9900732|NCT04090125|Placebo Comparator|Attention Control|Participants assigned to the ATT group will receive usual post-TKA physical therapy (PT) care, followed by two additional sessions with their physical therapist.
9993005|NCT01468038|Active Comparator|Sentra PM and trazodone|Active Sentra PM and active trazodone
9993006|NCT01468038|Placebo Comparator|placebo trazodone and placebo Sentra PM|trazadone-like placebo and Sentra PM-like placebo
9993007|NCT01468051|Experimental|40 μg (2 ml) four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
9993008|NCT01468051|Experimental|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
9993009|NCT01468064|Experimental|BMSCs group|
9993010|NCT01468064|Experimental|EPCs group|
9993011|NCT01468064|Placebo Comparator|Control group|
9993012|NCT01468090||Disease course|562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
9993013|NCT01468103|Experimental|PACS|primary angle closure suspects
9993014|NCT01468103|Experimental|PAC|primary angle closure
9993015|NCT01468116||RYGB patients with type 2 diabetes|Morbidly obese patients with type 2 diabetes undergoing gastric bypass surgery
9993016|NCT01468116||RYGB patients without type 2 diabetes|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
9993017|NCT01468116||Cholecystectomy patients without type 2 diabetes|Patients with normal glucose tolerance undergoing laparoscopically cholecystectomy
9993018|NCT01468129|Active Comparator|Cell Saver|
9993019|NCT01468129|No Intervention|Non Cell Saver|
9993020|NCT01468155|Active Comparator|Dabigatran|Dabigatran will be compared to historical data using other OAC methods for Pulmonary Vein Ablation
9993021|NCT01468168|Experimental|DE-101 Ophthalmic Suspension High Dose|
9993022|NCT01468168|Experimental|DE-101 Ophthalmic Suspension Low Dose|
9993023|NCT01468168|Placebo Comparator|DE-101 Ophthalmic Suspension Vehicle|
9993024|NCT01468194|Experimental|Breathing procedure 1|"Walking with breathing procedure 1."
9993025|NCT01468194|Experimental|Breathing procedure 2|"Walking with breathing procedure 2."
9993026|NCT01468194|No Intervention|Control group|Walking without any reglementation of breathing
9993027|NCT01468220|Placebo Comparator|normoxic training|6 weeks of endurance training under normoxia
9993028|NCT01468220|Active Comparator|hypoxic training|6 weeks of endurance training under hypoxia
9993029|NCT01468259|Experimental|Normal renal function|16 subjects with normal renal function (eGFR greater than 90 mL/min/1.73m²)
9993030|NCT01468259|Experimental|Mild RD|Eight (8) with mild (60 less than eGFR less than 89 mL/min/1.73m²)
9993031|NCT01468259|Experimental|Moderate RD|Eight with moderate (30 less than eGFR less than 59 mL/min/1.73m²),
9993032|NCT01468259|Experimental|Severe RD|Eight with severe (15 less than eGFR less than 29 mL/min/1.73m²)
9993033|NCT01468259|Experimental|End Stage Renal Disease|Eight with ESRD (eGFR < 15 mL/min/1.73m² and requiring hemodialysis)
9993034|NCT01468272|Active Comparator|reference treatment|Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
9993035|NCT01468272|Experimental|CHF 1535 NEXT DPI|CHF 1535 50/6 NEXT DPI
9993036|NCT01468285|Experimental|Treatment arm 1: betahistine dihydrochloride|
9993037|NCT01468285|Placebo Comparator|Treatment arm 2: placebo|
9993038|NCT01468298|Active Comparator|Isostretching|
9993039|NCT01468298|Active Comparator|Global Posture Reeducation|
9900733|NCT04088968|Experimental|Prehabilitation|Intervention: Patients allocated to the intervention group receive weekly counselling sessions in 6 weeks as an integrated prehabilitation program tailored to meet the individual patient's need for risk reduction at surgery. It is introduced via the surgical 'Engage in the process of change'. The smoking and alcohol cessation intervention follows the Gold Standard Programme and patients in the intervention group are introduced to a standardized exercise training programme taking individualized needs into account. Nutritional support is also individualized.
9900734|NCT04088968|No Intervention|Treatment as usual|Treatment as ususal covers shorter interventions, e.g. advice, brief counselling, and handing out the national folders on smoking and alcohol and surgery. Patients are ensured that they are free to access support to lifestyle changes in the community.
9900735|NCT04083508|Experimental|Malaria challenge|Malaria Sporozoite Challenge by mosquito bites.
9900736|NCT04083170|Experimental|Regimen A (fludarabine, cyclophosphamide, TBI, OTS)|Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive umbilical cord blood-derived hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
9900737|NCT04083170|Experimental|Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)|Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive umbilical cord blood-derived hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
9900738|NCT04080180|Active Comparator|Contingency Management (CM)|CM is a behavioral method that employs external rewards for target behavior. Participants will receive gift cards for adhering to treatment (attending physician visits and being adherent to buprenorphine-naloxone) for their first 4 clinic visits.
9900739|NCT04080180|Active Comparator|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM)|Participants will receive the BSM intervention at 4 timepoints.
9900740|NCT04080180|Active Comparator|BSM+CM|BSM+CM is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.
9900741|NCT04078191|Experimental|RA Subjects on Stable Therapy|RA subjects who are on stable treatment will receive a single dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m.
9900742|NCT04075396|Experimental|Part D: Outside of Korea|Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety, tolerability, efficacy and pharmacokinetics (PK) of Lazertinib.
9900743|NCT04073420||Surgical Valve Replacement and/or Repair Patients|
9900744|NCT04067427|Active Comparator|Mental training|AF ablation followed by 3 months of a daily app-based mental training for 10 to 15 minutes per session. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
9900745|NCT04067427|No Intervention|Control|AF ablation without subsequent mental training. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
9900746|NCT04067336|Experimental|Part 1a: Dose-Escalation|
9900747|NCT04067336|Experimental|Part 1b: Dose-Validation Expansion|"Cohort 1: KMT2A-r / NPM1-m patients will receive a dose previously studied in Part 1a~Cohort 2: KMT2A-r / NPM1-m patients will receive a dose previously studied in Part 1a"
9900748|NCT04064827|Experimental|Participants Receiving Paricalcitol|Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks
9900749|NCT04064346|Experimental|Lixivaptan - Part 1 and Part 2|Lixivaptan capsules, 100-200 mg twice a day (BID)
9900750|NCT04064346|Placebo Comparator|Placebo - Part 1|Matching placebo capsules BID
9900751|NCT04063410|Experimental|Screening (pPCA)|Patients undergo standard of care CTA and undergo pPCA MRI for up to 60 minutes before surgery.
9900752|NCT04062448|Experimental|Ibrutinib + Rituximab|Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
9900753|NCT04061967|Other|HPV self sampling test ordered|An invitation to order a HPV self sampling test through an online application will be sent by SMS
9900754|NCT04060927|Experimental|Group 1|Freebreathing SBRT with SGRT
9900755|NCT04060927|Experimental|Group 2|Breath hold SBRT with SGRT
9900756|NCT04060927|Experimental|Group 3|Breath hold SBRT with SGRT in combination with implanted fiducials
9900757|NCT04059822|Experimental|Slow and deep breathing|Daily practice of slow and deep breathing for 10 minutes per day. Breathing frequency will be 6 breaths per minute, with participants accessing a video aid to help guide their breathing. Breathing exercises will be conducted from enrolment until birth (maximum ~20 weeks if enrolment at 20 weeks gestation until ~40 weeks gestation birth)
9900758|NCT04057287||NASH related Cirrhosis|
9900759|NCT04057287||Healthy Controls|
9900760|NCT04057287||First Degree Relatives of NASH related Cirrhosis|
9900761|NCT04057287||HBV Disease Control|
9900762|NCT04056208|Active Comparator|Evening Pistachio Consumption|Participants will consume two ounces per day (57 g) of pistachios as an evening snack (i.e., after dinner and before sleep).
9900763|NCT04056208|Active Comparator|Usual care|Advice to consume a snack that contains 1-2 exchanges (15-30 g of carbohydrate) as an evening snack - this is consistent with the current standard of care for people with impaired fasting glucose.
9900764|NCT04051320|Experimental|Women with a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
9900765|NCT04051320|Experimental|Women without a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
9900766|NCT04047420|Experimental|Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Insert|On the first dosing visit (Visit 3), participants will receive a single TAF/EVG Insert for rectal administration. On the second dosing visit (Visit 7), after a washout period of at least 7 days, participants will receive two TAF/EVG Inserts for rectal administration. Each participant will be on study for approximately 6-13 weeks.
9900767|NCT04043286|No Intervention|Control group|Healing abutments are connected on the implants on the day of surgery, which will be subjected to multiple disconnection and reconnection during the prosthetic phase
9900768|NCT04043286|Experimental|Test group|Definitive abutments connected to the implants on the day of surgery. No disconnection or reconnection during the prosthetic phase
9900769|NCT04042376|Experimental|Ibrutinib 420 milligram (mg)|Participants will receive ibrutinib 420 mg once daily, continuously starting at Day 1 of Week 1 until disease progression or unacceptable toxicity, whichever occurs first.
9900770|NCT04036929|Experimental|Estrogen-bazedoxifene|Tablet, once daily for 6 months.
9900771|NCT04036929|Placebo Comparator|Placebo|Closely matched tablet, once daily for 6 months.
9900772|NCT04035226||Relapsed/refractory Multiple Myeloma|Patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody treatment will be observed.
9900773|NCT04034095||Cohort 1: ADT alone/ ADT + Bicalutamide|Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.
9900774|NCT04034095||Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide|Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.
9900775|NCT04032626|Experimental|Lenalidomide|Lenalidomide 10 mg/day taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
9900776|NCT04032626|Placebo Comparator|Placebo|Placebo taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
9900777|NCT04029844|Experimental|Colibri Device|Treatment
9900778|NCT04026529|Experimental|walking at incline|Subjects will walk on treadmill at slope and speed to equal 60% of their peak work rate as determined on baseline cardiopulmonary exercise test.
9900779|NCT04026113|Experimental|Linaclotide 72 μg|FC Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
9900780|NCT04026113|Experimental|Placebo|FC Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
9900781|NCT04026113|Experimental|Linaclotide 145 μg|IBS-C Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
9900782|NCT04026113|Experimental|Linaclotide 290 μg|IBS-C Participants: Single dose, once daily at approximately the same time each day, 30 minutes before any meal
9900783|NCT04024436|Experimental|Futibatinib|"Group/Cohort 1 Description HR+ HER2- Measurable Disease w/ FGFR2 Amplification~Group/Cohort 2 Description TNBC Measurable Disease w/ FGFR2 Amplification~Group/Cohort 3 Description HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification"
9900784|NCT04024436|Experimental|Futibatinib plus Fulvestrant|Group/Cohort 4 Description HR+ HER2- Measurable Disease w/ FGFR1 Amplification
9900785|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg|Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
9900786|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg|Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
9900787|NCT04022980|Experimental|Stage 1|Safety Run-In
9900788|NCT04022980|Experimental|Stage 2|Expansion Cohort
9900789|NCT04013971|Other|Game without AR, Game with AR, Traditional Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without AR, game with AR, traditional interface
9900790|NCT04013971|Other|Game without AR, Traditional Interface, Game with AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without AR, traditional interface, game with AR
9900791|NCT04013971|Other|Game with AR, Game without AR, Traditional Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with AR, game without AR, traditional interface
9900792|NCT04013971|Other|Game with AR, Traditional Interface, Game without AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with AR, traditional interface, game without AR
9900793|NCT04013971|Other|Traditional Interface, Game without AR, Game with AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game without AR, game with AR
9900794|NCT04013971|Other|Traditional Interface, Game with AR, Game without AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game with AR, game without AR
9900795|NCT04009499|Experimental|Bimekzumab dosage regimen|Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.
9900796|NCT04009408|Experimental|EMST therapy|Participants use the EMST device as per study protocol, set to 50% of the patient's maximal expiratory pressure, as measured by handheld manometer.
9900797|NCT04009408|Sham Comparator|Sham EMST therapy|Participants use a sham EMST device that has the spring removed as per study protocol, with no significant airflow resistance.
9900798|NCT04007523|No Intervention|Usual Care Group|Usual care per surgical ward standards
9900799|NCT04007523|Experimental|HELP Support System|This arm will receive the HELP Support System intervention only
9900800|NCT04007523|Experimental|Family Support System|This arm will receive the Family Support system intervention only
9900801|NCT04007523|Experimental|Combined Support Systems|Participants randomized to this arm will receive both HELP- and family-based support system interventions
9900802|NCT04005859|Active Comparator|CONTROL: IV Lido|CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)
9900803|NCT04005859|Experimental|EXPERIMENTAL: Exparel|EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)
9900804|NCT04004767||TRC-PAD Cohort|Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.
9900805|NCT04003623|Experimental|Pemigatinib|
9900806|NCT04001829|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel IV over 3 hours once weekly. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive trastuzumab and/or pertuzumab per institution routine care per treating physician's discretion.
9900807|NCT04001829|Experimental|Arm B (docetaxel)|Patients receive docetaxel IV over 1 hour once every 3 weeks. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive cyclophosphamide, doxorubicin, trastuzumab, and/or pertuzumab per institution routine care per treating physician's discretion.
9900808|NCT03992404|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
9900809|NCT03992404|Placebo Comparator|Placebo|"Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
9900810|NCT03987802||Fiasp®|Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice in India.
9900811|NCT03987282|Active Comparator|Enhanced usual care (EUC)|The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
9900812|NCT03987282|Experimental|Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model|The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
9667210|NCT03841058|Active Comparator|Abaloparatide|Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
9900813|NCT03986424|Experimental|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg once daily
9900814|NCT03986424|Active Comparator|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg twice daily
9900815|NCT03985930|Experimental|Distraction Group|Children between the ages of 3 and 6 years will be distracted using virtual reality content delivered through goggles. Since exposure to video screens has been previously discouraged by various scientific and professional medical organizations in children under 3 years of age, these children will be distracted using video projections of the same content.
9900816|NCT03985930|Active Comparator|Treatment as Usual|Children randomized to this group will receive the usual medical care.
9900817|NCT03984448|Active Comparator|Arm 1 (R-CHOP, DA-EPOCH-R)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen consisting of rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen consisting of rituximab IV on day 1, doxorubicin hydrochloride IV on days 1-4, etoposide IV on days 1-4, vincristine sulfate IV on days 1-4, prednisone PO BID on days 1-5, and cyclophosphamide IV on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
9993040|NCT01468363|Active Comparator|Group 1|"Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight as needed before a dialysis session.~If OH is positive value, we will try to reach dry weight by ultrafiltration without regard to the level of blood pressure.~If OH is negative value , we will not change dry weight."
9993041|NCT01468363|No Intervention|Group 2|BCM results obtained at the beginning and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
9993042|NCT01468376|Experimental|GLU-01|
9993043|NCT01468376|Experimental|GLU-02|
9993044|NCT01468376|Experimental|GLU-03|
9993045|NCT01468376|Experimental|GLU-04|
9993046|NCT01468376|Experimental|GLU-05|
9993047|NCT01468376|Experimental|GLU-06|
9993048|NCT01468389|Active Comparator|Taxanes or Platinum in combination with Capecitabine|The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.
9993049|NCT01468389|Experimental|chemotherapy followed by capecitabine alone|The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.
9993050|NCT01468402||Magnetic Resonanse Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
9993051|NCT01468441|Experimental|GnRH agonist|Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
9993052|NCT01468441|Active Comparator|GnRH antagonist|Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
9993053|NCT01468467|Experimental|AC220|
9993054|NCT01468480|Experimental|Pro Root MTA- standard method|application of MTA in second group and 24 hour interval before restoration
9993055|NCT01468480|Experimental|Pro Root MTA- single visit|Intervention/Control application of MTA in third group and 15 minute interval before restoration
9993056|NCT01468480|Experimental|MultiCal / LimeLite|application of Multical in forth group
9993057|NCT01468480|Active Comparator|Dycal|application of Dycal in first group as a pulp dressing agent
9993058|NCT01468493||steroid-sensitive FSGS|
9993059|NCT01468493||steroid-dependent and resistant FSGS|
9993060|NCT01468493||Healthy volunteers|
9993061|NCT01468506||Fistula patients|Consecutive patients with autogenous, brachio-cephalic, brachio-basilic or brachio-brachial arterio-venous fistula creation for hemodialysis
9993062|NCT01468519|Experimental|CSII|continuous subcutaneous insulin infusion
9993063|NCT01468519|Active Comparator|MDI|multiple daily insulin injections
9993064|NCT01468545||Group 1|
9993065|NCT01468545||Group 2|
9993066|NCT01468571|Experimental|Spironolactone|Drug: Spironolactone Drug: Placebo
9993067|NCT01468571|Experimental|Placebo|Drug: Placebo Drug: Spironolactone
9993068|NCT01468610|Active Comparator|Workers with MDD|
9993069|NCT01468623|Experimental|OnDose®|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
9993070|NCT01468623|Active Comparator|Body Surface Area (BSA)|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.
9993071|NCT01468636|Active Comparator|Oral Zinc|
9993072|NCT01468636|Placebo Comparator|Placebo|
9993073|NCT01468649|Experimental|Breast Cancer SLN Mapping|Fifty participants consented who will be undergoing standard of care for breast cancer SLN mapping with Tc-99m will be enrolled in this study.
9993074|NCT01468662||STEMI|
9993075|NCT01468688|Experimental|STI571 (imatinib mesylate) and BKM120|The study will comprise of 2 parts. A dose escalation and a dose expansion part. Patients will receive increasing doses of BKM120 (40, 60, 80, 100 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. 35 patients will enter the expansion phase with 18 patients having a pharmacokinetic (PK) run-in period of 8 days receiving imatinib monotherapy or BKM120 monotherapy.
9993076|NCT01468688|Experimental|STI571+BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
9993077|NCT01468688|Experimental|STI571 monotherapy run-in|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
9993078|NCT01468727|Experimental|xylitol wipe|
9993079|NCT01468727|Placebo Comparator|placebo wipe|
9993080|NCT01468753|Experimental|Vaginal Insemination|Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
9993081|NCT01468766|Active Comparator|Resistance training|
9993082|NCT01468766|Active Comparator|Relaxation training|
9993083|NCT01468779|Placebo Comparator|Sugar pill|The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period.
9993084|NCT01468779|Active Comparator|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
9993085|NCT01468922|Experimental|A|Combination pazopanib plus ARQ197 at doses established during escalation phase
9993086|NCT01468961|Experimental|Internet-based CBT|
9993087|NCT01469026|Active Comparator|Early PET/CT|
9993088|NCT01469026|Active Comparator|Conventional diagnostics including CT|
9993089|NCT01469078|Active Comparator|100 mg Monofer®|
9993090|NCT01469078|Active Comparator|200 mg Monofer®|
9993091|NCT01469078|Active Comparator|500 mg Monofer®|
9993092|NCT01469091|Active Comparator|Smoking intervention, Nicotine replacement therapy.|
9993093|NCT01469091|No Intervention|Controlgroup|
9993094|NCT01469104|Placebo Comparator|3 day fast|After receiving a standard diet on day 1, subject will fast on days 2, 3, and 4. Water and calorie-fee beverages will be allowed during this 72 hour period.
9993095|NCT01469104|Active Comparator|CHO-free diet|After receiving a standard diet on day 1, a carbohydrate-free diet will be provided on days 2, 3, and 4.
9993096|NCT01469117||Pediatric developmental disabilities|Children aged 1-13 years old with development disabilities, requiring enteral tube feeding for at least 14 days
9993097|NCT01469130|Experimental|MEK162|"MEK162 will be administered orally once on Day 1 of Cycle 1 and continuously on a BID schedule, starting on Day 2 of Cycle 1 and on Day 1 of subsequent cycles. Each cycle will be 28 days in duration. Dose will be escalated and starting dose is 30 mg. Any doses that are missed should be skipped and should not be replaced or made up during the evening dosing or on a subsequent day, whichever applies.~The prescribed BID doses should be taken 12 ± 2 hrs apart."
9993098|NCT01469143|Experimental|NN1218|
9993099|NCT01469143|Active Comparator|insulin aspart|
9993100|NCT01469156|Experimental|Ranibizumab 2.0 mg|Intraocular injection of 2.0 mg/0.05 cc ranibizumab.
9993101|NCT01469156|Active Comparator|Ranibizumab 0.5 mg|Intraocular injection of 0.5 mg/0.05 cc ranibizumab.
9993102|NCT01469169|Experimental|Arm 1|
9993103|NCT01469195||Group A - No lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
9993104|NCT01469195||Group B plus lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.
9993105|NCT01469260|No Intervention|Routine care|ACOG Exercise in Pregnancy pamphlet
9993106|NCT01469260|Experimental|Pedometer|ACOG Exercise in Pregnancy pamphlet, pedometer use, ultimate goal of 10,000 steps per day
9993107|NCT01469273|No Intervention|Control group|Only observation; observation period: 1 year.
9993108|NCT01469273|Experimental|Early Treatment group (E)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.
9993109|NCT01469273|Experimental|Late Treatment Group (L)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.
9993110|NCT01469286|Active Comparator|TEA|Needleless electroacupuncture at ST36 and PC6
9993111|NCT01469286|Placebo Comparator|Sham-TEA|Needleless acupuncture at sham-points
9993112|NCT01469312|Placebo Comparator|Control|The control arm consists of the traditional pasta.
9993113|NCT01469312|Active Comparator|Modified pasta|Dreamfields, Miracle Noodles
9900818|NCT03984448|Experimental|Arm 2 (R-CHOP, DA-EPOCH-R, venetoclax)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
9900819|NCT03983668|Experimental|CMP-001 plus pembrolizumab|Intratumoral administration of CMP-001 and intravenous administration of pembrolizumab
9900820|NCT03977584|Experimental|[^18F]GTP1 in Mutation Carriers: Crenezumab|Mutation-carrying participants receiving crenezumab in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
9900821|NCT03977584|Placebo Comparator|[^18F]GTP1 in Mutation Carriers: Placebo|Mutation-carrying participants receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
9900822|NCT03977584|Placebo Comparator|[^18F]GTP1 in Non-carriers of Mutation: Placebo|Non-carriers of the mutation receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
9900823|NCT03975829|Experimental|Dabrafenib and/or trametinib|"Patients in this study may receive one of the following treatments received in the parent study which are:~Patients who received monotherapy of either of dabrafenib or trametinib~Patients who received combination of dabrafenib and trametinib~Patients who discontinued treatment on parent study are still offered to participate in long-term follow-up"
9900824|NCT03975660|Experimental|Part 1 Device Calibration|50 patients requesting epidural labor analgesia will have pain levels monitored during labor.
9900825|NCT03975660|Experimental|Part 2 Device Validation|60 patients requesting epidural labor analgesia will have pain levels monitored during labor.
9900826|NCT03974152|Active Comparator|Own brand cigarette|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
9900827|NCT03974152|Experimental|ENDS: Subox Mini C with 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
9900828|NCT03974152|Experimental|ENDS: Subox Mini C with 18 mg nicotine regular (unprotonated)|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
9900829|NCT03972150|Experimental|Part I: BI 836880 alone|Part I followed by Part II
9900830|NCT03972150|Experimental|Part II: BI 836880 and BI 754091|
9900831|NCT03969901|Experimental|IMI/REL|Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
9900832|NCT03969901|Active Comparator|Active Control|Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.
9900833|NCT03969589|Experimental|Reproductive Life Planning-Mental Health Intervention|Reproductive Life Planning-Mental Health (RLP-MH) intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
9900834|NCT03969589|Other|Written materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
9900835|NCT03966157|Experimental|Nasal Bridle|Patients randomized to have nasal bridle.
9900836|NCT03966157|No Intervention|Standard|Patients randomized with adhesive tape.
9900837|NCT03965091|Experimental|Fremanezumab - Dose A|
9900838|NCT03965091|Experimental|Fremanezumab - Dose B|
9900839|NCT03965091|Placebo Comparator|Placebo|
9933347|NCT05352022|Experimental|Monthly Unconditional Financial Incentive|Individuals assigned to this group will receive diabetes education and a monthly incentive to supplement income and enhance ability to purchase healthy food options.
9900840|NCT03961737|Experimental|prostatic explants|A first series of biopsies will be performed during the procedure to place the gold grains prior to radiotherapy. Explants will be performed from these biopsies. Half of these explants will be irradiated with a research irradiator at a dose of 2 Gy then placed for 24 hours in an appropriate culture medium. The other half will be directly cultured for 24 hours. After 24 hours of incubation, half of the irradiated explants and half of the explants will be used to study the transcriptome. The tissues will be stored in RNAlater solution and then frozen at -80°C. The remaining half explants will be used for immunohistochemical analysis. Two years after the end of radiotherapy, a new series of biopsies will be performed for research, in order to verify histologically the effectiveness of radiotherapy.
9900841|NCT03959488|Experimental|MEDI8897|anti-RSV monoclonal antibody with an extended half-life
9900842|NCT03959488|Active Comparator|Palivizumab|anti-RSV monoclonal antibody
9900843|NCT03959345|Experimental|Combination therapy group|intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
9900844|NCT03959345|Active Comparator|Standard therapy group|intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment
9900845|NCT03955445|Experimental|Open Label LNP023|LNP023 capsules formulation
9900846|NCT03955146|Experimental|Pamrevlumab|
9900847|NCT03955146|Experimental|Placebo|
9900848|NCT03950973|Experimental|CareAvenue|Participants receive access to CareAvenue, an e-health tool, and receive one weekly automated telephone call and 4-5 text messages per week for 52 weeks.
9900849|NCT03950973|Active Comparator|Guest Assistance Program|Participants receive information about the Guest Assistance Program (GAP) and receive 3-4 text messages per week related to diabetes management and resources for 52 weeks.
9900850|NCT03950232|Experimental|Etrasimod 2 mg|
9900851|NCT03948568|Active Comparator|Concurrent Endocrine Therapy and Radiotherapy|Concurrent endocrine therapy and radiotherapy. Concurrent endocrine therapy will be defined as, the commencement of endocrine therapy around 2 weeks before (a minimum of 1 week before to a maximum of 4 weeks) commencement of radiotherapy and continued throughout radiotherapy.
9900852|NCT03948568|Active Comparator|Sequential Endocrine Therapy after Radiotherapy|Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.
9900853|NCT03941834|Active Comparator|BHV3000|
9900854|NCT03941834|Placebo Comparator|Placebo|
9900855|NCT03937154|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
9900856|NCT03937154|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
9900857|NCT03933904|Experimental|Sirolimus|Oral sirolimus: For adults, loading dose of 5 mg/m^2, rounded to the nearest mg, on day 1. For adults, starting on day 2, oral sirolimus daily at 2.5 mg/m^2/day (rounded to the nearest mg), target trough level 10-15 ng/mL by HPLC, for 12 months. For children, 2 mg/m^2/day, target trough level 5-15 ng/mL by HPLC.
9900858|NCT03932786||Retrospective(biospecimens, vision assessment, questionnaires)|
9900859|NCT03932786||Prospective (biospecimens, vision assessment, questionnaires)|
9900860|NCT03928743|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
9900861|NCT03928743|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
9900862|NCT03928704|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
9900863|NCT03928704|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
9900864|NCT03927989|Experimental|Treatment Arm|Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients
9900865|NCT03927989|Active Comparator|Standard Care|Advice to quit and brief discussion of tobacco use
9900866|NCT03924934||Possible CA-HRE|Patients with suspected CA-HRE, discharged home after a previous hospitalization or outpatient visit during which CA-HRE was isolated from a clinical culture (approximately 210 patients)
9900867|NCT03924934||HA-HRE|Hospitalized patients with healthcare-associated HRE, who are not discharged home (HA-HRE) (210 selected control patients)
9900868|NCT03924934||HA-HRE discharged home|Patients eventually discharged home, either directly or through another facility, after a hospitalization during which HA-HRE was isolated from a clinical culture (100)
9900869|NCT03924934||Community contacts|Contacts of patients with HRE (approximately 1,500)
9900870|NCT03924895|Experimental|Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.
9900871|NCT03924895|Active Comparator|Surgery alone|Participants receive standard of care surgery alone.
9900872|NCT03924895|Experimental|Enfortumab Vedotin + Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.
9900873|NCT03924869|Experimental|SBRT+Pembolizumab|Participants receive SBRT once every 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray [Gy] total) over approximately 2 weeks PLUS pembrolizumab 200 mg via intravenous (IV) infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
9900874|NCT03924869|Placebo Comparator|SBRT+Placebo|Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gy total) over approximately 2 weeks PLUS placebo (normal saline solution) via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
9900875|NCT03924856|Experimental|Pembrolizumab + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.
9900876|NCT03924856|Placebo Comparator|Placebo + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.
9900877|NCT03924336|Experimental|Advanced- platelets rich fibrin plus with open flap debridement|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, A-PRF+ of the required size will be filled into the intraosseous defect, the mucoperiosteal flaps will be repositioned and secured in place using 4-0 silk sutures
9900878|NCT03924336|Active Comparator|Open flap debridement (OFD)|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, The interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
9900879|NCT03921541|Experimental|Pegzilarginase|Weekly IV infusions of pegzilarginase plus individualized disease management for 24 weeks
9900880|NCT03921541|Placebo Comparator|Placebo|Weekly IV infusions of placebo plus individualized disease management for 24 weeks
9900881|NCT03921541|Experimental|Pegzilarginase Long Term Extension|After completion of 24 weeks DB treatment, weekly IV infusions of pegzilarginase plus individualized disease management for an additional 150 weeks, with the option to receive treatment by SC after 8 weeks of the LTE study.
9900882|NCT03919799|Experimental|Group 1|20 subjects will be randomized to receive orally administered belumosudil 200 mg QD double-blinded for the first 28 weeks. Subjects will then will be unblinded and continue on the same belumosudil dose for the remaining 24 weeks.
9900883|NCT03919799|Experimental|Group 2|20 subjects will be randomized to receive orally administered belumosudil 200 mg BID double-blinded for the first 28 weeks. Subjects will then will be unblinded, and continue on the same belumosudil dose for the remaining 24 weeks.
9900884|NCT03919799|Placebo Comparator|Group 3|20 subjects will be randomized to receive orally administered matched placebo double-blinded for the first 28 weeks. Subjects will then will be unblinded and re-randomized to one of the belumosudil doses (200 mg QD or 200 mg BID) in a 1:1 fashion.
9900885|NCT03917472|Experimental|Brolucizumab 6mg q4w|Brolucizumab 6 mg/0.05 mL every 4 weeks.
9900886|NCT03917472|Active Comparator|Aflibercept 2mg q4w|Aflibercept 2mg/0.05 mL every 4 weeks
9900887|NCT03915379|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-67571244. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
9900888|NCT03915379|Experimental|Part 2: Dose Expansion|Participants in 2 expansion cohorts of acute myeloid leukemia (AML) or either high-risk myelodysplastic syndromes (MDS) or very high-risk MDS will receive JNJ-67571244 at the RP2D determined in Part 1.
9900889|NCT03912987||Affected|Affected with ALS or a related disorder, including ALS-FTD, FTD, PLS, and PMA.
9900890|NCT03912987||Healthy Controls|Those never diagnosed with and not at particular risk for developing ALS or a related disorder.
9900891|NCT03912805|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
9993114|NCT01469325|Active Comparator|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil.
9993115|NCT01469325|Sham Comparator|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
9993116|NCT01469338|Experimental|Supportive care (management of therapy complications)|Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
9900892|NCT03912805|Experimental|ET-01|botulinum toxin, Type A, topical liniment, administered once at baseline
9900893|NCT03912636|Active Comparator|Diaphragmatic breathing in healthy volunteers in study1|Healthy volunteers will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
9900894|NCT03912636|Active Comparator|Diaphragmatic breathing in rumination patients in study1|Rumination patients will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
9900895|NCT03912636|Active Comparator|Deep slow breathing in healthy volunteers in study1|Healthy volunteers will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
9900896|NCT03912636|Active Comparator|Deep slow breathing in rumination patients in study1|Rumination patients will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
9900897|NCT03912636|Placebo Comparator|Normal breathing in healthy volunteers in study1|healthy volunteers will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
9900898|NCT03912636|Placebo Comparator|Normal breathing in rumination patients in study1|rumination patients will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
9900899|NCT03912636|Active Comparator|Diaphragmatic breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
9900900|NCT03912636|Active Comparator|Deep slow breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
9900901|NCT03912207|Experimental|Group 1, 2 Day Bronchoscopy|Group 1: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 1 volunteers will have a bronchoscopy 2 days post challenge
9900902|NCT03912207|Experimental|Group 2, 7 Day Bronchoscopy|Group 2: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 2 volunteers will have a bronchoscopy 7 days post challenge
9900903|NCT03912207|Experimental|Group 3, 14 Day Bronchoscopy|Group 3: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG (Arm A) and 3 volunteers will receive aerosol inhaled normal saline placebo (Arm B). All Group 3 volunteers will have a bronchoscopy 14 days post challenge Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted. For group 3 volunteers this will be offered after unblinding.
9900904|NCT03912207|Experimental|Group 4, 28 Day Bronchoscopy|Group 4: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 4 volunteers will have a bronchoscopy 28 days post challenge
9900905|NCT03912207|Experimental|Group 5, 56 Day Bronchoscopy|Group 5: 10 volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 5 volunteers will have a bronchoscopy 56 days post challenge
9900906|NCT03912207|Experimental|Group 6, Intradermal injection, 14 Day Bronchoscopy|Group 6: 6 volunteers will receive 1 x 10^6 cfu intradermal injection BCG + aerosol saline and will have a bronchoscopy 14 days post challenge All volunteers in group 6 will be offered an optional follow up at 12 months
9900907|NCT03912207|Experimental|Group 7, 14 Day Bronchoscopy|"Group 7: 10 volunteers will receive 1 x 107cfu aerosol inhaled BCG. All Group 7 volunteers will have a bronchoscopy 14 days post challenge.~Volunteers in group 7 and group 3 (arm A) will be offered an optional follow up at 12 months, in order of enrolment until 10 such visits have been conducted"
9900908|NCT03910478|Experimental|Self-collected Dried Blood Spot (DBS) monitoring|N=100 Subject collected DBS CMV monitoring with mobile technology support
9900909|NCT03910478|Active Comparator|Standard Monitoring Control|N=50 Standard care with office based testing
10212695|NCT05125731|Active Comparator|Parental presence|One of the parents will accompany the child during the dental treatment. The parent is allowed to sit next to the child without disturbing the interaction between the dentist and the child.
10212696|NCT05124795|Experimental|IMU-935 - low dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
9900912|NCT03904615|Active Comparator|Whey Protein|30 g of whey protein twice daily during hospitalization and for 30 days after discharge
9900913|NCT03904615|Active Comparator|Collagen Protein|30 g of collagen protein twice daily during hospitalization and for 30 days after discharge
9900914|NCT03904615|Placebo Comparator|Placebo|30 g of maltodextrin twice daily during hospitalization and for 30 days after discharge
9900915|NCT03904173||EMIT-1 - Multi-parameter tests|Patients with hormone sensitive HER2 negative primary breast cancer without lymph node metastasis. Treatment recommendations will be based on the Prosigna test result, in addition to conventional clinicopathological parameters.
9900916|NCT03899155|Experimental|Nivolumab Dose 1|Specified Dose on Specified Days
9900917|NCT03899155|Experimental|Nivolumab Dose 2|Specified Dose on Specified Days
9900918|NCT03898297||Healthy control|60 psychiatrically-healthy subjects will be enrolled as controls may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
9900919|NCT03898297||MDD|30 subjects with major depressive disorder (MDD) may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
9900920|NCT03898297||Bipolar|30 subjects with bipolar disorder may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
9933348|NCT05352022|Experimental|Monthly Unconditional Plus Healthy Food Purchasing Financial Incentive|Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, and an additional weekly incentive if they provide receipt for purchase of healthy food items from a grocery store.
9933349|NCT05352022|Experimental|Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial Incentive|Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, an additional weekly incentive if they provide receipt for purchase of healthy food items from a grocery store, and an incentive at the end of the study based on absolute drop in HbA1c.
9933350|NCT05352009|Experimental|Sling exercise training group|Participants will practice core muscle exercise in different positions with sling systems (Redcord®, Norway).
9933351|NCT05352009|Active Comparator|Conventional training group|Participants will practice balance exercise, including sit-to-stand, forward reaching, postural training on the therapeutic ball, maintaining standing balance with eyes open and progress to eyes close, and tandem stance.
9933352|NCT05351996|Active Comparator|Kinesiotape|The participants received kinesiotape to the rectus femoris muscle.
9933353|NCT05351996|Sham Comparator|Sham-kinesiotape|Non-specific taping was applied.
9933354|NCT05351983|Experimental|Organoid generation|All patients will included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation.
9933355|NCT05351970||Monofilament closure|Patients with midline emergency laparotomy, which closure was performed with monofilament suture
9933356|NCT05351970||Barbed closure|Patients with midline emergency laparotomy, which closure was performed with barbed suture
9933357|NCT05351957|Experimental|dry needling|This study has only 1 arm and the control group is their baseline data
10212697|NCT05124795|Experimental|IMU-935 - medium dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
10212698|NCT05124795|Experimental|IMU-935 - high dose, administered twice daily|main treatment phase of 3 cycles of 28 days; followed by extended treatment cycles for patients that show clinical benefit from treatment
10212699|NCT05119738||Three doses of BNT162b2.|Cancer patients on active cytotoxic treatment who received three doses of BNT162b2.
10212700|NCT05119738||Two doses of Coronavac and one of BNT162b2.|Cancer patients on active cytotoxic treatment who received two doses of Coronavac and one dose of BNT162b2.
10212701|NCT05118841|Experimental|ZX-4081 Dose Level 1|Starting dose (SD) of ZX-4081 administered orally twice daily (BID) in a 28-day cycle
10212702|NCT05118841|Experimental|ZX-4081 Dose Level 2|2-times the SD of ZX-4081 administered orally BID in a 28-day cycle
10212703|NCT05118841|Experimental|ZX-4081 Dose Level 3|4-times the SD of ZX-4081 administered orally BID in a 28-day cycle
10212704|NCT05118841|Experimental|ZX-4081 Dose Level 4|6-times the SD of ZX-4081 administered orally BID in a 28-day cycle
10212705|NCT05118841|Experimental|ZX-4081 Dose Level 5|8-times the SD of ZX-4081 administered orally BID in a 28-day cycle
10212706|NCT05118841|Experimental|ZX-4081 Dose Level 6|10-times the SD of ZX-4081 administered orally BID in a 28-day cycle
10212707|NCT05118841|Experimental|ZX-4081 Expansion Dose Level|Recommended Phase 2 Dose (RP2D) (to be determined) of ZX-4081 administered orally BID in a 28-day cycle
10212708|NCT05117931|Experimental|Amivantamab|Patients will receive amivantamab intravenously weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (patients <80kg) or 1400mg (patients ≥80kg). The initial dose will be administered over 2 days in split doses in order to mitigate the risk of infusion reactions. Therapy will continue for up to 2 years or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reason to discontinue treatment occurs-whichever comes first.
9993117|NCT01469351|Active Comparator|Drug|the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
9798160|NCT01619839|Experimental|300 mg NKTR-181|300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
9993118|NCT01469351|Placebo Comparator|placebo|non active intervention
9993119|NCT01469403|No Intervention|control group|Standard procedure for knee arthroplasty
9798161|NCT01619839|Experimental|400 mg NKTR-181|400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
9798162|NCT01619839|Placebo Comparator|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.
9798163|NCT01619852|Active Comparator|Group L|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
9798164|NCT01619852|Placebo Comparator|.9% normal saline placebo|.9% normal saline administered as a bolus then as a maintenance infusion for the length of the surgical case.
9798165|NCT01619865|Experimental|68Ga-DOTATOC PET/CT|68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors
9798166|NCT01619878|Experimental|Cohort 1|"One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.~Infants age >28 days."
9798167|NCT01619982|Active Comparator|Cefazolin 25 mg/kg body weight and vancomycin|"All infants < 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children.~Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight"
9900921|NCT03896724|Experimental|Group 1|"n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 1 will be randomised 2:1 into Groups1a and 1b for 5ug R21/50ug Matrix-M: control. Groups 1a and 1b will receive these second and third booster vaccinations each year prior to the malaria season"
9900922|NCT03896724|Experimental|Group 2|"n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 2 will be randomised 2:1 into Groups 2a and 2b or 5ug R21/50ug Matrix-M:ccontrol. Groups 2a and 2b will receive these second and third booster vaccinations each year prior to the malaria season"
9900923|NCT03896724|Placebo Comparator|Group 3 (control group)|n=150. Age 5-17 month-old. Rabies Vaccine by the end of the trial.
9900924|NCT03895203|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
9900925|NCT03895203|Active Comparator|Adalimumab dosage regimen|Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.
9900926|NCT03895203|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.
9900927|NCT03893617|Active Comparator|Propranolol group|This group will receive a single oral dose (80mg) of propranolol in a blinded capsule during their acute stress study visit.
9900928|NCT03893617|Placebo Comparator|Placebo group|This group will receive a single blinded capsule containing no active medication during their acute stress study visit.
9900929|NCT03889639|Experimental|Cohort 1: SAR442168 5 mg Then Placebo|Participants received SAR442168 5 milligrams (mg), orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900930|NCT03889639|Experimental|Cohort 1: SAR442168 15 mg Then Placebo|Participants received SAR442168 15 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900931|NCT03889639|Experimental|Cohort 1: SAR442168 30 mg Then Placebo|Participants received SAR442168 30 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900932|NCT03889639|Experimental|Cohort 1: SAR442168 60 mg Then Placebo|Participants received SAR442168 60 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900933|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 5 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 5 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900934|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 15 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 15 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900935|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 30 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 30 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900936|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 60 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 60 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
9900937|NCT03889353|Experimental|BCI sessions|up to 3 test sessions (Day-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (Day 1-Day 5 and Day 8-Day 12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
9900938|NCT03886168|Experimental|Immediate IGCIP|Immediate signal processing intervention of a biomedical device
9900939|NCT03886168|Active Comparator|Deferred IGCIP|Delayed signal processing intervention of a biomedical device
9900940|NCT03879655|Experimental|VTS-270|Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the subject, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.
9900941|NCT03879135|Experimental|On-Demand|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
9900942|NCT03879135|Experimental|Prophylaxis|Participants will receive recombinant von Willebrand factor (rVWF).
9900943|NCT03875664|Active Comparator|Intervention|Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
9900944|NCT03875664|Placebo Comparator|Placebo|Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
10212709|NCT05112627||Observational (biospecimen collection)|Patients undergo blood sample collection at baseline prior to SBRT or PCA, then at 14 days, 3 and 6 months after SBRT or PCA.
9900945|NCT03874715|Experimental|Switching arm: Alternative use of SAR341402 and NovoLog|Alternating use of SAR341402 and NovoLog, self-administered by subcutaneous injection at mealtime, starting with NovoLog for the first 4 weeks, then SAR341402 for 4 weeks, followed by NovoLog for 4 weeks and then SAR341402 for the last 4 weeks on top of Lantus as basal insulin.
9900946|NCT03874715|Active Comparator|Non-Switching arm: NovoLog|Continuous use of NovoLog, self-administrated by subcutaneous injection at mealtime, during the 16-week Treatment Period on top of Lantus as basal insulin.
9900947|NCT03873376|Experimental|Opt-in|Receive offer to order self-sampling kit
9900948|NCT03873376|Experimental|Opt-out|Receive self-sampling kit unsolicited
9900949|NCT03873376|Experimental|Control|Receive open reminder to be screened by physician
9900950|NCT03873259|Experimental|Treatment Group|Subjects in this arm receive the 10-minute burst wave lithotripsy intervention dose during their standard-of-care lithotripsy procedure.
9900951|NCT03870919|Other|Palbociclib + locoregional treatment|All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks (a delay of +/- 2 weeks to initiate the locoregional treatment is authorized after the day 1 of cycle 1 of palbociclib plus letrozole). After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression
9900952|NCT03870360|Experimental|HOLA: A Culturally-Tailored Health Promotion Intervention|16 week, multicomponent, health promotion intervention
9900953|NCT03870360|Active Comparator|Healthy lifestyles education program|Educational material on mental health, physical activity, and information on community resources
9900954|NCT03869866|Experimental|MenACYW conjugate vaccine|MenACYW conjugate single injection at Day 0
9900955|NCT03868930|Experimental|STEP-Home|The STEP-Home Arm involves a skills-based intervention focused on Emotional Regulation, Problem Solving, and Attention Training strategies.
9900956|NCT03868930|Active Comparator|PCGT|The Present Center Group Therapy (PCGT) Arm involves a nonspecific, supportive intervention, focused on identifying and discussing current life stressors.
9900957|NCT03868579|Experimental|Observational (pleuroscopy, medical chart review)|Patients undergo biopsy of the lining of the lung using pleuroscopy. Medical chart of patients is also reviewed.
9900958|NCT03865927|Experimental|GKT137831|GKT137831 will be administered orally, at a dose of 400 mg twice daily, for a total of 24 weeks.
9900959|NCT03865927|Placebo Comparator|Placebo Oral Tablet|Identically-appearing placebo oral tablets will be administered orally, twice daily, for a total of 24 weeks.
9900960|NCT03865667||Primary Total Hip Arthroplasty|Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroplasty) components including acetabular shells, acetabular liners and femoral heads.
9900961|NCT03865524|Experimental|Experimental|Total knee arthroplasty implanted with GPS navigation system.
9900962|NCT03865524|Active Comparator|Control|Total knee arthroplasty implanted with standard guides.
9900963|NCT03860272|Experimental|3-Week Monotherapy|3+3 Dose escalation: botensilimab, every 3 weeks, starting at dose level 0.1 milligrams/kilogram (mg/kg) up to 4 mg/kg, administered intravenously (IV) for up to 2 years.
9900964|NCT03860272|Experimental|6-Week Monotherapy|3+3 Dose escalation: botensilimab, every 6 weeks, starting at dose level 1 mg/kg up to 4 mg/kg, administered IV for up to 2 years.
9900965|NCT03860272|Experimental|6-Week Combination Therapy|3+3 Dose escalation: balstilimab, every 2 weeks, at dose level 3 mg/kg in combination with botensilimab, every 6 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg, administered IV for up to 2 years. An additional cohort will investigate balstilimab, every 3 weeks, at 450 mg in combination with botensilimab every 6 weeks, at 150 mg, administered IV for up to 2 years.
9900966|NCT03857594||Individuals at risk of hereditary cancer syndrome|All individuals at risk of a hereditary cancer syndrome with or without a known germline mutation from clinical genetic testing.
9900967|NCT03857529|Experimental|conventional tDCS concurrent with CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
9900968|NCT03857529|Experimental|unconventional tDCS concurrent with CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
9900969|NCT03857529|Experimental|conventional tDCS preceding CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
9900970|NCT03857529|Experimental|unconventional tDCS preceding CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
9900971|NCT03857529|Sham Comparator|sham tDCS with CCFES|sham tDCS preceding and concurrent with CCFES
9900972|NCT03856645|Experimental|OKG-0301 0.012% w/v|
9900973|NCT03856645|Experimental|OKG-0301 0.03% w/v|
9900974|NCT03856645|Placebo Comparator|Vehicle Control|
9900975|NCT03854929|Active Comparator|Ciprofloxacin|Each sachet CIPROFLOXACIN of 3g powder contains: 250mg Ciprofloxacin HCl, dissolved in water, dosed to 15mg/kg body weight /twice daily (apart 12 hours)/ 3 days.
9900976|NCT03854929|Experimental|Azithromycin|Each sachet AZICINE of 1.5 g powder contains: 250mg of Azithromycin dihydrate, dissolved in warm water, dosed to 10mg/kg body weight /daily/ 3 days
9667211|NCT03841058|Placebo Comparator|Placebo|Placebo administered subcutaneously with a pen once daily for 6 months
9900977|NCT03852511|Experimental|Intravenous|Patients will receive three single doses of NG-350A by IV infusion, followed by multiple cycles of check point inhibitor treatment.
9900978|NCT03851614|Experimental|Cohort A|Olaparib (given orally at a dose of 300 mg twice a day) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
9900979|NCT03851614|Experimental|Cohort B|Cediranib (given orally at a dose of 20 mg daily, 5 days on 2 days off) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
9900980|NCT03847038|Experimental|Intervention|Multimodal lifestyle-interventional. Participants are disclosed their 5-year dementia risk estimate
9900981|NCT03846232||Cognitive impairment. Alzheimer's disease|Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers)
9900982|NCT03846232||Cognitively unimpaired, preclinical Alzheimer's disease|Normal cognition as defined by the ALFA study cognitive workup Positive amyloid PET in the last 30 months
9900983|NCT03846232||Cognitively unimpaired, control|Normal cognition as defined by the ALFA study cognitive workup Negative amyloid PET in the last 30 months
9900984|NCT03845660|No Intervention|Usual Care|Providers taking care of patients randomized to this arm will have no alert related to the patients prognosis.
9900985|NCT03845660|Experimental|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
9900986|NCT03843190|Experimental|Take Off Pounds Sensibly (TOPS)|This group will receive TOPS intervention at the start of the study.
9900987|NCT03843190|Other|Waitlist control|This group will be the control group for the initial year of the study. Then at the completion of the study they will receive the TOPS intervention.
9900988|NCT03839823|Active Comparator|Comparator arm|Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine will be administer to patients enrolled in the control group. The chemotherapy regimen will be decided by the treating physician.
9900989|NCT03839823|Experimental|Ribociclib arm|"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.~Ribociclib (600 mg) is dosed orally for the first 21 days out of a 28 day cycle.~Letrozole (2.5 mg) or anastrozole (1 mg) are dosed orally daily (28 days out of the 28 day cycle).~Goserelin (3.6 mg) is continuously released via a subcutaneous implant injected on Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days."
9900990|NCT03839693|Placebo Comparator|Vehicle|Vehicle
9900991|NCT03839693|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
9900992|NCT03839693|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
9900993|NCT03838861|Active Comparator|Control|Standard follow-up in doctors setting
9900994|NCT03838861|Experimental|Intervention|Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
9900995|NCT03838601|Experimental|MET-4|Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
9900996|NCT03835884|Experimental|AR-13503 Implant 10.6 Dose|Single dose of AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
9900997|NCT03835884|Experimental|AR-13503 Implant 21.2 Dose|Single dose of AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
9900998|NCT03835884|Experimental|AR-13503 Implant 42.4 Dose|Single dose of AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
9900999|NCT03835884|Experimental|AR-13503 Implant 63.6 Dose|Dose of AR-13503 Implant 63.6 Dose (63.6 µg) administered into a single eye of up to 5 subjects (DME) who will be followed for 24 weeks. Subjects may qualify to receive an additional dose at Week 12.
9901000|NCT03834493|Experimental|Pembrolizumab + Enzalutamide|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression.
9901001|NCT03834493|Placebo Comparator|Placebo + Enzalutamide|Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression.
9901002|NCT03833167|Experimental|Pembrolizumab|Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.
9901003|NCT03833167|Placebo Comparator|Placebo|Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.
9901004|NCT03833154|Experimental|SoC SBRT + Durvalumab Therapy (Main Cohort)|"SBRT - delivered in 3, 4, 5 or 8 fractions.~Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met."
9901005|NCT03833154|Placebo Comparator|SoC SBRT + Placebo Therapy (Main Cohort)|"SBRT - delivered in 3, 4, 5 or 8 fractions.~Placebo (matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met."
9901006|NCT03833154|Experimental|SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, separate cohort)|"SBRT delivered in 3, 4, 5 or 8 fractions~Osimertinib 80mg every day [qd] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT"
9993120|NCT01469403|Active Comparator|Weight loss program|The intervention program consists of 8 weeks of low-diet, using formula foods, and dietary counseling before surgery. When using formula foods the patients can achieve a quicker weight reduction and a greater reduction in fat mass than using conventional dietetic hypo caloric diet.
9993121|NCT01469416|Active Comparator|Rosuvastatin|
9993122|NCT01469416|Experimental|Rosuvastatin + clopidogrel|
9993123|NCT01469429|Placebo Comparator|Arm I (Lozenge placebo)|Patients receive lozenge placebo PO QID.
10212710|NCT05110196|Experimental|Capmatinib|Capmatinib (Rahika®) film-coated tablet administered as 400 mg orally twice daily on a continuous dosing schedule for 24 weeks.
9993124|NCT01469429|Experimental|Arm II (LBR lozenge)|Patients receive lyophilized black raspberries lozenge PO (8gms/day)
9993125|NCT01469429|Placebo Comparator|Arm III (Saliva Substitute placebo)|Patients receive Saliva Substitute placebo PO QID.
9993126|NCT01469429|Experimental|Arm IV (LBR Saliva Substitute)|Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
9993127|NCT01469442|Experimental|external biliary duct stent|'External Biliary duct stent in the bile duct by cystic way'
9993128|NCT01469442|No Intervention|without external biliary duct stent|
9993129|NCT01469455|Experimental|DT01|
9993130|NCT01469468|Experimental|Single arm, fixed sequence dosing|
9993131|NCT01469481|Experimental|1|
9993132|NCT01469494|Active Comparator|DIEP flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
9993133|NCT01469494|Active Comparator|SIEA flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
9993134|NCT01469507|Experimental|V0220|
9993135|NCT01469507|Active Comparator|Hyaluronan|
10212711|NCT05107947|Experimental|Intervention biocentric light environment|In all study rooms, a biocentric lighting environment will be able to be created by activating a special lighting system. In these rooms, light will change dynamically both in spectral distribution and intensity during the day. During the day, color temperature and intensity are high (1000 lux and up to 6500 K) to decrease both intensity and color temperature during the evening.
9993136|NCT01469520|Active Comparator|Reference|Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
9993137|NCT01469520|Active Comparator|Test product|Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
9993138|NCT01469520|Active Comparator|Test Product|Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
9993139|NCT01469533|Experimental|experimental group|The experimental group receives the real spinal mechanical manipulation.
9993140|NCT01469533|Sham Comparator|control group|The control group receives the sham-manipulation procedure.
9993141|NCT01469559|Active Comparator|Novolin Toronto insulin|
9993142|NCT01469559|Placebo Comparator|Normal saline|
9993143|NCT01469572|Experimental|Sir-sphere radioembolization|Everolimus, Pasireotide and Sir-sphere radioembolization
9993144|NCT01469598|Experimental|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
10212712|NCT05107947|No Intervention|Control standard light environment|Standard static light environment.
10212713|NCT05102773||Ancillary-correlative (questionnaire, sample collection, CT)|Patients complete a FFQ at baseline, undergo collection of stool samples at baseline, within 2 days of starting corticosteroid treatment (if applicable), when asked for a control sample, and at 12 weeks, and undergo collection of blood samples and CT at baseline and 12 weeks.
10212714|NCT05102760|Active Comparator|Fascia Iliaca Compartment|Fascial Iliaca block (FIC) (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED
10212715|NCT05102760|Active Comparator|PENG Block|Pericapsular Nerve Group (PENG) Block (20mL of Bupivacaine 0.50%)
10212716|NCT05100342||Low-risk|Low-risk:score 0-6
10212717|NCT05100342||Intermediate-risk|Intermediate-risk: score 7-13
10212718|NCT05100342||High-risk|High-risk:score 14-20
10212719|NCT05098665|Active Comparator|Arm A - RCT telemonitoring|160 ATTR-CM patients assigned to receive telemonitoring intervention
10212720|NCT05098665|No Intervention|Arm B - RCT usual care|Control group of 160 ATTR-CM patients assigned to receive usual care
10212721|NCT05096923||UNC-CAYACC|Children, adolescents, and young adults diagnosed with cancer before the age of 40 enrolled at any point during the diagnosis-treatment-survivorship continuum.
10212722|NCT05095311|Experimental|Experimental group|This subset of 8 individuals will complete all 3 experimental study visits, and will ingest either 1) a placebo pill and placebo inhaler contents, 2) a placebo pill and nedocromil sodium (4 mg), or 3) a cetirizine HCl pill (10 mg) and placebo inhaler contents in a randomized order and double-blind fashion. This group will be composed of individuals who have a high histamine response to intense exercise.
10212723|NCT05095311|Placebo Comparator|Control-only group|This subset of 4 individuals will complete one of the experimental study visits, and will ingest either a placebo pill and placebo inhaler contents. This group will be composed of individuals who have a low histamine response to intense exercise.
10212724|NCT05095311|No Intervention|Selection pool|Twenty-six total individuals will be recruited for the initial portion of the study, and the aforementioned 12 (8 experimental, 4 control-only) will be a subset of the initial 26. The other 14 participants will not take part in further study.
10212725|NCT05093400||Normal Saliva|"saliva from normal healthy adults."
10212726|NCT05088694|Experimental|Intervention|Classrooms assigned to the intervention group will receive the Peaceful Coexistence (middle school) or Anti-extremism (high school) curricula.
10212727|NCT05088694|No Intervention|No intervention|Classrooms assigned to the No intervention group will receive general information during their sessions.
9798168|NCT01619982|Other|Cefazolin only 30mg/kg body weight|All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections
9798169|NCT01620047|Experimental|Femoral Nerve Fentanyl|Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
9798170|NCT01620047|Active Comparator|Femoral Nerve Ropivacaine|Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
9798171|NCT01620047|Placebo Comparator|Intravenous Fentanyl with placebo|Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
9993145|NCT01469611|Experimental|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
9993146|NCT01469624|Experimental|Test group|This group receives pentoxifylline
9993147|NCT01469624|No Intervention|Control group|
9993148|NCT01469650|Active Comparator|400 IU/day vitamin D|Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
9993149|NCT01469650|Experimental|800 IU/day vitamin D3|Subjects will receive 800 IU/day vitamin D3
9993150|NCT01469663||Healthy Control|Healthy participants without borderline personality or depression
9993151|NCT01469663||Major Depression, No Borderline Personality Disorder|With major depression and no borderline personality
9993152|NCT01469663||Major Depression + Borderline Personality Disorder|With major depression and borderline personality disorder
9993153|NCT01469663||No Major Depression, Borderline Personality Disorder|With no major depression, but with borderline personality disorder
9798172|NCT01620060|Experimental|Lurasidone oral tablets|Lurasidone 20, 40, 80, 120 or 160 mg/day
9798173|NCT01620086|Experimental|Patients|Patients with Schizophrenia who meet entry criteria for the study and first receive active repetitive transcranial magnetic stimulation for four days over a control site located at the vertex and then are randomized to receive repetitive Transcranial Magnetic Stimulation for four days over the temporal cortex at both 1 Hz and 10 Hz.
9798174|NCT01620086|Experimental|Controls|These subjects are normal controls without schizophrenia who receive sham, repetitive transcranial magnetic stimulation at 1 Hz for two days and then receive active, repetitive Transcranial Magnetic stimulation for two days. All stimulation is delivered at the control site located over the vertex.
9993154|NCT01469676|No Intervention|Control group|In the Control group, a standard arterial line filter was inserted on CPB circuit.
9993155|NCT01469676|Experimental|Filtering Group|In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
9993156|NCT01469689|Experimental|Google Adwords only|In these areas,the investigators will display online adverts using Google Adwords, with links to the investigators' project website, and from there to four other websites for depression.
9993157|NCT01469689|Experimental|Local organisation websites|In these areas, the investigators will try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
9993158|NCT01469689|Experimental|Google Ads and local websites|In these areas, the investigators will place Google Adwords and also try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
9993159|NCT01469689|No Intervention|Control|Control areas. No Intervention
9901007|NCT03824483|Experimental|BOVEN regimen|"Patients will be given zanubrutinib (160mg by mouth BID) and obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter). Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter."
9901008|NCT03823768|Active Comparator|Arm 1: Control|Tacrolimus immediate release twice daily for 6 months
9901009|NCT03823768|Experimental|Arm 2: Intervention|Envarsus daily for 6 months.
9901010|NCT03820973|Experimental|Brief CBT for Anxiety|Participants will receive Brief Cognitive Behavioral Therapy for Anxiety (bCBT). Sessions with clinicians will be provided via VA Video Connect to Home (VVC-H). Participants will have the option to select from a list of skills to tailor to his/her preferences. Participants will be able to receive up to 9 total sessions and generally last 30 to 40 minutes. For the purpose of this study, treatment duration will be limited to 3 months to ensure standardization of study outcome measures.
9901011|NCT03818035|Experimental|Part 1: Guselkumab|Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.
9901012|NCT03818035|Experimental|Part 2: Guselkumab q8w and Guselkumab q16w|Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder [SRe]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score >5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.
9901013|NCT03818035|Experimental|Part 2: Guselkumab q8w|Participants (Non SRe) in group 2c with a PASI score greater than (>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.
9901014|NCT03818035|Experimental|Part 3: Guselkumab Withdrawal|Participants from groups 2a and 2b with a PASI score <3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 116 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to [>=] 3) at week 68 or PASI >5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.
9901015|NCT03815591|Experimental|adolescents between ages of 10-16|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, attitudes, intentions, social norms, and behaviors around tobacco use, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
9901016|NCT03813537|No Intervention|Standard of Care|The control will be discharged with standard of care follow-up instructions and scheduled for a standard follow-up clinic visit within 2-3 weeks post-op.
9901017|NCT03813537|Experimental|Phone Call|The experimental group will receive a phone call intervention 3 days post-op. During this phone call, the patient will be asked questions using a study questionnaire based on the most frequent indications for readmission post colorectal surgery. Based on the responses, patients will be advised to maintain the scheduled appointment, visit the clinic within 48 hours, or go to the Emergency Department immediately.
9901018|NCT03812627|Experimental|Re-intervention of hip prosthesis made of ceramic or metal|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis with friction couples of: ceramic-on-ceramic or metal-on-metal~(25 patients by group)"
9901019|NCT03812627|Experimental|Re-intervention of hip prosthesis of stainless steel ball|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis of stainless steel ball."
9901020|NCT03812627|Experimental|Re-intervention of knee prosthesis|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 inpatient subjects for re-intervention of knee prosthesis polyethylene-on-metal."
9901021|NCT03812627|Experimental|Dead patients IMD holders autopsied|Autopsy: 80 dead patients IMD holders will be autopsied.
9901022|NCT03812627|Active Comparator|Dead patients non-IMD holders autopsied|Autopsy: dead patients non-IMD holders autopsied, 30 subjects in this arm.
9901023|NCT03812627|Active Comparator|patients before first prosthesis surgery|Before the initial prosthesis surgery: 30 patients Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections will be done
9901024|NCT03812588|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
9901025|NCT03812588|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
9901026|NCT03812588|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
9993160|NCT01469728|Experimental|Awake VATS|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
9901027|NCT03812588|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
9901028|NCT03809988|Experimental|Interventional Arm (Arm A)|Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
9901029|NCT03809988|Active Comparator|Control Arm (Arm B)|Patients will receive endocrine therapy (letrozole or fulvestrant).
9901030|NCT03809884|Experimental|Dietary Counselling|All enrolled patients will undergo a 1:1 counselling with a registered dietitian (with possible inclusion of family members, as appropriate). The dietitian will undertake an assessment of the comorbidities (e.g. diabetes), dietary intake, dietary habits (e.g. eating out, food preparation, socio-cultural aspects) and provide an individually tailored strategy to increase potassium in the diet. Secondly, on a weekly basis, the dietitian will contact the patient by telephone, or electronically (as preferred by the patient) to reinforce the advice and provide support/advice as necessary.
9901031|NCT03809884|Active Comparator|Potassium Citrate Supplement|Patients who are not able to successfully increase their potassium intake at 4 weeks with dietary counselling will receive potassium citrate supplements. They will receive oral potassium supplementation in the form of 50 to 100 mmol of potassium citrate (as 25 to 50 ml of the liquid solution).
9901032|NCT03809598|Experimental|Mindfulness Based Cognitive Therapy|MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
9901033|NCT03809598|No Intervention|Treatment as Usual|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
9901034|NCT03802721|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
9901035|NCT03802721|Experimental|Brussels sprouts before 50 ng dose|Subjects will consume 50 g (about 1/2 cup) of lightly steamed Brussels sprouts each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
9901036|NCT03802721|Experimental|DIM supplement before 50 ng dose|Subjects will consume 300 mg DIM supplement ( 2 capsules of BioResponse DIM® 150) each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP). A 300 mg DIM dose will be co-administrated with the 50 ng BaP dose
9901037|NCT03800537|Experimental|All Participants|All participants will receive the investigational MR Fingerprinting sequence.
9901038|NCT03798223|Experimental|180/low|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
9901039|NCT03798223|Experimental|180/high|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
9901040|NCT03798223|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
9901041|NCT03798223|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
9901042|NCT03797391|Experimental|Dose Escalation-Part 1, Expansion-Part 2|"In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks)."
9901043|NCT03786367||CTEPH|Clinically stable patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) recruited from the Pulmonary Hypertension outpatient clinics at Hotel Dieu Hospital, Kingston, Ontario.
9901044|NCT03786367||Control|Age and sex-matched healthy control data collected as part of previous studies will be used as historic controls for this study.
9901045|NCT03784911||During Cancer Treatment Group|Participants' body composition will be estimated using a SOZO device at 5 different time points across their cancer treatment. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, cancer distress assessment, ECOG performance status, hand grip strength test, and 24-hour food recall. DEXA scans will be performed before treatment and after completion of treatment.
9901046|NCT03783442|Experimental|Tislelizumab + chemotherapy|Tislelizumab administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
9901047|NCT03783442|Active Comparator|Placebo + chemotherapy|Placebo administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
9901048|NCT03781583|Experimental|HMD|"We have several versions (listed below) of a headworn smartHMD. Each can provide verbal and/or tactile feedback to the user. Feedback is controlled by either the experimenter or by computer vision algorithms.~1. The ODG Smartglasses is commercially available. This system uses computer vision to guide a user to the destination using audio and/ or vibration feedback.~2) Tactile stimulator array. This device uses an Arduino Micro, HC-05 Bluetooth Module, L293D Motor Driver and coin vibration motors attached to a head-worn headband or glasses frame. The motors can be controlled directly by an experimenter or by computer vision algorithms.~3) Computer Vision Navigation prototyping system consists of two components: Intel RealSense camera and Alienware M15 laptop.~All participants will receive the same 3 interventions: no HMD used, HMD worn but not active, and HMD worn and active. Participants may be tested with any or all of the systems described above."
9901049|NCT03773107|Experimental|Phase I|Cohort 1) 5mg ruxolitinib, Cohort 2) 10mg ruxolitinib, Cohort 3) 15mg ruxolitinib
9901050|NCT03773107|Other|Phase II|Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen
9901051|NCT03772925|Experimental|Treatment (belinostat, pevonedistat)|Patients receive belinostat IV QD over 30 minutes on days 1-5 and pevonedistat IV QD over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9901052|NCT03768960|Experimental|Daratumumab|Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.
9901053|NCT03767595|Experimental|ProACT Adjustable Continence Therapy for Men|Patients implanted with ProACT Adjustable Continence Therapy for Men
9901054|NCT03767517|Experimental|Active Intervention|Usual Care + Tele-consult Intervention
9901055|NCT03767517|Active Comparator|Usual Care|Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
9901056|NCT03765918|Experimental|Pembro Neoadjuvant+Pembro SOC Adjuvant|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles as a neoadjuvant prior to surgery. Following surgical resection, high risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 every 3 weeks (Q3W) for fifteen 21-day cycles plus standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 Q3W for fifteen 21-day cycles plus standard of care radiotherapy as adjuvant therapy.
9901057|NCT03765918|Active Comparator|No Neoadjuvant+SOC Adjuvant|Participants receive no neoadjuvant prior to surgery. Following surgical resection, high risk participants receive standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive standard of care radiotherapy as adjuvant therapy.
9901058|NCT03764878||Normal weight|BMI 18.5-24.9 kg/m^2 low risk pregnancy
9901059|NCT03764878||Pregestational diabetes mellitus|Type 1 or Type 2 diabetes mellitus diagnosed prior to the pregnancy or in the first trimester
9901060|NCT03764878||Obese|Pre-pregnancy BMI ≥ 30.0 kg/m^2
9901061|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 1|40 ml of preservative-free 1% chloroprocaine
9901062|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 2|40 ml of preservative-free 2% chloroprocaine
9901063|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 3|40 ml of preservative-free 3% chloroprocaine
9901064|NCT03748641|Experimental|Cohort 1: Participants with mCRPC and HRR Gene Alteration|Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
9993161|NCT01469728|Active Comparator|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
9993162|NCT01469754||Lymphoma Survivors|
9901065|NCT03748641|Experimental|Cohort 2: Participants with mCRPC and No HRR Gene Alteration|Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
9901066|NCT03748641|Experimental|Cohort 3 (Open-label): Participants with mCRPC|Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
9901067|NCT03746535|Active Comparator|patients without endometriosis|Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
9901068|NCT03746535|Experimental|patients with endometriosis|Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
9901069|NCT03744728|Active Comparator|Accelerate Pheno|Fast ID and AST of positive blood culture bottles using the Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System
9901070|NCT03744728|Active Comparator|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
9901071|NCT03742895|Experimental|Olaparib|Participants with HRRm or HRD-positive advanced cancer will receive oral olaparib, 300 mg twice daily (BID).
9901072|NCT03741127|Other|P-BCMA-101 treated|Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
9901073|NCT03737253|Active Comparator|Follitropin alpha|Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
9901074|NCT03737253|Active Comparator|Menotropin|Menotropin (Menopur, Ferring GmbH, Kiel, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
9901075|NCT03725202|Experimental|Arm A|Upadacitinib dose A administered daily + 26-week CS taper regimen
9901076|NCT03725202|Experimental|Arm B|Upadacitinib dose B administered daily + 26-week CS taper regimen
9901077|NCT03725202|Placebo Comparator|Arm C|Placebo administered daily + 52-week CS taper regimen
9901078|NCT03725059|Experimental|Pembrolizumab+Chemotherapy (KX/KA[E]C)|In the neoadjuvant setting, participants receive pembrolizumab (K) 200 mg via intravenous (IV) infusion once every 3 weeks (Q3W) + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by pembrolizumab 200 mg via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive pembrolizumab 200 mg via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
9998325|NCT01517217|Other|No girdle postoperative|patients undergoing major abdominal surgery will get NO individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
9901079|NCT03725059|Placebo Comparator|Placebo+Chemotherapy (PX/PA[E]C)|In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
9901080|NCT03724994||Study cohort|All patients with periampullary adenocarcinoma or pancreatic cancer receiving palliative or adjuvant chemotherapy (e.g. Gemcitabine, Folfirinox, etc.) in the Department of Oncology, Skåne University hospital, Malmö and Lund
9901081|NCT03711032|Experimental|BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)|Participants receive BCG (Induction and Maintenance) in combination with 200 mg pembrolizumab administered intravenously (IV) every 3 weeks (Q3W) for 35 doses (~2 years).
9901082|NCT03711032|Experimental|BCG Monotherapy: Post-induction Cohort A (Arm A-2)|Participants receive BCG monotherapy (Induction and Maintenance).
9901083|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)|Participants receive BCG (Induction and reduced Maintenance) in combination with 400 mg pembrolizumab administered IV every 6 weeks (Q6W) for 9 doses (~1 year).
9901084|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)|Participants receive BCG (Induction and full Maintenance) in combination with 400 mg pembrolizumab administered IV Q6W for 9 doses (~1 year).
9901085|NCT03711032|Experimental|BCG Monotherapy: BCG Naïve Cohort B (Arm B-3)|Participants receive BCG monotherapy (Induction and Maintenance).
9901086|NCT03709758|Experimental|Venetoclax+Daunorubicin+Cytarabine|"Venetoclax administered orally on days 1 to 11 daily~Daunorubicin administered intravenously on days 2-4~Cytarabine administered on days 2-8 by continuous IV infusion"
9901087|NCT03709667|Experimental|EX|Participants in this arm of the study will be randomized in to the exercise intervention.
9901088|NCT03709667|Placebo Comparator|CON|The control condition is a health-education intervention.
9901089|NCT03706989|Experimental|EEG for cardiac surgery patients|Patients who undergo elective cardiac surgery with cardiopulmonary bypass, from 18 to >75 years old.
9901090|NCT03705169|Experimental|Arm A, Cohort 1A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0.
9901091|NCT03705169|Experimental|Arm A, Cohort 1B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
9901092|NCT03705169|Experimental|Arm A, Cohort 2A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
9901093|NCT03705169|Experimental|Arm A, Cohort 2B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
9901094|NCT03705169|Experimental|Arm A, Cohort 3A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
9901095|NCT03705169|Experimental|Arm A, Cohort 3B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
9901096|NCT03705169|Experimental|Arm A, Cohort 4A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
9901097|NCT03705169|Experimental|Arm A, Cohort 4B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
9901098|NCT03705169|Experimental|Arm B, Cohort 5: SAR441236|Participants will receive 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
9901099|NCT03705169|Experimental|Arm B, Cohort 6: SAR441236|Participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
9901100|NCT03705169|Experimental|Arm B, Cohort 7: SAR441236|Participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
9901101|NCT03705169|Experimental|Arm B, Cohort 8: SAR441236|Participants will receive 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
9901102|NCT03705169|Experimental|Arm B, Cohort 9: SAR441236|Participants will receive 0.3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
9901103|NCT03705169|Experimental|Arm C, Cohort 10A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 0.3 mg/kg of SAR441236, administered as a single subcutaneous (SC) injection on Day 0.
9901104|NCT03705169|Experimental|Arm C, Cohort 10B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection on Day 0.
9901105|NCT03705169|Experimental|Arm C, Cohort 11A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
9901106|NCT03705169|Experimental|Arm C, Cohort 11B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
9901107|NCT03699163||Endoscopy patients|Patients who are attending hospital for a colonoscopy as part of their routine clinical care, or as part of the Bowel Cancer Screening Programme, will be asked to give a sample of their breath prior to the procedure.
9901108|NCT03699163||Colorectal cancer patients|Patients who have known pre-diagnosed colorectal cancer (adenocarcinoma) attending hospital as part of their clinical care will be asked to give a breath sample prior to their cancer operation.
9901109|NCT03697304|Experimental|Cohort 1 - Module A|
9901110|NCT03697304|Experimental|Cohort 2 - Module A|
9901111|NCT03697304|Experimental|Cohort 3 - Module A|
9901112|NCT03697304|Experimental|Cohort 1 - Module C|
9901113|NCT03697304|Experimental|Cohort 2 - Module C|
9901114|NCT03697304|Experimental|Cohort 3 - Module C|
9901115|NCT03697304|Experimental|Cohort 4 - Module C|
9901116|NCT03697304|Experimental|Cohort 5 - Module C|
9901117|NCT03696992|Experimental|NBI|Tandem colonoscopy with NBI follow by WL
9901118|NCT03696992|Active Comparator|BLI|Tandem colonoscopy with BLI follow by WLI
9901119|NCT03696992|Experimental|WLI|Tandem colonoscopy with WLI follow by WL
9901120|NCT03695510|Experimental|Study arm|afatinib + pembrolizumab
9901121|NCT03690674|Experimental|Lifestyle Enhancement for ADHD Program|There is no comparison/control arm.
9901122|NCT03690401||Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed before treatment and after completion of treatment. Moving On assessments will be performed at first and last study visits.
9901123|NCT03690401||Non-Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed at first and last study visits.
9901124|NCT03689140|Experimental|App-only|The intervention will consist of participants will only use a smoking cessation app
9901125|NCT03689140|Experimental|Telemedicine counseling only|The intervention will consist of participants will only use telemedicine counseling
9901126|NCT03689140|Experimental|App + telemedicine counseling|The intervention will consist of participants will only use a smoking cessation app + telemedicine counseling
9901127|NCT03689140|No Intervention|Usual Care|The participants will continue with usual care
9901128|NCT03688126|Experimental|Self-Guided Lifestyle Intervention|Lifestyle modification program that is developed by the participant to meet his/her specific needs.
9901129|NCT03688126|Experimental|Structured Lifestyle Intervention|Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.
9901130|NCT03686202|Experimental|Group A: Safety Cohort|Subjects with advanced solid tumors already on ICI will receive treatment with MET-4 in addition to SOC ICI. MET-4 is administered orally as an initial daily loading dose (5g) of MET-4 over 2 days followed by a daily maintenance dose (1.5g) of MET-4 and will be continued until unacceptable toxicity, progression of disease
9901131|NCT03686202|Experimental|Group B|Eligible subjects with advanced solid tumors starting ICI will be randomised in a 3:1 ratio stratifying for prior IO exposure, to receive MET-4 together with any approved PD-1/PD-L1 inhibitor as per SOC or control group. There will be a run-in period for subjects in the MET-4 treatment group. Following the run-in period of ICI therapy, subjects will be administered the same MET-4 dose as subjects in group A.
9901132|NCT03686202|Experimental|Group C|In group C, eligible subjects with advanced solid tumors whom are already on ICI with first unconfirmed PD on evaluation scans per investigator's assessment, will be randomised in a 1:1 ratio to receive MET-4 in addition to the PD-1/PD-L1 inhibitor as per SOC or control group. These subjects must be clinically stable and are to be continued on ICI at the discretion of the investigator. There will be no run-in period for this cohort. Subjects will be administered the same MET-4 dose as subjects in groups A and B.
9901133|NCT03682406|Experimental|CAMS-G|CAMS-G is an group-based adaptation of the Collaborative Assessment and Management of Suicidality (CAMS) that has been developed to address perceived burdensomeness and thwarted belongingness, two drivers of suicide risk. Ongoing assessment and treatment planning are completed using the CAMS Suicide Status Form in the group modality, with involvement from group members and group facilitators. Driver-focused intervention strategies and group process also occur in the group based upon the unique needs of the group members. Groups are 90-minutes in length and occur on a weekly basis.
9998326|NCT01517217|Other|Girdle postoperative|patients undergoing major abdominal surgery will get an individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
9901134|NCT03682406|Other|Care as Usual|Care as usual includes access to all existing forms of treatment that currently exist at the Robley Rex VAMC and affiliated CBOCs, such as individual and group psychotherapy, suicide prevention programming and case management, psychiatric care, social work services, and substance use disorder counseling. We will essentially track the control condition over time as they engage in the typical services provided to suicidal Veterans through the Robley Rex VAMC. The CAMS-G study participants will have access to the same services delivered as part of care as usual, with the only difference being their participation in the CAMS-G treatment for suicidality.
9901135|NCT03673527|Experimental|topical formulation of tacrolimus|
9901136|NCT03664687|Active Comparator|Zoledronate one dose (4 mg)|One 4 mg dose of Zoledronate
9901137|NCT03664687|Active Comparator|Zoledronate 4 mg every 6 months x 3 years|One 4 mg dose of Zoledronate given every 6 months for 3 years
9901138|NCT03663504|Active Comparator|No Preparation|No preparation before surgery
9901139|NCT03663504|Active Comparator|Oral Antibiotics|Oral antibiotics (neomycin and flagyl), to be taken the day before the surgery
9901140|NCT03658772|Experimental|Cohort 1|Single Agent run-in with grapiprant and then combination treatment of grapiprant and pembrolizumab.
9901141|NCT03658772|Experimental|Cohort 2|Participants will be treated with grapiprant in combination with pembrolizumab.
9901142|NCT03655691|Placebo Comparator|Vehicle|Vehicle / Placebo formulation
9901143|NCT03655691|Experimental|Dose 1|lower dose of ET-01
9901144|NCT03655691|Experimental|Dose 2|higher dose of ET-01
9901145|NCT03654248|Experimental|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
9901146|NCT03654248|Active Comparator|Individual Occupational Therapy|Individual intervention lasting 10 weeks
9933358|NCT05351944|Experimental|The intervention group (group A) DBT skills|"Will attend Dialectical Behavioral Therapy skills group for both the children and their parents, DBT is an evidence based comprehensive cognitive behavioral treatment for complex mental disorders and have been adapted for intractable behavioral disorders involving emotion dysregulation, skills will be provided in group therapy as fixed weekly sessions over 9-month duration for all the children and the parents in group A including:~Emotion regulation skills module over 8 weeks.~Mindfulness skills module over 3 weeks to be repeated 3 times over the whole course of therapy i.e., 9 weeks.~Interpersonal effectiveness skills module over 7 weeks.~Distress tolerance skills module over 8 weeks.~Walking the middle path skills module over 3 weeks."
9933359|NCT05351944|Active Comparator|the control group (group B)|Will receive psychoeducation and medications targeting ADHD symptoms (stimulants or atomoxetine according to FDA approved dose per age and weight) according to the international guidelines for management of ADHD according to symptom severity, given that assessment before and after intervention will be done by different medical personnel than those providing the intervention for the two groups.
9933360|NCT05351931|Active Comparator|SPC-flakes with or without Salovum|SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
9933361|NCT05351931|Placebo Comparator|SPC-flakes placebo with or without Salovum placebo|SPC-placebo flat dose of 75 g/d divided in 2 - 4 doses started 5 days prior to start of RCT and continued during the RCT. Salovum placebo egg powder 4 g/sachet. Four sachets, ie 16 g q 8 h for 5 days prior to start of RCT. The appropriate amount of Salovum placebo is mixed with 100 - 200 ml of suitable liquid, eg fruit juice, and ingested orally.
9933362|NCT05351918||migrain days|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
9933363|NCT05351918||consumption of analgesics|"Two methods of acupuncture stimulation will be compared. In all patients, DU 20 point and the same distal points will be used.~In the control group, all patients will receive the same local points, commonly used to treat migraine in our department.~In the study group, local points will be selected according to the site of the headache."
9933364|NCT05351905|Experimental|CBD oil|Participants will receive CBD (cannabidiol) oil for a total duration of 12 weeks.
9933365|NCT05351905|Experimental|CBD+THC oil|Participants will receive CBD (cannabidiol) oil in combination with THC (delta-9-tetrahydrocannabinol) for a total duration of 12 weeks.
9933366|NCT05351905|Placebo Comparator|Placebo oil|Participants will receive matching placebo oil for a total duration of 12 weeks.
9933367|NCT05351892|Experimental|Treatment A-B|Participants will receive a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
9933368|NCT05351892|Experimental|Treatment B-A|Participants will receive a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
9998327|NCT01517230|Active Comparator|intervention|seven clusters where radio media campaign will be broadcast.
9998328|NCT01517230|No Intervention|control|Seven clusters where radio media campaign won't be broadcast.
9998329|NCT01517256|Experimental|Early Intervention Group|
9901147|NCT03652064|Active Comparator|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
9901148|NCT03652064|Experimental|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
9901149|NCT03649971|Experimental|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
9901150|NCT03649971|Experimental|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
9901151|NCT03649971|Placebo Comparator|Placebo|Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
9901152|NCT03648541|Experimental|All Patients|1 arm solution for injection Spesolimab will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also
9901153|NCT03645694|Experimental|SSA|Individuals with memory concerns in the experimental arm received the prototype facial recognition technology, which included a smartphone and smartwatch. The smartphone was equipped with facial recognition software application; the smartwatch communicated information with the smartphone. Persons with memory concerns and their family care partners were given a demonstration on how to utilize the technology.
9901154|NCT03645694|No Intervention|Control|Control participants did not receive the technology; at the conclusion of follow-up, all controls were offered the technology to use.
9901155|NCT03643224|Experimental|Experimental|Radiofrequency Ablation. Catheter ablation to treat persistent atrial fibrillation using temperature-controlled ablation catheter
10212728|NCT05087563|Experimental|Neurolens|Our proprietary contoured prism lens design, commercially known as neurolens.
9901157|NCT03640481|Experimental|Arm A: belumosudil 200 mg QD|Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
9901158|NCT03640481|Experimental|Arm B: belumosudil 200 mg BID|Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
9901159|NCT03638791||Healthy controls|Matched Controls without treatment
9901160|NCT03638791||OCD|Exposure and response inhibition
9901161|NCT03636607|Experimental|Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
9901162|NCT03636607|Experimental|Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
9901163|NCT03633058|Experimental|0.75 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
9901164|NCT03633058|Experimental|1.5 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
9901165|NCT03631667|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
9901166|NCT03631667|Experimental|50 ng dose plus 1250 ng phenanthrene|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene
9901167|NCT03630913|Experimental|Tagged axillary metastatic node|"Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.~The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC."
9901168|NCT03617874|Active Comparator|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
9901169|NCT03617874|Placebo Comparator|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
9901170|NCT03615690|Experimental|Fasting Mimicking Diet|Three cycles of a 5-day reduced calorie diet
9901171|NCT03615690|Placebo Comparator|Regular Diet Control Arm|
9901172|NCT03613181|Experimental|ANG1005|ANG1005 Investigational Drug
9901173|NCT03613181|Active Comparator|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
9901174|NCT03608670|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
10212729|NCT05087563|Placebo Comparator|Control lens|A simple refractive error correction lens
10212730|NCT05085938||Gonadal veins embolisation|This group includes patients who have undergone coil embolization of gonadal vein
10212731|NCT05085873|Experimental|Sodium oxybate|
10212732|NCT05085873|Active Comparator|Midazolam|
10212733|NCT05084716|Experimental|Intervention|At the intervention site during healthcare facility outreach events, PrEP initiators will be offered guidance on selecting an adherence supporter during PrEP initiation. All outreach event attendees at the events will be offered the opportunity to attend the intervention workshops. Check-in reminder calls will be conducted systematically with PrEP users.
10212734|NCT05084716|No Intervention|Control|At the control site, healthcare facility staff will continue to provide PrEP according to the standard of care.
9993163|NCT01469793|Experimental|DMOT4039A Q3W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with 0.2 milligrams per kilogram (mg/kg), as intravenous infusion every 3 weeks (Q3W) to determine the maximum tolerated dose (MTD) of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
9993164|NCT01469793|Experimental|DMOT4039A Q3W: Dose Expansion|Participants will receive DMOT4039A at recommended phase 2 dose (RP2D) for Q3W dosing schedule as intravenous infusion Q3W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
9993165|NCT01469793|Experimental|DMOT4039A Q1W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with a dose 33% of MTD for Q3W dosing schedule, as intravenous infusion every week (Q1W) to determine the MTD of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
9993166|NCT01469793|Experimental|DMOT4039A Q1W: Dose Expansion|Participants will receive DMOT4039A at RP2D for Q1W dosing schedule as intravenous infusion Q1W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
9993167|NCT01469806||1 - PFJ|Patients who require primary partial knee arthroplasty of the patello-femoral joint.
9993168|NCT01469845|Active Comparator|hypertonic saline and usual care|
9993169|NCT01469845|Active Comparator|usual care (oxygen therapy)|
9993170|NCT01469858|Experimental|study group|fMRI
9993171|NCT01469871|Active Comparator|Hypafix Transparent dressing|The Hypafix Transparent dressing, a stretchable dressing, will be used to treat the patients in this group
9993172|NCT01469871|Active Comparator|Mepore Pro dressing|The Mepore Pro dressing, a self-adhesive perforated dressing, will be used to treat the patients in this group
9993173|NCT01469871|Active Comparator|Mepilex Border dressing|The Mepilex Border dressing, a self-adherent soft silicone dressing, will be used to treat the patients in this group
9997809|NCT01512199|Experimental|U3-1287 with trastuzumab + paclitaxel (Phase 1b)|The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
9997810|NCT01512199|Experimental|U3-1287 with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
9997811|NCT01512199|Placebo Comparator|Placebo with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 dose in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
9997812|NCT01512212|No Intervention|single group|FNAB will be perform first with standart technique and after with new FNAB apparatus
9997813|NCT01512238||Pharmaceutical care|
9997814|NCT01512238||Control|
9997815|NCT01512277|Experimental|3 administrations of 100 µg of rSh28GST|Adult volunteers (n=8) receive 100μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0, D28, and D150.
9997816|NCT01512277|Experimental|2 administrations of 300 µg of rSh28GST|Adult volunteers (n=8) receive 300μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0 and D28.
9997817|NCT01512277|Placebo Comparator|Placebo|Adult volunteers (n=8) receive aluminium hydroxide (Alum) alone at D0 and D28.
9997818|NCT01512290|Active Comparator|Theta burst treatment|patients randomized to this arm will receive 10 TBS treatments distributed over 5 days
9997819|NCT01512290|Placebo Comparator|sham treatment|
9997820|NCT01512303|Experimental|Sudarshan Kriya Yoga: SKY|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment. All are soothing and present-focused. Participants will be encouraged to learn all the breathing exercises, and to utilize the exercises the ones that seems most appropriate for their needs. 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3 hours/session).
9997821|NCT01512303|Experimental|Mindfulness-Based Stress Reduction: MBSR|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts, allowing the practitioner to calm his or her mind and come back to the present moment. The typical MBSR format will be adapted to match the SKY intervention. This intervention will include an 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3hrs/session).
9997822|NCT01512303|No Intervention|Wait-List Control: WLC|Participants will undergo no intervention. These participants will have the option of receiving one of the two interventions at the conclusion of the study.
9997823|NCT01512303|No Intervention|Non-PTSD control|Baseline measures only will be collected from a group of 50 combat-exposed veterans without PTSD to assess group differences on these measures prior to treatment.
9997824|NCT01512316|Active Comparator|d-Cycloserine Acquisition|d-Cycloserine will be given on day1, before acquisition
9997825|NCT01512316|Active Comparator|d-Cycloserine Extinction|d-Cycloserine will be administered on day2, before extinction
9997826|NCT01512316|Placebo Comparator|Placebo|A placebo pill will be administered on day1 and 2
9998330|NCT01517256|Placebo Comparator|Delayed Intervention Group|Initially wait-listed and served as control group. But later participants underwent the experimental intervention.
9901175|NCT03604445|Experimental|BI 905677|Schedule A: 3 week cycle (treatment every 3 weeks). Schedule B: 4 week cycle (treatment every 2 weeks). Recruitment into Schedule B will start after the MTD of Schedule A is reached.
9901176|NCT03599752|Experimental|Group 1A (chemotherapy, metastasectomy)|Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
9901177|NCT03599752|Experimental|Group 1B (metastasectomy)|Low risk patients undergo metastasectomy.
9901178|NCT03599752|Experimental|Group 2A (metastasectomy)|High risk patients undergo metastasectomy.
9901179|NCT03599752|Experimental|Group 2B (chemotherapy)|High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
9901180|NCT03595995|Experimental|Cohort 1|"Placebo (volume equivalent to 2.5 mg/kg UB-621)~2.5 mg/kg UB-621"
9901181|NCT03595995|Experimental|Cohort 2|"Placebo (volume equivalent to 5 mg/kg UB-621)~5 mg/kg UB-621"
9901182|NCT03595293|Experimental|Experimental Group for AUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When patients encounter the alcohol image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
9901183|NCT03595293|Sham Comparator|Sham Feedback Group for AUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When participants encounter the alcohol image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
9901184|NCT03595293|Experimental|Experimental Group for pOUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When patients encounter the pill image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
9901185|NCT03595293|Sham Comparator|Sham Feedback Group for pOUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When participants encounter the pill image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
9901186|NCT03593772|Active Comparator|Treatment arm|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
9933369|NCT05351879|Experimental|GAD-Alum (DIamyd) 40 μg/mL and Vitamin D|"Patients with a Vitamin D level <100 nmol/L (40 ng/mL) at screening will receive oral Vitamin D supplementation (2000 IU daily) for 60 days, starting 30 days prior to the injection.~On Visit 2 (Day 0), patients eligible for the study will receive one intralymphatic injection of 4µg Diamyd."
9933370|NCT05351866|Experimental|SparkRx|
9993174|NCT01469884|Experimental|Certican®|Arm1(conversion):Certican®+mycophenolate+prednisone
9993175|NCT01469884|Active Comparator|Tacrolimus or Cyclosporine|Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
9993176|NCT01469910|Experimental|Simotinib|
9993177|NCT01469910|Placebo Comparator|Placebo|
9993178|NCT01469923|Active Comparator|AZD2820|AZD2820 multiple injections
9993179|NCT01469923|Placebo Comparator|Placebo for AZD2820|Placebo for AZD2820 multiple injections
9993180|NCT01469936|Experimental|PERMEAPROTECT|
9993181|NCT01469936|Placebo Comparator|PLACEBO|
9993182|NCT01469949||Kinesthetic Imagery group|Subjects receiving Kinesthetic Imagery
9993183|NCT01469949||Visual Imagery Group|Subjects receiving visual imagery
9993184|NCT01469949||Control group|Subjects receiving measurement with intervention
9993185|NCT01469962||obese patients|
9993186|NCT01469975|Experimental|Arm A: Dose level 1|1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y
9993187|NCT01469975|Experimental|Arm B: Dose level 2|1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y
9993188|NCT01469975|Experimental|Arm C: Dose level 3|3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y
9993189|NCT01469988|Experimental|Testosterone|
9993190|NCT01469988|Placebo Comparator|Placebo|
9993191|NCT01470014||IVNC|
9993192|NCT01470014||differential diagnosis to IVNC|
9993193|NCT01470040|Experimental|discontinuation of aspirin therapy|
9993194|NCT01470040|Sham Comparator|continuation of aspirin therapy|patients will continue their pre-injury dose of low-dose aspirin therapy per previous medical indication
9993195|NCT01470053|Experimental|mometasone furoate + azelastin HCl|opaque suspension, four times each naris per day
9993196|NCT01470053|Active Comparator|mometasone furoate|opaque suspension, four times each naris per day
9993197|NCT01470053|Active Comparator|azelastine HCl|lucidus colorless liquid, two times each naris per day
9993198|NCT01470092|Active Comparator|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
9993199|NCT01470092|No Intervention|Placebo|Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
9993200|NCT01470157|Experimental|Ketamine|Oral Ketamine in addition to oral midazolam
9993201|NCT01470157|Placebo Comparator|Placebo|Normal saline (placebo) in addition to oral midazolam
9993202|NCT01470183||Lupus Nephritis Patients|"Male or female subjects age 18 and older~Must have confirmed diagnosis of Class III or Class IV lupus nephritis by biopsy~Must have stable disease on medication at time of enrollment"
9993203|NCT01470183||Control Patients|Any patient with an idiopathic glomerular disease who does not have lupus nephritis. This includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy.
9993204|NCT01470209|Experimental|Combination of BKM120 and everolimus|
9993205|NCT01470222|Experimental|Intervention Group|"Monthly, all-worksite activities will be implemented to raise awareness of healthy nutrition for weight control throughout the worksite. The purpose of the all-worksite activities is: a) to create a supportive worksite-wide atmosphere for the individuals enrolling in the weight loss support group, and b) to provide low-level weight loss support for individuals who wish to prevent weight gain.~Individuals with eligible weight (defined as BMI ≥ 25 kg/m2) without medical contradictions to weight loss, who wish to join a support group to lose weight, may enroll in the worksite weight control support group that will meet weekly for the first 10 weeks and then monthly until the end of the 6-month intervention"
9993206|NCT01470222|Experimental|Control Group (delayed intervention)|At the end of the study period, subjects will receive a 2-month structured intervention that will provide all of the resources and materials given to the intervention worksite as well as weight control support groups for employees interested in losing weight.
9993207|NCT01470235||Ovarian Cancer|"Women treated for ovarian cancer at the departments of obstetrics and gynecology, Aarhus University Hospital and Rigshospitalet, Copenhagen.~Expected recruitment: 200"
9993208|NCT01470235||Control patients|"Women referred to the departments of obstetrics and gynecology in Aarhus University Hospital and Rigshospitalet, Copenhagen on benign indication.~Expected recruitment: 200."
9993209|NCT01470235||HBOC/HNPCC|"Patients registered in the large Danish Register of HBOC( hereditary breast and ovarian cancer) and HNPCC (hereditary nonpolyposis colorectal cancer).~Expected recruitment: 200."
9993210|NCT01470261||ADHD medicated|Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.
9993211|NCT01470261||ADHD unmedicated controls|Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate
9993212|NCT01470261||Non-ADHD controls|Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.
9993213|NCT01470287|Experimental|Arm 1|
9993214|NCT01470300|Experimental|Standard ED|100% energy density
10212735|NCT05081869|Experimental|Online Yoga Based Exercise Program|A 50-minute online exercise program consisting of 5 categories will be created. The program will last 8 weeks, twice a week. In the first category, 20-30 seconds of stretching was applied to iliopsoas, hamstring, adductor, tensor fascia lata, piriformis, quadratus lumborum, quadriceps femoris and gastrocnemius muscles. In the second category, stabilization and pelvic mobilization exercises will be applied to the core muscles. Each exercise will be performed in 3 sets of 10 repetitions. In the third category, strengthening exercises will be done for the gluteal muscles, abdominal muscles, erector spine, quadriceps femoris and latissimus dorsi. Each exercise will be performed as 10 repetitions and 3 sets. In the fourth category, 3 sets and 10 repetitions of kegel exercises will be done. minute diaphragmatic breathing will be applied.
9901187|NCT03593772|Placebo Comparator|Control arm|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
9901188|NCT03593655|Experimental|Sequence A: Dapivirine vaginal ring + FTC/TDF|Participants will receive one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
9901189|NCT03593655|Experimental|Sequence B: FTC/TDF + Dapivirine vaginal ring|Participants will receive one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
9901190|NCT03593395|Active Comparator|Arm 1-A|Small sized Program Structured Education Based Transition Program [STE]
9901191|NCT03593395|Experimental|Arm 1-B|Small sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
9901192|NCT03593395|Active Comparator|Arm 2-A|Large sized program Structured Education Based Transition Program [STE]
9901193|NCT03593395|Experimental|2-B|Large sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
9901194|NCT03587805|Experimental|Tralokinumab, all subjects|"Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~From Week 2 up to Week 266*: SC injection of tralokinumab maintenance dose.~*The length of treatment for each subject will depend on when they enter the trial, and on which parent trial and country they come from."
9901195|NCT03584165|Experimental|BIIB111|Participants previously treated with sub-retinal injection of BIIB111 in antecedent studies 273CH301 (NCT03496012) and 273CH203 (NCT03507686) will be enrolled. Participants previously treated with this same sub-retinal injection (rAAV2-REP1) in antecedent studies 20150371 (NCT02553135), Pro00028599 (NCT02077361), THOR-TUE-01 (NCT02671539), CHM09/01 (NCT01461213) and REGEN2015 (NCT02407678) will also be invited for enrollment. This is a follow-up study, investigational product was administered in the previous study.
9901196|NCT03584165|Experimental|BIIB112|Participants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled. This is a follow-up study, investigational product was administered in the previous study.
9901197|NCT03584165|No Intervention|Untreated|Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery.
9901198|NCT03577418|Experimental|Clinician-facilitated educational intervention|
9901199|NCT03577418|Active Comparator|Enhanced usual care|
9901200|NCT03573310|Experimental|Part 1: Dose escalation and RP2D Selection|Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
9901201|NCT03573310|Experimental|Part 2:Dose Confirmation and Expansion|Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
9901202|NCT03571958|No Intervention|Traditional OHI (Control)|"Advice giving method of OHI known as tell-show-do to inform, demonstrate, and expect patient compliance."
9901203|NCT03571958|Experimental|BMI (Test)|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
9901204|NCT03565939|Active Comparator|Trichuris suis ova (TSO)|7500 TSO suspension, orally every second week for 24 weeks.
9901205|NCT03565939|Placebo Comparator|Placebo|Solution without TSO orally every second week for 24 weeks
9901206|NCT03562871|Experimental|Cohort A1|Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle
10213926|NCT02630368|Experimental|Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 2.~Control-arm phase II soft-tissue sarcoma :~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.~Number of subjects : 24"
9901207|NCT03562871|Active Comparator|Cohort A2|Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle
9933371|NCT05351866|Active Comparator|Psychoeducational Control|
9933372|NCT05351853|Other|Control Group|20 healthy individual will be in the control group. Participants of control group will not change their diet and will continue omnivore diet.
9901208|NCT03562871|Experimental|Cohort B1|Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
9901209|NCT03562871|Active Comparator|Cohort B2|Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
9901210|NCT03556475||Disease 1|Moderate to severe COPD Patients(n=90)
9901211|NCT03556475||Disease type 2-1)|Patients with Mild/moderate AECOPD (n=60)
9901212|NCT03556475||Disease type 2-2)|Patients with Severe AECOPD( n=60)
9901213|NCT03556475||Disease type 3|Non-COPD Patients with high risk factors (n=90)
9901214|NCT03555851||Recipient|Cyclophosphamide
9901215|NCT03555851||Donor|Specimen collection
9901216|NCT03549871|Experimental|Fitusiran|Fitusiran sub-cutaneous injection for 7 months
9901217|NCT03548207|Experimental|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
9901218|NCT03547882||Other|Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
9901219|NCT03547882||Patients|Ten interviews were conducted with VA patients receiving ORT.
9901220|NCT03545763||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
9901221|NCT03545763||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
9901222|NCT03545282|Experimental|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
9901223|NCT03545282|Other|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
9901224|NCT03544138|Other|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
9901225|NCT03539848|Experimental|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
9901226|NCT03539848|Active Comparator|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
9901227|NCT03539744|Experimental|Arm 1 VenDex|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
9901228|NCT03539744|Active Comparator|Arm 2 PomDex|Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
9901229|NCT03536884|Experimental|Bimekizumab dosage regimen 1|Subjects randomized to this arm will receive bimekizumab dosage regimen 1. At Week 16 subjects will be re-randomized and continue to receive bimekizumab regimen 1 or to switch to bimekizumab regimen 2. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
9901230|NCT03536884|Experimental|Bimekizumab dosage regimen 2|Subjects randomized to this arm will receive bimekizumab dosage regimen 2 starting at Week 16 after initial treatment on bimekizumab regimen 1 for 16 weeks. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
9901231|NCT03536884|Active Comparator|Secukinumab|Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
9901232|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the open label initial phase.
9901233|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the open label initial phase.
9901234|NCT03528681|Placebo Comparator|Matching Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase.
9901235|NCT03521102|Experimental|Acetaminophen 1000mg IV|NRS pain scores will be obtained at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.
9901236|NCT03521102|Active Comparator|Hydromorphone 0.5mg IV|NRS score will be checked at 5 minutes and every 15 minutes for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.
9901237|NCT03512392|Experimental|Conservative fluid and deresuscitation|"Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)~Daily assessment of eligibility for deresuscitation for 3 days (eligible if oedema in more than 1 site and cumulative fluid balance > 2 litres)~Deresuscitation to target negative daily fluid balance of 1 to 3 litres:~5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal"
9901238|NCT03512392|Active Comparator|Usual care|Usual care at the discretion of the treating team
9901239|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).
9901240|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.
9901241|NCT03501173||NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)|Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.
9901242|NCT03501173||mCRPC (Treatment-experienced in the nmCRPC or mCSPC Setting)|Participants will be defined as having mCRPC (treatment-experienced in the nmCRPC or mCSPC setting) if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7nmol/L]), the first treatment for mCRPC clinical state was started in the past 6months or is scheduled to begin, disease progression occurred while receiving active treatment (ARAT or chemotherapy) in the prior nmCRPC or mCSPC clinical state.
9901243|NCT03497676|Experimental|Cohort 1C: CAB|"Step 1: CAB administered orally as one 30 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: CAB LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (600 mg/3 mL), and at Week 8 (600 mg/3 mL)."
9901244|NCT03497676|Experimental|Cohort 1R: RPV|"Step 1: RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: RPV LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (900 mg/3 mL), and at Week 8 (900 mg/3 mL)."
9901245|NCT03497676|Experimental|Cohort 2: CAB + RPV|"Step 3: CAB administered orally as one 30 mg tablet once daily AND RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit for 4-6 weeks.~Step 4: First injection: CAB LA administered as one 600 mg (3 mL) IM injection AND RPV LA administered as one 900 mg (3 mL) IM injection, at Week 4b (Step 4 Entry) and at Week 8. Subsequent injections: starting at Week 16, CAB LA administered as a 600 mg (3 mL) IM injection AND RPV LA administered as a 900 mg (3 mL) IM injection, every eight weeks through Week 96."
9901246|NCT03496883|Active Comparator|Recombinant Activated Factor VII (rFVIIa)|rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset
9901247|NCT03496883|Placebo Comparator|Placebo|Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset
10212736|NCT05081869|Sham Comparator|Education Program|The informative training was given to both group members individually and online. In the training program; The female reproductive system organs, the structure of the pelvis, the location and functions of the pelvic floor muscles, the definition and physiology of menstruation, the types and risk factors of dysmenorrhea, the definition and symptoms of primary dysmenorrhea, treatment methods for coping with pain in primary dysmenorrhea were mentioned.
10212737|NCT05081375|Active Comparator|Enoxaparin|Enoxaparin dose will not be held for surgical procedure.
10212738|NCT05081375|Placebo Comparator|Placebo dose given and Enoxaparin dose held|Enoxaparin dose will be held and replaced by placebo and not given prior to surgical procedure.
10212739|NCT05077605|Experimental|Functional residual capacity|Functional residual capacity measure during and after extubation
10212740|NCT05077384|Experimental|Surufatinib|Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
9901253|NCT03484923|Experimental|Arm 1: LAG525 + Spartalizumab in unselected patients|Spartalizumab and LAG525 will be administered intravenously
9901254|NCT03484923|Experimental|Arm 2: Capmatinib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Capmatinib will be administered orally.
9901255|NCT03484923|Experimental|Arm 3: Canakinumab+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Canakinumab will be administered subcutaneously.
9901256|NCT03484923|Experimental|Arm 4: Ribociclib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Ribociclib will be administered orally.
9993215|NCT01470300|Experimental|Reduced ED - F/V|80% energy density by adding fruit and vegetables
10212741|NCT05076656|Experimental|Probiotics arm|Individuals who receive a probiotics pill daily: Lactobacillus fermentum D3 (PCT/EP 2012058214)
10212742|NCT05076656|Experimental|FMT arm|Individuals who receive a FMT in the form of pills with fecal material from a healthy donor.
10212743|NCT05076656|Placebo Comparator|Control arm|Individuals who receive a probiotics pill daily of placebo (milk powder)
10212744|NCT05074641|Experimental|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
10212745|NCT05074641|Active Comparator|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
10212746|NCT05074394|Experimental|COVI-DROPS|40 mg of COVI-DROPS administered intranasally
10212747|NCT05074394|Placebo Comparator|Placebo|2 mL placebo administered intranasally
10212748|NCT05063305|Experimental|Male Probiotic|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
10212749|NCT05063305|Placebo Comparator|Male Placebo|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
9798175|NCT01620138|Active Comparator|Pasireotide|"For non-cured patients with prolactinomas resistant to cabergoline, MRI will be performed immediately before and six months after the onset of pasireotide treatment. The anti-secretory effect will be evaluated by prolactin dosage every month.~For patients harboring a NFPA, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. In this case, the drug efficacy will be evaluated clinically by visual field and by MRI six months after pasireotide treatment."
9993216|NCT01470300|Experimental|Reduced ED - Fat|80% energy density by decreasing fat
9993217|NCT01470300|Experimental|Reduced ED - Plain water|80% energy density by adding plain water
9798176|NCT01620138|Active Comparator|cabergoline|In patients with non-functioning pituitary adenoma, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. The drug response will be evaluated clinically by visual field and by Magnetic resonance imaging (MRI) before medical treatment and after six months of cabergoline treatment at maximum dose.
9798177|NCT01620177|Experimental|0% THC with 0.065 g/dL BAC|
9798178|NCT01620177|Experimental|2.5-3.5% THC with 0.065 g/dL BAC|
9798179|NCT01620177|Experimental|6.0-7.5% THC and 0.065 g/dL BAC|
9798180|NCT01620177|Experimental|2.5-3.5% THC with 0 g/dL BAC|
9798181|NCT01620177|Experimental|6.0-7.5% THC with 0 g/dL BAC|
9798182|NCT01620177|Experimental|0% THC with 0 g/dL BAC|
9798183|NCT01620190|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle formula)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9800312|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
9800313|NCT01684423|Active Comparator|Comparator, Age: 6 - <12 years|Subjects aged from 6 - <12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
9800314|NCT01684436|Experimental|Punctal plug|Punctal plugs inserted into the study eye on Day 1.
9800315|NCT01684566|Experimental|Standard-Of-Care + episil(R)|Standard-Of-Care plus episil® administered as three consecutive pump-strokes for a total volume of 0.45 mL applied 3 times daily and additionally, as needed
9800316|NCT01684566|Other|Standard-Of-Care|Oral hygiene procedures
9800317|NCT01684592|Active Comparator|Standard care|Standard care for smokers during pregnancy and referral to 24/7 quitline postpartum (passive)
9800318|NCT01684592|Experimental|Standard care plus PPCC|Standard care for smoking during pregnancy and proactive phone-based postpartum continuing care (PPCC) for 6 months postpartum
9800319|NCT01684722|Active Comparator|Vitamin D + fish oil|Vitamin D and omega-3 fatty acids (fish oil)
9800320|NCT01684722|Active Comparator|Vitamin D + fish oil placebo|Vitamin D and fish oil placebo
9800321|NCT01684722|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and omega-3 fatty acids (fish oil)
9800322|NCT01684722|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
9800323|NCT01684748|Experimental|Olmesartan Medoxomil first, then No Drug|During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
9800324|NCT01684748|Experimental|No Drug first, then Olmesartan Medoxomil|During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.
9800325|NCT01684839|Other|new surgical treatment|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap taken from the homolateral dorsal branch of the digital nerve.
9800326|NCT01684878|Experimental|Part 1: Pertuzumab + Topotecan|Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
9800327|NCT01684878|Experimental|Part 1: Pertuzumab + Paclitaxel|Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
9800328|NCT01684878|Experimental|Part 2: Pertuzumab+Chemotherapy|Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
9800329|NCT01684878|Placebo Comparator|Part 2: Placebo+Chemotherapy|Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
9800330|NCT01684917|Experimental|Life style advice|reduce energy intake by 20% less than estimated energy expenditure.
9800331|NCT01684917|Active Comparator|UK background diet|Diet where energy intake will be matched with estimated energy expenditure.
9993218|NCT01470313|Experimental|PD-0360324|
9993219|NCT01470313|Placebo Comparator|Placebo|
9901257|NCT03484923|Experimental|Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients|Spartalizumab and LAG525 will be administered intravenously
9901258|NCT03482310|Experimental|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
9901259|NCT03480581|Experimental|Reverse First ICARE Training|Participants will engage in 12-sessions in the reverse direction followed by 12-sessions in the forward direction.
9901260|NCT03480581|Experimental|Forward First ICARE Training|Participants will engage in 12-sessions in the forward direction followed by 12-sessions in the reverse direction.
9901261|NCT03468426|Experimental|BI 836880 + ezabenlimab|
9901262|NCT03462719|Experimental|Treatment Arm A: Ibrutinib and Venetoclax (I+VEN)|Participants will initially receive ibrutinib (420 mg [milligrams]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
9901263|NCT03462719|Active Comparator|Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)|Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
9901264|NCT03461354|Experimental|A|Mucolox Arm
9901265|NCT03461354|Active Comparator|B|Sodium Bicarb Control Arm
9901266|NCT03449381|Experimental|Dose Escalation|
9901267|NCT03449381|Experimental|Dose Expansion|
9901268|NCT03439748|Experimental|Positive Affect Treatment|15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
9901269|NCT03439748|Active Comparator|Negative Affect Treatment|15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.
9901270|NCT03438474|Active Comparator|Arm A standard surgical procedure|"Standard surgical procedure for endometrial cancer:~total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)"
9901271|NCT03438474|Experimental|Arm B systematic lymphadenectomy (LNE)|"In addition to standard procedures as defined for Arm A:~systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels"
9901272|NCT03436979||Subjects|Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.
9901273|NCT03436485|Experimental|ODM-208 Part 1 Dose escalation|
9901274|NCT03436485|Experimental|ODM-208 Part 2 Dose expansion|
9901275|NCT03433911|Experimental|FemBloc|Investigational device and procedure
9901276|NCT03433911|Active Comparator|Control|Laparoscopic bilateral tubal sterilization
9901277|NCT03431350|Experimental|Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
9901278|NCT03431350|Experimental|Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)|Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
9901279|NCT03431350|Experimental|Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)|Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
9901280|NCT03431350|Experimental|Combination 3: Niraparib + AA-P|Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
9901281|NCT03429543|Experimental|Linagliptin|Linagliptin arm. Oral route. Linagliptin tablets administered once daily for 52 weeks
9901282|NCT03429543|Experimental|Empagliflozin|Empagliflozin arm. Oral route. Start with a low dose of empagliflozin administered once daily and randomly up titrate to the high dose of empagliflozin administered once daily if HbA1c ≥ 7% at week 12
9901283|NCT03429543|Placebo Comparator|Placebo|Placebo arm. Oral route. Placebo tablets administered once daily up to 26 weeks and then linagliptin or low dose of empagliflozin or high dose of empagliflozin administered once daily up to 52 weeks
9901284|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
9901285|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
9901286|NCT03418272||Ventilated Pediatric Intensive Care Unit patient Group|This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.
9901287|NCT03418272||Intubated OR patient Control Group|For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.
9901288|NCT03412565|Experimental|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
9901289|NCT03412565|Experimental|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m^2 orally on Days 1 to 4 of cycles 1 to 9.
9901290|NCT03412565|Experimental|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
9901291|NCT03412565|Experimental|Daratumumab + Carfilzomib + Dexamethasone (D-Kd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
9901292|NCT03407144|Experimental|Pembrolizumab + AVD (Group 1)|After receiving two 4-week cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) induction therapy, SER participants in Group 1 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) on Day 1 of each 3-week cycle (Q3W) in combination with two cycles of AVD chemotherapy (doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2 and dacarbazine 375 mg/m^2 on Days 1 and 15; cycle frequency every 4 weeks [Q4W]). All SERs in Group 1 will receive radiotherapy (RT) after completing AVD chemotherapy.
9933373|NCT05351853|Other|Vegetarian|20 healthy individual will be in the control group. Participants of this group will change their diet from omnivore to vegetarian (no meat /meat products) after the beginning of the study.
9993220|NCT01470326||Bazedoxifene Tablets|Subjects taking Bazedoxifene Tablets
9993221|NCT01470339|Placebo Comparator|placebo|migraine patients to receive placebo treatment
9993222|NCT01470339|Active Comparator|duloxetine|migraine patients to receive duloxetine
9993223|NCT01470352|Placebo Comparator|Placebo|
9993224|NCT01470352|Active Comparator|treatment|Duloxetine will be given in a daily dose of 30 mg for 5 weeks
9993225|NCT01470365|Experimental|Treatment (radiation therapy)|Patients undergo 3-dimensional CRT or IMRT QD, 5 days a week for 10-30 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
9993226|NCT01470378|Active Comparator|Control Group|This group will not be undergoing to manual lymphatic drainage
9993227|NCT01470378|Active Comparator|Study Group|This group will be undergoing to manual lymphatic drainage
9993228|NCT01470391|Experimental|Adductor-Canal-Blockade|
9993229|NCT01470391|Active Comparator|Femoral Nerve Block|
9993230|NCT01470404||adjuvant chemotherapy|Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
9993231|NCT01470430||ROP infants treated with intravitreal anti-VEGF agents|
9993232|NCT01470430||ROP infants treated with retinal laser photocoagulation|
9993233|NCT01470443|Active Comparator|GEMOX|"Gemcitabine 1,000 mg/㎡, day 1 and 8, every 3 weeks~Oxaliplatin 100 mg/㎡, day 1, every 3 weeks"
9993234|NCT01470443|Experimental|XELOX|Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks Oxaliplatin 130mg/㎡, day 1, every 3 weeks
9993235|NCT01470456|Experimental|SAR3419 + Rituximab|Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent.
9993236|NCT01470482|Other|No Tourniquet|We compare tourniquet or not in knee surgery
9993237|NCT01470482|Active Comparator|Tourniquet|We compare tourniquet or not in knee surgery
9993238|NCT01470495|Experimental|RFA+Sorafenib|to treat recurrent HCC both with RFA and Sorafenib
9993239|NCT01470495|Active Comparator|RFA group|To treat recurrent HCC with RFA
9993240|NCT01470508|Experimental|Family Enhancement|PAS is a 27-week program consisting of 25 sessions, 50 minutes in length, between an individual and a therapist. During six (6) family sessions, a family member will accompany the individual to therapy and will take an active role during the session. In this program, individuals and their family members will learn about ways to communicate about their relationship in the context of experiencing an eating disorder. PAS focuses on family-specific skills such as communication skills and problem solving skills while also incorporating eating disorders psychoeducation.
9993241|NCT01470508|Active Comparator|Cognitive Behavioral Therapy|Individuals meet their therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy.
9993242|NCT01470521|Experimental|Hookworm larvae (Necator americanus)|Participants will receive 25 live hookworm larvae
9993243|NCT01470521|Placebo Comparator|Placebo|Participant will receive pharmacopoeial grade water
9993244|NCT01470534|Experimental|Normal body weight|
9993245|NCT01470534|Experimental|Obese|
9993246|NCT01470534|Placebo Comparator|Normal Body Weight placebo|Participants of mormal body weight given placebo
9993247|NCT01470534|Placebo Comparator|Obese placebo|Participants who are obese given placebo
9993248|NCT01470560|Sham Comparator|Sham Yoga Group Treatment|Sham yoga group (control group) will attend 8 weekly sessions for 1-2 hours and will be lead by a certified yoga instructor. The yoga class will be based on Pantajali's Eight Fold Path which is the basis of Yoga. Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
9993249|NCT01470560|Active Comparator|MBSR Group Treatment|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
9993250|NCT01470573|Experimental|Progenitor Autologous Cells|Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
9993251|NCT01470586|Other|Surgery for colorectal cancer|Colorectal cancer patients
9993252|NCT01470586|No Intervention|Controls|Controls
9993253|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
9993254|NCT01470677|Experimental|application of Tachosil fibrin patches|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group.
9993255|NCT01470677|No Intervention|Control group|In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
9901293|NCT03407144|Experimental|Pembrolizumab + COPDAC-28 (Group 2)|After receiving two 4-week cycles of OEPA (vincristine, etoposide/etopophos, prednisone/prednisolone and doxorubicin) induction therapy, SER participants in Group 2 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) Q3W, in combination with 4 cycles of COPDAC-28 chemotherapy (cyclophosphamide 500 mg/m^2 on Days 1 and 8, vincristine 1.5 mg/m^2 with maximum single dose 2 mg on Days 1 and 8, prednisone/prednisolone 40 mg/m^2/day divided in 3 doses on Days 1 to 15, dacarbazine 250 mg/m^2 on Days 1 to 3; cycle frequency Q4W). SERs in Group 2 will receive RT if they have a positive Positron Emission Tomography (PET) response after completing COPDAC-28 chemotherapy.
9901294|NCT03405090|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
9901295|NCT03405090|Active Comparator|Combivent Bronchodilator|Single dose, nebulized Combivent bronchodilator (0.5 mg ipratropium bromide + 2.5 mg salbutamol). This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
9901296|NCT03404791|Experimental|Participants Ineligible for Radical Cystectomy|Participants will receive the TAR-200 transuretherally on Day 0 in to the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed on Day 21 via flexible or rigid cystoscopy. Participants will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Participants may undergo 21 day cycle every 3 months for a maximum of 3 cycles as maintenance (Up to 14 months). Each TAR-200 system will be removed at 21 days after insertion.
9901297|NCT03394456|Experimental|Intervention|Receive diabetes group visits/diabetes program
9901298|NCT03394456|No Intervention|Control|Receive usual care in the clinic, followed by group visits (wait list control) for cohorts 1-4 case-matched comparisons via chart review for cohort 5
9901299|NCT03392584||APR|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR)
9901300|NCT03392584||APR with VRAM|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) and subsequent reconstruction of the perineum with a vertical rectus abdominis myocutaneous flap (VRAM)
9901301|NCT03390504|Experimental|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]).
9901302|NCT03390504|Experimental|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
9933374|NCT05351853|Other|Vegan|20 healthy individual will be in the control group. Participants of this group will change their diet from omnivore to vegan (%100 plant based) after the beginning of the study.
9901303|NCT03390504|Experimental|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs).
9901304|NCT03390504|Experimental|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
9901305|NCT03386513|Experimental|Escalation and Expansion|"Escalation: IMGN632 was administered by IV on 2 different schedules for patients with relapsed/refractory AML or BPDCN.~Expansion: the study is currently enrolling in 2 BPDCN expansion cohorts at the RP2D:~Cohort 1: Relapsed or refractory BPDCN patients who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN)~Cohort 6: Pivotal cohort for frontline BPDCN patients who have not received prior systemic therapy. Patients may have received local therapy (radiotherapy, surgical excision, photodynamic therapy). Eligible patients must have a recurrence or progression in the field of local therapy OR disease outside the field of local therapy.~Other expansion cohorts not currently enrolling:~• Cohort 2: Relapsed AML; Cohort 3: Relapsed or refractory ALL; Cohort 4: Other relapsed or refractory hematologic malignancies; Cohort 5: Relapsed or refractory AML at alternate dose or schedule"
9901306|NCT03384654|Experimental|Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL|Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
9901307|NCT03384654|Experimental|Cohort 2: T-Cell ALL/LL|Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
9901308|NCT03381573||Roflumilast exposed|Patients with COPD ever exposed to Roflumilast
9901309|NCT03381573||Roflumilast unexposed|Patients with COPD never exposed to Roflumilast
9901310|NCT03378531|Experimental|AEB1102|Each patient may receive AEB1102 administered IV for up to approximately 4 years.
9901311|NCT03374553|Experimental|MINIject DO Integrated System CS636 (MINI DO636)|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery. In this arm the implant is placed using Dual Operator Delivery Tool (DODT)."
9901312|NCT03374553|Experimental|MINIject SO Integrated System CS636 (MINI SO636)|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery. In this arm the implant is placed using Single Operator Delivery Tool (SODT)."
9901313|NCT03372902||normal mammograms (BI-RADS 1 or 2)|
9901314|NCT03372902||suspicious lesion group (BI-RADS 4)|
9901315|NCT03372720|Experimental|Arm I (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart.
9901316|NCT03372720|Sham Comparator|Arm II (sham laser therapy)|Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I.
9901317|NCT03364868|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
9901318|NCT03364868|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
9901319|NCT03364686|Experimental|Biotin-Labeled Red Blood Cells Infusion|Each participant will receive 2 transfusions of biotin labeled red blood cells.
10212750|NCT05063305|Experimental|Female Probiotic|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
9901322|NCT03361306|Experimental|KRd-Elotuzumab|Carfilzomib, Revlimid, Dexamethasone, Elotuzumab
9901323|NCT03356132||Textured Group|Women undergoing primary and secondary breast augmentation with Silimed® Textured Silicone Gel-Filled Breast Implant.
9901324|NCT03356132||Polyurethane Group|Women undergoing primary and secondary breast augmentation with Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
9901325|NCT03355573|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 4 years.
9901326|NCT03345771|Active Comparator|Antimicrobial Barrier Dressing|postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7
9901327|NCT03345771|Active Comparator|Closed-incision Negative Pressure Therapy|portable NPWT device placed in the operating room from surgery to postoperative day 7
9901328|NCT03341962|Experimental|10 mg IMU-838 (Induction)|"Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
9901329|NCT03341962|Experimental|30 mg IMU-838 (Induction)|"Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
9901330|NCT03341962|Experimental|45 mg IMU-838 (Induction)|"Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
9901331|NCT03341962|Placebo Comparator|placebo (during induction)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging.
9901332|NCT03341962|Experimental|10 mg IMU-838 (Maintenance)|Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
9901333|NCT03341962|Experimental|30 mg IMU-838 (Maintenance)|Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
9901334|NCT03341962|Placebo Comparator|placebo (during maintenance)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).
9901335|NCT03341962|Experimental|30 mg IMU-838 (Open-label)|Two 15 mg tablets once daily of IMU-838 or one 30 mg tablet IMU-838 once daily for up to 10 years and up to 3 years in UK sites
9901336|NCT03333408|Active Comparator|Group A (Antibiotic)|Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.
9901337|NCT03333408|No Intervention|Group B (no Antibiotic)|Group B will not be given postoperative oral antibiotics upon discharge.
9901338|NCT03328065||Stable patients, early responders to treatment and caregivers|
9901339|NCT03328065||Stable patients and intermediate responders and c|Stable patients and intermediate responders to treatments and caregivers
9901340|NCT03328065||Doctors|
9901341|NCT03328065||Patients in therapeutic escape and their caregivers|
9901342|NCT03326856|Placebo Comparator|Vehicle|Vehicle
9901343|NCT03326856|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
9901344|NCT03326856|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
9901345|NCT03326856|Experimental|Dose 3|botulinum toxin, Type A, Dose 3
9901346|NCT03326856|Experimental|Dose 4|botulinum toxin, Type A, Dose 4
9901347|NCT03326791|Experimental|Intervention group|Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.
9901348|NCT03326791|Placebo Comparator|Control group|Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.
9901349|NCT03320876|Experimental|filgotinib|
9901350|NCT03320642|Experimental|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
9901351|NCT03313180|Experimental|All patients|
9901352|NCT03311451|Other|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
9901353|NCT03311412|Experimental|Sym021 Dose Level 1|Part 1, Sym021 monotherapy dose level 1
9901354|NCT03311412|Experimental|Sym021 Dose Level 2|Part 1, Sym021 monotherapy dose level 2
9901355|NCT03311412|Experimental|Sym021 Dose Level 3|Part 1, Sym021 monotherapy dose level 3
9901356|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 1|Part 2, Arm A: Sym021 RP2D in combination with dose level 1 of Sym022
9901357|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 2|Part 2, Arm A: Sym021 RP2D in combination with dose level 2 of Sym022
9901358|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 3|Part 2, Arm A: Sym021 RP2D in combination with dose level 3 of Sym022
9901359|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 4|Part 2, Arm A: Sym021 RP2D in combination with dose level 4 of Sym022
9901360|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 1|Part 2, Arm B: Sym021 RP2D in combination with dose level 1 of Sym023
9901361|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 2|Part 2, Arm B: Sym021 RP2D in combination with dose level 2 of Sym023
9901362|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 3|Part 2, Arm B: Sym021 RP2D in combination with dose level 3 of Sym023
9901363|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 4|Part 2, Arm B: Sym021 RP2D in combination with dose level 4 of Sym023
9901364|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 5|Part 2, Arm B: Sym021 RP2D in combination with dose level 5 of Sym023
9901365|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 6|Part 2, Arm B: Sym021 RP2D in combination with dose level 6 of Sym023
9901366|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 7|Part 2, Arm B: Sym021 RP2D in combination with dose level 7 of Sym023
9901367|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 1|Part 3, Sym021 in combination with Sym022 and Sym023
9901368|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 2|Part 3, Sym021 in combination with Sym022 and Sym023
9901369|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 3|Part 3, Sym021 in combination with Sym022 and Sym023
9901370|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 4|Part 3, Sym021 in combination with Sym022 and Sym023
9901371|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 5|Part 3, Sym021 in combination with Sym022 and Sym023
9901372|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 6|Part 3, Sym021 in combination with Sym022 and Sym023
9933375|NCT05351840|Experimental|Period I|D1~D7
9933376|NCT05351840|Experimental|Period II|D14~D23
9993256|NCT01470690|Active Comparator|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC alone)
9993257|NCT01470690|Active Comparator|omeprazole|Omeprazole 40 mg QD for 5 consecutive days (OME alone)
9993258|NCT01470690|Experimental|boceprevir+omeprazole|Omeprazole 40 mg QD for 5 consecutive days combined with boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC+OME)
9993259|NCT01470703|Experimental|ECMO arm|
9993260|NCT01470703|Active Comparator|conventional arm|
9993261|NCT01470729||Spinocerebellar Ataxia type 1 (SCA1)|Spinocerebellar Ataxia type 1 (SCA1)
9993262|NCT01470729||Spinocerebellar Ataxia type 2 (SCA2)|Spinocerebellar Ataxia type 2 (SCA2)
9993263|NCT01470729||Spinocerebellar Ataxia type 3 (SCA3)|Spinocerebellar Ataxia type 3 (SCA3)
9993264|NCT01470729||Spinocerebellar Ataxia type 7 (SCA7)|Spinocerebellar Ataxia type 7 (SCA7)
9993265|NCT01470742|Active Comparator|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
9993266|NCT01470742|Experimental|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
9993267|NCT01470755|Other|salbutamol - dose 1|Metered dose inhaler, 100µg+300µg per puff, administered one day
9993268|NCT01470755|Other|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
9993269|NCT01470755|Other|Salbutamol - dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
9993270|NCT01470755|Other|salbutamol - dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
9993271|NCT01470768|Other|Arm 1 - AA Formula with DHA and ARA|Marketed AA formula with Docosahexanoic Acid (DHA) and Arachidonic Acid (ARA)
9993272|NCT01470768|Other|Arm 2 - AA Formula with alternative levels of DHA and ARA|
9993273|NCT01470794|Experimental|Single Arm|Toca 511 vector/Toca FC prodrug
9993274|NCT01470807|Experimental|portable artificial pancreas system with CTR algorithms|This is the only arm of the study and concerns all patients.
9993275|NCT01470820|Active Comparator|Distance 20 cm|The infants were randomized by sealed and opaque envelopes to one of four phototherapy regimens. Either with distance from the phototherapy device to the mattress of 20, 29, 38 or 47 cm measured by a wood stick for each infant, corresponding to the distances to the infants of averagely 12, 21, 30 and 39 cm, respectively.
9993276|NCT01470820|Active Comparator|Distance 29 cm|
9993277|NCT01470820|Active Comparator|Distance 38 cm|
9993278|NCT01470820|Active Comparator|Distance 47 cm|
9993279|NCT01470833|No Intervention|Non-weight-bearing|"The group of non-weightbearing is instructed as follows:~Week 1 to 6 No weightbearing. Crutches are obligatory. Week 7 to 8 Full weightbearing is allowed.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
9993280|NCT01470833|Experimental|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weightbearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weightbearing is allowed. Week 5 to 8 Full weightbearing is allowed. Crutches should be avoided."
9993281|NCT01470846|Experimental|APD|patient with epidural analgesia
9993282|NCT01470846|Active Comparator|PCA|Patient with morphine analgesia
9993283|NCT01470885||glucose value|glucose value
9998234|NCT01516346|Active Comparator|Isosorbide dinitrate|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain placebo capsules.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
10212751|NCT05063305|Placebo Comparator|Female Placebo|• Participants will be instructed to take 1 capsule per day for the following 90 days. If a participant misses a day, they should resume taking 1 capsule per day the next day. The capsule should not be crushed or chewed. The capsule may be taken with or without food per participant preference. The participant should consistently take the capsule at a similar time each day (example: always take it in the morning or evening)
10212752|NCT05062174||mifepristone + surgery|Mifepristone is taken orally as a one-time only dose between 48 and 56 hours before your planned prophylactic mastectomy surgery
10212753|NCT05061186|Experimental|Resistive Expiratory muscle Training Group|Mild Resistive Expiratory muscle Training Group
10212754|NCT05061186|Active Comparator|Conventional Breathing Exercise Group|Breathing Ex: Pursed lip Breathing, Diaphragmatic breathing ex, incentive spirometer
10212755|NCT05059990|Experimental|Low Intensity Aerobic Exercises Group|stationary cycle for aerobic exercise
10212756|NCT05059990|Active Comparator|Active Exercises Group|Upper and lower limb range of Motion (ROM) & stretching exercises uses in active exercise group
10212757|NCT05059964|Experimental|Circuit Training program|circuit training for 4 weeks
9901373|NCT03307044|Experimental|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
9901374|NCT03304600|Experimental|Active stimulation|10 sessions (1 per day during 2 week) of active tDCS stimulation
9901375|NCT03304600|Sham Comparator|Sham Stimulation|10 sessions (1 per day during 2 week) of sham stimulation
9901376|NCT03303664|Experimental|IMPROVE Protocol|The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.
9901377|NCT03303664|No Intervention|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
9901378|NCT03302273|Experimental|Corneal Epithelial Stem Cell Transplant|The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.
10212758|NCT05059964|Active Comparator|Continuous aerobic exercise Group|aerobic exercise for 4 weeks
9901380|NCT03301220|No Intervention|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
9901381|NCT03301220|Experimental|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.
9901382|NCT03289741|Experimental|Octreotide then Lanreotide|Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
9901383|NCT03289741|Experimental|Lanreotide then Octreotide|Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
9901384|NCT03287947|Experimental|A|Nintedanib
10212759|NCT05053152|Placebo Comparator|Arm I (placebo, SABR)|Patients receive placebo PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
10212760|NCT05053152|Experimental|Arm II (relugolix, SABR)|Patients receive relugolix PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
10212761|NCT05052827|Active Comparator|Children|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
9901388|NCT03287154|Experimental|Active tDCS stimulations|Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).
9901389|NCT03287154|Sham Comparator|Sham tDCS|"Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks).~As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped."
9901390|NCT03287089|Active Comparator|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
9901391|NCT03287089|Placebo Comparator|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
9901392|NCT03285438|Experimental|Reduced dose of DOAC|A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 24 months (12 to 48 months)
9901393|NCT03285438|Active Comparator|Full dose of DOAC|A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 24 months (12 to 48 months).
9901394|NCT03277105|Experimental|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
9901395|NCT03277105|Active Comparator|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
9901396|NCT03259867|Experimental|Advanced Hepatocellular carcinoma|"PD-1 inhibitor (Nivolumab 480 mg Q4W IV ) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
9901397|NCT03259867|Experimental|Metastatic Gastro-esophageal cancer|"PD-1 inhibitor (Nivolumab 480 mg Q4W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
10212762|NCT05052827|Active Comparator|Adolescent Females|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
10212763|NCT05052827|Active Comparator|Adolescent Males|Participants underwent 3 metabolic trials in a randomized crossover fashion, where they were provided with an isonitrogenous quantities of either milk protein concentrate, soy protein isolate, and rice protein isolate following a standardized bout of variable intensity exercise.
9901400|NCT03258138|Experimental|More Intensive Program (MIP)|Participants will receive the more intensive program, which combines usual care with the full version of the healthy lifestyles program. Participants in this arm will meet weekly for group health and wellness learning sessions or brainstorming group sessions. In addition, they will meet monthly for individual sessions with a multidisciplinary health team, including a family physician, physical therapist and dietician to tailor their health goal development and action plans to their particular needs and situations. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
9901401|NCT03258138|Experimental|Less Intensive Program (LIP)|Participants will receive the less intensive program, which combines usual care along with health goal development. Participants in this arm will meet at baseline to set health goals with the support of a research assistant trained in theories of health behaviour and goal setting. They will also meet every three months to measure progress in achieving their goals. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
9901402|NCT03255915|Experimental|Arm 1|Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.
9901403|NCT03255915|Experimental|Arm 2|Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.
9901404|NCT03242889|Experimental|DARA SC|Participants will receive DARA SC (daratumumab 1800 milligram [mg] with Recombinant Human Hyaluronidase [rHuPH20] 30,000 units [U] that is 2000 U/milliliter [U/mL]) subcutaneous (SC) injection once weekly for the first 8 weeks in Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks in Cycles 3 to 6 (Days 1 and 15) for the following 16 weeks and then every 4 weeks (from Cycle 7 [Day 1]) in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
9901405|NCT03240692|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
9901406|NCT03234972|Experimental|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9 as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) or will have the option to switch to daratumumab subcutaneously (SC) on Day 1 of any cycle, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
9901407|NCT03234972|Experimental|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles). Participants who have sponsor-confirmed disease progression while being treated with Vd or on observation, will be offered the option for treatment with daratumumab monotherapy (16 mg/kg weekly for Cycles 1 and 2, every other week for Cycles 3 to 6, and every 4 weeks for Cycles 7 and onwards until disease progression, unacceptable toxicity, pregnancy, loss of follow-up, withdrawal of consent, or death [each cycle is 28 days]), if recommended by the site investigator.
9901408|NCT03227029|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
9901409|NCT03227029|Experimental|RSV 276 vaccine|Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
9901410|NCT03227029|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
9901411|NCT03217812|Active Comparator|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is greater than [>]2 milligram per deciliter [mg/dL] at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2) orally, once daily (on Days 1 to 4) and prednisone 60 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
9933377|NCT05351840|Experimental|Period III|D24~D30
10212764|NCT05052749|Experimental|High Intensity Resistance Training (HIRT)|In this HIRT group, participants will perform warm-up activity for 15 minutes then high intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
10212765|NCT05052749|Active Comparator|Low-moderate Resistance Exercise Training|In this low-moderate resistance training group, participants will perform warm-up activity for 15 minutes then low-moderate intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
9993284|NCT01470898|Experimental|anesthesia monitoring|Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.
9993285|NCT01470898|Experimental|no bispectral index monitoring|At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
9993286|NCT01470911|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
9993287|NCT01470911|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
9993288|NCT01470937|Experimental|Acarbose|acarbose 100 mg once daily
9993289|NCT01470937|Placebo Comparator|Placebo|Matched placebo was administered for acarbose 100 mg once daily
9993290|NCT01470950|Experimental|MotionMaker Training|Device description: MotionMaker™ is a stationary robotic system for the active mobilization of the lower limbs. With its proprietary 'Closed-Loop' technology, it is a novel and exciting development that offers a truly interactive patient training system Training 3 times a week with MotionMaker device together with conventional treatment
9993291|NCT01470963|Experimental|Referral template|Implementation of the referral templates at the GP office
9993292|NCT01470963|No Intervention|Control|Normal referral pattern
9993293|NCT01470976|Active Comparator|Goal-directed Therapy (GDT) Protocol|
9993294|NCT01470976|Active Comparator|Standard Protocol|
9993295|NCT01471002|Experimental|Renal cancer without nephrectomy|patients with renal cancer that cannot be offered a partial nephrectomy
9993296|NCT01471067|Experimental|Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|Myeloablative Regimen: Rituxan 375 mg/m^2 (B cell malignancy) by vein (IV) on Day -10; Busulfan AUC 4,000 IV either as an outpatient prior to admission or as an inpatient on Day -9; Clofarabine 30 mg/m^2 IV Day -7 to Day -4; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; Fludarabine 10 mg/m^2 IV on Days -7 to -4; Total Body Irradiation (TBI) 2 Gy on Day -3; with Cord Blood infusions on Day 0.
9993297|NCT01471067|Experimental|Fludarabine + Melphalan|Reduced Intensity: Fludarabine 40 mg/m^2 IV on Days -5 to -2; Melphalan 140 mg/m^2 IV on Day -2; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; with Cord Blood infusions on Day 0.
9993298|NCT01471080|Experimental|RFA group|using RFA to treat cavernous hemangiomas
9993299|NCT01471080|Active Comparator|hepatectomy group|using laparoscopic hepatectomy to treat cavernous hemangiomas of the liver
9993300|NCT01471106|Experimental|Group 1: Dasatinib 40 mg|Dasatinib 40 mg by mouth once a day for 3 months (+/- 7 days), At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
9993301|NCT01471106|No Intervention|Group 3: No Dasatinib|No treatment control group. At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
9993302|NCT01471106|Experimental|Group 2: Dasatinib 80 mg|Dasatinib 80 mg by mouth once a day for 3 months (+/- 7 days). At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
9901412|NCT03217812|Experimental|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion or daratumumab Subcutaneously (SC) at the discretion of the investigator, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
9901413|NCT03208231|Experimental|Arm 1: VRC01|Participants will receive VRC01 at Weeks 0, 2, 6, and 10.
9901414|NCT03208231|Active Comparator|Arm 2: No study treatment|Participants will not receive the study treatment.
9901415|NCT03207776|Other|Control|Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
9901416|NCT03207776|Other|Intervention|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).
9901417|NCT03205709|Active Comparator|Training Group 1|Computerized Cognitive Training
9901418|NCT03205709|Placebo Comparator|Training Group 2|Crossword puzzles
9901419|NCT03204643|Experimental|BH-VPN|A bundle of usual care components applied consistently and completely, plus access to mental health trained patient navigators and navigation services.
9901420|NCT03204643|No Intervention|Usual Care|The standard intervention (Control - Usual Care) is given in this population. May contain some of the BH-VPN components.
9901421|NCT03201965|Active Comparator|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
9901422|NCT03201965|Experimental|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
9901423|NCT03195374||Patients with chronic non-cancer pain|Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
9901424|NCT03195244|No Intervention|Observation|
9901425|NCT03195244|Active Comparator|One-on-one Aquatic Therapy|
9901426|NCT03195244|Experimental|Group Aquatic Therapy|
9998331|NCT01517269|Experimental|Education with simulator|Parent randomized to this group will be taught diabetes management with vignette and simulator
9901427|NCT03194854|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
9901428|NCT03194854|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
9901429|NCT03193216|Experimental|Alginate group|Patients in this group will be taking the study medication -- alginate solution in addition to standard of care twice daily proton pump inhibitor therapy
9901430|NCT03190200||MRI|Subjects with healthy knees
9901431|NCT03188068|Active Comparator|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
9901432|NCT03188068|Active Comparator|Sirolimus plus prednisolone|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks."
9901433|NCT03182829||Factor Xa inhibitor|"Patients on treatment with Apixaban, Edoxaban or Rivaroxaban are included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Factor Xa inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
9901434|NCT03182829||Thrombin inhibitor|"Patients on treatment with Dabigatran are included included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Thrombin inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
9901435|NCT03181789|Experimental|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
9901436|NCT03181789|Placebo Comparator|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
9901437|NCT03181789|Experimental|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
9901438|NCT03181789|Placebo Comparator|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
10212766|NCT05052047|Experimental|Brisk Walking Group|Brisk walking as training for 4 weeks
10212767|NCT05052047|Active Comparator|Conventional Breathing Exercise Group|Conventional Breathing exercise for 4 weeks
10212768|NCT05051072|Other|MRI in morphological sequence, diffusion tensor and resting functional|"standard anatomical sequences T1, FLAIR (Fluid Attenuated Inversion Recovery), TOF(Time-of-flight MR angiography) , DRIVE, sequence centered on the V after injection of gadolinated contrast product as part of routine care,~diffusion tensor sequence (DTI)"
10212769|NCT05050864|Active Comparator|internal ventricular shunt (neurosurgery)|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
10212770|NCT05050864|Active Comparator|endovacascular stenting (interventional neuroradiology)|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid.
10212771|NCT05049278|Active Comparator|Norepinephrine|Norepinephrine Bitartrate Hydrate : 4 mg/4 mL
10212772|NCT05049278|Active Comparator|Phenylephrine|Phenylephrine hydrochloride : 10 mg/1 mL
10212773|NCT05049148|Other|Patients requirering brain/medullary tumors excision|All patients requirering a surgery for brain or medullar excision
10212774|NCT05047913|Experimental|18F-FTX|The radioactive tracer (FAZA)
10212775|NCT05044078|Experimental|Group 1 (Autogenic Inhibition)|Autogenic Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the Conventional therapy including neck Isometric strengthening exercise (Neck Flexion, Extension, Both sides Rotation, and Neck Bending with each 5 rep, 10-sec hold, 1 set, in all sessions), Maitland Central posterio-anterior glide (Grade 1 and 2, 30 rep, 3 sets, in all sessions) and hot pack (10 minutes in all sessions on the back of the neck)
10212776|NCT05044078|Active Comparator|Group 2 (Reciprocal Inhibition)|Reciprocal Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the with same Conventional therapy as in group 1 .
10212777|NCT05039632|Experimental|Cohort I (NBTXR3, Abscopal, ipilimumab, ipilimumab)|Patients receive NBTXR3 intratumorally on day 1. Patients also receive ipilimumab IV over 90 minutes on day 8. Beginning day 15, patients undergo Abscopal radiation therapy over 1-2 weeks. Patients then receive ipilimumab IV over 90 minutes and ipilimumab IV over 30 minutes on day 29. Cycles with nivolumab repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
10212778|NCT05039632|Experimental|Cohort II (NBTXR3, RadScopal, ipilimumab, nivolumab)|Patients receive NBTXR3 intratumorally on day 1. Patients also receive ipilimumab IV over 90 minutes on day 8. Beginning day 15, patients undergo RadScopal radiation therapy over 1-2 weeks. Patients then receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 29. Cycles with nivolumab repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
9901439|NCT03170362|Experimental|Intervention group|Pharmacogenetic test results will be provided to the provider within 72 hours of randomization in order to facilitate choice in selecting antidepressants.
9901440|NCT03170362|No Intervention|Delay results group|The comparator arm will not receive results at the time of randomization but will get results after the 24 week assessment (thus the results are delayed).
9901441|NCT03164356|No Intervention|Arm 1|In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
9901442|NCT03164356|Experimental|Arm 2 - Experimental|Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
9901443|NCT03164356|No Intervention|Arm 3 - Control|Bioimpedance data will be collected from participants in Arm 3 in parallel with those in Arm 2. However, no data will be provided to the participant's prosthetist.
10212779|NCT05032157|Experimental|Arm 1: LOU064 (blinded)|LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
10212780|NCT05032157|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
10212781|NCT05029271|Other|InPen with Guardian 4 System Arm|"All subjects will move from phase 1 to phase 4 of the study.~Phase 1:~Blinded Continuous Glucose Monitoring (CGM) will be utilized while subjects are on their current MDI therapy.~Phase 2:~All subjects will utilize a smart bolus insulin pen injector (InPen™) and app with dose calculator (InPen™ Diabetes Management App).~Phase 3:~Subjects will continue on the InPen and InPen App utilizing the HCP insights gained during the titration follow-up visit.~Phase 4:~All subjects will utilize the InPen™ with the Guardian™ 4 system."
10212782|NCT05022134|Experimental|Intervention (CHOICE-AYA)|The impact of CHOICE-AYA contraceptive counseling on contraceptive use, satisfaction, and continuation will be assessed.
10212783|NCT05020587|Other|Open Pilot Trial|Open pilot trial of a group therapy manual.
10212784|NCT05018208||Arm 1 (wearable device[s], smartphone app)|Patients undergoing CAR-T therapy use the Biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks.
10212785|NCT05018208||Arm 2 (wearable device[s], smartphone app, questionnaires)|Patients undergoing radiation therapy (RT) for head and neck, lung, or gastrointestinal cancers use the Biofourmis wearable device(s) for 90 days after completion of RT. Patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of RT, after completion of RT, 3 months after completion of RT, and 1 year after completion of RT. In addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.
10212786|NCT05013359||Adolescents Living with Obesity (ALwO)|Recruited from online, general population consumer panels
10212787|NCT05013359||Health Care Providers (HCPs)|HCPs treating adolescents who have obesity
10212788|NCT05013359||Caregivers|A parent or legal guardian of an adolescent with obesity
10212789|NCT05013099|Experimental|Subjects with melanoma, Merkel cell, renal cell, or NSCLC|Eligible subjects will receive up to three 89Zr-Df-crefmirlimab PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion as follows: First scan within 14 days prior to the onset of IOT, and a second scan 4 to 6 weeks after start of immunotherapy. The second 89Zr-Df-crefmirlimab infusion and scan should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third 89Zr-Df-crefmirlimab PET scan at the principal investigator's (PI's) discretion.
10212790|NCT05011357|Experimental|Phenylephrine|Phenylephrine infusion (0.3 mcg/kg/hr)
10212791|NCT05011357|Placebo Comparator|Control|Saline infusion
10212792|NCT05011188|Experimental|Does Escalation|Up to two dose levels of FOR46 will be evaluated. Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required.
10212793|NCT05011188|Experimental|Dose Expansion|Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1, at the maximum tolerated dose (MTD) as determined in Phase 1b. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required.
10212794|NCT05009030||Study group|Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
10212795|NCT05008809|Experimental|Treatment|Active treatment with mFOLFOXIRI or mFOLFOX6 q2w up to six months followed by structured Follow-up for up to five years after randomization
10212796|NCT05008809|No Intervention|Control|Structured Follow-up for up to five years after randomization
10212797|NCT05007015|Experimental|Transanal Irrigation|This group will be instructed on the use of TAI to be perform daily for the three month duration of their treatment arm
10212798|NCT05007015|No Intervention|Tradition care Control arm|This group tradition care group will have no modification to the care they have received prior to commencing the study. The patients in this group will use the usual dietary modifications and medications prescribed by the treating team to manage their LARS. No changes will be made to the treatment regime prescribed by their surgeon.
10212799|NCT05005988|Experimental|Empowerment educational intervention|Three 30-minute sessions will be conducted with each mother in the intervention group, the first during the first week after admission, the second session within 7 days after the second session, and the third 3 to 2 days before discharge. An induction to the out-of-hospital kangaroo program will also take place on the day of admission to the program. Mothers will receive a booklet with general care contents and empowerment information.
10212800|NCT05005988|No Intervention|Usual intervention|Mothers receive information for home infant care, no theoretical perspective and no empowerment approach is considered
10212801|NCT05004376|No Intervention|Non-adherent control|Control subjects will receive no text intervention and a 150 day follow-up phone call.
10212802|NCT05004376|Experimental|Non-adherent intervention|Intervention subjects will receive the text messaging intervention and a 150 day follow-up phone call.
10212803|NCT05001347|Experimental|TJ004309 and Atezolizumab|TJ004309 20 mg/kg Q3W in combination with atezolizumab 1200 mg Q3W
9901458|NCT03143985|Experimental|Vactosertib + Pomalidomide|"Vactosertib tablets, taken once daily for the first and second dose levels and twice a day for third and fourth dose level levels for 5 days followed by 2 days without treatment, repeated for 28-day cycles until evidence of progressive disease, intolerable toxicity, or participant discontinuation.~For dose escalation - dosing initiated at 60 mg once daily by oral administration and will be increased to determine MTD. Provisional subsequent doses are 60, 120, once daily and 100 mg and 200 mg twice daily on days 1-5, 8-12, 15-19 and 22-26. Extension cohorts will enter at 200 mg twice daily (i.e. if MTD not defined) for 12 months until progression or intolerable toxicity.~POM is administered orally (4 mg/day daily on Days 1 - 21 days). Treatment will occur in a suitable outpatient ambulatory care setting that is equipped for monitoring of patients with hematopoietic malignancies undergoing early clinical trial research."
9901459|NCT03141359|Experimental|Single Arm|SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy
9901460|NCT03133221|Experimental|Oral Zydelig 150 mg BID|Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.
9901461|NCT03132337||Stem Cell Transplant|Serial Blood Draws
9901462|NCT03117816|Experimental|investigational arm A|There will be an overlapping treatment with AOP2014 and TKI for one month. After one month, the TKI therapy will be stopped and patient will receive only AOP2014 treatment for the next 14 months.
9901463|NCT03117816|Other|surveillance arm B|"This is an open-label study with a surveillance group as comparator arm. Similar as in the arm A, patient will discontinue TKI therapy one month after randomization. From then on patient will receive no further CML treatment."
9901464|NCT03112408|Experimental|FORWARD (Axe 1)|
9901465|NCT03112408|Experimental|BACKWARD (Axe 1)|
9901466|NCT03112408|Experimental|CONTROL (Axe 1)|
9901467|NCT03112408|Experimental|ADAPTATION (Axe 2)|
9901468|NCT03112408|Experimental|CONTROL (Axe 2)|
9901469|NCT03104517|Experimental|AMDC-USR (iltamiocel)|Autologous muscle-derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) is the study product.
9901470|NCT03104517|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
9901471|NCT03102996|Experimental|Verum|Patients will receive Nephrotrans.
9901472|NCT03102996|Placebo Comparator|Placebo|Patients will receive Placebo.
9901473|NCT03100786|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
9901474|NCT03100786|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
10212804|NCT04999839|Placebo Comparator|Placebo|Placebo of NDI-034858 study drug - Approximately 50 subjects will receive placebo, orally administered QD for 12 weeks.
10212805|NCT04999839|Experimental|NDI-034858 study drug - Dose 1|NDI-034858 study drug - orally administered QD for 12 weeks.
10212806|NCT04999839|Experimental|NDI-034858 study drug - Dose 2|NDI-034858 study drug - orally administered QD for 12 weeks.
10212807|NCT04999839|Experimental|NDI-034858 study drug - Dose 3|NDI-034858 study drug - orally administered QD for 12 weeks.
10212808|NCT04999839|Experimental|NDI-034858 study drug - Dose 4|NDI-034858 study drug - orally administered QD for 12 weeks.
10212809|NCT04996875|Experimental|CGT9486|
10212810|NCT04996628|Experimental|Pancreatic Quantitative Sensory Testing (P-QST)|Definite Chronic Pancreatitis patients undergoing decompressive invasive treatments (endoscopic therapy or surgery) to relieve main pancreatic duct obstruction due to stones and/or stricture for management of pain will undergo P-QST prior to clinically-indicated invasive treatment.
10212811|NCT04995900|Experimental|Intervention|Intervention period with active Heart Matters education delivered
10212812|NCT04995900|No Intervention|Control|Control period with no Heart Matters education delivered.
10212813|NCT04990206|Experimental|Intervention|TranS-C
10212814|NCT04987970|Experimental|Sequence 1|Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-386(2)- A single oral dose of 1 tablet under fasting condition
10212815|NCT04987970|Experimental|Sequence 2|Period 1: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition
10212816|NCT04985058||Patients with breast cancer|Patients with breast cancer treated with abemaciclib in combination with endocrine treatment
10212817|NCT04983732|Experimental|FL-101-IV|FL-101 single IV infusion over 60-minutes
10212818|NCT04983732|Experimental|FL-101-SC|FL-101 single SC injection
10212819|NCT04979988||Japanese patients with ALK+ NSCLC who received lorlatinib|lorlatinib as the second-line or later therapy after failure of alectinib treatment as the firstline therapy
10212820|NCT04976647|Active Comparator|A arm: HLX10+chemo|Participants receive 300mg HLX10 IV every 3 weeks (Q3W) in combination with carboplaitin (AUC5 or 6) IV Q3W and nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle.
10212821|NCT04976647|Experimental|B arm: HLX10+HLX07+chemo|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W with chemo.
10212822|NCT04976647|Experimental|C arm: HLX10+HLX07|Participants receive 300mg HLX10 IV Q3W plus 1500mg HLX07 IV Q3W.
10212823|NCT04975737|Experimental|Vaccine Group|3590 healthy volunteers who will receive 1 dose (0.5 ml) of the vaccine GamTBvac administered twice with an 8-week interval between administrations.
10212824|NCT04975737|Placebo Comparator|Placebo group|3590 healthy volunteers who will receive 1 dose (0.5 ml) of the placebo administered subcutaneously twice with an 8-week interval between administrations.
9901475|NCT03097666|Other|C2 Cryoballoon Swipe Ablation System|C2 Cryoballoon Swipe Ablation System
9901476|NCT03090750|Experimental|Lavender|Lavender oil
9901477|NCT03090750|Experimental|Bergamot|Bergamot oil
9901478|NCT03090750|Placebo Comparator|Water|Water
9901479|NCT03086876|Experimental|Stepping Stones Triple P|Trained practitioners will deliver Level 4 SSTP to parents in 6 weekly group sessions and will also provide 3 telephone of face to face contacts to each participant but they will not be involved in routine care for participants in either arm. Each therapist responsible for delivering SSTP will be trained in the Group Stepping Stones Training and Accreditation programme which includes three training days and a further half day accreditation workshop after 6 weeks. The group sessions not only educate but actively train the parents in skills and the individual consultations aim to facilitate independent problem solving. The learning objectives focus on maintaining behavioural change, using skills within a group learning environment, learning from peers in the group and sharing difficulties or achievements, providing support, considering if more intensive work is required, referring further if needed, talking about risk and protective factors operating within families.
9901480|NCT03086876|No Intervention|Treatment as usual (TAU)|"TAU will be available to participants in both arms of the trial. It may include a range of services such as:~1. Health visitor services; 2. Primary care engagement and advice; 3. Potentially some version of early intervention maybe provided by either community paediatric services or Child and Adolescent Mental Health Services, although our understanding is that very little is available for children of this age. 4. Parenting advice and support sessions by carers groups or other third sector organisations.~Parents allocated to TAU will receive a list of national and local resources and the Contact a Family guide to challenging behavior with tips and advice on social and health care supports."
9901481|NCT03076476|Active Comparator|DES-std group|(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
9901482|NCT03076476|Experimental|DES-slow group|"(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
9901483|NCT03076476|Experimental|BVS group|(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.
9901484|NCT03076385|Experimental|VAL-506440|
9901485|NCT03076385|Placebo Comparator|Placebo|
9901486|NCT03072862||Commercial Nucleus Cochlear Implant Systems|
9901487|NCT03063398||Patients after acute pancreatitis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
9901488|NCT03060213|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
9901489|NCT03060213|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
9901490|NCT03058588||Analysis with molecular biology|"Any patient with acute leukemia or other myeloid malignancy AND~a first- or second-degree relative with acute leukemia or other myeloid malignancies~a first- or second-degree relative with lymphoproliferative neoplasms~or with clinical features that resemble one of the familial myeloid malignancies predisposition syndromes"
9901491|NCT03056001|Experimental|Pembrolizumab + doxorubicin|Participants receive pembrolizumab IV infusion and doxorubicin IV injection on Day 1 of each cycle.
9901492|NCT03053245|Experimental|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
9901493|NCT03053245|Active Comparator|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
9901494|NCT03051516|Experimental|Arm I (recombinant human papillomavirus nonavalent vaccine)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
9901495|NCT03051516|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM at baseline, 2 months, and 6 months.
9901496|NCT03034200|Experimental|ONC201 phase 2 d1d2 weekly cohort|625 mg ONC201 by mouth daily for 2 consecutive days weekly
9901497|NCT03030612|Experimental|ARGX-110 with Azacytidine (AZA)|Phase 1: Participants will receive loading dose of ARGX-110 1 milligram per kilogram (mg/kg) body weight (cohort 1), 3 mg/kg body weight (cohort 2), 10 mg/kg body weight (cohort 3) or 20 mg/kg body weight (cohort 4) administered intravenously (IV) in combination with AZA standard dose of 75 milligram per meter square (mg/m^2) body surface area (BSA) administered subcutaneously (SC) / intravenously (IV). Phase 2: Participants will receive loading dose of ARGX-110 IV at a recommended dose for Phase 2 (RP2D) level from phase 1 in combination with AZA standard dose of 75 mg/m^2 BSA, administered SC/IV as per local practice.
9901498|NCT03015974||corticosteroid|pediatric IgA nephropathy treated with only corticosteroid
9901499|NCT03015974||corticosteroid and cyclophosphamide|pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
9901500|NCT03015974||corticosteroid and mycophenolate mofetil|pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
9901501|NCT03013504|Experimental|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
9901502|NCT03013504|Active Comparator|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
9901503|NCT03009227|Active Comparator|D2 lymph node dissection|Colonic resection with D2 lymph node dissection
9901504|NCT03009227|Experimental|D3 lymph node dissection|Colonic resection with D3 lymph node dissection
9901505|NCT02977442|Experimental|exercise|12 week exercise program, 5 days/week, 60 min/day
9901506|NCT02977442|No Intervention|standard of care|12 week standard of care recommendations
9901507|NCT02975700|Experimental|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
9901508|NCT02974049|Active Comparator|Standard Treatment|Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
9901509|NCT02974049|Experimental|ALB 400 mg x2 per year|Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
9901510|NCT02974049|Experimental|ALB 800 mg x2 per year|Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
9901511|NCT02974049|Experimental|ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg|Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
9901512|NCT02968836|Active Comparator|Active group|Blend of amino acids
9901513|NCT02968836|Placebo Comparator|Placebo group|maltodextrin only
10212825|NCT04966273|Experimental|Biosensors Microcatheter (BM)|Use of Biosensors Microcatheter
10212826|NCT04963816|Active Comparator|Group A Quadratus Lumborum Block with dexamethasone IV|QLB with (0.5 mL/kg of bupivacaine 0.25%) and IV dexamethasone (0.1-0.3 mg/kg with a maximum dose 10 mg) added to 5 mL normal saline
10212827|NCT04963816|Active Comparator|Group B Quadratus Lumborum Block with dexamethasone locally|QLB with (0.5 mL/kg of bupivacaine 0.25% plus dexamethasone 0.1 mg/kg), and IV 5 mL normal saline
10212828|NCT04963816|Placebo Comparator|Group C Quadratus Lumborum Block with bupivacaine alone|Patients will receive QLB (0.5 mL/kg of bupivacaine 0.25%) and IV 5 mL normal saline.
9901518|NCT02952248|Experimental|BI 754091|
9901519|NCT02950649||Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed and the data will be used for comparison with routine subjective preoperative assessment assessment.
9901520|NCT02950649||No Hemodynamic Monitored Guided Assesment|This group will have subjective assessment by the provider and this data will be compared to the device assessment of cardiac index..
9901521|NCT02948361|Experimental|QT Ultrasound breast scan|
9901522|NCT02941666||Collapse ON group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.
9901523|NCT02941666||Pre-collapse group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.
9901524|NCT02941666||FAI group|This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement.
9901525|NCT02941549|Placebo Comparator|Placebo|2 x placebo 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
9901526|NCT02941549|Experimental|1000 mg Epeleuton|1 x Epeleuton 500 mg capsule and 1 x placebo 500 mg capsule orally administered twice a day (4 capsules daily) for 16 weeks
9901527|NCT02941549|Experimental|2000 mg Epeleuton|2 x Epeleuton 500 mg capsules orally administered twice a day (4 capsules daily) for 16 weeks
9901528|NCT02937766|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)
9901529|NCT02937766|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)
9901530|NCT02927938|Other|Evaluable Cohort - Transplant Arm|"Other - Standard of Care Consolidation (HCT)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT); HMA-based induction subjects: Are candidates for (as determined by the investigator) and receive HCT"
9901531|NCT02927938|Other|Evaluable Cohort - Consolidation Chemo Arm|"Other - Standard of Care Consolidation (cytarabine-based chemo)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT)"
9901532|NCT02927938|No Intervention|Observational Cohort 1|Enrolled subjects who do not achieve a CR to induction therapy, regardless of diagnostic phenotype. Following completion of induction therapy and remission bone marrow aspirate, if a subject is determined to not have achieved a complete remission to induction therapy, he or she would be included in observational cohort 1.
9901533|NCT02927938|No Intervention|Observational Cohort 2|"Enrolled subjects who achieve a CR to induction therapy but meet one or more of the following criteria:~Lack the immunophenotype of interest,~Cytarabine based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit or refusal)] and do not receive consolidation therapy (cytarabine-based chemotherapy or HCT)~HMA-based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit, lack of donor, refusal)] and do not receive HCT~Final investigator determination of fit-ness can occur at any time until the start of consolidation therapy.~HMA-based induction subjects will not receive consolidation cytarabine-based chemotherapy as part of the evaluable cohort if they do not receive HCT."
9901534|NCT02922439|Experimental|Tailored Intervention|Individuals will interact with a chronic disease self-management application that provides information tailored to age, race, language (English or Spanish) and level of health literacy.
9993303|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
9993304|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.
9901535|NCT02922439|Active Comparator|Control|Individuals will interact with a chronic disease self-management application that provides the same information as the experimental intervention but is not personally tailored to level of health literacy.
9901536|NCT02920333|Experimental|tDCS+ rehab training|tDCS will be applied 10 days, followed by conventional rehab training. Anodal stimulation will be conducted at the intensity of 2 mA and last for 20 minutes over the affected primary motor cortex of cortical representation of the tibialis anterior muscle.
9901537|NCT02920333|Experimental|rTMS+ rehab training|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
9901538|NCT02920333|Sham Comparator|sham tDCS+ rehab training|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
9901539|NCT02918201|Experimental|topical tranexamic acid|tranexamic acid solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
9901540|NCT02918201|Placebo Comparator|placebo control|Saline solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
9901541|NCT02913131|Experimental|Part A: Feasibility Run-In|Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s).
9901542|NCT02913131|Experimental|Part B: Biomarker Cohort|Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.
9901543|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
9901544|NCT02902003|No Intervention|Control|Not eligible for program services
9901545|NCT02902003|Active Comparator|Empowering Families|"These couples will be eligible to participate in the Empowering Families program."
9901546|NCT02899052|Experimental|Venetoclax + Carfilzomib + Dexamethasone|"Part 1: Evaluate the safety and pharmacokinetic profiles while providing information to determine the appropriate doses of venetoclax and carfilzomib (VenKd) to be used in the VenKd combination in approximately 18 participants. The dose levels are Venetoclax 400 mg or 800 mg; Carfilzomib 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; Dexamethasone 40 mg~Part 2: Further evaluate the safety and efficacy profile of the VenKd combination selected after completion of Part 1 in approximately 22 additional participants. Participants may discontinue Kd but may continue receiving venetoclax once daily (QD) as monotherapy.~Part 3: Further evaluation of the efficacy of the VenKd combination after completion of Part 1 and Part 2 in 7 additional participants.~Part 4, An additional 65 participants t(11;14) positive will receive varying doses of the VenKd combination or carfilzomib and dexamethasone"
9901547|NCT02889874|No Intervention|A: Radiation Therapy & endocrine therapy|Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
9901548|NCT02889874|Experimental|B: No Radiation Therapy (ET only)|Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
9901549|NCT02883400|No Intervention|SOC-Standard of care|standard of care, nontreatment
9901550|NCT02883400|Experimental|spironolactone|spironolactone
9901551|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
9901552|NCT02878915|Active Comparator|Ultrasound guided femoral puncture|
9901553|NCT02878915|No Intervention|palpation guided femoral puncture|
9901554|NCT02869217|Experimental|Cohort B (retreatment)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 at a dose of 5x10^9 cells.~*Patients will only enter into this cohort if they have already been enrolled in another cohort prior"
9901555|NCT02869217|Experimental|Cohort C (double infusion)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 and Day 14 at a dose of 5x10^9 cells."
9933378|NCT05351827|Experimental|Mild Intermittent Hypoxia|This arm of the protocol will receive mild intermittent hypoxia (8% Oxygen) with end-tidal carbon dioxide maintained 1-3 millimeters of mercury above baseline, while in the laboratory. If diagnosed with sleep apnea, participants will be treated with continuous positive airway pressure for the duration of the intervention.
9933379|NCT05351827|Sham Comparator|Sham|This arm of the protocol will receive sham air (21 % Oxygen) while in the laboratory. No additional gases will be employed. If diagnosed with sleep apnea, participants will be treated with continuous positive airway pressure for the duration of the intervention.
9901556|NCT02856594|Experimental|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
9798184|NCT01620216|Experimental|Group I (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9798185|NCT01620216|Experimental|Group II (sutinib malate)|Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9798186|NCT01620216|Experimental|Group III (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9798187|NCT01620216|Experimental|Group IV (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
9798188|NCT01620216|Experimental|Group V (pacritinib)|Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9798189|NCT01620216|Experimental|Group VI (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9798190|NCT01620216|Experimental|Group VII (idelalisib)|Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9798191|NCT01620255|Placebo Comparator|Placebo|
9798192|NCT01620255|Experimental|Drug Dose Level 1|
9798193|NCT01620255|Experimental|Drug Dose Level 2|
9798194|NCT01620255|Experimental|Drug Dose Level 3|
9798195|NCT01620255|Experimental|Drug Dose Level 4|
9798196|NCT01620489|Experimental|Lira 1.8 mg|
9798197|NCT01620489|Placebo Comparator|Placebo|
9798198|NCT01620528|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
9798199|NCT01620528|Experimental|Elagolix 200 mg BID|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
9798200|NCT01620528|Placebo Comparator|Placebo|Placebo BID for the 6-month Treatment Period
9798201|NCT01620567|Placebo Comparator|chickpeas/potatoes|1 potato/day or 1 cup chickpeas
9798202|NCT01620567|Active Comparator|avocados|1 avocados/day
9798203|NCT01620593|Placebo Comparator|Placebo|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy.
9798204|NCT01620593|Active Comparator|Metformin|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
9798205|NCT01620762|Experimental|Cat-Pad Treatment 1|Cat-PAD Treatment 1
9798206|NCT01620762|Experimental|Cat-PAD Treatment 2|Cat-PAD Treatment regimen 2
9798207|NCT01620762|Placebo Comparator|Placebo|Placebo
9798208|NCT01620983|Experimental|Pain Coping Skills Training|The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
9798209|NCT01620983|Active Comparator|Arthritis Education|The eight one-hour perioperative arthritis education sessions will be delivered by nurse educators via telephone and will use a presentation and discussion format. Figures and discussion sessions will present information on the nature of arthritis, what to expect following knee arthroplasty, treatment of osteoarthritis, the role of exercise, joint protection and making future treatment decisions.
9798210|NCT01620983|Other|Usual Care|Patients randomly assigned to this arm will undergo usual care following knee arthroplasty.
9798211|NCT01621009|Active Comparator|Active bupropion + counseling|Active bupropion SR plus eight 10-minute individual counseling sessions.
9798212|NCT01621009|Active Comparator|Active bupropion , No counseling|Active bupropion, No counseling, only medication checks
9798213|NCT01621009|Placebo Comparator|Placebo medication + counseling|Placebo bupropion plus eight 10-minute individual counseling sessions
9798214|NCT01621009|Placebo Comparator|Placebo medication, No counseling|Placebo bupropion, No counseling, just medication checks
9798215|NCT01621126|Experimental|Intra-op neuromonitoring|
9798216|NCT01621178|Active Comparator|Insulin glargine|Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
9798217|NCT01621178|Experimental|0.75 mg Dulaglutide|0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
9798218|NCT01621178|Experimental|1.5 mg Dulaglutide|1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
9798219|NCT01621191|Experimental|60 mg Duloxetine|Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
9798220|NCT01621230|Active Comparator|Epidural fentanyl|A continuous epidural infusion of fentanyl 10 mcg/cc at a basal infusion rate of 10 ml/hr with a patient-controlled epidural analgesia (PCEA) demand dose of 5 mL/hr for pain. Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed.
9901557|NCT02856594|Placebo Comparator|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
9901558|NCT02855060|Experimental|Pelvic Binder|Commercially available device used to stabilize the pelvis
9901559|NCT02855060|No Intervention|No Binder|Standard of care
9901560|NCT02847559|Experimental|Treatment (bevacizumab, electric field therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9901561|NCT02842723|Experimental|Protontherapy|
9901562|NCT02841969|Active Comparator|Normal care - Prontosan|Patient wounds will be irrigated using the in-use product (Prontosan)
9901563|NCT02841969|Experimental|Investigational arm - Electrolysed water|Patient wounds will be irrigated using electrolysed water
9901564|NCT02836067|Other|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
9901565|NCT02836067|Other|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:~Questionnaires Blood Draw Bronchoscopy"
9901566|NCT02832856|Placebo Comparator|Control|"Control group members will receive a job readiness curriculum entitled Beginning to Work it Out (BWIO) that assists at-risk youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
9901567|NCT02832856|Experimental|Full Relationship Smarts Curriculum|This group receives the behavioral intervention of the healthy relationship education in the form of the full, 12-lesson RS+ curriculum over approximately 12 weeks.
9901568|NCT02832856|Experimental|Abridged Relationship Smarts Curriculum|"This group receives the behavioral intervention of the healthy relationship education in the form of the summary 8-lesson version of the RS+ curriculum - as well as four lessons on career planning and job readiness over approximately 12 weeks."
9901569|NCT02823574|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
9901570|NCT02823574|Active Comparator|Nivolumab and Ipilimumab-placebo|Specified dose on specified days
9901571|NCT02807636|Experimental|Atezolizumab+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
9901572|NCT02807636|Placebo Comparator|Placebo+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
9901573|NCT02807636|Experimental|Atezolizumab Monotherapy|Eligible participants will receive open-label atezolizumab as monotherapy.
9901574|NCT02799134|Experimental|group1|take Dexamethasone at 22:00 on the first day, 0.5mg
9901575|NCT02799134|Placebo Comparator|group2|take Vitamin C at 22:00 on the first day, 0.5mg
9901576|NCT02799134|Other|group3|take Dexamethasone at 15:00 on the second day, 0.5mg
9901577|NCT02792413|Experimental|Denosumab|Denosumab 60 mg, subcutaneous injection every 6 months for 24 months
9901578|NCT02792413|Placebo Comparator|Placebo|NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months
9901579|NCT02787785|No Intervention|Conventional Medical Therapy|This arm of the trial continues with their current conventional medical therapy.
9901580|NCT02787785|Active Comparator|Subcutaneous Implantable Cardioverter Defibrillator|This arm of the trial receives a subcutaneous implantable defibrillator.
9993305|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
9901581|NCT02773212|Experimental|d-Amphetamine and Contingency Management|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
9901582|NCT02773212|Active Comparator|d-Amphetamine alone|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
9901583|NCT02773212|Active Comparator|Placebo and Contingency Management|Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
9901584|NCT02771990|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
9901585|NCT02771990|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
9901586|NCT02762604|Experimental|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
9901587|NCT02762604|Active Comparator|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
9901588|NCT02757872|Active Comparator|Vitamin D and fish oil|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
9901589|NCT02757872|Active Comparator|Vitamin D and fish oil placebo|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary Supplement: Fish oil placebo Fish oil placebo
9901590|NCT02757872|Active Comparator|Vitamin D placebo and fish oil|"Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D placebo Vitamin D3 placebo"
9901591|NCT02757872|Placebo Comparator|Vitamin D placebo and fish oil placebo|Dietary Supplement: Vitamin D placebo Vitamin D3 placebo Dietary Supplement: Fish oil placebo Fish oil placebo
9901592|NCT02753790|Experimental|Intensity Modulated Radiotherapy (IMRT)|Radiation therapy to a dose of 60 Gray (Gy)/45 Gy to gross disease and 30 Gy to subclinical sites, delivered over 15 fractions
9901593|NCT02746796|Experimental|ONO-4538 + SOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
9901594|NCT02746796|Experimental|ONO-4538 + CapeOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
9901595|NCT02746796|Experimental|ONO-4538 + chemotherapy group (Part 2)|"With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
9901596|NCT02746796|Placebo Comparator|Placebo + Chemotherapy group (Part 2)|"With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
9901597|NCT02744976|Experimental|Prediabetes, metformin|Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations
9901598|NCT02744976|Active Comparator|Prediabetes, lifestyle|Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations
9901599|NCT02743819|Experimental|Treatment|Treatment with the combination of pembrolizumab and ipilimumab.
9901600|NCT02729753|Other|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of 360 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
9901601|NCT02729753|Other|CryoBalloon™ Swipe Ablation System|To evaluate CryoBalloon™ Swipe Ablation System for the ablation of 90 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
9993306|NCT01471119|Experimental|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
9993307|NCT01471132|Experimental|HIPEC|
9993308|NCT01471145|Experimental|Depot Naltrexone|
9993309|NCT01471158|Active Comparator|Azarga/Cosopt|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Azarga will be instilled one drop in each eye on Day One, after which Cosopt will be administered one drop in each eye on Day Two.
9993310|NCT01471158|Active Comparator|Cosopt/Azarga|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Cosopt will be administered one drop in each eye on Day One, after which Azarga will be administered one drop in each eye on Day Two.
9993311|NCT01471184|Experimental|Ectoin® Eye Drops/Nasal Spray|Eye Drops/Nasal Spray
9993312|NCT01471184|Placebo Comparator|Placebo Eye Drops/Nasal Spray|
9993313|NCT01471210|Experimental|Part 1 : Urelumab (BMS-663513) Dose escalation|Urelumab (BMS-663513) solution administered intravenously on specified days
9993314|NCT01471210|Experimental|Part 2 : Urelumab (BMS-663513) Cohort Expansion|Urelumab (BMS-663513) solution administered intravenously on specified days
9993315|NCT01471210|Experimental|Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions|Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
9993316|NCT01471210|Experimental|Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL|Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
9993317|NCT01471223||Patients receiving Belatacept in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
9993318|NCT01471223||Patients receiving CNI in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
9993319|NCT01471236|Experimental|Agili-c bi-phasic implant|mini-arthrotomy
9993320|NCT01471262||Elderly|Patients more or equal to 70 years old
9993321|NCT01471262||Young|Patients less than 70 years old
9993322|NCT01471275|Experimental|Jiangtangtiaozhi decoction|
9993323|NCT01471275|Active Comparator|metformin|
9993324|NCT01471288|Active Comparator|Group3|Normal controls
9993325|NCT01471288|Placebo Comparator|Group4|Normal controls
9993326|NCT01471288|Active Comparator|Group 1|Hypothyroid patients taking levothyroxin.
9993327|NCT01471288|Placebo Comparator|Group2|Hypothyroid patients taking levothyroxin
9993328|NCT01471314||Spontaneous migraine|
9993329|NCT01471327|Experimental|SB-240563, 10mg|IV, single dose at Day 1
9993330|NCT01471327|Experimental|Placebo|Saline IV, single dose at Day 1
9993331|NCT01471327|Experimental|SB-240563, 75mg|IV, single dose at Day 1
9993332|NCT01471327|Experimental|SB-240563, 250mg|IV, single dose at Day 1
9993333|NCT01471327|Experimental|SB-240563, 750mg|IV, single dose at Day 1
9993334|NCT01471366|Active Comparator|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products
9993335|NCT01471366|Active Comparator|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
9993336|NCT01471366|Active Comparator|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
9993337|NCT01471366|Active Comparator|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
9993338|NCT01471392|Experimental|Identigene STD Test Kit Arm|Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
9993339|NCT01471418|Experimental|Disease population|
9901602|NCT02724488||Part 1|Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors will have archival tumor specimens requested and used for whole exome sequencing (WES) of tumor DNA. 3 tubes of blood at a single time point will be collected for ctDNA analysis and germ line DNA analysis (to study normal variants) using next generation sequencing.
9901603|NCT02724488||Part 2|Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors (ICIs) or planning to have treatment with ICIs or other immunological therapy as standard of care will have image-guided fresh tumor core needle biopsy at a maximum of 3 time points: 1) prior to commencement of immune checkpoint inhibitors, 2) when disease response to therapy is confirmed using radiology RECIST 1.1 criteria and/or immune related response criteria, and 3) when radiological disease progression is confirmed by using RECIST 1.1. Blood samples for ctDNA analysis will be collected at the commencement of immunotherapy and every 6-12 weeks thereafter until radiological disease progression is confirmed.
9901604|NCT02719392|Active Comparator|Minocycline|Patients in the minocycline group will take 1 minocycline (100mg) and 2 NAC placebo capsules in the morning and 1 minocycline (100mg) and 2 NAC placebo capsules in the evening for a total of 6 capsules per day over the course of the study.
9901605|NCT02719392|Active Comparator|N-acetylcysteine|Patients in the NAC group will take 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the morning and 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
9901606|NCT02719392|Active Comparator|Minocycline + N-acetylcysteine|Patients in the minocycline NAC combination group will take 2 NAC (500mg) and 1 minocycline (100mg) capsule in the morning and 2 NAC (500mg) and 1 minocycline (100mg) capsule in the evening for a total of 6 capsules per day over the course of the study.
9901607|NCT02719392|Placebo Comparator|Placebo Control|Patients in the placebo control group will take 2 NAC placebo capsules and 1 minocycline placebo capsule in the morning and 2 NAC placebo capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
9901608|NCT02708134||Pediatric Cardiac Arrests|Pediatric cardiac arrests requiring chest compressions for at least 1 minute managed at clinical centers identified as part of standard clinical operations.
9901609|NCT02704130|Experimental|TAE + MWA combination therapy|In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
9901610|NCT02704130|Active Comparator|MWA monotherapy|Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
9901611|NCT02702986|Experimental|imILT of pancreatic cancer|10 patients suffering from LAPC will be submitted to immunostimulating interstitial laser thermotherapy (imILT) in a single-arm setting
9901612|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
9901613|NCT02699606|Experimental|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
9901614|NCT02697448|Active Comparator|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
9901615|NCT02697448|Active Comparator|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
9901616|NCT02685709|Experimental|Run-in phase|Oral octreotide capsules
9901617|NCT02685709|Experimental|RCT phase - Oral|Oral octreotide capsules
9901618|NCT02685709|Active Comparator|RCT phase - Injectables|Injectable somatostatin analogs (octreotide or lanreotide)
9901619|NCT02685709|Experimental|Combination phase (sub-study)|Octreotide capsules plus cabergoline
9901620|NCT02684851|Placebo Comparator|Placebo|Inactive
9901621|NCT02684851|Active Comparator|Tranexamic|Tranexamic acid: anti-fibrinolytic agents
9901622|NCT02676973|Active Comparator|Sacral Colpopexy|Sacral Colpopexy performed via open, robotic, or laparoscopic procedure.
9901623|NCT02676973|Active Comparator|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair: Sacrospinous Ligament Suspension (SSLS) and Uterosacral Ligament Suspension (USLS)
9901624|NCT02676973|Active Comparator|Apical Transvaginal Mesh Repair|Uphold™ LITE
9901625|NCT02674529|Active Comparator|Antidepressant Treatment|20mg of escitalopram will be taken over an 8-week period, starting with 10mg for the first week.
9901626|NCT02674529|Placebo Comparator|Placebo|A placebo pill will be taken over an 8-week period.
9901627|NCT02657005|Experimental|TK216 treatment|Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
9901628|NCT02655575|Experimental|BI + VR + CBT|"Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Vestibular Rehabilitation (VR) includes active exercises that provokes dizziness, Balance exercises and body awareness exercises in a group format.~Cognitive Behavioral Therapy (CBT) includes conversation and reflection about factors that may be a barrier to Activity and participation"
9901629|NCT02655575|Active Comparator|BI + phone calls|Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Phone Calls as follow-up at week 2 and 6 to reassure
9901630|NCT02653482|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg daily
9901631|NCT02653482|Placebo Comparator|Dapagliflozin matching placebo|Dapagliflozin matching placebo 10 mg daily
9993340|NCT01471431|Experimental|Spontaneous breathing trial|The spontaneous breathing trial will determine the extubation readiness of the subject.
9901632|NCT02651831||1A: Content Validation|"Up to 4 focus groups of 6-10 cancer patients each will be conducted each lasting approximately 90 mins. An additional 10 to 15 patients will undergo individual semi-structured interviews each lasting around 60 minutes.~10-12 expert clinicians experienced in treating patients with ICMs or managing ICM toxicities will participate in a survey, and group or individual interviews."
9901633|NCT02651831||1B: Face Validity|Patients who have been and are being treated with ICMs to complete draft questionnaire (FACT-ICM). Some patients who were involved in the first round of interviews will be re-interviewed, and interview naïve patients will also be included.
9901634|NCT02651831||2A: To measure test-retest reliability|Patients to complete FACT-ICM at at two time points separated by 5 to 14 days.
9901635|NCT02651831||2B: To confirm construct validity|To evaluate discriminative properties of FACT-ICM, scores will be compared between pre-defined groups of patients where differences are expected.
9901636|NCT02651831||2C: To determine responsiveness and MCID|"Responsiveness testing: Patients will complete FACT-ICM within a week of starting treatment, then while on treatment and within 30 days after end of treatment (EOT) with ICMs.~MCID testing: In addition to the FACT-ICM score, patients undergoing serial assessment for responsiveness will also indicate how much better or worse they are using a 5-point rating scale."
9901637|NCT02644369|Experimental|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
9901638|NCT02632409|Experimental|Nivolumab|Nivolumab dose as specified
9901639|NCT02632409|Placebo Comparator|Placebo|Placebo dose as specified
9901640|NCT02619253|Experimental|Dose Finding Cohort|Estimate the Recommended Phase 2 Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. Patients will be treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in 2 patient cohorts according to the 3 + 3 standard design (100 and 200 mg).
9901641|NCT02619253|Experimental|Expansion Cohort|Once the Expansion Test Dose is identified, the Dose Expansion Phase will be opened and the combination will be tested in patients with advanced renal cell or urothelial cell carcinoma. Forty-five patients with prior treatments will be enrolled in three expansion cohorts: 15 anti-PD1 naive renal and urothelial patients, 15 anti-PD1 resistant renal and urothelial patients (defined as patients with transient clinical response or without clinical response to prior immune-checkpoint inhibition), and 15 patients with androgen-sensitive or castration-resistant prostate cancer.
9901642|NCT02613650|Experimental|MEK162 and mFOLFIRI, all patients|
9901643|NCT02612194|Experimental|Cohort 1|c-MET high (> 50%), RON null (0-9%)
9901644|NCT02612194|Experimental|Cohort 2|c-MET + (10-100%), RON + (10-100%)
9901645|NCT02612194|Experimental|Cohort 3|c-MET null (0-9%), RON + (10-100%)
9901646|NCT02611089||Radial dysplasia patients|Recruited participants will have 2-3 small tissue biopsy samples taken during 1-2 of their planned reconstructive surgical procedures for radial dysplasia, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
9901647|NCT02611089||Control patients|Recruited participants will have 2-3 small tissue biopsy samples taken during their planned reconstructive surgery for hand trauma, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
9901648|NCT02595866|Experimental|Treatment (pembrolizumab and cART)|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients continue receiving their recommended combination antiretroviral therapy orally daily. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9993341|NCT01471431|No Intervention|Usual care|Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.
9993342|NCT01471470|Experimental|neoadjuvant|
9901649|NCT02592317|Experimental|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam [2 milligram {mg}], warfarin [10 mg], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine [30 mg]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
9901650|NCT02586207|Experimental|Single Arm|Pembrolizumab + Cisplatin + Radiation
9901651|NCT02584933|Experimental|ceritinib|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent ceritinib study at the time of the rollover.
9901652|NCT02578797|Experimental|Apalutamide|Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.
9901653|NCT02571725|Experimental|Olaparib and Tremelimumab|"Each cycle is 28 days:~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.~If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested~If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab~If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
9901654|NCT02552394|Experimental|HuJ591 Administration|6 subjects will be treated at 300 mg dose. The decision about treating subjects at the lower dose will depend upon their response. If ≥4 of 6 subjects respond at the 300 mg level, then 6 more subjects will be recruited at the 200 mg level. If ≥4 of 6 subjects respond at the 200 mg level than 6 more subjects will be recruited at the next dose level of 100 mg. If ≥ 4/6 subjects respond at this level, then 6 subjects will be recruited at the last dose level of 50 mg. At any level, if the first four consecutive subjects respond, the next two subjects will be enrolled in the same dose-level cohort and further subjects will be recruited at the next dose level. Response at every dose level is defined by conversion from an unfavorable CTC count at baseline to a favorable CTC count.
9901655|NCT02546934|Experimental|ABX, cisplatin|AP (ABX and cisplatin combination)
9901656|NCT02546934|Active Comparator|Gemcitabine, Cisplatin|GP (Gemcitabine and Cisplatin combination)
9901657|NCT02542397|Experimental|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
9901658|NCT02541968|Active Comparator|Face-to-face CBT|16 sessions of individual CBT delivered in 14 weeks.
9901659|NCT02541968|Experimental|Internet-based CBT|Internet-based CBT (ICBT) with therapist support (14 weeks).
9901660|NCT02541968|Experimental|ICBT without therapist support|Internet-based CBT without therapist support (14 weeks).
9901661|NCT02536794|Experimental|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
9998332|NCT01517269|Active Comparator|Control arm: standard diabetes education|Parents will receive standard diabetes education with a diabetes educator
9998333|NCT01517308|Active Comparator|Control Arm 24 weeks|PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
9901662|NCT02531516|Experimental|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
9901663|NCT02531516|Active Comparator|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
9901664|NCT02522468|Experimental|Radioactive Seed Localization|Radioactive Seeds
9901665|NCT02522468|Active Comparator|Wire Localization|Wire
9901666|NCT02519777|Placebo Comparator|Arm A: Placebo MVC and placebo DTG|In addition to their existing ART regimens, participants in Arm A received placebo for MVC and placebo for DTG.
9901667|NCT02519777|Experimental|Arm B: DTG and placebo MVC|In addition to their existing ART regimens, participants in Arm B received DTG and placebo for MVC.
9901668|NCT02519777|Experimental|Arm C: MVC and DTG|In addition to their existing ART regimens, participants in Arm C received MVC and DTG
9901669|NCT02519452|Experimental|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
9901670|NCT02519452|Experimental|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
9901671|NCT02519452|Experimental|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
9901672|NCT02519452|Experimental|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
9901673|NCT02519452|Experimental|Part 3: Dara-CF 1800 mg|Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
9901674|NCT02514525|Other|CryoBalloon Ablation System|Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
9901675|NCT02509039|Experimental|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
9901676|NCT02504697||Longitudinal Cohort|For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer > 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood and images will be collected.
9901677|NCT02503774|Experimental|Monotherapy|MEDI9447 (oleclumab) only
9901678|NCT02503774|Experimental|Combination|MEDI9447 (oleclumab) and MEDI4736 (durvalumab)
9901679|NCT02496585|Experimental|Nintedanib + Prednisone|The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
9901680|NCT02496585|Experimental|Placebo + Prednisone|Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
9901681|NCT02489318|Experimental|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
9901682|NCT02489318|Experimental|Placebo plus ADT|Participants will receive matching Placebo with ADT.
9998334|NCT01517308|Experimental|Active arm (48 weeks)|PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
9998335|NCT01517321|Experimental|E|
9901683|NCT02486965|Experimental|training group|"The training program consists of three sessions of 45 minutes of physical activity per week for 2 years. During the first 6-9 months, two individual workouts, supervised by a physiotherapist and a session in Living.~Depending on the capacity and exercise tolerance of the patient, patients realize the second phase of training until 2 years of the study: three exercise sessions from 45 to 60 minutes per week of which group session led by a professor of Adapted Physical Activity (APA) and 2 autonomous sessions.~Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms"
9901684|NCT02486965|Placebo Comparator|control group|A training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower than that of the training group
9998336|NCT01517321|Placebo Comparator|P|
9993343|NCT01471483||patient will receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
9993344|NCT01471483||patients will not receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
9993345|NCT01471496|Experimental|prophylactic injection therapy group|In addition to medical therapy which included 2x 30 mg Pantoprazole and intravenous fluids this group of the patients recieved injection therapy.
9993346|NCT01471496|No Intervention|control group|This group of the patients recieved medical therapy only.
9993347|NCT01471509|Placebo Comparator|Control|240 ml water
9993348|NCT01471509|Active Comparator|glucose|50 g glucose
9993349|NCT01471509|Active Comparator|Amino acid|1 mmol amino acid/kg lean body mass
9993350|NCT01471509|Active Comparator|amino acid plus glucose|50 g glucose plus 1 mmol amino acid/kg lean body mass
9993351|NCT01471535|Experimental|peginterferon alpha 2a|the inactive chronic HBsAg carriers were treated with peginterferon alpha 2a for 72 weeks and followed for 24 weeks.
9993352|NCT01471548|Experimental|TKI258|dose escalation
9993353|NCT01471587||Patients with COPD|
9993354|NCT01471600|No Intervention|No intervention|Group overnight fasting
9993355|NCT01471600|Active Comparator|Group drink|Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
9993356|NCT01471613|Experimental|Group C - Cord blood cell|Conventional treatment, cord blood cell transplant and placebo
9993357|NCT01471613|Placebo Comparator|Group A - Control|Conventional treatment and placebo
9993358|NCT01471613|Experimental|Group B - Lithium Carbonate|Conventional treatment and lithium carbonate
9993359|NCT01471613|Experimental|Group D - Combination Therapy|Conventional treatment, cell transplant and 6-weeks course of lithium carbonate
9997827|NCT01512329|Experimental|pacing|The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
9997828|NCT01512329|Active Comparator|relaxation|Relaxation therapy (3 one-on-one sessions weekly for 3 consecutive weeks) comprised of education about the role of stress in MS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
9997829|NCT01512342|Experimental|Pacing|The pacing self-management program focussed on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), CFS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
9997830|NCT01512342|Active Comparator|relaxation therapy|Relaxation therapy comprised of education about the role of stress in CFS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
9997831|NCT01512355|Experimental|dexmedetomidine|
9997832|NCT01512355|Placebo Comparator|placebo|
9997833|NCT01512381|Experimental|CRT|
9997834|NCT01512381|Active Comparator|pacemaker|
9997835|NCT01512394|Active Comparator|Standard bowel prep|Standard bowel prep
9997836|NCT01512394|Experimental|No bowel prep|No bowel prep
9997837|NCT01512420||Cohort|
9997838|NCT01512433|Active Comparator|True acupuncture|True acupuncture was a real acupuncture which had been used in conventional Chinese medicine practice
9997839|NCT01512433|Sham Comparator|Sham acupuncture|Sham acupuncture was a procedure which mimicked the real acupuncture procedure.
9997840|NCT01512459|Experimental|Venlafaxine MR Capsules 150|Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
9997841|NCT01512459|Active Comparator|Effexor XR 150 mg Capsules|Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
9997842|NCT01512472|Active Comparator|10 month degarelix therapy|
9997843|NCT01512472|Active Comparator|4 month degarelix therapy arm|
9997844|NCT01512485|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
9997845|NCT01512485|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
9997846|NCT01512498||Patients who underwent allogeneic HSCT|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are alive.
9997847|NCT01512511|Experimental|nitrous oxide|use nitrous oxide for pneumoperitoneum creation
9997848|NCT01512511|Placebo Comparator|carbon dioxide|use carbon dioxide for pneumoperitoneum creation
9997849|NCT01512524|Other|Patients With Traumatic Brain Injury|Study of the association between quality of life and MRI scans and endocrinology analysis (quantification of Growth Hormone) 18 months post-trauma.
9993360|NCT01471652|Active Comparator|Nutraceuticals|Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.
9993361|NCT01471652|Placebo Comparator|Placebo|
9993362|NCT01471665|Experimental|GSK2190915 100mg|This is a crossover study so patients will receive 100mg of GSK2190915 once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the placebo arm of the study.
9993363|NCT01471665|Placebo Comparator|Placebo|This is a crossover study so patients will receive placebo once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the GSK2190915 100mg arm of the study.
9993364|NCT01471678|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
9993365|NCT01471678|Experimental|Dutasteride (0.5mg)|Commercial formulation of dutasteride
9993366|NCT01471678|Experimental|Harnal-D Tablets and Harnal capsules|Commercial formulations of Harnal-D Tablets and Harnal Capsules both comprising 0.2mg tamsulosin HCl
9993367|NCT01471704|Experimental|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
9517569|NCT03305237|Experimental|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
9993368|NCT01471704|Active Comparator|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
9993369|NCT01471704|Active Comparator|INX-08189 50 mg & verapamil HCLER 240 mg|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
9993370|NCT01471717|Experimental|C 1:INX-08189 50 mg qd X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
9993371|NCT01471717|Active Comparator|C1: INX-08189 / Victrelis 800 mg TID X 3 days|Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days
9993372|NCT01471717|Active Comparator|C2: Victrelis 800 mg TID x 3 days|Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days
9993373|NCT01471717|Active Comparator|C 2:Victrelis 800 mg TID with INX-08189 50 mg QD|Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days
9993374|NCT01471717|Placebo Comparator|C1: Placebo with Victrelis 800 mg|Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days
9993375|NCT01471717|Placebo Comparator|C 2: Victrelis 800 mg with Placebo|Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days
9993376|NCT01471730|Placebo Comparator|Saline solution|
9993377|NCT01471730|Active Comparator|Fibrinogen|
9993378|NCT01471730|Active Comparator|Prothrombin complex|
9993379|NCT01471743|Experimental|Impact Advance Recovery (R)|3 supplements per day for 5 days pre-operatively
9993380|NCT01471743|Active Comparator|Standard Supplement|3 supplement per day for 5 days pre-operatively
9901685|NCT02484443|Experimental|Treatment (sargramostim and dinutuximab)|Patients receive sargramostim SC QD on days 1-14 and dinutuximab IV over 10 hours on days 4-7 (dinutuximab infusion may be extended up to a total of 20 hours per day for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
9901686|NCT02463500||DFU with/without osteomyelitis|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.
9901687|NCT02462460||Patients with BRCA mutation|The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
9901688|NCT02441491|Experimental|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, will be given by vein once every day to try to help your blood cells grow faster."
10212829|NCT04959422|Experimental|Active scheduling|Children who fail instrument vision screens will be scheduled at a community vision specialist office before departure from clinic and all no shows at the vision specialist office will be tracked and rescheduled.
10212830|NCT04957732|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, Standard of Care (SoC), which was normal saline, was used.
10212831|NCT04957732|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
10212832|NCT04956757|Experimental|Intervention Group|"exercise program consists of progressive scapula retraction exercises will be applied three times a week total 24 sessions.~Home exercise program will also advised two times a day."
9901693|NCT02408861|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third cycle of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth cycle of nivolumab. Treatment repeats every 14 days for up to 46 cycles of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.
9901694|NCT02408549|Experimental|Lacosamide|"Start dose~SP982 completers at V1:~LCM 10 mg/kg/day for pediatric subjects weighing <30 kg~LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to <50 kg~LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~SP982 Baseline failures at V1:~LCM 2 mg/kg/day for pediatric subjects weighing <50 kg~LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~Oral solution (pediatric subjects <50 kg):~Minimum LCM dose: 4 mg/kg/day~Maximum LCM dose: 12 mg/kg/day~Tablets (pediatric subjects ≥50kg):~Minimum LCM dose: 200 mg/day~Minimum LCM dose: 600 mg/day~Tablets (adult subjects):~Minimum LCM dose: 200 mg/day~Maximum LCM dose: 800 mg/day"
9901695|NCT02395666|Experimental|DFMO twice daily|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
9901696|NCT02392455||A|
9901697|NCT02390518|Experimental|Stereotactic Radiosurgery|
9901698|NCT02387255||Normal Volunteers|60 normal volunteers will be recruited. Each volunteer will undergo a single MRE scan (with Resoundant driver System ) of their abdominal aorta.
9901699|NCT02387255||Patients with AAA|Fifty to sixty five patients with AAA will be recruited. These patients will undergo MRE (with Resoundant driver system) of their AAA every six months for three years, or until the study ends or until the time of surgical repair or death due to rupture of AAA or other causes.
9901700|NCT02387255||Open Surgical Repair Patients|Fifty to sixty five patients patients undergoing open surgical repair will be recruited and undergo MRE (with Resoundant driver system) prior to surgery
9933380|NCT05351814|Active Comparator|Control group|Control group; traditional patellofemoral pain syndrome exercises; isometric exercises 3 sets of 10 repetitions in one session, balance exercise 30/45 sec, one leg balance exercise 45/60 sec , stretching exercises 4 sets 5 repetitions 20 sec duration, off kinetic chain (CHC) AND open kinetic chain (ACZ) exercises were planned as 3 sets for 4 weeks and 3 days a week.
9993381|NCT01471756|Experimental|iSnare with Gonak solution|
9993382|NCT01471756|Experimental|Snaremaster braided snare with Gonak solution|
9993383|NCT01471756|Experimental|iSnare with saline solution|
10212833|NCT04956757|No Intervention|Control Group|Control group will not perform scapula retraction exercises. AHD values of the control group will be compared to intervention groups both retracted and non-retracted conditions.
10212834|NCT04952805|Experimental|Interventional Arm _400 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 400 mg.
10212835|NCT04952805|Experimental|Interventional Arm _100 mg|To all the patients enrolled is admistrated with single dose of MAD0004J08 100 mg.
10212836|NCT04952805|Placebo Comparator|Placebo Arm|To all the patients enrolled is admistrated with single dose of placebo
10212837|NCT04951336|Experimental|Mushrooms|Drug: FoTv The dosage of FoTv is 8 capsules three times a day for 4 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary. Should swallowing capsules be an issue, they can be opened and dispensed into water or juice for easy ingestion.
9901701|NCT02359318|Experimental|Resin infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the no infiltration and de-bonding arm. The teeth that are included in this intervention arm are treated by resin infiltration using Icon (DMG, Germany) according to the manufacturers´ instruction. This is followed by bonding of new brackets (Gemini metal brackets, 3M Unitek). These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
9901702|NCT02359318|Placebo Comparator|No infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the resin infiltration and de-bonding arm. The teeth that are included in this intervention arm are left untreated new brackets (Gemini metal brackets, 3M Unitek) are bonded. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
9901703|NCT02359318|Other|Control and de-bonding|"Patients with brackets and without white spots are included in this group. After removal of the old brackets, new brackets (Gemini metal brackets, 3M Unitek) are bonded again. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
9901704|NCT02357810|Experimental|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9901705|NCT02343549|Experimental|Planned RT + TMZ + BEV + NovoTTF100A Device|Best standard of care radiation therapy (RT, 2 Gy given daily 5 days per week), temozolomide (TMZ, 75 mg/m2 administered daily), and bevacizumab (BEV, 10 mg/kg administered every 2 weeks as an IV infusion) for 6 weeks. After completion of chemoradiation, NovoTTF100A system was initiated, to be worn on average 18 hours or more a day for up to 12 months. The patients also continued with maintenance TMZ/BEV.
9901706|NCT02339233|Experimental|Epidural Stimulator|Eligible participants will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord
9901707|NCT02329847|Experimental|Cohort A1|Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
9901708|NCT02329847|Experimental|Cohort A2|Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
9901709|NCT02329847|Experimental|Cohort B1|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
9901710|NCT02329847|Experimental|Cohort B2|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
9993384|NCT01471756|Experimental|Snaremaster braided snare with saline solution|
9993385|NCT01471769|Experimental|pain management video|Experimental
9901711|NCT02329847|Experimental|Cohort B3|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
9901712|NCT02329847|Experimental|Cohort B4|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
9901713|NCT02328573|Experimental|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
9901714|NCT02328573|No Intervention|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
9901715|NCT02328105|Experimental|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
9901716|NCT02327195|Experimental|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
9901717|NCT02327195|Placebo Comparator|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
9901718|NCT02326311|Active Comparator|Fixed INTERIM TKI|"Intervention: fixed intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)"
9901719|NCT02326311|Experimental|Progressive INTERIM TKI|"Intervention: progressive intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)"
9901720|NCT02325427|Experimental|real tDCS|Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
9901721|NCT02325427|Sham Comparator|sham tDCS|Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
9901722|NCT02325427|No Intervention|no stimulation|Subjects will not received any intervention.
9901723|NCT02318355|No Intervention|Control|Control group that receives no intravenous fluid after blood donation
9901724|NCT02318355|Experimental|Lactated Ringers|Experimental group that receives two liters lactated ringers after blood donation.
9901725|NCT02318355|Experimental|Normal Saline|Experimental group that receives two liters normal saline after blood donation.
9901726|NCT02316106|Experimental|Arm A (Long Intense)|
9901727|NCT02316106|Experimental|Arm B (Intermediate)|
9901728|NCT02316106|Experimental|Arm C (Short Intense)|
9901729|NCT02315066|Experimental|PF-04518600|OX40 agonist
9901730|NCT02315066|Experimental|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
9901731|NCT02312960|Other|Arm 1|The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.
9901732|NCT02288637|Experimental|Conventional Olyset LLIN|High coverage (>80% access) of conventional Olyset LLIN The arm is the standard of care from the National Malaria Control Program
9901733|NCT02288637|Experimental|Olyset Plus LLIN|High coverage (>80% access) of Olyset Plus LLIN
9901734|NCT02288637|Experimental|Conventional Olyset LLIN and IRS|High coverage (>80% access) of conventional Olyset LLIN and high coverage IRS (>80% of the household sprayed) with pirimiphos methyl CS
9901735|NCT02288637|Experimental|Olyset Plus LLIN and IRS|High coverage (>80% access) of Olyset Plus LLIN and high coverage Indoor Residual Spraying (>80% of the household sprayed) with pirimiphos methyl CS
9993386|NCT01471769|Placebo Comparator|falls prevention video|placebo
9993387|NCT01471795||Study Population|150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
9993388|NCT01471808|Active Comparator|CSII|continuous subcutaneous insulin infusion
9993389|NCT01471808|Active Comparator|Metformin & Pioglitazone|CSII combined with metformin and pioglitazone
9993390|NCT01471808|Active Comparator|Sitagliptin|CSII combined with sitagliptin 100mg/d
9993391|NCT01471821|Experimental|simplification|Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
9993392|NCT01471821|Active Comparator|Continue with current treatment|
9993393|NCT01471847|Experimental|BEZ235 + Trastuzumab (Phase l /Phase ll)|"Phase l: Eligible patients will receive increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly trastuzumab at a fixed dose of 2 mg/kg. Treatment will be organized into cycles of 28 days.~Phase ll: Eligible patients will receive weekly trastuzumab (2 mg/kg) + oral BEZ235 on a continuous twice daily (BID schedule) at the MTD or RP2D.~Treatment will be organized into cycles of 21 days."
9993394|NCT01471847|Active Comparator|Lapatinib + Capecitabine (Phase II)|Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
9993395|NCT01471860|Experimental|Device and Medical Management|"Medical Management, to be determined by the participant's physician, described as:~Optimal pharmacological therapy: Prescribed to a beta blocker, a diuretic, and an ACE (Angiotensin-converting-enzyme) inhibitor or ARB (Angiotensin Receptor Blocker) unless contraindicated or not tolerated. These drugs must be used in a manner consistent with their labeling.~Stable pharmacological therapy: No more than a 50% increase or a 50% decrease of the dosage of any one medication, and post titration of all heart failure medications.~Participants should remain on their prescribed heart failure medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. Additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study."
9993396|NCT01471873||Keratoconus Group (KG)|Keratoconus group (KG) included patients with progressive keratoconus.
9993397|NCT01471873||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
9993398|NCT01471886|Active Comparator|Naproxen|Every 8 hours for 4 days.
9993399|NCT01471886|Experimental|Ketorolac Tromethamine|Every 8 hours for 4 days
9993400|NCT01471899|Active Comparator|Naproxen|2 tablets every 8 hours for 4 days.
9993401|NCT01471899|Experimental|Ketorolac Tromethamine|10 drops every 8 hours for 4 days
9993402|NCT01471925|Experimental|Esomeprazole (40mg) + Sodium Bicarbonate (721mg)|
9993403|NCT01471925|Active Comparator|Nexium®|
9993404|NCT01471938||Caucasians|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
9517570|NCT03305237|Experimental|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
9517571|NCT03305224|Other|Ra-223 + Enzalutamide|
9993405|NCT01471938||Afro Americans|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
9993406|NCT01471938||East and Southeast Asian|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
9993407|NCT01471938||Hispanics|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
9993408|NCT01471951|Experimental|single embryo transfer|
9993409|NCT01471964|Experimental|MLN8237 and Erlotinib|"Phase I Erlotinib 100 mg PO daily* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).~Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I."
9993410|NCT01471977|Experimental|education, counselling, default tracer|
9993411|NCT01471990|Active Comparator|PACAP38|
9993412|NCT01471990|Active Comparator|VIP|
9993413|NCT01472003|Experimental|ABT-806 Arm|Subjects with advanced solid tumors
9993414|NCT01472003|Experimental|ABT-806i Arm|Subjects with advanced solid tumors
9993415|NCT01472016|Experimental|Cohort A|ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
9993416|NCT01472016|Experimental|Cohort B|ABT-700 plus docetaxel.
9993417|NCT01472016|Experimental|Cohort C|ABT-700 plus FOLFIRI/cetuximab
9993418|NCT01472016|Experimental|Cohort D|ABT-700 plus erlotinib
9993419|NCT01472029|Experimental|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|
9993420|NCT01472042||Sports induced concussion|Exposure to sports induced concussion
9993421|NCT01472042||Routine Athletic Exertion|Exposure to routine athletic exertion (non-concussion control)
9993422|NCT01472042||Other Non-Penetrating Trauma to the Head|Exposure to other non-penetrating trauma to the head that is witnessed or self-reported
9993423|NCT01472055|Experimental|Fludarabine|Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients
9993424|NCT01472068|Experimental|Inko RS device|30 minutes of treatment with the Inko RS device, five days each week, for 12 weeks.
9993425|NCT01472094||Patients|All patients 65 years old with Stage I to III breast cancer who are beginning adjuvant or neo-adjuvant chemotherapy.
9993426|NCT01472120||P and C|"P: NAFLD patients~C: Healthy controls"
9901736|NCT02277444|Experimental|Golimumab + Methotrexate|Participants will receive 80 milligram per meter square (mg/m^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m^2 per week for participants with BSA less than [<] 1.67 meter square (m^2), or minimum of 15 mg/week for participants with BSA greater than or equal to [>=] 1.67 m^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m^2 every 8 weeks after completion of the Week 252 assessments.
9901737|NCT02265367|Experimental|Levomilnacipran|In the first three week period levomilnacipran is evaluated whereas in the second three week period placebo is evaluated
9901738|NCT02265367|Experimental|Placebo|In the first three week period placebo is evaluated whereas in the second three week period levomilnacipran is evaluated
9901739|NCT02261792|Active Comparator|A : 24 hours bed rest|24 hours bed rest
9901740|NCT02261792|Experimental|B : 24 hours Trendelenburg position|24 hours Trendelenburg position
9901741|NCT02257736|Experimental|Group 1: AAP and apalutamide|Participants will receive apalutamide 240 milligram (mg) (4*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
9901742|NCT02257736|Placebo Comparator|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
9901743|NCT02256631|Experimental|Dose Group 1|Infants in Dose Group 1 received a single VRC01 20 mg/kg injection less than 72 hours after birth.
9901744|NCT02256631|Experimental|Dose Group 2|Infants in Dose Group 2 received a single VRC01 40 mg/kg injection less than 72 hours after birth.
9901745|NCT02256631|Experimental|Dose Group 3|Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
9901746|NCT02256631|Experimental|Dose Group 4, Cohort 1|Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
9901747|NCT02256631|Experimental|Dose Group 4, Cohort 2|Infants in Cohort 2 received an initial VRC01LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC01LS was administered at Week 12 if an infant was still breastfeeding.
9901748|NCT02256631|Experimental|Dose Group 5, Cohort 1|Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
9901749|NCT02256631|Experimental|Dose Group 5, Cohort 2|Infants in Cohort 2 received an initial VRC07-523LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC07-523LS was administered at Week 12 if an infant was still breastfeeding.
9993427|NCT01472133||Young Healthy Volunteers|Healthy volunteers under the age of 40
9993428|NCT01472133||Older healthy volunteers|Healthy volunteers over the age of 70
9993429|NCT01472133||Patients with atrial fibrillation|Patients with permanent AF
9997850|NCT01512537|Active Comparator|UVB|UVB exposed group
9901750|NCT02252172|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
9901751|NCT02252172|Active Comparator|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
9901752|NCT02234388||Registry Participants|All patients who participate in the UCTD Registry will be put into this cohort and observed over approximately 3 years.
9933381|NCT05351814|Experimental|Core Stability group|Core stability group; In addition to traditional patellofemoral pain syndrome exercises; hip muscle strengthening exercises are 3 sets of 10 repetitions in each session, and (core) stabilization exercises are 1st and 2nd weeks 2 sets 15 repetitions 3rd and 4th weeks 2 sets 5 repetition was planned for 4 weeks and 3 days a week.
9933382|NCT05351801|Active Comparator|THC (Dronabinol)|Target dose of 10mg per day.
9933383|NCT05351801|Active Comparator|CBD (Epidolex)|Target dose of 800 mg per day.
9933384|NCT05351801|Active Comparator|THC + CBD (Nabiximols)|Target dose of 10.8 mg / 10 mg per day.
9933385|NCT05351801|Placebo Comparator|Placebo|Identical in appearance to the three active comparators.
9933386|NCT05351788|Experimental|SKB264+KL-A167|Participants received SKB264 followed by KL-A167
9933387|NCT05351788|Experimental|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
9933388|NCT05351788|Experimental|SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation)|Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin
9933389|NCT05351775|Experimental|Interventional AF detection arm|The patients will be monitored during index hospitalization according normal practice and additionally with a bed sensor, smartphone app, and patch-holter ECG. In addition, patients will have PDL monitoring device during hospitalization. During the index hospitalization, patients will download the CardioSignal app to their own smartphone or if patient does not have a smartphone one can be provided to the patient by the study group. Patients are asked to do the first recordings at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period. When discharged home, the study subject will have the bed sensor for home-based use up to 3 months. If the average pulse rate in the bed sensor recordings have increased with 20% or the device has recorded rhythm irregularity lasting over 5 minutes (could be longer to reduce false alarms), a 12-lead ECG will be taken, and in the case of a normal ECG, a 7-day Holter monitoring is performed.
9933390|NCT05351775|No Intervention|Standard of care treatment arm|Patient will be followed as in routine clinical practice.
9933391|NCT05351762|Experimental|study arm|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
9933392|NCT05351749|Experimental|New-prescription Alert / Existing-prescription notification to prescriber|
9933393|NCT05351749|Experimental|New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber|
9933394|NCT05351749|Experimental|New-prescription Alert/ Existing-prescription notification to pharmacist|
9933395|NCT05351749|Experimental|New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist|
9933396|NCT05351736|Experimental|Recent-onset schizophrenia|Patients diagnosed with schizophrenia with onset in the last 5 years that will be started on lurasidone or that have been on treatment with lurasidone for less than two weeks at the time of enrollment.
9933397|NCT05351723|Experimental|Intervention group|Intervention group: each session comprises (1) 50 min of physical exercise, (2) 20 min of break time or education on dementia and lifestyle habits, and (3) 50 min of cognitive training.
9933398|NCT05351723|Other|Control group|Control group: education on dementia and lifestyle habits.
9933399|NCT05351710|Experimental|Exposure-Based Treatment for Perfectionism|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 3 days at home (5 treatment sessions total).
9993430|NCT01472133||Patients with a pacemaker|Patients who have an implanted pacemaker that is continually pacing
9901753|NCT02195479|Active Comparator|Treatment Arm A (VMP Alone)|Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
9901754|NCT02195479|Experimental|Treatment Arm B (D-VMP)|Participants will receive velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
9901755|NCT02188264|Experimental|Treatment (selumetinib and cyclosporine)|Patients receive selumetinib PO BID on day -7 of course 1 and then on days 1-28 (one dose on day 1 only). Patients also receive cyclosporine PO BID on day -3 of course 1 and then on days 1-28 (one dose on day 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9901756|NCT02173613|Experimental|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
9901757|NCT02173613|No Intervention|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
9901758|NCT02173379|Experimental|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
9901759|NCT02173379|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
9901760|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
9901761|NCT02147418||Group 1: HPV-positive Cancer|Oropharyngeal cancer patients testing positive for human papillomavirus (HPV)
9901762|NCT02147418||Group 2: HPV-positive Cancer|Oropharyngeal cancer patients who test positive for human papillomavirus (HPV)
9901763|NCT02147418||Group 3: Healthy Controls|Patients with benign conditions
9901764|NCT02136134|Experimental|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
9901765|NCT02136134|Active Comparator|VELCADE+dexamethasone|VELCADE and dexamethasone.
9901766|NCT02129348|Active Comparator|Lithium Treatment Group|"The patient will be started on lithium 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on lithium blood level. Blood will be drawn at each study visit. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
9901767|NCT02129348|Placebo Comparator|Placebo Group|"The patient will be started on placebo 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on sham lithium blood level. Blood will be drawn for sham lithium levels at weeks 2, 4, 6, 8, and 12. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
9901768|NCT02123758|Experimental|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
9901769|NCT02123758|Experimental|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
9901770|NCT02098876|Active Comparator|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
9901771|NCT02098876|Active Comparator|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
9901772|NCT02080260|Experimental|Single Arm|Oral Regorafenib
9993431|NCT01472133||Patients with restricted chest movement|Patients whose chest expansion is less than 2.5cm
10212838|NCT04951336|Placebo Comparator|Placebo|Placebo: organic brown rice The dosage of Placebo is 8 capsules three times a day for 4 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary. Should swallowing capsules be an issue, they can be opened and dispensed into water or juice for easy ingestion.
10212839|NCT04949737||Helicobacter Pylori detection|Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).
10212840|NCT04946877||case group|100 ADHD patients; will be taken from outpatient clinic of child and adolescence psychiatry of Assiut university hospitals.
9901773|NCT02076009|Experimental|Daratumumab + lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
9901774|NCT02076009|Active Comparator|Lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
9901775|NCT02069925|Experimental|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
9901776|NCT02069925|Active Comparator|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
9901777|NCT02051933|Active Comparator|Botox|"Botox: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
9901778|NCT02051933|Placebo Comparator|Placebo|"Placebo: At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
9901779|NCT02047929|Active Comparator|Facilitator-Led|This approach to dissemination allows clinics some freedom to tailor the Asthma Shared Decision Making (SDM) Toolkit and training process for their specific environment and patient population while maintaining fidelity of certain key elements that are felt to be essential for success. The expertise of the trained Practice Facilitator will help guide the process of implementation at the practice level.
9901780|NCT02047929|Active Comparator|Traditional|"The most commonly used dissemination technique is active diffusion, which includes didactic presentations, academic detailing, exposure to journal publications and subject matter experts, and educational material distribution. We have defined this type of dissemination, traditional dissemination. For the purpose of this study, practices randomized to traditional dissemination will receive a lunchtime presentation by a physician champion / subject matter expert on shared decision making. The presentation will give an overview of the Asthma Shared Decision Making (SDM) Toolkit, access to the internet link with additional information, and a copy of all printed materials associated with the Toolkit."
9901781|NCT02047929|No Intervention|Control|A third group will be randomized into an arm with no formal dissemination. This arm will receive information only through passive exposure to the concepts of shared decision making. This would include introduction to the SDM concepts through the media, conferences, or social networks. Having this control in place will allow the research team to isolate the effect of both the FLOW approach and the traditional approach to dissemination.
9901782|NCT02043587|Experimental|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4~1A-C repeat x1(2A-C) then 3rd Course B (3B)~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint."
9901783|NCT02028559|Experimental|Treatment with Ultrasonic Propulsion|Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
9901784|NCT02028559|No Intervention|Control|Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
9901785|NCT01999569|No Intervention|Control|Control cycle. No intervention.
9901786|NCT01999569|Experimental|Letrozole|5mg daily
9901787|NCT01999556||Patient|Specimen Collection
9901788|NCT01999556||Relative|Specimen Collection
9901789|NCT01998971|Experimental|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
9901790|NCT01998971|Experimental|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
9901791|NCT01998971|Experimental|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
9901792|NCT01998971|Experimental|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
9901793|NCT01998971|Experimental|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
9901794|NCT01998971|Experimental|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
9901795|NCT01974440|Placebo Comparator|Treatment Arm A|Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab [BR] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for 6 cycles + placebo.
9901796|NCT01974440|Experimental|Treatment Arm B|Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).
9901797|NCT01972867|Experimental|NanoKnife Procedure|The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
9901798|NCT01969812|Experimental|Evie Slow-Release Insemination Device|Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
9901799|NCT01969812|Active Comparator|Traditional Intrauterine Insemination|Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
9901800|NCT01959464|Experimental|Crinone vaginal progesterone gel|"Crinone is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system containing a water swellable but insoluble polymer, polycarbophil. Crinone 8% is formulated to provide a long-acting vaginal retention, and is prescribed daily. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg of progesterone. The reported time to maximum progesterone concentration is 6.8 +/- 3.3 hours with use of a single dose of Crinone 8%. Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes.~On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream."
9901801|NCT01959464|Placebo Comparator|Placebo vaginal gel|The couple will be given a prefilled applicator containing either Crinone gel (progesterone) or placebo vaginal gel, data collection sheets and laboratory requisitions. On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream.
9901802|NCT01946204|Experimental|Treatment Arm A: Apalutamide|
9901803|NCT01946204|Placebo Comparator|Treatment Arm B: Placebo|
9901804|NCT01937052||Breast cancer patients|All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista®), Anastrozole (Arimidex®), Letrozole (Femara®) or Exemestane (Aromasin®) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires.
9901805|NCT01937039||Breast cancer patients|Participants have a known diagnosis of breast cancer and are receiving a breast cancer evaluation and/or treatment, who agree to sample collection, access, and follow-up as part of the repository.
9901806|NCT01937039||Benign breast disease|Participants have benign breast disease and are receiving a diagnostic procedure and/or evaluation, who agree to sample collection, access, and follow-up as part of the repository.
9901807|NCT01937039||Healthy volunteer|Participants have no known diagnosis of breast disease or abnormality and are undergoing routine screening or diagnostic breast imaging procedures and/or other clinical evaluation, who agree to sample collection, access, and follow-up as part of the repository.
9901808|NCT01921166|Active Comparator|clomiphene plus gonadotropins|clomiphene plus gonadotropins
9901809|NCT01921166|Active Comparator|Leuprolide flare|Leuprolide flare
9901810|NCT01900574|Experimental|Golimumab|
9901811|NCT01886963|Active Comparator|Control - Blinded use of SPY Elite|Group A will consist of intraoperative abdominal wall imaging prior to incision, followed by ventral hernia repair with subcutaneous advancement flaps without viewing the imaging contained within the Spy Elite system. A digital photograph will be taken before and immediately after initial incision, as well as immediately prior to and after closure. The patient will have digital photographs of the surgical wound taken by the surgical team daily until discharge, and on follow-up visits at one week, two weeks, four weeks and twelve weeks. After twenty patients have completed phase I, the surgical team will be unblinded to Spy Elite imaging. The Spy Elite imaging and all digital photographs of all patients will be reviewed.
9997851|NCT01512537|Active Comparator|Oral vitamin D tablet|Vitamin D supplementation
9901812|NCT01886963|Experimental|SPY - Unblinded Use of SPY Elite|Group B will have incision and advancement flap performed based on assessment of blood supply using the Spy Elite system, as well as potential flap revision if portions of the flap appear under-perfused in the pre-closure imaging. Patients will be blinded to whether or not their intraoperative Spy Elite imaging was used for operative planning. All patients will have digital photographs of the surgical wound taken by a blinded member of the surgical team daily until discharge, and on follow-up visits at one to two weeks, four weeks, and 12 weeks post-operatively. Digital photographs will be reviewed by a blinded surgeon, who will assess the wound for complications.
9901813|NCT01879085|Experimental|Combination therapy|Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9
9901814|NCT01845441|Experimental|Dexmedetomidine arm|Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR > 80 and BP > 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age > 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.
9901815|NCT01845441|Active Comparator|Control arm|Our usual standard of care is to attempt the intervention without sedation. As per attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be used to control aggressive patient movement that adversely affects the technical capacity of the procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.
9901816|NCT01821833|Experimental|Arm I (Omega-3 fatty acid)|"Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
9901817|NCT01821833|Placebo Comparator|Arm II (placebo)|"Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
9901818|NCT01804686|Experimental|Ibrutinib|
9901819|NCT01802281|Active Comparator|Hysteropexy|Uphold® LITE
9901820|NCT01802281|Active Comparator|Hysterectomy and USLS|Vaginal hysterectomy and uterosacral ligament suspension (USLS)
9901821|NCT01798173|Experimental|Cases: cirrhotic patients with hepatocellular carcinoma|
9901822|NCT01798173|Active Comparator|Controls: cirrhotic patients without hepatocellular carcinoma|
9901823|NCT01792687|Experimental|Treatment|ARN-509 when combined with the approved dose of abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily).
9901824|NCT01776840|Placebo Comparator|Treatment Arm A|
9901825|NCT01776840|Experimental|Treatment Arm B|
9901826|NCT01774253|Experimental|Vismodegib|Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated.
9901827|NCT01757730||Altered Stiffness|Tissue stiffness will be evaluated in subjects those with disease conditions where stiffness changes from normal. These studies will be repeated for reproducibility.
9901828|NCT01757730||Healthy Volunteers|Tissue stiffness will be evaluated in normal subjects to determine the normal values. These studies will be repeated for reproducibility.
9901829|NCT01736618||S-ICD System Implant Attempt|
10212841|NCT04946877||control group|100 normal children; they will be selected from neurology clinic complaining from minor neurological complaint e.g : headache, will match with the case group for age, sex and educational level.
10212842|NCT04946032|Active Comparator|4 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 4 cm.
10212843|NCT04946032|Active Comparator|5 cm epidural catheter|The epidural catheter will be thread into the epidural space at a length of 5 cm.
10212844|NCT04940208||post COVID-19 ICU survivors|Patients hospitalized to the ICU in the context of severe COVID-19 and discharged alive during the first French COVID-19 pandemic wave
9901834|NCT01666145|Experimental|Intraoperative Imaging|Laparoscopic microwave ablation surgery utilizing the Advanced Image Guidance system for needle placement.
9901835|NCT01653093|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
9901836|NCT01653080|Experimental|Dynamic contrast-enhanced MRI|Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
9901837|NCT01649388|Experimental|FCR001|Recipients 3-12 months post-living kidney transplantation undergo non-myeloablative conditioning followed by infusion of an enriched hematopoietic stem cell product derived from the same living donor's peripheral blood stem cells
9901838|NCT01615029|Experimental|Daratumumab|Participants will receive daratumumab along with Lenalidomide and dexamethasone.
9901839|NCT01515462|Experimental|OTL-103 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
9933400|NCT05351710|Active Comparator|Stress Management Condition|This arm consists of a 2-week, computerized, stress-management condition in which participants watch videos of health habits (e.g., nutrition, exercise, sleep) and relaxation videos. These sessions are completed every 3 days at home (5 sessions total).
10212845|NCT04939415|Experimental|modified Qing Fei Pei Du Tang|encapsulated modified Qing Fei Pai Du Tang
10212846|NCT04939415|Placebo Comparator|Placebo|Organic brown rice
10212847|NCT04938167|No Intervention|Standard arm|target preductal SpO2 - 91 to 95%
10212848|NCT04938167|Experimental|Intervention arm|target preductal SpO2 - 95 to 99%
10212849|NCT04933552||Siponimod-Exposed|Pregnant women with MS exposed to siponimod during pregnancy
10212850|NCT04933552||Disease-Matched Comparison|Pregnant women with MS not exposed to siponimod during pregnancy
9901840|NCT01505608|Active Comparator|Arm A- Temozolomide and Irinotecan|"Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.~Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover."
9901841|NCT01505608|Experimental|Arm B- Temozolomide/Irinotecan + TPI 287|"Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287~Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.~Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle."
9901842|NCT01483820|Experimental|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
9901843|NCT01412762||patient interviews|We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
9901844|NCT01363635||severe sepsis|severe sepsis/septic shock, organ failure, ICU death
9901845|NCT01361477||patient|"Prolonged ICU stay~Unplanned ICU admission~Complication/adversel during ICU admission~Result of intraoperative complications and admission to ICU 5 Result of early postoperative (within 7 days) and ICU admission"
9901846|NCT01355679|Experimental|Guided therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
9901847|NCT01351545||Unlicensed CBU|The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.
9901848|NCT01315392|Active Comparator|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for debridement and definitive closure.
9901849|NCT01315392|Active Comparator|immediate wound closure|traumatic and surgical wounds closed at initial surgical intervention
9901850|NCT01314118|Experimental|001|abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
10212851|NCT04933552||Healthy Comparison|Pregnant women who are neither diagnosed with MS nor with any other autoimmune disease, and not exposed to siponimod or any known teratogenic agent during pregnancy
10212852|NCT04933240|Active Comparator|Tamoxifen|tamoxifen 10mg daily for 7 days
9901853|NCT01227616|Experimental|Ferumoxytol|Intravenous (IV) iron
9901854|NCT01227616|Active Comparator|IV Iron Sucrose|Intravenous (IV) iron
9901855|NCT01193777|Placebo Comparator|Saline|
9901856|NCT01193777|Experimental|L-Carnitine|
9901857|NCT01192698|Experimental|IV interferon|IV interferon oral ribavirin
9901858|NCT01192698|No Intervention|Standard of care|standard of care
9901859|NCT01188096|Experimental|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
9901860|NCT01187368|Experimental|Evaheart LVAS (EVA2)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class III with dyspnea upon mild physical activity or Class IV heart failure.
9901861|NCT01187368|Active Comparator|HeartMate 3 (HM3)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class III with dyspnea upon mild physical activity or Class IV heart failure.
9901862|NCT01171898|Experimental|Dose Escalation Cohort (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
9901863|NCT01171898|Experimental|Non-metastatic CRPC (Phase 2)|Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
10212853|NCT04933240|Active Comparator|Estradiol|estradiol 1mg daily for 7 days
10212854|NCT04933240|Placebo Comparator|placebo|placebo daily for 7 days
10212855|NCT04932941|Experimental|MP1032|Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.
10212856|NCT04932941|Placebo Comparator|Placebo|Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.
10212857|NCT04930822|Active Comparator|Table Top Visual Intervention|Interventions will include six, 20 minute sessions using pen and paper word search, scanning activities, and saccade visual training. All activities will be conducted with an occupational therapist/investigator.
10212858|NCT04930822|Experimental|Bioness Integrated Therapy System Visual Intervention|Intervention will includes six sessions using the Bioness Integrated Therapy System for 20 minutes using the programs of visual scanning, visual pursuits and/or visual motor.All activities will be conducted with an occupational therapist/investigator.
9901864|NCT01171898|Experimental|Treatment-naive metastatic CRPC (Phase 2)|Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
9901865|NCT01171898|Experimental|Post-abiraterone metastatic CRPC (Phase 2)|Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
9901866|NCT01166386|Experimental|First steps treatment intervention|"A brief 10-session manualized acute neurobehavioral intervention program will be individually implemented with randomly assigned treatment participants. Session components include injury-related education, enhancement of self-awareness of deficits from the TBI, coping and cognitive skills training, and supported practice. The acronym FANCI refers to the name of the program which is First Steps Acute Neurobehavioral and Cognitive Intervention."
9901867|NCT01166386|Placebo Comparator|standard rehabilitation care|The controls will spend 10 one-half hours with a therapist viewing videos they choose from a menu, some of which have to do with brain injury. The therapist will interact naturally with the controls and occasionally relate the movie or film to brain injury rehabilitation.
9901868|NCT01148550||Group 1|Mitochondrial Hepatopathy Disease Group
9901869|NCT01148550||Group 2|Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1 Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1
9901872|NCT01114217|Experimental|Ferumoxytol|Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 [NCT01114139]. Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin <11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) <20% at any evaluation visit, (except study termination visit). Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV). The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1. The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
9901873|NCT01114204|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
9901874|NCT01114204|Active Comparator|Iron Sucrose|Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.
9901875|NCT01114139|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
9901876|NCT01114139|Placebo Comparator|Placebo|Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.
9901877|NCT01089101|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities.
9901878|NCT01059071|Experimental|DFMO and Etoposide|
9901879|NCT01043315||Hospitalized Cardiac Patient|Adults admitted to Coronary intensive unit being treated for acute cardiovascular conditions
9517572|NCT03305211|Other|Biological sample|biological sampling will be performed on patients requiring renal biopsy and well-phenotyped patients (diagnosis of renal disease)
9901880|NCT01027702|Experimental|Infusion of donor lymphocytes|Patients will receive an infusion of donor lymphocyte after T-cell depleted transplant.
9901881|NCT01002014|Experimental|Nipple Sparing Mastectomy|Patients who undergo nipple sparing mastectomy with preservation of the nipple areolar complex.
9901882|NCT00991887|No Intervention|No Radiation Therapy (XRT)|This group will not receive radiation therapy after surgery.
9901883|NCT00991887|Active Comparator|Radiation Therapy (XRT)|Radiotherapy will be administered no later than 72 hours postoperatively.
9901884|NCT00968864|Experimental|CliniMACS® (T cell depletion)|Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
9901885|NCT00956488|Experimental|supported treadmill ambulation training|
9901886|NCT00938145|Experimental|MRI+surgery|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
9901887|NCT00938145|Experimental|MRI+surgery+chemotherapy|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
9901888|NCT00934700|Experimental|Combination of hypothermia and xenon|Combination of hypothermia and inhaled xenon
9901889|NCT00934700|No Intervention|Hypothermia and standard intensive care|Hypothermia and standard intensive care
9901890|NCT00867568|Experimental|TPI 287|
9901891|NCT00812201||1|
9901892|NCT00785291|Active Comparator|Arm A (Paclitaxel)|Patients receive 90 mg/m^2 paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
9901893|NCT00785291|Experimental|Arm B (Nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
9901894|NCT00785291|Experimental|Arm C (Ixabepilone)|Patients receive ixabepilone IV over 60 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. (closed to accrual as of 7/18/11)
9901895|NCT00782288|Active Comparator|1|low dose 0.05mg digitoxin given once daily for 28 days
9901896|NCT00782288|Active Comparator|2|higher dose 0.1mg digitoxin daily for 28 days
9901897|NCT00782288|Placebo Comparator|3|placebo given daily for 28 days
9901898|NCT00777036|Experimental|Cohort 1: Imatinib-resistant/intolerant CP-CML|"Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² powder for oral suspension (PFOS) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
9901899|NCT00777036|Experimental|Cohort 2: Ph+ALL or AP- or BP-CML|"Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 96 mg/m² PFOS QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
9901900|NCT00777036|Experimental|Cohort 3: Newly diagnosed, treatment naïve CP-CML|"Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² PFOS QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
9901901|NCT00771654|Placebo Comparator|Placebo|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
9901902|NCT00771654|Experimental|Phentermine|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
9901903|NCT00770809|Experimental|Arm I (THL)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
9901904|NCT00770809|Active Comparator|Arm II (TH)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.
9901905|NCT00770809|Experimental|Arm III (TL)|Patients receive paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)
9901906|NCT00765310|Active Comparator|Lipoic Acid|600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
9901907|NCT00765310|Placebo Comparator|Placebo|Placebo two caps every morning on empty stomach
9901908|NCT00764270|Active Comparator|Lipoic acid treatment|Participants take lipoic acid with a washout period before or after placebo.
9901909|NCT00764270|Placebo Comparator|Placebo treatment|Participants take placebo with a washout period before or after lipoic acid treatment
9901910|NCT00756509|Experimental|nilotinib|nilotinib
9901911|NCT00712751||1|usual care (UC) which is the standard care that patients receive
9901912|NCT00712751||2|Cancer Survivorship Intervention-Sexual Health (CSI-SH)plus Usual Care (US)
9901913|NCT00697411||Experimental|Individuals with Aicardi syndrome and their first-degree relatives
9901914|NCT00678821|Experimental|1|Patients with PH will be randomized to either aerobic exercise training plus education (AET) or education only (Ed-only) treatments
9901915|NCT00678821|Active Comparator|2|A comparison group of patients with ILD who do not have secondary PH (ILD-only) will also undergo the AET arm
9933401|NCT05351697|Experimental|BR105|BR105 infusions will be administered weekly 21 days after the initial dose
9517573|NCT03305198|Experimental|Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry will have a capillary blood sampling from the earlobe
9901916|NCT00643864|Other|Mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same therapist who performed the pretests."
9901917|NCT00621751|Experimental|Carbamazepine|Carbamazepine 800 mg daily
9901918|NCT00621751|Placebo Comparator|Placebo|Placebo
9901919|NCT00605215|Placebo Comparator|Placebo|Participants will receive 1 capsule of placebo matching to laquinimod orally once daily for 24 months.
9901920|NCT00605215|Experimental|Laquinimod|Participants will receive 1 capsule of laquinimod 0.6 mg orally once daily for 24 months.
9901921|NCT00605215|Active Comparator|Avonex®|Participants will receive an injection of Avonex® 30 micrograms (mcg) given intramuscularly (IM) once weekly for 24 months.
9901922|NCT00605150||Patients enrolled|Total number of patients enrolled
9901923|NCT00571272||1|Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
9901924|NCT00571272||2|Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
9901925|NCT00571272||3|Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
9901926|NCT00571272||4|A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
9901927|NCT00571272||5|Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
9933402|NCT05351684|Experimental|Intensified|Group of patients whose treatment will be intensified with an additional 50mg of dolutegravir on top of regular treatment (Triumeq: ABC/3TC/DTG).
9933403|NCT05351684|No Intervention|Control|Group of patients without modification of baseline treatment (Triumeq: ABC/3TC/DTG).
9933404|NCT05351671|Experimental|Arm A|RLS-0071 lower dose group
9933405|NCT05351671|Experimental|Arm B|RLS-0071 higher dose group
9933406|NCT05351671|Placebo Comparator|Arm C|Placebo group
9933407|NCT05351658|Experimental|Temporary Cardiac Pacing with Active-Fixation Leads|
9933408|NCT05351645|Active Comparator|Treatment|Participants in the Treatment arm were assigned to read one each day during the two-week trial period. These articles described a personal experience suicide from a first-person perspective, and included positive messages. Before and after reading these articles, participants in the Treatment arm answered brief questions assessing current suicidal thoughts and other constructs. Participants in the Treatment group were administered follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs.
9933409|NCT05351645|No Intervention|Control|Participants in the Control arm answered questionnaires one time per day assessing suicidal thoughts and among other constructs (the same items as the Treatment group) during the two-week trial. Control participants did not receive the positive suicide related stories during the two-week trial period. Participants in the control group completed follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs (the same items as the Treatment group). After the follow-up phase was complete, participants in the Control group received the same intervention as those in the Treatment group.
9933410|NCT05351619|Experimental|An intervention group|An intervention group: will include 41 patients who will receive the oral care bundle.
9933411|NCT05351619|No Intervention|A control group|A control group: will include 41 patients who will receive the traditional oral care.
9933412|NCT05351606|Experimental|Brief Intervention|Participants will receive one time tobacco use cessation counseling and quitline number.
9933413|NCT05351606|Experimental|Intensive Intervention|Participants will receive intensive behavioral counseling spread over 12 sessions, Nicotine Replacement Therapy and Bupropion, and the quitline number.
9933414|NCT05351593|Experimental|Phase 1 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 & 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle.
9933415|NCT05351593|Experimental|Phase 2 (Tafasitamab, Lenalidomide)|Participants will be given 12mg of Tafasitamab on days 1, 4, 8, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycles 2 & 3, and days 1 and 15 for any cycle thereafter. Participants will also be given daily Lenalidomide on days 1-21 of each cycle at the recommended phase 2 dose.
9997852|NCT01512550|Active Comparator|instrumented hip guide technique|A mechanical device used to measure and decide how the hip prosthesis (ABG II modular) should be implanted
9901928|NCT00552513|Other|Early Coronary Intervention|Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (within 24 hours of randomisation).
9901929|NCT00552513|Other|Delayed Coronary Intervention|Delayed intervention: Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
9901930|NCT00496613||1|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with a combination of chemotherapy and hormonal therapy, matched on age and education
9901931|NCT00496613||2|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with hormonal therapy only matched on age and education
9901932|NCT00496613||3|Healthy women matched on age and education
9901933|NCT00368836|Experimental|BreathScreen PE + D-dimer|CO2/O2 ratio will be measured using the Breath Screen PE device. D-dimer levels will also be collected.
9901934|NCT00345553||1|Biliary atresia subjects who have their native liver
9901935|NCT00345553||2|Biliary atresia subjects who have had a liver transplant
9901936|NCT00302744|Experimental|Psilocybin|Single, 6-hour treatment with 0.2 mg/kg active psilocybin capsule.
9901937|NCT00302744|Active Comparator|Active Niacin Placebo|Each subject functioned as their own control, receiving niacin placebo capsule in a single 6-hour session.
9901938|NCT00290511|Experimental|R-FIND + Zevalin|Fludarabine 25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6.
9901939|NCT00265798|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9901940|NCT00248703|Experimental|Docetaxel|Patients with presence of disseminated tumor cells in bone marrow after (no-taxane) epirubicin-containing adjuvant treatment receive 6 cycles of docetaxel (100 mg/m2) 3 qw.
9901941|NCT00195091|Experimental|Tetrathiomolybdate (TM)|"Induction period - TM 40 mg is administered three x per day with meals and TM 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Maintenance Period - Total TM dose per day will be in 20 mg increments to tailor the therapy to individualized patient needs to maintain the Cp level at 5-17mg/dL. Thus all dose modifications will be dependent on individual patient Cp levels. TM 40 mg p.o. BID with meals and TM 20 mg at bedtime. Subjects who have no evidence of disease (NED) and are receiving a benefit of TM can continue taking the drug for up to 120 months."
9901942|NCT00167219|Experimental|Intent-to-Treat|Patients receiving study regimen.
9901943|NCT00061828||Biliary Atresia|Infants presenting with cholestasis who are diagnosed with biliary atresia.
9901944|NCT00061828||Non-Biliary Atresia|Infants presenting with cholestasis without a diagnosis of biliary atresia.
9901945|NCT00005780|Experimental|1|EPOCH-R followed by idiotype vaccine and GM-CSF
9901946|NCT00001711||Healthy Volunteers and Patients|Healthy volunteers and patients age 18 and older.
9901947|NCT00611091|Experimental|I|Intervention Group - (receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
9901948|NCT00611091|No Intervention|C|Control Group - (do not receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
9901949|NCT00611117|Experimental|1|High intensity exercise and high fat diet
9901950|NCT00611117|Experimental|2|Low intensity exercise and high fat diet
9901951|NCT00611143|Experimental|1|Atorvastatin group
9901952|NCT00611143|No Intervention|2|Control group
9901953|NCT00611156|Experimental|A|Spice
9901954|NCT00611156|Experimental|B|Spice
9901955|NCT00611156|Experimental|C|Spice
9901956|NCT00611156|Experimental|D|Spice
9901957|NCT00611156|Placebo Comparator|E|Placebo
9901958|NCT00611169|Experimental|1|Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose
9901959|NCT00611169|No Intervention|2|Aspirin, clopidogrel, unfractionated heparin
9901960|NCT00611182||1|Patients with Pulmonary Fibrosis
9901961|NCT00611195|Other|1|Larynx assessment under stimulation
9901962|NCT00611208|Experimental|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diptheria toxin)
9901963|NCT00611221|Active Comparator|1|Massage therapy by a regulated massage therapist
9901964|NCT00611221|Active Comparator|2|Massage by anyone else, eg. husband, nurse, doula
9901965|NCT00611260|Experimental|Meditation Cohort|25 patients will be given instruction in vipassana meditation. Vipassana meditation is thought to reduce the incidence of atrial and ventricular arrhythmias in patients with congestive heart failure, and improve their overall psychological profile.
9901966|NCT00611260|Active Comparator|Standard Care|25 patients will receive current standard of care to manage their congestive heart failure, implanted cardiac devices, and psychological health.
9901967|NCT00611273|Experimental|1|Patients who have presented to the investigator for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Note: Class 1 or Higher)7 (Appendix R) are candidates for this study.
9901968|NCT00611286|Experimental|1|treatment with Aspirin and clopidogrel for 24 months after coronary intervention with stents. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent.
9901969|NCT00611286|Active Comparator|2|Treatment with aspirin and clopidogrel for minimum 1 or 6 month(s) after BMS or DES implantation, respectively. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent
9901970|NCT00611312|Experimental|1|Cognitive Training
9901971|NCT00611338|Active Comparator|Standard of Care, Wait-List Control|Participants received standard medical care, which in most clinics included informational brochures provided by physicians and clinic staff. Participants were given HIV prevention information and materials in English and Spanish and were provided referrals for services. Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the wait-list control participants participated in the Trauma + HIV group arm.
9901972|NCT00611338|Active Comparator|HIV Prevention|Eight, 90 minute group sessions. Three of the sessions focused on health education (e.g., medication adherence, nutrition, exercise) and five focused on HIV prevention skills (e.g., condom skills, communication, social support). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the participants in this arm were given the option to receive the 3 trauma-focused sessions from the Trauma + HIV group arm.
9901973|NCT00611338|Active Comparator|HIV Prevention plus Trauma|The same format as the HIV Prevention arm with eight, 90 minute group sessions. The participants received the same five HIV prevention skills sessions along with three sessions that focused on reducing trauma-related stress (e.g., breathing training, relaxation exercises, grounding exercises, coping, trauma-related triggers). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months.
9901974|NCT00611364|Experimental|Study group|
9901975|NCT00611364|Active Comparator|Control group|
9901976|NCT00611377||1|
9901977|NCT00611390|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
9901978|NCT00611390|Placebo Comparator|2|spray containing placebo.
9901979|NCT00611416|Experimental|1|Active treatment A
9901980|NCT00611416|Experimental|2|Active treatment B
9901981|NCT00611416|Experimental|3|Active treatment C
9901982|NCT00611416|Active Comparator|4|Positive control
9901983|NCT00611416|Placebo Comparator|5|Placebo
9901984|NCT00611429|Experimental|Group A|Participants will receive treatment consisting of at least three individual counseling sessions and one group workshop over 12 months
9901985|NCT00611429|Active Comparator|Group B|Participants will receive treatment consisting of one individual counseling session and one group workshop during the last month of the study
9901986|NCT00611481|Experimental|Tai Chi|
9901987|NCT00611481|Active Comparator|B. Strength training|
9901988|NCT00611481|Other|C. Low-Impact|
9901989|NCT00611494|Active Comparator|A|MMF
9901990|NCT00611494|Active Comparator|B|EC-MPS
9901991|NCT00611520||1|Patients with COPD treated with budesonide/formoterol
9901992|NCT00611546|Placebo Comparator|1|Perenteral nutrition bottle and tubing are not protected from light
9901993|NCT00611546|Active Comparator|2|Perenteral nutrition bottle and tubing are protected from light
9993432|NCT01472146|Experimental|Zometa neoadjuvant HER2 breast cancer|"Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.~Drug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid"
9993433|NCT01472159|No Intervention|CGM-Usual Care|Routine CGM education
9993434|NCT01472159|Experimental|CGM-Teamwork|"Routine CGM education~CGM Family Teamwork Intervention"
9993435|NCT01472172|Experimental|Cryobiopsy|Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
9993436|NCT01472211|Experimental|intervention filter|children consuming purified and zinc enriched water delivered by a household-based water filter
9993437|NCT01472211|Placebo Comparator|placebo filter|children consuming purified water delivered by a household-based water filter
9993438|NCT01472211|Active Comparator|disinfection tablets|children will consume water treated with government promoted disinfection tablets (aquatabs)
9993439|NCT01472237|Active Comparator|Nutritional intervention|It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
9993440|NCT01472237|Placebo Comparator|Care as usual|The patients are referred to their cardiologyst and primary care physicians
9993441|NCT01472250||chemotherapy|Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
9993442|NCT01472263|Experimental|Pentoxifylline|
9993443|NCT01472263|Placebo Comparator|Placebo|
9993444|NCT01472276|No Intervention|Control|
9993445|NCT01472276|Active Comparator|Web-based program|
9993446|NCT01472302|Experimental|ASV|Adaptive Support Ventilation
9993447|NCT01472302|Active Comparator|PCV|Pressure Controlled Ventilation
9993448|NCT01472315|Active Comparator|medroxyprogesterone acetate|
9993449|NCT01472315|Placebo Comparator|Placebo|Placebo pills taken in the same way as the active comparator
9993450|NCT01472328|Experimental|Hyperbaric oxygen therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
9993451|NCT01472328|Sham Comparator|Hyperbaric room air|Effect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
9993452|NCT01472354|No Intervention|Standard of care referral to specialist|Subjects are referred for education, counseling and evaluation for HCV treatment to a specialty health care provider
9993453|NCT01472354|Experimental|LEAP-C Group Intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with HCV treatment to decrease decisional conflict, increase HCV knowledge, improve communication
9993454|NCT01472393|Experimental|Creatine supplementation|
9993455|NCT01472393|Placebo Comparator|Placebo|
9993456|NCT01472406|Experimental|Closed-loop session|The study consists of an evaluation of the Sansum Closed-loop Artificial Pancreas Device, insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, and a Safety Health Monitoring System. during a 24-hour closed-loop in a clinic environment (Sansum Diabetes Research Institute, Santa Barbara, CA).
9993457|NCT01472458|Active Comparator|Active Intervention|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
9993458|NCT01472458|No Intervention|Control Hospitals|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
9993459|NCT01472471||acute asthmatic children|Children hospitalized with a diagnosis of acute asthma exacerbation
9993460|NCT01472471||stable asthmatic children|Children with a history of asthma currently asymptomatic
9993461|NCT01472484|Experimental|lpa with high polyphenol|
9901994|NCT00611572|Active Comparator|1|Active iomazenil and ketamine
9901995|NCT00611572|Placebo Comparator|2|placebo iomazenil and ketamine
9901996|NCT00611585|Other|Hip Resurfacing|Birmingham Hip Resurfacing
9901997|NCT00611598||1|second primary lung cancer
9901998|NCT00611598||2|single primary lung cancer
9901999|NCT00611611||1|SLE
9902000|NCT00611611||2|healthy controls
9902001|NCT00611637|Experimental|1|
9902002|NCT00611650|Experimental|Arm I|Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
9902003|NCT00611650|Placebo Comparator|Arm II|Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
9902004|NCT00611663|Experimental|1|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE) at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)
9902005|NCT00611663|Placebo Comparator|2|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
9902006|NCT00611676|Experimental|A|All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
9902007|NCT00611689|Experimental|A|Imatinib and PTK/ZK222584
9902008|NCT00611741|Experimental|Drug intervention, longitudinal|Furosemide and Na supplements
9902009|NCT00611780|Experimental|1|Reduced tube voltage of 100kV.
9902010|NCT00611780|Active Comparator|2|Standard tube voltage of 120kV.
9902011|NCT00611793|Experimental|1|PTK787/ZK222584 and Bevacizumab
9902012|NCT00611819|Experimental|1|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
9902013|NCT00611819|Active Comparator|2|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
9902014|NCT00611832|Active Comparator|Standard|"Standard information-only version of the television series that includes only modeling and demonstration of the targeted parenting skills"
9902015|NCT00611832|Experimental|Enhanced|"Enhanced behavior activation version of the television series that includes all of the content of the standard information-only version, but is also designed to actively promote parental behavior change, through additional content elements addressing attributions, self-efficacy and expectancies, social support, and emotional reactivity."
9902016|NCT00611832|No Intervention|Control|Waitlist control
9902017|NCT00611871|Experimental|1|Propranolol following traumatic memory
9902018|NCT00611871|Active Comparator|2|Propranolol following neutral memory
9902019|NCT00611871|Placebo Comparator|3|Placebo following traumatic memory
9902020|NCT00611910|Experimental|DES|drug-eluting stents
9902021|NCT00611910|Active Comparator|BMS|bare metal stents
9902022|NCT00611936|Placebo Comparator|2|Second arm is placebo
9902023|NCT00611936|Experimental|1|One arm is atomoxetine 40 mg per day
9902024|NCT00611949|Active Comparator|1 Geranium Oil|
9902025|NCT00611949|Active Comparator|2 Geramium Oil|
9902026|NCT00611988|Experimental|1|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
9902027|NCT00611988|Active Comparator|2|Attention control group will receive routine follow-up phone calls
9902028|NCT00612001|Experimental|dendritic cell vaccine|
9902029|NCT00612027||1|patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.
9902030|NCT00612079|Experimental|2|Healthy volunteers with high sensory gating levels.
9902031|NCT00612079|Experimental|1|Healthy volunteers with low sensory gating levels.
9902032|NCT00612092|Experimental|1|Standard spiral CT protocol
9902033|NCT00612092|Active Comparator|2|Sequential CT protocol
9902034|NCT00612144|Experimental|1|Amaryl M group
9902035|NCT00612144|Active Comparator|2|Metformin group
9902036|NCT00612157|Active Comparator|OSA CPAP|
9902037|NCT00612157|Placebo Comparator|Placebo|
9902038|NCT00612196|Experimental|1|
9902039|NCT00612196|Experimental|2|
9902040|NCT00612196|Experimental|3|
9902041|NCT00612196|Experimental|4|
9902042|NCT00612196|Experimental|5|
9902043|NCT00612196|Experimental|6|
9902044|NCT00612196|Experimental|7|
9902045|NCT00612196|Experimental|8|
9902046|NCT00612196|Experimental|9|
9902047|NCT00612196|Placebo Comparator|10|
9902048|NCT00612209|Experimental|1|
9902049|NCT00612248|Experimental|SG|Study group
9902050|NCT00612248|No Intervention|CG|Control group
9902051|NCT00612261|Experimental|1|The group 1 patients receive AV sheathotomy for macular edema secondary to branch retinal vein occlusion.
9902052|NCT00612261|Active Comparator|2|The group 2 patients receive IVTA.
9902053|NCT00612274|Experimental|1|sirolimus, tacrolimus and short course methotrexate
9902054|NCT00612287|Experimental|A|
9902055|NCT00612300|Experimental|A-B|Gait training by an automatic gait trainer (Lokomat) for 3 weeks followed by 3 weeks of categorized gait training by a physical therapist
9902056|NCT00612300|Experimental|B-A|Categorized gait training by physical therapists for 3 weeks followed by 3 weeks of lokomat training
9902057|NCT00612326||1|Patients with newly diagnosed locally or regionally advanced transitional cell carcinoma of the bladder.
9902058|NCT00612365||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) for abdominal aortic calcium (AAC) who have undergone computed tomography (CT) scans of the abdomen
9902059|NCT00612378|Experimental|1|
9902060|NCT00612391|Experimental|Lateral, Minimally Invasive Approach|Lateral, Minimally Invasive Approach in GT fractures treated operatively (plates and screws)
9902061|NCT00612391|Active Comparator|Deltopectoral approach:|Deltopectoral approach for GT fracture treated operatively
9902062|NCT00612404||1|patients with gastrointestinal disorders who need an endoscopy.
9902063|NCT00612417|Experimental|1|recombinant FVIII
9902064|NCT00612417|Placebo Comparator|2|Placebo
9902065|NCT00612443|Experimental|1|non-contact Healing Touch treatment for 20-30 minutes once a week during the course of radiation therapy
9993462|NCT01472484|Experimental|lpa with low polyphenol|
9993463|NCT01472484|Experimental|control bean with low polyphenol|
9993464|NCT01472484|Experimental|control bean with high polyphenol|
9993465|NCT01472497|Experimental|glymepiride|
9993466|NCT01472510|Active Comparator|Arm 1:The PRN Group|You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
9993467|NCT01472510|Active Comparator|arm 2:The Monthly Group:|You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
9993468|NCT01472523||Controls|
9993469|NCT01472523||Aneuploidy|T13, 18, 21 and other chromosomal abnormalities yet to be determined
9993470|NCT01472536|Experimental|3-day sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms
9993471|NCT01472536|No Intervention|Control|No intervention
9993472|NCT01472575||Pre- rotavirus vaccination introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
9993473|NCT01472575||post rotavirus vaccine introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
9993474|NCT01472588|Experimental|Community Health Coach|DPP behavioral lifestyle intervention delivered by Community Health Coach (CHWs)
9993475|NCT01472588|Experimental|Public Health Coach|DPP behavioral lifestyle intervention delivered by health professionals (PHCs)
9993476|NCT01472588|Other|Self Help|Booklet, Aim for a Healthy Weight (DHHS, NIH-NHLBI) provided.
9993477|NCT01472601||FOLFOX_6|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, first 6 cycles, then Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, 6 cycles
9993478|NCT01472601||FOLFOX_12|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, total of 12 cycles
9993479|NCT01472614|Experimental|DLBS3233|
9993480|NCT01472627||Bortezomib treatment|Subjects receiving standard of care regimen including Bortezomib
9993481|NCT01472640|Active Comparator|Liraglutid|Liraglutid
9993482|NCT01472640|Placebo Comparator|Placebo|Placebo
9993483|NCT01472666|Experimental|Fat rich in MC-SFA|63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
9993484|NCT01472666|Experimental|Fat low on MC-SFA|63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
9993485|NCT01472666|Experimental|Casein protein|60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
9993486|NCT01472666|Experimental|Whey protein|60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.
9993487|NCT01472705||everolimus-eluting stents (EES)|Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
9993488|NCT01472705||biolimus-eluting stents (BES)|Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
9993489|NCT01472731|Experimental|GC1008 imaging and treatment|"Part 1: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake.~Part 2: 89Zr-GC1008 PET imaging in patients with relapsed malignant glioma and phase II extension study with therapeutic GC1008 in these patients"
9993490|NCT01472744|Experimental|Dance|Participants will be instructed in various forms of dances such as ballroom, swing, waltz, folk, and English country.
9993491|NCT01472744|Active Comparator|Strengthening, Stability, Stretching|Participants will be instructed in various forms of strength, stretching (flexibility) and stability (balance)exercises.
9993492|NCT01472744|Experimental|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate.
9993493|NCT01472744|Experimental|Walking + Nutritional Supplement|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. These participants will also be provided with a daily nutritionally balanced liquid, milk-based formula.
9993494|NCT01472783|Experimental|Veliparib|
9993495|NCT01472796|Active Comparator|Tekturna (Aliskirin) with vit. D supplementation|Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.
9993496|NCT01472796|Placebo Comparator|Tekturna (Aliskiren) with placebo|Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)
9993497|NCT01472809|Placebo Comparator|Placebo|Placebo tablets
9993498|NCT01472809|Experimental|ZYGK1|"ZYGK1 tablets; 0.125, 0.25, 0.5, 1, 2, ... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
9993499|NCT01472848|Experimental|Cohort 1|
9993500|NCT01472848|Experimental|Cohort 2|
9993501|NCT01472848|Experimental|Cohort 3|
9993502|NCT01472848|Experimental|Cohort 4|
9993503|NCT01472848|Experimental|Cohort 5|
9993504|NCT01472848|Active Comparator|Cohort 6|
9993505|NCT01472861|Placebo Comparator|No AECC|Routine procedures without AECC
9993506|NCT01472861|Experimental|AECC|Endometrial biopsy and Autologous endometrial coculture
9993507|NCT01472900|Experimental|Er:YAG laser|
9993508|NCT01472900|Active Comparator|BP gel|
9993509|NCT01472913|Active Comparator|Fibrin Sealent|
9993510|NCT01472913|Placebo Comparator|Saline water|
9993511|NCT01472926|Experimental|Tenecteplase 0.25 mg/kg|Intravenous tenecteplase 0.25 mg/kg (single bolus, maximum 25 mg)
9993512|NCT01472926|Active Comparator|Alteplase 0.9 mg/kg|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
9993513|NCT01472978|Active Comparator|Immediate antibiotic treatment|Patients will be treated with an antibiotic as soon as the aspirate obtained at the colonoscopy is found to be positive for C. diff.
9993514|NCT01472978|Sham Comparator|Delayed treatment with an antibiotic|Treatment will be started after a delay after the aspirate obtained at the colonoscopy is found to be C. diff positive.
9993515|NCT01473004|Experimental|Sirspheres, response evaluation|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
9993516|NCT01473017|Experimental|CBT-based guided self-help|Providing a guided self-help booklet to patients with anxiety/depression meeting criteria, with two telephone calls by a clinician to provide support with this.
9993517|NCT01473017|No Intervention|No CBT intervention|Control group in comparison to CBT guided self-help group
9993518|NCT01473030||Dutasteride|No PCa at Year 2 or Year 4
9993519|NCT01473030||Placebo|No PCa at Year 2 or Year 4
9993520|NCT01473056|Experimental|Dose 1 JTK-853|
9993521|NCT01473056|Experimental|Dose 2 JTK-853|
9667212|NCT03840525|Experimental|Qigong Intervention|The qigong intervention consists of 1 hour/week qigong classes for 12 weeks to be delivered virtually. The first 2 weeks will include 2 hours/week classes. In addition, each participant will be instructed to practice qigong at home for 90 minutes.
9993522|NCT01473056|Experimental|Dose 3 JTK-853|
9993523|NCT01473056|Experimental|Dose 4 JTK-853|
9993524|NCT01473056|Placebo Comparator|Placebo|
9993525|NCT01473069|Experimental|Dose 1 JTK-853, 400 mg ketoconazole|
9993526|NCT01473069|Experimental|Dose 2 JTK-853|
9993527|NCT01473069|Experimental|Dose 3 JTK-853|
9993528|NCT01473069|Experimental|Dose 4 JTK-853|
9993529|NCT01473069|Placebo Comparator|Placebo|
9993530|NCT01473082|Active Comparator|PFNA|Proximal Femoral Nail Antirotation (PFNA Synthes)
9993531|NCT01473082|Active Comparator|PFNA Augmentation|Proximal Femoral Nail Antirotation PFNA Augmentation (Synthes) with Traumacem V+ Synthes
9993532|NCT01473121||Group 1|
9993533|NCT01473147|Active Comparator|GLP-1|
9993534|NCT01473147|Placebo Comparator|Normal saline|
9993535|NCT01473173|Experimental|CJ-12420 50mg|"Single dose~8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)"
9993536|NCT01473173|Experimental|CJ-12420 100mg|"Single dose~8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)"
9993537|NCT01473173|Experimental|CJ-12420 200mg|"Single dose~8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)"
9993538|NCT01473173|Experimental|CJ-12420 400mg|"Single dose~8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)"
9993539|NCT01473173|Experimental|CJ-12420 100mg (repeated dose)|"Repeat doses~100mg is the anticipated dose~8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)"
9993540|NCT01473173|Experimental|CJ-12420 200mg (repeated dose)|"Repeat doses~200mg is the anticipated dose~8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)"
9993541|NCT01473173|Active Comparator|Esomeprazole 40mg|8 volunteers will be administered Esomeprazole 40mg
9993542|NCT01473225|Experimental|Calorie label|
9993543|NCT01473225|Active Comparator|No calorie label|
9993544|NCT01473238|Active Comparator|Desktop PC|Conventional institutional Desktop Personal Computers will be used to collect data of patients via a password protected encrypted interface.
9993545|NCT01473238|Experimental|Mobile|Novel Mobile Clinical Trial Management System on iPads will be used to collect data of patients via a password protected encrypted interface.
9993546|NCT01473251|Active Comparator|Avastin for Diabetic Macular Edema|1.25 mg avastin monthly for 4 months
9993547|NCT01473251|Active Comparator|Avastin for Exudative Macular Degeneration|1.25 mg Avastin monthly for 4 months
9993548|NCT01473251|Active Comparator|Lucentis for Exudative Macular Degeneration|0.5 mg Lucentis monthly for 4 months
9993549|NCT01473264|Placebo Comparator|Control|
9993550|NCT01473264|Experimental|High dose rhCC10|5 mg/kg study drug (rhCC10)
9993551|NCT01473264|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
9993552|NCT01473277|Active Comparator|BT-A (Dysport 500U)|
9993553|NCT01473277|Active Comparator|Triamcinolone acetonide|
9993554|NCT01473290|Experimental|Arm I|Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
9993555|NCT01473290|Placebo Comparator|Arm II|Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
9993556|NCT01473303|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 48 hours beginning on day 2 (mFOLFIRINOX) and ganitumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
9993557|NCT01473303|Experimental|Arm II|Patients receive mFOLFIRINOX as in arm I and placebo IV over 30-60 minutes on day 1.
9993558|NCT01473316|Experimental|A|
9993559|NCT01473329|Experimental|Structured Diabetes education|The intervention group received a structured DSME course. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
9997853|NCT01512550|No Intervention|conventional measuring technique|Standard way of implanting the prosthesis (ABG II standard) without special measuring device or computer navigation technique
9997854|NCT01512550|Active Comparator|computer assisted navigation|A method to use computer navigation when positioning and sizing the hip prosthesis (ABG II modular).
9997855|NCT01512563|Experimental|Paclitaxel ElutingCovered Metal Stent|
9997856|NCT01512563|Active Comparator|Covered Metal Stent|
9997857|NCT01512576|Experimental|acupuncture|All patients were treated at the basic points bilaterally situated in the local region (neck), distal region (low back, arms and legs) and ear. In addition, acupuncture treatment was performed according to the rules of traditional Chinese medicine and was semi-standardized. This means that the therapist was allowed to choose from a list of the following acupuncture points: GV14, Huatuojiaji C1-C7, GB20, SI11, GB21, TE15, SI14, BL17, MT10, SI3, BL64, TE5, GB41, Zero point, Jerome point, C0. The combination of acupuncture points were chosen individually, according to the patients' self-reported symptoms. In order to obtain the required information, patients had to fill out a Margolis pain diagram, and the acupuncturist questioned the patient and performed a tongue- and pulse diagnosis.
9997858|NCT01512576|Active Comparator|relaxation|For the relaxation treatment the method of guided imagery is applied. Guided imagery is a system of visualization. During guided imagery relaxation, the patient's state of consciousness is similar to one which occurs in meditative status. Patients are instructed to listen to a CD with relaxation music (Arcade TV-CD Ad Vissesr's Brainsessions, track 3). Patients will sit in an identical position like during the acupuncture treatment (i.e. on a relaxation chair) and listened to the audio CD by headphone.
9997859|NCT01512589|Experimental|Proton Beam Therapy (PBT)|"Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy (or at RBE (Relative Biologic Equivalence for PBT)) to be delivered to the periphery of the planning target volume (PTV)."
9997860|NCT01512589|Active Comparator|Intensity Modulated Radiation Therapy (IMRT)|Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy to be delivered to the periphery of the planning target volume (PTV).
9997861|NCT01512602|Active Comparator|Dialectical Behavior Therapy DBT|16 weeks DBT-treatment
9997862|NCT01512602|Active Comparator|CAMS|Collaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
9997863|NCT01512615|Experimental|Intervention group|Complex Cardiac Rehabilitation
9997864|NCT01512615|Experimental|Control group|Usual care
9997865|NCT01512628|Active Comparator|PENTA group|Pentaspan is administered as a colloid.
9997866|NCT01512628|Active Comparator|voluVEN group|Voluven is administered as a colloid.
9997867|NCT01512628|Active Comparator|voluLYTE group|Volulyte is administered as a colloid.
9997868|NCT01512641|Experimental|Children with Dissociative Disorders|Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
9902066|NCT00612443|Sham Comparator|2|A RN graduate assistant will provide a sham treatment of 20-30 minutes of presence.
9902067|NCT00612469|Placebo Comparator|NaF|Sodium fluoride application
9902068|NCT00612469|Experimental|V3|Topical application of 3% vancomycin
9902069|NCT00612469|Experimental|V10|Topical application of 10% vancomycin
9902070|NCT00612469|Active Comparator|CHX|Topical application of 1% chlorhexidine
9902071|NCT00612482|No Intervention|1|"Participants in the no intervention condition will receive the usual high school science curriculum."
9902072|NCT00612482|Experimental|2|"Participants in the experimental arm will receive the 5-lesson, science-based substance abuse prevention curriculum in their science classes."
9902073|NCT00612521|Other|1|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
9902074|NCT00612521|Other|2|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
9902075|NCT00612547||Observation|Children under the age of five years (2 months to 5 years) residing in the zone covered by the community-based service provider throughout the entire follow-up period
9902076|NCT00612612|Experimental|Treatment (obatoclax mesylate, fludarabine, rituximab)|"Patients receive obatoclax mesylate IV over 3 hours on days 1 and 3, fludarabine IV over 20-30 minutes on days 1-5, and rituximab IV over 4 hours on day 1 (days 1 and 3 of course 1 only). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo peripheral blood collection for correlative studies. Samples are analyzed for expression of pro- and anti-apoptotic Bcl-2 family members by western blot; apoptosis induction by measurement of lymphocyte count, Annexin V staining, and Caspase and PARP cleavage; activated Bax by immunoprecipitation; and Bax promoter polymorphism by PCR amplification and direct sequencing."
9902077|NCT00612625|Experimental|GLP-1|A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
9902078|NCT00612625|Experimental|Saline|A graded glucose infusion together with a continuous infusion of saline
9933416|NCT05351580||Advanced Parkinson's disease patients who receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who receive advance therapy during the study.
9933417|NCT05351580||Advanced Parkinson's disease patients who do not receive advance therapy during the study|All participants will have advanced Parkinson's disease and undergo smart watch monitoring. Participants in this cohort will be those who do not receive advance therapy during the study.
9933418|NCT05351567|Experimental|infertility educatıon group|women wıll educate with model about infertility
9933419|NCT05351567|No Intervention|control group (non-education)|Routıne care
9933420|NCT05351554|Experimental|Treatment Arm 1|Namilumab with prednisone, or equivalent
9933421|NCT05351554|Placebo Comparator|Treatment Arm 2|Placebo with prednisone, or equivalent
9933422|NCT05351554|Experimental|Treatment Arm 3|Namilumab with current dose of prednisone, or equivalent
9933423|NCT05351541|Experimental|Psilocybin in combination with zolpidem and modafinil|Single dose of Psilocybin (1mg-25mg) in combination with zolpidem (10mg) and modafinil (200mg)
9933424|NCT05351541|Experimental|Psilocybin in combination with zolpidem|Single dose of Psilocybin (1mg-25mg) in combination with zolpidem (10mg)
9933425|NCT05351541|Experimental|Psilocybin in combination with modafinil|Single dose of Psilocybin (1mg-25mg) in combination with modafinil (200mg)
9933426|NCT05351541|Experimental|Psilocybin in combination with placebo|Single dose of Psilocybin (1mg-25mg) in combination with placebo
9933427|NCT05351502|Experimental|Cohort 1|Subjects will receive 25,000 ppm NO
9933428|NCT05351502|Experimental|Cohort 2|Subjects will receive 50,000 ppm NO
9933429|NCT05351502|Experimental|Cohort 3|Subjects will receive 100,000 ppm NO
9933430|NCT05351502|Experimental|expansion|Subjects will receive the selected dose of NO
9933433|NCT05351476|Experimental|Resistance Exercise|Participants do regular resistance exercise for 12 weeks.
9933434|NCT05351476|Experimental|Endurance Exercise|Participants do regular endurance exercise for 12 weeks.
9933435|NCT05351463|Other|one arm study|in each case one site was assigned as control site and one site was assigned as test site.
9933436|NCT05351450|Experimental|A Lyophilized COVID-19 mRNA Vaccine|Participants received A Lyophilized COVID-19 mRNA Vaccine 0.5ml reconstituted by sterile water, 1 shots at Day0, intramuscular injection
9933437|NCT05351450|Placebo Comparator|Placebo|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 1 shots at Day0, intramuscular injection
9933438|NCT05351437|Active Comparator|MTx-COVAB36|Cohort 1 - 100 mg IV dose Cohort 2 - 500 mg IV dose Cohort 3 - 1000 mg IV dose Cohort 4 - 2000 mg IV dose MTx-COVAB36 will be administered as a single dose intravenously.
9933439|NCT05351437|Placebo Comparator|Placebo|Placebo (0.9% NaCl) will be administered as a single dose intravenously.
9933440|NCT05351424|Experimental|Audiovisual Intervention- Radiation Therapy Education|Audiovisual video will be provided to the subjects as educational material.
9933441|NCT05351424|Active Comparator|Written Brochure- Radiation Therapy Education|Written brochures will be provided to the subjects as educational material.
9933442|NCT05351424|Experimental|Audiovisual Intervention- Cancer Clinical Trials|Audiovisual video will be provided to the subjects as educational material.
9933443|NCT05351424|Active Comparator|Written Brochure- Cancer Clinical Trials|Written brochures will be provided to the subjects as educational material.
9935747|NCT03255031|Placebo Comparator|Diet Randomization-Placebo Comparator|Standard American (SA) diet consists of KD snacks and shakes 3x p/day (high in fat) in the proportions of carbohydrates, protein and fat of traditional western diet. SA will receive the same KD solid snacks, in order to keep the diets blind to participants. SA will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
9902079|NCT00612638|Experimental|1|Pts receiving Dilantin, Tegretol or Phenobarbital
9902080|NCT00612638|Experimental|2|Pts on anti-convulsants other than Dilantin, Tegretol / Phenobarbital / pts not on any anti-convulsants
9902081|NCT00612651|Other|enzyme-inducing anti-epileptic drugs (EIAEDs)|Patients receiving enzyme-inducing anti-epileptic drugs (EIAEDs)such as carbamazepine, phenobarbitol, phenytoin, phosphenytoin, oxcarbamazepine, primadone)
9902082|NCT00612651|Other|no enyzme-inducing anti-epileptic drugs|Patients on non CYP3A4-inducing anti-convulsants or patients not on any anti-convulsants.
9902083|NCT00612755|Experimental|1|Peginterferon alfa-2a 180 mcg/week + 1000-1200 mg/day ribavirin during 24 weeks
9902084|NCT00612755|No Intervention|2|
9902085|NCT00612781|Other|A|
9902086|NCT00612781|Other|B|
9902087|NCT00612794|Experimental|1|exenatide once weekly, 0.8mg
9902088|NCT00612794|Experimental|2|exenatide once weekly, 2.0mg
9902089|NCT00612794|Placebo Comparator|3|volume equivalent to 0.8mg of exenatide once weekly
9902090|NCT00612794|Placebo Comparator|4|volume equivalent to 2.0mg of exenatide once weekly
9902091|NCT00612833|Active Comparator|cautery excision with fascial interposition|Contraception using cautery and excision with fascial interposition
9902092|NCT00612833|Active Comparator|B|Cautery and excision without fascial interposition
9902093|NCT00612833|Active Comparator|C|Ligation and excision with fascial interposition
9902094|NCT00612846|Experimental|A|
9902095|NCT00612846|Experimental|B|
9902096|NCT00612872|Experimental|Assess [123-I]CLINDE and brain imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
9902097|NCT00612898|Experimental|1|800mg BID apricitabine plus optimised background
9902098|NCT00612898|Active Comparator|2|150mg BID lamivudine plus optimised background
9902099|NCT00612911||Major group|Patients with Idiopathic dilated cardiomyopathy
9902100|NCT00612950|Experimental|GLP-1|
9902101|NCT00612950|Experimental|GIP|
9902102|NCT00612950|Placebo Comparator|saline|
9902103|NCT00612976||1|Patients with COPD treated with budesonide/formoterol
9902104|NCT00612989|Experimental|1|Schedule 1
9902105|NCT00612989|Experimental|2|Schedule 2
9902106|NCT00612989|Experimental|3|Schedule 2, Neulasta-supported
9902107|NCT00613041||1|Patients with one or more pulmonary nodules 5-15 mm in diameter.
9902108|NCT00613054|Experimental|Zactima + Gleevec + Hydrea|
9902109|NCT00613067|Experimental|GAD|35 patients with Generalized Anxiety disorder
9902110|NCT00613093|Active Comparator|Patients with glioblastoma multiforme|
9902111|NCT00613093|Active Comparator|Patients with Anaplastic Glioma|
9902112|NCT00613132|Experimental|1|Pts receiving EIACDs
9902113|NCT00613132|Experimental|2|Pts not receiving EIACDs
9902114|NCT00613145|Active Comparator|A|Treatment with Capecitabine and Sorafenib
9902115|NCT00613145|Active Comparator|B|Treatment with Capecitabine and Sorafenib
9902116|NCT00613158||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with significant subclinical atherosclerosis (SA) and a low Framingham risk score
9902117|NCT00613158||2|Participants from MESA with no SA and a low Framingham risk score
9902118|NCT00613158||3|Healthy participants from Northwestern University
9902119|NCT00613184|Experimental|1|Nylon Flocked swab Left Nasal Wash right
9902120|NCT00613184|Experimental|2|Nylon Flocked swab R Nasal Wash L
9902121|NCT00613184|Experimental|3|Nasal Wash Left Nylon Flocked swab Right
9902122|NCT00613184|Experimental|4|Nasal Wash R Nylon flocked swab L
9902123|NCT00613197|Experimental|1 Epanova|
9902124|NCT00613197|Placebo Comparator|2 Placebo|
9902125|NCT00613210||1|women without contraction at 24-34 weeks of gestation
9902126|NCT00613210||2|women without contractions between 24-34 weeks of gestation with a history of preterm labor
9902127|NCT00613210||3|women with preterm contractions 24-34 weeks of gestation
9902128|NCT00613223|Experimental|Vandetanib and Etoposide|Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide.
9902129|NCT00613249|Experimental|A|
9902130|NCT00613249|Experimental|B|
9902131|NCT00613249|Placebo Comparator|C|
9902132|NCT00613288|Experimental|A|
9902133|NCT00613340|Experimental|1|Cervical medial branch blocks with 0.25 ml of injectate
9902134|NCT00613340|Experimental|2|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
9902135|NCT00613353||I|Caucasian and African American females between the ages of 18 and 65.
9902136|NCT00613392|Experimental|1|
9902137|NCT00613392|Placebo Comparator|2|
9902138|NCT00613418|Other|single|Historical control
9902139|NCT00613431|Experimental|1|6 dose groups, 9 subjects on active, 3 subjects on placebo in each group
9902140|NCT00613431|Placebo Comparator|2|3 subjects on placebo in each group
9902141|NCT00613444|Experimental|LumaCare LC-122M non-coherent light source|"Split Face Comparison. One half of subject's face will receive topical photosensitizer applications followed by LumaCare LC-122M non-coherent light source illumination. Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.~The other half of the face will not receive any treatment and will serve as internal control."
9902142|NCT00613457|Experimental|I|o Arm I (closed to accrual as of 6/30/2006): Patients receive prednisone (PRED) on days 8-28.
9902143|NCT00613457|Experimental|II|o Arm II (closed to accrual as of 6/30/2006): Patients receive dexamethasone (DEXA) on days 8-28.
9902144|NCT00613457|Experimental|Reintensification Arm I|o Arm I (standard reinduction therapy, protocol II [closed to accrual as of 6/30/2006]): SR and IR patients receive DEXA on days 1-22; VCR and doxorubicin hydrochloride (DOX) in weeks 2-5; ASP on days 8, 11, 15, and 18; CPM on day 36; ARA-C and thioguanine (TG) on days 36-49; and MTX IT on days 38 and 45. Patients then proceed to maintenance therapy.
9902145|NCT00613457|Experimental|Reintensification Arm II|• Arm II (reduced-intensity reinduction therapy, protocol III [closed to accrual as of 6/30/2006]): SR patients receive DEXA on days 1-15; VCR and DOX on days 1 and 8; ASP on days 1, 4, 8, and 11; CPM on day 15; ARA-C and TG on days 15-28; and MTX IT on days 16 and 23. Patients then proceed to maintenance therapy.
9902146|NCT00613457|Experimental|Reintensification Arm III|• Arm III (reduced-intensity reinduction/second delayed reinduction therapy [double reintensification therapy] [closed to accrual as of 6/30/2006]): IR patients receive reduced-intensity reintensification therapy as in arm II. After a 10-week interim maintenance phase, treatment repeats once for a second delayed course of reintensification therapy. Patients then proceed to maintenance therapy.
9902147|NCT00613457|Experimental|Reintensification Arm IV|"• Arm IV (standard reintensification therapy [closed to accrual as of 6/30/2006]): HR patients receive one sequence of the following HR therapy elements, in this order: 1, 2, 3, following standard reinduction therapy protocol II repeated twice after a four weeks Interim Maintenance phase. Patients then proceed to maintenance therapy.~Element HR-1: Patients receive DEXA on days 1-5; VCR on days 1 and 6; ARA-C twice on day 5; MTX and CPM every 12 hours on days 2-4 (5 doses); ASP on day 6 ; and MTX/ARA-C/PRED IT on day 1.~Element HR-2: Patients receive DEXA on days 1-5; vindesine on days 1 and 6; DNR on day 5; MTX and ifosfamide every 12 hours on days 2-4 (5 doses); ASP on day 6; and MTX/ARA-C/PRED IT on day 1.~Element HR-3: Patients receive DEXA on days 1-5; ARA-C every 12 hours on days 1-2 (4 doses); etoposide five times daily on days 3-5; ASP on day 5; and MTX/ARA-C/PRED IT on day 1."
9902148|NCT00613457|Experimental|Reintensification Arm V|"• Arm V (extended reintensification therapy [triple protocol III] [closed to accrual as of 6/30/2006]): HR patients receive HR therapy elements 3, 2, and 1 following reintensification therapy repeated the therapy element three times with 4-week interim maintenance phases in between. Patients then proceed to maintenance therapy.~Interim maintenance/maintenance therapy: Patients receive MTX once weekly and MP daily until week 104 plus IT MTX every eight weeks.~Radiotherapy: HR patients or patients with T-cell acute lymphoblastic leukemia or CNS disease undergo CNS radiotherapy."
9902149|NCT00613470|Experimental|Citalopram and escitalopram|"Citalopram tablet or solution starting at 20 mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.~Escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
9902150|NCT00613496|Placebo Comparator|2|Placebo treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
9902151|NCT00613496|Active Comparator|1|Irbesartan treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
9902152|NCT00613522||case|Fist ischaemic hemispheric stroke or TIA
9902153|NCT00613522||control|No ischaemic hemispheric stroke or TIA
9902154|NCT00613535|Active Comparator|Lavage debridement to remove loose fragments|Articular cartilage defect left untreated by surgical tool during partial meniscectomy
9902155|NCT00613535|Active Comparator|Mechanical Debridement|Remove large chondral flaps and loose fragments
9902156|NCT00613535|Active Comparator|RF based Debridement|Debridement to remove loose fragments followed by use of Paragon T-2 RF wand to smooth the base of the shoulder of the tear
9902157|NCT00613548|Active Comparator|1|CABG Alone
9902158|NCT00613548|Active Comparator|2|CABG + Mitral repair
9902159|NCT00613600|Experimental|1|Two 665 mg capsules of glucomannan three times a day for eight weeks
9902160|NCT00613600|Placebo Comparator|2|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
9902161|NCT00613613||1|High drug metabolism genotype All receive fenofibrate
9902162|NCT00613613||2|Low drug metabolism genotype All receive fenofibrate
9902163|NCT00613665|Experimental|1|
9902164|NCT00613665|Experimental|2|
9902165|NCT00613665|Experimental|3|
9902166|NCT00613665|Experimental|4|
9902167|NCT00613665|Placebo Comparator|5|
9902168|NCT00613665|Experimental|6|
9902169|NCT00613665|Experimental|7|
9902170|NCT00613678|Active Comparator|1|Exercise + Education: Eight group sessions (8-15 people) during which participants engage in muscular strength and flexibility exercises. In addition, weekly educational lectures on topics germane to osteoarthritis management are included.
9902171|NCT00613678|Experimental|2|Exercise + Activity Strategy Training: 7/8 sessions will be in a group format in which participants engage in muscular strength & flexibility exercises and listen to education lessons on management strategies for osteoarthritis. The remaining session includes a home assessment by an occupational therapist to facilitate adequate participation in daily living and leisure activities.
9902172|NCT00613691|Experimental|SPI-1620|SPI-1620 an endothelin B agonist
9902173|NCT00613717|Experimental|a|pre- and early postnatal iron
9902174|NCT00613717|Experimental|b|iron prenatal only
9902175|NCT00613717|Experimental|c|iron early postnatal only
9902176|NCT00613717|Active Comparator|d|no iron pre- or postnatal
9902177|NCT00613743|Placebo Comparator|1|D1-D3 receive placebo
9902178|NCT00613743|Active Comparator|2|receive D1 D3 morphine
9902179|NCT00613769|Active Comparator|ordinary per operative prophylaxis|cefuroxime(1500mg) i.v.+ metronidazole (1500mg)i.v.given at the time point of induction of anesthesia
9902180|NCT00613769|Experimental|Per oral alternative|Trimethoprim-sulfamethoxazole(160mg/800mg)p.o.+metronidazole (1200mg)p.o.given 06.00 am on the day of operation
9902181|NCT00613782|Active Comparator|1|Reandron 100 treatment
9667213|NCT03840525|Sham Comparator|Sham Qigong|This group will also have 1 hour/weekly class delivered virtually that includes movements that are similar to qigong but will not include the meditation or breathwork that will be included in the actual qigong intervention arm.
9667214|NCT03840525|No Intervention|Treatment-as-usual|This group will receive no classes.
9902182|NCT00613782|Placebo Comparator|2|Placebo
9902183|NCT00613795|Active Comparator|1|Lactobacillus
9902184|NCT00613795|Placebo Comparator|2|placebo
9902185|NCT00613808|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only for the two week screening period and then for 20 weeks thereafter
9902186|NCT00613808|Active Comparator|B Same treatment for 6 weeks, 200ppm NO gas|Subjects were treated by topical application of 200ppm Nitric Oxide gas delivered to the wound area for 8 hours per day for 6 weeks
9902187|NCT00613847|Active Comparator|1|Patients with invasive solid tumors
9902188|NCT00613847|Active Comparator|2|Patients with advanced solid tumors that express HER2 with tumors that are HER2 1+ by IHC or FISH.
9902189|NCT00613873||1|Women participating in a community based mammography or cervical screening program will also participate in colonoscopy screening. Participation will be measured by stating an interest in colorectal cancer screening and then following through with colonoscopy screening. Furthermore we will assess whether those complying with colonoscopy will also recommend colonoscopy screening for their spouses or household members.
9902190|NCT00613899|Other|Telesurveillance|"At time of discharge from hospital, 40 ALS patients willbe enrolled in a telesurveillance program (TP) for the management of cought at home.~Two hours of an in-hospital educational training will be provided to patients and caregivers on the use of:~air stacking with Ambu balloon~manual manoeuvres and~in-Exoflator device indications and use"
9902191|NCT00613912||A|Ambulant patients with major depression
9902192|NCT00613964|Placebo Comparator|Standard Therapy|Standard heart failure therapy excluding carperitide administration
9902193|NCT00613964|Active Comparator|Carperitide Therapy|Addition of carperitide administration to standard heart failure therapy
9902194|NCT00614003|Experimental|1|decision support
9902195|NCT00614016|Experimental|single|8 subjects total (6 active and 2 placebo)
9902196|NCT00614029|Experimental|A|IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh
9902197|NCT00614029|Experimental|B|Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh
9902198|NCT00614029|Experimental|C|Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.
9902199|NCT00614029|Experimental|D|IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.
9902200|NCT00614029|Experimental|E|IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh
9902201|NCT00614029|Experimental|F|Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm
9902202|NCT00614042|Experimental|1|Dose escalation and expansion cohorts
9902203|NCT00614068|Experimental|A|Participants will receive 12 sessions of trauma-focused cognitive behavioral therapy over 3 months.
9902204|NCT00614068|Active Comparator|B|Participants will receive 12 sessions of treatment as usual over 3 months.
9902205|NCT00614081|Experimental|1|Renal transplant recipients
9902206|NCT00614133|Experimental|1|Preoperative nutrition.
9902207|NCT00614133|Active Comparator|2|Preoperative fasting.
9902208|NCT00614146|Experimental|1|
9902209|NCT00614146|Active Comparator|2|
9902210|NCT00614159||GI Endoscopy|
9902211|NCT00614172|Experimental|Proton Radiotherapy|Two week course of proton radiotherapy to the breast.
9902212|NCT00614224|Experimental|A|Treadmill training group (TAEX)
9902213|NCT00614224|Active Comparator|B|Attention control group (CON)
9902214|NCT00614250|Experimental|Dose Level 1|
9902215|NCT00614250|Experimental|Dose Level 2|
9902216|NCT00614250|Experimental|Dose Level 3|
9902217|NCT00614250|Experimental|Dose Level 4|
9902218|NCT00614250|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
9902219|NCT00614263||Blinded Group|SEDline output is unknown to anesthesiologist.
9902220|NCT00614263||Unblinded Group|SEDline output is known to anesthesiologist.
9902221|NCT00614276||Phase I - Focus Groups|
9902222|NCT00614276||Phase II TENDRILS|Phase II - TENDRILS Program only.
9902223|NCT00614276||Phase II TENDRILS + Counseling|Phase II - TENDRILS + Sexual Counseling Sessions.
9902224|NCT00614328|Active Comparator|1|Naltrexone (50 mg once a day) + placebo baclofen + behavioral therapy (n=10)
9902225|NCT00614328|Active Comparator|2|Placebo naltrexone + baclofen (10 mg t.i.d) + behavior therapy (n=10)
9902226|NCT00614328|Active Comparator|3|Baclofen (10 mg t.i.d) + naltrexone (50 mg once per day) + behavior therapy (n=10)
9902227|NCT00614328|Placebo Comparator|4|Placebo baclofen + placebo naltrexone + behavior therapy
9902228|NCT00614341|Active Comparator|1, 2|"Pulse MedRelief SE 55~Continuous MedRelief SE 55"
9902229|NCT00614354|Experimental|1|
9902230|NCT00614419|Active Comparator|1|The Lichtenstein tension-free hernioplasty with polypropylene mesh
9935748|NCT03255018|Experimental|1|Subjects with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
9902231|NCT00614419|Experimental|2|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
9902232|NCT00614471|Active Comparator|1|
9902233|NCT00614471|Experimental|2|
9902234|NCT00614471|Experimental|3|
9902235|NCT00614536||001|
9902236|NCT00614549||Levetiracetam|Patients treated with Levetiracetam
9902237|NCT00614562|Experimental|NAVA|
9902238|NCT00614588||observation group|Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder catheter.
9902239|NCT00614640|Experimental|1|One 0.8 ml vaccine-containing patch and 1 placebo patch placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
9902240|NCT00614640|Experimental|2|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
9902241|NCT00614640|Experimental|3|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 7, 42, 49, 84, and 91
9902242|NCT00614653|Experimental|Bevacizumab, Erlotinib + Capecitabine|Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.
9933444|NCT05351411||combined progressive functional exercise|The initial implementation for the 8-week (3 days per week) combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike. The second part of the combined exercise program, the progressive resistance training program, is designed to be consistent with the resistance training section of the Canadian Physical Activity Guidelines for adults with MS. Each prescribed session consisted of 1-3 sets and 10-15 repetitions of 10 exercises targeting major muscle groups of the upper and lower extremities. The specific exercises prescribed included lunges, chair raises/squats, calf raises, knee flexion, knee extensions, shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, and abdominal curls.
9933445|NCT05351411||Placebo|Participants in the control group maintained their routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
9933446|NCT05351398||PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
9933447|NCT05351398||Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
9933448|NCT05351385||Covid +|Patients SARS-CoV-2 positive.
9933449|NCT05351385||Control|Patients with Pneumonia non-SARS-CoV-2 related
9933450|NCT05351372|Experimental|ULD protocol|ultra-low dose protocol in cone-beam computed tomography with a field of view including the cleft area
9667215|NCT03838042|Experimental|Nivolumab and Entinostat|Combination Study of Nivolumab and Entinostat
9933451|NCT05351372|Active Comparator|Standard dose protocol|Standard dose protocol in cone-beam computed tomography with a field of view including the cleft area
9933452|NCT05351359|Active Comparator|Active control|The patients from the active control group will receive brief physical activity advice from their general practitioners at baseline, and they will also receive the Fitbit tracker to self-monitor their daily steps.
9933453|NCT05351359|Experimental|Intervention|The patients in the intervention group will be exposed to the same procedures as those from the active control group, but will also receive a mHealth-enabled just-in-time adaptive intervention and regular monthly phone counselling in the first 6 months.
9935749|NCT03253744|Experimental|1/Tumor Irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy
9935750|NCT03253744|Experimental|2/Prostate and Tumor Irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate
9935751|NCT03253705||Controls|Healthy Controls
9902243|NCT00614666|Experimental|A|nikkomycin Z 50 mg BID versus placebo BID x 14 days
9902244|NCT00614666|Experimental|B|nikkomycin Z 250 mg BID versus placebo BID x 14 days
9902245|NCT00614666|Experimental|C|nikkomycin Z 500 mg BID versus placebo BID x 14 days
9902246|NCT00614666|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
9902247|NCT00614679|Experimental|1|single arm trial of experimental catheter lock solution
9902248|NCT00614718||1|Total number of patients receiving an ICD between 1993 and 2004 and not having re interventions due to malfunctioning leads.
9902249|NCT00614718||2|Patients with ICD lead failure receiving a new ICD lead
9902250|NCT00614718||3|Patients with ICD lead failure but intact shock-coil of the ICD lead receiving only an additional pace/sense lead.
9902251|NCT00614731|Experimental|ID immunizations (100 mcg)|Participants will receive a total of two 100 mcg intradermal (ID) KLH carrier-protein immunizations with 1 mg/ml KLH per immunization. Immunizations will be given 21 days apart at Visits 5 and 6.
9902252|NCT00614731|Experimental|Scarification by 3 jabs|Participants will receive two scarification immunizations by 3 jabs containing 20 mg/ml of KLH carrier-protein. The immunizations will occur 21 days apart at Visits 5 and 6.
9902253|NCT00614731|Experimental|ID immunizations (250 mcg)|Enrollment will begin after the safety data for Groups 1A and 2A have been reviewed. Participants in this group will receive two 250 mcg ID KLH vaccinations containing 10 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
9902254|NCT00614731|Experimental|Scarification by 15 jabs|Enrollment will begin after the safety data from groups 1A and 2A has been examined. Participants in this group will receive a total of two scarification immunizations by 5 needles used to administer 15 jabs, each containing, 20 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
9902255|NCT00614757|No Intervention|2|One half of the patients will take not medication for 30 days and then have labs redrawn
9902256|NCT00614757|Experimental|1|one half of the patients with insulin resistance will take 4ml of 20% N-acetylcysteine BID for 30 days
9902257|NCT00614770|Experimental|1|Standard White Light Colonoscopy
9902258|NCT00614770|Experimental|2|High Definition White Light Colonoscopy
9902259|NCT00614770|Experimental|3|Narrow Band Imaging Colonoscopy
9667216|NCT03837756|Placebo Comparator|Arm A: Placebo/Placebo|This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
9902260|NCT00614796|Experimental|1|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
9902261|NCT00614796|No Intervention|2|daily physical activity is assessed at baseline, 3 months, 9 months and 15 months. No counseling.
9902262|NCT00614809|Experimental|1|non-randomized open-label uncontrolled phase II trial
9902263|NCT00614835|Experimental|1 patients with completely resected uterine leiomyosarcoma|Docetaxel plus Gemcitabine
9902264|NCT00614848|Experimental|1|Endeavor Drug Eluting Coronary Stent
9902265|NCT00614848|Active Comparator|2|Driver bare-metal coronary stent
9902266|NCT00614861||001|
9902267|NCT00614887||2|Patients scheduled for elective cerebral aneurysmal surgery
9902268|NCT00614887||1|Patients with subarachnoid hemorrhage
9993560|NCT01473342|Other|Control & Intervention Phases|The control phase will run for 8 weeks, including survey completion and accelerometer wear during Week 1 and Week 8. The intervention phase will run for the 9 weeks following the control phase; where participants are assigned a smartphone to interact with the Mila Blooms gaming app and integrated social network & receive weekly supportive coaching phone calls from study staff for 8 weeks (Week 9 - Week 16) followed by accelerometer wear & survey completion during the 9th and final week (Week 17).
9993561|NCT01473433|Other|Control|Patients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
9993562|NCT01473433|Experimental|adiFLAP|Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
9993563|NCT01473446|No Intervention|Control|Standard monitoring. Initial optimization of fluid status is performed by pulse, BP and anaesthesiologist assessment with Ringer acetate. Followed by an infusion of 10ml/kg/t Ringer acetate. Urinary output and blood pressure is used as a surrogate parameter: the infusion rate is increased by a fall in blood pressure or urine output <0.5ml/kg/t. Bleeding replaced with HES 1:1, otherwise see table for fluid therapy page 9. Vasoactive agents (noradrenaline / phenylephrine) is given if the anesthesiologist considers this necessary. Postoperative give 1000ml Glucose 5%. HES or Ringer when low blood pressure, eventually noradrenaline as vasoactive agent.
9993564|NCT01473446|Experimental|Goal directed fluid therapy|
9993565|NCT01473459|Active Comparator|IVM Treatment|
9993566|NCT01473459|Active Comparator|Antagonist Protocol|
9993567|NCT01473472|Active Comparator|Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
9993568|NCT01473472|Placebo Comparator|Placebo of Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
9993569|NCT01473485|Experimental|ExAblate Transcranial Device|
9993570|NCT01473498|Experimental|Test group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients (A maximum dose of 1.2 mcg / kg / min is not exceeded). Key details, e.g., for drugs include dosage form, dosage, frequency and duration."
9993571|NCT01473498|Active Comparator|Control group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
9993572|NCT01473511|Experimental|Strongest Families Program + Usual care|50% randomized to receive Strongest Families intervention immediately as well as the usual care services available via the referring agency for the 22 month study period.
9993573|NCT01473511|No Intervention|Usual care|50% randomized will not receive Strongest Families Intervention during the 22 month study phase, but will receive the usual care services available via the referring agency. At the end of the 22 month study period study participants will be offered the Strongest Families Intervention services.
9993574|NCT01473537|Active Comparator|calcium lactate solution 75 mM|
9993575|NCT01473537|Active Comparator|calcium lactate solution 150 mM|
9993576|NCT01473537|Placebo Comparator|placebo|
9993577|NCT01473550|Experimental|Early Intervention|At Phase 1 (first 3 months of project), the 200 participants in Group 1 will be provided with a Personal Health Record (PHR) through TELUS Health Space, as well as they will be introduced to smart phone technology to ready them for deployment of the prompts and reminders. Two months later, they will be provided with a smart phone.
9667217|NCT03837756|Active Comparator|Arm B: Lefitolimod/Placebo|This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
9667218|NCT03837756|Active Comparator|Arm C: Placebo/3BNC117 + 10-1074|This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
9667219|NCT03837756|Active Comparator|Arm D: Lefitolimod/3BNC117 + 10-1074|This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
9667220|NCT03836352|Experimental|Arm 1 (All cohorts)|DPX-Survivac, Cyclophosphamide, Pembrolizumab
9902269|NCT00614952|Experimental|PR|
9902270|NCT00614952|Active Comparator|PSG|
9902271|NCT00614965|Experimental|1|IC
9902272|NCT00614965|Experimental|2|PC
9902273|NCT00614978|Experimental|I|Lapatinib plus temozolomide
9902274|NCT00615004||1-SSA|All patients receiving first-line depot SSA treatment, with either octreotide-LAR or lanreotide, achieving control of the disease, and with available follow-up after 12 months of treatment.
9902275|NCT00615004||2-Surgery|All patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach, who did not require any additional therapy for acromegaly and with available follow-up after 12 months of treatment
9902276|NCT00615043||TURBT group|Subjects undergoing transurethral resection of bladder tumor or other transurethral biopsy procedure who agree to provide bladder tissue specimens
9902277|NCT00615082|Experimental|Mindfulness-Based Stress Reduction|
9902278|NCT00615082|Active Comparator|Caregiver Education & Social Support|
9902279|NCT00615095||1|Cases will be patients 18 years or older with a histologically confirmed, second or multiple primary melanoma.
9902280|NCT00615095||2|Controls will be patients 18 years or older with a histologically confirmed first primary melanoma diagnosed no earlier than 12 months prior to the study start date.
9902281|NCT00615095||3|Healthy controls will be subjects 18 years or older recruited from the general population through random digit dialing. These subjects will have no history of melanoma. They will also be frequency matched to cases on the basis of sex and 10-year age group.
9902282|NCT00615121||arteries from PAD patients|peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
9902283|NCT00615121||arteries from Free Fib transfers|peripheral arteries from patients without evidence of peripheral arterial occlusive disease
9902284|NCT00615134|Experimental|1|
9902285|NCT00615134|Active Comparator|2|
9902286|NCT00615147||1|Patients to have a CT pulmonary angiogram for suspected pulmonary embolism will have a d-dimer drawn as is routinely done.
9902287|NCT00615160|Experimental|A|PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)
9902288|NCT00615160|Experimental|B|combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28
9902289|NCT00615173|Experimental|1|tacrolimus(fk506) treatment in induction and maintenance phase
9902290|NCT00615173|Active Comparator|2|intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase
9902291|NCT00615186|Experimental|A|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
9902292|NCT00615186|Active Comparator|B|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
9902293|NCT00615212|Active Comparator|Subjects receiving midazolam|Eligible subjects will receive midazolam oral syrup with a dose of 5 milligrams on Day 1.
9902294|NCT00615212|Active Comparator|Subjects receiving rosiglitazone|Eligible subjects will receive rosiglitazone oral tablet with a dose of 4 milligrams on Day 2.
9902295|NCT00615212|Active Comparator|Subjects receiving flurbiprofen|Eligible subjects will receive flurbiprofen oral tablet with a dose of 50 milligrams on Day
9902296|NCT00615212|Experimental|Subjects receiving GSK376501|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams from Day 4 to Day 10.
9902297|NCT00615212|Experimental|Subjects receiving GSK376501+ midazolam|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with midazolam oral tablet of 5 milligrams on Day 11.
9902298|NCT00615212|Experimental|Subjects receiving GSK376501 + rosiglitazone|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with rosiglitazone oarl tablet of 4 milligrams on Day 12.
9902299|NCT00615212|Experimental|Subjects receiving GSK376501 + flurbiprofen|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with flurbiprofen oral tablet of 50 milligrams on Day 13.
9902300|NCT00615225||Brain dead patients|All patients meeting criteria for brain death
9902301|NCT00615225||Healthy control|Any healthy volunteers accepting to give some blood
9902302|NCT00615225||Volunteers having hip surgery|Patients undergoing hip surgery for degenerative non-inflammatory hip disease
9902303|NCT00615238|Experimental|Diet plus continuous bouts|diet-plus-continuous bouts of vigorous aerobic exercise
9902304|NCT00615238|Experimental|Diet plus short bouts|diet-plus-short bouts of vigorous aerobic exercise accumulated throughout the day
9902305|NCT00615238|Experimental|Diet plus moderate lifestyle activity|diet-plus-moderate intensity lifestyle activity accumulated throughout the day
9902306|NCT00615277|Active Comparator|1|1: omega-3 fatty acid supplement
9902307|NCT00615277|Placebo Comparator|2|2: olive oil
9902308|NCT00615303|Placebo Comparator|2|
9902309|NCT00615303|Active Comparator|1|
9902310|NCT00615316|Experimental|A|
9902311|NCT00615316|Placebo Comparator|B|
9902312|NCT00615329||Soft tissue tumor|Any patient with soft tissue tumor will be asked to give a sample for this study
9902313|NCT00615355|Other|Body location|Different body locations receive specific treatments
9902314|NCT00615355|Active Comparator|Control|Treatment with narrow-band UVB
9902315|NCT00615368|Placebo Comparator|Placebo|Isotonic NaCl, intravenously injection
9902316|NCT00615368|Experimental|Active|Epoetin alfa, injected
9902317|NCT00615381|Active Comparator|Normal insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using normal intensive insulin infusion rates (0-10 U/hr).
9902318|NCT00615381|Experimental|Supraphysiologic insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using supraphysiologic insulin infusion doses (0.3 U/kg/hr) and exogenous dextrose to provide stable blood glucose levels .
9902319|NCT00615407||Alcohol Drinkers|Asthmatics who consume 3 or more alcoholic beverages per day (on average)
9902320|NCT00615407||Non Drinkers|Asthmatics who do not drink alcohol or consume less than or equal to 2 alcoholic beverages per month
9902321|NCT00615446|Experimental|A|
9902322|NCT00615498||Surgical cases|Subjects who are undergoing bariatric surgery
9902323|NCT00615498||Controls|Subjects who qualify for bariatric surgery but do not undergo the procedure
9902324|NCT00615511|Placebo Comparator|placebo|Approximately one third of subjects
9902325|NCT00615511|Experimental|Pregnenolone|
9902326|NCT00615563||genotype test|
9902327|NCT00615563||combined phenotype/genotype test|
9902328|NCT00615576|Experimental|Subjects receiving SB-656933|Eligible subjects will be randomized to receive once daily doses of 100 milligrams of SB- 656933 for 14 days.
9902329|NCT00615576|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 14 days.
9902330|NCT00615602|Experimental|1|FEC -> TXT+H 12m
9902331|NCT00615602|Experimental|2|FEC -> TXT+H 6m
9902332|NCT00615615|Experimental|Levetiracetam (LEV)|LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
9902333|NCT00615615|Placebo Comparator|Placebo|Subjects received Placebo matching to LEV treatment.
9902334|NCT00615628||family members|family members of the proband and father identified
9902335|NCT00615641||1|3 year old children
9902336|NCT00615641||2|4 year old children
9902337|NCT00615641||3|5 year old children
9902338|NCT00615654|Other|2|
9902339|NCT00615667|Experimental|tacrolimus(fk506) treatment|tacrolimus(fk506) treatment
9902340|NCT00615706||1|Asthmatics
9902341|NCT00615706||2|Healthy volunteers (without asthma)
9902342|NCT00615732|Experimental|1|qigong
9902343|NCT00615732|Active Comparator|2|exercise therapy
9902344|NCT00615732|No Intervention|3|
9902345|NCT00615745|Experimental|Single Arm|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
9902346|NCT00615758|Experimental|1|Tarceva
9902347|NCT00615771|Experimental|Day 2 embryo transfer|Embryos are transferred 2 days after fertilization.
9902348|NCT00615771|Active Comparator|Day 3 embryo transfer|Standard of care for women undergoing IVF with a limited number of embryos is to transfer all embryos on Day 3 after fertilization
9902349|NCT00615797|Experimental|1|Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
9902350|NCT00615797|Placebo Comparator|2|Group randomized to receive standard intervention for sydenham's chorea alone
9902351|NCT00615810|Active Comparator|2|Open label Kivexa (abacavir (as sulfate) 600 mg/lamivudine 300 mg) once daily for oral administration plus Sustiva (efavirenz 600 mg) once daily for oral administration
9902352|NCT00615810|Experimental|1|Open label Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration to be taken on an empty stomach
9902353|NCT00615823|Active Comparator|1|Atorvastatin group: receive atorvastatin 10 mg daily in addition to supportive care
9902354|NCT00615823|Placebo Comparator|2|Placebo group: receive matching placebo in addition to supportive care.
9902355|NCT00615862||AUD+ and AUD-|AUD stands for alcohol use disorders. Patients with alcohol use disorders are assigned the label AUD+. Patients without alcohol use disorders are assigned the label AUD-.
9902356|NCT00615875|Active Comparator|A|
9902357|NCT00615875|Placebo Comparator|P|
9902358|NCT00615888|Active Comparator|A|Traditional management including preoperative bowel washout, patient controlled analgesia (PCA), delayed start of enteral feeding
9902359|NCT00615888|Experimental|B|Fast track management including no bowel washout, patient controlled epidural anesthesia, early enteral feeding
9902360|NCT00615979||Miniature echo machine|Diagnostic capabilities Wireless transfer
9902361|NCT00616005|Other|1|Pts taking EIAEDs
9902362|NCT00616005|Other|2|Pts not taking EIAEDs
9902363|NCT00616044|Experimental|CSA|For CSA, an 22-G catheter (Spinocath, B.Braun Melsungen, Germany) over a 27-G Quincke needle was used. After identification of the epidural space with a Crawford needle, the catheter with the spinal needle inside was advanced through the epidural space until the dural puncture was felt and CSF was seen in the catheter. The catheter was then fed over the needle into the intrathecal space. The spinal needle and the modified Tuohy needle were removed and a luer connector and a filter previously filled with the anesthetic solution were attached to the catheter.
9902364|NCT00616044|Experimental|CSE|"CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany). The block consists of performing a spinal block via a 27-G spinal needle (Spinocan 125mm) introduced through an 18-G Tuohy needle (Perican 88mm) which was placed cranially directed in the epidural space. We did rotate the Tuohy needle between the spinal block and the insertion of the epidural catheter."
9902365|NCT00616057|Placebo Comparator|B|Maltodextrin, non digestible carbohydrate
9902366|NCT00616057|Experimental|A|fructans, non digestible carbohydrates fermented in the caeco-colon
9902367|NCT00616070|Experimental|1|Difluprednate
9902368|NCT00616070|Placebo Comparator|2|Vehicle
9902369|NCT00616083||1|Healthy breast fed infants
9902370|NCT00616096|Experimental|1|
9902371|NCT00616161|Experimental|1|Istaroxime dose of 0.5 microgram/kg body weight/minute of iv infusion for six ours
9902372|NCT00616161|Experimental|2|Istaroxime dose of 1.0 microgram/kg body weight/minute of iv infusion for six ours
9902373|NCT00616161|Experimental|3|Istaroxime dose of 1.5 microgram/kg body weight/minute of iv infusion for six ours
9902374|NCT00616161|Placebo Comparator|4|Placebo iv infusion for six ours
9902375|NCT00616174|Other|1|Active warming with Bair Hugger blanket
9902376|NCT00616187|Active Comparator|interferon|
9902377|NCT00616187|Sham Comparator|untreated|
9902378|NCT00616265|No Intervention|B|Group B. Only Usual Control
9902379|NCT00616265|Experimental|A|Group A: Cpap treatment plus Usual control
9902380|NCT00616291|Experimental|Group I|MHC Class I binding peptide at 1000 mcg
9902381|NCT00616291|Experimental|Group II|MHC Class II binding peptide at 1000 mcg
9902382|NCT00616291|Experimental|Group III|Combination MHC Class I and II binding peptide at 1000 mcg each
9902383|NCT00616304|Active Comparator|A|L-arginine infusion
9902384|NCT00616304|Placebo Comparator|S|Normal saline infusion
9902385|NCT00616369||1|"I:~For those patients who have had blood samples drawn as a result of participating in current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension study (X980515002), we would like to use their previously obtained blood and continue to draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies.~For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study (X030403017), these participants will also sign a consent form to participant in this new trial. We would like to use the previously obtained data from the X030403017 in part with this study.~As for the X980515002 expired patients, we would like to use the previously obtained data ONLY in part for this study that was collected as a result of the X980515002 study."
9902386|NCT00616369||2|"II:~Group 2: After signing a consent form, these participants will have a 12mL (less than 3 teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits."
9902387|NCT00616382|Experimental|Stepwise Indo|Stepwise escalating doses of indomethacin, until ductal closure or maximum of 1 mg/kg/dose.
9902388|NCT00616382|Experimental|PTX|Combined administration of indomethacin and pentoxifylline, an inhibitor of TNF alpha
9902389|NCT00616395||no grouping|IDE used for outcome measurement not for an intervention.
9902390|NCT00616408||A|Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR
9902391|NCT00616447|Experimental|1|
9902392|NCT00616447|Sham Comparator|2|
9902393|NCT00616460|Experimental|Bivalirudin|
9902394|NCT00616473||1 Nursing Home Staff|Direct care staff
9902395|NCT00616473||2 Family Members|Family members/Significant other of nursing home resident.
9902396|NCT00616486|Experimental|1|
9902397|NCT00616486|Placebo Comparator|2|
9902398|NCT00616512|Experimental|1|GF Strong Water Protocol/ water allowed between meals after oral care for selected clients/ Fraser Water Protocol
9902399|NCT00616538|Active Comparator|Cutivate(r)|Topical mid-strength steroid
9902400|NCT00616538|Experimental|EpiCeram(r)|EpiCeram(r) topical barrier repair cream.
9902401|NCT00616551|Experimental|A|
9902402|NCT00616551|Active Comparator|B|
9933454|NCT05351346|Experimental|R-CHOP-X|Patients in R-CHOP-X group will receive rituximab 375 mg/m² IV, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. For the remaining 5 cycles, they will receive orelabrutinib 150 mg/day PO on days 1-21, or lenalidomide 25 mg/day PO on days 1-10, or decitabine 10 mg/m² IV on days -5 to -1 followed by standard R-CHOP of every 21-day cycle.
9933455|NCT05351346|Active Comparator|R-CHOP|Patients in R-CHOP group will receive rituximab 375 mg/m² IV on day 1, cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² iv, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 2, and prednisone 100 mg/day PO on days 2-6 of every 21-day cycle for 6 cycles.
9935752|NCT03253705||Research Subjects|Research Subjects already enrolled on other NIH protocols
9935753|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
9902403|NCT00616616|Experimental|1|all subjects
9902404|NCT00616733|Experimental|1|
9902405|NCT00616733|Experimental|2|
9902406|NCT00616733|Experimental|3|
9902407|NCT00616746|Experimental|1|Three test days, within-subject design.
9902408|NCT00616824|Active Comparator|Traditional Method|Arm which uses the Serratus Anterior muscle mobilization for lateral coverage of the tissue expander
9902409|NCT00616824|Experimental|Dermamatrix Arm|Arm which uses Dermamatrix as the lateral expander coverage
9902410|NCT00616837|Active Comparator|Standard consultation|Standard care in orthopaedic outpatient clinic
9902411|NCT00616837|Experimental|Telemedicine consultation|Orthopaedic care in outpatient clinic by use of telemedicine.
9902412|NCT00616850|Active Comparator|Group A|Group A subjects will receive a continuous femoral block catheter and a Patient Controlled Analgesia (PCA).
9902413|NCT00616850|Experimental|Group B|Group B subjects will receive a low dose lidocaine (1.33 mg/kg/hr) infusion and a Patient Controlled Analgesia.
9902414|NCT00616850|Placebo Comparator|Group C|Group C subjects will receive placebo (preservative free normal saline) infusion and a Patient Controlled Analgesia.
9902415|NCT00616876|Experimental|1|Study group will receive 1% lactulose in all their feeds (human milk or preterm formula)
9902416|NCT00616876|Placebo Comparator|2|Control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula).
9902417|NCT00616889||1|Seroquel added to medication regime and sleep quality measured
9902418|NCT00616915|Other|1|Wellbutrin SR switched to Wellbutrin XL
9902419|NCT00616954|Experimental|1|with ATG-F
9902420|NCT00616954|No Intervention|2|control
9902421|NCT00616980|Active Comparator|Low Dose|
9902422|NCT00616980|Active Comparator|High Dose|
9902423|NCT00616980|Placebo Comparator|Saline|
9902424|NCT00616993|Placebo Comparator|2|Vehicle
9902425|NCT00616993|Experimental|1|Difluprednate
9902426|NCT00617006||Before (Control)|Study group representative of standard practice
9902427|NCT00617006||After(Treatment)|After treatment group with the personal hand hygiene device ie. Device Group.
9902428|NCT00617019||Parkinson's patients|Observational study to compare rates of impulse control disorders in patients taking different medications for Parkinson's Disease
9902429|NCT00617032|Active Comparator|1|1x10^10 DRP/mL tgAAC94
9902430|NCT00617032|Active Comparator|2|1x10^11 DRP/mL tgAAC94
9902431|NCT00617032|Placebo Comparator|3|Single dose tgAAC94 placebo
9902432|NCT00617045|Experimental|Duloxetine|type of experimental agent
9902433|NCT00617110|Sham Comparator|allergic clean air|subjects with allergic rhinitis will be exposed to clean air followed by LAIV
9902434|NCT00617110|Active Comparator|Allergic diesel|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
9902435|NCT00617110|Sham Comparator|control clean air|Healthy control subjects will be exposed to clean air followed by LAIV
9902436|NCT00617110|Sham Comparator|Control diesel|Healthy control will be exposed to diesel followed by LAIV
9902437|NCT00617136|Experimental|III|Prewarming by HotDog
9902438|NCT00617136|Active Comparator|I|Intraoperative warming by Bair Hugger
9902439|NCT00617136|Active Comparator|II|Intraoperative warming by HotDog
9667221|NCT03836352|Experimental|Arm 2 (Ovarian cohort only)|DPX-Survivac, Pembrolizumab
9902440|NCT00617214||All|Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program
9902441|NCT00617253|Experimental|A|
9902442|NCT00617253|Experimental|B|
9902443|NCT00617253|Experimental|C|
9902444|NCT00617253|Experimental|D|
9902445|NCT00617266|Active Comparator|Arm 1 Control Group|Distribution of pamphlets containing information on the hazards of tobacco
9902446|NCT00617266|Experimental|Arm 2|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
9902447|NCT00617266|Experimental|Arm 3|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
9902448|NCT00617266|Experimental|Arm 4|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
9902449|NCT00617292||Category 1, Group 1|Children who have 21OHD and received prenatal dexamethasone treatment
9902450|NCT00617292||Category 1, Group 2|Children who have 21OHD and did not receive prenatal dexamethasone treatment (control)
9902451|NCT00617292||Category 2|Mothers of children who received prenatal dexamethasone treatment
9902452|NCT00617318|Experimental|A|
9902453|NCT00617318|Placebo Comparator|B|
9902454|NCT00617370|Experimental|1|The regimen consists of EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 with pegfilgrastim subcutaneously (SQ) on day # 2, followed by paclitaxel (175 mg/m2) q 14 days x 6 with pegfilgrastim SQ on day # 2.
9902455|NCT00617435|Experimental|V|
9902456|NCT00617435|Experimental|N|
9902457|NCT00617435|Experimental|J|
9902458|NCT00617448|Active Comparator|I|conventional diathermy haemorrhoidectomy under spinal anaesthesia
9902459|NCT00617448|Active Comparator|II|conventional diathermy haemorrhoidectomy with local anaesthesia combined with intravenous sedation (group II)
9902460|NCT00617448|Active Comparator|III|Ligasure haemorrhoidectomy under spinal anesthesia
9902461|NCT00617448|Active Comparator|IV|Ligasure haemorrhoidectomy under local anesthesia
9902462|NCT00617474|Experimental|1|Group of patient with anemia, that treated by erythropoietin
9902463|NCT00617474|Placebo Comparator|2|Patients group with anemia that treated by placebo
9902464|NCT00617500|Active Comparator|Hormone|
9902465|NCT00617500|Experimental|flower therapy|
9902466|NCT00617500|Experimental|therapeutic touch|
9902467|NCT00617500|Experimental|auriculotherapy|
9902468|NCT00617513|Active Comparator|1|
9902469|NCT00617513|Active Comparator|2|
9902470|NCT00617513|Active Comparator|3|
9902471|NCT00617513|Placebo Comparator|4|
9902472|NCT00617578|Experimental|1|programming of VF therapy: ATP (antitachycardia pacing) One Shot ON
9902473|NCT00617578|Active Comparator|2|programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF
9902474|NCT00617617|Experimental|A|Dietary Supplement: Prevastein HC®
9902475|NCT00617617|Placebo Comparator|B|Placebo
9902476|NCT00617643|Active Comparator|2|Triomune® 30 one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
9902477|NCT00617643|Experimental|1|Triomune® 30 one tablet twice daily for two weeks
9902478|NCT00617656|Active Comparator|A|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
9902479|NCT00617656|Experimental|B1|Low RAP expression and any levels of BRCA1 expression: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
9902480|NCT00617656|Experimental|B2|Intermediate or high RAP expression and low or intermediate BRCA1 expression: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
9902481|NCT00617656|Experimental|B3|Intermediate or high RAP expression and high BRCA1 expression: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
9902482|NCT00617682|Active Comparator|Group 1|Group 1 (experimental)
9902483|NCT00617682|Placebo Comparator|Group 2|Group 2 (placebo comparator)
9902484|NCT00617695|Experimental|1|
9902485|NCT00617695|Placebo Comparator|2|
9902486|NCT00617721||1|patients with unexplained bleeding disorder
9902487|NCT00617721||2|healthy volunteers
9902488|NCT00617747|Experimental|1|
9902489|NCT00617747|Placebo Comparator|2|
9902490|NCT00617760|Experimental|1|Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects
9902491|NCT00617760|Active Comparator|2|PCV7 administration only, 85 subjects
9902492|NCT00617760|Active Comparator|3|MenC-TT vaccine only, 85 subjects
9902493|NCT00617812|Experimental|Shan5|
9902494|NCT00617838|Active Comparator|1|Optimization of gluten introduction by nutritional councelling
9902495|NCT00617838|No Intervention|2|No specific nutritional councelling. Follow-up of gluten introduction
9902496|NCT00617864|Experimental|1|Group will receive infusion of human albumin
9902497|NCT00617864|Placebo Comparator|2|Group will receive infusion of saline
9902498|NCT00617877|Experimental|1|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
9902499|NCT00617955||Surgical|Cardiac surgery patients that received Aprotinin or Amicar
9902500|NCT00618033|Active Comparator|1|
9902501|NCT00618033|Active Comparator|2|
9902502|NCT00618085|Experimental|1|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the experimental group will receive 2 instruction DVD's introducing them to motor imagery practice, taking 35 minutes in total. The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to help incorporate motor imagery within the therapy. Thereafter the therapist will help the patient use motor imagery as part of their normal treatment. The total amount spent on motor imagery during therapy sessions will be 6.5 hours in 6 weeks."
9902503|NCT00618085|Active Comparator|2|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the control group will receive 2 DVDs for 35 minutes in total. These will show background information on their condition, explaining the importance of practice of activities, and on the principles of motor learning and phased movement which underlie most therapy.The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to control for attention. The total amount the physiotherapist and occupational therapist spend with the patients should be the same in both groups."
9902504|NCT00618124|Experimental|A|
9902505|NCT00618150|Experimental|A|
9902506|NCT00618176|Experimental|B|
9902507|NCT00618176|Experimental|A|
9902508|NCT00618176|Experimental|C|
9902509|NCT00618215|Experimental|I|"ROE Group~Interventions:behaviorial"
9902510|NCT00618215|Experimental|2|"MIM Group~Interventions:behaviorial"
9902511|NCT00618241|Experimental|A|"Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34.~5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34."
9902512|NCT00618241|Active Comparator|B|"Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32.~One dose Lamotrigine 100 mg oral."
9902513|NCT00618280|Active Comparator|1|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
9902514|NCT00618280|Placebo Comparator|2|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
9902515|NCT00618293|Active Comparator|1|intravenous infusion of Haemate (dosage dependent on body weight)
9902516|NCT00618293|Placebo Comparator|2|intravenous infusion of 0.9% NaCl solution
9902517|NCT00618358|Experimental|Vascular Sealant)|
9902518|NCT00618358|Active Comparator|Gelfoam/Thrombin|
9902519|NCT00618384|Active Comparator|1|Patients with TACE therapy will be treated with Sorafenib (2 x 400 mg/day) until progressive disease
9902520|NCT00618397|Experimental|Arm 1|Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.
9902521|NCT00618423|Placebo Comparator|Physiologic saline|
9902522|NCT00618423|Active Comparator|Ketamine|
9902523|NCT00618462|Experimental|1|Participants will receive psychoeducation therapy plus case management and a referral to Gamblers Anonymous.
9902524|NCT00618462|Experimental|2|Participants will receive cognitive behavioral therapy plus contingency management and a referral to Gamblers Anonymous.
9902525|NCT00618462|Experimental|3|Participants will receive cognitive behavioral therapy and a referral to Gamblers Anonymous.
9902526|NCT00618475|Experimental|Treatment|Individual cognitive behavioral therapy (CBT)
9902527|NCT00618475|Other|Wait-list control|Individual cognitive behavioral therapy (CBT) after 3 month wait-list period
9902528|NCT00618488|Experimental|1|Bifidobacterium lactis
9902529|NCT00618488|Placebo Comparator|2|Placebo
9902530|NCT00618527|Experimental|1|Rebif with Cellcept
9902531|NCT00618527|Placebo Comparator|2|Rebif alone
9902532|NCT00618553|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation - Rehabilitation treatment given over about 3-4 weeks. Questionnaire regarding quality-of-life that lasts about 30 minutes.
9902533|NCT00618566|Experimental|Oregon|
9902534|NCT00618579|Experimental|LMWH arm - active LMWH|
9902535|NCT00618579|Placebo Comparator|LMWH arm - placebo|
9902536|NCT00618579|Experimental|Warfarin arm - active warfarin|
9902537|NCT00618579|Other|Warfarin arm - control|
9902538|NCT00618592|Experimental|CHO|
9902539|NCT00618592|No Intervention|FAST|
9902540|NCT00618605|Experimental|1|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
9902541|NCT00618605|Experimental|2|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^10 VP given at Days 0, 28, and 168
9902542|NCT00618605|Experimental|3|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^11 VP given at Days 0, 28, and 168
9902543|NCT00618605|Experimental|4|2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168
9902544|NCT00618644|Experimental|1|Ranibizumab injection
9902545|NCT00618657|Experimental|Arm I (HER-2 positive)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, carboplatin IV over 60 minutes, and trastuzumab IV over 90 minutes , then weekly over 30-60 minutes. Treatment repeats every week for 12 weeks in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
9935754|NCT03251989||1/Patient with a rare CNS diagnosis|A diagnosis of rare CNS Tumors
9902546|NCT00618657|Experimental|Arm II (HER-2 negative)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
9933456|NCT05351333|Experimental|Conditioning Open-Label Placebo|Days 1 to 3 will include the acquisition phase where the opioid medication will be prescribed on a schedule of 3-4 times per day and paired with an open-label placebo. Day 4 and 6 will be the evoked phase, and patients will receive only the open-label placebo pill. On day 5 the opioid medication will be re-introduced as pharmacological reinforcement.
9933457|NCT05351333|No Intervention|Treatment as usual|Patients in the standard of care group will receive their analgesic treatment through Spaulding Pharmacy as prescribed by their treating physicians. The treatment regime will include an opioid medication at the standard recommended dosage. Participants in this group will receive the treatment orally for 6 consecutive days.
9933458|NCT05351320|Experimental|WX-0593 single arm|"Part 1: Participants will receive WX-0593 monotherapy until disease progression or unacceptable toxicity.~Part 2: Participants will receive 1 or 2 cycles of WX-0593 monotherapy and subsequently with concurrent chemoradiation, followed by WX-0593 monotherapy until disease progression or unacceptable toxicity."
9933459|NCT05351307||POAG patients|OCT angiography will be performed
9933460|NCT05351307||Normal participants|OCT angiography will be performed
9933461|NCT05351294|Experimental|Arm 1|All enrolled patients will receive standard oncologic care at the discretion of the treating physicians, but will also complete the EORTC QLQ-C30, EQ-5D-5L, PTPQ, FAMCARE-P16 at baseline before randomization. Follow-up assessment using EORTC QLQ-C30, PTPQ, FAMCARE-P16 will occur every 3 months, and using EQ-5D-5L will occur every 1 month, for a total of 12 months. These will be administered during standard-of-care clinic or infusion center visits.
9933462|NCT05351294|Experimental|Arm 2|Patients enrolled in Arm 2 will also be seen be a radiation oncologist during the course of the study. The RO will review the patient's most recently completed EQ 5D-5L questionnaires and perform a complete History and Physical evaluation to determine if there is any immediate role for PRT. Based on the patient's type of cancer and areas of spread, the RO will also discuss types of symptoms that could develop in the future, and give instructions and educational materials to the patient so he/she can better identify those symptoms early on.
9933463|NCT05351281|No Intervention|Standard of care|Patients in the standard of care arm will receive the usual treatment
9933464|NCT05351281|Experimental|CDSS-OPTIMED|In the experimental arm, attending physicians will receive weekly medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The CDSS-OPTIMED will send a medication advice on a weekly basis, based on a weekly analysis of patient's medication. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
9933465|NCT05351268|Experimental|3DPCT and CT guided RISI|All patients were treated with clinical routine treatment: 3DPCT combined with CT guided radioactive seed implantation. Collect patient information and treatment information for analysis.
9933466|NCT05351255|Experimental|rTMS Intervention|In aim 2 of the study, participants receive a repetitive transcranial magnetic stimulation intervention called theta burst stimulation (TBS) to study its effect on motor learning behavior. All participants will complete 3 sessions in which they will receive continuous TBS, intermittent TBS, or sham TBS before completing a behavioral motor learning task. The order of TBS sessions will be counter-balanced across participants.
9933467|NCT05351242|Experimental|Intervention group|Must go to a sauna (min. Temperature 85℃) min. 4 times a week for 6 months. Each sauna bath must last at least 7 minutes. The intervention patients receive a subscription card for a sauna during the period. Patients will still receive standard treatment for their pulmonary disease.
9933468|NCT05351242|No Intervention|Control group|"Not allowed to go to a sauna for 6 months. Patients who come to do so, by e.g. an oversight, however, remain in the study, to avoid introducing bias. It will be registered as a protocol violation, but the patient will be included in Intention To Treat analysis and modified Intention To Treat analysis. Patients will still receive standard treatment for their pulmonary disease."
9933469|NCT05351229|Placebo Comparator|Placebo|Intrathecal saline
9933470|NCT05351229|Active Comparator|Morphine|Intrathecal morphine
9933471|NCT05351216||Cases|Individuals diagnosed with KHE and treated with sirolimus. After immunoglobulin and flow cytometry assays, as well as outpatient evaluation and assessment, those participants will be vaccinated with live attenuated vaccines or inactivated vaccines in a timely order according to the advice. （Sirolimus Rapamycin 0.8mg/m2 bid po）
9933472|NCT05351216||Controls|Healthy children with no immunodeficiency disease, vaccinated according to the National Immunization Program. Particpants should be age-matched with the case group.
9933473|NCT05351203|Active Comparator|caudal epidural group|"the patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock by betadine three times and will be covered by sterile drapes exposing the sacral area. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound linear transducer probe that is covered in sterile plastic bag . Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
9935755|NCT03246347|Experimental|Single Arm|Docetaxel + Enzalutamide + Androgen Deprivation Therapy
9935756|NCT03239899|Experimental|Pembrolizumab arm|Pembrolizumab 200mg will be administered as a one-time intravenous infusion over 30 minutes during the treatment phase of the study.
9935757|NCT03237858|Active Comparator|HeartLogic ON|ICD and CRT-D devices with HeartLogic alerts turned ON
9902547|NCT00618670|Experimental|1|Home-based program with progressive increases in exercise duration and intensity (i.e., cadence); walking duration will be longer for the home-based group because the intensity of walking will be lower than the graded treadmill walking performed by the supervised group
9902548|NCT00618670|Experimental|2|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 70% of exercise capacity
9902549|NCT00618670|Active Comparator|3|Light resistance training without any walking exercise
9902550|NCT00618683|Other|Study Arm|Mapping and Ablation
9902551|NCT00618696|Experimental|AHN-12|2.0, 5.0, 7.5, 10.0 or 12.5 mCi/m^2 of ^90Y-AHN-12 at Day 7/8
9902552|NCT00618709|Experimental|Cohort 1|ATX-101 (1 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
9902553|NCT00618709|Experimental|Cohort 2|ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
9902554|NCT00618709|Experimental|Cohort 3|3 subgroups in Cohort 3: 3a: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 3b: ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 3c: ATX-101 (2 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
9902555|NCT00618709|Experimental|Cohort 4|3 subgroups in Cohort 4: 4a: ATX-101 (8 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 4b: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 4c: ATX-101 (4 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
9902556|NCT00618735|Experimental|1|Subjects in Schedule A will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (Beginning at midnight).
9902557|NCT00618735|Experimental|2|Subjects in Schedule B will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (beginning at midnight). The second dose will be taken, following at least a 2-hour fast, 12 hours (+/- 2 hours) after the first dose, except on Day 1 of Cycle 1 and Day 1 of Cycle 2.
9902558|NCT00618761|Experimental|1|kidney-pancreas recipients
9902559|NCT00618761|Active Comparator|2|kidney recipients
9902560|NCT00618761|Active Comparator|3|healthy controls
9902561|NCT00618761|Active Comparator|4|beta-cell recipients
9902562|NCT00618800|Experimental|Pharmacist Care|Pharmacist Intervention
9902563|NCT00618800|Active Comparator|Control|Written information only group
9902564|NCT00618852|Experimental|1|Furosemide
9902565|NCT00618852|Placebo Comparator|2|
9902566|NCT00618865|Experimental|1|omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
9902567|NCT00618865|Placebo Comparator|2|Placebo (olive oil ethyl esters)
9902568|NCT00618878|Active Comparator|1|Electroacupuncture
9902569|NCT00618878|Active Comparator|2|Laser Therapy
9902570|NCT00618904|Experimental|1|Probiotic containing Lactobacillus and Bifidobacterium
9902571|NCT00618904|Placebo Comparator|2|Placebo
9902572|NCT00618930|Experimental|1|
9902573|NCT00618930|Active Comparator|2|Use of Fleet
9902574|NCT00618969|Experimental|Haploidentical allogeneic PBSC transp|Non-myeloablative preparative regimen (reduced-intensity) of busulfan, melphalan and alemtuzumab followed by a haploidentical-related peripheral blood stem cell transplant.
9902575|NCT00619008|Experimental|1|Ad libitum low carbohydrate diet
9902576|NCT00619008|Experimental|2|Ad libitum high complex carbohydrate diet
9902577|NCT00619008|Experimental|3|Energy-restricted high complex carbohydrate diet
9902578|NCT00619021|Experimental|Cohort 1|Patient receives gemcitabine 600 mg/m^2.
9902579|NCT00619021|Experimental|Cohort 2|Patient receives gemcitabine 800 mg/m^2.
9902580|NCT00619021|Experimental|Cohort 3|Patient receives gemcitabine 1000 mg/m^2.
9902581|NCT00619021|Experimental|Cohort 4|Patient receives gemcitabine 1200 mg/m^2.
9902582|NCT00619034|Experimental|latanoprost|Medical intervention cross-over
9902583|NCT00619034|Active Comparator|diclofenac|medical intervention
9902584|NCT00619034|Experimental|dorzolamide|dorzolamide eyedrops twice daily in one week
9902585|NCT00619047||Observation|
9902586|NCT00619086|Placebo Comparator|A, 1|Placebo 45 minutes prior to surgery
9902587|NCT00619086|Active Comparator|A, 2|8 mg Dexamethasone 45 minutes prior to surgery
9902588|NCT00619125||A|20 patients with IBS C
9902589|NCT00619125||D|20 Subjects without IBS
9902590|NCT00619125||B|20 patients with IBS D
9902591|NCT00619125||C|20 patients with IBS M
9902592|NCT00619138|Active Comparator|1|
9902593|NCT00619138|Active Comparator|2|
9902594|NCT00619164|Experimental|1|
9902595|NCT00619164|Experimental|2|
9902596|NCT00619164|Experimental|3|
9902597|NCT00619164|Placebo Comparator|4|
9902598|NCT00619203|Active Comparator|A|Two active ingredients
9902599|NCT00619203|Active Comparator|B|One active ingredient
9902600|NCT00619203|Active Comparator|C|One (other) active ingredient
10212859|NCT04925492|Experimental|Finding Optimal Scan Timing|Group A will receive two PET scans after the radiotracer injection to learn the best timing of the scan for the rest of the people in the study during participant's baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
9902601|NCT00619203|Placebo Comparator|D|
9902602|NCT00619268|Experimental|A|
9902603|NCT00619268|Active Comparator|B|
9902604|NCT00619268|Active Comparator|C|
9902605|NCT00619281||Oberservation|600 consecutive patients undergoing cardiac surgery
9902606|NCT00619320|Experimental|Safer Sex Skill Building (SSB)|Safer Sex Skill Building Intervention (SSB) A five session behavioral intervention focused on HIV/STD prevention and safer sex negotiation skills
9902607|NCT00619320|Active Comparator|2|one group session focused on standard HIV/STD education
9902608|NCT00619333|Other|1|
9902609|NCT00619346|Placebo Comparator|1|Placebo tablets resembling 100 mg tablet of active drug BID X 14 days
9902610|NCT00619346|Active Comparator|2|Pafuramidine maleate, 100 mg tablet, BID X 14 days
9902611|NCT00619372|Experimental|B|Low dose OKT3 with GC
9902612|NCT00619372|Experimental|C|Mid dose OKT3
9902613|NCT00619372|Experimental|D|Mid OKT3 dose with GC
9902614|NCT00619372|Experimental|E|High dose OKT3
9902615|NCT00619372|Experimental|F|GC only
10212860|NCT04925492|Experimental|Scan at Determined Optimal Timepoint|Group B participants will receive an injection of the radiotracer and undergo only one PET scan during a baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
9902616|NCT00619372|Experimental|A|Low dose OKT3
10212861|NCT04924322|Experimental|Enoxaparin (Older Children Prophylactic)|Prophylactic dose of enoxaparin for older children 1-17 years old.
10212862|NCT04924322|No Intervention|Control (Older Children)|Usual care without placebo for older children 1-17 years old.
10212863|NCT04924322|Experimental|Enoxaparin (Infants Therapeutic High Anti-Xa Target)|Therapeutic dose of enoxaparin for infants <1 year old with anti-Xa target of >0.5-1 IU/mL.
10212864|NCT04924322|Experimental|Enoxaparin (Infants Therapeutic Low Anti-Xa Target)|Therapeutic dose of enoxaparin for infants <1 year old with anti-Xa target of 0.2-0.5 IU/mL.
10212865|NCT04924322|No Intervention|Control (Infants)|Usual care without placebo for infants <1 year old.
10212866|NCT04922112|Experimental|Research group|Sleep apnea testing will be performed with this group, in the form of quality of life and sleep questionnaires, home sleep study results, as well as information collected from their electronic medical record. The investigator will also obtain blood laboratory specimens to measure serum TNF-alpha and IL-6.
10212867|NCT04919408|Experimental|Patients scheduled for cesarean section under spinal anesthesia|Patients scheduled for cesarean section under spinal anesthesia ASA I and II according to The ASA Physical Status Classification System
10212868|NCT04917861|Experimental|mRNA-1893 Low Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
10212869|NCT04917861|Experimental|mRNA-1893 High Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
10212870|NCT04917861|Experimental|mRNA-1893 High Dose (1-Dose Regimen)|Participants will receive placebo matching to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There will be 28-day (-3/+7 days) interval between vaccinations.
9902617|NCT00619398|Active Comparator|1|
9902618|NCT00619398|Experimental|2|
9902619|NCT00619411|Experimental|I|
9902620|NCT00619424|Experimental|pazopanib + erlotinib|Pazopanib and erlotinib are to be combined at different specified dose levels until an optimally tolerated dose level is identified. Pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit and erlotinib, an epidermal growth factor (EGFR) inhibitor, are to be combined in an effort to simultaneously block two tightly woven cell signaling pathways.
9902621|NCT00619424|Experimental|pazopanib + pemetrexed|Pazopanib and pemetrexed are to be combined at different specified dose levels until an optimally tolerated dose regimen is identified. Combination of an anti-VEGF therapy (such as bevacizumab) with systemic chemotherapy has demonstrated increased clinical efficacy in comparison with systemic chemotherapy alone in several malignancies. Hence, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit, was chosen to be combined with pemetrexed, a chemotherapeutic agent that inhibits the enzyme thymidylate synthase, in an effort to determine if an anti-angiogenesis inhibitor would enhance the activity of the approved chemotherapeutic agent pemetrexed.
9902622|NCT00619463|Experimental|exercise then monitor|8 weeks of aerobic exercise followed by 16 weeks of monitoring
9902623|NCT00619463|Experimental|monitor than exercise|8 weeks of monitoring followed by 16 weeks of aerobic exercise
9902624|NCT00619528|Experimental|1|No separate arms: All Enrolled Receive Same Treatment
9935758|NCT03237858|Placebo Comparator|HeartLogic OFF|ICD and CRT-D devices with HeartLogic alerts turned OFF
9902625|NCT00619541|Experimental|A|"5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days~Sorafenib 400 mg bid orally continuously~5-FU will be administered for a maximum of 12 cycles.~Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease."
9902626|NCT00619567|Experimental|Cognitive Stimulation|Subjects will be given Internet access to the Smartbrain cognitive stimulation program. They will complete exercises for ~30 minutes, at least three times per week, for a period of 24 weeks.
9902627|NCT00619567|No Intervention|Control|"These individuals will receive usual care during the 24 week follow-up period."
9902628|NCT00619580||positive E coli|positive E coli at UPMC
9902629|NCT00619593|Active Comparator|2|Standard follow-up in patients without appropriate ICD therapy
9902630|NCT00619593|Experimental|1|Following 1st appropriate ICD therapy, the patients have to be called to the clinic for intensified clinical diagnostics and, if necessary or useful, intensified therapy.
9902631|NCT00619632|Experimental|1|LC- Primary-care based lactation consultant meeting women pre- and post-natally.
9902632|NCT00619632|Experimental|2|Provider Prompt
9902633|NCT00619632|Experimental|3|LC+Provider Prompt
9902634|NCT00619632|No Intervention|Control|
9902635|NCT00619658|Experimental|1|All women undergoing medical abortion will have telephone follow-up approximately one week after using mifepristone and misoprostol.
9902636|NCT00619710|Experimental|1|Meropenem
9902637|NCT00619710|Active Comparator|2|Imipenem-cilastatin
9902638|NCT00619736|Experimental|NSA-789|
9902639|NCT00619736|Placebo Comparator|Placebo|
9902640|NCT00619749|Experimental|1|
9902641|NCT00619749|Placebo Comparator|2|
9902642|NCT00619788|Experimental|1|Patients receiving 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use
9902643|NCT00619814|Other|Cohort group|Cohort group of asymptomatic patients 50-80 years old with a positive fecal occult blood test done for colorectal cancer screening.
9902644|NCT00619840|Active Comparator|1|
9902645|NCT00619840|Placebo Comparator|2|
9902646|NCT00619905|Experimental|1|
9902647|NCT00619905|Placebo Comparator|2|
9902648|NCT00619931||1|APD791 or placebo
9902649|NCT00619931||2|APD791 or placebo
9667222|NCT03835689|Experimental|Strongest Families Program Self-Managed (no coaching)|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
9902650|NCT00619931||3|APD791 or placebo
9902651|NCT00619931||4|APD791 or placebo
9902652|NCT00619931||5|APD791 or placebo
9902653|NCT00619944|Experimental|1|Lumefantrine lopinavir drug interaction arm
9902654|NCT00619944|Active Comparator|2|lumefantrine only arm
9902655|NCT00619996|Experimental|1|
9902656|NCT00620009|No Intervention|Control|Therapists and patients record their estimates of the patient's Global Assessment of Functioning, but do not discuss these estimates in therapy sessions.
9902657|NCT00620009|Experimental|Empathy Feedback|Therapists and patients record their ratings of the patient's Global Assessment of Functioning and discuss these ratings.
9902658|NCT00620048|Experimental|Low dose of autologous CD34-positive cells (stem cells)|
9902659|NCT00620048|Experimental|High dose of autologous CD34-positive cells (stem cells)|
9902660|NCT00620087|Other|Diagnostic Arm|Women with core-biopsy proven atypia, LCIS, or radial scar who have not yet undergone surgical excision were enrolled in the diagnostic arm. A molecular breast imaging study will be obtained.
9902661|NCT00620087|Other|Surveillance arm|Women with a diagnosis of ADH, ALH, or LCIS within the past 5 years were enrolled in the surveillance arm. A molecular breast imaging study was done at enrollment (Year 0) and repeated at Yer 2 and Year 4. Patients continued with routine screening mammography during this time period.
9902662|NCT00620139||A|Some patients presenting with suspicious lesions of the oropharynx or oral cavity will need to undergo transoral biopsy in the clinic to confirm the diagnosis of carcinoma. Of those patients who choose to participate in the study, an extra piece of tumor will be harvested for investigational purposes related to this trial.
9902663|NCT00620152|Experimental|1|Low glycemic load diet
9902664|NCT00620152|Active Comparator|2|Low fat diet
9902665|NCT00620165|Experimental|1|
9902666|NCT00620165|Placebo Comparator|2|
9902667|NCT00620178||1|Candesartan
9902668|NCT00620178||2|Losartan
9902669|NCT00620204|Experimental|A|Atorvastatin group
9902670|NCT00620204|No Intervention|B|Control group
9902671|NCT00620217|Experimental|1|intramyocardial injection of bicistronic VEGF-A165/bFGF plasmid
9902672|NCT00620217|Placebo Comparator|2|intramyocardial injection of placebo plasmid
9902673|NCT00620230|Experimental|1|
9902674|NCT00620230|Placebo Comparator|2|
9902675|NCT00620243|Experimental|1|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
9902676|NCT00620269|Experimental|study arm 1|Induction (with Erlotinib X 3 cycles) -> CCRT with Erlotinib (X 2 cycles) -> continue Erlotinib (X 6 cycles)
9902677|NCT00620269|Experimental|study arm 3|Induction (IP X 3 cycles) -> CCRT with IP (X 2 cycles)
9902678|NCT00620269|Active Comparator|control arm|CCRT with IP (X 2 cycles) -> consolidation IP (X 3 cycles)
9902679|NCT00620269|Experimental|study arm 2|Induction (Erlotinib X 3 cycles) -> CCRT with IP (X 2 cycles) -> recurrence -> Erlotinib (until PD)
9902680|NCT00620295|Experimental|Gemcitabine / Bortezomib|"Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose on day 1 and day 8 of a 21 day cycle.~Bortezomib will be given 1 hour after gemcitabine by IVP over 3 to 5 seconds followed by a standard saline on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles."
9902681|NCT00620308|Experimental|CD-NP low-dose study drug|
9902682|NCT00620308|Experimental|CD-NP high-dose study drug|
9902683|NCT00620308|Placebo Comparator|Placebo|
9902684|NCT00620334||1|"ASTHMA:~PREVOUSLY DIAGNOSED MILD ASTHMA PATIENTS"
9902685|NCT00620334||2|"CONTROL:~PATIENTS WHO HAVE NEVER BEEN DIAGNOSED WITH ASTHMA"
9902686|NCT00620347|Experimental|Single arm|Single arm (sunitinib arm) until PD, unacceptable toxicity, patients refused
9902687|NCT00620360|Experimental|fructose|acute fructose administration
9902688|NCT00620386|Experimental|1|Intubation with Bonfils intubating fiberscope
9902689|NCT00620386|Active Comparator|2|Intubation with Macintosh laryngoscopy
9902690|NCT00620399|Experimental|1|brace
9902691|NCT00620399|Placebo Comparator|2|no brace
9902692|NCT00620412|Active Comparator|treatment|
9902693|NCT00620412|Placebo Comparator|placebo|
9902694|NCT00620438|Experimental|1|nevirapine arm
9902695|NCT00620438|Experimental|2|efavirenz arm
9902696|NCT00620438|Experimental|3|Rifampicin arm
9902697|NCT00620477|Experimental|1|injection in the knee joint with 20 ml of chirocaine 0.125%
9902698|NCT00620477|Placebo Comparator|2|injection in the knee joint with 20 ml of physiological fluid
9902699|NCT00620490|Experimental|1|Ropivacaine 0.5% 0.1 ml/kg per hour
9902700|NCT00620490|Placebo Comparator|2|
9902701|NCT00620529|Experimental|1|20/50 fish oil, 1000mg capsules, Ocean Nutrition 2050,4g/day.
9902702|NCT00620529|Placebo Comparator|2|olive oil capsules
9902703|NCT00620568|Experimental|1|
9902704|NCT00620568|Experimental|2|
9902705|NCT00620568|Experimental|3|
9902706|NCT00620568|Experimental|4|
9902707|NCT00620581|Placebo Comparator|Paroxetine 10mg;paroxetine 20mg; Placebo|
9902708|NCT00620594|Experimental|BEZ235 Alone, Dose Escalation|
9902709|NCT00620594|Experimental|BEZ235 + trastuzumab, Dose Escalation|
9902710|NCT00620594|Experimental|BEZ235 Alone, MTD Expansion|
9902711|NCT00620594|Experimental|BEZ235 + Trastuzumab, MTD Expansion|
9902712|NCT00620620|Placebo Comparator|Inhaled Placebo|Staccato Placebo
9902713|NCT00620620|Experimental|Inhaled Zaleplon 0.5 mg|Staccato Zaleplon 0.5 mg
9902714|NCT00620620|Experimental|Inhaled Zaleplon 1 mg|Staccato Zaleplon 1 mg
9902715|NCT00620620|Experimental|Inhaled Zaleplon 2 mg|Staccato Zaleplon 2 mg
9902716|NCT00620620|Experimental|Inhaled Zaleplon 4 mg|Staccato Zaleplon 4 mg
9902717|NCT00620633|Experimental|1|Patients with leukemia or myelodysplastic syndrome (MDS) who, following an HLA-matched allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated morphologically on peripheral blood smear or bone marrow aspirate
9902718|NCT00620646|Experimental|A|Aspirin plus increasing clopidogrel group
9902719|NCT00620646|Experimental|B|Aspirin, clopidogrel plus cilostazol group
9902720|NCT00620672|Other|1|The dietary supplement is 400 mg/day of the omega 3 fatty acid docosahexaenoic acid . The docosahexaenoic acid is provided in triglycerides from Martek Biosciences, Maryland. The supplement is a blend of soybean and canola oil, blended to resemble the usual fat composition of the diet. Both the supplement and placebo provide a total of about 10 calories per day to the diet.
9902721|NCT00620672|Other|2|Dietary supplement is vegetable oil, the placebo.
9902722|NCT00620724|Placebo Comparator|A|Placebo three times daily
9902723|NCT00620724|Experimental|B|20 mg of slow-release Nifedipine three times daily
9902724|NCT00620737|Experimental|Active Arm|Active Treatment
9902725|NCT00620737|Placebo Comparator|Control Arm|Placebo treatment
9902726|NCT00620789|Active Comparator|1|Cognitive-Behavior Therapy for insomnia (CBT-I) + Antidepressant medication
9902727|NCT00620789|Placebo Comparator|2|Cognitive Behavior Therapy for Insomnia (CBT-I) + placebo medication
9902728|NCT00620789|Sham Comparator|3|Antidepressant medication + Sleep Hygiene Control (SH)
9902729|NCT00620802|Experimental|A|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg)
9902730|NCT00620802|Active Comparator|B|Plavix (clopidogrel 75 mg)
9902731|NCT00620841||A|Patients treated with tacrolimus and experiencing a drug interaction
9933474|NCT05351203|Experimental|Erector spinae group|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
9933475|NCT05351190|Other|Treatment Arm|All participants will be given a rtCGM (Dexcom G6) to assess their glycemic control.
9933476|NCT05351177|Experimental|High-Intensity Interval Training Group|Participants in the High-Intensity Interval Training (HIIT) group will complete 8 weeks of twice-weekly HIIT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by 10 x 60 second repetitions on the cycle ergometer interspersed with 60 seconds rest. A five minute cooldown will follow on the cycle ergometer.
9933477|NCT05351177|Experimental|Concurrent Training Group|Participants in the Concurrent Training (CT) group will complete 8 weeks of twice-weekly CT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by two sets of four then eight repetitions of deadlift, squat, bench press and shoulder press resistance exercises. Thereafter, 5 x 60 second HIIT cycling intervals will be completed on a cycle ergometer, after which a five minute cooldown will ensue.
9933478|NCT05351164|Experimental|Patients with MSL|
9933479|NCT05351151|Experimental|"Regional anesthesia ALR"|The ALR group is made up of patients benefiting from the V2 and V3 ultrasound-guided ALR technique without mucosal infiltration.
9933480|NCT05351151|Active Comparator|Infiltration|"The Infiltration group is made up of patients who benefit from the infiltration technique by local anesthesia of the incision sites by the surgeon without recourse to ultrasound-guided LRA."
9933481|NCT05351138|Experimental|TENS Group|Transcutaneus electric nerve stimulation intervention will be done for a total of 12 weeks, 2 sessions of 20 minutes per week.
9933482|NCT05351138|Experimental|Masaj Group|Massage intervention will be done in the form of massage practise to the abdominal region, 2 sessions of 20 minutes per week.
9933483|NCT05351112||Patients who received the Anatomical Shoulder 2.0 Fracture|
9933484|NCT05351086|Experimental|Inhaled placebo and IV D.H.E. 45 1 mg|
9933485|NCT05351086|Experimental|Inhaled PUR3100 0.5 mg and IV placebo|
9933486|NCT05351086|Experimental|Inhaled PUR3100 1.0 mg and IV placebo|
9933487|NCT05351086|Experimental|Inhaled PUR3100 1.5 mg and IV placebo|
9933488|NCT05351073|Experimental|Normobaric Oxygen Inhalation Group|Participants in the intervention group will receive oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa) after randomization until adimisson to the hospital. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
9902732|NCT00620867|Experimental|Ibuprofen|
9902733|NCT00620867|Experimental|Celecoxib|
9902734|NCT00620867|Placebo Comparator|placebo|
9902735|NCT00620893|Active Comparator|1|1. PEG-400 based artificial tear
9902736|NCT00620893|Active Comparator|2|2. Systane
9902737|NCT00620906|Other|A|Manipulation
9902738|NCT00620919|Experimental|1|Drug + MDCT
9902739|NCT00620932|No Intervention|Control Group|These patients will continue with whatever routine exercise they already engage in.
9902740|NCT00620932|Experimental|Exercise Arm|These patients will participate in a controlled, supervised exercise program.
9902741|NCT00620958|Experimental|1|Participants will receive individual cognitive behavioral therapy with parent reinforcement training.
9902742|NCT00620958|Experimental|2|Participants will receive individual cognitive behavioral therapy with parent relationship training.
9902743|NCT00620958|Active Comparator|3|Participants will receive individual cognitive behavioral therapy alone.
9902744|NCT00620971|Experimental|1|NC/Avastin->DG/Avastin
9902745|NCT00620971|Experimental|2|DG/Avastin
9902746|NCT00620997|Experimental|1|"patients randomized to 0.05% Proparacaine drops on a PRN basis for up to 7 days~Acetaminophen with Codeine for breakthrough pain~topical Gatifloxacin drops"
9902747|NCT00620997|Placebo Comparator|2|"placebo drops on a PRN basis for up to 7 days post injury~Acetaminophen with Codeine for breakthrough pain~Gatifloxacin drops"
9902748|NCT00621010|Experimental|Cohort|
9902749|NCT00621036|Experimental|methotrexate IV once every 2 weeks|
9902750|NCT00621062|Active Comparator|High Ligation of the GSV|
9902751|NCT00621062|Active Comparator|Endovenous Laser Ablation|
9902752|NCT00621062|Active Comparator|Radiofrequency ablation|
9902753|NCT00621062|Active Comparator|Foam Sclerotherapy|
9902754|NCT00621075||1|Pulmonary Arterial Hypertension
9902755|NCT00621088|Active Comparator|Intertan|
9902756|NCT00621101|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
9902757|NCT00621101|Active Comparator|B|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
9667223|NCT03835689|Experimental|Strongest Families Program with Group Telephone Coaching|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
9902758|NCT00621101|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
9902759|NCT00621114|Active Comparator|1|Patients in group 1 will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
9902760|NCT00621114|Experimental|2|Patients in group 2 will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
9902761|NCT00621166|Other|1|generic lopinavir/ritonavir
9902762|NCT00621218|Active Comparator|1|
9902763|NCT00621218|Placebo Comparator|2|
9902764|NCT00621231|Placebo Comparator|1|
9902765|NCT00621231|Experimental|2|
9902766|NCT00621270|Experimental|1|BCI-540 80 mg once a day (q.d.)
9902767|NCT00621270|Experimental|2|BCI-540 80 mg three times a day (t.i.d.)
9902768|NCT00621270|Placebo Comparator|3|Placebo
9902769|NCT00621283|Experimental|1|Drug + MR with MRCP
9902770|NCT00621361|Experimental|1|
9902771|NCT00621361|Active Comparator|2|Etoposide + Cisplatin
9902772|NCT00621374|Experimental|Random Order 1|Randomization Order 1= 1)CONT, 2)CBT, 3)HYP, 4) CBT-HYP
9902773|NCT00621374|Experimental|Random Order 2|Randomization order 2= 1)CONT, 2)HYP, 3)CBT, 4) CBT-HYP
9902774|NCT00621387|Experimental|1|ofloxacin and roxithromycin
9902775|NCT00621387|Placebo Comparator|2|placebo
9667224|NCT03835689|No Intervention|Information Resource Website|They will not receive Strongest Families Intervention during the 10 month study phase, but will receive the usual care services and access to an Information Resource Website.
9902776|NCT00621426||Observation|Patients with end-stage renal disease (ESRD) treated with hemodialysis three (3) times per week for at least 3 continuous months
9902777|NCT00621439|Experimental|I|Receives 1 dose of Pegylated Interferon
9902778|NCT00621439|Placebo Comparator|II|Receives placebo
9902779|NCT00621452|Experimental|Treatment (autologous CD20 specific T-cells)|"CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.~IMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.~MAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.~Subjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse."
9902780|NCT00621465|Active Comparator|1|Participants will receive standard aftercare and community care services.
9902781|NCT00621465|Experimental|2|Participants will receive usual care and the Critical Time Intervention.
9902782|NCT00621478|Active Comparator|Cohort 1|"Cohort 1 (preconsented) patients will involve obtaining informed consent from the legally authorized representative of a potential study subject before they present to the ED in SE. Patient assent will be obtained for patients as per local IRB rules. The consent document (enclosed in this application) will inform parents that if their child comes to the ED and qualifies for the study based on study inclusion/exclusion criteria, they will be enrolled.~Patients who cannot be contacted to confirm consent will be enrolled in Cohort 2 (EFIC) as detailed below.~Patients in Cohort 1 will be randomized in a blinded fashion to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
9902783|NCT00621478|Active Comparator|Cohort 2|"Cohort 2 (EFIC) will include patients who appear in the ED with SE and qualify for the study but have not given prior consent. These patients will be enrolled under the EFIC regulations. The parent/guardian will be given the opportunity to object to participation or ask additional questions.~The child will be enrolled (dosed) with study medication under an EFIC. Once the child is stabilized, a research staff member will approach the parent or LAR to obtain informed consent to continue the child's participation in the study. If a parent or LAR refuses continued participation, then no further study procedures will be performed. Safety and data will be collected in accordance with federal regulations.~Cohort 2 will be randomized, like Cohort 1, to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
9902784|NCT00621491|Placebo Comparator|1|Single daily dose of Placebo during six months
9902785|NCT00621556|Experimental|1|Drug + MR with MRCP
9902786|NCT00621569|Active Comparator|1|Group intervention with no dietary focus
9902787|NCT00621569|Experimental|2|DASH diet intervention
9902788|NCT00621595|Active Comparator|1|Fasting
9902789|NCT00621608|Experimental|1|Hyperbaric Oxygen Therapy
9902790|NCT00621608|Sham Comparator|2|Placebo Hyperbaric Oxygen Chamber
9902791|NCT00621634|Experimental|1|Active treatment with omega-3 fish oil capsules (1 g each capsule, 50% DHA), 6 capsules each day for 12 weeks
9902792|NCT00621634|Placebo Comparator|2|Matching placebo treatment
9902793|NCT00621647|Experimental|1|1st fixed dose
9902794|NCT00621647|Experimental|2|2nd fixed dose
9902795|NCT00621647|Sham Comparator|3|Placebo
9902796|NCT00621660|Experimental|Acupuncture|
9902797|NCT00621660|Placebo Comparator|Sham|
9902798|NCT00621673|Other|Arm 1|
9902799|NCT00621699|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg tacrolimus)
9902800|NCT00621699|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
9902801|NCT00621699|Active Comparator|B|administration of 1 capsule Prograf(R) (5 mg tacrolimus)
9902802|NCT00621712|Active Comparator|A|Patients in group A will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
9902803|NCT00621712|Experimental|B|Patients in group B will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
9902804|NCT00621725|Experimental|1|
9902805|NCT00621790|Experimental|Fenoldopam|Fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min) for up to 4 days
9902806|NCT00621790|Placebo Comparator|Placebo|Placebo (normosaline), continuous perfusion
9902807|NCT00621816|Active Comparator|1|Blinded nitroprusside infusion
9902808|NCT00621816|Placebo Comparator|2|Blinded placebo infusion
9667225|NCT03835338|Experimental|Test Group|The test group will receive Pulmonary Vein Isolation, LAA Isolation and LAA Occlusion with the WATCHMAN LAAC Device
9902809|NCT00621829|Active Comparator|1|"High susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
9902810|NCT00621829|Active Comparator|2|"Low susceptibility ALOX5 gene polymorphisms. Low susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
9902811|NCT00621868|Experimental|1|Lowest dose
9902812|NCT00621868|Experimental|2|Low-middle dose
9902813|NCT00621868|Experimental|3|High-middle dose
9902814|NCT00621868|Experimental|4|Highest dose
9902815|NCT00621868|Placebo Comparator|5|placebo
9902816|NCT00621881|Experimental|1|750 mg naproxcinod
9902817|NCT00621907|Experimental|1|patient who received levobupivacaïne
9902818|NCT00621907|Placebo Comparator|2|patient who received placebo
9902819|NCT00621972||Observation|Chronic kidney disease patients presenting for fisulta evaluation with documented GFR<30ml/min by abbreviated MDRD calculation.
9902820|NCT00621998|Experimental|1|Flexible dose of olanzapine
9902821|NCT00621998|Active Comparator|2|Flexible dose of risperidone
9902822|NCT00622011|Experimental|1|zotepine , start from 50mg/day then titrate according to individual case
9902823|NCT00622011|Active Comparator|2|Risperidone, start from 1mg/day
9902824|NCT00622037|Active Comparator|1|PEG-400 based artificial tear
9902825|NCT00622037|Active Comparator|2|Systane
9902826|NCT00622050|Experimental|1|This arm will be experiencing the same protocol as the control group, only their TV viewing time will be reduced. The TV viewing time reduction is the experimental intervention.
9902827|NCT00622050|Active Comparator|Control|The control group will be experiencing the exact protocol; only their TV viewing time will not be reduced.
9902828|NCT00622076|Active Comparator|1|postoperative catheterization after anterior colporrhaphy during five days.
9902829|NCT00622076|Active Comparator|2.|postoperative catheterization after anterior colporrhaphy during two days
9902830|NCT00622089|Experimental|1|150mg DIO-902 + 10mg Atorvastatin
9902831|NCT00622089|Experimental|2.|300mg DIO-902 + 10mg Atorvastatin
9902832|NCT00622089|Experimental|3|450mg DIO-902 + 10mg Atorvastatin
9902833|NCT00622102|Experimental|1|50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
9902834|NCT00622102|Other|2|50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
9902835|NCT00622115|Experimental|A|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 4 hours following the last injection of enoxaparin
9902836|NCT00622115|Experimental|B|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 6 hours following the last injection of enoxaparin
9902837|NCT00622115|Experimental|C|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 10 hours following the last injection of enoxaparin
9902838|NCT00622128|Experimental|1|Pilot study. Developing intervention
9902839|NCT00622141|Active Comparator|A|Day 1: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg 7-day washout period will follow. Day 8: take generic GPO squinavir/Norvir
9902840|NCT00622141|Active Comparator|B|Day 1: take generic GPO squinavir/Norvir 7-day washout period will follow. Day 8: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg
9902841|NCT00622206|Active Comparator|1|Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
9902842|NCT00622219|Experimental|Drug Testing|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
9902843|NCT00622219|No Intervention|Control|Adolescents randomized to the control condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated) but will not be called for drug tests.
9902844|NCT00622245|Experimental|Lu AA34893: 4 mg|
9902845|NCT00622245|Experimental|Lu AA34893: 12 mg|
9902846|NCT00622245|Experimental|Lu AA34893: 18 mg|
9902847|NCT00622245|Other|Quetiapine fumarate|Active reference 300 mg
9902848|NCT00622245|Placebo Comparator|Placebo|
9902849|NCT00622258|Experimental|Everolimus|
9902850|NCT00622271|Other|Wait List Control|Patients and their families will be enrolled into either a treatment group or a wait list control (WLC) group to receive the group therapy intervention.
9902851|NCT00622310|Experimental|1 Exercise|Subjects in the EX group will perform supervised exercise 5 d/wk. Exercise will consist primarily of walking on an inclined motor-driven treadmill, but alternate activities will be permitted for 20% of the total exercise sessions (1 of 5 days). Exercise sessions will be preceded by a 5 min warm-up performed at a HR corresponding to 40% of VO2max. The initial exercise duration and intensity at baseline will be 20 minutes at an intensity that elicits a heart rate (HR) corresponding to 60% of VO2max. The target EE will be achieved by a gradual progression of exercise duration and intensity over the first 8 weeks of the exercise program. The target exercise intensity will be the workload corresponding to 75% of VO2max.
9902852|NCT00622310|Experimental|2 Walk|Subjects in the WALK group will also perform exercise 5 d/wk. Exercise will consist exclusively of walking on level grades, and will be prescribed in two equal duration bouts each day. Subjects in the WALK group will be individually prescribed a walking program based on the EE during moderate intensity walking. The target exercise intensity will be walking speeds corresponding 45% of VO2max.
9902853|NCT00622349|Experimental|A|
9902854|NCT00622349|Active Comparator|B|
9902855|NCT00622349|Experimental|C|
9902856|NCT00622362|Active Comparator|A|Subcutaneous administration
9902857|NCT00622362|Experimental|B|Sublingual administration
9902858|NCT00622362|Placebo Comparator|C|Sublingual administration
9902859|NCT00622375|Experimental|1|
9902860|NCT00622414|Experimental|Treatment (ziv-aflibercept)|"PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined.~PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
9667226|NCT03835338|Active Comparator|Control Group|The control group will receive Pulmonary Vein Isolation
9667227|NCT03835273||Control group|Fifty control participants who have not received upper gastrointestinal surgery.
9902861|NCT00622453||Registry of Arrhythmias|Screening of individuals with myotonic muscular dystrophy to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.
9902862|NCT00622479|Experimental|Arm 1|
9902863|NCT00622492||VV-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
9902864|NCT00622492||VA-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
9902865|NCT00622531||BNP Open|Subjects treated based on clinical assessment and knowledge of BNP values
9902866|NCT00622531||Control|Subjects treated based on clinical assessment alone
9902867|NCT00622557||Surgical|
9902868|NCT00622570|Experimental|1|Pentobarbital
9902869|NCT00622570|Active Comparator|2|thiopental
9902870|NCT00622596|Experimental|Mobile Access to Buprenorphine|High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
9902871|NCT00622609|Experimental|Subjects receiving GSK249320A|Eligible subjects will receive escalating doses of GSK249320A in cohort 1 to 6 with a starting dose of 0.04 milligrams/kilograms up to the maximum dose of 25 milligrams/kilograms, administered as a slow intravenous infusion over 1 hour on Day 1.
9902872|NCT00622609|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of sodium chloride in cohort 1 to 6, administered as a slow intravenous infusion over 1 hour on Day 1.
9902873|NCT00622622|Experimental|Phase I study|
9902874|NCT00622648|Experimental|A|Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)
9902875|NCT00622648|Placebo Comparator|B|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
9902876|NCT00622661|Other|1|Normal weight
9902877|NCT00622661|Other|2|Overweight
9902878|NCT00622674|Experimental|Bortezomib and Cetuximab|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2. A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
9902879|NCT00622687|Active Comparator|A|low dose iloprost therapy 0.5 ng/kg x min
9902880|NCT00622687|Active Comparator|B|high-dose therapy
9902881|NCT00622752|Experimental|1|EVT 302, 10 mg
9902882|NCT00622752|Experimental|2|EVT 302, 10 mg + NRT patch, 21 mg
9902883|NCT00622752|Experimental|3|NRT patch, 21 mg
9902884|NCT00622752|Placebo Comparator|4|Placebo to match EVT 302 and placebo patch to match NRT patch
9902885|NCT00622778||1|Patients from daily practice
9902886|NCT00622791||CABG group|Patients undergoing coronary artery bypass graft with cardiopulmonary bypass
9902887|NCT00622791||OPCAB group|Patients undergoing off-pump coronary artery bypass graft
9902888|NCT00622804|Other|1|Billroth-II (B-II)reconstruction
9902889|NCT00622804|Other|2|Roux en Y gastrojejunostomy (RY-GJ)
9902890|NCT00622804|Other|3|uncut Roux en Y gastrojejunostomy (uncut RY-GJ)
9902891|NCT00622817|Active Comparator|1|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
9902892|NCT00622817|Experimental|2|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
9902893|NCT00622843|Experimental|Group 1|PCV, 210 patients
9902894|NCT00622843|Active Comparator|Group 2|PPV, 110 patients
9902895|NCT00622843|Active Comparator|Group 3|PPV, HIV-negative, 25 patients
9902896|NCT00622856|Experimental|1|Psychological intervention for strengthening parental authority
9902897|NCT00622856|Active Comparator|2|Diabetes education- 5 sessions with diabetes nurse, taking place once a week
9902898|NCT00622856|No Intervention|3|Control group- regular treatment without any intervention
9902899|NCT00622882|Active Comparator|ID|Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
9902900|NCT00622882|No Intervention|NO ID|Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
9902901|NCT00622921|Other|1|Couples-based behavioral psychotherapy
9902902|NCT00622934|Active Comparator|1|
9902903|NCT00622934|Placebo Comparator|2|
9902904|NCT00622947|Active Comparator|repetitive transcranial magnetic stimulation|Low frequency ( 1 HZ) rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
9902905|NCT00622947|Sham Comparator|Placebo stimulation|Sham- rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
9902906|NCT00622960|Experimental|High MUFA diet|Those subjects assigned to a high monounsaturated fat diet
9902907|NCT00622960|Active Comparator|High CHO diet|Those subjects assigned to a high carbohydrate diet
9902908|NCT00622973|Other|A|Diffusion-weighted MRI
9902909|NCT00622973|Other|B|Sinerem (USPIO)- enhanced MRI
9902910|NCT00622986|Experimental|A1|perimenopausal women
9902911|NCT00622986|Placebo Comparator|A2|perimenopausal women
9902912|NCT00622986|Experimental|B1|early staged postmenopausal women
9902913|NCT00622986|Placebo Comparator|B2|early staged postmenopausal women
9902914|NCT00622999||All|All patients
9902915|NCT00623025|Experimental|1|
9902916|NCT00623025|Placebo Comparator|2|
9902917|NCT00623051|Experimental|1|Male circumcision by experimented doctor or nurse
9902918|NCT00623077|Experimental|Total Marrow Irradiation (MTI) with Tomotherapy|TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age), Melphalan 100 mg/m^2, Thiotepa 500 mg/m^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
9902919|NCT00623090|Experimental|1 Website|Participants receive the Login information for the Internet we developed on prostate cancer screening.
9902920|NCT00623090|Active Comparator|2 Booklet|Participants receive the education booklet we developed on prostate cancer screening.
9902921|NCT00623090|Placebo Comparator|3 Usual Care|Usual care: participants receive no intervention.
9902922|NCT00623142|No Intervention|A|Patients in this arm were not treated with HBO prior to CABG
9902923|NCT00623142|Experimental|B|Patients in this arm were treated with HBO prior to CABG
9902924|NCT00623155|No Intervention|1|Control group
9902925|NCT00623155|Experimental|2|Test group
9902926|NCT00623168|Experimental|Treatment Only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Ribavirin.
9902927|NCT00623207|Placebo Comparator|1|Pateints who achieve target haert rate or conclusive test will not be given Atropine
9902928|NCT00623207|Active Comparator|2|Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine
9902929|NCT00623220|Experimental|A|O2 and N2O
9902930|NCT00623220|Active Comparator|B|O2 only
9902931|NCT00623246|Active Comparator|1|Participants will receive motivational enhancement therapy (MET) for 12 weeks.
9902932|NCT00623246|Active Comparator|2|Participants will receive educational therapy (ED) for 12 weeks.
9902933|NCT00623246|No Intervention|3|Participants will receive standard clinical care.
9902934|NCT00623259|Experimental|1|
9902935|NCT00623285|Experimental|Group 1|
9902936|NCT00623285|Placebo Comparator|Group 2|
9902937|NCT00623298|Experimental|1|NET
9902938|NCT00623298|No Intervention|3|6-months baseline
9902939|NCT00623298|Experimental|2|group IPT
9902940|NCT00623324|Active Comparator|1|Aplindore titrated to safe and tolerable dose
9902941|NCT00623324|Placebo Comparator|2|
9902942|NCT00623337|Experimental|Newhints|Home visits
9902943|NCT00623337|No Intervention|Control|Community based surveillance volunteers will continue with current duties eg urging attendance at immunisation clinics and child health weeks
9902944|NCT00623350|Active Comparator|1|Acute Stroke Telephone consult for the decision of tPA within 3 hours of symptoms onset.
9902945|NCT00623350|Active Comparator|2|Acute Stroke consult via audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
9902946|NCT00623376|Active Comparator|1|first on treatment then on Placebo
9902947|NCT00623376|Placebo Comparator|2|first on placebo then on treatment
9902948|NCT00623389|Experimental|A|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
9902949|NCT00623402|Experimental|A|
9902950|NCT00623415|Active Comparator|Verum|flupirtine + interferon beta 1b
9902951|NCT00623415|Placebo Comparator|Placebo|placebo + interferon beta 1b
9902952|NCT00623519||1|Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole
9902953|NCT00623532|Experimental|CA|"Cognition and action are an inseparable whole while functioning, a new intervention based approach using familiarity based movements and non judgmental approach was labeled cognition-action."
9902954|NCT00623532|Active Comparator|AT|Adapted Tai Chi is based on Tai Chi like movements
9902955|NCT00623532|No Intervention|C|Control
9902956|NCT00623558|Active Comparator|1|Docetaxel+CDDP
9902957|NCT00623558|Experimental|2|Docetaxel+CDDP+Cetuximab
9902958|NCT00623571|Experimental|1|Patients treated by hospital-at-home service (GHHS)
9902959|NCT00623571|Active Comparator|2|Patients treated in a general medical ward (GMW)
9902960|NCT00623584|Experimental|1|Patients in this arm randomly receive a corneal graft cultured in a serum free culture medium
9902961|NCT00623584|Active Comparator|2|Patients in this arm randomly receive a corneal graft cultured in a serum supplemented culture medium
9902962|NCT00623649|Experimental|Cohort 1|VCH-916 100 mg three times a day (t.i.d.)
9902963|NCT00623649|Experimental|Cohort 2|VCH-916 200 mg (t.i.d.)
9902964|NCT00623649|Experimental|Cohort 3|VCH-916 300 mg twice daily for three days
9902965|NCT00623649|Experimental|cohort 4|VCH-916 400 mg twice daily for three days
9902966|NCT00623662|Active Comparator|1|Glucose infusion.
9902967|NCT00623662|Placebo Comparator|2|Normal saline infusion.
9902968|NCT00623675|Experimental|A|
9902969|NCT00623688|Experimental|1|Subjects receive active medication (albuterol) delivered by a Proair metered dose inhaler used with an Opti-chamber and placebo (normal saline solution) by nebulizer aerosol.
9902970|NCT00623688|Active Comparator|2|Subjects receive active medication (albuterol) delivered by nebulizer and placebo (no medicine) delivered by a demonstrator Placebo metered dose inhaler demonstrator.
9902971|NCT00623701|Placebo Comparator|1|sublingual placebo preparation
9902972|NCT00623701|Experimental|2|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose
9902973|NCT00623740|Experimental|1: hydrocortisone|1: active arm treated with low doses of HC during the first 10 days of life
9902974|NCT00623740|Placebo Comparator|2: Placebo|2:placebo arm treated with placebo at the same conditions than active arm
9902975|NCT00623753|Experimental|A|
9902976|NCT00623792|No Intervention|1|Usual preoperative care
9902977|NCT00623792|Experimental|2|Preoperative Lifestyle Intervention
9902978|NCT00623844|Experimental|Intervention|Physical activity intervention: structured daily 30-min activity classes at preschool, activity homeworks, parent and teacher education
9902979|NCT00623844|No Intervention|Control|Keep usual activities in kindergarten
9902980|NCT00623857|Active Comparator|1|Zinc
9902981|NCT00623857|Active Comparator|2|Vitamins and minerals other than zinc
9902982|NCT00623857|Active Comparator|3|Vitamins plus zinc and other minerals
9902983|NCT00623857|Placebo Comparator|4|Placebo for all vitamins and minerals
9902984|NCT00623870|Experimental|1|
9902985|NCT00623883|Experimental|1|All identified ACF eliminated by cold or hot colonoscopic biopsy forceps
9902986|NCT00623883|Sham Comparator|2|ACF quantified and observed, re-evaluated after one year
9902987|NCT00623909|Experimental|1|To demonstrate the safety of the AvicennaTM class IV laser for application over the skin of human subjects. This study was terminated prior to subject enrollment and closed.
9902988|NCT00623922|Experimental|1|Patient education
9902989|NCT00623922|No Intervention|2|Usual care
9902990|NCT00623948|Other|Arm 1|
9902991|NCT00623987|Active Comparator|A|warfarin treatment
9902992|NCT00623987|No Intervention|B|withholding warfarin therapy
9902993|NCT00624000|Experimental|1|IA administration of Alteplace vs. IV administration of Alteplace
9902994|NCT00624000|Active Comparator|2|IA administration of Alteplase vs.IV administration of Alteplase
9902995|NCT00624026|Experimental|1|
9902996|NCT00624039|Other|1|ultrasound biomicrocopic examinations and pilocarpine instillation
9902997|NCT00624078|Experimental|1|Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
9902998|NCT00624091|Experimental|1|Early-surgery, within 48 hours from randomization
9902999|NCT00624091|Active Comparator|2|State-to-the-art group. Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
9903000|NCT00624104||1|Lean male
9903001|NCT00624104||2|Males with type 2 diabetes
9903002|NCT00624117|Experimental|A|
9903003|NCT00624130|Experimental|Arm 1|
9903004|NCT00624130|Active Comparator|Arm 2|
9903005|NCT00624143|Active Comparator|1|Oral Voriconazole
9903006|NCT00624143|Active Comparator|2|IV Amphotericin B
9903007|NCT00624156||1|emotional disclosure writing intervention
9903008|NCT00624156||2|control writing
9903009|NCT00624182|Experimental|Phase I study|
9903010|NCT00624208|Active Comparator|1|Intravenous injection of droperidol 20 mcg.kg-1 and saline (group 1)
9903011|NCT00624208|Active Comparator|2|Intravenous injection of ondansetron 0.1 mg.kg-1 and saline (group 2
9903012|NCT00624208|Active Comparator|3|Intravenous injection of droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1 (group 3)
9903013|NCT00624208|Placebo Comparator|4|Intravenous injection of saline and saline (group 4)
9903014|NCT00624247|Other|Immediate|Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
9903015|NCT00624247|Other|Following Day|Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
9903016|NCT00624247|Other|Delayed|Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
9903017|NCT00624260|Active Comparator|2|Usual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)
9903018|NCT00624260|Experimental|1|Semi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)
9903019|NCT00624273|Other|1, active ulcers|sildenafil treatment
9903020|NCT00624299|Experimental|Botox|Botox
9903021|NCT00624299|Placebo Comparator|Placebo|Saline injection
9903022|NCT00624312|Active Comparator|1|Pre-operatively randomized to Procrit
9903023|NCT00624312|Placebo Comparator|2|Pre-operatively randomized to placebo
9903024|NCT00624325|Experimental|1|12 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
9903025|NCT00624325|Experimental|2|9 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
9903026|NCT00624325|Experimental|3|6 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
9903027|NCT00624403|Active Comparator|1|LMA ProSeal
9903028|NCT00624403|Experimental|2|I-Gel
9903029|NCT00624455|Active Comparator|1|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
9903030|NCT00624455|Placebo Comparator|2|Placebo
9903031|NCT00624481|Active Comparator|1|
9903032|NCT00624481|Experimental|2|
9903033|NCT00624481|Experimental|3|
9903034|NCT00624481|Experimental|4|
9903035|NCT00624481|Experimental|5|
9903036|NCT00624494|Active Comparator|Conventional monitoring|hemodynamic monitoring - conventional monitoring
9903037|NCT00624494|Active Comparator|Advanced monitoring|hemodynamic monitoring - advanced monitoring
9903038|NCT00624533|Active Comparator|A|Primary Health Care Conventional Physiotherapy Treatment (based in electrotherapy)
9903039|NCT00624533|Experimental|B|Group B was treated with the GDS Method (muscular and articular chains physiotherapy method)
9903040|NCT00624546||1|gerd patients
9903041|NCT00624546||2|non gerd controls
9903042|NCT00624598|Experimental|SMART Group|The experimental group will have a nutrition program based solely on measured resting metabolic rate. The nutrition plan will be a specific calorie level that will promote a 1-2.5 lb per week weight reduction. No experimental participants' nutrition plan will be below 1200 Kcal/day for women or 1600 Kcal/day for men. Second, the experimental group will receive a downloadable copy of a computerized nutrition software program (BalanceLog: Microlife USA, Inc. Golden, CO) that functions s on a Windows 2000-XP or Palm operating system.
9903043|NCT00624598|Active Comparator|Usual Care|Standard 1200 kcal/day diet (women) 1600 kcal/day diet (men) using a sample 3-day menu program. The diet will be follow current government based recommendations for carbohydrates (i.e. 55%), fat (30%), and protein (15%). Study participants will receive a standard paper-based food and exercise journal
9903044|NCT00624611|Active Comparator|1|Residual pump blood management post aortic cannula removal
9903045|NCT00624611|Experimental|2|Residual pump blood management post aortic cannula removal
9903046|NCT00624624||1|"Eugonadal men with Lapband"
9903047|NCT00624624||2|"Hypogonadal men with Lapband"
9903048|NCT00624624||3|Eugonadal men with gastric bypass procedure
9903049|NCT00624624||4|Hypogonadal men with gastric bypass procedure
9903050|NCT00624637|Other|A|infants after craniofacial surgery receive one massage with aromatherapy three hours postoperatively
9903051|NCT00624637|Other|B|infants after craniofacial surgery receive one massage with carrier oil three hours postoperatively
9903052|NCT00624637|No Intervention|C|no intervention, standard postoperative care
9903053|NCT00624663|Active Comparator|1|(1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule) X 2 per day, total of 5 intakes
9903054|NCT00624663|Active Comparator|2|(2 x 1.5 mg Exelon® Capsules) X 2 per day, total of 5 intakes
9903055|NCT00624663|Placebo Comparator|3|(2 x Placebo Capsules) X 2 per days, total of 5 intakes
9903056|NCT00624676|Experimental|A|LHA formulation
9903057|NCT00624676|Active Comparator|B|5% benzoyl peroxide
9903058|NCT00624689|Experimental|1|Modified formula
9903059|NCT00624689|No Intervention|2|Standard formula
9903060|NCT00624689|No Intervention|3|Breastfed
9903061|NCT00624702|Active Comparator|1|Active Comparator 1 different salt formulation of Indacaterol.
9903062|NCT00624702|Active Comparator|2|Active Comparator 2 different salt formulation of Indacaterol.
9903063|NCT00624702|Active Comparator|3|Active Comparator 3 different salt formulation of Indacaterol.
9903064|NCT00624702|Placebo Comparator|4|
9903065|NCT00624728|Experimental|A|
9903066|NCT00624754|Experimental|1|Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
9903067|NCT00624754|Placebo Comparator|2|Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system
9903068|NCT00624767|Experimental|1|Insulin Nasal Spray
9903069|NCT00624767|Active Comparator|2|NovoLog
9933489|NCT05351073|No Intervention|Control Group|Participants in the control group will not receive oxygen inhalation therapy during ambulance transportation. Participants will subsequently receive standard diagnosis and treatment service according to the guidelines during hospitalization.
9933490|NCT05351060|Experimental|3D model splinting intervention group|The researcher will scan the participant's forearm, wrist, and hand with an iPhone camera through the Comb O&P Scan App. Scans will be completed individually to maintain privacy. The entire Comb O&P platform is HIPAA compliant. The data is de-identified encrypted when it moves from the iPhone app to the computer through the cloud. Precision Valve Automation (PVA) will use the de-identified scans to print the 3D models which are a precise replica of the participant's hand. Once the researcher obtains the 3D models, resting hand splints will be fabricated on the 3D models to provide custom-made hand splint(s) to each participant. The participants will receive the splint(s) to wear during the hours of sleep for six weeks.
9933491|NCT05351047|Experimental|Cohort 1|Once weekly dosing for 4 weeks (Dosing Days 1, 8, 15 and 22) OR Once weekly dosing for 6 weeks (Dosing Days 1, 8, 15, 22, 29 and 36) randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
9933492|NCT05351047|Experimental|Cohort 2|Once weekly for 6 weeks dosing on Days 1, 8, 15, 22, 29 and 36 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
9933493|NCT05351047|Experimental|Cohort 3|Three times weekly for 6 weeks dosing each week on Days 1, 3, and 5 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
9933494|NCT05351047|Experimental|Cohort 4 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
9933495|NCT05351047|Experimental|Cohort 5 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
9933496|NCT05351021|Experimental|Group I (metformin group)|who will receive adjuvant paclitaxel in addition to metformin tablets (1700 mg daily) during the chemotherapy treatment duration.
9933497|NCT05351021|Placebo Comparator|Group II (control group)|who will receive adjuvant weekly paclitaxel.
9933498|NCT05351008|Experimental|Cognitive Physical Therapy group|The group will receive 4 months 3 times per week of cognitive physical therapy.
9903070|NCT00624793|Experimental|I. Standard|Standard - Formula Acup Protocol
9903071|NCT00624793|Experimental|2. Individualized|Individualized Acup protocol based on TCM diagnosis
9903072|NCT00624793|Sham Comparator|3|(Control Group) Sham acupuncture
9903073|NCT00624871|Active Comparator|A|Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days
9903074|NCT00624871|Placebo Comparator|B|Infants will receive equivalent amount of placebo
9903075|NCT00624884||A|Patients with moderate-to-severe aortic regurgitation having normal left ventricular ejection fraction
9903076|NCT00624884||B|Age, sex and bodymass index matched healthy subjects
9903077|NCT00624936|Experimental|Vidaza and Velcade|Vidaza 75mg/m2 IV over 30 min daily on days 1-7 This dose is the same for all dose levels. Velcade will be given immediately after Vidaza is completed at one of the following dose levels: 1, 2, 3, 4
9903078|NCT00624949||1|women with Turner syndrome
9903079|NCT00624949||2.|Control women
9903080|NCT00624962|Other|Correlative/Supportive Care|
9903081|NCT00624975|Experimental|Vaccine|
9903082|NCT00624975|Placebo Comparator|Placebo|
9903083|NCT00624988|Experimental|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
9903084|NCT00625001||1|Women with Turner syndrome
9903085|NCT00625001||2|Healthy control women
9903086|NCT00625014|Experimental|1|Healthy men
9903087|NCT00625027||Group 1|Children presenting to the Emergency Department under the care of a parent or guardian, between 0600 and 2400 during the study period.
9903088|NCT00625040||A|Obese patients without diabetes with a Body Mass Index > 37 kg/m2
9903089|NCT00625053|Experimental|1|Laparoscopic repair
9903090|NCT00625053|Active Comparator|2|Open repair
9903091|NCT00625079|Placebo Comparator|Pre-transplant placebo|There are two placebo comparators.... one for the group of patients with resting PAH and another for the group of patients with exercise PAH
9903092|NCT00625079|Experimental|Pre-transplant sildenafil|There are two active comparators, one group with resting PAH and another with exercise PAH, both receiving drug.
9903093|NCT00625079|No Intervention|Pre-transplant no PAH-specific therapy|this group of patients has no evidence for either resting or exercise PAH but will be followed without specific drug intervention
9903094|NCT00625092|Experimental|Hyperthermic Treatment|Patients receiving combination of hyperthermic intraperitoneal chemotherapy (HIPC) with oxaliplatin plus intraperitoneal 5-Fu and intraperitoneal leucovorin with peritoneal metastases.
9903095|NCT00625105|Active Comparator|Biofeedback|HRV coherence biofeedback procedure
9903096|NCT00625105|Sham Comparator|Sham intervention|Passive monitor viewing
9903097|NCT00625118||1|Children in receipt of a Hib containing vaccine at pre-school booster (3.5-6 years old).
9903098|NCT00625157|Experimental|1|
9903099|NCT00625157|Placebo Comparator|2|
9903100|NCT00625170|Active Comparator|1|Healthy men
9903101|NCT00625170|Active Comparator|2|Healthy men with a positive family anamneses of schizophrenia
9903102|NCT00625196|Experimental|Subjects receiving fluticasone foroate/ vilanterol|Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments.
9903103|NCT00625196|Active Comparator|Subjects receiving fluticasone foroate|Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler.
9903104|NCT00625196|Active Comparator|Subjects receiving vilanterol|Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler.
9903105|NCT00625196|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of placebo administered using a novel powder inhaler.
9903106|NCT00625209|Placebo Comparator|1|placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein C
9903107|NCT00625209|Active Comparator|2|Hydrocortisone plus fludrocortisone and a placebo of activated protein C
9903108|NCT00625209|Active Comparator|3|placebo of hydrocortisone, placebo of fludrocortisone and activated protein C
9903109|NCT00625209|Active Comparator|4|hydrocortisone plus fludrocortisone plus activated protein C
9903110|NCT00625222|Experimental|1|
9903111|NCT00625235|Other|1|High Carbohydrate diet
9903112|NCT00625235|Other|2|High Protein diet
9903113|NCT00625248||no anthithrombotic|procedures where there were no antithrombotics
9903114|NCT00625248||Antithrombotic - continued|patients who are on antithrombotics
9903115|NCT00625248||Discontinued Antithrombotic|Patients who were on antithrombotics but have been discontinued
9903116|NCT00625261|Experimental|1|The mothers of the two-years old children in the intervention group took part at the Heidelberg Parent-based Language Intervention HPLI
9903117|NCT00625261|No Intervention|2|Waiting group, no intervention until children were three years of age
9903118|NCT00625274|Experimental|1|Oral
9903119|NCT00625274|Experimental|2|Oral
9903120|NCT00625274|Experimental|3|Oral
9903121|NCT00625300|Active Comparator|1|Active treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
9903122|NCT00625300|Sham Comparator|Placebo|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (sham) over the motor cortex and the prefrontal cortex.
9903123|NCT00625313|Experimental|HMY Model YA-60BB IOL|Patients receiving a Hoya HMY Acrylic Foldable Intraocular Lens.
9903124|NCT00625339|Experimental|A|entecavir 0.5 mg QD
9903125|NCT00625339|Active Comparator|B|lamivudine 100 mg QD
9903126|NCT00625378|Experimental|Sorafenib (Nexavar, BAY43-9006)|All patients are treated with sorafenib according to the dosage scheme of their previous trial
9903127|NCT00625430|Experimental|1|Six Cohorts with escalating vector dose
9903128|NCT00625456|Experimental|Single Arm, dose escalation|dose escalation starting dose 1e5 pfu/kg bw to 3e7 pfu/kg bw; Recombinant Vaccinia GM-CSF (JX-594)
9903129|NCT00625469|Experimental|treatment with bosentan|patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion
9903130|NCT00625469|No Intervention|PAH group with no therapy|patients with resting or exercise PAH get randomized to receive no specific therapy
9903131|NCT00625469|No Intervention|No PAH and no therapy|patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation
9903132|NCT00625482|Active Comparator|Boys 1|OPV as usual
9903133|NCT00625482|Experimental|Boys 2|OPV plus BCG
9903134|NCT00625482|Active Comparator|Girls 1|OPV as usual
9903135|NCT00625482|Experimental|Girls 2|OPV plus BCG
9903136|NCT00625495|Experimental|1|IV Nexium
9903137|NCT00625495|Experimental|2|Oral Nexium
9903138|NCT00625521|Experimental|1|Drug: ASF 1096 0.5 % cream applied twice daily
9903139|NCT00625521|Placebo Comparator|2|Cream vehicle for ASF 1096 cream applied twice daily
9903140|NCT00625534|Experimental|1|Laparoscopic repair
9903141|NCT00625534|Active Comparator|2|Open tension free inguinal hernia mesh repair
9903142|NCT00625547|Experimental|1|
9903143|NCT00625547|Experimental|2|
9903144|NCT00625560|Experimental|A|entecavir 1.0 mg QD
9903145|NCT00625560|Active Comparator|B|lamivudine 100 mg QD
9903146|NCT00625599||1|Salvadorian students at the Evangelical University in non-health track studies over the age of 18. The students must accept the invitation to participate along with signing the informed consent to be eligible.
9903147|NCT00625599||2|Patients over the age of 45 presenting to Hospital Zacamil with an acute fracture. Patients must accept the invitation to the study and sign the informed consent to be eligible.
9903148|NCT00625677|Experimental|1|"Pediacel - 2,3,4 months Prevenar - 2,4 months Menjugate - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
9667228|NCT03835273||Minimally invasive surgery|Fifty patients who have undergone minimally invasive removal of oesophagus more than one year ago.
9903149|NCT00625677|Experimental|2|"Pediacel - 2,3,4 months Prevenar - 2,4 months Neis-vacC - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
9903150|NCT00625781|Experimental|B2|IGT randomized to treatment
9903151|NCT00625781|No Intervention|B1|"IGT randomized to no treatment"
9903152|NCT00625794|Experimental|1|8 weeks or counseling plus 6 weeks of nicotine nasal spray
9903153|NCT00625794|Active Comparator|2|8 weeks or counseling only.
9903154|NCT00625859|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
9903155|NCT00625859|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
9903156|NCT00625859|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
9903157|NCT00625859|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
9933499|NCT05351008|Active Comparator|Physical therapy group|The group will receive 4 months 3 times per week of physical therapy.
9903158|NCT00625859|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
9903159|NCT00625859|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
9903160|NCT00625898|Active Comparator|1A: TCH-H|Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)
9903161|NCT00625898|Experimental|1B: TCHB-HB|Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)
9903162|NCT00625898|Active Comparator|2A: TH-FEC-H|Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)
9903163|NCT00625898|Experimental|2B: THB-FEC-HB|Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)
9667229|NCT03835273||Open surgery|Fifty patients who have undergone open removal of oesophagus more than one year ago.
9903164|NCT00625911|Active Comparator|morphine only|standard analgesia protocol
9903165|NCT00625911|Experimental|morphine ketamine|alterantive regimen for intravenous patient controlled analgesia
9903166|NCT00625924||1|autogenous tissue breast reconstruction
9903167|NCT00625924||2|tissue expander/implant breast reconstruction
9903168|NCT00625924||3|mastectomy alone
9903169|NCT00625963||I,A|I=Pulmonary Hypertension Patients A=ILD patients with Pulmonary Hypertension Patients
9903170|NCT00625976|Experimental|1|
9903171|NCT00625976|Experimental|2|
9903172|NCT00626015|Experimental|Arm I|Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
9903173|NCT00626015|Experimental|Arm II|Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
9903174|NCT00626015|Experimental|Basiliximab|Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.
9903175|NCT00626041|Other|1|referral to primary care network for management of blood pressure, lipids and diabetes.
9903176|NCT00626054|Active Comparator|1|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
9903177|NCT00626054|Active Comparator|2|Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test.
9903178|NCT00626067|Active Comparator|1 Fully functional monitoring device|Fully functional monitoring device
9903179|NCT00626067|Active Comparator|2 Partially functional monitoring device|Partially functional monitoring device
9903180|NCT00626067|Sham Comparator|3 Non-functional monitoring device|Non-functional monitoring device
9903181|NCT00626119||Control|
9903182|NCT00626119||diseased|
9903183|NCT00626132|Experimental|Eucommia|Eucommia capsules two orally three times a day for 2 weeks
9903184|NCT00626132|Placebo Comparator|1|
9903185|NCT00626145|Placebo Comparator|1|Patients receive intracoronary injections of saline 7 days after PCI.
9667230|NCT03832049|Active Comparator|15 to 26 years - 3 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
9903186|NCT00626145|Experimental|2|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
9903187|NCT00626158|Experimental|Gem/Cape|
9903188|NCT00626171|Other|1|Allergen challenge
9903189|NCT00626184|Placebo Comparator|A|Placebo
9903190|NCT00626184|Active Comparator|B|Active study Drug: ALV003
9903191|NCT00626223|Experimental|A|patients treated with intravenous 5-MTHF (Prefolic®, Knoll, Milan, Italy) 50 mg at the end of each hemodialysis session; The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week
9903192|NCT00626223|Active Comparator|B|"treated with 5 mg per day of oral folic acid (Folina® Schwarz Pharma, Milan, Italy).~The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week"
9903193|NCT00626249|Experimental|T Inhalation powder in diabetic subjs w/ normal renal func|T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units
9903194|NCT00626249|Experimental|T Inhalation powder diabetic subj w/mild or moderate nephrop|T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units
9903195|NCT00626262|Experimental|1|20mg oral
9903196|NCT00626262|Experimental|2|20mg IV
9903197|NCT00626288|Experimental|A|Mesalazine cpr 800 mg t.i.d. for 12 weeks
9903198|NCT00626288|Placebo Comparator|B|Placebo cpr t.i.d. for 12 weeks
9903199|NCT00626301|Experimental|1|Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.
9903200|NCT00626314|Experimental|1|myoblast
9903201|NCT00626314|Sham Comparator|2|sham injection procedure
9903202|NCT00626353|Experimental|Intervention|Patients treated by an interdisciplinary, intersectoral and interventional team responsible for providing home-based rehabilitation.
9903203|NCT00626353|Active Comparator|Control|Control patients treated following standard care procedures in our department with no interference from the interventional team.
9903204|NCT00626418|Placebo Comparator|1|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
9903205|NCT00626418|Active Comparator|2|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
9903206|NCT00626457|Experimental|Maintenance First|
9903207|NCT00626457|Active Comparator|Weight Loss First|
9903208|NCT00626470|Active Comparator|-TSP|Patients operated without TSP
9903209|NCT00626470|Active Comparator|+TSP|Patients operated with TSP
9903210|NCT00626483|Experimental|CMV pp65-LAMP mRNA-loaded DC vaccination|Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF
9903211|NCT00626535|Experimental|1|20mg once daily
9903212|NCT00626535|Placebo Comparator|2|Oral once daily
9903213|NCT00626587|Placebo Comparator|A|Conventional diagnostic procedures (transbronchial biopsy and bronchial washing) for peripheral pulmonary lesions
9903214|NCT00626652|Experimental|1|
9903215|NCT00626665|Placebo Comparator|Placebo|One placebo tablet every alternate day for 6 weeks
9903216|NCT00626678|Experimental|1|Oral administration of prednisone and azathioprine throughout study
9903217|NCT00626678|Placebo Comparator|2|Oral administration of prednisone and placebo throughout study
9903218|NCT00626717|Experimental|1|
9903219|NCT00626717|Sham Comparator|2|
9903220|NCT00626756|Experimental|LI|arm controled by LIDCO technology
9903221|NCT00626756|No Intervention|CA|standard approach
9903222|NCT00626769||1|Postmenopausal women with established osteopenia receiving aglycone genistein 54 mg/day for 3 years
9903223|NCT00626769||2|Postmenopausal women with established osteopenia receiving placebo (Calcium and vitD) for 3 years
9903224|NCT00626834|Experimental|Vigabatrin Dose 1|
9903225|NCT00626834|Experimental|Vigabatrin Dose 2|
9903226|NCT00626834|Experimental|Vigabatrin Dose 3|
9903227|NCT00626834|Placebo Comparator|Matching placebo|
9903228|NCT00626847||1|Primary Open Angle Glaucoma (POAG)
9903229|NCT00626847||2|Controls (Normals, patients without glaucoma)
9903230|NCT00626873|Experimental|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
9933500|NCT05350982||Hospital Arm|Participants will be recruited to use the SalivaBio +/- SaliPac in a hospital setting. They will be provided with collecting instructions and will be guided by a member of the research team.
9933501|NCT05350982||Stimulated Home Arm|10 participants will be randomly selected by a random number generator. This arm will also be conducted in the Hospital, and the collection using a SalivaBio +/- SaliPac will still be observed by a member of the research team. These participants will receive the same information as those in the Hospital Arm, but will receive minimal input. This is to establish whether the collection instructions provided would be suitable to use in the home environment.
9933502|NCT05350969|Experimental|CDR132L 5 mg|CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
9933503|NCT05350969|Experimental|CDR132L 10 mg|CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57
9933504|NCT05350969|Placebo Comparator|Placebo|Placebo intravenous in single dose on Day 1, Day 29 and Day 57
9933505|NCT05350956|Experimental|Herombopag monotherapy|
9933506|NCT05350956|Experimental|Herombopag is treated in combination with rhTPO(Recombinant human thrombopoietin)|
9933507|NCT05350943|Experimental|HAIC+Toripalimab+Donafenib|HAIC(GEMOX)+Toripalimab+Donafenib
9933508|NCT05350930||R-CHOP or G-CHOP chemotherapy|Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
9933509|NCT05350917|Experimental|Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate|One arm study
9933510|NCT05350891|Experimental|endoscopic surgery combined with adjuvant immunotherapy|
9933511|NCT05350878|Experimental|Implementation Intervention|Through virtual and in-person meetings, the internal/external facilitation team will support sites in utilizing the multi-component implementation strategy for 7 months
9933512|NCT05350878|No Intervention|Implementation as Usual|In control 'implementation as usual' sites, no facilitation or implementation strategies will be provided. Controls will receive 1) an informational session on the text intervention during grand rounds/staff meetings and 2) flyers to provide patients with intervention enrollment information.
9933513|NCT05350865||HDV cohort|Chronic Hepatitis B (HBsAg+) with cirrhosis (APRI >1.5, FIB-4 > 3.25, Fibroscan > 12.5, imaging), PWID with HBV, HIV/HBV, HBV/HCV, aged 18 years and older
9933514|NCT05350852|Experimental|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10^6 cells/kg of ThisCART19A
9933515|NCT05350852|Experimental|ThisCART19A 8×10^6 cells/kg for dose level 2|Patients will receive 8×10^6 cells/kg of ThisCART19A
9933516|NCT05350852|Experimental|ThisCART19A 12×10^6 cells/kg for dose level 3|Patients will receive 12×10^6 cells/kg of ThisCART19A
9933517|NCT05350826|Experimental|Ambulatory medical assistance|Patient benefiting from the ambulatory medical assistance nurse program in addition to conventional care for patients chronic lymphoid leukemia under targeted therapy
9933518|NCT05350826|No Intervention|Conventional care|Patient benefiting from conventional care for patients chronic lymphoid leukemia under targeted therapy
9933519|NCT05350813|Experimental|PCT-guided arm|Group of patients whose duration of antibiotic therapy will depend on the level of procalcitonin (PCT) in plasma on days 0 and 1, then on the plasma PCT level every 48 hours and on the pSOFA (Pediatric Sequential Organ Failure Assessment) score every day until antibiotics are stopped in hospital or until discharge if the patient is discharged with an antibiotic treatment.
9933520|NCT05350813|Active Comparator|standard-of-care|A group of patients whose duration of antibiotic therapy will be determined by the type of infection, microbiological findings and clinical, biological and/or radiological course, according to standard practice based on guidelines.
9933521|NCT05350800|Experimental|BMS-986369, Part 1 dose escalation|
9933522|NCT05350800|Experimental|BMS-986369 under fasted conditions, Part 2 Food effect|
9933523|NCT05350800|Experimental|BMS-986369 under fed conditions, Part 2 Food effect|
9933524|NCT05350787|Experimental|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10^6 cells/kg of ThisCART19A
9933525|NCT05350787|Experimental|ThisCART19A 8×10^6 cells/kg as dose level 2|Patients will receive 8×10^6 cells/kg of ThisCART19A
9667231|NCT03832049|Experimental|9 to 14 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
9933526|NCT05350787|Experimental|ThisCART19A 12×10^6 cells/kg as dose level 3|Patients will receive 12×10^6 cells/kg of ThisCART19A
9933527|NCT05350774|Experimental|IVIg arm|IVIg arm IV immunoglobulin 0.4g/kg/day for 5 days
9933528|NCT05350774|Placebo Comparator|Placebo arm|IV normal saline 250ml for 5 days
9933529|NCT05350774|Experimental|Steroid arm|Steroid arm IV methylprednisolone 1g/day for 5 days
9933530|NCT05350761||Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
9933531|NCT05350761||Field Cohort|includes Proband, Other carriers in family, Family Controls
9903231|NCT00626938||sarcoidosis|sarcoidosis patients
9903232|NCT00626938||controls|healthy volunteers and other interstitial lung disease (ILD) patients
9903233|NCT00626951|Experimental|1|LMA Supreme
9903234|NCT00626951|Experimental|2|LMA ProSeal
9903235|NCT00626964||Lifestyle or bariatric surgery|Morbid Obesity with BMI >= 40 kg/m2 or BMI >= 35 with Comorbidity
9903236|NCT00626977||R|R group:15 mL of 0.125% ropivacaine (18.75 mg)
9903237|NCT00626977||RC|RC group:0.0625% ropivacaine (9.375 mg) plus 75 ug clonidine
9903238|NCT00626990|Active Comparator|RT alone|radiation therapy alone
9903239|NCT00626990|Active Comparator|RT & Concurrent CT|Radiotherapy and concurrent temozolomide chemotherapy
9903240|NCT00626990|Active Comparator|RT + Adjuvant CT|Radiotherapy plus adjuvant temozolomide chemotherapy
9903241|NCT00626990|Active Comparator|RT & Concurrent CT + adjuvant CT|Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy
9903242|NCT00627003|Experimental|1|
9903243|NCT00627003|Experimental|2|
9903244|NCT00627029|Experimental|Intervention|Care coordination, consisting variously (depending on the demonstration site)--nurse telephonic counseling, nurse in-person home visits, home telemonitoring equipment, and physician education and feedback.
9903245|NCT00627029|No Intervention|Control|Usual care in Medicare fee-for-service from beneficiaries' physicians and other health care providers
9903246|NCT00627055|Experimental|1|LPV/r monotherapy
9903247|NCT00627055|Active Comparator|2|LPV/r + 2NRTIs (TDF/FTC or TDF/3TC)
9903248|NCT00627068||1|High cardiovascular risk age over 61 years.
9903249|NCT00627068||2|Low Cardiovascular risk age over 61.
9903250|NCT00627068||3|High cardiovascular risk age over 25 but under 61.
9903251|NCT00627068||4|Low cardiovascular risk age over 25 under 61.
9903252|NCT00627081|Placebo Comparator|1|general anesthesia and thoracic epidural administration of saline
9903253|NCT00627081|Active Comparator|2|general anesthesia and thoracic epidural administration of chirocaine
9903254|NCT00627107|Experimental|A|A group of paraplegics.
9903255|NCT00627120|Experimental|1|1mg dose group
9903256|NCT00627120|Experimental|2|10mg dose group
9903257|NCT00627120|Experimental|3|100mg dose group
9903258|NCT00627120|Experimental|4|200mg dose group
9903259|NCT00627120|Experimental|5|400mg dose group
9903260|NCT00627120|Experimental|6|800mg dose group
9903261|NCT00627133|Experimental|1|
9903262|NCT00627146|Placebo Comparator|B|
9903263|NCT00627146|Active Comparator|A|ChAgly CD3
9903264|NCT00627159|Other|1|high risk
9903265|NCT00627159|Other|2|low to moderate risk
9903266|NCT00627185|Experimental|1|Intervention group (dental practices) that received the interactive motivational website for patient tobacco cessation
9903267|NCT00627185|Placebo Comparator|2|Control group (dental practices) that did not receive any materials or resources on tobacco cessation. This is a wait-list control.
9903268|NCT00627211|No Intervention|Room air insufflation|Air used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is current standard procedure, i.e. no experimental intervention.
9903269|NCT00627211|Experimental|CO2 insufflation|CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention.
9903270|NCT00627237|Experimental|Immediate start|Starts the 12 week intervention immediately after enrollment
9903271|NCT00627237|Experimental|Waitlist group|Starts the 12 week intervention 12 weeks after initial enrollment
9903272|NCT00627263|No Intervention|1|Participants will receive the usual cardiologic care for ICD patients provided by their medical team.
9903273|NCT00627263|Experimental|2|In addition to the usual cardiologic care for ICD patients provided by the participants medical team, those randomized to Intervention will receive the stress reduction treatment (SRT) program (see below).
9903274|NCT00627276|Experimental|Arm I|Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
9903275|NCT00627276|Placebo Comparator|Arm II|Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
9903276|NCT00627289||1|patients with chronic postherniotomy pain (>1 year), affecting everyday activities severely
9903277|NCT00627302|Active Comparator|2|Systane
9903278|NCT00627302|Active Comparator|1|PEG-400
9903279|NCT00627315||Surgery|Obese adult men and women who are undergoing bariatric surgery (gastric bypass or gastric banding).
9903280|NCT00627328||1|pacemaker patients with previously diagnosed AT.
9903281|NCT00627328||2|pacemaker patients without previously diagnosed AT.
9903282|NCT00627341|Experimental|Exposure and Response Prevention|Participants will receive Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa for 6 months.
9903283|NCT00627341|Active Comparator|Cognitive Behavior Therapy|Participants will receive cognitive behavioral therapy for anorexia nervosa for 6 months.
9903284|NCT00627380|Placebo Comparator|STOC|Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
9903285|NCT00627380|Experimental|YOGA|Yoga lifestyle intervention administered by certified yoga instructor.
9903286|NCT00627471|Active Comparator|A|This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
9903287|NCT00627471|Active Comparator|B|This is the control group, following the physician's standard practice.
9903288|NCT00627484||Group 1: GBP non-diabetic|Non-diabetic subjects scheduled to receive gastric bypass
9903289|NCT00627484||Group 2: BND non-diabetic|Non-diabetic subjects scheduled to receive gastric banding
9903290|NCT00627484||Group 3: GBP diabetic|Diabetic subjects scheduled to receive gastric bypass
9903291|NCT00627484||Group 4: VLCD diabetic|Diabetic subjects scheduled to receive very low calorie diet
9903292|NCT00627484||Group 5: SG diabetic|Diabetic subjects scheduled to receive sleeve gastrectomy
9903293|NCT00627510||A|all patients consecutively admitted to psychiatric inpatient treatment (naturalistic sample from routine psychiatric hospital intake)
9903294|NCT00627536|Experimental|1|Avotermin 5ng/100μL/linear cm wound margin
9903295|NCT00627536|Placebo Comparator|2|Placebo
9903296|NCT00627536|Experimental|3|Avotermin 50ng/100μL/linear cm wound margin
9903297|NCT00627536|Placebo Comparator|4|Placebo matched to avotermin 50ng/100μL/linear cm
9903298|NCT00627536|Experimental|5|Avotermin 200ng/100μL/linear cm
9903299|NCT00627536|Placebo Comparator|6|Placebo matched to avotermin 200ng/100μL/linear cm
9903300|NCT00627536|Experimental|7|Avotermin 500ng/100μL/linear cm wound margin
9903301|NCT00627536|Placebo Comparator|8|Placebo matched to avotermin 500ng/100μL/linear cm
9903302|NCT00627549|Active Comparator|1|
9903303|NCT00627549|Active Comparator|2|
9903304|NCT00627562|Experimental|1|robot assisted endoscopic head and neck surgery
9903305|NCT00627575|Active Comparator|Lamotrigine|Subjects will receive 40 milligram (mg) of Atrovastatin from Days 1-7, from Days 8-56 subjects will receive Lamotrigine and Subjects will receive 300 mg/day of Lamotrigine and 40 mg/day of atorvastatin each morning on Days 57-77.
9903306|NCT00627575|Active Comparator|phenytoin|Subjects will receive 40 mg of Atrovastatin from Days 1-7, from Days 8-28, subjects will receive 4mg/kg/day of phenytoin in the morning and will continue to take 40 mg/day of atorvastatin each morning. Subjects will receive taper dose of phenytoin from Days 29-30.
9903307|NCT00627588|Experimental|Dose Evaluation|To assess the safety and efficacy of up to three dose levels of ProSavin
9903308|NCT00627588|Sham Comparator|Sham element|The potential use of sham comparator to confirm efficacy
9903309|NCT00627614|Experimental|breast imaging study|
9903310|NCT00627627|Experimental|1|IPI-504
9903311|NCT00627640|Experimental|1|1 active (50 - 100 mg/day)
9903312|NCT00627640|Placebo Comparator|2|
9903313|NCT00627653|Experimental|1|
9903314|NCT00627692|Active Comparator|1|Prucalopride
9903315|NCT00627692|Active Comparator|2|Prucalopride
9903316|NCT00627692|Active Comparator|3|Prucalopride
9903317|NCT00627692|Placebo Comparator|5|Placebo
9903318|NCT00627692|Active Comparator|4|Prucalopride
9903319|NCT00627718|Other|A|All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
9903320|NCT00627731|Active Comparator|1|mPSL 240 mg per day for 5 days
9903321|NCT00627731|Experimental|2|PSL 40mg per day for 10 days
9993578|NCT01473550|Experimental|Later Intervention|A delayed implementation plan will be used (but will have no effect on the standard of care for the remaining 200 participants), so the remaining 200 participants in Group 2 will initially act as a control group, but at Phase 2 (six months later - approximately June 2012) the remaining 200 participants will be introduced to the technology in the same order (PHR -> Smart Phone). Group 2 will have the benefit of any enhancements made during Phase 1 of the project.
9993579|NCT01473576|Experimental|Nitrate|Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
9993580|NCT01473576|Placebo Comparator|Sodium chloride|Sodium chloride placebo group
9993581|NCT01473615|Experimental|Treatment As Usual + Mindfulness Based Cognitive Therapy|Subjects randomized into the intervention group will receive, a manualized 8-week MBCT group skills program with sessions that each last 2 hours, in addition to their treatment as usual (TAU).
9993582|NCT01473615|No Intervention|Treatment As Usual|Patients randomized into the TAU group will continue to receive their care as usual and be put on a waitlist. They will be offered the MBCT treatment after the completion of the study.
9993583|NCT01473628|Experimental|Radiation Therapy and Rituximab (Arm I)|Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
9993584|NCT01473628|Experimental|Radiation Therapy and Observation (Arm II)|Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
9993585|NCT01473641||New users of Nexplanon|
9993586|NCT01473654|Experimental|ADAPT tool|prediabetes counseling using ADAPT tool
9993587|NCT01473654|No Intervention|Control|
9993588|NCT01473667|Active Comparator|Superficial Cervical Plexus Block|
9993589|NCT01473667|Active Comparator|Local Infiltration|
9993590|NCT01473680||Patients who will receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
9993591|NCT01473680||Patients who will not receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
9993592|NCT01473680||Healthy Controls|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
9993593|NCT01473693||surgery-only group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
9993594|NCT01473693||induction chemotherapy group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.
9993595|NCT01473706||Consumers|Adults aged ≥ 65 years; Employed part-time, unemployed, retired, full-time or a homemaker; English speaking
9993596|NCT01473706||Caregivers of Consumers|Family, relative, friend, professional caregiver of an individual age ≥ 65 years; Lives with individual aged ≥ 65 years OR Visits individual aged ≥ 65 years five or more days a week; Makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs; English speaking
9993597|NCT01473719|Active Comparator|motivational intervention|7-session individual motivationally-based intervention
9993598|NCT01473719|Placebo Comparator|health education|7-session individual session focusing on health education
9993599|NCT01473771|Experimental|Caring Letter Condition (CL)|"In the Caring Letters (CL) group, participants will be emailed letters for two years on a planned schedule. The emailed letters are simple expressions of care and include standard contact information for available health care services."
9993600|NCT01473771|No Intervention|Usual Care (UC)|The participants in the Usual Care (UC) group will not receive the emails.
9993601|NCT01473784|Experimental|Transoral robotic surgery (TORS)|Patients will undergo TORS for oral and laryngopharyngeal benign and malignant lesions using the Da Vinci Robotic Surgical System. After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
9993602|NCT01473797|Experimental|cladribine|
9993603|NCT01473810|Experimental|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
9993604|NCT01473810|Experimental|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
9993605|NCT01473810|Experimental|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
9993606|NCT01473810|Placebo Comparator|Zero dose|Adjuvant only, i.e. 300 µl Endocine divided into two administrations, one for each nose cavity
9993607|NCT01473823|Placebo Comparator|Placebo oil|Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
9993608|NCT01473823|Active Comparator|Omega-3 LCPUFA|"The omega-3 LCPUFA supplementation comprises of 5 ml daily of Möller's Tran flavored with lemon. This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA."
9993609|NCT01473888|Other|T89|
9993610|NCT01473901|Experimental|BKM120 + Temozolomide (Concomitant Phase)|Cranial radiation: Days 1 - 5 every 7 days for 42 days60 Gy in 30 fractions; Temozolomide: 75 mg/m2 Daily, orally; BKM120: 0, or 40, or 60, or 80 mg/d Daily, orally or Days 1-5 every 7 days, orally
9993611|NCT01473901|Experimental|BKM120 + temozolomide with/without radiotherapy|"Adjuvant phase cycle 1:~Temozolomide 150 mg/m2 - Days 1 - 5 every 28 days Daily; BKM120 60, or 80, or 100 mg/d;~Adjuvant phase cycle 2+:~Temozolomide 200* mg/m2 - Day 1 ~ 5 every 28 days Daily BKM120 0, or 40, or 60, or 80 or 100 mg/d"
9993612|NCT01473914|Experimental|Low dose|"Standard renal vitamin plus low dose zinc and selenium plus vitamin E~1 capsule p.o, daily"
9993613|NCT01473914|Experimental|Medium dose|"Standard renal vitamin plus medium doses of zinc and selenium plus vitamin E~1 capsule p.o, daily"
9933532|NCT05350748||Cohort 1|Participants with myelodysplastic syndromes and associated malignancies
9933533|NCT05350748||Cohort 2|Participants (controls) without MDS or associated malignancies, contributing bone marrow
9933534|NCT05350735|Experimental|Intervention arm: SMS text reminders and medical card|Participants in this intervention arm will receive the routine medical card indicating return date for the subsequent doses of anti-rabies vaccine and SMS reminders sent a day before each dose until the scheduled date of the last dose of anti-rabies vaccine.
9933535|NCT05350735|No Intervention|Control arm: Medical card|Participants in the control arm will receive the routine medical card indicating return date for the subsequent doses of anti-rabies vaccine. No SMS text reminders will be sent to this group.
9933536|NCT05350722|Experimental|Pre-operative single dose partial breast irradiation|
9933537|NCT05350709|Active Comparator|mirror therapy|An exercise program has been prepared for patients for use in mirror therapy. In this exercise program, firstly, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages) is shown. The patient will repeat the movement for 3 minutes. The patient will hold the affected extremity behind the mirror with the healthy extremity, the patient will look towards the affected side from the mirror and try to do the movements with the affected extremity. . The treatment period will be 20 sessions, 5 days a week, for 4 weeks.The exercises will take 1 hour, including half an hour of mirror therapy and half an hour of conventional exercises.
9933538|NCT05350709|Active Comparator|action observational therapy|An exercise video has been prepared for the patients to watch for the action observation therapy. In this video, first of all, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist, etc.) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages, etc.). is shown. The patient will first watch the video of each movement, and then repeat the movement for 3 minutes. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks.The exercises will take 1 hour, including half an hour of action observational therapy and half an hour of conventional exercises.
9993614|NCT01473914|Active Comparator|Standard treatment|"Standard renal vitamin~1 capsule p.o, daily"
9993615|NCT01473927||1|Crohn's Disease patients
9993616|NCT01473927||2|Ulcerative colitis patients
9993617|NCT01473966|No Intervention|standard of care|patients receive standard care
9993618|NCT01473966|Experimental|Coffee orally|patients will receive standard of care plus coffee orally
9993619|NCT01473966|Experimental|coffee rectally|patients receive standard of care plus coffee rectally
9993620|NCT01473979|Active Comparator|Arm A) Secondary closure with the vacuum-assisted system (VAC|"after the diagnosis of the poststernotomy wound infection is established the clinical procedure is obtained as follows: firstly the empiric antibiotic therapy with vancomycin is induced. The lab samples including bacteriology test are obtained. Surgical debridement is made until occurrence of tissue bleeding. Finally VAC sponge is implanted wit the negative suction pressure of 75 mmHg.~The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 48/72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done."
9993621|NCT01473979|Active Comparator|Arm B) Surgical procedure by delayed primary closure|In the first step, after the diagnosis of the infection was done, and the empiric antibiotic therapy is induced with vancomycin in the first surgical intervention the sternal wires will be removed, the mediastinum is explored and extensive surgical debridement is performed until occurrence of tissue bleeding.The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed.
9993622|NCT01474031||20 DAA subjects|20 DAA subjects: THA with a Deltamotion articulating surface utilizing the Direct Anterior Approach
9993623|NCT01474031||Control group|healthy volunteers
9993624|NCT01474044|Placebo Comparator|Placebo|
9993625|NCT01474044|Active Comparator|Gastropyloric Complex Capsules|
9993626|NCT01474057|Experimental|DESTRESS-PC|A brief, nurse-assisted, Internet-based online self-management tool for PTSD (DESTRESS-PC), based on empirically valid cognitive-behavioral therapy (CBT) strategies and designed for implementation in a primary care setting. DESTRESS-PC stands for DElivery of Self-TRaining and Education for Stressful Situations for Primary Care.
9993627|NCT01474057|Active Comparator|OUC|Optimized Usual Care (OUC) for PTSD--usual PTSD treatment offered within the primary care setting, optimized by training PC providers in PTSD identification and treatment and providing basic care management including phone check-ins to monitor symptoms and feedback to providers.
9993628|NCT01474096|Experimental|implementation strategy|determining whether the use of implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding CPG in primary care is more effective than the usual practice of mere circulation.
9993629|NCT01474096|No Intervention|Conventional intervention|
9993630|NCT01474161|Placebo Comparator|Matching placebo|
9667232|NCT03832049|Experimental|4 to 8 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
9993631|NCT01474161|Active Comparator|GFT505 20mg - old formulation|Study Part I : dose level = 120mg
9993632|NCT01474161|Experimental|GFT505 60mg - new formulation|Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
9993633|NCT01474174||Supportive care (vaccine therapy)|Patients receive trivalent influenza vaccine IM on day 0.
9903322|NCT00627744|Placebo Comparator|BE 1|Patients in this arm are randomly assigned to treatment with placebo
9903323|NCT00627744|Active Comparator|BE 2|Patients in this arm are randomly assigned to treatment with Sitagliptin
9903324|NCT00627757||Food challenge test|"Patients~51 patients included"
9903325|NCT00627757||C|Controls 93 healthy controls are included
9903326|NCT00627783|Experimental|Intervention|Patients are referred to a cardiologist for a systematic detection of silent ischemia by a bicycle exercise test performed according to the French Society of Cardiology protocol after washout of cardiovascular medications likely to interfere with the test. Dipyridamole Single Photon Emission Computed Tomography (SPECT) is used in patients unable to perform the exercise test, with a sub-maximal negative exercise test result or with electrocardiographic abnormalities impairing the interpretation of the exercise test. Subsequent investigations (such as coronary angiography) and treatments (such as revascularization procedures) are left at the cardiologist's decision.
9903327|NCT00627783|No Intervention|Control|Patients are treated according current guidelines but are not referred to a cardiologist
9903328|NCT00627796|Experimental|A|Newly diagnosed patients with acromegaly
9903329|NCT00627809|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
9903330|NCT00627809|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
9903331|NCT00627822||Ward|Patients in the hospital ward
9903332|NCT00627822||Emergency room|Patients in the emergency waiting room
9903333|NCT00627822||Intensive care unit|Family members of patients admitted to the intensive care unit
9903334|NCT00627835|Experimental|Treatment Group 1: Cohort 1|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
9903335|NCT00627835|Experimental|Treatment Group 1: sorafenib and radiation: Cohort 2|Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
9903336|NCT00627835|Experimental|Treatment Group 2: Cohort 3|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
9903337|NCT00627835|Experimental|Treatment Group 2: Cohort 4|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
9903338|NCT00627835|Experimental|Treatment Group 2:Cohort 5|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
9903339|NCT00627874|Experimental|1|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
9903340|NCT00627874|No Intervention|2|
9993634|NCT01474187|Experimental|Irinotecan|irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week
9993635|NCT01474226|Experimental|Lysine Amino Acid|
9993636|NCT01474252|Experimental|RSI technique|"Intubation with RSI technique. RSI technique includes the administration of inductive and neuromuscular blocking agents to facilitate an intubation.~In this study, we have no restriction of medication use. Physicians can chose any of medication as an individual judgement."
9993637|NCT01474252|No Intervention|Non-RSI|Intubation without RSI technique. No any medication use during intubation period.
9993638|NCT01474265|Placebo Comparator|varenicline placebo|
9993639|NCT01474265|Active Comparator|varenicline|
9993640|NCT01474265|Active Comparator|Nicorette TX|
9993641|NCT01474265|Active Comparator|Nicorette TX optional|
9993642|NCT01474265|No Intervention|control group smokers|
9993643|NCT01474278|Experimental|1|
9993644|NCT01474278|Placebo Comparator|2|
9993645|NCT01474304|Active Comparator|Acetaminophen|Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.
9993646|NCT01474304|No Intervention|No acetaminophen|Patients will receive standard of care with no intraoperative doses of acetaminophen.
9993647|NCT01474330|Experimental|0.5-mg Pomalidomide or placebo (Cohort A)|A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions
9993648|NCT01474330|Experimental|1-mg Pomalidomide or placebo (Cohort B)|This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
9993649|NCT01474330|Experimental|2-mg Pomalidomide or placebo (Cohort C)|This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
9993650|NCT01474343|Experimental|SAF-301|
9993651|NCT01474356|No Intervention|BT (brachytherapy)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy only was performed.
9993652|NCT01474356|Experimental|BTHT (brachytherapy and hyperthermia)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy with interstitial hyperthermia was performed.
9993653|NCT01474369|Experimental|TAK-438 10 mg QD|
9993654|NCT01474369|Experimental|TAK-438 20 mg QD|
9993655|NCT01474369|Placebo Comparator|Placebo QD|
9993656|NCT01474382|Experimental|OraVerse|OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)
9993657|NCT01474382|Sham Comparator|Sham injection|Dentist simulates injection with dental syringe
9993658|NCT01474395|Experimental|D-serine 60 mg/kg|double blind dose of d-serine
9993659|NCT01474395|Placebo Comparator|Placebo D-serine|
9993660|NCT01474408|Experimental|interval training|4 x 4 minutes exercise at 90 - 95 % of peak heart rate separated with 3 minutes at 70 % of peaks heart rate
9993661|NCT01474408|Active Comparator|moderate exercise|moderate continuous exercise at 70 % of peak heart rate on venous function.
9993662|NCT01474408|Other|control|routine measurements, no exercise
9993663|NCT01474447|Experimental|Grinberg Method|
9993664|NCT01474460|Placebo Comparator|Control group|The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
9993665|NCT01474460|Experimental|Phytonadione|Patients receiving 200mcg of phytonadione.
9993666|NCT01474473|Experimental|CACIPLIQ20 and Cast Boot|This arm receives treatment by CACIPLIQ20 application every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
9993667|NCT01474473|Placebo Comparator|Placebo and Cast Boot|This arm receives a placebo (saline solution) every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
9993668|NCT01474499|Experimental|Docusate sodium and sorbitol rectal solution|
9993669|NCT01474499|Active Comparator|Glycerine|
9903341|NCT00627887|Experimental|ECT+pharmacotherapy|Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
9903342|NCT00627887|Active Comparator|pharmacotherapy|Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.
9903343|NCT00627900|Other|BMS|Implantation of a bare metal stent
9903344|NCT00627900|Other|SES|Implantation of a sirolimus-eluting stent
9903345|NCT00627913|Active Comparator|1|Healon 5
9903346|NCT00627913|Experimental|2|Retrobulbar Anesthetic Injection
9903347|NCT00627952|Active Comparator|amlodipine 10 mg|
9903348|NCT00627952|Active Comparator|manidipine 20 mg|
9903349|NCT00627965|Experimental|1|Sildenafil citrate
9903350|NCT00627965|Placebo Comparator|2|Placebo
9903351|NCT00628004|Experimental|1|
9903352|NCT00628004|Active Comparator|2|
9903353|NCT00628004|No Intervention|No treatment|No treatment as wound was healed
9903354|NCT00628017|Experimental|1|omega-3 PUFAs(180mg eicosapentaenoic acid[EPA] + 120mg docosahexaenoic acid[DHA]/capsule), 3 capsules twice daily, total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA
9903355|NCT00628017|Placebo Comparator|2|three identical placebo capsules twice daily which contained olive oil esters.
9903356|NCT00628043|Experimental|EPOCH|
9903357|NCT00628043|Placebo Comparator|placebo|
9903358|NCT00628056|Active Comparator|1|
9903359|NCT00628056|Placebo Comparator|2|
9903360|NCT00628069||Group 1|performers who will participate in the training sessions.
9903361|NCT00628069||Assistants|Assisants-paired with the performers and will be allowed to assists only, without the opportunity to practice the technical skills related to the task.
9903362|NCT00628082||HfpEF|Patients with Heart Failure with preserved ejection fraction
9903363|NCT00628082||Control|Healthy Volunteers
9903364|NCT00628121|Experimental|Cetrorelix 1 mg|
9903365|NCT00628121|Experimental|Cetrorelix 2 mg|
9903366|NCT00628121|Experimental|Cetrorelix 3 mg|
9903367|NCT00628160|Experimental|Terlipressin group|Terlipressin in continuous infusion plus alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
9903368|NCT00628160|Active Comparator|Control group|Alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
9903369|NCT00628173|Experimental|1|patients with refractory glaucoma who were candidate for AGV implantation allocated in superior site
9903370|NCT00628173|Experimental|2|patients with refractory glaucoma who were candidate for AGV implantation allocated in inferior site
9903371|NCT00628186|Experimental|1|Pancreaticojejunostomy has a risk factor of pancreatic fistula. Type of stent tube (external stent vs. short stent)across pancreaticojejunostomy was randomized for the patients with pancreaticoduodenectomy.
9903372|NCT00628225|No Intervention|1|Usual Care
9903373|NCT00628225|Experimental|2|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement)
9903374|NCT00628225|Experimental|3|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement + bupropion-SR)
9903375|NCT00628238|Active Comparator|A|Subjects younger than 65 years old.
9903376|NCT00628238|Active Comparator|B|Subjects aged 65 years and older
9903377|NCT00628264|Experimental|AP214|
9903378|NCT00628264|Placebo Comparator|Placebo|
9903379|NCT00628277|Experimental|1|Arm 1: high caloric expenditure exercise plus dietary counseling
9903380|NCT00628277|Active Comparator|2|Arm 2: low caloric expenditure exercise plus dietary counseling
9903381|NCT00628290|Experimental|1|
9903382|NCT00628290|Active Comparator|2|
9903383|NCT00628303|Experimental|1|Motavizumab
9903384|NCT00628303|Placebo Comparator|2|Placebo
9903385|NCT00628329||1|
9903386|NCT00628329||2|
9903387|NCT00628342|Experimental|1|
9903388|NCT00628342|Experimental|2|
9903389|NCT00628342|Placebo Comparator|3|
9903390|NCT00628381|Experimental|AA|24 ICU patients with severe sepsis will get a L-citrulline 8 h enteral supplementation.
9903391|NCT00628381|Active Comparator|AB|24 ICU patients with severe sepsis will get an alternative isocaloric amino acid supplementation (L-alanine) during 8 hours
9903392|NCT00628420|Other|1|Patients recieved single low dose of ACP-104
9903393|NCT00628420|Other|2|Patients recieved a high dose of ACP-104
9903394|NCT00628420|Other|3|Patients recieved a placebo
9903395|NCT00628433|Placebo Comparator|1|Placebo
9903396|NCT00628433|Experimental|2|HE3286 5 mg daily
9903397|NCT00628433|Experimental|3|HE3286 10 mg daily
9903398|NCT00628433|Experimental|4|HE3286 20 mg daily
9903399|NCT00628433|Experimental|5|HE3286 4 mg daily
9903400|NCT00628459|Active Comparator|1|
9903401|NCT00628459|Experimental|2|
9903402|NCT00628459|Experimental|3|
9903403|NCT00628485|Experimental|Low Stimulation|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation."
9903404|NCT00628485|Experimental|High Stimulation|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions."
9903405|NCT00628485|Placebo Comparator|Control Group|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises.
9903406|NCT00628511||observation|
9903407|NCT00628524||1|> 500 consecutive patients with coronary artery disease fulfilling eligibility criteria.
9903408|NCT00628537|Experimental|1|BION™ Experimental Group
9903409|NCT00628537|Active Comparator|2|Surface Stimulation Group
9903410|NCT00628537|Active Comparator|3|Control Group with conservative therapy (Range of motion exercises)
9903411|NCT00628550|Experimental|1|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive vasopressin (0.8 units/kg) rescue as the second vasopressor medication.
9903412|NCT00628550|Active Comparator|2|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive standard dose epinephrine (0.01 mg/kg)rescue as the second vasopressor medication.
9903413|NCT00628563||1|Asthma patients
9903414|NCT00628576|Active Comparator|1|UFH: patients treated with unfractionated heparin
9903415|NCT00628576|Experimental|2|FH: patients treated with low-molecular-weight (fractionated) heparin
9903416|NCT00628602|Experimental|Rx Group|BION Therapy Group
9903417|NCT00628602|Placebo Comparator|Control Group|control group
9903418|NCT00628615||2|male patients with lower urinary tract symptoms
9903419|NCT00628615||1|Female patients with overactive bladder syndrome
9903420|NCT00628654||Volunteers|Serum samples will be obtained from volunteers, but no tissue specimens. Volunteers will complete a questionnaire.
9903421|NCT00628654||Patients with cancer|Ascites from patients with ovarian, peritoneal, and fallopian tube cancers for basic science studies
9903422|NCT00628667|Experimental|1|
9903423|NCT00628667|Placebo Comparator|2|
9903424|NCT00628680|Experimental|AAT-023 (Zuragen Arm)|Active experimental consisting of AAT-023 (Zuragen)solution
9903425|NCT00628680|Active Comparator|Heparin|5000 units diluted with normal saline to the exact catheter lumen volume
9993670|NCT01474525|Experimental|Telemonitoring|
9993671|NCT01474525|Active Comparator|Usual Care|
9903426|NCT00628706|Experimental|A|Inhalation of THC, using a Volcano vaporizer
9903427|NCT00628706|Placebo Comparator|B|Inhalation of vehicle, using a Volcano vaporizer
9903428|NCT00628719|Experimental|1|a single dose of 10 mg/kg of liposomal amphotericin B
9903429|NCT00628719|Active Comparator|2|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
9903430|NCT00628732|Experimental|1|
9903431|NCT00628771|Active Comparator|Usual Care|Participants will receive usual care for their prenatal visits.
9903432|NCT00628771|Experimental|CenteringPregnancy Plus|Participants will receive the CenteringPregnancy Plus treatment program, which includes an HIV/STD prevention component.
9903433|NCT00628784|Experimental|Group 1|Specialized intestinal metaplasia (Barrett's esophagus) documented via endoscopic esophageal biopsy, with standard surveillance biopsies (four-quadrant biopsies obtained every 2-cm the entire length of the specialized intestinal metaplasia in the esophagus) performed within the past two years prior to study enrollment. Biopsies show either low grade dysplasia, indeterminate for dysplasia, or no dysplasia.
9903434|NCT00628784|Experimental|Group 2|Diagnosis of Barrett's esophagus and high grade dysplasia or intramucosal carcinoma. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). Endoscopic ultrasound* (EUS) demonstrating no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa (T1).
9903435|NCT00628784|Experimental|Group 3|Diagnosis of esophageal carcinoma (T1smN0 or T2N0 via EUS). Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement).
9903436|NCT00628784|Experimental|Group 4|Diagnosis of severe dysplasia within esophageal squamous mucosa on pathology review. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). EUS with no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa.
9903437|NCT00628797|Other|A UVA1 B no UVA1|half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
9903438|NCT00628797|Experimental|A UVA1|
9903439|NCT00628810|Experimental|FOLFIRI fort plus bevacizumab|Bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.
9903440|NCT00628823|No Intervention|A1|Gluten-containing diet
9903441|NCT00628823|Active Comparator|A2|Gluten-free diet
9903442|NCT00628836|Active Comparator|SE group|surface stimulation
9903443|NCT00628836|Experimental|BE group|BION stimulation
9903444|NCT00628849||1|This group will have 2 mm plates and screws placed according to Champy principles
9903445|NCT00628849||2|This group will have 2 mm plates placed according to modified Champy principles
9903446|NCT00628849||3|This group will have larger (2.3 mm or greater) plates and screws placed according to the AO technique
9903447|NCT00628888|Experimental|Unified Protocol for Adolescents (UP-A)|Participants receive the UP-A intervention for 8-21 weeks immediately following randomization.
9903448|NCT00628888|Experimental|Delayed Treatment/Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the UP-A treatment for 8-21 weeks.
9903449|NCT00628914|Experimental|1|Open label escitalopram plus eszopiclone for 8 weeks
9903450|NCT00628914|Other|2|Escitalopram and eszopiclone for initial 4 weeks, then switch to escitalopram and placebo for final 4 weeks.
9903451|NCT00628914|Placebo Comparator|3|Escitalopram plus placebo for 8 weeks
9903452|NCT00628940|Experimental|1|18F-fluoromethylcholine
9903453|NCT00628953|Experimental|1|
9903454|NCT00628953|Placebo Comparator|2|
9903455|NCT00628979|Other|1|CBT
9903456|NCT00628992|Other|1|
9993672|NCT01474564||Pts with Pancreatic Adenocarcinoma|This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
9993673|NCT01474577||pts who have had Rb-82 PET myocardial perfusion imaging|Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone.
9993674|NCT01474603||1|overweight or obese diabetic
9993675|NCT01474616|Other|Sit-to-Stand Activity|
9993676|NCT01474629|Active Comparator|probiotic-based dietary supplement|
9993677|NCT01474629|Placebo Comparator|placebo|
9667233|NCT03832049|Experimental|9 to 14 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
9667234|NCT03832049|Experimental|4 to 8 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
9993678|NCT01474642|Active Comparator|Capecitabine/Cisplatin(XP)|Capecitabine AND Cisplatin
9993679|NCT01474642|Active Comparator|Capecitabine/Paditaxel(XG)|Capecitabine + Paditaxel(genexol)
9993680|NCT01474668|Experimental|A|Experimental
9993681|NCT01474707|Experimental|Group one|Group1 will view the knowledge-based video only
9993682|NCT01474707|Experimental|Group two|Group two will view the motivational video only
9993683|NCT01474707|Experimental|Group three|Group three will view both knowledge-based and motivational videos
9993684|NCT01474707|Experimental|Group four|Group four will view the printed educational pamphlet and will not view either video
9993685|NCT01474720|Experimental|SLE patients|Subjects with mild SLE over age 50 years will receive open-label Zostavax vaccine.
9903457|NCT00628992|Active Comparator|2|
9903458|NCT00628992|Active Comparator|3|
9903459|NCT00628992|Active Comparator|4|
9903460|NCT00629005|Experimental|Arm 1|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus 1 hour of strength training for the arms and hands 3x/week
9903461|NCT00629005|Active Comparator|Arm 2|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus non-resisted arm and hand movements for 1 hour 3x/week
9903462|NCT00629031|Active Comparator|2|Paromomycin for 21 days @ 11mg/kg
9903463|NCT00629031|Experimental|1|Paromomycin for 14 days @ 11mg/kg
9903464|NCT00629044|Active Comparator|G|
9903465|NCT00629044|Active Comparator|AMD|
9903466|NCT00629044|Active Comparator|Healthy subjects|
9903467|NCT00629057|Experimental|1|Lowest dose level
9903468|NCT00629057|Experimental|2|Middle level dose
9903469|NCT00629057|Experimental|3|Highest dose level
9903470|NCT00629070|Experimental|ST|Traditional strength training
9903471|NCT00629070|Experimental|VT|Velocity-enhanced training
9903472|NCT00629096|Experimental|1|All included patients are assigned to arm 1, in which they are treated by the intervention
9903473|NCT00629135|Experimental|1|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 1: Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily.
9903474|NCT00629135|Active Comparator|2|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 2: Piperacillin / Tazobactam 4,5 g administered intravenously three times daily
9903475|NCT00629148|Active Comparator|combination chemotherapy|Simultaneous use of Vinorelbine and Capecitabine
9903476|NCT00629148|Experimental|sequential chemotherapy|Sequential use of Vinorelbine and Capecitabine
9903477|NCT00629161|Experimental|A|
9903478|NCT00629161|Placebo Comparator|B|
9903479|NCT00629174|Experimental|1|Exercise
9903480|NCT00629174|Experimental|2|Mental training (computer lessons)
9903481|NCT00629174|No Intervention|3|
9903482|NCT00629187|Experimental|1|
9903483|NCT00629200|Experimental|SSG + Intron A|Sodium Stibogluconate (SSG) 400 mg/m^2 intravenous (IV) daily on days 1-5 + Interferon Alfa-2b (Intron A) 3x10^6 units subcutaneously three times weekly
9903484|NCT00629213|Active Comparator|1|
9903485|NCT00629213|Placebo Comparator|2|
9903486|NCT00629226|Experimental|Group I|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22, 25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.
9903487|NCT00629226|Experimental|Group II|Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.
9903488|NCT00629252|Experimental|1|Schizophrenic patients treated with sertindole
9903489|NCT00629252|Active Comparator|2|Schizophrenic patients treated with risperidone
9903490|NCT00629252|No Intervention|3|Healthy controls without any treatment.
9993686|NCT01474720|Active Comparator|Healthy subjects|Healthy subjects aged 50 years and older without any history of autoimmune disease will receive zostavax vaccine. Immune responses to varicella zoster virus and adverse events will be compared to those seen in SLE patients
9903491|NCT00629291||1|Sickle cell anemia patients
9903492|NCT00629291||2|Sickle cell β thalassemia
9903493|NCT00629304|Placebo Comparator|1|standard visit at 3 and 6 months
9903494|NCT00629304|Active Comparator|2|PDA-FIT system + standard visit at 3 and 6 months
9903495|NCT00629304|Active Comparator|3|PDA-FIT system + 12 telephone visits + standard visit at 6 months
9903496|NCT00629317|Active Comparator|A|
9903497|NCT00629317|Placebo Comparator|B|
9903498|NCT00629330|Experimental|Multi-component Academic Detailing|Includes an interactive, digitized CDROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients.
9903499|NCT00629343|Experimental|Treatment|
9903500|NCT00629369|Experimental|A|subjects with Occlusion Support Device with active pushing in the second stage of labor
9903501|NCT00629369|No Intervention|2|Subjects without Occlusal Support Device with active pushing in the second stage of labor
9903502|NCT00629382|Experimental|1|
9903503|NCT00629382|Other|2|
9903504|NCT00629395|Experimental|1|Participate in 12 week computer program.
9903505|NCT00629434|Experimental|1|This arm will receive diabetes education via telemedicine
9903506|NCT00629434|Active Comparator|2|diabetes education in-person
10212871|NCT04917861|Placebo Comparator|Placebo|Participants will receive placebo matching to mRNA-1893 administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
10212872|NCT04915768|Experimental|Treatment|CH505 TF chTrimer plus adjuvants administered at months 0, 2, 4, 8 and 12.
10212873|NCT04914091||Patients with diffuse large B-cell lymphoma treated with CART-cells|
10212874|NCT04912687|Experimental|All patients|"For all patients, blood sample will be collected at inclusion (liquid biopsy) for sequencing.~As per standard management, for all of these patients, EGFR gene mutation will be also analyzed on archived tumor sample."
10212875|NCT04912024||Tablo Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on the Tablo Hemodialysis System at a dialysate flow rate of 300 mL/min
10212876|NCT04912024||Conventional Hemodialysis System|Participants who were prescribed acute intermittent renal replacement therapy on conventional hemodialysis systems (Non-Tablo) with dialysate flow rates of ≥ 500 mL/min
10212877|NCT04909190|No Intervention|1xIFU|Subjects in this arm are randomized to have a saline flush volume according to the IFU of the used device.
10212878|NCT04909190|Experimental|4xIFU|Subjects in this arm are randomized to have a saline flush volume of 4x of what is stated in the IFU of the used device.
10212879|NCT04906694|Experimental|COVI-DROPS|10, 20, or 40 mg of COVI-DROPS administered intranasally
10212880|NCT04906694|Placebo Comparator|Placebo|2 mL administered intranasally
10212881|NCT04902287|Experimental|TIES Engagement Strategies|Participants in this arm will receive a 30-minute TIES engagement intervention during their referral phone call.
10212882|NCT04902287|No Intervention|Referral as Usual|Participants in this arm will receive a standard call to schedule an intake appointment by an administrative assistant with no clinical training.
10212883|NCT04900506|Active Comparator|cemented hemiarthroplasty , posterior SPAIRE approach|Posterior SPAIRE approach: lateral decubitus position, preservation of the piriformis tendon and obturator internus, detatchment of obturator externus , capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair, repair of obturator externus.
10212884|NCT04900506|Active Comparator|cemented hemiarthroplasty, anterior approach|Anterior approach: supine position, both legs washed and draped, intermuscular plane between m. tensor fascia lata and m. sartorius, capsular T-incision, femoral neck resection, femoral canal reaming according to preoperative templating, third generation cementation technique, capsular repair
10212885|NCT04894214||"Sequential baseline PCV - FCV - VCV"|Each participant will be subjected to baseline pressure controlled ventilation (PCV) during 5 minutes, followed by 30 minutes of FCV with an evone respirator (Ventinova Medical B.V., Eindhoven, The Netherlands) and eventually 30 minutes of VCV. Respiratory rate (RR), positive end-expiratory pressure (PEEP) and inspiratory fraction of oxygen (FiO2) will be held constant. According to the manufacturers guidelines, an I:E ratio of 1:1 will be pursued during FCV. During FCV, the respirator will be set with the same PIP as during baseline PCV. For VCV, the same tidal volume as during baseline PCV will be set.
10212886|NCT04893278||Virtual reality|
10212887|NCT04891289|Experimental|HAI FUDR plus GemOx (Arm 1)|"Surgical HAI pump placement. 2. HAI FUDR [(0.12 mg/kg/day) x wt (kg) x (20ml) X 0.9) / pump flow rate (1ml/day)] and dexamethasone [1 mg/day * 20] / pump flow rate (1 ml/day) on Day 1 of each cycle.~Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. 3. Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/ m2 IV over 120 minutes on Days 1 and 15 of each cycle; however, for patients in Arm 1, initiation of systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first dose of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter."
10212888|NCT04891289|Active Comparator|GemOx alone (Arm 2)|Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/m2 IV over approximately 120 minutes) on Days 1 and 15 of each 28-day cycle.For patients in Arm 2, systemic therapy will be administered on Days 1 and Day 15 of each Cycle on a 28-day cycle basis, compromised of Gemcitabine and Oxaliplatin. If a patient randomized to Arm 2 has intrahepatic progression on any follow-up scan during study treatment, that patient will be eligible to crossover to Arm 1 and commence to pump placement surgery and HAI FUDR treatment. Patients with any extrahepatic progression will not be eligible to utilize the crossover arm. Arm 2 patients will have 28 days from date of the scan showing intrahepatic progression to proceed to the crossover arm.
10212889|NCT04891250|Experimental|Intervention|Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio
10212890|NCT04891250|Experimental|Prophylaxis|An additional group of patients will be recruited will be randomized to either Ivermectin as prophylaxis (Intervention) or Standard of Care with no ivermectin (Control arm) in a 1:1 ratio
9993687|NCT01474733|Experimental|educational intervention|participants undergo a series of educational interventions over 3 years
9993688|NCT01474759|Experimental|Portion size instruction|Advice on diet, physical activity, and behavior change. Instruction in food portion size.
9993689|NCT01474759|Experimental|Pre-portioned foods|Advice on diet, physical activity, and behavior change. Provision of pre-portioned foods.
9993690|NCT01474759|Active Comparator|Comparison|Advice on diet, physical activity, and behavior change. Advice on healthy eating for weight loss.
9993691|NCT01474785|Experimental|RYGB|Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.
9993692|NCT01474785|Experimental|VSG|Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.
9993693|NCT01474785|Experimental|Low Calorie Diet|Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.
9993694|NCT01474837|Experimental|Exercise with motivational interviewing|Young people with depression exposed to exercise with motivational interviewing
9993695|NCT01474837|No Intervention|Treatment as usual|Young people with depression receiving treatment as usual
10212891|NCT04889703|Experimental|15% Trichloroacetic acid (TCA) chemical peel|15% trichloroacetic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
10212892|NCT04889703|Experimental|30% Salicylic acid chemical peel|30% salicylic acid will be applied topically on the skin of the entire face in two separate clinic visits that are 4 weeks apart
10212893|NCT04889417|Experimental|Intervention|Computerized brain game training and online interactive physical exercise training
10212894|NCT04889417|Active Comparator|Control|Control computer games and online interactive stretching exercises.
10212895|NCT04887792|Active Comparator|Acetazolamide|acetazolamide capsules
10212896|NCT04887792|Active Comparator|Placebo|Identical gelatin capsules
10212897|NCT04887519||All Participants|Participants with advanced or metastatic ALK positive NSCLC who have been prescribed with brigatinib in real-world will be observed both prospectively and/or retrospectively at the local clinical practice setting and data will be taken from medical records of the routine visit after every 12 weeks from the start of treatment up to 24 weeks of follow up or death or cancer progression or treatment discontinuation, whichever occurs first.
10212898|NCT04883762|Experimental|Fecal Microbiota Transplantation (FMT)|Study subjects will undergo standard bowel preparation and diagnostic colonoscopy with routine biopsies for pathologic assessment. FMT will be performed at the proximal extent of the colon reached, according to the same protocol used in prior randomized studies. FMT will use healthy donor stool provided by OpenBiome, a nonprofit 501(c)(3) organization that provides clinicians and hospitals with screened, filtered and frozen stool to be used for FMT. Routine clinical and research biopsies will be collected during the FMT colonoscopy procedure.
10212899|NCT04882982|Experimental|Caria app|"The Caria app is publically available on the Apple app store. It is an interactive native app that provides education on menopause as well as symptom tracking/feedback features, social support as well as cognitive behavioral and relaxation techniques. Participants will be given an unlocked version with all content available at no charge. The app sends out occasional automated emails to users to remind of features of the app and to encourage them to return to the app. Users can opt out of reminder features."
10212900|NCT04882982|Active Comparator|Menopause education|Participants will receive educational material about menopause from the North American Menopause Society, a well respected menopause organization.
10212901|NCT04881656|Experimental|HIIYH|Help is in Your Hands is a series of online modules for parents with narrated videos of specific interactive strategies for supporting toddlers' communication development.
10212902|NCT04881656|No Intervention|Comparison|No additional materials
10212903|NCT04881149|Experimental|TempSure Device|The TempSure will be used on the flanks during this study.
10212904|NCT04880681|Experimental|Novel needle|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.
10212905|NCT04880681|Active Comparator|Standard Tru Cut needle|Standard tru cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000).
10212906|NCT04880187|Experimental|AXA1125 22.6g|22.6 g AXA1125 administered orally BID with or without food
10212907|NCT04880187|Experimental|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
10212908|NCT04880187|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
10212909|NCT04878484|Experimental|Cohort 1: TCRT-ESO-A2: 0.3 × 1010 TCRT-ESO-A2 cells * ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
10212910|NCT04878484|Experimental|Cohort 2: TCRT-ESO-A2: 1.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor.
10212911|NCT04878484|Experimental|Cohort 3: TCRT-ESO-A2 : 3.0 × 1010 TCRT-ESO-A2 cells ±30%|Subjects will be evaluated for DLTs up to 28 days post-TCRT-ESO-A2 infusion. Enrollment into a dose level will be suspended if two of no more than six subjects at a dose level experience dose-limiting toxicity. Prior to increasing the dose, a cohort management meeting will be held after the final enrolled subject has been followed for up to28 days. The decision to increase to the next dose level will be a joint decision of the clinical site Investigators and Sponsor. At each cohort, there will be at least 7 days between infusion of each subject in the cohort.
9903507|NCT00629447|Experimental|1|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
9903508|NCT00629460||1|there is only one group/cohort. This is a non-therapeutic study.
9903509|NCT00629473|Experimental|Arm AM: advanced malignancies|Dose Escalation - 9 dose cohorts NPI-0052 on Days 1, 8, 15 every 28 days NPI-0052 doses ranging from 0.1 to 0.9 mg/m2
9903510|NCT00629473|Experimental|Arm MM: multiple myeloma|Dose Escalation - 8 dose cohorts NPI-0052 on Days 1, 4, 8, 11 every 21 days NPI-0052 doses ranging from 0.075 to 0.6 mg/m2 Dexamethasone 20 mg oral or IV day before and day after NPI-0052 dosing.
9903511|NCT00629486|Experimental|cytokines were determined|prevalence of genetic polymorphisms of interleukin 1B was measured in HBV-related hepatocellular carcinoma
9903512|NCT00629512|Experimental|1|20mg oral daily
9903513|NCT00629512|Experimental|2|40mg oral daily
9903514|NCT00629512|Placebo Comparator|3|
9903515|NCT00629564|Active Comparator|1|20mg oral
9903516|NCT00629564|Active Comparator|2|15 minute intravenous infusion
9903517|NCT00629603|Experimental|cytokine polymorphisms, HCV infection|Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease
9903518|NCT00629616|Experimental|Arm A|Anastrozole
9903519|NCT00629616|Experimental|Arm B|Fulvestrant
9903520|NCT00629629|Other|I, Intervention|
9903521|NCT00629642|Experimental|I.Solifenacin succinate 10mg (2x5mg 1/day)|Oral
9903522|NCT00629642|Experimental|II.Solifenacin succinate 5mg (5mg 1/day)|Oral
9903523|NCT00629642|Active Comparator|III.Oxybutynin hydrochloride 15mg (5mg 3/day)|Oral
9903524|NCT00629642|Placebo Comparator|IV. Placebo|Oral
9903525|NCT00629655||1|healthy people, male
9903526|NCT00629655||2|male patients with cerebral infarction, chronic stage
9903527|NCT00629681|Experimental|1|
9903528|NCT00629694|Active Comparator|A-T|
9903529|NCT00629694|Experimental|A-M|
9903530|NCT00629733|Experimental|Ro-14|
9903531|NCT00629746|Experimental|NIM (Nerve Integrity Monitor)|
9903532|NCT00629759|Experimental|1|1e8 pfu (plaque forming units)total dose each treatment day
9903533|NCT00629759|Experimental|2|3e8 pfu (plaque forming units) total dose each treatment day
9903534|NCT00629759|Experimental|3|1e9 pfu (plaque forming units) total dose each treatment day
9903535|NCT00629759|Experimental|4|3e9 pfu (plaque forming units) total dose each treatment day
9903536|NCT00629824|Active Comparator|A|110 naïve CHC patients who are 65 to 80 years of age
9903537|NCT00629824|Active Comparator|B|140 naïve CHC patients who are 50 to 64 years of age
9903538|NCT00629824|Active Comparator|C|40 HCV-1 infected patients with an RVR who are 65-80 years of age will receive 24 weeks of treatment
9903539|NCT00629837|Experimental|Arm 1|
9903540|NCT00629837|Experimental|Arm 2|
9903541|NCT00629837|Active Comparator|Arm 3|
9903542|NCT00629837|Active Comparator|Arm 4|
9903543|NCT00629876|Experimental|Peginesatide|
9903544|NCT00629889|Active Comparator|Levetiracetam|Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
9903545|NCT00629889|Active Comparator|Pregabalin|Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year
9903546|NCT00629902||A1|Patients with prosthesis-patient mismatch after mitral valve replacement
9903547|NCT00629902||A2|Patients without prosthesis mismatch after mitral valve replacement
9903548|NCT00629928|Experimental|1|20mg capsule once daily
9903549|NCT00629928|Experimental|2|40mg capsule daily
9903550|NCT00629928|Placebo Comparator|3|
9903551|NCT00629954||I|
9903552|NCT00629967|Active Comparator|A|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
9903553|NCT00629967|Active Comparator|B|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
9903554|NCT00629993|Experimental|Multi-component Academic Detailing|"Multi-component, academic detailing regarding ACS guidelines on cervical cancer screening approaches.~Includes an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients."
9903555|NCT00630019|Experimental|1|
9903556|NCT00630019|Active Comparator|2|
9903557|NCT00630045|Experimental|1|2~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis
9903558|NCT00630045|Active Comparator|2|no neoadjuvant chemotherapy, resect the liver metastasis directly
9903559|NCT00630084|Active Comparator|A|40 naïve CHC patients concomitant with malignancy other than hepatocellular carcinoma
9903560|NCT00630084|Active Comparator|B|80 naïve CHC patients without malignancy
9903561|NCT00630110|Active Comparator|docetaxel|docetaxel (75 mg/m2)
9903562|NCT00630110|Experimental|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
9903563|NCT00630123||1|Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
9903564|NCT00630123||2|Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
9903565|NCT00630136||A|Adult parent or legally authorized representative (LAR) of child who has consented to undergo an out-patient endoscopy at Children's Mercy Hospital as a diagnostic procedure
9903566|NCT00630149|Experimental|1|
9903567|NCT00630188|Experimental|1|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with physician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
9903568|NCT00630188|Active Comparator|2|Highway Safety video
9903569|NCT00630214|No Intervention|C|No supplements after total thyroidectomy and central neck dissection
9903570|NCT00630214|No Intervention|D|No central neck dissection group (total thyroidectomy alone)
9903571|NCT00630214|Active Comparator|A|Oral calcium plus vitamin D supplements after total thyroidectomy and central neck dissection
9903572|NCT00630214|Active Comparator|B|Oral calcium alone supplement after total thyroidectomy and central neck dissection
9903573|NCT00630227|Experimental|Single|all patients are treated with the experimental therapy
9903574|NCT00630240||1|only one arm for study
9903575|NCT00630279|Placebo Comparator|1|
9903576|NCT00630279|Experimental|2|
9903577|NCT00630279|Experimental|3|
9903578|NCT00630279|Experimental|4|
9903579|NCT00630370|Placebo Comparator|1|2 Placebo tablets, TID, orally, 58 days
9903580|NCT00630370|Experimental|2|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
9903581|NCT00630370|Experimental|3|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
9903582|NCT00630370|Experimental|4|2 ATI 40mg tablets, TID, orally, 58 days
9903583|NCT00630383|Experimental|1|Patients will receive 25 live hookworm larvae.
9903584|NCT00630383|Placebo Comparator|2|Patients will receive 0.01 % histamine solution.
9903585|NCT00630422||64|All Patients
9933539|NCT05350709|Active Comparator|conventional therapy|Conventional therapy includes range of motion exercises, walking and balance exercises. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks. The exercises will last for half an hour daily.
9933540|NCT05350696|Active Comparator|Erector Spinae Plane block group|(30 patients) will receive bilateral ultrasound guided erector spinae plane block using plain bupivacaine 100 mg diluted to volume using normal saline to achieve 50% concentration ( 50 mg plain pubivicaine in each side ).
9933541|NCT05350696|Active Comparator|Intravenous Morphine group|(30 patients) will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
9933542|NCT05350683|No Intervention|Control group|EVAR patients no ischemic preconditioning
9933543|NCT05350683|Active Comparator|Preconditioning Group|EVAR patients with remote ischemic preconditioning
9933544|NCT05350670|Experimental|perineal massage and cold compress group|
9933545|NCT05350670|No Intervention|no intervention group|
9933546|NCT05350657|Experimental|Ketogenic Diet|Subjects will be provided with foods following a ketogenic diet for 15 consecutive days.
9903586|NCT00630435|Experimental|1|
9903587|NCT00630435|Experimental|2|
9903588|NCT00630435|Experimental|3|
9903589|NCT00630435|Active Comparator|4|
9903590|NCT00630448||Group 1|Control Group. Normal (healthy) individuals without Von Willebrand Disease.
9903591|NCT00630448||Group 2|Case Group. Individuals with known Von Willebrand Disease.
9903592|NCT00630474|Active Comparator|1|nasal application of xylometazoline
9903593|NCT00630474|Placebo Comparator|2|nasal application of placebo
9903594|NCT00630500|Active Comparator|Memantine|Active treatment with memantine
9903595|NCT00630500|Placebo Comparator|Placebo|Placebo matching active study drug
9903596|NCT00630513|Experimental|E|3 days regimen with Ertapenem
9903597|NCT00630513|Active Comparator|AS|3 days treatment with Ampicillin-Sulbactam
9903598|NCT00630578|Active Comparator|1|Cognitive Processing Therapy
9903599|NCT00630578|No Intervention|2|Arm 2 participants will monitor their symptoms for a period of 10 weeks, prior to being crossed over into active treatment. This will allow investigators to account for the passage of time without intervention when tracking symptoms.
9903600|NCT00630591|Experimental|Standardized Materials Group|
9903601|NCT00630591|Experimental|Independent Tailored Intervention|
9903602|NCT00630591|Experimental|Partner-Assisted Tailored Intervention|
9903603|NCT00630630|Experimental|1|
9903604|NCT00630630|Placebo Comparator|2|
9903605|NCT00630643|Placebo Comparator|1|
9903606|NCT00630643|Experimental|2|
9903607|NCT00630669|Active Comparator|1|Rubber band ligation
9903608|NCT00630669|Active Comparator|2|Bipolar coagulation
9903609|NCT00630682|Active Comparator|Dextroamphetamine|Active drug
9903610|NCT00630682|Placebo Comparator|Placebo|Placebo of drug
9903611|NCT00630695|Experimental|1|Lanreotide LP 90
9903612|NCT00630695|Placebo Comparator|2|
9903613|NCT00630708|Active Comparator|1|Benazepril group
9903614|NCT00630708|Active Comparator|2|Losartan group
9903615|NCT00630708|Active Comparator|3|Benazepril+Losartan group
9903616|NCT00630721|Other|IFNbeta-1b|no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
9903617|NCT00630760|Experimental|1|NRX 194204 capsules in escalating doses, starting at 3mg/m2.
9903618|NCT00630851|Experimental|1|
9903619|NCT00630851|Placebo Comparator|2|
9903620|NCT00630890|Experimental|1|External beam radiation with Cyberknife radiosurgery boost and concurrent capecitabine
9903621|NCT00630903|Active Comparator|A|8-MOP + UVA x 24 weeks
9903622|NCT00630903|Active Comparator|B|IFN alone, 2 weeks, 8-MOP + UVA irradiation + IFN, 22 weeks
9903623|NCT00630929|Active Comparator|A|
9903624|NCT00630929|Placebo Comparator|C|
9903625|NCT00630929|Experimental|B|
9903626|NCT00630942|Experimental|Single Arm, active treatment|
9903627|NCT00630981||Intervention group|"Combined psychotherapy and pharmacological treatment~Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.~Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered."
9903628|NCT00631033|Placebo Comparator|1|Placebo
9903629|NCT00631033|Experimental|2|Diazoxide
9903630|NCT00631033|Experimental|3|Metformin + Diazoxide
9903631|NCT00631046|Experimental|Fish Oil|containing n-3 LCPUFA
9903632|NCT00631046|Placebo Comparator|Sunflower oil|containing n-6 PUFA
9903633|NCT00631072|Other|GM-CSF +INKT|"INKT will be administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.~GM-CSF will be given subcutaneously once daily for 10 days beginning the second day of the second and third infusion"
9903634|NCT00631085|Other|1|
9903635|NCT00631098|Experimental|1|Cannulation of external jugular vein and cannulation of cubital vein
9903636|NCT00631124|Experimental|Arm 1|
9903637|NCT00631124|Experimental|Arm 2|
9903638|NCT00631176|No Intervention|1|
9903639|NCT00631176|Experimental|2|
9903640|NCT00631202|Experimental|I|Treatment arm
9903641|NCT00631215|Experimental|1|Healthy Adults
9903642|NCT00631228||1|The group will be monitored to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
9903643|NCT00631241|Experimental|Intraoperative Lymphatic Mapping|Single Photon Emission Computed Tomography - First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients. Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
9933547|NCT05350631|No Intervention|Control|only follow-ups consultations, phone contact and TVE workshop with the AJA mobile team centralized by the IDEC
9993696|NCT01474850|Active Comparator|open lung|The lung recruitment maneuver (RM) immediately after intubation using pressure controlled ventilation, increase in peak inspiratory pressure up to 30 cm H2O during tidal ventilation, respiratory rate 4/min and positive end expiratory pressure (PEEP) 15 cm H20. PEEP 7 cm H2O until extubation. Inspiratory oxygen concentration (FiO2) 40% during recovery from anesthesia.
9993697|NCT01474850|No Intervention|control|No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
9993698|NCT01474902|Experimental|Treatment group|"The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or~1 mg/kg/dose SC q12h for patients > 2 months old~Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn."
9993699|NCT01474902|No Intervention|No-treatment|
9993700|NCT01474928|Experimental|Group 2: community video group|In each community intervention group two subject viewed the patient role played community video
9993701|NCT01474928|Experimental|Group three: both videos group|In each community intervention group three subject viewed two videos (the patient role played community and physician-led knowledge videos)
9993702|NCT01474928|Active Comparator|Group four: pamphlet group|In each community intervention group four subject read an educational pamphlet only - act as active comparator group
9993703|NCT01474928|Experimental|Group one: knowledge video group|In each community intervention group one subject viewed the physician-led knowledge video
9993704|NCT01474941|Experimental|5 mg QD PF-04620110 or Placebo|
9993705|NCT01474941|Experimental|5 mg BID PF-04620110 or Placebo|
9993706|NCT01474941|Experimental|Optional Arm, PF-04620110 or Placebo|
9993707|NCT01474967|Experimental|Lower metformin dose group|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
10212912|NCT04878263|Active Comparator|Control group|
10212913|NCT04878263|Experimental|FIL-EAS ic group|
10212914|NCT04877366|Active Comparator|ARM A: Sprinkled Format REDUCOSE|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
10212915|NCT04877366|Placebo Comparator|ARM B: Placebo B: Standard Meal|A placebo matching to the test product will be used as control
10212916|NCT04877366|Placebo Comparator|ARM C: Placebo C: Acarbose|Acarbose 100 mg tablet (provided in open-label format)
10212917|NCT04875715|Experimental|Almond oil|Almond Oil Pressed Cold
10212918|NCT04875715|Active Comparator|Hydroquinone|Hydroquinone 2% cream
10212919|NCT04874233|Experimental|Active Treatment: HU6 150 mg; N = 20|
10212920|NCT04874233|Experimental|Active Treatment: HU6 300 mg; N = 20|
10212921|NCT04874233|Experimental|Active Treatment: HU6 450 mg; N = 20|
10212922|NCT04874233|Placebo Comparator|Placebo Comparator Non-active study drug N = 20|
10212923|NCT04873739||20 patients SLE with dry eye|Anterior segment OCT for SLE patients with dry eye
10212924|NCT04873739||30 patients SLE without dry eye|Anterior segment OCT for SLE patients without dry eye
10212925|NCT04873739||50 normal subjects as control group of similar age and gender|Anterior segment OCT for normal subjects
10212926|NCT04873375|Experimental|Cemiplimab|After inclusion, all patients will be treated with Cemiplimab 350mg intravenously every three weeks
10212927|NCT04868682|Experimental|Behavioral Education Intervention I|Manual-based education program provided in individual sessions
10212928|NCT04868682|Active Comparator|Behavioral Education Intervention II|Manual-based education program provided in individual sessions
10212929|NCT04859985|Experimental|SELUTION SLR DEB|Device: SELUTION SLR DEB. For patients randomized to the DEB strategy, all target lesions should be treated with DEB after appropriate lesion preparation, but provisional DES implantation is acceptable if the angiographic result is considered insufficient either after lesion preparation of after DEB treatment (poor flow, dissection type C or higher, residual stenosis > 30%). For bifurcation lesions, when both main and side- branch are considered to require treatment, a DEB should be used for both.
10212930|NCT04859985|Other|DES|Device: Drug Eluting Stent. For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
10212931|NCT04857931|Active Comparator|Colchicine 0.5 mg die|Colchicine 0.5 mg die
10212932|NCT04857931|Active Comparator|Colchicine 0.5 mg bid|Colchicine 0.5 mg bid
10212933|NCT04857931|Placebo Comparator|Placebo|Placebo
10212934|NCT04857359|Experimental|Dipraglurant TID|
10212935|NCT04857359|Placebo Comparator|Placebo TID|
10212936|NCT04842864|Experimental|Young|10 healthy men and women 18-35 yo.
10212937|NCT04842864|Active Comparator|Older adults|10 healthy men and women 65-85 yo
10212938|NCT04842123|Other|Atrial fibrillation (AF)|Patients with a known history of AF who are in AF at the time of study screening.
10212939|NCT04842123|Other|Normal Sinus Rhythm (SR)|Patients with no known diagnosis of AF or other arrhythmia
10212940|NCT04838522||All Study Participants|Participants with chronic idiopathic constipation who are treated with prucalopride 2 milligrams (mg) oral tablets which was initiated prior to enrollment, and are breastfeeding their infant at the time of enrollment and sample collection will be observed prospectively.
10212941|NCT04826328|Experimental|FX301 Low Dose Low Volume|65 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
10212942|NCT04826328|Experimental|FX301 Low Dose High Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
10212943|NCT04826328|Experimental|FX301 High Dose Low Volume|130 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
10212944|NCT04826328|Experimental|FX301 High Dose High Volume|260 mg of funapide given as a single injection nerve block adjacent to the sciatic nerve of the popliteal fossa
9903644|NCT00631254|Active Comparator|1|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
9903645|NCT00631254|Active Comparator|2|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
9903646|NCT00631267|Placebo Comparator|1|Manual Manipulation
9903647|NCT00631267|Active Comparator|2|Finger Trap Traction
9903648|NCT00631280|Experimental|Choice|
9903649|NCT00631280|Active Comparator|Recommendation|
9903650|NCT00631293|Experimental|1|administration of lactisole
9903651|NCT00631293|Placebo Comparator|2|administration of placebo
9903652|NCT00631306||Bottle number 615|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
9903653|NCT00631306||Bottle number 429|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
9903654|NCT00631345|Experimental|Lifestyle|This Group-Based Lifestyle Intervention (Phases 1 and 2) will be led by lay health counselors (LHCs). The 6-month Phase 1 includes weekly meetings on nutrition and physical activity, psychosocial factors related to health behaviors, and question and answer periods. The 18-month Phase 2 will consist of monthly group meetings and individual telephone contacts. Intervention participants who choose to participate in the study continuation (Phase 3) will be further randomized to receive either extended group or self-directed maintenance. Those who are randomized to receive Extended Group Maintenance (Phase 3) will continue attending monthly meetings; those who receive Self-Directed Maintenance (Phase 3) will no longer attend groups.
9903655|NCT00631345|Other|Comparison|The comparison condition exceeds the usual care provided to similar community members and is an individual education program that builds on an increased awareness of existing community resources. In the initial trial, these subjects will receive two individual sessions with the RD and a monthly newsletter. In the study continuation, comparison participants will receive biannual nutrition counseling and a monthly newsletter.
9903656|NCT00631384|Experimental|1|Women to be asked to bring husbands for couple VCT
9903657|NCT00631384|Active Comparator|2|Women to receive individual VCT
9903658|NCT00631397||Premature Infants|Premature Infants weighing less than 1500 gms
9903659|NCT00631423||1|Patients with vena cava inferior thrombosis
9903660|NCT00631423||2|Patients with isolated lower-extremity DVT matched for gender and age
9903661|NCT00631436||1|If the individuals who meet the blast exposure criteria have a PCL score above 50 and meet the Hoge et al PCL criteria, thus indicating likely PTSD, they will be invited to participate as members of the Blast Exposed + PTSD group.
9903662|NCT00631436||2|Other individuals meeting the blast exposure criteria will be invited to participate in the as members of the Blast Exposed + No PTSD group if they have PCL scores below 30.
9903663|NCT00631436||3|Individuals reporting that they were not exposed to explosive blast will be recruited to participate. Those not exposed to blast but with PCL scores over 50 and meeting the Hoge et al PCL criteria will be invited to participate as members of the No Blast + PTSD group.
9903664|NCT00631436||4|Individuals not exposed to blast with PCL scores below 30 will be invited to participate as members of the No Blast + No PTSD group.
9903665|NCT00631462|Experimental|1|
9903666|NCT00631501|Placebo Comparator|2|
9903667|NCT00631501|Experimental|Doxycycline|100 mg twice daily
9903668|NCT00631514|No Intervention|1|Hypertensive persons taking either lisinopril/hydrochlorothiazide fixed combination or amlodipine all the time.
9903669|NCT00631514|Experimental|2|Intervention: NSAID. Hypertensives with osteoarthritis taking already amlodipine (5-10 mg o.d. per os) were randomized to the following drug interventions: to take either acetaminophen (1000 mg t.i.d. per os), piroxicam (10-20 mg o.d. per os) or ibuprofen (400-600 mg t.i.d. per os) for 1 month
9903670|NCT00631514|Experimental|3|Hypertensives with osteoarthritis taking already lisinopril/hydrochlorothiazide (20/12.5 mg o.d. per os), were sequentially randomized to the following drug interventions: acetaminophen (1000 mg t.i.d.), ibuprofen (400-600 mg t.i.d.) or piroxicam (10-20 mg o.d.), for 1 month each
9993708|NCT01474967|Active Comparator|Higher metformin dose group|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
9993709|NCT01475006|Experimental|Part I Dose Exploration|Pre-specified nominal doses are proposed in the dose exploration. Intermediate doses may also be used if required based on the CRM design.
9993710|NCT01475006|Experimental|Part II Dose Expansion|Dose selected from Part 1 dose exploration
9993711|NCT01475019|Experimental|PCOS obese Orlistat|Obese PCOS women treated with Orlistat, diet and physical exercise
9993712|NCT01475019|Experimental|Obese Orlistat|Obese women (non PCOS) treated with Orlistat, diet and physical exercise
9993713|NCT01475019|Experimental|PCOS obese diet|Obese PCOS women treated with diet and physical exercise
9993714|NCT01475019|Experimental|PCOS obese Sibutramine|Obese PCOS women treated with Sibutramine, diet and physical exercise
9993715|NCT01475032|Experimental|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
9993716|NCT01475032|Active Comparator|BDP|BDP for 12 weeks
9993717|NCT01475032|Active Comparator|BDP+FF|free combo BDP+FF for 12 weeks
9993718|NCT01475045||Turbuhaler inhaler use|
9993719|NCT01475045||Discus inhaler use|
9993720|NCT01475045||Elpenhaler inhaler use|
9993721|NCT01475084|Experimental|Cryobiopsy, forceps biopsy|"Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation.~Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps."
9993722|NCT01475149||aPL positive - group 1|aPL positive with APS, receiving HCQ
9993723|NCT01475149||aPL positive - group 2|aPL positive with APS and SLE, receiving HCQ
9993724|NCT01475149||aPL positive - group 3|aPL positive without APS but with SLE, receiving HCQ
9993725|NCT01475149||aPL positive - group 4|aPL positive without APS or SLE, receiving HCQ
9993726|NCT01475149||aPL negative - group 1|aPL negative with SLE, receiving HCQ
9993727|NCT01475149||aPL negative - group 2|aPL negative with SLE, not receiving HCQ
9993728|NCT01475188|Placebo Comparator|placebo|20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
9993729|NCT01475188|Active Comparator|Specific subcutaneous immunotherapy|21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens
9993730|NCT01475201|Experimental|Step Count Prescription Arm|The active trial arm intervention consists of usual care plus step count prescription delivered by the treating doctor, over a one-year period.
9993731|NCT01475201|Active Comparator|Usual care arm|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week). Consistent with clinical practice guidelines, our collaborating doctors have indicated that the usual care of the target population requires clinic visits at roughly three-month intervals to ensure vascular risk factor monitoring and management.
9993732|NCT01475227|Experimental|Arm A- early Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 2 to day 15
9993733|NCT01475227|Experimental|Arm B- late Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 15 to day 28
9993734|NCT01475240||Group 1: Controls|HIV-infected patients on stable > 6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with normal bilirubin
9903671|NCT00631527|Experimental|Sunitinib Malate, Hormone Ablation + RT|Sunitinib Malate + Hormone Ablation (Leuprolide or Goserelin + Bicalutamide) + Radiation Therapy (RT)
9903672|NCT00631592|Other|GSK1349572|GSK1349572
9903673|NCT00631605||1|
9903674|NCT00631605||2|
9903675|NCT00631618|Experimental|Suntinib|Suntinib
9903676|NCT00631631||Mifamurtide (L-MTP-PE)|Mifamurtide (L-MTP-PE), intravenous, at a dose of 2 mg/m^2 twice weekly (at least 3 days apart) for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
9903677|NCT00631683||MICU-1|Mechanically ventilated patients who are about to start a weaning trial at the medical intensive care unit of Memorial Hermann Hospital.
9903678|NCT00631709|Experimental|1|Pacemaker Patients
9903679|NCT00631722|Experimental|A|
9903680|NCT00631722|Active Comparator|B|
9903681|NCT00631761|Experimental|1|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas of the human bladder.
9903682|NCT00631761|Placebo Comparator|2|The control group will be instructed to read a urethrocystoscopy textbook chapter at home
9903683|NCT00631774|Active Comparator|1|a meal replacement program with Glucerna SR on top of the exchange-diet plan
9903684|NCT00631774|Active Comparator|2|an caloric-matched exchange-diet plan only.
9903685|NCT00631800|Placebo Comparator|Placebo|Placebo
9903686|NCT00631800|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 7, 14
9903687|NCT00631800|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 7, 14
9903688|NCT00631813|Active Comparator|1|Prucalopride 0.5 mg
9903689|NCT00631813|Active Comparator|2|Prucalopride 1 mg
9903690|NCT00631813|Active Comparator|3|Prucalopride 2 mg
9903691|NCT00631813|Placebo Comparator|4|
9903692|NCT00631839||1|There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
9903693|NCT00631865|Experimental|cell transplantation group|Epidermal Cell transplantation in patients with vitiligo
9903694|NCT00631878|Placebo Comparator|Placebo|
9903695|NCT00631878|Experimental|10 mg/kg|10 mg/kg was given on Days 0, 14
9903696|NCT00631878|Experimental|30 mg/kg|30 mg/kg was given on Days 0, 14
9903697|NCT00631878|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 14
9903698|NCT00631878|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 14
9903699|NCT00631904||Single Observation|Patients with permanent pacemakers undergoing medically indicated MRI scanning.
9903700|NCT00631943|Experimental|1|
9903701|NCT00631982|Experimental|Group I|patients with PCO undergoing in vitro maturation and subsequently IVF and embryo transfer
9903702|NCT00631995|Experimental|Group 1|
9903703|NCT00631995|Experimental|Group 2|
9903704|NCT00631995|Experimental|Group 3|
9903705|NCT00631995|Experimental|Group 4|
9903706|NCT00631995|Experimental|Group 5|
9903707|NCT00631995|Active Comparator|Group 6|
9903708|NCT00632008|Experimental|1|SBG
9903709|NCT00632008|Placebo Comparator|2|
9903710|NCT00632034|Experimental|1|
9903711|NCT00632060|No Intervention|1|Standard Care Control Group - Participants randomized to the standard care group will continue their use of non-prescription or prescription medication and reduced duty loads, as prescribed by the credentialed medical provider.
9903712|NCT00632060|Experimental|2|Manual / Manipulative Therapy Group: Participants randomized to the M/MT group will receive a course of M/MT along with standard care. The patient will see the chiropractor twice a week for the entire course of the study, regardless of manipulation or not.
9903713|NCT00632073|Experimental|VCV + Failing HAART|Vicriviroc plus failing highly-active antiretroviral therapy
9903714|NCT00632086|Experimental|1|Single oral dose of 325 mg aspirin administered as PA32540
9903715|NCT00632086|Experimental|2|aspirin core
9903716|NCT00632086|Active Comparator|3|active
9903717|NCT00632164||1|Cervical adjustments
9903718|NCT00632164||2|Thoracic adjustments
9903719|NCT00632242|Experimental|TTP Remission Cohort 1|Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL
9903720|NCT00632242|Experimental|TTP Remission Cohort 2|Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL
9903721|NCT00632242|Experimental|TTP Remission Cohort 3|Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL
9993735|NCT01475240||Group 2: Cases|HIV-infected patients on stable >6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with HBR (>2.5 X upper limit)
9903722|NCT00632242|Experimental|Acute TTP Cohort 4|Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL
9903723|NCT00632242|Experimental|vWD-Type2b Cohort 5|Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.
9903724|NCT00632255||1|Patients with CML who have been treated with Imatinib (Glivec) within 6 months of diagnosis as first line therapy. Initial therapy with Hydroxyurea is permitted
9903725|NCT00632268|Experimental|A|Drug:RAD001 Drug:Cisplatin Drug:5-FU
9903726|NCT00632294||Retrieved Allograft|Patients that require the retrieval of a bone allograft (transplant).
9903727|NCT00632307||1|COPD
9903728|NCT00632307||2|lung cancer
9903729|NCT00632307||3|airway infection
9903730|NCT00632307||4|interstitial lung disease
9903731|NCT00632307||5|sleep apnea
9903732|NCT00632307||6|pulmonary disorders with pleural infusions
9903733|NCT00632307||7|sarcoidosis
9903734|NCT00632307||8|healthy persons
9903735|NCT00632320||S, 1, A|group (success or failure), case number, measurement method
9903736|NCT00632333|Experimental|1|
9903737|NCT00632346||1 group|200 patients presenting to the Adolescent Medicine Clinic at Brooke Army Medical Center between the ages of 18 and 23 years-old.
9903738|NCT00632372||HeartPOD™ System with Cardiac Resynchronization Therapy|All patients will receive both a HeartPod device and a CRT-D device.
9933548|NCT05350631|Experimental|Experimental|using a digital tool in addition to follow-ups by consultations, phone contact and PTE workshop with the AJA mobile team centralized by the IDEC
9933549|NCT05350618||Asymptomatic controls|A single transperineal ultrasound assessment session will be conducted by two independent physiotherapists with an expertise in pelvic floor rehabilitation
9933550|NCT05350618||Women with provoked vestibulodynia|A single transperineal ultrasound assessment session will be conducted by one physiotherapist with an expertise in pelvic floor rehabilitation
9933551|NCT05350605|Experimental|Experimental: Laid back breastfeding position education group|Breastfeeding education will be given to pregnant women in the laid-back breastfeeding position group, which includes the laid back breastfeeding position with a lactation simulation model.
9993736|NCT01475266|Experimental|EO9 (Apaziquone)|
9993737|NCT01475266|Placebo Comparator|Placebo|
9903739|NCT00632385|Experimental|A|
9903740|NCT00632398|Active Comparator|Attention control (reading)|Caregivers read to patients from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks.
9903741|NCT00632398|Experimental|Touch, Caring and Cancer DVD program|Caregivers apply the instruction of the Touch, Caring and Cancer DVD program for patients for recommended 20 minutes at least 3 times per week for 4 weeks.
9903742|NCT00632437||Speckle-Contrast Imaging|
9903743|NCT00632450||1|
9903744|NCT00632476|Placebo Comparator|A|Participants will receive a placebo capsule throughout pregnancy.
9993738|NCT01475292|Experimental|RV568 treatment group low dose|
9903745|NCT00632476|Active Comparator|B|Participants will receive a vitamin C capsule throughout pregnancy.
9903746|NCT00632476|No Intervention|C|A group of non-smoking pregnant women will not receive placebo or vitamin C.
9903747|NCT00632515||Questionnaire|Patients with Colorectal Cancer and their First Degree Relatives (FDRs).
9903748|NCT00632528|Experimental|1|Administration of MEOPA gaz during postoperative physical therapy
9903749|NCT00632528|Placebo Comparator|2|Administration of medical air during postoperative physical therapy
9903750|NCT00632554|Experimental|1|prednisolone therapy for three months
9903751|NCT00632554|Active Comparator|2|prednisolone therapy for six months
9903752|NCT00632567|Experimental|1|caesarean section
9903753|NCT00632567|Active Comparator|2|vaginal delivery
9903754|NCT00632580|Active Comparator|1|intraarticular injection with local anesthetic
9903755|NCT00632580|Experimental|2|intracapsular injection with local anesthetic
9903756|NCT00632593|Active Comparator|Circular Stapled|Patients operated performing the gastric pouch of the gastric bypass with a circular staple device
9903757|NCT00632593|Active Comparator|Handsewn anastomosis|Patients operated performing the gastric pouch of the gastric bypass in a handsewn manner
9903758|NCT00632606|Active Comparator|Arm 1|magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
9903759|NCT00632606|Active Comparator|Arm 2|metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
9903760|NCT00632645|Experimental|1|Olanzapine Mylan
9903761|NCT00632645|Active Comparator|2|Xenazine
9903762|NCT00632645|Active Comparator|3|Tiapridal
9903763|NCT00632658||Patients with cGVHD|Pediatric Patients with cGVHD will be asked to participate in an interview with their Physician. The interview will ask the pediatric patients questions about their cGVHD. The interview will be audio-recorded.
9903764|NCT00632671||Obese persons cohorte|constitution of a prospective data collection (biological, clinical, paraclinical and questionnaires) in morbidly obese persons.
9903765|NCT00632684|Active Comparator|1|Participants in Phase 1 will undergo four interviews, including a single treatment planning session.
9903766|NCT00632684|Experimental|2|Participants in Phase 2 will receive the adaptive treatment model.
9903767|NCT00632697|Active Comparator|1|
9903768|NCT00632697|Placebo Comparator|2|
9903769|NCT00632710|Experimental|b|laser
9903770|NCT00632710|Placebo Comparator|a|laser placebo
9903771|NCT00632762|Active Comparator|1|Amantadine MANTADIX
9903772|NCT00632762|Placebo Comparator|2|placebo
9903773|NCT00632775|Active Comparator|1|Subjects in this arm will receive hypotonic (0.45% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
9903774|NCT00632775|Active Comparator|2|Subjects in this arm will receive isotonic (0.9% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
9903775|NCT00632788||intervention group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between March 1, 2007 and Oct. 31, 2007
9903776|NCT00632788||control group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between April 1, 2006 and Feb. 28, 2007
9903777|NCT00632801|Other|A|Chewing gum or not
9903778|NCT00632840|Placebo Comparator|P|placebo group
9903779|NCT00632840|Active Comparator|Feno|Fenofibrate
9903780|NCT00632840|Active Comparator|ATV|Atorvastatin
9903781|NCT00632853|Active Comparator|Arm A - Standard Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days"
9933552|NCT05350605|Experimental|Experimental: Upright breastfeeding position education group|Breastfeeding education will be given to pregnant women in the upright breastfeeding position group, which includes the upright breastfeeding position with a lactation simulation model.
9903782|NCT00632853|Experimental|Arm B - High Dose Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days"
9903783|NCT00632866|Experimental|1|Active treatment : Hydroxychloroquine
9903784|NCT00632866|Placebo Comparator|2|Placebo
9903785|NCT00632905||1|Normal - BMD with T-score at or above -1.0
9903786|NCT00632905||2|Osteopenic - BMD with T-score between -1.1 and -2.4
9903787|NCT00632905||3|Osteoporotic - BMD with T-score at or below -2.5
9903788|NCT00632957|Active Comparator|Fish oil|
9903789|NCT00632957|Placebo Comparator|Placebo|
9903790|NCT00632996|Experimental|1|
9903791|NCT00633035|Active Comparator|1|oral esomeprazole tablet dissolved in water given through NG tube
9903792|NCT00633035|Active Comparator|2|intravenous famotidine injection
9903793|NCT00633048|Experimental|NSA-789|active drug
9903794|NCT00633048|Placebo Comparator|placebo|placebo
9903795|NCT00633113|Active Comparator|1|- Medial Parapatellar Arthrotomy (MPPA) technique
9903796|NCT00633113|Active Comparator|2|- Subvastus (SV) technique
9903797|NCT00633178|Experimental|Group Interpersonal Therapy (IPT)|Participants will receive group interpersonal therapy.
9903798|NCT00633178|Active Comparator|Treatment as Usual (ETAU)|Participants will receive psychiatric treatment as usual.
9903799|NCT00633178|No Intervention|No Treatment|Participants are healthy and will receive no treatment.
9903800|NCT00633191|Experimental|Anti-pseudomonas IgY gargle|Intervention: Gargles with anti-pseudomonas IgY every night
9903801|NCT00633230|Active Comparator|1|standardized herbal formula, Sho-saiko-to (SST): 3 capsules containing 700 mg of the SST herbal extract/capsule and 28 mg of the excipients, magnesium stearate and silicon dioxide/capsule 2 x day
9903802|NCT00633230|Placebo Comparator|2|placebo capsules that look and smell identical to the active Sho-saiko-to (SST) capsules
9903803|NCT00633282|Experimental|Lifestyle intervention|Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
9903804|NCT00633282|Experimental|Life style intervention, pioglitazone|Life style intervention with pioglitazone 15mg qd for 16 weeks
9903805|NCT00633282|Experimental|Life style intervention, berberine|Life style intervention with berberine 0.5g tid for 16 weeks
9903806|NCT00633295|Experimental|nilotinib|
9903807|NCT00633308|Experimental|A|Long hemodialysis
9903808|NCT00633321|Experimental|1|TA-NIC 100 μg
9903809|NCT00633321|Experimental|2|TA-NIC 250 μg
9903810|NCT00633321|Placebo Comparator|3|
9903811|NCT00633347|Active Comparator|A|A: Antagonist
9903812|NCT00633347|Active Comparator|B|Agonist GnRH
10212945|NCT04826328|Placebo Comparator|Normal Saline|Low or high matching volume of preservative-free normal saline given as a single injection adjacent to the sciatic nerve of the popliteal fossa
9903813|NCT00633386|Experimental|A|
9903814|NCT00633386|Placebo Comparator|B|
9903815|NCT00633412|Experimental|1|20mg Oral tablet daily
9903816|NCT00633412|Experimental|2|40mg Oral tablet daily
9903817|NCT00633412|Active Comparator|3|150mg oral twice daily
9903818|NCT00633438|Placebo Comparator|B|
9903819|NCT00633438|Experimental|A|
9903820|NCT00633451|Experimental|1|Manual Therapy + Exercise
9903821|NCT00633451|Active Comparator|2|Exercise Only
9903822|NCT00633490|Experimental|A|
9903823|NCT00633503||A-Observation|All patients undergoing pedicle and free tissue transfer.
9903824|NCT00633516||Medical tool|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
10212946|NCT04825431|Experimental|TAS-205, [14C]TAS-205|
10213927|NCT02630368|Experimental|Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide|"Single-arm phase II clinical trial.~Experimental phase II Group breast cancer :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 32"
9903825|NCT00633529|Experimental|I|Single arm: triple combination
9903826|NCT00633542|Experimental|TD|thalidomide-dexamethasone
9903827|NCT00633542|Active Comparator|ID|Interferon-dexamethasone
9903828|NCT00633568|Active Comparator|A|One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
9903829|NCT00633568|Experimental|B|Three courses of induction chemotherapy followed by consolidation chemoradiotherapy
9903830|NCT00633581|Experimental|1|Intravenous injections of 10 grams(20ml as a solution) of vitamin C with 100ml of normal saline over 30 minutes.
9903831|NCT00633581|Placebo Comparator|2|Intravenous injections of 120ml of normal saline over 30 minutes.
9903832|NCT00633620|Experimental|colonoscopy|Non-NBI HDTV colonoscopy
9903833|NCT00633633|Other|Group 1|Usual Care
9903834|NCT00633633|Experimental|Group 2|Exercise Training + Dietary Counseling
9903835|NCT00633646|Active Comparator|1|low protein diet
9903836|NCT00633646|Active Comparator|2|low protein diet with keto acids
9903837|NCT00633646|Active Comparator|3|high protein diet
9903838|NCT00633659|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
9903839|NCT00633659|Experimental|Control|Voluven (HES 130/0.4)
9903840|NCT00633672|Experimental|1|20mg Oral tablet daily
9903841|NCT00633672|Experimental|2|40mg oral tablet daily
9903842|NCT00633672|Active Comparator|3|150mg oral twice daily
9903843|NCT00633685|Experimental|Fluoxetine|Receives Fluoxetine at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
9903844|NCT00633685|Placebo Comparator|Placebo|
9903845|NCT00633698|Active Comparator|1|Nicotinic acid (niacin)
9903846|NCT00633698|Placebo Comparator|2|Placebo
9903847|NCT00633711|Active Comparator|fixed CPAP|
9903848|NCT00633711|Experimental|Auto-CPAP|"Auto-CPAP Weinmann Somnosmart2"
9903849|NCT00633724|Experimental|1|
9903850|NCT00633737|Experimental|1|Stress reduction intervention
9903851|NCT00633737|No Intervention|2|Standard care
9903852|NCT00633763||1|Healthy individuals with normal C-peptide levels following i.v. glucagon challenge. These individuals will be administered 18F-fallypride and then subjected to PET-CT scanning of the pancreas and brain. The subject will be positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen carried out (with subjects breathing normally). A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame). The subject will then be repositioned for a low-dose CT scan of the head (15-20 secs) following which a 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).
9903853|NCT00633763||2|Patients with longstanding T1DM and <20% C-peptide levels following i.v. glucagon challenge will be consented. 18F-Fallypride injected intravenously and subjects allowed to wait for approx 1 hr for the uptake.(b) Subject positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen (pancreas) carried out (with subjects breathing normally).(c) A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame).(d) Subject repositioned for a low-dose CT scan of the head (15-20 secs).(e) A 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).(f) End of PET/CT scanning procedures. Subject taken out of the scanner.
9903854|NCT00633776|Experimental|1|Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 1; Formoterol 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 2
9903855|NCT00633776|Active Comparator|2|Formoterol fumarate 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 1; Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 2
9903856|NCT00633802|Placebo Comparator|2|
9903857|NCT00633802|Experimental|1|
9903858|NCT00633815||Fontan patients|Subjects will undergo exercise testing in both the supine and upright positions
9903859|NCT00633815||Healthy controls|Subjects will undergo exercise testing in both the supine and upright positions
9903860|NCT00633828|Experimental|A Intervention group|Increased physical education in primary school (daily)
9903861|NCT00633828|No Intervention|B Control group|Normal physical education in primary school (typically once per week)
9903862|NCT00633841|Active Comparator|1|AFFITOPE AD02 without adjuvant
9903863|NCT00633841|Active Comparator|2|AFFITOPE AD02 with adjuvant
9903864|NCT00633854||1|30 volunteer subjects who are age 60 and older
9903865|NCT00633906|Experimental|1|HORIZONS HIV Intervention. Two-session, group-based interactive intervention.
9903866|NCT00633906|Active Comparator|2|Enhanced standard-of-care session. One hour, video-based and brief discussion.
9903867|NCT00633958|Experimental|18F-FLT|All subjects will receive 18F-FLT prior to PET imaging.
9903868|NCT00633971|Experimental|A|Complex lymphedema therapy (which includes compression stocking use)
9903869|NCT00633971|Other|B|Standard of care (compression stocking use at 30-40 mm Hg)
9993739|NCT01475292|Experimental|RV568 treatment group high dose|
9993740|NCT01475292|Placebo Comparator|Placebo treatment group|
9993741|NCT01475318|Experimental|misoprostol + mifepristone + letrozole|
9993742|NCT01475344|Active Comparator|Human Fibrinogen Concentrate|"Fibrinogen Concentrate will be administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
9993743|NCT01475344|Placebo Comparator|Placebo|"Placebo administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
9993744|NCT01475357|Other|Arm 1: NPO pre-operative|1) Current care - NPO (nothing by mouth) postnatal intestinal function of neonates with complex CHD who receive enteral trophic breastmilk (10cc/kg/day) feeds (intervention) vs NPO (nothing by mouth) in the pre-operative period.
9903870|NCT00634062|Active Comparator|1|
9903871|NCT00634062|Placebo Comparator|2|
9903872|NCT00634075|Experimental|1|
9903873|NCT00634075|Placebo Comparator|2|
9903874|NCT00634140|Experimental|1|ezetimibe
9903875|NCT00634140|Placebo Comparator|2|placebo for 4-6 weeks
9903876|NCT00634192|Experimental|1|
9903877|NCT00634192|Experimental|2|
9903878|NCT00634205|Experimental|A|Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin
9903879|NCT00634218|Active Comparator|1|Mail-based Self Help (MSH) treatment. Participants will receive the self-help manual developed specifically for LGBT smokers.
9903880|NCT00634218|Active Comparator|2|Mail-based Self Help plus an Internet-based Smoking Treatment (IST). In the IST condition, participants will receive the manual plus access to an Internet-based intervention that includes social support.
9903881|NCT00634218|Active Comparator|3|Mail-based Self-Help plus Telephone Counseling (TC). In the TC condition, participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions.
9903882|NCT00634218|Active Comparator|4|Mail-based Self-Help plus an Internet-based Intervention plus Telephone Counseling. Participants will receive a self-help manual, have access to an internet-based smoking treatment and participante in 6 telephone counseling sessions.
9903883|NCT00634231|Experimental|AdV-tk|AdV-tk + valacyclovir in combination with standard of care radiation
9903884|NCT00634257||Patients|Patients with advanced cancer receiving palliative care.
9903885|NCT00634257||Caregivers|Primary caregivers of Patients with advanced cancer receiving palliative care.
9903886|NCT00634296|Active Comparator|G2|Inspiratory muscle training added by aerobic training to aerobic training alone
9903887|NCT00634309|Active Comparator|1|
9903888|NCT00634309|Placebo Comparator|2|
9903889|NCT00634335||sk|professional Israeli bicyclists
9903890|NCT00634348|Active Comparator|Aripiprazole|
9903891|NCT00634348|Active Comparator|Ziprasidone|
9903892|NCT00634361|Experimental|A|
9903893|NCT00634374|No Intervention|1|Oral Syringe
9903894|NCT00634374|Active Comparator|2|Rx medibottle
9903895|NCT00634387|Active Comparator|A|Anthocyans
9903896|NCT00634387|Placebo Comparator|B|no effective agent
9933553|NCT05350605|No Intervention|No Intervention: Control Group|Mothers in the control group will receive routine hospital care
9933554|NCT05350592|Active Comparator|Tocilizumab + Dobutamine|Tocilizumab IV 280 mg (100mL/hour, 1 hour) Dobutamine IV 5 micrograms/kg/minute (5mL/hour, 24 hours)
9933555|NCT05350592|Active Comparator|Tocilizumab + Placebo|Tocilizumab IV 280 mg (100mL/hour, 1 hour) NaCl 0,9% IV (5mL/hour, 24 hours)
9933556|NCT05350592|Active Comparator|Placebo + Dobutamine|NaCl 0,9% IV (100mL/hour, 1 hour) Dobutamine IV 5 micrograms/kg/minute (5mL/hour, 24 hours)
9933557|NCT05350592|Placebo Comparator|Placebo + Placebo|NaCl 0,9% IV (100mL/hour, 1 hour) NaCl 0,9% IV (5mL/hour, 24 hours)
9933558|NCT05350579|Experimental|Yogurt Intervention|Participants assigned to the yogurt group were provided with a biweekly supply of yogurt at every other visit and were directed to consume one serving daily (5-ounce, 141 grams) and to store the remaining yogurt at 40˚ F or lower until consumed. Additionally, all participants were instructed to keep a log of any yogurt consumption time and changes to bowel health. The ingredients of the yogurt include Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (L. bulgaricus, S. thermophilus), and Vanilla Extract. The intervention meets the Codex Alimentarius definition of yogurt. In addition, the yogurt lacked preservatives, added fruit or pectin, was not enriched with added prebiotics or probiotics.
9933559|NCT05350579|No Intervention|Diet Control|The control group was asked to abstain from yogurt consumption. Diet (including yogurt consumption) was monitored by weekly 24-hour dietary recalls throughout the study period.
9933560|NCT05350566|Experimental|Sprint interval training group (SIT group)|The model of sprint interval training (SIT) consists of six 30 s all-out cycling bouts on a cycle ergometer, with 4 min rests between tests.
9933561|NCT05350566|Experimental|Moderate intensity continuous training (MICT group)|The moderate intensity continuous training (MICT) consists of 1h cycling on a cycle ergometer at 50% of the maximal aerobic power output
9933562|NCT05350553||Healthy Control|Patients 45-75 years of age without Type 2 Diabetes and without chronic low back pain.
9933563|NCT05350553||Type 2 Diabetic with Painful Neuropathy|Patients 45-75 years of age with Type 2 Diabetes and experiencing painful neuropathy (painful numbness or tingling in hands and/or feet)
9933564|NCT05350553||Chronic Low Back Pain as a Result of Lumber Disc Aberrancy|Patients 45-75 years of age with chronic low back pain as a direct result of non-operative lumber disc aberrancy (lumbar disc herniation, protrusion, or extrusion).
9993745|NCT01475357|Active Comparator|Arm 2: Fresh Breast Milk pre-operative|2) Intervention - Trophic mother's own fresh (non-frozen) breastmilk gavage feeds via nasogastric tube every 3 hours at 10 cc/kg/day
9903897|NCT00634400|Active Comparator|1|
9903898|NCT00634400|Placebo Comparator|2|
9903899|NCT00634413|Experimental|1|
9903900|NCT00634413|Placebo Comparator|2|
9903901|NCT00634426||1|De novo surgical cohort
9903902|NCT00634426||2|Nonoperative treatment cohort
9903903|NCT00634426||3|Secondary surgical treatment cohort
9903904|NCT00634439||A|All patients 18 years or older who received a first dispensing of atomoxetine during the time period of the study (January 1, 2003 through December 31, 2006) and had at least 6 months of continuous enrollment prior to first dispensing are included in the study cohort. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. The study entry date for this cohort is the date of first atomoxetine dispensing.
9903905|NCT00634439||B|All patients 18 years or older who received a first dispensing of a stimulant medication (methylphenidate or mixed salts of amphetamine) during the time period of the study with no dispensing of the same drug in the prior 6 months and had at least 6 months of continuous enrollment prior to the first dispensing are identified. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. Patients who are matched to atomoxetine initiators using this propensity score method are retained and followed as one comparator cohort. The study entry date is the date of the first dispensing of a comparator ADHD medication.
9903906|NCT00634439||C|Patients with at least 6 months of continuous enrollment in the database, and without a history of arrhythmia or heart failure during the baseline period are sampled and frequency matched on age and gender to the atomoxetine cohort in a 2:1 ratio. Study entry dates are assigned so as to be similar to the distribution of study entry dates in the atomoxetine cohort. Patients identified and matched as initiators of atomoxetine or stimulant ADHD medications are not eligible for inclusion in this cohort
9903907|NCT00634452|Experimental|MDX-1401|MDX-1401 iv at various doses
9903908|NCT00634465||1|
9903909|NCT00634478|Experimental|1|preleminiscal radiation deep brain stimulation
9903910|NCT00634478|Active Comparator|2|VIM deep brain stimulation
9903911|NCT00634491|Active Comparator|1|150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
9903912|NCT00634491|Active Comparator|2|Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
9903913|NCT00634491|Active Comparator|3|normal salin 1cc/kg/hr before and after angiography
9903914|NCT00634530|Other|I, Intervention|
9903915|NCT00634556|Experimental|levodopa solution 2mg/ml for i.v. use|"levodopa solution in saline, given intravenously, dosed as per final protocol in Black et al 2003."
9903916|NCT00634556|Placebo Comparator|Placebo|normal saline i.v.
9903917|NCT00634595|Experimental|A|E10A combined with Cisplatin and Paclitaxel
9903918|NCT00634595|Active Comparator|B|Cisplatin and Paclitaxel
9903919|NCT00634608|No Intervention|Survey|Control group participants are sent a survey within one week of clinic visit
9903920|NCT00634608|Experimental|Health Information Prescription|Health Information Prescription is emailed to participants within 24 hours of clinic visit.
9903921|NCT00634634|Experimental|Sorafenib and Letrozole|
9903922|NCT00634660|Active Comparator|0.001 mg/kg|One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.
9903923|NCT00634660|Active Comparator|0.003 mg/kg|One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.
9903924|NCT00634660|Active Comparator|0.01 mg/kg|One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.
9903925|NCT00634660|Active Comparator|0.03 mg/kg|One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.
9903926|NCT00634660|Active Comparator|0.1 mg/kg|One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.
9903927|NCT00634660|Active Comparator|0.3 mg/kg|One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.
9903928|NCT00634660|Active Comparator|1.0 mg/kg|One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.
9903929|NCT00634673|Other|TT|patients homozygous for Thr54 (TT)
9903930|NCT00634673|Other|AA|patients homozygous for Ala54 (AA)
9903931|NCT00634686|Experimental|1|
9903932|NCT00634686|Placebo Comparator|2|
9903933|NCT00634699|Experimental|One|Ischemic Compression on Triggers Points on Muscles along the Median Nerve. Active Comparator
9903934|NCT00634712|Active Comparator|1|
9903935|NCT00634712|Placebo Comparator|2|
9903936|NCT00634725|Active Comparator|Arm 1 (A1) - Gemcitabine|Gemcitabine 2 months, then stop until progression
9903937|NCT00634725|Experimental|Arm 2 (B1) Gemcitabine + Erlotinib|B1 Gemcitabine + Erlotinib (100mg/d) 2 months, then erlotinib maintenance (150 mg/d)until progression
9903938|NCT00634725|Experimental|Arm 3 (A2) CRT|A2 CRT then stop until progression
9903939|NCT00634725|Experimental|Arm 4 (B2) CRT then erlotinib|B2 CRT then erlotinib maintenance (150mg/d) until progression
9903940|NCT00634738|Experimental|one|
9903941|NCT00634764||Pregnant|Pregnant women who present to MUSC's Cannon Place or Prenatal Wellness Center
9903942|NCT00634790|Active Comparator|alprazolam group|
9903943|NCT00634816||Chemotherapy recipients|Subjects who have undergone chemotherapy will receive DXA scan
9903944|NCT00634855||Complicated|Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
9903945|NCT00634855||Normal|Women with normal pregnancies
9903946|NCT00634868|Sham Comparator|1|The device is emitting a sham light
9903947|NCT00634868|Experimental|2|The device is emitting curative light
9903948|NCT00634881|Experimental|Cohort A: Alemtuzumab i.v.|Intravenous administration of alemtuzumab according to the 3 + 3 dose escalation design.
9903949|NCT00634881|Experimental|Cohort B: Alemtuzumab s.c.|After i.v. MTD (maximum tolerable dosage) has been determined, subcutaneous dose escalation is performed according to the same escalation rules as for cohort A, starting with the recommended dose level of i.v. application.
9903950|NCT00634894|Experimental|Femara|
9903951|NCT00634894|Placebo Comparator|Placebo|
9903952|NCT00634946|Experimental|I|
9903953|NCT00634946|Experimental|II|
9903954|NCT00634946|Experimental|III|
9903955|NCT00634946|Placebo Comparator|IV|
9903956|NCT00634959|Experimental|1|
9903957|NCT00634959|Experimental|2|
9903958|NCT00634959|Experimental|3|
9903959|NCT00634959|Experimental|4|
9903960|NCT00634959|Placebo Comparator|5|
9903961|NCT00634985|Experimental|A|
9903962|NCT00634998|Placebo Comparator|2|1000mg Placebo capsules orally twice daily for 90 days
9903963|NCT00634998|Experimental|1|1000mg Vitamin C capsules orally twice daily for 90 days
9903964|NCT00635037|Experimental|A|"G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~G2(n=15) was submitted to classical and trigger point acupuncture twice a week."
9903965|NCT00635063|Experimental|AD 923|
9903966|NCT00635063|Active Comparator|MSIR|
9903967|NCT00635076|Placebo Comparator|Placebo group|
9903968|NCT00635076|Active Comparator|Alprazolam XR group|
9903969|NCT00635115|Experimental|1|
9903970|NCT00635115|Active Comparator|2|
9903971|NCT00635141|Experimental|1|
9903972|NCT00635141|Experimental|2|
9903973|NCT00635180|Experimental|1|1: Healthy subjects
9903974|NCT00635206|Active Comparator|1|Auto M series device set to Bi Flex
9903975|NCT00635206|Active Comparator|2|Set to standard CPAP
9903976|NCT00635258||GnRH-ant|Patients were treated with a GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
9903977|NCT00635258||GnRH-a|GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.
9903978|NCT00635284|Experimental|ABI-009|
9903979|NCT00635297|Active Comparator|1|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty
9903980|NCT00635297|Experimental|2|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty. The adjacent vertebrae will be treated with 3-5 ml of PMMA
9903981|NCT00635310|Active Comparator|HD patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)
9903982|NCT00635310|Active Comparator|Ordinary patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)
9903983|NCT00635323|Experimental|A|
9903984|NCT00635375|Experimental|1|LED fiberoptic blanket phototherapy
9903985|NCT00635375|Experimental|2|metal halide phototherapy
9903986|NCT00635375|Active Comparator|3|LED bank phototherapy
9903987|NCT00635375|Experimental|4|Combination metal halide phototherapy plus LED fiberoptic blanket phototherapy
9903988|NCT00635388|Sham Comparator|1|
9903989|NCT00635388|Experimental|2|
9903990|NCT00635388|Experimental|3|
9903991|NCT00635401|Experimental|0.5 mg BID|
9903992|NCT00635414|Experimental|1|40mg administered orally
9903993|NCT00635414|Experimental|2|15 minute intravenous infusion
9903994|NCT00635440|Active Comparator|A|
9903995|NCT00635440|Sham Comparator|B|
9903996|NCT00635466|Experimental|Lap, 1|Patients undergoing laparoscopic surgery for rectal carcinoma
9903997|NCT00635518|Other|I, Intervention|
9903998|NCT00635531|Placebo Comparator|Placebo group|
9903999|NCT00635531|Active Comparator|Alprazolam XR group|
9904000|NCT00635544|Experimental|1|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
9904001|NCT00635544|Active Comparator|2|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
9904002|NCT00635583|Experimental|Increased Dairy Consumption|Increased Dairy Consumption - Each subject in this arm will receive three additional servings of dairy to consume each day for 18 months.
9904003|NCT00635583|No Intervention|Control|This group will not receive the intervention but will continue their normal diet; they will act as the control.
9904004|NCT00635596|Experimental|I|
9904005|NCT00635622|Experimental|1|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
9904006|NCT00635622|Placebo Comparator|2|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
9904007|NCT00635635|Active Comparator|1|Guided Imagery Audio
9904008|NCT00635635|Active Comparator|2|Music Audio
9904009|NCT00635674|Experimental|Group I - compliant|CPAP use for more than 4 hr/night
9904010|NCT00635674|Active Comparator|Group 2-noncompliant|CPAP for less than 4 hr/night
9667235|NCT03828201|Experimental|Investigational: DRAMATIC-16 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
9904011|NCT00635687|Experimental|Fibroscan|
9904012|NCT00635713|Experimental|1|Faslodex 125mg and Arimidex 1 mg
9904013|NCT00635713|Experimental|2|Faslodex 250mg and Arimidex 1mg
9904014|NCT00635726|Experimental|1|MVAC -> GEM+CDDP
9904015|NCT00635752|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy (TF-CBT)
9904016|NCT00635752|Active Comparator|2|Participants will receive sessions of treatment as usual (TAU)
9904017|NCT00635791|Experimental|Sorafenib tosylate and vorinostat|Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9904018|NCT00635843|Experimental|MAVERICK™ Disc|
9904019|NCT00635843|Active Comparator|Fusion|
9904020|NCT00635869||ARCC standard|RNs on unit receiving basic ARCC information with staff nurse champion
9904021|NCT00635869||ARCC enhanced|RNs on unit receiving ARCC standard content plus with an EBP mentor
9904022|NCT00635869||C|RNs on the unit receiving the placebo intervention
9904023|NCT00635895|Active Comparator|1|Manual Lymph Drainage Therapy is a manual therapy method
9904024|NCT00635895|Active Comparator|2|Connective Tissue Massage
9904025|NCT00635921|Active Comparator|I ziprasidone|
9904026|NCT00635921|Placebo Comparator|II placebo|
9904027|NCT00635947|Active Comparator|1|isotonic solution - 1.5L
9904028|NCT00635947|Active Comparator|2|water- 1.5L
9904029|NCT00635947|Placebo Comparator|3|water-200mL
9904030|NCT00635960|Experimental|1|Patients randomly assigned to treatment
9904031|NCT00635960|Placebo Comparator|2|Patients randomly assigned to placebo
9904032|NCT00635986|Experimental|A|group 1 (n = 14) patients received 5 mL of a 100 mcg Fentanyl solution in saline without preservative by the epidural route and 2 mL saline intravenously. Group 2 (n = 15) patients received 5 mL saline by the epidural route and 2 mL (100 mcg) Fentanyl intravenously
9904033|NCT00636012|Experimental|1|verum acupuncture
9904034|NCT00636012|Sham Comparator|2|sham acupuncture
9904035|NCT00636025||Observational|
9904036|NCT00636051||1|staff Registered Nurses receiving EBP peer mentoring
9904037|NCT00636051||2|staff Registered Nurses not receiving EBP peer mentoring
9904038|NCT00636064|Placebo Comparator|A|
9904039|NCT00636064|Experimental|B|
9904040|NCT00636064|Experimental|C|
9904041|NCT00636103|Experimental|CUF2|
9904042|NCT00636103|Placebo Comparator|Placebo|
9904043|NCT00636116|Experimental|Group 1|Anavip with Anavip Maintenance Therapy
9904044|NCT00636116|Experimental|Group 2|Anavip with Placebo Maintenance Therapy
9904045|NCT00636116|Active Comparator|Group 3|CroFab with CroFab Maintenance Therapy
9904046|NCT00636129||1|Relaxation Response + Stress Management Curriculum
9904047|NCT00636142|Active Comparator|1|Infliximab
9904048|NCT00636142|Placebo Comparator|2|Placebo
9904049|NCT00636233||Anencephaly|Fetuses with anencephaly, parents and siblings
9904050|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/4|
9904051|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/6|
9904052|NCT00636246|Active Comparator|sertraline-satellite|
9904053|NCT00636246|Active Comparator|sertraline-main|
9904054|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/2|
9904055|NCT00636246|Placebo Comparator|Placebo|
9904056|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-main|
9904057|NCT00636246|Active Comparator|[S,S]-reboxetine-main|
9904058|NCT00636285|Placebo Comparator|1|Placebo
9904059|NCT00636285|Experimental|2|BSYX-A110, Dosed intravenously, 3mg/kg
9904060|NCT00636285|Experimental|3|BSYX-A110, Dosed intravenously, 10mg/kg
9904061|NCT00636298|Experimental|A|Single arm treatment with combination of cetuximab and bevacizumab
9904062|NCT00636311|Active Comparator|1|IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine)
9904063|NCT00636311|Experimental|2|B-IGEV (Bortezomib + IGEV)
9904064|NCT00636324|Experimental|1|Nasal CPAP, level of 7 to 9 cmH2O
9904065|NCT00636324|Active Comparator|2|Nasal CPAP, level 4 to 6 cmH2O
9667236|NCT03828201|Experimental|Investigational: DRAMATIC-24 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
9904066|NCT00636337|Experimental|1|Participants meeting inclusion criteria will be provided with a laptop computer outfitted with a wireless card for the duration of the intervention and will be trained in the use of RoboMemo in the clinic by study personnel. Although many participants may have ready access to home computers, we decided that all participants will be required to use laptops provided by the study for two reasons: 1) to ensure that coaches and participants are blind to treatment condition (as described above), and 2) to ensure that participants will always have access to the intervention program (i.e., they will not compete with other family members for computer time). Once trained, children will complete the intervention at home. The intervention will consist of four 30- to 45-minute sessions per week for 8 weeks (total = 32 sessions). This intervention schedule is similar to the schedule employed by Klingberg and colleagues in their home-based CT trials with ADHD children.
9904067|NCT00636337|Placebo Comparator|2|The design will be a double-blind, placebo-controlled trial in which half of the participants will be randomized to the intervention condition and half will receive a comparison computer program. Specifically, participants assigned to the comparison (placebo) condition will complete a modified version of the CT at home. The treatment and comparison CT programs begin identically, at the lowest difficulty level. Those in the treatment condition will complete activities of increasing difficulty over the intervention period. Those in the placebo condition, in contrast, will complete the same basic tasks during each session of the intervention, regardless of performance. In this way, a true estimate can be obtained of the efficacy of the treatment program.
9904068|NCT00636376|Experimental|1|Single arm--no randomization. All subjects enrolled will have vitals collected and three ultrasounds at different levels of head of the bed elevations.
9904069|NCT00636402|Experimental|1|Vessel Sealing System Tonsillectomy (VSST)
9904070|NCT00636402|Active Comparator|2|Cold Knife Tonsillectomy (CKT)
9933565|NCT05350540|Experimental|ICG|This study will use intraoperative ICG imaging to assess recipient pharyngeal tissue perfusion. The ICG is the vascular contrast agent and the SPY Elite is the imaging device. 3mL of ICG will be injected using a peripheral IV access, followed by a 10mL saline flush. The pharyngeal mucosa will be imaged to quantify the tissue perfusion. Poorly perfused areas (less than 25%) will be debrided
9933566|NCT05350540|No Intervention|Control|Patients assigned to the observation (control) group will undergo standard of care reconstruction of mucosa
9933567|NCT05350527|Experimental|Arm A: Web platform and video information support|After usual preoperative information delivered by surgeon, patients allocated to Arm will be able to access to video information support and web platform.
9933568|NCT05350527|No Intervention|Arm B: Standard Preoperative information|Patients randomized in Arm B will only receive usual preoperative information delivered by the surgeon.
9933569|NCT05350514||T1D|Young adults with youth-onset type 1 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
9933570|NCT05350514||T2D|Young adults with youth-onset type 2 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
9933571|NCT05350514||NDM|Age-similar group of young adults without diabetes (n=5)
9933572|NCT05350501|Experimental|Patients With Minimal Residual Disease of Colorectal Cancer|Patients With Circulating Tumor DNA-defined Minimal Residual Disease of Colorectal Cancer Stage II, III, or IV After Completion of Curative Therapy
9933573|NCT05350488||Stroke Survivors <1 year|Group A will include participants that are less than 1 year out from their most recent stroke.
9933574|NCT05350488||Stroke Survivors >1 year|Group B will include participants that are greater than 1 year out from their most recent
9933575|NCT05350488||Caregivers|Group C will include participants' identified caregivers.
9933576|NCT05350475|Experimental|Proton therapy|"Radiation: Proton Therapy 78 Gray (Gy) in 39 fractions with 56 Gy to the Pelvic Lymph Nodes (LN), 5 days a week.~Androgen Deprivation Therapy (ADT) for three years, starting 3 months before Proton Therapy."
9933577|NCT05350475|Active Comparator|Photon Therapy|Radiation: Photon Therapy 78 Gy in 39 fractions with 56 Gy to the pelvic LN, 5 days a week. ADT for three years, starting 3 months before Photon Therapy.
9933578|NCT05350462||Agboville, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
9933579|NCT05350462||Bangolo, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
9933580|NCT05350462||Man, Côte d'Ivoire|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
9933581|NCT05350462||Homa Bay, Kenya|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
9933582|NCT05350462||Kwale, Kenya|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
9993746|NCT01475383|Active Comparator|PF-03654746|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
9993747|NCT01475383|Placebo Comparator|Placebo|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
9904071|NCT00636415|Experimental|A|G1 patients received morphine intra-articular route G2 patients received bupivacaine without epinephrine.
9904072|NCT00636428|Active Comparator|1|Oral midazolam
9904073|NCT00636428|Active Comparator|2|IV Midazolam
9904074|NCT00636454|Active Comparator|1|This group will serve as the control group and will receive only the care usually given to OA patients.
9904075|NCT00636454|Experimental|2|This group will take part in the 10-session treatment program that will teach patients cognitive and behavioral skills to cope with pain.
9904076|NCT00636467|Experimental|No label|Injection of Nanocis® or Nanocoll® (Tc-colloid) on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
9904077|NCT00636493|Experimental|Vein Occlusion Eye|Eye with retinal vein occlusion receiving fluocinolone acetonide sustained drug delivery device
9904078|NCT00636519|Experimental|Stage A|Botulism Antitoxin Bivalent (Equine) Types A and B Vs. Placebo
9904079|NCT00636519|Experimental|Stage B|Botulism Antitoxin Heptavalent (Equine) Types A-G Vs. Placebo
9904080|NCT00636545|Experimental|Part 1|Cohort 1- Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a dose of 300 mg to the first subject enrolled and, in the absence of dose-limiting toxicity, in increasing increments of 100 mg to each successive subject enrolled to a maximum dose of 1000 mg.
9904081|NCT00636545|Experimental|Part 2|Genasense will be administered as a 2-hour intravenous infusion twice weekly for 3 weeks at a dose established based on Part 1 of the study.
9904082|NCT00636545|Experimental|Cohort 2|Also in Part 1 of the study, Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a starting dose of 1100 mg and increasing in increments of 100 mg to the MTD. Patients will be pretreated with a corticosteroid.
9904083|NCT00636558|Experimental|CVA21|IV administration of CVA21 in a dose escalation manner
9904084|NCT00636584|Experimental|1|arm1: sodium nitroprusside group
9904085|NCT00636584|Placebo Comparator|2|arm2: control group,saline infused instead of sodium nitroprusside
9904086|NCT00636597||1|
9904087|NCT00636623|Other|2|Pilates exercises
9904088|NCT00636623|Other|1|Connective tissue massage
9904089|NCT00636662||all|any patient exhibiting symptoms of influenza
9904090|NCT00636688|Experimental|1|Behavioral (Lifestyle Counseling)
9904091|NCT00636688|Active Comparator|2|Control group
9904092|NCT00636714|Experimental|Nurse-directed|Using nursing judgement to control blood glucose
9904093|NCT00636714|Active Comparator|Nomogram-directed|Blood glucose control directed by pre-approved paper nomogram
9904094|NCT00636727|Active Comparator|1|arthrocentesis
9904095|NCT00636727|Active Comparator|2|arthroscopy
9904096|NCT00636727|Active Comparator|3|arthroplasty
9904097|NCT00636740|Experimental|B|MER-101 20mg Tablets Regimen 1
9904098|NCT00636740|Experimental|C|MER-101 20mg Tablets Regimen 2
9904099|NCT00636740|Active Comparator|A|Zometa Injection
9904100|NCT00636753||1|schizophrenic patients
9904101|NCT00636753||2|controls
9904102|NCT00636766|Experimental|1|
9904103|NCT00636779||1|Up to five hundred eligible patients seen at each of the nine participating Integrative Medicine Centers will be approached (by mail, phone, at the time of their visit, etc.) and invited to consent to the paper and pencil study.
9904104|NCT00636831|Placebo Comparator|cont|
9904105|NCT00636831|Active Comparator|intervention|
9904106|NCT00636844||Group A|Patients receiving chemotherapy (anthracycline and/or adjuvant trastuzumab) for the first time
9904107|NCT00636857|Experimental|I|Perioperative fluid management based on body weight
9904108|NCT00636857|Active Comparator|II|Perioperative fluid management based on Lean Body Mass (LBM)
9904109|NCT00636896|Experimental|1|Olanzapine 10 mg plus modafinil 200 mg
9904110|NCT00636896|Placebo Comparator|2|Olanzapine plus Placebo
9904111|NCT00636909|Experimental|1|Study treatment arm with G-CSF
9904112|NCT00636922|Experimental|Everolimus with 5-azacitidine|Everolimus increasing oral doses days 5-21 each cycle 5-azacitidine 75mg sub cutaneously 7 doses in 21 days
9904113|NCT00636935|Experimental|1|Antibiotic only therapy in patients with PCP and a pO2 of > 70mmHg.
9904114|NCT00636935|Experimental|2|Antibiotics and Corticosteroid therapy in patients with PCP and pO2 >70 mmHg.
9904115|NCT00636935|Active Comparator|3|Standard of care therapy for patients with PCP and pO2 < 70mmHg.
9904116|NCT00637065|Active Comparator|1|Bosentan tablets (62.5mg bd for first 4 weeks, then 125mg bd as tolerated)
9904117|NCT00637065|Placebo Comparator|2|Placebo tablets
9904118|NCT00637078|Active Comparator|1|Drug: Fix dose combination therapy
9904119|NCT00637078|No Intervention|2|Guidelines based management
9904120|NCT00637091|Experimental|EGFR expression|Patients' accrual will be adjusted by EGFR expression (positive vs. negative)
9904121|NCT00637104|Experimental|A - Mar-tyn|It includes the implant of the Mar-tyn TiN coated stent
9904122|NCT00637104|Active Comparator|B - Vision|Includes all the patients treated with the Vision stent
9904123|NCT00637143|Experimental|1|Oral
9904124|NCT00637143|Active Comparator|2|Oral
9904125|NCT00637169|Experimental|1|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 85-89%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
9904126|NCT00637169|Active Comparator|2|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 91-95%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
9904127|NCT00637208|Experimental|1|
9904128|NCT00637208|No Intervention|2|Watch-full follow-up
9904129|NCT00637234|Experimental|1|
9904130|NCT00637234|Placebo Comparator|2|
9904131|NCT00637260|Experimental|A|
9904132|NCT00637260|Sham Comparator|B|
9904133|NCT00637325|Experimental|A|"In the maintenance study:~ARM A: maintenance of trastuzumab~In the 2nd line study:~ARM A: trastuzumab plus chemotherapy treatment"
9904134|NCT00637325|No Intervention|B|"In the maintenance study:~ARM B: interruption of trastuzumab treatment~In the 2nd line study:~ARM B: chemotherapy alone"
9904135|NCT00637338|Experimental|PF-04603629|The dose range initially planned is 3 mg up to 70 mg, although the specific doses administered may be modified based on emerging study data.
9904136|NCT00637338|Placebo Comparator|Placebo|
9904137|NCT00637351||Group A|Subjects with diagnosed pneumonia & positive culture of streptococcus pneumoniae
9904138|NCT00637351||Group B|Subjects with diagnosed pneumonia & positive culture of non-typable haemophilus influenzae
9904139|NCT00637390|Experimental|one|
9904140|NCT00637403|Active Comparator|I|Megestrol acetate concentrated suspension in subjects with normal renal function
9904141|NCT00637403|Experimental|II|Megestrol acetate concentrated suspension in subjects with mild renal impairment
9904142|NCT00637403|Experimental|III|Megestrol acetate concentrated suspension in subjects with moderate renal impairment
9904143|NCT00637403|Experimental|IV|Megestrol acetate concentrated suspension in subjects with severe renal impairment
9904144|NCT00637403|Experimental|V|Megestrol acetate concentrated suspension in subjects with end stage renal disease
9904145|NCT00637429||General Co-infection|Individuals with HIV infection and hepatitis B surface antigen positive results who are currently receiving or planning to commence HAART.
9904146|NCT00637442|Experimental|CASL-MRI|Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
9904147|NCT00637468|Experimental|1|Local intra-arterial fibrinolysis (LIF)
9904148|NCT00637468|Active Comparator|2|Conservative standard therapy
9904149|NCT00637481|Experimental|Arm I (lower dose atorvastatin calcium)|Participants receive oral atorvastatin once daily for 3 months.
9904150|NCT00637481|Experimental|Arm II (atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm I) once daily for 3 months.
9904151|NCT00637481|Experimental|Arm III (higher dose atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm II) once daily for 3 months.
9904152|NCT00637481|Other|Arm IV (no intervention)|Participants do not receive treatment. Participants undergo blood sample collection and fine needle aspiration of breast tissue at baseline and at 3 months for correlative biomarker studies.
9904153|NCT00637507|No Intervention|2|Patients treated solely with a pressure- and volume-limited ventilatory strategy (target plateau pressure of 30 cm H2O) aimed at minimizing lung stress and strain, and thus, ventilator-induced lung injury.
9904154|NCT00637507|Experimental|1|Intermittent application of High-frequency Oscillation (HFO) and Tracheal Gas Insufflation (TGI) according to pre-specified criteria described in the Detailed Description. HFO-TGI sessions are interspersed with lung protective conventional mechanical ventilation until the PaO2/FiO2 ratio stabilizes at >150 mm Hg.
9904155|NCT00637520||1|Subjects with NAFLD
9904156|NCT00637520||2|Subjects without liver disease
9904157|NCT00637520||3|Subjects with non-steatotic hepatitis
9904158|NCT00637533|Placebo Comparator|Placebo|Saline injection
9904159|NCT00637533|Experimental|Botulinum Toxin Type A|Sympathetic Blockade containing Botulinum Toxin Type A
9904160|NCT00637546|Experimental|A,1|Physiotherapy
9904161|NCT00637559|Experimental|1|40mg twice daily
9904162|NCT00637559|Experimental|2|40mg three times daily
9904163|NCT00637559|Experimental|3|20mg three times daily
9904164|NCT00637598|Experimental|Tomosynthesis scans|This is a case-only study with only one group/cohort. All women receive both mammography and tomosynthesis imaging.
9904165|NCT00637624|Active Comparator|1|N-Acetylcysteine
9904166|NCT00637624|Placebo Comparator|2|Placebo
9904167|NCT00637650|Experimental|B|"Experimental group: patients in whom stone dust was left for spontaneous elimination"
9904168|NCT00637650|Other|A|Control group: Patients in whom all fragments resulting from laser lithotripsy of ureteral stones were actively retrieved
9904169|NCT00637663|Experimental|A|entecavir 0.5 mg QD
9904170|NCT00637663|Active Comparator|B|lamivudine 100 mg QD
9904171|NCT00637676|Active Comparator|1|Implantation of PleurX-Pleural catheter plus talc pleurodesis
9904172|NCT00637676|Active Comparator|2|talc pleurodesis, no implantation of PleurX-Pleural catheter
9904173|NCT00637702|Experimental|ARRY-334543|
9904174|NCT00637741|Experimental|Everflex 200|study group treated with at least one 200 mm Everflex stent
9904175|NCT00637767|Experimental|radio-labelled anti-CD66 monoclonal antibody|Up to 4mg radio-labelled anti-CD66 monoclonal antibody. Plus standard treatment
9904176|NCT00637767|Active Comparator|No IMP - standard treatment|No IMP - standard treatment
9904177|NCT00637793|Placebo Comparator|1|Placebo capsules
9904178|NCT00637793|Experimental|2|2 capsules in the am of each treatment period
9904179|NCT00637793|Experimental|3|2 capsules in the am of each treatment period
9904180|NCT00637793|Experimental|4|2 capsules in am of each treatment period
9904181|NCT00637845|Experimental|1|40mg once daily
9904182|NCT00637845|Active Comparator|2|30mg twice daily
9904183|NCT00637858|Placebo Comparator|1|
9904184|NCT00637858|Active Comparator|2|Lyc-o-Mato 5mg
9904185|NCT00637858|Active Comparator|3|Lyc-o-Mato 15mg
9904186|NCT00637858|Active Comparator|4|Lyc-o-Mato 30mg
9904187|NCT00637858|Active Comparator|5|Lycopene capsules (non Lyc-o-mato) 15 mg
9904188|NCT00637871|Experimental|1|
9904189|NCT00637871|Active Comparator|2|
9904190|NCT00637897|Experimental|Paricalcitol (Zemplar)|Paricalcitol (Zemplar)
9904191|NCT00637910|Experimental|Erlotinib Arm|
9904192|NCT00637910|Active Comparator|Docetaxel Arm|
9904193|NCT00637936|Active Comparator|1|Group 1 is given 30% oxygen during and 2 hours after surgery
9904194|NCT00637936|Active Comparator|2|Group 2 is given 80% during and 2 hours after surgery.
9904195|NCT00637949|Experimental|1|
9904196|NCT00637949|Active Comparator|2|
9904197|NCT00637962|Experimental|Active product|CN54gp140 + gel
9904198|NCT00637962|Placebo Comparator|Gel alone|Gel alone
9904199|NCT00637975|Experimental|A|oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
9904200|NCT00637975|Active Comparator|B|pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops
9904201|NCT00637988|Experimental|1|Nexium 40mg
9904202|NCT00637988|Experimental|2|Nexium 40mg + aspirin
9904203|NCT00637988|Experimental|3|Nexium 40mg + Rofecoxib 25 mg
9904204|NCT00637988|Active Comparator|4|Rofecoxib 25mg
9904205|NCT00638040||1|The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
9904206|NCT00638053|Experimental|1|
9904207|NCT00638066|Experimental|1|
9904208|NCT00638066|Active Comparator|2|
9904209|NCT00638079|Experimental|A|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal
9904210|NCT00638079|Active Comparator|B|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast
9904211|NCT00638092|Experimental|Iodine|This is the hypothetical active arm
9904212|NCT00638092|Placebo Comparator|Placebo|this is the hypothetical placebo
9904213|NCT00638131|Experimental|1|Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
9904214|NCT00638131|Placebo Comparator|2|placebo given bid same as experimental arm;
9904215|NCT00638144||1|patients with resolved infection
9904216|NCT00638144||2|chronically infected patients
9904217|NCT00638170|Active Comparator|A|Cranberry juice
9904218|NCT00638170|Placebo Comparator|B|Placebo juice
9904219|NCT00638196|Experimental|1|placebo/active crossover
9904220|NCT00638209|Active Comparator|I|
9904221|NCT00638209|Placebo Comparator|P|
9993748|NCT01475396|Experimental|Aerobic Exercise|
9993749|NCT01475396|Experimental|Anaerobic Exercise|
9993750|NCT01475396|No Intervention|Unchanged condition|
9904222|NCT00638248|Active Comparator|1|Desmoteplase 90µg/kg BW
9904223|NCT00638248|Active Comparator|2|Desmoteplase 125 µg/kg BW
9904224|NCT00638248|Placebo Comparator|3|Placebo
9904225|NCT00638261|Other|left/right|left or right body side
9904226|NCT00638300|Experimental|1|large pore dialyzers (FX80, Fresenius, Germany)
9904227|NCT00638300|Experimental|2|small pore dialyzers ( F8HPS, Fresenius, Germany)
9904228|NCT00638300|Experimental|A|dialysate bicarbonate concentration of 33 mEq/l
9904229|NCT00638300|Experimental|B|dialysate bicarbonate concentration of 40 mEq/l
9904230|NCT00638300|Experimental|I|dialysate calcium concentration of 3 mEq/L
9904231|NCT00638300|Experimental|II|dialysate calcium concentration of 2.5 mEq/L
9904232|NCT00638313|Placebo Comparator|Placebo|
9904233|NCT00638313|Experimental|PF-04603629|
9904234|NCT00638326|No Intervention|1|Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
9904235|NCT00638326|Experimental|2|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
9904236|NCT00638326|Active Comparator|3|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel
9904237|NCT00638339||1|critically ill patients undergoing invasive mechanical ventilation in medical ICU and CCU
9904238|NCT00638339||2|critically ill patients undergoing noninvasive mechanical ventilation in medical ICU and CCU
9904239|NCT00638391||1|all patients treated with Anastrozole
9904240|NCT00638417|Experimental|maximal strength training|maximal dynamic strength training
9904241|NCT00638417|Other|conventional rehabilitation|rehabilitation as usual
9904242|NCT00638430||1|low myopic group
9904243|NCT00638430||2|moderate myopic group
9904244|NCT00638469|Other|left/right|left or right body side
9904245|NCT00638482|Experimental|1|Hydrochlorothiazide
9904246|NCT00638495|Experimental|1|
9904247|NCT00638495|Placebo Comparator|2|
9904248|NCT00638547|Experimental|Intent-to-Treat|All patients who have received at least one dose of Laronidase.
9904249|NCT00638560|Experimental|1|"Antioxidant treatment arm:~Vitamin E, 400 IU po, once daily Vitamin C, 1g po, twice daily"
9904250|NCT00638560|Placebo Comparator|2|Control
9904251|NCT00638586||1|Femoral access
9667237|NCT03828201|Experimental|Investigational: DRAMATIC-32 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
9904252|NCT00638586||2|Radial access
9904253|NCT00638599|Experimental|1|LMA® is placed after anesthesia induction till the end of operation
9904254|NCT00638599|Active Comparator|2|Standard tracheal tube is inserted after anesthesia induction till the end of operation
9904255|NCT00638612|Experimental|A resectable|Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
9904256|NCT00638612|Experimental|B locally advanced|"Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.~Enrollment has been completed for Arm B."
9904257|NCT00638638|Experimental|1|"Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus.~Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty."
9904258|NCT00638638|Experimental|2|"Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus.~Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min."
9904259|NCT00638677|Placebo Comparator|1|Sorbitol tablet
9904260|NCT00638677|Placebo Comparator|2|Xylitol tablet
9904261|NCT00638677|Active Comparator|3|Xylitol + BB12 tablet
9904262|NCT00638729|Active Comparator|Midazolam|Pre-anesthetic medication with midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
9904263|NCT00638729|Active Comparator|Clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
9904264|NCT00638729|Placebo Comparator|Placebo|Pre-anesthetic medication with an inert tablet, p.o., 60-90 min prior to estimated induction time
9904265|NCT00638742|Experimental|1|
9904266|NCT00638768|Active Comparator|Physiotherapy|Including 10 individual visits with a physiotherapist and home exercises
9904267|NCT00638768|No Intervention|2|Usual care
9904268|NCT00638781|Active Comparator|1|Desmoteplase 62.5 µg/kg BW i.v. bolus
9904269|NCT00638781|Active Comparator|2|Desmoteplase 90 µg/kg BW i.v. bolus
9904270|NCT00638781|Active Comparator|3|Desmoteplase 125 µg/kg BW i.v. bolus
9904271|NCT00638781|Placebo Comparator|4|Placebo i.v. bolus
9904272|NCT00638794||Surgical|Patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
9904273|NCT00638794||Observational|Consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications
9904274|NCT00638807|Experimental|A|
9904275|NCT00638807|Placebo Comparator|B|
9904276|NCT00638833|Active Comparator|A|Memantine 30 mg/day
9904277|NCT00638833|Placebo Comparator|B|Placebo
9904278|NCT00638872|Experimental|1|PDRN
9904279|NCT00638872|Placebo Comparator|placebo|placebo
9904280|NCT00638911||Patients with hypertention|
9904281|NCT00638950|Placebo Comparator|Placebo|
9904282|NCT00638950|Active Comparator|n-3 LC-PUFA|
9904283|NCT00638976|Other|1.Integrilin, GSK|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
9904284|NCT00638976|Placebo Comparator|2|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
9904285|NCT00639015|Experimental|1|Phenylephrine
9904286|NCT00639015|Active Comparator|2|Norepinephrine
9904287|NCT00639028|Other|1|Ankle echography
9904288|NCT00639028|Other|2|echography + stress radiography
9904289|NCT00639028|Other|3|stress radiography
9904290|NCT00639041|Placebo Comparator|placebo|
9904291|NCT00639041|Active Comparator|n-3 LC-PUFA|
9904292|NCT00639054||Newly diagnosed patients|Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
9904293|NCT00639054||Relapse patients|Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
9904294|NCT00639054||Healthy controls|Healthy blood and bone marrow donors. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) for genetic analyses serving to compare normal bone marrow with bone marrow from multiple myeloma patients.
9904295|NCT00639067||1|"Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
9904296|NCT00639067||2|"Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
9904297|NCT00639067||3|"Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
9904298|NCT00639067||4|"Apparently healthy individuals having no signs and symptoms of lung carcinoma.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
9904299|NCT00639080||Entire study population|All study subjects.
9904300|NCT00639106|Experimental|A|Expander Placement WITH Alloderm
9904301|NCT00639106|Active Comparator|B|Expander Placement WITHOUT Alloderm
9904302|NCT00639171||1|Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
9904303|NCT00639171||2|Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
9904304|NCT00639184|Experimental|1|Home intervention program
9904305|NCT00639184|Active Comparator|2|health education counseling
9904306|NCT00639197|Active Comparator|1|To Tunnel
9904307|NCT00639197|Active Comparator|2|Not to tunnel
9904308|NCT00639210|Other|A|Supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.
9904309|NCT00639210|No Intervention|B|
9904310|NCT00639249|Placebo Comparator|P|Placebo
9904311|NCT00639249|Experimental|A1|SA4503
9904312|NCT00639249|Experimental|A2|SA4503
9904313|NCT00639262|Experimental|Cohort 1 - Brain Metastasis|Sorafenib and Radiotherapy
9904314|NCT00639262|Experimental|Cohort 2 - Gliomas|Sorafenib and Radiotherapy, plus Temozolomide
9904315|NCT00639288|Experimental|1|modified CPT-C
9904316|NCT00639314|Experimental|1|In PpPD, the proximal duodenum was divided 3-4cm distal to the pylorus ring
9904317|NCT00639314|Active Comparator|2|In PrPD, the stomach is divided just above the pylorus ring. the nearly total stomach more than 95% was preserved.
9904318|NCT00639327|Experimental|A|CPT-11+ S-1
9904319|NCT00639327|Active Comparator|B|CPT-11
9904320|NCT00639353|Active Comparator|spherical contact lens|Subjects will wear and evaluate a spherical soft contact lens daily for 2 weeks
9904321|NCT00639353|Experimental|toric contact lens|Subjects will wear and evaluate a toric soft contact lens daily for 2 weeks
9904322|NCT00639392|Placebo Comparator|2|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.
9904323|NCT00639392|Experimental|1|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
9904324|NCT00639405||1|subjects who are diagnosed with parathyroid adenomas. There will be 6 subjects who have not had surgery and 25 subjects who have had surgery.
9904325|NCT00639431|Experimental|1|Direct observation of a sequence of right foot movements performed by the experimenter while visualizing moving the amputated or phantom right foot.
9904326|NCT00639431|Experimental|2|Direct observation of a sequence of left foot movements performed by the experimenter while visualizing moving the amputated or phantom left foot.
9904327|NCT00639431|Experimental|3|Direct observation of a sequence of left and right foot movements performed by the experimenter while visualizing moving the amputated or phantom left and right feet.
9904328|NCT00639431|Experimental|4|Mental visualization with closed eyes of a sequence movements performed with the right amputated or phantom foot.
9904329|NCT00639431|Experimental|5|Mental visualization with closed eyes of a sequence movements performed with the left amputated or phantom foot.
9904330|NCT00639431|Experimental|6|Mental visualization with closed eyes of a sequence movements performed with the left and right amputated or phantom feet.
9904331|NCT00639444|Active Comparator|Gluten free diet|the intervention in this group is keeping a gluten-free diet from 0 to 12 months
9904332|NCT00639444|No Intervention|Gluten containing diet|infants in this group are started on gluten-containing cereals at 6 months (control group)
9904333|NCT00639483|Experimental|A|
9904334|NCT00639483|Placebo Comparator|B|
9904335|NCT00639496|Experimental|1|patients taking NAC 600 mg t.i.d.
9904336|NCT00639496|Placebo Comparator|2|
9904337|NCT00639522|Experimental|A|
9904338|NCT00639561|Experimental|A|diet composed of 10g of fibre per day
9904339|NCT00639561|Experimental|B|diet composed of 40g of fibre per day
9904340|NCT00639613||1|Patients with type 2 diabetes
9904341|NCT00639613||2|Healthy subjects
9904342|NCT00639652||1. 3D-histology|Nodular, micronodular, or sclerosing BCCs
9904343|NCT00639652||2. Shave excision|Superficial BCCs
9904344|NCT00639691|Experimental|1|
9904345|NCT00639730|Experimental|A|This is open-label - all patients are placed on the diet. There is no control or placebo arm.
9904346|NCT00639743|Experimental|group A|tenecteplase (group A)
9904347|NCT00639743|Placebo Comparator|group B|placebo ( group B)
9904348|NCT00639756|Other|1|Placebo
9904349|NCT00639756|Active Comparator|2|Allopurinol given for 2 weeks with diet
9904350|NCT00639782|Active Comparator|ONX|On-X heart Valve Replacement
9904351|NCT00639782|Active Comparator|SJM|SJM heart valve replacement
9904352|NCT00639795|Active Comparator|A|Patients randomized to receive thoracic paravertebral nerve blockade in addition to general endotracheal anesthesia during video assisted thoracoscopy procedure
9904353|NCT00639795|Sham Comparator|B|Patients randomized to receive sham single-injection thoracic peripheral nerve blockade (no injection) in addition to general endotracheal anesthesia
9904354|NCT00639808|Placebo Comparator|1|
9904355|NCT00639808|Experimental|2|TZP-101
9904356|NCT00639821||inflammatory bowel disease|Patients with refractory inflammatory bowel disease (ulcerative colitis and Crohn's disease) before and after treatment with infliximab.
9904357|NCT00639834|Experimental|1|Active MDX-1342 given in combination with Methotrexate
9904358|NCT00639847|No Intervention|group 1|this is the standard of care control group. The control group will be instructed to return to their regular physicians for routine follow up at a time to be specified by the physician.
9904359|NCT00639847|Active Comparator|Group 2|Group 2 will receive routine home visits from nurses provided by a home health care agency.
9904360|NCT00639847|Active Comparator|Group 3|In-home asthma management program (AMP) provided by respiratory therapists. The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
9904361|NCT00639873|Experimental|AS 2mg/kg|Artesunate monotherapy 2mg/kg/day for 7 days
9904362|NCT00639873|Experimental|AS 4mg/kg|Artesunate monotherapy 4mg/kg/day for 7 days
9904363|NCT00639873|Active Comparator|QD Control|Quinine-doxycycline for 7 days
9904364|NCT00639912|Active Comparator|A: low volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/kg/hour for 12 hours after the procedure, starting in the Cath Lab.
9904365|NCT00639912|Active Comparator|B: high volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath lab.
9904366|NCT00639912|Active Comparator|C: low volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
9904367|NCT00639912|Active Comparator|D: high volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
9904368|NCT00639925|Experimental|Phase I study|
9904369|NCT00639938|Active Comparator|1|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery"
9904370|NCT00639938|Experimental|2|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6"
9904371|NCT00639938|Experimental|3|"Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery"
9904372|NCT00639951|Active Comparator|A Normal dose Group|20 vials up front in a Single Dose of Antivipmyn in 500 ml of solution IV, administered in 60 minutes. After 12 hours, it has to be perfomed a clinical evaluation of the patient. Each patient is going to have clinical studies of coagulation time and also the fibrinogen measures, this at 2, 4, 6, 8, 10, 12, 48, 72, 96 hours.All patients who have received at least one dose of medication study will be contacted by telephone to investigate the presence of symptoms suggestive of continuing with effect snake venom, or the presence of an adverse event, or any signs or symptoms indicating the presence of a hypersensitivity response to Antivipmyn® including serum sickness. If symptoms suggestive of an adverse event were discovered, the patient will referred for appropriate treatment.
9904373|NCT00639951|Placebo Comparator|B Placebo Group|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®. The treatment schedule for each subject is a dose of 5 vials Antivipmyn® every 2 hours to complete 20 vials, the total duration is 6 hours of the treatment. Each dose IV shall apply in physiological solution 250ml, and finish its application in 15 minutes. For pediatric patients the volume administered should not exceed the recommended fluid volume according to your body weight. After the assessment at 12 hours, it can be administered at the discretion of more antivenom attending by the physician.
9904374|NCT00639964|Other|type 1 diabetic pregnant women|type 1 diabetic pregnant women
9904375|NCT00639964|Other|type 2 diabetic pregnant women|type 2 diabetic pregnant women
9904376|NCT00639964|Other|healthy pregnant women|healthy pregnant women with normal glucose tolerance
9904377|NCT00639977|Sham Comparator|2|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
9904378|NCT00639977|Active Comparator|1|20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming)
9904379|NCT00639977|No Intervention|3|
9904380|NCT00639990|Active Comparator|Control|Patients without lung injury and brain injury
9904381|NCT00639990|Experimental|Brain No ALI 1|Patients with brain injury and no lung injury within 72 hours from ICU entry
9904382|NCT00639990|Experimental|Brain No ALI 2|Patients with brain injury and no ALI after 72 hours from ICU entry
9904383|NCT00639990|Experimental|Brain ALI|Patients with brain injury and Acute Lung Injury (ALI)
9904384|NCT00640003|Experimental|1|
9904385|NCT00640003|Experimental|2|
9933583|NCT05350462||Hoima, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
9933584|NCT05350462||Bugiri, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
9933585|NCT05350449|Experimental|Loving kindness meditation|
9933586|NCT05350449|No Intervention|Waitlist control|The arm will eventually get the intervention.
9933587|NCT05350436|Experimental|Young adult non singers|
9933588|NCT05350436|Experimental|Young adult singers|
9933589|NCT05350436|Experimental|Older adult non singers|
9933590|NCT05350436|Experimental|Older adult singers|
9933591|NCT05350423|Experimental|Thulium Fibre Laser (TFL)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Thulium fibre laser (TFL)
10213928|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP|"Experimental phase II soft-tissue sarcoma :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 47"
9904386|NCT00640029|Experimental|1|Cervical - Arthroplasty
9904387|NCT00640029|Active Comparator|2|Cervical - Arthrodesis
9904388|NCT00640029|Experimental|3|Lumbar - Over 50 years - Arthroplasty
9904389|NCT00640029|Active Comparator|4|Lumbar - Over 50 years - Arthrodesis
9904390|NCT00640029|Experimental|5|Lumbar - Under 50 years - Arthroplasty
9904391|NCT00640055|Active Comparator|1|Coordinator (non-physician)
9904392|NCT00640055|Placebo Comparator|2|Physician
9904393|NCT00640068||1|All patients in whom a clinical CCTA was ordered by their physician at a participating site. Patient must have a prescription for CCTA ordered by their physician.
9904394|NCT00640081|Active Comparator|D|Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment
9904395|NCT00640081|Experimental|E|Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment
9904396|NCT00640094|Experimental|A: Melatonin|Melatonin: intravenous infusion and intracoronary bolus
9904397|NCT00640094|Placebo Comparator|B: Placebo of melatonin|Placebo: intravenosus infusion and intracoronary bolus
9904398|NCT00640120||1|Asthmatic subjects
9904399|NCT00640120||2|Healthy subjects
9904400|NCT00640159|Experimental|A|Open label switch from current oral selegiline dose to orally disintegrating selegiline (Zelapar) titrated to a dose of 2.5 mg QD.
9904401|NCT00640172||Anemic Elderly|
9904402|NCT00640172||Non-anemic adults (non-elderly, without bone marrow biopsy)|
9904403|NCT00640172||Non-anemic adults (non-elderly, with bone marrow biopsy)|
9904404|NCT00640172||Non-anemic Elderly (control without bone marrow biopsy)|
9904405|NCT00640172||Non-anemic Elderly (control, with bone marrow biopsy)|
9904406|NCT00640198|Active Comparator|Group 1 Memantine|Patients included in this group will receive memantine alone followed by memantine combined with intensive speech-language therapy.
9904407|NCT00640198|Placebo Comparator|Group 2|Patients included in this group will receive placebo alone followed by memantine combined with intensive speech-language therapy.
9904408|NCT00640211||PIPET B|Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
9904409|NCT00640237|Experimental|1|Arm 1 - the patients will receive two large doses of vitamin D.
9904410|NCT00640237|No Intervention|2|Arm 2 - the patients vitamin D status will be checked during the hospitalization and they will receive the recommendation to treat the vitamin D deficiency in the out-patient department.
9904411|NCT00640263|Experimental|1|infant peri-exposure prophylaxis with lopinavir/ritonavir
9904412|NCT00640263|Active Comparator|2|infant peri-exposure prophylaxis with lamivudine
9904413|NCT00640276|Active Comparator|T|Lifestyle modification + active drug(Pitavastatin)
9904414|NCT00640276|Other|C|Lifestyle Modification
9904415|NCT00640302||PIPET A|Patients presenting at study sites with the recognised clinical case definition for pandemic influenza (to be distributed by State and Commonwealth Departments of Health when first clinical case occurs) will be eligible to be enrolled on the study. Informed consent to participate in the study will be sought including parental/guardian consent for minors and presumed consent for adults who are incapacitated (consistent with NHMRC requirements).
9904416|NCT00640354|Experimental|1|Pediatric residents randomized to having an automated external defibrillator
9904417|NCT00640354|Active Comparator|2|Pediatric residents randomized to having a manual defibrillator
9904418|NCT00640367|Experimental|IA thrombolysis|IA recombinant tissue plasminogen activator and/or mechanical thrombolysis
9904419|NCT00640367|Active Comparator|IV rtPA|IV recombinant tissue plasminogen activator
9904420|NCT00640380|Experimental|1|CPVB with NS
9904421|NCT00640380|Active Comparator|2|CPVB with LOR
9904422|NCT00640406|Experimental|STN|Device: Dynamic Renal Stent plus Best Medical Treatment
9904423|NCT00640406|Active Comparator|BMT|Drug: Best Medical Treatment
9904424|NCT00640432|Active Comparator|A|
9904425|NCT00640432|Experimental|B|
9904426|NCT00640445|Experimental|Expressive Writing|Participants assigned to the Expressive Writing (EW) condition will write about their deepest thoughts and feelings associated with their experience transitioning from being a soldier to being a civilian for 20 minutes a day for 4 days within a week.
9904427|NCT00640445|Active Comparator|Control Writing|Those assigned to control writing condition will write factually about the information needs of veterans transitioning from active duty to civilian status for 20 minutes on 4 days within one week.
9904428|NCT00640445|No Intervention|No Writing Control|Treatment As Usual
9904429|NCT00640458|Placebo Comparator|Placebo|Study Period 1 or 2
9904430|NCT00640458|Experimental|Experimental|Study Period 1 or 2
9904431|NCT00640471|Active Comparator|Brivanib|
9904432|NCT00640471|Active Comparator|Placebo|
9904433|NCT00640497|Experimental|1|Treatment arm
9904434|NCT00640536||1|Newly diagnosed obstructive sleep apnea patients without systemic and pulmonary arterial hypertension
9904435|NCT00640536||2|Age, sex and and body mass index-matched matched healthy subjects
9904436|NCT00640549|Placebo Comparator|2|
9904437|NCT00640549|Active Comparator|1|
9904438|NCT00640575|Experimental|A|Local
9904439|NCT00640575|Active Comparator|B|Systemic
9904440|NCT00640588|Experimental|1|Telbivudine
9904441|NCT00640588|Active Comparator|2|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
9904442|NCT00640627|Experimental|A|
9904443|NCT00640627|Placebo Comparator|B|
9904444|NCT00640640|Experimental|A|All study patients will be evaluated in a similar way
9904445|NCT00640666|Experimental|Physical activity intervention|Behavior change intervention
9904446|NCT00640666|No Intervention|Standard of care with written materials|Written materials
9904447|NCT00640679|Active Comparator|Clopidogrel Tapering|
9904448|NCT00640679|Active Comparator|Abrupt Clopidogrel Interruption|
9904449|NCT00640692||1|
9904450|NCT00640692||2|
9904451|NCT00640705|Active Comparator|A|Topical diclofenac sodium patch
9904452|NCT00640705|Placebo Comparator|B|Topical patch identical in appearance to active comparator, except without diclofenac sodium
9904453|NCT00640744|Other|A|An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
9904454|NCT00640757|Active Comparator|Low Methionine 1|Methionine deficient diet
9904455|NCT00640757|Placebo Comparator|Placebo 2|Placebo comparator methionine complete diet
9904456|NCT00640770|Active Comparator|balloon angioplasty|balloon angioplasty
9904457|NCT00640770|Experimental|Drug eluting stent|CYPHER SELECT+ Coronary or Infrapopliteal Stent
9904458|NCT00640783|Experimental|1|Mediterranean diet
9904459|NCT00640783|Active Comparator|2|Control diet
9904460|NCT00640796|Experimental|Treatment|Participants undergo haploidentical donor derived natural killer cell infusion (cells obtained from donors and selected using CliniMACS cell selection system) and chemotherapy (cyclophosphamide, fludarabine, interleukin-2, mesna).
9904461|NCT00640809|Experimental|A|
9904462|NCT00640809|Placebo Comparator|B|
9904463|NCT00640809|Active Comparator|C|
9904464|NCT00640848|Experimental|1|
9904465|NCT00640848|Experimental|2|
9904466|NCT00640848|Experimental|3|
9904467|NCT00640848|Experimental|4|
9904468|NCT00640848|Experimental|5|
9904469|NCT00640874||PIPET C|Contact group members of people with diagnosed influenza who are recommended to receive NA inhibitor prophylaxis for short periods of time will be enrolled following provision of informed consent.
9904470|NCT00640887|Experimental|1|RBT associated with EFV based ART
9904471|NCT00640887|Experimental|2|RBT associated with NVP based ART
9904472|NCT00640887|Experimental|3|RBT associated with LPV/r based ART
9904473|NCT00640900|Experimental|Commercial program at center|
9904474|NCT00640900|Experimental|Commercial program over the telephone|
9904475|NCT00640900|Other|Usual care|Weight loss counseling
9904476|NCT00640913||I|Twenty consecutive patients operated on with low anterior resection of the rectum for cancer with a defunctioning stoma who accept participation.
9904477|NCT00640939|Active Comparator|A|Topical diclofenac sodium patch
9904478|NCT00640939|Placebo Comparator|B|Topical patch identical in appearance to active comparator
9904479|NCT00640965|Experimental|A|DP-VPA
9904480|NCT00640965|Placebo Comparator|B|
9904481|NCT00640991|No Intervention|Control|Patients assigned to the control arm will receive usual care for AMI, according to local practice of each participating centre.
9904482|NCT00640991|Experimental|Intervention|The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.
9904483|NCT00641004|Experimental|1|Rebamipide 100mg TID for 12 weeks
9904484|NCT00641004|Active Comparator|2|Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
9904485|NCT00641017|Experimental|1 and 2 - Adults|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
9904486|NCT00641017|Experimental|3A - Seropositive Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
9904487|NCT00641017|Placebo Comparator|3B - Seropositive Children|One dose of 1x10^6 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
9904488|NCT00641017|Experimental|4A - Seronegative Infants and Children|One immunization of 1x10^5 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
9904489|NCT00641017|Placebo Comparator|4B - Seronegative Infants and Children|One dose of 1x10^5 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
9904490|NCT00641017|Experimental|5A - Seronegative Infants and Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
9904491|NCT00641017|Placebo Comparator|5B - Seronegative Infants and Children|One dose of rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
9904492|NCT00641082|Experimental|1|Clevudine
9904493|NCT00641082|Active Comparator|2|Adefovir
9904494|NCT00641095|Experimental|Fludarabine/Cyclophosphamide/Rituximab|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3 Rituximab 375mgs/m2 day 1 iv infusion~Every 28 days"
9904495|NCT00641095|Active Comparator|Fludarabine/Cyclophosphamide|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3~Every 28 days"
9904496|NCT00641134|Other|A|A:Home-Based exercise program,-at discharge from in-Hospital CR program-, with one reinforcement session each month for the first 6 months.
9904497|NCT00641134|No Intervention|B|Usual care, after CR, consisting of recommendation on usefulness of physical exercise and standard follow-up visits and functional assessment at 6 and 12 months.
9904498|NCT00641160|Experimental|Cohort 1|
9904499|NCT00641160|Experimental|Cohort 2|
9904500|NCT00641160|Experimental|Cohort 3|
9904501|NCT00641173|Experimental|1|paroxetine v placebo
9904502|NCT00641173|Placebo Comparator|2|placebo
9904503|NCT00641186|Experimental|A|sodium oxybate 4.5 to 9.0 gms per night
9904504|NCT00641199|Active Comparator|1|Jarrow-Dophilus EPS
9904505|NCT00641199|Placebo Comparator|2|Placebo
9904506|NCT00641212|Experimental|1|Budesonide
9904507|NCT00641212|Placebo Comparator|2|
9904508|NCT00641225|Experimental|1|SBI-087
9904509|NCT00641238||Early stage NSCLC|Early stage non-small cell lung cancer
9904510|NCT00641251|Active Comparator|1|intensive medical management
9904511|NCT00641251|Active Comparator|2|Roux-en-Y gastric bypass with intensive medical management
9904512|NCT00641303|Sham Comparator|Arm I (control)|Patients receive 8 weekly sessions of sham acupuncture treatment comprising 20 minutes of a non-penetrating device consisting of a retractable needle and an adhesive tube on the skin using the Park Sham Device (PSD) in 14 non-acupuncture points. Patients may receive 4 free acupuncture sessions (not sham) after the 12 or 24-week follow-up visit.
9904513|NCT00641303|Experimental|Arm II (treatment)|Patients receive 8 weekly sessions of acupuncture treatment comprising 20 minutes of needle insertion in 15 acupuncture points including CV 4, CV 6, CV12 and bilateral LI 4, MH 6, GB 34, ST 36, KI 3, BL 65.
9904514|NCT00641316|Experimental|1|Teeth extraction followed by natural healing
9904515|NCT00641316|Experimental|2- FDBA/TCP|
9904516|NCT00641316|Experimental|3 FDBA/TCP+PRP|
9904517|NCT00641316|Experimental|4 FDBA/TCP + PDGF|
9904518|NCT00641329|Experimental|1|
9904519|NCT00641329|Placebo Comparator|2|
9904520|NCT00641342|Active Comparator|onlay mesh|
9904521|NCT00641342|Active Comparator|sublay mesh|
9904522|NCT00641342|No Intervention|no mesh|
9904523|NCT00641368|Experimental|1|R4Power Program
9904524|NCT00641368|Other|2|Waitlist Control
9904525|NCT00641394|Experimental|1|Psychotherapy: Emotional Freedom Techniques (EFT), a psychotherapy intervention with a somatic component
9904526|NCT00641394|Active Comparator|2|Psychotherapy: Cognitive Behavioral Therapy (CBT), a psychotherapy intervention
9904527|NCT00641394|No Intervention|3|
9904528|NCT00641407|Experimental|1|
9904529|NCT00641407|Active Comparator|2|
9904530|NCT00641433|Experimental|experimental|Subjects will daily dress their nail bed with oxidized regenerated cellulose collagen-silver, until healing occurs.
9904531|NCT00641433|Active Comparator|Control|Topical silver sulfadiazine cream will be applied daily to the wound bed until healing has occured.
9904532|NCT00641446|Experimental|1|Pulmicort
9904533|NCT00641446|Active Comparator|2|Varivax
9904534|NCT00641459||001|
9904535|NCT00641472|Experimental|1|Budesonide inhalation suspension
9904536|NCT00641472|Active Comparator|2|Montelukast sodium
9904537|NCT00641498|No Intervention|Control|Usual therapy
9904538|NCT00641498|Experimental|Active group|Individual supportive psychotherapy initiated in the Emergency department
9933592|NCT05350423|Experimental|Holmium:Yttrium-Aluminum-Garnet (Ho:YAG)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Holmium:Yttrium-Aluminum-Garnet (Ho:YAG) laser
9904539|NCT00641511|Experimental|1 (Medication arm - SYN117 aka Nepicastat)|"Veterans will be receiving the study medication Nepicastat initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily; During the 8 weeks (weeks: 7-14) extension phase, those from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed for an additional 8 weeks. Those who have a prior defined positive clinical response to the study medication, Nepicastat, will be continued on open label Nepicastat at 120mg once daily, in order to assess further improvement and safety; those who do not have a positive clinical response during the 6 weeks RCT will be offered the addition of the standard first-line PTSD pharmacotherapy, Paroxetine. Paroxetine is an allowed concomitant medication (i.e. rescue medication) and is not considered a research medication or subject of a research question during the 8 weeks extension phase."
9904540|NCT00641511|Placebo Comparator|2 (Placebo arm)|During the 6 weeks ( weeks: 1-6) double- blind, randomized clinical trial (RCT) phase, the veterans who have been randomized to the placebo treatment group will be receiving placebo pills. During the 8 weeks (weeks: 7-14) extension phase, all veterans from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed by the study team for an additional 8 weeks. The veterans on the placebo during the RCT will receive the study medication at end of the study week 6, the medication will be initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily for 8 weeks until the end of the study.
9904541|NCT00641524|Other|treatment|Iron depletion via phlebotomy
9904542|NCT00641537|Placebo Comparator|Cladribine Low/Placebo (LLPP)|
9904543|NCT00641537|Placebo Comparator|Cladribine High Dose/Placebo (HLPP)|
9904544|NCT00641537|Experimental|Cladribine Low/Low Dose (LLLL)|
9904545|NCT00641537|Experimental|Cladribine High/Low Dose (HLLL)|
9904546|NCT00641537|Experimental|Placebo/Cladribine Low Dose (PPLL)|
9904547|NCT00641537|No Intervention|Placebo/No Treatment|
9904548|NCT00641537|No Intervention|Cladribine 3.5 mg/kg/No Treatment|Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
9904549|NCT00641537|No Intervention|Cladribine 5.25 mg/kg/No Treatment|Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
9904550|NCT00641550|Experimental|2|Pregnant women starting to practice physical exercise at 13 weeks(Walking moderate activity)
9904551|NCT00641550|Experimental|3|Pregnant women starting exercise at 20 weeks
9904552|NCT00641550|No Intervention|1|Pregnant women without exercise practice.
9904553|NCT00641602|Experimental|1|Nexium
9904554|NCT00641602|Active Comparator|2|Prevacid
9904555|NCT00641615|Experimental|Phase 1|
9904556|NCT00641628||1|
9904557|NCT00641654|Active Comparator|A|Patients having previously received 24 weeks of therapy with pegylated interferon and ribavirin will be treated with pegylated interferon alfa-2a kD (PEGASYS) plus ribavirin, (Copegus) for a treatment period of 48 weeks, with a follow-up period of 24 weeks irrespective of the level of HCV-RNA measured in plasma on treatment day 27.
9904558|NCT00641654|Active Comparator|B|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having detectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 48 weeks, with a follow-up period of 24 weeks.
9904559|NCT00641654|Active Comparator|C|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having undetectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 24 weeks, with a follow-up period of 24 weeks.
9904560|NCT00641680|Experimental|1|Budesonide
9904561|NCT00641680|Active Comparator|2|Fluticasone propionate
9904562|NCT00641680|Placebo Comparator|3|
9904563|NCT00641693|Experimental|1|Nasal Spray
9904564|NCT00641693|Placebo Comparator|2|
9904565|NCT00641758|Placebo Comparator|Placebo|
9904566|NCT00641758|Active Comparator|Pycnogenol|
9904567|NCT00641784|Experimental|1|Oral Nifedine
9904568|NCT00641784|Active Comparator|2|Intravenous Magnesium
9904569|NCT00641810|Experimental|A|After one week at usual levels of caffeine use, patients are asked to reduce their caffeine consumption to no more than 2 cups of coffee (or equivalent) for one week and then to zero for two weeks.
9904570|NCT00641823||1|
9904571|NCT00641823||2|
9904572|NCT00641823||3|
9933593|NCT05350410|Experimental|HALT-AD|"This arm includes cognitively normal midlife and older-adult participants with the following inclusion criteria:~Signed informed consent must be obtained and documented (from the participant)~Sufficient proficiency in English or Spanish to undergo clinical assessment and participate~Ages 50-85~Montreal Cognitive Assessment-Telephone/Blind Version (T-MoCA) score ≥18/22~Technical ability to participate~Sufficient vision and hearing to participate~Ability to sit comfortably for a period of at least 30 minutes~A total of 20 participants will be enrolled at UCSD~10 will complete the English version~10 will complete the Spanish version~Aim is to recruit 50% women and to enroll a diverse participant sample across varied age ranges within both language groups."
9933594|NCT05350397|Experimental|Acupressure group|The patients in the intervention group were informed about what acupressure was and why it was applied. An acupressure wristband was correctly worn on both wrists to provide patients with adequate pressure on the HT7 point for 5 minutes
9933595|NCT05350397|Placebo Comparator|Placebo Group|Patients in the placebo group were informed about what acupressure was and why it was applied. In order not to apply pressure to the Shenmen (HT7) pressure point in the patients in this group, the acupressure wristband was placed on both wrists in an inverted and loose manner and the wristband was worn for 5 minutes, the procedure was completed.
9933596|NCT05350397|No Intervention|Control group|No procedure was applied to the patients in the control group. The patients received routine treatment and care.
9933597|NCT05350371|Experimental|Placebo|
9933598|NCT05350371|Experimental|Pirfenidone Treatment|
9933599|NCT05350358||Patients who have undergone surgical treatment with LeMaitre Cardial Dialine II|Subject who has undergone surgical treatment for the replacement or bypass in aneurysmal and/or occlusive diseases and for arterial reconstruction in patients requiring systemic heparinization with LeMaitre Cardial Dialine II.
9933600|NCT05350332|Experimental|Negative Pressure Ventilator|Participants with obstructive sleep apnea (OSA) who are being evaluated for surgical treatment of their OSA and having a routine clinical DISE will have their lung volume increased with a non-invasive negative pressure ventilator. Participants will also have a pulmonary function test performed per routine clinical protocol, but for research purposes only (i.e., not part of usual care).
9933601|NCT05350319||Patients planning for total or reverse shoulder arthroplasty|Adult patients who are planning to undergo a total or reverse shoulder arthroplasty
9933602|NCT05350319||Retrospective group of patients who have already undergone preoperative planning|Retrospective cohort of patients who have undergone preoperative planning with a conventional shoulder CT for total or reverse shoulder arthroplasty.
9933603|NCT05350306|Experimental|Chincup|Patients will be treated with occipital chincup and bonded bite block.
9933604|NCT05350306|Active Comparator|Untreated subjects|Patients will not undergone any treatment for 16 months.
9933605|NCT05350293|Active Comparator|Molded abutment|A plastic abutment that is provided by the implant manufacturer will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture. A plastic abutment that the implant manufacturer provides will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture.
9933606|NCT05350293|Experimental|3D printed abutment|The customised abutment will be made using a laser printer with a Cr-Co mixture after being designed using a special computer program.
9933607|NCT05350280|Experimental|Low-intensity electrical current (LIEC)|A removable device containing a small electrical circuit will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
9933608|NCT05350280|Active Comparator|Traditional fixed orthodontic appliance|The maxillary arch will be levelled and aligned. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction.
9933609|NCT05350267|Experimental|Treatment|HALO is a mixed-delivery intervention (online learning, digital technologies, telehealth visits) co-designed with mothers that (a) uniquely tailors intervention content to integrate post-bariatric surgery guidelines to recommendations to reduce child obesity risk, (b) teaches mothers evidence-based parenting behaviors to support intergenerational lifestyle and home food environment changes, and (c) addresses unique barriers to family-level change identified by mothers post-bariatric surgery.
9933610|NCT05350267|Active Comparator|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
9904573|NCT00641849|Active Comparator|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
9904574|NCT00641849|Active Comparator|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
9904575|NCT00641888||1|10 patients starting on non-nucleoside reverse transcriptase inhibitor based regimen. 5 women and 5 men.
9904576|NCT00641888||2|10 patients starting a protease inhibitor based regimen. 5 women and 5 men.
9904577|NCT00641901||Observation|Pregnant women with gingivitis
9904578|NCT00641914|Experimental|1|
9904579|NCT00641914|Placebo Comparator|2|
9904580|NCT00641927|Experimental|1|Antidepressant
9904581|NCT00641927|Active Comparator|2|Drug
9904582|NCT00641940|Experimental|1|Girls in Transition (GT) program
9904583|NCT00641940|Other|2|Waitlist control
9904584|NCT00641953|Experimental|A|IMX-150 (0.3%) 0.5 g topically BID each foot
9904585|NCT00641953|Experimental|B|IMX-150(0.6%) 0.5 g topically BID to each foot
9904586|NCT00641953|Placebo Comparator|C|Placebo 0.5 g topically BID to each foot for 4 weeks
9904587|NCT00641979|Experimental|1|Rhinocort
9904588|NCT00641979|Placebo Comparator|2|
9904589|NCT00641992||1|Response to medical treatment
9904590|NCT00641992||2|Failure to medical treatment (surgery or percutaneous resolution)
9904591|NCT00642005|Experimental|1|Humidified and warmed carbon dioxide laparoscopic insufflation.
9904592|NCT00642005|Placebo Comparator|2|Cold and dry carbon dioxide laparoscopic insufflation.
9904593|NCT00642031|Experimental|Triciribine|Triciribine 15 mg/m^2 intravenous (IV) Weekly Over 1 Hour On Days 1, 8, and 15.
9904594|NCT00642044|Experimental|A|The eye with the worst visual acuity receives the treatment. (the other eye serve as control).
9904595|NCT00642044|No Intervention|B|The eye with the best visual acuity do not receive the treatment.
9904596|NCT00642070||Host|Women with current symptoms of a urinary tract infection
9904597|NCT00642083|Experimental|1|viabahn stent-graft
9904598|NCT00642096|Experimental|1|Metoprolol Succinate + Hydrochlorothiazide
9904599|NCT00642096|Active Comparator|2|Metoprolol Succinate
9904600|NCT00642096|Active Comparator|3|Hydrochlorothiazide
9904601|NCT00642109|Other|TVT|Tension-free Vaginal Tape (TVT)
9904602|NCT00642109|Other|TOT|Transobturator Tape outside-in (TOT Monarc)
9904603|NCT00642109|Other|TVT-O|Transobturator Tape inside-out (TVT-O)
9904604|NCT00642122|Experimental|1|Pulmicort RESPULES
9904605|NCT00642122|Experimental|2|Pulmicort TURBUHALER
9904606|NCT00642135|Active Comparator|1|Premature newborns and neonates treated using Phenylephrine and tropicamide eyedrops
9904607|NCT00642135|Active Comparator|2|Premature newborns and neonates treated using insert Mydriasert®
9904608|NCT00642187|Experimental|1|Pulmicort
9904609|NCT00642187|Placebo Comparator|2|Placebo
9904610|NCT00642200|Active Comparator|1|Patients receive Lichtenstein hernioplasty as a treatment for recurrent inguinal hernia.
9904611|NCT00642200|Active Comparator|2|Patients receive laparoscopic TEP as a treatment for recurrent inguinal hernia.
9904612|NCT00642213||ischemic stroke sample with DNA|We prospectively collected 450(1999), 502(2005), and 512(2010) ischemic stroke patients who agreed to participate and also most provided a sample for DNA. The cohort data consists of a baseline interview, medical record abstraction and various timeframes of followup interviews from 3 months to 3 years. See website (www.gcnkss.com for data forms)
9904613|NCT00642213||stroke data from medical record review|The second part of the study is a retrospective medical record review of all potential ischemic strokes, TIAs, and Hemorrhagic strokes in our 5 county region that occurred in all study years.
9904614|NCT00642226|Active Comparator|1|Grid Laser
9904615|NCT00642226|Experimental|2|Vitrectomy in combination with 20 mg triamcinolone
9904616|NCT00642239|Placebo Comparator|2|Concurrent radiochemotherapy and placebo
9904617|NCT00642239|Experimental|1|concurrent radiochemotherapy and Sodium Glycididazole
9904618|NCT00642252|Experimental|B|226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
9904619|NCT00642252|Active Comparator|A|ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
9904620|NCT00642265|Experimental|1|operative treatment
9904621|NCT00642265|Active Comparator|2|conservative treatment
9998337|NCT01517334|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
9993751|NCT01475409|Experimental|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, tuberculin skin test (TST) and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset.
9993752|NCT01475422|Experimental|Conversation Maps Diabetes Education|
9993753|NCT01475422|Active Comparator|Usual Care|
9993754|NCT01475435|Active Comparator|chronic periodontitis|Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.
9993755|NCT01475435|Placebo Comparator|periodontally healthy individuals|Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.
9993756|NCT01475435|Active Comparator|chronic periodontitis with diabetes type 2|Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis
9993757|NCT01475435|Placebo Comparator|periodontally healthy individuals with diabetes type 2|Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline
9993758|NCT01475448|Experimental|Sedentary older adults - running|Sedentary older adults (60 years old or more) recruited from local community
9993759|NCT01475448|Active Comparator|Sedentary older adults - walking|Sedentary older adults (60 years old or more) recruited from local community
9993760|NCT01475526|Experimental|Intervention|El Valor de Nuestra Salud Store Intervention
9993761|NCT01475526|No Intervention|Control|No intervention. Business as usual
9993762|NCT01475539|Experimental|Group A (Sequential 1): IPV-OPV-OPV|Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
9993763|NCT01475539|Experimental|Group B (Sequential 2): IPV-IPV-OPV|Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
9993764|NCT01475539|Experimental|Group C (Reference): OPV-OPV-OPV|Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)
9993765|NCT01475552|Experimental|abciximab|
9993766|NCT01475552|Active Comparator|control|
9993767|NCT01475565||African-American women|Observational study--no intervention
9993768|NCT01475565||Caucasian women|Observational study--no intervention
9993769|NCT01475578|Experimental|STA-1|"STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally~Dummy Ergoloid Mesylates tablet (Placebo), 2 tablets/time, 3 times/day, orally"
9993770|NCT01475578|Active Comparator|Ergoloid Mesylates|"Ergoloid Mesylates tablet, 2 tablets/time, 3 times/day, orally before meal~Dummy STA-1 capsule (Placebo), 2 capsules/time, 3 times/day, orally"
9993771|NCT01475591|No Intervention|Multimodal rehabilitation|The arm intervention is just multimodal rehabilitation.
9993772|NCT01475604|Active Comparator|Targeted pulsed electromagnetic field|
9993773|NCT01475604|Sham Comparator|Sham|
10212947|NCT04825184|Experimental|Body image chatbot|The artificial intelligence chatbot, Topity, is designed to target sociocultural risk and protective factors for body image using eight therapeutic techniques derived from several evidence-based theories, including media literacy, cognitive behaviour theory and positive body image. The intervention aims to engage users in techniques that teaches users how to 1) Critically analyse and evaluate media content to reduce vulnerability to negative media influences (i.e., media literacy theory; 10); 2) Identify and challenge unhelpful thinking styles and behaviours that perpetuate body image distress (i.e., cognitive behaviour theory; 11); and 3) Appreciating the features, functions and health of the body, beyond it's appearance (i.e., positive body image theory; 12). Users will be assessed on state body satisfaction and affect before and after engaging with a technique to assess the immediate impact of the micro-intervention.
9993774|NCT01475617|Experimental|Novel Multivitamin/Mineral Supplement|These subjects will be given a novel multivitamin/mineral supplement post RYGB bariatric surgery for 6 months duration.
10212948|NCT04825184|No Intervention|Assessment only|The comparison control condition will be assessment only. This is informed by a care as usual framework; whereby, Brazilian adolescents are not currently offered online body image prevention or intervention resources at school or within the community.
10213929|NCT02630368|Experimental|Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP|"Experimental phase II breast cancer :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 32"
10213930|NCT02616965|Experimental|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
10213931|NCT02613416|Experimental|Denosumab|6 monthly subcutaneous injections of denosumab
10213932|NCT02601014|Experimental|Nivolumab and ipilimumab|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
10213933|NCT02601014|Experimental|Enzalutamide plus Nivolumab and Ipilimumab|Patients will continue on standard of care enzalutamide, with the addition of nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
10213934|NCT02598999|Experimental|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
10213935|NCT02598999|Experimental|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
10213936|NCT02598999|Experimental|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in CF patients in healthy volunteers
10213937|NCT02598999|Experimental|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in healthy volunteers and in patients (CF and NCFBE)
9904622|NCT00642291|Experimental|1|Treatment naive pediatric patients (Group 1: ages 3 to 24 months)were to receive emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
9904623|NCT00642291|Experimental|2|Treatment naive or experienced pediatric patients (Group 2: ages 7 to 12 years; Group 3: ages 13-17 years) received emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
9904624|NCT00642317||Asian Youth and Tobacco Control|Smoking Questionnaire for self-identified Chinese or Vietnamese participants.
9904625|NCT00642330|Active Comparator|I|
9904626|NCT00642330|Active Comparator|O|
9904627|NCT00642343|Placebo Comparator|1|Children with severe to profound deafness that have not received any intervention.
9904628|NCT00642343|Active Comparator|2|Children with an unilateral cochlear implant.
9904629|NCT00642343|Active Comparator|3|Children with bilateral cochlear implants.
9904630|NCT00642343|Active Comparator|4|Children who receive their second implant during the duration of the study.
9904631|NCT00642395|Experimental|1|bortézomib
9904632|NCT00642408|Experimental|MMN|multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
9904633|NCT00642408|Active Comparator|IFA|iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
9904634|NCT00642421|Experimental|Population A|Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.
9904635|NCT00642421|Experimental|Population B|Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.
9904636|NCT00642434|Active Comparator|1|study drug
9904637|NCT00642434|Active Comparator|2|study drug
9904638|NCT00642447|Experimental|1|
9904639|NCT00642486|Active Comparator|1|laboratory-based testing
9904640|NCT00642486|Active Comparator|2|home-based testing
9904641|NCT00642499|Experimental|1|
9904642|NCT00642499|Placebo Comparator|2|
9904643|NCT00642512|Experimental|1|
9904644|NCT00642512|Active Comparator|2|
9904645|NCT00642512|Other|3|
9904646|NCT00642512|Placebo Comparator|4|
9904647|NCT00642525|Experimental|A|A prospective, blinded, intraindividual controlled study is conducted with patients with transthoracic esophagectomy due to esophageal cancer. A radiographic contrast study is performed prior to endoscopy at the 5th to 7th postoperative day.
9904648|NCT00642538|Experimental|1|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
9904649|NCT00642538|Experimental|2|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
9904650|NCT00642538|Experimental|3|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
9904651|NCT00642538|Placebo Comparator|4|TIP (placebo comparison)
9904652|NCT00642538|Active Comparator|5|10 ug subcutaneous control
9904653|NCT00642551|Active Comparator|MK-7|1 capsule per day existing of 180 µg menaquinone-7
9904654|NCT00642551|Placebo Comparator|Placebo|1 placebo capsule per day for three years
9904655|NCT00642564||001|
9904656|NCT00642577|Experimental|1|
9904657|NCT00642577|Active Comparator|2|
9904658|NCT00642590||1|Healthy couples who are planning their first pregnancy.
10212949|NCT04818112|Experimental|Behavioral ATVV intervention|A multi-sensory behavioral intervention that includes auditory, tactile, visual and vestibular (ATVV) stimulation contingent upon infant cues.
10212950|NCT04818112|Active Comparator|Attention control|An attention control group that receives education on safe infant care and the same amount of attention as the intervention group.
10212951|NCT04814433|Experimental|Topical lidocaine and bupivacaine alone|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
10212952|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
10212953|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and tranexamic acid|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
10212954|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and aminocaproic acid;|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid
10212955|NCT04813172|Experimental|Head and neck cancer patients|Patients from the Eye and Ear Institute Survivorship Clinic who are diagnosed with head and neck cancer.
10212956|NCT04809623|Experimental|GS-5718|Participants will receive GS-5718 orally once daily for 4 weeks
10212957|NCT04809623|Experimental|Placebo|Participants will receive placebo orally once daily for 4 weeks
10212958|NCT04807179|Experimental|Alexandrite Laser|Single arm, self-controlled
9904659|NCT00642629|Active Comparator|1|STA-5326 mesylate
9904660|NCT00642629|Placebo Comparator|2|Placebo
9904661|NCT00642681||1: TI Inhalation Powder|Technosphere® Insulin (TI) Inhalation Powder
9904662|NCT00642720|Other|pegvisomant-placebo|patients in this arm received(as addition)for the first 8 weeks Pegvisomant and the later for 8 weeks Placebo. This was divided by a 4 weeks wash-out period.
9904663|NCT00642720|Other|placebo-pegvisomant|Patient received for the first 8 weeks Pegvisomant and after a wash out period of 4 weeks the received 8 of placebo treatment
9904664|NCT00642733|Experimental|1|
9904665|NCT00642785||1|Patients with active oral or genital HSV skin lesions
9904666|NCT00642785||2|Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment
9904667|NCT00642785||3|Patients with active shingles/zoster
9904668|NCT00642785||4|Patients with post herpetic neuralgia
9904669|NCT00642824|Experimental|1|
9904670|NCT00642837||001|
9904671|NCT00642837||002|
9904672|NCT00642837||003|
9904673|NCT00642837||004|
9904674|NCT00642837||005|
9904675|NCT00642837||006|
9904676|NCT00642837||007|
9904677|NCT00642837||008|
9904678|NCT00642837||009|
9904679|NCT00642863|Experimental|Low birth iron|Infants with low birth iron who receive vitamins A and D + iron
9904680|NCT00642863|Experimental|Marginal birth iron 1|Infants with marginal birth iron randomized to receive vitamins A and D + iron
9904681|NCT00642863|Active Comparator|Marginal birth iron 2|Infants with marginal birth iron randomized to receive vitamins A and D without iron
9904682|NCT00642863|Active Comparator|Normal birth iron|Infants with normal birth iron who receive vitamins A and D without iron
9904683|NCT00642863|Experimental|Combined ID|Marginal-birth-iron vitamins only-treated infants who have IDA at 9 mo.
9904684|NCT00642863|Experimental|Early postnatal IDA|Infants with IDA at 9 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks
9904685|NCT00642863|Experimental|Late postnatal IDA|Infants with IDA at 18 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks. These infants were also not anemic when screened at 9 months.
9904686|NCT00642876|Active Comparator|Control|The Control cohort are patients that receive the fusion treatment.
9904687|NCT00642876|Experimental|Investigational|The Investigational cohort are the study patients that received the PRESTIGE® Cervical Disc.
9904688|NCT00642889|Experimental|High Dose|150-200mg/day
9904689|NCT00642889|Experimental|Low dose|50-100mg/day
9904690|NCT00642889|Placebo Comparator|Placebo|
9904691|NCT00642928|Placebo Comparator|Placebo|
9904692|NCT00642928|Experimental|BF 2.649-5 mg|
9904693|NCT00642928|Experimental|BF 2.649 10 mg|
9904694|NCT00642928|Experimental|BF 2.649 20 mg|
9904695|NCT00642928|Experimental|BF 2.649 40 mg|
9904696|NCT00642967|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Participants will receive subcutaneous methoxy polyethylene glycol-epoetin beta every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
9904697|NCT00642980|Active Comparator|Clindamycin Cure 1|Arm 1
9904698|NCT00642980|Active Comparator|Clindamycin Cure 2|Arm 2
9904699|NCT00642980|Placebo Comparator|Placebo|Arm placebo
9904700|NCT00643019|Experimental|SAFE Intervention|Behavioral Intervention
9904701|NCT00643019|Other|Control|Sexually Transmitted Infection Risk Reduction Counseling
9904702|NCT00643032|Active Comparator|I|
9904703|NCT00643032|Active Comparator|II|
9904704|NCT00643045|Experimental|1|Low dose (50-100mg/day)
9904705|NCT00643045|Experimental|2|High dose (150-200 mg/day)
9904706|NCT00643045|Placebo Comparator|3|
9904707|NCT00643058|Experimental|1|Sterile Saline, LPS endotoxin
9904708|NCT00643071|Experimental|1|
9904709|NCT00643084|Experimental|1|patients will consume a low residue diet prior to surgery and have no routine bowel preparation
9904710|NCT00643084|Other|2|standard bowel preparation
9904711|NCT00643136|Experimental|Pregabalin|
9904712|NCT00643136|Placebo Comparator|Placebo|
9904713|NCT00643149|Experimental|1|
9904714|NCT00643149|Experimental|2|
9904715|NCT00643175||1|Osteoporosis in patients with fragility hip fractures.
9904716|NCT00643188|Experimental|1|"Radiofrequency ablation of atrial fibrillation:~Subjects assigned to the catheter AF ablation strategy will undergo ablation within 48 hours after baseline evaluation. The aim of the procedure is to achieve isolation of all Pulmonary Veins (PVs) and to restore sinus rhythm. Only radiofrequency catheter based AF ablation is permitted; other methods, like cryoablation, ultrasound and laser, are not permitted in this study.~Before ablation, a transesophageal echocardiogram must be performed in order to rule out presence of atrial thrombi.~Anticoagulation should be initiated, or continued, for at least six months post ablation. Six months after successful ablation and in absence of any recurrence of AF, antiarrhythmic drugs should be discontinued."
9993775|NCT01475617|Active Comparator|Standard of care supplement|These subjects will be given the standard recommended regimen at Johns Hopkins Bayview Medical Center post RYGB bariatric surgery for 6 months duration.
9904717|NCT00643188|Active Comparator|2|"Conventional treatment:~Subjects assigned to the conventional treatment strategy will be treated according to current guidelines for the management of patients with chronic heart failure and/or atrial fibrillation. Efforts to maintain sinus rhythm in this study arm are recommended.~Anticoagulation will be initiated, if not already started, and maintained throughout the study according to current guidelines."
9904718|NCT00643214|Experimental|1|Twice daily topical application
9904719|NCT00643214|Placebo Comparator|2|Twice daily topical application
9904720|NCT00643227|Experimental|1|
9904721|NCT00643227|Experimental|2|
9904722|NCT00643240|Experimental|111 In-BU-12|111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.
9904723|NCT00643253|Experimental|1|Receipt of behavioral interventions to encourage breastfeeding.
9904724|NCT00643253|No Intervention|2|Standard of Care
9904725|NCT00643266|Experimental|1|Recollection training via graduated increases in task difficulty, carried out over 36 sessions over 9 training days
9904726|NCT00643266|Active Comparator|2|Computer-delivered information sessions about memory and aging with Jeopardy-like games to engage participants
9904727|NCT00643292|Experimental|1|
9904728|NCT00643292|Experimental|2|
9904729|NCT00643305|Experimental|1|Skills Building with Motivational Interviewing (SB-MI)- combines education and general skills-building participants can use to reduce their at-risk behavior for HIV with increasing motivation to change HIV risk behaviors
9904730|NCT00643305|Active Comparator|2|Skills Building (SB) - provides education and general skills-building for reduction of HIV risk behaviors.
9904731|NCT00643318|Experimental|CyberKnife Stereotactic Radiosurgery|
9904732|NCT00643331|Experimental|1|Exercise performed at the gym and at home
9904733|NCT00643331|No Intervention|2|Usual care no additional exercise
9904734|NCT00643344|Experimental|CALMM+|Participants receiving CALMM intervention, ie program that combines stress reduction, mindful eating practices with diet and exercise
9904735|NCT00643344|Active Comparator|TLC|Participants receiving diet and exercise classes only
10212959|NCT04805125|Active Comparator|Moderna mRNA COVID-19 vaccine|The Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) is administered intramuscularly as a series of two doses (0.5 mL each), given 28 days apart.
9904736|NCT00643357|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox® 170 bar)
9904737|NCT00643357|Placebo Comparator|B|50%Oxygen/50% Nitrogen premix
9904738|NCT00643370||1|single arm study
9904739|NCT00643409|Experimental|1|
9904740|NCT00643409|Experimental|2|
9904741|NCT00643422||Observation|
9904742|NCT00643435|Experimental|1|These residents receive training provided by standardized patient instructors, in use of self-efficacy enhancing interviewing techniques to support patient health behavior change,
9904743|NCT00643435|Active Comparator|2|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
9904744|NCT00643461||Adhesive A|
9904745|NCT00643461||Adhesive B|
9904746|NCT00643461||Adhesive C|
9904747|NCT00643474|Experimental|A|
9904748|NCT00643474|Experimental|B|
9904749|NCT00643526|Experimental|Injection Site: First Thigh Then Abdomen|Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.
9904750|NCT00643526|Experimental|Injection Site: First Abdomen then Thigh|Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.
9904751|NCT00643539|Experimental|1|
9904752|NCT00643539|Experimental|2|
9904753|NCT00643591||Observational|Patients with a primary glioblastoma
9904754|NCT00643617|Other|Heterogeneous dose|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with CyberKnife Stereotactic Radiosurgery
9904755|NCT00643630|Experimental|1|Twice daily topical application
9904756|NCT00643630|Placebo Comparator|2|Twice daily topical application
9933611|NCT05350254|Experimental|Stratified Maintenance Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~Participants in the Stratified Maintenance Care group will be classified based on the MAINTAIN instrument into: not a candidate, good candidate, and very good candidate for maintenance care:~Participants showing a good response to the initial care and classified as not a candidate or a good candidate for maintenance care will be given home exercise recommendations. Return for further manual treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-guided care).~Participants classified as having a good response to the initial care and very good candidates for maintenance care, will have visits with tapering manual treatments and home exercise recommendations. They will then be recommended maintenance care with pre-planned visits at 4-12 week intervals (aiming at increasing the interval as soon as possible)."
9993776|NCT01475630|Other|control|information, avoiding parafunctions
9993777|NCT01475630|Experimental|physical therapy|mobilisation, exercises ,..
10212960|NCT04805125|Active Comparator|Comirnaty® (Pfizer / BioNTech) mRNA COVID-19 vaccine|"Active:~The comparator product is the first licensed vaccine against SARS-CoV-2 in Switzerland.~Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 (30 µg) Comirnaty®, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 21 days later."
10212961|NCT04798651|Experimental|patients with multiple sclerosis or clinically isolated syndrome|subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome
10213938|NCT02588651|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
10213939|NCT02581787|Experimental|Treatment (fresolimumab, SABR)|In Phase 1: Patients receive fresolimumab IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12 in total of 5 subjects. In Phase 2: . Fresolimumab will be administered IV at the dose selected in the preceding Phase 1 on Days 1, 15 and 36 and SABR will be administered in 4 fractions between Days 8 and 12.
9904757|NCT00643643|Experimental|A|
9904758|NCT00643643|Experimental|B|
9904759|NCT00643643|Experimental|C|
9904760|NCT00643643|Experimental|D|
9904761|NCT00643643|Placebo Comparator|E|
9904762|NCT00643656|Experimental|A|Mixture of 50% nitrous oxide and 50% oxygen
9904763|NCT00643656|Placebo Comparator|B|Mixture of 50% oxygen and 50% nitrogen
9904764|NCT00643695|Experimental|1|Home-based walking program
9904765|NCT00643695|Other|2|educational intervention
9904766|NCT00643708||A|14 cases
9904767|NCT00643708||B|14 cases
9904768|NCT00643708||C|14 cases
9904769|NCT00643708||D|14 Cases
9904770|NCT00643721||D,FR|Young healthy athletes
9904771|NCT00643734|Experimental|1|
9904772|NCT00643734|Experimental|2|
9904773|NCT00643747|Experimental|A|Injection of vector
9904774|NCT00643773|Experimental|A|Leucine supplement
9904775|NCT00643773|Placebo Comparator|B|Wheat flour
9904776|NCT00643786|Experimental|A|Oxygène
9904777|NCT00643786|Placebo Comparator|B|Air Médical
9904778|NCT00643799|Experimental|A|
9904779|NCT00643799|Active Comparator|B|
9904780|NCT00643799|Placebo Comparator|C|
9904781|NCT00643812|Experimental|1|"The Early intervention arm received a gun locker at baseline"
9904782|NCT00643812|Active Comparator|2|Households in this arm received a gun locker at 12 months following the baseline survey
9904783|NCT00643825|Active Comparator|A: prolonged adj TMZ|
9904784|NCT00643825|Other|B : Stop and Go|Rechallenging patients with TMZ at relapse
9904785|NCT00643838|Experimental|A|Misture of 50% nitrous oxide and 50% oxygen
9904786|NCT00643877|Experimental|B|PHRAC was performed 7 days before surgery. Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
9904787|NCT00643877|No Intervention|A|Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
9904788|NCT00643903|Experimental|1|Participants will receive five individual sessions of coping effectiveness training.
9904789|NCT00643903|Active Comparator|2|Participants will receive standard care and one delayed group workshop of coping effectiveness training.
9904790|NCT00643929||Observational|Subjects who have participated in a prior eltrombopag study, receiving either placebo or eltrombopag
9904791|NCT00643942||1|
9904792|NCT00643955||DS|Individual with Down Syndrome
9904793|NCT00643968|Active Comparator|1|TDF+EFV
9904794|NCT00643968|Experimental|2|TDF+3TC+EFV
9904795|NCT00643994|Experimental|CyberKnife Stereotactic Radiosurgery|
9904796|NCT00644007|Placebo Comparator|Group 1|
9904797|NCT00644007|Experimental|Group 2|
9904798|NCT00644020||Group 1|the Tyroserleutide for injection at the dosage of 3mg/d
9904799|NCT00644020||Group 2|the Tyroserleutide for injection at the dosage of 6mg/d
9904800|NCT00644020||Group 3|the Tyroserleutide for injection at the dosage of 12mg/d
9904801|NCT00644020||Group 4|the placebo group
9904802|NCT00644033|Active Comparator|1|
9904803|NCT00644033|Active Comparator|2|
9904804|NCT00644033|Placebo Comparator|3|
9904805|NCT00644046|No Intervention|1|Chronic kidney disease patient with standardized nephrology care
9904806|NCT00644046|Active Comparator|2|chronic kidney disease patient with multidisciplinary predialysis care
9904807|NCT00644085|Experimental|1|oral administration of aspirin 100 mg
9904808|NCT00644085|Placebo Comparator|2|oral administration of placebo
9904809|NCT00644098|Placebo Comparator|Placebo|cellulose and soybean oil
9904810|NCT00644098|Experimental|Intervention|soluble fibre complex and medium chain triglycerides
9904811|NCT00644111|Placebo Comparator|1|Control group receiving saline placebo through an epidural catheter
9904812|NCT00644111|Active Comparator|2|Experimental group receiving active medication through the epidural catheter
9904813|NCT00644124|Experimental|Aflibercept RCHOP 14|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 2 weeks. A dose of 2.0 mg/kg administered as Dose Level 1, 4.0 mg/kg as Dose Level 2, and 6.0 mg/kg dose as Dose level 3.
9993778|NCT01475656||Levetiracetam as first line|Babies who receive levetiracetam as a first line drug for seizures
9904814|NCT00644124|Experimental|Aflibercept RCHOP 21|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 3 weeks. A dose of 3.0 mg/kg administered as Dose Level 1, 6.0 mg/kg as Dose Level 2, and 8.0 mg/kg dose as Dose level 3.
9904815|NCT00644137|Experimental|A|pregabalin 300mg/day given in conjunction with smoking cigarettes.
9904816|NCT00644137|Experimental|2|cigarettes given in conjunction with pregabalin
9904817|NCT00644150|Experimental|1|Physicians of county level will receive Ai Shi Zi training provided by experts in the fields of HIV/STIs, behavioral counseling, and stigma reduction.
9904818|NCT00644150|Experimental|2|Physicians of township level will receive Ai Shi Zhi training provided by the county level physicians.
9904819|NCT00644150|Experimental|3|HIV/STI patients will receive standard of care and specialized care from physician participants trained in Ai Shi Zi.
9904820|NCT00644150|No Intervention|4|Physicians of county level who will not participate in Ai Shi Zi training
9904821|NCT00644150|No Intervention|5|Physicians of township level who will not participate in Ai Shi Zi training
9904822|NCT00644150|Sham Comparator|6|HIV/STI patients who will receive standard care only
9904823|NCT00644163|Experimental|1|Participants will receive Eban HIV/STD Risk Reduction Intervention.
9904824|NCT00644163|Active Comparator|2|Participants will receive Eban Health Promotion Intervention.
9904825|NCT00644176|Experimental|1|
9904826|NCT00644176|Experimental|2|
9904827|NCT00644202|Experimental|Group 1|Intervention Group
9904828|NCT00644202|No Intervention|Group 2|Usual Care Group
9904829|NCT00644215|Experimental|1|5-FU injection has been done
9904830|NCT00644215|Experimental|2|Mitomycin drop has been administrated
9904831|NCT00644241|Experimental|stem cell|
9904832|NCT00644254||Resected DPAC|145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.
9904833|NCT00644267|Active Comparator|1|Subjects will use a telemedicine system for blood pressure control
9904834|NCT00644267|No Intervention|2|Patients with hypertension receiving usual care by a primary care physician
9904835|NCT00644293|Experimental|1|
9904836|NCT00644293|Experimental|2|
9904837|NCT00644306|Placebo Comparator|A|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
9904838|NCT00644306|Active Comparator|B|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
9904839|NCT00644371|Experimental|1|
9904840|NCT00644397||Blade Plate Group|95-degree Angled Blade Plate
9904841|NCT00644397||Locking Plate Group|4.5mm Condylar Locking Plate
9904842|NCT00644410|Active Comparator|1|The number of mesenchymal stromal cells reached after two culture expansion passages.
9904843|NCT00644410|Placebo Comparator|2|Saline
9904844|NCT00644436|Experimental|1|Single topical application
9904845|NCT00644436|Active Comparator|2|Single topical application
9904846|NCT00644449|Experimental|1|
9904847|NCT00644449|Experimental|2|
9904848|NCT00644462||1|Asthmatic subjects
9904849|NCT00644462||2|Healthy subjects
9904850|NCT00644475|Experimental|2|Imidapril
9904851|NCT00644475|Active Comparator|1|Candesartan
9904852|NCT00644488|Experimental|A1|Active
9904853|NCT00644501|Experimental|1|
9904854|NCT00644514|Experimental|LPS endotoxin inh f/u bronchoscopy|Participants receive inhalation of LPS endotoxin, followed by bronchoscopy in this study.
9904855|NCT00644527|Experimental|1|Listening to one of two different specific music programs (Group A), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
9904856|NCT00644527|Experimental|2|Listening to one of two different specific music programs (Group B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
9904857|NCT00644527|Sham Comparator|3|Control I (Group C) : Listening 30 min in the morning and 30 min in the evening to unspecific music (Mozart) over 5 weeks.
9904858|NCT00644527|No Intervention|4|Control II (Group D): Waiting list. - Each 50% of the subjects will be assigned randomly to either Group A (arm 1) and B (arm 2) after 5 weeks of waiting time.
9904859|NCT00644540|Experimental|1|
9904860|NCT00644540|Active Comparator|2|
9904861|NCT00644553|Active Comparator|A|
9904862|NCT00644553|Active Comparator|B|
9904863|NCT00644566|No Intervention|TAU|Treatment as usual. These subjects and their providers were told to pursue treatment services as they normally would do.
9904864|NCT00644566|Experimental|shared care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
9904865|NCT00644579|Active Comparator|1|bLAC high dose
9904866|NCT00644579|Active Comparator|2|bLAC low dose
9904867|NCT00644579|Placebo Comparator|3|
9904868|NCT00644605|Active Comparator|Arm 1|
9904869|NCT00644605|Active Comparator|Arm 2|
9904870|NCT00644605|Active Comparator|Arm 3|
9904871|NCT00644605|Placebo Comparator|Arm 4|
9904872|NCT00644618|Active Comparator|A|
9904873|NCT00644618|Experimental|B|
9904874|NCT00644631|Active Comparator|Arm 1|
9904875|NCT00644631|Placebo Comparator|Arm 2|
9904876|NCT00644644||1|monitored
9904877|NCT00644644||2|control
9904878|NCT00644670|Experimental|Previous Treatment with a Usual Maintenance Dose of a Statin|
9904879|NCT00644670|Experimental|Statin-Naive|
9904880|NCT00644696|Experimental|Irinotecan and Bortezomib|Irinotecan and Bortezomib will both be administered
9904881|NCT00644709|Experimental|Arm A|
9904882|NCT00644722|Active Comparator|1|Single use metallic blades
9904883|NCT00644722|Active Comparator|2|Classic reusable metallic blades
9904884|NCT00644735|Experimental|1|Nexium
9904885|NCT00644735|Active Comparator|2|Prevacid
9904886|NCT00644748|Experimental|Gabapentin group|
9904887|NCT00644761|Other|Treatment Arm 1|Adefovir dipivoxil 10 mg once daily with tacrolimus or cyclosporine for 14 days
9904888|NCT00644774|Active Comparator|1|
9904889|NCT00644774|Active Comparator|2|
9904890|NCT00644800|Experimental|Arm A|
9904891|NCT00644813||Scapular with glenoid neck fractures|Collect outcome and radiological data on patients with scapular fractures involving the glenoid neck (bone joining the shoulder joint and the scapular body) for a period of 1 year.
9904892|NCT00644826|Experimental|1|
9904893|NCT00644826|No Intervention|2|
9904894|NCT00644852||001|
9904895|NCT00644891|Active Comparator|1|
9904896|NCT00644891|Active Comparator|2|
9904897|NCT00644904|Experimental|Treatment|Starting dose of 4,000 IU per day of Vitamin D3 titrating up to a dose of 40,000 IU per day of Vitamin D3 by month six. In the second six-month part of the trial, patients titrate back down to 4,000 IU per day of Vitamin D3 and then discontinue it completely at the end of the 12 month trial period.
9904898|NCT00644904|Other|Control|Patients are allowed to supplement with up to 4,000 IU per day of Vitamin D3 if desired.
9904899|NCT00644930|Experimental|1|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated.
9904900|NCT00644930|Active Comparator|2|Patients in the standard therapy group without indications for urgent intubation were only given standard medical therapy (such as oxygen, antibiotics, and bronchodilators), and IMV through an endotracheal tube was applied when intubation criteria were met.
9904901|NCT00644943|Active Comparator|1|
9904902|NCT00644943|Active Comparator|2|
9904903|NCT00644956|Active Comparator|Arm 1|
9904904|NCT00644956|Active Comparator|Arm 2|
9904905|NCT00644982|Experimental|Sertaline group|
9904906|NCT00644982|Active Comparator|Venlafaxine group|
9904907|NCT00645034|Active Comparator|Arm 1|
9904908|NCT00645034|Placebo Comparator|Arm 2|
9904909|NCT00645060|Experimental|Y-90-DOTA-M5A anti-CEA antibody|
9904910|NCT00645073|Active Comparator|A|
9904911|NCT00645073|Active Comparator|B|
9904912|NCT00645086|Active Comparator|A|
9904913|NCT00645086|Active Comparator|B|
9904914|NCT00645112|Active Comparator|1|
9904915|NCT00645112|Active Comparator|2|
9904916|NCT00645125|Active Comparator|1|
9904917|NCT00645125|Active Comparator|2|
9904918|NCT00645138|Active Comparator|Paravertebral Block|Patients receiving Paravertebral Block.
9904919|NCT00645138|Active Comparator|General Anesthesia|Patients receiving General Anesthesia.
9904920|NCT00645151|Experimental|High Risk|
9904921|NCT00645151|Experimental|Low Risk|
9904922|NCT00645151|Experimental|Medium Risk|
9904923|NCT00645203|Other|1|
9904924|NCT00645216|Experimental|CP-945,598 with Grapefruit Juice|CP-945,598 with Grapefruit Juice
9904925|NCT00645216|Experimental|CP-945,598 alone|CP-945,598 alone
9904926|NCT00645229|Experimental|Arm A|
9904927|NCT00645242|Experimental|Arm A|
9904928|NCT00645255|Other|1|Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
9904929|NCT00645255|Placebo Comparator|2|Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
9904930|NCT00645268|Active Comparator|Arm 1|
9904931|NCT00645268|Placebo Comparator|Arm 2|
9904932|NCT00645268|Other|Open-Label Arm|
9904933|NCT00645281|Experimental|tolterodine ER group|
9933612|NCT05350254|Active Comparator|Standard Chiropractic Care|"All participating patients will receive pragmatic chiropractic care for the initial 3 weeks (6 visits) and home exercise recommendations.~In the Standard chiropractic care group, participating patients will receive a standard (pragmatic) chiropractic care in which treatment will be provided based on the clinician's judgement and home exercise recommendations. This may or may not include maintenance care depending on the clinicians' standard operating procedures. All treatments provided will be recorded. Return for further treatment will be recommended if they have a relapse or exacerbation of symptoms (symptom-based)."
9933613|NCT05350241|Experimental|Split-belt treadmill walking group|Participants in this group performed repeated split-belt treadmill training with an error-augmentation strategy.
9933614|NCT05350241|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program
9933615|NCT05350215|Placebo Comparator|Placebo oral capsules|Placebo (2 pills) before sleep for a week
9933616|NCT05350215|Active Comparator|Atomoxetine and DAW2020 oral capsules|DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep
9933617|NCT05350202||Cohort receiving empagliflozin|Patients will receive first prescription of empagliflozin as routine therapy for Heart Failure with reduced Ejection Fraction (HFrEF).
9933618|NCT05350202||Cohort receiving drugs with another mechanism of action|Patients will receive Heart Failure therapy with drugs with another mechanism of action.
9933619|NCT05350189||Gadavist Single-dose vial|Data will be collected from contrast-enhanced Magnetic Resonance Imaging (MRI) using Gadavist from a single-dose vial of 7.5 or 10 or 15 milliliters (mL).
9933620|NCT05350189||Gadavist IBP|Data will be collected from contrast-enhanced MRI using Gadavist from an IBP of either 30 or 65 milliliters (mL), and from Gadavist via a single-dose vial due to insufficient product remaining in an IBP during the IBP cohort.
9933621|NCT05350176|Experimental|Experimental group|
9904934|NCT00645294|Other|Treatment Group A|ADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
9904935|NCT00645294|Other|Treatment Group B|ADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
9904936|NCT00645294|Other|Treatment Group C|ADV 10 mg single dose on Day 1 in 12-17 year old age group
9904937|NCT00645320|Experimental|A|
9904938|NCT00645346|Experimental|1|Subjects will receive either 5, 10 or 20 mcg of the vaccine
9904939|NCT00645346|Placebo Comparator|2|Subjects will receive placebo control
9904940|NCT00645372|Active Comparator|A|
9904941|NCT00645372|Experimental|B|
9904942|NCT00645385||MRS of the neural system|MRS to study epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism.
9904943|NCT00645398|Experimental|A|
9904944|NCT00645398|Experimental|B|
9904945|NCT00645398|Experimental|C|
9904946|NCT00645398|Placebo Comparator|D|
9904947|NCT00645424|Experimental|Arm A|
9904948|NCT00645424|Experimental|Arm B|
9904949|NCT00645424|Experimental|Arm C|
9904950|NCT00645463|Experimental|Group A|
9904951|NCT00645463|Experimental|Group B|
9904952|NCT00645489|Other|1|Control condition is wait-list control.
9904953|NCT00645489|Experimental|2|Active treatment condition: psychoeducational intervention for patients with HF
9904954|NCT00645515|Experimental|Arm A|
9904955|NCT00645515|Active Comparator|Arm B|
9904956|NCT00645541|Experimental|Axillary Reverse Mapping (ARM)|
9904957|NCT00645580|Experimental|A|
9904958|NCT00645606|No Intervention|Observation|Observation every 8 weeks during 2 years
9904959|NCT00645606|Experimental|rituximab arm|rituximab :500 mg/m² every 8 weeks during 2 years
9904960|NCT00645619||1|Patients with pure viral pneumonia
9904961|NCT00645619||2|Patients with viral pneumonia along with secondary bacterial pneumonia
9904962|NCT00645619||3|Patients with significant bacterial pneumonia
9904963|NCT00645619||4|Patients with congenital heart disease undergoing cardiopulmonary bypass who have no pneumonia
9904964|NCT00645684|Experimental|A|one layer running suture technique
9904965|NCT00645684|Experimental|B|two-layer suture technique
9904966|NCT00645723|Experimental|A|Intravenous colistin and nebulized colistin
9904967|NCT00645723|Placebo Comparator|B|intravenous colistin and saline solution nebulized
9904968|NCT00645736||1|Single cohort
9904969|NCT00645749|Experimental|Helminth ova|Subjects serving as their own controls (baseline - end-of-treatment) will receive a dose of 2,500 ova, in liquid form, every 2 weeks
9904970|NCT00645775|Placebo Comparator|1|Compare active to placebo
9904971|NCT00645801|Active Comparator|1|Patients will receive both Amitiza and GoLYTELY
9904972|NCT00645801|Placebo Comparator|2|Patients will receive Amitiza Placebo plus GoLYTELY
9904973|NCT00645814|Placebo Comparator|A|
9904974|NCT00645814|Active Comparator|B|
9904975|NCT00645814|Active Comparator|C|
9904976|NCT00645879|Experimental|OKG, Glutamine, and Disodium Citrate|Ornithine Alpha Ketoglutarate for 4 weeks, followed by 2 week washout period. 4 weeks Glutamine, followed by 2 week washout period. 4 weeks Disodium Citrate, followed by 2 to 12 week washout period. Then continue an additional 30 weeks on Disodium Citrate (drug producing the best increment in plasma glutamine levels).
9904977|NCT00645892|Active Comparator|A|
9904978|NCT00645892|Placebo Comparator|B|
9904979|NCT00645905|Active Comparator|A|
9904980|NCT00645905|Placebo Comparator|B|
9904981|NCT00645918|Active Comparator|A|"Tailored clopidogrel regimen - an additional clopidogrel 600-mg loading dose (eight 75-mg tablets taken orally; daily 150 mg clopidogrel dose plus additional 450 mg clopidogrel) on the day of randomization and then 150-mg clopidogrel every day thereafter for 6 months."
9904982|NCT00645918|Placebo Comparator|B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months."
9904983|NCT00645918|Placebo Comparator|C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.
9904984|NCT00645957|Active Comparator|2|This group will have a red rubber drain(s) placed during surgery. This drain(s) will be irrigated intra and post-operatively
9904985|NCT00645957|Active Comparator|1|This group will have a penrose drain(s) placed during surgery to facilitate drainage post-operatively. This drain (s) will not be irrigated.
9904986|NCT00645983|Experimental|1|Chamomile Extract
9904987|NCT00645983|Placebo Comparator|2|Anxiolytic Therapy
9904988|NCT00645996|Experimental|1|
9904989|NCT00645996|Placebo Comparator|2|Cornflour
9904990|NCT00646009|Experimental|1|budesonide/formoterol
9904991|NCT00646009|Active Comparator|2|fluticasone/salmeterol
9904992|NCT00646009|Active Comparator|3|albuterol
9904993|NCT00646035|Placebo Comparator|A|
9904994|NCT00646035|Placebo Comparator|B|
9904995|NCT00646061|Experimental|1|morphine, ketorolac, and buscopan
9904996|NCT00646061|No Intervention|2|morphine and ketorolac
9904997|NCT00646074|Experimental|1|Self-Care TALK
9904998|NCT00646074|No Intervention|2|
9904999|NCT00646087|Experimental|Ketamine (6K)|6K: 6 ketamine injections (0.5 mg/kg of ketamine) every other day for 12 days
9905000|NCT00646087|Active Comparator|Ketamine/Placebo (2K4P)|2K4P = two active ketamine injections(2K) and four placebo (saline) injections over 12 days.
9905001|NCT00646100|Active Comparator|TACE|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization
9905002|NCT00646100|No Intervention|control|best support care
9905003|NCT00646126|Active Comparator|1|1:Active comparator sulfadoxine-pyrimethamine plus artesunate
9905004|NCT00646126|Placebo Comparator|2|2:placebo comparator
9905005|NCT00646178|Active Comparator|A|
9905006|NCT00646178|Placebo Comparator|B|
9905007|NCT00646191|Active Comparator|A|
9905008|NCT00646191|Active Comparator|B|
9905009|NCT00646191|Active Comparator|C|
9905010|NCT00646204|Experimental|1|memantine 10 mg bid
9905011|NCT00646204|Placebo Comparator|2|2 tabs bid
9905012|NCT00646217|Experimental|1|SELF CARE Talk
9905013|NCT00646217|No Intervention|2|Comparison Group
9905014|NCT00646230|Experimental|Single arm of CIV infusion of emulsion 4-HPR|Single arm study of continuous intravenous infusion (CIV) of emulsion 4-HPR
9905015|NCT00646243||1 Heart Failure|216 consecutive consenting patients with refractory heart failure candidate to cardiac resynchronization therapy by clinical and electrocardiographic criteria
9905016|NCT00646243||2 Healthy subjects|120 healthy subject includes defined as absence of history and symptoms of any cardiovascular disease, normal physical examination and ECG.
9905017|NCT00646256|No Intervention|no training|
9905018|NCT00646256|Experimental|COGPACK training|
9905019|NCT00646269|Active Comparator|1|
9905020|NCT00646269|Experimental|2|
9905021|NCT00646269|Experimental|3|
9905022|NCT00646269|Experimental|4|
9905023|NCT00646295|Experimental|A|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
9905024|NCT00646308||I|Adult patients with GH deficiency due to a nonsecreting pituitary tumor
9905025|NCT00646308||2|Adult patients with a nonsecreting pituitary tumor but without GH deficiency
9905026|NCT00646321|Experimental|1|budesonide/formoterol
9905027|NCT00646321|Active Comparator|2|budesonide
9905028|NCT00646334|Experimental|A|Optilene® Mesh Elastic
9905029|NCT00646334|Active Comparator|B|Ultrapro® Mesh
9905030|NCT00646347|Experimental|A|Conventional stroke upper limb rehabilitation is given
9905031|NCT00646347|Active Comparator|B|Neuro Hand Orthosis Program is given
9905032|NCT00646360|Experimental|1|Docosahexonic acid (400 mg/day)
9905033|NCT00646360|Placebo Comparator|2|
9905034|NCT00646386|Active Comparator|A|
9905035|NCT00646386|Placebo Comparator|B|
9905036|NCT00646412|Experimental|A|A-Part® Gel
9905037|NCT00646412|No Intervention|B|untreated control group
9905038|NCT00646425|Experimental|1|Basiliximab
9905039|NCT00646425|Placebo Comparator|2|
9905040|NCT00646438|Active Comparator|1|strict glucose control (study arm)
9905041|NCT00646438|No Intervention|2|standard insulin treatment (control arm)
9905042|NCT00646464||2|Children 6-12 years old diagnosed as not suffering from ADHD
9905043|NCT00646464||1|children 6-12 diagnosed as ADHD
9905044|NCT00646477|Experimental|A|Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow
9905045|NCT00646477|Experimental|B|Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast
9905046|NCT00646477|Experimental|C|Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow
9905047|NCT00646477|Experimental|D|Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast
9905048|NCT00646490||A|patients with parapneumonic pleural effusion due to community acquired pneumonia
9905049|NCT00646490||B|patients with pleural effusion of other etiologies
9905050|NCT00646503|Experimental|1|600 mg/day, oral telbivudine for 52 weeks
9905051|NCT00646516|Experimental|1|
9905052|NCT00646529|Experimental|1|budesonide/formoterol
9905053|NCT00646529|Active Comparator|2|budesonide
9905054|NCT00646594|Experimental|1|budesonide/formoterol
9905055|NCT00646594|Active Comparator|2|fluticasone/salmeterol
9905056|NCT00646607|Experimental|A|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 3 months or XELOX (capecitabine and oxaliplatin) for 12 weeks.
9905057|NCT00646607|Active Comparator|B|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 6 months or XELOX (capecitabine and oxaliplatin) for 24 weeks.
9905058|NCT00646620|Experimental|1|budesonide/formoterol
9905059|NCT00646620|Active Comparator|2|fluticasone/salmeterol
9905060|NCT00646620|Active Comparator|3|albuterol
9905061|NCT00646633|Active Comparator|Acupuncture & educ|Patients will receive a total of 8 acupuncture treatments. In each of the first four sessions, they will also receive patient education.
9905062|NCT00646633|No Intervention|2. Standard care|Patients in the control arm will continue to receive standard care from their physician.
9905063|NCT00646685|Other|1|
9905064|NCT00646685|Other|2|
9905065|NCT00646698||1|Premenopausal Upper Body Obese (UBO) women with waist-hip ratio > 0.85 and BMI > 28
9905066|NCT00646698||2|Premenopausal Lower Body Obese (LBO) women with waist hip ratio < 0.8 and BMI > 28
9905067|NCT00646698||3|Premenopausal lean women with BMI < 25
9905068|NCT00646711|Experimental|Sequence Group I|Depakote Delayed Release/Depakote Sprinkle
9905069|NCT00646711|Experimental|Sequence Group II|Depakote ER
9905070|NCT00646724|Experimental|1|cotransplantation of islet and mesenchymal stem cell
9905071|NCT00646737|Experimental|1|Mycophenolate sodium
9905072|NCT00646750|Experimental|1|BEAM preceded by Ybritumomab Tiuxetan (Zevalin)
9905073|NCT00646789|Experimental|1|MK0633
9905074|NCT00646802|Active Comparator|A|Progesterone 200 mg
9905075|NCT00646802|Placebo Comparator|B|Placebo
9905076|NCT00646815|Experimental|a|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency
9905077|NCT00646815|No Intervention|Control|Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.
9905078|NCT00646828||without PHA1|patients without mineralocorticoid receptor mutation
9905079|NCT00646828||PHA 1|patients with a rare disease, pseudohypoaldosteronism type 1, due to heterozygous inactivating mutations of the mineralocorticoid receptor
9905080|NCT00646841|Experimental|A|
9905081|NCT00646854|Active Comparator|Arm A|
9905082|NCT00646854|Experimental|Arm B|
9905083|NCT00646867|Experimental|1|Experimental
9905084|NCT00646867|Placebo Comparator|2|Placebo
9905085|NCT00646880|Active Comparator|Propiverine/tolterodine group|
9905086|NCT00646880|Active Comparator|Tolerodine/propiverine group|
9905087|NCT00646893|No Intervention|1|Control: assisted hatching, without Preimplantation Genetic Diagnosis
9905088|NCT00646893|Experimental|2|Test: embryo biopsy with Preimplantation Genetic Diagnosis
9905089|NCT00646919||1|All pre-operative pediatric patients in our outpatient clinic
9905090|NCT00646932|Experimental|1|
9905091|NCT00646932|Experimental|2|
9905092|NCT00646932|Experimental|3|
9905093|NCT00646932|Experimental|4|
9905094|NCT00646945|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
9905095|NCT00646945|Placebo Comparator|B|50% oxygen/50% Nitrogen premix
9905096|NCT00646971|Experimental|1|CPAP
9905097|NCT00646971|Sham Comparator|2|sham CPAP
9905098|NCT00646984|Active Comparator|1|Standard continuous antiretroviral therapy
9905099|NCT00646984|Experimental|2|CD-4 guided interruption arm
9905100|NCT00646984|Experimental|3|Viral load driven treatment interruption
9933622|NCT05350176|Placebo Comparator|Placebo group|
10213940|NCT02581085|Placebo Comparator|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
10213941|NCT02581085|Active Comparator|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
9905101|NCT00646997||1|Patients with postoperative atrial fibrillation
9905102|NCT00646997||2|Patients without postoperative atrial fibrillation.
9905103|NCT00647023|Experimental|A|
9905104|NCT00647049|Experimental|A|first diagnosis of PCNSL: combined chemotherapy with methotrexate
9905105|NCT00647049|Experimental|B|Patients with relapse or progressive disease of PCNSL after methotrexate containing chemotherapy
9905106|NCT00647075|Experimental|1|Yunzhi extract 3.5 g/day
9905107|NCT00647075|Placebo Comparator|2|Placebo
9905108|NCT00647088||aortic stenosis|various age and disease severity
9905109|NCT00647088||Controls|Controls free of valvular disease
9905110|NCT00647101|Experimental|Latanoprost group|
9905111|NCT00647114|Experimental|1|V930
9905112|NCT00647114|Experimental|2|V932
9905113|NCT00647127|Active Comparator|Buprenorphine|
9905114|NCT00647127|Active Comparator|Fentanyl|
9905115|NCT00647127|Placebo Comparator|Placebo|
9905116|NCT00647140|Experimental|1|18F-L6DOPA PET
9905117|NCT00647153|Experimental|Radiation: iodine I 123 anti-CEA recombinant diabody T84.66|
9905118|NCT00647166|Experimental|1|Drug: corticosteroid and azathioprine
9905119|NCT00647166|Placebo Comparator|2|Drug: corticosteroid and placebo
9905120|NCT00647179||1|Patients recently diagnosed with acromegaly
9905121|NCT00647192|Active Comparator|1|Eplerenone treatment
9905122|NCT00647192|Placebo Comparator|2|
9905123|NCT00647205|Sham Comparator|1|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count > 350/mm3
9905124|NCT00647205|Sham Comparator|2|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 < 350/mm3)
9905125|NCT00647205|Sham Comparator|3|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 < 350/mm3)
9905126|NCT00647205|Sham Comparator|4|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 > 350/mm3)
9905127|NCT00647205|Sham Comparator|5|HIV infected patients with active TB
9905128|NCT00647205|Sham Comparator|6|HIV negative patients with active TB
9905129|NCT00647218|Experimental|Experimental|
9905130|NCT00647244|Active Comparator|1|Tenofovir
9905131|NCT00647244|Active Comparator|2|Abacavir
9905132|NCT00647257|Active Comparator|A|
9905133|NCT00647257|Placebo Comparator|B|
9905134|NCT00647283|Experimental|1|Stable liver transplant recipients fulfilling inclusion criteria.
9905135|NCT00647309||1|
9905136|NCT00647309||2|
9905137|NCT00647322|Experimental|1|Reduction in anti-epileptic medications
9905138|NCT00647322|Active Comparator|2|No change in medication. Unchanged treatment
9905139|NCT00647335||1|Women with diagnosis of PCOS
9905140|NCT00647361|Experimental|NAVA|
9905141|NCT00647374||1|
9905142|NCT00647413|No Intervention|1|
10213942|NCT02579096|Active Comparator|allopurinol / Sham Comparator (febuxostat)|Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling febuxostat will be given with allopurinol
10213943|NCT02579096|Active Comparator|febuxostat / Sham Comparator (allopurinol)|febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling allopurinol will be given with febuxostat
10213944|NCT02577406|Experimental|AG-221 plus Best supportive care (BSC)|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
10213945|NCT02577406|Active Comparator|Conventional care regimen (CCR)|Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
10213946|NCT02553733|Active Comparator|Beetroot juice (Beet-It Organic Shot)|Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
10213947|NCT02553733|Placebo Comparator|Beetroot juice placebo (Beet-It Organic Placebo)|Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
10213948|NCT02552277|Experimental|PDA-002 Dose Level 1: 3 x 10^6 cells|3 x 10^6 PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
10213949|NCT02552277|Experimental|PDA-002 Dose Level 2: 30 x 10^6 cells|30 x 10^6 PDA-002 cells administered IM on study Days 1, 29, and 57.
10213950|NCT02552277|Placebo Comparator|Placebo|Subjects will receive placebo administered IM on study days 1, 29, and 57.
10213951|NCT02538666|Experimental|Nivolumab monotherapy|Nivolumab intravenous fusion
10213952|NCT02538666|Experimental|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
10213953|NCT02538666|Placebo Comparator|Placebo|Placebo
10213954|NCT02536118||Patients implanted with Micra System|Patients implanted with a Micra Transcatheter Pacing System are eligible for enrollment into the Micra PA Registry.
10213955|NCT02527200|Experimental|Liraglutide|
10213956|NCT02527200|Placebo Comparator|Placebo|
10213957|NCT02516696|Experimental|BiRD treatment regimen|Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
10213958|NCT02516696|Active Comparator|Rd treatment regimen|Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
9905143|NCT00647413|Experimental|2|expert system intervention on smoking behaviour + feedback of a biomarker
9905144|NCT00647452|Experimental|1|Healthy male volunteers
9905145|NCT00647452|Experimental|2|Healthy female volunteers
9905146|NCT00647465|Active Comparator|1|IFNalpha 2b
9905147|NCT00647465|Placebo Comparator|2|Placebo
9905148|NCT00647478||1|AD
9905149|NCT00647478||2|Control elderly subjects with normal cognitive function
9905150|NCT00647478||3|MCI
9905151|NCT00647491|Experimental|20 mg|20 mg adalimumab eow
9905152|NCT00647491|Experimental|40 mg|40 mg adalimumab eow
9905153|NCT00647491|Experimental|80 mg|80 mg adalimumab eow
9905154|NCT00647491|Placebo Comparator|Placebo|Placebo eow
9905155|NCT00647504||1|Restenosis in Bare metal stent
9905156|NCT00647504||2|Restenosis in Drug eluting stent
9905157|NCT00647504||3|Stent thrombosis
9905158|NCT00647504||4|Control group
9905159|NCT00647517|Experimental|ultracet|
9905160|NCT00647517|Placebo Comparator|placebo|
9905161|NCT00647530|Experimental|Pre&Post Op Chemo|12 weeks of OxFP neuoadjuvantly followed by surgery and 18 weeks of OxFP
9905162|NCT00647530|Experimental|Pre&Post Op Chemo with P-mab|12 weeks of OxFP and panitumumab neuoadjuvantly followed by surgery and 18 weeks of OxFP alone.
9905163|NCT00647530|Active Comparator|Post Op Chemo|surgery followed by 24 weeks of OxFP.
9905164|NCT00647543|Experimental|High Risk|
9905165|NCT00647543|Experimental|Low Risk|
9905166|NCT00647543|Experimental|Medium Risk|
9905167|NCT00647569|Experimental|A|No previous major abdominal surgery
9905168|NCT00647569|Experimental|B|Previous major abdominal surgery
9905169|NCT00647595|Experimental|A|Women in this group will exercise 3x per week at a moderate/vigorous level for 45 min per session through their 36 week of pregnancy.
9905170|NCT00647595|No Intervention|B|Women in this group will continue their usual activities throughout their pregnancy.
9905171|NCT00647608|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
10213959|NCT02511106|Experimental|AZD9291|AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
10213960|NCT02511106|Placebo Comparator|Placebo AZD9291|Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
10213961|NCT02496936|Experimental|Saturated Fat (SFA)|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
10213962|NCT02496936|Experimental|Monounsaturated Fat (MUFA)|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
10213963|NCT02496936|Experimental|Polyunsaturated Fat Linoleic (PUFA-LA)|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
10213964|NCT02496936|Experimental|Polyunsaturated Fat Alpha-Linolenic (ALA)|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
10213965|NCT02496936|Experimental|Polyunsaturated Fat Long Chain Omega-3 (LCn3)|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
10213966|NCT02491099|Experimental|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
10213967|NCT02477358|Experimental|PRF Treated|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
10213968|NCT02477358|No Intervention|Control|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
10213969|NCT02476058|Experimental|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
10213970|NCT02476058|Experimental|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
10213971|NCT02476058|Placebo Comparator|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
10213972|NCT02468596|Experimental|Patients|Patients suffering from anti-MAG neuropathy
10213973|NCT02451553|Experimental|Treatment (afatinib dimaleate, capecitabine)|Patients receive afatinib dimaleate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10213974|NCT02432209|Active Comparator|Intensive Lifestyle Mod. Intervention|The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is brand name Orlistat, a gastric lipase inhibitor that limits gut fat absorption), and moderate physical activity (goal of reaching 10,000 steps a day). The pretreatment intervention will last 16 weeks and is designed to promote a weight loss of approximately 7% of total body weight.
10213975|NCT02432209|Placebo Comparator|Standard Lifestyle Intervention|Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detailed instruction of physical activity will not be provided.
10213976|NCT02432092||Affected|participants with cardiomyopathy
10213977|NCT02432092||Family Members of affected|Family members of participants with cardiomyopathy (can be affected or unaffected)
10213978|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
9905172|NCT00647608|Active Comparator|2|Inderal® LA Capsules 160 mg
9905173|NCT00647621|Experimental|1|Extended Phenytoin Sodium Capsules 100 mg
9905174|NCT00647621|Active Comparator|2|Dilantin® Kapseals® 100 mg
9905175|NCT00647634|Experimental|1|Alprazolam Extended-Release Tablets 3 mg;
9905176|NCT00647634|Active Comparator|2|Xanax XR® Tablets 3 mg
9905177|NCT00647647|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
9905178|NCT00647647|Active Comparator|2|Lamisil® Tablets 250 mg
9905179|NCT00647660|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
9905180|NCT00647660|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
9905181|NCT00647673|Experimental|1|Verapamil HCL Extended-Release Capsules 300 mg
9905182|NCT00647673|Active Comparator|2|Verelan® PM Extended-release Capsules 300 mg
9905183|NCT00647686|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
9905184|NCT00647686|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
9905185|NCT00647712|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
9905186|NCT00647712|Active Comparator|2|Depakote ER® Tablets 500 mg
9905187|NCT00647725|Active Comparator|I|Active phrase analgesia
9905188|NCT00647725|Active Comparator|II|Latent phrase analgesia
9905189|NCT00647738|Experimental|1|
9905190|NCT00647738|Active Comparator|2|
9905191|NCT00647751|Experimental|1|Lamotrigine Tablets 25 mg
9905192|NCT00647751|Active Comparator|2|Lamictal® Tablets 25 mg
9905193|NCT00647764|Experimental|Single Arm|
9905194|NCT00647777|Experimental|1|Olanzapine Tablets 5 mg
9905195|NCT00647777|Active Comparator|2|Zyprexa® Tablets 5 mg
9905196|NCT00647790||1|Patients with a confirmed diagnosis of invasive breast cancer who are undergoing surgery.
9905197|NCT00647816|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
9905198|NCT00647816|Active Comparator|2|Inderal® LA Capsules 160 mg
9905199|NCT00647829|Active Comparator|Arm 1|
9905200|NCT00647829|Active Comparator|Arm 2|
9905201|NCT00647829|Placebo Comparator|Arm 3|
9905202|NCT00647842|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
9905203|NCT00647842|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
9905204|NCT00647855|Experimental|1|Levothyroxine Sodium Tablets 300 μg
9905205|NCT00647855|Active Comparator|2|Synthroid® Tablets 300 μg
9905206|NCT00647868|Experimental|Groups 1 and 2|Twice daily (7:00 am and 12:00 am or 7:00 am and 10:00 pm) dosing with intranasal testosterone for 14 days
9905207|NCT00647868|Experimental|Groups 3a and b|Single daily administration of testosterone (at 7:00 am or 10:00 pm) for 14 days
9905208|NCT00647868|No Intervention|Group 4|24-h blood sampling in healthy eugonadal controls
9905209|NCT00647881|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
9905210|NCT00647881|Active Comparator|2|Paxil CR™ Tablets 25 mg
9905211|NCT00647894|Experimental|1|Alprazolam Extended-Release Tablets 1 mg
9905212|NCT00647894|Active Comparator|2|Xanax XR Tablets 1 mg
9905213|NCT00647907|Experimental|A|
9905214|NCT00647920|Experimental|40 mg|
9905215|NCT00647920|Placebo Comparator|Placebo|
9905216|NCT00647946|Experimental|A|Stop zidovudine (ZDV) or stavudine (d4T) and start tenofovir DF 300mg once daily along with the other antiviral drugs that are used as part of their HAART regimen
9905217|NCT00647946|Active Comparator|B|Stop zidovudine (ZDV) or stavudine (d4T) and start abacavir 300mg twice daily along with the other antiviral drugs that are used as part of their HAART regimen
9905218|NCT00647959|Experimental|1|Doxycycline Tablets, 150mg
9905219|NCT00647959|Active Comparator|2|Adoxa Tablets 150 mg
9905220|NCT00647972|Experimental|1|Olanzapine Tablets 20 mg
9905221|NCT00647972|Active Comparator|2|Zyprexa® Tablets 20 mg
9905222|NCT00647985|Experimental|1|Fexofenadine Tablets 180 mg
9905223|NCT00647985|Active Comparator|2|Allegra® Tablets 180 mg
9905224|NCT00648011|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
9905225|NCT00648011|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
9905226|NCT00648024|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
9905227|NCT00648024|Active Comparator|2|Agrylin® Capsules 1 mg
9905228|NCT00648050|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
9905229|NCT00648050|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
9905230|NCT00648063|Experimental|1|Letrozole Tablets 2.5 mg
9905231|NCT00648063|Active Comparator|2|Femara® Tablets 2.5 mg
9905232|NCT00648076|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
9905233|NCT00648076|Active Comparator|2|Depakote ER® Tablets 500 mg
9905234|NCT00648089|Experimental|1|
9905235|NCT00648089|No Intervention|2|
9905236|NCT00648128|Active Comparator|2|
9905237|NCT00648128|Experimental|1|
9905238|NCT00648141|Experimental|A|
9905239|NCT00648141|Experimental|B|
9905240|NCT00648141|Active Comparator|C|
9905241|NCT00648154|Experimental|1|Letrozole Tablets 2.5 mg
9905242|NCT00648154|Active Comparator|2|Femara® Tablets 2.5 mg
9905243|NCT00648180|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
9905244|NCT00648180|Active Comparator|2|Adoxa Tablets 100 mg
9905245|NCT00648193|Experimental|1|Paroxetine hydrochloride 40 mg tablet
9905246|NCT00648193|Active Comparator|2|Paxil® 40 mg Table
9905247|NCT00648206||1|drivers of motorised vehicles suspected of driving under the influence of psychoactive drugs or alcohol
9905248|NCT00648206||2|drivers stopped in police traffic controls and breathalysed positive for alcohol
9905249|NCT00648219|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
9905250|NCT00648219|Active Comparator|2|Benicar® Tablets 40 mg
9905251|NCT00648232|Experimental|A|Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
9905252|NCT00648232|Experimental|B|Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
9905253|NCT00648232|Experimental|C|Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
9905254|NCT00648232|Experimental|D|Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
9905255|NCT00648232|Active Comparator|E|Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
9905256|NCT00648232|Active Comparator|F|Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
9905257|NCT00648245|Experimental|1|
9905258|NCT00648245|Experimental|2|
9905259|NCT00648245|Experimental|3|
9905260|NCT00648245|Placebo Comparator|4|
9905261|NCT00648245|Experimental|5|
9905262|NCT00648258|Active Comparator|Arm 1|
9905263|NCT00648258|Active Comparator|Arm 2|
9905264|NCT00648271|Experimental|1|Metoprolol Tartrate Tablets 25 mg
9905265|NCT00648271|Active Comparator|2|Lopressor® Tablets 50 mg
9905266|NCT00648297|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
9905267|NCT00648297|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
9905268|NCT00648310|Active Comparator|1|arm 1: Tolterodine 4 mg once daily for 12 weeks
9905269|NCT00648310|Experimental|2|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
9905270|NCT00648323|Experimental|A|
9905271|NCT00648336|Experimental|1|Mercaptopurine 50 mg
9905272|NCT00648336|Active Comparator|2|Purinethol® Tablets 50 mg
9905273|NCT00648349|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
9905274|NCT00648349|Active Comparator|2|Aciphex® Delayed-Release Tablets 20 mg
9905275|NCT00648362|Experimental|1|Glimepiride Tablets 1 mg
9905276|NCT00648362|Active Comparator|2|Amaryl® Tablets 1 mg
9905277|NCT00648388|Experimental|1|Cilostazol Tablets 100 mg
9905278|NCT00648388|Active Comparator|2|Pletal® Tablets 100 mg
9905279|NCT00648401|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
9905280|NCT00648401|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
9933623|NCT05350163|Experimental|HLA Matched Cohort 1|5 x 105/kg at 6-7, 4-5 and 2-3 weeks post-transplant
9905281|NCT00648414|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
9905282|NCT00648414|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
9905283|NCT00648414|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
9905284|NCT00648414|Experimental|4|Duragesic 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
9905285|NCT00648414|Experimental|5|Duragesic 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
9905286|NCT00648414|Experimental|6|Duragesic 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
9905287|NCT00648427|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
9905288|NCT00648427|Active Comparator|2|Paxil CR™ Tablets 25 mg
9905289|NCT00648440|Experimental|1|Midodrine HCl Tablets 5 mg
9905290|NCT00648440|Active Comparator|2|ProAmatine® Tablets 5 mg
9905291|NCT00648466|Experimental|1|Sumatriptan Succinate Tablets 100 mg
9905292|NCT00648466|Active Comparator|2|Imitrex® Tablets 100 mg
9905293|NCT00648479|Experimental|1|
9905294|NCT00648479|Active Comparator|2|
9905295|NCT00648492|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
9905296|NCT00648492|Active Comparator|2|Glucophage® XR 500 mg
9905297|NCT00648505|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
9905298|NCT00648505|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
9905299|NCT00648518|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
9905300|NCT00648518|Active Comparator|2|Glucophage® XR Tablets 750 mg
9905301|NCT00648531|Experimental|1|Balsalazide Disodium Capsules 750 mg
9905302|NCT00648531|Active Comparator|2|Colazal® Capsules 750 mg
9933624|NCT05350163|Experimental|HLA Matched Cohort 2|5 x 105/kg starting time point X, 1 x 1 06/kg 3-4 weeks after first dose, 1 x 106/kg 3-4 weeks after second dose
9933625|NCT05350163|Experimental|HLA Matched Cohort 3|5 x 105/kg starting time point X, 1 x 1 06/kg 3-4 weeks after first dose, 3 x 106/kg 3-4 weeks after second dose
9933626|NCT05350163|Experimental|HLA Mismatched Cohort 1|1 x 105/kg at 6-7, 4-5 and 2-3 weeks post-transplant
9933627|NCT05350163|Experimental|HLA Mismatched Cohort 2|1 x 105/kg starting time point X, 5 x 1 05/kg 3-4 weeks after first dose, 5 x 105/kg 3-4 weeks after second dose
9933628|NCT05350163|Experimental|HLA Mismatched Cohort 3|1 x 105/kg starting time point X, 5 x 1 05/kg 3-4 weeks after first dose, 1 x 106/kg 3-4 weeks after second dose
9933629|NCT05348668|Experimental|Hybrid dose-fraction Radiotherapy Arm|Patients in this arm would receive hybrid dose-fraction radiotherapy combined with immune checkpoint inhibitors.
9933630|NCT05344157|Experimental|XSTEM-OA|Single intra-articular injection of XSTEM-OA
9933631|NCT05343715|Experimental|Agalsidase Beta from Biosidus|Participants received a single infusion at a dose 1 mg/kg
9933632|NCT05343715|Active Comparator|Fabrazyme (Sanofi-Genzyme)|Participants received a single infusion at a dose 1 mg/kg
9933633|NCT05342805|Experimental|Subtotal stomach|The vessels at the anastomosis of right and left gastric arteries were separated, then the proximal haft of lesser curvature and cardia was resected using linear staplers.
9933634|NCT05342805|Active Comparator|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler.
9933635|NCT05334121|Experimental|Product - Beta Alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
9933636|NCT05334121|Placebo Comparator|Control group - Placebo|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
9933637|NCT05333471|Experimental|Interventional|As this is a single arm study, this arm includes all participants. Participants will receive fecal microbiota transplantation (FMT) delivered by colonoscopy as a treatment for chronic granulomatous disease (CGD)-associated colitis (AC).
9933638|NCT05330013|No Intervention|Control|Healthy volunteers who are age and sex matched
9933639|NCT05330013|Experimental|Subjects with HFpEF|Subjects are defined as patients with a diagnosis of HFpEF clinically confirmed by a licensed physician or advanced practitioner who meet the inclusion and exclusion criteria and are able to provide informed consent.
9933640|NCT05328440|Experimental|Arm A|HR-positive/HER2-positive MBC
9933641|NCT05328440|Experimental|Arm B|HR-negative/HER2-positive MBC
9933642|NCT05328115|Active Comparator|ALZ-101 125 μg|Intra muscular injection of 125 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
9933643|NCT05328115|Active Comparator|ALZ-101 250 μg|Intra muscular injection of 250 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
9933644|NCT05328115|Placebo Comparator|Placebo|Saline solution mixed adjuvant and dosed once a month at four doses
9933645|NCT05328050||Achondroplasia|
9933646|NCT05328050||Hypochondroplasia|
9933647|NCT05327023|No Intervention|Donor Arm|Donors for Recipients in Arms 1-4
9905303|NCT00648544|Experimental|1|
9905304|NCT00648544|Active Comparator|2|
9905305|NCT00648557|Experimental|1|Levothyroxine Sodium Tablets 200 mg
9905306|NCT00648557|Active Comparator|2|Synthroid Tablets 200 mg
9905307|NCT00648570|Experimental|1|Escitalopram Oxalate Tablets 20 mg
9905308|NCT00648570|Active Comparator|2|Lexapro® Tablets 20 mg
9905309|NCT00648583|Experimental|1|Ondansetron Tablets 24 mg
9905310|NCT00648583|Active Comparator|2|Zofran® Tablets 24 mg
9905311|NCT00648596|Placebo Comparator|Arm 2|
9905312|NCT00648596|Active Comparator|Arm 1|
9905313|NCT00648609||Home-based palliative care services|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
9905314|NCT00648609||Standard of care|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
9905315|NCT00648622|Experimental|1|Carvedilol Tablets 12.5 mg
9905316|NCT00648622|Active Comparator|2|Coreg® Tablets 12.5 mg
9905318|NCT00648661|Experimental|1|Escitalopram Oxalate Tablets 20 mg
9905319|NCT00648661|Active Comparator|2|Lexapro® Tablets 20 mg
9905320|NCT00648674|Experimental|1|Apligraf
9905321|NCT00648687|Experimental|I|this group will receive oral water and glucose prior to eye exam
9905322|NCT00648687|No Intervention|II|this group is the control group.
9905323|NCT00648700|Experimental|1|Levothyroxine Sodium Tablets 300 μg
9905324|NCT00648700|Active Comparator|2|Levothroid® Tablets 300 μg
9905325|NCT00648713|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
9905326|NCT00648713|Active Comparator|2|Lamisil® Tablets 250 mg
9905327|NCT00648726|Active Comparator|Arm 1|
9905328|NCT00648726|Active Comparator|Arm 2|
9905329|NCT00648726|Active Comparator|Arm 3|
9905330|NCT00648765|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
9905331|NCT00648765|Active Comparator|2|Agrylin® Capsules 1 mg
9905332|NCT00648778|Experimental|1|Loxapine Succinate Capsules 25 mg
9905333|NCT00648778|Active Comparator|2|Loxitane® Capsules 25 mg
9905334|NCT00648791|Experimental|1|Finasteride Tablets 5 mg
9905335|NCT00648791|Active Comparator|2|Proscar Tablets 5 mg
9905336|NCT00648804|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
9905337|NCT00648804|Active Comparator|2|Zofran ODT® Tablets 8 mg
9905338|NCT00648817|Placebo Comparator|Group 1|"Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14 days of the study.~Tenofovir DF placebo tablet QD for the last 14 days of the study."
9905339|NCT00648817|Active Comparator|Group 2|"Tenofovir DF placebo tablet QD for the first 14 days of the study.~Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14 days of the study."
9905340|NCT00648830|Experimental|1|Clarithromycin 250 mg immediate-release oral tablet
9993779|NCT01475656||Phenobarbital as first line|Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug
9993780|NCT01475669|Experimental|Fibrinogen Concentrate (Human)|
9993781|NCT01475669|Placebo Comparator|Placebo|
9993782|NCT01475682||1|"167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point."
9993783|NCT01475695|Experimental|Single cohort|14C GSK2251052
9993784|NCT01475708||no symptoms|patients with erythema migrans and no additional newly onset symptoms treated with doxycycline
9993785|NCT01475708||mild symptoms|patients with erythema migrans and mild unspecific newly onset symptoms treated with doxycycline
9993786|NCT01475708||severe symptoms-lumbar puncture|"patients with erythema migrans and newly onset intense neurologic symptoms with lumbar puncture performed, treated with doxycycline"
9993787|NCT01475747||Observational - SPRINT trial subjects|Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
9993788|NCT01475760|Active Comparator|K2CG chewing gum (20 mg chitosan)|
9993789|NCT01475760|Active Comparator|K2CG chewing gum (60 mg chitosan)|
9993790|NCT01475760|No Intervention|Standard of Care|
9993791|NCT01475773||Adults (starting from age 17)|adults seeking orthodontic treatment at the university of Leuven
9993792|NCT01475799|Experimental|Percutaneous Aortic Valve 18F System|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
9993793|NCT01475812||COPD hyperinflation|
9993794|NCT01475864||Incomplete biliary stone extraction.|
9905341|NCT00648830|Active Comparator|2|Biaxin® (Clarithromycin) 250 mg tablet
9905342|NCT00648843|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
9905343|NCT00648843|Active Comparator|2|Ditropan XL® Tablets 5 mg
9905344|NCT00648856|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
9905345|NCT00648856|Active Comparator|2|Zoloft® Tablets 100 mg
9905346|NCT00648882|Experimental|1|LEVOTHYROXINE SODIUM TABLETS,USP 300 mcg;
9905347|NCT00648882|Active Comparator|2|SYNTHROID® 300 mcg Tablets
9905348|NCT00648921|Experimental|1|Olanzapine Tablets 5 mg
9905349|NCT00648921|Active Comparator|2|Zyprexa® Tablets 5 mg
9905350|NCT00648934|Experimental|1|Topiramate Sprinkle Capsules 25 mg
9905351|NCT00648934|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
9905352|NCT00648947|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
9905353|NCT00648947|Active Comparator|2|Plavix® Tablets 75 mg
9905354|NCT00648960|Experimental|1|
9905355|NCT00648960|Active Comparator|2|
9905356|NCT00648973|Experimental|1|Diphenhydramine 50 mg
9905357|NCT00648973|Experimental|2|Diphenhydramine 25 mg
9905358|NCT00648973|Active Comparator|3|Pseudoephedrine 120 mg
9905359|NCT00648986|Experimental|1|Uncontrolled, Open-Label Pilot Study
9905360|NCT00648999|Active Comparator|1|
9905361|NCT00648999|Active Comparator|2|
9905362|NCT00649012|Experimental|1|Pioglitazone HCl Tablets 45 mg
9905363|NCT00649012|Active Comparator|2|Actos® Tablets 45 mg
9905364|NCT00649038|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
9905365|NCT00649038|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
9905366|NCT00649051|Experimental|1|Metolazone Tablets 2.5 mg
9905367|NCT00649051|Active Comparator|2|Zaroloxyn® Tablets 2.5 mg
9905368|NCT00649064|Experimental|Ziprasidone|
9905369|NCT00649077|Experimental|1|Meloxicam Tablets 15 mg
9905370|NCT00649077|Active Comparator|2|Mobic® Tablets 15 mg
9905371|NCT00649090|Active Comparator|Exemestane group|
9905372|NCT00649103|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
9905373|NCT00649103|Active Comparator|2|Accupril® Tablets 40 mg
9905374|NCT00649116|Experimental|1|Metoprolol Tartrate Tablets 100 mg
9905375|NCT00649116|Active Comparator|2|Lopressor® Tablets 100 mg
9905376|NCT00649129|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
9905377|NCT00649129|Active Comparator|2|Ditropan XL® Tablets 10 mg
9905378|NCT00649142|Active Comparator|A|Open sutured mesh repair
9905379|NCT00649142|Active Comparator|B|Laparoscopic mesh glue fixation
9905380|NCT00649155|Experimental|1|Ciprofloxacin Extended-Release Tablets 500 mg
9905381|NCT00649155|Active Comparator|2|Cipro® XR Tablets 500 mg
9905382|NCT00649168|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
9905383|NCT00649168|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
9905384|NCT00649181|Experimental|1|Metolazone Tablets 5 mg
9905385|NCT00649181|Active Comparator|2|Zaroloxyn® Tablets 5 mg
9905386|NCT00649194|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
9905387|NCT00649194|Active Comparator|2|Aciphex® Tablets 20 mg
9905388|NCT00649207|Experimental|1|"This is an open label study; therefore, there are no numbered/labeled study arms.~This is a dose escalation study, ABT-888 dose will be escalated in conjunction with two schedules of whole brain radiation therapy (WBRT). Subjects may be treated WBRT for 3 weeks (15 days) or 2 weeks (10 days)."
9905389|NCT00649233|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
9905390|NCT00649233|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
9905391|NCT00649246||1|"controls:~healthy individuals with no family history of type 1 diabetes"
9905392|NCT00649246||2|"high-risk:~Subjects with islet autoantibodies or high-risk diabetes genes"
9905393|NCT00649246||3|"type 1 diabetes:~subjects with type 1 diabetes"
9905394|NCT00649259|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
9905395|NCT00649259|Active Comparator|2|Ditropan XL® Tablets 10 mg
9905396|NCT00649272|Experimental|1|Oxybutynin Chloride Extended-Release Tablets, 15 mg
9993795|NCT01475877||Nepafenac|
9905397|NCT00649272|Active Comparator|2|Ditropan XL® Extended-release tablets, 15 mg
9905398|NCT00649285|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
9905399|NCT00649285|Active Comparator|2|Macrobid® Capsules 100 mg
9905400|NCT00649298|Experimental|extended hours|24 or more hours per week of hemodialysis
9905401|NCT00649298|Active Comparator|standard hours|18 or less hours per week of hemodialysis
9905402|NCT00649311|Experimental|Eplerenone group|
9905403|NCT00649311|Active Comparator|Losartan group|
9905404|NCT00649324|Experimental|1|Hydrochlorothiazide Tablets 50 mg
9905405|NCT00649324|Active Comparator|2|Hydrochlorothiazide Tablets 50 mg
9905406|NCT00649337|Experimental|1|Adjunct screening with sonocine
9905407|NCT00649350|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
9905408|NCT00649350|Active Comparator|2|Glucophage XR 750 mg
9905409|NCT00649363|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
9905410|NCT00649363|Active Comparator|2|Zofran ODT® Tablets 8 mg
9905411|NCT00649376|Experimental|1|Fexofenadine Tablets 180 mg
9905412|NCT00649376|Active Comparator|2|Allegra® Tablets 180 mg
9905413|NCT00649402|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
9905414|NCT00649402|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
9905415|NCT00649415|Active Comparator|Arm 1|
9905416|NCT00649415|Active Comparator|Arm 2|
9905417|NCT00649441|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
9905418|NCT00649441|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
9905419|NCT00649454|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
9905420|NCT00649454|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
9905421|NCT00649467|Experimental|1|Topiramate Sprinkle Capsules 25 mg
9905422|NCT00649467|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
9905423|NCT00649480|Experimental|1|BALSALAZIDE DISODIUM CAPSULES, 750 MG
9905424|NCT00649480|Active Comparator|2|COLAZAL® Capsules 750 mg
9905425|NCT00649493|Experimental|1|Rabeprazole Sodium Tablets 20 mg
9905426|NCT00649493|Active Comparator|2|Aciphex® Tablets 20 mg
9905427|NCT00649506|Experimental|1|Nitrofurantoin Macrocrystals 100 mg Capsules
9905428|NCT00649506|Active Comparator|2|Macrodantin® 100 mg Capsules
9905429|NCT00649519|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
9905430|NCT00649519|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
9905431|NCT00649532|Experimental|1|Ondansetron Tablets 24 mg
9905432|NCT00649532|Active Comparator|2|Zofran® Tablets 24 mg
9905433|NCT00649558|Experimental|1|Pioglitazone HCl Tablets 45 mg
9905434|NCT00649558|Active Comparator|2|Actos® Tablets 45 mg
9905435|NCT00649571|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
9905436|NCT00649571|Active Comparator|2|Adoxa Tablets 100 mg
9905437|NCT00649584|Experimental|1|SGN-35 alone or in combination with gemcitabine
9905438|NCT00649597|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
9905439|NCT00649597|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
9905440|NCT00649610|Active Comparator|Arm 1|
9905441|NCT00649610|Active Comparator|Arm 2|
9905442|NCT00649623|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
9905443|NCT00649623|Active Comparator|2|Benicar® Tablets 40 mg
9905444|NCT00649636|Experimental|1|Fluoxetine Capsules 40 mg
9905445|NCT00649636|Active Comparator|2|Prozac Pulvules 40 mg
9905446|NCT00649649|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
9905447|NCT00649649|Active Comparator|2|Accupril® Tablets 40 mg
9905448|NCT00649662|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
9905449|NCT00649662|Active Comparator|2|Cipro® XR Tablets 1000 mg
9905450|NCT00649675|Experimental|1|Meloxicam Tablets 15 mg
9905451|NCT00649675|Active Comparator|2|Mobic® Tablets 15 mg
9905452|NCT00649688|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
9905453|NCT00649688|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
9905454|NCT00649701|No Intervention|1|
9905455|NCT00649701|Experimental|2|Text-based webpage
9905456|NCT00649701|Experimental|3|Talking about HIV video
9905457|NCT00649701|Experimental|4|The Morning After video
9905458|NCT00649701|Experimental|5|Both videos
9905459|NCT00649714|Experimental|1|Zonisamide Capsules 100 mg
9905460|NCT00649714|Active Comparator|2|Zonegran® Capsules 100 mg
9905461|NCT00649727|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
9905462|NCT00649727|Active Comparator|2|Ditropan XL® Tablets 10 mg
9905463|NCT00649740|Experimental|1|Topiramate Sprinkle Capsules 25 mg
9905464|NCT00649740|Active Comparator|2|Topamax® Sprinkle Capsule 25 mg
9905465|NCT00649753|No Intervention|A|
9905466|NCT00649753|Experimental|B|
9905467|NCT00649753|Experimental|C|
9905468|NCT00649753|Experimental|D|
9905469|NCT00649766|Active Comparator|1|tailored print messages to encourage eye examination behavior
9905470|NCT00649766|Active Comparator|2|targeted print messages to encourage eye examination behavior
9905471|NCT00649779|Experimental|1|albuterol sulfate extended-release 8 mg tablets
9905472|NCT00649779|Active Comparator|2|VoSpire™ ER 8 mg tablets
9905473|NCT00649805|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
9905474|NCT00649805|Active Comparator|2|Verelan® PM extended-release capsules controlled-onset 300 mg
9905475|NCT00649818|Experimental|1|Lorazepam Tablets 2 mg
9905476|NCT00649818|Active Comparator|2|Ativan Tablets 2 mg
9905477|NCT00649831|Active Comparator|Group 2|
9905478|NCT00649831|Active Comparator|Group 1|
9905479|NCT00649844|Active Comparator|A|
9905480|NCT00649844|Experimental|B|
9905481|NCT00649857|Experimental|1|Cetirizine HCl Tablets 10 mg
9905482|NCT00649857|Active Comparator|2|Zyrtec® 10 mg
9905483|NCT00649870|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
9905484|NCT00649870|Active Comparator|2|Valtrex® Tablets 1000 mg
9905485|NCT00649883|Experimental|1|
9905486|NCT00649883|Active Comparator|2|
9905487|NCT00649896|Experimental|1|Mylan Estradiol Transdermal System 0.025 mg/day
9905488|NCT00649896|Active Comparator|2|Climara® Transdermal System 0.025 mg/day
9905489|NCT00649909||Observation|Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c >8%.
9905490|NCT00649922|Placebo Comparator|Double Blind|
9905491|NCT00649922|Experimental|Open Label|
9905492|NCT00649935|Experimental|1|Azithromycin Tablets 600 mg
9905493|NCT00649935|Active Comparator|2|Zithromax® Tablets 600 mg
9905494|NCT00649948|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
9905495|NCT00649948|Active Comparator|2|Glucophage XR 500 mg
9905496|NCT00649974|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
9905497|NCT00649974|Active Comparator|2|Valtrex® Tablets 1000 mg
9905498|NCT00649987|Experimental|1|Albuterol Sulfate Extended-Release Tablets 8 mg
9905499|NCT00649987|Active Comparator|2|VoSpire® ER Tablets 8 mg
9905500|NCT00650000|Experimental|1|Modafinil Tablets 200 mg
9905501|NCT00650000|Active Comparator|2|Provigil® Tablets 200 mg
9905502|NCT00650013|Experimental|1|Midodrine HCl Tablets 5 mg
9905503|NCT00650013|Active Comparator|2|ProAmatine® Tablets 5 mg
9905504|NCT00650039|Active Comparator|Arm 1|
9905505|NCT00650039|Active Comparator|Arm 2|
9905506|NCT00650039|Placebo Comparator|Arm 3|
9905507|NCT00650052|Experimental|1|Zonisamide Capsules 100 mg
9905508|NCT00650052|Active Comparator|2|Zonegran® Capsules 100 mg
9905509|NCT00650065|Experimental|1|Cetirizine HCl Tablets 10 mg
9905510|NCT00650065|Active Comparator|2|Zyrtec® Tablets 10 mg
9905511|NCT00650117|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
9905512|NCT00650117|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
9905513|NCT00650117|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
9905514|NCT00650117|Experimental|4|Duragesic 25 mcg/h + Scotch Duct Tape (3M)
9905515|NCT00650117|Experimental|5|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
9905516|NCT00650117|Experimental|6|Duragesic 25 mcg/h + Microfoam Tape (3M)
9905517|NCT00650130||1|drivers of motorised vehicles suspected of being under the influence of psychoactive drugs
9905518|NCT00650143|Active Comparator|1|"Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.~n=74"
9905519|NCT00650143|Placebo Comparator|2|"NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.~n=74"
9905520|NCT00650156|Experimental|40 mg adalimumab|
9905521|NCT00650156|Experimental|80 mg Adalimumab|
9905522|NCT00650169|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
9905523|NCT00650169|Active Comparator|2|Plavix® Tablets 75 mg
9905524|NCT00650195|Experimental|1|Metolazone Tablets 10 mg
9905525|NCT00650195|Active Comparator|2|Zaroloxyn® Tablets 10 mg
9905526|NCT00650208|Experimental|1|Lamotrigine Tablets 25 mg
9905527|NCT00650208|Active Comparator|2|Lamictal® Tablets 25 mg
9905528|NCT00650221|Experimental|1|
9905529|NCT00650221|Active Comparator|2|
9905530|NCT00650234|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
9905531|NCT00650234|Active Comparator|2|Glucophage® XR Tablets 500 mg
9905532|NCT00650247|Experimental|1|Sumatriptan Succinate Tablets 100 mg
9905533|NCT00650247|Active Comparator|2|Imitrex® Tablets 100 mg
9905534|NCT00650273|Experimental|1|Azithromycin Tablets 600 mg
9905535|NCT00650273|Active Comparator|2|Zithromax® Tablets 600 mg
9905536|NCT00650286|Experimental|1|Modafinil Tablets 200 mg
9905537|NCT00650286|Active Comparator|2|Provigil® Tablets 200 mg
9905538|NCT00650299|Experimental|1|Alprazolam Extended-release Tablets 3 mg
9905539|NCT00650299|Active Comparator|2|Xanax XR® Tablets 3 mg
9905540|NCT00650312|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
9905541|NCT00650312|Active Comparator|2|Glucophage® XR Tablets 500 mg
9905542|NCT00650325|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
9905543|NCT00650325|Active Comparator|2|Zoloft® Tablets 100 mg
9905544|NCT00650338|Experimental|1|<described in intervention>
9905545|NCT00650338|Experimental|2|<described in intervention>
9905546|NCT00650338|Experimental|3|<described in intervention>
9905547|NCT00650338|Placebo Comparator|4|<described in intervention>
9905548|NCT00650338|Active Comparator|5|<described intervention>
9905549|NCT00650351|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
9905550|NCT00650351|Active Comparator|2|Cipro® XR Tablets 1000 mg
9905551|NCT00650364|Experimental|1|Midodrine HCl Tablets 5 mg
9905552|NCT00650364|Active Comparator|2|ProAmatine® Tablets 5 mg
9905553|NCT00650377|Experimental|1|Finasteride Tablets 5 mg
9905554|NCT00650377|Active Comparator|2|Proscar® Tablets 5 mg
9905555|NCT00650403|Experimental|1|Paroxetine hydrochloride 40 mg tablet
9905556|NCT00650403|Active Comparator|2|Paxil® 40 mg Tablet
9905557|NCT00650416|Experimental|1|Carvedilol Tablets 12.5 mg
9905558|NCT00650416|Active Comparator|2|Coreg® Tablets 12.5 mg
9905559|NCT00650429|Experimental|Arm A|
9905560|NCT00650442|Experimental|1|Estradiol Transdermal System Placebo - Alternate Adhesive
9905561|NCT00650442|Placebo Comparator|2|Estradiol Transdermal System Placebo - Current Adhesive
9905562|NCT00650455|Active Comparator|Arm 2|
9905563|NCT00650455|Placebo Comparator|Arm 3|
9905564|NCT00650455|Active Comparator|Arm 1|
9905565|NCT00650468|Experimental|1|early steroid cessation
9905566|NCT00650468|Experimental|2|long-term maintenance steroids
9905567|NCT00650481|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
9905568|NCT00650481|Active Comparator|2|Ditropan XL® Tablets 5 mg
9905569|NCT00650494|Experimental|1|Valacyclovir Hydrochloride Tablets 1000mg
9905570|NCT00650494|Active Comparator|2|Valtrex® Tablets 1000 mg
9905571|NCT00650507|Experimental|1|
9905572|NCT00650507|Active Comparator|2|
9905573|NCT00650520|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
9905574|NCT00650520|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
9905575|NCT00650533|Experimental|1|Glimepiride Tablets 1 mg
9905576|NCT00650533|Active Comparator|2|Amaryl® Tablets 1 mg
9905577|NCT00650559|Experimental|1|Experimental surgical intervention.
9905578|NCT00650572|Experimental|ARRY-380|
9905579|NCT00650598|Active Comparator|Arm 1|
9905580|NCT00650598|Active Comparator|Arm 2|
9905581|NCT00650611|Active Comparator|Low-Dose Ziprasidone|
9905582|NCT00650611|Active Comparator|High-Dose Ziprasidone|
9905583|NCT00650624|Active Comparator|Arm 1|
9905584|NCT00650624|Active Comparator|Arm 2|
9905585|NCT00650624|Active Comparator|Arm 3|
9905586|NCT00650624|Placebo Comparator|Arm 4|
9905587|NCT00650637|Experimental|1|
9905588|NCT00650637|Experimental|2|
9905589|NCT00650676||A|
9905590|NCT00650715|Active Comparator|VG|Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
9905591|NCT00650715|Placebo Comparator|CG|The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
9905592|NCT00650741||1|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), no repetition of test
9905593|NCT00650741||2|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), Repetition with Nitroglycerin
9905594|NCT00650741||3|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), repetition of test with the Endotect
9905595|NCT00650754|Experimental|DHEA|Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
9905596|NCT00650754|Placebo Comparator|Placebo|Blinded placebo
9905597|NCT00650780||1|All of the subjects will have measurements of Gc concentration and phenotype
9905598|NCT00650884|No Intervention|1|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CONTROL PATIENTS will only be treated with Standard of Care during this 12 week trial, but will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch after completion of this study.
9905599|NCT00650884|Experimental|2|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). EXPERIMENTAL PATIENTS will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
9905600|NCT00650884|Other|3|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CROSS-OVER patients will be initially treated only with Standard of Care, and after six weeks, they will be Crossed-Over and fit with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
9905601|NCT00650897|Experimental|A|Patients with Diabetes Mellitus and Major Depression
9993796|NCT01475890|Active Comparator|7000IU/day|29 subjects will be randomized to receive 7000IU/day of vitamin D3.
9905602|NCT00650910|Experimental|lapatinib + digoxin|All subjects received 0.5mg digoxin on Days 1 and 9 with daily dosing of 1500mg oral lapatinib starting on Day 2 and continuing through Day 9. Subjects could continue past Day 9 on daily oral lapatinib until Week 10 when they could transfer into a rollover study (EGF19060 or EGF111767).
9905603|NCT00650923|Experimental|Arm 1|See Detailed Description
9905604|NCT00650962|Active Comparator|CPR first|Compression First (CF)
9905605|NCT00650962|Active Comparator|Analysis First|Rhythm analysis first
9905606|NCT00650975|Active Comparator|ELCA|Laser Thromboablation
9905607|NCT00650975|Active Comparator|PTCA|PTCA (Direct Stenting)
9905608|NCT00650988|Experimental|Barrett's Esophagus with intramucosal carcinoma (IMCA)|
9905609|NCT00650988|Experimental|Barrett's Esophagus with High Grade Dysplasia (HGD)|
9905610|NCT00651027|Experimental|A|
9905611|NCT00651027|Experimental|B|
9905612|NCT00651027|Experimental|C|200 mg
9905613|NCT00651066|Experimental|1|RBT (150 mg TPW during 3 weeks switch to 150mg OD for the following 3 weeks) associated with LPV/r based ART
9905614|NCT00651066|Experimental|2|RBT (150 mg OD during 3 weeks switch to 150mg TPW for the following 3 weeks) associated with LPV/r based ART
9905615|NCT00651092|Active Comparator|A1|since the two methods of turbinectomy are in used on a regular basis there is no way to perform double blind study- both the surgeon and the patients are well aware of the operation they are about to go. we just compare several parameters in patients who are anyway about to undergo an operation in a specific method that is used by their surgeon
9905616|NCT00651092|Active Comparator|A2|the resection of the inferior turbinates will be performed endonasally with an endoscopical instruments
9905617|NCT00651105|Experimental|1|
9905618|NCT00651105|Placebo Comparator|2|
9905619|NCT00651196||1|Type 1 diabetics
9905620|NCT00651196||Healthy controls|Healthy age and sex matched controls
9905621|NCT00651209|Experimental|1|Sub-group 1- continue telbivudine if HBV DNA non-detectable at week 24 Sub-group 2- tenofovir added to telbivudine in patients if HBV DNA detectable at week 24
9905622|NCT00651222||1|All deceased patients who underwent brachytherapy at Chicago Prostate Center between 10/14/1997 and 6/15/2007
9993797|NCT01475890|Placebo Comparator|Placebo|29 subjects will be randomized to receive placebo.
9905623|NCT00651235|Experimental|B|In combination therapy,the maximal dose of Losartan is 100 mg/day for adult and 50 mg/day for children. 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children
9905624|NCT00651235|Active Comparator|A|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
9905625|NCT00651287|Active Comparator|quinapril 20 mg|
9905626|NCT00651287|Active Comparator|quinapril 20 mg+hydrochlorothiazide 12.5 mg|
9905627|NCT00651287|Active Comparator|quinapril 40 mg|
9905628|NCT00651300|Experimental|Group 1|
9905629|NCT00651300|Placebo Comparator|Group 2|
9905630|NCT00651326|Active Comparator|Antiandrogen; LHRH; Docetaxel, Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel
9905631|NCT00651326|Active Comparator|Antiandrogen; LHRH; Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)
9905632|NCT00651339||A|
9905633|NCT00651352|Experimental|2 mg nicotine prototype|2 mg nicotine prototype
9905634|NCT00651352|Active Comparator|2 mg nicotine lozenge|marketed formulation
9905635|NCT00651352|Experimental|4 mg nicotine prototype|4 mg
9905636|NCT00651352|Active Comparator|4 mg nicotine lozenge|4 mg
9905637|NCT00651365|Experimental|001|
9905638|NCT00651417|Active Comparator|1|Organic Germanium tablets 5 times a day
9905639|NCT00651417|Placebo Comparator|2|Placebo tablets 3 -5 times per day
9905640|NCT00651430||A|
9905641|NCT00651443|Experimental|1|
9905642|NCT00651456|Active Comparator|1|Standard Chemotherapy
9905643|NCT00651456|Experimental|2|Standard Chemotherapy + bevacizumab (Avastin)
9905644|NCT00651469|Experimental|Arm 1|
9905645|NCT00651469|Placebo Comparator|Arm 2|
9905646|NCT00651495|Experimental|1|Participants receive a $50 financial incentive if they view at least 3 of 5 patient decision aids in a group screening.
9905647|NCT00651495|Active Comparator|2|No financial incentive for watching patient decision aids in group screenings
9905648|NCT00651521||1|CKD stage 1 patients
9905649|NCT00651521||2|CKD stage 2 patients
9905650|NCT00651521||3|CKD stage 3a patients
9905651|NCT00651521||4|CKD stage 3b patients
9905652|NCT00651521||5|CKD stage 4 patients
9905653|NCT00651521||6|CKD stage 5 patients
9905654|NCT00651547|Experimental|1|
9905655|NCT00651547|Active Comparator|2|
9905656|NCT00651547|Active Comparator|3|
9905657|NCT00651586|Experimental|1|Gatifloxacin 0.3% ophthalmic solution
9905658|NCT00651586|Active Comparator|2|Ciprofloxacin 0.3% ophthalmic solution
9905659|NCT00651599|Placebo Comparator|Arm 2|
9905660|NCT00651599|Experimental|Arm 1|
9905661|NCT00651612|Experimental|1|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
9905662|NCT00651612|Active Comparator|2|Concurrent Brimonidine 0.2% and 0.5% Timolol
9905663|NCT00651651|Experimental|1|Symbicort
9905664|NCT00651651|Active Comparator|2|budesonide
9905665|NCT00651651|Active Comparator|3|formoterol
9905666|NCT00651677|Active Comparator|HAL Proctectomy|Hand-assisted laparoscopic proctectomy
9905667|NCT00651677|Active Comparator|SL Proctectomy|"straight laparoscopic proctectomy"
9905668|NCT00651690|Experimental|1|Botulinum Toxin Type A
9905669|NCT00651690|Placebo Comparator|2|Saline
9905670|NCT00651703|Experimental|1|
9905671|NCT00651703|Experimental|2|
9905672|NCT00651703|Experimental|3|
9905673|NCT00651703|Experimental|4|
9905674|NCT00651716||Allogeneic Stem Cell Transplant Patients|Patients undergoing allogeneic stem cell transplant (SCT). Potential study candidates will be identified by participating physicians.
9905675|NCT00651729|Experimental|1|Botulinum Toxin Type A
9905676|NCT00651768|Experimental|1|
9905677|NCT00651768|Sham Comparator|2|
9933648|NCT05327023|Experimental|Phase I Dose Escalation, Cohort 1 (matched)|DLI at escalating doses (1 x 10^6 CD3+ cells/kg, 3 x 10^6 CD3+ cells/kg, and 1 x 10^7 CD3+ cells/kg) on day +7 or +21 to assess for safety and determine Phase II dose (up to 18 evaluable patients)
9933649|NCT05327023|Experimental|Phase I Dose Escalation, Cohort 2 (haploidentical)|DLI at escalating doses (1 x 10^5 CD3+ cells/kg, 3 x 10^5 CD3+ cells/kg, and 1 x 10^6 CD3+ cells/kg) on day +7 or +21 to assess for safety and determine Phase II dose (up to 18 evaluable patients)
9933650|NCT05327023|Experimental|Phase II Efficacy, Cohort 1 (matched)|DLI at maximally tolerated, safe dose (from Phase I) to assess secondary clinical outcomes at this dosing level (up to 14 additional evaluable patients in each cohort)
9933651|NCT05327023|Experimental|Phase II Efficacy, Cohort 2 (haploidentical)|DLI at maximally tolerated, safe dose (from Phase I) to assess secondary clinical outcomes at this dosing level (up to 14 additional evaluable patients in each cohort)
9993798|NCT01475903||sleeve gastrectomy|
9993799|NCT01475929|Active Comparator|Probiotic low|Lower dose of probiotic supplement
9993800|NCT01475929|Placebo Comparator|Placebo|
9905678|NCT00651781|Experimental|1|"Phase I:3 dose levels Cytarabine (200 mg/m2- 500 mg/m2-1000 mg/m2) with scheme Flag-Ida in combination with Velcade until determinate the appropriate dose.~Phase II:~Fludarabine, Cytarabine and Idarubicin in combination with 2 times per week of Velcade administration. Each 28-day treatment, patients will be evaluated, and in absence of disease progression or unacceptable toxicity, patients will start second cycle with Bortezomib in monotherapy two times per week followed by a 10 days rest period. That is, patients who response with acceptable toxicity will receive the combined sequential scheme twice (as induction and consolidation)."
9905679|NCT00651833|Experimental|1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. Patient will also receive cisplatin, 75 mg/m2 as a 1- to 3-hour infusion on Day 1 of each cycle.
9905680|NCT00651846|Experimental|Arm 1|
9905681|NCT00651846|Active Comparator|Arm 2|
9905682|NCT00651859|Experimental|1|Bimatoprost 0.01% Ophthalmic Solution
9905683|NCT00651859|Experimental|2|Bimatoprost 0.03% Ophthalmic Solution
9905684|NCT00651859|Placebo Comparator|3|Bimatoprost Vehicle Ophthalmic Solution
9905685|NCT00651872||Marx|
9905686|NCT00651885|Placebo Comparator|2 arm|
9905687|NCT00651885|Experimental|1 arm|treprostinil dienthalomine
9905688|NCT00651898||A|This group will receive the circulating water garment
9905689|NCT00651898||B|This group will receive the circulating water mattress and be covered by a forced air warming device for both the upper body and lower body connected to two warmers.
9905690|NCT00651950||Operator Dependence|
9905691|NCT00651976|Experimental|treatment|
9905692|NCT00651989||A|healthy individuals
9905693|NCT00652002|Experimental|1|
9905694|NCT00652002|Active Comparator|2|budesonide
9905695|NCT00652002|Active Comparator|3|formoterol
9905696|NCT00652015||1|Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
9905697|NCT00652015||2|Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
9905698|NCT00652041|Experimental|1|Induction: 6 alternating cycles Bortezomib-Melfalan-Prednisone or Bortezomib- Adriamycine-Melfalan-Prednisone and Thalidomide-Cyclophosphamide-Dexamethasone, followed by other 6 maintenance cycles
9905699|NCT00652054|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
9905700|NCT00652067||1|Only one patient is being treated under a single patient IND.
9905701|NCT00652106|Experimental|1|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
9905702|NCT00652106|Active Comparator|2|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
9905703|NCT00652106|Active Comparator|3|0.2% brimonidine ophthalmic solution
9905704|NCT00652119|Experimental|Paclitaxel + Carboplatin + Avastin|"Paclitaxel Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.~Carboplatin Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.~Avastin Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle."
9905705|NCT00652132|Active Comparator|Arm I (cisplatin)|Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
9935759|NCT03235219|Experimental|Cohort 1 to 4: JNJ-64565111 or Placebo|Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.
9905706|NCT00652132|Experimental|Arm II (cisplatin + STS)|Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
9905707|NCT00652158|Experimental|A|
9905708|NCT00652171|Active Comparator|1|17 Patients - Mean age of 26 years old, 14 female and 3 male - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
9905709|NCT00652171|Placebo Comparator|2|17 Patients - 11 females and 6 males mean age of 29 years old - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
9905710|NCT00652184|Placebo Comparator|1|Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
9905711|NCT00652184|Active Comparator|2|Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10
9905712|NCT00652184|Experimental|3|Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
9905713|NCT00652184|Other|4|Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10
9905714|NCT00652197||Extraventricular Drainage|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
9905715|NCT00652210|Experimental|MPM|Subject tissue was reviewed using multiphoton microscopy
9905716|NCT00652223|Experimental|1|
9905717|NCT00652236||FCT|Patients passing a function- centred rehabilitation
9905718|NCT00652236||PCT|Patients passing a pain-centred rehabilitation
9993801|NCT01475929|Active Comparator|Probiotic high|Higher dose of probiotic supplement
9993802|NCT01475942|Active Comparator|Probiotic|Lactobacillus
9993803|NCT01475942|Placebo Comparator|Placebo|Sucrose
9993804|NCT01475968|Active Comparator|Ultrafine Air Pollution Particulate Matter|<2.5 microns concentrated from outside ambient air
9993805|NCT01475968|Sham Comparator|Filtered Air|Filtered Air
9993806|NCT01475981|Experimental|Dose 1 JTK-853 (fasted condition)|
9993807|NCT01475981|Experimental|Dose 2 JTK-853 (fasted condition)|
9993808|NCT01475981|Experimental|Dose 3 JTK-853 (fasted condition)|
9993809|NCT01475981|Experimental|Dose 2 JTK-853 (fed condition)|
9993810|NCT01475981|Experimental|Dose 3 JTK-853 (fed condition)|
9993811|NCT01475981|Experimental|Dose 4 JTK-853 (fed condition)|
9993812|NCT01475981|Experimental|Dose 5 JTK-853 (fed condition)|
9993813|NCT01475981|Experimental|Dose 6 JTK-853 (fed condition)|
9993814|NCT01475981|Experimental|Dose 7 JTK-853 (fed condition)|
9993815|NCT01475981|Experimental|Dose 5 JTK-853 (high-fat fed condition)|
9993816|NCT01475981|Placebo Comparator|Placebo|
9993817|NCT01475994|Experimental|Challenge with grass pollen|
9993818|NCT01475994|Placebo Comparator|Challenge with clean air|
9993819|NCT01476007|Experimental|oral Cobalamin (vitamin B12)|oral Cobalamin (vitamin B12)
9993820|NCT01476007|Experimental|intramuscular Cobalamin (vitamin B12)|intramuscular Cobalamin (vitamin B12)
9993821|NCT01476020||no clopidogrel 6 months after DES|Patients with a single treatment antiplatelet therapy (aspirin) 6 months after drug-eluting stent implantation (Xience V Abbott company), including a 12-, 24- and 36-month follow-up analysis.
9993822|NCT01476020||2 antiplatelet therapy 2 years after DES|patients with dual antiplatelet therapy with clopidogrel and aspirin 24 months after drug-eluting stent implantation, including a 12-, 24- and 36-month follow-up analysis.
9993823|NCT01476033|Active Comparator|fruit, berry and vegetable concentrate|20 ladies receive an encapsulated, powdered fruit, berry and vegetable concentrate for 8 weeks
9993824|NCT01476033|Placebo Comparator|20 women with placebo|placebo for 8 weeks
9993825|NCT01476046|Experimental|GSK1995057|Single intravenous dose
9993826|NCT01476046|Placebo Comparator|Placebo|Single intravenous dose
9993827|NCT01476059|Other|telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
9993828|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
9993829|NCT01476072|No Intervention|no treatment|MRI scans only
9993830|NCT01476085|No Intervention|no treatment|no treatment
9905719|NCT00652249||Extraventricular Drainage/Pressure|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
9905720|NCT00652262|Experimental|Arm 1|
9905721|NCT00652275|Experimental|A|"Biological/Vaccine: 189 volunteers will receive the Malaria vaccine MSP3 Long Synthetic Peptide (LSP)~Arms: MSP3 LSP vaccine Biological/Vaccine:MSP3 LSP 30 micrograms of MSP3 LSP~Arms: I, MSP3 LSP vaccine"
9905722|NCT00652275|Active Comparator|B|189 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
9905723|NCT00652288|Active Comparator|Catheter day 4|Adolescents with type 1 diabetes with catheters day #4
9905724|NCT00652288|Active Comparator|Catheter day 1|Adolescents with type 1 diabetes with catheter day #1
9905725|NCT00652288|Active Comparator|Aspart and Detemir|Adolescents with type 1 diabetes
9905726|NCT00652288|Active Comparator|Lispro and Glargine|Adolescents with type 1 diabetes
9905727|NCT00652353|Experimental|Intervention|Participants will be given a standardized information sheet providing a mnemonics to help remember the Ottawa Ankle and foot Rules.
9905728|NCT00652353|Placebo Comparator|0|control group
9905729|NCT00652379|Experimental|1|Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
9905730|NCT00652379|Active Comparator|2|Somatostatin analog, unaltered dosage
9905731|NCT00652392|Experimental|1|
9905732|NCT00652392|Placebo Comparator|2|
9905733|NCT00652405|Experimental|treatment A|four weeks of white wine consumption (25g alcohol/day; ~2.5 standard drinks)
9905734|NCT00652405|Placebo Comparator|Treatment B|Four weeks of water
9905735|NCT00652418|Active Comparator|Arm 1|
9905736|NCT00652418|Experimental|Arm 2|
9905737|NCT00652470|Active Comparator|ETV|
9905738|NCT00652470|Active Comparator|CSF Shunt|
9905739|NCT00652483|Experimental|1|Brimonidine ophthalmic solution 0.1%
9905740|NCT00652483|Active Comparator|2|Brimonidine ophthalmic solution 0.2%
9905741|NCT00652496|Experimental|1|Bimatoprost 0.01% ophthalmic solution
9905742|NCT00652496|Experimental|2|Bimatoprost 0.015% formulation 1 ophthalmic solution
9905743|NCT00652496|Experimental|3|Bimatoprost 0.015% formulation 2 ophthalmic solution
9905744|NCT00652496|Experimental|4|Bimatoprost 0.02% ophthalmic solution
9905745|NCT00652496|Active Comparator|5|Bimatoprost 0.03% ophthalmic solution
9905746|NCT00652509|Experimental|1|IDEA
9905747|NCT00652509|Active Comparator|2|IE
9905748|NCT00652509|No Intervention|3|UC: Patients receive no research intervention.
9905749|NCT00652522|Active Comparator|A|Best Medical Treatment, ICD/CRT implant
9905750|NCT00652522|Experimental|B|AF Ablation, ICD/CRT implant
9905751|NCT00652561|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
9905752|NCT00652587|Experimental|A, LRTACE|hepatectomy with adjuvant transcatheter arterial chemoembolization
9905753|NCT00652587|Active Comparator|B, LR|hepatectomy alone
9905754|NCT00652600|Experimental|A|Subjects received Par formulated product under fed conditions
9905755|NCT00652600|Active Comparator|B|Subjects received Wyeth Pharmaceuticals formulated product under fed conditions
9905756|NCT00652613|Active Comparator|1|3 dimensional conformal radiotherapy
9905757|NCT00652613|Experimental|2|Intensity Modulated Radiation Therapy (IMRT)
9905758|NCT00652639|Experimental|A|Subjects received the kali formulated products under fasting conditions
9905759|NCT00652639|Active Comparator|B|Subjects received the Roche formulated products under fasting conditions
9905760|NCT00652665|Experimental|A|Subjects received kali product under fasting conditions
9905761|NCT00652665|Active Comparator|B|Subjects received Aventis product under fasting conditions
9905762|NCT00652704|Experimental|A|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions
9905763|NCT00652704|Active Comparator|B|Subjects received the reference product, Monodox (Oclassen) under fed conditions
9993831|NCT01476098|Placebo Comparator|Arm 1|incremental doses capsaicin
9905764|NCT00652704|Experimental|C|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions
9905765|NCT00652730|Experimental|A|Subjects received the Par formulated product under fasting conditions
9905766|NCT00652730|Experimental|B|Subjects received the Par formulated product under fed conditions
9905767|NCT00652730|Active Comparator|C|Subjects received the Bristol-Myers Squibb formulated product under fed conditions
9905768|NCT00652756|Experimental|1|Patient is placed on a transport ventilator.
9905769|NCT00652756|Other|2|Patient is ventilated using the current standard at this institution.
9905770|NCT00652769|Active Comparator|B|Control arm: Current practice for diagnosing and staging lung cancer. Most patients with intra-thoracic disease suspected of lung cancer will undergo bronchoscopy (or CT guided biopsy), PET scan and possibly mediastinoscopy.
9905771|NCT00652769|Experimental|A|Active arm: A new pathway for the diagnosis and staging of lung cancer with endobronchial (EBUS) or endoscopic ultrasound (EUS) as a first test. If EBUS or EUS is negative the patient will have PET scan +/- mediastinoscopy.
9905772|NCT00652782|Experimental|1|rolofyline 2.5 mg IV QD
9905773|NCT00652782|Experimental|2|rolofyline 15 mg IV QD
9905774|NCT00652782|Experimental|3|rolofyline 30 mg IV QD
9905775|NCT00652782|Experimental|4|rolofyline 60 mg IV QD
9905776|NCT00652782|Placebo Comparator|5|placebo for rolofyline IV QD
9905777|NCT00652795|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
9905778|NCT00652795|Active Comparator|B|Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.
9905779|NCT00652808|Active Comparator|Arm 1|
9905780|NCT00652808|Active Comparator|Arm 2|
9905781|NCT00652821|Experimental|A|Subjects received Kali product under fed condition
9905782|NCT00652821|Active Comparator|B|Subjects received Ortho-Mcneil product under fed conditions
9905783|NCT00652873|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fed conditions
9905784|NCT00652873|Active Comparator|B|Subjects received the reference product, Dostinex under fed conditions
9905785|NCT00652886|Experimental|A|Subjects received Kali's products under fasting conditions
9905786|NCT00652886|Active Comparator|B|Subjects received BTG products under fasting conditions
9905787|NCT00652912|Experimental|A|Subjects received the Kali formulated products under fasting conditions
9905788|NCT00652912|Active Comparator|B|Subjects received the Roche's product under fasting conditions
9905789|NCT00652925|Experimental|High Dose|
9905790|NCT00652925|Experimental|Low Dose|
9905791|NCT00652925|Active Comparator|Naproxen|Control comparator, 15 mg/kg/dy target dose
9905792|NCT00652964||Observation|a family of congenital central hypoventilation syndrome
9905793|NCT00652977|Active Comparator|I|The delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head.
9905794|NCT00652977|Other|II|Standard care at delivery: Manual support of the perineum
9905795|NCT00653003|Experimental|A|Subjects received Kali formulated product under fed conditions
9905796|NCT00653003|Active Comparator|B|Subjects received Aventis formulated products under fed conditions
9905797|NCT00653055|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fasting conditions
9905798|NCT00653055|Active Comparator|B|Subjects received the reference product, Dostinex under fasting conditions
9905799|NCT00653081|Active Comparator|A|Supervised Exercises performed at ulleval Hospital for patients with shoulder pain. Dosage: 45 minutes each time, max 2-3 times a week in max 12 weeks
9905800|NCT00653081|Active Comparator|B|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
9905801|NCT00653094|Other|A|
9905802|NCT00653107|Experimental|A|Stent followed by 3 brachytherapy fractions
9905803|NCT00653107|Active Comparator|B|3 fractions of brachytherapy
9905804|NCT00653120|Experimental|A|Subjects received Par Products under fasting conditions
9905805|NCT00653120|Active Comparator|B|Subjects received Wyeth Pharmaceuticals product under fasting conditions
9905806|NCT00653146|Experimental|Mindfulness-based stress reduction|The MBSR program includes meditation techniques, body scan, awareness of breathing, mindful yoga, eating meditation, and walking meditation, and meets for 2 hours, once weekly for 8 weeks.
9905807|NCT00653146|Placebo Comparator|Healthy Lifestyles Program|The Healthy Lifestyles Program includes information on nutrition and physical activity, and meets for 2 hours, once weekly for 8 weeks.
9905808|NCT00653172|Experimental|1|NXL103
9905809|NCT00653172|Active Comparator|3|
9905810|NCT00653172|Experimental|2|NXL103
9905811|NCT00653198||A|Cases
9905812|NCT00653198||B|Controls
9905813|NCT00653237|Other|1|crossover trial. insertion of both devices consecutively, computer randomized order
9905814|NCT00653250|Experimental|Therapeutic Intervention|Correlative
9905815|NCT00653302|Experimental|1|Lantus once a day plus Glucophage 1000mg, twice a day per os
9905816|NCT00653315|Experimental|A|Subjects received kali product under fasting conditions
9905817|NCT00653315|Active Comparator|B|Subjects received Ortho-Mcneil product under fasting conditions
9905818|NCT00653354|Active Comparator|Arm 1|
9905819|NCT00653354|Active Comparator|Arm 2|
9905820|NCT00653354|Placebo Comparator|Arm 3|
9905821|NCT00653367|Experimental|NS|Nerve section of intercostal nerve during surgery
9905822|NCT00653367|No Intervention|Control|Control
9905823|NCT00653380|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
9905824|NCT00653380|Active Comparator|B|Subjects received Oclassen's product (Monodox) under fasting conditions.
9905825|NCT00653393|Experimental|A|Subjects received Kali product under fasting conditions
9905826|NCT00653393|Active Comparator|B|Subjects received Parnate product under fasting conditions
9905827|NCT00653419|Experimental|A|Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
9905828|NCT00653419|Active Comparator|B|Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
9905829|NCT00653445|Experimental|1|Rosuvastatin 40mg/Ezetimibe 10mg combination therapy
9905830|NCT00653445|Experimental|2|Rosuvastatin 40 mg
9905831|NCT00653458|Experimental|A|Subjects received Kali formulated products under fed conditions
9905832|NCT00653458|Active Comparator|B|Subjects received GlaxoSmithKline's formulated products under fed conditions
9905833|NCT00653471|Active Comparator|Lean|Lean patients
9905834|NCT00653471|Active Comparator|Obese no OSA|Obese patients without osa
9905835|NCT00653471|Active Comparator|Obese osa|Obese patients with osa
9905836|NCT00653484|Experimental|Physical Activity Only|Physical Activity
9905837|NCT00653484|Experimental|Dietary Energy Restriction|Energy restriction
9905838|NCT00653484|Experimental|Physical Activity+Dietary Energy Restriction|Physical Activity ad Energy Restriction
9905839|NCT00653497|Experimental|1|Community-based aquatic exercise program (Arthritis Foundation Aquatics Program). Two classes per week, 45-60 minutes in duration.
9905840|NCT00653497|No Intervention|2|Usual care; abstention from initiation of new exercise programs. Invited to participate in Arthritis Foundation Aquatics Program after study completion.
9905841|NCT00653510|Experimental|Euglycemic|The patients will be examined with a blood glucose at around 5-7 mmol/L.
9905842|NCT00653510|Experimental|Hyperglycemic|The patients will be examined with a blood glucose at around 18-20 mmol/L
9905843|NCT00653549|Experimental|A|Subjects received Par formulated product under fasting conditions
9993832|NCT01476098|Active Comparator|Arm 2|incremenrtal doses casaicin
9993833|NCT01476111||Group 1|Patients with primary invasive breast cancer
9993834|NCT01476124|Experimental|Regimen A|Morphine placebo + GEn 600 mg
9993835|NCT01476124|Experimental|Regimen B|Morphine Extended release (60 mg) + GEn placebo
9993836|NCT01476124|Experimental|Regimen C|Morphine Extended release (60mg) + GEn 600 mg
9993837|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 1|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
9993838|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 2|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
9993839|NCT01476137|Experimental|Part 1: Cohort 1|GSK1120212 1.5mg + GSK2110183 50mg
9993840|NCT01476137|Experimental|Part 1: Cohort 2|GSK1120212 1.5mg + GSK2110183 100mg
9993841|NCT01476137|Experimental|Part 1: Cohort 3a|GSK1120212 2mg + GSK2110183 100mg
9993842|NCT01476137|Experimental|Part 1: Cohort 3b|GSK1120212 1.5mg + GSK2110183 125mg
9993843|NCT01476137|Experimental|Part 1: Cohort 4a|GSK1120212 2mg + GSK2110183 125mg
9993844|NCT01476137|Experimental|Part 2A: GSK1120212 2mg|Maximum tolerated dose of GSK1120212 as determined in prior single-agent trials
9993845|NCT01476137|Experimental|Part 2A; GSK2110183 125mg|GSK2110183 125mg
9993846|NCT01476137|Experimental|Part 2A: GSK2110183 MTD|Maximum tolerated dose (MTD) as determined in ongoing single agent trial PKB115340
9993847|NCT01476150||Dongcheng|
9993848|NCT01476150||Haidian|
9993849|NCT01476150||Xicheng|
9993850|NCT01476150||Chaoyang|
9993851|NCT01476150||Chongwen|
9993852|NCT01476150||Tongzhou|
9993853|NCT01476150||Fengtai|
9993854|NCT01476150||Xuanwu|
9993855|NCT01476176|Experimental|Experimental paracetamol formulation|experimental formulation
9993856|NCT01476176|Active Comparator|paracetamol marketed formulation|Paracetamol marketed formulation
9993857|NCT01476189|Experimental|Experimental paracetamol formulation|test formulation
9993858|NCT01476189|Active Comparator|Marketed paracetamol|Marketed paracetamol
9993859|NCT01476189|Active Comparator|Higher dose marketed paracetamol|higher dose marketed paracetamol
9993860|NCT01476215|Experimental|Fast dissolution suspension|
9993861|NCT01476215|Experimental|Medium dissolution suspension|
9993862|NCT01476215|Experimental|Slow dissolution suspension|
9993863|NCT01476215|Active Comparator|Marketed suspension|
9993864|NCT01476228|Experimental|study group|EEG recording
9993865|NCT01476241||EarNoseThroatGroup|a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery
9993866|NCT01476241||SurgeryGroup|a historic cohort group of patients with the PEG tube placed in the Department of Surgery from September 2005 until September 2009
9993867|NCT01476254||Cholecystectomy|Women scheduled for laparoscopic cholecystectomy
9993868|NCT01476254||Hysterectomy|Women scheduled for laparoscopic hysterectomy
9993869|NCT01476280|Sham Comparator|Palonosetron|
9993870|NCT01476280|Sham Comparator|Ramosetron|
9993871|NCT01476306|Placebo Comparator|In-patient care|
9993872|NCT01476306|Experimental|Telemedicine care|
9993873|NCT01476319|No Intervention|control|
9993874|NCT01476319|Experimental|video|
9993875|NCT01476332|Experimental|Group 1: Cis-UCA 0.5% eye drops|
9993876|NCT01476332|Experimental|Group 2: Cis-UCA 2.5% eye drops|
9993877|NCT01476332|Placebo Comparator|Group 3: Placebo for cis-UCA, eye drops|
9993878|NCT01476358|Active Comparator|Vitamin A|Capsule containing oil vehicle with Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
9905844|NCT00653549|Active Comparator|B|Subjects received Roche formulated product under fasting conditions
9905845|NCT00653562|Experimental|1|Patients will receive placebo in one part and zolpidem in the other part
9905846|NCT00653575||1|Women who report a history of childhood sexual abuse
9905847|NCT00653575||2|Women who do not report a history of childhood sexual abuse
9905848|NCT00653588|Experimental|1|rosuvastatin (40 mg)
9905849|NCT00653588|Active Comparator|2|atorvastatin (80 mg)
9933652|NCT05323916|Active Comparator|"Neuroproprioceptive facilitation, inhibition"|"According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, participants undergoes one hour a day of individual physiotherapy on a neurophysiological basis - neuroproprioceptive facilitation, inhibition, which, by combining appropriate stimuli in a suitable time sequence, maintains optimal motor pathway function and optimal irritability of control or regulation structures."
9933653|NCT05323916|Active Comparator|Technology based physical therapy|According to the doctor's indication, a multidisciplinary team participates in the program. The practitioner from each clinical field (rehabilitation and physical medicine, physiotherapy, occupational therapy, clinical speech therapy and psychology) selects appropriate treatment methodologies for each patient (three hours). In addition, they will undergo physiotherapy for an hour a day using the implementation of modern technologies based on the principles of sensorimotor learning, i.e. repeating specific and targeted functions in different environments / conditions in order to strengthen the memory footprint and initiate structural changes in the central nervous system. According to the indication, participants will be offered one of the robotic systems using an exoskeleton (Gloreha, Erigo and Meditutor, Lokomat and Ekso) or a therapy using virtual environment.
9933654|NCT05323916|Experimental|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|The concept of therapy implementing the ICF model is based on a comprehensive, so-called biopsychosocial approach to the patient and his/her disease (four hours). The key is to set individual goals of the therapy together with the rehabilitator and with the use of so-called ICF core sets, which individually take into account the given situation of the rehabilitated person. This approach includes interdisciplinary diagnosis of the current condition, i.e. not only based on the diagnosis, but also on the functional status and activities performed, it also takes into account the socio-psychological background of the patient.
9933655|NCT05323916|Placebo Comparator|Control group|Participants will undergo standard care.
9933656|NCT05323825|Experimental|Experimental group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
9933657|NCT05323825|Placebo Comparator|Control group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
9933658|NCT05321550||Fibromyalgia patients|Fibromyalgia patients diagnosed according to the 2010 ACR-criteria
9933659|NCT05321550||Neck pain patients|"Patients with non-specific, idiopathic neck pain complaints~Patients with neck pain complaints of traumatic origin type whiplash grade 1 (pain, stiffness or tenderness of the neck and no objective physical abnormalities) and grade 2 (neck complaints and musculoskeletal disorders such as reduced range of motion and tender pain points) according to the Quebec Task Force on Whiplash Associated Disorders"
9933660|NCT05321550||Low back pain patients|Patients with non-specific, idiopathic back pain complaints
9933661|NCT05321550||Healthy controls|Age, sex and BMI-matched healthy controls
9933662|NCT05319535|Active Comparator|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in the investigators' prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
9933663|NCT05319535|Experimental|Enhanced REP|Enhanced REP begins with the same activities as Foundational REP. Sites randomized to receive Enhanced REP will continue with Foundational REP and also receive higher intensity support for a period of approximately 4 months. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship and CONNECT, a complexity science-based bundle of interaction-oriented activities designed to supplement implementation efforts by promoting team function and readiness for change. Facilitation will be provided by Function QUERI team members.
9933664|NCT05317299|Active Comparator|Resistance Exercise Group|During 8 week progressive resistance exercises (three times a week)
9933665|NCT05317299|Active Comparator|Plyometric Exercise Group|During 8 week progressive plyometric exercises (three times a week)
9933666|NCT05317299|Active Comparator|High Intensity Interval Training Group|During 8 week progressive Hight Intensity Interval Training (three times a week)
9933667|NCT05316012|Experimental|Residents|5 residents - fase 1 Intervention device: smart diaper (diaper, sensor and strips, without alerting system) 15 residents, of which 5 residents of study phase 1 Intervention device: smart diaper (diaper, sensor and strips, with alerting system)
9933668|NCT05312385|Experimental|Isoflurane|Inhaled isoflurane administered via Sedaconda ACD-S
9933669|NCT05312385|Active Comparator|Propofol|Propofol administered as intravenous infusion
9933670|NCT05309044|Active Comparator|Planetary Health Diet Group|Diet proportional to the EAT-Lancet reference diet, in addition to a behavioral change protocol.
9933671|NCT05309044|Active Comparator|Low-fat diet group|Low-fat, low-calorie diet and a behavioral change protocol
9933672|NCT05309044|Placebo Comparator|Waiting list group|Waiting list group
9933673|NCT05308914||Resilience Study Cohort|Observational, descriptive longitudinal cohort design. See inclusion and exclusion criteria for more information
9933674|NCT05307913|Experimental|EIT-guided PEEP|PEEP titration by EIT
9933675|NCT05307913|Active Comparator|Table-guided PEEP|PEEP selection by the lower PEEP/FiO2 table
9905850|NCT00653601||1|Patients who receive bridge therapy with tirofiban who were previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures
9905851|NCT00653601||2|"Patients who do NOT receive bridge therapy previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures. This will entail of a matching case-control for the following characteristics.~# of RF for stent thrombosis~types of stents~time frame when the stents were placed~procedure type"
9905852|NCT00653614|Experimental|Arm 1|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle
9905853|NCT00653614|Experimental|Arm 2|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle
9905854|NCT00653614|Experimental|Arm 3|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle
9905855|NCT00653614|Experimental|Arm 4|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle
9905856|NCT00653614|Experimental|Arm 5|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle
9905857|NCT00653614|Experimental|Arm 6|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle
9905858|NCT00653627|Experimental|A|Study of BCG quantification and immunogenicity 2 weeks after BCG vaccination
9905859|NCT00653627|Experimental|B|Study of BCG quantification and immunogenicity 4 weeks after BCG vaccination
9905860|NCT00653640|Experimental|1|body weight supported treadmill training
9905861|NCT00653640|Placebo Comparator|2|traditional physical therapy
9905862|NCT00653653||Group A|Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.
9905863|NCT00653692||Observational|Poly drug dependent women
9905864|NCT00653705|Active Comparator|Probiotic|Children given probiotic BB12 enriched yogurt drink.
9905865|NCT00653705|Placebo Comparator|Control|Children given dairy drink.
9905866|NCT00653731|Experimental|Snoezelen ©|
9905867|NCT00653731|Experimental|Reminiscence|
9905868|NCT00653731|Experimental|10 min activation|
9905869|NCT00653731|Active Comparator|Talk|
9905870|NCT00653744|Experimental|1|Rosuvastatin
9905871|NCT00653744|Active Comparator|2|Atorvastatin
9905872|NCT00653770|Experimental|1|FP85A at day 0
9905873|NCT00653770|Experimental|2|MVA85A at day 0 and FP85A at day 28
9905874|NCT00653770|Experimental|3|FP85A at day 0 and MVA85A at day 28
9905875|NCT00653809||A, 1, I|Caucasian women without preeclampsia or PIH, delivering their first child
9905876|NCT00653809||A, 1, II|Caucasian women with preeclampsia or PIH, delivering their first child
9905877|NCT00653809||A, 2, I|African-american women without preeclampsia or PIH, delivering their first child
9905878|NCT00653809||A, 2, II|African-American women with preeclampsia or PIH, delivering their first child
9905879|NCT00653809||B, 1, I|Caucasian women without preeclampsia or PIH, delivering at least their second child
9905880|NCT00653809||B, 1, II|Caucasian women with preeclampsia or PIH, delivering at least their second child
9905881|NCT00653809||B, 2, I|African-american women without preeclampsia or PIH, delivering at least their second child
9905882|NCT00653809||B, 2, II|African-american women with preeclampsia or PIH, delivering at least their second child
9905883|NCT00653822|Experimental|1a|IV
9905884|NCT00653822|Placebo Comparator|1b|IV
9905885|NCT00653822|Experimental|2a|Lower SC dose
9905886|NCT00653822|Placebo Comparator|2b|SC to match lower dose
9905887|NCT00653822|Experimental|3a|Higher SC dose
9905888|NCT00653822|Placebo Comparator|3b|SC to match higher dose
9905889|NCT00653848|Experimental|Docetaxel arm|six of docetaxel every third week + hormonal treatment
9905890|NCT00653848|No Intervention|Control|hormonal treatment only
9905891|NCT00653874|Experimental|1: TcB|transcutaneous bilirubinometry (TcB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
9905892|NCT00653874|Active Comparator|2: CaB|clinical assessment of jaundice (CaB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
9905893|NCT00653887|Active Comparator|A|biofeedback (active group)
9905894|NCT00653887|Placebo Comparator|B|discussion about digestive tract (placebo group)
9905895|NCT00653900||1|All patients undergoing elective, invasive cardiac procedure on plavix prior to admission
9905896|NCT00653926|Active Comparator|A|Group A (Active) receives a multimodal injection intra- and postoperatively
9905897|NCT00653926|Placebo Comparator|P|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
9905898|NCT00653952|Experimental|001|
9905899|NCT00653952|Active Comparator|002|
9905900|NCT00653965|Experimental|1|Rosuvastatin
9905901|NCT00653965|Active Comparator|2|Atorvastatin
9905902|NCT00653978|Experimental|1|patients receiving one stent
9905903|NCT00653978|Active Comparator|2|patients receiving two stents
9905904|NCT00654017|Placebo Comparator|placebo|
9905905|NCT00654017|Active Comparator|sildenafil|
9905906|NCT00654043|Experimental|A|Subjects received Par formulated products under fed conditions
9905907|NCT00654043|Active Comparator|B|Subjects received Roche formulated products
9905908|NCT00654056|Experimental|L1|Actrapid infusion, 0.5 mU/kg/min.
9905909|NCT00654056|Experimental|L2|Actrapid infusion 1.5 mU/kg/min
9905910|NCT00654056|Experimental|H1|Actrapid infusion 3.0 mU/kg/min
9905911|NCT00654056|Experimental|H2|Actrapid infusion 5.0 mU/kg/min
9798221|NCT01621230|Placebo Comparator|Epidural bupivacaine plus fentanyl|A continuous epidural infusion of bupivacaine plus fentanyl during the second stage (i.e. 10 cm dilation) of labor. Epidural infusion are 10 ml/hr basal infusion plus 5 ml/hr demand dose via patient-controlled epidural analgesia (PCEA). Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed .
9798222|NCT01621477|Experimental|Treatment|"All study participants.~Interventions: clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, tacrolimus, mycophenolate mofetil"
9798223|NCT01621490|Experimental|Part 1-Cohort 1 and 2: Nivolumab|Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
9798224|NCT01621490|Experimental|Part 2-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
9798225|NCT01621490|Experimental|Part 3-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
9798226|NCT01621490|Experimental|Part 3-Arm B: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
9798227|NCT01621490|Experimental|Part 4-Arm D: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
9798228|NCT01621490|Experimental|Part 4-Arm E: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
9798229|NCT01621542|Experimental|WT2725|WT2725; injection
9798230|NCT01621633|Experimental|Group 1: mild hepatic impairment|LCZ696 200 mg, given as a single oral dose
9798231|NCT01621633|Experimental|Group 2: moderate hepatic impairment|LCZ696 200 mg, given as a single oral dose
9798232|NCT01621633|Experimental|Group 3: healthy volunteers|LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2
9798233|NCT01621672|Experimental|Revlimid|Revlimid dosing will be in the morning at the same time each day
9798234|NCT01621672|No Intervention|No further treatment|No treatment control.
9798235|NCT01621776|Active Comparator|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
9798236|NCT01621776|Active Comparator|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
9798237|NCT01621776|Active Comparator|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
9798238|NCT01621802|Experimental|Inv _MMR_CO Group|Subjects received one dose of the study vaccine Priorix along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
9798239|NCT01621802|Active Comparator|Com_MMR_CO Group|Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
9798240|NCT01621802|Experimental|Inv_MMR_I Group|Subjects received one dose of Priorix at Visit 1 (Day 0).
9798241|NCT01621802|Active Comparator|Com_MMR_I Group|Subjects received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
9798242|NCT01621802|Experimental|Inv _MMR_S Group|Subjects in this safety cohort received one dose of Priorix at Visit 1 (Day 0).
9798243|NCT01621802|Active Comparator|Com_MMR_S Group|Subjects in this safety cohort received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
9798244|NCT01621880|Active Comparator|Bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9798245|NCT01621880|Active Comparator|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
9798246|NCT01622010|Experimental|Standard care with video enhancement|"Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol. In addition are provided a copy of Keeping the Beat with Physiotherapy: Heart Failure edition education DVD related to heart failure, exercise and self management."
9798247|NCT01622010|Active Comparator|Standard care|Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol.
9798248|NCT01622231|Experimental|GW685698X|GW685698X 55mcg/day
9798249|NCT01622257|Experimental|Cavitation US|Cavitation ultrasound was done using ultrasonic cavitation machine 2 times per week for 3 months
9798250|NCT01622257|Experimental|Metformin|Metformin oral tablets 500 mg were given three times daily
9798251|NCT01622257|Experimental|Cavitation US + metformin|Combination of both Cavitation US + Metformin
9798252|NCT01622296|Active Comparator|Sodium Bicarbonate with Lidocaine|
9798253|NCT01622296|Placebo Comparator|Lidocaine with no buffer|
9798254|NCT01622348|Placebo Comparator|Placebo|Saline for Injection
9798255|NCT01622348|Active Comparator|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection
9905912|NCT00654082|Active Comparator|Arm 1|
9905913|NCT00654082|Placebo Comparator|Arm 2|
9905914|NCT00654108|Experimental|Cohort 1: vaccine dosage level 1 or placebo|Vaccine dose level 1: 1 X 10^7 colony forming unit (CFU) or placebo, treated with Cipro on days 7-11.
9905915|NCT00654108|Experimental|Cohort 2: vaccine dosage level 2 or placebo|Vaccine dose level 2: 1 X 10^8 CFU or placebo, treated with Cipro on days 7-11.
9905916|NCT00654108|Experimental|Cohort 3: vaccine dosage level 3 or placebo|Vaccine dose level 3: 1 X 10^9 CFU or placebo, treated with Cipro on days 7-11.
9905917|NCT00654108|Experimental|Cohort 4: vaccine dosage level 4 or placebo|Vaccine dose level 4: 1 X 10^10 CFU or placebo, treated with Cipro on days 7-11.
9905918|NCT00654121|Active Comparator|1|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
9905919|NCT00654121|No Intervention|2|
9905920|NCT00654173|Experimental|1|Rosuvastatin
9905921|NCT00654173|Active Comparator|2|Simvastatin
9905922|NCT00654173|Active Comparator|3|Atorvastatin
9905923|NCT00654212|Active Comparator|1|endoluminal stenting followed by laparoscopic resection (endo-laparoscopic limb, the study group)
9905924|NCT00654212|Other|2|emergency open surgery (open limb, the control group)
9905925|NCT00654225|Experimental|1|Rosuvastatin
9905926|NCT00654225|Active Comparator|2|Atorvastatin
9905927|NCT00654277|Experimental|A|Subjects received Kali formulated products under fasting conditions
9905928|NCT00654277|Active Comparator|B|Subjects received GlaxoSmithKine product under fasting conditions
9905929|NCT00654290|Experimental|P|Propranolol from 7 days pre-operation to 5 days post CABG
9905930|NCT00654290|Active Comparator|A|Amiodarone treated 7 days pre-operation to 5 days post CABG
9905931|NCT00654290|Active Comparator|AP|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
9905932|NCT00654303|Experimental|1|Rosuvastatin
9905933|NCT00654316|Experimental|1|BCG delivered intradermally into the deltoid region in volunteers who have received BCG 10 - 20 years previously.
9905934|NCT00654342|Other|1|In vivo injection group
9905935|NCT00654342|Other|2|Ex vivo injection group
9905936|NCT00654394|Experimental|1|
9905937|NCT00654407|Experimental|1|Rosuvastatin
9905938|NCT00654407|Active Comparator|2|Atorvastatin
9905939|NCT00654407|Active Comparator|3|Simvastatin
9905940|NCT00654433|Experimental|I|
9905941|NCT00654446|Experimental|1|Rosuvastatin
9905942|NCT00654446|Active Comparator|2|Simvastatin
9905943|NCT00654459||A|
9905944|NCT00654459||B|
9905945|NCT00654472||A|Mitral valve area above 1.5 cm2
9905946|NCT00654472||B|Mitral valve area 1.5 cm2 and below 1.5 cm2
9905947|NCT00654485|Experimental|1|Rosuvastatin
9905948|NCT00654485|Active Comparator|2|Atorvastatin
9905949|NCT00654524|Experimental|1|Patients in this arm will be treated with goserelin depot-3.6mg plus add-back therapy.
9905950|NCT00654524|No Intervention|2|The patient with advanced endometriosis（stage III-IV）confirmed histologically after conservative laparoscopic surgery will be suggested to prepare for spontaneous pregnancy rather than any medical administration.
9905951|NCT00654537|Experimental|1|Rosuvastatin
9905952|NCT00654537|Active Comparator|2|Atorvastatin
9905953|NCT00654537|Active Comparator|3|Pravastatin
9905954|NCT00654537|Active Comparator|4|Simvastatin
9905955|NCT00654550|Experimental|1|
9905956|NCT00654576|Active Comparator|1|the comparator arm will only receive one of the seven antipsychotic
9905957|NCT00654576|Experimental|2|the experimental group will receive one of the seven study drugs combination with psychosocial intervention
9905958|NCT00654589|Experimental|deferasirox|
9905959|NCT00654667|Placebo Comparator|2|Placebo
9905960|NCT00654667|Experimental|Experimental 1|Resveratrol
9905961|NCT00654680|Experimental|Arm 1|
9905962|NCT00654680|Placebo Comparator|Arm 2|
9905963|NCT00654693||monitored|patients hospitalized for longer than 24 hours and are located on the 4th, 5th, and 6th floors of the Vanderbilt University Medical Center Round Wing
9905964|NCT00654719|Active Comparator|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
9905965|NCT00654719|Placebo Comparator|Placebo|
9905966|NCT00654758|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel.
9905967|NCT00654771||1|women undergoing evaluation for pre-eclampsia
9905968|NCT00654797|Experimental|eProtocol|
9905969|NCT00654810|Experimental|1|Low intensity group (40% of maximal exercise capacity)
9905970|NCT00654810|Experimental|2|High intensity group (80% of maximal exercise capacity)
9905971|NCT00654849|Experimental|1|compare security and effectiveness of use Electrosurgical Bipolar Plasmakinetic Vessel Sealing
9905972|NCT00654849|Active Comparator|2|traditional abdominal hysterectomy technique with the use of sutures
9905973|NCT00654862|Experimental|1|Subjects with stage 1 hypertension
9905974|NCT00654862|Experimental|2|Subjects with optimal blood pressure
9905975|NCT00654888|Active Comparator|1|Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
9905976|NCT00654888|Active Comparator|2|automated lamellar keratectomy without mitomycin
9905977|NCT00654914|Experimental|Arm 1|
9905978|NCT00654966|Experimental|1|Heart failure patients
9905979|NCT00654966|Active Comparator|2|Healthy subjects
9905980|NCT00654979|Experimental|Single arm|SafeFlo IVC Filter
9905981|NCT00655018|Experimental|Vitamin group|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
9905982|NCT00655018|Placebo Comparator|2|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
9905983|NCT00655031|Experimental|1|Pomegranate concentrate (POMx)
9905984|NCT00655031|Placebo Comparator|2|Fruit flavored juice low in antioxidants
9905985|NCT00655044||Type 1 and type 2 diabetes patients|
9905986|NCT00655109|Active Comparator|1|Olopatadine
9905987|NCT00655109|Active Comparator|2|Fluticasone
9905988|NCT00655109|Placebo Comparator|3|Placebo nasal spray
9905989|NCT00655109|Placebo Comparator|4|Placebo Eyedrops
9905990|NCT00655122|Active Comparator|Dalteparin sodium|
9905991|NCT00655122|Placebo Comparator|Placebo|
9905992|NCT00655135|Placebo Comparator|1|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received placebo administered intravenously to patients on Day 1 and Day 29.
9905993|NCT00655135|Experimental|2|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 0.5 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
9905994|NCT00655135|Experimental|3|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 2 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
9905995|NCT00655148|Experimental|A|DTaP-IPV vero vaccination at 2, 3½, 5 and 16 months of age
9905996|NCT00655148|Active Comparator|B|DTaP-IPV mkc vaccination at 2, 3½, 5 and 16 months of age
9905997|NCT00655174|Placebo Comparator|1|
9905998|NCT00655174|Experimental|2|
9905999|NCT00655174|Experimental|3|
9906000|NCT00655187||Group A|Cases
9906001|NCT00655187||Group B|Controls
9906002|NCT00655200||A|
9906003|NCT00655213|Active Comparator|1|AAISafeR mode programming
9906004|NCT00655213|Active Comparator|2|DDD with long AV Delay programming
9906005|NCT00655213|Active Comparator|3|DDDAMC mode programming
9906006|NCT00655213|Other|4|AAISafer mode programming in non randomized patients
9906007|NCT00655226|Experimental|CBT skills based group sessions|Cognitive Behavioral Therapy skills based group sessions
9906008|NCT00655226|Active Comparator|Hepatitis C educational support groups|Hepatitis C educational support groups
9906009|NCT00655239|Active Comparator|Control|Participants will use commercially available computer games.
9906010|NCT00655239|Experimental|Active|Participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
9906011|NCT00655239|Active Comparator|Healthy Control|Healthy participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
9906012|NCT00655265|Experimental|Colesevelam hydrochloride film-coated tablets|
9906013|NCT00655265|Placebo Comparator|Placebo|
9906014|NCT00655278|Experimental|1|T2000 at 600-1000 mg daily
9906015|NCT00655291|Placebo Comparator|A|
9906016|NCT00655291|Experimental|B|
9906017|NCT00655304|Active Comparator|1|Treatment with 6-8 hours of Prometheus (R) liver support dialysis
9906018|NCT00655304|Active Comparator|2|Treatment with 6-8 hours of CVVHDF
9906019|NCT00655317|Active Comparator|1|Treatment Acupuncture Group (Therapeutic Acupuncture Treatment): treatment with actual acupuncture needles
9906020|NCT00655317|Sham Comparator|2|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
9906021|NCT00655330|Active Comparator|1|Valsartan (160mg/day)is given in combination with Placebo
9906022|NCT00655330|Experimental|2|Valsartan (160mg/day) + Probucol (750mg/day)
9906023|NCT00655343|Experimental|ATG-F|"ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)~cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
9906024|NCT00655343|No Intervention|non-ATG-F|"cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
9933676|NCT05305911|Active Comparator|Treatment Group|Treatment group will receive dapagliflozin in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
9993879|NCT01476358|Placebo Comparator|Placebo|Capsule containing oil vehicle withOUT Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
9993880|NCT01476371|Experimental|Mindfulness-based group treatment|8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
9993881|NCT01476371|No Intervention|Treatment as usual|Treatment as usual (including individual CBT and medication)
9993882|NCT01476384|Experimental|Glucose drink|75 gram glucose, dissolved in 250 ml water
9993883|NCT01476384|Placebo Comparator|Placebo|250 ml water
9993884|NCT01476397|Active Comparator|control infant formula|partially hydrolyzed whey infant formula
9993885|NCT01476397|Experimental|test infant formula|partially hydrolyzed whey infant formula with probiotic
9993886|NCT01476410|Experimental|Treatment (antibody-drug conjugate and combination chemo)|"LEAD-IN: Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
9993887|NCT01476423||A|
9993888|NCT01476436|Experimental|LCHF diet|Advice of a diet low in carbohydrate
9993889|NCT01476436|Active Comparator|Usual diet|Subjects shall continue to eat their usual daily diet with no low carbohydrate intervention
9993890|NCT01476462||ALL diagnosed 1980-2007|Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
9993891|NCT01476488|No Intervention|Advagraf|single group, conversion of prograf to advagraf
9993892|NCT01476501|Experimental|2,000 IU/day vitamin D|2,000 IU/day vitamin D for 6 months (n=60).
9993893|NCT01476501|Experimental|40,000 IU/month vitamin D|40,000 IU/month for 6 months (n=60).
9993894|NCT01476514|Experimental|1|"In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients."
9993895|NCT01476527|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
9993896|NCT01476540|Experimental|Deep Brain Stimulation|Deep Brain Stimulation
9993897|NCT01476553|Experimental|Intervention arm|Extensive Intraperitoneal Lavage (EIPL)
9993898|NCT01476566|Experimental|Educational intervention|A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented.
9993899|NCT01476566|No Intervention|Control group|
9993900|NCT01476579|Other|Non-invasive CT coronary angiography|This study is evaluating diagnostic accuracy of non-invasive CT coronary angiography with invasive coronary angiography.
9993901|NCT01476592|Experimental|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
9993902|NCT01476605|Active Comparator|PrT-DMS|1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
9993903|NCT01476605|Experimental|PrT-D|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
9993904|NCT01476605|No Intervention|Waitlist|
9993905|NCT01476605|Active Comparator|Platelet rich plasma|
9993906|NCT01476618||Denver VA OIF/OEF and mental health providers|Denver VA OIF/OEF and mental health providers
9993907|NCT01476631|Experimental|Arm A: 30 minutes walking|First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
9798256|NCT01622348|Active Comparator|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection
9933677|NCT05305911|Placebo Comparator|Placebo Group|Placebo Group will receive placebo in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
9798257|NCT01622543|Active Comparator|Folfox plus Bevacizumab and Reolysin|
9798258|NCT01622543|Active Comparator|Folfox plus Bevacizumab|
9798259|NCT01622569|Active Comparator|OPN-375 100 μg BID|"Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
9798260|NCT01622569|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
9798261|NCT01622569|Active Comparator|OPN-375 200 μg BID|"Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
9798262|NCT01622569|Active Comparator|OPN-375 400 μg BID|"Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
9798263|NCT01622660|Experimental|Gemcitabine and Pazopanib|This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.
9798264|NCT01622673|Experimental|RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours After Raltegravir in treatment period 5. There was a 2-day washout between treatment periods.
9798265|NCT01622673|Experimental|TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
9798266|NCT01622673|Experimental|MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
9798267|NCT01622673|Experimental|RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
9798268|NCT01622673|Experimental|TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
9798269|NCT01622673|Experimental|MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
9798270|NCT01622699|Experimental|Transcutaneous bilirubin measurements|In this intervention group, the initial visual assessment of jaundice wille be followed by measurement by transcutaneous bilirubinometer
9798271|NCT01622699|Active Comparator|Visual assessment of neonatal jaundice|In this control group (standard of care) the visual assessment will be followed by measurement of blood bilirubin as indicated by the physician
9798272|NCT01623037|Experimental|CoolSculpting Treatment Group|The single arm will include all subjects treated on each flank with the CoolSculpting System and CoolCurve+ applicator. Treatment temperature and duration are defined in the protocol.
9798273|NCT01623050|Experimental|SinuSys Dilation System|Maxillary Sinus Dilation
9798274|NCT01623115|Placebo Comparator|Placebo|Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
9798275|NCT01623115|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
9798276|NCT01623154|Other|BreathTek UBT|Comparison of Urea hydrolysis rate (UHR) values derived from Delta over Baseline (DOB)values obtained from the POCone and UBiT-IR300
9798277|NCT01623271|Experimental|CRPS I Pain Subjects|"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day"
9798278|NCT01623310|Experimental|OPN-375 400 μg BID|OPN-375 400 μg BID for 12 months
9798279|NCT01623323|Other|Fluticasone|
9798280|NCT01623466|Experimental|AG890-6.5|Evaluate levonorgestrel delivery in AG890-6.5
9798281|NCT01623466|Experimental|AG890-12.5|Evaluate levonorgestrel delivery in AG890-12.5
9798282|NCT01623479||Hypotrichosis of the Eyelashes|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
9798283|NCT01623531|Active Comparator|RiaSTAP|Intravenous fibrinogen(RiaSTAP) will be administered according to FIBTEM based calculation formula
9798284|NCT01623531|Placebo Comparator|Intravenous saline|Intravenous saline (placebo) will be calculated according to FIBTEM based calculation formula
9798285|NCT01623596|Experimental|Fingolimod|
9798286|NCT01623596|Active Comparator|Disease Modifying Therapy|2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
9798287|NCT01623739|Active Comparator|Type 1 implant placement|Placement of a dental implant: Implant is placed immediately following tooth extraction in one surgical procedure
9798288|NCT01623739|Active Comparator|Type 2 implant placement|Placement of a dental implant: Once the tooth is extracted. The site is left to heal for 4 to 8 weeks before a dental implant is placed during a second surgical procedure.
9798289|NCT01623752||Patients with Rheumatoid Arthritis|
9798290|NCT01623752||Patients with Psoriasis Arthritis|
9798291|NCT01623830|Experimental|Reactivation + VRE|Virtual reality exposure therapy (VRE) for the fear of flying (FOF) preceded by a reminder of the feared stimulus (a virtual reality clip of a virtual airplane taxiing and taking off) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions
9798292|NCT01623830|Active Comparator|Neutral Cue + VRE|VRE for the FOF preceded by a neutral cue (a virtual reality clip of a virtual living room) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions.
9798293|NCT01623869|Experimental|Treatment (trebananib)|Patients receive 30 mg/kg trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9798294|NCT01624090|Experimental|1/mithramycin|Single agent intravenous (IV) mithramycin
9798295|NCT01624142|Experimental|Evolocumab|Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
9798296|NCT01624168|Placebo Comparator|Anxiety Management Education|
9798297|NCT01624168|Experimental|10 week tai chi intervention|10 week course in Evidence Based Tai Chi meeting 2 times per week
9798298|NCT01624168|Experimental|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
9798299|NCT01624194|Active Comparator|Oxytocin nasal spray|Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
9998338|NCT01517334|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
9906025|NCT00655395|Experimental|1|"Laromustine 300 mg/m2 (cohort 1) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
9906026|NCT00655395|Experimental|2|"Laromustine 400 mg/m2 (cohort 2) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
9906027|NCT00655395|Experimental|3|"Laromustine 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
9906028|NCT00655395|Experimental|5|"Laromustine will be administered at the recommended phase II dose on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
9906029|NCT00655395|Experimental|4|"Laromustine 600 mg/m2 (cohort 4) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
9906030|NCT00655408|Active Comparator|A|"For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency.This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron.~Group 1 administered in the government healthcare clinic. Group 2 administered children's home.~The study showed treatment compliance in both groups."
9906031|NCT00655421|Experimental|Unaided|Unaided Visual Inspection of the Oral Cavity
9906032|NCT00655421|Experimental|VelScope|VelScope assisted examination of the oral cavity
9906033|NCT00655421|Experimental|Toluidine|Examination of oral cavity after the local application of Toluidine Blue dye
9933678|NCT05304923|Experimental|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
9933679|NCT05304923|Placebo Comparator|nasal cannula oxygen supply|Oxygen supplementation is delivered via a nasal cannula to the participants during sedation.
9933680|NCT05301114|Experimental|Intervention participants|Among patients who completed the social needs screening as a part of standard of care, all stage I-III Black cancer survivors will be invited to participate in a three or six-month community health worker intervention. The community health worker will assess social needs and provide three or six months of support depending on risk level.
9933681|NCT05301088|Experimental|Chocolate Scent|
9933682|NCT05301088|Experimental|Stress Ball|
9933683|NCT05301088|No Intervention|Control|
9933684|NCT05297162|Experimental|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"Single-arm case-control imaging trial designed to compare in parallel PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy (experimental test) with mpMRI/TRUS fusion prostate biopsy (standard test) in men suspected for PCa after at least one negative biopsy."
9933685|NCT05296161|No Intervention|Standard interval dosing|The standard group will receive ocrelizumab every 24 weeks following the current label.
9933686|NCT05296161|Experimental|Personalized B cell tailored ocrelizumab treatment|The personalized group will start with B cell measurements 24 weeks after the last infusion (baseline). The infusion interval will never be shorter than 24 weeks. The personalized group will start the study with a possible extension of the interval. The infusion will be postponed as long as CD19 B cell count stays below 10 cells/µL (determined every 4 weeks). When CD19 B cell count exceeds or is equal to 10 cells/µL, ocrelizumab infusion will be scheduled within two weeks
9933687|NCT05293106|Active Comparator|Pathogen-reduced (PR) platelet transfusions|FDA approved and already used in this patient population
9798300|NCT01624194|Placebo Comparator|Placebo nasal spray|The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.
9906034|NCT00655434||SAA|Sexually Active Adults- Intercourse in the last twelve months with at least one sexual partner. Subjects must be ≥ 18 years old. No more than 60% of one gender.
9906035|NCT00655447||1|all women having a hysterectomy with oophorectomy
9906036|NCT00655447||2|all women having a hysterectomy without removal of ovaries
9906037|NCT00655460|Experimental|eProtocol|
9906038|NCT00655512|Active Comparator|1|
9906039|NCT00655512|Active Comparator|2|
9906040|NCT00655512|Active Comparator|3|
9906041|NCT00655512|Active Comparator|4|
9906042|NCT00655512|Placebo Comparator|5|
9906043|NCT00655525|Active Comparator|1|
9906044|NCT00655525|Placebo Comparator|2|
9906045|NCT00655577|No Intervention|2|Control group
9906046|NCT00655577|Experimental|1|Exercise group
9906047|NCT00655590|Experimental|Arm 1|
9906048|NCT00655590|Active Comparator|Arm 2|
9906049|NCT00655590|Placebo Comparator|Arm 3|
9906050|NCT00655603|Experimental|1|10 patients with Type 2 Diabetes Mellitus
9906051|NCT00655603|Experimental|2|10 healthy, matched control participants
9906052|NCT00655616|Active Comparator|1|The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
9906053|NCT00655616|Placebo Comparator|2|The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast
9906054|NCT00655655|Experimental|Arm I|See Detailed Description
9906055|NCT00655681|Experimental|A|Receives pamidronate 1mg/kg
9906056|NCT00655681|Placebo Comparator|B|receives saline injection
9906057|NCT00655720|Active Comparator|1|
9906058|NCT00655720|Experimental|2|
9906059|NCT00655720|Experimental|3|
9906060|NCT00655785|Experimental|Phase 1/2 study|
9906061|NCT00655798|Placebo Comparator|1|
9906062|NCT00655798|Active Comparator|2|
9906063|NCT00655798|Active Comparator|3|
9906064|NCT00655798|Active Comparator|4|
9906065|NCT00655824|Experimental|Ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
9906066|NCT00655837|Experimental|1|
9906067|NCT00655902|Experimental|1|
9906068|NCT00655902|Placebo Comparator|2|
9906069|NCT00655915||Injection Patients|Those patients who receive corticosteroid injections for carpal tunnel syndrome
9906070|NCT00655941|Experimental|1|Dietary instruction (low-energy diet. This is given by instructions in groups of 8
9906071|NCT00655941|Active Comparator|2|Exercise
9906072|NCT00655941|No Intervention|3|Control
9906073|NCT00655954||Healthy volunteers non smoker|18 volunteers
9906074|NCT00655954||Healthy volunteers smoker|15 volunteers
9906075|NCT00655954||Chronic Obstructive Pulmonary Disease COPD|39 volunteers
9906076|NCT00655967|Experimental|1|Acamprosate(Campral)
9906077|NCT00655993|Placebo Comparator|1|placebo drug
9906078|NCT00655993|Active Comparator|2|simvastatin
9906079|NCT00656032|Active Comparator|1|SOC medication for treatment of renal osteodystrophy
9906080|NCT00656032|Active Comparator|2|alternate SOC medication for treatment of renal osteodystrophy
9906081|NCT00656045|Experimental|A|Arm A focuses on increasing the participant's physical activity level.
9906082|NCT00656045|Experimental|B|Arm B focuses on decreasing the amount of time the participant spends watching Television.
9906083|NCT00656071||1|Control -- postoperative mechanical ventilation patients without ARDS
9906084|NCT00656071||2|Cases -- postoperative mechanical ventilation patients with ARDS
9906085|NCT00656110|Experimental|1-T|Treatment Group
9906086|NCT00656110|Placebo Comparator|2-P|Placebo comparator
9906087|NCT00656123|Experimental|CY and colon GVAX|
9906088|NCT00656149|Active Comparator|Telerehabilitation of hand function|Intervention: for one hour per day participants perform exercise therapy on a home-based tele-rehabilitation workstation, the Rehabilitation Joystick for Computerized Exercise (ReJoyce) with which participants play computer games associated with activities of daily life. A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system. Hand grasp-release is assisted with functional electrical stimulation (FES) triggered voluntarily by the participant with the use of a wireless earpiece with a sensor that detects toothclicks.
9906089|NCT00656149|Active Comparator|Conventional exercise therapy|Intervention: for one hour per day participants perform conventional range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 with the use of the ReJoyce tele-rehabilitation min). A remote therapist coaches each one-hour session A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system.
9906090|NCT00656188|Placebo Comparator|Arm 2|
9906091|NCT00656188|Active Comparator|Arm 1|
9906092|NCT00656214|Active Comparator|A|Patients with symptomatic oral lichen planus
9906093|NCT00656214|Placebo Comparator|B|Patients with symptomatic oral lichen planus
9906094|NCT00656240|Experimental|1|
9906095|NCT00656240|Experimental|2|
9906096|NCT00656253|Experimental|A|
9906097|NCT00656253|Placebo Comparator|B|
9906098|NCT00656266|Placebo Comparator|tacrolimus & corticosteroids|Standard post-transplant immunosuppression medications: tacrolimus and corticosteroids
9906099|NCT00656266|Experimental|low-dose tacrolimus + steroids + MMF|Comparison arm: low-dose tacrolimus + steroids + MMF
9906100|NCT00656279|Experimental|1|Intensive dietary phosphorus education
9906101|NCT00656279|No Intervention|2|Standard dietary education consists of the dietitian assessing laboratory values and dietary intake and providing dietary education for abnormal values using handouts developed for specific nutrients.
9906102|NCT00656318||Group 1 (Zovia)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
9906103|NCT00656318||Group 2 (Necon)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
9906104|NCT00656331|Active Comparator|1|Amlodipine
9906105|NCT00656331|Active Comparator|2|HCTZ
9906106|NCT00656383|Active Comparator|1|Client is randomized to receive leg ulcer treatment in the home
9906107|NCT00656383|Active Comparator|2|Client randomized to receive leg ulcer care in the clinic
9906108|NCT00656396|Active Comparator|Control|Standard care
9906109|NCT00656396|Experimental|Intervention|Point of care monitoring used
9906110|NCT00656422|Experimental|insulin Levemir|
9906111|NCT00656422|Experimental|insulin Lantus|
9798301|NCT01624233|Experimental|80 mg ixekizumab|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
9798302|NCT01624259|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
9798303|NCT01624259|Active Comparator|Liraglutide|"Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
10212962|NCT04794335||Patients undergoing resection of intestine for therapeutic purposes|Tissue will be accepted from all eligible donors who consent to having their intestine removed for therapeutic purposes. This tissue would normally be disposed of as medical waste, used for research purposes. The tissue will be studied in the lab in a series of experiments involving GABA agonists and antagonists. Each GABA agonist and/or agonists/antagonist combination will be studied on intestine tissue randomly assigned to one of four groups defined by patient sex (m/f) and the application of inflammatory mediators (+/-). Thus, four groups are needed per GABA agonist and agonist/antagonist combination and seven agonist/antagonist combinations will be tested for a total of 28 experimental groups. But all of these groups will be generated from all patients recruited for the study.
10212963|NCT04789499|Experimental|Theophylline|400mg theophylline capsule diluted in 240 mL isotonic nasal saline lavage twice daily.
10212964|NCT04789499|Placebo Comparator|Placebo|500mg lactose capsule diluted in 240 mL isotonic nasal saline lavage twice daily.
10212965|NCT04782947|Experimental|EAW+ES+RT|The exoskeletal assisted walking with epidural simulation and resistance training (EAW+ES+RT) group will undergo 6 months of supervised EAW +ES (3X per week) followed by additional 6 months of EAW+ES (3X per week) and progressive RT twice weekly (2X per week). In the EAW+ES+RT group, RT will be administered for 12 weeks using an open kinematic chain approach of applying surface NMES and ankle weights followed by 12 weeks twice weekly of gradually using the implanted ES to perform sit-to-stand approach (i.e. using their body weights to load the exercising muscles in a closed kinematic fashion).
10212966|NCT04782947|Experimental|EAW+ delayed-ES +no-RT|The control exoskeletal assisted walking with delayed epidural simulation and without resistance training (EAW+ delayed-ES +no-RT) group will enroll in 6 months of EAW without ES (3X per week) and then this will be followed by additional 6 months (3x per week) of EAW+ES (i.e., delayed entry approach) without conducting RT and will perform either passive movement of passive stretching (2X per week).
10212967|NCT04782609|Experimental|20 mg Icapamespib cohort|Icapamespib will be administered orally once daily for each 28-day cycle. The initial dose in this trial will be 20 mg
10212968|NCT04782609|Experimental|dose expansion cohort|dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D)
9798304|NCT01624363||Patients undergoing EUS|Patients undergoing EUS for non-pancreatic treatment.
9798305|NCT01624467|Experimental|Necitumumab|800 mg necitumumab, administered once per week as an intravenous infusion (IV)
9798306|NCT01624506||Magnetic Sphincter Augmentation|Patients will be treated with magnetic sphincter augmentation via the LINX Reflux Management System
9798307|NCT01624506||Fundoplication|Patients treated with laparoscopic fundoplication
9798308|NCT01624662|Active Comparator|OPN-375 100 mcg|Double-Blind Treatment Phase: OPN-375 100 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
9798309|NCT01624662|Active Comparator|OPN-375 200 mcg|Double-Blind Treatment Phase: OPN-375 200 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
9798310|NCT01624662|Active Comparator|OPN-375 400 mcg|Double-Blind Treatment Phase: OPN-375 400 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
9798311|NCT01624662|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matched Placebo BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
9798312|NCT01624870||CoreValve aortic valve|Implantation of CoreValve aortic valve
9798313|NCT01624740|Experimental|Low Rate Followed By High Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received low rate stimulation (2 Hz) for 3-4 days, followed by high rate stimulation (1200 Hz) for 3-4 days.
9798314|NCT01624740|Experimental|High Rate Followed By Low Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received high rate stimulation (1200 Hz) for 3-4 days, followed by low rate stimulation (2 Hz) for 3-4 days.
9798315|NCT01624948|Experimental|Everolimus+Tacrolimus/Prednisone|This arm (group 1) will undergo mycophenolic acid (MPA) discontinuation with the addition of Zortress (everolimus) to their current regimen of tacrolimus and prednisone; All patients in group 1 will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
9798316|NCT01624948|Active Comparator|Standard of care: 50% reduction of MPA|This arm (group 2) patients will continue with tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of the MPA dose, which is the standard immunosuppression treatment for renal transplant recipients with evidence of BKV infection. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
9798317|NCT01624974|Experimental|MK-1029/Placebo|Participants received 4 weeks treatment with MK-1029 150 mg once daily (QD) + ML 10 mg QD in Period III and Placebo QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
9798318|NCT01624974|Experimental|Placebo/MK-1029|Participants received 4 weeks treatment with Placebo QD + ML 10 mg QD in Period III and MK-1029 150 mg QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
9798319|NCT01625000|Experimental|MP-214 3mg|
9798320|NCT01625000|Experimental|MP-214 6mg|
9798321|NCT01625000|Experimental|MP-214 9mg|
9798322|NCT01625000|Active Comparator|Risperidone 4mg|
9906112|NCT00656435|Experimental|A|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
9906113|NCT00656435|No Intervention|B|Patients will not receive bevacizumab pretreatment
9906114|NCT00656461|Experimental|1|
9906115|NCT00656500|Active Comparator|1|Brief assistance with smoking abstinence
9906116|NCT00656500|Experimental|2|Brief intervention to promote quitline utilization
9906117|NCT00656526|Placebo Comparator|A01L|
9906118|NCT00656526|No Intervention|B01C|
9906119|NCT00656565||1|subjects with bronchiectasis
9906120|NCT00656578|Experimental|1|4975
9906121|NCT00656578|Placebo Comparator|2|Drug, Single dose, solution
9906122|NCT00656604|Experimental|Women with breast cancer|Patients undergo DCE-MRI and MRS prior to their breast cancer surgery.
9906123|NCT00656604|No Intervention|Healthy volunteers|Women without breast cancer undergo DCE-MRI and MRS.
9906124|NCT00656643|Experimental|1|
9906125|NCT00656643|Experimental|2|
9906126|NCT00656643|Experimental|3|
9906127|NCT00656643|Placebo Comparator|4|
9906128|NCT00656682|Active Comparator|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian. Registered Dietitian Counseling Alone
9906129|NCT00656682|Experimental|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based diabetes prevention lifestyle intervention offered by the community. Dietitian Counseling Plus Community Group Lifestyle Intervention.
9906130|NCT00656695|Experimental|1|taking Iminoral
9906131|NCT00656695|Active Comparator|2|taking Neoral
9906132|NCT00656708|Experimental|PB|All patients admitted to the burn unit during the prospective portion (interventional portion) of the study who have open wounds will have Kerlix AMD applied to their wounds; only those patients consenting to the study will have data abstracted.
9906133|NCT00656721|Experimental|Flutter Valve|This a crossover study, so all subjects performed both, control and experimental interventions. In Flutter Valve intervention the subjects remained comfortably seated, breathing through the device for 15 minutes, starting off from the total pulmonary capacity, and being free to cough. Thereafter, a 5-min session of cough ensued. In the control intervention the subjects followed the same sequence of the Flutter Valve intervention, but the metallic sphere and the cover of the device were removed. Since the patients were not acquainted with the valve, they did not know its proper assembly. As in the Flutter Valve intervention, during 15 minutes the patients could expectorate spontaneously and return to the device. A 5-min coughing session took place.
9906134|NCT00656734|Experimental|MDX 1411|Dose Escalation Cohorts
9906135|NCT00656747|Active Comparator|Arm 2|
9906136|NCT00656747|Experimental|Arm 1|
9906137|NCT00656760|Experimental|A|All patients have PET/CT and biopsies with the surgeon blinded to the result of PET/CT. Additional biopsies are performed (or not) after the surgeon has the PET/CT results revealed.
9906138|NCT00656773|Experimental|1|
9906139|NCT00656773|Active Comparator|2|
9906140|NCT00656786|Experimental|Group 1|Subjects will be treated if, after starting treatment with an EGFRi, acute signs and symptoms of rash on the face/neck and/or upper chest emerge, that are suspected of being related to the EGFRi treatment.
9906141|NCT00656786|Experimental|Group 2|Subjects will receive pre-emergent rash treatment starting 1 day prior to beginning EGFRi therapy
9906142|NCT00656812|Experimental|Treatment Arm|Combination therapy Rituximab plus 2CdA
9906143|NCT00656825|Active Comparator|Panel I|The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio
9906144|NCT00656825|Active Comparator|Panel II|The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio
9906145|NCT00656825|Active Comparator|Panel III|The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio
9906146|NCT00656825|Placebo Comparator|Placebo|Patients from each panel will be given placebo in a 4:8 ratio.
9906147|NCT00656838|Active Comparator|1|Patient has had PCP contact (letter, phone call, office visit, educational materials).
9906148|NCT00656838|No Intervention|2|Usual Care
9906149|NCT00656864|Active Comparator|1|Pioglitazone arm
9906150|NCT00656864|Placebo Comparator|2|Placebo arm
9906151|NCT00656929|Active Comparator|1|Vitamin D3 50 mcg (2000 IU) daily
9906152|NCT00656929|Placebo Comparator|2|Placebo tablets
9906153|NCT00656942||Healthy|"subjects with no pain and no opioid treatment for at least six months~subjects receive quantitative sensory testing (QST)"
9906154|NCT00656942||Pain, no opioid|"subjects have chronic pain but have not taken any opioid medication for at least 3 months~subjects receive QST"
9906155|NCT00656942||Pain, opioid|"subjects have chronic pain and have been taking opioid medication for at least 3 months~subjects receive QST"
9906156|NCT00656955||Renal cancer patients|Renal cancer patients
9906157|NCT00656981|Experimental|Arm 1|
9906158|NCT00656981|Placebo Comparator|Arm 2|
9906159|NCT00656994|Experimental|Ramelteon 16 mg QD|
9906160|NCT00656994|Placebo Comparator|Placebo|
9906161|NCT00657007|Placebo Comparator|Placebo|IV infusion over 2 hours
9906162|NCT00657007|Experimental|Belimumab 1 mg/kg|1 mg/kg IV infused over 2 hours
9906163|NCT00657007|Experimental|Belimumab 4 mg/kg|4 mg/kg IV infused over 2 hours
9906164|NCT00657007|Experimental|Beimumab 10 mg/kg|10 mg/kg IV infused over 2 hours
9906165|NCT00657007|Experimental|Belimumab 20 mg/kg|20 mg/kg IV infused over 2 hours
9906166|NCT00657033|Experimental|Arm 1|
9906167|NCT00657033|Experimental|Arm 2|
9906168|NCT00657059|Active Comparator|Pred group|Pred Group: Prednisone treatment Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.
9906169|NCT00657059|Active Comparator|MMF Group|MMF Group: MMF treatment Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month.
9906170|NCT00657059|Active Comparator|Pred plus MMF Group|"Pred plus MMF Group: Prednisone plus MMF treatment. Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.~Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month."
9906171|NCT00657098||Observation|
9906172|NCT00657111|Experimental|A1|Subjects 01-08; 5 mg CS-8958
9906173|NCT00657111|Placebo Comparator|A2|Subjects 01-08; placebo
9906174|NCT00657111|Experimental|B1|Subjects 09-16; 10 mg CS-8958
9906175|NCT00657111|Placebo Comparator|B2|Subjects 09-16; placebo
9906176|NCT00657111|Experimental|C1|Subjects 17-24; 20 mg CS-8958
9906177|NCT00657111|Placebo Comparator|C2|Subjects 17-24; placebo
9906178|NCT00657111|Experimental|D1|Subjects 25-32; 40mg CS-8958
9906179|NCT00657111|Placebo Comparator|D2|Subjects 25-32; placebo
9906180|NCT00657124|Experimental|1|receive a preoperative supplementation with carbohydrate and branched-chain amino acids-enriched nutrient
9906181|NCT00657124|Placebo Comparator|2|receive a preoperative supplementation without carbohydrate and branched-chain amino acids-enriched nutrient
9906182|NCT00657137|Experimental|A|apricoxib + lapatinib + capecitabine
9906183|NCT00657137|Placebo Comparator|B|placebo + lapatinib + capecitabine
9906184|NCT00657163|Experimental|1|fluoxetine
9906185|NCT00657163|Placebo Comparator|2|Placebo
9906186|NCT00657202|Experimental|Ranibizumab|
9906187|NCT00657228|Placebo Comparator|2|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) plus an equal volume bolus of normal saline after the first doses are administered.
9798323|NCT01625000|Placebo Comparator|Placebo|
9798324|NCT01625013|Experimental|Synvisc-One|
9798325|NCT01625091|Active Comparator|naltrexone|The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.
9798326|NCT01625091|Placebo Comparator|placebo pill|The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.
9798327|NCT01625104|Experimental|Group 1: Aggressive Intervention Strategy|"Hospitals were randomized to an aggressive intervention strategy or to business as usual. The hospitals randomized to the aggressive intervention strategy underwent the following:~Grand Rounds conducted by physician and nurse from the Coordinating Center. This included a formal presentation on the evidence supporting rapid time to treatment in STEMI patients and evidence based strategies for reducing treatment delays.~Discussion with staff regarding perceived barriers to treatment and suggestions/ideas for strategies to overcome these barriers~Follow-up monthly phone conferences to continue to discuss strategies and ideas sharing~Written plan from sites detailing plans to change processes of care."
9798328|NCT01625104|Placebo Comparator|Group 2: Control Strategy|"Hospitals randomized to the control group were instructed to conduct business as usual."
9798329|NCT01625169|Other|HIV + pregnant women|Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
9798330|NCT01625182|Experimental|Fingolimod (FTY720)|Participants received Fingolimod 0.5 mg orally once daily.
9798331|NCT01625182|Placebo Comparator|Placebo|Participants received matching placebo to Fingolimod orally once daily.
9798332|NCT01625221|Experimental|Magnetic anal sphincter augmentation|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
9798333|NCT01625338|Experimental|SOF+RBV 12 Weeks|SOF+RBV for 12 weeks
9798334|NCT01625338|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
9798335|NCT01625338|Experimental|SOF+RBV+Peg-IFN 12 Weeks|SOF+RBV+Peg-IFN for 12 weeks
9798336|NCT01625377|Active Comparator|Tacrolimus|From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
9798337|NCT01625377|Experimental|Everolimus (RAD001)|"From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest)."
9798338|NCT01625416|Experimental|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
9798339|NCT01625416|No Intervention|Usual Care|Usual care control patients will be given a list of available community resources and encouraged to proceed using all resources available to them.
9798340|NCT01625455|Active Comparator|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
9798341|NCT01625455|Placebo Comparator|Placebo|Matching placebo will be given in place of aprepitant
9798342|NCT01625507|Experimental|PANDA intervention|12 week nutritional intervention, including 6 classroom/community sessions, plus two sample collection visits.
9798343|NCT01625689|Experimental|SIIL LAIV|SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
9798344|NCT01625689|Placebo Comparator|Placebo|Placebo identical in appearance to experimental vaccine.
9798345|NCT01625845|Experimental|Pentoxifylline + Standard Treatment|"Pentoxifylline: Pentoxifylline is phosphodiesterase inhibitor that interferes with proinflammatory cytokine signaling and synthesis. Participants will be instructed to take pentoxifylline 400 mg p.o. t.i.d. for 12 weeks.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
9798346|NCT01625845|Placebo Comparator|Placebo + Standard Treatment|"Placebos: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
9798347|NCT01625897|Experimental|MP-214 1.5-9mg|
9798348|NCT01625897|Active Comparator|Risperidone 2-12mg|
9798349|NCT01625910|Experimental|behavioral counseling|Receive counseling via motivational interviewing seeking to encourage health eating habits and increased physical activity
9798350|NCT01625910|Placebo Comparator|Instructions in school readiness and performance|Parents receive instructions in school readiness and performance
9798351|NCT01625923|Experimental|Olanzapine|An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
9906188|NCT00657228|Experimental|1|Standard therapy plus a one-time bolus of heparin at 80 U/kg (maximum dose of 10,000 Units) given immediately after the first doses of standard treatment.
9906189|NCT00657241|Active Comparator|A|Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)
9906190|NCT00657241|Active Comparator|B|Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).
9906191|NCT00657254|Experimental|Arm 1|
9906192|NCT00657293|Sham Comparator|C|In an attempt to make the groups comparable in terms of attention, the control group will receive a sham.
9906193|NCT00657293|Active Comparator|ATP|Patients will undergo a specific arm training program (ATP).
9906194|NCT00657306|Experimental|1|Hydrocortisone, 50 mg/6 h per day
9906195|NCT00657306|Placebo Comparator|2|dextrose solution 5%
9906196|NCT00657319||A|
9906197|NCT00657345||1|This is a tissue acquisition and collection protocol that will analyze potential cellular changes that occur after treatment with trastuzumab.
9906198|NCT00657384|Experimental|acid tranexamic|acid tranexamic
9906199|NCT00657384|Placebo Comparator|2|Nacl 0.9%
9906200|NCT00657397|Experimental|A|Methadone inducted by a primary care physician
9906201|NCT00657397|Active Comparator|B|Methadone inducted (in CSAPA)
9906202|NCT00657410|Experimental|ARM A - PDN|PDN is administered orally at the daily dose of 1 mg/Kg for 4 consecutive weeks (from day 0 to day 28), then, therapy is tapered within 14 days. The patients considered NOT RESPONDER at day 42 or WHO HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be crossed to ARM B.
9906203|NCT00657410|Experimental|ARM B - DXM|"DXM is administered orally at single fixed daily doses of 40 mg for 4 consecutive days, every 14 days, for 3 consecutive courses. If platelet count is £ 20x109/L or bleeding symptoms related to thrombocytopenia are present, lowdose DXM (0.035 mg/Kg/day) between courses is given. The patients (either from ARM A+B or from ARM B) considered NOT RESPONDER at day 46 or who HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be considered OFF TREATMENT.~For these patients a second line therapy will be considered, according to the medical practice of the Centre (splenectomy or other)."
9906204|NCT00657423|Experimental|1|
9906205|NCT00657423|Active Comparator|2|
9933688|NCT05293106|Active Comparator|Large volume delayed sampling - LVDS|FDA approved and already used in this patient population
9933689|NCT05291533|Other|Patients using VR Mindfulness Program|Participants are inpatients on any NYP/WCM unit that use VR mindfulness programs; any patient referred for a psychological or neuropsychological evaluation by their treatment team will have the opportunity to complete the VR program. The study is seeking to evaluate the feasibility and preliminary efficacy of the VR mindfulness intervention.
9933690|NCT05290064|Experimental|1/UPF HH, UPF HL, UNF LL, UPF LL|Four diets in the order specified
9933691|NCT05290064|Experimental|2/ UPF HL, UPF LL, UPF HH, UNF LL|Four diets in the order specified
9933692|NCT05290064|Experimental|3/ UPF LL, UNF LL, UPF HL, UPF HH|Four diets in the order specified
9933693|NCT05290064|Experimental|4/ UNF LL, UPF HH, UPF LL, UPF HL|Four diets in the order specified
9933694|NCT05288868|Experimental|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
9933695|NCT05288868|No Intervention|Caregiver Satisfaction|Caregivers who accompany their children with autism to the clinic will be surveyed for their comfort scores before and after the study participants' educational intervention
9933696|NCT05286827|Experimental|Arm 1|Olaparib, taken orally, twice daily
9933697|NCT05286814|Experimental|1/ HAIP +M9241+FOLFOX or FOLFORI|M9241+HAIP FUDR and Dexamethasone chemotherapy in combination with FOLFOX or FOLFIRI
9906206|NCT00657449|Active Comparator|Arm 1|
9906207|NCT00657449|Active Comparator|Arm 2|
9906208|NCT00657462|Experimental|A|Receives the intervention (reminders displayed at the startup of the application) for both periods (period 1 and period 2) of the study.
9906209|NCT00657462|Active Comparator|B|Receives the intervention (reminders displayed at the application startup) only during the second period (period 2) of the study.
9906210|NCT00657475|Experimental|2|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin low dose (150 UI/Kg).
9906211|NCT00657475|Active Comparator|1|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin Full Dose (300 UI/Kg)
9906212|NCT00657488|Experimental|A|Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
9906213|NCT00657488|Active Comparator|B|Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
9906214|NCT00657514|Active Comparator|A|Drug arm - 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
9906215|NCT00657514|Placebo Comparator|P|Placebo arm - 1 tablet po bid up to 2 tablets po bid if tolerated
9906216|NCT00657527|Experimental|1|Rosuvastatin
9906217|NCT00657527|No Intervention|2|Diet
9906218|NCT00657566|Active Comparator|1|antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function
9906219|NCT00657566|Experimental|2|4 +/- 1 days of antibiotics
9906220|NCT00657579|Experimental|1|
9906221|NCT00657579|Experimental|2|
9906222|NCT00657579|Experimental|3|
9906223|NCT00657579|Placebo Comparator|4|
9906224|NCT00657631|Experimental|A|Acceptance and Commitment Therapy will be administered to all subjects.
9906225|NCT00657644|Experimental|Arm 1|
9906226|NCT00657670|Experimental|1|Ready-made spectacles
9906227|NCT00657670|Active Comparator|2|Spectacles
9906228|NCT00657683|Experimental|1|
9906229|NCT00657683|Placebo Comparator|2|
9906230|NCT00657696||Group 1|Physicians and staff in VA non-contract primary care outpatient clinics and patients seen in last 12 months in the same clinics
9906231|NCT00657696||Group 2|Patients seen in last 12 months in Group 1 clinics
9906232|NCT00657722|Experimental|1|Angiography and Computed Tomography
9906233|NCT00657735|Experimental|1|Deep TMS treatment
9906234|NCT00657735|Sham Comparator|2|inactive stimulation
9906235|NCT00657748|Experimental|1|
9906236|NCT00657761|Placebo Comparator|Placebo|Saline solution 0.9% sc/12h for 7 days
9906237|NCT00657761|Experimental|Enfuvirtide|Enfuvirtide 90 mg/12h sc for 7 days
9906238|NCT00657774|Experimental|1|FlutiForm 250/10 ug
9906239|NCT00657774|Experimental|2|FlutiForm 100/10 ug
9906240|NCT00657774|Active Comparator|3|Oral Prednisone 10 mg
9906241|NCT00657774|Placebo Comparator|4|Placebo inhaler and/or placebo tablets
9906242|NCT00657787||PTSD|Combat-exposed men and women with PTSD deployed to OIF/OEF.
9906243|NCT00657787||High Utilizers|A comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD
9906244|NCT00657787||Not OIF/OEF|A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones
9906245|NCT00657800|Experimental|Group 1|Behavioral - Intensified coordinated inpatient diabetes education program (IDEP)
9906246|NCT00657800|No Intervention|Group 2|Diabetes education as is typically provided by clinical staff
9906247|NCT00657813|Experimental|Access [123I]MNI-330 and SPECT Imaging|
9906248|NCT00657839|Experimental|Arm 1|
9906249|NCT00657839|Placebo Comparator|Arm 2|
9906250|NCT00657852|Experimental|Pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
9906251|NCT00657852|Placebo Comparator|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
9993908|NCT01476631|Experimental|Arm B: 60 minutes walking|First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
9993909|NCT01476657|Experimental|IPI-145|IPI-145 is administered orally as a capsule formulation. The IPI-145 drug product is supplied as 1 mg, 5 mg, 25 mg, and 100 mg formulated capsules. IPI-145 will be administered orally daily during each 28-day cycle. Patients will be evaluated for DLTs in the dose escalation portion of the study during Cycle 1 (28 days), after which treatment may continue for additional cycles.
9993910|NCT01476670||Posterior fossa tumor|Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study.
9993911|NCT01476683|Experimental|FCT|A single 2 x100 mg dose of an experimental Racecadotril Film-coated tablet (FCT) administered orally with 240 ml of water, with a 7- day washout between visits.
9993912|NCT01476683|Experimental|RPB|A single 2 x100 mg dose of an experimental Racecadotril Powder Blend administered orally with 240 ml of water, with a 7- day washout between visits.
9667238|NCT03828201|Experimental|Investigational: DRAMATIC-40 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
9667239|NCT03825510|Experimental|Treatment Arm|
9993913|NCT01476683|Active Comparator|TFT|A single 2 x 100 mg dose of a marketed Tiorfast® capsule administered orally with 240 ml of water, with a 7-day washout between visits.
9993914|NCT01476683|Active Comparator|TFR|A single 175 mg dose of a marketed Tiorfanor® 175 mg FCT administered orally with 240 ml of water, with a 7-day washout between visits.
9993915|NCT01476735|Active Comparator|split-dose polyethylene glycol solution|first dose (1,5 l) of polyethylene glycol solution taken at 6-7.00 in the evening before colonoscopy, second dose (1,5 l) taken at 5.30-6.00 in the morning of a day of colonoscopy; additional bisacodyl taken at 12.00 at the day before colonoscopy
9993916|NCT01476735|Active Comparator|Individual preparation for colonoscopy|
9993917|NCT01476761|Active Comparator|MicroCutter Stapling Device|Patients undergoing surgical treatment with the MicroCutter Stapling Device
9993918|NCT01476774|Active Comparator|Buprenorphine Transdermal System|
9993919|NCT01476774|Active Comparator|Tramadol CR|
9993920|NCT01476787|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles.~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
9993921|NCT01476787|Active Comparator|Control|• ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
9993922|NCT01476800|Experimental|YM178 OCAS alone|
9993923|NCT01476800|Active Comparator|Ketoconazole alone|
9993924|NCT01476800|Experimental|YM178 OCAS and ketoconazole|
9993925|NCT01476813|Experimental|Glyco 25|BDP/FF (400/24 daily)+ Glyco 25µg daily
9993926|NCT01476813|Experimental|Glyco 50|BDP/FF (400/24 daily)+ Glyco 50 µg daily
9993927|NCT01476813|Experimental|Glyco 100|BDP/FF (400/24 daily)+ Glyco 100µg daily
9993928|NCT01476813|Active Comparator|BDP/FF 400/24|BDP/FF 400/24
9993929|NCT01476865||Healthy|normal, healthy people
9993930|NCT01476865||RA|rheumatoid arthritis patients
9993931|NCT01476878|Experimental|Open Arm|Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
9993932|NCT01476891|Active Comparator|Wait-List|Wait-list Control Group. The control group will receive the next available online MBSR program.
9993933|NCT01476891|Active Comparator|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
9993934|NCT01476917|Experimental|Treatment|Subjects that completed the ATLAST Study
9993935|NCT01476930|Experimental|cupping serkangabin|migraine cases treated by cupping and serkangabin syrup
9993936|NCT01476930|Active Comparator|conventional|migraine cases treated by conventional drug treatment protocols
9993937|NCT01476943||Patient treated with Belatacept at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
9993938|NCT01476943||Patient treated with CNI at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
9993939|NCT01476956||Rheumatoid Arthritis|
9517574|NCT03305185|Experimental|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
9993940|NCT01476969|Experimental|Manual Tourniquet|
9993941|NCT01476982||Emergency Department Patients|Patients presenting to the Emergency Department complaining of chest pain.
9993942|NCT01476995||Controls|Men and women ages 18-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
9993943|NCT01476995||Five Diagnosis Group|Men and women ages 18-85 with at least one active medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
9993944|NCT01477021|Experimental|Treatment (NY-ESO-1 specific CD8+ T cells)|Patients receive cyclophosphamide IV on days -3 and -2. Patients receive NY-ESO-1-specific T cells IV on day 0.
9993945|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 6 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 6 months.
9993946|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 6 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 6 months.
9993947|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 3 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 3 months.
9993948|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 3 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 3 months.
9997869|NCT01512654|Other|algorithm DIAdvisor activated|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
9997870|NCT01512654|Other|algorithm of DIAdvisor disactivated|Glucosepredictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
9997871|NCT01512680|Experimental|Type 1 diabetes patient|Type 1 diabetes patient are included in this study to have an education to Functional Insulin Therapy (intervention)
9997872|NCT01512706|Experimental|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
9997873|NCT01512706|Experimental|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
9993949|NCT01477047||Patients receiving primary hip or knee arthoplasty|
9993950|NCT01477060|Other|ARM A - Lapatinib|hormonal therapy + lapatinib (1250mg/die) until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
9993951|NCT01477060|Other|ARM B - Metformin|Hormonal therapy + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
9993952|NCT01477060|Other|ARM C - Lapatinib + Metformin|Hormonal therapy + lapatinib + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
9993953|NCT01477073|Experimental|FSH-GEX 75 IU|follitropin epsilon 75 IU QD
9993954|NCT01477073|Experimental|FSH-GEX 150 IU|follitropin epsilon 150 IU QD
9993955|NCT01477073|Experimental|FSH-GEX 150 IU QAD|follitropin epsilon 150 IU QAD
9993956|NCT01477073|Active Comparator|recombinant FSH|Gonal-f 150 IU QD
9993957|NCT01477073|Active Comparator|urinary FSH|Bravelle 150 IU QD
9993958|NCT01477073|Placebo Comparator|Placebo|Placebo QD
9993959|NCT01477086||Hip fracture|We included patients with traumatic hip fracture, with surgery and who are admitted for rehabilitation
9993960|NCT01477099|Experimental|Toothbrushing with a manual brush|Toothbrushing with a manual brush
9993961|NCT01477099|No Intervention|No toothbrushing|no toothbrushing
9993962|NCT01477112|Experimental|Supplemented Diabetics (DB)|Diabetics supplemented with betacarotene for 45 days
9993963|NCT01477112|Experimental|Unsupplemented Diabetics (DS)|Diabetics without betacarotene supplementation
9993964|NCT01477112|Active Comparator|Supplemented Controls (CB)|Controls supplemented with betacarotene for 45 days
9667240|NCT03824756|Experimental|NGO supported GMP program|Intervention: NGO supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
9993965|NCT01477112|Active Comparator|Unsupplemented Controls (CS)|Controls without betacarotene supplementation
9993966|NCT01477125|Experimental|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
9993967|NCT01477125|Placebo Comparator|Control version of Flex|30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
9993968|NCT01477138||DDD(R)|SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.
9993969|NCT01477138||AAI(R)<=>DDD(R)|SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum
9906252|NCT00657865|Active Comparator|1|Ramipril
9906253|NCT00657865|Placebo Comparator|2|Placebo
9906254|NCT00657878|Experimental|non platinum based chemotherapy|a non platinum based therapy (corresponding to stealth liposomal doxorubicin, or topotecan, or gemcitabine,or any other drug approved in clinical practice for the treatment of patients with ovarian cancer after previous platinum-based chemotherapy) followed by a platinum based chemotherapy at disease progression
9906255|NCT00657878|Active Comparator|platinum based chemotherapy|platinum based chemotherapy (corresponding to the combination of carboplatin + paclitaxel, or carboplatin + gemcitabine for patients with significant but lower than grade 3 neuropathy at baseline) followed by a non platinum based chemotherapy at disease progression
9906256|NCT00657891|Placebo Comparator|1|Placebo Injection
9906257|NCT00657891|Experimental|2|Xolair at 0.016 mg/kg/IgE(iu/ml)/4 wks
9906258|NCT00657904|Experimental|1|
9906259|NCT00657904|Placebo Comparator|2|
9906260|NCT00657930||A|
9906261|NCT00657943|Experimental|1M|Metformin + Levemir x1
9906262|NCT00657943|Placebo Comparator|1P|Placebo + Levemir x1
9906263|NCT00657943|Experimental|2M|metformin + NovoMix
9906264|NCT00657943|Placebo Comparator|2P|Placebo + NovoMix
9906265|NCT00657943|Experimental|3M|Metformin + 4x therapy
9906266|NCT00657943|Placebo Comparator|3P|Placebo + 4x therapy
9906267|NCT00657969||1|CAD-group (Cervical Artery Dissection - group): consecutive patients with cervical artery dissection, with or without associated cerebral ischemia, hospitalized in one of the participating neurological centers; standardized inclusion and exclusion criteria apply
9906268|NCT00657969||2|IS-group (Ischemic Stroke - Group): patients selected among consecutive patients hospitalized for an ischemic stroke without CAD, in the same centers as patients from group1, frequency-matched on age and gender with group1; standardized inclusion and exclusion criteria apply
9906269|NCT00657969||3|HC-group (Healthy Control - Group): DNA of healthy individuals from existing DNA-databases will be used as controls for the Belgian, French, German and Swiss centers; the other centers are recruiting their own age- and sex-matched healthy controls; individuals from the 3 groups (CAD, IS and HC) are strictly matched on geographical origin in order to avoid stratification bias
9906270|NCT00657982|Experimental|1|RAD001 10 BID 6 weeks before definite treatment for localized prostate cancer
9906271|NCT00657995|Experimental|2|Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
9906272|NCT00658034|Active Comparator|1|Acupuncture
9906273|NCT00658034|Sham Comparator|2|Placebo Acupuncture
9906274|NCT00658060||1|"1.Fulfilling the Tel Hashomer criteria for the diagnosis of FMF [5].~2.Suffering from episodes of exertional leg pain and or exertional ankle edema~3.18-45 years old~4.On a stable (≥ 2 weeks) dose of oral colchicine therapy~5.Non-smokers"
9906275|NCT00658060||2|"Control group~1.Healthy subjects~2.18-45 years old~3.Non-smokers"
9906276|NCT00658073|Active Comparator|A|Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.
9906277|NCT00658073|Active Comparator|B|Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.
9906278|NCT00658073|Active Comparator|C|Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A.
9906279|NCT00658099||A|
9906280|NCT00658099||B|
9906281|NCT00658125|Experimental|Experimental|
9906282|NCT00658164|Experimental|1|
9906283|NCT00658177|Experimental|Arm 1|
9906284|NCT00658177|Placebo Comparator|Arm 2|
9906285|NCT00658190||1|Women obtaining routine Pap tests for cervical cancer screening
9906286|NCT00658203|Active Comparator|1|PEA optimized CRT
9906287|NCT00658203|Other|2|Standard optimized CRT
9906288|NCT00658216||Longitudinal|Prospective study : cohort of consecutive patients recruited over 2 years
9906289|NCT00658229|Experimental|Strength training group|A four months strength training program during androgen deprivation therapy for prostate cancer patietns.
9906290|NCT00658229|No Intervention|Control group|Patients in the control group are not discouraged from performing normal activities. They are however asked not to start a strength training program or increase their activity level in the same period as the experimental group is performing their strength training program. We will offer the control group a modified strength training program after the post-intervention assessment.
9906291|NCT00658242||I|Subjects having Craniofacial surgery
9906292|NCT00658255|Experimental|1|
9906293|NCT00658255|Active Comparator|2|
9906294|NCT00658268|Experimental|1|
9906295|NCT00658268|Placebo Comparator|2|
9906296|NCT00658281||OBI KV System + CBCT Scanning|Breast cancer patient radiation treatment set up using OBI KV system and CBCT scanning or CT-on-rail system to verify standard EPID for positioning.
9906297|NCT00658307|Experimental|1|
9906298|NCT00658307|Experimental|2|
9906299|NCT00658307|Sham Comparator|3|
9906300|NCT00658346||1|HIV-1 group O infected patients
9906301|NCT00658346||2|HIV-1 group M infected patients
9906302|NCT00658398|Experimental|ICP to prevent alcohol misuse.|Interactive Computer Program (ICP) to prevent alcohol misuse.
9906303|NCT00658398|Sham Comparator|ICP to enhance balanced diet|2. Interactive Computer Program to enhance balanced diet (sham intervention)
9906304|NCT00658450|Experimental|Cognitive rehabilitation training|Children in this arm will the receive the intervention comprising of 16 cognitive rehabilitation training (CRT) exercises for 8 weeks. These exercises will train different cognitive skills including attention, visual spatial processing, logical skills and memory.
9906305|NCT00658450|No Intervention|Treatment as usual|Children in this group will not receive any intervention, they will undergo the usual post discharge treatment for brain injured children at Mulago Hospital (the study site). This is the treatment as usual (TAU) group.
9906306|NCT00658463|Experimental|1|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
9906307|NCT00658463|Placebo Comparator|2|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
9906308|NCT00658476|Experimental|Omega-3 Fatty Acids|Adolescents receive cognitive behavior therapy in combination with Omega-3 fatty acid supplements.
9906309|NCT00658476|Placebo Comparator|Placebo|Adolescents receive cognitive behavior therapy in combination with placebo.
9906310|NCT00658489|Active Comparator|1|Residents randomized to the promotion of oral health group will receive training consisting of 7 modules (3 on the Bright Futures curriculum and 4 on oral health promotion). They will then enroll 3 patient-child dyads from their practice who present for a well child care visit. Outcomes will be obtained by completing pre- and post-study surveys. Residents will be observed by a faculty preceptor during 3 different patient encounters, and will receive feedback at the end of the 6 month study period.
9906311|NCT00658489|Active Comparator|2|Residents randomized to the prevention of iron deficiency group will complete one web-based module.
9906312|NCT00658502||1|
9906313|NCT00658502||2|
10212969|NCT04776993|Experimental|Methimazole|Antithyroid drugs (at individualized dosage) for 72 weeks and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
10212970|NCT04776993|Active Comparator|Thyroid ablation|Radioiodine therapy or total thyroidectomy (according to ultrasound thyroid volume) and a cumulative dose of 4.5 g of methylprednisolone divided into 12 weekly infusions
9906314|NCT00658580|Active Comparator|A|Every 3 weeks intravenous cisplatin plus etoposide
9906315|NCT00658580|Experimental|B|Every 3 weeks intravenous epirubicin plus ifosfamide plus etoposide
9906316|NCT00658593|Active Comparator|GEMCAP|Gemcitabine 1000mg/m2 IV days 1 and 8 ever 21 days; Capecitabine 650mg/m2 PO BID days 1-14 every 21 days.
9906317|NCT00658593|Active Comparator|Gemcitabine Alone|Gemcitabine 1000mg/m2 IV days 1, 8 and 15 every 28 days
9906318|NCT00658645|Experimental|Bifeprunox|
9906319|NCT00658645|Placebo Comparator|Placebo|
9906320|NCT00658645|Active Comparator|Quetiapine|
9906321|NCT00658671|Experimental|1|Dose-escalation
9906322|NCT00658671|Experimental|2|Advanced cancer, excluding patients with colorectal or ovarian cancers
9906323|NCT00658671|Experimental|3|Recurrent or resistant epithelial ovarian cancer
9906324|NCT00658671|Experimental|4|Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
9906325|NCT00658710|Active Comparator|1|patients who continue physical therapy sessions during two months.
9906326|NCT00658710|No Intervention|2|patients who stop physical therapy sessions during two months
9906327|NCT00658749|Experimental|1|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
9906328|NCT00658749|Placebo Comparator|2|Physiologic saline solution
9906329|NCT00658827||Group 1a: Remicade Cohort|Female patients who were exposed to Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
10212971|NCT04776928|Experimental|Provider-level push report notifications|Push reports will be sent via using a secure email client. The email will be sent to the email address provided to the study team by the surgeon or site.
10212972|NCT04776928|No Intervention|No intervention|Sites who did not sign Exhibit B-1.
10212973|NCT04776044|Experimental|ATR-002|Participants will receive 900mg ATR-002 on day 1 (6 tablets with 150mg ATR-002; once daily), and 600mg ATR-002 on days 2 - 6 (4 tablets; once daily)
10212974|NCT04776044|Placebo Comparator|Placebo|Participants will receive matching tablets placebo on day 1 (6 tablets, once daily), and matching tablets placebo on days 2 - 6 (4 tablets per day, once daily)
9906330|NCT00658827||Group 1b: Remicade Cohort|Infants born to Group 1a patients.
9906331|NCT00658827||Group 2a: Other Anti-TNF agents Cohort|Female patients who were exposed to anti-TNFs other than Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
9906332|NCT00658827||Group 2b: Other Anti-TNF agents Cohort|Infants born to Group 2a patients.
9906333|NCT00658827||Group 3a: Non-biologic Systemic Therapy Control Cohort|Female patients who were exposed to systemic therapy other than biologic agents at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
9906334|NCT00658827||Group 3b: Non-biologic Systemic Therapy Control Cohort|Infants born to Group 3a patients.
9906335|NCT00658827||Group 4a: Population Control Cohort|Female patients with no record of the diseases of interest and no exposure to biologic or non-biologic systemic therapy at any time during pregnancy (and up to 3 months prior to LMP, if the information is available).
9906336|NCT00658827||Group 4b: Population Control Cohort|Infants born to Group 4a patients.
9906337|NCT00658840|Experimental|1|"Primary objectives :~To evaluate the tumor response rate, local control rate and compliance (acute and late toxicity, esp. gastrointestinal tract toxicity) of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma~Secondary objectives :~To evaluate the impact of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma by analyzing the progression-free survival rate and overall survival rate."
9906338|NCT00658853|Active Comparator|1|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a 5% graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
9906339|NCT00658853|Active Comparator|2|4 times 4 minutes interval training in hyperoxia - 100% oxygen
9906340|NCT00658853|Active Comparator|3|One leg at a time training 4 times 4 minutes interval training using cycling ergometer
9906341|NCT00658905|Active Comparator|rhBSSL|
9906342|NCT00658905|Placebo Comparator|Placebo|
9906343|NCT00658918|Active Comparator|1|Ciclesonide 200µg
9906344|NCT00658918|Active Comparator|2|Ciclesonide 100µg
9906345|NCT00658918|Active Comparator|3|Ciclesonide 25µg
9906346|NCT00658918|Placebo Comparator|4|Placebo
9906347|NCT00658931|Experimental|Treatment|
9906348|NCT00658944||A|Patients suffering from stress or mixed urinary incontinence
9906349|NCT00658957|Experimental|A|Daily standard wound care and topical application of the gentamicin-collagen sponge twice weekly
9906350|NCT00658957|Placebo Comparator|B|Daily standard wound care and topical application of the placebo sponge twice weekly
9906351|NCT00658983|Experimental|1|Autologous Platelet Enriched Gel
9906352|NCT00658983|Active Comparator|2|Metalloproteinase Inhibitor (Promogran)
9906353|NCT00659009|Active Comparator|1|Barometric pressure equivalent to sea level (760 mm Hg).
9906354|NCT00659009|Experimental|2|Barometric pressure equivalent to 6000 feet (609 mm Hg)
9906355|NCT00659009|Experimental|3|Barometric pressure equivalent to 8000 feet (565 mm Hg).
9906356|NCT00659022|Active Comparator|A|immediate surgery of the primary colorectal tumor, no neoadjuvant therapy
9906357|NCT00659022|Experimental|B|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
9906358|NCT00659022|Experimental|C|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
9906359|NCT00659022|Experimental|D|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
9906360|NCT00659035||IT|Subjects receiving 1-10 mg/day of morphine or its equivalent doses of opioid medications through intrathecal route. Intrathecal medications are administered through a catheter in spinal cord
9933698|NCT05286814|Experimental|2/HAIP +M9241+GemOx|M9241+HAIP FUDR and Dexamethasone chemotherapy in combination with GemOx
9798352|NCT01625988|Experimental|LY2951742|LY2951742: 150 milligrams (mg), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
9798353|NCT01625988|Placebo Comparator|Placebo|Placebo: 0.9% Sodium Chloride, Untied States Pharmacopoeia (USP), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
9798354|NCT01626079|Experimental|MitraClip System|Percutaneous mitral valve repair using MitraClip System
9798355|NCT01626079|No Intervention|Control Group|Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.
9798356|NCT01626092|Experimental|Intent-To-Treat Patients|Patients with high-risk lysosomal and peroxisomal disorders treated with preparative regimen (Campath-1H 0.3 mg/kg intravenous (IV) on days -12 through -8, clofarabine 40 mg/m^2 IV on days -9 through -5, melphalan 140 mg/m^2 IV on day -4 and Total Body Irradiation with Marrow Boosting [ first dose of 200 cGy single dose; 5 doses of 160cGy for marrow boosting - 1000cGy cumulative exposure] by Volumetric-Modulated Arc Therapy [VMAT] on days -3 through -1). Hematopoietic stem cell transplantation will be infused on Day 0. Post-transplant immunosuppression to follow: Mycophenolate mofetil (MMF) begin day -3 and continue to day +30 or 7 days after engraftment, whichever is later; Cyclosporine A (CsA) begin day -3 and then taper at day +100 if related donor, day +180 for unrelated donor.
9798357|NCT01626118|Experimental|Indomethacin 40 mg TID|
9993970|NCT01477151|Active Comparator|sevoflurane|These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
10212975|NCT04773899|Other|Cohort C1|COVID19 (+) ICU patients with COVID19 pneumonia.
9798358|NCT01626118|Experimental|Indomethacin 40 mg BID|
9798359|NCT01626118|Placebo Comparator|Placebo|
9798360|NCT01626118|Experimental|Indomethacin 20 mg TID|
9798361|NCT01626352|Experimental|Bendamustine/Ofatumumab|All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
10212976|NCT04773899|Other|Cohort C2|COVID19 (-) matched ICU patients
10212977|NCT04773899|Other|Cohort C3|COVID19 (-) ASA 1 non-hospitalized patients
10212978|NCT04772755|No Intervention|Usual Care|Participants will receive usual care that follows administration of a vaccine and will have a 20 minute post vaccination observation period.
10212979|NCT04772755|Experimental|Buzzy ® and Electronic Game|Buzzy® will be applied to arm receiving vaccination for 30-60 seconds prior to vaccination and removed following vaccination. For the electronic game, participants will be instructed to select a game from a prepopulated list of games on a tablet provided by the study team and then play that game for a specified amount of time before, during and after the vaccination administration.
10212980|NCT04770233|Active Comparator|Early ACL reconstruction|Early ACL reconstruction is performed within 12 weeks after ACL injury and is followed by rehabilitation led by a physiotherapist. ACL surgical technique and rehabilitation is pragmatic according to the routines at the including centre.
10212981|NCT04770233|Active Comparator|Primary ACL rehabilitation|"Primary ACL rehabilitation is active rehabilitaion led by a physiotherapist. Active rehabilitation will begin as early as possible after the ACL injury. The goal of rehabilitation is to stabilized the knee without an operation.~ACL reconstruciton is still an option after 6 months if the knee is unstable or do not allow adequat return to physical activity. If the patient sustain new knee injuries secondary to the ACL injury or has major instability, ACL reconstruction may be necessary before 6 months. The patients randomized to active rehabilitation will be routinely followed-up at his/her local hospital at 6 months."
10212982|NCT04768153||Patients|
10213979|NCT02422381|Experimental|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
10213980|NCT02418195|Active Comparator|MDD with recent Suicide Attempt|All subjects with Major Depressive Disorder with a recent Suicide Attempt (in the past 2 weeks) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
9798362|NCT01626391|Experimental|TRx0237|
9798363|NCT01626391|Placebo Comparator|Placebo|
9798364|NCT01626456|Experimental|ALKS 9072, Low|
9798365|NCT01626456|Experimental|ALKS 9072, High|
9798366|NCT01626495|Experimental|CART-19 T Cells|The subject's thawed T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). The T cells will be infused over 10-15 minutes on days Days 0, and 1. Day 14 is tentative based on response.
9798367|NCT01626664|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
9798368|NCT01626664|Active Comparator|investigator's choice|Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
9798369|NCT01626690|Experimental|Pre-Warming|
9798370|NCT01626690|Active Comparator|Control|
9798371|NCT01626820|Experimental|Fluviral Adults Group|Subjects 18-60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
9798372|NCT01626820|Experimental|Fluviral Elderly Group|Subjects above 60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
9798373|NCT01626859|Experimental|MP-214 3mg|
9798374|NCT01626859|Experimental|MP-214 6mg|
9798375|NCT01626859|Experimental|MP-214 9mg|
9798376|NCT01626872|Experimental|MP-214 3mg|
9798377|NCT01626872|Experimental|MP-214 6mg|
9798378|NCT01626872|Experimental|MP-214 9mg|
9798379|NCT01626872|Active Comparator|Risperidone 4mg|
9798380|NCT01626885|Experimental|MP-214 1.5-9 mg|
9798381|NCT01626989|Active Comparator|BiPAP auto SV Advanced|BiPAP auto SV Advanced
9798382|NCT01626989|Experimental|BiPAP auto SV 4|Auto Servo Ventilation Device
9906361|NCT00659035||Oral|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone), but not also receiving anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
9906362|NCT00659035||Oral + Anticonvulsant|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone) and anticonvulsants (gabapentin, pregabalin, topiramate), but not also receiving muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
9906363|NCT00659035||Control -Pain|Subject not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
9906364|NCT00659035||Control -No Pain|Age-matched volunteers (NO PAIN) not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
9906365|NCT00659048|Active Comparator|1|Ciclesonide 200µg
9906366|NCT00659048|Placebo Comparator|2|Placebo
9906367|NCT00659074|Experimental|A|Ondansetron ODT
9906368|NCT00659074|Active Comparator|B|Zofran ODT
9906369|NCT00659087|Experimental|Femoral Block|Those receiving femoral block in addition to usual pain management
9906370|NCT00659087|Active Comparator|Usual Care|Those receiving only usual pain management without a femoral block
9906371|NCT00659100|Experimental|A|
9906372|NCT00659152||1: ALI/ARDS|
9906373|NCT00659178|Experimental|SB-485232 plus pegylated liposomal doxorubicin|Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.
9906374|NCT00659204|Experimental|nano-silver gel|
9906375|NCT00659204|Active Comparator|alcohol-based gel|
9906376|NCT00659217|Experimental|2|mesenchymal stem cell Autologous MSC transplantation
9906377|NCT00659243|Experimental|rhBSSL|
9906378|NCT00659243|Placebo Comparator|Placebo|
9906379|NCT00659282||A|biphasic insulin aspart
9906380|NCT00659321|Active Comparator|1|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
9906381|NCT00659321|Placebo Comparator|2|16 weeks treatment with placebo
9906382|NCT00659347|Active Comparator|1|
9906383|NCT00659347|Placebo Comparator|2|
9906384|NCT00659386|Experimental|A|Patients with chronic idiopathic cardiomyopathy and EMB proven high PVB19 virus load.
9935760|NCT03235219|Experimental|Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo|Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.
9906385|NCT00659412|Experimental|Course A1|
9906386|NCT00659412|Placebo Comparator|Course A2|
9906387|NCT00659412|Experimental|Course B|Open-label extension
9906388|NCT00659451|Experimental|2|Losartan
9906389|NCT00659451|Active Comparator|1|Amlodipine
9906390|NCT00659464||1|Children who present to the heart center exercise stress lab for investigation of syncope
9906391|NCT00659477|Experimental|single arm|
9906392|NCT00659503|Active Comparator|1|Ciclesonide 200µg
9906393|NCT00659503|Placebo Comparator|2|Placebo
9906394|NCT00659516||1|intubated patients
9906395|NCT00659516||2|non intubated patients
9906396|NCT00659542|No Intervention|1|mesh fixation by absorbable sutures
9906397|NCT00659542|Experimental|2|mesh fixation by cyanoacrylate glue
9906398|NCT00659555|Experimental|Treatment A receivers|Subjects received pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution in Period 1
9906399|NCT00659555|Experimental|Treatment B receivers|Subjects received ketoconazole, daily 400 mg oral dose on Days 1 to 8; pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution on Day 5 in Period 2
9906400|NCT00659594|Active Comparator|1|Ciclesonide 200µg
9906401|NCT00659594|Placebo Comparator|2|Placebo
9906402|NCT00659620|Experimental|1|transplantation of mesenchymal stem cell
9906403|NCT00659659|Experimental|1|MEDI-563
9906404|NCT00659659|Experimental|2|MEDI-563
9906405|NCT00659659|Placebo Comparator|4|Placebo
9906406|NCT00659659|Placebo Comparator|5|Placebo
9906407|NCT00659685|Experimental|A|Subjects received Kali formulated products under fasting conditions
9906408|NCT00659685|Active Comparator|B|Subjects received GlaxoSmithKline formulated products under fasting conditions
9906409|NCT00659698|Experimental|1|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
9906410|NCT00659698|No Intervention|2|glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale
9906411|NCT00659750|Active Comparator|1|Ciclesonide 200µg
9906412|NCT00659750|Placebo Comparator|2|Placebo
9906413|NCT00659763||A|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill the ROM III criteria for IBS
9906414|NCT00659763||B|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill he ROME III criteria for IBS
9906415|NCT00659776|Active Comparator|1|Subjects with MS or any other inflammatory process
9906416|NCT00659776|Active Comparator|2|Subjects with stroke
9906417|NCT00659776|Active Comparator|3|Subjects receive ferumoxytol before cardiac surgery or CNS vascular surgery
9906418|NCT00659776|Active Comparator|4|Subjects receive ferumoxytol after cardiac surgery or CNS vascular surgery
9906419|NCT00659841|Active Comparator|1|Ciclesonide 200µg
9906420|NCT00659841|Placebo Comparator|2|Placebo
10212983|NCT04765644|Active Comparator|Celecoxib|"Phase 1: Twenty volunteers will receive celecoxib 200 mg, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
10212984|NCT04765644|Placebo Comparator|Placebo|"Phase 1: Twenty volunteers will receive a placebo capsule, 2 times/day (total 400 mg/day) for 7 days. At this point, the study team will perform an interim analysis of the data. If our primary endpoint is not achieved we may revise our endpoints and/or if additional power is required, we may recruit up to an additional n=20 volunteers per group. This analysis may also serve as a stop-go checkpoint for continuation of the second phase of the study. If we do not see any effects of celecoxib on endothelial or cardiovascular function, we will not proceed to phase 2. If we do see a negative effect, we will proceed to phase 2.~In phase 2 participants will be re-invited to the study site following a 4-8 week washout period. Participants will then receive either treatment with placebo + 10g L-arginine supplementation (20 participants) or celecoxib + 10g arginine supplementation (20 participants) for a total of 7 days"
10212985|NCT04760873|Experimental|Cryotherapy for GAVE|Subjects will undergo cryotherapy for GAVE
10213981|NCT02418195|Active Comparator|MDD with Suicidal Ideation no attempt|All subjects with Major Depressive Disorder with recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
9906421|NCT00659854|Placebo Comparator|Non milk or soy based formula|25 infants , non milk or soy based formula .
9906422|NCT00659854|Active Comparator|2|Intervention with milk based formula will be given to 25 infants.
9906423|NCT00659867|Experimental|A|Chromoscopy-guided endomicroscopy with targeted biopsies
9906424|NCT00659867|Active Comparator|B|Standard endoscopy with random and targeted biopsies
9906425|NCT00659893|Experimental|1|Cohort 1 One 25 cm2 treatment area; on one arm
9906426|NCT00659893|Experimental|2|Cohort 2 One 50cm2 contiguous treatment area; on one arm
9906427|NCT00659893|Experimental|3|Cohort 3 Two 25cm2 treatment areas; one on each arm
9906428|NCT00659893|Experimental|4|Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm
9906429|NCT00659893|Experimental|5|Cohort 5 One 75cm2 contiguous treatment area; on one arm
9906430|NCT00659893|Experimental|6|Cohort 6 Two 50cm2 contiguous treatment area; one on each arm
9906431|NCT00659893|Experimental|7|Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm
9906432|NCT00659893|Experimental|8|Cohort 8 One 100cm2 contiguous treatment area; on one arm
9906433|NCT00659906|Experimental|1|Progressive resistance training program 3 times a week for 12 months
9906434|NCT00659906|Active Comparator|2|Flexibility training 3 times a week for 12 months
9906435|NCT00659919|Placebo Comparator|Placebo|The patients in this arm received placebo
9906436|NCT00659919|Active Comparator|Trazodone|The patients on this arm received Trazodone for 3 consecutive days
9906437|NCT00659932|Experimental|1|
9906438|NCT00659932|Active Comparator|2|
9906439|NCT00659958|Experimental|1|
9906440|NCT00659971|Experimental|1|PAC113 0,15% mouthrinse
9906441|NCT00659971|Experimental|2|PAC113 0,075% mouthrinse
9906442|NCT00659971|Experimental|3|PAC113 0,0375% mouthrinse
9906443|NCT00659971|Active Comparator|4|Nystatin suspension
9906444|NCT00659997|Active Comparator|1|1 Individuals treated with Albendazole
9906445|NCT00659997|Active Comparator|2|Individuals treated with Levamisole
9906446|NCT00660036|Experimental|Gemtuzumab ozogamicin/Mitoxantrone/Etoposide|
9906447|NCT00660062|Experimental|Escitalopram 10 mg daily|Escitalopram 10 mg daily
9906448|NCT00660062|Experimental|Escitalopram 20 mg daily|Escitalopram 20 mg daily
9906449|NCT00660062|Experimental|escitalopram 30 mg daily|escitalopram 30 mg daily
9906450|NCT00660062|Active Comparator|Nortriptylin 100 mg daily|Nortriptylin 100 mg daily
9906451|NCT00660088||1|10 gram x 7 days, then 20 gram x 7 days active ingredient of original formulation
9906452|NCT00660088||2|20 grams x 14 days active ingredient of original formulation
9906453|NCT00660088||3|10 grams x 7 days; then 20 grams x 7 days of low protein formulation
9906454|NCT00660088||4|20 grams x 14 days of low protein formulation
9906455|NCT00660088||5|10 grams x 7 days; then 20 grams x 7 days of high protein formulation
9906456|NCT00660088||6|20 grams x 14 days of high protein formulation
9906457|NCT00660101|Experimental|1|5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
9906458|NCT00660101|Experimental|2|2.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
9906459|NCT00660101|Experimental|3|0.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
9906460|NCT00660140|Experimental|Gemcitabine + Carboplatin|"Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles."
9906461|NCT00660153|Experimental|single arm; multiple cohort|Single arm; multiple cohort
9906462|NCT00660166|Experimental|1|
9906463|NCT00660205||operation|Patients with upper gastro intestinal cancer who underwent surgery
9906464|NCT00660205||palliation|Patients with upper gastro intestinal cancer who did not underwent surgery
9906465|NCT00660205||control|Persons with no cancer who accepted to be control with blood samples and flow doppler ultrasound examination of both legs.
9906466|NCT00660231|Experimental|GemBex|Gemcitabine days 1 and 8 of a 3 week cycle (4 cycles total - 12 weeks) Bexarotene daily: in combination with Gemcitabine during first 12 weeks, then Bexarotene maintenance until disease progression.
9906467|NCT00660244||1|
9906468|NCT00660257|Experimental|No.1: 1.25 ug|
9906469|NCT00660257|Experimental|No.2: 2.5 ug|
9906470|NCT00660257|Experimental|No.3: 5.0 ug|
9906471|NCT00660257|Experimental|No. 4: 10 ug|
9933699|NCT05286788|Experimental|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
9933700|NCT05286580|Experimental|Intervention|o Sequential deployment of standardized M&M toolkit at a regional M&M conference.
9906472|NCT00660270|Experimental|Arm 1|"Surgery (pancreaticoduodenectomy, either standard or pylorus-preserving, with either standard or extended lymph node dissection, with or without portal vein resection) should occur at 8 weeks (plus or minus 2, not to exceed 10)~Radiation therapy will occur 8 weeks (plus or minus 2, not to exceed 10) postoperatively. Daily dose of 1.8 Gy five days per week. The first 45 Gy will be given to planning target volume 1. After 45 Gy, portals will be reduced to encompass planning target volume 2. The boost dose will be 5.4 Gy.~Cisplatin IV 25 mg/m2 on days 1, 8, 15, 22, 29, and 36 during radiation.~5-FU CIVI at 175 mg/m2/d on days 1-38 without interruption during radiation.~Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.~Gemcitabine IV 1000 mg/m2 4 weeks after conclusion of radiation (on a 3 weeks on/1 week off schedule) on days 71, 78, 85, 99, 106, and 113."
9906473|NCT00660296|Other|2|Air insufflation in colonoscopy
9906474|NCT00660296|Other|1|CO2 insufflation in colonoscopy
9906475|NCT00660322|No Intervention|Control|Families assigned to the control arm will receive usual asthma care from the child's primary care provider.
9906476|NCT00660322|Experimental|Intervention|The Telephone Asthma Program and usual care.
9906477|NCT00660335|Experimental|1|
9906478|NCT00660361||A|individuals co-infected with HIV-HBV and receiving tenofovir as aprt of their HAART regimen
9906479|NCT00660374|Active Comparator|A|
9906480|NCT00660374|Experimental|B|
9906481|NCT00660413|Experimental|AMG|Acceleromygraphy monitoring
9906482|NCT00660413|Active Comparator|MMG|Mechanomyography monitoring
9906483|NCT00660426|Experimental|Dose Level 1 (starting level)|"Oxaliplatin 85 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
9906484|NCT00660426|Experimental|Dose Level 2|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
9906485|NCT00660426|Experimental|Dose Level 3|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
9906486|NCT00660426|Experimental|Dose Level 4|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 1000 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
9906487|NCT00660439|Experimental|A|Treatment group, receives Narrative Exposure Therapy immediately after first assessment. Patients are assessed 1 and 6 months after treatment.
9906488|NCT00660439|No Intervention|B|Waiting list control group, receives no intervention for 3 months after first assessment. A second assessment is then administered and patients receives Narrative Exposure Therapy. Patients are assessed 1 and 6 months after treatment.
9906489|NCT00660452|Active Comparator|1|360 active patients with house dust mites related asthma with or without allergic rhinitis
9906490|NCT00660452|Placebo Comparator|2|180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.
9906491|NCT00660465||A18|
9906492|NCT00660478|Active Comparator|1|Zotarolimus eluting stent
9906493|NCT00660478|Active Comparator|2|Sirolimus stent
9906494|NCT00660491|No Intervention|1|Control
9906495|NCT00660491|No Intervention|2|moderate exercise training group
9906496|NCT00660491|Experimental|3|high intensity exercise group
9906497|NCT00660569||1|Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA
9906498|NCT00660634|No Intervention|B|
9906499|NCT00660634|Experimental|A|Endovascular angioplasty/stenting
9906500|NCT00660647|Experimental|methotrexate + adalimumab|Methotrexate and intraarticular triamcinolone hexacetonide plus adalimumab.
9906501|NCT00660647|Placebo Comparator|methotrexate + placebo|Methotrexate and intraarticular triamcinolone hexacetonide and placebo
9906502|NCT00660686|Experimental|1|Progressive resistance training program 3 times a week for 12 months
9906503|NCT00660686|Active Comparator|2|Seated flexibility training 3 times a week for 12 months
9906504|NCT00660712||1|Patients with bipolar disorder
9933701|NCT05285904||Ofatumumab|Population under routine medical care prescribed Ofatumumab in an early Relapsing Multiple Sclerosis
9906505|NCT00660725|Other|Vandetanib/GEMOX|All subjects receive the same combination study drug and follow the same study schedule. As a phase 1 study, only the doses will vary between subjects.
9906506|NCT00660738||01|Patients with clinical and spirometric diagnosis of COPD, with FEV1<80%
9906507|NCT00660751|Active Comparator|1|
9906508|NCT00660751|Placebo Comparator|2|
9906509|NCT00660764||1|Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca
9906510|NCT00660777|Sham Comparator|1|Control Group
9906511|NCT00660777|Active Comparator|2|Therapy Group
9906512|NCT00660803||1|Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
9906513|NCT00660842|Experimental|A|weekly chemotherapy
9906514|NCT00660842|Active Comparator|B|every 3 weeks chemotherapy
9906515|NCT00660855|Other|Arm 1|
9906516|NCT00660868||1|Patients with posttraumatic, idiopathic, and postinflammatory cause of smell loss; patients age between 18 and 50 years. Odor threshold better than 1.
9906517|NCT00660894|Experimental|tegafur-gimeracil-oteracil potassium|Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
9906518|NCT00660894|Active Comparator|tegafur-uracil and folinate calcium|Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.
9906519|NCT00660920|Experimental|ponatnib|Comparison of different dosages of ponatinib given orally once per day.
9906520|NCT00660933|Active Comparator|Group A|Group A: Administration of intravenous iron sucrose.
9906521|NCT00660933|Placebo Comparator|Group B|Group B: Administration of intravenous NaCl 0,9%.
9906522|NCT00660946||37 dialysis patients|37 chronic hemodialysis patients on warfarin requiring Laboratory INR monitoring for anticoagulation management.
9906523|NCT00660972|Experimental|1|Oral RAL and FTC/TDF for 72 weeks
9906524|NCT00660998|Experimental|Arm 1|
9906525|NCT00660998|Placebo Comparator|Arm 2|
9906526|NCT00661011|Experimental|A|Lobectomy followed by mediastinal concomitant chemoradiotherapy
9906527|NCT00661024|Placebo Comparator|1|RLN visualization alone
9906528|NCT00661024|Experimental|2|IONM of the RLN
9906529|NCT00661063|Experimental|K|drug - ketamine 1% gel
9906530|NCT00661063|Placebo Comparator|P|vehicle gel
9906531|NCT00661063|Experimental|M|association of ketamine and clonidine gel
9906532|NCT00661063|Experimental|C|clonidine gel
9906533|NCT00661076|Experimental|1|
9906534|NCT00661076|Experimental|2|
9906535|NCT00661076|Active Comparator|3|
9906536|NCT00661102|Experimental|1|
9906537|NCT00661102|Active Comparator|2|
9906538|NCT00661102|Placebo Comparator|3|
9906539|NCT00661115|Experimental|Arm 1|
9906540|NCT00661115|Placebo Comparator|Arm 2|
9906541|NCT00661128||1|European American people who have experienced SCA.
9906542|NCT00661128||2|European American people who have not experienced SCA.
9906543|NCT00661128||3|African American people who have experienced SCA.
9906544|NCT00661128||4|African American people who have not experienced SCA.
9906545|NCT00661167|Experimental|1|ABI-007
9906546|NCT00661180|Experimental|Arm 1|
9906547|NCT00661206|Active Comparator|Clopidogrel|
9906548|NCT00661206|Placebo Comparator|Placebo|
9906549|NCT00661219|Active Comparator|Arm 1|
9906550|NCT00661219|Placebo Comparator|Arm 2|
9906551|NCT00661245|Experimental|TOGA|The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.
9906552|NCT00661245|Sham Comparator|Control|A gastric sleeve is not formed.
9906553|NCT00661284||Ⅰ|Subject who have participated in previous studies and achieved DAS28 of < 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
9906554|NCT00661297|Experimental|Arm 1|
9906555|NCT00661297|Placebo Comparator|Arm 2|
9906556|NCT00661310|Experimental|I|Intervention by team consisting of Doctor, pharmacist and nurse
9906557|NCT00661310|No Intervention|C|
9933702|NCT05280457|Experimental|nivolumab-GX-188E-GX-I7|
9906558|NCT00661323||1|Healthy volunteers will be recruited through the use of an approved study recruitment flyer.
9906559|NCT00661323||2|Chemotherapy patients will be approached at the time of their nuclear scan to rule out cardiac disease prior to chemotherapy. These patients will be referred to the study by their doctor for the assessment of heart function.
9933703|NCT05279313|Experimental|Centanafadine Hydrochloride|"Adolescents (13 to 17 years of age, inclusive) to receive 328.8 mg daily.~Children (4 to 12 years of age, inclusive) will receive weight-based doses of centanafadine ranging from 82.2 mg to 328.8 mg daily"
9933704|NCT05279157|Experimental|ADASCs Group|5 patients, who will receive adipose tissue mesenchymal stem cells in a single dose as study treatment
9933705|NCT05279157|Experimental|Acellular laminas group|5 patients, who will receive decellularized corneal laminas as treatment medication
9933706|NCT05279157|Experimental|ADASCs recellularized laminas group|5 patients, who will receive adipose tissue mesenchymal cells combined with decellularized corneal laminas as study treatment in a single intervention
9933707|NCT05278208|Experimental|Phase I-II|"Pediatric patients (4 -12 years, Phase I) and adolescent and young adult patients (>12years, Phase II) with recurrent/progressive high-grade central nervous system tumors and meningiomas that express SST2A and demonstrate uptake on DOTATATE PET will receive Lutathera once every 8 weeks (1 cycle) for a total of 4 doses over 8 months~Phase I starting dose will be 200 mCi*(BSA/1.73m2), corresponding to the BSA-adjusted FDA approved adult Lutathera dosing. The first cycle will be used as the DLT period. Once MTD/RP2D is established, an efficacy expansion cohort of up to 10 patients will be opened to determine the preliminary efficacy of MTD/RP2D of Lutathera in this cohort~Phase II patients will receive the adult RP2D of 200 mCi every 8 weeks to determine the anti-tumor activity of Lutathera in this patient population, through evaluation of 6-month PFS as the primary efficacy endpoint. Response will be assessed on imaging (brain/spine MRI and DOTATATE PET) following every cycle."
9933708|NCT05276128|Other|WWB Reference|White wheat bread (WWB) without lipid supplements. The effects of this high glycaemic product on postprandial glucose and insulin responses are well studied.
9517575|NCT03305185|Active Comparator|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
9517576|NCT03305172|No Intervention|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
9933709|NCT05276128|Experimental|WWB 5g active lipids|WWB supplemented with 5 g active lipids, and 10 g control lipids
9933710|NCT05276128|Experimental|WWB 10g active lipids|WWB supplemented with 10g active lipids, and 5 g control lipids
9933711|NCT05276128|Experimental|WWB 15g active lipids|WWB supplemented with 15g active lipids, and 0 g control lipids
9933712|NCT05276128|Active Comparator|WWB 15 g control lipids|WWB supplemented with 15g control lipids
9933713|NCT05275426|Experimental|Ewing sarcoma|Participants have a diagnosis of Ewing sarcoma as molecularly defined by an EWSR1 fusion with an ETS-transcription factor family member including FLI1, ERG, ETV1, ETV4, and FEV
9933714|NCT05271565|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
9933715|NCT05271565|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
9906560|NCT00661349|Active Comparator|1|Nevirapine
9906561|NCT00661349|Experimental|2|Lopinavir/ritonavir
9906562|NCT00661375|Experimental|Arm 1|
9906563|NCT00661440|Other|1|
9906564|NCT00661440|Other|2|
9906565|NCT00661518||1|Patients scheduled for conventional aneurysm repair
9906566|NCT00661518||2|Patients scheduled for endovascular aneurysm repair
9906567|NCT00661596|Experimental|Arm 1|
9906568|NCT00661596|Placebo Comparator|Arm 2|
9906569|NCT00661635|Active Comparator|Arm 1|
9906570|NCT00661635|Active Comparator|Arm 2|
9906571|NCT00661635|Placebo Comparator|Arm 3|
9906572|NCT00661648|No Intervention|1|glucose levels were controlled using sliding scale
9906573|NCT00661648|Experimental|2|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
9906574|NCT00661700|Placebo Comparator|Arm 2|
9906575|NCT00661700|Experimental|Arm 1|
9906576|NCT00661739|Experimental|Singular Arm|Bendamustine treatment
9906577|NCT00661752||FBP studies|standard filtered backprojection image processing/reconstruction of full-time acquisition data
9906578|NCT00661752||half-time WBR|wide-beam reconstruction of simulated half-time acquisitions from standard full-time acquisitions
9906579|NCT00661752||Quarter-time stress|4 seconds per stop post-stress SPECT acquisitions reconstructed by the wide-beam reconstruction method
9667241|NCT03824756|Active Comparator|Non-supported GMP program|Comparison: Non-supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
9906580|NCT00661752||Quarter-time rest|6 seconds per stop rest SPECT acquisitions reconstructed by the wide-beam reconstruction method
9906581|NCT00661765|Active Comparator|Chantix immediate release tablet formulation|
9906582|NCT00661765|Experimental|Varenicline transdermal delivery system|
9906583|NCT00661791|No Intervention|A|Control Group receives routine care.
9906584|NCT00661791|Experimental|B.|massage group, receives massage only.
9906585|NCT00661791|Experimental|C.|Massage and Exercise group, receives both massage and exercise.
9906586|NCT00661804||Thalassemia cohort|"Thalassemia as documented by clinical diagnosis, including:~thalassemia (intermedia or major); HbH disease; HbH with non-deletional mutations, e.g., HbH Constant Spring E beta-thalassemia; Homozygous alpha-thalassemia (i.e., 4-gene alpha deletion or equivalent null alpha mutation); Other thalassemic conditions not explicitly excluded; Thalassemia intermedia due to heterozygous beta mutation with alpha-gene excess."
9906587|NCT00661804||Successful SCT cohort|Individuals who have received a successful hematopoietic SCT, defined as engraftment of all three cell lines and transfusion independence by 100 days post-transplant, for any of the disorders listed above;Monitored for end-organ injury related to thalassemia prior to their successful SCT;Participants who were enrolled in TCRN Registry or had a successful SCT after 01 Jan 2002.
9906588|NCT00661817|Active Comparator|1|Participants in this group will receive usual medical care and reading materials on weight loss.
9906589|NCT00661817|Experimental|2|Participants in this group will take part in the lifestyle modification program.
9906590|NCT00661843|Experimental|1|Intervention group: Intervention constitutes of 2 supervised yoga classes per week incorporating gentle Yoga postures, relaxation and meditation sequences In addition: daily home based sessions of yogic relaxation and meditation using a pre-recorded audio CD
9906591|NCT00661843|No Intervention|2|Control in waiting to be crossed over after control phase completed. Participants of this group studied using same objective and subjective outcome measures.
9906592|NCT00661856|Active Comparator|1|Soy Protein group 25g of Soy protein with no Isoflavones
9906593|NCT00661856|Experimental|2|Soy Isoflavone group 25g of Soy Protein with 90mg of Isoflavones
9906594|NCT00661856|Placebo Comparator|3|25g of Milk protein
9906595|NCT00661869|Active Comparator|Wellness Group|
9906596|NCT00661908||1|insulin-treated diabetic subjects of North-western part of Switzerland
9906597|NCT00661921|Active Comparator|40 mg AMG 108 Q2W|
9906598|NCT00661921|Active Comparator|150 mg AMG 108 Q2W|
9906599|NCT00661921|Active Comparator|75 mg AMG 108 Q2W|
9906600|NCT00661921|Placebo Comparator|Placebo Q2W|
9906601|NCT00661934||1|Dialysis Group
9906602|NCT00661934||2|Cardiac Malfunction Group
9906603|NCT00661947||Public|General public. Those who are not currently taking any medication besides birth control pills.
9906604|NCT00661973|Experimental|overall|
9906605|NCT00661986|Experimental|1|dark chocolate 6 g/day
9906606|NCT00661986|Active Comparator|2|dark chocolate 25 g/day
9906607|NCT00662051||OCP Users|
9906608|NCT00662051||Non-users of OCPs|
9906609|NCT00662064||1|Patients with lower urinary tract dysfunction
9906610|NCT00662064||2|Controls with normal lower urinary tract function
9906611|NCT00662077|Experimental|1|Ibandronate + Lifestyle modifications
9906612|NCT00662077|Other|2|Lifestyle modifications
9906613|NCT00662103|Active Comparator|progressive, aerobic exercise program|Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
9906614|NCT00662103|Active Comparator|progressive, resistance exercise program|Patients undergo resistance exercise training 3 days a week for 18 months.
9906615|NCT00662103|Active Comparator|flexibility and relaxation training [control]|Patients perform a series of whole body flexibility (stretching) and relaxation (guided imagery, progressive neuromuscular relaxation, focused breathing) exercises 3 days a week for 18 months.
9906616|NCT00662116|Experimental|1|
9906617|NCT00662116|Placebo Comparator|2|
9906618|NCT00662142|Experimental|1|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
9906619|NCT00662168||observation|Individuals with a diagnosis of carcinoid carcinoma
9906620|NCT00662181||H, NH|HIV positive patients with and without lipodystrophy
9906621|NCT00662194||1|HIV-HBV co-infected and receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
9906622|NCT00662194||2|HIV-HBV co-infected and receiving ART and CD4 count 200-500 cells/mm3
9906623|NCT00662194||3|HIV-HBV co-infected and receiving ART and CD4 count <200cells/mm3
9906624|NCT00662194||4|HIV-HBV co-infected and not receiving ART
9906625|NCT00662194||5|HIV-HCV co-infected & receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
9906626|NCT00662194||6|HIV-HCV co-infected and receiving ART and CD4 count 200-500 cells/mm3
9906627|NCT00662194||7|HIV-HCV co-infected and receiving ART and CD4 count <200cells/mm3
9906628|NCT00662194||8|HIV-HCV co-infected and not receiving ART
9906629|NCT00662220|Active Comparator|Standard dose|Standard-dose ribavirin (12-15 mg/kg/day) in combination with peginterferon 180µg QW
9906630|NCT00662220|Experimental|High dose|High-dose ribavirin (25-29 mg/kg/day) in combination with peginterferon 180µg QW
9906631|NCT00662246|Experimental|1|"Primary objectives :~to determine the recommended dose (i.e., the safest and most effective dose) by evaluating frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to proton beam radiotherapy for HCC."
9906632|NCT00662272|Experimental|1|Arm includes treatment with Fluzone® vaccine mixed with study product JVRS-100 adjuvant
9906633|NCT00662272|Active Comparator|2|Arm includes treatment with half adult dose of Fluzone® vaccine
9906634|NCT00662272|Active Comparator|3|Arm includes treatment with full adult dose Fluzone® vaccine
9906635|NCT00662285|Other|A: Niferex|100 mg Fe++
9906636|NCT00662324||1|Trial experienced cancer patients and their primary caregivers.
9906637|NCT00662324||2|Trial naive cancer patients and their caregivers.
9906638|NCT00662324||3|Health care professionals who are involved in running Phase I, II or III clinical trials.
9906639|NCT00662337|Experimental|1|Diphenydramine HCl
9906640|NCT00662350||Symptomatic Benign Protate Hypertrophy|Symptom Score (IPSS) greater than 15, requiring invasive treatment, Prostate size greater than 25 g, Prostatic urethra length between 2.0 cm and 5.5 cm
9906641|NCT00662376|Experimental|Test|oral nutritional supplement (assignment: according to consecutive random numbers)
9906642|NCT00662376|Placebo Comparator|Control|placebo (assignment: according to consecutive random numbers)
9906643|NCT00662402|Experimental|1-Extensive Consultations|Intervention- Receives extensive consulting services
9906644|NCT00662402|No Intervention|2-Regular levels of service|Control - Receives regular levels of service; one hour free services from each of the 4 units, with option to pay for more.
9906645|NCT00662415|Other|1|12 non-amputee control subjects will be scanned at 0, 2 and 4 weeks but will not recieve mirror therapy.
9906646|NCT00662415|Experimental|2|24 unilateral lower extremity amputee subjects will recieve daily mirror therapy for phantom limb pain and will be scanned at 0, 2, and 4 weeks.
9906647|NCT00662428|Experimental|Intervention|
9906648|NCT00662428|Active Comparator|Control|
9906649|NCT00662441|Experimental|Arm 1|
9906650|NCT00662454|Active Comparator|I|10 normal weight women (BMI < 25 kg/m2)
9906651|NCT00662454|Active Comparator|II|10 obese women (BMI >30 kg/m2)
9906652|NCT00662467|Active Comparator|1|aspirin and clopidogrel
9906653|NCT00662467|Experimental|2|aspirin, clopidogrel, and warfarin
9906654|NCT00662480|Experimental|1|Invited to screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
9906655|NCT00662480|No Intervention|2|Participants which are not offered vascular screening
9906656|NCT00662493|Experimental|1|Motor control retraining program
9906657|NCT00662519|Experimental|Neulasta|Subjects will receive Neulasta subcutaneously every 2 weeks for 12 weeks (6 doses). In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
9906658|NCT00662519|Placebo Comparator|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
9906659|NCT00662571||A|"Our hypothesis is that effective acamprosate response in alcohol dependent subjects may be influenced by genetically controlled variation in the functionality of the N-methyl-D-aspartate receptor (NMDA) and/or the type 5 metabotropic glutamate receptor (mGluR5). Hypothesis confirmation could lead to development of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations.~There will be no placebo drug given. Just measurement of genetic response."
9906660|NCT00662584|Experimental|1|This was an open-label study - all subjects received the intervention (rTMS treatment)
9906661|NCT00662610|Experimental|naproxcinod 375 mg - 750 mg -1125 mg bid|dose escalating
9906662|NCT00662610|Active Comparator|naproxen 250 mg -500 mg -750 mg bid|dose escalating
9906663|NCT00662623|Experimental|1|
9906664|NCT00662623|Active Comparator|2|Usual Care (Standard Care)
9798383|NCT01627002|Experimental|PA401|PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
9798384|NCT01627002|Placebo Comparator|Placebo|Placebo
9798385|NCT01627067|Experimental|Everolimus + Exemestane + Metformin|Patients take one 25 mg tablet of exemestane once daily, everolimus 10 mg orally per day and metformin 500 mg orally per day for three days. If there are no dose limiting toxicities, dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily. Drugs will be taken immediately after a meal at the same time each day.
9798386|NCT01627249|Active Comparator|Ranibizumab|
9798387|NCT01627249|Experimental|Aflibercept|
9798388|NCT01627249|Experimental|Bevacizumab|
9798389|NCT01627288|Experimental|Boost Radiation: Dose Level 1|2.4 Gy X 25 fractions = 60 Gy
9798390|NCT01627288|Experimental|Boost Radiation: Dose level 2|2.6 Gy X 25 fractions = 65 Gy
9798391|NCT01627288|Experimental|Boost Radiation: Dose level 3|2.8 Gy x 25 fractions = 70 Gy
9798392|NCT01627288|Experimental|Experimental: Boost Radiation Dose Level 0|"If the 2 dose limiting toxicities are documented at dose level 1, therapy will be de-escalated to Dose level 0 defined below.~Dose level 0: 2.2 Gy X 25 fractions = 55 Gy"
9798393|NCT01627327|Experimental|fluticasone furoate/vilanterol|inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
9798394|NCT01627327|Active Comparator|tiotropium bromide|anticholinergic
9798395|NCT01627340|Experimental|Diabetes Group|Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
9798396|NCT01627340|Active Comparator|Control Group|Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
9798397|NCT01627574|Experimental|Motivational Intervention|There are two, 45-60 minute sessions of tailored Motivational Interviewing (MI). The first session occurs at the enrollment of the study, the second at 3 month follow-up.
9798398|NCT01627574|Active Comparator|Didactic Educational Intervention|There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
9800332|NCT01684917|Other|Metabolomic inquiry|This inquiry took place prior to the randomized controlled trial and include 50 volunteers who will then be asked to volunteers of the weight loss study. Were randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option.
9800333|NCT01684930|Experimental|BR Juice (Beet-It Stamina Shot) and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
9800334|NCT01684930|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
9800335|NCT01684943|Experimental|Multiplex pharmacokinetic profiling|Multiplex pharmacokinetic profiling of regular human insulin, insulin aspart, insulin lispro, insulin glulisine, and regular human insulin. All subjects participated in the single study arm and received injections of each type of insulin. Blood samples were drawn at intervals for pharmacokinetic profiling.
9800336|NCT01684943|Experimental|Continuous insulin monitoring|Continuous insulin monitoring (CIM) of insulin lispro. Some subjects participated in the CIM sub-study, which is distinct from the Multiplex Pharmacokinetic Profiling study. This intervention involved administering insulin lispro and monitoring pharmacokinetic profile of the drug using blood samples and an investigational continuous insulin monitoring system.
9800337|NCT01685021|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody
9800338|NCT01685060|Experimental|LDK378|Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
9906665|NCT00662636|Experimental|Arm I|Patients receive oral dasatinib and lapatinib ditosylate once daily on days 1-28.
9906666|NCT00662662||Oropharyngeal Cancer|
9906667|NCT00662662||Non-Oropharyngeal Cancer|
9906668|NCT00662688|Active Comparator|chemotherapy|chemotherapy at investigator's discretion
9906669|NCT00662688|Experimental|dalteparin|dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.
9906670|NCT00662701|Active Comparator|1|Catheter RF ablation with complete circumferential ablation around the right and PVs, and additional lines between the lower and upper PVs, and towards the mitral valve ring.
9906671|NCT00662701|Active Comparator|2|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
9906672|NCT00662714|Experimental|1|Repaglinide; oral
9906673|NCT00662714|Active Comparator|2|short-acting Insulin (Actrapid)
9906674|NCT00662727|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
9906675|NCT00662727|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
9906676|NCT00662753|Active Comparator|home monitoring|home blood pressure monitor
9906677|NCT00662753|Experimental|monitor & phone call|home blood pressure monitor + phone calls
9906678|NCT00662779|Experimental|1|15 mcg arformoterol nebulizer + 1 inhalation of placebo inhalation powder
9906679|NCT00662779|Active Comparator|2|1 inhalation of formoterol fumarate inhalation powder (12 mcg/inhalation) + 2 ml of normal saline nebulizer
9906680|NCT00662779|Placebo Comparator|3|1 inhalation of placebo inhalation powder + 2 ml of normal saline nebulizer
9906681|NCT00662805||Salmeterol/Fluticasone propionate (50/500 μg)|Open label, 6 visits, single arm study
9906682|NCT00662844|Placebo Comparator|A1 vitamin D3 400IU|Orally for one year
9906683|NCT00662844|Placebo Comparator|A2 vitamin D3 800IU|Orally for one year
9906684|NCT00662844|Placebo Comparator|A3 vitamin D3 1600IU|Orally for one year
9906685|NCT00662844|Placebo Comparator|A4 Vitamin D3 2400 IU|Orally for one year
9906686|NCT00662844|Placebo Comparator|Placebo|Placebo for one year
9906687|NCT00662870|Experimental|DAPTACEL Lot 1|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 1
9906688|NCT00662870|Experimental|DAPTACEL Lot 2|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 2
9906689|NCT00662870|Experimental|DAPTACEL Lot 3|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 3
9906690|NCT00662870|Active Comparator|Pentacel|Participants receiving Pentacel vaccine
9906691|NCT00662883|Experimental|A|"PMI-150 (intranasal ketamine HCl), day 1~mometasone furoate, days 2-15~PMI-150 (intranasal ketamine HCl), day 15"
9906692|NCT00662896|Experimental|naproxcinod 375 mg bid|
9906693|NCT00662896|Active Comparator|naproxen 250 mg bid|
9906694|NCT00662896|Active Comparator|ibuprofen 600 mg tid|
9906695|NCT00662896|Experimental|naproxcinod 750 mg bid|
9906696|NCT00662896|Active Comparator|naproxen 500 mg bid|
9906697|NCT00662922||1|patients with hypoglycemia during intensive care
9906698|NCT00662922||2|patients without hypoglycemia during intensive care
9906699|NCT00662935|Experimental|2|the sequence of stimulation begins by OFF
9798399|NCT01627691|Experimental|Lotus Valve System|Patients enrolled will receive the Lotus Valve.
9798400|NCT01627782|Placebo Comparator|Placebo 3 times/week|
9798401|NCT01627782|Experimental|Ketamine 3 times/week|
9798402|NCT01627782|Experimental|Ketamine 2 times/week|
9798403|NCT01627782|Placebo Comparator|Placebo 2 times/week|
9798404|NCT01627860|Active Comparator|Topiramate add-on therapy|
9798405|NCT01627860|Experimental|Topiramate monotherapy|
9798406|NCT01628016|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%.~ABMT intervention: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes (4 sessions a week, roughly one session every other day with for each session)."
9798407|NCT01628016|Placebo Comparator|Placebo training|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 218 trials, and the time to complete a PT session is approximately 10 minutes as well.
9798408|NCT01628016|No Intervention|blank control|Participants only complete assessment at each point time.
9798409|NCT01628042|Experimental|Participants With Severe Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
9798410|NCT01628042|Experimental|Participants With Moderate Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
9798411|NCT01628042|Experimental|Participants With Mild Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
9798412|NCT01628042|Experimental|Healthy Matched Control Participants|Participants receive a single oral dose of vibegron 100 mg on Day 1.
9798413|NCT01628107|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
9798414|NCT01628120|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
9798415|NCT01628159|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
9798416|NCT01628198|Experimental|Renal denervation group|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
9798417|NCT01628250|Active Comparator|laparoscopic complete mesocolic excision|Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
9798418|NCT01628250|Active Comparator|D3 laparoscopic colectomy|Randomized group of patients receiving laparoscopic colectomy with D3-resection
9798419|NCT01628367|Experimental|Membrane|Test (membrane): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the test group will receive a high-density PTFE (d-PTFE) membrane over the socket.
9798420|NCT01628367|Active Comparator|Collagen plug|Control (collagen plug): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the control group will receive a collagen wound dressing over the socket.
9798421|NCT01628393|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
9798422|NCT01628393|Experimental|Ozanimod 1 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
9906700|NCT00662935|Experimental|1|the sequence of stimulation begins by ON
9798423|NCT01628393|Placebo Comparator|Placebo|Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.
9798424|NCT01628510|Active Comparator|Traditional NICU Positioning|Methods of positioning in the NICU have been used for several decades. These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper® The continued use of these methods of positioning is the control group in the current study.
9798425|NCT01628510|Experimental|Dandle Roo/Dandle Wrap|The new Dandle Roo and Dandle Wrap were developed by NICU professionals to support the neurodevelopment of the preterm infant, and this device is produced by Dandle Lion Medical. The Dandle Roo/Wrap provides all around contact, containment, and proprioceptive input, (which more closely mimics the uterine environment) and can decrease excitability and promote self-regulation, while also allowing for movement with recoil back to flexion.
9798426|NCT01628523||All ED patients requiring mechanical ventilation|
9798427|NCT01628549|Experimental|P005672-HCl approximately 0.75 mg/kg/day|One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
9798428|NCT01628549|Experimental|P005672-HCl approximately 1.5 mg/kg/day|Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
9798429|NCT01628549|Experimental|P005672-HCl approximately 3.0 mg/kg/day|Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
9798430|NCT01628549|Placebo Comparator|Placebo|Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks
9798431|NCT01628588||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
9798432|NCT01628601||POAG or OHT|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
9798433|NCT01628614||POAG or OHT|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
9798434|NCT01628692|Experimental|Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
9798435|NCT01628692|Experimental|Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
9798436|NCT01628692|Experimental|Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
9800339|NCT01685073|Experimental|Zolpidem|Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder
9800340|NCT01685073|Placebo Comparator|Placebo|Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder
9798437|NCT01628692|Experimental|Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day.
9798438|NCT01628718|Active Comparator|CPT-C|Cognitive Processing Therapy, cognitive version only (CPT-C) delivered in 12 60-minute one-on-one treatment sessions.
9798439|NCT01628718|Experimental|Adaptive Disclosure (AD)|Adaptive Disclosure delivered in eight 90-minute one-on-one treatment sessions.
9798440|NCT01628848|Experimental|SPM 962|SPM 962 transdermal patch
9798441|NCT01628848|Placebo Comparator|Placebo|Placebo transdermal patch
9798442|NCT01628874|Experimental|Lidocaine Injection|0.5 mL (5mg) of 1% lidocaine injection given with the J-Tip
9798443|NCT01628874|Active Comparator|lidocaine 2.5% and prilocaine 2.5% (EMLA) Cream|Patients in this arm will receive 1g EMLA cream if they are in the younger age group and 10g EMLA cream if they are in the older age group. This will be placed for a minimum of 30 minutes.
9798444|NCT01628913|Experimental|BEZ235|Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
9798445|NCT01628913|Active Comparator|Everolimus|Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
9798446|NCT01628926|Experimental|SPM 962|SPM 962 transdermal patch
9798447|NCT01628926|Active Comparator|Ropinirole|Ropinirole tablet
9798448|NCT01628926|Placebo Comparator|Placebo|SPM962 placebo patch and Ropinirole placebo tab
9798449|NCT01628965|Experimental|SPM 962|SPM 962 transdermal patch
9798450|NCT01629134||Volbella|Subjects treated with JUVÉDERM VOLBELLA™ according to the physician's experience and Directions for Use
9798451|NCT01629290|Active Comparator|Enamel Pro|Varnish containing 5%NaF
9798452|NCT01629290|Active Comparator|Duraphat|Varnish containing 5%NaF
9993971|NCT01477151|Experimental|isoflurane|These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
9993972|NCT01477164|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of high intensity aerobic training.
9993973|NCT01477164|Active Comparator|Combined|The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
9993974|NCT01477164|Experimental|Resistance Exercise Training|Participants will perform 12-weeks of resistance exercise training.
9993975|NCT01477190|Experimental|Spinal group|Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
9993976|NCT01477190|Active Comparator|PCA group|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
9993977|NCT01477203|Active Comparator|Escitalopram|50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
9993978|NCT01477203|No Intervention|Remitted Patients|
9993979|NCT01477203|No Intervention|Healthy Controls|
9993980|NCT01477216|Experimental|Measuring method|To compare glycemic responses and GI values from capillary and venous blood and to compare glucose solution with white bread as the reference food and to study the effect of the number of reference tests on GI values.
9993981|NCT01477216|Experimental|Mixed meals|To examine the glycaemic and insulinaemic responses of a mashed potato-based meal when a high fat food (rapeseed oil) or a high protein food (chicken breast) or fat, protein and salad together were added to the meal. Furthermore, we studied how the predicted and measured GI values of the mixed meal differed from each other.
9993982|NCT01477216|Experimental|Coffee|To examine the effects of two different coffee portions with glucose and caffeine-containing soft drinks on postprandial glucose and insulin responses. Further objectives were to study how coffee and different accompaniments affect glucose and insulin responses.
9993983|NCT01477216|Experimental|Snacks|To measure GI and II values for Finnish snack foods
9993984|NCT01477216|Experimental|Berries|To study the effects of berries on glycemic and insulinemic responses
9993985|NCT01477216|Experimental|GIs of low-carbs|To measure glycemic and insulinemic responses to low-carbohydrates foods
9993986|NCT01477216|Experimental|Glucose metabolism and BMI|To examine the effects of overweight and glucose tolerance on the glucose, insulin and lipid responses to an HGI meal and an LGI meal. Furthermore, the second aim was to study the effect of BMI and glucose tolerance on the GI measured.
9993987|NCT01477216|Experimental|Insulin measurement|To compare how methodological choices affect measured insulin values
9993988|NCT01477216|Experimental|Alcohol|To investigate the effect of alcohol on postprandial glucose and insulin responses, and to determine glycemic and insulinemic indices values for beer and non-alcoholic beer.
9993989|NCT01477242|Experimental|Ondansetron|Ondansetron use group
9993990|NCT01477242|Placebo Comparator|Placebo|Placebo group
9993991|NCT01477255||Cancer patient|Patient participants will include children and adolescents between the ages of 8-17 years who have been recently diagnosed with cancer. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
9997874|NCT01512706|Experimental|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
10213982|NCT02418195|Active Comparator|MDD without Suicidal Ideation no attempt|All subjects with Major Depressive Disorder without recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
9906701|NCT00662948|Experimental|A|Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg
9906702|NCT00662948|Active Comparator|B|Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months
9906703|NCT00662961|Experimental|1|Periosteum
9906704|NCT00662961|Experimental|2|Bone
9906705|NCT00662974|Experimental|A|parturients during the second stage of labor massaged by Wheat Germ Oil
9906706|NCT00662974|Experimental|B|parturients during the second stage of labor massaged by almond oil
9906707|NCT00662987|Placebo Comparator|Group B|Received 3 days of amoxicillin followed by 4 days of placebo
9906708|NCT00662987|Active Comparator|Group A|Received 7 days of amoxicillin
9906709|NCT00663000||acromegalics|"Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).~Written informed consent"
9906710|NCT00663013|Active Comparator|1|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
9906711|NCT00663013|Active Comparator|2|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
9906712|NCT00663052|Experimental|Group A|A
9906713|NCT00663052|Experimental|Group B|B
9906714|NCT00663065|Experimental|arm 1|
9906715|NCT00663078|Experimental|A|Group A: Women from GP practices and area of Knowle West, Bristol
9906716|NCT00663078|Experimental|B|Group B: Women from Wellspring, GP practice or geographical area of Barton Hill Bristol.
9906717|NCT00663091|Experimental|Bacteriophages|
9906718|NCT00663104|Active Comparator|1|exercise (3 sessions/week)
9906719|NCT00663104|Active Comparator|2|"exercise and phytoestrogen (cimicifuga racemosa)"
9906720|NCT00663104|Placebo Comparator|3|wellness control, placebo
9906721|NCT00663130|Experimental|Arm 1|
9906722|NCT00663130|Active Comparator|Arm 2|
9906723|NCT00663143||Stromal Cell Sample|
9906724|NCT00663156|Experimental|subject|10 subjects receiving breast augmentation with fat grafting
9906725|NCT00663156|Other|control|10 control will have breast augmentation using breast implants
9906726|NCT00663182|Experimental|A|Patients with decompensated HBV-related cirrhosis
9906727|NCT00663182|No Intervention|B|Untreated
9906728|NCT00663221|Placebo Comparator|1|
9906729|NCT00663221|Experimental|2|
9906730|NCT00663247|Placebo Comparator|B|placebo used as control for comparison with active drug
9906731|NCT00663247|Active Comparator|A|
9906732|NCT00663273|Experimental|1|Lactic acid in small quantity during 21 days.
9906733|NCT00663286|Experimental|1|
9906734|NCT00663286|Active Comparator|2|
9906735|NCT00663286|Active Comparator|3|
9906736|NCT00663286|Placebo Comparator|4|
9906737|NCT00663299|Other|Trufill Detachable Coil System|There is only one treatment arm in the registry and it is all patients receiving treatment with Trufill Detachable Coil System. The use of bare platinum coils for the endovascular occlusion of cerebral aneurysms.
9906738|NCT00663325|Experimental|1|Lactic acid in small quantity during 21 days
9906739|NCT00663338|Experimental|A|All patients receive placebo or rotigotine at some stage in the trial but the exact point is randomized.
9906740|NCT00663351|Active Comparator|1|Investigational: Reflection Ceramic-Ceramic Hip System. Ceramic femoral head component and the ceramic acetabular cup insert are composed of Biolox forte aluminum oxide material.
9935761|NCT03233724|Experimental|1/Dose Escalation|DAC-THU + pembrolizumab at escalating doses
9935762|NCT03233724|Experimental|2/Dose Expansion|DAC-THU + pembrolizumab at the dose established in Arm 1
10213983|NCT02418195|No Intervention|Healthy Controls|Healthy Control subjects without a psychiatric diagnosis will have a one-time blood draw to examine miRNAs.
10213984|NCT02392637|Experimental|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10213985|NCT02388659||Brain MRI/MRS Patients|3 Tesla Scanning: MRI/MRS of glioma and non-glioma patients.
10213986|NCT02376699|Experimental|IV Monotherapy in Solid Tumors|SEA-CD40 administered IV
10213987|NCT02376699|Experimental|IV Monotherapy in Lymphomas|SEA-CD40 administered IV
10213988|NCT02376699|Experimental|Combination Therapy in Solid Tumors|SEA-CD40 (administered IV) + pembrolizumab
10213989|NCT02376699|Experimental|SC Monotherapy in Solid Tumors|SEA-CD40 administered SC
10213990|NCT02376699|Experimental|SC Monotherapy in Lymphomas|SEA-CD40 administered SC
10213991|NCT02376699|Experimental|Combination Therapy in Pancreatic Cancer|SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel
10213992|NCT02372630|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
10213993|NCT02372630|Active Comparator|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
9906741|NCT00663351|Active Comparator|2|Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
9906742|NCT00663364|Active Comparator|I|Physiogel AI Lotion
9906743|NCT00663364|Active Comparator|II|Physiogel Lotion twice daily
9933716|NCT05270213|Experimental|Treatment Group A-1|For Treatment Group A-1, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418. Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
9933717|NCT05270213|Experimental|Treatment Group A-2|For Treatment Group A-2, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418 in combination with pembrolizumab 200 mg IV (administered on Day 1 and every 3 weeks). Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
9933718|NCT05270213|Experimental|Treatment Group B|After dose escalation phase is completed in both monotherapy and combination therapy setting (A-1 and A-2), an expansion treatment group will be enrolled, and subjects (n=20- 40) will be treated with a fixed dose of RBS2418 to be selected by the Sponsor in consultation with the SRC and after reviewing the totality of the dose escalation data both as monotherapy and combination therapy.
9933719|NCT05268341|Experimental|Treatment|computer assisted intervention targeting expressive grammar for preschoolers with DLD
9933720|NCT05268341|No Intervention|No treatment|business as usual classroom (educational) services
9933721|NCT05266222||People with respiratory infection|Persons with suspected or documented respiratory infection
9933723|NCT05261126|Experimental|MK-0616 Dose 1|MK-0616 Dose 1 administered orally once daily (QD) for 8 weeks
9933724|NCT05261126|Experimental|MK-0616 Dose 2|MK-0616 Dose 2 administered orally QD for 8 weeks
9933725|NCT05261126|Experimental|MK-0616 Dose 3|MK-0616 Dose 3 administered orally QD for 8 weeks
9933726|NCT05261126|Experimental|MK-0616 Dose 4|MK-0616 Dose 4 administered orally QD for 8 weeks
9933727|NCT05261126|Placebo Comparator|Placebo|Placebo administered orally QD for 8 weeks
9933728|NCT05259774|Experimental|Relizema cream|Relizema cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
9933729|NCT05259774|No Intervention|Vehicle|Cream, topically applied twice a day in all the affected areas for three cycles of 13 (±2) consecutive days.
9933730|NCT05258227|Experimental|Proprioceptive Strength Training|"Conservation physical therapy includes TENS 15 min + Infrared 15 min simultaneously.~Proprioceptive strength training for 30 min includes following exercises:~Strengthening of Quadriceps Ankle extensors and Hip abductors strengthening Zigzag walking Heel to toe walk forward and backwards toe to heel Standing on one leg while holding wall, eyes open and eyes closed"
9933731|NCT05258227|Experimental|Core Instability Strength Training|"Conservational therapy includes TENS for 15 min+ Infrared for 15 min simultaneously.~Core instability strength training for 30 minutes includes following exercises:~Quadriceps stretch, crook lying, abdominal hallowing Dynamic Hamstrings stretch Bridging arms at side Crook lying+lifting both legs at right angle with hands resting on thighs"
9933732|NCT05257798|Experimental|PF-06823859|Participants will receive 900 mg of PF-06823859 via intravaneous (IV).
9933733|NCT05257798|Placebo Comparator|Placebo|Participants will receive placebo via IV.
9933734|NCT05255900||metyrapone treatment|hypercortisolemic patients taking metyrapone since less than a week (usually 250 mg/day, maximum dose 6000 mg/day)
9933735|NCT05254600|Experimental|Intervention group|Intervention group will attend the RISE for Nurse Leaders program, which consists of nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC)
9933736|NCT05254600|Active Comparator|Wait-list control group|Control group will attend the RISE for Nurse Leaders program after the 3-month wait-list period
9933737|NCT05254106||Paclitaxel drug-eluting devices|Patients treated by at least one paclitaxel drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
9933738|NCT05254106||Non-drug-eluting devices|Patients exclusively treated by a non-drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
9933739|NCT05252533|Experimental|Cohort 1: Juvenile Psoriatic Arthritis (jPsA)|Participants (aged greater than or equal to [>=] 5 to less than [<] 18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating health care professional (HCP).
9933740|NCT05252533|Experimental|Cohort 2: Pediatric Psoriasis (PsO)|Participants (aged >=6 to <18 years) will receive ustekinumab at the dose and frequency as prescribed by their treating HCP.
9933741|NCT05251727|Experimental|Lowest Dose|Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)
9933742|NCT05251727|Experimental|Low Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
9933743|NCT05251727|Experimental|Medium Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
9933744|NCT05251727|Experimental|High Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
9998339|NCT01517347|Experimental|Interleukin-2|Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
9517577|NCT03305172|Experimental|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
9906744|NCT00663390|Experimental|I|
9906745|NCT00663416|Experimental|1|
9906746|NCT00663416|Placebo Comparator|2|
9906747|NCT00663442|Experimental|1|OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose)
9906748|NCT00663455|Other|A|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
9906749|NCT00663455|No Intervention|B|Standard CSA-dosing without reduction. Therapy control by C2-monitoring.
9906750|NCT00663468||A|
9906751|NCT00663481|Experimental|1|CoFactor
9906752|NCT00663481|Experimental|2|CoFactor
9906753|NCT00663481|Active Comparator|3|Leucovorin
9906754|NCT00663520||1|"Women with chest pain and Clean heart vessels"
9906755|NCT00663520||2|Healthy volunteers
9906756|NCT00663533|No Intervention|Device study only.|
9906757|NCT00663559|Other|1|This study has only one arm with Sunitinib
9906758|NCT00663585|Experimental|1|Structured Intervention Group
9906759|NCT00663585|Active Comparator|2.Comparison group|Unstructured comparison group
9906760|NCT00663598|Experimental|Arm 1|
9906761|NCT00663624|Experimental|Experimental|Subcutaneous aspart insulin every 2 hours
9906762|NCT00663624|Placebo Comparator|Active Comparator|Usual care as prescribed by the ED physicians
9906763|NCT00663650|Active Comparator|1|Permanent Section Control
9906764|NCT00663650|Active Comparator|2|Frozen Section Control
9906765|NCT00663663|Experimental|1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
9906766|NCT00663663|Experimental|2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
9906767|NCT00663689|Experimental|1|non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity
9906768|NCT00663715||1|Pediatric Patients of ages 11-17
9906769|NCT00663728|Experimental|Arm 1|
9906770|NCT00663728|Placebo Comparator|Arm 2|
9906771|NCT00663741|Experimental|Arm 1|
9906772|NCT00663741|Experimental|Arm 2|
9906773|NCT00663741|Experimental|Arm 3|
9906774|NCT00663754|Active Comparator|1|Participants will receive a mailed brochure about body image only.
9906775|NCT00663754|Active Comparator|2|Participants will receive the 4-hour dissonance-based eating disorder prevention program.
9906776|NCT00663754|Experimental|3|Participants will receive the 8-hour dissonance-based eating disorder prevention program.
9906777|NCT00663806|Experimental|Arm 1|
9906778|NCT00663806|Experimental|Arm 2|
9906779|NCT00663832|Experimental|LBH589|
9906780|NCT00663845|Experimental|Arm 1|
9906781|NCT00663845|Placebo Comparator|Arm 2|
9906782|NCT00663884|Experimental|M|Mitiglinide
9906783|NCT00663884|Active Comparator|V|Voglibose
9906784|NCT00663897|Experimental|1|Treatment with lansoprazole (30 mg) once daily for 14 days
9906785|NCT00663897|Active Comparator|2|Treatment with mosapride (5 mg) thrice daily for 14 days
9906786|NCT00663949|Active Comparator|A,1,II|patients in this arm takes 25 mg captopril q8h
9906787|NCT00663949|Active Comparator|A,2,II|
9906788|NCT00663975|Experimental|1|DCI-1020 Capsules contain an enteric-coated buffered microspheres of pancrelipase, encapsulated in clear capsules. Capsules are equivalent to 4,000 USP units of lipase
9906789|NCT00663988|Experimental|III|The effect of human partial facial allotransplantation
9906790|NCT00664001|Placebo Comparator|Control|Placebo tablet
9906791|NCT00664001|Active Comparator|Intervention|Anti-oxidant supplementation
9906792|NCT00664014|Experimental|Tolvaptan|
9906793|NCT00664014|Placebo Comparator|Placebo|
9906794|NCT00664053|Experimental|1|DHEA and Yoga
9906795|NCT00664053|Active Comparator|2|DHEA and exercise
9906796|NCT00664053|Active Comparator|3|Placebo and Yoga
9906797|NCT00664053|Placebo Comparator|4|Placebo and exercise
9906798|NCT00664079||1|Patients who are receiving vasoactive medications and/or are mechanically ventilated.
9906799|NCT00664092|No Intervention|1|Usual Aftercare Condition
9906800|NCT00664092|Experimental|2|Oxford House Condition
9906801|NCT00664092|Experimental|3|Therapeutic Community Condition
9906802|NCT00664118|Active Comparator|1|Doula combined epidural analgesia in the latent phase of first stage of labor
9906803|NCT00664118|Sham Comparator|2|Epidural analgesia in the latent phase of the first stage of labor without doula accompany
9906804|NCT00664131||1|
9906805|NCT00664157|Other|2|40 patients with an idiopathic Parkinson's disease and 40 healthy paired volunteers (control group)
9906806|NCT00664170|Experimental|1|ANX-514
9906807|NCT00664170|Active Comparator|2|Taxotere
9906808|NCT00664183|Experimental|1|
9517578|NCT03305172|Experimental|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
9906809|NCT00664183|Experimental|2|
9906810|NCT00664196|Experimental|1|
9906811|NCT00664248|Experimental|1|
9906812|NCT00664248|Active Comparator|2|
9906813|NCT00664248|Active Comparator|3|
9906814|NCT00664248|Placebo Comparator|4|
9906815|NCT00664274|Other|CRT Group|
9906816|NCT00664287|Experimental|Group 1|Patients will remain on existing lipid-modifying therapy throughout the study. Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
9906817|NCT00664287|Placebo Comparator|Group 2|Patients will remain on existing lipid-modifying therapy throughout the study. Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
9906818|NCT00664300||2|One group with Gilles de la Tourette's Syndrome One group with healthy paired volunteers
9906819|NCT00664313|Experimental|1|Linezolid 600 mg po QD
9906820|NCT00664313|Placebo Comparator|2|Placebo
9906821|NCT00664339|Active Comparator|Vaccine|Flu Vaccine
9906822|NCT00664339|Other|Control|Conventional treatment therapy for heart failure
9906823|NCT00664352|Experimental|1|
9906824|NCT00664352|Experimental|2|
9906825|NCT00664352|Experimental|3|
9906826|NCT00664352|Experimental|4|
9906827|NCT00664352|Other|5|
9906828|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 1|Eligible subjects will receive GSK958108 with a starting dose of 1 milligram. The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
9906829|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 2|Eligible subjects will start dosing once the cohort 1 has completed the treatment phase and the initial dose will be the same as top dose in Cohort1.The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
9906830|NCT00664391|Experimental|1|
9906831|NCT00664404|Other|fMRI|Functional Magnetic Resonance Imaging (fMRI)
9906832|NCT00664417|Experimental|1|
9906833|NCT00664417|Experimental|2|
9906834|NCT00664417|Experimental|3|
9906835|NCT00664417|Experimental|4|
9906836|NCT00664417|Experimental|5|
9906837|NCT00664417|Experimental|6|
9906838|NCT00664417|Active Comparator|7|
9906839|NCT00664417|Active Comparator|8|
9906840|NCT00664417|Placebo Comparator|9|
9906841|NCT00664443||Dispatch-assisted CPR|Emergency ambulance dispatcher interaction to provide dispatch-assisted CPR instructions in order to determine bystander CPR rates and the impact of instructions on survival to hospital discharge
9906842|NCT00664456|Active Comparator|AHT group|Randomized patients undergo 3-month neoadjuvant therapy (NHT)within 14 days and receive 9-month adjuvant therapy (AHT) following after Iodine I-125 implantation (TPPB).
9906843|NCT00664456|Active Comparator|Non-AHT group|Rondomized patients undergo 3-month neoadjuvant therapy (NHT) within 14 days and receive Iodine I-125 implantation therapy (TPPB). 40 weeks observation is followed under no further treatment.
9906844|NCT00664469|Experimental|EZE+statin|ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
9906845|NCT00664469|Active Comparator|Stat2|patients on statins has their dose doubled for 6 weeks followed by another 6 weeks in which ezetimibe is added or the statin dose is doubled again.
9906846|NCT00664495|No Intervention|C|Control
9906847|NCT00664495|Active Comparator|DWL|Diet Weight Loss
9906848|NCT00664495|Active Comparator|EWL|Exercise Weight Loss
9906849|NCT00664495|Active Comparator|EWS|Exercise Without Weight Loss
9906850|NCT00664508|Active Comparator|Lateral approach|Lateral approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
9906851|NCT00664508|Active Comparator|Anterior approach|Anterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
9798453|NCT01629290|Active Comparator|Vanish|Varnish containing 5%NaF
9798454|NCT01629290|Placebo Comparator|Placebo|Bland varnish containing no NaF
9798455|NCT01629381|Experimental|Rivaroxaban|Oral Rivaroxaban 10 mg od for 7 days
9798456|NCT01629381|Placebo Comparator|Placebo|oral placebo od for 7 days
9798457|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 5mg|All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
9798458|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 10mg|All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
9798459|NCT01629589|Experimental|Adacel® Vaccine Group|Participants randomized to receive a single dose of Adacel® vaccine
9798460|NCT01629589|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine
9798461|NCT01629615|Experimental|BKM120|
9798462|NCT01629667|Experimental|Tralokinumab 400 milligram (mg)|Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
9798463|NCT01629667|Experimental|Tralokinumab 800 mg|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
9798464|NCT01629667|Placebo Comparator|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
9798465|NCT01629693|Experimental|Air Optix|Lotrafilcon B contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
9798466|NCT01629693|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
9798467|NCT01629706|Experimental|PV+ClearCare / PV+Renu (Phase 1)|Balafilcon A contact lens pre-soaked overnight in ClearCare cleaning and disinfecting system worn in 1 eye for two hours and four hours at a time, separate days, with Balafilcon A contact lens pre-soaked overnight in renu multi-purpose solution worn in the fellow eye
9798468|NCT01629706|Experimental|Habitual (Phase 2)|Phase 2: Habitual contact lenses worn bilaterally on a daily wear basis for 4 weeks with habitual lens care
9798469|NCT01629771||Lymphatic Filariasis|
9798470|NCT01629771||Patients without Lymphatic Filariasis|
9798471|NCT01629784|Other|CLE and sun counseling|
9798472|NCT01629797|Other|Acne Vulgaris|Patients with Acne vulgaris will receive educational teaching on Acne
9798473|NCT01629823|Sham Comparator|CPAP less than 1 cm H₂O|
9798474|NCT01629823|Experimental|CPAP 10cm H₂O|
9798475|NCT01629823|Experimental|CPAP 5cm H₂O|
9798476|NCT01629862|Active Comparator|Active CPAP|Therapeutic continuous positive airway pressure (CPAP).
9798477|NCT01629862|Placebo Comparator|Sham CPAP|Sham (non-therapeutic) continuous positive airway pressure.
9798478|NCT01629953|Active Comparator|Group Based Vocational Rehabilitation|Group vocational intervention
9798479|NCT01629953|Experimental|Supported Employment Condition|Group vocational intervention + supported employment
9798480|NCT01629966|Placebo Comparator|Placebo|Dose-matched placebo one per day, oral administration
9798481|NCT01629966|Experimental|Vilazadone 20mg|Vilazodone 20mg once per day, oral administration.
9798482|NCT01629966|Experimental|Vilazodone 40mg|Vilazodone 40mg once per day, oral administration
9798483|NCT01630109|Active Comparator|Metoclopramide 5 mg|Pro-motility agent
9798484|NCT01630109|Active Comparator|Metoclopramide 10 mg|Pro-motility agent
9798485|NCT01630109|Placebo Comparator|Placebo control|Placebo to be used as the control group
9798486|NCT01630135|Experimental|GW685698X|GW685698X 55mcg/day
9798487|NCT01630135|Placebo Comparator|Placebo|Placebo
9798488|NCT01630200|Active Comparator|Roflumilast|Active arm including patients who receive the study drug (500µg Roflumilast once daily)
9798489|NCT01630200|Placebo Comparator|Placebo|Control arm including patients who receive the placebo tablet (once daily)
9798490|NCT01630616|Experimental|Adolescents Odanacatib 10 mg|Study drug (single oral dose of odanacatib 10 mg) was administered following at least an 8-hour fast to adolescents.
9906852|NCT00664508|Active Comparator|Posterior approach|Posterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
9906853|NCT00664547|No Intervention|C|
9906854|NCT00664547|Active Comparator|DWL|Diet Weight Loss
9906855|NCT00664547|Active Comparator|EWL|Exercise Weight Loss
9906856|NCT00664547|Active Comparator|EWS|Exercise without weight loss
9906857|NCT00664586|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) will be administered as an intravenous infusion over 24 hours, weekly. Dose will commence in the first cohort with 100 mg per hour (2400 mg in a 24 hour period)with escalation in the 5 cohorts of 3 to 6 patients with increments of 25 mg per hour to a maximum of 200 mg/hr (4800 mg/24 hour period) or until MTD is defined. When the MTD has been declared, then 11 additional subjects will be enrolled at the MTD dose level (to total 14 subjects treated in dosage cohort).
9906858|NCT00664599|Experimental|1|Rituximab
9906859|NCT00664599|Active Comparator|2|Cytotoxics combination
9906860|NCT00664612|Experimental|1|Air Traq then Macintosh
9906861|NCT00664612|Experimental|2|Macintosh then AirTraq
9906862|NCT00664677|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off).
9906863|NCT00664690|Experimental|1|celebrex
9906864|NCT00664690|Placebo Comparator|2|placebo
9906865|NCT00664703|Experimental|Lobeline 7.5 mg|Sublingual tablet
9906866|NCT00664703|Experimental|Lobeline 15 mg|Sublingual tablet
9906867|NCT00664703|Experimental|Lobeline 30 mg|Sublingual tablet
9906868|NCT00664703|Active Comparator|Methylphenidate HCl 15 mg|Capsule
9906869|NCT00664703|Active Comparator|Methylphenidate HCl 30 mg|Capsule
9906870|NCT00664703|Placebo Comparator|Lobeline 0 mg (placebo)|Sublingual tablet
9906871|NCT00664703|Placebo Comparator|Methylphenidate HCl 0 mg (placebo)|Capsule
9906872|NCT00664729|Active Comparator|1|Caloric Restriction
9906873|NCT00664729|Experimental|2|Caloric restriction + Moderate-intensity aerobic exercise
9906874|NCT00664729|Experimental|3|Caloric restriction + Vigorous-intensity aerobic exercise
9906875|NCT00664768|Experimental|New Neocate|new Neocate
9906876|NCT00664768|Active Comparator|Neocate Infant|Neocate Infant formula
9906877|NCT00664794|Active Comparator|without acromioplasty|
9906878|NCT00664794|Active Comparator|with acromioplasty|
9906879|NCT00664820|Experimental|Treatment group|Will receive two Urex-CAP-5 (probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14) capsules daily for 3 months.
9906880|NCT00664833|Experimental|Arm 2|
9906881|NCT00664833|Other|Arm 4|
9906882|NCT00664833|Experimental|Arm 3|
9906883|NCT00664833|Experimental|Arm 1|
9906884|NCT00664846|Experimental|1|
9906885|NCT00664846|Active Comparator|2|
9906886|NCT00664872|Experimental|case management|
9906887|NCT00664885|Experimental|CSCT|
9906888|NCT00664898|Experimental|1|
9906889|NCT00664911|Other|Chemotherapy|chemotherapy regimen
9906890|NCT00664950|Active Comparator|SHS|sliding hip screw
9906891|NCT00664950|Active Comparator|InterTAn IM Nail|interTAN IM nail
9906892|NCT00664963|Experimental|1|YUKON Sirolimus-eluting Stent
9906893|NCT00664963|Active Comparator|2|YUKON Stent (uncoated)
9906894|NCT00664976|Experimental|1|Electroconvulsive therapy
9906895|NCT00664976|Active Comparator|2|Treatment as usual
9906896|NCT00665028||1|Postoperative myocardial ischemia
9906897|NCT00665041|Experimental|PR1|
9906898|NCT00665041|Placebo Comparator|PL1|
9906899|NCT00665054|Experimental|Arm 1|
9906900|NCT00665054|Placebo Comparator|Arm 2|
9906901|NCT00665093||A|
9906902|NCT00665093||B|
9933745|NCT05251727|Experimental|Highest Dose|"Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
9933746|NCT05251727|Placebo Comparator|Placebo|"Lyophilized placebo reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)"
9933747|NCT05249569|Experimental|Axitinib / Avelumab /Bavituximab|Axitinib 5 mg PO BID Avelumab 10 mg/kg IV every 2 weeks (2 doses in a 4-week cycle) Bavituximab 3 mg/kg IV every 1 week (4 doses in a 4-week cycle) Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
9933748|NCT05248425|No Intervention|Usual Care|All participants will answer questionnaires at specified time points. This arm will receive usual care and their questionnaire responses will not be reviewed.
9933749|NCT05248425|Experimental|Monitored|All participants will answer questionnaires at specified time points. The monitored arm will have their responses reviewed for new or worsening symptoms which will be assessed and managed by a study nurse in addition to usual care.
9933750|NCT05244980|Experimental|MAD Cohorts 1-4 TDM-105795 topical solution|Multiple dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01% or 0.02%
9933751|NCT05244980|Placebo Comparator|Placebo for TDM-105795 topical solution|Multiple dose administration of Placebo forTDM-105795 Topical Solution
9935763|NCT03226704||1|Patients 3-39 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to one or more standard regimens and/or deemed incurable by standard therapy.
9935764|NCT03225196||Samples|We seek to measure a 665 exRNAs spanning a variety of classes in plasma from 4095 young to middle-aged adult participants in the Third Generation cohort of the FHS
9935765|NCT03225183||1|Framingham Heart Study participants
9998340|NCT01517347|No Intervention|controlled group|controlled standard risk leukemia received regular transplantation without IL-2 intervention
9906903|NCT00665106|Experimental|cohort 1|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
9906904|NCT00665106|Experimental|cohort 2|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
9906905|NCT00665106|Experimental|cohort 3|5 up to 6 patients per arm. Emulsion at 3.2% of drug product.
9906906|NCT00665106|Experimental|cohort 4|5 up to 6 patients per arm. Oily solution at 3.4% of drug product.
9906907|NCT00665119|Experimental|treatment|Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.
9906908|NCT00665158|Active Comparator|UC|Usual Care Group
9906909|NCT00665158|Active Comparator|BI|Behavioural Intervention Group
9906910|NCT00665184|Experimental|High force LE resistance training|High force lower extremity resistance training + Standard exercise care. The high force lower extremity resistance training group will participate in a 3 day per week progressive eccentric ergometry program that will be gradually increased over 3 weeks from 5-20 minutes per day and remain at that duration for the next 9 weeks. In addition, they will engage in exercises including moderate intensity aerobic training, concentric upper extremity resistance training and stretching (axial mobility exercises).
9906911|NCT00665184|Active Comparator|Standard Care Control Group|"Standard care exercise group: The standard care control group is an active control group, i.e., individuals who will engage in our standard of care (an evidence based exercise program). These exercises include moderate intensity aerobic training (15 minutes), concentric upper extremity resistance training (5-10 minutes), balance training (5 minutes), and stretching (axial mobility exercises-5-10 minutes)."
9906912|NCT00665197|Active Comparator|Protracted Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 30 Gy in 10 fractions of 3.0 Gy"
9906913|NCT00665197|Experimental|Short Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 20 Gy in 5 fractions of 4.0 Gy"
9906914|NCT00665236|Experimental|1|Craniosacral therapy administered once a week for an hour by a trained craniosacral therapist.
9906915|NCT00665236|Active Comparator|2|Low-strength static magnets placed around the body for periods of up to an hour once a week.
9906916|NCT00665249|Active Comparator|Full Motivational Interviewing|"This condition consisted of all the standard elements of MI, both the non-directive and directive strategies (Miller & Rollnick, 2002). Rogerian elements, such as warmth, egalitarianism, genuineness, and a client-centered approach to the therapeutic relationship, are commonly referred to as MI Spirit (Moyers, Martin, Manual, Hendricksen, & Miller, 2005). MI is comprised of MI spirit and includes specific directive strategies geared to focus the client toward targeted behavior change, such as confidence and importance rulers, visualization of behavior change, or a decisional balance. The directive elements of MI are those that selectively reinforce positive change talk or enhance discrepancy between a client's wish to change and stay with the status quo."
9906917|NCT00665249|Active Comparator|No Intervention: Self Change|Participants in this condition were not assigned to treatment, but were asked to attempt to change on their own during the 8-week follow-up period. SC participants were told that research had shown that some individuals could reduce their drinking without professional help; that participating in the IVR might facilitate their efforts; and that they would be offered professional treatment at the end of the 8-week period. As noted in the Introduction, SC was selected rather than a traditional wait-list control because the aim of the study was to decompose MI into its 3 hypothesized components that include self-change.
9906918|NCT00665249|Active Comparator|Spirit-Only Motivational Interviewing|While this condition retained the Rogerian elements to MI, directive elements were excluded. For example, SOMI consisted of the non-directive elements including therapist stance (warmth, genuineness, egalitarianism), emphasis on client responsibility to change, extensive use of reflective listening skills (e.g., open-ended questions, simple reflections), and avoidance of MI-inconsistent behaviors (advise, confront, take expert role, interpretation). Reflective listening was focused on the whole experience of the client and the client's affect, and targeting a particular behavior or eliciting change talk about drinking was proscribed. Furthermore, tools utilized frequently in MI to develop discrepancy, such as amplified or double-sided reflections, were proscribed.
9906919|NCT00665262|Experimental|1|comibined use of tramacet and naloxone infusion perioperatively
9906920|NCT00665314|Experimental|AMD3100 added to a G-CSF Mobilisation regimen|AMD3100 added to a G-CSF Mobilisation regimen
9906921|NCT00665314|Active Comparator|G-CSF plus placebo|G-CSF plus placebo
9906922|NCT00665327|Experimental|Arm 1|
9906923|NCT00665327|Active Comparator|Arm 2|
9906924|NCT00665340|Placebo Comparator|Arm 1|
9906925|NCT00665340|Experimental|Arm 2|
9906926|NCT00665379|Active Comparator|1|Regular compression therapy with non elastic trico bandaging
9906927|NCT00665379|Active Comparator|2|New two layer compression bandage coban 2
9906928|NCT00665405||PN|Control - Induced or natural labor under anesthesia
9906929|NCT00665405||PC|Case - Cesarean section under anesthesia
9906930|NCT00665418|Experimental|1|
9906931|NCT00665483|Experimental|1|Skin Prick Test
9906932|NCT00665496|Experimental|Arm 1|
9906933|NCT00665496|Placebo Comparator|Arm 2|
9906934|NCT00665509|Experimental|1|
9906935|NCT00665522||001|fentanyl iontophoretic transdermal system (40mcg) No Placebo 40 mcg per dose maximum of 6 doses/hourtotal maximum 80 doses/24 hours
9906936|NCT00665522||002|IV PCA with standard of care opioid analgesia per 24 hour period
9906937|NCT00665535|Other|2. High Risk|High risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 10-12)
9906938|NCT00665535|Other|1. Moderate Risk|Moderate risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 13 and 14)
9906939|NCT00665548||Normal Subjects|Female subjects scoring Kellgren & Lawrence grade 0.
9906940|NCT00665548||OA Subjects|Female subjects with Kellgren & Lawrence score of 2 or 3.
9906941|NCT00665574|Experimental|1|ActaVisc
9906942|NCT00665574|Experimental|2|ActaVisc Mx Intra-articular Injection
9667262|NCT03799861||Epoch 1: Care prior to HBB training|A period of demographic and birth outcome data collection for a retrospective cohort of all infants born in the three study hospitals during the 18 months prior to the start of Epoch 2, reflecting care prior to HBB training.
9906943|NCT00665574|Placebo Comparator|3|Saline
9906944|NCT00665574|Active Comparator|4|Corticosteroid
9906945|NCT00665587||A = MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation together with MAZE procedure
9906946|NCT00665587||B = non-MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation (without MAZE procedure).
9906947|NCT00665600|Experimental|1|Levalbuterol 0.63 mg TID
9906948|NCT00665600|Experimental|2|Levalbuterol 1.25 mg TID
9906949|NCT00665600|Active Comparator|3|Racemic Albuterol 2.5 mg TID
9906950|NCT00665600|Placebo Comparator|4|Placebo TID
9906951|NCT00665639|Experimental|1|Daily dose
9906952|NCT00665639|Active Comparator|2|
9906953|NCT00665639|Experimental|3|Every other day dose, alternating with placebo
9906954|NCT00665665|Experimental|A|
9906955|NCT00665665|Experimental|B|
9906956|NCT00665665|Experimental|C|
9906957|NCT00665665|Experimental|D|
9906958|NCT00665678|Experimental|1|paroxetine
9906959|NCT00665678|Placebo Comparator|2|placebo
9906960|NCT00665691||1|
9906961|NCT00665717|Active Comparator|A|Pravastatin 40 mg QD for 4 days
9906962|NCT00665717|Active Comparator|B|Raltegravir 400mg BD for 4 days
9906963|NCT00665717|Experimental|C|Interaction between pravastatin and raltegravir
9906964|NCT00665730|Experimental|Sepraspray|Sepraspray Powder applied on the viscera directly under the midline incision followed by incision closure. Sepraspray dose applied was between 2 g and 4 g per patient.
9906965|NCT00665730|No Intervention|Control|No anti-adhesion treatment used.
9906966|NCT00665743|Experimental|A|PN400 (naproxen/esomeprazole)
9906967|NCT00665743|Active Comparator|B|naproxen 500 mg
9906968|NCT00665743|Active Comparator|C|naproxen 500 mg
9906969|NCT00665756|Active Comparator|1|second trabeculectomy
9906970|NCT00665756|Active Comparator|2|Ahmed silicone drainage device implantation
9906971|NCT00665795||1Patients with Graves´orbitophathy.|Patients with Graves´orbitophathy.
9906972|NCT00665795||2 Patients with detected DON|Patients with Graves´orbitophaty and detected dysthyroid optic neuropathy (DON)
9906973|NCT00665808||A|
9906974|NCT00665808||B|
9906975|NCT00665834|Placebo Comparator|1|Rosuvastatin 20 mg versus placebo 20 mg
9906976|NCT00665834|Active Comparator|2|rosuvastatin 20 mg versus atorvastatin 80 mg
9906977|NCT00665860|Placebo Comparator|1|Placebo
9906978|NCT00665860|Active Comparator|2|
9906979|NCT00665860|Active Comparator|3|
9906980|NCT00665873|Active Comparator|A|Antibiotics
9906981|NCT00665873|Active Comparator|B|No Antibiotics
9935766|NCT03225157||1|Adult patients with head and neck squamous cell carcinoma of the upper aerodigestive tractwho will undergo cisplatin chemotherapy with concurrent radiation.
9906982|NCT00665886|Experimental|1|"Experimental Group (Closed System):~Nexiva® Safety IV Catheter from BD (Becton Dickinson). The catheter has wings, a passive safety feature, an integrated Y extension tubing integrated and needle-less access using a split septum BD QSyte®. In order to completely close the Y connector a second Q-Syte® is added from the moment of catheter insertion"
9906983|NCT00665886|Active Comparator|2|"Control group (Open System):~A 'mounted' system consisting of the Vasocan® Safety catheter of B. Braun Medical, SA. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3, from BD) is added. This comes as one unit (tap and tubing are integrated). When not in use the three-way tap ('stopcock') remains closed using a red cork Luer/Luer-Lock Sollner®, made by Amebil, SA."
9906984|NCT00665899|Experimental|Cancer-Focused Relationship Enhancement|Cancer-Focused Relationship Enhancement
9906985|NCT00665899|Experimental|Couple's Cancer Education|Couple's Cancer Education
9906986|NCT00665899|No Intervention|Usual Care|Cancer-Related Community and Internet Resources
9906987|NCT00665912|Other|1|Standard post-lobectomy wound care plus use of PRP and PPPc in the thoracic cavity.
9906988|NCT00665912|Active Comparator|2|Standard post-lobectomy wound care in the thoracic cavity
9906989|NCT00665938|Active Comparator|1|
9906990|NCT00665938|Experimental|2|
9906991|NCT00665938|Experimental|3|
9906992|NCT00665951|Active Comparator|A|Kaletra tablets
9906993|NCT00665951|Experimental|B|Lopimune granules
9906994|NCT00665951|Experimental|C|Lopimune tablets
9906995|NCT00665964|Experimental|X-3|X-3 polyethylene which is a new highly cross-linked poly that is theorized to be more durable in vivo
9906996|NCT00665964|Active Comparator|N2Vac polethylene|conventional polyethylene
9906997|NCT00665977|Sham Comparator|A|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
9906998|NCT00665977|Active Comparator|Double Blind Treatment Group 2|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
9906999|NCT00665977|Active Comparator|Double Blind Treatment Goup 1|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
9907000|NCT00665990|Other|Treatment|All participants will receive bevacizumab, sorafenib, and cyclophosphamide until maximum tolerated dose is reached.
9907001|NCT00666016|Experimental|1|TRO19622 500 mg
9907002|NCT00666042|Experimental|A|Vigamox delivered as spray
9907003|NCT00666042|Active Comparator|B|Patients will receive the commercially available Vigamox drops
9907004|NCT00666055||Group 1|30 post-menopausal HIV-infected women
9907005|NCT00666055||Group 2|12 pre-menopausal HIV-infected women
9907006|NCT00666068|Experimental|1|"Patients with hypopituitarism~Cross over design: see interventions 1-2"
9907007|NCT00666068|Placebo Comparator|2|"Parallel design:~Healthy controls to be compared with placebo condition in patients with hypopituitarism"
9907008|NCT00666081|Experimental|Cohort 1|GSK690693 for injection. This is a dose escalation study.
9907009|NCT00666094|Active Comparator|endurance training|supervised endurance training
9907010|NCT00666094|Experimental|strength training|Supervised strength training
9907011|NCT00666120|Active Comparator|1|Cow's milk based infant formula
9907012|NCT00666120|Active Comparator|2|Partially hydrolyzed cow's milk based infant formula
9907013|NCT00666133|No Intervention|2|Women in Group II (standard of care) will receive an 8 mL loading dose containing 4g magnesium sulfate administered manually per standard hospital protocol. The solution will be diluted with normal saline according to standard hospital practice, and given IV over 20 minutes. For women in Group II, the IV loading dose will be followed immediately with 20 mL treatment by IM injection, given as 10 mL (5 g magnesium sulfate) into each buttock. This dose will be followed by 10 mL treatments (5g magnesium sulfate) every four hours, injected into alternate buttock. Treatment will be discontinued when clinically indicated.
9935767|NCT03225144||Patients|patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols
9935768|NCT03225131||0|participants without AMD meaning no large drusen (= 125 microns) or advanced AMD in either eye
9907014|NCT00666133|Experimental|1|Women in Group I (Springfusor® arm) will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4will be administered using the Springfusor® pump. For women in Group I, the administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours for upto 24 hours postpartum.
9907015|NCT00666146||1|Case Families ( Family with a schizophrenia proband)
9907016|NCT00666146||2|Control Families
9907017|NCT00666146||3|Control subjects
9907018|NCT00666159|Experimental|1|
9907019|NCT00666159|Active Comparator|2|
9907020|NCT00666185|Experimental|1|
9907021|NCT00666185|Active Comparator|2|
9907022|NCT00666237|Experimental|Tube shunt surgery group|Participants in this group will receive a tube shunt surgery (Baerveldt Glaucoma implant).
9907023|NCT00666237|Experimental|Trabeculectomy with Mitomycin C|Participants in this group will receive a Trabeculectomy surgery with Mitomycin C
9907024|NCT00666250|No Intervention|Baseline|Baseline values off chocolate supplement
9907025|NCT00666250|Experimental|Low Dose|Low dose of dietary supplement 30 ml tid (Activ Xocai Drink)
9907026|NCT00666250|Experimental|High-dose|High dose of dietary supplement 90 ml tid (Xocai Activ drink)
9907027|NCT00666302|Experimental|1|
9907028|NCT00666302|Active Comparator|2|
9907029|NCT00666315||Harmonic|Group operated with Harmonic device
9907030|NCT00666315||Conventional|Group operated with Electrocauery and Clip/Suture
9907031|NCT00666341|Placebo Comparator|Placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
9907032|NCT00666341|Experimental|20 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
9907033|NCT00666341|Experimental|40 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
9907034|NCT00666341|Experimental|80 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
9907035|NCT00666341|Experimental|120 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
9907036|NCT00666354|Active Comparator|1|
9907037|NCT00666354|Active Comparator|2|
9907038|NCT00666354|Active Comparator|3|
9907039|NCT00666367|Active Comparator|1|Vitamin D (D-cure) will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
9907040|NCT00666367|Placebo Comparator|2|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
9907041|NCT00666380|Experimental|10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
9907042|NCT00666380|Experimental|50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
9907043|NCT00666393|Experimental|001|
9907044|NCT00666432||1|Controls
9907045|NCT00666432||2|Patient Family
9907046|NCT00666432||3|Patients
9907047|NCT00666445||1|Patients diagnosed with Alzheimer's Disease
9907048|NCT00666445||2|Aged-matched normal controls
9907049|NCT00666471|Experimental|1|MICE
9907050|NCT00666471|Active Comparator|2|SPA ligation
9907051|NCT00666484|Experimental|Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2|"OEPA (28day cycle):~Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15"
9907052|NCT00666484|Experimental|Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
9907053|NCT00666484|Experimental|Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
9907054|NCT00666510||Bronchospasm|Patients who presented bronchospasm during anesthesia induction
9907055|NCT00666510||Asthma|Patients who presented bronchospasm during anesthesia induction and were identified as asthmatics
9907056|NCT00666510||Control|Patients who were submitted to anesthesia induction and showed no complications
9907057|NCT00666523|Experimental|1|
9907058|NCT00666523|Placebo Comparator|2|
9907059|NCT00666575|Experimental|Gabapentin|
9907060|NCT00666575|Placebo Comparator|Placebo|
9907061|NCT00666601|Experimental|Pilot study|3 subjects, open lable, microdialysis single dose.
9907062|NCT00666601|Experimental|Main Study|12 subjects, open label, single dose of 600 mg.
9907063|NCT00666614|Other|Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
9907064|NCT00666614|Other|Standard Care|Normal Hospital Environment
9907065|NCT00666627|Active Comparator|1|Ibandronate
9907066|NCT00666627|Active Comparator|2|Risedronate
9907067|NCT00666627|Active Comparator|3|Alendronate 70mg once weekly
9907068|NCT00666627|No Intervention|4|Young women control group
9907069|NCT00666640||1|50 subjects who have suffered a hip fracture
9907070|NCT00666640||2|50 age matched controls
9907071|NCT00666692|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab
9907072|NCT00666744|Experimental|1|Exercise Intervention - additional lower limb exercises will be completed by the person with stroke with the assistance of his/her family for 35 minutes daily for a period of 8 weeks.
9907073|NCT00666744|No Intervention|2|Participants in this group will receive routine exercise therapy following stroke
9907074|NCT00666770|Experimental|Gabapentin 250 mg|
9907075|NCT00666770|Experimental|Gabapentin 500 mg|
9907076|NCT00666770|Placebo Comparator|Placebo|
9907077|NCT00666783|Experimental|PAL|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
9907078|NCT00666783|Active Comparator|GRA|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
9907079|NCT00666796|Placebo Comparator|A|
9907080|NCT00666796|Experimental|B|
9907081|NCT00666796|Experimental|C|
9907082|NCT00666796|Experimental|D|
9800341|NCT01685138|Experimental|LDK378 (Ceritinib)|Participants on this arm took oral LDK378 750 mg once daily.
9800342|NCT01685203|Experimental|Group 1|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
9800343|NCT01685203|Experimental|Group 2|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants
9800344|NCT01685203|Experimental|Group 3|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants
9800345|NCT01685203|Experimental|Group 4|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
9800346|NCT01685203|Experimental|Group 5|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants
9907083|NCT00666809|Active Comparator|Arm 1|
9907084|NCT00666809|Placebo Comparator|Arm 2|
9907085|NCT00666874|Experimental|1|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
9907086|NCT00666874|Active Comparator|2|General information about healthy food choices and exercise
9933752|NCT05242458||Participants with Crohn's Disease (CD)|Participants with moderate-to-severe active CD enrolled in ImproveCareNow (ICN) pediatric Inflammatory bowel disease (IBD) registry will be observed who are being treated with ustekinumab under real world setting and will be divided into 9 cohorts. Cohorts 1-6 for age group >=2 to <18 years (pediatric), cohorts 7-9 for young adults within age group >=18 to <26 years. Cohort 1: participants with moderate-severe CD and body weight >=40 kg, cohort 2: participants with moderate-severe CD and body weight <40 kg, cohort 3: all participants with moderate-severe CD, cohort 4: participants with active disease and body weight >=40 kg, cohort 5: participants with active disease and body weight <40 kg, cohort 6: all participants treated with ustekinumab, cohort 7: young adults with moderate-severe CD, cohort 8: young adults with active-disease; and cohort 9: all young adults treated with ustekinumab. Only data available per routine clinical practice will be collected within this study.
9933753|NCT05240001|Experimental|Thulium Fibre Laser (TFL)|Patients randomized to this arm will undergo treatment using the TFL.
9933754|NCT05240001|Experimental|MOSES Holmium Laser|Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
9933755|NCT05237986||Cohort 1|Participants with relapsed/refractory leukemias or lymphomas, scheduled to receive CAR T-cell therapy.
9933756|NCT05237986||Cohort 2|Caregivers (informants)
9933757|NCT05237973||Neuromuscular disorders|Diagnosed with a neuromuscular disorder such as motor neuron disorder, myopathy or have findings consistent with a peripheral neuropathy.
9933758|NCT05237973||Normal volunteers|No known abnormal muscle or nerve disorders
9933759|NCT05237934||Cohort 1|Participants with confirmed/suspected NENs including ACC
9933760|NCT05236738|Experimental|Treatment Sequence Group 1|
9933761|NCT05236738|Experimental|Treatment Sequence Group 2|
9907087|NCT00666887|Active Comparator|Minocycline|Minocycline 100 mg oral for up to 24 months
9907088|NCT00666887|Placebo Comparator|Placebo|Lactose Monohydrate NF (Spray-dried) 235 mg/cap Magnesium Stearate NF 1 mg/cap Croscarmellose Sodium NF 4 mg/cap Stearic Acid 10 mg/cap Placebo CAP Lt orange OP-Purple OP (APO 100)
9907089|NCT00666939|Experimental|A|
9907090|NCT00666939|Experimental|B|
9907091|NCT00666939|Placebo Comparator|C|
9907092|NCT00666952|Experimental|1|
9907093|NCT00666952|Active Comparator|2|
9907094|NCT00666991|Experimental|Nanotax, 50 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity
9907095|NCT00666991|Experimental|Nanotax, 82.5 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 82.5 mg/m2 once every 28 days until progression or unacceptable toxicity
9907096|NCT00666991|Experimental|Nanotax, 125 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 125 mg/m2 once every 28 days until progression or unacceptable toxicity
9907097|NCT00666991|Experimental|Nanotax, 175 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 175 mg/m2 once every 28 days until progression or unacceptable toxicity
9907098|NCT00666991|Experimental|Nanotax, 225 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 225 mg/m2 once every 28 days until progression or unacceptable toxicity
9907099|NCT00666991|Experimental|Nanotax 275 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 275 mg/m2 once every 28 days until progression or unacceptable toxicity
9907100|NCT00667030|Experimental|Lifestyle Modification|Combined hypocaloric diet and aerobic exercise training
9907101|NCT00667043|Active Comparator|Study group 1|Midazolam and fentanyl; continuous intravenous infusions
9907102|NCT00667043|Active Comparator|Study group 2|Propofol and remifentanil; continuous intravenous infusion
9907103|NCT00667056|Experimental|1|
9907104|NCT00667056|Placebo Comparator|2|
9907105|NCT00667069|Other|A Relapse|Radiotherapy and Hormonotherapy only if relapse
9907106|NCT00667069|Experimental|B Immediate treatment|Radiotherapy and Hormonotherapy at randomization
9907107|NCT00667082|Experimental|NPI-0052 + Vorinostat Dose-Escalation|4 dose-escalation cohorts
9907108|NCT00667108|Experimental|Gabapentin 250 mg|
9907109|NCT00667108|Experimental|Gabapentin 500 mg|
9907110|NCT00667108|Placebo Comparator|Placebo|
9907111|NCT00667134||1|Subjects with diffuse scleroderma
9907112|NCT00667134||2|Subjects with limited scleroderma
9907113|NCT00667134||3|Subjects without a fibrosing or autoimmune disease.
9907114|NCT00667147|Experimental|A|
9907115|NCT00667147|Experimental|B|
9907116|NCT00667160|Experimental|1|
9907117|NCT00667160|Active Comparator|2|
9907118|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-5kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (5kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
9907119|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-25 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (25kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
9907120|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-50 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (50kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
9907121|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-100 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (100kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
9907122|NCT00667212|Active Comparator|2|Supportive Psychotherapy
9907123|NCT00667212|Active Comparator|1|Cognitive Behavioral Therapy (Cognitive Restructuring, Relaxation, and Coping Skills Training: CRCST)
9907124|NCT00667264|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
9907125|NCT00667264|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
9907126|NCT00667290|Experimental|1|
9907127|NCT00667290|No Intervention|2|
9907128|NCT00667303||1|
9907129|NCT00667316||A|Workers from companies and workers' health care organizations who go for their periodic medical checkup.
9907130|NCT00667407|Experimental|1|Levalbuterol 1.25 mg
9907131|NCT00667407|Active Comparator|2|Racemic Albuterol 2.5 mg
9907132|NCT00667433|Other|Single Arm|Single arm where subjects will receive Raltegravir 400 mg BID along with Truvada once a day for 104 weeks
9907133|NCT00667472|Experimental|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
9907134|NCT00667472|Experimental|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
9907135|NCT00667485|Experimental|Weekly Rapamcyin|Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks
9907136|NCT00667485|Experimental|Daily Rapamycin|Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks
9907137|NCT00667498|Experimental|1|
9907138|NCT00667498|Placebo Comparator|2|
9907139|NCT00667524||I|
9907140|NCT00667537|Experimental|Radium-223 chloride|IV administrations of 100 kBq/kg b.w (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization). Two administrations took place with an interval of 6 weeks
9907141|NCT00667667|Active Comparator|1|vertical vibration device (using Vibrafit whole body vibration platforms)
9907142|NCT00667667|Active Comparator|2|side-alternating vibration device (using Board 3000 whole body vibration platforms)
9907143|NCT00667667|Sham Comparator|3|wellness-control group
9907144|NCT00667680|Active Comparator|1|anodal tDCS
9907145|NCT00667680|Sham Comparator|2|Sham tDCS
9907146|NCT00667706|Active Comparator|1|Patients who will undergo Laparoscopic Sleeve Gastrectomy
9907147|NCT00667706|Active Comparator|2|Patients who will undergo Laparoscopic Roux-en-Y Gastric Bypass
9907148|NCT00667758|Experimental|1|Cetrorelix
9907149|NCT00667758|Placebo Comparator|2|NaCl solution
9907150|NCT00667784||Anxiety Assessment|Minor Donors + Sibling Non-Donors + Parents or Legal Guardians
9907151|NCT00667797|Experimental|1|levalbuterol 1.25 mg
9907152|NCT00667797|Active Comparator|2|Racemic albuterol 2.5 mg
9907153|NCT00667914|Experimental|Orthogeriatric unit|Geriatric work-up on hip-fracture patients
9907154|NCT00667914|Active Comparator|Orthopedic care as usual|Traditional care in the orthopedic unit
9907155|NCT00667927|Other|1|
9907156|NCT00667940|Experimental|Workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
9907157|NCT00667940|No Intervention|Delayed workshop|No specific intervention until after follow-up assessment, then receives same workshop.
9907158|NCT00667966|Experimental|Vardenafil + Placebo|Subjects received single dose of 10 mg vardenafil followed by 20 mg vardenafil and then crossed over to 10 mg placebo followed by 20 mg placebo.
9907159|NCT00667966|Experimental|Placebo + Vardenafil|Subjects received single dose of 10 mg placebo followed by 20 mg placebo and then crossed over to 10 mg vardenafil followed by 20 mg vardenafil.
9907160|NCT00667979|Experimental|Arm 1|
9907161|NCT00667979|Placebo Comparator|Arm 2|
9907162|NCT00668005|Experimental|Arm 1|
9907163|NCT00668005|Placebo Comparator|Arm 2|
9907164|NCT00668018|Experimental|Arm 1|
9907165|NCT00668031|Experimental|Arm 1|
9907166|NCT00668031|Placebo Comparator|Arm 2|
9907167|NCT00668044|Experimental|Arm 1|
9907168|NCT00668044|Experimental|Arm 2|
9907169|NCT00668057|Experimental|Arm 1|
9907170|NCT00668057|Experimental|Arm 2|
9907171|NCT00668057|Experimental|Arm 3|
9907172|NCT00668057|Placebo Comparator|Arm 4|
9907173|NCT00668057|Placebo Comparator|Arm 5|
9907174|NCT00668057|Placebo Comparator|Arm 6|
9907175|NCT00668070|Experimental|ASP9831 Low Dose|
9907176|NCT00668070|Experimental|ASP9831 Higher Dose|
9907177|NCT00668070|Placebo Comparator|Placebo|
9907178|NCT00668096|Placebo Comparator|Arm 2|
9907179|NCT00668096|Experimental|Arm 1|
9907180|NCT00668109|Experimental|Arm 1|
9907181|NCT00668109|Active Comparator|Arm 2|
9907182|NCT00668122|Experimental|Arm 1|
9907183|NCT00668122|Experimental|Arm 2|
9907184|NCT00668135|Experimental|Arm 1|
9907185|NCT00668135|Placebo Comparator|Arm 2|
9907186|NCT00668161|Experimental|1|Exercise
9907187|NCT00668161|No Intervention|2|Control
9907188|NCT00668174|Experimental|1|Exercise
9907189|NCT00668174|No Intervention|2|Control
9907190|NCT00668239|Active Comparator|1|Laser treatment: laser was applied to the macular region according to the modified grid technique in inverted C, preserving 500 μ of the foveolus and avascular zone, with 100μ diameter shots, energy varying from 0.2 to 0.5 joules, with a time of exposure between 0.2 and 0.4 seconds. One hundred and fifty to 200 shots were applied according to the size of the retinal area². ND YAG laser (Crystal Focus (EMERED®) was used
9907191|NCT00668239|Experimental|2|triamcinolone as previously described
9907192|NCT00668252||1|Non menopausal women
9907193|NCT00668252||2|age matched men
9907194|NCT00668252||3|Menopausal women
9907195|NCT00668252||4|age matched men
9907196|NCT00668278|Active Comparator|A|Laryngeal Mask Airway insertion
9907197|NCT00668278|Active Comparator|B|I-gel insertion
9907198|NCT00668291||CNC|Primary pigmented nodular adrenocortical disease (PPNAD) and the Carney complex (CNC)
9907199|NCT00668291||MC-L|cardiac myxoma or isolated lentiginosis
9907200|NCT00668304|Experimental|Arm 1|
9907201|NCT00668330|Active Comparator|Ibandronate+alfacalcidol+calcium|Bonviva
9907202|NCT00668330|Active Comparator|Placebo ibandronate+alfacalcidol+calcium|
9907203|NCT00668343|Active Comparator|1|
9907204|NCT00668343|Placebo Comparator|2|
9907205|NCT00668356|Experimental|1|
9907206|NCT00668356|Active Comparator|2|
9907207|NCT00668369|Experimental|1|Liver transplant recipients with HCV infection fulfilling inclusion criteria.
9907208|NCT00668408|Other|LTOT group|Study group: optimal medical therapy plus LTOT = or > 15 hours pro die
9907209|NCT00668408|Other|Non LTOT group|control group: optimal medical therapy without LTOT
9907210|NCT00668421|Experimental|CEP-701 (Lestaurtinib)|Subject is to receives Lestaurtinib, in Phase 1: standard cohort dose escalation; Phase 2: single stage design to estimate the percentage of subjects with a 15% or greater reduction in JAK2 V617F allele frequency in peripheral blood granulocytes in 6 months of treatment
9907211|NCT00668447|Experimental|1|Soy protein and isoflavone tablets
9907212|NCT00668447|Active Comparator|2|Soy protein and placebo tablets
9907213|NCT00668447|Active Comparator|3|control protein and Isoflavone tablets
9907214|NCT00668447|Placebo Comparator|4|control protein and placebo tablets
9907215|NCT00668473||1|Subjects with diffuse scleroderma
9907216|NCT00668473||2|Healthy controls
9907217|NCT00668512|Experimental|Antimelanoma injection-GSL alpha-Gal|Intervention consists of injection of a single melanoma metastasis with two injections of GSL alpha-Gal separated by four weeks. Both injections done with the same dose of GSL alpha-GAL each time. Phase 1 dose escalating scheme: 0.1mg, 1 mg, 10mg
9907218|NCT00668551||1|Telemedicine care
9907219|NCT00668551||2|Standard of care
9907220|NCT00668590|Experimental|1|
9907221|NCT00668590|Active Comparator|2|
9907222|NCT00668603|Experimental|2|Postmenopausal women with severe vasomotor symptoms
9907223|NCT00668603|Experimental|1|Postmenopausal women without vasomotor symptoms
9907224|NCT00668616|Active Comparator|1|
9907225|NCT00668616|Experimental|2|
9907226|NCT00668642|Experimental|A: Dutasteride During First Off-Cycle|Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle
9907227|NCT00668642|Placebo Comparator|B: Placebo During First Off-Cycle|Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle
9907228|NCT00668655||1|Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea
9907229|NCT00668681|Active Comparator|Endorefix|Evaluation of EndoRefix Endovascular Delivery System and Staple
9907230|NCT00668694|No Intervention|1|Anemia without stimulation.
9907231|NCT00668694|Experimental|2|Anemia with stimulation
9907232|NCT00668694|No Intervention|3|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled without stimulation
9907233|NCT00668694|No Intervention|4|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled with stimulation
9907234|NCT00668720|Experimental|1|
9907235|NCT00668720|Sham Comparator|2|
9933762|NCT05236738|Experimental|Treatment Sequence Group 3|
9907236|NCT00668759|Experimental|1|"Vernakalant Injection:~In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes."
9907237|NCT00668759|Active Comparator|2|"Amiodarone Injection:~In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF."
9907238|NCT00668798||A|mother CMV positive
9907239|NCT00668798||B|mother CMV negative
9907240|NCT00668850|Experimental|1|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
9907241|NCT00668850|Active Comparator|2|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
9907242|NCT00668876|Active Comparator|1|Group A: perioperative immunonutrition
9907243|NCT00668876|Active Comparator|2|Group B: postoperative immunonutrition
9907244|NCT00668876|Active Comparator|3|Group C: control
9907245|NCT00668915||A|Primary arthroplasty
9907246|NCT00668941|Experimental|1|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a continuous regimen of daily teriparatide (20 mcg subcutaneously) for 48 months, in addition to alendronate. Biopsies will be performed at Week 7 or Month 7.5. The participants will then have the option to be followed while taking alendronate alone for 24-48 months.
9907247|NCT00668941|Experimental|2|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a cyclical regimen of teriparatide, in addition to alendronate. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an aption to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
9907248|NCT00668941|Active Comparator|3|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will continue taking alendronate alone. Biopsies will be performed at Week 7 and then participants in this group will be offered teriparatide as part of Group 2 or 3.
9907249|NCT00668941|Experimental|4|Participants in this group will receive a continuous regimen of teriparatide (20 mcg delivered subcutaneously) daily for 48 months. Biopsies will be performed at Week 7 or Month 7.5. At 24 months the participants will then have the option of taking alendronate and remaining in the study for another 24 months.
9907250|NCT00668941|Experimental|5|Participants in this group will receive a cyclical regimen of teriparatide. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an option to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
9907251|NCT00668941|Active Comparator|6|Participants in this group will take only calcium and vitamin D supplements. Biopsies will be performed at Week 7. Participants will then be offered the standard care for osteoporosis or they may enter the study in Group 4 or 5.
9907252|NCT00668954|Active Comparator|Pomegranate Juice|
9907253|NCT00668954|Placebo Comparator|Placebo Juice (non-Pomegranate)|
9933763|NCT05236257||Larotrectinib|Pediatric patients with IFS harboring an NTRK gene fusion who have been enrolled in the SCOUT study.
9933764|NCT05236257||Standard care|Pediatric patients with IFS harboring an NTRK gene fusion in the eligible external cohort(s).
9933765|NCT05236075|Experimental|patients with polysomnography diagnostic of obstructive sleep disorders moderate to severe|
9933766|NCT05235971|Experimental|Episodic Future thinking (EFT)|Participants will receive up to 3 messages a day that include assessment and intervention messages.The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.
9933767|NCT05235971|Experimental|Volitional choice (VC)|VC creates structured if-then plans to dismantle context-linked alcohol use. Participants will receive up to 3 messages a day that include assessment and intervention messages.
9933768|NCT05235971|Experimental|Episodic Future thinking plus Volitional choice|Participants will receive both EFT and VC interventions with text messages.
9933769|NCT05235971|Other|Monitoring only|This is a control group in which participants will receive general psychoeducation.
9933770|NCT05233397|Experimental|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
9933771|NCT05232838|Experimental|Treatment Arm|The Treatment Arm receives the eShunt Implant.
9935769|NCT03225131||1|participants with large drusen (= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye
9935770|NCT03225131||2|participants with bilateral large drusen (= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes
9935771|NCT03225131||3|participants with large drusen (= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye
9935772|NCT03225131||4|participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye
9907254|NCT00668967|Other|Reference|marketed extended release verapamil tablet
9907255|NCT00668967|Other|Test|reformulated extended release verapamil tablet
9907256|NCT00668980||Study group|20 infants with Down syndrome
9907257|NCT00668980||Control Group|15 typically developing children
9907258|NCT00668993|Experimental|A, B|A is treatment group B is waitlist group
9907259|NCT00669006||1|New patients with a diagnosis of Neuropathic Pain
9907260|NCT00669097|Experimental|TKI258|
9907261|NCT00669123|Placebo Comparator|2|
9907262|NCT00669123|Experimental|1|Chondroitin sulphate
9907263|NCT00669136|Other|1|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
9907264|NCT00669149|Experimental|1|group without anticoagulant therapy
9907265|NCT00669149|Active Comparator|2|group with heparin
9907266|NCT00669149|Active Comparator|3|group with enoxaparin
9907267|NCT00669149|Active Comparator|4|group with bivalirudin
9907268|NCT00669201||1|healthy young volunteers Inclusion: age 18-40, Exclusion: wrist trauma/surgery
9907269|NCT00669201||2|"patients with know osteoarthritis wrist changes according to pre-existing x-rays No age limits~exclusion: previous wrist surgery"
9907270|NCT00669201||3|Mixed group of 50 patients that perform routine MRI of the wrist for various indications
9907271|NCT00669227|Active Comparator|1|autologous stem cells, Ficoll preparation, intracoronary administration at the same day of bone marrow cell aspiration
9907272|NCT00669227|Placebo Comparator|2|placebo is visually indistinguishable from verum due to integration of autologous erythrocytes, intracoronary administration the same day of bone marrow aspiration
9907273|NCT00669253|Experimental|1|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
9907274|NCT00669253|Active Comparator|2|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods (ultrasonic and manual means)
9907275|NCT00669253|Active Comparator|3|Surgery at baseline for all deep pockets using conventional methods (ultrasonic and manual means)
9907276|NCT00669266||Tumor|Tumor material and corresponding biosamples from patients with adrenal tumors
9907277|NCT00669266||control group|Biomaterial from patients without adrenal tumor
9907278|NCT00669305||Cohort 1|Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental models
9907279|NCT00669344|Placebo Comparator|II|Placebo
9907280|NCT00669344|Experimental|I|Rivastigmine
9907281|NCT00669435|Active Comparator|1|Amlodipine and Simvastatin
9907282|NCT00669435|Experimental|2|Losartan and Simvastatin
9907283|NCT00669474|Other|1|Suction curettage
9907284|NCT00669474|Active Comparator|2|Treatment with Botox
9907285|NCT00669487|Experimental|1. GPO-VIR S 1 pill orally every 12 hours|
9907286|NCT00669487|Experimental|2 GPO-VIR Z 1 pill orally every 12 hours|
9907287|NCT00669487|Experimental|3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr|
9907288|NCT00669513|No Intervention|1|
9907289|NCT00669513|Experimental|2|Partial sleep deprivation
9907290|NCT00669526|Active Comparator|SMHC referral|Referral to local Specialty Mental Health Care Services
9907291|NCT00669526|Experimental|BCBT|Brief Cognitive Behavioral Therapy
9907292|NCT00669591|Experimental|1|Patients will receive up to six (6) 28-day cycles of docetaxel plus weekly bavituximab during the treatment phase. During the follow-up phase, patients will continue to receive weekly bavituximab until disease progression
9907293|NCT00669643|Active Comparator|R-MDT PB|R-MDT PB group: standard/regular treatment recommended by WHO - All patients presenting fewer than 6 skin lesions will receive the standard treatment regimen for paucibacillary patients as the intervention; Intervention - PB 6 doses of rifampicin and dapsone
9907294|NCT00669643|Experimental|U-MDT PB|U-MDT PB group: a unified treatment for all patients - All patients presenting fewer than 6 lesions (WHO PB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - PB 6 doses of rifampicin, clofazimine and dapsone
9907295|NCT00669643|Experimental|R-MDT MB|R-MDT MB group: standard/regular treatment recommended by WHO - All patients presenting 6 skin or more lesions will receive the standard treatment regimen for multibacillary patients as the intervention; Intervention - MB 12 doses of rifampicin, clofazimine and dapsone
9907296|NCT00669643|Experimental|U-MDT MB|U-MDT MB group: a unified treatment for all patients - All patients presenting 6 lesions or more (WHO MB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - MB 6 doses of rifampicin, clofazimine and dapsone
9907297|NCT00669656|Experimental|Prostate Health Cocktail|
9907298|NCT00669695|Placebo Comparator|Stat/CPAP|Atorvastatin and CPAP treatments
9907299|NCT00669695|Placebo Comparator|Stat/sham CPAP|Atorvastatin and sham CPAP treatments
9907300|NCT00669695|Sham Comparator|Placebo/CPAP|Placebo and CPAP treatments
9907301|NCT00669695|Active Comparator|Placebo/sham CPAP|Placebo and sham CPAP treatments
9907302|NCT00669708|Active Comparator|1|ph5 Eucerin Lotion with cooling compound
9907303|NCT00669708|Placebo Comparator|2|ph5 Eucerin Lotion
9907304|NCT00669721|Experimental|A|This patients start a run in period with LMWH schedule as hemodialysis circuit anticoagulation. Then they'll undergo hemodialysis with LMWH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to UFH schedule. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
9907305|NCT00669721|Active Comparator|B|The patients randomized to receive UFH will start a run in period with this heparin schedule. Then they'll undergo hemodialysis with UFH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to LMWH. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
9907306|NCT00669747|Experimental|A|Carboplatin infused into DCIS-involved duct on Days 1 & 15
9907307|NCT00669747|Experimental|B|Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15
9907308|NCT00669747|Placebo Comparator|C|Normal Saline infused into DCIS-involved duct Days 1 & 15
9907309|NCT00669760||Observation|CF-patients with persistent culture of Staphylococcus aureus in their respiratory specimens
9907310|NCT00669773|Experimental|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
9907311|NCT00669773|Experimental|Docetaxel|
9907312|NCT00669786|Active Comparator|HMG|Human Menopausal Gonadotropin (HMG)
9907313|NCT00669786|Active Comparator|r-FSH|Recombinant Follicle Stimulating Hormone
9907314|NCT00669799|Experimental|1|clyndamyacin
9907315|NCT00669799|Experimental|2|gentamicin
9907316|NCT00669825|Placebo Comparator|A|Placebo
9907317|NCT00669825|Active Comparator|B|ALV003 (Active Study Drug)
9907318|NCT00669838||PL|Patients who receive local anesthesia with 2% lidocaine without epinephrine
9907319|NCT00669838||LE|Patients who receive local anesthesia with 2% lidocaine with 1:100.000 epinephrine
9907320|NCT00669890|Experimental|study 515|
9907321|NCT00669929||1|patients visited to Severance hospital
9907322|NCT00669929||2|patients visited to Youngdong Severance hospital
9907323|NCT00669929||3|patients visited to Wonju Christian hospital
9907324|NCT00669981|Experimental|1|Participants will receive immediate cognitive behavioral couples therapy for PTSD.
9907325|NCT00669981|Active Comparator|2|Participants will receive delayed cognitive behavioral couples therapy for PTSD after a 3-month waitlist period.
9907326|NCT00669994|Experimental|Arm 1|
9907327|NCT00670020|Experimental|1|supplemental perioperative oxygen
9907328|NCT00670020|No Intervention|2|Normal
9907329|NCT00670059|Active Comparator|A|group: single embryo transfer without aneuploidy screening
9907330|NCT00670059|Experimental|B|group: single embryo transfer with aneuploidy screening
9907331|NCT00670098|Experimental|1|
9907332|NCT00670098|Experimental|2|
9907333|NCT00670124|No Intervention|1|Standard medical treatment
9907334|NCT00670124|Active Comparator|2|Standard medical treatment plus hypothermia (33°C) maintained for 72 hours
9907335|NCT00670163|Experimental|1|Participating community will provide Comunidades Positivas plus enhanced partner therapy.
9907336|NCT00670163|Experimental|2|Participating community will provide enhanced partner therapy alone.
9907337|NCT00670163|Experimental|3|Participating community will provide Comunidades Positivas alone.
9907338|NCT00670163|Active Comparator|4|Participating community will provide standard of care.
9907339|NCT00670176|Experimental|I|
9907340|NCT00670189|Experimental|BMS-833923|
9907341|NCT00670215|Experimental|Arm 1|
9907342|NCT00670215|Experimental|Arm 2|
9907343|NCT00670254|Experimental|Hydrocortisone|
9907344|NCT00670254|Placebo Comparator|Placebo|
9907345|NCT00670280|Experimental|Intervention Group|Those randomized to the Intervention group will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit.
9907346|NCT00670280|Active Comparator|UC Group|Those randomized to the Usual Care group will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
9907347|NCT00670280|Active Comparator|UC-RM Group|Those randomized to the Usual Care - Reduced Measurement group will receive the same information as the Usual Care group but will be measured less often (only at 6 months post-intervention).
9907348|NCT00670293||Subjects with anorexia nervosa|Underweight participants with anorexia nervosa who will restore normal weight levels after inpatient treatment will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
9907349|NCT00670293||Healthy weight controls|Participants who are healthy controls will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
9798491|NCT01630616|Experimental|Adolescents Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to adolescents.
9798492|NCT01630616|Placebo Comparator|Adolescents Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to adolescents.
9798493|NCT01630616|Experimental|Young Adults Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to young adults.
9798494|NCT01630616|Placebo Comparator|Young Adults Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to young adults.
9798495|NCT01630694|Active Comparator|Difficult intubation patients|patients who were difficult to intubate during previous anesthetics provided by the staff anesthesiologists.
9798496|NCT01630694|Placebo Comparator|Control|The control group will consist of patients with the easy laryngoscopy and intubation, recruited prospectively.
9798497|NCT01630811|Experimental|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg), oral, once daily
9798498|NCT01630811|Placebo Comparator|Placebo|Oral, once daily
9798499|NCT01630889|Experimental|Roxadustat|Participants previously randomized to roxadustat will receive roxadustat at the same dose and frequency assigned at the last dose in the previous FibroGen study. Dose adjustments will be implemented (up to a maximum roxadustat dose of 3.0 mg/kg or 400 mg, whichever is lower) every 4 weeks to maintain Hb levels at 10.0-12 grams (g)/deciliter (dL). However, if a participant, at any dose, experiences an event of excessive hematopoiesis then the participant's dose will be immediately reduced, or an event of rapidly declining Hb then the participant's dose will be immediately increased. Participants will be permitted to receive roxadustat for up to 8 years.
9798500|NCT01631071|Experimental|Elderly subjects aged over 60 years|
9798501|NCT01631071|Experimental|Adults from 18 to 60 years old inclusive|
9798502|NCT01631110|Experimental|Elderly subjects aged over 60 years|
9798503|NCT01631110|Experimental|Adults from 18 to 60 years old inclusive|
9798504|NCT01631149|Experimental|Deep surgical block|Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
9798505|NCT01631149|Active Comparator|Moderate/normal surgical block|A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.
9798506|NCT01631188|Experimental|Aortic Valve Replacement|During surgery your doctor will utilize a new technique using surgical equipment that have already been FDA Approved for other indication. The combination of the equipment and technique will be experimental and will be closely evaluated during and after each case.
9798507|NCT01631214|Active Comparator|Alendronate/Alendronate|Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
9798508|NCT01631214|Experimental|Romosozumab/Alendronate|Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
9798509|NCT01631227|Experimental|Eprosartan|Eprosartan + Placebo Eprosartan Mesylate
9798510|NCT01631227|Active Comparator|Eprosartan Mesylate|Eprosartan Mesylate + Placebo Eprosartan
9798511|NCT01631331|Experimental|Treatment (vismodegib and Mohs surgery)|Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
9798512|NCT01631435|Other|bowel prep regimen|Each study subject will undergo a bowel preparation followed by a PillCam procedure.
9798513|NCT01631474|Experimental|Low-dose active, BID|low dose of CB-03-01, 0.1% applied twice a day
9798514|NCT01631474|Experimental|Medium-dose active, BID|medium dose of CB-03-01, 0.5% applied twice a day
9798515|NCT01631474|Experimental|High-dose active, QD|high dose of CB-03-01, 1% applied once a day
9798516|NCT01631474|Experimental|High-dose active, BID|high dose of CB-03-01, 1% applied twice a day
9798517|NCT01631474|Placebo Comparator|Vehicle, QD or BID|vehicle cream, applied once or twice a day
9798518|NCT01631552|Experimental|Sacituzumab Govitecan-hziy (SG) 8 mg/kg|Participants will receive sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
9798519|NCT01631552|Experimental|SG 10 mg/kg|Participants will receive SG 10 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
9907350|NCT00670319|Experimental|1|Raloxifene HCL 60 mg orally once a day
9907351|NCT00670319|Experimental|2|Raloxifene HCL 120 mg orally once a day
9907352|NCT00670319|Placebo Comparator|3|
9907353|NCT00670345|Experimental|1|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
9907354|NCT00670345|Placebo Comparator|2|Patients belonging to the control group will receive the same volume of saline infusions.
9907355|NCT00670371||1|Patients having the following diagnoses are eligible for inclusion into the study: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, affective psychosis with mood incongruent delusions, psychotic disorder not otherwise specified or patients being actively psychotic.
9907356|NCT00670371||2|Closest relative(s) /informal caregiver(s)
9907357|NCT00670384|Active Comparator|Dose Group A|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
9907358|NCT00670384|Active Comparator|Dose Group B|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
9907359|NCT00670384|Placebo Comparator|Placebo|
9907360|NCT00670397|Experimental|Treatment (PDT)|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9907361|NCT00670410|Experimental|Arm A - Related Donor|Related donor transplant: Patients with a related donor (5/6 or 6/6 HLA matched) will receive immunotherapy with a non-myeloablative preparative regimen of Busulfan and Fludarabine followed by allogeneic stem cell transplant (AlloSCT).
9907362|NCT00670410|Experimental|Arm B - Cord Blood Donor|Unrelated cord blood transplant: Patients without a related donor will receive immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by allogeneic stem cell transplant (AlloSCT) with either an unrelated umbilical cord blood donor (4/6, 5/6, or 6/6 HLA matched), or a related umbilical cord blood donor (3/6, 4/6, 5/6, or 6/6 HLA matched). Patients will receive Thymoglobulin ((rabbit) Anti-Thymocyte Globulin (ATG)) during the preparative regimen. GVHD prophylaxis will be Tacrolimus and mycophenolate mofetil (MMF).
9907363|NCT00670436|Active Comparator|A 1|paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery
9907364|NCT00670436|Active Comparator|A2|historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)
9907365|NCT00670475|Active Comparator|P (Pircoxicam Group)|in this arm 100 patients with osteoarthritis of knee will receive piroxicam gel in blinded 60 grams tubes,they will be instructed to use 1 gram of piroxicam gel (with inserted dispensing device) three times in a day on the affected knee.
9907366|NCT00670475|Experimental|O (olive oil group)|in this arm 100 patients with osteoarthritis of knee will receive virgin olive oil in blinded 60 grams tubes,they will be instructed to use 1 gram of olive oil (with inserted dispensing device) three times in a day on the affected knee.
9907367|NCT00670501|Experimental|1|LY333334 40 micrograms/day plus calcium and vitamin D
9907368|NCT00670501|Experimental|2|LY333334 20 micrograms/day plus calcium and vitamin D
9907369|NCT00670501|Placebo Comparator|3|Placebo plus calcium and vitamin D
9907370|NCT00670514|Active Comparator|1 Nix Individual|High Treatment Intensity
9907371|NCT00670514|Placebo Comparator|2 Fimpa dig fri|Low Treatment Intensity
9907372|NCT00670553|Experimental|LBH589|
9907373|NCT00670566|Experimental|1|
9907374|NCT00670618|Experimental|1|CPP-ACP (GC Tooth Mousse)
9907375|NCT00670618|Experimental|2|GCC-ACP (GC MI Paste Plus)
9907376|NCT00670618|Experimental|3|Fluoride (Elmex Medical Gel)
9907377|NCT00670618|No Intervention|4|Control group
9907378|NCT00670657|Experimental|1|AmBisome® 2 mg/kg/day in a unique daily IV administration
9907379|NCT00670670|Experimental|1|CPP-ACP (GC Tooth Mousse)
9907380|NCT00670670|Experimental|2|CPP-ACP (GC MI Paste Plus)
9907381|NCT00670670|No Intervention|3|Control group
9907382|NCT00670683||A|
9907383|NCT00670696|Experimental|A|Rapydan medicated plaster administered 30 minutes prior to cannulation on Visit 1 and tetracaine gel administered 45 minutes prior to cannulation on Visit 2.
9935773|NCT03223623|Active Comparator|FHD|adults with Focal Hand Dystonia
9907384|NCT00670696|Active Comparator|B|Tetracaine gel administered 45 prior to cannulation on Visit 1 and then Rapydan administered 30 minutes prior to cannulation on Visit 1
9907385|NCT00670722||A|
9907386|NCT00670722||B|
9907387|NCT00670722||C|
9907388|NCT00670722||D|
9907389|NCT00670761|Active Comparator|1|treatment with 600mcg oral misoprostol
9907390|NCT00670761|Active Comparator|2|treatment with 400mcg sublingual misoprostol
9907391|NCT00670761|Active Comparator|3|treatment with Manual Vacuum Aspiration (MVA)
9907392|NCT00670787|Active Comparator|Combination pill|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
9907393|NCT00670787|No Intervention|Control group|combination therapy of angiotensin receptor antagonists (losartan potassium 50mg, candesartan 8mg, valsartan 80mg, telmisartan 40mg or olmesartan 20mg) and thiazide or thiazide-like diuretics (hydrochlorothiazide 6.25-12.5mg, trichlormethiazide 0.5-1.0mg, indapamide 0.5-1.0mg or chlorthalidone 6.25-12.5mg)
9907394|NCT00670813|Experimental|Modafinil (Vigil)|"Modafinil Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives 200 mg of Modafinil each at 12:00, 24:00 and again at 12:00 o' clock"
9907395|NCT00670813|Placebo Comparator|Placebo|"Placebo Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives Placebo at 12:00, 24:00 and again at 12:00 o' clock"
9907396|NCT00670826|Experimental|1|Use of the Dynatherm Medical vitalHEAT vH2 Temperature Management System to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
9907397|NCT00670826|Active Comparator|2|Use of the Arizant Healthcare Bair Hugger Temperature Management System & Bair Hugger Upper Body Blanket to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
9907398|NCT00670839|Active Comparator|A|GenHevac-B 20 microgram intramuscular use at M0, M1 and M6
9907399|NCT00670839|Experimental|B|GenHevac-B 40 microgram intramuscular use at M0, M1 and M6
9907400|NCT00670852||I|Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study.
9907401|NCT00670865|Experimental|eDischarge|The eDischarge arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use the electronic discharge summary program.
9907402|NCT00670865|No Intervention|Traditional|"The traditional arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use traditional, dictated discharge summaries."
9907403|NCT00670878|Experimental|A|
9907404|NCT00670878|Active Comparator|B|
9907405|NCT00670891|Experimental|HBOT|HBOT
9907406|NCT00670904|Active Comparator|1|Pharmacist-delivered group program for smoking cession.
9907407|NCT00670904|Placebo Comparator|2|Brief standard care session for tobacco smoking cessation delivered over the telephone.
9933772|NCT05230511|Experimental|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Treatment Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
9933773|NCT05230511|Other|Intravesical Bladder Wash (Treatment Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and daily during instillations for 2 days after the final instillation. Subjects will remain in this phase 6 months.
9935774|NCT03223623|Placebo Comparator|Healthy Volunteer|adult healthy volunteers
9935775|NCT03223610|Experimental|Arm 1: Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
9907408|NCT00670917|Active Comparator|L14 acupoint|
9907409|NCT00670917|Sham Comparator|Sham Point|
9907410|NCT00670943||A|Patients with stable CAD with scheduled discontinuation of clopidogrel
9907411|NCT00670943||B|Patients with stable CAD not taking clopidogrel
9907412|NCT00670969||A|People who will have the portable measurement taken first and handheld measurement taken second
9907413|NCT00670969||B|People who will have the handheld measurement taken first and portable measurement taken second
9907414|NCT00671008||A|
9907415|NCT00671008||B|
9907416|NCT00671021||1|Patients suffering from stable CAD, on chronic ASA therapy
9907417|NCT00671047||1|SLE subjects with flares in the last 12 months in specific organ systems.
9907418|NCT00671086|Experimental|Ramelteon 8 mg QD|
9907419|NCT00671086|Experimental|Ramelteon 16 mg QD|
9907420|NCT00671099|Experimental|1|Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
9907421|NCT00671099|Placebo Comparator|2|Placebo
9907422|NCT00671112|Experimental|Everolimus and Bortezomib|Patients will receive a combination of Everolimus by mouth and Bortezomib intravenously for a 21 day cycle.
9907423|NCT00671125|Experimental|Ramelteon 8 mg QD|
9907424|NCT00671125|Experimental|Ramelteon 16 mg QD|
9907425|NCT00671125|Placebo Comparator|Placebo|
9907426|NCT00671138|Active Comparator|I|Arm I will be inoculated with the human hookworm necator americanus at weeks 0 and 12.
9907427|NCT00671138|Placebo Comparator|II|Arm II participants will receive and identical sham-inoculums comprising a diluted amount of 0.2ml McIlhenny & Co Tabasco Pepper Sauce®
9907428|NCT00671151|Active Comparator|1|Low-dose theophylline on top of standard therapy for COPD exacerbation
9907429|NCT00671151|No Intervention|2|Standard therapy for COPD exacerbation
9907430|NCT00671190|Experimental|Ramelteon 1 mg QD|
9907431|NCT00671190|Experimental|Ramelteon 2 mg QD|
9907432|NCT00671190|Experimental|Ramelteon 4 mg QD|
9907433|NCT00671190|Experimental|Ramelteon 8 mg QD|
9907434|NCT00671190|Placebo Comparator|Placebo QD|
9907435|NCT00671216|Experimental|Period 1|Subjects will receive first placebo, then GSK233705, GW642444 and combination of GSK233705 and GW642444
9907436|NCT00671216|Experimental|Period 2|Subjects will receive first combination of GSK233705 and GW642444, then placebo, GSK233705 and GW642444
9907437|NCT00671216|Experimental|Period 3|Subjects will receive first GSK233705, then GW642444, combination of GSK233705 and GW642444 and later placebo
9907438|NCT00671216|Experimental|Period 4|Subjects will receive first GW642444, then combination of GSK233705 and GW642444, placebo, and later GSK233705
9907439|NCT00671229||1|African American
9907440|NCT00671229||2|Caucasian
9907441|NCT00671242||I|L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
9907442|NCT00671242||Nuclear|
9907443|NCT00671255|Experimental|Ramelteon 4 mg QD|
9907444|NCT00671255|Experimental|Ramelteon 8 mg QD|
9907445|NCT00671255|Placebo Comparator|Placebo|
9907446|NCT00671268|Experimental|1|strict subcutaneous
9907447|NCT00671268|Placebo Comparator|2|strict subcutaneous
9907448|NCT00671281|Experimental|B|This group will be the experimental group which will receive tranexamic acid in oral form three days before and six days after surgery.
9907449|NCT00671281|Placebo Comparator|A|This will be the control group which will take the placebo medication for 3 days before and six days after their functional endoscopic sinus surgery (FESS).
9907450|NCT00671294|Experimental|Ramelteon and Placebo QD (9 possible combinations total)|
9907451|NCT00671307|Placebo Comparator|Placebo|Placebo
9907452|NCT00671307|Experimental|Low dose|3 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
9907453|NCT00671307|Experimental|Mid-dose|6 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
9907454|NCT00671307|Experimental|High dose|6 mg/kg of rhu-pGelsolin given a an IV infusion over 1 hour once a day for 3 days
9907455|NCT00671320|Active Comparator|Arm 1|
9907456|NCT00671320|Active Comparator|Arm 2|
9907457|NCT00671333|Active Comparator|1|(LRTI) Ligament reconstruction and tendon interposition
9907458|NCT00671333|Active Comparator|2|Ascension PyroDisk
9907459|NCT00671346||1|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg and vitamin B12 0.4 mg
9907460|NCT00671346||2|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg, vitamin B12 0.4 mg and B6 40 mg.
9907461|NCT00671346||3|Participants in NORVIT and WENBIT allocated to daily oral treatment with vitamin B6 40 mg.
9907462|NCT00671346||4|Participants in NORVIT and WENBIT allocated to daily oral treatment with placebo
9907463|NCT00671359|Experimental|after fast|Administration of a single oral dose of 600mg TR-701 to subjects in the fasted state.
9907464|NCT00671359|Experimental|After high fat food|Administration of a single oral dose of 600mg TR-701 to subjects in the fed state.
9907465|NCT00671372|Experimental|Cohorts 1-5|
9907466|NCT00671372|Experimental|Cohorts 6, 6A, 7, 7A|
9907467|NCT00671385||Women 21-50 years old|Women without a diagnosis of cancer or a history of cancer.
9907468|NCT00671398|Experimental|Ramelteon 8 mg QD|
9907469|NCT00671398|Experimental|Ramelteon 16 mg QD|
9907470|NCT00671398|Placebo Comparator|Placebo|
9935776|NCT03223610|Experimental|Arm 2: Dose Escalation|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
9935777|NCT03223610|Experimental|Arm 3: Dose Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
9907471|NCT00671411|Experimental|1|Patients entering into this protocol will also have a preoperative renal contrast enhanced US for this research study. Renal mass US contrast enhancement results will be compared with surgical pathological findings to determine if contrast enhancement patterns of the renal masses correlate with benign and malignant histopathology, and/or malignant histologic subtype.
9907472|NCT00671450||Group 1|Participants will be patients diagnosed with PTSD but with no history of TBI. Participants must be between the ages of 19 and 39. Participants must be compentent to sign a consent form and be willing ot participate in a vision screening.
9907473|NCT00671463|Experimental|1|Pre-operative pancreatic duct stenting
9907474|NCT00671463|No Intervention|2|Control group, no endoscopy and no stent pre-operatively
9907475|NCT00671541|Active Comparator|Merogel stent vs. Nasopore Stent|This study has two arms consiting of 50 subjects each (100 total) Arm 1 will recieve the standard stent (merogel)in their right sinus and a nasopore stent in their left sinus.
9907476|NCT00671541|Experimental|bacitracin vs. gentamicin treated stent|The second arm will consist of 50 new subjects. These 50 subjects will have a nasopore stent placed in the left sinus. The first 25 subjects will have nasopore stent placed postoperatively with a bacitracin soaked nasopore in right sinus the second 25 will have a gentamycin soaked nasopore stent in right sinus.
9907477|NCT00671567|Experimental|Ramelteon 8 mg QD|
9907478|NCT00671567|Experimental|Ramelteon 16 mg QD|
9907479|NCT00671567|Placebo Comparator|Placebo|
9907480|NCT00671580|Experimental|A|PZ-601
9907481|NCT00671580|Experimental|B|PZ-601
9907482|NCT00671580|Active Comparator|C|Standard of Care
9907483|NCT00671593|Experimental|Experimental inhaled dust mite|All subjects receive the same experimental inhaled challenge interventions
9907484|NCT00671632|Experimental|Ramelteon, triazolam, and placebo (56 poss. combinations)|Ramelteon, triazolam, and placebo (56 possible combinations total)
9907485|NCT00671645|Experimental|1|
9907486|NCT00671697|Experimental|Dose Level 1 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
9907487|NCT00671697|Experimental|Dose Level 2 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
9907488|NCT00671697|Experimental|Dose Level 3 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
9907489|NCT00671736|Experimental|1|daily inhalation
9907490|NCT00671736|Experimental|2|inhalation every other day
9907491|NCT00671736|Experimental|3|inhalation twice a week
9907492|NCT00671736|Placebo Comparator|4|daily inhalation
9907493|NCT00671775||Bariatric surgery patients|
9907494|NCT00671775||Weight loss programs|
9907495|NCT00671801|Experimental|Irinotecan + Lenalidomide|Irinotecan 200 mg/m^2 intravenous once every 2 weeks on days 1 and 15; Lenalidomide orally 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
9907496|NCT00671814|Experimental|1|Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
9907497|NCT00671814|Placebo Comparator|2|Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
9907498|NCT00671814|Active Comparator|3|Oral doses of 600mg linezolid given twice daily for 21 days.
9907499|NCT00671827||Robotic Gynecologic Surgery|Patients who have undergone or will undergo a robotic-assisted gynecologic procedure.
9907500|NCT00671866||1|Agricultural Workers
9907501|NCT00671866||2|Non - Agricultural Workers
9907502|NCT00671866||3|Kibbitz Residents working else where
9907503|NCT00671892|Experimental|Challenge|"Experimental Challenge Challenge 1 saline 5000EU 10,000EU 20,000EU~Challenge 2 Saline 40,000EU 80,000EU"
9907504|NCT00671905|Active Comparator|1|Circumferential PV isolation
9907505|NCT00671905|Active Comparator|2|HF stimulation-guided and anatomic ablation of the main right and left atrial GP.
9907506|NCT00671905|Active Comparator|3|HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation
9907507|NCT00671944|Experimental|1|Low protein diet
9907508|NCT00671957||Patients undergoing gastric bypass|"Patients undergoing gastric bypass surgery and who are participants in Longitudinal Assessment of Bariatric Surgery (LABS-2).~Inclusion Criteria:~No acute illnesses~Weight less than 227 kg (limit of Bod Pod and Treadmill)~Able to walk at 2.4 mph for 15 minutes (needed for the energy expenditure testing)~No tobacco use~Ability to stop alcohol consumption during test phases~For female subjects; no plans for pregnancy in 24 months and menstrual cycles of 21-35 days~No history of eating disorder~No history of current substance abuse~No history of chest pain or shortness of breath at rest or on exertion.~Negative pregnancy in women."
9907509|NCT00671996|Active Comparator|A|Mangafodipir treatment
9907510|NCT00671996|Placebo Comparator|B|
9907511|NCT00672035|Experimental|1|7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
9907512|NCT00672035|Experimental|2|7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
9907513|NCT00672035|Experimental|3|22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
9907514|NCT00672035|Experimental|4|22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
9907515|NCT00672035|Experimental|5|37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
9907516|NCT00672035|Experimental|6|37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
9907517|NCT00672035|Experimental|7|50µg LT Dose placed at the Deltoid on Day 0 and Day 21
9907518|NCT00672035|Experimental|8|50µg LT Dose placed at the Lower Back on Day 0 and Day 21
9907519|NCT00672035|Placebo Comparator|9|Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21
9907520|NCT00672035|Placebo Comparator|10|Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21
9907521|NCT00672048|Other|1|
9907522|NCT00672048|Other|2|Control group to receive annual continuing education
9907523|NCT00672061|Experimental|Ramelteon 16 mg QD or Placebo QD|
9907524|NCT00672087||A|Chronic prostatitis/chronic pelvic pain syndrome patients
9907525|NCT00672087||B|Painful bladder syndrome/interstitial cystitis patients
9907526|NCT00672087||C|Asymptomatic controls
9907527|NCT00672113|Experimental|Arm 1|
9907528|NCT00672113|Active Comparator|Arm 2|
9907529|NCT00672152|Experimental|A-WT1 derived peptides|"Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:~WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL~WT peptide #2: HLA-A24 restricted: CMTWNQMNL~WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
9907530|NCT00672165|Experimental|1|This is a phase I, dose-escalation trial. The starting dose level will be 0.5 μCi/kg of 225Ac-HuM195. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose limiting toxicity. Six patients will be treated at the maximum tolerated dose
9907531|NCT00672217|Placebo Comparator|Behavioral Placebo Therapy|Behavioral Placebo Treatment
9907532|NCT00672217|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (CBTI)
9907533|NCT00672230|Experimental|Lut Supp|
9907534|NCT00672269||1|Families with carcinoid in multiple family members
9907535|NCT00672282|Placebo Comparator|A|
9907536|NCT00672282|Active Comparator|B|
9907537|NCT00672295|Experimental|Dasatinib, paclitaxel,and carboplatin|Combination of dasatinib, paclitaxel,and carboplatin
9907538|NCT00672308|Experimental|1|Benefiber (25 g/L)
9907539|NCT00672308|Experimental|2|Benefiber (50 g/L)
9907540|NCT00672308|Experimental|3|the reduced-osmolarity WHO-ORS without Benefiber.
9907541|NCT00672334|Placebo Comparator|2|sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day
9907542|NCT00672334|Experimental|1|The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction
9907543|NCT00672347|Active Comparator|B|compare caudal anesthesia with bupivacaine alone or in addition to morphine, clonidine or both
9907544|NCT00672347|Active Comparator|C|compare caudal anesthesia with bupivacaine plus clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or morphine plus clonidine
9907545|NCT00672347|Active Comparator|M|compare caudal anesthesia with bupivacaine plus morphine with caudal anesthesia with bupivacaine alone or in addition to clonidine or morphine plus clonidine
9907546|NCT00672347|Active Comparator|CM|compares caudal anesthesia with bupivacaine, morphine and clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or clonidine
9907547|NCT00672360|Experimental|1|
9907548|NCT00672360|Placebo Comparator|2|
9907549|NCT00672373|Experimental|A|Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
9907550|NCT00672373|Placebo Comparator|B|Matching placebo treatment
9907551|NCT00672399|Experimental|Sequence 1|Period 1 = placebo exenatide/placebo moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
9907552|NCT00672399|Experimental|Sequence 2|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
9907553|NCT00672399|Experimental|Sequence 3|Period 1 = placebo exenatide/moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/placebo moxifloxacin
9907554|NCT00672399|Experimental|Sequence 4|Period I = placebo exenatide/moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
9907555|NCT00672399|Experimental|Sequence 5|Period I = placebo exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/moxifloxacin
9907556|NCT00672399|Experimental|Sequence 6|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
9907557|NCT00672464|Active Comparator|Olanzapine only|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine
9907558|NCT00672464|Experimental|Added Metformin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin
9907559|NCT00672464|Experimental|Added Simvastatin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Simvastatin
9907560|NCT00672464|Experimental|Added Metf. + Simv.|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin and Simvastatin
9907561|NCT00672464|No Intervention|Matched Controls|Matched Control Subjects by age, race, and gender
9907562|NCT00672503||1|Patients who acquired a CA-UTI in the PICU between 2004-2007.
9907563|NCT00672503||2|Patients who did not acquire a CA-UTI while hospitalized in the PICU but had an indwelling urinary catheter between 2004-2007.
9907564|NCT00672503||A|Nurses currently employed in the PICU at Children's Mercy Hospital.
9907565|NCT00672503||a|Root Cause Analysis on all patients who acquired a CA-UTI during 2009.
9907566|NCT00672529|Active Comparator|Intervention Group|
9907567|NCT00672529|Placebo Comparator|Placebo Group|
9907568|NCT00672542|Experimental|A|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from untreated monocytes
9907569|NCT00672542|Experimental|B|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with control siRNA
9907570|NCT00672542|Experimental|C|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with siRNA targeting the three inducible immunoproteasome subunits
9907571|NCT00672568|Experimental|1|4975
9907572|NCT00672568|Experimental|2|4975
9907573|NCT00672568|Experimental|3|4975
9907574|NCT00672568|Placebo Comparator|4|Placebo
9907575|NCT00672581|Experimental|1|Control (healthy volunteers)
9907576|NCT00672581|Experimental|2|Mild Hepatic Impairment
9907577|NCT00672581|Experimental|3|Moderate Hepatic Impairment
9907578|NCT00672581|Experimental|4|Severe Hepatic Impairment
9907579|NCT00672607|Experimental|1|
9907580|NCT00672607|Placebo Comparator|2|
9907581|NCT00672659|Active Comparator|1|Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
9907582|NCT00672659|Placebo Comparator|2|Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
9907583|NCT00672672|Experimental|II|Patients who do not receive platlet gel.
9907584|NCT00672685|Experimental|1|Omega-3 group without any intervention
9907585|NCT00672685|Experimental|2|Omega-3 combined group (Omega-3 + multi-domain intervention)
9907586|NCT00672685|Experimental|3|Placebo combined group (Placebo + multi-domain intervention)
9907587|NCT00672685|Placebo Comparator|4|Placebo group without any intervention
9907588|NCT00672698||I|VASCULAR SURGERY
9907589|NCT00672698||II|DIGESTIVE SURGERY
9907590|NCT00672698||III|BILIARY TRACT SURGERY
9907591|NCT00672711||C|APS
9907592|NCT00672711||B|HPS
9907593|NCT00672711||A|LPS
9907594|NCT00672724|Experimental|Ramelteon 8 mg QD|
9907595|NCT00672724|Placebo Comparator|Placebo|
9907596|NCT00672750||I|Patients of Dr C Miller who have undergone laparoscopic myomectomy from 1999- to present
9907597|NCT00672763|Active Comparator|A|Standard corticosteroid treatment PLUS Vitamin D3 (Colecalciferol).
9907598|NCT00672763|Placebo Comparator|B|Standard corticosteroid treatment PLUS placebo (Migliol Oil)
9907599|NCT00672776|Experimental|1|paroxetine
9907600|NCT00672776|Placebo Comparator|2|placebo
9907601|NCT00672789|Experimental|1|Blood Smear Education
9907602|NCT00672789|Active Comparator|2|Standard education
9907603|NCT00672802|Experimental|Ramelteon 16 mg QD and Placebo QD|
9907604|NCT00672828|Active Comparator|Non-tailored CRC screening brochure|Participants undergo a baseline interview via telephone and receive a non-tailored CRC screening brochure in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
9907605|NCT00672828|Experimental|Interactive computer intervention|Participants undergo a baseline interview via telephone and complete an interactive computer intervention in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
9907606|NCT00672867|Experimental|1|Clevudine
9907607|NCT00672867|Active Comparator|2|Adefovir
9933774|NCT05230511|Experimental|Intravesical Lactobacillus RhamnosusGG and Bladder Wash (Prophylaxis Phase)|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation in response to trigger symptoms, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. They will then instill the LGG® mixture every 2 days for the remainder of the 6 months. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
9933775|NCT05230511|Other|Intravesical Bladder Wash (Prophylaxis Phase)|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. They will then instill the saline BW every 2 days for the remainder of the 6 months. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time) and biweekly post-instillation. Subjects will remain in this phase 6 months.
9933776|NCT05229666|Other|Cognitive Challenge|
9933777|NCT05229601|Experimental|HFB301001|Participants will receive HFB301001 via intravenous infusions
9933778|NCT05228314|Experimental|Standard dose SCB-2020S with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-2020S with CpG/alum adjuvant
9933779|NCT05228314|Experimental|Low dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with low dose squalene based adjuvant
9933780|NCT05228314|Experimental|Low dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 low dose of SCB-2020S with standard dose squalene based adjuvant
9933781|NCT05228314|Experimental|Standard dose SCB-2020S with low dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with low dose squalene based adjuvant
9933782|NCT05228314|Experimental|Standard dose SCB-2020S with standard dose squalene based adjuvant|Day 1 and 22 standard dose of SCB-2020S with standard dose squalene based adjuvant
9933783|NCT05228314|Active Comparator|Standard dose SCB-2019 with CpG/alum adjuvant|Day 1 and 22 standard dose of SCB-20219 with standard CpG/alum adjuvant
9933784|NCT05226598|Experimental|Pembrolizumab/Vibostolimab + Carboplatin + Cisplatin + Paclitaxel + Nab-paclitaxel + Pemetrexed|Participants receive pembrolizumab/vibostolimab (co-formulation of 200mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous.
9933785|NCT05226598|Active Comparator|Pembrolizumab + Carboplatin + Cisplatin + Paclitaxel + Nab-paclitaxel + Pemetrexed|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous.
9933786|NCT05223699|Experimental|Single dose MGTA-117|Dosing of MGTA-117 prepared and administered by IV infusion.
9933787|NCT05216367|Experimental|Cohort 1 (healthy subjects)|8 healthy subjects with normal hepatic function will receive a single dose of 5 mg (1x5 mg) fruquintinib
9933788|NCT05216367|Experimental|Cohort 2 (moderate hepatic impairment)|8 subjects with moderate hepatic impairment will receive a single dose of 2 mg (2 x 1 mg) fruquintinib
9907608|NCT00672880|Experimental|1|Psychotherapy
9907609|NCT00672880|Active Comparator|2|Spine Education
9907610|NCT00672880|Placebo Comparator|3|Standard Care
9907611|NCT00672893||Observation|Patients who present to the clinic with airway obstruction and who are designated to undergo intervention
9907612|NCT00672906|Experimental|1|Group Parent Training/Adolescent Skills Training
9907613|NCT00672906|Active Comparator|Active Comparator|Family Therapy according to the Maudsley Model
9907614|NCT00672919|Experimental|Pioglitazone QD|(and stable statin therapy)
9907615|NCT00672945|Experimental|PRX-03140|
9907616|NCT00672945|Placebo Comparator|Placebo|
9907617|NCT00672971|Experimental|1|4% dimethicone foam
9907618|NCT00672971|Active Comparator|2|1% permethrin
9907619|NCT00673023|Experimental|1|
9907620|NCT00673023|Experimental|2|
9907621|NCT00673023|Experimental|3|
9907622|NCT00673036||1|Adults (female and male) with a acute coronary syndrome
9907623|NCT00673140|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
9907624|NCT00673205|Placebo Comparator|A|
9907625|NCT00673205|Active Comparator|B|
9907626|NCT00673218|Placebo Comparator|1|Saline injection to match active
9907627|NCT00673218|Experimental|Treatment|Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
9907628|NCT00673270|Experimental|1|Fludrocortisone and Hydrocortisone
9907629|NCT00673270|Experimental|2|Fludrocortisone and placebo of Hydrocortisone
9907630|NCT00673270|Experimental|3|Placebo of Fludrocortisone and Hydrocortisone
9907631|NCT00673270|Placebo Comparator|4|Placebo of Fludrocortisone and placebo of Hydrocortisone
9907632|NCT00673283|Experimental|A|
9907633|NCT00673296|Other|A|Patients receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
9907634|NCT00673322|Experimental|Gene Modified T Cells|Modified T cells
9907635|NCT00673335|Experimental|Treatment arm|Letrozole, 1 tablet
9907636|NCT00673335|Placebo Comparator|Placebo|Comparator, 1 tablet
9907637|NCT00673348||1|Patients suspected of invasive fungal infection (proven or probable cases) with immunocompromised state (for example, during neutropenia, receiving HSCT) in Catholic Hematopoietic Stem Cell Transplantation [HSCT] Center in Seoul, Korea.
9907638|NCT00673374||1|All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
9907639|NCT00673426|Experimental|A|
9907640|NCT00673491|Experimental|1|Patients treated according to clinical pathways
9907641|NCT00673491|No Intervention|2|Patients treated according to usual care
9907642|NCT00673504|Experimental|A|Gemcitabine + Sunitinib
9907643|NCT00673504|Other|B|Gemcitabine
9907644|NCT00673517||1|Patients randomized to high frequency oscillation
9907645|NCT00673517||2|Patients randomized to conventional lung protective ventilation
9907646|NCT00673530|Experimental|1|evidence based clinical nutrition concept
9907647|NCT00673530|Other|2|care as usual
9907648|NCT00673543||1|Pregnant women with insulin requiring diabetes
9907649|NCT00673543||2|Pregnant women without insulin requiring diabetes
9907650|NCT00673556|Experimental|Course A1|
9907651|NCT00673556|Placebo Comparator|Course A2|
9907652|NCT00673556|Experimental|Course B|Open label extension
9907653|NCT00673582|Experimental|1|10 mg/day rosuvastatin for 96 weeks
9907654|NCT00673582|Placebo Comparator|2|Placebo
9907655|NCT00673608|Experimental|Deferasirox|
9907656|NCT00673621|Experimental|1|
9907657|NCT00673634|Active Comparator|1|Standard preoxygenation
9907658|NCT00673634|Active Comparator|2|BiPAP assisted preoxygenation
9907659|NCT00673647|Experimental|1|Individual psychotherapy including cognitive behavioral components, motivational interviewing techniques and case management
9907660|NCT00673647|No Intervention|2|Delayed treatment control group
9907661|NCT00673686|Active Comparator|Arm 2|
9907662|NCT00673686|Experimental|Arm 1|
9907663|NCT00673699||A|Seventy dyspeptic consecutive patients that going upper gastrointestinal endoscopy
9907664|NCT00673725|Experimental|1|
9907665|NCT00673751|Placebo Comparator|2|subcutaneous isotonic saline
9907666|NCT00673751|Active Comparator|1|subcutaneous GLP-2
9907667|NCT00673777|Experimental|A|
9907668|NCT00673803|Other|A|cataract surgery, implantation of a Polylens Y10
9907669|NCT00673803|Other|B|cataract surgery, implantation of a Polylens Y30
9907670|NCT00673829|Experimental|Phase Ia|
9907671|NCT00673829|Experimental|Phase Ib: Control|
9907672|NCT00673842|Experimental|Implantable Cardioverter Defibrillator + Usual Care|Medtronic ICD
9907673|NCT00673842|Active Comparator|Usual Care|Usual post-MI care
9907674|NCT00673868|Experimental|1|
9907675|NCT00673868|No Intervention|2|
9907676|NCT00673907|Sham Comparator|1|Clean air
9907677|NCT00673907|Experimental|2|Wood smoke particle concentration of 200 ug/m3
9907678|NCT00673907|Experimental|3|Wood smoke particle concentration of 400 ug/m3
9907679|NCT00673946|Active Comparator|1|In this arm, patients are monitored with oximeters displaying true saturation values
9907680|NCT00673946|Experimental|2|In this arm, patients are monitored with oximeters with displayed saturations 3 percentage points above true values
9907681|NCT00673972|Active Comparator|EPS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
9907682|NCT00673972|Active Comparator|PDS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
9907683|NCT00673985|Active Comparator|1|"PTA Only: Active Comparator~Percutaneous transluminal angioplasty (PTA) alone"
9907684|NCT00673985|Experimental|2|"Test Arm: Experimental~The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral artery (SFA) disease."
9907685|NCT00674037|Experimental|inclusion with financial motivation|75 euros for each patient included
9907686|NCT00674037|No Intervention|no incentive|no incentive
9907687|NCT00674050|Experimental|1|
9907688|NCT00674063|Experimental|1|Dose regimen 1
9907689|NCT00674063|Experimental|2|Dose regimen 2
9907690|NCT00674076||sleep apnea|a patient has been diagnosed as having obstructive sleep apnea
9907691|NCT00674076||control|a case who has a negative polysomography or noraml score of Pittsburg sleep questionaire
9907692|NCT00674089|Active Comparator|1|Routine Post-partum Care and Vitamin A supplementation (50,000 IU) to the Newborn
9907693|NCT00674089|Placebo Comparator|2|Routine Post-partum Care with Placebo to the Newborn
9907694|NCT00674102|Experimental|ASA404|
9907695|NCT00674141|Other|1|only one experimental treated group
9907696|NCT00674167|Experimental|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel and cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
9907697|NCT00674167|Experimental|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
9907698|NCT00674167|Experimental|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycles.
9907699|NCT00674180||1|a workbook alone
9907700|NCT00674180||2|a workbook alone and the addition of computerized tailoring using onsite computer kiosks with touch screen monitors
9907701|NCT00674180||3|a workbook, the addition of computerized tailoring using onsite computer kiosks with touch screen monitors, and staff consultations.
9907702|NCT00674193||Observational (pharmacological study)|Patients undergo blood and urine collection prior to, periodically during, and after treatment with dactinomycin and vincristine for pharmacokinetic, pharmacodynamic, and pharmacogenetic analysis. Samples are analyzed using a liquid chromatography-tandem mass spectrometry assay. Genomic DNA extracted from peripheral blood mononuclear cells is isolated and analyzed by polymerase chain reaction and genotyping assays for genetic variation in genes relevant to the pharmacology of dactinomycin and vincristine.
9907703|NCT00674232|Experimental|Misoprostol|Group 1 randomized to take single dose of 600 mcg oral misoprostol
9907704|NCT00674232|Other|Surgical treatment|Group 2 randomized to receive standard surgical treatment as per local protocol (D&C or MVA)
9907705|NCT00674245|Active Comparator|Pantoprazole|40 mg once daily for four weeks improves sleep quality in patients with GERD
9907706|NCT00674245|Placebo Comparator|placebo|To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.
9907707|NCT00674258|Experimental|B|
9907708|NCT00674271||Diabetics|100 patients with newly diagnosed (<5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.
9907709|NCT00674271||Controls|100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender
9907710|NCT00674336|Experimental|Shellfish with Norovirus|We dosed shellfish with Norovirus and challenged human volunteers with Shellfish that had norovirus
9907711|NCT00674375|Experimental|1|Primary care clinicians (physicians, nurse practitioners, and physician assistants) randomized to the intervention arm will receive electronic alerts within the electronic medical record system during office visits with patients complaining of chest pain.
9907712|NCT00674375|No Intervention|2|Primary care clinicians randomized to the 'no intervention' arm will evaluate and treat patients complaining of chest pain without the aid of electronic risk alerts.
9907713|NCT00674401|Active Comparator|1|"In patients with paroxysmal atrial fibrillation: Empirical pulmonary vein antrum circumferential isolation.~In patients with persistent atrial fibrillation: Empirical circumferential PV antrum isolation w/out roof line."
9907714|NCT00674401|Active Comparator|2|"In patients with paroxysmal atrial fibrillation: High frequency sites ablation in the LA.~In patients with persistent atrial fibrillation: A combined approach involving pulmonary vein antrum isolation w/out roof line and high frequency sites ablation"
9907715|NCT00674414|Active Comparator|Arm I|Patients receive trastuzumab (Herceptin®) IV once weekly for 6 weeks. Patients then undergo surgery.
9907716|NCT00674414|Experimental|Arm II|Patients receive trastuzumab as in arm I and oral everolimus once daily for 6 weeks. Within 24 hours after completing everolimus, patients undergo surgery.
9907717|NCT00674427|Experimental|CR|Subjects who are in CR ater 6-12 weeks after aDLI
9907718|NCT00674427|Experimental|Not in CR|Subjects not in CR after 6-12 weeks after aDLI
9907719|NCT00674453|Experimental|Lasofoxifene 0.25 mg/d|
9907720|NCT00674453|Placebo Comparator|Placebo|
9907721|NCT00674505|Other|Treatment, Open label, Single Group Assignment|
9907722|NCT00674518|Experimental|Counseling|One-on-one sessions conducted by a professional motivational counselor to explore ways to help motivate participants to exercise, eat healthier, and lose weight.
9907723|NCT00674518|Experimental|Group|A nutrition and exercise specialist will lead and teach a group of 4 to 5 subjects in healthy nutrition, exercise and weight loss habits
9907724|NCT00674518|Active Comparator|MD Advice|A physician will provide exercise and nutrition advice to participants immediately following testing
9907725|NCT00674531|Other|1|Enterovirus RNA analysis
9907726|NCT00674544|No Intervention|Control group|No intervention, regular kindergarten program
9907727|NCT00674544|Experimental|Intervention group|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
9907728|NCT00674648|Experimental|1|This is a non-randomized single institution phase I dose escalation trial, designed to evaluate the toxicity and anti-viral activity of CMV-pp65 peptide-specific T cell lines, generated in vitro from CMV seropositive normal HSCT and 3rd party donors, when adoptively transferred to treat recipients of these transplants who have a CMV infection or persistent CMV antigenemia and are therefore at high risk of a life-threatening CMV infection.
9907729|NCT00674687|Placebo Comparator|Sequence 1|
9907730|NCT00674687|Experimental|Sequence 2|
9907731|NCT00674713|Experimental|A|Patients receiving acupuncture at P6 point plus physiological saline solution
9907732|NCT00674713|Active Comparator|B|Patients receiving ondansetron plus sham acupuncture
9907733|NCT00674713|Other|C|Patients receiving ondansetron plus acupuncture at P6 point
9907734|NCT00674713|Placebo Comparator|D|Patients receiving physiological saline solution plus sham acupuncture
9907735|NCT00674726||Group I|Patients with acute appendicitis
9907736|NCT00674726||Group II|Patients with acute gastroenteritis
9907737|NCT00674752|Experimental|A|
9907738|NCT00674752|Experimental|B|
9907739|NCT00674752|Placebo Comparator|C|
9907740|NCT00674778|Experimental|1|Radial approach
9907741|NCT00674778|Active Comparator|2|Femoral approach
9907742|NCT00674830|Experimental|1|professionally administered cognitive-behavioral therapy
9907743|NCT00674830|Experimental|2|self-administered form of cognitive behavioral therapy
9907744|NCT00674830|Placebo Comparator|3|usual care
9907745|NCT00674843|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
9907746|NCT00674856|Experimental|naproxcinod|naproxcinod 750mg(375mg caps x2), administered twice a day.
9907747|NCT00674869|Experimental|1|pit and fissure sealant on one randomized tooth by pair of permanent molar
9907748|NCT00674869|No Intervention|2|No intervention
9907749|NCT00674882||Participants|Data Collection
9907750|NCT00674895|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
9907751|NCT00674908|Experimental|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
9907752|NCT00674908|Active Comparator|Easy 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
9907753|NCT00674921|Placebo Comparator|1|It will comprise patients randomized to receive the placebo (stop cotrimoxazole prophylaxis) at CD4 counts of 200 or more but less than 350 cells/ul as they continue with HAART. Patients will be followed until they achieve a CD4 count of 350 cells/ul.
9907754|NCT00674921|Active Comparator|2|It will comprise patients randomized to continue with cotrimoxazole prophylaxis and HAART at CD4 counts of 200 or more but less than 350 cells/ul. These patients will be followed until they achieve a CD4 count of 350 cells/ul and above, at which point they will be considered for the second randomization.
9907755|NCT00674921|Placebo Comparator|A|This arm will comprise patients who have achieved a CD4 count of 350 or more cells/ul either at the beginning of the study or once they have reached this threshold at the end of follow up in arms 1 and 2. They (including those previously in Arm 1) will receive the placebo (stop cotrimoxazole prophylaxis) after the second randomization but continue with HAART.
9907756|NCT00674921|Active Comparator|B|It will comprise patients randomized to continue or start with cotrimoxazole prophylaxis and HAART at CD4 of 350 or more cells/ul after second randomization. Some of them will have used cotrimoxazole prophylaxis whilst they were in arm 2 and others in arm 1 will restart cotrimoxazole prophylaxis at this stage.
9907757|NCT00674934|Experimental|1|Radiation
9933789|NCT05216367|Experimental|Cohort 3 (mild hepatic impairment)|8 subjects with mild hepatic impairment will receive a single dose of 5 mg (1 x 5 mg) fruquintinib
9933790|NCT05216354|Experimental|Cohort 1 (healthy subjects)|8 subject with normal renal function will be administered 5mg (1 x 5 mg capsule) fruquintinib
9933791|NCT05216354|Experimental|Cohort 2 (severe renal impairment)|8 subjects with severe renal impairment will be administered 2 mg (2 x 1 mg capsules) fruquintinib
9933792|NCT05216354|Experimental|Cohort 3 (moderate renal impairment)|8 subjects with moderate renal impairment will be administered 5 mg (a x 5 mg capsule) fruquintinib
9933793|NCT05215847|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
9933794|NCT05215639||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
9933795|NCT05214963|Active Comparator|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation
9933796|NCT05214963|Sham Comparator|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation
9933797|NCT05214742||Silver-Russell Syndrome|
9933798|NCT05214742||Beckwith-Wiedemann Syndrome|
9933799|NCT05214742||Temple Syndrome|
9933800|NCT05213728|Experimental|Cohort 1|Single 1E11 dose administered via multiple sub-doses over a 4-hour period in adults (18-55 yrs).
9933801|NCT05213598||Adults with FALD|male and female subjects >=18 years of age who historically underwent Fontan procedure due to a severe CHD and thus are at risk for FALD by virtue of their altered physiology
9933802|NCT05213572||subjects w sickle cell disease|to evaluate heart, lung, liver, kidney, brain, and neurocognitive function post-hematopoietic stem cell transplant (HSCT) in subjects with sickle cell disease (SCD) who undergo curative therapies
9933803|NCT05212168|Active Comparator|Active Vaccine Arm|Subjects receiving Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
9933804|NCT05212168|Placebo Comparator|Placebo Arm|Subject receiving Placebo oral tablets similar in appearance and number to active vaccine tablets
9933805|NCT05212012|Experimental|D,L-methadonehydrochloride + mFOLFOX6|"Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)~Treatment with mFOLFOX6 every two weeks; will be administered:~Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1) LV at a dose of 400 mg/m² iv over two hours (day 1) 5-FU at a dose of 2400 mg/m² iv over 46 hours (day 1-3)"
9933806|NCT05211895|Experimental|Arm A: Durvalumab + Domvanalimab|Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months
9933807|NCT05211895|Active Comparator|Arm B: Durvalumab + Placebo|Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months
9907758|NCT00674960|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
9907759|NCT00674999|Experimental|1|Amnion with processing procedures involving the use of trypsin-Edetic Acid(EDTA)
9798520|NCT01631552|Experimental|SG 12 mg/kg|Participants will receive SG 12 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
9798521|NCT01631552|Experimental|SG 18 mg/kg|Participants will receive SG 18 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
9798522|NCT01631630|Experimental|Pioglitazone|Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
9798523|NCT01631630|Placebo Comparator|Placebo|Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
9798524|NCT01631656|Experimental|Azelaic Acid plus Laser|Azelaic acid 15% twice daily on half the face for 6 weeks, plus laser treatment with Nd:Yag laser once at 2 weeks.
9798525|NCT01631656|Active Comparator|Laser only|laser treatment on all face once at 2 weeks with no azelaic acid on one side of the face
9798526|NCT01631682|Active Comparator|Propranolol|a single dose of 40mg propranolol may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
9798527|NCT01631682|Active Comparator|Reactivation with time delay|For those not receiving propranolol on visit 2, one experimental CS will be reactivated, followed by a 10 minute break and subsequently extinction
9798528|NCT01631682|Experimental|Mifepristone|a single dose of 1800mg (200mg tablets) mifepristone may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
9798529|NCT01631682|Experimental|Intranasal oxytocin|A single 32IU dose of Syntocinon (intranasal oxytocin) is given to begin visit 2, followed by a 10 minute wait and subsequent CS reactivation.
9798530|NCT01631747|Active Comparator|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
9798531|NCT01631747|Experimental|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
9798532|NCT01631812|Experimental|SPM 962|
9798533|NCT01631825|Experimental|SPM 962|SPM 962 transdermal patch
9798534|NCT01631864|Experimental|LCZ696|LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
9798535|NCT01631864|Active Comparator|amlodipine|amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
9798536|NCT01631929|Active Comparator|One bag|IV infusion of fluids, electrolytes and dextrose using one bag
9798537|NCT01631929|Experimental|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
9798538|NCT01632150|Experimental|Elotuzumab + Thalidomide + Dexamethasone + Cyclophosphamide|
9798539|NCT01632202|Active Comparator|Seprafilm Slurry|The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
9798540|NCT01632202|Placebo Comparator|Placebo|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
9798541|NCT01632215|Experimental|preoperative gabapentine,|Gabapentine
9798542|NCT01632215|Placebo Comparator|sugar pill|Placebo group
9907760|NCT00674999|Experimental|2|Amnion with processing procedures involving the use of Dispase II
9907761|NCT00674999|Active Comparator|3|Prepared Antibiotic ointment Polysporin, Bacitracin and Mycostatin
9907762|NCT00675012|Experimental|A|
9907763|NCT00675038||1|Study participants will be patients who are cared for by the St. Jude Hematology Division and have developed iron overload and require liver biopsy.
9907764|NCT00675064|Experimental|Anti-malarial experimental drug|After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules.
9907765|NCT00675064|Active Comparator|Matching placebo|After randomization subjects will receive matching placebo of GSK3697969.
9907766|NCT00675077|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
9907767|NCT00675090|Experimental|GSK239512|GSK239512 oral tablets
9907768|NCT00675090|Placebo Comparator|Placebo|Placebo to match tablets
9907769|NCT00675129|Experimental|1|Dialectical behavioral therapy
9907770|NCT00675129|Active Comparator|2|Enhanced Usual Care (standard care plus monitoring and patient safety protocol implemented)
9907771|NCT00675142|Experimental|1|IUI 36 hours after ovulation induction
9907772|NCT00675142|Experimental|2|IUI 42 hours after ovulation induction
9907773|NCT00675142|Experimental|3|IUI 48 hours after ovulation induction
9907774|NCT00675155|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
9907775|NCT00675181|Active Comparator|A, 1|A, 1 = Melatonin
9907776|NCT00675181|Placebo Comparator|A, 2|A,2 = Placebo
9907777|NCT00675207|Active Comparator|1|Brimonidine purite 0.15%
9907778|NCT00675207|Active Comparator|2|Dorzolamide 2%
9907779|NCT00675207|Active Comparator|3|Brinzolamide 1%
9907780|NCT00675220||A|
9907781|NCT00675233|Experimental|Treatment PDT|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
9907782|NCT00675246|Experimental|A|Antenatal corticoid therapy
9907783|NCT00675272|Active Comparator|1|hydrocortisone treatment 50mg iv x4
9907784|NCT00675272|Placebo Comparator|2|Placebo iv every 6 hours
9907785|NCT00675285|Active Comparator|1|
9907786|NCT00675285|Placebo Comparator|2|
9907787|NCT00675298||1|Men with chronic prostatitis/chronic pelvic pain syndrome
9907788|NCT00675298||2|Women with painful bladder syndrome/interstitial cystitis
9907789|NCT00675298||3|Children with overactive bladder
9907790|NCT00675298||4|Bulgarian cohort with chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis and children with overactive bladder
9907791|NCT00675298||5|Asymptomatic healthy controls
9907792|NCT00675311|Active Comparator|DM-Standard|The conventional disease management group will receive management under the site's usual program offering, which includes, but is not limited to, compliance with the prescribed treatment regimens, dietary management, exercise programs, and other measures recommended by the American Diabetes Association (ADA) and the Association of American Endocrinologists (AACE).
9907793|NCT00675311|Active Comparator|DM-Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology that includes mobile phone client software with web-based companion software, Bluetooth glucose meter cradle, and web-based clinical management software for the clinical management team. The core of the system is the patient's cell phone which is used as an input device and which enables patients to maintain an electronic diary of information such as meal times, blood glucose, insulin use, weight, blood pressure, and exercise. The device is customizable to collect only the information relevant to the patient with diabetes and their healthcare provider. The patient with diabetes enters diary information on his or her mobile phone. No immediate or real-time information is provided to patients as part of this study.
9907794|NCT00675324|Active Comparator|A|Traditional bowel preparation with Laxabon
9907795|NCT00675324|Active Comparator|B|Bowel preparation with nutritional drinks
9907796|NCT00675337|Active Comparator|perineum|infants maintained at the level of the perineum until umbilical cord clamping
9907797|NCT00675337|Experimental|abdomen|infants placed on the maternal abdomen prior to cord clamping
9907798|NCT00675350|Experimental|Homoharringtonine|
9907799|NCT00675363|Active Comparator|PS|Nurse-directed protocols for administering sedation and/or analgesia by continuous infusion.
9907800|NCT00675363|Active Comparator|PS + DI|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
9907801|NCT00675389|Experimental|A|Peer Health Workers Intervention
9907802|NCT00675389|Experimental|B|Peer Health Workers and Mobile Phone Intervention
9907803|NCT00675389|No Intervention|C|Control
9907804|NCT00675402||1|Patients referred to the vascularsurgeon with complaints of claudication for their first time, will be asked to participate with the study, with respect toward the in- and exclusion criteria.
9907805|NCT00675467||Group 1|Early cancer group-children ages 10-13 years
9907806|NCT00675467||Group 2|Early cancer group-children ages 14 to 18 years
9907807|NCT00675467||Group 3|Early cancer group-parents of patients ages 10-18 years
9907808|NCT00675467||Group 4|Advanced cancer group-children ages 10-13 years
9907809|NCT00675467||Group 5|Advanced cancer group-children ages 14-18 years
9907810|NCT00675467||Group 6|Advanced cancer group-parents of children ages 10-18 years
9907811|NCT00675467||Group 7|End of life group - parents of children ages birth to 18 years of age at time of death
9907812|NCT00675480|Experimental|T|Patients treated with thrombectomy: T
9907813|NCT00675480|Active Comparator|P|Patients treated with standard PCI with stent implantation
9907814|NCT00675493||A|
9907815|NCT00675519|Experimental|BI|
9907816|NCT00675532|Experimental|1|Primary Care Counseling
9907817|NCT00675532|Experimental|2|Cognitive-behavioral psychotherapy (CBT)
9907818|NCT00675545|Experimental|docetaxel and prednisolone|"Patients in study will receive both chemotherapeutic agents on day 1 and day 8 of every 21-day cycle as described below:~Docetaxel 30 mg/m2 over 1 hour IV infusion, followed by~Carboplatin (AUC 2) over 1 hour IV infusion~Additonal medication required: IV Dexamethasone 10 mg followed by PO dexamethasone 4 mg 8 hourly x 4 doses, starting 12 hours after starting iv docetaxel."
9907819|NCT00675610|No Intervention|usual care|providers are not trained and patients are not coached
9907820|NCT00675610|Experimental|intervention arm|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
9907821|NCT00675649|Experimental|001|
9907822|NCT00675649|Placebo Comparator|002|
9907823|NCT00675662|Experimental|1|Stratification by angiotensin converting enzyme (ACE) genotype
9907824|NCT00675662|Placebo Comparator|2|Waiting list controls
9907825|NCT00675675|Active Comparator|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training (HRT) plus functional assessment/intervention designed to identify and ameliorate environmental triggers for and consequences to tics that might serve to maintain and/or generalize these symptoms
9907826|NCT00675675|Other|Minimal Contact Waitlist|Bimonthly phone check-in to assess illness severity and maximize subject retention
9907827|NCT00675688|Experimental|A|
9907828|NCT00675688|Active Comparator|B|
9907829|NCT00675688|Placebo Comparator|C|
9907830|NCT00675701|Placebo Comparator|A|Placebo by mouth
9907831|NCT00675701|Experimental|B|lixivaptan
9907832|NCT00675701|Active Comparator|C|moxifloxacin
9907833|NCT00675714|Experimental|1|Humatrope subcutaneous(SQ) 0.05-0.2 mg/kg/day for up to 2 years post burn
9907834|NCT00675714|Experimental|2|Ketoconazole by mouth (PO) given twice a day throughout hospitalization for up to 2 years post burn
9907835|NCT00675714|Experimental|3|Oxandrolone PO given daily throughout hospitalization for up to 2 years post burn
9907836|NCT00675714|Experimental|4|Propranolol PO given daily throughout hospitalization for up to 2 years post burn
9907837|NCT00675714|Experimental|5|Oxandrolone and propranolol PO to be given daily for up to 2 years post burn
9907838|NCT00675714|Experimental|6|Humatrope SQ and Propranolol PO to be given daily for up to 2 years post burn
9907839|NCT00675714|Placebo Comparator|7|Placebo PO to be given for up to 2 years post burn
9907840|NCT00675714|Experimental|8|Exercise--hospital supervised intensive exercise program
9907841|NCT00675714|Experimental|9|Exercise--home or community based exercise program
9907842|NCT00675740|Experimental|1|
9907843|NCT00675740|Active Comparator|2|physical exercise
9907844|NCT00675740|No Intervention|3|control
9907845|NCT00675753||Preterm group|Preterm (36 6/7 weeks gestation or earlier) mothers and their newborns.
9907846|NCT00675753||Term group|Term (> 37 weeks gestation) mothers and their newborns.
9907847|NCT00675779|Experimental|2|oral contraceptive + atorvastatin
9907848|NCT00675779|Active Comparator|1|oral contraceptive
9907849|NCT00675805|Active Comparator|Group I|IVIG infusion with filter
9907850|NCT00675805|Placebo Comparator|Group II|IVIG infusion without filter
9907851|NCT00675818|Experimental|1|CVVH: Patients in this arm will receive CVVH at a replacement fluid rate of 35 mL/kg/h.
9907852|NCT00675818|Active Comparator|2|CVVHD: Patients in this arm will receive CVVHD at a dialysate flow rate of 35 mL/kg/h.
9907853|NCT00675831|Experimental|CD25+ Treg depleted DLI dose schema|"Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema:~Dose level -C: 3x10^7 (CD3+Dose (#cells/kg*))~Dose level -B: 1x10^7 (CD3+Dose (#cells/kg*))~Dose level -A: 1x10^6 (CD3+Dose (#cells/kg*)) *Recipient's body weight in Kg"
9907854|NCT00675857|Placebo Comparator|A|
9907855|NCT00675857|Active Comparator|B|
9907856|NCT00675870|Experimental|1|
9907857|NCT00675883||Prospective|500 patients who will be enrolled in the MS Alliance program will be consented to participate in this study.
9907858|NCT00675883||Retrospective|500 patient chart reviews will be completed for patients who were enrolled in the MS Alliance program between two (2) to three (3) years ago.
9907859|NCT00675896|Experimental|1|Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator, using patient tolerance and response as guidelines over the duration of the trial.
9907860|NCT00675896|Placebo Comparator|2|Placebo
9907861|NCT00675935|Experimental|1|One high-risk medical unit at each hospital will be randomly assigned to receive the fall prevention toolkit
9907862|NCT00675935|No Intervention|2|One high-risk medical unit at each hospital will be randomly assigned to receive usual care as it relates to fall prevention; i.e., receives no intervention.
9907863|NCT00675961|Experimental|1|Behavioral Counseling Intervention (BCI) plus treatment as usual (TAU) (i.e. standard referral to and management by an addictions specialist)
9907864|NCT00675961|Experimental|2|Naltrexone/ Brief Behavioral Compliance Enhancement Treatment (BBCET) plus TAU
9907865|NCT00675961|Experimental|3|BCI + Naltrexone/BBCET plus TAU
9907866|NCT00675961|Active Comparator|4|Treatment as Usual (TAU)
9907867|NCT00675974|Experimental|1|Pressure garment therapy
9907868|NCT00675974|No Intervention|2|No pressure garment therapy
9907869|NCT00676000|Active Comparator|1|Interrupted vaginal closure
9907870|NCT00676000|Active Comparator|2|Continuous vaginal closure
9907871|NCT00676039|Active Comparator|1|"Crossover Effexor / NOVO-Venlafaxine~Examination of the bioequivalence of Effexor (Wyeth Pharmaceuticals) and NOVO-Venlafaxine (NOVOPHARM).~Both drugs will be given at the dose of 75 mg/day (one capsule per day) for 4 consecutive days. A washout period (corresponding to 10 half-life of the active metabolite desmethylvenlafaxine) will be respected after receiving each medication."
9907872|NCT00676039|Active Comparator|2|"Crossover Celexa/Gen-citalopram~Examination of the bioequivalence of Celexa (Lundbeck, Brand Name) and Gen-Citalopram (Genpharm, Generic). Both drugs will be given at the dose of 40 mg/day (one tablet per day) for 8 consecutive days. A washout period (corresponding to 10 half-life of citalopram) will be respected after receiving each medication."
9907873|NCT00676104|Experimental|Treatment|
9907874|NCT00676104|Sham Comparator|Control|
9907875|NCT00676117|Experimental|1|
9907876|NCT00676117|Active Comparator|2|
9907877|NCT00676156|Active Comparator|A|This arm involves a 1-day pharmacokinetics study of three different formulations of oral lipoic acid.
9907878|NCT00676156|Active Comparator|B|This arm will examine the pharmacokinetics of LA with and without fish oil supplement in a cross over design.
9907879|NCT00676156|Active Comparator|C|This arm will include the study of a single dose of R enantiomer lipoic acid.
9907880|NCT00676169||Observational|Pa negative or concurrently enrolled in the EPIC Clinical Trial
9907881|NCT00676234|No Intervention|1|
9907882|NCT00676234|Experimental|2|Administration of intravenous rhu Epo on Day 0
9907883|NCT00676247||preterm|Very-low-birth-weight preterm infants with brain lesion
9907884|NCT00676247||full-term|Healthy fullterm infants
9907885|NCT00676260|Experimental|Pioglitazone QD|
9907886|NCT00676260|Placebo Comparator|Placebo QD|
9907887|NCT00676273|Active Comparator|1|TVTO
9907888|NCT00676273|Active Comparator|2|TVTS
9907889|NCT00676312|Experimental|1|Cross-over treatment with increasing doses of PTH134, placebo and active comparator.
9907890|NCT00676325|Active Comparator|1|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction were eligible for participation.traditional colporrhaphy in this group.
9907891|NCT00676325|Active Comparator|2|The NAZCA TC™ POP REPAIR SYSTEM (polypropylene mesh repair),promedon™ , cordoba, argentina, is used to repair anterior vaginal prolapse by a transobturator and pre pubic approach . Helical needles are used to anchor graft to the pelvic sidewall at two points transobturator, the other two arms pre pubic needles is used. We designed this randomized control trial to compare the anatomic success rates, effect on quality of life and sexual symptom scores, and rates of adverse events of the procedure with polypropylene mesh with that of anterior colporrhaphy, with planned follow-up of 1 years.
9907892|NCT00676351|Other|A|body plethysmography Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
9907893|NCT00676377|Experimental|1|Neostigmine
9907894|NCT00676377|Placebo Comparator|2|Placebo
9907895|NCT00676390|Other|1|Congestive Heart failure patients
9907896|NCT00676416||1|Propofol general anesthesia for asthmatic patients
9907897|NCT00676416||2|Propofol general anesthesia for non-asthmatic patients
9907898|NCT00676429|Experimental|1|Ziprasidone Hydrochloride oral solution with individual titration from 5 mg to 40 mg per day
9907899|NCT00676429|Placebo Comparator|2|Placebo oral solution
9907900|NCT00676442|Other|1|PN400 administered after meal
9907901|NCT00676442|Other|2|PN400 administered prior to meal
9907902|NCT00676442|Other|3|PN400 administered prior to meal
9907903|NCT00676442|Other|4|PN400 followed by fast
9907904|NCT00676468|Other|1|Active Montelukast + Fish Oil Placebo
9907905|NCT00676468|Other|2|Active Fish Oil + Montelukast Placebo
9907906|NCT00676468|Other|3|Active Montelukast + Active Fish Oil
9907907|NCT00676481|Active Comparator|1|Phase III participants who are educated about risk of HIV infection before receiving a rapid HIV test
9907908|NCT00676481|No Intervention|2|Phase III participants who are not educated about risk of HIV infection before receiving a rapid HIV test
9907909|NCT00676507|Experimental|Treatment|Treatment Arm: This course of therapy is Best Support Care (BSC) plus monthly intradermal (ID) injections of Lucanix™ (belagenpumatucel-L) consisting of 25,000,000 cells in a volume of 0.40 mL.
9907910|NCT00676507|Placebo Comparator|Control Arm|Control Arm: This course of therapy is Best Support Care (BSC) plus a placebo injection that consists of 0.15% Intralipid® in solution composed of the cryopreservation formulation minus the gene modified cells and dimethyl sulfoxide (DMSO) in a volume of 0.40 mL.
9907911|NCT00676533|Experimental|Arm 1|
9907912|NCT00676559|Experimental|Group 1|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
9907913|NCT00676559|Experimental|Group 2|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
9907914|NCT00676559|Experimental|Group 3|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks in combination with ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
9907915|NCT00676624||Uveitis|Patients suffering from uveitis, who have vitrectomy performed for diagnostic purpose
9907916|NCT00676624||Control group|"Patients suffering from either Epiretinal fibrosis og Macula hole who have vitrectomy performed for curative reasons"
9907917|NCT00676637||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
9907918|NCT00676702|Experimental|001|Pancrelipase in combination with Ensure Plus 3 pancrelipase MT 21 capsules containing a total of 63 000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
9907919|NCT00676702|Active Comparator|002|Ensure Plus A high-fat liquid meal of 500 ml of Ensure Plus
9907920|NCT00676728|Experimental|JNJ-26481585|
9907921|NCT00676741||A|
9907922|NCT00676741||B|
9907923|NCT00676741||C|
9907924|NCT00676767|Experimental|1|
9907925|NCT00676767|Active Comparator|2|
9907926|NCT00676767|Placebo Comparator|3|
9907927|NCT00676845|Placebo Comparator|1|A 3-week placebo run-in period.
9907928|NCT00676845|Experimental|2|Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
9907929|NCT00676845|Experimental|3|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
9907930|NCT00676845|Experimental|4|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.
9907931|NCT00676871|Experimental|1|MEDI-538
9907932|NCT00676871|Experimental|2|MEDI-538
9907933|NCT00676871|Experimental|3|MEDI-538
9907934|NCT00676871|Experimental|4|MEDI-538
9907935|NCT00676871|Experimental|5|MEDI-538
9907936|NCT00676871|Experimental|6|MEDI-538
9907937|NCT00676871|Experimental|7|MEDI-538
9907938|NCT00676884|Experimental|1|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
9907939|NCT00676884|Placebo Comparator|2|placebo control
9933808|NCT05211336|Experimental|1: Lenalidomide + nivo window; followed by VIPOR-Nivo|Nivolumab on day 1 with lenalidomide (days 1-14) for a 21-day cycle. Following Window, VIPOR-Nivo (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in 21-day cycles for up to 6 cycles
9933809|NCT05211323|Experimental|Arm A (bevacizumab, atezolizumab, gemcitabine, cisplatin)|Patients receive bevacizumab IV over 30-90 minutes on day 1, atezolizumab IV over 30-60 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV on days 1 and 8. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9933810|NCT05211323|Active Comparator|Arm B (gemcitabine, cisplatin)|Patients receive gemcitabine IV over 30 minutes and cisplatin IV on days 1 and 8. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9933811|NCT05209230|Experimental|Continuous renal replacement therapy arm|Echocardiographic evaluation (with 2D speckle tracking analysis of left ventricular segmental function) 1 hour before and 3 hours after the initiation of continuous renal replacement therapy (continuous veno venous hemofiltration) initiation
9933812|NCT05209230|Other|Control arm|Two echocardiographic evaluations (with 2D speckle tracking analysis of left ventricular segmental function) at an interval of 4 hours, before the continuous renal replacement therapy initiation.
9933813|NCT05206929|Experimental|Arm 1|Arm 1 will receive instruction to use pain and discomfort as the safe limits for their upper limb use during daily activities at post operative discharge.
9933814|NCT05206929|Active Comparator|Arm 2|Arm 2 will receive the standard sternal precautions at time of post operative discharge.
9933815|NCT05203380|No Intervention|Part A|Assessed in a single visit and no study-related treatment will be given.
9933816|NCT05203380|Experimental|Part B|Patients in Part A may also enroll in Part B provided they meet the eligibility criteria.
9933817|NCT05202327|Placebo Comparator|Placebo|Two placebo capsules thrice daily for 56 days (8 weeks).
9933818|NCT05202327|Experimental|Low-dose|One placebo capsule and 1 PDC-1421 Capsule, thrice daily for 56 days (8 weeks).
9933819|NCT05202327|Experimental|High-dose|Two PDC-1421 Capsules thrice daily for 56 days (8 weeks).
9933820|NCT05199584|Experimental|200 mg ENV-101|ENV-101 (taladegib) tablets, 200 mg once-daily in 28-day cycles
9933821|NCT05199584|Experimental|300 mg ENV-101|ENV-101 (taladegib) tablets, 300 mg once-daily in 28-day cycles
9935778|NCT03223610|Experimental|Arm 4: Dose Expansion|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
9935779|NCT03222973|Experimental|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
9907940|NCT00676936|Experimental|Methylprednisolone|Methylprednisolone 16 mg twice daily
9907941|NCT00676936|Placebo Comparator|Placebo|Placebo capsules twice daily
9907942|NCT00676949|Experimental|1|cyclophosphamide dose escalation, level 1:150mg/m2,level 2: 300mg/m2, level 3: 300mg/m2x2, with 5 kinds o tumor specific antigen peptides followed by low dose IL-2, 6 patients will be enrolled for each level.
9907943|NCT00676962|Experimental|Facilitation|Therapists receive assistance with adopting CBT
9907944|NCT00676975|Active Comparator|Traditional Chinese Medicine|Traditional Chinese Medicine 17g herbal extract
9907945|NCT00676975|Placebo Comparator|Traditional Chinese Medicine Placebo|Placebo
9907946|NCT00676988||Observation|Subjects with Luminal Crohn's Disease receiving infliximab
9907947|NCT00677027|Experimental|1|
9907948|NCT00677027|Placebo Comparator|2|
9907949|NCT00677066|Experimental|1|Children discharged home with oxygen
9907950|NCT00677066|No Intervention|2|Children remain in hospital for oxygen therapy
9907951|NCT00677118|Experimental|Concurrent and adjuvant|Concurrent chemoradiotherapy plus adjuvant chemotherapy
9907952|NCT00677118|Active Comparator|Concurrent|Concurrent chemoradiotherapy
9907953|NCT00677131|Active Comparator|1|To read the package insert of the drug
9907954|NCT00677131|Active Comparator|2|To read the education information provided by the Pharmacy of NTUH
9907955|NCT00677131|Active Comparator|3|Oral education provided by the pharmacist
9907956|NCT00677144|Experimental|OS (oxalipaltin+S-1)|OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
9907957|NCT00677144|Active Comparator|XELOX (oxalipaltin+capecitabine)|XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
9907958|NCT00677157||screening|participants evaluated for possible inclusion in a natural history or intervention protocol
9907959|NCT00677170|Experimental|1|MLN4924
9907960|NCT00677183||SN###.#1|All children in this cohort will have biopsy-proven NASH.
9907961|NCT00677183||SN###.#2|This cohort will be parents (mother and father when possible) of child subjects with biopsy-proven NASH.
9907962|NCT00677196|Active Comparator|1|The LMA StoneBreakerTM
9907963|NCT00677196|Active Comparator|2|Pneumatic Lithotripsy
9907964|NCT00677209|Active Comparator|A|house dust mite allergics will undergo autovaccine immunization
9907965|NCT00677222|Experimental|1|Treatment arm
9907966|NCT00677222|No Intervention|2|Registry Arm -standard of care
9907967|NCT00677248|Placebo Comparator|1|Ezetimibe and placebo
9907968|NCT00677248|Experimental|2|Eprotirome dose 1 and ezetimibe
9907969|NCT00677248|Experimental|3|Eprotirome dose 2 and ezetimibe
9907970|NCT00677248|Experimental|4|Eprotirome dose 3 and ezetimibe
9907971|NCT00677261|Experimental|1|
9907972|NCT00677261|Experimental|2|
9907973|NCT00677261|Sham Comparator|3|
9907974|NCT00677274|Active Comparator|1|Epidural analgesia initiated at the cervix 0cm
9907975|NCT00677274|Active Comparator|2|Epidural analgesia initiated at the cervix 0.5cm
9907976|NCT00677274|Active Comparator|3|Epidural analgesia initiated at the cervix 1.0cm
9907977|NCT00677274|Active Comparator|4|Epidural analgesia initiated at the cervix 1.5cm
9907978|NCT00677274|Active Comparator|5|Epidural analgesia initiated at the cervix 2.0cm
9907979|NCT00677274|Active Comparator|6|Epidural analgesia initiated at the cervix 3.0cm
9907980|NCT00677274|Active Comparator|7|Epidural analgesia initiated at the cervix 4.0cm
9907981|NCT00677274|Active Comparator|8|Epidural analgesia initiated at the cervix 5.0cm
9907982|NCT00677287|Experimental|A|
9907983|NCT00677300|Experimental|Group A|Will receive Raltegravir (400mg twice daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
9907984|NCT00677300|Active Comparator|Group B|Will receive Tenofovir (300mg once daily) + Emtricitabine (200mg once daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
9907985|NCT00677326|Experimental|A|Peptide administered
9907986|NCT00677339|Active Comparator|1|Active L-arginine plus active vitamin D
9907987|NCT00677339|Active Comparator|2|Placebo L-arginine plus active Vitamin D
9907988|NCT00677339|Active Comparator|3|Active L-arginine plus placebo vitamin D
9907989|NCT00677339|Placebo Comparator|4|placebo L-arginine plus placebo vitamin D
9907990|NCT00677378||EXPERIMENTAL|Children undergoing an endoscopy for retrosternal chest pain, epigastric pain, regurgitation, heart burn or dyspepsia.
9907991|NCT00677378||CONTROL|Children undergoing an endoscopy for reasons not stated in the experimental group condition (i.e. celiac disease, rectal bleeding, polyps, weight loss, malabsorption).
9907992|NCT00677391|Active Comparator|1|
9907993|NCT00677391|Placebo Comparator|2|
9907994|NCT00677404|Experimental|stem cell recipient|the patients with peripheral vascular disease who receive bone marrow derived mono nuclear cells
9907995|NCT00677430||Questionnaire + Digital Imaging|A brief questionnaire packet will be completed. Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
9907996|NCT00677443|Experimental|S-1 and Oxaliplatin|"S-1 and Oxaliplatin~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks"
9907997|NCT00677443|Active Comparator|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin
9907998|NCT00677456|Active Comparator|1|Patients will receive R-Y reconstruction after total gastrectomy as intervention
9907999|NCT00677456|Active Comparator|2|Patients will receive P-Y reconstruction after total gastrectomy as intervention
9908000|NCT00677456|Active Comparator|3|Patients will receive Pouch reconstruction after total gastrectomy as intervention.
9908001|NCT00677456|Active Comparator|4|Patients will receive P-I reconstruction after total gastrectomy as intervention.
9908002|NCT00677469|Experimental|I|Cholestyramine 2g BID, Methimazole 10mg TID, and Propranolol 20mg BID
9908003|NCT00677469|Experimental|II|Cholestyramine 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
9908004|NCT00677469|Placebo Comparator|III|Placebo powder 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
9908005|NCT00677482||1|Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.
9908006|NCT00677495|Experimental|Gluten-free diet|Gluten-free diet
9908007|NCT00677508||C FR|Children with constipation and fecal incontinence.
9908008|NCT00677508||C|Children with constipation but without fecal incontinence.
9908009|NCT00677508||P-C FR|Parents of children with constipation and/or fecal incontinence.
9908010|NCT00677521|Experimental|1|
9908011|NCT00677547||1|Kidney transplant recipients
9908012|NCT00677547||2|Healthy volunteers
9908013|NCT00677573|Active Comparator|UrFSH|
9908014|NCT00677586|Experimental|1|simultaneous resection of liver metastasis and the colorectal primary tumor
9908015|NCT00677586|Active Comparator|2|staged resection of the liver metastasis and the colorectal primary tumor
9908016|NCT00677599|Active Comparator|Intervention A|Experimental arm enriched with flavonoids
9908017|NCT00677599|Placebo Comparator|Intervention B|
9908018|NCT00677612|Experimental|A|
9908019|NCT00677625||Liver Disease (LD)|These child subjects have some form of liver disease (including those who need a liver transplant) or have already had a liver transplant.
9908020|NCT00677638|Experimental|1|Embracer implantation
9908021|NCT00677651||1|Five caucasian women
9908022|NCT00677651||2|Five caucasian men
9908023|NCT00677664|Active Comparator|A|Group which received Copaxone
9908024|NCT00677664|Placebo Comparator|B|Group which received Mannitol
9908025|NCT00677703|No Intervention|Standard Care|Participants will receive standard care without daily reminders.
9908026|NCT00677703|Experimental|Text Messages|Participants will receive a daily text message reminder for 6 months
9908027|NCT00677716|Experimental|131I-chTNT-1/B MAb (Cotara)|
9908028|NCT00677729|Active Comparator|1|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline (NaCl)
9908029|NCT00677729|Placebo Comparator|2|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl)
9908030|NCT00677742|Experimental|1|enhanced initial supply of oral contraception
9908031|NCT00677742|Active Comparator|2|conventional initial supply of oral contraception
9908032|NCT00677755|Experimental|Mf+Ms|The women in mifepristone combined misoprostol group (Mf+Ms) received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
9908033|NCT00677755|Experimental|Ms-alone|The control group (Ms-alone) patients were only administered 0.8 mg of misoprostol orally on day 3.
9908034|NCT00677768||Early ALS|
9908035|NCT00677768||Suspected ALS|
9908036|NCT00677768||Disease Mimics of ALS|
9908037|NCT00677768||Healthy Controls|
9908038|NCT00677781||F64|We investigate a cohort of 20 consecutive patients undergoing hepatic or pancreatic surgery (Pilot study)
9908039|NCT00677794|Active Comparator|1|Clear fluids only after lunch.
9908040|NCT00677794|Active Comparator|2|Two sachets of picosalax the evening prior to Video Capsule Endoscopy (VCE).
9908041|NCT00677794|Active Comparator|3|Polyethylene glycol, 2 liters the evening prior to Video Capsule Endoscopy (VCE).
9908042|NCT00677846||3|Patients with symptoms of deep venous thrombosis less than for 2 weeks, with thrombus occluding without any reperfusion in color mode in the common femoral vein (CFV), the femoral vein (FV) or the popliteal vein (PV)
9908043|NCT00677859|Experimental|Single dose Arm|There will be six cohorts of three patients each. Three escalating doses of MultiStem will be evaluated.
9908044|NCT00677859|Experimental|Repeat Dose Arm|There will be six cohorts of three patients each. Four dosing regimens will be evaluated,varying doses at three times weekly or five times weekly.
9908045|NCT00677872|Experimental|1|
9908046|NCT00677937|Experimental|1|Intervention to include education and ongoing support
9908047|NCT00677937|No Intervention|2|Control to receive standard care
9908048|NCT00677950|Experimental|1|OP-1 Putty
9908049|NCT00677950|Active Comparator|2|Autograft
9908050|NCT00677963|Other|1|Patients with symptomatic 70-99% carotid stenosis who are operated on.
9908051|NCT00677976||IBS|Children between the ages of 10 and 18 who meet Rome III criteria for IBS as determined by a pediatric gastroenterologist.
9908052|NCT00677976||Control|Healthy children between the ages of 10 and 18.
9908053|NCT00677989||LA|LA group: patients with perforated appendicitis treated by laparoscopic operation intentionally
9908054|NCT00677989||OA|OA group:patients with perforated appendicitis treated by open approach
9908055|NCT00678002||QOL###|All child subjects in this cohort will be listed for or already have received a solid organ transplant (kidney, heart, or liver).
9908056|NCT00678054|Experimental|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
9908057|NCT00678067|Placebo Comparator|Placebo|12 hypercholesterolemic children 3-13 years of age
9908058|NCT00678067|Experimental|DHA+EPA group|12 hypercholesterolemic children 3-13 years of age
9908059|NCT00678067|Experimental|DHA Group|12 hypercholesterolemic children 3-13 years of age
9908060|NCT00678093|Experimental|SNAG|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
9908061|NCT00678106|Experimental|1|
9908062|NCT00678145|Experimental|Healthy|Healthy individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
9908063|NCT00678145|Experimental|Type 1 Diabetes|T1D individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
9908064|NCT00678158|Experimental|1|Patients with metastatic disease to soft tissue.
9908065|NCT00678158|Experimental|2|Patients with metastatic disease to lymph nodes.
9908066|NCT00678158|Experimental|3|Patients with metastatic disease to the bone.
9908067|NCT00678197|Experimental|A|
9908068|NCT00678197|Experimental|B|
9908069|NCT00678197|No Intervention|C|
9908070|NCT00678236|Active Comparator|1|Refobacin Bone Cement R
9908071|NCT00678236|Active Comparator|2|Refobacin Plus Bone Cement
9908072|NCT00678275|Other|A|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, RECEIVING ATG in conditioning regimen
9908073|NCT00678275|Other|B|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, NOT RECEIVING ATG in conditioning regimen
9908074|NCT00678314|Active Comparator|Group A|
9908075|NCT00678314|Active Comparator|Group B|
9908076|NCT00678314|Placebo Comparator|Group C|
9908077|NCT00678327|Active Comparator|Arm I|Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9908078|NCT00678327|Active Comparator|Arm II|Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9908079|NCT00678327|Experimental|BEACOPP-14 chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9908080|NCT00678327|Experimental|BEACOPP-escalated chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9908081|NCT00678340|Active Comparator|1|WACA and PVI
9908082|NCT00678340|Active Comparator|2|PVAC
9908083|NCT00678353||1|Follow-up to S01-01US, conducted to expand information
9908084|NCT00678366|Experimental|1|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
9908085|NCT00678366|Active Comparator|2|pure carbon dioxide pneumoperitoneum
9908086|NCT00678405|Active Comparator|WLm / WLnm|Best supportive care
9908087|NCT00678405|Experimental|FTm / FTnm|Breathlessness Intervention Service
9908088|NCT00678431|Placebo Comparator|Arm 1|Liquid placebo
9908089|NCT00678431|Experimental|Arm 2|Liquid Resveratrol with Glucose, and Malate
9908090|NCT00678457|Experimental|ondansetron/olanzapine|"ondansetron (4 μg/kg b.i.d.)~olanzapine (9 μg/kg)"
9908091|NCT00678457|Placebo Comparator|placebo|placebo
9908092|NCT00678483|Experimental|1|10 mg
9908093|NCT00678483|Experimental|2|20 mg
9908094|NCT00678509|Experimental|A|
9908095|NCT00678548|Experimental|guided imagery|CD
9908096|NCT00678548|Active Comparator|pain diary|Pain diary
9908097|NCT00678600|Active Comparator|Standard (static) Computer Alerts|Participants in this arm will be assigned to standard care. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Provider computer alerts will be posted on the participant's electronic health record summary page.
9908098|NCT00678600|Experimental|Enhanced Computer Alerts|Participants in this arm will be assigned to the enhanced alert arm. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Providers will receive population and asynchronous computer alerts with improved functionality.
9908099|NCT00678613|Placebo Comparator|1, Primary prophylaxis|"Patients with liver cirrhosis with ascites having ascitic fluid protein <1 gm/dl will be included in this arm.~They will be randomized between probiotics and placebo."
9908100|NCT00678613|Active Comparator|2, secondary prophylaxis|"Patients with liver cirrhosis with ascites having history of prior SBP will be included in this arm.~They will be randomized between probiotics and norfloxacin."
9908101|NCT00678626|Experimental|Arm A|combination of CP-751,871 + docetaxel administered
9908102|NCT00678626|Active Comparator|Arm B|chemotherapy
9908103|NCT00678678|Active Comparator|I - Spirometer|
9908104|NCT00678678|Active Comparator|II - Kit Epap®|Device with Spring load by mask,produced by Brazil (critical med)
9908105|NCT00678704|Placebo Comparator|Arm 3|
9908106|NCT00678704|Experimental|Arm 1|
9908107|NCT00678704|Experimental|Arm 2|
9908108|NCT00678717|Active Comparator|Healthy|Healthy volunteers
9908109|NCT00678717|Experimental|Chronic Visceral Pain|Chronic Visceral Pain patients. Participants will be tested before and after implantation of a Spinal Cord Stimulator (implantation of the Spinal Cord Stimulator is done as usual care and is not a study procedure)
9908110|NCT00678769|Experimental|Group A (temsirolimus on days 15 and 22 course 1)|Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
9908111|NCT00678769|Experimental|Group B (cixutumumab on days 15 and 22 of course 1)|Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
9908112|NCT00678769|Experimental|Group C (temsirolimus on days 1, 8, 15, and 22)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
9908113|NCT00678847|Placebo Comparator|B|
9908114|NCT00678847|Active Comparator|A|
9908115|NCT00678873|Experimental|Surgical group|Patients with ultrasound proven symptomatic cholelithiasis (gallstones).
9908116|NCT00678912|Experimental|1|Children are mechanically ventilated with Smartcare/PS
9908117|NCT00678912|No Intervention|2|Children are mechanically ventilated with usual care
9908118|NCT00678925|Active Comparator|1|Choline supplement given from 18-weeks pregnancy through 90 days postpartum
9908119|NCT00678925|Placebo Comparator|2|Placebo capsules given from 18 weeks pregnancy through 90 days postpartum
9908120|NCT00678938|Experimental|1|
9908121|NCT00678938|Experimental|2|
9908122|NCT00678938|No Intervention|3|
9908123|NCT00678964|Experimental|A|
9908124|NCT00678964|Active Comparator|B|
9908125|NCT00678977|Experimental|Arm A|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, and 1000 mg/m2 gemcitabine. Intermediate dose levels may also be explored. Intravenous gemcitabine will be given on Day 1 and 8 of Cycle 1 and each subsequent cycle.~Cohort expansion phase - patients will receive gemcitabine alone, at the OTR dose starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR beginning on Day 2 Cycle 1 after the last blood sample for gemcitabine analysis is collected, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib. On Day 1 of Cycle 2 patients will receive the simultaneous administration of gemcitabine and pazopanib"
9908126|NCT00678977|Experimental|Arm B|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, 1000 mg/m2 gemcitabine and 60 mg/m2 cisplatin. Doses of gemcitabine may range from 600 to 1250 mg/m2. Doses of cisplatin may range from 60 to 80 mg/m2. Intermediate dose levels may also be explored. Pazopanib administered starting on Day 1 of Cycle 1, gemcitabine co-administration on Day 1 and 8, and cisplatin on Day 1 in each 21-day cycle.~Cohort expansion - patients will receive gemcitabine and cisplatin alone, at the OTR doses, starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR dose beginning on Day 2 of Cycle 1, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib"
9908127|NCT00678990|Experimental|Open, single arm|Transplantation of islets with heparin coating.
9908128|NCT00679003|Experimental|1|Social learning and cognitive behavioral therapy (SLCBT)
9908129|NCT00679003|Active Comparator|2|Education and support (ES)
9908130|NCT00679068|Experimental|1|treatment with Bosentan
9908131|NCT00679094|Experimental|Arm I|Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.
9908132|NCT00679107|Experimental|1|autogenous bone graft with the addition of OP-1 Putty
9908133|NCT00679107|Active Comparator|2|autogenous bone graft alone
9908134|NCT00679120|Active Comparator|1|Cemented single pegged femur with standard tibial bearing tray
9908135|NCT00679120|Active Comparator|2|Cemented twin pegged femur with standard tibial bearing tray
9908136|NCT00679120|Active Comparator|3|Cementless tibial bearing tray and femur (porous coated and HA coated)
9908137|NCT00679133|Experimental|1|
9908138|NCT00679146|Active Comparator|1|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
9908139|NCT00679146|Active Comparator|2|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
9908140|NCT00679159|Experimental|1|24 children (5 x 10^7pfu)
9908141|NCT00679159|Experimental|2|36 infants (2.5 x 10^7pfu)
9908142|NCT00679159|Experimental|3|36 infants (5 x 10^7 pfu)
9908143|NCT00679159|Experimental|4|36 infants (1 x 10^8pfu)
9908144|NCT00679159|Placebo Comparator|5|36 infants (Prevenar vaccine)
9908145|NCT00679185|Experimental|Experimental-EW|four emotion focused writing assignments
9908146|NCT00679185|Active Comparator|control group|non-emotional writing control
9798543|NCT01632241|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
9798544|NCT01632241|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
9798545|NCT01632267||Depression and anxiety|Subjects with a primary diagnosis of depression or anxiety disorder.
9798546|NCT01632280|Active Comparator|Active tDCS|In this arm, participants will receive active tDCS (2mA, 20 min per session). The anode electrode will be placed over the right inferior frontal gyrus, defined as F8 (10-20 EEG system), with the cathode electrode placed over the contralateral supraorbital area, above the left eyebrow. During each session they will also perform a computerized task designed to engage the inhibitory control circuit when confronted with food stimuli.
10213994|NCT02341014|Experimental|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
9798547|NCT01632280|Sham Comparator|Sham tDCS|Participants will receive sham tDCS sessions with the same duration and electrode montage as in the real tDCS arm. In this case, current will be applied for 30 s only according to standard procedures, and participants will perform a control task where they will observe and provide responses for the same food and non-food pictures as in the active group task, but without requirement of inhibitory control for performance.
9798548|NCT01632306|Experimental|LY2090314 + Gemcitabine|LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
9798549|NCT01632306|Experimental|LY2090314 + FOLFOX|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
9798550|NCT01632306|Experimental|LY2090314 + Gemcitabine + Nab-paclitaxel|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.
9798551|NCT01632345|Experimental|Doravirine 25 mg|Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
9798552|NCT01632345|Experimental|Doravirine 50 mg|Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
9798553|NCT01632345|Experimental|Doravirine 100 mg|Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
9798554|NCT01632345|Experimental|Doravirine 200 mg|Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
9798555|NCT01632345|Active Comparator|Efavirenz|Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.
9798556|NCT01632423||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
9798557|NCT01632566|Placebo Comparator|Placebo|Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
9798558|NCT01632566|Experimental|LY3031207|Daily oral administration of 25 milligrams (mg) LY3031207 up to 450 mg LY3031207 for 28 days.
9798559|NCT01632566|Active Comparator|Celecoxib|Daily oral administration of 400 mg celecoxib for 28 days. Positive control for LY3031207.
9798560|NCT01632566|Other|LY3031207 + Simvastatin|Daily oral administration of 75 mg LY3031207 or 225 mg LY3031207 for 28 days. Single, oral 10 mg simvastatin open-label dose administered before and after 28-day dosing of LY3031207.
10213995|NCT02310204|Experimental|multidisciplinary education program|individual and group education sessions over a 6-month period
10213996|NCT02310204|Active Comparator|Standard psoriasis care alone|Standard psoriasis care alone
10213997|NCT02280902||Patient with immunologic and inflammatory diseases|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
10213998|NCT02270814|Experimental|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by~cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by~cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle~Cisplatin or carboplatin may be given at the discretion of the investigator.~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle~cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
9908147|NCT00679198|Experimental|1|We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers
9908148|NCT00679198|No Intervention|2|Standard care
9908149|NCT00679224||ambrisentan prescribed subjects|ambrisentan prescribed subjects
9908150|NCT00679237|Active Comparator|Multifactorial intervention|Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
9908151|NCT00679237|No Intervention|Control|no intervention
9908152|NCT00679250|Experimental|Levocetirizine|Active drug
9908153|NCT00679250|Placebo Comparator|placebo|placebo to levocetirizine
9908154|NCT00679276||1|Patients having surgical repair of a vaginal prolapse .
9908155|NCT00679315|Experimental|Alpha blocker|alfuzosin hydrochloride XL 10mg
9908156|NCT00679315|Placebo Comparator|Placebo|Placebo
9908157|NCT00679328|Experimental|1|Surgical implantation of OP-1
9908158|NCT00679328|Active Comparator|2|Surgical implantation of bone graft material
9908159|NCT00679393|Other|Fix|Open reduction internal fixation of severely comminuted calcaneal fracture (Sanders IV)
9908160|NCT00679393|Other|Fuse|Primary subtalar fusion of severely comminuted calcaneal fractures (Sanders IV).
9908161|NCT00679406|Experimental|1|Brief Behavioral Treatment for Insomnia
9908162|NCT00679419||Group 0 (Controllgroup)|eGFR >= 90 ml/min/1.73m^2 and no proteinuria
9908163|NCT00679419||Group 1|eGFR >= 90 ml/min/1.73m^2 and proteinuria
9908164|NCT00679419||Group 2|eGFR 60 - 89 ml/min/1.73m^2
9908165|NCT00679419||Group 3|eGFR 30 - 59 ml/min/1.73m^2
9908166|NCT00679419||Group 4|eGFR 15 - 29 ml/min/1.73m^2
9908167|NCT00679419||Group 5|eGFR < 15 ml/min/1.73m^2 or requiring dialysis
9908168|NCT00679445|Experimental|A|Device: NeoVista Ophthalmic System A single procedure using the NeoVista Ophthalmic System plus an injection of Lucentis.
9908169|NCT00679458|Experimental|1.|Study drug: buprenorphine and ultra-low-dose naloxone
9908170|NCT00679458|Active Comparator|2.|Study drug: buprenorphine
9908171|NCT00679471||Pre-Term|Infants born pre-term with birthweight less than 1KG
9908172|NCT00679471||Full-Term Infants|Well infants who are born full-term
9908173|NCT00679484|Experimental|1|
9908174|NCT00679484|Experimental|2|
9908175|NCT00679497|Experimental|1|MVA HIV-B
9908176|NCT00679497|Placebo Comparator|2|Placebo
9908177|NCT00679510|Active Comparator|rosuvastatin|Rosuvastatin Patients were randomly allocated rosuvastatin (crestor) 10 mgs. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
9908178|NCT00679510|Placebo Comparator|Placebo|Placebo. Patients were randomly allocated placebo. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
9908179|NCT00679523|Experimental|Group 1|AN2690 Solution, 5.0%
9908180|NCT00679523|Experimental|Group 2|AN2690 Solution, 7.5%
9908181|NCT00679536|Experimental|A|All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)
9908182|NCT00679562|Experimental|1|
9908183|NCT00679562|Placebo Comparator|2|
9908184|NCT00679575||1|Cases : Patients with a first myocardial infarction
9908185|NCT00679575||2|Referents : Patients recruited by a GP during a routine consultation
9908186|NCT00679614|Experimental|1|Group A oral tramacet 2 tablets preoperatively, 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. Naloxone infusion starting preop at 0.25ug/kg/hr and continuing during hospital stay (an equivalent of 400ug over 24 hours in a 70 kg man). The infusion will be discontinued 1 hour before patient discharge.
9908187|NCT00679614|Active Comparator|2|Group B will receive oral tramacet 2 tablets preoperatively and then 2 tablets every 6 hours for five days. ( or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). This group will also receive saline infusion at 4-6mls / hour for the duration of the hospital stay.
9908188|NCT00679614|Active Comparator|3|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay.
9908189|NCT00679640||1|Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
9908190|NCT00679653|Active Comparator|1|verapamil/trandolapril
9908191|NCT00679653|Active Comparator|2|metoprolol/HCT
9908192|NCT00679653|Active Comparator|3|felodipine/ramipril
9908193|NCT00679666|Sham Comparator|Sham treatment|Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit.
9908194|NCT00679666|Active Comparator|Treatment Arm|After randomization, the active arm will have the collagen crosslinking intervention.
9908195|NCT00679679|Experimental|Metformin|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
9908196|NCT00679679|Placebo Comparator|Placebo|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
9908197|NCT00679692||3:|three arms for study
9908198|NCT00679705|Experimental|1|Ritodrine (Pre-Par)
9908199|NCT00679705|Experimental|2|Atosiban (Tractocile)
9908200|NCT00679705|Placebo Comparator|3|Placebo
9908201|NCT00679744|Active Comparator|4 dose levels|Pyrimethamine at 6.25, 12.5, 25 and 37.5 mg/day will be evaluated sequentially, starting from 6.25 mg/day. Escalation from 6.25 mg/day to 12.5 mg/day, and from 12.5 mg/day to 25 mg/day, will not perform until all patients in the previous dose cohort have been treated for 4 weeks and until results obtained 4 weeks after treatment initiation do not reveal toxicity. Additionally, escalation from 25 mg/day to 37.5 mg/day will not perform until all patients in the 25-mg/day cohort have been treated for 8 weeks, and until results obtained 4 weeks after the 8-week treatment do not reveal toxicity. Dose escalation is considered complete, if 2 patients experience a Grade 3 Adverse Event (AE) or if 1 patient experiences a Grade 4 AE at a particular cohort.
9908202|NCT00679770|Experimental|Group 1|AN2690 Solution: 2.5%
9908203|NCT00679770|Experimental|Group 2|AN2690 Solution: 5%
9908204|NCT00679770|Experimental|Group 3|AN2690 Solution: 7.5%
9908205|NCT00679770|Placebo Comparator|Group 4|AN2690 Solution Vehicle
9908206|NCT00679796||Group A|Subjects with PCR confirmed varicella
9908207|NCT00679796||Group B|Age- and practice-matched control subjects
9908208|NCT00679822||Heart Failure|Heart Failure Out Patients at OSU
9908209|NCT00679835|Experimental|Group 1|8 mg/kg over a one hour infusion
9908210|NCT00679835|Experimental|Group 2|10mg/kg over a one or two hour infusion
9908211|NCT00679848|Experimental|1|Transoral Suturing
9908212|NCT00679861|Experimental|3|A practitioner delivered counselling and an expert system intervention is implemented in practices allocated to this arm
9908213|NCT00679861|Experimental|1|A practitioner delivered counselling intervention was implemented in practices allocated to this arm
9908214|NCT00679861|Experimental|2|A computer expert system intervention was implemented in practices allocated to this arm
9908215|NCT00679874||I|Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.
9908216|NCT00679887|Experimental|A|Ischemic compression on trigger points located around the shoulder. Active comparator. Ischemic compression, 5 weeks
9908217|NCT00679900|Experimental|1|
9908218|NCT00679900|Active Comparator|2|
9908219|NCT00679965|Experimental|Group 1|AN2690 Solution, 2.5%
9908220|NCT00679965|Experimental|Group 2|AN2690 Solution: 5%
9908221|NCT00679965|Experimental|Group 3|AN2690 Solution, 7.5%
9908222|NCT00679965|Placebo Comparator|Group 4|AN2690 Solution Vehicle
9908223|NCT00679978||A|A: etidronate
9908224|NCT00680004||1|Preoperative patients planned for a CT prior to an endograft implantation procedure
9908225|NCT00680004||2|Patients who underwent a complicated endograft implant and/or with increased risk of complications
9908226|NCT00680030||1|
9908227|NCT00680082||1|Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
9908228|NCT00680095|Experimental|A|AN2690 Solution, 2.5%
9908229|NCT00680095|Experimental|B|AN2690 Solution, 7.5%
9908230|NCT00680095|Experimental|C|AN2690 Solution, 5.0%
9908231|NCT00680095|Active Comparator|D|AN2690 Solution, Vehicle
9908232|NCT00680095|Active Comparator|E|Sodium Lauryl Sulfate, 0.5%
9908233|NCT00680134|Experimental|Group/Cohort 1|AN2690 1% Solution (30 subjects)
9908234|NCT00680134|Experimental|Group/Cohort 2|AN2690 5% Solution (30 subjects)
9935780|NCT03222973|Placebo Comparator|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
9908235|NCT00680147|Experimental|Brief HPV vaccine informational intervention|Because we anticipated that knowledge and awareness of the HPV vaccine would be low in our study population, our CASI survey included a brief, informational overview of key facts concerning HPV vaccination prior to assessing vaccine acceptance, perceived barriers to vaccination, and intentions to vaccinate. The overview lasted approximately 3 minutes and consisted of a brief overview of key HPV vaccination facts that were presented visually (on the computer screen) and read aloud using a digital recording. HPV and vaccine knowledge, awareness, and attitudes items were administered prior to participants hearing the informational overview.
9908236|NCT00680173|Active Comparator|A|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin achieve a sustained virological response
9908237|NCT00680173|Active Comparator|B|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin did not achieve a sustained virological response
9908238|NCT00680199||1|Primary Insomnia
9908239|NCT00680199||2|Good Sleepers
9908240|NCT00680212|Other|1|dietary carotenoids
9908241|NCT00680238|No Intervention|A|Embryo selection for transfer based on a Day 3 score only.
9908242|NCT00680238|Active Comparator|B|Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
9908243|NCT00680264||Operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level Curve >40 degrees on sitting film, A spinal fusion is being undertaken and the patient/family is proceeding with the spinal fusion (with any level of distal fusion).
9908244|NCT00680264||Non-operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level, Curve >40 degrees on sitting film, A spinal fusion is not being undertaken either because the family has refused surgery or because it is not recommended at this point.
9908245|NCT00680277|Experimental|1|
9908246|NCT00680277|Experimental|2|
9908247|NCT00680290|Experimental|1|Exercise group
9908248|NCT00680303|Experimental|1|The child will receive the Lidcombe Program 2x per week
9908249|NCT00680303|Experimental|2|The child will receive the Lidcombe Program once every 2 weeks (fortnightly visits)
9908250|NCT00680303|Other|3|The child will receive the standard Lidcombe Program once per week (control)
9908251|NCT00680329||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
9908252|NCT00680355|Other|Golden rice meal with 10g fat|10 g corn oil in the Golden Rice meal
9908253|NCT00680355|Other|Golden Rice with 0g fat|0g corn oil eating with the Golden Rice meal
9908254|NCT00680355|Other|Golden Rice meal with 5 g fat|5 g corn oil in the Golden Rice meal
9908255|NCT00680381|Active Comparator|1|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly therapist phone calls for eight weeks.
9908256|NCT00680381|Active Comparator|2|Following 12 weeks of FFT, weekly one-hour group therapy for eight weeks
9908257|NCT00680381|Active Comparator|3|Following 12 weeks of FFT, an eight-week, customized series of therapist visits with the adolescent, family, teachers, coaches and others who can support the adolescent's reduced level of drug use.
9908258|NCT00680394|Experimental|mifepristone+misoprostol|200 mg mifepristone+ 800 mcg buccal misoprostol
9908259|NCT00680394|Experimental|misoprostol|800 mcg buccal misoprostol+placebo
9908260|NCT00680433|Experimental|Active|Ketamine
9908261|NCT00680433|Placebo Comparator|Placebo|Saline (placebo)
9908262|NCT00680446|Experimental|1|
9908263|NCT00680498|Active Comparator|1|
9908264|NCT00680498|Active Comparator|2|
9908265|NCT00680511|Active Comparator|1|Family therapy combined with methamphetamine-specific group treatment.
9908266|NCT00680511|Active Comparator|2|Family Therapy.
9908267|NCT00680537|No Intervention|1|Control group
9908268|NCT00680537|Experimental|2|Exercise group
9908269|NCT00680563|Experimental|1|
9908270|NCT00680576|Active Comparator|1|Eight weeks of individual CBT for adolescents who have completed six weeks of group therapy and continue to use drugs.
9908271|NCT00680576|Active Comparator|2|Eight weeks of FFT for adolescents who have received six weeks of group therapy and continue to use drugs.
9908272|NCT00680589|Experimental|1|Injection of mouse TYRP2 DNA in patients with highrisk melanoma.
9908273|NCT00680602|Experimental|1|Group Cognitive Behavior Therapy
9908274|NCT00680602|Active Comparator|2|Selective Serotonin Reuptake Inhibitor
9908275|NCT00680615|Experimental|Usual Care|
9908276|NCT00680615|Experimental|Enhanced|
9993992|NCT01477255||Control|For each pediatric patient enrolled, a child without a history of a serious medical illness will be recruited from the larger community who is matched on variables of age, race/ethnicity, gender, and socioeconomic status. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
9993993|NCT01477268|Other|zoloft|Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
9993994|NCT01477281|Experimental|Venafon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
9993995|NCT01477281|Active Comparator|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
9993996|NCT01477294|Experimental|Caffeine|Intervention with Caffeine in a random order
9993997|NCT01477294|Placebo Comparator|Placebo|Placebo (malt dextrin) administered in a random order
9993998|NCT01477307||hypocaloric diet|The included patients are assigned to a hypocaloric standardized diet for 3 weeks.
9993999|NCT01477346|Other|Nurse intervention|Nurse led package of care based on current recommended best practice.
9994000|NCT01477346|Other|Standard care|Continuing standard general practitioner led care
9994001|NCT01477359||CS screened as underlying etiology|"Patients with active Clinically Manifest CS~Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS"
9994002|NCT01477372|Experimental|Exercise group|Supervised exercise program
9994003|NCT01477372|No Intervention|Control|Sedentary pregnant woman
9994004|NCT01477385|Active Comparator|Resin Infiltration|Resin Infiltration 30% Silver Diammine Fluoride Placebo Dental Flossing
9994005|NCT01477385|Experimental|30% Silver Diammine Fluoride|30% Silver Diammine Fluoride Resin Infiltration Placebo Dental Flossing
9994006|NCT01477385|Active Comparator|Oral Hygiene|Dental Flossing 30% Silver Diammine Fluoride Placebo Resin Infiltration Placebo
9994007|NCT01477398|Active Comparator|inspired CO2|Inspired CO2
9994008|NCT01477398|No Intervention|No intervention: Standard of Care|tidal volume and respiratory rate are not changed during recovery from anesthesia
9994009|NCT01477411|Experimental|PA21 and Digoxin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
9994010|NCT01477411|Experimental|No PA21; Digoxin with food|The maximum dosage of Digoxin will be 0.5 mg/day
9994011|NCT01477411|Experimental|PA21 with food and Digoxin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
9994012|NCT01477424|Experimental|PA21 and Warfarin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day
9994013|NCT01477424|Experimental|No PA21; Warfarin with food|The maximum dosage of Warfarin will be 10 mg/day
9994014|NCT01477424|Experimental|PA21 with food and Warfarin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day
9994015|NCT01477437|Experimental|Intervention (experimental) Group|
9994016|NCT01477437|No Intervention|Control group|
9994017|NCT01477476|Active Comparator|Active Treatment|14 subjects with receive active treatment with Anakinra.
9994018|NCT01477476|Placebo Comparator|Placebo|7 subjects will receive the placebo comparator.
9994019|NCT01477489|Experimental|Treatment|
9994020|NCT01477502|Active Comparator|individual homeopathic treatment|participants receive homeopathic treatment in addition to standard prevention measures for UTI
9994021|NCT01477502|Other|standard prophylaxis|
9994022|NCT01477515||End stage renal disease patient|
9994023|NCT01477515||Matched controls|
9994024|NCT01477541|Experimental|PM/ON integration arm|Health centers where professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
9994025|NCT01477541|No Intervention|Control|
9994026|NCT01477554|No Intervention|Control|Hospitals randomized to the control arm do not receive any intervention.
9994027|NCT01477554|Experimental|PRONTO training|PRONTO training is delivered to medical teams at hospitals randomized to this arm.
9994028|NCT01477580|Experimental|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|
9994029|NCT01477580|Experimental|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
9994030|NCT01477580|Experimental|Medium-dose Non-adjuvanted V180|
9994031|NCT01477580|Experimental|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|
9994032|NCT01477580|Experimental|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
9994033|NCT01477580|Experimental|Medium-Dose V180 with Alhydrogel™ adjuvant|
9994034|NCT01477580|Experimental|High-dose Non-adjuvanted V180|
9994035|NCT01477580|Experimental|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|
9994036|NCT01477580|Experimental|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
9994037|NCT01477580|Experimental|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|
9994038|NCT01477580|Experimental|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|
9994039|NCT01477580|Experimental|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|
9994040|NCT01477580|Placebo Comparator|Placebo|
9994041|NCT01477593|Experimental|Group I|
9994042|NCT01477593|Active Comparator|Group II|
9994043|NCT01477593|Active Comparator|Group III|
9994044|NCT01477606|Experimental|Midostaurin|
9994045|NCT01477619|Experimental|Smokers|Split into BMI categories
9994046|NCT01477619|Experimental|Non-Smokers|Gender, age, and BMI matched to Smokers
9994047|NCT01477619|Experimental|Elderly|
9994048|NCT01477632|Experimental|A|
9994049|NCT01477632|Experimental|B|
9908277|NCT00680641|Active Comparator|A|Simvastatin 40mg
9908278|NCT00680641|Placebo Comparator|B|Placebo
9908279|NCT00680654|Experimental|Arm 1|
9908280|NCT00680667|Experimental|Trametes Versicolor|Females with Stage I-III infiltrating ductal adenocarcinoma of the breast being treated with Trametes versicolor capsules for 6 weeks after receiving radiation therapy.
9908281|NCT00680693|Experimental|1|Mindfulness-based stress management 8-week program
9908282|NCT00680693|Active Comparator|2|Psycho-educational support group for women with IBS
9908283|NCT00680719|Active Comparator|1|Family Therapy plus HIV prevention
9908284|NCT00680719|Active Comparator|2|Family Therapy only.
9908285|NCT00680732|Experimental|A1|Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)
9908286|NCT00680732|Experimental|A2|Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)
9908287|NCT00680732|Experimental|B1|Iron and folic acid (IFA) and weekly chloroquine (CQ)
9908288|NCT00680732|Experimental|B2|Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)
9908289|NCT00680758|Experimental|Therapeutic Intervention|
9908290|NCT00680849||1|Treatment condition from first study. This is a follow-up study.
9908291|NCT00680849||2|Control condition from first study.
9908292|NCT00680875|Experimental|Intervention|5th and 6th grade students who attend schools randomly assigned to the intervention condition.
9908293|NCT00680875|No Intervention|Usual Curriculum|5th and 6th grade students attending schools randomly assigned to the usual curriculum control condition.
9908294|NCT00680888||1|Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006
9908295|NCT00680940|Active Comparator|Chemotherapy|Paclitaxel + Cisplatin
9908296|NCT00680940|Experimental|Chemoimmunotherapy|Paclitaxel + Cisplatin + Mycobacterium w
9908297|NCT00680966|Experimental|TX1|Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)
9908298|NCT00680966|Experimental|TX 2|ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)
9908299|NCT00680966|Experimental|TX 3|Combination of an augmented FFT and ACWD - Integrated treatment
9908300|NCT00681005|Active Comparator|Rabeprazole|Rabeprazole 1 # qd
9908301|NCT00681005|Active Comparator|pantoprazole|Pantoprazole 1# qd
9908302|NCT00681018|Experimental|1|Liquid human milk fortifier
9908303|NCT00681018|Active Comparator|2|Powder human milk fortifier
9908304|NCT00681070|Active Comparator|Arm1: Non-absorbable sutures|use of non-absorbable sutures in facial laceration in this arm
9908305|NCT00681070|Active Comparator|Arm 2: Absorbable sutures|use of absorbable sutures in this arm
9908306|NCT00681122||1|Standard therapy
9908307|NCT00681122||2|Standard therapy + educational material
9908308|NCT00681135|Experimental|1|
9908309|NCT00681135|Experimental|2|
9908310|NCT00681135|Experimental|3|
9908311|NCT00681135|Active Comparator|4|
9908312|NCT00681148|Experimental|A|Botox injection
9908313|NCT00681148|Placebo Comparator|B|Saline injection
9908314|NCT00681161|Other|A|
9908315|NCT00681174|Active Comparator|Control|Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
9908316|NCT00681174|Experimental|CROxy|The intervention group will receive controlled-release oxycodone 1 h pre-operatively
9908317|NCT00681213|Experimental|A|Tacrolimus/Sirolimus
9908318|NCT00681213|Experimental|B|Tacrolimus/MMF
9908319|NCT00681213|Experimental|C|Neoral/Sirolimus
9908320|NCT00681239|Experimental|A|Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
9908321|NCT00681252|Experimental|A|
9908322|NCT00681278||1|Hypertension patients with Type II Diabetes mellitus
9908323|NCT00681304||1|Only one group of participants will be studies. There are no controls.
9908324|NCT00681317|Experimental|1|
9908325|NCT00681330|Experimental|A|
9908326|NCT00681343|Experimental|A|Thymoglobulin Induction
9908327|NCT00681343|Experimental|B|Campath-1H Induction
9908328|NCT00681343|Experimental|C|Daclizumab Induction
9908329|NCT00681356|Experimental|1|4975 - 15 mg
9908330|NCT00681356|Placebo Comparator|2|Placebo
9908331|NCT00681356|Experimental|3|4975 - truncated for Phase 3
9908332|NCT00681369||1|Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
9908333|NCT00681382||1|Asthma patients using inhaled steroids as maintenance treatment
9908334|NCT00681395|Experimental|1|ABT-143 capsules 20/135 mg
9908335|NCT00681395|Active Comparator|2|ABT-335 135mg and rosuvastatin 20mg
9908336|NCT00681395|Experimental|3|ABT-143 capsules 5/45mg
9908337|NCT00681395|Active Comparator|4|ABT-335 45mg and rosuvastatin 5mg
9908338|NCT00681408|Active Comparator|Omega 3 recipient arm|
9908339|NCT00681408|Placebo Comparator|Placebo|Placebo fish oil
9908340|NCT00681421|Experimental|A|
9908341|NCT00681434|Experimental|1|bilateral training
9908342|NCT00681434|Active Comparator|2|Unilateral training
9908343|NCT00681447|Other|Group I|Lumbar interlaminar epidural injection with local anesthetic only
9908344|NCT00681447|Other|Group II|Lumbar Interlaminar Epidural Injection with local anesthetic wiht 6 mg of non-particulate Celestone
9908345|NCT00681460|Active Comparator|1|gestational diabetes, insulin therapy
9908346|NCT00681460|Experimental|2|gestational diabetes, metformin therapy
9908347|NCT00681486|Active Comparator|A, 1|Ghrelin
9908348|NCT00681486|Active Comparator|A, 2|Ghrelin.
9908349|NCT00681499||malignant|eg. hepatocellular carcinoma, colorectal liver metastases
9908350|NCT00681499||benign|eg. liver cysts, traumatic liver injuries, adenoma etc
9908351|NCT00681525|Experimental|A|ABT-335 135 mg
9908352|NCT00681525|Experimental|B|Atorvastatin 80 mg and Ezetimibe 10 mg
9908353|NCT00681525|Experimental|C|ABT-335 135 mg, Atorvastatin 80 mg and Ezetimibe 10 mg
9908354|NCT00681551|Active Comparator|Arm 1|
9908355|NCT00681551|Experimental|Arm 2|
9908356|NCT00681577|Experimental|A|
9908357|NCT00681603|Experimental|1|13 cases that accepted subconjunctival injection of bevacizumab
9908358|NCT00681616|Placebo Comparator|1|Compartment Monitoring System with Active Fluid Removal
9908359|NCT00681616|Active Comparator|2|Compartment Monitoring System (CMS) without fluid removal
9908360|NCT00681642||1|Corneal epithelial tissue with wound cultured in human autoserum
9908361|NCT00681642||2|Corneal epithelial tissue with wound cultured in umbilical cord serum
9908362|NCT00681681||1|Men and women with 1 or more cardiovascular risk factors
9908363|NCT00681694||MRBT|MRI-assisted brachytherapy, the experimental arm
9908364|NCT00681694||USBT1|Standard ultrasound-guided brachytherapy performed by group 1 (control arm 1)
9994050|NCT01477632|Active Comparator|C|
9908365|NCT00681694||USBT2|Standard ultrasound-guided brachytherapy performed by group 2 (control group 2)
9908366|NCT00681707||1|Hypertension patients recovering from stroke
9908367|NCT00681720|Experimental|1|
9908368|NCT00681733|Experimental|A|Pioglitazone
9908369|NCT00681733|Active Comparator|B|Pentoxifylline
9908370|NCT00681746|Experimental|1|
9908371|NCT00681759||1|Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro).
9908372|NCT00681759||2|420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA)
9908373|NCT00681759||3|Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms.
9908374|NCT00681772|Experimental|Arm 1|
9908375|NCT00681785|Active Comparator|A|5000IE dalteparine
9908376|NCT00681785|Placebo Comparator|B|NaCL 0.9%
9908377|NCT00681798|Active Comparator|Dose level 1|Vandetanib 100mg/day plus Gemcitabine
9908378|NCT00681798|Active Comparator|Dose level 2|Vandetanib 300mg/day plus Gemcitabine
9908379|NCT00681798|Active Comparator|Dose level 3|Vandetanib 100mg/day plus Gemcitabine plus CapecitabineDose
9908380|NCT00681798|Active Comparator|Dose level 4|Vandetanib 300mg/day plus Gemcitabine plus CapectiabineDose
9908381|NCT00681837||1|children from 0 to 17 years old
9908382|NCT00681850||1|Control group
9908383|NCT00681850||2|Benchmarking group
9908384|NCT00681876|Experimental|1|Irinotecan+Avastin+Erbitux
9908385|NCT00681902|Experimental|1|Jet lidocaine
9908386|NCT00681902|Placebo Comparator|2|Jet saline
9908387|NCT00681915|Experimental|1|
9908388|NCT00681928||Breast Cancer patients receiving aromatase treatment|
9908389|NCT00681928||Healthy female controls age 60 and older|
9908390|NCT00681941|Experimental|1|Sevelamer Carbonate Tablets Dosed Three Times A Day
9908391|NCT00681954||1, 2, 3|
9908392|NCT00681967|Experimental|Cohort 1|post operative combination of gefinib and RT
9908393|NCT00681967|Experimental|Cohort 2|combination of gefitinib with RT and Chemotherapy in non operated patients
9908394|NCT00681980|Experimental|A, 2, III|Patients with side effects to corticosteroids
9908395|NCT00681980|Experimental|B|patient with corticosteroids
9908396|NCT00681980|Experimental|3|Valproic acid and corticosteroids
9908397|NCT00681993|Active Comparator|Standard ddAC chemotherapy with concurrent radiation therapy|Standard dose-dense Adriamycin and Cyclophosphamide (ddAC) chemotherapy and concurrent radiation therapy (RT)
9908398|NCT00681993|Active Comparator|Standard AC chemotherapy with concurrent RT|Standard Adriamycin and Cyclophosphamide (AC) chemotherapy and concurrent radiation therapy
9908399|NCT00681993|Active Comparator|Standard TCarbo H chemotherapy with concurrent RT|Standard Taxotere, Carboplatin and Herceptin (TCarbo H) chemotherapy and concurrent radiation therapy
9908400|NCT00681993|Active Comparator|Standard TAC chemotherapy with concurrent RT|Standard Taxotere, Adriamycin and Cyclophosphamide (TAC) chemotherapy with concurrent radiation therapy
9908401|NCT00681993|Active Comparator|Standard TC chemotherapy with concurrent RT|Standard Taxotere and Cyclophosphamide (TC) chemotherapy with concurrent radiation therapy
9908402|NCT00682006|Experimental|A|In this arm we recruited 2,400 subjects who received Intervention.
9908403|NCT00682006|Experimental|B|In this Arm, we recruited 2,400 subjects who received intervention.
9908404|NCT00682006|Experimental|C|In this Arm, we recruited 2,400 subjects who received intervention.
9908405|NCT00682006|No Intervention|D|In this Arm, we recruited 2,400 subjects for Observation and comparison. This was the prime control group.
9908406|NCT00682019|Experimental|Arm 1|
9908407|NCT00682019|Placebo Comparator|Arm 2|
9908408|NCT00682032|Experimental|AIM 2: subjects with suspected or definitive NSCLC diagnosis|1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
9908409|NCT00682032|Experimental|AIM 3: subjects with resectable NSCLC|1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
9908410|NCT00682045||T-SPOT.TB positive|T-SPOT.TB positive patients
9908411|NCT00682058||LABS patients|Bariatric surgery patients with 35>BMI kg/m2<60 prior to surgery will undergo follow-up post-bariatric surgery.
9908412|NCT00682071||1|transabdominal ultrasound (TAS) guided embryo transfer
9908413|NCT00682071||2|transvaginal ultrasound (TVS) guided embryo transfer
9908414|NCT00682084||1|Patients recently diagnosed with Cushing's syndrome
9908415|NCT00682097|Experimental|1|
9908416|NCT00682097|Experimental|2|
9908417|NCT00682097|Experimental|3|
9908418|NCT00682097|Experimental|4|
9908419|NCT00682097|Experimental|5|
9908420|NCT00682097|Experimental|6|
9908421|NCT00682097|Experimental|7|
9908422|NCT00682136|Active Comparator|1|Open Laparotomy Arm: All patients enrolled in the study who are undergoing elective open laparotomy surgery.
9908423|NCT00682136|Active Comparator|2|Laparoscopic Arm: All patients enrolled in the study who are undergoing elective laparoscopic abdominal surgery.
9908424|NCT00682149|Placebo Comparator|Group 1|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
9908425|NCT00682149|Active Comparator|Group 2|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
9908426|NCT00682162|Sham Comparator|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
9908427|NCT00682162|Active Comparator|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
9908428|NCT00682175||Observation|Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.
9908429|NCT00682188|Experimental|CI|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
9908430|NCT00682188|Active Comparator|II|Six individual sessions with the school nurse over 2 months to check weight and behavior changes and provide a series of six pamphlets on weight and weight management
9908431|NCT00682201||1|Healthy pregnant women
9908432|NCT00682214|Active Comparator|A, Choelcalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
9908433|NCT00682214|Placebo Comparator|B, Lactose|
9908434|NCT00682227|Experimental|1|
9908435|NCT00682240|Active Comparator|group 3|"Group 3: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation.~Intervention: All patients will receive a multi-session panretinal laser treatment according to the conventional protocol, using a conventional laser system."
9908436|NCT00682240|Active Comparator|group 2|"Group 2: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group 2.~Intervention: This group will receive multi-session panretinal laser treatment. The treatment will be performed using Pascal laser system."
9908437|NCT00682240|Active Comparator|group 1|"Group 1: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group1.~Intervention: One group will receive a single-session panretinal laser treatment, performed using Pascal laser system."
9908438|NCT00682240|Active Comparator|group 4|"Group 4: 20 patients with persistent central or para-central diabetic macular edema receiving focal or grid laser treatment. As the treatment will be performed according to the conventional protocol (single spot), only the Pascal laser system will be used.~Intervention: focal or grid laser treatment"
9908439|NCT00682266|Experimental|Aerobic interval training|intensity-controlled interval training
9908440|NCT00682266|Experimental|MTG|multidisciplinary approach
9908441|NCT00682279|No Intervention|This is a single-arm, dose escalation|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
9908442|NCT00682292|Active Comparator|1, ATG|Thymoglobulin induction during 8 days (1.25 mg/kg per day) associated with tacrolimus, mycophenolate mofetil and steroids
9908443|NCT00682292|Active Comparator|2, Daclizumab|Dacluzamb induction (five infusions, 1 mg/kg per infusion) associated with tacrolimus, mycophenolate mofetil and steroids
9908444|NCT00682305|Other|Single-Arm|Single-Arm
9908445|NCT00682370|Experimental|A1|0.3 mg/kg heme arginate
9908446|NCT00682370|Experimental|A2|1 mg/kg heme arginate
9908447|NCT00682370|Experimental|A3|3 mg/kg heme arginate
9908448|NCT00682370|Placebo Comparator|P|Placebo
9994051|NCT01477645||Leaded ammunition|
9994052|NCT01477645||Non-leaded ammunition|
9994053|NCT01477645||Modified non-leaded ammunition|
9994054|NCT01477658||Congenital AV Block|Patients diagnosed with Congenital Complete Atrioventricular Heart Block
9994055|NCT01477658||Postoperative AV Block|Patients diagnosed with postoperative AV block
9994056|NCT01477671||Study Group|Participants aged between 5 and 10 year-old on day of inclusion.
9994057|NCT01477697|Active Comparator|Omega-3|50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
9994058|NCT01477697|Placebo Comparator|Placebo|50 mg/kg per day of vehicle
9994059|NCT01477723|Experimental|Experimental Oral Nutrition Supplement|Experimental ONS orally Two 8 fl oz servings/day
9994060|NCT01477723|No Intervention|No Product|
9994061|NCT01477736|Active Comparator|Botulinum toxin A|
9994062|NCT01477736|Active Comparator|oxybutynin|
9994063|NCT01477775|Active Comparator|Standard of Care|The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.
9994064|NCT01477775|Experimental|Customized choice of the oral P2Y12 receptor blocker|The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.
9994065|NCT01477788||women, sonographic ovarian mass|women that will arrive to the sonographic unit of the gynecological department with the sonographic diagnosis of ovarian mass
9994066|NCT01477801|Experimental|CHOLECALCIFEROL|
9994067|NCT01477801|Placebo Comparator|PLACEBO|
9994068|NCT01477814|Active Comparator|physician chart reminder|either a paper or an electronic reminder placed on the subject's medical record to remind the physician to screen for colorectal cancer
9994069|NCT01477814|Active Comparator|chart reminder, educational mat'ls, FIT|physician chart reminder plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test
9994070|NCT01477814|Active Comparator|CR, ed mat'ls, FIT, phone call|physician chart reminder (CR) plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test, and a motivational telephone call designed to elicit barriers and preferences and motivate individuals to complete a CRC screening test.
9994071|NCT01477827||Healthy volunteers|Healthy adolescents aged 12-15 years
9994072|NCT01477840|Experimental|Misoprostol|
9908449|NCT00682383|Other|ARM 1|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
9933822|NCT05199051|Experimental|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|"For Gemtuzumab ozogamicine administrated during the induction phase at D1, D4 and D7, 3mg/m2/day (5mg max), IV, 2h of infusion.~For Cytarabine during induction and consolidation phase at D1 to D5, 1000 mg/m2, IV, 2h of infusion.~For Gilteritinib during induction phase from D10 for 14 consecutive days, per os, two doses level study with dose level 1 (80mg/d) in part 1 or dose level 2 (80 or 120mg/d depending of the result of part 1) in part 2.~During consolidation (2 cycles max) from D8 for 14 consecutive days, per os, 120mg/d or reduced dose of 80 mg/kg is planned to be used in patients receiving concomitantly CYP3A4 inhibitors.~During the maintenance (24 months max) dose level 2 (120mg/d), per os."
9933823|NCT05194969|Active Comparator|Wet-to-dry Dressings|Participants in this arm will receive standard of care wet-to-dry dressings.
9933824|NCT05194969|Experimental|Petrolatum with Non-Stick Gauze|Participants in this arm will receive petrolatum with non-stick gauze.
9933825|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, 12 to < 18 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
9933826|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, 12 to < 18 years|Day 1: placebo, Day 22 and 43: SCB-2019
9933827|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, 12 to < 18 years|Day 1 and 43: SCB-2019, Day 22: placebo
9933828|NCT05193279|Experimental|Low dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
9933829|NCT05193279|Experimental|Mid dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
9933830|NCT05193279|Experimental|High dose SCB-2019, 5 to < 12 years|Day 1 and 22: SCB-2019
9933831|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, 5 to < 12 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
9933832|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, 5 to < 12 years|Day 1: placebo, Day 22 and 43: SCB-2019
9933833|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, 5 to < 12 years|Day 1 and 43: SCB-2019, Day 22: placebo
9933834|NCT05193279|Experimental|Low dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
9933835|NCT05193279|Experimental|Mid dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
9933836|NCT05193279|Experimental|High dose SCB-2019, 2 to < 5 years|Day 1 and 22: SCB-2019
9933837|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, 2 to < 5 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
9933838|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, 2 to < 5 years|Day 1: placebo, Day 22 and 43: SCB-2019
9933839|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, 2 to < 5 years|Day 1 and 43: SCB-2019, Day 22: placebo
9933840|NCT05193279|Experimental|Low dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
9933841|NCT05193279|Experimental|Mid dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
9933842|NCT05193279|Experimental|High dose SCB-2019, birth to < 2 years|Day 1 and 22: SCB-2019
9994073|NCT01477866|Experimental|citogenex|citogenex + conventional therapy
9933843|NCT05193279|Experimental|SCB-2019/SCB-2019/placebo, birth to < 2 yrs|Day 1 and 22: SCB-2019, Day 43: placebo
9933844|NCT05193279|Experimental|Placebo/SCB-2019/SCB-2019, birth to < 2 years|Day 1: placebo, Day 22 and 43: SCB-2019
9933845|NCT05193279|Experimental|SCB-2019/placebo/SCB-2019, birth to < 2 years|Day 1 and 43: SCB-2019, Day 22: placebo
9933846|NCT05192889|Experimental|Block 1|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Vincristine, Pegaspargase, Erwinia asparaginase, Calaspargase Pegol, Dasatinib, Leucovorin, Intrathecal (IT) MHA (methotrexate/hydrocortisone/cytarabine)"
9933847|NCT05192889|Experimental|Block 2|"Block 2a Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Navitoclax, Dexamethasone, Cytarabine, Pegaspargase, Erwinia asparaginase, Calaspargase Pegol, Dasatinib, IT MHA, Radiation~Block 2b Therapy:~Patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Blinatumomab, Dexamethasone, Dasatinib, IT MHA~Following Block 2 of therapy, late (≥36 months from diagnosis) first relapse B-ALL who are MRD negative after Block 1 will continue chemotherapy using adapted R3 intensification, interim, and continuation therapies.~Patients receive intervention according to the Detailed Description section with the following:~Methotrexate, Mercaptopurine, IT MHA, Leucovorin, Dexamethasone, Vincristine, Cyclophosphamide, Etoposide, Cytarabine, Dasatinib, Pegaspargase, Erwinia asparaginase, Calaspargase Pegol, Radiation"
9994074|NCT01477866|Active Comparator|conventional therapy|conventional therapy
9994075|NCT01477879|Active Comparator|Versabase/20% S. purpurea extract|
9994076|NCT01477879|Placebo Comparator|placebo (versabase gel only)|placebo used will be versabase gel alone
9994077|NCT01477905|Experimental|Remi50 no prime|For using experimental target control infusion device (TCIs), targeting an effect-site concentration (Ceff) of 4.0 ng/ml, were randomly performed using 50 μg/ml (Remi50) of remifentanil, and without PRIMING,
9994078|NCT01477905|Experimental|Remi20 no prmie|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and without PRIMING
9994079|NCT01477931|Experimental|Wellbutrin XL|
9994080|NCT01477957|Experimental|Surgery|bariatric surgery
9994081|NCT01477983|Active Comparator|ATP guide additional ablation - AAD|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: AAD for 90 days
9994082|NCT01477983|Active Comparator|Control - AAD|UNDER-ATP trial: Control, EAST-AF trial: AAD for 90 days
9994083|NCT01477983|Active Comparator|ATP guide additinal ablation - Control|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: Control
9994084|NCT01477983|Active Comparator|Control - Control|UNDER-ATP trial: Control, EAST-AF trial: Control
9994085|NCT01477996|Active Comparator|Group 1|27-gauge needle
9994086|NCT01477996|Active Comparator|Group 2|30-gauge needle
9994087|NCT01478022|Active Comparator|Isosorbide Dinitrate 20 mg|Isosorbide Dinitrate 10 mg b.i.d
9994088|NCT01478022|Active Comparator|Ibuprofen 200 mg|Ibuprofen 200 mg daily, capsule
9994089|NCT01478022|Experimental|Isosorbide dinitrate and Ibuprofen|Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily
9994090|NCT01478035|Experimental|phenytoin prophylaxis|Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
9994091|NCT01478035|Placebo Comparator|placebo|placebo vials and pills labeled as phenytoin prophylaxis vials and pills
9994092|NCT01478061|Active Comparator|anastomoses in blood vessels and grafts|
9994093|NCT01478074|Experimental|FLAG + NK Cells + ALT-801|
9994094|NCT01478126|Experimental|Glutamine|Intravenous glutamine infusion perioperatively and 24 hours after surgery
9994095|NCT01478126|Placebo Comparator|Placebo|
9994096|NCT01478139|Experimental|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
9994097|NCT01478139|Experimental|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
9994098|NCT01478152|Experimental|Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
9994099|NCT01478165|Placebo Comparator|Tiva group (Group T)|
9994100|NCT01478165|Active Comparator|TIVA plus palonosetron group (Group T+P)|
9994101|NCT01478230|Experimental|N1/3-I5|5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
9994102|NCT01478230|Active Comparator|NX-I10|10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
9994103|NCT01478269||Cases of aggressive B-cell lymphoma|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
9994104|NCT01478282|Active Comparator|Rivaroxaban|Healthy donors subjected to 20mg/day for 5 days
9994105|NCT01478282|Active Comparator|Dabigatran|Healthy volunteers subjected to 150 mg/12hours for 5 days
9994106|NCT01478295|Experimental|CuidaCare Intervention|Regular care in consultation or home and Structured nursing care (CuidaCare intervention): improved strategies for coping, health education on self-care and dependent care and emotional support. 10 visits are structured, with a periodicity of approximately 2 visits per month and last for 30 to 40 minutes each
9994107|NCT01478295|Active Comparator|Control Group/Usual Care|Usual care in consultation or home, which is to respond to the specific demands of care of the caregiver, using the resources of the nursing discipline.
9994108|NCT01478334|Experimental|Exercise then control|
9994109|NCT01478334|Experimental|Control then exercise|
9994110|NCT01478386|Other|Viscosupplementation injections|Control group will receive a series of three viscosupplementation injections into the affected knee
9908450|NCT00682409|Other|1|Analysis of the value of the imaging of distribution and the late sequence to differentiate the cholesteatoma of the fibrosis in the follow-up operating post at the child
9908451|NCT00682422||Parent & Child Dyad|
9908452|NCT00682474|Experimental|CI|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
9908453|NCT00682474|Active Comparator|II|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
9908454|NCT00682487||1|patients admitted to the cardiology department with acute Myocardial infarction.
9908455|NCT00682487||2|patients admitted to an internal medicine department due to reasons other than an acute thrombotic event
9908456|NCT00682500|Experimental|1|Calfactant treatment
9908457|NCT00682500|Placebo Comparator|2|
9908458|NCT00682513||ATP1A3 Mutation|Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members
9908459|NCT00682526||Pre-study Period (Group 1 and Group 2).|"The TIME-MC study was conducted from June 2003 to June 2008 at NEMC (Figure 1) and from May 2005 to September 2008 at the six larger medical centers (Figure 2). Two groups were studied. Group 1 included patients at NEMC and Group 2 included patients at the other six medical sites. The study was divided into three periods:~Pre-study period (Group 1 and Group 2). No PH-ECG transmission system was available."
9908460|NCT00682526||Study Period (Group 1 and Group 2)|Study period (Group 1 and Group 2). PH-ECG transmission to a cardiologist's hand-held device was attempted through pre-assigned EMS ambulances equipped with a wireless ECG transmission device in addition to a STEMI code system. In Group 1, this referred to the pilot study at NEMC from June 2003 to May 2005.
9908461|NCT00682526||Post-study period (Group 1)|Post-study period (Group 1). PH-ECG transmission and a STEMI code system implemented after the pilot study period.
9908462|NCT00682552|Experimental|1|"A cervico-vaginal cervical smear will be realized before every colposcopique examination.~A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized."
9908463|NCT00682578|Experimental|Artekin|Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
9908464|NCT00682578|Active Comparator|Standard treatment|"The standard treatment for uncomplicated falciparum and vivax malaria are as follows:~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine"
9908465|NCT00682630|Experimental|Study Group 1|Study Period 1: Treatment A (clinical trial reference tablets) 43 Days wash out Study Period 2: Treatment B (to-be-marketed tablets) 43 Days follow-up
9908466|NCT00682630|Experimental|Study Group 2|Study Period 1: Treatment B (to-be-marketed tablets) 43 Days wash out Study Period 2: Treatment A (clinical trial reference tablets). 43 Days follow-up
9908467|NCT00682656|Active Comparator|A - N- methyl glucamine|Glucantime® , max day of 1,215 mg
9908468|NCT00682656|Experimental|B - Azithromycin|Zithromax ® , one dose 500 mg
9908469|NCT00682669|Experimental|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
9908470|NCT00682669|Active Comparator|HLC|A Healthy Living Course (HLC) consisting of an 8-week program of lectures and discussion on health-related topics.
9908471|NCT00682682|Experimental|1|all study participants will have 4 visits: VR alone, VR + opioid, opioid alone, and no VR/opioid
9908472|NCT00682721|Active Comparator|2|Valacyclovir 1 gm daily x number of days active in the study
9908473|NCT00682721|Placebo Comparator|1|
9908474|NCT00682747|Experimental|HBO|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)
9908475|NCT00682747|No Intervention|non HBO|
9994111|NCT01478386|Experimental|Off-loading knee brace|
9908476|NCT00682760|Active Comparator|1|Korean botulinum toxin A treatment
9908477|NCT00682760|Placebo Comparator|2|Botox treatment
9908478|NCT00682773|No Intervention|1|Usual care, no educational intervention.
9908479|NCT00682773|Experimental|2|Usual care, nursing home nursing staff receive educational intervention on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
9908480|NCT00682812|Active Comparator|1|125 womens with normal cervix
9908481|NCT00682812|Other|2|105 womens with an intraepithelial lesion
9908482|NCT00682812|Other|3|105 womens with a cancer of the cervix
9908483|NCT00682825|Experimental|1|Bispectral index-guided protocol
9908484|NCT00682825|Active Comparator|2|End-tidal anesthetic gas-guided protocol
9908485|NCT00682877||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
9908486|NCT00682877||Gastroparesis|Subjects with documented gastroparesis
9908487|NCT00682903|Experimental|1|This arm will benefit from the nonstop measure of the subcutaneous glucose during the hospitalization and the week on returning to the place of residence,
9933848|NCT05192408|Experimental|Multi-component intervention|"Individual intervention will comprise:~Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone.~Initial sessions will last around 30 minutes and subsequent sessions will last 15 to 30 minutes."
9994112|NCT01478386|Experimental|Viscosupplementation and knee brace|
9798561|NCT01632579|Placebo Comparator|Placebo|Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.
9798562|NCT01632579|Experimental|LY3023703|Up to 6 single escalating doses of LY3023703 [0.1 milligram (mg) up to 60 mg] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.
9798563|NCT01632579|Active Comparator|400 mg Celecoxib|Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.
9798564|NCT01632683|Active Comparator|C-MAC|Providers will utilize the C-MAC video laryngoscope equipped with a D-blade to facilitate intubation
9798565|NCT01632683|Active Comparator|Glidescope|Providers will utilize the Glidescope video laryngoscope equipped with the #4 blade to facilitate intubation
9798566|NCT01632709|Active Comparator|Sympathetic nerve block of bupivacaine|Sympathetic nerve block of bupivacaine
9798567|NCT01632709|Placebo Comparator|Dry needling at the sympathetic ganglion|Placebo/ Dry needling at the sympathetic ganglion
9798568|NCT01632709|Active Comparator|Neuroma injection of bupivacaine|Neuroma injection of bupivacaine
9798569|NCT01632709|Placebo Comparator|dry needling at the neuroma|Placebo/ dry needling at the neuroma
9798570|NCT01632735|Experimental|Mobile Continuing Care|Behavioral: 12-week Structured Texting intervention focused on recovery monitoring, feedback for self-management, social support and education
9798571|NCT01632735|No Intervention|Standard Continuing Care as Usual|Continuing care as usual to 12-step facilitation (Anonymous group)
9798572|NCT01632800|Experimental|Single arm study|Each subjects will undergo escalating exposure to magnetic field
9798573|NCT01632891|Experimental|LPV/r-based ART|Participants were prescribed to LPV/r-based antiretroviral therapy (ART) for 15 days, which includes lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate; followed by an nNRTI-based ART, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
9798574|NCT01632891|Experimental|nNRTI-based ART|Participants were prescribed to nNRTI-based ART for 15 days, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, followed by an nNRTI-based ART and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
9798575|NCT01632904|Experimental|ruxolitinib and hydroxyurea (HU)-placebo|
9798576|NCT01632904|Active Comparator|HU and ruxolitinib-placebo|
9798577|NCT01632995|Experimental|Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
9798578|NCT01633060|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
9798579|NCT01633060|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
9798580|NCT01633112|Experimental|fingolimod 0.5 mg|orally once daily
9798581|NCT01633112|Experimental|fingolimod 0.25mg|orally once daily
9798582|NCT01633112|Active Comparator|glatiramer acetate 20 mg|subcutaneous once daily
9798583|NCT01633788|Experimental|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
9798584|NCT01633788|Experimental|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
9798585|NCT01633788|Experimental|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
9798586|NCT01633788|Placebo Comparator|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
9798587|NCT01633827|Placebo Comparator|Placebo|Subjects will receive both a sugar pill and room air during their overnight sleep studies
9798588|NCT01633827|Active Comparator|Treatment|Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies
9798589|NCT01633853|Experimental|Vitamin D2 Treatment|Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
9798590|NCT01633853|Active Comparator|1,25(OH)2 Vitamin D3|Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
9798591|NCT01633892|Experimental|Fat Grafting|
9798592|NCT01633944|Placebo Comparator|Placebo|Twice Daily Dosing
9798593|NCT01633944|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
9994113|NCT01478399|Experimental|Impaired Renal Function|Subjects have impaired renal function matched to subjects with normal renal function by age and weight.
9994114|NCT01478399|Experimental|Normal Renal Function|Subjects have normal renal function matched to subjects with impaired renal function by age and weight.
9994115|NCT01478412||Males with prostate adenocarcinoma|English speaking males with histologically confirmed prostate adenocarcinoma and diagnosis of low risk or intermediate risk prostate cancer.
9994116|NCT01478425|Experimental|Active|Lipidic Microemulsion
9994117|NCT01478425|Placebo Comparator|Control|Saline nose-spray device
9994118|NCT01478438|Experimental|Treat and Excise|All subjects will be treated with Interstitial Laser Therapy (ILT) followed by excision no later than 28 days post ablation.
9994119|NCT01478451|Experimental|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
9994120|NCT01478451|Experimental|Exercise|exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized)
9994121|NCT01478451|No Intervention|Control|control shoulder (randomized)
9994122|NCT01478464|No Intervention|Control group|Control group, does not receive any intervention
9994123|NCT01478464|Experimental|Massage group|Massage will be performed on the left or right hamstring muscle (randomized) for ten minutes with a massage roller. The contralateral leg will not be massaged, but serve as a non-massaged control leg to assess possible cross-over effects from the massaged leg
9994124|NCT01478477|Experimental|Arm I (omega-3 fatty acid supplement)|Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)
9994125|NCT01478477|Placebo Comparator|Arm II (placebo)|Typical American Diet oils (TAD)
9994126|NCT01478477|Experimental|Clinical Assessments|Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)
9994127|NCT01478477|Experimental|Assessment of therapy complications|Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.
9994128|NCT01478477|Experimental|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained
9994129|NCT01478477|Experimental|Correlative/special studies|Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.
9994130|NCT01478490|Experimental|Treatment Arm 1A|mirabegron, poor metabolizers
9994131|NCT01478490|Experimental|Treatment Arm 1B|mirabegron, extensive metabolizers
9994132|NCT01478490|Experimental|Treatment Arm 2|mirabegron/metoprolol
9994133|NCT01478503|Experimental|Treatment Arm A|mirabegron
9994134|NCT01478503|Placebo Comparator|Treatment Arm B|matching placebo
9994135|NCT01478516|Experimental|Plasmin|eyes with macular edema
9994136|NCT01478529|Experimental|Treatment Arm A|low dose of mirabegron
9994137|NCT01478529|Experimental|Treatment Arm B|high dose of mirabegron
9994138|NCT01478568|Experimental|mirabegron / desipramine|
9994139|NCT01478607|Experimental|1. Qutenza 30 minutes + SOC|
9994140|NCT01478607|Experimental|2. Qutenza 60 minutes + SOC|
9994141|NCT01478607|No Intervention|3. SOC|Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.
9994142|NCT01478633|Experimental|Galantamine|
9994143|NCT01478646|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
9994144|NCT01478646|Experimental|Reflectory breathing therapy|first: reflectory breathing therapy second: conventional breathing therapy
9994145|NCT01478659|Active Comparator|Control bar and yogurt|
9994146|NCT01478659|Experimental|Fiber bar and yogurt|
9994147|NCT01478672|No Intervention|Standard care|
9994148|NCT01478672|Experimental|Health coaching and and Life-long Monitoring|
9994149|NCT01478685|Experimental|Arm A: CC-486 plus Carboplatin|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability. Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
9908488|NCT00682916|Active Comparator|1|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
9908489|NCT00682916|Placebo Comparator|2|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
9908490|NCT00682955|Active Comparator|B|This group has been given Zinc Sulphate in Suspension Form.
9908491|NCT00682955|Active Comparator|A|This group has been given Tablets of Zinc Sulphate.
9908492|NCT00682994|Other|Decision Making|Questionnaire + Interview
9908493|NCT00683007|Active Comparator|1|Crystalloid
9908494|NCT00683007|Active Comparator|2|Hypertonic Saline
9908495|NCT00683033|Active Comparator|A|Brief counseling based on public health service guidelines.
9908496|NCT00683033|Experimental|B|Brief counseling based on public health service guidelines for quitting smoking plus prize-based contingency management
9908497|NCT00683059|Experimental|Nab-paclitaxel|
9908498|NCT00683072||1|
9908499|NCT00683098||1|patients, who had a endoscopic total extraperitoneal repair of recurrent inguinal hernia between 1995 and 2008
9908500|NCT00683111|Active Comparator|1|oral esomeprazole 20 mg daily
9908501|NCT00683111|Active Comparator|2|oral famotidine 40mg daily
9908502|NCT00683124|Experimental|Losartan|Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
9908503|NCT00683124|Experimental|Nebivolol|Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.
9908504|NCT00683124|Experimental|Losartan+Nebivolol|"Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.~Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years."
9908505|NCT00683137|Active Comparator|Arm 1|
9908506|NCT00683137|Active Comparator|Arm 2|
9908507|NCT00683137|Active Comparator|Arm 3|
9908508|NCT00683150||Endothelial Function Test|Patients scheduled to have major abdominal or thoracic surgery.
9908509|NCT00683176|Active Comparator|1|
9908510|NCT00683176|Placebo Comparator|2|
9908511|NCT00683202|Active Comparator|1|Acetylsalicylic acid 100 mg daily perorally
9908512|NCT00683202|Placebo Comparator|2|Placebo daily perorally
9908513|NCT00683228|Other|Counseling|some caregivers will be provided counseling related to the hazards of secondhand smoke exposure
9908514|NCT00683241|Experimental|1|Subjects with stage II to IV recurrent epithelial ovarian carcinoma or recurrent primary peritoneal cancer, from whom solid tumor, ascites or pleural effusion will be harvested and available and sufficient for lysate preparation; and whose largest tumor nodule is ≤ 2.5 cm. Subjects may have undergone chemotherapy or other therapy following tumor harvesting and prior to enrollment (apheresis).
9908515|NCT00683267|Experimental|1|Study treatment, 4975, is instilled directly into surgical site
9908516|NCT00683267|Placebo Comparator|2|Placebo is instilled directly into surgical site
9908517|NCT00683280|Active Comparator|Standard of Care|Medication (varenicline) for 12 weeks (Day 1 through 84) and brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35).
9908518|NCT00683280|Experimental|Standard of Care plus Contingency Management|Medication (varenicline) for 12 weeks (Day 1 through 84), brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35), plus prize-based contingency management for carbon monoxide samples and urinary cotinine samples that meet smoking abstinence criteria.
9908519|NCT00683345|Active Comparator|Anakinra|Anakinra self-administered s.c. in a dose of 100mg daily
9908520|NCT00683345|Placebo Comparator|Placebo|Placebo self-adminsitered s.c in a dose 0.67ml daily
9908521|NCT00683358|Experimental|1|
9908522|NCT00683371|Active Comparator|1|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery
9908523|NCT00683371|Placebo Comparator|2|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery.
9908524|NCT00683397||A|Patients with acute or previous venous thromboembolism >18 years of age
9908525|NCT00683436|Experimental|1|adipiplon 6 mg
9908526|NCT00683436|Experimental|2|adipiplon 9 mg
9908527|NCT00683436|Placebo Comparator|3|Placebo
9908528|NCT00683436|Experimental|4|Ambien CR 12.5 mg
9908529|NCT00683462|Placebo Comparator|1|
9908530|NCT00683462|Experimental|2|
9908531|NCT00683462|Experimental|3|
9908532|NCT00683488|Experimental|1|Focus groups with adolescents with SA (Substance Abuse) will be conducted at each site (one group with 5 to 6 adolescents per site) to provide information on the areas of the intervention in need of adaptation in order to reflect the context of HIV infection.
9908533|NCT00683488|Experimental|2|The first intervention trial will enroll 9 participants (3 participants per site). Exit interviews of participants will assess acceptability, feasibility, and relevance of the intervention. Quantitative assessments pre and post intervention using audio computer-assisted self-interviewing (ACASI) will document immediate changes in substance use, sexual risk, and adherence to medical care. Additional qualitative feedback from interviews with mental health providers and study coordinators will address feasibility, acceptability, and relevance of the intervention and its methods.
9908534|NCT00683488|Experimental|3|The revised intervention will be implemented with 20 participants (6 to 8 at each site). Exit interviews with subjects and feedback from mental health providers and study coordinators will provide the same qualitative information as in the first intervention trial. Quantitative data on participant outcomes such as substance use, sexual risk, and adherence to medical care will be collected pre, post and 3 month post intervention through ACASI.
9908535|NCT00683501|Experimental|1|dosage X mg BID
9908536|NCT00683501|Experimental|2|dosage Y mg BID
9908537|NCT00683501|Experimental|3|dosage Z mg BID
9908538|NCT00683501|Experimental|4|dosage 2Z mg BID
9908539|NCT00683501|Placebo Comparator|5|Placebo BID
9908540|NCT00683514|Other|A|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~cycle 3 & 4 (q 21 days) = chemotherapy : oral vinorelbine (60 mg/m2 d1, d8 for cycle 1, 80 mg/m2 d1 & d8 for cycle 2) and cisplatin (80 mg/m2 d1) plus Best Supportive Care"
9908541|NCT00683514|Other|B|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~Best Supportive Care only"
9908542|NCT00683527|Experimental|1|Starting oral iron at day 14 of life (Early Iron group)
9908543|NCT00683527|No Intervention|2|No iron supplementation till 60 days of life (Control group)
9908544|NCT00683553|Experimental|I5NP drug|
9908545|NCT00683553|Placebo Comparator|Placebo|
9908546|NCT00683566|Experimental|1|A session in condition ON DOPAMINE and the other one in condition OFF DOPAMINE.
9908547|NCT00683579||1|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are initiating HAART with possibility of de-intensification (early treatment).
9908548|NCT00683579||2|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are not initiating treatment.
9908549|NCT00683579||3|Participants with CD4+ T cells < 350 cells/mm3 who are initiating treatment.
9908550|NCT00683579||4|Participants with CD4+ T cells < 350 cells/mm3 who are not initiating treatment.
9908551|NCT00683670|Experimental|Dendritic Cell Vaccine (First Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
9908552|NCT00683670|Experimental|Dendritic Cell Vaccine (Second Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
9908553|NCT00683670|Experimental|Dendritic Cell Vaccine (Third Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 6 weeks for a total of 3 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 in order to collect PBMC for immune monitoring.
9908554|NCT00683683|Other|Cooling|Cardiac arrest patients will be cooled to 32-34°C within 6 hours of ED arrival
9908555|NCT00683709||Counselling as Usual|Discussing Clozapine medication, diet and exercise as per clinical protocol potential weight changes
9908556|NCT00683709||Cognitive Behavoural Therapy|Counselling about Clozapine medication, diet and exercise in a structured fashion using Cognitive Behavioural Therapy about potential weight changes
9908557|NCT00683735|Active Comparator|Treatment A|sitagliptin and placebo
9908558|NCT00683735|Active Comparator|Treatment B|placebo and metformin
9908559|NCT00683735|Active Comparator|Treatment C|sitagliptin and metformin
9908560|NCT00683735|Placebo Comparator|Treatment D|placebo
9908561|NCT00683748||Kidney transplant|
9908562|NCT00683748||Liver transplant|
9908563|NCT00683761|Experimental|1|
9908564|NCT00683813|No Intervention|UC|usual care
9908565|NCT00683813|Experimental|vCRP|
9908566|NCT00683839|Experimental|2|"Dental practitioners provide the following intervention:~5As plus nicotine replacement therapy The 5As consist of: Ask, Advise, Assess, Assist and Arrange."
9908567|NCT00683839|No Intervention|1|Usual Care Control: Patients receive treatment as usual.
9908568|NCT00683865|Active Comparator|Arm 1|
9908569|NCT00683865|Experimental|Arm 2|
9908570|NCT00683969|Experimental|1|
9908571|NCT00683969|Placebo Comparator|2|
9908572|NCT00683982|Active Comparator|1|This group will receive oral nitazoxanide preparation
9908573|NCT00683982|Active Comparator|2|This group will receive a mix combination of probiotics
9908574|NCT00683982|Placebo Comparator|3|This is the control group receiving only oral or systemic hydration solutions
9908575|NCT00683995|Experimental|1|KW-2246 (fentanyl citrate)
9908576|NCT00684008|Experimental|I|"Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.~CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.~CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.~CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml."
9908577|NCT00684034|Other|1|Volunteer healthy
9908578|NCT00684034|Other|2|Patient dialysis patient
9908579|NCT00684034|Other|3|Not dialysed chronic renal insufficient patient
9908580|NCT00684099|Experimental|1|
9908581|NCT00684112|Experimental|Gabapentin|Single dose preoperative gabapentin
9908582|NCT00684112|Placebo Comparator|Placebo Control|Single dose preoperative placebo control
9908583|NCT00684125|Experimental|1|mediastinal drainage will be accomplished using a 28F or 32F chest tube in the anterior mediastinum and a 19F Blake drain located in the posterior pericardial cavity.
9908584|NCT00684125|Active Comparator|2|mediastinal drainage will be accomplished using two 28F or 32F chest tubes located in the anterior mediastinum.
9908585|NCT00684151||1|Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months
9908586|NCT00684164|Experimental|1|Subjects in the treatment group will receive standard medical treatment plus Conivaptan administered as a 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
9908587|NCT00684164|Placebo Comparator|2|Subjects in the placebo control group will receive an equivalent volume loading dose of D5 followed by an infusion of D5 in the same manner as the experimental group.
9908588|NCT00684190|Experimental|1|AZD3355 150 mg
9908589|NCT00684190|Experimental|2|Esomeprazole 40mg
9908590|NCT00684190|Experimental|3|AZD3355 150mg/Esomeprazole 40mg
9908591|NCT00684216|Active Comparator|1|capecitabine followed by hormonal treatment
9908592|NCT00684216|Active Comparator|2|hormonal treatment followed by capecitabine
9908593|NCT00684229|Active Comparator|Regional anesthesia and analgesia|Regional anesthesia and analgesia (either epidural or paravertebral anesthesia).
9908594|NCT00684229|Active Comparator|general anesthesia followed by opioid analgesia|Subjects randomized to arm 2 will receive general anesthesia followed by opioid analgesia.
9908595|NCT00684268|Experimental|on treatment nonresponders|naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
9908596|NCT00684268|Experimental|Nonresponders to previous antiviral combination therapy|Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy
9908597|NCT00684281|Other|1|Subject control
9908598|NCT00684281|Experimental|2|40 patients before hand include in a program
9908599|NCT00684294|Experimental|TAG Vaccine 1 x 10^7 cells/ injection|TAG Vaccine 1 x 10^7 cells/injection
9908600|NCT00684294|Experimental|TAG Vaccine 2.5 X 10^7 cells/injection|TAG Vaccine 2.5 X 10^7 cells/injection
9908601|NCT00684333|Experimental|group 1|volunteers
9908602|NCT00684346|Experimental|1|
9908603|NCT00684437|Experimental|Factual Gain-Framed|Smoking Risk Message - Factual Gain-Framed (FGF)
9908604|NCT00684437|Experimental|Factual Loss-Framed|Smoking Risk Message - Factual Loss-Framed (FLF)
9908605|NCT00684437|Experimental|Emotional Gain-Framed|Smoking Risk Message - Emotional Gain-Framed (EGF)
9908606|NCT00684437|Experimental|Emotional Loss-Framed|Smoking Risk Message - Emotional Loss-Framed (ELF)
9908607|NCT00684450|Active Comparator|1|in vivo protamine titration in cardiac surgery. The titration is done during administration of protamine each 3 minutes to reach 2 consecutive ACT defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds. .The protamine is stopped when this values are obtain. Follow-up is done 15 minutes and 3 hours post-protamine
9908608|NCT00684450|Active Comparator|2|standard protamine administration ACT is done during administration of protamine each 3 minutes the values are recorded but the totality of protamine is given. Follow-up is done 15 minutes and 3 hours post-protamine
9933849|NCT05192408|Other|Usual Care|"Patient Education Materials (PEMs) on:~Exercise in older adults (Stay Active, Stay Strong and Stay Steady) - 3 different levels tailored to frailty level and for progression~Falls prevention~FoF"
9933850|NCT05190510||Patient with atheromatous stenosis of the internal carotid artery|
9933851|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K: 1e6 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K, and safety of dose will be determined.
9933852|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K+1:1e7 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+1, and safety of dose will be determined.
9933853|NCT05189925|Experimental|IV infusion of gp91-Grans at dose K+2: 1-5e8 cells/kg|Adult CGD patients without systemic infection will participate in a dose-escalation trial to identify the most effective yet safe dose of study agent. Subjects enrolled will receive 1 administration of study agent at dose K+2, and safety of dose will be determined.
9933854|NCT05189236|Other|Control Group (Only Algorithm of Febrile Neutropenia Management)|The algorithm of febril neutropenia management is used to treat children who are followed up at the paediatric oncology service, where the study will be conducted, due to febrile neutropenia. The control group will consist of children who have been treated using this algorithm (only the Algorithm of Febrile Neutropenia Management).
9933855|NCT05189236|Experimental|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|The experimental group will consist of the children who will be applied to cold steam in addition to this algorithm (Algorithm of Febrile Neutropenia Management + cold steam application).
9933856|NCT05185947|Experimental|1/ IP Catheter Placement and Bidirectional Chemotherapy|IP and IV paclitaxel administration with oral nilotinib
9994150|NCT01478685|Experimental|Arm B: CC-486 plus ABI-007|"CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability~ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2"
9994151|NCT01478685|Experimental|Arm C: CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
9908609|NCT00684463|Experimental|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent
9908610|NCT00684489|Active Comparator|A; B|
9908611|NCT00684489|Active Comparator|2|Arm A is assignment to a clinical hypertension specialist Arm B is assigned renin-guided therapeutics
9908612|NCT00684489|Active Comparator|A is clinical hypertension specialist|Arm A is assigned to a clinical hypertension specialist
9908613|NCT00684489|Active Comparator|Arm B is renin-guided therapeutics|This group will be assigned to renin-guided therapeutics
9908614|NCT00684502|Experimental|1|Oral solution.
9908615|NCT00684502|Placebo Comparator|2|Oral solution
9908616|NCT00684528|Active Comparator|a|This group will receive Metformin and placebo.
9908617|NCT00684528|Experimental|2|The second arm will receive Metformin and Januvia
9908618|NCT00684580||Observational Group|Data Collection
9908619|NCT00684606|Experimental|1|Transcervical Foley catheter with IV Oxytocin
9908620|NCT00684606|No Intervention|2|Transcervical Foley catheter only
9908621|NCT00684619|Experimental|Arm A|Nelarabine
9908622|NCT00684632|Experimental|1|KW-2246
9908623|NCT00684632|Placebo Comparator|2|Placebo
9908624|NCT00684658|Experimental|1|TeenCope: Internet-based Coping Skills Training
9908625|NCT00684658|Active Comparator|2|Managing Diabetes: Internet-based Diabetes Education
9908626|NCT00684684|Experimental|1|
9908627|NCT00684697|Placebo Comparator|1|low iron dose
9908628|NCT00684697|Active Comparator|2|intermediate iron dose
9908629|NCT00684697|Experimental|3|High Iron dose
9908630|NCT00684710|Experimental|PAZ-417|
9908631|NCT00684710|Placebo Comparator|Placebo|
9908632|NCT00684801||Usual care (control group)|Patients undergo usual care as determined by core cancer team.
9908633|NCT00684801||DMP (experimental group)|Patients undergo a systematic approach regarding specific domains related to their disease focusing on supportive care and symptom management determined by a multidisciplinary team of providers to help patients and caregivers manage.
9994152|NCT01478698|Experimental|Single dose|The first 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled into a dialysate bag and infused for a 4 hour intraperitoneal dwell.
9798596|NCT01634100|Experimental|A (Reference)|Empagliflozin (BI 10773), Film-coated tablet, single dose
9798597|NCT01634100|Experimental|B (Test 1)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Rifampicin,Film-coated tablet single dose
9798598|NCT01634100|Experimental|C (Test 2)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Probenecid Tablet twice daily
9798599|NCT01634113|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler
9798600|NCT01634113|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler
9798601|NCT01634113|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler
9798602|NCT01634139|Experimental|Tiotropium high dose QD|
9798603|NCT01634139|Experimental|Tiotropium low dose QD|
9798604|NCT01634139|Experimental|Placebo QD|
9798605|NCT01634152|Placebo Comparator|Placebo QD|
9798606|NCT01634152|Experimental|Tiotropium low dose QD|
9798607|NCT01634152|Experimental|Tiotropium medium dose QD|
9798608|NCT01634165|Experimental|0.3 U/kg LY2963016|Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
9798609|NCT01634165|Experimental|0.3 U/kg Lantus|Single 0.3 U/kg subcutaneous dose of Lantus
9798610|NCT01634165|Experimental|0.6 U/kg LY2963016|Single 0.6 U/kg subcutaneous dose of LY2963016
9798611|NCT01634165|Experimental|0.6 U/kg Lantus|Single 0.6 U/kg subcutaneous dose of Lantus
9798612|NCT01634178|Experimental|Sequence 1: Apremilast Fasted / Fed|In Period 1 participants will receive a single 30 mg apremilast tablet administered under fasted conditions and in Period 2 participants will receive a single 30 mg apremilast tablet administered after a high fat meal.
9798613|NCT01634178|Experimental|Sequence 2: Apremilast Fed / Fasted|In Period 1 participants will receive a single 30 mg apremilast tablet administered after a high fat meal and in Period 2 participants will receive a single 30 mg apremilast tablet administered under fasted conditions.
9908634|NCT00684827|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose"
9908635|NCT00684827|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose.
9908636|NCT00684853|Active Comparator|1|
9908637|NCT00684853|Active Comparator|2|
9994153|NCT01478698|Experimental|2 doses|The next 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled twice a day for one day
9994154|NCT01478698|Experimental|4 doses|The next 5 consented participants will be administered tPA 10mg + DNase 5mg twice a day for 2 days.
9994155|NCT01478698|No Intervention|control|Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.
9994156|NCT01478711|Active Comparator|Intervention|A clinical decision support tool for the care and management of premature infants will be embedded into the electronic health record.
9994157|NCT01478711|No Intervention|No Intervention|No intervention, No clinical decision support tool will be used for non-intervention sites.
9994158|NCT01478724|Placebo Comparator|Placebo|Animal proteins
9994159|NCT01478724|Experimental|Milk protein fraction dose 1|
9994160|NCT01478724|Experimental|Milk protein fraction dose 2|
9994161|NCT01478737|Sham Comparator|Sham|Vitrectomy only
9994162|NCT01478737|Active Comparator|Intravitreal Ozurdex|Intravitreal Ozurdex after vitrectomy
9994163|NCT01478750|Experimental|emulsified fat, orally|At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
9994164|NCT01478750|Experimental|intragastric administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
9994165|NCT01478750|Experimental|intraduodenal administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
9994166|NCT01478750|Experimental|intragastric, non-emulsified fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
9994167|NCT01478776|Active Comparator|diabetes, omega-3|patient with type 2 diabetes who receive 4gr/day omega-3
9994168|NCT01478776|Placebo Comparator|placebo, diabetes|patient with type 2 diabetes who receive 4 cap of placebo/day
9994169|NCT01478789|Experimental|Water dispersible Plant Sterol (WD-PS)|WD-PS dairy product (a novel formulation for dispersible free sterols in aqueous media produced)2g/d of free plant sterol
9994170|NCT01478789|Experimental|Esterified plant sterol (PS-Ester)|PS-Ester enriched dairy product (2g/d free plant sterol)
9994171|NCT01478789|Placebo Comparator|placebo|100 g/d yogurt with no added plant sterol
9994172|NCT01478802|Active Comparator|CMV Arm|Patients with moderate-to-severe Acute Respiratory Distress Syndrome treated solely with lung protective, low volume high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description section.
9997875|NCT01512706|Experimental|1280Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
9997876|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
9997877|NCT01512706|Experimental|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
9908638|NCT00684866|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (8 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (8 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects."
9908639|NCT00684866|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects.
9908640|NCT00684892|Experimental|1|
9908641|NCT00684931|Experimental|1|patients with Attention Deficit Disorder with or without Hyperactivity
9908642|NCT00684931|Sham Comparator|2|healthy volunteer without Attention Deficit Hyperactivity Disorder
9908643|NCT00684957|Active Comparator|1|Subject taking growth hormone
9908644|NCT00684957|Active Comparator|2|Subject taking recombinant human IGF-1
9908645|NCT00684970|Other|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118 (single arm)
9908646|NCT00685009||1|Women from the Women's Health Initiative study taking estrogen hormone therapy
9908647|NCT00685009||2|Women from the WHI study taking estrogen plus progesterone hormone therapy
9908648|NCT00685009||3|Women from the WHI study taking placebo
9908649|NCT00685022|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study."
9908650|NCT00685022|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study.
9908651|NCT00685048|Experimental|1|psychoeducation
9908652|NCT00685048|Experimental|2|brief advice
9908653|NCT00685048|Experimental|3|Motivational Enhancement Therapy (MET)/Cognitive-Behavioral Therapy (CBT)
9908654|NCT00685061|Experimental|A|Thymoglobulin Induction
9908655|NCT00685061|Experimental|B|Campath-1H Induction
9908656|NCT00685061|Experimental|C|Daclizumab Induction
9908657|NCT00685074|Experimental|Brief computer-delivered intervention for drug use|A single interactive computer intervention based primarily on Motivational Interviewing principles.
9908658|NCT00685074|Placebo Comparator|Time control for drug use|An series of innocuous and therapeutically inactive computer segments.
9997878|NCT01512706|Experimental|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
9997879|NCT01512706|Experimental|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
9908659|NCT00685126|Experimental|A|"Low dose levalbuterol (0.15 mg, 0.31 mg or 0.63 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
9908660|NCT00685126|Experimental|B|"High dose levalbuterol (0.31 mg, 0.63 mg or 1.25 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
9908661|NCT00685126|Active Comparator|C|"Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
9908662|NCT00685152|Experimental|Active rTMS|Repetitive Transcranial Magnetic Stimulation
9908663|NCT00685152|Sham Comparator|2|Device: Sham (placebo)
9908664|NCT00685191|Experimental|1|HIV-1-infected subjects initiating raltegravir-including salvage therapy
9908665|NCT00685204|Experimental|A|This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.
9908666|NCT00685217|Experimental|TVT Secur surgical device|Single incision tape device
9908667|NCT00685217|Active Comparator|TVT surgical device|Usual care retropubic tape device
9908668|NCT00685230|Experimental|1|Alacramyn and midazolam as needed
9908669|NCT00685230|Placebo Comparator|2|placebo and midazolam as needed
9908670|NCT00685243|Active Comparator|Fraxel|Fraxel laser treatment
9908671|NCT00685243|Active Comparator|PDL|Pulsed dye laser treatment
9908672|NCT00685269|Active Comparator|A|eszopiclone 3 mg QD
9908673|NCT00685269|Placebo Comparator|B|placebo tablet
9908674|NCT00685282|Other|COGNITIVE BEHAVIORAL INTERVENTIONS|PSYCHOLOGICAL INTERVENTIONS TO INCLUDE, RELAXATION, STRESS REDUCTION, GUIDED IMAGERY, BREATHING EXERCISES
9908675|NCT00685321|Experimental|1|deep TMS treatment
9908676|NCT00685321|Sham Comparator|2|inactive treatment
9997880|NCT01512706|Experimental|1280Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
9997881|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
9908677|NCT00685347|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
9908678|NCT00685347|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
9908679|NCT00685386|Experimental|I|
9908680|NCT00685386|Placebo Comparator|II|Room air will be used for insufflation as the placebo comparator arm.
9908681|NCT00685412|Experimental|0.6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
9908682|NCT00685412|Experimental|2mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
9908683|NCT00685412|Experimental|6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
9908684|NCT00685425|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
9908685|NCT00685425|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
9908686|NCT00685464|Active Comparator|2|Intravenous bolus Abciximab.
9908687|NCT00685464|Active Comparator|Abciximab|Intracoronary bolus abciximab.
9908688|NCT00685490||Surgical|Retrospective chart review of 70 eyes of 70 consecutive patients who underwent PPV, with and without ILM peeling, for persistent macular edema associated with BRVO
9908689|NCT00685529|Active Comparator|A|12 µg of racemic formoterol fumarate BID
9908690|NCT00685529|Experimental|B|15 µg of nebulized arformoterol tartrate inhalation solution BID
9908691|NCT00685529|Active Comparator|C|24 µg of racemic formoterol fumarate BID
9908692|NCT00685542|Experimental|1|Diacerein 50mg bid
9908693|NCT00685542|Placebo Comparator|2|placebo 50mg bid
9908694|NCT00685568|Experimental|Arm I|Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
9908695|NCT00685568|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
9908696|NCT00685581|Experimental|A|Arms A: the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
9908697|NCT00685581|Experimental|B|Arms B: the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed.
9908698|NCT00685581|Experimental|C|Arms C: the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed.
9908699|NCT00685594|Experimental|1|Cholecalciferol 20.000 IU per week for 5 years
9908700|NCT00685594|Placebo Comparator|2|
9908701|NCT00685607|Experimental|1|loperamide-simethicone
9908702|NCT00685607|Placebo Comparator|2|matching placebo
9908703|NCT00685620|No Intervention|Group 1|Standard care following detoxification
9908704|NCT00685620|Active Comparator|Group 2|Recovery housing following detoxification
9908705|NCT00685620|Experimental|Group 3|Recovery housing plus counseling
9908706|NCT00685633|Active Comparator|Arm A|Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.
9908707|NCT00685633|Active Comparator|Arm B|In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.
9908708|NCT00685646|Experimental|Arm I|Patients receive maximum androgen-blockade therapy and zoledronic acid for up to 24 courses.
9908709|NCT00685646|Active Comparator|Arm II|Patients receive maximum androgen-blockade therapy for up to 24 courses.
9908710|NCT00685672|Experimental|1|adrenalin
9908711|NCT00685672|Placebo Comparator|2|placebo
9908712|NCT00685711|Placebo Comparator|1|Placebo intradermal n = 2 with each dose level of Cat-PAD.
9908713|NCT00685711|Experimental|2|Intradermal injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 12 nmol may be administered to an additional cohort of 6 subjects.
9908714|NCT00685711|Placebo Comparator|3|Placebo subcutaneous n = 2 with each dose level of Cat-PAD.
9908715|NCT00685711|Experimental|4|Subcutaneous injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12, 20 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 20 nmol may be administered to an additional cohort of 6 subjects.
9908716|NCT00685724|Experimental|1|Following 2 sessions of MET intervention received by all patients, patients in Condition 1 receive no further intervention.
9908717|NCT00685724|Experimental|2|Patients in Condition 2 will receive 8 sessions of the CBT (Cognitive Behavioral Therapy) intervention.
9908718|NCT00685724|Experimental|3|Patients in Condition 3 will receive 8 sessions of CBT plus aftercare treatment.
9908719|NCT00685737|Active Comparator|1|1-MNA-Low Dose
9908720|NCT00685737|Active Comparator|2|1-MNA-High Dose
9908721|NCT00685737|Placebo Comparator|3|Placebo
9908722|NCT00685776|Experimental|Anacetrapib|Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
9908723|NCT00685776|Placebo Comparator|Placebo|Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.
9908724|NCT00685789|Experimental|Acupuncture with Deqi|Needles were inserted and manipulated manually using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation of soreness, numbness, fullness, aching, cool, warmth, heaviness and radiating sensation (Deqi) occurred. The needles were retained for 30 min.
9908725|NCT00685789|Active Comparator|Acupuncture without Deqi|Needles were simply inserted and retained for 30 min, without any other stimulation.
9908726|NCT00685815|Experimental|24 participants|Intravenous Iron (FCM)
9908727|NCT00685815|Placebo Comparator|12 participants|Placebo
9908728|NCT00685828|Active Comparator|Arm I|Patients receive low-dose oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
9908729|NCT00685828|Experimental|Arm II|Patients receive high-dose oral imatinib mesylate twice daily in the absence of disease progression or unacceptable toxicity.
9908730|NCT00685841|Experimental|A|Arformoterol 50 mcg QD and placebo MDI
9908731|NCT00685841|Experimental|B|Arformoterol 25 mcg BID and placebo MDI
9908732|NCT00685841|Experimental|C|Arformoterol 15 mcg BID and placebo MDI
9908733|NCT00685841|Active Comparator|D|Salmeterol MDI 42 mcg BID and placebo inhalation solution
9908734|NCT00685841|Placebo Comparator|E|Placebo BID MDI and inhalation solution
9908735|NCT00685867|Experimental|1|Rapid detection
9908736|NCT00685867|Other|2|Enhanced infection control
9908737|NCT00685893|No Intervention|Control Arm|6 Community hospital ICUs receiving delayed intervention activities after the completion of the randomized trial
9908738|NCT00685893|Experimental|Intervention Arm|6 community hospital ICUs receiving 5-component intervention.
9908739|NCT00685906|Experimental|1|
9908740|NCT00685906|Active Comparator|2|
9908741|NCT00685971|Experimental|Vitamin D|vitamin
9908742|NCT00685971|Placebo Comparator|Placebo|
9908743|NCT00685984||1|
9908744|NCT00685984||2|
9908745|NCT00685984||3|
9908746|NCT00686010|Placebo Comparator|1|Placebo
9908747|NCT00686010|Experimental|2|JTT-705 300mg
9908748|NCT00686010|Experimental|3|JTT-705 600mg
9908749|NCT00686010|Experimental|4|JTT-705 900mg
9908750|NCT00686023|Active Comparator|1|DHS fixation
9908751|NCT00686023|Active Comparator|2|IMN fixation
9997882|NCT01512706|Experimental|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
9908752|NCT00686049||Study Group|Participants will complete two audio computer assisted self interviews on laptop computers. This study will also involve the abstraction of participants' viral load and CD4 counts from their medical charts.
9908753|NCT00686062|Experimental|1|Women in this arm view the interactive, computerized, prenatal testing decision tool (PT Tool) we created.
9908754|NCT00686062|Active Comparator|2|Women in this arm view the age-appropriate computerized version of the educational pamphlet on prenatal testing developed and distributed by the State of California
9908755|NCT00686101||1|Normal control subjects (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, who are not actively trying to quit smoking at the time of the interview, and who must be free from Axis I psychotic disorder.)
9908756|NCT00686101||2|Subjects with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, and who are not actively trying to quit smoking at the time of the interview.)
9908757|NCT00686114|Experimental|A|Enlarged field + Paclitaxel + Cisplatin + Tarceva
9908758|NCT00686114|Experimental|B|Enlarged field + Paclitaxel + Cisplatin
9908759|NCT00686114|Active Comparator|C|Conventional field + Paclitaxel + Cisplatin + Tarceva
9908760|NCT00686114|Active Comparator|D|Conventional field + Paclitaxel + Cisplatin
9908761|NCT00686140|Experimental|Celecoxib, immune adjustor|Celecoxib
9908762|NCT00686140|Placebo Comparator|Placebo|Placebo looks like the active drug celecoxib, with the same dose
9908763|NCT00686179|Experimental|1|Escalating doses of AZD3480 during 6 days
9908764|NCT00686179|Experimental|2|Repeated doses of AZD3480 during 6 days
9908765|NCT00686179|Placebo Comparator|3|Placebo during 6 days
9908766|NCT00686179|Active Comparator|4|Placebo during 5 days, active day 6
9908767|NCT00686218|Experimental|Treatment (panobinostat, imatinib mesylate)|Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9908768|NCT00686244|Experimental|Training Group|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
9908769|NCT00686244|No Intervention|Control Group|No guided training. Exercise optional after detailed consulting and handing over an information dossier for adequate physical activity.
9908770|NCT00686270|Experimental|1|apricitabine
9908771|NCT00686283|Other|Exercise prescription|Each adolescents with type 1 or type 2 diabetes received individual fitness testing and a personalized exercise program prescription developed by an exercise physiologist. Pretest and posttest measures of glucose control and cardiorespiratory fitness, heart rate variability, metabolic control, lipid profile, body composition, and inflammatory markers, as well as psychological outcomes (i.e., diabetes quality of life) were completed.
9997883|NCT01512706|Experimental|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
9908772|NCT00686296|Active Comparator|Group II|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing. Gauze dressing changes will continue per standard of care until the scheduled follow-up visits (first or second visit). At the scheduled follow-up visits, the subject will have a Taliderm™ dressing applied and left in place until the next scheduled dressing change (up to eight hours), then will continue standard of care wet to dry gauze dressing changes until next scheduled follow-up visit.
9908773|NCT00686296|Other|III|standard wet to dry dressing with gauze
9908774|NCT00686296|Active Comparator|group I|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing
9908775|NCT00686322|Other|1|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
9908776|NCT00686374|Experimental|Any adalimumab|Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
9933857|NCT05183867|Experimental|Healthy Minds Program (HMP) app|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
9933858|NCT05183867|Active Comparator|Psychoeducation app|Participants will receive access to the 4-week HMP Foundations module with guided meditation practices removed. The active control will include only the didactic content included in HMP without the guided meditation practices.
9933859|NCT05183867|No Intervention|Usual Care|Participants will receive access to HMP at the end of the study and will be encouraged to continue with their usual care.
9933860|NCT05183230|Experimental|Proof-of-Concept WellPATH-PREVENT (R61)|
9933861|NCT05183230|Experimental|Optimized WellPATH-PREVENT (R33)|
9933862|NCT05183230|No Intervention|Attention Control Usual Care (R33)|The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team.
9933863|NCT05179460||Clean Cohort|Clean cohort refers to cohort of participants who had their first documented exposure to pentosan polysulfate sodium (PPS; Elmiron) on or after 22 May 2018 and who are assumed to have had shorter exposure (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
9933864|NCT05179460||Overall Cohort|Overall cohort refers to cohort of participants who had their first documented exposure to PPS (Elmiron) any time beginning 01 January 2015 and who are assumed to have relatively longer exposure (the earliest available data based on the linked database between the intelligent research in sight (IRIS) registry and Komodo database in this study).
9933865|NCT05179460||Interstitial Cystitis (IC) Cohort|IC cohort refers to cohort of participants who had at least one IC diagnosis beginning 01 January 2015 and had no documented exposure to PPS based on the records from the Komodo database (the earliest available data based on the linked database between the IRIS registry and Komodo database in this study).
9933866|NCT05178550|Experimental|Group 1 (low dose-high dose)|Participants receive 25 IU/kg heparin on days 1 and 2, and 50 IU/kg Heparin on days 4 and 5
9933867|NCT05178550|Experimental|Group 2 (high dose-low dose)|Participants receive 50 IU/kg heparin on days 1 and 2, and 25 IU/kg Heparin on days 4 and 5
9933868|NCT05178329|Active Comparator|Intervention group|The patients undergoing intervention exercise.
9933869|NCT05178329|Placebo Comparator|Control Group|The patients undergoing the normal exercise program
9933870|NCT05177861|Other|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
9933871|NCT05175209|Other|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
9933872|NCT05173506||Adolescent Depression Screening|"> 3 visits to clinic~Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10:G40)~Age > 12 years at last visit (before CHICA-CN)~Computer assistant depression screening and management"
9933873|NCT05173506||Genetic Testing|"> 3 visits to clinic~Diagnosis of global developmental delay - International Classification of Diseases, Tenth Revision - autistic disorder (ICD-10: F84)~Age < 6 years at last visit (before CHICA-CN)~Computer reminders to test for genetic disorders"
9933874|NCT05173506||Rescue seizure therapy|"> 3 visits to clinic~Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10: G40)~Age < 18 years at last visit (before CHICA-CN)~Computer reminders to prescribe and adjust rescue anti-seizure medications"
9933875|NCT05173506||Adolescent Transition|"> 3 visits to clinic~Age > 13 years at last visit (before CHICA-CN)~Computer supported screening and counseling regarding transition to adult care"
9933876|NCT05170412||Patients|outpatient adults with the diagnosis of Sickle Cell Disease
9933877|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Treatment Naive|Treatment Naive
10213999|NCT02253316|Experimental|Consolidation: Ixazomib, Lenalidomide, & Dexamethasone|Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, & dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 55 mg of lenalidomide will be administered on daily on Days 1-21.
9908777|NCT00686400||1: FE|FE = first episode schizophrenia
9908778|NCT00686400||2: CO|CO = age and gender-matched control subjects
9908779|NCT00686413|Experimental|1|
9908780|NCT00686413|Experimental|2|
9908781|NCT00686426|Active Comparator|1|Low Dairy
9908782|NCT00686426|Experimental|2|Adequate Dairy
9908783|NCT00686439|Experimental|adalimumab|
9908784|NCT00686452||1|Swimmers without AHR
9908785|NCT00686452||2|Swimmers with asymptomatic AHR
9908786|NCT00686452||3|Swimmers with symptomatic AHR and use only of beta-2 adrenargic
9908787|NCT00686452||4|Swimmers with asthma and inhaled corticosteroids
9908788|NCT00686452||5|Healthy Subjects
9908789|NCT00686452||6|Healthy subjects with AHR
9908790|NCT00686452||7|Healthy subjects with symptomatic AHR (asthma) but without treatment
9908791|NCT00686465|Other|PET/CT scan|PET/CT scan
9908792|NCT00686478|Experimental|interferon alpha 2b (Intron A)|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
9908793|NCT00686478|Placebo Comparator|Placebo|Placebo administered subcutaneously once a day for 7 days, then three times a week for 23 weeks.
9908794|NCT00686491||1|Triathletes
9908795|NCT00686491||2|Cold air athletes
9908796|NCT00686491||3|Swimmers
9908797|NCT00686491||4|Other sports elite athletes
9908798|NCT00686491||5|Control subjects
9908799|NCT00686530||1|
9908800|NCT00686556|Experimental|Cohort -1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 12 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
9908801|NCT00686556|Experimental|Cohort 1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 15 Gy on Days -5 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
9908802|NCT00686556|Experimental|Cohort 2|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 18 Gy on Days -6 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
9908803|NCT00686556|Experimental|Cohort 3|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 21 Gy on Days -7 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
9908804|NCT00686556|Experimental|Cohort 4|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 24 Gy on Days -8 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
9908805|NCT00686608|Experimental|Glucose|IV glucose
9908806|NCT00686608|Active Comparator|Fructose|
10214000|NCT02253316|Experimental|Maintenance Arm 1: Ixazomib|Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxicity.
9994173|NCT01478802|Experimental|HFO-RMs Arm|Patients with moderte-to-severe Acute Respiratory Distress Syndrome treated initially with a 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO)-Recruitment Maneuvers (RMs), and then with lung protective CMV interspersed to additional HFO-RMs sessions (if required according to study protocol). The protocolized use of HFO-RMs may extend until day 10 post-randomization, according to pre-specified oxygenation criteria. Full details are provided in the Detailed Description Section.
9994174|NCT01478815|Placebo Comparator|Standard Care|
9994175|NCT01478815|Experimental|Contingency management for abstinence from drugs|
9994176|NCT01478841|Experimental|Polyphenols|9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
9994177|NCT01478841|Placebo Comparator|placebo|9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).
9994178|NCT01478867||Celiac patients|
9994179|NCT01478880|Experimental|cTBS|
9994180|NCT01478880|Sham Comparator|Sham cTBS|
9994181|NCT01478893|Experimental|SEL-068|
9994182|NCT01478893|Placebo Comparator|Saline|
9994183|NCT01478906||elderly ,adult|
9994184|NCT01478932|Experimental|Diaphragmatic Breathing Retraining|
9994185|NCT01478945|Active Comparator|Dermfix 1000 active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB"
9994186|NCT01478945|Active Comparator|Waldmann active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB (Waldmann)"
9994187|NCT01478945|Sham Comparator|Dermfix 1000 placebo|Manual placebo hand held NB-UVB unit
9994188|NCT01478984|Active Comparator|one staged PCI|the patient randomized to this arms complete the myocardial revascularization in one stage PCI, the investigators treat all lesions.
9994189|NCT01478984|Active Comparator|multistaged PCI|the patients randomized to this arms in the first stage the investigators treat only the culprit lesion and in second stage the investigators treat the other vessels
9994190|NCT01478997|Experimental|Flexsure Capsules|Investigational Product
9994191|NCT01478997|Placebo Comparator|Carboxy Methyl Cellulose Capsules|Placebo
9994192|NCT01479023|Experimental|Cohort 1|"64Cu-DOTA-U3-1287 at a radiotracer dosage of 8-15 mCI and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~Patient will have option to continue to Part 2 (extension phase)."
9994193|NCT01479023|Experimental|Cohort 2|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~9.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
9994194|NCT01479023|Experimental|Cohort 3|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~12.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
9994195|NCT01479023|Experimental|Cohort 3a|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~15.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
9994196|NCT01479023|Experimental|Cohort 4|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~18.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
9994197|NCT01479023|Experimental|Cohort 5|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~TBD (to be determined) mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
9994198|NCT01479023|Experimental|Part 2 (extension phase)|Loading dose of 18.0 mg/kg unlabeled U3-1287 followed by 9.0 mg/kg unlabeled U3-1287 every 3 weeks.
9994199|NCT01479036|Active Comparator|docetaxel and epirubicin|DE chemotherapy alone
9994200|NCT01479036|Experimental|docetaxel and epirubicin plus endostatin|chemotherapy plus endostatin
9994201|NCT01479049|Experimental|MP group|Hearts are arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L) during cardiac surgery.
9994202|NCT01479049|Active Comparator|HP group|Hearts were arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L) during cardiac operation
9994203|NCT01479062|Experimental|participation in Alive-PD|Alive-PD lifestyle intervention with multi-channel delivery
9994204|NCT01479062|Placebo Comparator|Control|Usual care
9994205|NCT01479075|Experimental|intranasal insulin in patients|intranasal insulin is applied to diabetic patients under fasting conditions
9994206|NCT01479075|Experimental|intransal insulin in study participants|intranasal insulin is applied to healthy patients under fasting conditions
9994207|NCT01479075|Placebo Comparator|placebo in patients|placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
9908807|NCT00686608|Placebo Comparator|Saline|
9908808|NCT00686660|Experimental|1|C-W G: in training period, patients do cycling on cycle ergometry at hospital. in non-training period, patients walk at community.
9908809|NCT00686660|Other|2|C-nonW G: in training period, patients do cycling at cycle ergometry at hospital, in non-training period, patients don't walk at community.
9908810|NCT00686660|Experimental|3|W-W G: in training period, patients do walking along 60 meters place at hospital, in non-training period, patients do walking in community
9908811|NCT00686660|Other|4|W-nonW G: in training period, patients do walking along 60 meter place, in non-training period,patients don't walk at community.
9908812|NCT00686673|Experimental|A|Providing Videotape-based material & tailored workbook to make informed choice of disclosing terminal illness to patients
9908813|NCT00686673|Other|B|"Attention control arm:~Providing videotape-based material & non-tailored workbook about pain control"
9908814|NCT00686738||A|"Study group will be made up of patients hospitalized to National Cancer Center, Korea, aged between 5 and 40 years, and diagnosed with high grade osteosarcoma by histological exam.~In this group, TGF-b1 measurement, PET/CT and MRS examination at diagnosis, after 1st cycle chemotherapy, and 2nd or 3rd chemotherapy (just before surgery) will be made.~In addition, evaluation of NF-kB expression status in tumor specimens at diagnostic biopsy and tumor removing surgery will be done.~The results of above studies will be correlated with the necrosis fractions of the tumor tissues removed by surgery."
9908815|NCT00686751|Experimental|A|"There is only one arm in this study. Each subject will be studied through 3 phases lasting a total of 4 weeks:~Phase 1: administration of study medication at the end of hemodialysis treatment.~Phase 2: no administration of study medication. Phase 3: administration of study medication at the beginning of hemodialysis."
9908816|NCT00686764||Group 1|Trans-femoral amputees that meet the eligibility criteria.
9908817|NCT00686816|Placebo Comparator|1|
9908818|NCT00686816|Experimental|2|
9908819|NCT00686868|Experimental|30mg|active
9908820|NCT00686868|Experimental|3mg|active
9908821|NCT00686868|Experimental|0.3mg|active
9908822|NCT00686868|Placebo Comparator|placebo|placebo
9908823|NCT00686868|Experimental|60mg|60mg
9908824|NCT00686868|Experimental|100mg|100mg
9908825|NCT00686946||NRAMP|Participants take their antipsychotic medication as prescribed by their clinical treating teams.
9908826|NCT00686985|Experimental|A|
9908827|NCT00687011|Experimental|Palonosetron-dexamethasone|
9908828|NCT00687037|Experimental|I|Cetylpyridinium chloride during 21 days.
9908829|NCT00687050|Active Comparator|1|HIV-positive hemodialysis patients (as a high risk group for cachexia) will be given daily drinks of Renilon 7.5 (125 ml, 2 kcal/ml) as peroral supplemental nutrition on top to their recommended high-protein, high-caloric diet.
9908830|NCT00687050|No Intervention|2|Chronic hemodialysis patients randomized to no peroral supplemental nutrition
9908831|NCT00687050|Active Comparator|3|Chronic hemodialysis patients randomized to peroral supplemental nutrition.
9908832|NCT00687063||A|
9908833|NCT00687089||Subutex group|People who used opiates and willing to start with subutex treatment
9908834|NCT00687128|Experimental|1|Low-intensity aerobic exercise
9908835|NCT00687128|Experimental|2|Moderate-intensity aerobic exercise
9908836|NCT00687128|Active Comparator|3|Non-aerobic stretching exercise
9908837|NCT00687141|Experimental|1|
9908838|NCT00687141|Placebo Comparator|2|
9908839|NCT00687154|Active Comparator|1 Sitting|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 1 sitting
9908840|NCT00687154|Active Comparator|4 Sittings|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 4 sittings.
9908841|NCT00687180|Active Comparator|I|MMF
9908842|NCT00687180|Active Comparator|II|
9908843|NCT00687206|Experimental|1|
9908844|NCT00687232|Experimental|1|AZD4818
9908845|NCT00687232|Placebo Comparator|2|
9908846|NCT00687245|Experimental|1|esomeprazole magnesium 5 mg, weight 8 kg to < 20kg
9908847|NCT00687245|Experimental|2|esomeprazole magnesium 10 mg, weight 8 kg to < 20kg
9908848|NCT00687245|Experimental|3|esomeprazole magnesium 10 mg, weight > 20 kg
9908849|NCT00687245|Experimental|4|esomeprazole magnesium 20 mg, weight > 20 kg
9908850|NCT00687258|Experimental|1|VitabranE ViE: Vitamin E-bonded polysulfone dialyzer
9908851|NCT00687258|No Intervention|2|APS-U (Asahi Polysulfone APS): Polysulfone dialyzer
9908852|NCT00687284||A|
9908853|NCT00687310|Other|1|Educational Intervention At the initial visit (Visit 1), patients in the educational intervention group will complete a short Needs Assessment Questionnaire to help the investigator/nurse determine which section(s) of the tailored patient education booklet to give to, educate, and provide instruction on to the patient. This may, at the discretion of the investigator, include providing their patient with a peak flow meter and instructions on its use.Visit 2 will be scheduled for 1-month after the Visit 1 for the education intervention group. All educational materials provided at Visit 1 will be reviewed with the patient at Visit 2. The investigator/nurse will reassess the patient's use of the Turbuhaler® and asthma treatment plan. Patients will also be asked about any adverse events that may have occurred since Visit 1 and/or are observed at Visit 2. Once Visit 2 is completed with the patient, the investigator/nurse will complete the Educator Satisfaction Questionnaire.
9908854|NCT00687336|Active Comparator|1|Empirical eradication treatment
9908855|NCT00687336|Active Comparator|2|Eradication treatment according to a diagnostic test (URT, histological test, breath test or serology).
9908856|NCT00687349|Experimental|Intervention Arm|The training program will assign resident or NP student to a rotation. They will be receiving the educational intervention during 8 half-day sessions.
9908857|NCT00687349|No Intervention|Control Arm|Resident or NP student is assigned to usual education.
9908858|NCT00687375|Other|1|Laparoscopic Inguinal Hernia Repair- Transabdominal preperitoneal (TAPP) approach
9908859|NCT00687375|Other|2|Laparoscopic Inguinal Hernia Repair- Totally extra peritoneal (TEP) Approach
9908860|NCT00687388|Active Comparator|Alpha-blocker|Alpha-blocker only
9908861|NCT00687388|Active Comparator|NSAID|NSAID only
9908862|NCT00687388|Experimental|alpha-blocker and NSAID|Combination treatment of alpha-blocker and NSAID
9908863|NCT00687414||adults|male and female with MDS and MPD and AML
9908864|NCT00687414||Healthy|Healthy control group
9908865|NCT00687427||A|Group A - 25 individuals or more, that start occupational therapy and agree to participate in the research.
9908866|NCT00687427||B|Group B- 25 individuals or more, half a year after hand injury that were treated in occupational therapy at the same institute.
9908867|NCT00687427||C|Group C - 25 individuals or more, a year after hand injury that were treated in occupational therapy at the same institute
9908868|NCT00687466|Experimental|1|Insulin yes
9908869|NCT00687466|No Intervention|2|Insulin no
9908870|NCT00687479||1-NGT|normal glucose tolerance
9908871|NCT00687479||2-GDM|Gestational Diabetes mellitus
9908872|NCT00687479||3.GIGT|Gestational Impaired glucose tolerance
9908873|NCT00687518|Experimental|1|erythropoietin
9908874|NCT00687518|Placebo Comparator|2|Saline serum
9908875|NCT00687570|Other|B|Nutritional drinks 7 days before surgery instead of traditional Bowel preparation with Laxabon®
9908876|NCT00687570|Other|A|Traditional bowel preparation with Laxabon®
9908877|NCT00687622|Experimental|GSK1120212|Part 1 will identify the maximum tolerated dose using a dose-escalation procedure. Part 2 will explore further the safety, tolerability, and clinical activity of GSK1120212 in subjects with pancreatic, melanoma, non-small cell lung, and KRAS or BRAF mutation-positive colorectal cancer. Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic markers in tumor tissue
9908878|NCT00687648|Experimental|Arm I|Patients receive aromatase inhibitor (anastrozole, letrozole, or exemestane) as previously prescribed. Patients also receive oral cyclophosphamide once daily on days 1-28 and oral methotrexate twice on days 15, 16, 22, and 23 of course 1. For all subsequent courses, patients receive oral cyclophosphamide once daily and oral prednisolone once daily on days 1-28 and oral methotrexate twice on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment with cyclophosphamide, methotrexate, and prednisolone repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9908879|NCT00687648|Active Comparator|Arm II|Patients receive cyclophosphamide, methotrexate, and prednisolone as in arm I.
9908880|NCT00687661|Active Comparator|1|Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
9908881|NCT00687661|Placebo Comparator|2|Arm #2 will include patients randomized to receive placebo therapy for 24 months
9908882|NCT00687700|Experimental|All subjects|Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.
9908883|NCT00687726|Experimental|G1|Standing balance and mini squat training
9908884|NCT00687726|Active Comparator|G2|Isometric knee extension exercise
9908885|NCT00687752||1|hydramnios
9908886|NCT00687752||2|normal
9908887|NCT00687765|Experimental|1|
9908888|NCT00687778||1|100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
9933878|NCT05170399|Experimental|Chronic Lymphocytic Leukemia - Treatment Break for BTKi Therapy|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9908889|NCT00687791|Experimental|1|20 enrolled patients will be chosen according to the enrollment acceptance criteria. The evidence for the determination of enrolled patients shall be recorded, reviewed and approved. 2> Phacotrabeculectomy is performed.3> After completing phacotrabeculectomy, implant/place ologen™ Collagen Matrix on top of the scleral flap under the conjunctiva. For every inspection and observation, the detailed description and/or inspection data shall be recorded. If any unwanted adverse event is observed during inspection and observation, it shall be recorded and be reported to the investigation conductor.
9908890|NCT00687843|Active Comparator|1|The TS-1 group
9908891|NCT00687843|Experimental|2|The TS-1+PSK Group
9908892|NCT00687869|Experimental|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
9908893|NCT00687869|Active Comparator|usual care|Usual stroke aftercare plus patient-information-notes
9908894|NCT00687895|Experimental|1|training in clinical algorithm plus microscopy
9908895|NCT00687895|Experimental|2|clinical algorithm
9908896|NCT00687895|No Intervention|3|Control
9908897|NCT00687921||A|patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy.
9908898|NCT00687934|Experimental|Ganetespib|Ganetespib once weekly infusion, dose escalation study, with treatment until progression
9908899|NCT00687947|Experimental|1|MA-patients
9908900|NCT00687947|Experimental|2|FHM-patients
9908901|NCT00687947|Active Comparator|3|Healthy controls
9908902|NCT00687960|Experimental|1|Resistant Starch Type 4-Raw
9908903|NCT00687960|Experimental|2|Resistant Starch Type 4-cooked
9908904|NCT00687960|Active Comparator|3|Puffed wheat
9908905|NCT00687960|Placebo Comparator|4|Dextrose
9908906|NCT00687999|Other|1|
9908907|NCT00688025||1|Insomniacs: Individuals reporting difficulty falling asleep or staying asleep within the past month for more than 3 days per week. Individuals much also meet screening criteria based on an overnight polysomnograph of latency to persistent sleep >20 minutes and/or >60 minutes of wake after sleep onset.
9908908|NCT00688025||2|Controls: Individuals reporting no difficulty falling asleep or staying asleep and objective sleep measures based on an overnight polysomnograph of latency to persistent sleep <20 minutes and/or <60 minutes of wake after sleep onset.
9908909|NCT00688038|Experimental|Laser Ablation + MRTI|Magnetic resonance thermal imaging = MRTI
9908910|NCT00688051|Experimental|1|
9908911|NCT00688077|Experimental|1|
9908912|NCT00688077|Placebo Comparator|2|NaCl 0,9% 2 ml, single subcutaneous injection
9908913|NCT00688090|Experimental|Low-Dose Peptide Cohort|
9908914|NCT00688090|Experimental|High-Dose Peptide Cohort|
9908915|NCT00688116|Experimental|ganetespib|
9908916|NCT00688129|Experimental|KITS Program|The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
9908917|NCT00688129|No Intervention|Services as usual|
9908918|NCT00688142||1|Individuals with shift work sleep disorder
9908919|NCT00688142||2|Healthy night shift workers without shift work sleep disorder
9908920|NCT00688168||Symptom Assessments|Patients diagnosed with multiple myeloma (MM) complete questionnaires with Neurocognitive Testing and Neurosensory Testing
9908921|NCT00688194|Active Comparator|Arm I|Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9908922|NCT00688194|Active Comparator|Arm II|Patients receive fulvestrant and placebo as in arm I. Patients also receive aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according to standard treatment regulations.
9908923|NCT00688194|Active Comparator|Arm III|Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9908924|NCT00688194|Active Comparator|Arm IV|Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients also receive AI therapy according to standard treatment regulations.
9908925|NCT00688207|Experimental|Rosiglitazone|An open-label, single, oral dose of 4mg of rosiglitazone in the morning under fasted conditions
9908926|NCT00688220||1|Those wearing garments fabricated with Celliant
9908927|NCT00688220||2|Those not wearing garments fabricated using Celliant (placebo).
9908928|NCT00688233|Experimental|F-seifi|
9908929|NCT00688272|Experimental|Arm 1|Eltrombopag 75 mg QD x 6 days
9908930|NCT00688272|Active Comparator|Arm 2|Ciprofloxicin 500mg BID x 6 days
9908931|NCT00688272|Placebo Comparator|Arm 3|Placebo QD x 6 days
9908932|NCT00688285|Active Comparator|1|education and automated clinical alerts
9908933|NCT00688285|Active Comparator|2|education session alone
9908934|NCT00688298|Experimental|Arm 1|Female patients Greater than or 18 years of age, diagnosed with Stress Urinary Incontinence (SUI).
9908935|NCT00688311|Experimental|Synbiotic|Ingestion of synbiotic dietary supplement
9908936|NCT00688311|Placebo Comparator|Placebo|Ingestion of the Placebo
9908937|NCT00688337||1|Patients with newly diagnosed breast cancer. Clinically nodal negative.
9908938|NCT00688350|Experimental|Behavioral feedback|Behavioral feedback intervention to improve adherence to antihypertensive medication
9908939|NCT00688350|No Intervention|Control|Control group
9908940|NCT00688363|Experimental|1|No blood-glucose self-control, no HbA1c
9908941|NCT00688363|Experimental|2|Blood-glucose self-control, no HbA1c
9908942|NCT00688363|Experimental|3|No blood-glucose self-control, HbA1c
9908943|NCT00688363|Experimental|4|Blood-glucose self-control, HbA1c
9908944|NCT00688389||healthy|
9908945|NCT00688389||DF|
9908946|NCT00688389||DHF|
9908947|NCT00688402|Experimental|1|IR Formulation 65 mg
9908948|NCT00688402|Experimental|2|IR Formulation 150 mg
9908949|NCT00688402|Experimental|3|MR formulation, 1h 65 mg
9908950|NCT00688402|Experimental|4|MR Formulation, 1h 150 mg
9908951|NCT00688402|Experimental|5|MR Formulation, 2h 150 mg
9908952|NCT00688428|Experimental|1|combination capsule of Esomeprazole 40mg + ASA 325mg
9908953|NCT00688428|Experimental|2|Esomeprazole 40 mg capsule and ASA 325 mg tablet
9908954|NCT00688454||Pt with hypercholesteremia|Patients treated with CRESTOR because of hypercholesteremia
9908955|NCT00688480|Placebo Comparator|I|CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH
9908956|NCT00688480|Active Comparator|2|
9908957|NCT00688493|Experimental|20 mg single dose of dapagliflozin|20 mg dapagliflozin
9908958|NCT00688493|Experimental|150 mg single dose of dapagliflozin2|150 mg dapagliflozin
9908959|NCT00688493|Active Comparator|400 mg single dose of moxifloxacin|Moxifloxacin
9908960|NCT00688493|Placebo Comparator|Placebo|Placebo
9908961|NCT00688506|Experimental|1|Combined sono-electro-magnetic therapy
9908962|NCT00688506|Placebo Comparator|2|placebo therapy
9933879|NCT05170399|Experimental|Chronic Lymphocytic Leukemia - Treatment with B-cell lymphoma 2 (BCL-2) Inhibitor|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9667263|NCT03799861||Epoch 2: HBB with NeoBeat|Implementation of Helping Babies Breathe training in combination with NeoBeat for detection of HR in non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for prospective cohort of all infants born in the three study hospitals for a 9-month period.
9933880|NCT05170399|Experimental|Chronic Lymphocytic Leukemia - Treatment with BTKi|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9933881|NCT05170399|Experimental|Chronic Lymphocytic Leukemia: Not Receiving Active Treatment|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9933882|NCT05170399|Experimental|Follicular Lymphoma - Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9908963|NCT00688532||1|Prostate cancer patients treated with bicalutamide or not
9908964|NCT00688532||2|General population cohort
9908965|NCT00688558|Experimental|1|JTT-705 600 mg and simvastatin 40 mg
9908966|NCT00688558|Placebo Comparator|2|Placebo and simvastatin 40 mg
9908967|NCT00688571|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PV conduit.
9908968|NCT00688584|Experimental|1|
9908969|NCT00688584|Placebo Comparator|2|
9908970|NCT00688584|No Intervention|No intervention control|
9908971|NCT00688649|Active Comparator|1|Standard ONS
9908972|NCT00688649|Active Comparator|2|High Energy ONS
9908973|NCT00688675||Treated GERD pts|Previously diagnosed GERD patients on treatment in Switzerland
9908974|NCT00688714|Experimental|1|
9908975|NCT00688714|Placebo Comparator|2|
9908976|NCT00688727|Experimental|1|Cognitive behavioural Therapy
9908977|NCT00688727|Active Comparator|2|Standard Care
9908978|NCT00688779|Experimental|1|
9908979|NCT00688779|Placebo Comparator|2|
9908980|NCT00688805|Experimental|Arm 1|
9908981|NCT00688805|Placebo Comparator|Arm 2|
9908982|NCT00688818|Experimental|Quetiapine and existing psychotropics|
9908983|NCT00688818|Placebo Comparator|Placebo and existing psychotropics|
9908984|NCT00688831|Experimental|A|AZD1305 solution for iv infusion
9908985|NCT00688831|Placebo Comparator|B|NaCl solution for iv infusion
9908986|NCT00688857|Experimental|A|Diazoxide choline controlled-release coated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 9 through 16).
9908987|NCT00688857|Experimental|B|Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release coated tablets administered orally once daily (Days 9 through 16)
9908988|NCT00688883|Experimental|Arm 1|
9908989|NCT00688896|Experimental|1|JTT-705 600 mg and pravastatin 40 mg
9908990|NCT00688896|Experimental|2|JTT-705 300 mg and pravastatin 40 mg
9908991|NCT00688896|Placebo Comparator|3|Placebo and pravastatin 40 mg
9908992|NCT00688961|No Intervention|1|Baseline
9908993|NCT00688961|Experimental|2|Aspirin (1 day after a single, 625 mg dose)
9908994|NCT00688961|Experimental|3|Omacor
9908995|NCT00688961|Experimental|4|Omacor plus aspirin
9908996|NCT00688974||Roux-en-Y gastric bypass|Patients with class 3 obesity and type 2 diabetes submitted to Roux-en-Y gastric bypass
9908997|NCT00688974||Adjustable gastric banding|Patients with class 3 obesity and type 2 diabetes submitted to adjustable gastric banding
9908998|NCT00688974||Healthy controls|Non-obese, non-diabetic adults
9908999|NCT00688987|Active Comparator|1|Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.
9909000|NCT00688987|Active Comparator|2|isocaloric diet
9909001|NCT00689000|Experimental|CHR-2797 (tosedostat)|oral, once daily administration of CHR-2797 to determine safety & anti-disease activity.
9909002|NCT00689013|No Intervention|1|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the first month of observation. These patients have not been exposed to pharmacist-driven interventions utilized in this study. This group serves as the control group.
9909003|NCT00689013|Experimental|2|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the second month of observation. These patients may or may not have been exposed to pharmacist-driven interventions utilized in this study. This group serves as the study/intervention group.
9909004|NCT00689039|Experimental|A|AZD1305 ER tablet
9909005|NCT00689039|Placebo Comparator|B|Placebo tablet
9909006|NCT00689065|Experimental|CALAA-01|
9909007|NCT00689156|Active Comparator|Regimen 1|Epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times three followed by docetaxel 100 mg/m2 intravenously day 1 every 3 weeks times three
9909008|NCT00689156|Experimental|Regimen 2|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
9909009|NCT00689169|Experimental|Experimental|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
9909010|NCT00689182|Experimental|A|All patients will receive phlebotomy
9909011|NCT00689195|Experimental|C|Curcumin
9909012|NCT00689195|Experimental|A|Ashwagandha extract
9909013|NCT00689234|Placebo Comparator|A|"At time of inclusion randomised in the no intervention arm (the subjects will be re-evaluated 6 months later and will get intervention at that time (cross-over protocol)"
9909014|NCT00689234|Active Comparator|B|At time of inclusion the subject get the intervention
9909015|NCT00689247|Experimental|A|AZD1305 given as oral solution
9909016|NCT00689247|Experimental|B|AZD1305 given as iv infusion
9909017|NCT00689286|Experimental|"BION twitch stimulation"|"The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation."
9909018|NCT00689286|Experimental|BION tetanic-frequency stimulation|The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions.
9909019|NCT00689286|No Intervention|Standardized program|A third group of experimental subjects will have a standardized program of voluntary exercise.
9909020|NCT00689312|Active Comparator|1|
9909021|NCT00689312|Experimental|2|
9909022|NCT00689312|Experimental|3|
9909023|NCT00689364||CTTCT+CWMT|"CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least.~CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline)."
9909024|NCT00689364||CWMT cohort|CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
9909025|NCT00689377||1|Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus
9909026|NCT00689403|Experimental|Part A: 2x2 crossover|4 different AZD1305 ER formulations
9909027|NCT00689403|Experimental|Part B: 3x3 crossover|2 different AZD1305 ER formulations and a reference formulation
9909028|NCT00689416|Experimental|1|
9909029|NCT00689416|Placebo Comparator|2|
9909030|NCT00689442|Experimental|1|JTT-705 600 mg and atorvastatin 20 mg
9909031|NCT00689442|Placebo Comparator|2|Placebo and atorvastatin 20 mg
9909032|NCT00689455||1|Primary care population
9909033|NCT00689468|Placebo Comparator|1|"Osteopathic sham treatment plus placebo Echinacea drops"
9909034|NCT00689468|Active Comparator|2|Active Echinacea drops plus sham osteopathic treatment
9909035|NCT00689468|Active Comparator|3|"Active osteopathic manipulation plus placebo Echinacea drops"
9909036|NCT00689468|Active Comparator|4|Active osteopathic manipulation plus active Echinacea drops.
9909037|NCT00689507|Experimental|Dose Escalation Phase(Part A):|1,10, 30, 100 or 300 mg of LY2127399 IV on day 1 of specific 21 day cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each 21 day cycle
9909038|NCT00689507|Experimental|Dose Confirmation Phase (Part B1):|Dose determined by PK/PD modeling, LY2127399 IV on day 2 of Cycle 1 and on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each cycle
9909039|NCT00689507|Experimental|Dose Confirmation Phase (Part B2):|Dose determined by PK/PD modeling, LY2127399 IV on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of specific cycles
9909040|NCT00689520|Experimental|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months.
9909041|NCT00689520|Active Comparator|acenocoumarol|tinzaparin for 1 weeks followed by acenocoumarol for 6 months
9909042|NCT00689546||I/A|All cases of acute viral hepatitis irrespective of type (A, B, E) with underlying Type 2 diabetes mellitus
9909043|NCT00689546||I/B|Age and sex matched non- diabetic patients with acute viral hepatitis (irrespective of type) recruited from all the patients of acute viral hepatitis registered during the time period in which cases were recruited.
9909044|NCT00689546||II/A|All diabetic who have acute icteric viral hepatitis due to HEV infection
9909045|NCT00689546||II/B|Age and sex matched diabetic who have acute icteric viral hepatitis due to hepatiits virus other than HEV.
9909046|NCT00689559|Experimental|1|AZD3480 + Aripiprazole
9909047|NCT00689559|Experimental|2|Placebo + Aripiprazole
9909048|NCT00689585|Placebo Comparator|1|
9909049|NCT00689585|Experimental|2|
9909050|NCT00689598|Placebo Comparator|III|Placebo
9909051|NCT00689598|Experimental|Experimental|Drug intervention
9909052|NCT00689624|Experimental|1|FOLFOXIRI+Erbitux
9909053|NCT00689637|Experimental|1|AZD3480 + warfarin
9909054|NCT00689637|Experimental|2|Placebo+ warfarin
9909055|NCT00689650|Experimental|A|
9909056|NCT00689650|No Intervention|B|
9909057|NCT00689663|Active Comparator|1|Dissection staring at the triangle of calots. Dissection with electrocautery.
9909058|NCT00689663|Active Comparator|2|Dissection as fundus first with electrocautery.
9909059|NCT00689663|Active Comparator|3|Dissection as fundus first with ultrasonic dissection.
9909060|NCT00689676||Study Group|20 very low birth weight preterm toddlers
9909061|NCT00689676||Control Group|20 full-term toddlers
9909062|NCT00689689|Active Comparator|Fully Coated Prodigy Stem (AML)|Total hip arthroplasty with fully coated prodigy stem (AML)
9909063|NCT00689689|Active Comparator|Cemented Endurance Hip Stem|Total hip arthroplasty with cemented Endurance hip stem component
9909064|NCT00689715|Experimental|EP|Single treatment arm
9909065|NCT00689741|Experimental|A|
9909066|NCT00689741|Placebo Comparator|B|
9909067|NCT00689754|Active Comparator|NGA|Patients will receive the standard of care to proceed with nasogastric tube placement, aspiration and lavage up to 1L of normal saline
9909068|NCT00689754|No Intervention|NO NGA|Patient presenting with Upper GI hemorrhage going straight to endoscopy.
9909069|NCT00689767|Experimental|A|This arm will receive the coated stent
9909070|NCT00689767|Active Comparator|B|This arm will receive a bare metal stent
9909071|NCT00689780|Experimental|1|AZD1940 + Placebo
9909072|NCT00689780|Other|2|
9909073|NCT00689806|Placebo Comparator|Placebo|
9909074|NCT00689806|Active Comparator|Lovastin|
9909075|NCT00689832|Experimental|A|
9909076|NCT00689832|Active Comparator|B|
9909077|NCT00689845|Experimental|Cohort 1|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also receive oral prednisolone on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
9909078|NCT00689845|Experimental|Cohort 2|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
9909079|NCT00689845|Experimental|Cohort 3|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV and doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; methotrexate IV on days 8, 36, and 64; vincristine IV on days 8, 22, 36, 50 ,64, and 78; bleomycin IV on days 22, 50, and 78; and oral prednisolone on days 1-84, followed by a taper.
9909080|NCT00689845|Experimental|Cohort 4|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV on days 1, 29, and 57; doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; etoposide phosphate IV on days 15, 16, 43, 44, 71, and 72; vincristine IV and bleomycin IV on days 8, 22, 36, 50, 64, and 78; and oral prednisolone on days 1-84, followed by a taper.
9909081|NCT00689845|Experimental|Cohort 5|Patients receive rituximab IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1; vindesine IV and bleomycin IV on days 1 and 5; oral prednisone on days 1-5; methotrexate intrathecally on day 2; and G-CSF SC on days 6-13 for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses of R-ACVBP, patients receive consolidation therapy comprising high-dose methotrexate IV, rituximab IV, ifosfamide IV, etoposide phosphate IV, and cytarabine SC according to protocol GELA LNH03-2B.
9909082|NCT00689858|Experimental|1|Period 1: Cilostazol, Ginkgo biloba Period 2:Cilostazol, placebo
9909083|NCT00689858|Active Comparator|2|Period 1: Cilostazol, placebo Period 2: Cilostazol, Ginkgo biloba
9909084|NCT00689897|Experimental|1|In acupuncture treatment, immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation, the needles are retained for 30 minutes.
9798614|NCT01634191|Experimental|Elderly: Apremilast 30 mg|Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.
9798615|NCT01634191|Experimental|Younger: Apremilast 30 mg|Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.
9798616|NCT01634243|Experimental|SPM 962|SPM 962 transdermal patch
9798617|NCT01634256|Experimental|Fermented turmeric|
9798618|NCT01634256|Placebo Comparator|Placebo|
9798619|NCT01634269|Experimental|MDT-2111 TAVI 23 mm|Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
9798620|NCT01634360|Experimental|Perampanel (1-4 mg)|Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204), and dosed placebo or perampanel. Subjects started this open-label extension study on perampanel 1 mg once daily for two weeks, followed by 2 mg once daily for two weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
9798621|NCT01634555|Experimental|ramucirumab (IMC-1121B) and FOLFIRI|Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
9798622|NCT01634620||FeNO|Participants with chronic obstructive pulmonary disease (COPD) will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
9798623|NCT01634659|Other|Delefilcon A, then narafilcon B|Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
9798624|NCT01634659|Other|Narafilcon B, then delefilcon A|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
9798625|NCT01634854|Active Comparator|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
9798626|NCT01634854|Active Comparator|Intravenous Oxytocin|"2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
9798627|NCT01635062|Experimental|calcitriol|Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
9798628|NCT01635062|Placebo Comparator|placebo|Subjects will receive placebo for 3 weeks.
9798629|NCT01635101|Experimental|Low Dose Acetaminophen|Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours
9798630|NCT01635101|Experimental|High Dose Acetaminophen|Participants receive a low dose of acetaminophen (IV) for 24 hours
9798631|NCT01635101|Placebo Comparator|Placebo|Participants receive matching placebo (IV) for 24 hours
9798632|NCT01635153|Active Comparator|Protein calorie supplement plus micronutrient|
9798633|NCT01635153|Placebo Comparator|Micronutrient alone|
9909085|NCT00689897|Active Comparator|2|In acupuncture treatment, immediately after insertion of a needle, it is NOT manually rotated backwards or forwards to induce the DeQi sensation, and retained for 30 minutes.
9909086|NCT00689949|Other|folic acid|
9909087|NCT00689962|Experimental|1|Patients with unstable Lisfranc foot fracture-dislocations that receive bioabsorbable screw fixation through surgery.
9909088|NCT00689962|Active Comparator|2|Patients with unstable Lisfranc fracture-dislocations of the foot that receive steel screw fixation through surgery.
9909089|NCT00689988|Experimental|SG|Study Group: five children with Down syndrome submitted to speech-language intervention with AAC intervention
9909090|NCT00690001||1|HIV-1 infected patients in Taiwan
9909091|NCT00690014|Experimental|A|
9909092|NCT00690027|Active Comparator|A|"Objective: See Brief Summary, page 2. Eligibility: Patients who require > 2 units blood transfusion for bleeding esophageal varices due to cirrhosis.~Randomization: By the blind card method to emergency portacaval shunt (EPCS) or emergency endoscopic sclerotherapy (EST) followed by long-term repetitive EST.~Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 8hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months, or rebleeding after varices were obliterated.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong. Data Collection on line, analysis by biostatistician Florin Vaida, PhD External Advisory, Data Monitoring and Safety Committee by 3 senior academicians."
9909093|NCT00690027|Active Comparator|B|Emergency endoscopic sclerotherapy
9909094|NCT00690053|Experimental|1|
9909095|NCT00690079|Experimental|AZD1386|7 groups receiving a specified volume of the active component AZD1386 at different points of time.
9909096|NCT00690079|Placebo Comparator|Placebo|7 groups receiving a specified volume of placebo at different points of time
9909097|NCT00690092|Active Comparator|1|Volunteers with a history of pulmonary coccidioidomycosis verified by serology and/or histology or mycology.
9909098|NCT00690092|Active Comparator|2|Volunteers without a history of pulmonary coccidioidomycosis confirmed by serology (naive).
9909099|NCT00690092|Active Comparator|3|Volunteers with a history of pulmonary histoplasmosis but no history of coccidioidomycosis confirmed by serology.
9909100|NCT00690105|Experimental|A|
9909101|NCT00690105|Active Comparator|B|
9909102|NCT00690118|Active Comparator|1|
9909103|NCT00690118|Placebo Comparator|2|
9909104|NCT00690131|Experimental|1|
9909105|NCT00690131|No Intervention|2|
9909106|NCT00690144|Experimental|simulation group|the trainees in the simulation group receive simulation-based training
9909107|NCT00690170|Active Comparator|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotine IV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
9909108|NCT00690170|Placebo Comparator|Placebo Comparator|-Placebo administration: Normal saline (sodium chloride 0.9%)over 95 minutes
9909109|NCT00690170|Active Comparator|Ketamine and Placebo|"Ketamine administration: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes~Placebo administration: Normal saline (sodium chloride 0.9%)over 94 minutes"
9909110|NCT00690170|Active Comparator|Nicotine and Placebo|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg)IV (in the arm), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
9909111|NCT00690196|Experimental|1|Tai Chi Chih
9909112|NCT00690196|Active Comparator|2|Cognitive Behavioral Therapy
9909113|NCT00690222|No Intervention|TM|Topical mydriasis without pseudoexfoliation
9909114|NCT00690222|Experimental|ICM|Intracameral mydriasis without pseudoexfoliation
9909115|NCT00690222|No Intervention|TM - PXF|Topical mydriasis with pseudoexfoliation
9909116|NCT00690222|Experimental|ICM - PXF|Intracameral Mydriasis with pseudoexfoliation
9909117|NCT00690248||1|Bipolar patients admitted to a psychiatric Unit due to an acute mania episode.
9909118|NCT00690261||lung cancer|patients diagnosed of lung cancer with malignant pleural effusions
9909119|NCT00690287|Experimental|Part A, arm 1|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food
9909120|NCT00690287|Experimental|Part A, arm 2|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food
9909121|NCT00690287|Experimental|Part B, arm1, 2, and 3|"AZD6370 dose x mg o.d.~dose x/2 mg b.i.d.~dose x/4 mg q.i.d."
9909122|NCT00690287|Experimental|Part B, arm 4|4) Placebo
9909123|NCT00690313|Active Comparator|Arm 1|Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
9909124|NCT00690313|Active Comparator|Arm 2|Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
9909125|NCT00690326|Experimental|A|"treatment type: behavioral(lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
9909126|NCT00690326|Placebo Comparator|B|Arm B given placebo comparator ie pamphlets
9933883|NCT05170399|Experimental|Follicular Lymphoma - Treatment with Targeted Therapies|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9933884|NCT05170399|Experimental|Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia - Treatment with Targeted Therapies|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9933885|NCT05170399|Experimental|Other Non-Hodgkin Lymphoma and Waldenstron Macrobulinemia - Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
9933886|NCT05169723|Experimental|Respiratory Activity 1|
9933887|NCT05169723|Experimental|Respiratory Activity 2|
9933888|NCT05169723|Experimental|Respiratory Activity 3|
9933889|NCT05169723|Experimental|Respiratory Activity 4|
9933890|NCT05169723|Experimental|Respiratory Activity 5|
9933891|NCT05165160|Experimental|Eligible patients|
9933892|NCT05163080|Active Comparator|Arm A|Peptide Vaccine (SurVaxM) in emulsion with Montanide given together with locally administered Sargramostim plus adjuvant oral Temozolomide
9933893|NCT05163080|Placebo Comparator|Arm B|Saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide
9933894|NCT05162911|Active Comparator|Ask, Advise, Assist (AAA) and Refer.|Patients will receive Ask, Advise, Assist (AAA) and refer to the quitline as the intervention.
9933895|NCT05162911|Active Comparator|AAA plus referral to onsite counselor (Counsel).|Patients will receive Ask, Advise, Assist plus referral to onsite counselor.
9933896|NCT05162911|Active Comparator|AAA+Counsel+N (Nicotine gum).|Patients will receive Ask, Advise, Assist, plus referral to onsite counselor and nicotine gum.
9933897|NCT05162391|Other|Contingency management|All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
9933898|NCT05157490|Experimental|Mindfulness training|Completion of guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
9933899|NCT05157490|No Intervention|Control|
9933900|NCT05157022|Active Comparator|Focus extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
9933901|NCT05157022|Active Comparator|Radial extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
9933902|NCT05157022|Sham Comparator|Sham extracorporeal shock wave therapy|A total of 4 sessions of ESWT at 1-week intervals were applied to to the sacrococcygeal area
9933903|NCT05156463|No Intervention|Control|Participants will receive standard follow-up survivorship care, an accelerometer to measure physical activity and NCCN (National Comprehensive Cancer Network) patient materials.
9933904|NCT05156463|Experimental|Treatment|Participants will receive same materials as standard of care group. In addition participants will use PAI Activity tool, Garmin activity tracker and exercise logs, and also receive periodic exercise coaching.
9933905|NCT05155501|Active Comparator|Robot-assisted radical prostatectomy (RP)|The conventional robotic-assisted radical prostatectomy is the gold standard approach to prostate cancer surgery.
9909127|NCT00690391||Surgical observation|patients with cancer in a palliative setting and in need of surgical interventions
9909128|NCT00690404|Experimental|1|
9909129|NCT00690417|Placebo Comparator|1|
9909130|NCT00690417|Active Comparator|2. 2500 IU vitamin D in a food preparation|Daily ingestion of 2500 IU vitamin D in a food preparation.
9909131|NCT00690469||Observational (biomarker analysis)|"Participants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology.~Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available.~For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened."
9909132|NCT00690521|Active Comparator|1|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
9909133|NCT00690521|Active Comparator|2|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
9909134|NCT00690534|Active Comparator|CMAY|Insulin in young
9909135|NCT00690534|Experimental|IMAY|L-NMMA + insulin in young
9909136|NCT00690534|Experimental|SNPY|SNP in young
9909137|NCT00690534|Active Comparator|CSNP|Insulin in elderly
9909138|NCT00690534|Experimental|ISNP|SNP in elderly
9909139|NCT00690534|Experimental|SNPE|SNP in elderly
9909140|NCT00690534|Active Comparator|CMealO|Meal in elderly
9909141|NCT00690534|Experimental|SMealO|SNP+meal in elderly
9909142|NCT00690534|Active Comparator|MealY|meal in young
9909143|NCT00690534|Experimental|ExIns|insulin+exercise in elderly
9909144|NCT00690534|Experimental|ExMeal|meal+exercise in elderly
9909145|NCT00690547||Test Group|
9909146|NCT00690560|Experimental|R-CHOP14 chemotherapy|
9909147|NCT00690625|Experimental|A|MyoRx cream
9909148|NCT00690625|Placebo Comparator|B|Placebo cream, same composition as experimental cream, without Omega 3 fatty acid
9909149|NCT00690638|Placebo Comparator|1|Placebo
9909150|NCT00690638|Experimental|2|PHX1149T 200 mg
9909151|NCT00690638|Experimental|3|PHX1149T 400 mg
9909152|NCT00690651|Active Comparator|2|this group will rest in bed with operated leg well elevated for 48 hour and then mobilize with physiotherapist with aim for discharge home when safe.
9909153|NCT00690651|Experimental|1|mobilize with physiotherapist within 24 hours of surgical fixation of fractured ankle
9909154|NCT00690664||B|Caucasian women
9909155|NCT00690664||A|African American women
9909156|NCT00690690|Experimental|video|
9909157|NCT00690690|Active Comparator|HCT|Offer of HIV counseling and testing
9909158|NCT00690703|Experimental|1|Treatment
9909159|NCT00690729|Experimental|1|Bibliotherapy - cognitive behavior therapy focusing on exposure and response prevention directed by the family
9909160|NCT00690729|Active Comparator|2|Cognitive Behavioral Therapy - therapist-directed exposure response prevention over a 12-week period
9909161|NCT00690768|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
9909162|NCT00690768|Active Comparator|B|Pars plana vitrectomy only
9909163|NCT00690781|Experimental|Casein Pulse|"casein is the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
9909164|NCT00690781|Experimental|Casein Spread|"casein is the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
9909165|NCT00690781|Experimental|MSP Pulse|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
9909166|NCT00690781|Experimental|MSP Spread|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
9909167|NCT00690807|Experimental|1|PH-10 treatment
9909168|NCT00690846|Experimental|1|40 mg weekly subcutaneous injection of adalimumab
9909169|NCT00690859||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
9909170|NCT00690885|Experimental|1|lozenges containing 150 IU of natural human interferon-alpha
9909171|NCT00690885|Placebo Comparator|2|matching placebo lozenges
9909172|NCT00690911|Experimental|1|open label adalimumab 40mg
9909173|NCT00690937|Experimental|1 ECS|Low dose treatment
9909174|NCT00690937|Experimental|2 ECS|High dose treatment
9909175|NCT00690937|Active Comparator|3 Colesevelam|Active control treatment
9909176|NCT00690937|Placebo Comparator|4 Placebo|Placebo matched to low dose treatment
9909177|NCT00690937|Placebo Comparator|5 Placebo|Placebo matched to high dose treatment
9909178|NCT00690976|Experimental|1.Group Intervention|A group-based intervention consisting of 4 sessions lasting approximately 90 minutes each. Using a variety of pedagogical and interactive approaches, facilitators will introduce new concepts and skills.
9909179|NCT00690976|Active Comparator|2. HCT|Offer of HIV counseling and testing
9909180|NCT00691041|Experimental|1|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
9994208|NCT01479075|Experimental|placebo in study participants|placebo spray is applied intranasally in healthy participants under fasting conditions
9909181|NCT00691041|No Intervention|2|HIV/STI counseling and testing and a single 15 minute session of resources available in the community
9909182|NCT00691067|Experimental|Mifepristone|600mg of Mifepristone
9909183|NCT00691067|Placebo Comparator|Placebos|Placebo
9909184|NCT00691080||ASD children|"ASD children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects).~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness."
9933906|NCT05155501|Experimental|Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)|A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate. These structures are disrupted and removed during conventional radical prostatectomy.
9933907|NCT05155059|Sham Comparator|Control|Sham TMS stimulation using a sham coil
9933908|NCT05155059|Experimental|Treatment|Active TMS stimulation using an active TMS coil
9933909|NCT05155046|Experimental|18F-DCFPyL imaging|18F-DCFPyL imaging with routine imaging (mpMRI)
9909185|NCT00691080||"Healthy control children"|"Healthy control children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children.~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids;~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions.~(8) No sibling with a diagnosis of Autism Spectrum Disorder."
9909186|NCT00691119|Experimental|A|Relaxation and Visualization Therapy group
9909187|NCT00691119|Active Comparator|B|Health education group
9909188|NCT00691119|No Intervention|C|Control group
9909189|NCT00691145|Experimental|1|
9909190|NCT00691158|Placebo Comparator|1- Normal Saline|4.7 mls normal saline IV bolus
9909191|NCT00691158|Active Comparator|2 Metreleptin|IV Leptin bolus
9909192|NCT00691158|Active Comparator|3 Pramlintide|IV Pramlintide bolus at Timpoint +0 and +30 minutes
9909193|NCT00691158|Active Comparator|4 Leptin plus Pramlintide|leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes
9909194|NCT00691171||1|GERD: Patients with established diagnoses of GERD based on ICD-9 codes
9909195|NCT00691171||2|Atypical GERD: Patients without an established diagnosis of GERD with atypical symptoms that could be due to GERD (e.g., asthma)
9909196|NCT00691171||3|Chronic NSAID users: Patients using chronic NSAIDs who are at increased risk of GI complications (defined as previous diagnosis of peptic ulcer disease; age 75 or older; or concomitant use of corticosteroids, anticoagulants, or aspirin)
9909197|NCT00691184|Experimental|Group 1|0% Terbinafine HCl Nail Lacquer for 28 days.
9909198|NCT00691184|Experimental|Group 2|10% Terbinafine HCl Nail Lacquer.
9909199|NCT00691184|Active Comparator|Group 3|1% Lamisil® Cream
9909200|NCT00691184|Active Comparator|Group 4|Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
9909201|NCT00691236|Active Comparator|A|standard chemotherapy which is Adriamycin, Cisplatinum and Ifosfamide
9909202|NCT00691236|Experimental|B|zoledronic acid prior to standard chemotherapy
9909203|NCT00691236|Experimental|C|zoledronic acid alone 4mg IV 3 weekly for 6 doses
9909204|NCT00691249|Experimental|1|Resistant starch type 4-Raw
9909205|NCT00691249|Experimental|2|Resistant starch type 4-Raw
9909206|NCT00691249|Experimental|3|Resistant starch type 4-Cooked
9909207|NCT00691249|Experimental|4|Resistant starch type 4-Cooked
9909208|NCT00691249|Placebo Comparator|5|Shredded wheat
9909209|NCT00691262|Experimental|1|
9909210|NCT00691275|Placebo Comparator|2|Saline
9909211|NCT00691275|Active Comparator|1|Zofran
9909212|NCT00691288|Experimental|1|
9909213|NCT00691288|Experimental|2|
9909214|NCT00691314|Experimental|1|
9909215|NCT00691314|Active Comparator|2|
9909216|NCT00691340||1|Control 1 (young subjects)
9909217|NCT00691340||2|Control 2 (old subjects)
9909218|NCT00691340||3|Glaucoma patients
9909219|NCT00691340||4|Alzheimer patients
9909220|NCT00691379|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
9909221|NCT00691392|Experimental|1|Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB
9909222|NCT00691392|Placebo Comparator|2|Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler
9909223|NCT00691405|Experimental|A1|Arformoterol 5 mcg BID for 14 days
9909224|NCT00691405|Experimental|A2|Arformoterol 15 mcg BID for 14 days
9909225|NCT00691405|Experimental|A3|Arformoterol 25 mcg BID for 14 days
9909226|NCT00691405|Placebo Comparator|A4|Placebo inhalation solution BID for 14 days
9909227|NCT00691405|Experimental|B1|Arformoterol 15 mcg QD for 14 days
9909228|NCT00691405|Experimental|B2|Arformoterol 25 mcg QD for 14 days
9909229|NCT00691405|Experimental|B3|Arformoterol 50 mcg QD for 14 days
9909230|NCT00691405|Placebo Comparator|B4|Placebo inhalation solution QD for 14 days
9909231|NCT00691418|Active Comparator|1|600 mg per day of docosahexaenoic acid (DHA)
9909232|NCT00691418|Placebo Comparator|2|Placebo
9909233|NCT00691457|Experimental|1|Opti-Free contact lens solution
9909234|NCT00691457|Active Comparator|2|ReNu Multiplus contact lens solution
9909235|NCT00691457|Active Comparator|3|Clear Care contact lens solution
9909236|NCT00691470|Experimental|1. ATI-5923|Dose adjusted ATI-5923
9909237|NCT00691470|Active Comparator|2. Coumadin|Dose adjusted Coumadin (warfarin)
9909238|NCT00691496|Experimental|1|Receives HIV testing and counseling and 5 week intervention
9909239|NCT00691496|No Intervention|2|Receives only HIV Testing and Counseling
9909240|NCT00691548|Experimental|1|
9909241|NCT00691561|Experimental|1|Participants receive HIV counseling and testing and 8 intervention sessions to assist them with reducing unsafe sexual behaviors.
9909242|NCT00691561|No Intervention|2|Participants receive HIV counseling and testing only.
9909243|NCT00691587|Experimental|1|Low-dose KB001, a monoclonal antibody
9909244|NCT00691587|Experimental|2|High-dose KB001, a monoclonal antibody
9909245|NCT00691587|Placebo Comparator|3|Placebo
9909246|NCT00691613|Experimental|1|EPO
9909247|NCT00691613|Placebo Comparator|2|NaCl
9909248|NCT00691626|Experimental|Arm 1: CBT for Insomnia plus Imagery Rehearsal|CBT for Insomnia plus Imagery Rehearsal
9909249|NCT00691626|Active Comparator|Arm 2: CBT for Insomnia|CBT for Insomnia
9909250|NCT00691639||1|Patients who are or were participants in any Alcon AL-3789 study.
9909251|NCT00691678|Experimental|chondroitin and glucosamine|Postmenopausal breast cancer patients that have joint symptoms induced by aromatase inhibitors and are receiving chondroitin and glucosamine.
9909252|NCT00691691|Experimental|1|Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
9909253|NCT00691743||1|Primary care
9909254|NCT00691756|Experimental|1|Cold blood renal perfusion
9909255|NCT00691756|Active Comparator|2|Cold crystalloid renal perfusion
9909256|NCT00691769||I|CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
9909257|NCT00691769||II|patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
9909258|NCT00691769||III|Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.
9909259|NCT00691782||1|African American females between the ages of 21 and 60
9909260|NCT00691795|Experimental|CLONIDINE|Participants randomized to this arm of the study receive 75 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
9909261|NCT00691795|Experimental|FENTANYL|Participants randomized to this arm of the study receive 75 micrograms fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
9909262|NCT00691821|Active Comparator|1|Standard Dressings
9909263|NCT00691821|Experimental|2|Negative Pressure Wound Therapy
9909264|NCT00691834|Experimental|1|Intracoronary delivery of unfractionated bone marrow mononuclear cells
9909265|NCT00691834|Placebo Comparator|2|Intracoronary delivery of placebo
9909266|NCT00691847||1|Bilateral post refractive procedure
9909267|NCT00691860|Experimental|1|Patients receiving conventional sigmoid end colostomy plus a lightweight mesh Ultrapro®
9909268|NCT00691860|Other|2|Patients receiving conventional sigmoid end colostomy, without mesh
9909269|NCT00691873|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
9909270|NCT00691873|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
9909271|NCT00691886|No Intervention|1|Subjects randomized to arm 1 of the study will recieve standard of care conscious sedation for EBUS; midasolam and or fentanyl.
9909272|NCT00691886|Active Comparator|2|Subjects undergoing EBUS randomized to arm 2 of the study will recieve demedetomadine hydrochloride plus standard of care conscious sedation
9909273|NCT00691899|Experimental|1|
9909274|NCT00691899|Placebo Comparator|2|
9909275|NCT00691912|Experimental|Myocet/Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
9909276|NCT00691925||1|bilateral post refractive surgery subject
9909277|NCT00691977|Experimental|A|Radiation Therapy followed by prostatectomy
9909278|NCT00691990|Active Comparator|A|Classic thyroidectomy with drains
9909279|NCT00691990|Active Comparator|B|Classic thyroidectomy without drains
9909280|NCT00692016|Other|Arm 1|
9909281|NCT00692016|Other|Arm 2|
9909282|NCT00692042|Experimental|1|
9909283|NCT00692055|Experimental|1|PN400
9909284|NCT00692055|Active Comparator|2|naproxen 375 mg
9909285|NCT00692068||A|with residual renal function
9909286|NCT00692068||B|without residual renal function
9909287|NCT00692081|Experimental|A|8 group sessions social competence training (CBT)
9909288|NCT00692081|Active Comparator|B|special vocational training as usual
9909289|NCT00692107|Active Comparator|1|68 Gy
9909290|NCT00692107|Experimental|2|78 Gy
9909291|NCT00692120|Experimental|1|
9909292|NCT00692120|Experimental|2|
9909293|NCT00692120|Experimental|3|
9909294|NCT00692120|Experimental|4|
9909295|NCT00692146|Experimental|1|36 subjects receiving a specified volume of the active component AZD1386 in a single dose.
9909296|NCT00692146|Placebo Comparator|2|36 subjects receiving a specified volume of placebo in a single dose.
9909297|NCT00692159|Experimental|1|Dose finding single arm
9909298|NCT00692172|Experimental|1|
9994209|NCT01479075|Experimental|taNVS|Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
9798634|NCT01635218|Experimental|Individualized homeopathic treatment|Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
9798635|NCT01635218|Experimental|Fluoxetine|Selective serotonin reuptake inhibitor.
9798636|NCT01635218|Placebo Comparator|Placebo|Fluoxetine placebo plus individualized homeopathic placebo
9798637|NCT01635244|Active Comparator|Freestyle|Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
9798638|NCT01635244|Active Comparator|Magna Ease|Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
9798639|NCT01635244|Active Comparator|Trifecta|Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
9798640|NCT01635283|Experimental|Treatment (tumor lysate-pulsed autologous dendritic cells)|Patients receive autologous glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 0, 14, and 28.
9798641|NCT01635439|Active Comparator|Propess|Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
9798642|NCT01635439|Active Comparator|Prostin E2|PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.
9798643|NCT01635504|Experimental|botulinum toxin A|
9798644|NCT01635764|Experimental|Adalimumab Every Week|Adalimumab 40 mg every week.
9798645|NCT01635855|Experimental|Belotero|Belotero® Hyaluronic acid dermal filler
9798646|NCT01635881|Experimental|Emerge|Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
9798647|NCT01635920|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
9798648|NCT01635920|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
9798649|NCT01635933|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn in daily wear modality for 4 weeks. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
9798650|NCT01635933|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn in daily wear modality for 4 weeks, with a replacement pair dispensed at 14 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
9909299|NCT00692224|Active Comparator|1|study group received zinc gluconate in a dose of 10 mg/day
9909300|NCT00692224|Placebo Comparator|2|placebo group received placebo which was identical in color, taste and appearance and packaged in similar looking bottles.
9909301|NCT00692263|Experimental|A|Escitalopram - tramadol
9909302|NCT00692263|Experimental|B|Placebo - tramadol
9909303|NCT00692263|Experimental|C|placebo - placebo
9909304|NCT00692302|Experimental|SAFETY I|Phase I participants who will receive SAFETY
9909305|NCT00692302|Experimental|SAFETY II|Phase II participants who will receive SAFETY
9909306|NCT00692302|Active Comparator|Control|Phase II participants who will receive enhanced usual care
9909307|NCT00692315|Experimental|Methyl B12|Subcutaneous injection of 75 micrograms/Kg
9909308|NCT00692315|Experimental|Folinic Acid|400 micrograms orally twice a day
9909309|NCT00692328|Active Comparator|1|The subjects will be told they receive levodopa or acupuncture.
9909310|NCT00692328|Placebo Comparator|2|The subjects will be told they receive placebo/sham levodopa or acupuncture.
9909311|NCT00692328|Experimental|3|The subjects will be told they have 50% chance of receiving real or placebo/sham levodopa or acupuncture.
9909312|NCT00692367|Other|Exercise|Structured exercise program
9909313|NCT00692380|Experimental|A|Fractionated Radiation Therapy followed by Carboplatin and Taxol
9909314|NCT00692393|Active Comparator|1|Surgery : Hartmann intervention
9909315|NCT00692393|Experimental|2|Surgery : primary resection with anastomosis with protective stoma
9909316|NCT00692458|Experimental|1|odanacatib
9909317|NCT00692458|Placebo Comparator|2|placebo
9909318|NCT00692471||1|Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance
9909319|NCT00692471||2|Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome
9909320|NCT00692497|Active Comparator|1|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
9909321|NCT00692497|No Intervention|2|Patients in the control group are randomised to use the regular patient pathway prior to day case outpatient surgery. All these patients are referred to the surgical outpatient clinic. At the outpatient clinic patients are examined by a surgeon and indications for surgery is decided by the surgeon. If indicated, patients are then referred to outpatient surgery and the surgical procedure is performed several weeks after the examination.
9909322|NCT00692510|Experimental|1|AZD3480 + cocktail
9909323|NCT00692510|Placebo Comparator|2|Placebo + cocktail
9909324|NCT00692523|Active Comparator|1|The control group will receive 8 recreational therapy sessions over a 2-week (14 day) period, to be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
9909325|NCT00692523|Experimental|2|Patients randomized to Wii technology will receive an intensive program consisting of 8 Wii gaming sessions, 60 minutes each, over a 2-week (14 day) period. These 8 sessions can be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
9909326|NCT00692536|Active Comparator|1|NNR
9909327|NCT00692536|Active Comparator|2|MPD
9909328|NCT00692549|Experimental|Ultrasound|use of ultrasound
9909329|NCT00692549|No Intervention|no ultrasound|no ultrasound
9909330|NCT00692562|Experimental|A|
9909331|NCT00692575|Experimental|1: Experimental|Problem-solving, education based telephone counseling.
9909332|NCT00692575|Sham Comparator|2: No intervention|Standard of care control group
9909333|NCT00692588||Placebo|Subjects who received placebo in DARAD Trial
9909334|NCT00692588||Doxycycline|Subjects who received doxycycline in DARAD Trial
9909335|NCT00692588||Rifampicin|Subjects who received rifampicin in DARAD Trial
9909336|NCT00692588||Doxycycline and Rifampicin|Subjects who received doxycycline and rifampicin in DARAD Trial
9909337|NCT00692588||Control|Normal controls
9909338|NCT00692601|Experimental|1|acute oral ingestion of 3 mg capsiate
9909339|NCT00692601|Experimental|2|acute oral ingestion of 10 mg capsiate
9909340|NCT00692601|Placebo Comparator|3|acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules)
9909341|NCT00692614|Experimental|1|100 mcg triamcinolone acetonide
9909342|NCT00692614|Experimental|2|500 mcg triamcinolone acetonide
9909343|NCT00692614|Experimental|3|925 mcg triamcinolone acetonide
9909344|NCT00692614|No Intervention|4|sham control - not implanted, no medication
9909345|NCT00692640|Experimental|1|
9909346|NCT00692653|Experimental|P4|Participant uses P4 program before meeting with his clinician to discuss treatment options.
9909347|NCT00692653|No Intervention|Usual care+|Usual care plus participant is directed to reputable websites highly rated in research literature to learn more about prostate cancer treatments.
9909348|NCT00692705|Other|1|Alzheimer's Disease (AD) patients
9909349|NCT00692705|Other|2|Healthy volunteers
9909350|NCT00692731||Active|Tea catechin sport beverage
9909351|NCT00692731||Control|Control beverage
9909352|NCT00692744||Randomized microsurgical|After randomization, this group was constituted of patients treated by microsurgical clipping.
9909353|NCT00692744||Randomized endovascular|After randomization, this group was constituted of patients treated by endovascular coiling.
9909354|NCT00692744||Prospective observational microsurgical|The randomization was ethically unsuitable because of the aneurysm predisposed to the microsurgical clipping after discussion into the neurovascular interdisciplinary team.
9909355|NCT00692744||Prospective observational endovascular|The randomization was ethically unsuitable because of the aneurysm morphology predisposed to the endovascular coiling after discussion into the neurovascular interdisciplinary team.
9909356|NCT00692744||Prospective observational conservative|This group was constituted of patients whom no curative treatment of the aneurysm sac could not be proposed.
9909357|NCT00692757|Experimental|A|Hypochlorous acid
9909358|NCT00692757|Active Comparator|B|Iodopovidone
9909359|NCT00692796|Experimental|1|
9909360|NCT00692809||1|HIV+ve+LTBI (n=100)
9909361|NCT00692809||2|HIV+ve+clinical TB (n=50)
9909362|NCT00692809||3|HIV-ve+clinical TB (n=15)
9909363|NCT00692809||4|Normal control (n=15)
9909364|NCT00692835|Active Comparator|A|Patients with mini Video Assisted Thyroidectomy (miVAT)
9909365|NCT00692835|Active Comparator|B|Immediate postoperative course of patients with classic Thyroidectomy (cTT)
9909366|NCT00692848|Experimental|PCT+|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm procalcitonin result is revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him
9909367|NCT00692848|No Intervention|PCT-|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm, procalcitonin is not revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him.
9909368|NCT00692887||1|Subjects diagnosed as new CNV or treated CNV
9909369|NCT00692900|Experimental|1|intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin
9909370|NCT00692900|Experimental|2|intravenous (IV) oxaliplatin and intraperitoneal(IP) docetaxel
9909371|NCT00692926|Other|20% primed UCB|20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
9909372|NCT00692926|Other|20% un-primed|20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
9909373|NCT00692926|Other|Double- 1 unit primed|patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
9909374|NCT00692926|Other|Double- 1 unit unprimed|Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted
9909375|NCT00692952|Experimental|1|120 subjects using BenZalkonium Chloride Contraceptive Gel
9909376|NCT00692952|Active Comparator|2|120 subjects using Nonoxynol-9 contraceptive gel
9909377|NCT00692991||1|People undergoing percutaneous coronary interventions.
9909378|NCT00693004|Placebo Comparator|Placebo|
9909379|NCT00693004|Experimental|PRX-03140|
9909380|NCT00693004|Active Comparator|donepezil|
9909381|NCT00693030|Active Comparator|1|Device, Sirolimus drug-eluting stents implanted in overlap
9909382|NCT00693030|Active Comparator|2|Device, paclitaxel polymer drug eluting stent
9909383|NCT00693030|Active Comparator|3|Device, zotarolimus drug eluting stent
9909384|NCT00693030|Active Comparator|4|bare metal coronary stents
9909385|NCT00693043|No Intervention|Standard anesthesia group|Patients randomized to arm 1 received standard of care anesthesia for pleuroscopy. Duration of the procedure will be recorded. Pain management will be monitored prior to, intraoperatively and at the end of the procedure.
9909386|NCT00693043|Experimental|Lidocaine Group|Patients randomized to arm two will receive a reduced topical dose of lidocaine of 2mg/kg and additional lidocaine 3mg/kg infused into the pleura cavity. Duration of procedure will be monitored from the time initial dose of intradermal lidocaine until the start of surgical wound closing, pain scale will be administered prior to the procedure and at the end of the procedure. Lidocaine serum levels will be monitored at 30, 60, and 120 minutes after initial intradermal administration of lidocaine.
9909387|NCT00693056|Placebo Comparator|1|
9909388|NCT00693056|Experimental|2|
9909389|NCT00693056|Experimental|3|
9909390|NCT00693056|Experimental|4|
9909391|NCT00693069|Active Comparator|1|Clopidogrel 300 mg the day before PCI
9909392|NCT00693069|Experimental|2|Clopidogrel 600 mg the day before PCI
9909393|NCT00693069|Experimental|3|300 mg followed by 75 mg daily started one week prior to angiography
9909394|NCT00693069|Experimental|4|300 mg followed by 150 mg daily started one week prior to angiography
9909395|NCT00693082|Experimental|1|
9909396|NCT00693095|Experimental|1|CMV-ALT + CMV-DCs
9909397|NCT00693095|Experimental|2|CMV-ALT + Saline
9909398|NCT00693108|Experimental|1|Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles
9909399|NCT00693108|No Intervention|2|
9909400|NCT00693121|Placebo Comparator|Placebo|Identical capsule to amantadine hydrochloride active intervention, administered twice daily x 14 days
9909401|NCT00693121|Active Comparator|Amantadine|Amantadine hydrochloride 100mg capsule administered twice daily x 14 days
9909402|NCT00693134||Myocarditis Patients|Patients initially diagnosed with myocarditis.
9909403|NCT00693134||Control Patients|Patients with no known cardiomyopathies
9909404|NCT00693147|Active Comparator|A|mini Video Assisted Thyroidectomy (miVAT)
9909405|NCT00693147|Active Comparator|B|Classic Total Thyroidectomy
9909406|NCT00693186|Experimental|1|
9909407|NCT00693186|Experimental|2|
9909408|NCT00693199|Experimental|1|
9909409|NCT00693199|Active Comparator|2|
9909410|NCT00693199|Experimental|3|
9909411|NCT00693212|Experimental|a|This arm was only open to subjects entering the second, open-label phase. All subjects were given open-label methylphenidate. Dosing was flexible.
9909412|NCT00693212|Experimental|MPH|This is the active treatment arm of the double-blind placebo controlled phase. Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
9909413|NCT00693212|Placebo Comparator|PBO|This 2 week arm is the placebo part of the crossover design. Subjects receive placebo in a manner similar to the MPH arm. It lasts 2 weeks.
9909414|NCT00693251|Experimental|bifurcation stent technique|crush technique
9909415|NCT00693251|Active Comparator|bifurcation stent techniqe|provisional T stenting
9909416|NCT00693264|Experimental|1|Participants will take 1- 750 mg capsule of Hoodia gordonii and have the primary and secondary outcomes measured over an 8 hour visit.
9909417|NCT00693264|Placebo Comparator|2|Participants will take a placebo capsule and have the primary and secondary outcome measures taken over an 8 hour study day.
9909418|NCT00693290|Active Comparator|1|Fleet plus low residue diet sheet.
9909419|NCT00693290|No Intervention|2|No intervention, usual care, Fleet plus liquid only diet
9909420|NCT00693316|Experimental|ORM-12741|
9909421|NCT00693316|Placebo Comparator|Placebo|
9909422|NCT00693342|Experimental|Arm I|Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
9909423|NCT00693342|Experimental|Arm II|Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
9909424|NCT00693355|Experimental|1|sodium butyrate
9909425|NCT00693355|Placebo Comparator|2|NaCl
9909426|NCT00693381|Experimental|1|Tacrolimus/MMF/steroids throughout the study
9909427|NCT00693381|Experimental|2|Tacrolimus/MMF/steroids with MMF reduction from week 7 to 12 and MMF discontinuation at month 3
9909428|NCT00693407|Experimental|1, FD patients|Eighty male and female FD patients according to Rome III criteria (Drossman, 2006), aged 18 to 70 years, will be recruited from primary and secondary care via advertisements and our referral networks
9909429|NCT00693407|Experimental|2,Healthy controls|Forty male and female healthy volunteers, aged 18 to 70 years without any gastrointestinal pathology or history of significant abdominal pain, bowel disorders, bloating or discomfort during the last 3 months will be recruited.
9909430|NCT00693433|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9909431|NCT00693446|Other|2|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time."
9909432|NCT00693446|Other|1|Patients receive Tacrolimus from day 0 to the end of the study (Arm Tacrolimus).
9909433|NCT00693511|Experimental|Circuit Training|Participants received CT exercise training two times per week for approximately 60-90 min per session for 16 wk
9909434|NCT00693511|Experimental|Circuit training + motivational interviewing|Participants in the CT + MI group received the same CT classes but also received four individual MI and four group MI sessions throughout the 16-wk program by two trained research staff
9909435|NCT00693511|No Intervention|Control|No intervention
9909436|NCT00693524|Experimental|1|Tacrolimus + Anti-IL2R AB + Mycophenolate mofetil
9909437|NCT00693524|Active Comparator|2|Tacrolimus + Steroid
9909438|NCT00693537|Experimental|A|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
9909439|NCT00693537|No Intervention|B|Control
9909440|NCT00693563|No Intervention|Control Group|The Control Group will receive usual care following discharge from the inpatient rehabilitation unit.
9909441|NCT00693563|Experimental|Treatment Group|Scheduled Telephone Intervention
9909442|NCT00693576|Experimental|A|patients who will take simvastatin 20 mg daily
9909443|NCT00693589|Active Comparator|R|Rosuvastatin treatment for 6 weeks and after that combined treatment with rosuvastatin and vitamin supplementation for additional 6 weeks
9909444|NCT00693589|Active Comparator|V|Vitamin supplementation with folic acid, vitamin B12 and B6 for 6 weeks and after that combined treatment with vitamin supplementation and rosuvastatin
9909445|NCT00693602|Experimental|1|
9909446|NCT00693615|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
9909447|NCT00693615|Experimental|Group B|Formulation 2 of the vaccine [with Al(OH)3]
9909448|NCT00693615|Experimental|Group C|Formulation 3 of the vaccine (without adjuvant)
9909449|NCT00693641|Active Comparator|1|"Safe Sea™ jellyfish sting inhibitor (barrier, or repellent) lotion"
9909450|NCT00693641|Placebo Comparator|2|Regular sun lotion
9909451|NCT00693667|Placebo Comparator|A|Placebo
9909452|NCT00693667|Active Comparator|B|250 mg active ingredient
9909453|NCT00693667|Active Comparator|C|500 mg active ingredient
9909454|NCT00693667|Active Comparator|D|750 mg active ingredient
9909455|NCT00693680|Active Comparator|1|zinc + imipramine
9909456|NCT00693680|Placebo Comparator|2|placebo + imipramine
9909457|NCT00693732|Active Comparator|1, IBS patients|
9909458|NCT00693732|Experimental|2,Healthy controls|
9909459|NCT00693758|No Intervention|1|healthy volunteers without intervention
9909460|NCT00693758|No Intervention|2|patients with suspected coronary artery disease without intervention
9909461|NCT00693758|Experimental|3|Healthy volunteers during adenosine infusion
9909462|NCT00693758|Experimental|4|Healthy volunteers during changes of breathing gases (CO2, O2)
9909463|NCT00693758|Experimental|5|patients with suspected coronary artery disease during adenosine infusion
9909464|NCT00693758|Experimental|6|patients with suspected coronary artery disease during changes of breathing gases
9909465|NCT00693758|Experimental|7|Assessment of reactive hyperemia in arms of healthy volunteers to improve sequences
9909466|NCT00693771|Experimental|1|
9909467|NCT00693797||I, observation|patients with aortic stenosis
9909468|NCT00693797||II, observation|patients with aortic stenosis
9909469|NCT00693823|Active Comparator|1|Femoral-popliteal surgical bypass with prosthetic graft
9909470|NCT00693823|Active Comparator|2|Interventional angioplasty and placement of an ePTFE covered stent graft within the femoral-popliteal artery as an endoluminal bypass percutaneously
9909471|NCT00693849|Active Comparator|A|Escitalopram
9909472|NCT00693849|Active Comparator|B|Sertraline
9909473|NCT00693849|Active Comparator|C|Venlafaxine-XR
9909474|NCT00693849|No Intervention|D|Healthy matched controls
9909475|NCT00693862|Experimental|Stalevo|
9909476|NCT00693862|Active Comparator|levodopa/carbidopa|
9909477|NCT00693888|Experimental|interventional group|individual comprehensive primary advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
9909478|NCT00693888|No Intervention|Control group|only informative flyer, no further advice in any direction
9909479|NCT00693901|Experimental|1|Parks will be assigned to the community-based participatory research condition.
9909480|NCT00693901|Active Comparator|2|Parks will be assigned to the director-only condition.
9909481|NCT00693901|No Intervention|3|Parks will be assigned to the control condition and will receive no intervention.
9909482|NCT00693914||1: Brain Tumor Survivors (n=50)|
9909483|NCT00693914||2: Healthy Sibling Controls (n=40)|
9909484|NCT00693914||Solid Tumor Survivors (n=40)|
9909485|NCT00693927|Active Comparator|1|Unmanipulated PBSC
9909486|NCT00693927|Experimental|2|CD8-Depleted PBSC
9933910|NCT05155033|Experimental|1 - Pembro and IL-2|Course 1: pembrolizumab (200 mg IV) on Day 1 of each cycle with aldesleukin (600,000 IU/kg intravenous bolus every eight hours) continuing for up to 4 days (maximum 10 doses) for 2 cycles (each 21 days). Course 2: pembrolizumab (200 mg IV) on Day 1 of each cycle for 2 cycles (each 21 days).
9933911|NCT05153889|Other|Intensive care unit|systematic intensive care unit (ICU) monitoring
9933912|NCT05153889|Experimental|General cardiology ward|Group without ECG monitoring
9933913|NCT05149846|Other|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
9933914|NCT05149846|No Intervention|Controll|No pre-conditioning, standard care
9933915|NCT05148234|Experimental|escalating dose of treatment for HR-MDS|escalating doses of BMS-986253 + DNMTi
9933916|NCT05148234|Experimental|escalating doses of treatment for LR-MDS|escalating doses of BMS-986253
9933917|NCT05148234|Experimental|phase II dose of BMS-986253 for HR-MD|phase II dose of BMS-986253 + DNMTi
9933918|NCT05148234|Experimental|phase II dose of BMS-986253 for LR-MDS|phase II dose of BMS-986253
9933919|NCT05145738|Experimental|C-Raven + Avatar|Computer delivered intervention with Avatar as virtual counselor plus linkage to community health worker
9933920|NCT05145738|Active Comparator|C-Raven|Computer-delivered intervention without virtual counselor, with linkage to community health worker
9933921|NCT05138575|Active Comparator|Empagliflozin + Potassium Chloride (KCl)|"Empagliflozin (10 mg daily) + Potassium Chloride (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
9933922|NCT05138575|Active Comparator|Empagliflozin + Potassium Nitrate (KNO3)|"Empagliflozin (10 mg daily) + Potassium Nitrate (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
9933923|NCT05138575|Placebo Comparator|Potassium Chloride (KCl) + Placebo for Empa|"Potassium Chloride (6 mmol three times daily) + Placebo for Empagliflozin~Placebo arm will be 6 weeks in duration followed by a 2 week washout period."
9933924|NCT05135208||experimental group|patients positioned with 3D camera
9933925|NCT05135208||control group|patients positioned by experienced radiology assistants
9933926|NCT05133596|Experimental|Study population|Adult subjects up to 55 years of age with persistent olfaction disorder after a symptomatic episode of COVID-19.
9933927|NCT05132296|Experimental|GROUP I (CLIP)|Patients undergo 60 minute sessions of nutrition education for 12 weeks and behavioral intervention 26 weeks. Patients receive FitBit and undergo physical activity for 30-60 minutes 5 days a week (aerobic activity) and 2 days a week (resistance training).
9933928|NCT05132296|Active Comparator|GROUP II (usual care)|Patients have access to all usual care supportive services.
9933929|NCT05131061||aldosterone-producing adenoma(APA)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI ≥ 4; If LI between 2 and 4, should be combined with contralateral inhibition index < 1 or CT indicate typical adenomas on the dominant side.
9933930|NCT05131061||bilateral adrenal hyperplasia(BAH)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI < 2; or LI between 2 and 4 but does not meet the UPA conditions
9994210|NCT01479075|Placebo Comparator|Sham stimulation|Sham stimulation in the ear lobe is applied for 14 min in healthy participants
9994211|NCT01479088|Experimental|cinacalcet tab or extemporaneous solution po added to SoC|"Subjects who meet all inclusion/exclusion criteria at baseline will be given cinacalcet 30mg film-coated tablet, for oral use added to phosphate binders and vitamin D analogue.~For subjects receiving a cinacalcet dose <30mg, commercially available cinacalcet 30mg tab will be ground and diluted with a 5% dextrose solution. Then, an aliquot of this solution corresponding to the individually prescribed dose will be administered as indicated.~Initial dosing of cinacalcet will be 0.5-0.75mg/kg or 30 mg po once daily (OD) each evening with food.~During the cinacalcet dose-titration 6-month period for efficacy assessment, the dose will be increased on monthly basis by 0.5 mg/kg or by 30mg OD to achieve the target iPTH value <180 pg/mL, as tolerated by the subject, up to maximum of 180mg OD in absence of signs of hypocalcemia, according to the current summary of product characteristics."
9994212|NCT01479101||MammaPrint, BluePrint, neo-adj CT or HT|All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
9994213|NCT01479114|No Intervention|control group|
9994214|NCT01479114|Experimental|G-CSF group|
9994215|NCT01479114|No Intervention|Non-GCSF group|
9994216|NCT01479153|Active Comparator|Subclavian catheterization|
9994217|NCT01479153|Active Comparator|Internal Jugular catheterization|
9994218|NCT01479153|Active Comparator|Femoral Catheterization|
9994219|NCT01479166||affected patients with small airway disease (SAD)|20 patients suffering from mild cystic fibrosis and involvement of small airways
9994220|NCT01479166||affected patients without small airway disease (SAD)|20 patients suffering from mild cystic fibrosis without SAD
9994221|NCT01479166||non-affected patients|20 matched controls not suffering from cystic fibrosis
9994222|NCT01479179|Experimental|AMG 479 + Trastuzumab|AMG 479 18 mg/kg or 12 mg/kg intravenously (IV) 30 minutes after trastuzumab. Trastuzumab loading dose (Week 1) 8 mg/kg IV over 90 minutes; maintenance dose 6 mg/kg IV over 30 minutes every 3 weeks.
9994223|NCT01479192|Experimental|Fenretinide|100mg: 2cps/day for 5 years followed by
9994224|NCT01479192|Placebo Comparator|Placebo|matched placebo 2 cps/day for 5 years
9994225|NCT01479205||mite allergic patients without SIT|patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy
9994226|NCT01479205||mite allergic patients with SIT|patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy
9994227|NCT01479218|Other|PDA Occluder|single arm
9994228|NCT01479231|Experimental|dexlansoprazole|
9994229|NCT01479244|Experimental|NeuVax™|NeuVax™ in WFI solution with Leukine®
9994230|NCT01479244|Active Comparator|Leukine®|Leukine® with WFI
9994231|NCT01479257||Bilingual Latinos|Bilingual Houston area Latinos surveyed for 7 continuous days with objective and subjective assessments using accelerometer and smart phone.
9994232|NCT01479283|Active Comparator|Short-Arm Antibiotic Regimen|"Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
9994233|NCT01479283|Experimental|Long-Arm Antibiotic Regimen|"Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
9994234|NCT01479296|Experimental|Group 1: rAd5 Plus Placebo|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection in their right arm (1×10^10 PU), and placebo vaccine injections in their left arm, right thigh, and left thigh.
9994235|NCT01479296|Experimental|Group 2: Separated Vaccine Components|Participants will receive the rAd5 gag-pol vaccine injection in their right arm (0.5×10^10 PU), the rAd5 env A vaccine injection in their left arm (0.17×10^10 PU), the rAd5 env B vaccine injection in their right thigh (0.17×10^10 PU), and the rAd5 env C vaccine injection in their left thigh (0.17×10^10 PU).
9994236|NCT01479296|Experimental|Group 3: Divided Dose rAd5|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection divided into fourths, with one fourth of the total dose given in each of 4 sites: right arm, left arm, right thigh, and left thigh (each at 0.25×10^10 PU).
9994237|NCT01479387||Group 1|
9994238|NCT01479400||infants who were exposed to antipsychotics as fetus|
9994239|NCT01479400||infants who were not exposed to antipsychotics as fetus|
9798651|NCT01635998|Experimental|Intervention arm|These subjects will undergo routine catheter ablation of atrial fibrillation PLUS renal sympathetic denervation with the Boston Scientific Vessix Renal Denervation System.
9798652|NCT01635998|No Intervention|Control arm|These subjects will undergo routine catheter ablation of atrial fibrillation only.
9798653|NCT01636063|Experimental|Mifepristone|Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
9798654|NCT01636063|Active Comparator|Misoprostol|Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.
9798655|NCT01636076|Experimental|QMF149|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
9798656|NCT01636076|Active Comparator|Salmeterol xinafoate/fluticasone propionate|Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
9798657|NCT01636102|Experimental|Arm 1|
9798658|NCT01636206|Placebo Comparator|Placebo|Placebo
9798659|NCT01636206|Experimental|Lifitegrast|Active
9798660|NCT01636258|No Intervention|Arm A: Control group|These participants will continue to receive their usual care from their primary medical care team.
9798661|NCT01636258|Experimental|Arm B|Arm includes diet instruction, exercise, stress management, and culinary education
9798662|NCT01636284|Experimental|JX-594 recombinant vaccina GM-CSF|JX-594 recombinant vaccina GM-CSF
9798663|NCT01636297|Experimental|Forced exercise|Exercise on stationary cycle that was controlled by a motor to augment voluntary cycling rate by 35%
9798664|NCT01636297|Experimental|Voluntary Exercise|Exercise on a stationary cycle without motor assistance
9798665|NCT01636297|No Intervention|No Exercise|Participants received no exercise intervention and served as the control group
9798666|NCT01636362|Experimental|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
9798667|NCT01636414|Active Comparator|Hemovac drain|
9798668|NCT01636414|Active Comparator|Re-infusion drain|
9798669|NCT01636414|Active Comparator|Tranexamic drain|
9798670|NCT01636453|Experimental|Liberty Stent arm|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
9798671|NCT01636661|Experimental|Transcranial Direct Current Stimulation|Receiving active tDCS
9798672|NCT01636661|Sham Comparator|Sham tDCS|tDCS equipment set to placebo setting.
9798673|NCT01636687|Placebo Comparator|Placebo|Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
9798674|NCT01636687|Experimental|Secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
9798675|NCT01636687|Experimental|Secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.
9798676|NCT01636713|Experimental|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
9798677|NCT01636713|Experimental|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
9798678|NCT01636713|Placebo Comparator|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
9798679|NCT01636765||All participants|Patients with facial erythema associated with rosacea. There was no intervention in this study.
9798680|NCT01636778|Experimental|SB-497115-GR|investigational product for thrombocytopenia
9798681|NCT01636882|Experimental|CVA21|Dose of CAVATAK up to 3 x 10⁸ TCID50 for an additional 9 treatments at 3-week intervals
9798682|NCT01636934|Experimental|Minocycline|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Minocycline 100 mg capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
9798683|NCT01636934|Placebo Comparator|Placebo|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
9909487|NCT00693940|Experimental|1|Participants will receive treatment with group mediated cognitive behavioral sessions.
9909488|NCT00693940|Active Comparator|2|Participants will receive treatment with health education sessions.
9909489|NCT00693953||1|Year one
9909490|NCT00693953||2|Year two
9909491|NCT00693966|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
9909492|NCT00693966|Experimental|Group B|Formulation 2 of the vaccine
9909493|NCT00693966|Experimental|Group C|Formulation 3 of the vaccine
9909494|NCT00693966|Experimental|Group D|Formulation 4 of the vaccine [with Al(OH)3]
9909495|NCT00694005|Active Comparator|bifurcation stent techniqe|"cross over stenting without kissing balloon angioplasty leave alone"
9909496|NCT00694005|Experimental|bifurcation stent technique|kissing balloon angioplasty
9909497|NCT00694031|Active Comparator|A|Hemodialysis
9909498|NCT00694031|Experimental|B|On-line hemodiafiltration
9909499|NCT00694044|Active Comparator|Weekly titration|
9909500|NCT00694044|Active Comparator|Two Week QD|
9909501|NCT00694044|Active Comparator|Two Week BID|
9909502|NCT00694044|Placebo Comparator|Placebo|
9909503|NCT00694057|Placebo Comparator|Placebo|Placebo capsules BID
9909504|NCT00694057|Experimental|Active|HE3286 10 mg (5 mg BID)
9909505|NCT00694083|Experimental|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles).
9909506|NCT00694174|Active Comparator|1|2 ml sucrose 25% oral solution one time only dose by mouth
9909507|NCT00694174|Placebo Comparator|2|sterile water 2 ml one time only dose given by mouth prior to heel lance
9909508|NCT00694200|Experimental|1|Vinorelbine metronomic + bevacizumab
9909509|NCT00694213|Experimental|1|
9909510|NCT00694213|Experimental|2|
9909511|NCT00694213|Experimental|3|
9909512|NCT00694213|Placebo Comparator|4|
9909513|NCT00694226|Experimental|1|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
9909514|NCT00694226|Active Comparator|2|Treatment as usual (TTU): Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol. After completing the assessment individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis
9909515|NCT00694239|No Intervention|B|Standard Care
9909516|NCT00694239|Experimental|A|Risk Assessment plus standard care
9909517|NCT00694252|Experimental|1|Lapatinib
9909518|NCT00694265||1|Surgical treatment
9909519|NCT00694265||2|Conservative treatment
9909520|NCT00694291|Experimental|1|Sorafenib 400 mg orally twice daily
9909521|NCT00694291|Placebo Comparator|2|Placebo
9909522|NCT00694330|Experimental|GM-K562 Vaccination|
9909523|NCT00694343|Experimental|Group A|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
9909524|NCT00694343|Active Comparator|Group B|1000 mL Ringer's Lactate solution
9909525|NCT00694408|Active Comparator|Steroid immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid containing immunosuppression regimen post transplant. This group of patients will receive steroids in conjunction with other prescribed immunosuppressive agents. Intervention is use of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management
9994240|NCT01479413||Schizophrenia|
9994241|NCT01479452|Other|Bariatric surgery|Bariatric surgery
9994242|NCT01479452|Other|Controls|Usual care
9994243|NCT01479491||Case Group|Children aged < 12 months presenting with IS and covered by the Japan Medical Data Centre Company Limited (JMDC), Tokyo referred to as the JMDC Medical Data Bank (JMDC-MDB).
9994244|NCT01479504|Experimental|1A(nedaplatin and IMRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)
9994245|NCT01479504|Active Comparator|1B(cisplatin and IMRT)|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)
9994246|NCT01479504|Experimental|2A(nedaplatin and CRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)
9994247|NCT01479504|Active Comparator|2B((cisplatin and CRT))|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)
9994248|NCT01479556|Placebo Comparator|Placebo|Study subjects wil be randomized to the Placebo arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
9994249|NCT01479556|Active Comparator|Pregabalin|Study subjects wil be randomized to the Pregabalin arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
9994250|NCT01479608|Experimental|A: Transplantation or resection (randomized)|Liver transplantation or liver resection by 1:1 randomization (open label)
9994251|NCT01479608|Experimental|B: Liver transplantation|For non-resectable patients metachronous disease.
9994252|NCT01479608|Experimental|C:Liver transplantation|For non-resectable patients synchronous disease.
9994253|NCT01479608|Experimental|D:Liver transplantation|For non-resectable patients synchronous disease.
9994254|NCT01479634|Active Comparator|Arm A|Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
9994255|NCT01479634|Active Comparator|Arm B|Treatment for HIV in participants with CD4+ cell counts >350 cells/uL
9994256|NCT01479647|Experimental|PH-797804 1 mg Fasted|Subjects will receive a single 1 mg dose in the fasted state
9994257|NCT01479647|Experimental|PH-797804 1 mg Fed|Subjects will receive a single 1 mg dose following a high-fat meal
9994258|NCT01479647|Experimental|PH-797804 10 mg Fasted|Subjects will receive a single 10 mg dose in the fasted state
9994259|NCT01479647|Experimental|PH-797804 10 mg Fed|Subjects will receive a single 10 mg dose following a high-fat meal
9994260|NCT01479647|Experimental|PH-797804 24 mg Fed|Subjects will receive a single 24 mg dose following a high-fat meal
9994261|NCT01479660|Placebo Comparator|Control|
9994262|NCT01479660|Experimental|Probiotic|
9994263|NCT01479673|No Intervention|Control group|"Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the liberal  regimen, i.e. according to local practice."
9994264|NCT01479673|Experimental|Indirect Calorimetry|Study group: Indirect Calorimetry (IC) Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry measurement of Resting Energy Expenditure (REE).
9994265|NCT01479686|Active Comparator|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
9994266|NCT01479686|Experimental|intraoperative MRI|iMRI guided resection in adults with glioma
9994267|NCT01479699|Placebo Comparator|Placebo capsule|Four placebo capsules containing safflower oil only
9994268|NCT01479699|Active Comparator|Olive leaf extract capsule|Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
9994269|NCT01479712|Active Comparator|Irrigation|This is the arm that will receive irrigation.
9994270|NCT01479712|No Intervention|No Irrigation|This is the arm that will not receive irrigation.
9994271|NCT01479738|Experimental|Capitate bone grafting|18 patients with PIP joint defects were included in the study. There were 13 male and 5 female patients with a mean age of 31 years (range, 18-47 years). The injury occurred in the right hand in 11 patients and on the left hand in 7. The injured PIP joints were in the index finger (n=7), long finger (n=9), and ring finger (n=2).
9994272|NCT01479751|Experimental|ketamine|Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
9994273|NCT01479751|Experimental|priming|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
9994274|NCT01479751|No Intervention|Roc 0.9|Patients receive Roc 0.9 mg/kg as an induction dose.
9994275|NCT01479751|No Intervention|Control|Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.
9994276|NCT01479751|Experimental|Mg|Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.
9997884|NCT01512706|Experimental|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
9994277|NCT01479790|No Intervention|Visante AS-OCT and Cirrus AS-OCT|The tear meniscus is the thin concave strip of the tear film near the eyelid margins. During the acquisition the participants place their chins on a chin rest and look at a fixation light/target. This whole procedure should not take more than 5 minutes. The patients are allowed to blink freely except for during the acquisition time of less than 5 seconds. The procedure will be repeated for the upper and lower tear meniscus of both eyes.
9994278|NCT01479790|Experimental|Thermography measurement|"In total, four pairs of thermographic sequences on the ocluar surface temperature from volunteers will be taken.~A thermographic sequence will be captured from each eye.~After 20 minutes, a second pair of thermographic sequences will be captured.~An eye mask with a temperature of not more than 40 deg C (will be worn by the volunteer for 5 minutes and a third pair of thermographic sequences will be captured immediately after mask removal.~A fourth pair of thermographic sequences will be captured 1 hour after mask removal."
9994279|NCT01479803|Active Comparator|EchoTip HD ProCore 22 Gauge|first passage in the pancreatic tumor with the EchoTip HD ProCore 22 Gauge then with the EchoTip 22 Gauge
9994280|NCT01479803|Active Comparator|Echo Tip 22 Gauge|First passage through the tumor with the EchoTip 22 Gauge then with Echotip HD ProCore 22 Gauge
9994281|NCT01479829|Active Comparator|ESC + CBX|Escitalopram 10 mg twice day plus Celecoxib 200 mg twice daily.
9994282|NCT01479829|Placebo Comparator|ESC + PBO.|Escitalopram 10 mg twice day plus placebo administered twice daily.
9994283|NCT01479842|Experimental|Treatment (enzyme inhibitor, chemo, monoclonal antibody)|Patients receive BTK inhibitor PCI-32765 PO QD on days 1-28. Patients also receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue receiving BTK inhibitor PCI-32765 PO in the absence of disease progression or unacceptable toxicity.
9994284|NCT01479855||Patients|Patients referred to a memory clinic due to memory problems and their healthy spouse
9994285|NCT01479881|Experimental|001|a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.
9994286|NCT01479881|Experimental|002|TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.
9994287|NCT01479881|Experimental|003|a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.
9994288|NCT01479881|Experimental|004|TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.
9994289|NCT01479894||Sample Collection|This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
9994290|NCT01479907|Active Comparator|Synbiotics|"A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, IONIA Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 [11] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days."
9994291|NCT01479907|Placebo Comparator|Placebo|The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
9994292|NCT01479920|Active Comparator|DCEAS|"Dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
9994293|NCT01479920|Sham Comparator|n-CEA|"Non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
9994294|NCT01479933|Experimental|Vitamin D 40|Vitamin D3 40 micrograms (1600 IU) per day
9994295|NCT01479933|Experimental|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
9994296|NCT01479933|Placebo Comparator|Placebo|
9994297|NCT01479946|Experimental|Early Electrochemotherapy|Electrochemotherapy is given as early as possible after the discovery of skin metastases
9994298|NCT01479946|No Intervention|Delayed or no Electrochemotherapy|patients are to be treated for their breast cancer according to clinical routine with electrochemotherapy as an option only after 6 months from randomization
9909526|NCT00694408|Active Comparator|Steroid free immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid free immunosuppression regimen post transplant. The patients in this arm will receive immunosuppression but not steroids to compare with those treated with steroids to measure differences in rejection and safety of a steroid free immunosuppressive regimen. Intervention is omission of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management. No steroids will be used routinely in this arm
9909527|NCT00694421||1|"adults who participate in study, Social and Psychological Risks for Infectious Disease here at Children's Hospital of Pittsburgh"
9909528|NCT00694421||2|"children 2-6 years who participate in Role of Virus and Genetic Susceptibility study here at Children's Hospital of Pittsburgh"
9909529|NCT00694434||1|Patients with 2 or more frozen blastocyst that scored GES 70 or better in the fresh cycle.
9909530|NCT00694434||2|Patients with 2 or more frozen blastocysts scoring GES <70 in the fresh cycle.
9909531|NCT00694447|Experimental|Real acupuncture|Real acupuncture
9909532|NCT00694447|Sham Comparator|Sham acupuncture|Sham acupuncture
9909533|NCT00694460|Experimental|1|
9909534|NCT00694460|Experimental|2|
9909535|NCT00694460|Experimental|3|
9909536|NCT00694460|Experimental|4|
9909537|NCT00694460|Active Comparator|5|
9909538|NCT00694486||1|Healthy adult volunteers
9909539|NCT00694499||Observation|Patients with blunt liver injury
9909540|NCT00694512|Placebo Comparator|1|low fat diet for two weeks.
9909541|NCT00694512|Active Comparator|2|High fat diet for two weeks followed by blood sampling.
9909542|NCT00694512|Active Comparator|3|Medium Chain Triglyceride diet
9909543|NCT00694525||1|Women in this group will have 21-OHD CAH.
9909544|NCT00694525||2|Women in this group will be healthy controls and will not have 21-OHD CAH.
9909545|NCT00694538|Active Comparator|1|100 patients are being treated with a single laser beam over pain area.
9909546|NCT00694538|Experimental|2|100 patients are being treated with interferential laser from two independent sources
9909547|NCT00694577|Experimental|Group 1|Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions BID in one week
9909548|NCT00694577|Experimental|Group 2|Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions BID in one week
9909549|NCT00694577|Experimental|Group 3|Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions BID in one week
9909550|NCT00694590|Experimental|plerixafor|
9909551|NCT00694616|Other|1|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
9909552|NCT00694616|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
9909553|NCT00694629|Active Comparator|1|rifampin, isoniazid, pyrazinamide, ethambutol
9909554|NCT00694629|Experimental|2|rifapentine 10 mg/kg, isoniazid, pyrazinamide, ethambutol
9909555|NCT00694629|Experimental|3|rifapentine 15 mg/kg, isoniazid, pyrazinamide, ethambutol
9909556|NCT00694629|Experimental|4|rifapentine 20 mg/kg, isoniazid, pyrazinamide, ethambutol
9909557|NCT00694642|Active Comparator|selected CD133+cells|Transendocardial injection of selected CD133+cells
9909558|NCT00694642|No Intervention|no injection|Boths groups were treated with G-CSF, underwent an apheresis and NOGA mapping
9909559|NCT00694655|Other|vaccine|There are no arms for this study. All participants will receive the YFV vaccine if they meet the screening criteria.
9909560|NCT00694668|Experimental|1|Cognitive Behavioural Treatment
9909561|NCT00694668|Experimental|2|Mindfulness Based Cognitive Therapy-training
9909562|NCT00694694|Experimental|1AZ+AQ|Azithromycin + artesunate
9909563|NCT00694694|Active Comparator|2AL|Artemether-lumefantrine
9909564|NCT00694720|Experimental|Dose Level 1|
9909565|NCT00694720|Experimental|Dose Level 2|
9909566|NCT00694720|Experimental|Dose Level 3|
9909567|NCT00694720|Experimental|Dose Level 4|
9909568|NCT00694720|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
9909569|NCT00694733|Placebo Comparator|1|Men on placebo injections for 4 months
9909570|NCT00694733|Active Comparator|2|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
9909571|NCT00694733|Active Comparator|3|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
9909572|NCT00694733|Placebo Comparator|4|Women on placebo cream
9909573|NCT00694733|Active Comparator|5|Women on estrogen cream
9909574|NCT00694746|Experimental|Fish oil|Omega-3-acid ethyl esters in the form of fish oil capsules with ram up from 1g to 4 g/day (capsules 1g)
9909575|NCT00694746|Placebo Comparator|Placebo|Placebo
9909576|NCT00694759|Active Comparator|A|Pioglitazone will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
9909577|NCT00694759|Active Comparator|B|Metformin will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
9909578|NCT00694759|Placebo Comparator|C|Placebo will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
9909579|NCT00694772|Active Comparator|Electrocautery|
9909580|NCT00694772|Experimental|Coblation|
9909581|NCT00694785|Experimental|Group NT3|Patients will receive a total dose of approximately 1.7 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL
9909582|NCT00694785|Experimental|Group T3|Patients will receive a total dose of approximately 1.4 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
9909583|NCT00694785|Experimental|Group NT6|Patients will receive a total dose of approximately 3.9 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL.
9909584|NCT00694785|Experimental|Group T6|Patients will receive a total dose of approximately 3.1 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
9909585|NCT00694798|Experimental|Mw|All enrolled patients to receive Mycobacterium w
9909586|NCT00694811|Experimental|A|1 week of re-feeding
9909587|NCT00694811|Experimental|B|6 weeks of re-feeding
9909588|NCT00694824||A|
9909589|NCT00694837|Experimental|B|
9994299|NCT01479959|Active Comparator|No PEEP level|protocol conducted while no PEEP is applied
9994300|NCT01479959|Active Comparator|effective PEEP level (PEEPeff)|PEEP level allowing the entire expiratory volume to go through the upper airways during quiet breathing
9994301|NCT01479959|Active Comparator|intermediate PEEP level (PEEP50)|50% of PEEPeff
9994302|NCT01479972|Experimental|VPM1002|
9994303|NCT01479972|Active Comparator|BCG|
9994304|NCT01479998|Active Comparator|Standard care and nicotine replacement therapy|standard care is 4 counseling sessions and nicotine replacement therapy
9994305|NCT01479998|Experimental|standard care plus NRT plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
9909590|NCT00694863|Experimental|1|In this open-label study all patients included are treated in the experimental group.
9994306|NCT01480011|Experimental|lactobacillus lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
9909591|NCT00694876||1|Adequate Health Literacy (as determined by TOFHLA)
9909592|NCT00694876||2|Inadequate Health Literacy (as determined by TOFHLA)
9909593|NCT00694889|Active Comparator|1|Participants will use commercially available computer games.
9909594|NCT00694889|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
9909595|NCT00694889|Active Comparator|3|Healthy participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
9909596|NCT00694902|Experimental|Sequence 1 of Cohort-I|Subjects in Sequence 1 will receive Placebo during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
9909597|NCT00694902|Experimental|Sequence 2 of Cohort-I|Subjects in Sequence 2 will receive 10 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
9909598|NCT00694902|Experimental|Sequence 3 of Cohort-I|Subjects in Sequence 3 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
9909599|NCT00694902|Experimental|Sequence 4 of Cohort-I|Subjects in Sequence 4 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
9909600|NCT00694902|Experimental|Sequence 5 of Cohort-II|Subjects in Sequence 5 will receive Placebo during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
9909601|NCT00694902|Experimental|Sequence 6 of Cohort-II|Subjects in Sequence 6 will receive 30 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
9909602|NCT00694902|Experimental|Sequence 7 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
9994307|NCT01480037||Elderly|Individuals between 60 and 70 years-old
9994308|NCT01480037||Long-lived|Individuals above 85 years-old
9994309|NCT01480037||Young|Individuals between 20 and 30 years-old
9997885|NCT01512706|Experimental|1280Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 children aged 24 months-5 years months old on day 0, 28
9997886|NCT01512706|Placebo Comparator|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
9994310|NCT01480050|Experimental|Dose Finding and Dose Expansion|"DOSE FINDING 4 Levels~For all Levels:~Cycle 1 Mibefradil QID dosing, Days 1-8 (to accommodate PKs) (*2 doses on Days 1 and 8) Temozolomide daily at 150-200 mg/m2, Days 9-13;~Cycles 2+ Mibefradil QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12~DOSE EXPANSION 28-day cycles FLT PET scans, Baseline x2, Day 7 Mibefradil MTD determined at Dose Finding QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12"
9994311|NCT01480063||Fampyra|Fampyra administered as prescribed in routine clinical practice.
9994312|NCT01480102|Placebo Comparator|Group B- No Block|Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
9994313|NCT01480102|Active Comparator|Group A- Paravertebral block|Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
9994314|NCT01480141|Experimental|Single Arm Study|Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
9994315|NCT01480167|Active Comparator|RF-TVA with STABILIT Vertebral Augmentation System|All RadioFrequency-Targeted Vertebral Augmentation (RF-TVA) arm participants will be treated with the StabiliT Vertebral Augmentation System. This system is a commercially available device in the United States designed to perform percutaneous vertebral augmentation (also known as kyphoplasty).
9994316|NCT01480167|Active Comparator|Non Operative Management|All non-operative management (NOM) arm participants will receive non-operative standard of care management, which can include: analgesics, bed rest, back braces, physiotherapy, rehabilitation programs, and walking aids according to standard practices of participating institutions.
9994317|NCT01480180|Experimental|Prophylaxis|
9994318|NCT01480180|Experimental|On-demand|
9994319|NCT01480193|Active Comparator|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
9994320|NCT01480193|Experimental|Integrative Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
9994321|NCT01480245|Experimental|Continuous Dosing|GSK2402968 6mg/kg/week
9994322|NCT01480245|Experimental|Intermittent Dosing|GSK2402968 6mg/kg/week
9994323|NCT01480245|No Intervention|Natural History Observation|The objective of this arm will be to explore DMD disease progression in a naturalistic setting once discontinuing active treatment
9994324|NCT01480271|Experimental|Part 1 Cohort 1 GSK2445053|2ng GSK2245053
9994325|NCT01480271|Placebo Comparator|Part 1 Cohort 1 Placebo|Placebo
9994326|NCT01480271|Experimental|Part 1 Cohort 2 GSK2445053|20ng GSK2445053
9994327|NCT01480271|Placebo Comparator|Part 1 Cohort 2 Placebo|Placebo
9994328|NCT01480271|Experimental|Part 1 Cohort 3 GSK2245053|100ng GSK2445053
9994329|NCT01480271|Placebo Comparator|Part 1 Cohort 3 Placebo|Placebo
9994330|NCT01480271|Experimental|Part 1 Cohort 4 GSK2445053|200ng GSK2445053
9994331|NCT01480271|Placebo Comparator|Part 1 Cohort 4 Placebo|Placebo
9994332|NCT01480271|Experimental|Part 1 Cohort 5 GSK245053|400ng GSK2445053
9994333|NCT01480271|Placebo Comparator|Part 1 Cohort 5 Placebo|Placebo
9994334|NCT01480271|Experimental|Part 1 Cohort 6 GSK2445053|1000ng GSK2245053
9994335|NCT01480271|Placebo Comparator|Part 1 Cohort 6 Placebo|Placebo
9994336|NCT01480271|Experimental|Part 1 Cohort 7 GSK2445053|2000ng GSK2445053
9994337|NCT01480271|Placebo Comparator|Part 1 Cohort 7 Placebo|Placebo
9994338|NCT01480271|Experimental|Part 1 Cohort 8 GSK2445053|4000ng GSK2445053
9994339|NCT01480271|Placebo Comparator|Part 1 Cohort 8 Placebo|Placebo
9994340|NCT01480310|Experimental|A|
9994341|NCT01480310|Experimental|B|
9994342|NCT01480323|Experimental|Ipilimumab|Ipilimumab i.v. + Interleukin-2 intratumoral
9994343|NCT01480336|Placebo Comparator|Amiodarone with Placebo|
9994344|NCT01480336|Active Comparator|Amiodarone with Ranolazine|
9994345|NCT01480362|Experimental|Negative Pressure Wound Therapy|The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment,using a sealed wound dressing connected to a vacuum pump.
9994346|NCT01480362|Active Comparator|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
9994347|NCT01480375|Experimental|Navigo™ and Smartbx™ system.|all biopsy cores were handled using the Smartbx™ system. part of the procedures were performed with both Navigo™ and Smartbx™ system.
9994348|NCT01480375|No Intervention|standard method|all biopsy cores were handled using standard method - shaking the biopsy needle into formalin vial. no navigation system.
9994349|NCT01480388|Placebo Comparator|Placebo|
9994350|NCT01480388|Experimental|JNJ-39758979 (10 mg/d)|
9994351|NCT01480388|Experimental|JNJ-39758979 (30 mg/d)|
9994352|NCT01480388|Experimental|JNJ-39758979 (100 mg/d)|
9994353|NCT01480388|Experimental|JNJ-39758979 (300 mg/d)|
9994354|NCT01480401|Experimental|low-sodium diet|(1500 mg daily)
9798684|NCT01636947|Experimental|Aprepitant Regimen|Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
9798685|NCT01636947|Active Comparator|Control Regimen|Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
9798686|NCT01636960|Experimental|Participants receiving PegIFN alfa-2b|Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
9798687|NCT01636986|Experimental|DT1|Delefilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
9798688|NCT01636986|Active Comparator|1DAVM|Etafilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
9798689|NCT01637077|Experimental|Arm I (pain therapy)|Patients receive pregabalin PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
9798690|NCT01637077|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
9798691|NCT01637090|Experimental|all patients on study|"This will be a prospective, phase II non-randomized, open label study of single agent everolimus for the treatment of CTCL recurrent or refractory to at least one previous treatment other than topical medication. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations and assessment of tumor burden in tissue and blood.~This study will be conducted in 2 stages. During stage 1 we will enroll a maximum of 11 subjects to evaluate response rate and will only continue to stage 2, if we observe two or more responses. During stage 2, we will expand the study to an overall N of 28 patients."
9798692|NCT01637142|Experimental|LY2140023 + [14C]-LY2140023|Treatment Period 1: On Day 1, a single oral dose of 80 milligrams (mg) LY2140023 (parent compound) followed by a single 2-hour intravenous (IV) infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nanocuries (nCi) [14C]-LY2140023.
9798693|NCT01637142|Experimental|LY2140023 + [14C]-LY404039|Treatment Period 2: On Day 1, a single oral dose of 80 mg LY2140023 (parent compound) followed by a single 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi [14C]-LY404039 (active metabolite).
9798694|NCT01637246||POAG or OHT|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
9798695|NCT01637272|Experimental|SOM230|Subjects with dumping syndrome treated with pasireotide
9798696|NCT01637402|Experimental|Standard Dose|1000 milligrams (mg) abiraterone acetate in combination with prednisone taken once a day until progression defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
9798697|NCT01637402|Experimental|Escalated Dose|Participants who progressed on the standard dose will be assigned 1000 milligrams (mg) abiraterone acetate in combination with prednisone taken twice a day for at least 12 weeks until progression as defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
9798698|NCT01637584|Experimental|Prazosin|Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
9798699|NCT01637584|Placebo Comparator|Placebo|A placebo is a sugar pill, which will be used to compare with the results of the active medication
9798700|NCT01637623|Active Comparator|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.
9798701|NCT01637623|Active Comparator|Allopurinol|Allopurinol 300 mg daily for 6 weeks
9798702|NCT01637623|Placebo Comparator|Placebo|Placebo capsule daily for 6 weeks
9798703|NCT01637870|Experimental|Negative pressure pump|Will have the Prevena negative pressure wound system placed at the time of surgery.
9798704|NCT01637922|Active Comparator|Methadone group|patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
9798705|NCT01637922|Active Comparator|Buprenorphine|patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.
9798706|NCT01637935||Pioglitazone exposed group|Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
9994355|NCT01480401|No Intervention|moderate-sodium diet|sodium (100 mmol or 2300 mg daily; Usual Care)
9994356|NCT01480414|Experimental|4times injection|the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
9994357|NCT01480414|Experimental|one injection|Patients with peripheral artery disease underwent cell transplantation just one time.
9997887|NCT01512719|Experimental|POEM procedure|Patients with achalasia that undergo POEM
9997888|NCT01512732||healthy control group|Young (20-49) and Older (50-70) healthy group (n=60)
9997889|NCT01512732||Parkinson's disease patients|(n=30).
9997890|NCT01512732||Major depressive disorder patients|(n=30).
9997891|NCT01512784|Experimental|HIV-infected adolescents and young adults|female and male HIV-infected subjects aged from 13-27 years old
9997892|NCT01512784|Active Comparator|healthy adolescents and young adults|female and male healthy adolescents and young adults aged 13-27 years
9997893|NCT01512823|Experimental|Interactive educational intervention|Two education sessions (four-hours and two-hours respectively), emailed notes and reminders
9997894|NCT01512823|Experimental|Didactic educational intervention|Education alone
9997895|NCT01512836|Experimental|Case Management|The patients who are randomized to the intervention group will be assigned to case management. The case manager is expected to integrate care from a health maintenance and promotion perspective, where the overall goal is the promote and support the patients self care (see intervention description).
9997896|NCT01512836|No Intervention|Usual Care|Patients randomized to the usual care group will receive conventional health and social services. Patients in this group will not receive support from a case manager.
9997897|NCT01512862|Experimental|Calcitriol|
9997898|NCT01512862|No Intervention|Placebo|
9997899|NCT01512875||biopsy proven H. pylori|Patient must have lived in the districts of Lima, Peru listed in the protocol.
9997900|NCT01512901|Experimental|1|
9997901|NCT01512901|Experimental|2|
9997902|NCT01512901|Sham Comparator|3|
9997903|NCT01512914|Placebo Comparator|CONTROL group|
9997904|NCT01512914|Experimental|PREOPERATIVE nebulization|
9997905|NCT01512914|Experimental|POSTOPERATIVE nebulization|
9997906|NCT01512914|Active Comparator|INSTILLATION group|
9997907|NCT01512927||ESRD with regular hemodialysis|
9997908|NCT01512953|No Intervention|no PPI|Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
9997909|NCT01512953|Experimental|PPI|Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
9997910|NCT01512966|Experimental|VTE 2Q4 first, then VTE 2Q8|VEGF Trap-Eye [BAY86-5321; EYLEA (aflibercept) Injection] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)
9997911|NCT01512992|Experimental|Home telehealth|
9997912|NCT01512992|No Intervention|Usual care|
9997913|NCT01513005|Experimental|Laparoscopic Sleeve Gastrectomy|
9997914|NCT01513018|Active Comparator|high (10 ml/kg) tidal volumes|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
9997915|NCT01513018|Active Comparator|low tidal volume (5 ml/kg)|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
9997916|NCT01513031|Experimental|Phone follow-up|All study participants will be receiving education and monthly telephone follow-up.
9997917|NCT01513044|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
9997918|NCT01513044|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
9997919|NCT01513057|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
9997920|NCT01513057|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
9997921|NCT01513070|Experimental|Quick-Acting Heart Reliever group|Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets
9997922|NCT01513070|Active Comparator|Isosorbide Dinitrate group|Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets
9997923|NCT01513083|Experimental|Mild hepatic dysfunction|
9997924|NCT01513083|Experimental|Moderate hepatic dysfunction|
9997925|NCT01513083|Experimental|Normal hepatic function|
9997926|NCT01513096|No Intervention|Split-dose PEG|Bowel preparation using split dose PEG without prokinetics
9997927|NCT01513096|Active Comparator|Split dose PEG with prokinetics|Bowel preparation using split-dose PEG with prokinetics
9997928|NCT01513109|Experimental|Treatment arm|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion
9997929|NCT01513135|Experimental|Group A, Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin; administered intradermally 3 times at weeks 0, 4 & 8
9997930|NCT01513135|Placebo Comparator|group B, Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin, administered intradermally 3 times at weeks 0, 4 & 8
9997931|NCT01513161|Active Comparator|TRK-820 5μg|Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days
9997932|NCT01513161|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg capsule & one placebo capsule)by oral route once daily for 14 days
9997933|NCT01513161|Placebo Comparator|Placebo|Taking Placebo(two placebo capsule) by oral route once daily for 14 days
9909603|NCT00694902|Experimental|Sequence 8 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
9909604|NCT00694902|Experimental|Cohort III|Subjects in Cohort III after randomization will either receive 1000 microgram GSK610677 or placebo.
9909605|NCT00694915|Experimental|Mw|Mycobacterium w
9909606|NCT00694915|Active Comparator|BCG|bacillus Calmette-Guerin (BCG)
9909607|NCT00694941|Experimental|E|ONO-2506PO in the presence of Riluzole
9909608|NCT00694954|Experimental|1|Wireless capsule endoscopy
9909609|NCT00694954|Active Comparator|2|Standard Care
9909610|NCT00694967|Active Comparator|1|McDonald cerclage
9909611|NCT00694967|Active Comparator|2|17 hydroxyprogesterone caproate
9909612|NCT00694980|Experimental|1|
9909613|NCT00694993|Experimental|Subjects receiving GSK1004723 + placebo in cohort I and II|Eligible subjects will receive GSK1004723 nasal spray with single doses of 50 micrograms, 100 micrograms, 200 micrograms, 500 micrograms and 1000 micrograms. Subjects will also receive placebo nasal spray.
9909614|NCT00694993|Experimental|Subjects receiving GSK1004723 200 micrograms in cohort III|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 200 micrograms given once daily for 14 days.
9909615|NCT00694993|Experimental|Subjects receiving placebo in cohort III|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
9909616|NCT00694993|Experimental|Subjects receiving GSK1004723 1000 micrograms in cohort IV|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 1000 micrograms given once daily for 14 days.
9909617|NCT00694993|Experimental|Subjects receiving placebo in cohort IV|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
9909618|NCT00695006|Sham Comparator|II|Sham Traction
9909619|NCT00695006|Active Comparator|I|Traction
9909620|NCT00695045|Experimental|1|patients in this group got 100mcg of intrathecal morphine.
9909621|NCT00695045|Experimental|2|patients in this group got 200 mcg intrathecal morphine
9909622|NCT00695045|Experimental|3|patients in this group given 300 mcg intrathecal morphine.
9909623|NCT00695058|Experimental|1|Women with stress incontinence treated with active TMNS (vibration)
9909624|NCT00695058|Placebo Comparator|2|Women with stress incontinence treated with placebo TMNS (vibration)with an amplitude of 0
9909625|NCT00695058|Experimental|3|Women with overactive bladder syndrome treated with active TMNS (vibration)
9909626|NCT00695058|Placebo Comparator|4|Women with overactive bladder syndrome treated with placebo TMNS (vibration)with an amplitude of 0
9909627|NCT00695058|Experimental|5|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with active TMNS (vibration)
9909628|NCT00695058|Placebo Comparator|6|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with placebo TMNS (vibration)with an amplitude of 0
9909629|NCT00695071|Active Comparator|A|
9909630|NCT00695084|Experimental|1|Treatment with Constraint-Induced Movement Therapy
9909631|NCT00695123||Only 1 participant group (cohort)|The subject may have a blood disorder, may be a stem cell transplant donor, or may be a healthy volunteer.
9909632|NCT00695162|Other|1|hearing impaired inpatients
9909633|NCT00695162|Other|2|Non-hearing-impaired inpatients
9909634|NCT00695201|Experimental|1|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
9909635|NCT00695201|Experimental|2|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
9909636|NCT00695214|Other|1|OSA Patients considering surgical treatment
9909637|NCT00695227|Experimental|Screening for Barrett's Esophagus|
9909638|NCT00695240|Experimental|Bupiv analgesia|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. The catheter was placed in the operating room with a peel-away trocar and attached to the pump. The trocar was inserted through a 5 mm stab incision made near the superior part of the pubic bone between the genitoinguinal fold and the midline of the symphysis. Once through the incision, the trocar is advanced subcutaneously and made to exit the posterior fourchette just beneath the posterior vaginal mucosa where it is advanced by tenting up the skin.
9909639|NCT00695266||1|
9909640|NCT00695331|Experimental|1|Titrated Oral Misoprostol Solution
9909641|NCT00695331|Active Comparator|2|Intravenous Oxytocin
9909642|NCT00695344|Experimental|1|Everolimus 2 times per day + cyclosporin low dose +/- steroids
9909643|NCT00695344|Active Comparator|2|Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
9909644|NCT00695383|Experimental|1|
9667264|NCT03799861||Epoch 3: HR-guided HBB|Implementation of HR-guided Helping Babies Breathe training with NeoBeat for measurement of HR throughout resuscitation of non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for a prospective cohort of all infants born in the three study hospitals for a 9-month period.
9909645|NCT00695383|Active Comparator|2|
9909646|NCT00695422||Specimen Collection|Blood collection, anal cytology and biopsy of observed lesions. Additional cervical cytology and biopsy for females.
9909647|NCT00695448|Experimental|Cohorts|The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.
9909648|NCT00695461|Experimental|1|Receives Lactobacillus plantarum 299v in an oatmeal drink, at a concentration of 10(9) colony-forming-units/ml, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
9909649|NCT00695461|Placebo Comparator|2|Receives oatmeal drink, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
9909650|NCT00695474||A|The cohort consists of type 2 diabetics from the outpatient clinic at Silkeborg Hospital.
9909651|NCT00695487|Experimental|1|Receives 0.125mg/kg THC before emergence
9909652|NCT00695487|Placebo Comparator|2|Receives NaCl before emergence
9909653|NCT00695513|Experimental|I|BENEO synergy1
9909654|NCT00695526|Active Comparator|A|
9909655|NCT00695552|Experimental|1|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
9909656|NCT00695552|Placebo Comparator|2|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises.
9909657|NCT00695591||1SevereRLD,NMD|Patients with FEV1<40%
9909658|NCT00695591||2VerySevereRLD,NMD|FEV1<30%
9909659|NCT00695591||3NINV|FEV1<25%,on non invasive ventilation
9909660|NCT00695591||ModerateRLD,NMD|Patients with FEV1 40-50% of predicted
9909661|NCT00695604|Placebo Comparator|1|"Placebo Comparator~All patients assigned to this group will receive:~Placebo via Metered Dose Inhaler (MDI).~Albuterol via MDI."
9909662|NCT00695604|Active Comparator|2|"Active Comparator~All patients assigned to this group will receive:~Fluticasone via MDI.~Albuterol via MDI."
9909663|NCT00695617|Experimental|A|citrate first
9909664|NCT00695617|Experimental|B|no anticoagulation first
9909665|NCT00695630|Experimental|1|Flumazenil 2mL
9909666|NCT00695630|Placebo Comparator|2|Saline, 2mL SM
9909667|NCT00695643|Experimental|A|
9909668|NCT00695643|Placebo Comparator|B|
9909669|NCT00695656||1|
10212986|NCT04760483|Experimental|Transperineal Laser Ablation for BPH|"Ceftriaxone 250 mg IM as antibiotic prophylaxis. Local Anesthesia: perineal skin will be infiltrated with 10 cc of Lidocaine 2% and then each neurovascular bundle will be infiltrated with 5 - 10 cc. Nitrous self-administered anesthesia will be available.~One or two laser fibers from Echolaser x4 will be placed in each of the two prostate lobes using the plan. Treatment will be executed following Echolaser smart Interface planning, needles will follow targeted location using stepper grid under a transperineal approach in a sagittal plane. Ablation with 5 watts power per fiber, a total of ~ 1800 J will be delivered. We will evaluate pain measures and procedure tolerance using visual analog pain scale Upon completion we will measure coagulation zone with TRUS. Before discharge, trial of void will be conducted. Patients with a residual greater than 200 cc will have an indwelling catheter placed and will be discharged with it."
10212987|NCT04757519|Experimental|DPP-GLB Standard|Participants in this group will receive the standard Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
9933933|NCT05126927|Experimental|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
9933934|NCT05126030|Experimental|Primary Cohort|Device: Topaz TTVR system
9933935|NCT05125679|Experimental|Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous injection at Weeks 0, 4, 12, 20 and 28.
10212988|NCT04757519|Experimental|DPP-GLB Enhanced|Participants in this group will receive the enhanced Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.
10212989|NCT04750265|Experimental|Robotic assisted early mobilization|Early mobilization therapy assisted with robotics
10212990|NCT04750265|No Intervention|Standard Care|Mobilization according to standard care by staff
10212991|NCT04748094||Free-breathing versus Compression|This cohort of volunteers and patients will undergo imaging on the MR-Linac investigating free-breathing motion, and comparing it to motion using an abdominal compression device.
10212992|NCT04748094||Free-breathing versus Breath-holding|This cohort of volunteers and patients will undergo imaging on the MRSim investigating free-breathing motion and comparing it to visually-guided breath-hold motion (and reproducibility).
10212993|NCT04747314|Experimental|Antidepressant (AD)|Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks. Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months.
10212994|NCT04747314|Experimental|Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment. Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months.
9933944|NCT05119894|Experimental|Brexpiprazole LAI: Dose 1|
9933945|NCT05119894|Experimental|Brexpiprazole LAI: Dose 2|
9933946|NCT05119894|Experimental|Brexpiprazole LAI: Dose 3|
9933947|NCT05119894|Experimental|Brexpiprazole LAI: Dose 4|
9994358|NCT01480453||Trabecular Metal Humeral Stem|Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.
9909670|NCT00695708|Experimental|BFT|20 schizophrenic patients
9909671|NCT00695708|Active Comparator|CP|19 schizophrenic patients
9909672|NCT00695708|No Intervention|HCG|20 healthy age and sex matched subjects
9909673|NCT00695734||Hemodialysis|Patients under chronic hemodialysis for chronic end stage renal failure
9909674|NCT00695747|No Intervention|1|Standard 1 site Procedure using a fornix based incision, performed superiorly
9909675|NCT00695747|Experimental|2|2 Site Combined Procedure
9909676|NCT00695799||1|Anesthesia Providers at UMDNJ
9909677|NCT00695812||1|Siblings of children with Autism
9909678|NCT00695812||2|Siblings of children with typical development
9909679|NCT00695825|Experimental|A1|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
9909680|NCT00695825|Experimental|A2|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
9909681|NCT00695838||1|
9909682|NCT00695851|Experimental|1|15 mg/m2 weekly of PCK3145
9909683|NCT00695851|Experimental|2|7.5 mg/m2 twice per week of PCK3145
9909684|NCT00695877|Experimental|1|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
9909685|NCT00695877|Experimental|2|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^10 virus particles (VP) given at Days 0, 28, and 168
9909686|NCT00695877|Experimental|3|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^11 virus particles (VP) given at Days 0, 28, and 168
9909687|NCT00695877|Experimental|4|1 injection of rAd5.ENVA.48 HIV-1 vaccine or placebo at a dose determined by the safety data from Arms 1, 2 and 3 given at Day 0.
9909688|NCT00695890||1|Healthy volunteers
9909689|NCT00695942||1|pregnancy women
9909690|NCT00695994|Experimental|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle.
9909691|NCT00695994|Experimental|Gemcitabine and carboplatin|Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
9909692|NCT00696007|Experimental|1|A neoadjuvant chemotherapy (gemcitabine and cisplatin) regimen administered before surgery-nephroureterectomy for upper tract TCC
9909693|NCT00696007|Other|2|A retrospective cohort group (approximately 60 subjects) identified from an institutional cancer registry who have undergone a nephroureterectomy alone over the past five years
9909694|NCT00696033|Experimental|1|Oral Lorazepam
9909695|NCT00696033|Experimental|2|Oral Diazepam
9909696|NCT00696033|Placebo Comparator|3|Oral placebo
9909697|NCT00696059|Other|1|Open-label, one arm only. All patients receiving active drug according to recommendations (adalimumab (Humira) 40 mg subcutaneously every other week).
9909698|NCT00696085|Other|I|Pregnant women are recruited and screened for alcohol use using a validated alcoholism screening questionnaire. Those who screen positive are then entered into the next phase of the study.
9909699|NCT00696098|Experimental|1|sodium butyrate
9909700|NCT00696098|Placebo Comparator|2|
9909701|NCT00696111|Experimental|1A|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive estrogen plus placebo for another 6 weeks.
9909702|NCT00696111|Experimental|1B|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive progesterone plus placebo for another 6 weeks.
9909703|NCT00696111|Experimental|3|Randomized to receive CPAP (continuous positive airway pressure) treatment for 6 weeks.
9909704|NCT00696124|Experimental|Cohort 1|2mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
9909705|NCT00696124|Experimental|Cohort 2|4mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
9909706|NCT00696124|Experimental|Cohort 3|8mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
9909707|NCT00696124|Experimental|Cohort 4|16mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
9909708|NCT00696150|Placebo Comparator|loss of resistance|Anterior psoas compartment nerve block inserted using loss of resistance
9909709|NCT00696150|Active Comparator|nerve stimulator|Anterior psoas compartment nerve block inserted using nerve stimulator
9909710|NCT00696150|Active Comparator|ultrasound|Anterior psoas compartment nerve block inserted using ultrasound
9909711|NCT00696163||A|
9909712|NCT00696176|Experimental|A|STAT 3 decoy administration
9909713|NCT00696202|Experimental|Arm 1|
9909714|NCT00696215|Placebo Comparator|1|
9909715|NCT00696215|Active Comparator|2|Rasagiline
9909716|NCT00696228|Placebo Comparator|AFN A|High Fat Diet Placebo
9994359|NCT01480466|Experimental|Obesity tools in electronic health record|This arm will consist of a new set of tools within the electronic health record to help primary care clinicians address overweight and obesity with their patients.
9994360|NCT01480466|No Intervention|Standard care|This arm is standard care for overweight/obesity.
9994361|NCT01480492|No Intervention|therapy|
9909717|NCT00696228|Experimental|AFN B|MUFA
9909718|NCT00696228|Experimental|AFN C|PUFA
9909719|NCT00696228|Experimental|AFN D|SFA
9909720|NCT00696280||Group 1|"All patients will be given the Functional Living Index - Emesis (FLIE) standardized questionnaire during their scheduled clinic visit prior to receiving chemotherapy.~This is a self-administered questionnaire. Patients will complete the questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours, 72 hours, and 96 hours) of their first and third cycles of chemotherapy.~Patients will also be interviewed by a trained CRA or research nurse over the telephone 24-48 hours following carboplatin administration in order to assess the severity of the delayed nausea and vomiting."
9909721|NCT00696319|Experimental|1|Arm 1 will go through a rehabilitation protocol with perturbation training exercises.
9909722|NCT00696319|Experimental|2|Arm 2 will go through a rehabilitation protocol with traditional exercises for balance and stability training.
9909723|NCT00696345||1|Colorectal cancer patients, Stages I-IV
9909724|NCT00696345||2|Non colorectal cancer patients, verified by colonoscopy
9909725|NCT00696358|Active Comparator|A|308 nm excimer lamp
9909726|NCT00696358|Active Comparator|B|308 nm excimer laser
9909727|NCT00696397||A|adult men and women between 18 and 50 years of age with atopic dermatitis
9909728|NCT00696462|No Intervention|A|Patients in Group A will undergo passive warming with a warmed cotton blanket placed over their upper extremities
9909729|NCT00696462|Active Comparator|B|Patients in Group B will have a forced-air warming device applied to the upper body above the waist at the 43 degree Celsius setting.
9909730|NCT00696475|Experimental|1|Diazoxide equivalent dose
9909731|NCT00696475|Experimental|2|Diazoxide equivalent dose
9909732|NCT00696475|Experimental|3|Diazoxide equivalent dose
9909733|NCT00696475|Placebo Comparator|4|
9909734|NCT00696514|Placebo Comparator|2|placebo capsule, once per day
9909735|NCT00696514|Experimental|1|Vitamin B12 and folic acid capsule, once a day
9909736|NCT00696527||1|
9909737|NCT00696540|Experimental|1|Salbutamol is diluted in hypertonic (3%) saline.
9909738|NCT00696540|Active Comparator|2|Salbutamol is diluted in normal (0.9%) saline.
9909739|NCT00696553|Active Comparator|B1|Nutrition
9909740|NCT00696553|Experimental|B2|Nutrition plus Exercise
9909741|NCT00696566|Experimental|A|All subjects will receive Clopidogrel and Rifampicin.
9909742|NCT00696579|Active Comparator|A|Group A received BCG instillation 14 days after II look-TURB:6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
9909743|NCT00696579|Experimental|2|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
9909744|NCT00696631|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
9909745|NCT00696631|Placebo Comparator|Placebo|matching placebo tablets
9909746|NCT00696644||Patients with severe osteoporosis|Postmenopausal women and men aged > 21 years old affected by severe osteoporosis
9909747|NCT00696683||A|Patients from the identified scorpion envenomation cases, who met inclusion/exclusion criteria.
9909748|NCT00696722|Experimental|1|Placebo treatment first, atazanavir treatment second
9909749|NCT00696722|Experimental|2|Atazanavir treatment first, placebo treatment second
9909750|NCT00696735|Active Comparator|1|standard chemotherapy arm, the CHVP (cyclophosphamide, low-dose doxorubicin, teniposide, and prednisone) regimen consisted of cyclophosphamide (600 mg/m2), doxorubicin (25 mg/m2), and teniposide (60 mg/m2), all administered intravenously on day 1, and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
9909751|NCT00696735|Experimental|2|VCAP (cyclophosphamide, high-dose doxorubicin, prednisone, and vincristine) regimen as a first-line therapy combining vindesine (3 mg/m2) on day 1, cyclophosphamide (1500 mg/m2) on day 2, doxorubicin (80 mg/m2) on day 2, and prednisolone (50 mg/m2) on days 1 to 5, every 3 weeks.19,31,32 Patients in CR, VGPR, or PR after the second or third VCAP cycle continued on to stem-cell harvesting and received, before transplantation, one course of IMVP16 (ifosfamide, methotrexate, and VP-16), which combined ifosfamide (1.5 g/m2) and VP16 (100 mg/m2) on days 1 through 3, and methotrexate (30 mg/m2) on days 1 and 10. Patients with less than PR after the VCAP cycles received, as salvage therapy, 2 to 3 courses of DHAP (dexamethasone, high-dose cytarabine, and cisplatin) combining cisplatine (100 mg/m2) on day 1, cytarabine (4 g/m2) on day 2, and dexamethasone (40 mg/m2) on days 1 through 4. If at least a PR was obtained after DHAP, stem cells were harvested or patients were considered as failures
9909752|NCT00696748|Active Comparator|1|Men receiving Nebido
9909753|NCT00696748|Placebo Comparator|2|Men receiving Placebo
9909754|NCT00696813||paliperidone ER|Newly switched to or started on Paliperidone ER, not longer than 2 weeks ago
9909755|NCT00696813||Any other oral antipsychotic|Newly switched to or started on any other oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago
9909756|NCT00696839|No Intervention|1|Usual care (adherence education)
9909757|NCT00696839|Experimental|2|Usual care and Cognitive Behavioral Therapy sessions
9909758|NCT00696852|Active Comparator|Mindfulness Meditation|
9909759|NCT00696852|Active Comparator|Yoga|
9909760|NCT00696852|Active Comparator|Conventional Stress Reduction|
9909761|NCT00696865|Experimental|1|
9909762|NCT00696865|Placebo Comparator|2|
9909763|NCT00696891|Experimental|Group A|
9909764|NCT00696891|Active Comparator|Group B|
9909765|NCT00696904|Other|1|Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose
9909766|NCT00696904|Other|2|HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID
9909767|NCT00696904|Other|3|Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect
9909768|NCT00696917|Active Comparator|Group A|Three doses according to 0, 1, 6-month schedule
9909769|NCT00696917|Experimental|Group B|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
9909770|NCT00696917|Experimental|Group C|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
9909771|NCT00696917|Experimental|Group D|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
9909772|NCT00696943|Experimental|18F-ML-10,|Pre-treatment baseline and post treatment follow-up 18F ML-10 PET/CT sessions.
9909773|NCT00696956|Placebo Comparator|A|Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)
9909774|NCT00696956|Active Comparator|2|Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)
9909775|NCT00696969|Active Comparator|1|
9909776|NCT00696969|Experimental|2|
9909777|NCT00696969|Experimental|3|
9909778|NCT00696969|Experimental|4|
9909779|NCT00696982|Experimental|A|diabetic patients who are treated with metformin wiyh HBA1C>7% will get sitagliptin
9909780|NCT00696982|Experimental|B|diabetic patients who are treated with metformin with HBA1C>7% will get glibenclamide
9909781|NCT00696995||A|
9909782|NCT00697008||GERD patients|Patients with typical GERD symptoms
9909783|NCT00697021|Active Comparator|1|Patients who suffered acute STEMI and were treated by PPCI and by Aspirin 100mg and Plavix 75mg and showed on treatment platelet over-reactivity observed by TEG system on the 5th day after admission to ICCU
9909784|NCT00697021|Other|2|Patients who suffered acute STEMI and were treated by PPCI and recieved by Aspirin 100mg and Plavix 75mg and showed platelet inhibition observed by TEG system on the 5th day after admission to ICCU
9909785|NCT00697034|Experimental|1|Study subjects will be patients with chronic plaque-type psoriasis
9909786|NCT00697047|No Intervention|1- Usual Care|Usual Care (UC) includes an annual birthday letter with information on overdue screening tests including CRC screening.
9909787|NCT00697047|Experimental|2 - Automated Mailing|Usual care plus automated mailing. Mailing 1 is a pamphlet about screening choices and number to call for colonoscopy. Mailing 2 is a FIT kit if not requesting colonoscopy. Mailing 3 is a Reminder letter.
9909788|NCT00697047|Experimental|3 - Automated Mailing Plus Assisted|Usual care, automated mailing plus, if screening is still not completed, phone assistance by a medical assistant (MA) who asks about patients screening intent, and provides brief assistance to complete this (e.g. sends another fecal test, assists with provider order for a colonoscopy).
9909789|NCT00697047|Experimental|4 - Auto Plus Assisted Plus Navigation|Usual care, automated mailing, phone assistance by a medical assistant, plus navigation by a registered nurse (RN) if still not screened. Navigators are trained to use motivational interviewing techniques. They assess CRC and procedure risk, facilitate screening choice, address barriers, and provide follow-up until screening is completed.
9909790|NCT00697060|Experimental|Stage 1/2|Imexon plus docetaxel
9909791|NCT00697086|Experimental|1|
9909792|NCT00697086|Placebo Comparator|2|
9909793|NCT00697125|Active Comparator|Group A|
9909794|NCT00697125|Experimental|Group B|
9909795|NCT00697125|Experimental|Group C|
9909796|NCT00697138|Experimental|A|
9909797|NCT00697151|Active Comparator|Warfarin|Warfarin (target International Normalized Ratio: 1.4 to 2.8) plus placebo aspirin
9909798|NCT00697151|Active Comparator|Aspirin|Aspirin 325 mg plus placebo warfarin
9909799|NCT00697164|Placebo Comparator|1|Patients in group I received intravenous quinine followed by oral ACT for a total period of 6 days.
9909800|NCT00697164|Experimental|2|Patients in group II received antimalarial drug as in group I and in addition 1500U/kg/day of rHUEPO for the initial 3 days.
9909801|NCT00697216|Experimental|Group A|
9909802|NCT00697216|Active Comparator|Group B|
9909803|NCT00697229|Experimental|Group A|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
9909804|NCT00697229|Experimental|Group B|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
9909805|NCT00697229|Experimental|Group C|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
9909806|NCT00697229|Experimental|Group D|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
9909807|NCT00697229|Experimental|Group E|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
9909808|NCT00697229|Experimental|Group F|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
9909809|NCT00697229|Experimental|Group G|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
9909810|NCT00697229|Experimental|Group H|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
9909811|NCT00697242|Experimental|Group A|
9909812|NCT00697242|Experimental|Group B|
9909813|NCT00697242|Experimental|Group C|
9909814|NCT00697242|Active Comparator|Group D|
9909815|NCT00697242|Experimental|Group E|
9909816|NCT00697281|Experimental|1|Dose level 1
9909817|NCT00697281|Experimental|2|Dose level 2
9909818|NCT00697281|Experimental|3|Dose level 3
9909819|NCT00697281|Experimental|4|Dose level 4
9909820|NCT00697281|Experimental|5|Dose level 5
9909821|NCT00697294|Experimental|Supplement|Subjects will serve as their own control in this single-arm protocol. All subjects will receive 400 IU/day of vitamin D as the intervention. Comparisons will be made between Caucasian and Hispanic infants.
9909822|NCT00697320||A|
9909823|NCT00697333|No Intervention|A|Irradiation of all tumor manifestations detectable by CT and/or positron emission tomography using fluoro-deoxy-glucose including a part of eventual atelectasis and the whole affected lymph node stations by 60 - 74 Gy/2Gy) irradiation of elective lymph node stations up to 50 Gy/2 Gy
9909824|NCT00697333|Experimental|B|Irradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy
9909825|NCT00697359|Experimental|1|There is only one group in this cohort study.
9909826|NCT00697372|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
9909827|NCT00697372|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
9909828|NCT00697385|Experimental|TA|on treatment
9909829|NCT00697398|Placebo Comparator|1|Sound placebo
9909830|NCT00697398|Experimental|2|Sound
9909831|NCT00697424|Experimental|1|All subjects will be placed on continuous positive airway pressure (CPAP) therapy during a full night sleep study or polysomnography (PSG). The subjects will spend 2 hours on sub-therapeutic CPAP 4 cmH2O of pressure and the remainder on there therapeutic pressure. Values reported on the device will be compared to scored values from manual scoring of the sleep study.
9517579|NCT03305172|Experimental|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
9909832|NCT00697437|Experimental|docetaxel only|
9909833|NCT00697437|Experimental|docetaxel with ketoconazole|
9909834|NCT00697450||All participants|
9994362|NCT01480505||High myopic eye|Persons with high Myopia suffered from Rhegmatogenous Retinal detachment
9667265|NCT03794661|Experimental|Single Arm|Clinician programmer electrode screening mode tool
9667266|NCT03780829|Experimental|hypoxia plus training|combined hypoxia treatment with exercise training
9909835|NCT00697476|Experimental|Vorinostat/Topotecan|"Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2"
9667267|NCT03780829|Sham Comparator|sham hypoxia plus training|combined sham hypoxia treatment with exercise training
9667268|NCT03780829|Experimental|hypoxia plus training plus NMDA agonist|combined hypoxia treatment with exercise training and with NMDA agonist treatment
9667269|NCT03780829|Placebo Comparator|hypoxia plus training plus sham NMDA agonist|combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
9909836|NCT00697489|Active Comparator|1|unique surgery
9909837|NCT00697489|Active Comparator|2|Double surgery
9909838|NCT00697502|Experimental|Group 2: TSER 3R/3R|Cohorts of 3-6 patients in each genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
9909839|NCT00697502|Experimental|Group 1: TSER 2R/2R or 2R/3R|Cohorts of 3-6 patients in this genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
9933948|NCT05116566||Patients|Three distinct sub-cohorts will be targeted for recruitment to represent perspectives across the advancing illness course: patients ≤3 months from a poor- prognosis diagnosis (cohort 1), patients ≤ 3 months from disease relapse or progression (cohort 2), and patients actively enrolled on a phase I/II trials (cohort 3).For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent patient is eligible for enrollment if the parent consents for the patient's enrollment but declines his/her own enrollment.
9933949|NCT05116566||Parents|Four distinct sub-cohorts of parents will be targeted for recruitment, including cohorts 1-3 and a fourth bereavement cohort. For cohorts 1-3, patient-parent dyads will be enrolled when eligible; however, an independent parent is eligible for enrollment if the patient declines enrollment, but the parent wishes to participate.
9933950|NCT05116566||Oncologist|Pediatric oncologists who treat or refer patients for treatment at St. Jude Children's Research Hospital (SJCRH) will be eligible to participate.
9933951|NCT05112601|Experimental|Arm I (nivolumab and ipilimumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 every other cycle. Treatment with nivolumab and ipilimumab repeats every 3 weeks for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or CR. Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for 12 months in the absence of disease progression or unacceptable toxicity."
9933952|NCT05112601|Active Comparator|Arm II (nivolumab)|"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.~MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for 12 months in the absence of disease progression or unacceptable toxicity."
9933953|NCT05108870|Experimental|Phase 1: Dose-Finding Group 1 - Drug Combination 1|"All participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel.~- HB-201 will be administered on cycle 1 day 15, cycle 2 day 15, and cycle 3 day 15 with three 21-day cycles of carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15"
9909840|NCT00697528||Group control with healthy subjects|Healthy subjects without thyroid disease, ocular disease and previous surgery in the orbit or eye used in the study.
9909841|NCT00697528||Graves' Ophthalmopathy - fibrotic phase|Patients that are clinically inactive (CAS equal or lower than 2). This group will be subdivided in the miogenic and lipogenic groups.
9909842|NCT00697528||Graves' Ophthalmopathy - active phase|Patients that are clinically active, presenting a CAS of 4 or more points, with or without disthyroid optic neuropathy.
9909843|NCT00697554|Experimental|Group A|
9909844|NCT00697554|Active Comparator|Group B|
9909845|NCT00697567|Experimental|Group A|HSV seropositive subjects
9909846|NCT00697567|Experimental|Group B|HSV seronegative subjects
9909847|NCT00697567|Experimental|Group C|HSV seropositive subjects
9909848|NCT00697567|Experimental|Group D|HSV seronegative subjects
9909849|NCT00697580|No Intervention|1|Control (C)
9909850|NCT00697580|Experimental|2|Nutrition (N)
9909851|NCT00697580|Experimental|3|Strength Training & Nutrition (ST + N)
9909852|NCT00697580|Experimental|4|Circuit Training & Nutrition (CT + N)
9909853|NCT00697606|Experimental|A|Seprafilm®
9909854|NCT00697606|Sham Comparator|B|Control
9909855|NCT00697632|Experimental|1|
9909856|NCT00697645|Sham Comparator|1|Patients with stroke will be treated with usual stroke care and sham TMS will be applied
9909857|NCT00697645|Experimental|2|Deep TMS applied over the motor strip in patients with stroke in addition to usual stroke care.
9909858|NCT00697658||001|
9909859|NCT00697671|Other|Strata A|Patients with ALL, CML, JMML, MDS, or NHL with bone marrow relapse after stem cell transplant.
9909860|NCT00697671|Other|Strata B|Patients with ALL, CML, JMML , MDS, or NHL with primary induction failure and persistent disease; or participants with relapsed ALL, CML, JMML, MDS, or NHL with persistent disease after re-induction
9909861|NCT00697749|Experimental|Group A|
9909862|NCT00697749|Active Comparator|Group B|
9909863|NCT00697775|Experimental|Group A|HBV-MPL Formulation A at months 0 and 6
9909864|NCT00697775|Experimental|Group B|HBV-MPL Formulation B at months 0 and 6
9909865|NCT00697775|Experimental|Group C|HBV-MPL Formulation A at month 0 and Engerix™-B at month 6
9909866|NCT00697775|Active Comparator|Group D|Engerix™-B at months 0, 1, 6
9909867|NCT00697814|Experimental|Clomiphene|Clomiphene 50 mg/day for 12 weeks
9909868|NCT00697840|Experimental|Group A|
9909869|NCT00697840|Active Comparator|Group B|
9909870|NCT00697840|Experimental|Group C|
9909871|NCT00697853|Active Comparator|Group A|
9909872|NCT00697853|Experimental|Group B|
9909873|NCT00697853|Experimental|Group C|
9909874|NCT00697853|Experimental|Group D|
9909875|NCT00697853|Experimental|Group E|
9909876|NCT00697866|Experimental|Group A|HBV-MPL Lot A
9909877|NCT00697866|Experimental|Group B|HBV-MPL Lot B
9909878|NCT00697866|Experimental|Group C|HBV-MPL Lot C
9909879|NCT00697866|Active Comparator|Group D|Engerix™-B
9909880|NCT00697879|Experimental|1|Oral, once daily administration of CHR-3996 to determine safety and tolerability
9909881|NCT00697892|Experimental|Group A4|healthy volunteers assigned to the efavirenz with artemether/lumefantrine intervention
9909882|NCT00697892|Experimental|Group A3|healthy volunteers assigned to the lopinavir/ritonavir with artemether/lumefantrine intervention
9909883|NCT00697905|Experimental|A|
9909884|NCT00697905|Active Comparator|B|
9909885|NCT00697931|Experimental|Group A|
9909886|NCT00697931|Active Comparator|Group B|
9909887|NCT00697957|No Intervention|2|Control group
9909888|NCT00697957|Experimental|1|Exercise
9909889|NCT00697970|Experimental|Group A|
9909890|NCT00697970|Experimental|Group B|
9909891|NCT00697970|Experimental|Group C|
9909892|NCT00697970|Experimental|Group D|
9909893|NCT00697970|Experimental|Group E|
9909894|NCT00697970|Active Comparator|Group F|
9909895|NCT00697983||Fracture cohort|Patients of 50 years and above with a clinical, non-pathological fracture, who attend an osteoporosis outpatient clinic at the Maastricht University Medical Center for standard medical care (including bone densitometry by DXA-scan).
9909896|NCT00698048||1|Controls
9909897|NCT00698048||2|Sepsis
9909898|NCT00698048||3|Septic Shock
9909899|NCT00698061|Experimental|Group A|
9909900|NCT00698061|Active Comparator|Group B|
9909901|NCT00698074|Experimental|1|Cardiac Resynchronisation Therapy
9909902|NCT00698087|Experimental|Group A|
9909903|NCT00698087|Active Comparator|Group B|
9909904|NCT00698087|Experimental|Group C|
9909905|NCT00698100|Experimental|1|Patients will get human tyrosinase vaccination.
9909906|NCT00698100|Experimental|2|Patient will get mouse tyrosinase DNA vaccination.
9909907|NCT00698113|Active Comparator|1|This group receives the massage intervention for a period of six weeks. Children and parents are asked to journal weekly for the six week period.
9909908|NCT00698113|No Intervention|2|The control group does not receive any massage intervention during the initial six weeks of the study. The children are asked to journal during this six week period.
9909909|NCT00698126||A|
9909910|NCT00698126||B|
9909911|NCT00698152||ArComXL® polyethylene|ArComXL® polyethylene
9909912|NCT00698165||Patients|1200 adults with mild to severe Alzheimer's disease
9909913|NCT00698165||Caregivers|1200 informal caregivers
9909914|NCT00698178||NERD|patients with typical gastro-reflux symptoms but no erosions were discernible on upper gastrointestinal endoscopy
9909915|NCT00698178||EE|Patients with both typical gastroesophageal reflux symptoms and characteristic flam-like erosions as demonstrated on upper gastrointestinal endoscopy
9909916|NCT00698178||FD|Patients report no typical reflux symptoms but fulfill diagnostic criteria of functional dyspepsia, whose upper gastrointestinal endoscopy are negative.
9909917|NCT00698191|Experimental|1|
9909918|NCT00698243|Experimental|Schedule 1|Once daily for 3 days every 7 days
9909919|NCT00698243|Experimental|Schedule 2|Once weekly
9909920|NCT00698243|Experimental|Schedule 3|Once daily
9909921|NCT00698256|Experimental|1|
9909922|NCT00698256|Placebo Comparator|2|
9909923|NCT00698269||A|
9909924|NCT00698269||B|
9909925|NCT00698269||C|
9909926|NCT00698282|Experimental|1|
9909927|NCT00698282|Experimental|2|
9909928|NCT00698282|Placebo Comparator|3|
9909929|NCT00698321|Experimental|1|Participating schools will deliver HIV/STD prevention modules.
9909930|NCT00698321|Active Comparator|2|Participating schools will deliver general health promotion modules.
9909931|NCT00698334|Experimental|HIV infected|HIV infected patients with active TB
9909932|NCT00698334|Active Comparator|HIV negative|HIV negative patients with active TB
9909933|NCT00698347||M2a-Magnum™ Hip System|Patients who received the M2a-Magnum™ Hip System
9909934|NCT00698360||A|MDRD 10-30
9909935|NCT00698360||B|MDRD 30-60
9909936|NCT00698360||C|MDRD 60-80
9909937|NCT00698360||D|MDRD > 80
9909938|NCT00698373||1|PET study
9909939|NCT00698399||1|Live Donor
9909940|NCT00698399||2|Cadaveric Donor
9909941|NCT00698412|Experimental|1|Cane group
9909942|NCT00698412|No Intervention|2|Control Group
9909943|NCT00698425|Experimental|1: 0 mA-min (0 mA for 4 min)|Ocular iontophoresis 0 mA-min (0 mA for 4 minutes)
9909944|NCT00698425|Experimental|2: 4 mA-min (2 mA for 2 min), + polarity|Ocular iontophoresis 4 mA-min (2 mA for 2 minutes), positive polarity
9909945|NCT00698425|Experimental|3: 5 mA-min (2.5 mA for 2 min), +|Ocular iontophoresis 5 mA-min (2.5 mA for 2 minutes), positive polarity
9909946|NCT00698425|Experimental|4: 6 mA-min (3 mA for 2 min), + polarity|Ocular iontophoresis 6 mA-min (3 mA for 2 minutes), positive polarity
9909947|NCT00698425|Experimental|5: 7 mA-min (3.5 mA for 2 min), +|Ocular iontophoresis 7 mA-min (3.5 mA for 2 minutes), positive polarity
9909948|NCT00698425|Experimental|6: 8 mA-min (4 mA for 2 min), + polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), positive polarity
9909949|NCT00698425|Experimental|7: 7 mA-min (3.5 mA for 2 min), -|7 mA-min (3.5 mA for 2 minutes), negative polarity
9909950|NCT00698425|Experimental|8: 8 mA-min (4 mA for 2 min), - polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), negative polarity
9909951|NCT00698425|Experimental|9: 20 mA-min (4 mA for 5 min), +|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), positive polarity
9909952|NCT00698425|Experimental|10: 20 mA-min (2 mA for 10 min), +|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), positive polarity
9909953|NCT00698425|Experimental|11: 20 mA-min (4 mA for 5 min), -|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), negative polarity
9909954|NCT00698425|Experimental|12: 20 mA-min (2 mA for 10 min), -|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), negative polarity
9909955|NCT00698425|Experimental|13: 0 mA-min (0 mA for 10.5 min)|Ocular iontophoresis 0 mA-min (0 mA for 10.5 minutes)
9909956|NCT00698425|Experimental|14: 13.5 mA-min (4.5 mA for 3 min), +|Ocular iontophoresis 13.5 mA-min (4.5 mA for 3 minutes), positive polarity
9909957|NCT00698425|Experimental|15: 15 mA-min (5 mA for 3 min), +|Ocular iontophoresis 15 mA-min (5 mA for 3 minutes), positive polarity
9909958|NCT00698425|Experimental|16: 16.5 mA-min (5.5 mA for 3 min), +|Ocular iontophoresis 16.5 mA-min (5.5 mA for 3 minutes), positive polarity
9909959|NCT00698425|Experimental|17: 18 mA-min (6 mA for 3 min), +|Ocular iontophoresis 18 mA-min (6 mA for 3 minutes), positive polarity
9909960|NCT00698425|Experimental|18: 19.5 mA-min (6.5 mA for 3 min), +|Ocular iontophoresis 19.5 mA-min (6.5 mA for 3 minutes), positive polarity
9909961|NCT00698425|Experimental|19: 20 mA-min (7 mA for 3.84 min), +|Ocular iontophoresis 20 mA-min (7 mA for 3.84 minutes), positive polarity
9909962|NCT00698438|Active Comparator|a|Implantation of Ex-PRESS mini glaucoma shunt under a scleral flap
9909963|NCT00698438|Active Comparator|b|Trabecolectomy
9909964|NCT00698464|Experimental|Pasireotide|
9909965|NCT00698490|Experimental|Group A|HSV-seronegative subjects
9909966|NCT00698490|Experimental|Group B|HSV-seropositive subjects
9909967|NCT00698490|Experimental|Group C|HSV-seronegative subjects
9909968|NCT00698490|Experimental|Group D|HSV-seronegative subjects
9909969|NCT00698490|Experimental|Group E|HSV-seronegative subjects
9909970|NCT00698503||M2a- 38™ Hip System|
9909971|NCT00698529|No Intervention|No POL Training|Participating NGOs and their staff will receive no specialized training.
9909972|NCT00698529|Experimental|Face-to-Face|Participating NGOs and their staff will receive training through face-to-face seminars held at the NGOs and through post-seminar consultation telephone calls.
9909973|NCT00698529|Experimental|Distance Learning|Participating NGOs and their staff will receive training through Web-based seminars and through post-seminar consultation telephone calls.
9909974|NCT00698542||1|Patients in the NCU at VUH
9909975|NCT00698555|Experimental|Group A|
9909976|NCT00698555|Experimental|Group B|
9909977|NCT00698555|Experimental|Group C|
9909978|NCT00698555|Experimental|Group D|
9909979|NCT00698555|Experimental|Group E|
9909980|NCT00698555|Active Comparator|Group F|
9909981|NCT00698568|Experimental|Group A|
9909982|NCT00698568|Placebo Comparator|Group B|
9909983|NCT00698594|Active Comparator|1|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
9909984|NCT00698594|Active Comparator|2|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
9909985|NCT00698594|Placebo Comparator|3|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
9909986|NCT00698607|Experimental|E6|Everolimus-eluting stent 6-month clopidogrel therapy
9909987|NCT00698607|Active Comparator|S6|Sirolimus-eluting stent 6-month clopidogrel therapy
9909988|NCT00698607|Experimental|E12|Everolimus-eluting stent 12-month clopidogrel therapy
9909989|NCT00698607|Active Comparator|S12|Sirolimus-eluting stent 12-month clopidogrel therapy
9909990|NCT00698633||M2a- Taper™ Hip System|M2a- Taper™ Hip System
9909991|NCT00698659||patients on anti-VEGF therapy|"This study aims to assess the pharmacodynamic effects of anti-VEGF therapy. The following groups of patients will be approached:~Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab, sunitinib, and sorafenib) as part of routine clinical management or on clinical studies~All patients must be aged aged ≥ 21 years All patients must have a signed written informed consent prior to study enrollment. A separate consent will be obtained from patients already involved in a clinical study using anti-VEGF treatment.~Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments."
9909992|NCT00698672|Active Comparator|2|articulation Spectron EF CoCr/ Reflection All-Poly Eto-sterilized
9909993|NCT00698672|Active Comparator|3|articulation Spectron Ef CoCr/ Reflection All-Poly XLPE
9909994|NCT00698672|Active Comparator|4|articulation Spectron EF Oxinium/ Reflection All-Poly Eto-sterilized
9909995|NCT00698672|Active Comparator|5|articulation Spectron EF Oxinium/ Reflection XLPE
9909996|NCT00698672|Active Comparator|1|articulation Charnley/ Ogee
9909997|NCT00698698||Non diabetic|Normal age and sex matched population
9909998|NCT00698698||Grade 1|Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
9909999|NCT00698698||Grade 2|Moderate non proliferative diabetic retinopathy
9910000|NCT00698698||Grade 3|Severe non proliferative diabetic retinopathy
9910001|NCT00698698||Grade 4|Proliferative diabetic retinopathy and advanced diabetic eye disease
9910002|NCT00698711|Experimental|1|"Three groups of 5 patients enrolled sequentially comprised from will receive MUC-2-KLH vaccines at the following g amounts of MUC-2-KLH per vaccination.~10 + 100 μg QS21 30 + 100 μg QS21 3 + 100 μg QS21"
9910003|NCT00698724|Active Comparator|1|Group 1: Xibrom, Optive
9910004|NCT00698724|Active Comparator|2|Group 2: Xibrom, Pred Forte
9910005|NCT00698750||Copeland™ Humeral Resurfacing Head|Copeland™ Humeral Resurfacing Head
9910006|NCT00698763|Experimental|A|Levosimendan
9910007|NCT00698763|Placebo Comparator|B|Placebo
9910008|NCT00698776|Experimental|Active|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
9910009|NCT00698802|Experimental|A|
9910010|NCT00698802|Active Comparator|B|
9910011|NCT00698828|Experimental|Group 1|SUN11031 for injection, low dose, twice daily for 12 weeks
9910012|NCT00698828|Experimental|Group 2|SUN11031 for injection, higher dose, twice daily for 12 weeks
9910013|NCT00698828|Placebo Comparator|Group 3|Placebo injection, twice daily for 12 weeks
9910014|NCT00698854||Vanguard™ Complete Knee System|Vanguard Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
9994363|NCT01480544|No Intervention|Mothers at endline|Data collected on new mothers (up to three weeks after childbirth) in 180 clusters with 100 mothers in each cluster at endline.
9994364|NCT01480544|Experimental|Treatment 1|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for clinical improvements in quality of maternity care in the providers' patient populations and the catchment areas served by the providers.
9994365|NCT01480544|Experimental|Treatment 2|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for improvement in maternal and infant health outcomes in the providers' patient populations and in the catchment areas served by the providers.
9994366|NCT01480544|No Intervention|Control|Data collected on new mothers (up to three weeks after childbirth) and providers with no incentives
9994367|NCT01480557|Active Comparator|Liquefaction group|Subjects that were operated for cataract using liquefaction technology
9994368|NCT01480557|Active Comparator|Torsional ip group|Subjects that were operated for cataract using torsional ip technology
9994369|NCT01480609|Active Comparator|Dose-Dialysis|Subjects will be dosed with study drug followed by a scheduled dialysis session
9994370|NCT01480609|Active Comparator|Dialysis-Dose|Subjects will be dosed following the completion of their scheduled dialysis session
9994371|NCT01480622|Experimental|TDF tablets|Tenofovir disoproxil fumarate tablets
9994372|NCT01480635||Incomplete Colonoscopy|
9994373|NCT01480648|Experimental|BI144807|Subjects receive a single oral dose of BI144807solution
9994374|NCT01480648|Placebo Comparator|Placebo|Subjects receive a single oral dose of placebo solution
9994375|NCT01480661|Active Comparator|Roflumilast|
9994376|NCT01480661|Placebo Comparator|Placebo|
9994377|NCT01480687|Experimental|Omega-3 fatty acid|
9994378|NCT01480687|Active Comparator|Ciprofibrate|
9994379|NCT01480700|Experimental|rich-eggs|subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
9994380|NCT01480700|Active Comparator|standard eggs|subjects consume 2 standard eggs per day
9994381|NCT01480713|Experimental|Monotherapy with IPs+ Raltegravir 400 mg|Lopinavir/r 400/100 mg every 12 hours + Raltegravir 400 mg every 12 hours or Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
9994382|NCT01480726||Open vein harvest|Conventional open vein harvest from the lower leg
9994383|NCT01480726||Endoscopic vein harvest|Endoscopic vein harvest from the calf
9994384|NCT01480739|Experimental|1|AZD5069 100 mg capsules (50 mg BD) for 7 days
9994385|NCT01480739|Experimental|2|Placebo twice daily for 7 days
9994386|NCT01480752|Active Comparator|Lornoxicam|
9994387|NCT01480752|Placebo Comparator|normal saline|
9994388|NCT01480752|Placebo Comparator|no injection|
9994389|NCT01480765|Placebo Comparator|Control: Placebo + Placebo|Placebo capsules and Placebo infusion
9994390|NCT01480765|Active Comparator|Pregabalin and Placebo infusion|Pregabalin capsules and Placebo infusion
9994391|NCT01480765|Active Comparator|Pregabalin + Ketamine infusion|Pregabalin capsules + Ketamine infusion
9994392|NCT01480778|Experimental|LNG+EE2|pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
9994393|NCT01480778|Active Comparator|Nordette|pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
9994394|NCT01480791|Active Comparator|Hydrochlorothiazide|Treatment of patients with hydrochlorothiazide and effect on small arteries
9994395|NCT01480791|Experimental|Aliskiren|Treatment of patients with aliskiren and effect on small arteries
9994396|NCT01480791|No Intervention|Normotensive non diabetic subjects|A comparator non intervention normotensive non diabetic group of healthy subjects will be used for baseline comparison of primary and secondary endpoints
9994397|NCT01480804|Experimental|Geriatric diabetes team intervention group|The subjects in this group underwent evaluation for barriers to self care by a diabetes educators well versed with age specific barriers. After consideration of patients clinical, functional, and psychosocial background a geriatric diabetes team devised strategy to help patients cope respective barriers. A care manager then implemented the coping strategies by educating patients and caregivers. She also made home visits to assess any safety issues not know to clinic based geriatric team. She helped the patients and caregivers with all aspects of care coordination. Patients in this group received phone contact from care managers as many times as needed over the six month intervention period.
9994398|NCT01480804|No Intervention|Attention Control Group|The subjects in the group received similar, in person, contact as the intervention group. An educator, separate from the one involved in the intervention team, called patents in this group for a total of eleven time within the first six months. The phone calls were forces toward general discussion without any diabetes related advice.
9994399|NCT01480817|Active Comparator|Sorafenib|Sorafenib 400mg po bid
9997934|NCT01513174|Active Comparator|Gefitinib|Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.
9997935|NCT01513174|Experimental|Gefitinib in combination with olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.
9910015|NCT00698854||Vanguard™ Patient-Specific Femur|Vanguard Total Knee System used in combination with Signature technique to provide a patient-specific femur
9910016|NCT00698880|Active Comparator|HVE|Hepatic vein embolization after portal vein embolization
9910017|NCT00698880|No Intervention|PVE|Only portal vein embolization, historical control group
9910018|NCT00698893|Experimental|Group A|
9910019|NCT00698893|Experimental|Group B|
9910020|NCT00698906|Experimental|Group A|
9910021|NCT00698906|Experimental|Group B|
9910022|NCT00698906|Experimental|Group C|
9910023|NCT00698906|Experimental|Group D|
9910024|NCT00698906|Experimental|Group E|
9910025|NCT00698906|Active Comparator|Group F|
9910026|NCT00698919||Development cohort|A first group of one hundred patients with SIRS will be included to evaluate the accuracy of this new test.
9910027|NCT00698919||Validation Cohort|Depending on the result of the previous (development) cohort we will more accurately evaluate the need of number of patients with SIRS to include in the second cohort of patients.
9910028|NCT00698945|Active Comparator|2|Alphagan
9910029|NCT00698945|Active Comparator|1|Istalol and Optive
9910030|NCT00698958|Active Comparator|1|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
9910031|NCT00698958|Experimental|2|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
9910032|NCT00698984|Active Comparator|1|30 mg BONISTEIN(R) 150 ug Vitamin K1 800 IU Vitamin D3 1000 mg PUFA 500 mg Calcium
9910033|NCT00698984|Placebo Comparator|2|500 mg Calcium
9910034|NCT00699023|Experimental|1|ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
9910035|NCT00699023|Placebo Comparator|2|placebo + simvastatin tablets 20 mg/die six weeks
9910036|NCT00699036|Experimental|1|avandia
9910037|NCT00699036|Experimental|2|avandia plus metformin
9910038|NCT00699036|Experimental|3|avandia plus losartan
9910039|NCT00699049|Placebo Comparator|Alpha blocker and placebo|
9910040|NCT00699049|Experimental|Alpha blocker and solifenacin|
9910041|NCT00699062|Placebo Comparator|Placebo pill|The patients allocated into this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator plus placebo for 6 months.
9910042|NCT00699062|Experimental|Singular pill|The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months
9910043|NCT00699088||Balance® Microplasty™ Hip System|
9910044|NCT00699101|Experimental|A|Conture Multi-Lumen Balloon
9910045|NCT00699114|Placebo Comparator|Placebo|Single dose placebo capsule
9910046|NCT00699114|Active Comparator|Ibuprofen 400 mg|Single dose ibuprofen 400 mg capsule
9910047|NCT00699114|Active Comparator|Ibuprofen 600 mg|Single dose ibuprofen 600 mg capsule
9910048|NCT00699114|Active Comparator|Ibuprofen 800 mg|Single dose ibuprofen 800 mg capsule
9910049|NCT00699114|Active Comparator|Paracetamol 500 mg|Paracetamol 500 mg (acetaminophen) capsule
9910050|NCT00699114|Active Comparator|Paracetamol 1000 mg|Single dose paracetamol 1000 mg (acetaminophen) capsule
9910051|NCT00699114|Active Comparator|Paracetamol 1000 mg + codeine 60 mg|Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule
9910052|NCT00699127|Experimental|1|The group that will have lecture of information regarding infants in NICU.
9910053|NCT00699127|No Intervention|2|The group that will not have lecture of information regarding NICU hospitalization
9910054|NCT00699166|Experimental|1|
9910055|NCT00699166|Experimental|2|
9910056|NCT00699166|Placebo Comparator|3|
9910057|NCT00699179||A|
9910058|NCT00699231|Active Comparator|Group A1|Non-responders to vaccination after at least 7 previous injections
9910059|NCT00699231|Experimental|Group A2|Non-responders to vaccination after at least 7 previous injections
9910060|NCT00699231|Active Comparator|Group B1|Vaccine-responders requiring a booster dose
9910061|NCT00699231|Experimental|Group B2|Vaccine-responders requiring a booster dose
9910062|NCT00699231|Active Comparator|Group C1|Volunteers participating in the hospital's vaccination program
9910063|NCT00699231|Experimental|Group C2|Volunteers participating in the hospital's vaccination program
9910064|NCT00699231|Active Comparator|Group D1|Unvaccinated haemodialysis patients
9910065|NCT00699231|Experimental|Group D2|Unvaccinated haemodialysis patients
9910066|NCT00699244|Experimental|Peripheral placement of local anesthesia|to receive ultrasound guided peripheral placement of local anesthetic
9910067|NCT00699244|Active Comparator|Central placement of local anesthesia|to receive central placement of local anesthetic
9910068|NCT00699257||Oxford® Partial Knee System|
9910069|NCT00699270||Biomet Humeral Stems|Biomet Humeral Stems: Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems
9910070|NCT00699296|Experimental|1|
9910071|NCT00699309||Taperloc® Microplasty™ Hip System|
9910072|NCT00699322|Experimental|1|Sitagliptin
9910073|NCT00699322|Active Comparator|2|Glimepiride
9910074|NCT00699361|Experimental|1|Measurement before Pantoprazole application
9910075|NCT00699361|Experimental|2|Measurements after Pantoprazole application
9933954|NCT05108870|Experimental|Phase 1: Dose-Finding Group 2 - Drug Combination 2|"All participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel.~Participants will be given 3 doses of HB-201 & HB-202 alternating two vector therapy. Patients will receive 2 doses of HB-202 and 1 dose of HB-201. HB-202 will be administered on cycle 1 day 15 and cycle 3 day 15, and HB-201 will be administered on cycle 2 day 15 with three 21-day cycles of chemotherapy with carboplatin on day 1 and paclitaxel 100mg/m2 on days 1, 8, and 15."
9933955|NCT05108870|Experimental|Phase 2: Efficacy Arm 1 - HB-201 + Chemotherapy|"Participants in this group will receive HB-201 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
9933956|NCT05108870|Experimental|Phase 2: Efficacy Arm 2 - HB-201 and HB-202 + Chemotherapy|"Participants in this group will receive alternating doses of HB-201 and HB-202 combined with chemotherapy using carboplatin and paclitaxel at the dose established in the first phase of the study.~After completing treatment at the established phase 2 dose, subjects will receive surgery, radiotherapy alone, or chemotherapy with radiotherapy together based on how their tumor responds to the medications."
9933957|NCT05108623|Experimental|Part 1: Monotherapy with agenT-797|3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.
9933958|NCT05108623|Experimental|Part 2: agenT-797 in Combination with approved ICIs|Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care
9933959|NCT05106153|Experimental|Qualification Phase: Treatment Sequence YXZ|Participants will receive a single oral dose of suvorexant (Treatment Y) in qualification period 1, followed by single oral dose of placebo (Treatment X) in qualification period 2 and then single oral dose of zolpidem (Treatment Z) in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
9933960|NCT05106153|Experimental|Qualification Phase: Treatment Sequence ZYX|Participants will receive Treatment Z in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
9933961|NCT05106153|Experimental|Qualification Phase: Treatment Sequence XZY|Participants will receive Treatment X in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
9933962|NCT05106153|Experimental|Qualification Phase: Treatment Sequence YZX|Participants will receive Treatment Y in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
9933963|NCT05106153|Experimental|Qualification Phase: Treatment Sequence ZXY|Participants will receive Treatment Z in qualification period 1, followed by Treatment X in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during qualification phase. Each treatment will be separated by washout of at least 3 days.
9910076|NCT00699387|Experimental|Benznidazole|Treatment of pediatric Chagas disease with benznidazole
9910077|NCT00699426|Active Comparator|Nexium + Yoghurt|
9910078|NCT00699426|Placebo Comparator|Nexium + Placebo|
9910079|NCT00699426|Placebo Comparator|Placebo+ Yoghurt|
9910080|NCT00699426|Placebo Comparator|placebo+placebo|
9910081|NCT00699439|Active Comparator|A|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the paper-based flow-chart will be printed out to place on the chart.
9910082|NCT00699439|No Intervention|B|If a patient is identified as having an asthma exacerbation by the Bayesian Network, and assigned to the control group, no flow-chart will be printed out.
9910083|NCT00699452|Active Comparator|1|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
9910084|NCT00699452|Placebo Comparator|2|Placebo
9910085|NCT00699465|Active Comparator|1|Early enoxaparin
9910086|NCT00699465|Placebo Comparator|2|Late enoxaparin
9910087|NCT00699478|Experimental|1|post total gastrectomized patients due to gastric cancer who has vitamin B12 deficiency - given oral vitamin B 12 supplementation
9910088|NCT00699504|Experimental|Lead in Phase|Supratherapeutic dose of cangrelor
9910089|NCT00699504|Experimental|A|therapeutic dose cangrelor treatment
9910090|NCT00699504|Experimental|B|supratherapeutic dose cangrelor treatment
9910091|NCT00699504|Active Comparator|C|active comparator treatment
9910092|NCT00699504|Placebo Comparator|D|placebo treatment
9910093|NCT00699530||Hyperprolactinemia|Patients recently diagnosed with hyperprolactinemia
9910094|NCT00699543|Experimental|C|Coroflex Please stent implantation
9910095|NCT00699543|Active Comparator|T|Taxus stent implantation
9910096|NCT00699569|Experimental|1|Patients receiving active investigational product
9910097|NCT00699569|Placebo Comparator|2|Patients receiving Placebo
9910098|NCT00699595||Term pregnant women|Healthy women scheduled for elective Cesarean section.
9910099|NCT00699621|Active Comparator|1|Platelet transfusion
9910100|NCT00699621|No Intervention|2|No platelet transfusion
9910101|NCT00699686|Active Comparator|Glargine|During this arm/phase patients take subcutaneous glargine daily for 3 months.
9910102|NCT00699686|Experimental|Detemir|During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.
9910103|NCT00699712|Experimental|A|Open-label regimen of doses 1 and 2 of CDNP
9910104|NCT00699712|Experimental|B|Open-label regimen of doses 2 and 3 of CDNP
9910105|NCT00699712|Experimental|C|Open-label regimen of doses 3 and 4 of CDNP
9910106|NCT00699725||1|NSAID patients with risk factors treated with gastroprotective drugs
9910107|NCT00699738|Experimental|1|Healthy women during pregnancy and in the postpartum period, breastfeeding
9910108|NCT00699738|Active Comparator|2|Healthy women during pregnancy and in the postpartum period,bottlefeeding
9910109|NCT00699738|No Intervention|3|Healthy non-pregnant women
9910110|NCT00699764|Experimental|Group A|
9910111|NCT00699764|Placebo Comparator|Group B|
9910112|NCT00699777|Experimental|1|One risedronate 150 mg tablet administered orally after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
9910113|NCT00699777|Active Comparator|2|Two risedronate 75 mg tablets administered as a single oral dose after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
9910114|NCT00699829||1|Mohs' micrographic surgery (MMS)
9910115|NCT00699829||2|Conventional surgery
9910116|NCT00699868|Experimental|1|Infection to CMV
9910117|NCT00699868|Other|2|"Group control CMV"
9910118|NCT00699881|Experimental|A|administer cetuximab in combination with modified FOLFIRI
9910119|NCT00699894|Experimental|1|aprepitant 40 mg + normal saline IV
9910120|NCT00699894|Active Comparator|2|placebo PO + ondansetron 4 mg IV
9910121|NCT00699920|Experimental|1|Coarsucam double-layer artesunate/amiodaquine tablets
9910122|NCT00699920|Active Comparator|2|Coartem (artemether/lumefantrine) fixed-dose combination tablets
9910123|NCT00699933||1|Evaluation of one study cohort
9910124|NCT00699946|Active Comparator|1|
9910125|NCT00699946|Placebo Comparator|2|
9910126|NCT00699959||1|patients with heart failure
9910127|NCT00699959||2|patients without heart failure
9910128|NCT00699985||1|Behcet's Disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD).
9910129|NCT00699985||2|Non-Behcet's Disease patients were patients mimicking BD.
9910130|NCT00700024|Active Comparator|1|testim
9910131|NCT00700024|Experimental|2|placebo
9910132|NCT00700024|Experimental|3|training
9910133|NCT00700037|Experimental|1|Atorvastatin 20mg
9910134|NCT00700037|Active Comparator|2|atorvastatin 5mg
9910135|NCT00700050||CF Females|CF females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
9910136|NCT00700050||Non-CF Females|Non-CF control females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
9910137|NCT00700050||CF Males|CF males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
9910138|NCT00700050||Non-CF males|Non-CF control males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
9994400|NCT01480817|Experimental|TACE for HCC with portal vein invasion|Antineoplastic agents are directly injected into the hepatic artery, allowing high intratumoral concentrations of drugs and thereby reducing systemic side effects. The mixture of chemotherapeutic agents and iodized oil is almost completely retained in neoplastic nodules and can remain in HCC tissue for a long time. Subsequent mechanical embolization of the artery feeding the neoplasm causes ischemic damage to the tumor and prolongs the duration of the effects of chemotherapeutic agents.
9994401|NCT01480830|No Intervention|Standard colonoscopy|
9994402|NCT01480830|Experimental|Magnetic endoscopic imaging colonoscopy|
9994403|NCT01480856|Active Comparator|Cobedding|Newborn twins are settled in a single bed : this is cobedding
9994404|NCT01480856|Placebo Comparator|Single -bedding|Newborn twins are settled in two beds : this is single-bedding
9994405|NCT01480869|Active Comparator|Conventional vitamin D and calcium supplementation|Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
9994406|NCT01480869|Experimental|vitamin D supplementation tailored to vitamin D deficiency|"Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level < 30 ng/mL"
9994407|NCT01480882|Active Comparator|Conventional Chest PhysioTherapy|Conventional Chest Physiotherapy (CCPT) is delivered by professional physiotherapist for 15 minutes.
9994408|NCT01480882|Experimental|Mechanical percussion|"Mechanical percussion will be delivered by a device called LEGA for 15 minutes"
9994409|NCT01480895|No Intervention|Post GDM follow-up group.|
9994410|NCT01480895|Experimental|lifestyle intervention group.|The women in this group had participated in lifestyle intervention by diet instructions and physical exercise program.
9994411|NCT01480908|Experimental|VSD, +Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and have a postoperative right bundle branch block, about 20 patients
9994412|NCT01480908|Experimental|VSD, -Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and does not have a postoperative right bundle branch block, about 20 patients
9994413|NCT01480908|Experimental|Control|Healthy control subjects, about 20 patients
9994414|NCT01480921|Experimental|home based exercise training|
9994415|NCT01480921|Active Comparator|supervised exercise training|
9994416|NCT01480934||Group:A-cases-Patients with a history of Diabetes Mellitus|(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
9994417|NCT01480934||Group - B:controls|Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).
9994418|NCT01480947|Experimental|Bio-Three|add-on treatment of the probiotics (Bio-three)
9994419|NCT01480947|No Intervention|control treatment|control treatment (intravenous fluid, oral rice and half strength milk formula)
9994420|NCT01480960|Active Comparator|Whole body vibration training|Whole body vibration training in addition to pulmonary rehabilitation
9994421|NCT01480960|No Intervention|No whole body vibration training|Pulmonary rehabilitation without whole body vibration training
9994422|NCT01480973|Experimental|MRI post lung SBRT|Feasibility of MRI to differentiate between benign and malignant changes seen after lung SBRT.
9994423|NCT01480986|Experimental|Treatment arm|This is a single arm trial. The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
9994424|NCT01480999||Laparotomy (open surgery)|
9910139|NCT00700089|Experimental|A|The concept is to support and guide the person shortly after the in-hospital treatment for self-injury through a recommended follow-up or after treatment based on assertive principles. The intervention is an indicated prevention strategy targeting people with suicide attempts and deliberate self-harm as a high-risk group. They will be offered 8-20 assertive outreach contacts. The outreach contacts will be home visits focusing on providing support and motivating patients to comply with follow-up treatment.
9910140|NCT00700089|Placebo Comparator|B|Standard treatment consists of referral to a range of different treatment modalities depending on the diagnosis and clinical and social condition of the patient. In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
9910141|NCT00700128|Experimental|Group 2|Frovatriptan or placebo given in a certain sequence depending on what group that the woman are randomized to.
9910142|NCT00700128|Experimental|Group1|Group I will receive in a different sequence either frovatriptan 2.5 mg or placebo bid starting the last day of taking OC and continuing during the hormone free interval (HFI) of 4 days.
9910143|NCT00700154|Experimental|Insulin infusion (aspart)|
9910144|NCT00700154|No Intervention|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
9910145|NCT00700167|Experimental|1|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.~The vaccines will be given during an outpatient visit. If for some reason, you happen to be in the hospital, you can still receive the vaccines. These visits should take no longer than 15-30 minutes."
9910146|NCT00700193|Other|Group A|Equal to or greater 6 months to less than 3 years old
9910147|NCT00700193|Other|Group B|Equal to or greater 3 years to less than 9 years old
9910148|NCT00700206|Experimental|1|Dose Schedule 1: Two weeks treatment with Telintra 3000 mg per day in two divided doses followed by one week with no treatment per three week cycle.
9910149|NCT00700206|Experimental|2|Dose Schedule 2: Three weeks treatment with Telintra 2000 mg per day in two divided doses followed by one week with no treatment per four week cycle.
9910150|NCT00700219||1|Women presenting in preterm labor with intact amniotic membranes
9910151|NCT00700232||1|Normal multiparous pregnant women without intrahepatic cholestasis of pregnancy (control group)
9910152|NCT00700245|Active Comparator|EXO|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction),
9910153|NCT00700245|Active Comparator|DIO|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet)
9910154|NCT00700245|Active Comparator|DEX|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).
9910155|NCT00700284|Placebo Comparator|A|
9910156|NCT00700284|Experimental|B|
9910157|NCT00700297|Active Comparator|Colchicine|Patients who received Colchicine and went on placebo after 4 months
9910158|NCT00700297|Placebo Comparator|Placebo|Patients who received placebo and went on Colchicine after 4 months
9910159|NCT00700323|Active Comparator|1|Patients receiving active product
9910160|NCT00700323|Placebo Comparator|2|Patients receiving placebo
9910161|NCT00700349|No Intervention|1|Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to continue receiving no loan.
9910162|NCT00700349|Experimental|2|"Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to receive a second look, to be reconsidered for a loan by loan officers."
9910163|NCT00700388|Experimental|1|TPEP added to conventional manually assisted breathing techniques (MABT)
9910164|NCT00700388|Active Comparator|2|Manually assisted breathing techniques (MABT) alone
9910165|NCT00700414||Participants|Any participant who meets eligibility criteria and consents to participate in the trial.
9910166|NCT00700453|Active Comparator|Control 1 Group|Subjects randomized to the Control 1 group will abstain from playing any video games for the entire study participation.
9910167|NCT00700453|Active Comparator|VG1- Control 2 Group|Subjects randomized to the Control 2 group will play a selected violent video game for 60-120 minutes/day during week 2 of the study and will abstain from any video game play during week 3 of the study.
9910168|NCT00700453|Active Comparator|VG1- VG2 group|Subjects randomized for VG1-VG2 group will play 60-120 minutes/day of a violent video game during weeks 2 & 3 of study participation.
9910169|NCT00700453|Active Comparator|VG1-CT group|Subjects randomized to the VG1-CT group will play 60-120 minutes of a selected violent video game during week 2 of the study and play a selected computerized cognitive training program for 60-120 minutes/day during week 3 of the study.
9910170|NCT00700466||1|Patients with hypertension and/or tachycardia prior to induction of anesthesia requiring i.v. beta-blockade for treatment of raised hemodynamic
9994425|NCT01480999||Laparoscopic surgery|
9910171|NCT00700466||2|Patients with normal hemodynamic values prior to induction of anesthesia not requiring treatment
9910172|NCT00700479|Experimental|A|Aldosterone plus low salt diet
9910173|NCT00700479|Experimental|B|Aldosterone plus high sodium diet
9910174|NCT00700479|Placebo Comparator|C|Placebo plus low sodium diet
9910175|NCT00700479|Placebo Comparator|D|placebo plus high sodium diet
9910176|NCT00700492|No Intervention|control|
9910177|NCT00700492|Experimental|utrogestan|daily use of vaginal progesterone capsules
9910178|NCT00700505|Experimental|Heating Garment|FlowPants(R) Garment with Heating
9910179|NCT00700518|Placebo Comparator|1.|placebo cream applied to 2 adjacent fingers on non-dominant hand one time
9910180|NCT00700518|Active Comparator|2|0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand
9910181|NCT00700518|Active Comparator|3|1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
9910182|NCT00700518|Active Comparator|4|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time
9910183|NCT00700518|Active Comparator|5|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
9910184|NCT00700531|Experimental|1|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on the Gambro HCO 1100 dialysers
9910185|NCT00700531|Active Comparator|2|Patients receive standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
9910186|NCT00700544|Active Comparator|B|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~-idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
9910187|NCT00700544|Experimental|A|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)~10 to 20 mg (according to body weigh) of norethandrolone daily~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
9910188|NCT00700557|Active Comparator|Probiotics - Lactobacillus casei and Bifidobacterium breve|"Yakult LB®~1 sachet (1g) of Lactobacillus casei and Bifidobacterium breve - 6 x 108 UFC/g on a juice three times a day"
9910189|NCT00700557|Placebo Comparator|maize starch|725mg on juice three times a day
9910190|NCT00700583|Experimental|1|
9910191|NCT00700609|Experimental|1|"Attachment Based Family Therapy (ABFT)~ABFT developed by Dr. Guy Diamond and colleagues is a brief, 12 week, manualized family-based intervention."
9910192|NCT00700609|Active Comparator|2|"Treatment as usual (TAU)~No attempt is made to standardize TAU. Regular clinical staff will provide mental health services."
9910193|NCT00700648||A|
9910194|NCT00700674||1|Entropy group
9910195|NCT00700674||2|Control
9910196|NCT00700687|Experimental|1|PA32540
9910197|NCT00700687|Experimental|2|PA32540 and celecoxib
9910198|NCT00700687|Active Comparator|3|aspirin and celecoxib
9910199|NCT00700700|Active Comparator|CRT-ON/CRT-OFF|Group initially randomized to CRT-ON, then cross-over to CRT-OFF
9910200|NCT00700700|Active Comparator|CRT-OFF/CRT-ON|Group initially randomized to CRT-OFF, then cross-over to CRT-ON
9910201|NCT00700726||A.|participants with atopic and non-atopic asthma
9910202|NCT00700765||A|
9910203|NCT00700830||A|
9910204|NCT00700856|Experimental|1|metformin 2000 mg + pioglitazone 15-45 mg
9910205|NCT00700856|Active Comparator|2|metformin 2000 mg + glibenclamide 5-15 mg or metformin 2000 mg + gliclazide 30-120 mg or metformin 2000 mg + glimepiride 2-6 mg
9910206|NCT00700869|Experimental|1|Tracheal tube withdrawal governs by respiratory behaviour status
9910207|NCT00700895|Experimental|Pharmacogenetics-guided dosing group|For patients randomized to the pharmacogenetics-guided dosing group, this 10mls of blood will be immediately sent for genotyping studies. Genotyping results will be available for pharmacogenetics-guided dosing within 3 working days, (ranging 3 to 5 days). During this period, if patients need to be initiated on anticoagulation, a low molecular weight heparin, Fraxiparine, will be given. Fraxiparine will be overlapped with warfarin for 2 to 3 days until target INR is achieved. Elective cases should have the pharmacogenetics-based warfarin dose available at the time of warfarin therapy.
9910208|NCT00700895|Experimental|Traditional dosing group|For patients randomized to the traditional dosing regime, the blood will be stored and genotyped retrospectively at the end of the study. Overlapping of warfarin with Fraxiparine or heparin till target INR is achieved is allowed for this group as per normal clinical practice. All warfarin dosage adjustments based on INR results will be according to the current protocol used by the NUH Anticoagulant Clinic.
9910209|NCT00700908|Experimental|1|Automated telephone intervention
9910210|NCT00700908|Active Comparator|2|Usual care
9910211|NCT00700921|Experimental|Active Drug (Lovastatin)|
9910212|NCT00700921|Placebo Comparator|Placebo (inactive comparator)|
9910213|NCT00700947|Experimental|1|Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.
9910214|NCT00700947|No Intervention|2|Patients will be surgically treated for severe primary mitral regurgitation as a routine clinical care if they want to be treated surgically or develop symptoms or significant adverse left ventricular remodeling or left ventricular dysfunction.
9910215|NCT00700947|No Intervention|3|Health Control includes the subjects with no remarkable past medical history and not currently taking any medications. Normal subjects will be used for comparison with patients with severe primary mitral regurgitation in term of clinical, echocardiographic and neuro-hormonal findings.
9910216|NCT00700960||A|
9910217|NCT00700986|Experimental|1|
9910218|NCT00700986|Placebo Comparator|2|
9910219|NCT00701012|Experimental|1|low ligation, which the IMA is ligated below the origin of the left colic artery
9910220|NCT00701012|Active Comparator|2|high ligation, which the IMA is ligated at its origin from the aorta
9910221|NCT00701025||1|35 asthmatic participants with EIB
9910222|NCT00701025||2|35 without EIB
9910223|NCT00701077|Experimental|1|3,4-Di-amino-Pyridine : a single 20 mg dosing
9910224|NCT00701077|Placebo Comparator|2|
9910225|NCT00701142|Active Comparator|Haemocomplettan® P|Intravenous infusion during aortic surgery
9910226|NCT00701142|Placebo Comparator|Saline solution|
9910227|NCT00701155||A|
9910228|NCT00701194|Experimental|1|EIFC/MTFC-P
9910229|NCT00701194|No Intervention|2|Services as usual
9910230|NCT00701194|No Intervention|Community Comparison|Non-maltreated community pre-schoolers from low-income biological families.
9910231|NCT00701220|Active Comparator|1|Patients with Ischemic Cardiomyopathy receiving Lipitor.
9910232|NCT00701220|Active Comparator|2|NonIschemic Cardiomyopathy receiving Lipitor treatment
9910233|NCT00701220|No Intervention|3|Healthy subjects with no history of high cholesterol, heart disease, or heart attacks
9910234|NCT00701233|Active Comparator|2|Corticosteroid injection into Carpal Tunnel
9910235|NCT00701233|Active Comparator|1|Botulinum toxin injection into Carpal Tunnel
9910236|NCT00701246|Experimental|I|I Treatment: a daily dose (5 times a week) of either 4,2 mg/kg/day of ferrous sulfate + folic acid (50 mcg)
9910237|NCT00701246|Placebo Comparator|II|II Treatment of anemic children with 4,2 mg/kg/day of ferrous sulfate and folic acid placebo.
9910238|NCT00701246|Experimental|III|Prevention of anemia in non-anemic children ( 5 times a week)- 1,4 mg/kg/day of ferrous sulfate and folic acid
9910239|NCT00701246|Placebo Comparator|IV|1,4 mg/kg/day of ferrous sulfate plus folic acid placebo, five days a week.
9910240|NCT00701259|Experimental|1|15 mg lansoprazole
9910241|NCT00701259|Experimental|2|30 mg lansoprazole
9910242|NCT00701259|Placebo Comparator|3|placebo
9910243|NCT00701272||1|Patients undergoing liver transplant for end-stage liver disease due to Hepatitis C
9910244|NCT00701272||2|"Control population:~Patients undergoing liver transplantation for end-stage liver disease due to alcoholic cirrhosis"
9910245|NCT00701285|Active Comparator|1|strong statin
9910246|NCT00701285|Active Comparator|2|mild statin
9910247|NCT00701298|Active Comparator|Group 1 (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose disease is not responding after the first course may crossover to group 2.
9910248|NCT00701298|Experimental|Group 2 (chemotherapy and antineoplastic agent)|Patients receive decitabine as in group 1 and pegylated interferon alfa-2b subcutaneously on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9910249|NCT00701324|Experimental|Arm A|BI 811283, 24h infusion d1 and d15 every 4 weeks
9910250|NCT00701324|Experimental|Arm B|BI 811283, 24h infusion d1 every 3 weeks
9910251|NCT00701337|Experimental|1 Oral|oestradiol by oral administration - Estrofem 2 mg
9910252|NCT00701337|Experimental|2 patch|oestradiol par patch - Estrapatch 60microg/24h
9910253|NCT00701350||1|Women presenting with preterm gestation and ruptured membranes
9910254|NCT00701428|Active Comparator|1|Hypertensive Men and Women Without OSA on Losartan (n=30)
9910255|NCT00701428|Active Comparator|2|Hypertensive Men and Women With OSA on Losartan (n=30)
9910256|NCT00701428|Experimental|3|Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)
9910257|NCT00701454||1|Healthy participants (physically and mentally).
9910258|NCT00701467||Observation|
9910259|NCT00701480|Experimental|1|skin cleanser contained Hibiscus sabdariffa
9910260|NCT00701480|Active Comparator|2|marketed skin cleanser
9933964|NCT05106153|Experimental|Qualification Phase: Treatment Sequence XYZ|Participants will receive Treatment X in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment Z in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
9933965|NCT05106153|Experimental|Treatment Phase: Treatment Sequence ABFCED|Participants will receive a single oral dose of placebo (Treatment A) in treatment period 1, followed by single oral dose of suvorexant (Treatment B) in treatment period 2, single oral Dose 3 of seltorexant (Treatment F) in treatment period 3, single oral dose of zolpidem (Treatment C) in treatment period 4, single oral Dose 2 of seltorexant (Treatment E) in treatment period 5 and then a single oral Dose 1 of seltorexant (Treatment D) in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
9933966|NCT05106153|Experimental|Treatment Phase: Treatment Sequence BCADFE|Participants will receive Treatment B in treatment period 1, followed by Treatment C in treatment period 2, Treatment A in treatment period 3, Treatment D in treatment period 4, Treatment F in treatment period 5 and then Treatment E in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
9994426|NCT01480999||Robotic assisted surgery|
9994427|NCT01481012||Group I: Cardiopulmonary Bypass + Heart Transplantation|CPB for orthotopic heart transplantation (excluding any patients with VADs)
9910261|NCT00701506|Experimental|1|"15 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~PENS for 20 minutes:~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~Minimal twitch for 5 minutes.~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~Electrodes placed on quadriceps and hamstrings."
9910262|NCT00701506|Placebo Comparator|2|"5 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~Placebo PENS for 20 minutes:~Electrodes placed on quadriceps and hamstrings."
9910263|NCT00701532|Experimental|1|active
9910264|NCT00701532|Placebo Comparator|2|Placebo
9910265|NCT00701545||1|Patients with von Willebrand disease treated with Humate P® ivr in Canada
9910266|NCT00701571|Experimental|1|3 cohorts: 18-21 years, 40-60 years, and older than 60 years
9910267|NCT00701610||1|All infants born in our hospital between August 2007 and August 2009 will participate.
9910268|NCT00701623|Experimental|1|patients treated with heparin
9910269|NCT00701623|Experimental|2|Patients treated with heparin
9910270|NCT00701623|Active Comparator|3|patients treated with folder water directly on the injured area
9910271|NCT00701649|Experimental|1|
9910272|NCT00701649|Placebo Comparator|2|
9910273|NCT00701688|Experimental|Dose Level 1|Palifermin 40 mcg/kg/day intravenous
9910274|NCT00701688|Experimental|Dose Level 2|Palifermin 60 mcg/kg/day intravenous
9910275|NCT00701688|Experimental|Dose Level 3|Palifermin 90 mcg/kg/day intravenous
9910276|NCT00701740|Active Comparator|A|A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
9910277|NCT00701740|Active Comparator|B|11 subjects received only the same moisturizer/sunscreen
9910278|NCT00701753||Olanzapine|Subjects treated with olanzapine as part of their routine clinical care
9910279|NCT00701753||Risperidone|Subjects treated with risperidone as part of their routine clinical care
9910280|NCT00701753||Quetiapine|Subjects treated with quetiapine as part of their routine clinical care
9910281|NCT00701792|Active Comparator|1|surgery : liver transplantation
9910282|NCT00701792|Active Comparator|2|standard care for liver disease
9910283|NCT00701831|Experimental|1|Insulin glargine
9910284|NCT00701844|Experimental|Experimental Writing Type 1|
9910285|NCT00701844|Experimental|Experimental Writing type 2|
9910286|NCT00701844|Active Comparator|Control writing type 1|
9910287|NCT00701844|Placebo Comparator|Control writing type 2|
9910288|NCT00701857|Experimental|Pemetrexed, Cisplatin, Radiation Therapy|Concomitant Pemetrexed and CDDP Plus Radiation Therapy
9910289|NCT00701870|Experimental|ezatiostat hydrochloride (Telintra®)|Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
9910290|NCT00701870|No Intervention|No Intervention|Chemotherapy with docetaxel and carboplatin alone
9910291|NCT00701909|Experimental|1|During the first wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK) before the WCP according to randomization. During the second wound care procedure, they will receive the drugs and doses that they had not received the first time.
9910292|NCT00701909|Active Comparator|2|During the second wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK), whichever drugs and doses that they had not received the first time.
9910293|NCT00701948||A-1|Proven nosocomial bacterial infection (NBI)
9910294|NCT00701948||A-2|Possible NBI
9910295|NCT00701948||B-1|Absence of NBI
9910296|NCT00701948||B-2|Probable absence of NBI
9910297|NCT00701961|Experimental|1|Pregnat women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
9910298|NCT00701961|Active Comparator|2|Non-pregnant women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
9910299|NCT00701974|Experimental|1|patients treated with collagenase (IRUXOL)
9910300|NCT00701974|Experimental|2|patients treated with collagenase (Kollagenase)
9910301|NCT00701987|Experimental|1|ALS-357 applied topically twice weekly for four weeks.
9910302|NCT00701987|Experimental|2|ALS-357 applied topically every other day for four weeks.
9910303|NCT00701987|Experimental|3|ALS-357 applied topically once daily for four weeks.
9910304|NCT00701987|Experimental|4|ALS-357 applied topically twice daily for four weeks.
9910305|NCT00702000||1.|Those with ICU-acquired weakness
9910306|NCT00702013||1|
9910307|NCT00702013||2|
9910308|NCT00702013||3|
9910309|NCT00702013||4|
9910310|NCT00702013||5|
9910311|NCT00702013||6|
9910312|NCT00702013||7|
9910313|NCT00702013||8|
9910314|NCT00702026|Experimental|1|
9910315|NCT00702026|Placebo Comparator|2|
9910316|NCT00702039||1|Those patients receiving intravitreal injections who will be listening to classical music during injection.
9910317|NCT00702039||2|Those patients receiving intravitreal injections who will not be listening to any music during injection.
9910318|NCT00702065||1|
9910319|NCT00702065||2|
9910320|NCT00702078|Other|usual care|follow-up according to todays best practice.
9910321|NCT00702078|Experimental|cooperation|Follow-up from the hospital and the primary healthcare in cooperation
9910322|NCT00702117|Active Comparator|A|IV flecainide in atrial fibrillation
9910323|NCT00702117|Experimental|B|IV ajmaline in atrial fibrillation
9910324|NCT00702117|Active Comparator|c|iv procainamide in ventricular tachycardia
9910325|NCT00702117|Experimental|d|iv ajmaline in ventricular tachycardia
9910326|NCT00702117|Active Comparator|e|iv flecainide in diagnosis of Brugada Sd
9910327|NCT00702117|Experimental|f|iv ajmaline in diagnosis of Brugada Sd
9910328|NCT00702130|Experimental|A|this arm will receive Pravastatin 40 mg per os daily
9910329|NCT00702130|No Intervention|1|
9910330|NCT00702156|Experimental|1|Bisoprolol
9910331|NCT00702156|Placebo Comparator|2|Identical appearance matching placebo
9910332|NCT00702182|Experimental|Conventional Vinorelbine, Erlotinib|Escalating doses of vinorelbine on Day 1 and Day 8 of 21 Day cycle; Erlotinib 100 mg OD
9910333|NCT00702182|Experimental|Metronomic Vinorelbine, Erlotinib|Escalating doses of vinorelbine TIW; erlotinib 100 mg OD
9910334|NCT00702247|Experimental|1|
9910335|NCT00702286||1|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
9910336|NCT00702286||2|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
9910337|NCT00702312|Experimental|Study group|Study group that will attend low-salt educational community programme
9910338|NCT00702312|No Intervention|Control group|Subjects in this arm will have routine medical and dietetic treatment for low-salt reduction.
9910339|NCT00702416|Experimental|US Group|In this group, the continuous block will be performed under real-time ultrasound (US) guidance.
9910340|NCT00702416|Active Comparator|ENS Group|In this group, the continuous block will be performed with an electrical nerve stimulation (ENS) technique.
9910341|NCT00702429|Experimental|1|Patients achieve of parodontopathies
9910342|NCT00702429|Placebo Comparator|2|Patients without parodontales diseases
9910343|NCT00702442|Placebo Comparator|A|Placebo Administrated 30min prior to operation
9910344|NCT00702442|Experimental|B|0.625 mg Droperidol administrated i.v 30 min prior surgery
9910345|NCT00702455|Active Comparator|Self-Directed|
9910346|NCT00702455|Active Comparator|Guided|
9910347|NCT00702481|Experimental|Nimotuzumab/CDDP/RT|Open label treatment arm of Nimotuzumab and cisplatin and radiation
9910348|NCT00702572|Experimental|1|Phase I dose escalating scheme
9910349|NCT00702572|Experimental|2|Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
9910350|NCT00702598|Experimental|1|Telephone-based Cognitive Behaviour Therapy
9910351|NCT00702598|Placebo Comparator|2|Telephone reminder calls
9910352|NCT00702611|Experimental|1|Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
9910353|NCT00702611|Active Comparator|2|Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks
9910354|NCT00702676|Experimental|1|Quetiapine Fumarate Immediate Release
9910355|NCT00702676|Experimental|2|Quetiapine Fumarate Extended Release
9910356|NCT00702728|Experimental|1|Furosemide and matched saline hydration by RenalGuard system
9910357|NCT00702728|Active Comparator|2|Standard IV saline infusion
9910358|NCT00702793|Experimental|1|Smoking cessation drug - varenicline
9910359|NCT00702832|Experimental|Vestibular rehabilitation|early supported vestibular rehabilitation
9910360|NCT00702832|Active Comparator|standard|standard treatment
9910361|NCT00702858|Active Comparator|1|Blue Citrus either months 1-3 or 4-6
9910362|NCT00702858|Placebo Comparator|2|Placebo
9910363|NCT00702871|Active Comparator|1|Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
9910364|NCT00702871|Active Comparator|2|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
9910365|NCT00702910|Experimental|GW642444M/lactose|GW642444M/lactose 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
9910366|NCT00702910|Experimental|GW642444M/MgSt|GW642444M/MgSt 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
9910367|NCT00702910|Placebo Comparator|Placebo|Placebo containing lactose, single inhaled dose for two days treatment in each treatment sequence (crossover design)
9910368|NCT00702936|Active Comparator|R|Twenty-five patients assigned to ramipril 5 mg daily
9910369|NCT00702936|Active Comparator|T|Twenty-five patients assigned to Telmisartan 80 mg daily
9910370|NCT00703001|Active Comparator|1--Educational Intervention|Students in this arm will receive several in-class educational modules on basic oral health topics.
9910371|NCT00703001|Active Comparator|2--Referral intervention|Parents of student subjects will receive assistance in accessing oral health care for their child
9910372|NCT00703040||Component 1|Existing linkage to care protocols will be obtained from the 15 sites. This component does not involve study subjects.
9910373|NCT00703040||Component 2|Person-to-person or telephone interviews with ATN clinical site staff and staff from their community partners will be audio-taped.
9910374|NCT00703040||Component 3|Notes from direct observation of the linkage to medical care process within sites will be taken.
9910375|NCT00703066|Experimental|1|three doses of 30µg GMZ2,
9910376|NCT00703066|Experimental|2|3 doses of 100 µg of GMZ2
9910377|NCT00703066|Active Comparator|3|Rabies vaccine
9910378|NCT00703079||Group A|>15 patients treated only with SSA (octreotide-LAR or lanreotide depot)
9910379|NCT00703079||Group B|>15 patients treated with surgery after a period of SSA treatment of 6-24 months
9910380|NCT00703079||Group C|>15 patients cured after surgery only
9910381|NCT00703079||Group D|>15 patients treated with surgery first and then with SSA after 6-12 months
9910382|NCT00703105|Experimental|Autologous Dendritic Cell Vaccination|DC vaccination with 1 x 10(6th) tumor lysate or WT1 and MUC1 peptide and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals(6 weeks)
9910383|NCT00703131||1|Anal Fistula Plug
9910384|NCT00703144|Experimental|Pharmacokinetic|
9910385|NCT00703170|Experimental|Dose Level 1 (original)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 30 mg/m2 once every 4 weeks"
9910386|NCT00703170|Experimental|Dose Level 1 (revised)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
9910387|NCT00703170|Experimental|Dose Level 2|"Temsirolimus IV 25 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
9910388|NCT00703183|Experimental|1|ACU-4429
9910389|NCT00703183|Placebo Comparator|2|matching placebo
9910390|NCT00703196|Experimental|Arm I|Patients receive oral folic acid pill once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
9910391|NCT00703196|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
9910392|NCT00703209|Active Comparator|1|Patients who are randomized to receive surgical care, will receive the nerve decompression, along with similar incisions on the opposite leg, but no decompression on that leg. This will serve as the patient's control leg, and also blind them to the treatment leg.
9910393|NCT00703209|No Intervention|2|Subjects who are not randomized to receive the surgical procedure will be followed up with the same clinic visits as the patients who are receiving the surgical procedure.
9910394|NCT00703248|Experimental|1|
9910395|NCT00703248|No Intervention|2|
9910396|NCT00703274|Experimental|Navigation Group|Participants enrolled in this group will receive education concerning primary and secondary PROTECT DC goals. Primary PROTECT DC goals adhere to the following medication directives: 1) Anti-hypertensive, 2) Lipid Lowering, 3) Anti-Coagulant, and 4) Anti-Diabetic. PROTECT DC secondary goals include the following behaviors 1) Smoking Cessation, 2) Consuming an AHA Diet, 3) Regular Exercise, and 4) Knowledge of Stroke Risk and Warning Signs. Participants will also receive assistance with overcoming resource-related barriers to the PROTECT DC goals.
9910397|NCT00703274|No Intervention|Control Group|Participants enrolled in this group will receive periodic follow up through mailings, phone calls etc to ensure availability for 1 year assessment.
9910398|NCT00703287|Sham Comparator|A2|Generic physiotherapy
9910399|NCT00703287|Experimental|A1|Specialized Physiotherapy
9910400|NCT00703300|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.
9910401|NCT00703313|Active Comparator|2|described in intervention
9910402|NCT00703313|Active Comparator|3|described in intervention
9910403|NCT00703313|Active Comparator|1|described in intervention
9910404|NCT00703352|Active Comparator|1|Eplerenone
9910405|NCT00703352|Placebo Comparator|2|Placebo
9910406|NCT00703365|Experimental|1|Sorafenib
9910407|NCT00703378|Experimental|Group 1|Group 1: normal liver function
9910408|NCT00703378|Experimental|Group 2|Group 2: AST and/or ALT up to 1-5 x upper limit of normal; SAP 1- 5x upper limit of normal, total bilirubin within normal limits
9910409|NCT00703378|Experimental|Group 3|Group 3: Any SAP and AST/ALT >5-10 x upper limit of normal and/or total bilirubin 1-1.5 x upper limit of normal
9910410|NCT00703417||1|Healthy post-menopausal women
9910411|NCT00703417||2|Diabetic without fracture
9910412|NCT00703417||3|Diabetic with fracture
9910413|NCT00703430|Experimental|1|Memantine
9910414|NCT00703456|Experimental|1|Balance Training, 3 times a week for 4 weeks
9910415|NCT00703456|No Intervention|2|Education/No intervention
9910416|NCT00703469|Experimental|1|
9910417|NCT00703469|Placebo Comparator|2|
9910418|NCT00703482|Placebo Comparator|1|
9910419|NCT00703482|Active Comparator|2|
9910420|NCT00703482|Active Comparator|3|
9910421|NCT00703482|Experimental|4|
9910422|NCT00703482|Experimental|5|
9910423|NCT00703482|Experimental|6|
9910424|NCT00703482|Experimental|7|
9910425|NCT00703521|Placebo Comparator|1,2,3,4,5|"Rabies vaccine 1.0 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.5 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 28,and 1 year~Japanese encephalitis vaccine 0.25 mL subcutaneous"
9910426|NCT00703547|Experimental|Subjects receiving treatment in cohort 1|Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).
9910427|NCT00703547|Experimental|Subjects receiving treatment in cohort 2|Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)
9910428|NCT00703560||1|HIV and HCV genotype 1 coinfected (any race)
9910429|NCT00703560||2|HCV genotype 1 (any race)
9910430|NCT00703586|Experimental|1|"ARM A:~Intensification with maraviroc for 24 weeks at one of the following doses:~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~600 mg orally BID when coadministered with efavirenz or nevirapine"
9910431|NCT00703586|Active Comparator|2|"ARM B~Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc."
9910432|NCT00703599|Experimental|1|This is the only arm and that is the treatment group.
9910433|NCT00703612|Experimental|Treatment Group|This is the only arm and that is the treatment group.
9910434|NCT00703625|Experimental|Cohort 1|"Temsirolimus IV 15 mg weekly~Docetaxel 60 mg/m2 IV once every three weeks."
9910435|NCT00703625|Experimental|Cohort 2|"Temsirolimus IV 25 mg weekly~Docetaxel IV 60 mg/m2 once every 3 weeks"
9910436|NCT00703625|Experimental|Cohort 1A|"Temsirolimus IV 15 mg weekly~Docetaxel IV 50 mg/m2 every 3 weeks."
9910437|NCT00703638|Experimental|Sorafenib/Pemetrexed/Cisplatin|Patients receiving a dose escalation scheme of daily oral sorafenib (200 mg or 400 mg bid) when given in combination with fixed dose intravenous pemetrexed and cisplatin for the treatment of solid tumors.
9910438|NCT00703651|Experimental|1|
9910439|NCT00703651|Experimental|2|
9910440|NCT00703651|Active Comparator|3|
9910441|NCT00703690|Experimental|1|MK0767; 2.5 mg/day
9910442|NCT00703690|Experimental|2|MK0767; 5mg/day
9910443|NCT00703690|Experimental|3|MK0767; 10 mg/day
9910444|NCT00703690|Active Comparator|4|fenofibrate 200 mg
9910445|NCT00703690|Placebo Comparator|5|Matching Placebo
9910446|NCT00703703|Experimental|1|Darifenacin
9910447|NCT00703703|Active Comparator|2|Tolterodine
9910448|NCT00703703|Placebo Comparator|3|Placebo
9910449|NCT00703742|Experimental|A,1|A: Escitalopram, 20 mg/day,8weeks
9910450|NCT00703755|Experimental|1|
9910451|NCT00703755|Experimental|2|
9910452|NCT00703755|Experimental|3|
9910453|NCT00703755|Experimental|4|
9910454|NCT00703755|Experimental|5|
9910455|NCT00703755|Experimental|6|
9910456|NCT00703755|Placebo Comparator|7|
9910457|NCT00703768||A|Patients who have been identified as having a doubling in PSA from nadir of greater than one year
9910458|NCT00703768||B|Patients who have been identified as having a doubling in PSA from nadir of less than one year.
9910459|NCT00703794||AXIUM Coils|
9910460|NCT00703807|Experimental|1|Daily oral RAD001 for 21 days in combination with oral topotecan on days 1-5 of a 21 day cycle
9910461|NCT00703833|Experimental|1|Drug
9910462|NCT00703833|Placebo Comparator|2|Placebo
9910463|NCT00703872|Experimental|1|Oral HDV-Interferon
9910464|NCT00703872|Experimental|2|Injectable HDV-Interferon + ribavarin
9910465|NCT00703950|Experimental|A,1|Cup feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
9910466|NCT00703950|Active Comparator|A,2|bottle feeding - conventional method Bottle feeding is the conventional method to feed preterm infant before breastfeeding or to substitute breastfeeding. We are using this method in the control group.
9910467|NCT00703989|Experimental|I|Patients with Type 1 diabetes
9910468|NCT00703989|No Intervention|II|Age-matched male subjects without Type 1 diabetes
9910469|NCT00704002|Experimental|A|antegrade intramedullary splinting
9910470|NCT00704002|Active Comparator|B|conservative treatment
9910471|NCT00704015|Experimental|A|Smoking cessation
9910472|NCT00704015|No Intervention|B|
9910473|NCT00704054|Experimental|1|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
9910474|NCT00704067|Experimental|1|Supported employment for 12 months plus cognitive training for the first 12 weeks
9910475|NCT00704067|Active Comparator|2|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks
9910476|NCT00704080|Experimental|1|
9910477|NCT00704106||Group 1|Persistent viremia after 48 weeks or longer.
9910478|NCT00704106||Group 2|<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
9910479|NCT00704106||Group 3|Patients who responded to adefovir and were switched to entecavir.
9910480|NCT00704106||Group 4|Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.
9910481|NCT00704145|Experimental|A|Device, paclitaxel drug-eluting stent
9910482|NCT00704210|Sham Comparator|B|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
9994428|NCT01481012||Group II: Cardiopulmonary Bypass + Pulsatile LVAD|CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
9910483|NCT00704210|Experimental|A|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
9910484|NCT00704223||A|
9910485|NCT00704236|Experimental|A|
9910486|NCT00704236|Placebo Comparator|B|
9910487|NCT00704249|Experimental|1|Full-dose nevirapine from baseline (200 mg bid).
9910488|NCT00704249|Active Comparator|2|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
9910489|NCT00704275|Experimental|A|0.05% cyclosporin
9910490|NCT00704275|Active Comparator|B|Refresh
9910491|NCT00704288|Experimental|1|
9910492|NCT00704301|Experimental|1|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Rivastigmine: two times 1,5 mg a day; The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
9910493|NCT00704301|Placebo Comparator|2|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Placebo: 2 times a day
9910494|NCT00704314|Active Comparator|1|Simvastatin therapy, 80 mg/d for 8 weeks
9910495|NCT00704314|Placebo Comparator|2|Placebo, one pill daily for 8 weeks
9910496|NCT00704366|Experimental|1|AZD0530
9910497|NCT00704392|Experimental|1|
9910498|NCT00704431|Experimental|darapladib|darapladib
9910499|NCT00704457||A|One arm study. Urine collection.
9910500|NCT00704470|Active Comparator|1|Classic one-day simulator training for intensivists.
9910501|NCT00704470|Experimental|2|Crew resource management training
9910502|NCT00704509|Experimental|Bifeprunox|
9910503|NCT00704509|Placebo Comparator|Placebo|
9910504|NCT00704509|Active Comparator|Quetiapine|
9910505|NCT00704548|Active Comparator|1|Simvastatin 40 mg
9910506|NCT00704548|Placebo Comparator|2|
9910507|NCT00704561|Active Comparator|DES|Zotarolimus drug-eluting stent
9910508|NCT00704561|Active Comparator|BMS|bare metal stent
9910509|NCT00704574||A|
9910510|NCT00704600|Experimental|nelfinavir|see intervention
9910511|NCT00704639|Experimental|Single arm|Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
9910512|NCT00704652||A|Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
9910513|NCT00704652||B|Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.
9910514|NCT00704665|Placebo Comparator|2|Placebo
9910515|NCT00704665|Experimental|A|10ug/kg/day or 25/ug/kg/day
9910516|NCT00704678|Experimental|1|1g bid
9910517|NCT00704678|Active Comparator|2|0.8 g tid
9910518|NCT00704678|Experimental|3|1.5 g tid
9910519|NCT00704678|Active Comparator|4|1.6 g tid
9910520|NCT00704691|Experimental|Lenalidomide|
9910521|NCT00704743|Active Comparator|1|Cylindrical cast
9910522|NCT00704743|Active Comparator|2|Modified sugar tong cast
9910523|NCT00704743|Active Comparator|3|Volar dorsal splint
9910524|NCT00704756||Arm 1|Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium.
9910525|NCT00704795||1|Patients with type 1 diabetes mellitus
9910526|NCT00704795||2|Healthy control subjects matched for body mass index (BMI), age and gender.
9997936|NCT01513200|Placebo Comparator|UFH + Placebo|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
9910527|NCT00704821|Experimental|Stage 1|In Stage 1, PTC299 will be given orally twice a day (BID) each day at about the same time each day for the first 28 days of each cycle. Each cycle will constitute a 4-week (28 days) period followed by a ≥2-week (14-day) washout period. Participants will be assigned to 0.3 milligrams (mg)/kilograms (kg)/dose BID, 0.6 mg/kg/dose BID, or 1.2 mg/kg/dose BID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
9910528|NCT00704821|Experimental|Stage 2|In Stage 2, PTC299 will be given BID or 3 times a day (TID) orally each day at about the same time each day; therefore, 84 (for BID) or 126 (for TID) doses of PTC299 will be delivered during the 6-week (42-day) period in each cycle. Each participant will be assigned to 100 mg/dose BID, 100 mg/dose TID, 120 mg/dose TID, 160 mg/dose TID, or 200 mg/dose TID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
9910529|NCT00704821|Experimental|Stage 3|In Stage 3, PTC299 will be given BID or TID (for total of 42 [for BID] or 63 [for TID] doses) orally about same time per day starting on Day 1 in each 3-week (21-day) cycle. Starting dose will be 1 dose level below maximum tolerated dose (MTD) from Stage 2 or 80 mg/dose BID if 100 mg/dose TID in Stage 2 exceeds MTD. Dose escalation will be based on safety evaluations by Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant. Participants will also receive docetaxel as a 1-hour IV infusion on Day 1 per cycle at starting dose of 75 mg/m^2 with body surface area calculation based on body weight. Dose will be sequentially reduced to 60 and 50 mg/m^2 in participants with a docetaxel-related dose-limiting toxicity (DLT). Participants will be medicated with oral corticosteroids with docetaxel administration. Recommended dose is 8 mg BID dexamethasone for 3 days starting 1 day prior to docetaxel administration.
9910530|NCT00704821|Experimental|Stage 4|In Stage 4, PTC299 will be given orally each day continuously starting on first day of each cycle at about same time per day; so, 42 doses of PTC299 will be delivered for 3 weeks (21-day) in Cycle 1 (BID dosing), and 84 doses will be delivered for 3-weeks (21-day) in Cycle 2 and beyond (TID dosing). For Cycle 1, participants will be assigned to 600, 800, or 1000 mg/dose BID sequentially based on safety evaluations by Sponsor's medical monitor at enrollment. For Cycle 2 and beyond, participants will receive PTC299 160 mg/dose TID. During Cycle 1, Cohort 1 participants will eat a meal containing of ≤15 grams (g) of dietary fat and Cohort 2 participants will eat a meal containing of ≤25 g of dietary fat prior to each dose of PTC299. If ≤2 of 6 participants had experienced DLT during Cycle 1 in either diet plan, then the dose will be escalated to 800 mg BID in Cohort 3 at the optimal diet. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
9910531|NCT00704834||1|Normal Controls
9910532|NCT00704834||2|Patients with a clinically isolated syndrome (CIS)
9910533|NCT00704834||3|Patients with relapsing, remitting Multiple Sclerosis (RRMS) who are not on treatment
9910534|NCT00704834||4|Patients with Chronic Progressive Multiple Sclerosis who are not on treatment
9910535|NCT00704860|Experimental|TR|TR- Subjects defined as having treatment resistant depression, who have failed at least 2 adequate trials of an antidepressant. Subjects will be treated in an open label trial for their depression, with the goal of sustained remission.
9910536|NCT00704886|No Intervention|1|verbal
9910537|NCT00704886|Experimental|2|video
9910538|NCT00704899|Experimental|2|anti-depressants
9910539|NCT00704899|Experimental|1|physiotherapy
9910540|NCT00704951||Patients|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
9910541|NCT00704977|Active Comparator|1|Pterygium surgery using alcohol 20% + wound closure by bare sclera technique
9910542|NCT00704977|Active Comparator|2|"Alcohol 20% for pterygium separation + wound closure by sliding flap technique.~The main steps of surgery are described below.Wound closure technique is as follows.~Disection of conjunctiva adjascent to the wound, bringing the dissected conjunctiva to the wound area and suturing by vicril 6/0 sutures"
9910543|NCT00704977|Active Comparator|3|"Alcohol 20 % for pterygium separation + using amniotic membrane and biological glue for wound closure.~The steps of surgery are as described below, wound closure technique is as follows.~Amniotic membrane is applied with its mesenchimal side to conjunctiva and glued by biological glue (main ingradients: calcium and thrombin)"
9910544|NCT00704990|Experimental|A|All study participants take part in the experimental arm
9910545|NCT00705042|Experimental|A|25 mg
9910546|NCT00705042|Experimental|B|50 mg
9910547|NCT00705055||1|Normal Males
9910548|NCT00705055||2|Normal Females
9910549|NCT00705055||3|Abnormal Males
9910550|NCT00705055||4|Abnormal Females
9910551|NCT00705094||1|Testicular cancer patients who have received surgery and are scheduled for surveillance
9910552|NCT00705094||2|Testicular cancer patients who have received surgery and are scheduled for chemotherapy
9910553|NCT00705120|Other|1|
9910554|NCT00705120|Other|2|
9910555|NCT00705172||A|
9910556|NCT00705185||1|Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
9910557|NCT00705185||2|Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)
9910558|NCT00705198||Newly diagnosed patients|Patients treated with temozolomide for newly diagnosed malignant glioma
9667366|NCT03656159|Experimental|Cognitive-Behavioral group therapy|The intervention will include behavioral activation, cognitive restructuring, and stress/anger management strategies (e.g. abdominal breathing, progressive muscle relaxation). In addition, knowledge about memory management and sleep disorders will be provided.
9910559|NCT00705198||Relapsed patients|Patients treated with temozolomide for relapsed malignant glioma
9910560|NCT00705198||Newly diagnosed anaplastic astrocytoma patients|Patients treated with temozolomide for newly diagnosed anaplastic astrocytoma
9910561|NCT00705276|Experimental|I|
9910562|NCT00705302|Experimental|patient education including self-help|Patients in the arm will participate in a three months patient education and exercise program including a self-help group in 3 months of time.
9910563|NCT00705302|Active Comparator|patient education|Patients in arm 2 will participate in the same patient education and exercise program as arm 1, but without an additional self-help group.
9910564|NCT00705315|Experimental|1|Bevacizumab->Epirubicin->Docetaxel
9910565|NCT00705328|Experimental|1|
9910566|NCT00705328|Experimental|2|
9910567|NCT00705328|Experimental|3|
9910568|NCT00705354|Active Comparator|1|Control group undergoing standard ESS will have a saline soaked Nasopore sponge placed during surgery and will receive routine oral antibiotics post-operatively
9910569|NCT00705354|Experimental|2|Treatment group undergoing ESS will have Nasopore sponge soaked with Bacitracin, but will not receive oral antibiotics post-operatively
9910570|NCT00705380|Experimental|1|Participants will receive cognitive behavioral therapy with panic control treatment.
9910571|NCT00705380|Active Comparator|2|Participants will receive cognitive behavioral therapy with panic control treatment after a 12-week waitlist period.
9910572|NCT00705419||Previous vicriviroc 30 mg QD|Subjects who previously received vicriviroc 30 mg daily in a Phase 2 or 3 clinical trial.
9910573|NCT00705419||Previous vicriviroc 20 mg QD|Subjects who previously received vicriviroc 20 mg daily in a Phase 2 or 3 clinical trial.
9910574|NCT00705419||Control Group|Subjects who previously received active control or placebo in a Phase 2 or 3 clinical trial involving vicriviroc.
9910575|NCT00705445|Active Comparator|A|This group will not receive any of the intervention supplements. The group will only receive nutritional counselling and education, and treatment provided for any encountered illness according to IMCI guidelines.
9910576|NCT00705445|Experimental|B|"This group will receive micronutrient supplements containing microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid.~This group will also receive Nutritional Counselling and Education and treatment according to IMCI Guidelines for any serious illness."
9910577|NCT00705445|Experimental|C|"This group will receive Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, Folic Acid, and Zinc.~This group will also receive nutritional counselling, education and treatment according to IMCI Guidelines in case of any untoward illness."
9910578|NCT00705458|Experimental|CTA|Initial EKG-gated computed tomography angiography of the coronary arteries
9910579|NCT00705458|Active Comparator|MPI|Initial nuclear stress myocardial perfusion imaging
9910580|NCT00705471||Infliximab|Because of the difficulty of finding subjects with exactly the same disease severity, information will be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.
9910581|NCT00705497|Experimental|1|
9910582|NCT00705510|Active Comparator|A|
9910583|NCT00705510|Placebo Comparator|B|
9910584|NCT00705549|Experimental|1|Gemzar/Cisplatin
9910585|NCT00705549|Experimental|2|Taxotere/Cisplatin
9910586|NCT00705549|Experimental|3|Cisplatin/Navelbine metronomic
9910587|NCT00705549|Experimental|4|Taxotere/Gemzar
9910588|NCT00705549|Experimental|5|Gemzar
9910589|NCT00705549|Experimental|6|Taxotere
9910590|NCT00705549|Experimental|7|Navelbine metronomic
9910591|NCT00705549|Experimental|8|Alimta/Cisplatin
9910592|NCT00705549|Experimental|9|Alimta/Gemzar
9910593|NCT00705549|Experimental|10|Taxotere
9910594|NCT00705549|Experimental|11|Alimta
9910595|NCT00705562|Experimental|1|Experimental milk protein based infant formula with varying carbohydrate and protein source
9910596|NCT00705562|Experimental|2|Experimental milk protein based infant formula with varying carbohydrate and protein source
9910597|NCT00705562|Experimental|3|Experimental milk protein based infant formula with varying carbohydrate and protein source
9910598|NCT00705562|Experimental|4|Experimental milk protein based infant formula with varying carbohydrate and protein source
9910599|NCT00705562|Experimental|5|Experimental milk protein based infant formula with varying carbohydrate and protein source
9910600|NCT00705588|Experimental|1|Patients treated with epoprostenol (Flolan) will be given tadalafil (Cialis).
9910601|NCT00705588|Experimental|2|Patients receiving iloprost (Ventavis) will receive vardenafil (Levitra)
9910602|NCT00705601||1|
9910603|NCT00705627|Experimental|B|Drug: cisplatin. Patients in the control arm received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
9994429|NCT01481012||Group III: Cardiopulmonary Bypass + Continuous Flow LVAD|CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
9994430|NCT01481012||Group IV: Cardiopulmonary Bypass + CABG Surgery|CPB for CABG surgery
9994431|NCT01481025|Experimental|Cimicifuga+Hiperico|80 + 450 mg / tablet
9994432|NCT01481025|Active Comparator|Cimicifuga Herbarium|80 mg / caps
9994433|NCT01481025|Active Comparator|Aplause®|20 mg / tablet
9994434|NCT01481038||Group dialysis patients|Patient on hemodialysis with central venous catheter
9994435|NCT01481038||Group hematology patients|Patients with hemato-oncologic underlying disease (plus/minus hematopoietic stem cell transplantation HSCT) and central venous catheter
9994436|NCT01481064|Active Comparator|Multifaceted approach|After baseline measurement a multifaceted approach will start for 1 year, including audit and feedback, an educational outreach visit, and patient-mediated interventions.
9994437|NCT01481064|No Intervention|Usual care|After baseline measurement no intervention will occur in these hospitals.
9994438|NCT01481090|Active Comparator|Electro-Acupuncture|Group will receive 4 acupuncture treatments over 14 days during hormone treatment
9994439|NCT01481090|No Intervention|Control|Group will not receive acupuncture.
9994440|NCT01481103|Active Comparator|Acupuncture group|Participants will keep a headache diary for 4weeks and then attend eight weekly acupuncture sessions. Acupuncture will be done by a licensed acupuncturist and will last approximately 25 minutes. Following the acupuncture sessions, participants will keep a headache diary for an additional 4 weeks
9994441|NCT01481103|No Intervention|Control group|participants will be asked to maintain a daily diary of headache occurrences and OTC medication use for 16 weeks.
9994442|NCT01481142|Experimental|Adacolumn|
9994443|NCT01481168|Active Comparator|"Pacemaker on"|DDD+/-R pacing
9994444|NCT01481168|Placebo Comparator|"Pacemaker off"|ODO pacing
9994445|NCT01481168|Experimental|Implantable Loop Recorder|Implantable loop recorder in adenosine test negative patients
9994446|NCT01481181|Experimental|zinc enriched water|zinc enriched purified water at 2-6mg/l per day
9994447|NCT01481181|No Intervention|purified water only|non zinc enriched, purified drinking water
9994448|NCT01481181|No Intervention|control group|group of households receiving hygiene practice recommendations and water guard (water purifying solution)
9994449|NCT01481194|Experimental|ACVDL|ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
9994450|NCT01481207||neonates with perinatal asphyxia|neonates with suspected perinatal asphyxia (HIE)
9994451|NCT01481220|Experimental|Azacitidine + Eltrombopag|
9994452|NCT01481233|Experimental|Single arm|Colchicine 0.5 mg BID x 21 days
9994453|NCT01481246||Normal Aging/Cognitive Decline|Health adults as well as adults with MCI and early stage AD are being recruited in the study
9994454|NCT01481259|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every 21 days
9994455|NCT01481259|Active Comparator|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days
9994456|NCT01481285||healthy adults|The study will cover 992 healthy adults. 496 men and 496 women in an age range of 18 to 65 years are planned to be recruited.
9994457|NCT01481298||LVNC|12 patients with left ventricular non-compaction cardiomyopathy
9994458|NCT01481298||HCM|10 patients with hypertrophic cardiomyopathy
9667367|NCT03651895|Active Comparator|Treatment Group|Metformin 500mg bd
9994459|NCT01481298||DCM|11 patients with dilatative cardiomyopathy
9994460|NCT01481298||controls|24 healthy controls
9994461|NCT01481311||Patients before dialysis treatment|
9994462|NCT01481311||Patients after dialysis treatment|
9994463|NCT01481337||Polypectomy or mucosal endoscopic resection under aspirin|
9994464|NCT01481350|Experimental|Sildenafil|All patient will be treat with a intravenous administration of the drug from the beginning of the intervention, for a maximum of 72 hours.
9994465|NCT01481363|Active Comparator|Treatment as usual|Half of participants recruited will be randomly assigned to the control group to receive treatment as usual. This is will be based on a single one hour consultation which will include communication advice and information.
9994466|NCT01481363|Experimental|The Talking Sense treatment|Half of carer participants recruited will be randomly assigned to receive the Talking Sense treatment. This will be conducted one to one and individualised over 3 sessions and no more than 4.5 hours during no more than 8 weeks.
9994467|NCT01481389|Active Comparator|Theobromine drink|
9994468|NCT01481389|Active Comparator|Cocoa drink|
9994469|NCT01481389|Placebo Comparator|Placebo drink|
9994470|NCT01481389|Active Comparator|Cocoa and theobromine drink|
9910604|NCT00705640|Experimental|Arm 1A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
9910605|NCT00705640|Experimental|Arm 1B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
9910606|NCT00705640|Experimental|Arm 1C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
9910607|NCT00705640|Experimental|Arm 1D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
9910608|NCT00705640|Experimental|Arm 1E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
9910609|NCT00705640|Experimental|Arm 2A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
9910610|NCT00705640|Experimental|Arm 2B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
9910611|NCT00705640|Experimental|Arm 2C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
9910612|NCT00705640|Experimental|Arm 2D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
9910613|NCT00705640|Experimental|Arm 2E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
9910614|NCT00705692|Experimental|Levamisole|Two 50 mg levamisole tablets daily, six days before and six days after Td vaccination.
9910615|NCT00705692|Placebo Comparator|Placebo|Two placebo tablets daily, six days before and six days after Td vaccination.
9910616|NCT00705705|Experimental|1|Participating social networks will receive standard HIV risk-reduction counseling and network leadership training on HIV prevention.
9910617|NCT00705705|Active Comparator|2|Participating social networks will receive standard HIV risk-reduction counseling.
9910618|NCT00705744|Experimental|I|
9910619|NCT00705770|Placebo Comparator|1|Placebo treatment with vehicle
9667368|NCT03651895|Placebo Comparator|Placebo Group|Placebo
9910620|NCT00705770|Experimental|2|Low dose of study medication
9910621|NCT00705770|Experimental|3|Middle dose of study medication
9910622|NCT00705770|Experimental|4|High dose of study medication
9910623|NCT00705796|Experimental|Group 1|Group 1 will be treated with MPP10, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
9910624|NCT00705796|Active Comparator|Group 2|Group 2 will be treated with AndroGel® 50 mg, once daily in the morning after washing/showering.
9910625|NCT00705822|Experimental|1|Docetaxel + Estramustine + Hydrocortisone
9910626|NCT00705822|Active Comparator|2|Docetaxel + Prednisone
9910627|NCT00705835|Experimental|1|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Six patients will start on 50μg rsPSMA +0.5 mg Alhydrogel® Weeks 1,2,3 and 7.
9910628|NCT00705835|Experimental|2|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Eight patients will start on 250μg rsPSMA + 1.0 mg Alhydrogel Weeks 1,2,3 and 7
9933967|NCT05106153|Experimental|Treatment Phase: Treatment Sequence CDBEAF|Participants will receive Treatment C in treatment period 1, followed by Treatment D in treatment period 2, Treatment B in treatment period 3, Treatment E in treatment period 4, Treatment A in treatment period 5 and then Treatment F in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
9933968|NCT05106153|Experimental|Treatment Phase: Treatment Sequence DECFBA|Participants will receive Treatment D in treatment period 1, followed by Treatment E in treatment period 2, Treatment C in treatment period 3, Treatment F in treatment period 4, Treatment B in treatment period 5 and then Treatment A in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
9933969|NCT05106153|Experimental|Treatment Phase: Treatment Sequence: EFDACB|Participants will receive Treatment E in treatment period 1, followed by Treatment F in treatment period 2, Treatment D in treatment period 3, Treatment A in treatment period 4, Treatment C in treatment period 5 and then Treatment B in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
9933970|NCT05106153|Experimental|Treatment Phase: Treatment Sequence FAEBDC|Participants will receive Treatment F in treatment period 1, followed by Treatment A in treatment period 2, Treatment E in treatment period 3, Treatment B in treatment period 4, Treatment D in treatment period 5 and Treatment C in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
9933971|NCT05105867|Experimental|anti-CD19 UCAR-T treatment|Anti-CD19 UCAR-T is an allogeneic CAR-T. A single infusion.
9933972|NCT05104736|Experimental|PT-112|PT-112 will be administered intravenously on Days 1, 8 and 15 of a 28-day cycle at a dose of 360 mg/m2 until disease progression, development of intolerable adverse events, or until 8 years after an individual participant has been on study
9933973|NCT05104723|Experimental|XELJANZ (tofacitinib)|Tofacitinib is self-administered orally at 5 mg twice per day for 3 months.
9933974|NCT05104463|Experimental|CST-2032 (3mg)/CST-107 (3mg) to Placebo|Subjects will receive daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.
9933975|NCT05104463|Experimental|Placebo to CST-2032 (3mg)/CST-107 (3mg)|Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days.
9933976|NCT05104463|Experimental|CST-2032 (6mg)/CST-107 (3mg) to Placebo|Subjects will receive daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.
9994471|NCT01481402|Placebo Comparator|Placebo-liothyronine|3 months of placebo followed by 3 months of Liothyronine treatment.
9933977|NCT05104463|Experimental|Placebo to CST-2032 (6mg)/CST-107 (3mg)|Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days.
9933978|NCT05102721|Experimental|Experimental|Single arm, all patients serially enrolled to combination doses of Avelumab and Pepinemab
9933979|NCT05100667|Experimental|Mental fatigue|Stroop task
9933980|NCT05100667|Placebo Comparator|Control MF|Emotionally neutral documentary
9933981|NCT05100654|No Intervention|No post-operative oral antibiotics|Patients will only receive 24hr of IV peri-operative antibiotics
9933982|NCT05100654|Active Comparator|6 days of oral antibiotics|Patients will receive 24hr of IV peri-operative antibiotics and then 6 days of oral antibiotics
9933983|NCT05100628|Experimental|Dose-Escalation Cohort 1: NOX66 800 mg + Doxorubicin|
9933984|NCT05100628|Experimental|Dose-Escalation Cohort 2: NOX66 1200 mg + Doxorubicin|
9933985|NCT05100628|Experimental|Dose-Escalation Cohort 3: NOX66 1800 mg + Doxorubicin|
9933986|NCT05100628|Experimental|Dose-Expansion Cohort: NOX66 + Doxorubicin|
9994472|NCT01481402|Other|Liothyronine-Placebo|3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
9994473|NCT01481428|Active Comparator|Attention Control|
9994474|NCT01481428|Experimental|Computer-facilitated HIV intervention|
9994475|NCT01481441|Other|SonoVue|Ultrasound Contrast Agent
9994476|NCT01481454|Experimental|Group 1: QIV Lot 1|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
9994477|NCT01481454|Experimental|Group 2: QIV Lot 2|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
9994478|NCT01481454|Experimental|Group 3: QIV Lot 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
9994479|NCT01481454|Active Comparator|Group 4: TIV|Participants will receive the Trivalent Influenza Vaccine (TIV).
9994480|NCT01481467|Experimental|Intervention|Influenza vaccination implementation strategy applied.
9994481|NCT01481467|No Intervention|Control|Usual care.
9994482|NCT01481480|Experimental|Latissimus dorsi tendon transfer|A Latissimus dorsi tendon transfer is performed
9994483|NCT01481480|Active Comparator|Arthroscopic repair|An arthroscopic repair is performed
9994484|NCT01481493|Experimental|Active Treatment|BT061 monoclonal antibody (subcutaneous)
9994485|NCT01481493|Placebo Comparator|Placebo|subcutaneous injection of placebo
9994486|NCT01481506|Experimental|Telemonitoring|
9994487|NCT01481506|No Intervention|Usual care|
9994488|NCT01481519|Active Comparator|dexamethasone 0.1%/povidone-iodine 0.4%|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
9994489|NCT01481519|Placebo Comparator|artificial tears|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
9994490|NCT01481532|Experimental|Cohort 3|The third cohort will include up to 18 patients with Crotoxin doses of 0.12 to 1.16 mg per m2 in which the dose escalation speed will be faster. Drug is administered over 48 hour intervals using ambulatory infusion pumps; treating on an outpatient basis. Subjects will receive increasing doses over the course of 35 treatment days (15 dose levels).
9994491|NCT01481584|Experimental|Canola protein|Canola protein (Brassica juncea; incorporated in a drink)
9994492|NCT01481584|Active Comparator|Reference protein|Reference Protein (soy protein isolate; incorporated in a drink)
9994493|NCT01481584|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
9994494|NCT01481584|No Intervention|Run-in|Run-in period (three days before intervention, defined diet)
9994495|NCT01481597|Experimental|deuteporfin 1mg/kg|
9994496|NCT01481597|Active Comparator|deuteporfin 2.5mg/kg|
9994497|NCT01481597|Active Comparator|deuteporfin 5mg/kg|
9994498|NCT01481597|Active Comparator|deuteporfin 7.5mg/kg|
9994499|NCT01481597|Placebo Comparator|placebo|
9994500|NCT01481610|Experimental|Lumiracoxib group|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.
9994501|NCT01481610|Active Comparator|Diclofenac group|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
9994502|NCT01481623|Other|Gene identification and phenotyping|Identification of patients (probands), questionnaire and informed consent of patients and their families, biological sampling, DNA and RNA extraction, genetic study for gene identification, re-contact of family members and relatives (with consent) for metabolic study of mutation carriers, and complementary studies of homozygous patients in some cases
9994503|NCT01481636||No treatment, OSA (AHI >15)|Patients with OSA recruited prior to receiving NHS treatment.
9994504|NCT01481649||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
9910629|NCT00705848||1|10 patients with tracheobronchomalacia
9910630|NCT00705848||2|10 patients with tracheal stenosis
9910631|NCT00705848||3|10 patients with normal airways (no known airway diseases)
9910632|NCT00705861|Placebo Comparator|1|
9910633|NCT00705861|Experimental|2|
9910634|NCT00705887|No Intervention|Control|Brochure from the American Academy of Dermatology on protecting your skin from UV rays.
9910635|NCT00705887|Experimental|Intervention|Participation in a brief motivational enhancement session. These participants also received the same American Academy of Dermatology brochure on protecting your skin from UV rays.
9910636|NCT00705900|Experimental|1|LCD Solution: 2 applications / day
9910637|NCT00705900|Active Comparator|2|Calcipotriol cream: 2 applications / day
9910638|NCT00705913|Active Comparator|1|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
9910639|NCT00705913|Active Comparator|2|
9910640|NCT00705926|Experimental|A1|Antiretroviral therapy followed by discontinuation at Week 12.
9910641|NCT00705926|Experimental|A2|Antiretroviral therapy followed by discontinuation at Week 32.
9910642|NCT00705926|Placebo Comparator|B|No treatment.
9910643|NCT00705952|Experimental|1|
9910644|NCT00705965|Experimental|1|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
9910645|NCT00705965|Active Comparator|2|Usual cardiological care including one information session.
9910646|NCT00705978|Experimental|1|
9910647|NCT00705978|Placebo Comparator|2|
9910648|NCT00706017||A|
9910649|NCT00706069|Experimental|1|Vinorelbine oral plus Capecitabine
9910650|NCT00706108||1|Simulation of anesthesia induction with critical incidents: Analysis of technical and non-technical performance (15 Teams)
9910651|NCT00706108||2|Analysis of technical and non-technical performance in live anesthesia inductions (40 teams)
9910652|NCT00706108||3|Simulation of anesthesia inductions with advanced simulated critical incidents or events and analysis of technical and non-technical performance (max. 50 teams)
9910653|NCT00706173|Experimental|Hydrocortisone|
9910654|NCT00706173|Placebo Comparator|Placebo|
9910655|NCT00706199||Group A|donors
9910656|NCT00706225|Experimental|1|Bazedoxifene and Conjugated Estrogens (BZA & CE)
9910657|NCT00706251||Primary|All the patients in our medical center who underwent nasolacrimal intubation, due to mild epiphora, during the years 2000-2007.
9910658|NCT00706277|Active Comparator|TIVA|patients receiving total intravenous anesthesia (TIVA)
9910659|NCT00706277|Active Comparator|balanced|patients receiving balanced anesthesia
9910660|NCT00706290|Experimental|Intervention - CBT|Participants randomized to the intervention group received cognitive behavioral therapy (CBT) for anxiety after completing a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. After completing the CBT intervention, consisting of 6-7 sessions over the course of 2-3 months, participants completed a post-intervention assessment identical to the baseline.
9910661|NCT00706290|No Intervention|Routine Care Control|Participants randomized to the control condition completed a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. They then received routine medical care. After 2 months and after completing the post clinical assessment identical to the baseline, they were offered the opportunity to receive the CBT intervention for free. This ensured that all participants ultimately received cognitive-behavioral therapy if desired, while permitting an examination of the effect size for the intervention compared to routine care.
9910662|NCT00706303|Active Comparator|1 Intervention group|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
9910663|NCT00706303|No Intervention|2|Usual care. The control group will receive usual care, as decided by their GP and or hospital consultant, and the patient themselves (e.g., NHS 24 helpline). They will be asked to complete diary cards and receive telephone follow up calls as an attention control, similar to the intervention group.
9910664|NCT00706316|Experimental|EBV-Specific CTLs and CD45 Mab|A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10^7 cells/m2. Dose Level II: 5 x 10^7 cells/m2. Dose Level III: 1 x 10^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.
9910665|NCT00706368|Experimental|1|Participants in this group will perform self-tests for the first half of the study and will have clinical examinations for the second half of the study
9910666|NCT00706368|Experimental|2|Participants in this group will have clinical examinations for the first half of the study and will perform self-tests for the second half of the study
9910667|NCT00706459||1|Patients with lumbar back pain scheduled for back surgery.
9910668|NCT00706459||2|Patients with degenerative disease without classic discogenic back pain
9910669|NCT00706459||3|Normal control without back pain.
9910670|NCT00706459||4|Post Surgical discectomy patients
9910671|NCT00706459||5|disc specimens
9910672|NCT00706576|Experimental|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
9910673|NCT00706602||1|Swiss COPD cohort
9910674|NCT00706602||2|Dutch COPD cohort
9910675|NCT00706667|Placebo Comparator|1|Placebo for EPO and for Ferinject ®
9910676|NCT00706667|Active Comparator|2|Only Ferinject ® , Placebo for EPO
9910677|NCT00706667|Active Comparator|3|Ferinject ® + EPO
9910678|NCT00706680|Experimental|1|All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.
9910679|NCT00706693|Active Comparator|Glucose|BD glucose tablets (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
9910680|NCT00706693|Active Comparator|Fructose|Fruit to Go (TM) is taken PO in response to a hypoglycemic event by participants randomized to this arm
9910681|NCT00706693|Active Comparator|Sucrose|Skittles (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
9910682|NCT00706732|Active Comparator|T1|
9910683|NCT00706732|Active Comparator|T2|
9910684|NCT00706732|Placebo Comparator|C1|
9910685|NCT00706732|Placebo Comparator|C2|
9910686|NCT00706745|Placebo Comparator|placebo|The control oil is based on the general fat consumption in a Western population and consists of an equal amount (4 gr) of fat. It is a blend of palm (80%) and soybean oil (20%). Two capsules will be taken in the morning and two in the evening.
9910687|NCT00706745|Active Comparator|oil rich in cis9, trans11 CLA|Subjects will receive daily 4 g of CLA oil (2.6 g cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
9910688|NCT00706758|Active Comparator|1|Structured patients group intervention - IBS school
9910689|NCT00706758|Active Comparator|2|Written information - IBS-guidebook
9910690|NCT00706771|Active Comparator|Sodium bicarbonate|sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
9910691|NCT00706771|Active Comparator|Sodium chloride|sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
9910692|NCT00706862|Experimental|1|Talactoferrin, Carboplatin, Paclitaxel
9910693|NCT00706862|Placebo Comparator|2|Placebo, Carboplatin, Paclitaxel
9910694|NCT00706875||1|30 patients survived GTD post treatment for 0 - 5 years.
9910695|NCT00706875||2|30 patients survived GTD post treatment 6 - 10+ years.
9910696|NCT00706888|Active Comparator|1|Female with active product
9910697|NCT00706888|Active Comparator|2|Male with active product
9910698|NCT00706888|Placebo Comparator|3|Female with placebo
9910699|NCT00706888|Placebo Comparator|4|Male with placebo
9910700|NCT00706953|Active Comparator|001|
9910701|NCT00707018|Experimental|External rotation shoulder sling|External rotation shoulder sling
9910702|NCT00707018|Active Comparator|Internal rotation shoulder sling|Internal rotation shoulder sling
9910703|NCT00707044|Experimental|A|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
9910704|NCT00707044|Active Comparator|B|control group, care as usual, 24 hours intensive care stay
9910705|NCT00707070|Experimental|1|efalizumab 1 mg/kg/week subcutaneous plus acitretin 0.4 mg/kg/day oral
9910706|NCT00707070|Placebo Comparator|2|efalizumab 1 mg/Kg/week subcutaneous plus oral placebo
9910707|NCT00707083|Active Comparator|Standard- or Intermediate-Risk Maintenance Arm I|Patients receive oral mercaptopurine and oral methotrexate on days 1-56, dexamethasone IV on days 1-5 and 29-33, vincristine IV on days 1 and 29, and methotrexate IT on day 50. Treatment repeats every 8 weeks for up to 8 (girls)-11 (boys) courses.
9910708|NCT00707083|Experimental|Standard- or Intermediate-Risk Maintenance Arm II|Patients receive oral mercaptopurine once daily on days 8-28 and 36-56; oral methotrexate once on days 8,15, 22, 36, 43, and 50; dexamethasone IV on days 1-5 and 29-33; and vincristine IV on days 1 and 29. Patients also receive methotrexate IT on day 1, every 8 weeks, for 8 courses.
9910709|NCT00707122|Other|1, Albumin and Crystalloids|Treatment
9910710|NCT00707122|Other|2, Crystalloids|Control
9910711|NCT00707135|Experimental|1|
9910712|NCT00707148|Active Comparator|Group 2: Control|16 pregnant women to receive: antepartum: saline; postpartum; Tdap vaccine.
9910713|NCT00707148|Experimental|Group 1: Intervention|32 pregnant women to receive: antepartum: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine; postpartum: saline.
9910714|NCT00707148|Active Comparator|Group 3: Control|32 non-pregnant women to receive a single dose of Tdap vaccine.
9910715|NCT00707187|Experimental|1|35 doses of study medication, IC 351 (20 mg) -- crossover to placebo
9910716|NCT00707187|Experimental|2|35 placebo pills followed with 35 study medication (20 mg)
9910717|NCT00707200||1|Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.
9910718|NCT00707200||2|Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.
9910719|NCT00707226||1|15 patients with primary open angle glaucoma
9910720|NCT00707226||2|15 age matched healthy subjects
9933987|NCT05098652|Active Comparator|Pilot group|Serve as own controls. Complete baseline surveys, 3 weeks of daily diaries, receive 12 weeks of CuRB-IT, complete 3 weeks of daily diaries.
9910721|NCT00707252|Experimental|Phase I/II|Phase I: Polyphenon E + Erlotinib - Polyphenon E 200, 400 and 800 mg/day dose levels evaluated in a step-wise manner with Erlotinib 150 mg/day to establish Maximum Tolerated Dose (MTD) of Polyphenon E. Phase II consists of MTD of Polyphenon E established in Phase I, administered alone for two weeks and thereafter together with Erlotinib 150 mg/day.
9910722|NCT00707265|Experimental|Investigational|Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.
9910723|NCT00707265|Active Comparator|Control|The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
9910724|NCT00707278|Experimental|All patients|All participants enrolled.
9910725|NCT00707317||1|HIV infected individuals
9910726|NCT00707317||2|patients with chronic renal failure
9910727|NCT00707317||3|patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)
9910728|NCT00707317||4|patients with rheumatoid arthritis
9910729|NCT00707317||5|stem cell transplant recipients
9910730|NCT00707317||6|immunocompromised patients with confirmed tuberculosis
9910731|NCT00707317||7|immunocompetent controls with no known risk of exposure or tuberculosis
9910732|NCT00707330|Experimental|1|Subjects randomised to this arm will first be treated with Clarithromycin for a week, then have a 2-week washout, and finally one week of no treatment
9910733|NCT00707330|Active Comparator|2|Subjects randomised to this arm will first receive one week of no treatment, then have a 2-week washout, and finally be treated with Clarithromycin for a week
9910734|NCT00707356|Experimental|WST11(TOOKAD® Soluble)|Treatment with WST11-mediated VTP
9910735|NCT00707369|Experimental|test|Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
9910736|NCT00707369|Placebo Comparator|control|Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
9910737|NCT00707382|Other|Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1) the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment in accordance with the current guidelines from Sct. Hans hospital. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described in the clinical guidelines."
9910738|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
9910739|NCT00707382|No Intervention|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
9910740|NCT00707421|Placebo Comparator|1|placebo, artificial tears
9910741|NCT00707421|Active Comparator|3|corticosteroid , CS
9910742|NCT00707421|Active Comparator|2|non-steroidal anti-inflammatory drug, NSAID
9910743|NCT00707460|Active Comparator|1|Please, see design section for details.
9910744|NCT00707460|Experimental|2|"Traditional Diet~Please, see design section for details."
9910745|NCT00707460|Experimental|3|"Healthy Store-bought Diet~Please, see design section for details."
9910746|NCT00707473|Experimental|Treatment (docetaxel, cisplatin, and fluorouracil)|"INDUCTION CHEMOTHERAPY: Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 30-180 minutes or carboplatin IV on day 1, and fluorouracil IV continuously on days 1-4. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~Patients who achieve CR or PR receive 1 additional course of treatment and undergo chemoradiotherapy over 6-7 weeks. Patients who have SD or PD to induction therapy, or less than a complete response to chemoradiotherapy undergo surgery and radiation therapy."
9910747|NCT00707499|Experimental|1|
9910748|NCT00707525|No Intervention|1|Natural cycle oocyte donation
9910749|NCT00707525|Active Comparator|2|"Stimulated cycle oocyte donation.~Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).~Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.~COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations."
9910750|NCT00707538|Experimental|1|
9910751|NCT00707551|Experimental|1|Ketoconazole tablet + AZD1305 Extended Release tablet
9910752|NCT00707551|Experimental|2|Verapamil Extended Release tablet + AZD1305 Extended Release tablet
9910753|NCT00707551|Experimental|3|AZD1305 Extended Release tablet
9910754|NCT00707564|Experimental|1|HemCon Dental Dressing
9910755|NCT00707564|Active Comparator|2|Gauze with pressure
9910756|NCT00707590|Experimental|Part A|"A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days~G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day"
9994505|NCT01481662||retrospective|cases retrospectively reported the last 20 years
9910757|NCT00707590|Experimental|Part B|"A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days"
9910758|NCT00707590|Experimental|Part C|"A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days~B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days"
9910759|NCT00707603||Hepatitis C subjects|Due to start therapy for Hepatitis C
9910760|NCT00707603||Controls|Healthy males
9910761|NCT00707616||A|Subjects without type 2 diabetes living in Olmsted County, MN
9910762|NCT00707629||Insulin Pump Therapy|Children on insulin pumps for at least three years. Subjects must have type 1 diabetes for at least five years and diagnosed under the age of 5.
9910763|NCT00707642|Experimental|1|Low Dose WN-80E API (5 µg) + Alhydrogel (3.5 mg)
9910764|NCT00707642|Experimental|2|Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)
9910765|NCT00707642|Experimental|3|High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)
9910766|NCT00707642|Experimental|4|High Dose WN-80E API (50 µg), no adjuvant
9910767|NCT00707668||Control|Chung-ju cohort populations aged over 30 year-old
9910768|NCT00707681|Active Comparator|I|MS-20
9910769|NCT00707681|Placebo Comparator|2|Placebo
9910770|NCT00707694||Probands|Ashkenazi Jews ages 95 and older
9910771|NCT00707694||Offspring|Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95
9910772|NCT00707694||Controls|Ashkenazi Jewish people with no family history of longevity
9910773|NCT00707707|Experimental|1|paclitaxel + AZD2281
9910774|NCT00707720|Experimental|TERIS procedure|TERIS procedure for the treatment of obesity
9910775|NCT00707772|Active Comparator|1|Genotype 2 or 3 in Hemophilic Patients with HCV
9910776|NCT00707772|Active Comparator|2|Other Genotypes (except 2 or 3) in Hemophilic Patients with HCV
9910777|NCT00707785|Experimental|1|Sepsis - vitamin A
9910778|NCT00707785|Placebo Comparator|2|Sepsis - placebo
9910779|NCT00707785|Experimental|3|NEC - vitamin A
9910780|NCT00707785|Placebo Comparator|4|NEC - Placebo
9910781|NCT00707798|Experimental|Formulation 1|
9910782|NCT00707798|Experimental|Formulation 2|
9910783|NCT00707798|Experimental|Formulation 3|
9910784|NCT00707798|Experimental|Formulation 4|
9910785|NCT00707798|Experimental|Formulation 5|
9910786|NCT00707798|Experimental|Formulation 6|
9910787|NCT00707798|Active Comparator|23 valent pneumococcal vaccine|
9910788|NCT00707824|Placebo Comparator|1|1= placebo
9910789|NCT00707824|Active Comparator|2|2=nalbuphine 5 mg
9910790|NCT00707824|Active Comparator|3|3=nalbuphine 10 mg
9910791|NCT00707837|Experimental|Infant Formula|Preterm infant formulas containing lipid soluble compounds
9910792|NCT00707837|Active Comparator|Preterm formulas|Standard preterm infant formula and discharge formulas
9910793|NCT00707850|Experimental|1|Thalassemic Patients with HCV
9910794|NCT00707876|Experimental|1|Dose 1 versus non-contrast MRA
9910795|NCT00707876|Experimental|2|Dose 2 versus non-contrast MRA
9910796|NCT00707876|Experimental|3|Dose 3 versus non-contrast MRA
9910797|NCT00707902|Active Comparator|2|"Drug: Echinacea/sage~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.~Arms: 1"
9910798|NCT00707902|Active Comparator|1|"Drug: Chlorhexidine/lidocaine~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days."
9910799|NCT00707928|Active Comparator|1|1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
9910800|NCT00707928|Placebo Comparator|2|2=placebo with the same volume as NTG 100-200 microgram of IV.
9910801|NCT00707941|Experimental|1|Oseltamivir for 5 days for patients with illness duration < 48 hours
9910802|NCT00707941|Placebo Comparator|2|Placebo for 5 days for patients with illness duration < 48 hours
9910803|NCT00707941|Experimental|3|Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
9910804|NCT00707941|Placebo Comparator|4|Placebo for 5 days for patients with illness duration ≥ 48 hours
9910805|NCT00708006|Experimental|1|HGS1029
9910806|NCT00708149|Active Comparator|1|lansprazole 30 mg qd from NG route or orally
9910807|NCT00708149|Placebo Comparator|2|control group without any PPI, H2 blockers or other medications for treating peptic ulcers.
9933988|NCT05098652|Experimental|Immediate Intervention|Complete baseline survey, complete 3 weeks of daily diaries, receive 12 weeks of CurB-IT, then complete 3 rounds of 21-day daily diaries while receiving attention during the 12-week intervals between daily diaries.
9910808|NCT00708188|Experimental|Multidetector raw CT|
9910809|NCT00708240|Experimental|Escitalopram|
9910810|NCT00708253|Active Comparator|SBE|
9910811|NCT00708253|Active Comparator|DBE|
9910812|NCT00708266|Placebo Comparator|V2|28 hours continuous saline venous infusion.
9910813|NCT00708266|Experimental|V3|28 hours continuous lipid-heparin venous infusion.
9910814|NCT00708279|Experimental|A|After establishing a baseline for the first 4 weeks of trial involvement, thereby providing their own control group, all participants begin the intervention phase of osteopathic manipulation.
9910815|NCT00708318|Experimental|A, B, C|
9910816|NCT00708331|Experimental|1|
9910817|NCT00708344|Active Comparator|Group 1|Usual elective titration regimen
9910818|NCT00708344|Active Comparator|Group 2|Active elective titration regimen
9910819|NCT00708357|Other|1|homozygous mutant: CC allele of the eNOS T-786C gene
9910820|NCT00708357|Other|2|homozygous mutant: TT allele of the eNOS T-786C gene
9910821|NCT00708370|Active Comparator|COACH|
9910822|NCT00708370|Placebo Comparator|Standard Care|
9910823|NCT00708383|Experimental|1|Embryo culture medium supplemented with 0.5% HSA and 10% SSS
9910824|NCT00708383|Active Comparator|2|Embryo culture medium supplemented with 0.5% HSA only
9910825|NCT00708396|Experimental|Patients|Patients which diagnosed as OCD and schizophrenia
9910826|NCT00708409||1|Autograft operations with the subcoronary technique
9910827|NCT00708409||2|Autograft operations with the root replacement technique
9910828|NCT00708474|Experimental|OsseoFit™|Treatment of bone graft site with OsseoFit™ Porous Tissue Matrix™.
9910829|NCT00708474|No Intervention|Open|Treatment of bone graft site without OsseoFit™ Porous Tissue Matrix™.
9910830|NCT00708487|Experimental|1|5% oxygen embryo culture condition
9910831|NCT00708487|Active Comparator|2|21% oxygen embryo culture condition
9910832|NCT00708539|Active Comparator|1|Crinone vaginal gel 8% 90 mg once daily
9910833|NCT00708539|Active Comparator|2|Progesterone mic 400 mg three times daily
9910834|NCT00708578|Active Comparator|1|Administration of 4 mg of Glimepiride with Insulin Glargine
9910835|NCT00708578|Active Comparator|2|Administration of 1500 mg of Metformin with Insulin Glargine
9910836|NCT00708578|Experimental|3|Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine
9910837|NCT00708591|Experimental|1|
9910838|NCT00708604|Experimental|1|Islet transplantation
9910839|NCT00708630|Experimental|1|Provision of extended symptom side effects information
9910840|NCT00708630|No Intervention|2|Standard information on side effects
9910841|NCT00708656|Experimental|1: once daily|Three 800mg tablets of mesalazine (Asacol®) in the morning
9910842|NCT00708656|Active Comparator|2: tds|Mesalazine (Asacol®) 800mg given three times daily
9910843|NCT00708669|Active Comparator|TAXUS group|
9910844|NCT00708669|Active Comparator|Cypher group|
9910845|NCT00708695||Free Transportation|The 166 families in this treatment condition received free transportation for scheduled prenatal care appointments. This group did not receive any postpartum services or assessments.
9910846|NCT00708695||Transportation, Child Screening/Referral|The 514 families received: 1) free transportation for prenatal care; and 2) child developmental screening and referral services.
9910847|NCT00708695||Prenatal Nurse Home-Visiting|The 230 families received: 1) free transportation for prenatal care; and 2) nurse home-visiting during pregnancy and postpartum (one visit).
9910848|NCT00708695||Nurse Home Visiting through Age 2|The 228 families: 1) free transportation for prenatal care; 2) nurse home-visiting during pregnancy and through child's second birthday; and 3) child developmental screening and referral.
9910849|NCT00708747|Experimental|B|Patients were randomised to receive a commercially available standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) containing all important transport and inhibitor proteins as well as immunoglobulins
9910850|NCT00708747|Active Comparator|A|Patients were randomised to receive a 5% albumin solution
9910851|NCT00708760||2|web based learning group
9910852|NCT00708760||1|paper based learning group
9910853|NCT00708773|Experimental|Single Arm|
9910854|NCT00708799|Experimental|Arm 1|Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
9910855|NCT00708799|No Intervention|Arm 2|Standard antibiotic therapy
9910856|NCT00708812|Active Comparator|The control group|paclitaxel-carboplatin
9910857|NCT00708812|Experimental|The treatment group|paclitaxel-carboplatin plus Endostar
9910858|NCT00708825||1|surgical outcome, observation
9910859|NCT00708838||1|
9910860|NCT00708838||2|
9910861|NCT00708838||3|
9910862|NCT00708838||4|
9910863|NCT00708838||5|
9910864|NCT00708890|Experimental|Intervention group|
9910865|NCT00708890|No Intervention|Control group|Will only get a standard information about TSG group (information about meeting etc.)
9910866|NCT00708903|Experimental|1|HKI-272
9910867|NCT00708903|Placebo Comparator|2|Placebo
9910868|NCT00708903|Active Comparator|3|Moxifloxacin
9910869|NCT00708929|Other|1|14 subjects homozygous HH for the Tyr402His single nucleotide polymorphism
9910870|NCT00708929|Other|2|14 subjects homozygous TT for the Tyr402His single nucleotide polymorphism
9910871|NCT00708968|Experimental|FOCUS Intervention|Dyads randomized to this arm received the FOCUS Program, 3 home visits and 2 phone calls by trained nurses.
9910872|NCT00708968|No Intervention|Standard Care|
9910873|NCT00708981|Active Comparator|Study Group|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.~Patient enhanced self-management provided by combined diabetes-renal education curriculum.~Behavior and social intervention~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
9910874|NCT00708981|No Intervention|Control Group|Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management.
9910875|NCT00709007|Experimental|DAART|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
9910876|NCT00709007|Active Comparator|SAT|Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
9910877|NCT00709020|Experimental|White Button Mushroom Extract|
9910878|NCT00709046|Experimental|1|High dose pantoprazole infusion
9910879|NCT00709046|Active Comparator|2|standard dose pantoprazole infusion
9910880|NCT00709072|Experimental|1|SMS reminders
9910881|NCT00709072|No Intervention|2|control group
9910882|NCT00709085||1|HCC patients without liver cirrhosis
9910883|NCT00709085||2|HCC patients with liver cirrhosis
9910884|NCT00709137|Active Comparator|1|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)
9994506|NCT01481662||Prospective|"Diffusion tensor magnetic resonance imaging of the brain:~new cases prospectively reported"
9667369|NCT03646617|Active Comparator|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks or every 4 weeks until disease progression.
9994507|NCT01481675||BPDLL group|Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
9994508|NCT01481675||LSG group|Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively
9994509|NCT01481688|No Intervention|Control|Routine haemodialysis sessions as per usual
9994510|NCT01481688|Experimental|Intradialytic exercise|One hour of exercise completed during haemodialysis.
9994511|NCT01481688|Active Comparator|Extra time|30 minutes extra dialysis time.
9994512|NCT01481701|Experimental|intravenous chemotherapy|treatment of ovarian carcinoma in relapse
9994513|NCT01481714|Active Comparator|Sodium Picosulphate preparation the day before|"Preparation the day before of the procedure using sodium picosulphate:~A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
9994514|NCT01481714|Experimental|Split-dose sodium picosulphate preparation|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
9994515|NCT01481727|Placebo Comparator|cpap sham|non invasive mechanical ventilation type cpap sham manoeuver
9994516|NCT01481727|Active Comparator|high-intensity NIMV|Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)
9994517|NCT01481753|Active Comparator|Braun arm|patients received Braun enteroenterostomy
9994518|NCT01481753|Active Comparator|Non Braun Arm|Patients do not receive a Braun enteroenterostomy
9994519|NCT01481766|Experimental|Iron plus dietary counseling (Non-anemic iron deficiency)|
9994520|NCT01481766|Placebo Comparator|Placebo plus dietary counseling (Non-anemic iron deficiency)|
9994521|NCT01481766|No Intervention|Iron sufficient|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
9994522|NCT01481766|Active Comparator|Iron deficiency anemia|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
9994523|NCT01481805||Hepatocellular carcinoma patients treated with sorafenib|
9994524|NCT01481818|Experimental|radioprotector|
9994525|NCT01481831|Active Comparator|H PALO day 1|Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
9994526|NCT01481831|Experimental|H PALO day 1,3,5|Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
9994527|NCT01481831|Active Comparator|M PALO day 1|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
9994528|NCT01481831|Experimental|M PALO day 1,3,5|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
9994529|NCT01481844|Experimental|sequential treatment|1.drugs experimental-Sequential -PPI( Lansoprazole 30mg x2/day) + amoxicillin 1gx2/day for 5days, followed by 5 days of PPI(Lansoprazole 30mg x2/day) + ( Clarithromycin500mg x2/day and Tinidazole 500mg x2/day )
9994530|NCT01481844|Active Comparator|quadruple therapy|Quadruple drug regimen (i.e.-14 days of PPI (Lansoprazole 30mg x2/day) + Bismuth Subsalicylate 525mg X4/day + Metronidazole 500mg x3/day + Tetracycline 500mg x4/day )-is standard of care as second line treatment in eradication of H pylori
9667370|NCT03646617|Experimental|HFRT|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
9994531|NCT01481857|Experimental|Thoracolumbar proprioception|
9994532|NCT01481857|Experimental|Segmental Stabilization|
9994533|NCT01481870|Active Comparator|Sorafenib-sunitinib|Sorafenib is first line treatment followed by sunitinib.
9994534|NCT01481870|Active Comparator|Sunitinib-sorafenib|Sunitinib is first line treatment followed by sorafenib.
9994535|NCT01481883|Experimental|Raloxifene Hydrochloride 120mg oral per day|120mg raloxifene plus antipsychotic drug
9994536|NCT01481883|Placebo Comparator|Placebo tablet - one per day|Lactose pill plus antipsychotic medication
9994537|NCT01481909|Placebo Comparator|Sugar Pill|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
9910885|NCT00709137|Active Comparator|2|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)
9910886|NCT00709150|Experimental|1|Patients will receive collaborative depression care management.
9910887|NCT00709150|Active Comparator|2|Patients will receive enhanced usual care.
9910888|NCT00709163|Active Comparator|1|
9910889|NCT00709163|Placebo Comparator|2|
9910890|NCT00709176|Experimental|Brief|Dyads randomized to BRIEF arm received the Brief FOCUS Program (two home visits and one phone call by a trained nurse) in addition to standard clinical care.
9910891|NCT00709176|Experimental|Extensive|Dyads randomized to EXTENSIVE arm received the Extensive FOCUS Program (4 home visits and two phone calls by a trained nurse) in addition to standard clinical care.
9910892|NCT00709176|No Intervention|Control|Dyads randomized to CONTROL arm continued with standard clinical care.
9910893|NCT00709254|Active Comparator|Treatment Group A|Subjects received an i.v. dose of fentanyl (200 µg)
9910894|NCT00709254|Experimental|Treatment Group B|Subjects received a single dose of 3 mL AeroLEF (500 µg/1 mL)
9910895|NCT00709254|Experimental|Treatment Group C|Subjects received multiple doses of 3 mL AeroLEF (500 µg/1 mL) every 12 hours for a total of five doses over a 3 days
9910896|NCT00709280|Experimental|Active treatment group|7% Hypertonic Saline administered via inhalation twice daily for 48 ± 4 weeks
9910897|NCT00709280|Active Comparator|Control group|0.9% Isotonic Saline administered via inhalation twice daily for 48 ± 4 weeks
9910898|NCT00709293|Placebo Comparator|1|
9910899|NCT00709293|Active Comparator|2|
9910900|NCT00709345|Experimental|Group Home|Participants will receive cognitive behavioral sessions.
9910901|NCT00709345|Active Comparator|Control|Participants will receive time-matched attention control sessions.
9910902|NCT00709358|Active Comparator|2|Detection by blood culture
9910903|NCT00709358|Experimental|1|Test LightCycler SeptiFast® (Roche)
9910904|NCT00709384|Experimental|Prophylactic intervention|"We performed a prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone). Conduction times between electrodes placed on both sides of the lesions are measured on the second postoperative day. Coronary angiography and electrophysiology study using an electroanatomic mapping system to assess conduction across the line and to try to induce atrial flutter are performed three month after the operation.~There is only an intervention arm, no control arm"
9910905|NCT00709397||Observation|antiretroviral-experienced patients requiring raltegravir to construct an adequately potent antiretroviral regimen.
9910906|NCT00709410|Experimental|1|This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.
9910907|NCT00709423|Active Comparator|1|
9910908|NCT00709423|Placebo Comparator|2|
9910909|NCT00709436|Experimental|1|PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.
9910910|NCT00709436|Placebo Comparator|2|Placebo at time 0 and specified time points thereafter.
9910911|NCT00709449|Experimental|1|20 patients with age related macular degeneration
9910912|NCT00709449|Experimental|2|20 patients with primary open angle glaucoma
9910913|NCT00709449|Experimental|3|20 age and sex matched control subjects
9910914|NCT00709475||A|
9910915|NCT00709488|Experimental|Litx™ BPH Therapy|
9910916|NCT00709501|Experimental|1|"Participants in the intervention condition are encouraged to access the Achieve Together website at least once each week. During each login, the following activities will occur:~Users will enter their weight and height, how well their plan for a healthy weight has been going, and clarify their goal weight.~Users will answer questions about each habit they are using to lose weight~Users will receive automated feedback about each habit and will be encouraged to change or delete habits that are being used but not helpful, more consistently use habits that are helpful but not used being used and to continue to use habits that are helpful and being used consistently.~Users are encouraged to search for habits that have helped people of similar age and gender to themselves."
9910917|NCT00709501|No Intervention|2|Participants in the control condition will have to wait 12 weeks before accessing the Achieve Together website. These participants will be a given a log where they can document weekly weight measurements (this part did not happen).
9910918|NCT00709514|Experimental|DCB-WH1 ointment|DCB-WH1 ointment 1.25%, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
9910919|NCT00709514|Placebo Comparator|Placebo|Placebo, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
9910920|NCT00709527|Experimental|1|
9910921|NCT00709540|Experimental|single|10 subjects (8 active and 2 placebo)
9910922|NCT00709553|Experimental|1|midazolam, one single dose of 705mg
9910923|NCT00709553|Experimental|2|ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )
9910924|NCT00709566|No Intervention|Control|Waiting List control.
9910925|NCT00709566|Active Comparator|Exercise therapy|
9910926|NCT00709566|Experimental|Combined therapy|Combined Exercise therapy and Manual Therapy
9910927|NCT00709579|Placebo Comparator|placebo|
9910928|NCT00709579|Active Comparator|RV3391A|
9910929|NCT00709657|Experimental|1|patients with age-related macular degeneration, which are already scheduled for intravitreal anti-VEGF therapy in one eye are measured before and after treatment.
9910930|NCT00709670|Experimental|whole population who receive both tests|this arm includes the whole study population who will receive both tests: MSCT and stress echocardiography
9910931|NCT00709683||A|
9910932|NCT00709709|Experimental|1|Scan
9910933|NCT00709748|Active Comparator|1|Subjects in this study arm will receive treatment (fully active) Empi Select TENS devices.
9910934|NCT00709748|Placebo Comparator|2|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
9910935|NCT00709787||Hypertensive Subjects undergoing primary prevention|
9910936|NCT00709800|Experimental|2|
9910937|NCT00709800|Experimental|3|
9910938|NCT00709800|Experimental|4|
9910939|NCT00709800|Placebo Comparator|5|
9910940|NCT00709800|Experimental|1|
9910941|NCT00709813|No Intervention|1|
9910942|NCT00709813|Experimental|2|
9910943|NCT00709917||A|
9910944|NCT00709930|Active Comparator|1,Exposed to ELF-EMF|Device: Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF
9910945|NCT00709930|Placebo Comparator|2,Placebo|Device: Placebo device with no magnetic fields
9910946|NCT00709969|Experimental|1|Artemether-lumefantrine
9910947|NCT00710047|Experimental|1|Fasting state
9910948|NCT00710047|Experimental|2|after high-fat breakfast
9910949|NCT00710060|Experimental|1|Participating communities will receive the Community Popular Opinion Leader intervention and HIV/STD educational materials.
9910950|NCT00710060|Active Comparator|2|Participating communities will receive HIV/STD educational materials only.
9910951|NCT00710073|Experimental|A|Combined sono-electro-magnetic therapy
9910952|NCT00710086|Active Comparator|1|Intravenous administration of hydromorphone intermittently
9910953|NCT00710086|Experimental|2|Remifentanil intravenous patient-controlled analgesia
9910954|NCT00710099|Experimental|1|
9910955|NCT00710099|Active Comparator|2|SNP iontophoresis
9910956|NCT00710125|Experimental|GPX-150 for Injection|GPX-150 is administered IV on Day 1, followed by a 20 day rest period, every 3 weeks.
9910957|NCT00710138|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
9517580|NCT03305172|Experimental|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
9910958|NCT00710138|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
9933989|NCT05098652|Active Comparator|Delayed intervention|Complete baseline survey, complete 3 weeks of daily diaries, receive 12 weeks of attention, complete 3 weeks of daily diaries, receive 12 weeks of CurB-IT, then complete 2 rounds of 21-day daily diaries while receiving attention during the 12-week intervals between daily diaries.
9933990|NCT05098548||patients with Chronic limb threatening ischemia|"All patients with Chronic limb threatening ischemia present with one or more of the following:~Rest pain (Rutherford category 4)~Minor tissue loss (Rutherford category 5) admitted to the department of Vascular surgery for Endovascular Intervention with provided written informed consent."
9933991|NCT05096481|Experimental|PEP-CMV|Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles.
9933992|NCT05095272|Experimental|Healthy malaria-naive US adults|A single dose of cryopreserved inoculum containing blood-stage P. vivax will be administered IV
9933993|NCT05094570|Experimental|Dupilumab treatment|Treatment with dupilumab to demonstrate decreased staph prevalence and improve microbial diversity
9933994|NCT05093972|Experimental|Panel A: Mild HI|Participants with mild HI receive a single oral dose of MK-8507 400 mg on Day 1.
9933995|NCT05093972|Experimental|Panel B: Moderate HI|Participants with moderate HI receive a single oral dose of MK-8507 400 mg on Day 1.
9933996|NCT05093972|Active Comparator|Panel C: Healthy Controls|Healthy matched control participants receive a single oral dose of MK-8507 400 mg on Day 1.
9997937|NCT01513200|Experimental|UFH + Bendavia|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
9933997|NCT05093933|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily. The vericiguat dose will be titrated to 5 mg and to 10 mg.
9933998|NCT05093933|Placebo Comparator|Placebo|Participants receive a starting matching placebo to vericiguat dose of 2.5 mg taken orally once daily. The matching placebo dose will be sham titrated to 5 mg and to 10 mg.
9933999|NCT05092971|Other|Clinic|Tasks to be completed in OP4 clinic
9934000|NCT05092971|Other|fMRI|Tasks to be completed in fMRI
9997938|NCT01513226|Experimental|Dim light|Day and nighttime dim light conditions
9997939|NCT01513252|Experimental|1|Gröber and Buschke test
9997940|NCT01513265|Active Comparator|RASP|
9910959|NCT00710151||1|Subjects with PCNSL who have survived disease-free for 2 years or more. Treatments will vary depending upon site of enrollment and will include chemotherapy, blood brain barrier disruption (BBBD) with chemotherapy, radiation, and stem cell transplantation.
9910960|NCT00710164|Experimental|A|
9910961|NCT00710164|Placebo Comparator|B|
9910962|NCT00710190|Experimental|Rheos Implant|
9910963|NCT00710216|Active Comparator|A|
9910964|NCT00710216|Experimental|B|
9910965|NCT00710229|Active Comparator|A|Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
9910966|NCT00710229|Active Comparator|B|Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
9910967|NCT00710242|Experimental|1|DF01
9910968|NCT00710242|Placebo Comparator|2|
9910969|NCT00710255||Asthmatics|Asthmatics with exercise induced bronchospasm
9910970|NCT00710268|Experimental|1|Dose Escalation Study 50, 100, 200, 400 mg
9910971|NCT00710281|Other|2D/3D Phase contrast MR|
9910972|NCT00710320||Cover and Uncover|Procedure/Surgery
9910973|NCT00710333|Placebo Comparator|1|500ng dose
9910974|NCT00710333|Experimental|2|
9910975|NCT00710359|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
9910976|NCT00710359|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
9910977|NCT00710372|Experimental|1|CYT006-AngQb
9910978|NCT00710372|Placebo Comparator|2|
9910979|NCT00710398|Experimental|Control|A group consuming twice daily (post-exercise and in morning/afternoon) drinks containing no dairy protein or calcium. Daily protein intake (15% total kcals) should be from non-dairy sources (i.e. meat, egg, fish, chicken, wheat gluten).
9910980|NCT00710398|Experimental|Dairy Protein|A group consuming twice daily drinks (post-exercise and morning) containing 1% chocolate milk (in 1.5 cup servings = 3 cups/d). Daily protein intake is set at 15% total kcals with ~8% coming from dairy sources.
9910981|NCT00710398|Experimental|High Dairy Protein|A group consuming twice daily drinks of 1% artificially sweetened chocolate milk (in 1.5 cup servings = 3 cups/d). Their diet contains 30% protein (as opposed to only 15% in the Con and DairyPro groups) with at least 50% of that coming from dairy sources.
9910982|NCT00710411||A, 2|Polytraumatized patients with ISS > 18 and healthy controls
9910983|NCT00710437||1|Dexmedetomidine - used
9910984|NCT00710437||2|Dexmedetomidine - not used
9997941|NCT01513265|No Intervention|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care with registration of drug use at admission and discharge without interference of RASP or clinical pharmacist.
9910985|NCT00710450||1|Allergic Asthma
9910986|NCT00710450||2|Allergic Rhinitis
9910987|NCT00710463||Control group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated.
9910988|NCT00710463||NIV treatment group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated, plus newly introduced nocturnal non invasive ventilation.
9910989|NCT00710476|Experimental|1|Insemination of the oocytes with a lower concentration of spermatozoa.
9910990|NCT00710476|No Intervention|2|Insemination with a normal concentration of spermatozoa.
9910991|NCT00710502|Experimental|1|Transvaginal NOTES Cholecystectomy (Phase 1)
9910992|NCT00710502|Active Comparator|2|Laparoscopic Cholecystectomy (Phase 2)
9910993|NCT00710502|Experimental|3|Transvaginal NOTES cholecystectomy (Phase 2)
9910994|NCT00710515|Experimental|1|with food
9910995|NCT00710515|Experimental|2|without food
9910996|NCT00710528|Experimental|one arm|
9910997|NCT00710541|Experimental|NPPV group|Subjects in this arm receive standard COPD treatment, LTOT if indicated, and NPPV with ventilators designed for 'non invasive ventilation'(Resmed VPAP III ST-A, Weinmann Ventimotion, Tyco Healthcare Knight Star 330)
9910998|NCT00710541|No Intervention|control gorup|Subjects in this arm receive standard COPD treatment and LTOT if indicated.
9910999|NCT00710619||A|
9994538|NCT01481909|Active Comparator|Rupafin|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
9994539|NCT01481922|Active Comparator|Whitacre 22 gauge|lumbar puncture performed with a Whitacre 22 gauge (BD)
9994540|NCT01481922|Experimental|Whitacre 24 gauge|lumbar puncture performed with a Whitacre 24 gauge (BD)
9994541|NCT01481948|Experimental|story plus behaviorial procedures|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will also engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
9994542|NCT01481948|Active Comparator|story only|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will not engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
9994543|NCT01481948|No Intervention|Wait list control|This group will participate in data collection only; after the 3rd data collection point, they will be given access to the intervention
9994544|NCT01481961|Experimental|rTMS arm|
9994545|NCT01481987|Experimental|Epiretinal Membrane|The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned.
9994546|NCT01481987|No Intervention|Control|Subjects with normal visual acuity and OCT profile
9994547|NCT01482000|Experimental|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
9994548|NCT01482000|Active Comparator|Control|The control group will get the usual care with some additional tests for the study.
9997942|NCT01513278|Placebo Comparator|Control arm|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201, the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
9997943|NCT01513278|Active Comparator|APN201|APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel)
9997944|NCT01513304|Experimental|Chiropractic manual therapy|
9997945|NCT01513343|Experimental|Parent and child classes|Parent and child groups focused on self-regulation of eating
9997946|NCT01513343|No Intervention|Treatment as usual|Treatment as usual
9997947|NCT01513356|Experimental|CBKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days
9997948|NCT01513369|Experimental|ferric carboxymaltose|Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
9997949|NCT01513369|Placebo Comparator|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
9997950|NCT01513382|Experimental|Methylene Blue|The effect of methylene blue dye in detection and total excision of pilonidal sinus will be studied histopathologically.
9997951|NCT01513395|No Intervention|Immediate|"Participants randomized to the Immediate or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time)."
9998341|NCT01517360|Active Comparator|Placebo+Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
9911000|NCT00710645||Arm I|50 subjects with multiple sclerosis will be tested one time on the Lido Workset. The test will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
9911001|NCT00710645||Arm II|25 normal subjects will be tested on the Lido workset. The testing will be performed one time for each patient and will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected control subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
9911002|NCT00710658|Experimental|1|Patients had access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as to a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
9911003|NCT00710658|No Intervention|2|The control group receiving usual care
9911004|NCT00710671||Phase 1|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from four participating AMTU sites.
9911005|NCT00710671||Phase 2|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from all fifteen AMTU sites.
9911006|NCT00710697|Experimental|Single Arm|Picoplatin
9911007|NCT00710723|Experimental|1|vitrification
9911008|NCT00710723|No Intervention|2|Slow freezing
9911009|NCT00710736|Experimental|ARRY-334543 + capecitabine|
9911010|NCT00710775|Other|1|Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
9911011|NCT00710788|Experimental|1|sevelamer as Phosphate-binder treatment
9911012|NCT00710788|Active Comparator|2|Calcium carbonate
9911013|NCT00710827|Experimental|Arm 1|
9911014|NCT00710827|Placebo Comparator|Arm 2|
9911015|NCT00710853|Experimental|1|YiRen Qi gong weekly class for 8 weeks
9911016|NCT00710853|Experimental|2|Tai Chi weekly class for 8 weeks
9911017|NCT00710853|Active Comparator|3|Hatha yoga weekly class for 8 weeks
9911018|NCT00710892|Experimental|Dose Level 1-3|Administration of suicide gene-modified allodepleted T cells.
9911019|NCT00710957||CHS All Stars|CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n~1100).
9911020|NCT00710983|Active Comparator|A|Oral polio vaccine
9911021|NCT00710983|No Intervention|B|No oral polio vaccine
9911022|NCT00711048|Experimental|1|30 mg, oral, single dose
9911023|NCT00711048|Experimental|2|95 mg, oral, single dose
9911024|NCT00711048|Placebo Comparator|3|Oral solution, single dose
9911025|NCT00711061||1|18-25 year old males, growth hormone deficient, who completed growth hormone treatment 3-5 years prior to enrollment in study
9911026|NCT00711061||2|18-25 year old males, healthy, never treated with growth hormones.
9911027|NCT00711074|Experimental|1|
9911028|NCT00711126|Experimental|Arm 1|HVTs
9911029|NCT00711126|Experimental|Arm 2|HVTs
9911030|NCT00711126|Experimental|Arm 3|HVTs
9911031|NCT00711126|Experimental|Arm 4|HVTs
9911032|NCT00711126|Experimental|Arm 5|HVTs
9911033|NCT00711126|Experimental|Arm 6|HVTs
9911034|NCT00711139||1|AFFITOPE AD01
9911035|NCT00711139||2|AFFITOPE AD01 + Adjuvant
9911036|NCT00711152|Experimental|JADE with CHW|Patients will be enrolled into JADE program and will undergo annual comprehensive assessment (CA) with personalized JADE report with additional support by the CHW.
9911037|NCT00711152|Active Comparator|JADE only|Patients will be enrolled into JADE program and undergo annual comprehensive assessment (CA) with personalized JADE report without additional support by the CHW.
9994549|NCT01482013|Experimental|HPP854|Oral HPP854 once a day for 28 days.
9911038|NCT00711165|Placebo Comparator|Placebo|Placebo, 2 puffs, bid
9911039|NCT00711165|Experimental|Memetasone|Mometasone
9911040|NCT00711178|Active Comparator|A|2 hours sunlight
9911041|NCT00711178|Active Comparator|B|3 hours of sunlight
9911042|NCT00711204|Placebo Comparator|1|
9911043|NCT00711204|Active Comparator|2|
9911044|NCT00711217|Experimental|#1 Medical food|
9911045|NCT00711217|Placebo Comparator|#2 Control|
9911046|NCT00711230|Experimental|1: Low dose DermaVir|"Dosage: 0.2 mg DNA~Dosage form: 1.6 mL DNA/PEIm nanomedicine~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
9911047|NCT00711230|Experimental|2: Low dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
9911048|NCT00711230|Experimental|3: Medium dose DermaVir|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
9994550|NCT01482013|Placebo Comparator|Placebo|Oral, placebo once a day for 28 days.
9911049|NCT00711230|Experimental|4: Medium dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
9911050|NCT00711230|Experimental|5: High dose DermaVir|"Dosage: 0.8 mg DNA~Dosage form: 6.4 mL DNA/PEIm nanomedicine~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
9911051|NCT00711230|Experimental|6: High dose Placebo|"Dosage form: 6.4 mL Placebo~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
9911052|NCT00711256|Active Comparator|1|No sunscreen applied
9911053|NCT00711256|Active Comparator|2|Sunscreen applied 0.5 mg/cm2
9911054|NCT00711256|Active Comparator|3|Sunscreen applied 1mg/cm2
9911055|NCT00711256|Active Comparator|4|Sunscreen applied 2mg/cm2
9911056|NCT00711282|Experimental|A|
9911057|NCT00711282|Experimental|B|
9911058|NCT00711295|Experimental|Cohort 1, Treatment Arm 1|"Stratum A (18-59 ys)/B(>=60 ys): 120 healthy volunteers per stratum will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Among Stratum A volunteers, 60 will participate in antibody kinetics evaluation and 30 in cellular immunity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio. Subjects in Treatment Arm 1 will be included in the immunologic determination of lot-to-lot consistency."
9911059|NCT00711295|Experimental|Cohort 1, Treatment Arm 2|"Stratum A (18-59 ys)/B(>=60 ys): 60 healthy volunteers per stratum will receive 2 vaccinations with 3.75 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio."
9911060|NCT00711295|Experimental|Cohort 1, Treatment Arm 3|"Stratum A (18-59 ys): 2060 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in safety evaluation only.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine."
9911061|NCT00711295|Experimental|Cohort 2, Treatment Arm 1|"300 immune compromised individuals 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21.~100 will participate in immunogenicity evaluation and 30 in cellular immunity evaluation."
9911062|NCT00711295|Experimental|Cohort 3, Treatment Arm 1|300 chronically ill patients 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
9911063|NCT00711295|Experimental|Cohort 1, Treatment Arm 4|"Stratum A (18-59): 540 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity assessment.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine.~Subjects in Treatment Arm 4 will be included in the immunologic determination of lot-to-lot consistency."
9911064|NCT00711308|Experimental|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
9911065|NCT00711308|Active Comparator|acenocoumarol|tinzaparin followed by acenocoumarol for 6 months
9911066|NCT00711321||2|AFFITOPE AD02 with adjuvant
9911067|NCT00711321||1|AFFITOPE AD02 without adjuvant
9911068|NCT00711373|Experimental|Unilateral and Bilateral Amputees|
9911069|NCT00711386|Experimental|Cohort A|50mg dose once daily for 7 days.
9911070|NCT00711386|Experimental|Cohort B|100mg dose once daily for 8 days.
9911071|NCT00711386|Experimental|Cohort C|200mg dose once daily for 8 days.
9911072|NCT00711386|Experimental|Cohort D|400mg dose once daily for 7 days.
9911073|NCT00711399||group A|Study group
9911074|NCT00711438|Experimental|FT|Breathlessness Intervention Service (BIS)
9911075|NCT00711438|Active Comparator|WL|Best supportive care
9911076|NCT00711451|Active Comparator|manual|Manual removal of placenta
9911077|NCT00711451|Active Comparator|expressed|expressed placental removal
9911078|NCT00711503|Placebo Comparator|2|The patients are instructed to administer placebo by subcutaneous injection
9911079|NCT00711503|Experimental|1|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
9911080|NCT00711542|Active Comparator|1|Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
9911081|NCT00711542|Placebo Comparator|2|Intracoronary infusion of Placebo after NSTEMI
9911082|NCT00711568|Experimental|Arm 1|Left dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
9911083|NCT00711568|Experimental|Arm 2|Right dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
9911084|NCT00711568|Sham Comparator|Arm 3|Left or right dorsolateral frontal 20 Hz sham TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
9911085|NCT00711581|Experimental|A|Subjects will undergo a laparoscopic cholecystectomy. The gallbladder will be retracted using the Endograb retractor.
9911086|NCT00711620|Experimental|Thymosin alpha 1+Standard Therapy|Patients receive treatment based on SSC guideline with additional thymosin alpha1
9911087|NCT00711620|Placebo Comparator|normal saline+standard therapy|Patients receive treatment based on SSC guideline with additional normal saline.
9911088|NCT00711633|Experimental|1|the fermented preterm formula (FPF)
9911089|NCT00711633|Placebo Comparator|2|formula adapted for preterm infants (PF)
9911090|NCT00711659||1|all third year medical students starting their pediatric clerkship rotation
9911091|NCT00711672||1|Medical Oncologists treating patients with metastatic colorectal cancer
9911092|NCT00711672||2|Patients with metastatic colorectal cancer receiving re-staging CT scans
9911093|NCT00711698|Active Comparator|1|In this arm patients will be randomized to receive a bolus of narcotic followed by PCA.
9911094|NCT00711698|Active Comparator|2|In this arm patients will be randomized to the current standard of care of bolus narcotic treatment.
9911095|NCT00711724||MGH 1|Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
9911096|NCT00711776|Experimental|Subjects receiving new formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
9911097|NCT00711776|Active Comparator|Subjects receiving current formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
9911098|NCT00711776|Experimental|Subjects receiving new formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
9911099|NCT00711776|Active Comparator|Subjects receiving current formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
9911100|NCT00711776|Experimental|Subjects receiving new formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
9911101|NCT00711776|Active Comparator|Subjects receiving current formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
9911102|NCT00711789|Active Comparator|Angiotensin II|
9911103|NCT00711789|Placebo Comparator|Placebo|
9911104|NCT00711815||UA|HPV positive
9911105|NCT00711841|Placebo Comparator|saline solution|Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours
9911106|NCT00711841|Active Comparator|Dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
9911107|NCT00711854|Experimental|1|trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
9911108|NCT00711854|Active Comparator|2|Linezolid
9911109|NCT00711893||ICD and CRT-D|Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
9911110|NCT00711906|Experimental|1|HIV-negative women taking CTX as chemoprophylaxis
9911111|NCT00711906|Active Comparator|2|HIV-negative women taking SP as IPT
9911112|NCT00711906|Experimental|3|HIV-positive women (CD4> 200) taking CTX as chemoprophylaxis
9911113|NCT00711906|Active Comparator|4|HIV-positive women (CD4 > 200) taking SP as IPT
9911114|NCT00711919|Active Comparator|1|Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
9911115|NCT00711919|Active Comparator|2|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
9911116|NCT00711984|Active Comparator|1|Renal artery stenting and Best medical treatment
9911117|NCT00711984|Active Comparator|2|Best medical treatment alone
9911118|NCT00712023|Active Comparator|1|warming by circulating-water mattress
9911119|NCT00712023|No Intervention|2|Forced-air warming mattress
9911120|NCT00712036|Active Comparator|Interim|Methadone maintenance for up to 4 months with emergency counseling only for individuals on program waiting lists.
9911121|NCT00712036|Active Comparator|Comprehensive|Methadone Treatment provided with counseling as usual.
9911122|NCT00712036|Active Comparator|Restored|Methadone Treatment with counseling provided by a clinician with a lower caseload than counseling as usual.
9911123|NCT00712049|Active Comparator|1|Nicotinic acid + Simvastatin
9911124|NCT00712049|Active Comparator|2|Simvastatin
9911125|NCT00712062|Experimental|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
9911126|NCT00712088|Experimental|1: Group Intervention|Group level intervention
9911127|NCT00712088|Active Comparator|2: HCT|Offer of HIV counseling and testing
9911128|NCT00712101|Experimental|1|Abciximab bolus administration intracoronary
9911129|NCT00712101|Active Comparator|2|Abciximab bolus intravenously
9911130|NCT00712114|Experimental|Cohort 1|10 mg HE3286 (1 x 5 mg HE3286, BID)
9911131|NCT00712114|Experimental|Cohort 2|20 mg HE3286 (2 x 5 mg HE3286 BID)
9911132|NCT00712114|Experimental|Cohort 3|40 mg HE3286 (4 x 5 mg HE3286 BID)
9911133|NCT00712127|Experimental|Diet and Exercise|Diet and Exercise for Class II and Class III Obesity
9911134|NCT00712127|Experimental|Diet and Exercise-Delayed|Diet and Exercise-Delayed for 6 months for Class II and Class III Obesity
9911135|NCT00712127|No Intervention|Control|Normal weight, overweight and Class I obesity
9911136|NCT00712140|Active Comparator|Arm I|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
9911137|NCT00712140|Experimental|Arm II|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
9934001|NCT05092269|Experimental|Ustekinumab|Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004, CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study.
9934002|NCT05089370|Experimental|Oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Mucosal Melanoma|
9934003|NCT05084313|Experimental|Manual therapy group|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include 40 healthy individuals.
9934004|NCT05084313|Active Comparator|Deep-slow breathing group|Patients in this group will do deep-slow paced breathing exercise. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
9934005|NCT05084313|Other|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
9934006|NCT05078905||Individuals Receiving Vaccine|Individuals receiving a vaccination for an emerging infection, like SARS-CoV-2
9517581|NCT03305107|Experimental|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of chocolate milk"
9517582|NCT03305107|Experimental|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of water"
9798707|NCT01637935||Pioglitazone unexposed group|Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
9911138|NCT00712205|Placebo Comparator|A|20 Patients with asthma in a crossover design
9911139|NCT00712205|Active Comparator|B|20 Patients with asthma in a crossover design
9911140|NCT00712218|Active Comparator|A|
9911141|NCT00712218|Experimental|B|
9911142|NCT00712231||phakic eyes|the cases did not accept any intraocular surgery
9911143|NCT00712231||pseudophakic eyes|tht cases did not accept any intraocular surgery expect for cataract surgery
9911144|NCT00712257|Other|Spectranetics Laser plus Gore Viabahn Endoprosthesis|Spectranetics Laser for optimal debulking followed by adjunctive PTA plus GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface placement
9798708|NCT01637961|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9798709|NCT01638000|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once daily for 12 weeks.
9798710|NCT01638000|Active Comparator|Solifenacin 5 mg|Participants who received solifenacin 5 mg once daily for 12 weeks.
9798711|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ1|Participants who completed 015K-CL-RAJ1 (NCT02305849) study and met eligible criteria received starting dose of 50 milligrams (mg) peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
9800347|NCT01685203|Experimental|Group 6|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants
9800348|NCT01685203|Experimental|Group 7|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis
9800349|NCT01685203|Experimental|Group 8|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis
9800350|NCT01685216|Experimental|velaglucerase alfa|IV infusion, 60 U/kg, every other week for 1 year
9800351|NCT01685229||Balloon Sinus Dilation|Subjects with chronic sinusitis electing to have a balloon sinus dilation
9800352|NCT01685229||Medical Management|Subjects with chronic sinusitis electing to continue with medical therapy
9800353|NCT01685242|Experimental|AC-170 0.24%|
9800354|NCT01685242|Placebo Comparator|AC-170 0%|
9800355|NCT01685320|Active Comparator|Direct laryngoscope|Includes cases in which the forces applied by Macintosh direct laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
9800356|NCT01685320|Active Comparator|Indirect laryngoscope|Includes cases in which the forces applied by GlideScope indirect laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
9800357|NCT01685372|Experimental|Fluzone High Dose|Fluzone High Dose 0.5 mL intramuscularly (IM) given once
9800358|NCT01685372|Active Comparator|Fluzone|Fluzone 0.5mL IM given once
9800359|NCT01685411|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|Patients treated with Allopurinol, Keppra, Busulfan, Cyclophosphamide, Filgrastim, antithymocyte globulin, Tacrolimus, Mycophenolate mofetil and allogeneic hematopoietic stem cell transplant infusion.
9800360|NCT01685437|Experimental|AA4500|collagenase clostridium histolyticum
9800361|NCT01685463|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technology that can focally stimulate the brain of an awake individual. The brain stimulation techniques could theoretically improve the efficacy of smoking cessation.
9800362|NCT01685463|Placebo Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rTMS determination, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT Transcutaneous Electrical nerve stimulation device.
9800363|NCT01685567|Experimental|MICHI NPS+f|The MICHI™ NPS+f is a flow reversal circuit consisting of two proprietary sheaths connected by standard surgical tubing. The sheaths each have a standard hemostasis valve and sidearm. An in-line flow regulator allows the clinician to modify to the flow through the circuit (either high flow or low flow) in addition to permitting temporary cessation of flow.
9800364|NCT01685684|Experimental|Oxycodone DETERx|
9800365|NCT01685684|Placebo Comparator|Placebo|
9800366|NCT01685697|Active Comparator|Laerdal Mask|Mask ventilation with a Laerdal face mask
9800367|NCT01685697|Experimental|F&P Mask|Mask ventilation with a F&P face mask
9800368|NCT01685801|Experimental|Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
9800369|NCT01685801|Experimental|Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
9800370|NCT01685801|Experimental|Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
9911145|NCT00712283|Placebo Comparator|D|healthy volunteers
9911146|NCT00712283|Active Comparator|C|healthy volunteers
9911147|NCT00712283|Active Comparator|B|healthy volunteers
9911148|NCT00712283|Active Comparator|A|healthy volunteers
9911149|NCT00712309|Active Comparator|1|Percutaneous transluminal angioplasty (PTA)
9911150|NCT00712309|Active Comparator|2|Primary stenting
9911151|NCT00712322|Experimental|Cohort 1|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.030 mg/kg/day).
9911152|NCT00712322|Experimental|Cohort 2|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.0625 mg/kg/day).
9911153|NCT00712322|Experimental|Cohort 3|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.125 mg/kg/day).
9911154|NCT00712322|Experimental|Cohort 4|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.250 mg/kg/day).
9911155|NCT00712361|Experimental|Group A|The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age > 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
9911156|NCT00712374|Experimental|Intervention|Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post
9911157|NCT00712387|No Intervention|A|General surgical trainees who will receive the 'traditional' training programme; i.e. will receive whatever clinical training on a patient their supervising consultant deems appropriate. This is the way junior surgeons are currently trained. They will also receive the standard didactic teaching on the School for Surgeons e-learning resource.
9911158|NCT00712387|Active Comparator|B|Surgical trainees who are assigned to the 'proficiency-based progression' training programme. These trainees will be required to train on the virtual reality simulator (Lap Sim™) for a laparoscopic cholecystectomy. Trainees will have objectively set goals to reach on the simulator and will have to demonstrate proficiency before they are permitted to progress to the next, more challenging level. Group B will also receive the standard School for Surgeons instruction but, unlike Group A, they will have to demonstrate proficiency on the didactic module before they progress to the operating theatre
9911159|NCT00712400|Active Comparator|1|Latanoprost 0.005%, Xalatan®
9911160|NCT00712400|Placebo Comparator|2|Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)
9911161|NCT00712439|Experimental|1|
9911162|NCT00712439|Placebo Comparator|2|
9911163|NCT00712452|Other|1|systemic lupus erythematosus
9911164|NCT00712452|Other|2|breast cancer
9911165|NCT00712452|Other|3|Hodgkin disease
9911166|NCT00712465|Experimental|1|AZD1305 tablet
9911167|NCT00712465|Experimental|2|AZD1305 tablet + digoxin
9911168|NCT00712465|Active Comparator|3|Digoxin
9911169|NCT00712478||A|
9911170|NCT00712491|Experimental|1|
9911171|NCT00712491|Experimental|2|
9911172|NCT00712504|Experimental|1|SU011248 in combination with docetaxel
9911173|NCT00712517|Active Comparator|1|Patients will receive propofol anesthesia during varicose vein stripping surgery.
9911174|NCT00712517|Active Comparator|2|Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.
9911175|NCT00712556||Flourine 18-fluorodeoxyglucose PET|PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
9911176|NCT00712569||1|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information.
9911177|NCT00712569||2|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information.
9911178|NCT00712569||3|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it.
9911179|NCT00712582|Experimental|Consolidation A|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is < 80% will receive 3 cycles of standard dose ICE Chemotherapy."
9911180|NCT00712582|Experimental|Consolidation B|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is ≥80% will receive 2 cycles of augmented RICE Chemotherapy (as per MSKCC protocol 03-075)."
9911181|NCT00712582|Experimental|Consolidation C|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Consolidation C: Patients with biopsy proven disease after induction therapy. Patients whose bone marrow remain positive at interim restaging will have the option of getting an allogeneic[m3] stem cell transplant, in lieu of an ASCT, if they have an acceptable HLA match donor. The allogeneic[m4] stem cell transplant regimen will be decided by the MSK Bone Marrow Transplant Service."
9911182|NCT00712595|Experimental|1|Mifepristone 10 mg daily for three months
9911183|NCT00712595|Experimental|2|Mifepristone 5 mg daily for three months
9911184|NCT00712608|Active Comparator|1|Marketed cow's milk-based formula
9911185|NCT00712608|Experimental|2|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
9911186|NCT00712608|Experimental|3|Cow's milk based formula with prebiotic, different level of fatty acids and fat and a different calcium source
9911187|NCT00712621|Other|I|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm I: Quality of life is assessed at baseline and at 3 and 6 months."
9911188|NCT00712621|Other|II|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm II: Quality of life is assessed at baseline and at 3 and 6 months."
9911189|NCT00712634|Experimental|CMV-seropositive participants|Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
9911190|NCT00712634|Experimental|CMV-seronegative participants|Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
9911191|NCT00712647|Active Comparator|1|Asbestos-exposed participants and heavy smokers
9911192|NCT00712647|Placebo Comparator|2|Asbestos-exposed participants and heavy smokers
9911193|NCT00712660|Experimental|A|In the active-ITAREPS group, the e-mail ALERT message feedback to the investigator will be activated. The core study intervention was 20% antipsychotic dose increase within 24 hours in response to a Pharmacological Intervention Requiring Event (PIRE) defined as either: A) the receipt of any INITIAL ALERT (IA) e-mail. A dose increase was obligatory in such cases regardless of the current clinical status of the patient; or B) the receipt of an ALERT EMERGENCY (AE) e-mail after which the investigator confirmed clinical worsening via phone contact with the patient. AE is defined as further worsening in EWSQ scores during 3 week period after announcement of IA.
9911194|NCT00712660|Placebo Comparator|TAU|In the treatment-as-usual study arm (control, non-active ITAREPS), the e-mail ALERT message feedback will not be activated. In this group, even in the presence of early warning sings, the investigators will be kept blinded to the EWSQ scores, will receive no ALERT message and thus no early pharmacologic intervention based on the ITAREPS program will be prompted. Treatment in the control group will consist of routine clinical and medication management with the frequency of visits common in the outpatient clinical settings. There will be no intevention based on ITAREPS.
9911195|NCT00712686|Active Comparator|A1|
9911196|NCT00712686|Active Comparator|B1|
9911197|NCT00712764|Active Comparator|1|
9911198|NCT00712764|Placebo Comparator|2|
9911199|NCT00712777|Active Comparator|1|homozygote mutant: Insertion/Insertion (40 patients)
9517583|NCT03305107|Experimental|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
9911200|NCT00712777|Active Comparator|2|homozygote mutant: Deletion/Deletion (40 patients)
9911201|NCT00712790|Experimental|Sequential Radioembolization-Sorafenib|Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (Y) resin microspheres given as a single procedure.
9911202|NCT00712803|Experimental|1|One subcutaneous vaccination (10^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
9911203|NCT00712803|Experimental|2|One subcutaneous vaccination (10^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
9911204|NCT00712816|Experimental|A|
9911205|NCT00712816|Active Comparator|B|
9911206|NCT00712829|Experimental|1|123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later.
9911207|NCT00712829|Experimental|2|123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later.
9911208|NCT00712842||1|Patients with non or mild non-proliferative diabetic retinopathy
9911209|NCT00712842||2|Healthy control subjects
9911210|NCT00712855|Experimental|A|mapatumumab and sorafenib
9911211|NCT00712868|Experimental|1|Lactic Acid once a day during 21 days
9911212|NCT00712894|Experimental|D|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
9911213|NCT00712894|Active Comparator|V|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
9911214|NCT00712894|Active Comparator|N|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.
9911215|NCT00712907|Active Comparator|1|vitamin C (Mayrhofer)
9911216|NCT00712907|Placebo Comparator|2|Placebo
9911217|NCT00712933|Experimental|1|1 mg/kg dose of belimumab given IV every 28 days.
9911218|NCT00712933|Experimental|2.|10 mg/kg dose of belimumab given IV every 28 days.
9911219|NCT00712946||1|Arteriosclerosis obliterans patients undergoing elective vascular surgery
9911220|NCT00712946||2|Healthy age-matched volunteers
9911221|NCT00712972||1|"Patients enrolled in this study are those whom present to our institution for elective knee arthroscopy. All patients scheduled to receive a knee arthroscopy scheduled through the office of Dr. Harold Battenfield will be asked to participate in the study on the day of their procedure as long as they do not fall into one of the exclusion criteria categories.~Patients will not be allowed to participate in this study if they have an allergy to iodine or shell fish, if they have a knee effusion diagnosed clinically on the day of surgery, if the knee or surrounding tissues display cellulitis or other signs of infection, or if the patient has had a traumatic accident to their knee which significantly changes its anatomical relationships"
9911222|NCT00712998||1|Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
9911223|NCT00712998||2|Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
9911224|NCT00712998||3|Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.
9911225|NCT00713011|Experimental|Arm 1|
9911226|NCT00713011|Active Comparator|Arm 2|
9911227|NCT00713024||1|Healthy control subjects
9911228|NCT00713024||2|Patients having neuropathic pain
9911229|NCT00713037|Experimental|(18F)-FMISO/CT|The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).
9911230|NCT00713050|Experimental|Experimental|Computer-based Aphasia therapy
9911231|NCT00713050|Active Comparator|Control|Control Arm - Healthy subjects.
9911232|NCT00713063|Experimental|1|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
9911233|NCT00713063|Active Comparator|2|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
9911234|NCT00713076|Experimental|1|Polyquaternium-preserved Multi-purpose solution
9911235|NCT00713089||1|75 subjects randomised into the placebo arm of an ongoing randomised double-blind placebo controlled clinical trial at National University Hospital, Singapore
9934007|NCT05078892||Adolescents (12-17)|Adolescents 12-17 with Turner Syndrome
9517584|NCT03305107|Experimental|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
9517585|NCT03305094|Active Comparator|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
9911236|NCT00713089||2|The expecting mothers visiting at the well mother clinics at Gadjah Mada University Hospital were invited to participate in the study
9911237|NCT00713102||1|The group includes 10189 patients with on board medical or surgical emergencies.
9911238|NCT00713141||1|Early breast cancer
9911239|NCT00713154|Placebo Comparator|1|Placebo group
9911240|NCT00713154|Active Comparator|2|Control Group
9911241|NCT00713167|Experimental|Grape Seed Extract|Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules
9911242|NCT00713167|Placebo Comparator|Placebo|Placebo enrolled patients who are randomly assigned to receive placebo of Grape Seed Extract
9911243|NCT00713180|No Intervention|1|Pterygium free participants
9911244|NCT00713180|Experimental|2|Pterygium participants
9911245|NCT00713193|Experimental|1|Patients in this arm will receive cyclosporine (Neoral) at a dose of 2-3 mg/kg orally as an adjunct to plasma exchange.
9911246|NCT00713193|Active Comparator|2|Patients in this arm will receive prednisone at a dose of 1 mg/kg as an adjunct to plasma exchange.
9911247|NCT00713232||test construction|university student living in Taiwan for more than 5 years No known neurological, psychiatric or speech language disorders
9911248|NCT00713232||normative data|normal subjects 20-80 y/o Living in Taiwan for at least 5 years No know neurological, psychiatric and speech-language disorders
9911249|NCT00713271|Experimental|1|Low dose
9911250|NCT00713271|Experimental|2|intermediate dose
9911251|NCT00713271|Experimental|3|high dose
9911252|NCT00713271|Placebo Comparator|4|
9911253|NCT00713297||Observation|Those who will use the new CPOE system
9911254|NCT00713336|Experimental|1|ZD4054 + Moxifloxacin placebo
9911255|NCT00713336|Active Comparator|2|ZD4054 placebo + Moxifloxacin
9911256|NCT00713336|Experimental|3|ZD4054 + ZD4054 placebo + Moxifloxacin placebo
9911257|NCT00713336|Placebo Comparator|4|ZD4054 Placebo + Moxifloxacin placebo
9911258|NCT00713362|Active Comparator|1|Surgery: Video-assisted thoracoscopic surgery
9911259|NCT00713362|Active Comparator|2|Chest tube drainage
9911260|NCT00713440|Experimental|1|10 healthy Caucasian subjects without family history of diabetes
9911261|NCT00713466||1|all third year medical students entering their pediatric clerkship at the Medical College of Wisconsin
9911262|NCT00713505|Experimental|Arm I (parent intervention program and usual care)|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care). Parents also receive 8 weekly face-to-face training sessions (75-90 minutes each) with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
9911263|NCT00713505|Active Comparator|Arm II (wait-list/usual care control [UCC])|Child participants and their families undergo usual care as in arm I and are placed on a wait-list.
9911264|NCT00713557||1|patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
9911265|NCT00713557||2|patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
9911266|NCT00713557||3|patients with non-ST-elevation ACS treated by immediate PCI
9911267|NCT00713557||4|patients with non ST-elevation ACS treated by elective PCI
9911268|NCT00713557||5|STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
9911269|NCT00713557||6|STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).
9911270|NCT00713570||A,1,II|
9911271|NCT00713622|Active Comparator|1|
9911272|NCT00713622|Active Comparator|2|
9911273|NCT00713635||1|Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
9911274|NCT00713635||2|Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
9911275|NCT00713635||3|Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
9911276|NCT00713635||4|Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
9911277|NCT00713674|No Intervention|1|No Treatment
9911278|NCT00713674|Experimental|2|Theraworx intranasal
9911279|NCT00713674|Active Comparator|3|mupirocin antibiotic ointment intranasal
9911280|NCT00713687|Experimental|1|Treatment by combination of photodynamic therapy and chemotherapy
9911281|NCT00713713|Experimental|1|Two different tidal volumes (6 and 12 ml.kg-1 of ideal weight) are alternatively delivered to patients 30 minutes each one. The order of the two tidal volumes is randomized. Between the two study tidal volumes, patient returns for 30 minutes to the tidal volume used before the study recruitment.
9911282|NCT00713726|Active Comparator|F|Patients that received continued infusion of fentanyl at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
9911283|NCT00713726|Experimental|T|Patients that received continued infusion of tramadol at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
9911284|NCT00713739|Experimental|1|Alfuzosin 10mg daily
9911285|NCT00713739|Active Comparator|2|Nifedipine XL 30mg daily
9911286|NCT00713739|Active Comparator|3|Doxazosin 4 mg daily
9911287|NCT00713739|Active Comparator|4|Prazosin 1 mg BID
9911288|NCT00713765|Experimental|A|AZD3480 + Donepezil
9911289|NCT00713778|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
9911290|NCT00713778|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel
9911291|NCT00713778|Active Comparator|3|Laparotomic ovarian cystectomy using suture
9911292|NCT00713791|Experimental|1|There are 5 variations of the ZD4054 (Zibotentan) 10mg tablet - A, B, C, D, and E. A minimum washout period of 1 week will occur between each treatment period.
9911293|NCT00713804|Experimental|GC|Genetic counseling (GC): One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
9911294|NCT00713804|Active Comparator|EB|Educational Booklet (EB): One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
9911295|NCT00713804|No Intervention|WT|Waitlist (WT)
9911296|NCT00713843|Experimental|1 Manual Therapy Utrecht|"Manual Therapy Utrecht (MTU) During the first consultation the manual therapist enquires about the complaints of the patient. The manual therapist conducts a number of measurements according to protocol. During treatment preferred movements are executed by the manual therapist in the patient's joints. The treatment techniques used by the manual therapist are very gentle mobilizations, without high velocity thrust techniques and are in general painless. In Manual Therapy Utrecht (MTU) it is common to give advices and recommend exercises.~A treatment session lasts between 30 and 60 minutes (repeated after one or two weeks). The maximum number of sessions is six.~The manual therapist has a minimum of five years of working experience."
9911297|NCT00713843|Active Comparator|2 Physical Therapy - Exercise Therapy|"The physical therapist conducts a complaint related function examination. Treatment consist of active exercises, manual traction or stretching and massage. The aims of active exercises are improvement of strength, mobility and movement coordination. Specific mobilization techniques are not a part of physiotherapeutic treatment. Treatment sessions take place no more than twice a week with a maximum of nine sessions (approximately 30 minutes) with a minimum of twenty minutes on active exercise therapy combined with instruction.~To prevent overlap with MTU (experimental arm), physical therapists are selected who are not (also) trained as manual therapists or have started this education.~The physical therapist has at least five years of working experience."
9911298|NCT00713856|Active Comparator|1|
9911299|NCT00713856|Active Comparator|2|
9911300|NCT00713869||1|Patients between the ages of 21 and 35 undergoing in-vitro fertilization will be included in this study.
9911301|NCT00713869||2|Recipients using only frozen donor eggs
9911302|NCT00713882||Observational|
9911303|NCT00713895|Active Comparator|Standard Self-Help|receive a standard self-help manual in Chinese and English of the participants' choice at baseline
9911304|NCT00713895|Experimental|Expert System|receive an expert system intervention that included the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
9911305|NCT00713934|Experimental|1|
9911306|NCT00713934|Experimental|2|
9911307|NCT00713947|Active Comparator|A|Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
9911308|NCT00713947|Experimental|B|Pantoprazole
9911309|NCT00713947|Placebo Comparator|C|Placebo
9911310|NCT00713960||1|Patients in secondary prevention of cardiovascular disease in primary care
9911311|NCT00713973||1|Submitted to the American protocol for prophylaxis of deep vein thrombosis
9667371|NCT03643848|Experimental|Sleep with Sound Cues|Sounds played at time of memory encoding will be replayed during sleep to cue memory processing.
9667372|NCT03643848|Sham Comparator|Sleep with Sham Cues|Sounds that were not played at time of memory encoding will be played during sleep as a sham comparison
9911312|NCT00713973||2|Submitted to the Brazilian protocol for prophylaxis of deep vein thrombosis
9911313|NCT00713973||3|Submitted to the SBCP modified protocol for prophylaxis of deep vein thrombosis
9911314|NCT00713986|Sham Comparator|Noanalgesia|Patients in this group wil receive 2 mL of water PO 2 minutes prior to vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
9911315|NCT00713986|Experimental|Skin-to-skin|Patients in this group wil receive 2mL of water 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
9911316|NCT00713986|Experimental|Glucose|Patients in this group wil receive 2mL of glucose 25% 2 minutes prior vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
9911317|NCT00713986|Experimental|Skin&Glucose|Patients in this group wil receive 2mL of glucose 25% PO 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
9934008|NCT05078892||Parents of Adolescents (12-17)|Parents of Adolescents (12-17)with Turner Syndrome
9934009|NCT05078892||Young Adults (18-25)|Young Adults (18-25)with Turner Syndrome
9934010|NCT05078879|Experimental|Treatment Arm|Patients with GCPC3 will receive daily Empagliflozin for 12 months.
9934011|NCT05078593|Experimental|HLX26 Group|The initial dose of HLX26 is 60 mg, and 5 dose levels are designed: 60 mg, 150 mg, 300 mg, 500 mg, and 800 mg (Q3W). Patients will receive the treatment until they have been in therapy for 2 years, develop progressive disease (PD) without any clinical benefit, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
9934012|NCT05076396|Experimental|PM14|Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
9934013|NCT05072483||Healthy controls|Healthy controls for exploratory analyses, where the measurements were not commonly performed previously in other populations, for qualitative comparison with CADASIL population
9934014|NCT05072483||Subjects with CADASIL|Adult genetically-confirmed patients with a wider range of CADASIL disease duration and debility
9934015|NCT05069948|Experimental|HeadOn intervention|Participants are given access to HeadOn - a web application that delivers a CBT programme to patients following concussion.
9934016|NCT05069636|Experimental|Lymphatic OMM plus Moderna COVID-19 Vaccine regimen|Patients receive OMM treatments that will include thoracic inlet and outlet myofascial release, pectoral traction myofascial release, and Miller Thoracic Lymphatic Pump technique plus the Moderna COVID-19 Vaccine regimen.
9934017|NCT05069636|Sham Comparator|Light Touch plus Moderna COVID-19 Vaccine regimen|Patients receive a series of light touch techniques plus the Moderna COVID-19 Vaccine regimen.
10212995|NCT04747314|Experimental|Antidepressant (AD) + Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will receive a combination of antidepressant medication and physical therapy for 8 months, in addition to their current opioid prescription and weaning guidelines, if applicable. No re-randomization will be done in this treatment group.
10214001|NCT02253316|Experimental|Maintenance Arm 2: Lenalidomide|Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
10214002|NCT02245230|Active Comparator|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
9667373|NCT03643744|Active Comparator|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
9667374|NCT03643744|Placebo Comparator|PDT + Placebo|Patient receiving PDT taking placebo.
9667375|NCT03643744|Active Comparator|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
9667376|NCT03643744|Placebo Comparator|Control + Placebo|Control subject not receiving PDT taking placebo.
9667377|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
9667378|NCT03641859|No Intervention|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 1 (usual care): the procedure of care will be the same as usual."
9798712|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ3|Participants who completed 015K-CL-RAJ3 (NCT02308163) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
9798713|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ4|Participants who completed 015K-CL-RAJ4 (NCT02305849) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
9798714|NCT01638052|No Intervention|0.25% Bupivacaine|This is our standard of care concentration
9798715|NCT01638052|Experimental|0.25% Bupivacaine + Clonidine|These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.
9798716|NCT01638312||HIV infection patient and health people|The study does not have intervention
9798717|NCT01638390|Other|Treatment of Myopia|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
9798718|NCT01638416|Active Comparator|Standard of care|Blood Transfusion Standard of care- oldest blood.
9798719|NCT01638416|Other|Arm B|Blood Transfusion Freshest blood.
9798720|NCT01638429|Experimental|Obese/overweight, prediabetic methane positive|Neomycin Rifaximin
9798721|NCT01638468|Experimental|AngioJet Ultra PE Thrombectomy System|Patients are treated with the AngioJet Ultra PE Thrombectomy System
9798722|NCT01638507|Other|Resolute Integrity|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
9798723|NCT01638546|Experimental|Arm I (veliparib and temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
9798724|NCT01638546|Active Comparator|Arm II (placebo and temozolomide)|Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
9798725|NCT01638559|Experimental|Immunosuppression withdrawal|Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
9798726|NCT01638819|Experimental|Autologous Cord Blood Stem Cells|
9798727|NCT01638819|Placebo Comparator|Placebo|Saline
9798728|NCT01639001|Experimental|Crizotinib|Crizotinib
9911318|NCT00713999|Experimental|STI/PZQ 1|Baseline and post-treatment follow-up (anti-STI and praziquantel Rx)
9911319|NCT00714012||1 Visualization users|End users of the domain specific visualizations.
9911320|NCT00714025|Experimental|I|40 patients with metastatic or locally advanced transitional bladder cancer with failed platinum-based chemotherapy receiving RAD001 10mg daily PO.
9911321|NCT00714038||1|Patients with asthma in primary care
9911322|NCT00714064|Active Comparator|23vPPV in Pregnancy|
9911323|NCT00714064|Active Comparator|23vPPV at Birth|
9911324|NCT00714064|Other|Control|Control
9911325|NCT00714077||adjuvant capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
9911326|NCT00714077||adjuvant oxaliplatin and capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
9911327|NCT00714090|Active Comparator|A|Double active comparator : venlafaxine (150 mg/day) and rTMS (5 times/week)
9911328|NCT00714090|Experimental|B|active rTMS (5 times/week) and sham venlafaxine (150 mg/day)
9911329|NCT00714090|Sham Comparator|C|sham rTMS (5 times/week) and active venlafaxine (150 mg/day)
9911330|NCT00714103|Experimental|8-Chloro-Adenosine|Starting dose for first cohort of patients 45 mg/m2 intravenous over 1 hr daily for 5 days every 4 weeks (± 3 days).
9911331|NCT00714116|Experimental|SBI-087|
9911332|NCT00714129|Experimental|1|Weight loss diet - normal diet
9911333|NCT00714129|Experimental|2|Weight loss diet - low in simple sugars (specifically fructose)
9911334|NCT00714142|Active Comparator|1|Normal volunteers
9911335|NCT00714142|Active Comparator|2|Renal failure patients on dialysis
9911336|NCT00714142|Active Comparator|3|Renal artery stenosis patients
9911337|NCT00714155||1|Physical examination, questionnaires, retrospective chart review
9911338|NCT00714155||2|Questionnaires, retrospective chart review
9911339|NCT00714155||3|Retrospective chart review
9911340|NCT00714194|Other|1|Patients in the control group will receive continuous sedative infusions without daily interruption of sedatives based on the standard clinical practice of the TICU.
9911341|NCT00714194|Experimental|2|Patients in the intervention group will receive daily interruption of sedative.
9911342|NCT00714207|Experimental|NOT Intervention|Students in this arm of the study were randomized to receive the reformatted NOT program
9911343|NCT00714207|Active Comparator|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
9911344|NCT00714207|Experimental|KB intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
9911345|NCT00714207|Active Comparator|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
9911346|NCT00714220||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911347|NCT00714220||Neurological Control|Subjects having been diagnosed with a non-ALS neurological condition
9911348|NCT00714220||Healthy Control|Subjects in good health without any neurological conditions
9911349|NCT00714246|Experimental|Phase I - Dose Level 1|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
9911350|NCT00714246|Experimental|Phase I - Dose Level 2A|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
9911351|NCT00714246|Experimental|Phase I - Dose Level 2B|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
9911352|NCT00714246|Experimental|Phase I - Dose Level 3|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
9911353|NCT00714246|Experimental|Phase I - Dose Level 4|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
9911354|NCT00714246|Experimental|Phase I - Dose Level 5|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
9911355|NCT00714246|Experimental|Phase II|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
9911356|NCT00714298|Other|1|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. Treating physicians, biologist physician will be blinded to the results of the markers.
9911357|NCT00714324||1|Paper screening
9911358|NCT00714324||2|Electronic screening
9911359|NCT00714337|Experimental|1|fasting state
9911360|NCT00714337|Experimental|2|fasting state
9911361|NCT00714337|Experimental|3|non-fasting state
9911362|NCT00714337|Experimental|4|fasting state
9911363|NCT00714337|Experimental|5|non-fasting state
9911364|NCT00714350||Simulator Group - With Display|ICU nurses who viewed the new ICU display visualization
9994551|NCT01482026|Experimental|Treated patients|Patients for whom ADHD treatment is introduced at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
9994552|NCT01482026|Experimental|Non treated patients|Patients for whom no ADHD treatment is required at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
9994553|NCT01482039|No Intervention|Standard Ultrasound|Current standard of care - one abdominal view of the cervix to rule out placenta previa
9994554|NCT01482039|Experimental|Sequential Screen|Start with 3 abdominal views of the cervix with measurement. If 3 adequate views cannot be obtained, or if measurement is less than 3cm, then will perform transvaginal scan for measurement.
9994555|NCT01482039|Experimental|Screening Transvaginal Ultrasound|Obtain 3 adequate cervical length measurements using transvaginal ultrasound
9994556|NCT01482052|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
9994557|NCT01482052|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
9994558|NCT01482078||Receive MgSO4 infusion|Parturients who present to the hospital at less than 34 weeks gestational age with potential pre-term labor, pre-term rupture of membranes or intrauterine growth restriction
9994559|NCT01482078||Do not receive MgSO4 infusion|"We will approach a control group of subjects: i.e. parturients undergoing cesarean section (elective or emergency) with neuraxial anesthesia.~We will seek to ensure that the control group is similar to the study group with respect to the following parameters:~Number of singleton or multiple pregnancy~Parity of parturients~Anesthetic technique (spinal or epidural)~Time of cesarean section (08:00-19:59 or 20:00 to 07:59) Once informed consent is obtained these subjects will be treated identically to the study group in terms of anesthetic management and data collection."
9994560|NCT01482104|Experimental|MAL-PDT re-treatment|1 treatment of MAL-PDT with re-treatment of non-complete responders
9994561|NCT01482104|Active Comparator|usual MAL-PDT|2 MAL-PDT treatments 1 week apart
9994562|NCT01482117|Active Comparator|Clopidogrel|single oral administration of 300mg of clopidogrel
9994563|NCT01482117|Active Comparator|Cilostarole|single oral administration of 100mg of cilostazole
9994564|NCT01482117|Active Comparator|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
9994565|NCT01482130|Experimental|Training group|All participants in the training group will pursue a 12 weeks of strength training.
9994566|NCT01482130|Other|Controls|The control group will be encouraged to follow a training program according to recommended exercise guidelines
9994567|NCT01482143|Experimental|All Study subjects|
9994568|NCT01482156|Experimental|RAD001 + BEZ235|Patients will receive first dose of RAD001 at 2.5mg/5mg/10 mg weekly or 2.5mg/5mg daily in combination of BEZ235 at 50 mg/100 mg/200 mg/300 mg/400 mg twice a day. In the initial cohort of the dose finding phase, patients will receive a single 2.5 mg dose of RAD001 on Cycle 1 Day 1 and the combination therapy of RAD001 2.5 mg/week and BEZ235 200 mg bid starting on Cycle 1 Day 8. Dose escalation phase: patients will start RAD001 and BEZ235 on Cycle 1 Day 1 with both study drugs being administered at the center. Dose expansion phase: the first 15 patients enrolled at selected sites will take RAD001 as monotherapy from Day 1 to Day 7 (for PK sampling). The combination therapy of RAD001 and BEZ235 will start on Day 8. All remaining patients will receive the combination therapy of RAD001 and BEZ235 starting on Cycle 1 Day 1.
9994569|NCT01482234|Experimental|pedometers only|Participants randomized to this arm will receive pedometers only. They will participate in baseline and 3 months data collection.
9994570|NCT01482234|Experimental|pedometers + prompts|Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
9994571|NCT01482234|Experimental|pedometer + prompt + messages|Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
9994572|NCT01482234|No Intervention|Control|Participants randomized to this group will participate in data collection only; they will not receive an intervention.
9994573|NCT01482247|Active Comparator|L-arginine|
9994574|NCT01482247|Placebo Comparator|Placebo Supplement|
9994575|NCT01482260||Primary Cutaneous Malignant Melanoma|
9994576|NCT01482260||Cutaneous Malignant Melanoma Metastases|
9994577|NCT01482260||Benign Melanocytic Nevi|
9994578|NCT01482273|Active Comparator|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
9994579|NCT01482273|Active Comparator|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
9994580|NCT01482299|Experimental|RAD001 (everolimus)|
9994581|NCT01482338|Experimental|DSG|The low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
9994582|NCT01482338|Active Comparator|DRSP|The other low-dose oral contraceptive pill which consists of 20 microgram ethinyl estradiol and 3 mg drospirenone were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
9994583|NCT01482364|Experimental|HOTMAN-driven therapeutic approach arm|"Hotman-driven therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System."
9911365|NCT00714350||Simulator Group - Without Display|"ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional spreadsheet style presentation of ICU trends of data"
9911366|NCT00714363|Active Comparator|1|LASIK
9911367|NCT00714363|Active Comparator|2|SBK
9911368|NCT00714376|Experimental|Docetaxel|Docetaxel (Taxotere) 75 mg/m² IV every 3 weeks for 8 cycles.
9911369|NCT00714402||a|children with proven of probable invasive bacterial infections
9911370|NCT00714428||Group 1: Item Development|Individuals with TBI to provide input to relevant questions for quality of life measure in TBI
9911371|NCT00714428||Group 2: Item Development|Clinicians who treat those with deployment related TBI to obtain their feedback on relevant questions pertaining to quality of life measures in TBI.
9911372|NCT00714428||Group 3: Instrument Development|Individuals with deployment TBI who will complete the Beta version of the TBI QOL measure.
9911373|NCT00714441|Active Comparator|2|Computer Automated Self-Management (CASM). Please see description below for CASM.
9911374|NCT00714441|Active Comparator|3|Computer Automated Self-Management and Problem Solving Therapy (CAPS). Please see descriptions below for CAPS (also refer to CASM with is included in the CAPS program).
9911375|NCT00714441|Active Comparator|1|Lifestyle and Activities Education Program (LEAP-AHEAD). Please see description below for LEAP-AHEAD.
9911376|NCT00714454|Active Comparator|APS|
9911377|NCT00714454|Placebo Comparator|Vehicle|
9911378|NCT00714467|Active Comparator|1|Expert system (stage-based manual and 3 individualized tailored feedback reports) only for smokers, paired-supporters (family or friend participant) do not receive any study intervention
9911379|NCT00714467|Experimental|2|Expert system (stage-based manual and 3 individualized tailored feedback report) to all the smoker participants; a family assisted intervention in a form of a self-help booklet that discusses specific strategies to work with smokers at each stage of change to the paired-supporters
9911380|NCT00714480|Other|Group I|Administration of anti-thymocyte globulin post-operative days -6,-4,-2, and 0
9911381|NCT00714480|Other|Group II|Administration of anti-thymoglobulin post-operative days -2, 0, 2 and 4
9911382|NCT00714480|Other|Group III|Administration of anti-thymocyte globulin post-operative days 0, 2, 4 and 6
9911383|NCT00714506|Experimental|Intervention|lifestyle weight reduction - low fat eating, low calorie and physical activity
9911384|NCT00714506|Active Comparator|Control|physical activity plus successful aging health education
9911385|NCT00714519|Experimental|1|
9911386|NCT00714519|Placebo Comparator|2|
9911387|NCT00714532|Active Comparator|1|Expert system only, which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months.
9911388|NCT00714532|Experimental|2|"The intervention consists of 3 components:~Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
9911389|NCT00714545|No Intervention|prospective study|This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug-eluting stents. Beta irradiation with a 40-mm strontium/yttrium-90 source. No placebo will be used in this trial.
9911390|NCT00714610||1|Unilateral or bilateral large head metal on metal primary total hip arthroplasty
9911391|NCT00714636||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911392|NCT00714636||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
9911393|NCT00714649|Other|I-1|"This is a phase I/II trial. PhaseI: The delay between the last administration of cetuximab and surgery will be progressively reduced. Five delay schedules are pre-defined before final administration of 3 preoperative doses of cetuximab with a 24-hour delay between the last dose of cetuximab and surgery. The cohort size is 3 patients per delay schedule, extended to 6 patients if one limiting toxicity is observed.~Phase II: will proceed if delay schedule V is safe. The patients included in delay schedule V of the Phase I part of the study will be involved in the phase II analysis. Recruitment of a total of 12 patients (3-6 of delay schedule V in phase I plus an additional 3-9 patients)."
9911394|NCT00714675|Experimental|1|Citrulline
9911395|NCT00714675|Active Comparator|2|Amino acids
9798729|NCT01639001|Active Comparator|Chemotherapy|Chemotherapy [Option at Investigator's Choice]
9911396|NCT00714701||High Risk Group 1|familial Peutz-Jeghers syndrome
9911397|NCT00714701||High Risk Group 2|familial pancreatic cancer relatives
9911398|NCT00714701||High Risk Group 3|germline mutation carriers BRCA1, BRCA2, PRSS, PALB2, p16
9911399|NCT00714701||High Risk Group 4|young-onset pancreatic cancer relative
9911400|NCT00714701||High Risk Group 5|both parents affected
9911401|NCT00714701||Control 1|negative controls
9911402|NCT00714701||Control 2|chronic pancreatitis
9911403|NCT00714701||Control 3|pancreatic cancer
9911404|NCT00714701||Control 4|intraductal papillary mucinous neoplasm (IPMN)
9911405|NCT00714727|Other|1|
9911406|NCT00714766|Experimental|A|
9911407|NCT00714779|Active Comparator|1|Fluoxetine
9911408|NCT00714779|Active Comparator|2|Short-term psychodynamic psychotherapy
9911409|NCT00714805||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911410|NCT00714805||Healthy Control|Subjects having no known ailment.
9911411|NCT00714818|Experimental|GC|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
9911412|NCT00714818|Active Comparator|EB|Educational Booklet: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants
9911413|NCT00714818|No Intervention|WT|Waitlist
9911414|NCT00714831|Active Comparator|CG|Control Group
9911415|NCT00714831|Experimental|IG|Intervention Group
9911416|NCT00714857|Experimental|1|Patients receiving dexmedetomidine sedation
9911417|NCT00714896|Other|1|Assessment only + referral list to State quitline and smoking cessation education classes at Kaiser
9911418|NCT00714896|Experimental|2|Participants will receive self-help information handouts, expert system intervention that includes a stage-based manual and individualized written feedback reports plus in-person brief stage-appropriate counseling at baseline and 3-month assessment. Current smokers who indicate desire to quit smoking or former smokers who indicate high cravings for cigarettes will be offered nicotine replacement medications. Participants will receive three telephone counseling sessions delivered between baseline and 3 month at weeks 2, 4 and 8. As-needed telephone check-calls will be provided to participants on and 2 days after quit date, or to participants who have quit smoking and anticipate high risk situations.
9911419|NCT00714909||1|
9911420|NCT00714922|Active Comparator|1|PRK
9911421|NCT00714922|Active Comparator|2|SBK
9911422|NCT00714935|Experimental|3|Decision Counseling Program(DCP) combined with Coronary Artery Disease Decision Aid (CAD-DA) described in Arm 2
9911423|NCT00714935|No Intervention|1|
9911424|NCT00714935|Experimental|2|"Behavioral: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
9911425|NCT00714961|Experimental|1|
9911426|NCT00714961|Placebo Comparator|2|
9911427|NCT00714974|No Intervention|1|Standard of care
9911428|NCT00714974|Experimental|2|Sedation based on BIS value, oer treating physician discretion.
9911429|NCT00714987||1: High level PEEP|
9911430|NCT00714987||2: Low level PEEP|
9911431|NCT00715000|Experimental|1|SRO
9911432|NCT00715000|Active Comparator|2|classical hydration via intravenous infusion
9911433|NCT00715039|Active Comparator|lorazepam|
9911434|NCT00715039|Placebo Comparator|placebo|
9911435|NCT00715039|Active Comparator|paroxetine|
9911436|NCT00715052|Experimental|1|40 consecutive one hour treatments at 1.5 ATA with 100% O2
9911437|NCT00715052|No Intervention|2|
9911438|NCT00715065||2|Healthy control subjects (who do not faint at the sight of blood)
9911439|NCT00715065||1|People who faint at sight of blood
9911440|NCT00715091|Experimental|1|continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
9911441|NCT00715091|Active Comparator|2|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
9911442|NCT00715143|Other|N|This treatment arm includes ceramic-on-ceramic hip device
9911443|NCT00715156||A|Subjects with mild (S1) reaction to peach fruit
9911444|NCT00715156||B|Subjects with severe reaction to peach fruit
9911445|NCT00715169|Active Comparator|1|
9911446|NCT00715169|Placebo Comparator|2|
9911447|NCT00715182|Experimental|TKI258|
9911448|NCT00715195|Experimental|1|Cognitive-behavioral therapy : 50 patients planned
9911449|NCT00715195|No Intervention|2|50 patients planned
9911450|NCT00715221||1|Normal Weight
9911451|NCT00715221||2|Obese without diabetes
9911452|NCT00715221||3|Obese with diabetes
9994584|NCT01482364|Placebo Comparator|Control arm|Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
9994585|NCT01482377|Experimental|Part A: RO5479599 Dose Escalation|Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
9994586|NCT01482377|Experimental|Part B: RO5479599 Dose Escalation + Cetuximab|Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
9994587|NCT01482377|Experimental|Part C: RO5479599 Dose Escalation + Erlotinib|Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599.
9994588|NCT01482377|Experimental|Imaging (IMG) Substudy|RO5479599 will be administered with zirconium- 89-labeled RO5479599.
9994589|NCT01482416|Experimental|Estrogen use|climacteric women will use conjugated equine estrogens
9994590|NCT01482416|Placebo Comparator|use of Placebo|climacteric women will use placebo
9994591|NCT01482442|Active Comparator|sorafenib group|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
9994592|NCT01482442|Active Comparator|radioembolization group|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
9994593|NCT01482455|Placebo Comparator|Clamp/Glycerol|"Glycerol infusion (glycerol in 0.9% saline provided by the pharmacy of the Vienna General Hospital, will be applied at a rate of 0.7 mg.kg-1.min-1) in order to match the lipid-induced rise in serum glycerol concentrations in the same experimental setting. 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
9994594|NCT01482455|Active Comparator|OGTT/Lipid|On study-day 1, four hours after start of a triglyceride/heparin infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
9994595|NCT01482455|Placebo Comparator|OGTT/Glycerol|On study-day 2, four hours after start of a glycerol infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
9911453|NCT00715234|Experimental|Reminder/recall notices for vaccines|This group will receive up to 4 recall messages (both letters and computer-generated phone messages) reminding them to get their vaccines. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
9911454|NCT00715234|No Intervention|Usual Care|This group will receive usual care. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
9911455|NCT00715247||Affected Population|Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
9911456|NCT00715247||Healthy Female Controls|Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
9911457|NCT00715260||UP Patients on HD|Uremic Pruritus (UP) patients maintained on hemodialysis (HD)
9911458|NCT00715273|Active Comparator|1 - single therapy group|Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
9911459|NCT00715273|Experimental|2 - double therapy group|Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
9911460|NCT00715273|Experimental|3 - triple therapy group|Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group
9911461|NCT00715286|Active Comparator|A|Conventional arm: primary surgery followed by chemotherapy
9911462|NCT00715286|Experimental|B|Neoadjuvant chemotherapy followed by interval debulking
9911463|NCT00715312|Experimental|A|
9911464|NCT00715325|Experimental|A|
10212996|NCT04747314|Experimental|AD -> EFAR|"Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months. Those re-randomized to receive EFAR for another 4 months will receive a combination of antidepressant medication and physical therapy, in addition to their current opioid prescription and weaning guidelines, if applicable."
10212997|NCT04747314|Experimental|EFAR -> AD|"Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months. Those re-randomized to receive AD for another 4 months will be under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks."
10212998|NCT04745624||manual compression cohort|Manual compression cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via manual compression
10212999|NCT04745624||VASCADE cohort|VASCADE cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via VASCADE device closure
10213000|NCT04740645||NOCDURNA cohort|
10213001|NCT04740645||Lower urinary tract symptoms (LUTS) Cohort|
10213002|NCT04740047||Pulmonary Nodule|Pulmonary nodule is suitable for elective bronchoscopy with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information or with suspected metastatic disease.
9911465|NCT00715351||A|
10213003|NCT04738617|Experimental|Warm-up based on small-sided games|Intervention A is based on football-specific small-sided games (SSGs), consisting of 4 versus 4 matches (with mini-goals), performed in a 30 m by 24 m court (Giménez et al., 2018), using five sets of 90 seconds of work interspersed with 30 seconds of pause, in a total duration of 10 minutes.
9911466|NCT00715351||B|
9911467|NCT00715364|Experimental|1|
10213004|NCT04738617|Experimental|Warm-up based on potentiation principles (e.g., speed, change of direction, plyometrics)|"Intervention B is based on speed, COD and plyometrics (i.e., a potentiation protocol), inspired by ideas presented by Howe, Coward, and Price (2017). Participants will perform five repetitions of the following exercises, in this order: unilateral hurdle hops and lateral hurdle hops with each lower limb; CMJ; broad jump; forward in and out; slalom jumps; lateral scissor jumps; single leg linear hops. Each intervention will last ~10 minutes and will be applied in the football field."
10213005|NCT04733222|Experimental|Perturbation training|"Participants randomized to the treadmill perturbation training will initially perform three sessions performed within a week followed by a booster-session after six months."
9911468|NCT00715364|Placebo Comparator|2|
9911469|NCT00715377|Experimental|1|
10213006|NCT04733222|Active Comparator|Treadmill walking|"Participants randomized to the walking group will undergo three initial sessions within a week and a booster-session after six months."
10213007|NCT04730193|Placebo Comparator|Control|Participants randomized to placebo group will receive placebo capsule
10213008|NCT04730193|Experimental|Caffeine|Participants randomized to caffeine group will receive 100mg caffeine capsule
10213009|NCT04725084||High Flow Nasal Cannula oxygen therapy treatment|Patients treated only by high flow nasal cannula oxygen therapy
10213010|NCT04725084||Non-Invasive Ventilation treatment|Patients treated by non-invasive ventilation (combined or not with HFNC)
9911470|NCT00715416|Experimental|1|primary nitinol stent placement of superficial femoral artery lesions
10213011|NCT04725084||Continuous Positive Airway Pressure treatment|Patients treated by continuous positive airway pressure (combined or not with HFNC)
10213012|NCT04725006|Experimental|Stimulation in individuals with implanted stimulation systems|During psychophysical stimulation trials, an external stimulator will be connected to the SCS lead, a volley of stimulation will be performed, and the subject will be asked to respond to standard psychophysical questions, as well as to provide any additional comments.
10213013|NCT04724161||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Changara, Guro, and Chemba districts.
10213014|NCT04723355|Experimental|QuoreOne|In this single arm of the study, the participant will use 2 Holter systems simultaneously for 24 hours, the QuoreOne system from QuoreTech and the Cardiolight system from Cardios.
10213015|NCT04721145|Experimental|Dexcom G6 Continuous Glucose Monitor|Children with type 1 diabetes will wear a continuous glucose monitor (CGM) for 10 days.
10213016|NCT04720872|Experimental|Experimental group|"Manual therapy: 4 sessions, 1 session per week (20 minutes approximately).~Physical therapist-directed vestibular rehabilitation: 4 weeks, 1 session per week with the physical therapist (30 minutes approximately), after manual therapy.~Home based vestibular rehabilitation: 4 weeks (2 sessions per day)."
10213017|NCT04720872|No Intervention|Control group|Home based vestibular rehabilitation: 4 weeks (2 sessions per day). The participants attended the center once a week to check correct execution of the exercises.
10213018|NCT04717765|Experimental|Preventive in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the first day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
10213019|NCT04717765|Active Comparator|Preventive in oral mucositis caused by chemo or radiotherapy - Vit E|"Topical Vit. E spray, from the first day to the last day, every day that the chemo or radiotherapy treatment is administered.~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
9934028|NCT05067933|Experimental|Part 1 Cohort 1a (Naïve, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
9934029|NCT05067933|Experimental|Part 1 Cohort 1b (Naïve, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
9934030|NCT05067933|Experimental|Part 1 Cohort 1c (Naïve, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
9934031|NCT05067933|Experimental|Part 1 Cohort 1d (Naïve, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
9934032|NCT05067933|Experimental|Part 1 Cohort 2a (Prior vaccinated, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
9934033|NCT05067933|Experimental|Part 1 Cohort 2b (Prior vaccinated, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
9934034|NCT05067933|Experimental|Part 1 Cohort 2c (Prior vaccinated, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
9934035|NCT05067933|Experimental|Part 1 Cohort 2d (Prior vaccinated, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
9934036|NCT05067933|Experimental|Part 2 Healthy Adults: Active vaccine|Repeat dose vaccinations with VXA-CoV2-1.1-S at dose selected from Part 1 in healthy male and female adult volunteers 18 to 75 years old
9934037|NCT05067933|Placebo Comparator|Part 2 Healthy Adults: Placebo control|Repeat dose administration with matching placebo tablets in healthy male and female adult volunteers 18 to 75 years old
9934038|NCT05067855|Experimental|Pilates exercise program group|The pilates exercise program group will perform five exercises
9934039|NCT05062083|Other|One arm|All particpants will receive the same tests
9934040|NCT05057702|Experimental|Individualized Treatment Recommendation|Participants will receive an individualized treatment recommendation including a combination of up to four FDA-approved drugs within 21 business days of tissue acquisition using the results of real-time high-throughput drug screening, whole exome sequencing (WES), and RNA sequencing.
9934041|NCT05055336|Experimental|Gastroparesis|Participants in this group are children diagnosed with gastroparesis per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
9934042|NCT05055336|Experimental|Dyspepsia|Participants in this group are children diagnosed with functional dyspepsia per gastric emptying scintigraphy. Participants will be receiving a gastric emptying breath test three times over the course of 6 months and an ultrasound of the stomach once.
9934043|NCT05055336|Experimental|Healthy Controls|Participants in this group are children that do not have gastroparesis, functional dyspepsia, or any other gastroenterology condition. Participants will be getting an ultrasound once.
9934044|NCT05052216||NORM|healthy children
9934045|NCT05052216||OSA|children with obstructive sleep apnea
9934046|NCT05050916|Experimental|1/High Dose Vitamin D|Deficient women will be randomized to either the IOM recommended RDA, 4,200 IU/week, or the Endocrine Society recommendation for deficiency, 50,000 IU/week.
9934047|NCT05050916|Experimental|2/Low Dose Vitamin D|Deficient women will be randomized to either the IOM recommended RDA, 4,200 IU/week, or the Endocrine Society recommendation for deficiency, 50,000 IU/week.
9934048|NCT05050916|Placebo Comparator|3/Placebo|Sufficient women who will receive placebo instead of Vitamin D supplementation.
9934049|NCT05050487|Experimental|treatment|patient will recieve pericapsular nerve group block
9934050|NCT05050487|Experimental|treatement|patient will receive lumbar erector spinae plane block
9934051|NCT05049798||Cohort 1: Guselkumab|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
10213020|NCT04717765|No Intervention|Preventive in oral mucositis caused by chemo or radiotherapy - mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the first to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
10213021|NCT04717765|Experimental|Curative in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy|"Application of LLL phototherapy from the tenth day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed.~Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point."
10213022|NCT04717765|Active Comparator|Curative in oral mucositis caused by chemo or radiotherapy - mucositis Vit E|"Topical Vit. E spray, application from the tenth day, and until the last day, every day that the chemo or radiotherapy treatment is administered.~Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day."
10213023|NCT04717765|No Intervention|Curative in oral mucositis caused by chemo or radiotherapy- mouthwash|Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the tenth to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.
10213024|NCT04717765|Experimental|Preventive osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + extraction|"For patients who need dental extraction for the adequacy of the oral cavity. Application of LLL phototherapy on the day the dental extraction is performed and every 72hr, totaling 5 applications. It must be done at least 3 months before the beginning of the chemo or radiotherapy treatment.~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of the root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
9911471|NCT00715416|Active Comparator|2|balloon angioplasty of superficial artery lesions with secondary stent placement in case of >30% residual stenosis after the procedure
9911472|NCT00715455|Active Comparator|Unfractionated Heparin|Unfractionated Heparin
9911473|NCT00715455|Experimental|REG1 Partial Rev.|REG1 with partial reversal
9911474|NCT00715455|Experimental|REG1 Total Rev.|REG1 with total reversal
9911475|NCT00715494|No Intervention|Group 1 - Control|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
9911476|NCT00715494|Experimental|Group 2 - Intervention|Participants in the experimental group will receive a focused set of interdisciplinary home-based interventions over a 12 week period.
9911477|NCT00715507||1|For the phase of the study in which the utility of the graphical medication monitor is assessed, the monitor will not be shown to anesthesiologists placed in the control condition.
9911478|NCT00715507||2|In the experimental condition, anesthesiologists will be shown the medication monitor to aid their expertise and decision-making.
9911479|NCT00715572|Active Comparator|A|
9911480|NCT00715572|Active Comparator|B|
9911481|NCT00715585|Active Comparator|Active Control|patients receive 3 individualized visits with a health educator for education on general diabetes and health promotion
9911482|NCT00715585|Experimental|Intervention 1|patients receive 3 individualized visits with an rd-cde for education focused on modified plate method
9911483|NCT00715585|Experimental|intervention 2|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
9911484|NCT00715598||Neuropathic Pain|Subjects in this group experience chronic neuropathic pain.
9911485|NCT00715598||Musculoskeletal Pain|Subjects in this group experience chronic musculoskeletal pain.
9911486|NCT00715637|Experimental|Arm A|Amonafide in Combination with Cytarabine
9911487|NCT00715637|Active Comparator|Arm B|Daunorubicin in Combination with Cytarabine
9911488|NCT00715663||A|
9911489|NCT00715689|Experimental|A|
9911490|NCT00715689|Experimental|B|
9911491|NCT00715689|Experimental|C|
9911492|NCT00715689|Experimental|D|
9911493|NCT00715702|Experimental|1|Patients with Moderate renal impairment and matched volunteers
9911494|NCT00715702|Experimental|2|Patients with Mild or Severe renal impairment and matched volunteers. Type of patient group determined after safety review of 1st group data
9911495|NCT00715715|No Intervention|1|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients not treated with steroids: The patients will receive 6 weeks of sugar pills (placebo) before taking Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
9911496|NCT00715715|Experimental|2|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
9934052|NCT05049798||Cohort 2: Interleukin-17 inhibitor (IL-17i)|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
9934053|NCT05047354||Disorders of cholesterol synthesis and metabolism|Disorders of cholesterol synthesis and metabolism
9934054|NCT05047354||Smith-Lemli-Opitz syndrome|Smith-Lemli-Opitz syndrome
9934055|NCT05045677|Experimental|Digital DBT intervention group|Digital intervention group plus standard care
9934056|NCT05045677|Active Comparator|Standard care|Standard care alone
9934057|NCT05044780||Cohort 1/SARS-CoV-2 positive|Participants with molecular testing positive for SARS-CoV-2
9934058|NCT05044780||Cohort 2/SARS-CoV-2 negative|Participants with molecular testing negative for SARS-CoV-2
9934059|NCT05043324|Experimental|AIDS, HIV, HBV, HCV, co-infections.|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.
9934060|NCT05043324|Experimental|"stable cancer, acquired or congenital immunodeficiency."|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.
9934061|NCT05042219||COPD (ICS)|COPD before initiation of inhaled corticosteroid therapy
9934062|NCT05042219||COPD (LTOT-NIV)|COPD before initiation of long term oxygen therapy or domiciliary long-term non-invasive ventilation
9934063|NCT05042219||COPD (Roflumilast )|COPD before initiation of Roflumilast therapy
9934064|NCT05042219||Bronchial asthma (antibody)|Bronchial asthma before initiation of antibody therapy
9934065|NCT05042219||Bronchial asthma (ICS)|Bronchial asthma before initiation of inhaled corticosteroid therapy
9934066|NCT05042219||Pulmonary fibrosis|Pulmonary fibrosis before initiation of antifibrotic therapy
9934067|NCT05041972|Experimental|Cohort 1: HER2 Mutated Non-Small Cell Lung Cancer (NSCLC)|Intervention: Drug: ARX788
9934068|NCT05041972|Experimental|Cohort 2: HER2 Mutation Breast Cancer|Intervention: Drug: ARX788
9934069|NCT05041972|Experimental|Exploratory Cohort A: Other HER2-Mutated tumors|Intervention: Drug: ARX788
9934070|NCT05041972|Experimental|Cohort 3: HER2 Amplification Biliary Tract Cancer (BTC)|Intervention: Drug: ARX788
9934071|NCT05041972|Experimental|Cohort 4 HER2 Amplification Colorectal (CRC), Ovarian Endometrial, NSCLC, and other solid tumors|Intervention: Drug: ARX788
9934072|NCT05041972|Experimental|Cohort 5: HER2 Mutation or HER2 Amplification Solid Tumors|Intervention: Drug: ARX788
9934073|NCT05041387||1|patients, male or female, who are age 18 or older, diagnosed or suspected of having a neuromuscular disorder or neurodegenerative disorder.
9934074|NCT05041374||Study Cohort|Patients with known or suspected gastrointestinal disease
9934075|NCT05041231|Sham Comparator|Sham (group A)|Treatment procedure performed with the device that will not provide the bioactive light (laser)
9934076|NCT05041231|Experimental|PBT (group B)|Treatment procedure performed with the device that will provide the bioactive light (laser)
9934077|NCT05039359|Active Comparator|FlecIH-103 (flecainide acetate inhalation solution)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1. Dosing will continue until conversion of AF to SR is observed for ≥1 minute or the full dose (120 mg eTLD) is administered, whichever occurs first.
9934078|NCT05039359|Placebo Comparator|Vehicle-matched inhalation solution (placebo)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1.
9934079|NCT05037266|Experimental|55 - 64 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
9934080|NCT05037266|Experimental|At least 65 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
9934081|NCT05036915|Experimental|Control group (Pacifier randomly 30 min)|Pacifier is randomly given to the infant for 30 min independent from feeding during the day
9911497|NCT00715780||A|
9911498|NCT00715806|Experimental|1|
9911499|NCT00715806|Active Comparator|2|
9911500|NCT00715845|Experimental|2|
9911501|NCT00715858|Active Comparator|1 AD doxycycline + rifampin|Participants with AD allocated to doxycycline 100 mg bid od and rifampin 300 mg od for 12 months
9911502|NCT00715858|Active Comparator|2 AD doxycycline|
9911503|NCT00715858|Active Comparator|3 AD rifampin|Participants with AD allocated to rifampin 300 mg od od and placebo matched to doxycycline bid for 12 months
9911504|NCT00715858|Placebo Comparator|4 AD placebo|Participants with AD allocated to placebo matched to doxycycline and placebo matched to rifampin for 12 months
9911505|NCT00715858|No Intervention|5 Control|Age-matched cognitively healthy participants (untreated)
9911506|NCT00715871|Experimental|Active Smokers|Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.
9911507|NCT00715897|Experimental|Treatment- HBOT|HBOT treatment: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
9911508|NCT00715897|No Intervention|control-HBOT|Cross group: Patients in the cross group were evaluated three times-baseline, after 2 months control period of no treatment and after a consequent 2 month of HBOT
9911509|NCT00715923|Experimental|1|Modified consent form
9911510|NCT00715923|Active Comparator|2|Standard consent form
9911511|NCT00715936|Active Comparator|Control|Routine services for infants and young children delivered by the Lady Health Workers of the National Programme for Family Planning and Primary Healthcare (Basic Health and Nutrition Education and Services)
9911512|NCT00715936|Experimental|ECD Group|Stimulation and care for development (plus basic health and nutrition education and services)
9911513|NCT00715936|Experimental|Enhanced Nutrition|Care for Nutrition: Enhanced education messages and Sprinkles for children aged 6-24 months (plus basic health and nutrition education and services)
9911514|NCT00715936|Experimental|ECD and Enhanced Nutrition|Stimulation and care for development and care for nutrition (plus basic health and nutrition education and services)
9911515|NCT00715975|Experimental|1|The patients will be treated with halobetasol once a day for 15 days.
9911516|NCT00715975|Experimental|2|The patients will be treated with clobetasol once a day for 15 days.
9911517|NCT00715988|Experimental|Scheme 1|Patients who are feeding or not feeding and mechanically ventilated, >/=3 d of age and 29 0/7wks-48 6/7 wks PMA, treated with i.v. bolus doses or infusion of fentanyl, morphine or methadone for clinical indications, with arterial/venous line in place & expected treatment for at least 1-2 more days. Pk sampling = 0.5 ml blood samples x6/infant. ECG monitoring. Three patients will be enrolled in 5 PMA groups. Should apnea or hypotension occur, dosages for Treatment Scheme 2 will be reduced (50%); more patients will be studied in Treatment Scheme 1 to insure that the lower dose is well tolerated & effective.
9911518|NCT00715988|Experimental|Scheme 2|Patients defined in Scheme 1, tolerating feeds for >/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..
9911519|NCT00716001|Active Comparator|NAC|
9911520|NCT00716001|Placebo Comparator|nonNAC|
9911521|NCT00716014|Active Comparator|Foot 1|An active drug injection of TD101 is injected into a callus on the bottom of one foot.
9911522|NCT00716014|Placebo Comparator|Foot 2|An injection of placebo (normal saline) is injected into a callus on the bottom of one foot.
9911523|NCT00716027|Active Comparator|1|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
9911524|NCT00716027|Experimental|2|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
9911525|NCT00716040|Experimental|Intervention|The intervention group will be submitted to four social-psychological individual sessions with a pre-trained health professional.
9911526|NCT00716040|Other|Control|The control group will be submitted to the usual care of the health service.
9911527|NCT00716053|Experimental|BLVR|
9911528|NCT00716053|Sham Comparator|Saline|
9911529|NCT00716105|Placebo Comparator|Control|Standard Infant Formula
9911530|NCT00716105|Experimental|Test Product|Infant formula with different level of proteins
9911531|NCT00716105|No Intervention|Breast Milk|Breastfeeding reference group
9911532|NCT00716118||1|IVF patients.
9911533|NCT00716131||ALS|Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
9911534|NCT00716131||Neuro|Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
9911535|NCT00716131||Healthy|Normal Controls
9911536|NCT00716131||Autopsy|
9911537|NCT00716157||Observation|Adult patients receiving both radiation therapy and chemotherapy
9911538|NCT00716170||A:|Patients with type 2 diabetes mellitus
9911539|NCT00716183|Experimental|Probiotic 1|Women receiving Lactobacillus salivarius HN6
9911540|NCT00716183|Experimental|Probiotic 2|Women receiving Lactobacillus reuteri CR20
9911541|NCT00716183|Experimental|Probiotic 3|Women receiving Lactobacillus fermentum LC40
9911542|NCT00716183|Active Comparator|beta-lactam|The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist
9911543|NCT00716209||1|Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)
9911544|NCT00716222||1|Obese adolescent and young adult with sleep disorder
9911545|NCT00716222||2|Obese adolescent and young adult without sleep disorder
9911546|NCT00716222||3|Lean adolescent and young adult with sleep disorder
9911547|NCT00716235||DCD|Children with a diagnosis of DCD
9911548|NCT00716235||Autism|Children with a diagnosis of Autism disorder
9911549|NCT00716235||ADHD|Children with a diagnosis of ADHD
9911550|NCT00716235||Control|Control group - children with no neurological or psychiatric problems
9911551|NCT00716248|Experimental|1|
9911552|NCT00716248|Active Comparator|2|
9911553|NCT00716287||1|Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.
9911554|NCT00716300||1|obese and insulin resistant subjects
9911555|NCT00716300||2|lean and normolipidaemic subjects
9911556|NCT00716326|Active Comparator|1|Subjects in this study arm will receive active treatment with Cefar TENS device which delivers therapeutic electrical currents 2-3x over sensory threshold in the area of pain.
9911557|NCT00716326|Placebo Comparator|2|Subjects in this study arm will receive placebo treatment with manipulated Cefar TENS device which delivers electrical currents just below sensory threshold in the area of pain.
9911558|NCT00716339|Active Comparator|1|motivated
9911559|NCT00716339|No Intervention|2|control
9911560|NCT00716365|Experimental|HemCon|"The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis.~The HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will be used to shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's."
9911561|NCT00716391|Active Comparator|Group A|TPF plus concomitant treatment with cisplatin and conventional radiotherapy.
9911562|NCT00716391|Experimental|Group B|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
9911563|NCT00716404||1|All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.
9911564|NCT00716430|Active Comparator|QI|Quality Improvement Centres
9911565|NCT00716430|No Intervention|Non-QI|No Quality Improvement Programme
9911566|NCT00716469|Experimental|LS11 Administration|"Treatment will be given with a standard 3+3 light dose escalation. The Treatment Period will be 28 days. The LS11 dose will be 30mg/m2. The initial light dose will be 50 J/cm. If criteria for dose escalation are met, then the light dose will be escalated to 100J/cm, 150J/cm and 200J/cm. Once the maximum light dose is determined, up to 6 additional patients will be treated at that level to gain further experience with this modality prior to phase II testing. In particular, at least 3 subjects <12 years of age will be enrolled at the maximum tolerable dose (MTD) to allow for further evaluation of safety in younger children. If grade 3 or 4 toxicities are noted at light dose level #1, the LS11 dose will be decreased to 20mg/m2 (2/3 of the standard dose)."
9911567|NCT00716508|Active Comparator|A|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
9911568|NCT00716508|Active Comparator|B|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
9911569|NCT00716521|Placebo Comparator|Placebo|groups of 3-4 subjects for overnight polysomnography assessments
9911570|NCT00716521|Experimental|Low dose Zolpidem|
9911571|NCT00716521|Experimental|High dose zolpidem|
9911572|NCT00716547|Experimental|1|
9911573|NCT00716547|Experimental|2|
9911574|NCT00716547|Active Comparator|3|
9911575|NCT00716547|Placebo Comparator|4|
9911576|NCT00716560||A|Metastatic melanoma treatment with Dartmouth regimen
9911577|NCT00716573|Experimental|1|Introduction of everolimus associated with CNI (ciclosporin or tacrolimus) reduction (50%) to the current immunosuppression schedule
9911578|NCT00716573|No Intervention|2|Maintain of their current immunosuppressive therapy
9911579|NCT00716599|No Intervention|Control|Health centers continue with standard-of-care empiric case management
9911580|NCT00716599|Experimental|RDT training|Health centers randomly selected to receive training and RDTs, for use in routine patient case management
9911581|NCT00716612|Placebo Comparator|2|PO Placebo QD
9911582|NCT00716612|Experimental|1|PO Coenzyme Q 10 QD
9911583|NCT00716638|Experimental|Treatment group 1|Trauma-focused Cognitive Behavior Therapy (TF-CBT)
9911584|NCT00716638|Experimental|Treatment group 2|Eye Movement Desensitization and Reprocessing (EMDR)
9911585|NCT00716664|Experimental|1|The experimental group receives the intervention in addition to normal optimal care
9911586|NCT00716664|Active Comparator|2|The active comparator, or control group, receives normal optimal care only
9911587|NCT00716677||1|
9911588|NCT00716677||2|
9911589|NCT00716690|Experimental|treatment|
9911590|NCT00716703|Experimental|1|cohort = pediatric patients in the ED (3-18 yo) with abdominal pain suspicious for appendicitis that are to undergo CT scan
9911591|NCT00716716|Experimental|rFIXFc|Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg
9911592|NCT00716729||Pateints with longstanding hip and/groin pain|
9911593|NCT00716755|Experimental|Dose Reduction|See Intervention
9911594|NCT00716768|Active Comparator|Laparoscopic Inguinal Hernia Repair|
9911595|NCT00716768|Active Comparator|Open Inguinal Hernia Repair|
9911596|NCT00716781||1 (first year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed according to the CDC protocol. Blood cultures and CBC were performed and the infant was observed for 48 hours. Participating hospital were free to perform any additional test, such as CRP, MiniESR, etc
9911597|NCT00716781||2 (second year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed with clinical observation only. Clinical surveillance was based on 3 signs: 1. Skin appearance (pink, pale, mottled, cyanotic); 2. Respiratory rate (>50 or <50 breaths per minute); 3. Dyspnea (Yes / No)
9911598|NCT00716833|Active Comparator|Preemptive|Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
9911599|NCT00716833|Placebo Comparator|Postoperative|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.
9911600|NCT00716846|Active Comparator|statin-1|simvastatin
9911601|NCT00716846|Active Comparator|statin-2|atorvastatin
9911602|NCT00716846|Active Comparator|statin-3|pitavastatin
9911603|NCT00716872|Experimental|ImmedSHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
9911604|NCT00716872|Experimental|ImmedSHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
9911605|NCT00716872|Experimental|DelaySHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
9911606|NCT00716872|No Intervention|DelaySHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
9911607|NCT00716885||CHF|"Informed consented participants are recruited among all patients admitted to the OLVG hospital.~Inclusion criteria:~Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy~Dyspnoe NYHA class III and IV~Optimal and constant heart failure treatment according to the ESC guidelines~Exclusion criteria:~Renal failure (creatinine >1.70 mg/dl)~Signs of infection or inflammation"
9911608|NCT00716885||Control|The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.
9911609|NCT00716898||1|"A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.~B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.~C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent"
9911610|NCT00716898||2|"A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.~B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent"
9911611|NCT00716924|Experimental|1|300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
9911612|NCT00716924|Experimental|2|600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
9911613|NCT00716924|Experimental|3|600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
9911614|NCT00716937|Experimental|1|Excision of the cyst and Karydakis flap
9911615|NCT00716937|Experimental|2|Excision of the cyst and laying open
9911616|NCT00716950|Experimental|1|valsartan/amlodipine
9911617|NCT00716950|Active Comparator|2|losartan/amlodpine
9911618|NCT00717002||1|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
9911619|NCT00717002||2|Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
9911620|NCT00717080|Experimental|Arm 1|IOL surgery with Capsular Tension Ring
9911621|NCT00717080|Placebo Comparator|Arm 2|IOL surgery without Capsular Tension Ring
9911622|NCT00717119||1|Patients with sprain of ankle treated with NSAID
9911623|NCT00717132|Experimental|Individual Behavioral Modification|Individual behavioral weight control treatment; parent and child are treated separately for 15 total sessions.
9911624|NCT00717132|Active Comparator|Family-based Behavioral Modification|Family-based behavioral weight control treatment; parent and child are treated together for 15 total sessions.
9911625|NCT00717145|Experimental|1|One risedronate 20 mg DR tablet taken following an overnight fast, followed by a 4-hour fast.
9911626|NCT00717145|Experimental|2|One risedronate 20 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
9911627|NCT00717145|Experimental|3|One risedronate 35 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
9911628|NCT00717145|Experimental|4|One risedronate 35 mg IR tablet taken following an overnight fast, 30 minutes before ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
9911629|NCT00717158|No Intervention|I|Usual medical care. They received written healthy lifestyle information
9911630|NCT00717158|Active Comparator|2|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
9911631|NCT00717171|Placebo Comparator|1|
9911632|NCT00717171|Experimental|2|
9911633|NCT00717210|Active Comparator|A|Conventional Radiotherapy
9911634|NCT00717210|Experimental|B1/2|1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)
9911635|NCT00717223||Parents with children with diabetes|parents who have children 18 or younger with diabetes
9911636|NCT00717262|Experimental|1|HQK-1001
9911637|NCT00717262|Placebo Comparator|2|
9911638|NCT00717301||Head Trauma|Patients presenting to any of the AHCC/ERNES Emergency Departments with head trauma.
9911639|NCT00717301||Control subjects|Patients presenting to the Univ of Rochester Medical Center/Strong Memorial Hospital Outpatient Laboratory for routine blood draw.
9911640|NCT00717340|Experimental|tivozanib (AV-951) + paclitaxel|
9911641|NCT00717353||1|Lung cancer
9911642|NCT00717379|Active Comparator|1|steroid regimen 1
9911643|NCT00717379|Experimental|2|steroid regimen 2
9911644|NCT00717392||Hippotherapy_ADHD|10 children with ADHD who receive hippotherapy
9798730|NCT01639040|Experimental|Placebo QW|Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
9798731|NCT01639040|Experimental|Dupilumab 300 mg QW|Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days
9798732|NCT01639144|Active Comparator|Receiving PRP and PPP.|Administration of PRP and PPP to surgical site.
9798733|NCT01639144|No Intervention|Control|Group not receiving autogenous PRP and PPP.
9798734|NCT01639157|Experimental|Buspirone|Subjects will be maintained on 30 mg buspirone daily.
9798735|NCT01639157|Placebo Comparator|Placebo|Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).
9798736|NCT01639222|Experimental|Calcium 500 mg and Vitamin D3 800 IU|"Period 1: Low calcium meals for up to 3 days.~Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals."
9798737|NCT01639339|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
9798738|NCT01639339|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
9798739|NCT01639352|Experimental|SOM230|60mg of SOM230 via injection intramuscularly every 28 days
9798740|NCT01639443|Experimental|Fast-tracked|"'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots."
9798741|NCT01639443|No Intervention|Control|Patients who are scheduled routinely
9798742|NCT01639469|Experimental|Structured exercise|Structured exercise instruction by smartphone
9798743|NCT01639469|Active Comparator|lifestyle exercise|Lifestyle exercise program taught via smartphone
9798744|NCT01639495|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
9798745|NCT01639560|Active Comparator|Varenicline|1 mg of varenicline twice per day for 12 weeks.
9798746|NCT01639560|Placebo Comparator|placebo|1 placebo tablet twice a day for 12 weeks
9798747|NCT01639599|Placebo Comparator|dexamethasone|dexamethasone 5mg iv during anesthesia induction
9798748|NCT01639599|Active Comparator|dexamethasone, haloperiol 1mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 1mg iv 30 min before end of anesthesia
9798749|NCT01639599|Active Comparator|dexamethasone + haloperidol 2mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 2mg iv 30 min before end of anesthesia
9798750|NCT01639664|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
9798751|NCT01639664|No Intervention|Control group|standard practice
9798752|NCT01639703|Experimental|CT perfusion|arm with CT perfusion
9798753|NCT01639729|Experimental|Sequence 1 - Treatment A, B, C, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral
9798754|NCT01639729|Experimental|Sequence 2 - Treatment A, B, D, C|15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal
9798755|NCT01639729|Experimental|Sequence 3 - Treatment A, C, B, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral
9798756|NCT01639729|Experimental|Sequence 4 - Treatment A, C, D, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual
9798757|NCT01639729|Experimental|Sequence 5 - Treatment A, D, B, C|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal
9798758|NCT01639729|Experimental|Sequence 6 - Treatment A, D, C, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual
9798759|NCT01639742|Experimental|All Participants|All participants who had new texture round breast implants surgically implanted.
9798760|NCT01639755|Experimental|All Participants|Al participants who had new texture shaped breast implants surgically implanted.
9798761|NCT01639833|Experimental|Veriset Hemostatic Patch|Topical Hemostat
9798762|NCT01639833|Active Comparator|TachoSil®|Topical Hemostat
9798763|NCT01639872|Experimental|Clozapine|The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.
9798764|NCT01639872|Active Comparator|Risperidone|The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.
9798765|NCT01640054|Experimental|Dosing regimen|Open label Oral treatment 100mg once daily
9798766|NCT01640171|Other|Top Anesthesia 1 Eye SC Lidocaine 1 Eye|"One eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Acuvail Intra-vitreal Anti-VEGF Drug~Fellow Eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Xylocaine 2% Injectable Anesthetic Acuvail Intra-vitreal Anti-VEGF Drug"
9798767|NCT01640184|Active Comparator|Active vitamin D|Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in Kidney Developement Improvement Global Outcomes (KDIGO) guidelines.
9798768|NCT01640184|Experimental|Ultrasonic ablation|Patients in Ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequency ablation.
9911645|NCT00717392||Hippotherapy_ASD|10 children with ASD who receive hippotherapy
9911646|NCT00717392||Control_ADHD|10 children with ADHD who DO NOT receive hippotherapy
9911647|NCT00717392||Control_ASD|10 children with ASD who DO NOT receive hippotherapy
9911648|NCT00717431|Experimental|Hippocampal Stimulation|Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
9911649|NCT00717431|Sham Comparator|Hippocampal Implantation|Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
9911650|NCT00717444|Experimental|1|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
9911651|NCT00717444|Experimental|2|contingency management for abstinence plus 12-step facilitation therapy
9911652|NCT00717470|Active Comparator|Prograf + MMF + Steroids|oral
9911653|NCT00717470|Active Comparator|Advagraf (dose 1) + MMF + steroids|oral
9911654|NCT00717470|Active Comparator|Advagraf (dose 2) + MMF + steroids|oral
9911655|NCT00717470|Active Comparator|Advagraf + MMF + Basilixmab + steroids|oral
9911656|NCT00717483||Type 1 diabetes|children with type 1 diabetes
9911657|NCT00717496|Experimental|A|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. This group will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
9911658|NCT00717496|No Intervention|B|Mothers assigned to the control group will receive usual care. This group will also receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream.
9911659|NCT00717509||clozapine group|"chronic schizophrenia~have been taking clozapine at leaset one year~without diabetes, pulmonary tuberculosis"
9911660|NCT00717548|Experimental|A|
9911661|NCT00717561|Experimental|Arm 1|
9911662|NCT00717561|Active Comparator|Arm 2|
9934082|NCT05036915|Experimental|Experimental Group (Pacifier randomly 30 min+ routine 5 min before each feeding)|Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.
9934083|NCT05035420|Experimental|Healthy Volunteer|Healthy Volunteer
9934084|NCT05035407|Experimental|Treatment at dose levels 1 through 7|Non-myeloablative, lymphocyte depleting preparative regimen, followed by KK-LC-1 TCR T cells plus aldesleukin at escalating doses
9934085|NCT05033990||Healthy Controls|Participants with no smoking history (< 100 cigarettes in lifetime); post-bronchodilator FEV1/FVC > 0.70; post-bronchodilator FEV1 > 80% predicted; and post-bronchodilator FVC > 80% predicted.
9934086|NCT05033990||Gold 0|"Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC > 0.70 and FEV1 > 80% predicted.~GOLD stands for the Global initiative for Chronic Obstructive Lung Disease."
9934087|NCT05033990||Preserved Ratio Impaired Spirometry (PRISm)|Participants with with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC > 0.70 and FEV1 < 80% predicted.
9934088|NCT05033990||Gold 1 - 2|Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-80% predicted.
9934089|NCT05033080|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
9934090|NCT05033080|Active Comparator|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
9934091|NCT05031507||1|Subjects with rare skeletal disorders
9934092|NCT05030766|Experimental|MT plus NRT Group|Participants who receive the Mindfulness Training (MT) intervention for 4 weeks in addition to 6 weeks of Nicotine Replacement Therapy (NRT).These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
9911663|NCT00717600|Experimental|1|Oral probiotics
9911664|NCT00717613||1|Observational cohort study
9911665|NCT00717639|Experimental|1|single arm study, all patients will undergo Vasovist-enhanced MRA
9911666|NCT00717652|Experimental|1|arbutin, tretinoin, triamcinolone
9911667|NCT00717652|Active Comparator|2|Triluma
9911668|NCT00717665|Experimental|A, 1, I|
9911669|NCT00717665|Active Comparator|A, 2, I|
9911670|NCT00717678|Experimental|Prograf-XL + MMF|
9911671|NCT00717678|Active Comparator|Prograf + MMF|
9911672|NCT00717691|Experimental|1|Immediate fitting with dynamic splinting following diagnosis of hallux limitus.
9911673|NCT00717691|No Intervention|2|Control arm; patients only treated with standard of care following diagnosis of hallux limitus.
9911674|NCT00717704|Experimental|1|All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.
9798769|NCT01640184|Active Comparator|Parathyroidectomy|Patients in parathyroidectomy group will be treated by parathyroid surgery.
9798770|NCT01640197|Placebo Comparator|Placebo|Methyl Cellulose administered in identical capsules as the active.
9798771|NCT01640197|Active Comparator|500mg resveratrol|Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
9798772|NCT01640249|Placebo Comparator|Placebo|Participants received placebo capsule orally with approximately 200 to 300 milliliter (mL) of room temperature water in the morning.
9798773|NCT01640249|Experimental|LY3006072|Participants received LY3006072 capsules starting at 1 milligram (mg) and escalating doses of 3 mg, 10 mg, 20 mg and 40 mg.
9798774|NCT01640288|Other|Normal Subjects|Subjects with Normal Lung Function by Pulmonary Function Tests (e.g. Spirometry) with or without smoking as a risk factor (non-smokers, ex-smokers, current smokers)
9798775|NCT01640288|Other|Subjects with COPD|Subjects diagnosed with COPD by GOLD criteria.
9798776|NCT01640314|Experimental|Cell derived subunit trivalent nonadjuvanted vaccine|
9798777|NCT01640327|Experimental|TIVf|
9798778|NCT01640340|Experimental|Arm I (palonosetron hydrochloride)|Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.
9798779|NCT01640340|Experimental|Arm II (ondansetron)|Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.
9798780|NCT01640366|Experimental|PICO negative pressure|Single-use Negative Pressure Wound Therapy
9798781|NCT01640366|No Intervention|Standard of care dressing arm|Sterile gauze adhesive strips
9798782|NCT01640379|Experimental|TECH-N|Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
9798783|NCT01640379|No Intervention|Control|Participants receive enhanced standard of care
9798784|NCT01640548||Cohort|
9798785|NCT01640808|Experimental|NIK-333(peretinoin)|
9798786|NCT01640808|Placebo Comparator|Placebo|
9911675|NCT00717717|No Intervention|Control|No intervention except repeated measurements of physical capacity
9911676|NCT00717717|Experimental|Intervention|Intervention: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
9911677|NCT00717730|Placebo Comparator|A|Placebo dietary supplement
9911678|NCT00717730|Experimental|B|Folic acid
9911679|NCT00717730|Experimental|C|Vitamin B12
9911680|NCT00717730|Experimental|D|Folic acid and Vitamin B12
9911681|NCT00717743||1|Patients diagnosed with RCC.
9911682|NCT00717782|Experimental|1|"Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland).~A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
9911683|NCT00717782|Placebo Comparator|2|"Patients in the placebo group received a 0·6-ml injection of saline.~A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
9911684|NCT00717795||1|Arm 1 - Physical Activity intervention
9911685|NCT00717795||2|Arm 2 - Wait-list control
9911686|NCT00717808|Active Comparator|1|During the study the patient will either receive tranilast (300mg twice a day) or a placebo drug for a period of seven days. The patient will then have a seven day break followed by another period of seven days in which the patient will receive the other medication.
9911687|NCT00717808|Placebo Comparator|2|The patient will receive the placebo twice a day for 7 days whilst taking their weekly methotrexate dose
9911688|NCT00717821|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
9911689|NCT00717821|Active Comparator|Epoetin Beta or Darbepoetin Alfa|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will continue to receive the same treatment (epoetin beta or darbepoetin alfa at the same dose, same administration intervals, and the same route of administration). When necessary, dose adjustments will be performed according to Summary of Product Characteristics (SmPC). Total duration of treatment will be up to 48 weeks.
9911690|NCT00717834|Experimental|Cohort 1, Treatment Arm 1|Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
9911691|NCT00717834|Experimental|Cohort 1, Treatment Arm 2|Same as Cohort 1, Treatment Arm 1
9911692|NCT00717834|Experimental|Cohort 1, Treatment Arm 3|Same as Cohort 1, Treatment Arm 1
9911693|NCT00717834|Experimental|Cohort 1, Treatment Arm 4|Same as Cohort 1, Treatment Arm 1
9911694|NCT00717834|Experimental|Cohort 2, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
9911695|NCT00717834|Experimental|Cohort 2, Treatment Arm 2|Same as Cohort 2, Treatment Arm 1
9911696|NCT00717834|Experimental|Cohort 3, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 10 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1b and Cohort 2 Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
9911697|NCT00717834|Experimental|Cohort 3, Treatment Arm 2|Same as Cohort 3, Treatment Arm 1
9911698|NCT00717847||1|Any patient with NSCLC receiving erlotinib or gefitinib
9911699|NCT00717847||2|Patients with unexpected and/or severe treatment related toxicity whilst receiving EGFR TKI.
9911700|NCT00717899|Active Comparator|1|School children from Haifa bay region, Israel.
9911701|NCT00717925|Experimental|1|
9911702|NCT00717938|Other|A|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
9911703|NCT00717938|Experimental|B|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
9911704|NCT00717951|Experimental|A|"Arm A is docetaxol+capecitabine chemotherapy"
9911705|NCT00717951|Experimental|B|"Arm B is docetaxol+cisplatin chemotherapy"
9911706|NCT00717990|Experimental|1|XELIRI/Avastin
9911707|NCT00718003||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911708|NCT00718016||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911709|NCT00718068|Experimental|Continuous|This group will receive potassium chloride by continuous infusion on a sliding-scale system based on serum potassium level.
9911710|NCT00718068|Active Comparator|Intermittent|This arm will form the control group and receive potassium chloride by intermittent infusion as per conventional management
9911711|NCT00718107||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911712|NCT00718133|Experimental|1|Children at school age from Haifa bay region
9911713|NCT00718146|Experimental|Group 1|Age 16 to 60 years
9911714|NCT00718146|Experimental|Group 2|Age over 60 years
9911715|NCT00718185||A|Patients receiving sildenafil as standard of care
9911716|NCT00718198||1|Group admitted 1 (one) month before CPOE protocol changes were made
9911717|NCT00718198||2|Group admitted 1 (one) year after CPOE protocol changes were made
9911718|NCT00718250|Experimental|cohort 1|AML Cell Vaccine alone
9911719|NCT00718250|Experimental|cohort 2|Donor leukocytes alone
9911720|NCT00718250|Experimental|cohort 3|AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)
9911721|NCT00718250|Experimental|cohort 4|AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)
9911722|NCT00718276|Active Comparator|1|25(OH)D
9911723|NCT00718276|Active Comparator|2|vitamin D3
9911724|NCT00718289|Experimental|Citrate|Citrate dialysate for haemodialysis
9911725|NCT00718289|Active Comparator|Acetate|Acetate dialysate
9911726|NCT00718341|Active Comparator|1|
9911727|NCT00718341|Placebo Comparator|2|
9911728|NCT00718354|Active Comparator|B|Standard Chemotherapy (upto 6 cycles)
9911729|NCT00718354|Experimental|A|Enoxaparin: 1 mg/kg once daily in addition to standard chemotherapy up to 6 months
9911730|NCT00718380|Experimental|Group 1|Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
9911731|NCT00718380|Experimental|Group 2|Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
9911732|NCT00718380|Experimental|Group 3|Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
9911733|NCT00718380|Experimental|Group 4|Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
9911734|NCT00718393||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911735|NCT00718406|Active Comparator|A|A=metoprolol
9911736|NCT00718406|Active Comparator|B|B=metoprolol plus morphine
9911737|NCT00718432|Active Comparator|UC group|Usual care with education
9911738|NCT00718432|Experimental|ENIC group (IC group in 2009 study)|Exercise and nutritional integrated care
9911739|NCT00718432|Experimental|PSTIC group (IC group in 2009 study)|Problem solving therapy integrated care
9911740|NCT00718445||MND|"Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine~Patients seen in the Department of Neurology at Drexel University College of Medicine"
9911741|NCT00718458||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911742|NCT00718458||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
9911743|NCT00718471|Experimental|1|Enoxaparin
9911744|NCT00718471|Active Comparator|2|UFH
9911745|NCT00718484|Experimental|A|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
9911746|NCT00718484|Active Comparator|B|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
9911747|NCT00718497||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
9911748|NCT00718536|Experimental|1|Addition of raltegravir 800 mg QD to HAART
9911749|NCT00718562|Experimental|Nilotinib|
9911750|NCT00718575|Experimental|1|Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
9911751|NCT00718575|No Intervention|2|Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
9911752|NCT00718601|Experimental|1|3+3 cohort dose escalation
9911753|NCT00718614|Other|1|Patients with long standing IDDM (>10 years) and no diabetic retinopathy
9911754|NCT00718614|Other|2|Patients with long standing IDDM (>10 years) and mild non-proliferative diabetic retinopathy
9911755|NCT00718614|Other|3|Patients with long standing IDDM (>10 years) and moderate to severe non-proliferative diabetic retinopathy
9911756|NCT00718614|Other|4|healthy volunteers, matched for age and sex
9911757|NCT00718627|Experimental|HHLivC Therapy Group|
9911758|NCT00718653|Experimental|1|lutein
9911759|NCT00718653|Experimental|2|Lutein plus green tea extract
9911760|NCT00718679|Experimental|1|Study drug
9911761|NCT00718679|Placebo Comparator|2|Placebo
9911762|NCT00718705|Experimental|1|josamycin
9911763|NCT00718705|Placebo Comparator|2|Placebo
9911764|NCT00718731|Experimental|1|Subject on active drug
9911765|NCT00718731|Placebo Comparator|2|Subject on placebo
9911766|NCT00718744|Experimental|A|In each individual patient, 10 mg/ml histamine dihydrochloride solution and a phenolated saline solution will be applied as positive and negative control respectively.
9911767|NCT00718757|Experimental|1|
9911768|NCT00718783||Retinoblastoma|
9911769|NCT00718796|Experimental|1|Individualized naturopathic treatment consisting of dietary and lifestyle advice and individualized supplementation
9911770|NCT00718796|Active Comparator|2|Current care control provided by participants' medical doctor
9911771|NCT00718822|Experimental|I|5% oxygen concentration in the culture atmosphere
9911772|NCT00718822|Experimental|II|20% oxygen concentration in the culture atmosphere
9911773|NCT00718835|Active Comparator|Contingent Voucher condition|Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
9911774|NCT00718835|Placebo Comparator|Noncontingent control condition|Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
9911775|NCT00718848||1|These are patients treated with conventional hemodialysis (4 hours/session, 3 sessions/week) who convert to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week).
9911776|NCT00718848||2|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elect to remain on this dialysis schedule and agree to the study-related investigations at baseline and one year thereafter.
9911777|NCT00718874|Experimental|A, 1|low-carbohydrate (42%)
9911778|NCT00718874|Experimental|A,2|standard carbohydrate (55%) based on ADA recommendations
9911779|NCT00718913|Experimental|1|TCX ->RT -> TCX
9911780|NCT00718926||Sjogren|Sjogren syndrome with dry eye
9911781|NCT00718926||non-Sjogren|dry eye without Sjogren syndrome
9911782|NCT00718926||Short-BUT|Dry eye by shortened tear break up time
9911783|NCT00718926||control|normal patients
9911784|NCT00718939|Other|Rheos ON|Study participants in this arm will have the device turn on for six months and remains on.
9911785|NCT00718939|Other|Rheos OFF|Study participants in this arm will have the device turned off for 6 months and then turned on.
9911786|NCT00718952|Experimental|A|Patients in group A will receive vardenafil in double-blinded treatment period.
9911787|NCT00718952|Placebo Comparator|B|Patients in group A will receive placebo in double-blinded treatment period.
9911788|NCT00718978|Other|B|the investigators grafted sheets based on the HYAFF11p80® scaffold (the one with the lowest degree of esterification)
9911789|NCT00718978|Other|A|the investigators grafted sheets based on the HYAFF11® scaffold (the one with the highest degree of esterification).
9911790|NCT00718978|Other|A-B|the investigators grafted sheets based on the HYAFF11® scaffold and sheets based on the HYAFF11p80 ® scaffold
9911791|NCT00718991|Experimental|1|CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions
9911792|NCT00719004|Experimental|Normals|Normal volunteers having Ultrasound scan of foot.
9911793|NCT00719017|Experimental|Vaginectomy group|Upper vaginectomy
9911794|NCT00719017|Experimental|Brachytherapy group|Post-operative brachytherapy
9911795|NCT00719017|Active Comparator|Control group|Standard treatment
9911796|NCT00719030|Experimental|1|Pomegranate pill
9911797|NCT00719030|Placebo Comparator|2|
9911798|NCT00719056|Experimental|1|Surgical chemoprophylaxis of one dose of teicoplanin upon introduction of anesthesia for total hip or knee arthroplasty.
9911799|NCT00719056|Active Comparator|2|Surgical chemoprophylaxis with multiple dose of other antimicrobials for up to six consecutive days for total hip or knee arthroplasty.
9911800|NCT00719082||AARP Community|Members of AARP Geriatric Community
9911801|NCT00719095|Experimental|1-week buprenorphine taper|1-week buprenorphine taper + behavioral therapy + urine toxicology
9911802|NCT00719095|Experimental|2-week buprenorphine taper|2-week buprenorphine taper + behavioral therapy + urine toxicology
9911803|NCT00719095|Experimental|4-week buprenorphine taper|4-week buprenorphine taper + behavioral therapy + urine toxicology
9911804|NCT00719108|Experimental|Wosulin R|Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
9911805|NCT00719108|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
9911806|NCT00719121|No Intervention|A|No Treatment
9911807|NCT00719121|Active Comparator|B|R115866 (0.35% gel)
9911808|NCT00719121|Active Comparator|C|R115866 Vehicle gel
9911809|NCT00719121|Active Comparator|D|Differin™, 0.1% adapalene gel
9911810|NCT00719147||1|
9911811|NCT00719173|Experimental|Arm I|Patients receive aprepitant 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving aprepitant, patients receive an infusion of cyclophosphamide on day 1. During course 2, patients crossover and receive treatment as in arm II.
9798787|NCT01640834|Experimental|100 mg LY2409021|"LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.~Placebo: 2 capsules, administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
9798788|NCT01640834|Experimental|300 mg LY2409021|"LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
9798789|NCT01640834|Placebo Comparator|Placebo|"Placebo: 3 capsules administered as a single oral dose on Day 2.~Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3."
9798790|NCT01640873|Experimental|MK-8655 80 mg/MK-8655 320 mg|Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
9798791|NCT01640873|Placebo Comparator|Placebo|Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
9798792|NCT01640925|Active Comparator|Chlorhexidine gluconate bathing|Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
9798793|NCT01640925|Placebo Comparator|Standard bathing|Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
9798794|NCT01640951|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
9798795|NCT01640951|Experimental|AIN457 150 mg - Start of relapse (SoR)|"Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
9798796|NCT01640951|Experimental|AIN457 300 mg - Fixed Interval (FI)|2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
9798797|NCT01640951|Experimental|AIN457 300 mg - Start of Relapse (SoR)|"Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
9798798|NCT01640951|Experimental|AIN457 300 mg - Open Label (OL)|Open Label - Secukinumab 300mg every 4 weeks
9798799|NCT01640964|Experimental|Part A: Terlipressin acetate|Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
9798800|NCT01640964|Experimental|Part A: Serelaxin (RLX030)|Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
9798801|NCT01640964|Experimental|Part B Serelaxin (RLX030)|The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.
9798802|NCT01641042|Experimental|Healthy Group|The subjects in the Healthy group will be age-matched to the subjects in the At-risk group. Subjects will receive 2 doses of the investigational vaccine.
9798803|NCT01641042|Experimental|At-risk Group|This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
9798804|NCT01641081|Experimental|Experimental 1|Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
9798805|NCT01641081|Experimental|Experimental 2|Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
9798806|NCT01641081|Active Comparator|Active Comparator 1|Foradil Aerolizer, Low Dose
9798807|NCT01641081|Active Comparator|Active Comparator 2|Foradil Aerolizer, High Dose
9798808|NCT01641081|Placebo Comparator|Placebo|Dose matched placebo
9798809|NCT01641120|Experimental|30 gauge|Subjects used a 30 gauge needle for intramuscular injection of Avonex.
9798810|NCT01641120|Experimental|25 gauge|Subjects used a 25 gauge needle for intramuscular injection of Avonex.
9798811|NCT01641133|Active Comparator|Synflorix Group|Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
9798812|NCT01641133|Experimental|Prevnar 1 Group|Subjects who were primed with Prevnar 13 and Synflorix vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.
9798813|NCT01641133|Experimental|Prevnar 2 Group|Subjects who were primed with two doses of Prevnar 13 vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
9798814|NCT01641159|Active Comparator|Buspirone plus TAU|Buspirone titrated to 60 mg/day for the 15-week active study
9798815|NCT01641159|Placebo Comparator|Placebo plus TAU|Placebo taken daily for the 15-week active study
9798816|NCT01641198|Active Comparator|Configuration 1|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at two sites, SC (Screw-Vent) at one site
9798817|NCT01641198|Experimental|Configuration 2|Device placement: B (Brånemark) at one site, SW (Swede-Vent) at two sites, SC (Screw-Vent) at two sites
9798818|NCT01641198|Experimental|Configuration 3|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at one site, SC (Screw-Vent) at two sites
9798819|NCT01641237|Experimental|Low ppm fluoride dentifrice|Low ppm fluoride as sodium fluoride in a silica base dentifrice
9798820|NCT01641237|Experimental|Medium ppm fluoride dentifrice|Medium ppm fluoride as sodium fluoride in a silica base dentifrice
9798821|NCT01641237|Experimental|High ppm fluoride dentifrice|High ppm fluoride as sodium fluoride in a silica base dentifrice
9798822|NCT01641237|Placebo Comparator|No fluoride dentifrice|no added fluoride in a silica base dentifrice
9911812|NCT00719173|Experimental|Arm II|Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment as in arm I.
9911813|NCT00719199|Experimental|1|IMO 2055 is a novel phosphorothioate oligodeoxynucleotide that is an agonist of Toll-like Receptor 9 (TLR9).
9517586|NCT03305094|Experimental|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
9911814|NCT00719238|Experimental|1|
9911815|NCT00719238|Active Comparator|2|
9911816|NCT00719251|Experimental|HVG|The patients received standard nursing care and HVPC
9911817|NCT00719251|Experimental|LG|These patients received standard nursing care and LLLT
9911818|NCT00719251|Active Comparator|CG|The control group only was treated with standard nursing care
9911819|NCT00719290|Active Comparator|1|Phacoemulsification with intraocular lens implant alone
9911820|NCT00719290|Active Comparator|2|Phacoemulsification with intraocular lens implant and goniosynechialysis
9911821|NCT00719303|Experimental|Group I (lifestyle intervention)|Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
9911822|NCT00719303|Active Comparator|Group II (observation)|Participants receive a study notebook containing general study-related information. Participants are not asked to record diet or physical activity but are provided a single sample diary in their study notebook. Participants receive telephone contact on a sliding scale similar to the intervention group, but at less frequent intervals (22 versus 33 calls over the course of the intervention).
9911823|NCT00719316|Experimental|Group 1|Patients receive Aliskiren 300mg for 6 weeks
9911824|NCT00719316|No Intervention|Group 2|4 weeks no antihypertensive medication
9911825|NCT00719368||pain-free control|Pain-free controls from previous prospective study (KF 01294867), operated >2 years previously
9911826|NCT00719368||Pain Patients|Patients with persistent postherniotomy pain lasting >1 year and pain related impaired daily function
9911827|NCT00719381|Active Comparator|1|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
9911828|NCT00719381|No Intervention|2|Patients in this arm will receive no intervention
9911829|NCT00719394|Experimental|GSI 136|
9911830|NCT00719394|Placebo Comparator|placebo|
9911831|NCT00719407|Experimental|A|All enrolled patients will be in this single arm, who will receive experimental drug treatment.
9911832|NCT00719420|Experimental|1|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid for 14 days (with or without omeprazole 20 mg bid)
9911833|NCT00719420|Active Comparator|2|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
9911834|NCT00719433|Experimental|1|
9911835|NCT00719433|Active Comparator|2|
9934093|NCT05030766|Experimental|CM plus NRT Group|Participants who receive the Contingency Management (CM) intervention for 4 weeks in addition to 6 weeks of NRT. These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
9934094|NCT05030766|Experimental|MT plus NRT with additional CM Group|Participants who received the MT intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional CM intervention for another 4 weeks.
9934095|NCT05030766|Experimental|CM plus NRT with additional MT Group|Participants who received the CM intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional MT intervention for another 4 weeks.
9911836|NCT00719459|Experimental|1|Hospira Iron Sucrose
9517587|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in shoulder surgery.|Arm 1 shoulder replacement, both primary and reverse
9517588|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in arhroscopic shoulder surgery.|Arm 2 arthroscopic rotator cuff repair
9517589|NCT03305042||21-54 y|Ages 21-54 y
9911837|NCT00719459|Active Comparator|2|Venofer
9911838|NCT00719485|Experimental|1|Educational program
9911839|NCT00719485|No Intervention|2|Standard care
9911840|NCT00719511|Experimental|1|Patch allergen dose 1
9911841|NCT00719511|Experimental|2|Patch allergen dose 2
9911842|NCT00719511|Experimental|3|Patch allergen dose 3
9911843|NCT00719511|Experimental|4|Placebo
9911844|NCT00719524|Experimental|1|
9911845|NCT00719589||1|Patient who have had implantation of an interstim.
9911846|NCT00719602|Active Comparator|1|Previously received single-dose nevirapine (SD NVP); assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
9911847|NCT00719602|Active Comparator|2|Have not previously received SD NVP; assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
9911848|NCT00719641||Phase 1: Single Colonoscopy|Feasibility testing using the segmental stiffening wire
9911849|NCT00719641||Phase 2; Not randomized|Phase 2 participants who did not have looping during first colonoscopy
9911850|NCT00719641||Phase 2: Randomized to SSW during first colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to subsequent use of segmental stiffening wire, then colonoscopy with no segmental stiffening wire upon repeat colonoscopy the next day.
9911851|NCT00719641||Phase 2: Randomized to SSW during second colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to no subsequent use of the segmental stiffening wire that day, then colonoscopy with segmental stiffening wire upon repeat colonoscopy the next day.
9911852|NCT00719654||EOS-Preeclampsia|Women with symptoms of early-onset preeclampsia
9911853|NCT00719654||Normal|Women who do not have symptoms of early-onset preeclampsia
9911854|NCT00719693|Experimental|A|ABT-143 under low-fat meal condition
9911855|NCT00719693|Experimental|B|ABT-143 under fasting meal condition
9911856|NCT00719745|Active Comparator|1|
9911857|NCT00719745|Experimental|2|
9911858|NCT00719758|Experimental|1|Cross-over study
9911859|NCT00719771|Other|Global® AP™ Shoulder|Global® AP™ Shoulder
9911860|NCT00719784|Experimental|1|All patients recruited will have VRI recordings done. There is no comparative arm.
9911861|NCT00719797|Experimental|Arm I (FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
9911862|NCT00719797|Experimental|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
9911863|NCT00719823|Other|1|
9911864|NCT00719875|Experimental|1|
9911865|NCT00719927|Experimental|1|Comadre Treatment
9911866|NCT00719927|Active Comparator|2|Non Support Partner Treatment
9911867|NCT00719940|Experimental|1|Cognitive behavioral therapy
9911868|NCT00719940|Placebo Comparator|2|Waiting group
9911869|NCT00719979|Experimental|iCBT and TeleCoaching|Participants received the technology-assisted behavioral intervention (iCBT + TeleCoaching).
9911870|NCT00719979|Experimental|iCBT(MoodManager)|Participants received Internet-based cognitive behavioral therapy only.
9911871|NCT00719979|Active Comparator|Treatment as usual / Wait-list control|Participants received treatment as usual . For wait-list control, participants were not provided any intervention for 6 weeks, after which they were allowed to choose coached or self-directed moodManager.
9911872|NCT00719992|Experimental|1|positive ETT, High HS-CRP
9911873|NCT00719992|Active Comparator|2|positive ETT, Low HS-CRP
9911874|NCT00720005||Aspheric Acrysof ResTOR Lens|Implantation of Aspheric Acrysof ResTOR
9911875|NCT00720018|Experimental|Period 1|NP101 Patch
9911876|NCT00720018|Experimental|Period 2|NP101 Patch
9911877|NCT00720018|Experimental|Period 3|NP101 Patch
9911878|NCT00720018|Experimental|Period 4|NP101 Patch
9911879|NCT00720018|Experimental|Period 5|NP101 Patch
9911880|NCT00720070|Experimental|Arm I|Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.
9911881|NCT00720070|Active Comparator|Arm II|Patients undergo neck dissection and receive standard concurrent CRT. Patients undergo PET/CT scan at 9-13 weeks after completion of CRT.
9911882|NCT00720135|Experimental|Arm I|Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
9911883|NCT00720161|Active Comparator|A|Metformin during 12 months and then 6 months Placebo
9911884|NCT00720161|Placebo Comparator|B|Placebo during 6 months, afterwards 12 months metformin
9911885|NCT00720174|Experimental|Treatment (cixutumumab and doxorubicin hydrochloride)|Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
9911886|NCT00720200|Experimental|1|
9911887|NCT00720200|Active Comparator|2|
9911888|NCT00720239|No Intervention|0|
9911889|NCT00720239|Experimental|1|Experimental Group 1 (n = 10) will receive TalidermR to the wound once during the treatment phase.
9911890|NCT00720239|Experimental|2|Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
9911891|NCT00720239|Experimental|3|Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
9911892|NCT00720252|Experimental|A|
9911893|NCT00720265|Active Comparator|1|
9911894|NCT00720265|Experimental|2|
9911895|NCT00720291|Active Comparator|Metronidazole|Subjects who are randomly assigned to receive metronidazole 500 mg po for a period of 7 days following diagnosis of asymptomatic BV.
9911896|NCT00720291|Placebo Comparator|Placebo|Subjects who are randomly assigned to receive a placebo for a period of 7 days following the diagnosis of asymptomatic BV.
9911897|NCT00720304|Experimental|oral erlotinib hydrochloride|
9911898|NCT00720395||1|Women with bipolar disorder who are preconception or pregnant. Primary focus on predictors of postpartum bipolar disorder relapse and burden of illness through first six months postpartum
9911899|NCT00720408|Experimental|Prograf-XL + MMF|
9911900|NCT00720408|Active Comparator|Prograf + MMF|
9517590|NCT03305042||55-74 y|Ages 55-74 y
9517591|NCT03305042||>75 y|Age >75 y
9911901|NCT00720421|Other|1|AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy
9911902|NCT00720421|Other|2|AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 1mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy
9911903|NCT00720421|Other|3|AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy
9911904|NCT00720421|Other|4|AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy
9911905|NCT00720460||Experimental|Healthy Volunteers
9911906|NCT00720486|Experimental|1|Participants will receive Juvenile Justice Anger Management for Girls plus treatment as usual.
9911907|NCT00720486|Active Comparator|2|Participants will receive treatment as usual.
9911908|NCT00720512|Active Comparator|Arm I|Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9911909|NCT00720512|Experimental|Arm II|Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9911910|NCT00720525||1|Patients with diastolic heart failure
9911911|NCT00720525||2|Patients without diastolic heart failure
9911912|NCT00720538|Experimental|1|Thalidomide
9911913|NCT00720538|Placebo Comparator|2|Placebo
9911914|NCT00720577|Active Comparator|1|
9911915|NCT00720577|Active Comparator|2|
9911916|NCT00720577|Active Comparator|3|
9911917|NCT00720590|Experimental|1|Participants will receive treatment with atazanavir and placebo lopinavir/ritonavir.
9911918|NCT00720590|Experimental|2|Participants will receive treatment with lopinavir/ritonavir and placebo atazanavir.
9911919|NCT00720590|Placebo Comparator|3|Participants will receive treatment with placebos for both drugs.
9911920|NCT00720616|Experimental|1|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
9911921|NCT00720642||PSAP|This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.
9911922|NCT00720642||NPSAP|Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.
9911923|NCT00720655|Experimental|Fatty fish|
9911924|NCT00720655|Experimental|Lean Fish|
9911925|NCT00720655|Placebo Comparator|Control diet|
9911926|NCT00720668||1|patient with hepatocellular carcinoma after radiofrequency ablation
9911927|NCT00720694|Active Comparator|Verum|"Device: Duolith SD1 (Storz Medical AG) - Focused Extracorporeal shock wave therapy.~The total energy flux density was increased continuously from 0.01 to 0.25 mJ/mm 2 within 500 introductory impulses. Thereafter, 2000 treatment impulses with 0.25 mJ/mm 2 (four impulses per second) were administered per session,and the interventionwas repeated up to a total of three sessions in weekly intervals."
9911928|NCT00720694|Sham Comparator|Placebo / Sham|Sham Duolith SD1 (Storz Medical AG). The placebo group received identical sham intervention with an air- filled standoff that prevented the transmission of shock waves. The placebo handpiece was identical in design, shape, and weight to ensure that there was no way for the participants to identify the placebo handpiece.
9911929|NCT00720707|Experimental|(CAF+ADM+EMD)|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
9911930|NCT00720707|Active Comparator|(CAF + ADM)|root coverage procedure by using a coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM)
9911931|NCT00720720|Active Comparator|1|plant sterol enriched margarine
9911932|NCT00720720|Placebo Comparator|2|placebo margarine
9911933|NCT00720733|Experimental|1|Skills Building Group
9911934|NCT00720733|Active Comparator|2|Personal Interview Group
9911935|NCT00720772|Experimental|A|
9911936|NCT00720772|No Intervention|B|
9911937|NCT00720811|Experimental|ACT, antibiotic, paracetamol|CHWs will test children with acute febrile illness for malaria using RDTs, and for pneumonia by counting their respiratory rate with RRTs. Treatment will then be provided on the basis of the test results, in line with national guidelines. Children with a positive RDT will receive artemether-lumefantrine in Burkina Faso and Uganda, and artesunate-amodiaquine in Ghana. Children with a cough and a high respiratory rate will receive amoxicillin in Ghana and Uganda, and cotrimoxazole in Burkina Faso. Additionally, paracetamol (PCT) will be provided to all children with an axillary temperature > 38.5°C.
9911938|NCT00720811|No Intervention|Presumptive fever management|Presumptive treatment of malaria with ACTs. No antibiotic treatment available
9911939|NCT00720824|Active Comparator|1|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions
9911940|NCT00720824|Placebo Comparator|2|Office routine
9911941|NCT00720837|Experimental|Laser Interstitial Thermal Therapy|Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
9911942|NCT00720850|Experimental|lenalidomide|lenalidomide therapy p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
9911943|NCT00720889||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
9911944|NCT00720889||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
9911945|NCT00720902|Active Comparator|A|Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion.
9911946|NCT00720902|Active Comparator|B|Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient.
9911947|NCT00720915|Other|No Anticoagulant Therapy|No Anticoagulant Therapy
9911948|NCT00720915|Other|Anticoagulant Therapy|Continue on anticoagulant therapy
9911949|NCT00720928|Other|single group|"Posterior uveitis patients having complete or incomplete type of Behcet's disease; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.~Selection of study eye : For patients with unilateral uveitis, the study eye will be the affected eye; for patients with bilateral uveitis, the study eye will be the more severely affected eye (i.e., the eye having suffered more recurrences in the previous year, or if equal, the eye having received more therapy in the previous year, or if equal, the eye having the worse VA, or if equal, the eye clinically judged to be the more severely affected eye)."
9911950|NCT00720954|Other|A|CT guided pleural needle biopsy
9911951|NCT00720954|Other|B|Thoracoscopy
9911952|NCT00720967|Active Comparator|1|Control Group (Open heart surgery alone)
9911953|NCT00720967|Experimental|2|Intraoperative Modified Ultrafiltration (MUF) Group (Open heart surgery with intraoperative MUF)
9911954|NCT00720967|Experimental|3|Preoperative Hemodialysis Group (Open Heart Surgery after preoperative hemodialysis)
9911955|NCT00720993||1|Control group - patients scheduled for routine colonoscopy procedures with no self or family history or other GI conditions.
9911956|NCT00720993||2|Case group - patients with confirmed colorectal carcinoma scheduled for surgery or observed during routine colonoscopy screening.
9911957|NCT00721006|Experimental|MESENDO|All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
9911958|NCT00721006|Placebo Comparator|placebo|All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion
9911959|NCT00721019|Experimental|5-hour bedtime|
9911960|NCT00721019|Experimental|8.5-hour bedtime|
9911961|NCT00721032|Experimental|1|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
9911962|NCT00721032|Active Comparator|2|Anti-arrhythmic group.
9911963|NCT00721045|Active Comparator|A1|15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.
9911964|NCT00721045|Sham Comparator|A2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
9911965|NCT00721045|Active Comparator|B1|15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.
9911966|NCT00721045|Sham Comparator|B2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
9911967|NCT00721045|Active Comparator|C1|15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.
9911968|NCT00721045|Sham Comparator|C2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
9911969|NCT00721058|Other|1|
9911970|NCT00721071|Experimental|1|
9911971|NCT00721084||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
9911972|NCT00721084||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
9911973|NCT00721240|Experimental|single-arm|This investigation is a single-center, two-phase, single-arm study. In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
9911974|NCT00721266|Experimental|1|
9911975|NCT00721305|Experimental|1|In this arm, subjects will receive 40 mg of Lovastatin (2 tablets of 20 mg each, p.o.), in a daily doses, during twelve months
9911976|NCT00721305|Placebo Comparator|2|In this arm, subjects will receive placebo (2 tablets which will look externally identical to lovastatin: wrapped in the same way, with the same size, shape and color)
9911977|NCT00721318||1|Patients diagnosed with rheumatoid arthritis
9911978|NCT00721318||2|Population controls to the subjects of group 1
9911979|NCT00721331|Experimental|CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)|
9911980|NCT00721331|Experimental|CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)|
9911981|NCT00721331|Experimental|0.1% nortriptyline HCl|
9911982|NCT00721331|Active Comparator|0.1% mometasone furoate|
9911983|NCT00721331|Placebo Comparator|Active ingredient free vehicle cream of CRx-197|
9911984|NCT00721344|Experimental|1|
9911985|NCT00721344|Experimental|2|
9911986|NCT00721344|Experimental|3|
9911987|NCT00721344|Experimental|4|
9911988|NCT00721370|Experimental|1|Patients imaged using ICG:HSA and NIR imaging system
9911989|NCT00721383|Experimental|Treatment|Physical activity and caregiver skill-building
9911990|NCT00721383|Active Comparator|Control|caregiver skill-building
9911991|NCT00721422|Experimental|Group 1-Normal|
9911992|NCT00721422|Experimental|Group 2-Mild|
9911993|NCT00721422|Experimental|Group 3-Moderate|
9911994|NCT00721422|Experimental|Group 4-Severe|
9911995|NCT00721435|Experimental|3D Tomosynthesis & 3D Ultrasound for breast masses|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
9911996|NCT00721435|Experimental|3D Tomosynthesis/ 3D Ultrasound for healthy subjects|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
9911997|NCT00721461|Experimental|1|V930
9911998|NCT00721474|Experimental|1|Bosutinib fasting
9911999|NCT00721474|Experimental|2|Bosutinib fed
9912000|NCT00721487||Fluconazole|30 evaluable patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy.
9912001|NCT00721526|Experimental|Disulfiram plus lorazepam|Disulfiram plus lorazepam
9912002|NCT00721552|Experimental|I|prednisolone + sitagliptin
9912003|NCT00721552|Experimental|II|prednisolone + sitagliptin-placebo
9912004|NCT00721552|Experimental|III|prednisolone-placebo + sitagliptin
9912005|NCT00721552|Placebo Comparator|IV|prednisolone-placebo + sitagliptin-placebo
9912006|NCT00721552|No Intervention|Healthy controls|12 healthy men will be included to assess postprandial microvascular function.
9912007|NCT00721552|No Intervention|Type 2 diabetic subjects|12 men with type 2 diabetes will be included in order to assess postprandial microvascular function.
9934096|NCT05028569|Experimental|BOTOX Dose A|Participants will receive BOTOX Dose A on Week 0 and Week 12. Eligible participants will receive BOTOX Dose A on Week 24 and Week 36.
9934097|NCT05028569|Experimental|BOTOX Dose B|Participants will receive BOTOX Dose B on Week 0 and Week 12. Eligible participants will receive BOTOX Dose A on Week 24 and Week 36.
9934098|NCT05028569|Placebo Comparator|Placebo|Participants will receive placebo on Week 0 and Week 12. Eligible participants will receive BOTOX Dose A on Week 24 and Week 36.
9934099|NCT05027958|Other|1|TST+ IGRA+
9934100|NCT05027958|Other|2|TST- IGRA-
9934101|NCT05027945|Experimental|Arm A|Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis
9934102|NCT05027945|Experimental|Arm B|Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis
9934103|NCT05027932|Experimental|Group A|15 participants receiving IM BPL-1357 &amp; IN Placebo
9934104|NCT05027932|Experimental|Group B|15 participants receiving IN BPL-1357 &amp; IM Placebo
9934105|NCT05027932|Sham Comparator|Group C|15 participants receiving IM and IN placebo
9934106|NCT05027347||100 healthy people|10 ml blood and tissue biopsy were collected from each patient
9934107|NCT05027347||100 gastric cancer patients|10 ml blood and tissue biopsy were collected from each patient
9934108|NCT05027230|Experimental|Consecutive doses of low-dose of STSP-0601|
9934109|NCT05027230|Experimental|Consecutive doses of high-dose of STSP-0601|
9934110|NCT05027074|Experimental|MK-2060 Low Dose|MK-2060 low dose administered via intravenous (IV) infusion as a loading dose: Every other day (QOD) during week 1 (3 administrations), then once a week (QW) after week 1
9934111|NCT05027074|Experimental|MK-2060 High Dose|MK-2060 high dose administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then QW after week 1
9934112|NCT05027074|Placebo Comparator|Placebo|Placebo (normal saline) administered via IV infusion as a loading dose: QOD during week 1 (3 administrations), then once a week after week 1
9934113|NCT05026177|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks
9934114|NCT05026177|Experimental|Simufilam 50 mg|Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
9934115|NCT05026177|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
9934116|NCT05026138||Biological relatives without HPV|Biological relatives without current HPV disease serving as controls to be compared with those from affected participants for evaluation of the differences between people with HPV and without.
9934117|NCT05026138||Participants with HPV|Patients with recurrent HPV related diseases refractory to standard-of-care medical or surgical interventions.
9934118|NCT05023096|Active Comparator|Menthol+Tobacco|Menthol+Tobacco - where both menthol and tobacco flavored liquids for electronic nicotine delivery systems are available to choose from
9934119|NCT05023096|Experimental|Tobacco|Tobacco - where only tobacco flavored liquid is available for electronic nicotine delivery systems
9934120|NCT05023096|Experimental|Unflavored|Unflavored - where only unflavored liquid is available for electronic nicotine delivery systems
9934121|NCT05020743||Patients with ALSP|
9934122|NCT05020743||Asymptomatic carriers of the CSF1R gene mutation|
9934123|NCT05019729|Experimental|Group 2|5 mg/kg IV
9934124|NCT05019729|Experimental|Group 3|5 mg/kg SC
9934125|NCT05019729|Experimental|Group 4|20 mg/kg IV
9934126|NCT05019729|No Intervention|Group 5|Nothing
9934127|NCT05019729|Experimental|Group 6|5 mg/kg IM
9934128|NCT05019729|Experimental|Group1|1 mg/kg IV
9934129|NCT05019534|Experimental|Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)|Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid
9934130|NCT05017571|No Intervention|Adults no obesity, insulin resistance, or inflammation|Adults without obesity, insulin resistance or inflammation
9934131|NCT05017571|No Intervention|Adults with obesity, but no insulin resistance/inflammation|Adults with obesity, but without insulin resistance or inflammation
9934132|NCT05017571|Experimental|Colchicine - Adolescents|Adolescents given Colchicine 0.6 mg per day (1 capsule per day)
9934133|NCT05017571|Experimental|Colchicine - Adults|Adults given Colchicine 0.6 mg per day (1 capsule per day)
9934134|NCT05017571|Placebo Comparator|Placebo - Adolescents|Adolescents given Placebo (1 capsule per day)
9934135|NCT05017571|Placebo Comparator|Placebo - Adults|Adults given Placebo (1 capsule per day)
9934136|NCT05017025|Experimental|Treatment (osimertinib, aurora A kinase inhibitor LY3295668)|Patients receive osimertinib PO QD and aurora A kinase inhibitor LY3295668 PO BID on days 1-28. Treatment repeats every 28 days for 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
9934137|NCT05014438|Placebo Comparator|Placebo|
9934138|NCT05014438|Experimental|Treatment BMS-986166 Dose 1|
9934139|NCT05014438|Experimental|Treatment BMS-986166 Dose 2|
9934140|NCT05014438|Experimental|Treatment BMS-986166 Dose 3|
9934141|NCT05014438|Experimental|Treatment Branebrutinib|
9934142|NCT05014061|Experimental|Adenosine|Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours
9934143|NCT05014061|No Intervention|Controll|Standard of care
9912008|NCT00721565|Experimental|1|behavior change intervention
9912009|NCT00721565|No Intervention|2|written materials
9912010|NCT00721591||A|Subjects opting for treatment with unfractionated heparin
9912011|NCT00721591||B|Subjects opting for treatment with low molecular weight heparin
9912012|NCT00721604||1|patients with mean arterial pressure lower than 65 mmHg
9912013|NCT00721643|Experimental|1|Healthy control, 5g dry power of angel's plant (Angelica keiskei)
9912014|NCT00721643|Experimental|2|Metabolic syndrome, 5g dry powder of angel's plant (Angelica keiskei)
9912015|NCT00721656|Placebo Comparator|Placebo|
9912016|NCT00721656|Experimental|KLS-0611|
9912017|NCT00721682||Case|The CASE group will be composed of children for whom the medical team will have chosen to carry out a sign of alert of ill-treatment during his hospitalization and with no plausible cause of traumatism
9912018|NCT00721682||control|The Control group will be composed of children, consulting with the emergency care for traumatism, not having a sign of alarm and having a plausible cause of traumatism.
9912019|NCT00721708|Experimental|1|Carnosine(450 mg)
9912020|NCT00721708|Experimental|2|Beef (150g)
9912021|NCT00721708|Experimental|3|chicken (150g)
9912022|NCT00721708|Experimental|4|Chicken broth (obtained from 150 g of chicken breast)
9912023|NCT00721721|Experimental|1|Participants will follow a low sodium diet for Days 1 through 7, a high sodium diet for Days 7 through 14, and a high sodium diet plus potassium supplement regimen for Days 14 through 21.
9912024|NCT00721747|Experimental|Unique arm|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
9912025|NCT00721773|Experimental|ACE inhibitor, benazepril|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day according to BP control and tolerability.
9912026|NCT00721773|Experimental|Angiotensin receptor blocker, valsartan|Valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
9912027|NCT00721773|Experimental|RAS inhibitors, benazepril+valsartan|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day, and valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
9912028|NCT00721773|Active Comparator|non-RAS inhibitors, control|Drug: antihypertensive agents, except ACE inhibitors and ARBs. Administration of antihypertensive agents will select as follows: CCB→β-blocker→α-blocker.
9912029|NCT00721786|Experimental|San Francisco Internet Stop Smoking Site|"UCSF/SFGH Internet Stop Smoking Study site~Internet Stop Smoking site (TC4) with several intervention elements from which the participants may choose as many as they wish~The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: www.dejardefumar.ucsf.edu"
9994596|NCT01482455|Active Comparator|Clamp/Lipid|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
9994597|NCT01482468|Active Comparator|continuous infusion|continuous infusion of palonosetron added to prophylactic single injection of palonosetron
9912030|NCT00721812|Other|Part A|Single dose escalation
9912031|NCT00721812|Other|Part B|14 day repeat dose escalation
9912032|NCT00721812|Other|Part C|Fixed dose food effect
9912033|NCT00721825|Active Comparator|1|Neuroaid
9912034|NCT00721825|Placebo Comparator|2|Neuroaid matched placebo
9912035|NCT00721838||1|Surgery group
9912036|NCT00721838||2|Control - Lifestyle modification program
9912037|NCT00721864||Affected Population|Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
9912038|NCT00721877|Experimental|Arm I|Participants receive oral resveratrol once daily for 4 weeks.
9912039|NCT00721890|Experimental|1|
9912040|NCT00721903|Active Comparator|Healthy Subjects|Ultrasound scan
9912041|NCT00721903|Active Comparator|Cancer|120 women diagnosed by biopsy to have breast cancer will have an ultrasound scan
9912042|NCT00721916|Experimental|1|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
9912043|NCT00721916|Active Comparator|2|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
9912044|NCT00721929|Experimental|adrenal mass group|
9912045|NCT00721981||1|Regular treatment for non-small cell lung cancer (NSCLC)
9912046|NCT00721994||1|IDE subjects who received the Cormet Hip Resurfacing device
9912047|NCT00722033|Other|A|< 30 weeks of gestation
9912048|NCT00722059|Experimental|1|Subjects will undergo a 3D breast Tomosynthesis imaging scan. This is a one time breast imaging scan will last approximately 15 minutes.
9912049|NCT00722085||Observational|
9912050|NCT00722098|Experimental|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
9994598|NCT01482468|Placebo Comparator|singel injection|continuous infusion of normal saline added to prophylactic single injection of palonosetron
9994599|NCT01482494||Pompe suspected patients|"Patients who go to an Internal Medicine clinic for examination of a limb-girdle myopathy.~Patients with asymptomatic hyper-CK-emia. Patients with a prior diagnosis of polymyositis. Patients with a myopathy of uncertain origin and respiratory insufficiency. Patients with polymyositis unresponsive to steroid therapy"
9994600|NCT01482520||Renal cell carcinoma|
9994601|NCT01482520||Hepatocellular carcinoma patients|
9994602|NCT01482533||Revision Total Hip Arthroplasty|
9994603|NCT01482533||Revision Total Knee Arthroplasty|
9994604|NCT01482546||Water Colonoscopy Method|As first described by Dr. Felix W. Leung, the maneuvers can be summarized as warm water infusion in lieu of air insufflation combined with suction removal of all residual colonic air and residual feces by water exchange. The air pump will be turned off before insertion of the colonoscope into the rectum to avoid accidental insufflation of air. Warm water (at 36-37ºC) maintained using a water bath and heat saver envelop will be infused intermittently. The minimum amount of water needed to distend the colon and open the lumen will be used during scope insertion. Cecal intubation will be suggested by appropriate movement of the endoscopic image on the monitor screen when the right lower quadrant is palpated or the appendiceal orifice visualized under water. The cecum will then be distended by air to confirm visualization of the ileocecal valve and appendiceal orifice. No specific limit will be set for the volume of water to be used.
9994605|NCT01482546||Air Colonoscopy Method|The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
9994606|NCT01482559|Placebo Comparator|dextrose 5%|IV Infusion
9994607|NCT01482559|Experimental|Dopamine Hydrochloride|IV Infusion
9994608|NCT01482572||Gene profiling Success|
9994609|NCT01482585||early stage lung adenocarcinoma|
9994610|NCT01482611|Experimental|Panel 1: Caucasian|10, 75 and 300 mg JNJ-47910382 or placebo
9994611|NCT01482611|Experimental|Panel 2: Caucasian|30, 150, 600 mg JNJ-47910382 or placebo
9994612|NCT01482611|Experimental|Panel 3: Japanese|Session VIII and X: Doses of JNJ-47910382 or placebo to be determined
9994613|NCT01482611|Experimental|Panel 4: Japanese|Session IX: Dose of JNJ-47910382 or placebo to be determined
9994614|NCT01482624|Active Comparator|VISCOSEAL® SYRINGE|
9994615|NCT01482624|Other|Standard arthroscopic meniscal surgery|
9994616|NCT01482637||CAS|There are no separate groups. All subjects are being asked to complete the CAS measure.
9994617|NCT01482650|Experimental|Baska mask|
9994618|NCT01482650|Active Comparator|single use laryngeal mask airway (LMA)|
9994619|NCT01482663|No Intervention|Chronic hand eczema patients|Written information sheets and a 14-minutes DVD about hand eczema handed out by the dermatologist
9994620|NCT01482663|Experimental|Behavioral: Healthy Skin Clinic|1-2 counselling sessions with a nurse, tailored according to individual risks and resources and user access to a website comprising a self-monitoring log, a patients' forum and the possibility of communication with the intervention team of nurses
9994621|NCT01482676||1|controls (normal bladder function)
9994622|NCT01482676||2|acontractile bladder
9994623|NCT01482676||3|overactive bladder
9994624|NCT01482676||4|bladder pain syndrome
9994625|NCT01482689|Experimental|Fish oil capsule|
9994626|NCT01482689|Experimental|Multivitamin tablet|
9994627|NCT01482702|Experimental|weight loss intervention|Behavioral weight loss intervention
9994628|NCT01482702|Experimental|Weight Loss plus Resistance Training|Behavioral weight loss intervention with the addition of resistance training
9994629|NCT01482702|Active Comparator|Comparator|Group of women who did not receive chemotherapy
9994630|NCT01482741||Pts undergoing chemotherapy for Stage IV colorectal carcinoma|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
9994631|NCT01482741||Parents of pediatric patients stage 1-3 neuroblastoma|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
9994632|NCT01482741||Women who have undergone tx for early stage breast cancer|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
9994633|NCT01482741||Men undergoing surveillance imaging after tx for testicular ca|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
9994634|NCT01482741||Men & women enrolled in the MSKCC lung ca screening program|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
9994635|NCT01482741||Men and women enrolled in the thoracic survivorship|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
9994636|NCT01482754|Experimental|Rituximab Infusion at 90-minutes|
9912051|NCT00722098|Placebo Comparator|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
9912052|NCT00722150|Active Comparator|Arm 1|"Oral Artesunate (standard dose)"
9912053|NCT00722150|Active Comparator|Arm 2|"Oral Artesunate (ARC1 dose)"
9912054|NCT00722150|Experimental|Arm 3|"Oral Artesunate (experimental high dose)"
9912055|NCT00722163|Experimental|1|behavioural
9912056|NCT00722163|Active Comparator|2|befriending
9912057|NCT00722163|No Intervention|3|TAU
9912058|NCT00722176|Experimental|1|BL-1020 10 mg
9912059|NCT00722176|Experimental|2|BL-1020 10-30 mg
9912060|NCT00722176|Active Comparator|3|risperidone
9912061|NCT00722189||A|All patients treated
9912062|NCT00722202|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1, 4, 15, 45, 90, 180, and 300 mg
9912063|NCT00722202|Placebo Comparator|placebo|2 placebo subjects per group
9912064|NCT00722215|Placebo Comparator|1|Placebo control arm of study
9912065|NCT00722215|Experimental|2|BQ-123 arm of study
9912066|NCT00722215|Active Comparator|3|Nifedipine arm of study
9912067|NCT00722228|Experimental|Autologous or Allogeneic tumor cells|Intervention: 5 vaccine doses, 3 weeks apart, injected subcutaneously.
9912068|NCT00722241||A|Adult subjects (at least 18 years of age) with a diagnosis of type 1 diabetes (~80%) or insulin-treated type 2 diabetes (~20%); method of insulin delivery may be multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
9912069|NCT00722254||PPH|Subjects diagnosed with primary pulmonary hypertension (PPH)
9912070|NCT00722254||Myelofibrosis|Subjects diagnosed with Primary or Secondary Myelofibrosis
9912071|NCT00722280|Experimental|Hand Transplantation|Described above
9912072|NCT00722293|Experimental|Arm A|once daily oral administration of pazopanib for Days 1-21 days in combination with epirubicin given as a bolus intravenous administration on Day 3
9912073|NCT00722293|Experimental|Arm B|once daily oral administration of pazopanib for Days 1-8 of a 3-week cycle in combination with epirubicin (bolus intravenous administration) on Day 3
9912074|NCT00722293|Experimental|Arm C|epirubicin (bolus intravenous administration) on Day 1 with once-daily oral administration of pazopanib for Days 14-21 of a 3-week cycle
9912075|NCT00722293|Experimental|Arm D|once-daily oral administration of pazopanib (according to schedule selected from either Arm A, B, or C) (3 week cycle) in combination with doxorubicin (bolus intravenous administration) on Day 1 or 3, depending on the schedule selected from either Arm A, B, or C
9912076|NCT00722306|Experimental|A425|A425 Treated
9912077|NCT00722319||A|Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
9912078|NCT00722332|Experimental|1|HBV-related liver transplant patients
9912079|NCT00722345|Placebo Comparator|1|
9912080|NCT00722345|Experimental|2|
9912081|NCT00722384|Experimental|1|0.1 mg bevasiranib in the study eye
9912082|NCT00722384|Experimental|2|0.33 mg bevasiranib in the study eye,
9912083|NCT00722384|Experimental|3|1.0 mg bevasiranib in the study eye
9912084|NCT00722384|Experimental|4|1.5 mg bevasiranib in the study eye
9912085|NCT00722384|Experimental|5|3.0 mg bevasiranib in the study eye.
9912086|NCT00722410|No Intervention|A|
9912087|NCT00722410|Experimental|B|VSL#3 for 4 weeks
9912088|NCT00722410|Experimental|C|Mechanical bowel cleansing followed by VSL#3 for 4 weeks.
9912089|NCT00722462|Experimental|1|Active acupuncture
9912090|NCT00722462|Sham Comparator|2|Sham Acupuncture- acupuncture at neutral points
9912091|NCT00722462|No Intervention|3|Embryo transfer with no acupuncture
9912092|NCT00722475|Experimental|IvIg|Repeated infusions of intravenous immunoglobulin in early pregnancy
9912093|NCT00722475|Placebo Comparator|placebo|infusion of human albumin CSL Behring 5%
9912094|NCT00722488|Experimental|1|MLN4924
9912095|NCT00722501|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
9912096|NCT00722501|Placebo Comparator|placebo|2 placebo subjects per group
9912097|NCT00722514|Experimental|IG|Patient education
9912098|NCT00722514|Other|CG|without patient education
9912099|NCT00722527||Affected Population|Subjects with an elevated hemoglobin concentration or an elevated platelet count
9912100|NCT00722540|Experimental|A|
9912101|NCT00722540|Experimental|B|
9912102|NCT00722540|Experimental|C|
9912103|NCT00722540|Experimental|D|
9912104|NCT00722540|Experimental|E|
9912105|NCT00722579|Experimental|A|The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
9912106|NCT00722605|Experimental|1|cone-beam CT based
9912107|NCT00722618|Active Comparator|Intervention|Written materials, telephone based education
9912108|NCT00722618|Other|Comparison|Written materials
9912109|NCT00722631|Experimental|1|up to 30 mg pioglitazone, tablet, orally, once daily
9912110|NCT00722631|Active Comparator|2|up to 4 mg/day glimepiride, tablet, orally, once daily
9912111|NCT00722670|Experimental|Woman-focused (WF)|Woman-focused intervention (Women's CoOp)
9912112|NCT00722670|Active Comparator|Treatment as Usual (TAU)|TAU (substance abuse treatment only)
9912113|NCT00722683|Experimental|Ultrasound Imaging|Ultrasound Imaging with Contrast
9912114|NCT00722709|Experimental|LA|Use of Ropivacaine
9912115|NCT00722709|Placebo Comparator|Placebo|Use of 0.9% saline
9912116|NCT00722735|Experimental|1|Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule
9912117|NCT00722735|Active Comparator|2|Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets
9912118|NCT00722748||Genebank|By creating a genebank from patient's blood donations we will ultimately be able to define genes for various cardiovascular conditions.
9912119|NCT00722774|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
9912120|NCT00722839|Experimental|Group A|Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
9912121|NCT00722839|Experimental|Group B|Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
9912122|NCT00722852|Experimental|1|
9912123|NCT00722852|Placebo Comparator|2|
9912124|NCT00722891|Active Comparator|Purevision Lens with ReNu|Purevision Lenses with ReNu Multiplus Solution
9912125|NCT00722891|Active Comparator|Purevision Lenses with RepleniSH|Purevision Lenses with Optifree RepleniSH Solution
9912126|NCT00722904||1|patients undergoing routine post-intervention surveillance of aortic coarctation
9912127|NCT00722904||2|Healthy volunteers
9912128|NCT00722930|Experimental|1. Consolidation with Y90 Ibritumomab Tiuxetan|1. Consolidation with Y90 Ibritumomab Tiuxetan
9912129|NCT00722943|Active Comparator|DMT group|These infants will receive tactile stimulation and developmental massage by a licensed therapist. This intervention will be done behind a screen in order to blind the therapy to NICU staff and parents.
9912130|NCT00722943|Placebo Comparator|SHAM control|These infants will have no tactile stimulation or developmental massage done. The therapist will stand behind a screen but will not touch the infant. The screen will blind the NICU staff and parents to the study arm.
9912131|NCT00722956|Experimental|1|AZD5672 + atorvastatin
9912132|NCT00722969|Experimental|A|
9912133|NCT00722982||1|
9912134|NCT00722982||2|
9912135|NCT00722995|Active Comparator|1|Sleeve gastrectomy
9912136|NCT00722995|Active Comparator|2|Gastric Bypass
9912137|NCT00723047|Experimental|1|
9912138|NCT00723060|Active Comparator|1|escitalopram high dose group
9912139|NCT00723060|Active Comparator|2|escitalopram conventional group
9912140|NCT00723112||Affected Group|Adult subjects with the diagnosis of MDS based on the French-American-British classification system.
9912141|NCT00723112||Healthy Controls|Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected
9912142|NCT00723151|Experimental|Low Intensity|One hour of intervention per week
9912143|NCT00723151|Experimental|High Intensity|Five hours of intervention per week, one hour per day for five days per week
9912144|NCT00723164|Active Comparator|FM|Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
9912145|NCT00723164|Placebo Comparator|NaCl|A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
9912146|NCT00723216|Active Comparator|1|Enoxaparin
9912147|NCT00723216|Other|2|Intermittent Pneumatic Compression (IPC)
9912148|NCT00723268|Active Comparator|Prednisolone|
9912149|NCT00723268|Active Comparator|Colchicine|
9912150|NCT00723307|Experimental|Metformin|
9912151|NCT00723307|Placebo Comparator|Placebo|
9912152|NCT00723320|No Intervention|P+N|placebo without lifestyle intervention
9912153|NCT00723320|Experimental|D+N|Atorvastatin 10mg/d
9912154|NCT00723320|Experimental|P+A|lifestyle intervention without Atorvastatin
9912155|NCT00723320|Experimental|D+A|lifestyle intervention and Atorvastatin 10mg/d
9912156|NCT00723333||Affected Group|Patients > 60 years of age with Primary Myelofibrosis that have undergone an allogeneic transplant
9912157|NCT00723346|Experimental|1|
9912158|NCT00723346|Experimental|2|
9912159|NCT00723346|Experimental|3|
9912160|NCT00723346|Active Comparator|4|
9912161|NCT00723359|Experimental|BT062|BT062 single agent dose escalation
9912162|NCT00723385|Placebo Comparator|Placebo|Placebo administration for 12 weeks with repeated 25-OH D determinations over 12 weeks, dietary, sunshine questionnaire recording
9912163|NCT00723385|Experimental|Vitamin D|Vitamin D (1000 or 2000 IU/day)
9912164|NCT00723411|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
9912165|NCT00723411|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
9912166|NCT00723411|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.
9912167|NCT00723424|Experimental|1|AZD5672 + Digoxin (single dose on day 12)
9912168|NCT00723424|Experimental|2|AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)
9912169|NCT00723463|Experimental|A|To determine if apparent diffusion coefficient values can differentiate tumors from normal tissues using a 3T MRI scan.
9912170|NCT00723476|Active Comparator|A|Participants will receive three 60- to 90-minute health education control sessions.
9517592|NCT03305029|Experimental|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
9912171|NCT00723476|Experimental|B|Participants will receive three 60- to 90-minute Family Centered Advanced Care Planning sessions.
9912172|NCT00723502|Experimental|1|
9912173|NCT00723502|Experimental|2|
9912174|NCT00723515|Active Comparator|G1|NaF (sodium fluoride varnish) with 2.26% of fluoride
9912175|NCT00723515|Experimental|G2|NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)
9912176|NCT00723541|Experimental|A|Develop a computer-aided diagnostic system that will aid in the screening and detection of breast abnormalities/cancer
9912177|NCT00723567||Affected Group|Family members of northern European descent in which members have different erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.
9912178|NCT00723619||1|Children and adolescent from German schools in the region Wesel, Hannover and Düsseldorf, selected via special school lists
9912179|NCT00723658|No Intervention|Observation|Non-symptomatic patients are monitored monthly for 3 months, then every 3 months thereafter.
9912180|NCT00723658|Experimental|Treatment|"Symptomatic pts: 2 cycles VTDPACE+R:~dex 40 mg PO D1-4 thalid 200 mg PO D1-4 cisplatin 10 mg/m2 IV D1-4 dox 10 mg/m2 IV D1-4 cyclophos 400 mg/m2 IV D1-4 etoposide 40 mg/m2 IV D1-4 bortezomib 1.0 mg/m2 IV D1,4,8,11 ritux 375 mg/m2 IV D1,8,15 lovenox 40 mg/d SQ D1-platelets >50,000/mcl GCSF 10 mcg/kg/d IV D9-WBC <2,000/mcl apheresis >/= 20x10^6 when WBC and CD34 within normal range, up to 4 cycles~st Trans: mel 200 mg/m2 IV D-1 bortezomib 1.3 mg/m2 IV D-4, -1 PBSC >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 500 ml IV D-1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1~nd Trans: BCNU 300 mg/m2 IV D-5 etoposide 200 mg/m2 IV D-5 to -2 AraC 400 mg/m2 IV D-5 to -2 mel 140 mg/m2 IV D-1 PBSC infusion >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 150 ml/hr IV D-5 to -1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1"
9912181|NCT00723671|Experimental|metabolic peaks|
9912182|NCT00723684|Placebo Comparator|Placebo group|This group will receive no real EEG-Neurofeedback.
9912183|NCT00723684|Experimental|NF group|This group will receive real EEG-Neurofeedback
9912184|NCT00723762||1|Resident of Hattie Larlham long-term care facility receiving VPA
9912185|NCT00723762||2|Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to >1 year), age, and gender; one control patient per VPA patient.
9912186|NCT00723762||3|Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.
9912187|NCT00723775|Other|Part 1|GSK706769 new vs. current formulation; GSK706769 alone vs. GSK706769 plus Kaletra
9912188|NCT00723775|Other|Part 2|GSK706769 alone for 10 days; GSK706769 + Kaletra for 14 days
9912189|NCT00723853|Experimental|Group 1|Reach-Out Program, Nutritional and Exercise Intervention
9912190|NCT00723853|Active Comparator|Group 2|Reach-In Program, Standard of Care
9912191|NCT00723866|Experimental|1|BtxA+mCIMT (combination group)
9912192|NCT00723866|Placebo Comparator|2|BtxA+ conventional rehabilitation (control group)
9912193|NCT00723879||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.
9912194|NCT00723918|Active Comparator|1|methadone plus SAB placebo
9912195|NCT00723918|Experimental|2|methadone plus active SAB
9994637|NCT01482780|Experimental|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
9994638|NCT01482780|No Intervention|Control|normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
9994639|NCT01482793|Active Comparator|AVAMAX|Avamax vertebroplasty kits provided by Care Fusion
9994640|NCT01482793|No Intervention|Simulated injection procedure|Patient will be unaware as to whether the control procedure or vertebroplasty had been performed since full sterile preparation, sedation and simulated injection procedure will be used.
9994641|NCT01482806|Experimental|Computerized CBT + Internet Support Group|Guided patient access to Beating the Blues plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants (CCBT+ISG; N=300).
9994642|NCT01482806|Experimental|Computerized CBT Alone|Guided patient access to Beating the Blues, a proven-effective, on-line 8-session CCBT program approved for use in the United Kingdom (CCBT-alone; N=300).
9994643|NCT01482806|No Intervention|Usual Care|"Primary care physicians' usual care for mood and anxiety disorders (UC; N=100)."
9994644|NCT01482832|Experimental|Experimental|Behavioral: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
9994645|NCT01482832|Active Comparator|Control|Behavioral: Standard care Participants assigned to receive standard care will focus on prenatal education including issues associated with pregnancy and postpartum. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
9994646|NCT01482845|Experimental|Group 1|
9994647|NCT01482845|Experimental|Group 2|
9994648|NCT01482858|Experimental|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
9994649|NCT01482858|Placebo Comparator|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
9994650|NCT01482871|Experimental|Arm 1.5 mg ALG-1001|Group Using 1.5 mg per 100 ul of ALG-1001
9994651|NCT01482871|Experimental|Arm 2.5 mg ALG-1001|Group Using 2.5 mg per 100 ul of ALG-1001
9994652|NCT01482871|Experimental|Arm 5.0 mg ALG-1001|Group Using 5.0 mg per 100 ul of ALG-1001
9994653|NCT01482871|Experimental|Arm 7.5 mg ALG-1001|Group Using 7.5 mg per 100 ul of ALG-1001
9994654|NCT01482897|Experimental|corticoïd|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
9994655|NCT01482897|Placebo Comparator|physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
9994656|NCT01482897|Sham Comparator|feigning of peridural infiltration|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
9994657|NCT01482897|No Intervention|no intervention|natural evolution of discal sciatica
9994658|NCT01482923||Treatment As Usual (TAU)|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
9994659|NCT01482923||Aspiration, Inspiration Respiration, or AIR|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
9994660|NCT01482936|Experimental|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg
9994661|NCT01482949|Experimental|AGS-003 in combination with sunitinib|Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.
9994662|NCT01482975|Experimental|Smoking and Alcohol Prevention|TTM expert system
9994663|NCT01482975|Active Comparator|Diet and Exercise|TTM expert system
9994664|NCT01482988||Critical care patients antipated to stay more than 72 hours|
9994665|NCT01483001|Experimental|Sensitivity Assay|Patients treated with a treatment chosen by sensitivity assay in vitro
9994666|NCT01483014|Experimental|imatinib|
9994667|NCT01483053|Active Comparator|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
9994668|NCT01483053|Active Comparator|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
9994669|NCT01483066|Experimental|ShapeMatch Instrumentation|
9994670|NCT01483066|Active Comparator|Usual Instrumentation|
9994671|NCT01483092|Experimental|inulin|
9994672|NCT01483092|Placebo Comparator|maltodextrin|
9994673|NCT01483105|Experimental|DVD self-hypnosis|This group will receive standard care, and parents/children in this group will receive in the mail a set of questionnaires and the DVD self-hypnosis training program. Parents will be asked to review these materials and practice the training at home with their children for one week leading up to the procedure Parents will also be asked to try to use these techniques with their child during his or her upcoming VCUG procedure.
9994674|NCT01483105|No Intervention|Standard care|Children in this arm will receive standard care and parents/children will be mailed a set of questionnaires to complete before and after your child's upcoming VCUG.
9994675|NCT01483131|Experimental|Low intensity resistance training|
9994676|NCT01483131|Experimental|High intensity resistance training|
9994677|NCT01483131|Experimental|Low intensity resistance training with vascular occlusion|
9994678|NCT01483157|Experimental|low intensity with vascular occlusion|
9994679|NCT01483157|Experimental|high intensity resistance training|
9994680|NCT01483157|No Intervention|no exercise training|
9994681|NCT01483170|Experimental|Fexinidazole|
9994682|NCT01483170|Placebo Comparator|Placebo fexinidazole|
9994683|NCT01483196|Experimental|Diagnostic (TCD)|Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
9994684|NCT01483222|Experimental|QUIKDRAW Pro|Wearing an inelastic lumbar support for 6 months
9994685|NCT01483222|Experimental|MUELLER 4581|Wearing an elastic lumbar support for 6 months
9994686|NCT01483222|No Intervention|Blank Control|Receiving no intervention
9994687|NCT01483235|Experimental|Reduced cardiac rehabilitation (rCRP)|The rCRP is the intervention group, compared to the standard cardiac rehabilitation program group (sCRP). The rCRP will have the core elements of the sCRP, that is, in-hospital exercise sessions, dietary counseling, educational sessions, follow-up with the cardiologist, dietician and exercise specialist. The only difference will be the number of in-hospital exercise sessions (10 sessions for the rCRP v/s 32 sessions for the sCRP). Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
9994688|NCT01483235|Active Comparator|Standard cardiac rehabilitation (sCRP)|The standard cardiac rehabilitation (sCRP) follows the standard cardiac rehabilitation program model of a four-month period. Patients receive an initial intake evaluation by a cardiologist, nurse, exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counseling, medical care, psychological screening and smoking cessation if needed.
9994689|NCT01483248|Experimental|Intervention|Conventional therapy plus MenSCs treatment
9994690|NCT01483248|Active Comparator|No intervention|"Conventional therapy plus placebo treatment:~Oral or intravenous administration"
9994691|NCT01483261|Experimental|Trauma-Focused Cognitive Behavioral Therapy|
9994692|NCT01483261|No Intervention|Waiting List Control|
9994693|NCT01483274|Experimental|Safety|Decitabine and donor lymphocyte infused dendritic cell (DC).
9994694|NCT01483274|Active Comparator|Vaccine|Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides
9994695|NCT01483287|Active Comparator|Enzyme|Capsules with alpha-galactosidase (enzyme) (400 GaIU x 3) are ingested at breakfast, lunch and dinner.
9994696|NCT01483287|Placebo Comparator|Placebo|3 capsules with a non-active substance are ingested at breakfast, lunch and dinner
9994697|NCT01483300|Experimental|lobaplatin|gemcitabine plus lobaplatin
9994698|NCT01483300|Active Comparator|cisplatin|gemcitabine plus cisplatin
9994699|NCT01483326||Cohort|
9994700|NCT01483339|Experimental|Metacognitive Therapy|
9994701|NCT01483339|Experimental|Exposure and Response Prevention|
9994702|NCT01483391|Active Comparator|Enhanced Care|Three sessions of family education and three sessions of individual support over 4 months.
9994703|NCT01483391|Experimental|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training.
9994704|NCT01483404||Patient with fracture of femural neck|All patient with fracture of the femural neck in the listed period of time
9994705|NCT01483417|Experimental|SILS|Laparoscopic hysterectomy including LAVH, LH(a), and TLH using SILS port
9994706|NCT01483417|Active Comparator|Conventional multi-port laparoscopic hysterectomy|3-4 ports laparoscopic hysterectomy including LAVH, LH(a), or TLH
9994707|NCT01483430|Placebo Comparator|Placebo|
9994708|NCT01483430|Experimental|Ginseol Kg1, high dose|
9994709|NCT01483430|Experimental|Ginseol Kg1, low dose|
9994710|NCT01483443|Experimental|Oophrectomy group|Patient undergone oophrectomy along with primary tumor
9994711|NCT01483443|No Intervention|without oophrectomy|Patient group without oophrectomy
9994712|NCT01483456|Other|Usual care|
9912196|NCT00723918|Placebo Comparator|3|methadone placebo plus SAB placebo
9912197|NCT00723970|Experimental|A|Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase
9912198|NCT00723983|Active Comparator|Period 1|Subject dosed with oral sumatriptan succinate during an acute migraine attack.
9912199|NCT00723983|Active Comparator|Period 2|Subject dosed with oral sumatriptan during a non-migraine period.
9912200|NCT00723983|Experimental|Period 3 and Period 6|Subject dosed with NP101 during an acute migraine attack.
9912201|NCT00723983|Experimental|Period 4 and Period 5|Subject dosed with NP101 study patch during a non-migraine period.
9912202|NCT00723996||Group 1|Women receiving a CRC-related questionnaire and a CRC educational video.
9912203|NCT00723996||Group 2|Women who receive only a CRC-related questionnaire.
9912204|NCT00723996||Group 3|Women who receive neither questionnaire nor educational video.
9912205|NCT00724022|Other|A|Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4
9912206|NCT00724022|Experimental|B|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4
9912207|NCT00724022|Experimental|C|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin
9912208|NCT00724035|Experimental|Infraclavicular|This group will receive an ultrasound-guided infraclavicular brachial plexus block.
9912209|NCT00724035|Active Comparator|Axillary|This group will receive an ultrasound-guided axillary brachial plexus block.
9912210|NCT00724074|Experimental|S|Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
9912211|NCT00724074|Active Comparator|C|Usual care - post operative pain medications as per the knee arthroplasty care map.
9912212|NCT00724087|Experimental|5.5-hour bedtime|
9912213|NCT00724087|Experimental|8.5-hour bedtime|
9912214|NCT00724113|Active Comparator|1|infiltration intra articular
9912215|NCT00724113|Experimental|2|ARTHRO distension plus intensive mobilisation
9912216|NCT00724139|Experimental|1|patients (aged 50-75) with Symptomatic knee OA for at least 6 months, fulfilled American College of Rheumatology clinical criteria for OA of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the Kellgren & Lawrence scale.
9912217|NCT00724165|Experimental|1|
9912218|NCT00724165|Active Comparator|2|
9912219|NCT00724178|Experimental|A|Oral cholecalciferol (100,000 IU) administered orally every 60 days plus calcium carbonate (1 gram)given daily
9912220|NCT00724178|Placebo Comparator|B|Double placebo
9912221|NCT00724191||A|Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
9912222|NCT00724204|Placebo Comparator|A|Children that consumed a follow on formula without Lactobacillus salivarius CECT5713
9912223|NCT00724204|Active Comparator|B|Children that consumed a follow on formula with Lactobacillus salivarius CECT5713
9912224|NCT00724217|Experimental|Normal weight|BMI < 26
9912225|NCT00724217|Experimental|Overweight|BMI >= 26
9912226|NCT00724230||Arm 1|Overall study population.
9912227|NCT00724256|Experimental|1|
9912228|NCT00724256|Active Comparator|2|
9912229|NCT00724269|Active Comparator|Opti Free RepliniSH|Opti Free RepliniSH
9912230|NCT00724269|Active Comparator|ReNu Multi-Plus|ReNu Multi-Plus
9912231|NCT00724295||Arm 1|Overall study population
9912232|NCT00724321|Other|Iloprost and placebo|Each participant will undergo testing at sea level and altitude after inhalation of iloprost and placebo, sequence is randomly assigned.
9912233|NCT00724399||Observations|Women attending screening mammography and gynecology visit
9912234|NCT00724399||A|Women attending their annual screening mammography and gynecology clinic visits.
9912235|NCT00724412|Active Comparator|Systane|Systane
9912236|NCT00724412|Active Comparator|Optive|Optive
9912237|NCT00724438||1|Obese women: women with a body mass index (BMI) >30
9912238|NCT00724438||2|Normal weight women: women with a BMI <25
9912239|NCT00724516|Experimental|Novel Breast Compression Paddle|Women scheduled to undergo a breast mammography wire localization procedure will have a new breast compression paddle will be used Instead of using the regular wire localization mammography compression paddle.
9994713|NCT01483469|Active Comparator|Concept Proof|
9994714|NCT01483469|Experimental|Receptor Occupancy|
9994715|NCT01483482|Other|Conservative treatment|"The group allocated to conservative treatment is treated with a simple sling. The sling is removed when the patient is pain free.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
9994716|NCT01483482|Other|Surgical treatment|"Patients allocated to surgical treatment are operated with a superior locking plate.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
9994717|NCT01483495||Diagnostic tool|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
9994718|NCT01483508|Active Comparator|Flavanol and procyanidins|
9994719|NCT01483508|Experimental|Flavanols only|
9994720|NCT01483508|Experimental|Procyanidins only|
9994721|NCT01483521|Experimental|Waitlist families|"Experimental arm consisted of randomized waitlist families who received home visitation where mothers were taught to play with their children in a developmentally appropriate manner and also engaged in a co-construction task.~Control arm families did not get any active intervention. Parents from both arm types completed pre and post questionnaires to measure child's externalizing behaviors and parenting stress.~Parents from experimental group were encouraged to keep a diary of their play record."
9994722|NCT01483534|Experimental|Targeted Lung Denervation|Targeted Lung Denervation
9994723|NCT01483547||Neurosurgical|
9994724|NCT01483547||Non-neurosurgical|
9994725|NCT01483573|Experimental|straight leg raise|stretch the muscle
9994726|NCT01483573|Experimental|neural mobilization|stretch the nerve
9994727|NCT01483586|Experimental|KLTc high dose|6 KLTc gelcaps taken four times a day
9994728|NCT01483586|Experimental|KLTc low dose|3 KLTc gelcaps taken four times a day
9994729|NCT01483612|Experimental|Lifestyle counseling|
9994730|NCT01483612|No Intervention|control|
9994731|NCT01483638|Experimental|Experimental|axitinib
9994732|NCT01483638|Placebo Comparator|control|placebo
9994733|NCT01483677|Experimental|Nintendo Wii|Subjects in this arm of the study play a game (Boomblox) on the Nintendo Wii for 30 minutes.
9994734|NCT01483677|Active Comparator|Playstation2|Subjects in this arm of the study play a game (Time Crisis 2) on the Playstation 2 for 30 minutes.
9994735|NCT01483703||Diagnostic tool|Laser Speckle Imaging of Critical Care Neonates
9517593|NCT03305003|Active Comparator|Communication modality: spiral notebook|
9517594|NCT03305003|Experimental|Communication modality: mobile application|
9994736|NCT01483716|No Intervention|Control|NIV alone
9994737|NCT01483716|Experimental|Intervention|Rehabilitation arm
9994738|NCT01483729|Active Comparator|Part 1 A|
9994739|NCT01483729|Experimental|Part 1 B|
9994740|NCT01483729|Experimental|Part 1 C|
9994741|NCT01483729|Active Comparator|Part 2 D|
9994742|NCT01483729|Experimental|Part 2 E|
9994743|NCT01483729|Experimental|Part 2 F|
9997952|NCT01513395|Experimental|Interval|"Participants randomized to the Interval or experimental arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time"
9997953|NCT01513408|Experimental|CD8/Foxp3|patient suffering from non-metastatic breast cancer
9997954|NCT01513421||Active vacuum pressure drainage|
9997955|NCT01513421||Free drainage|
9912240|NCT00724529||Serious Active Crohns Disease|Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.
9912241|NCT00724529||Fistula-Type Active Crohns Disease|Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.
9912242|NCT00724529||Ankylosing Spondylitis|Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.
9912243|NCT00724542|No Intervention|Control|Placebo with lifestyle intervention
9912244|NCT00724542|Experimental|Drug|Voglibose tablets with lifestyle intervention
9912245|NCT00724555||1|Adults living in DC neighborhoods with high proportions of underserved adults. The age of the cohort members will reflect the age of DC residents who suffer most from stroke.
9912246|NCT00724581|Experimental|A|
10213025|NCT04717765|Active Comparator|Preventive osteonecrosis resulting from chemo or radiotherapy - LPRF+ extraction|"For patients who need dental extraction for the adequacy of the oral cavity. LPRF placement on the day the tooth extraction is performed. The procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.~After the LPRF has been placed, the suture should be done in a way that facilitates healing for primary intention."
10213026|NCT04717765|No Intervention|Preventive osteonecrosis resulting from chemo or radiotherapy - extraction only|"For patients who need dental extraction for the adequacy of the oral cavity, the procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment.~The suture should be done in a way that facilitates healing for primary intention."
9912250|NCT00724620|Experimental|Early Responders (ER)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have responded to therapy at Treatment Week 12 (ie, who are Early Responders defined by HCV-RNA[-] at Treatment Week 12) will continue the combined treatment for a total of 48 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
9912251|NCT00724620|Experimental|Slow Responders (SR): Decrease in viral load >=2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have a slow response to therapy at Treatment Week 12 (ie, Slow Responders who are not HCV-RNA[-] at Treatment Week 12 but decrease >=2 log) will continue the combined treatment for a total of 72 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
9912252|NCT00724620|Experimental|Nonresponders (NR): Decrease in viral load <2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have not responded to therapy at Treatment Week 12 (ie, Nonresponders who are not HCV-RNA[-] at Week 12 of Treatment and/or have a decrease in viral load <2 log) will stop treatment at Treatment Week 12.
9912253|NCT00724633|Other|1|standard dialysate Na 140 mEq/L
9912254|NCT00724633|Active Comparator|2|dialysate sodium equal to patient's predialysis serum Na
9912255|NCT00724633|Active Comparator|3|dialysate sodium lower than patient's predialysis plasma sodium
9912256|NCT00724646||1|Habilitation assistants
9912257|NCT00724646||2|Parents/ legal guardians
9912258|NCT00724659|Experimental|Ultrasound Pre-Arthrogram|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
9912259|NCT00724659|Experimental|Ultrasound Post-Arthrogram|Ultrasound of the joint(s) after the clinically scheduled arthrogram of the same joint(s), performed while the body still has a contrast agent in it from the arthrogram. The contrast agent varies with different joint areas, but is usually iodine based (like Ultravist.)
9912260|NCT00724672||ETA|RA patients who were scheduled to receive etanercept 50 mg subcutaneously once weekly
9912261|NCT00724672||IFX|RA patients who were scheduled to receive infliximab 3 mg/kg IV at Weeks 0, 2, and 6
9912262|NCT00724672||ADA|RA patients who were scheduled to receive adalimumab 40 mg subcutaneously biweekly
9912263|NCT00724672||non-diseased controls|Healthy individuals who contributed their RNA/cDNA samples prior to the study and for whom ethical approval has already been obtained.
9912264|NCT00724685|Placebo Comparator|Placebo|
9912265|NCT00724685|Experimental|Active|
9912266|NCT00724724|Experimental|1|Butylphthalide Soft Capsules + Aspirin
9912267|NCT00724724|Active Comparator|2|Aspirin
9912268|NCT00724737|Active Comparator|fMRI of the brain, no surgery|Healthy volunteers will undergo an fMRI (functional MRI of the brain).
9912269|NCT00724737|Experimental|fMRI of the brain, presurgical|Patients scheduled to have brain surgery will undergo an fMRI (functional MRI of the brain).
9912270|NCT00724763|Experimental|1|Treatment group.
9912271|NCT00724763|Sham Comparator|2|control group
9912272|NCT00724776|Experimental|1|Open-label treatment with albinterferon alfa 2b escalating single dose
9912273|NCT00724828||1|
9912274|NCT00724880|Experimental|1|Clopidogrel is stopped 5 days prior to surgery
9912275|NCT00724880|Experimental|2|Clopidogrel is stopped 3 days prior to surgery
9912276|NCT00724880|Experimental|3|Clopidogrel is stopped 0 days prior to surgery
9912277|NCT00724906|Experimental|Parkinsonian Syndromes|Subjects with Parkinsonian Syndromes
9517595|NCT03304990||Family History of CA|Hereditary cancer genetic screening based on risk factors
9912278|NCT00724906|Experimental|Non-Parkinsonian Syndromes|Subjects with Non-Parkinsonian Syndromes
9912279|NCT00724919||1|
9912280|NCT00724997|Other|cohort I|dose level I: 6.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
9912281|NCT00724997|Other|cohort II|dose level II: 6.7 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
9912282|NCT00724997|Other|cohort III|dose level III: 7.0 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
9912283|NCT00724997|Other|cohort IV|dose level IV: 7.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
9912284|NCT00724997|Other|cohort V|dose level V: 7.7 log10 TCID50/volunteer, 16 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
9912285|NCT00725023|Experimental|1|Treatment: TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
9912286|NCT00725023|Other|2|Treatment: Dummy TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
9912287|NCT00725062|Experimental|Patients Receiving CD4+/CD25+ cells|CD4+/CD25+ cells given intravenously over 15-60 minutes on Day -2 (prior to peripheral blood progenitor cell transplant)
9912288|NCT00725088|Experimental|1|exercise training group
9912289|NCT00725088|No Intervention|2|control group
9912290|NCT00725114|Active Comparator|Tetrodotoxin|
9912291|NCT00725114|Placebo Comparator|Sugar injection|
9912292|NCT00725140||Single|
9912293|NCT00725166||Young|Young men 19-25 years old
9912294|NCT00725166||Old|old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
9912295|NCT00725179||1|Patients receiving oral NAC treatment
9912296|NCT00725179||2|Patients receiving IV NAC treatment
9912297|NCT00725192|Active Comparator|1|Cognitive Processing Therapy
9912298|NCT00725192|Experimental|2|Hypnosis plus Cognitive Processing Therapy.
9912299|NCT00725218|Placebo Comparator|1|Saline 5 ml injection 10 min prior to propofol administration.
9912300|NCT00725218|Experimental|2|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
9912301|NCT00725231|Active Comparator|Arm A|Chemotherapy with dose dense CHOP-14, 6 cycles
9912302|NCT00725231|Experimental|Arm B|Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
9912303|NCT00725244|Active Comparator|1|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
9912304|NCT00725244|Active Comparator|2|"Argon Plasma Coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
9912305|NCT00725257|Active Comparator|1|Low-carbohydrate, energy-restricted, Mediterranean-type diet
9517596|NCT03304990||Risk Factors for CA|No dx of CA
9517597|NCT03304990||Suspected or Confirmed Diagnosis of CA|Suspected or confirmed diagnosis of cancer
9517598|NCT03304964|Experimental|100 mg FP-025 (b.i.d)|
9517599|NCT03304964|Experimental|200 mg FP-025 (b.i.d.)|
9912306|NCT00725257|Active Comparator|2|Low-fat diet
9912307|NCT00725335|Experimental|group A,non-pringle group|Intervention of curative resection of HCC Without pringle manoeuvre in this arm
9912308|NCT00725335|Active Comparator|pringle group(B)|when the curative resection of HCC performed, the pringle manoeuvre will be routinely applied.
9912309|NCT00725348|Experimental|A|R115866
9912310|NCT00725400|Active Comparator|1|Patients will receive a Cetuximab and Radiation Therapy.
9912311|NCT00725400|Active Comparator|2|Patients will undergo Surgery before or after Radiation Therapy.
9912312|NCT00725426|Experimental|1|Bosutinib
9912313|NCT00725439|Experimental|A|Talarozole
9912314|NCT00725465||LAP surgery with CO2 colonoscopy|30 surgical patients, male and female undergoing laparoscopic surgical treatment for colorectal conditions such as neoplasm or rectal prolapse managed with intra-operative carbon dioxide (co2)colonoscopy for standard care of their medical condition.
9912315|NCT00725517|Experimental|1|Icodextrin group
9912316|NCT00725517|No Intervention|2|Glucose group
9912317|NCT00725556|Other|1|Speech therapy
9912318|NCT00725569|Active Comparator|A|Bellis perennis and Staphysagria (C6)
9912319|NCT00725569|Active Comparator|B|Bellis perennis and Staphysagria (C30)
9912320|NCT00725569|Placebo Comparator|C|Placebo Remedy
9912321|NCT00725582|Experimental|A|
9912322|NCT00725582|Placebo Comparator|B|
9912323|NCT00725595||E, 2, III|To treat CSR with ASV and Bilevel ventilators
9912324|NCT00725634|Experimental|AV-299 Dose Escalation Arm|AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
9912325|NCT00725634|Experimental|AV-299 in combination with erlotinib|AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors
9912326|NCT00725647||Treated PDA|Infants who had a PDA which the attending physicians treated medically or surgically.
9912327|NCT00725660||1|Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination.
9912328|NCT00725673||1|GOLD II COPD patients with osteoporosis
9912329|NCT00725673||2|GOLD II COPD patients with a normal bone mineral density
9912330|NCT00725738|Experimental|A|"Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA over-the-wire catheter."
9912331|NCT00725777|Experimental|A|
9912332|NCT00725790|Experimental|A|Vardenafil treatment group
9517600|NCT03304964|Experimental|400 mg FP-025 (b.i.d)|
9517601|NCT03304964|Experimental|200 mg FP-025 (single dose; fasted)|
9912333|NCT00725790|Placebo Comparator|B|Placebo treatment group
9912334|NCT00725829|Experimental|1|simvastatin 40g + ezetimibe 10g once a day
9912335|NCT00725829|Placebo Comparator|2|simvastatin 40g + placebo once a day
9912336|NCT00725855|Experimental|1|1 mg dose
9912337|NCT00725855|Experimental|2|5 mg dose
9912338|NCT00725855|Experimental|3|15 mg dose
9912339|NCT00725855|Experimental|4|50 mg dose
9912340|NCT00725855|Placebo Comparator|5|Placebo dose
9912341|NCT00725868|Other|1|Data private hospitals, angioplasty, sampling of blood
9912342|NCT00725894||1|The Pediatric Locking Nail was designed to provide stable sub-rigid fixation of femoral fractures in children
9912343|NCT00725907|Experimental|1|PGRF
9912344|NCT00725907|Placebo Comparator|2|saline
9912345|NCT00725946|Experimental|Iodine-124 PET-CT scan|
9912346|NCT00725972|Experimental|Augmented Oxygen Delivery Group|"Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.~Intervention: Augment O2 Delivery by hemodynamic protocol. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)"
9912347|NCT00725972|Sham Comparator|Control|Patients having the same types of surgery but receiving usual anesthetic care. Intervention: High Risk Surgery. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)
9912348|NCT00725985|Experimental|Cladribine 5.25 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.
9912349|NCT00725985|Experimental|Cladribine 3.5 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
9912350|NCT00725985|Placebo Comparator|Placebo (ITP)|Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
9912351|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (OLMP)|Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
9912352|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (OLMP)|Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
9912353|NCT00725985|Experimental|Placebo, Rebif (OLMP)|Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
9912354|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
9912355|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
9517602|NCT03304964|Experimental|200 mg FP-025 (single dose; fed condition)|
9934144|NCT05012111||Cohort 1|Severe Aplastic Anemia(SAA): Age 2 and older; Previous diagnosis of bone marrow failure
9934145|NCT05012111||Cohort 2|Other Marrow Failure: Age 2 and older; Previous diagnosis of bone marrow failure;
9994744|NCT01483755|Experimental|Postconditionned|36 postconditionned patients
9994745|NCT01483755|Sham Comparator|Conventional intervention|36 control patients with conventional primary percutaneaous intervention (PCI)
9912356|NCT00725985|Experimental|Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
9912357|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
9912358|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
9912359|NCT00725985|Experimental|Placebo, Rebif (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
9912360|NCT00725998||1|"The ECAP characteristics have been analyzed in 13 children implanted younger than three years old.~Series Study Results:~During the first year of CI use there was a significant statistical growth for the amplitude of N1 peak, in basal electrodes, between the second and third returns. There were not any significant differences obtained for N1 peak, latency, slope, neither for p-NRT nor recovery time, among the returns."
9912361|NCT00726011|Experimental|Tetrodotoxin|There is only one arm; active treatment with TTX
9912362|NCT00726076|Experimental|Treatment|The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment.
9912363|NCT00726076|Experimental|Control|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
9912364|NCT00726102|Active Comparator|Meat|Provide locally available meat daily to infants from 6 to 18 mos of age
9912365|NCT00726102|Active Comparator|Control|Daily provision of cereal to infants from 6-18 mos
9912366|NCT00726102|Active Comparator|Fortified rice cereal|Provide equi-caloric serving of fortified rice cereal on daily basis from 6-18 months of age
9912367|NCT00726115|Placebo Comparator|1|arm placebo
9912368|NCT00726115|Experimental|2|arm drug
9912369|NCT00726128||VueLock™ Anterior Cervical Plate Group|VueLock™ Anterior Cervical Plate, Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
9912370|NCT00726154|Other|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
9934146|NCT05012111||Cohort 3|Telomere Biology Disorders(TBD): Age 2 and older; Previous diagnosis of bone marrow failure
9934147|NCT05012111||Cohort 4|Inherited Bone Marrow Failure(IBMF)Syndromes: Age 2 and older; Previous diagnosis of bone marrow failure
9934148|NCT05012111||Cohort 5|Family Screening: Age 2 and older; First degree family member with a known or suspected inherited bone marrow failure syndrome
9994746|NCT01483768|Experimental|Arm A:|Sleeve gastrectomy for morbid obesity
9517603|NCT03304951|Experimental|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
9912371|NCT00726154|Other|Collaborative care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
9912372|NCT00726193||1 - standard films|Tibia reconstruction surgery with OsteoGen™ with standard radiographs
9912373|NCT00726193||2 - Standard films plus CT|Tibia reconstruction surgery with OsteoGen™ with standard radiographs and additional CT scan at 10 and 18 weeks.
9912374|NCT00726206|Other|1|Recording of the movements Recording of the electroencephalogram
9912375|NCT00726219|Other|1|Insertion distance of femoral catheter: 3cm
9912376|NCT00726219|Other|2|Insertion distance of femoral catheter: 7cm
9912377|NCT00726245|Experimental|1|PRGF
9912378|NCT00726245|Placebo Comparator|2|physiological saline
9912379|NCT00726258|Placebo Comparator|1|Drip of physiological serum
9912380|NCT00726258|Active Comparator|2|Drip of ketamine
9912381|NCT00726271|Experimental|active|"Subjects will complete the Zung Depression and Anxiety Scales. At the first visit the subject's medication list, weight, height, and waist measurement will be obtained. The goal is to recruit a minimum of 20 patients.~Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease subjects.~They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils."
9912382|NCT00726310||SpineLink® , SpineLink® II Group|Spinal fusion surgery with SpineLink®
9912383|NCT00726349||Observation|Patients undergoing isolated elective total hip or knee arthroplasty (primary or revision surgery for a non-malignant condition), aged 60 years or older and able to walk prior to surgery.
9912384|NCT00726362||1|patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
9912385|NCT00726401|Active Comparator|1|
9912386|NCT00726401|Placebo Comparator|2|
9912387|NCT00726427|Experimental|1|8 increasing oral single doses given to 8 groups (3 on active and 1 on placebo in each group)
9912388|NCT00726427|Experimental|2|2 oral doses of AZD1656 given to 2 groups together with food
9912389|NCT00726440|Active Comparator|Group1-patient|The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.
9912390|NCT00726440|Active Comparator|Group2-diabetologist|"The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:~HbA1c>=7.5%~1 severe hypoglycaemia or more~More than 4 benign hypoglycaemia per week~According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:~step 1: 3 sensors per month~step 2: 4 sensors per month~step 3: 5 sensors per month~step 4: continuous use"
9912391|NCT00726440|Placebo Comparator|Group3-Control|Usual follow up with self-monitoring blood glucose.
9517604|NCT03304938|Active Comparator|Lavender oil|
9517605|NCT03304938|Placebo Comparator|vehicle (Almond oil)|
9912392|NCT00726466|Experimental|I|This is an open-label, study of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg/kg/wk subcutaneous dose of Efalizumab in in subjects with AMD.
9912393|NCT00726492|Experimental|CSWD + Hydro|Continuous short wave diathermy and hydrotherapy
9912394|NCT00726492|Experimental|Hydro alone|Hydrotherapy alone
9912395|NCT00726492|Experimental|CSWD alone|Continuous short wave diathermy alone
9912396|NCT00726492|No Intervention|Control|No treatment
9912397|NCT00726505|Active Comparator|Group 1|Subjects with T2DM - Dapagliflozin 5 mg
9912398|NCT00726505|Active Comparator|Group 2|Subjects with T2DM - Dapagliflozin 20 mg
9912399|NCT00726505|Active Comparator|Group 3|Healthy Subjects - Dapagliflozin 20 mg
9912400|NCT00726531|Experimental|OEP|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
9912401|NCT00726531|Experimental|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
9912402|NCT00726531|No Intervention|TAU|Treatment as usual
9912403|NCT00726544|Placebo Comparator|Placebo|
9912404|NCT00726544|Active Comparator|Low Dose|
9912405|NCT00726544|Active Comparator|Medium Dose|
9912406|NCT00726544|Active Comparator|High Dose|
9912407|NCT00726570|Experimental|SCD + LMWH|This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
9912408|NCT00726570|Active Comparator|LMWH only|Patients in this group will receive only standard LMWH therapy during their ICU stay.
9912409|NCT00726583|Experimental|Investigational Drug|Dose Escalation
9912410|NCT00726596|Experimental|Hydroxychloroquine|Hydroxychloroquine - 400 mg (cohort A) Hydroxychloroquine - 600 mg (cohort B)
9912411|NCT00726635|Active Comparator|1|Women in this arm will not receive a psychological intervention but rather will have a conversation with a nurse for one hour (attention control).
9912412|NCT00726635|Experimental|2|Cognitive intervention: Women in this arm will receive a cognitive psychological intervention(cognitive technique:self-talk)
9912413|NCT00726635|Experimental|3|Psycho-physiological intervention: Women in this arm will receive a psycho-physiological intervention (relaxation and guided imagery)
9912414|NCT00726687|Experimental|single|Single arm designed to elicit Maximum Tolerated Dose
9912415|NCT00726700|Active Comparator|Arm I (without rituximab)|Patients receive pegfilgrastim subcutaneously (SC) on day 2 or 4 and CHOP comprising cyclophosphamide IV, doxorubicin IV, vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2 weeks for up to 6-8 courses in the absence of disease progression or unacceptable toxicity.
9912416|NCT00726700|Experimental|Arm II (with rituximab)|Patients receive pegfilgrastim and CHOP for up to 6-8 courses as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.
9912417|NCT00726726|Other|A|
9912418|NCT00726726|Experimental|B|
9912419|NCT00726726|Experimental|C|+ Other
9912420|NCT00726765||Referral Strategy 1|"Patient meets at least one of the following three criteria:~Inflammatory back pain~Human leukocyte antigen B27 (HLA-B27)~Sacroiliitis demonstrated by imaging (X-ray, magnetic resonance imagining [MRI], bone scan [if previously available])"
9912421|NCT00726765||Referral Strategy 2|"Patient meets at least two of the following six criteria:~Inflammatory back pain~HLA-B27~Sacroiliitis (on imaging)~Family history of AS~Good response of back pain to nonsteroidal anti-inflammatory drugs (NSAIDs)~Known Extra Articular Manifestations (Uveitis, Iridocyclitis, Psoriasis, Inflammatory Bowel Disease)"
9912422|NCT00726778||A, Observational|Healthy European American, African American, and Hispanic American children aged 7-12
9517606|NCT03304925|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
9517607|NCT03304912||Cohort|The cohort will be comprised of women who inject drugs who are eligible for PrEP.
9912423|NCT00726791|Experimental|1|high frequency rTMS applied to the motor cortex
9912424|NCT00726804|Other|2|
9912425|NCT00726817|Placebo Comparator|1|enemas, once daily, containing saline
9912426|NCT00726817|Experimental|2|enemas, once daily, containing 50mM butyrate
9912427|NCT00726817|Experimental|3|enemas, once daily, containing 100mM butyrate
9912428|NCT00726843|Active Comparator|1|8 weeks of Yoga, followed by 8 weeks of follow-up
9912429|NCT00726843|Active Comparator|2|8 weeks of follow-up, followed by 8 weeks of yoga
9912430|NCT00726869|Experimental|Cohort 1|2.5 mg/kg
9912431|NCT00726869|Experimental|Cohort 2|5.0 mg/kg
9912432|NCT00726869|Experimental|Cohort 3|10.0 mg/kg
9912433|NCT00726869|Experimental|Cohort 4|20.0 mg/kg
9912434|NCT00726934|Active Comparator|Neutropenic Diet|Participants will be instructed to follow a Neutropenic Diet. This group will receive the same information as the Food Safety Arm with some additional recommendations for avoiding high bacteria foods during length of time on study.
9912435|NCT00726934|Active Comparator|FDA Food Safety Guidelines|Participants will be instructed to follow the FDA Food Safety Guidelines
9912436|NCT00726947|Experimental|1|Ultrasound imaging of Acute DVT (deep vein thrombosis)
9994747|NCT01483781|Experimental|Canagliflozin|
9994748|NCT01483781|Placebo Comparator|Placebo|
9994749|NCT01483794||Genital warts treated|Patients that have had treatment on their genital warts
9994750|NCT01483794||Genital warts on treatment|Patients currently being treated for genital warts
9994751|NCT01483833|Active Comparator|Iferanserin|Iferanserin administration intra-anally twice daily for 14 days
9994752|NCT01483833|Placebo Comparator|Placebo|Placebo administration intra-anally twice daily for 14 days
9994753|NCT01483846|Experimental|AV-101|"Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.~--------------------------------------------------------------------------------"
9994754|NCT01483846|Placebo Comparator|microcrystalline cellulose|Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
9994755|NCT01483859|Other|right hepatectomy with preoperative LSM|patients undergoing right hepatectomy with preoperative LSM between August 2007 and July 2011
9994756|NCT01483885|Experimental|TENS 4Hz|
9994757|NCT01483885|Experimental|Interferential Current 4Hz|
9994758|NCT01483885|Placebo Comparator|TENS|
9994759|NCT01483885|Placebo Comparator|Interferential Current|
9994760|NCT01483885|Experimental|Manual Acupuncture|
9994761|NCT01483885|Experimental|TENS 100 Hz|
9994762|NCT01483885|Experimental|Interferential Current 100Hz|
9994763|NCT01483911|Experimental|ALX-0171|
9994764|NCT01483911|Placebo Comparator|Placebo|
9994765|NCT01483950||Patients with hypercholesterolaemia|
9994766|NCT01483976|Active Comparator|Oral medical nutritional supplement without AN777|orally over a three hour period
9994767|NCT01483976|Experimental|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
9994768|NCT01483989|Experimental|SYSTANE® Gel Drops Lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
9994769|NCT01484002||Crosslinked polyethylene liners|Polyethylene liners from joint replacements that were crosslinked and heat treated to eliminate free radicals.
9994770|NCT01484002||Conventional polyethylene liners|Polyethylene liners from joint replacements that manufactured from conventional UHMWPE and terminally sterilized by methods that did not involve gamma-irradiation.
9994771|NCT01484015|Experimental|Arm I (standard infusion)|Patients receive cefepime hydrochloride IV over 30 minutes.
9994772|NCT01484015|Experimental|Arm II (prolonged infusion)|Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
9994773|NCT01484067|Experimental|Patch|At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
9994774|NCT01484067|No Intervention|No Patch|No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
9912437|NCT00726947|Experimental|2|Ultrasound imaging of Chronic DVT (deep vein thrombosis)
9912438|NCT00726960|Experimental|1|Aprepitant
9912439|NCT00726960|Placebo Comparator|2|Placebo
9912440|NCT00726973|Experimental|1|Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
9912441|NCT00726973|Active Comparator|2|Ranibizumab monotherapy
9912442|NCT00727012|Other|SJM® Rigid Saddle Ring|The SJM® Rigid Saddle Ring is an annuloplasty ring comprised of a titanium core surrounded by a double-velour, polyester fabric sewing cuff.
9912443|NCT00727038|Experimental|1|Lucentis (ranibizumab) with conventional treatment
9912444|NCT00727038|No Intervention|2|Conventional treatment
9912445|NCT00727051||1|Liver and lung transplant candidates referred for coronary angiography will be invited to participate in the study.
9912446|NCT00727077||IntronA/Rebetol|Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites
9912447|NCT00727103|Active Comparator|1 Varenicline|Varenicline will be dispensed in 0.5 mg (blue capsules containing a 0.5 mg varenicline tablet) and 1 mg (red capsules containing a 1 mg varenicline tablet) capsules taken orally. During the first 3 days of medication, participants will take one blue capsule (0.5 mg tablet) of varenicline daily. If the medication is well-tolerated, the dose will be increased to one blue capsule (0.5 mg) po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 red capsule (1 mg) po twice daily. At the end of the 8th week, varenicline will be discontinued.
9912448|NCT00727103|Placebo Comparator|2 Placebo|Placebo will be dispensed in blue and red color coded capsules. During the first 3 days, participants will take one blue capsule po daily. If the medication is well-tolerated, the dose will be increased to one blue capsule po twice daily for 4 days. On day 8, the patients will take 1 red capsule po twice daily. At the end of the 8th week, placebo will be discontinued.
9912449|NCT00727116|Experimental|State-wide|All parents of newborns in Pennsylvania hospitals will receive the parent education materials
9912450|NCT00727116|Experimental|Central PA|All of Central PA new parents will receive the state-wide hospital-based intervention. In half of the 31 central PA counties, all primary care providers having offices in those counties provide an office-based booster intervention to new parents. The other half of central PA counties will receive the state-wide, hospital-based intervention, but not the office-based booster intervention.
9912451|NCT00727142|Active Comparator|open shunt|functioning shunt
9912452|NCT00727142|Active Comparator|closed shunt|NON FUNCTIONING SHUNT
9912453|NCT00727155|Experimental|1|Treatment
9912454|NCT00727155|No Intervention|2|Waitlist
9912455|NCT00727181|Other|Trifecta Valve|The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.
9912456|NCT00727285||A|CF patients followed by the Adult CF Program at National Jewish Health meeting criteria for an acute pulmonary exacerbation.
9912457|NCT00727324|Experimental|1|BIAP
9912458|NCT00727350|Experimental|1|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
9912459|NCT00727363|Placebo Comparator|1|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
9912460|NCT00727363|Experimental|2|5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.
9912461|NCT00727376||Observation|Esophageal cancer patients
9912462|NCT00727389|Other|groups of women|To evaluate the capacity of muscular function and articular amplitude in the aged women
9912463|NCT00727428|Experimental|Group A|
9912464|NCT00727454|Placebo Comparator|1 Control|No treatment
9912465|NCT00727454|Experimental|2 CPAP|Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA
9912466|NCT00727467|Experimental|A|"On Days 1-8 of the trial, participants in Group A will be given the iPod with some music on the device to allow all participants to become familiar with the device i.e. turning device on and off, increasing and decreasing the volume. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group A will be allocated to the 'intervention' phase. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks. On Days 15-23, participants in Group A will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat."
9912467|NCT00727467|Active Comparator|B|"On Days 1-8 of the trial, participants in Group B will be given the iPod with some music on the device to allow all participants to become familiar with the device. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group B will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat. On Days 15-23, participants in Group B will be allocated to the 'intervention phase'. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks."
9912468|NCT00727480|Experimental|A|Ultrasound Imaging of fingertips
9912469|NCT00727493|Active Comparator|1|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
9912470|NCT00727493|Placebo Comparator|2|placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
9912471|NCT00727493|No Intervention|3|dental implant, calcium 1000mg and Vitamin D 800 IU daily
9912472|NCT00727519|Experimental|PG|
9912473|NCT00727519|Experimental|PL|
9912474|NCT00727545|Experimental|1|
9912475|NCT00727584|Active Comparator|Arm I (multi-fraction radiotherapy)|Patients undergo 5 fractions of 20 Gy external-beam radiotherapy.
9912476|NCT00727584|Experimental|Arm II (single-fraction radiotherapy)|Patients undergo 1 fraction of 8 Gy external beam radiotherapy.
9912477|NCT00727662|Experimental|1|Yoga
9912478|NCT00727662|Active Comparator|2|A Wellness Seminar series
9912479|NCT00727675|Other|1|Integrated Cognitive Behavioral Therapy for pain reduction and opioid dependence.
9912480|NCT00727701|Experimental|1|Will receive usual wound prevention care, aftercare summaries, and regular surveillance.
9912481|NCT00727701|No Intervention|2|Will receive usual wound prevention and surveillance only.
9912482|NCT00727701|No Intervention|3|Will receive usual wound prevention only.
9912483|NCT00727727||Parkinsonian patients|
9912484|NCT00727753||Ranibizumab|
9912485|NCT00727753||Bevacizumab|
9912486|NCT00727753||Dry AMD|
9934149|NCT05012098|Experimental|1/Arm 1|Treatment with Bintrafusp alfa
9934150|NCT05010967|Experimental|High intensity interval training|High intensity interval training will be administered three days a week for 8 weeks. six series with 3 minutes rest period between series. For first 4 weeks the series would consist of 30 seconds of exercise and 30 seconds rest. exercises will consist of burpees, skipping, lunges, 1-legged squat, leg lever, push ups. for next four weeks the duration of exercise will be 45 seconds followed by 30 seconds recovery.
9934151|NCT05010967|Active Comparator|Yoga Training|Yoga will be administered 3 days a week for 8 weeks. the session would be of 30-50 minutes with 5 minutes breathing followed by 15-35 minutes yoga and 10 minutes supine meditation. cat-cow stretch, child's pose, downward dog, plank, cobra pose will be used.
9934152|NCT05010837|Experimental|Kinesio taping with abdominal exercises|Kinesio taping will be applied along with abdominal exercises.
9934153|NCT05010837|Active Comparator|Abdominal Exercises|Only abdominal exercises will be administered to the participants.
9934154|NCT05009979|Experimental|1/Baseline and Post-treatment Imaging|18F-DCFPyL PET/CT imaging, CT and/or MRI and standard of care local ablative treatment
9934155|NCT05007990||Active|Participants include individuals who are caregivers of an individual with a chronic medical condition, OR individuals who support caregivers of an individual with a chronic medical condition.
9934156|NCT05007990||Bereaved|Participants include individuals who were caregivers of an individual with a chronic medical condition who has died, OR individuals who support the caregiver.
9934157|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles.
9934158|NCT05007106|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.
9934159|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) until meeting discontinuation criteria.
9934160|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd until meeting discontinuation criteria.
9934161|NCT05007106|Experimental|Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy.
9934162|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria.
9934163|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy.
9934164|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as background therapy.
9934165|NCT05007106|Experimental|Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy.
9994775|NCT01484080|Experimental|Arm I: BIBF1120+Paclitaxel|2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
9912487|NCT00727766|Experimental|Cohort 1|Clofarabine 1 mg for 14 days followed by 14 days of rest. Each cycle is 28 days long.
9912488|NCT00727766|Experimental|Cohort 2|Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
9912489|NCT00727766|Experimental|Cohort 3|Clofarabine 3 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
9912490|NCT00727766|Experimental|Cohort 4|Clofarabine 4 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
9912491|NCT00727766|Experimental|Cohort 5|Clofarabine 5 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
9912492|NCT00727766|Experimental|Cohort 6|Clofarabine 6 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
9912493|NCT00727779|Experimental|metabolic syndrome|intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
9912494|NCT00727779|Active Comparator|control subjects|intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
9912495|NCT00727792|Experimental|Group 2 - Research MRI|Subjects will have additional sequences and/or modification to MRI sequences.
9912496|NCT00727792|Active Comparator|Group 1 - Clinical MRI|Clinically ordered MRI scan. Subjects will not have any additional sequences or modifications to their clinically ordered MRI
9912497|NCT00727870|Other|1|After the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem dressing.
9912498|NCT00727870|Other|2|Arm 2: after the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem Silver dressing.
9912499|NCT00727870|Other|3|Arm 3: after the two biopsies, one site will be covered with Shapes by PolyMem dressing and the other site will be covered the Shapes by PolyMem Silver dressing.
9912500|NCT00727883||1|Post menopausal women treated with adjuvant TAM for breast cancer
9912501|NCT00727896|Experimental|1 is experimental with SMS|Arm 1 is experimental with SMS intervention
9912502|NCT00727896|Active Comparator|2 is (active comparator) standard care|Arm 2 is the usual care arm (standard care)
9912503|NCT00727922|Experimental|1|
9912504|NCT00727948|Experimental|receive aspirin|
9912505|NCT00727974||1|"Diagnostic Criteria for CVS:~3 or more different episodes of vomiting, normal health between episodes, no abnormal test results to account for vomiting [such as endoscopic biopsies (looking at a body part with a lighted tube), hydronephrosis (water block kidney drainage), cholelithiasis (gallstones), pancreatitis (swelling of the pancreas), and hypoglycemia (too little sugar in the blood)];"
9912506|NCT00727974||2|"Diagnostic Criteria for Migraine:~5 or more different headaches, complete return to health in between headaches, headaches last 2-48 hours and get in the way everyday activity, headache affects one side of head, with pounding moderate-to-severe pain, one of the following: nausea, vomiting, photophobia (fear of light), phonophobia (fear of sound)."
9912507|NCT00727987|Experimental|CNTO 148 50 mg + methotrexate|
9912508|NCT00727987|Experimental|CNTO 148 100 mg + methotrexate|
9912509|NCT00727987|Placebo Comparator|Placebo + methotrexate|
9912510|NCT00728000|Experimental|chemotherapy regimen|Gemcitabine and oxaliplatin are given intravenously (into the vein) every 2 weeks. Erlotinib is a pill that is taken by mouth daily.
9912511|NCT00728013|Experimental|A|intensive statin group
9912512|NCT00728013|Experimental|B|moderate statin group
9912513|NCT00728026||1|Cyclic Vomiting Syndrome
9912514|NCT00728026||2|Irritable Bowel Syndrome
9912515|NCT00728026||3|Postural Orthostatic Tachycardia Syndrome
9912516|NCT00728026||4|Functional Abdominal Pain
9912517|NCT00728026||5|Chronic Nausea
9912518|NCT00728052|Experimental|Subjects receiving treatment sequence ABCD|Subjects will receive treatment sequence ABCD; A= placebo, B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, and D = GSK598809 dose 3.
9912519|NCT00728052|Experimental|Subjects receiving treatment sequence BACD|Subjects will receive treatment sequence BACD; B= GSK598809 dose 1 (75 milligrams), A= placebo, C = GSK598809 dose 2 and D = GSK598809 dose 3
9912520|NCT00728052|Experimental|Subjects receiving treatment sequence BCAD|Subjects will receive treatment sequence BCAD; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, A= placebo and D = GSK598809 dose 3.
9912521|NCT00728052|Experimental|Subjects receiving treatment sequence BCDA|Subjects will receive treatment sequence BCDA; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, D = GSK598809 dose 3 and A= placebo.
9912522|NCT00728065|Experimental|1|White Bread (control)
9912523|NCT00728065|Experimental|2|White Bread (control)
9912524|NCT00728065|Experimental|3|White bread with 7.32 grams Salba hispanica
9912525|NCT00728065|Experimental|4|White bread with 15.58 grams Salba hispanica
9912526|NCT00728065|Experimental|5|White bread with 24 grams Salba hispanica
9912527|NCT00728065|Experimental|6|Rice Milk (control)
9912528|NCT00728065|Experimental|7|Rice Milk (control)
9912529|NCT00728065|Experimental|8|Rice Milk with 7.32 grams Salba hispanica
9912530|NCT00728065|Experimental|9|Rice Milk with 15.58 grams Salba hispanica
9912531|NCT00728065|Experimental|10|Rice Milk with 24 grams Salba hispanica
9912532|NCT00728078|Experimental|1|low-dose thalidomide adjuvant therapy after RFA for HCC
9912533|NCT00728078|No Intervention|2|control group
9912534|NCT00728104||1|The General Questionnaire: help to understand which characteristics of CVS patients are associated with both beneficial and harmful effects of these treatments
9912535|NCT00728104||2|The Co-Enzyme Q10 Questionnaire: to be completed by individuals who ever taken co-enzyme Q10
9912536|NCT00728104||3|The L-Carnitine Questionnaire: to be completed by individuals who have ever taken L-carnitine
9912537|NCT00728104||4|The Amitriptyline Questionnaire: to be completed by individuals who have ever taken amitriptyline
9912538|NCT00728117|Experimental|ibuprofen-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
9912539|NCT00728117|Experimental|ibuprofen-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
9912540|NCT00728117|Experimental|indomethacin-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
9912541|NCT00728117|Experimental|indomethacin-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
9994776|NCT01484080|Active Comparator|Arm II: Paclitaxel|Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
9912542|NCT00728143|Active Comparator|1|Healthy subjects
9912543|NCT00728143|Experimental|2|Diabetic subjects
9912544|NCT00728156|Active Comparator|C|Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
9912545|NCT00728156|Placebo Comparator|P|Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
9912546|NCT00728195|Placebo Comparator|Placebo First, Then Olanzapine|Participants will receive 2 matching placebo capsules orally twice daily for 6 consecutive weeks, then 2 matching placebo capsules orally in the morning and olanzapine 10 milligram (mg) capsule along with matching placebo capsule orally in the evening for next 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 5 weeks.
9912547|NCT00728195|Experimental|JNJ-37822681 10 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 10 mg capsule orally twice a day for 12 consecutive weeks.
9912548|NCT00728195|Experimental|JNJ-37822681 20 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 20 mg capsule orally twice a day for 12 consecutive weeks.
9994777|NCT01484106|Experimental|Treatment group|"Patients will be randomized (1:1, stratified by site, in permutation blocks of 4) to the Treatment or Standard Care arms."
9912549|NCT00728195|Experimental|JNJ-37822681 30 mg|Participants will receive JNJ-37822681 30 mg (one 10 mg capsule along with JNJ-37822681 20 mg capsule) orally twice a day for 12 consecutive weeks.
9912550|NCT00728195|Active Comparator|Olanzapine|Participants will receive 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with matching placebo capsule orally in the evening for 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 11 consecutive weeks.
9912551|NCT00728208|Experimental|GSK372475|Drug
9912552|NCT00728221|Placebo Comparator|1|Placebo capsules (3g)
9912553|NCT00728221|Experimental|2|Whole Korean Red Ginseng root (3g)
9912554|NCT00728221|Experimental|3|Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
9912555|NCT00728221|Experimental|4|Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
9912556|NCT00728234||1|all infants born below 30 weeks gestational age at the medical university vienna within the study period (01/2000 - 12/2002)
9912557|NCT00728273|Experimental|MMF|multi-micronutrient-fortified biscuit plus placebo deworming-treatment
9912558|NCT00728273|Experimental|Alb|placebo biscuit plus deworming treatment with Albendazole
9912559|NCT00728273|Experimental|MMF + Alb|multiple micronutrient-fortified biscuits with deworming treatment with Albendazole
9912560|NCT00728273|Placebo Comparator|placebo|placebo biscuit (non-fortified) and placebo deworming treatment
9912561|NCT00728286||Type 2 diabetes mellitus|We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
9912562|NCT00728299|Experimental|1|
9912563|NCT00728299|Placebo Comparator|2|
9912564|NCT00728312|Active Comparator|1|Aripiprazole (Abilify), flexible dosing 5-15 mg per day
9912565|NCT00728312|Placebo Comparator|2|Placebo look-alike, flexible dosing 5-15 mg per day
9912566|NCT00728325|Active Comparator|1|Standard Vocational Rehabilitation (VRP)
9912567|NCT00728325|Experimental|2|Supported Employment (SE)
9912568|NCT00728338|Experimental|1|Martek Biosciences Corporation Neuromins Capsules 7.5 g DHA oil/day
9912569|NCT00728338|Placebo Comparator|2|7.5 g/ day olive oil
9912570|NCT00728377|Active Comparator|Heath & Wellness|
9912571|NCT00728377|Experimental|Exercise|
9912572|NCT00728390|Experimental|1|
9912573|NCT00728403|Experimental|1|American Ginseng and American Red Ginseng Capsules
9912574|NCT00728403|Experimental|2|American Ginseng Capsules
9912575|NCT00728403|Placebo Comparator|3|Placebo Capsules
9912576|NCT00728429|No Intervention|standard of care|normal anthracycline therapy
9912577|NCT00728429|Experimental|exercise program|
9994778|NCT01484106|Active Comparator|Control|Standard of Care
9912578|NCT00728442|Experimental|1|medical decision based on computerized guideline-based decision support system
9912579|NCT00728442|No Intervention|2|
9912580|NCT00728455|Experimental|A|
9912581|NCT00728455|Experimental|B|
9912582|NCT00728455|Experimental|C|
9912583|NCT00728455|Experimental|D|
9912584|NCT00728455|Experimental|E|
9912585|NCT00728533|Experimental|1|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 360 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months"
9912586|NCT00728533|Experimental|2|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 480 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months."
9912587|NCT00728546|Experimental|INA dose adjustment, NAT2|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
9912588|NCT00728559|Experimental|1|preemptive trocar site analgesia
9912589|NCT00728559|Experimental|2|trocar site pre skin closure analgesia
9912590|NCT00728559|No Intervention|3|control
9912591|NCT00728572|Experimental|Experimental|Participant will receive a brief exam, a Basic Technique apex contact adjustment and Surface EMG.
9912592|NCT00728572|Sham Comparator|Sham|Participants will receive a sham Basic Technique adjustment (an adjacent contact not indicated by examination)and surface EMG.
9912593|NCT00728585|Experimental|Arm I (palifermin)|Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
9912594|NCT00728585|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
9912595|NCT00728598||1|Proliferative diabetic retinopathy, active.
9912596|NCT00728598||2|Proliferative diabetic retinopathy, quiescent.
9912597|NCT00728598||3|Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
9912598|NCT00728611|Experimental|1|
9912599|NCT00728611|Active Comparator|2|
9912600|NCT00728611|Placebo Comparator|3|
9912601|NCT00728637|Experimental|1|Participants took part in the Family Passport to Heart Health Program.
9912602|NCT00728637|Active Comparator|2|Participants took part in a control group.
9912603|NCT00728650||Observation|Patients with primary or metastatic hepatic malignancies
9912604|NCT00728663|Experimental|Arm: Cetuximab and Docetaxel|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
9912605|NCT00728715|Experimental|A|Medium Dose of budesonide-formoterol
9912606|NCT00728715|Active Comparator|B|High dose of inhaled budesonide (1600 mcg/day)
9912607|NCT00728767|Experimental|1|
9912608|NCT00728767|Placebo Comparator|2|
9912609|NCT00728780|Experimental|A|ABT-143 15/135mg
9912610|NCT00728780|Active Comparator|B|ABT-335 135mg and rosuvastatin 15mg
9912611|NCT00728832|Active Comparator|1|No test dose + DepoDur + flush with 1 mL normal saline
9912612|NCT00728832|Experimental|2|Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline
9912613|NCT00728832|Experimental|3|Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline
9912614|NCT00728832|Experimental|4|Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline
9912615|NCT00728832|Experimental|5|Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline
9912616|NCT00728897|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
9912617|NCT00728897|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= 4x25 milligrams GSK598809 capsule given in fasted state, C= 100 milligrams GSK598809 capsule given in fed state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
9912618|NCT00728897|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= 100 milligrams GSK598809 capsule in given fasted state, A= 4x25 milligrams GSK598809 capsule given in fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
9912619|NCT00728897|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= 100 milligrams GSK598809 capsule in given fasted state, C= 100 milligrams GSK598809 capsule given in fed state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
9912620|NCT00728897|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= 100 milligrams GSK598809 capsule given in fed state, A= 4x25 milligrams GSK598809 capsule given in fasted state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
9912621|NCT00728897|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= 100 milligrams GSK598809 capsule given in fed state, B= 100 milligrams GSK598809 capsule in given fasted state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
9912622|NCT00728975||1|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
9912623|NCT00728975||2|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
9994779|NCT01484145|Active Comparator|6 mA.min, 20 mins|
9912624|NCT00728975||3|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
9912625|NCT00728975||4|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
9912626|NCT00728975||5|Vancouver Coastal Cottage Hospice inpatients
9912627|NCT00728975||6|Vancouver Coastal Richmond Palliative Care Program patients
9912628|NCT00728975||7|Vancouver Coastal Lions Gate Palliative Care Unit inpatients
9994780|NCT01484145|Experimental|6 mA/min, 20 mins, clamping|
9994781|NCT01484145|Experimental|6 mA/min, 20 mins, debridement, clamping|
9994782|NCT01484145|Experimental|15 mA/min, 30 mins, clamping|
9994783|NCT01484145|Experimental|15 mA/min, 50 mins, debridement, clamping|
9994784|NCT01484158||Myocardial Infarction|Patients with myocardial infarction
9994785|NCT01484171|Active Comparator|idarubicin|The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
9994786|NCT01484171|Experimental|microtransplantation|The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
9994787|NCT01484184|Active Comparator|buspirone or levodopa/carbidopa|Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.
9994788|NCT01484184|Placebo Comparator|Placebo|First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.
9994789|NCT01484210|Experimental|Elpenhaler Active - Diskus Placebo|Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
9994790|NCT01484223|Experimental|Experimental Group|Intervention group: Structured nursing intervention
9994791|NCT01484223|No Intervention|No intervention|Control group: conventional intervention or non_support
9994792|NCT01484262||Liraglutide|
9994793|NCT01484262||Any insulin|
9994794|NCT01484327||Carvedilol, LVEF, Heart Failure|Patients with Heart Failure on carvedilol therapy measured for their LVEF value
9994795|NCT01484353|Experimental|Intervention group|This is the only arm in the study. They will be compared before and after
9994796|NCT01484366|Active Comparator|intramedullary nailing and plating|intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
9994797|NCT01484366|Active Comparator|plating|plating of both the radius and ulna in the treatment of both bone forearm fractures
9994798|NCT01484379|Experimental|unilateral neck exploration|unilateral neck exploration of elderly with primary hyperparathyroidism
9912629|NCT00728975||8|Providence Health St Paul's Hospital Palliative Care Unit inpatients
9912630|NCT00728975||9|Providence Health Marion Hospice inpatients
9912631|NCT00728975||10|Vancouver Island Health Authority Victoria Hospice inpatients
9912632|NCT00728975||11|Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
9912633|NCT00728975||12|Fraser Health Mission Hospice inpatients
9912634|NCT00728975||13|Fraser Health Langley Hospice inpatients
9912635|NCT00729001|Experimental|Group A|Human Rotavirus Vaccine - Formulation 1
9994799|NCT01484405|Other|anterolateral approach|surgical intervention THA anterolateral approach
9994800|NCT01484405|Other|posterior approach|surgical intervention THA posterior approach
9994801|NCT01484418|Experimental|A Exposure long|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
9994802|NCT01484418|Experimental|B Exposure short|See above exposure long. This treatment comprises 5 exposure sessions.
9994803|NCT01484418|Active Comparator|C Cognitive behavioural psychotherapy|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
9994804|NCT01484444||gastrointestinal cancer|
9912636|NCT00729001|Experimental|Group B|Human Rotavirus Vaccine - Formulation 2
9798823|NCT01641367|Experimental|Cohort A|"Under Protocol version 1.0:~No resistance to NRTIs, PIs, or NNRTI~• Continue current second-line regimen; NRTIs could be modified~Changed under LOA#2 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified~Changed under LOA#3 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued."
9912637|NCT00729001|Placebo Comparator|Group C|
9912638|NCT00729040|Active Comparator|1|Stepping Up to Health only
9912639|NCT00729040|Experimental|2|Stepping up to Health PLUS online message boards to talk with other participants
9912640|NCT00729079|Active Comparator|1|Subject will be randomly assigned to work with providers at Clinton Medical Associates
9912641|NCT00729079|Active Comparator|2|Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125
9912642|NCT00729118|Experimental|Lenalidomide + Vorinostat|Maintenance post autologous transplant
9912643|NCT00729131||A|Control group: subjects are homozygotic for major allele for TNF-308 promoter polymorphism.
9912644|NCT00729131||B|Case Group: subjects are homozygotic or heterozygotic for minor allele of TNF-308 promoter polymorphism.
9912645|NCT00729196|Experimental|1|Low-Glycemic Load Diet
9912646|NCT00729196|Active Comparator|2|Low-Fat Diet
9912647|NCT00729209|Experimental|ARRY-371797 (Schedule 1)|
9912648|NCT00729209|Experimental|ARRY-371797 (Schedule 2)|
9912649|NCT00729209|Placebo Comparator|Placebo|
9912650|NCT00729222|Placebo Comparator|1|Placebo
9912651|NCT00729222|Experimental|2|rolofylline
9912652|NCT00729235|Experimental|1|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
9912653|NCT00729235|Experimental|2|Slow VT zone programmed with ATP therapies (therapy arm).
9912654|NCT00729261|Experimental|armA I|Patients remain intubated until the patients Glasgow coma score improves to greater than 8.
9912655|NCT00729261|Experimental|arm 2|Patients that meet standard airway and ventilatory criteria for extubation but have a Glasgow coma score of less than or equal to 8 are immediately extubated.
9912656|NCT00729274|Active Comparator|hypertonic saline solution|Hypertonic Saline 3% solution alone.
9912657|NCT00729274|Placebo Comparator|nebulized normal saline solution|2 nebulisation with 30 minute interval (max 4ml)
9912658|NCT00729287|Placebo Comparator|Arm I|Patients receive oral placebo daily in addition to standard care.
9912659|NCT00729287|Experimental|Arm II|Patients receive oral selenium daily in addition to standard care.
9912660|NCT00729300|Placebo Comparator|1|Placebo
9912661|NCT00729300|Experimental|2|disulfiram
9912662|NCT00729313|Experimental|1|"Drug: Lanreotide 30 mg microparticle formulation~One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h~For non-responders patients lanreotide will be stopped."
9912663|NCT00729313|Placebo Comparator|2|"One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment."
9912664|NCT00729339|Active Comparator|1|lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
9912665|NCT00729339|Active Comparator|2|lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
9912666|NCT00729352||Control group|18-35 yr old healthy subjects with wild type genotype for NQO1.
9912667|NCT00729352||Case group|18-35 yr old healthy subjects who are homozygotic for minor allele of NQO1 Pro187Ser polymorphism
9912668|NCT00729391|Experimental|1|Women's CoOp
9912669|NCT00729391|Active Comparator|2|Nutrition (Attention-Control)
9912670|NCT00729391|Active Comparator|3|Voluntary Counseling and Testing
9912671|NCT00729404|Experimental|Arm 1|
9912672|NCT00729404|Experimental|Arm 2|
9912673|NCT00729443|Experimental|1|
9912674|NCT00729443|Placebo Comparator|2|
9912675|NCT00729456|No Intervention|1|
9912676|NCT00729456|Other|2|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
9912677|NCT00729495|Active Comparator|1|marketed celecoxib
9912678|NCT00729495|Experimental|2|overencapsulated celecoxib
9912679|NCT00729508|Experimental|1|
9912680|NCT00729508|Experimental|2|
9912681|NCT00729508|Experimental|3|
9912682|NCT00729508|Experimental|4|
9912683|NCT00729508|Placebo Comparator|5|
9912684|NCT00729547|Placebo Comparator|2|Psychotherapy placebo session
9912685|NCT00729547|Experimental|1|Neurofeedback training which enhance left frontal alpha wave.
9912686|NCT00729573||1|Participants in MTN-003. Participants will remain a part of their assigned MTN-003 study groups.
9912687|NCT00729599|Experimental|1|Cetylpyridinium chloride during 21 consecutive days.
9934166|NCT05005962||Acute ischemic patients suffering with stroke|Acute ischemic patients treated with commercially available neurothrombectomy devices in India. The device can be either a stent retriever or aspiration catheter to treat the stroke as per the labeling indications of the products.
9798824|NCT01641367|Experimental|Sub-cohort B1|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• Best available NRTIs, RAL, & DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• Best available NRTIs, RAL, & DRV/RTV"
9934167|NCT05003895|Experimental|1/ Arm 1|Escalating doses of CAR-T cells
9934168|NCT05003895|Experimental|2/ Arm 2|MTD of CAR-T cells
9934169|NCT05003245|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
9934170|NCT05003245|Active Comparator|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
9934171|NCT05002569|Experimental|Arm A: Relatlimab + Nivolumab|Combination
9934172|NCT05002569|Experimental|Arm B: Nivolumab|Monotherapy
9934173|NCT05001698|Experimental|Anifrolumab|All eligible participants will receive anifrolumab via intravenous (IV) infusion pump.
9934174|NCT05001503|Experimental|Intervention Group|The clinical team has access to the Stability UO software. All other care is given as standard.
9934175|NCT05001503|No Intervention|Control Group|Standard care given.
9934176|NCT04999202|Experimental|Dose escalation of BAY2416964|Up to four dose levels of BAY2416964 (as determined in the first in human mono-therapy study of BAY2416964) will be given in combination with standard dose Pembrolizumab.
9934177|NCT04999202|Experimental|Dose expansion of BAY2416964 in tumor type specific cohort|To determine the RP2D of BAY2416964 in combination therapy with pembrolizumab. Participants will be enrolled in up to 3 tumor type-specific cohorts including relapsed/refractory non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and urothelial cancer.
9934178|NCT04994977|Experimental|Intra-arterial Chemotherapy|Subjects are pre-treated with heparin, and then given single doses of Melphalan, Carboplatin, and Topotecan consecutively via intra-arterial infusion. Multiple arteries may be used, with the total dose of the drugs remaining the same.
9934179|NCT04990388|Experimental|Stage 1: UX053 Dose Level 1S|Participants to receive a single, peripheral intravenous (IV) infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
9912688|NCT00729638|Experimental|Single arm|Single arm phase I study
9912689|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 1)|BMS-936559 (MDX-1105)
9912690|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 2)|BMS-936559 (MDX-1105)
9912691|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 3)|BMS-936559 (MDX-1105)
9912692|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 4)|BMS-936559 (MDX-1105)
9912693|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 5)|BMS-936559 (MDX-1105)
9912694|NCT00729703|Experimental|1|Dual-chamber detection and activated treatment (at least ATP) in the slow VT-zone plus activated AAIsafeR pacing (basic rate 60 bpm).
9912695|NCT00729703|Experimental|2|Single-chamber ICD following clinical practice but with a monitoring zone active to allow the documentation of all occurring ventricular arrhythmias
9912696|NCT00729716|Experimental|A|BioCart™II treatment
9912697|NCT00729716|Active Comparator|B|Microfracture procedure
9912698|NCT00729729|Placebo Comparator|1|Placebo
9912699|NCT00729729|Experimental|2|Slow release PCA derivative
9912700|NCT00729729|Experimental|3|Slow release PCA derivative higher dose
9912701|NCT00729742|Experimental|Part 1|erlotinib
9912702|NCT00729742|Experimental|Part 2|erlotinib + dalotuzumab
9912703|NCT00729755|Experimental|Creatine|The subjects with major depressive disorder, treated with creatine in addition to escitalopram
9912704|NCT00729755|Placebo Comparator|Placebo|The subjects with major depressive disorder, treated with placebo in addition to escitalopram
9912705|NCT00729768|Experimental|1|
9912706|NCT00729768|Active Comparator|2|
9912707|NCT00729794|Experimental|Study Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
9912708|NCT00729794|Placebo Comparator|Control Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
9912709|NCT00729872|Experimental|1|AG011: low dose
9912710|NCT00729872|Placebo Comparator|2|Placebo: low dose
9912711|NCT00729872|Experimental|3|AG011: mid dose
9912712|NCT00729872|Placebo Comparator|4|Placebo: mid dose
9912713|NCT00729872|Experimental|5|AG011: high dose
9912714|NCT00729872|Placebo Comparator|6|Placebo: high dose
9912715|NCT00729885|Experimental|1 Goggle I|Optimized Goggle
9912716|NCT00729885|Sham Comparator|2 Google II|Goggle with 20 Degree error
9912717|NCT00729898||A|
9912718|NCT00729911|Active Comparator|AF ablation|"Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting."
9912719|NCT00729911|Active Comparator|Amiodarone|Amiodarone is taken orally on a daily basis.
9912720|NCT00729963|Experimental|1|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
9912721|NCT00729963|Active Comparator|2|A standard reference group, which was paired according to age and BMI, received CPAP as a treatment for OSA.
9912722|NCT00729976|Experimental|1|Ibuprofen Suppository
9912723|NCT00729976|Active Comparator|2|Ibuprofen suspension
9912724|NCT00729989|No Intervention|1|
9912725|NCT00729989|Experimental|2|
9912726|NCT00730002|Active Comparator|1- Healthy Subjects|Healthy Subjects- receive MRA
9912727|NCT00730002|Active Comparator|2 - patients with SLE, no neuropsych|Systemic Lupus Erythematosus(SLE) patients without neuropsychiatric symptoms - receive MRA
9912728|NCT00730002|Active Comparator|3 - patients with SLE with neuropsych|20 symptomatic neuropsychiatric systemic lupus erythematosus(NPSLE) patients.
9912729|NCT00730002|Active Comparator|4- healthy patients from other cohort|10 Healthy Controls (HC) from an existing cohort as part of another sponsored study.
9912730|NCT00730054|Active Comparator|1|Clonidine
9912731|NCT00730054|Active Comparator|2|Remifentanil
9912732|NCT00730054|Experimental|4|Remifentanil+clonidine
9912733|NCT00730054|Placebo Comparator|3|Placebo
9912734|NCT00730067|Experimental|1|Sildenafil treatment
9912735|NCT00730067|Placebo Comparator|2|placebo
9912736|NCT00730080||Sapropterin (Kuvan)|Individuals with phenylketonuria (PKU) who are beginning treatment with sapropterin.
9912737|NCT00730080||Control|Healthy individuals without phenylketonuria (PKU).
9912738|NCT00730093|Other|A|
9912739|NCT00730106||1|Patients with pre-defined alarm symptoms
9912740|NCT00730106||2|Patients without pre-defined alarm symptoms
9912741|NCT00730119||Neonates|Subjects ages birth to 30 days
9912742|NCT00730119||Infants|Subjects aged >30 days to 2 years
9997956|NCT01513434|Active Comparator|transtibial technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via tibial tunnel.
9798825|NCT01641367|Experimental|Sub-cohort B2|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• ETR, RAL, and DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• ETR, RAL, and DRV/RTV"
9798826|NCT01641367|Experimental|Sub-cohort B3|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC"
9798827|NCT01641367|Experimental|Cohort C|"Under Protocol version 1.0:~Resistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)~• Best available NRTIs, RAL, and DRV/RTV~Changed under LOA#2:~Resistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure~• Best available NRTIs, RAL, and DRV/RTV"
9798828|NCT01641367|Experimental|Cohort D|"Under Protocol version 1.0:~Multiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:~• Best available regimen, including study-provided and any locally available drugs~Changed under LOA#2:~Not eligible for Cohort A, B, or C:~• Best available regimen, including study-provided and any locally available drugs~Updated under protocol v2.0:~• Best available ART regimen, including study-provided and any locally available non-experimental drugs"
9798829|NCT01641380|No Intervention|Control|Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment.
9798830|NCT01641380|Experimental|Text Messaging Intervention|Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication.
9798831|NCT01641445|Active Comparator|Topiramate|Topiramate (200 mg) taken orally daily
9798832|NCT01641445|Placebo Comparator|Sugar pill|"Placebo (sugar pill) taken orally daily"
9798833|NCT01641471|Experimental|Active TENS|Active TENS (EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using the TENS unit immediately following surgery and continuing throughout the 6 weeks postoperatively.
9798834|NCT01641471|Placebo Comparator|Placebo TENS|Placebo TENS (Placebo EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using a sham TENS unit (appears identical to Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation) immediately following surgery and continuing throughout the 6 weeks postoperatively.
9798835|NCT01641640|Experimental|Sofosbuvir+PEG+RBV|
9798836|NCT01641653|Placebo Comparator|placebo|half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR
9798837|NCT01641653|Active Comparator|Midazolam|half of the patients will receive Midazolam 1-2.5mg prior to entering the OR
9798838|NCT01641692|Experimental|GSK573719 15.6 mcg|GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
9798839|NCT01641692|Experimental|GSK573719 31.25 mcg|GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
9798840|NCT01641692|Experimental|GSK573719 62.5 mcg|GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
9798841|NCT01641692|Experimental|GSK573719 125 mcg|GSK573719 (Umeclinidium bromide) 125 mcg once-daily
9798842|NCT01641692|Experimental|GSK573719 250 mcg|GSK573719 (Umeclinidium bromide) 250 mcg once-daily
9798843|NCT01641692|Experimental|GSK573719 15.6 mcg twice-daily|GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
9798844|NCT01641692|Experimental|GSK573719 31.25 mcg twice daily|Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
9798845|NCT01641692|Placebo Comparator|Matched Placebo|Matched Placebo arm
9798846|NCT01641809|Experimental|Arm 1 GSK1265744 10 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
9798847|NCT01641809|Experimental|Arm 2 GSK1265744 30 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
9798848|NCT01641809|Experimental|Arm 3 GSK1265744 60 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
9798849|NCT01641809|Active Comparator|Arm 4 Efavirenz 600 mg|In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).
9798850|NCT01641822|Active Comparator|AZLI|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI for 28 days followed by TIS for 28 days.
9912743|NCT00730119||Adults|Subjects aged 18 years of age or older
9912744|NCT00730145|Experimental|PD-0332334|
9912745|NCT00730184|Active Comparator|1|Participants receive potassium bicarbonate in dosage of 90 mmol/d. This compound has no other name.
9912746|NCT00730184|Placebo Comparator|2|Participants receive placebo as microcrystalline cellulose. This compound has no other name.
9912747|NCT00730197|Experimental|1|NISOLDIPINE EXTENDED-RELEASE TABLETS, 40 MG
9912748|NCT00730197|Active Comparator|2|Sular® Extended Release 40 mg tablets
9912749|NCT00730210|Active Comparator|a: PTH (1-84) 100 ug s.c.inj. once a day|PTH (1-84) 100 ug subcutaneous injections once a day
9912750|NCT00730210|Placebo Comparator|b: placebo 100 ug s.c. inj. once a day|placebo 100 ug sub cutaneous injection once a day
9912751|NCT00730249|Active Comparator|1|
9912752|NCT00730249|Placebo Comparator|2|
9912753|NCT00730262|Experimental|Single-Arm|
9912754|NCT00730288|Experimental|1|Received monovalent Vero dengue vaccine in Study DIV12
9912755|NCT00730288|Experimental|2|Received Yellow fever vaccine in Study DIV12
9912756|NCT00730288|Experimental|3|Flavivirus-naive subjects
9912757|NCT00730314|Experimental|1|Unrelated donor
9912758|NCT00730314|Experimental|2|Cord Blood
9912759|NCT00730340|Active Comparator|1|Patients will receive closure of the tonsillar fossae following tonsillectomy.
9912760|NCT00730340|Active Comparator|2|Patients will not receive closure to one or both tonsillar fossa following a tonsillectomy
9912761|NCT00730366|Experimental|1|Experimental: IPTp-SP + promotion: Active Comparator
9912762|NCT00730366|Experimental|2|IPTp-SP alone (without promotion)
9912763|NCT00730366|Active Comparator|3|Weekly CQ prophylaxis
9912764|NCT00730379|Experimental|1|ridaforolimus (MK8669) + dalotuzumab (MK0646)
9912765|NCT00730392|Experimental|1 drug, 2 placebo|"Etanercept~Placebo"
9912766|NCT00730418|Experimental|doxazosin 4mg|doxazosin 4mg group
9912767|NCT00730418|Experimental|doxazosin 8mg|doxazosin 8mg group
9912768|NCT00730431|Experimental|IDX184 5 mg|Healthy participants will be administered a single 5 mg dose of IDX184.
9912769|NCT00730431|Experimental|IDX184 10 mg|Healthy participants will be administered a single 10 mg dose of IDX184.
9912770|NCT00730431|Experimental|IDX184 25 mg|Healthy participants will be administered a single 25 mg dose of IDX184.
9912771|NCT00730431|Experimental|IDX184 50 mg|Healthy participants will be administered a single 50 mg dose of IDX184.
9912772|NCT00730431|Experimental|IDX184 75 mg|Healthy participants will be administered a single 75 mg dose of IDX184.
9912773|NCT00730431|Experimental|IDX184 100 mg|Healthy participants will be administered a single 100 mg dose of IDX184.
9912774|NCT00730431|Placebo Comparator|Placebo|Healthy participants will be administered placebo matching IDX184.
9912775|NCT00730457|Experimental|A|Intramuscular (i.m.) vaccination of a single dose of 0.1 µg, 0.3 µg, 1 µg, 2 µg, 3 µg, 5 µg and 8 µg of STF2.HA1 (SI) (VAX125).
9912776|NCT00730470|Experimental|1|
9912777|NCT00730496|Experimental|1|the study group, 45 women
9912778|NCT00730496|No Intervention|2|the control group, 45 women
9912779|NCT00730535|Experimental|Tolterodine 1|
9912780|NCT00730535|Experimental|Toterodine 3|
9912781|NCT00730535|Experimental|Tolterodine 6|
9912782|NCT00730548|Experimental|1|Remote Arm (OptiVol plus Connexus Telemetry plus CareLink plus Intervention Algorithm), Clinical Management Alerts ON
9912783|NCT00730548|No Intervention|2|No Care Alerts available, standard treatment of the patient
9912784|NCT00730561|No Intervention|1|
9912785|NCT00730561|Experimental|2|Hematopoietic stem cell transplantation
9912786|NCT00730574|No Intervention|B|The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .
9912787|NCT00730574|Experimental|A|The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)
9912788|NCT00730587||1|Full-term healthy infants ages 5 months to 3 years.
9912789|NCT00730600|Experimental|1|1= THAI traditional massage
9912790|NCT00730613|Experimental|Treatment (therapeutic autologous lymphocytes)|Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.
9912791|NCT00730626|Experimental|1|L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract
9912792|NCT00730626|Experimental|2|L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract
9912793|NCT00730626|Placebo Comparator|3|Placebo
9912794|NCT00730652|Experimental|MDX1411|An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.
9912795|NCT00730743|Experimental|1|Intermittent clamp group
9912796|NCT00730743|No Intervention|2|No clamp group
9912797|NCT00730769|Experimental|Single arm|Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
9912798|NCT00730782|Active Comparator|1|The experimental vaccine PfAMA1 formulated in Alhydrogel
9912799|NCT00730782|Active Comparator|2|The experimental vaccine PfAMA1 formulated in Montanide ISA720
9912800|NCT00730782|Active Comparator|3|The experimental vaccine PfAMA1 formulated in ASO2A
9912801|NCT00730795|Experimental|Group A|Subjects receiving the low-dose antigen candidate TB vaccine
9912802|NCT00730795|Experimental|Group B|Subjects receiving the high-dose antigen candidate TB vaccine
9912803|NCT00730808|Experimental|Test|Oral nutritional supplement: assignment according to consecutive random numbers.
9912804|NCT00730808|Placebo Comparator|Control|Assignment according to consecutive random numbers.
9912805|NCT00730821|Experimental|1|
9912806|NCT00730860|Experimental|RFA+TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
9912807|NCT00730860|Active Comparator|RFA only|treatment of hepatocellular carcinoma by radiofrequency ablation only
9912808|NCT00730873|Experimental|A|continuous positive airway pressure
9912809|NCT00730938|Active Comparator|1|
9912810|NCT00730938|Placebo Comparator|2|Saline placebo
9912811|NCT00730951|Experimental|1|0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)
9912812|NCT00730951|Experimental|2|1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)
9912813|NCT00730951|Experimental|3|3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)
9912814|NCT00730951|Experimental|4|6g Korean Red Ginseng (12 capsules)
9912815|NCT00730951|Experimental|5|6g Corn Starch Control (12 capsules)
9912816|NCT00730977|Experimental|single|single arm, open label, 4 doses tested.
9912817|NCT00730990|Experimental|Cohort 1|This arm will have no active treatment.
9912818|NCT00730990|Experimental|Cohort 2|
9912819|NCT00731003|Experimental|I|ATD procedure
9912820|NCT00731003|Experimental|II|Oxitriptan
9912821|NCT00731003|Placebo Comparator|III|Amino acid mixture with tryptophan
9912822|NCT00731003|Placebo Comparator|IV|Placebo capsule
9912823|NCT00731016|Other|1|Zoledronic acid, pravastatin
9912824|NCT00731029|Experimental|Group A|The subjects in this group will be 18-60 years.
9912825|NCT00731029|Experimental|Group B|The subjects in this group will be > 60 years.
9912826|NCT00731029|Active Comparator|Group C|The subjects in this group will be 18-60 years.
9912827|NCT00731029|Active Comparator|Group D|The subjects in this group will be > 60 years.
9912828|NCT00731068|Experimental|1|PRGF
9912829|NCT00731068|Placebo Comparator|2|
9912830|NCT00731107|Active Comparator|1|Veress Needle laparoscopic entry
9912831|NCT00731107|Active Comparator|2|XCEL bladeless trocar laparoscopic entry
9912832|NCT00731146|Active Comparator|1 - Ultrasound|Participants will receive an ultrasound guided interscalene brachial plexus block
9912833|NCT00731146|Active Comparator|2 - Nerve Stimulator|Participants will receive a nerve stimulator guided interscalene brachial plexus block
9912834|NCT00731159||A|"Sperm capacitation:~Sperm capacitation is measured in a sample of the same ejaculated sperm unit given for fertilizing human oocytes in an IVF treatment cycle"
9912835|NCT00731172|Experimental|1|20 mg copaxone(glatiramer acetate)subcutaneous injection(daily through week 12)
9912836|NCT00731172|Placebo Comparator|2|placebo subcutaneous injection(daily through week 12)
9912837|NCT00731224|Experimental|1|
9912838|NCT00731237||1|The procedures undergone by this group will be evaluated for: Acute performance, deliverability and resource utilization during the procedure in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience.
9912839|NCT00731250|Placebo Comparator|PART 1-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
9912840|NCT00731250|Experimental|PART 1-Visit 1-Capsaicin|Eligible subjects will receive incremental capsaicin doses
9912841|NCT00731250|Placebo Comparator|PART 1-Visit 2-Placebo|Eligible subjects will receive matching placebo tablets
9912842|NCT00731250|Experimental|PART 1-Visit 2-Capsaicin|Eligible subjects will receive maximum capsaicin dose
9912843|NCT00731250|Placebo Comparator|PART 1-Visit 3-Placebo|Eligible subjects will receive matching placebo tablets
9912844|NCT00731250|Experimental|PART 1-Visit 3-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
9912845|NCT00731250|Placebo Comparator|PART 2-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
9912846|NCT00731250|Experimental|PART 2-Visit 1-SB-705498|Eligible subjects will receive SB-705498 tablets
9912847|NCT00731250|Experimental|PART 2-Visit 2-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
9912848|NCT00731263|Experimental|1|The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
9912849|NCT00731276|Other|Four Regimens|"The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.~Four Regimens are:~Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly~Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly"
9912850|NCT00731289|Experimental|1|single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
9912851|NCT00731289|Active Comparator|2|single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
9912852|NCT00731302|Experimental|Aspirin and Meloxicam|Arm: Aspirin and Meloxicam Each participant will receive 81 mg aspirin per day for 7 days, followed by meloxicam 7.5 mg daily plus aspirin 81 mg daily for 5 days
9912853|NCT00731315|Experimental|Treatment Group 1 - uncomplicated UTI|Would receive computer-assisted treatment for a uncomplicated UTI.
9912854|NCT00731315|Active Comparator|Control Group 1|Qualified for expedited treatment for uncomplicated cystitis but would receive usual care in the Emergency Department of Community Health Center.
9912855|NCT00731315|Experimental|Treatment Group 2 - Complicated Cystitis|Would receive expedited treatment for complicated cystitis with longer antibiotic course than the simple UTI patients.
9912856|NCT00731315|Active Comparator|Control Group 2|Qualified for expedited treatment for complicated cystitis treatment but would receive usual care in the clinic or emergency department.
9912857|NCT00731354|Active Comparator|SAL|Each patient will have Suction Assisted Lipoplasty procedure on one side of the body (this will be considered the control side)
9912858|NCT00731354|Active Comparator|VAL|Each patient will have VASER- assisted lipoplasty on the opposite side of the body. This will be the comparison side.
9912859|NCT00731367|Active Comparator|Gelled|Aquacel Ag gelled.
9912860|NCT00731367|Active Comparator|Adherent|Aquacel Ag adherent
9912861|NCT00731380|Experimental|ABI-007 escalation; then radiation + AUC|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-FU 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
9912862|NCT00731393|Experimental|Group A|Subjects aged between 6 months and 3 years.
9912863|NCT00731393|Experimental|Group B|Subjects aged 3 to 6 years.
9912864|NCT00731393|Active Comparator|Group C|Subjects aged between 6 months and 3 years.
9912865|NCT00731393|Active Comparator|Group D|Subjects aged 3 to 6 years.
9912866|NCT00731419|Active Comparator|SEMS|Self expanding metal stent compared to plastic stent. Both recognised forms of treatment for condition
9912867|NCT00731419|Active Comparator|Plastic stent|
9912868|NCT00731432|Experimental|A|Transmucosal Herbal Periodontal Patch (THPP)
9912869|NCT00731432|Placebo Comparator|B|Placebo Patch
9912870|NCT00731471|Experimental|1|12 Healthy adults infected with HIV
9912871|NCT00731471|Experimental|2|12 HIV+ adults on antiretroviral therapy
9912872|NCT00731497|Active Comparator|1|children in households/villages using Solar Water Disinfection (SODIS) method of disinfecting household drinking water
9912873|NCT00731497|No Intervention|2|children in households/villages where Solar Water Disinfection (SODIS) has not been implemented
9912874|NCT00731510|Experimental|1|Carbohydrate supplements (drinks and gels)
9912875|NCT00731510|Placebo Comparator|2|Primarily Aspartame plus natural flavourings. Powder dissolved in water to provide non-distinguishable placebo drink.
9934180|NCT04990388|Experimental|Stage 1: UX053 Dose Level 2S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
9934181|NCT04990388|Experimental|Stage 1: UX053 Dose Level 3S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
9934182|NCT04990388|Experimental|Stage 1: UX053 Dose Level 4S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
9934183|NCT04990388|Experimental|Stage 2: UX053 Dose Level 1R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker every 2 weeks (Q2W) for 5 doses.
9934184|NCT04990388|Experimental|Stage 2: UX053 Dose Level 2R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
9912876|NCT00731523|Experimental|1|
9912877|NCT00731536||Patients with Hepatosplenic T-cell Lymphoma (HSTCL)|
9912878|NCT00731562|Experimental|Varenicline Controlled Release, Fasted|
9912879|NCT00731562|Experimental|Varenicline Controlled Release, Fed|
9912880|NCT00731601|Experimental|1|pantoprazole 40mg/q6h IV infusion for three days
9912881|NCT00731601|Active Comparator|2|pantoprazole 8mg/h for three days
9912882|NCT00731627|Placebo Comparator|1|placebo
9912883|NCT00731627|Active Comparator|11|simvastatin
9912884|NCT00731705||1|Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants OR First-degree relatives of patients evaluated for stem cell transplantation
9912885|NCT00731796||1|Stroke victims with a visual field deficit that undergo vision restoration therapy
9912886|NCT00731796||2|Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
9912887|NCT00731796||3|Stroke victims that do not have a visual field deficit
9912888|NCT00731796||4|Normal individuals who have not had a stroke and do not have a visual field deficit
9912889|NCT00731809|Other|1|PET CT
9912890|NCT00731835|No Intervention|Group I|1. Wound Care (group 1)--Best standard wound care with aggressive debridement
9912891|NCT00731835|Active Comparator|Group 2|"2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization~Endovascular revascularization is the intervention"
9912892|NCT00731848|Experimental|1|Intervention 1
9912893|NCT00731861|Experimental|1|Paclitaxel plus PTK787
9912894|NCT00731913||1|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
9912895|NCT00731913||2|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
9912896|NCT00731926|Experimental|1|
9912897|NCT00731926|Active Comparator|2|
9912898|NCT00731926|Placebo Comparator|3|
9912899|NCT00731952|Experimental|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
9912900|NCT00731965|Experimental|1|Measles, mumps, rubella booster vaccination within 3 months after randomisation
9912901|NCT00731965|No Intervention|2|Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation
9912902|NCT00731978|No Intervention|Standard|Standard intraoperative fluid management
9912903|NCT00731978|Experimental|Restricted|Restricted intraoperative fluid management
9912904|NCT00731991|Active Comparator|ART|ART to the levator scapulae.
9912905|NCT00731991|Active Comparator|PNF|PNF to the levator scapulae.
9912906|NCT00731991|Placebo Comparator|Control|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
9912907|NCT00732004|Experimental|1|Group 1
9912908|NCT00732004|Experimental|2|Group 2
9912909|NCT00732004|Experimental|3|Group 3
9912910|NCT00732017|Experimental|HVPC-|This group received standard physical therapy treatment and HVPC with negative polarity.
9912911|NCT00732017|Active Comparator|CG|The control group received only standard physical therapy treatment.
9912912|NCT00732017|Experimental|HVPC+|This group received standard physical therapy treatment and HVPC using active electrodes with positive polarity.
9912913|NCT00732043|Experimental|1|
9912914|NCT00732043|Experimental|2|
9912915|NCT00732043|Placebo Comparator|3|
9912916|NCT00732056|Experimental|1|3+3 cohort dose escalation
9912917|NCT00732082|Active Comparator|Dose Level 0|Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
9912918|NCT00732082|Experimental|Dose Level 1|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 3 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free period."
9912919|NCT00732082|Experimental|Dose Level 2|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 6.5 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
9912920|NCT00732082|Experimental|Dose Level 3|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 13 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
9912921|NCT00732082|Experimental|Dose Level 4|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 26 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
9912922|NCT00732095|Experimental|Experimental|Immediate Ad
9994805|NCT01484457|Experimental|Closed-loop control system|"The objective of this study is to automate glucose control in subjects with type 1 diabetes using a computer control algorithm in a controlled in-clinic research setting.~The controller will be evaluated under two conditions:~restoring euglycemia (80-140 mg/dL) when the controller is initiated during a period when the subject's glucose is above the euglycemic range;~restoring euglycemia (80-140 mg/dL) when the controller is challenged with a small unannounced meal (~25 g CHO)."
9994806|NCT01484470|No Intervention|Unmanipulated arm|Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
9994807|NCT01484470|Experimental|Stemx Arm|StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU). The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg. This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
9994808|NCT01484483||Cohort|
9994809|NCT01484509||Intermittent claudication|
9994810|NCT01484522||Group A|Influenza A 2009 Monovalent vaccine
9994811|NCT01484522||Group B|Influenza A 2009 monovalent vaccine
9994812|NCT01484522||Group C|Influenza A 2009 monovalent vaccine
9994813|NCT01484535|Other|Ankle aspiration|ankle aspiration
9994814|NCT01484535|Placebo Comparator|placebo procedure|placebo procedure
9994815|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE|Low dose of adjuvant.
9798851|NCT01641822|Placebo Comparator|Placebo|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: placebo to match AZLI for 28 days followed by TIS for 28 days.
9994816|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE|Higher dose of adjuvant.
9994817|NCT01484548|Active Comparator|20 ug LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
9994818|NCT01484574|Experimental|Low dose|Stempeucel - CLI will be administered at the lowest dose
9994819|NCT01484574|Experimental|Intermediate dose|Stempeucel - CLI will be administered at intermediate dose
9994820|NCT01484574|No Intervention|Control arm|Standard protocol of care alone
9994821|NCT01484587|Experimental|001|
9994822|NCT01484587|Placebo Comparator|002|
9994823|NCT01484600|Experimental|Group 1|
9994824|NCT01484600|Experimental|Group 2|
9994825|NCT01484613||Quadripolar lead|All participants receive a CRT-D system with quadripolar lead
9994826|NCT01484639|Active Comparator|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
9994827|NCT01484639|Active Comparator|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
9994828|NCT01484665|Experimental|Participants (Males, age 50-75 yrs)|Eligible men will be identified from the administrative database and electronic medical record at the University of Minnesota (EMR) at least 24 hours prior to the clinic visit. They will be asked to complete the PROCASE Decision-Aid.
9994829|NCT01484678||Age Matched Controls|"Age matched non-affected (non-DMD) boys * This arm is full~Age matched non-affected men, matched for men with Becker MD *Recruiting"
9994830|NCT01484678||Boys/Men with DMD|This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. *Recruiting
9994831|NCT01484678||Adults with Becker MD|This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. * Recruiting
9994832|NCT01484691|No Intervention|Healthy non-asthmatic controls|Healthy non-asthmatic controls who will be studied at one point in time and serve as a control group for the baseline bronchoscopy and evaluation of T-cell miRNA expression.
9994833|NCT01484691|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
9994834|NCT01484691|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthma (randomized to 8 weeks of no inhaled corticosteroid treatment). Asthmatics not on inhaled corticosteroids, randomized to no change in treatment for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline and again after 8 weeks without treatment with inhaled corticosteroids.
9994835|NCT01484704||No treatment|
9994836|NCT01484704||MRI|
9994837|NCT01484717|Active Comparator|Standard Care|Telephone counseling plus nicotine patch
9994838|NCT01484717|Experimental|Contingency management for abstinence from cigarettes|Telephone counseling and nicotine patch plus contingency management
9994839|NCT01484730||Vascular Occulsion|Multi-Spectral & Laser Speckle Imaging
9994840|NCT01484743||Patients with parastomal hernia repair|Patients registered in the Danish Ventral Hernia database
9994841|NCT01484756|Placebo Comparator|calcium carbonate 500 mg|Control group received one daily tablet of calcium carbonate 500 mg for 6 months
9994842|NCT01484756|Experimental|daily multi micronutrient supplement|Experimental group received one daily multi micro-nutrient supplement tablet for 6 months
9994843|NCT01484782|Experimental|Interactive Voice Response (IVR) calls|Weekly automated telephone assessment and behavior change calls focused on blood pressure management. The experimental group will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
9994844|NCT01484782|No Intervention|Usual care|This group received results of blood pressure readings. PCP referrals. Educational materials about hypertension and self-management. At follow-up, patients received home blood pressure monitoring cuffs.
9994845|NCT01484795|Experimental|Continuous positive airway pressure|
9798852|NCT01641835||Normals|No eye disease.
9994846|NCT01484795|Experimental|BILEVEL|
9994847|NCT01484821|Active Comparator|Arm A|Volunteers (18 -30 years)
9994848|NCT01484821|Active Comparator|Arm B|Volunteers (70 years or older)
9994849|NCT01484821|Experimental|Arm C|70 years patient or older with curative cares for cancer
9994850|NCT01484847|Experimental|PF-00299804|Patients with locally advanced head and neck squamous cell carcinoma will be treated with a single dose (45mg) of PF-00299804 via G-Tube on an empty stomach
9994851|NCT01484860|Experimental|AUY922|AUY922 will be administered as a weekly infusion at a dose of 70 mg/m2 based on the recommended phase II dose from the phase I study or alternate dose based on the phase I study final results.The drug will be continued until disease progression or unacceptable toxicity. One cycle will be defined as 4 weeks of treatment.
9994852|NCT01484886|Experimental|Restrictive transfusion strategy|RBC will be transfused if the hemoglobin level falls below 7 for bi-ventricular repairs and under 9.0 for single ventricle palliations.
9912923|NCT00732108|Experimental|topiramate|topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
9912924|NCT00732108|Placebo Comparator|2|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
9912925|NCT00732121|Active Comparator|1|Sitagliptin
9912926|NCT00732121|Placebo Comparator|2|Placebo arm
9912927|NCT00732147|Placebo Comparator|2|Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
9912928|NCT00732147|Experimental|1|Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
9912929|NCT00732173|Experimental|Arm I|"Patients receive a lifestyle intervention, Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED), on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact."
9912930|NCT00732173|Active Comparator|Arm II|Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
9912931|NCT00732186|Experimental|Group 1 and Group 2|
9912932|NCT00732277|Experimental|Treatment|Patients in this arm will be given the following IMP intraveneously at 6 hour intervals - hydrocortisone (100mg/m2/24 hours)
9912933|NCT00732277|No Intervention|Control|in each phase of study 15 patients will receive no IMP as control arm
9912934|NCT00732290|Active Comparator|1|Clopidogrel then fluoxetine+clopidogrel
9912935|NCT00732290|Active Comparator|2|Fluoxetine+clopidogrel then clopidogrel
9912936|NCT00732329|Experimental|A|"optimized home based occupational therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
9912937|NCT00732329|No Intervention|B|treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without optimized occupational therapy
9912938|NCT00732342|No Intervention|1|Standard Treatment
9912939|NCT00732342|Experimental|2|Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
9912940|NCT00732342|Experimental|3|Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
9912941|NCT00732342|Experimental|4|Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
9912942|NCT00732355||I|known syphilis infected patients
9912943|NCT00732355||U|presumed uninfected patients
9912944|NCT00732407|Experimental|1|Patients with diabetes melittus treated with an ACE inhibitor will be treated with aliskiren
9912945|NCT00732407|Experimental|2|Patients with diabetes melittus treated with an ACE inhibitor will be given losartan
9912946|NCT00732420|Experimental|Treatment Arm A|Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.
9912947|NCT00732420|Experimental|Treatment Arm B|Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.
9912948|NCT00732433|Experimental|digital mammogram|"Digital mammography is a non-invasive imaging technique to obtain an x-ray image of the breast.~Two-view digital mammogram of the breast with a lesion that has been recommended for biopsy during the subject's regular clinical care. The digital mammogram is then analyzed by a computer program."
9912949|NCT00732446|Active Comparator|2|antibiotic /steroid combination compared with individual administration of steroid and antibiotic
9912950|NCT00732446|Experimental|1|combination antibiotic steroid compared with individual administration of steroid and antibiotic - new therapeutic indication
9912951|NCT00732459||1|electro-acupuncture preconditioning group
9912952|NCT00732459||2|control group
9912953|NCT00732485|Active Comparator|Fenofibrate|
9912954|NCT00732485|Placebo Comparator|Placebo|
9912955|NCT00732511|Experimental|1|Coreg Cr will be up-titrated as needed to achieve blood pressure <130/80
9912956|NCT00732511|Active Comparator|2|Toprol XL will be up-titrated at weekly intervals to achieve a blood pressure <130/80 mm Hg
9912957|NCT00732524|Active Comparator|Glipizide arm|Glipizide XL is an insulin secretagogue and is an extended release tablet designed to provide a controlled rate of delivery. Glipizide XL was chosen because it is the most frequently used discharge oral medication in our ED. It has a quick onset of action within a few hours after oral ingestion, lasts for 24 hours and has a powerful glucose lowering effect. In addition, there are very few contraindications to Glipizide XL and there is published literature regarding their use in subjects with severe hyperglycemia
9912958|NCT00732524|Active Comparator|Glipizide + Glargine|Insulin Glargine is a recombinant human basal insulin analog. It was chosen since it is a non-peaking insulin with cover for 24 hours. It can be injected subcutaneously only once a day and has a low incidence of hypoglycemia
9912959|NCT00732537|Experimental|Inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour. The gas was then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off).
9912960|NCT00732537|Placebo Comparator|Placebo|The Oxygen at high concentration (>90%), which was standard therapy for PPHN, was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda).
9912961|NCT00732550|Experimental|Single trocar|Patients will undergo cholecystectomy by the single trocar approach
9912962|NCT00732550|Active Comparator|Standard lap cholecystectomy|Standard lap choly
9912963|NCT00732576|Active Comparator|1|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA)
9912964|NCT00732576|Active Comparator|2|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
9912965|NCT00732576|Active Comparator|3|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
9912966|NCT00732576|Active Comparator|4|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
9912967|NCT00732576|Active Comparator|5|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA)
9912968|NCT00732576|Active Comparator|6|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
9912969|NCT00732576|Active Comparator|7|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
9912970|NCT00732576|Active Comparator|8|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
9912971|NCT00732589|Experimental|A|Suprascapular nerve block
9912972|NCT00732589|Experimental|B|therapeutic ultrasound
9912973|NCT00732602|Active Comparator|B|GLP-2 infusion
9912974|NCT00732602|Placebo Comparator|C|Sodium-chloride infusion
9912975|NCT00732602|Active Comparator|A|GIP-infusion
9912976|NCT00732628||Boomerang percutaneous closure unit|patients having a Boomerang percutaneous closure device after a Neurointerventional study
9912977|NCT00732693|Experimental|1|Treatment with standard sex steroid replacement regimen
9912978|NCT00732693|Experimental|2|Treatment with physiologic sex steroid regimen
9912979|NCT00732706|Other|Sartorius Twitch|Femoral Nerve detection using Sartorius Twitch
9912980|NCT00732706|Other|Quadriceps Twitch|Femoral Nerve detection using Quadriceps Twitch
9912981|NCT00732719|Placebo Comparator|Profile A|Device worn; no pressure given (placebo)
9912982|NCT00732719|Active Comparator|Profile B|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
9912983|NCT00732719|Active Comparator|Profile C|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
9912984|NCT00732719|Active Comparator|Profile D|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
9912985|NCT00732719|Active Comparator|Profile E|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
9912986|NCT00732719|Active Comparator|Profile F|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
9912987|NCT00732719|Active Comparator|Profile G|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
9912988|NCT00732732|Experimental|Green banana|Subjects receiving green banana powder.
9912989|NCT00732732|Placebo Comparator|Placebo|Microcrystalline cellulose given as placebo
9912990|NCT00732745|Experimental|Phase II arm I|Patients receive docetaxel IV over 1 hour on days 1 and 8, oxaliplatin IV over 2 hours on day 1, and oral vandetanib (at the maximum tolerated dose determined in phase I) once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
9912991|NCT00732745|Active Comparator|Phase II arm II|Patients receive docetaxel and oxaliplatin as in arm I. Patients also receive an oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
9912992|NCT00732771|Experimental|LCI696 1mg bid|
9912993|NCT00732784|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and calcium supplement on day 15).
9912994|NCT00732784|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and calcium supplement on day 1, Gleevec® alone on day 15).
9912995|NCT00732810|Experimental|Breast cancer randomized to SCH 727965|
9912996|NCT00732810|Active Comparator|Breast cancer randomized to capecitabine|
9912997|NCT00732810|Experimental|SCH 727965 in breast cancer after progression on capecitabine|
9912998|NCT00732810|Experimental|NSCLC randomized to SCH 727965|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
9912999|NCT00732810|Active Comparator|NSCLC randomized to erlotinib|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
9913000|NCT00732810|Experimental|SCH 727965 in NSCLC after progression on erlotinib|Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010
9913001|NCT00732823|Placebo Comparator|Profile A|No device worn
9913002|NCT00732823|Active Comparator|Profile B|Foot 40 mmHg, ankle 40 mmHg, mid-calf 35 mmHg, upper calf 30 mmHg
9913003|NCT00732823|Active Comparator|Profile C|Foot 50 mmHg, ankle 50 mmHg, mid-calf 45 mmHg, upper calf 40 mmHg
9913004|NCT00732823|Active Comparator|Profile D|Foot 60 mmHg, ankle 60 mmHg, mid-calf 55 mmHg, upper calf 50 mmHg
9913005|NCT00732836|Experimental|HAI Abraxane MTD|Dose escalation beginning Day 1, Cycle 2 dose level 180 mg/m^2 for maximum tolerated dose (MTD) of Hepatic Arterial Infusion of Abraxane (HAI Abraxane) following same dose intravenous Abraxane in Cycle 1 of 21 day cycle.
9913006|NCT00732836|Experimental|HAI Abraxane Expansion|HAI Abraxane dose expansion at MTD or dose level 3 (260 mg/m^2) if MTD not defined.
9913007|NCT00732849|No Intervention|1|Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
9913008|NCT00732849|No Intervention|2|Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
9994853|NCT01484886|Experimental|Liberal RBC transfusion strategy|RBCs will be transfused for Hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
9994854|NCT01484899||PAH|Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg
9994855|NCT01484899||CTEPH|Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.
9994856|NCT01484899||Controll group|Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
9994857|NCT01484925||With Barrett's Esophagus|Patients who have been diagnosed in the past with Barrett's Esophagus
9994858|NCT01484925||Without Barrett's Esophagus|Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
9994859|NCT01484964|Experimental|Treatment A|ASP015K Formulation 1 with moderate-fat meal
9994860|NCT01484964|Experimental|Treatment B|ASP015K Formulation 2 under fasting conditions
9994861|NCT01484964|Experimental|Treatment C|ASP015K Formulation 2 with moderate-fat meal
9994862|NCT01484990|Experimental|1|
9994863|NCT01485016||ambulatory epilepsy subjects|
9994864|NCT01485029|Experimental|NP children|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
9994865|NCT01485042|Experimental|Dose Escalation|This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.
9994866|NCT01485068|Experimental|Danubio|
9994867|NCT01485081|Experimental|Danubio|
9994868|NCT01485107|Experimental|Ultherapy™ treatment on the décolleté|All enrolled subjects will receive the study treatment.
9994869|NCT01485133||Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
9994870|NCT01485133||Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered via a needle adaptor or the built-in scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
9994871|NCT01485146|Experimental|Cohort 1|8 Healthy Subjects in Phase I Unit
9994872|NCT01485146|Experimental|Cohort 2|8 Healthy Subjects in Phase I Unit
9994873|NCT01485146|Experimental|Cohort 3|8 Healthy Subjects in Phase I Unit
9994874|NCT01485159||All|All subjects enrolled in the study
9994875|NCT01485185|Experimental|Gabapentin lower dose alone|low dose
9994876|NCT01485185|Active Comparator|Gabapentin higher dose alone|higher dose
9994877|NCT01485185|Experimental|Gabapentin in combination with donepezil|Gabapentin lower dose and donepezil
9994878|NCT01485185|Placebo Comparator|Placebo|Placebo
9994879|NCT01485198|Active Comparator|Control|Patients treated with Acetaminophen
9994880|NCT01485198|Experimental|Experimental|Patients who underwent a BMASC extraction and joint infusion
9994881|NCT01485211|Experimental|crosslinking with hypoosmolar riboflavin|Riboflavin and UVA-induced corneal cross-linking increases the stability of keratoconic corneas. The current inclusion criteria require a minimum stromal thickness of 400 µm. Hypo-osmolar riboflavin solution increases the stromal thickness before CXL in cases with preoperatively thin corneas.
9994882|NCT01485224|Experimental|Thalidomide|"Single arm study:~Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
9994883|NCT01485237||Severe H1N1 pneumonia in adult patients|Severe adult H1N1 pneumonia patients undergoing antiviral and oxygen therapy, mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO, HFO)in Winnipeg
9994884|NCT01485237||Severe pneumonia in adults not H1N1|Patients admitted to the hospital and/or ICU with viral pneumonia, bacterial pneumonia, septic shock, ARDS in Winnipeg
9994885|NCT01485289||Investigational Stabilimax|
9994886|NCT01485289||Control, Posterolateral Fusion|
9994887|NCT01485302|Experimental|Cohort 1|Dose 1 IV infusion
9994888|NCT01485302|Experimental|Cohort 2|Dose 2 IV infusion
9994889|NCT01485302|Experimental|Cohort 3|Dose 3 IV infusion
9994890|NCT01485302|Experimental|Cohort 4|Dose 4 IV infusion
9994891|NCT01485302|Experimental|Cohort 5|Dose 1 SC injection
9994892|NCT01485302|Experimental|Cohort 6|Dose 2 SC injection
9913009|NCT00732849|Experimental|3|Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
9667415|NCT03604393|Experimental|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
9913010|NCT00732849|Experimental|4|Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
9913011|NCT00732862|Experimental|1|Baseline clamp study before treatment phase.
9913012|NCT00732862|Active Comparator|2|Final clamp experiment after 6 months intensive therapy.
9913013|NCT00732888|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Tasigna® once daily on days 1 and 15 (i.e., Tasigna® alone on day 1, and combination of Tasigna® and calcium supplement on day 15).
9913014|NCT00732888|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Tasigna® once daily on days 1 and 15 (i.e., combination of Tasigna® and calcium supplement on day 1, Tasigna® alone on day 15).
9913015|NCT00732914|Active Comparator|1|Sunitinib (first-line) followed by Sorafenib (second-line)
9913016|NCT00732914|Experimental|2|Sorafenib (first-line) followed by Sunitinib (second-line)
9913017|NCT00732927|Experimental|1|parnaparin, low molecular weight heparin
9913018|NCT00732927|Active Comparator|2|aspirin
9913019|NCT00732953|Active Comparator|1|Genous stent implantation with paclitaxel-eluting balloon therapy
9913020|NCT00732953|Active Comparator|2|Genous stent implantation
9913021|NCT00732966|Experimental|1|Hypertensive patients will be treated with losartan for one months
9913022|NCT00732966|Experimental|2|Hypertensive patients will be treated with valsartan
9913023|NCT00732979|Experimental|A|Infrahepatic inferior vena cava clamping The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
9913024|NCT00732979|Active Comparator|B|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
9913025|NCT00733018|Active Comparator|A|Diet A - Western diet
9913026|NCT00733018|Active Comparator|B|Diet B - Balanced diet
9913027|NCT00733031|Experimental|gemcitabine|gemcitabine administered in combination with AZD6918
9913028|NCT00733031|Experimental|pemetrexed|pemetrexed administered in combination with AZD6918
9913029|NCT00733031|Experimental|AZD6918|AZD6918 administered alone
9913030|NCT00733044|Experimental|Specialized Care|Stepped-care cognitive behavioural approach with elements from tinnitus retraining therapy
9913031|NCT00733044|Active Comparator|Usual Care|Audiological diagnostics and intervention and, if necessary, one or more consultations with a social worker with a maximum of ten one hour session
9913032|NCT00733057|Experimental|1|Minocycline treatment
9913033|NCT00733057|Placebo Comparator|2|Placebo
9913034|NCT00733083|Active Comparator|1|0,1 mg/kg of oxycodone
9913035|NCT00733083|Active Comparator|2|0,1 mg/kg of morphine
9913036|NCT00733083|Active Comparator|3|0,5 mg/kg dexamethasone (max 24 mg
9913037|NCT00733083|Placebo Comparator|4|NaCl 0,9%
9913038|NCT00733109|Active Comparator|excision of the lesion|
9913039|NCT00733109|No Intervention|espontaneous regression|
9913040|NCT00733122|Experimental|A|GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
9913041|NCT00733148||1|Routine Care
9913042|NCT00733148||2|Insulin infusion based on model predictive algorithm (MPC)
9913043|NCT00733161|Active Comparator|1|Passive leg cycle exercise with stretching and resistance training
9913044|NCT00733161|Active Comparator|2|Stretching and resistance training
9913045|NCT00733174|Experimental|1|Rosiglitazone
9913046|NCT00733174|Placebo Comparator|2|Placebo
9913047|NCT00733187|Experimental|1|
9913048|NCT00733200|No Intervention|Control group|
9913049|NCT00733239|Experimental|1|Receives 2-4 of the drugs listed under Intervention
9913050|NCT00733265|Experimental|AZD6140|
9913051|NCT00733317|Active Comparator|1-Budesonide nebulized suspension|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times and will not give after 3 doses
9913052|NCT00733317|Placebo Comparator|2- 0.9% saline|Children will receive 2 ml of saline every 20 minutes for 3 times and will not give after 3 doses
9913053|NCT00733382|Experimental|1|
9913054|NCT00733382|Active Comparator|2|
9913055|NCT00733395|Experimental|1|Tart cherry juice
9913056|NCT00733395|Placebo Comparator|2|Fruit juice
9913057|NCT00733434|Experimental|1|Patients receiving PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
9913058|NCT00733434|Placebo Comparator|2|Patients receiving 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
9913059|NCT00733460|Experimental|BF-PET|
9913060|NCT00733473|Active Comparator|1 Budesonide|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 1 mg nebulized budesonide 2 times a day upto 5 days
9994893|NCT01485315|Active Comparator|Liberal blood transfusion|Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less
9913061|NCT00733473|Placebo Comparator|2 Placebo saline|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 2ml of nebulized saline 2 times a day upto 5 days
9913062|NCT00733486|Other|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
9934185|NCT04990388|Experimental|Stage 2: UX053 Dose Level 3R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
9934186|NCT04990388|Experimental|Stage 2: UX053 Dose Level 4R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
9934187|NCT04990388|Placebo Comparator|Stage 2: Placebo Dose|Participants randomized to receive a single, peripheral IV infusions of matching placebo, plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
9934188|NCT04985708||Patient with AMICS are likely to benefit from MCS|later
9934189|NCT04985708||Develop and maintain a patient registry of AMICS|later
9934190|NCT04985708||Classify patients based on shock severity.|later
9934191|NCT04983251||U3 Women|Women in under-studied, under-represented, and under-reported (U3) populations.
9934192|NCT04978337|Experimental|Treatment A: Rilematovir|Participants will receive oral dose of rilematovir 250 milligrams (mg), twice daily (bid) for 7 days.
9934193|NCT04978337|Placebo Comparator|Treatment B: Placebo|Participants will receive oral dose of placebo matching to rilematovir, bid for 7 days.
9934194|NCT04977479|Active Comparator|Active Vaccine|Participant receives the active mRNA COVID-19 vaccine
9934195|NCT04977479|Placebo Comparator|Placebo|All participants crossover and receive active vaccine but which day placebo vs active is given is randomized and blinded.
9934196|NCT04977466||Group #1 / Pregnant Female NIH Participants|Female NIH study participants.
9934197|NCT04977466||Group #2 / Male and Female Partners|Male or female partners of women who participated in NIH intramural clinical trials and that became pregnant.
9934198|NCT04977466||Group #3 / Pregnant Female Partners of Male or Female NIH Clinical Trial Partici|Female partners of NIH intramural clinical trial participants who became pregnant while their partner was or within 1 year after the last day of intervention after their partner was on a study.
9934199|NCT04977466||Group #4 / Neonate or Offspring of a Pregnant Female Participant or Pregnant Fe|Offspring from birth to 12 months of age and born to female participants / female partners.
9934200|NCT04977245|Experimental|MBSR Intervention|The intervention group will take part in a group-based mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. This MBSR program will have a shortened session length of 1.5 hours compared to the traditional 2 hours, to reduce caregiver burden. Caregivers will be trained in meditation practices, like awareness of one's breath, body scan, and loving kindness meditation. Participants will also learn about mindfulness and stress theory, and have group discussions covering topics such as self-compassion.
9934201|NCT04977245|Active Comparator|Self-Guided Meditation eCourse|Participants in the active control group will participate in a self-guided, online program named GARDEN. The self guided material teaches skills about increasing the daily experience of positive emotion as a mechanism to assist with stress coping. The program consists of eight skills introduced and discussed over an eight week period.
9934202|NCT04975997|Experimental|Daratumumab in combination with CC-220 and dexamethasone - Dose 1|Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
9934203|NCT04975997|Experimental|Daratumumab in combination with CC-220 and dexamethasone - Dose 2|
9934204|NCT04975997|Experimental|Daratumumab in combination with CC-220 and dexamethasone - Dose 3|
9934205|NCT04975997|Active Comparator|Daratumumab in combination with dexamethasone and bortezomib|Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
9934206|NCT04975906||Participants|All inpatient admissions with serum lactate, ketones and/or salicylates performed, and with urea, electrolytes and creatinine at the same time. The patients will be grouped into patients with organic (gap) acidosis (elevated serum lactate, ketones and/or salicylates) and patients with no organic acidosis.
9934207|NCT04974307|Experimental|Device|use of OrCam MyEye 2.0
9667416|NCT03604393|Experimental|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
9934208|NCT04971590||Participants with Lupus Nephritis|
9913063|NCT00733525|Experimental|Stepped Care|Participants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
9913064|NCT00733525|Active Comparator|Cognitive Behavioral Therapy|Participants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.
9913065|NCT00733538|Active Comparator|1|patients receiving zometa treatment
9913066|NCT00733538|No Intervention|2|No treatment, just follow-up
9913067|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 1|Eligible subjects will receive repeat oral doses of GSK962040 given as 10 milligrams once daily tablet for 14 days.
9913068|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 2|Eligible subjects will receive repeat oral doses of GSK962040 given as 30 milligrams once daily tablet for 14 days.
9913069|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 3|Eligible subjects will receive repeat oral doses of GSK962040 given as 100 milligrams once daily tablet for 14 days.
9913070|NCT00733551|Placebo Comparator|Subjects receiving placebo in cohort 1, 2 and 3|Eligible subjects will receive repeat oral doses of placebo tablets given once daily for 14 days in cohort 1, 2 and 3.
9913071|NCT00733564|Active Comparator|1|Paracervical block will be performed
9913072|NCT00733564|Experimental|2|Propofol anesthesia will be performed
9913073|NCT00733564|Experimental|3|Sevoflurane anesthesia will be performed
9913074|NCT00733577|Experimental|Cohort 1|15 mg SB756050 or placebo
9913075|NCT00733577|Experimental|Cohort 2|Planned dose for Cohorts 2 50mg SB756050 or placebo
9913076|NCT00733577|Experimental|Cohort 3|Planned dose for Cohort 3 150mg SB756050 or placebo
9913077|NCT00733577|Experimental|Cohort 4|Planned dose for Cohort 4 600mg SB756050 or placebo
9913078|NCT00733603|Sham Comparator|Global Therapeutic Massage (GTM)|Non-specific somatic treatment with full-body Western massage.
9913079|NCT00733603|Active Comparator|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
9913080|NCT00733616|Experimental|1|
9913081|NCT00733642|Experimental|PF-04360365 1 mg/kg|
9913082|NCT00733642|Experimental|PF-04360365 3 mg/kg|
9913083|NCT00733642|Experimental|PF-04360365 5 mg/kg|
9913084|NCT00733642|Experimental|PF-04360365 10 mg/kg|
9913085|NCT00733681|Experimental|PFC Sigma RP TC3 Revision Knee System|Revision knee surgery with the PFC Sigma RP TC3 Revision Knee System (mobile bearing).
9913086|NCT00733694|Other|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
9913087|NCT00733707|Experimental|1|Text messaging reminders
9913088|NCT00733707|No Intervention|2|No text messaging reminder
9913089|NCT00733720|Active Comparator|1|Each subject will receive all 3 doses of suboxone and placebo
9913090|NCT00733733|Active Comparator|ATG|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
9913091|NCT00733733|No Intervention|Control|Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.
9913092|NCT00733772|Experimental|A|healthy lifestyle counseling + 30 grams/day supplement of Flaxseed
9913093|NCT00733772|Sham Comparator|B|TLC diet
9913094|NCT00733785|Experimental|2mg tablet|2 mg tablet fasted
9913095|NCT00733785|Experimental|4 mg tablet|4 mg tablet fasted
9913096|NCT00733785|Experimental|8mg tablet|8 mg tablet fasted
9913097|NCT00733785|Experimental|2 x 4 mg tablets|2 x 4mg tablets fasting
9913098|NCT00733785|Experimental|2 x 2mg tablets|2 x 2mg tablets fasting
9913099|NCT00733785|Experimental|8 mg tablet fed|8 mg tablet fed
9913100|NCT00733785|Experimental|Repeat dose|8 mg once a day for 6 days
9913101|NCT00733798|Experimental|1|
9913102|NCT00733811|Experimental|1|Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
9913103|NCT00733811|Active Comparator|2|Deferiprone alone at 75 mg/kg divided into three oral daily doses
9913104|NCT00733837|Experimental|A|This is a repeated measures study. All participants experience the same conditions.
9913105|NCT00733850|Experimental|1|Kanglaite Injection plus Gemcitabine
9913106|NCT00733850|Active Comparator|2|Gemcitabine
9913107|NCT00733863|Experimental|1|
9913108|NCT00733863|Placebo Comparator|2|
9913109|NCT00733876|Experimental|A|
9913110|NCT00733889|Experimental|1|
9913111|NCT00733915|Experimental|Single arm|Cohort of total knee replacements with LCS Complete knee implants
9913112|NCT00733928|Other|1 - All Polyethylene Tibia|Total knee replacement with an all polyethylene tibial tray
9913113|NCT00733928|Active Comparator|2 - Poly & Metal Tibia|Total knee replacement with a metal-backed tibial component
9798853|NCT01641861|Experimental|Control arm|control arm is dental caries removal using the conventional method. Dental caries will be removed using rotary instrument following the usual procedures employed by the dentist.
9798854|NCT01641861|Experimental|Intervention arm|Intervention arm is dental caries removal using Papacarie®. The dentist will apply Papacarie® to dental cavity in order to soften the carious dentine. Dental caries will be removed using hand instrument.
9798855|NCT01641900|Experimental|Schizophrenia|"Outpatients with a Structural Clinical Interview confirmed DSM-IV diagnosis of schizophrenia.~All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week."
9798856|NCT01641900|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use. All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week.
9798857|NCT01641926|Experimental|HBeAg(+) PEG-Intron|HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
9798858|NCT01641926|Active Comparator|HBeAg(+) PEGASYS|HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
9798859|NCT01641926|Experimental|HBeAg(-) PEG-Intron|HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
9798860|NCT01641926|Active Comparator|HBeAG(-) PEGASYS|HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
9798861|NCT01641939|Active Comparator|Standard taxane therapy|Docetaxel will be administered at 75 milligram per meter square (mg/m^2) intravenous (IV) on Day 1 of a 21-day cycle, or paclitaxel will administered at 80 mg/m^2 IV weekly (Days 1, 8, and 15 of a 21 day cycle) according to investigator choice until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
9798862|NCT01641939|Experimental|trastuzumab emtansine 2.4 mg|Trastuzumab emtansine will be administered on Day 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
9798863|NCT01641939|Experimental|trastuzumab emtansine 3.6 mg|Trastuzumab emtansine will be administered on Day 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
9798864|NCT01641952||Rituximab|Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
9798865|NCT01641978||ICU patients|neurological level in critical patients
9798866|NCT01641991|Experimental|Arm B: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
9798867|NCT01641991|Experimental|Arm C: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 14, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
9798868|NCT01641991|Experimental|Arm D: 0.25mL BioThrax®|BioThrax® 0.25mL subcutaneously on Days 0,14, and 28,and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
9798869|NCT01641991|Experimental|Arm A: 0.50mL BioThrax®|BioThrax® 0.50 ml subcutaneously on Days 0, 14, and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
9798870|NCT01642056|Experimental|EPI-743, then Placebo|Received EPI-743, 15mg/kg up to a maximum dose of 200 mg orally or via gastric tube three times daily with meals, then placebo three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
9798871|NCT01642056|Placebo Comparator|Placebo, then EPI-743|Received Placebo three times daily orally or via gastric tube with meals, then EPI-743, 15mg/kg up to a maximum dose of 200 mg three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
9798872|NCT01642082|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9798873|NCT01642147|Experimental|Patients undergoing craniotomy|"Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed."
9798874|NCT01642147|Active Comparator|Patients undergoing abdominal surgery|Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.
9798875|NCT01642212|Experimental|Oral Budesonide Suspension|Taken once or twice daily for up to 40 weeks
9798876|NCT01642212|Placebo Comparator|Matching Placebo|Taken once or twice daily for 20 weeks
9798877|NCT01642238|Experimental|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
9913114|NCT00733941|Experimental|High frequency training|24 interval exercises performed 8 times per week
9913115|NCT00733941|Experimental|Normal frequency training|24 interval exercises performed 3 times per week
9913116|NCT00733967|Placebo Comparator|Placebo|Matching oral placebo capsules as control.
9913117|NCT00733967|Active Comparator|Varenicline|See assigned interventions.
9913118|NCT00734045||1|Subjects with diagnosed congestive heart failure
9913119|NCT00734045||2|Subjects not diagnosed with congestive heart failure
9913120|NCT00734058|Experimental|Persistent AF|Treatment arm to be compared with historical control.
9913121|NCT00734084|Other|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
9913122|NCT00734110|Experimental|P.F.C. Sigma Total Knee Replacement System|Primary total knee arthroplasty using the fixed bearing P.F.C. Sigma Total Knee Replacement System.
9913123|NCT00734123|Experimental|1|Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.
9913124|NCT00734123|Active Comparator|2|Participants assigned to control group (2) will be followed according to the clinical standard of care.
9913125|NCT00734136|Other|1|50 surgical subjects undergoing either liver transplantation or hepatic resection
9913126|NCT00734136|Other|2|50 Subjects with Liver disease who are are not surgical candidates
9913127|NCT00734175|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
9913128|NCT00734201|Experimental|1|Randomised to a parallel group comparison of either one of four doses of study drug (1mg, 2mg, 5mg, 25mg) or placebo. Dosed once daily for 28 days
9913129|NCT00734227|Active Comparator|A|"Randomization: By the blind card method to TIPS or emergency portacaval shunt. Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 24 hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong data collection on line, analysis by biostatistician Florin Vaida, PhD. External Advisory, Data Monitoring and Safety Committee by 3 senior academicians.~Procedure: Emergency portacaval shunt."
9913130|NCT00734227|Active Comparator|B|Procedure: Emergency TIPS.
9913131|NCT00734240|Experimental|A|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo
9913132|NCT00734240|Experimental|B|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913133|NCT00734240|Experimental|C|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913134|NCT00734240|Experimental|AA|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo
9913135|NCT00734240|Experimental|BB|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913136|NCT00734240|Experimental|CC|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913137|NCT00734240|Experimental|G|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913138|NCT00734240|Experimental|H|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913139|NCT00734240|Experimental|I|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913140|NCT00734240|Experimental|GG|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913141|NCT00734240|Experimental|HH|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913142|NCT00734240|Experimental|II|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
9913143|NCT00734240|Experimental|F (100 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
9913144|NCT00734240|Experimental|Dose-Titration 1|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
9913145|NCT00734240|Experimental|F (200 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
9913146|NCT00734240|Experimental|Dose-Titration 7|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
9913147|NCT00734266||1 Control|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
9913148|NCT00734266||2 COPD|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
9913149|NCT00734279|Experimental|1|Girls with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
9913150|NCT00734279|Experimental|2|Girls with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
9913151|NCT00734279|Experimental|3|Boys with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
9913152|NCT00734279|Experimental|4|Boys with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
9913153|NCT00734318|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 micrograms (2 puffs bd)
9913154|NCT00734318|Experimental|Flutiform 50/5 micrograms|Flutiform 50/5 micrograms (2 puffs bd)
9913155|NCT00734318|Active Comparator|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|Flixotide pMDI 250 mcg (2 puffs bd) + foradil pMDI 24 50/5 mcg (bd)
9913156|NCT00734318|Active Comparator|Flixotide pMDI 250 micrograms|Flixatide pMDI 250 micrograms (2 puffs bd)
9913157|NCT00734331||IBD|Inflammatory bowel disease patients
9913158|NCT00734331||Control|Average risk patients undergoing screening colonoscopy
9913159|NCT00734357|Experimental|Isovue Arm|Subjects with a clinically scheduled CT examination will be given the contrast Isovue. The investigators of this study will determine which contrast medication subjects will receive using randomization.
9913160|NCT00734357|Experimental|Omnipaque Arm|Subjects with a clinically scheduled CT examination will be given the contrast Omnipaque. The investigators of this study will determine which contrast medication subjects will receive using randomization
9913161|NCT00734370|Experimental|VRET|Virtual Reality Exposure Therapy for agoraphobic participants
9913162|NCT00734370|Active Comparator|Exposure in vivo|Standard exposure in vivo for panic disorder
10213027|NCT04717765|Experimental|Curative osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and application of LLL phototherapy on the day of surgery and every 72hr, totaling 5 applications. The suture should be done in a way to facilitate healing for primary intention.~Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of what would be the dental root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point."
10213028|NCT04717765|Active Comparator|Curative osteonecrosis resulting from chemo or radiotherapy - LPRF + sequestrectomy|"Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and placement of the LPRF on the day of surgery will be performed.~After the LPRF is placed, the suture should be done in a way that facilitates healing for primary intention."
10213029|NCT04717765|No Intervention|Curative osteonecrosis resulting from chemo or radiotherapy - sequestrectomy only|"Patients who were diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy and removal of necrotic tissue will be performed.~The suture should be done in a way that facilitates healing for primary intention."
10213030|NCT04712656||OSA Subjects Treated with CPAP|Patients with moderate to severe OSA (ODI4>15/h) who accept CPAP therapy.
10213031|NCT04711369|Active Comparator|Intervention group (laser therapy)|Participants allocated to the laser-therapy group will receive 2 laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
9913163|NCT00734370|No Intervention|Wait-list control|Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
9913164|NCT00734383|Experimental|1|Propofol Cardioprotection
9913165|NCT00734383|Experimental|2|Volatile Anesthesia Preconditioning
9913166|NCT00734422|Experimental|VRET with yohimbine|Virtual Reality Exposure Therapy will be combined with the administration of yohimbine hydrochloride
9913167|NCT00734422|Placebo Comparator|VRET with placebo|Virtual Reality Exposure Therapy will be combined with an inactive placebo pill (Albochin).
9913168|NCT00734448|Experimental|A,1|Gestational diabetes patients who take myo-inositol
9913169|NCT00734513|Experimental|1|Partner-assisted Emotional Disclosure
9913170|NCT00734513|Active Comparator|2|Cancer Education
9913171|NCT00734526|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
9913172|NCT00734526|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
9913173|NCT00734526|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
9913174|NCT00734526|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
9913175|NCT00734552|Active Comparator|1|α-Keto Acid plus low protein diet
9913176|NCT00734552|Other|2|Normal protein diet
9913177|NCT00734565|Experimental|1|
9913178|NCT00734669||1|Type 2 diabetic patients on glibenclamide at individual dosage up to 7 mg/day for more than one year prone to hypoglycemic events
9913179|NCT00734682|Experimental|Nanoliposomal CPT-11|All patients are treated with nanoliposomal CPT-11
9913180|NCT00734695|Experimental|1|Baruch Pade Medical Center
9913181|NCT00734695|Active Comparator|2|Rambam Medical Center
9913182|NCT00734695|Active Comparator|3|Soroka Medical Center
9913183|NCT00734708|Experimental|A|positive drug (0.3% Trafermin contained)
9913184|NCT00734708|Placebo Comparator|P|control
9913185|NCT00734721|Active Comparator|A|Presentation of factual information video
9913186|NCT00734721|Active Comparator|B|Presentation of injection syringe/needle
9913187|NCT00734721|Active Comparator|C|Presentation of emotional information video
9913188|NCT00734721|Active Comparator|D|Stress relaxation music
9913189|NCT00734760|Experimental|A|a tailored, face-to-face education and counseling intervention with a nurse lasting approximately 45 minutes, followed by a telephonic reinforcement in 30 days
9913190|NCT00734760|No Intervention|B|care-as-usual with data collection at the same time points as the experimental group
9913191|NCT00734786|Placebo Comparator|2|Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
10213032|NCT04711369|Sham Comparator|Control group (sham laser therapy)|Participants allocated to the control group will receive 2 sham laser treatments over a period of 3 months. Laser therapy will be performed according to a standardized protocol.
10213033|NCT04705818|Experimental|Cohort A: pancreatic cancer|Patients with pancreatic cancer will be treated by durvalumab prescribed in association with tazemetostat
9913192|NCT00734812|Active Comparator|1|Laparoscopic supracervical hysterectomy (LSH)
9913193|NCT00734812|Active Comparator|2|Total Laparoscopic Hysterectomy (TLH)
9913194|NCT00734825|Active Comparator|1|IV contrast
9913195|NCT00734825|Active Comparator|2|IV contrast and oral contrast
9913196|NCT00734838|Experimental|Core needle biopsy|Patients needing a needle biopsy of a breast mass
9913197|NCT00734838|Placebo Comparator|Reduction mammoplasty|Any patients scheduled for a reduction mammoplasty who would like to participate in a study to better understand breast cancer
9913198|NCT00734864|Other|1|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
9913199|NCT00734864|Other|2|Subjects NOT taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
9913200|NCT00734877|Active Comparator|ARM A|The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
9913201|NCT00734877|Experimental|ARM B|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD- PACE
9913202|NCT00734916|Active Comparator|1|Omegaven 10%
9913203|NCT00734916|Active Comparator|2|Intralipid 10%
9913204|NCT00734916|Placebo Comparator|3|Placebo
9913205|NCT00734942|Experimental|1|intervention group
9913206|NCT00734942|No Intervention|2|waiting group
9913207|NCT00734955|Experimental|Reduction Mammoplasty|Patients undergoing reduction mammoplasty
9913208|NCT00734955|Experimental|Mastectomy|Patients undergoing mastectomy
9913209|NCT00734955|Experimental|Lumpectomy|Patients undergoing a lumpectomy
9913210|NCT00735020|Experimental|1|
9913211|NCT00735020|Active Comparator|2|
9913212|NCT00735046||1|Intervention
9913213|NCT00735046||2|control
9913214|NCT00735059|Experimental|1|treatment with dialyzer ELISIO 170H
9913215|NCT00735059|Active Comparator|2|treatment with dialyzer PES-170DS
9913216|NCT00735098|Experimental|1|KBA exercise protocol
9913217|NCT00735098|Experimental|2|strength training exercise protocol
9913218|NCT00735098|Experimental|3|KBA and strength training protocol
9913219|NCT00735098|Sham Comparator|4|
9913220|NCT00735111|Experimental|Karnofsky Performance Status Score|
9913221|NCT00735124|Active Comparator|Single pre-op dose of Gabapentine|Active treatment with the study drug
9913222|NCT00735124|Placebo Comparator|Placebo|Placebo arm for blinding the medication
9913223|NCT00735137|No Intervention|A|Expectant management in twin pregnancy
9913224|NCT00735137|Experimental|B|Vaginal pessary treatment in twin pregnancy
9913225|NCT00735137|No Intervention|C|Expectant management in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
9913226|NCT00735137|Experimental|D|Vaginal pessary treatment in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
9913227|NCT00735150||1|25 female and 5 male BRCA carriers
9913228|NCT00735163|Experimental|A|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
9913229|NCT00735176|Experimental|Artificial Cervical Disc|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
9913230|NCT00735176|Active Comparator|ACDF|Anterior cervical discectomy and fusion (ACDF)
9913231|NCT00735189|Experimental|1|Patient continues to receive anticoagulation care from the Anticoagulation Management Service
9913232|NCT00735189|Active Comparator|2|Patient receives anticoagulation care from their usual primary care physician
9913233|NCT00735228|Active Comparator|1|Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
9913234|NCT00735228|Active Comparator|2|Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
9798878|NCT01642238|Active Comparator|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
9798879|NCT01642251|Experimental|Arm A (veliparib)|Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9798880|NCT01642251|Active Comparator|Arm B (placebo)|Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9798881|NCT01642277|Experimental|Women using Solifenacin for OAB treatment|Solifenacin treated women: Women with OAB who are prescribed solifenacin
9798882|NCT01642277|No Intervention|Control: Women without OAB|Women without OAB who are not prescribed solifenacin.
9798883|NCT01642407|Experimental|Sildenafil|
9798884|NCT01642485|Active Comparator|Moxifloxacin 400 mg fasted|Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
9913235|NCT00735280|Experimental|Reduced dose of unfractionated heparin|
9798885|NCT01642485|Experimental|Moxifloxacin 400 mg fed|"Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.~Additionally, Caucasian vs Japanese subjects were analysed."
9798886|NCT01642589|Experimental|Menactra® Group|Participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
9798887|NCT01642589|Active Comparator|Tdap - Adacel® Group|Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)
9798888|NCT01642602|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.
9798889|NCT01642615|Experimental|Healing Phase: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
9798890|NCT01642615|Experimental|Maintenance Phase: Dexlansoprazole 30 mg|Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
9798891|NCT01642615|Experimental|Maintenance Phase: Placebo|Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
9798892|NCT01642914|Experimental|Linaclotide 290 micrograms|Linaclotide 290 micrograms
9798893|NCT01642914|Experimental|Linaclotide 145 Micrograms|Linaclotide 145 micrograms
9798894|NCT01642914|Placebo Comparator|Placebo|Matching placebo
9798895|NCT01643044|Experimental|Alcohol intervention|Participants in this condition review tailored videos and normed feedback regarding their alcohol use and possible consequences of drinking. Next participants view a goal setting section describing possible ways to quit drinking alcohol and the participant is able to indicate a change goal (if any) and is helped through a specific change plan, should they set a change goal.
9994894|NCT01485315|Active Comparator|Restrictive blood transfusion|Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less
9994895|NCT01485328|Active Comparator|AMARGOL|per oral solution 40 mL single dose
9798896|NCT01643044|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
9798897|NCT01643213|Experimental|BSC approved SCS Trial Therapy w/ OMG|Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)
9798898|NCT01643213|Active Comparator|Non Boston Scientific SCS Trial Therapy|Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment
9798899|NCT01643382|Experimental|Tight glucose control|Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
9798900|NCT01643382|Active Comparator|Standard glucose control|Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.
9798901|NCT01643408|Experimental|Open-Label Erwinaze|
9798902|NCT01643473|Active Comparator|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
9798903|NCT01643473|Experimental|Tailored Adherence Intervention|Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers
9798904|NCT01643616|Active Comparator|group US|"Ultrasound guided block :~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
9798905|NCT01643616|Active Comparator|group NS|"Nerve stimulation technique:~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
9798906|NCT01643668|Experimental|BuClo RIC + SCT|Busulfan and Clofarabine (BuClo) reduced intensity conditioning (RIC) followed by allogeneic stem cell Transplantation (SCT)
9798907|NCT01643707||Phase I|Control
9798908|NCT01643707||Phase II|Treatment
9798909|NCT01643772|Experimental|Oxycodone Hydrochloride 5 mg Capsules|Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
9798910|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules|Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
9798911|NCT01643772|Experimental|Oxycodone Hydrochloride 20 mg Capsules|Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
9798912|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules(multi-dose)|Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
9798913|NCT01643798|Placebo Comparator|Saline|Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
9798914|NCT01643798|Active Comparator|Naloxone|Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
9798915|NCT01643850|Experimental|MCS110|Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
9798916|NCT01643850|Placebo Comparator|Placebo|Part A: single-dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion) Part B: single dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion administered i.v. at Day 1, followed by 6 doses of placebo to match MCS110 (10 mg/kg)
9798917|NCT01643850|Experimental|MCS110 3 mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion)
9798918|NCT01643850|Experimental|MCS110 5 mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion)
9798919|NCT01643850|Experimental|MCS110 10 mg/kg|Part C: MCS110 10 mg/kg (i.v. infusion)
9798920|NCT01643850|Experimental|MCS110 3 mg/kg & MCS110 10mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
9798921|NCT01643850|Experimental|MCS110 5 mg/kg & MCS110 10mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
9798922|NCT01643876|Experimental|Palatal brushing|Palatal brushing after each meal for 3 months.
9798923|NCT01643902|Experimental|IV tPA|Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
9798924|NCT01643928|Experimental|Rituximab-Pfizer|
9798925|NCT01643928|Active Comparator|Rituximab-EU+Rituximab-Pfizer|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses.
9798926|NCT01643928|Active Comparator|Rituximab-US+Rituximab-Pfizer|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses.
9798927|NCT01644058|Experimental|Immediate loading|Immediate loading of 2 endo-osseous mandibular implants
9798928|NCT01644149|Experimental|Stratis Jet Injector|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
9798929|NCT01644149|Active Comparator|Needle and Syringe|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
9994896|NCT01485328|Placebo Comparator|Vehicle without active principles|per oral solution 40 mL single dose
9994897|NCT01485341|Active Comparator|gluten|gluten is administered blindly versus placebo for 15 days at 10 g/day
9994898|NCT01485341|Placebo Comparator|rice starch|placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
9994899|NCT01485367|Active Comparator|Adapalene gel 0.3%|All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
9994900|NCT01485367|Active Comparator|Adapalene gel 0.3 %|All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
9994901|NCT01485406|Experimental|Pn Group|Toddlers 12-23 months of age receiving GSK2830930A vaccine.
9994902|NCT01485406|Active Comparator|Control Group|Toddlers 12-23 months of age receiving Synflorix.
9994903|NCT01485432||P group|Group P: Fluid Management according to measurements with PiCCO®
9994904|NCT01485432||C group|Group C: Conventional fluid management
9994905|NCT01485445|Experimental|Fluticasone Furoate (single strip configuration)|400mcg, administered as 2 inhalations of 200mcg
9994906|NCT01485445|Experimental|Fluticasone Furoate (two strip configuration)|400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate
9994907|NCT01485445|Experimental|Fluticasone Furoate/Vilanterol|400/50mcg, administered as 2 inhalations of 200/25mcg
9994908|NCT01485458|Experimental|Early surgery|
9994909|NCT01485458|Active Comparator|Delayed surgery|
9994910|NCT01485471||Medical Tool|Diffuse optical spectroscopy imaging ear exam
9994911|NCT01485484||Sinus|Optic imaging use near-infrared trans-illumination methods
9994912|NCT01485497|Other|3D endoscopic Fourier Domain OCT|3D endoscopic Fourier Domain OCT
9798930|NCT01644175|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
9994913|NCT01485510|Experimental|Glasgow Infant and Family Team (GIFT)|A service developed by Charles Zeanah and colleagues in New Orleans, that aims to improve the mental health of maltreated infants.
9994914|NCT01485510|Active Comparator|Family Assessment & Contact Service|A social-work based service that aims to assess maltreated children and make recommendations about their future care.
9997957|NCT01513434|Active Comparator|Transportal technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via anteromedial portal.
9997958|NCT01513486|Experimental|Immobilization with NMES|Immobilization with daily NMES
9997959|NCT01513486|Placebo Comparator|Immobilization without NMES|Immobilization without daily NMES
9997960|NCT01513499|Active Comparator|Oxytocin|Intranasal oxytocin
9997961|NCT01513499|Placebo Comparator|Placebo|Intranasal placebo
9997962|NCT01513525|Experimental|Abdomen|
9997963|NCT01513525|Experimental|Thigh|
9997964|NCT01513525|Experimental|Upper arm|
9798931|NCT01644175|Experimental|Alirocumab|Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
9997965|NCT01513564|Experimental|Conservative treatment program|"The control group were supervised isometric passive and active exercises by a physiotherapist. On the second day patients were allowed to sit in a chair being instructed to a low intensity exercise training program with regard to back pain and fear of activity. From the third or fourth day stair training, low intensity exercise, daily walks and instruction in home training were allowed.~The intervention group received the same training program but with a faster program plus a higher intensity exercise-training program."
9997966|NCT01513577|Experimental|Minimal invasive pedicular screw|
9997967|NCT01513577|Experimental|Standard open insertion|
9997968|NCT01513603|Experimental|CLAG-M|
9997969|NCT01513616|Experimental|Pulmonary rehabilitation|A supervised 8-wk outpatient pulmonary rehabilitation program consisting of multi-modality exercise training and COPD self-management education.
9997970|NCT01513616|Sham Comparator|Usual care control|An 8-wk control period consisting of usual medical care which included optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education.
9997971|NCT01513642|Other|Incentive spirometry|
9997972|NCT01513642|No Intervention|Breath Stacking|
9997973|NCT01513655|Experimental|LTNIV group|"LTNIV group is discharged with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.~Furthermore, the patients are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
9997974|NCT01513655|No Intervention|Control group|"Patients in the control group are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
9997975|NCT01513668|Experimental|Acetaminophen extended release Gel tabs|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
9997976|NCT01513668|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA
9997977|NCT01513681|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
9994915|NCT01485523||Patients|A = Patients with allergic rhinitis sensitized to dust mites
9913236|NCT00735293|Other|Treatment|There is only one arm to this study. All patients will receive treatment with the VASER for their axillary hyperhidrosis/bromidrosis
9913237|NCT00735319|No Intervention|A|In the 7 control Capital Health community health centers, babies will be followed up according to the current policy. Bilirubin determinations will be performed at the discretion of the visiting nurse if the infant is inappropriately jaundiced or at the request of the physician if risk factors are present. Transcutaneous Bilirubinometers will not be available in each of these 7 centers for all the duration of the study.
9913238|NCT00735319|Experimental|B|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained.Depending on the level of bilirubin obtained and whether risk factors (gestational age < 38 weeks, blood group incompatibility with DAT positive) are present or not, a different management plan will apply. The algorithm is based on curves established by Bhutani et al to predict the risk of significant hyperbilirubinemia based on predischarge bilirubin measurements.
9913239|NCT00735332|Experimental|Single-Arm|
9913240|NCT00735345|Experimental|Treatment Arm|Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy
9913241|NCT00735358|Active Comparator|A|Single dose cyanoacrylate in one shot
9913242|NCT00735358|Experimental|B|Double doses cyanoacrylate in one shot
9913243|NCT00735410|Experimental|1|
9913244|NCT00735423||No groups|IDE used for outcome measurement not intervention
9913245|NCT00735488||A|Thalassemia Minor carriers
9913246|NCT00735488||B|Sickle cell carriers
9913247|NCT00735501||A|
9934209|NCT04971226|Experimental|Asciminib|Patients will take asciminib 80 mg QD under fasting conditions on ongoing basis; Patients will be randomized 1:1 asciminib versus Investigator selected TKIs
9934210|NCT04971226|Active Comparator|Investigator selected TKIs|"Patients will take on ongoing basis the Investigator selected TKIs that will include one of the below treatments:~Imatinib 400 mg QD administered with food Nilotinib 300 mg BID administered under fasting conditions Dasatinib 100 mg QD administered with or without a meal Bosotunib 400 mg QD administered with food"
9934211|NCT04969926||Patients with confirmed, suspected or at risk of developing parathyroid disorder|Parathyroid (and related disorders) will be evaluated and their biospecimens collected to define the molecular signature and clinical spectrum of their disorder
9934212|NCT04969913||19 + years|Healthy adults over the age of 19 years
9934213|NCT04969913||Ages 11 - 18 years|Healthy children between the ages of 11 and 18 years
9934214|NCT04969913||Ages 5 - 10 years|Healthy children between the ages of 5 and 10 years
9934215|NCT04969913||Ages 6 months - 4 years|Healthy infants between the ages of 6 months and four years
9934216|NCT04969549|Other|Theta-burst stimulation (TBS)|Receive active iTBS, 1800 pulses, 100% MT over dlPFC.
9934217|NCT04969315|Experimental|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-10 is determined
9934218|NCT04968288||Cohort 1|Subjects with KSHV-associated MCD
9934219|NCT04967703|Experimental|Ultrasound therapy protocol|Patients in group A received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes).
9934220|NCT04967703|Experimental|Radial shock wave therapy protocol|Patients in group B received radial shock wave therapy protocol with the following parameters: (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz.
9934221|NCT04967703|Experimental|Combined therapy protocol|Patients in group C received a combination of both ultrasound therapy and radial shock wave therapy protocol.
9934222|NCT04966663|Experimental|Adjuvant chemo-immunotherapy therapy|"All participants will have blood taken for ctDNA testing.~A cycle is 21 days. Pemetrexed (for participants with non-squamous non-small cell lung cancer), intravenously (by vein) on Day 1 of Cycles 1-4, OR gemcitabine (for all other participants) on Days 1 and 8 of Cycles 1-4.~Cisplatin*, intravenously (by vein) on Day 1 of Cycles 1-4 Nivolumab, intravenously (by vein) on Day 1 of Cycles 1-4~*If cisplatin is not tolerated, carboplatin may be given instead"
9934223|NCT04966663|Other|Observation|"All participants will have blood taken for ctDNA testing.~Participants will be followed as per standard of care every 3 months."
9934224|NCT04965493|Experimental|Arm A (PVR)|Fixed duration pirtobrutinib in combination with venetoclax and rituximab
9934225|NCT04965493|Active Comparator|Arm B (VR)|Venetoclax with rituximab
9934226|NCT04963725||Participants Initiating Therapy with Ustekinumab|Data will be collected for participants in Japan who have had an inadequate response, or been intolerant to, conventional or biologic therapies. The treating physician has made the decision to initiate ustekinumab induction therapy in the routine clinical practice - either as a first or subsequent biologic therapy initiating for their moderate to severe ulcerative colitis.
9934227|NCT04963166||12-17 years of age|12-17 years of age
9934228|NCT04963166||2-6 years of age|2-6 years of age
9934229|NCT04963166||7-11 years of age|7-11 years of age
9994916|NCT01485523||Control Subjects|B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
9994917|NCT01485549||MSA Patients|Patients suffering from Multiple system atrophy (MSA)
9994918|NCT01485549||Controls|Patients requiring spinal tap without being affected by a neurodegenerative disorder.
9994919|NCT01485562|Active Comparator|Misoprostol|women who experience a PPH will be randomized to receive 800 misoprostol (four tablets of 200 mcg administered sublingually)
9994920|NCT01485562|Placebo Comparator|placebo|women who experience a PPH will be randomized to receive 4 placebo tablets administered sublingually
9994921|NCT01485575||Filter use during vitrectomy|
9994922|NCT01485601|Experimental|MT10109|Clostridium botulinum toxin type A
9994923|NCT01485601|Active Comparator|Botox (registered trade mark)|Clostridium botulinum toxin type A
9994924|NCT01485653|Experimental|Mepivacaine, Ultrasound Axillary Block|Group 1) 20mL 1.5% mepivacaine Group 2) 30mL 1.5% mepivacaine
9994925|NCT01485679|Experimental|positrons emission tomography|
9994926|NCT01485692|Active Comparator|ziprasidone injection|ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
9994927|NCT01485692|Active Comparator|haloperidol + midazolam, injection|Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
9994928|NCT01485692|Active Comparator|haloperidol + promethazine, injection|haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
9994929|NCT01485692|Active Comparator|olanzapine, injection|olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
9994930|NCT01485718|Active Comparator|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
9994931|NCT01485718|Placebo Comparator|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
9994932|NCT01485731|Experimental|Nelfinavir + Cisplatin + Pelvic Radiation Therapy|Nelfinavir in combination with Cisplatin and Pelvic Radiation Therapy
9994933|NCT01485744|Experimental|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|
9994934|NCT01485757|Experimental|L-arginine|
9994935|NCT01485809|Experimental|Gefitinib|
9994936|NCT01485822||TRAVATAN|As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
9994937|NCT01485822||Treatment Naive|No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
9994938|NCT01485835|Experimental|Ganetespib + Bortezomib + Dexamethasone|"Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 100 mg/m²~Cohort 2: 100 mg/m²~Cohort 3: 120 mg/m²~Cohort 4: 144 mg/m²~Cohort 5: 173 mg/m²~Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 1.0 mg/m²~Cohort 2, 3, 4, 5: 1.3 mg/m²~Dexamethasone: Oral prior to bortezomib~Cohort 1, 2, 3, 4, 5: 20 + 20 mg~Day of and following bortezomib"
9994939|NCT01485848|Active Comparator|Paclitaxel|A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
9994940|NCT01485848|Experimental|Paclitaxel + EP-100|Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
9994941|NCT01485900|Experimental|Cohort 1|Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
9994942|NCT01485900|Experimental|Cohort 2|Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
9994943|NCT01485913|Experimental|Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
9994944|NCT01485913|No Intervention|No Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
9994945|NCT01485926|Experimental|Docetaxel, Carboplatin and Trastuzumab|Arm A- 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
9913248|NCT00735527|Experimental|1|Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
9913249|NCT00735527|Active Comparator|2|Intra-venous lorazepam 0.1 mg/kg (max 4 mg)
9913250|NCT00735540||A|Acute organic diseases
9913251|NCT00735540||B|Patients with chronic diseases
9913252|NCT00735540||C|Patients with psychiatric diagnosis
9913253|NCT00735579||Study group|Patients undergoing major abdominal surgery
9913254|NCT00735592||A|Children discharged with the recommendation of performing a follow up X rays after lobar pneumonia
9913255|NCT00735605|Active Comparator|1:BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
9913256|NCT00735605|Active Comparator|2 BTX A|Injected with BTX-A in the left lateral position; anesthesia was not required
9913257|NCT00735605|Active Comparator|3: PDPR|Inner half of puborectalis sling was divided on each side by using a scalpel NO
9913258|NCT00735631|Experimental|1|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
9913259|NCT00735683|Placebo Comparator|1|
9913260|NCT00735683|Experimental|2|
9913261|NCT00735683|Experimental|3|
9913262|NCT00735683|Experimental|4|
9913263|NCT00735683|Experimental|5|
9913264|NCT00735683|Experimental|6|
9913265|NCT00735722|Active Comparator|Concomitant HIFU ablation|HIFU AF Ablation
9913266|NCT00735722|No Intervention|Best medical treatment|Best medical treatment
9913267|NCT00735748|Experimental|1|Tramadol per os (Tradonal Odis® orodispersible tablets)
9913268|NCT00735748|Active Comparator|2|Tramadol IV (Tradonal® IV)
9913269|NCT00735761|Experimental|1|ME-609 (5% acyclovir and 1% hydrocortisone)
9913270|NCT00735761|Active Comparator|2|Acyclovir in ME-609 vehicle (5% acyclovir)
9913271|NCT00735774|Experimental|11C-ORM-13070|
9913272|NCT00735800|Active Comparator|Supportive Counseling|
9913273|NCT00735800|Experimental|Problem-Solving|
9913274|NCT00735813|Experimental|A|Tunneled central venous catheters locked with Taurolock
9913275|NCT00735813|Active Comparator|B|Tunneled central venous catheter locked with heparin
9913276|NCT00735865|Active Comparator|1|
9913277|NCT00735865|Active Comparator|2|
9913278|NCT00735865|Active Comparator|3|
9913279|NCT00735865|Active Comparator|4|
9913280|NCT00735930|Experimental|Treatment (alvocidib, lenalidomide)|Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9913281|NCT00735995|Experimental|A|Individual CBT
9913282|NCT00735995|Experimental|B|Group CBT
9913283|NCT00735995|No Intervention|C|Waiting-list control
9913284|NCT00736008||A|Patients with thromboembolic events
9913285|NCT00736021|Experimental|A|Single arm (open label study): Provide twelve weeks of treatment with high does (40 mg daily) of escitalopram to trauma survivors with chronic PTSD.
9913286|NCT00736047|Active Comparator|1|
9913287|NCT00736047|Placebo Comparator|2|
9913288|NCT00736060||1|Sickle cell anemia
9913289|NCT00736060||2|Sickle cell thalassemia
9913290|NCT00736086||1|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
9913291|NCT00736112|Experimental|BMT and food allergy|trial subjects will receive food allergy testing and management in conjunction with BMT (Bilateral Myringotomy with Tympanostomy Tubes). Food allergy management involves parental education on how to avoid the specific offending foods.
9913292|NCT00736112|Experimental|BMT and adenoidectomy|"involves BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and food allergy testing and management.~Food allergy management involves parental education on how to avoid the specific offending foods."
9913293|NCT00736112|Active Comparator|BMT alone|The standard protocol for children presenting with initial Chronic OME is to perform a BMT (Bilateral Myringotomy with Tympanostomy Tubes).
9913294|NCT00736138|Active Comparator|1|training and pellots
9913295|NCT00736138|No Intervention|2|control
9913296|NCT00736151|Experimental|1|Ralfinamide administered orally at rising doses of 80 - 320 mg/day
9913297|NCT00736151|Active Comparator|2|Placebo controlled with randomization of 2:1
9913298|NCT00736164|Experimental|Arm I|Patients receive oral selenomethionine once daily for 8-9 weeks.
9913299|NCT00736164|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 8-9 weeks.
9913300|NCT00736177|Active Comparator|Control|Patients in the control group will undergo conventional IVF cycles with fresh blastocyst transfer.
9913301|NCT00736177|Experimental|Test group|Patients in the Test group will have their embryos cryopreserved for transfer in a second cycle.
9913302|NCT00736203||A|non-smokers
9913303|NCT00736268|Experimental|CST|Telephone-based Enhanced Coping Skills Training (CST)
9913304|NCT00736268|Other|UMC|Usual Medical Care and COPD education and symptom monitoring (UMC)
9913305|NCT00736281|No Intervention|Placebo Food Drops|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
9913306|NCT00736281|Active Comparator|Food Drops|Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).
9913307|NCT00736294|Experimental|Ramipril|Inhibition Conversion Enzyme
9913308|NCT00736294|Placebo Comparator|Placebo|Placebo
9913309|NCT00736307|Experimental|1|Cultured limbal stem cells Transplantation
9913310|NCT00736320|Active Comparator|A|2 cycles ABVD followed by 20 Gy IF-RT irrespective of FDG-PET results after chemotherapy
9913311|NCT00736320|Experimental|B|2 cycles ABVD followed by 20 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
9913312|NCT00736346|Active Comparator|1|
9913313|NCT00736346|Active Comparator|2|
9913314|NCT00736346|Active Comparator|3|
9913315|NCT00736346|No Intervention|4|
9913316|NCT00736372|Experimental|Investigational Drug|Dose Escalation
9913317|NCT00736398||Observation|Spinal fusion
9913318|NCT00736411|Active Comparator|1|IVF
9913319|NCT00736411|Other|II|treatment
9913320|NCT00736424||1|Have received bilateral AN stimulation of the anterior nucleus (AN) of the thalamus for epilepsy or are receiving it at the time of enrollment
9913321|NCT00736437|Experimental|1|ME-609
9913322|NCT00736437|Placebo Comparator|2|Vehicle
9913323|NCT00736463|Active Comparator|1|Aimvastatin 80 mg
9913324|NCT00736463|Active Comparator|2|Atorvastatin 80 mg
9913325|NCT00736515|Experimental|Combination therapy|The subjects allocated into this arm will receive the combination therapy of oral administration of 60~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
9913326|NCT00736515|Active Comparator|monotherapy|The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.
9913327|NCT00736528|Experimental|PF-04447943 05 mg dose|
9913328|NCT00736528|Experimental|PF-04447943 15 mg dose|
9913329|NCT00736528|Experimental|PF-04447943 45 mg dose|
9913330|NCT00736528|Placebo Comparator|Placebo|
9913331|NCT00736541|Experimental|2|
9913332|NCT00736593|Experimental|1|
9913333|NCT00736606|Experimental|Period 1|simvastatin
9913334|NCT00736606|Experimental|Period 2|simvastatin + AZD9056
9913335|NCT00736619|Experimental|1|"Cetuximab loading dose, 400 mg/m2 intravenously (IV) IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days~Cetuximab 250 mg/m2 weekly IV X 7 weeks~Albumin-bound paclitaxel (Abraxane®) weekly IV X 7 weeks, according to dose escalation scheme"
9913336|NCT00736658|Experimental|AZD1386|4 groups receiving a specified volume of the active component AZD1386 at different points of time.
9913337|NCT00736658|Placebo Comparator|Placebo|Included in each dose group
9913338|NCT00736671||Observational Parkinson's Disease|Observational study of subjects with Parkinson disease
9913339|NCT00736671||Observational Normal Control aubjects|Observational study of normal control subjects
9913340|NCT00736684|Active Comparator|1|Proximal Femoral Nail AntirotationTM (PFNA)
9913341|NCT00736684|Other|2|Gamma Nail 3TM (Gamma3)
9913342|NCT00736697|Experimental|1|
9913343|NCT00736710|Experimental|1|
9913344|NCT00736710|Sham Comparator|2|
9913345|NCT00736736|Active Comparator|Leg Press|Leg Press exercise for 3 times/week and sustain for 8 weeks.
9913346|NCT00736736|Experimental|Hip Exercise|Additional hip abductor and hip external rotator strength training to leg press exercise for people in this group. All participants received exercise for 3 times per week for 8 weeks.
9913347|NCT00736736|No Intervention|Control|Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
9913348|NCT00736749||Observational (long-term follow-up)|Within 3 months of enrollment of ALTE05N1, patients receive a mailed packet introducing the LTFC. Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.
9913349|NCT00736762|Experimental|GPR|Global postural re-education intervention
9913350|NCT00736788|Experimental|1|Four different oral dose levels of a suspension containing AZD1704
9913351|NCT00736788|Placebo Comparator|2|oral suspension
9913352|NCT00736801|Experimental|A|Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
9913353|NCT00736814|Active Comparator|Arm I|Patients receive standard chemotherapy of docetaxel and carboplatin.
9913354|NCT00736814|Experimental|Arm II, Genotype A1|Patients receive docetaxel and vinorelbine ditartrate.
9913355|NCT00736814|Experimental|Arm II, Genotype A2|Patients receive gemcitabine hydrochloride and vinorelbine ditartrate.
9913356|NCT00736814|Experimental|Arm II, Genotype B1|Patients receive docetaxel and carboplatin.
9913357|NCT00736814|Experimental|Arm II, Genotype B2|Patients receive gemcitabine hydrochloride and carboplatin.
9913358|NCT00736827||Patients with non-septic shock|Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
9913359|NCT00736827||Patients with septic shock|Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
9913360|NCT00736866|Experimental|Acetylcysteine|
9913361|NCT00736866|Placebo Comparator|Control|
9913362|NCT00736892||A|All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of > 200 to <300 mmHg or ≤ 200 mmHg.
9913363|NCT00736918|Experimental|Case management|Case management
9913364|NCT00736918|Active Comparator|Enhanced usual care|Enhanced usual care
9913365|NCT00736931|Experimental|1|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
9913366|NCT00736931|Active Comparator|2|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
9913367|NCT00736931|Active Comparator|3|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
9913368|NCT00736931|Placebo Comparator|4|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
9913369|NCT00736970|Experimental|1|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus
9913370|NCT00736983|Active Comparator|1|Adalimumab
9913371|NCT00736983|Placebo Comparator|2|ciprofloxacin
9913372|NCT00737035|Experimental|1-Intervention|For 16 weeks, participants will have access to an interactive healthcare communication application (IHCA).
9913373|NCT00737035|Active Comparator|2- Control|For 16 weeks, participants will have access to generally available Internet-based information about parenting, trauma, and child development.
9913374|NCT00737087|Other|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
9913375|NCT00737126|Placebo Comparator|1|Administration of an oral placebo pill
9913376|NCT00737126|Experimental|2|Administration of oral folic acid
9913377|NCT00737139|Active Comparator|1|Intra-articular Injection of Marcaine/Epinephrine
9913378|NCT00737139|Active Comparator|2|Intra-articular Injection of Marcaine alone
9913379|NCT00737152|Experimental|1|All subjects will take RAS 130 administered orally in tablet form at a starting dose of 4 mg once a day or 2 mg tablets twice a day.
9913380|NCT00737165|Experimental|Multimodal community intervention|Multimodal suicide prevention program
9913381|NCT00737165|Active Comparator|Community intervention as usual|Suicide prevention program as usual
9913382|NCT00737191|Active Comparator|Arm I|Patients receive oral opioid and oral placebo once daily for 4 weeks.
9913383|NCT00737191|Experimental|Arm II|Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.
9913384|NCT00737191|Experimental|Arm III|Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.
9913385|NCT00737217||Parkinson's disease|
9997978|NCT01513681|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
9913386|NCT00737217||Normal Controls|
9913387|NCT00737256|Experimental|1|
9913388|NCT00737256|Active Comparator|2|
9913389|NCT00737295|Experimental|US|There will be no experimental or control group, rather each individual will act as his/her own control.
9913390|NCT00737308|Experimental|A|crown for clasp
9913391|NCT00737334|Active Comparator|1|All patients will have continuous EEGo, BIS and FORE-SIGHT monitoring, which will be correlated with arterial to jugular venous lactate differences.
9913392|NCT00737347|No Intervention|1|usual care. Subjects had one 90 minute visit with registered dietitian
9913393|NCT00737347|Active Comparator|2.|Standard care. Subjects had 4 sessions with registered dietitian
9913394|NCT00737347|Active Comparator|3|Intensive care. subjects had 10 visits with registered dietitian
9913395|NCT00737373|Experimental|1|FLOT
9913396|NCT00737373|Active Comparator|2|FLO
9913397|NCT00737412|Active Comparator|1|The probiotic Bio-K+ CL1285 RX®
9913398|NCT00737412|Placebo Comparator|2|Placebo
9913399|NCT00737425|Active Comparator|1|
9913400|NCT00737425|Sham Comparator|2|
9913401|NCT00737451||skin itching|
9913402|NCT00737490|Active Comparator|1|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm"
9913403|NCT00737490|Active Comparator|2|"Simultaneous BiV pacing. Simultaneous Arm"
9913404|NCT00737503|Experimental|1|All eligible children in the experimental arm will be vaccinated with the Rotavirus vaccine
9913405|NCT00737503|No Intervention|2|Children will not be vaccinated with rotavirus vaccine.
9913406|NCT00737542|Placebo Comparator|A|
9913407|NCT00737542|Experimental|B|
9934230|NCT04959188||Bereaved family caregivers|Bereaved family caregivers (parents or spouses/partners) of individuals who died from complications associated with dyskeratosis congenita or a related telomere biology disorder.
9934231|NCT04959188||Caregivers|Family and/or caregivers of individuals with dyskeratosis congenita or a related telomere biology disorder.
9934232|NCT04959188||Patients|Individuals with dyskeratosis congenita or a related telomere biology disorder.
9934233|NCT04959175|No Intervention|Donors|Collection of research samples on bone marrow donors
9934234|NCT04959175|Experimental|Older, HLA-matched|Subjects age 60-85 with hematologic malignancies and an HLA-matched related or unrelated donor
9934235|NCT04959175|Experimental|Older, HLA-mismatched|Subjects age 60-85 with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
9934236|NCT04959175|Experimental|Younger, HLA-matched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-matched related or unrelated donor
9934237|NCT04959175|Experimental|Younger, HLA-mismatched|Subjects age 18-60 unfit for MAC with hematologic malignancies and an HLA-haploidentical or HLA-mismatched unrelated donor
9997979|NCT01513694|Experimental|MSC seeded onto a phosphate ceramic|Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.
9997980|NCT01513707||Hemodialysis group|Hemodialysis group
9997981|NCT01513707||peritoneal dialysis group|peritoneal dialysis group
9798932|NCT01644188|Experimental|Alirocumab 75 /up to 150 mg Q2W|Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
9798933|NCT01644188|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.
9798934|NCT01644240|Experimental|TD-8954 Dose 1|
9798935|NCT01644240|Placebo Comparator|Placebo|
9798936|NCT01644240|Experimental|TD-8954 Dose 2|
9798937|NCT01644292|Experimental|EPIC Wheels Training Intervention|EPIC Wheels skills training program
9798938|NCT01644331|Experimental|Tolvaptan|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)
9798939|NCT01644331|Placebo Comparator|Placebo|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)
9798940|NCT01644396|Other|Adalimumab|Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
9798941|NCT01644474|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
9798942|NCT01644474|Experimental|Alirocumab 75/Up to 150 mg Q2W|SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
9798943|NCT01644500|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
9798944|NCT01644500|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
9798945|NCT01644500|Active Comparator|Glimepiride|1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
9798946|NCT01644565|Experimental|Group A-1|Recombinant fimbrial adhesin dscCfaE: 1 ug of dscCfaE ID on study days 0, 21 and 42
9798947|NCT01644565|Experimental|Group A-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5: 2.6 ug of Chimera ID on study days 0, 21 and 42
9798948|NCT01644565|Experimental|Group A-3|Modified E. coli heat labile enterotoxin LTR192G: 100 ng of LTR192G ID on study days 0, 21 and 42
9798949|NCT01644565|Experimental|Group B-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
9798950|NCT01644565|Experimental|Group B-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 2.6 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
9798951|NCT01644565|Experimental|Group C-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 5 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
9798952|NCT01644565|Experimental|Group C-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 12.9 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
9798953|NCT01644565|Experimental|Group D-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 25 ug dscCfaE + 100 ng LTR192G ID on study days 0, 21 and 42
9798954|NCT01644565|Experimental|Group D-2|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1250 ug dscCfaE + 50 ng LTR192G TCI on study days 0, 21 and 42
9798955|NCT01644617|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
9798956|NCT01644617|Experimental|MK-8237 6 Developmental Units (DU)|MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
9798957|NCT01644617|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
9913408|NCT00737555|Experimental|1|Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
9913409|NCT00737620|Active Comparator|propaten graft|
9913410|NCT00737620|Active Comparator|Standard graft|
9913411|NCT00737646|Other|1|Usual care
9913412|NCT00737646|Experimental|2|Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
9913413|NCT00737646|Experimental|3|"Clinic-focused and patient focused intervention: The clinic focused-intervention as described in Arm 2 will be combined with a patient-focused intervention.~Patient focused intervention: CRC education packets, based upon previously developed CDC CRC patient education materials, have been adapted for each study site. These CRC educational packets will be mailed to average-risk patients aged 50-80 years who are due for CRC screening (based on electronic records) and who schedule a non-acute ambulatory care visit in clinics assigned to the patient-focused intervention. A cover letter signed by the patient's physician will be included with each packet. The packets will be mailed approximately 1 week before the medical appointment."
9913414|NCT00737659|Experimental|1|Concentration Controlled (CC)group will receive an individually adjusted MMF dosing regimen based on the plasma concentrations of mycophenolic acid (MPA,the active metabolite of mycophenolate mofetil).
9913415|NCT00737659|Active Comparator|2|Fixed dose (FD) group will receive an a priori set dose of 2mg\day MMF, the recommended dose, with a possible secondary adaptation by the clinician based on criteria of clinical efficacy, toxicity or interactions with other medications.
9913416|NCT00737685|Experimental|Fludarabine|
9913417|NCT00737724|Experimental|Group 1|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
9913418|NCT00737724|Experimental|Group 2|Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy
9913419|NCT00737750|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
9913420|NCT00737750|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
9913421|NCT00737750|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
9913422|NCT00737763|Experimental|A|This group will receive weekly efalizumab injections for 6 months
9913423|NCT00737763|Placebo Comparator|B|This group will receive placebo injections for 6 months
9913424|NCT00737776||A|
9913425|NCT00737789|Experimental|Mesalazine once/day|Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
9913426|NCT00737789|Active Comparator|Mesalazine twice/day|Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).
9913427|NCT00737802||Normal Control|Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
9994946|NCT01485926|Experimental|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|Arm B - 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
9994947|NCT01485939|Placebo Comparator|placebo patch|
9994948|NCT01485939|Active Comparator|lidocaine patch|
9994949|NCT01485952|Experimental|SEN0014196 (Low Dose)|10 mg, once daily administration (immediate release capsule)
9994950|NCT01485952|Experimental|SEN0014196 (High dose)|100 mg, once daily administration (immediate release capsule)
9994951|NCT01485952|Placebo Comparator|Placebo|Once daily (immediate release capsule)
9994952|NCT01485965|Experimental|Fasted condition|Subjects in the Fasted group will take study drug after an overnight fast (since at least midnight). Additionally, on PK assessment days, no food will be allowed for at least 4 hours after study drug administration.
9994953|NCT01485965|Experimental|Fed condition|Subjects in the Fed group will take study drug within 30 minutes after starting breakfast; these subjects will otherwise maintain their normal eating schedule.
9798958|NCT01644643|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
9994954|NCT01485978|Active Comparator|Ramipril blinded|oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years
9994955|NCT01485978|Placebo Comparator|placebo to ramipril|Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.
9994956|NCT01485978|Other|open label ramipril|Open label treatment with ramipril as per protocol, if randomization is refused.
9994957|NCT01486004|Experimental|001|35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total) + 150 mg capsule once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle
9994958|NCT01486017|Experimental|Treatment A|ASP015K oral dose low strength
9994959|NCT01486017|Experimental|Treatment B|ASP015K oral dose medium strength
9994960|NCT01486017|Experimental|Treatment C|ASP015K oral dose high strength
9994961|NCT01486056||healthy patients, may have epilepsy|Subjects at least 12 years old and in general good health for Phase I, and at least 18 years old and in general good health for Phase II. It is desired, but not required, for subjects to have epilepsy and taking at least 1 antiepileptic medication.
9994962|NCT01486069||Dentofacial Deformity|Patients with dentofacial deformities candidate to orthognathic surgery
9994963|NCT01486082||Empirical OCA|This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
9994964|NCT01486082||OCA after antibiogram|This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
9994965|NCT01486095|Experimental|AXXESS + Biomatrix|After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
9994966|NCT01486095|Active Comparator|Culotte technique: Xience V/Prime|The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
9994967|NCT01486108|Experimental|Tonic|5 hz stimulation at an amplitude that the patient find bearable (+/- 1.5 mA)
9994968|NCT01486108|Experimental|Sham|no stimulation, patient receive a sham stimulation (actually the IPG is not running)
9994969|NCT01486108|Experimental|burst|500 hz burst at 5 hz stimulation
9994970|NCT01486121|Other|S.O.S.-V|
9994971|NCT01486121|No Intervention|Standard|
9994972|NCT01486134|Experimental|procedure|
9994973|NCT01486147|Experimental|Visual|Group provided with nutrition information using visual nutrient profiling tool
9994974|NCT01486147|Other|Table|Group provided nutrition information using table format
9994975|NCT01486160||nursing home residents|participants in this group are nursing home residents
9994976|NCT01486160||Nursing home employees|Participants in this group are health care workers, employees at the nursing home
9994977|NCT01486173||Premature infants with a GA < 32 Weeks|
9994978|NCT01486173||New born with a GA > 37Weeks|
9994979|NCT01486186|Experimental|traditional chinese medicine|The experimental group will receive three type of TCM, they are Baofei granule, Bufeijianpi granule and Bufeiyishen granule.
9994980|NCT01486186|Placebo Comparator|placebo|placebo chinese medicine in addition to best care according to clinical guidelines for COPD patients
9994981|NCT01486212||Healthy volunteers.|Male aged 18-40 years. Non-smokers. No known familiar disposition to vascular/heart diseases. No intake of prescription medicine.
9994982|NCT01486225|Other|Innothera's brand Stokings|Innothera's branded grip-top silicone band stokingc
9994983|NCT01486225|Other|Other than Innothera's brand|
9997982|NCT01513720|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
9994984|NCT01486251|Experimental|experimental|"axitinib will be given BID orally. One cycle is defined as a 14-day period (7 days ON / 7 days OFF). The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
9994985|NCT01486290|Experimental|Geriatric Diabetes Team Intervention|The subjects in this group underwent evaluation for barriers to self care by a diabetes educator well versed with age specific barriers. After consideration of patient clinical, function, and psychosocial background, a geriatric diabetes team devised strategy to help patients cope with respective barriers. An office based diabetes diabetes educator conveyed the strategy to patient and caregivers viz phone calls. the educator called study participants up wot eleven times over a sex month period.
9994986|NCT01486290|No Intervention|Atention Control Arm|The subjects in the group received similar, in person contact, as the intervention group. an educator, separate from the one involved in the intervention team, called patients in this group for a total of eleven times within the first six months. The Phone calls were focused toward general discussion without any diabetes related advice.
9994987|NCT01486303|Experimental|Facial Cosmetic Acupuncture|28 Patients with grade III to IV wrinkling on the face, according to the Glogau classification system, were treated with Facial Cosmetic Acupuncture.
9994988|NCT01486329|Experimental|VXM01|Investigational anti-angiogenic live cancer vaccine
9994989|NCT01486329|Placebo Comparator|Placebo|Placebo control
9994990|NCT01486342||Group 1|Mechanically ventilated patients without acute lung injury and lung injury prediction score < 4
9994991|NCT01486355|Experimental|Early measles vaccine|Receives an early measles vaccine in addition to the standard measles vaccine at 9 months of age
9994992|NCT01486355|No Intervention|No early measles vaccine|Receives only the standard measles vaccine at 9 months of age
9994993|NCT01486368|Experimental|PF-03446962|
9994994|NCT01486381|Experimental|BIAsp 30|
9994995|NCT01486394|Experimental|Focused sonography|Intervention group: After the primary evaluation by a physician in the emergency department, focused sonography of the patients heart, lungs and deep veins in the legs are performed. Hereafter the further examinations and treatment are done according to hospital guidelines.
9994996|NCT01486394|No Intervention|Usual treatment and diagnostic work-up|Control group: After the primary evaluation by a physician in the emergency department. Hereafter the further examinations and treatment are done according to hospital guidelines.
9994997|NCT01486407||Intravenous (IV) drug delivery|patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
9994998|NCT01486407||Intraosseous (IO) drug delivery|Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
9994999|NCT01486420|Active Comparator|Open surgery|
9995000|NCT01486420|Active Comparator|Corticosteroid Injection|
9995001|NCT01486433|Experimental|Epanova and Simvastatin|
9995002|NCT01486433|Active Comparator|Simvastatin|
9995003|NCT01486459|Experimental|PCI with lithium|Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
9995004|NCT01486459|No Intervention|Standard|Prophylactic cranial irradiation alone.
9995005|NCT01486472||GC patients receiving adjuvant S-1 chemotherapy|
9995006|NCT01486485|Experimental|heparinized saline priming group|Experimental group : heparinized saline priming group
9995007|NCT01486485|Active Comparator|nafamostat infusion group after heparinized saline priming|active comparator : nafamostat infusion group after heparinized saline priming
9995008|NCT01486511||Liver resection patients|All patients that underwent elective liver resection for both malignant and benign diseases.
9995009|NCT01486524||DrotAA Treatment Group|Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
9995010|NCT01486524||Control Group (non-DrotAA treated)|Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).
9997983|NCT01513720|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
9995011|NCT01486550|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
9995012|NCT01486550|Placebo Comparator|Sodium Chloride 9mg/ml|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
9995013|NCT01486563|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
9995014|NCT01486563|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
9995015|NCT01486576|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
9995016|NCT01486576|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
9995017|NCT01486602|Experimental|Concurrent therapy + consolidation therapy|"Concurrent Therapy (1 cycle = 14 days, Cycles 1-3): Patients will receive paclitaxel 45 mg/m^2 by IV over 1 hour weekly followed by carboplatin AUC 2 by IV over 30-60 minutes for 4 weeks (there will be no chemotherapy during Cycle 3). Patients will receive radiotherapy concurrently for up to 5.5 weeks, depending on the cohorts the patient is registered defined per the protocol.~Consolidation Therapy (1 cycle = 21 days, Cycles 4-5): Four weeks following the end of radiotherapy patients will receive paclitaxel 200 mg/m^2 by IV over 3 hours followed by carboplatin AUC 6 by IV over 30-60 minutes on day 1 of each 21 day cycle for a total of 2 cycles (days 1 and 22)."
9995018|NCT01486628|Placebo Comparator|levodopa and carbidopa|
9995019|NCT01486628|Placebo Comparator|Placebo|Saline solution for subcutaneous administration
9995020|NCT01486641|Active Comparator|Anterolateral approach|"Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
9995021|NCT01486641|No Intervention|Posterolateral approach|"Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
9995022|NCT01486654|Active Comparator|Anodal stimulation|
9995023|NCT01486654|Active Comparator|Cathodal stimulation|
9995024|NCT01486654|Placebo Comparator|Sham stimulation|
9995025|NCT01486667|Placebo Comparator|sugar pill|
9995026|NCT01486667|Active Comparator|Levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients. Serum levels of TSH and FT4 will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
9995027|NCT01486680|Active Comparator|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|
9995028|NCT01486680|Active Comparator|Laparoscopic Sleeve Gastrectomy|
9995029|NCT01486706|Experimental|Gabapentin|Two to three months of behavioral therapy prior to start of Gabapentin 100mg/capsule, initially 1 capsule once a day for 1 week then titrate dosage according to symptoms until maximum dose of 1500mg/day Placebo tablet of Solifenacin Succinate will titrate dose same as Solifenacin arm according to symptoms of patient
9995030|NCT01486706|Active Comparator|Solifenacin Succinate|Two to three months of behavioral therapy prior to Solifenacin Succinate 5mg/tablet initially 1 tablet once a day then titrate dosage according to symptoms upto maximum dose of 10mg/day Placebo form of Gabapentin will titrate dosage same as Gabapentin group according to symptoms of patient
9995031|NCT01486706|Placebo Comparator|Placebo|Two to three months of behavioral therapy prior to Placebo form of Gabapentin and Solifenacin and titrate accordingly same as the treatment arms
9995032|NCT01486732|Experimental|Umbilical Cord Blood & Rehabilitation|Allogeneic umbilical cord blood infusion and active rehabilitation
9995033|NCT01486732|Active Comparator|Placebo Umbilical Cord Blood & Rehabilitation|Placebo Umbilical Cord Blood infusion and active rehabilitation
9798959|NCT01644643|Active Comparator|Best Available Therapy|IV treatment
9995034|NCT01486745||Normal colonoscopy|
9995035|NCT01486745||Colonic polyps|
9995036|NCT01486745||Colorectal cancer patients|
9995037|NCT01486745||Breast & Prostate Cancer patients|
9995038|NCT01486771|Experimental|IV Macugen Q6|Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
9995039|NCT01486771|Experimental|IV Mac Q6 Arm|Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections
9995040|NCT01486771|Experimental|Pan Retinal Photocoagulation|Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
9995041|NCT01486797|Experimental|NOX-A12|
9995042|NCT01486823|Experimental|Cohort A|
9995043|NCT01486823|Experimental|Cohort B|
9995044|NCT01486836||ICD therapy|
9913428|NCT00737802||GERD Patients|GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
9913429|NCT00737802||Barrett's patients|Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.
9913430|NCT00737815|Active Comparator|A|Magnesium citrate: a total of 500 mg of elemental magnesium
9913431|NCT00737815|Placebo Comparator|B|Placebo pills
9913432|NCT00737828|Active Comparator|A|Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)
9913433|NCT00737828|Experimental|B|Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold & ventilatory equivalents
9913434|NCT00737841|Experimental|A|Bifidobacterium breve
9913435|NCT00737841|Placebo Comparator|B|Placebo
9913436|NCT00737854|Experimental|1 ARM|Otherwise healthy patients with oral lichen planus (precancerous/erosive OLP)
9913437|NCT00737867|Experimental|A|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
9913438|NCT00737867|Active Comparator|B|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert's formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
9913439|NCT00737880|Active Comparator|1|In situ organ perfusion using HTK solution during pancreas procurement
9913440|NCT00737880|Active Comparator|2|In situ perfusion using UW solution during pancreas procurement
9913441|NCT00737906|Experimental|I|Surgical turbinate reduction procedure
9913442|NCT00737919|Active Comparator|1|A group of subjects consuming daily 2 grams of plant stanols 4-6 weeks before the operation
9913443|NCT00737919|Active Comparator|2|A group of patients consuming daily 2 grams of plant sterols 4-6 weeks before the operation
9913444|NCT00737932|Experimental|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
9913445|NCT00737932|Placebo Comparator|Placebo|Matching placebo
9913446|NCT00737945||2|
9913447|NCT00737958||1|Patients with documented stable coronary artery disease, symptoms of stable angina pectoris, and a positive standard BRUCE exercise stress test at 3 - 13 minutes.
9913448|NCT00737971|Active Comparator|A|Avastin intravitreal injection D0, Week 4, Week 8
9913449|NCT00737971|Active Comparator|B|Triamcinolone intravitreal injection
9913450|NCT00737971|Active Comparator|C|Avastin + Triamcinolone intravitreal injection simultaneously
9913451|NCT00737984|No Intervention|1|Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
9913452|NCT00737984|Active Comparator|2|Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
9913453|NCT00737997|Placebo Comparator|1|
9913454|NCT00737997|Experimental|2|
9913455|NCT00738010|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
9913456|NCT00738010|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
9913457|NCT00738010|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
9913458|NCT00738036||Group P|Exposed to an acute painful phenomenon requiring an analgesic management
9913459|NCT00738036||Group C|Control, not exposed to acute pain
9913460|NCT00738075||PD+FOG|Patients with Parkinson's disease prone to freezing
9913461|NCT00738088|Experimental|1|Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c
9913462|NCT00738114||1|group without hyperglycemia (fasting blood glucose below 126mg/dl) approximately 1000 patients
9913463|NCT00738114||2|group with hyperglycemia (fasting blood glucose above 125 mg/dl) or history of diabetes approximately 500 patients
9913464|NCT00738127|Experimental|1|Group I (treatment with our technique) Eighteen patients (18 wrists) were available for long-term follow-up at an average of 47.8 months after surgery. There were 11 men and seven women. Their mean age at the time of surgery was 35.4 years (range, 22 to 56 years). The dominant hand was involved in 12 patients and the nondominant hand, in six.
9913465|NCT00738127|Experimental|2|Group II (treatment with Inoue et al.'s technique) Fifteen patients (15 wrists) were evaluated at an average of 51 months. Nine patients were men and 6 were women. The mean age of the group at the time of surgery was 37.5 years (range, 24 to 58 years). The dominant hand was involved in 10 and nondominant hand, in seven.
9913466|NCT00738140|Experimental|A|Intensive lifestyle intervention based on the Diabetes Prevention Program
9913467|NCT00738140|No Intervention|B|Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
9913468|NCT00738153||A|
9913469|NCT00738166|Experimental|II|organic animal manure
9913470|NCT00738166|Active Comparator|III|conventional
9913471|NCT00738166|Experimental|I|organic green manure
9913472|NCT00738179|Experimental|1|CPAP plus standard care of cardiovascular risk factors
9913473|NCT00738179|Active Comparator|2|Standard care alone
9913474|NCT00738192|Active Comparator|1|Fentanyl delivered for controlling awaking pain
9913475|NCT00738192|Active Comparator|2|Sufentanil delivered for controlling awaking pain
9913476|NCT00738192|Active Comparator|3|Butorphanol delivered for controlling awaking pain
9913477|NCT00738205||1|
9913478|NCT00738205||2|
9913479|NCT00738218|Other|MDCT|Single Arm study. All patients underwent MDCT.
9913480|NCT00738231|Active Comparator|I|"Group I's training material consisted of a brochure with the information we wanted the public to know about heart disease. The brochure had such titles as Cardiovascular Diseases, let us protect our hearts, the importance of cholesterol in preventing heart diseases, watch out for blood pressure, quit smoking for your health, weight watching, nutrition, food to avoid in cardiovascular disease, an easy method: exercise and exercise control, and an appropriate body weight vs. height chart for adults"
9913481|NCT00738231|Active Comparator|II|The Group II training material document was a letter in the form of a prescription in which the individual was addressed by name, the risk factors established at the first stage were explained, and the suggested measures for protection from such risk factors were indicated.
9913482|NCT00738244||1|Normal hearing listeners
9913483|NCT00738244||2|Listeners with mild-to-moderate sensorineural hearing loss
9913484|NCT00738257|Experimental|Parmidronate|
9913485|NCT00738296|Active Comparator|A|Group A: Comparator
9913486|NCT00738296|Active Comparator|B|Group B: Comparator
9913487|NCT00738296|Experimental|C|Group C: Drug
9913488|NCT00738309||Operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment is recommended to prevent progression of the curvature or to correct trunk deformity (unacceptable cosmesis).
9913489|NCT00738309||Non-operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment was not undertaken.
9913490|NCT00738322|Experimental|1|
9913491|NCT00738322|Placebo Comparator|2|
9913492|NCT00738348|Active Comparator|2|250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
9913493|NCT00738348|Placebo Comparator|1|250mL of 5% glucose was injected though the vein at 10mL per an hour
9913494|NCT00738413|Active Comparator|Arm 1|Subjects will be treated for 6 days with deferoxamine.
9913495|NCT00738413|Active Comparator|Arm 2|Subjects will be treated for 6 days with deferasirox.
9913496|NCT00738413|Experimental|Arm 3|Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.
9995045|NCT01486862|Experimental|BIAsp 30|
9995046|NCT01486875||BIAsp 30|
9913497|NCT00738439||Operative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees requiring surgery.
9913498|NCT00738439||Nonoperative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees not requiring surgery.
9913499|NCT00738452|Experimental|Treatment (chemo, monoclonal antibody therapy, radiation)|CHEMORADIOTHERAPY: Patients undergo external beam radiation therapy 5 days a week for 45 days. Beginning within 24 hours of the start of radiation therapy, patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 OR cisplatin IV over 60 minutes on days 1, 8, 29, and 36 and etoposide IV over 60 minutes on days 1-5 and 29-33. CONSOLIDATION RADIOIMMUNOTHERAPY: Beginning 6-10 weeks after completion of chemoradiotherapy, patients with stable disease, partial response, or complete response receive a therapeutic dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV. Treatment continues in the absence of disease progression or unacceptable toxicity.
9913500|NCT00738478|Experimental|A|Arm A: with nasogastric tube
9913501|NCT00738478|Active Comparator|B|Arm B: without nasogastric tube
9913502|NCT00738491||1|Patients with stable angina pectoris and documented coronary heart disease recruited in Edinburgh
9913503|NCT00738491||2|Patients with stable angina pectoris and documented coronary heart disease recruited in London
9913504|NCT00738504||1|
9913505|NCT00738504||2|
9913506|NCT00738504||Group 1|Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
9913507|NCT00738504||Group 2|Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
9913508|NCT00738517|Active Comparator|1|Immunoadsorption with subsequent immunoglobulin substitution
9913509|NCT00738517|No Intervention|2|
9913510|NCT00738556|Active Comparator|1|Full cover stenting of coronary lesions
9913511|NCT00738556|Active Comparator|2|Spot-stenting of significantly stenotic parts of a coronary lesion
9913512|NCT00738569|Experimental|Raltegravir|
9913513|NCT00738595|Experimental|1|EVT 302, 5 mg once Daily
9913514|NCT00738595|Placebo Comparator|2|Placebo once daily
9913515|NCT00738595|Experimental|3|EVT 302 plus open label Nicotine replacement
9913516|NCT00738595|Active Comparator|4|Placebo plus nicotine replacement therapy
9913517|NCT00738608||1|33 pat. with verum
9913518|NCT00738608||2|33 Pat. with placebo
9913519|NCT00738621|Active Comparator|1|Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia
9913520|NCT00738621|Placebo Comparator|A,2|Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia
9913521|NCT00738634|Experimental|Physical activity mediated|"Self-motivated physical activity intervention~Materials mailed to participants"
9913522|NCT00738634|Active Comparator|Nutrition control|"Nutrition attention-control arm.~Delivered by researcher."
9913523|NCT00738634|Experimental|Physical activity researcher contact|"Self-motivated physical activity intervention~Delivered by researcher."
9913524|NCT00738647|Active Comparator|Ceram X|Fillings made with a traditional composite material (Ceram X)
9913525|NCT00738647|Experimental|Filtek Silorane|Fillings made with a new composite material (Filtek silorane)
9913526|NCT00738660|Experimental|A|single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.
9995047|NCT01486888|Experimental|Formulation A|
9995048|NCT01486888|Active Comparator|Formulation B|
9995049|NCT01486901|Experimental|Formulation A|
9995050|NCT01486901|Active Comparator|Formulation B|
9667417|NCT03604393|Experimental|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
9913527|NCT00738686|Experimental|1|Single-arm study, no placebo or control group
9913528|NCT00738712|Experimental|New MRI techniques|New hardware or software technologies designed to improve MRI (Magnetic Resonance Imaging) exams.
9913529|NCT00738725||1|Survey only
9913530|NCT00738725||2|Imaging group
9913531|NCT00738725||3|Non-imaging group
9913532|NCT00738751|Experimental|Dose Escalation Followed by Expansion|Eligible participants were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at 4 planned dose levels (DLs).
9913533|NCT00738764|Experimental|Cohort 1|PDL192 Dose Level 1
9913534|NCT00738764|Experimental|Cohort 2|PDL192 Dose Level 2
9913535|NCT00738764|Experimental|Cohort 3|PDL192 Dose Level 3
9913536|NCT00738764|Experimental|Cohort 4|PDL192 Dose Level 4
9913537|NCT00738764|Experimental|Cohort 5|PDL192 Dose Level 5
9913538|NCT00738764|Experimental|Cohort 6|PDL192 Dose Level 6
9913539|NCT00738777|Active Comparator|1|Anastrozole
9913540|NCT00738777|Experimental|2|Anastrozole + Fulvestrant
9913541|NCT00738777|Active Comparator|3|Tamoxifen
9913542|NCT00738777|Other|4|Tamoxifen (pre-menopausal and male patients)
9913543|NCT00738790|Experimental|1|Preoperative radiotherapy with five fractions of 5 Gy during one week and boost 4 Gy after 1 week interval, total dose 29 Gy; after 6 weeks full-thickness local excision
9913544|NCT00738790|Active Comparator|2|"Radiochemotherapy with 28 fractions of 1,8 Gy plus boost 5,4 Gy in 3 fractions~+ simultaneous bolus 5-Fluorouracil and leucovorin; after 6 weeks full-thickness local excision"
9913545|NCT00738803|Experimental|1|Leg Length and offset measurement arm
9913546|NCT00738816|Other|Intervention|Systematic medication review
9913547|NCT00738829|Experimental|Treatment Arm|Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy
9913548|NCT00738842|Experimental|1|
9913549|NCT00738842|Placebo Comparator|2|
9913550|NCT00738855|Active Comparator|1|Gastrografin group
9913551|NCT00738855|Placebo Comparator|2|Control group
9913552|NCT00738920|Active Comparator|MC-CBT|Self Administered Cognitive Behavior Therapy
9913553|NCT00738920|Active Comparator|Standard-CBT|Therapist Administered Cognitive Behavior Therapy
9913554|NCT00738920|Active Comparator|Education/Support|Behavioral Patient Education/Counseling
9913555|NCT00738933|Active Comparator|A|A group of patients consuming 2 grams plant stanols 4-8 weeks before the operation
9913556|NCT00738933|Active Comparator|E|A group of patients consuming daily 2 grams plant sterols 4-8 weeks before the operation.
9913557|NCT00738933|Placebo Comparator|C|
9913558|NCT00738946|Experimental|2|Amodiaquine+pyrimethamine versus placebo
9913559|NCT00738959|Experimental|1|
9913560|NCT00738985|Placebo Comparator|ezetimibe/simvastatin 10/20 mg + placebo|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe (+) simvastatin 10/20 mg + placebo for 12 weeks. Safety and efficacy parameters are measured at baseline and 12 weeks later
9913561|NCT00738985|Active Comparator|ezetimibe/simvastatin 10/20 mg + MK0524A|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe/simvastatin 10/20 mg + MK0524A 1 gr for 6 weeks, if efficacy achieved will continue with ezetimibe (+) simvastatin 10/20 mg + MK0524A 1 gr + placebo; if not achieved, will receive ezetimibe (+) simvastatin 10/20 mg + MK0524A 2 gr for 6 weeks.
9913562|NCT00738998|Experimental|Questionnaire and Telephone Assessments|Breast cancer patients assigned to one or two groups: Group 1) enrolled at beginning of anastrozole treatment; or Group 2) if beginning third year of anastrozole treatment.
9913563|NCT00739011|Experimental|1|
9913564|NCT00739037|Placebo Comparator|A|
9913565|NCT00739037|Experimental|B|
9913566|NCT00739076|Experimental|1|Virtual Reality Hypnosis
9913567|NCT00739076|Experimental|2|Virtual Reality Distraction
9913568|NCT00739076|Experimental|3|Standard treatment.
9913569|NCT00739115|Experimental|1|Heliox gas added to nasal CPAP for the first 72 hours of life
9913570|NCT00739115|No Intervention|2|Conventional nasal CPAP for the first 72 hours of life
9913571|NCT00739128|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intramuscular route
9913572|NCT00739128|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intradermal route
9913573|NCT00739141|Experimental|1|There are three chemotherapy drugs involved. They are called fludarabine (5 doses), cyclophosphamide (1 dose), and thiotepa (2 doses). Also two days of radiation therapy. This is called Total Body Irradiation or TBI. The TBI if given for two days before, the transplant. On transplant day, the cord blood cells will be given through a catheter. The immune suppressing drugs given are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through the catheter. Later they can be given as tablets.
9913574|NCT00739154||1|glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment
9913575|NCT00739154||2|glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin
9913576|NCT00739154||3|glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment
9913577|NCT00739167||Y90 Group|Patients receiving treatment with radioembolization.
9913578|NCT00739167||TACE Group|Patients receiving treatment with transcatheter arterial embolization
9913579|NCT00739167||RFA Group|Patients receiving treatment with radiofrequency ablation.
9913580|NCT00739180|Other|Control|Standard care control
9913581|NCT00739180|Active Comparator|Aerobic Exercise|
9913582|NCT00739180|Active Comparator|Resistance Exercise|
9913583|NCT00739193|Placebo Comparator|Placebo|Placebo Control
9913584|NCT00739193|Experimental|PM101|PM101
9913585|NCT00739193|Active Comparator|Amiodarone IV|Amiodarone IV
9913586|NCT00739206|Experimental|Cohort 1|Adult patients with uncomplicated malaria
9913587|NCT00739206|Experimental|Cohort 2|Pediatric patients with uncomplicated malaria
9913588|NCT00739206|Experimental|Cohort 3|Pediatric patients with severe malaria
9913589|NCT00739219|Active Comparator|eNO group|eNO measurement is used to inform asthma management decisions
9913590|NCT00739219|No Intervention|control group|Asthma is managed according to existing standard of care
9913591|NCT00739232|Active Comparator|Active|Active
9913592|NCT00739232|Placebo Comparator|Placebo|Placebo
9913593|NCT00739258||HIDU|intravenous drug user (IDU) with HIV infected
9913594|NCT00739258||IDU|intravenous drug user (IDU) without HIV
9913595|NCT00739258||MH|persons receiving methadone maintenance treatment
9934238|NCT04954313|Experimental|Treatment Group|The Treatment Group will receive the same periodontal treatment in addition to having subgingival chlorhexidine irrigation. All subjects will also complete a set of questionnaires (PANAS & PMT) using an online form. A subset of 50 subjects from each group will be randomly selected to have oral images captured using an intra-oral scanner at Baseline and a subset of follow-up visits. Additionally, subjects in the Treatment Group will also receive brief behavioral advice from dental professionals focusing mainly on motivation and acknowledgement.
9934239|NCT04954313|Active Comparator|Control Group|"The Control Group will receive an initial periodontal treatment consisting of a pre-procedural rinse and scaling & root planning (SRP).~Subjects in the Control Group will receive no products during the course of the study. They will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) at the end of the study.Subjects will be scheduled to receive flow mediated dilation (FMD) and carotid intima media thickness (IMT) measurements prior to Baseline and approximately 4 weeks after their Baseline visit."
9934240|NCT04954157|Placebo Comparator|Healthy Subjects|This arm will consist of health subjects, not infected with COVID-19
9934241|NCT04954157|Active Comparator|COVID 19 Subjects|This arm will consist of subjects who are currently diagnosed with COVID-19 and fit all other criteria to be enrolled in this study.
9934242|NCT04951609|Experimental|Seltorexant|Participants will receive weight based dose of Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6). Participants will continue baseline selective serotonin reuptake inhibitor (SSRI) antidepressant (Fluoxetine and Escitalopram) orally once daily.
9934243|NCT04951609|Placebo Comparator|Placebo|Participants will receive matching placebo tablets to seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
9934244|NCT04950309|Experimental|OPM Array studies|Testing of a final 49-61 channel OPM MEG system and any interim arrays
9934245|NCT04949841|Experimental|As-needed treatment with delgocitinib|Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.
9934246|NCT04948658||Patient 13-21|Adolescents (13 to age 21) who undergo puberty and menarche with subsequent premature ovarian insufficiency
9934247|NCT04948658||patient 4-12|Girls with Turner Syndrome and galactosemia age 4 to 12 who are at increased risk of early ovarian insufficiency
9995051|NCT01486914|Experimental|NN2000|
9995052|NCT01486914|Active Comparator|IAsp|
9995053|NCT01486940|Experimental|Basal/bolus regimen 1|
9995054|NCT01486940|Active Comparator|Basal/bolus regimen 2|
9913596|NCT00739271|Active Comparator|Study arm|Early enteral feed 48 hours after abdominal surgery
9913597|NCT00739271|Active Comparator|Control arm|Traditional treatment where patient is kept on a nasogastric drainage for a few days after abdominal surgery, wait for bowel sounds to appear and then start enteral feeds.
9913598|NCT00739388|Experimental|Arm: 5-azacytidine|5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.
9913599|NCT00739414|Experimental|LBH589 (Panobinostat)|
9913600|NCT00739440|Experimental|I|Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
9913601|NCT00739440|Experimental|II|Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
9913602|NCT00739453|Experimental|Schedule 1|OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
9913603|NCT00739453|Experimental|Schedule 2|OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
9913604|NCT00739453|Experimental|Schedule 3|OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
9913605|NCT00739466|Experimental|low dose|Liposomal Alendronate dose of 0.001 mg
9913606|NCT00739466|Experimental|high dose|Liposomal Alendronate dose of 0.01 mg
9913607|NCT00739466|Placebo Comparator|placebo|IV saline infusion
9913608|NCT00739479|Active Comparator|1|Patients will be randomized to receive PHWP. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
9913609|NCT00739479|Placebo Comparator|2|Patients will be randomized to receive PHG. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
9913610|NCT00739492|Active Comparator|1|deposit based incentive
9913611|NCT00739492|Active Comparator|2|"deposit based incentive framed with maintenance period"
9913612|NCT00739492|No Intervention|3|Control arm, no financial incentive
9913613|NCT00739505|Experimental|Cohort 1|3 HPP patients are to be enrolled in Cohort 1 and receive a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 1 is at 8 weeks.
9913614|NCT00739505|Experimental|Cohort 2|Cohort 2 will begin when the safety and PK data for Cohort 1 weeks 1-4 has been reviewed by the DSMB. Cohort 2 will enroll 3 HPP patients and will receive a higher dose level than Cohort 1. Cohort 2 patients will have a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 2 is at 8 weeks.
9913615|NCT00739518|Experimental|MRI scan - new technology|The patient's clinical MRI scan will also utilize some new technology, such as a change in software or additional MRI sequences
9913616|NCT00739531||Asthmatics|Subjects with asthma
9913617|NCT00739544|Other|1|Quantitative sensory testing (QST) of healthy women to create reference values for QST evaluation of women treated for breast cancer
9913618|NCT00739570|No Intervention|1|
9913619|NCT00739570|Active Comparator|2|Activator chiropractic technique basic scan protocol
9913620|NCT00739609|Experimental|1|
9913621|NCT00739635|Experimental|1|
9913622|NCT00739635|Placebo Comparator|2|
9667418|NCT03604393|Experimental|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
9913623|NCT00739687|Experimental|ALT-711|Alagebrium 200 mg BID
9913624|NCT00739687|Experimental|Placebo|Placebo
9913625|NCT00739700||A|There is only one cohort of subjects, the critically ill. The NIBP will be correlated with the IABP in each subject.
9913626|NCT00739713|Experimental|SB|Sea buckthorn oil group
9913627|NCT00739713|Placebo Comparator|PL|Placebo group
9913628|NCT00739830|Experimental|1|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
9913629|NCT00739830|Active Comparator|2|Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
9913630|NCT00739869||1|Participants will include women who participated in the Women's Health Initiative Memory Study.
9913631|NCT00739895||Athletes|high performing athletes
9913632|NCT00739921|Experimental|1|"Patients with sinusitis compared to patients without.~To find out if any specific type of fungus or mold is correlated with chronic sinus disease. The study will add new information about the different types of fungus and mold found in the human nose."
9913633|NCT00739947||1|Standard of Care
9913634|NCT00739986|Experimental|1|Semapimod 60 mg IV x 1 day, placebo IV x 2 days
9913635|NCT00739986|Experimental|2|Semapimod 60 mg IV x 3 days
9913636|NCT00739986|Placebo Comparator|3|Placebo comparator IV x 3 days
9913637|NCT00740012|Active Comparator|Even, low numbers|They start with a alarm- clock night. No venous blood drawing.
9913638|NCT00740012|Active Comparator|Even, high numbers|They start with a nurse performing blood glucose determination. No venous blood drawing.
9913639|NCT00740012|Active Comparator|Uneven, low numbers|They start with an alarm- clock night and have venous blood drawing.
9913640|NCT00740012|Active Comparator|Uneven, high numbers|They start with a nurse performing blood glucose determination and have venous blood drawing.
9913641|NCT00740025||QD|Women who received their meds as QD administration
9913642|NCT00740025||BID|Women who received their gonadotropins as a BID dose
9913643|NCT00740038|Active Comparator|1|Active Control: Usual Care
9913644|NCT00740038|Experimental|2|Stress Management Intervention
9913645|NCT00740038|Experimental|3|Exercise Intervention
9913646|NCT00740038|Experimental|4|Combined Stress Management and Exercise Intervention
9913647|NCT00740103|Experimental|1|Semapimod 60 mg IV x 3 days q 6 - 8 weeks
9913648|NCT00740142|Active Comparator|1|Interventional arm: oral L-ornithine-L-aspartate and oral lactulose
9913649|NCT00740142|Placebo Comparator|2|Oral lactulose
9913650|NCT00740155|Experimental|Group 1|
9913651|NCT00740155|Experimental|Group 2|
9913652|NCT00740155|Experimental|Group 3|
9913653|NCT00740155|Experimental|Group 4|
9913654|NCT00740155|Active Comparator|Group 5|
9913655|NCT00740168||TG|Bevacizumab treatment group with metastasized cancer
9913656|NCT00740194|Experimental|1|Aromatase inhibition
9913657|NCT00740194|Active Comparator|2|Estradiol
9913658|NCT00740272|Experimental|1|AF ablation + pacemaker
9913659|NCT00740272|Active Comparator|2|Pacemaker
9913660|NCT00740285|Experimental|1|
9913661|NCT00740285|Placebo Comparator|2|
9913662|NCT00740298|Active Comparator|1|Sweet Taste
9913663|NCT00740298|Active Comparator|2|warmth
9913664|NCT00740311|Experimental|Filling|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
9913665|NCT00740311|No Intervention|Without filling|
9913666|NCT00740324|Active Comparator|N|
9913667|NCT00740324|Active Comparator|B|
9913668|NCT00740324|Active Comparator|G|
9913669|NCT00740337||COPD|Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).
9913670|NCT00740337||Control|Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.
9913671|NCT00740350|Experimental|Experimental|Logan Basic chiropractic adjustments during pregnancy.
9913672|NCT00740363|Experimental|A|Patients will receive 4 weeks of treatment with sitagliptin once daily
9913673|NCT00740363|Placebo Comparator|B|No treatment for 4 weeks
9913674|NCT00740415|Experimental|ARM RiBVD|"RiBVD 6 cycles every 28 days day 1 :~Rituximab /Mabthera®, 375 mg/m2 en IV~Bendamustine, 90 mg/m2 en IVD~Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD~Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD"
9913675|NCT00740428|Experimental|G1|pregnants for the first time who will receive the physical therapy guide
9913676|NCT00740441|Experimental|A|AS1411 treatment
9913677|NCT00740454||A|Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography
9913678|NCT00740493|Active Comparator|1|18 months of active warfarin therapy
9913679|NCT00740493|Placebo Comparator|2|18 months of placebo of warfarin
9913680|NCT00740519||A|
9913681|NCT00740532||Observation|Breast cancer patients treated with Herceptin-based therapy
9913682|NCT00740545|Placebo Comparator|2|
9913683|NCT00740545|Experimental|1|
9913684|NCT00740558|Active Comparator|1|Two groups received a traditional chiropractic adjustment of the lumbar 5 and the other group received a manually assisted mechanical force adjustment of the lumbar 5.
9913685|NCT00740558|Sham Comparator|2|The investigators had two groups, one for each chiropractic technique used in the research project and we had a control group
9913686|NCT00740571|Active Comparator|1|Strategy in which patient starts with amitriptyline
9913687|NCT00740571|Active Comparator|2|Strategy in which patient starts with pregabalin
9913688|NCT00740649|Experimental|1|HSD-016
9913689|NCT00740649|Other|2|placebo
9913690|NCT00740662||1|Distal gastric bypass
9913691|NCT00740675|Experimental|1|"At post-discharge follow-up visit with PCP, PCP views:~Discharge medication reconciliation screen.~Prompts to perform post-discharge reconciliation at the first post-discharge visit."
9913692|NCT00740675|No Intervention|Uusual care|PCPs manage the patient's medications after hospital discharge as they normally would.
9913693|NCT00740688|Experimental|Experimental Group|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
9913694|NCT00740688|Sham Comparator|Sham Group|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
9913695|NCT00740701|Sham Comparator|Sham TMS|A Sham TMS coil, designed to elicit sham cerebellar transcranial magnetic stimulation, is used to administer sham TMS pulses after letters are presented.
9913696|NCT00740701|Experimental|TMS|A genuine TMS coil is used to administer cerebellar transcranial magnetic stimulation pulses after letter presentation.
9913697|NCT00740740||1|Patients scheduled for elective conventional aneurysm repair
9913698|NCT00740740||2|Patients scheduled for emergent conventional aneurysm repair
9913699|NCT00740740||3|Patients scheduled for aortic bypass surgery
9913700|NCT00740753|Other|Treatment|yttrium 90 (TheraSphere) administration
9913701|NCT00740766|Experimental|Monitored|
9913702|NCT00740766|No Intervention|Unmonitored|
9913703|NCT00740818|No Intervention|A|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
9913704|NCT00740818|Sham Comparator|B|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
9913705|NCT00740818|Experimental|C|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
9913706|NCT00740844|No Intervention|1|No intermittent pneumatic compression of the lower limbs during patient hospitalisation in réanimation unit
9913707|NCT00740844|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
9913708|NCT00740883|Active Comparator|1|18 months of active warfarin therapy
9913709|NCT00740883|Placebo Comparator|2|18 months of placebo of warfarin
9913710|NCT00740896|Active Comparator|1|Participants smoke 8 cigarettes in 4 hours.
9913711|NCT00740896|Sham Comparator|2|Participants are not allowed to smoke for 4 hours.
9913712|NCT00740909|No Intervention|MAC|Minimal Attention Control
9913713|NCT00740909|Experimental|CBT|Cognitive Behavioral Therapy
9913714|NCT00740922||1|
9913715|NCT00740935|Other|1|Cohort of vaccinated infants against rotavirus
9913716|NCT00740948|Experimental|1|Rituximab
9913717|NCT00740948|Placebo Comparator|2|Placebo
9913718|NCT00740961||Patients with cancer|Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
9913719|NCT00740961||Patients without cancer|non-cancer patients, seeking care at out-patient clinics
9913720|NCT00740987|No Intervention|1|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
9913721|NCT00740987|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
9913722|NCT00741000|Experimental|Experimental|Cervical low force mobilization procedure.
9913723|NCT00741052|Experimental|1|Ciprofloxacin
9913724|NCT00741052|Active Comparator|2|Azithromycin
9913725|NCT00741078|Experimental|atorvastatin, amlodipine|
9913726|NCT00741117|Active Comparator|Low Bilirubin Group|Low Bilirubin Group: subjects with a bilirubin level less than or equal to 10 mg/dl
9913727|NCT00741117|Active Comparator|Medium Bilirubin Group|Medium Bilirubin Group: subjects with a bilirubin level from 11mg/dl to 30 mg/dl
9913728|NCT00741117|Active Comparator|High Bilirubin Group|High Bilirubin Group: subjects with a bilirubin level greater than or equal to 30 mg/dl
9913729|NCT00741130||C|normal volunteers
9913730|NCT00741130||G|glaucoma patients
9913731|NCT00741143|Experimental|1|Group that receives NaFeEDTA fortified wheat flour
9913732|NCT00741143|Placebo Comparator|2|Unfortified wheat flour
9995055|NCT01486953|Active Comparator|sevoflurane|Anesthesia with sevoflurane
9995056|NCT01486953|Experimental|Desflurane|Anesthesia with desflurane
9995057|NCT01486979|Experimental|Low dose|
9995058|NCT01486979|Active Comparator|High dose|
9995059|NCT01486992|Experimental|Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
9995060|NCT01487005||elderly subjects|Healthy
9995061|NCT01487018|Experimental|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
9995062|NCT01487018|Active Comparator|Traditional Surgery|To compare with the experimental arm.
9995063|NCT01487031|Experimental|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room.
9995064|NCT01487031|Active Comparator|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
9995065|NCT01487057||Thyroid cancer, lipids, LT4 withdrawal|
9995066|NCT01487057||Thyroid cancer, Lipids, LT4 substitution|
9995067|NCT01487070|Experimental|Macugen (Pegaptanib Sodium)|Open-label, single-center trial. Subjects will recieve intravitreous injections of Macugen 7-14 days before Vitrectomy.
9995068|NCT01487096|Placebo Comparator|Placebo|"Placebo (for teriflunomide),~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
9995069|NCT01487096|Experimental|Teriflunomide 7 mg|"Teriflunomide 7 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
9995070|NCT01487096|Experimental|Teriflunomide 14 mg|"Teriflunomide 14 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
9995071|NCT01487122|Experimental|Continuous Microwave|
9995072|NCT01487122|Experimental|Pulsed Microwaves|
9995073|NCT01487122|Sham Comparator|sham microwaves|
9995074|NCT01487135|Experimental|EVP-6124|A single low dose of 8-mg EVP-6124 and A single high dose of 80-mg EVP-6124
9995075|NCT01487135|Placebo Comparator|Placebo|Cranberry juice (180 mL)
9995076|NCT01487135|Active Comparator|Moxifloxacin|A single dose of 400-mg Moxifloxacin
9995077|NCT01487187|Active Comparator|immediate umbilical cord clamping|The control group will receive immediate cord clamping at birth which is the standard of care in our institution
9995078|NCT01487187|Experimental|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord.
9995079|NCT01487213|No Intervention|Controls|Routine follow-up at the clinic 2-3 weeks after the treatment
9995080|NCT01487213|Other|Home self test|Intervention
9997984|NCT01513733|Experimental|Tasquinimod single dose|
9997985|NCT01513733|Experimental|tasquinimod 0.25 mg followed by 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
9997986|NCT01513733|Experimental|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
9997987|NCT01513772|Placebo Comparator|Control|
9667419|NCT03603223|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
9997988|NCT01513772|Active Comparator|Dexmedetomidine|
9997989|NCT01513785|Active Comparator|group R20A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R20A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 20 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
9997990|NCT01513785|Active Comparator|group R10A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R10A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 10 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
9997991|NCT01513798|Experimental|Exercise under observation|Modified paleolithic diet and exercise 3 sessions/week under observation
9997992|NCT01513798|Experimental|General advice on exercise|Modified paleolithic diet and general advice on exercise
9997993|NCT01513811|Active Comparator|group PEG|This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
9997994|NCT01513811|Active Comparator|group PEG+Itp|Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
9997995|NCT01513811|Active Comparator|group PEG+4Itp|Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
9997996|NCT01513824|Active Comparator|stress management, acupressure|bio feedback guided stress management by daily measurement of pressure pain sensitivity followed by acupressure´for 3 months
9997997|NCT01513824|No Intervention|bio feedback guided, stress management|control without treatment
9997998|NCT01513850|Experimental|Hepabulin IV|
9997999|NCT01513863|Experimental|Metronidazole Topical Gel 1%|
9998000|NCT01513863|Active Comparator|Metronidazole Topical Gel 1% (Metrogel )|
9998001|NCT01513863|Placebo Comparator|Placebo|
9998002|NCT01513915|Active Comparator|A parent only group CBT|"There was a Group cognitive behavioral intervention -based on parent training component of FRIENDS program- for parents of children with anxiety disorders who were allocated to intervention group."
9998003|NCT01513915|No Intervention|Waiting list group|Parents of children with anxiety disorders who met the inclusion criteria and gave written informed consent and were allocated to wait list group.
10213034|NCT04705818|Experimental|Cohort B: not MSI-H or MMR-deficient colorectal cancer|Patients with colorectal cancer will be treated bydurvalumab prescribed in association with tazemetostat
9913733|NCT00741169|Experimental|Treatment Sequence ABC|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence will consist of Treatment A (TMC435350 200 mg once daily for 7 days), Treatment B (rifampin 600 mg once daily for 7 days), and Treatment C (TMC435350 200 mg once daily+rifampin 600 mg once daily for 7 days). Participants will receive 1 treatment (A, B, or C) during each treatment session. There will be 3 treatment sessions, each treatment session will be separated by 10 days.
9913734|NCT00741169|Experimental|Treatment Sequence BCA|
9913735|NCT00741169|Experimental|Treatment Sequence CAB|
9913736|NCT00741169|Experimental|Treatment sequence CBA|
9913737|NCT00741169|Experimental|Treatment Sequence BAC|
9913738|NCT00741169|Experimental|Treatment Sequence ACB|
9913739|NCT00741182|Experimental|Femur PTH(1-34)|24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
9913740|NCT00741182|No Intervention|Femur Control|"24 participants with trochanteric fractures will be assigned to no treatment"
9913741|NCT00741182|Experimental|Humerus PTH(1-34)|24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
9913742|NCT00741182|No Intervention|Humerus Control|"24 participants with collum chirurgicum fracture will be assigned to no treatment."
9913743|NCT00741195|Experimental|1|Docetaxel/Bevacizumab
9913744|NCT00741208|Other|1|Patients randomized to receive soy isoflavone twice daily for 2 weeks. Patients will cross-over and receive placebo medication for 2 weeks later in the study
9913745|NCT00741208|Other|2|Patients randomized to receive placebo medication twice daily for 2 weeks. Patients will cross-over and receive soy isoflavone for 2 weeks later in the study
9934248|NCT04948619|Other|Arm A - Single booster vaccines|Those subjects randomized to Arm A, single dose vaccine boosters, will receive non live vaccine boosters at the 3 and 12 month visits. Boosters for live vaccines will be given at the 6 month visit. Boosters will only be given as applicable for low titers tested at the baseline assessment visit.
9934249|NCT04948619|Other|Arm B - Staged revaccination series|Those subjects randomized to Arm B, the full revaccination series, will receive vaccines when titers are low (below normal range) at baseline. When indicated, non-live vaccines will be given at the 3 month visit and live vaccines at the 6 month visit.
9934250|NCT04946851||non-treatment-seeking individuals|Participants across the spectrum of drinking (from non-drinkers to heavy drinkers) who are not interested in treatment for alcohol use disorder
9934251|NCT04946851||treatment-seeking individuals with alcohol use disorder|Volunteers with an AUD diagnosis who are seeking treatment for the condition
9934252|NCT04946656|Experimental|SPG block|The sphenopalatine ganglion will be blocked with bipuvacaine for this study
9934253|NCT04946318|Placebo Comparator|24-week Placebo|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 24 weeks
9934254|NCT04946318|Placebo Comparator|12-week wash out + 12-week Placebo|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and Placebo inhaled once daily for 12 weeks"
9934255|NCT04946318|Placebo Comparator|12-week Placebo|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with Placebo inhaled once daily for 12 weeks
9934256|NCT04946318|Experimental|24-week CSJ117|Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated once daily for 24 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
9934257|NCT04946318|Experimental|12-week wash out + 12-week CSJ117|"Participants who will enter the extension study after the last treatment visit (week 12) of the core study and will be treated with Placebo inhaled once daily for 12 weeks washout period and then they will be treated once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 12 weeks."
9913746|NCT00741221|Experimental|1|Pemetrexed/Bevacizumab
9913747|NCT00741234|Experimental|A|Advanced solid tumors
9913748|NCT00741234|Experimental|B|Advanced hematologic malignancies
9913749|NCT00741234|Experimental|C|Myelodysplastic Syndrome
9913750|NCT00741312|Experimental|I|
9913751|NCT00741312|Active Comparator|II|
9913752|NCT00741325||G-CSF plus plerixafor|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received plerixafor, prior to undergoing apheresis.
9913753|NCT00741325||G-CSF plus placebo|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received placebo, prior to undergoing apheresis.
9913754|NCT00741351|Experimental|IF|Sevoflurane (Inhalation)+Fentanyl
9913755|NCT00741351|Experimental|IR|Sevoflurane (Inhalation)+Remifentanyl
9913756|NCT00741351|Experimental|ER|Propofol (Endovenous)+ Remifentanyl
9913757|NCT00741364|Active Comparator|1|vitamin D3 (400 IU/d)
9913758|NCT00741364|Active Comparator|2|vitamin D3 (10,000 IU/d)
9913759|NCT00741364|Active Comparator|3|vitamin D3 (40,000 IU/d)
9913760|NCT00741377|Experimental|BHQ880 + zoledronic acid|BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle.
9913761|NCT00741403|Experimental|A|IV Infusion of CPI-613 on Days 1,4,8,11,15,18 of 28 day cycle in patients with advanced malignancies
9913762|NCT00741416||Case|Those with a diagnosis of Coronary Artery Disease
9913763|NCT00741416||Control|Those who do not have Coronary Artery Disease (are healthy) but are matched to a Case participant by age, gender, and ethnicity.
9913764|NCT00741429||Ex-TI|Ex-Technosphere® Insulin Inhalation Powder (subjects previously received TI Inhalation Powder)
9913765|NCT00741429||Non Ex-TI|Non Ex-Technosphere® Insulin Inhalation Powder (subjects previously received another anti-diabetic medication)
9913766|NCT00741481||1|all study population
9913767|NCT00741494|No Intervention|1|HBA score over 65% control
9913768|NCT00741494|No Intervention|2|HBA score over 65%, non-participant (to even out the participation between patients with low HBA scores and those with high HBA scores)
9913769|NCT00741494|Active Comparator|3|HBA score over 65%. PICSI dish is used to select the sperm for ICSI.
9913770|NCT00741494|Experimental|4|HBA score less than 65%. PICSI dish used to select sperm for ICSI.
9913771|NCT00741494|No Intervention|5|HBA Score less than 65%. Control
9913772|NCT00741507|Active Comparator|1|No alcohol drinking
9913773|NCT00741507|Active Comparator|2|Mild alcohol drinking
9913774|NCT00741507|Active Comparator|3|Moderate alcohol drinking
9913775|NCT00741507|Active Comparator|4|Severe over alcohol drinking
9913776|NCT00741507|Active Comparator|5|Alcohol-dependent
9913777|NCT00741520|Placebo Comparator|1|Control group
9913778|NCT00741520|Active Comparator|2|CPAP
9913779|NCT00741546||A|Patients referred for cardiac surgery intervention
9913780|NCT00741559|Experimental|1|
9913781|NCT00741572||1|
9913782|NCT00741572||2|
9913783|NCT00741585|Active Comparator|1|Treatment with all prescribed hypertension medications on awakening
9913784|NCT00741585|Active Comparator|2|Treatment with at least one prescribed hypertension medication at bedtime
9913785|NCT00741624|Experimental|1|bilateral post refractive surgery subject
9913786|NCT00741637|Experimental|Vaccine|Live attenuated oral CholeraGarde® (5x107 to 1x109 CFU) vaccine
9913787|NCT00741637|Placebo Comparator|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
9913788|NCT00741650|Experimental|1|Information and peer advisor
9913789|NCT00741650|Experimental|2|Information, peer advisor and referral to further treatment
9913790|NCT00741650|No Intervention|3|Treatment as usual
9913791|NCT00741663|Active Comparator|A|
9913792|NCT00741663|Experimental|B|
9913793|NCT00741676|Active Comparator|2|
9913794|NCT00741676|Experimental|1|
9913795|NCT00741689|Experimental|1|AZD1656 in 6 increasing oral single doses given to 6 groups (5 on active and 1 on placebo in each group)
9913796|NCT00741702|Experimental|Intervention group|A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.
9913797|NCT00741702|No Intervention|Control group|Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.
9913798|NCT00741728||general population|Observational study of 10000 adult men and women from the general population who benefited from a free extensive health check up in Paris, France
9913799|NCT00741754|Experimental|I, II|compare the amount of salivary flow of the same patient at different times.
9913800|NCT00741767|Other|Salmeterol-fluticasone|Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.
9913801|NCT00741767|Other|Placebo|Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.
9913802|NCT00741780||G-CSF plus plerixafor|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
9913803|NCT00741780||G-CSF plus placebo|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
9913804|NCT00741806|Experimental|GHB04L1|Single dose, dose escalation
9913805|NCT00741806|Placebo Comparator|SPGN buffer|
9913806|NCT00741832|Experimental|I|Patients breath while a conical positive expiratory pressure device during exercises
9913807|NCT00741832|Active Comparator|C|Patients (normal) breath during exercise
9913808|NCT00741845|Active Comparator|1|intravaginal metronidazole 750mg + 200mg miconazole
9913809|NCT00741845|Active Comparator|2|intravaginal metronidazole 750mg
9913810|NCT00741845|Active Comparator|3|intravaginal metronidazole 37.5mg
9913811|NCT00741884|Experimental|Arm 1|
9913812|NCT00741884|Experimental|Arm 2|
9913813|NCT00741884|Experimental|Arm 3|
9913814|NCT00741884|Active Comparator|Arm 4|
9913815|NCT00741884|Placebo Comparator|Arm 5|
9913816|NCT00741897|Experimental|1|Fexofenadine
9913817|NCT00741910|Experimental|1|Semapimod 60 mg IV q 6 - 10 weeks
9913818|NCT00741923|Experimental|Bean group|A group consuming 5 cups/week of navy beans for a month
9913819|NCT00741949|Experimental|1|
9913820|NCT00741949|Placebo Comparator|2|
9913821|NCT00741962|Experimental|1|
9913822|NCT00741962|Placebo Comparator|2|
9913823|NCT00741975|Experimental|1|Affect Management
9913824|NCT00741975|Active Comparator|2|General Health Promotion
9913825|NCT00742014|Experimental|1|
9913826|NCT00742040|Experimental|1|
9913827|NCT00742040|Active Comparator|2|
9913828|NCT00742066|Experimental|I|Irbesartan
9913829|NCT00742066|Active Comparator|II|Felodipine
9913830|NCT00742066|Placebo Comparator|III|Placebo
9913831|NCT00742092|Experimental|1|miglustat
9913832|NCT00742092|Placebo Comparator|2|placebo
9913833|NCT00742105|Experimental|BGT226|
9913834|NCT00742118|Experimental|2|patient with chronic inflammatory intestinal disease
9913835|NCT00742118|Other|3|patient having no symptoms
9913836|NCT00742118|Experimental|1|patient with irritable bowel syndrome
9913837|NCT00742131|Experimental|Subjects receiving GSK1363089|Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.
9913838|NCT00742144|Experimental|ofatumumab|Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia
9913839|NCT00742157|No Intervention|UNMC Group|Compare the low and high dose effects of Growth Hormone from previously pooled patients (high dose) and UNMC patients (low dose).
9913840|NCT00742196||1|No parapapillary atrophy
9913841|NCT00742196||2|Parapapillary atrophy
9913842|NCT00742222|Other|single arm, treatment with FDA cleared technology|Patients who have early stage breast cancer, and are candidate for intracavitary accelerated partial breast irradiation may be considered for this study.
9913843|NCT00742248|Active Comparator|A|Formoterol pMDI
9913844|NCT00742248|Active Comparator|B|Formoterol dry powder
9913845|NCT00742248|Placebo Comparator|C|Placebo pMDI DPI
9913846|NCT00742261|Experimental|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
9913847|NCT00742287|Placebo Comparator|1|placebo
9913848|NCT00742287|Active Comparator|2|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
9913849|NCT00742300|Experimental|A|Treatment Group
9913850|NCT00742339|Active Comparator|1|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
9913851|NCT00742339|Experimental|2|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.
9913852|NCT00742352||Breast cancer patients|
9913853|NCT00742352||Lung cancer patients|
9913854|NCT00742365||A|Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
9995081|NCT01487239|Experimental|A|[14C]-GDC-0980 administered as a 10-mg oral dose
9995082|NCT01487252|Active Comparator|Healthy Controls|
9995083|NCT01487252|Active Comparator|Delayed Sleep Phase Disorder|
9995084|NCT01487278|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
9995085|NCT01487278|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
9995086|NCT01487291||Psychotic patients|Inpatients and outpatients followed at Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
9995087|NCT01487304||Low dose HRT|
9995088|NCT01487317|Experimental|Rivastigmine transdermal patch|
9995089|NCT01487317|Placebo Comparator|placebo|
9995090|NCT01487330|Experimental|Subjects receiving TAVI valve|
9995091|NCT01487343||breast or gastrointestinal cancer pts taking capecitabine|This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
9995092|NCT01487356||Patients undergoing colonoscopy|Data was collected on all adult patients undergoing outpatient colonoscopy at St. Paul's Hospital from May 2008 to June 2009. Exclusion criteria were prior colon resection and repeat colonoscopy for the purpose of endoscopic therapy for known lesions.
9995093|NCT01487369||Insulin Aspart|
9995094|NCT01487382||Insulin Aspart|
9995095|NCT01487395|Active Comparator|Donepezil|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
9995096|NCT01487395|Placebo Comparator|Placebo|The placebo will be presented as tablet comparable to ARICEPT
9995097|NCT01487408||Insulin Aspart|
9995098|NCT01487421||SIT|
9995099|NCT01487434|Experimental|Check & Connect|Check and Connect Structured Mentoring and Case Management
9995100|NCT01487447|Experimental|Intervention|
9995101|NCT01487447|Active Comparator|Control|
9995102|NCT01487460|Experimental|TAP311 in Healthy Volunteers|
9995103|NCT01487460|Placebo Comparator|Matching Placebo|Healthy Volunteers and Patients will be treated in Placebo group.
9995104|NCT01487460|Experimental|TAP311 and Simvastatin|
9995105|NCT01487460|Experimental|TAP311 in Patients|
9995106|NCT01487473|Active Comparator|Mindfulness-Based Stress Reduction|
9995107|NCT01487473|No Intervention|Waitlist Control|
9995108|NCT01487486||Normal patients|Women with infertility diagnosis of male factor only or women who are oocyte donors
9995109|NCT01487486||Polycystic Ovary Syndrome, High BMI|Women with Polycystic Ovary Syndrome with a BMI between 30-35
9995110|NCT01487486||Polycystic Ovary Syndrome, Low BMI|Women with Polycustic Ovary Syndrom with a BMI between 20 & 25
9995111|NCT01487512|Experimental|Sequence 1: Treatment A-D-B-C|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
9995112|NCT01487512|Experimental|Sequence 2: Treatment B-A-C-D|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
9995113|NCT01487512|Experimental|Sequence 3: Treatment C-B-D-A|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
9995114|NCT01487512|Experimental|Sequence 4: Treatment D-C-A-B|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
9995115|NCT01487538|Experimental|intervention group|
9995116|NCT01487538|Active Comparator|Standard Advice Group|
9995117|NCT01487551|Experimental|paquinimod|
9995118|NCT01487564|Experimental|Hydromorphone 16 mg|
9995119|NCT01487590|Active Comparator|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
9995120|NCT01487590|Placebo Comparator|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
9995121|NCT01487616||Women with previous preterm birth|Women with history of preterm birth (birth of a baby of less than 37 weeks gestational age, where labour was spontaneous) regardless of past pregnancy history.
9995122|NCT01487616||Women with previous miscarriage|Women with history of miscarriage (spontaneous pregnancy loss before 24 weeks of gestation), regardless of past pregnancy history.
9995123|NCT01487616||Women with previous term births|Women with previous term births (37 or more weeks of gestation)
9995124|NCT01487629|Experimental|Bevacizumab|Treatment of macular edema with intravitreal Bevacizumab
9995125|NCT01487629|Experimental|Ranibizumab|Treatment of macular edema with intravitreal Ranibizumab
9995126|NCT01487642|Experimental|Telephone counselling|
9995127|NCT01487642|Experimental|Proactive telephone counselling|
9995128|NCT01487642|Experimental|web-based smoking cessation programme|
9995129|NCT01487642|Active Comparator|Self-help material|
9995130|NCT01487655||healthy age matched controls|
9995131|NCT01487655||normal tension glaucoma patients|
9995132|NCT01487655||primary open angle glaucoma patients|
9995133|NCT01487681||Invasive cervical cancer|
9913855|NCT00742365||B|Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
9913856|NCT00742378||C|Normal controls
9667420|NCT03600844|Experimental|Phase 1 Intervention|Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.
9913857|NCT00742378||G|Glaucoma
9913858|NCT00742430||Resistant|patients who are resistant to standard antithrombotic drugs
9913859|NCT00742430||Nonresistant|patients who are not resistant to standard dual antithrombotic drugs
9913860|NCT00742443|Other|1|Active versus Placebo within patient
9913861|NCT00742443|Other|2|Active vs. Placebo within patient
9913862|NCT00742443|Other|3|Active vs. Active within patient
9913863|NCT00742456|Experimental|I|Glucose
9913864|NCT00742456|Placebo Comparator|II|Placebo
9913865|NCT00742521|Active Comparator|1|Euglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
9913866|NCT00742521|Active Comparator|2|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
9913867|NCT00742521|Active Comparator|3|Euglycemic glucose clamp procedure x 2 with cortisol infusion of 2ug/kg on Day 1 and hypoglycemic glucose clamp procedure on Day 2.
9913868|NCT00742521|Active Comparator|4|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
9913869|NCT00742547|No Intervention|Control group|No telephone counseling + usual care
9913870|NCT00742547|Experimental|Telephone Counseling|Telephone counseling + usual care
9913871|NCT00742599|Active Comparator|N|
9913872|NCT00742599|Placebo Comparator|P|
9913873|NCT00742612|Active Comparator|1|ARC1779 Injection
9913874|NCT00742612|Placebo Comparator|2|Placebo (normal saline)
9913875|NCT00742638|Experimental|The arm 1|Quetiapine fumarate tablet:25mg and 200mg
9913876|NCT00742638|Active Comparator|The arm 2|Sodium valproate tablet 200mg
9913877|NCT00742664|Experimental|1|Will receive 12 sessions of twice weekly psychotherapy targeting obsessive-compulsive symptoms.
9913878|NCT00742664|Placebo Comparator|2|
9913879|NCT00742677|Experimental|Group 1 (early feeding)|Patients are offered a liquid diet on day 1 for 24 hours following surgery. Beginning on day 2, patients who tolerate a liquid diet are offered a light regular diet until hospital discharge.
9913880|NCT00742677|Active Comparator|Group 2 (traditional feeding)|Patients are offered nothing by mouth on days 1 and 2 following surgery. Beginning on day 3, patients are offered a liquid diet for 24 hours. Beginning on day 4, patients who tolerate a liquid diet (absence of nausea and vomiting) are offered a semi-solid diet for 24 hours. Beginning on day 5, patients who tolerate a semi-solid diet are offered a light regular diet until hospital discharge.
9913881|NCT00742690|Active Comparator|1|35 patients with cirrhosis and type 1 HRS
9913882|NCT00742690|Experimental|2|35 patients with cirrhosis and type 1 HRS
9913883|NCT00742703|Experimental|1|
9913884|NCT00742703|Active Comparator|2|
9913885|NCT00742729|Experimental|Arm 1|Educational small group session with free FOBT kit
9913886|NCT00742729|Experimental|Arm 2|Educational small group session with no FOBT kit
9995134|NCT01487681||Cervical intraepithelial neoplasia 2/3|
9995135|NCT01487681||Cervical intraepithelial neoplasia 1|
9995136|NCT01487694|Experimental|Cimicifuga racemosa|patients receive cimicifuga racemosa rhizome and root extract 40 mg/day (equivalent to triterpene glycosides 12.3 mg)
9995137|NCT01487694|Placebo Comparator|Placebo|Placebo containing no active ingredient which match the drug in bottle, shape, color and smell
9995138|NCT01487707|Experimental|Voluntary Health Worker (VHW) Program|
9995139|NCT01487707|Experimental|VHW program plus Safe Birth Kit|
9995140|NCT01487707|Experimental|VHW program plus Folk Media Activities|
9995141|NCT01487720|Experimental|GEMOX|GEMOX treatment
9995142|NCT01487746||treatment|Stroke patients
9995143|NCT01487746||Controls|healthy controls
9995144|NCT01487759|Active Comparator|Prebiotic|
9995145|NCT01487759|Placebo Comparator|Placebo|
9995146|NCT01487772||Hip-fracture patients|Hip-fracture patients admitted to Orthopaedic Department of Danderyd Hospital
9995147|NCT01487785|Experimental|LDE225+gemcitabine|Increasing doses of LDE225 (from 400 mg) once a day + 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28 day cycle.
9995148|NCT01487798|Experimental|Treatment period 1|
9995149|NCT01487798|Active Comparator|Treatment period 2|
9995150|NCT01487811|Experimental|Formulation 1|
9995151|NCT01487811|Active Comparator|Formulation 2|
9995152|NCT01487824||Preterm-born Young Adults|
9995153|NCT01487824||Term-born Young Adults|
9995154|NCT01487837|Active Comparator|Fibrinogen if FibTEM < 8 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 8 mm
9995155|NCT01487837|Experimental|Fibrinogen if FibTEM < 13 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 13 mm
9995156|NCT01487876|Experimental|LAM+DNA vaccine|lamivudine (LAM) chemotherapy and DNA vaccine
9995157|NCT01487876|Placebo Comparator|LAM+Placebo|"Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.~lamivudine (LAM) chemotherapy and Placebo"
9995158|NCT01487889|Experimental|Rapeseed oil|Study group receive commercial vegetable-potato-meat-meals containing rapeseed oil as part of complementary food
9995159|NCT01487889|Experimental|Fatty fish|Study group receive 2 times per week a vegetable-potato-meat-meals as part of complementary food.
9995160|NCT01487889|Active Comparator|Corn oil|Study group receive commercial vegetable-potato-meat-meals containing corn oil as part of complementary food
9995161|NCT01487902|Experimental|ADT arm|Concomitant androgen deprivation treatment
9995162|NCT01487902|Active Comparator|No ADT arm|No concomitant androgen deprivation treatment arm
9995163|NCT01487915|Active Comparator|GCb|Gemcitabine plus Carboplatin
9995164|NCT01487915|Experimental|GemOx|Gemcitabine plus Oxaliplatin
9995165|NCT01487967|Experimental|Intervention|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
9995166|NCT01487967|No Intervention|Control|Parents will receive education on ADHD and its treatment, and otherwise receive standard care.
9995167|NCT01487980|Active Comparator|Early cord clamping|Within 30 seconds after birth.
9995168|NCT01487980|Experimental|Delayed cord clamping|Between 2 and 3 minutes after birth
9995169|NCT01487993|Active Comparator|Metformin|Metformin with lifestyle intervention during 18 months
9995170|NCT01487993|Placebo Comparator|Placebo|Placebo and lifestyle intervention during 18 months
9995171|NCT01488006||Bigliani/Flatow Shoulder System|Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
9995172|NCT01488032||high-tension glaucoma|subjects with IOP>22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
9995173|NCT01488032||low-tension glaucoma|subjects with IOP<22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
9995174|NCT01488045|Active Comparator|Fentanyl and Midazolam|Fentanyl and Midazolam sedation for colonoscopy discomfort
9995175|NCT01488045|Active Comparator|Propofol|Propofol sedation for colonoscopy discomfort
9995176|NCT01488058|Other|Group 2|Waitlist control
9995177|NCT01488058|Experimental|Group 1|CBM intervention (OxIGen) plus Internet based Cognitive Behavioural Therapy for depression
9995178|NCT01488084|Experimental|"Pedicled no-touch SVG harvesting"|Saphenous vein harvested with a pedicle of surrounding fat and distension with heparinized blood at arterial pressure. No manual distention.
9995179|NCT01488084|Active Comparator|Conventional open SVG harvesting|Saphenous vein is harvested with an open technique, stripped of adventitia, and manually distended with crystalloid solution.
9995180|NCT01488110|Experimental|Migraine medical device|Treatment with an active nasal probe
9995181|NCT01488110|Placebo Comparator|Inactive migraine medical device|Treatment with an inactive nasal probe.
9995182|NCT01488123|Experimental|Ayurvedic Intervention|
9995183|NCT01488136|Active Comparator|Diazoxide|Oral diazoxide 7 mg/kg
9995184|NCT01488136|Placebo Comparator|Placebo|Matched placebo
9995185|NCT01488162||Cohort|
9995186|NCT01488175|Active Comparator|with tourniquet|
9995187|NCT01488175|Placebo Comparator|without tourniquet|
9995188|NCT01488201|Experimental|KHK4827|
9995189|NCT01488201|Placebo Comparator|Placebo|
9798960|NCT01644695||Candidate for BARS procedure.|The subjects selected for this trial were over 18 years of age with an appropriate complex, incisional hernia. These patients were consented and treated with the BARS(bony anchoring reinforcement system)procedure.
9798961|NCT01644890|Experimental|NK105|
9995190|NCT01488214|Experimental|Scleroderma patient|Evaluation of Scleroderma patient
9995191|NCT01488214|Placebo Comparator|Healthy subjects|Evaluation of healthy subjects
9995192|NCT01488227|Experimental|Vitamin D|Vitamin D
9995193|NCT01488227|Placebo Comparator|Oil pill|Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
9995194|NCT01488240|Active Comparator|Proximal|part of scar proximal to heart
9995195|NCT01488240|Active Comparator|Distal|part of scar distal to heart
9995196|NCT01488253|Experimental|acute GVHD prevention by sirolimus based regimen|The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.
9995197|NCT01488266|Experimental|aripiprazole augmentation|
9995198|NCT01488266|Active Comparator|different class of antidepressant|
9995199|NCT01488292|Experimental|RECAP social skills and reading program|
9995200|NCT01488292|No Intervention|Control group (services as usual)|Control Group (services as usual)
9995201|NCT01488305|No Intervention|Only government regular program|One arm is control arm, in this arm no additional program is added in government regular program
9995202|NCT01488305|Experimental|AAMA arm (HFP and IYCF BCC)|Second arm is AAMA project intervention which includes HFP activities, ENA and BCC activities
9995203|NCT01488305|Experimental|MNP added in AAMA|It is actually a intervention arm
9995204|NCT01488331||Cohort|
9995205|NCT01488344|Experimental|BIBF 1120|
9995206|NCT01488357||Early stage breast cancer patients receiving mastectomy|
9995207|NCT01488383|Experimental|Stevioside capsules 200mg|Capsules of 200mg Stevioside
9995208|NCT01488383|Active Comparator|Sodium Saccharin 250 capsules|Capsules of 250mg Saccharin
9995209|NCT01488396|Experimental|0.05%cyclosporin eye drop|
9995210|NCT01488422|Active Comparator|Group 1|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
9995211|NCT01488422|Active Comparator|Group 2|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
9995212|NCT01488435|Placebo Comparator|Cow's Milk|Powdered whole cow's milk
9995213|NCT01488435|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
9995214|NCT01488461||patients ataxic|
9995215|NCT01488474||Diabetes Mellitus (DM)|Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
9995216|NCT01488474||Control (C)|Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
9995217|NCT01488500|Experimental|Filtered air exposure|3 hour exposure to filtered air with intermittent exercise
9995218|NCT01488500|Experimental|Wood smoke exposure|3 hour exposure to dilute wood smoke generated from incomplete combustion in a wood burning stove at approximately 300 mcg/m3
9995219|NCT01488500|Experimental|Wood pellet smoke emission|3 hour exposure to dilute wood smoke generated from wood pellets during incomplete combustion during intermittent exercise at approximately 300 mcg/m3
9995220|NCT01488513|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sphingosine kinase-2 inhibitor ABC294640 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9995221|NCT01488526|No Intervention|Control arm: HBIG & vaccine for infants|Provide standard of care to mothers and standard immunoprophylaxis to their infants
9995222|NCT01488526|Experimental|TDF treatment arm|tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants
9995223|NCT01488539|Experimental|STAIR/NT|Patients will receive STAIR/NT treatment
9995224|NCT01488539|Other|Treatment as Usual (TAU)|Patients will receive Treatment as Usual (TAU)
9995225|NCT01488552|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
9995226|NCT01488565|Experimental|Azacitidine and Eltrombopag|Vidaza (azacitidine) Revolade (eltrombopag)
9995227|NCT01488604|Experimental|PNS|2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
9995228|NCT01488604|Sham Comparator|SNS|2 sprays of sham nasal spray per nostril 4 times per day for 7 days
9995229|NCT01488630|No Intervention|Treatment as Usual|Chart review only.
9995230|NCT01488630|Experimental|STaRS|Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
9995231|NCT01488643||OBESITY PATIENTS|PATIENTS WITH BMI >35
9995232|NCT01488643||CONTROL TEAM BMI <35|
9995233|NCT01488656|Placebo Comparator|Placebo dietary supplements|Visually identical inactive dietary supplement pack
9995234|NCT01488656|Experimental|Active dietary supplements|Combination of antioxidants, minerals, fish oil, proflavanol and vitamin D
9995235|NCT01488669|Experimental|Robotic neck dissection|Robotic neck dissection was performed via modified face lift or retroauricular approach using the robotic arms, while conventional neck dissection was conducted after transverse skin incision from the mastoid tip to the midline.
9995236|NCT01488669|Active Comparator|Conventional neck dissection|Neck dissection is performed after an external transverse skin incision.
9995237|NCT01488682|Experimental|Harmonic scalpel|Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
9995238|NCT01488682|Active Comparator|conventional hand tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels.
9995239|NCT01488695|Experimental|GlideScope Groove|Patient will be intubated using the GlideScope Groove device.
9995240|NCT01488695|Active Comparator|Control|Control Group: Macintosh Blade
9995241|NCT01488721||General Newborn Population-Prospective|Specimens prospectively collected in the course of routine newborn screening originating from hospitals, birthing centers, and/or clinics.
9995242|NCT01488721||Newborn Specimens-Confirmed Positive|Banked confirmed positive specimens that were originally collected as part of the newborn screening program, but when found to screen positive for a disease, were followed up clinically to definitively diagnose the subject with the disease (CF, CAH or CH). Follow up results were reported to the sites by the treating clinicians.
9995243|NCT01488734|Experimental|Mushroom with 600 IU vitamin D2|Mushroom with 600 IU of vitamin D2 daily and placebo tablet
9995244|NCT01488734|Experimental|Mushroom with 4000 IU Vitamin D2|Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
9995245|NCT01488734|Active Comparator|600 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
9995246|NCT01488734|Active Comparator|4000 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
9995247|NCT01488747|Experimental|Coromega Omega-3 Squeeze|5.03 g
9995248|NCT01488747|Experimental|Coromega Nectar|12.22 g
9995249|NCT01488747|Experimental|Barleans Swirl|17.45 g
9995250|NCT01488747|Active Comparator|Nordic Omega-3 Softgel|4 softgels
9995251|NCT01488760||Nineteen women with low back pain|
9798962|NCT01644890|Active Comparator|Paclitaxel|
9995252|NCT01488760||Twenty pain-free women|
9995253|NCT01488773||ICS + salmeterol|"Patients treated with both inhaled glucocorticosteroid (ICS) and salmeterol (long-acting β2-agonist).~90 patients met the inclusion criteria for this group."
9995254|NCT01488773||ICS + montelukast|"Patients treated with both inhaled glucocorticosteroid (ICS) and montelukast (leukotriene receptor antagonist).~42 patients met the inclusion criteria for this group."
9995255|NCT01488786|Experimental|BrainPort Vision Device|Single Arm
9995256|NCT01488799|Active Comparator|MI-CBT|
9995257|NCT01488799|Active Comparator|CBT alone|
9998004|NCT01513941|Experimental|Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)|All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
9998005|NCT01513954||IVF population|Long Lupron IVF Population
9998006|NCT01513954||IUI patients|Patients undergoing IUI
9998007|NCT01513980|No Intervention|Control group|Treatment as usual
9998008|NCT01513980|Experimental|Self monitoring for patients with COPD|Procedure: self-monitoring for patients with severe COPD
9998009|NCT01513980|Experimental|Nurse monitoring for patients with COPD|Procedure: nurse-monitoring for patients with severe COPD
9998010|NCT01513993|No Intervention|Control group|Treatment as usual
9998011|NCT01513993|Experimental|Telemonitoring for patients with Congestive Heart Failure|
9998012|NCT01514006||Study Cohort|Patients, aged 65 or above, undergoing elective primary unilateral hip arthroplasty in a fast-track setting.
9998013|NCT01514019|Experimental|Acebutolol|Acebutolol 200 mg capsule (Acetanol®)
9998014|NCT01514019|Placebo Comparator|Placebo|
9998015|NCT01514032|Active Comparator|Extracorporal shockwave lithotripsy|
9998016|NCT01514032|Active Comparator|Retrograde intrarenal surgery|
9995258|NCT01488812||Hip-fracture patients|All the hip-fracture patients admitted to the Orthopaedic Depart of Danderyd Hospital between 1st June 2007- 1st June 2008 who fulfilled the inclusion criteria of the study.
9995259|NCT01488825|No Intervention|Wait-list control group|The wait-list control group received no intervention, or instruction and they were observed with their usual care for 12-weeks intervention period. Upon completion of the study, this group received 12 weeks of yoga intervention.
9995260|NCT01488825|Experimental|Yoga Intervention Group|The yoga sessions developed specifically for study participant consisted of 12 weekly 60-minute designed to benefit in episodic tension type headache.
9995261|NCT01488838|Experimental|Arm 1:|Radiation: 60-66 Gy in 2 Gy daily fractions Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
9995262|NCT01488838|Active Comparator|Arm 2:|Radiation: 60-66 Gy in 2 Gy daily fractions
9995263|NCT01488864|Experimental|Applied Relaxation (AR)|
9995264|NCT01488864|No Intervention|Untreated Control Group (CG)|The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
9995265|NCT01488903||Premenopausal Women|600 health premenopausal Women
9995266|NCT01488903||Postmenopausal women|600 healthy postmenopausal women
9995267|NCT01488916||Vitamin D deficiency|patients with serum vitamin D levels of the lower tertile
9995268|NCT01488916||Vitamin D inadequacy|patients with serum vitamin D levels of the middle tertile
9995269|NCT01488916||Reference group|patients with serum vitamin D levels of the upper tertile
9995270|NCT01488942|Experimental|monetary reinforcer|Subjects randomized to this arm will receive an escalating reinforcer initially for attendance at each clinic visit (until month 6 after starting HAART) and subsequently (until month 12 after starting HAART) will receive an escalating variable reinforcer for each month in which a viral load at or below 100 copies/mL is maintained
9995271|NCT01488942|No Intervention|no reinforcer|All subjects will receive HAART and standard medical care, but subjects in the control arm will not receive monetary reinforcers.
9995272|NCT01488955|Experimental|Ibuprofen|Ibuprofen 400 mg oral once daily from day 0 for 3 days, placebo granulate oral day 0
9995273|NCT01488955|Experimental|Fosfomycin-Trometamol|Fosfomycin-Trometamol (Monuril) 3 g granulate oral at day 0, placebo to Ibuprofen once a day from day 0 for 3 days
9995274|NCT01488968|Active Comparator|Standard|Standard Radiation Treatment
9995275|NCT01488968|Experimental|Hypofractionated|Hypofractionated
9995276|NCT01489007||Vegetarian Children|"Self-described lacto-ovo vegetarians for the past 6 months (Subjects who include a small amount of fish or chicken in the diet (not more than 2 servings total/week of both combined) will be allowed to participate in this study as these are not major iron contributors to the diet. Subjects must not have eaten any red meat however for 6 months.) Control subjects will be non-vegetarians."
9995277|NCT01489033|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
9995278|NCT01489033|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
9995279|NCT01489033|Experimental|Group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
9995280|NCT01489033|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
9995281|NCT01489033|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
9995282|NCT01489033|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
9995283|NCT01489059|Experimental|Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Dose Escalation
9995284|NCT01489059|Experimental|Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Dose Escalation
9995285|NCT01489059|Experimental|Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Cohort Expansion
9995286|NCT01489059|Experimental|Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Cohort Expansion
9995287|NCT01489059|Active Comparator|Part 2 - Arm 3: Ipilimumab monotherapy|Cohort Expansion
9995288|NCT01489072|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia
9995289|NCT01489072|Active Comparator|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia
9995290|NCT01489098||Breast Fed reference group|3 and 5 year olds from the above group
9995291|NCT01489098||Infant formula - protein level 1|3 ad 5 year olds from the above group
9995292|NCT01489098||Infant formula - protein level 2|3 and 5 year olds from the above group
9995293|NCT01489124|Experimental|0.5 g of imipenem by 0.5-hr infusion|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
9995294|NCT01489124|Experimental|0.5 g of imipenem by 2-hr infusion|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
9995295|NCT01489124|Experimental|1 g of imipenem by 2-hr infusion|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
9995296|NCT01489137|Experimental|neurosurgery with fixation|
9995297|NCT01489163|Experimental|Lifestyle Counseling|
9995298|NCT01489163|No Intervention|Control|
9995299|NCT01489176|Experimental|Regadenoson; Optison|Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography.
9913887|NCT00742729|Sham Comparator|Arm 3|Control
9913888|NCT00742742|Experimental|A|Nutrition advice (accroding to AHA recommendation) + 30 grams/day supplement of walnuts,walnuts were incorpatated into bread that provided to the participants
9913889|NCT00742742|Sham Comparator|B|Registed dietians give the advice for health lyfestyle
9913890|NCT00742755|Experimental|Prospective Intervention|Peer navigator intervention
9913891|NCT00742768|Active Comparator|1|softgel capsules
9913892|NCT00742768|Active Comparator|2|Gelpell capsules
9913893|NCT00742794||1|Hymenoptera sting allergic patients under immunotherapy
9913894|NCT00742807|Experimental|1|Administration of low dose of alfentanil hydrochloride before paracervical block
9913895|NCT00742807|Active Comparator|2|Administration of alfentanil hydrochloride dose after paracervical block
9913896|NCT00742820|Experimental|1|Calcium Acetate Oral Solution 667 mg per 5 mL
9913897|NCT00742820|Active Comparator|2|Calcium Acetate 667 mg Gelcaps
9913898|NCT00742820|Other|3|Calcium Citrate 950 mg Caplets
9913899|NCT00742833|Experimental|3|
9913900|NCT00742833|Placebo Comparator|1|
9913901|NCT00742846|Active Comparator|Group 1|The patient receives intra-articular steroid and local anesthetic injection under fluoroscopy.
9913902|NCT00742846|Active Comparator|Group 2|The patient receives subacromial steroid and local anesthetic injection under fluoroscopy.
9913903|NCT00742846|Active Comparator|Group 3|The patient receives intra-articular local anesthetic injection under fluoroscopy.
9913904|NCT00742846|Active Comparator|Group 4|The patient receives subacromial local anesthetic injection under fluoroscopy.
9913905|NCT00742898|Experimental|1|Non-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
9913906|NCT00742898|Active Comparator|2|Diagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
9913907|NCT00742911|Experimental|1|
9913908|NCT00742937|Placebo Comparator|A|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of vitamin E will be administer.
9913909|NCT00742937|Experimental|B|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of 200,000 UI of retinol palmitate (vitamin A)plus vitamin E will be administer.
9913910|NCT00742950|Active Comparator|I|Nasal 2.8-mm corneal incision
9913911|NCT00742950|Active Comparator|II|Temporal 2.8-mm corneal incision
9913912|NCT00742950|Active Comparator|III|Superior 2.8-mm corneal incision
9913913|NCT00742976|Active Comparator|1|8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
9913914|NCT00742976|Active Comparator|2|8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard
9913915|NCT00742989|Experimental|A|OLT administration
9913916|NCT00742989|Sham Comparator|B|placebo-OLT
9913917|NCT00743028|Experimental|1|
9913918|NCT00743028|Experimental|2|
9913919|NCT00743028|Experimental|3|
9913920|NCT00743028|Experimental|4|
9913921|NCT00743028|Experimental|5|
9913922|NCT00743028|Experimental|6|
9913923|NCT00743041|Experimental|1|Standard of Care plus EFT (Emotional Freedom Techniques)
9913924|NCT00743041|No Intervention|2|Standard of Care (SOC)
9934258|NCT04946318|Experimental|12-week CSJ117|Participants who will enter the extension study after the last follow-up visit (week 24) of the core study will be treated with once daily for 12 weeks with the same dose of CSJ117 they received in the core study. CSJ117 (0.5 mg, 1 mg, 2 mg, 4 mg and 8 mg) inhaled once daily for 24 weeks.
9934259|NCT04944940||Healthy Volunteers|Healthy male participants who are age and gender matched to the SBMA participants
9934260|NCT04944940||Patients with Spinal and bulbar muscular atrophy (SBMA)|Male participants with genetically confirmed SBMA
9934261|NCT04942054|Experimental|SCO-120|
9934262|NCT04941768||Avelumab + Axitinib|There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.
9934263|NCT04941274|Experimental|1/Dose Determination/De-Escalation|Abemaciclib (de-escalating dose)
9934264|NCT04941274|Experimental|2/Dose Expansion: Group 2a|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 15 participants previously treated with at least 1 line of systemic therapy.
9934265|NCT04941274|Experimental|2/Dose Expansion: Group 2b|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 10 previously untreated participants.
9934266|NCT04940039|Experimental|Paliperidone Palmitate|Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their usual clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.
9934267|NCT04939064||ART Infertile|Women that are part of a couple diagnosed with unexplained infertility that conceived on the first embryo transfer (ET) attempt
9934268|NCT04939064||Early Implantation Failure (EIF)|Infertility defined by a failure to conceive after: a) three or more failed transfers of high-quality blastocyst(s) (grade 3BB or higher); or b) two or more transfers of euploid blastocyst
9934269|NCT04939064||Early Pregnancy Failure (EPF)|defined by two or more biochemical pregnancies after transfer of a high-quality or euploid blastocyst with a positive hCG 12 days after ET but without subsequent clinical signs of pregnancy
9995300|NCT01489202|Active Comparator|platinum chromium EES|Patients undergoing PCI with stenting will have implantation of platinum chromium everolimus-eluting stents
9798963|NCT01645098|Experimental|Dexmedetomidine 1 mcg/kg|Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
9798964|NCT01645098|Experimental|Dexmedetomidine 0.5 mcg/kg|Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
9798965|NCT01645111|Active Comparator|Clevidipine|
9798966|NCT01645176|Experimental|Hydroxychloroquine/Atorvastatin open label|
9798967|NCT01645280|Placebo Comparator|Group 1|
9798968|NCT01645280|Experimental|Group 2|
9798969|NCT01645280|Experimental|Group 3|
9798970|NCT01645280|Experimental|Group 4|
9798971|NCT01645280|Experimental|Group 5|
9798972|NCT01645306|Placebo Comparator|Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol|Placebo control with PBS, 1% sucrose and 4% mannitol
9798973|NCT01645306|Active Comparator|40 mg Revacept|low dose Revacept 40mg in PBS, 1% sucrose, 4% mannitol
9798974|NCT01645306|Active Comparator|120 mg Revacept|high dose revacept 120mg in PBS, 1% sucrose, 4% mannitol
9798975|NCT01645735|Experimental|Ceftaroline|Ceftaroline fosamil 600 mg Intravenous (IV) administration over 60 minutes, every 8 hours (q8h); dosing to be adjusted for renal function; treatment duration 5 to 14 days
9798976|NCT01645735|Active Comparator|Ceftriaxone plus vancomycin|Ceftriaxone 2 g IV over 30 minutes once per day (q24h) plus vancomycin 15 mg/kg IV every 12 hours (q12h) initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
9798977|NCT01645930|Experimental|Ixazomib+Lenalidomide+Dexamethasone|Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)
9798978|NCT01646021|Experimental|Ibrutinib|
9798979|NCT01646021|Experimental|Temsirolimus|
9798980|NCT01646073|Experimental|Adalimumab|Adalimumab 40 mg every other week (eow)
9798981|NCT01646073|Placebo Comparator|Placebo|placebo
9798982|NCT01646125|Experimental|AUY922 arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.~AUY922 was to be administered weekly."
9798983|NCT01646125|Active Comparator|chemotherapy arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.~Pemetrexed or docetaxel was to be was to be given once every three weeks."
9798984|NCT01646138|Experimental|Challenge Virus|The Ca/04/2009/H1N1 Vero Grown Challenge Virus was administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
9798985|NCT01646151||Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
9798986|NCT01646177|Placebo Comparator|Placebo|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
9798987|NCT01646177|Active Comparator|50 mg etanercept|Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
9798988|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
9798989|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
9798990|NCT01646203|Experimental|IMC-TR1|"Part A - Dose Escalation:~Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle~Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles~Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles~Part B - Disease Specific Cohort Expansion:~Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose."
9798991|NCT01646216|Experimental|Split-belt treadmill training|Split-belt treadmill exercise
9798992|NCT01646255|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
9798993|NCT01646255|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
9798994|NCT01646268|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
9798995|NCT01646268|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
9798996|NCT01646320|Experimental|Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR|
9798997|NCT01646320|Experimental|Arm 2: Placebo + Saxagliptin + Metformin IR|
9798998|NCT01646346|Experimental|4D Conformal Image-Guided Partial Breast RT|This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.
9798999|NCT01646385||etanercept|adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
9799000|NCT01646385||nbDMARD|biologic-naive adult rheumatoid arthritis patients with DAS28 >4.2 treated with non-biologic anti-rheumatic drugs(s).
9799001|NCT01646398|Experimental|>= 65-year age group-13vPnC|
9799002|NCT01646398|Active Comparator|>= 65-year age group-23vPS|
9913925|NCT00743067|Experimental|Cohort 1|Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
9913926|NCT00743067|Experimental|Cohort 2|Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
9934270|NCT04939064||Normal Fertile|Women with proven parity based on spontaneous conception without fertility treatment or prior diagnosis of infertility, normal uncomplicated pregnancy, birth of at least one healthy baby
9934271|NCT04939064||Recurrent Pregnancy Loss (RPL)|defined as the loss of two or more pregnancies after transfer of a high-quality or euploid blastocyst with a positive HCG 12 days after ET and subsequent clinical signs of pregnancy
9934272|NCT04938830|Experimental|MK-1654|Participants will receive intramuscular (IM) injections of MK-1654 and placebo
9934273|NCT04938830|Active Comparator|Palivizumab|Participants will receive IM injections.
9934274|NCT04933617|Experimental|1- Dose Escalation|Copanlisib (IV) per dose level (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle in combination with standard dosing DA-EPOCH-R to determine RP2D and MTD of copanlisib. Up to 6 cycles total.
9934275|NCT04933617|Experimental|2 - Dose Expansion|Copanlisib (IV) at the RP2D or MTD on days 1 and 5 of each 21-day cycle in combination with standard dosing DA-EPOCH-R. Up to 6 cycles total.
9934276|NCT04933565|Experimental|ORG-129|Single ascending dose, 4 cohorts, followed by multiple ascending dose, 4 cohorts and food interaction cohort
9934277|NCT04933565|Placebo Comparator|Placebo|Single ascending dose, 4 cohorts, followed by multiple ascending dose, 4 cohorts and food interaction cohort
9934278|NCT04933539|Experimental|Arm 1|Daratumumab SC (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); Carfilzomib IV (Days 1, 8, 15 of the 28-day cycle); Dexamethasone PO/IV (Days 1, 8, 15, 22 of the 28-day cycle)
9934279|NCT04927442||Covid-19 patients|Patients, male or female, 18 to 65 years old, who tested positive for COVID-19 (PCR or rapid test) =5 days before enrollment.
9934280|NCT04927429||Affected participants|Participants with a clinically indicated referral for cardiac MRI
9934281|NCT04927429||Healthy participants|Healthy individuals of various ethnicities to serve as reference ranges
9934282|NCT04927416|Experimental|Differentiated thyroid cancer (DTC)|Patients with DTC but not HTC
9934283|NCT04927416|Experimental|Hurthle cell thyroid cancer (HTC)|Molecularly and histologically unique subtype of DTC - Hurthle cell thyroid cancer (HTC),
9934284|NCT04927416|Experimental|Medullary thyroid cancer (MTC)|Patients with metastatic thyroid cancer of neuroendocrine origin - medullary thyroid cancer (MTC)
9934285|NCT04926922||HONOR participants at Month 12|Adult participants who agree to participate and meet the study-specific eligibility criteria at their Month 12 HONOR study visit
9934286|NCT04926415|Experimental|Normal Weight|This arm consists of study participants with a body mass index (BMI) of less than 25. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
9934287|NCT04926415|Experimental|Overweight|This arm consists of study participants with a body mass index (BMI) of more than 25 but less than 30. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
9934288|NCT04926415|Experimental|Obese|This arm consists of study participants with a body mass index (BMI) of more than 30. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
9934289|NCT04926194|Experimental|Patient with MDS/MPN|DSCs will be given 1 × 10^6 cells per kilogram of participant's body weight intravenously, administered once per week up to a maximum of six weeks depending on the clinical response.
9934290|NCT04923178||1/Non-invasive urothelial cancer|Participants with high-grade and, low-grade non-invasive bladder cancer
9934291|NCT04923178||2/Muscle invasive bladder and high-grade upper tract urothelial cancer|Participants with muscle invasive bladder and invasive upper tract urothelial cancer
9934292|NCT04923178||3/Variant urothelial cancer|Participants diagnosed with a urothelial variant histologies at any stage
9934293|NCT04923178||4/Metastatic Urothelial cancer|Participants diagnosed with urothelial cancer who cannot be placed in cohorts 1-3
9934294|NCT04923178||5/Localized rare genitourinary tumors|Participants with localized rare genitourinary tumors treated with curative intent
9934295|NCT04923178||6/Locally advanced and metastatic rare genitourinary tumors|Participants with locally advanced and metastatic rare genitourinary tumors
9934296|NCT04919629|Experimental|Cohort 2B-1 (pegcetacoplan, pembrolizumab)|
9934297|NCT04919629|Experimental|Cohort 2B-2 (pegcetacoplan, pembrolizumab, bevacizumab)|
9934298|NCT04919629|Experimental|Cohort 2B-3 (bevacizumab)|
9934299|NCT04919369|Experimental|Treatment (tretinoin, atezolizumab)|Patients receive tretinoin PO on days 1-3 of cycles 1-3. Patients also receive atezolizumab IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9934300|NCT04919226|Experimental|Peptide Receptor Radionuclide Therapy (PRRT) Arm|
9934301|NCT04919226|Active Comparator|CAPTEM(Capecitabine-Temozolomide), Everolimus, FOLFOX(Folinic acid + Fluorouracil + Oxaliplatin)|
9934302|NCT04918771|Experimental|Rafamin|Tablet for oral use.
9934303|NCT04918771|Placebo Comparator|Placebo|Tablet for oral use.
9995301|NCT01489202|Active Comparator|cobalt chromium everolimus-eluting stent|Patients undergoing PCI with stenting will have implantation of cobalt chromium everolimus-eluting stents
9995302|NCT01489215|Experimental|"Clinical group-presence intervention"|"The Presence intervention is based on based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine."
9995303|NCT01489215|Experimental|"Clinical group-checking intervention"|"The Checking training is based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine"
9995304|NCT01489215|No Intervention|Control Group|
9995305|NCT01489228|Experimental|High Dose E1224|High Dose (HD - 8weeks) Group
9995306|NCT01489228|Experimental|Low Dose E1224|Low Dose (LD - 8 weeks) Group
9995307|NCT01489228|Experimental|Short Dose E1224|Short Dose (SD - 4 weeks) Group
9995308|NCT01489228|Placebo Comparator|Placebo|Placebo (8 weeks) Group
9995309|NCT01489228|Active Comparator|Benznidazol|BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days
9995310|NCT01489241|No Intervention|Usual care|Patients in the control group receive usual care and visit the outpatient department at 4 and at 12 weeks after discharge when pulse rate, oxygen saturation and spirometry is performed. In the case of clinical deterioration during the study, the patients contact as usual their general practitioner. Usual care of COPD patients consists of regular visits to the specialist or primary care clinics every time a medication change is made or a medical examination is needed
9995311|NCT01489241|Experimental|Telemonitoring|
9995312|NCT01489267|No Intervention|Control group|Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
9995313|NCT01489267|Experimental|Stem cell transplantation|10 patients in the group accept stem cell transplantation.
9995314|NCT01489293||atopic subjects|Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
9995315|NCT01489293||non-atopic subjects|Control group without atopic diseases.
9995316|NCT01489306|Experimental|MDT-637|Active formulation
9995317|NCT01489306|Placebo Comparator|Placebo|Matched Placebo Comparator
9995318|NCT01489319|Experimental|Nl Wt PCOS - Nl Abdominal Adiposity|10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA
9995319|NCT01489319|Experimental|Nl Wt PCOS - Increased Abdominal Adiposity|10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA
9995320|NCT01489319|No Intervention|Obese PCOS|10 obese women with PCOS
9995321|NCT01489319|No Intervention|Nl Wt Controls - Nl Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA
9995322|NCT01489319|No Intervention|Nl Wt Controls - Increased Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA
9995323|NCT01489319|No Intervention|Obese Controls|10 obese ovulatory women serving as controls
9995324|NCT01489345|Experimental|Arm 1: Experimental|
9995325|NCT01489345|Placebo Comparator|Arm 2: Placebo Comparator|
9995326|NCT01489371|Experimental|Treatment (EGEN-001, pegylated liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and EGEN-001 IP over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9995327|NCT01489384||3 months: Discontinue vs continue DMARDS|At 3 months those patients who achieved a change in DAS28 of 1.2 or greater will be randomized to discontinue versus continue DMARDs and will be followed for an additional 15 months
9995328|NCT01489384||6 months: discontinue vs continue DMARDs|(Protocol amendment 4.0)At 6 months, those patients still on Cimzia and DMARD therapy who were not randomized at month 3 AND achieve a change in DAS28> 1.2 will be randomized to discontinue versus continue DMARDs and will be followed for an additional 12 months.
9995329|NCT01489384||6 months: D/C vs Cont'd DMARDs if change in DAS28|(Protocol amendment 4.0)At 6 months, if the change in DAS28 is at least 0.6 and there is a decision to continue Cimzia, then the patients will be randomized to discontinue versus continue DMARDs with Cimzia and will be followed for an additional 12 months.
9995330|NCT01489384||3 or 6 months: stop CIMZIA and treat as per SOC|(Protocol amendment 4.0)If a change in DAS28 of <0.6 occurs at 6 months (at 3 months for protocol amendment 6.1)in patients not randomized at month 3 then the patient will stop Cimzia and treatment will be standard of care. However, patient will still be followed until the end of study.
9995331|NCT01489397|Experimental|Gastric intestinal metaplasia|
9995332|NCT01489397|Placebo Comparator|Normal|
9995333|NCT01489410|Active Comparator|Drug-Eluting Beads with Doxorubicin|Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
9995334|NCT01489410|Active Comparator|Lipiodol Ethanol Mixture (LEM)|Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
9995335|NCT01489436|Active Comparator|Single port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary; this device is placed percutaneously without the need for a trocar. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port, adequate hemostasis is ensured, the umbilical trocar removed, and the single operative site will be closed and sterile dressings applied (four Band-Aids).
9995336|NCT01489436|Active Comparator|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder. Trocar sites will be closed and sterile dressings applied (four Band-Aids).
9995337|NCT01489449|Placebo Comparator|Stent|Stent Implantation (DES or BMS), no further treatment
9995338|NCT01489449|Active Comparator|DCB|"DEBonly strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection"
9995339|NCT01489462|Experimental|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
9995340|NCT01489462|Experimental|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
9995341|NCT01489462|Active Comparator|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
9995342|NCT01489488|Experimental|Arm 1|
9995343|NCT01489488|Experimental|Arm 2|
9995344|NCT01489488|Experimental|Arm 3|
9995345|NCT01489488|Experimental|Arm 4|
9995346|NCT01489488|Experimental|Arm 5|
9995347|NCT01489501|Experimental|only one arm available|Caomecs transplantation on eye cornea.
9995348|NCT01489514||Peanut allergic subjects|
9995349|NCT01489540|Active Comparator|new diagnostic strategy|Combination of laser Doppler imaging and clinical assessment of burn depth
9995350|NCT01489540|No Intervention|current diagnostic strategy|Clinical assessment of burn depth
9995351|NCT01489566|Active Comparator|Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d
9995352|NCT01489566|Placebo Comparator|the placebo|
9995353|NCT01489592|Experimental|curcumin|oral administration of 6g of curcumin
9995354|NCT01489592|Placebo Comparator|placebo|oral administration of 12 sugar pill
9995355|NCT01489605|Experimental|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
9995356|NCT01489605|Active Comparator|Control: Standard GlideScope|Control: Patients will be intubated using standard practice, a standard GlideScope (Verathon)
9995357|NCT01489618|Active Comparator|PPS|Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
9995358|NCT01489618|Experimental|PnCJ PPS|Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
9998017|NCT01514058|Active Comparator|EUS-FNA First|Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
9913927|NCT00743067|Experimental|Cohort 3|Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
9913928|NCT00743067|Experimental|Cohort 4|Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
9913929|NCT00743067|Experimental|Cohort 5|Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
9913930|NCT00743080|Experimental|1|Laparoscopic myomectomy and supracervical hysterectomy using GYNECARE MORCELLEX
9913931|NCT00743080|Active Comparator|2|Laparoscopic myomectomy and supracervical hysterectomy using ROTOCUT G1
9913932|NCT00743132||1|Postoperative no renal dysfunction
9913933|NCT00743132||2|Postoperative renal dysfunction
9913934|NCT00743171||1|Good adherent patient: patient performed ≥ 80% of predicted HS within 24 months
9913935|NCT00743171||2|Moderate adherent patient: patient performed ≥ 50% of predicted HS within 24 months
9913936|NCT00743171||3|Non-adherent patient: patient performed < 50% of predicted HS within 24 months.
9913937|NCT00743210|Experimental|1|Oral L-citrulline, 3 grams once per day for 3 weeks.
9913938|NCT00743210|Placebo Comparator|2|Placebo, 3 grams once per day for 3 weeks.
9913939|NCT00743223||1|Study-group: The volunteers were selected on a randomized form among the individuals who went to the clinic of orofacial pain and temporomandibular disorders of São Paulo Hospital.
9913940|NCT00743223||2|Control-group: The volunteers were selected on a randomized form among the individuals who went to the dental offices of the researchers.
9913941|NCT00743236|Experimental|Arm I|Patients undergo warm ischemia followed by partial nephrectomy.
9913942|NCT00743236|Experimental|Arm II|Patients undergo cold ischemia followed by partial nephrectomy.
9913943|NCT00743301|Active Comparator|Olive oil|
9913944|NCT00743301|Experimental|Palm olein|
9913945|NCT00743301|Active Comparator|Lard|
9913946|NCT00743327||1|Participants receiving ADT and pioglitazone
9913947|NCT00743327||2|Participants receiving ADT only
9913948|NCT00743327||3|Participants not receiving ADT and in remission from prostate cancer
9913949|NCT00743353|Experimental|A|16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
9913950|NCT00743379|Experimental|A|TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
9913951|NCT00743379|Experimental|B|TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
9913952|NCT00743379|Experimental|C|TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
9913953|NCT00743405|Other|Cohort 1|Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan
9913954|NCT00743405|Other|Cohort 2|Subjects will be receive GSK1034702 5 mg following the dose escalation plan
9913955|NCT00743418|Other|1|Healthy controls Mini Mental State evaluation score >28/30
9913956|NCT00743418|Other|2|Mild Cognitive Impairment: Mini Mental State Evaluation Score (MMSE)=26-28/30
9913957|NCT00743418|Other|3|Mild Dementia: Mini Mental State Evaluation Score (MMSE)=21-25/30
9913958|NCT00743457||VPS Patients|Children 6 months-18 years with VPS and symptoms of possible shunt failure
9913959|NCT00743470|Experimental|A, B|Group 1 receives regimen A and B. A: Healthy volunteers, receiving one 150 mg rifabutin QD alone. B: Healthy volunteers, receiving 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
9995359|NCT01489631|Active Comparator|epidural analgesia|The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.
9995360|NCT01489631|Active Comparator|local infiltration|The second group will receive local infiltration with ropivacaine of the knee during surgery.
9995361|NCT01489631|Active Comparator|local infiltration and gabapentin|The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.
9995362|NCT01489644|Experimental|Treatment period 1|
9995363|NCT01489644|Experimental|Treatment period 2|
9995364|NCT01489644|Experimental|Treatment period 3|
9995365|NCT01489644|Active Comparator|Treatment period 4|
9995366|NCT01489683|Experimental|control|3 ml of normal saline was instilled to larynx and trachea
9995367|NCT01489683|Active Comparator|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea before endotracheal intubation
9995368|NCT01489696|Experimental|Treatment Arm 1|tamsulosin singles doses; mirabegron multiple dose
9995369|NCT01489696|Experimental|Treatment Arm 2|mirabegron single doses; tamsulosin multiple dose
9995370|NCT01489709||Vesicare group|Who receive vesicare
9995371|NCT01489722|Experimental|AZD1208|Single ascending dose escalation of 3 - 6 patient cohorts until maximum tolerated dose (MTD) is established. Up to 12 patients may be included at any dose not determined to be intolerable. Safety expansion using MTD in up to 44 Acute myelogenous leukemia (AML) patients.
9995372|NCT01489735||1|
9995373|NCT01489761|Active Comparator|zotarolimus-eluting stent|Resolute Integrity or Resolute Onyx stent
9995374|NCT01489761|Experimental|everolimus-eluting stent|Xience Prime or Xience Xpedition or Xience Alpine stent
9995375|NCT01489774|Placebo Comparator|Placebo|
9995376|NCT01489774|Experimental|CJ-12406|CJ-12406 Tablet, daily for 1 day or bid for 10 days
9995377|NCT01489787|Experimental|Phase I : HIFU|
9995378|NCT01489787|Experimental|Phase IIa : HIFU|
9995379|NCT01489787|Experimental|Phase IIb : HIFU|
9995380|NCT01489800|Experimental|Early Feeding|Introduction of clear liquid diet 24 hours after extubation with advancement to regular diet 24 hours thereafter if there is no significant nausea or vomiting.
9995381|NCT01489800|No Intervention|Control Feeding|Standard of care with introduction of clear liquid diet at time of return of bowel function as determined by flatus. Advancement to full diet 24 later if clear diet well tolerated.
9995382|NCT01489839||Periodontal diseased|Subjects with periodontal disease will be enrolled. Subjects with mild disease will have at least 4 teeth with at least 1 site with pocketing of 5 mm or more and concomitant attachment greater than or equal to 2 mm, and radiographic evidence of mesial or distal alveolar bone loss around at least 2 of the affected teeth. Subjects with severe disease will have at least 8 teeth with a site having >5mm pocketing and loss of 3 mm attachment with evidence of alveolar bone loss in 2 teeth.
9995383|NCT01489839||Periodontally healthy|Periodontally healthy subjects have no teeth with pocketing of 4 mm or greater and attachment loss, with the exception of the distal of the second molars where a pocket of 4 mm and concomitant attachment of up to 2 mm will be acceptable. Healthy subjects can have up to 3 sites with gingival recession and no radiographic evidence of alveolar bone loss.
9995384|NCT01489852|Active Comparator|Estrogen pre-treatment|
9995385|NCT01489852|No Intervention|Control|The control group did not receive any pre-treatment.
9995386|NCT01489865|Experimental|ABT-888 and mFOLFOX-6|ABT-888 orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
9995387|NCT01489878||β-lactams|amoxicillin-clavulanate or penicillins M
9995388|NCT01489878||macrolides|
9995389|NCT01489878||fluoroquinolones|
9995390|NCT01489878||synergistins|
9995391|NCT01489904|Experimental|Botulinum Toxin|Botulinum Toxin type-A
9995392|NCT01489904|No Intervention|Control Treatment|No intervention
9995393|NCT01489917|No Intervention|Compression without adjustment|TR band (Terumo medical) applied. The TR band is then deflated gradually till pulsatile bleeding is observed under the transparent plastic inflatable chamber and then 1-2 cc of air is placed back in the TR band chamber to stop bleeding. The band is left in place for 2 hours and not adjusted further unless patient complained of symptoms or bleeding occurred.
9998018|NCT01514058|Active Comparator|ERCP with stent placement first|Patients will undergo ERCP with stent placement first, followed by EUS-FNA.
9998019|NCT01514071|Experimental|Pop-up picture|
9913960|NCT00743470|Experimental|C|Group 2 receives regimen C. C: 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
9913961|NCT00743496|Experimental|Group 1|Participants who consent to the study will receive Anti-GD2 antibody.
9913962|NCT00743522||Control|PROVE Trial settings
9913963|NCT00743522||Experimental|Pre-selected settings
9913964|NCT00743535|Experimental|1|Transobturatory correction of anterior defect plus TOT
9913965|NCT00743535|Active Comparator|2|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
9913966|NCT00743548|Active Comparator|1|Interdental brush (IB), the intervention is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
9913967|NCT00743548|Placebo Comparator|2|Dental floss (DF), the positive control, is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
9913968|NCT00743561|Other|1|
9913969|NCT00743587|Placebo Comparator|A|
9913970|NCT00743587|Active Comparator|B|
9913971|NCT00743587|Active Comparator|C|
9913972|NCT00743587|Active Comparator|D|
9913973|NCT00743600|Experimental|1|Patients with shoulder pain who were clinically referred to Ultrasound for evaluation
9913974|NCT00743600|Active Comparator|2|healthy volunteers who do not have shoulder pain
9913975|NCT00743626|Other|1|Healthy patients screened for cervical cancer
9913976|NCT00743639|Other|1|Interventional
9913977|NCT00743678|Experimental|NEO|NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab
9913978|NCT00743691|No Intervention|Arm1|Make a diagnosis of Neonatal infections and refer patients according to IMNCI guideline
9913979|NCT00743691|Active Comparator|2|Health extension Workers will Make a diagnosis of Neonatal infections and treat with antibiotics when referal is not possible
9913980|NCT00743743|Experimental|1|receive 1 Longevinex brand capsule daily containing 215 mg of resveratrol active ingredient
9913981|NCT00743743|Placebo Comparator|2|Receive 1 capsule daily for 52 weeks containing placebo for comparison to experimental arm
9913982|NCT00743756|Experimental|1|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
9913983|NCT00743756|Experimental|2|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
9913984|NCT00743756|Other|3|20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)
9913985|NCT00743769|Active Comparator|2|"Thymosin Beta 4~A single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD (once a day)"
9913986|NCT00743769|Placebo Comparator|1|Placebo A single bolus injection of 0.0 mg QD of thymosin beta 4
9913987|NCT00743821||TBI Patients|Individuals who have suffered a mild traumatic brain injury and have persistent post-concussive symptoms (PCS)
9913988|NCT00743821||Normals|Individuals of comparable age and education who have not suffered a traumatic brain injury
9913989|NCT00743834|Other|A|Effectiveness of Luvox CR plus Web-based CBT for OCD
9913990|NCT00743847|Placebo Comparator|placebo|
9913991|NCT00743847|Active Comparator|varenicline 0.5 mg BID|
9913992|NCT00743847|Active Comparator|varenicline 1mg BID|
9913993|NCT00743860|Experimental|Single dose|single oral dose
9913994|NCT00743860|Experimental|Repeat Dose|28 day repeat dose
9913995|NCT00743873|Placebo Comparator|2|saline
9913996|NCT00743873|Experimental|1|Plasma Rich in Growth Factors (PRGF)
9913997|NCT00743886|Placebo Comparator|2|saline
9913998|NCT00743886|Experimental|1|Plasma Rich in Growth Factors (PRGF)
9913999|NCT00743899|Experimental|1|The aggressive group
9914000|NCT00743899|Experimental|2|The conservative group
9914001|NCT00743912|Experimental|1|open-label rifaximin 550 mg TID
9914002|NCT00743951|Experimental|1 Patient decision aid|Patient decision aid about treatment options for osteoarthritis
9914003|NCT00743951|Active Comparator|2 Usual care|Usual patient educational materials
9914004|NCT00743964|Experimental|ECX|Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
9914005|NCT00743964|Active Comparator|CX|Cisplatin and capecitabine combination chemotherapy will be administered.
9914006|NCT00743977|Active Comparator|A|
9914007|NCT00743977|Experimental|B|
9914008|NCT00743990|Active Comparator|A|
9914009|NCT00743990|Placebo Comparator|B|
9914010|NCT00743990|No Intervention|3|no intervention
9914011|NCT00744016|Placebo Comparator|2|Placebo
9914012|NCT00744016|Active Comparator|1|Granulated mesalamine
9914013|NCT00744029|Active Comparator|Intervention group|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
9914014|NCT00744029|No Intervention|Control group|No intervention was performed
9914015|NCT00744068|Experimental|1|Structured Directive Telephone Support Calls
9914016|NCT00744068|Experimental|2|Structured Non-Directive Telephone Continuing Care Support
9914017|NCT00744068|Experimental|3|Unstructured Directive Telephone Support
9914018|NCT00744068|Experimental|4|Unstructured Non-Directive Telephone Support
9914019|NCT00744068|No Intervention|5|
9914020|NCT00744094|Placebo Comparator|1|placebo drink
9914021|NCT00744094|Experimental|2|protein drink
9914022|NCT00744133|Experimental|Group 1: 1, 3, or 5 bites|Part A: 18 subjects receive 1, 3, or 5 bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
9914023|NCT00744133|Experimental|Group 2: N bites|Part B: 20 subjects receive N bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
9914024|NCT00744146|Experimental|1|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 50 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
9914025|NCT00744146|Experimental|2|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 100 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
9914026|NCT00744146|Experimental|3|"Eight volunteers total.~Randomized such that six volunteers will receive Protexia as a single 250 mg dose and two volunteers will receive saline placebo of the same volume on Study Days 1 and 72.~Volunteers to be followed for approximately 142 days total."
9914027|NCT00744146|Experimental|4|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 500 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
9914028|NCT00744146|Experimental|5|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 750 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
9914029|NCT00744159||OC|Open colorectal resection
9914030|NCT00744159||LC|Laparoscopic colorectal resection
9914031|NCT00744172|Active Comparator|I|laparoscopy
9914032|NCT00744172|Active Comparator|2|vaginal
9914033|NCT00744172|Active Comparator|3|abdominal
9914034|NCT00744185|Placebo Comparator|2|30-days placebo treatment
9914035|NCT00744185|Experimental|1|30-days propranolol treatment
9914036|NCT00744198|Active Comparator|1|Autologous sling
9914037|NCT00744198|Active Comparator|2|Synthetic sling
9914038|NCT00744198|Active Comparator|3|Biological sling
9914039|NCT00744224|Placebo Comparator|1|
9914040|NCT00744224|Active Comparator|2|
9914041|NCT00744224|Active Comparator|3|
9914042|NCT00744250|Other|1|"Pre-treatment vs. post-treatment-~In the first phase, before administration of the capsules and liquid diet, baseline gastric and duodenal secretions will be aspirated via the oro-enteric tube. Subjects will get 5 placebo capsules at Time=0 given orally with the liquid Lundh diet. Pancreato-biliary and duodenal secretions in the duodenal region will be aspirated continuously over the first 20 min. Gastric and duodenal fluids will be aspirated from 20-180 min at specified time points. Following a rest of 1 hour, the same process will be repeated with the drug capsules. At the end of the study the catheter will be removed and patient will be offered a meal."
9934304|NCT04916613|Experimental|ADT + darolutamide|ADT + darolutamide 600 mg po bid
9934305|NCT04916613|Placebo Comparator|ADT + placebo|ADT + placebo po bid
9934306|NCT04915183|Other|1|randomization to either placebo or atorvastin
9934307|NCT04915183|No Intervention|2|observational
9934308|NCT04913805|Active Comparator|Potassium Nitrate|Potassium Nitrate (KNO3) 6 mmol three times daily
9934309|NCT04913805|Active Comparator|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate (KNO3) 6 mmol three times daily + Propionyl-L-Carnitine (PLC) 1000 mg twice daily + Nicotinamide Riboside (NR) 300 mg three times daily
9934310|NCT04913805|Placebo Comparator|Potassium Chloride|Potassium Chloride (KCl) 6 mmol three times daily
9934311|NCT04903028|Sham Comparator|Sham rTMS|Participants will be fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device with adjustable output amplitude and powered by a 9-V battery. We will use electrode stimulation with 10 Hz over DLPFC, total 3000 pulses or 1 Hz over mOFC total 900 pulses. The sham-TMS scalp discomfort was matched to that of active TMS. During real TMS there was no current flowing through the scalp electrodes.
9934312|NCT04903028|Active Comparator|Active rTMS 10 Hz DLPFC|A stimulation frequency of 10 Hz, pulse train duration (on time) of 5 seconds, inter-train interval (off time) of 10 seconds (15 second cycle time), E-field-modeling to determine TMS intensity and coil orientation, total of 60 trains, session time of 15 minutes, and 3000-total pulses per day, will be delivered over the left DLPFC.
9934313|NCT04903028|Active Comparator|Active rTMS 1 Hz mOFC|A stimulation frequency of 1Hz, E-field-modeling to determine TMS intensity and coil orientation, session time of 15 minutes, and 900-total pulses per day, will be the same for all subjects (both active and sham). TMS will be delivered over the left mOFC.
9934314|NCT04902443|Experimental|1/Dose De-Escalation|Treatment with pomalidomide at de-escalating doses if necessary and nivolumab at a fixed dose
9934315|NCT04902443|Experimental|2/Dose Expansion|Nivolumab + pomalidomide (at optimal dose determined in dose escalation portion of the study) for up to 30 participants
9934316|NCT04902274|Experimental|Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the experimental group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute application of tDCS during each treatment session via the Halo Sport (Halo Neuroscience, San Francisco, CA) headset. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
9934317|NCT04902274|Sham Comparator|Sham Transcranial Direct Current Stimulation plus Physical Therapy|Participants in the sham control group will receive the current standard of care in ankle inversion sprain rehabilitation plus a 20-minute sham tDCS treatment, where the patient is wearing the tDCS headset, but stimulation is only applied for 30 seconds of the 20-minute period. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes.
9934318|NCT04901377||Combined oral contraception: Estradiol valerate / Dienogest|Young women (18-35 years of age) using estradiol valerate / dienogest in real clinical practice.
9934319|NCT04900298|Experimental|Intervention Arm|Use of SafeHaven hand hygiene system in the operating room
9934320|NCT04900298|No Intervention|Control Arm|Standard of care hand hygiene
9934321|NCT04896086|Experimental|Group 1A-1B|20 mcg of FluMos-v1
9934322|NCT04896086|Experimental|Group 2A-2B|60 mcg of FluMos-v1
9934323|NCT04896086|Active Comparator|Group 3A-3B|standard dose of 60 mcg of the licensed QIV Flucelvax
9934324|NCT04896073|Experimental|1/Minnelide|Minnelide 2mg Days 1-21 of 28 day cycle (x12)
9934325|NCT04896060||Ecological Momentary Assessment (EMA) volunteers|Volunteers with access to mobile device with Wi-Fi and data recruited for an additional 1-week daily assessment study utilizing EMA to examine COVID-19 related stress and eating behavior in real-time
9934326|NCT04896060||General global population volunteers|Newly recruited volunteers 18 and above from the general global population that agree to participate in the COVID study
9934327|NCT04896060||NIDDK-Phoenix study volunteers|Previous research participants, who signed consents that allow data sharing that agree to participate in the COVID study
9934328|NCT04891614|Experimental|Treatment|Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.
9934329|NCT04890093|Experimental|1/Dose Escalation|Dose escalation of PEN-866 along with fixed doses of vincristine and temozolomide
9934330|NCT04890093|Experimental|2/MTD/RP2D|PEN-866 at the MTD or RP2D from phase 1 plus vincristine and temozolomide
9934331|NCT04889144|Experimental|Arm I (PLAN intervention)|Patients participate in PLAN intervention, consisting of 3 coaching sessions over 45-60 minutes each with a health coach.
9934332|NCT04889144|Active Comparator|Arm II (Best practice)|Patients receive usual care.
9934333|NCT04888936||NCI RASopathies Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
9934334|NCT04888936||NCI RASopathies Field Cohort|includes Proband, Other carriers in family, Family Controls
9914043|NCT00744289|No Intervention|Arm 1|Participants in Arm 1 will not receive any financial incentive after the second and third dose of hepatitis B vaccine have been administered.
9914044|NCT00744289|Other|Arm 2|Participants in Arm 2 will receive a small financial incentive after the second and third dose of the hepatitis B vaccine
9914045|NCT00744302|Experimental|PCD|Physiological calcium (1.25 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
9914046|NCT00744302|Active Comparator|NCD|Normal calcium (1.5 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
9914047|NCT00744315|Other|1|Controlled
9914048|NCT00744341|Experimental|1|
9914049|NCT00744341|Experimental|2|
9914050|NCT00744341|Experimental|3|
9914051|NCT00744341|Experimental|4|
9914052|NCT00744341|Placebo Comparator|5|
9914053|NCT00744354|Experimental|Non-Randomized Open Label Single Arm|Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
9914054|NCT00744393|Active Comparator|A|Active drug
9914055|NCT00744393|Placebo Comparator|P|Placebo drug
9914056|NCT00744406|Experimental|1|
9914057|NCT00744406|Experimental|2|
9914058|NCT00744406|Experimental|3|
9914059|NCT00744419|Experimental|3 age groups|Assigned to the arm based on age.
9914060|NCT00744445|Active Comparator|0800|r-HuEPO administered at 0800 hrs
9914061|NCT00744445|Active Comparator|1500|r-HuEPO administered at 1500 hrs
9914062|NCT00744445|Active Comparator|2200|r-HuEPO administered at 2200 hrs
9914063|NCT00744458|Active Comparator|1|
9914064|NCT00744458|Active Comparator|2|
9914065|NCT00744458|Active Comparator|3|
9914066|NCT00744510|Experimental|1|Reflexology
9914067|NCT00744510|No Intervention|2|
9914068|NCT00744536|Experimental|Lenalidomide and Melphalan|Lenalidomide + Melphalan both given metronomically
9914069|NCT00744549|Experimental|A|This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
9914070|NCT00744549|Experimental|B|This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
9914071|NCT00744562|Experimental|Open-label OMP-21M18|
9914072|NCT00744575||1|Chronic Back Pain
9914073|NCT00744575||2|Healthy Sex & Age Matched Controls
9914074|NCT00744588||alcohol dependence|Alcohol-dependent subjects currently being treated in an inpatient treatment facility.
9914075|NCT00744601||1|Patients with Cocaine Addiction
9914076|NCT00744601||2|Healthy Control Volunteers
9914077|NCT00744614||1|Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation
9914078|NCT00744640|Experimental|single|single arm study with triple combination chemotherapy
9914079|NCT00744666|Experimental|1|Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is > or equal to 21 mmHg, then IVTA will be withheld. If the IOP < 21mmHg, then patients will receive an injection of IVTA.
9914080|NCT00744666|No Intervention|2|Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).
9914081|NCT00744679|Experimental|Natalizumab 300 mg|Natalizumab infused at 300 mg every 28 days during the screening and assessment periods of the study which continues the therapy of the previous 12 months and maintains steady-state pharmacokinetics.
9914082|NCT00744705||1|Normal subjects who received routine health check-up in a comprehensive medical testing center
9914083|NCT00744744||Survey|
9914084|NCT00744835|Experimental|1|Ablation Management
9914085|NCT00744900|Experimental|A|
9914086|NCT00744913|Experimental|1|
9914087|NCT00744913|Active Comparator|2|
9914088|NCT00745004|Experimental|1|Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days.
9914089|NCT00745004|Placebo Comparator|2|Placebo 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days.
9914090|NCT00745017|Experimental|1|
9914091|NCT00745017|Experimental|2|
9914092|NCT00745017|Experimental|3|
9914093|NCT00745043|Placebo Comparator|R302|Daily placebo capsules
9914094|NCT00745043|Active Comparator|R303|Daily metoprolol 95mg capsules
9914095|NCT00745043|Active Comparator|R304|Daily propranolol 80mg capsules
9914096|NCT00745043|Active Comparator|Open Label|Daily Metoprolol 190mg capsules
9934335|NCT04888923||Healthy Controls|General public population, including females and males, who are over the age of 18, with a mixture of races and ethnicities representative of North Carolina.
10213035|NCT04705818|Experimental|Cohort C: metastatic solid tumor|Patients with metastatic solid with positive interferon gamma signature and/or presence of tertiary lymphoid structurestumor will be treated bydurvalumab prescribed in association with tazemetostat
10213036|NCT04705818|Experimental|Cohort D: soft-tissue sarcoma|Patients with soft-tissue sarcoma will be treated by durvalumab prescribed in association with tazemetostat
10213037|NCT04704843|Experimental|Module A (Without Gluten-Challenge): Guselkumab or Placebo|Participants in Module A (without gluten-challenge) will receive intravenous (IV) infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by subcutaneous (SC) injection of guselkumab or matching placebo at Week 12.
10213038|NCT04704843|Experimental|Module B (With Gluten-Challenge): Guselkumab or Placebo|Participants in Module B (with gluten-challenge) will receive IV infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by SC injection of guselkumab or matching placebo at Week 12.
10213039|NCT04704648|Other|Surgical Excision|Treatment involves EXCISION ONLY (surgery) for the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP). Standard of care topical antibiotics are given for infection prevention following surgery. No drugs or device treatments are administered for treatment of OSSN in this protocol.
9934341|NCT04886271|Experimental|HX009|
9934342|NCT04884815|Experimental|Stage 1: UX701 Dose Level 1|Participants randomized to receive a single, peripheral intravenous (IV) infusion of UX701 at dose level 1 plus prophylactic oral corticosteroids.
9934343|NCT04884815|Placebo Comparator|Stage 1: Placebo for Dose Level 1|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
9934344|NCT04884815|Experimental|Stage 1: UX701 Dose Level 2|Participants randomized to receive a single, peripheral IV infusion of UX701 at dose level 2 plus prophylactic oral corticosteroids.
9934345|NCT04884815|Placebo Comparator|Stage 1: Placebo Dose Level 2|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
9934346|NCT04884815|Experimental|Stage 1: UX701 Dose Level 3|Participants randomized to receive a single, peripheral IV infusion of UX701 at dose level 3 plus prophylactic oral corticosteroids.
9934347|NCT04884815|Placebo Comparator|Stage 1: Placebo Dose Level 3|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
9934348|NCT04884815|Experimental|Stage 2: UX701|Participants randomized to receive a single, peripheral IV infusion of UX701 at a dose selected in Stage 1 plus prophylactic oral corticosteroids.
9934349|NCT04884815|Placebo Comparator|Stage 2: Placebo|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
9934350|NCT04884815|Experimental|Stage 3: UX701|Participants originally randomized in Stage 1 or Stage 2 to placebo will be eligible for a single, peripheral IV infusion of UX701 at the selected dose plus prophylactic oral corticosteroids.
9934351|NCT04884815|Placebo Comparator|Stage 3: Placebo|Participants originally randomized in Stage 2 to UX701 will receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
9934352|NCT04883346|Experimental|Liraglutide|Treated with Liraglutide
9935781|NCT03218488||Participants 6-18 years of Age With Moderate to Severe Plaque Psoriasis|All Participants diagnosed with moderate to severe plaque psoriasis who will either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study as per routine clinical practice, will be monitored for the long-term safety of ustekinumab and long-term effects of ustekinumab on growth and development. The primary data source for the study will be the medical records of participants and standardized questionnaires (completed by the physician and by the participant/parent).
10213040|NCT04704219|Experimental|Pembrolizumab + Lenvatinib|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
10213041|NCT04698538|No Intervention|Educational Materials|Caregivers in this arm will receive intervention material, but no coaching. The material consists of a self-guided module introducing caregivers to the developmental concepts of joint engagement, social communication, and play.
9914097|NCT00745147|Experimental|A|Chinese herbal formula + Placebo of duphalac
9914098|NCT00745147|Active Comparator|B|Duphalac + Placebo of Chinese herbal formula
9914099|NCT00745160||1|Never-smokers with lung cancer
9914100|NCT00745173|Other|1|
9914101|NCT00745186|Active Comparator|1|Glucagen
9914102|NCT00745186|Experimental|2|Mayne Glucagon
9914103|NCT00745199|Experimental|1|Patients on hemodialysis with pruritus, receiving cromolyn sodium
9914104|NCT00745199|Experimental|2|patients on hemodialysis with pruritus, receiving placebo
9914105|NCT00745199|No Intervention|3|Patients on hemodialysis but without pruritus who do not receive any treatment.
9914106|NCT00745225|Experimental|Active intervention arm|Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
9914107|NCT00745225|Placebo Comparator|placebo pill|placebo comparator
9914108|NCT00745238|Experimental|Myotonic Dystrophy 1|
9914109|NCT00745264|Experimental|2|400 mg Ketoprofen from Diractin to 4 joints
9914110|NCT00745264|Experimental|3|100 and 400 mg Ketoprofen used concomittant with heat
9914111|NCT00745264|Experimental|4|100 and 400 mg Ketoprofen concomittant with moderate exercise
9914112|NCT00745264|Experimental|1|100 mg ketoprofen to 2 joints
9914113|NCT00745303||1|Subjects in this group received TCC training for 3 months
9914114|NCT00745303||2|Subjects in this group received no TCC training within 3 months
9914115|NCT00745329||2|"patients~healthy volunteers"
9914116|NCT00745342|Experimental|Teamwork Group|Families randomized to the Teamwork Group received the behavioral family teamwork intervention.
9914117|NCT00745342|No Intervention|Standard Care|Families in the Standard Care group received standard diabetes care and equal attention from study staff between visits to schedule appointments and encourage regular diabetes follow-up care.
9914118|NCT00745355||1|new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion
9914119|NCT00745381||1|This registry will be open to all patients with GEPNET or NET of unknown primary.
9914120|NCT00745407|Experimental|fenofibrate 160 mg, placebo|
9914121|NCT00745433||A|Repaglinide add-on to metformin.
9914122|NCT00745446|Experimental|1|1 hour exposure to filtered air
9914123|NCT00745446|Experimental|2|1 hour exposure to diesel exhaust (300mcg/m3)
9914124|NCT00745446|Experimental|3|1 hour exposure to filtered diesel exhaust
9914125|NCT00745459|Experimental|N|20 mL NPO-11
9914126|NCT00745472||1|
9914127|NCT00745472||2|
9914128|NCT00745485|Experimental|Zoldronic|
9914129|NCT00745511|Active Comparator|1|
9914130|NCT00745511|Active Comparator|2|
9914131|NCT00745511|Placebo Comparator|3|
9914132|NCT00745537|Experimental|Adolescent Mother|aged less than 17 years old and recently gave birth
9914133|NCT00745563|Experimental|A|
9914134|NCT00745576|Experimental|1|
9914135|NCT00745589|Active Comparator|higher dose sevelamer|first-line higher dose sevelamer hydrochloride
9914136|NCT00745589|Active Comparator|low dose sevelamer|second-line fixed low-dose sevelamer hydrochloride added to calcium carbonate
9914137|NCT00745602|Experimental|1|Patients referred for elective direct current cardioversion (DCCV) of atrial fibrillation.
9914138|NCT00745641||1|Sixty patients with abdominal illness and scheduled abdominal X-ray computed tomography examination will be included.
9914139|NCT00745667|Active Comparator|1|laparoscopic
9998020|NCT01514084||PEM group|Patients whose lacerations have been repaired by PEM trained physicians.
9914140|NCT00745667|Active Comparator|2|open correction
9914141|NCT00745680||A|A: AMI patient
9914142|NCT00745693|Experimental|1|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
9914143|NCT00745693|Experimental|2|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
9914144|NCT00745693|Experimental|3|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
9914145|NCT00745693|Experimental|4|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
9914146|NCT00745706|Other|A|Implantable Loop Recorder (ILR) implant
9914147|NCT00745719|Experimental|1|surgical total parathyroidectomy with forearm autografting
9914148|NCT00745732|Experimental|Radiation Therapy + ZD6474|"Radiation Therapy - Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.~ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth."
9914149|NCT00745745|Active Comparator|1|Apical ICD lead placement
9914150|NCT00745745|Experimental|2|Mid-Septal ICD lead placement
9914151|NCT00745771|Active Comparator|1|200 mg Ketoprofen
9914152|NCT00745771|Active Comparator|2|100 mg Ketoprofen
9914153|NCT00745784||1|Young spouses/domestic partners (20-49 years old) of cancer patients who have died from cancer.
9914154|NCT00745797|Experimental|Prophylactic WBRT|Take the whole brain radiotherapy radiotherapy
9914155|NCT00745797|No Intervention|Observer Group|The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
9914156|NCT00745810||1|sequential changes before and after cardiopulmonary bypass including ROS, antioxidant status, leukocyte elastase, complements, inflammatory cytokines
9914157|NCT00745836|Experimental|atorvastatin 10 mg, 80 mg|
9914158|NCT00745862||1|female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment
9914159|NCT00745888||1|age > 18 y/o Patients admitted to surgical ICU
9914160|NCT00745914|Experimental|1|Pioglitazone drug 15mg daily for 3 months then 30mg for 9 months (Peroxisome Proliferator-Activated Receptor-gamma agonist)
9914161|NCT00745914|Placebo Comparator|2|placebo comparator drug 15mg daily for 3months, then 30mg for 9 months
9914162|NCT00745927|No Intervention|Room air insufflations|Room air will be used for insufflations during colonoscopy
9914163|NCT00745927|Active Comparator|CO2 insufflations|CO2 will be used for insufflations during colonoscopy
9914164|NCT00745953|Active Comparator|Valsartan|This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
9914165|NCT00745953|Active Comparator|Hydrochlorothiazide|This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
9914166|NCT00746005|Experimental|1|3 g EPA-DHA
9914167|NCT00746005|Placebo Comparator|2|Placebo: sunflower oil
9914168|NCT00746031|Active Comparator|1|GnRH analogue-Zoladex
9914169|NCT00746031|Active Comparator|2|GnRH antagonist plus GnRH analogue
9914170|NCT00746031|No Intervention|3|
9914171|NCT00746044||1|Healthy volunteers >18y, 20 male, 20 female
9914172|NCT00746057|Other|1|Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
9914173|NCT00746070||A, primary aldosteronism|patients approved to be aldosteronism
9914174|NCT00746070||B, essential hypertension|patients approved to be essential hypertension
9914175|NCT00746083|Experimental|Intervention group|
9914176|NCT00746083|No Intervention|Control group|
9914177|NCT00746109|Placebo Comparator|NOPACKING|The comparison group will undergo a routine incision and drainage procedure but will not have packing placed inside the abscess cavity.
9914178|NCT00746109|Experimental|PACKING|This group will receive wound packing as per usual protocol
9914179|NCT00746135|Active Comparator|A|Conventional Biventricular Stimulation: RV Apex and LV Lead Tip
9914180|NCT00746135|Active Comparator|B|"Anodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = Anodal-cathodal Bi-V."
9914181|NCT00746135|Active Comparator|C|Anodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
9914182|NCT00746148|Experimental|1|Reflexology
9914183|NCT00746148|No Intervention|2|No intervention
9914184|NCT00746161|Active Comparator|1|Roux-en-Y
9914185|NCT00746161|Experimental|2|double tract reconstruction
10213042|NCT04698538|Experimental|JASPER intervention|The caregivers randomized to intervention, will meet twice a week with UCLA staff to do session planning one day and JASPER remote, live coaching another day. The caregivers are expected to meet with the UCLA team twice a week.
9998021|NCT01514084||GP group|Patients whose lacerations have been repaired by general pediatricians.
10213043|NCT04697459|Experimental|HD-EX (patient with intradialytic exercise)|will be enrolled in a 16 week intradilatytic exercise program.
10213044|NCT04697459|No Intervention|HD (patients with standard HD)|patients with standard hemodialysis (e.g. without exercise).
10213045|NCT04692922||Patients with disorders of consciousness|patients with a diagnosis of coma, vegetative state, or minimally conscious state minus (i.e. minimally conscious state without language function)
10213046|NCT04691427|Experimental|Active Virtual Reality-Based Vision Therapy|Virtual reality vision therapy where participants will be playing a custom-designed video game to act as a therapeutic intervention on a consumer-available virtual reality headset.
10213047|NCT04690907|Experimental|Intervention group|Dietary intervention: Written material on healthy diet during pregnancy, 2 virtual dietary counseling sessions given by a dietician. Otherwise basic care and counseling at maternity care clinics.
10213048|NCT04690907|No Intervention|Control group|Written material on healthy diet during pregnancy, otherwise basic care and counseling at maternity care clinics.
10213049|NCT04687358||Active RP|Patients who are currently under the care of a physician for treatment of RP, currently on treatment for RP, and have had an episode (recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis) in the last 3 years prior to enrollment. Once included in the registry, these patients will have both retrospective and prospective follow-up and data collection (hybrid design).
10213050|NCT04687358||Inactive RP|Patients who have had a diagnosis of RP, have not had an episode for 3 years and have not been prescribed any treatment for RP in the last 3 years, prior to enrolling in the registry. Once included in the registry, data collected from these patients will be retrospective only.
10213051|NCT04685811|Experimental|68Ga-PSMA-cyclotron Vesus 68Ga-PSMA-generator|Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
9995394|NCT01489917|Experimental|Patent hemostasis & heparin|TR-band is placed and positioned similarly to the other study arm. However, in theses cases, patency is evaluated at the time of application of the TR-band, and monitored every 15 minutes afterwards till the band is removed and hemostasis completed. After TR-band placement, if maintenance of radial artery patency is obtained, no heparin is administered and TR band is left in place for 1-hour. If radial artery patency is not maintained, a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the band is left in place for 2 hours.
9995395|NCT01489930|Experimental|Endurance Exercise|Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise
9995396|NCT01489930|Experimental|Resistance Exercise|Participants will perform 8-weeks of whole-body resistance exercise training.
9995397|NCT01489930|Experimental|Control / Combined Training|Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.
9995398|NCT01489943|Experimental|All subjects receiving treatment|During the treatment subjects will receive Midazolam 3 mg on Day 1, Pioglitazone 15 mg on Day 2, Omeprazole 40 mg on Day 3, Rosuvastatin 10 mg on Day 4, GSK1605786 500 mg twice daily (BID) from Day 5 to 10, GSK1605786 500 mg BID + Midazolam 3 mg on Day 11, GSK1605786 500 mg BID + Pioglitazone 15 mg on Day 12, GSK1605786 500 mg BID + Omeprazole 40 mg on Day 12, GSK1605786 500 mg BID + Rosuvastatin 10 mg on Day 14 as single sequence.
9995399|NCT01489982|Experimental|Light therapy|For patients who have sleep maintenance insomnia light therapy will be administered daily. If patients suffer only from sleep onset insomnia, this light therapy will be given upon awakening in the morning. Light boxes will be provided by Litebook company. In the active therapy group, the intensity of the light will be set at 10,000 lux with a head-to-light distance of 20cm. Patients will be instructed to let the light shine indirectly on their eyes (i.e. they do not look directly at the light). Patients can be reading, eating, watching TV, etc., during the time of light therapy.
9995400|NCT01489982|Experimental|CBT and sleep hygiene training|This will involve education about sleep in general, giving techniques related to sleep and relaxation, tips on stress management, etc.. This will take place at the Lady Davis Institute of the Jewish General Hospital. There will be 6 weekly sessions totalling 90 minutes - most of the time this will be in a group setting, with a maximum of 6 patients per group. Light therapy will also be part of this treatment strategy. There will be separate gropus for English and French-speaking patients
9995401|NCT01489982|Experimental|Insomnia medications|Pharmacologic treatment will be individualized depending on patient characteristics and initial response. It will consist of two potential treatments - Doxepin or Zopiclone. Both of these agents are currently used commonly in the general population and also in PD patients. The agents will be prescribed exactly as any other medical prescription (i.e. patients will fill their own prescriptions at their own pharmacy).The decision for which agent to use will be as follows: a)If patients suffer from sleep onset insomnia (with or without sleep maintenance insomnia), or if doxepin is contraindicated, Zopiclone will be prescribedb) or b)If patients suffer from sleep maintenance insomnia only (or if Zopiclone is contraindicated), Doxepin will be the first choice agent.
9995402|NCT01489982|Placebo Comparator|Placebo intervention of light therapy|The inactive/placebo intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles. This therefore functions as a placebo condition for the active light therapy protocol. Patients be informed that some forms of light therapy will be expected to be less active, but we will not disclose what type of condition is inactive.
9995403|NCT01489995|Experimental|Reference|Fasted
9995404|NCT01489995|Experimental|Glucose Drink|Fed
9995405|NCT01489995|Experimental|Before High Fat Meal|Fed
9995406|NCT01489995|Experimental|Before Light Meal|Fed
9995407|NCT01489995|Experimental|After Light Meal|Fed
9995408|NCT01490008|Experimental|Veregen|Veregen® (sinecatechins) Ointment, 15%, local application of 250 mg corresponding to 0.5 cm strand of ointment, 3 times daily (total dose of 750 mg/d)
9995409|NCT01490008|Active Comparator|Tea|"Lipton® Green Limone, a green tea beverage; oral intake of 500 mL green tea, 3 times daily (total dose on 1500 mL/d)"
9995410|NCT01490021|Experimental|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
9995411|NCT01490021|Placebo Comparator|rTMS/Placebo TBS|rTMS/Placebo TBS
9995412|NCT01490034|Experimental|Energy dense beverage|Metabolic effects of consuming energy dense beverages before and after regular consumption
9995413|NCT01490034|Experimental|Energy dense solid food form|Metabolic effects of consuming energy dense solid foods before and after regular exposure.
9914186|NCT00746174|Active Comparator|Rosiglitazone|Subjects in this arm will be randomly assigned to treatment with Rosiglitazone 4mg daily. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The dose will then be increased to Rosiglitazone 8mg daily (if indicated). The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
9914187|NCT00746174|Placebo Comparator|Placebo|Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
9914188|NCT00746200|Experimental|A|
9914189|NCT00746200|Sham Comparator|S|
9914190|NCT00746226|Active Comparator|A|Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
9914191|NCT00746226|Placebo Comparator|B|"Numbers 612-624 and 800-811~Microcrystalline cellulose"
9914192|NCT00746265|Active Comparator|SBT|Standard behavioral treatment based on the LEARN manual.
9914193|NCT00746265|Active Comparator|ABT|Acceptance-based group that is based on the behavioral interventions contained in LEARN manual
9914194|NCT00746278|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
9914195|NCT00746278|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
9914196|NCT00746278|Active Comparator|3|Laparoscopic ovarian cystectomy using suture
9914197|NCT00746291|Experimental|A|Traumatic brain injury
9914198|NCT00746291|Experimental|B|Cerebral palsy
9914199|NCT00746291|Experimental|C|Controls
9914200|NCT00746304||1|infantile esotropia
9914201|NCT00746304||2|acquired esotropia
9914202|NCT00746317|Experimental|1|
9914203|NCT00746343|Experimental|IRRI|"The integrated risk reduction intervention (IRRI) consists of three components:~psychiatric treatment by a study psychiatrist~assessment, referral, monitoring, and coordination by a certified registered nurse practitioner (CRNP) of medical treatment provided by the subject's own primary care physician~a healthy lifestyle behaviors program delivered by a lifestyle coach. The treating psychiatrist will work in collaboration with a CRNP and a lifestyle coach. The CRNP will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care and will follow-up on adherence to the medical treatment recommendations. The CRNP will be responsible for coordinating the psychopharmacological care provided by the psychiatrist, the healthy lifestyle behaviors program that will be delivered by the lifestyle coach, and the medical care provided by the subject's PCP."
9914204|NCT00746343|Experimental|PCCM|"Psychiatric Care with Medical Monitoring (PCMM)~The psychiatric care with medical monitoring condition (PCMM) consists of two components:~psychiatric treatment by a study psychiatrist~assessment and referral by a psychiatric research nurse for medical treatment provided by the subject's own primary care physician.~The treating psychiatrist will be assisted by a psychiatric nurse clinician who will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care."
9914205|NCT00746369|No Intervention|2|
9914206|NCT00746369|Experimental|Intervention|IMARA HIV Prevention Intervention. Three individual sessions for incarcerated female teens.
9914207|NCT00746382|Active Comparator|1|Roflumilast cream 0.5%
9914208|NCT00746382|Placebo Comparator|2|Placebo cream
9914209|NCT00746408||Main 1|Insurants of the health insurance company BARMER using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
9914210|NCT00746408||Main 2|Insurants of the health insurance company BARMER using search engines and portals to gather internet information about the type of headache they suffer from.
9914211|NCT00746408||Online 1|Internet users using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
9914212|NCT00746408||Online 2|Internet users using search engines and portals to gather internet information about the type of headache they suffer from.
9914213|NCT00746434|Active Comparator|1|Roflumilast cream 0.5%
9914214|NCT00746434|Placebo Comparator|2|Placebo cream
9914215|NCT00746447|Experimental|3.0g OD|
9914216|NCT00746447|Experimental|1.5g OD|
9914217|NCT00746447|Active Comparator|0.5g TID|
9914218|NCT00746460|Experimental|A|Behavioral
9914219|NCT00746473||1|15 HIV-1 infected individuals, with or without AIDS, who had never received ARV. These patients had not yet been indicated for ARV, or had had HIV-1 infection diagnosed a few days before inclusion in this study.
9914220|NCT00746473||2|"27 HIV-1 infected individuals, sick or not, on ARV treatment, five with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and one nonnucleoside reverse transcriptase inhibitor (NNRTI), and 22 on HAART with two NRTI, or one NRTI and one NNRTI, and one protease inhibitor (PI), and VL equal to or greater than 50 copies of plasma RNA/mL.~Treatment duration in this group varied between three and 145 months (mean 53.62 months; median 42 months)."
9914221|NCT00746473||3|31 HIV-1 infected individuals on ARV treatment, 16 on HAART with two NRTI, or one NRTI and one NNRTI, and one PI, and 15 with two NRTI and one NNRTI. All G3 patients had undetectable VL for at least the past 6 months. Treatment in this group varied between five to 108 months (mean 48.13 months; median 42 months).
9998022|NCT01514084||PNP group|Patients whose lacerations have been repaired by PNPs.
9995414|NCT01490034|Experimental|Eenergy dilute beverages|Metabolic effects of consumption of energy dilute beverages on a regular basis.
9995415|NCT01490034|Experimental|Energy dilute solid food form|Metabolic effects of consuming energy dilute sold foods before and after regular exposure.
9995416|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 40 mg/m²|Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²
9914222|NCT00746473||4|20 blood donors without clinical complaints and negative for anti-HIV-1/2 antibodies. None of them showed any sign of disease.
9914223|NCT00746486|Experimental|A|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
9914224|NCT00746486|Active Comparator|B|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
9914225|NCT00746499|Experimental|1|No control group, only one active arm with subjects taking Raltegravir.
9914226|NCT00746525|Experimental|Brain Computer Interface Training Stroke Experimental Group|Individuals in the stroke experimental group received treatment with BCI, FES, and motor learning targeted at their upper extremity motor deficits following stroke.
9914227|NCT00746538|Experimental|1|metallic stent group
9914228|NCT00746538|Active Comparator|2|plastic stent group
9914229|NCT00746629|Active Comparator|Prescribed Skills|Behavioral skills are all prescribed and considered necessary tools expected to be used consistently, completely, and uniformly by all participants throughout treatment
9914230|NCT00746629|Experimental|Self-Directed Skills|Behavioral skills are considered a tool box from which families are encouraged to select skills that best apply to that family's situation in attempts to help their child make eating and activity change.
9914231|NCT00746642|Experimental|A|"Glucose measurements using Mellitor device."
9914232|NCT00746642|Active Comparator|B|"Glucose measurements conducted by using gold standard, Yellow Springs glucose analyzer"
9914233|NCT00746655|Other|SBRT / TACE|
9914234|NCT00746681|Experimental|A|Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
9914235|NCT00746681|Active Comparator|B|Tolterodine SR 4 mg once daily
9914236|NCT00746681|Placebo Comparator|C|Placebo
9914237|NCT00746681|Experimental|D|Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
9914238|NCT00746681|Experimental|E|Pregabalin 150 mg twice daily
9914239|NCT00746707|Experimental|1|use of octyl-2-cyanoacrylate adhesive glue for perineal tear grade 1 in 80 women
9914240|NCT00746707|Active Comparator|3|use of traditional suturing for perineal tear grade 1 in 50 women
9914241|NCT00746720|Experimental|A, 1|Study part 1 (n = 8)
9914242|NCT00746720|Placebo Comparator|A, 2|Study part 1 (n = 4)
9914243|NCT00746720|Experimental|B, 1|Study part 2 (n = 20)
9914244|NCT00746720|Placebo Comparator|B, 2|Study part 2 (n = 20)
9914245|NCT00746759||Standard of Care|
9914246|NCT00746772|Active Comparator|1|Patients with oral lichen planus
9914247|NCT00746772|Placebo Comparator|2|Patients with oral lichen planus
9914248|NCT00746811|Other|1|P-OM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment.
9914249|NCT00746811|Other|2|Placebo for the first six weeks of treatment. P-OM3 for the second six weeks of treatment.
9914250|NCT00746824|Experimental|1|"AM dose: 0.85 mg~PM dose: placebo"
9914251|NCT00746824|Experimental|2|"AM dose: 0.85 mg~PM dose: 0.85 mg"
9914252|NCT00746824|Experimental|3|"AM dose: 2.55 mg~PM dose: placebo"
9914253|NCT00746824|Experimental|4|"AM dose: placebo~PM dose: 2.55 mg"
9914254|NCT00746824|Experimental|5|"AM dose: 2.55 mg~PM dose: 2.55 mg"
9914255|NCT00746824|Experimental|6|"AM dose: placebo~PM dose: placebo"
9914256|NCT00746837|Experimental|1|Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
9914257|NCT00746837|Experimental|2|2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose
9914258|NCT00746850|Experimental|H|early LC within 72 hours after the diagnosis with H (Harmonic)
9914259|NCT00746850|Active Comparator|MD|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
9914260|NCT00746876|Active Comparator|Unipolar|15 patients randomized for treatment with a unipolar hip hemiarthroplasty
9914261|NCT00746876|Active Comparator|Bipolar|15 patients randomized for treatment with a bipolar hip hemiarthroplasty
9914262|NCT00746902|Active Comparator|1|Arm 1: Active CPAP, a nasal continuous positive airway pressure
9914263|NCT00746902|Sham Comparator|2|Arm 2 : Sham CPAP :Placebo/CPAP
9914264|NCT00746967|Other|Arm 1|
9517608|NCT03304899|Experimental|Case group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).~Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.~Dose (mg/kg body weight) = ([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
9914265|NCT00746980|Experimental|Treatment|Subjects receiving drug
9914266|NCT00746993|Experimental|1|Structured contraceptive counseling and routine care.
9914267|NCT00746993|No Intervention|2|Routine care.
9914268|NCT00747019|Experimental|PBPA|
9914269|NCT00747019|Active Comparator|PE|
9914270|NCT00747032|Active Comparator|1|NYC 0462 Ointment
9914271|NCT00747032|Placebo Comparator|2|Placebo
9914272|NCT00747045|Experimental|Low tidal volume|Tidal volume of 6 mL/Kg ideal body weight
9914273|NCT00747045|Active Comparator|Usual care|Tidal volume of 10 mL/Kg ideal body weight
9914274|NCT00747058|Experimental|healthy volunteers|
9914275|NCT00747058|Placebo Comparator|Placebo|
9914276|NCT00747071|Experimental|1|Hospitalized patients with Clostridium difficile associated diarrhea.
9914277|NCT00747071|Experimental|2|Close hospital contacts of each index case
9914278|NCT00747084|Experimental|Arm 1: Study Treatment|Study Treatment: warm water loading of the sigmoid colon and warm water irrigation for dealing with colonic spasms.
9914279|NCT00747084|No Intervention|Arm 2: Control Treatment|Control Treatment: no water loading and waiting for spasms to subside.
9914280|NCT00747097|Experimental|1|gemcitabine+cetuximab
9914281|NCT00747110|Experimental|A|9mg budesonide OD
9914282|NCT00747110|Active Comparator|B|3g mesalazine OD
9914283|NCT00747162|Experimental|1|We will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
9914284|NCT00747175|Experimental|1|3 (alt.4) gradually increasing repeated oral doses of AZD1656 given to 3 (alt.4) groups (6 on active and 2 on placebo in each group)
9914285|NCT00747175|Experimental|2|Oral dose of AZD1656 titrated during 3 days to a tolerable dose (15 on active and 5 on placebo)
9914286|NCT00747188|Experimental|2|
9914287|NCT00747188|No Intervention|A, 2, III|
9914288|NCT00747201|Active Comparator|2 Packaged intervention only|Patients will be seen by providers who receive the intervention package only.
9914289|NCT00747201|Experimental|1 Packaged intervention, training, and technical assistance|Patients will be seen by providers who receive the packaged intervention, along with provider training and ongoing technical assistance.
9914290|NCT00747253|Experimental|Single Active Arm|Only Arm. Patients treated using AutoLITT System.
9914291|NCT00747279|Experimental|1|Carbohydrate restrictive strategy
9914292|NCT00747279|Active Comparator|2|Intensive insulin therapy
9914293|NCT00747292|Active Comparator|Epidural|Epidural
9914294|NCT00747292|Active Comparator|2|Spinal
9914295|NCT00747292|Active Comparator|3|Patients in this limb receive a PCA
9914296|NCT00747305|Experimental|Sunitinib|Sunitinib will be administered for 8 weeks prior to sugery
9914297|NCT00747331|Experimental|A|
9914298|NCT00747331|Placebo Comparator|B|
9914299|NCT00747357|Experimental|1|Balloon first
9914300|NCT00747357|Experimental|2|Stent First
9914301|NCT00747370|Other|1|16 healthy volunteers with no complaints of urinary symptoms and without urogenital prolapse of more than first degree.
9914302|NCT00747370|Other|2|Forty two stress urinary incontinence patients without prior urogenital prolapse or incontinence operation and without genital prolapse more than first degree
9914303|NCT00747370|Other|3|16 genital prolapse women without prior prolapse operations or any symptoms of incontinence
9914304|NCT00747383|Active Comparator|1|
9914305|NCT00747383|Active Comparator|2|
9914306|NCT00747396|Experimental|Foster Care Placement Group|Children randomized to this group were placed in high quality foster care developed for the study.
9914307|NCT00747396|No Intervention|Care As Usual Group|Children randomized to this group remained in institutional care.
9914308|NCT00747409|Active Comparator|Hum|use of human regular insulin and NPH insulin
9914309|NCT00747409|Active Comparator|Ana|use of insulin aspart and insulin detemir
9914310|NCT00747422|Experimental|I|
9914311|NCT00747487|Experimental|1|Idebenone
9914312|NCT00747487|Placebo Comparator|2|Placebo
9914313|NCT00747513|Experimental|I|intervention group
9914314|NCT00747526|Experimental|Rabeprazole sodium 5 mg|
9914315|NCT00747526|Experimental|Rabeprazole sodium 10 mg|
9914316|NCT00747539||1|This group will be composed of 165 HCV-infected people who are not also HIV infected.
9914317|NCT00747539||2|This group will be composed of 165 HCV-infected people who are also HIV infected.
9914318|NCT00747578||1|"AS patients who fit the modified New York criteria (1984)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
9914319|NCT00747578||2|"RA patients who fit the American College of Rheumatology (ACR) criteria (1987)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
10213052|NCT04682730|Experimental|Deliberative Loop|28-page Context-Setting Document; 2-page addendum to Context-Setting Document; 90 minute Deliberative session; 8-page post-session survey
9995417|NCT01490047|Experimental|rhTNF-α 50 µg/m² + Caelyx 40 mg/m²|Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²
9914320|NCT00747578||3|"SLE patients who fit the ACR revised criteria for the classification of SLE (1997)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
9914321|NCT00747604||Increlex patients|Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
9914322|NCT00747630|Experimental|Intervention|The group selected to watch the video.
9914323|NCT00747656||1|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and not eligible for bypass based on transport time
9914324|NCT00747656||2|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and eligible for bypass based on transport time, if 12 lead PHECG was possible
9914325|NCT00747656||3|12 lead ECG subjects with prehospital notification transported to nearest receiving ED adn not eligible for bypass to PCI center based on transport time
9914326|NCT00747656||4|12 lead PHECG subjects with prehospital notification bypassed past the nearest receiving ED to the PCI center.
9914327|NCT00747708|Experimental|Peripheral|Patients are randomised in a 1:1 ratio to receive granulocyte-colony stimulating factor (G-CSF) or placebo injection
9914328|NCT00747708|Experimental|Percutaneous intracoronary injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
9914329|NCT00747708|Experimental|Percutaneous intramyocardial injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intramyocardial injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
9914330|NCT00747721|Experimental|1|Dexmedetomidine
9914331|NCT00747760||1|Extended family members
9914332|NCT00747760||2|Control- subjects from the same town without known thyroid diseases
9914333|NCT00747799|Experimental|1|Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
9914334|NCT00747877|Experimental|Arm I|Patients receive high-dose melphalan IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.
9914335|NCT00747877|Experimental|Arm II|Patients receive low-dose cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.
9914336|NCT00747890|Active Comparator|I|
9914337|NCT00747890|Other|II|
9914338|NCT00747942|No Intervention|A|exercise referral to lifestyle activities at the level of moderate intensity without support
9914339|NCT00747942|Active Comparator|B|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
9914340|NCT00747968|Active Comparator|glp-1-analogue|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned
9914341|NCT00747968|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned.
9914342|NCT00747981|Experimental|A|Thoracic CT Scan
9914343|NCT00747994||1|
9914344|NCT00748007|Experimental|A|
9914345|NCT00748007|Placebo Comparator|Placebo|Placebo
9914346|NCT00748020|Active Comparator|group 1|Erythematogenic irradiation scheme
9914347|NCT00748020|Active Comparator|group 2|Suberythematogenic irradiation scheme
9914348|NCT00748046|Experimental|Radium-223 chloride (Xofigo, BAY88-8223)|The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
9914349|NCT00748059|Experimental|A|Patients with Orthostatic Hypotension
9914350|NCT00748111|Experimental|1|Sudden cardiac death hospitalized
9914351|NCT00748111|Experimental|2|Acute myocardial infarction
9914352|NCT00748111|Experimental|3|Angioplasty procedures programmed
9914353|NCT00748111|Experimental|4|Sudden cardiac death hospitalized without coronary syndrome
9914354|NCT00748137|Active Comparator|Fixed dose|Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
9914355|NCT00748137|Experimental|ezy-BICC dose calculation card|variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
9914356|NCT00748150|Experimental|1|
9914357|NCT00748163|Experimental|Stage IV Non-Small Cell Lung Cancer Patients|Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.
9914358|NCT00748176||A|
9914359|NCT00748202|Active Comparator|1|intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
9914360|NCT00748202|Active Comparator|2|subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.
9914361|NCT00748228|Experimental|A|10 mEq/day dietary sodium
9914362|NCT00748228|Experimental|B|150 mEq/day dietary sodium
9914363|NCT00748228|Experimental|C|300 mEq/day dietary sodium
9914364|NCT00748280|Experimental|1|ORCT
9914365|NCT00748280|Experimental|2|PCEM/PMTA
9914366|NCT00748293|No Intervention|A|PEG-ELS 2000 ml ingestion in the morning of colonoscopy
9914367|NCT00748293|Other|B|Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy
9914368|NCT00748306|Experimental|GSK2190915|Intervention
9914369|NCT00748306|Placebo Comparator|Placebo|
9914370|NCT00748319|Other|1|Detection of KIR receptor
9914371|NCT00748332|Active Comparator|1|Standard oral nutritional supplement
9914372|NCT00748332|Experimental|2|Omega-3-enriched oral nutritional supplement
9914373|NCT00748345|Experimental|1|Caspofungin (drug)
9914374|NCT00748358|Experimental|drug|drug
9914375|NCT00748371|Experimental|1|ASA 40mg daily for 8 weeks followed by 3 weeks of observation
9914376|NCT00748371|Experimental|2|ASA 1300mg daily for 8 weeks followed by 3 weeks of observation
9914377|NCT00748371|Placebo Comparator|3|Placebo: one Avicel (cellulose) capsule by mouth twice daily
9914378|NCT00748384||1|Self trained subjects
9914379|NCT00748384||2|supervised trained subjects
9914380|NCT00748397|Experimental|A|
9914381|NCT00748423|Experimental|1|Nitric Oxide in nitrogen
9914382|NCT00748423|Placebo Comparator|2|Nitrogen
9914383|NCT00748436|Placebo Comparator|A|Matching placebo twice a day
9914384|NCT00748436|Experimental|B|Betahistine 24 mg twice a day (48 mg/day total)
9914385|NCT00748436|Experimental|C|Betahistine 48 mg twice a day (96 mg/day total)
9914386|NCT00748449|Active Comparator|1|CT Colonography
9914387|NCT00748449|Active Comparator|2|Colonoscopy
9914388|NCT00748462|Experimental|1|Fractional CO2 laser resurfacing
9914389|NCT00748475|Experimental|Neurofeedback|
9914390|NCT00748488|Experimental|A|Physical Therapy aimed to promote the level of physical activity
9914391|NCT00748488|Active Comparator|B|Physical Therapy aimed to move safely
9914392|NCT00748527|Active Comparator|Arm I|Patients receive carboplatin IV over 30-60 minutes on day 1.
9914393|NCT00748527|Experimental|Arm II|Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
9914394|NCT00748592|Placebo Comparator|Placebo|
9914395|NCT00748592|Experimental|PD 0200390, 5 mg|
9914396|NCT00748592|Experimental|PD 0200390, 15 mg|
9914397|NCT00748592|Experimental|PD 0200390, 30 mg|
9914398|NCT00748618|Other|1|Standard vitamin treatment
9914399|NCT00748618|Active Comparator|2|50,000 I.U. of vitamin D3
9914400|NCT00748631|Experimental|1|balloon Kyphoplasty
9914401|NCT00748644|Experimental|1|Experimental drug = rituximab for maintenance
9914402|NCT00748644|Active Comparator|2|Comparator drug = azathioprine for maintenance
9914403|NCT00748670|Experimental|A|
9914404|NCT00748696|No Intervention|1|No intervention
9914405|NCT00748696|Experimental|2|patient receiving oral nutrition supplement
9914406|NCT00748696|Experimental|3|resistance training
9914407|NCT00748696|Experimental|4|patients receiving resistance training and oral nutritional supplement
9914408|NCT00748722||1|Female patients, age 18-60 years, suitable for breast reconstruction using the lower abdominal tissue.
9934353|NCT04882072|Experimental|Ustekinumab|"Double-blind (DB) Period: Participants will receive weight-ranged based ustekinumab (6 milligrams/kilogram[mg/kg]) as IV infusion at Week 0 followed by ustekinumab 90mg injection SC 8 weeks after initial IV dose, then every 8 weeks (q8w) thereafter until the end of the DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~Open Label Extension (OLE) period: Participants will receive ustekinumab SC injection at Week OL-0, followed by ustekinumab 90mg SC injection with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from first SC administration after end of DB period whichever is later.~Long-term Extension (LTE) Period: Participants who completed OLE period may be eligible to enter LTE and continue to receive ustekinumab 90mg SC injection q8w."
9934354|NCT04882072|Placebo Comparator|Placebo|"DB period: Participants will receive placebo intravenous (IV) infusion at Week 0 followed by placebo subcutaneous (SC) injection administration, 8 weeks after the initial IV dose, then q8w thereafter until the end of DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~OLE period: Participants will receive ustekinumab SC at Week OL-0, followed by SC administration of ustekinumab with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from the first SC administration after the end of DB period, whichever is later.~LTE Period: Participants who complete their participation in OLE period may be eligible to enter the LTE and continue to receive 90 mg SC ustekinumab q8w."
9995418|NCT01490047|Experimental|rhTNF-α 100 µg/m² + Caelyx 40 mg/m²|Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²
10213053|NCT04680403|Experimental|supervised exercise plan|patients will receive a tailored exercise regimen and behavior change techniques focused on adherence to the exercise program. These will be delivered by using a video platform, much liker telehealth clinic appointments. These telehealth visits will be over a 12-week period, occur 3 times a week, and last for 1 hour each.
10213054|NCT04680390|Experimental|Active-kINSHIP navigation intervention|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
10213055|NCT04680390|Active Comparator|Control-Standard Care|The control arm will be standard-of-care, which is as-needed case management for justice-involved women.
10213056|NCT04680260|Active Comparator|A: Standard of care|Standard decision making regarding adjuvant chemotherapy with fluoropyrimidine and oxaliplatin as per institutional standards.
10213057|NCT04680260|Experimental|B: ctDNA guided therapy approach|Post ablation ctDNA results will be used for treatment decision.
10213058|NCT04678193||COVID19 PCR positive test and negative or high risk asymptomatic|Patient population COVID-19 infection risk assessment real time epidemiology with 27000 subjects
9799003|NCT01646645|Experimental|Group I|This is a single-arm non-randomized single institution phase 2 trial, designed to evaluate the therapeutic activity of CMVpp65-CTLs generated from seropositive HSCT donors when adoptively transferred into transplant recipients with persistent CMV infection or viremia. Patients eligible for this trial will be consenting recipients of related or unrelated HSCT who have an active CMV infection or persistent CMV viremia for ≥ 2 weeks despite treatment with anti-viral agents or who cannot be maintained on anti-viral therapy due to treatment related toxicity.
9799004|NCT01646671|Experimental|LCZ696 200 mg|All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
9799005|NCT01646671|Experimental|LCZ696 400 mg|All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
9799006|NCT01646671|Experimental|LCZ696 400 mg plus other hypertension (HTN) medications|All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
9799007|NCT01646762|Experimental|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9799008|NCT01646814|Experimental|PL2200|Investigational product, PL2200
9799009|NCT01646814|Active Comparator|Aspirin tablets|Active comparator, 325 mg aspirin tablets
9799010|NCT01646827|Experimental|Deltoid|Deltoid injection site
9799011|NCT01646827|Experimental|Gluteal|Gluteal injection site
9799012|NCT01647217|Experimental|Terpinen-4-ol Treatment Arm|8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
9799013|NCT01647217|Placebo Comparator|Placepo Pads Contol Arm|9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
9800371|NCT01685801|Experimental|Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
9800372|NCT01685840|Experimental|Usual Care|Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
9800373|NCT01685840|Experimental|Biomarker-Guided Care|Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
9800374|NCT01685983|Experimental|Abiraterone actetate and Prednisolone|
9800375|NCT01685996|Experimental|zonisamide|participants will receive zonisamide capsules (up to 300 mg) to take once a day.
9800376|NCT01685996|Placebo Comparator|Placebo|Participants will receive placebo capsules to take once a day
9800377|NCT01686152|Experimental|Investigational Test Product|Imiquimod Cream, 3.75% (Teva)
9914409|NCT00748735||A1|heart failure patients undergoing CRT implantation
9800378|NCT01686152|Active Comparator|Reference Listed Drug|Zyclara® (imiquimod Cream), 3.75% (Medicis)
9800379|NCT01686152|Placebo Comparator|Vehicle|Vehicle of Test Product (Teva)
10213059|NCT04678193||COVID19 PCR positive test Stage 1 infection|Patient population of PCR positive COVID-19 Stage 1 infection in registry targeted for ECL-19 treatment for reduced hospitalization with 2700 subjects (10% ECL-19 and 20% Placebo)
9914410|NCT00748748|Experimental|1|Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
9914411|NCT00748761|Experimental|OCD Active CBT|Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
9914412|NCT00748761|Active Comparator|OCD Waitlist|Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
9914413|NCT00748761|No Intervention|Healthy Controls|Healthy control children will be given no intervention.
9914414|NCT00748774||MDASI-BT|MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) questionnaire given to patients with a primary brain tumor and their caregivers.
9914415|NCT00748787|Experimental|1|
9914416|NCT00748787|Placebo Comparator|2|
9914417|NCT00748800|Experimental|1|
9914418|NCT00748800|Active Comparator|2|
9914419|NCT00748813|Other|1|
9914420|NCT00748891|Experimental|1|Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression
9914421|NCT00748930||Cohort 1|Subjects previously enrolled in the ATTRACT trial from three Canadian sites.
9914422|NCT00748995||Neurocognition Deployment Health Study (NDHS) participants|Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.
9914423|NCT00749008||Term Infants|High risk infants with history of respiratory insufficiency requiring NICU care.
9914424|NCT00749008||Preterm Infants|Infants less than 37 weeks gestational age.
9914425|NCT00749021|Active Comparator|Regimen 1|Intravitreal injection of Ranibizumab monthly for 12 months.
9914426|NCT00749021|Active Comparator|Regimen 2|Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
9914427|NCT00749021|Active Comparator|Regimen 3|Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
9914428|NCT00749021|Active Comparator|Regimen 4|Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
9914429|NCT00749034|Experimental|1|VPM1002 in three dosages
9914430|NCT00749034|Active Comparator|2|BCG
9914431|NCT00749047|Experimental|1|Open label arm
9914432|NCT00749060|Other|1|conventional treatment
9914433|NCT00749060|Other|2|kyphoplasty by balloons
9914434|NCT00749060|Other|3|vertebroplasty
9914435|NCT00749086|Experimental|2|balloon kyphoplasty
9914436|NCT00749086|Active Comparator|1|vertebroplasty
9914437|NCT00749099|Placebo Comparator|Phase I|All subject participate in Phase I
9914438|NCT00749099|Active Comparator|Phase II|All subject participate in Phase II
9914439|NCT00749112|Experimental|A|
9914440|NCT00749138|Experimental|tamoxifen|open label giving of tamoxifen
9914441|NCT00749151|No Intervention|Literature|
9914442|NCT00749151|Experimental|Lit + Counseling|
9914443|NCT00749177|Active Comparator|2|Traditional Healing arm Provides Traditional Healing options only
9914444|NCT00749177|Active Comparator|3|Traditional Healing and usual standard of care arm Subjects will access both treatment options
9914445|NCT00749177|Active Comparator|1|Treatment as usual
9914446|NCT00749229|Other|1|Balloon kyphoplasty
9914447|NCT00749242|Other|1|conventional orthopedic brace with antalgic treatment
9914448|NCT00749242|Other|2|balloon kyphoplasty introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
9914449|NCT00749255||FFDM|a sum of at least 200 cancer cases, mammographically visible, on at least one image view (including masses and calcifications)
9914450|NCT00749281||1|Patients with angiographically confirmed significant CAD
9914451|NCT00749281||2|Patients without significant CAD
9914452|NCT00749294||Observation|
9914453|NCT00749307|Experimental|1|
9914454|NCT00749307|Placebo Comparator|2|
9914455|NCT00749320|Other|ASL MRI|ASL MRI performed at different time intervals on participants receiving sunitnib or pazopanib for treating RCC
9914456|NCT00749333|Experimental|1|
9914457|NCT00749333|Placebo Comparator|2|
9914458|NCT00749346|Experimental|A|Treatment with concomitant Alimta and NovoTTF-100L
9914459|NCT00749359|Experimental|open label treatment|On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1.
9914460|NCT00749372|Other|1|Patients who meet eligibility will be sent for radiographic imaging to include T2* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
9914461|NCT00749385|Experimental|1|PN 400
9914462|NCT00749385|Active Comparator|2|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)
9914463|NCT00749385|Active Comparator|3|Enteric-coated naproxen tablet (500mg)
9914464|NCT00749385|Active Comparator|4|EC esomeprazole capsule (20mg)
9914465|NCT00749424|Experimental|1|crushing technique
9914466|NCT00749424|Active Comparator|2|provisional T stenting technique
9914467|NCT00749450|Experimental|Arm I|Patients receive OxMdG or XELOX combination chemotherapy for a total of 12 courses for treatment lasting a total of 24 weeks.
9914468|NCT00749450|Experimental|Arm II|Patients receive OxMdG or XELOX combination chemotherapy for a total of 6 courses for treatment lasting a total of 12 weeks.
9914469|NCT00749489|Experimental|Femoral Nerve Block|Intervention patients will have a continuous fascia iliaca blocks placed by a regional anesthesiologist 24 hours after the initial single injection femoral nerve block or at the time of surgery.
9914470|NCT00749489|No Intervention|No Intervention|No intervention
9914471|NCT00749502|Experimental|Part A-Dose escalation and confirmation|
9914472|NCT00749502|Experimental|Part B - Prostate/Ovarian Cancer Cohort|
9914473|NCT00749502|Experimental|Part C - T-PLL/CLL cohort|
9914474|NCT00749502|Experimental|Part D - CRC, endometrial, breast, and ovarian cancer cohort|
10213060|NCT04676932|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory will be applied to the intervention groups.~Care will given when women after receiving the HSG attendance appointment. Care will terminated on the 15 minutes after the end of HSG undergoing.~The time of the study 1-3 days for each women. Intervention Nursing Care Based on Kolcaba's Comfort Theory"
9914475|NCT00749528||1|Children vith recurrent wheezing
9914476|NCT00749528||2|Healthy children
9914477|NCT00749541||1normal catheter.|
9914478|NCT00749541||abnormal catheter.|
9914479|NCT00749554|Active Comparator|Disc biacuplasty|
9914480|NCT00749554|Placebo Comparator|Sham treatment.|
9914481|NCT00749567|Experimental|1|Erlotinib/Bevacizumab
9914482|NCT00749593||CaHASE 1|Adults with CAH
9914483|NCT00749619|Experimental|A|
10213061|NCT04676932|No Intervention|Routine hospital schedule|The researcher sincerely answered all questions asked by the control group during the HSG period.
9914484|NCT00749619|Experimental|B|
9914485|NCT00749619|No Intervention|C|
9914486|NCT00749645|Active Comparator|1 - FANG(30)|1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)
9914487|NCT00749645|Placebo Comparator|2 - Placebo|2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)
9914488|NCT00749710|Active Comparator|1|immediate operation - ORIF - of hip fracture in patient treated with clopidogrel
9914489|NCT00749710|Active Comparator|2|ORIF - surgical treatment patients not on antiaggregant therapy
9914490|NCT00749723|Experimental|1: P-HIT-REZ 2005|"intravenous chemotherapy with carboplatin/etoposide,followed by~high dose chemotherapy with thiotepa, carboplatin, etoposide and autologous stem cell transplantation if patient have achieved a complete remission or~maintenance therapy with oral trofosfamide, etoposide"
9914491|NCT00749723|Experimental|2: P-HIT-REZ 2005|"oral chemotherapy with temozolomide, followed by~high dose chemotherapy with temozolomide, thiotepa and autologous stem cell transplantation if patient have achieved a complete remission~maintenance therapy with oral temozolomide or in case of progression with oral trofosfamide, etoposide"
9914492|NCT00749723|Experimental|3: E-HIT-REZ 2005|Phase II: oral chemotherapy with temozolomide after progression oral trofosfamide, etoposide
9914493|NCT00749723|Experimental|Intraventricular Etoposide|Phase II, intraventricular chemotherapy with etoposide
9914494|NCT00749736|Active Comparator|1|4000 IU of cholecalciferol per day
9914495|NCT00749736|Active Comparator|2|1 mcg of doxercalciferol per day.
9914496|NCT00749736|Placebo Comparator|3|placebo for six months
9914497|NCT00749801|Active Comparator|A|nattokinase-mono formula (3500FU)
9914498|NCT00749801|Experimental|B|Nattokinase compound-multiple formulae
9914499|NCT00749801|Placebo Comparator|C|Placebo
9914500|NCT00749814|Experimental|A|Study group will receive melatonin.
9914501|NCT00749814|Placebo Comparator|B|Placebo
9914502|NCT00749814|No Intervention|C|No intervention control group.
9914503|NCT00749827|Active Comparator|1|Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours
9914504|NCT00749827|Active Comparator|2|Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
9914505|NCT00749840||HIV Care Questionnaire|Patients with a new diagnosis of HIV infection.
9934355|NCT04881162|Experimental|NOVIS Transcarotid Neuroprotection System (NPS)|Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS.
9998023|NCT01514084||RN group|Patients whose lacerations have been repaired by suture RNs.
10213062|NCT04672798|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinical trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
10213063|NCT04672798|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive treatment from their mental health clinician which may include safety planning.
10213064|NCT04672044|Active Comparator|active rTMS+Exercise|active rTMS
10213065|NCT04672044|Sham Comparator|sham rTMS+Exercise|sham rTMS
9914506|NCT00749853|Experimental|1|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
9914507|NCT00749853|Active Comparator|2|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
9914508|NCT00749866|Active Comparator|1|Nebulised Gentamicin
9914509|NCT00749866|Placebo Comparator|2|Nebulised 0.9% Saline
9914510|NCT00749905|Experimental|1|Low fiber diet for 5 days prior to procedure
10213066|NCT04671355|Experimental|Trimbow|Pressurized metered dose inhaler
10213067|NCT04671355|Active Comparator|Relvar|Dry powder inhaler
9914511|NCT00749905|Active Comparator|2|regular diet
9914512|NCT00749918|Experimental|1|Each subject was evaluated and data was collected before and after the intervention
9914513|NCT00749983|Experimental|1|creatine intake
9914514|NCT00749983|Placebo Comparator|2|placebo (dextrose) intake
9914515|NCT00750009|Experimental|Arm I (PRE-ACT)|Patients receive tailored feedback and video content to address clinical trial barriers following baseline assessment.
9914516|NCT00750009|Active Comparator|Arm II (control)|Patients receive generic clinical trials educational feedback taken from NCI publications following baseline assessment.
9914517|NCT00750022|Experimental|E1|
9914518|NCT00750022|Active Comparator|A1|
9914519|NCT00750035|Experimental|1|total abdominal hysterectomy and
9914520|NCT00750035|Experimental|2|Subtotal hysterectomy
9914521|NCT00750074||1|"During volume assist-control ventilation, a 0.4 second end-inspiratory pause will be set and the following pressures measured: peak pressure; plateau pressure; and PEEP. The following ventilator settings will be recorded: inspiratory flow; expired tidal volume; and rate. The presence or absence of autoPEEP will be noted.~During pressure-control ventilation, the flow versus time waveform will be printed from the ventilator using a conventional computer printer for later analysis. The following ventilator settings will be recorded: inspiratory pressure; PEEP; and expired tidal volume."
9914522|NCT00750087||1|Schizophrenia patients stabilized on Seroquel XR
9914523|NCT00750100|Active Comparator|A|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.
9914524|NCT00750100|Experimental|B|Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
9914525|NCT00750113|Experimental|Arm 1|
9914526|NCT00750113|Experimental|Arm 2|
9914527|NCT00750113|Experimental|Arm 3|
9914528|NCT00750178|Experimental|A|MK0683
9914529|NCT00750230|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 30 days.
9914530|NCT00750256|Experimental|Cohorts|This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
10213068|NCT04663620|Active Comparator|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
10213069|NCT04663620|Placebo Comparator|No Saving Babies Lives Programme|Control arm
10213070|NCT04660929|Experimental|Group 1 and Group 2|Both groups will receive the full dose manufactured per patient. Group 1 will undergo intra subject dose escalation of IV administrations of up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5. Group 2 will receive the full dose IV on Day 1 of up to 5 billion cells.
10213071|NCT04652453|Experimental|Post-Intervention Group (Geriatrics Bundle)|Enrolled participants in the intervention arm will receive all 3 components of the geriatrics bundle: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
10213072|NCT04652453|No Intervention|Pre-Intervention Group (Control)|Participants in the control arm will be enrolled prior to implementation of the geriatrics bundle to gather preliminary data about the secondary outcomes.
10213073|NCT04651400||COVID-19 patients who had received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
10213074|NCT04651400||COVID-19 patients who had not received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
9914531|NCT00750334|Experimental|Part A|clofarabine Dose Escalation
9914532|NCT00750334|Experimental|Part B|Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.
9914533|NCT00750386|Experimental|1|Paclitaxel/Carboplatin
9914534|NCT00750399|Experimental|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab on a monthly basis depending on response to treatment
9914535|NCT00750412|Experimental|TeenScreen|
9914536|NCT00750412|No Intervention|Treatment As Usual|
9914537|NCT00750425|Experimental|1|Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
9914538|NCT00750451|Experimental|LMWH|Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
9914539|NCT00750451|Active Comparator|Control|Women in the control arm are administered routine luteal phase support without the addition of LMWH
9914540|NCT00750477|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 8 weeks
9914541|NCT00750477|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 8 weeks
9914542|NCT00750516||Lacid|Hypotensive, non pregnant by history, non comfort care Emergency Department patients.
9914543|NCT00750529|Experimental|Galantamine|
9914544|NCT00750568||Group 1|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages 2 years to 6 years"
9914545|NCT00750568||Group 2|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 6 years to 12 years"
9914546|NCT00750568||Group 3|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 12 years to 18 years"
9914547|NCT00750581|Placebo Comparator|Standard dose group|The infants randomized to the standard dose group will receive indomethacin (0.1 mg/kg) at 24 hr intervals for 5 days. These infants will also receive 5 extra doses of normal saline infusion of similar volume at 12 hrly intervals between the indomethacin schedules to match the Escalating dose Indomethacin Schedule
9914548|NCT00750581|Active Comparator|Escalating dose group|The infants randomized to the Escalating dose group will receive indomethacin started at 0.2 mg/kg/dose every 12 hours for 2 doses with stepwise increment in indomethacin dose by 0.1 mg/kg/dose every 24 hours upto maximum dose of 0.6 mg/kg/dose
9914549|NCT00750594||1|
9914550|NCT00750594||2|
9914551|NCT00750620|Experimental|1. Severe renal impairment|severe renal impairment
9914552|NCT00750620|Experimental|2. Moderate renal impairment|moderate renal impairment
9914553|NCT00750620|Experimental|3. Mild renal impairment|mild renal impairment
9914554|NCT00750620|Experimental|4. Normal renal function|normal renal function
9914555|NCT00750646||A|Subject's adherence to prescribed therapy will be monitored with an electronic compliance device.
9914556|NCT00750659|Experimental|1|Nilotinib treatment
9914557|NCT00750698|Experimental|1|"Erlotinib-responsive patients are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months."
9914558|NCT00750698|Experimental|2|"Erlotinib-nonresponsive patients are those who either progressed immediately during treatment with erlotinib (i.e. after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months."
9914559|NCT00750711|Experimental|KT,2|There are two arms in this study: KT2 arm and KT4 arm. Patients in KT2 arm will be ablated with the 2 mm irrigated catheter and patients in KT4 mm will be ablated with the 4 mm irrigated catheter.
9914560|NCT00750724|Placebo Comparator|B|2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks
9914561|NCT00750724|Experimental|A|2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks
9934356|NCT04880434|Experimental|Brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma will receive conditioning chemotherapy consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg, with a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 3.
9934357|NCT04879329|Experimental|Disitamab vedotin|Disitamab vedotin monotherapy
9934358|NCT04879160||1/ Cohort 1A|Clinician raters familiar with NF1
9934359|NCT04879160||2/ Cohort 1B|Clinician raters without specific NF1 familiarity
9934360|NCT04879160||3/ Cohort 2A|Non-clinician raters familiar with NF1
9934361|NCT04879160||4/ Cohort 2B|Non-clinician raters without specific NF1 familiarity
9934362|NCT04879160||5/ Cohort 3|Subjects with NF1
9934363|NCT04877977||Healthy Volunteers|Individuals who previously signed consent for ETPB research as healthy volunteers
9934364|NCT04877977||Mood Disorder Patients|Individuals with mood disorders who previously signed consent for ETPB research
9934365|NCT04871074|Active Comparator|Cognitively unimpaired|Results of most recent testing with the source cohort indicate the participant is cognitively unimpaired as judged by consensus or expert review.
9934366|NCT04871074|Active Comparator|Mild Cognitive Impairment|Abnormal cognitive status of MCI as judged by consensus or expert review using NIA-AA 2018 criteria.
9934367|NCT04871074|Active Comparator|Mild dementia|Abnormal cognitive status of dementia as judged by consensus or expert review using NIA-AA 2018 criteria.
9914562|NCT00750763|Active Comparator|1|PEG (Colonlytely) - 4 litres
9914563|NCT00750763|Active Comparator|2|Picosulphate (Picolax/Picoprep) - 2 sachets
9914564|NCT00750763|Active Comparator|3|Sodium Phosphate (Fleet) - 2 bottles
9914565|NCT00750802|Experimental|1|
9914566|NCT00750802|Experimental|2|
9914567|NCT00750802|Active Comparator|3|
9914568|NCT00750802|Placebo Comparator|4|
9914569|NCT00750854|Experimental|NEM Treatment 1|NEM Formulation X (#0802), 500 mg, once daily, orally
9914570|NCT00750854|Experimental|NEM Treatment 2|NEM Formulation Y (#0505), 500 mg, once daily, orally
9914571|NCT00750932||T|Control
9914572|NCT00750932||M|Minor with cystic fibrosis
9914573|NCT00750932||A|Adult with cystic fibrosis
9914574|NCT00750945|Experimental|A|Treadmill with Music cueing group
9914575|NCT00750945|Active Comparator|B|Treadmill group
9914576|NCT00750945|Placebo Comparator|C|Home walking group
9914577|NCT00750958|No Intervention|1|ED patients that are not monitored with conventional therapy.
9914578|NCT00750971|Experimental|1|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
9914579|NCT00750971|Active Comparator|2|Best currently available immunosuppressive/immunomodulatory therapy
9914580|NCT00750984|Experimental|1|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
9914581|NCT00750984|Active Comparator|2|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
9914582|NCT00750997||Hypertonic saline|Hypertonic resuscitation
9914583|NCT00750997||Control: normal saline|Normal saline resuscitation
9914584|NCT00751010||1|In a mailed survey (Part 1 of this study), 127 women with a documented diagnosis of IC agreed to be contacted for an in-office examination.
9914585|NCT00751049|Experimental|PhXA41|
9914586|NCT00751049|Active Comparator|timolol|
9914587|NCT00751062|Active Comparator|Timolol|
9914588|NCT00751062|Experimental|PhXA41|
9914589|NCT00751088|Active Comparator|1|Patients treated with Ajust positioning
9914590|NCT00751088|Active Comparator|2|Patients treated with MiniArc positioning
9914591|NCT00751088|Active Comparator|3|Patients treated with TVT secur system
9914592|NCT00751088|Active Comparator|4|Patients treated with tension free vaginal tape
9914593|NCT00751127|Active Comparator|Timolol|
9914594|NCT00751127|Experimental|PhXA41|
9914595|NCT00751192|Experimental|A|
9914596|NCT00751192|Active Comparator|B|
9914597|NCT00751205|Experimental|Arm 1|
9914598|NCT00751205|Placebo Comparator|Arm 2|
9914599|NCT00751244|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
9914600|NCT00751244|Active Comparator|2|12 weekly sessions of one-to-one PCT (psychotherapy)
9914601|NCT00751244|Other|3|90-day wait-list group
9914602|NCT00751257|Experimental|1|2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
9914603|NCT00751257|Placebo Comparator|2|"Identically appearing placebo pills, packaged in an N-acetylcysteine slurry so that placebo will retain smell similar to active NAC capsules"
9914604|NCT00751270|Experimental|A|Arm A for unresectable malignant glioma was closed due to poor accrual.
9914605|NCT00751270|Experimental|B|Arm B for resectable malignant glioma completed the Phase I accrual and long term follow up continues. A follow on study at dose level 3 was opened as a Phase 2a study (see BrTK02).
9914606|NCT00751283|Experimental|1|GRST Peripheral Catheter System
9914607|NCT00751309||1|Lung and heart-lung transplanted subjects.
9914608|NCT00751322|Active Comparator|1|RBC transfusion of 5 days or less storage age
9914609|NCT00751322|Active Comparator|2|RBC transfusion of conventional storage age
9914610|NCT00751361|Active Comparator|1|Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks
9914611|NCT00751361|No Intervention|2|No treatment control group
9914612|NCT00751374|Other|group A|Topical gentamicin cream
9914613|NCT00751374|Active Comparator|Group B|topical gentamicin cream alternates with mupirocin cream at monthly basis
9914614|NCT00751387||1|
9914615|NCT00751413|Experimental|1|MK0633
9914616|NCT00751452||1|
9914617|NCT00751452||2|
9914618|NCT00751465|Active Comparator|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997)
9914619|NCT00751465|Active Comparator|Standard CBT|standard Cognitive Behavior Therapy, standard CBT following the model of Clark and Wells (1995).
9914620|NCT00751465|No Intervention|Wait list control|Wait list control group
9914621|NCT00751478|Experimental|A|2 Placebo capsules (whole) + ALO-01 2 x 60 mg capsules (crushed) in apple juice + apple juice (MSIR placebo)
9914622|NCT00751478|Experimental|B|2 x 60 mg ALO-01 (whole) + 2 x placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
9914623|NCT00751478|Active Comparator|C|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + 120 mg MSIR in apple juice
9914624|NCT00751478|Placebo Comparator|D|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
9914625|NCT00751491|Active Comparator|III|
9914626|NCT00751491|Active Comparator|A|
9914627|NCT00751491|Placebo Comparator|placebo|
9914628|NCT00751517|Active Comparator|A|Cyclophosphamide
9914629|NCT00751517|Experimental|B|Methotrexate
9914630|NCT00751556|Experimental|Arm 1|
9914631|NCT00751556|Active Comparator|Arm 2|
9914632|NCT00751569||A1|A group of 3 to 5 pregnant women as donors for umbilical cord blood
9914633|NCT00751582|Experimental|2|Food supplementation and nutrition education
9914634|NCT00751582|Experimental|1|Nutrition Education only
9914635|NCT00751595|Experimental|ARM A (Tat Protein 7.5 or 30 microg 5X)|Group I: Subjects receiving 5 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 5 intradermal immunization with Tat (30 microg).
9914636|NCT00751595|Experimental|ARM B (Tat Protein 7.5 or 30 microg, 3X)|Group I: Subjects receiving 3 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 3 intradermal immunization with Tat (30 microg)
9914637|NCT00751608|Experimental|1|
9914638|NCT00751608|Active Comparator|2|
9914639|NCT00751608|Placebo Comparator|3|
9914640|NCT00751647|Other|A1|Population receiving the CF specific outpatient PT services.
9914641|NCT00751673||TESS prosthesis|Consecutive series of patients with a TESS prosthesis.
9914642|NCT00751686||RV GE Group|
9914643|NCT00751699|Experimental|1|Asacol 6x400 mg Q24h at 7 am for 7 days
9914644|NCT00751699|Experimental|2|Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days
9914645|NCT00751699|Experimental|3|Lialda 2x1.2g Q24h at 7 am for 7 days
9914646|NCT00751712||Back of skull cerebral oximeter sensor|All patients enrolled will receive non-invasive oxygen perfusion monitoring on the back of the skull during their standard of care congenital heart surgery
9914647|NCT00751738|Experimental|1|125 mg azimilide
9998024|NCT01514097||Fractures reduced|
9914648|NCT00751751|Experimental|1|oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks
9914649|NCT00751751|Active Comparator|2|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.
9914650|NCT00751764|Experimental|1|
9914651|NCT00751816||Supportive Care|head and neck cancer survivors who are undergoing chemotherapy and radiation therapy
9914652|NCT00751829|Experimental|1|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP
9914653|NCT00751829|Active Comparator|2|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
9914654|NCT00751842|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
9914655|NCT00751842|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
9914656|NCT00751842|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
9914657|NCT00751855|Active Comparator|1|Prolonged Exposure therapy with Hydrocortisone
9914658|NCT00751855|Placebo Comparator|2|Prolonged Exposure therapy with placebo
9914659|NCT00751868|Experimental|ARM 1|FEC e Ixabepilone. A goal of 48 patients will be enrolled in this study by 16 Italian centres of the GIM (Gruppo Italiano Mammella) Group. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled in the study
9914660|NCT00751907|Experimental|Atorvastatin|40mg Atorvastatin nightly for 4 months
9914661|NCT00751907|Placebo Comparator|Placebo|matching placebo nightly for 4 months
9914662|NCT00751920|Experimental|1|
9914663|NCT00751946|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
9914664|NCT00751946|Active Comparator|2|12 weekly sessions of one-to-one ETAU (psychotherapy)
9914665|NCT00751959|Active Comparator|2|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
9914666|NCT00751959|Experimental|1|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
9934368|NCT04870827||Affected Subjects|Subjects diagnosed with moderate- severe psoriasis
9934369|NCT04870827||Healthy Controls|Females and males 18 years of age or older
9995419|NCT01490047|Experimental|rhTNF-α 150 µg/m² + Caelyx 40 mg/m²|Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²
9995420|NCT01490047|Experimental|rhTNF-α 200 µg/m² + Caelyx 40 mg/m²|Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²
9995421|NCT01490047|Experimental|rhTNF-α 250 µg/m² + Caelyx 40 mg/m²|Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²
9995422|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 30 mg/m²|Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²
9995423|NCT01490099|Experimental|Treatment period 1|
9995424|NCT01490099|Active Comparator|Treatment period 2|
9995425|NCT01490112||IAsp|
9995426|NCT01490164||scoliosis|young adults requiring surgical correction
9995427|NCT01490177|Experimental|One|
9995428|NCT01490203||Group 1: HCC resection/RFA|Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
9995429|NCT01490203||Group 2: Potential liver donor|Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
9995430|NCT01490216|Other|lisdexamfetamine|open label
9995431|NCT01490229|Active Comparator|Ezetimibe|Patients assigned to ezetimibe will receive for 1 year ezetimibe (10 mg/day)
9995432|NCT01490229|Active Comparator|Nutraceuticals|Patients assigned to nutraceuticals will receive for 1 year 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg
9995433|NCT01490255|Active Comparator|Ranolazine|Patients will receive ranolazine (750 mg bid) for 15 days
9995434|NCT01490255|Active Comparator|Amlodipine|Patients will receive amlodipine (10 mg once daily) for 15 days
9995435|NCT01490268|Active Comparator|Sufentanil Group 1|Sufentanil Low Titration
9995436|NCT01490268|Active Comparator|Sufentanil Group 2|Sufentanil High Titration
9995437|NCT01490281|Experimental|water-based exercise intervention|
9995438|NCT01490281|Experimental|land-based exercise intervention|
9995439|NCT01490281|No Intervention|Control group|
9995440|NCT01490307|Experimental|FCU offered|
9995441|NCT01490307|No Intervention|No feedback or services offered|
9995442|NCT01490320|Placebo Comparator|Control|Parents in control group experienced a routine primary care visit.
9995443|NCT01490320|Experimental|Handout intervention|"Caregivers assigned to the hand-out group were instructed to read the AAP hand-out Pulling the Plug On TV Violence. This 2 page hand-out emphasizes the negative effect that television has on children's behavior and makes recommendations about limiting media. The RA did not supervise the reading of the handout."
9995444|NCT01490320|Experimental|Multimedia intervention|"Caregivers assigned to the multimedia group were instructed to watch Recommendation 3: Decrease Exposure to Violence from the Play Nicely program, a 5 minute video in English and Spanish that teaches caregivers about the negative impact of violent media and instructs parents about the importance of limiting media. The intervention was presented to the parents on a mobile laptop computer."
9995445|NCT01490333|Experimental|2500 IU Vitamin D3|
9995446|NCT01490333|Active Comparator|400 IU Vitamin D3|
9995447|NCT01490346||ART treated individuals|
9995448|NCT01490372||GDM offspring|Children born from gestational diabetes mellitus pregnancy
9995449|NCT01490372||No-GDM offspring|Children born from a normal pregnancy
9995450|NCT01490385|Active Comparator|LED Phototherapy|LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch).
9995451|NCT01490385|No Intervention|Control: conventional orthodontic tooth movement|
9995452|NCT01490398|Experimental|Rosuvastatin|Rosuvastatin 10mg qd for 12 months.
9995453|NCT01490411|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV.
9995454|NCT01490411|Experimental|20 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
9995455|NCT01490411|Experimental|80 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
9998025|NCT01514097||Fractures splinted|
9914667|NCT00751985|Experimental|1|Personalized normative feedback (PFI). The PFI was a single-session intervention; it was displayed in a single screenshot and addressed the participant by name. It consisted of a summary of the participant's weekly consumption, a comparison with maximum drinking limits and a graphical comparison of the participant's consumption to the average level in the municipality (gender-specific), followed by information about health and social risks of heavy drinking as well as links for further self-help material and a local alcohol treatment facility.
9914668|NCT00751985|Experimental|2|Self-help material (SHM). The SHM was a single-session intervention and was displayed in a single screenshot. It consisted of information about maximum drinking limits, followed by information about health and social risks of heavy drinking as well as links for further standardized self-help material and a local alcohol treatment facility.
9914669|NCT00751985|Placebo Comparator|3|Control
9914670|NCT00752011|Experimental|Carboplatin + TAS-106|Carboplatin starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle. TAS-106 starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
9914671|NCT00752024|Experimental|1|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
9914672|NCT00752024|Active Comparator|2|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
9914673|NCT00752037|Other|1|open label single arm
9914674|NCT00752063|Experimental|A|All subjects will receive Sorafenib with Capecitabine and Oxaliplatin
9914675|NCT00752076|Experimental|1|We collected malignant pleural effusion for NSCLC cell lines with different EGFR mutations development and then we can compare the difference responses and signal pathways in these cell lines. We can also explore the detailed mechanism of TKI responsive cancer cell and try to develop other agent to enhance the pathways.
9914676|NCT00752115|Active Comparator|A|Sildenafil plus carboplatin and weekly paclitaxel
9914677|NCT00752115|Placebo Comparator|P|carboplatin and weekly paclitaxel
9914678|NCT00752141|Experimental|1|oral oxybutynin
9914679|NCT00752141|Experimental|2|oxybutynin topical gel
9914680|NCT00752141|Placebo Comparator|3|placebo tablets plus placebo gel
9914681|NCT00752167||Case|all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
9914682|NCT00752167||Control|control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
9914683|NCT00752180|Experimental|Wosulin R|Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
9914684|NCT00752180|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
9914685|NCT00752245|Experimental|1|Dialysis during 4 hours
9914686|NCT00752245|Active Comparator|2|Dialysis during 6 hours
9914687|NCT00752245|Active Comparator|3|Dialysis during 8 hours
9914688|NCT00752271||1|24 adults with meniscal damage for which arthroscopy is clinically indicated
9914689|NCT00752271||2|8 adults who have already undergone meniscal resection to serve as positive controls
9914690|NCT00752284|Experimental|A|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
9914691|NCT00752284|Active Comparator|B|"Control Group:~total excision of lower wisdom tooth"
9914692|NCT00752323|Experimental|Arm I: Newly diagnosed GBM 10mg/kg|Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours before the midpoint of surgery.
9914693|NCT00752323|Experimental|Arm II: Newly diagnosed GBM 20mg/kg|Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
9914694|NCT00752323|Experimental|Arm III: Recurrent GBM 10mg/kg|Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours before the midpoint of surgery.
9914695|NCT00752323|Experimental|Arm IV: Recurrent GBM 20mg/kg|Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
9914696|NCT00752362|Active Comparator|1|Percutaneous coronary intervention with bare metal stent
9914697|NCT00752362|Experimental|2|Percutaneous coronary intervention with paclitaxel-eluting stent
9914698|NCT00752362|Experimental|3|Percutaneous coronary intervention with sirolimus-eluting stent
9998026|NCT01514110|Experimental|RAD001|
9998027|NCT01514123|Experimental|Arm A - VGX-100 alone|Dose escalation of VGX-100 monotherapy
9914699|NCT00752375|Active Comparator|A|Eligible children will be randomized to antibiotic prophylaxis. Children under 3 months will receive amoxicillin 10mg/kg once per day. Children >3months will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component). Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day.
9914700|NCT00752375|Placebo Comparator|B|Eligible children will then be randomized to placebo.
9914701|NCT00752401|Active Comparator|1|6800 IU/day of Cholecalciferol (Vitamin D3) orally for one year
9914702|NCT00752401|Placebo Comparator|2|Oral placebo solution daily for one year
9914703|NCT00752414|Experimental|1|MP-376 Inhalation Solution
9914704|NCT00752414|Placebo Comparator|2|Placebo
9914705|NCT00752453|Experimental|1|Dialysis during 4 hours
9914706|NCT00752453|Experimental|2|Dialysis during 6 hours
9914707|NCT00752453|Experimental|3|Dialysis during 8 hours
9914708|NCT00752479|Experimental|1|
9914709|NCT00752479|Active Comparator|2|
9914710|NCT00752492|Active Comparator|Study intervention|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. Ventilation will be assisted to maintain tidal volume of 8-10 mL/kg and respiratory rate of 20-25 breaths per minute to achieve minute ventilation of 15-20 L/min. Isocapnia manifold will maintain end-tidal PCO2 in range of 40-50 mm Hg.
9914711|NCT00752531|Experimental|HAT|
9914712|NCT00752531|No Intervention|Control|
9914713|NCT00752583|Experimental|1|Peritoneal dialysis
9914714|NCT00752583|Active Comparator|2|Haemodialysis
9914715|NCT00752596|Experimental|1|1 tablet of 125 mg/day of azimilide 2HCl, oral
9934370|NCT04866823|Experimental|Medically Tailored Meals|A series of medically tailored meals appropriate for women with gestational diabetes will be developed in partnership with chefs from a local community kitchen and catering company. Meals will create a slight caloric deficit in order to promote gradual weight loss, but with sufficient energy intake and macronutrient balance to allow breastfeeding. These meals will be roughly 40% carbohydrate, 30% protein, and 30% fat in composition. Study Team will plan up to 20 unique lunch and dinner meals for the series. Each meal will be prepared to be between 450-600 kcal and to contain 6 ounces of protein, 4 ounces of vegetable and I cup of whole grain (at a minimum). Participants will receive detailed recipe cards and nutrition information with each meal. In addition to receiving the medically tailored meals, participants will be advised to supplement their own breakfast +/- snacks to reach a total daily calorie goal determined by starting BMI category.
9934371|NCT04866823|No Intervention|Usual Care Comparison Group|Participants in this group will receive written materials on self-care, nutrition, and physical activity in the postpartum period and community resources for healthy living.
9934372|NCT04866810|Experimental|1|Intervention
9934373|NCT04866810|Other|2|Control- Standard diet and Exercise
9934374|NCT04865679|Experimental|Axoguard Nerve Cap®|"Active Comparator: Porcine derived extracellular matrix (ECM) based Nerve Termination Device~Implantation of appropriate diameter of Axoguard Nerve Cap® (sizes 5-7 mm) at the time of surgery"
9934375|NCT04864886||Healthy volunteers|Control group
9934376|NCT04864886||Patients with atopic dermatitis|Physician-diagnosed atopic dermatitis
9934377|NCT04864886||Patients with primary immunodeficiency|Confirmed by genetic diagnosis or suspected by genetic variant of unconfirmed significance and a history consistent with immunodeficiency
9934378|NCT04864886||Patients with psoriasis|Physician-diagnosed psoriasis
9914716|NCT00752674|Experimental|1|Neuromuscular balance
9914717|NCT00752687|Other|1|Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers
9914718|NCT00752687|Other|2|HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD
9914719|NCT00752700|No Intervention|1|Control group
9914720|NCT00752700|Active Comparator|2|Conventional resistance training program (CRT)
9914721|NCT00752700|Experimental|3|Whole body vibration resistance training (WBV) on the FITVIBE-platform
9914722|NCT00752713||1|Patients presenting to hospital with AMI
9914723|NCT00752713||2|healthy volunteers as control group
9914724|NCT00752739|Placebo Comparator|Arm I|Patients receive oral placebo once daily for 48 months in the absence of disease progression or unacceptable toxicity.
9914725|NCT00752739|Experimental|Arm II|Patients receive low-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
9914726|NCT00752739|Experimental|Arm III|Patients receive high-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
9914727|NCT00752804|Experimental|1|Dialysis during 4 hours
9914728|NCT00752804|Active Comparator|2|Dialysis during 6 hours
9914729|NCT00752804|Active Comparator|3|Dialysis during 8 hours
9914730|NCT00752817|Experimental|SC|Subjects (surgical trainees) randomised to train under a proficiency-based progression virtual reality simulation curriculum
9914731|NCT00752817|Active Comparator|CC|Subjects (surgical trainees) randomised to the current surgical training curriculum
9914732|NCT00752830|Experimental|1|AZD0328 administration during fasting condition
9914733|NCT00752830|Experimental|2|AZD0328 administration after food intake
9914734|NCT00752843|Experimental|1|
9914735|NCT00752869|Placebo Comparator|B|This group will meet the same inclusion and exclusion criteria as the group receiving the study drug
9914736|NCT00752869|Active Comparator|A|This arm will receive the active medication dutasteride
9914737|NCT00752921|Active Comparator|A|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
9914738|NCT00752921|Placebo Comparator|B|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
9914739|NCT00752934|Experimental|group a|Baclofen followed by Placebo
9914740|NCT00752934|Experimental|group b|Placebo followed by Baclofen
9914741|NCT00752947|Experimental|A|
9914742|NCT00752947|Active Comparator|B|
9914743|NCT00752960||A|Patients receiving olanzapine
9914744|NCT00752960||B|patients receiving risperidone
9914745|NCT00752960||C|Patients receiving quetiapine
9914746|NCT00752960||D|Patients receiving aripiprazole
9914747|NCT00752960||E|patients receiving ziprasidone
9914748|NCT00752999|Experimental|A|150 mg tablet, oral, twice-a-day
9914749|NCT00752999|Placebo Comparator|B|Placebo tablet, oral, twice-a-day
9914750|NCT00753025|Experimental|CD133|
9914751|NCT00753025|Experimental|TNC|
9914752|NCT00753025|Placebo Comparator|Placebo|
9914753|NCT00753051|Active Comparator|1.|clozapine as the main agent and it will be adjuncted by haloperidol
9914754|NCT00753051|Active Comparator|2.|clozapine as the main agent and it will be adjuncted by electroconvulsive therapy
9914755|NCT00753064|Active Comparator|AScVS|a clinical scoring system for dose requirement for AScVS is evolved based on sweating, pulse rate, respiratory rate, blood pressure, CNS effects and presence of priapism. Computed doses were given according to clinical grading as intravenous bolus slowly.
9914756|NCT00753064|Active Comparator|Prazosin.|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
9914757|NCT00753064|Active Comparator|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin (500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
9914758|NCT00753090|Experimental|VG DDRP|This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee.
9914759|NCT00753090|Active Comparator|VG CR|This arm utilizes the Vanguard™ Cruciate Retaining Knee.
9914760|NCT00753103|Experimental|1|Patients with active vasculitis who receive infliximab in addition to standard immunosuppressive therapy
9914761|NCT00753103|Active Comparator|2|Patients with active ANCA associated vasculitis who receive standard immunosuppression but no infliximab
9914762|NCT00753129|Active Comparator|1|Start with turning to prone position without head elevation, after 2 hours 30° head elevation, after 2 hours back to PP without head elevation.
9914763|NCT00753129|Active Comparator|2|Start with turning to prone position with 30° head elevation, after 2 hours PP without head elevation, after 2 hours back to 0° PP.
9914764|NCT00753168|Experimental|1|OT-730 ophthalmic solution
9914765|NCT00753168|Active Comparator|2|timolol maleate ophthalmic solution
9914766|NCT00753168|Placebo Comparator|3|placebo eye drops
9914767|NCT00753181|Experimental|A1|Diabetes Meal Plan with Experimental Diabetes-Specific nutritional shake
9914768|NCT00753181|Active Comparator|A2|Usual diet
9914769|NCT00753181|Experimental|A3|Diabetes Meal Plan with Experimental Diabetes-Specific Nutritional Shake, diabetes specific Cereal, and diabetes specific snack bars.
9914770|NCT00753194||1|"Newborns that show a Pass On the newborn hearing screening program before hospital discharge"
9914771|NCT00753194||2|"Newborns that show a fail and will be retested in 15 days."
9914772|NCT00753207|Experimental|Lapatinib and Epirubicin|Fixed dose of lapatinib in combination with escalating dose of epirubicin.
9914773|NCT00753246|Placebo Comparator|Arm B|adults with TMZ, RT
9914774|NCT00753246|Experimental|Arm A|adults with TMZ, RT, nimotuzumab
9914775|NCT00753259|Experimental|AF Clinic|
9914776|NCT00753259|Active Comparator|Care as Usual|
9914777|NCT00753311|Active Comparator|Rizatriptan|Patients with migraine with and without aura will be enrolled and randomly provided with study drug (rizatriptan 10 mg MLT or placebo, ratio 1:1). Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
9914778|NCT00753311|Placebo Comparator|placebo|Patients who met all the study entry criteria were enrolled and randomly allocated to receive either rizatriptan 10 mg wafer or placebo (ratio 1:1).Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
9914779|NCT00753324|Experimental|Routine three-drug antiretroviral prophyalxis|Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
9914780|NCT00753324|No Intervention|Control arm|A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
9914781|NCT00753350|Experimental|1|Sensate™ anti-Obesity device
9914782|NCT00753389||1|
9914783|NCT00753402|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
9914784|NCT00753402|Active Comparator|B|IV Endotoxin plus IV epinephrine
9914785|NCT00753428||Baseline evaluation|Prior to the implementation of the pilot project of giving routine HAART as a method of PMTCT, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households for the first round.
9914786|NCT00753428||Following implementation|Two years after full implementation of the pilot project of giving routine HAART for PMTCT across all sites, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households. [Note: At time of implementation, we used the same sampling frame for each community. Because of the population increased observed in parts of Kafue, the final number of households significantly exceeded the minimum threshold.]
9914787|NCT00753441|Experimental|A|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
9914788|NCT00753441|Active Comparator|B|Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)
9914789|NCT00753467|Experimental|1|IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
9914790|NCT00753467|Experimental|2|IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
9914791|NCT00753467|Active Comparator|3|Adefovir dipivoxil monotherapy (10 mg QD) 30 days
9914792|NCT00753493|Experimental|1|This is a one arm pharmacokinetic and safety study.
9914793|NCT00753532|Placebo Comparator|MRI(+ve),|121 volunteers in MRI(+ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 62 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 59 received placebo. They were followed up every 3 months for a period of 2 years for their blood biochemistry profile and MRI of the brain was conducted at baseline, 12 months and 24 months..
9914794|NCT00753532|Placebo Comparator|MRI(-ve)|120 volunteers in MRI(-ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 63 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 57 received placebo. They were followed up every 3 months for a period of 1 year for their blood biochemistry profile and MRI of the brain was conducted at baseline and 12 months.
9914795|NCT00753558|Placebo Comparator|2|Oral solution of 0.45% saline and oral solution of H2O & saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene
9914796|NCT00753558|Active Comparator|1|Oral solution and buccal gel of gentamicin and polymyxin E
9914797|NCT00753571|Active Comparator|1|1,CTG,po
9914798|NCT00753571|Placebo Comparator|2|
9914799|NCT00753597|Experimental|1|Receiving active treatment
9914800|NCT00753662|Active Comparator|1|15 patients in group 1 will be treated with 1Hz frequency
9914801|NCT00753662|Active Comparator|2|15 patients in group 2 will be treated with 1Hz frequency 10Hz
9914802|NCT00753662|Sham Comparator|3|15 patients in group 3 will be treated with SHAM (1Hz/10Hz)
9914803|NCT00753740|Experimental|12mg/m2/dose|12mg per meter squared per dose
9914804|NCT00753740|Experimental|15mg/m2/dose|15mg per meter squared per dose
9914805|NCT00753740|Placebo Comparator|Placebo|5% dextrose infusion (placebo)
9914806|NCT00753779|Experimental|1|colesevelam HCl Tablets and simvastatin tablets
9914807|NCT00753779|Placebo Comparator|2|simvastatin and Welchol placebo
9914808|NCT00753792|Active Comparator|1|methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
9914809|NCT00753792|Experimental|2|methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered
9914810|NCT00753818|Experimental|1|
9914811|NCT00753818|Experimental|2|
9914812|NCT00753818|Experimental|3|
9914813|NCT00753818|Other|4|Control
9914814|NCT00753831|Experimental|1|Aurosling
9914815|NCT00753857|Experimental|1|Participants received 2 ads for drugs to reduce cardiovascular risk with drug facts boxes second pages.
9914816|NCT00753857|Active Comparator|2|Participants receive the same 2 advertisements for drugs to reduce cardiovascular risk with the standard second page (i.e., brief summary)
9914817|NCT00753870|Experimental|A|Otherwise healthy smokers
9914818|NCT00753883|Active Comparator|1|simvastatin 20 mg/qd for 8 weeks, and then add on ezetrol 10mg (if ldl-c . 160mg/dl) for another 8 weeks.
9914819|NCT00753883|Active Comparator|2|ezetrol 10 mg/qd for 8 weeks, and then add on simvastatin 20 mg qd (if ldl-c . 160mg/dl) for another 8 weeks
9914820|NCT00753909|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
9914821|NCT00753961|Active Comparator|1|fermented dairy product
9914822|NCT00753961|Placebo Comparator|2|non fermented acidified dairy product.
9914823|NCT00753974||biological specimen|Biological specimen is taken from cardiovascular procedures that would have been discarded
9914824|NCT00753987|Experimental|1|
9914825|NCT00754000||Cohort 1|All patients in study
9914826|NCT00754026|Active Comparator|1|
9914827|NCT00754026|Active Comparator|2|
9914828|NCT00754039|Experimental|1|Welchol + TriCor
9914829|NCT00754039|Placebo Comparator|2|Welchol + placebo
9914830|NCT00754078|Other|1|anal cancer patients treated with tomotherapy and chemotherapy
9914831|NCT00754091|Experimental|1|
9914832|NCT00754104|Experimental|A|
9914833|NCT00754117||All patients|All patients
9914834|NCT00754143|Placebo Comparator|A|Placebo
9914835|NCT00754143|Experimental|B|FG-3019 5 mg/kg
9914836|NCT00754143|Experimental|C|FG-3019 10 mg/kg
9914837|NCT00754182|Experimental|A|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with synthetic glue
9914838|NCT00754182|Active Comparator|B|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with subcuticular suture
9914839|NCT00754195|Active Comparator|1|Insertion distance of thoracic epidural catheter: 3 cm
9914840|NCT00754195|Active Comparator|2|Insertion distance of thoracic epidural catheter: 5 cm
9914841|NCT00754195|Active Comparator|3|Insertion distance of thoracic epidural catheter: 7 cm
9914842|NCT00754260|Experimental|Caffiene reduction group|Caffeine reduction group Intervention is to counseling to reduce caffeine intake
9914843|NCT00754260|No Intervention|No caffeine reduction group|No Caffeine reduction group Intervention is to not counsel regarding caffeine intake
9914844|NCT00754273||1|PAL samples collected for pneumonia evaluation
9914845|NCT00754286|Experimental|Aromatherapy|Participants will be given aromatherapy wand at the onset of their chemotherapy treatment.
9914846|NCT00754286|Placebo Comparator|Placebo|Participants will be given the placebo wand at the onset of their chemotherapy treatment. Placebo wands will look identical to the scented wands but will not contain a scent.
9914847|NCT00754312|Experimental|1|ER positive
9914848|NCT00754312|Experimental|2|ER negative and/or PR negative histology
9914849|NCT00754312|Experimental|3|triple negative histology (for ER, PR, HER-2)
9914850|NCT00754351|Experimental|1|Bevacizumab->Docetaxel->Gemcitabine
9914851|NCT00754364|Experimental|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2 infusion) plus Carboplatin (AUC5 infusion)
9914852|NCT00754364|Active Comparator|Gemcitabine|Gemcitabine 1250 mg/mq
9914853|NCT00754403|Experimental|Pioglitazone 30 mg QD + Metformin 1000 mg QD|
9914854|NCT00754403|Active Comparator|Metformin 1000 mg QD|
9914855|NCT00754416||S.E.S prosthesis|Consecutive series of patients with a S.E.S prosthesis.
9914856|NCT00754429|Experimental|A|Losartan 50mg qd for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
9914857|NCT00754429|Active Comparator|B|Amlodipine 5 mg q.d for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
9914858|NCT00754481|Active Comparator|1|
9914859|NCT00754481|Experimental|2|
9914860|NCT00754507|Experimental|1|colesevelam tablets and atorvastatin tablets
9914861|NCT00754507|Placebo Comparator|2|colesevelam HCl placebo tablets and atorvastatin tablets
9914862|NCT00754533|Other|1|Continuous training
9914863|NCT00754533|Other|2|Interval training
9914864|NCT00754585||I|"All participants will perform the five Chair Support tasks: (1) quiet standing, sitting, (2) upper back unsupported, (3) sitting, upper back unsupported with Logic Back in place, (4) sitting in a standard ergonomic chair, and (5) sitting in a standard ergonomic chair with Logic Back in place. Aside from the Quiet Standing trials which will be performed first, the order of Chair Support will be randomized. Participants will perform the Chair Support task for 30 minutes while quietly watching a movie DVD of their choice. The DVDs provided will the light in content without a lot of suspense or emotion. Data will be collected for the final two minutes of each 30-minute trial."
9914865|NCT00754637||510(k) Inclusion Criteria|Any person meeting the inclusion criteria for the device may be included in this study. These patients tend to be those seeking relief from painful or debilitating knee joint disease.
9914866|NCT00754663|Active Comparator|1|exercise training
9914867|NCT00754663|Placebo Comparator|2|control arm: normal behavior, no additional exercise will be advised
9914868|NCT00754689|Active Comparator|Arm 1|Metformin 500mg twice daily (bid) + placebo
9914869|NCT00754689|Active Comparator|Arm 2|Metformin 1000mg bid + placebo
9914870|NCT00754689|Active Comparator|Arm 3|Rimonabant 20mg once daily (od) + placebo
9914871|NCT00754689|Experimental|Arm 4|Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid
9914872|NCT00754689|Experimental|Arm 5|Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid
9934379|NCT04862858|Active Comparator|Intervention|The educational outreach intervention will entail a multi-faced strategy to provide patients resources to learn more about reducing their risk for heart disease and supporting providers in the care of their patients by sharing recent guideline-recommended treatments for these high-risk individuals.
9934380|NCT04862858|No Intervention|Control|Patients and primary care providers randomly selected and assigned to the control arm will not receive any of the educational outreach communications.
9934381|NCT04860778|Experimental|BDNF Essentials|A proprietary blend of botanical extracts and isolates.
10213075|NCT04651400||Non-COVID-19 patients who had received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
10213076|NCT04651400||Non-COVID-19 patients who had not received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
9934384|NCT04857996|Experimental|UBX1325|
9934385|NCT04857996|Sham Comparator|Sham Control|
9934386|NCT04857034|Experimental|Active Treatment: BMS-986165 Dose 1|
9934387|NCT04857034|Experimental|Active Treatment: BMS-986165 Dose 2|
9934388|NCT04857034|Placebo Comparator|Placebo|
9934389|NCT04856722|Experimental|mini-PNL group|In which PCNL will be performed using miniature nephroscope
9934390|NCT04856722|Experimental|RIRS group|In which RIRS will be performed using a flexible ureteroscope
9934391|NCT04856722|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
9934392|NCT04852692||Part A: Retrospective Phase|Retrospective collection of data for eligible participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) who initiated salvage treatments from initiation point (administration starting point of the salvage treatment) of the identified last-line of conventional salvage therapy for cGVHD treatment as their second-forth line therapy and will be collected for up to 24 weeks from the initiation point.
9934393|NCT04852692||Part B: Prospective Phase|Prospectively enroll participants with steroid dependent/refractory cGVHD that are decided to be treated with ibrutinib in second-fourth line therapy for the treatment of cGVHD. Participants will continue to receive corticosteroids as a standard of care.
9934394|NCT04852302|Experimental|Arm 1|Remote CALM therapy for participants with newly or recurrent PBT
9934395|NCT04852289||>=65 Female|Older Females
9934396|NCT04852289||>=65 Male|Older Males
9934397|NCT04852289||18-64 Female|Young Females
9934398|NCT04852289||18-64 Male|Young Males
9934399|NCT04852276||Control particpants|Control participants will be healthy volunteers, and may include unaffected relatives of immunodeficient/dysregulated participants
9934400|NCT04852276||Patients with immunodeficiencies and immune dysregulations|Affected patients with evidence of a primary or secondary immune deficiency or dysregulation
9934401|NCT04850963|Active Comparator|Group 1 - anodal tDCS|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 1 (anodic tDCS) the anodic electrode (5x5 cm) will be applied to the primary motor area (C3/C4) ipsilateral to the lesion and the reference electrode (6x9 cm) to the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
9935785|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg|Modakafusp alfa 0.001 up to 14 milligram per kilogram (mg/kg), infusion, intravenously (IV), once every week (Q1W) on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by once on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by once on Day 1 of each 28-day treatment cycle until treatment discontinuation.
10213077|NCT04650178||Observational (questionnaire, quality of life)|Patients complete an online questionnaire over 15 minutes about their experiences regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
10213078|NCT04644991|Experimental|Kinesiotape|Experimental group consisting of transfemoral amputees who kinesiology tape will be applied
10213079|NCT04644991|Sham Comparator|ShamKinesiotape|The placebo group of transfemoral amputees who shame kinesiology tape will be applied
10213080|NCT04640246|Experimental|TBX-3400|TBX-3400 by intravenous infusion
10213081|NCT04640142|Experimental|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion
10213082|NCT04639518|Experimental|Sub-study 1|Pre-term formulas with HMO
10213083|NCT04639518|Experimental|Sub-study 2|Pre-term formulas without HMO
10213084|NCT04634318|Active Comparator|Respiratory rehabilitation program group (RR).|Post-COVID-19 patients carrying out a respiratory rehabilitation program (RR).
10213085|NCT04634318|Experimental|Respiratory tele-rehabilitation program group (TRR).|Post-COVID-19 patients carrying out a respiratory tele-rehabilitation program (TRR).
10213086|NCT04627675|Experimental|1A: Age 18-50; CORVax|Healthy volunteers age 18-50 will receive CORVax
10213087|NCT04627675|Experimental|1B: Age 18-50; CORVax + pIL-12|Healthy volunteers age 18-50 will receive CORVax + pIL-12
9914873|NCT00754702|Experimental|1|Vinorelbine metronomic/Lapatinib
9914874|NCT00754715|Experimental|AZD2516|
9914875|NCT00754715|Placebo Comparator|Placebo|
9914876|NCT00754728|Experimental|I|
9914877|NCT00754754|Experimental|Brain Retraction Monitoring Sensor|
9914878|NCT00754819|Active Comparator|1|Colchicine 1mg daily oral
9914879|NCT00754819|Placebo Comparator|2|Placebo 1 capsule daily oral
9914880|NCT00754858|Experimental|belotecan and Cisplatin|belotecan 0.5 mg/m2 and Cisplatin 60mg/m2
9914881|NCT00754871|Experimental|Arm 1|
9914882|NCT00754871|Experimental|Arm 2|
9914883|NCT00754871|Experimental|Arm 3|
9914884|NCT00754871|Experimental|Arm 4|
9914885|NCT00754884|Experimental|A|200 U.I. of intranasal salmon calcitonin
9914886|NCT00754884|Placebo Comparator|B|intranasal saline solution and glycerol
9914887|NCT00754897||1|"We will do a database search to identify children less than 1 year of age that have undergone inguinal hernia surgery during the years of 1999-2007, and children who have had inguinal hernia surgery between the ages of 1 and 3 years during the years 1999-2007.~We will then do a telephone interview of the parents of these children to determine if there are siblings that are within three years of age and have not have any exposure to anesthetics agents or sedatives before their 3rd birthday."
9914888|NCT00754910||Group 1|Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
9914889|NCT00754975|Experimental|I|JACTAX LD DES
9914890|NCT00754975|Active Comparator|II|TAXUS™ Libertè™ DES
9914891|NCT00755001||with Plasma HA|BiHapro Hip stem with PPS Ti + Plasma HA
9914892|NCT00755001||with BoneMaster HA|BiHapro Hip stem with PPS Ti + BoneMaster HA
9914893|NCT00755014|Experimental|2|Forty subjects are randomized to a group (n=20) that consumed red wine (100 ml) or a group (n=20) that consumed beer (250 ml) daily for 3 weeks
9914894|NCT00755053|Active Comparator|Clotrimazole tablet (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
9914895|NCT00755053|Experimental|Clotrimazole ovule (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
9914896|NCT00755066|Experimental|F|Fluticasone propionate 200 µg intranasal
9914897|NCT00755066|Placebo Comparator|P|Placebo intranasal spray
9914898|NCT00755092|Active Comparator|1|Doula for Nulliparous women
9914899|NCT00755092|Active Comparator|2|Doula for Multiparous women
9914900|NCT00755118|Experimental|1|LoHP/AIO/Avastin->CPT-11/AIO/Erbitux
9914901|NCT00755144|Experimental|1|ROCC
9914902|NCT00755144|Active Comparator|2|LCS
9914903|NCT00755157|Experimental|1|Docetaxel(metronomic)/Bevacizumab
9914904|NCT00755170|Experimental|1|Vinorelbine metronomic + bevacizumab
9914905|NCT00755209|Placebo Comparator|Transamin|"Drug: tranexamic acid~Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours"
9914906|NCT00755248||1|Pts undergoing CABG or OPCAB
9914907|NCT00755300||1|Standard Total Knee Replacement
9914908|NCT00755300||2|Computer Guided Knee Replacement
9914909|NCT00755352|Experimental|1|pravastatin tablets and Welchol tablets
9914910|NCT00755352|Placebo Comparator|2|pravastatin tablets and Welchol placebo tablets
9914911|NCT00755378|Experimental|1|
9914912|NCT00755378|Placebo Comparator|2|
9914913|NCT00755391|Placebo Comparator|supportive psychotherapy|supportive psychotherapy: 14 sessions
9914914|NCT00755391|Active Comparator|cognitive behavior therapy|cognitive behavior therapy: 14 sessions
9914915|NCT00755404|Active Comparator|A|
9914916|NCT00755404|Experimental|B|
9914917|NCT00755443|Experimental|2|
9914918|NCT00755443|Placebo Comparator|1|Bare metal stent
9914919|NCT00755456|Active Comparator|Glucose solution|
9914920|NCT00755456|Experimental|Glucose and L-carnitine solution|
9914921|NCT00755469|Experimental|1|
9914922|NCT00755482|Active Comparator|1|Subjects were given Aquamin F
9914923|NCT00755482|Placebo Comparator|2|Subjects were given a maltodextran placebo
9914924|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin 3 mg QD|
9914925|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin Placebo QD|
9914926|NCT00755495|Active Comparator|Ramelteon Placebo QD and Doxepin 3 mg QD|
9914927|NCT00755495|Placebo Comparator|Placebo|
9914928|NCT00755508|Experimental|Ramelteon 4 mg QD and Gabapentin 400 mg QD|
9914929|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin 800 mg QD|
9914930|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin Placebo QD|
9914931|NCT00755508|Active Comparator|Gabapentin 800 mg QD|
9914932|NCT00755508|Placebo Comparator|Placebo|
9914933|NCT00755521|No Intervention|B|
9914934|NCT00755521|Experimental|A|adding Etoricoxib to the basic therapeutic regimen
9914935|NCT00755534|Experimental|1|Irinotecan+Erbitux -> XELOX+Erbitux
9914936|NCT00755534|Experimental|2|XELOX+Erbitux ->Irinotecan+Erbitux
9914937|NCT00755547|Experimental|High Intensity|70-85% of peak oxygen uptake for 30 min 3-5 days/week.
9914938|NCT00755547|Experimental|Low Intensity|40-55% of peak oxygen uptake for 60 min 3-5 days/week
9914939|NCT00755547|No Intervention|Sedentary Control|Regular activities of daily living for 6 months
9914940|NCT00755560|Active Comparator|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
9914941|NCT00755560|Placebo Comparator|Placebo|Placebo BID for 15 days
9914942|NCT00755573|Active Comparator|Pregabalin|Pregabalin 300 mg - 600 mg BID
9914943|NCT00755573|Placebo Comparator|Placebo|Placebo arm
9914944|NCT00755586|Experimental|A|
9914945|NCT00755586|Experimental|B|
9914946|NCT00755586|No Intervention|C|
9914947|NCT00755599|Active Comparator|1|Vaginal speculum examinations done without stirrups.
9914948|NCT00755599|Active Comparator|2|Speculum examination with feet in stirrups.
9914949|NCT00755638|Experimental|single|8 subjects (6 active and 2 placebo)
9914950|NCT00755651|Experimental|H Pipelle|Endometrial sample obtained using the H Pipelle
9914951|NCT00755651|Active Comparator|Pipelle|Endometrial sample obtained with standard Pipelle
9914952|NCT00755664|Active Comparator|Low-dose complex B-vitamins|Intervention group receives Low-dose complex B-vitamins every day. Low-dose complex B-vitamins contain 400µg of folic acid, 2mg of vitamin B6, 10µg of vitamin B12 and 50mg vitamin C. Daily supplementation lasts for 12 months
9914953|NCT00755664|Placebo Comparator|Vitamin C|Control group receives Vitamin C (50mg)every day. Daily supplementation lasts for 12 months.
9914954|NCT00755677|Other|pulses|Interventional. Participants are registered sequentially to undergo daily consumption of pulses for eight weeks
9914955|NCT00755690|Active Comparator|1|"High/ Low Phosphate diet I. A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet.~II. A five-day low phosphate diet / A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder III. A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet.~IV. A five-day high phosphate diet / A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder.~V. A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet / A five-day high phosphate diet.~VI. A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet / A five-day low phosphate diet."
9914956|NCT00755690|Active Comparator|2|High/ Low Phosphate diet
9914957|NCT00755690|Active Comparator|3|High/ Low Phosphate diet
9914958|NCT00755703|Experimental|Group 1|There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
9914959|NCT00755703|Experimental|Group 2|There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
9914960|NCT00755703|Experimental|Group 3|There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
9914961|NCT00755703|Placebo Comparator|Experimental: Group 4|There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
9914962|NCT00755729|Experimental|OCH|fast from midnight the night before surgery, and consume 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
9914963|NCT00755729|No Intervention|FSD|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
9914964|NCT00755742|Experimental|Group 1 - Viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
9914965|NCT00755742|Active Comparator|Group 2 - Non-viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy.
9914966|NCT00755742|Experimental|Group 3 - Viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
9914967|NCT00755742|Active Comparator|Group 4 - Non-viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy
9914968|NCT00755781|Active Comparator|CIS|CIS in addition to standard immunosuppressive regimen.
9914969|NCT00755781|No Intervention|SOC|Standard of care (SOC) therapy for lung transplant recipients
9914970|NCT00755820||EXP-DCS/Exposure-D-cycloserine|Exposure Therapy + D-Cycloserine
9914971|NCT00755820||EXP-PBO|Exposure Therapy + Placebo
9914972|NCT00755820||SP|Supportive psychotherapy
9914973|NCT00755833||A|
9914974|NCT00755859|Experimental|1|Six month steroid course plus azathioprine
9914975|NCT00755859|Active Comparator|2|six month steroid course
9914976|NCT00755872|Experimental|1|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
9914977|NCT00755872|Experimental|2|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
9914978|NCT00755872|Experimental|3|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
9914979|NCT00755872|Experimental|4|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
9914980|NCT00755898|Active Comparator|1|Patients with a medical diagnosis of cancer appearing at outpatient clinics for treatment and/or monitoring of their disease status
9914981|NCT00755898|Active Comparator|2|Healthy adult volunteers
9914982|NCT00755950|Experimental|1|280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
9914983|NCT00755950|Placebo Comparator|3|Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
9914984|NCT00755950|Experimental|2.|420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
9914985|NCT00755963|Experimental|1|
9914986|NCT00755963|Experimental|2|
9914987|NCT00755963|Placebo Comparator|3|Placebo
9914988|NCT00755976|Experimental|Epirubicin hydrochloride (75mg/m2 i.v.) Sulindac: 600mg|
9914989|NCT00755989|Placebo Comparator|1|group to receive topical gel without morphine
9914990|NCT00755989|Experimental|2|Morphine gel
9914991|NCT00756015|Active Comparator|Early Motion|Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
9914992|NCT00756015|Other|Immobilization|Immobilization following rotator cuff repair.
9914993|NCT00756028|Experimental|1|Patients receiving short protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-antagonist (Orgalutran®: Ganirelix)
9914994|NCT00756028|Active Comparator|2|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®: Nafarelin)
9914995|NCT00756041|Experimental|TAK-128 100 mg QD|
9914996|NCT00756067|Experimental|Formulation 1|
9914997|NCT00756067|Experimental|Formulation 2|
9914998|NCT00756067|Experimental|Formulation 3|
9914999|NCT00756067|Experimental|Formulation 4|
9915000|NCT00756067|Experimental|Formulation 5|
9915001|NCT00756067|Experimental|Formulation 6|
9915002|NCT00756067|Active Comparator|23 valent pneumococcal vaccine|
9915003|NCT00756080|Experimental|1|After receiving a 7-day oral supplementation with citrulline, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with placebo, as a cross-over study design will be used.
9915004|NCT00756080|Placebo Comparator|2|After receiving a 7-day oral supplementation with placebo, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with citrulline, as a cross-over study design will be used.
9915005|NCT00756132||Bloods Only (B)|Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
9915006|NCT00756132||A-Cog|Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
9915007|NCT00756132||Control (C)|Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
9915008|NCT00756132||A1-Cog|Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
9915009|NCT00756145|Experimental|1|Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline
9915010|NCT00756145|Experimental|2|Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline
9915011|NCT00756145|Experimental|3|Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline
9915012|NCT00756171|Experimental|1|Verum; colesevelam
9915013|NCT00756171|Placebo Comparator|2|placebo
9915014|NCT00756184|Active Comparator|A|Intervention will consist of intensive teaching on the nature of glaucoma, value of IOP control, need to adhere to medical therapy and counseling on the proper use of travoprost eye drops.
9915015|NCT00756184|Placebo Comparator|B|"Intervention with travoprost therapy and TDA monitoring. Patients of this arm will also be prescribed travoprost and will be followed up in a standard clinical fashion. This group will receive a comparable amount of personal physician attention, but will not be given adherence, or glaucoma education and will not be told that their adherence will be monitored. Their attention placebo intervention will discuss the importance and techniques of good eye health (sunglasses, vitamins, cataract development, etc but no details, or discussion of either glaucoma or adherence) will insure that the study results are not a result of a change in physician attention to a patient, per se, rather than adherence training."
9915016|NCT00756197|Experimental|Cryo Spray Ablation Group 1|4 cycles of 10 seconds each
9915017|NCT00756197|Experimental|Cryo Spray Ablation Group 2|2 cycles of 20 seconds each
9915018|NCT00756223|Experimental|Arm A|BI 831266 24h infusion on day 1 and day 15 every 4 weeks
9915019|NCT00756223|Experimental|Arm B|BI 831266 24h infusion on day 1 every 3 weeks
9915020|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.005 mcg/kg|
9915021|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.05 mcg/kg|
9915022|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
9915023|NCT00756249|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
9915024|NCT00756249|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
9915025|NCT00756249|Placebo Comparator|Placebo|
9915026|NCT00756301|Active Comparator|Traditional Technique|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
9915027|NCT00756301|Experimental|Alternative Technique|Local anesthetic (Lidocaine) injected using an alternative technique (inserting the numbing needle into the deeper tissues first and injecting numbing medication from there up to the skin).
9915028|NCT00756301|No Intervention|No Anesthetic|No local anesthetic is used.
9915029|NCT00756340|Experimental|1|"Dose Level 0, Bevacizumab IV every 2 weeks 8 mg/kg, Everolimus 4 mg/m^2~Dose Level 1 (starting dose), Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 4 mg/m^2~Dose Level 2, Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 5 mg/m^2"
9915030|NCT00756353||Wave 1|
9915031|NCT00756353||Wave 2|
9915032|NCT00756366|Active Comparator|1|Heart Failure-OSA Group, randomized to early CPAP
9915033|NCT00756366|Active Comparator|2|Heart Failure-OSA Group, randomized to late CPAP
9915034|NCT00756366|Other|3|Heart Failure- no OSA, no CPAP therapy, observational group
9915035|NCT00756379|Experimental|Intensive lifestyle modification|P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
9915036|NCT00756379|No Intervention|Current standard of care|Current standard of care medical management as provided by primary physician.
9915037|NCT00756392|Other|1|
9915038|NCT00756405|Active Comparator|Diet Group|Increased antioxidant diet and placebo pill.
9915039|NCT00756405|Active Comparator|Supplement Group|Usual diet and antioxidant supplement.
9915040|NCT00756405|Placebo Comparator|Placebo|Usual diet and placebo pill.
9915041|NCT00756431|Active Comparator|Screw without HA Coating (Hiploc)|
9915042|NCT00756431|Experimental|Screw with HA Coating (Hiploc)|
9915043|NCT00756483||M, 1|Male patients that have undergone total knee replacement
9915044|NCT00756483||F, 1|Female patients that have undergone total knee replacement
9915045|NCT00756483||M, 2|Male patients that have undergone total hip replacement
9915046|NCT00756483||F, 2|Female patients that have undergone total hip replacement
9915047|NCT00756535|Experimental|1|Group-based exercise training during hospitalization
9915048|NCT00756535|Active Comparator|2|Usual treatment and rehabilitation during hospitalization
9915049|NCT00756587|Active Comparator|I|Group one received feeding by bottle as the standard method of feeding in the NICU
9915050|NCT00756587|Experimental|II|Group 2 received all feeding by cup
9915051|NCT00756626|Experimental|1|Intervention group receives bottle weaning intervention from WIC nutritionist
9915052|NCT00756626|No Intervention|2|Control standard of care
9915053|NCT00756691||1|First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours
9915054|NCT00756691||2|Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours
9915055|NCT00756704|No Intervention|Baseline Period|
9915056|NCT00756704|Experimental|Intervention Period|
9934402|NCT04850963|Active Comparator|Group 2 - tDCS dualsite|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. In group 2 (dualsite tDCS) two active electrodes (5x5 cm) will be used, which will be positioned over the primary motor area (C3/C4) and over the dorsolateral prefrontal cortex (F3 or F4) in the ipsilateral hemisphere. For this stimulation modality, two active electrodes (anodic) and a reference electrode (6x9 cm) will be used on the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
9934403|NCT04850963|Placebo Comparator|Group 3 - tDCS sham|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 3 (simulated tDCS) the positioning of the electrodes will be the same as for group 1, however the device will be configured in sham mode in which the current will cease 30 seconds after the start of stimulation.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
9998028|NCT01514123|Experimental|Arm B - VGX-100 plus bevacizumab|Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
9915057|NCT00756743|Experimental|PF-04802540|
9915058|NCT00756743|Placebo Comparator|Placebo|
9915059|NCT00756756|Experimental|1|post MI post PCI and G-CSF infusion
9915060|NCT00756756|Placebo Comparator|2|post MI and post PCI only placebo infused
9915061|NCT00756769||1|Patients with SLE
9915062|NCT00756769||2|Related unaffected controls
9915063|NCT00756769||3|Unrelated unaffected controls
9915064|NCT00756782|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
9915065|NCT00756782|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
9915066|NCT00756795|Experimental|Attention Control|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Patient will be taught how to keep the Activity diary to record walking and physical activities.~Structured Interview will be conducted at baseline and post-intervention. All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis"
9915067|NCT00756821||SMA cohort|Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
9915068|NCT00756821||Control cohort|Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
9915069|NCT00756834||Mammography Image Collection|Acquired images
9915070|NCT00756834||CAD Radiologist Reader|Retrospective reader study
9915071|NCT00756847|Experimental|1|
9915072|NCT00756860|Active Comparator|2|30 subjects will be randomized on Day -1
9915073|NCT00756860|Experimental|1|30 subjects will be randomized on Day -1
9915074|NCT00756873|Placebo Comparator|1|
9915075|NCT00756873|Experimental|2|Etoricoxib 90 mg qd.
9915076|NCT00756873|Experimental|3|Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)
9915077|NCT00756899||Obese|Chilren with BMI of >95th percentile
9915078|NCT00756899||Non-obese|Children with BMI of <85th percentile
9915079|NCT00756912|Experimental|1|
9915080|NCT00756925||1|Cocaine dependent females
9915081|NCT00756925||2|Cocaine dependent males
9915082|NCT00756951|Placebo Comparator|1|Placebo
9915083|NCT00756951|Active Comparator|2|SCV-07 at a dose of 0.02 mg/kg
9915084|NCT00756951|Active Comparator|3|SCV-07 at a dose of 0.10 mg/kg
9915085|NCT00756990|Experimental|Single group|Depot Naltrexone
9915086|NCT00757016|Placebo Comparator|B|0.99 ml saline solution 9mg/ml and 0.01 ml fat emulsion will be given once to the sacrospinous ligament insertion.
9915087|NCT00757016|Active Comparator|A|1 ml triamcinolone 20mg/ml (Lederspan), Meda AB, Solna, Sweden) and 1 ml lidocaine hydrochloride 10mg/ml (Xylocain), Astra Zeneca, Södertälje, Sweden)
9915088|NCT00757029|Other|open label|
9915089|NCT00757042|Active Comparator|AMG 157|Six subjects in each cohort (cohort 1 to 8) will receive AMG 157 in Part A 18 subjects in cohorts 9 and 10 (Part B) will receive AMG 157
9915090|NCT00757042|Placebo Comparator|placebo|2 subjects of each cohort (cohort 1 to 8) will receive placebo in Part A 6 subjects in cohorts 9 and 10 (Part B) will receive placebo
9915091|NCT00757055|Active Comparator|1|Patients on ivabradine titrated to heart rate
9915092|NCT00757055|Placebo Comparator|2|No therapy given
9915093|NCT00757068|Active Comparator|SBT|Women assigned to SBT (blue) will receive a six month program that offers to help them stay quit after having a baby.
9915094|NCT00757068|Experimental|CBT|Women assigned to CBT (pink) will receive a six month treatment designed to provide support and address the concerns of women who have just had a baby and do not want to resume smoking.
9995456|NCT01490411|Experimental|160 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
9995457|NCT01490411|Experimental|320 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
9995458|NCT01490424||sepsis|SIRS plus inflammation
9995459|NCT01490424||Control|normal person under medical examination
9995460|NCT01490437|Experimental|PemCis|Pemetrexed plus Cisplatin
9998029|NCT01514175|Experimental|ibuprofen versus ketoralac|IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
9998030|NCT01514188|Active Comparator|Doxorubicin|
9998031|NCT01514188|Experimental|INNO-206|
9998032|NCT01514214|Active Comparator|Winged perimeter stent|Patients who receive the Viaduct stent during ERCP
9998033|NCT01514214|Active Comparator|polyethylene stent arm|Patient who receive the traditional polyethylene stent during ERCP
9998034|NCT01514227|Experimental|Short-term DAPT (6 months) group|6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
9998035|NCT01514227|Experimental|Long-term DAPT (18 months) group|18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
9998036|NCT01514253|Experimental|glucose 25%|1 ml of glucose once
9998037|NCT01514253|Experimental|infant formula|Materna RTF stage 1
9998038|NCT01514253|Placebo Comparator|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
9998039|NCT01514266|Experimental|Curcumin+bioprine|The study involves active arm of Curcumin+Bioprine
9998040|NCT01514266|Placebo Comparator|Placebo|
9998041|NCT01514305||Type 1 Diabetes Mellitus (TIDM)Type 2 Diabetes Mellitus (T2DM)|Adults that have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
9998042|NCT01514331|Active Comparator|PSV+VG|Neonates who require mechanical ventilation and randomised to pressure support + volume guarantee (PSV+VG) mode
9998043|NCT01514331|Active Comparator|SIMV+VG|Neonates who require mechanical ventilation and randomised to synchronised intermittant mandatory ventilation + volume guarantee (SIMV+VG) mode
9998044|NCT01514344|Experimental|intralesional rituximab|
9998045|NCT01514409|Experimental|5-Hydroxytryptophan|
9998046|NCT01514409|Placebo Comparator|Placebo|
9998047|NCT01514435|Experimental|ECT verum group|Patients with treatment refractory depression treated with ECT
9998048|NCT01514487|Experimental|pH 7.7|
9998049|NCT01514487|Experimental|pH 7.9|
9998050|NCT01514487|Experimental|pH 8.15|
9998051|NCT01514500|Experimental|Single dose (SD)|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
9998052|NCT01514500|Experimental|Multiple dose (MD)|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
9998053|NCT01514526|Experimental|Dovitinib|Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
9998054|NCT01514539|Other|Four weeks Postpartum Lactating|women between 18 and 45 who delivered their first child 4 weeks prior and who were currently lactating and planning to lactate for one year postpartum.
9998055|NCT01514539|Other|Control Never Pregnant|women between 18 and 45 who have never been pregnant
9998056|NCT01514552|Placebo Comparator|Placebo gummy|Each 6 gram placebo gummy contains 79% corn syrup (Karo, ACH Food Companies, Memphis, TN), 20% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL), 1% artificial strawberry flavors (Kool-Aid Kraft Foods, East Hanover, NJ).
9998057|NCT01514552|Active Comparator|Strawberry gummy|Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
9998235|NCT01516346|Active Comparator|Isosorbide dinitrate + Hydralazine|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain the active ingredient Hydralazine.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks.~Dosage of Hydralazine will be 37.5mg (if Stage 1) OR 75mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
10213088|NCT04627675|Experimental|2A: Age > 50; CORVax|Healthy volunteers age > 50 will receive CORVax
9799014|NCT01647282|Experimental|Sc/RP with minocycline micropheres|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root. Local application of minocycline microspheres will be done after scaling and root planing (Sc/RP) has been completed
9799015|NCT01647282|Active Comparator|Sc/RP alone|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root
9799016|NCT01647438|Other|Print Health Education|Participants receive print health education materials
9799017|NCT01647438|Experimental|Lifestyle Intervention|Six weekly health education classes and phone counseling.
9799018|NCT01647464||Contrast administration|Patients undergoing contrast-enhanced echo.
9799019|NCT01647516|Experimental|Ozanimod 0.5 mg|Participants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
9799020|NCT01647516|Experimental|Ozanimod 1 mg|Participants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
9799021|NCT01647516|Placebo Comparator|Placebo|Identically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.
9799022|NCT01647542|Experimental|TAK-875 25 mg|TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.
9799023|NCT01647542|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.
9799024|NCT01647542|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
9799025|NCT01647581|Experimental|Clip|A clip is been placed at the polypectomy site.
9799026|NCT01647581|Placebo Comparator|No Clip|A hemoclip is not placed at the site of the polypectomy.
9799027|NCT01647711|Experimental|Afatinib|Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
9799028|NCT01647737|Active Comparator|MighTeaFlow|4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
9799029|NCT01647737|Active Comparator|Xylitol|4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
9799030|NCT01647945|Placebo Comparator|Placebo|
9799031|NCT01647945|Experimental|FK506 level < 2|
9799032|NCT01647945|Experimental|FK506 level 2-3|
9799033|NCT01647945|Experimental|FK506 level 3-5|
9995461|NCT01490476|Experimental|RAD001|Patient with Neurofibromatosis Type 2 and Vestibular Schwannoma treated with RAD001.
9995462|NCT01490489|Other|Pregnent women with blood sample|
9915095|NCT00757081|Experimental|1|
9915096|NCT00757094||I|Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan
9915097|NCT00757107|Experimental|Taperloc Microplasty|Patients with primary osteoarthritis with Taperloc microplasty non inferiority
9915098|NCT00757107|Active Comparator|Taperloc Standard|Patients with primary osteoarthritis Taperloc standard
9915099|NCT00757120||1|This group will include current and former smokers who have emphysema.
9915100|NCT00757120||2|This group will include current and former smokers who do not have emphysema.
9915101|NCT00757133|Experimental|1|Conventional laparotomy closure
9915102|NCT00757133|Active Comparator|2|Laparotomy closure with mesh augmentation
9915103|NCT00757159|Experimental|1|
9915104|NCT00757159|Active Comparator|2|
9915105|NCT00757185|Experimental|1|GNRH antagonist alone
9915106|NCT00757185|Experimental|2|GnRH with Testosterone
9915107|NCT00757198|Experimental|1|remifentanil o.1 mcg/kg/min
9915108|NCT00757198|Active Comparator|2|remifentanil 0.3 mcg/kg/min
9915109|NCT00757224|No Intervention|non-smoking|
9915110|NCT00757224|No Intervention|smoking parents A|
9915111|NCT00757224|Experimental|smoking parents B|Parents will be educated on the hazards of passive smoke exposure and ways to reduce it
9915112|NCT00757250|Experimental|1|Dose Cohort 1: 50 mcg/kg/day of TXA127
9915113|NCT00757250|Experimental|2|Drug Cohort 2: 100 mcg/kg/day TXA127
9915114|NCT00757250|Experimental|3|Drug Cohort 3: 200 mcg/kg/day TXA127
9915115|NCT00757250|Experimental|4|Drug Cohort 4: 300 mcg/kg/day TXA127
9915116|NCT00757250|Experimental|5|Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.
9915117|NCT00757276||1|"All patients > 18 years who are tested for the diagnosis of DI because of a history of polyuria (> 40 ml/kg per 24 hours) in the presence of polydipsia Patients with known DI will be contacted whether they agree to participate in the study and to undergo again a water deprivation test to measure copeptin to confirm the diagnosis.~The investigators hypothesize that basal copeptin levels can reliably differentiate between the 5 groups(central, nephrogenic, psychogenic and partial forms) with a sensitivity and specificity >80%."
9915118|NCT00757289|Experimental|1|PRP injection
9915119|NCT00757289|Active Comparator|2|Corticosteroid Injection
9915120|NCT00757302|Experimental|I|For the first 10 patients, only a pre-operative procedure will be performed.
9915121|NCT00757302|Experimental|II|The last 100 patients will receive the complete procedure.
9915122|NCT00757315|Experimental|1|
9915123|NCT00757315|Active Comparator|2|
9915124|NCT00757328||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
9915125|NCT00757341|Experimental|SKI-606|
9915126|NCT00757354|Experimental|Metal on Metal cementless hip|Metal on Metal cementless hip arthroplasty
9915127|NCT00757367|Experimental|TI Inhalation Powder|TI Inhalation Powder, single dose, 60 units
9915128|NCT00757380|Active Comparator|Group 1|Trypan Blue
9915129|NCT00757380|Active Comparator|Group 2|Brillant Blue
9915130|NCT00757393|Active Comparator|1|
9915131|NCT00757393|Experimental|2|
9915132|NCT00757406||1|Test group - Lymphedema sufferers
9915133|NCT00757406||2|Control group - healthy volunteers
9915134|NCT00757419|Experimental|1|
9915135|NCT00757419|Placebo Comparator|2|
9915136|NCT00757458|Active Comparator|1|TCI with EDTA
9915137|NCT00757458|Active Comparator|2|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol containing EDTA
9915138|NCT00757458|Active Comparator|3|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol without EDTA
9915139|NCT00757458|Active Comparator|4|Target controlled infusion of propofol without EDTA
9915140|NCT00757471|Active Comparator|Group 1|Brillant Blue
9915141|NCT00757471|Active Comparator|Group 2|Indocyanine Green
9915142|NCT00757510||Congenital heart disease|All subjects will have known or suspected congenital heart disease
9915143|NCT00757523|Active Comparator|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation).
9915144|NCT00757523|Experimental|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation).
9915145|NCT00757536|Active Comparator|Group 1|
9915146|NCT00757536|Active Comparator|Group 2|
9915147|NCT00757575||1|
9915148|NCT00757640|No Intervention|B|no cholecystectomy
9915149|NCT00757640|Experimental|A|cholecystectomy
9915150|NCT00757653|Active Comparator|1|Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
9915151|NCT00757653|Experimental|2|
9915152|NCT00757653|Active Comparator|3|
9915153|NCT00757679|Experimental|Milnacipran|
9915154|NCT00757679|Placebo Comparator|Placebo|
9915155|NCT00757692|Experimental|A|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
9915156|NCT00757692|Active Comparator|B|Bicalutamide at 50 mg will be administered orally, daily and continuously.
9915157|NCT00757718|Active Comparator|CPAP treatment|Subjects will have repeat polysomnography on the second night, while wearing a continuous positive airway pressure (CPAP) device. Morning bloodwork will be drawn for inflammatory mediators.
9915158|NCT00757718|Experimental|Oral appliance|Subjects will have repeat polysomnography on the second night, while wearing an oral appliance, as well as a Breathe-Right nasal strip. Morning bloodwork will be drawn for inflammatory mediators.
9915159|NCT00757731|Experimental|Minalcipran 100 mg|
9915160|NCT00757731|Experimental|Minalcipran 150 mg|
9915161|NCT00757731|Experimental|Minalcipran 200 mg|
9915162|NCT00757744|Experimental|A|Methadone maintenance treatment with Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
9915163|NCT00757744|Active Comparator|B|Methadone maintenance treatment with standard drug counseling
9915164|NCT00757770|Experimental|Group HRV Lot A|
9915165|NCT00757770|Experimental|Group HRV Lot B|
9915166|NCT00757770|Experimental|Group HRV Lot C|
9915167|NCT00757770|Active Comparator|Group Placebo|
10213089|NCT04627675|Experimental|2B: Age > 50; CORVax + pIL-12|Healthy volunteers age > 50 will receive CORVax + pIL-12
9915168|NCT00757809|Experimental|QD|Once daily
9915169|NCT00757809|Experimental|BID|Twice daily
9915170|NCT00757835|Active Comparator|Travoprost/timolol therapy|treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.
9915171|NCT00757835|Active Comparator|Latanoprost/timolol therapy|Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.
9915172|NCT00757874|Experimental|Tacrolimus cream|
9915173|NCT00757874|Active Comparator|Clobetasol cream|
9915174|NCT00757887|Experimental|EHMI8|Previously protected volunteers, N=10
9915175|NCT00757887|Active Comparator|control|5 malaria-naive volunteers
9915176|NCT00757900|Active Comparator|1|To receive a sub-unit influenza vaccine
9915177|NCT00757900|No Intervention|2|
9915178|NCT00757913|Experimental|1|n-3 enriched nutrition
9915179|NCT00757913|Placebo Comparator|2|isocaloric nutrition without n-3 supplement
9915180|NCT00757926|Experimental|1|
9915181|NCT00757926|Placebo Comparator|2|
9915182|NCT00757939|Experimental|AD Participants|Participants with a diagnosis of mild-to-moderate AD
9915183|NCT00757939|Experimental|Cognitively Normal Elderly Participants|Elderly participants with no cognitive impairment
9915184|NCT00757978|Placebo Comparator|1|Clozapine plus placebo
10213090|NCT04627246|Experimental|PEP-DC + Nivolumab + SOC|PEP-DC: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides Nivolumab SOC: Standard of Care Chemotherapy
9915185|NCT00757978|Active Comparator|2|Clozapine plus memantine
9915186|NCT00758004|Other|Reference|Commercial 80 mg atorvastatin tablet
9915187|NCT00758004|Other|Test|Pediatric appropriate atorvastatin 40mg formulation
9915188|NCT00758017|Experimental|Acupuncture 1|
9915189|NCT00758017|Active Comparator|Acupuncture 2|
9915190|NCT00758082|Active Comparator|1|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support
9915191|NCT00758082|Experimental|2|PDA-phone + phone consultations + standard visit at 3 months
9915192|NCT00758121||Observation|Heart failure patients with an implanted CRT-D
9915193|NCT00758134|Experimental|A|Trastuzumab 6 mg/Kg
9915194|NCT00758186|Experimental|Colonic-stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction.
9915195|NCT00758186|Active Comparator|Emergency surgery|Emergency surgery: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction.
9915196|NCT00758199|Active Comparator|2|Moxifloxacin
9915197|NCT00758199|Placebo Comparator|3|Prednisolone Acetate
9915198|NCT00758199|Active Comparator|1|Bromfenac
9915199|NCT00758212|Experimental|A|The experimental group will consist of HIV/AIDS patients(approx.50) who volunteer to receive a reduced dose Influenza vaccine using mesotherapy as a mode of injecting the vaccine intradermally.
9915200|NCT00758225|Experimental|only one arm|
9915201|NCT00758238|Experimental|myBP intervention|participants will receive access to hypertension self-management tools and support via a personal patient electronic health record
9915202|NCT00758238|No Intervention|usual care|participants allocated to usual care may still opt to use the personal patient electronic health record, but will not have access to the hypertension self-management tools until after the intervention period. The usual care group will be given a web-link for patient hypertension management resources
9915203|NCT00758251||1|Adult schizophrenia patients already on Seroquel XR therapy
9915204|NCT00758277|Active Comparator|Levetiracetam|
9915205|NCT00758277|Placebo Comparator|Placebo|
9915206|NCT00758316|Active Comparator|1|Thoracoscopy with pleurodesis Patients will then undergo standard medical thoracoscopy in the endoscopy center including the use of moderate sedation, prophylactic antibiotics for 1 week and 20F chest tube insertion at the end of the procedure.
9915207|NCT00758316|Experimental|2|Combined thoracoscopy with pleurodesis and pleurx catheter. In the combined procedure group, a PleurxTM tunnelled catheter will be inserted under ultrasound guidance. As this procedure will be done concurrently with thoracoscopy, there is no estimated increase in endoscopy time.
9915208|NCT00758329||1|
9915209|NCT00758355||M2A magnum|Consecutive series of patients received Total Hip Resurfacing with ReCap/Magnum
9915210|NCT00758355||Recap Magnum|Consecutive series of patients received Total Hip Replacement with ReCap/Magnum
9995463|NCT01490502|Active Comparator|Low-dose vitamin D3|
9998058|NCT01514578|Experimental|TRV130A|
10213091|NCT04626128|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of 0.03 mg CLS-AX
10213092|NCT04626128|Experimental|Cohort 2 (Low-mid Dose)|Subjects will receive a low-mid dose of 0.10 mg CLS-AX
10213093|NCT04626128|Experimental|Cohort 3 (High-mid Dose)|Subjects will receive a high-mid dose of 0.50 mg CLS-AX
10213094|NCT04625725|Experimental|AZD7442|"Approximately 5150 participants will be randomized in a 2:1 ratio~• Arm 1 (n=approximately 3433) will receive a single dose (× 2IM injections) of 300 mg of AZD7442"
10213095|NCT04625725|Placebo Comparator|Placebo|"Approximately 5150 participants will be randomized in a 2:1 ratio~• Arm 2 (n=approximately 1717) will receive saline placebo"
9915211|NCT00758368|Experimental|Ambulatory Pump|Participants will receive apomorphine via a pump. Participants in the Continuous Delivery Arm will self-administer apomorphine continuously (12-14 hours a day) using a portable pump.
9915212|NCT00758368|Active Comparator|Subcutaneous Injections|Participants will receive apomorphine via an injection pen. Participants in the Intermittent Delivery Arm will self-administer apomorphine at intervals, via a injection, using pen injector.
10213096|NCT04625725|Experimental|Sub-study AZD7442 Arm 1|"Approximately 500 participants will receive AZD7442 in the repeat dose sub-study.~-Sub-study Arm 1 (~ 12 month repeat dose interval): Participants who received AZD7442 300 mg IM on Day 1 of the parent study will receive a second dose of AZD7442 300mg IM on sub-study Day 1."
9934404|NCT04850196|Experimental|TEAS group|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
9934405|NCT04850196|Sham Comparator|Control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS.
9934406|NCT04849806||COPD patients (n=60)|"The following parameters will be determined in 60 consecutive patients with COPD without established cardiovascular disease (i.e. without an indication for beta blocker therapy or other pharmacological treatments attacking on the neurohormonal pathways like angiotensin-converting enzyme inhibitors or mineralocorticoid receptor antagonists).~OSA severity.~Determination of PH and right HF severity (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography;~Comprehensive lung function and inspiratory muscle function testing ;Assessment of daytime hypoxia (PaO2 <55 mmHg) and hypercapnia (PaCO2 >45 mmHg) using capillary blood gas analysis;~Assessment of systemic inflammation"
9934407|NCT04849806||Controls (n=20)|(and in a group of healthy controls [3:1] matched for age, sex and BMI).
10213097|NCT04625725|Experimental|Sub-study AZD7442 Arm 2|"Approximately 500 participants will receive AZD7442 in the repeat dose sub-study.~-Sub-study Arm 2(~ 6 month repeat dose interval): Participants who received placebo on Day 1 of the parent study will receive their first dose of AZD7442 300mg IM on sub-study Day1 followed by a second dose on sub-study Day 183."
9934408|NCT04847466|Experimental|1/Arm 1|1-week lead in for PD-L1 CAR NK cell monotherapy followed by combination therapy of Pembrolizumab plus N-803
9934409|NCT04847063|Experimental|1/ HIPEC: Oxaliplatin Randomized treatment assignment|HIPEC with intraperitoneal oxaliplatin and IV 5-FU, randomly assigned
9934410|NCT04847063|Experimental|2/ HIPEC: Mitomycin C Randomized treatment assignment|HIPEC with intraperitoneal mitomycin C, randomly assigned
9934411|NCT04847063|Experimental|3/ HIPEC: Cisplatin, Doxorubicin Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and doxorubicin, in addition to IV sodium thiosulfate, randomly assigned
9934412|NCT04847063|Experimental|4/ HIPEC: Cisplatin, Mitomycin C Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and mitomycin C, in addition to IV sodium thiosulfate, randomly assigned
9934413|NCT04847050|Experimental|1|100 mcg (0.5 mL) mRNA-1273 injection (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29
9934414|NCT04847050|Experimental|2|100 micrograms (0.5 mL) mRNA-1273 injection on D1
9934415|NCT04846374||PowerPort Subjects|This study will involve a chart review of patients at UNC who were referred for change from a vortex port to a powerflow port.
9934416|NCT04846309|Experimental|Treatment: all patients|
9934417|NCT04844411|Experimental|Arm A: JNJ-67835989 (Oral Suspension)|Participants will receive a single oral suspension dose of JNJ-67835989 on Day 1 in Part 1 and Part 2.
10213098|NCT04625088|Experimental|Standardized liquid test meal|
9934418|NCT04844411|Placebo Comparator|Arm B: Placebo|Participants will receive a single oral solution placebo on Day 1 in Part 1 only (except food effect cohorts).
10213099|NCT04625088|Experimental|Atropine + Standardized liquid Test meal|
10213100|NCT04614545|Experimental|Virtual Visits|"All patients will be seen face to face on visit 1. Patient will be evaluated by an obesity-medicine specialist and also by a registered dietitian and exercise physiologist via telemedicine. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated), and will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored remotely and patients will receive a remote scale and a remote blood pressure cuff.~Subjects will then initiate 3 one to one virtual visits with the obesity specialist. On each of this visit the five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. A personalized nutrition and exercise program will be developed. If felt relevant by the provider, subjects may also be referred to a mental health specialist and/or sleep clinic. All medical care will be provided virtually."
10213101|NCT04614545|Active Comparator|Face to face visits|"All patients independently of the randomization arm will be seen face to face on visit 1. Patients will be evaluated by an obesity-medicine specialist and patient will also be seen face to face by a registered dietitian and exercise physiologist. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated). Patients will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored in each of the visits.~Subjects will then initiate 3 face to face visits with the obesity specialist provider every 4 weeks. The five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress.~The patient will be provided a personalized nutrition and exercise program and may be referred to a mental health specialist and/or sleep clinic per provider discretion. All medical care will be provided via a face-to-face manner."
10213102|NCT04614103|Experimental|Cohort 1|Patients whose tumors did not express programmed cell death-ligand 1 (PD-L1) (tumor proportion score [TPS] < 1%) prior to their CPI treatment.
10213103|NCT04614103|Experimental|Cohort 2|Patients whose tumors expressed PD-L1 (TPS ≥ 1%) prior to their CPI treatment.
9915213|NCT00758381|Experimental|A|"Sorafenib 400 mg po bid, continuously~Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days."
9915214|NCT00758381|Active Comparator|B|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days
9915215|NCT00758407|Active Comparator|1|
9915216|NCT00758407|Placebo Comparator|2|
9915217|NCT00758433|Active Comparator|1|Civamide patch 0.0075%
9915218|NCT00758433|Active Comparator|2|Civamide patch 0.0150%
9915219|NCT00758433|Placebo Comparator|3|Placebo patch
9915220|NCT00758446|Experimental|A|BLX-028914 50 mg
9915221|NCT00758446|Experimental|B|BLX-028914 15 mg
9915222|NCT00758446|Placebo Comparator|C|Placebo
9915223|NCT00758472||Hip Resurfacing|
9915224|NCT00758511|Active Comparator|1|Orally administrated 25%sucrose before,during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
9915225|NCT00758511|Active Comparator|2|facilitated tucking before, during and after heel stick across 5 heel stick during the first 14 days of postnatal life
9915226|NCT00758511|Active Comparator|3|orally administrated 25% sucrose AND facilitated tucking before, during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
9915227|NCT00758537||Patients with chronic kidney disease stage 3|
9915228|NCT00758537||patients with chronic kidney disease stage 4|
9915229|NCT00758537||patients with chronic kidney disease stage 5 (ESRD)|
9915230|NCT00758537||Controls (no kidney disease)|
9915231|NCT00758615|Experimental|I|Walking School Bus Intervention
9915232|NCT00758615|No Intervention|C|Usual school procedures for student transportation to school
9915233|NCT00758628|Active Comparator|1|Bromfenac
9915234|NCT00758628|Placebo Comparator|2|Blink
9915235|NCT00758641|Experimental|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
9915236|NCT00758641|Active Comparator|Steroid Injection|Corticosteroid injections
9915237|NCT00758654||1|Patients with suspected or known stable coronary artery disease
9915238|NCT00758654||2|Healthy subjects as a control group
9915239|NCT00758693|Experimental|1|Bendamustine + Rituximab
9915240|NCT00758732|Experimental|1|Docetaxel/carboplatin
9915241|NCT00758732|Experimental|2|Docetaxel/Caelyx
9915242|NCT00758797|Experimental|1|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
9915243|NCT00758810||1|Patients without cardiac rehabilitation
9915244|NCT00758810||2|Patients with cardiac rehabilitation
9915245|NCT00758849|Placebo Comparator|1|
9915246|NCT00758849|Active Comparator|2|
9915247|NCT00758888|Experimental|Treatment|Place the blocks under the pelvis for 2 minutes
9915248|NCT00758888|Active Comparator|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
9915249|NCT00758888|Sham Comparator|Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
9915250|NCT00758901||1 ROCC Knee prosthesis|Consecutive series of patients with ROCC Knee prosthesis.
9915251|NCT00758927|Placebo Comparator|2|Placebo administration for 10 weeks with exercise and diet therapy
9915252|NCT00758927|Experimental|1|Omacor 4 gram per day with exercise and diet therapy for 10 weeks
9915253|NCT00758940|Experimental|1|Acrysof ReSTOR multifocal IOL
9915254|NCT00758992||Immunodeficient mice|Please see the Study Description for complete information.
9915255|NCT00759005|Experimental|A, 4|
9915256|NCT00759044||AMD|Patients diagnosed with AMD
9915257|NCT00759044||DME|Patients diagnosed with DME
9915258|NCT00759057|Experimental|1 - Investigational|Dynesys Non-Fusion Spinal System
9915259|NCT00759057|Active Comparator|2 - Control|Silhouette Posterior Pedicle Screw System as an adjunct to Posterior Lateral Fusion with Autograft.
9915260|NCT00759070|Active Comparator|1|Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)
9915261|NCT00759070|Active Comparator|2|Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)
9915262|NCT00759083|Experimental|1|Patients with HIT/HITTS who require anticoagulation for PCI
9915263|NCT00759122|Active Comparator|1|VENLAFAXINE
9915264|NCT00759122|Placebo Comparator|2|
9915265|NCT00759200|Experimental|alb-interferon arm 1|
9915266|NCT00759200|Experimental|alb-interferon arm 2|
9915267|NCT00759200|Experimental|alb-interferon arm 3|
9915268|NCT00759200|Experimental|alb-interferon arm 4|
9915269|NCT00759200|Active Comparator|peg-interferon|
9915270|NCT00759213||1|Any infant with a length of stay in the NICU of at least 7 days.
9915271|NCT00759239|Experimental|1|One drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 am and 1 drop of Timolol vehicle as placebo in each eye at 9 pm for 12 weeks.
9915272|NCT00759239|Experimental|2|One drop of Timolol vehicle as placebo in each eye at 9 am and one drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 pm for 12 weeks.
9915273|NCT00759265|Experimental|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
9915274|NCT00759265|No Intervention|control|No intervention was prescribed
9995464|NCT01490502|Active Comparator|High-dose vitamin D3|
9995465|NCT01490515|Active Comparator|Morphology embryo evaluation|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
9995466|NCT01490515|Experimental|non-invasive metabolomic profiling|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
9995467|NCT01490541||Gastric intestinal metaplasia patient|
9995468|NCT01490554|Experimental|autologous fibroblast grafts|autologous fibroblast grafts
9995469|NCT01490567|Placebo Comparator|placebo|Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
9995470|NCT01490567|Active Comparator|donepezil|Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
9995471|NCT01490593||Patients with Eye Injuries|The database is being established to record the number and types of eye injuries occurring in Canada. Thus there is only one cohort group, individuals who have sustained an eye injury.
9995472|NCT01490606|Experimental|knee OA project|12 sessions of PT, 6 INDIVIDUAL AND 6 GROUP TREATMENTS
9995473|NCT01490606|No Intervention|conventional PT|
9995474|NCT01490619|Experimental|Healthy Thinking in Teens|Group-based, manualized program, based on cognitive behavioral therapy techniques.
9995475|NCT01490619|Active Comparator|Advanced Diabetes Education|Group-based, manualized program designed to provide diabetes education, focused on adolescent-specific topics.
9995476|NCT01490645||one group (all patients)|
9995477|NCT01490658|Experimental|Treatment period 1|
9995478|NCT01490658|Experimental|Treatment period 2|
9995479|NCT01490658|Active Comparator|Treatment period 3|
9995480|NCT01490671|Experimental|Group 1a (tenofovir gel)|Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
9995481|NCT01490671|Placebo Comparator|Group 1b (placebo gel)|Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
9995482|NCT01490671|Experimental|Group 2a (tenofovir gel)|Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
9995483|NCT01490671|Placebo Comparator|Group 2b (placebo gel)|Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
9995484|NCT01490671|Experimental|Group 3a (tenofovir gel)|Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
9995485|NCT01490671|Placebo Comparator|Group 3b (placebo gel)|Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
9995486|NCT01490671|Experimental|Group 4a (tenofovir gel)|Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
9995487|NCT01490671|Placebo Comparator|Group 4b (placebo gel)|Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
9995488|NCT01490736|Experimental|LTS/Vehicle|Within subject control study
9995489|NCT01490749|Experimental|XELOX/Radiation/Carboplatin/RAD001|Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
9995490|NCT01490762|Active Comparator|Regular Human Insulin|Subcutaneous injection
9995491|NCT01490762|Experimental|TI and Regular Human Insulin|All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
9995492|NCT01490775|Experimental|eMedonline access|patients will be followed for 3 months with access to eMedonline
9915275|NCT00759278||1|Group of 30 women who are pregnant as subjects that take antihypertensive medication
9915276|NCT00759278||2|Group of 30 women who are pregnant and do not take antihypertensive medications as a control group
9915277|NCT00759291|Active Comparator|Acipimox|Acipimox treatment QID for 7 days
9915278|NCT00759291|Placebo Comparator|Placebo|Placebo treatment QID for 7 days
9915279|NCT00759317|Active Comparator|1|venlafaxine
9915280|NCT00759317|Placebo Comparator|2|
9915281|NCT00759343||Control Group|"The control subjects of this study will be asked to undergo renal ultrasound examination, if available, or will be asked to complete a disease history form to determine the presence or lack of a kidney stone. Urine and serum will then be taken for storage until further analysis.~Controls will be asked to undergo a screening renal ultrasound to ensure they are stone free, this will take approximately 45 minutes. If the controls are asked to complete the history form, this will not take more than 20 minutes. They will also give a blood and urine sample during this time to bring the total extra time up to at most 60 minutes for controls."
9915282|NCT00759343||Stone Group|"The stone group will undergo standard diagnostic procedures for their condition and recovery process. Serum and urine for storage and analysis will be taken prior to stone treatment and 6 weeks following stone treatment. This will allow for the determination of differences in a stone patient's protein profile while they have their stone and after they are stone free. All patients will be required to have a stone patient metabolic evaluation which includes serum and urine testing. The analysis will focus on the serum and urine sample that they provide.~The stone patient will be asked to undergo one extra tube of blood during their preoperative assessment which should only add a few seconds to their visit."
9915283|NCT00759369|Experimental|1|Water prescription
9915284|NCT00759382||I|Patients with non-small cell lung carcinoma treated with curative intent
9915285|NCT00759421|Experimental|1|
9915286|NCT00759421|Active Comparator|2|
9915287|NCT00759434|Active Comparator|Surgery|
9915288|NCT00759434|Experimental|EVLT|
9915289|NCT00759447||3D investigational imaging|Patients enrolled will be imaged with a 3D mammogram in one of 3 speeds of acquisition
9915290|NCT00759447||3D Imaging with commercial Mammography Device|
9915291|NCT00759460|Experimental|1|
9915292|NCT00759460|Active Comparator|2|
9915293|NCT00759499||Debridement|The intent of this protocol is to salvage wound material that is normally destined for destruction, so it can be used in wound-related scientific studies. This clinical wound material can be studied in order to better understand the molecular, cellular, or ecological components of the wound system. These studies may be able to provide important insights into the keys of wound healing, wound persistence, or wound deterioration.
9915294|NCT00759512|Active Comparator|Arm 1|This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care
9915295|NCT00759512|No Intervention|Arm 2|Standard of Care
9915296|NCT00759538||1|lung transplant patients performing a three week lasting rehabilitation program
9915297|NCT00759551|Experimental|Azilsartan 2.5 mg QD|
9915298|NCT00759551|Experimental|Azilsartan 5 mg QD|
9915299|NCT00759551|Experimental|Azilsartan 10 mg QD|
9915300|NCT00759551|Experimental|Azilsartan 20 mg QD|
9915301|NCT00759551|Experimental|Azilsartan 40 mg QD|
9915302|NCT00759551|Placebo Comparator|Placebo QD|
9915303|NCT00759551|Active Comparator|Olmesartan 20 mg QD|
9915304|NCT00759590||1|ALI/ARDS patients
9915305|NCT00759616|Experimental|1|
9915306|NCT00759629|Experimental|A|Interventional treatment group - Patients assigned to PCI will receive the loading dose of clopidogrel, aspirin plus a bolus of heparin and be transferred immediately for interventional treatment. They will receive abciximab as a bolus followed by a continuous infusion of for 12 hours.
9915307|NCT00759629|Active Comparator|B|Conservative treatment group - Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards.
9915308|NCT00759720|Experimental|TAK-559 16 mg QD + Glyburide QD|
9915309|NCT00759720|Experimental|TAK-559 32 mg QD + Glyburide QD|
9915310|NCT00759720|Active Comparator|Glyburide QD|
9915311|NCT00759733||1|Pregnant women with a history of cardiac disease (study group)
9915312|NCT00759733||2|Pregnant women with no history of heart disease (control group)
9915313|NCT00759746|Active Comparator|Weight Maintenance Education|Participants assigned to this group will receive the Weight Maintenance Education intervention. They will meet every other week during the maintenance phase of the study for a total of 16 sessions over 8 months. During the visit, participants will participate in a series of interactive workshops within child and parent groups to learn general information about healthy eating and physical activity.
9915314|NCT00759746|Experimental|SFM+ Low Dose|Participants assigned to this group will receive the SFM+ Low Dose.
9915315|NCT00759746|Experimental|SFM+ High Dose|Participants assigned to this group will receive the SFM+ High Dose.
9915316|NCT00759824|Experimental|1|Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
9915317|NCT00759837|Experimental|1|
9915318|NCT00759850|Active Comparator|A|Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)
9915319|NCT00759850|Experimental|B|Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)
9915320|NCT00759850|Experimental|C|Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)
9915321|NCT00759889||wound biopsy|diabetic foot,venous leg ulcer, decubitus ulcer
9915322|NCT00759928|Experimental|Erlotinib/Sorafenib|Patients will receive erlotinib 150 mg once daily by mouth and sorafenib 400 mg twice daily by mouth. The study will begin with a 2-week run-in period (which will begin on Day 14 of the study, and continue through Day 1 of the study), in which erlotinib will be dosed alone at 150 mg once daily. Patients will continue taking erlotinib as a single agent at 150 mg once daily through Day 1. After the 2-week run-in period, patients will receive continuous dosing of both agents (erlotinib 150 mg once daily and sorafenib 400 mg twice daily) in cycles of 28 days each. Toxicity will be assessed every cycle (every 4 weeks) for all patients. Because this is not an efficacy study, restaging tumor measurements will be at the discretion of the physician every 8 weeks during treatment. Patients with objective response or stable disease will continue therapy; patients with disease progression or unacceptable toxicity will be discontinued from the study.
9915323|NCT00759980||Platelet Number|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to the total number of platelets
9915324|NCT00759980||Platelet Mass|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to a combination of platelet number and platelet size (mass)
9915325|NCT00759993|Experimental|A,1|chromium piccolinate 1000mg
9915326|NCT00759993|Placebo Comparator|A,2|matching placebo
9915327|NCT00760032|Experimental|Active|Ciprofloxacin
9915328|NCT00760032|Placebo Comparator|Placebo|Placebo
9915329|NCT00760045|Experimental|1|AL-43546 0.15%
9915330|NCT00760045|Experimental|2|AL-43546 0.25%
9915331|NCT00760045|Active Comparator|3|AL-43546 0%(Vehicle)
9915332|NCT00760045|Active Comparator|4|0.1% sodium hyaluronate ophthalmic solutio
9915333|NCT00760058|Experimental|1|AcrySof® IQ intraocular lens
9915334|NCT00760058|Active Comparator|2|Tecnis® Aspheric intraocular lens
9915335|NCT00760058|Active Comparator|3|Akreos® MI60 intraocular lens
9915336|NCT00760071||1CF-patients<6|Patients with diagnoses of cystic fibrosis from birth to the age of 6 years
9915337|NCT00760071||2 controls|age matched controls
9915338|NCT00760097|Experimental|AtCDS|Transcranial direct stimulation
9915339|NCT00760110||1 Morning hypertension and normotension|Based on HBP, subjects were divided into MH and MN patients
9915340|NCT00760110||2 Clinic hypertension and normotension|Based on CBP, subjects were divided into CH and CN patients
9915341|NCT00760123|Experimental|1|Early Physical Therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
9915342|NCT00760123|Other|2|Educational Strategy: instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
9915343|NCT00760149|Placebo Comparator|1|50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
9915344|NCT00760149|Active Comparator|2|50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
9915345|NCT00760149|Active Comparator|3|50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
9915346|NCT00760162||HSCB, Brooklyn, NY|State University of New York Brooklyn, NY 11203
9915347|NCT00760162||2. Nephrology Associates,|Scarborough, ON CANADA, LI H IC5
9915348|NCT00760162||3.New York Harbor VA Medical Center|NYU School of Medicine New York, NY.10010
10213104|NCT04614103|Experimental|Cohort 3|"Patients whose tumors do not express PD-L1 (TPS < 1%) prior to their CPI treatment and who are unable to safely undergo a surgical harvest for TIL generation due to at least one of the following:~Unacceptable surgical risk~Surgically approachable lesion is required for Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessment"
9915349|NCT00760162||4.Hospital Juarez De Mexico|Madero, Mexico, D.FC.P. 07760
9915350|NCT00760162||5. Hospital Italiano de Buenos Aires|Buenos Aires, Argentina.
9915351|NCT00760162||6. National Hospital|Abuja, Nigeria
9915352|NCT00760175|Active Comparator|intradermal|
9915353|NCT00760175|Active Comparator|intramuscular|
10213105|NCT04614103|Experimental|Cohort 4|Patients who have been previously treated with LN-145 in Cohort 1, 2, or 3 of this study.
10213106|NCT04611477|Placebo Comparator|Placebo|One capsule/day to be taken orally 30 minutes before breakfast
10213107|NCT04611477|Active Comparator|Synbiotic365 Ver 5|One capsule/day to be taken orally 30 minutes before breakfast
9915354|NCT00760201||1|Hospital executives, physician administrators and hospital legal counsel
9915355|NCT00760227|Other|1: HPI-C|Child Intervention Only Group
9915356|NCT00760227|Other|2: HPI-CP|Parent and Child Intervention Group
9915357|NCT00760227|No Intervention|3: SC|Standard Care Control Group- No Intervention
9915358|NCT00760240||Glaucoma patients|This is a group of patients with restricted visual fields or ETDRS visual acuity of 20/60 or worse
9915359|NCT00760240||Retina patients|A group of patients with retinal pathology(ARMD, CME, diabetic retinopathy) contributing to their decreased vision.
9915360|NCT00760253||1|pure propofol by TCI pump with titration.
9915361|NCT00760253||2|10ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
10213108|NCT04611477|Active Comparator|Synbiotic365 Ver 7|One capsule/day to be taken orally 30 minutes before breakfast
10213109|NCT04611087||Observational (focus group, interview)|"PHASE I: Participants attend 4 sessions of focus groups.~PHASE II: Participants attend virtual Zoom interviews or one-on-one interviews."
9915362|NCT00760253||3|20ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
9915363|NCT00760292||1|Type 2 Diabetic Patients
9915364|NCT00760292||2|Non-diabetic individuals
9915365|NCT00760305|Experimental|1|Patients who received the Pro-Self psychoeducational intervention
9915366|NCT00760305|No Intervention|2|Patients who received standard care
9915367|NCT00760357||Retrospective Anaylsis|Once the patients are identified that have a full thickness wound on a limb clearly identified as having critical limb ischemia, these patients will be evaluated
9915368|NCT00760396|Experimental|Group 1|40mg QD dose group
10213110|NCT04610671|Experimental|Participants Receiving CG0070 & Nivolumab|Both CG0070 (x 6 instillations) and nivolumab (x 2 doses) will be administered at their single-agent dose and schedule.
10213111|NCT04602936|Active Comparator|Solriamfetol|All medication will be 37.5 mg encapsulated soriamfetol tablets or matching encapsulated placebo tablets supplied in numbered containers for dispensing to patients. The minimum dose of solriamfetol during the trial will be 37.5 mg/day; the maximum dose will be 150 mg/day. At the Baseline Visit (Visit 0), participants will be instructed to take one capsule of solriamfetol 37.5 mg or matching placebo in the morning for the first 7 days. Thereafter, at Visit 1, solriamfetol or placebo will be increased to 75 mg/day, if tolerated. Beginning on day 15 (Visit 2), solriamfetol or placebo will be increased to 150 mg/day, if tolerated. Study medication dosage may be decreased, or a scheduled increase may not be made, because of side effects. Study medication will be administered as a single daily dose in the morning.
9915369|NCT00760396|Experimental|Group 2|100mg QD dose group
9915370|NCT00760396|Experimental|Group 3|200mg QD dose group
9915371|NCT00760396|Experimental|Group 4|200mg BID dose group
9915372|NCT00760409||Radiation Injury|Radiation Injury Recurrent symptoms after radiation therapy of a brain tumor are not always the result of tumor recurrence but may represent radiation necrosis of the brain.
9915373|NCT00760409||Tumor Recurrence|Symptoms are the result of actual tumor recurrence
9915374|NCT00760422||With fever|
9915375|NCT00760422||Without fever|
9915376|NCT00760500||1|
9915377|NCT00760565|Experimental|1|
9915378|NCT00760565|Placebo Comparator|10|
9915379|NCT00760565|Experimental|11|
9915380|NCT00760565|Placebo Comparator|12|
9915381|NCT00760565|Placebo Comparator|2|
9915382|NCT00760565|Experimental|3|
9915383|NCT00760565|Placebo Comparator|4|
9915384|NCT00760565|Experimental|5|
9915385|NCT00760565|Placebo Comparator|6|
9915386|NCT00760565|Experimental|7|
9915387|NCT00760565|Placebo Comparator|8|
9915388|NCT00760565|Experimental|9|
9915389|NCT00760604|Active Comparator|A|En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
9915390|NCT00760604|Active Comparator|B|Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
9915391|NCT00760630|Experimental|CDP LFC|all patients will have this calculation based upon diagnostic parameters with IVUS and FFR and/or CFR
9934419|NCT04844411|Experimental|Arm C: JNJ-67835989 (Oral Solid Dose)|Participants will receive a single oral solid dose (tablet) of JNJ-67835989 on Day 1 in Part 3.
9934420|NCT04840654|Active Comparator|Caudal block|This group will receive the Caudal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
10213112|NCT04602936|Placebo Comparator|Placebo|Placebo (i.e., inactive compound for comparison)
10213113|NCT04600960|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take eltrombopag at the indicated dose.
10213114|NCT04597671|Experimental|Arm A|Durvalumab with low-dose PCI
10213115|NCT04597671|Active Comparator|Arm B|Durvalumab with observation
10213116|NCT04593550||Observational (BrainCheck, 3D-CAM, EEG)|Patients undergo cognitive function assessment BrainCheck over 10 minutes before surgery, day 1 after surgery, and day 2 after surgery (if patients are still admitted to the hospital) and 3D-confusion assessment over 10 minutes BID on day 1 after surgery and day 2 after surgery (if patients are still admitted to the hospital). Patients also undergo EEG during surgery and collection of blood samples 30-60 minutes after surgery.
10213117|NCT04590014|Active Comparator|Conventional HVNI Device Design (Control)|The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea.
10213118|NCT04590014|Experimental|New HVNI Device Design (Randomized)|The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
10213119|NCT04588727|Experimental|AZD3366 Dose 1 Part A|Randomized healthy subjects will receive Dose 1 of AZD3366.
9934421|NCT04840654|Active Comparator|Pudendal Block|This group will receive the Pudendal block during their operation (50 patients circumcision, 50 patients hypospadias). This group consist of 100 subjects
9934422|NCT04840615|Experimental|1/Intratumoral LMB-100 Administration|Those with pleural or peritoneal mesothelioma receiving intratumoral administration of LMB-100 + ipilimumab in for up to 4 cycles (cycles 1 and 2 include LMB-100 plus ipilimumab; cycles 3 and 4 consist of ipilimumab only)
9934423|NCT04839991|Experimental|Multi center open label Dose Escalation followed by Cohort Expansion: Part 2A|Patients will receive CB307 IV infused every 7 days. Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2A arm will enrol patients with PSMA+ solid tumours. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
9995493|NCT01490775|Active Comparator|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
9995494|NCT01490827||Argus II Retinal Prosthesis|Patients implanted with an Argus II Retinal Prosthesis
9995495|NCT01490853||CML and interpheron alpha|Adult Ph+CML pts in CCgR after IFN alpha.
9995496|NCT01490879|Experimental|Nexagon® Low Dose|Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
9995497|NCT01490879|Experimental|Nexagon® Medium Dose|Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
9995498|NCT01490879|Experimental|Nexagon® High Dose|Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
9995499|NCT01490879|Placebo Comparator|Nexagon® vehicle|Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
9995500|NCT01490905|Active Comparator|Theramine active and ibuprofen placebo|2 capsules Theramine twice daily with one ibuprofen-like placebo once daily.
9995501|NCT01490905|Active Comparator|Theramine and Ibuprofen (Theraprofen)|Two capsules Theramine twice daily with Ibuprofen 400mg once daily.
9995502|NCT01490905|Active Comparator|Theramine placebo and Ibuprofen|Two Theramine-like placebo twice daily and one ibuprofen 400mg.
9995503|NCT01490944|Active Comparator|Iron and Folic Acid|
9995504|NCT01490944|Experimental|Iron, Folic acid and cyanocobalamin|
9995505|NCT01490983|Experimental|eMedonline access|patients will have access to eMedonline access for 3 months
9995506|NCT01490983|Other|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
9995507|NCT01490996|Active Comparator|Chemotherapy only|Patients receiving up to 12 cycles of therapy. Standard care pathway management.
9995508|NCT01490996|Experimental|Chemotherapy plus curcumin|Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.
9995509|NCT01491048|Active Comparator|THA Physiotherapy|Physiotherapy care during the period of hospitalization after THA.
9995510|NCT01491048|Active Comparator|No physiotherapy after THA|No Physiotherapy care during the period of hospitalization after THA.
9995511|NCT01491061|Active Comparator|Ranolazine|Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)
9995512|NCT01491061|Placebo Comparator|Placebo|Placebo
9995513|NCT01491074|Placebo Comparator|NaCl 0.9% 100 ml|
9995514|NCT01491074|Experimental|Tocilizumab 280 mg|Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl
9995515|NCT01491087|Experimental|PENTAXIM® vaccine group|
9995516|NCT01491100||Group 1|
9995517|NCT01491126||examinees undergoing bidirectional endoscopy|Study population will include sequential examinees undergoing bidirectional endoscopy, age> 18 years
9995518|NCT01491139|Experimental|single arm|"All patients will receive induction chemotherapy (cisplatin and 5-FU), followed by cisplatin chemotherapy and radiotherapy in addition to oral olaparib.~Induction chemotherapy (21 day cycle)~Drug: cisplatin 80mg/m2 (day 1)~Drug: 5-FU (fluorouracil) 1000mg/m2/day (day 1-4 continuous infusion)~olaparib plus chemoradiotherapy (8 weeks)~Drug: olaparib~Drug: Cisplatin~Radiation"
9995519|NCT01491152|Experimental|WBV Training|
9995520|NCT01491152|No Intervention|Control|No WBV Training. Standard of Care.
9995521|NCT01491165|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
9995522|NCT01491191|Experimental|PEA|Administration of PEA from 8 days before surgical operation until 30 days after surgery.
9995523|NCT01491191|Active Comparator|Sugar pill|Administration of placebo from 8 days before surgical operation until 30 days after surgery.
9995524|NCT01491204|Experimental|paclitaxel +HM30181|
9995525|NCT01491230||25 autologous/25 allogeneic patients|
9995526|NCT01491243|Active Comparator|Intensive treatment group|Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings
9995527|NCT01491243|Active Comparator|Standard treament group|Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings
9995528|NCT01491256|Active Comparator|High dose Atorvastatin|Arm of pre-procedural high dose atorvastatin loading
9995529|NCT01491256|Placebo Comparator|Control|No pre-procedural high dose atorvastatin loading
9995530|NCT01491269|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
9995531|NCT01491269|No Intervention|Control condition|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
9995532|NCT01491282||No treatment|
9995533|NCT01491295|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
9995534|NCT01491295|Experimental|Tenofovir|Switch from lamivudine/adefovir add on threatment to tenofovir monotherapy
9995535|NCT01491308|Active Comparator|Restrictive|Hemoglobin concentrations will be maintained in the range of 7.5 to 9.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 7.5 g per deciliter.
9915392|NCT00760656||Research Participants|Participants with a diagnosis of childhood malignancy treated or followed at SJCRH
9517609|NCT03304899|Active Comparator|Control group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...)."
9517610|NCT03304886||Migraineurs|with a migraine
9915393|NCT00760656||Control Participants|Siblings, parents, relatives or friends of St. Jude patients or former patients or SJCRH employees who are not SJLIFE study team members or supervised by a SJLIFE study team members
9915394|NCT00760682|Experimental|1|30 preoperative HBO sessions, sequestrectomy and 10 postoperative HBO sessions. The duration of each session is 90 minutes. 100 % oxygen is inhaled during decompression to 2.4 ATA.
9915395|NCT00760682|No Intervention|2|Sequestrectomy without HBO treatment
9915396|NCT00760695|Active Comparator|A|the patients in this arm are receiving 2,5 mg dronabinol twice daily
9915397|NCT00760695|Placebo Comparator|B|the patients in this arm are receiving 2,5 mg placebo twice daily
9915398|NCT00760708||undergoing persantine stress test|
9915399|NCT00760721|Experimental|1|Educational small group session with HBV screening resources provided
9915400|NCT00760721|Sham Comparator|2|Educational small group discussion, diet/physical activity resources provided
9915401|NCT00760734|Experimental|Hyperbaric oxygen therapy-TBI/PCS|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
9915402|NCT00760734|Experimental|Hyperbaric Oxygen Therapy-PCS/PTSD|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
9915403|NCT00760760|Experimental|n-3 PUFA|
9915404|NCT00760760|Placebo Comparator|Control|
9915405|NCT00760773|Experimental|1|
9915406|NCT00760773|Experimental|2|
9915407|NCT00760773|Placebo Comparator|3|
9915408|NCT00760786|Active Comparator|1|Intensive lipid lowering plus Omega3-fatty acid
9915409|NCT00760786|Active Comparator|2|Moderate lipid lowering plus Omega3-fatty acid
9915410|NCT00760786|Active Comparator|3|Intensive lipid lowering plus placebo
9915411|NCT00760786|Active Comparator|4|Moderate lipid lowering plus placebo
9915412|NCT00760799|Active Comparator|1|Standard discectomy without anular repair
9915413|NCT00760799|Experimental|2|Standard Discectomy with anular repair
9915414|NCT00760812|Experimental|1|This group will first receive the Early Social Interaction Project parent-implemented intervention (PII) for 9 months, followed by the Early Social Interaction Project information, education, and support (IES) intervention for 9 months.
9915415|NCT00760812|Experimental|2|The group will first receive IES for 9 months, followed by PII for 9 months.
9915416|NCT00760825|Experimental|Vaccine|killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)
9915417|NCT00760851|Experimental|1|Bb-12 supplemented strawberry yogurt drink
9915418|NCT00760851|Placebo Comparator|2|Regular strawberry yogurt drink with no Bb-12 added
9915419|NCT00760864|Experimental|TAK-715 25 mg BID|
9915420|NCT00760864|Experimental|TAK-715 50 mg BID|
9915421|NCT00760864|Experimental|TAK-715 100 mg BID|
9915422|NCT00760864|Active Comparator|Methotrexate|
9915423|NCT00760890|Experimental|A|Medicinal Iron
9915424|NCT00760890|Experimental|B|Iron fortified wet pack cereal
9915425|NCT00760890|No Intervention|C|Control
9915426|NCT00760903||> 18 years moderate head trauma|Group I: (Pilot group): 5-10 patients > 18 years old, gender and race indifferent with moderate head trauma.
9915427|NCT00760903||> 18, gender and race indifferent|Group II: 30 patients > 18 years old, gender, and race indifferent with moderate head trauma
9915428|NCT00760903||Pediatric|Group III: 30 patients < 18 years old, gender and race indifferent with moderate head trauma (pediatric patient group)
9915429|NCT00760903||Pre-evaluated|Group IV: 10-20 patients age, gender and race indifferent with moderate head trauma that have been examined with conventional MRI of the brain, MRS and DTI as clinically requested. The images of these patients will be evaluated retrospectively for data- point collection.
9915430|NCT00760903||Control Group|Group V (control group): 20 volunteers without prior history of traumatic brain injury or neurological problems.
9915431|NCT00760916|Placebo Comparator|Placebo|placebo
9915432|NCT00760916|Active Comparator|UT-15C 0.25 mg|UT-15C 0.25 mg
9915433|NCT00760916|Active Comparator|UT-15C 1 mg|UT-15C 1 mg
9915434|NCT00760916|Active Comparator|UT-15C 5 mg|UT-15C 5 mg
9915435|NCT00760942|Active Comparator|1|Liquid human milk fortifier
9915436|NCT00760942|Active Comparator|2|Powdered human milk fortifier
9915437|NCT00760968|Experimental|TAK-783 100 mg QD + Methotrexate|
9915438|NCT00760968|Active Comparator|Methotrexate|
9517611|NCT03304886||Control|Participants without migraine
9517612|NCT03304860|Experimental|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
9915439|NCT00760981|Experimental|Imatinib|200 mg orally daily and 400 mg orally daily for 4 weeks.
9915440|NCT00761020|Experimental|Mefloquine|Mefloquine 250 mg orally daily x 3 days beginning 2 days prior to challenge and then weekly for 4 weeks post challenge.
9517613|NCT03304847|Other|Ablation|Radio-frequency catheter ablation
9915441|NCT00761020|Sham Comparator|Control|
9915442|NCT00761033|Experimental|music|children will listen to music during procedure
9915443|NCT00761033|Other|Standard care|Standard care
9915444|NCT00761059|Active Comparator|Glucose 20%|
9915445|NCT00761059|Placebo Comparator|placebo|
9915446|NCT00761072||1|The source of data will be from spinal surgery procedures performed at CHOP from 4/1/07 to 3/31/08 using a TIVA anesthetic technique of propofol/remifentanil infusions
9915447|NCT00761098|Active Comparator|1|Standard Care (albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
9915448|NCT00761098|Experimental|2|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
9915449|NCT00761124|Experimental|1|Educational small group session regarding prostate cancer
9915450|NCT00761124|Other|2|Printed material regarding general prostate cancer information provided.
9915451|NCT00761163|Experimental|1|
9915452|NCT00761163|Experimental|2|
9915453|NCT00761163|Experimental|3|
9915454|NCT00761228|Active Comparator|Apomorphine|Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
9915455|NCT00761228|Placebo Comparator|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
9915456|NCT00761332||Teriparatide|Patients treated with teriparatide
9915457|NCT00761332||Antiresorptive|Patients treated with antiresorptive therapy
9915458|NCT00761358|Experimental|Z-338|
9915459|NCT00761358|Placebo Comparator|placebo|
9915460|NCT00761384|Experimental|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
9915461|NCT00761397||Study Program Group|
9915462|NCT00761397||Usual Care Group|
9915463|NCT00761410|Other|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
9915464|NCT00761423|Experimental|1|Combination of eccentric exercises and injection of PRP
9915465|NCT00761423|Placebo Comparator|2|Combination of eccentric exercises and physiological saline injection
9915466|NCT00761436|Experimental|Arm 1|
9915467|NCT00761449|Experimental|1|1. lenalidomide
9915468|NCT00761475|Placebo Comparator|1|primary closure of the midline
9915469|NCT00761475|Active Comparator|2|onlay mesh supported closure
9915470|NCT00761475|Active Comparator|3|sublay mesh supported closure
10213120|NCT04588727|Experimental|AZD3366 Dose 2 Part A|Randomized healthy subjects will receive Dose 2 of AZD3366.
10213121|NCT04588727|Experimental|AZD3366 Dose 3 Part A|Randomized healthy subjects will receive Dose 3 of AZD3366.
10213122|NCT04588727|Experimental|AZD3366 Dose 4 Part A|Randomized healthy subjects will receive Dose 4 of AZD3366.
10213123|NCT04588727|Experimental|AZD3366 Dose 5 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.
10213124|NCT04588727|Experimental|AZD3366 Dose 6 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.
10213125|NCT04588727|Experimental|AZD3366 Dose 7 Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.
10213126|NCT04588727|Placebo Comparator|Placebo Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.
10213127|NCT04588727|Experimental|AZD3366 Dose X Part B|Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.
10213128|NCT04588727|Placebo Comparator|Placebo Dose X Part B|Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.
10213129|NCT04581330|Experimental|DEKA SmartXide C02 laser|One half of the subject's neck will be treated with ablative fractional CO2 laser.
10213130|NCT04581330|No Intervention|Control|The other half of the subject's neck will not be treated with the ablative fractional CO2 laser.
10213131|NCT04576247|Experimental|Combined aerobic and resistance exercise|12 weeks of supervised resistance exercise and unsupervised aerobic exercise.
10213132|NCT04576182|Experimental|Supportive-Expressive|Participants will receive supportive-expressive treatment for 16 weeks.
10213133|NCT04576182|Experimental|Emotion-Focused|Participants will receive Emotion-Focused treatment for 16 weeks.
10213134|NCT04573582|Experimental|Enasidenib (CC-90007) tablet|Participants will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
10213135|NCT04569695|Experimental|Part 1: Cohort A: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 once daily (QD) on Day 1 followed by washout period of 4 days and then Dose 1 of JNJ-70033093 QD from Days 5 to 12.
10213136|NCT04569695|Experimental|Part 1: Cohort B: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 twice daily (BID) from Days 1 to 8.
10213137|NCT04569695|Experimental|Part 1: Cohort C: JNJ-70033093|Participants will receive Dose 2 of JNJ-70033093 BID from Days 1 to 8.
10213138|NCT04569695|Experimental|Part 2: Cohort D: JNJ-70033093|Participants will receive Dose 3 of JNJ-70033093 QD on Day 1 followed by washout period of 4 days and then Dose 3 of JNJ-70033093 BID from Days 5 to 12 in Cohort D. Dose escalation to Part 2: Cohort D will occur only after the safety and tolerability data of the Part 1 are assessed.
10213139|NCT04565145|Experimental|Kava Pharmacokinetics Group|75 mg kava dietary supplement capsules per day for one week.
10213140|NCT04565145|Placebo Comparator|Placebo|Three placebo capsule per day for one week
9517614|NCT03304834|Experimental|ECHOPULSE|Arm of patient treated by HIFU
9915471|NCT00761488|Experimental|1|AcrySof® Toric IOL
9915472|NCT00761501|Experimental|1|
9915473|NCT00761501|Active Comparator|2|
9915474|NCT00761501|Active Comparator|3|
9915475|NCT00761540|Experimental|A1|
9915476|NCT00761540|Placebo Comparator|A2|
9915477|NCT00761540|Experimental|B1|
9915478|NCT00761540|Placebo Comparator|B2|
9517615|NCT03304808|Experimental|device|
9517616|NCT03304808|Active Comparator|behavioral|
9915479|NCT00761540|Experimental|C1|
9915480|NCT00761540|Placebo Comparator|C2|
9915481|NCT00761553|Experimental|1|Solid dietary supplements with exercise
9915482|NCT00761553|Experimental|2|Solid dietary supplements without exercise
9915483|NCT00761553|Experimental|3|Liquid dietary supplements with exercise
9915484|NCT00761553|Experimental|4|Liquid supplements without exercise
9915485|NCT00761566|Experimental|1|
9915486|NCT00761566|Experimental|2|
9915487|NCT00761644|Experimental|Doxil, Bevacizumab + Temsirolimus|"Doxil day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.~Bevacizumab day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.~Temsirolimus days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes."
9915488|NCT00761670|Active Comparator|1|
9915489|NCT00761670|Active Comparator|2|
9915490|NCT00761683||1|Patients diagnosed with endometriosis
9915491|NCT00761696|Experimental|IPI-926|Oral daily dosing
9915492|NCT00761722|Experimental|Arm 1|"subcutaneous and oral azacitidine~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle."
9915493|NCT00761722|Experimental|Arm 2|"Oral Azacitidine~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
9915494|NCT00761787||1|Heart transplanted subjects.
9915495|NCT00761839|Experimental|Arm 1|These patients receive the experimental intervention--the after-care summary.
9915496|NCT00761839|Active Comparator|Arm 2|These patients are the control group and receive usual care.
9915497|NCT00761852|Active Comparator|1|Ruboxistaurin
9517617|NCT03304808|No Intervention|waiting list|
9517618|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
9915498|NCT00761852|Placebo Comparator|2|Placebo
9915499|NCT00761878|Active Comparator|Skin treatment|
9915500|NCT00761904|Experimental|receipt of free generic samples|
9915501|NCT00761904|No Intervention|usual prescribing|
9915502|NCT00761917||1: Normal|Subjects without dry eye symptoms based on questionnaire.
9915503|NCT00761917||2: Dry Eye|Subjects with dry eye symptoms based on questionnaire.
9915504|NCT00761982|Other|bone marrow stem cells|Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.
9915505|NCT00761995|Active Comparator|Azopt|topical eye drop dosed 1 drop 3 times daily
9915506|NCT00761995|Active Comparator|Cosopt|topical eye drop
9915507|NCT00762008||Heart Failure|
9915508|NCT00762047|Experimental|Durasphere|
9915509|NCT00762047|Sham Comparator|Sham|
9915510|NCT00762060||Active|Surgical site continuous local anesthetic infusion with ONQ silver Soaker System
9915511|NCT00762060||Control|Hospital standard of care for pain management (Patient controlled analgesia or epidural)
9915512|NCT00762099|Active Comparator|1|Pregabalin Group
9915513|NCT00762099|Placebo Comparator|2|Placebo group
9915514|NCT00762112|Experimental|TAK-559 32 mg QD|
9915515|NCT00762125|Experimental|Cognitive restructuring and coping skills training (CR+ST)|
9915516|NCT00762125|Experimental|Exposure therapy (ET)|
9915517|NCT00762125|Experimental|Combination (COMB) treatment|
9915518|NCT00762125|Active Comparator|Attention control (AC) treatment|
9915519|NCT00762138|Other|Autologel System|Autologel System produces platelet rich plasma gel
9915520|NCT00762151|Placebo Comparator|Negative Control|Regular Toothpaste
9915521|NCT00762151|Active Comparator|Positive Control|Standard anti-plaque and anti-bacterial toothpaste.
9915522|NCT00762151|Active Comparator|Prototype|AN0128 Toothpaste
9915523|NCT00762190|Experimental|TAK-559 32 mg QD + Insulin|
9915524|NCT00762190|Active Comparator|Insulin|
9915525|NCT00762242||1|Blood sampling and brachial artery ultrasound
9915526|NCT00762255|Experimental|A - Phase I Dose Escalation|Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
9915527|NCT00762255|Experimental|B - Treatment at Maximum Tolerated Dose (MTD)|MTD - Treatment at maximum tolerated dose
9915528|NCT00762281|Other|Treatment of Hyperopic LASIK|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
9915529|NCT00762294||644-001|Women treated for breast cancer who will be starting Arimidex or Femara
9915530|NCT00762333||Myocardial Infarction|
9915531|NCT00762346|Experimental|1|
9915532|NCT00762398||Adult patient undergoing a surgery|Adult patient undergoing a surgery in the supine position and require an arterial line for anesthesia/surgery purposes
9915533|NCT00762437|Experimental|1|
9915534|NCT00762489|Other|TAT vs. RT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Rectal Temperature (RT).
9915535|NCT00762489|Other|TAT vs. AT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Axillary Temperature (AT).
9915536|NCT00762567|Experimental|1|phenylephrine
9915537|NCT00762593|Experimental|1|transvaginal electrical stimulation with a home use programmable device used 30 minutes every day during 8 weeks
9998059|NCT01514578|Placebo Comparator|Dextrose in Water|
9995536|NCT01491308|Active Comparator|Liberal|Hemoglobin concentrations will be maintained in the range of 10.0 to 12.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 10.0 g per deciliter.
9995537|NCT01491321|Experimental|Bee Venom Acupuncture & Loxoprofen|
9995538|NCT01491321|Placebo Comparator|Sham Bee Venom Acupuncture & Loxoprofen|
9995539|NCT01491334||Asymptomatic|Asymptomatic women presenting at various ages without prolapse condition.
9995540|NCT01491334||Symptomatic|Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
9995541|NCT01491347||alcohol dependent|
9995542|NCT01491360|Experimental|LaserACE(R) procedure performed|The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.
9995543|NCT01491373|Experimental|rhBMP-2/ACS|
9995544|NCT01491373|Active Comparator|Autograft|
9995545|NCT01491386|Experimental|rhBMP-2/ACS|
9995546|NCT01491386|Active Comparator|Autogenous Bone|
9995547|NCT01491399|Experimental|INFUSE™ Bone Graft/CORNERSTONE-SR™|
9995548|NCT01491399|Active Comparator|Autogenous bone/CORNERSTONE-SR™|
9995549|NCT01491412||Acute psychotic episode in schizophrenia|Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
9995550|NCT01491425|Experimental|rhBMP-2/ACS|
9995551|NCT01491425|Active Comparator|Autogenous Bone|The control group of patients from another study (Protocol ID: C-9702 Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic DDD).
9995552|NCT01491438|Experimental|PRGF and conventional treatment|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
9995553|NCT01491438|Active Comparator|Conventional treatment alone|Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
9995554|NCT01491451|Experimental|rhBMP-2/ACS|
9995555|NCT01491451|Active Comparator|Autogenous bone|
9995556|NCT01491464|Experimental|rhBMP-2/ACS|
9995557|NCT01491464|Active Comparator|Autogenous bone|
9995558|NCT01491477|Experimental|INFUSE™ Bone Graft|
9995559|NCT01491477|Active Comparator|Autogenous bone|
9995560|NCT01491503|Experimental|Montelukast and levocetirizine|
9995561|NCT01491503|Active Comparator|Montelukast|
9995562|NCT01491503|Active Comparator|Levocetirizine|
9995563|NCT01491542|Experimental|rhBMP-2 / ACS|
9995564|NCT01491542|Active Comparator|Autogenous bone|
9995565|NCT01491555||DMD patients|35 boys ages 2 through 30 with DMD
9995566|NCT01491555||Control Group|35 healthy boys ages 2 through 30
9995567|NCT01491581|Experimental|micronutrient enriched bar|bar enriched with micronutrients
9995568|NCT01491581|Placebo Comparator|control arm|normal bar
9995569|NCT01491620|Experimental|532 nm KTP laser treatment|
9995570|NCT01491646||Pulmonary Hypertension|Previous diagnosis of PH by right heart catheterization
9995571|NCT01491646||Healthy Controls|Healthy controls without lung/heart conditions
9995572|NCT01491659|Active Comparator|Amoxicillin/clavulanate/Idoform Plus|
9995573|NCT01491659|Placebo Comparator|Amoxicillin/clavulanate/Placebo|
9995574|NCT01491685||Pregnant|
9995575|NCT01491685||Non- Pregnant|
9995576|NCT01491698|Experimental|pts undergoing Roux-en-Y pouch reconstruction (RYP)|This is a pilot randomized controlled trial comparing changes in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
9995577|NCT01491698|Active Comparator|pts undergoing conventional Roux-en-Y reconstruction (RYC)|This is a pilot randomized controlled trial comparing change in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
9995578|NCT01491711|Active Comparator|Fractionated 5-ALA HCl 20% gel PDT|Twice on day 1
9995579|NCT01491711|Active Comparator|Methylaminolevulinate PDT in 2 sessions|On day 1 and 8
9995580|NCT01491724||pCLE images|
9995581|NCT01491750|Experimental|GUIDED IMAGERY|
9995582|NCT01491750|Placebo Comparator|AUDIO BOOK|
9995583|NCT01491815|Active Comparator|Active conventional therapy (ACT)|Non-biological DMARD's: Methotrexate plus steroids or Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids
10213141|NCT04564898|Experimental|trifluridine/tipiracil plus capecitabine and bevacizumab|
10213142|NCT04562779|Experimental|XR Naltrexone|Participants will receive a single dose of extended-release, injectable naltrexone prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
9915538|NCT00762593|Placebo Comparator|2|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
9915539|NCT00762658|Experimental|1|AN2728 Ointment, 5%
9915540|NCT00762658|Experimental|2|AN2728 Ointment, 2%
9915541|NCT00762658|Experimental|3|AN2728 Ointment, 0.5%
9915542|NCT00762658|Placebo Comparator|4|AN2728 Ointment Vehicle
9915543|NCT00762658|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
9915544|NCT00762658|Active Comparator|6|Protopic® Ointment (tacrolimus 0.1 %)
9915545|NCT00762671|Placebo Comparator|2|Placebo
9915546|NCT00762671|Active Comparator|1|Ebselen
9915547|NCT00762684|Experimental|TAK-559 32 mg QD|
9915548|NCT00762684|Placebo Comparator|Placebo QD|
9915549|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 5 mg QD|
9915550|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 40 mg QD|
9915551|NCT00762736|Active Comparator|Pioglitazone 15 mg QD|
9915552|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 5 mg QD|
9915553|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 40 mg QD|
9915554|NCT00762736|Active Comparator|Pioglitazone 45 mg QD|
9915555|NCT00762749|Experimental|diphenhydramine HCl|diphenhydramine HCl / Children's Benadryl Allergy Liquid
9915556|NCT00762775|Experimental|1|Calcium supplementation and placebo
9915557|NCT00762775|Experimental|2|Vitamin D supplementation and placebo
9915558|NCT00762775|Experimental|3|Calcium and Vitamin D supplementation
9915559|NCT00762775|Placebo Comparator|4|Placebos only
9915560|NCT00762814|Experimental|Parkinson subjects with freezing|"Each subject will have been diagnosed with Parkinson disease and will serve as his/her own control. Inclusion criteria: history of consistent freezing with ambulation in a straight line and/or when turning, normal central and peripheral neurological function, at least grade 4 strength and normal joint ranges of motion in both legs, normal somatosensory function in the feet (joint position sense), except for their neurological diagnosis and use of levodopa, each must have had clear benefit from levodopa for at least some of his/her PD symptoms, and all subjects with PD must be able to walk independently for 10 feet.~Exclusion criteria include: serious medical problem that would impair the ability to undergo testing, use of neuroleptic or other dopamine-blocking drug, use of drugs that might affect balance, history or evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease, or participants who are unable to provide informed consent."
9915561|NCT00762840|Experimental|Apexum|the tooth is treated by a standard root canal treatment, supplemented by Apexum Ablator protocol, in which the periapical lesion tissue is minced and removed through the root canal, in a minimally invasive fashion.
9915562|NCT00762840|Active Comparator|Control|the tooth is subject to conventional endodontic procedure alone, (standard root canal treatment)
9915563|NCT00762879||No treatment|
9915564|NCT00762905|Active Comparator|1|LiquiBand Laparoscopic
9915565|NCT00762905|Active Comparator|2|Dermabond
9915566|NCT00762944||Biomet TMJ Replacement System|All patients required total reconstruction of the temporomandibular joint (unilateral or billateral)
9915567|NCT00762957|Experimental|TAK-559 16 mg QD + Metformin QD|
10213143|NCT04562779|Experimental|IV Ketamine|Participants will receive a single dose of intravenous ketamine (0.5mg/kg over 40 minutes) prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
10213144|NCT04562779|Active Comparator|Linkage|Participants will receive no single-dose addiction medication prior to hospital discharge, but will receive enhanced linkage to follow-up addiction care.
10213145|NCT04560621|Experimental|MAPS+|
10213146|NCT04560621|No Intervention|Standard of Care|
10213147|NCT04556838|Experimental|VVN001, 1%|VVN001, 1% ophthalmic solution
10213148|NCT04556838|Experimental|VVN001, 5%|VVN001, 5% ophthalmic solution
10213149|NCT04556838|Placebo Comparator|Vehicle|VVN001 Ophthalmic Solution Placebo
10213150|NCT04555551|Experimental|Targeted MCARH109 CAR Modified T cells|Patients will undergo leukapheresis of peripheral blood for further T cell enrichment; activation and genetic modification using a lentiviral vector encoding a GPRC5D targeted CAR (MCARH109). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. These modified T cell infusions will be administered 2-7 days following completion of conditioning chemotherapy.
10214003|NCT02245230|Experimental|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
10214004|NCT02224573|Experimental|GWP42003-P|
10214005|NCT02211599|Experimental|15% protein meal and sweetened beverage|Breakfast and lunch will each contain 15% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
10214006|NCT02211599|Experimental|30% protein meal and sweetened beverage|Breakfast and lunch will each contain 30% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
10214007|NCT02210650|Other|Ureteral stone removal|Group 1 will receive the standard treatment of having only the ureteral stone removed
10214008|NCT02210650|Other|Asymptomatic kidney stones and ureteral stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the ureteral stone
9995584|NCT01491815|Active Comparator|Biologic agent 1|Cimzia: Certolizumab-pegol plus Methotrexate and steroids
9995585|NCT01491815|Active Comparator|Biologic agent 2|Orencia: Abatacept plus Methotrexate and steroids
9995586|NCT01491815|Active Comparator|Biologic agent 3|RoActemra: Tocilizumab plus Methotrexate and steroids
9995587|NCT01491867|Experimental|Travoprost arm|All individuals receive travoprost 0.003% 1/day in both eyes after 6 weeks wash-out for 3 months
9995588|NCT01491880|Experimental|Child Anxiety Program by Telephone|The child anxiety program by telephone is an adaptation of Ron Rapee's Cool Kids Outreach Program (Lyneham and Rapee, 2006) for child anxiety, with appropriate adaptations made to meet the needs of rural Latino families (including a Spanish translation). This is a parent mediated program, where parents are taught how all the skills of cognitive behavior therapy (CBT) and how to apply these skills to these children's anxieties. Children are also expected to participate, however all direct contact that a therapist may have, is with the parent only.
9995589|NCT01491880|Experimental|Child Anxiety Program- Self Help|Families randomized to the Self-Help CBT condition will receive program materials along with instructions for completing weekly assignments. Specifically, they will receive the same materials as families in the telephone-based condition however in the self-help group, parents and children are expected to read the materials for that week and complete the workbook activities without planned therapist involvement. Instead they will be given the option to initiate a telephone call to the therapist, if they have questions or need extra support.
9995590|NCT01491906|Experimental|Text-Messaging|The group that receives the behavioral counseling and text messaging lifestyle intervention
9995591|NCT01491906|No Intervention|Usual Care|This group will receive usual care
9995592|NCT01491997|Active Comparator|Mind Body Medicine Course 1|The subject of each course is Mind/Body medicine. One course is learning about the mind and the body through experiences. The other is learning about the mind and the body through experiences. Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. . You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
9995593|NCT01491997|Active Comparator|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
9995594|NCT01492010|Experimental|25 g protein|25 g whey protein
9995595|NCT01492010|Experimental|6.25 g protein supplemented with leucine|6.25 g protein supplemented with leucine
9517619|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
9517620|NCT03304782||Preterm birth|Data collected using Fitbit activity tracker from women with delivery prior to 37 weeks gestation
9517621|NCT03304782||Full-term birth|Data collected using Fitbit activity tracker from women with delivery after 37 weeks gestation
9915568|NCT00762957|Experimental|TAK-559 32 mg QD + Metformin QD|
9915569|NCT00762957|Active Comparator|Metformin QD|
9517622|NCT03304769|No Intervention|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
9915570|NCT00762983||Group 1|Pediatric patients who are treated with Claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous)
9915571|NCT00763022|Experimental|TAK-559 16 mg QD|
9915572|NCT00763022|Experimental|TAK-559 32mg QD|
9915573|NCT00763022|Placebo Comparator|Placebo QD|
9934424|NCT04839991|Experimental|Multi center open label Dose Escalation followed by Cohort Expansion: Part 2B|Patients will receive CB307 IV infused every 7 days. Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2B arm will enrol patients with PSMA+ metastatic, castration resistant prostate cancer patients with mutations of sponsor interest. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
9934425|NCT04839588||Usability study, healthy volunteers and those with cognitive impairments following chemotherapy|"2 elderly healthy volunteers and 2 participants with lasting cognitive impairments following chemotherapy for breast cancer. All will perform evaluation of a computer-based experimental system. Participants will be~Female Either healthy or breast cancer survivor;~Age 20 to 65 years;~Have st least 12 years of formal education;~Be English speakers;"
9934426|NCT04833361||Mothers|Mothers of children with coloboma.
9934427|NCT04829669||Participants with Major Depressive Disorder (MDD) and Active Suicidal Ideation with Intent|Participants with MDD (moderate or severe) and active suicidal ideation with intent as defined/confirmed by healthcare team will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical chart review, carer and clinician-reported outcome measures records of each participant.
9934428|NCT04829318|Experimental|Esketamine|Participants who were randomly assigned to the esketamine arm in Study 54135419TRD3013 (NCT04338321), had esketamine nasal spray administered through Week 30 (every 2 weeks dosing) or Week 31 (once weekly dosing), completed the maintenance phase at Week 32 will continue to receive esketamine nasal spray once weekly or every 2 weeks along with serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI) in this long-term extension (LTE) study. Participants will receive esketamine nasal spray until it is commercially available in participant's country.
9934429|NCT04827238||Patients with Elevated Gradients Post Transcatheter Aortic Valve Replacement|Patients who have an echocardiographic transaortic mean gradient ≥ 20mmHg OR VARC-3 criteria for ≥ moderate hemodynamic valve deterioration post TAVR on any TTE > 1 month post-TAVR
9934430|NCT04826341|Experimental|1/Phase I|Dose escalated Sacituzumab Govitecan and Berzosertib
9934431|NCT04826341|Experimental|2/Phase II|Sacituzumab Govitecan and Berzosertib treatment with identified MTD based on phase I.
9934432|NCT04823988||Adults 18 and over|Adults 18 and over
9934433|NCT04821271|Experimental|1|Individuals in Arm 1 will receive daily double-blinded TS-161 for three weeks during Test Session 1 and daily double-blinded placebo for three weeks during Test Session 2.
9934434|NCT04821271|Experimental|2|Individuals in Arm 2 will receive daily double-blinded placebo for three weeks during Test Session 1 and daily double-blinded TS-161 for three weeks during Test Session 2.
9934435|NCT04819256|Experimental|Intervention arm|Providers use PACE-It mobile application as a care co-ordination platform
9934436|NCT04819256|No Intervention|Usual care|Providers use usual modes of communication (e.g., phone calls, emails)
9934437|NCT04817345|Experimental|Plerixafor|Participants will receive a subcutaneous dose of 0.24 mg/kg of plerixafor once daily (Q24hr) x 2 days.
9934438|NCT04817254|Experimental|Arm 1|Nivolumab + Ipilimumab 1mg/kg + TMZ
9934439|NCT04817254|Experimental|Arm 2|Nivolumab + Ipilimumab 3mg/kg + TMZ
9934440|NCT04815356|Experimental|Experimental therapy: Dose Escalation|Escalating doses of autologous anti-CD22-CAR T-cells in subjects to determine the MTD
9934441|NCT04815356|Experimental|Experimental therapy: Dose Expansion|Autologous anti-CD22-CAR T-cells at the MTD
9934442|NCT04814368|Experimental|LNA043|Placebo to canakinumab + LNA043
9934443|NCT04814368|Placebo Comparator|Placebo|Placebo to canakinumab
9934444|NCT04814368|Experimental|canakinumab + LNA043|canakinumab + LNA043
9934445|NCT04814368|Experimental|canakinumab|canakinumab
9995596|NCT01492010|Experimental|6.25 g whey protein with EAA|6.25 g protein supplemented with a mixture of essential amino acids devoid of leucine
9915574|NCT00763074|Placebo Comparator|Control|Conventional education of life style intervention for type 2 diabetes
9915575|NCT00763074|Active Comparator|Diet|Dietary calorie restriction
9915576|NCT00763074|Active Comparator|Exercise|Encourage to increase exercise amount: more than 60min's of exercise with moderate activity level two times per day
9915577|NCT00763074|Active Comparator|Diet and exercise|Intervention for both of exercise and diet
9915578|NCT00763087|Active Comparator|nonweightbearing exercise|
9915579|NCT00763087|Placebo Comparator|nonexercising control|
9915580|NCT00763087|Experimental|weightbearing exercise|
9915581|NCT00763100||Breast cancer|Patients in treatment or post-treatment for breast cancer
9915582|NCT00763113|Experimental|1|Vanguard PS Knee
9915583|NCT00763113|Active Comparator|2|Vanguard CR Knee
9915584|NCT00763126|Active Comparator|Spouse present,|
9915585|NCT00763126|Active Comparator|spouse absent|
9915586|NCT00763152||stability of Beacons in prostatic bed|Patients implanted with the Calypso transponders following radical prostatectomy for prostate cancer will be followed for observation of transponder stability.
9915587|NCT00763165|Active Comparator|A|
9915588|NCT00763165|Placebo Comparator|B|
9915589|NCT00763178|Experimental|PTSD|Duloxetine
9915590|NCT00763204|Experimental|1|AN2728 Cream, 2%
9915591|NCT00763204|Experimental|2|AN2728 Cream, 1%
9915592|NCT00763204|Experimental|3|AN2728 Cream, 0.3%
9915593|NCT00763204|Placebo Comparator|4|AN2728 Cream Vehicle
9915594|NCT00763204|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
9915595|NCT00763217||stroke patient cohort|Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
10213151|NCT04551378||Observational (survey)|Patients and survivors complete a survey online over 20-30 minutes at baseline about COVID-19 specific psychological distress, health care utilization, health behavior, social and financial disruptions, HRQoL, their social support, perceived benefits under times of stress, and the ability to manage stress. Patients and survivors may be contacted again at 6 months and 1 year for COVID-19 research.
10213152|NCT04549337|Experimental|4X4|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up with a heart rate of 60-70% of HRmax followed by 4 intervals of 4 minutes at an intensity that will induce at least 85% of HRmax (we will start with 75% of watt max).~Each interval is separated by 3-minute active pauses, biking at 50-70% of HRmax. Following this a 3-minute cooldown (at warm up intensity) will be performed."
10213153|NCT04549337|Active Comparator|6X1|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up on 30% of watt-max followed by 6 intervals of 1 minute at 100% of the watt-max.~Each interval is interspersed by 3-minute active pauses at 30% of watt-max. Following this a 7-minute cooldown (at warm up intensity) will be performed."
9915596|NCT00763230|Experimental|active|Full active tDCS treatment
10213154|NCT04549337|Active Comparator|10-20-30|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up at 60-70% of HRmax followed by 3 intervals of 5 minutes interspersed by 3 minutes on 50-70% of HRmax.~Each interval consists of 5 minutes of 5 repeated 30-20-10 intervals, consisting of 30 seconds at easy pace, 20 seconds at medium pace and 10 seconds at all-out. Following this a 7-minute cooldown (at warm up intensity) will be performed."
10213155|NCT04547790|Experimental|Psyllium group|Subjects will take psyllium once daily for the first three days, then twice daily starting Day 4 until the end of the study.
10213156|NCT04547790|Experimental|Wheat Dextrin group|Subjects will take wheat dextrin once daily for the first three days, then twice daily starting Day 4 until the end of the study.
10213157|NCT04545905||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Gaoua, Banfora, and Orodara districts.
9915597|NCT00763230|Sham Comparator|sham|Placebo tDCS will be give
9915598|NCT00763295||HIV infection|
9915599|NCT00763308|Experimental|1|Participants will use the Web-based Heart Healthy program.
9915600|NCT00763308|No Intervention|2|Participants will receive treatment as usual.
9915601|NCT00763347|Experimental|SYR-619 12.5 mg QD|
9915602|NCT00763347|Experimental|SYR-619 50 mg QD|
10213158|NCT04541537|Experimental|Sorbstar®|Odour sampling : rub hands with Sorbstars® before and post-surgery
10213159|NCT04541537|Experimental|Dog Detection|Odour sampling :sleep over a night with a compress on the affected breast before and after surgery
9915603|NCT00763347|Experimental|SYR-619 100 mg QD|
9915604|NCT00763347|Experimental|SYR-619 200 mg QD|
9915605|NCT00763347|Placebo Comparator|Placebo QD|
9915606|NCT00763347|Active Comparator|Alogliptin 25 mg QD|
9915607|NCT00763373||1|Observation group
9915608|NCT00763373||2|Intervention group
10213160|NCT04541212||Cohort A|Prospective
10213161|NCT04541212||Cohort B|Retrospective/Prospective
10213162|NCT04540757||Surgery|Surgery and systemic anti-cancer therapy (with or without radiotherapy) given in any order
10213163|NCT04540757||No surgery|Radiotherapy and systemic anti-cancer treatment given in any order (with or without adjuvant immunotherapy if indicated).
10213164|NCT04540042|Experimental|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
10213165|NCT04540042|Placebo Comparator|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
10213166|NCT04540042|Experimental|SelK2 (Part 2)|I.V., single-dose (Day 1)
10213167|NCT04540042|Placebo Comparator|Placebo (Part 2)|I.V., single-dose (Day 1)
10213168|NCT04538482|Experimental|DASH Diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber)
10213169|NCT04538482|Active Comparator|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber)
10213170|NCT04526769||COVID-19 Patients|All patients aged 18 years and above who present to Fairview/UMN ERs or ICUs with confirmed or suspect COVID-19 based on the attending physician's judgment will be included.
10213171|NCT04523363|Experimental|Metformin|Study subjects will be randomized to the metformin medication arm. They will take a 500 mg tablet orally twice a day starting at 14 weeks of pregnancy until delivery.
9517623|NCT03304769|Experimental|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
9517624|NCT03304756|Experimental|CAP|Cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
9915609|NCT00763399|Experimental|97-0549B|
9915610|NCT00763425|Experimental|1|
9915611|NCT00763425|Active Comparator|2|
9915612|NCT00763438|Experimental|Sertindole|
9915613|NCT00763477|Placebo Comparator|saline injections|
9915614|NCT00763516|Experimental|Proton radiation and chemotherapy|"Proton radiation~Capecitabine chemotherapy on radiation days~Surgery~Gemcitabine chemotherapy"
9915615|NCT00763542|Experimental|I|Combined treatment: CBT for SUD plus structured writing therapy for PTSD
9915616|NCT00763542|Active Comparator|II|CBT for SUD only
9915617|NCT00763568|Experimental|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
9915618|NCT00763594|Active Comparator|IPT|Interpersonal Psychotherapy for Major Depressive Disorder
9915619|NCT00763594|Experimental|BRT|Brief Relational Therapy adapted for treatment of Major Depressive Disorder
9915620|NCT00763607||1|Radically resected Non small cell lung cancer patients in stage I-III
9915621|NCT00763620|Experimental|1|Catheter for mini bronchoalveolar lavage
9915622|NCT00763633|Active Comparator|highB6|high vitamin B6
9915623|NCT00763633|Active Comparator|lowB6|low vitamin B6
9915624|NCT00763659|Active Comparator|1|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
9915625|NCT00763659|Active Comparator|2|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
9915626|NCT00763659|Placebo Comparator|3|Placebo
9915627|NCT00763672|Other|A|sFlt-1 status known
9915628|NCT00763672|Other|B|sFlt-1 status unknown
9915629|NCT00763685|Active Comparator|etoricoxib 120 mg|active control
9915630|NCT00763685|Placebo Comparator|2|Placebo
9915631|NCT00763685|Active Comparator|3|Paracetamol 1 g and etoricoxib 120 mg
9915632|NCT00763711|Experimental|Injection with Needle Guide|
9915633|NCT00763724||1|Duloxetine
9915634|NCT00763724||2|Venlafaxine
9915635|NCT00763724||3|SSRI
9915636|NCT00763724||4|TCA
9915637|NCT00763724||5|Multiple Antidepressants
9915638|NCT00763724||6|Depressed (not antidepressant treated)
9915639|NCT00763724||7|General population
9915640|NCT00763737|Experimental|FETO|prenatal FETO at 30-31+6 weeks and removal at 34-34+6 wks, followed by standardized postnatal care
9915641|NCT00763737|No Intervention|Expectant management|expectant management during pregnancy followed by standardized neonatal care
9915642|NCT00763763|Experimental|1|imatinib in combination with chemotherapy by vincristin and dexamethasone
9915643|NCT00763776|Other|1|Liver transection by clamp crushing technique
9915644|NCT00763776|Other|2|Liver transection by the ultrasonic dissector
9915645|NCT00763789|Experimental|1|Local anaesthesia and remifentanil sedation
9915646|NCT00763789|Other|2|Total intravenous anaesthesia
9915647|NCT00763802||MNPDR|Type 2 diabetic patients with Mild non-prolipherative retinopathy.
9915648|NCT00763841|Experimental|1|Stimulation will be given daily at a particular site for three days a week
9915649|NCT00763841|Sham Comparator|2|
9995597|NCT01492023||control|control group: no intervention
9995598|NCT01492023||neuropsychological rehabilitation|intervention group: neuropsychological rehabilitation (13 times 60 minutes, once per week, during 13 weeks) control group: no intervention
9995599|NCT01492036||Gene Transfer Therapy|Study participants receiving gene therapy product at MD Anderson Cancer Center
9995600|NCT01492049|Experimental|Patient Decision Aid (PtDA)|Participants view Patient decision aid (PtDA) video.
9995601|NCT01492049|Active Comparator|Control|Participants view a video on Essential Hypertension.
9995602|NCT01492062|Experimental|closed-loop control|Multiple Model Predictive Controller
9995603|NCT01492075|Active Comparator|Continuous infusion|Continuous infusion of LA intraabdominally
9995604|NCT01492075|Experimental|PCRA (Intermittent injection)|Patient controlled LA intraabdominally
9995605|NCT01492114|Experimental|Resveratrol first|"Subjects in the group resveratrol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
9995606|NCT01492114|Active Comparator|Placebo first|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
9995607|NCT01492127|No Intervention|Blood test|Blood test :carcinoma in cirrhotic patients
9995608|NCT01492153||NovoLet® device|
9995609|NCT01492166||Novolet®|
9995610|NCT01492179|Active Comparator|Intravenous Lidocaine|Intravenous lidocaine would be administered as an infusion for pain management both intra- and post-operatively.
9995611|NCT01492179|Active Comparator|Intra-abdominal Lidocaine|Lidocaine would be administered intermittently, once each hour intra-abdominally for postoperative pain management.
9995612|NCT01492179|Placebo Comparator|Normal saline|Normal saline would be administered intra-abdominally and intravenously in the same patient. Rescue analgesia in the form of morphine (PCA) would be used for pain management.
9995613|NCT01492192|Experimental|RCC Patients Antiangiogenic treatment|
9995614|NCT01492205||Human insulin|
10213172|NCT04523363|No Intervention|Standard of Care|Study subjects will be randomized to standard of care and receive routine prenatal care without further intervention for their prediabetes.
10213173|NCT04523168|Experimental|Chronic Refractory Angina|Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.
10213174|NCT04521699|Experimental|CalmioGo + Standard of care|Use of CalmiGO stress management device once daily + standard of care during the 12 weeks of Cardiac rehabilitation
10213175|NCT04521699|No Intervention|Standard of Care|Stand of care alone with 12 weeks of Cardiac rehabilitation
9517625|NCT03304743||Post-menopausal women|A cohort of 124 consecutive post-menopausal women that performed a DXA scan within the previous 12 months
9995615|NCT01492218||NovoLet®|
9995616|NCT01492231||Chart Review|Chart review of patients who had a procedure done at H. H. Chao Comprehensive Digestive Disease Center
9995617|NCT01492244||Patients with knee pain and a known diagnosis|
9995618|NCT01492257|No Intervention|SDM Control|The control arm will consist of usual care, patients will receive existing educational materials.
9995619|NCT01492257|Experimental|SDM Intervention|RCT intervention will include a package of decision and communication aids question-asking, and information recall. The intervention includes digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
9998060|NCT01514591||Non-elective Cesarean Delivery|We will only enroll patients undergoing non-elective CS with an 'epidural top-up' for surgical anesthesia. By definition, our study will only apply to laboring women with working labor epidurals (which were provided for labor analgesia).
9998061|NCT01514604||Little or no experience.|All participants will be asked to declare their degree of experience in the technique being studied. Those declaring themselves as 'New to in-plane ultrasound guided needling. Little or no experience in technique' belong to this cohort and will form the study group.
9998062|NCT01514604||Regular practitioner. Teaching|Participants declaring themselves as 'Regularly incorporate in-plane ultrasound guided needling in clinical practice. Teaching technique to others' fall within this cohort and form the 'control' group allowing application of a realistic acceptable failure rate to Cusum analysis of the study group.
9998063|NCT01514604||Some exposure. Infrequent clinical use.|Participants declaring themselves as belonging to this group will not form part of the analysis. They will be welcome to complete training and receive feedback on their performance according to the study protocol.
9998064|NCT01514656|Active Comparator|Video Self-Instruction (VSI) kit|Individuals will learn CPR using American Heart Association's Video Self-Instruction kit. Main data points being collected at various increments over 12 months are: 1) CPR quality at 6 to 12 months 2) Comfort Level using the skills they learned
9998065|NCT01514656|Experimental|Video-only|Individuals will learn CPR skills using a Video training method. Main data points being collected at various increments over 12 months are: 1) CPR Skills at 6 to 12 months 2) Comfort Level with using CPR
10213176|NCT04517825||Target Population|HIV positive individuals attending Bugoye ART clinic
10213177|NCT04517435|Experimental|ME-401 + R-CHOP|Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP. ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
10213178|NCT04516499||f-FTLD mutation carriers|All participants must be from a family with f-FTLD mutations. The f-FTLD mutation carrier group members will have their genetic status tested and included in this group if a f-FTLD mutation is observed. Participants do not need to know or be told their genetic status.
10213179|NCT04516499||Non-mutation carriers from families with f-FTLD mutations|All participants must be from a family with f-FTLD mutations. The non-mutation carrier group members will have their genetic status tested and included in this group if they do not have a f-FTLD mutation. Participants do not need to know or be told their genetic status.
9915650|NCT00763880|Experimental|Lidocaine|Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
9915651|NCT00763880|Placebo Comparator|Normal Saline|Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site
9915652|NCT00763893|Placebo Comparator|A: Placebo|placebo
9915653|NCT00763893|Active Comparator|B: Losartan|Losartan
9915654|NCT00763906|Placebo Comparator|1|Patients were assigned to norepinephrine infused at the clinician's discretion.
9915655|NCT00763906|Active Comparator|2|Patients were assigned to norepinephrine infused under computerized fuzzy logic control.
9915656|NCT00763932|Experimental|1|
9915657|NCT00763945||1|Patients representing to the hospital with acute coronary syndrome
9915658|NCT00763984|Active Comparator|1 Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT
9915659|NCT00763984|Experimental|2 Bladder Health Class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
9915660|NCT00763997|Experimental|1|Dipyrone
9915661|NCT00763997|Active Comparator|2|Ibuprofen
9915662|NCT00763997|Active Comparator|3|Acetaminophen
9915663|NCT00763997|Placebo Comparator|4|Parecoxib/Valdecoxib
9915664|NCT00764010|No Intervention|1|No dietary counseling, placebo capsules for omega-3
9915665|NCT00764010|Active Comparator|2|Dietary counseling, placebo capsules for omega-3
9915666|NCT00764010|Active Comparator|3|No dietary counseling, omega-3 capsules
9915667|NCT00764010|Active Comparator|4|Dietary counseling and omega-3 capsules
9915668|NCT00764023||No treatment|
9915669|NCT00764023||human samples|
9915670|NCT00764036|Experimental|experimental arm only|add-on therapy with 100, 150 or 200 mg oral artesunate once daily
9915671|NCT00764049|Experimental|1: Single pass albumin dialysis|Patients entered in the pilot study.
9915672|NCT00764062|Experimental|1|7-day amoxicillin treatment (1g per os twice daily)
9915673|NCT00764062|Active Comparator|2|3-day amoxicillin (1g per os twice daily) + 4-day placebo treatment (1g per os twice daily)
9915674|NCT00764075|Experimental|1|guided implantation of the left ventricular lead
9915675|NCT00764075|Placebo Comparator|2|standard implantation of the left ventricular lead
9915676|NCT00764075|Experimental|Pilot Group|feasibility of guided placement of CRT-leads in 20 Patients
9915677|NCT00764088||Anaysis of Full Thickness wounds|To demonstrate the effectiveness or ineffectiveness of novel treating agents or agents used for compassionate rescue, subjects and their wounds will be analyzed retrospectively and their non-identifiable information will be compiled in the form of case studies. Subjects who demonstrated characteristics of interest (e.g. healing) as determined by the PI will be chosen for case studies.
9915678|NCT00764101|Experimental|1|9 sessions of attentional bias modification (computerized training program)
9915679|NCT00764101|Placebo Comparator|2|Attentional control condition (placebo training program)
9915680|NCT00764114|Active Comparator|1|- group A : during 6 weeks after the inclusion
9915681|NCT00764114|Active Comparator|2|-group B : during 12 weeks after the inclusion
9915682|NCT00764127||Obese Control|
9915683|NCT00764127||Normal Control|
9915684|NCT00764127||OVERWEIGHT ADOLESCENT PATIENTS UNDERGOING BARIATRIC SURGERY|
9915685|NCT00764140||2|Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
9915686|NCT00764140||1|Patients with hepatocellular carcinoma and Healthy controls
9915687|NCT00764153|Other|Internal fixation|Closed reduction and internal fixation with two parallel screws (Olmed)
9915688|NCT00764153|Other|Bipolar hemiarthroplasty|Hemiarthroplasty with Charnley/ Hastings prosthesis
9915689|NCT00764166|Experimental|1|
9915690|NCT00764166|Active Comparator|2|
9915691|NCT00764179|Experimental|1|hyperproteinic milk
9915692|NCT00764179|Active Comparator|2|Normoproteinic milk
9915693|NCT00764192|Experimental|1|14 HD patients are studied before and after a single HD using a polysulphone dialyser.
9915694|NCT00764205||Study Group|Troponin measured prior to hospital arrival
9915695|NCT00764205||Control Group|Patients transported to hospital without troponin measurements enroute
9915696|NCT00764218|Experimental|SAS+HTA+|Obstructive sleep apnea syndrome and hypertension
9915697|NCT00764218|Experimental|SAS+HTA-|non hypertensive patients with obstructive sleep apnea syndrome
9915698|NCT00764218|Experimental|SAS-HTA+|hypertensive patients without obstructive sleep apnea syndrome
9915699|NCT00764218|Experimental|SAS-HTA-|non hypertensive patients without obstructive sleep apnea syndrome
9915700|NCT00764231|Experimental|Exercise|This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.
9915701|NCT00764231|Other|Wait list control|This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.
9915702|NCT00764244|Active Comparator|1|Vitrectomy
9915703|NCT00764244|Active Comparator|2|Intravitreal triamcinolone injections
9915704|NCT00764244|Active Comparator|3|Laser photocoagulation
9915705|NCT00764257|Experimental|PREVELLE Shape|
9915706|NCT00764257|Active Comparator|Restylane|
9915707|NCT00764283|Experimental|1|Tegaderm dressing
9915708|NCT00764283|Active Comparator|2|Epi-Fix dressing
9915709|NCT00764283|Active Comparator|3|Lockit-Plus dressing
9915710|NCT00764296||no treatment|The information obtained by the evaluation of both acute and chronic wounds is pivotal to truly understanding the intercellular tactics used by wound biofilms which work to disrupt host tissue and to evade the host's immune system.
9915711|NCT00764335||unilateral normal|total hip arthroplasty one side, normal offset of medial femoral head
9915712|NCT00764335||bilateral normal|total hip arthroplasty both sides, normal offset of medial femoral head
9915713|NCT00764335||bilateral abnormal offset|total hip arthroplasty both sides, abnormal offset of medial femoral head
9915714|NCT00764335||controls|Healthy, age-matched control group
9915715|NCT00764348||no treatment|
9915716|NCT00764374|Experimental|1|
9915717|NCT00764387|Experimental|Arm 1|
9915718|NCT00764387|Active Comparator|Arm 2|
9915719|NCT00764400|Experimental|Errorless Naming Treatment|
9915720|NCT00764400|Experimental|Verbal+Gestural Facilitation|
9915721|NCT00764413|Active Comparator|1|Both study arms receive both active treatment = methylprednisolone and an inactive treatment = Sodium chlorid (dummy)
9915722|NCT00764413|Active Comparator|2|Both arms receives both active treatment and inactive treatment = dummy. Active treatment is methylprednisolone, inactive treatment is sodium chlorid.
9915723|NCT00764426|Active Comparator|non-alcoholic beverages|dealcoholised red wine, de-alcoholised beer, water
9915724|NCT00764426|Active Comparator|alcoholic beverages|red wine, beer, ethanol
9915725|NCT00764439|Active Comparator|1|Standard NRT user direction
9915726|NCT00764439|Experimental|2|Novel NRT user direction
9915727|NCT00764530|Experimental|Investigational|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell.
9915728|NCT00764530|Active Comparator|Control Device|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head.
9915729|NCT00764556|Experimental|Tight glycaemic control|Intravenous or subcutaneous insulin to control blood glucose to 4.4-6.5mM
9915730|NCT00764569||Oral Tissue measurement|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
9915731|NCT00764582|Experimental|1|
9915732|NCT00764582|Active Comparator|2|
9915733|NCT00764595|Experimental|imatinib mesylate|All patients start imatinib mesylate as oral dose of 400 mg/d once daily after meal within 28 days after enrollment, and continue the treatment until 3 years after enrollment of the last patient.
9915734|NCT00764608||No Treatment|
9915735|NCT00764621|Experimental|Arm 1|
9915736|NCT00764621|Active Comparator|Arm 2|
9915737|NCT00764621|Active Comparator|Arm 3|
9915738|NCT00764647|Experimental|Single arm|Education program for family caregivers of frail elders.
9915739|NCT00764686|Experimental|1|Low disease severity group
9915740|NCT00764686|Experimental|2|Higher disease severity group
9915741|NCT00764712|Active Comparator|Matias protocol|A protocol based on the absolute glucose value - Matias protocol (Matias)
9915742|NCT00764712|Active Comparator|Bath protocol|A protocol based on the relative glucose change - Bath protocol (Bath)
9915743|NCT00764712|Active Comparator|eMPC|a computer-based model predictive control algorithm with variable sampling rate (eMPC)
9915744|NCT00764725|Active Comparator|A|MTX+SSZ+Plaquenil
9915745|NCT00764725|Active Comparator|B|MTX+Infliximab
9915746|NCT00764764|Active Comparator|I|Group I - Shoulder treatment only
9915747|NCT00764764|Experimental|II|Cervical and shoulder treatment
9915748|NCT00764777|Experimental|Stenting|
9915749|NCT00764803||2|Subjects who meet the indications for use and are implanted with the Encore MJS™ Knee System.
9915750|NCT00764803||1|Subjects who meet the indications for and are implanted with the Encore 3DKnee™ system.
9915751|NCT00764816|Active Comparator|1 grain (soy) protein diet:|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
9915752|NCT00764816|Active Comparator|2 casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
9915753|NCT00764842||CLP Hip|
9915754|NCT00764855||1|Patients undergoing a surgery with general anesthesia
9915755|NCT00764894||Foundation Knee|Retrospective data collection on 510(k) approved device
9915756|NCT00764907|Experimental|Arm I|During reinduction, patients receive 1 course of protocol II.
9915757|NCT00764907|Experimental|Arm II|During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.
9915758|NCT00764907|Experimental|Arm III|During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.
9934446|NCT04813627||Participants with R0 resected Stage II (high risk) or Stage III CRC|The participants eligible for this epidemiological study are those with completely resected Stage II (high risk)/III CRC (per the American Joint Committee on Cancer (AJCC) 8th revised edition staging system) due to receive standard of care chemotherapy for at least 3 months following surgery.
9934447|NCT04813484|Experimental|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
9934448|NCT04812340|Active Comparator|High intensity Circuit training|Intervention will consist of 6 series with 3 minutes rest period between the series. The series will consist of burpees, skipping, 1 legged squats, leg levers, and push-ups. the exercise volume will be increased progressively over 8 weeks.
9934449|NCT04812340|Active Comparator|Low intensity interval training|the intervention will consist of 4 series of Low-intensity exercises with 3 minutes of rest. the series will comprise of jogging and walking. the Exercise volume will be increased gradually.
9934450|NCT04808427|Experimental|1/Arm 1|Ultrasound ablation of focal prostate cancer
9934451|NCT04806282||1/All Patients|Documented hearing instability
9934452|NCT04805047|Experimental|Intervention:education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
9934453|NCT04805047|No Intervention|control|regular care
9934454|NCT04804813||Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 26 weeks. Participants received interventions as part of routine medical care.
9934455|NCT04802174|Experimental|1/ Phase I|Dose escalation of Berzosertib + lurbinectedin
9934456|NCT04802174|Experimental|2/ Phase II|Berzosertib + lurbinectedin at MTD
9934457|NCT04799301|Experimental|Diet with 20% of carb intake from soda|This group will receive a weight-maintaining diet with 20% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
9934458|NCT04799301|Experimental|Diet with 50% of carb intake from soda|This group will receive a weight-maintaining diet with 50% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
9934459|NCT04799301|Experimental|Diet with no soda|This group will receive a weight-maintaining diet without soda. All 50% of carbohydrates will originate from sources other than corn and sugar cane.
9934460|NCT04799288|Experimental|Teriflunomide|Teriflunomide 14 mg daily
9934461|NCT04799197|Experimental|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
9934462|NCT04798274|Experimental|Active cTBS|This intervention involves active repetitive magnetic stimulation. The coil emits a magnetic field
9934463|NCT04798274|Sham Comparator|Sham cTBS|This intervention involves sham (placebo) repetitive transcranial magnetic stimulation. The coil is blinded, but does not emit any magnetic field
9934464|NCT04796649|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
9934465|NCT04796649|Active Comparator|Standard treatment + Sham laser|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
9934466|NCT04796597|Experimental|Single-arm|Implantation of subcutaneous leads and connection to an external EEG amplifier
9915759|NCT00764920||Skin Imaging|non-invasive imaging modalities for assessment of skin
9915760|NCT00764933|Experimental|1|Structured information
9915761|NCT00764933|Sham Comparator|2|Unspecific conversation
9915762|NCT00764959||Linear Hip|Encore Linear Hip System
9915763|NCT00764972|Experimental|Sorafenib and Vinorelbine|
9915764|NCT00764985||Syncope|
9915765|NCT00764998|Active Comparator|Fluviral|
9915766|NCT00764998|Placebo Comparator|placebo|
9915767|NCT00765011|Experimental|Group A|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
9915768|NCT00765011|Other|Grupo B|Surgery
9915769|NCT00765024|Active Comparator|Albendazole|Albendazole for 7 days
9915770|NCT00765024|Experimental|ivermectin|ivermectin 200 mcg/kg single dose
9915771|NCT00765024|Experimental|ivermectin 2 doses|ivermectin 200 mcg/kg two doses in 2 weeks
9915772|NCT00765050|Experimental|CD133+ cells|CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs.
9915773|NCT00765089|Experimental|Pulmonary Vein isolation|Patients in this arm will receive pulmonary vein isolation during surgery
9915774|NCT00765089|No Intervention|Standard of care|Subjects in this arm will receive standard of care and no pulmonary vein isolation
9915775|NCT00765115|Experimental|1|100 mg LY 450139 oral
9915776|NCT00765115|Experimental|2|140 mg LY450139 oral
9915777|NCT00765115|Experimental|3|280 mg LY450139 oral
9915778|NCT00765115|Experimental|4|Placebo
9915779|NCT00765141||No treatment|
9915780|NCT00765154|Active Comparator|Group 1|Immediate switch from NNRTI/PI to DRV/r
9915781|NCT00765154|Active Comparator|Group 2|Switch after 10 weeks from NNRTI/PI to DRV/r
9915782|NCT00765167|Placebo Comparator|A|
9915783|NCT00765167|Active Comparator|B|
9915784|NCT00765167|Active Comparator|C|
9915785|NCT00765180|Active Comparator|2|The investigators evaluate beneficial effect of colonoscopy using narrow band imaging (NBI) for colorectal adenoma detection.
9915786|NCT00765180|Experimental|1|The investigators evaluate the beneficial effect of colonoscopy with a transparent retractable extension (TRE) device on colorectal adenoma detection rate.
9915787|NCT00765219|Experimental|1|CBT with ACS
9915788|NCT00765219|Experimental|2|CBT with Counselor
9915789|NCT00765219|Active Comparator|3|Usual Care
9915790|NCT00765271|Active Comparator|Group 2|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Raltegravir 400 mg (2 x 200mg tablets) twice daily from days 2 to 15 Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 16 to day 29)
9915791|NCT00765271|Active Comparator|Group 1|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 2 to day 15) Raltegravir 400 mg (2 x 200mg tablets) twice daily from day 16 to 29
9915792|NCT00765284||Treatment|Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
9915793|NCT00765284||Placebo|Five subjects will be low HDL-C male volunteers who will receive only aspirin.
9915794|NCT00765297|Experimental|1|Healthy young 18-40years
9915795|NCT00765297|Experimental|2|Healthy elderly
9915796|NCT00765349||All patients undergoing major surgery|
9915797|NCT00765401||Group A|The subject with positive breath Test for H.pylori and/or positive stool antigen test
9915798|NCT00765401||Group B|The subject with negative breath Test for H.pylori and negative stool antigen test
9915799|NCT00765414|Experimental|1|
9915800|NCT00765440|Placebo Comparator|Arm I|Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.
9915801|NCT00765440|Experimental|Arm II|Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.
9915802|NCT00765440|Experimental|Arm III|Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.
9915803|NCT00765453|Experimental|Intracoronary|Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
9915804|NCT00765453|Placebo Comparator|Placebo|Placebo infusion
9915805|NCT00765479|Experimental|Arm I|Patients receive an oral soy protein isolate beverage once daily.
9915806|NCT00765479|Placebo Comparator|Arm II|Patients receive an oral casein placebo beverage once daily.
9915807|NCT00765492|Experimental|1|
9915808|NCT00765492|Placebo Comparator|2|
9915809|NCT00765505|Experimental|1|Exercise Group
9915810|NCT00765505|Experimental|Health Education Group|
9915811|NCT00765544|Experimental|Arm 1|Anklebot
9915812|NCT00765544|Experimental|Arm 2|Body-weight supported treadmill training
9915813|NCT00765544|Experimental|Arm 3|Combination therapy (Anklebot and BWSTT)
9915814|NCT00765557|Active Comparator|MiraLAX|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to MiraLAX versus placebo.
9915815|NCT00765557|Placebo Comparator|Placebos|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to placebo versus MiraLAX.
9915816|NCT00765583|Experimental|restylane|Restylane arm with different re-treatment schedules
9915817|NCT00765596||1 RYGB|Subjects undergoing RYGB with gastric tube placement
9915818|NCT00765596||2 Matched controls|Subjects matched by BMI, age, gender to RYGB group
9915819|NCT00765609||1|Using the information distributed with over-the-counter medication (The Patient Information Leaflet or PIL)
9915820|NCT00765609||2|Paediatric Analgesia Slide (the new device)
9915821|NCT00765622||G2|G2 = control group (no incontinence)
9915822|NCT00765622||G1|G1 = urinary incontinence
9915823|NCT00765635|Experimental|2|Taponoto ® (potassium carbonate 20 mg/1 ml, ethyl alcohol, glycerol 480, thymol 0.4; Teofarma Iberica S.A., Barcelona, Spain),
9915824|NCT00765635|Placebo Comparator|3|sterile saline solution (NaCl 0.9%, Braun Medical SA, Barcelona, Spain).
9915825|NCT00765635|Experimental|1: Chlorobutanol|ceruminolytic product, Otocerum® (Chlorobutanol 50 mg/1 ml, phenol 10 mg/1 ml, turpentine essence 0.15 ml/1 ml, ethyl alcohol; Reig Jofre laboratories, Barcelona, Spain),
9915826|NCT00765687|No Intervention|Observation|
9915827|NCT00765713|Experimental|CPAP|Continuous positive airway pressure
9915828|NCT00765713|No Intervention|Conventional|Hygienic-dietetic recommendations
9915829|NCT00765739|Experimental|1|The group who will get neuromuscular electrical stimulation (NMES)
9915830|NCT00765739|Active Comparator|2|The group who will do the voluntary muscle contraction
9915831|NCT00765752||1 Primary Insomnia|Individuals with insomnia not related to another identified cause.
9915832|NCT00765752||3 Healthy comparison subjects|Healthy subjects with no history of insomnia
9915833|NCT00765791|Active Comparator|1|Level IIB is dissected
9915834|NCT00765791|Active Comparator|2|Level IIB is not dissected
9915835|NCT00765869|Experimental|1|Bowel cancer screening decision aid, DVD and Question Prompt List (QPL)
9915836|NCT00765869|Experimental|2|Bowel cancer screening decision with DVD only
9915837|NCT00765869|Active Comparator|3|Australian Government Bowel Cancer Screening consumer information booklet
9915838|NCT00765908|Experimental|A|Patients undergoing elective PCI will be randomised to 90 second balloon inflations rather than the standard less than 30 second inflations in order to induce peri-ischaemic conditioning.
9995620|NCT01492283||NAFLD|Non alcoholic fatty liver disease without type 2 diabetes
9995621|NCT01492283||NAFLD+T2D|Non alcoholic fatty liver disease with type 2 diabetes
9995622|NCT01492283||T2D|Type 2 diabetics without non alcoholic fatty liver disease
9995623|NCT01492283||cirrhosis|Patients with liver cirrhosis
9995624|NCT01492283||Kontrol groups|Healthy control subjects
9995625|NCT01492296|Active Comparator|conventional fasting|patients were evaluated after fasting for 8 hours
9995626|NCT01492296|Experimental|Short fasting|patients who were evaluated with endoscopy after fasting for two hours
9995627|NCT01492322||Sated and withdrawal group|To determine differences in TRODAT binding to the DAT between a smoker when sated and when in withdrawal
9995628|NCT01492335|Experimental|Cognitive Report|Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
9995629|NCT01492335|Experimental|Treatment As Usual|Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
9995630|NCT01492348|Experimental|STEPS UP Intervention|STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
9995631|NCT01492348|Active Comparator|Optimized Usual Care (OUC)|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system.
9995632|NCT01492374|Experimental|Arm 1: BMS-241027 (0.003 mg/kg)|
9995633|NCT01492374|Experimental|Arm 2: BMS-241027 (0.01 mg/kg)|
9995634|NCT01492374|Experimental|Arm 3: BMS-241027 (0.03 mg/kg)|
9995635|NCT01492374|Experimental|Arm 4: Placebo matching BMS-241027|
9995636|NCT01492387|No Intervention|Local standard of care|Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.
9995637|NCT01492387|Experimental|Individualized arm|Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
9995638|NCT01492413|Experimental|Online basic lifestyle counseling (OBLI)|Subjects receive one online informational class.
9995639|NCT01492413|Experimental|Online lifestyle counseling (OLC)|Subjects receive 12 weekly online classes with a focus on behavior modification for weight loss.
9995640|NCT01492413|Experimental|OBLI intervention plus a fortified diet beverage (BEV)|Subjects receive online basic lifestyle information (OBLI) plus a fortified diet beverage.
9995641|NCT01492413|Experimental|OLC plus fortified diet beverage (BEV)|Subjects receive OLC plus diet beverage (BEV).
9995642|NCT01492452|No Intervention|guidelines|22 parents in the intervention group were randomized and received standardized guidelines for nursing:The guidelines took around an hour and involved pre-operative care such as bathing with detergent solution, pre-anesthetic administration (as prescribed), preoperative fasting (as prescribed), clothing, hygiene care and nail oral. They were also provided information on the endotracheal tube, tubes, catheters, epicardial pacemaker wires and electrodes to be used in the perioperative period and which remain for some period after surgery, as well as possible complications.
9995643|NCT01492465|Active Comparator|AMG 876|
9995644|NCT01492465|Placebo Comparator|Placebo|
9995645|NCT01492491|No Intervention|standard HFR therapy|standard HFR hemodiafiltration therapy
9995646|NCT01492491|Active Comparator|SUPRA-HFR therapy|SUPRA-HFR hemodiafiltration therapy
9995647|NCT01492504||Subjects with chronic hepatitis C|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C
10213180|NCT04515667|Experimental|Mindfulness|
9995648|NCT01492517|Sham Comparator|Clean air exposure|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to clean air for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC.
10213181|NCT04515667|Placebo Comparator|Control|
10213182|NCT04509050||Part A|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
10213183|NCT04509050||Part B|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.
10213184|NCT04503993|Experimental|Hepatitis B Healthy Planet Arm|This is a single arm study where all patients eligible patients will receive a hepatitis B order set
10213185|NCT04498650|Placebo Comparator|Placebo|
10213186|NCT04498650|Experimental|300 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-24: 300 mg BID
10213187|NCT04498650|Experimental|600 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-12: 300 mg BID Dose in weeks 12-24: 600 mg BID
10213188|NCT04491578|Experimental|ACP programme|It is a theory-driven ACP programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model and shared decision-making model.
10213189|NCT04484922|Experimental|Dexmedetomidine|
10213190|NCT04484922|Placebo Comparator|Control|
10213191|NCT04482400|Experimental|NEAT!2|Participants randomized to this arm will use the NEAT!2 app and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
10213192|NCT04482400|Active Comparator|MyKneeGuide|Participants randomized to this arm will use the MyKneeGuide app/website and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
10213193|NCT04481958|Experimental|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
10213194|NCT04481074|Experimental|Inspiratory muscle training group|Group intervention: home-based interval inspiratory muscle training during 8 weeks, two sessions with two sets of 30 breaths with one minute rest between them. Load set is determinated weekly, aiming 50% of actual PImax and according to Borg Score.
10213195|NCT04480164|Experimental|NDMC 40 mg/day|Oral administration of two NDMC 20mg capsules per day over 6 weeks
10213196|NCT04480164|Experimental|NDMC 60 mg/day|Oral administration of three NDMC 20mg capsules per day over 6 weeks
10213197|NCT04480164|Experimental|NDMC 120 mg/day|Oral administration of six NDMC 20mg capsules per day over 6 weeks
10213198|NCT04480164|Placebo Comparator|Placebo|Oral administration respectively, according to the experimental arm considered, of two, three or six placebo capsules per day over 6 weeks
10213199|NCT04479514|Experimental|Preventative Skin Care Routine|"Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.~Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment."
10213200|NCT04478890||Observational Group|Characterize right ventricular function while undergoing LVAD implantation
10213201|NCT04477928||Study Group|Children receiving routine primary care at a Sanford facility
10213202|NCT04475250|Experimental|Tetragraph|
10213203|NCT04475133|Experimental|Low-frequency and high-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are continuous stimulation of low frequency (2 hz) and high intensity (slightly painful) during 16 minutes."
10213204|NCT04475133|Experimental|High-frequency and low-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.~The parameters are high frequency (100 hz) and low intensity trains. There are 5 trains, 5 second active current and 55 second without current per train.~The current is off on the first 11 minutes and the next 5 minutes it will be on. The total time is 16 minutes."
10213205|NCT04475133|Sham Comparator|Control group|The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve without current during 16 minutes.
10213206|NCT04473963|Experimental|EGF-Guided Ablation Therapy|"Subjects randomized to therapy will be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software)."
10213207|NCT04473963|No Intervention|Control - No Ablation Therapy|"Subjects randomized to control will not be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software). The subjects will be cardioverted (as applicable) and the procedure will end."
10213208|NCT04471909|Experimental|Chronic Dissection|
9934467|NCT04794829||Vaccinated|Received influenza and/or SARS-CoV-2 vaccine
9934468|NCT04785924|Other|Observation Treatment Group|All patients observed while treated with IMI/REL.
9934469|NCT04783545|Experimental|Single Ascending Dose Cohorts 1-6|Drug: VLX-1005
9934470|NCT04783545|Placebo Comparator|Single Ascending Dose Cohorts 1-6, Placebo|Drug: Placebo
9934471|NCT04783545|Experimental|Multiple Ascending Dose Cohorts 7-9|Drug: VLX-1005
9934472|NCT04783545|Placebo Comparator|Multiple Ascending Dose Cohorts 7-9, Placebo|Drug: Placebo
9934473|NCT04781881||Entresto|Patients administered Entresto by prescription
9934474|NCT04781322|Experimental|Intervention|Heavy drinking healthy volunteers
9934475|NCT04781322|Placebo Comparator|Placebo|Heavy drinking healthy volunteers
9934476|NCT04781309|Experimental|NT-I7|480 microgram/kg IM (initial dose)
9934477|NCT04774289||1|Participants with NF1 seen at the NIH from 1/1/1998 to 1/1/2020
9934478|NCT04773353|Experimental|Follitropin Delta (FE 999049)|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
9934479|NCT04773353|Experimental|Follitropin Alfa (GONAL-F)|rFSH. Follitropin alfa for subcutaneous injection
9934480|NCT04772170||Current Challenge Study Participant|Current participation in a respiratory virus challenge study at the NIH CC
9934481|NCT04770493|Experimental|Lamotrigine|Lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks
9934482|NCT04770493|Placebo Comparator|Placebo|Identical matching placebo capsules
9934483|NCT04768686|Experimental|FLX475 and pembrolizumab combination therapy|"Cohort 1: EBV negative / CPI naïve gastric cancer patient who has had a disease progression after at least 2 prior systemic treatments for advanced or metastatic gastric cancer~Cohort 2: EBV positive / CPI naïve gastric cancer patient (as determined by standard methods, e.g. EBER ISH or LMP-1 IHC) who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer"
9934484|NCT04767061|Active Comparator|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. During Period 3, they will restart beta-blockers, gradually uptitrating until reaching their home dose and finally during period 4, we will again conduct a dose reduction until off of beta blockers."
9934485|NCT04767061|Active Comparator|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers and finally during Period 4, we will uptitrate them back to their home dose of beta blockers."
9915839|NCT00765908|Active Comparator|B|Control group. These patients will have a standard procedure with balloon inflations of 30 seconds or less as per standard.
9915840|NCT00765921|Experimental|1.0 mg ranibizumab|1.0 mg intravitreal injection given bi-monthly for 22 months
9915841|NCT00765921|Experimental|0.5 mg ranibizumab|0.5 mg intravitreal injection given bi-monthly for 22 months
9915842|NCT00765934|Other|Rapydan|Internal control. Blood from both arms will be drawn. Only one arm of the subject is treated with Rapydan.
9915843|NCT00765973|Experimental|A|Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
9915844|NCT00765973|Experimental|B|Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
9915845|NCT00765986||1|Patients with inoperable NSCLC undergoing RT or Chemo-RT
9915846|NCT00766012|Experimental|1|4 dose panels receiving a specified volume of AZD2066 oral solution once daily for 11 days
9915847|NCT00766012|Placebo Comparator|2|Included in each dose panel
9915848|NCT00766025|Experimental|Rosuvastatin Calcium|
9915849|NCT00766064|Experimental|Paliperidone Dosing|Paliperidone Dosing up to 6 weeks, with a maximum dosage of 6mg
9915850|NCT00766103|Other|crossover: hypo- and hypercarbia|
9915851|NCT00766129|Experimental|T|Implantation of Taxus stent into saphenous vein graft
9915852|NCT00766129|Experimental|C|Implantation of Luc-Chopin stent into saphenous vein graft
9915853|NCT00766155|Active Comparator|Arm I|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9915854|NCT00766155|Experimental|Arm II|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9915855|NCT00766168|Active Comparator|Control|FluoroPerm 30 RGP lens daily wear
9915856|NCT00766168|Experimental|HDS HI 1.54|New rigid gas permeable contact lens material material
9915857|NCT00766181||1: Lifestyle|Observatonal
9915858|NCT00766181||2: Lifestyle|Observational
9915859|NCT00766207|Experimental|multi-faceted decision support|Multi-faceted decision support
9915860|NCT00766207|Active Comparator|control|stream-lined clinical alert
9915861|NCT00766220|Active Comparator|SIR-Spheres + Therapy|SIR-Spheres with Cetuximab + Irinotecan Therapy
9915862|NCT00766220|Active Comparator|Therapy Only|Cetuximab + Irinotecan Therapy
9915863|NCT00766233|Active Comparator|1|Hyperthermal treatment once per week
9915864|NCT00766233|Active Comparator|2|Hyperthermal treatment 3 times a week
9915865|NCT00766246|Experimental|First-line|Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
9915866|NCT00766246|Experimental|Maintenance|Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
9915867|NCT00766259||1|Hemodialysis
9915868|NCT00766259||2|Intensive care
9915869|NCT00766259||3|vascular patients with open wounds
9915870|NCT00766259||4|nursing home
9915871|NCT00766259||5|skin infections
9915872|NCT00766259||6|control- ambulatory care clinic patients with no infections
9915873|NCT00766272|Experimental|Arm 1|Body-weight supported treadmill training
9915874|NCT00766285|Active Comparator|TIV|50 subjects to receive 45 mcg of TIV administered on Day 0 and Day 28.
9915875|NCT00766285|Experimental|rHAO|50 subjects to receive 405 mcg of rHAO administered on Day 0 and Day 28.
9915876|NCT00766298|Experimental|1|Weight Loss
9915877|NCT00766298|Experimental|2|Exercise
9915878|NCT00766298|Experimental|3|Exercise and Weight Loss
9915879|NCT00766311|Other|1|This single-arm feasibility trial will evaluate the administration of an aggressive exercise regimen.
9915880|NCT00766337|Experimental|Dose Group 1|
9915881|NCT00766337|Experimental|Dose Group 2|
9915882|NCT00766337|Placebo Comparator|Dose Group 3|
9915883|NCT00766350|Active Comparator|amitriptyline|
9915884|NCT00766350|Experimental|quetiapine|
9915885|NCT00766389||1|Defined glaucoma patients
9915886|NCT00766389||2|Glaucoma suspects and normal controls
9915887|NCT00766402|Experimental|Tramadol/Acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
9915888|NCT00766402|Active Comparator|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
9915889|NCT00766441|Active Comparator|1|Sitagliptin 100mg
9915890|NCT00766441|Active Comparator|2|Sulphonylurea
9915891|NCT00766480|Experimental|Regimen 1|Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on days 1-4 and 29-32. Patients undergo salvage surgery if needed.
9915892|NCT00766480|Experimental|Regimen 2|Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and salvage surgery as in regimen 1.
10213209|NCT04471909|Experimental|Aneurysm|
10213210|NCT04471909|Experimental|Penetrating Aortic Ulcer and/or Intramural Hematoma|
10213211|NCT04469803|Experimental|No nap, brief nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
10214009|NCT02204709|Experimental|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
10214010|NCT02204709|Experimental|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
10214011|NCT02204709|Experimental|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
10214012|NCT02164643|Experimental|Florbetapir (18F)|
10214013|NCT02164643|Experimental|Flutemetamol (18F)|
10214014|NCT02155920|Experimental|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
10214015|NCT02130492|Experimental|FDG arm|Patients will receive increasing doses of FDG.
10214016|NCT02123823|Active Comparator|Everolimus 10mg + Exemestane 25mg|Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally
10214017|NCT02123823|Experimental|BI836845 + Everolimus + Exemestane|Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally
10214018|NCT02123823|Experimental|PhI - BI836845 + Everolimus + Exemestane|Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg
10214019|NCT02088775|Experimental|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
10214020|NCT02052882|Experimental|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
10214021|NCT02037945|Experimental|pts with brain mets going for surgery|"This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal hot spots (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue."
10214022|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
10214023|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
9915893|NCT00766519|Experimental|Optimization|volume optimization: continuous monitoring of the respiratory-induced arterial pulse pressure variation during surgery and systematic minimization to 10% or less by volume loading
9915894|NCT00766519|Active Comparator|control; standard volume administration|standard volume administration
9915895|NCT00766545|Experimental|cilostazol|cilostazol oral tablet 100 mg, twice daily
9915896|NCT00766545|Placebo Comparator|placebo|placebo of cilostazol, twice daily
9915897|NCT00766558||1 Disclosure|Traumatic writing prompts provided. Participant is assigned a potential stress-producing topic for written disclosure.
9915898|NCT00766558||2 control|Received nontraumatic writing prompts. Participant assigned a non-stressful writing condition
9915899|NCT00766623|Experimental|High fat meal|A high fat milkshake containing 95g of fat
9915900|NCT00766623|Experimental|Control meal|Milkshake comparable with a normal breakfast
9915901|NCT00766623|Experimental|High fat meal 2|A high fat milkshake containing 95g of fat
10213212|NCT04469803|Experimental|No nap, longer nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
10213213|NCT04469803|Experimental|Brief nap, no nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
10214024|NCT02013583||Glucose Transporter Type I Deficiency|No interventions
10214025|NCT01991067|Active Comparator|HSCT patients / TBE virus vaccine|Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
9915902|NCT00766623|Experimental|High fat meal 3|A high fat milkshake containing 95g of fat
9915903|NCT00766623|Experimental|Control meal 2|Milkshake comparable with a normal breakfast
9915904|NCT00766623|Experimental|Control meal 3|Milkshake comparable with a normal breakfast
9915905|NCT00766714|Experimental|1|Cook K-SOFT-5100 catheter
9915906|NCT00766714|Active Comparator|2|Frydman classical catheter
9915907|NCT00766740|Active Comparator|1|thrombectomy
9915908|NCT00766740|Active Comparator|2|Standard PCI
9915909|NCT00766766|Experimental|1|Experimental Intervention Group
9915910|NCT00766766|No Intervention|2|Standard Care Control
9915911|NCT00766779|Experimental|Transplant Arm|Hematopoietic cell transplantation after Reduced Intensity Conditioning
9915912|NCT00766779|Active Comparator|Conventional Chemotherapy|The non-transplant treatment approach for consolidation
9915913|NCT00766792|Experimental|1|Nocturnal dialysis
9915914|NCT00766792|Active Comparator|2|Standard dialysis
9915915|NCT00766805|Active Comparator|EVL + Drugs|Patients randomized to the EVL plus drugs therapy received EVL plus beta-blocker (propranolol) and nitrate (ISMN).
9915916|NCT00766805|Placebo Comparator|EVL alone|Patients assigned to the EVL group underwent variceal band ligation alone till variceal obliteration.
9915917|NCT00766818|Experimental|1|Kaletra
9915918|NCT00766844|Experimental|Active|Spinal cord stimulation
9915919|NCT00766857|Experimental|1. Exenatide|
9915920|NCT00766857|Active Comparator|2. Insulin glargine|
9915921|NCT00766870|Experimental|1|
9915922|NCT00766870|Experimental|2|
9915923|NCT00766870|Experimental|3|
9915924|NCT00766870|Other|4|
9915925|NCT00766870|Placebo Comparator|5|
9915926|NCT00766896|Active Comparator|Aspirin Sensitive|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time >= 150 seconds~Chrono-Log Model 700 Whole-Blood: < 1Ω with 0.75 mM of arachidonic acid~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) > 0.50~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L < 10Ω~Plateletworks: aggregation <60% with arachidonic acid will be considered sensitive~VerifyNow Aspirin Assay (Accumetrics): < 550 aspirin reaction units (ARUs)~Impact-R (Diamed) < 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
9915927|NCT00766896|Active Comparator|Platelet with hyperreactivity to aspirin|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time < 150 s~Chrono-Log Whole-Blood: above or = 1Ω with 0.75 mM of AA~Chrono-Log Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) below 0.50~Chrono-Log Whole-Blood: with collagen 1 mg/L above or = 10Ω~Plateletworks: aggregation of more than 60% with arachidonic acid will be considered resistant~VerifyNow Aspirin Assay (Accumetrics): ≥ 550 aspirin reaction units (ARUs)~Impact-R (Diamed) > 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
9915928|NCT00766909|Experimental|CsA|Cyclosporine
9915929|NCT00766909|Experimental|Tac|Tacrolimus
9915930|NCT00766909|Placebo Comparator|Placebo|placebo/saline
9915931|NCT00766935||1 - lymphoedema group|Females with previously diagnosed unilateral Lymphoedema of the arm, who have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy.
9915932|NCT00766935||2 - healthy individuals|Healthy females aged between 18-75 years chosen randomly from the population of Queensland, Australia.
9915933|NCT00766948||No Treatment|
9915934|NCT00766961|Active Comparator|TAE group|Trans-catheter arterial embolization
9915935|NCT00766961|Active Comparator|Surgery group|Surgery
9934492|NCT04757584|Active Comparator|Beta Blocker ABAB Sequence|"This arm will follow an ABAB sequence. A representing ON beta blockers and B representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. During Period 3, they will restart beta-blockers, gradually uptitrating until reaching their home dose and finally during period 4, we will again conduct a dose reduction until off of beta blockers."
9934493|NCT04757584|Active Comparator|Beta Blocker BABA Sequence|"This arm will follow a BABA sequence. A representing ON beta blockers and B representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers and finally during Period 4, we will uptitrate them back to their home dose of beta blockers."
9934494|NCT04755413|Experimental|Optimization Group|Participants with CAD and a BRS greater than 0 who are randomized to the Optimization Group have treatment goals that include achieving LDL-C<70 mg/dL, hemoglobin A1c <7%, blood pressure <130/80 mmHg, smoking cessation, at least 30 minutes of moderate-intensity aerobic activity 5 days a week and weight loss to body mass index <30 kg/m2. To achieve these goals, both pharmacological and lifestyle interventions will be considered and individualized for each patient.
9934495|NCT04755413|Active Comparator|Usual Care Group|Participants with CAD and a BRS greater than 0 who are randomized to the usual care group will receive standard of care therapy prescribed by their primary care physician and/or cardiologist. Patients and their physicians will be informed that their BRS is ≥1 and they have been randomized to the usual care group.
9934496|NCT04755413|Other|Registry Group|Participants with BRS of 0 at baseline and after 3 months will undergo follow-up including measurements of BRS at the time-points specified for the randomized subjects and also for adverse events. Laboratory results and questionnaire data will be obtained on the phone.
9934497|NCT04755205||Cohort 1|Subjects with confirmed olfactory neuroblastoma.
9934498|NCT04754776|Experimental|Low dose|5 x 10^9 vp ChAdOx1 RVF delivered intramuscularly
9934499|NCT04754776|Experimental|Medium dose|2.5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
9934500|NCT04754776|Experimental|High dose|5 x 10^10 vp ChAdOx1 RVF delivered intramuscularly
9934501|NCT04754100|Experimental|Allogeneic iNKT Cells|3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks (each cycle is 14 days [2 weeks]).
9934502|NCT04750928|Experimental|1/ Phase I Dose Escalation|Abemaciclib orally twice daily at escalating doses to determine the MTD/RP2D
9934503|NCT04750928|Experimental|2/ Phase II Objective Response Rate|Abemaciclib orally twice daily at the RP2D
9934504|NCT04750915||AARP|Members of AARP, aged 50-71 years and who resided in one of six states or in two metropolitan areas in the United States
9934505|NCT04746872|Experimental|Alinity m HR HPV|The Alinity m HR HPV IUO assay is a qualitative in vitro test that amplifies and detects HR HPV DNA in cervical cells collected in liquid media. The assay can differentiate between HPV 16, HPV 18, HPV 45 and non-HPV 16/18/45 genotypes [(31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68)].
9934506|NCT04743596||Sarcoidosis group|Consecutive patients with clinical and radiological (CT scan) suspect of sarcoidosis as assessed by a respiratory physician.
9934507|NCT04742400|Experimental|Tolebrutinib (Cohort A)|Tolebrutinib 60 mg/day for 48 weeks, Tolebrutinib 120 mg/day for 96 weeks
9934508|NCT04742400|Experimental|Tolebrutinib (cohort B)|Tolebrutinib 120 mg daily
9934509|NCT04742400|Experimental|tolebrutinib (initial cohort)|Tolebrutinib 60 mg daily
9934510|NCT04742387||1|Medical records of subjects enrolled on various studies conducted by HAMB/CCR from 1/1/2005 to 12/1/2020
9934511|NCT04739813|Experimental|Arm 1: Dose Escalation|Venetoclax (PO) 800mg at escalating doses (2 dose levels) on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at escalating doses (2 dose levels) on day 2 of each 21-day cycle (maximum 6 cycles) to determine MTD of polatuzumab and venetoclax.
9934512|NCT04739813|Experimental|Arm 2: Dose Expansion|Venetoclax (PO) at the MTD days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at the MTD of each 21-day cycle (maximum 6 cycles)
9934513|NCT04738825|No Intervention|Treatment as Usual (TAU)|Participants randomized to TAU will receive a health handout on HIV risk reduction approaches, including PrEP and OUD-related care, and where to access such services. They will receive standard care as provided by the community-based organization and by their medical provider.
9934514|NCT04738825|Experimental|Contingency Management with stepped care to PrEP Adherence and Support Services (CoMPASS)|"Participants randomized to Compass will also receive a health handout on HIV risk reduction approaches. They will also receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12, will be stepped up to receive PrEP adherence and support services (n=5)."
9934515|NCT04737720||1|This is an expanded use protocol for a named subject.
9915936|NCT00766974|Active Comparator|1|Anti-embolism Knee High compression stocking
9915937|NCT00766974|Active Comparator|2|20-30mmHg Knee High Jobst Compression Stocking
9915938|NCT00767013|Experimental|AVS, CAD|DSCT
9915939|NCT00767026|Experimental|1|
9915940|NCT00767026|Active Comparator|2|
9915941|NCT00767052|Experimental|Active|AZD1236 tablet
9915942|NCT00767052|Placebo Comparator|Placebo|Placebo tablet
9915943|NCT00767052|Other|Relative bioavailability|AZD1236 Oral suspension
9915944|NCT00767052|Other|Relative bioavailability tablet|AZD1236 tablet
9915945|NCT00767065|Active Comparator|Cardiac Computed Tomography (CCT)|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. CCT will be available Monday to Friday from 9am until 5pm. Patients will be entered into the study provided CCT can be undertaken within 24 hours of troponin result. Therefore, the only period during which a patient will be ineligible for inclusion will be between 5pm on a Friday and 9am the following Sunday. Studies will be reported at CWH by one of 2 experienced radiologists trained in CCT and results passed to the referring team on the same day.
9915946|NCT00767065|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will undergo further care as dictated by the responsible clinician. Except for CCT, all standard investigations will be available to the responsible clinician and may be used at their discretion. CCT does not form part of current in-patient management at our hospital.
9915947|NCT00767091|Active Comparator|Active treatment|A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
9915948|NCT00767091|Placebo Comparator|placebo|transdermal patch of placebo
9915949|NCT00767130||1|receiving atorvastatin
9915950|NCT00767130||2|receiving simvastatin
9915951|NCT00767130||3|receiving rosuvastatin
9915952|NCT00767156|Active Comparator|SBA24 capsule plus Omega7 cream|the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream
9915953|NCT00767156|Active Comparator|SBA24 capsule plus base cream|the subjects took SBA24 sea buckthorn oil capsule and apply a base cream
9915954|NCT00767156|Active Comparator|Omega7 Cream|The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day
9915955|NCT00767156|Placebo Comparator|Base cream|The subjects use base cream on the face, twice per day
9915956|NCT00767169|Experimental|coated implant and control|
9915957|NCT00767182||Pregnant patients with VPP antecedent|Pregnancy women consulting for an scan during their 12th week of amenorrhea at the University Hospital of Saint Etienne will be studied in this clinical trial. They have an history of VPP (Vascular Placental Pathology). They will have to give a blood sample.
9915958|NCT00767195||1. Control group|Patients in the intensive care unit who have no pulmonary edema
9915959|NCT00767195||2. Study group 1|Patients with cardiogenic pulmonary edema in the intensive care unit
9915960|NCT00767195||3. Study group 2|Patients with non-cardiogenic pulmonary edema in the intensive care unit
9915961|NCT00767208|Experimental|type 2 diabetic subjects|
9915962|NCT00767208|Experimental|overweight healthy subjects|
9915963|NCT00767221|Experimental|A|The patient is his own control. Endpoint variables are measured before, during and after treatment.
9915964|NCT00767247||1|Male or female with arterial hypertension
9915965|NCT00767260|Experimental|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
9915966|NCT00767260|Experimental|BM-MNC|Autologous Bone Marrow mononuclear cell Infusion
9915967|NCT00767260|Experimental|HOT|hyperbaric oxygen therapy
9915968|NCT00767260|Active Comparator|Control|stand medical therapy (enhanced hemoglucose monitor, health and diet counseling and insulin injection)
9915969|NCT00767377|Experimental|EOF5 Group|The regimen of 5-day Continuous infusion of FU combined with Epirubicin and Oxaliplatin will be used in the patients recruited in this trial.
9915970|NCT00767390||ACL Patch|
9915971|NCT00767403|Experimental|1|
9915972|NCT00767403|Active Comparator|2|
9915973|NCT00767403|Active Comparator|3|
9915974|NCT00767429|Experimental|1|subjects with fall risk
9915975|NCT00767442||1|Health volunteer
9915976|NCT00767442||2|Patient with suspected oral mucosa lesion
9915977|NCT00767468|Experimental|Bilirubin Normal to 3x Upper Limit of Normal|
9915978|NCT00767468|Experimental|Bilirubin >3x to 6x Upper Limit of Normal|
9915979|NCT00767481|Experimental|Travoprost/Brinzolamide PM, Vehicle AM|Travoprost/Brinzolamide PM, Vehicle AM
9915980|NCT00767481|Experimental|Travoprost/Brinzolamide AM, Vehicle PM|Travoprost/Brinzolamide AM, Vehicle PM
9915981|NCT00767481|Active Comparator|Cosopt|Cosopt BID
9915982|NCT00767494|Experimental|1|Travoprost/Brinzolamide AM, Vehicle PM
9915983|NCT00767494|Experimental|2|Travoprost/Brinzolamide PM, Vehicle AM
9915984|NCT00767494|Active Comparator|3|AZOPT AM and PM
9915985|NCT00767494|Active Comparator|4|TRAVATAN PM, Vehicle AM
9915986|NCT00767559|Active Comparator|1|"Variable dose warfarin: 5 mg beginning the night before surgery, followed by 5mg the PM of surgery*, and then variable daily dose,until day 30 follow-up.~(target INR 2.0-2.5)"
9915987|NCT00767559|Active Comparator|2|"Fondaparinux:~2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*,or 6-8 hours after epidural catheter removal, and continued until follow-up (28 days +/-2) from day of surgery."
9915988|NCT00767559|Active Comparator|3|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily follow-up at Day 28 (+/-2 days from surgery)."
9915989|NCT00767585||A:|70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
9915990|NCT00767585||B|70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
9915991|NCT00767585||C|70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
9915992|NCT00767585||D|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
9915993|NCT00767585||E|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
9915994|NCT00767585||F|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
9915995|NCT00767585||G|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
9915996|NCT00767585||H|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
9915997|NCT00767598|Active Comparator|A|Vardenafil
9915998|NCT00767598|Active Comparator|B|Sildenafil
9915999|NCT00767598|Active Comparator|C|Udenafil
9916000|NCT00767637|Experimental|Arm 1|
9916001|NCT00767663|Experimental|1|dipyridamole
9916002|NCT00767663|Placebo Comparator|2|placebo
9916003|NCT00767689|Experimental|vitamin B6|patient receiving xeloda and vitamin B6
9916004|NCT00767689|Placebo Comparator|2 placebo|patient receiving xeloda and placebo
9916005|NCT00767715|Experimental|A|Patients will be given olanzapine
9916006|NCT00767715|Active Comparator|B|Patients will be given either haloperidol or zuclopentixol
9916007|NCT00767728|Active Comparator|1|Mesalamine pellets
9916008|NCT00767728|Placebo Comparator|2|Placebo
9916009|NCT00767741|Experimental|with treatment|
9916010|NCT00767754|Other|paroxetine cr|single arm
9916011|NCT00767780||3|Patients suffering from ankle fractures and instability
9916012|NCT00767780||4|Patients suffering from hip osteoarthritis
9916013|NCT00767780||5|Patients who underwent total knee replacement or total hip replacement
9916014|NCT00767780||1|Patients suffering from bilateral knee osteoarthritis
9916015|NCT00767780||2|Patients suffering fron non specific low back pain
9916016|NCT00767793|Placebo Comparator|Arm 1|One drop in each eye every 12 hours for seven days
9916017|NCT00767793|Experimental|Arm 2|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
9916018|NCT00767793|Experimental|Arm 3|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
9916019|NCT00767793|Experimental|Arm 4|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
9916020|NCT00767871|Experimental|Escitalopram|escitalopram (10-20mg) to panic patients
9916021|NCT00767897||CKD stage 3 or 4|Girls and Boys age 9-18 with CKD stage 3 or 4
9916022|NCT00767897||On dialysis|Girls and Boys age 9-18 who are on dialysis
9916023|NCT00767897||Transplanted|Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
9916024|NCT00767897||Healthy|Girls and Boys age 9-18
9916025|NCT00767949|Experimental|1|iSONEP
9916026|NCT00767962|Other|1|talc pleurodesis under medical thoracoscopy
9916027|NCT00767962|Other|2|pleurodesis under video-assisted thoracoscopy surgery
9916028|NCT00767975|No Intervention|2|For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
9916029|NCT00767975|Experimental|1|Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
9916030|NCT00767988|Active Comparator|A|Urex-cap-5 capsules (2x10^9 cfu each of RC-14 and GR-1) 1:1 ratio
9916031|NCT00767988|Placebo Comparator|B|Capsule 1:1
9916032|NCT00768014||1|Healthy term pregnant women in labor without any pain relief
9916033|NCT00768014||2|Healthy term pregnant women received TENS
9916034|NCT00768014||3|Healthy term pregnant women received epidural anesthesia
9916035|NCT00768105|Experimental|1|
9916036|NCT00768105|Placebo Comparator|2|
9916037|NCT00768131|Experimental|A1 FISH (+)|
9916038|NCT00768131|Active Comparator|B1 FISH (+)|
9916039|NCT00768131|Experimental|A2 FISH (-)|
9916040|NCT00768131|Active Comparator|B2 FISH (-)|
9916041|NCT00768157|Experimental|antiviral group|Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC)
9916042|NCT00768157|Active Comparator|control group|Procedure/Surgery (radical resection of HBV-related HCC) without Drug of antiviral treatment - close observation without antiviral treatment
9916043|NCT00768170|Experimental|1|MK0633
9916044|NCT00768183|Experimental|Regimen A|KADIAN Capsule + alcohol (under fasting conditions)
9916045|NCT00768183|Experimental|Regimen B|KADIAN Capsule + alcohol (under fed conditions)
9916046|NCT00768183|Experimental|Regimen C|KADIAN Capsule + water (under fasting conditions)
9916047|NCT00768183|Experimental|Regimen D|Morphine sulfate IR oral solution + water (under fasting conditions)
9916048|NCT00768209|Experimental|Treatment A|
9916049|NCT00768235|Experimental|1: yoga group|Yoga group
9916050|NCT00768235|No Intervention|2: control group|
9916051|NCT00768326|Experimental|Zicronapine. Study Part A|
9916052|NCT00768326|Experimental|Zicronapine. Study Part B|
9916053|NCT00768326|Experimental|Zicronapine. Study Part C|
9916054|NCT00768326|Experimental|Zicronapine. Study Part D|
9916055|NCT00768326|Experimental|Zicronapine. Study Part E|
9916056|NCT00768326|Placebo Comparator|2A, 2B, 2C, 2D, 2E|
9916057|NCT00768339|Experimental|1|Single agent AEG35156 as 2hr IV infusion, weekly dosing in Patients with relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas
9916058|NCT00768352|Other|Education Intervention|
9916059|NCT00768365||group 1|patients with adrenal incidentaloma
9916060|NCT00768365||group 2|Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group (group 2).
9916061|NCT00768365||group 3|The other control group (group 3) of 35 healthy individuals matched for sex, age, BMI, metabolic syndrome criteria, cardiovascular risk parameters, menopausal status, smoking status, consumption of alcohol, usage of antihypertensive drugs, insulin or oral hypoglycaemic agents to perform a 1:1 case-control analysis.
9916062|NCT00768378|Experimental|Perceived stimulation|When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
9916063|NCT00768378|Experimental|Subliminal stimulation|When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
9916064|NCT00768391|Experimental|IMC-3G3|All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
9916065|NCT00768404|Experimental|A|
9916066|NCT00768417||Participants|Participants completed all 3-arms of this cross-over design study.
9916067|NCT00768456|Active Comparator|1|Local infiltration with Ropivacaine
9916068|NCT00768456|Placebo Comparator|2|Local infiltration with Placebo (NaCl)
9916069|NCT00768495||One Cohort|
9916070|NCT00768508|Experimental|Ondansetron|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy
9916071|NCT00768508|Experimental|Naltrexone|Naltrexone 50 mg/day + Cognitive Behavioral Therapy
9916072|NCT00768508|Experimental|Ondansetron + Naltrexone|Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy
9916073|NCT00768508|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
9916074|NCT00768547||By protocol|Where the test are predefined
9916075|NCT00768547||By degression|The group where the doctor decided which test are to be taken.
9916076|NCT00768573||1. Taste test|
9916077|NCT00768586||1|Extreme premature infants under the 28th week of gestation.
9916078|NCT00768612|Experimental|1|Lowest dose
9916079|NCT00768612|Experimental|2|Middle dose
9916080|NCT00768612|Experimental|3|Highest dose
9916081|NCT00768612|Active Comparator|4|Positive Control
9916082|NCT00768638|Active Comparator|Atorvastatin 10mg|
9916083|NCT00768638|Active Comparator|Atorvastatin 40mg|
9916084|NCT00768690|Other|1|Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole
9916085|NCT00768690|Other|2|Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID
9916086|NCT00768690|Other|3|Healthy volunteers, receiving 600mg ABT-333 or placebo, BID
9916087|NCT00768690|Other|4|Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID
9916088|NCT00768690|Other|5|"Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID*~*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed."
9916089|NCT00768729|Experimental|1|"Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.~Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months."
9916090|NCT00768768|Active Comparator|1|Iontophoretic Dose Level 1
9916091|NCT00768768|Active Comparator|2|Iontophoretic Dose Level 2
9916092|NCT00768768|Active Comparator|3|Iontophoretic Dose Level 3
9916093|NCT00768768|Active Comparator|4|Iontophoretic Dose Level 4
9916094|NCT00768768|Active Comparator|5|Iontophoretic Dose Level 5
9916095|NCT00768781|Active Comparator|Mindfulness-Based Stress Reduction|
9916096|NCT00768781|Active Comparator|Mindfulness-Based Therapy for Insomnia|
9916097|NCT00768781|Other|Behavioral Therapy for Insomnia (Delayed treatment condition)|
9916098|NCT00768794|Active Comparator|Acidolphilus|In the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
9916099|NCT00768807|Sham Comparator|Sham CPAP|Patients submitted to SHAM CPAP use for 06 months
9916100|NCT00768807|Active Comparator|CPAP|OSA patients submitted to 06 months of CPAP treatment
9934516|NCT04731714|Other|Experimental: rhythmic MNS, then arrhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS.
9934517|NCT04731714|Other|Experimental: arrhythmic MNS, then rhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS.
9934518|NCT04728165||control group|Age (+/-5 yrs) and BMI (+/- 5 kg/m2) matched control male subjects for inclusion in the control group
9934519|NCT04728165||psoriasis group|Males between the ages of 18 and 70 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group
9934520|NCT04722718|Experimental|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Drug:Sintilimab;Drug:Apatinib;Drug:Albumin-Bound Paclitaxel(Nab-Paclitaxel);Drug:Carboplatin
9934521|NCT04720547|Experimental|Zolpidem, then No Treatment|Participants will be administered zolpidem for the first night study, and No Treatment during the second night study.
9934522|NCT04720547|Experimental|No Treatment, then Zolpidem|Participants will be administered zolpidem for the second night study, and No Treatment during the first night study.
9934523|NCT04718285|Experimental|Montelukast|3x10 mg oral montelukast first day (morning, noon time and evening) and rest of the 13 days 1 x 10 mg montelukast.
9934524|NCT04718285|Experimental|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast at the first day and rest of the 13 days1 x 10 mg, concurrently.
9934525|NCT04718285|Active Comparator|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
9934526|NCT04717349||Family Members of PAG patients|Clinical evaluation of family members that would provide clinical information related to the diagnosis of a proband in future research.
9934527|NCT04717349||PAG patient|Pediatric and adolescent patients with gynecologic conditions.
9934528|NCT04717336|Placebo Comparator|PERIOD 1|Participant will be instructed to take 3 pills per day for a total of 3 grams.Participant will take Sodium Chloride or placebo for a two week period
9934529|NCT04717336|Placebo Comparator|PERIOD 2|Participant will be instructed to take 3 pills per day for a total of 3 grams.Participant will take Sodium Chloride or placebo for a two week period
9934530|NCT04717336|No Intervention|WASHOUT OUT PERIOD|Participant will have a wash-out period for three-weeks
9934531|NCT04717284|Experimental|Self-compassion intervention (SCI)|Self-compassion prompt.
9934532|NCT04717284|Other|Control condition|Neutral prompt during the initial administration and no intervention during the two-week follow-up.
9934533|NCT04715893|Experimental|Ostomy belt group|Participants in this group will receive ostomy belts for eight weeks.
9934534|NCT04714892||Healthy control|BMI of 18.5-29.9 kg/m2
9934535|NCT04714892||Obese|BMI of 30-39.9 kg/m2
9934536|NCT04711590||Successful extubation|The patients pass the spontaneous breathing trial and are successful extubated without reintubation within 72 hours. .
9934537|NCT04711590||Failed extubation|The patients pass the spontaneous breathing trial and are successful extubated with reintubation within 72 hours. .
9934538|NCT04711512||Single Arm (All Participants)|Within this arm, participants are randomized to one of the interventions described below at each of 4 times per day.
9934539|NCT04708470|Experimental|1/Arm 1|Dose escalation/de-escalation of entinostat and dose escalation of NHS-IL12 with fixed dose of bintrafusp alfa
9934540|NCT04708470|Experimental|2/Arm 2|RP2D of entinostat, NHS-IL12, and bintrafusp alfa
9934541|NCT04708431||Female subjects relatives who are carriers of the AR gene difference|We will enroll 50 female subjects relatives AIS subjects who are carriers of the AR gene difference
9934542|NCT04708431||Female subjects relatives who are not carriers of the AR gene|We will enroll 50 female subjects relatives of AIS subjects who are not carriers of the AR gene.
9934543|NCT04708431||Healthy male subjects relatives|We will enroll 50 healthy male subjects of AIS relative subjects
9916101|NCT00768846|Active Comparator|1|Endeavor Resolute Stent
9916102|NCT00768846|Active Comparator|2|Xience V Stent
9916103|NCT00768859|Experimental|1|paclitaxel, trastuzumab and carboplatin
9916104|NCT00768885|Active Comparator|PureVision 1|PureVision soft contact lens design #1.
9916105|NCT00768885|Experimental|PureVision 2|PureVision soft contact lens design #2
9916106|NCT00768911|Experimental|1|
9916107|NCT00768924||1|Spinal fusion patients
9916108|NCT00768937|Experimental|Treatment arm|all patients will be treated with sorafenib
9916109|NCT00768950||Spondyloarthropathies|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset spondyloarthritis, and undifferentiated spondyloarthritis) as defined by the AMOR criteria
9916110|NCT00768963|Experimental|1|Patients will receive one injection of ranibizumab 3 days prior to surgery
9916111|NCT00768963|Experimental|2|Patients will undergo one injection of ranibizumab at the time of surgery
9916112|NCT00769028|Experimental|AIMSPRO|
9916113|NCT00769028|Placebo Comparator|Placebo|
9916114|NCT00769041|Placebo Comparator|placebo|
9916115|NCT00769041|Active Comparator|moxifloxacin|
9916116|NCT00769041|Experimental|avanafil therapeutic|avanafil 100mg - therapeutic dose
9916117|NCT00769041|Experimental|avanafil supratherapeutic|avanafil 800mg - supratherapeutic dose
9916118|NCT00769054|Active Comparator|1|Local Infiltration with Ropivacaine
9916119|NCT00769054|Placebo Comparator|2|Local Infiltration with Placebo
9916120|NCT00769080||1|Standard Treatment plus PSP
9916121|NCT00769080||2|Standard Treatment
9916122|NCT00769093|Active Comparator|Group 1|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The first study group (n=6) will receive bevacizumab, the antiangiogenic agent for three weeks, then dexamethasone for three weeks.
9916123|NCT00769093|Active Comparator|Group 2|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
9916124|NCT00769106|No Intervention|B (control group)|regular treatment and follow up
9916125|NCT00769106|Experimental|A (CIK group)|cytokine-induced killer cell treatment plus regular treatment and follow up
9916126|NCT00769145|Experimental|Ranibizumab|Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally
9916127|NCT00769158|Experimental|Topiramate + Naltrexone|Combination of Topiramate and Naltrexone
9916128|NCT00769158|Placebo Comparator|Placebo|
9916129|NCT00769171|Active Comparator|Arm 2|
9916130|NCT00769171|Experimental|Arm 1|
9916131|NCT00769197||1|Children with birth/time of neurologic insult less than 28 weeks of gestation
9916132|NCT00769197||2|Children with birth/time of neurologic insult at more than 28 weeks of gestation
9916133|NCT00769210|Experimental|A|
9916134|NCT00769236|Other|1|Patients with crohn disease
9916135|NCT00769236|Other|2|Patients reached by hemorrhagic first side-colitis
9916136|NCT00769236|Other|3|Patients controls
9916137|NCT00769262|Active Comparator|Aggressive Weaning|Infants will be weaned from the isolette using our current NICU standard of care.
9916138|NCT00769262|Experimental|Conservative Weaning|Infants will be weaned from the isolette using a modified conservative weaning schedule.
9916139|NCT00769275||1|Screening at start study with Adenosine vasodilator stress Tc-99m Sestamibi SPECT imaging
9916140|NCT00769275||2|No screening
9916141|NCT00769288|Experimental|I|Patients will receive a 1-hour infusion of FAU on days 1-5.
9916142|NCT00769301||1|Not hospitalized cancer patients under active treatment
9916143|NCT00769301||2|Caregivers of these cancer patients
9916144|NCT00769353|Experimental|Cognitive Behavioral Therapy-PASCET|Primary and Secondary Coping Enhancement Training (PASCET)
9916145|NCT00769353|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy (SNDT)
9916146|NCT00769366|Experimental|Psychotherapy|Psychotherapy and medical therapy
9916147|NCT00769366|Active Comparator|Control|Optimal medical therapy
9916148|NCT00769405|Experimental|Arm I|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery). Patients also undergo CHIP comprising oxaliplatin intraperitoneally during surgery and hyperthermia for 30 minutes.
9916149|NCT00769405|Experimental|Arm II|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery).
9916150|NCT00769418|Experimental|1|odanacatib (MK0822)
9916151|NCT00769418|Placebo Comparator|2|placebo to odanacatib (MK0822)
9916152|NCT00769431|No Intervention|Focus group|
9916153|NCT00769457|Experimental|1|Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data
9916154|NCT00769457|No Intervention|2|Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink
9916155|NCT00769470|Active Comparator|Arm I|Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9916156|NCT00769470|Experimental|Arm II|Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9916157|NCT00769470|Experimental|Arm III|Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9916158|NCT00769496|Experimental|Arm 1|
9916159|NCT00769509|Experimental|preterm formula|Assessment of energy expenditure of preterm infant during fed with preterm formula
9916160|NCT00769509|Active Comparator|human milk with fortifier|Assessment of energy expenditure by indirect calorimetry during fed with human milk with fortifier
9916161|NCT00769522|Experimental|FCR|
9916162|NCT00769522|Experimental|BR|
9916163|NCT00769535|Experimental|HSP70 and TNF polymorphisms|
9916164|NCT00769548|Experimental|Arm 1|Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
9916165|NCT00769548|Experimental|Arm 2|Neoadjuvant TAS given 2 months before and during RT to the prostate only.
9916166|NCT00769548|Experimental|Arm 3|RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
9916167|NCT00769548|Experimental|Arm 4|RT to the prostate only followed by 4 months of TAS.
9916168|NCT00769574|Experimental|1|Patients with coronary syndrome
9916169|NCT00769574|Other|2|Subjects without coronary syndrome
9916170|NCT00769587|Experimental|Thalidomide|Use of thalidomide
9916171|NCT00769626|Experimental|Early Treatment|
9916172|NCT00769626|Active Comparator|Usual Care|
9916173|NCT00769665||Systane Ultra|Systane Ultra
9916174|NCT00769665||Sensitive Eyes|Sensitive Eyes
9916175|NCT00769678|Active Comparator|Stimulation of diaphragm|
9916176|NCT00769691||Group A|Adult patients undergoing cardiac surgery
9916177|NCT00769717|Experimental|Wellness-Centered|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
9916178|NCT00769717|Active Comparator|Weight-Centered|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
9916179|NCT00769730||1|Patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by transcatheter arterial chemoembolization were included.
9934544|NCT04708431||Subjects with androgen receptor mutations|500 Subjects with confirmed androgen receptor mutations
9934545|NCT04706663||Cohort 1|Subjects with histologically confirmed prostate cancer and genomic testing results
9916180|NCT00769756||2|"Financial incentive~For the parents the financial incentive was 5 euros for every kilogram of weight-loss. For children the weight loss was calculated differently, taking into account the individual need of each child to lose weight. Children with a body mass index between the 90th and 97th age-adjusted BMI-percentile were asked to maintain their weight, and were paid in dependence on how well they managed to achieve this goal. Children with age-adjusted BMI-percentiles between 97 and 99, or above the 99th age-adjusted BMI-percentile received 5 euros per weight losses of respectively 500 g or 1 kg."
9916181|NCT00769756||1|The telemedical equipment consisted of a weighing scale for each family, an accelerometer for each participant, and a Homebox for each family which received the data from the scale and the accelerometers via bluetooth and transfered them via a telephone link to a server in Munich.
9916182|NCT00769756||3|The basic diet for all participants was supported by a list giving the calorie contents of a large variety of food-stuffs. The dual diet group received a second list giving the glycemic index (GI) for a large variety of carbohy-drates. Emphasis was placed on a preference for low-GI carbohydrates but not on avoidance of carbohydrates as required by the Atkins diet.
9916183|NCT00769769|Experimental|Telephone-based psychotherapy|
9916184|NCT00769769|Active Comparator|Face-to-face psychotherapy|
9916185|NCT00769782|Experimental|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
9916186|NCT00769834||CKD|The cohort comprises of patients who are diagnosed to have chronic kidney disease as defined by the K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease-2002.
9916187|NCT00769847||Sagittal synostosis|Male and female infants from 1-6 months of age with isolated, single suture sagittal craniosynostosis.
9916188|NCT00769873|Active Comparator|Lovenox|Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days after laparoscopic splenectomy
9916189|NCT00769873|No Intervention|No Lovenox|Patients do NOT receive Lovenox post laparoscopic splenectomy
9916190|NCT00769899|Experimental|1|
9916191|NCT00769899|Placebo Comparator|2|
9916192|NCT00769912|Experimental|1|50% N2O- 50%O2 mixture administration during the intervention
9916193|NCT00769912|Placebo Comparator|2|Placebo (air) during the intervention
9916194|NCT00769925|Experimental|Therapist Assisted Bibliotherapy-Primary Care (TAB-PC)|
9916195|NCT00769925|Experimental|Cognitive Behavior Therapy-Primary Care (CBT-PC)|
9916196|NCT00769938|Active Comparator|Aspirin + clopidogrel + oral anticoagulation|
9916197|NCT00769938|Active Comparator|Oral anticoagulants + clopidogrel|
9916198|NCT00769990|Experimental|Genistein|Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
9916199|NCT00770003|Experimental|1|
9916200|NCT00770003|Placebo Comparator|2|
9916201|NCT00770016|Experimental|1|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism
9916202|NCT00770042|Experimental|Group 1|Ketoconazole 400 mg qd for 5 days (Days 2-6) plus a single dose of 50 mg avanafil on Days 1 and 6
9916203|NCT00770042|Experimental|Group 2|Erythromycin 500mg every 12 hours for 5 days (Days 2-6) plus a single dose of 200 mg Avanafil on Days 1 and 6.
9916204|NCT00770042|Experimental|Group 3|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8) plus a single dose of 50 mg avanafil on Days 1 and 8
9916205|NCT00770068||Experimental group|All participants testing positive for tree and ragweed pollen allergies, as determined by levels of immunoglobulin E (IgE) antibodies
9916206|NCT00770068||Control group|All participants testing negative for tree and ragweed pollen allergies, as determined by levels of IgE antibodies
9916207|NCT00770094|Active Comparator|Group 1|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the AMO/VISX CustomVue™ wavefront guided Excimer Laser System performed on the contralateral eye
9916208|NCT00770094|Active Comparator|Group 2|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System performed on the contralateral eye
9916209|NCT00770094|Active Comparator|Group 3|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment in one eye of the subject and the Bausch and Lomb Planoscan™ Excimer Laser System performed on the contralateral eye
9916210|NCT00770107|Active Comparator|Thiamine|
9916211|NCT00770107|Placebo Comparator|Placebo|
9916212|NCT00770159|Experimental|1|MK0822
9916213|NCT00770159|Placebo Comparator|2|Placebo to MK0822
9916214|NCT00770172|Experimental|Arm I|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
9916215|NCT00770172|Experimental|Arm II|Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.
9916216|NCT00770185|Experimental|Ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
9916217|NCT00770198||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
9916218|NCT00770198||chronic HCV hepatitis|chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
9916219|NCT00770237|Experimental|Cues|Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
9916220|NCT00770263|Experimental|Dose Level 1A|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 10 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 10 mg IV on days 8, 15, and 22 during subsequent cycles."
9916221|NCT00770263|Experimental|Dose Level 1|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 15 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 15 mg IV on days 8, 15, and 22 during subsequent cycles."
9916222|NCT00770263|Experimental|Dose Level 2|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 20 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 20 mg IV on days 8, 15, and 22 during subsequent cycles."
9916223|NCT00770263|Experimental|Dose Level 3|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
9916224|NCT00770263|Experimental|Dose Expansion Phase|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
9916225|NCT00770276||Bariatric surgery|Bariatric surgery
9916226|NCT00770276||conservative Therapie|diet and exercise
9916227|NCT00770354|Experimental|1|AS1402 plus letrozole
9916228|NCT00770354|Active Comparator|2|Letrozole
9916229|NCT00770393|Experimental|1|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging.
9916230|NCT00770393|Active Comparator|2|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
9916231|NCT00770445|Experimental|Pioglitazone 15mg BID|Insulin therapy added
9916232|NCT00770445|Experimental|Pioglitazone 15mg + Metformin 850mg BID|Insulin Therapy Added
9916233|NCT00770445|Active Comparator|Metformin 850mg BID|Insulin therapy added
9916234|NCT00770458||Pregnant women|Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome
9916235|NCT00770471|Experimental|Dose Escalation|
9916236|NCT00770497|Experimental|Pioglitazone 15 mg to 30 mg QD|
9916237|NCT00770497|Active Comparator|Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD|
9916238|NCT00770497|Active Comparator|Ramipril 2.5 mg to 5 mg QD|
9916239|NCT00770536|Experimental|Part 1|In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy [(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)].
9916240|NCT00770536|Experimental|Part 2|The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
9916241|NCT00770575|Experimental|Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD|
9916242|NCT00770575|Active Comparator|Atorvastatin 20mg to 40 mg QD|
9916243|NCT00770614|Active Comparator|1|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
9916244|NCT00770614|Active Comparator|2|Isotonic Saline (0.9% sodium chloride) 1 mL/kg/h for 12 hours after the procedure
9916245|NCT00770614|Placebo Comparator|3|Placebo
9916246|NCT00770627|Placebo Comparator|Placebo caps|
9916247|NCT00770627|Active Comparator|Omega 3 caps|
9916248|NCT00770640|Experimental|Pioglitazone 30mg QD|(and variable insulin therapy)
9916249|NCT00770640|Placebo Comparator|Placebo QD|(and variable insulin therapy)
9916250|NCT00770666|Experimental|1|Nicotine patch, nicotine inhaler, bupropion
9916251|NCT00770666|Active Comparator|2|Nicotine patch
9916252|NCT00770705|Experimental|1|Group receiving phenoxybenzamine
9916253|NCT00770705|Other|2|Historical control
9916254|NCT00770718|Experimental|Recombinant Activated Factor VII|The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given. If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
9916255|NCT00770718|Experimental|Prothrombin Complex Concentrate (PCC)|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
9916256|NCT00770718|Active Comparator|Fresh Frozen Plasma (FFP)|The last five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
9916257|NCT00770731|Experimental|Torisel + Hycamtin + Velcade|"Torisel starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle.~Hycamtin starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle.~Velcade starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle."
9916258|NCT00770731|Experimental|Expansion Group|"Torisel + Hycamtin + Velcade Expansion Group~Addition of 10 participants at highest tolerated dose level"
9916259|NCT00770744|Experimental|Zicronapine|
9916260|NCT00770744|Active Comparator|Olanzapine|
9916261|NCT00770783|Experimental|Magnetic Seizure Therapy (MST)|
9916262|NCT00770783|Active Comparator|Electroconvulsive Therapy (ECT)|
9916263|NCT00770796|Placebo Comparator|Placebo|placebo
9916264|NCT00770796|Active Comparator|Atorvastatin|80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
9934546|NCT04706663||Cohort 2|Subjects with histologically confirmed prostate cancer who deemed to be an exceptional responder with or without genomic testing results
9934547|NCT04705350|Experimental|Zampilimab Cohorts|Participants will be randomized to receive predefined single doses of zampilimab.
9934548|NCT04705350|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo to maintain the blinding.
10213214|NCT04469803|Experimental|Brief nap, longer nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
10213215|NCT04469803|Experimental|Longer nap, brief nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
10213216|NCT04469803|Experimental|Longer nap, no nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
10213217|NCT04463992|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
9934549|NCT04704674||0.5 - 5 years|Age bracket for infants/children up to age five years
9934550|NCT04704674||10 - 18 years|Age bracket for children 10 - 18 years
9934551|NCT04704674||19 + years|Age bracket for adults over 19 years
9934552|NCT04704674||5 - 10 years|Age bracket for children ages 5 - 10 years
10213218|NCT04463992|Active Comparator|Behavioral:Program participants|The control group arm will receive usual care as provided by their local oncologists.
10213219|NCT04447222||Observational (survey)|Participants complete a survey online over 35-45 minutes about their experiences regarding the COVID-19 pandemic.
10213220|NCT04446390|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care). Chew xylitol gum 2 pieces four times per day for 5 minutes after meals."
9934553|NCT04704609||Imaging Analysis of patients with uveitis|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
9934554|NCT04703322|Experimental|Pexidartinib|Participants with TGCT who will receive oral pexidartinib 800 mg (400 mg twice daily [BID]).
9934555|NCT04699604|Active Comparator|Levocetirizine (LTZ)|Participants will take Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children >11 years per recommended doses) in addition to their current asthma regimen.
9934556|NCT04699604|Placebo Comparator|Placebo|Participants will take a placebo solution previously developed by the Children's Mercy Investigational Pharmacy to match the color, flavor, and consistency of the active drug in addition to their current asthma regimen.
9934557|NCT04698343|Experimental|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
9934558|NCT04694131|Other|MS|All participants will receive all conditions and the order of all conditions will be counterbalanced across participants. Statistical comparisons will be within-subjects. There will be two experiment days, during which TMS will be delivered during the behavioral tasks (spatial task trials and encoding phase of the memory task). Participants will receive TMS delivered to parietal cortex on one day and vertex stimulation on the other day. Each experiment day will include one block of TMS delivered prior to task trial onsets and one block delivered simultaneously with trial onsets.
9934559|NCT04693234|Other|Tislelizumab and Ociperlimab (BGB-A1217) Combination (Cohort 1)|Participants will receive tislelizumab 200 milligrams (mg) on Day 1 followed by the administration of ociperlimab (BGB-A1217) 900 mg of each 21-day cycle.
9934560|NCT04693234|Other|Tislelizumab Monotherapy (Cohort 2)|Tislelizumab 200 mg will be administered on Day 1 of each 21-day cycle
9934561|NCT04692831|Experimental|89Zr-ss-pertuzumab administration|For standard first in-human dosimetry, the first 6-8 patients who receive 89Zr-sspertuzumab will be followed by PET/CT imaging at 3 timepoints: 24 hours post administration (scan 1), 3-4 days post administration (scan 2) and 5-8 days post administration (scan 3). Once the optimal imaging timepoint for 89Zr-ss-pertuzumab is determined from these 6-8 patients, the remaining 12-14 participants will undergo a single timepoint PET/CT at the optimal imaging timepoint.
9934562|NCT04692675|Experimental|AS + mpMRI|Active surveillance (AS) with the following: a) Initial PSA and DRE screen; then, PSA screening every 12 months, with DRE every year mpMRI or prostate biopsy is performed; b) Initial mpMRI and then prior to all biopsies; c) Initial systemic prostate biopsy and MRI/US fusion-guided prostate biopsy of all suspicious lesions; then, every 2 years for 5 years and then every 3 years
9934563|NCT04690829||control|control with non-inflammatory related eye disease
9934564|NCT04690829||control (healthy participant)|healthy volunteer
9916265|NCT00770822|Experimental|Device, HIFU|High Intensity Focused Ultrasound
9916266|NCT00770822|Active Comparator|Device, brachytherapy|Brachytherapy
9916267|NCT00770835|Experimental|Pioglitazone and Metformin QD|(along with lifestyle modification)
9916268|NCT00770835|Active Comparator|Glibenclamide and Metformin QD|(along with lifestyle modification)
9916269|NCT00770887||Study participants|This study will enroll 50 English-speaking/literate women at least 18 years of age of any race who have sought contraception with DMPA at the Planned Parenthood of Southwest and Central Florida clinics in Tampa and Fort Myers. Patients who choose to begin DMPA or who have already been using DMPA will be approached regarding voluntary participation in the study. Because DMPA is contraindicated in pregnancy, women with a positive urine pregnancy will not be eligible. Should a woman become pregnant during the study, she will receive no further DMPA injections
9916270|NCT00770900|Experimental|Montelukast|Asthmatic children and teenagers took montelukast daily.
9916271|NCT00770900|Placebo Comparator|Placebo|Placebo to montelukast tablet daily.
9916272|NCT00770926|Experimental|Program immediately|Receives the lifestyle program as soon as possible after randomization
9916273|NCT00770926|No Intervention|Wait list control|Wait one year and at the end of the year, is offered the option of participating in the program
9916274|NCT00770952|Experimental|Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD|
9916275|NCT00770952|Active Comparator|Glimepiride 4 mg to 6 mg QD|
9916276|NCT00770978|Experimental|Ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
9916277|NCT00770978|Experimental|Ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
9916278|NCT00771004|Experimental|Pioglitazone 30 mg to 45 mg QD|
9916279|NCT00771004|Placebo Comparator|Placebo QD|
9916280|NCT00771017|Active Comparator|Arm I|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
9916281|NCT00771017|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
9916282|NCT00771043|No Intervention|TYSABRI|
9916283|NCT00771043|No Intervention|AVONEX|
9916284|NCT00771069||1|Type II Diabetes Mellitus patients with Complication and Hypertension
9916285|NCT00771095|Active Comparator|Control (available) podcast|
9916286|NCT00771095|Experimental|Enhanced podcast|
9916287|NCT00771108|No Intervention|control|Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
9916288|NCT00771108|Experimental|Exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
9916289|NCT00771121|Active Comparator|new emulsion|
9916290|NCT00771121|Placebo Comparator|new emulsion placebo|
9916291|NCT00771147||Group 1|
9916292|NCT00771186||children with vocal fold immobility|
9916293|NCT00771199|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl|
9916294|NCT00771212||001|
9916295|NCT00771225|Other|prolapse surgery with fascial repair|
9916296|NCT00771225|Other|prolapse surgery with mesh repair|
9916297|NCT00771251|Experimental|CNTO 148 50 mg|
9916298|NCT00771251|Experimental|CNTO 148 100 mg|
9916299|NCT00771251|Experimental|Placebo|
9916300|NCT00771303||Ct scan|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer measurement, lower limb compression ultrasonography and multi-slice computed tomography.
9916301|NCT00771329|Experimental|1|BIIB023
9916302|NCT00771329|Placebo Comparator|2|
9916303|NCT00771342|Experimental|1|1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days
9916304|NCT00771342|Placebo Comparator|2|Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days
9916305|NCT00771355||1|Subjects with vitiligo.
9916306|NCT00771355||2|Subjects with melasma.
9916307|NCT00771355||3|Subjects with post-inflammatory hyper-pigmentation.
9916308|NCT00771355||4|Subjects with post-inflammatory hypo-pigmentation.
9916309|NCT00771368|Experimental|Nitric Oxide|gaseous nitric oxide delivered topically for 30 minutes
9916310|NCT00771381|Experimental|1|18F-FAZA + FluGlucoScan Injection
9916311|NCT00771394|Placebo Comparator|1. Tamsulosin alone|
9916312|NCT00771394|Experimental|2. Tamsulosin + solifenacin (low dose)|
9916313|NCT00771394|Active Comparator|3. Tamsulosin + solifenacin (high dose)|
9916314|NCT00771420|Active Comparator|1|0.01mg/kg and 0.03mg/kg CAM-3001
9916315|NCT00771420|Active Comparator|2|0.1mg/kg CAM-3001
9916316|NCT00771420|Active Comparator|3|0.3mg/kg CAM-3001
9916317|NCT00771420|Active Comparator|4|1.0mg/kg CAM-3001
9916318|NCT00771420|Active Comparator|5|3.0mg/kgCAM-3001
9916319|NCT00771420|Active Comparator|6|10.0mg/kg CAM-3001
9916320|NCT00771420|Placebo Comparator|7|Placebo
9916321|NCT00771433|Experimental|Group 1|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses.
9916322|NCT00771433|Experimental|Group 2|Patients receive G-CSF SC once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they experience an episode of neutropenia.
9916323|NCT00771459|Active Comparator|Ropivacaine|
9916324|NCT00771459|Placebo Comparator|Placebo|
9916325|NCT00771485|Experimental|1|
9916326|NCT00771485|Other|2|
9916327|NCT00771498|Other|lopinavir|Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
9916328|NCT00771511|Experimental|1|Capsaicin cream applied to cervix after lidocaine gel
9916329|NCT00771511|Placebo Comparator|2|only lidocaine applied to the cervix
9916330|NCT00771524|Experimental|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
9916331|NCT00771524|No Intervention|Control|Standard of care antibiotics prior to hip replacement surgery
9916332|NCT00771563|Active Comparator|Arm A|Chemotherapy without LMWH
9916333|NCT00771563|Experimental|Arm B|Chemotherapy with LMWH
9916334|NCT00771576||A. Healthy Controls|subjects w/ predicted normal BCM (healthy, normalweight, nondiabetic individuals who have stimulated insulin and cpeptide levels within the normal range);
9916335|NCT00771576||B. Longstanding T1D|subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or not measurable stimulated insulin and c peptide levels);
9916336|NCT00771576||C. Obese Subjects|subjects with predicted increased beta cell mass (euglycemic obese subjects with fasting hyperinsulinemia).
9916337|NCT00771589|Experimental|Prosthesis|Motorized External Knee prosthesis for above knee amputees. Comprised of agonist and antagonist actuators to mimic behavior of knee joint during locomotion.
9916338|NCT00771628|Experimental|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
9916339|NCT00771628|Active Comparator|2 Malleable|
9916340|NCT00771641|Active Comparator|Standard Fractionation|Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks
9916341|NCT00771641|Experimental|Hyperfractionation|Hyperfractionation: 1.2 Gy/Fx, b.i.d. (> 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks
9916342|NCT00771641|Experimental|Accelerated Hyperfractionation with split|Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (> 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy
9916343|NCT00771641|Experimental|Accelerated fractionation with concomitant boost|Accelerated fractionation with concomitant boost
9916344|NCT00771680||A|
9916345|NCT00771706|Experimental|Proton Pump Inhibitor|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
9916346|NCT00771706|Placebo Comparator|Sugar Pill|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough
9916347|NCT00771719|Experimental|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
9916348|NCT00771732|Experimental|1|Light therapy
9916349|NCT00771732|Sham Comparator|2|"6 minute session given with machine off"
9916350|NCT00771771|Active Comparator|Day unit rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation in a day unit, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
9916351|NCT00771771|Active Comparator|Home rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation treatment in their homes, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
9916352|NCT00771771|No Intervention|Treatment as usual|Patients will receive rehabilitation treatment after today's principles and routines.
9916353|NCT00771784||1|Short term endotracheal intubation.
9916354|NCT00771784||2|Long term endotracheal intubation.
9916355|NCT00771797|Experimental|1|Treatement with low dose flavanoids over 60 days
9916356|NCT00771797|Experimental|2|Treatment with high dose flavanoids over 60 days
9916357|NCT00771823|Active Comparator|2|
9916358|NCT00771823|Active Comparator|1|"Maraviroc 300 mg twice daily for the first 14 days of the study.~Placebo twice daily for the last 14 days of the study"
9916359|NCT00771862|Placebo Comparator|1. standard care|1 day of perineural ropivacaine 0.2% infusion followed by 4-5 days of normal saline infusion.
9916360|NCT00771862|Active Comparator|2: experimental care|4-5 days of perineural ropivacaine 0.4% infusion.
9916361|NCT00771888|Other|1|lanreotide
9916362|NCT00771940|Active Comparator|Ghrelin|
9995649|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
9995650|NCT01492517|Other|Diesel exhaust exposure|Exposure to diesel exhaust will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to diesel exhaust (up to 300 ug/m3). Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. The DE will be generated from a diesel generator used to power a load bank that is located outside the Human Studies Facility, and subsequently introduced into the exposure chamber after different dilutions with clean HEPA and charcoal filtered and humidified air to give a chamber concentration of up to 300 μg/m3.
9998066|NCT01514656|Active Comparator|Recruitment with Volunteers|Volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
9998067|NCT01514656|Active Comparator|Recruitment with Nurses|Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
10213221|NCT04446390|Active Comparator|preventive regimen using Fluoride based toothpaste(colgate)|preventive regimen using Fluoride based toothpaste (colgate cavity protection). Participants will be using a fluoride-based toothpaste (colgate cavity protection), (1450 ppm Sodium monofluorophosphate). chew xylitol gum 2 pieces four times per day for 5 minutes after meals.
10213222|NCT04441749||nCLE Analysis|Needle based confocal laser endomicroscopy (nCLE) employs a small fiber which can be passed through a biopsy needle to enable real time microscopic imaging of cells. With resolution of 3.5 microns it is possible to identify key features consistent with malignancy and pulmonary fibrosis
10213223|NCT04440566|Experimental|Systemic lupus erythematosus (SLE)|
10213224|NCT04436913|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care)."
10213225|NCT04436913|Experimental|preventive regimen using Fluoride based toothpaste (Signal).|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride)
10213226|NCT04436913|Active Comparator|Fluoride toothpaste and fluoride varnish|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride) and fluoride varnish
10213227|NCT04429880|Experimental|Oxytocin|Oxytocin 17 micrograms infusion over 10 minutes
10213228|NCT04427761||pancreatic cancer health-illness transition|In this prospective longitudinal correlational study, a convenience sample of patients with pancreatic cancer receiving chemotherapy will be asked to report on their health-illness transition experiences and their level of distress.
10213229|NCT04426786|Active Comparator|Immediate intervention start: active exercise|Immediately starts the six month intervention of active exercise following the baseline scan.
10213230|NCT04426786|Placebo Comparator|Delayed intervention start: passive exercise|Starts the six month intervention of active exercise six months after the baseline scan. During the six month delay, participants in this arm undergo passive exercise.
10213231|NCT04426006|Other|PRO-SERO-COV|Blood sample and self-administered questionnaire
10213232|NCT04424537|Placebo Comparator|Control|"A control group will consume 2 meal replacement beverages(MRBs) made with whey protein~The control diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
10213233|NCT04424537|Active Comparator|Low protein(LP) diet|"This group will consume 2 meal replacement beverages(MRBs) containing low protein (goal to reduce total protein by 2/3rds).~LP diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
10213234|NCT04424537|Experimental|Low branched-chain amino acids (BCAA)|"The group on low-BCAA diet will consume 2 meal replacement beverages (MRBs) per day made with BCAD2 (branched chain amino acid) powder (lacking BCAAs).~BCAD2 powder(Mead Johnson) is a fortified medical food powder that does not contain the BCAAs isoleucine, leucine, or valine, but provides all other essential and nonessential AAs, carbohydrates, fat, vitamins, and minerals.~No overall calorie reduction will be implemented for any group.~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
10213235|NCT04412707|Active Comparator|Arm A|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a PVC and cycle 2 and onwards melflufen will be administered via a CVC.
9916363|NCT00771966|Placebo Comparator|Standard treatment|
9916364|NCT00771966|Active Comparator|SV maximization|
9916365|NCT00771979|Experimental|1|
9916366|NCT00772044|Active Comparator|Provent|Those receiving the active device
9916367|NCT00772044|Sham Comparator|Sham|Those receiving sham device
9916368|NCT00772057|Active Comparator|Propranolol group|
9916369|NCT00772057|Placebo Comparator|Placebo group|
9916370|NCT00772083|Experimental|1|
9916371|NCT00772083|Active Comparator|2|standard approach currently being used
9916372|NCT00772096|Experimental|Verum|
9916373|NCT00772096|No Intervention|No treatment|
9916374|NCT00772122|Experimental|Granulocyte colony stimulating factor|The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
9916375|NCT00772122|Placebo Comparator|placebo (saline solution)|The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
9916376|NCT00772161|Experimental|Sequence 1|First treatment week (day 1 to day 7) 20mg Ritalin LA; second treatment week (day 8 to day 14) 20mg Medikinet retard.
9916377|NCT00772161|Experimental|Sequence 2|First treatment week (day 1 to day 7) 20mg Medikinet retard; second treatment week (day 8 to day 14) 20mg Ritalin LA.
9916378|NCT00772174|Experimental|Pioglitazone + Metformin|
9916379|NCT00772174|Active Comparator|Metformin|
9916380|NCT00772187|Experimental|1|General anesthesia + I.V pca
9916381|NCT00772187|Experimental|2|General anesthesia + spinal analgesia + I.V pca
9916382|NCT00772200||Observational (neuropsychological and behavioral tests)|Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
9916383|NCT00772213|Experimental|MIGTS treatment|controlled trial (quasi-randomized) versus controls (=conventional treatment not in the MIGTS)
9916384|NCT00772213|No Intervention|controls (=conventional treatment not in the MIGTS)|
9916385|NCT00772226|Active Comparator|music|
9916386|NCT00772226|Placebo Comparator|Pillow without music|
9916387|NCT00772239|Experimental|Rotem|ROTEM: Rotation thromboelastometry
9916388|NCT00772239|Active Comparator|S|Standard coagulation managment procedure
9916389|NCT00772252||1|patient with hepatic failure undergoing liver support treatment in surgical intensive care unit
9916390|NCT00772265|Experimental|Wosulin N|Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL
9916391|NCT00772265|Active Comparator|Novolin N|Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.
9916392|NCT00772278|Active Comparator|CAS|carotid artery stenting
9916393|NCT00772278|Active Comparator|CEA|carotid endarterectomy
9916394|NCT00772291|Placebo Comparator|placebo|
9916395|NCT00772291|Active Comparator|pregabalin|
9916396|NCT00772317|Experimental|HIFU|High Intensity Focused Ultrasound
9916397|NCT00772356|Experimental|A|
9916398|NCT00772356|Active Comparator|B|
9916399|NCT00772395|Active Comparator|Risedronate|
9916400|NCT00772395|Placebo Comparator|Placebo|
9916401|NCT00772408||TB|patients with pulmonary TB
9916402|NCT00772408||control|healthy controls
9916403|NCT00772421||Responder|A subject having at least a 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase
9916404|NCT00772421||Non-responder|A subject with a less than 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase.
9916405|NCT00772460|Active Comparator|Forced Air|Warming with forced air (BairHugger)
9916406|NCT00772460|Experimental|Conductive Warming|Warming with the conductive device (HotDog)
9916407|NCT00772473||1 group, usual acute triptan treatment|
9916408|NCT00772486|Experimental|Experimental: ISF35 and FCR|ISF35 and FCR
9916409|NCT00772499|Experimental|1|olmesartan medoxomil tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
9916410|NCT00772499|Active Comparator|2|Atenolol tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
9916411|NCT00772512|Experimental|A|
9916412|NCT00772512|Experimental|B|
10213236|NCT04412707|Active Comparator|Arm B|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a CVC and cycle 2 will be administered via a PVC. From cycle 3 and onwards melflufen will be administered via CVC.
10213237|NCT04410198|Experimental|Roxadustat|
9916413|NCT00772512|Placebo Comparator|C|
9916414|NCT00772551|Active Comparator|1|
9916415|NCT00772551|Active Comparator|2|
9916416|NCT00772564|Experimental|Atorvastatin 80 mg|
9916417|NCT00772564|Experimental|Atorvastatin 10 mg|
9916418|NCT00772616|Experimental|1|Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).
9916419|NCT00772616|Active Comparator|2|Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria
9916420|NCT00772655|Experimental|Study Therapy|Induction therapy with a single course of 90Yttrium-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111Indium-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 up to a maximal dose of 12.000 MBq [if platelets are below 150000/µl only 11 MBq/kg are administered). Observation for patients achieving complete clinical and molecular response or partial clinical response. Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2 (t14;18)-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
9916421|NCT00772681|Experimental|1|
9916422|NCT00772694|Experimental|sorafenib|drug
9916423|NCT00772746||exercise|Respiratory and cognitive exercises in panic disorder patients.
9916424|NCT00772759|Experimental|1|Dry powder for oral inhalation
9916425|NCT00772759|Placebo Comparator|2|Dry powder for oral inhalation
9916426|NCT00772811|No Intervention|Flu-Mel|Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
9934565|NCT04690829||uveitis|patients with a diagnosis of uveitis or ocular inflammation
10213238|NCT04408794|Experimental|Vazegepant (BHV-3500)|10 mg intranasal (IN) up to 8 times per month, up to 1 year
10213239|NCT04402242|Sham Comparator|"SCS Group"|"Receiving anesthesia according to routine standard care, with the use of the hidden NOL (used to compare the data at the end of anesthesia with those of the classic BIS - without monitoring of the anesthesia by the NOL (without adjustment of treatments ))"
10213240|NCT04402242|Experimental|NOL Group|Receiving anesthesia monitored by the NOL
10213241|NCT04400058|Experimental|Octagam 10%|Octagam 10%
9934566|NCT04690816||Healthy Volunteers|Healthy Volunteers to have a comparative group,without an underlying autoimmune disease or other significant medical problems
9934567|NCT04690816||Systemic Autoimmune Diseases|Patients with associated systemic autoimmune diseases.
9934568|NCT04687800|Experimental|Dextenza 0.4mg|Intracanalicular insert
9934569|NCT04687800|Active Comparator|Durezol 0.05%|difluprednate ophthalmic emulsion
9934570|NCT04685200||Controls|90 controls to collect epidemiological data as well as blood samples, nasal swabs, salivary samples and stool samples from family members and cohabitants of subjects affected with PSC.
9934571|NCT04685200||PSC Pariticipants|40 patients with PSC diagnosed by standard clinical, biochemical, or imaging features (including up to 30 with a known diagnosis of IBD)
9934572|NCT04684615||AmBiGen|Individuals who are enrolled in AmBiGen over the last 3 years
9934573|NCT04681807|Experimental|Emotion Recognition Training|
9934574|NCT04681807|Active Comparator|Active Control Training|
9934575|NCT04681144||Radium-223-dichloride (Xofigo, BAY88-8223)|Patients with metastatic castration-resistant prostate cancer (mCRPC)
9934576|NCT04678089||Health group|The healthy control group mainly collected patients with other chronic diseases or blood tumors who did not meet the exclusion criteria and were not diagnosed with multiple myeloma. Also，we need some healthy volunteers. Healthy volunteers refer to people without serious physical disease, immune disease and family history of mental illness.There is no distinction between age, gender and nationality.
9934577|NCT04678089||Multiple Myeloma group|In the exposure group, all patients with multiple myeloma met the inclusion and did not meet exclusion criteria, including planning for autologous stem cell transplantation or not. There is no distinction between age, gender and nationality.
9934578|NCT04674618|Experimental|US-assisted nusinersen administration|A paramedian sagittal oblique view will be used to identify with ultrasound specific lumbar interspaces. After local anesthesia the spinal needle will be used to identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
9934579|NCT04674618|No Intervention|landmark based nusinersen administration|The desired intervertebral space will be first identified by manual palpation of surface landmarks and marked on the skin. After local anesthesia the spinal needle will be usedto identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
10213242|NCT04400058|Placebo Comparator|Placebo|Placebo
10213243|NCT04390945|Experimental|Camrelizumab Combined With Concurrent Radiotherapy and Chemotherapy|Camrelizumab (200mg Q2W, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons) Simultaneous radiotherapy (50-50.4Gy / 1.8-2Gy / 25-28F) Chemotherapy (Capecitabine, 625mg/m2, bid, oral, d1-5, qw, total 5 weeks).
10213244|NCT04384445|Experimental|Zofin Plus Standard Care|Participants in this group will receive standard of care plus Zofin on day 0, day 4 and day 8.
9916427|NCT00772824|No Intervention|1|10 patients (30 cycles) of chemotherapy will receive placebo
9916428|NCT00772824|Active Comparator|2|Intravenous glutamine
9916429|NCT00772824|Experimental|3|Oral Glutamine
9916430|NCT00772837|Experimental|1.H.Pylori Eradication Group|The eradication group will receive triple therapy (omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BID and Amoxycillin 1g BID) for 1 week for the eradication of H. pylori
9916431|NCT00772837|Placebo Comparator|2.Control Placebo Group|The control group will receive omeprazole 20 mg BID for 1 week along with placebo antibiotics for 1 week
9916432|NCT00772850||Antegrade nailing, humeral fractures|We included patient's age and gender, fracture location, fracture cause, presence of nail removal, post-operative period and comorbidity or associated disease as independent variables. Fracture location was either humeral neck or humeral shaft. Humeral neck fractures were defined as fractures above surgical neck of the humerus. Meanwhile, humeral shaft fractures were defined as fractures below surgical neck of the humerus and 5 cm above the olecarnon fossa. Humeral shaft fractures were separated into three groups: proximal third shaft fractures, middle third shaft fractures and distal third shaft fractures. Fracture causes included simple falls and traffic accidents.
9916433|NCT00772876|Experimental|P1446A-05|Single arm of the study drug. This being a dose escalation study, patient will receive a dose depending on the stage of the trial.
9916434|NCT00772902|Experimental|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
9916435|NCT00772902|Active Comparator|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
9916436|NCT00772980|Experimental|1|Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
9916437|NCT00772980|Placebo Comparator|2|Drug: Placebo Double-blind treatment period of 17 weeks placebo
9916438|NCT00772993||1|Primary open angle glaucoma
9916439|NCT00772993||2|Normal Control
9916440|NCT00772993||3|Myopia with no evidence of glaucoma
9916441|NCT00772993||4|Myopia with evidence og glaucoma
9916442|NCT00773006||A|Stable/elective PCI patients
9916443|NCT00773006||B|NSTEMI PCI patients
9916444|NCT00773006||C|STEMI PCI patients
9916445|NCT00773045||pain training program|ICU Patients treated with or without pain management protocol
9916446|NCT00773058|Active Comparator|glucocorticoid+RAI|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI
9916447|NCT00773058|Placebo Comparator|placebo + RAI|no glucocorticoid But ATCH test hints RAI
9916448|NCT00773058|Active Comparator|glucocorticoid|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI
9916449|NCT00773058|Placebo Comparator|placebo|no glucocorticoid But ATCH test does not hint RAI
10213245|NCT04384445|Placebo Comparator|Placebo Plus Standard Care|Participants in this group will receive standard of care plus placebo (Saline) on day 0, day 4 and day 8.
10213246|NCT04381364|Experimental|Medical treatment|Treatment with ciclesonide
10213247|NCT04381364|No Intervention|Standard of Care|Standard Medical Care
9916450|NCT00773071|Experimental|A|"Single photon emission computed tomography/computed tomography (SPECT/CT) guided lymphatic mapping and sentinel lymphadenectomy (LM/SL) vs. complete lymph node dissection (CLND)~All cervical cancer and vulvar cancer patients will undergo CLND according to the standard of care in gynecologic cancers as recommended by the International Federation of Gynecology and Obstetrics (FIGO).~Patients with FIGO IA2 and IB1 cervical cancers will be scheduled for radical hysterectomy and pelvic lymph node dissection.~Patients with FIGO IB and II vulvar cancers and those of patients with FIGO III with clinically negative regional lymph nodes will be scheduled for vulvectomy and inguinal lymph node dissection."
9916451|NCT00773084|Active Comparator|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
9916452|NCT00773110|Experimental|1 Albumin|Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
10213248|NCT04378907|Active Comparator|Cigarette Smokers: 0 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
10213249|NCT04378907|Experimental|Cigarette Smokers: 4 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 6 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
10213250|NCT04378907|Experimental|Cigarette Smokers: 15 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
10213251|NCT04378907|Experimental|Cigarette Smokers: 30 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
10213252|NCT04375384|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.
10214026|NCT01991067|Active Comparator|healthy volunteers / TBE virus vaccine|Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
9916453|NCT00773110|Placebo Comparator|2 Gelofusin|Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery
9916454|NCT00773123||1|Primary open angle glaucoma
9916455|NCT00773123||2|Normal controls
9916456|NCT00773149|Experimental|1|all included patients
9916457|NCT00773162|Placebo Comparator|1|
9916458|NCT00773162|Active Comparator|2|
9916459|NCT00773188|Experimental|1|
9916460|NCT00773201|Experimental|1|Healthy subjects
9916461|NCT00773214|Experimental|exercise|
9916462|NCT00773227|Experimental|1|All patients included
9916463|NCT00773240|Experimental|1|Grazax
9916464|NCT00773240|Placebo Comparator|2|
9916465|NCT00773318|Experimental|A|"Patients with histologically proven AJCC stages I - II - III prostate cancer including men with clinical T3N0M0 disease, men with PSA > 10 mg/ml, and men with Gleason score of 8-10. Prostate cancer patients scheduled for prostatectomy and pelvic lymph node dissection (CLND).~Arm A = SPECT/CT guided LM/SL versus CLND"
9916466|NCT00773331|Experimental|1|
9916467|NCT00773331|Active Comparator|2|
9916468|NCT00773435|Active Comparator|1. Echinacea purpurea|
9916469|NCT00773435|Placebo Comparator|2. placebo|
9799034|NCT01647958|Experimental|Treatment Arm|Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
9916470|NCT00773448|Active Comparator|Limited Malignancy Screening|
9916471|NCT00773448|Experimental|Extensive Malignancy Screening|Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis
9916472|NCT00773500||1|Providers adopting electronic prescribing in New York City, New York
9916473|NCT00773500||2|Providers adopting electronic prescribing in the Taconic region of New York
9916474|NCT00773526|Experimental|1|
9916475|NCT00773539|Active Comparator|1|
9916476|NCT00773539|Active Comparator|2|
9916477|NCT00773539|Active Comparator|3|
9916478|NCT00773552|Experimental|solifenacin succinate|Group randomized into solifenacin succinate treatment
9916479|NCT00773552|Placebo Comparator|placebo|Group randomized into placebo
9916480|NCT00773565|Other|Optifast|Patients included take part at a weight reduction program over one year.
9916481|NCT00773578||1|atopic asthmatic children exposed to environmental tobacco smoke
9916482|NCT00773578||2|atopic asthmatic children unexposed to environmental tobacco smoke
9916483|NCT00773591|Active Comparator|Botulinum Toxin Typ A|
9916484|NCT00773591|Placebo Comparator|Placebo|
9916485|NCT00773617|Experimental|1|Integrative cognitive affective therapy (ICAT)
9916486|NCT00773617|Active Comparator|2|Cognitive behavioral therapy (CBT)
9916487|NCT00773630|Active Comparator|A|Intake of Pletal 100 mg tablets dose together with 200 ml water
9916488|NCT00773630|Experimental|B|Intake of Pletal 100 mg ODT dose without water
9916489|NCT00773630|Experimental|C|Intake of Pletal 100 mg ODT dose together with 200 ml water
9916490|NCT00773630|Active Comparator|D|Intake of Pletal 100 mg ODT dose without water
9916491|NCT00773643|Experimental|Tissue Sample|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
9916492|NCT00773656||1|patients treated for a prostate adenocarcinoma
9916493|NCT00773708|Experimental|1|intensify their triple-drug therapy with Raltegravir (RAL)
9916494|NCT00773708|No Intervention|2|Continue with the same antiretroviral therapy
9916495|NCT00773721|Experimental|1|Volunteers who are currently using CPAP treatment will trial a new mask system for up to five weeks
9916496|NCT00773760||dosing|
9916497|NCT00773799||rehabilitation center's hospitalized patients|
9916498|NCT00773812|Experimental|Active Mecamylamine|There will be 12 children in this arm. These children will receive the active medication (mecamylamine).
9916499|NCT00773812|Placebo Comparator|Placebo|There will be 8 children in this arm. These children will receive placebo instead of the active medication.
10214027|NCT01976455||20% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
9916500|NCT00773825||1|Pregnancy after ICSI or IVF
9916501|NCT00773825||2|Pregnancy after ovarian stimulation
9916502|NCT00773825||3|natural pregnancy
9916503|NCT00773851|Other|A|transfacial sutures
10214028|NCT01976455||40% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
9916504|NCT00773851|Other|B|staples
9916505|NCT00773877||1|Primary open angle glaucoma
9916506|NCT00773877||2|Normal Controls
9916507|NCT00773890|Experimental|TRF-1101|Daily treatment with TRF-1101
9916508|NCT00773890|Placebo Comparator|Placebo|Daily treatment with placebo
9916509|NCT00773929|Experimental|1|3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort
9916510|NCT00773942|No Intervention|Usual care|Study subjects receive usual care, without the intervention.
9916511|NCT00773942|Experimental|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
9916512|NCT00773942|Experimental|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and a brief chart synopsis including patient medical history, medication history, and relevant laboratory information.
9916513|NCT00773981|Active Comparator|1|Endoluminal vacuum therapy.
9916514|NCT00773981|No Intervention|2|Patients not receiving vacuum therapy should be treated with a catheter with daily rinsing for a minimum of 7 days.
9916515|NCT00773994|Other|Normal velopharyngeal mechanism|All participants in this study are normal healthy adults, who have agreed to undergo to a videofluoroscopic Televex. These participants are acceptable control subjects because they are not diagnosed with VPI and/or submucous cleft palate (SMCP) and the velopharyageal mechanism functions the same in adults as it does in children. This procedure will take approximately 3 minutes to 5 minutes.
9916516|NCT00774007|Placebo Comparator|Placebo|Placebo
9916517|NCT00774007|Active Comparator|Mesalazine|mesalazine 800 mg t.i.d.
9916518|NCT00774020|Experimental|1|
9916519|NCT00774033|Experimental|1|Treatment of acute burn in adults and children by epidermal cell spray
9916520|NCT00774033|Active Comparator|2|Treatment of acute burn in adults and children by classic skin grafts
9916521|NCT00774072|Active Comparator|Tobramycin 80 mg|applied once daily via Pari Sinus nebulizer
9916522|NCT00774072|Placebo Comparator|isotonic saline|applied once daily via Pari Sinus nebulizer
9916523|NCT00774085||Patients with Schizophrenia|Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
10214029|NCT01966471|Active Comparator|Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane|Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
10214030|NCT01966471|Experimental|Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab|Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
10214031|NCT01940835||Type 1 Diabetes|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
10214032|NCT01940835||Healthy Control Group|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
10214033|NCT01928732|Active Comparator|CPT|Cognitive Processing Therapy (CPT) - a type of cognitive therapy for treating PTSD.
10214034|NCT01928732|Active Comparator|PE|Prolonged Exposure (PE) - a type of exposure therapy for treating PTSD.
10214035|NCT01927744|Experimental|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
10214036|NCT01927744|Experimental|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
10214037|NCT01925573|Other|Optune+RT+Bevacuzimab|"Part 1:~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.~Part 2:~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.~Part 3:~Adjuvant Bevacizumab and Optune"
10214038|NCT01842360|Experimental|MV130|The subjects will receive daily dose of MV130 during 12 months
10214039|NCT01842360|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 12 months
10214040|NCT01838096|Experimental|THA|
10214041|NCT01793623||nonemergent heart surgery, atrial tissue|patients undergoing non-emergent heart surgery
10214042|NCT01787643|Experimental|Standing desk|Installation of standing desk
9799035|NCT01647958|Active Comparator|Control|Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial. Patients will be offered TIF crossover procedure upon completion of month-6 follow-up visit.
9799036|NCT01648101|Experimental|Retigabine 900mg|900mg total daily dose
10213253|NCT04373642|Experimental|Pembrolizumab + QUADSHOT Radiotherapy|"Combination Treatment~Pembrolizumab by IV once on day 1 of 21 day cycle, begin 7 days before the first round of QUAD SHOT radiotherapy.~QUAD SHOT radiotherapy twice a day for two days, begin 7 days after the first dose of pembrolizumab; repeat every 28 days for up to 3 rounds.~Maintenance Treatment~Pembrolizumab by IV once on day 1 of 21 day cycle~On day 21, if the medical oncologist feels that the patient may safely continue treatment, patient will receive a new 21 days cycle of treatment with pebrolizumab."
10213254|NCT04373031|Experimental|Control|Control Arm: (Pembro + ACT): Pembrolizumab induction (single-dose 200mg IV), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
10213255|NCT04373031|Experimental|Arm A|• Arm A: (Pembro + IRX-2 + ACT): Pembrolizumab (single-dose 200mg IV) + cyclophosphamide (single-dose 300 mg/m2 IV) + IRX-2 induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by IRX-2 re-induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
10213256|NCT04372524||Allogeneic HSC Transplant recipients|"Five possible patient scenarios are anticipated to occur in those who underwent allogeneic HSCT:~Early event (e.g. death, non-engraftment) occurring before day 100.~No late-acute or chronic GvHD ever develops at any time point in the first year post-transplant (regardless of whether or not classical acute GvHD develops in the first 100 days after transplant).~Early-onset chronic GvHD (including overlap syndrome) occurred before day 60.~Early-onset chronic GvHD (including overlap syndrome) occurred between day 60 and day 100.~Chronic GvHD after Day 100, Late-acute GvHD (de-novo or recurrent) after day 100, or cases of overlap syndrome occurred after day 100."
10213257|NCT04366544|Other|Time Point 1: Baseline/Pre-preparatory Samyama|"Survey link for participant~Survey link for spouse/ control~Stool collection from home~Blood sample at home provided by at home phlebotomy services or at Isha Center group meditation by study personnel."
10213258|NCT04366544|Other|Time point 2: Post-Preparatory/Pre-Samyama|"Online Surveys~Participant~Spouse~Stool collection from IIIS/home~Blood sample collection: on site at IIIS/home EEG and fMRI"
9799037|NCT01648101|Experimental|Retigabine 600mg|600mg total daily dose
10213259|NCT04366544|Other|Timepoint 3: Immediate Post-Samyama|"Online survey to be completed~Survey link for participant~Survey link for spouse~Blood sample collection: on site at IIIS o Participant only - Not spouse/significant other. EEG and fMRI"
10213260|NCT04366544|Other|Timepoint 4: 3 months Post Samyama|"Blood draw at home by at home phlebotomist~Post program online survey follow up to be completed~Survey link for participant~Survey link for spouse: https~Stool collection from home"
9799038|NCT01648101|Placebo Comparator|Placebo|Placebo
10213261|NCT04363164|Experimental|Arm A: Enzalutamide|Patients randomized to Arm A will receive continuous therapy with standard dose Enzalutamide (160 mg oral daily).
10214043|NCT01780220|Experimental|abiraterone|Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy
10214044|NCT01775085|Experimental|Meaning-Centered Group for Breast Cancer Survivors (MCG-BCS)|
10214045|NCT01775085|Active Comparator|Discussion Group (DG)|
9799039|NCT01648140|Experimental|T40|Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm
9799040|NCT01648140|Experimental|T60|Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
9799041|NCT01648140|Active Comparator|PRT|Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm
9799042|NCT01648140|Experimental|G4|Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
9799043|NCT01648166||lung cancer cases|subjects with lung cancer who are greater than 17 years of age and live in Appalachian Kentucky
9799044|NCT01648166||control subjects|subjects without lung cancer, greater than 17 who reside in Appalachian Kentucky
9799045|NCT01648283|Experimental|Methadone arm|"Intravenous racemic methadone HCl, 6.0 mg bolus~Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)"
9799046|NCT01648322|Experimental|80 µg/kg/dose of F-627|This dose of F-627 given only to subjects that are to have TC chemotherapy.
9799047|NCT01648322|Experimental|240 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
9799048|NCT01648322|Experimental|320 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
9799049|NCT01648322|Active Comparator|Neulasta® (pegfilgrastim)|Given to subjects receiving TC or TAC chemotherapy.
9799050|NCT01648348|Experimental|Arm I (bevacizumab and TRC105)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9799051|NCT01648348|Active Comparator|Arm II (bevacizumab)|Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9799052|NCT01648452|Experimental|NT-501 CNTF-releasing implant|Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline
9799053|NCT01648491|Experimental|Stem Cell treatment|Muscle Biopsy and Injection of autologous stem cells
9799054|NCT01648530||Participants with Migraines|Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
9799055|NCT01648582|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
9799056|NCT01648582|Experimental|0.75 mg Dulaglutide|0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
9916524|NCT00774098|Placebo Comparator|Control Group|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
9916525|NCT00774098|Experimental|GICP|
9916526|NCT00774111|Experimental|Sequence 1|
9916527|NCT00774124|Experimental|1 Telemedicine|Usual care plus telemonitoring
9916528|NCT00774124|Active Comparator|2 Standard of Care|Standard of care - women will monitor and record blood glucose levels four times a day.
9916529|NCT00774150|Experimental|1. Cognitive Behavioral Therapy|
9916530|NCT00774150|Active Comparator|2. Client Centered Therapy|
9916531|NCT00774176||1|Phase 1 & Gene Expression:Hospitalized COPD exacerbators
9916532|NCT00774176||2|Phase 2: COPD group
9916533|NCT00774176||3|Genetic Association Studies: COPD and Healthy Controls
9916534|NCT00774189|Experimental|1|clarithromycin 250 mg tablets of Ranbaxy Laboratories
9916535|NCT00774189|Active Comparator|2|Biaxin 250 mg tablets
9916536|NCT00774228|Experimental|I-ZIP Ocular Bandage|I-Zip bandage application
9916537|NCT00774228|Active Comparator|Oasis 24 hour Soft Shield Collagen Corneal Shield|Oasis shield application
9916538|NCT00774241|Experimental|1|
9916539|NCT00774280|No Intervention|ArmI(BuCy)|"Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4~Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2"
9916540|NCT00774280|No Intervention|Arm II (BuFlu)|"Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.~Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2"
9916541|NCT00774293|Experimental|1|Arnica 5CH and Bryonia 9CH (homeopathic drugs)
9916542|NCT00774293|Placebo Comparator|2|placebo Arnica 5CH and Bryonia 9CH
9916543|NCT00774319|Active Comparator|1|Induction Chemotherapy with TPF Then: cisplatin 100 mg/m2 on day 1, 22 and 43 combined with conventional radiotherapy
9916544|NCT00774319|Active Comparator|2|Induction chemotherapy with TPF Then cisplatin 40mg/m2 on day 1,8,15,22,29 and 35 combined with accelerated radiotherapy
9916545|NCT00774358|Experimental|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
9916546|NCT00774371|Experimental|1|The intervention program consists of group sessions provided according to the following schedule: weekly for 4 months, every other week for two months, and follow-up monthly sessions through 18 months of active subject participation. The time points for data collection from all subjects are baseline, 6 months, and 18 months. The group sessions offered to the treatment study arm are closed-group contingents with an average of 12-15 women assigned to each group.
9916547|NCT00774384|Active Comparator|1|Immunisation with NZ MenB OMV vaccine (NZ98/254)
10213262|NCT04363164|Experimental|Arm B: Sequential Testosterone and Enzalutamide|Patients in Arm B will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 (i.e. cycle 1). On Day 1 of cycle 2, patients will stop testosterone and begin enzalutamide 160 mg po q day for 56 days. Each cycle is 56 days. On Day 1 of cycle 3, patient will not take enzalutamide and will again receive injection of testosterone. Patients will continue to alternate one cycle of testosterone (2 injections) with one cycle of 56 days of enzalutamide.
10214046|NCT01774721|Experimental|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
9916548|NCT00774384|No Intervention|2|No vaccine
9916549|NCT00774423|Placebo Comparator|Placebo|MAIN EXCIPIENT OF THE RILUTEK
9916550|NCT00774423|Active Comparator|Riluzole|RILUTEK
9916551|NCT00774436|Experimental|Patients scheduled to receive Focal Cryotherapy|After enrollment, patients will undergo a repeat transrectal ultrasound- guided prostate biopsy (minimum of 12 cores) to confirm the low-risk nature of their cancer. For study purposes, patients must meet the original entry crieteria on this repeat biopsy. If the patient meets the repeat-biopsy enrollment criteria, they will be treated with focal cryotherapy, meaning cryoablation of the regions of the prostate containing cancer. Efficacy is defined as all negative biopsy cores at the site of the focal ablation on a repeat transrectal biopsy 6 months after cryoablation. At baseline (prior to the re-staging biopsy), 3 months after focal cryotherapy, and at 6 months after focal cryotherapy (prior to the repeat prostate biopsy used to define efficacy), the patient will complete quality of life questionnaires as standard for all patients in the Urology Service.
9916552|NCT00774449||1|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion
9916553|NCT00774462|Experimental|1|
9916554|NCT00774475|Placebo Comparator|1: standard therapy|clopidogrel 75 mg/day
9916555|NCT00774475|Active Comparator|2: doubled therapy|clopidogrel 150 mg/day
9916556|NCT00774501|Experimental|treatment of metastatic liver disease|The intervention is the use of image guidance with general anesthesia and suspended ventilation during treatment delivery. This will allow precise localization and delivery of dose to the tumor.
9916557|NCT00774514|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
9916558|NCT00774514|Experimental|NO2 exposure|1 hour exposure to nitrogen dioxide at 4ppm during intermittent exercise
9916559|NCT00774527|No Intervention|ArmI(CyATG)|•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
9916560|NCT00774540|Experimental|1|Ketorolac
9916561|NCT00774540|Placebo Comparator|2|saline
9916562|NCT00774553|Experimental|1|AZD1656
9916563|NCT00774553|Placebo Comparator|2|Placebo
9916564|NCT00774592|Experimental|1|Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
9916565|NCT00774592|Experimental|2|FOYC plus Goal For It (GFI)
9916566|NCT00774592|Active Comparator|3|Wonderous Wetlands plus GFI
9916567|NCT00774592|Experimental|Grade 10-BFOOY+CImPACT|Youth receives HIV intervention; parents receive parental monitoring intervention
9916568|NCT00774592|Experimental|Grade 10 BFOOY+GFI|Youth receive HIV prevention intervention and parents receive attention control intervention on career planning
9916569|NCT00774592|Experimental|BFOOYand no parent intervention|Youth receive HIV prevention intervention; parents receive no intervention
9916570|NCT00774592|Placebo Comparator|Health and FAmily life|Youth receive standard of care (current curriculum); parents receive no intervention
9916571|NCT00774605|Experimental|Varenicline free base solution|
9916572|NCT00774605|Experimental|Varenicline transdermal delivery system|
9916573|NCT00774618|Experimental|Resection|Those subjects undergoing resection with or without plate fixation
9916574|NCT00774618|No Intervention|Nonoperative|These patients were not considered candidates for surgical intervention by the investigators, declined surgical intervention, or did not receive insurance approval for surgery
9916575|NCT00774631|Experimental|Hypothermia|mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming
9916576|NCT00774631|Active Comparator|No hypothermia|no hypothermia, according to local recommendations and guidelines of medical societies and literature
9916577|NCT00774644|Experimental|1|clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
9916578|NCT00774644|Active Comparator|2|BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
9934580|NCT04673357|Experimental|Open- Label Ustekinumab Intravenous (IV): Induction Period|All participants will receive a single IV administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
9934581|NCT04673357|Experimental|Ustekinumab Subcutaneous (SC) Every 8 Weeks (q8w): Maintenance Period|Participants will receive SC administration of ustekinumab q8w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at maintenance weeks (Weeks M)-0, M-8, M-16, M-24, M 32, and M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
9934582|NCT04673357|Experimental|Ustekinumab SC Every 12 Weeks (q12w): Maintenance Period|Participants will receive SC administration of ustekinumab q12w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
9934583|NCT04673175|Experimental|Ceftolozane-Tazobactam|Participants receive ceftolozane-tazobactam by injection directly into the vein (intravenously, IV) every 8 hours for 10-14 days.
9934584|NCT04671212||Orthopedic Surgery Patients|Participants receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
9934585|NCT04669574||Group 1|Participants who are newly diagnosed and have initiated front-line treatment.
9934586|NCT04669574||Group 2|Participants who have previously had one progression.
9934587|NCT04669574||Group 3|Participants who have previously had a second recurrence.
9934588|NCT04669574||Group 4|Participants who are on imaging surveillance and not receiving anti-neoplastic treatment
9934589|NCT04667403|Experimental|Telemedicine|"Pain is monitored, from the patient's home, using a computer application accessible from a smartphone or a computer with internet access.~This application will allow the patient to describe his or her pain by means of a self-questionnaire. Healthcare professionals (nurse coordinator, pain specialist and oncologist) will thus be able to remotely interpret the data collected, enabling them to provide patients with a rapid response to adapt their pain treatment without the patient having to travel to the establishment."
9934590|NCT04665752||Affected Participants|Participants previously diagnosed with COVID-19.
9934591|NCT04664478||Subjects with abnormal elastogenesis|Participants with genetic variant in the connective tissue target genes
9934592|NCT04663321|Experimental|MK-1942 Daily Dose Group|Participants receive a total daily dose titrated from 5 mg to 20 mg of MK-1942 twice daily (BID), orally, over 4 weeks of treatment duration: 5 mg in Week 1, 10 mg in Week 2, and 20 mg in Weeks 3 and 4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
9934593|NCT04663321|Experimental|MK-1942 Intermittent Dose Group|Participants receive a total daily dose of 10 mg of MK-1942 twice weekly (BIW), orally, for Weeks 1-4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
9934594|NCT04663321|Placebo Comparator|Placebo|Participants receive a dose-matched placebo BID, orally, for 4 weeks. Participants receive matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
9934595|NCT04662255|Experimental|Arm A (Pirtobrutinib)|Orally
9934596|NCT04662255|Active Comparator|Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib)|Investigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country.
9934597|NCT04661085||Patients with a suspected infection|Acutely admitted patients from the emergency department across 3 sites who have a suspected infection.
9934598|NCT04657575|No Intervention|ASTI|ECT guided with ASTi 2-4 min
9934599|NCT04657575|Active Comparator|Narcotrend|ECT guided with ECT
9934600|NCT04655404|Experimental|Larotrectinib|Larotrectinib will be administered orally, twice daily, at 100 mg/m2 continuously on a 28-day cycle schedule.
9934601|NCT04653922|Experimental|Bioengineered corneal substitute|A cell-free, sterilized bioengineered corneal substitute made from medical grade collagen
9916579|NCT00774683||Sub-study Group A|Six HIV-positive African American women from the main study, CID 0706
9916580|NCT00774696|Experimental|1|Clarithromycin 500 mg Tablets
9916581|NCT00774696|Active Comparator|2|BIAXIN® 500 mg tablets
9916582|NCT00774709||1|
10213263|NCT04363164|Experimental|Arm C: Variable Sequential Testosterone and Enzalutamide|Patients in Arm C will receive intramuscular injection with testosterone cypionate (T) at a dose of 400 mg every 28 days x 2 injections per cycle. Patients will remain on high dose T for at least one cycle. Each cycle is 56 days. Patients with declining PSA will remain on high dose T for additional cycles of 2 injections until PSA progression occurs based on PCWG3 criteria. Patients with PSA progression (≥25% increase in PSA from baseline) will stop T injection. These patients will then be started on Enzalutamide. Patients on enzalutamide with PSA decline after one 56 day cycle will continue on Enzalutamide until PSA progression occurs. Patients with PSA progression (≥25% increase in PSA from baseline) will stop Enzalutamide and will restart injections of T with 2 injections/cycle. These cycles of switching between T and Enza with onset of PSA progression will continue until clinical and/or radiographic progression occurs.
10213264|NCT04361838|Active Comparator|Prayer|Patients will receive a daily prayer and standard of care treatment from multi-denominational group while in the ICU.
10213265|NCT04361838|No Intervention|No Prayer|Patients will receive standard of care treatment while in the ICU.
9916583|NCT00774722|Experimental|Metronidazole|
9916584|NCT00774722|Placebo Comparator|Placebo|
9916585|NCT00774735|Experimental|Sequence 1|
9916586|NCT00774735|Experimental|Sequence 2|
9916587|NCT00774774|Placebo Comparator|2|No intervention
9916588|NCT00774774|Experimental|1|Mask
9916589|NCT00774813|Active Comparator|A|Nexalin 1.3mA device + placebo antidepressant
9916590|NCT00774813|Active Comparator|B|Nexalin 15mA device + placebo antidepressant
9916591|NCT00774813|Placebo Comparator|C|Placebo device + SSRI (Citalopram or similar)
9916592|NCT00774826|Experimental|1|R-CVP x 3; Restaging if> RP then R-CVP x 5
9916593|NCT00774826|Experimental|2|R-CHOP x 3; Restaging if > RP then R-CHOP x 3 plus 2 Rituximab
9916594|NCT00774826|Experimental|3|R-FM x 3; Restaging if > RP then R-FM x 3 plus 2 Rituximab
9916595|NCT00774839||Newly diagnosed stage II-III colon cancer 65 years or older|Medicare-eligible (≥ or = to 65 years) patients diagnosed with stage II - III colon cancer, are at least 4 months into chemotherapy and up to 7 months post-chemotherapy.
9916596|NCT00774865||Surgical|Patients who have previously undergone robotic bypass surgery
9916597|NCT00774878|Experimental|Arm A|
9916598|NCT00774878|Active Comparator|Arm B|
9916599|NCT00774917|Experimental|Numen|
9916600|NCT00774943|Active Comparator|AMG 557|
10213266|NCT04351958|Experimental|"Augmented Reality (No Time Wasted)"|
10213267|NCT04337827|Experimental|Rituximab and Acalabrutinib|Participants will receive treatment of Rituximab weekly for 4 weeks, and Acalabrutinib twice daily for 4 weeks. Response assessment via diagnostic CT scans will dictate further treatment decisions.
10213268|NCT04332068|Active Comparator|Arm 1|Permethrin cream plus placebo tablets
10213269|NCT04332068|Experimental|Arm 2|Ivermectin (200 µg/kg) plus placebo cream
10213270|NCT04332068|Experimental|Arm 3|Ivermectin (400 µg/kg) plus placebo cream
10213271|NCT04332068|Experimental|Arm 4|Ivermectin (800 µg/kg) plus placebo cream (except the Bangladesh site)
10213272|NCT04330833|Active Comparator|Enhanced Usual Care Parent Education|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the enhanced usual care parent education group.
10213273|NCT04330833|Experimental|Novel Communication Intervention|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the novel communication intervention group.
10213274|NCT04328909|Experimental|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
10213275|NCT04328909|Active Comparator|Control Group|Usual care - No E-Care app will be provided
10213276|NCT04327024|Experimental|Verinurad 12 + allopurinol|"Dose [mg] verinurad/allopurinol:~Step 1 - titration_3/100 Step 2 - titration_7.5/200 Step 3 - target dose 12/300"
9916601|NCT00774943|Placebo Comparator|Placebo|
9916602|NCT00774956|Experimental|1|Subject with shoulder impingement
9916603|NCT00774956|Active Comparator|2|Healthy persons
9916604|NCT00774969|Experimental|All|6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
9916605|NCT00774982|Experimental|1 6MP Test Formulation|1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation, for targeted ileal delivery
9916606|NCT00774982|Active Comparator|2. 6MP Reference Formulation|2 x 50 mg oral tablet, PURINETHOL
9916607|NCT00775008|Experimental|podcast|
9916608|NCT00775008|Active Comparator|Web group|
9916609|NCT00775034|Experimental|1|Study group (Tisseel®)
9916610|NCT00775034|Other|2|Control group
9916611|NCT00775047|Experimental|Pharmacy|Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists
9916612|NCT00775047|Active Comparator|Planned Parenthood clinic|Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic.
9916613|NCT00775073|Experimental|Treatment|Bevacizumab (Avastin) & Everolimus (RAD001)
9916614|NCT00775099|Experimental|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
9916615|NCT00775099|Experimental|Diesel Exhaust Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 during intermittent exercise
9916616|NCT00775099|Experimental|Filtered Diesel Exposure|1 hour exposure to diesel exhaust with all particulates filtered out using teflon filter with intermittent exercise
9916617|NCT00775099|Experimental|PALAS Exposure|1 hour exposure to pure carbon particles produced by PALAS generator during intermittent exercise
9916618|NCT00775112|Experimental|1|with pillow
9916619|NCT00775112|No Intervention|2|without pillow
9916620|NCT00775151|Experimental|1|amlodipine 10 mg tablet of Ranbaxy
9916621|NCT00775151|Active Comparator|2|Norvasc® 10 mg tablets
9916622|NCT00775164|Experimental|pioglitazone|Pioglitazone: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
9916623|NCT00775164|Active Comparator|Metformin|Metformin XR; 1000 mg once daily for 16 weeks.
9916624|NCT00775177|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
9916625|NCT00775177|Active Comparator|2|Adoxa ® 100mg tablets of Bradley Pharmaceuticals, Inc
9916626|NCT00775216|No Intervention|Standard care|Standard behavioral counseling
9916627|NCT00775216|Experimental|Intervention|"Behavioral counseling intervention augmented with an interactive health promotion telephone helpline"
9916628|NCT00775242|Experimental|Estradiol and progesterone injection|Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P
9916629|NCT00775255|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
9916630|NCT00775255|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
9916631|NCT00775281||1|
9916632|NCT00775281||2|
9916633|NCT00775281||3|
9916634|NCT00775294|Experimental|maraviroc|Single arm trial looking at the pharmacokinetics of maraviroc in healthy volunteers.
9916635|NCT00775307|Placebo Comparator|B|Placebo 400 mg/day (24 weeks)
9916636|NCT00775307|Experimental|A|Pazopanib 400 mg/day (24 weeks)
9916637|NCT00775320||Brain tumor FLT-PET|Those diagnosed with a brain tumor and are to undergo surgery
9916638|NCT00775333||1|Patients with diabetes and carpal tunnel syndrome
9916639|NCT00775333||2|Non-diabetic patients with carpal tunnel syndrome
9916640|NCT00775359|Experimental|1|Fenofibrate 160mg Tablets of Ranbaxy
9916641|NCT00775359|Active Comparator|2|TriCor® 160 mg Fenofibrate Tablets
9916642|NCT00775372|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
9916643|NCT00775372|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
9916644|NCT00775385|Active Comparator|A|Standard chemotherapy
9916645|NCT00775385|Experimental|B|Customized treatment
9916646|NCT00775398||A|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who received topical THROMBIN-JMI® during the study surgery.
9916647|NCT00775398||B|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who did not received THROMBIN-JMI® during the study surgery.
9916648|NCT00775398||C|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did receive THROMBIN-JMI® during the study surgery.
9916649|NCT00775398||D|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN-JMI® during the study surgery.
9916650|NCT00775424|Experimental|PENNVAX-B alone|PENNVAX-B alone
9916651|NCT00775424|Experimental|PENNVAX-B+IL12|PENNVAX-B+IL12
9916652|NCT00775424|Experimental|PENNVAX-B+IL15|PENNVAX-B+IL15
9916653|NCT00775424|Placebo Comparator|PLACEBO|PLACEBO
9916654|NCT00775476|Active Comparator|NAC|2.4 g - 4.8 g of NAC daily starting after 3 month open label titration period.
9916655|NCT00775476|Placebo Comparator|Placebo|2.4 g - 4.8 g of placebo per day after 3 month open label titration period.
9916656|NCT00775489|Active Comparator|1|Steroid nasal spray (beclomethasone)
9916657|NCT00775489|Placebo Comparator|2|Normal saline nasal spray
9916658|NCT00775502|Experimental|BIW-8962, monoclonal antibody|
9916659|NCT00775515|Experimental|one|laparoscopic prostatectomy
9916660|NCT00775541|Experimental|Vitamin C|2 gms vitamin C
9916661|NCT00775554|Other|traditional hematoma block|people will receive traditional hematoma block for closed forearm fractures
9916662|NCT00775554|Other|ultrasound guided hematoma block|pts. will receive a hematoma block using bedside ultrasound to guide the placement
9916663|NCT00775567|Active Comparator|1|30g fructose dissolved in water twice a day
9916664|NCT00775567|No Intervention|No Intervention|
9916665|NCT00775580|Experimental|1|atenolol 100 mg Capsules of Ranbaxy
9916666|NCT00775580|Active Comparator|2|Tenormin 100mg capsules
9916667|NCT00775619|Active Comparator|2|Coreg® 12.5 mg tablets
9916668|NCT00775619|Experimental|1|Carvedilol 12.5 mg tablets
9916669|NCT00775632|Active Comparator|Standard of Care|The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate.
9916670|NCT00775632|Experimental|Cyclosporine and Campath|The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD.
9916671|NCT00775697|Experimental|Montelukast|the single arm will receive montelukast
9916672|NCT00775710|Active Comparator|1|Non-invasive ventilation is maintained during three nights after recovery of an episode of hypercapnic respiratory failure.
9916673|NCT00775710|No Intervention|2|Discontinuation of NIV after the recovery of hypercapnic respiratory failure, without prolong it during night.
9916674|NCT00775736||A|
9916675|NCT00775749|Experimental|1|The nicotine patch will be applied prior to surgery and remain on the right upper back for 24 hours.
9916676|NCT00775749|Placebo Comparator|2|The placebo patch has no active ingredients and the same inactive ingredients as the nicotine patch. It will be administered the same fashion as the nicotine patch.
9916677|NCT00775762|Active Comparator|aspirin|
9916678|NCT00775762|Active Comparator|clopidogrel|
9916679|NCT00775762|Active Comparator|clopidogrel plus aspirin|
9916680|NCT00775775||TBI|Patients with moderate to severe TBI
9916681|NCT00775788|Experimental|Implant Failure|
9916682|NCT00775788|Experimental|Post mastectomy breast reconstruction|
9916683|NCT00775788|Experimental|Congenital malformations|
9916684|NCT00775788|Experimental|Breast Ptosis|
9916685|NCT00775788|Experimental|Micromastia|
9916686|NCT00775788|Experimental|Asymmetric Breasts|
9916687|NCT00775801|Experimental|Treatment|FLD
9916688|NCT00775801|Active Comparator|Control|
9916689|NCT00775814|Experimental|Candesartan + Hydrochlorothiazide QD|
9916690|NCT00775814|Active Comparator|Hydrochlorothiazide QD|
9916691|NCT00775827|Experimental|1|fenofibrate 160 mg tablets of Ranbaxy Laboratories
9916692|NCT00775827|Active Comparator|2|Tricor 160 mg tablets
9916693|NCT00775840|Experimental|Candesartan QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
9916694|NCT00775840|Placebo Comparator|Placebo QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
9916695|NCT00775866|Experimental|MRI guided prostate biopsy|
9916696|NCT00775879|Experimental|A|2.5% target concentration
9916697|NCT00775879|Active Comparator|B|2.5% manually selected
9916698|NCT00775905|Experimental|1|amlodipine 10 mg tablets of Ranbaxy
9916699|NCT00775905|Active Comparator|2|Norvasc® 10 mg tablets
9916700|NCT00775918|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
9916701|NCT00775918|Active Comparator|2|Adoxa ® 100 mg tablets of Bradley Pharmaceuticals Inc
9916702|NCT00775957||1|FLT-PET Scan
9916703|NCT00775957||2|FDG-PET Scan
9916704|NCT00775996|Experimental|1|15 mg clorazepate dipotassium tablets of ranbaxy
9916705|NCT00775996|Active Comparator|2|(TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets
9916706|NCT00776022|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
9916707|NCT00776022|Active Comparator|2|Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
9916708|NCT00776048||ABI|Acquired brain injury with lower limb spasticity
9916709|NCT00776048||Healthy Controls|Age matched healthy controls
9916710|NCT00776074|Experimental|Leuprorelin (GF)|
9916711|NCT00776074|Experimental|Leuprorelin (GC)|
9916712|NCT00776087|Experimental|1 = Home Monitoring|Remote monitoring of ICD and CRT-D function and patient status
9916713|NCT00776087|Active Comparator|2 = No Home Monitoring|Home Monitoring option is switched off
9916714|NCT00776113|Active Comparator|2|Carvedilol 12.5 mg tablets
9916715|NCT00776113|Experimental|1|Carvedilol 12.5 mg tablets
9916716|NCT00776126||1|All enrolled subjects will undergo digital breast tomosynthesis.
9916717|NCT00776139|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
9916718|NCT00776139|Experimental|2|Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
9916719|NCT00776165|Experimental|1|Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
9916720|NCT00776165|Active Comparator|2|Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
9916721|NCT00776191|Active Comparator|Physioneal 35 vs. 40|Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.
9995651|NCT01492517|Other|18Ozone|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O). Exposure to 0.3ppm 18O will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
9995652|NCT01492530|Experimental|6-session, small group|Men of African American Legacy Empowering Self (MAALES) Intervention, a six-session, theoretically grounded, small-group intervention held over 3 weeks. Includes an additional 2 booster sessions at 6 and 18 weeks following Session 6.
9995653|NCT01492530|Active Comparator|HIV Education & Risk Reduction Session|20-30 minute standard, client-centered HIV education and risk-reduction session administered over the phone or in person. Similar to that received during pre-test counseling for HIV testing.
9995654|NCT01492543|Experimental|Aiyi®|Tegafur Gimeracil Oteracil Potassium Capsule
9995655|NCT01492556|Experimental|Etoposide|Etoposide Capsules
9995656|NCT01492569|Experimental|Arm I (TAPS at the P6 point)|Patients undergo TAPS at the true acupuncture point (P6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm II for the second course of chemotherapy.
9995657|NCT01492569|Sham Comparator|Arm II (TAPS at a non-P6 point)|Patients undergo TAPS at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm I for the second course of chemotherapy.
9995658|NCT01492608|Active Comparator|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
9995659|NCT01492608|Placebo Comparator|Natriumchlorid|Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).
9995660|NCT01492647|Experimental|JNJ 10229570-AAA 1.2%|
9995661|NCT01492647|Experimental|JNJ 10229570-AAA 3.6%|
9995662|NCT01492660|Experimental|Echogenic needle and catheter|The echogenic needle will be positioned using ultrasonography and neurostimulation with an end point of plantar or dorsiflexion with 0.6mA of current strength. The catheter will be inserted using ultrasonography alone. 20 Ml of 2% mepivacaine will be inserted using the catheter. The distribution of drug will be evaluated using short axis and long axis views. Sensory motor block evaluation every 5 minutes for 30 minutes. Duration of block procedure, number of passes and success will be evaluated
9995663|NCT01492660|Active Comparator|Neurostimulation|The non echogenic needle will be positioned using ultrasonography and neurostimulation with plantar or dorsiflexion as the end point with 0.6mA current.The catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current.
9995664|NCT01492699|Experimental|PRX-03140|PRX-03140 for the treatment of PTSD
9995665|NCT01492712|Experimental|Low-high-low blood target concentration|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
9995666|NCT01492712|Experimental|High-low-high target blood concentration|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
9995667|NCT01492725|Experimental|Intra-arterial Clot Retrieval after iv tPA|
9995668|NCT01492725|Active Comparator|Standard care iv tPA|
9995669|NCT01492738|No Intervention|Control Group|Participants will be asked to make themselves comfortable lying on a massage table for 20 minutes.
9995670|NCT01492738|Active Comparator|Acupuncture group|Acupuncture group will receive one acupuncture treatment for twenty minutes.
9995671|NCT01492751||Spanish Multicentric Clinically Localized Prostate Cancer|A consecutive sample of clinically localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy and prostate brachytherapy in 10 Spanish hospitals.
9995672|NCT01492764||Active Group|This group will receive brief ablation at localized sources (Focal Impulse and Rotor Modulation, FIRM)
9995673|NCT01492764||Control Group|This group receives traditional ablation for this disorder
9995674|NCT01492790|Experimental|Cholecystectomy first|Patients enrolled in this arm will undergo emergency cholecystectomy first without any common bile duct imaging
10214047|NCT01774721|Active Comparator|gefitinib|Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.
10214048|NCT01747447|Placebo Comparator|Vitamin D placebo + fish oil placebo|
10214049|NCT01747447|Active Comparator|Vitamin D placebo + fish oil|
10214050|NCT01747447|Active Comparator|Vitamin D + fish oil placebo|
10214051|NCT01747447|Active Comparator|Vitamin D + fish oil|
10214052|NCT01746836|Experimental|Ponatinib hydrochloride|Patients receive ponatinib hydrochloride PO QD. Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
10214053|NCT01709331|Experimental|Corifollitropin alfa 150 μg + hCG|During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
9916722|NCT00776191|Active Comparator|Physioneal 40 vs. 35|Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks
9916723|NCT00776204|Active Comparator|1|Drug Eluting Stent
9916724|NCT00776204|Active Comparator|2|Drug Eluting Stent
9916725|NCT00776204|Active Comparator|3|Drug Eluting Stent
9916726|NCT00776217|Experimental|1|loratadine 10 mg orally disintegrating tablets
9916727|NCT00776217|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
9916728|NCT00776243||wDM|Early diabetes
9916729|NCT00776243||pDM|Poorly controlled diabetic patients
9916730|NCT00776256|Active Comparator|1|effect of beta-glucan
9916731|NCT00776256|Active Comparator|2|effect of fructo-oligosaccharide
9916732|NCT00776256|Active Comparator|3|effect of beta-glucan and fructooligosaccharide
9916733|NCT00776256|Placebo Comparator|4|no beta-glucan nor fructooligosaccharide
9916734|NCT00776269|Experimental|argon laser|
9916735|NCT00776282|Experimental|1|loratadine 10 mg orally disintegrating tablets
9916736|NCT00776282|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
9916737|NCT00776321|Placebo Comparator|1|
9916738|NCT00776321|Experimental|Eprotirome dose 1|
9916739|NCT00776321|Experimental|Eprotirome dose 2|
9916740|NCT00776334|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
9916741|NCT00776334|Active Comparator|2|Monopril® 40mg tablets
9916742|NCT00776347|Experimental|donepezil|
9916743|NCT00776360|Experimental|oxytocin, gastric emptying|Oxytocin is given to study the gastric emptying rate
9916744|NCT00776360|Placebo Comparator|oxytocin|sodium chloride is given to study gastric emptying rate
9916745|NCT00776399|Experimental|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
9916746|NCT00776425|Experimental|Epoetin Beta 150 IU/kg|Participants with solid and lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 150 IU per kg of body weight thrice weekly.
9916747|NCT00776425|Experimental|Epoetin Beta 30000 IU|Participants with lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 30000 IU once weekly.
9916748|NCT00776438|Experimental|Study Group 1|Adult, age 18 to 40 years
9916749|NCT00776438|Experimental|Study Group 2|Adult, age 18 to 40 years
9916750|NCT00776438|Experimental|Study Group 3|Elderly, age 60 to 85 years
9916751|NCT00776438|Experimental|Study Group 4|Elderly, age 60 to 85 years
9916752|NCT00776451||1|Subjects diagnosed with Dry AMD
9934602|NCT04652973||1/Prostate cancer dataset|Biopsy-proven prostate cancer patients who have abdomen CT studies that were available in the clinical PACS (picture archiving system) in the Clinical Center.
9934603|NCT04652973||2/Multiphase CT dataset|Men or women of all age and race, who have Multiphase abdomen-pelvic CT studies that were available in the PACS.
9934604|NCT04651244||Patients with suspected acute pyelonephritis|Patients admitted in the ED with suspected infection, where the initial medical assessment raises suspicion of APN.
9934605|NCT04650815||1 - 5 Years|Infants and Children up to age 5 years in the Sabou Health District
9934606|NCT04650815||10 - 18 Years|Children ranging in age 10 to 18 years in the Sabou Health District
9934607|NCT04650815||19 + Years|Adults ranging in ages 19 years to 65 years in the Sabou Health District
9934608|NCT04650815||5 - 10 Years|Children ranging in age 5 years through 10 years in the Sabou Health District
9934609|NCT04649710|Experimental|Cohort 1: Dose 1 or placebo|Chinese participants
9934610|NCT04649710|Experimental|Cohort 2: Dose 2 or placebo|Chinese participants
9934611|NCT04649710|Experimental|Cohort 3: Dose 1 or placebo|Korean participants
9934612|NCT04649710|Experimental|Cohort 4: Dose 2 or placebo|Korean participants
9934613|NCT04647708|Experimental|Part A (Cohort 1): M5049 Dose A|
9934614|NCT04647708|Experimental|Part A (Cohort 2): M5049 Dose B|
9934615|NCT04647708|Experimental|Part A (Cohort 3): M5049 Dose C|
9934616|NCT04647708|Experimental|Part A (Cohort 4): M5049 Dose D|
9934617|NCT04647708|Placebo Comparator|Part A: Placebo|
9934618|NCT04647708|Experimental|Part B (Cohort 5): M5049 Dose E|
9934619|NCT04647708|Placebo Comparator|Part B: Placebo|
9934620|NCT04645160|Experimental|1/ Phase I|Tivozanib, P.O. daily at 0.89 mg (given on Days 1-21 of every 28-day cycle) with intra-patient escalation to 1.34 mg daily (given on Days 1-21 of every 28-day cycle) and possible dose de-escalation to 0.89 mg every other day (without interruption for a 28-day cycle) if needed to determine RP2D
9934621|NCT04645160|Experimental|2/ Phase II|Tivozanib at the RP2D established in Phase I
9934622|NCT04645147|Experimental|EBV gp_350 Ferritin Vaccination|Adult participants with or without prior EBV infection will receive 3 doses of vaccine
9934623|NCT04643002|Active Comparator|Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 1)|"Isatuximab dose, intravenous (IV) weekly (QW) × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~Pomalidomide dose os (PO) daily Day 1 to Day 21.~Dexamethasone dose PO QW."
9934624|NCT04643002|Experimental|Experimental: isatuximab + SAR439459 + dexamethasone) (Substudy 2|"Part 1: SAR439459 in combination with isatuximab and dexamethasone. 2 dose levels (DLs) of intravenous (IV) SAR439459:~DL1 SAR439459 dose Q2W.~DL2 SAR439459 dose Q2W.~Isatuximab dose IV every week (QW) × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~Dexamethasone fixed dose and schedule: QW per os (PO). In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).~Part 2:~SAR439459 dose, IV Q2W.~Isatuximab dose, IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).~Dexamethasone fixed dose and schedule: QW PO. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8)."
9916753|NCT00776477|Experimental|1|
9916754|NCT00776477|Active Comparator|2|
9916755|NCT00776490|Experimental|1|Glimepiride 1 MG Tablets of ranbaxy
9916756|NCT00776490|Active Comparator|2|AMARYL® 1 mg tablets
9916757|NCT00776503|Experimental|B|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)
9916758|NCT00776503|Experimental|A|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)
9916759|NCT00776516|Experimental|1|mirabegron alone
9916760|NCT00776516|Experimental|2|mirabegron and rifampin
9916761|NCT00776529|Experimental|A Sensorimotor first|In each of nine sessions: first sensorimotor exercises, then strengthening exercises
9916762|NCT00776529|Experimental|B Sensorimotor & strength alternated|In each of nine sessions: Strength and sensorimotor exercises alternated
9916763|NCT00776542|Experimental|1|Minocycline 100 mg tablets of ranbaxy
9916764|NCT00776542|Active Comparator|2|Minocin 100mg tablets
9916765|NCT00776568|Active Comparator|2|
9916766|NCT00776568|Experimental|1|
9916767|NCT00776581||1|Records regarding combined spinal-epidural analgesia (CSEA) with patient-controlled analgesia (PCA) pump
9916768|NCT00776581||2|Records regarding combined spinal-epidural analgesia with intermittent bolus injection (IBI)
9916769|NCT00776581||3|Records regarding epidural analgesia (EA) with patient-controlled pump
9916770|NCT00776581||4|Records regarding epidural analgesia with intermittent bolus injection
9916771|NCT00776607|Experimental|Insulin|Insulin: NovoMix 30. Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal.
9916772|NCT00776607|Active Comparator|Tablet|Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.
9916773|NCT00776620|Experimental|1|Glimepiride 1 MG Tablets of Ranbaxy
10213277|NCT04327024|Experimental|Allopurinol alone|"Dose [mg] verinurad/allopurinol:~Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose 0/300"
10213278|NCT04327024|Placebo Comparator|Placebo|Placebo [mg] in 3 steps 0/0
9916774|NCT00776620|Active Comparator|2|AMARYL® 1 mg tablets
9916775|NCT00776633|Experimental|Short triple|6 weeks triple therapy
9916776|NCT00776633|Active Comparator|Long triple|6 months triple therapy
9916777|NCT00776646|Experimental|1|hydrochlorothiazide 50 mg tablet
9916778|NCT00776646|Active Comparator|2|hydrochlorothiazide 50 mg tablet
9916779|NCT00776672|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
9916780|NCT00776672|Active Comparator|2|Monopril® 40mg tablets
9916781|NCT00776685|Experimental|learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
9916782|NCT00776685|Experimental|learning to cope with your sensation seeking|cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
9916783|NCT00776685|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
9916784|NCT00776685|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
9916785|NCT00776698|Experimental|1|
9916786|NCT00776724|Active Comparator|1|docetaxel-epirubicin for 4 cycles before surgery
9916787|NCT00776724|Experimental|2|Tailored regimens, base on immunohistochemical study of the tumor biopsy tissue, for 4 cycles before surgery.
9916788|NCT00776750|Experimental|influenza vaccination|All participants received a standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection. The vaccine contained 15 μg hemagglutinin of each of the following influenza strains: A/ New Caledonia/20/99 (H1N1), A/ Panama/2007/99 (H3N2), and B/Shangdong/7/97, recommended by WHO as components of the influenza vaccine for the epidemic season 2003/2004.
9916789|NCT00776763|Experimental|Avastin|
9916790|NCT00776802|Experimental|GCS-10|
9916791|NCT00776828|Active Comparator|TAT|triple antiplatelet therapy : aspirin, clopidogrel and cilostazol
9916792|NCT00776828|Placebo Comparator|DAT|dual antiplatelet therapy : aspirin, clopidogrel
9916793|NCT00776841|Placebo Comparator|Placebo|Placebo control single dose
9916794|NCT00776841|Experimental|Dose 1|Dose 30 mg
9916795|NCT00776841|Experimental|Dose 2|Dose 100 mg
9916796|NCT00776841|Experimental|Dose 3|Dose 300 mg
9916797|NCT00776841|Experimental|Dose 4|Dose 900 mg
9916798|NCT00776841|Experimental|Dose 1 repeated|Dose 30 mg for 4 days
9916799|NCT00776841|Experimental|Dose 2 repeated|Dose high for 4 days
9916800|NCT00776867|Experimental|perifosine|This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
9916801|NCT00776880||1|Patients assessed with ASA physical status scale
9916802|NCT00776880||2|Patients assessed with PPS scale
9916803|NCT00776906|Experimental|1|PTX-coated balloon
9916804|NCT00776906|Active Comparator|2|Bare balloon
9916805|NCT00776932||Knee OA|Those over the age of 50 who have frequent pain in their knee that has lasted for at least six months.
9916806|NCT00776958||Ovarian or Breast Cancer Study Registry|
9916807|NCT00776971|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
9916808|NCT00776971|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
9916809|NCT00776971|Active Comparator|Semi-skimmed milk|202kJ/100mL
9916810|NCT00776971|Placebo Comparator|Water|0kJ/100mL
9916811|NCT00777010|Active Comparator|Healthy high carbohydrate diet|Participants will follow a typical, higher carbohydrate dietary intervention with emphasis on lower glycemic carbohydrate foods and monounsaturated fatty acid consumption
9916812|NCT00777010|Experimental|Carbohydrate restricted, ketogenic diet|Paricipants will follow a carbohydrate restricted dietary intervention designed to induce ketone metabolism
9916813|NCT00777075|Active Comparator|L-arginine|
9916814|NCT00777075|Placebo Comparator|placebo|
9916815|NCT00777114|Experimental|All patients|
9916816|NCT00777140|Active Comparator|1. Deferoxamine|Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
10213279|NCT04325529||remitted MDD|Unmedicated Remitted Participants with Past History of MDD
10213280|NCT04325529||Control subjects|healthy control subjects
10213281|NCT04324840|Experimental|Part A|
10213282|NCT04324840|Experimental|Part B - CC-90010 + Temozolomide (TMZ) + Radiotherapy (RT)|
10213283|NCT04324840|Other|Part B - Standard TMZ + RT|Control
10213284|NCT04322669|Experimental|Pidotimod|
10213285|NCT04322669|Placebo Comparator|Placebo|
10213286|NCT04319718|Active Comparator|High Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)."
10213287|NCT04319718|Active Comparator|Low Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)."
10213288|NCT04307394|Experimental|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
10213289|NCT04305613||Cohort|Patients with locally advanced non-small cell lung cancer
10213290|NCT04304651|Active Comparator|Limited cancer screening|Limited screening alone.
10213291|NCT04304651|Experimental|Limited cancer screening + FDG PET/CT|Limited screening + FDG PET/CT
10213292|NCT04303078|Experimental|Children with Cerebral Palsy (Cases)|Children meeting inclusion/exclusion criteria with a diagnosis of cerebral palsy.
10213293|NCT04303078|Other|Typically Developing Children (Controls)|Children meeting inclusion/exclusion criteria without a diagnosis of cerebral palsy or other condition.
9916817|NCT00777140|Placebo Comparator|2. Placebo|Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)
9916818|NCT00777166|Active Comparator|1|oxytocin 5 units
9916819|NCT00777166|Active Comparator|2|oxytocin, 10 units
9916820|NCT00777192||Symptoms in Colorectal Cancer|Colorectal Cancer Patients Receiving Oxaliplatin Chemotherapy
9916821|NCT00777218|Active Comparator|1|
9916822|NCT00777218|Active Comparator|2|
9916823|NCT00777218|Active Comparator|3|
9916824|NCT00777244|No Intervention|Follow-up|Arm B
9916825|NCT00777244|Experimental|Mitotane|Arm A
9916826|NCT00777270|Experimental|1 continuous|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
9916827|NCT00777270|Experimental|2 interrupted|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
9916828|NCT00777322|Experimental|Interventional study|Patients with known keratoconus or pellucid marginal degeneration will be invited to join the study. The study is partly a continuation in the management of patients who have had previous keratophakia, who will have near-normal or supra-physiological levels of corneal thickness. It is also intended for patients with relatively mild keratoconus who have sufficient corneal thickness to allow a limited laser ablation whilst still leaving a residual stromal bed of at least 350μ.
9916829|NCT00777361|Experimental|AZD3480 iv|Single iv infusion AZD3480
9916830|NCT00777361|Experimental|Oral [14C] AZD3480|Single oral dose [14C]AZD3480
9916831|NCT00777374|Experimental|1|Allergen containing patch
9916832|NCT00777374|Placebo Comparator|2|Placebo patch
9916833|NCT00777387|Active Comparator|1|slow-freeze
9916834|NCT00777387|Active Comparator|2|vitrification
9916835|NCT00777400|Experimental|1|Efalizumab will be started on Day 0 until the end of the study at Week 24. At the end of the first week, after efalizumab is started, cyclosporine or tacrolimus will be decreased by 50% and at 2 weeks the dose of cyclosporine or tacrolimus will be completely discontinued. At 12 weeks Cellcept or myfortic will be discontinued and the patient will be converted to sirolimus for the remainder of the study.
9916836|NCT00777413|Experimental|1|Minocycline 100 mg tablets of Ranbaxy
9916837|NCT00777413|Active Comparator|2|Minocin 100mg tablets
9916838|NCT00777426||Thai HAD individuals (25 cases)|
9916839|NCT00777426||Thai Non-HAD individuals (25 cases)|
9916840|NCT00777426||Thai Non-infected individuals (10 cases)|
9916841|NCT00777439|Other|Domperidone|All eligible subjects will receive domperidone in an open label, single group assignment.
9916842|NCT00777452||1|active surveillance
9916843|NCT00777452||2|radical prostatectomy
9916844|NCT00777452||3|external beam radiotherapy
10213294|NCT04296396|Experimental|Individualized Opioid Prescription|Individualized opioid prescription protocol and shared decision making
10213295|NCT04296396|Other|Fixed Opioid Prescription|fixed opioid prescription of 20 tablets of oxycodone 5mg
10213296|NCT04291521||Adult trauma patients requiring RSI|Patients who received an induction medication for intubation.
10213297|NCT04289961|Other|Single Arm|Observational study of CTC microemboli in portal vein blood samples.
10213298|NCT04287179|Experimental|Semaglutide 0.50 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.50 mg.
10213299|NCT04287179|Active Comparator|Semaglutide 0.25 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.25 mg.
10213300|NCT04281537||Patient with Fabry Disease on ERT (agalsidase alfa)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase alfa)
9916845|NCT00777452||4|high intensity focused ultrasound
9916846|NCT00777465||KDIGO 0|Patients with no acute kidney injury after cardiac surgery
9916847|NCT00777465||KDIGO 1|Patients with acute kidney injury KDIGO stage 1 after cardiac surgery (Increase in SCr by ≥ 0.3 mg/dL (≥ 26.5 lmol/L) or 1.5 to 1.9 times baseline)
9916848|NCT00777465||KDIGO 2|Patients with acute kidney injury KDIGO stage 2 after cardiac surgery (2.0 to 2.9 times baseline SCr)
9916849|NCT00777465||KDIGO 3|Patients with acute kidney injury KDIGO stage 3 after cardiac surgery (3.0 times baseline or more; or increase in SCr to ≥ 4.0 mg/dL; or initiation of renal replacement therapy)
9916850|NCT00777504|Active Comparator|A|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.
9916851|NCT00777504|Active Comparator|B|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.
9916852|NCT00777517|Other|Reference|Commercial 10 mg Lipitor formulation tablet
9916853|NCT00777517|Other|Test|Atorvastatin pediatric formulation
9916854|NCT00777530|Experimental|1|
9916855|NCT00777543|Other|Control|The control is the wholegrain bread enriched with bran that has not been pretreated.
9916856|NCT00777543|Experimental|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
9916857|NCT00777569|Experimental|Extra-low nicotine cigarettes|
9916858|NCT00777569|Experimental|Nicotine-free cigarettes|
9916859|NCT00777569|Active Comparator|Medicinal Nicotine|
9916860|NCT00777595|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
9916861|NCT00777595|Experimental|Treatment B|Single supratherapeutic dose of CHF 4226 pMDI
9916862|NCT00777595|Placebo Comparator|Treatment C|Single dose of placebo
9916863|NCT00777595|Active Comparator|Treatment D|Single dose of moxifloxacin
9916864|NCT00777621|Active Comparator|Calorie restriction|
9916865|NCT00777621|Active Comparator|Exercise|
9916866|NCT00777621|Experimental|Calorie restriction and exercise|
9916867|NCT00777647|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
9916868|NCT00777647|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
9916869|NCT00777647|Active Comparator|Semi-skimmed milk|202kJ/100mL
9916870|NCT00777647|Placebo Comparator|Water|0kJ/100mL
9916871|NCT00777686||MRI/MRS Scanning|Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
9916872|NCT00777699|Experimental|1|
9916873|NCT00777725||1|Chronic stable left sided HF patients
9916874|NCT00777725||2|Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc
9916875|NCT00777725||3|Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis
9916876|NCT00777725||4|Control subjects with no evidence of heart disease.
9916877|NCT00777738|Experimental|bortezomib|bortezomib
9916878|NCT00777777|Experimental|1|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
9916879|NCT00777816|Active Comparator|1|
9916880|NCT00777816|Placebo Comparator|2|
9916881|NCT00777842|Experimental|1|Device
9916882|NCT00777868|Experimental|1|
9916883|NCT00777868|Experimental|2|
9916884|NCT00777868|Experimental|3|
9916885|NCT00777868|Placebo Comparator|4|
9916886|NCT00777894|Experimental|Radiation: 3-dimensional conformal radiation therapy|
9916887|NCT00777907|Active Comparator|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm.
9916888|NCT00777907|Experimental|Pipeline|Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm.
9916889|NCT00777933|Active Comparator|cyclosporine|
9916890|NCT00777933|Experimental|Tacrolimus|
9916891|NCT00777959|Experimental|Open Label|ridaforolimus (MK8669)+ bicalutamide
9916892|NCT00777959|Experimental|Ridaforolimus|ridaforolimus (MK8669)+ bicalutamide
9916893|NCT00777959|Placebo Comparator|Placebo|Placebo + bicalutamide
9916894|NCT00777972|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited
9916895|NCT00777972|Active Comparator|2|Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet
9916896|NCT00777985|Experimental|1|
9916897|NCT00777985|Active Comparator|2|
9916898|NCT00777998|Experimental|A|Auto-Allo Tandem Stem cell Transplantation plus maintenance therapy with Thalidomide and DLI
9916899|NCT00777998|Active Comparator|B|Auto-Auto Tandem stem cell Transplantation plus maintenance therapy with Thalidomide
9916900|NCT00778011|Active Comparator|1|
9916901|NCT00778011|Active Comparator|2|
9916902|NCT00778011|Active Comparator|3|
9916903|NCT00778024|Experimental|1|fluoxetine HCL 40 mg capsules of ranbaxy
9916904|NCT00778024|Active Comparator|2|PROZAC® 40 mg capsules
9916905|NCT00778037|Experimental|1|Cyclobenzaprine hydrochloride 10 mg tablet of ranbaxy
9916906|NCT00778037|Active Comparator|2|Flexeril® 10 mg tablets
9916907|NCT00778050|Experimental|1|amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited
9916908|NCT00778050|Active Comparator|2|Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals (600mg dose)
9916909|NCT00778063|Placebo Comparator|saline|intranasal saline will be given 30 minutes prior to surgery
9916910|NCT00778063|Experimental|dexmedetomidine|2 mcg/kg dexmedetomidine will be given intranasally 30 minutes prior to surgery
9916911|NCT00778076|Active Comparator|HAG|Patients that will receive a Hyaluronic acid treatment course consisting of 3 consecutive injections one week apart.
9916912|NCT00778076|Placebo Comparator|PG|Those patients that receive 3 consecutive placebo injections one week apart.
9995675|NCT01492790|Active Comparator|Sequential common bile duct imaging/cholecystectomy|Patients enrolled in this arm will undergo common bile duct imaging and, if needed, ERCP first followed by emergency cholecystectomy
9995676|NCT01492803|Placebo Comparator|Placebo|Subjects randomized to the placebo arm.
9995677|NCT01492803|Experimental|Probiotics|The probiotics use in the study contains two strains of Lactobacillus plantarum. Each dose of the active study agent contains contains 1 g maltodextrin plus the probiotic bacteria Lp299v (5 x 109 cfu) and Lp299 (5 x 109 cfu).
9995678|NCT01492816|Experimental|Intervention Group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members.
9995679|NCT01492842||Youth with behaviorally-acquired HIV who enrolled in ATN 106|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive, who have enrolled in ATN 106.
9995680|NCT01492855|Experimental|Operative treatment|
9995681|NCT01492855|Experimental|Conservative treatment|
9995682|NCT01492881|Experimental|Vorinostat, Bortezomib, Doxil|"Induction therapy will consist of up to 8 cycles of vorinostat, bortezomib, and doxil. One cycle is defined as 21 days.~Maintenance therapy will consist of Vorinostat and bortezomib. One maintenance cycle is 28 days and repeated for up to 1 year."
9995683|NCT01492894|Active Comparator|50% decrease in calcineurin inhibitor|
9995684|NCT01492894|Active Comparator|Rapamune|
9995685|NCT01492907|Active Comparator|Healthy Control Participants|age/sex matched normal controls - the subject will swallow a capsule with a dietary relevant dose of MeIQx
9995686|NCT01492907|Active Comparator|Pancreatic Cancer Patients|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
9995687|NCT01492920|Experimental|Arm I (acetyl-L-carnitine hydrochloride)|Patients receive ALC PO BID on days 1-21 (during chemotherapy treatment).
9995688|NCT01492920|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-21 (during chemotherapy treatment) (maximum of 8 courses).
9995689|NCT01492946||Elective surgical patients|Elective surgical patients in the Charité University Berlin Campus Charité Mitte
9995690|NCT01492959||Insulin human|
9995691|NCT01492972|Active Comparator|Radiation Alone|Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
9995692|NCT01492972|Experimental|Radiation + Androgen Suppression|Androgen Suppression Therapy x 6 months + Radiation
9995693|NCT01492985|Placebo Comparator|Vaccine placebos|Vaccine placebos corresponding to the dilutant of these vaccines
9995694|NCT01492985|Experimental|Vaccine arm|
9995695|NCT01492998|Experimental|Guggulsterone|One arm of 15 chronically HCV genotype one infected patients
9995696|NCT01493011|Experimental|chemotherapy & WBH|Standard chemotherapy protocol combined with whole body hyperthermia
9995697|NCT01493011|No Intervention|chemotherapy|standard chemotherapy protocol for advanced NSCLC
9995698|NCT01493037|Other|PICSO|PICSO treatment for 90 minutes
9995699|NCT01493050|Experimental|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
9995700|NCT01493050|Active Comparator|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
9995701|NCT01493076||Baby-S group|The baby-sphincterotome was in patients in whom biliary sphincterotomy was clinically indicated but in whom after standard techniques to gain biliary access had failed (study population).
9995702|NCT01493102|Active Comparator|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
9995703|NCT01493102|Active Comparator|Norepinephrine|Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
9995704|NCT01493115|Experimental|Sequence 1|Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2)
9916913|NCT00778089|Other|Open Label Single Arm|All enrolled subjects will have a skin test composed of Bovine Collagen and Lidocaine.
9916914|NCT00778115|Experimental|1|Loperamide HCl 2 mg and simethicone 125 mg tablets of ranbaxy
9916915|NCT00778115|Active Comparator|2|Imodium® Advanced caplets
9916916|NCT00778128|Experimental|1|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8."
9916917|NCT00778128|Experimental|2|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1."
9916918|NCT00778141|Experimental|1|metformin HC1 750 mg extended-release tablets
9916919|NCT00778141|Active Comparator|2|Glucophage® XR 750 mg tablets
9916920|NCT00778154||Alendronate 3 to < 5 years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
9916921|NCT00778154||Risedronate 3 to < 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
9916922|NCT00778154||Alendronate ≥ 5 Years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
9916923|NCT00778154||Risedronate ≥ 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.
9916924|NCT00778180|Experimental|1|furosemide 80 mg tablets of Ranbaxy
9916925|NCT00778180|Active Comparator|2|Lasix® (furosemide) 80 mg tablets
9916926|NCT00778193|Placebo Comparator|Placebo|
9916927|NCT00778193|Active Comparator|Naproxen|
9916928|NCT00778193|Experimental|Aspirin|
9916929|NCT00778193|Experimental|Clopidogrel|
9916930|NCT00778193|Experimental|Celecoxib|
9916931|NCT00778219||A|Patients needing intubation of single lumen tracheal tube and performed using laryngoscope
9916932|NCT00778219||B|Patients needing intubation of single lumen tracheal tube and performed using lightwand
9916933|NCT00778219||C|Patients needing intubation of double lumen endobronchial cath and performed using laryngoscope
9916934|NCT00778232|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
9916935|NCT00778232|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd
9916936|NCT00778245|Experimental|1|cefprozil 500mg tablets of Ranbaxy
9916937|NCT00778245|Active Comparator|2|CEFZIL ® 500 mg tablets of Bristol-Myers Squibb Company, USA
9916938|NCT00778271|Experimental|1|Gabapentin 400mg capsules
9916939|NCT00778271|Active Comparator|2|Neurontin® 400 mg capsules
9916940|NCT00778284|Experimental|1|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
9916941|NCT00778284|Active Comparator|2|Augumentin chewable tablets of Glaxosmithkline
9916942|NCT00778297|Experimental|Group 1|
9916943|NCT00778297|Active Comparator|Group 2|
9934625|NCT04643002|Experimental|experimental: isatuximab + dexamethasone + belantamab mafodotin (Substudy 3)|"Part 1: belantamab mafodotin in combination with isatuximab and dexamethasone. 2 dose levels (DLs) of intravenous (IV) belantamab mafodotin: DL1 belantamab mafodotin dose Q4W.~DL2 belantamab mafodotin dose Q4W.~Isatuximab dose, intravenous (IV) weekly (QW) × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~Dexamethasone fixed dose and schedule: QW PO.~Part 2:~Isatuximab dose, intravenous (IV) weekly (QW) × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).~belantamab mafodotin dose IV Q4W.~Dexamethasone fixed dose and schedule: QW PO."
9934626|NCT04641143|Active Comparator|Troriluzole|Troriluzole - 2 100mg capsules once daily for the first two weeks. Troriluzole - 2 140mg capsules once daily from week two through week ten.
9934627|NCT04641143|Placebo Comparator|Placebo|Placebo - 2 100mg capsules once daily for the first two weeks. Placebo - 2 140mg capsules once daily from week two through week ten.
9934628|NCT04639843|Experimental|1- Experimental Treatment: Dose Escalation|Duvelisib (PO BID) at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of C1 and days 1-14 of all other cycles of each 21- day cycle (max 8 cycles) with CC-486 (5-azacitidine) (PO) at 300mg/day on days 1-10, romidepsin at 12mg/m2 (IV) on Days 1 and 8 of each cycle and doxorubicin (IV) at 25 mg/ m2 on Day 1 of cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy), to determine RP2D of duvelisib and doxorubicin
9934629|NCT04639843|Experimental|2 - Experimental Treatment: Dose Expansion|Duvelisib (PO BID) at RP2D on days -14 to 14 of C1 and days 1-14 of all other 21-day cycle (max 8 cycles) with CC-486 (5-azacitidine) at 300mg/day (PO) on days 1-10, romidepsin at 12mg/m2 (IV) on days 1 and 8 of each cycle, and doxorubicin at 25 mg/m2 on day 1 of Cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy
9934630|NCT04639830||Children with a known risk|Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder.
9934631|NCT04639830||Children with no known risk|Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders.
9934632|NCT04637815|Experimental|Intervention|The intervention will consist of four sessions spaced two weeks apart that will last approximately 30 minutes each and consist of two parts: a network interview to capture network data about the time period since their last interview and a discussion of a resulting network visualization conducted in a motivational interviewing style. Participants will receive the intervention as part of existing case management.
9934633|NCT04637815|Active Comparator|Usual Care|As part of residency, participants receive regular case management meetings.
9934634|NCT04633252|Experimental|1/Dose Escalation|Docetaxel plus M9241 dose escalation with optional prednisone and ADT as part of SOC
9934635|NCT04633252|Experimental|2/Safety Run-in|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
9799057|NCT01648582|Active Comparator|Insulin Glargine|Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.
9916944|NCT00778323|Experimental|A,2, II|
9916945|NCT00778349|Experimental|1|Metformin solution 100 mg/mL under fasting condition
9916946|NCT00778349|Experimental|2|Metformin solution 100 mg/mL, after low fat meal
9916947|NCT00778349|Experimental|3|Metformin solution 100 mg/mL, after high fat meal
9916948|NCT00778362||Splenectomy|all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.
9916949|NCT00778388|Active Comparator|IC43 50|IC43 50 mcg with AI(OH)3
9916950|NCT00778388|Active Comparator|IC43 100 with|IC43 100 mcg with AI(OH)3
9916951|NCT00778388|Active Comparator|IC43 100 w/o|IC43 100 mcg w/o AI(OH)3
9916952|NCT00778388|Active Comparator|IC43 200|IC43 200 mcg with AI(OH)3
9916953|NCT00778388|Placebo Comparator|Placebo|Placebo (0,9% NaCl)
9916954|NCT00778401|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
9916955|NCT00778401|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd.
9916956|NCT00778414|Experimental|1|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension of ranbaxy
9916957|NCT00778414|Active Comparator|2|Augmentin ES - 600
9916958|NCT00778427|Experimental|1|metformin hydrochloride 1000 mg tablets of Ranbaxy
9916959|NCT00778427|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
9916960|NCT00778453|Experimental|Hospital-based mCIT|Hospital-based modified constraint-induced therapy(mCIT)
9916961|NCT00778453|Experimental|Hospital-based BIT|Hospital-based bilateral isokinematic training (BIT)
9916962|NCT00778453|Experimental|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
9916963|NCT00778453|Experimental|Home-based BAT|Home-based bilateral arm training(BAT)
9916964|NCT00778453|Experimental|Home-based TR|Home-based traditional rehabilitation (TR)
9916965|NCT00778453|Experimental|Home-based mCIT|Home-based modified constraint-induced therapy (mCIT)
9916966|NCT00778466|Experimental|1|metformin hydrochloride 1000 mg tablets of ranbaxy
9916967|NCT00778466|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
9916968|NCT00778479|Experimental|Sepraspray|Receive Sepraspray
9916969|NCT00778479|No Intervention|Control|no treatment
9916970|NCT00778492||No Treatment|Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
9916971|NCT00778505|Experimental|1|closed-loop administration of propofol and remifentanil using bispectral index as the controller
9916972|NCT00778505|Active Comparator|2|manual administration of propofol and remifentanil according to bispectral index values
9916973|NCT00778518|Active Comparator|1|low dose
9916974|NCT00778518|Active Comparator|2|Medium dose
9916975|NCT00778518|Active Comparator|3|High Dose
9916976|NCT00778544|Experimental|1|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension of Ranbaxy
9916977|NCT00778544|Active Comparator|2|Augmentin ES-600
9916978|NCT00778557|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL (Ranbaxy Laboratories Limited, India)
9916979|NCT00778557|Active Comparator|2|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
9916980|NCT00778557|Active Comparator|3|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
9916981|NCT00778570||ASA|Participants treated for Excimer laser vision correction using Advanced Surface Ablation (ASA).
9916982|NCT00778570||LASIK|Participants treated for Excimer laser vision correction using Laser-Assisted In Situ Keratomileusis (LASIK)
9916983|NCT00778583|Experimental|1|Nitrofurantoin 100 mg capsules of Ranbaxy
9916984|NCT00778583|Active Comparator|2|Macrobid 100 mg capsules
9916985|NCT00778596|Experimental|Prednisolone priming|Prednisolone priming 4 weeks, then treated with telbivudine.
9916986|NCT00778596|Placebo Comparator|Placebo priming|Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.
9916987|NCT00778609|Experimental|Arm 1|
9916988|NCT00778609|Active Comparator|Arm 2|
9916989|NCT00778661|Experimental|1|amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy
9916990|NCT00778661|Active Comparator|2|Augmentin® tablets of glaxosmithkline
9916991|NCT00778674|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
9916992|NCT00778674|Active Comparator|2|Lotensin® HCT tablets
9916993|NCT00778713|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited
9916994|NCT00778713|Active Comparator|2|Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet)
9916995|NCT00778726|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets of Ranbaxy
9916996|NCT00778726|Active Comparator|2|Lotensin® HCT tablets
9916997|NCT00778739|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
9916998|NCT00778739|Active Comparator|2|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
9916999|NCT00778752|Experimental|A|"Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.~Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21~Dose-level 0: 5 mg/d, day 1-21~Dose-level 1: 10 mg/d, day 1-21~Dose-level 2: 15 mg/d, day 1-21"
9917000|NCT00778765|Experimental|1|400 mg Gabapentin Capsules of Ranbaxy
9917001|NCT00778765|Active Comparator|2|Neurontin® 400 mg Gabapentin Capsules
9917002|NCT00778778|Experimental|1|Cefprozil 500mg tablets of ranbaxy
9917003|NCT00778778|Active Comparator|2|CEFZIL ® 500 mg cefprozil tablets of BMS, USA
9917004|NCT00778778|Active Comparator|3|CEFZIL ® 500 mg tablets, BMS Canada
9917005|NCT00778791|Experimental|1|metformin HC1 750 mg extended-release tablets
9917006|NCT00778791|Experimental|2|Glucophage® XR 750 mg tablets
9917007|NCT00778804|Experimental|telemedicine|Web-based monitoring in addition to usual clincial care with quarterly visits
9917008|NCT00778804|No Intervention|Control|Ususal care with quarterly visits
9917009|NCT00778843|Experimental|Viusid|
9917010|NCT00778843|Placebo Comparator|Placebo|Placebo three oral sachets daily during 24 weeks
9917011|NCT00778856|Experimental|Hand Transplant|
9917012|NCT00778882|Experimental|VM106|
9917013|NCT00778908|Experimental|A|Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy
9917014|NCT00778908|Other|B|Conventionally fractionated IMRT with concomitant cisplatin chemotherapy
9917015|NCT00778934|Experimental|1|Intimate Health Gel
9917016|NCT00778947|Active Comparator|1|
9917017|NCT00778947|Active Comparator|2|
9917018|NCT00778960|Experimental|Slow Breathing Group|
9917019|NCT00778960|Experimental|Meditation Group|
9917020|NCT00778960|Experimental|Meditation and Slow Breathing Group|
9917021|NCT00778960|Placebo Comparator|Sitting Quietly Group|
9917022|NCT00778973|Experimental|1|sertraline 100 mg tablets of Ranbaxy
9917023|NCT00778973|Active Comparator|2|Zoloft® 100 mg tablets
9917024|NCT00778986|Experimental|remote monitoring|group of patients that will be using the heart failure remote patient monitoring system in addition to the usual care they receive at the University Health Network Heart Failure Clinic
9917025|NCT00778986|No Intervention|control|group of patients provided with usual care at the University Health Network Heart Failure Clinic
9917026|NCT00779012|Experimental|Remicade|
9917027|NCT00779051|Experimental|1|Zolipidem 10mg tablets of Ranbaxy
9917028|NCT00779051|Active Comparator|2|Ambien® 10mg tablets
9917029|NCT00779064|Experimental|Arm 1|
9917030|NCT00779064|Experimental|Arm 2|
9917031|NCT00779077||cystic fibrosis|adults and children with cystic fibrosis
9917032|NCT00779090|Experimental|Group A_RM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
9995705|NCT01493115|Experimental|Sequence 2|Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine)
9995706|NCT01493115|Experimental|Sequence 3|Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1)
9995707|NCT01493128||stable sinus rhythm|
9995708|NCT01493128||permanent atrial fibrillation|
9995709|NCT01493128||paroxysmal atrial fibrillation|
9995710|NCT01493141||MOMHR|Patients who have had metal-on metal hip resurfacing (MOMHR)
9995711|NCT01493141||THA|Patients who have had metal-on-polyethylene or ceramic total hip arthroplasty (THA)
9995712|NCT01493154|Experimental|Cohort 1 - DNA Vaccine (Dose 0.5 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 0.5 mg/dose) + Cyclophosphamide (200 mg/m2)
9995713|NCT01493154|Experimental|Cohort 2 - DNA Vaccine (Dose 1.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 1.0 mg/dose) + Cyclophosphamide (200 mg/m2)
9995714|NCT01493154|Experimental|Cohort 3 - DNA Vaccine (Dose 2.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 2.0 mg/dose) + Cyclophosphamide (200 mg/m2)
9995715|NCT01493154|Experimental|Cohort 4 - DNA Vaccine (Dose 4.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 4.0 mg/dose) + Cyclophosphamide (200 mg/m2)
9995716|NCT01493193|Active Comparator|Endurance training with constant work load|
9995717|NCT01493193|Experimental|Pyramid-Training|
9995718|NCT01493193|Experimental|High-intensity interval training|
9995719|NCT01493206|Experimental|intraoperative radiotherapy|
9995720|NCT01493219||Epilepsy|Blood and urine sample collection, pre and post op
9995721|NCT01493219||Glioma|Blood and urine sample collection, pre and post op
9995722|NCT01493232|Experimental|Denture, edentulous patient, treatment|Dentures with different type of occlusion
9995723|NCT01493232|Experimental|Denture, Edentulous patient, treatment|Dentures with different type of occlusion
9995724|NCT01493245|Experimental|JNS020QD|
9995725|NCT01493258|No Intervention|Control Group|The study participants randomized to the Group 2 will serve as a control. At the beginning of the study, they will receive a CERSG brochure printed from the AHRQ site. They will be asked to study it to the best of their ability throughout the day.
9995726|NCT01493258|Experimental|iCOPE Intervention group|iCOPE intervention group will receive a CERSG brochure via the iCOPE system.
9995727|NCT01493297|Other|Retinyl palmitate|Labeled iron as FeSO4 (4 mg) added to a test meal with or without retinyl palmitate (1000 RE)
9995728|NCT01493297|Other|Beta-carotene|Labeled iron as FeSO4 (4 mg) added to a test meal with or without beta-carotene (1000 RE)
9995729|NCT01493310|Experimental|Arm A (hormone therapy, chemotherapy)|Patients will receive mifepristone and nab-paclitaxel in 28-day treatment cycles. Patients receive mifepristone once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Treatment cycles are repeated every 28 days in the absence of disease progression or unacceptable side effects.
9995730|NCT01493310|Active Comparator|Arm B (chemotherapy)|"Patients will receive nab-paclitaxel and placebo for a 28-day treatment cycle (Cycle 1).~Patients receive placebo once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Patients then cross-over to Arm A after completion of the first treatment cycle."
9995731|NCT01493323|Experimental|Control|
9995732|NCT01493323|Experimental|Depressive attempters|
9995733|NCT01493336|Experimental|Capecitabine RTD|
9995734|NCT01493336|Active Comparator|Xeloda|
9995735|NCT01493349||Controls|No diverticular disease or other gastrointestinal and liver diseases
9995736|NCT01493349||Uncomplicated diverticular disease|
9995737|NCT01493349||History of complicated diverticular disease|
9995738|NCT01493349||Current complicated diverticular disease|
9995739|NCT01493362||1|Participants with Bulimia Nervosa
9995740|NCT01493362||2|Participants who are healthy controls
9995741|NCT01493388||A|
9995742|NCT01493401|Experimental|Midurethral sling|Currently available midurethral procedures for stress urinary incontinence can be used.
9995743|NCT01493440|Other|Atosiban|
9995744|NCT01493453|Experimental|Single Arm - aCD19z cells, interleukin 2, Chemotherapy|
9995745|NCT01493466||Normal|normal person under physical examination
9995746|NCT01493466||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
9995747|NCT01493466||spesis|sepsis is defined as SIRS plus confirmed infection.
9995748|NCT01493466||severe sepsis|"severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
9995749|NCT01493466||death|sepsis patients within 48 hours before death
9995750|NCT01493479|Experimental|Fractionated Initial Zevalin|
9995751|NCT01493492||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
9995752|NCT01493492||sepsis|"Sepsis~sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
9995753|NCT01493492||non-survivors with sepsis|sepsis patients who died within 28 days
9995754|NCT01493518|Placebo Comparator|PLACEBO|
9917033|NCT00779090|No Intervention|Group A_NRM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
9917034|NCT00779090|Experimental|Group B_RM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
9917035|NCT00779090|No Intervention|Group B_NRM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
9917036|NCT00779129|Experimental|Single Arm|Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2
9917037|NCT00779181|Experimental|ADX415 (high dose)|A high dose of ADX415
9917038|NCT00779181|Experimental|ADX415 (mid level dose)|A mid level dose of ADX415
9917039|NCT00779181|Experimental|ADX415 (low dose)|A low dose of ADX415
9917040|NCT00779181|Placebo Comparator|Placebo|
9917041|NCT00779194|Experimental|1|SLE subjects receiving the study drug, Rapamune.
9917042|NCT00779194|No Intervention|2|Healthy control group donating blood for the main study.
9917043|NCT00779194|No Intervention|3|SLE subjects donating blood for Genetic sub-study
9917044|NCT00779194|No Intervention|4|Healthy control subjects donating blood for the Genetic sub-study
9917045|NCT00779207|Experimental|1|weight loss
9917046|NCT00779207|Experimental|2|Weight loss and exercise
9917047|NCT00779220|Placebo Comparator|1|
9917048|NCT00779220|Experimental|2|
9917049|NCT00779220|Experimental|3|
9917050|NCT00779220|Experimental|4:|
9917051|NCT00779233|Experimental|1|Zidovudine tablets 300 mg of Ranbaxy
9917052|NCT00779233|Active Comparator|2|RETROVIR ® 300 mg tablets (GlaxoSmithKline)
9917053|NCT00779272||1|Without preoperative chemotherapy
9917054|NCT00779272||2|With preoperative chemotherapy
9917055|NCT00779298||Healthy subjects|Healthy subjects, without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus
9917056|NCT00779337|Experimental|Single group study|Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.
9917057|NCT00779350|Experimental|1|sertraline 100 mg tablets of ranbaxy
9917058|NCT00779350|Active Comparator|2|Zoloft® 100 mg tablets
9917059|NCT00779363|Experimental|Implanted Device|
9917060|NCT00779376|Experimental|1|Zidovudine 300mg tablets of Ranbaxy
9917061|NCT00779376|Active Comparator|2|Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline
9917062|NCT00779389|Experimental|Arm A|Erlotinib 150 mg
9917063|NCT00779389|Experimental|Arm B|Dasatinib + placebo
9917064|NCT00779389|Experimental|Arm C|Erlotinib (150 mg) plus Dasatinib (100 mg) for 14-21 days.
9917065|NCT00779389|Placebo Comparator|Arm D|Placebo for 14-21 days
9917066|NCT00779415||Partial Rotator Cuff Tear|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of shoulder pain and were treated by the Orthopaedic Department
9917067|NCT00779441|Experimental|1|Zolpidem 10mg tablets of ranbaxy
9917068|NCT00779441|Active Comparator|2|AmbienÂ® 10mg tablets
9917069|NCT00779454|Other|KRAS wildtype|
9917070|NCT00779454|Other|KRAS mutation|Inclusion has been completed in the KRAS mutation arm.
9917071|NCT00779480|Experimental|KW-2449|Sequential dose escalation in separate cohorts of 3+3 design from 450 mg/day to 800 mg/day total daily dose.
9917072|NCT00779493|Active Comparator|A|Curcumin 900mg twice daily by mouth
9917073|NCT00779493|Placebo Comparator|B|Placebo capsule to be made by Swanson Vitamins to simulate the capsule.
9917074|NCT00779571|Experimental|Crispbread|Intervention: Crispbread LCD
9917075|NCT00779571|Active Comparator|Liquid meal replacement|Intervention: LMR LCD
9917076|NCT00779597|No Intervention|Care as usual|Care as usual, i.e. standard pain treatment and standard care
9917077|NCT00779597|Experimental|SCION-PAIN program|SCION-PAIN program - Additionally to standard pain treatment, patients from the intervention wards received, the SCION-PAIN program consisting of 3 modules: pharmacologic pain management, non-pharmacologic pain management and discharge management.
9917078|NCT00779610|Experimental|Active|Vibration with forearm flexion (active contraction)
9917079|NCT00779610|Sham Comparator|Passive|Vibration without forearm flexion (passive)
9917080|NCT00779649|Active Comparator|MoviPrep|
9917081|NCT00779649|Active Comparator|HalfLytely|
9917082|NCT00779714|Experimental|A (individualized combined chemotherapy)|
9917083|NCT00779714|Active Comparator|B (DTIC monochemotherapy)|
9917084|NCT00779753|Experimental|Neonates|Sixteen neonates admitted to the Neonatal Intensive Care Unit (NICU) at the Hospital for Sick Children (SickKids) will be required for this study. The diagnoses will include, but are not limited to, the following: Trachea-esophageal fistula and/or esophageal atresia, Congenital diaphragmatic hernia, imperforate anus, Hirschsprung's disease, Malrotation with or without volvulus, Intestinal atresias, Gastroschisis, Omphalocele, Necrotizing enterocolitis, Respiratory distress syndrome.
9917085|NCT00779805|Experimental|1|Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
9917086|NCT00779805|Active Comparator|2|Sudafed 120 mg ER tablets
9917087|NCT00779818|Experimental|Group 1|Treatment by electrical acupuncture
9917088|NCT00779818|Experimental|Group 2|Treatment by laser
9917089|NCT00779831|Experimental|1|120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
9917090|NCT00779831|Active Comparator|2|(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
9917091|NCT00779844|Experimental|1|obese patients
9917092|NCT00779844|Active Comparator|2|lean patients
9917093|NCT00779922|Experimental|group 1 to 5|
9917094|NCT00779935|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
9917095|NCT00779948||Targon FN|
9917096|NCT00779948||DHS|
9917097|NCT00779974||s/p Total Shoulder Arthroplasty|The subject population for this study consists of adult patients with a primary diagnosis of osteoarthritis who have had a total shoulder arthroplasty preformed by the PI between September 2003 through December 2007.
9917098|NCT00779987|Other|Autologous serum -Systane|Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
9917099|NCT00779987|Other|Systane- Autologous serum|Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
9917100|NCT00780013|Experimental|1|metformin hydrochloride (HCI) liquid 500 mg/5 mL of Ranbaxy
9917101|NCT00780013|Active Comparator|2|Glucophage® 1000 mg tablets
9917102|NCT00780039|Experimental|Single Arm|Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.
9917103|NCT00780052|Experimental|1|c-myb AS ODN as a 24-hour continuous infusion over 7 days
9917104|NCT00780078||1|Patients intubated orotracheally for over 6 days
9917105|NCT00780091||1|classical monitoring strategy
9917106|NCT00780091||2|optimized monitoring strategy
9917107|NCT00780104|Experimental|Rapamycin + MEC|
9917108|NCT00780130||Group 1|male & female college students ages 20 to 50, asymptomatic normals
9917109|NCT00780169|Experimental|sorafenib +FOLFIRI|This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.
9917110|NCT00780182|Experimental|1|All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
9917111|NCT00780195|Experimental|1|Single 2 hour hyperinsulinemic euglycemic clamp study at ~90 mg/dl.
9917112|NCT00780195|Experimental|2|Single 2 hour hyperinsulinemic hypoglycemic clamp study at ~70 mg/dl.
9917113|NCT00780195|Experimental|3|Single 2 hour hyperinsulinemic hypoglycemic clamp at ~60 mg/dl.
9917114|NCT00780195|Experimental|4|Single, 2 hour hyperinsulinemic hypoglycemic clamp at ~50 mg/dl.
9917115|NCT00780221||control|patients without coronary artery disease
9917116|NCT00780221||case|patients with coronary artery disease
9917117|NCT00780247||Alaska residents|"50 healthy community dwelling males or females."
9917118|NCT00780247||Hawaiian residents|"50 healthy community dwelling males or females at each site"
9934636|NCT04633252|Experimental|3/mCSPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
9934637|NCT04633252|Experimental|4/mCRPC: Dose Expansion|Docetaxel plus M9241 RP2D with optional prednisone and ADT as part of SOC
9934638|NCT04631042||impulsive compulsive|Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired.
9934639|NCT04630028|Experimental|Induction Period (I): Ustekinumab|All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
9934640|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)|Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
9934641|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)|Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
9934642|NCT04619082|Experimental|TAF prophylaxis|Using TAF to prevent HBV reactivation for HBsAg-positive cancer patients
9934643|NCT04618874|Experimental|ROSE group|Ultrasound-assisted percutaneous needle aspiration with rapid on-site evaluation
9995755|NCT01493518|Experimental|AMG 557|
9917119|NCT00780260|Experimental|1|5 session strengths-based case management intervention delivered by a professional case manager and a peer support specialist team
9917120|NCT00780260|Active Comparator|2|5 session strengths-based case management intervention delivered by a professional case manager.
9917121|NCT00780286|Experimental|1|
9917122|NCT00780286|Active Comparator|2|
9917123|NCT00780299|Active Comparator|2|control
9917124|NCT00780299|Experimental|1|HDHP
9917125|NCT00780312|No Intervention|2|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse before onset of radiotherapy treatment.
9917126|NCT00780312|Experimental|1|physiotherapy
9917127|NCT00780325|Experimental|1|CG100649, single oral dose of 2 mg
9917128|NCT00780325|Experimental|2|CG100649, single oral dose of 8 mg
9917129|NCT00780325|Active Comparator|3|Celecoxib, single oral dose of 200 mg
9917130|NCT00780325|Active Comparator|4|Naproxen, single oral dose of 500 mg
9917131|NCT00780325|Active Comparator|5|Acetazolamide, single oral dose of 250 mg
9917132|NCT00780325|Placebo Comparator|6|Placebo, single oral administration
9917133|NCT00780351||SLEDD-f, vanco|Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
9917134|NCT00780377|Experimental|Bradykinin|Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.
9917135|NCT00780390|Placebo Comparator|CRPS patients without spinal cord stimulation|CRPS patients declining spinal cord stimulation therapy. Autonomic Function will be assessed at baseline and again within 2 years.
9917136|NCT00780390|Experimental|CRPS patients: candidates for spinal cord stimulator|CRPS patients who are candidates for spinal cord stimulator implant. These patients will have Autonomic Function assessments before and after the Standard of Care spinal cord stimulation implant
9917137|NCT00780429||1|MMF+cyclosporine
9917138|NCT00780429||2|MMF+tacrolimus
9917139|NCT00780429||3|MMF+sirolimus
9917140|NCT00780468|Active Comparator|1|Existing diet plan
9917141|NCT00780468|Experimental|2|New diet plan
9917142|NCT00780507||1|Patients are in a state of remission
9917143|NCT00780507||2|Patients are in a flare
9917144|NCT00780520|Experimental|1|
9917145|NCT00780520|Placebo Comparator|2|
9917146|NCT00780585||1|Subjects who participated in previous Org 24448 trials
9917147|NCT00780598|Experimental|Tosedostat|oral, once daily administration of tosedostat to evaluate its efficacy, safety and tolerability
9917148|NCT00780624|Active Comparator|NIPPV|The NIPPV group receiving NIPPV treatment.
9917149|NCT00780624|Active Comparator|Control|The Control group receiving nCPAP treatment.
9934644|NCT04618874|No Intervention|US NAB group|Ultrasound-assisted percutaneous needle aspiration without rapid on-site evaluation
9934645|NCT04618432||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed head and neck or communication disorder.
9995756|NCT01493570|Experimental|BI 409306 low dose|Film-coated tablet
9995757|NCT01493570|Experimental|BI 409306 low dose II|Film-coated tablet
9995758|NCT01493570|Experimental|BI 409306 medium dose|Film-coated tablet
9995759|NCT01493570|Experimental|BI 409306 high dose|Film-coated tablet
9995760|NCT01493570|Experimental|Placebo|Film-coated tablet
9995761|NCT01493583||severely obese women|
9995762|NCT01493583||Women after Roux-en Y gastric bypass surgery|Women recruited for this group had undergone Roux-en Y gastric bypass surgery at least one year before. In this women measurement of brain activity and gastrointestinal and metabolic response took place between 13 and 106 month after surgery.
9995763|NCT01493583||lean women|
9995764|NCT01493609|No Intervention|Waitlist Control|
9995765|NCT01493609|Experimental|Click-East app|Participants will receive a copy of the game immediately following recruitment and assessment.
9995766|NCT01493622|Placebo Comparator|placebo|Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
9995767|NCT01493622|Active Comparator|minocycline|Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
9995768|NCT01493635|Active Comparator|Standard 3 Step approach.|Standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
9995769|NCT01493635|Experimental|2 Step approach.|2 Step approach of the WHO analgesic ladder (Step 1 - Step 3).
9995770|NCT01493648|Experimental|Vitamin D|
9995771|NCT01493648|Placebo Comparator|Placebo|
9995772|NCT01493661||Group 1|Men with Total Sleep Time ≤ 6h that will undergo 25 percent of chronic sleep restriction of their TST
9995773|NCT01493661||Group 2|Men with Total Sleep Time (range 7-8h)that will undergo 25 percent of chronic sleep restriction of their TST
9995774|NCT01493661||Group 3|Men with Total Sleep Time ≥ 9h that will undergo 25 percent of chronic sleep restriction of their TST
9995775|NCT01493674|No Intervention|placebo tablets|two identical tablets, but composed of crystalline cellulose, lactose and colouring
9995776|NCT01493674|Experimental|a suplemented group|two 5-mg tablets of folic acid
9995777|NCT01493700|Experimental|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
9995778|NCT01493700|Active Comparator|electrically heated circuit|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
9995779|NCT01493713|Experimental|Bevacizumab, XELOX|Bevacizumab in combination with XELOX
9995780|NCT01493726|Experimental|ALKS 9072, Low dose|
9995781|NCT01493726|Experimental|ALKS 9072, Med dose|
9995782|NCT01493726|Experimental|ALKS 9072, High dose|
9995783|NCT01493726|Placebo Comparator|Placebo|
9995784|NCT01493739||lymphadenopathy|
9995785|NCT01493752|Active Comparator|Nitrate-rich beetroot juice|Six weeks once daily dose of nitrate rich beetroot juice
9995786|NCT01493752|Placebo Comparator|Nitrate deplete beetroot juice|six weeks daily dose beetroot juice (nitrate deplete)
9995787|NCT01493765||Benchmarking|All resident study subjects will drill virtual temporal bones within the computer based system. The performance data will be used to validate the rating metrics and computer scoring process.
9995788|NCT01493817||Basic science (biomarker analysis)|Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample are then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.
9995789|NCT01493843|Experimental|Arm A: 340 mg pictilisib + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P).
9995790|NCT01493843|Placebo Comparator|Arm B: Placebo + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm A during the first 4 cycles with carboplatin + paclitaxel or after chemotherapy has been completed (Cycle >/= 5).
9995791|NCT01493843|Experimental|Arm C: 340 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
9995792|NCT01493843|Placebo Comparator|Arm D: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm C during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
9995793|NCT01493843|Experimental|Arm E: 260 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
9917150|NCT00780637|Experimental|Bradykinin|Patients receive 0, 10, 20, and 40 ng/min/100cc forearm volume of intrabrachial bradykinin, for 5 minutes at each dose. Forearm blood flow will be measured by strain gauge plethysmography, blood samples will be obtained to measure t-PA, PAI-1 at each dose. FMD and Radial artery tonometry will also be performed under resting conditions.
9917151|NCT00780650|Experimental|1|
9917152|NCT00780650|Placebo Comparator|2|
9917153|NCT00780663|Experimental|Quarfloxin|Single arm study - open label.
9917154|NCT00780702|Experimental|Arm 1|
9917155|NCT00780702|Placebo Comparator|Arm 2|
9917156|NCT00780728|Active Comparator|Sildenafil|
9917157|NCT00780754|Experimental|dutasteride|treatment group
9917158|NCT00780754|Active Comparator|watchful waiting strategy|
9917159|NCT00780767|Experimental|Thrombectomy arm|
9917160|NCT00780780|Active Comparator|1|Triamcinolone intravitreal injection + Nepafenac eye drops
9917161|NCT00780780|Other|2|Triamcinolone intravitreal injection
9917162|NCT00780793|Active Comparator|1-M : Maintenance|Usual care
9917163|NCT00780793|Experimental|2 -S : Spacing of TNF-blocker injections|Spacing of TNF-blocker injections
9917164|NCT00780806|Experimental|1|Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months
9917165|NCT00780819|Experimental|PoleStar N20 intraoperative MRI|PoleStar N20 intraoperative MRI
9917166|NCT00780832|Active Comparator|1|Caffeine reduction through diet and beverage counselling
9917167|NCT00780832|Active Comparator|2|Anticholinergic medication
9917168|NCT00780845||AKI (-)|Patients without acute kidney injury after on-pump CABG
9917169|NCT00780845||AKI (+)|Patients with acute kidney injury after on-pump CABG
9917170|NCT00780858||Ganirelix|Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
9917171|NCT00780858||Control|Patients without premature lutenization (progesterone >1,2 ng/ml) underwent a only one IUI.
9917172|NCT00780884|Experimental|acupuncture needles|Acupuncture needles named acuzone needles. The acuzone needles are sterile and single use, manufactured by DONG BANG MEDICAL CO.,LTD.
9917173|NCT00780897||1|POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
9917174|NCT00780897||2|Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
9917175|NCT00780923|Experimental|CPAP|
9917176|NCT00780949|Experimental|1: Crohn's disease patient|intestinal biopsies
9917177|NCT00781001|Placebo Comparator|1|Placebo cannabis
9917178|NCT00781001|Experimental|2|Active cannabis - 1% THC by weight
9917179|NCT00781001|Experimental|3|Active cannabis - 4% THC by weight
9917180|NCT00781001|Experimental|4|Active cannabis - 7% THC by weight
9917181|NCT00781027|Active Comparator|1|Torsional phacoemulsification
9917182|NCT00781027|Active Comparator|2|Longitudinal phacoemulsification
9917183|NCT00781040||Neutropenic patients|Adult AML and ASCT patients with neutropenic fever.
9917184|NCT00781053|Experimental|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months.
9917185|NCT00781066|Experimental|1|Controlled cord traction (CCT)
9917186|NCT00781066|Active Comparator|2|No CCT
9917187|NCT00781092|Experimental|1|Systane Ultra
9917188|NCT00781092|Active Comparator|2|Bausch and Lomb Sensitive Eyes
9917189|NCT00781105|Experimental|1|
9917190|NCT00781131|Placebo Comparator|1|
9917191|NCT00781131|Experimental|2|Pregabalin 75 mg
9917192|NCT00781131|Experimental|3|Pregabalin 150 mg
9917193|NCT00781144||1|first year osteopathic students
9917194|NCT00781144||2|fourth and fifth year osteopathic students
9917195|NCT00781144||3|experienced osteopathic clinicians
9917196|NCT00781157|Experimental|1|
9917197|NCT00781183|Experimental|pulmonary rehabilitation|patients that are enrolled in pulmonary rehabilitation
9917198|NCT00781196|Experimental|1|Oral folic acid
9917199|NCT00781196|Placebo Comparator|2|placebo
9917200|NCT00781209|Experimental|Exp|Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI & Mini Mental Status Examination
9917201|NCT00781248|Experimental|1|starting with active NG Shield
9917202|NCT00781248|Experimental|2|Starting with inactive NG Shield
9917203|NCT00781261|Placebo Comparator|Control|Subjects in the control group will receive a placebo drug for a 1 year period
9917204|NCT00781261|Active Comparator|Zoledronic Acid|Subjects in this intervention group will be given 5mg Zoledronic acid as a single injection
9917205|NCT00781287|Experimental|Raltegravir + 3-drug anti-HIV therapy|
9917206|NCT00781287|Active Comparator|3-drug anti-HIV therapy|
9917207|NCT00781300|Active Comparator|Loteprednol|
9917208|NCT00781300|Active Comparator|Dexamethasone|
9917209|NCT00781352|Active Comparator|group 1|Colorectal surgery with 65% nitrous oxide administration
9917210|NCT00781352|Active Comparator|group 2|Colorectal surgery with nitrogen administration
9917211|NCT00781378|Active Comparator|Group 1|rt-PA 100 mg continuous intravenous infusion for 2 hours
9917212|NCT00781378|Experimental|group 2|rt-PA 50 mg continuous intravenous infusion for 2 hours
9917213|NCT00781417|Active Comparator|1|Cholecalciferol 50,000 IU once a week for 12 weeks then every other week for 40 weeks
9917214|NCT00781417|Placebo Comparator|Placebo|Placebo
9917215|NCT00781430|Experimental|1|
9917216|NCT00781469||Naive patients|12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
9917217|NCT00781469||Patients in remission|6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
9917218|NCT00781469||Patients still have active disease|12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2
9917219|NCT00781482|Experimental|1|This is a crossover study. Each study drug will be administered (one at a time and in random order) to each subject on separate occasions over the course of the study.
9917220|NCT00781495||type 2 diabetes mellitus|
9917221|NCT00781521|Experimental|1|Floxin otic solution twice a day for 7 days
9917222|NCT00781534|Active Comparator|1. Ginseng|Ginseng group
9917223|NCT00781534|Active Comparator|2. Ginsenosdie RE|Ginsenoside RE (a metabolite of ginseng) group
9917224|NCT00781534|Placebo Comparator|3. Placebo|"placebo (sugar pill) group"
9917225|NCT00781547|Experimental|Recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
9917226|NCT00781547|Placebo Comparator|Placebo|
9917227|NCT00781560||1|patients being diagnosed as dyslipidemia but not receiving Crestor®
9917228|NCT00781560||2|hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
9917229|NCT00781573|Experimental|1|Clopidogrel (75 mg/day) is continued for another year at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
9917230|NCT00781573|No Intervention|2|Clopidogrel (75 mg/day) is stopped at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
9917231|NCT00781586|Experimental|Arm 1|
9917232|NCT00781586|Active Comparator|Arm 2|
9917233|NCT00781586|Placebo Comparator|Arm 3|
9917234|NCT00781625|Active Comparator|Probiotic vaginal capsules|Probiotic vaginal capsule, placebo oral capsule
9917235|NCT00781625|Placebo Comparator|placebo|placebo oral capsule, placebo vaginal capsule
9917236|NCT00781625|Active Comparator|Probiotic oral capsules|Probiotic oral capsules, placebo vaginal capsules
9917237|NCT00781664|Experimental|A|AN2718 Cream SF Vehicle
9917238|NCT00781664|Experimental|B|AN2718 Cream SF, 0.3%
9917239|NCT00781664|Experimental|C|AN2718 Cream SF, 1%
9917240|NCT00781664|Experimental|D|AN2718 Gel Vehicle
9917241|NCT00781664|Experimental|E|AN2718 Gel, 1.5%
9917242|NCT00781664|Experimental|F|AN2718 Gel, 2.5%
9917243|NCT00781664|Experimental|G|AN2718 Gel, 5%
9917244|NCT00781664|Experimental|H|AN2718 Gel, 7.5%
9917245|NCT00781664|Active Comparator|I|Sodium Lauryl Sulfate, 0.5%
9917246|NCT00781677||MDD|
9917247|NCT00781690|Experimental|1|Treatment with Evodial with reduction of heparin across study period
9917248|NCT00781703|Other|DIAMOND Care Model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.
9917249|NCT00781716|Active Comparator|Cypher Stent|Cypher Sirolimus-Eluting Coronary Stent System
9917250|NCT00781716|Active Comparator|Endeavor Stent|Endeavor Zotarolimus-Eluting Coronary Stent System
9917251|NCT00781729|Experimental|1|Yoga, one hour class, 3 times per week, for 24 weeks
9917252|NCT00781729|Placebo Comparator|2|Luncheon Seminar Series, once per month, for 24 weeks
9917253|NCT00781755|Experimental|1|VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
9917254|NCT00781755|Placebo Comparator|2|PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
9917255|NCT00781781|Experimental|1|"High risk patients (at least one GVHD high risk criterion):~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive)."
9917256|NCT00781781|Experimental|2|"Low Risk patients (no GVHD high risk criterion):~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive)."
9917257|NCT00781794|Experimental|1|Dose 1
9917258|NCT00781794|Experimental|2|Dose 2
9917259|NCT00781794|Placebo Comparator|3|
9917260|NCT00781807|Experimental|1|The prospective intervention group with nutrition management, home-based bicycle ergometer training program and psychosocial support
9917261|NCT00781820|Placebo Comparator|Arm 2|
9917262|NCT00781820|Experimental|Arm 1|
9917263|NCT00781833|Experimental|Treatment|Intramuscular Electrical Stimulation
9917264|NCT00781846|Experimental|1|30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
9917265|NCT00781846|Experimental|2|40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
9917266|NCT00781846|Experimental|3|40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks
10213301|NCT04281537||Patient with Fabry Disease on ERT (agalsidase beta)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase beta)
10213302|NCT04281537||Caregiver|Caregiver of patient with Fabry Disease on ERT
10213303|NCT04280744|Experimental|Music therapy|Music listening intervention provided by a board certified music therapist.
10213304|NCT04280315||Cases|"Cases are patients with type 1 diabetes in three age strata:~20 participants in the age of 2-10 years~20 participants in the age of 11-20 years~10 participants with more than 30 years of diabetes duration"
10213305|NCT04280315||Controls|Controls are age and sexmatched with the cases and are recruited from the neuropediatric clinic at Herlev Hospital as well as relatives and parents of patients in the whole Pediatric Department
10213306|NCT04261894|Experimental|OPTIMIZE|This arm includes implementation of the OPTIMIZE perinatal care checklist with patient navigation support.
10213307|NCT04261894|No Intervention|Standard Care|This arm includes provision of standard perinatal care.
9917267|NCT00781872|Experimental|Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously|Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments
9917268|NCT00781924||biopsy|
9917269|NCT00781976|Placebo Comparator|1|
9917270|NCT00781976|Active Comparator|2|
9917271|NCT00781989||Rheumatoid Arthritis patients|Patients with seropositive Rheumatoid Arthritis with symptom onset of less than three years
9917272|NCT00782002|Experimental|IMC-18F1|
9917273|NCT00782015|Active Comparator|almonds|3 oz/d almonds
9917274|NCT00782015|Placebo Comparator|Placebo|NCEP Step 2 diet
9917275|NCT00782028|No Intervention|Standard Care|No intervention consists of routine well child care
9917276|NCT00782028|Other|Centering parenting/Group well child care|
9917277|NCT00782041|Experimental|1|Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
9917278|NCT00782054|Active Comparator|Active|moisturizer with endopeptidases
9917279|NCT00782054|Placebo Comparator|Placebo|moisturizer without endopeptidases
9917280|NCT00782080|Experimental|Sedariston|Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.
9917281|NCT00782080|Placebo Comparator|Placebo campsule|Placebo provided by the company given orally in capsules (size 1 )twice daily
9934646|NCT04610866|Experimental|1|Subjects will be treated with a maintenance dose of mitapivat previously assessed for safety and tolerability in the Phase I study for an initial 48 weeks and undergo safety monitoring, evaluation of pharmacokinetics and pharmacodynamics, and assessment of secondary laboratory and clinical endpoints at pre-specified intervals during the study period.
9934647|NCT04609085||Participants with Rare Diseases|Participants with history of rare disease
9934648|NCT04609072||Healthy volunteers|Up to 200,000 men and women aged 40 to 65 years, with no personal history of cancer, and patients or members of participating integrated health care systems.
9934649|NCT04602221|Experimental|Treatment sequence: T1-T2-R|"Treatments:~T1: Lamotrigine T2: BI 409306 T3: BI 425809 R: Placebo"
9934650|NCT04602221|Experimental|Treatment sequence: T1-R-T2|
9934651|NCT04602221|Experimental|Treatment sequence: T1-T3-R|
9934652|NCT04602221|Experimental|Treatment sequence: T1-R-T3|
9934653|NCT04602221|Experimental|Treatment sequence: T2-T1-R|
9934654|NCT04602221|Experimental|Treatment sequence: T2-R-T1|
9934655|NCT04602221|Experimental|Treatment sequence: T2-T3-R|
9934656|NCT04602221|Experimental|Treatment sequence: T2-R-T3|
9934657|NCT04602221|Experimental|Treatment sequence: T3-R-T1|
9934658|NCT04602221|Experimental|Treatment sequence: T3-T1-R|
9934659|NCT04602221|Experimental|Treatment sequence: T3-T2-R|
9934660|NCT04602221|Experimental|Treatment sequence: T3-R-T2|
9934661|NCT04602221|Experimental|Treatment sequence: R-T1-T2|
9934662|NCT04602221|Experimental|Treatment sequence: R-T2-T1|
9934663|NCT04602221|Experimental|Treatment sequence: R-T1-T3|
9934664|NCT04602221|Experimental|Treatment sequence: R-T3-T1|
9934665|NCT04602221|Experimental|Treatment sequence: R-T2-T3|
9934666|NCT04602221|Experimental|Treatment sequence: R-T3-T2|
9934667|NCT04599855|Experimental|Esketamine 56 Milligram (mg)|Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale [MADRS] assessment).
9934668|NCT04599855|Experimental|Esketamine 84 mg|Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
9934669|NCT04599855|Experimental|Placebo|Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
9934670|NCT04599634|Experimental|Experimental treatment: FL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-days each, Cycles -2 and -1), then venetoclax will be added at target dose (dose determined from Arm 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax will be 6 cycles (28-days each, Cycles 1-6); further treatment will be response-adapted.
9934671|NCT04599634|Experimental|Experimental treatment: FL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax 800mg PO combination administered to 6 patients for six (6) cycles (28-days each, Cycles 1-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 600mg with magrolimab and obinutuzumab.
9935786|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 2 weeks (Q2W) on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
9917282|NCT00782106|Experimental|1|Tolerability of subcutaneous infusions
9917283|NCT00782106|Experimental|2|Tolerability of subcutaneous infusions and pharmacokinetics
9917284|NCT00782145|Experimental|Arm I|"Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.~The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant."
9917285|NCT00782145|Active Comparator|Arm II|Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
9917286|NCT00782197|Experimental|1|PRGF
9917287|NCT00782197|Active Comparator|2|Hyaluronic Acid
9917288|NCT00782223||1|Hip X-rays DDH
9917289|NCT00782223||2|Hip X-rays, CP
9917290|NCT00782223||3|Long standing lower Limb X-rays
9917291|NCT00782223||4|Scoliosis, AP X-rays
9917292|NCT00782223||5|Scoliosis Lateral X-rays
9917293|NCT00782236|Active Comparator|Straumann BoneCeramic|In the test group, the subjects will receive the Bone Graft Material Straumann BoneCeramic in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
9917294|NCT00782236|Active Comparator|Freeze Dried Allograft Bone|In the control group, the subjects will receive Bone Graft Material Freeze Dried Allograft Bone in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
9917295|NCT00782249|Experimental|1|Vagus nerve stimulation paradigm #1
9917296|NCT00782249|Experimental|2|Vagus nerve stimulation paradigm #2
9917297|NCT00782249|Experimental|3|Vagus nerve stimulation paradigm #3
9917298|NCT00782262|Other|Group 1 (n=20)|BP < 140/90, no diabetes mellitus and fasting glucose < 5.5
9917299|NCT00782262|Other|Group 2 (n=20)|BP > 140/100, no diabetes mellitus and fasting glucose < 5.5
9917300|NCT00782262|Other|Group 3 (n=20)|BP <140/100, no diabetes mellitus, fasting glucose 5.5 - 6.9
9917301|NCT00782301|Active Comparator|Maraviroc|
9917302|NCT00782301|Active Comparator|Etravirine|
9917303|NCT00782314||1|patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month
9917304|NCT00782314||2|patients with SMART treatment with Symbicort Turbuhaler for at least 1 month
9917305|NCT00782327|Experimental|1|Losartan
9917306|NCT00782327|Placebo Comparator|2|Placebo
9917307|NCT00782353|Experimental|Cohort 1|Subjects randomized 8:2 (active:placebo) to receive ANA598 200 mg bid
9917308|NCT00782353|Experimental|Cohort 2|Subjects randomized 8:2 (active:placebo) to receive ANA598 400 mg bid
9917309|NCT00782353|Experimental|Cohort 3|Subjects randomized 8:2 (active:placebo) to receive ANA598 800 mg bid
9917310|NCT00782366||Genetic Testing Group|Those who will receive predictive genetic risk assessments
9917311|NCT00782366||Control|Those who will receive standard of care
9917312|NCT00782405|Experimental|1|quetiapine
9917313|NCT00782405|Active Comparator|2|mirtazapine
9917314|NCT00782457|Active Comparator|OPEN SURGERY|
9917315|NCT00782457|Experimental|LAPAROSCOPIC SURGERY|
9917316|NCT00782470||Group 1|
9917317|NCT00782470||Group 2|
9917318|NCT00782470||Group 3|
9917319|NCT00782522|Experimental|1|Eccentric training program
9917320|NCT00782522|Active Comparator|2|Traditional training program
9917321|NCT00782548|Active Comparator|1|Test product A (1 x 30 mg KADIAN)
9917322|NCT00782548|Active Comparator|2|Reference product B (1 x 30 mg Avinza)
9917323|NCT00782561|Experimental|FG-3019|FG-3019 5 mg/kg
9917324|NCT00782587|Experimental|Arm 1|Single arm, open label, single dose, intravesical instillation of Chemophase (combination of rHuPH20 and mitomycin) for appropriate superficial bladder cancer patients within 6 hours of TURBT.
9917325|NCT00782600|Experimental|50 mg oral suspension|once daily for one day
9917326|NCT00782600|Experimental|50 mg CR Type 1|once daily for one day
9917327|NCT00782600|Experimental|50 mg CR Type 2|once daily for one day
9917328|NCT00782600|Experimental|50 mg SR Type 3|once daily for one day
9917329|NCT00782613|Active Comparator|1|Two psoriatic plaques of similar surface area and severity will be identified for each subject. ALT-2074 will be applied topically twice daily to 1 of the 2 target plaques, and the placebo control to the other plaque for a period of 28 days in amounts sufficient to cover the entire surface area of the target plaque, extending to 1 cm outside of the plaque border.
9917330|NCT00782613|Placebo Comparator|2|Placebo
9917331|NCT00782652|Active Comparator|1|inhaled nitric oxide at 40 or 80ppm
9917332|NCT00782652|Placebo Comparator|2|inhaled nitrogen at either 40 or 80ppm
9917333|NCT00782665|Active Comparator|Group 1|Patients who have labored and subsequently delivered by cesarean section
9917334|NCT00782665|Placebo Comparator|2|Patients who electively select cesarean section
9917335|NCT00782691||Head-and-neck cancer patients.|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
9917336|NCT00782704||1|questionnair for Patients
9917337|NCT00782704||2|questionnaire for Nurses
9917338|NCT00782704||3|questionnaire for Physicians
9917339|NCT00782730||Bladder Scan Group|Patients who agree to enroll in the trial and allow their known bladder volumes and residual bladder volumes to be measured by actual volumes retrograde instilled, and also by bladder scanner ultrasound.
9917340|NCT00782743||1|patients with required new anticoagulation with phenprocoumon 1/2 of them with a GFR< 60 ml/min and >15 ml/min
9917341|NCT00782743||2|patients with required therapy with ASS, 1/2 of them with a GFR <60 ml/min and >15 ml/min
9917342|NCT00782808||1 HIV DNA will be stratified by high|
9917343|NCT00782808||2 HIV DNA will be stratified by low|
9917344|NCT00782847|Active Comparator|with DiaNe program|study subjects which participated in the DiaNe consultation and support program
9917345|NCT00782847|No Intervention|without DiaNe program|study subjects which received standard care by diabetologist and/or nephrologist
9917346|NCT00782860||unsuccessful termination|unsuccessful termination of early pregnancy failure with Misoprostol
9917347|NCT00782860||successful termination|successful termination of early pregnancy failure with Misoprostol
9917348|NCT00782873||obese subjects|BMI > 35
9917349|NCT00782899||1|Schizophrenic patients with a acute episode treated in outpatients clinics
9917350|NCT00782925|Experimental|1|"Study intervention:~A face/profile X-ray of their entire spine at baseline~Educational program~Exercise program~Self-led exercises~A follow-up at 12 and 24 months with their occupational therapist.~A follow-up at 18 months with a physical therapist.~Workers received also at the end of the educational program written standardized information about back pain (the back book, an information booklet) 1.~Coudeyre E., Tubach F., Rannou F. & all, Effect of simple information booklet on pain persistance after an acute episode of low back pain: a non- randomised trial in a primary care setting. PLoS ONE. 2007 ; 2 : e706"
9917351|NCT00782925|No Intervention|2|"Control intervention :~No intervention~A face/profile X-ray of their entire spine at baseline~A follow-up at 12 and 24 months with their occupational therapist,~A follow-up at 18 months with a physical therapist."
9917352|NCT00782938||low SAA|
9917353|NCT00782938||high SAA|
9917354|NCT00782951|Experimental|Org 28611|
9917355|NCT00782951|Active Comparator|morphine sulfate|
9917356|NCT00782951|Placebo Comparator|Placebo|
9917357|NCT00782964||1|Outpatient with major depressive disorder, who has a change in pharmacological therapeutical plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent) for at least 6 weeks.
9917358|NCT00782977|Sham Comparator|1|Nasal cannulae with no oxygen flow
9917359|NCT00782977|Active Comparator|2|Nasal cannulae with oxygen flow at 5 L/minute
9917360|NCT00782977|Active Comparator|3|Nasal cannulae with oxygen flow at 10 L/minute
9917361|NCT00782990|Active Comparator|tvt group|Surgical treatment for incontinence: TVT
9917362|NCT00782990|Active Comparator|Burch group|Surgical treatment for incontinence: Colposuspension
9917363|NCT00783003|Experimental|Long acting muscarinic receptor antagonist (LAMA)|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
9917364|NCT00783003|Experimental|Long acting Beta 2 agonist (LABA)|Inhaled Long Acting Beta 2 agonist (LABA) which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
9917365|NCT00783003|Experimental|LAMA with LABA|Inhaled Long Acting Muscarinic receptor Antagonist (LAMA) and a inhaled Long Acting Beta 2 Agonist (LABA), both in development for treatment of Chronic Obstructive Pulmonary Disease and taken in combination.
9917366|NCT00783003|Placebo Comparator|Placebo|Matching placebo, no intervention.
9917367|NCT00783016|Experimental|Morphine|
9917368|NCT00783016|No Intervention|Placebo|
9917369|NCT00783029||Healthy Subjects|Healthy participants between the ages of 21 and 65 years old.
9917370|NCT00783042|Active Comparator|1|
9917371|NCT00783042|Placebo Comparator|2|
9917372|NCT00783055|Experimental|Treatment|12 weeks of individually tailored intervention programmes based on participants individual wishes for daily activities e.g.ADL, mobility, social, mental or creative that they want to improve, conserve - and/or to revive.
9917373|NCT00783068|Active Comparator|GTS-21|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0).
9917374|NCT00783068|Placebo Comparator|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
9917375|NCT00783081|Experimental|low dose K-134|
9917376|NCT00783081|Experimental|mid dose K-134|
9917377|NCT00783081|Experimental|high dose K-134|
9917378|NCT00783081|Active Comparator|Comparator|
9917379|NCT00783081|Placebo Comparator|Placebo|
9917380|NCT00783107|Experimental|Cyclosporine|
9917381|NCT00783107|Placebo Comparator|Placebo|Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
9917382|NCT00783120|Experimental|1|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold).
9917383|NCT00783120|Sham Comparator|2|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session)
9917384|NCT00783159|Experimental|A|Training I
9995794|NCT01493843|Placebo Comparator|Arm F: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm E during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
9998068|NCT01514656|Active Comparator|Prompting to practice skills|Individuals will be prompted every two months and encouraged to practice the skills that they learned. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
9998069|NCT01514656|Active Comparator|No prompting to practice skills|Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
9998070|NCT01514695|Experimental|Fentanyl|Fentanyl arm
9998071|NCT01514695|Placebo Comparator|Placebo|Placebo of identical appearance
9998072|NCT01514708|Experimental|AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose|
9998073|NCT01514721|Experimental|DuoTrav|Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks
9998074|NCT01514747||ELBW infants|
9998075|NCT01514773||ICD placement|Those subjects who have an ICD.
9998076|NCT01514773||No ICD placement|Those subjects who have not had an ICD placed.
9998077|NCT01514799|Active Comparator|standard length bp limb, long alimentary limb|our normal way of doing a gastric bypass 60 cm BP limb
9998078|NCT01514799|Experimental|Long BP limb|200 cm BP limb
9998079|NCT01514812|Experimental|YM150-placebo sequence group|YM150+digoxin; Washout; Placebo+digoxin
9998080|NCT01514812|Experimental|placebo-YM150 sequence group|Placebo+digoxin; Washout; YM150+digoxin
9998081|NCT01514825|Experimental|YM150 low dose group|
9998082|NCT01514825|Experimental|YM150 middle dose group|
9998083|NCT01514825|Experimental|YM150 high dose group|
9998084|NCT01514825|Placebo Comparator|placebo group|
9998085|NCT01514838|Experimental|1941 group|Once daily over a 24-week treatment period
9998086|NCT01514838|Active Comparator|acarbose group|Once daily over a 24-week treatment period
9998087|NCT01514851|Experimental|Arm 1|750-2250mg/day, tid (three times a day), 8 weeks
9998088|NCT01514851|Active Comparator|Arm 2|1500-4500mg/day, tid, 8 weeks
9917385|NCT00783159|Experimental|B|Training II
9917386|NCT00783159|Active Comparator|C|Control
9917387|NCT00783172|Experimental|OGF & Gemcitabine|Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.
9917388|NCT00783185|Experimental|ACT|Anti-Cannabis-Consumption-Training
9917389|NCT00783185|Active Comparator|CG|Control group
9917390|NCT00783250|Experimental|Salbutamol+Tiotropium|Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms
9917391|NCT00783250|Placebo Comparator|placebo + Tiotropium|Placebo using MDI + administration of Tiotropium after 20 minutes
9917392|NCT00783276|Placebo Comparator|Sugar Pill|Placebo
9917393|NCT00783276|Active Comparator|SYN115|
9917394|NCT00783315|Active Comparator|1|Self-Directed Weight Loss Program (Control Group)
9917395|NCT00783315|Experimental|2|Call-Center Directed (CCD) Weight Loss Program
9917396|NCT00783315|Experimental|3|In-Person Directed (IPD) Weight Loss Program
9917397|NCT00783328|Experimental|1|Open label single arm trial
9917398|NCT00783341|Experimental|GAP-134|
9917399|NCT00783341|Placebo Comparator|placebo|
9917400|NCT00783380|Experimental|Virosomal influenza vaccine|
9917401|NCT00783380|Active Comparator|Subunit influenza vaccine|
9917402|NCT00783393|Experimental|Single arm|"The study consists of two steps:~Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and~Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1."
9917403|NCT00783445|Experimental|1|Exercise in a community setting while supervised by a coach
9917404|NCT00783445|Active Comparator|2|Self-exercise plan based on an individualized prescription after an initial fitness evaluation
9917405|NCT00783471|Experimental|1|Erlotinib followed by Docetaxel
9917406|NCT00783471|Experimental|2|Docetaxel followed by Erlotinib
9917407|NCT00783484|Experimental|Cohort 1|PF-03716539 crossover, single dose escalation (doses subject to change).
9917408|NCT00783484|Experimental|Cohort 2|PF-03716539 crossover, single dose escalation (doses subject to change).
9917409|NCT00783484|Experimental|Cohort 3|Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
9917410|NCT00783484|Experimental|Cohort 4|Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
9917411|NCT00783484|Experimental|Cohort 5|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
9917412|NCT00783484|Experimental|Cohort 6|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).
9917413|NCT00783497||1|Caucasian Americans
9917414|NCT00783497||2|African Americans
9917415|NCT00783510||HUMIRA® Treatment Arm|For patients taking HUMIRA®
9917416|NCT00783510||Methotrexate Treatment Arm|For patients taking Methotrexate
9917417|NCT00783523|Active Comparator|Doxycycline|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
9917418|NCT00783523|Placebo Comparator|Placebo|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
9917419|NCT00783536|Experimental|1|"Clinical and demographic information~Clinical and Laboratory information"
9917420|NCT00783536|Active Comparator|2|"Clinical and demographic information~Clinical and Laboratory information"
9917421|NCT00783549|Experimental|Cohort 1|6 active 2 placebo
9917422|NCT00783549|Experimental|Cohort 2|9 active 3 placebo
9917423|NCT00783549|Experimental|Cohort 3|Optional cohort
9917424|NCT00783549|Experimental|Cohort 4|12 active
9917425|NCT00783549|Experimental|Cohort 5|12 active
9917426|NCT00783562|Experimental|1|
9917427|NCT00783562|Active Comparator|2|
9917428|NCT00783575||Inflammatory Bowel Disease|Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD) are chronic, life-long, destructive inflammatory conditions of the gastrointestinal tract.
9917429|NCT00783601|Experimental|1|Treatment Sequence 1: MK0524 + placebo, MK0524 + montelukast, placebo, placebo, placebo + montelukast
9917430|NCT00783601|Experimental|2|Treatment sequence 2: Placebo, montelukast, placebo, MK0524, MK0524 + montelukast
9917431|NCT00783627||1|Patient with sickle cell disease
9917432|NCT00783627||2|Healthy volunteers
9917433|NCT00783640|Experimental|1|Lactic Acid
9917434|NCT00783666|Experimental|1|Lactic Acid
9917435|NCT00783679|Other|1|Twenty adult spontaneously breathing patients without intubation and mechanical ventilation recruited from the cardiac catheterization laboratory. All will be post-heart-transplant patients coming for yearly evaluation.
9917436|NCT00783731|Experimental|Low dose midazolam|
9917437|NCT00783744|Experimental|1|Insulin Glargine + Glimepiride + Metformin
9917438|NCT00783744|Active Comparator|2|Insulin monotherapy with premixed insulin NPH 30/70
9917439|NCT00783757|Experimental|Optical Imaging|Tomographic Optical Imaging Arm
9917440|NCT00783770||30-33 weeks|mother infant pairs with gestation of 30-33 weeks
9917441|NCT00783770||34-37 weeks|mother infant pairs with gestation of 34-37 weeks
9917442|NCT00783770||38-42 weeks|mother infant pairs with gestation of 38-42 weeks
9917443|NCT00783783||Poor metabolizers|Patients with CYP2D6 genotypes predictive of poor metabolizer phenotype
9917444|NCT00783783||Non poor metabolizers|Patients with CYP2D6 genotypes predictive of intermediate, extensive, or ultra-rapid metabolizer phenotypes
9917445|NCT00783822|Other|intervention|rapid genetic counseling and testing
9917446|NCT00783822|No Intervention|control|usual care
9917447|NCT00783861|Experimental|1|Lactic Acid (Dermacyd Femina)
9917448|NCT00783887||1|Patients with suspected or confirmed primary ciliary dyskinesia after ciliary investigations who accepted to participate to the genetic studies
9917449|NCT00783900|Active Comparator|metoprolol|
9917450|NCT00783900|Active Comparator|biatrial pacing|
9917451|NCT00783926|Experimental|Cohort 1|60 subjects randomized in an equal number to six different vaccine doses
9917452|NCT00783926|Experimental|Cohort 2|Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
9917453|NCT00783939|Experimental|1|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
9917454|NCT00783978||1|Children with chronic lung disease
9917455|NCT00783991||IVR-PC|This group will have instruments administered through interactive voice response (IVR) and personal computer (PC).
9917456|NCT00783991||PP-PC|This group will have instruments administered through paper and pencil (PP) and PC.
9917457|NCT00783991||PDA-PC|This group will have instruments administered by personal digital assistant (PDA) and PC.
9917458|NCT00783991||PC-PC|This group will have all instruments administered through PC.
9917459|NCT00784004|Other|Volunteers|Ten healthy volunteers
9917460|NCT00784004|Other|Patients|Sixteen patients with respiratory insufficiency
9917461|NCT00784017|Active Comparator|asparaginase medac|
9917462|NCT00784017|Experimental|recombinant asparaginase|
9934672|NCT04599634|Experimental|Experimental treatment: MZL, MCL, and CLL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax ramp-up to target dose of 400mg over 5 weeks (35 days, Cycle 1) administered to 6 patients. Triplet combination of magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for five (5) additional cycles (28-days each, Cycles 2-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 200mg with magrolimab and obinutuzumab.
9995795|NCT01493856|Active Comparator|Rosuvastatin+Olmesartan|single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg
9995796|NCT01493856|Experimental|DWJ1276|Single dose of DWJ1276
9917463|NCT00784056|Experimental|1|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
9917464|NCT00784069|Experimental|1|Lactic Acid (Dermacyd Breeze)
9917465|NCT00784082||Homozygous SS sickle cell children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS sickle cell children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease , taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
9917466|NCT00784082||Homozygous SS children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease, taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
9917467|NCT00784108|Other|Diagnostic tool|Modulated Imaging measure effect of Photodynamic therapy treatment
9917468|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
9917469|NCT00784121|Experimental|1|Lactic Acid (Dermacyd Breeze)
9917470|NCT00784160|Experimental|1|Lactic Acid
9917471|NCT00784186|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
9917472|NCT00784186|Experimental|misoprostol|800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
9917473|NCT00784212|Experimental|Cohort 1|
9917474|NCT00784212|Experimental|Cohort II|
9917475|NCT00784212|Experimental|Cohort III|
9917476|NCT00784290|Experimental|1|Orantinib
9917477|NCT00784316|Active Comparator|metoprolol|
9917478|NCT00784316|Active Comparator|amiodarone|
9917479|NCT00784329|Experimental|Optical Frequency Domain Imaging|Optical Frequency Domain Imaging System used during Lung and Bronchial biopsies to detect cancerous tissue. Tissue imaging results will be compared to tissue biopsy results.
9917480|NCT00784342||Stable|Patients who are stable have not had a COPD exacerbation in the past 2 months.
9917481|NCT00784342||Exacerbation|Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
9917482|NCT00784355|Experimental|1:Laparoscopic cholecystectomy|Surgery
9917483|NCT00784355|No Intervention|2:controls|non-surgical control group
9917484|NCT00784381||1|
9917485|NCT00784381||2|These units use the same electronic prescribing system, but had no counselling software
9917486|NCT00784394|Experimental|Arm I (diindolylmethane)|Participants receive a single dose of diindolylmethane PO on day 1.
9917487|NCT00784394|Placebo Comparator|Arm II (placebo)|Participants receive a single dose of placebo orally (PO) on day 1.
9917488|NCT00784407|Active Comparator|FOCUS (group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
9917489|NCT00784407|Active Comparator|HARMONIC ACE (group B)|Patients submitted to total thyroidectomy with the use of the HARMONIC ACE harmonic scalpel device
9917490|NCT00784420|Active Comparator|UK-453,061|
9917491|NCT00784420|Active Comparator|Raltegravir|
9917492|NCT00784420|Experimental|UK-453,061 plus Raltegravir|
9917493|NCT00784433|Experimental|alcohol 1|
9917494|NCT00784433|Experimental|alcohol 2|
9917495|NCT00784433|Placebo Comparator|control|
9917496|NCT00784446|No Intervention|XELOX, Bevacizumab, Imatinib|
9917497|NCT00784472|Active Comparator|oxycodone|
9917498|NCT00784472|Active Comparator|morphine|
9917499|NCT00784485|Experimental|Xolair injections|All subjects receive active drug (Xolair-see 'interventions').
9917500|NCT00784498|Active Comparator|midazolam/ketamine|Patients with orthopedic injuries requiring painful manipulation
9917501|NCT00784498|Active Comparator|propofol|Patients with orthopedic injuries requiring painful manipulation
9917502|NCT00784511|Experimental|1 vitamin D3|vitamin D3, 4000 IU/d
9917503|NCT00784511|Placebo Comparator|2|placebo
9917504|NCT00784537|Other|Arm A|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to first arm:~No radiotherapy."
9917505|NCT00784537|Other|Arm B|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to second arm:~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease."
9917506|NCT00784576||Cardiac surgery patients|Individuals consecutively scheduled for cardiac surgery
9917507|NCT00784589|Experimental|Rituximab|
9917508|NCT00784589|Active Comparator|Corticotherapy|General Corticotherapy
9917509|NCT00784615||1|Women with polycystic ovaries, oligo or anovulation and hyperandrogenism.
9917510|NCT00784615||2|Women with polycystic ovaries and oligo or anovulation without hyperandrogenism
9917511|NCT00784615||3|Women with normal ovaries, oligo or anovulation and hyperandrogenism
9917512|NCT00784615||4|Women with normal ovaries, oligo or anovulation and hyperandrogenism
9917513|NCT00784615||5|Women with out polycystic ovary syndrome
9917514|NCT00784680|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
9917515|NCT00784680|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
9917516|NCT00784680|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
9917517|NCT00784706|Experimental|CIT with eye-patching|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log. Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
9917518|NCT00784706|Experimental|constraint-induced therapy|The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
9917519|NCT00784706|Active Comparator|conventional therapy|traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
9917520|NCT00784732|Experimental|1|
9917521|NCT00784732|Experimental|2|
9917522|NCT00784732|Active Comparator|3|
9917523|NCT00784745|Experimental|Dexamethasone|
9917524|NCT00784797|Active Comparator|pitocin|high dose pitocin drip 48 hours after mifepristone preparation.
9917525|NCT00784797|Active Comparator|misopristol|vaginal and oral misopristol 48 hours after mifepristone preparation.
9917526|NCT00784823|Experimental|Combined dose intense Melphalan with bortezomib (MTD)|"The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.~Combined dose intense Melphalan with maximum tolerated dose of bortezomib (MTD)"
9917527|NCT00784862|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
9917528|NCT00784862|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
9917529|NCT00784862|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
9917530|NCT00784888||Aromatase inhibitors|Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment
9917531|NCT00784914|Active Comparator|Cohort 1|Patients do not receive temsirolimus.
9917532|NCT00784914|Experimental|Cohort 2|48 hours after surgery, patients receive one 200 mg dose of temsirolimus IV.
9917533|NCT00784940|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
9917534|NCT00784940|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
9917535|NCT00784940|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
9917536|NCT00784953||1|Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
9917537|NCT00784966|Active Comparator|1|Two weeks etanercept post islet transplant
9917538|NCT00784966|Active Comparator|2|Two months etanercept treatment post islet transplant
9917539|NCT00784992|No Intervention|1|Endonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
9917540|NCT00784992|Active Comparator|2|Endonasal DCR without silicone tubes (this is the 'intervention' arm)
9917541|NCT00785005||1|Females with Type 2 Diabetes
9917542|NCT00785005||2|Females without Type 2 Diabetes
9917543|NCT00785018|Active Comparator|C1-esterase inhibitor|Endotoxin 2ng/kg followed by C1- esterase inhibitor 100 U/kg infusion
9917544|NCT00785018|Placebo Comparator|Placebo|Endotoxin 2ng/kg followed by saline 0.9%(placebo) infusion
9917545|NCT00785031|Active Comparator|internet based intervention|
9917546|NCT00785031|No Intervention|usual care|Patients receive their usual care from their specialist or general practitioner.
9917547|NCT00785057||1|Hypertension patients with history of stroke
9917548|NCT00785057||2|Hypertension patients without history of stroke
9917549|NCT00785070||1|Perioperative
9917550|NCT00785083|Experimental|1|
9917551|NCT00785083|Placebo Comparator|2|
9917552|NCT00785096||Patients|Patients who admit for a minor or major surgical intervention
9917553|NCT00785096||Nurses|Medical staff of the University Hospital of Zurich
9917554|NCT00785096||Physicians|Medical staff of the University Hospital of Zurich and other institutions
9917555|NCT00785109|Experimental|1|100 patients daily additional intake of 2mg vitamin k1
9917556|NCT00785109|Placebo Comparator|2|100 patients no additional intake of vitamin K
9917557|NCT00785135|Active Comparator|Standard (Treatment)|
9917558|NCT00785135|Sham Comparator|Placebo (control)|
9917559|NCT00785148|Experimental|1|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
9917560|NCT00785174|Active Comparator|continuous positive airway pressure|respiratory assistance
9917561|NCT00785174|Active Comparator|NIPSV|respiratory assistance using face mak and ventilator to provide inspiratory pressure support and positive end expiratory pressure
9917562|NCT00785200|Experimental|Chlorhexidine|Approximately 500 detainees housed in approximately 23 detention tanks will be enrolled and receive 2% chlorhexidine-soaked disposable wash cloths (Sage Products, Inc.) to clean their skin on Mondays, Wednesdays, and Fridays for 6 months. Newly arrived detainees in the tanks will be offered enrollment in the study on a biweekly schedule.
9917563|NCT00785200|Placebo Comparator|Water|Approximately 500 detainees in approximately 23 detention tanks will receive water-soaked wash cloths to clean their skin each Monday, Wednesday, and Friday for a 6-month period. If detainees newly arrive to these study tanks, they will be offered enrollment on a biweekly schedule.
9995797|NCT01493869|Experimental|Group 1|Subjects with normal hepatic function: healthy normal adult subjects
9799058|NCT01648699|Experimental|Osmotic Release Oral System (OROS) Hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
9799059|NCT01648764|Experimental|LY2334737 - Arm A|LY2334737 administered orally at escalating doses [40 milligrams (mg) - 200 mg] every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
9799060|NCT01648764|Experimental|LY2334737 - Arm B|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug then repeated (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
9799061|NCT01648790|Experimental|5 mg Prasugrel (ODT1)|5 mg Prasugrel as orally disintegrating tablet without Magnasweet® (ODT1) formulation administered once in the fasted state.
9799062|NCT01648790|Experimental|5 mg Prasugrel (ODT2)|5 mg Prasugrel as orally disintegrating tablet containing Magnasweet® (ODT2) formulation administered once in the fasted state.
9799063|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Suspension|5 mg Prasugrel as ODT2 formulation dispersed in water administered once, in the fasted state.
9799064|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Fed|5 mg Prasugrel as ODT2 formulation administered once, following a standardized breakfast.
9799065|NCT01648790|Experimental|2 mg Prasugrel (ODT2)|2 mg Prasugrel as ODT2 formulation administered once in the fasted state.
9799066|NCT01648920||FeNO|Participants with suspected but undiagnosed asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit. Following that they will have a Methacholine Challenge (MCC) test performed according to the ATS guidelines and the Allergy and Asthma Specialists Procedure for conducting MCC tests
9799067|NCT01649180|Experimental|Axitinib|Axitinib will be given orally and will continue until progression of disease.
9799068|NCT01649232|Experimental|active tDCS|The patients with ADHD received electro-stimulation at 20 sessions with 2 mAmp 1 session per day alternative days. The investigators used an ERP analysis derived of 20 channel EEG recordings during resting state and visual CPT to define the tDCS site and polarity at refractory ADHD patients to conventional treatments. Time courses, topography and amplitude of ERPs, correlated with clinical scores, were compared with the controls average (data base)to guide the selection of personal tDCS parameters. The following relation shown how many patients were submitted to intervention in each electrode, according to their polarity: Anodal tDCS: T5, T6, etc. Cathodal tDCS: T5, T6, etc.
9799069|NCT01649232|No Intervention|controls|Healthy people that not receive tDCS
9799070|NCT01649271|Experimental|Phase Ia, group 1|afatinib escalating dose with 3-weekly trastuzumab
9799071|NCT01649271|Experimental|Phase Ia, group 2|afatinib at MTD dose with weekly trastuzumab
9799072|NCT01649271|Experimental|Phase Ib|afatinib at MTD level with 3-weekly trastuzumab
9799073|NCT01649297|Experimental|empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
9799074|NCT01649297|Experimental|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
9799075|NCT01649297|Experimental|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
9799076|NCT01649297|Experimental|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
9799077|NCT01649297|Placebo Comparator|Placebo|Patients receive placebo matching Empagliflozin
9799078|NCT01649362|No Intervention|Control group|"No prefeeding oral stimulation~Infants in the control group received neither oral stimulation nor a pacifier before or during gavage feeding."
9799079|NCT01649362|Experimental|Oral stimulation, interventional group|"Infants in the interventional group received pre-feeding oral stimulation. The intervention started on infants born within 32 gestational weeks when the patients were stable and tube-fed, receiving more than 100 ml/kg/day of milk. On infants born after 32 weeks, the intervention started immediately after clinical stability was achieved.~The pre-feeding oral stimulation program consisted of a 15-minute stimulation program delivered by one of the eight trained nurses or one trained member from the medical staff in accordance with the stimulation program proposed by Fucile, Gisel and Lau.~The stimulation program was administered 15 to 30 minutes prior to tube feeding, once daily for at least 10 days. The program was stopped when the infants attained more than three oral feedings per day. The program was interrupted if the infants were medically unstable and/or had episodes of desaturation, apnoea and/or bradycardia during the intervention"
9799080|NCT01649375|Experimental|Secukinumab 75 mg|Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
9799081|NCT01649375|Experimental|Secukinumab 150 mg|Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
9799082|NCT01649375|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
9799083|NCT01649427|Experimental|Prograf|Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
9799084|NCT01649427|Experimental|Tacroliums Hexal|Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
9995798|NCT01493869|Experimental|Group 2|Subjects with mild hepatic impairment: adult subjects with a Child-Pugh grade A (score 5-6).
9995799|NCT01493869|Experimental|Group 3|Moderate hepatic impairment: adult subjects with a Child-Pugh grade B (score 7-9).
9995800|NCT01493869|Experimental|Group 4|Severe hepatic impairment: adult subjects with a Child-Pugh grade C (score 10-15).
9995801|NCT01493882|Placebo Comparator|Placebo|
9995802|NCT01493882|Experimental|JNJ-39758979 30 mg/d|
9995803|NCT01493882|Experimental|JNJ-39758979 100 mg/d|
9995804|NCT01493882|Experimental|JNJ-39758979 300 mg/d|
9995805|NCT01493895|Active Comparator|control group,|The control group will be treated with a sham B-cure laser machine, emitting only green indicator light and no 808nm laser.
9995806|NCT01493895|Experimental|study, LLLT-808 B-cure laser machine|The study group will be treated with the LLLT-808 B-cure laser machine, emitting the 808nm laser beam together with a green indicator light.
9995807|NCT01493908|Active Comparator|High price|
9995808|NCT01493908|Active Comparator|Low price|
9995809|NCT01493908|Active Comparator|Low price participants aware paying part|
9995810|NCT01493908|Active Comparator|No price|
9995811|NCT01493908|Active Comparator|Free of charge|
9995812|NCT01493921|Experimental|SR-T100 gel|Patient group receiving medication SR-T100 gel with active ingredient under investigation, enrolled subjects randomly assigned to this group to accurately depict statistical significance of the measured outcome.
9995813|NCT01493921|Active Comparator|Vehicle gel|Patients given placebo with non-SR-T100 ingredients as they are being administered to patients, subjects are under random assignments from patient pool to depict statistically significant outcome measurement.
9995814|NCT01493934|Active Comparator|Healthy volunteers|First injection in human, on 6 healthy volunteers, sequentially : volunteer number1, then volunteers n°2 to n° 6, before infusion in type 2 diabetic patients.
9995815|NCT01493934|Experimental|type 2 diabetic patients|After completion of the study for the 6 healthy volunteers, infusion in 6 type 2 diabetic patients.
9995816|NCT01493973|Experimental|Epoetin alfa|Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks
9995817|NCT01493973|Placebo Comparator|Placebo|Placebo 1200 IU/Kg s.c. every 12 weeks
9995818|NCT01493999|Active Comparator|Prasugrel arm|A loading dose of 60 mg prasugrel in patients with HPR after 600 mg clopidogrel.
9995819|NCT01493999|Active Comparator|Clopidogrel reloading|A maximum of three adjusted loading doses of 600 mg clopidogrel until normal platelet reactivity is achieved in patients with HPR after the first 600 mg clopidogrel.
9995820|NCT01494012|Experimental|Treatment (SBRT)|Patients undergo SBRT 5 days a week for approximately 1 week in the absence of disease progression or unacceptable toxicity.
9995821|NCT01494025|Experimental|Diet and Exercise|
9995822|NCT01494064||Retrospective|Included patients have been no specific nursing practice.
9995823|NCT01494064||Prospective|Standardization of nursing supervision of included patients using a grid of appropriate surveillance for the prevention of complications in the ICU
9995824|NCT01494077||EUS-FNA of Pancreatic Cyst|Patients who have a pancreatic cyst requiring standard of care EUS-FNA that yields 2.25 ML (or greater) of fluid will be included in the study.
9995825|NCT01494090|Active Comparator|Rosuvastatin|
9799085|NCT01649557|Experimental|Open-label OPDC-34712|
9799086|NCT01649596|Active Comparator|Warming Gown|Comparison of two types of warming processes prior to, during, and after the surgery procedure.
9995826|NCT01494090|Placebo Comparator|placebo|
9995827|NCT01494103|Experimental|iCaspase9-transduced T cells|"The 5 dose levels are:~1 x 10^4 T cells/kg~1 x 10^5 T cells/kg~5 x 10^5 T cells/kg~1 x 10^6 T cells/kg~5 x 10^6 T cells/kg~AP1903 will be administered if there is development of Grade 1 or greater GvHD."
9995828|NCT01494116|Experimental|10 mL syringe size|
9995829|NCT01494116|Experimental|20 mL syringe size|
9995830|NCT01494116|Experimental|30 mL syringe size|
9995831|NCT01494116|Experimental|60 mL syringe size|
9995832|NCT01494142||ADEH-Staph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph+ participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
9995833|NCT01494142||ADEH-Staph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph- participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
9995834|NCT01494142||ADEH+|Atopic Dermatitis with previous or current Eczema Herpeticum.We will try to include a minimum of 150 Non-Hispanic Caucasian ADEH+ participants. ADEH+ participants of other racial/ethnic groups will not be excluded
9995835|NCT01494142||ADEV+|Atopic Dermatitis with previous or current Eczema Vaccinatum. ADEV+ sub-phenotype is very rare so all eligible participants will be enrolled.
9917564|NCT00785200|No Intervention|Usual care|Approximately 500 detainees in approximately 23 detention tanks will be enrolled. These detainees will not receive any intervention. They will be followed for 6 months, and newly arrived detainees will be offered enrollment on a biweekly schedule.
9917565|NCT00785252|Experimental|1|EZIO
9917566|NCT00785252|Experimental|2|Central line
9917567|NCT00785265|Experimental|Group Based|60-minute group session involving other study patients who have been assigned to this condition and their guests.
9917568|NCT00785265|Active Comparator|Home-Based|60-minute educational intervention in their home, which will be delivered by an African American health educator.
9917569|NCT00785265|No Intervention|Standard Care|60-minute individual session with an African American health educator.
9917570|NCT00785278||1|Able-bodied participants: Able-bodied individuals will be asked to propel a wheelchair at a self-selected speed for a period of time during which data will be collected on their propulsion biomechanics. It is assumed, for the purpose of the study, that un-learned able-bodied individuals learning to propel a wheelchair reflect newly injured individuals who are just getting accustomed to a new chair.
9917571|NCT00785278||2|Participants with paraplegia: Individuals who are at least 1-year post injury and have used a manual wheelchair as their primary means of locomotion during this time, will be assumed to be, for the purpose of this study, experienced wheelchair users.
9917572|NCT00785304||Traumatic Brain Injury|Active Duty military blast-related TBI patients
9917573|NCT00785304||Other Injury Control|Active duty military patients with other injuries but no TBI
9917574|NCT00785317|Experimental|Angemin|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP
9917575|NCT00785317|Active Comparator|Activelle|1 mg of oral E2 in continuous combination with 0.5 mg of NETA
9917576|NCT00785330|Other|A|Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
9917577|NCT00785330|Experimental|B|rituximab in addition to standard GVHD prophylaxis
9917578|NCT00785343|Active Comparator|Conventional Treatment|
9917579|NCT00785343|Experimental|Robotic and Conventional Therapy|
9917580|NCT00785369|Other|1|Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
9917581|NCT00785382|Placebo Comparator|1|
9917582|NCT00785382|Experimental|2|
9917583|NCT00785395|Experimental|A|
9917584|NCT00785408|Experimental|1|
9917585|NCT00785408|Experimental|2|
9917586|NCT00785408|Experimental|3|
9917587|NCT00785408|Placebo Comparator|4|
9917588|NCT00785408|Placebo Comparator|5|
9917589|NCT00785408|Placebo Comparator|6|
9917590|NCT00785421|Experimental|A|"Patients with KPS > 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c."
9917591|NCT00785421|Active Comparator|B|"Patients with KPS > 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c."
9917592|NCT00785434|Experimental|Active|Active escitalopram
9917593|NCT00785447|Other|1|Twenty healthy subjects between 18 to 59 years of age meeting ASA I-II criteria, undergoing elective surgery, requiring general anesthesia and being able to breathe through both their nose and mouth.
9917594|NCT00785460|Experimental|Benfotiamine and Smoking|
9917595|NCT00785460|Placebo Comparator|Smoking alone|
9917596|NCT00785473|Active Comparator|1|cholecalciferol, calcium carbonate
9917597|NCT00785473|Placebo Comparator|2|capsules not containing cholecalciferol, otherwise identical to Active comparator; calcium carbonate
9917598|NCT00785499|Experimental|skim milk|skim milk
9917599|NCT00785499|Experimental|whey|Whey milk drink
9799087|NCT01649596|Other|Standard of Care Warming|Standard of care warming with hospital-issued blankets.
9799088|NCT01649609|Active Comparator|Reduction of standard immunosuppression|Low dose Tacrolimus with low dose Mycophenolate acid
9799089|NCT01649609|Active Comparator|mTOR Arm|Low dose Sirolimus with low dose Mycophenolate acid (mTOR Substitution)
9799090|NCT01649765|Experimental|Arm 1|belimumab 10mg/kg IV monthly
9799091|NCT01649765|Placebo Comparator|Arm 2|Normal Saline IV monthly
9799092|NCT01649791|Experimental|Treatment (lenalidomide as chemoprevention)|Patients receive lenalidomide PO once daily for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9799093|NCT01649804|Experimental|RoActemra/Actemra single arm|
9799094|NCT01649856|Experimental|A: Rituximab SC|
9799095|NCT01649856|Active Comparator|B: Rituximab IV|
9799096|NCT01649869|Active Comparator|Active|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive valganciclovir HCl 16.0 mg/kg orally twice a day for 6 weeks
9799097|NCT01649869|Placebo Comparator|Placebo|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive placebo orally twice a day for 6 weeks
9799098|NCT01649947|Experimental|Cohort 2: Bevacizumab ineligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Hydroxychloroquine 200 mg PO BID
9799099|NCT01649947|Experimental|Cohort 1: Bevacizumab eligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for Hydroxychloroquine 200 mg PO BID
9799100|NCT01650194|Experimental|Enzalutamide + Abiraterone + Prednisone|Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
9799101|NCT01650246|Experimental|lesinurad 400 mg|
9799102|NCT01650259||Oral antidiabetic drug (OAD)|
9799103|NCT01650259||Trazenta|
9799104|NCT01650298|No Intervention|Control|Remote transmissions were scheduled per each institution's device monitoring protocol. Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
9799105|NCT01650298|Experimental|Tailored Anticoagulation (TAC)|"Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net.~Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed"
9799106|NCT01650324|Experimental|DBPR108|
9799107|NCT01650324|Placebo Comparator|matching placebo|
9799108|NCT01650402|Experimental|Intensive|Intensive anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 130 mmHg
9799109|NCT01650402|Active Comparator|Standard|Standard anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 145 mmHg
9799110|NCT01650519|Active Comparator|IV ibuprofen|Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
9799111|NCT01650519|Active Comparator|IV ketorolac|A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
9995836|NCT01494142||Non-atopic|Non-atopic healthy participants. A minimum of 250 non-atopic participants will be enrolled. Non-atopic participants will serve as a control group for the genetic, biomarker, Staph characterization, and microbiome studies.
9995837|NCT01494155|Experimental|Hydroxychloroquine|Hydroxychloroquine with chemoradiation
9995838|NCT01494194|Placebo Comparator|placebo for food challenge|
9995839|NCT01494194|Experimental|ASP Skin prick solution|
9995840|NCT01494194|Experimental|ASP sorbet|
9995841|NCT01494207|Experimental|Lifestyle intervention|Participants will receive the intervention (counseling) or usual care (control group)
9995842|NCT01494220||Living donor liver transplantation|Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
9995843|NCT01494246|Experimental|electronic mail|
9995844|NCT01494246|No Intervention|brief advise|
9995845|NCT01494259|Experimental|Bupivacaine (Treatment) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the bupivacaine. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of 0.5% bupivacaine, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
9995846|NCT01494259|Placebo Comparator|Saline (Placebo) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the saline. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of normal saline, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
9995847|NCT01494272||Group CB (Caudal Before-study group)|This group will receive caudal ropivacaine and epinephrine after induction of general anesthesia prior to surgical incision
9995848|NCT01494272||Caudal After (CA)-control group|This group will receive caudal ropivacaine with epinephrine after completion of surgery but before emergence from anesthesia
9995849|NCT01494272||Local Infiltration After (LIA) control group|This group will receive local infiltration of ropivacaine around the surgery site at the conclusion of surgery but before emergence from anesthesia
9995850|NCT01494285|Experimental|ARK-E021 5% foam|
9995851|NCT01494285|Experimental|ARK-E021 10% foam|
9995852|NCT01494285|Placebo Comparator|Placebo foam|
9995853|NCT01494311|Active Comparator|Placebo patch and lidocaine injection|Fourty-five patients were randomly assigned to receive a placebo patch, looking identically to the Rapydan patch and subsequent subcutaneous injection of 0.5 ml of lidocaine 1%.
9995854|NCT01494311|Experimental|Lidocaine/tetracaine patch|Fourty-five patients were randomly assigned to receive a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution.
9995855|NCT01494337|Active Comparator|HOLEP|HOLEP In the first arm, holmium laser enucleation of the prostate will be done
9995856|NCT01494337|Active Comparator|PVEP/XPS|PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
9995857|NCT01494389||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
9995858|NCT01494389||sepsis|SIRS + infection
9995859|NCT01494389||Normal|not SIRS and have no infection
9995860|NCT01494402|Experimental|D961S|2 way crossover
9995861|NCT01494402|Experimental|esomeprazole + buffered acetylsalicylic acid|2 way crossover
9995862|NCT01494415|Experimental|chemoradiotherapy|This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
9995863|NCT01494428|Experimental|rhBMP-2/ACS|
9995864|NCT01494428|Active Comparator|Autogenous Bone|
9995865|NCT01494441|Experimental|rhBMP-2/BCP|
9917600|NCT00785499|Experimental|casein|casein milk drink
9917601|NCT00785499|Active Comparator|water|Danish mineral water
9917602|NCT00785551|Experimental|1|quinine sulfate 648mg in subjects with normal renal function (CLcr > 80mL/min)
9917603|NCT00785551|Experimental|2|quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr > 50 to 80 mL/min)
9917604|NCT00785551|Experimental|3|quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)
9917605|NCT00785590|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
9917606|NCT00785642|Experimental|1|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
9917607|NCT00785655|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
9917608|NCT00785681|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
9917609|NCT00785694|Experimental|B|One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
9917610|NCT00785694|No Intervention|A|Multiple instillations of mitomycin C after transurethral resection in white light alone.
9917611|NCT00785720|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
9917612|NCT00785733||1|Moderate and severe asthma patients stabilized on Symbicort SMART
9917613|NCT00785746|Experimental|core|strength training of the core muscles.
9917614|NCT00785746|No Intervention|stretch and strength|This program consists of general stretching exercises and peripheral muscle strengthening exercises with a special emphasis on strengthening the upper extremity muscles because of their importance for ADL but not necessarily balance.
9917615|NCT00785811|Experimental|1|L-arginine aspartate (Targifor)
9917616|NCT00785811|Placebo Comparator|2|Placebo
9917617|NCT00785824||1 A-A Breastfeeding Mothers|Group 1: Postpartum African-American breastfeeding women at 6-8 weeks post childbirth, and again at 12-14 weeks post childbirth
9917618|NCT00785824||2 - AA Bottlefeeding Mothers|Group 2: Postpartum African-American bottlefeeding women at 6-8 weeks post childbirth and again at 12-14 weeks post childbirth.
9917619|NCT00785824||3 - AA Normal Controls|Group 3: Normal African-American non-pregnant controls who are age-matched to Group 1
9917620|NCT00785837|No Intervention|Before Hidrotherapy|
9917621|NCT00785837|Experimental|Hidrotherapy|
9917622|NCT00785850|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
9917623|NCT00785863|Placebo Comparator|Placebo|
9917624|NCT00785863|Active Comparator|Remifentanil|
9917625|NCT00785863|Active Comparator|Ketorolac and remifentanil|
9917626|NCT00785863|Active Comparator|Parecoxib and remifentanil|
9934673|NCT04599634|Experimental|Experimental treatment: mzl, MCL, CLL dose expansion|Window of magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg combination for two (2) cycles (28-day cycles, Cycles -2 and -1), then venetoclax safety ramp-up to target dose (dose determined from Arm 2) over 5 weeks (35-days, Cycle 1). Triplet combination treatment with magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for 5 additional cycles (28-days each, Cycles 2-6); further treatment will be response-adapted.
9934674|NCT04598828|Experimental|Treatment 1|Participants will receive Experimental treatment 1 stimulation for a duration of 12 weeks, twice daily for 19 minutes
9934675|NCT04598828|Experimental|Treatment 2|Participants will receive Experimental treatment 2 stimulation for a duration of 12 weeks, twice daily for 19 minutes
9934676|NCT04595760||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
9934677|NCT04593342|Active Comparator|Standard + B-Cure Pro|Subjects from the Standard + B-Cure Pro group will receive standard care and in addition will self-treat at home with the B-Cure device
9934678|NCT04593342|Sham Comparator|Standard + Sham|Subjects from the Standard + Sham group will receive standard care and in addition will self-treat at home with the sham B-Cure device
9934679|NCT04593290|Experimental|Mild Cognitive Impairment (MCI)|MCI is defined as an early stage of cognitive decline that lies between normal age-matched cognitive function and the onset of very mild forms of dementia, and is associated with a slight but noticeable decline in abilities such as memory and thinking skills. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
9934680|NCT04593290|Active Comparator|Cognitively Healthy|This group is 40-85 years old and has no significant neurological or psychiatric disease. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
9934681|NCT04592562|Experimental|GAE Arm|Patients who meet study eligibility will be scheduled to undergo the Genicular Artery Embolization procedure and will subsequent be followed for 12 months after their procedure.
9934682|NCT04591483||Affected|Patients with Stargardt-like macular dystrophy 3 who are >= 10 years of age.
9934683|NCT04591431|Experimental|Tailored Therapy|"Patients will be treated with target therapy and/or immunotherapy according to their genomic profile evidenced by the FO (Foundation One) profiling. Patients will be treated with one or more drugs of the following list according to their genomic profile and independently from their type of cancer:~TARGETED THERAPY (MOLECULAR TARGET) ERLOTINIB (EGFR mutation) TRASTUZUMAB, PERTUZUMAB, TDM1, LAPATINIB (ERBB2 amplifications/mut) EVEROLIMUS (mTOR mutations, AKT mut) VEMURAFENIB, COBIMETINIB (BRAFV600E mutations) ALECTINIB, BRIGATINIB (ALK, RET) PALBOCICLIB (CDK4/6, CDKN2A/p16) PONATINIB (Bcr-abl) VISMODEGIB (SMO/PTCH1) ITACITINIB (JAK mutation) INCB054828 (FGFR1/2/3) IPATASERTIB (PI3K, AKT, PTEN) ENTRECTINIB (NTRK1/2/3 -TRK fusion proteins-, ROS1)~IMMUNOTHERAPY (BIOMARKERS) ATEZOLIZUMAB, NIVOLUMAB, IPILIMUMAB (MSI, HIGH TUMOR MUTATIONAL BURDEN, OTHER ) Drugs will be administered according to their respective SmPCs (or IBs in case of drugs under development)."
9934684|NCT04591431|Active Comparator|Standard of Care|Patients will be treated according the current version of the AIOM (Italian Association of Medical Oncology) guidelines for their type of cancer. As an example, patients could be treated with standard chemotherapy and/or targeted therapy according to the histological results.
9995866|NCT01494441|Experimental|rhBMP-2/BCP/TSRH® Spinal System|
9917627|NCT00785876|No Intervention|1|Control Sites
9917628|NCT00785876|Experimental|2|Intervention Sites
9917629|NCT00785915|Experimental|1|
9917630|NCT00785915|Placebo Comparator|2|given (2 subjects in each ethnic/dose group)
9917631|NCT00785941|Experimental|IMC-A12|"All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each Cohort. When all patients complete a cohort, dose escalation to the next Cohort will occur.~A treatment cycle will consist of IMC-A12 administered intravenously, once every other week for 4 weeks, for a total of 2 doses; followed by a 2-week observation period."
9917632|NCT00785967|Experimental|1|raltegravir 400mg bid + Truvada 1 tab qd
9917633|NCT00785967|Active Comparator|2|efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
9917634|NCT00785993|Active Comparator|Control Group|Fresh donor oocytes
9917635|NCT00785993|Experimental|Group I|vitrified donor oocytes
9917636|NCT00786006|Experimental|Arm 1|FOLFIRI.3
9917637|NCT00786006|Active Comparator|Arm 2|FOLFOX
9917638|NCT00786045|Experimental|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
9917639|NCT00786045|No Intervention|Control|The investigators have devised a series of mobility-related tasks that can be easily and safely carried out at home without ongoing professional supervision
9917640|NCT00786071||Rett syndrome girls|The study population consists of a well-defined group of Dutch RTT thirteen girls with complete clinical, molecular and neurophysiological work-up.
9917641|NCT00786084||1|Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
9917642|NCT00786084||2|Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
9917643|NCT00786097|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
9917644|NCT00786110|Experimental|1 arm only|"One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up~Intervention: Sorafenib plus Paclitaxel"
9917645|NCT00786123|Experimental|VSL#3|Patients taking probiotics (VSL#3)
9917646|NCT00786123|Placebo Comparator|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
9917647|NCT00786136|Experimental|1|perioperative rosuvastatin administration for at least 5 dosages
9917648|NCT00786136|Placebo Comparator|control|blank control of perioperative statin administration
9917649|NCT00786149|Experimental|1|Participants will receive NRT and Motivational Interviewing counseling
9917650|NCT00786149|Active Comparator|2|Varenicline plus brief advice
9917651|NCT00786162|Experimental|Intervention|Internet-based hypertension self-management platform
9917652|NCT00786162|Active Comparator|Control|Installation of BP cuff for communal use at the worksite
9917653|NCT00786214|Experimental|Acupuncture|Patients given acupuncture treatment
9917654|NCT00786214|Sham Comparator|Sham acupuncture|Patients given sham acupuncture treatment
9917655|NCT00786227||Legacy HAQ-DI first, PROMIS 20-item short form first|To eliminate effects due to order of administration, patients with RA will be randomized to complete either the Legacy measure HAQ-DI first in the assessment battery or the PROMIS 20-item short forms first.
9917656|NCT00786240|Experimental|A|
9917657|NCT00786240|Experimental|B|
9917658|NCT00786253|Experimental|Arm 1|
9917659|NCT00786253|Experimental|Arm 2|
9917660|NCT00786266|Active Comparator|NIOSH shiftwork booklet|
9917661|NCT00786266|Experimental|Sleep Enhancement Training System|
9917662|NCT00786279|Placebo Comparator|1|150 cc daily of flavored, calorie-free beverage without alcohol
9917663|NCT00786279|Experimental|2|150 cc flavored, calorie-free beverage with 15 gm ethanol daily
9917664|NCT00786292|Other|Noisy PSV|Assisted mechanical ventilation with noisy PSV
9917665|NCT00786292|Other|PSV|Assisted mechanical ventilation with PSV
9917666|NCT00786305|Experimental|1: nebulized ceftazidime and amikacin|
9917667|NCT00786305|Active Comparator|2: intravenous ceftazidime and amikacin|
9917668|NCT00786318|Experimental|ziprasidone|
9917669|NCT00786318|Active Comparator|Standard therapy|
9917670|NCT00786331|Active Comparator|A|Monochemotherapy
9917671|NCT00786331|Experimental|B|Combination chemotherapy
9995867|NCT01494441|Active Comparator|Autograft/TSRH® Spinal System|
9917672|NCT00786344|Experimental|Lifestyle Redesign|
9917673|NCT00786344|No Intervention|No Treatment Control|The no treatment control arm did not receive the intervention during the first six-month period. However the intervention, which has been proven to be beneficial, was administered to the control arm immediately following the 6 month assessment.
9917674|NCT00786357|Experimental|Intervention|
9917675|NCT00786370|Active Comparator|Propofol|
9917676|NCT00786370|Experimental|Dexmedetomidine|
9917677|NCT00786383|Experimental|IMC-1121B|IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
9917678|NCT00786396|Experimental|DAART|Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
9917679|NCT00786396|No Intervention|2|SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
9917680|NCT00786435||1|Those with a cervical spinal cord injury
9917681|NCT00786435||2|Those with a thoracic spinal cord injury
9917682|NCT00786435||3|Healthy, control group
9917683|NCT00786448||Group 1|
9917684|NCT00786500|Active Comparator|Gynostemma pentaphyllum tea|
9917685|NCT00786500|Placebo Comparator|Placebo tea|
9917686|NCT00786513|Active Comparator|Control Arm|
9917687|NCT00786513|Experimental|Intervention Arm|
9917688|NCT00786552|Experimental|chemotherapy|
9917689|NCT00786578||1|overweight runners (BMI>25)
9917690|NCT00786578||2|lean runners (BMI<24)
9917691|NCT00786591||Acute Pancreatitis Patients|Patients presenting with clinical features compatible with acute pancreatitis
9917692|NCT00786591||Control|Preoperative patients going for elective cholecystectomy
9917693|NCT00786604||1|Those with a cervical spinal cord injury
9917694|NCT00786604||2|Those with a thoracic spinal cord injury
9917695|NCT00786604||3|Healthy, control group
9917696|NCT00786617||Nurse-driven|Mechanically ventilated patients weaned by nurse-driven ventilator weaning protocol
9917697|NCT00786617||Physician-initated|Mechanically ventilated patients weaned by physician-initiated, non-protocol methods
9917698|NCT00786630|Experimental|Case Management|
9917699|NCT00786630|Experimental|Facilitated Treatment Alliance|
9934685|NCT04588948|Experimental|Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
9917700|NCT00786669|Experimental|Bevacizumab+TEM/VCR/IRN/CEF|"Bevacizumab(IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles~Temozolomide (TEM) 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.~Vincristine (VCR) 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).~Irinotecan (IRN) 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles~Cefexime (CEF) 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity"
9917701|NCT00786695|Placebo Comparator|Placebo|Identical looking Placebo
9917702|NCT00786695|Experimental|esomeprazole|esomeprazole (40 mg o d) for 14 days
9917703|NCT00786708||NGAL|Urine that would otherwise be discarded will be obtained from a convenience sample of patients admitted to the hospital through the emergency room who meet the inclusion / exclusion criteria for this study.
9917704|NCT00786721||Diffuse Optical Spectroscopy|muscle properties scanning
9917705|NCT00786734|Experimental|Pitavastatin Group|
9917706|NCT00786734|Other|Usual Care Group|
9917707|NCT00786747|Experimental|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
9917708|NCT00786747|Active Comparator|Non-tailored control computer program|This program provides non-tailored, generic information about colorectal cancer screening, in the user's preferred language (English or Spanish).
9917709|NCT00786773||1|GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy
9917710|NCT00786786||1|Spinal Cord Injury
9917711|NCT00786812|Other|CAMN107A2109 Extension Patients|
9917712|NCT00786812|Other|AMN107 Naive|
9917713|NCT00786851|Experimental|1|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
9917714|NCT00786877|Experimental|Improved biomass cookstove with exterior ventilation|"In phase 1, installation of an improved cookstove with ventilation to exterior is the active arm.~In phase 2, this improved biomass cookstove is the control arm."
9917715|NCT00786877|No Intervention|Traditional cookstove|In phase 1, the control arm is the traditional standard open burning cookstove in house.
9917716|NCT00786877|Experimental|Phase 2 invervention arm (LPG stove)|In phase 2 of this project, households are individually randomized to either continuation of the improved biomass stove from phase 1, or a new LPG stove and gas for 12 months.
9917717|NCT00786890||no treatment|observational, no treatment needed
9917718|NCT00786929|Experimental|drainage|
9917719|NCT00786929|Active Comparator|2|Conservative treatment
9917720|NCT00786942|Active Comparator|1|autologous bone graft
9917721|NCT00786942|Experimental|2|without bone graft
9917722|NCT00786968|Experimental|intrathecal laronidase|drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
9917723|NCT00786981|Other|Epidural steroid injection and physical therapy|
9917724|NCT00786981|Other|Epidural steroid injection|
9917725|NCT00787007|Experimental|1|10 mg
9917726|NCT00787007|Experimental|2|20 mg, fasted and fed
9917727|NCT00787007|Experimental|3|40 mg
9917728|NCT00787007|Experimental|4|80 mg
9917729|NCT00787007|Experimental|5|160 mg
9917730|NCT00787007|Experimental|6|320 mg
9917731|NCT00787007|Placebo Comparator|7|placebo capsule
9917732|NCT00787033|Experimental|1|Dose escalation study with Expansion Cohorts at RP2D and Schedule
9917733|NCT00787072|Experimental|1|
9917734|NCT00787072|Placebo Comparator|2|
9917735|NCT00787085||Case|Patients hospitalized with a urine or blood culture positive for fungi
9917736|NCT00787085||Control|Patients hospitalized with a urine culture negative for fungi
9917737|NCT00787098|No Intervention|1|RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
9995868|NCT01494454|Experimental|rhBMP-2/BCP|
9995869|NCT01494454|Active Comparator|Autograft|
9917738|NCT00787098|Experimental|2|Identical procedures for date recruitment, consent and data collection will occur. In this phase, the Project Manager will promote the use of the ETM protocol through coaching (e.g., reminding staff of benefits of mobility, identification of available resources, or suggesting cessation of bedrest orders) and by participating in planning at least one 20-minute activity.
9917739|NCT00787111|Experimental|Fluoxetine ODT|Fluoxetine ODT ranging from 2mg to 54mg
9917740|NCT00787163|Experimental|1|amnioinfusion
9917741|NCT00787163|No Intervention|2|expectant management
9917742|NCT00787215||no treatment|observational: no treatment involved
9917743|NCT00787280|Experimental|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
9917744|NCT00787280|Experimental|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
9917745|NCT00787293|Experimental|1|Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
9917746|NCT00787306|Experimental|Multi-faceted Cardiovascular Decision Support|Risk factor active surveillance, multi-disciplinary disease management and decision aid intervention
9917747|NCT00787306|Other|Control Usual Care|Usual care in a wait-list control arm that receives the experimental intervention after 6 months.
9917748|NCT00787345|Other|Surgery residents|general surgery residents undergoing evaluation and training in MBP during CVC placement as per department policy are eligible for the study.
9917749|NCT00787358|Active Comparator|ZT-031|
9917750|NCT00787358|Placebo Comparator|Placebo|
9917751|NCT00787371|Experimental|0.25 Dose Group|PegIntron 0.25 mcg/kg SC QW for 12 weeks
9917752|NCT00787371|Experimental|0.5 Dose Group|PegIntron 0.5 mcg/kg SC QW for 12 weeks
9917753|NCT00787371|Experimental|1.0 Dose Group|PegIntron 1.0 mcg/kg SC QW for 12 weeks
9917754|NCT00787371|No Intervention|No-treatment Control|No treatment (no placebo)
9917755|NCT00787384|Experimental|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
9917756|NCT00787397|Experimental|1. Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy-Sleep
9917757|NCT00787410|Experimental|1|
9917758|NCT00787436|No Intervention|1|Standard of care with normal treatment
9917759|NCT00787436|Active Comparator|Thalidomide|Standard of care and treatment using Thalidomide
9917760|NCT00787462|Active Comparator|Active|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
9917761|NCT00787462|Placebo Comparator|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
9917762|NCT00787475|Experimental|1|CHW intervention
9917763|NCT00787475|No Intervention|2|Enhanced usual care (brochure mailings)
9917764|NCT00787488|Experimental|1|Chemotherapy plus Hyperthermia
9917765|NCT00787501|Active Comparator|SSRIs|Selective Serotonin Reuptake Inhibitors
9917766|NCT00787501|Active Comparator|CBT|Cognitive Behavior Therapy
9917767|NCT00787540||I|Coronary Slow Flow Patients
9917768|NCT00787540||II|Coronary Artery Occlusion Patients
9917769|NCT00787553|Active Comparator|cefazolin|
9917770|NCT00787553|Active Comparator|tinidazole|
9917771|NCT00787553|Active Comparator|cefazolin plus tinidazole|
9917772|NCT00787579|Active Comparator|Bifocal spectacles|
9917773|NCT00787579|Active Comparator|Prismatic bifocals|
9917774|NCT00787579|No Intervention|Single vision spectacles|
9917775|NCT00787592||Silver Sulfadiazide (SSD)|Patients that receive SSD as the topical debriding agent
9917776|NCT00787592||Collagenase|Patients that receive collagenase as the debriding agent
9917777|NCT00787657||Arm 1|
9917778|NCT00787670|Experimental|Gastric Bypass Surgery|Gastric Bypass Surgery consists of a laparoscopic approach and includes the creation of an isolated 10-15-ml proximal gastric pouch, a retro-colic, retro-gastric Roux-en-Y gastrojejunostomy with linear stapler technique, a 100-cm Roux-limb, a 30-cm biliopancreatic limb, and a stapled end-side enteroenterostomy.
9917779|NCT00787670|Active Comparator|Diabetes Support and Education|Diabetes Support and Eduction. Subjects attend three educational/social support sessions for 1 year after enrollment. The educational sessions offered for diabetes support and education including informational sessions on diet/nutrition and exercise. These sessions are informational only and do not teach behavioral self-regulation skills. Different nutrition and exercise topics are covered each session. Education
9917780|NCT00787670|Active Comparator|Tissue Control Group|Tissue control group includes subjects who are undergoing other non-gastric bypass abdominal surgery. A pea size piece of omentum and subcutaneous fat will be collected.
9917781|NCT00787683|Experimental|Home-monitoring|Patients receive an additional home-monitoring (remote-monitoring) device (CardioMessengerII) following Biotronik Lumax ICD implantation. The device enables regular transmission and examination of ICD information via home-monitoring. Follow-up appointments in outpatient clinic are changed compared to standard care. While follow-up 1, 12, and 24 months after ICD implantation consist of outpatient clinic appointments, follow-up 3, 6, and 18 months after ICD implantation are conducted remotely.
9917782|NCT00787683|No Intervention|Standard care|Patients randomised to the standard care group receive no home-monitoring device (CardioMessengerII) following Lumax ICD implantation. Patients have scheduled follow-up appointments at the ICD outpatient clinics at 1, 3, 6, 12, 18, and 24 months after ICD implantation.
9917783|NCT00787696|Experimental|Skills Training|intervention group received information, motivation and skills training: condom application, assertive communication & problem solving
9917784|NCT00787696|Active Comparator|Health Education|Comparsion group received information and motivation
9917785|NCT00787709|Experimental|1|Receives Pathways universal school-based health promotion curriculum from 4th-6th grade
9917786|NCT00787709|No Intervention|2|Control group of students who do not receive the intervention
9917787|NCT00787735|Experimental|Integrated Care|Integrated Substance Abuse and Psychiatric Care (ISAP). Subjects received both their substance abuse and psychiatric care within the ATS clinic. Counseling compliance will be measured over time.
9917788|NCT00787735|Active Comparator|Parallel Care|Parallel Substance Abuse and Psychiatric Care (PSAP). Subjects received their substance abuse treatment at the ATS clinic. Their psychiatric care was received at Community Psychiatry. Counseling compliance will be measured over time.
9934686|NCT04588948|Experimental|Non-Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
9934687|NCT04585919|Experimental|Paired Screening Intervention|
9934688|NCT04585919|No Intervention|Usual Care Control|In this stepped wedge design, all sites have a period of being in usual care, and then providing the Paired Screening Intervention. Sites serve as their own controls in this design.
9934689|NCT04583423|Experimental|MK-3655 Low Dose|MK-3655 low dose by subcutaneous (sc) injection once every 4 weeks (Q4W).
9934690|NCT04583423|Experimental|MK-3655 Middle Dose|MK-3655 middle dose by sc injection Q4W.
9934691|NCT04583423|Experimental|MK-3655 High Dose|MK-3655 high dose by sc injection Q4W.
9934692|NCT04583423|Placebo Comparator|Placebo|Matching placebo to MK-3655 by sc injection Q4W.
9934693|NCT04582916|Other|One Arm|All subject receive the same tests
9934694|NCT04582903||Biological Relative|Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
9934695|NCT04582903||Confirmed or Suspected SARS-CoV-2 infection|Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current),typically but not always supported by a positive PCR test for viral RNA
9934696|NCT04582903||Exposed but Uninfected|Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavyor extensive COVID-19 exposure in the workplace or home environment
9934697|NCT04580914|Experimental|Treatment with Ablation Catheter|Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
9934698|NCT04579237||1/All Subjects|Data will be derived from primary studies on all subjects.
9934699|NCT04577014|Experimental|Phase I: Safety Run-In / Dose Level 0|A safety run-in (dose level 0 in Table 1, below) will be performed and enroll 6 patients with advanced high-grade sarcoma who are treatment naïve. Cycle one will consist of gemcitabine plus docetaxel at the institution's standard dose and schedule: 900 mg/m2 of gemcitabine on days 1 and 8, and 75 mg/m2 of docetaxel on day 8. Intravenous Retifanlimab at a flat dose of 210 mg will be administered every 3 weeks starting on C2D1 for a total of two cycles (cycles 2 and 3). All visits are to be done +/-3 days of the scheduled timepoints.
9917789|NCT00787813|Active Comparator|1|N-Acetyl Cysteine
9917790|NCT00787813|Placebo Comparator|2|placebo
9917791|NCT00787826|Experimental|Vaccination|Live Francisella Tularensis Vaccine
9917792|NCT00787865||Krabbe Disease|Children with infantile Krabbe disease
9917793|NCT00787865||Low Enzyme/No Krabbe Disease|Children without disease who have low enzyme levels
9917794|NCT00787865||Control|Children with no disease and normal enzyme levels
9917795|NCT00787865||Motor Disability|Children at risk of developing motor disability
9917796|NCT00787878||A|
9917797|NCT00787878||B|
9917798|NCT00787878||C|
9917799|NCT00787969|Experimental|Treatment (rituximab, cladribine, temsirolimus)|Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9917800|NCT00787995||MPS IVA|Subjects with mucopolysaccharidosis IVA (Morquio Syndrome)
9917801|NCT00788021||Tacrolimus|Recipients of deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
9917802|NCT00788021||Sirolimus|Recipients of deceased or living donor renal transplants maintained on immunosuppressive regimen using sirolimus
9917803|NCT00788021||Healthy controls|Age, race and gender-matched individuals not on immunosuppressive regimens. Whenever possible an transplant recipient's donor may be recruited to serve as healthy control
9917804|NCT00788034|Experimental|Lu AA21004|
9917805|NCT00788034|Placebo Comparator|Placebo|
9917806|NCT00788047|Other|Regimen A (Reference)|
9917807|NCT00788047|Experimental|Regimen B (Test)|
9917808|NCT00788060|Experimental|RAD001|
9917809|NCT00788099|Experimental|1|Plitidepsin and Sorafenib
9917810|NCT00788099|Experimental|2|Gemcitabine and Plitidepsin
9917811|NCT00788112|Experimental|Vorinostat|
9917812|NCT00788138|Experimental|1|Vitamin D3 250,000 PO Once
9917813|NCT00788138|Placebo Comparator|2|Matching Placebo
9917814|NCT00788164|Experimental|Groups 1-3|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
9917815|NCT00788164|Experimental|Group 4|Patients receive topical imiquimod on days 1, 29, and 57.
9917816|NCT00788164|Experimental|Group 5|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.
9917817|NCT00788190|Other|Surgery|Surgical intervention to reduce Distal Radius Fracture
9917818|NCT00788190|Other|Conservative Treatment|Conservative treatment of Distal Radius Fractures
9917819|NCT00788203||5-keys program|Counseling re family feeding behaviors.
9917820|NCT00788203||Lifestyle counseling|Counseling re healthy eating for child and family
9917821|NCT00788216||Healthy Volunteers|Women over the age of 18 without the diagnosis of cervical cancer.
9917822|NCT00788216||Cervical Cancer Patients|Women over the age of 18 with a history of cervical cancer treated with surgery or chemoradiation.
9917823|NCT00788229|Experimental|1. Study Drugs|
9917824|NCT00788229|Experimental|2. Study Drug|
9917825|NCT00788229|Experimental|3. Study Drug|
9917826|NCT00788229|Placebo Comparator|4. Placebo|
9917827|NCT00788242|Experimental|1|Administration of glucose-insulin-potassium
9917828|NCT00788242|Placebo Comparator|2|
9917829|NCT00788281|Experimental|A|laparoscopic surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
9917830|NCT00788281|Active Comparator|B|open surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
9917831|NCT00788294|Active Comparator|10 mg IV|
9917832|NCT00788294|Active Comparator|5 mg SC|
9917833|NCT00788294|Active Comparator|10 mg SC|
9917834|NCT00788294|Active Comparator|19 mg SC|
9917835|NCT00788307|Experimental|Experimental Arm|
9917836|NCT00788320|Placebo Comparator|Placebo|Placebo three times a week for 8 weeks
9917837|NCT00788320|Experimental|Cholecalciferol|Vitamin D3 50,000 IU three times a week for 8 weeks
9917838|NCT00788333|Experimental|A|Combination
9917839|NCT00788346|Experimental|Computerized Alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
9917840|NCT00788346|Experimental|Alerts PLUS Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
9917841|NCT00788346|No Intervention|Usual Care|Usual Care
9917842|NCT00788398|Active Comparator|Saline, gravity flow|
9917843|NCT00788398|Active Comparator|Saline, Low Pressure|
9917844|NCT00788398|Active Comparator|Saline, High Pressure|
9917845|NCT00788398|Active Comparator|Soap, Gravity Flow|
9917846|NCT00788398|Active Comparator|Soap, low pressure|
9917847|NCT00788398|Active Comparator|Soap, high pressure|
9917848|NCT00788424|Experimental|AS101 Cream|Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.
9917849|NCT00788424|Experimental|Placebo|Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.
9917850|NCT00788463|Experimental|Aerosol|
9917851|NCT00788463|Active Comparator|Spray|
9917852|NCT00788476||Childhood Cancer Survivors|
9917853|NCT00788476||Primary Caregivers|
9917854|NCT00788515|Experimental|1|
9917855|NCT00788515|Active Comparator|2|
9917856|NCT00788554|Active Comparator|1|
9917857|NCT00788554|Active Comparator|2|
9917858|NCT00788567|Experimental|1|
9917859|NCT00788606|Experimental|bevacizumab and Rituximab|This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
9917860|NCT00788619|Active Comparator|Day 3 transfer|Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
9917861|NCT00788619|Active Comparator|Day 5 transfer|Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.
9917862|NCT00788632|Experimental|educational materials|Patient educational DVD and brochure
9917863|NCT00788632|Other|physician education|Physician web modules
9917864|NCT00788632|Experimental|System intervention|Self-referral letter with toll-free number provided
9917865|NCT00788645|Experimental|Forecast|COPD patients receiving advice and poor weather warning
9917866|NCT00788645|Experimental|No Forecast|COPD patients receiving advice and poor weather warning
9917867|NCT00788645|No Intervention|Control|Age matched non - COPD subjects
9917868|NCT00788658|Placebo Comparator|Diet modifications|Diet consultation and life style modifications for 6 sessions
9917869|NCT00788658|Active Comparator|Cognitive therapy|6 sessions of cognitive behavioral therapy
9917870|NCT00788671|Experimental|Treatment (levonorgestrel-releasing intrauterine system)|Patients undergo placement of a levonorgestrel-releasing intrauterine system.
9917871|NCT00788723|Experimental|1|Patients with severe brain injury, awake, but have cognitive problems
9917872|NCT00788723|Experimental|2|Patients with severe brain injury and disorders of consciousness ( in minimally conscious or in vegetative state)
9917873|NCT00788723|Experimental|3|Healthy volunteers
9917874|NCT00788749|Placebo Comparator|Placebo|Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
9917875|NCT00788749|Experimental|Prednisolone|25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months
9917876|NCT00788762||Villagers in Taxiarchis|
9917877|NCT00788788|Active Comparator|1|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
9917878|NCT00788788|Active Comparator|2|Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
9917879|NCT00788788|Active Comparator|3|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
9917880|NCT00788801|Experimental|Baseline|
9917881|NCT00788801|Experimental|ABT-614 Low Dose|
9917882|NCT00788801|Experimental|ABT-614 High Dose|
9917883|NCT00788814|Other|Control|Control group
9917884|NCT00788840|Active Comparator|1. Insulatard|
9917885|NCT00788840|Active Comparator|2. Detemir|
9917886|NCT00788853||A|
9917887|NCT00788866|Experimental|Pomegranate juice|This arm with receive 8oz of pomegranate juice per day.
9917888|NCT00788866|Placebo Comparator|Placebo|This group will take 8oz of placebo juice that lacks pomegranate daily
9917889|NCT00788879|Experimental|1|This study arm is located in Brownsville, Texas. This community is exposed to the TSSC media messages as well as may be visited by the lay health workers and see the built environment changes
9917890|NCT00788879|No Intervention|2|The control group is located in Laredo. This community is not exposed to the TSSC messages nor does the campaign work to actively change the built environment or use lay health workers to share physical activity and nutrition information.
9917891|NCT00788905|Experimental|A|"Subject will continue conventional hemodialysis therapy for one week (no intervention phase) and then swtich to the Allient system for two weeks (active comparator phase)."
9917892|NCT00788918|Experimental|Chronic hepatitis C treatment|30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.
9917893|NCT00788918|No Intervention|Healthy Controls|50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)
9917894|NCT00788918|No Intervention|Former HCV infected|20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.
9917895|NCT00788918|No Intervention|Chronic HCV patient - no treatment|20 chronic HCV patients without pending antiviral treatment.
9917896|NCT00788931|Experimental|IV LBH589 + trastuzumab + paclitaxel|i.v. panobinostat
9917897|NCT00788931|Experimental|Oral LBH589 + trastuzumab + paclitaxel|oral panobinostat
9917898|NCT00788944|Other|1|
9917899|NCT00788970|Experimental|Acupressure|Acupressure adjuvant therapy
9917900|NCT00788970|Placebo Comparator|Placebo acupressure|Sham acupressure adjuvant therapy
9917901|NCT00788970|No Intervention|No treatment|Wait list group (no treatment)
9917902|NCT00788996|Experimental|Lifestyle counseling|Usual care
9917903|NCT00789022||1|40 subjects in a First Psychotic Episode
9917904|NCT00789022||2|20 First Degree relatives
9917905|NCT00789022||3|20 Healthy subjects
9917906|NCT00789048|No Intervention|Surgeon doesn't see|The surgeon doesn't see the radiograph prior to surgery
9917907|NCT00789048|Experimental|Surgeon does see|The surgeon can see the radiograph prior to surgery
9917908|NCT00789087|Active Comparator|1. Videothoracoscopic talc poudrage (VT)|
9917909|NCT00789087|Active Comparator|2. Talc slurry through a chest tube (DT)|
9917910|NCT00789100||1|Group provided with home-based monitor
9917911|NCT00789100||2|Group receives no home-based monitor
9917912|NCT00789139|Other|AF monitoring by ICM|Only one arm
9917913|NCT00789165|Experimental|Quinidine|Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.
9917914|NCT00789165|Active Comparator|no therapy|Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
9917915|NCT00789178||patients with fibromyalgia|
9917916|NCT00789178||patients with active RA|
9917917|NCT00789204|Experimental|GPR|Global Postural Re-Education
9917918|NCT00789204|Active Comparator|SEP|Standard Exercise Programm
9917919|NCT00789217|Active Comparator|In-house penicillin testing preparation|In-house penicillin testing prepared from alkali-treated penicillin G
9917920|NCT00789217|Active Comparator|Commercial penicillin test kit|Commercial penicillin test kit order from Diater company
9917921|NCT00789217|Active Comparator|Penicillin G Sodium|Penicillin G Sodium from routine clinical use
9917922|NCT00789230|Active Comparator|primary suture|
9917923|NCT00789230|Active Comparator|mesh enforced closure|
9917924|NCT00789243|Active Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, local ischaemic preconditioning will be induced by inflating a cuff around the non-dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
9917925|NCT00789243|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
9917926|NCT00789243|Placebo Comparator|3|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, sham will be performed by inflating a cuff to 10 mmHg for 5 mins followed by 5 mins of deflation. This cycle will be repeated 3 times.
9917927|NCT00789269|Experimental|1|rhubarb
9917928|NCT00789269|Placebo Comparator|2|
9917929|NCT00789282|Active Comparator|Usual Care Group|The 'usual care' study arm (control) will reflect current patterns of care for patients with thpe 2 diabetes in the Capital Health region
9917930|NCT00789282|Experimental|Enhanced Care Group|In the enhanced care group(intervention arm) the participants will receive a multifactorial intervention with three main components that include: optimized medical management, 2) support for development of enhanced patient self management skills, and 3) organized proactive follow-up by chronic disease management teams to support improvement in care.
9917931|NCT00789295|Active Comparator|Mediterranean diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%)
9917932|NCT00789295|Active Comparator|Low-Carbohydrates diet|Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)
9917933|NCT00789308|Active Comparator|Standard of Care|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) without LMW-DS
9917934|NCT00789308|Experimental|LMW-DS|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) and LMW-DS
9917935|NCT00789347||1|Healthy volunteers
9917936|NCT00789347||2|Patient with neuropathic pain
9917937|NCT00789347||3|patients without neuropathic pain
9917938|NCT00789386|Experimental|Remifentanil|
9917939|NCT00789386|Placebo Comparator|Midazolam|Active Placebo
9917940|NCT00789399|Active Comparator|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
9917941|NCT00789399|Placebo Comparator|Placebo|
9917942|NCT00789412||Expected ICU|Patients with expected postoperative admission to the ICU. Baseline measurement of SSI. Exploration prior to weaning.
9917943|NCT00789412||Unexpected ICU|Patients with unexpected stay at the ICU. No baseline measurement of SSI. Exploration in 'steady state' of analgosedation.
9917944|NCT00789425|Active Comparator|1|a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
9917945|NCT00789425|Placebo Comparator|2|Placebo (starch) + 1000 mg of calcium per day.
9917946|NCT00789451|Sham Comparator|1|no ischaemia - only sham. Blood pressure cuff inflation up till 10 mmHg on the upper arm for 20 mins.
9917947|NCT00789451|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated around the upper arm for 20 minutes to induce ischaemia.
9917948|NCT00789464|Other|ARM A|Probiotics drops plus placebo elixir
9917949|NCT00789464|Other|ARM B|TMP/SMZ elixir plus placebo drops
9917950|NCT00789503|Experimental|Bread fortified with vitamin D3 and calcium|
9917951|NCT00789516||1|Normal control
9917952|NCT00789516||2|B thalassemia regular transfusion
9917953|NCT00789516||3|B thalassemia post transplantation
9917954|NCT00789542|Experimental|Intermittent Pneumatic Compression|SCD Express device applied with thigh length sleeves for up to 30 days
9917955|NCT00789542|Other|Routine care|Routine care which might include: early mobilisation, adequate hydration, aspirin if ischaemic stroke and graduated compression stockings according to local protocols.
9917956|NCT00789568|Experimental|Sapropterin Dihydrochloride 100mg/kg and placebo Moxifloxacin|A single dose of 100mg/kg of Sapropterin Dihydrochloride taken along with placebo Moxifloxacin.
9917957|NCT00789568|Experimental|Sapropterin Dihydrochloride 20mg/kg and placebo Moxifloxacin|A single dose of 20mg/kg of Sapropterin Dihydrochloride taken along with a placebo Moxifloxacin.
9917958|NCT00789568|Active Comparator|Sapropterin Dihydrochloride placebo and Moxifloxacin|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with 400mg of Moxifloxacin.
9917959|NCT00789568|Placebo Comparator|Sapropterin Dihydrocholide placebo and Moxifloxacin placebo|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with placebo of Moxifloxacin.
9917960|NCT00789594|Experimental|Laboratory Monitoring|Laboratory Monitoring
9917961|NCT00789594|Experimental|Result management|Result management
9917962|NCT00789594|Experimental|Both interventions|Both laboratory monitoring and result management interventions
9917963|NCT00789594|No Intervention|Usual care|Usual care
9917964|NCT00789607|Active Comparator|MRI-guided FM|
9917965|NCT00789607|Active Comparator|TRUS-guided FM|
9917966|NCT00789620|Active Comparator|1|Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h
9917967|NCT00789620|Placebo Comparator|2|NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h
9934700|NCT04577014|Experimental|Phase I: Dose De-escalation Level 1|"If ≤ 1 patient out of 6 at dose level 0 has a dose-limiting toxicity during this safety run-in, then the dose de-escalation portion of the protocol will commence.~Dose Level 1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 900 mg/m2 Docetaxel (Day 8) - 75 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
9934701|NCT04577014|Experimental|Phase I: Dose De-escalation Level -1|"Dose Level -1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 750 mg/m2 Docetaxel (Day 8) - 60 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
9934702|NCT04577014|Experimental|Phase I: Dose De-escalation Level -2|"Dose Level -2:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 675 mg/m2 Docetaxel (Day 8) - 50 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
9934703|NCT04577014|Experimental|Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma|"(UPS/MFS)~After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints."
9934704|NCT04577014|Experimental|Liposarcoma/LPS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
9934705|NCT04577014|Experimental|Leiomyosarcoma/LMS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
9935787|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
9995870|NCT01494480|Experimental|stem cell transplantation|After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
9917968|NCT00789646|Experimental|NSS/Lidocaine|First injection: Normal saline Second injection: 2% Lidocaine without adrenaline
9917969|NCT00789646|Experimental|Lidocaine/NSS|First injection: 2% Lidocaine without adrenaline Second injection: Normal saline
9917970|NCT00789659|Experimental|VAC dressing|The patients whose postoperative wound will be dressed with a negative pressure (V.A.C.) dressing.
9917971|NCT00789711||A|
9917972|NCT00789711||B|
9917973|NCT00789763|Experimental|Sorafenib + gemcitabine + radiotherapy|
9917974|NCT00789789||1|
9917975|NCT00789841||Patients with NET and diarrhea.|
9917976|NCT00789893||Women with cervical, endometrial, rectal or anal cancer|Women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal cancer who will receive external beam pelvic radiation or brachytherapy
9917977|NCT00789906||1|350 healthy women , aged from 18 to 89
9917978|NCT00789906||2|350 healthy men, aged from 18 to 89
9917979|NCT00789919|No Intervention|1|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital for standard inpatient management of their disease.
9917980|NCT00789919|Experimental|2|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital and their infant is delivered as soon as possible after 34 weeks gestation. As there is no determined optimal time of delivery in these patients, delivery is the intervention.
9917981|NCT00789932|Experimental|CBT|
9917982|NCT00789932|Active Comparator|Usual Care|
9917983|NCT00789945|Placebo Comparator|Study Arm A|Study Arm A will be the primary control arm.
9917984|NCT00789945|Experimental|Study Arm B|Study Arm B will serve as the intervention arm.
9917985|NCT00790049|Experimental|ARRY-371797|
9917986|NCT00790049|Placebo Comparator|Placebo|
9917987|NCT00790101|Experimental|1|Risedronate 35mg once a week
9917988|NCT00790101|Active Comparator|2|Raloxifene 60mg daily
9917989|NCT00790101|Placebo Comparator|3|
9917990|NCT00790114|Experimental|1|
9917991|NCT00790140|Active Comparator|Immunonutrition Prosure|This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
9917992|NCT00790140|Placebo Comparator|Standard enteral nutrition Ensure Plus|This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
9917993|NCT00790153|Active Comparator|1|AZD1656
9917994|NCT00790153|Active Comparator|2|Insulin
9917995|NCT00790166|Active Comparator|CPAP + ThermoSmart™ humidity|
9917996|NCT00790166|Active Comparator|CPAP + Conventional humidity|
9917997|NCT00790166|Active Comparator|CPAP + No added humidity|
9917998|NCT00790179|Active Comparator|PCA;active comparator|Patients with intravenous PCA hydromorphone alone
9917999|NCT00790179|Active Comparator|CFB|Patients with a continuous femoral block (CFB) + PCA hydromorphone
9918000|NCT00790179|Active Comparator|CLPB|Patients with a continuous lumbar plexus block + PCA hydromorphone
9918001|NCT00790231||men|observation of the urinary function with and without thoracic epidural anesthesia
9918002|NCT00790231||women|observation of the urinary function with and without thoracic epidural anesthesia
9918003|NCT00790244|Experimental|Arm 2|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
9918004|NCT00790244|Experimental|Arm 3|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
9918005|NCT00790244|Experimental|Group B|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
9918006|NCT00790244|Experimental|Arm 1|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
9918007|NCT00790257|Experimental|Monolayer Cellular Device|Encapsulated human islets allotransplantation transplanted in subcutaneous tissue in Type 1 diabetes patient
9918008|NCT00790283|Experimental|Numen|
9918009|NCT00790283|Active Comparator|Vision/MiniVision|
9918010|NCT00790309||Weight loss surgery|This group will be comprised of people having weight loss surgery: Roux-en Y gastric bypass, vertical sleeve gastrectomy, or adjustable gastric banding
9918011|NCT00790309||Abdominal surgery|This group will be comprised of people having abdominal surgeries such as nissen fundoplication or cholecystectomy.
9918012|NCT00790309||Lean|This group will be comprised of normal weight healthy volunteers.
9918013|NCT00790322|Experimental|Active|
9918014|NCT00790322|Placebo Comparator|Placebo|
9918015|NCT00790348||1|Patients who on Januvia
9918016|NCT00790348||2|Patients on Janumet (Combination of Januvia and Metformin)
9918017|NCT00790348||3|Patients on Metformin
9918018|NCT00790361||Control|"Controls (healthy volunteers) will have two scans (fMRI, MRS and DTI) six months apart to determine reproducibility.~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
9918019|NCT00790361||CCS Participants|"CCS participants will have three scans (fMRI, MRS and DTI), one acutely (up to 48 hours after injury), one subacutely (15 days after injury), and one late (6 months after injury).~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
9918020|NCT00790374|Experimental|Cohort 1|6 patients have been enrolled, the cohort has been completed.
9918021|NCT00790374|Experimental|Cohort 2|6 patients have been enrolled in cohort 2, the cohort has been completed.
9918022|NCT00790374|Experimental|Cohort 3|5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
9918023|NCT00790387|Experimental|1 High dose tirofiban and enoxaparin|"Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg .~Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours."
9918024|NCT00790387|Active Comparator|2 tirofiban and unfractionated heparin|"Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours.~UFH heparin was administered as a bolus of 70 U/kg and additional heparin was given to maintain the activated clotting time (ACT) at 250"
9918025|NCT00790413|Experimental|High-dose MIBG with haploidentical stem cell transplantation|High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft
9918026|NCT00790439|Experimental|LMW-SD|18 participants randomized to immunosuppression with Low Molecular Weight Sulfated Dextran (LMW-SD)
9918027|NCT00790439|Active Comparator|Control Group, Standard of Care|18 participants randomized to immunosuppression without Low Molecular Weight Sulfated Dextran (LMW-SD)
9918028|NCT00790465|Active Comparator|1|dark chocolate consumption during manometry and 2 weeks treatment with dark chocolate
10213308|NCT04259424|Experimental|Aerobic Exercise + Upper Extremity Rehabilitation|Subjects will receive a total of 18 intervention sessions. In each intervention session, subjects will perform 15 minutes of aerobic exercise on a stationary cycle followed by 200 repetitions of an upper extremity rehabilitation program.
9995871|NCT01494493|Experimental|rhBMP-2/ACS|
9918029|NCT00790465|Other|2|placebo comparator: 7 grams of placebo-chocolate at day 1 during manometry, and than crossover to treatment with dark chocolate for 2 weeks.
9918030|NCT00790491|Experimental|Lifestyle counseling|
9918031|NCT00790504||1 study group|Women with multiple gestations recruited from the prenatal care or high risk pregnancy units
9918032|NCT00790504||2 control group|Women with singleton gestation recruited from the prenatal care or high risk pregnancy units
9918033|NCT00790517|Experimental|1|Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
9918034|NCT00790517|No Intervention|2|Usual care
9918035|NCT00790530|Experimental|ATO-SR|Automated Telephone Outreach with Speech Recognition
9918036|NCT00790530|No Intervention|Usual Care|Usual Care
9918037|NCT00790595|Experimental|Group A|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
9918038|NCT00790595|Experimental|Group B|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
9918039|NCT00790595|Experimental|Group C|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
9918040|NCT00790595|Experimental|Group D|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
9918041|NCT00790595|Experimental|Group E|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
9918042|NCT00790634||Parkinson's Disease|Patients with idiopathic Parkinson's disease
9918043|NCT00790634||Obsessive-compulsive disorder|Individuals with a diagnosis of obsessive-compulsive disorder
9918044|NCT00790634||OCD controls|Healthy controls, matched in age and number to obsessive-compulsive group
9918045|NCT00790634||PD controls|Healthy controls, matched in age and number to Parkinson's disease group
9918046|NCT00790686|Experimental|1|Memokath 051
9918047|NCT00790725|Other|PAV|Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
9918048|NCT00790725|Other|PS|Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
9918049|NCT00790764|Placebo Comparator|Placebo|20 individuals will receive placebo.
9918050|NCT00790764|Experimental|MESENDO|"Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the high or low dose treatment groups."
9995872|NCT01494493|Active Comparator|Autogenous Bone|
9918051|NCT00790816|Experimental|Group 1|Study Drug
9918052|NCT00790816|Experimental|Group 2|Study Drug
9918053|NCT00790881|Other|Antiretroviral-naive|Antiretroviral-naive included as control group
9918054|NCT00790881|Active Comparator|Nevirapine-based antiretroviral therapy|Nevirapine-based antiretroviral therapy
9918055|NCT00790894|Active Comparator|1|
9918056|NCT00790894|Experimental|2|
9918057|NCT00790920|Experimental|Desmoteplase|
9918058|NCT00790920|Placebo Comparator|Placebo|
9918059|NCT00790946|Active Comparator|Valsartan|Valsartan 80 to 160mg
9918060|NCT00790946|No Intervention|standard therapy|
9918061|NCT00790959|Experimental|SASA!|
9918062|NCT00790959|Active Comparator|Control|
9918063|NCT00790972|Placebo Comparator|2|Identical-appearing placebo
10213309|NCT04258462|Experimental|Diagnostic (HP 13C pyruvate MRI)|Patients receive HP 13C pyruvate IV and then undergo 13C MRI scan 1-2 minutes post HP 13C pyruvate injection. Patients may receive an optional second HP 13C pyruvate injection and undergo 13C pyruvate MRI scan 15 to 60 minutes following completion of the first scan.
10213310|NCT04258137|Experimental|Experimental procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
10213311|NCT04258137|No Intervention|Standard procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managedby initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
9918064|NCT00790972|Active Comparator|1|two sprays in each nostril three times daily for one week
9918065|NCT00790985|Experimental|flavocoxid 500 mg|flavonoid mixture
9918066|NCT00790985|Active Comparator|naproxen|nonsteroidal anti-inflammatory drug
9918067|NCT00790998|Experimental|Moxidectin|Moxidectin 8mg
9918068|NCT00790998|Active Comparator|Ivermectin|Ivermectin 150 mcg/kg
9918069|NCT00791011|Experimental|Cohort 4|AMG 655 (intermediate dose) with Vorinostat
9918070|NCT00791011|Experimental|Cohort 1|AMG 655 (low dose) with Bortezomib
9995873|NCT01494519|Active Comparator|Treament Arm 1|Definitive fixation with an external ring fixator.
9995874|NCT01494519|Active Comparator|Treatment arm 2|Definitive fixation with a locked IM nail or plate
9995875|NCT01494558|Active Comparator|PE concurrent chemotherapy|Radiotherapy concurrently with PE chemotherapy
9995876|NCT01494558|Active Comparator|PC concurrent chemotherapy|Radiotherapy concurrently with PC chemotherapy
9995877|NCT01494571||90 pediatric, 7 to 14 year old subjects|
9995878|NCT01494571||30 pediatric, 5 to 6 year old subjects|
9995879|NCT01494571||30 pediatric, 3 to 4 year old subjects|
9995880|NCT01494571||30 pediatric, 1 to 2 year old subjects|
9995881|NCT01494571||30 pediatric, 6 to 12 month old subjects|
9995882|NCT01494571||30 pediatric, 4 to 6 month old subjects|
9995883|NCT01494571||30 pediatric, 2 to 4 month old subjects|
9995884|NCT01494597|Experimental|Isavuconazole and cyclosporine|Isavuconazole three times per day (TID) for two days followed by once a day (QD) for 6 days. Cyclosporine single doses on Days 1 and 15.
9995885|NCT01494623|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the RMT. Stimulation will be delivered at either 20 Hz or 10 Hz, depending on the patients' tolerance to the stimulation, with 50 stimulation trains of 30 stimuli each (i.e., 1500 stimuli) and an intertrain interval of 30 sec. 25 trains will be applied to to the left or right hemisphere followed by the other hemisphere.
9995886|NCT01494623|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
9995887|NCT01494636|Experimental|GSK2339345 (solution) (part A)|Part A
9995888|NCT01494636|Experimental|GSK2339345/ Placebo/ Lidocaine (nebulised) (part B)|Part B
9995889|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554|Participants will receive a single, low dose of 100 milligrams (mg) RO5509554 in 7-day PK run-in period (Cycle 0), followed by dose escalation from Day 1 of Cycle 1. RO5509554 will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%). The doses will be escalated further until MTD/OBD as single agent is reached.
9995890|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554 + Paclitaxel|RO5509554 will be administered in combination with a fixed dose of weekly (QW) paclitaxel (80 milligrams per square meter [mg/m^2]). The starting dose for RO5509554 in combination with paclitaxel will be 2 dose levels below to that of the highest dose of monotherapy RO5509554. Escalation of RO5509554 in combination with QW paclitaxel will start in a standard 3 + 3 design until MTD/OBD as combination dose is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of paclitaxel and lower dose of RO5509554. If insufficient safety, pharmacokinetic or pharmacodynamic data have been collected at the MTD/OBD, up to an additional 4 participants may be enrolled at that dose level.
9995891|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554|Participants will receive RO5509554 1000 mg Q2W, Q3W or initial biweekly followed by monthly maintenance.
9995892|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554 + Paclitaxel|Participants will receive RO5509554 1000 mg Q2W in combination with a fixed dose of QW paclitaxel (80 mg/m^2).
9995893|NCT01494701|Experimental|Cohort 1 (n=6)|
9995894|NCT01494701|Experimental|Cohort 2 (n=6)|
9995895|NCT01494701|Experimental|Cohort 3 (n=6)|
9995896|NCT01494701|Experimental|Cohort 4 (n=10)|
9995897|NCT01494714|Experimental|Closed-patch test|
9995898|NCT01494727|Experimental|CJ Amlodipine/Valsartan 10/160mg|
9995899|NCT01494727|Active Comparator|Novartis Exforge 10/160mg|
9918071|NCT00791011|Experimental|Cohort 2|AMG 655 (low dose) with vorinostat
9918072|NCT00791011|Experimental|Cohort 5|AMG 655 (high dose) with Bortezomib
9918073|NCT00791011|Experimental|Cohort 6|AMG 655 (high dose) with Vorinostat
9918074|NCT00791011|Experimental|Cohort 7|Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib
9918075|NCT00791011|Experimental|Cohort 3|AMG 655 (intermediate dose) with Bortezomib
9918076|NCT00791024|Experimental|single arm|
9918077|NCT00791050|Experimental|1 Thermo|
9918078|NCT00791050|No Intervention|2 Control|
9918079|NCT00791063|Experimental|18F ML-10|Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
9918080|NCT00791115|Experimental|prostatectomy after radiotherapy|
9918081|NCT00791141|Experimental|Cetuximab|Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
9918082|NCT00791206|Experimental|1|
9918083|NCT00791206|Other|2|
9918084|NCT00791245||1|DeNovo NT
9918085|NCT00791271|Experimental|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
9918086|NCT00791297|Active Comparator|1|Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
9918087|NCT00791297|Active Comparator|2|Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
9918088|NCT00791310|Experimental|TEP|Performance of of TEP coupled to scanner X
9918089|NCT00791362|Other|improvement programme CVD|
9918090|NCT00791362|Other|improvement programme other conditions|
9918091|NCT00791375|Experimental|Physical Activity Intervention|Participants in this arm will be given access to a website designed to help them increase their levels of physical activity
9918092|NCT00791375|Placebo Comparator|Cancer Website Control Group|Participants in this arm will be given information on cancer-related websites (that do not provide information on physical activity)
9667421|NCT03600844|Active Comparator|Phase 1 Comparison/Phase 2 Intervention|During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.
9918093|NCT00791427||AMD Patients|
9918094|NCT00791440|Experimental|1|Up to 26 sessions (over a 30 week period) of weekly, individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
9918095|NCT00791440|Active Comparator|2|30 weeks of standard psychiatric treatment.
9918096|NCT00791453||I|Established patients at the Clarksdale Diabetes and Metabolism Center
9918097|NCT00791466|Experimental|1|
9918098|NCT00791466|Placebo Comparator|2|
9918099|NCT00791505|Active Comparator|Ciprofloxacin|750 mg a day during 10 days
9918100|NCT00791505|Active Comparator|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
9918101|NCT00791531|Experimental|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
9918102|NCT00791544|Experimental|Dose Level -1|0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
9918103|NCT00791544|Experimental|Dose Level 1|1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
9918104|NCT00791544|Experimental|Dose Level 2|3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
9918105|NCT00791544|Experimental|Dose Level 3|6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
9918106|NCT00791544|Experimental|Dose Level 4|12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
9918107|NCT00791544|Experimental|Dose Level 5|18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
9918108|NCT00791544|Experimental|Combination cohort 1|AVE1642 selected dose in combination with sorafenib
9918109|NCT00791544|Experimental|Combination cohort 2|AVE1642 selected dose in combination with erlotinib
9918110|NCT00791570|Experimental|A|
9918111|NCT00791596|Experimental|1|The first Arm received the intervention between baseline and the first follow-up, whereas the second Arm was the Control group
9918112|NCT00791596|Experimental|2|The second Arm received the intervention between the third and the fourth follow-up, whereas the first Arm was the Control group
9918113|NCT00791635||Observational (questionnaires)|"RETROSPECTIVE PORTION: Patients who have undergone pelvic exenteration complete one set of QOL questionnaires.~PROSPECTIVE PORTION: Patients undergoing pelvic exenteration complete questionnaires over 20-40 minutes within 2 weeks before surgery, and at 4-12 weeks, 6 months, and 1, 2, 3, 4, 5, and 10 years after surgery regarding feelings, abilities, depression, coping, social support, sexual function and body image. Patients with cervical cancer may complete 1 additional questionnaire during each of these visits."
9918114|NCT00791687||PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
9918115|NCT00791687||NON PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
9918116|NCT00791726||1|Patients with noninfectious uveitis and macular edema
9918117|NCT00791739|Experimental|one arm study|
9918118|NCT00791752|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
9918119|NCT00791752|Placebo Comparator|2|Placebo
9918120|NCT00791791|Other|1|increasing remifentanil administration
9918121|NCT00791791|Other|2|decreasing remifentanil concentration
9918122|NCT00791804|Experimental|Single Arm|
9918123|NCT00791830|Active Comparator|Irbesartan|
9918124|NCT00791830|Placebo Comparator|Placebo|
9918125|NCT00791856|Active Comparator|1|28 cm2 testosterone patch
9918126|NCT00791856|Experimental|2|14 cm2 testosterone patch
9934706|NCT04577014|Experimental|Vascular Sarcoma|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
9934707|NCT04577014|Experimental|Other Soft tissue sarcoma/STS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
9934708|NCT04575766|Experimental|Dose escalation study of FT-7051|
9934709|NCT04574583|Experimental|1/Sequential Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN M7824 +CV301
9934710|NCT04574583|Experimental|2/Combination Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN Escalating doses of SX-682 + M7824 + CV301
9934711|NCT04574583|Experimental|3/Disease-Specific Expansion|RP2D of SX-682 + M7824 + CV301
9934712|NCT04573062||Post COVID patients|Individuals whom have previously had COVID -19 infection.
9934713|NCT04569591|Experimental|1|patients aged 8 or older with Cushing's Disease who are surgical candidates for resection of ACTH producing pituitary adenoma within 12 weeks of PET imaging
9934714|NCT04566926|Experimental|Part 1: Cohort 1 (Placebo or JNJ-64140284)|Participants will receive matching placebo in Treatment A or JNJ-64140284 (as formulation 1) in Treatment B or JNJ-64140284 (as formulation 2) in Treatment C on Day 1 under fasted condition. Participants will receive treatment in either of the 6 treatment sequences (ABC, BCA, CAB, CBA, ACB or BAC) in Period 1, 2, or 3 under fasted condition. Each period is separated by washout period of 5 days.
9934715|NCT04566926|Experimental|Part 1: Cohort 2 (Placebo or JNJ-64140284)|Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.
9934716|NCT04566926|Experimental|Part 2: Cohorts 1-7 (JNJ-64140284 or Placebo)|Participants will receive JNJ 64140284 formulation 1 or 2 or matching placebo under fasting condition in Cohorts 1 to 7 on Day 1.
9934717|NCT04566926|Experimental|Part 3: Cohorts 1-2 (JNJ-64140284 or placebo)|Participants will receive JNJ-64140284 formulation 1 or 2 or matching placebo under fed condition in Cohorts 1 to 2 on Day 1.
9934718|NCT04566419|Active Comparator|Control group|Oxygen delivered by Venturi Mask
9934719|NCT04566419|Experimental|HFNC - high flow nasal cannulae|Oxygen delivered by high flow nasal cannula (HFNC) 60 l/min
9934720|NCT04566133|Experimental|1/Arm 1|Trametinib + hydroxychloroquine (HCQ)
9934721|NCT04565067||1|COVID-19 recovered adult patients
9934722|NCT04564287||Patient|Patients with history of Covid-19 infection and persistent neurological symptoms
9934723|NCT04564274||1|patients with rare and common diseases
9934724|NCT04563702|Experimental|Low Dose VXA-CoV2-1|Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1. A subset will also receive a second dose at Day 29
9934725|NCT04563702|Experimental|High Dose|High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1
9934726|NCT04562129|Experimental|Treatment|HD IL2 (600,000 units/kg/dose IV) will be given during week 1 of the 2 initial cycles or each course. Ipilimumab will be given concurrently at the low dose of 1 mg/kg during week one of the 2 initial cycles of each course for up to 2 doses, total. Nivolumab will be given on during week one of the 3rd cycle of each course. No systemic treatment will be administered during the 4th cycle. Patients without evidence of disease progression (RECIST v.1.1) or limiting toxicities will be offered additional courses of treatment for up to a maximum of 3 courses, total.
9934727|NCT04559620|Experimental|Maternal voice|Mother's voice will be played for 1 week between week 2 and 3 of life
9934728|NCT04559620|No Intervention|Control|NO intervention between week 2 and 3
9934729|NCT04557995|Experimental|Erythropheresis treatment|Erythropheresis treatment was was added to routine treatment
9934730|NCT04557995|No Intervention|Routine treatment|Oxygen delivery and basic care
9934731|NCT04557969||1/ Cohort 1|Patients with histologically confirmed or clinical presentation suspicious of GIST
9918127|NCT00791882|Experimental|1|"Group of behaviors by which someone express feelings, attitudes, wishes,opinions and rights , in an adequate manner regarding situation and context.~Social skills are the substrate for social competence, which is the ability to find and legitimate relevant and personal goals"
9918128|NCT00791882|No Intervention|2|Control group will attend the same number of sessions, but without intervention of the therapists
9918129|NCT00791895|Experimental|A|
9918130|NCT00791960|Active Comparator|Dimenhydrinate|Dimenhydrinate
9918131|NCT00791960|Placebo Comparator|Placebo|Placebo
9918132|NCT00791986|No Intervention|control|The patients in this control group do not conduct any breathing training.
9918133|NCT00791986|Experimental|ULB|The patients conduct controlled slow breathing training using the WPTB device without inspiratory resistance.
9918134|NCT00791986|Experimental|LB|The patients breath in against resistance using WPTB device.
9918135|NCT00792012|Experimental|Glioblastoma Multiforme Patients|Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy
9918136|NCT00792038||1|OCD patients
9918137|NCT00792038||2|Normal Controls
9918138|NCT00792051|Active Comparator|1|Influenza vaccine
9918139|NCT00792051|Placebo Comparator|2|
9918140|NCT00792064||1|Kidney-Tx-recipients
9918141|NCT00792064||2|Liver-Tx-recipients
9918142|NCT00792064||3|Heart-Tx-recipients
9918143|NCT00792064||4|Lung-Tx-recipients
9918144|NCT00792090|Experimental|1|Fermented milk
9918145|NCT00792090|Active Comparator|2|Standard milk
9918146|NCT00792129||Control|Posterior unilateral interbody fusion using an open approach midline incision (TLIF)
9918147|NCT00792129||Experimental|MiLIF procedure with specialized Atavi instrumentation and minimally invasive visualization capabilities
9918148|NCT00792168|Active Comparator|1. Venlafaxine|
9918149|NCT00792168|Placebo Comparator|2. Placebo|
9918150|NCT00792181|Experimental|1|Medical intervention - with benzodiazepines (Midazolam).
9918151|NCT00792181|Experimental|2|Course intervention - a professional development course for caregivers.
9918152|NCT00792181|Experimental|3|Combination of both medical interventions and a professional development course for caregivers.
9918153|NCT00792181|No Intervention|4|No intervention at all = a control group
9918154|NCT00792194|Experimental|training group|supervised training program 3 times a week with coach.
9918155|NCT00792194|No Intervention|group without training|a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
9918156|NCT00792207|Experimental|Intervention|"Intervention Group:~The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data recorded by an activity monitor."
9918157|NCT00792207|Active Comparator|Control|The control group will use an activity monitor and will have access to a website to monitor activity, but will not receive the Virtual Coach program.
9918158|NCT00792220|Experimental|MSU|
9918159|NCT00792220|Active Comparator|OCCM|
9918160|NCT00792233|Experimental|1|Participants taking anti-TNF medications will be monitored for signs of their disease for 6 months. If, after 6 months, their disease has become inactive, they will stop taking anti-TNF medications for up to 8 months. If participants who are no longer taking anti-TNF medications have a disease flare-up, they will begin treatment again.
9918161|NCT00792246|Experimental|graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
9995900|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 7.5 μg|split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
9918162|NCT00792246|Experimental|No graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
9918163|NCT00792285|Experimental|Automated Telephone Outreach|Automated Telephone Outreach with Speech Recognition
9918164|NCT00792285|No Intervention|Usual Care|Usual Care
9918165|NCT00792311|Experimental|Tsui test|Tsui test administration.
9918166|NCT00792324|Active Comparator|Group 1|Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
9918167|NCT00792324|Active Comparator|Group 2|One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
9918168|NCT00792337|Active Comparator|simvastatin|simvastatin in combination with budesonide
9918169|NCT00792337|Placebo Comparator|B1-6-12|Budesonide in combination with B1-6-12
9918170|NCT00792350||Group 1|
9918171|NCT00792376|Experimental|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
9918172|NCT00792376|Active Comparator|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
9918173|NCT00792389|Experimental|1|Patients receiving warmed, humidified gas
9918174|NCT00792389|Active Comparator|2|Patients receiving cool, day gas
9918175|NCT00792402||1 control group|Computerized data collection of outcome measures in usual care
9918176|NCT00792402||2 intervention group|Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.
9918177|NCT00792415||1|Limited continuous opioid exposure (at least 120 and less than 156 hours)
9918178|NCT00792415||2|Extended continuous opioid exposure (156 hours or more)
9918179|NCT00792441|No Intervention|intervention group|Patients with mechanical ventilated who met the criteria for weaning from medical doctor in Srinagarind hospital, Khon Kaen University
9918180|NCT00792454|Experimental|exercise training/renal rehabilitation|Experimental arm will undergo 12 weeks of training in exercise, meditation, and nutrition education.
9918181|NCT00792454|No Intervention|control|Control co-hort will receive usual chronic kidney disease care and no exercise, meditation or dietary education intervention.
9918182|NCT00792480|Experimental|Intensive Counseling Group|
9918183|NCT00792480|No Intervention|Routine care group|"The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics & Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle."
9918184|NCT00792493|Experimental|ORM-12741|
9918185|NCT00792493|Placebo Comparator|Placebo|
9918186|NCT00792519|Experimental|CBT|group cognitive behavioral treatment
9918187|NCT00792519|Active Comparator|HIV support group|group support
9918188|NCT00792532||iMRI|
9918189|NCT00792558|Experimental|Single Arm|
9918190|NCT00792584|Experimental|1|patients treats with etravirine for 6 weeks
9918191|NCT00792584|Experimental|2|patients treats with efavirenz for 6 weeks
9918192|NCT00792597||spine or hip surgery|
9918193|NCT00792649||1|screening colonoscopy with HD+ endoscopes
9918194|NCT00792649||2|screening colonoscopy with standardvideoendoscopes
9918195|NCT00792662|Experimental|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
9918196|NCT00792662|Placebo Comparator|Placebo|Standard inactive pill.
9918197|NCT00792675|Experimental|Exercise|
9918198|NCT00792740|Placebo Comparator|Placebo capsules|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)"
9918199|NCT00792740|Experimental|ITF2357|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)."
9918200|NCT00792753|Experimental|1. DESyne DES|Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System
9918201|NCT00792753|Active Comparator|2. Medtronic Endeavor DES|Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System
9918202|NCT00792753|Experimental|3. DESyne BD DES|Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System
9918203|NCT00792766|Experimental|RAD001|
9918204|NCT00792792||Tissue transfer skin flap|Modulated Imaging Spectroscopy
9918205|NCT00792818|Experimental|curcuma domestica|1,500 mg/day (oral) divided into 3 times for 28 days
9918206|NCT00792818|Active Comparator|Ibuprofen|1,200 mg/day (oral) divided into 3 times for 28 days
9995901|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
9918207|NCT00792844|Experimental|Bio-K capsule|1 capsule of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for duration of antibiotic therapy and 7 days after or until discharge, whichever comes first
9918208|NCT00792844|Active Comparator|Bio-K liquid|98 g of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever comes first
9918209|NCT00792844|No Intervention|no Bio-K|No lactobacillus product - standard infection control procedures (i.e. handwashing, etc.)
9918210|NCT00792857|Experimental|CTAP201 Injection at dose a|CTAP201 at dose a
9918211|NCT00792857|Experimental|CTAP201 Injection|CTAP201 at dose b or dose c
9918212|NCT00792857|Active Comparator|Doxercalciferol at dose a|Active at dose a
9918213|NCT00792857|Active Comparator|Doxercalciferol|Active at dose b or dose c
9918214|NCT00792870|Experimental|SURI Enhanced|
9918215|NCT00792870|Active Comparator|SURI Standard|
9918216|NCT00792883||patients ARDS|142 Patients in respiratory failure with a diagnosis of ARDS hospitalized at the ICU.
9918217|NCT00792883||Patients non ARDS|432 patients in respiratory failure from other causes (ARDS being formally excluded), hospitalized at the same ICU.
9918218|NCT00792883||Healthy controls|626 healthy patients undergoing elective surgery at the Pediatric Surgery Department or recruited from the pediatric ambulatory.
9918219|NCT00792896|Experimental|1|Family conference + education materials
9918220|NCT00792896|No Intervention|2|education materials
9918221|NCT00792961|Experimental|Endomicroscopy|Endomicroscopy is performed in addition to the patient's indicated robot-assisted prostate surgery
9918222|NCT00792974||COPD by GOLD-criteria III and IV|
9918223|NCT00793000|Experimental|Cohort 1|
9918224|NCT00793000|Experimental|Cohort 2|
9918225|NCT00793000|Experimental|Cohort 3|
9918226|NCT00793000|Experimental|Cohort 4|
9918227|NCT00793000|Experimental|Cohort 5|
9918228|NCT00793000|Experimental|Cohort 6|
9918229|NCT00793000|Experimental|Cohort 7|
9918230|NCT00793000|Experimental|Cohort 8|Japanese volunteers, low dose previously tested (based on PK)
9918231|NCT00793000|Experimental|Cohort 9|Japanese volunteers, intermediate dose previously tested (based on PK)
9918232|NCT00793000|Experimental|Cohort 10|Japanese volunteers, high dose previously tested (based on safety)
9918233|NCT00793013|Experimental|ARDS Net Low Tidal Volume|
9918234|NCT00793013|Experimental|APRV Ventilation|
9918235|NCT00793026|Experimental|1|Dermacyd Breeze Pocket BR (Lactic Acid)
9918236|NCT00793052|Experimental|A|
9918237|NCT00793065||1|Physicians that are using paper-based medical charts and who are not receiving Medical Home redesign incentives.
9918238|NCT00793065||2|Physicians that are using Electronic Health Records (EHRs) and who are not undergoing Medical Home redesign.
9918239|NCT00793065||3|Physicians that are using Electronic Health Records (EHRs) and undergoing Medical Home redesign.
9918240|NCT00793091|Active Comparator|1|
9918241|NCT00793091|Placebo Comparator|2|
9918242|NCT00793117|Experimental|1|poly vinil chloride packing
9918243|NCT00793130|Other|Coltect|Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
9918244|NCT00793143||Sleeve|
9918245|NCT00793143||Bypass|
9918246|NCT00793156|Placebo Comparator|Placebo|Patients will be randomized into Placebo group
9918247|NCT00793156|Active Comparator|2|2.5 µg group randomized
9918248|NCT00793156|Active Comparator|3|5.0 µg group randomized
9918249|NCT00793195|Active Comparator|1) Intralipid|Fat Emulsions for Intravenous Nutrition
9918250|NCT00793195|Experimental|2) SMOFlipid|Fat Emulsions for Intravenous Nutrition
9918251|NCT00793208|Experimental|Vaccine|vaccine composed of lethally irradiated semi-allogeneic human fibroblasts transfected with genomic tumor DNA from the patient's own tumor
9918252|NCT00793221|Other|Sirolimus-eluting stent|Implantation of sirolimus-eluting coronary stent
9918253|NCT00793221|Active Comparator|Everolimus-eluting stent|Implantation of everolimus-eluting coronary stent
9918254|NCT00793234|Experimental|1|0.3 mg/kg TB-402
9918255|NCT00793234|Experimental|2|0.6 mg/kg TB-402
9918256|NCT00793234|Experimental|3|1.2 mg/kg TB-402
9918257|NCT00793234|Active Comparator|4|
9918258|NCT00793260|Active Comparator|Usual Support Group|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
9995902|NCT01494740|Placebo Comparator|split-virion, non-adjuvanted vaccine of seasonal influenza|split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.
9995903|NCT01494766|Other|Tyrosine|"Dietary Supplement: L-Tyrosine~Other Names:~NOW Brand L-Tyrosine 750 mg Tablets~-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study."
9995904|NCT01494779|Experimental|Somatropin Test|Somatropin of Blausiegel Indústria e Comércio Ltda.
9995905|NCT01494779|Active Comparator|Saizen|Somatropin of Merck Serono
9995906|NCT01494805|Experimental|Low Dose rAAV.sFlt-1|
9995907|NCT01494805|Experimental|High Dose rAAV.sFlt-1|
9995908|NCT01494805|Active Comparator|Control - ranibizumab only|
9995909|NCT01494831|Experimental|TF-CBT|
9995910|NCT01494831|No Intervention|Waiting List control|
9995911|NCT01494844|Other|Device interface comfort assessment|Single group rates one noninvasive respiratory monitoring interface and then another.
9995912|NCT01494857|Experimental|Adalimumab|Adalimumab 40 mg
9995913|NCT01494883|No Intervention|Treatment as usual|
9995914|NCT01494883|Experimental|Mindfulnes Based Stress Reduction|A weekly training of eight session lasting two and a half hours.
9995915|NCT01494909|Experimental|Ensure plus|Ensure sip feeds during 6 hours. After 2 hours pancreatic intake
9995916|NCT01494935|Experimental|Normal glycemic diet|COntrol diet with fat and glycemic index similar to typical American diet.
9995917|NCT01494935|Experimental|High-fat, high-glycemic diet|High-fat, high-glycemic diet
9995918|NCT01494948|Placebo Comparator|placebo|skin test negative
9995919|NCT01494948|Active Comparator|allergic|Skin test positive
9995920|NCT01494961|Experimental|Couple-oriented post-test HIV counseling|Women received couple-oriented post-test HIV counseling
9995921|NCT01494961|No Intervention|Standard post-test HIV counseling|Women received post-test HIV counseling as per standard site protocol
9995922|NCT01494974|Active Comparator|FP7 implant|
9995923|NCT01494974|Active Comparator|FP8 implant|
9995924|NCT01495026|Experimental|Fixed dose combination product|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg
9995925|NCT01495026|Experimental|Dutasteride|Commercial formulation of Dutasteride 0.5mg
9995926|NCT01495026|Experimental|Harnal-D Tablets|Commercial formulation of Harna--D Tablets comprising 0.2mg Tamsulosin Hydrochloride
9995927|NCT01495039|Active Comparator|Nystatin|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
9995928|NCT01495039|Placebo Comparator|Control|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.
9995929|NCT01495052|No Intervention|Usual care group|The usual care group was used as control group and didn't receive any intervention except standard health advice at the beginning and the end of the study.
9995930|NCT01495052|No Intervention|diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention.
9995931|NCT01495052|Experimental|50g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
9995932|NCT01495052|Experimental|100g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
9918259|NCT00793260|Experimental|Enhanced Support Group|The Enhanced-Support Group intervention used more sophisticated predictive models, more extensive outreach to engage individuals, and provided tighter feedback loops to inform the care support process.
9918260|NCT00793273||A|
9918261|NCT00793286|Other|A|Mesh fixation by staples
9918262|NCT00793286|Other|B|Mesh fixation by glue
9918263|NCT00793299|Experimental|Video Illness Narrative|single arm pilot study
9918264|NCT00793338|Experimental|Sildenafil|All patients will receive open-label treatment with sildenafil.
9918265|NCT00793364|Active Comparator|Stanol ester|Stanol-ester administration group
9918266|NCT00793364|Placebo Comparator|Placebo spread|Placebo spread group
9918267|NCT00793364|Other|Mediterranean diet group|Mediterranean diet group
9918268|NCT00793377|Experimental|ADOC x 4 + Tam 20|Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
9918269|NCT00793377|Experimental|AC x 4 - Doc x 4 + Tam 20|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy
9918270|NCT00793390||inflammatory breast cancer cases|inflammatory breast cancer cases
9918271|NCT00793390||non-inflammotory breast cancer cases|non-inflammatory breast cancer cases
9918272|NCT00793390||visitor controls without cancer|visitor controls without breast cancer- those visiting cancer patients
9918273|NCT00793416|Experimental|ShuntCheck measure|All patients will have ShuntCheck measurements along with radionuclide shunt patency testing.
9918274|NCT00793442||Novel Endothelial Markers Derivation|"Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants.~From the ProCESS subjects, the researchers will include those who were: 1) recruited by participating centers who participated in other components of this ancillary study or 2) who were sequentially enrolled from periods derived from the beginning, middle, and end of the ProCESS study."
9918275|NCT00793442||Novel Endothelial Marker Validation|Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants; the researchers will recruit a sequential 300 patient validation set.
9918276|NCT00793468|Placebo Comparator|Placebo Arm|Subjects in placebo arm will be taking placebo once daily for 12 weeks from week 5 to 16.
9918277|NCT00793468|Experimental|GSK598809 Arm|Subjects in GSK598809 arm will be taking GSK598809 once daily for 12 weeks from weeks 5 to 16.
9918278|NCT00793481||Diagnostic tool|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
9918279|NCT00793494|Experimental|Probaclac|Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
9918280|NCT00793494|Placebo Comparator|Placebo|
9918281|NCT00793507|Experimental|1: Intervention Group|All participants in the intervention group will be receiving standard preventive dental care received by children in their dental providers' office. These intervention children will receive dental scaling, cleaning and fluoride varnish at visits every three to six months. All participants in the intervention group will receive active reminder/recall from the hygienist, encouraging the participants to return every three to six months for the oral exam, cleaning, scaling and fluoride application.
9918282|NCT00793507|Active Comparator|2: Control Group|The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist.
9918283|NCT00793559|Active Comparator|terlipressin bolus|1 mg of terlipressin received one time only
9918284|NCT00793559|Experimental|terlipressin drip|
9918285|NCT00793637||Surgical|Patients with proximal and/or distal tibial, femoral and/or humeral fractures treated with intramedullary nails and the Angular Stable Locking System(ASLS)
9918286|NCT00793663|Experimental|1|The effect of xenon as an anaesthetic on the depth of hypnosis.
9918287|NCT00793663|Active Comparator|2|The effect of sevoflurane as an anesthetic on the depth of hypnosis
9918288|NCT00793663|Experimental|3|Dexamethasone as prevention of postoperative nausea and vomiting after xenon or sevoflurane anesthesia
9918289|NCT00793663|Placebo Comparator|4|
9918290|NCT00793663|Experimental|5|Ondansetron, to determine the onset-time of ondansetron when used as rescue medication for postoperative nausea and vomiting
9918291|NCT00793663|Placebo Comparator|6|
9918292|NCT00793676|Other|A= Asthma|
9918293|NCT00793676|Other|B= COPD|
9918294|NCT00793676|Other|C= Control|
9918295|NCT00793689||total thyroidectomy|patients undergoing total thyroidectomy
9918296|NCT00793702|Experimental|A|two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)
9918297|NCT00793702|Experimental|B|two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)
9918298|NCT00793702|Experimental|C|two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)
9918299|NCT00793702|Experimental|D|two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)
9918300|NCT00793702|Experimental|E|one injection 1.0 µg rdESAT-6 + rCFP-10
9918301|NCT00793715|Active Comparator|1|Decompressive laparotomy with temporary abdominal closure
9918302|NCT00793715|Active Comparator|2|Patients who will receive percutaneous puncture with placement of abdominal catheter
9918303|NCT00793728|Active Comparator|Antrectomy|
9918304|NCT00793728|Active Comparator|Without antrectomy|
9918305|NCT00793741||1|Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate
9918306|NCT00793741||2|Healthy control subjects
9918307|NCT00793754|No Intervention|1|
9918308|NCT00793754|Experimental|2|Aspirin 100 mg / day
9918309|NCT00793754|Experimental|3|Atorvastatin 40 mg / day
9918310|NCT00793754|Experimental|4|Aspirin 100 mg / day + Atorvastatin 40 mg / day
9918311|NCT00793767|Placebo Comparator|placebo|placebo
9918312|NCT00793767|Experimental|Erythropoietin|acute administration of erythropoietin
9934732|NCT04557176|Experimental|POC CRP-based TB screening|Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.
9934733|NCT04557176|No Intervention|Symptom-based TB screening|Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
9934734|NCT04557059|Active Comparator|Interventional Cohort (Group 1): RT+ LHRHa|Participants who are PSMA-PET-positive will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization.
9934735|NCT04557059|Experimental|Interventional Cohort (Group 2): RT+LHRHa + Apalutamide|Participants who are PSMA-PET-positive receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization. Participants will also receive 240 milligram (mg) of apalutamide starting within 3 days after randomization as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days.
9934736|NCT04557059|No Intervention|Observational Cohort(Group3) PSMA-PET Negative Participants|Participants who are PSMA-PET-negative at screening, will be enrolled in the Observational Cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year.
9934737|NCT04553913|Experimental|cooling device placed|A basic medical grade cooling pad will be secured to the non operative leg. Intermittent coolness will be assessed and subject will inform recovery room staff when sensation returns.
9934738|NCT04553913|No Intervention|standard of care no intervention|Subjects in intervention arm will serve as their own control; standard nursing pinprick testing on the same (non-operative) thigh
9934739|NCT04545736|Experimental|Metformin|Oral administration of metformin
9934740|NCT04544293|Experimental|Molgramostim|Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
9934741|NCT04544293|Placebo Comparator|Placebo|Double-blind treatment with placebo nebulizer solution once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
9934742|NCT04543903|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
9934743|NCT04541030||GPS Cohort 1|Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason <= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy
9934744|NCT04538378|Experimental|1/Arm 1|Combination of durvalumab and olaparib
9934745|NCT04535414|Experimental|1/ Arm 1|Bethesda protocol (investigational)
9934746|NCT04535414|Active Comparator|2/ Arm 2|Cambridge method (control) with confocal endomicroscopy
9934747|NCT04534023|Experimental|trial group|
9934748|NCT04534023|Placebo Comparator|control group|
9995933|NCT01495065|Experimental|Part A|Japanese subjects in cohort 1 and 2 will receive treatments A, B and C. Caucasian subjects in cohort 3 will receive treatment B and C.
9995934|NCT01495065|Experimental|Part B|Subjects in cohort 4 and 5 will receive repeat doses of IV GSK2251052 for 10 days.
9995935|NCT01495078|Experimental|Telemonitoring|Patients with follow-up telemonitoring
9995936|NCT01495078|No Intervention|Non - telemonitoring|Patients with usual face follow-up
9995937|NCT01495104|Experimental|Single Arm|
9995938|NCT01495117|Active Comparator|Povidone Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
9995939|NCT01495117|Active Comparator|Chlorhexidine Gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
9995940|NCT01495130|Experimental|Diagnostic (TRUS)|Patients undergo TRUS during RALP.
9995941|NCT01495143|Active Comparator|Healthy group|Eight healthy volunteers (five males and three females) with a body mass index of 23.8 and without chronic metabolic disease or low back pain. They are all non-smokers and non-medicated.
9995942|NCT01495143|Experimental|Surgery group|"Two MD catheters is placed in the paraspinal muscle at the level of midpoint of incision bilaterally.~A reference catheter is placed in the deltoid muscle."
9995943|NCT01495156|Experimental|Lithium/Adjunctive SGA|
9995944|NCT01495156|Placebo Comparator|Placebo/Adjunctive SGA|
9995945|NCT01495169|Experimental|Iloperidone|Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks
9995946|NCT01495182|Experimental|Dietary Fiber - Dose 1|Dietary fiber will be added to study foods
9995947|NCT01495182|Experimental|Dietary Fiber - Dose 2|Dietary fiber will be added to study foods
9995948|NCT01495182|Active Comparator|Control|Study foods with no added fiber will be given
9995949|NCT01495195|Experimental|Donepezil, high-dose|Titration of donepezil to 22.5 mg daily
9995950|NCT01495195|Experimental|Selegiline & low-dose donepezil|Low-Dose Donepezil [titrated to 10 mg daily] and transdermal selegiline [6 mg daily]
9995951|NCT01495195|Experimental|Selegiline & high-dose donepezil|High-Dose Donepezil [titrated to 22.5 mg daily] and transdermal selegiline [6 mg daily]
9995952|NCT01495195|Placebo Comparator|Sugar pill|Inert pill for comparison
9995953|NCT01495208|Experimental|aflibercept|
9995954|NCT01495234|Experimental|Cohort 1|Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
9995955|NCT01495234|Experimental|Cohort 2|Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
9995956|NCT01495260|Experimental|N-acetylcysteine, lipoic acid and vitamin E|Two Dose titration design
9995957|NCT01495273|Experimental|Nerve stimulator|Experimental group; will undergo transtracheal injection with needle connected to nerve stimulator.
9995958|NCT01495273|Active Comparator|Standard needle/syringe|Control group; will undergo transtracheal injection with standard needle/syringe assembly.
9995959|NCT01495299||cataract patients with glaucoma|
9995960|NCT01495312|Experimental|SLT|
9995961|NCT01495325|Sham Comparator|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
9995962|NCT01495325|Active Comparator|Woodsmoke Exposure|1 hour exposure to dilute woodsmoke at a concentration of 1000µg/m3 during intermittent exercise
9995963|NCT01495338|Experimental|AC-170 0.17%|
9995964|NCT01495338|Experimental|AC-170 0.24% (Formulation 1)|
9995965|NCT01495338|Experimental|AC-170 0.24% (Formulation 2)|
9995966|NCT01495338|Placebo Comparator|Olopatadine hydrochloride 0.2%/Tears Naturale II|
9995967|NCT01495351|Experimental|ABT-888/Bortezomib|Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
9995968|NCT01495364|Experimental|NBS10|active treatment - CD34+ cells
9995969|NCT01495364|Placebo Comparator|placebo|matching placebo
9995970|NCT01495377|Active Comparator|Remifentanil|
9995971|NCT01495377|Placebo Comparator|Placebo|
9995972|NCT01495377|Experimental|Technetium|
9995973|NCT01495377|Experimental|Dynamometer|
9995974|NCT01495403|Experimental|hydroxychloroquine|
9995975|NCT01495429|Experimental|PICC line (Peripherally)|placement of a picc line
9995976|NCT01495429|Active Comparator|CICVC (central insertion)|placement of a centrally inserted central venous catheter
9995977|NCT01495442|Active Comparator|modified Handihaler DPI|
9995978|NCT01495442|Placebo Comparator|standard Handihaler DPI|
9995979|NCT01495455||Knee osteoarthritis|
9995980|NCT01495455||No knee pain/osteoarthritis|
9995981|NCT01495494|Active Comparator|Marketed nasal strip|Marketed nasal strip
9995982|NCT01495494|Experimental|Prototype nasal dilator|Prototype nasal dilator
9995983|NCT01495507||Patellofemoral Instability|Patients with diagnosis of patellofemoral instability receiving MPFL-reconstruction as part of the clinical routine
9918313|NCT00793806||Medical Tool|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
9918314|NCT00793832|Active Comparator|1|Supervised exercise.
9918315|NCT00793832|Active Comparator|2|Diet Advice
9918316|NCT00793845|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (total body irradiation, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
9918317|NCT00793858|Active Comparator|1|placebo in left nostril, isotonic ciclesonide in right
9918318|NCT00793858|Active Comparator|2|hypotonic ciclesonide in left nostril, placebo in right
9918319|NCT00793858|Active Comparator|3|hypotonic ciclesonide in right and left nostrils
9918320|NCT00793858|Active Comparator|4|isotonic ciclesonide in both right and left nostrils
9918321|NCT00793858|Placebo Comparator|6|placebo in both right and left nostrils
9918322|NCT00793858|Active Comparator|5|isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
9918323|NCT00793884||Diabetes Education|Latino individuals with diabetes who are attending the Emory Latino Diabetes Education Program (ELDEP) will be followed in order to collect outcomes on clinical measurements. The class curriculum follows the American Association of Diabetes Educators (AADE) seven self-care behaviors: healthy eating, being active, monitoring, medication use, problem-solving and healthy coping. Program participants attend an initial 3 hour diabetes education class conducted in Spanish and then are invited to return to monthly follow-up sessions covering topics of meal planning, exercise, medications and complications. The follow-up sessions include activities such as dance lessons, cooking demonstrations, and sharing.
9918324|NCT00793897|Experimental|Sequential allocation of patients in two dosing schedules|
9918325|NCT00793923|Experimental|Combination Therapy|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
9918326|NCT00793923|Active Comparator|Monotherapy|intravitreal injection of 0.5 mg ranibizumab
9918327|NCT00793962|Experimental|hypofractionation radiotherapy|breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
9918328|NCT00793962|Active Comparator|conventional fractionation radiotherapy|breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
9918329|NCT00793975|Experimental|IMC-1121B|"All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.~A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.~When all patients complete a cohort, dose escalation to the next cohort will occur."
9918330|NCT00793988|Active Comparator|1|Group receiving vibration-assisted anaesthesia
9918331|NCT00793988|Placebo Comparator|2|Group receiving switched-off vibrating device
9918332|NCT00794001|Experimental|Data Feedback|The intervention is systematic feedback on performance (using predefined quality indicators) to cardiology, ED, and EMS-stakeholders and staff.
9667448|NCT03571789|Experimental|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
9918333|NCT00794014|Experimental|Conservative strategy|
9918334|NCT00794014|Experimental|Aggressive strategy|
9918335|NCT00794027|Other|Yoga group|Patients with heart failure
9918336|NCT00794053|Experimental|study group|The members in this group will undergo intervention by having surgery and lymph node detection by dye staining
9918337|NCT00794066||1|TIA
9918338|NCT00794066||2|Ischemic stroke
9918339|NCT00794066||3|Hemorrhagic stroke
9918340|NCT00794079|Experimental|A|omega-3 fatty acids
9918341|NCT00794079|Placebo Comparator|B|corn oil
9918342|NCT00794092|Experimental|Sinerem|MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
9918343|NCT00794105||Normal ears|
9918344|NCT00794105||Otitis media ears.|
9918345|NCT00794183|Active Comparator|1|AVD set by taking the larger of 0.50ms or A-V interval 0.30
9918346|NCT00794183|Active Comparator|2|AVD set by taking the larger of 0.50ms or A-V interval 0.50
9918347|NCT00794183|Active Comparator|3|AVD set by taking the larger of 0.50ms or A-V interval 0.70
9918348|NCT00794209|Experimental|1|
9918349|NCT00794222|Experimental|Mood monitoring|The mobiletype monitoring intervention group will monitor their current activities, current mood, responses to negative mood, any recent stressors and coping strategies. Other activities monitored include eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
9918350|NCT00794222|No Intervention|Comparison monitoring program|"The mobiletype monitoring comparison group will monitor their current activities, eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.~This program excludes questions about mood, stress and coping strategies."
9918351|NCT00794235|Other|Sorafenib and Dacarbacine|
9918352|NCT00794261|Experimental|Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
9918353|NCT00794261|Active Comparator|Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
9918354|NCT00794274|Experimental|Open label drug|"Drug: CC-100004~After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis"
9918355|NCT00794287||1|Hymenoptera allergic patients before allergen specific immunotherapy
9918356|NCT00794287||2|Hymenoptera allergic patients after allergen specific immunotherapy
9918357|NCT00794300||Acute myocardial infarction patients|
9918358|NCT00794326|Experimental|PDsol 12|Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
9918359|NCT00794326|Active Comparator|Gambrosol trio 40|Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
9918360|NCT00794391|Experimental|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
9918361|NCT00794391|Active Comparator|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
9918362|NCT00794443|Experimental|1. Monthly - Dose 1|Monthly intermittent administration, dose 1
9918363|NCT00794443|Experimental|2. Monthly - Dose 2|Monthly intermittent administration, dose 2
9918364|NCT00794443|Active Comparator|3. Daily|Daily administration
9918365|NCT00794456|Experimental|1|Association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L.
9918366|NCT00794456|Active Comparator|2|Valeriana officinalis 50 mg
9918367|NCT00794612|Experimental|1|Dermacyd Femina Pocket BR (Lactic Acid)
9918368|NCT00794625|Experimental|1|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
9918369|NCT00794625|Experimental|2|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
9918370|NCT00794625|Placebo Comparator|3|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
9918371|NCT00794651||OA|moderate to severe osteoarthritis of the knee
9918372|NCT00794690|Experimental|black cohosh extract, liver|100 postmenopausal women
9918373|NCT00794703|Experimental|1. Micafungin|
9995984|NCT01495520|Active Comparator|Ranolazine|Patients will receive ranolazine 750 mg bid for 30 days
9995985|NCT01495520|Placebo Comparator|Placebo|Patients will receive placebo for 30 days
9995986|NCT01495533|Placebo Comparator|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
9995987|NCT01495533|Active Comparator|drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
10213312|NCT04258137|Experimental|Experimental procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
9995988|NCT01495546|Experimental|Early loading|
9995989|NCT01495546|Active Comparator|late loading|
9995990|NCT01495624|Placebo Comparator|Ropivacaine with perineural dexamethasone|30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
9995991|NCT01495624|Active Comparator|Ropivacaine with systemic steroid|30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
9995992|NCT01495650|Experimental|Intervention arm|
9995993|NCT01495650|No Intervention|Control arm|Routine practice
9995994|NCT01495663|Other|Single Group|I-131-CLR1404
9995995|NCT01495715|Experimental|Idebenone|
9995996|NCT01495715|Placebo Comparator|Placebo|
9995997|NCT01495728|Experimental|Thrust Manipulation -Thoracic Spine|Mid and Upper Thoracic Spine
9995998|NCT01495728|Placebo Comparator|Sham Manipulation|Mid and Upper Thoracic Spine
9995999|NCT01495754|Experimental|coffee3|
9996000|NCT01495754|Experimental|coffee6|
9996001|NCT01495754|Placebo Comparator|water|
9996002|NCT01495767||females, males|females: patients of female sex males: patients of male sex
9996003|NCT01495780|Experimental|Remote Health Monitoring|Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
9996004|NCT01495806|Experimental|Glucomannan|5 g 2x 10 day
9996005|NCT01495806|Placebo Comparator|Placebo|
9996006|NCT01495832|Experimental|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
9996007|NCT01495832|Active Comparator|Control Group|The control group will consume comparator foods for 12 weeks.
9996008|NCT01495871|Active Comparator|Amino acids|Amino acid supplementation for 6 weeks
9996009|NCT01495871|Placebo Comparator|Placebo|Supplementation of placebo (inert components)for 6 weeks
9996010|NCT01495871|Active Comparator|Valine|Valine supplementation for 6 weeks
9996011|NCT01495884|Experimental|Lapatinib (Tyverb™) and (Myocet™)|
9996012|NCT01495897|Other|Healthy|Healthy volunteers
9996013|NCT01495897|Experimental|Dystonia|patients with Primary Dystonia
9996014|NCT01495897|Experimental|Parkinson|patients with Parkinson's disease
10213313|NCT04258137|No Intervention|Standard procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
10213314|NCT04257474||Assessing Health Services Utilization Model (HSUM)|150 women with a high lifetime breast cancer risk will be recruited from mammography and primary care clinics. Researchers will assess HSUM factors influencing screening breast MRI utilization. Results will identify participant-level HSUM factors significantly associated with screening outcomes.
10213315|NCT04257474||Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi-structured qualitive interviews exploring factors impacting utilization of screening breast MRI
10213316|NCT04256369||Primary Cohort|Starting premixed Olimel N9E and follow for electrolyte irregularities.
10213317|NCT04252144|Experimental|GERD|Patients with verified gastroesophageal reflux disease
10213318|NCT04252144|Other|Contol|Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination
10213319|NCT04246606||ER+/HER2- infiltrating early breast cancer|Patients with ER+/HER2- infiltrating early breast cancer for which EndoPredict molecular signature was performed.
10213320|NCT04240405||Elderly people without cognitive impairment|
10213321|NCT04240405||Amnestic type mild cognitive impairment patients (aMCI)|
10213322|NCT04240405||Dysexecutive type mild cognitive impairment patients (dMCI)|
10213323|NCT04240171||dapagliflozin|Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.
10213324|NCT04240171||glimepiride|Group 2 (n=30): are the patients who are prescribed glimepiride
10213325|NCT04239092|Experimental|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
10213326|NCT04239092|Experimental|9-ING-41 plus Irinotecan|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days (cycle duration is 21 days).
10213327|NCT04239092|Experimental|9-ING-41 plus Irinotecan plus Temozolomide|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days. Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 ((cycle duration is 21 days).
10213328|NCT04239092|Experimental|9-ING-41 plus Cyclophosphamide plus Topotecan|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5. Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5. 9-ING-41 intravenous infusion twice weekly (cycle duration is 21 days).
9996015|NCT01495897|Experimental|Essential tremor|patients with essential tremor with or without deep brain stimulation
9996016|NCT01495910|Experimental|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
9996017|NCT01495936|Active Comparator|Continuous Positive Airway Pressure|"After 20 minutes ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-ventilated lung at a pressure of 5cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
9996018|NCT01495936|Active Comparator|RM + Positive End Expiratory Pressure|"After 20 minutes of ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm RM + Positive End Expiratory pressure which is a Recruitment Maneuver (RM) followed by Positive End Expiratory Pressure (RM-PEEP) which will be applied to the ventilating lung at a pressure of 5cmH2O."
9996019|NCT01495949|Active Comparator|etomidate|
9996020|NCT01495949|Active Comparator|thiopentone|
9996021|NCT01495962|Active Comparator|Botulinum Toxin A injection|
9996022|NCT01495962|Placebo Comparator|Placebo (Normal Saline) injection|
9996023|NCT01496001|Experimental|Cohort|
9996024|NCT01496014||severe open fractures of the tibia bone|
9996025|NCT01496027||term newborns|
9996026|NCT01496027||Preterm Newborns (32-37 GA)|
9996027|NCT01496040|Experimental|rAAV2/4.hRPE65|"3 cohortes of 3 patients each.~All the patients enrolled in the study will receive a single subretinal injection in one eye. The eye, that will be injected, will be the eye with the poorest visual acuity."
9996028|NCT01496053|Active Comparator|AndoSan|AndoSan given to IBD patients
9996029|NCT01496053|Sham Comparator|Sugar extract|Sugar extract to IBD patients
9996030|NCT01496079||Inactivated influenza vaccine in pregnancy|Healthy pregnant women who elect to receive inactivated influenza vaccine in early pregnancy (< 20 weeks gestation) and their infants
9996031|NCT01496079||No inactivated influenza vaccine during pregnancy|Healthy pregnant women who decline inactivated influenza vaccine in pregnancy and their infants
9996032|NCT01496092|Experimental|Keto Acid supplemented with usual protein diet|
9996033|NCT01496092|No Intervention|usual protein diet|
9996034|NCT01496105|Active Comparator|lidocaine spray 10%|
9996035|NCT01496105|Placebo Comparator|Saline|
9996036|NCT01496144|Experimental|Manual therapy and active exercises|Spinal manipulation /mobilisation
9996037|NCT01496144|Placebo Comparator|Detuned ultrasound and active exercises|
9996038|NCT01496170|Experimental|Treatment A: MK-8931 12 mg|Participants receiving 12 mg MK-8931 for 7 days
9996039|NCT01496170|Experimental|Treatment B: MK-8931 40 mg|Participants receiving MK-8931 40 mg for 7 days
9996040|NCT01496170|Placebo Comparator|Treatment C: Placebo matching MK-8931 12 mg or 40 mg|Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
9996041|NCT01496170|Experimental|Treatment D: MK-8931 60 mg|Participant receiving MK-8931 60 mg for 7 days
9996042|NCT01496170|Placebo Comparator|Treatment E: Placebo matching MK-8931 60 mg|Participants receiving placebo matching MK-8931 60 mg for 7 days
9996043|NCT01496196|Active Comparator|tranexamic acid-500 mg/5 ml 3-4 times a day|tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
9996044|NCT01496196|Placebo Comparator|tranexamic|placebo arm
9996045|NCT01496209|Sham Comparator|Placebo control|
9996046|NCT01496209|Experimental|Group: Cardiosphere Treatment|Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)
9996047|NCT01496235|Active Comparator|Dark chocolate|Presence of 70% cocoa solids
9996048|NCT01496235|Placebo Comparator|White chocolate|
9996049|NCT01496261|Active Comparator|Clopidogrel and Aspirin|
9996050|NCT01496261|Experimental|Coprigerl|
9996051|NCT01496300|Sham Comparator|Manual|Manual Implantation of THA
9996052|NCT01496300|Experimental|Navigated|Navigated Implantation of THA
9996053|NCT01496326|Experimental|Ibuprofen|
9996054|NCT01496326|Placebo Comparator|Placebo|
9996055|NCT01496339|Active Comparator|Traditional therapy control|
9996056|NCT01496339|Experimental|Stem cell infusion|
9996057|NCT01496378|Experimental|Problem-Solving Skills Training|In addition to standard medical care, parents in the problem-solving skills training group will receive 8 sessions (1 hour each) of individual problem-solving therapy over 8 weeks. Caregivers will be asked to complete the first training session and at least 3 subsequent sessions in person at their local treatment facility (Seattle Children's Hospital or Oregon Health and Science University). Remaining sessions will be completed via telephone.
9996058|NCT01496378|No Intervention|Standard Care|Parents and children in the Standard Care group will continue with the care that has been prescribed for their child's pain problem by their treating physician, which may include medications, physical therapy, and mental health intervention.
9996059|NCT01496391||Healthy Participants|eGFR ≥60 ml/min/1.73m^2, healthy prospective kidney donor
9918374|NCT00794703|Active Comparator|2. Itraconazole|
9918375|NCT00794716|Experimental|NRL972|
9918376|NCT00794742||Burn Wounds|Patients with burn wounds
9918377|NCT00794755|Active Comparator|Vitamin K|
9918378|NCT00794755|Placebo Comparator|Placebo|
9918379|NCT00794781|Experimental|1|
9918380|NCT00794807|Experimental|Alefacept|
9918381|NCT00794872||1|Patients with stage 3 CKD
9918382|NCT00794872||2|Patients with stage 4 CKD
9918383|NCT00794872||3|Patients without evidence for CDK
9918384|NCT00794885|Experimental|Enalapril/folic acid|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
9918385|NCT00794885|Active Comparator|Enalapril|Enalapril maleate 10 mg per day is given
9918386|NCT00794898|Experimental|Arm 1|Remicade in the treatment of patients with active RA despite treatment with MTX.
9918387|NCT00794911|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
9918388|NCT00794911|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
9918389|NCT00794911|No Intervention|Standard Care|
9918390|NCT00794976|Experimental|1|Dexamethasone Iontophoretic Patch (low dose)
9918391|NCT00794976|Experimental|2|Dexamethasone Iontophoretic Patch (high dose)
9918392|NCT00794976|Experimental|3|Dexamethasone Passive Patch
9918393|NCT00794976|Placebo Comparator|4|Placebo Patch
9918394|NCT00794989|Experimental|Arm 1: Intervention|Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.
9918395|NCT00794989|Other|Arm 2: Observational|Patients do not receive ground flaxseed.
9918396|NCT00795015|Active Comparator|leuven|these patients had their IV insulin controlled by using the protocol adapted from van den Berghe et al. University of Leuven, Belgium, NEJM Nov. 2001
9918397|NCT00795015|Active Comparator|glucommander|these subjects had IV insulin controlled by a computer program called the glucommander described by Davidson, P et al Diabetes Care Oct. 2005
9918398|NCT00795028|Active Comparator|1|Standard Care for people after a hip fracture
9918399|NCT00795028|Experimental|2|Standard Care + exercise intervention
9918400|NCT00795041||1|10 women with indication for ART with ICSI or IVF
9918401|NCT00795054||allogeneic stem cell recipients|Pediatric and adult allogeneic stem cell transplant recipients and their care givers.
9918402|NCT00795067||Carotid atherosclerosis group|Patients who undergo carotid ultrasound examination for carotid atherosclerosis screening
9918403|NCT00795080||1|Normal volunteers who do not have malformations in their cerebral spinal fluid (CSF)
9918404|NCT00795080||2|Patients with incidentally discovered Chiari 1 DVS malformation of the cerebral spinal fluid (CSF)
9918405|NCT00795080||3|Patients with known Chiari or any other CVJ malformations undergoing a workup prior to surgery. Research images will be added to the clinically ordered exams ordered at 3 months and 1 year after surgery.
9918406|NCT00795093||1|552 GERD patients, partial responders to PPI treatment
9918407|NCT00795106|Active Comparator|Capsaicin patch|Patches will contain capsaicin 0.1% (500 mcg)
9918408|NCT00795106|Placebo Comparator|Placebo patch|Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing.
9918409|NCT00795119|Experimental|NIRS|Children who undergo NIRS
9918410|NCT00795171|Experimental|Docetaxel + Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
9918411|NCT00795171|Active Comparator|Taxotere|docetaxel 75mg/m2 day1 q 21d x 4 cycles
9918412|NCT00795197||Screening Group|Screening Group
9918413|NCT00795223|Active Comparator|1|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
9918414|NCT00795223|Active Comparator|2|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
9918415|NCT00795223|Active Comparator|3|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
9918416|NCT00795223|Active Comparator|4|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
9918417|NCT00795249|Experimental|smoker|Individuals who have a habit of chronic smoking without any coronary risk factors
9918418|NCT00795249|No Intervention|non-smoker|the age-matched healthy volunteers
9918419|NCT00795262|Placebo Comparator|placebo comparator|Quinapril 40 mg (Accupril)plus placebo will be given for 8 weeks.
9918420|NCT00795262|Active Comparator|Active comparator|Quinapril 40 mg plus Alpha Lipoic Acid (ALA)on vascular effects of patients with diabetes and hypertension
9918421|NCT00795314|Active Comparator|1|Propofol-fentanyl combined anesthesia
9918422|NCT00795314|Experimental|2|Propofol-butorphanol combined anesthesia
9918423|NCT00795327|Experimental|1|single arm study
9918424|NCT00795353||1. Amevive Exposure|Canadian subjects with moderate to severe chronic plaque psoriasis
9918425|NCT00795379|Experimental|IE|Participants will complete an at home four-week, intervention targeting their negative cognitions triggered by physical sensations. The goal of IE is to purposefully induce bodily sensations related to autonomic arousal so that participants can learn that those sensations are not harmful. IE and Cognitive restructuring have been found to be superior to progressive muscle relaxation as a way to avoid aversive autonomic sensations.
9918426|NCT00795379|No Intervention|2|waitlist control
9918427|NCT00795392||1|Patients assessed with ASA physical status scale
9918428|NCT00795392||2|Patients assessed with full-scale psychological factors
9918429|NCT00795405|Sham Comparator|1|No exposure to sporting events
9918430|NCT00795405|Experimental|2|Exposure to sporting events
9918431|NCT00795444|Experimental|Maraviroc|Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc.
9918432|NCT00795457|Experimental|1|Patients must have undergone surgery or biopsy alone ≤16 weeks prior to study entry (no postoperative radiation or chemotherapy).
9918433|NCT00795457|Experimental|2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥6 months prior to enrollment, and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression.
9918434|NCT00795470|No Intervention|No catheter change no antimicrobial|Urinary catheter will not be changed and no antimicrobials will be prescribed
9918435|NCT00795470|Active Comparator|Antimicrobial and catheter change|
9918436|NCT00795470|Active Comparator|Catheter change and NO antimicrobial|
9918437|NCT00795470|Active Comparator|Antimicrobial and NO catheter change|
9918438|NCT00795483|Experimental|1-ANNUAL|1. Zoledronic acid + Lifestyle modifications (experimental)
9918439|NCT00795483|Other|2-CONTROL|2. Lifestyle modifications (control)
9918440|NCT00795483|Experimental|3-BIENNIAL|3. Zoledronic acid + Lifestyle modifications (experimental)
9918441|NCT00795496||AD patients|AD patients who fulfill the inclusion criteria for the study
9918442|NCT00795548|Experimental|5-Azacitidine|5-Azacitidine in addition to standard donor lymphocyte infusions.
9918443|NCT00795561|Experimental|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
9918444|NCT00795561|Active Comparator|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
9918445|NCT00795574|Experimental|infliximab|Double blind placebo cross-over
9918446|NCT00795574|Placebo Comparator|Placebo|Double blind placebo controlled cross-over
9918447|NCT00795587|Active Comparator|mannitol high dose|mannitol 20% 0,8 g/ kg on minutes
9918448|NCT00795587|Active Comparator|mannitol low dose|mannitol 20% 0,4 g/ kg on minutes
9918449|NCT00795613|Experimental|PET pos|Patients With Interim Pet Positive Proceed To Escalated Beacopp Regimen
9918450|NCT00795613|Other|PET negative|Patients With Interim-Pet Negative Continue The Conventional ABVD Regimen
9918451|NCT00795626|Experimental|Lifestyle counseling|"Two groups:~control - conventional care~intervention - systematic education in the reduction of the risk estimate to cardiovascular events"
9918452|NCT00795652|Experimental|Distance Treatment|50% randomized to receive Distance Treatment for postpartum depression
9918453|NCT00795652|No Intervention|Usual Care Services|50% randomized to receive usual care services for postpartum depression
9918454|NCT00795691|Experimental|Low-carbohydrate diet|The low-carbohydrate diet was based on the Atkins weight loss diet. The daily intake goals were to restrict intake of carbohydrate to 20-25 grams for the first 2-week phase. If body weight decreased, the daily goal for carbohydrate was increased by 5 grams. If body weight increased, the daily goal for carbohydrate intake was decreased by 5 grams. The minimum goal for carbohydrate intake was 20 grams per day and the maximum goal was 50 grams per day.
9918455|NCT00795691|Active Comparator|Low-fat diet|The low-fat diet was based on the algorithm used to restrict fat and calorie intake in the Diabetes Prevention Program. The daily goals for fat intake was based on an algorithm to reduce total calorie intake to achieve a one pound weight loss per week with 25% of calories from fat.
9918456|NCT00795730|Placebo Comparator|placebo|
9918457|NCT00795730|Experimental|NSA-789|
9918458|NCT00795756|Experimental|Intrathecal DepoCyte|I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
9918459|NCT00795756|Active Comparator|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
9918460|NCT00795782|Experimental|UniCND|Limited/ipsilateral central lymph node dissection
9996060|NCT01496391||Moderate Renal Function Impairment|eGFR 30-59 ml/minute/1.73m^2
9996061|NCT01496391||Severe Renal Function Impairment|eGFR <30 mL/minute/1.73m^2
9996062|NCT01496404|Experimental|Electrocautery|Epidermis and dermis incised with cutting setting of electrocautery.
9996063|NCT01496404|Active Comparator|Scalpel|Control, incision of epidermis and dermis with scalpel.
9996064|NCT01496417|Experimental|Belatacept therapy|20 Patients receiving belatacept based immunosuppressive protocol for 12 months post-transplantation.
9996065|NCT01496443|Experimental|TAK-875 & Glimepiride QD|TAK-875 50 mg, tablets, orally and glimepiride 2 mg, capsules, orally and glimepiride placebo matching capsules, orally, once daily on dosing days for up to 19 days.
9996066|NCT01496482||Patients without dry eye symptoms|Patients without dry eye symptoms as measured by standard questionnaire.
9996067|NCT01496482||Patients with dry eye symptoms|Patients with dry eye symptoms as measured by standard questionnaire.
9996068|NCT01496495|Experimental|ARRY-614|
9996069|NCT01496508|Experimental|HFOV|A SLE5000 infant ventilator was used as the high-frequency ventilator.HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg.Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min.
9996070|NCT01496508|Experimental|CV|A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to <60/min. The weaning process was initiated when the following parameters were achieved: PIP <18 cmH2O, PEEP <4 cmH2O, and FIO2 <0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
9996071|NCT01496521|Experimental|Aspirin|
9996072|NCT01496521|Experimental|Tea Polyphenols|
9996073|NCT01496521|No Intervention|Control|
9996074|NCT01496534|Active Comparator|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
9996075|NCT01496534|Active Comparator|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
9996076|NCT01496547|Experimental|intensive chemo - RIC preparation|The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
9996077|NCT01496573||Basic science (biomarker analysis)|Archived tumor tissue samples are analyzed for CRKL expression.
9996078|NCT01496638|Experimental|"No side branch treatment group"|Implantation of coronary stent in bifurcation lesion
9996079|NCT01496638|Experimental|"Stenting of main vessel and side branch group"|Implantation of coronary stent in bifurcation lesion
9996080|NCT01496651|Active Comparator|Percutaneous coronary intervention|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
9918461|NCT00795782|Active Comparator|BiCND|Comprehensive/bilateral central lymph node dissection
9918462|NCT00795782|No Intervention|NoCND|No central lymph node dissection
9918463|NCT00795795|Active Comparator|with PGS|IVF cycles with Preimplantation Genetic Screening (PGS)
9918464|NCT00795795|Active Comparator|Without PGS|IVF cycle without Preimplantation Genetic Screening
9918465|NCT00795808|Experimental|BMI > 32|Women with BMI > 32
9918466|NCT00795808|Experimental|BMI </= 32|Women with BMI </= 32
9918467|NCT00795834|Placebo Comparator|Beverage|
9918468|NCT00795834|Active Comparator|High Polyphenol Beverage|
9918469|NCT00795847|Experimental|1. Preminent|Patients with blood pressure self-measurement-proven morning hypertension are treated with Preminent 1T qd for 3 months.
9918470|NCT00795847|Active Comparator|2. High-dose losartan|Patients with blood pressure self-measurement-proven morning hypertension are treated with losartan 100 mg qd for 3 months.
9918471|NCT00795860|Active Comparator|Weight loss - diet only|
9918472|NCT00795860|Experimental|Weight loss plus exercise|
9918473|NCT00795899|Experimental|1|Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression
9918474|NCT00795912|Active Comparator|1|Atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
9918475|NCT00795912|No Intervention|2|Usual medical care of heart failure
9918476|NCT00795925|Experimental|propiverine hydrochloride|
9918477|NCT00795938|Active Comparator|Conventional Oral Tablet With Water|
9918478|NCT00795938|Experimental|Experimental Tablet With Water|
9918479|NCT00795938|Experimental|Experimental Tablet Without Water|
9918480|NCT00795964|Experimental|1|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
9918481|NCT00795964|Active Comparator|2|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
9918482|NCT00795977|Experimental|dendritic cells|
9918483|NCT00796042|Active Comparator|1|Usual Care
9918484|NCT00796042|Experimental|2|Individualized, Community-based, Pressure management and Mobility program:
9918485|NCT00796055|Experimental|1|MEDI-547
9918486|NCT00796094||Evaluation of tissue elasticity|Evaluate the potential importance of tissue elasticity in the assessment soft tissue structures.
9918487|NCT00796133|Active Comparator|1|0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
9918488|NCT00796133|Active Comparator|2|1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
9918489|NCT00796133|Active Comparator|3|1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
9918490|NCT00796159||Olmesartan medoxomil + HCTZ|
9918491|NCT00796172|Experimental|1|Medication adherence system (MAS) plus counseling from doctors
9918492|NCT00796172|Active Comparator|2|Usual care
9918493|NCT00796198|Active Comparator|Xalatan+Cosopt|Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
9918494|NCT00796198|Active Comparator|Xalatan|when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
9918495|NCT00796211|Experimental|1|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
9918496|NCT00796211|Experimental|2|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
9918497|NCT00796211|Active Comparator|3|0.1% nortriptyline HCl topical cream
9918498|NCT00796211|Active Comparator|4|0.005% calcipotriol topical cream
9918499|NCT00796211|Placebo Comparator|5|Vehicle of CRx-197 topical cream (placebo)
9918500|NCT00796237|Experimental|WBV|In their regular physiotherapy sessions, the subjects in the experimental group will receive whole body vibration therapy for a duration of 4 weeks during their stay in the Tung Wah Hospital.
9918501|NCT00796237|Active Comparator|CON|The subjects in this group will not receive whole body vibration therapy.
9918502|NCT00796250|Experimental|Group A|
9918503|NCT00796250|Active Comparator|Group B|
9918504|NCT00796263|Other|HAART|"The proposed HAART regimen consists of:~2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications~Dolutegravir(DTG) 50 mg orally once daily"
9918505|NCT00796341|Experimental|1|
9918506|NCT00796341|No Intervention|2|
9918507|NCT00796354|Active Comparator|NRL920|
9918508|NCT00796354|Placebo Comparator|Placebo|
9918509|NCT00796393|Experimental|2|Subject with active product, not vaccinated against influenza.
9918510|NCT00796393|Placebo Comparator|3|Subject with placebo, vaccinated against influenza.
9918511|NCT00796393|Placebo Comparator|4|Subject with placebo, not vaccinated against influenza.
9918512|NCT00796393|Experimental|1|Subject with active product, vaccinated against influenza
9918513|NCT00796458|Active Comparator|Arm I|Patients continue to receive LHRH-A therapy until disease progression.
9918514|NCT00796458|Experimental|Arm II|Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9918515|NCT00796484|Experimental|1|
9918516|NCT00796497|Experimental|ondansetron|
9918517|NCT00796536|Experimental|1|Participants will undergo 12 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
9918518|NCT00796536|Active Comparator|2|Participants will received 12 weeks of pain education and a pre- and post-intervention MRI brain scan.
9918519|NCT00796575|Experimental|CS-8080|3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
9918520|NCT00796575|Placebo Comparator|placebo|placebo
9918521|NCT00796588|No Intervention|Control group|Patients undergoing liver surgery without the designated intervention
9918522|NCT00796588|Other|RIPC|application of pneumatic tourniquet in patients undergoing liver surgery
9918523|NCT00796601|Experimental|Esreboxetine|
9918524|NCT00796601|Placebo Comparator|Placebo|
9918525|NCT00796679|Experimental|1|paricalcitol
9918526|NCT00796679|Placebo Comparator|2|placebo
9918527|NCT00796692|Experimental|Group 2|Low molecular weight heparin
9918528|NCT00796692|Active Comparator|Group 1|Unfractionated heparin(UFH)
9918529|NCT00796770|Experimental|Dendritic Cell Vaccine|Autologous dendritic cells generated using GM-CSF and interferon alpha, loaded with HIV lipopeptides and activated with lipopolysaccharide
9918530|NCT00796783||1|Patients with presumed Cushing's disease who have failed pituitary surgery and/or radiation and require medical treatment for recurrent or persistent Cushing's syndrome.
9918531|NCT00796796|Experimental|Cohort 1 (Starting Dose)|"Temsirolimus 20 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
9918532|NCT00796796|Experimental|Cohort 2|"Temsirolimus 25 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
9918533|NCT00796809||Biologics|Patients receiving TNF inhibitors or biologic agents
9918534|NCT00796809||DMARD|Patients receiving methotrexate without any biologic
9918535|NCT00796887|Experimental|Niaspan® 500mg|
9918536|NCT00796887|Experimental|Niaspan® 1000mg|
9918537|NCT00796887|Placebo Comparator|Placebo|
9918538|NCT00796900|Experimental|Dantrolene|
9918539|NCT00796900|Placebo Comparator|Placebo|
9918540|NCT00796913|Active Comparator|Stop of medication after remission|"After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:~Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487."
9918541|NCT00796913|No Intervention|Medication for 2 yrs after remission|See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
9918542|NCT00796913|Experimental|Se-yeast 200 Microgr/day + arm A|Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.
9918543|NCT00796939|Active Comparator|Green Light Mask|
9918544|NCT00796939|Placebo Comparator|Red light mask|
9918545|NCT00796952|Active Comparator|Usual Care|"Patient management by the attending Radiation oncologist as usual."
9918546|NCT00796952|Experimental|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their chemo-radiation treatment (up to a maximum of 6 weeks)
9918547|NCT00796952|Sham Comparator|Valchuff|"Standardised sham swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of chemo-radiation treatment."
9918548|NCT00796965|Experimental|1|
9918549|NCT00796965|Placebo Comparator|2|
9918550|NCT00797004||endoscopic sinus procedure candidates|
9918551|NCT00797017||001|
9918552|NCT00797017||002|
9918553|NCT00797017||003|
9918554|NCT00797017||004|
9918555|NCT00797017||005|
9918556|NCT00797017||006|
9918557|NCT00797017||007|
9918558|NCT00797030|Active Comparator|1|Ten HIV-positive-patients with dry eye diagnosis received sodium carboxymethylcellulose 0.5% drops (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) for six months.
9918559|NCT00797030|Other|2|Ten HIV-positive-patients with dry eye received sodium carboximethylcelullose 0.5% (1 drop 4 times per day) during six months
9918560|NCT00797043||Photon/Proton Radiation Therapy|Data consolidation and analysis
9918561|NCT00797056|Experimental|G-CSF|
9918562|NCT00797056|Placebo Comparator|Placebo|
9918563|NCT00797069|Active Comparator|standard nutritional product|Standard nutritional product not specific for diabetes
9918564|NCT00797069|Active Comparator|diabetes specific product|Diabetes specific nutritional product
9918565|NCT00797069|Experimental|Experimental diabetes specific product|Diabetes specific experimental nutritional product
9918566|NCT00797082|Experimental|1|"MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy~Diabetic patients~Coronary insufficiency"
9918567|NCT00797121|Experimental|Preoperative biliary drainage|
9918568|NCT00797121|No Intervention|Controlled group|
9918569|NCT00797134||DR|Diabetic Retinopathy
9918570|NCT00797186|Other|Intensive therapy|There is one arm in this trial. All patients receive the same therapy. The goal is to compare a noninvasive and invasive imaging technique in the same population.
9918571|NCT00797199||1-Treatment Group 1|Women receiving HRT treatment of Premarin.
9918572|NCT00797199||2-Treatment Group 2|Women receiving combination HRT treatment of Premarin + Provera.
9918573|NCT00797199||3- Treatment Group 3|Women receiving combination HRT treatment of Premarin + Prometrium.
9918574|NCT00797199||4- Controls|Women not on HRT or healthy controls.
9918575|NCT00797238||NSCLC stage III|Taiwanese NSCLC patients with stage III
9918576|NCT00797251||Right posterior section group|Patients with tumors in the right posterior section of the liver (segments 6-7)
9918577|NCT00797264|Experimental|A|Ketamine pre and per operative, and morphine postoperative
9918578|NCT00797264|Active Comparator|B|NaCl pre and per operative, and morphine postoperative
9918579|NCT00797264|Experimental|C|Ketamine and morphine postoperative
9918580|NCT00797290||Photon/Proton Radiation Therapy|Photon/Proton Radiation Therapy
9918581|NCT00797303|Experimental|1|A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
9918582|NCT00797329||observation|adult men with alcohol and polydrug use according to DSM-IV criteria, hospitalized in maximum security department between 2002 - 2008
9918583|NCT00797342|Other|first of three dosing cohorts|
9918584|NCT00797342|Other|second of three dosing cohorts|
9918585|NCT00797342|Other|third of three dosing cohorts|
9918586|NCT00797368|Experimental|Manual Therapy and Exercise|Manual Therapy and Exercise
9918587|NCT00797368|Active Comparator|Home Exercise|Home Exercise
9918588|NCT00797381||1|
9918589|NCT00797381||2|
9918590|NCT00797394|Experimental|Treated|
9918591|NCT00797394|Active Comparator|Control|
9918592|NCT00797420|Other|Loading Dose|Loading Dose
9996081|NCT01496651|Active Comparator|Coronary artery bypass graft operation|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
9996082|NCT01496677|Experimental|Elderly subjects (65 or older)|
9800380|NCT01686165|Experimental|Belinostat Yttrium Ibritumomab Tiuxetan|Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
9800381|NCT01686373|Experimental|Activa Dose II Real tDCS|Actual delivery of electrical stimulation
9800382|NCT01686373|Placebo Comparator|Activa Dose II Sham tDCS|Sham delivery of electrical stimulation
9800383|NCT01686438|Experimental|CBT-I delivery by video teleconferencing|Groups of participants will receive a cognitive behavioral therapy for insomnia program delivered by a trained psychologist using video teleconferencing.
9800384|NCT01686438|Active Comparator|In-person CBT-I delivery|Groups of participants will receive a cognitive behavioral therapy for insomnia (CBT-I) program by meeting in-person with a trained psychologist.
9800385|NCT01686451|Experimental|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
9800386|NCT01686451|Active Comparator|Simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
9800387|NCT01686503|Experimental|2/5 dose intradermal IPV|Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
9800388|NCT01686503|Experimental|1/5 dose intradermal IPV|Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
9800389|NCT01686503|Active Comparator|full dose intramuscular IPV|Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
9800390|NCT01686503|Active Comparator|2/5 dose intramuscular IPV|Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
9800391|NCT01686568|Experimental|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
9800392|NCT01686568|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
9800393|NCT01686581||BOTOX®|BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
9800394|NCT01686633|Experimental|Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.
9800395|NCT01686633|Experimental|Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days
9800396|NCT01686633|Experimental|Arm 3: Fluticasone Furoate 100 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days
9800397|NCT01686646|Active Comparator|highest dose Paracetamol + caffeine|highest dose of Paracetamol and caffeine
9800398|NCT01686646|Active Comparator|low-dose Paracetamol + caffeine|lowest dose of Paracetamol and caffeine
9800399|NCT01686646|Active Comparator|high dose paracetamol|highest dose paracetamol
9800400|NCT01686646|Active Comparator|low dose paracetamol|lowest dose paracetamol
9918593|NCT00797420|Other|Loading & high dose|Loading dose & high dose Fluconazole
9918594|NCT00797433||Mechanical ventilation|All male patients with acute respiratory failure requiring mechanical ventilation
9918595|NCT00797446||Photon/Proton Radiation Therapy|Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.
9918596|NCT00797472|Active Comparator|Arm I: R-mabHD|Anti-hodgkin disease agent
9918597|NCT00797472|Active Comparator|Arm II: ABVD|
9918598|NCT00797485|Active Comparator|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9918599|NCT00797485|Experimental|Arm II|Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9918600|NCT00797498||Xerostomia Questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
9918601|NCT00797524||DR|Diabetic Retinopathy
9918602|NCT00797524||ARMD|Age-Related Macular Degeneration
9918603|NCT00797524||ME|Macular Edema
9918604|NCT00797550|Active Comparator|Control|The Control arm of the study will receive bone autograft.
9918605|NCT00797550|Experimental|Treatment|The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
9918606|NCT00797576||1/Cases|Subjects whom had cardioversion aborted due to LAA thrombus or suspicion of LAA thrombus on TEE.
9918607|NCT00797576||2/Controls|Subjects with underlying atrial fibrillation undergoing elective TEE as clinically indicated for any reason.
9918608|NCT00797589|Experimental|Ringer lactate|Crystalloid solution
9918609|NCT00797589|Experimental|HES solution (Tetraspan®)|Balanced colloid solution
9918610|NCT00797602||Proton Radiation|
9918611|NCT00797615|Placebo Comparator|Alternative Intervention|12-week alternate intervention program focused on building self-esteem and social self-efficacy
9918612|NCT00797615|Active Comparator|Active Intervention|12-week intervention program focused on dietary intake and physical activity
9918613|NCT00797628|Experimental|Information Prescription|"Providers will give usual care to patients who smoke and a paper prescription with the name and url of the Smoking Coach website. The smoking coach website is a tailored, public health intervention for smoking cessation."
9918614|NCT00797628|Experimental|QUIT-PRIMO|Providers will give usual care to patients who smoke and then refer patients to the online smoking cessation system electronically.
9918615|NCT00797641||1|Patients admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
9918616|NCT00797654|Experimental|1|Participants will receive pre and post HIV-test counseling and an information-motivation-behavior skills training combined with cognitive processing therapy
9918617|NCT00797654|Active Comparator|2|Participants will receive pre and post HIV-test counseling
9918618|NCT00797680|Experimental|72 hours hypothermia|72 hours hypothermia
9918619|NCT00797680|Experimental|24 hours hypothermia|24 hours hypothermia
9918620|NCT00797693|Experimental|Vaginal Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
9918621|NCT00797693|Experimental|Oral Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
9918622|NCT00797706|Placebo Comparator|Vehicle|
9918623|NCT00797706|Experimental|Low dose|
9918624|NCT00797706|Experimental|High dose|
9918625|NCT00797719|Experimental|All|This is a single arm study. All patients enrolled will be in this arm.
9918626|NCT00797745|Active Comparator|Standard of Care|"PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.~Subjects with >= 1 log decrease from baseline in HCV-RNA levels after 12 weeks, but still above the lower limit of quantitation, have the option of crossing over to PegIntron, ribavirin plus SCH 900518 400 mg and ritonavir 100 mg daily for 12 weeks. This is followed by standard of care, PegIntron and ribavirin, for a total treatment duration of up to 48 weeks."
9918627|NCT00797745|Experimental|2|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
9918628|NCT00797745|Experimental|3|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
9934749|NCT04532749|Experimental|Seltorexant|Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
9934750|NCT04532749|Placebo Comparator|Placebo|Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).
9934751|NCT04526613||'healthy' LTBI+ controls who are negative for all of the below|'healthy' LTBI+ controls who are negative for all of the below conditions
9934752|NCT04526613||healthy LTBI negative controls with none of the above conditio|healthy LTBI negative controls with none of the above conditions
9934753|NCT04526613||LTBI+ and helminth infection (positive stool qPCR and/or serol|LTBI+ and helminth infection (positive stool qPCR and/or serology
9934754|NCT04526613||LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)|LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)
9934755|NCT04526613||LTBI+ and uncontrolled DM (HbA1c >8%)|LTBI+ and uncontrolled DM (HbA1c >8%)
9934756|NCT04526613||LTBI+ with more than one of the conditions defined in groups 1|LTBI+ with more than one of the conditions defined in groups 1-3
9934757|NCT04524663|Experimental|Camostat mesilate|Patients will receive camostat mesilate for 10 days in addition to standard of care treatment.
9934758|NCT04524663|Placebo Comparator|Placebo|Study participants will receive placebo to match camostat mesilate for 10 days in addition to standard of care treatment.
9934759|NCT04522076||COVID-19 with pneumonia|patients with positive COVID 19 by PCR and pneumonia by CT
9934760|NCT04522076||COVID-19 without pneumonia|patients with positive COVID 19 by PCR and absent of pneumonia by CT
9934761|NCT04522076||Patients with pneumonia and without COVID 19|patients with negative COVID 19 by PCR and with pneumonia by CT
9934762|NCT04522076||Patients without pneumonia and COVID 19|Patients with suspected COVID-19 and/or pneumonia at the pre-hospital stage that were not confirmed in hospital
9934763|NCT04521439|Experimental|MS Patients Group|
9934764|NCT04521439|Sham Comparator|Healthy Volunteers Group|
9934765|NCT04517994|Experimental|Active Treatment|The intervention includes components from empirically validated interventions for intimate relationship difficulties and PTSD. This includes core themes of trust, self-esteem, power and control, conflict-management skills, and communication skills training.
9934766|NCT04517994|Active Comparator|Supportive Treatment|Broadly based on the principles and techniques of client centered (Rogerian) therapy, and the fundamental principles and practices for experiential group psychotherapy as specified by Yalom. The group also draws upon the work of Murphy's Supportive Therapy protocol specifically for group intervention with domestic abuse perpetrators.
9934767|NCT04514510|Experimental|ISO|Subjects with sickle cell disease; Isoquercetin 1000mg once daily 28 days.
9934768|NCT04514510|Placebo Comparator|Placebo|Subjects with sickle cell disease; placebo once daily for 28 days.
9934769|NCT04513912|Experimental|Seltorexant|Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
9934770|NCT04513912|Active Comparator|Quetiapine Extended-Release (XR)|Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.
9934771|NCT04513522|Experimental|Nivolumab + ipilimumab|
9934772|NCT04505852|Experimental|EMBRACE USERS|Embrace wristband users
9934773|NCT04501081||1|DFNA patients and their family members (affected)
9934774|NCT04501081||2|DFNA patients and their family members (unaffected)
9934775|NCT04496960|Placebo Comparator|Placebo group|Receiving placebo
9934776|NCT04496960|Experimental|Subjects with SS|Receiving tofacidinib
9934777|NCT04492956|Experimental|Ecopipam HCl ~2mg/kg/day|Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks
9934778|NCT04492956|Placebo Comparator|Matching Placebo|Matching placebo tablets for daily, oral administration for 12 weeks
9934779|NCT04491955|Experimental|1/Arm 1|CEA/ MUC1 Vaccines + M7824 + N-803 (Triple Therapy).
9934780|NCT04491955|Experimental|2/Arm 2A|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); dose escalation of NHS-IL12.
9934781|NCT04491955|Experimental|3/Arm 2B|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); fixed dose of NHS-IL12.
9934782|NCT04491877|Experimental|Cohort 1 (RSV vaccine formulation 1)|1 administration of RSV vaccine formulation 1 on Day 0
9934783|NCT04491877|Placebo Comparator|Cohort 1 (Placebo)|1 administration of placebo on Day 0
9934784|NCT04491877|Experimental|Cohort 2 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
9934785|NCT04491877|Placebo Comparator|Cohort 2 (Placebo)|2 administrations of placebo on Day 0 and Day 56
9934786|NCT04491877|Experimental|Cohort 3 (RSV vaccine formulation 2)|1 administration of RSV vaccine formulation 2 on Day 0
9934787|NCT04491877|Placebo Comparator|Cohort 3 (Placebo)|1 administration of placebo on Day 0
9934788|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
9934789|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 2)|2 administrations of RSV vaccine formulation 2 on Day 0 and Day 56
9918629|NCT00797745|Experimental|4|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
9918630|NCT00797745|Experimental|5|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
9918631|NCT00797745|Experimental|6|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
9918632|NCT00797745|Experimental|7|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
9918633|NCT00797758|Experimental|1|Umbilical cord blood transplantation after reduced intensity conditioning
9918634|NCT00797771|Experimental|A|"Adi insulin pump users"
9934790|NCT04491877|Placebo Comparator|Cohort 4 (Placebo)|2 administrations of placebo on Day 0 and Day 56
9934791|NCT04490174||Healthy participants|Healthy adults without a current active COVID-19 infection or current symptoms consistent with COVID-19 at the first clinic visit
9934792|NCT04488952|Experimental|nerve block combined with general anesthesia group|Patients in this group receive nerve block combined with general anesthesia.
9934793|NCT04488952|Experimental|spinal anesthesia group|Patients in this group receive spinal anesthesia.
9934794|NCT04488952|Placebo Comparator|control group|This group is used to obtain the learning effect.
9934795|NCT04488263||Cohort 1|Subjects with confirmed/suspected NENs.
9934796|NCT04480554|Experimental|Methadone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone (MET) and antiretroviral therapy (cART).
9934797|NCT04480554|Experimental|Buprenorphine/naloxone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone and antiretroviral therapy (cART).
9934798|NCT04480554|Experimental|XR-Naltrexone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with monthly injection extended-release naltrexone (XR-NTX) and antiretroviral therapy (cART).
9934799|NCT04479072|Active Comparator|Intervention Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of aspirin 81 mg.
9934800|NCT04479072|Placebo Comparator|Placebo Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of a placebo pill
9934801|NCT04479072|No Intervention|Observational Arm|60 subjects will be placed in the observational arm. These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.
9996083|NCT01496677|Experimental|Younger adults (18-45 years old)|
9934802|NCT04478136||Major bleeders (MB)|Additional blood to be drawn from patients on ECMO who have a major bleeding event.
9934803|NCT04478136||Non-major bleeders (NMB)|
9934804|NCT04476992|Active Comparator|NO High Concentration|Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.
9934805|NCT04476992|Experimental|NO High Concentration + Continuous Low Concentration|"Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.~This arm will receive in addition a continuous low flow of Nitric Oxide at 20 ppm among the high concentration treatments."
9935788|NCT03215030|Experimental|Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD|Modakafusp alfa TBD, infusion, IV, once every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
9918635|NCT00797810|Experimental|therapy|
9918636|NCT00797836|Experimental|Quantiferon Gold|
9918637|NCT00797849|Active Comparator|1|Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.
9918638|NCT00797849|Sham Comparator|2|Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.
9918639|NCT00797875|Experimental|1|PNF stretching x 5 repetitions for 3 days
9918640|NCT00797875|Active Comparator|2|passive stretching
9918641|NCT00797888|Experimental|Telephonic|Tailored telephonic intervention to improve HbA1c for participants in the diabetes registry
9918642|NCT00797888|Active Comparator|Standard registry|People with diabetes who are in the A1c registry may receive letters from the DOHMH to promote improved A1c and also give lists of bronx resources for healther foof and activites
9918643|NCT00797901|Experimental|Collaborative Care, Treatment as Usual|
9918644|NCT00797914||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
9918645|NCT00797927|Experimental|1. quetiapine|quetiapine would replace the original conventional antipsychotic agent
9918646|NCT00797927|No Intervention|2. conventional antipsychotics|
9918647|NCT00797940|Experimental|Single Arm|Up to 42 subjects with first recurrence or progression of GBM
9918648|NCT00797953|Experimental|Low dose|2 capsules of T89 with 1 placebo capsule each time, twice daily. The daily dose is 250 mg.
9918649|NCT00797953|Experimental|High dose|3 capsules of T89 each time, twice daily. The daily dose is 375 mg
9918650|NCT00797953|Placebo Comparator|Placebo|3 placebo capsules (PC) each time, twice per day. The daily dose is 0 mg.
9918651|NCT00797979|Experimental|1|Skull Grip bone fixation
9918652|NCT00797979|Active Comparator|2|Standard skull bon flap fixation, sutures
9918653|NCT00797992|Experimental|1|Myopic eyes with retinal neovascularization
9918654|NCT00798031|Other|1|a minimum of two dental implants, but up to 3 dental implants, will be placed in each of 20 subjects. All surgical procedures will be performed as outpatient procedures at the College of Dentistry and implant placement will follow a one-stage procedure under local anesthesia. Placement of the 2-3 dental implants is the only intervention.
9918655|NCT00798044|Experimental|Feedback to counselors|substance abuse counselors received feedback reports on their average performance and on the average performance of the clinic as a whole. Feedback reports contained information on average alliance, treatment satisfaction, and drug/alcohol use.
9918656|NCT00798044|No Intervention|Treatment as Usual|No feedback reports were provided in this arm.
9918657|NCT00798057||Proton Radiation|
9918658|NCT00798070|Experimental|Arm A: dtEC→dtT|Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week
9918659|NCT00798070|Active Comparator|Arm B: FEC→T|Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel
9918660|NCT00798109|Experimental|Motivational Therapy|Four motivational interview for cannabis abuse in schizophrenia population during one month
9918661|NCT00798109|Other|Usual Care|Usual care with intensive psychotherapy
9918662|NCT00798122|Experimental|Women|IVUS and MRI performed in women with no obstructive CAD at angiography
9918663|NCT00798148|Experimental|MIBG|
9918664|NCT00798187||Homogeneous Support Group|
9918665|NCT00798187||Heterogeneous Support Group One|
9918666|NCT00798187||Heterogeneous Support Group Two|
9918667|NCT00798200|Other|Exercise|All participants will take part in a supervised, structured, exercise program
9918668|NCT00798213|Experimental|Participants with AML randomized to SCH 727965|
9918669|NCT00798213|Active Comparator|Participants with AML randomized to gemtuzumab ozogamicin|
9918670|NCT00798213|Experimental|AML treated w/ SCH 727965 after prog. on gemtuzumab ozogamicin|
9918671|NCT00798213|Experimental|Participants with ALL treated with SCH 727965|
9918672|NCT00798226|Active Comparator|1|n-3 fatty acid
9918673|NCT00798226|Placebo Comparator|2|Olive oil
9918674|NCT00798239|Active Comparator|Control|The control arm is Iliac Crest Autograft
9918675|NCT00798239|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
9918676|NCT00798239|Experimental|Prefix 750|Prefix (AMPLEX) B2A Enhanced Ceramic Granules
9918677|NCT00798252|Experimental|Arm A (Capecitabine + Brivanib alaninate)|
9918678|NCT00798252|Experimental|Arm B (Doxorubicin + Brivanib alaninate)|
9918679|NCT00798252|Experimental|Arm C (Ixabepilone + Brivanib alaninate)|
9918680|NCT00798252|Experimental|Arm D (Docetaxel + Brivanib alaninate)|
9918681|NCT00798252|Experimental|Arm E (Paclitaxel + Brivanib alaninate)|
9918682|NCT00798278|Experimental|Urokinase|urokinase infusion for 3 days
9918683|NCT00798278|Active Comparator|Thoracoscopic|Video-Assisted Thoracoscopic
9918684|NCT00798291|Placebo Comparator|Ad lib diet/placebo|Ad lib diet and control product placebo
9918685|NCT00798291|Experimental|Ad lib diet/AN 777|Ad lib diet and AN 777
9918686|NCT00798291|Active Comparator|Ad lib diet/placebo/exercise|Diet ad lib; exercise; and placebo
9918687|NCT00798291|Experimental|Ad lib diet/ AN 777/ exercise|Diet ad lib; AN 777; exercise
9918688|NCT00798343|Active Comparator|Seasonal vaccine|Seasonal influenza vaccination
9918689|NCT00798343|Experimental|Pandemic vaccine|MF59-adjuvanted H5N1 monovalent vaccine
9918690|NCT00798356|Other|1|Yoga training
9918691|NCT00798382|Experimental|1: Soy formula|experimental soy formula #1
9918692|NCT00798382|Active Comparator|2: Soy Formula|Commercially available soy formula
9918693|NCT00798382|Experimental|3: Soy formula|experimental soy formula #2
9918694|NCT00798395|Experimental|Treatment 1|
9918695|NCT00798395|Experimental|Treatment 2|
9918696|NCT00798395|Placebo Comparator|Treatment 3|
9918697|NCT00798395|Active Comparator|Treatment 4|
9918698|NCT00798408|Experimental|1|Participants will maintain current physical activity and take a fluid supplement.
9918699|NCT00798408|Experimental|2|Participants will maintain current physical activity and take a solid supplement.
9918700|NCT00798421||Heathcare worker|health care worker exposed to patient with influenza
9918701|NCT00798447|Experimental|lipid emulsion with n-3 FA|
9918702|NCT00798447|Active Comparator|lipid emulsion without n-3 FA|
9918703|NCT00798460|Active Comparator|Lamivudine plus adefovir|
9918704|NCT00798460|Active Comparator|Clevudine plus adefovir|
9918705|NCT00798473|Experimental|1|Zoledronic acid, 0.06 mg/kg IV in a single infusion, maximum of 4 mg
9918706|NCT00798473|Placebo Comparator|2|IV saline infusion
9918707|NCT00798499||1|Laboratory variables
9918708|NCT00798512|Experimental|1|Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
9918709|NCT00798525|Active Comparator|PR1|Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
9918710|NCT00798525|Active Comparator|PR2|Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor
9918711|NCT00798538|Active Comparator|Integrated|Provision of buprenorphine induction and management, substance abuse counseling and HIV care at one clinic.
9918712|NCT00798538|Placebo Comparator|Non-integrated|Buprenorphine induction, substance abuse counseling and HIV care will be managed at multiple locations, respectively: the Community Health Care Van, the Yale AIDS Program, and individuals' HIV clinics.
9918713|NCT00798551|Other|Risk counseling|Risk counseling regarding elevated blood pressure
9918714|NCT00798616|Placebo Comparator|Responders/Placebo|Albuterol responders being given placebo
9918715|NCT00798616|Active Comparator|Responders/Steroids|albuterol responders being given steroids
9918716|NCT00798616|Placebo Comparator|Non-responders/placebo|non-albuterol responders being given placebo
9918717|NCT00798616|Active Comparator|non-responders/steroids|non-albuterol responders being given steroids
9918718|NCT00798629|Experimental|Vaccine Dose Escalation|Dose Escalation: Intradermal DC Injection. Level 1: Cell Dose: 2 x 10^6 Level 2: Cell Dose: 1 x 10^7 Level 3: Cell Dose: 2 x 10^7
9918719|NCT00798642|Active Comparator|Hypnotherapy|
9918720|NCT00798642|Placebo Comparator|Standard care|
9918721|NCT00798642|Placebo Comparator|Mind Body Therapy|
9918722|NCT00798668|Experimental|1|participants continue current exercise and take liquid supplement
9918723|NCT00798668|Experimental|2|Participants continue current exercise and take solid supplement
9918724|NCT00798668|Experimental|3|Participants continue current sedentary behavior and take liquid supplements
9918725|NCT00798668|Experimental|4|Participants continue current sedentary behavior and take solid supplements
9918726|NCT00798681|Experimental|1|Patients will receive RTU TPN with olive-oil as the primary source of lipids
9918727|NCT00798681|Active Comparator|2|CNF parenteral nutrition made with olive oil as the primary source of lipids
9918728|NCT00798681|Active Comparator|3|CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
9918729|NCT00798733||Non-Operative|Surgeon treated the patient non-operatively
9918730|NCT00798733||Operative|Surgeon treated the patient operatively
9918731|NCT00798746||Pyloric Drainage Procedure|Esophagectomy with pyloric drainage procedure
9918732|NCT00798746||No Pyloric Drainage Procedure|Esophagectomy without pyloric drainage procedure
9918733|NCT00798772|Experimental|A: Broad spectrum micronutrients|"The experimental treatment medications (micronutrients and antioxidants) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
9918734|NCT00798772|Active Comparator|B: Identical appearing multivitamins|"The active comparator/control medications (identical appearing RDA multivitamins and minerals) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
9918735|NCT00798785|Experimental|group I ATG-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30"
9918736|NCT00798785|Experimental|group II ATG-Rituximab-MMF-TAC|"Two clinical implants in the liver:~First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5"
9918737|NCT00798785|Experimental|group III ATG-Basilixumab-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5"
9918738|NCT00798785|Experimental|group IV omentum|"Two clinical implants: first in the omentum followed by a clinical implant in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10"
9918739|NCT00798798|Experimental|Implantable Tissue Expansion Device|Will apply externally implantable tissue expansion device for 2 days
9918740|NCT00798811|Other|KSPNO-S-081|Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor
9918741|NCT00798811|Other|KSPNO-S-082|High-dose Chemotherapy and Autologous Stem Cell Rescue in Infants and Young Children with Newly Diagnosed High-risk Brain Tumor To Avoid or Reduce Craniospinal Radiation
9918742|NCT00798811|Other|KSPNO-S-083|High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Recurrent Brain Tumor or Non-germinomatous Germ Cell Tumor with Inadequate Response to Conventional Treatment
9918743|NCT00798824|Active Comparator|Indwelling nasogastric tube placement|
9918744|NCT00798824|Active Comparator|Intermittent orogastric tube placement|
9918745|NCT00798837|Other|IMAX|"There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions.~A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
9918746|NCT00798850|Active Comparator|PTA|
9918747|NCT00798850|Active Comparator|SEP|
9918748|NCT00798850|Active Comparator|PTA+SEP|
9918749|NCT00798863|Experimental|operative group|The patients of the group will have the operation of two step video assisted submandibular sialadenectomy.
9918750|NCT00798876|Placebo Comparator|Standard Western Diet|Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
9918751|NCT00798876|Experimental|Low-Fat Diet|Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
9918752|NCT00798902|Active Comparator|Control|Iliac Crest Autograft
9918753|NCT00798902|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
9918754|NCT00798915|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
9918755|NCT00798915|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
9918756|NCT00798915|Experimental|Type 2 diabetes mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
9918757|NCT00798941|Experimental|pain intervention|music and massage for 30 minutes
9918758|NCT00798941|Experimental|thirst intervention|sterile water mouth spray, lip moisturizer,mouth swab
9918759|NCT00798941|No Intervention|control|
9918760|NCT00798954|Active Comparator|TAXUS|
9918761|NCT00798954|Active Comparator|Cypher|
9918762|NCT00798980||Arm 1|
9918763|NCT00798993|Active Comparator|Structured exercise program|Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
9918764|NCT00798993|Experimental|Vitamin D|Cholecalciferol 2000U per day will be given to all participants for the duration of the study
9918765|NCT00798993|Placebo Comparator|Usual exercise|Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
9918766|NCT00799006|Placebo Comparator|Placebo|
9918767|NCT00799006|Experimental|PF-04620110|
9918768|NCT00799032|Other|Stent|Catania Stent
9918769|NCT00799045|Experimental|Aspirin + clopidogrel|Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
9918770|NCT00799045|Active Comparator|Aspirin|Aspirin (80 mg/day) for 3 months following ASD closure.
9918771|NCT00799071|Experimental|posaconazole|posaconazole as antifungal prophylaxis
9918772|NCT00799084|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
9918773|NCT00799084|Experimental|AVR|Receives symptom management assistance from an Automated telephone system
9918774|NCT00799097||Endoscopic Sinus Surgery|Subjects who have failed maximum medical management and have elected for endoscopic sinus surgery
9918775|NCT00799136|Other|One|Rituxan with EPOCH and Antiretrovirals
9918776|NCT00799149|Active Comparator|Gabapentin|Gabapentin (1200 mg) administered 30-90 min before the patient entered the operating room; Subsequent doses of Gabapentin (1200 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
9918777|NCT00799149|Active Comparator|Etoricoxib|Etoricoxib (120 mg)administered 30-90 min before the patient entered the operating room; Subsequent doses of etoricoxib (120 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
9918778|NCT00799149|Placebo Comparator|Sugar pill|Sugar pill administered 30-90 min before the patient entered the operating room. Subsequent doses of Sugar pill were administered on the mornings (08H00) of the first, second, and third postoperative days.
9918779|NCT00799162||Women with a scheduled cesarean section|
9918780|NCT00799175|Active Comparator|1 Group A(Active)|Group A (Active) receives a multimodal injection intra- and postoperatively
9918781|NCT00799175|Placebo Comparator|2 Group P (Placebo)|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
9918782|NCT00799188|No Intervention|1|reduction of immunosuppression
9918783|NCT00799188|Experimental|2|switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)
9918784|NCT00799201|Experimental|Control|Sennosides liquid 5mL (8.8mg) every 6 hours plus docusate sodium liquid 10mL (100mg) every 12 hours
9918785|NCT00799214|Placebo Comparator|1|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
9918786|NCT00799214|Experimental|2|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
9918787|NCT00799214|Active Comparator|3|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
9918788|NCT00799240|Active Comparator|Arm A Pemetrexed Cisplatin|Arm A: Pemetrexed, cisplatin: pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days. Patients will be treated for a maximum of 6 cycles.
9918789|NCT00799240|Experimental|Arm B Permetrexed, Cisplatin, MK-0646|Pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days in combination with MK-0646 given IV, 10 mg/Kg, Days 1, 8 and 15 weekly
9918790|NCT00799266|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
9918791|NCT00799266|Placebo Comparator|Placebo|Twice yearly i.v of infusion of Placebo (similar dosing as active drug)
9918792|NCT00799279|Experimental|Follow-up Counseling Arm|smoking cessation training for providers,practice tools for providers, patient quit plan, and follow-up telephone counselling for smokers
9918793|NCT00799279|Active Comparator|Practice Support Arm|smoking cessation training for providers,practice tools for providers, patient quit plan for smokers.
9918794|NCT00799305||COPD patients|
9918795|NCT00799331|Experimental|A|AZD5985
9918796|NCT00799331|Experimental|B|placebo
9918797|NCT00799344||Stent|Catania Stent
9918798|NCT00799370|Experimental|1|Early weight bearing: immediate in postoperative
9918799|NCT00799370|Experimental|2|Delayed weight bearing: 2 months after surgery
9918800|NCT00799461|Experimental|Arm I (full website access w/ PST; first study only)|Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
9918801|NCT00799461|Experimental|Arm II (full website access without PST)|Patients receive full access to INSPIRE website for 6 months as in arm I.
9918802|NCT00799461|Sham Comparator|Arm III (delayed website access)|Patients do not have access to INSPIRE website for 6 months. After 6 months, patients receive full access to INSPIRE website for 3 months.
9918803|NCT00799500|Experimental|Weekly screening|Screening and treatment of bacterial vaginosis during pregnancy through self-administered weekly vaginal pH determination.
9918804|NCT00799500|No Intervention|Observation|Usual care
9918805|NCT00799513|Experimental|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
9918806|NCT00799526|Experimental|Ex Vivo Transplantation|Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
9918807|NCT00799565|Experimental|1|Subject with a Mitral Valvular Prolapse
9918808|NCT00799565|Experimental|2|Healthy Volunteers
9918809|NCT00799656|Experimental|1|First period: Ataciguat - Second period: Placebo
9918810|NCT00799656|Experimental|2|First period: Placebo - Second period: Ataciguat
9918811|NCT00799669||MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
9918812|NCT00799669||MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
9918813|NCT00799682|Active Comparator|Xalatan®|
9918814|NCT00799682|Active Comparator|Travatan Z®|
9918815|NCT00799721||1|VLBW infants with erythropoietin therapy
9918816|NCT00799721||2|VLBW infants without erythropoietin therapy.
9918817|NCT00799734|Active Comparator|alternative medicine|Intake of prepacked Chinese herbal medicine (EXD), one sachet of granules (15g extracted granules) twice a day
9918818|NCT00799734|Placebo Comparator|placebo|placebo therapy of 15g granules with similar colour and taste.
9918819|NCT00799747|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
9918820|NCT00799747|Placebo Comparator|2|Placebo
9918821|NCT00799760|Experimental|1|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
9918822|NCT00799760|Active Comparator|2|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
9918823|NCT00799760|Active Comparator|3|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
9918824|NCT00799799|Experimental|NK|patient treated as per protocol
9918825|NCT00799838|Experimental|Ketoprofen + Amoxicillin|Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
9918826|NCT00799838|Placebo Comparator|Amoxicillin|Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
9918827|NCT00799851|Active Comparator|Variceal band ligation|VBL was performed with a multiband ligation device (Euroligator System®). The first band was placed at or close to the gastroesophageal junction, with subsequent bands being placed proximally in a slightly spiral pattern. All visible varices within the distal esophagus were treated, with a maximum of 10 bands being placed in each session. There was a 3-week interval between each treatment session. When VBL was technically impossible due to scarring, sclerotherapy with ethanolamine oleate was performed on thin vessels.
9918828|NCT00799851|Active Comparator|cyanoacrylate injection|"CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®). Before injection of the Histoacryl-Lipiodol mixture, the catheter was filled up with 1 ml of Lipiodol. After puncturing the EV, the mixture was injected inside it and followed by injection of 1 ml of distilled water. Finally the catheter was retracted. To minimize the risk of embolism, a maximum of two medium or large vessels, in opposite walls, were treated in each session and not more than 0.5 ml of Histoacryl® was injected into each vessel.~A second injection was performed in any EV that maintained blood flow (medium or large size, blue, depressive at palpation with the catheter), in a bi-weekly interval basis. A chest x-ray was performed to evaluate the location of the Histoacryl-Lipiodol solution. Small vessels were treated with ethanolamine oleate sclerotherapy."
9918829|NCT00799890|Experimental|Sunphenon|
9918830|NCT00799890|Placebo Comparator|Placebo|
9918831|NCT00799916|Active Comparator|Voluven|Resuscitation fluid: Voluven (R)
9918832|NCT00799916|Active Comparator|Saline|Resuscitation fluid: Saline solution
9918833|NCT00799929|Active Comparator|ARM A - Mini IVF|The Mini IVF method entails pre-treatment with oral contraceptive pills. Ovarian stimulation is achieved using an oral anti-estrogen in conjunction with injections of gonadotropin (225IU-600IU per cycle), with initial dose of 75IU-150IU per injection. Ovulation is induced by a GnRH (gonadotropin-releasing hormone) agonist nasal spray/hCG (human chorionic gonadotropin) injection. Retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. Blastocyst stage embryos are vitrified using the CryoTop method. No fresh embryo transfer is conducted. Subsequently, SET of a thawed blastocyst is performed in a natural cycle/HRT that does not involve ovarian stimulation. SETs are conducted until pregnancy is achieved or all vitrified blastocysts have been used.
9918834|NCT00799929|Active Comparator|Arm B - Conventional IVF|The standard IVF method entails pre-treatment with a GnRH analog injections in the midluteal phase. Controlled ovarian hyperstimulation is achieved with injections of gonadotropin (150IU-300IU/day). Ovulation is induced by hCG injection and retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. If this occurs on day 5, then fresh SET/DET (single embryo transfer/double embryo transfer) is performed. Remaining blastocysts are cryopreserved and transferred in subsequent natural cycles/HRT (hormone replacement therapy) that does not involve ovarian stimulation.
9918835|NCT00799955|Placebo Comparator|1|Subjects will receive 100 micrograms of spinal morphine, at the time of spinal needle insertion (standard care at BCW). At the end of the case, one of two investigators, using ultrasound, will visualize the transversus abdominis plane. A capped needle will be pushed against the skin to mimic the pressure sensation of the TAP block. The needle will not break the skin and nothing will be injected in this control group. The procedure will then be repeated on the other side. A dressing will be applied on each side to blind the subject and researcher to which group she is in.
9918836|NCT00799955|Active Comparator|2|No additional spinal medications will be given. At the end of the case, one of the two investigators, under sterile conditions, and using ultrasound, will visualize the tip of a blunt regional anaesthesia needle entering the transversus abdominis plane. After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected, under vision, into the transversus abdominis plane, on each side. The subjects will still have spinal anesthesia of the abdomen and therefore will not feel needle insertion as sharp although most will have a sensation of pressure. A dressing will be applied over the needle's entry points.
9918837|NCT00799968|Active Comparator|Group 1|UK-12h group
9918838|NCT00799968|Experimental|Group 2|UK-2h group
9918839|NCT00799994||1|Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
9918840|NCT00799994||2|Patients who have received no intervention
9918841|NCT00800007|Active Comparator|ANZ-521|
9918842|NCT00800007|Placebo Comparator|Placebo|
9918843|NCT00800033|Experimental|Aerobic exercise training|
9918844|NCT00800033|Placebo Comparator|Resistance exercise training|
9918845|NCT00800033|Experimental|pulse diet|Pulse based diet containing peas, lentils, and beans
9918846|NCT00800033|No Intervention|Regular diet|
9918847|NCT00800046|Experimental|AccuCinch® Ventriculoplasty System|Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.
9918848|NCT00800059|Experimental|Treatment|Treatment with TMI and autologous Stem Cell transplant
9918849|NCT00800072|Experimental|oxygen therapy|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
9918850|NCT00800085|No Intervention|FDR of type 1 diabetes patients receiving glucose 20%|First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
9918851|NCT00800098|Placebo Comparator|Placebo|Placebo cream matched on consistency, color, and smell
9918852|NCT00800098|Active Comparator|Active|AARP active arthritis cream
9918853|NCT00800111|Other|Treatment|Endothelial keratoplasty procedure is performed.
9918854|NCT00800124|No Intervention|1|Cemented hemiprosthesis
9918855|NCT00800124|Active Comparator|2|Non-cemented hemiprosthesis
9918856|NCT00800137|Active Comparator|Bridging anti-coagulation|Low Molecular Weight Heparin or IV unfractionated Heparin
9918857|NCT00800137|Experimental|Continued oral anti-coagulation|Coumadin
9918858|NCT00800163|Experimental|ED Physician Activation/Immediate Transfer|
9918859|NCT00800215|Experimental|1|
9918860|NCT00800215|Placebo Comparator|2|
9918861|NCT00800215|Experimental|3|
9918862|NCT00800215|Placebo Comparator|4|
9918863|NCT00800228||1|Eight men and eight women to define the time course of changes in MBG \ and OLC accompanying sodium loading
9918864|NCT00800228||2|32 additional women to determine whether breathing pattern is predictive of sodium sensitivity in that gender. Women are being studied in the second experiment because they, but not men, have been shown to have an association of breathing pattern with high perceived stress11 and an association of high resting end tidal CO2 with high resting blood pressure.
9918865|NCT00800267|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
9918866|NCT00800267|Active Comparator|latanoprost 0.005%|
9918867|NCT00800267|Active Comparator|Timolol - 0.5%|
9918868|NCT00800280|Experimental|Single dose PD 0332334|
9918869|NCT00800280|Experimental|Single dose PD 0332334 with steady-state cimetidine|
9918870|NCT00800293||Cohort Group 1|Subject Numbers 1 to 29
9918871|NCT00800293||Cohort Group 2|Subject Numbers 20 to 59
9918872|NCT00800293||Cohort Group 3|Subject Numbers 60 to 89
9918873|NCT00800293||Cohort Group 4|Subject Numbers 90 to 116
9918874|NCT00800306|Experimental|levosimendan|
9918875|NCT00800306|Active Comparator|Control|
9918876|NCT00800319|Experimental|RDC-0313, 5mg|5 mg of RDC-0313; single dose
9918877|NCT00800319|Experimental|RDC-0313, 15 mg|15 mg RDC-0313; single dose
9918878|NCT00800319|Experimental|RDC-0313, 25mg|25 mg RDC-0313; single dose
9918879|NCT00800319|Experimental|RDC-0313, 50 mg|50 mg RDC-0313; single dose
9918880|NCT00800319|Experimental|RDC-0313, 75 mg|75 mg RDC-0313; single dose
9918881|NCT00800319|Placebo Comparator|Placebo|volume-match placebo; single dose
9918882|NCT00800332|Experimental|1|
9918883|NCT00800332|Experimental|2|
9918884|NCT00800332|Placebo Comparator|3|
9918885|NCT00800358|Experimental|1|Oral Paricalcitol in varying doses
9918886|NCT00800358|Active Comparator|2|Calcitriol
9918887|NCT00800371||JIA|Patients with JIA
9918888|NCT00800410|No Intervention|Information on community resources|Participants received information about free and publicly available community resources on healthy lifestyle activities
9918889|NCT00800410|Experimental|Community Health Worker services|
9918890|NCT00800423|Experimental|brimonidine|"50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.~they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
9918891|NCT00800423|Active Comparator|2 tmolol|"50 patients receiving timolol maleate 0.5% drops in the operated eye~1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
9918892|NCT00800423|No Intervention|3|50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
9918893|NCT00800462|Active Comparator|Oxybutynin Cl|
9918894|NCT00800462|Active Comparator|Trospium Cl|
9918895|NCT00800462|Active Comparator|Darifenacin Hydrogren Bromide (HBr)|
9918896|NCT00800475|Active Comparator|Test Drug|
9918897|NCT00800475|Active Comparator|Reference Drug|
9918898|NCT00800501|Experimental|sNN0029|
9918899|NCT00800501|Placebo Comparator|Placebo|
9918900|NCT00800527|Active Comparator|1|Gabapentin
9918901|NCT00800527|Active Comparator|2|Diclofenac
9918902|NCT00800553|Experimental|donepezil|donepezil, 5 mg p.o. for approx 2 weeks
9918903|NCT00800553|Placebo Comparator|placebo|placebo
9918904|NCT00800566|Experimental|Oral Clofarabine|
9918905|NCT00800579|Experimental|1|GS-9411 0.6 mg
9918906|NCT00800579|Experimental|2|GS-9411 1.2 mg
9918907|NCT00800579|Experimental|3|GS-9411 2.4 mg
9918908|NCT00800579|Placebo Comparator|4|Inhaled volume-matched sterile saline placebo
9918909|NCT00800592|Active Comparator|10 mg sildenafil bolus|10 mg sildenafil bolus
9918910|NCT00800618|Experimental|PF-02413873|PF-2413873 active treatment
9918911|NCT00800618|Placebo Comparator|Placebo|Placebo
9918912|NCT00800644||Evaluation Group|Bone Mineral Density Test + MRI or CT + Blood Test
9918913|NCT00800670|Experimental|Lower dose|Lower dose of Ad5Ag85A: 10^8pfu
9918914|NCT00800670|Experimental|Higher dose|Higher dose of vaccine Ad5Ag85A: 10^9pfu
9918915|NCT00800696|Experimental|oral care|intervention: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx.
9918916|NCT00800696|No Intervention|control|continue to receive oral care as performed today.
9918917|NCT00800709|Experimental|Memantine|
9918918|NCT00800722|Experimental|Treatment of Port Wine Stain|Rapamycin Treatment of Port Wine Stain
9918919|NCT00800748|Experimental|Group A|Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.
9918920|NCT00800748|Experimental|Group B|Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.
9918921|NCT00800748|Experimental|Group C|Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.
9918922|NCT00800761|Active Comparator|Deferoxamine alone|comparison of deferoxamine subcutaneous 40mg/kg/die alone versus combined therapy deferoxamine-deferiprone
9918923|NCT00800761|Active Comparator|Deferoxamine plus Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
9918924|NCT00800774|Experimental|1|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
9918925|NCT00800787|Experimental|Arm One: Nabi-HB|All subjects will be administered Nabi HB Subcutaneously
9918926|NCT00800800|Active Comparator|1|Rosuvastatin 40 mg
9918927|NCT00800800|Placebo Comparator|2|placebo
9918928|NCT00800813||open, laparoscopic, or robotic-assisted lap|Patients will also be assessed for penile length and the presence of Peyronie's Disease at these specified times.
9918929|NCT00800930|Active Comparator|1|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
9918930|NCT00800930|Placebo Comparator|2|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
9918931|NCT00800943|Experimental|Campath-1H|
9918932|NCT00800956|Experimental|Single oral dose of [14C]-esreboxetine|
9918933|NCT00800969|Other|all patients|all patients with Adenocarcinoma
9918934|NCT00800995|Sham Comparator|Control|
9918935|NCT00800995|Experimental|SOD|
9918936|NCT00801008|Experimental|Exercise and Relaxation Intervention|Participants in this arm will receive a 12 week exercise and relaxation intervention
9918937|NCT00801008|No Intervention|Wait List Control Condition|Participants in this arm will be offered the exercise and relaxation intervention after a 12 week delay.
9918938|NCT00801021|Experimental|Frio Oral Rinse|Prescription Mouth Rinse
9918939|NCT00801034|Placebo Comparator|1|Calcium tablets
9918940|NCT00801034|Active Comparator|2|Potassium tablets
9918941|NCT00801047|Experimental|1|Epidural group
9918942|NCT00801047|Active Comparator|2|Remifentanil iv PCA
9918943|NCT00801073|Experimental|Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
9918944|NCT00801086|Experimental|1|MTS-01 (7% Tempol gel)
9918945|NCT00801086|Placebo Comparator|2|Vehicle
9918946|NCT00801112||1|PD patients with residual renal function >200ml with BIA monitor.
9918947|NCT00801112||2|PD patients with residual renal function <200ml with BIA monitor.
9918948|NCT00801112||3|PD patients with residual renal function >200ml without BIA monitor
9918949|NCT00801112||4|PD patients with residual renal function <200ml without BIA monitor
9918950|NCT00801151|Experimental|Vorinostat, vinorelbine|Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
9918951|NCT00801164|Experimental|Frio Oral Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
9918952|NCT00801164|Experimental|Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
9918953|NCT00801177|Experimental|IMC-11F8 (Every week)|Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
9918954|NCT00801177|Experimental|IMC-11F8 (Every other week)|Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.
9918955|NCT00801190|Active Comparator|HES (130/0.4)|33 ml/kg i.v. HES (130/0.4)
9918956|NCT00801190|Placebo Comparator|Ringer's Lactate|33 ml/kg i.v. Rigner's Lactate
9918957|NCT00801203|Experimental|1|Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)
9918958|NCT00801203|Experimental|2|Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)
9918959|NCT00801216|Experimental|High-dose sequential chemoimmunotherapy|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
9918960|NCT00801255|Experimental|Cohort A|
9918961|NCT00801255|Experimental|Cohort B|
9918962|NCT00801255|Experimental|Cohort C|
9918963|NCT00801255|Experimental|Cohort D|
9918964|NCT00801255|Experimental|Cohort E|
9918965|NCT00801255|Experimental|Cohort F|
9918966|NCT00801255|Experimental|Cohort G|
9918967|NCT00801268|Active Comparator|emodin|
9918968|NCT00801268|Experimental|Triptolide Woldifii|TW60mg/d
9918969|NCT00801281|Active Comparator|R-CVP|Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2
9918970|NCT00801281|Experimental|R-CHOP|Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1
9918971|NCT00801307|Experimental|1|He/O2 78:22
9918972|NCT00801307|Experimental|2|He/O2 65:35
9918973|NCT00801307|Active Comparator|3|Medical Air
9918974|NCT00801320|Experimental|Cohort 1|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF
10213329|NCT04235101|Experimental|SYD985 + Niraparib|SYD985, Intravenous, every 3 weeks (Q3W) Niraparib taken orally and either 100 mg, 200 mg or 300 mg once daily for either 1, 2 or 3 weeks.
10213330|NCT04231591||ACDH Pregnancy - Study group|Pregnant women with known adult congenital heart disease.
10213331|NCT04231591||Uncomplicated pregnancy - Control group|Healthy women with an uncomplicated pregnancy
9918975|NCT00801320|Experimental|Cohort 2|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF and topical Imiquimod at site of vaccination
9934806|NCT04476446|Experimental|Intranasal Esketamine|Induction Phase: Participants will self-administer esketamine intranasally 56 milligram (mg) on Day 1 followed by 56 mg or 84 mg (as a flexible dose regimen) twice per week for 4 weeks. Participants greater than or equal to (>=) 65 years old will start at a dose of 28 mg on Day 1. Maintenance Phase: Participants will self-administer esketamine 56 mg or 84 mg intranasally once per week from Week 5 to Week 9. Subsequently from Week 9, based on the investigator's clinical judgment, participants will self-administer esketamine 56 mg or 84 mg intranasally once or twice a week.
9934807|NCT04476277|Experimental|1|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
9934808|NCT04465214||1/Cohort 1|Participants with a diagnosis of cancer who are under active treatment on a protocol at NIH
9934809|NCT04459468||HCC for Lipiodol TACE|These patients will standard of care Lipiodol TACE treatment. No research intervention is planned
9934810|NCT04459468||Healthy controls|Healthy controls from public database
9934811|NCT04459468||HCC patients|HCC patients will be used for biomarker validation.
9934812|NCT04458935||Participants|Participants with retinal hemangioblastoma (RH) managed with trans-scleral cryotherapy at the NIH.
9934813|NCT04456673|Experimental|Dupilumab|Dupilumab administered every 2 weeks
9934814|NCT04456673|Placebo Comparator|Placebo|Placebo dose administered every 2 weeks
9934815|NCT04450927||1|Data collection and treatment according to guidelines of standard of medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
9934816|NCT04450745|Experimental|Exercise in hypoxia|Patients randomized to this arm will have training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above see level( indoor air composition: 15,4% of O2 and 84,7% of N)
9934817|NCT04450745|Experimental|Exercise in normoxia|Patients randomized to this arm will have the same training program in normoxic conditions
9934818|NCT04449549|Experimental|1|Nilotinib will be administered at 300 mg orally BID; Paclitaxel will be administered IV at 80 mg/m2 on Days 1, 8, and 15 in 28-day cycles.
9934819|NCT04447027|Experimental|1- Experimental Treatment: Dose Escalation|Lenalidomide by oral intake at escalating doses of 5, 10, 15, or 20 mg/day on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle, to determine MTD
9934820|NCT04447027|Experimental|2 - Experimental Treatment: Dose Expansion|Lenalidomide by oral intake at MTD on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle
9934821|NCT04447014||Cohort 1|Subjects with confirmed adrenocortical cancer (ACC)
9934822|NCT04444921|Active Comparator|Arm A (carboplatin, paclitaxel)|Patients receive carboplatin IV on day 1, and paclitaxel IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9934823|NCT04444921|Experimental|Arm B (carboplatin, paclitaxel, nivolumab)|Patients receive carboplatin on day 1, paclitaxel IV on days 1, 8 and 15, and nivolumab IV over 30 minutes on days 1 and 15 of cycle 1, and then on day 1 only of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles for carboplatin and paclitaxel, and up to 2 years for nivolumab in the absence of disease progression or unacceptable toxicity.
9934824|NCT04444804||Rivaroxaban|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
9934825|NCT04444804||Low-molecular-weight heparin (LMWH) and Phenprocoumon|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
9934826|NCT04442425||1DF/NoPain_IV-VI_Female|Worst pain in past month = 0; Skin Type IV-VI, Female
9934827|NCT04442425||1DM/NoPain_IV-VI_Male|Worst pain in past month = 0; Skin Type IV-VI, Male
9934828|NCT04442425||1LF/NoPain_I-III_Female|Worst pain in past month = 0; Skin Type I-III, Female
9934829|NCT04442425||1LM/NoPain_I-III_Male|Worst pain in past month = 0; Skin Type I-III, Male
9934830|NCT04442425||2DF/MildPain_IV-VI_Female|Worst pain in past month = 1-3; Skin Type IV-VI, Female
9934831|NCT04442425||2DM/MildPain_IV-VI_Male|Worst pain in past month = 1-3; Skin Type IV-VI, Male
9934832|NCT04442425||2LF/MildPain_I-III_Female|Worst pain in past month = 1-3; Skin Type I-III, Female
9934833|NCT04442425||2LM/MildPain_I-III_Male|Worst pain in past month = 1-3; Skin Type I-III, Male
9934834|NCT04442425||3DF/ModPain_IV-VI_Female|Worst pain in past month = 4-6; Skin Type IV-VI, Female
9934835|NCT04442425||3DM/ModPain_IV-VI_Male|Worst pain in past month = 4-6; Skin Type IV-VI, Male
9934836|NCT04442425||3LF/ModPain_I-III_Female|Worst pain in past month = 4-6; Skin Type I-III, Female
9934837|NCT04442425||3LM/ModPain_I-III_Male|Worst pain in past month = 4-6; Skin Type I-III, Male
9934838|NCT04442425||4DF/SeverePain_IV-VI_Female|Worst pain in past month = 7-10; Skin Type IV-VI, Female
9934839|NCT04442425||4DM/SeverePain_IV-VI_Male|Worst pain in past month = 7-10; Skin Type IV-VI, Male
9934840|NCT04442425||4LF/SeverePain_I-III_Female|Worst pain in past month = 7-10; Skin Type I-III, Female
9934841|NCT04442425||4LM/SeverePain_I-III_Male|Worst pain in past month = 7-10; Skin Type I-III, Male
9934842|NCT04439526||Participants with Facial Psoriasis|Participants with moderate facial psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
9934843|NCT04439526||Participants with Genital Psoriasis|Participants with moderate genital psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
9996084|NCT01496690|Active Comparator|pregabalin|The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.
9918976|NCT00801359|Active Comparator|BSSplus|
9918977|NCT00801359|Experimental|Ringer|
9918978|NCT00801411|Experimental|Arm I|Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.
9918979|NCT00801411|Active Comparator|Arm II|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.
9918980|NCT00801424|Experimental|standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
9667449|NCT03568318|Placebo Comparator|Placebo / Upadacitinib + Topical Corticosteroids|Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
9918981|NCT00801437||Xalacom treatment|patients with primary glaucoma
9918982|NCT00801450|Experimental|Intravitreal (IVI)|
9918983|NCT00801450|Experimental|SubTenon´s (STI)|
9918984|NCT00801463|Experimental|Large pred|Prednisone 60mg/d*8 wks
9918985|NCT00801463|Experimental|small pred|Pred 30mg/d*8wks
9918986|NCT00801489|Experimental|Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)|See Detailed Description
9918987|NCT00801502|Other|Control|No change in diet
9918988|NCT00801502|Active Comparator|Oily fish|Two portions of salmon per week from week 20 of pregnancy until giving birth
9918989|NCT00801528|Active Comparator|Ropivacaine|Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr
9918990|NCT00801528|Active Comparator|Diclofenac|Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr
9918991|NCT00801528|Placebo Comparator|Water for injection|Continuous wound instillation of water for injection at a rate set of 10 mL/hr
9918992|NCT00801541||AMD|Patients with wet AMD in one eye and dry AMD in the other eye (study eye).
9918993|NCT00801554||ASD|Children and adults with Autism Spectrum Disorders.
9918994|NCT00801554||Non-ASD|Healthy volunteers who have never been diagnosed with an Autism Spectrum Disorder in their lifetime.
9918995|NCT00801567|Experimental|1|All subjects will receive the intervention (MRS scan).
9918996|NCT00801580|Experimental|1|The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C [cytarabine]).
9918997|NCT00801593||Children with JIA|
9918998|NCT00801606|Experimental|Study drug containing zinc alone|Zinc 20 mg daily
9918999|NCT00801606|Experimental|Study drug Micronutrient without zinc|micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.
9919000|NCT00801606|Experimental|Study drug Micronutrient with zinc|micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).
9919001|NCT00801606|Placebo Comparator|Placebo|Placebo only
9919002|NCT00801619||Intervention|Receive decision support when reviewing bilirubin results in the clinical information systems/electronic health record
9919003|NCT00801619||Control|No decision support
9919004|NCT00801645|Experimental|Obese exercise|
9919005|NCT00801645|No Intervention|Obese Control|
9919006|NCT00801645|Experimental|Lean Exercise|
9919007|NCT00801645|No Intervention|Lean Control|
9919008|NCT00801671|Active Comparator|1|
9919009|NCT00801671|Sham Comparator|2|
9919010|NCT00801697|Experimental|1A|rAD5-naive participants will receive rAd35 intramuscularly at study entry and rAd5 intramuscularly at Month 6
9919011|NCT00801697|Placebo Comparator|1B|Participants will receive rAd35 placebo intramuscularly at study entry and rAd5 placebo intramuscularly at Month 6
9996085|NCT01496690|Placebo Comparator|Pregabalin Placebo Capsules|
9996086|NCT01496703||renal transplantation with MMF from day 1|
9996087|NCT01496716||Hip Osteoarthritis|
9996088|NCT01496729|Active Comparator|Transversus abdominis plane (TAP) block with ropivacaine|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure
9996089|NCT01496729|Sham Comparator|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
9996090|NCT01496742|Experimental|Bevacizumab+MetMAb|
9996091|NCT01496742|Active Comparator|Bevacizumab+Placebo|
9996092|NCT01496742|Experimental|Pemetrexed+MetMAb|
9996093|NCT01496742|Active Comparator|Pemetrexed+Placebo|
9996094|NCT01496755|Placebo Comparator|Placebo|
9996095|NCT01496755|Experimental|RG7667|
9996096|NCT01496768|Experimental|Leucine|
9996097|NCT01496768|Placebo Comparator|Alanine|
9667450|NCT03568318|Experimental|Upadacitinib 15 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
9996098|NCT01496781|Experimental|EndoClot|This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
9996099|NCT01496781|Active Comparator|Hemoclip|This arm is used as a control treatment group to compare with Endoclot treatment.
9996100|NCT01496794||Endophthalmitis cultures|
9996101|NCT01496820|Experimental|GO2KA1|
9996102|NCT01496820|Placebo Comparator|Placebo|
9996103|NCT01496833|Experimental|Endovascular|Total endovascular arch reconstruction
9996104|NCT01496859|Experimental|Baska|
9996105|NCT01496911|Experimental|Levocetirizine (5 mg)|
9996106|NCT01496911|Active Comparator|Hydroxyzine (50 mg)|
9996107|NCT01496911|Placebo Comparator|Placebo|
9996108|NCT01496924|Other|speech therapy group|All dysphagic patients will be submitted to speech therapy
9996109|NCT01496937|Experimental|GLPG0974 oral solution|GLPG0974 oral solution
9996110|NCT01496937|Placebo Comparator|Placebo oral solution|Placebo oral solution
9996111|NCT01496950|Active Comparator|Active Comparator: Active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
9996112|NCT01496950|Placebo Comparator|Placebo|10Hz placebo rTMS delivered to the vertex
9996113|NCT01496963||group a)|Patients with pulmonary artery pressure (PAP) assessed (by echocardiogram) <36 mmHg or a tricuspid regurgitant jet velocity (TG) <3 m / sec and data on PAP and mean left ventricular ejection fraction (LVEF) > 50%
9996114|NCT01496963||group b)|"Patients with:~PAP estimated (by echocardiography)> 40 mmHg or TG> 3.2 m / sec and LVEF> 50% As indicated by the Guidelines, patients b) with increased PAP (TG> 3.2 m / sec or> 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP."
9996115|NCT01496963||group c)|patients with PAP estimated (by echocardiography) in the range of values > 3 m / sec (TG) and <3.2 m / sec or> 36 mm Hg and <40 mmHg and LVEF> 50%
9996116|NCT01496989|Experimental|Group 1: HIV-MAG followed by Ad35-GRIN/ENV|HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)
9996117|NCT01496989|Experimental|Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)
9996118|NCT01496989|Experimental|Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)
9996119|NCT01496989|Experimental|Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)
9996120|NCT01496989|Experimental|Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12|Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)
9996121|NCT01497002|Active Comparator|standard arm|standard treatment arm
9996122|NCT01497002|Experimental|OSHO - intensified consolidation|Intermediate dose AraC
9667451|NCT03568318|Experimental|Upadacitinib 30 mg QD + Topical Corticosteroids|Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
9919012|NCT00801697|Experimental|2A|rAD5-naive participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd5 intramuscularly at Month 6
9919013|NCT00801697|Placebo Comparator|2B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd5 placebo intramuscularly at Month 6
9919014|NCT00801697|Experimental|3A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
9919015|NCT00801697|Placebo Comparator|3B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
9919016|NCT00801697|Experimental|4A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
9919017|NCT00801697|Placebo Comparator|4B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
9919018|NCT00801710|Experimental|BridgePoint Medial System|
9919019|NCT00801736|Experimental|Platinum Arm|Cisplatin (IMP) / Pemetrexed (IMP)
9919020|NCT00801736|Experimental|Non Platinum Arm|Paclitaxel (IMP) / Pemetrexed (IMP)
9919021|NCT00801788|Experimental|Egalet® oxycodone Treatment A|Single Dose Administration
9919022|NCT00801788|Experimental|Egalet® oxycodone Treatment B|Single Dose Administration
9919023|NCT00801788|Experimental|Egalet® oxycodone Treatment C|Single Dose Administration
9919024|NCT00801788|Active Comparator|Active comparator|Single Dose Administration
9919025|NCT00801814|Placebo Comparator|1|White Bread
9919026|NCT00801814|Placebo Comparator|2|White Bread and Margarine Control
9919027|NCT00801814|Placebo Comparator|3|Glucose drink control
9919028|NCT00801814|Experimental|4|"White bread and margarine~or~Glucose drink"
9919029|NCT00801814|Experimental|5|"White bread and margarine~or~Glucose drink"
9919030|NCT00801814|Experimental|6|"White bread and margarine~or~Glucose drink"
9919031|NCT00801853|Experimental|Aerovant 1|Aerovant 1mg bid
9919032|NCT00801853|Experimental|Aerovant 2|Aerovant 3mg bid
9919033|NCT00801853|Experimental|Aerovant 3|Aerovant 10mg bid
9919034|NCT00801853|Placebo Comparator|Placebo Control|Placebo Control
9919035|NCT00801866|Experimental|Group 1|Panretinal Photocoagulation + Bevacizumab
9919036|NCT00801866|Experimental|Group 2|Panretinal Photocoagulation
9919037|NCT00801879|Active Comparator|Mupirocin ointment|0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
9919038|NCT00801879|Placebo Comparator|Placebo ointment|0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
9919039|NCT00801905|Active Comparator|1: Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
9919040|NCT00801905|Placebo Comparator|2: placebo|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
9919041|NCT00801918|Other|DD Alone|Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
9919042|NCT00801918|Experimental|DD with ICE Chemotherapy|For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
9919043|NCT00801944|Experimental|I|Solifenacin succinate 5/10mg
9919044|NCT00801944|Experimental|II|Placebo
9919045|NCT00801957|Experimental|1|tacrolimus ointment 0.03%
9919046|NCT00801957|Active Comparator|2|hydrocortisone acetate 1% and butyrate 0.1%
9919047|NCT00801957|Other|3|Control group vaccination and challenge dose only
9919048|NCT00801970|Experimental|1 - Pregnant - Tokophobic|Psychoanalysis treatment.
9919049|NCT00801970|Experimental|2 - Pregnant - Tokophobic|Cognitive-Behavioral treatment.
9919050|NCT00801970|Experimental|3 - Non-pregnant - Tokophobic|Group Therapy
9919051|NCT00801970|No Intervention|4 - Control|Pregnant and non-pregnant non-tokophobic women will answer questionnaires. Won't receive therapy.
9919052|NCT00801996||1. Prostate Cancer|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males ages 40 years or older~Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.~Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care~Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0~Exclusion Criteria:~• Patient refuses consent"
9919053|NCT00801996||2. Normal Healthy Controls|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)~Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer~Exclusion Criteria:~Individuals with family history of prostate cancer~Individuals not deemed in good overall health by the investigator will not be accepted into the study"
9919054|NCT00802009|Experimental|1|Dexamethasone 8mg added to routine local anesthetic during brachial plexus blockade.
9919055|NCT00802009|Active Comparator|2|Routine anesthetic solution (30 cc 1.5% mepivicaine) used during brachial plexus blockade.
9919056|NCT00802035|Active Comparator|IR am|30 mg, single dose, morning administration (immediate release [IR])
9919057|NCT00802035|Experimental|ER am|30 mg; single dose; morning administration (extended release [ER])
9919058|NCT00802035|Experimental|ER pm|30 mg; single dose; evening administration
9919059|NCT00802035|Active Comparator|IR pm|30 mg; single dose; evening administration
9919060|NCT00802048|Experimental|1|48h postoperative infusion of ropivacaine
9919061|NCT00802048|Placebo Comparator|2|48h postoperative infusion of NaCl.
9919062|NCT00802087|Experimental|Egalet® hydrocodone treatment A|Single Dose administration
9919063|NCT00802087|Experimental|Egalet® hydrocodone Treatment B|Single Dose Administration
9919064|NCT00802087|Experimental|Egalet® hydrocodone Treatment C|Single Dose Administration
9919065|NCT00802087|Experimental|Egalet® hydrocodone Treatment D|Single Dose Administration
9919066|NCT00802087|Active Comparator|Active Comparator|Single Dose Administration
9919067|NCT00802126|Experimental|Bevacizumab and verteporfin|
9919068|NCT00802139|Experimental|venoferrum group|
9919069|NCT00802139|Active Comparator|Bolgre group|
9919070|NCT00802152|Experimental|Home Monitoring|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
9919071|NCT00802152|No Intervention|Usual Care|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
9919072|NCT00802165|Experimental|Electroacupuncture Treatment Group|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
9919073|NCT00802165|Sham Comparator|Sham Treatment Group|Sham electroacupuncture treatment gives comparison to the experimental group
9919074|NCT00802191||Control Group|Participants with no movement disorders.
9919075|NCT00802191||Movement Disorders Participants|Participants have a movement disorder
9919076|NCT00802217|Active Comparator|Cohort 1|Civamide liquid filled softgel capsule 5 mg
9919077|NCT00802217|Active Comparator|Cohort 2|Civamide liquid filled soft gel capsules 2 x 5 mg
9919078|NCT00802230|Active Comparator|1|Carvedilol IR
9919079|NCT00802230|Active Comparator|2|Metoprolol Succinate
9919080|NCT00802256|Experimental|A|teeth which are treated with Mineral Trioxide Aggregate (MTA) material
9919081|NCT00802256|Experimental|B|teeth which are treated with new Endodontic Cement (NEC) material
9919082|NCT00802269|Experimental|Reduced Fluence Parameters|Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW)
9919083|NCT00802269|Active Comparator|Traditional parameters|Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW)
9919084|NCT00802282|Experimental|1|First of 5 groups, as described in the protocol and to which volunteers are blinded
9919085|NCT00802282|Experimental|2|Second of 5 groups, as described in the protocol and to which volunteers are blinded
9919086|NCT00802282|Experimental|3|Third of 5 groups, as described in the protocol and to which volunteers are blinded
9919087|NCT00802282|Experimental|4|Fourth of 5 groups, as described in the protocol and to which volunteers are blinded
9919088|NCT00802282|Experimental|5|Fifth of 5 groups as described in the protocol and to which volunteers are blinded
9919089|NCT00802295|Active Comparator|standard dosis protocol|Administration of standard dosis of gonadotrophins for ovarian stimulation.
9919090|NCT00802295|Experimental|2|Administration of low dosis of Gonadotrophins for ovarian stimulation
9919091|NCT00802308|Experimental|Treatment A|Single dose administration of Egalet® morphine with alcohol
9919092|NCT00802308|Experimental|Treatment B|Single dose administration of Egalet® morphine with alcohol
9919093|NCT00802308|Experimental|Treatment C|Single dose administration of Egalet® morphine with alcohol
9919094|NCT00802308|Placebo Comparator|Treatment D|Single dose administration of Egalet® morphine with water
9919095|NCT00802321|Experimental|dutasteride|
9919096|NCT00802334|Experimental|1|
9919097|NCT00802373|Experimental|I|Solifenacin succinate 5/10mg
9919098|NCT00802373|Experimental|II|Tolterodine 4mg
9919099|NCT00802399|Other|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
9919100|NCT00802451|Active Comparator|Test Drug|
9919101|NCT00802451|Active Comparator|Reference Drug|
9919102|NCT00802477|Experimental|1|Application of Autologous Blood Products to surgical site during mastectomy.
9919103|NCT00802477|Active Comparator|2|Standard Modified Radical Mastectomy
9919104|NCT00802490|Active Comparator|Intervention|20 sessions of EEG biofeedback training
9919105|NCT00802490|Placebo Comparator|Control|Only 1 session of EEG biofeedback training
9919106|NCT00802516|Placebo Comparator|1. placebo|placebo margarine
9919107|NCT00802516|Experimental|2. stanol ester|margarine with plant stanol ester
9919108|NCT00802516|Experimental|3. sterol ester|margarine with plant sterol ester
9919109|NCT00802542||1|Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
9919110|NCT00802555|Experimental|ARQ 197|
9919111|NCT00802581|Experimental|1|Ensuring circumferential spread of local anesthetic around the sciatic nerve.
9919112|NCT00802581|Active Comparator|2|Single shot injection of local anesthetic near the sciatic nerve will be performed, without ensuring circumferential spread.
9919113|NCT00802594|Experimental|DB289|
9919114|NCT00802646|Experimental|1|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of preservative-free normal saline will be administered through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
9919115|NCT00802646|Active Comparator|2|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of combined spinal epidural anesthetic through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
9919116|NCT00802698|Experimental|Group 1|
9919117|NCT00802711|Experimental|Arm I|Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
9919118|NCT00802711|Experimental|Arm II|Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
9934844|NCT04439071|Experimental|PTC299 + Standard of Care (SOC)|"Participants will receive PTC299 at 200 milligrams (mg), administered orally, twice daily (BID) on Days 1 to 7, then at 50 mg administered orally, once daily (QD) on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
9919119|NCT00802724|Experimental|1 Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
9919120|NCT00802724|Active Comparator|2 Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
9919121|NCT00802750|Experimental|A|
9919122|NCT00802750|Experimental|B|
9919123|NCT00802763||vaginitis|
9919124|NCT00802776|Active Comparator|FLAK|Femtosecond laser assisted keratoplasty
9919125|NCT00802776|Active Comparator|PKP|Penetrating Keratoplasty
9919126|NCT00802802|Experimental|Cohort I, Step 1|HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs
9919127|NCT00802802|Experimental|Cohort II|HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
9919128|NCT00802802|Experimental|Cohort I, Step 2|HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy
9919129|NCT00802815|Experimental|Etanercept|
9919130|NCT00802828|Active Comparator|Test Product|
9919131|NCT00802828|Active Comparator|Reference Product|
9919132|NCT00802906|Active Comparator|1|1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
9919133|NCT00802906|Active Comparator|2|initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
9919134|NCT00802906|No Intervention|3|control
9919135|NCT00802932||Partial Breast Radiation|1. Patients receiving Partial breast radiation
9919136|NCT00802932||Whole Breast Radiation|2. Patients receiving whole breast radiation
9919137|NCT00802958||Cohort Group 1|Subjects number 1 to 30
9919138|NCT00802958||Cohort Group 2|Subjects number 31 to 56
9919139|NCT00802958||Cohort Group 3|Subject Numbers 57 to 76
9919140|NCT00802971|Experimental|1: FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
9919141|NCT00802971|No Intervention|2: Control|
9919142|NCT00803088|Experimental|1|Treatment of airways with the Alair System
9919143|NCT00803127||no treament|
9919144|NCT00803140|Active Comparator|Cautery Arm|Cautery to make skin incision
9919145|NCT00803140|Active Comparator|Scalpel Incision|Scalpel to make skin incision
9919146|NCT00803166||Cohort Group 1|Subjects number 1 to 30
9919147|NCT00803166||Cohort Group 2|Subjects number 31 to 60
9919148|NCT00803192|Active Comparator|Test Drug|
9919149|NCT00803192|Active Comparator|Reference Drug|
9919150|NCT00803218||Cohort Group 1|Subjects number 1 to 26
9919151|NCT00803218||Cohort Group 2|Subjects number 27 to 56
9919152|NCT00803231||Retrospective cohort|Patient treated with Xigris between January 2006 and November 2008.
9996123|NCT01497002|Experimental|OSHO - allografting as consolidation|allogeneic stem cell Transplantation versus no transplantation
9996124|NCT01497015|Experimental|memory training|memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
9996125|NCT01497015|Experimental|speed of processing training|Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
9996126|NCT01497015|Experimental|waitlist control|Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
9996127|NCT01497028||Plicated Gastric Banding|
9996128|NCT01497028||Standard Gastric Banding|
9996129|NCT01497080||1|
9996130|NCT01497080||activity level|
9996131|NCT01497080||no treatment|
9996132|NCT01497093|Experimental|Pomalidomide/Bortezomib/Dexamethasone|1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
9996133|NCT01497106|Experimental|Calorie restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks.
9996134|NCT01497106|Active Comparator|Control|Participants will continue their normal living for entire time of the study, totaling 16 weeks.
9996135|NCT01497119|Experimental|JNJ-39758979, 300 mg|
9996136|NCT01497119|Experimental|JNJ-39758979, 100 mg|
9996137|NCT01497119|Placebo Comparator|Placebo|
9996138|NCT01497132|Experimental|Vitamin D3|
9996139|NCT01497132|Placebo Comparator|Placebo|
9996140|NCT01497158|Active Comparator|Control Group|Participants who received only self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home.
9996141|NCT01497158|Active Comparator|Active Group|Participants who received self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home and biomarker feedback from the urine of cohabitating adult non-smoker in the home.
9996142|NCT01497184|Experimental|DLI (Adults)|Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
9996143|NCT01497184|Experimental|DLI any time|Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
9996144|NCT01497184|Experimental|DLI Pediatrics|Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
9996145|NCT01497184|Experimental|DLI - Haplo-Identical Family Donor|Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
9996146|NCT01497210|Experimental|EASH|
9996147|NCT01497223|Experimental|MGCD290 and Fluconazole|Oral Administration of MGCD290 and Fluconazole
9996148|NCT01497223|No Intervention|Fluconazole|This is an Active Comparator: Oral Administration of Fluconazole with Placebo
9996149|NCT01497236|Experimental|Experimental: Ready to Use Terapeutic Food (RUTF)|
9996150|NCT01497236|Experimental|Multi Micronutrient Powder (MNP)|
9996151|NCT01497236|No Intervention|no supplement|
9996152|NCT01497249|Placebo Comparator|Placebo|Placebo Beverage
9996153|NCT01497249|Active Comparator|A dietary fiber (FCHO)|15g/BID
9996154|NCT01497288|Experimental|Sequence 1 (A-B-C)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)"
9996155|NCT01497288|Experimental|Sequence 2 (A-C-B)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment~B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)"
9996156|NCT01497301|No Intervention|Standard Individual Medical Appointment|
9996157|NCT01497301|Active Comparator|Group Visits|
9996158|NCT01497314|Other|Low Lactose Infant Formula|
9996159|NCT01497327|Experimental|PSI-352938 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
9996160|NCT01497327|Experimental|PSI-352938 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
9996161|NCT01497327|Experimental|PSI-352938 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
9996162|NCT01497327|Experimental|PSI-7977 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
9996163|NCT01497327|Experimental|PSI-7977 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
9996164|NCT01497327|Experimental|PSI-7977 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
9996165|NCT01497340|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth with a plastic clamp placed at 1 cm from its cutaneous insertion.
9996166|NCT01497340|Experimental|position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weight measurement. The cord will be clamped at 2 minutes after birth .
9996167|NCT01497353|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth. New weigh will be obtained after that.
9996168|NCT01497353|Experimental|Position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weigh measurement. The cord will be clamped at 2 minutes after birth .
9998089|NCT01514877|Experimental|Icotinib plus Whole Brain Radiotherapy|Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.
9998090|NCT01514890||Telaprevir|
9998091|NCT01514890||Boceprevir|
9998092|NCT01514903|Active Comparator|viagra,anti-erectile dysfunction agent|
9998093|NCT01514903|Experimental|HIP0908|
9998094|NCT01514929|Experimental|Supratherapeutic Dose|20mg/kg ACHN-490 Injection
9998095|NCT01514929|Experimental|Possible Therapeutic Dose|15mg/kg ACHN-490 Injection
9998096|NCT01514929|Active Comparator|Moxifloxacin|400mg moxifloxacin
9998097|NCT01514929|Placebo Comparator|Placebo|Placebo
9998098|NCT01514942|Other|Insulin resistant patients|
9998099|NCT01514942|Other|Non-insulin resistant patients|
9998100|NCT01514968|Experimental|DNV/r+cyclosporine|
9998101|NCT01514968|Active Comparator|cyclosporine|
9998102|NCT01514968|Active Comparator|danoprevir+ritonavir|
9998103|NCT01514981|Experimental|AMG 761|
9998104|NCT01514981|Placebo Comparator|Placebo|
9998105|NCT01514994|Experimental|AngioScore's Valvuloplasty Scoring Balloon|
9998106|NCT01515020|Active Comparator|vancomycin monotherapy|vancomycin monotherapy: standard therapy
9998107|NCT01515020|Experimental|daptomycin monotherapy|daptomycin monotherapy: experimental therapy
9998108|NCT01515033|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
9998109|NCT01515033|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
9998110|NCT01515059||Bariatric sugery patients|Obese patients who are awaiting either a gastric bypass or sleeve gastrectomy
9998111|NCT01515085||biopsy proven glioma, no prior treatment|
9998112|NCT01515111||Internal Medicine Staff|All interns, residents and attendings training (or working) at an Internal Medicine department of a Guatemalan teaching hospital.
9998113|NCT01515124|No Intervention|Lymphedema Care Only|"All 4 groups receive lymphedema care as follows:~2 custom fitted compression garments (baseline and 6 months)~evaluations for flare-ups at request (and at each measurement time point)~lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions."
9998236|NCT01516346|Placebo Comparator|Placebo|"Research pharmacy-formulated capsules will be given to subjects in two bottles. For this interventional arm, both the bottles will contain placebo capsules.~Dosage will be same regardless of up-titration from Stage 1 dosing to Stage 2 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
9998237|NCT01516359||patients with cardiac surgery|
9998238|NCT01516372|Experimental|Treatment 1|Healthy Volunteers will receive Treatments ABDC
9998239|NCT01516372|Experimental|Treatment 2|Healthy Volunteers will receive Treatments BCAD
9998240|NCT01516372|Experimental|Treatment 3|Healthy Volunteers will receive Treatments CDBA
9996169|NCT01497379|Experimental|intra-individual implant ON|intra-individual implant activation
9996170|NCT01497379|Placebo Comparator|intra-individual implant OFF|intra-individual implant deactivation
9996171|NCT01497392|Experimental|Treatment (dovitinib lactate, gemcitabine, and capecitabine)|Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9996172|NCT01497405|Active Comparator|Test, Treat, Retain(TTR) only|Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
9996173|NCT01497405|Experimental|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
9996174|NCT01497431|Experimental|Arm I (Se-methyl-seleno L-cysteine)|Participants receive Se-methyl-seleno L-cysteine on days 1-84.
9996175|NCT01497431|Experimental|Arm II (selenomethionine)|Participants receive selenomethionine PO on days 1-84.
9996176|NCT01497431|Placebo Comparator|Arm III (placebo)|Participants receive placebo PO on days 1-84.
9996177|NCT01497444|Experimental|sorafenib and TH-302|Patients will be administered sorafenib tablets to take twice daily by mouth, every day of each cycle. Patients will also be given TH-302 intravenously (IV) on days 8, 15 and 22 of each cycle. A cycle is 28 days.
9996178|NCT01497457|Experimental|MR saline peritoneography|Patients that will undergo MR saline peritoneography
9996179|NCT01497470|Experimental|Paclitaxel/carboplatin with custirsen|Custirsen added to standard paclitaxel/carboplatin chemotherapy
9996180|NCT01497483|Active Comparator|Pravastatin alone|Subjects will be dosed with Pravastatin alone (40 mg)
9996181|NCT01497483|Experimental|Pravastatin and Cyclosporine|Subjects will be dosed with pravastatin and cyclosporine.
9996182|NCT01497522|Experimental|Vildagliptin|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
9996183|NCT01497522|Placebo Comparator|Placebo|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
9996184|NCT01497535|Experimental|Insulin detemir|
9996185|NCT01497535|Active Comparator|Insulin glargine|
9996186|NCT01497548|Experimental|Methylphenidate add on to Mirtazapine|Methylphenidate add on to the usual treatment (Mirtazapine)
9996187|NCT01497548|Placebo Comparator|Placebo add on to Mirtazapine|Non active compund add on to the usual treatment (Mirtazapine)
9996188|NCT01497561|Experimental|insulin detemir|
9996189|NCT01497561|Active Comparator|insulin NPH|
9996190|NCT01497574|Experimental|Insulin detemir|
9996191|NCT01497574|Active Comparator|Insulin glargine|
9996192|NCT01497587|Experimental|Insulin detemir|
9996193|NCT01497600|Experimental|insulin detemir|
9996194|NCT01497600|Active Comparator|insulin NPH|
9996195|NCT01497626|Experimental|Bortezomib plus lapatinib|Combination treatment with lapatinib and bortezomib
9996196|NCT01497639|Active Comparator|Process 1|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of interleaving stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to double-monopolar stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
9996197|NCT01497639|Active Comparator|Process 2|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of double-monopolar stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to interleaving stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
9996198|NCT01497652|Active Comparator|Treatment Group|Treatment group will receive Rasagiline (Azilect) 1mg daily
9996199|NCT01497652|Placebo Comparator|Placebo Group|will receive placebo daily
9996200|NCT01497678|Other|Extracellular Matrix|Implantation of Extracellular Matrix
9996201|NCT01497691|Other|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol.
9996202|NCT01497691|Sham Comparator|Sham NIPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. The pressure settings will be fixed at a positive end-expiratory pressure (PEEP) of 5-8 cm H2O.
9998241|NCT01516372|Experimental|Treatment 4|Healthy Volunteers will receive Treatments DACB
9998242|NCT01516385||spinal cord injury|
9998243|NCT01516385||other neurological conditions|
9919153|NCT00803231||Prospective cohort|Patient treated with Xigris between November 2008 and November 2009.
9919154|NCT00803257|Experimental|1|Lumbrical splint and lumbrical stretches
9919155|NCT00803257|Active Comparator|2|Lumbrical Splint and regular exercises
9919156|NCT00803257|Active Comparator|3|Regular splint and lumbrical exercises
9919157|NCT00803257|Active Comparator|4|Regular splint and regular exercises
9934845|NCT04439071|Placebo Comparator|Placebo + SOC|"Participants will receive PTC299-matching placebo administered orally, BID on Days 1 to 7, then administered orally, QD on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
9934846|NCT04436380||Relapsed SAA Patients|Patients with Severe Aplastic Anemia who Relapsed after Immunosuppressive Therapy
9934847|NCT04436367||SAA patients with Monosomy 7|Severe Aplastic Anemia Patients who Developed High Risk Clonal Evolution with Chromosome 7 Abnormalities after Immunosuppressive Therapy
9934848|NCT04432597|Experimental|1/Arm 1A|HPV vaccine at 1x10(11) Viral Particles (VP) (DL1) and at 5x10(11) VP (DL2)
9934849|NCT04432597|Experimental|2/Arm 1B|HPV vaccine at RP2D plus M7824 at 1200 mg
9934850|NCT04432597|Experimental|3/Arm 2A|HPV vaccine at RP2D given as neoadjuvant or induction therapy
9934851|NCT04432597|Experimental|4/Arm 2B|HPV vaccine at RP2D plus M7824 at 1200 mg given as neoadjuvant or induction therapy
9934852|NCT04431024||Cancer patients|Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS
9934853|NCT04431024||Relatives of cancer patients|First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)
9934854|NCT04431011||Participants|Healthy right-handed participants aged 18-50
9934855|NCT04426825|Experimental|Atezolizumab plus Bevacizumab|Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death.
9934856|NCT04424927|Experimental|PRV-015 Low Dose|PRV-015 Low Dose, sterile solution for subcutaneous administration
9934857|NCT04424927|Experimental|PRV-015 Medium Dose|PRV-015 Medium Dose, sterile solution for subcutaneous administration
9934858|NCT04424927|Experimental|PRV-015 High Dose|PRV-015 High Dose, sterile solution for subcutaneous administration
9934859|NCT04424927|Placebo Comparator|Placebo|Placebo, sterile solution for subcutaneous administration
9934860|NCT04423783|Experimental|Spider gamification app|Participants play the spider gamification app twice a day for 7 days
9934861|NCT04423783|Experimental|Online exposure + spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play the spider gamification app twice a day for 7 days
9934862|NCT04423783|Active Comparator|Online exposure + non-spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play a non-spider gamification app twice a day for 7 days
9934863|NCT04421014|Active Comparator|Ketone Ester/ Arm 1|25 participants
9934864|NCT04421014|Placebo Comparator|Placebo/ Arm 2|25 participants
9934865|NCT04419870||Group 1a|Patients with mitochondrial disease who are ill with suspected or confirmed COVID19
9934866|NCT04419870||Group 1b|Patients with mitochondrial disease who are NOT ill with acute infection
9934867|NCT04419870||Group 2|Family members of patients with mitochondrial disease in Group 1
9934868|NCT04418661|Experimental|SAR442720 + Pembrolizumab|"Part 1:~SAR442720 (also known as RMC-4630) will be administered orally twice a week (BIW) followed by pembrolizumab which is given intravenously (IV) once every 3 weeks (Q3W). The dose of SAR442720 will be escalated or de-escalated depending on the emerging safety data of the combination."
9934869|NCT04418661|Experimental|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score > 50%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
9934870|NCT04418661|Experimental|SAR442720 + Pembrolizumab: Non-small cell lung cancer with Tumor proportion score 1-49%|"Part 2:~SAR442720 dose will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
9934871|NCT04418661|Experimental|SAR444270 + adagrasib: Dose Escalation|Part 3A; SAR442720 and adagrasib will be administered orally on a continuous basis.
9934872|NCT04418661|Experimental|SAR444270 + adagrasib: Dose Expansion|"Part 3B:~Once SAR442720 dose is confirmed in Part 3A SAR442720 and adagrasib will be administered orally on a continuous basis."
9934873|NCT04418661|Experimental|SAR442720 + Pembrolizumab continuous|"Part 4:~SAR442720 will be administered orally in combination with Pembrolizumab which is given by IV infusion once every 3 weeks (Q3W) or once every 6 weeks (Q6W)"
9934874|NCT04417673||Sickle Cell Disease|Individuals with sickle cell disease
9934875|NCT04417660|Experimental|Bintrafusp alfa (M7824)|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
9934876|NCT04417127|Experimental|Microfinance with Integrated Community-based Care|20 microfinance groups with n=450 participants will be randomized to receive the ICB intervention.
9919158|NCT00803296||Obese patients with type 2 diabetes|Patients with type 2 diabetes and BMI>33
9919159|NCT00803296||Obese subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BMI>33
9919160|NCT00803296||Lean subjects with type 2 diabetes|Patients with type 2 diabetes and BM<25
9919161|NCT00803296||Lean subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BM<25
9919162|NCT00803309|Active Comparator|A|PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
9919163|NCT00803309|Active Comparator|B|PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up
9919164|NCT00803322||1|communities where tuberculosis patients followed the conventional health facility based tuberculosis case finding and treatment
9919165|NCT00803322||2|community where suspects of pulmonary tuberculosis were identified by community health workers and received treatment in the community
9919166|NCT00803335|Active Comparator|Premarin cream 0.5gm|Application of 0.5gm of vaginal estrogen cream nightly until surgery.
9919167|NCT00803335|Active Comparator|Premarin cream 1.0gm|Application of 1.0gm of vaginal estrogen cream nightly until surgery.
9919168|NCT00803335|No Intervention|No intervention|Women in this arm will not apply any cream or moisturizers to the vagina until surgery, ie no intervention.
9919169|NCT00803348|Active Comparator|1|Initial Bolus dose of 0.2% ropivicaine followed by 0.2% ropivicaine infusion until day 2 post-op
9919170|NCT00803348|Experimental|2|Initial Bolus dose of 0.2% ropivicaine followed by 0.1% ropivicaine infusion until day 2 post-op
9919171|NCT00803348|Placebo Comparator|3|Initial Bolus dose of 0.375% ropivicaine followed by saline infusion until day 2 post-op
9919172|NCT00803374|Experimental|0.1 mg/kg|
9919173|NCT00803374|Experimental|0.3 mg/kg|
9919174|NCT00803374|Experimental|1.0 mg/kg|
9919175|NCT00803374|Experimental|3.0 mg/kg|
9919176|NCT00803374|Experimental|10 mg/kg|
9919177|NCT00803387||Patients taking Xalatan with ocular dryness or irritation|"patient must already be using xalatan for at least 1 month prior to study enrollment in both eyes and have complaints of dry eye and/or irritation.~any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)"
9919178|NCT00803426|Active Comparator|1|Local anesthetic will be injected above the division of the sciatic nerve.
9919179|NCT00803426|Experimental|2|Local anesthetic will be injected below the division of the sciatic nerve, around the common peroneal and tibial nerves.
9919180|NCT00803439||Cohort Group 1|Subjects number 1 to 20
9919181|NCT00803439||Cohort Group 2|Subjects number 21 to 40
9919182|NCT00803439||Cohort Group 3|Subjects number 41 to 60
9919183|NCT00803439||Cohort Group 4|Subjects number 61 to 80
9919184|NCT00803465||Cohort Group 1|Subjects number 1 to 24
9919185|NCT00803465||Cohort Group 2|Subjects number 25 to 44
9919186|NCT00803465||Cohort Group 3|Subjects number 45 to 68
9919187|NCT00803465||Cohort Group 4|Subjects number 69 to 91
9919188|NCT00803465||Cohort Group 5|Subjects Number 92 to 115
9919189|NCT00803478|Active Comparator|Hinge position|superior vs. temporal
9919190|NCT00803478|Active Comparator|Hinge width|45 vs 90 degrees
9919191|NCT00803478|Active Comparator|Flap Thickness|110 vs 130 microns
9919192|NCT00803491|Experimental|Problem based learning program|PBL intervention - a self-promoting PBL program for patients with rheumatic diseases.
9919193|NCT00803491|Active Comparator|Control group|Traditional rheumatological care.
9934877|NCT04417127|Active Comparator|Microfinance with Standard of Care|20 microfinance groups with n=450 participants will be randomized to continue to receive standard of care from an AMPATH-supported rural health facility.
9996203|NCT01497691|Active Comparator|BiPAP|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. Settings will be adjusted based on the age and clinical presentation of the child.
9996204|NCT01497717|Experimental|Adalimumab, Behcet with arthritis|
9996205|NCT01497730||CR FB|Subjects receiving a Cruciate Retaining Fixed Bearing implant configuration
9996206|NCT01497730||PS FB|Subjects Receiving a Posterior Stabilized Fixed Bearing implant configuration
9996207|NCT01497730||CR RP|Subjects receiving a Cruciate Retaining Rotating Platform implant configuration
9996208|NCT01497730||PS RP|Subjects receiving a Posterior Stabilized Rotating Platform implant configuration
9996209|NCT01497743|Placebo Comparator|placebo|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
9996210|NCT01497743|Active Comparator|Probiotic|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
9996211|NCT01497769|Experimental|Group 1|Aerosol inhaled MVA85A and intradermal saline placebo
9996212|NCT01497769|Experimental|Group 2|Intradermal MVA85A and inhaled aerosol saline placebo
9996213|NCT01497782|Experimental|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
9996214|NCT01497782|No Intervention|No instructor feedback|Control group who did not receive instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
9996215|NCT01497821|Experimental|Dose exploration|Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
9996216|NCT01497821|Experimental|Dose expansion|Dose and dosing frequency selected from Part 1 dose exploration.
9996217|NCT01497847||travelers to tropical destinations|
9996218|NCT01497873|Experimental|Belotecan|Camtobell Injection
9996219|NCT01497873|Active Comparator|Topotecan|Hycamtin Injection
9996220|NCT01497886|Active Comparator|Hip Hop Stroke educational program|Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.
9996221|NCT01497886|Placebo Comparator|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
9996222|NCT01497912|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
9996223|NCT01497912|Placebo Comparator|Placebo|Matched placebo tablets
9919194|NCT00803530|Experimental|1|"Loading phase (week 1): ATO 0.3 mg/Kg/die for 5 consecutive days.~Subsequent phase (from week 2 to week 16): ATO 0.25 mg/kg twice a week (day 2 and 5 of every week).~Ascorbic acid 1000 mg IV within 30 minutes after each arsenic trioxide infusion for 16 consecutive weeks."
9919195|NCT00803556|Experimental|Arm 1|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin"
9919196|NCT00803556|Experimental|Arm 2|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin"
9919197|NCT00803582|Experimental|Experimental|Traditional acupuncture
9919198|NCT00803582|Sham Comparator|Placebo|Placebo acupuncture
9919199|NCT00803582|No Intervention|No-treatment|no treatment
9919200|NCT00803608|Active Comparator|02|Current standard of care insole
9919201|NCT00803608|Experimental|01|TrueContour® insole
9919202|NCT00803673|Experimental|Active|100mcg 719
9919203|NCT00803673|Experimental|Active 2|500mcg '719
9919204|NCT00803673|Experimental|Active 3|1000mcg '719
9919205|NCT00803673|Placebo Comparator|Placebo|Placebo '719
9919206|NCT00803699|Placebo Comparator|Placebo|Capsule contains no selenium
9919207|NCT00803699|Active Comparator|Selenium as L-selenomethionine|50, 100, or 200 micrograms of selenium
9919208|NCT00803725|Active Comparator|1|Mepivicaine for spinal anesthesia
9919209|NCT00803725|Experimental|2|Mepivacaine with Fentanyl for spinal anesthesia
9919210|NCT00803764|Active Comparator|Test Product|
9919211|NCT00803764|Active Comparator|Reference Product|
9919212|NCT00803803|Experimental|Pilocarpine Concentration|Varying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
9919213|NCT00803803|Experimental|Pilocarpine Frequency|Varying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
9919214|NCT00803816|Other|Addition of everolimus to standard care|refractive to cyclosporine A (CsA) received additional everolimus.
9919215|NCT00803855|Experimental|AZD1446 Oral or placebo|Single oral administration of AZD1446 or placebo
9919216|NCT00803855|Experimental|AZD1446 Oral, with or without food|Single oral administration of AZD1446 with or without food
9919217|NCT00803868|Experimental|1|Varenicline
9919218|NCT00803868|Placebo Comparator|2|Placebo
9919219|NCT00803881||CF patients of all age groups|Longitudinal prospective assessment of upper and lower airway colonization in all patients attended in the Jena University CF centre
9919220|NCT00803894|Active Comparator|A|MK0752 1000 mg
9919221|NCT00803894|Active Comparator|B|MK0752 350 mg
9919222|NCT00803894|Placebo Comparator|C|Placebo
9919223|NCT00803907|Experimental|nodular BCC of the eyelid|Patients with nodular BCC of the eyelid
9919224|NCT00803920||Exenatide|
9919225|NCT00803920||Exenatide LAR|
9919226|NCT00803933|Experimental|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
9919227|NCT00803933|Active Comparator|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
9919228|NCT00803946|Active Comparator|Test Product|
9919229|NCT00803946|Active Comparator|Reference Product|
9919230|NCT00803972|Experimental|Stage 1: 3 U insulin plus rHuPH20|Participants will receive 3 Units (U) of regular insulin (100 U/milliliter [mL]), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 micrograms (μg)/mL recombinant human hyaluronidase (rHuPH20).
9919231|NCT00803972|Experimental|Stage 1: 12 U insulin plus rHuPH20|Participants will receive 12 U of regular insulin (100 U/mL), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 μg/mL rHuPH20.
9919232|NCT00803972|Experimental|Stage 2: insulin plus rHuPH20|Participants will receive 6, 12, and 24 U regular insulin (100 U/mL) in a randomly assigned order, with each insulin dose administered once with and once without 5 μg/mL rHuPH20.
9919233|NCT00803972|Experimental|Stage 3: 1.5 U insulin lispro plus rHuPH20|Participants will receive 1.5 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
9996224|NCT01497925|Experimental|ADI-PEG 20|
9996225|NCT01497951|Experimental|Aminolaevulinic acid|
9996226|NCT01497951|Placebo Comparator|Placebo|
9996227|NCT01497964|Experimental|Cabazitaxel|Cabazitaxel, several dosages
9996228|NCT01497977|Experimental|soya phytoestrogens|
9996229|NCT01497977|Experimental|red clover phytoestrogens|
9996230|NCT01497977|No Intervention|No drugs|
9996231|NCT01497990|Experimental|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
9996232|NCT01498003|Placebo Comparator|Control group|normal saline was applied to those randomized to control group, with same use as tirofiban
9996233|NCT01498003|Experimental|Tirofiban group|after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion
9996234|NCT01498016|Experimental|Iv-Busulfan|iv busulfan 1.6mg/kg given q12h
9996235|NCT01498029|Active Comparator|Randomized to Microfracture|This group of patients who have been randomised to receive microfracture procedure will be the control group for this study
9996236|NCT01498029|Experimental|Randomized to CAIS|This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study
9996237|NCT01498042||stroke, thrombolysis, over 80, outcome|To study the outcome of stroke patients over 80 years treated with thrombolysis.
9996238|NCT01498055||CIK therapy group|
9996239|NCT01498055||control group|
9996240|NCT01498081|Experimental|Single dose of AZD2115 25 µg|
9996241|NCT01498081|Experimental|Single dose of AZD2115 80 µg|
9996242|NCT01498081|Experimental|Single dose of AZD2115 240 µg|
9996243|NCT01498081|Placebo Comparator|Single doses of placebo|
9996244|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg|
9996245|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg + tiotropium 18 µg|
9996246|NCT01498094|Active Comparator|Control|Standard low-flow oxygen therapy.
9996247|NCT01498094|Experimental|Intervention|High Flow Nasal Cannula Oxygen Therapy
9996248|NCT01498133|Experimental|skin-to-skin contact|Newborns in the study group had skin-to-skin contact with their mothers in the NICU, twice a day (morning and evening) for 60 minutes, for seven days (including weekends).
9996249|NCT01498133|No Intervention|control group|The control group (n = 49) received routine care without skin-to-skin contact.
9996250|NCT01498159|Experimental|Pharmacist + Health Promoter|Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.
9996251|NCT01498159|Active Comparator|Pharmacist|Participants will receive support from pharmacist.
9996252|NCT01498172|Experimental|NMIBC at intermediate risk of progression|
9996253|NCT01498172|Experimental|NMIBC at high risk of progression|
9996254|NCT01498172|Experimental|NMIBC at low risk of progression|
9996255|NCT01498198|Experimental|Expedited Surgery|Participants will have surgery within 3 months
9996256|NCT01498198|Experimental|Non Operative Management|Participants will undergo non operative care for as long as they are improving, and will return to the surgeon when no progression is reached.
9996257|NCT01498211|Experimental|Biopsy|
9996258|NCT01498224|Active Comparator|Suture|Suture application
9996259|NCT01498224|Experimental|ReSure Sealant|Sealant application
9996260|NCT01498237|Experimental|Photoacoustic endoscopy|This is a one-arm, feasibility study to determine how well the experimental procedure photoacoustic endoscopy will evaluate the human endometrial cavity in vivo.
9996261|NCT01498250||basal cell carcinoma|
9996262|NCT01498250||non-lesional skin|
9996263|NCT01498315||Women following hysterecomy|
9996264|NCT01498354|Experimental|2-D high definition TEO (transanal endoscopic operation)|
9996265|NCT01498354|Active Comparator|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge
9996266|NCT01498367|No Intervention|Usual care|Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
9996267|NCT01498367|Experimental|Telemonitoring of diabetes 2 patients|Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient's home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.
9996268|NCT01498380|Experimental|Dexmedetomidine Rapid Bolus|All subjects will receive a rapid bolus of dexmedetomidine following induction of anesthesia with propofol and remifentanil and placement of laryngeal mask airway.
9996269|NCT01498393|Other|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
9996270|NCT01498406|Experimental|high dose vitamin D3|4,000 IU of vitamin D3 daily for 8 months
9996271|NCT01498406|Active Comparator|low dose vitamin D3|400 IU of vitamin D3
9996272|NCT01498432|Experimental|Heliox21|
9996273|NCT01498432|Active Comparator|Air O2|
9996274|NCT01498497||PR-021 Eosinophilic Esophagitis (EoE) Subjects|Subjects who received study drug and completed PR-021 study
9996275|NCT01498510|No Intervention|treatment-as-usual (TAU)|The standard medical treatment provided to chronic pain patients at the study site pain specialty practice
9996276|NCT01498510|Experimental|TAU plus web-based intervention|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that teaches chronic pain patients with aberrant behavior self-management skills to reduce pain severity and medication misuse and improve functioning
9996277|NCT01498523|Experimental|raw camel milk|
9996278|NCT01498523|Experimental|camel milk powder solution|
9996279|NCT01498523|Active Comparator|raw cow milk|
9996280|NCT01498523|Active Comparator|Glucose solution|
9996281|NCT01498562|Experimental|Gefitinib plus Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) and Nimotuzumab (200mg weekly)
9996282|NCT01498562|Active Comparator|Gefitinib alone|Mono-therapy group: Gefitinib(250mg daily)
9996283|NCT01498614|Experimental|Affect school|Affect school is an educational intervention which includes 8 group sessions followed by 10 individual meetings with therapist
9996284|NCT01498614|Active Comparator|Basal body awareness|Basal body awareness is an educational method with 9 group sessions followed by 6 individual meetings
9996285|NCT01498627||Case Group|Subjects in this group are incident cases (i.e. newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
9996286|NCT01498627||Control Group|Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
9996287|NCT01498666|Experimental|L. reuteri protectis tablets|one tablet a day for 4 weeks
9996288|NCT01498666|Placebo Comparator|Placebo tablet|one tablet a day for 4 weeks
9996289|NCT01498705||Hemmorhagic Stroke|"Hospitalization for an admitting diagnosis of hemorrhagic stroke admitted to the neurosurgical intensive care unit~Age greater than 18 years~No evidence of ischemic cerebrovascular injury"
9996290|NCT01498718|Experimental|Group 1A (18-50 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
9996291|NCT01498718|Experimental|Group 2A (51-70 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
9996292|NCT01498718|Placebo Comparator|Group 1B (18-50 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
9996293|NCT01498718|Placebo Comparator|Group 2B (51-70 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
9996294|NCT01498731|Experimental|Copeptin|"Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions.~To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software Praxis-connect i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.~Patients who test positive for Copeptin will be treated as by standard practise."
9996295|NCT01498731|No Intervention|Standard|Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
9996296|NCT01498757||Patients treated with Taxane/5-FU/platinum based chemo.|
9996297|NCT01498783|Experimental|Treatment|"Participants meeting the eligibility requirements.~Intervention: 5-fluorouracil"
9996298|NCT01498796|Experimental|Ketorolac|
9996299|NCT01498796|Placebo Comparator|Placebo|
9996300|NCT01498835|Experimental|Combined Sunitinib and irradiation|Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
9996301|NCT01498848|Active Comparator|Soybean oil|Families were given soybean oil for cooking during 4 weeks
9996302|NCT01498848|Active Comparator|Sunflower oil|Families were given sunflower oil for cooking during 4 weeks
9996303|NCT01498861|Other|Run-In Period|Ortho-Cyclen for 21 days. Only for subjects who are not already taking Ortho-Cyclen prior to the study
9996304|NCT01498861|Experimental|Sequence AB|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
9996305|NCT01498861|Experimental|Sequence BA|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
9996306|NCT01498874|Placebo Comparator|Placebo|
9996307|NCT01498874|Experimental|low dose gevokizumab|
9996308|NCT01498874|Experimental|high dose gevokizumab|
9996309|NCT01498900||Repaglinide|
9996310|NCT01498913||Repaglinide|
9996311|NCT01498926|Experimental|Glycerol|
9996312|NCT01498926|Active Comparator|Mannitol|
9996313|NCT01498939|Experimental|IDet 0.2 U/kg|
9996314|NCT01498939|Experimental|IDet 0.4 U/kg|
9996315|NCT01498939|Experimental|IDet 0.8 U/kg|
9996316|NCT01499004|Experimental|Treatment A|tofacitinib (CP-690,550) modified-release formulation A-Fed
9996317|NCT01499004|Experimental|Treatment B|tofacitinib (CP-690,550) modified-release formulation B1-Fed
9996318|NCT01499004|Experimental|Treatment C|tofacitinib (CP-690,550) modified-release formulation A-Fasted
9996319|NCT01499004|Experimental|Treatment D|tofacitinib (CP-690,550) modified-release formulation B1-Fasted
9919234|NCT00803972|Experimental|Stage 3: 6 U insulin lispro plus rHuPH20|Participants will receive 6 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
9919235|NCT00803972|Experimental|Stage 4: 95 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 95 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
9919236|NCT00803972|Experimental|Stage 4: 50 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 50 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
9919237|NCT00803972|Experimental|Stage 4: 25 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 25 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
9919238|NCT00803985|Active Comparator|Lichtenstein|Open operation with onlay light weight polypropylene mesh
9919239|NCT00803985|Active Comparator|Total Extraperitoneal repair (TEP)|Laparoscopic operation with preperitoneal nonfixated mesh
9919240|NCT00804011|Experimental|1|Automatic tube compensation plus pressure support
9919241|NCT00804011|Active Comparator|2|Pressure support alone
9919242|NCT00804024||ClearWay™ RX|
9919243|NCT00804037|Active Comparator|Ethanol|
9919244|NCT00804037|Active Comparator|Ethanolamine Oleate|
9919245|NCT00804050|Experimental|Infusion A: rEPO|rEPO for 4 mounths consequently
9919246|NCT00804050|Experimental|Infusion B combined r-EPO|rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently
9919247|NCT00804063||1|glaucoma patients
9919248|NCT00804063||2|non-glaucoma controls
9919249|NCT00804076|Experimental|NP2|Intradermal injection
9919250|NCT00804089|Experimental|1|Traditional needle acupuncture
9919251|NCT00804089|Active Comparator|2|Myofascial trigger point dry needling
9919252|NCT00804089|Active Comparator|3|Myofascial trigger point acupressure
9919253|NCT00804102|Active Comparator|Retinitis pigmentosa|
9919254|NCT00804102|Active Comparator|Macula off|condition after treatment of retinal detachment
9919255|NCT00804102|Active Comparator|Primary open angle Glaucoma|
9919256|NCT00804102|Active Comparator|Hereditary Macular Degeneration|
9919257|NCT00804102|Active Comparator|Treated Retina detachment|
9919258|NCT00804102|Active Comparator|Retinal Artery Occlusion|
9919259|NCT00804102|Active Comparator|Retinal Vein Occlusion|
9919260|NCT00804102|Active Comparator|Non-Arteriitic-Anterior-Ischemic Optic-Neuropathy|
9919261|NCT00804102|Active Comparator|Hereditary autosomal dominant Optic atrophy|
9919262|NCT00804102|Active Comparator|dry Age-related Macular Degeneration|
9919263|NCT00804102|Active Comparator|Ischemic Macula edema|
9919264|NCT00804102|Sham Comparator|Non-stimulated|
9919265|NCT00804115|No Intervention|1|Latanoprost in combination with Pilocarpine
9919266|NCT00804115|No Intervention|2|Timolol or Cosopt
9919267|NCT00804180|Other|Coping skills intervention|Self-Injection Anxiety Counseling: Evaluation of a group treatment for injection-related anxiety. The intention of the study is to obtain basic evaluation of a clinical treatment offered in a natural clinic setting, and does not include a control group, or procedure for random assignment of participants.
9919268|NCT00804206|Experimental|Group A|Bevacizumab before panretinal photocoagulation.
9919269|NCT00804206|Experimental|Group B|Bevacizumab after panretinal photocoagulation
9919270|NCT00804219|Experimental|TBE low responder|
9919271|NCT00804219|Experimental|FSME responder|
9919272|NCT00804219|Experimental|hepatitis B non-responder|
9919273|NCT00804232|Experimental|1|effects on child health of family-based home care compared to traditional hospital-based care,
9919274|NCT00804232|Experimental|2|effects on child health of family-based psychological treatment compared to traditional hospital-based treatment
9919275|NCT00804245|Experimental|radiolabeled choline tracer scans|PET-CT scans supplemented with Choline 11 tracer
9919276|NCT00804271|Other|Memantine|
9919277|NCT00804284||Pentacel Group|Infants initiated on PENTACEL® vaccine
9919278|NCT00804284||Other DTap vaccines Group|Infants initiated on other DTaP vaccines
9919279|NCT00804310|Experimental|Lapatinib and Ixabepilone|
9919280|NCT00804323|Experimental|Group 1|Patients with open-angle glaucoma
9919281|NCT00804336|Experimental|Pasireotide and RAD001|RAD001 was administered orally as a once-daily dose. Pasireotide s.c. was self-administered s.c. twice daily for 4 weeks. If pasireotide s.c. was tolerated, patients received pasireotide LAR i.m. at the corresponding dose level. Pasireotide s.c. was continued for an additional 2 weeks after administration of pasireotide LAR until anticipated steady-state levels of pasireotide LAR were achieved. Pasireotide LAR was administered every 28 days. Cycles for everolimus and pasireotide LAR were repeated every 28 days.
9919282|NCT00804375|Experimental|2PX|Pain medication
9919283|NCT00804375|Placebo Comparator|placebo|placebo
9919284|NCT00804388|Active Comparator|1|Uncemented total hip replacement, 32 mm caput
9919285|NCT00804388|Active Comparator|2|Uncemented total hip replacement, 36 mm caput
9919286|NCT00804401|Active Comparator|Test Product|
9919287|NCT00804401|Active Comparator|Reference Product|
9919288|NCT00804414|Experimental|1|
9919289|NCT00804414|Placebo Comparator|2|
9919290|NCT00804427|Experimental|Fish oil (90% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.
9919291|NCT00804427|Experimental|Fish oil (60% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.
9919292|NCT00804427|Experimental|Fish oil (ethyl esters)|Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.
9919293|NCT00804427|Placebo Comparator|Soy oil|Soy oil supplement with identical total fat content, taken in two divided doses with main meals.
9919294|NCT00804440|Active Comparator|Test Product|
9919295|NCT00804440|Active Comparator|Reference Product|
9919296|NCT00804453|Active Comparator|1|Standard blood line
9919297|NCT00804453|Experimental|2|Cartridge blood line
9919298|NCT00804466|Experimental|Women referred to colposcopy clinic|Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
9919299|NCT00804479||no treatment|Available 301 subjects enrolled in CALM-PD Available 82 subjects enrolled in CALM-PD imaging substudy
9919300|NCT00804492|Experimental|1|To establish an integrated intervention model for prevention of elderly fall
9919301|NCT00804492|Experimental|2|To perform a RCT to investigate the effectiveness of the multicenter, multifaceted intervention program
9919302|NCT00804505|Experimental|1|Test arm daily wear hybrid contact lens.
9919303|NCT00804505|Other|2|Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
9919304|NCT00804518|Experimental|Exercise intervention|
9919305|NCT00804531|Experimental|Visipaque - Hydrocortancyl|Administration of two treatments for the experimental arm
9919306|NCT00804531|Placebo Comparator|Visipaque|Administration of only one treatment in intra discal of visipaque
9919307|NCT00804544|Experimental|1|Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.
9919308|NCT00804557||Uro-Ease Spirus Catheter|10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
9919309|NCT00804557||Standard Urinary Catheter|10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.
9919310|NCT00804622|Active Comparator|1|tenofovir disproxil fumarate 300 mg monotherapy
9919311|NCT00804622|Active Comparator|2|telbivudine 600 mg monotherapy
9919312|NCT00804622|Active Comparator|3|telbivudine 600 mg and tenofovir disproxil fumarate 300 mg
9919313|NCT00804661||1|Children and adults with cystic fibrosis
9919314|NCT00804674|Active Comparator|1 bupivacain|
9919315|NCT00804674|Placebo Comparator|2 placebo|
9919316|NCT00804700|Active Comparator|Control Group|Subjects will be given a 60 minute lecture on the benefits of regular exercise and how music can enhance the exercise experience. Subjects will be individually instructed how to use the Precor elliptical trainer at the Yates fitness center while listening to music. Subjects are instructed to exercise using the elliptical trainer for periods of 45 -55 minutes at a time as frequently as they like with a minimum frequency of once per week. Subjects will also be encouraged to exercise regularly by walking, jogging or engaging in other forms of physical activity during the intervention period. A fitness attendant will be on hand to supervise their exercise activity, but will not give specific advice how to exercise, other than to make sure they are exercising safely.
9919317|NCT00804700|Experimental|Intervention Arm|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
9919318|NCT00804726|Experimental|Akreos MI Five-O|Accommodating intraocular lens
9919319|NCT00804739|Experimental|MITT|Mothers will be assigned to the Mother-Infant Treatment Team (MITT)and will receive either psychotherapy or sertraline or both as well as outreach.
9919320|NCT00804752|Experimental|Vitamin D|An addition of Vitamin D to the standard treatment
9919321|NCT00804765|Experimental|1|Therapeutic education
9919322|NCT00804765|Placebo Comparator|2|
9919323|NCT00804778||CABG,general anesthesia|their CO and CI was measured with USCOM and Swan-ganz cco respectively.
9919324|NCT00804778||group 1|co measured with swan-ganz cco combined with vigilance
9919325|NCT00804791|Active Comparator|Systane|One drop dispensed into each eye
9919326|NCT00804791|Active Comparator|Unisol|One drop dispensed into each eye
9919327|NCT00804804|Experimental|Y1|young volunteers (20-30 years), morningness chronotype
9919328|NCT00804804|Experimental|Y2|young volunteers (20-30 years), eveningness chronotype
9919329|NCT00804804|Experimental|O1|Aged volunteers (65-75 years), morningness chronotype
9919330|NCT00804804|Experimental|O 2|aged volunteers (65-75 years), eveningness chronotype
9919331|NCT00804817|Active Comparator|Care as usual|Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
9934878|NCT04417127|No Intervention|Standard of Care without Microfinance|n=300 participants who receive care at an AMPATH health facility and who are not involved in microfinance will serve as matched contemporaneous controls. These participants will be actively followed over the 18-months of the trial.
9799112|NCT01650545|Experimental|Liposomal Aerosol Cyclosporine|Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
9799113|NCT01650545|Active Comparator|Conventional oral immune suppression|"Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well."
9799114|NCT01650558|Active Comparator|Standard of Care Prophylaxis (TS)|Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
9799115|NCT01650558|Experimental|Chloroquine (CQ) prophylaxis|Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
9799116|NCT01650558|No Intervention|Discontinuation of standard of care|Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.
9799117|NCT01650584|Experimental|ISTA Tears|Sterile ophthalmic solution
9799118|NCT01650584|Active Comparator|Systane|Sterile ophthalmic solution
9799119|NCT01650636|Experimental|Cognitive Behavioral Stress Management|
9799120|NCT01650636|Active Comparator|Health Information|
9799121|NCT01650779|Experimental|Agalsidase beta|
9799122|NCT01650805|Experimental|ponatinib|
9799123|NCT01650805|Active Comparator|imatinib|
9799124|NCT01650831|Active Comparator|Clinical Suspicion of Hpylori|All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
9799125|NCT01650844|Experimental|School-based Telemedicine Enhanced Asthma Mangement Group|We will use a web-based system to assess asthma severity or control and will send a symptom report to the child's primary care physician (PCP). Children randomized to the SB-TEAM group, will receive a telemedicine visit in the school health office at the start of the school year to provide an initial asthma assessment. The telemedicine provider will deliver brief asthma education and referrals to community resources, and will send a guideline-based preventive medication prescription electronically to a local pharmacy. The pharmacy will deliver the medications to home and school, and the school nurse will administer the medication as directly observed therapy throughout the school year. Follow-up telemedicine assessments will occur twice during the study period. These follow-up visits will focus on assessment of control, assessment of ongoing triggers or co-morbid conditions, and brief asthma education.
9799126|NCT01650844|Active Comparator|Enhanced Usual Care Group|Children randomized to the enhanced usual care group will receive a symptom assessment using national care guidelines, a recommendation for appropriate preventive medications, and asthma education materials. We will use the web-based system to send a symptom report to the child's PCP with guideline-based recommendations for preventive care. We will provide systematic feedback to the family and providers at the same intervals as in the SB-TEAM group's telemedicine visits, by prompting providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the PCP.
9799127|NCT01651000|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
9799128|NCT01651000|Placebo Comparator|Sugar pill to CTAP101 30 μg capsule|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
9799129|NCT01651039|Experimental|Panobinostat, Lenalidomide and Dexamethasone|All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
9799130|NCT01651052|Experimental|Aortic Bioprosthesis, Model 11000|Aortic valve replacement therapy
9799131|NCT01651078||Main cohort|Patients with radiographic evidence of lesion regrowth following prior treatment with stereotactic radiosurgery (regardless of the process being suspected recurrent or progressive brain metastasis versus radiation necrosis) and who already scheduled for NeuroBlate procedure.
9799132|NCT01651104|Experimental|Adjuvanted Trivalent Influenza Virus Vaccine|
9799133|NCT01651117|No Intervention|Usual Care|Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
9799134|NCT01651117|Experimental|Peer Mentoring|Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
9799135|NCT01651117|Experimental|Peer Mentoring FFM (from former mentee)|Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
9799136|NCT01651195|Active Comparator|Probiotic tablet (military recruits)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
9799137|NCT01651195|Placebo Comparator|Placebo tablet (military recruits)|Crystalline cellulose 2 x 2, 3 weeks
9799138|NCT01651195|Active Comparator|Probiotic tablet (reserve officer candidates)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
9799139|NCT01651195|Placebo Comparator|Placebo tablet (reserve officer candidates)|Crystalline cellulose 2 x 2, 3 weeks
9919332|NCT00804817|Experimental|SCION-HSCT program|"Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
9919333|NCT00804830|Experimental|chemotherapy|Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
9919334|NCT00804856|Experimental|Schedule A|BI 6727 (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c.
9919335|NCT00804856|Experimental|Schedule B|BI 6727 (d1 and 15 - one hour iv.)
9919336|NCT00804856|Active Comparator|Schedule C|LD-ARA C monotherapy (2 x 20 mg/d s.c.)
9919337|NCT00804869||1|PalmScan biometric group
9919338|NCT00804869||2|A-mode ultrasonography biometric group
9919339|NCT00804882||1|Mexican Americans with heart failure and metabolic syndrome
9919340|NCT00804882||2|Mexican Americans with heart failure without metabolic syndrome
9919341|NCT00804882||3|Non-Hispanic White Americans with heart failure and metabolic syndrome
9919342|NCT00804882||4|Non-Hispanic White Americans with heart failure without metabolic syndrome
9919343|NCT00804895|Experimental|1|subcutaneous injection of Cortivazol ALTIM, 3,375mg
9919344|NCT00804895|Placebo Comparator|2|PROAMP, subcutaneous serum physiological saline
9919345|NCT00804934||0|
9919346|NCT00804947|Experimental|Intravenous busulfan and melphalan|
9919347|NCT00804960|Experimental|Letrozole|1) Letrozole/ Recombinant FSH
9919348|NCT00804960|Active Comparator|Standard IVF|luteal phase GnRHa suppression/gonadotropin
9919349|NCT00805012|Active Comparator|1|docetaxel+CDDP
9919350|NCT00805012|Experimental|2|docetaxel+S-1
9919351|NCT00805051||Severe aortic stenosis|Patients undergoing aortic valve replacement because of severe aortic stenosis
9934879|NCT04413799|Active Comparator|lidocaine/ ketamine infusion|Lidocaine/ ketamine infusion will be monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
9934880|NCT04413799|Active Comparator|paravertebral block with ropivacaine|Paravertebral block catheter will be placed by Anesthesiology led Acute Pain Service. Once the catheter is inserted, a ropivacaine bolus and infused with ropivacaine, monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
9934881|NCT04412265||Covid 19 patients|The study will be conducted on all patients hospitalized affected by pneumonia COVID related.
9934882|NCT04411199|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
9934883|NCT04411199|Other|Standard of Care|The SoC for prophylactic antibiotic treatment is based on international guidelines
9934884|NCT04411147||Close Contacts|Individuals without COVID-19 diagnosis, lived in same home as a survivor during illness, were within 6 feet of a COVID-19 case for a prolonged period of time or had direct contact with secretions
9934885|NCT04411147||COVID-19 Survivor|Individuals with documented prior COVID-19 infection and who have recovered
9934886|NCT04410991|Experimental|SAR442168|Dose 1 of oral SAR442168 daily + placebo to match the teriflunomide tablet once daily
9934887|NCT04410991|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
9934888|NCT04410978|Experimental|SAR442168|Dose 1 of oral SAR442168 + placebo to match the teriflunomide tablet once daily
9934889|NCT04410978|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
9934890|NCT04410523|Experimental|CSJ117 0.5 mg|0.5 mg
9934891|NCT04410523|Experimental|CSJ117 1 mg|1 mg
9934892|NCT04410523|Experimental|CSJ117 2 mg|2 mg
9934893|NCT04410523|Experimental|CSJ117 4 mg|4 mg
9934894|NCT04410523|Experimental|CSJ117 8 mg|8 mg
9934895|NCT04410523|Placebo Comparator|Placebo|0 mg
9934896|NCT04408963|Experimental|Group 1|5 mg/kg IV
9934897|NCT04408963|Experimental|Group 2|5 mg/kg SC
9934898|NCT04408950||Patients with uncharacterized immune defects|Patients with uncharacterized immune defects
9934899|NCT04408950||Unaffected biological relatives|Unaffected biological relatives
9934900|NCT04407897|Experimental|Radiotherapy|Patients with oligometastatic lesions, fulfilling the inclusion/exclusion criteria's will be assigned to SABR.
9934901|NCT04403880||Group 1|"Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~1A: Persons with asymptomatic infection, ages 18 through 55, inclusive~1B: Persons with asymptomatic infection, age > 55~1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55~1D: Persons with symptomatic infection (ie, COVID-19), age > 55"
9934902|NCT04403880||Group 2|"Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3~2A: Persons 18 through 55 years of age~2B: Persons > 55 years of age"
9934903|NCT04403880||Group 3|Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)
9934904|NCT04403386||non-smokers|Participants who have never smoked or do not currently reside with a smoker
9934905|NCT04403386||Smokers|Participants who currently smokes and has smoked for at least 5 years
9934906|NCT04402788|Active Comparator|Arm I (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9919352|NCT00805064|Active Comparator|ischemic CRVO|treatment was applied to this entity
9919353|NCT00805064|Active Comparator|non ischemic CRVO|treatment was applied to this entity
9919354|NCT00805064|Active Comparator|BRVO|treatment was applied to this entity
9919355|NCT00805077|Experimental|1|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
9919356|NCT00805077|Other|2|tidal volume of 10 ml/kg of ideal body weight without PEEP
9919357|NCT00805090|Active Comparator|Sporanox|Active arm approved as an anti-fungal being used to compare HPβCD when administered in DIC075V compared to Sporanox.
9919358|NCT00805090|Experimental|Dyloject|Diclofenac Sodium
9919359|NCT00805103|Experimental|(HFA-SRT) in Large-Volume Brain Metastases|
9919360|NCT00805116|Experimental|1|Whale blubber oil
9919361|NCT00805116|Active Comparator|2|Cod liver oil
9919362|NCT00805155||Cohort Group 1|Subjects number 1 to 20
9919363|NCT00805155||Cohort Group 2|Subjects number 21 to 50
9919364|NCT00805155||Cohort Group 3|Subject Numbers 51 to 80
9919365|NCT00805181||Acute uncomplicated pyelonephritis|
9919366|NCT00805220|Active Comparator|1|Regular overground walking without poles
9919367|NCT00805220|Experimental|2|Nordic Walking
9919368|NCT00805233|Experimental|1|Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
9919369|NCT00805233|Active Comparator|2|ranibizumab injection alone.
9919370|NCT00805246||Pulmonary Embolism (PE)|Subjects diagnosed with PE by CT will be recruited.
9919371|NCT00805259|Active Comparator|1. Atomistic|payment for own work
9919372|NCT00805259|Active Comparator|2. Altruistic|payment for partner's work
9919373|NCT00805259|Active Comparator|3. Team-based|payment for relative performance of combined effort of each team
9919374|NCT00805259|No Intervention|4. Control|access to software but no financial incentives
9919375|NCT00805272|Experimental|1|
9919376|NCT00805298|Active Comparator|methylprednisolone|
9919377|NCT00805298|Placebo Comparator|placebo|
9919378|NCT00805298|Active Comparator|lidocaine|
9919379|NCT00805298|Active Comparator|bupivacaine|
9919380|NCT00805311|Experimental|CEA Group|Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
9919381|NCT00805311|Active Comparator|OMT Group|Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
9919382|NCT00805376|Experimental|Group A: DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
9919383|NCT00805376|Experimental|Group B: DNX-2401 + Surgery|DNX-2401 injection + Tumor removal
9919384|NCT00805402|Experimental|1 flow cytometry|flow cytometry
9919385|NCT00805415|Experimental|Arm 1|
9919386|NCT00805415|Experimental|Arm 2|
9919387|NCT00805428||2|control group
9919388|NCT00805428||patients with UC|patients with UC, without corticosteroid or immunosuppressive therapy
9919389|NCT00805506||Diabetes Insulin Treated|People with type 1 or type 2 diabetes on insulin.
9919390|NCT00805519|Active Comparator|Glucosamine and chondroitin sulfate|in this group patients will receive Glucosamine and chondroitin sulfate oral dietary supplementation
9919391|NCT00805519|Experimental|P :glucosa, chondroitin, Prednis|in this group patients will receive glucosamine and chondroitin sulfate plus Prednisolone oral administration
9919392|NCT00805519|Experimental|Glucosa, Chondroitin, Chloroquine|in this group pateints will orally receive Glucosamine and Chondroitin sulfate plus Chloroquine.
9919393|NCT00805519|Experimental|Glucosa, Chondro, Prednis,Chloroq|in this group patients will receive Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine
9919394|NCT00805558|Experimental|Moxifloxacin|Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
9919395|NCT00805558|Active Comparator|Ciprofloxacin plus metronidazole|Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
9919396|NCT00805571||Adult|Adult patients with end-stage kidney disease awaiting kidney transplantation.
9919397|NCT00805571||Pediatric|Children with end-stage kidney disease awaiting kidney transplantation.
9919398|NCT00805597|Experimental|radiotherapy|radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region
9919399|NCT00805597|Active Comparator|no radiotherapy|no radiotherapy
9919400|NCT00805610|Experimental|Hepatocyte Transplantation|Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
9919401|NCT00805623|No Intervention|AW|no pacifier , no sucrose
9919402|NCT00805623|Active Comparator|AS|sucrose without pacifier
9919403|NCT00805623|No Intervention|PW|
9919404|NCT00805623|Experimental|PS|Pacifier and sucrose interventional
9919405|NCT00805649|Experimental|1|eyes with predominately classic lesions
9919406|NCT00805649|Experimental|2|eyes with occult lesions
9919407|NCT00805662|Experimental|Oxytocin|Intranasal oxytocin during IUI
9919408|NCT00805688||Symptom Study|Questionnaires + Blood Draw + Pedometer used to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
9919409|NCT00805701|Active Comparator|0.5mg Avodart|.5mg avodart capsule orally once a day during 13 months
9919410|NCT00805701|Placebo Comparator|Placebo|placebo capsule orally daily for 13 months
9919411|NCT00805714||Acute myocardial infarction|AMI patients who are in need to be treated by statins
9996320|NCT01499004|Experimental|Treatment E|tofacitinib (CP-690,550) modified-release formulation B2-Fasted
9919412|NCT00805753|Active Comparator|Arm 1 ACTH 40 units|Receive ACTH at the dose of 40 units sub-cutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days.
9919413|NCT00805753|Active Comparator|Arm 2 ACTH 80 units|Receive ACTH at the dose of 80 units sub-cutaneously for up to 12 weeks.
9919414|NCT00805831|Experimental|A|Aortic anastomosis surgery will be conducted using HDH device.
9919415|NCT00805844||1|Spine surgery with Motor Evoked Potential monitoring without SedLine monitoring visible.
9919416|NCT00805844||2|Spine surgery with Motor Evoked Potential Monitoring with SedLine monitoring visible.
9919417|NCT00805883|Experimental|1|
9919418|NCT00805896|Experimental|1|Songyou Granule
9919419|NCT00805896|Placebo Comparator|2|
9919420|NCT00805909|Experimental|NI-0401|5 daily infusions of escalating doses of NI-0401
9919421|NCT00805922||A|
9919422|NCT00806000||Athletes|
9919423|NCT00806013||1|CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
9919424|NCT00806013||2|CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
9919425|NCT00806013||3|CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier
9919426|NCT00806039|Other|1|Early renal involvement
9919427|NCT00806039|No Intervention|2|control
9919428|NCT00806065|Experimental|1|
9919429|NCT00806091||COPD subjects|healthy subjects
9919430|NCT00806104|Experimental|1|Fructo-oligosaccharides
9919431|NCT00806104|Placebo Comparator|2|Maltodextrins
9919432|NCT00806117|Active Comparator|Radiotherapy (RT)|Radiotherapy
9919433|NCT00806117|Experimental|Concurrent chemoirradiation (CCRT)|"Concurrent chemoirradiation:~External beam radiation with concurrent weekly platinum chemotherapy"
9919434|NCT00806117|Experimental|Sequence chemo and radiation (SCRT)|"Sequence chemotherapy and radiotherapy:~2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation"
9919435|NCT00806143|Active Comparator|1|patients will undergo sequential bilateral rTMS treatment
9919436|NCT00806143|Active Comparator|2|patients will undergo unilateral low frequency right sided DLPFC rTMS
9919437|NCT00806169|Experimental|1|group I (n=17) nonproliferative DR and ischemic maculopathy
9919438|NCT00806169|Experimental|2|group II (n=38) nonproliferative DR without ischemic maculopathy
9919439|NCT00806169|Experimental|3|group III (n=18) proliferative DR with or without ischemic maculopathy
9919440|NCT00806182||Pediatric case-controls|These are children who underwent lumbar puncture and blood drawing for diagnostic testing for non-inflammatory neurological or non-neurological disorders, and whose samples were retrieved from the clinical lab under a linked Institutional Review Board (IRB) protocol.
9919441|NCT00806182||Pediatric OMS|These are patients treated by the P.I. based on clinical decision making, not a clinical trial (this is an observational study). The types of treatments are varied, and, on the initial evaluation, the patients may be untreated or already tried on various immunotherapies. They range from monotherapy with steroids, ACTH, or IVIg, to disease modifying agents, such as rituximab, cyclophosphamide, and other chemotherapy, typically adjunctively or as combination therapy.
9919442|NCT00806208|Active Comparator|1|MEDI 507 and Methylprednisolone
9919443|NCT00806208|Active Comparator|2|MEDI-507 and Methylprednisolone
9919444|NCT00806208|Active Comparator|3|MEDI-507 and Methylprednisolone
9919445|NCT00806208|Active Comparator|4|MEDI-507 and Methylprednisolone
9919446|NCT00806208|Placebo Comparator|5|Placebo
9919447|NCT00806273|Active Comparator|Group 2|For Group II, the ultrasonic irrigation system involves using an initial irrigation with a conventional syringe followed by ultrasonic irrigation.
9919448|NCT00806273|Active Comparator|Group 1|For Group I, needle irrigation will be delivered into the pulp chamber using a syringe tip placed above the access opening and removed with high volume suction.
9919449|NCT00806299|Experimental|1|Drug (including placebo)
9919450|NCT00806299|Experimental|2|Drug (including placebo)
9919451|NCT00806299|Experimental|3|Drug (including placebo)
9919452|NCT00806312||1 PAH|Patients who are ≥ 18 years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis as part of their clinical care will be approached for consent and participation in this study.
9919453|NCT00806312||2. Control|Patients who present with symptoms of PAH and whose clinical right heart catheterization doesn't support this diagnosis will be enrolled as control subjects.
9919454|NCT00806325||AML|Adult patients with AML admitted for treatment of the same
9919455|NCT00806338|Experimental|Trodusquemine (MSI-1436) 3mg/m2|
9919456|NCT00806338|Experimental|Trodusquemine (MSI-1436) 6mg/m2|
9919457|NCT00806338|Experimental|Trodusquemine (MSI-1436) 10mg/m2|
9919458|NCT00806338|Placebo Comparator|Placebo|
9919459|NCT00806429|Experimental|1|transvaginal appendectomy
9919460|NCT00806429|No Intervention|2|
9919461|NCT00806468|Experimental|Desmopressin|Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
9919462|NCT00806481|Active Comparator|1|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
9919463|NCT00806481|Placebo Comparator|2|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
9919464|NCT00806507||Echocardiogram + Blood Test|Additional Echocardiogram views performed in 5-10 minutes of regularly scheduled echocardiograms plus blood tests measuring of hormones and metabolic proteins (such as sugars and acids).
9919465|NCT00806533||HES 130 / 0.42|paediatric patients aged up to 12 years requiring non-emergency volume replacement therapy with HES 130/0.42
9919466|NCT00806559|Active Comparator|Usual room|Patients in this arm will see their clinician in the usual clinical exam room
9919467|NCT00806559|Experimental|Re-designed room|Patients assigned to this arm will see the physician in a redesigned clinical exam room
9919468|NCT00806572|Experimental|Treatment|
9919469|NCT00806572|No Intervention|Control|
9919470|NCT00806611|Experimental|50% Ethanol|Operating surgeon injects 20 ml of 50% ethanol on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
9919471|NCT00806611|Placebo Comparator|Placebo|Operating surgeon injects 20 ml of saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
9919472|NCT00806637|Experimental|1|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
9919473|NCT00806637|Active Comparator|2|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
9919474|NCT00806650||Blood draw for diagnosis testing|
9919475|NCT00806663|Experimental|Sunitinib Arm|Sutent sunitinib 37 mg once daily (4 weeks on/2 weeks off)
9919476|NCT00806689||Cardiac surgery patients|Patients in atrial fibrillation being scheduled for cardiac surgery and concomitant ablation procedure
9919477|NCT00806728|Experimental|1|MEDI-507
9919478|NCT00806728|Experimental|2|MEDI-507
9919479|NCT00806741|Active Comparator|1|NG-monomethyl-L-arginine (L-NMMA)
9919480|NCT00806741|Active Comparator|2|Phenylephrine
9919481|NCT00806741|Placebo Comparator|3|Physiological saline solution
9919482|NCT00806754|Active Comparator|1|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and placebo azelastine nasal spray ( two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
9919483|NCT00806754|Active Comparator|2|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and azelastine nasal spray (137 mcg/spray, two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
9919484|NCT00806780|No Intervention|1|routine surgery with cholangiography
9919485|NCT00806780|Experimental|2|routine cholangiography
9919486|NCT00806832||Medical clowns treatment|Patients scheduled for an elective cataract surgery will receive pre-operative conventional treatment and in addition will be exposed to medical clowns effect
9919487|NCT00806832||Conventional treatment only|Patients scheduled for elective cataract surgery will receive only conventional pre-operative treatment
9919488|NCT00806845||HIV infected individuals, HIV controllers|CD4+ T cell count > 350/µl, HIV load < 1000 copies/ml
9919489|NCT00806845||HIV infected individuals, early progressors|CD4+ T cell count > 350/µl, HIV load > 1000 copies/ml
9919490|NCT00806845||HIV infected individuals, late progressors|CD4+ T cell count < 200/µl
9919491|NCT00806845||HIV infected individuals, late progressors with therapy|CD4+ T cell count < 200/µl, under ART
9919492|NCT00806845||Healthy individuals|Uninfected
9919493|NCT00806858||A|
9919494|NCT00806871|Active Comparator|A|
9919495|NCT00806871|Active Comparator|B|
9919496|NCT00806871|Placebo Comparator|C|
9919497|NCT00806884|Other|Control Arm1|Normal optimal medical and physiotherapy treatment
9919498|NCT00806884|Experimental|Treatment Arm 2|Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care
9919499|NCT00806897||A|
9919500|NCT00806910|Active Comparator|Treatment|Subjects will be treated with Intravenous Vaprisol along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
9919501|NCT00806910|Placebo Comparator|Placebo|Subjects will be given Placebo (at the same rate of Vaprisol given in the treatment arm) along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
9919502|NCT00806923|Experimental|1|
9919503|NCT00806923|Experimental|2|
9919504|NCT00806923|Placebo Comparator|3|
9919505|NCT00806936||A|
9919506|NCT00806936||B|
9919507|NCT00806962|Experimental|Vaccine Arm 1|50 µg Norwalk VLP Vaccine + Adjuvant/Excipients
9919508|NCT00806962|Experimental|Vaccine Arm 2|100 µg Norwalk VLP Vaccine + Adjuvant/Excipients
9919509|NCT00806962|Active Comparator|Adjuvant/Excipients (MPL)|14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL
9919510|NCT00806962|Sham Comparator|Empty device|Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.
9919511|NCT00806975|Other|usability and preference|
9919512|NCT00807027|No Intervention|Control Group|The study subjects randomly assigned to the control group is given Temozolomide chemotherapy and radiation therapy for 6 weeks according to the clinical test plans, and then administers Temozolomide only for 6 weeks.
9919513|NCT00807027|Experimental|Test Group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after surgery by administering Temozolomide chemotherapy and radiation therapy same as control group with Immuncell-LC (14 times).
9919514|NCT00807053|Active Comparator|1|Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
9919515|NCT00807053|Active Comparator|2|Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
9919516|NCT00807053|Active Comparator|3|Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
9919517|NCT00807053|Placebo Comparator|4|Placebo
9919518|NCT00807066|Experimental|A|Gefitinib
9919519|NCT00807066|Active Comparator|B|Platinum based chemotherapy
9919520|NCT00807079|Experimental|single arm|
9919521|NCT00807105|Experimental|depressive patients|patients suffering from deppresion
9919522|NCT00807118|Experimental|A (Cohort I)|
9919523|NCT00807118|Experimental|B (Cohort I)|
9919524|NCT00807118|Experimental|C (Cohort I)|
9919525|NCT00807118|Experimental|B (Cohort II)|
9919526|NCT00807118|Experimental|D (Cohort II)|
9919527|NCT00807118|Experimental|E (Cohort II)|
9934907|NCT04402788|Experimental|Arm II (atezolizumab, radiation therapy)|Patients receive atezolizumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy QD on days 1-5 during weeks 1-5 only.
9934908|NCT04401761||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are treated with a combination of rivaroxaban and acetylsalicylic acid.
9934909|NCT04401449||Acutely illl subjects|COVID-19 subjects treated at the Clinical Center, followed through recovery and into convalescence
9934910|NCT04401449||Recovered subjects|COVID-19 subjects who were treated at other hospitals, followed through recovery and into convalescence
9934911|NCT04401436||COVID 19 patients|Study participants will be adults who either have COVID-19 or who have recently recovered from the disease(recovered per Centers for Disease Control and Prevention guidelines).
9934912|NCT04396873|Other|Only one arm|All subjects receive the same tests
9934913|NCT04394871||ALS4 Patients|Patients with ALS4 inherited defect in the senataxin (SETX) gene.
9934914|NCT04394871||Disease Control Participants|Disease control participants with mutation in other genes which alter RNA processing (e.g., RNASEH1+2 and loss of function SETX mutations in patients with ataxia and oculomotor apraxia type 2[AOA2]).
9934915|NCT04394871||Related, Unaffected Healthy Controls|Unrelated, unaffected healthy relatives of the ALS4 and disease control groups enrolled as controls.
9934916|NCT04394871||Unrelated, Healthy Controls|Unrelated, healthy volunteers who are age and sex matched to the affected ALS4 and disease control participants.
9934917|NCT04391816||Study Participants|Participants that were previously enrolled in the NIAAA Screening Protocol.
9934918|NCT04383444||SARS-CoV-2 exposure|NIH staff exposed to SARS-CoV-2 or current or previous SARS-CoV-2 infection, but currently asymptomatic
9934919|NCT04383314|Experimental|Exercise Program Group|Participants will be prescribed an individualized 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (ACSM) Guidelines.
9996321|NCT01499004|Experimental|Treatment F|tofacitinib (CP-690,550) immediate-release formulation-Fasted
9919528|NCT00807131|Experimental|1|Patient follow-up
9919529|NCT00807131|Experimental|2|Counseling
9919530|NCT00807131|Experimental|3|Drug dispensing
9919531|NCT00807131|Active Comparator|4|pharmacy usual care
9919532|NCT00807157|Placebo Comparator|2|Every morning subjects will consume a stick of placebo during 30 days
9919533|NCT00807157|Experimental|1|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
9919534|NCT00807170|Experimental|ZACTIMA TM|
9919535|NCT00807183|Placebo Comparator|Tx1|Inactive air filter
9919536|NCT00807183|Experimental|Tx2|New EPA-certified woodstove
9919537|NCT00807183|Experimental|Tx3|Active air filter
9919538|NCT00807196|Experimental|T|
9919539|NCT00807222|Active Comparator|lisdexamfetamine dimesylate|30, 50, or 70 mg
9919540|NCT00807222|Placebo Comparator|placebo|
10213332|NCT04230954|Experimental|Cabozantinib (XL 184) Plus Pembrolizumab|A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
10213333|NCT04230161||Standard LLIN|This group receives Yahe LN ITNs during the mass distribution campaign.
9919541|NCT00807287|Experimental|1|Placement of jejunal feeding tube using the unguided frictional method
9919542|NCT00807287|Active Comparator|2|Jejunal tube placement using the endoscopic method
9919543|NCT00807300|Active Comparator|brachytherapy|
9919544|NCT00807300|Other|TACE|transarterial chemoembolization
9919545|NCT00807313||At best response|Patients with oligometastatic colorectal cancer, who presents at best response under chemotherapy, will receive stereotactic body radiotherapy on their residual disease
9919546|NCT00807313||No indication for chemotherapy|Patients with oligometastatic colorectal cancer, who are progressive under chemotherapy or who are no candidates for (further) chemotherapy, will receive stereotactic body radiotherapy on the sites of disease.
9919547|NCT00807326|Experimental|Loperamide/simeticone Caplets|Drug (including placebo)
9919548|NCT00807326|Active Comparator|Loperamide/simeticone Chewable Tablets|Drug (including placebo)
9919549|NCT00807326|Active Comparator|Probiotic Capsules|Drug (including placebo)
9919550|NCT00807339|Experimental|1|Phase I dose escalation
9919551|NCT00807352||level 2|Patients triaged level 2
9919552|NCT00807352||level 3|patients triaged level 3
9919553|NCT00807352||level 4|patients triaged level 4
9919554|NCT00807352||level 5|patients triaged level 5
9919555|NCT00807378||1|AIDS PATIENTS
9919556|NCT00807378||2|NON-AIDS PATIENTS
9919557|NCT00807391|Other|TBCA/TBNA|Under fluoroscopy first transbronchial forceps biopsy is performed, afterwards in random order transbronchial catheter aspiration(TBCA) and transbronchial needle aspiration (TBNA).
9919558|NCT00807430|Experimental|1|24 patients receiving active treatment
9919559|NCT00807430|Placebo Comparator|2|Placebo treatment
9919560|NCT00807443|Experimental|Raltegravir|
9919561|NCT00807469||1|20 healthy individuals not susceptible for COPD (age 18-40 years, >0>10 packyears, FEV1/VC >70%, FEV1 >85% predicted)
9919562|NCT00807469||2|20 healthy individuals susceptible for COPD (age 18-40 years >20 packyears, FEV1/VC >70%, FEV1 >85% predicted) and high prevalence of COPD in smoking family members older than 45 years
10213334|NCT04230161||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
9919563|NCT00807469||3|20 healthy individuals very susceptible for COPD (age 18-40 years, > 0 > 10 packyears, FEV1/VC >70%, FEV1 >85% predicted), and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
9919564|NCT00807469||4|30 healthy individuals not susceptible for COPD (age 40-75 years, >20 packyears, FEV1/VC >70%, FEV1 >85% predicted)
9919565|NCT00807469||5|30 COPD patients with GOLD stage II (age 40-75 years, >10 packyears, FEV1/VC <_70%, FEV1 50-80% predicted)
9919566|NCT00807482||1|People who have been definitively diagnosed with primary ciliary dyskinesia (PCD).
9919567|NCT00807508|Experimental|1|daily leucine supplementation
9919568|NCT00807508|Placebo Comparator|2|daily placebo supplementation
9919569|NCT00807521|Active Comparator|1|High dose bolus of dexamethasone before surgery
9919570|NCT00807521|Placebo Comparator|2|Placebo control
9919571|NCT00807534|Active Comparator|ipratropium bromide|acute bronchodilation: ipratropium bromide
9919572|NCT00807534|Placebo Comparator|placebo|placebo nebulization
9919573|NCT00807547|Active Comparator|Allergy vaccination|Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals
9919574|NCT00807547|Placebo Comparator|Subcutaneous injections|Placebo injections
9919575|NCT00807625|Active Comparator|IUCD|Assigned to use a copper intrauterine device
9919576|NCT00807625|Active Comparator|DMPA|Assigned to use Depo Provera
9919577|NCT00807677|Experimental|1|TAK-901
9919578|NCT00807703|Experimental|1|Select Stim: see summary
9919579|NCT00807716|Experimental|walking skill group|weight-bearing 12 times, 70 minutes
9919580|NCT00807716|Active Comparator|usual physiotherapy care|partial weight-bearing, 12 times, 40 minutes
9934920|NCT04382235||Covid-19 related Pneumonia patients|The cohort is defined by subjects with a diagnosis of COVID 19-related pneumonia requiring non-invasive ventilatory support.
9934921|NCT04378439|Active Comparator|intervention group|7 community health leaders; 56 social network members
9934922|NCT04378439|Active Comparator|delayed-intervention|7 community health leaders; 56 social network members
9934923|NCT04377100||Adults 18 and over|Adults 18 and over
9998244|NCT01516398||Preterm infants|No interventions were performed. Group consisted of preterm infants enrolled in the study.
10213335|NCT04230161||Standard LLIN and IRS|This group receives Yahe LN ITNs during the mass distribution campaign and IRS.
10213336|NCT04227717||Thoracic, lumbar and sacral spine lesions|Participants will have thoracic, lumbar and sacral spine lesions
10214054|NCT01689740|Experimental|Lead in: 125 mg MDMA (Open Label)|Participants receive open-label MDMA with an initial dose of 125 mg, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
9919581|NCT00807729|Active Comparator|ERCP|All ERCP's were performed by one of the authors (JPC), a fulltime faculty member and gastroenterology fellowship instructor in the presence and concurrence of the principal author/ surgeon (SJR). Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
9919582|NCT00807729|Active Comparator|Lap CBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
9919583|NCT00807755|Experimental|Phase I Dose-Escalation|This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.
9919584|NCT00807781|Experimental|Mammaglobin-A DNA vaccine|"Patients will receive vaccine day 1 (week 1), week 4 (day 29 +/- 7), week 8 (day 57 +/- 7) with at least 21 days between injection days.~All injections will be given intramuscularly using a jet delivery device.~Patients will be administered the vaccine in lateral shoulder and buttocks positions that will be rotated with each administration in the above order."
9919585|NCT00807794|Experimental|1|MEDI-507
9919586|NCT00807794|Experimental|2|MEDI-507
9919587|NCT00807794|Experimental|3|MEDI-507
9919588|NCT00807794|Experimental|4|MEDI-507
9919589|NCT00807794|Experimental|5|MEDI-507
9919590|NCT00807807|Placebo Comparator|1|Participants will receive placebo folic acid.
9919591|NCT00807807|Experimental|2|Participants will receive 100 mcg of folic acid.
9919592|NCT00807807|Experimental|3|Participants will receive 400 mcg of folic acid.
9919593|NCT00807807|Experimental|4|Participants will receive 1000 mcg of folic acid.
9919594|NCT00807807|Experimental|5|Participants will receive 2000 mcg of folic acid.
9919595|NCT00807833||CBF measurement|"It is a proof of concept study, aimed to evaluate whether the optimal CPP, defined by the best PRx, corresponds to the acceptable CBF values.~Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be monitored on clinical ground will be also monitored with a TD probe and routinely tested for cerebral autoregulation, thus obtaining the CBF corresponding at a given the best CPP and autoregulation status."
9919596|NCT00807859|Experimental|Cohort A1|
9919597|NCT00807859|Experimental|Cohort A3|
9919598|NCT00807859|Experimental|Cohort B1|
9919599|NCT00807859|Experimental|Cohort B3|
9919600|NCT00807872|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
9919601|NCT00807911|Active Comparator|Adjuvant FL|FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
9919602|NCT00807911|Experimental|Adjuvant FOLFOX|FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)
9919603|NCT00807963|Experimental|Stage 1: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).
9919604|NCT00807963|Experimental|Stage 2: ZA|Participants will receive a dose/concentration of ZA administered without rHuPH20.
9919605|NCT00807963|Experimental|Stage 3: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of rHuPH20 with ZA.
9919606|NCT00807963|Experimental|Stage 4: ZA|Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.
9919607|NCT00807963|Experimental|Stage 4: ZA with rHuPH20|Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.
9919608|NCT00807976||Study group|Type 2 diabetic patients aged 70 years and older.
9919609|NCT00807976||Control group|Patients aged 70 years and older, with no history of type 2 diabetes mellitus.
9919610|NCT00808002|Experimental|1|From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD
9919611|NCT00808002|Active Comparator|2|Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine
9919612|NCT00808041||Treatment|Breast cancer patients undergoing hormonal therapy before surgery.
9919613|NCT00808054|Experimental|Glucose and EMLA|Received glucose oral and topical EMLA
9919614|NCT00808054|Experimental|Glucose and placebo|Received glucose and no EMLA
10214055|NCT01689740|Placebo Comparator|Active placebo dose MDMA (25 mg)|Participants receive initial dose of 25 mg MDMA, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
9919615|NCT00808054|Experimental|Oral placebo and EMLA|Received oral placebo and EMLA
9919616|NCT00808093|Other|fixed sequence|fixed sequence (14 days fasted followed by 14 days either high fat or standard meal
9919617|NCT00808106||Albinism|Patients with albinism
9919618|NCT00808145|Experimental|Gemcitabine/Cisiplatin/Sorafenib|All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs
9919619|NCT00808158||1|Children ages 9 to 10 years old, with a body mass index (BMI) in the 50th to 98th percentile range
9919620|NCT00808171|Experimental|EMLA and Livopan|Administered EMLA and Livopan
9919621|NCT00808171|Experimental|EMLA and gas placebo|Administered EMLA and oxygen
9919622|NCT00808171|Experimental|Livopan and placebo cream|Administered Livopan and placebo cream
9919623|NCT00808184|Active Comparator|CPT-11|
9919624|NCT00808197|Experimental|1|Observatory, longitudinal, 3-years follow up study
9919625|NCT00808223|Experimental|1. alefacept|
9919626|NCT00808262|Experimental|TNFa Kinoid dose 1|
9919627|NCT00808262|Experimental|TNFa Kinoid dose 2|
9919628|NCT00808262|Experimental|TNFa Kinoid dose 3|
9919629|NCT00808275|Experimental|Dairy calcium|Diet with dairy calcium sources
9919630|NCT00808275|Experimental|Non-dairy calcium|Diet with non-dairy calcium sources
9919631|NCT00808301|Other|A/B|This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.
9919632|NCT00808314|Active Comparator|LL for CAD|Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
9919633|NCT00808314|Active Comparator|CAD|Subjects with existing mild-moderate ishemia demonstrated by a recent (< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
9919634|NCT00808327|Active Comparator|1|Bupivacaine alone
9919635|NCT00808327|Active Comparator|2|Bupivacaine plus Fentanyl
9919636|NCT00808366|Experimental|RV4104A ointment|
9919637|NCT00808366|Active Comparator|bifonazole-urea ointment|
9919638|NCT00808379|Other|Arm 2 (Radiation + boost )|"Radiation dose to pelvis will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Boost Field - Will be given to all the patients in the radiotherapy alone followed by surgery arm.~The boost will be given with by 3dimensional conformal radiotherapy to a dose of 15-20 Gy. After 45Gy the boost will be planned on the original tumor volume."
9919639|NCT00808379|Active Comparator|Arm 1 (standard) Chemoradiation|"The Radiation dose will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles."
9919640|NCT00808392|Experimental|1|
9919641|NCT00808392|Active Comparator|2|
9919642|NCT00808418|Experimental|Cohort|
9919643|NCT00808431|Experimental|Lifestyle counseling|Lifestyle counseling
9919644|NCT00808457||patients with suspected pneumonia|
9919645|NCT00808496|Experimental|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline.
9919646|NCT00808496|Active Comparator|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists.
9919647|NCT00808496|Placebo Comparator|Standard of Care|Diagnostic imaging results (MRI or radiography) reported to upon requisition.
9919648|NCT00808522|Experimental|hCG|Patients at high risk for breast cancer will be treated with hCG
9919649|NCT00808522|No Intervention|routine care|Patients receiving routine care will be followed
9919650|NCT00808535||diabetics|
9919651|NCT00808535||healthy controls|
9919652|NCT00808548||Lifestyle counseling|
9919653|NCT00808561|Active Comparator|1 Alternative Fistula|
9919654|NCT00808561|Active Comparator|2 Forearm AV Graft|
9919655|NCT00808574|Experimental|Intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
9919656|NCT00808574|No Intervention|Control|No risk assessment or presentation
9919657|NCT00808587||No Treatment|
9919658|NCT00808600|Other|resource-activating training, intensified exercise training|combination of the two interventions: resource-activating behavioural training and intensified exercise training
9919659|NCT00808600|Other|resource-activating training, moderate exercise training|combination of the two interventions: resource-activating training and moderate exercise training
9919660|NCT00808600|Other|relaxation training, intensified exercise training|combination of the two interventions: relaxation training and intensified exercise training
9919661|NCT00808600|Other|relaxation training, moderate exercise training|combination of the two interventions: relaxation training and moderate exercise training
9919662|NCT00808613|Active Comparator|1|Optetrak Posterior Stabilized
9919663|NCT00808613|Active Comparator|2|Optetrak Hi-Flex
9919664|NCT00808626|Experimental|99mTc-rBitistatin|
9919665|NCT00808678|Experimental|1|ABT-143 capsules 20/135 mg
9919666|NCT00808678|Active Comparator|2|ABT-335 135 mg and rosuvastatin 20 mg
9919667|NCT00808691||1|Patients with sepsis
9919668|NCT00808691||2|Patient admitted for postoperative care
9919669|NCT00808691||3|Patients with ARDS
9919670|NCT00808691||4|Patients with ARF
9919671|NCT00808691||5|Patients who receive liver support treatment
9919672|NCT00808691||6|Patients wiht brain death
9919673|NCT00808717|Experimental|High dose Atorvastatin 80 mg|Administered Atorvastatin 80 mg before intervention
9919674|NCT00808717|Active Comparator|Control|Administered Atorvastatin 10 mg before intervention
9919675|NCT00808730|Experimental|1|fiberoptic fibroscopy
9919676|NCT00808743|Active Comparator|Group 1|Patients receive oral celecoxib twice daily and oral placebo twice daily
9919677|NCT00808743|Experimental|Group 2|Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily
9919678|NCT00808756|Experimental|1: Intervention|This group will be fed a diet enriched with fermentable carbohydrates.
9919679|NCT00808756|Placebo Comparator|2: Placebo.|The placebo group will be fed a diet without addition of fermentable carbohydrates. This placebo formula will have the same nutritional values than the intervention (energy, proteins, carbohydrates, fat, vitamins & minerals).
9919680|NCT00808756|No Intervention|BF|The 2 intervention groups will be compared with a breast-fed infants control group.
9919681|NCT00808782|Sham Comparator|Sham rTMS|Sham 5Hz rTMS.
9919682|NCT00808782|Experimental|rTMS|Active 5Hz deep TMS.
9919683|NCT00808795|Experimental|N-acetylcysteine|
9919684|NCT00808795|Placebo Comparator|Placebo|
9919685|NCT00808860|Placebo Comparator|Placebo group|Gliclazide + Placebo tea
9919686|NCT00808860|Active Comparator|GP group|Gliclazide + Gynostemma pentaphyllum tea
9919687|NCT00808873|Experimental|1|brief education and 6 follow-up visits
9919688|NCT00808873|No Intervention|2|treatment-as-usual
9919689|NCT00808912|Active Comparator|1|Subjects will exercise in a high air pollutant environment after ingesting a standard dose of sildenafil.
9919690|NCT00808912|Active Comparator|2|Subjects will exercise in a low pollutant environment after ingesting a standard dose of sildenafil.
9919691|NCT00808912|Placebo Comparator|3|Subjects will exercise in a high pollutant environment after ingesting a placebo.
9919692|NCT00808912|Placebo Comparator|4|Subjects will exercise in a low pollutant environment after ingesting a placebo.
9919693|NCT00808925|Experimental|research arm|
9919694|NCT00808938|Experimental|Active Treatment|
9919695|NCT00808951|Experimental|Artemether -lumefantrine|Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
9919696|NCT00808951|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
9919697|NCT00808977|Experimental|Dersalazine|
9919698|NCT00808977|Active Comparator|Mesalazine|
9919699|NCT00808977|Placebo Comparator|Placebo|
9919700|NCT00808990|Experimental|OSA and NAFLD patients using CPAP|OSA and NAFLD patients using CPAP being followed for 6 months.
9919701|NCT00808990|No Intervention|control|OSA and NAFLD patients not using CPAP being followed for 6 months.
9934924|NCT04372615|Active Comparator|Inebilizumab|"Approximately 58 patients will receive Inebilizumab in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
9934925|NCT04372615|Placebo Comparator|Placebo|"Approximately 58 patients will receive placebo in addition to first line immunotherapy.~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).~All participants will also receive a 3 day course of IVIg."
9934926|NCT04370795|Active Comparator|Group 1|Patients will be treated with Total Body Irradiation (TBI)
9934927|NCT04370795|Active Comparator|Group 2|Patients will not be treated with Total Body Irradiation (TBI)
9934928|NCT04370509|Experimental|Cohort A (Pembrolizumab monotherapy)|"Preoperative treatment consists of 200mg pembrolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles (9 weeks).~Within 14-21 days following the end of treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.~Within 21-42 days after surgery, patients with R0 resection or R1 resection receive 400 mg pembrolizumab every 42 days for up to 9 cycles (1 year) and patients with R2 resection receive pembrolizumab every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
9935789|NCT03215030|Experimental|Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg|Dose(s) for Phase 2 will be based on safety and tolerability results from the preceding Phase 1 dose escalation cohorts. Participants in Phase 2 cohorts will receive modakafusp alfa TBD as a single agent. Participants in at least 1 cohort will receive modakafusp alfa TBD and modakafusp alfa TBD and dexamethasone 40 mg, orally, once weekly of each 28-day treatment cycle until treatment discontinuation.
10213337|NCT04227353|Experimental|HEAL ABC|Participants allocated to the intervention will be encouraged to follow the HEAL ABC resources in order to make a healthy eating and active lifestyle change. This will be achieved by setting specific goal(s) and by making concrete plan(s) to implement changes in their everyday life. Interventions will be delivered in the form of written resources that will guide participants. Supportive phone calls using motivational interviewing techniques will be provided to participants every two weeks to encourage lifestyle changes.
9919702|NCT00809003||Sjogren's group|
9919703|NCT00809003||Dry eye|
9919704|NCT00809003||Normals|
9919705|NCT00809042|Experimental|1|Hydroxyurea
9919706|NCT00809042|Active Comparator|2|L-carnitine and hydroxyurea
9919707|NCT00809042|Active Comparator|4|L-carnitine , magnesium chloride and hydroxyurea
9919708|NCT00809042|Active Comparator|3|magnesium chloride and hydroxyurea
9919709|NCT00809068|Active Comparator|1|fenofibrate and tibolone
9919710|NCT00809068|Sham Comparator|2|tibolone
9919711|NCT00809081|Other|1|1. Enteral Feeding
9919712|NCT00809081|No Intervention|2|Total Parental support
9919713|NCT00809107|Experimental|1|HCG GROUP
9919714|NCT00809107|No Intervention|2|LH pick
9919715|NCT00809172|Active Comparator|1|Ciclosporin
9919716|NCT00809172|Experimental|2|Methotrexate
9919717|NCT00809198|Experimental|Sodium Hyaluronate|Sodium Hyaluronate (Kynex)
9919718|NCT00809198|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium (Refresh Plus)
9919719|NCT00809211|Experimental|Nilotinib|
9919720|NCT00809224||ALS|ALS group should have ALS.
9919721|NCT00809224||Control|The control group should not have ALS or any other neurological/psychiatric disorder, and must be over the age of 40.
9919722|NCT00809237|Experimental|Gefitinib, Hydroxychloroquine|"For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.~After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg of Gefitinib and the MTD dose of HCQ."
9919723|NCT00809250|Experimental|GM-K562/leukemia cell vaccine|Biological/Vaccine: GM-K562/leukemia cell vaccine Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
9919724|NCT00809289|Experimental|One|
9919725|NCT00809289|Placebo Comparator|Two|
9919726|NCT00809289|Active Comparator|Three|Administration of a single oral dse of 400mg moxifloxacin
9919727|NCT00809302|Experimental|1|aplindore 2 mg MR total daily dose
9919728|NCT00809302|Experimental|2|aplindore 6 mg MR total daily dose
9919729|NCT00809302|Experimental|3|aplindore 12 mg MR total daily dose
9919730|NCT00809302|Placebo Comparator|4|Placebo
9919731|NCT00809315|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
9919732|NCT00809315|Experimental|Fostering Healthy Futures (FHF) Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
9919733|NCT00809367|Other|Collection of Leukemia Cells|Other: Collection of Leukemia Cells Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
9919734|NCT00809380|Experimental|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
9919735|NCT00809380|Active Comparator|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
9919736|NCT00809393|Active Comparator|low dose|low dose tranexamic acid
9919737|NCT00809393|Experimental|high dose|
9919738|NCT00809419|Experimental|A|NeoVista Ophthalmic System procedure + Lucentis
9919739|NCT00809432|Experimental|Visit 1|2 hour city centre kerbside walk in Beijing China
9919740|NCT00809432|Experimental|Visit 2|2 hour city centre kerbside walk in Beijing China
9919741|NCT00809484||1: Low risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
9919742|NCT00809484||2:Moderate risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
9919743|NCT00809484||3:High risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week
9919744|NCT00809536|Other|Cohort 1|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
9919745|NCT00809536|Other|Cohort 2|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
9919746|NCT00809549|Placebo Comparator|Normal Saline|
9919747|NCT00809549|Experimental|Filgrastim|
9919748|NCT00809601|Experimental|1|
9919749|NCT00809627|Experimental|1|IV caffeine with saline and opiate
9919750|NCT00809627|Placebo Comparator|2|IV saline with opiate
9919751|NCT00809640|Active Comparator|1|The intervention group will receive prevention of low back pain education through a Back Comic-Book, and their beliefs/knowledge will be tested twice after intervention.
9919752|NCT00809640|No Intervention|2|The control group will receive no intervention, and their beliefs/knowledge on low back pain will be tested twice after the first assessment.
9919753|NCT00809653|Experimental|Visit 1|2 hour walk in city centre location in Beijing China
9919754|NCT00809653|Experimental|Visit 2|2 hour walk in city centre location in Beijing China
9919755|NCT00809666|No Intervention|Mercury|All subsequent blood pressure recording done using mercury sphygmomanometry
9919756|NCT00809692|Active Comparator|1|50 subjects with allergic disease receiving histamine challenges by the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
9919757|NCT00809692|Experimental|2|150 additional subjects with allergic disease; undergo genotyping; laser Dopper assessment
9919758|NCT00809705|Experimental|1|
9919759|NCT00809705|Experimental|2|
9919760|NCT00809705|Placebo Comparator|3|
9919761|NCT00809718|Other|raltegravir and rifapentine|Concomitant administration of raltegravir and rifapentine in healthy volunteers
9919762|NCT00809731||Observational Group|All commercially available 2nd-generation antipsychotic with an indication of treating schizophrenia will be prescribed by the physician according to normal practices
9919763|NCT00809770|Experimental|1|Contingency management
9919764|NCT00809770|Other|2|Non Contingent Control Condition
9919765|NCT00809796|Experimental|single arm|Use of pentamidine in second and/or third line metastatic colon cancer
9919766|NCT00809822|Active Comparator|1|Intravenous immunoglobulin
9919767|NCT00809822|Placebo Comparator|2|Physiological saline
9919768|NCT00809861|Active Comparator|1|volar locking plating of distal radius fractures
9919769|NCT00809861|Active Comparator|2|
9919770|NCT00809874|Active Comparator|Casein|
9919771|NCT00809874|Active Comparator|Whey Isolate|
9919772|NCT00809874|Active Comparator|Whey Hydrolysate|
9919773|NCT00809874|Active Comparator|Alphalact-Albumin|
9919774|NCT00809887|Placebo Comparator|1|ALT with placebo with systemic Micafungin therapy
9919775|NCT00809887|Experimental|2|ALT with Micafungin and heparin with systemic Micafungin therapy
9919776|NCT00809900||Dietary Supplement|Cranberry Juice Consumption
9919777|NCT00809913|Experimental|Short treatment|7 days of standard antibiotic treatment (preferably ciprofloxacin) followed by 7 days of placebo
9919778|NCT00809913|Active Comparator|Standard treatment|14 days of standard antibiotic treatment (initial b-lactam or fluoroquinolone followed by ciprofloxacin through the 8th till 14th day)
9919779|NCT00809939|Active Comparator|1|previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
9919780|NCT00809939|Active Comparator|2|previous preterm delivery, treatment with daily vaginal natural progesterone
9919781|NCT00809939|Active Comparator|3|short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
9919782|NCT00809939|Active Comparator|4|short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
9919783|NCT00809952||Recombinat FSH|
9919784|NCT00810004|Experimental|Ferinject|Intravenous infusion of iron
9919785|NCT00810004|Placebo Comparator|Placebo|NaCL 0,9%
9919786|NCT00810017|Experimental|Single arm study|Etoposide 100mg/m2 daily x 3 days Q3W and Trastuzumab 8mg/kg loading dose then 6mg/kg, then single agent until disease progression
9919787|NCT00810030|Experimental|FERINJECT® (Ferric carboxymaltose)|
10213338|NCT04227353|No Intervention|HEALTH|Participants allocated to the control group will be referred to publicly available resources on healthy lifestyle recommendations but will not receive any additional support.
10213339|NCT04221815|Active Comparator|IVUS guided PCI|Patients will receive a pre-PCI IVUS, IVUS guided stent sizing and optimization per study protocol, post-PCI IVUS
10213340|NCT04221815|Placebo Comparator|Angiographic-guided PCI|Patients will receive angiography guided PCI and angiographic optimization per local standard practice, as well as a post-PCI IVUS blinded to the investigator
9919788|NCT00810030|Active Comparator|VENOFER® (Iron Sucrose)|
9919789|NCT00810056|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
9919790|NCT00810056|Experimental|Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Fostering Healthy Futures program (FHF) including weekly therapeutic skill groups and mentoring over a 9-month period.
9919791|NCT00810121|Experimental|1|Ketoprofen 100 mg b.i.d. for 5 days
9919792|NCT00810121|Experimental|2|Ketoprofen 150 mg b.i.d. for 5 days
9919793|NCT00810134|Other|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
9919794|NCT00810134|Other|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
9919795|NCT00810160|Active Comparator|1|Permeate
9919796|NCT00810160|Active Comparator|2|GOS
9919797|NCT00810160|Active Comparator|3|Bifidobacterium infantis
9919798|NCT00810160|Active Comparator|4|Bifidobacterium animalis
9919799|NCT00810173|Experimental|1|This group received call phone support to incentive the increase of the number of steps during 6 weeks
10213341|NCT04221490|Experimental|Treatment|Treatment with the Edwards EVOQUE Tricuspid Transcatheter Valve Replacement System
9919800|NCT00810173|No Intervention|2|This group just received a pedometer to register the number of steps for 6 weeks but this group don´t received a phone call.
9919801|NCT00810186||Newborns needing respiratory monitoring|Premature and term newborn infants (male/female)
9919802|NCT00810212|Active Comparator|1|Autograft
9919803|NCT00810212|Experimental|2|Low Dose MPCs
9919804|NCT00810212|Experimental|3|Medium Dose MPCs
9919805|NCT00810212|Experimental|4|High Dose MPCs
9919806|NCT00810225||1|GWI: veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
9919807|NCT00810225||2|HC: healthy veterans of the 1990-1991 Persian Gulf War
9919808|NCT00810238|Experimental|1|Optimal standard of care + C-Cure
9919809|NCT00810238|No Intervention|2|Optimal standard of care
9919810|NCT00810251||MatrixRIB|
9919811|NCT00810316|Other|Treatment A|
9919812|NCT00810316|Other|Treatment B|
9919813|NCT00810316|Other|Treatment C|
9919814|NCT00810329||1|This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.
9919815|NCT00810329||2|The healthy control group
9919816|NCT00810381|Active Comparator|1|"Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):~0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes"
9919817|NCT00810381|Active Comparator|2|"Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):~0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes"
9919818|NCT00810381|Active Comparator|3|"Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):~0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes"
9919819|NCT00810381|Placebo Comparator|4|Physiologic saline solution
9919820|NCT00810433|Experimental|Arm 1|
9919821|NCT00810446||rifabutin|Patients administered Rifabutin.
9919822|NCT00810472|Experimental|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
9919823|NCT00810472|Placebo Comparator|Random graft assignment|
9919824|NCT00810485|Experimental|ADX10059 50 mg|twice-daily
9919825|NCT00810485|Experimental|ADX10059 100 mg|twice-daily
9919826|NCT00810485|Experimental|ADX10059 150 mg|twice-daily
9919827|NCT00810485|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
9919828|NCT00810524|Experimental|A|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
9919829|NCT00810524|Active Comparator|B|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
9919830|NCT00810524|Experimental|C|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
9919831|NCT00810524|Active Comparator|D|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
9919832|NCT00810550|Other|LV systolic dysfunction|Diagnostic Testing
9919833|NCT00810563|Placebo Comparator|1|Saline solution 0.9% 5mL in each portal
9919834|NCT00810563|Active Comparator|2|Bupivacaine 0.5% 5mL in each portal
9919835|NCT00810589|Experimental|1|
9996322|NCT01499017|Experimental|Cohort A|Each subjects in Cohort A will receive 3 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-4.
9996323|NCT01499017|Experimental|Cohort B|Each subjects in Cohort B will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
9996324|NCT01499056|Experimental|hip osteoarthritis|The patients with hip joint osteoarthritis who underwent cell injection
9996325|NCT01499069|Experimental|Antimuscarinic agents|
9996326|NCT01499108|Experimental|Liraglutide|single-group study were participants recieve Liraglutide
9996327|NCT01499121|Other|Sunitinib|Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
9996328|NCT01499186|No Intervention|Control group|There will be no participation in a training program. The control group will perform all measurements.
9996329|NCT01499186|Experimental|Intervention group|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators. These subjects will perform all measurements.
9996330|NCT01499212|Experimental|I:E ratio 1:1|
9996331|NCT01499225|Experimental|YH14642 A-I|
9996332|NCT01499225|Experimental|YH14642 A-II|
9996333|NCT01499225|Experimental|YH14642 A-III|
9996334|NCT01499225|Active Comparator|Active Comparator B|
9996335|NCT01499225|Active Comparator|Active Comparator C|
9996336|NCT01499225|Placebo Comparator|Placebo|
9996337|NCT01499238|Active Comparator|nasal SIMV|rate: 30-50/min, PIP: 16, PEEP: 4-6, fİO2: 40%
9996338|NCT01499238|Active Comparator|nasal CPAP|PEEP: 4-6 mmHg, Fio2: 40%
9996339|NCT01499251|Experimental|Macitentan|Macitentan in combination with dose-dense temozolomide
9996340|NCT01499264|Experimental|MySkin patch|Hydrogel e polyurethane film
9996341|NCT01499264|Active Comparator|Traditional Dressing|
9998114|NCT01515124|Experimental|Exercise only|The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.
9998115|NCT01515124|Experimental|Weight loss only|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.
9998116|NCT01515124|Experimental|Exercise and Weight loss combined|Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.
9998117|NCT01515137|Experimental|Arm A erlotinib plus sulindac|erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A),
9998118|NCT01515137|Experimental|Arm B erlotinib|erlotinib (150 mg PO QD) (Arm B)
9998119|NCT01515137|Experimental|Arm C|placebo (for Erlotinib) QD (Arm C).
9919836|NCT00810589|Active Comparator|2|
9919837|NCT00810628|Experimental|1|All subjects in same investigative group with same CBT intervention.
9919838|NCT00810654|Experimental|ANPEP|Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
9919839|NCT00810654|Placebo Comparator|Placebo|
9919840|NCT00810667|Experimental|Lu AE58054|
9919841|NCT00810667|Placebo Comparator|Placebo|
9919842|NCT00810680|Experimental|Valproic acid|
9919843|NCT00810706|No Intervention|1: observation only|Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
9919844|NCT00810706|Active Comparator|2: Exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment
9919845|NCT00810745|Experimental|rectal resection|
9919846|NCT00810758|Experimental|PF-04878691|
9919847|NCT00810784||1|Patients cared for before our intervention.
9919848|NCT00810784||2|Patients cared for after our intervention.
9919849|NCT00810823||1:Gastric bypass/diabetes|Patients undergoing gastric bypass surgery, and who are diagnosed with type 2 diabetes.
9919850|NCT00810823||2:Gastric bypass/not Diabetic|Patients undergoing gastric bypass surgery, not diagnosed with diabetes.
9919851|NCT00810836|Active Comparator|1|BG00012 480 mg/day
9919852|NCT00810836|Active Comparator|2|BG00012 720 mg/day
9919853|NCT00810836|Placebo Comparator|3|
9919854|NCT00810849|Placebo Comparator|Prednisolone|Six-week tapering course of prednisolone and those assigned to the prednisolone control arm will receive the same number of identically-coated placebo tablets.
9919855|NCT00810849|Placebo Comparator|Mycobacterium w|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months).
9919856|NCT00810862|Experimental|Pimecrolimus|Pimecrolimus 1% cream
9919857|NCT00810862|Placebo Comparator|2|Placebo cream over affected study area
9919858|NCT00810875||hepatitis C|pregnant women with hepatitis C virus infection and their infants
9919859|NCT00810875||controls|pregnant women without hepatitis C infection and their infants
9919860|NCT00810914|Experimental|1|Continuous epidural infusion of medication for method of pain relief
9919861|NCT00810914|Experimental|2|continuous epidural infusion in conjuction with patient controlled anesthesia (PCA)
9919862|NCT00810914|Experimental|3|patient controlled anesthesia only this arm has pt controlled medication delivery. (PCA)
9919863|NCT00810927|Active Comparator|1|Phenylephrine (Neosynephrine®, Abbott Laboratories, North Chicago, IL, USA) dose: 1µg/(kg.min), infusion period 20 minutes
9919864|NCT00810927|Active Comparator|2|NG-monomethyl-L-arginine (L-NMMA, Clinalfa, Läufelfingen, Switzerland) dose: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/(kg.min) over 15 minutes
9919865|NCT00810927|Placebo Comparator|3|Physiologic saline solution
9919866|NCT00810940|Active Comparator|1|Control: Standard treatment for severe head trauma including mannitol
9919867|NCT00810940|Experimental|2|Study drug plus standard treatment
9919868|NCT00810953|Experimental|single arm|Use of pentamidine in locally advanced or metastatic pancreatic cancer
9919869|NCT00810992|Active Comparator|1 Program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
9919870|NCT00810992|Experimental|2 Program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
9919871|NCT00811005|Active Comparator|Acitretin-PUVA combination|"Acitretin-PUVA combination:~Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment.~PUVA treatment (see below) will be applied thrice weekly in addition to acitretin until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
9919872|NCT00811005|Experimental|Fumaric acid ester -PUVA combination|"FAE monotherapy:~Patients randomized to this group will receive FAE in weekly incremental doses (initial daily dose: 30 mg dimethylfumarate (DMF), highest daily dose: 720 mg DMF) starting two weeks prior to additional PUVA treatment.~FAE-PUVA combination:~PUVA treatment will be applied thrice weekly in addition to FAE until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
9919873|NCT00811031|Experimental|Taxotere + Prednisone|
9919874|NCT00811044||Entry|This group is just entering the study and will need to be genotyped.
9919875|NCT00811044||Affected|This group has been genotyped and has the gene undergoing study at that time.
9919876|NCT00811044||Control|This group has been genotyped and does not have the gene currently under study.
9919877|NCT00811083|Active Comparator|DMSA- 1 round|Subjects receive 1 round of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 3 months of placebo
9919878|NCT00811083|Active Comparator|DMSA-7 rounds|Participants receive 7 rounds of DMSA over 4 months; each round consists of 3 days of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 11 days off (no treatment), and then repeating.
9919879|NCT00811096|Experimental|Treatment Arm|
9919880|NCT00811096|Active Comparator|Comparator Arm|Comparator Arm
9919881|NCT00811109|No Intervention|Standard|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity
9919882|NCT00811109|Active Comparator|2|With Blood Volume on-line monitoring only
9919883|NCT00811109|Active Comparator|3|With Blood volume and Blood temperature on-line monitoring
9934929|NCT04370509|Experimental|Cohort B (Pembrolizumab + VEGF-TKI)|"Preoperative treatment consists of 200 mg pembrolizumab IV on day 1 of each cycle, and 5mg axitinib (a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)) PO BID on days 1-42 of each cycle. Axitinib maybe titered in select patients after cycle 1. Treatment repeats every 21 days for up to 3 cycles (9 weeks).~Within 14-21 days following the end of pre-operative treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.~Within 21-42 days after surgery, patients with an R0 or R1 resection receive 400 mg pembrolizumab and 1, 3, 5, 7 or 10 mg axitinib PO BID every 42 days for up to 9 cycles (1 year), and patients with an R2 resection receive pembrolizumab IV and axitinib PO BID every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
9934930|NCT04362865||COVID-19 infection|Patients with confirmed or suspected COVID-19 infections
9934931|NCT04362865||No COVID-19 infection|Patients without confirmed or suspected COVID-19 infections (i.e., normal donors)
9934932|NCT04360278||Plasma Donors|Persons who have recovered from COVID-19 or have been immunized against SARS-CoV-2 who meet criteria to donate plasma.
9934933|NCT04360018|Active Comparator|arm one|participants receive alcohol beverage
9934934|NCT04360018|Placebo Comparator|arm two|Placebo
9934935|NCT04359186|Experimental|Treatment Interruption Arm|
9934936|NCT04358107||1|Medical records of subjects enrolled on various ACC studies conducted by CCR
9934937|NCT04353804|Experimental|Computerized Cognitive Rehabilitation|Computerized Cognitive Rehabilitation
9934938|NCT04353804|Active Comparator|Active Control computer games|Active Control computer games
9934939|NCT04349189||Group 1|50 Men and Women with sickle cell disease and VTE
9934940|NCT04349189||Group 2|50 Men and Women with sickle cell disease but no VTE
9934941|NCT04349189||Group 3|50 Men and Women with sickle cell trait
9934942|NCT04349189||Group 4|50 ethnically matched Men and Women without sickle cell disease, sickle cell trait, or VTE
9934943|NCT04348240||Group 1|asymptomatic or mildly symptomatic high-risk subjects with unknown SARS-CoV-2 status but with known history of close personal contact with a COVID-19 positive person.
9934944|NCT04348240||Group 2|asymptomatic or mildly symptomatic (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) subjects who are COVID-19 positive.
9934945|NCT04348240||Group 3|COVID-19 positive individuals retesting negative can be enrolled to complete the electronic questionnaire(s) and allow evaluation of history of symptoms.
9934946|NCT04348240||Group 4|COVID-19 positive individuals enrolled and admitted to the NIH Clinical Center for other protocols.
9934947|NCT04345536||Patients hospitalized with confirmed Covid-19|All patients hospitalized with confirmed Covid-19
9934948|NCT04344470|Experimental|Healthy Volunteers|Healthy Volunteers
9934949|NCT04342884||Clients of Wake Forest Baptist Health (WFBH)|
9934950|NCT04342884||Health care workers of Wake Forest Baptist Health (WFBH)|
9934951|NCT04340505||Active uveitis patients.|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist and requires an injectable fluocinolone acetonide implant to treat their inflammation.
10214056|NCT01689740|Experimental|Full dose MDMA (125 mg)|Participants receive initial dose of 125 mg MDMA, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
10214057|NCT01682824||Group I (questionnaire, nutritional assessment)|Patients complete the TFEQ-R18v2 questionnaire, a dietary intake assessment, and the EQ-EMA questionnaire online.
10214058|NCT01682824||Group II (questionnaire, nutritional assessment)|Patients complete the EQ-EMA questionnaire, a dietary intake assessment and the TFEQ-R18v2 questionnaire.
10214059|NCT01656434|Experimental|NOMAC-E2|Participants received a NOMAC-E2 tablet (2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NOMAC-E2 tablets on Days 1 to 24 and placebo tablets on Days 25 to 28.
10214060|NCT01656434|Active Comparator|NETA-EE|Participants received a NETA-EE tablet (1 mg norethisterone acetate and 10 μg ethinylestradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NETA-EE tablets on Days 1 to 24; EE 10 μg tablets on Days 25 and 26; and ferrous fumarate 75 mg tablets on Days 27 and 28.
10214061|NCT01637688||Amino acid formula|Comparison of growth between subjects who are fed with a newly innovated amino acid formula (NAAF) and who are fed with either Neocate or nutramigen AA.
9919885|NCT00811161|Experimental|needle free injector of HA|
9919886|NCT00811200|Active Comparator|1: Lucentis|
9919887|NCT00811200|Active Comparator|2: Kenalog|
9919888|NCT00811200|Sham Comparator|3: No treatment|
9919889|NCT00811213|Experimental|1|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
9919890|NCT00811213|Active Comparator|2|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
9919891|NCT00811226||Patients|Patients with arterial hypertension Stade I or Stade II
9919892|NCT00811239|Other|control group|As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
9919893|NCT00811239|Active Comparator|antivenom group|The patients included during the third year (2006) were treated with antivenom therapy and supportive care.
9919894|NCT00811265|Experimental|Simulated ExAblate MRgFUS|Patients undergoing simulated ExAblate MRgFUS device use
9919895|NCT00811278||step1|asthma patients on step 1 therapy
9919896|NCT00811278||step 2|asthma patients on step 2 therapy
9919897|NCT00811278||healthy|non-asthmatics
9919898|NCT00811291|Placebo Comparator|1|
9919899|NCT00811291|Active Comparator|2|folic acid and B-vitamin supplement
9919900|NCT00811304||US group|All patients admitted to the labor and delivery suite who request an epidural for labor analgesia.
9919901|NCT00811330|Experimental|1: Atorvastatin 80 mg.|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
9919902|NCT00811330|No Intervention|2: No Atrovastatine|
9919903|NCT00811343|Experimental|1|
9919904|NCT00811356|Experimental|Single Dose, Repeat Dose, Drug-Drug Interaction|"GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121."
9919905|NCT00811369|Experimental|1|Fulvestrant + ZACTIMA Group
9919906|NCT00811369|Placebo Comparator|2|Fulvestrant + Placebo Group
9919907|NCT00811421|Active Comparator|Trial 1: IPTp-SP+LLITNs|HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)
9919908|NCT00811421|Experimental|Trial 1: IPTp-MQ (full dose) + LLITNs|HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
9919909|NCT00811421|Experimental|Trial 1: IPTp-MQ (split dose)+LLITNs|HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs
9919910|NCT00811421|Experimental|Trial 2: CTX+IPTp-Placebo+LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)
9919911|NCT00811421|Experimental|Trial 2: CTX + IPTp-MQ+ LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
9919912|NCT00811447|Experimental|1|Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
9919913|NCT00811447|Active Comparator|2|Cisplatin 75 mg/m² on Day 1, 5-FU 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
9919914|NCT00811460|Experimental|1|
9919915|NCT00811486|No Intervention|Usual care|Group II
9919916|NCT00811486|Experimental|Spironolactone and conivaptan|Group I
9919917|NCT00811538||1 1 (Liv*)|i.v. thrombolysis with rtPA
9919918|NCT00811538||2 (L*)|intraarterial thrombolysis
9919919|NCT00811603|Active Comparator|1|Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
9919920|NCT00811603|Experimental|2|Patients who receive antibiotic prophylaxis prior to skin incision
9919921|NCT00811629||control group|
9919922|NCT00811668|Experimental|CPAP before SOMNOVentCR|started with CPAP and continued with SOMNOvent CR
9919923|NCT00811668|Experimental|SOMNOVentCR before CPAP|began with SOMNOvent CR and ended with CPAP
9919924|NCT00811681|Experimental|Pioglitazone|pioglitazone
9919925|NCT00811681|Placebo Comparator|Control|placebo
9919926|NCT00811694||a|15 male and 15 female patients with glaucoma
9919927|NCT00811694||b|30 sex matched healthy volunteers
9919928|NCT00811707||1: volunteers|non-pregnant female
9919929|NCT00811707||2: parturients|parturients was scheduled to receive lumbar epidurals for elective cesaeran delivery labor analgesia
9919930|NCT00811746|Experimental|1|Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG
9919931|NCT00811746|Active Comparator|2|Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG
9919932|NCT00811746|Other|3|Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.
9919933|NCT00811772|Active Comparator|Bare metal stent|Implantation of one or more bare metal stent(s) to to treat coronary artery stenosis
9919934|NCT00811772|Experimental|Drug eluting stent|Implantation of one or more drug eluting stent(s) to treat coronary artery stenosis
9919935|NCT00811811|Experimental|1|Behavioral neurocardiac training
9919936|NCT00811811|Active Comparator|2|Autogenic relaxation training
9919937|NCT00811824|Active Comparator|1|Immediate physical activity and dietary change intervention
9919938|NCT00811824|Other|2|Delayed physical activity and dietary change intervention
9919939|NCT00811837|Experimental|Remifentail|Remifentanil Infusion
9919940|NCT00811837|Active Comparator|Midazolam|Active Placebo
9919941|NCT00811863||1|Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
9919942|NCT00811863||2|Subjects with severe renal insufficiency defined as an eGFR <30 mL/min/1.73 m2 and ESRD defined as requiring dialysis
9919943|NCT00811915|Experimental|Sirolimus|"Group A : Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14.~Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
9919944|NCT00811915|Active Comparator|B|Tacrolimus (Advagraf) dose to obtain a trough level between 4 and 10 ng/ml
10213342|NCT04220216|Experimental|H4H fitness program|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Patients will attend the 16-week program of boxing conditioning.~This 16-week program will include supervised exercises designed to improve strength, flexibility, balance,and cardiopulmonary fitness.~There will be 4, 1-hour sessions each week per participant"
10213343|NCT04219085|Active Comparator|Routine Care|Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
10213344|NCT04219085|Experimental|Continuous Glucose Monitor|Monitoring of control of gestational diabetes with use of a continuous glucose monitor
10213345|NCT04218877||Children with atopic dermatitis|Children 1-3 years old with atopic dermatitis
10213346|NCT04218877||Children without atopic dermatitis|
10213347|NCT04218877||Children with genetic predisposition|Children with genetic predisposition to atopic dermatitis, but without manifestations
10213348|NCT04214691|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
10213349|NCT04214691|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8H ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
10213350|NCT04207749|Experimental|LID015385|LID015385 contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
10213351|NCT04207749|Active Comparator|Biofinity|Comfilcon A contact lenses worn at least 5 days per week and 8 hours per day in a daily wear modality (that is, not worn while sleeping) for approximately 3 months. CLEAR CARE will be used for nightly cleaning and disinfection.
10213352|NCT04205630|Experimental|SYD985|SYD985, Intravenous, every 3 weeks (Q3W)
10213353|NCT04204941|Experimental|Tazemetostat + Doxorubicin Arm|"Tazemetostat (800 mg) administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
10213354|NCT04204941|Experimental|Placebo + Doxorubicin Arm|"Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond.~Doxorubicin 75 mg/m2 IV on day 1 of cycles 1-6."
10213355|NCT04202393|Experimental|Integrated Treatment Adherence Program (ITAP)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
10213356|NCT04202393|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
10213357|NCT04198766|Experimental|Part 1 INBRX-106 Escalation|INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.
10213358|NCT04198766|Experimental|Part 2 INBRX-106 Expansion|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D.
10213359|NCT04198766|Experimental|Part 3 INBRX-106 Escalation in Combination with Pembrolizumab|INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.
10213360|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D in combination with pembrolizumab.
9919945|NCT00811967|Experimental|Treatment Arm|
9919946|NCT00811967|No Intervention|Control Arm|
9919947|NCT00811980||Heathy Subjects|
9919948|NCT00811993|Experimental|1|
9919949|NCT00811993|Experimental|10|
9919950|NCT00811993|Experimental|11|
9919951|NCT00811993|Experimental|12|
9919952|NCT00811993|Experimental|13|
9919953|NCT00811993|Experimental|2|
9919954|NCT00811993|Experimental|3|
9919955|NCT00811993|Experimental|4|
9919956|NCT00811993|Experimental|5|
9919957|NCT00811993|Experimental|6|
9919958|NCT00811993|Experimental|7|
9919959|NCT00811993|Experimental|8|
9919960|NCT00811993|Experimental|9|
9919961|NCT00812019|Experimental|3.75_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
9919962|NCT00812019|Experimental|3.75_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
9919963|NCT00812019|Experimental|3.75_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
9919964|NCT00812019|Experimental|3.75_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
9919965|NCT00812019|Experimental|7.5_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
10213361|NCT04198116|Experimental|Varenicline + Guanfacine ER|Varenicline (2mg/day) + Guanfacine extended release (6mg/day ER). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Guanfacine ER (6mg/day) administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM for both medications.
10213362|NCT04198116|Active Comparator|Varenicline|Varenicline (2mg/day). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
9919966|NCT00812019|Experimental|7.5_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
9919967|NCT00812019|Experimental|7.5_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
9919968|NCT00812019|Experimental|7.5_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
9919969|NCT00812019|Experimental|15_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
9919970|NCT00812019|Experimental|15_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
9919971|NCT00812019|Experimental|15_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
9919972|NCT00812019|Experimental|15_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
9919973|NCT00812045|Experimental|1|
9919974|NCT00812045|Placebo Comparator|2|
9919975|NCT00812058|Experimental|RG2417|Oral RG2417 taken twice daily for 8 weeks
9919976|NCT00812058|Placebo Comparator|Placebo|Oral placebo taken twice daily for 8 weeks
9919977|NCT00812084||CAP cohort|Includes cases that were hospitalized because of a community-acquired pneumonia during the study period, and for which we had a baseline EQ-5D score from the start of the study period. These CAP cases are prospectively followed for up to one year using questionnaires for health status and (health) resources.
9919978|NCT00812084||Controls cohort|For each CAP cases, two controls are matched based on age, sex and baseline EQ-5D score measured at the start of the study. These controls are prospectively followed for up to one year using questionnaires for health status and (health) resources.
9919979|NCT00812123|Experimental|Calcineurin free|Immunosuppression with Sirolimus, Mycophenolate and Steroids
9919980|NCT00812123|Active Comparator|Calcineurin|Immunosuppressive therapy with Cyclosporin A, Mycophenolate and Steroids
9919981|NCT00812162|Experimental|1|High protein diet.
9919982|NCT00812162|Experimental|2|Lower protein diet.
9919983|NCT00812175||Group 1|
9919984|NCT00812188|Active Comparator|Medium Dose UVA-1|Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
9919985|NCT00812188|Active Comparator|High Dose UVA-1|High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
9919986|NCT00812214|Experimental|1|
9919987|NCT00812214|Placebo Comparator|2|
9919988|NCT00812227|Experimental|Psychodynamic psychotherapy|
9919989|NCT00812266|Experimental|A|Topotecan + cisplatin
9919990|NCT00812266|Active Comparator|B|Etoposide + carboplatin
9919991|NCT00812279|Experimental|1. SMAR|Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
9919992|NCT00812279|Active Comparator|2 Conventional cigarette (CC)|Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
9919993|NCT00812279|Active Comparator|3. smoking cessation (SC)|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
9919994|NCT00812318|Experimental|Treatment A|GSK1265744 10mg oral solution
9919995|NCT00812318|Experimental|Treatment B|GSK1265744 5mg tablet, fasted
9919996|NCT00812318|Experimental|Treatment C|GSK1265744 5mg tablet, fed
9919997|NCT00812344|Experimental|1|
9919998|NCT00812344|Active Comparator|2|AZD0837 + Ketoconazole
9919999|NCT00812357||1|Patients treated with Symbicort basic treatment
9920000|NCT00812357||2|Patients treated with Symbicort basic treatment + treatment of symptoms as needed
9920001|NCT00812370|Experimental|open label|
9920002|NCT00812396|Active Comparator|1|Low dose testosterone
9920003|NCT00812396|Active Comparator|2|High dose testosterone
9920004|NCT00812396|Placebo Comparator|3|Placebo
9920005|NCT00812409|Experimental|1|Control group: non-protein supplement with resistance and aerobic exercise.
9920006|NCT00812409|Experimental|2|Low protein supplement with resistance and aerobic exercise.
9920007|NCT00812409|Experimental|3|Moderate protein supplement with resistance and aerobic exercise.
9920008|NCT00812409|Experimental|4|High protein supplement with resistance and aerobic exercise.
9920009|NCT00812422|Experimental|Dexibuprofen 1|Dexibuprofen 2.5 or 5 mg/kg
9920010|NCT00812422|Experimental|Dexibuprofen 2|Dexibuprofen 3.5 or 7 mg/kg
9920011|NCT00812422|Active Comparator|Ibuprofen|Ibuprofen 5 or 10 mg/kg
9920012|NCT00812435|Experimental|Eptifibatide|PCI with administration of eptifibatide
9920013|NCT00812448|Experimental|tea catechin extracts containing mask|wearing the tea catechin extracts containing mask
9920014|NCT00812500|Experimental|1|Young men, age 21-46 years.
9920015|NCT00812500|Experimental|2|Old Men, age 63-81 years.
9920016|NCT00812500|Experimental|3|Young women, age 21-46 years.
9920017|NCT00812500|Experimental|4|Old women, age 63-81 years.
9920018|NCT00812539|Experimental|"Diabetes Connected Health Tool Deluxe"|Subjects enrolled into the intervention arm will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal, where they can view their glucose readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to these subjects' information on the web portal).
9920019|NCT00812539|Active Comparator|"Diabetes Connected Health Tool Basic"|Control group will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal. where they can view their glucose readings in tabular form. Their physicians will not have access to this information.
9920020|NCT00812552||Case|Late or very late drug-eluting stent thrombosis
9920021|NCT00812552||Control|No drug-eluting stent thrombosis
9920022|NCT00812578|Active Comparator|Cholecalciferol|
9920023|NCT00812578|Placebo Comparator|Placebo pill|
9920024|NCT00812617|Experimental|Mineral water 1|
9920025|NCT00812617|Experimental|Mineral water 2|
9920026|NCT00812630|Experimental|1|In the second part of the trial, subjects will apply MENT or placebo gel transdermally for 12 weeks and will have 24-hour blood pressure monitoring at baseline, Week 6 and Week 12.
9920027|NCT00812656||Stroke Panel group|Patients undergoing cardiac surgery with the use of cardiopulmonary bypass
9920028|NCT00812669|Experimental|Fludarabine, Cylophosphamide and Rituximab|
9920029|NCT00812695|No Intervention|1|
9920030|NCT00812695|Active Comparator|2|CPAP
9920031|NCT00812721|Placebo Comparator|1|Preservative Free Saline
9920032|NCT00812721|Active Comparator|2|Optive (TM)
9920033|NCT00812721|Active Comparator|3|Refresh Moderate/Severe (TM)
9920034|NCT00812721|Active Comparator|4|Systane (TM)
9920035|NCT00812721|Active Comparator|5|Systane Ultra (TM)
9920036|NCT00812734||surgery|
9920037|NCT00812747||1|
9920038|NCT00812760|Experimental|1|
9920039|NCT00812773|Experimental|3 day repeat dose|
9920040|NCT00812799|Active Comparator|Grass pollen extract|Subjects will receive 19.000 BU grass pollen extract daily sublingually
9920041|NCT00812799|Placebo Comparator|Placebo control|Subjects will receive matching placebo control daily sublingually
9920042|NCT00812825|Experimental|PF-04173127|
9920043|NCT00812825|Active Comparator|Prednisolone|
9920044|NCT00812825|Placebo Comparator|Placebo|
9920045|NCT00812825|Sham Comparator|Solution Placebo|
9920046|NCT00812825|Experimental|PF-04171327 Tablet|
9920047|NCT00812864|Experimental|Capecitabine|
9920048|NCT00812903|No Intervention|Control|Control group
9920049|NCT00812903|Experimental|Exercise|Intervention group
9920050|NCT00812942|Active Comparator|fobt|faecal occult blood test
9920051|NCT00812942|Active Comparator|colonoscopy|colonoscopy screening
9920052|NCT00812994|Placebo Comparator|Placebo|
9920053|NCT00812994|Experimental|Escitalopram|
9920054|NCT00813007||Questionnaire|Radical trachelectomy outcomes for cervical cancer
9920055|NCT00813020|Experimental|A|
9920056|NCT00813020|Experimental|B|
9920057|NCT00813020|Experimental|C|
9934953|NCT04339790||New study participant|Individuals who respond to study website or advertisements for the study who have not previously been a NIMH study participant
9934954|NCT04339790||NIMH Study Participant|Individuals who have previously consented for a NIMH study
9934955|NCT04339777|Active Comparator|Arm A|Low Intensity, Intermediate Intensity and High Intensity Conditioning with or without alemtuzumab
9934956|NCT04339777|Active Comparator|Arm B|Intermediate Intensity Conditioning with or without Alemtuzumab
9934957|NCT04339764|Experimental|Participants receiving intervention|Participants receiving intervention
9934958|NCT04339751|Experimental|single center, prospective pilot study|effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease
9934959|NCT04338321|Experimental|Esketamine Arm|Participants will receive treatment with esketamine nasal spray (28 milligram [mg] [initial dose for elderly participants 65 to 74 years of age and adults of Japanese ancestry; may be used throughout the study in these populations; may be uptitrated in 28 mg increments], 56 mg [initial dose for adult participants aged 18 to 64 years and may be used for all age groups throughout the study], or 84 mg [maximum dose esketamine nasal spray may be uptitrated to]) twice-weekly with a flexible dose regimen from Day 1 until Week 4, once weekly from Week 5 to Week 8 and once-weekly or once every 2 weeks from Week 9 to Week 32 in combination with continuing serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI).
9934960|NCT04338321|Active Comparator|Comparator Arm|Participants will continue to take their current SSRI/SNRI augmented with quetiapine extended release (XR) as per the Summary of Product Characteristics (SmPC) (or local equivalent, if applicable). In adult participants aged 18 to 64 years, the initial dose is 50 mg/day on Days 1-2, 150 mg/day on Days 3-4 [lowest effective dose]; a further dose increase to 300 mg/day on Day 5 and onward will be based on individual participant evaluation. In elderly participants aged 65 to 74 years, the initial dose is 50 mg/day on Days 1-3, 100 mg/day on Days 4-7, and 150 mg/day on Day 8; a further dose increase to 300 mg/day will be based on individual participant evaluation no earlier than Day 22.
9934961|NCT04334954||Healthy Volunteers|Healthy Volunteers
9934962|NCT04334759|Experimental|Arm A: Durvalumab + Chemotherapy, then Durvalumab Maintenance|Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
9934963|NCT04334759|Active Comparator|Arm B: Chemotherapy, then Observation|Standard Chemotherapy for 4 to 6 cycles, followed by Observation
9934964|NCT04327583|Experimental|Coordinated pharmaceutical path|Patients treated with anti-cancer oral therapy who benefit a specific pharmaceutical follow-up by the healthcare facilities pharmacist and by the dispensary pharmacist
9934965|NCT04327583|No Intervention|Standard of care|Patients treated with anti-cancer oral therapy who who do not benefit from an additional pharmaceutical intervention
9934966|NCT04327206|Experimental|BCG vaccine|Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
9934967|NCT04327206|Placebo Comparator|0.9% Saline|Participants will receive a single 0.1 mL dose of 0.9%NaCl injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
9934968|NCT04324112|Experimental|Arm 1/Experimental therapy|Treatment with encorafenib and binimetinib
9934969|NCT04323397|Experimental|nasal high frequency oscillatory ventilation|"nHFO: flow 8-10 L/minute, frequency 10 Hz, MAP = MAP (before extubation) + 2 or 8 (preterm), 10 (term) cmH2O, dP = 2-3 times of MAP with visible chest oscillations or 25-35 cmH2O, I:E = 1:1, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%"
9934970|NCT04323397|Experimental|nasal synchronized intermittent positive pressure ventilation|"nSIPPV: flow 8-10 L/minute, rate 60/minute, PIP = PIP (before extubation) + 2-5 or 20 (preterm), 25 (term) cmH2O, PEEP = 5 cmH2O, IT = 0.5 s, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%. The highest trigger sensitivity avoiding auto triggering was selected."
9934971|NCT04322383|Experimental|Arm 1/Experimental therapy|Treatment with binimetinib
9934972|NCT04318925||1|Persons with diagnosed or suspected tick-borne disease age >=18 years
9934973|NCT04317118||Neurodevelopmental|Individuals between 8 and 17 years old with neurodevelopmental disorders
9934974|NCT04316559|Placebo Comparator|Placebo|Placebo capsule
9934975|NCT04316559|Experimental|TRV734|TRV734 at different doses vs. oxycodone for withdrawal suppression
9934976|NCT04316546|Experimental|MK-7075 (miransertib)|This is a single-arm study. All study participants will be taking the experimental drug, MK-7075 (miransertib).
9934977|NCT04316078|Experimental|personalized engagement platform|Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects.
9934978|NCT04316078|No Intervention|control group|The control group will not be registered to the PEP nor receive any PEVs.
9935790|NCT03215030|Experimental|Part 3 (Dose Extension): Modakafusp alfa 120 mg|Participants will receive modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
9920058|NCT00813033|Other|patient decision aid|
9920059|NCT00813046|Experimental|gpASIT+TM|
9920060|NCT00813059|Experimental|1|
9920061|NCT00813072|Experimental|1. PEP02|liposome irinotecan
9920062|NCT00813072|Active Comparator|2. irinotecan|
9920063|NCT00813072|Active Comparator|3. docetaxel|
9920064|NCT00813085|Other|Electronic disease management decision support|An electronic Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS).
9920065|NCT00813085|No Intervention|2|Usual care by Family Physician
9920066|NCT00813137|Experimental|Folfox4 plus Endostar|
9920067|NCT00813189|Experimental|1 : early start (GH treatment) group|in the early start group, patients were treated with growth hormone for one year immediately after randomisation
9920068|NCT00813189|No Intervention|2 :delayed start (GH treatment) group|in the delayed start group patients took GH treatment for 1 year , 6 months after randomisation
9920069|NCT00813202|Experimental|Nesiritide|
9920070|NCT00813215|Experimental|1|Relatives to patients with type 2 diabetes.
9920071|NCT00813215|Active Comparator|2|Controls with no family history of type 2 diabetes.
9920072|NCT00813241|Active Comparator|A|A single dose of 200 mg celecoxib capsule administered as 1 x 200 mg celecoxib capsule, (Reference Formulation)
9920073|NCT00813241|Experimental|B|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet formulation containing granule type A1
9920074|NCT00813241|Experimental|C|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type B2
9920075|NCT00813241|Experimental|D|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type C1
9920076|NCT00813254||Questionnaire|Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
9920077|NCT00813267|Experimental|stem cell|mesenchymal stem cell infusion and bone marrow mononuclear cell infusion
9920078|NCT00813280||hyperglycemia|hospitalized patients with BG >300 ml/dL
9920079|NCT00813306|Experimental|A|AZD2066
9920080|NCT00813306|Placebo Comparator|B|Placebo
9920081|NCT00813306|Experimental|C|AZD2066
9920082|NCT00813306|Experimental|D|AZD2066
9920083|NCT00813306|Placebo Comparator|E|Placebo
9920084|NCT00813332|Experimental|1|Endostar combined with Docetaxel for Advanced NSCLC: All eligible patients will receive Endostar in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Endostar treatment will continue after completion of first 4 cycles until disease progression.
9920085|NCT00813332|Placebo Comparator|2|Docetaxel combined with placebo for Advanced NSCLC: All eligible patients will receive placebo in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Placebo will continue after completion of first 4 cycles until disease progression.
9920086|NCT00813345|Experimental|A - Light therapy|Light therapy (1500 lux)
9920087|NCT00813345|Placebo Comparator|B - identical control lamp|identical control lamp
9920088|NCT00813371|Active Comparator|1|Airway Pressure Release Ventilation Arm
9920089|NCT00813371|Active Comparator|2|ARDSnet protocol
9920090|NCT00813384|Experimental|Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208.
9920091|NCT00813384|Experimental|Dose Expansion|The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
9920092|NCT00813397|Experimental|Sepraspray|Receive Sepraspray
9920093|NCT00813397|No Intervention|Control|No Treatment, No Placebo
9920094|NCT00813436|Experimental|1|Oxytocin
9920095|NCT00813436|Placebo Comparator|2|Placebo
9920096|NCT00813449|Experimental|A|Experimental group : Endostar combined with dacarbazine
9920097|NCT00813449|Placebo Comparator|2|Control group : Dacarbazine combined with placebo
9920098|NCT00813475|Experimental|tight control|
9920099|NCT00813475|Experimental|standard control|basal bolus insulin regimen
9920100|NCT00813514|Experimental|1|Open longitudinal study with observer masked analysis
9920101|NCT00813527|Experimental|Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD|
9920102|NCT00813527|Active Comparator|Fenofibrate 145 mg QD|
9920103|NCT00813540|Experimental|1|Exercise
9920104|NCT00813540|Other|2|Usual Care, no intervention
9920105|NCT00813553|Placebo Comparator|beta-alanine 0|
9920106|NCT00813553|Experimental|beta-alanine 1|
9920107|NCT00813553|Experimental|beta-alanine 2|
9920108|NCT00813618|Experimental|1|MEDI-507
9920109|NCT00813618|Experimental|2|MEDI-507
9920110|NCT00813618|Experimental|3|MEDI-507
9920111|NCT00813631|Experimental|silver-releasing dressings|Silver, in its common ionic (active) form (Ag+), is particularly attractive as an antibacterial agent because it can be readily incorporated into dressing materials. Silver-dressing are wound products designed to control infection and provide a wound environment conducive to management exudates, pain, and malodour.
9920112|NCT00813644||1|uromentor training
9920113|NCT00813644||2|non uromentor training
9920114|NCT00813657|Experimental|Lifestyle counseling|
9920115|NCT00813670|Experimental|Cohort 1: Single dose of XPF-001|
9920116|NCT00813670|Experimental|Cohort 2: Single dose of XPF-001|
9920117|NCT00813670|Experimental|Cohort 3: Single dose of XPF-001|
9920118|NCT00813670|Experimental|Cohort 4: Single dose of XPF-001|
9920119|NCT00813670|Experimental|Cohort 5: Single dose of XPF-001|
9920120|NCT00813670|Experimental|Cohort A: Repeated doses of XPF-001|
9920121|NCT00813670|Experimental|Cohort B: Repeated doses of XPF-001|
9920122|NCT00813670|Experimental|Cohort C: Repeated doses of XPF-001|
9920123|NCT00813683|Experimental|1|"Stimulation of 67 Bladder point"
9920124|NCT00813683|Sham Comparator|2|"Stimulation of 45 Stomach point (sham)"
9920125|NCT00813696|Experimental|A|cisplatin + gemcitabine
9920126|NCT00813696|Active Comparator|B|gemcitabine
9920127|NCT00813722|Active Comparator|phone calls|patients received phone calls
9920128|NCT00813722|Placebo Comparator|no phone calls|patients received no phone calls
9920129|NCT00813722|Active Comparator|current treatment|calcium chanel blocker and at1 antagonist
9920130|NCT00813722|Active Comparator|tradittional treatment|beta blocker and diuretic
9920131|NCT00813735|Experimental|Eszopiclone|Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg
9920132|NCT00813735|Placebo Comparator|Placebo|Drug: Placebo, Drug: Escitalopram 10mg or 20mg
9920133|NCT00813774|Active Comparator|Reference|Lyophilized formulation (reference)
9920134|NCT00813774|Experimental|Liquid|Liquid Formulation (test)
9920135|NCT00813774|Experimental|Pre-filled Syringe|Pre-filled syringe (test)
9920136|NCT00813787||A. glioma|A. glioma population
9920137|NCT00813787||B. Normal brain|B. Normal brain
9920138|NCT00813826|Experimental|SLC022|300mg TID
9920139|NCT00813826|Placebo Comparator|Placebo|Matching placebo capsule
9920140|NCT00813839|Experimental|1 SmartCare|automated ventilator controlled adjustment of pressure support
9920141|NCT00813839|Active Comparator|2 spontaneous breathing Trial|daily SBT on minimum pressure support
9920142|NCT00813852|Experimental|2|exercise training, CPAP, and inspiratory muscle strengthening program
9920143|NCT00813878||Normal participants|
9920144|NCT00813878||Breast Cancer Patients|
9920145|NCT00813891|Active Comparator|Pre-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
9920146|NCT00813891|Active Comparator|Post-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
9920147|NCT00813891|Active Comparator|No PDT|Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
9920148|NCT00813930|Experimental|INTERxVENT Program|Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
9920149|NCT00813930|No Intervention|Usual medical care|Each participant randomized to this group will not receive any formal intervention but will receive the same care over the 6-month period as he/she usually receives from his/her health care team. Participants in this group will undergo the same baseline and outcome assessment as those in the intervention group, including blood pressure (BP) measurement, physical assessment (height, weight, waist measurement) and blood collection (blood glucose and cholesterol levels), as well as completion of the 'Baseline Assessment' and 'Follow-up' questionnaires.
9920150|NCT00813969|Experimental|Autologous MSC transplantation|
9920151|NCT00814021|Experimental|sunitinib,|
9920152|NCT00814034||1:Tamoxifen|
9920153|NCT00814034||2:Steroidal Aromatase Inhibitor|
9920154|NCT00814034||3:Non-steroidal Aromatase Inhibitor|
9920155|NCT00814060|Experimental|1|40-mg tablet
9920156|NCT00814060|Experimental|2|240-mg tablet
9920157|NCT00814060|Experimental|3|80-mg capsule
9920158|NCT00814086|Experimental|Treatment (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9920159|NCT00814099|Active Comparator|1|Participants will receive care at a pediatric ICU that is continuing the usual approach to sedation management.
9920160|NCT00814099|Experimental|2|Participants will receive care at a pediatric ICU that is implementing the team approach to sedation management.
9920161|NCT00814112||1 septic shock|septic shock, ICU
9920162|NCT00814112||2 controls|matched controls
9920163|NCT00814125|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
9920164|NCT00814125|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
9920165|NCT00814125|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
9920166|NCT00814151||MicroPhage|Blood Culture positive specimens available within 24 hours of alarm.
9920167|NCT00814151||Standard of Care|Blood Culture positive specimens.
9920168|NCT00814190|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
9920169|NCT00814190|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
9920170|NCT00814203||Chronic obstructive lung disease|those with a condition
9920171|NCT00814216|Experimental|QAV680|
9920172|NCT00814216|Placebo Comparator|Placebo|
9920173|NCT00814216|Active Comparator|Fluticasone Propionate Inhaler|
9920174|NCT00814229|Active Comparator|Vaccine 1|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
9920175|NCT00814229|Active Comparator|vaccine 2|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
9920176|NCT00814229|Active Comparator|Vaccine 3|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
9920177|NCT00814229|Active Comparator|Vaccine 4|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
9920178|NCT00814229|Active Comparator|Vaccine 5|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
9920179|NCT00814229|Active Comparator|Vaccine 6|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
9920180|NCT00814229|Active Comparator|Vaccine 7|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
9920181|NCT00814229|Active Comparator|Vaccine 8|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
9920182|NCT00814229|Active Comparator|Vaccine 9|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
9920183|NCT00814229|Active Comparator|Vaccine 10|influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection
9920184|NCT00814229|Active Comparator|Vaccine 11|influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection
9920185|NCT00814229|Active Comparator|Vaccine 12|influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection
9920186|NCT00814229|Active Comparator|Vaccine 13|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
9920187|NCT00814229|Active Comparator|Vaccine 14|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
9920188|NCT00814242|Active Comparator|hepatectomy|Patients with HCC adjacent to major blood vessels recieved radical resection.
9920189|NCT00814242|Experimental|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation
9920190|NCT00814268|Experimental|Combination therapy|Administration of Aspirin + Clopidogrel for 30 days
9920191|NCT00814268|Active Comparator|Monotherapy|Administration of Aspirin + Clopidogrel placebo for 30 days
9920192|NCT00814281|Placebo Comparator|1|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
9920193|NCT00814281|Placebo Comparator|2|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
9920194|NCT00814281|Experimental|3|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
9920195|NCT00814281|Experimental|4|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
9920196|NCT00814359|Experimental|Magic Mouthwash Plus Sucralfate|
9920197|NCT00814359|Active Comparator|Benzydamine HCl|
9920198|NCT00814385|Active Comparator|Vaccine arm 1|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
9920199|NCT00814385|Active Comparator|Vaccine arm 2|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
9920200|NCT00814385|Active Comparator|Vaccine arm 3|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
9920201|NCT00814385|Active Comparator|Vaccine arm 4|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
9920202|NCT00814385|Active Comparator|Vaccine arm 5|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
9920203|NCT00814385|Active Comparator|vaccine arm 6|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
9920204|NCT00814385|Active Comparator|Vaccine arm 7|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
9920205|NCT00814385|Active Comparator|Vaccine arm 8|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
9920206|NCT00814385|Active Comparator|Vaccine arm 9|No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks
9920207|NCT00814398|Experimental|SET on day 3|Single embryo transfer on day 3 of embryo development
9920208|NCT00814398|Experimental|DET on day 3|Double embryo transfer on day 3 of embryo development
9920209|NCT00814398|Experimental|SET on day 5|Single embryo transfer on day 5 of embryo development
9920210|NCT00814398|Experimental|DET on day 5|Double embryo transfer on day 5 of embryo development
9920211|NCT00814411|Experimental|Group Counseling|Group family planning counseling
9920212|NCT00814411|Active Comparator|Individual Counseling|Individual family planning counseling with gynecological patients who have unmet need
9920213|NCT00814424|Active Comparator|1|ERCP patients monitored using currently marketed smart biteblock o2
9920214|NCT00814424|Experimental|2|ERCP patients monitored using experimental biteblock delivering up to 10 lit/min oxygen
9920215|NCT00814437||Donors|Oocyte donor
9920216|NCT00814476|Active Comparator|2|Regular treated group in the first segment and CareLink treated group in the second segment
9920217|NCT00814476|Experimental|1. CareLink team supported group|CareLink team supported group
9920218|NCT00814515|Active Comparator|1|Ciclosporin 0.1%
9920219|NCT00814515|Placebo Comparator|2|Vehicle
9920220|NCT00814528|Experimental|1|"Application of 5-ALA PDT to some lesions on skin with Blue U light source (417 nm)."
9920221|NCT00814528|Experimental|2|5-FU, Imiquimod or treatment with cryotherapy to lesions on the skin.
9920222|NCT00814541|Experimental|1|Relapsed patients, previously treated with VAD or VAD like regimen (VAMP, C-VAMP and Z-Dex are examples of VAD like therapy) and who have had autologous transplants at least 1 year previously.Patients may proceed directly to PAD therapy or have had a maximum of one other line of therapy before PAD.
9920223|NCT00814541|Experimental|2|Relapsed patients, previously treated with VAD or VAD-like regimen who have not had autologous transplantation and achieved at least PR (Appendix A). Patients may proceed directly to PAD therapy or have had a maximum of two other lines of therapy before PAD.
9920224|NCT00814541|Experimental|3|Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
9920225|NCT00814554|No Intervention|control|no intervention was carried out in high school
9920226|NCT00814554|Experimental|Educational strategy|Educational strategy was carried out in high school.
9920227|NCT00814554|Experimental|Screening strategy|Screening strategy was carried out in high school.
9920228|NCT00814554|Experimental|Environmental strategy|Environmental strategy was carried out in high school.
9920229|NCT00814554|Experimental|Educational and Screening strategies|Educational strategy and Screening strategy were carried out in high school
9920230|NCT00814554|Experimental|Screening and Environmental strategies|Screening strategy and Environmental strategy were carried out in high school
9920231|NCT00814554|Experimental|Educational and Environmental strategies|Educational strategy and Environmental strategy were carried out in high school
9920232|NCT00814554|Experimental|the three strategies|Educational strategy, Screening strategy and Environmental strategy were carried out in high school.
9920233|NCT00814567|Active Comparator|Arm I (control)|Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.
9920234|NCT00814567|Experimental|Arm II|Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
9920235|NCT00814567|Experimental|Arm III|Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
9920236|NCT00814593|Experimental|Arm I|Patients undergo intracranial placement of polifeprosan 20 with carmustine implant (Gliadel® wafer) at the time of therapeutic craniotomy.
9920237|NCT00814593|Experimental|Arm II|Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
9920238|NCT00814606|Experimental|Single Group|8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing < 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).
9920239|NCT00814619|Experimental|Arm I|Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
9920240|NCT00814619|Active Comparator|Arm II|Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.
9920241|NCT00814645|Active Comparator|Dose level 1|a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization
9920242|NCT00814645|Active Comparator|Dose level 2|a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
9920243|NCT00814645|Active Comparator|Dose level 3|a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
9920244|NCT00814645|Active Comparator|Dose level 4|a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
9920245|NCT00814645|Placebo Comparator|Expansion arm|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
9920246|NCT00814723|Active Comparator|Fluvastatin|Fluvastatin 80 mg MR
9920247|NCT00814723|Active Comparator|Fluvastatin + Ezetimibe|Fluvastatin MR 80 mg plus Ezetimibe 10 mg
9920248|NCT00814736|Experimental|UK369,003 + Placebo or sildenafil|All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo
9920249|NCT00814749|Active Comparator|surgical therapy|
9920250|NCT00814749|Active Comparator|individual management|
9920251|NCT00814762|Experimental|HIV 732462 Group|Subjects received 2 doses of the HIV Vaccine 732462 into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
9920252|NCT00814762|Placebo Comparator|Placebo Group|Subjects received 2 doses of the placebo vaccine into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
9920253|NCT00814814||Cardiopulmonary arrest|
9920254|NCT00814840|Active Comparator|Triple-site group|Triple-site resynchronization group
9920255|NCT00814840|Active Comparator|Standard resynchronization group|Standard (double-site) resynchronization group
9920256|NCT00814853||Extubation readiness testing|Patients who pass the ERT.
9920257|NCT00814866|Other|Adalimumab|Open label
9920258|NCT00814905|Placebo Comparator|vaginal delivery 1|no further antibiotics after delivery (the patient will receive a saline infusion instead of antibiotics)
9920259|NCT00814905|Active Comparator|vaginal delivery antibotics2|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following vaginal delivery
9920260|NCT00814905|Other|cesarean delivery one dose3|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
9920261|NCT00814905|Other|cesarean multiple antibiotics 4|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
9920262|NCT00814918|Experimental|1|5-ALA Application and exposure using Blu-U light to 1/2 of face.
9920263|NCT00814918|Experimental|2|5-ALA Application and exposure using Candela V-beam Pulse Dye Laser to 1/2 of face.
9920264|NCT00814931|Experimental|1|Treatment Group
9920265|NCT00814931|Placebo Comparator|2|
9920266|NCT00814944|Experimental|Dose Group 1|
9920267|NCT00814944|Experimental|Dose Group 2|
9920268|NCT00814944|Experimental|Dose Group 3|
9920269|NCT00814944|Placebo Comparator|Dose Group 4|
9920270|NCT00814957|Experimental|Open-label|D3 receptor antagonist
9920271|NCT00814996||1: employment|
9920272|NCT00814996||2: unemployment|
9920273|NCT00815009|No Intervention|A (Std of Care)|Standard of Care/Control, including Lifestyle Advice (attend a basic healthy nutrition class as well as follow up appointments with GI MD).
9920274|NCT00815009|Experimental|B (Low Fat)|Standard of Care, plus Low Fat Diet and Moderate Exercise
9920275|NCT00815009|Experimental|C (Mod Fat)|Standard of Care, plus Moderate Fat/Low Processed Carbohydrate Diet and Moderate Exercise
9920276|NCT00815009|Experimental|D (Exercise only)|Standard of Care plus Moderate Exercise only
9920277|NCT00815022|Active Comparator|1|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
9920278|NCT00815022|Experimental|2|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
9920279|NCT00815022|Experimental|3|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
9920280|NCT00815022|Experimental|4|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
9920281|NCT00815022|Experimental|5|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
9920282|NCT00815022|Experimental|6|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
9920283|NCT00815048|Active Comparator|Remifentanil|"Atropine~Remifentanil"
9920284|NCT00815048|Placebo Comparator|Fentanyl|"Atropine~Fentanyl~Succinylcholine"
9935791|NCT03215030|Experimental|Part 3 (Dose Extension): Modakafusp alfa 240 mg|Participants will receive modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
9920285|NCT00815074||1|Women in the military who have returned from deployment within the past 12 months.
9920286|NCT00815100|Placebo Comparator|Placebo|
9920287|NCT00815100|Active Comparator|Ivabradine|
9920288|NCT00815113||1|First degree relative of gastric cancer patient
9920289|NCT00815113||2|Consecutive gastro-esophageal reflux patients
9920290|NCT00815126|Active Comparator|Mucocutaneous symptoms from NSAIDs|
9920291|NCT00815126|Active Comparator|Respiratory symptoms from NSAIDs|
9920292|NCT00815126|Active Comparator|NSAIDs tolerant individuals|
9920293|NCT00815139||ZES group|Groups who were treated with zotarolimus eluting stent
9920294|NCT00815152|Experimental|1|Twenty five caregivers will randomly be assigned to receive active coping skills training and 25 caregivers will randomly receive usual care at The Preston Robert Tisch Brain Tumor Center at Duke.
9920295|NCT00815152|Placebo Comparator|2|Caregivers that will receive ususal care.
9920296|NCT00815165||Protocol 04-039 subjects|At least 50 and maximum of 100 healthy adolescent female subjects aged 12-17 years who were vaccinated in protocol 04-039 will be enrolled.
9920297|NCT00815165||Positive and Negative Controls|Approximately 100 screened subjects will be enrolled to serve as positive and negative controls.
9920298|NCT00815178|Experimental|Inspiratory muscle training|
9920299|NCT00815178|Placebo Comparator|Placebo|
9920300|NCT00815204||posttraumatic stress disorder|
9920301|NCT00815204||history of trauma exposure but no PTSD|
9920302|NCT00815204||healthy controls|
9920303|NCT00815217|Experimental|1 lipoaspirate|wounds which have received the lipoaspirate
9920304|NCT00815217|Placebo Comparator|2 control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
9920305|NCT00815243|Experimental|Telemed|Group of trauma&orthopedic patients - for determination of clinical strategy and treatment plan telemedicine will be used
9920306|NCT00815243|Active Comparator|InternalControl|Group of trauma&orthopedic patients from 3rd level trauma center - for determination of clinical strategy and treatment plan usual clinical approaches will be used
9920307|NCT00815243|Active Comparator|ExternalControl|Group of trauma&orthopedic patients from 1-2rd level trauma centers (in rural and small municipal hospitals) - for determination of clinical strategy and treatment plan personal arriving of the expert by the car (so-called Urgent Expert Care) will be used
9920308|NCT00815256|Experimental|Cross linking (CXL)|Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
9920309|NCT00815269|Active Comparator|1|Halothane anesthesia: induction and maintenance with different doses
9920310|NCT00815269|Experimental|2|Isoflurane anesthesia: induction and maintenance with different doses
10213363|NCT04183452||17-Hydroxyprogesterone Caproate 250 mg IM Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 250 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
10213364|NCT04183452||17-Hydroxyprogesterone Caproate 275 mg SC Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 275 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
10213365|NCT04171960||Acute Blood Biomarker Branch|"Blood draw within 12 hours of injury for i-STAT Testing then processing for storage for future use~Blood draw between 12 to 24 hours of injury then processing for storage for future use~In-Person Outcome Assessment"
10213366|NCT04171960||Acute Blood Biomarker Plus Follow-up Branch|"Blood draw at 2 weeks and 6 months following injury then processing for storage for future use~In-Person Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury~Phone Outcome Assessment at 3 months following injury~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury"
10213367|NCT04167345|Placebo Comparator|Parts A1, A2 and B Combined: Placebo|Participants received placebo matched to VX-814 in the treatment period for 28 days.
10213368|NCT04167345|Experimental|Part A1: VX-814 100 milligrams (mg)|Participants received VX-814 100 mg every 12 hours (q12h) in the treatment period for 28 days.
10213369|NCT04167345|Experimental|Part A1: VX-814 200 mg|Participants received VX-814 200 mg q12h in the treatment period for 28 days.
10213370|NCT04167345|Experimental|Parts A1 and A2 Combined: VX-814 400 mg|Participants received VX-814 400 mg q12h in the treatment period for 28 days.
10213371|NCT04167345|Experimental|Part B: VX-814 600 mg|Participants received VX-814 600 mg q12h in the treatment period for 28 days.
10213372|NCT04166994|Experimental|IMPACT Intervention|Incorporate a rehabilitation approach to slowly increasing KT recipients' physical activity in addition to individualized dietary intervention at every post-transplant appointment through six months post-transplant, with follow-up at 12 months post-transplant.
10213373|NCT04166994|Other|Usual Care|No exercise or diet specialization.
10213374|NCT04165941|Experimental|DRI cell therapy|The only arm will receive the DRI modified gamma delta T cells following standard therapy with radiation and temozolomide chemotherapy concurrent.
10213375|NCT04165135||Haemophilia A Without FVIII Inhibitors|
10213376|NCT04157894||Standard LLIN|This group receives Interceptor ITNs during the mass distribution campaign.
10213377|NCT04157894||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
10213378|NCT04157894||Piperonyl butoxide LLIN|This group receives PBO ITNs during the mass distribution campaign.
9920311|NCT00815269|Experimental|3|Sevoflurane anesthesia: induction and maintenance with different doses
9920312|NCT00815269|Experimental|4|Desflurane anesthesia: induction and maintenance with different doses
9920313|NCT00815269|Experimental|5|Enflurane anesthesia: induction and maintenance with different doses
9920314|NCT00815282|Other|Patients|patients were girls aged 15 to 18 immunised with the HPV vaccine according to dutch vaccination guidelines
9920315|NCT00815334|Experimental|Patients with decreased bladder compliance|Patients who have decreased bladder compliance
9920316|NCT00815334|Active Comparator|Patients with normal bladder compliance|Patients who have normal bladder compliance
9920317|NCT00815373|Active Comparator|1|Cosopt* b. i. d. (dosed morning and bedtime) will be administered topically
9920318|NCT00815373|Active Comparator|2|Xalacom* q.d.(dosed bedtime) and placebo vehicle q.d. (dosed morning) topically in the other group
9920319|NCT00815386|Experimental|PTMA implanted|Enrolled patients receiving a PTMA implant
9920320|NCT00815399|Experimental|1|
9920321|NCT00815399|Active Comparator|2|
9920322|NCT00815412|Active Comparator|Counseling in use of health care|
9920323|NCT00815412|Active Comparator|Counseling in diet, exercise|
9920324|NCT00815412|Placebo Comparator|Contol group|
9920325|NCT00815425||African Americans with RA|1063 participants with RA
9920326|NCT00815425||African-Americans without RA|550 participants without RA
9920327|NCT00815438|Experimental|Surgical Procedure|Laparoscopic transvaginal cholecystectomy with endoscopic assistance.
9920328|NCT00815451|Placebo Comparator|placebo dark chocolate|polyphenol-poor dark chocolate
9920329|NCT00815451|Experimental|polyphenol-rich dark chocolate|
9920330|NCT00815464|Experimental|Antiviral Therapy|Liquid Acupuncture(Herb Acupoints Injection) Therapeutics was researched and developed by Herbalist Yu Ru Lin in early of 1950s and used by Yu Medical Garden till now. It is an integrated therapeutics,according to individual condition, select the Acupoints(not limit to current used common acupoints) and proper herbs made individually.It is a special medical treatment conception, which theory is utilizing patients' condition, mobilizing their individual internal curability,therefore the final efficacy can be retrieved.
9920331|NCT00815477|Active Comparator|1|Waitlist control with generic Information about lifestyle and hypertension
9920332|NCT00815477|Experimental|2|Web-based intervention of lifestyle counseling messages based on the transtheoretical model of readiness for change.
9920333|NCT00815503|Active Comparator|Ropivacaine|
9920334|NCT00815503|Placebo Comparator|Saline|
9920335|NCT00815542|Active Comparator|double balloon catheter|Cervical ripening by double balloon catheter
9920336|NCT00815542|Placebo Comparator|prostaglandins E2|cervical ripening using prostaglandins E2
9920337|NCT00815555||1|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
9920338|NCT00815568|Experimental|Regimen|Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
9920339|NCT00815581|Other|photorefraction|
9920340|NCT00815620||1|patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy
9920341|NCT00815620||2|patients undergoing surgery or radiofrequency ablation
9920342|NCT00815620||3|patients undergoing peptide receptor radiotherapy
9920343|NCT00815646|Experimental|Sildenafil|Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.
9920344|NCT00815672|No Intervention|Treatment Arm 1|Usual Care: Standard care monitoring
9920345|NCT00815672|Experimental|Treatment arm 2|Home-based Exercise: Progressive walking and resistance exercise treatment.
9920346|NCT00815724|Experimental|1|Participants will take part in a distance learning group.
9920347|NCT00815724|No Intervention|2|Participants in the control group will not receive any study materials or take part in any study activities.
9920348|NCT00815737|Experimental|A|
9920349|NCT00815737|Placebo Comparator|B|
9920350|NCT00815750|Other|Phase I - Information Gathering|
9920351|NCT00815750|Other|Phase 2 - Decision Aid|
9920352|NCT00815763|Experimental|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
9920353|NCT00815763|Placebo Comparator|placebo|infusion placebo (group B)once a day and continued for 14 days
9920354|NCT00815789|Experimental|Intervention|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
9920355|NCT00815789|No Intervention|Control|Receive educational material about CVD reduction at baseline
9920356|NCT00815815|Active Comparator|Continued inpatient treatment|Participants will undergo inpatient hospital treatment until they have gained enough weight to be discharged.
9920357|NCT00815815|Experimental|Sequenced treatment|Participants will begin with inpatient treatment, transition to day patient treatment, and then transition to outpatient treatment.
9920358|NCT00815828|Other|1|Group that don't do the resistance exercises
9920359|NCT00815854|Experimental|Folate|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
9920360|NCT00815854|Placebo Comparator|Placebo|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
9920361|NCT00815867|Experimental|A|Patient will receive Epoetin Beta
9920362|NCT00815867|No Intervention|B|
9920363|NCT00815880|Active Comparator|Implantable Counterpulsation Therapy|The study is a single arm study with 20 patients being treated with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. These patients will receive the C-Pulse System Implant as intervention therapy. There is not a control arm in this feasibility study.
9920364|NCT00815893|Experimental|1 dex group|received dexmedetomidine (1.0 mcg/kg) infusion
9920365|NCT00815893|Placebo Comparator|2 control group|received 0.9% saline
9920366|NCT00815893|Active Comparator|3 Propofol group|received 1% propofol using effect-site TCI(Base Primea, Fresenius, France)
9920367|NCT00815906|Experimental|SBI-087 0.15 mg IV|
9920368|NCT00815906|Experimental|SBI-087 0.5 mg IV|
9920369|NCT00815906|Experimental|SBI-087 100 mg SC|
9920370|NCT00815906|Experimental|SBI-087 200 mg SC|
9920371|NCT00815932|Experimental|1-CRPS|10 tDCS naïve patients with CRPS-related neuropathic pain in upper limb
9920372|NCT00815932|Experimental|2-DN|20 tDCS naïve patients with diabetic neuropathy
9920373|NCT00815932|Experimental|3-RPNP|20 tDCS naïve patients with resistant peripheral neuropathic pain
9920374|NCT00815932|Experimental|4-CIPN|10 tDCS naïve patients with CIPN-Chemotherapy Induced Pain Neuropathy patients
9920375|NCT00815945|Experimental|PegLiposomal Doxorubicin + Carboplatin|Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)
9920376|NCT00815958|Experimental|A|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
9920377|NCT00815958|Active Comparator|B|Reaming with conventional reamer
9920378|NCT00815971||NSCLC|Patients with non-small cell lung cancer carcinoma treated with erlotinib
9920379|NCT00815984||Schoolchildren with asthma.|Schoolchildren with asthma.
9920380|NCT00816010|Experimental|1|Lifestyle and compliance counseling via telephone contact with structured set of questions and reinforcements provided
9920381|NCT00816010|No Intervention|2|Control arm with usual care as per local hospital practice
9920382|NCT00816049|Active Comparator|6MPfixed|Fixed dose 6-mercaptopurine days 30-85
9920383|NCT00816049|Experimental|6MPindividualized|Individualized dose increments of 6-mercaptopurine days 30-85
9920384|NCT00816075|Experimental|1, Distilled water|the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
9920385|NCT00816088||neutropenia|Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
9920386|NCT00816127|Experimental|1|DDAVP
9920387|NCT00816127|Active Comparator|2|Standard Treatment
9920388|NCT00816140|Active Comparator|Klaricid, triple therapy|Klaricid based triple therapy
9920389|NCT00816140|Experimental|Cravit, triple therapy|Cravit based triple therapy
9920390|NCT00816153|Experimental|PVI|PVI guided fluid management
9920391|NCT00816153|No Intervention|Control|
9920392|NCT00816192|Active Comparator|1|"The externally irrigated-tip catheter is an open system in which saline is continuously infused and empties into the blood pool. For the externally irrigated-tip catheter, RF energy delivery settings were: power ≤ 35 watts and temperature ≤ 43°C with a variable flow-rate to obtain a temperature around 40°C."
9920393|NCT00816192|Experimental|2|"For the internally irrigated tip catheter (reference catheter), radiofrequency (RF) energy delivery settings will be: power ≤ 35 watts, temperature ≤ 47◦C and a fixed flow rate of 0.6 ml/s.~The advantage of the Chili thermo-cooled tip system is that no saline solution leaves the catheter system and flows into the patient."
9920394|NCT00816205|Experimental|Single Arm|This is an open label, dose-finding study. After detrminig baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 3 Coated Suppositories per study.
9920395|NCT00816218|Experimental|Pioglitazone|Fifty type 2 diabetic patients (25 diet-treated and 25 treated with diet plus sulfonylurea) will have pioglitazone, 45 mg daily; added to their therapeutic regimen. All patients will be closely monitored and, in addition to periodic contacts and clinical visits, metabolic and vascular parameters will be assessed at the beginning and after 3 and 6 months of therapy. Euglycemic hyperinsulinemic clamp with muscle biopsies will be performed at the beginning and after 6 months of treatment.
9920396|NCT00816231|Experimental|Alcohol and Nicotine Group|Alcohol and Nicotine Drug/Cue Interactions
9920397|NCT00816231|Active Comparator|Alcohol Only Group|Alcohol Only Drug/Cue Interactions
9920398|NCT00816231|Active Comparator|Nicotine Only Group|Nicotine Only Drug/Cue Interactions
9920399|NCT00816231|Placebo Comparator|Placebo and Placebo Group|Placebo Only Drug/Cue Interactions
9920400|NCT00816244|Experimental|Atorvastatin|
9920401|NCT00816270|Experimental|1|Experimental operatory wound closure with liquid bandage (Johnson & Johnson, Skillman, NJ, USA).
9920402|NCT00816296||Controls|Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
9920403|NCT00816296||Liver Disease|Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
9920404|NCT00816309|Experimental|Acapella Physiotherapy|Physiotherapy with acapella versus no physiotherapy
9920405|NCT00816309|No Intervention|No physiotherapy|Physiotherapy with acapella versus no physiotherapy
9920406|NCT00816322|Active Comparator|omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
9920407|NCT00816322|Placebo Comparator|Placebo|high oleic oil
9920408|NCT00816335|Experimental|Arm 1|F-FDG-directed surgery for known or suspected malignancy using gamma detection probes.
9920409|NCT00816374|Other|1|Group I
9920410|NCT00816374|Other|2|Group II
9920411|NCT00816387|Active Comparator|IUI|Intrauterine insemination using standard catheter
9920412|NCT00816387|Experimental|FSP|Fallopian tube sperm perfusion using a commercial device for hysterosalpingography and tubal hydropertubation
9920413|NCT00816426|Other|1|Dosing 2 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
9920414|NCT00816426|Other|2|Dosing 4 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
9920415|NCT00816426|Other|3|Dosing 8 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
9920416|NCT00816426|Other|4|Dosing 12 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
9920417|NCT00816426|Other|5|Dosing 24 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
9920418|NCT00816465|Experimental|1|Patients receiving Hoodia
9920419|NCT00816465|Placebo Comparator|2|Patients receiving placebo
9920420|NCT00816478|Experimental|1|Galactose
9996342|NCT01499316|Experimental|High Flow oxygen|10 minute of 10/L min of inhaled oxygen with reservoir bag.
9996343|NCT01499316|Experimental|Room Air|
9996344|NCT01499329||Patient receiving stent therapy|
9996345|NCT01499342||Rutherford category 2 - 5|
9996346|NCT01499381||Routine prostate biopsy patients|
9996347|NCT01499394||Normal|"Donor samples reflective of a normal non-disease state"
9996348|NCT01499394||Disease state or condition|Donor samples reflective of a known disease state or condition
9996349|NCT01499407|Active Comparator|Standard abciximab bolus|
9996350|NCT01499407|Experimental|ClearWay-infused abciximab|
9996351|NCT01499407|Experimental|Thrombectomy plus ClearWay-infused abciximab|
9996352|NCT01499407|Active Comparator|Thrombectomy plus standard abciximab bolus|
9996353|NCT01499433|Experimental|caspofungin|
9996354|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Morning|
9996355|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Evening|
9996356|NCT01499446|Experimental|GW685698X (fluticasone furoate) 250mcg Evening|
9996357|NCT01499446|Placebo Comparator|Placebo|
9996358|NCT01499459|Experimental|autologous mesenchymal stem cell transplantation|
9996359|NCT01499472|Active Comparator|shock wave therapy, shortened wound healing time|
9996360|NCT01499472|Other|normal wound care|standard of care intervention
9996361|NCT01499485|Experimental|Acetazolamide|
9996362|NCT01499485|Placebo Comparator|placebo|
9996363|NCT01499537|Active Comparator|Percutaneous Drainage|Percutaneous Transhepatic Biliary Drainage (PTBD)
9996364|NCT01499537|Experimental|EUS-guided drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
9996365|NCT01499550|Experimental|TNI application|In this study arm the patient is treated with humidified transnasal high flow (TNI) plus oxygen (result flow: 20 L/min).
9996366|NCT01499550|Active Comparator|Oxygen treatment|Long term oxygen treatment (LOT) is the routine treatment in patients suffering from COPD. In this study arm the patient is treated with his individual oxygen flow rate.
9996367|NCT01499589||RA in block room|Performing regional anesthesia in the block room
9996368|NCT01499589||RA inside OR|Performing regional anesthesia inside the main orthopedic operating room
9996369|NCT01499602|Experimental|LNG-IUS|Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up.
9996370|NCT01499602|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
9996371|NCT01499615||children undergoing general anesthesia|The intervention was the application of 4 ekg electrodes so as to non-invasivly measure cardiac output
9996372|NCT01499628|No Intervention|Group 1-Control|No extra training will be given.
9996373|NCT01499628|Active Comparator|Group 2-Control plus supervised reading|The same amount of contact time as Groups 3 and 4 - three 45 minute sessions completed over three weeks.
9996374|NCT01499628|Experimental|Group 3-EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
9996375|NCT01499628|Experimental|Group 4-EVT at the TRL|Eccentric viewing training at the Trained Retinal Locus (TRL), using reading/target cards and microperimeter. Three 45 minute sessions completed over three weeks.
9996376|NCT01499641|Active Comparator|Epidural steroid|1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root
9996377|NCT01499641|Experimental|None epidural steroid|
9996378|NCT01499680||NV in XLIF|This group will have the XLIF procedure done using NV.
9996379|NCT01499693|Experimental|Magnesium Pantoprazole 20mg|
9996380|NCT01499693|Active Comparator|Magnesium Pantoprazole 40mg|
9996381|NCT01499706|No Intervention|Standard of Care Control|Participants will receive standard sexual risk reduction services available to them through medical and community-based organizations
9996382|NCT01499706|Experimental|1-session motivational interviewing|Participants will receive a single session of motivational interviewing delivered over the telephone
9996383|NCT01499706|Experimental|4-session motivational interviewing|Participants will receive four weekly sessions of motivational interviewing delivered over the telephone.
9996384|NCT01499719||Surgical checklist|Compliance for surgical checklist
9996385|NCT01499732||Early Rheumatoid Arthritis|Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms < or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
9996386|NCT01499732||Healthy subjects without rheumatoid arthritis|Healthy subjects without rheumatoid arthritis
9996387|NCT01499732||Established Rheumatoid Arthritis|Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms > or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
9996388|NCT01499745|Active Comparator|Exercise Training at Pulmonary Rehabilitation Program|Exercise Training at Pulmonary Rehabilitation Program 2 weekly sessions of 60 min for 12 weeks
9996389|NCT01499745|Placebo Comparator|Standard Treatment for IPF|Continue for normal live with standard treatment
9996390|NCT01499758|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
9996391|NCT01499758|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
9996392|NCT01499771|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
9996393|NCT01499771|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
9996394|NCT01499784|Experimental|Pelvic Floor muscle Training|educational class for behavioral modification and group exercise class for pelvic floor muscle training
9996395|NCT01499797|No Intervention|regular medical care|Identified community dwelling frail elderly people receiving regular medical care in their primary care setting
9996396|NCT01499797|Experimental|The CareWell programme|Identified community dwelling frail elderly people receiving care in line with the CareWell programme
9996397|NCT01499823||Patients with high-grade glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
9996398|NCT01499836|Experimental|general anesthesia and PVB|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given. After intubation, paravertebral injections will be performed under ultrasound guidance.
9996399|NCT01499836|Experimental|sedation and PVB|After sedation with midazolam and fentanyl, the patients in sedation and PVB group will receive PVB. paravertebral injections will be performed under ultrasound guidance.Intraoperative sedation will be provided with propofol titrated to moderate sedation.
9996400|NCT01499836|Active Comparator|general anesthesia|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given.
9996401|NCT01499875|Other|Phenoxymethylpenicillin|It is a descriptive trial to find out about the pharmacokinetics
9996402|NCT01499901|Experimental|sequential|implantation bilateral sequential
9996403|NCT01499901|Experimental|simultaneous|implantation bilateral simultaneous
9996404|NCT01499914|Experimental|Influenza vaccination|Influenza vaccination in patients with cystic fibrosis
9996405|NCT01499927|Active Comparator|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
9996406|NCT01499927|No Intervention|no electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support
9996407|NCT01499953|Experimental|Rivaroxaban|Rivaroxaban for 45 days oral dose: 10 mg OD
9996408|NCT01499953|Active Comparator|Fondaparinux|Fondaparinux for 45 days subcutaneous application: 2,5 mg OD
9996409|NCT01499966|Experimental|group POP|PLASTER OF PARIS
9996410|NCT01499966|Experimental|TG|TUBIGRIP
9996411|NCT01499979|No Intervention|Vascular inflow occlusion|Patients that will receive intermittent vascular inflow occlusion, the standard method for vascular occlusion at our institution, during liver resection.
9996412|NCT01499979|Experimental|Hypothermic perfusion|Patients will receive in situ hypothermic perfusion of the future remnant liver during liver resection.
9996413|NCT01499992|Experimental|aquatic physical therapy|aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focussing on the shoulder.
9996414|NCT01499992|No Intervention|standard care|
9996415|NCT01500005|Experimental|vitamin D|Baby D3 drops
9996416|NCT01500018|Experimental|Crossover Treatment Sequence 1|Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg
9996417|NCT01500018|Experimental|Crossover Treatment Sequence 2|Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg
9996418|NCT01500018|Experimental|Crossover Treatment Sequence 3|Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg
9996419|NCT01500018|Experimental|Crossover Treatment Sequence 4|Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo
9996420|NCT01500018|Experimental|Crossover Treatment Sequence 5|Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg
9996421|NCT01500018|Experimental|Crossover Treatment Sequence 6|Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg
9998120|NCT01515150||Out-patients in diverticulitis|All patient with acute uncomplicated diverticulitis how accept participation in the study will be enrolled in the study.
9920421|NCT00816491|Active Comparator|A|Conventional white light colonoscopy
9920422|NCT00816491|Experimental|B|Chromoendoscopy
9920423|NCT00816504|Experimental|1|Galactose
9920424|NCT00816517|Experimental|botulinum toxin|injection of botulinum toxin type A
9920425|NCT00816530||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
9920426|NCT00816543|Experimental|1|3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy.
9920427|NCT00816569|Experimental|Keratoconus|One eye of Keratoconus patient
9920428|NCT00816608||type 2 diabetes|
9920429|NCT00816621|Experimental|ABC for Children Adopted Internationally|ABC for Children Adopted Internationally: 10 session in home intervention that targets parent nurturance, synchrony, pseudo-autistic behaviors, and indiscriminate sociability
9920430|NCT00816621|Active Comparator|DEF for Children Adopted Internationally|DEF for Children Adopted Internationally: 10 session in home intervention that targets cognitive and motor delays
9920431|NCT00816634|Active Comparator|1|"Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks"
9920432|NCT00816634|Active Comparator|2|"XT Regimen:~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks"
9920433|NCT00816647|Active Comparator|1|Medial patellofemoral ligament reconstruction
9920434|NCT00816647|Active Comparator|2|Medial reefing
9920435|NCT00816660|Experimental|1|
9920436|NCT00816660|Active Comparator|2|
9920437|NCT00816673|Placebo Comparator|placebo|
9920438|NCT00816673|Experimental|Circadin|
9920439|NCT00816686|Experimental|1. AGS-16M18 Dose 1|
9920440|NCT00816686|Experimental|2. AGS-16M18 Dose 2|
9920441|NCT00816686|Experimental|3. AGS-16M18 Dose 3|
9920442|NCT00816686|Experimental|4. AGS-16M18 Dose 4|
9920443|NCT00816686|Experimental|5. AGS-16M18 Dose 5|
9920444|NCT00816699|Placebo Comparator|1|Routine anesthetic risk information
9920445|NCT00816699|Active Comparator|2|Preprint preoperative risk information
9920446|NCT00816712|Active Comparator|A|Testosterone - 300 mg IM
9920447|NCT00816712|Active Comparator|B|Testosterone - 100 mg IM
9920448|NCT00816712|Placebo Comparator|C|Placebo - IM
9920449|NCT00816725|Experimental|Self-help course and information|
9934979|NCT04312659||Infliximab|Participants with pediatric Crohn's disease (CD) who were treated with Infliximab (IFX) and signed the Informed Consent Form (ICF) for the study will be enrolled case by case. Each participants will be followed up for at least 30 weeks. After 30 weeks, participants continuing IFX treatment will be followed up, with a maximum follow-up period of 102 weeks. The primary data source will be participants medical records for all data entered into the CRF.
9934980|NCT04312126||Arm 1|46 healthy young (18-35) volunteers
9934981|NCT04312126||Arm 2|46 healthy older (50-80) volunteers
9934982|NCT04312126||Arm 3|46 chronic (>6 months post-stroke) stroke patients
9934983|NCT04305431|Experimental|1/All Subjects|Second phase participants
9934984|NCT04304820|Experimental|SAA|Subjects with SAA treated with early initiation of oral treatment
9934985|NCT04303728|Experimental|Muscle ultrasound|Muscle ultrasound will be performed for the patient on admission and at 1-2 months from inpatient rehabilitation.
9934986|NCT04303117|Experimental|Arm 1/Monotherapy|Treatment with NHS-IL12 at de-escalating doses if necessary
9934987|NCT04303117|Experimental|Arm 1a/Monotherapy Expansion|Treatment with NHS-IL12 at MTD
9934988|NCT04303117|Experimental|Arm 2/Combination therapy|Treatment with NHS-IL12 at MTD and M7824 at a fixed dose
9934989|NCT04301089|Experimental|Experimental intervention|Experimental VR Intervention, Survey or Questionnaire Completion and Sample Submission
9934990|NCT04295837|Experimental|ABLE - A Better everday LifE|A home-based occupational therapy intervention addressing ADL task performance issues among persons living with chronic conditions. The ABLE intervention is occupation-focused and -based, and follows a structured process of assessment, goalsetting, intervention and evaluation.
9934991|NCT04295837|Active Comparator|Usual care|Community-based occupational therapy addressing ADL task performance issues among persons living with chronic conditions
9934992|NCT04294693||Pediatric Population|The investigator intends to collect information on all total joint arthroplasty patients identified within the surgical practice of Dr. Nathan Donaldson for non-tumor related diagnoses at Children's Hospital Colorado.
9934993|NCT04294641|Experimental|Intervention|Determine response rate via continuous daily dose by mouth to determine efficacy
9934994|NCT04293744|Experimental|Colloid priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL PrimECC.
9934995|NCT04293744|Active Comparator|Standard priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).
9934996|NCT04291105|Experimental|Melanoma intratumoral|Melanoma, IV & IT VV1 + cemiplimab Patients will receive both intravenous (IV) VV1 and intratumoral (IT) VV1 on Day 1. Will also receive an infusion of cemiplimab on Day 8.
9934997|NCT04291105|Experimental|Melanoma IV|Melanoma, IV + cemiplimab Patients will receive both IV VV1 and cemiplimab on Day 8.
9934998|NCT04291105|Experimental|Melanoma IV Triplet|Melanoma Patients will receive IV VV1 and ipilumumab (single dose) on Day 1 and cemiplimab on Day 8 and then every 21 days.
9934999|NCT04291105|Experimental|Non-small Cell Lung Cancer First Line Triplet|IV VV1 and ipilumumab (single dose) on Day 1 and cemiplimab on Day 8, then every 21 days.
9935000|NCT04289571|Experimental|Participants|Participants with retinal disease, healthy volunteers
9935001|NCT04287868|Experimental|Arm 1|Triple Therapy: PDS0101 + NHS-IL12 + M7824; The dose level of NHS-IL12 may decrease depending on DLT events. The dose level of HVP vaccine and M7824 will remain constant.
9920450|NCT00816764|Experimental|1. AGS-8M4 Dose 1|
9920451|NCT00816764|Experimental|2. AGS-8M4 Dose 2|
9920452|NCT00816764|Experimental|3. AGS-8M4 Dose 3|
9920453|NCT00816764|Experimental|4. AGS-8M4 Dose 4|
9920454|NCT00816790|Active Comparator|Dose Adjusted|This arm will receive their broad spectrum antibiotic as an adjusted dose based on their renal function as measured when sepsis is diagnosed and antimicrobials are initiated
9920455|NCT00816790|Experimental|Unadjusted Dose|This arm will receive their broad spectrum antibiotic as an unadjusted dose regardless of their renal function
9920456|NCT00816803|Experimental|BM transplant with physiotherapy|Autologous BM transplant
9920457|NCT00816803|Active Comparator|Physiotherapy only|conventional physical therapy for chronic spinal cord injury.
9920458|NCT00816816|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
9920459|NCT00816855|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
9920460|NCT00816868|Experimental|non-small cell lung cancer (NSCLC)|erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)
9920461|NCT00816881|Experimental|1|flutter mucus clearance device
9920462|NCT00816881|No Intervention|2|Observation
9920463|NCT00816894|Experimental|D-serine arm|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes.
9920464|NCT00816894|Active Comparator|Olanzapine arm|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
9920465|NCT00816920||1|Outpatients with suspected leg DVT after exclusion of proximal DVT
9935002|NCT04287868|Experimental|Arm 2|Triple Therapy: PDS0101 + NHS-IL12 + M7824; Accrual will be expanded first to 8 participants and then to 20 evaluable participants at the dose level selected in Arm 1 if more than 3 of 8 participants have an objective response.Triple Therapy: PDS0101 + NHS-IL12 + M7824; Reduced doses.
9920466|NCT00816933|Experimental|one port|Patients undergo one port appectomy. Skin incision about 2cm size is made upon umbilicus and dissection is performed to make opening. Then, wound retractcor(Alexis) is iserted on opening site and wound is extended. Rubber glove built-in three 5mm trocars is applied over wound retractor. Pneumoperitoneum is achieved via trocar and appendectomy is performed. After appendectomy, wound is repaired.
9920467|NCT00816933|Active Comparator|Three ports|"Paitents will undergo three port appendectomy. 10 mm trocar is inserted on umbilicus, and two 5mm trocas is inserted low abdomen, left flank respectively.~Appendectomy is performed vis these trocas. After operation, wounds are repaired."
9920468|NCT00816946|No Intervention|Routine LHW Advice|Arm receiving routine advice by their local Lady Health Workers (LHWs)
9920469|NCT00816946|Active Comparator|Enhanced LHW Advice|Arm receiving enhanced nutrition and health advice from the local Lady Health Workers (LHWs)during their routine community visits.
9920470|NCT00816959|Active Comparator|Arm I: R-mabHDI and ABVD|
9920471|NCT00816959|Active Comparator|Arm II: ABVD|
9920472|NCT00816985|Experimental|Liposuction + Questionnaires|Liposuction, followed by Quality of Life Questionnaires and extended follow-up period.
9920473|NCT00816998|Other|Early|Participants randomized to this arm will begin physical therapy of their fractured wrist approximately one week following surgery
9920474|NCT00816998|Other|Delayed|Participants randomized to this group will begin physical therapy of their fractured wrist approximately 6 weeks from their surgery. This is the approximate time frame in which therapy begins for patients not involved in the study. The term Delayed refers to therapy being delayed in starting from those in the study who begin therapy at one week post-operatively, not a delay in current care practice.
9920475|NCT00817011|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
9920476|NCT00817011|Active Comparator|non-SSRI treated group|non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
9920477|NCT00817024|Experimental|Xuefu Zhuyu Capsules|
9920478|NCT00817024|Active Comparator|Sheng Mai Capsules|
9920479|NCT00817024|Placebo Comparator|Placebo|
9920480|NCT00817037|Experimental|Sitaxsentan|"Once daily oral sitaxsentan 100mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
9920481|NCT00817037|Placebo Comparator|Placebo|"Once daily oral placebo tablet given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
9920482|NCT00817037|Active Comparator|Nifedipine|"Open labeled active comparator~Once daily oral nifedipine 30mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
9920483|NCT00817102|Other|CorCTA|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures
9920484|NCT00817115|No Intervention|1|Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
9920485|NCT00817115|Experimental|2|Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
9920486|NCT00817128|Experimental|1|PEPT after randomization
9920487|NCT00817128|Experimental|2|CBO after randomization
9920488|NCT00817141||Without urinary catheter|
9920489|NCT00817154|Experimental|Hopes-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
9920490|NCT00817167|Experimental|inReach (A)|Bronchoscopy procedure is planned using inReach planning software
9920491|NCT00817167|Active Comparator|Control (B)|Bronchoscopy procedure is planned using standard CT viewer software
9920492|NCT00817180|Active Comparator|A|Positive Expiratory Pressure (PEP) - an airway clearance technique
9920493|NCT00817180|Active Comparator|B|High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.
9920494|NCT00817193|Experimental|Physical Activity|Participants will begin to participate in walking sessions and strength building classes that will be offered at each location. Participants will be asked to attend a minimum of 1 strength class per week, with a target of doing 150 minutes of moderate exercise each week. The exercise classes will include stretching and counseling to help participants understand and address the barriers to becoming and staying involved in regular exercise.
9920495|NCT00817193|Active Comparator|Wellness|Participants will begin to participate in a wellness program that will meet at each site twice per month. The first meeting will involve a lecture or presentation on a wellness-related topic. The second meeting will follow-up on concepts that were introduced in the first meeting, and will also to provide participants an opportunity to share experiences. Participants will be asked to attend both wellness sessions each month for whole year that the program is running.
9920496|NCT00817232|Experimental|Treatment 1|50 microamp amplitude
9920497|NCT00817232|Experimental|Treatment 2|500 microamp amplitude
9920498|NCT00817245|Active Comparator|1|Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
9920499|NCT00817245|No Intervention|2|No medical treatment
9920500|NCT00817258|Other|1|All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
9920501|NCT00817271|Experimental|1|
9920502|NCT00817271|Experimental|2|
9920503|NCT00817284|Experimental|arm I|Bevacizumab + Irinotecan and concomitant radiotherapy
9920504|NCT00817284|Experimental|Arm II|Bevacizumab and Temozolomide and concomitant radiotherapy
9920505|NCT00817297|Other|V60 Mask, Then Conventional Mask|Experimental V60 Mask Ventilator for treating adult patients with COPD, then Comparator Conventional Mask Ventilator for treating adult patients with COPD
9920506|NCT00817297|Other|Conventional Mask, Then V60 Mask|Comparator Conventional Mask noninvasive Ventilator for treating adult patients with COPD, then Experimental V60 Mask noninvasive Ventilator for treating adult patients with COPD.
9920507|NCT00817310||Severe IVH|Infants born at less than 1500g with diagnosis of Grade II or IV IVH
9920508|NCT00817310||control|infants born at less than 1500g without IVH on HUS
9920509|NCT00817323|Experimental|Quetiapine fumurate (Seroquel)|See Detailed description
9920510|NCT00817375|Experimental|SSRI treated group|SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
9920511|NCT00817375|Active Comparator|non-SSRI treated group|non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
9920512|NCT00817388||1|patients will be asked to provide a urine specimen and complete a questionnaire.
9920513|NCT00817427|No Intervention|Baseline|CKD subjects and healthy, matched controls will have measures of cardiovascular function (BP, HR) measure of hormonal fluid balance (renin/aldosterone) measure and measures of glucose metabolism (response to glucose load and over 24 hr profile) with 3 days of habitual sleep time
9920514|NCT00817427|Experimental|CKD- Sleep extension|Measures as in baseline but with bed time increased by 2 hours
9920515|NCT00817427|Experimental|Controls short sleep|Measures as in baseline but with sleep disruption
9920516|NCT00817440|No Intervention|Control|control: muscle and fat biopsies and basal aminoacid and glucose turnover
9920517|NCT00817440|Experimental|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
9920518|NCT00817440|Experimental|Fasting|3 days of fasting and then the same as arm 1
9920519|NCT00817453||1|Clinically diagnosed Early iPD
9920520|NCT00817453||2|Age/gender matched controls without neurodegenerative diagnosis
9920521|NCT00817453||atypical or late Parkinsonian Syndromes|Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.
9920522|NCT00817466|Experimental|Racemic adrenaline, fixed intervals|Active drug with fixed intervals of inhalation, adjusted at least every 24h.
9920523|NCT00817466|Experimental|Racemic adrenalin, on demand|Racemic adrenaline, inhalations on demand (max every 2 hrs)
9920524|NCT00817466|Active Comparator|Saline, fixed intervals|Saline inhalation fixed intervals, adjusted at least every 24 hrs
9920525|NCT00817466|Active Comparator|saline on demand|Saline inhalations on demand, max every 2 hrs, adjusted every 12 hrs
9920526|NCT00817492||1|Subjects with mild to moderate kidney disease
9920527|NCT00817492||2|Healthy Control Subjects
9920528|NCT00817505|Active Comparator|1|AZD1656 tablet + food
9920529|NCT00817505|Active Comparator|2|AZD1656 susp. without food
9920530|NCT00817505|Active Comparator|3|AZD1656 tablet
9920531|NCT00817518|Experimental|1|
9920532|NCT00817518|Experimental|2|
9920533|NCT00817544|Experimental|ORM-12741|ORM-12741
9920534|NCT00817557|Active Comparator|Loteprednol|Loteprednol BID
9920535|NCT00817557|Placebo Comparator|Rewetter|Rewetter BID
9920536|NCT00817570||1|Transfemoral Amputees using the C- Leg knee.
9920537|NCT00817570||2|Transfemoral Amputees using a Multiaxial Knee.
9920538|NCT00817570||3|Able bodied.
9920539|NCT00817583|Experimental|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.
9920540|NCT00817609|Experimental|A|
9920541|NCT00817609|Placebo Comparator|B|
9920542|NCT00817622|Placebo Comparator|A|"Placebo, Placebo :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day) Placebo pearl + corn oil 400 mg per day for 12 weeks"
9920543|NCT00817622|Active Comparator|B|"EPA, Placebo :~EPA pearls,500 mg QID for 12 Weeks (2000 mg per day),From MINAMINUTRITION Company(Belgium)+ Placebo pearl ,corn oil 400 mg per day for 12 weeks"
9920544|NCT00817622|Placebo Comparator|C|"Placebo ,Vitamin E :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day)+ Vitamin E pearls, 400 mg from DANA Company(IRAN) per day for 12 weeks"
9920545|NCT00817622|Active Comparator|D|"EPA, Vitamin E :~EPA pearls,500 mg QID From MINAMINUTRITION Company(Belgium) for 12 Weeks (2000 mg EPA per day)+ Vitamin E pearls, 400 mg from DANA Company ( IRAN) per day for 12 weeks"
9920546|NCT00817648|Experimental|1|Quetiapine fumarate, flexible doses(600-750 mg/d)
9920547|NCT00817648|Active Comparator|2|risperidone, flexible doses(3-6 mg/d)
9920548|NCT00817661|Experimental|1|Vitamin A group
9920549|NCT00817661|Placebo Comparator|2|Placebo group
9920550|NCT00817674||1|CKD subjects
9920551|NCT00817674||2|Healthy Controls
9920552|NCT00817687|Experimental|1|
9920553|NCT00817687|No Intervention|2|
9920554|NCT00817700|No Intervention|Normal (8 hours) sleep time|Subjects are studied under normal sleep time conditions.
9935792|NCT03206099||Biological relatives|Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
9996422|NCT01500018|Experimental|Crossover Treatment Sequence 7|Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg
9996423|NCT01500018|Experimental|Crossover Treatment Sequence 8|Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo
9998121|NCT01515163|Experimental|Exercise|3-month exercise training program
9920555|NCT00817700|Experimental|Sleep restriction|"Sleep restriction to 4 hours of sleep per night.~Overnight sleep recording, measures of endocrine and metabolic (from blood), cardiovascular (measures of blood pressure and heart rate), performance ( before and after sleep restriction and after sleep recovery."
9920556|NCT00817713|Active Comparator|anthelminthic treatment|Albendazol plus fix-dose Praziquantel plus Ivermectin
9920557|NCT00817713|No Intervention|HIV care, no anthelminthic treatment|HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines
9920558|NCT00817726||1- RBD|polysomnographically diagnosed RBD patients. RBD is a sleep disorder diagnosed by a sleep lab in which the individual has muscle movements during the phase of deep sleep during which the muscles should be relaxed. Suspicion of RBD by history will be confirmed during screening.
9920559|NCT00817726||2 - control|"control:~must not have any neurological degenerative diagnosis.~must NOT have RBD.~must be able to age and/or gender-match to RBD and PD subjects already enrolled."
9920560|NCT00817739|Active Comparator|Continuous Therapy|Continuous complete androgen suppression therapy with leuprorelin 3.75 mg sustained release (SR), injection, subcutaneously once every 28 days and flutamide, 250 mg, tablet, orally thrice daily until there are signs of disease progression.
9920561|NCT00817739|Experimental|Intermittent therapy|Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach >=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are <normal (that is, <4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
9920562|NCT00817752|Experimental|1|Receives Ashwagandha herb.
9920563|NCT00817765|Active Comparator|Posaconazole alone|400mg posaconazole BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
9920564|NCT00817765|Active Comparator|Fosamprenavir ritonavir|Fosamprenavir 700mg / ritonavir 100mg BID for 10 days
9920565|NCT00817765|Experimental|Fosamprenavir posaconazole|Fosamprenavir 700mg / posaconazole 400mg BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
9920566|NCT00817791|Experimental|HBO|
9920567|NCT00817830|Experimental|lodenafil carbonate|Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
9920568|NCT00817869|Experimental|New Flooring|Will receive 8.3mm thick floor covering (Omnisports EXCEL) to replace previous floor covering.
9920569|NCT00817869|No Intervention|Standard Flooring|Ward will remain with standard floor covering. The overlay will have a comparable slip resistance rating to the new flooring. The sub-floor will also be comparable.
9920570|NCT00817882|Experimental|1|individually targeted vocational rehabilitation
9920571|NCT00817882|Active Comparator|2|routine back pain rehabilitation
9920572|NCT00817895|Experimental|5-FU+Cisplatin|50 HCC patients will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin into liver incisal margin after tumor is resected.
9920573|NCT00817895|Active Comparator|5-FU|50 HCC patients will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected.
9920574|NCT00817895|Experimental|control|
9920575|NCT00817908||1|Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.
9920576|NCT00817921||1|former premature children treated by ibuprofen
9920577|NCT00817921||2|former premature children not treated by ibuprofen
9920578|NCT00817921||3|former term children (control)
9920579|NCT00817934||PREVENTION AND TREATMENT|PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
9920580|NCT00817947|Active Comparator|Usual airway clearance technique|Airway clearance using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure or oscillating positive expiratory pressure
9920581|NCT00817947|Other|HFCWO|High frequency chest wall oscillation
9799140|NCT01651208|Experimental|Motivational interviewing (MINT)|The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
9920582|NCT00817960|Experimental|Methylphenidate|
9920583|NCT00817973|Active Comparator|Casein|
9920584|NCT00817973|Active Comparator|Whey|
9920585|NCT00817973|Active Comparator|Cod|
9920586|NCT00817973|Active Comparator|Gluten|
9920587|NCT00818025|No Intervention|Standard of Care|All subjects will receive standard care to prepare for discharge that consists of a one-on-one, pre-discharge educational session delivered by the transplant coordinator prior to hospital discharge and provision of a reference binder for each lung transplant recipient to take home.
9920588|NCT00818025|Experimental|Pocket PATH hand-held device|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
9920589|NCT00818038||TYSABRI|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
9920590|NCT00818051|Active Comparator|Arm I (control)|Patients undergo sequential boost dose intensity-modulated radiotherapy (IMRT) 5 days a week for 4.6 weeks (23 fractions; 56 Gy).
9920591|NCT00818051|Experimental|Arm II|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 48 Gy).
9920592|NCT00818051|Experimental|Arm III|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 53 Gy).
9920593|NCT00818064|Experimental|A, HV|Dose cohort 1 (3 subjects active, 1 placebo)
9920594|NCT00818064|Experimental|B, HV|Dose cohort 2 (3 subjects active, 1 placebo)
9920595|NCT00818064|Experimental|C, HV|Dose cohort 3 (3 subjects active, 1 placebo)
9920596|NCT00818064|Experimental|D, HV|Dose cohort 4 (3 subjects active, 1 placebo)
9920597|NCT00818064|Experimental|E, HV|Dose cohort 5 (3 subjects active, 1 placebo)
9920598|NCT00818064|Experimental|A, RA|Dose cohort 1 (3 subjects active, 1 placebo)
9920599|NCT00818064|Experimental|B, RA|Dose cohort 2 (3 subjects active, 1 placebo)
9920600|NCT00818064|Experimental|C, RA|Dose cohort 3 (3 subjects active, 1 placebo)
9920601|NCT00818077||Metformin, Type 2 Diabetes|
9920602|NCT00818090|Experimental|TP|paclitaxel and cisplatin every 3 weeks
9920603|NCT00818103|Experimental|Atorvastatin, β-interferon, EPO|
9920604|NCT00818129|Experimental|1|
9920605|NCT00818129|Placebo Comparator|2|
9920606|NCT00818142||eating disorder, type 1 diabetes|Individuals diagnosed with type 1 diabetes and an eating disorder who withhold their insulin.
9920607|NCT00818155|Experimental|desvenlafaxine succinate SR|desvenlafaxine succinate SR
9920608|NCT00818155|Placebo Comparator|Placebo|
9920609|NCT00818181|Experimental|Solution of birch pollen allergen extract|In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
9920610|NCT00818194|Experimental|A. tacrolimus first|Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
9920611|NCT00818194|Experimental|B. cyclosporine first|Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
9920612|NCT00818220|Experimental|1-Delayed Cord Clamping (DCC)|Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
9920613|NCT00818220|Active Comparator|2-Immediate Cord Clamping (ICC)|Routine care which is immediate cord clamping
9920614|NCT00818233||Observation|Variability will be assessed between each examiner.
9920615|NCT00818285|No Intervention|1|Physicians in this arm will be using the standard electronic prescription interface.
9920616|NCT00818285|Experimental|2|In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
9920617|NCT00818298|Experimental|1|ziprasidone
9920618|NCT00818311|Other|5|
9920619|NCT00818350|Experimental|SUNITINIB|
9920620|NCT00818402||Non-small cell lung cancer patients|
9920621|NCT00818415|Experimental|Arm 1|
9920622|NCT00818415|Active Comparator|Arm 2|
9920623|NCT00818428|Active Comparator|1|Speech Production Intervention + Articulation Parent Group
9920624|NCT00818428|Experimental|2|Speech Production Intervention + Dialogic Reading Parent Group
9920625|NCT00818428|Experimental|3|Speech Perception Intervention + Articulation Parent Group
9920626|NCT00818428|Experimental|4|Speech Perception Intervention + Dialogical Reading Parent Group
9920627|NCT00818467|Experimental|Tanning spray|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
9920628|NCT00818467|Active Comparator|UVB|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
9920629|NCT00818506||Late onset MDD|Patients with major depressive disorder between 50 and 70 years of age that did not suffer from depression before the age of 50.
9920630|NCT00818506||Controls|Healthy controls (matched for age, sex, and tobacco use status)
9920631|NCT00818532||1|Measurement device
9920632|NCT00818545|Placebo Comparator|2|
9920633|NCT00818545|Experimental|hydroxypropyltetrahydropyrantriol|
9935003|NCT04286438|Experimental|Bentracimab (PB2452) Infusion - Open Label Active Drug|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. Patients with uncontrolled major or life-threatening bleeding.~Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. For patients in need of urgent surgery or invasive procedure."
9935793|NCT03206099||Healthy volunteers|Select internal controls
9920634|NCT00818558|Experimental|1|stade IA [pT1 N0M0]
9920635|NCT00818558|Experimental|2|stade IB [pT2 N0M0]
9920636|NCT00818558|Experimental|3|stade IIA [pTI N1M0]
9920637|NCT00818558|Experimental|4|stade IIB [pT2 N1 et T3N0M0]
9920638|NCT00818558|Experimental|5|control groupe [tabagic subject]
9920639|NCT00818558|Experimental|6|Control group B [intervention for a pulmonaire non tumoral pulmonary lesion]
9920640|NCT00818584|Experimental|1. micafungin lower dose|
9920641|NCT00818584|Experimental|2. micafungin higher dose|
9920642|NCT00818597|Experimental|EISS-treatment|In this arm patients receive additional treatment with the EISS-bioreactor
9920643|NCT00818610|Experimental|Monotherapy|
9920644|NCT00818610|Active Comparator|Bi-therapy|
9920645|NCT00818636|Experimental|Expressive Writing|In addition to attending group therapy as usual, participants write about their feelings about an issue of their choosing three times during a two week period for at least 20 minutes each time.
9920646|NCT00818636|Active Comparator|Treatment as Usual|Participants attend group therapy as usual only.
9920647|NCT00818675|Experimental|Ridaforolimus|
9920648|NCT00818675|Placebo Comparator|Placebo|
9920649|NCT00818688||1|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
9920650|NCT00818688||2|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
9920651|NCT00818701|Placebo Comparator|1: low dose BNP alone|low dose BNP with placebo
9920652|NCT00818701|Active Comparator|2: low dose BNP + PDEVI|low dose BNpo + PDEVI
9920653|NCT00818714|Experimental|1|Dose escalation study to define the maximum tolerated boost dose of stereotactic body radiation therapy (SBRT) to the residual primary tumor after definitive therapy with concurrent chemotherapy and external beam radiation.
9920654|NCT00818740|Experimental|ORM-12741 i.v.|
9920655|NCT00818740|Experimental|ORM-12741 oral solution|
9920656|NCT00818740|Experimental|ORM-12741 oral capsule with food|
9920657|NCT00818740|Experimental|ORM-12741 oral capsule without food|
9920658|NCT00818792|Active Comparator|Drug-eluting stent Xience V|
9920659|NCT00818792|Active Comparator|Bare-metal stent Vision|
9920660|NCT00818818|Experimental|Meglumine antimoniate|Treated with 5mg/kg/d of pentavalent antimony (meglumine antimoniate) intravenously for 20 consecutive days.
9920661|NCT00818857|Active Comparator|1|Early intervention.
9920662|NCT00818857|Active Comparator|2|Delayed intervention
9920663|NCT00818870|Active Comparator|Omeprazole 20 mg|
9920664|NCT00818870|Experimental|Vecam 20/300|
9920665|NCT00818870|Experimental|Vecam 40/300|
9920666|NCT00818909|Experimental|Systane|Systane ocular product
9920667|NCT00818935|Experimental|Low-Intermediate-Glycemic Index diets|
9920668|NCT00818935|Active Comparator|High GI diet|
9920669|NCT00818948|Placebo Comparator|Placebo|2 subjects of each cohort (cohort 1 to 6) will receive placebo
9920670|NCT00818948|Other|AMG811|Six subjects in each cohort (cohort 1 to 6) will receive AMG 811
9920671|NCT00818987|Other|Operative|Treatment arm - intervention = Open Reduction Internal Fixation or Reduction & Immobilization
9920672|NCT00818987|No Intervention|Non Operative|Placebo arm
9920673|NCT00819000||Treated MS Subjects|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
9920674|NCT00819065|Active Comparator|1-BTA Lanzhou/Allergan|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
9920675|NCT00819065|Active Comparator|2. BTA Allergan/Lanzhou|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.
9920676|NCT00819078|Active Comparator|Bupropion Sr|40 adolescent patients
9920677|NCT00819078|Placebo Comparator|Placebo (sugar pill)|40 adolescent patients will receive placebo
9920678|NCT00819104|Experimental|1|FDC of Metoprolol XL 50mg + Amlodipine 5mg
9920679|NCT00819104|Experimental|2|FDC of Metoprolol XL 25mg + Amlodipine 2.5mg
9920680|NCT00819104|Active Comparator|3|Extended release Metoprolol succinate
9920681|NCT00819104|Active Comparator|4|Extended release Metoprolol succinate
9920682|NCT00819104|Active Comparator|5|Amlodipine 5mg in immediate release formulation
9920683|NCT00819117|Active Comparator|Transvenous Lead (TVN CRT)|Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)
9920684|NCT00819117|Experimental|Epicardial Lead (EPI CRT)|Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)
9920685|NCT00819195||RRMS|Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care
9920686|NCT00819195||HC|Healthy control volunteers
9920687|NCT00819208|Active Comparator|Physical Activity Program + General Health Education Materials|Intervention Arm
9920688|NCT00819208|Active Comparator|General Health Education Materials|Control Arm
9920689|NCT00819273||1|patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
9920690|NCT00819299|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.
9920691|NCT00819312|Active Comparator|Arm 1|
9920692|NCT00819325|Experimental|Intensive glycemic control|Included routine use of pioglitazone (30 mg/d) for 6 months in addition to titration of their other oral hypoglycemic agents in order to get the HbA1c<6%.
9920693|NCT00819325|Active Comparator|conservative glycemic control|Included titration of oral hypoglycemic agents to get HbA1c<7% without the use of a thiazolidinedione.
9920694|NCT00819338|Active Comparator|polyunsaturated|5g per day of polyunsaturated fatty acids (3.5g EPA and DHA).
9920695|NCT00819338|Placebo Comparator|monounsaturated|5g a day of oleic enriched sunflower oil
9920696|NCT00819351|Experimental|PEG-asparaginase 6 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
9920697|NCT00819351|Active Comparator|PEG-Asparaginase 2 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
9920698|NCT00819364|Experimental|1|Participants with autism will receive BCRI intervention program.
9920699|NCT00819364|Active Comparator|2|Participants with autism will receive standard care available in the community.
9920700|NCT00819377|Placebo Comparator|Normal saline|Normal saline by inhalation over 15 min
9920701|NCT00819377|Active Comparator|Milrinone|Inhaled milrinone 5 mg(as for the injectable solution)
9920702|NCT00819416|Experimental|1|5% albumin
9920703|NCT00819416|Other|2|Normal saline
9920704|NCT00819429|Experimental|1|"Omega-3 + Standard treatment~Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure."
9920705|NCT00819429|Experimental|2|"Social skills + Omega-3 placebo + Standard treatment~Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. They will also undergo a manualised group social problem solving skills training protocol of 12 weekly 1-hour sessions (Ang & Ooi, 2003a, 2003b). There will be booster sessions scheduled at 3-week intervals after the initial treatment period of 12 weeks, for a total of 4 booster sessions."
9920706|NCT00819429|Experimental|3|"Omega-3 + Social skills + Standard treatment~Children in this group will receive omega-3 supplement and social skills training on top of standard treatment. Procedures for administration of Omega-3 supplement are similar to those stated in (1) and (2)."
9920707|NCT00819429|Placebo Comparator|4|"Omega-3 placebo + Standard treatment.~Children in this group will receive placebo as well as a course of the standard treatment. Procedure for administering the placebo capsules is similar to that outlined in (2)."
9920708|NCT00819442|Placebo Comparator|1|patients without heart failure, with cardiobiopsy
9920709|NCT00819442|Experimental|2|patients with heart failure in NYHA class I, II
9920710|NCT00819442|Experimental|3|Patients with heart failure in NYHA class III, IV
9920711|NCT00819455|Active Comparator|2|In person lifestyle advice at baseline, 6, 12, 18 months.
9920712|NCT00819455|Experimental|1|In person lifestyle advice at baseline, 6, 12, 18 months. Receive reminders by internet based, mobile phone text messaging (Frequency, time and number(s) of messages according to participants requirement)
9920713|NCT00819468|Experimental|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7-9) will receive 20 mg of teduglutide.
9920714|NCT00819468|Active Comparator|Healthy Volunteers|Healthy volunteers with normal hepatic function matched to hepatic impaired participants by age, gender, BMI, and renal function as measured by creatinine will receive 20 mg of teduglutide.
9920715|NCT00819481||3DKnee|Post Market Study
9920716|NCT00819494|Sham Comparator|Healthy controls|
9920717|NCT00819494|Active Comparator|Patients with immediate reactions|
9920718|NCT00819520|Experimental|Ivermectin|ivermectin Stromectol®)
9920719|NCT00819520|Active Comparator|Malathion|malathion(Prioderm®)
9920720|NCT00819533|Experimental|sensor|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
9920721|NCT00819559|Active Comparator|Open PCRT group|Patients who underwent preoperative chemoradiotherapy and open resection
9920722|NCT00819559|Experimental|Open no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and open resection
9920723|NCT00819559|Active Comparator|LAP PCRT group|Patients who underwent preoperative chemoradiotherapy and laparoscopic resection
9920724|NCT00819559|Experimental|LAP no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and laparoscopic resection
9920725|NCT00819572|Experimental|1|DLX105 low dose
9920726|NCT00819572|Experimental|2|DLX105 high dose
9920727|NCT00819572|Placebo Comparator|3|
9920728|NCT00819598||SUSPECTED ARTERIAL DISEASE|
9920729|NCT00819611|Experimental|Working memory training|
9920730|NCT00819611|Sham Comparator|Control version of working memory training|
9920731|NCT00819624|Other|Interactive Voice Response System|
9920732|NCT00819624|Other|Personal Digital Assisstant|
9996424|NCT01500018|Experimental|Crossover Treatment Sequence 9|"Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:~Phentermine 45 mg"
9996425|NCT01500018|Experimental|Crossover Treatment Sequence 10|Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg
9996426|NCT01500018|Experimental|Crossover Treatment Sequence 11|Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg
9996427|NCT01500018|Experimental|Crossover Treatment Sequence 12|Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg
9996428|NCT01500018|Experimental|Crossover Treatment Sequence 13|Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg
9996429|NCT01500018|Experimental|Crossover Treatment Sequence 14|Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg
9996430|NCT01500044|Active Comparator|Conventional Rehabilitation Program|The conventional program consists in cervicothoracic mobilizations and stabilization exercises. This program is based on the intervention used in clinical practice, and on programs proposed in two RCTs evaluating individuals with neck and arm pain that do not include any specific mobilization or exercise leading to the opening of the intervertebral foramen. Four mobilisation techniques will be executed at each treatment session. However, the therapists will not be allowed to use techniques that specifically open the intervertebral foramen of the affected segment, two segments above and two segments below.
9996431|NCT01500044|Experimental|Program targeting the opening of foramen|"The same interventions as for the conventional rehabilitation program will be applied, except:~Of the four mobilisation techniques, there will be two mandatory techniques targeting the opening of the intervertebral foramen on the same side and at the same level as the radiculopathy: global contralateral rotation mobilisation and ipsilateral lateral shearing in a flexion position. The therapist, according to the biomechanical evaluation results, will choose the two other mobilisation techniques."
9996432|NCT01500070|Experimental|Drug-eluting stent|Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
9996433|NCT01500148|Experimental|Intevention-PMVr Procedure|
9996434|NCT01500161|Experimental|Single Arm|The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.
9996435|NCT01500174|Experimental|active UVC device|Three times per week irradiation of wound base and periwound skin
9996436|NCT01500174|Placebo Comparator|Placebo UVC device|Three times per week irradiation of wound base and periwound skin
9996437|NCT01500265||Patient naive|Patient with hepatitis B virus naive untreated
9996438|NCT01500265||Patient with TDF|Patient with hepatits B treated with Tenofovir
9996439|NCT01500265||Patient with ETV|Patient with hepatitis B virus treated with Entecavir
9996440|NCT01500291||Anesthesiologist|
9996441|NCT01500291||Nurse anesthetist|
9996442|NCT01500304|Experimental|Minimally invasive surgery|Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
9799141|NCT01651208|Active Comparator|Mailed DVD|A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.
9996443|NCT01500330|Experimental|cupping massage|12 weeks home use of cupping massage (delivered by the partner or friend) twice a week for 20 minutes
9996444|NCT01500330|Active Comparator|control group|progressive muscle relaxation twice a week for 20 minutes
9996445|NCT01500343|Experimental|Saccharomyces boulardii|
9996446|NCT01500343|Placebo Comparator|Placebo|
9996447|NCT01500356|Experimental|Diet alone|Weight loss intervention that focuses only on reducing energy intake of the diet.
9996448|NCT01500356|Experimental|Diet plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
9996449|NCT01500356|Experimental|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
9996450|NCT01500369|Active Comparator|remote ischemic conditiong|"Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
9998122|NCT01515163|No Intervention|Control|Control group
9998123|NCT01515163|Experimental|Healthy control|
9920733|NCT00819650|Experimental|Licartin|patients who receive Licartin therapy after liver resection
9920734|NCT00819650|No Intervention|placebo|control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
9920735|NCT00819663||Crohns patients|Established Crohn's disease patients who underwent CTE imaging before and after initiating infliximab therapy
9920736|NCT00819676||subjects with asthma|
9920737|NCT00819676||healthy subjects|
9920738|NCT00819702|Experimental|Model Care|The Model Care approach was implemented in 7 practices, where PCPs were trained to address major risk factors for CM, including maternal depression, alcohol/substance abuse, intimate partner violence, food insecurity, harsh punishment and major stress. We taught how they can be briefly assessed and initially addressed. The initial training consisted of one 4-hour in-person session. Use of the Parent Screening Questionnaire (PSQ) was discussed, as was the importance of applying it universally during regular checkups. PCPs SEEK Parent Handouts on each targeted problem. We held 1-hour booster sessions every 6 months over the subsequent 2.5 years.
9920739|NCT00819702|No Intervention|Standard Care|PCPs in Standard Care group served as the controls. They continued to practice as usual.
9920740|NCT00819715||1|Small for gestational age preterm infants
9920741|NCT00819715||2|Appropriate for gestational preterm infants
9920742|NCT00819728|Experimental|Taxotere/Irinotecan|
9920743|NCT00819754|Experimental|IXO regimen + bevacizumab|This is phase I/II safety and efficacy study. There is only one arm of Irinotecan, Xeloda and Oxaliplatin (IXO) regimen with Avastin (bevacizumab)
9920744|NCT00819806|Experimental|A|PF-3512676, and three MHC class I Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102 will be administered in three separate subcutaneous (under the skin) injections.
9920745|NCT00819806|Experimental|B|This vaccine injection contains all the same components of Arm A and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm). Cyclophosphamide is an agent that is thought to increase the anti-tumor response of vaccines.
9920746|NCT00819806|Experimental|C|PF-3512676, Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102, NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-1 157-170 will be administered in three separate subcutaneous injections.
9920747|NCT00819806|Experimental|D|This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
9920748|NCT00819806|Experimental|E|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein will be administered in three separate subcutaneous injections.
9920749|NCT00819806|Experimental|F|This vaccine injection contains all the same components of Arm E and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
9920750|NCT00819819|Active Comparator|1 Gluten containing diet|Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
9920751|NCT00819819|Active Comparator|2 Gluten free diet|Non gluten containing food starch added to diet from 6-12 months
9920752|NCT00819845|Experimental|Ramipril|
9667452|NCT03565445|Experimental|ASP1948 Dose Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1948. Each dose level will enroll approximately 3 or 4 participants. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM). Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
9920753|NCT00819845|Experimental|Carvedilol|
9920754|NCT00819858|Experimental|RUTF|RUTF supplement (Plumpynut®) of 500 kcal/day for 2 weeks
9920755|NCT00819858|No Intervention|control|no supplement given
9920756|NCT00819871||PLI|patients with postoperative lung injury
9920757|NCT00819871||without PLI|patients without postoperative lung injury
9920758|NCT00819871||PLI/PKI|patients with at least one organ injury of lung or kidney after surgery
9920759|NCT00819871||without PLI/PKI|patients without lung or kidney injury after surgery
9920760|NCT00819884|Experimental|1|twice daily during 4 days
9920761|NCT00819884|Experimental|2|once daily during 4 days
9920762|NCT00819923|Experimental|1|Patients receiving bio-active stent during the intervention
9920763|NCT00819923|Active Comparator|2|Patients receiving everolimus-eluting stent during the intervention
9920764|NCT00819936|Experimental|2|Backward walking,
9920765|NCT00819936|Active Comparator|1|Forward walking
9920766|NCT00819949|Experimental|Arm 1|Potential eligible subjects for the trial will be individuals between ages 18-85, with a confirmed diagnosis of PD that experience freezing.
9920767|NCT00819962|Other|TAP|ksu
9920768|NCT00819975|Active Comparator|Casein|
9920769|NCT00819975|Active Comparator|Whey Isolate|
9920770|NCT00819975|Active Comparator|Whey Hydrolysate|
9920771|NCT00819975|Active Comparator|Alphalact-Albumin|
9920772|NCT00819988|Placebo Comparator|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
9920773|NCT00819988|Experimental|Pregabalin|Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance > 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
9920774|NCT00820001|Experimental|Acute Treatment Protocol Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
9920775|NCT00820001|Experimental|Acute Treatment Protocol No-Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
9920776|NCT00820001|Active Comparator|Treatment As Usual|Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
9920777|NCT00820001|Other|No Intervention Healthy Comparison|The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).
9920778|NCT00820014|Experimental|1|ESBA105 eye drops
9920779|NCT00820014|Placebo Comparator|2|Placebo control (vehicle)
9996451|NCT01500369|Placebo Comparator|Standard Care|Patients in the control group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the treatment group, patients in the control group will undergo the same 30 minute delay before induction of anesthesia and surgery
9996452|NCT01500395||Stent Graft and open surgery|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.
9996453|NCT01500408|Other|Commercial INFB followed by Investigational INFB|Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)
9996454|NCT01500408|Other|Investigational INFB followed by Commercial INFB|Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)
9996455|NCT01500421|Experimental|TH - Endovacular alone|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).
9996456|NCT01500421|Experimental|TH - Endovascular + nasopharyngeal induction|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).
9996457|NCT01500421|No Intervention|Standard Treatment|Patients are treated with standard care in the stroke ward.
9996458|NCT01500421|Experimental|TH - Surface Cooling|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)
9996459|NCT01500473|Experimental|Females with CCHS > 16 years old on desogetrel|
9996460|NCT01500486||PenMate device|
9996461|NCT01500512||Observation (observe patients undergoing SLN dissection)|Patients receive standard therapy including sentinel lymph node dissection. Patients are then observed to collect information about treatment and outcomes every 2 months for 2 years.
9996462|NCT01500538|Experimental|Eltrombopag and vorinostat combination therapy|Daily oral intake of 400mg vorinostat if necessary with combination therapy eltrombopag commencing at 50mg per day increasing to a maximum of 200mg per day
9996463|NCT01500564|Sham Comparator|Sham tDCS and motor training: sham comparator|"Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Intervention: placebo tDCS Other: Motor Training"
9996464|NCT01500564|Experimental|Anodal tDCS and motor training: experimental|"Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Interventions:~Device: anodal tDCS~Other: motor Training during physiotherapy"
9996465|NCT01500577|Experimental|Nimesulide|Nimesulide 100 mg (capsules), 100mg/die every day for 1 year. Oral administration
9996466|NCT01500577|Experimental|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
9996467|NCT01500577|Placebo Comparator|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
9996468|NCT01500590|Experimental|renin-angiotensin system blockers|Those eligible patients will be randomized into 2 groups. One group use renin-angiotensin systems (RAS) blockers to control their blood pressure, the other group will use other types of anti-hypertensive agents other than RAS blockers
9996469|NCT01500590|Active Comparator|non-renin angiotensin system blockers|"These includes norvasc adalat retard natrilix betaloc aldomet~amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg once daily to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg once daily to 500mg twice daily"
9996470|NCT01500603|Experimental|Experimental|Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
9996471|NCT01500603|Active Comparator|Active comparator|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
9799142|NCT01651260|Other|Endotracheal (ET) tube securement device|Single arm study evaluated an experimental ET tube securement device with a bite block.
9799143|NCT01651351|Experimental|Cohort 1|"Day 1:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min~Day 15:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min"
9998124|NCT01515202|Experimental|Panel 1: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
9799144|NCT01651351|Experimental|Cohort 2|"Day 1:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min~Day 15:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min"
9799145|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1|
9996472|NCT01500616|Experimental|open label telaprevir|Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.
9996473|NCT01500642|Active Comparator|sublingual immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
9996474|NCT01500642|Active Comparator|vestibular immunotherapy|15 patients treated with vestibular immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
9996475|NCT01500642|Active Comparator|sublingual doubled immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at doubled dose (400 STU / dose) from June to August 2001
9996476|NCT01500655|Experimental|Catheter|An ultrasound guided block of the LFCN is performed, followed by the placement of a catheter underneath the fascia iliaca.
9996477|NCT01500655|Experimental|Ultrasound guided LFCN block|An ultrasound guided regional nerve block --using ropivacaine 0.2%-- will be performed around the lateral femoral cutaneous nerve (LFCN).
9996478|NCT01500655|No Intervention|Control|This group gets the current standard of care--the donor site is infiltrated with 0.25% bupivacaine.
9996479|NCT01500668|Active Comparator|Treatment|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
9996480|NCT01500668|Placebo Comparator|Control|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
9996481|NCT01500707|Experimental|SCH 900800|Participants receiving a single dose of SCH 900800
9996482|NCT01500785|Active Comparator|levosimendan|
9996483|NCT01500785|Placebo Comparator|placebo|
9996484|NCT01500798|Placebo Comparator|Placebo|
9996485|NCT01500798|Experimental|Bardoxolone methyl|
9996486|NCT01500811|Experimental|chondrocyte|Patients with sever hip osteoarthritis who underwent intra articular cell injection.
9996487|NCT01500824|Experimental|Crizotinib|
9996488|NCT01500837|Active Comparator|RIFAMPIN|CLINDAMYCIN + RIFAMPIN
9996489|NCT01500837|Active Comparator|LEVOFLOXACIN|CLINDAMYCIN + LEVOFLOXACIN
9996490|NCT01500850|Active Comparator|NPH insulin + insulin glulisine|Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
9996491|NCT01500850|Active Comparator|NPH insulin + human insulin|Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
9996492|NCT01500850|Experimental|Insulin glargine + insulin glulisine|Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
9996493|NCT01500850|Experimental|Insulin Glargine + Human insulin|Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
9996494|NCT01500863|Active Comparator|hCG|
9799146|NCT01651442|Active Comparator|Sleep Medication 1|
9996495|NCT01500863|Experimental|Triptorelin 0.2mg s.c.|
9996496|NCT01500863|Experimental|0.2mg triptorelin plus estradiol/progesterone|
9996497|NCT01500863|Experimental|0.2mg tripoterlin plus single bolus hCG 1500 IU|
9996498|NCT01500863|Experimental|0.2mg tripoterlin plus multiple boluses hCG 500 IU|
9996499|NCT01500863|Experimental|0.2mg tripoterlin plus multiple doses recLH|
9996500|NCT01500876|Experimental|Study Arm|Single Arm
9996501|NCT01500889|Active Comparator|CLI sphincterotomy|Conventional Lateral internal sphincterotomy LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
9920780|NCT00820053|No Intervention|no adjuvant TACE|controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
9920781|NCT00820053|Experimental|adjuvant TACE|patients who adjuvant TACE after liver resection
9920782|NCT00820079|Experimental|ADX10059 120 mg|Twice-daily
9920783|NCT00820079|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
9920784|NCT00820092|Active Comparator|Xerecept 1.0|1.0 ug/kg/hr hCRF -24 hour IV infusion
9920785|NCT00820092|Active Comparator|Xerecept 2.0|2.0 ug/kg/hr-24 hour IV infusion
9920786|NCT00820092|Active Comparator|Xerecept 3.0|3.0 ug/kg/hr-24 hour infusion
9920787|NCT00820105|Experimental|ADX10059 25 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
9920788|NCT00820105|Experimental|ADX10059 50 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
9920789|NCT00820105|Experimental|ADX10059 100 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
9920790|NCT00820105|Placebo Comparator|ADX10059 Matching Placebo|Weeks 1-2: once daily Weeks 3-12: twice daily
9920791|NCT00820118|Experimental|Intermittent treatment|6 months on antiretroviral treatment and 6 months off treatment
9920792|NCT00820131|Experimental|1|
9920793|NCT00820131|Active Comparator|2|
9920794|NCT00820144|Experimental|1|voie nasale 0.25 mg
9920795|NCT00820144|Experimental|2|0.5mg of CTB by oral way
9920796|NCT00820144|Experimental|3|1mg of dukoral by oral way
9920797|NCT00820144|Experimental|4|0.25mg of CTB by sublingual way
9920798|NCT00820144|Experimental|5|1mg of CTB by sublingual way
9920799|NCT00820157|Active Comparator|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE
9920800|NCT00820157|Experimental|TACE|TACE alone
9920801|NCT00820183|Experimental|quality improvement plan|It will be the group of primary health care teams who will undertake the quality improvement plan for hypertensive patients
9920802|NCT00820183|No Intervention|non intervention|It will be the group of primary health care teams that will not undertake the quality improvement plan for hypertension control
9920803|NCT00820261||Diarrhea|children and infants (less than 5 years of age) presenting with severe diarrhea will be enrolled
9920804|NCT00820274|Experimental|amniotic membranes|
9920805|NCT00820313|Other|Lifestyle Intervention|Comprehensive lifestyle intervention for reversal of heart disease
9920806|NCT00820326|Active Comparator|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
9920807|NCT00820326|Placebo Comparator|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
9920808|NCT00820339|Active Comparator|Selective Hepatic Vascular Exclusion|Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
9920809|NCT00820339|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
9920810|NCT00820352|Active Comparator|bosentan|Patients in this arm receive bosentan twice a day for 12 weeks
9920811|NCT00820352|Placebo Comparator|placebo|patients in this arm receive 12 placebo twice a day for 12 weeks
9920812|NCT00820378||atherosclerosis|Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors
9920813|NCT00820391|Experimental|KIDNET|Narrative Exposure Therapy for Children
9920814|NCT00820391|Experimental|Meditation/Relaxation|
9920815|NCT00820404|Experimental|1|BLI-489
9920816|NCT00820404|Placebo Comparator|2|Placebo
9920817|NCT00820417|Experimental|a|Dose-escalation
9920818|NCT00820417|Experimental|B|Maximum tolerated dose (MTD)
9920819|NCT00820430||Control--Non-Osteoporotic Knee|Kellgren-Lawrence (KL) scale score of 0, Age: 18-35 years
9920820|NCT00820430||Minimal Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 1 or 2, Age: Older than 18; no upper limit
9920821|NCT00820430||Moderate Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 3, Age: Older than 18; no upper limit
9920822|NCT00820456||Colorectal Cancer, Hepatic Metastasis|Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
9920823|NCT00820456||Primary Tumor Undefined, Hepatic Metastasis|Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
9935004|NCT04285580|Experimental|Bimatoprost SR 10 μg|Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
9935005|NCT04285580|Other|LUMIGAN 0.01%|Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
9996502|NCT01500889|Active Comparator|GroupII: V-Y advancement flap|The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide. Figures 1, 2, 3 and 4 illustrate the procedure.
9996503|NCT01500889|Active Comparator|TLIS with VY anoplasty|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
9996504|NCT01500902|Other|vascular testing|We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
9996505|NCT01500915|Experimental|ranibizumab|
9996506|NCT01500941|Active Comparator|probiotics|
9996507|NCT01500941|Placebo Comparator|maltodextrin|
9996508|NCT01500954||squamous cell carcinoma|
9996509|NCT01500954||non-lesional skin|
9996510|NCT01500967|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
9996511|NCT01500967|Experimental|Manipulations|Shi-style manipulations is a cervical manipulation for cervical radiculopathy.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
9996512|NCT01500980|Experimental|Pilot Phase|Pilot phase will include 6 subjects and will investigate the timing of PQ dosing relative to parasite exposure.
9996513|NCT01500980|Experimental|Chloroquine, ITV, primaquine, malaria challenge|
9996514|NCT01500980|Active Comparator|Sporozoite negative vaccine|
9667499|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
9667500|NCT03507257||Cognitively Normal (CN) Controls|"Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living~Mini-Mental State Exam score between 26-30~CDR score = 0~flortaucipir (18F-AV-1451) PET scanning"
9667501|NCT03507257||Early Onset non-Alzheimer's Disease (EOnonAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
9667502|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
9996515|NCT01500980|Active Comparator|Primaquine placebo|
9996516|NCT01500980|No Intervention|malaria challenge|
9996517|NCT01500993|Active Comparator|5-Fluorouracil (5-FU)|Drug - 5FU based chemoradiotherapy and chemotherapy
9667503|NCT03497390|Active Comparator|EMERALD|Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 6 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
9667504|NCT03497390|Placebo Comparator|Usual care|Usual management without any workshop or program
9667505|NCT03496207|Placebo Comparator|Placebo|Placebo SC every 21 days plus SOC for 24 weeks
9667506|NCT03496207|Experimental|Sotatercept 0.3 mg/kg|Sotatercept, 0.3 mg/kg SC every 21 days plus SOC for 24 weeks
9667507|NCT03496207|Experimental|Sotatercept 0.7 mg/kg|Sotatercept, 0.7 mg/kg SC every 21 days plus SOC for 24 weeks
9667508|NCT03493646|Active Comparator|Azacitidine|6 cycles of azacitidine (28 day cycle)
9667509|NCT03493646|Experimental|CC 486|6 cycles CC 486 (28 day cycle)
9667510|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
9667511|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
9667512|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
9667513|NCT03493529||Obesity Clas III|BMI> 40 Kg/m2
9996518|NCT01500993|Experimental|Capecitabine|Drug - Capecitabine-based radiochemotherapy and chemotherapy
9996519|NCT01501006||Patient Roles|Physician communication styles will be evaluated with different patient roles.
9996520|NCT01501019|No Intervention|Sjogren and Myositis Control (no control for takayasu's)|
9667515|NCT03487627|Experimental|Electronic and Care Support Manager Contact|Participants receive electronic content and contact with a Care Support Manager
9920824|NCT00820469|Experimental|1|Patients treated by rituximab
9920825|NCT00820469|Experimental|2|Patients treated by rituximab and plasma exchange
9920826|NCT00820482|Active Comparator|Group A|Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
9920827|NCT00820482|Experimental|Group B|75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
9920828|NCT00820495|Experimental|Web + Phone|Highly interactive tailored Web-based smokeless tobacco cessation program plus phone counseling
9920829|NCT00820495|Experimental|Web Only|Highly interactive tailored Web-based smokeless tobacco cessation program
9920830|NCT00820495|Experimental|Phone Only|Phone counseling intervention for smokeless tobacco cessation
9920831|NCT00820495|Experimental|Control|Usual care (initial call plus self-help materials)
9920832|NCT00820508|Experimental|1|Oral, once daily administration of CHR-2845 to determine safety and tolerability
9920833|NCT00820521|Experimental|active|
9920834|NCT00820521|Placebo Comparator|placebo|
9920835|NCT00820547|Experimental|(FEC / Docetaxel) + Bevacizumab|Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year
9920836|NCT00820560|Experimental|INCB07839 100mg, immediate release (IR) capsules|
9920837|NCT00820560|Experimental|INCB07839 200 mg IR capsules|
9920838|NCT00820586|Experimental|Mononuclear bone marrow derived cells|Intramyocardial injection of total mononuclear bone marrow derived cells
9920839|NCT00820586|Experimental|Selected CD34+ bone marrow derived cells|Intramyocardial injection of selected CD34+ bone marrow derived cells
9920840|NCT00820625|Active Comparator|1|ablation: pulmonary vein isolation
9920841|NCT00820625|Active Comparator|2|ablation: pulmonary vein isolation with additional ablation of fragmented potentials
9920842|NCT00820638|Experimental|1|observational
9920843|NCT00820651|Placebo Comparator|Placebo|
9920844|NCT00820651|Experimental|Diamel|
9920845|NCT00820677|Experimental|DVD/Video|Parents of newborns in the experimental group attending their first baby visit will be shown a video about newborn care.
9920846|NCT00820690||Clinical stage III|Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)
9920847|NCT00820716|Experimental|CA|Exercise training with alternate load
9920848|NCT00820716|Active Comparator|CC|Exercise training with constant load
9920849|NCT00820729||1|Patients with interstitial pulmonary disease
9920850|NCT00820742||Phase IV Post Marketing Surveillance Study|Open-label, observational study
9920851|NCT00820768|Experimental|ABI-010|
9920852|NCT00820781|Active Comparator|Portacaval shunt|Undergo portacaval shunt surgery
9920853|NCT00820781|Active Comparator|Sclerotherapy|Undergo endoscopic sclerotherapy
9920854|NCT00820794|Experimental|Cohort 1a|Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
9920855|NCT00820794|Experimental|Cohort 1b|Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.
9920856|NCT00820807|Experimental|1|3g/day
9920857|NCT00820807|Experimental|2|6g/day
9920858|NCT00820807|Placebo Comparator|Placebo beverage|0g/day
9920859|NCT00820820|Active Comparator|Rouvax|
9920860|NCT00820820|Placebo Comparator|Placebo|Sub cutaneous injection of vehicle
9920861|NCT00820833|Placebo Comparator|1|Standard infant formula
9920862|NCT00820833|Experimental|2|Test formula
9920863|NCT00820833|No Intervention|3|Breastfeeding reference group
9920864|NCT00820859|Experimental|1|
9920865|NCT00820859|Active Comparator|2|
9920866|NCT00820885|Other|cohort A|20 mg dose 20 mg/ML concentration and placebo
9920867|NCT00820885|Other|Cohort AR|20 mg in 50 mg/ml concentration and placebo
9920868|NCT00820885|Other|Cohort C|25 mg in 50mg/ml concentration and placebo
9996521|NCT01501019|Experimental|Sjogren, Myositis and Takayasu's Trained|
9996522|NCT01501032|Experimental|Closed Loop Control- MD-Logic|The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
9996523|NCT01501045|Experimental|healthy subjects|healthy subjects
9996524|NCT01501045|Experimental|pain patients|Migraine and muscle headache patients
9996525|NCT01501058|Experimental|case group|
9996526|NCT01501058|Other|waitlist control group|For this group, same intervention with the Experimental group will be provided after waiting for 14 weeks.
9996527|NCT01501071|Experimental|esophageal calibration|Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation
9996528|NCT01501071|No Intervention|Control|Standard Laparoscopic Nissen fundoplication without esophageal calibration
9996529|NCT01501084|Active Comparator|Exenatide|Exenatide injection 10 mcg subcutaneous
9996530|NCT01501084|Placebo Comparator|Saline|.2cc SC injection of sterile normal saline
9996531|NCT01501097|No Intervention|Control group|
9996532|NCT01501097|Experimental|early HV-crrt|
9996533|NCT01501123|Experimental|Haloperidol|IM Haloperidol
9996534|NCT01501123|Active Comparator|IM Midazolam|
9996535|NCT01501136|Experimental|sequential trial,DDGP, radiotherapy|sequential DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment followed by radiotherapy
9996536|NCT01501136|Experimental|sequential trial,VIPD, radiotherapy|sequential VIPD（cisplatin，Etoposide,Ifosfamide,dexamethasone，Mesna） regiment followed by radiotherapy
9996537|NCT01501136|Experimental|sequential trial, radiotherapy,DDGP|sequential radiotherapy followed by DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
9667516|NCT03487627|Active Comparator|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
9996538|NCT01501136|Experimental|sequential trial,radiotherapy, VIPD|sequential radiotherapy followed by VIPD（cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna）regiment chemotherapy
9996539|NCT01501136|Experimental|Radiotherapy|Suitable type intensity-modulated radiation therapy (IMRT) 50GY
9996540|NCT01501149|Experimental|DDGP regiment|DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
9996541|NCT01501149|Experimental|SMILE Regiment|Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment
9996542|NCT01501175||patients with suspected SVT|patients with suspected SVT and inhabitants of the Saint Etienne region
9998125|NCT01515202|Experimental|Panel 2: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
9998126|NCT01515202|Experimental|Panel 3: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
9998127|NCT01515202|Experimental|Panel 4: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
9998128|NCT01515202|Experimental|Panel 5: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
9998129|NCT01515215|Active Comparator|High-frequency Left rTMS|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 42 Trains, 5 second duration, 25 second inter-train interval."
9998130|NCT01515215|Active Comparator|Bilateral rTMS|"Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval."
9998131|NCT01515215|Sham Comparator|Sham rTMS|Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
9998132|NCT01515228|Active Comparator|Xience Prime stent|everolimus eluting stent
9998133|NCT01515228|Experimental|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent
9998134|NCT01515254|No Intervention|No intervention- control group|Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken. The control group subjects will have the opportunity to receive the intervention at the end of the study
9998135|NCT01515254|Experimental|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
9998136|NCT01515280||Chronic cough|Patients taking part in supplementary study must be randomised to main study which includes a placebo arm and treatment arm
9998137|NCT01515293|Experimental|Single Incision Laparoscopic Appendectomy|
9998138|NCT01515293|Experimental|Conventional appendectomy|Conventional appendectomy
9998139|NCT01515358|Placebo Comparator|Placebo|Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
9998140|NCT01515358|Experimental|LY3000328|Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
9998245|NCT01516398||Term control infants|No interventions were performed. Group consisted of term infants enrolled in the study to serve as controls for the preterm infant group.
9996543|NCT01501188|Experimental|Kinesio taping|Specific type of muscle and joint taping
9996544|NCT01501188|Placebo Comparator|Kinesio taping placebo|Kinesio taping placebo
9996545|NCT01501201|Experimental|Gastric By-Pass|group treated with Gastric By-Pass
9996546|NCT01501201|Active Comparator|optimized medical management|group receiving an optimized medical management
9996547|NCT01501214|Active Comparator|Atosiban|
9996548|NCT01501214|Placebo Comparator|Placebo|Normal saline
9996549|NCT01501227|Active Comparator|Taper Guard Endotracheal Tube|Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
9996550|NCT01501227|Sham Comparator|conventional endotracheal tube|Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
9996551|NCT01501240||liver cirrhosis, liver transplantation|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1 month will be eligible population in the study
9996552|NCT01501253|Experimental|CKD-828 2.5/40mg|CKD-828 2.5/40mg
9996553|NCT01501253|Experimental|CKD-828 2.5/80mg|CKD-828 2.5/80mg
9996554|NCT01501253|Active Comparator|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg
9996555|NCT01501266||Faslodex|
9996556|NCT01501279|Experimental|pudendal nerve block|USG guided pudendal nerve block performed under general anesthesia
9996557|NCT01501279|No Intervention|no nerve block|Control group without nerve block
9996558|NCT01501292||Immature oocytes (GV, M-I)|
9996559|NCT01501292||Mature oocytes (M-II)|
9998141|NCT01515371|Experimental|IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
9998142|NCT01515371|Placebo Comparator|Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
9998143|NCT01515384|Experimental|Type 1 Diabetes|
9998144|NCT01515384|Experimental|Type 2 Diabetes|
9998145|NCT01515384|Experimental|Healthy Controls|
9998146|NCT01515397|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
9998147|NCT01515397|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
9998148|NCT01515436|Active Comparator|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
9998149|NCT01515436|Active Comparator|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
9998150|NCT01515501|Other|Endoscopic mucosal resection|At time of rectal section biopsy all subjects will under go the additional intervention of an endoscopic muscosal resection.
9799147|NCT01651442|Active Comparator|Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1|
9799148|NCT01651442|Active Comparator|Sleep Medication 2 Following Sleep Medication 1|
9998151|NCT01515553|Experimental|Formulation 4|
9998152|NCT01515553|Experimental|Final formulation 4|
9998153|NCT01515579|Experimental|Formulation 3|
9998154|NCT01515579|Experimental|Formulation 4|
9998155|NCT01515592|Experimental|15 mcg/kg|
9998156|NCT01515592|Experimental|20 mcg/kg|
9998157|NCT01515592|Experimental|25 mcg/kg|
9998158|NCT01515631||Study|Patients with alagille syndrome
9998159|NCT01515644|Experimental|Intervention group I|Intervention group I: Powder based Infant formula with Inulin I
9998160|NCT01515644|Experimental|Intervention group II|Intervention group II: Powder based Infant formula with Inulin II
9998161|NCT01515644|Placebo Comparator|Intervention group III|Intervention group III: Powder based Infant formula without Inulin
9998162|NCT01515670||Fast-track THA/TKA|Any patient receiving THA/TKA in the participating wards
9998163|NCT01515683|Experimental|An anaesthetic nurse|
9998164|NCT01515683|Active Comparator|Theatre nurse + An anaesthetic nurse|Support from theatre nurse and an anaesthetic nurse
9998165|NCT01515683|Experimental|A nurse from ward + an anaesthesic nurse|Support from a nurse from the ward and an anaesthetic nurse
9998166|NCT01515683|Experimental|Optional relative + an anaesthetic nurse|Support from an optional relative and an anaesthetic nurse
9998167|NCT01515709||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of COPD
9998168|NCT01515722|Experimental|Health education intervention (HEI)|
9998169|NCT01515722|No Intervention|No intervention|
9998170|NCT01515735||pseudoexfoliation|The study group composted of the patients with pseudoexfoliation syndrome
9998171|NCT01515761|Active Comparator|Postero-lateral|Left ventricular lateral wall lead position
9998172|NCT01515761|Active Comparator|Antero-lateral|Left ventricular lateral wall lead position
9998173|NCT01515774|Active Comparator|Group 1|Give QD dose first then BID dosing
9998174|NCT01515774|Active Comparator|Group 2|Give BID dosing and then QD dosing
9998175|NCT01515787|Experimental|Group 1|"Patients will receive FOLFOX chemotherapy once every two weeks for 6 cycles total over a period of 12 weeks. After completing FOLFOX chemotherapy, the patient will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor. If the tumor has not decreased in size by at least 20%, the patient will receive 5FUCMT (radiation with chemotherapy). If the tumor has decreased in size by 20%, then the patient will proceed directly to surgery.~If all borders of the tumor are normal post surgery, then the patient receives six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal then the patient receives chemoradiation therapy for 5.5 weeks after surgery. After chemoradiation, additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization."
9998246|NCT01516411|Active Comparator|Cognitive app|Cognitive app promotes behavior change via goal setting, feedback, and problem solving
9920869|NCT00820885|Other|Cohort D|15 mg in 50mg/ml concentration and placebo
9920870|NCT00820885|Other|Cohort E|10 mg in 50mg/ml concentration and placebo
9920871|NCT00820885|Other|Cohort F|30mg in 50mg/ml concentration and placebo
9920872|NCT00820885|Other|Cohort H|50mg in 50mg/ml concentration and placebo
9920873|NCT00820885|Other|cohort I|80mg in 50mg/ml concentration and placebo
9920874|NCT00820911|Active Comparator|cyclosporine (reduced exposure) / everolimus|
9920875|NCT00820911|Experimental|AEB071 300 mg b.i.d. / everolimus|
9920876|NCT00820911|Experimental|AEB071 200 mg b.i.d. / everolimus|
9920877|NCT00820963|Experimental|Arm I|Patients undergo standard radiotherapy 5 days a week for 6 weeks.
9920878|NCT00820963|Experimental|Arm II|Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
9920879|NCT00820963|Experimental|Arm III|Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9920880|NCT00820976|No Intervention|control|remission induction with cytosine arabinoside amd idarubicine
9920881|NCT00820976|Experimental|G-CSF|G-CSF was administered starting on Day 8 until neutrophil recovery
9920882|NCT00820989|Experimental|A|Time points after IV Endotoxin administration compared to baseline (immediately before Endotoxin administration).
9920883|NCT00821028|Experimental|Paclitaxel|Participants will receive Paclitaxel.
9920884|NCT00821054|Experimental|Period 1|Treatment A, B or C
9920885|NCT00821054|Experimental|Period 2|Treatment A, B or C
9920886|NCT00821054|Experimental|Period 3|Treatment A, B or C
9920887|NCT00821067|Active Comparator|1|A 6 gm/day (3 gm/bid) dose of D-ribose
9920888|NCT00821067|Placebo Comparator|2|A 6 gm/day (3 gm/bid) dose of dextrose.
9920889|NCT00821080|Experimental|Vandetanib and Sirolimus|Single arm study
9920890|NCT00821106|Experimental|Right transradial approach|Coronary diagnostic or interventional procedures performed through right radial approach
9920891|NCT00821106|Experimental|Left transradial approach|Diagnostic or interventional procedures performed through left radial approach
9920892|NCT00821132||ALS families|Patients with either inherited or sporadic ALS or PLS and selected family members
9920893|NCT00821145|Active Comparator|1|50 patients operated using a conventional open surgery to exclude an abdominal aortic aneurysm
9920894|NCT00821145|Experimental|2|50 patients operated using a total laparoscopic aortic aneurysm resection
9920895|NCT00821145|Active Comparator|3|25 patients using a laparoscopic approach for AAA resection with a stapled proximal anastomosis
9920896|NCT00821158|Placebo Comparator|1|Placebo tablet and iv
9920897|NCT00821158|Experimental|2|Placebo tablet and intervention iv
9920898|NCT00821158|Experimental|3|Intervention tablet and placebo iv
9920899|NCT00821197|Active Comparator|long-limb bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
9920900|NCT00821197|Active Comparator|Distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
9920901|NCT00821210|Sham Comparator|2|
9920902|NCT00821210|Active Comparator|1|
9920903|NCT00821223|Active Comparator|manual small incision cataract surgery|surgical intervention by small incision cataract surgery
9920904|NCT00821223|Other|phacoemulsification|surgical intervention by phacoemulsification
9920905|NCT00821262|Experimental|sevoflurane|The study group will receive Sevoflurane for a 4-6 hours period (from anesthesia induction to transfer to ICU).
9920906|NCT00821262|Active Comparator|propofol|The control group will receive propofol for the same 4-6 hours period.
9920907|NCT00821275|Active Comparator|pregnancy expectation|The patients who desire for future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
9920908|NCT00821275|Active Comparator|No pregnancy expectation|The patients who don't desire for reserving uterus and/ or future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
9920909|NCT00821288|Experimental|Survivorship Intervention|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention
9920910|NCT00821288|Active Comparator|Facing Forward|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention Facing Forward: Life after Cancer Treatment manual
9920911|NCT00821340|Experimental|rAAV2-hRPE65|
9920912|NCT00821353|Active Comparator|RFCA|
9920913|NCT00821353|Active Comparator|Drug|
9920914|NCT00821366|Active Comparator|1|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment only group
9920915|NCT00821366|Active Comparator|2|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment and ARV peer adherence support group
9920916|NCT00821366|Active Comparator|3|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment, ARV peer adherence support and nutritional support group
9920917|NCT00821366|No Intervention|4|Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment - comparison/control group
9920918|NCT00821392|Active Comparator|1 Febuxostat 40mg|
9920919|NCT00821392|Active Comparator|2 Febuxostat 80mg|
9920920|NCT00821392|Active Comparator|3 Febuxostat 120mg|
9920921|NCT00821392|Sham Comparator|4 Allopurinol 300mg|
9920922|NCT00821392|Placebo Comparator|5 Placebo|
9920923|NCT00821405||peritoneal dialysis|peritoneal dialysis patient lasting for more than 3 months
9920924|NCT00821418|Experimental|PulsHaler first|
9920925|NCT00821418|Placebo Comparator|Placebo first|
9920926|NCT00821444|Active Comparator|Geodon fed|Commercial Geodon (ziprasidone) capsules given with food
9920927|NCT00821444|Experimental|B16 Fasted|Experimental reduced food effect formulation given without food
9920928|NCT00821444|Experimental|B16 Fed|Experimental reduced food effect formulation given with food
9920929|NCT00821457|Active Comparator|Group 1|250ng Juvista vs placebo
9920930|NCT00821457|Active Comparator|Group 2|500 ng Juvista vs placebo
9920931|NCT00821470|Experimental|bone marrow graft group|core decompression + bone marrow implantation into the necrotic lesion
9920932|NCT00821470|Active Comparator|control|core decompression
9920933|NCT00821483|Placebo Comparator|1: placebo|
9920934|NCT00821483|Active Comparator|2 Frovatriptan|
9920935|NCT00821496|Experimental|Oral Contraceptive|
9920936|NCT00821535|Other|Active group|maraviroc dosing group
9920937|NCT00821548|Experimental|1|Electrostimulation of the muscles of the scapular belt and the femoris quadristocks
9920938|NCT00821574|Experimental|1|Fluvastatin: daily 80 mg, oral
9920939|NCT00821574|Experimental|2|Valsartan
9920940|NCT00821574|Experimental|3|Hydrochlorothiazide
9920941|NCT00821600|Experimental|001|risperidone IR and LAI formulation 1 mg risperidone IR single injection followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
9920942|NCT00821652|Other|Dose-esclation|Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.
9920943|NCT00821652|Experimental|2|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.
9920944|NCT00821665|Experimental|Sucrose|Sucrose
9920945|NCT00821665|Placebo Comparator|Water|Water
9920946|NCT00821691|Other|1|"Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps~5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)"
9920947|NCT00821691|Other|2|"Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps~5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)"
9920948|NCT00821717|Experimental|1:|
9920949|NCT00821717|Placebo Comparator|2|
9920950|NCT00821743|Other|1|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
9920951|NCT00821756|Experimental|1|Assertive intervention in OPAC-style: Outreach,problem solving,adherence,continuity
9920952|NCT00821756|No Intervention|2|Control arm: Treatment as usual
9920953|NCT00821834|Experimental|Clopidogrel|"Patients received:~clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose,~ticlopidine matching placebo twice daily."
9920954|NCT00821834|Active Comparator|Ticlopidine|"Patients received:~ticlopidine 100 mg twice daily,~clopidogrel matching placebo once daily."
9920955|NCT00821847||1:experimental|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30 ml/min (estimated with cockcroft and Gault formulae)
9920956|NCT00821860|Experimental|Arm I|Patients undergo video-assisted thoracoscopic cytoreductive pleurectomy either at the time of biopsy or after confirmation of biopsy results.
9920957|NCT00821860|Active Comparator|Arm II|Patients undergo talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy either at the time of biopsy or after confirmation of biopsy results.
9996560|NCT01501305|Placebo Comparator|Placebo|Mineral rehydration solution
9996561|NCT01501305|Active Comparator|Carob powder|Carob powder and probiotics
9996562|NCT01501318|Active Comparator|Personalized feedback plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.Treatment as usual with participants receiving a personalized feedback report about the risks associated with their current substance use behaviors and a brief (5-15 minute) motivational interviewing based education session provided by a trained health coach.
9996563|NCT01501318|Experimental|Personalized feedback report alone|Provision of the personalized feedback report alone.
9996564|NCT01501331||RRT diagnostic tool|Patients implanted with an Energen device or successor.
9996565|NCT01501357|Experimental|multilevel filaments toothbrush|Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments)
9996566|NCT01501357|Active Comparator|cross toothbrushing|Children will brush with cross toothbrushing.
9996567|NCT01501370|Experimental|ZLd|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive:~Cohort 1: ZLd association:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle.~Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
9996568|NCT01501370|Active Comparator|Ld|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~• Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
9996569|NCT01501396|Experimental|Arm A (megestrol alone)|Megestrol acetate 800 mg PO daily x 8 weeks
9996570|NCT01501396|Experimental|Arm B (megestrol plus mirtazapine)|"Megestrol acetate 800 mg PO daily x 8 weeks~Mirtazapine 15 mg PO at bedtime x 1 week followed by 30 mg PO at bedtime x 7 weeks"
9996571|NCT01501409|Experimental|Group I|
9996572|NCT01501409|Active Comparator|Group II|
9996573|NCT01501409|Active Comparator|Group III|
9996574|NCT01501422|Experimental|Estrogen|Use estrogen patch for 8 weeks
9996575|NCT01501422|Experimental|Placebo|Use placebo patch for 8 weeks
9996576|NCT01501435|Experimental|CJ-30039|Incrementally Modified Drugs of fenofibric acid
9996577|NCT01501435|Active Comparator|fenofibric acid|Greencross Lipidil Supra 160mg
9996578|NCT01501448|Active Comparator|OCP|
9996579|NCT01501448|Active Comparator|Oral estradiol valerate|
9996580|NCT01501474||CholangioFlex and Fluorescent in situ Hybridization(FISH)|
9996581|NCT01501487|Active Comparator|HER2 negative patients|"In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:~TAC chemotherapy~TC chemotherapy~Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy"
9996582|NCT01501487|Active Comparator|Her2 positive patients|The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
9996583|NCT01501500|Active Comparator|botulinum toxin type A. HV angle|intramuscular injection of BTA into target muscle
9996584|NCT01501500|Placebo Comparator|Normal saline, HV angle|intramuscular injection of normal saline into target muscle
9996585|NCT01501539|No Intervention|Standard postop gastrostomy tube care|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions and the gastrostomy tube will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. Standard postop gastrostomy tube care. Insertion site cleaned with soap and water. No dressing added.
9996586|NCT01501539|Experimental|Standard hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
9996587|NCT01501539|Experimental|Silver hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
9996588|NCT01501552|No Intervention|Treatment as usual|In the no-intervention treatment as usual group, a package, containing a summary card of the national guideline recommendation, will be delivered to each provider unit without demonstration. In Poland, the summary card will be adapted from the PHEPA guidelines (ref) for the purposes of this trial. The treatment as usual group will be requested to screen and offer person-to-person SBI at the PHCU.
9998247|NCT01516411|Active Comparator|Social app|Social app promotes behavior change via social relationships and feedback
9996589|NCT01501552|Experimental|Training & support (T&S)|The T&S only group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
9996590|NCT01501552|Experimental|Financial incentive|The financial incentive only group will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
9996591|NCT01501552|Experimental|E-SBI|The e-SBI (online screening and brief intervention)only group are expected to refer identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
9996592|NCT01501552|Experimental|T&S and financial incentive|The T&S and financial incentive group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. Also, they will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
9996593|NCT01501552|Experimental|T&S and e-SBI|The T&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
9996594|NCT01501552|Experimental|Financial incentive and e-SBI|The financial incentive and e-SBI (online screening and brief intervention) group will be paid for screening and referral performance instead of actual delivery of e-SBI by themselves as in line with the e-SBI only group, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
9996595|NCT01501552|Experimental|T&S, financial incentive and e-SBI|The T&S, financial incentive and e-SBI (online screening and brief intervention) group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Also, they are expected to offer screening at the PHCU and to refer screen positive patients to e-SBI programmes. Additionally, they will be paid for screening and referral performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
9996596|NCT01501565|No Intervention|Control|Standard analgesic therapy: iv Metamizol 2 g q8h
9996597|NCT01501565|Experimental|TAP|"Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.~Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles."
9996598|NCT01501578||telomerase mutation|Patients with interstitial lung disease and telomerase mutation
9996599|NCT01501578||control|Patients with idiopathic pulmonary fibrosis and without telomerase mutation
9996600|NCT01501591|Other|Hydroxyzine|This group will receive a first generation H-1 receptor antagonist, hydroxyzine (25 mg) twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
9996601|NCT01501591|Other|Placebo|This group will receive a placebo twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
9996602|NCT01501591|Other|Hydroxyzine/placebo|This group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design.
9998248|NCT01516411|Active Comparator|Affect app|Affect app promotes behavior change via game-like elements including the use of a bird avatar as a visual representation of one's activities and operant conditioning
9998249|NCT01516411|Active Comparator|Nutrition app|Nutrition app promotes behavior change bvia tracking of food consumption
9998250|NCT01516450|Active Comparator|GSK1550188 200mg for SC|Single SC dose of belimumab 200mg
9996603|NCT01501617|Experimental|HSC- Hair Stimulating Complex|Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
9996604|NCT01501617|Placebo Comparator|Dulbecco's Modified Eagle Medium, DMEM|Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.
9996605|NCT01501630||PET/CT and MRI|all patients will benefit from PET/CT and MRI
9996606|NCT01501643|Active Comparator|Spirometry|Spirometry
9996607|NCT01501643|Experimental|Non invasive positive pressure ventilation|Non invasive positive pressure ventilation
9996608|NCT01501669|No Intervention|Capecitabine alone arm|X arm
9996609|NCT01501669|Experimental|Irinotecan plus capecitabine arm|
9996610|NCT01501682||primary suture|operated with primary suture
9996611|NCT01501682||other mesh|operated with insertion of another mesh
9996612|NCT01501682||ventralex|operated with insertion of ventralex mesh
9996613|NCT01501695|Experimental|5LGr, granule and placebo tablet|"Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
9996614|NCT01501695|Active Comparator|tiapride tabletand mimic 5LGr granule|"Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.~Duration: 8 weeks."
9996615|NCT01501695|Placebo Comparator|placebo, granule and tablet|"This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
9996616|NCT01501708|Experimental|Caspofugin based combination therapy|"Caspofugin based combination therapy:~Patients will recieve caspofungin with voriconazole or amphotericin B"
9996617|NCT01501721|Experimental|Exercise|Home-based exercise program
9996618|NCT01501721|Experimental|Nutritional counseling|Nutrition counseling aiming to reduce suggar intake
9996619|NCT01501734|Experimental|all patients with symptomatic CHF|"Single arm prospective study~Study population will include all patients referred to our outpatient clinic for congestive heart failure for a two-year period, who will be screened for sleep apnea and found to have sleep disordering breathing (SDB).~200 patients will visit the outpatient clinic for congestive heart failure.~Approximately 30% will be eligible for this study."
9996620|NCT01501747|Active Comparator|overt drug|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving such medication.
9996621|NCT01501747|Placebo Comparator|Placebo (Covert drug)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
9996622|NCT01501760|Experimental|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at inclusion, 1 month, 2 month.
9996623|NCT01501760|Placebo Comparator|Placebo|Three subconjunctival injections of 0.5 ml of Nacl at inclusion, 1 month, 2 month.
9996624|NCT01501773|Experimental|Autologous bone marrow stem cell|
9996625|NCT01501773|No Intervention|Control|
9996626|NCT01501786|Sham Comparator|control|propofol and saline are administered
9996627|NCT01501786|Experimental|Ket10|ketamine is co-administered with propofol
9920958|NCT00821912|Experimental|Taxotere Xeloda|"Taxotere i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule.~Xeloda orally day 1-14 every 3 weeks."
9920959|NCT00821938|Active Comparator|CRT-ICD|
9920960|NCT00821938|Placebo Comparator|DDD-ICD|
9920961|NCT00821990|Active Comparator|Chemotherapy|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
9920962|NCT00821990|Active Comparator|Supportive care|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
9920963|NCT00822003|Active Comparator|1|Human GLP-1
9920964|NCT00822003|Placebo Comparator|2|Placebo tablet
9920965|NCT00822029|Experimental|1|FOSAMAX (oral bisphosphonate)
9920966|NCT00822029|Placebo Comparator|2|PLACEBO
9920967|NCT00822042||1|Patients with corticotherapy lasting more than 3 months
9920968|NCT00822055|Active Comparator|1|brimonidine/timolol Fixed-combination monotherapy
9920969|NCT00822055|Active Comparator|2|dorzolamide/timolol fixed-combination monotherapy
9920970|NCT00822055|Active Comparator|3|prostaglandin analogue + brimonidine/timolol fixed combination
9920971|NCT00822055|Active Comparator|4|prostaglandin analogue + dorzolamide/timolol fixed combination
9920972|NCT00822068|Experimental|anodal tDCS|
9920973|NCT00822068|Active Comparator|2|cathodal tDCS
9920974|NCT00822068|Placebo Comparator|3|sham stimulation
9920975|NCT00822081|Active Comparator|1|brimonidine/timolol. Fixed-combination monotherapy.
9920976|NCT00822081|Active Comparator|2|dorzolamide/timolol. Fixed-combination monotherapy.
9920977|NCT00822081|Active Comparator|3|prostaglandin analogue+ brimonidine/timolol fixed combination.
9920978|NCT00822081|Active Comparator|4|prostaglandin analogue+dorzolamide/timolol fixed combination.
9920979|NCT00822133|Active Comparator|lodocaine|lidocaine 5% cream will be put on the skin
9920980|NCT00822133|Experimental|ketamine|ketamine 5% will be put on the skin
9920981|NCT00822133|Placebo Comparator|placebo|non-active cream will be put on the skin
9920982|NCT00822146|Experimental|1|
9996628|NCT01501786|Experimental|Ket20|ketamine is co-administered with porpofol
9920983|NCT00822198|Experimental|plantar vibration|Subject will use Juvent plantar vibration device daily in the home or office for six months.
9920984|NCT00822211|Experimental|Vildagliptin Dose 1|
9920985|NCT00822211|Experimental|Vildagliptin Dose 2|
9920986|NCT00822211|Placebo Comparator|Placebo|
9920987|NCT00822224|Experimental|1|Use of MEOPA during the painful care
9920988|NCT00822250|Other|1|cutting hair, skin phenotype description
9920989|NCT00822263|Placebo Comparator|2|control
9920990|NCT00822263|Experimental|1|Active medicine
9920991|NCT00822276||ADEH+ participants colonized with MSSA|
10213379|NCT04155710|Experimental|Cohort 1a|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + low dose IL-2.
9920992|NCT00822276||ADEH+ participants colonized with MRSA|
9920993|NCT00822276||Uncolonized ADEH+ participants|
9920994|NCT00822276||ADEH- participants colonized with MSSA|
9920995|NCT00822276||ADEH- participants colonized with MRSA|
9920996|NCT00822276||Uncolonized ADEH- subjects|
9920997|NCT00822276||Non-atopic uncolonized S. aureus participants|
9935006|NCT04271735|Experimental|NR arm|Subjects will take two capsules of nicotinamide riboside by mouth (250mg NR) twice daily for a total of 4 weeks.
9935007|NCT04271735|Placebo Comparator|Placebo arm|Subjects will take two capsules of nicotinamide riboside by mouth (placebo) twice daily for a total of 4 weeks
9935008|NCT04271436|Experimental|PET/CT + PET/MR|-Eligible patients will have imaging assessments (as part of the study) performed at three time-points: pre-treatment, following cycle 1 of treatment, and following cycle 2 of treatment. Baseline FDG PET/CT will be a standard-of-care procedure. If possible, PET/CT imaging will be performed, followed immediately by PET/MR imaging during each imaging session. At minimum, PET/MR should be obtained at least once during each time-point (i.e. either during the FDG or FLT procedure). FDG imaging and FLT imaging should be performed at least 24 hours apart and no more than 7 days apart.
9935009|NCT04270422|Experimental|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial, twice a week, 12 sessions
9935010|NCT04270422|Active Comparator|Usual physiotherapy|Usual evidence based physiotherapy, twice a week, 12 sessions
9935011|NCT04270409|Experimental|Isatuximab, lenalidomide, and dexamethasone (ILd)|Isatuximab intravenous (IV) administration on Days 1, 8, 15, and 22 during Cycle 1 (28 days per cycle), and Days 1 and 15 during Cycles 2-12, and Day 1 during subsequent cycles; lenalidomide per os (PO) administration on Days 1 to 21; and dexamethasone IV administration only on Day 1 during Cycle 1 and PO on Days 8, 15 and 22 of Cycle 1 and Days 1, 8, 15, and 22 of subsequent cycles
9935012|NCT04270409|Active Comparator|Lenalidomide and dexamethasone (Ld)|Lenalidomide PO administration on Days 1 to 21 and dexamethasone PO administration on Days 1, 8, 15, and 22 of every 28-day cycle
9935013|NCT04269889|Experimental|Treatment arm|Diamond-Blackfan anemia patients
9935014|NCT04267861||1|Medical records of subjects enrolled on NCI protocols 15-C-0179 and 18-C-0056
10213380|NCT04155710|Experimental|Cohort 1b|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + high dose IL-2.
10213381|NCT04155710|Experimental|Cohort 2|CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
10213382|NCT04155710|Experimental|Cohort 3|CLL/SLL patients without del 17p who progressed or progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
9799149|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1 Following Sleep Medication 1|
9799150|NCT01651442|Active Comparator|Sleep Medication 1 Following Non-drug Sleep Therapy 1|
9799151|NCT01651780|Experimental|Bivalirudin|Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.
9799152|NCT01651780|Active Comparator|Unfractionated heparin (UFH)|The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.
9799153|NCT01651793|Active Comparator|Caffeinated cocoa|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
9799154|NCT01651793|Active Comparator|Cocoa|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
9799155|NCT01651793|Active Comparator|Caffeine|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
9799156|NCT01651793|Placebo Comparator|Placebo|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
9799157|NCT01651806|Active Comparator|Females receiving a uniform dose of TA|Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
9799158|NCT01651806|Active Comparator|Weighted dose of TA in female patients|Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
9799159|NCT01651806|Active Comparator|Tranexamic acid weighted dose male|Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
9799160|NCT01651806|Active Comparator|Uniform single dose TA male patient|Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
9799161|NCT01651806|No Intervention|Historical Cohort|"25 patients with no TA use in their surgical history.~A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651."
9996629|NCT01501799|Experimental|Adapalene 0.1% and benzoyl peroxide 2.5% topical gel|
9996630|NCT01501799|Active Comparator|EPIDUO™ (adapalene 0.1% and benzoyl peroxide 2.5%) Gel|
9996631|NCT01501799|Placebo Comparator|Vehicle Gel|
9996632|NCT01501812||Schizophrenia|Subjects who are suffering from Schizophrenia or Schizoaffective disorder acording to the DSM-IV-R criteria
9996633|NCT01501812||Control|Healthy subjects without any mental ilness in axis I or II.
9996634|NCT01501812||Bipolar|Subjects who are suffering from bipolar I or 2 disorder acording to the DSM-IV-R criteria
9996635|NCT01501812||MDD|Subjects who are suffering from Major Depressive disorder acording to the DSM-IV-R criteria
9996636|NCT01501812||Anxiety|Subjects who are suffering from Panic disorder or from Generalized Anxiety disorder acording to the DSM-IV-R criteria
9996637|NCT01501812||PTSD|Subjects who are suffering from Post Traumatic Stress Disorder acording to the DSM-IV-R criteria
9996638|NCT01501825|Active Comparator|single channel|Single Channel with a coil placed over the left PFC (10 Hz).
9996639|NCT01501825|Experimental|four channels|"Four channels:~10 Hz over the left PFC.~1 Hz over the right PFC.~10 Hz over the left parietal cortex.~1 Hz over the right parietal cortex."
9996640|NCT01501864|Experimental|School Support Group|School Support Intervention
9996641|NCT01501864|No Intervention|Control|No school support
9996642|NCT01501877|Experimental|Distress Tolerance|Acceptance and Commitment Therapy based Distress Tolerance (DT) smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
9996643|NCT01501877|Active Comparator|Standard Smoking Cessation|Standard smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
9996644|NCT01501890|Active Comparator|Progesterone|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
9996645|NCT01501890|Placebo Comparator|Placebo|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
9996646|NCT01501903|Active Comparator|Standard|Biopsy using standard technique of FNA
9996647|NCT01501903|Other|Fanning|Biopsy using fanning technique
9996648|NCT01501916|Experimental|vitamin d|
9996649|NCT01501916|Placebo Comparator|Placebo|
9996650|NCT01501942|Experimental|Active|The active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
9996651|NCT01501942|Placebo Comparator|Inactive product|The matching placebo is an oral solution of phosphate buffered saline
9996652|NCT01501968|Active Comparator|Colistin|Colistimethate sodium 2.5-5mg/kg iv
9996653|NCT01501968|Experimental|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv and ascorbic acid 2 grams iv every 12 hours
9996654|NCT01501994|Experimental|Walking workstation, counseling, accelerometry feedback|2 week baseline: accelerometer with no feedback 12 experimental: Use of the walking workstation, counseling on increasing activity levels, feedback from the accelerometer 12 week crossover: Feedback from accelerometer, no counseling or walking workstation
9996655|NCT01501994|Other|Control then crossover|2 week baseline: accelerometer with no feedback 12 week control period: accelerometer with no feedback 12 week crossover period: accelerometer with feedback, counseling on increasing activity, and use of a walking workstation
9998176|NCT01515787|Active Comparator|Group 2|Patients receive 5FUCMT including chemotherapy and radiation therapy for 5.5 weeks. Patients will be given either 5-fluorouracil or capecitabine and radiation therapy. After the chemoradiation therapy is completed, patients will proceed directly to surgery. Post-surgery, patients will receive FOLFOX chemotherapy once every two weeks for 8 cycles total over a period of 16 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization.
9998251|NCT01516450|Active Comparator|GSK1550188 200mg for IV|Single IV dose of belimumab 200 mg
9998252|NCT01516463|Active Comparator|Collagenase Santyl|
9998253|NCT01516463|Sham Comparator|Bacitracin|
9996656|NCT01502007|Experimental|Accelerometer feedback and lifestyle counseling|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling.
9996657|NCT01502007|Experimental|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The control group will continue to wear the fitbit for the next 24 weeks without any feedback or activity counseling. Following the 26th week of the study, the subjects in the control group will complete the same program given to the experimental group in weeks 2 through 26.
9996658|NCT01502020|Active Comparator|Zyclara™|
9996659|NCT01502020|Experimental|Generic Imiquimod Cream, 3.75%|
9996660|NCT01502020|Placebo Comparator|Vehicle Cream|
9996661|NCT01502046|Experimental|Sativex|
9996662|NCT01502046|Placebo Comparator|Placebo|
9996663|NCT01502059|Experimental|Pilates Group|This group keep their usual treatment and did a Pilates treatment twice a week (one hour each class) during 90 days.
9996664|NCT01502059|No Intervention|Control Groups|This group keep their usual treatment and can do the Pilates training after the end of the study.
9996665|NCT01502098|Active Comparator|Early passive motion|Pendulum exercises starting on the first postoperative day. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises were not permitted until four weeks after surgery.
9996666|NCT01502098|No Intervention|Immobilization|Immobilization with sling during a month. Pendulum exercises starting on the fourth postoperative week. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises.
9996667|NCT01502111||Airway management|Patients receiving advanced airway management in physician manned helicopter emergency medical services over a 12-month period.
9920998|NCT00822302|Placebo Comparator|1.Saline Infusion|Patients randomised to this arm will receive an infusion of saline
9920999|NCT00822302|Active Comparator|2.recHDL|Patients randomised to the active comparator arm of the study will receive 40mg/kg reconstituted High density lipoproteins (lot nos 05422-00006) over a period of 4 hours, 24 hours prior to carotid endarterectomy.
9921000|NCT00822315|Active Comparator|1|efavirenz
9921001|NCT00822315|Experimental|2|raltegravir 400 mg
9921002|NCT00822315|Experimental|3|raltegravir 800 mg
9921003|NCT00822367|Experimental|Nutritional suplements|
9921004|NCT00822380|Experimental|Anemic children|
9921005|NCT00822393|Active Comparator|1|Busulfan
9921006|NCT00822393|Experimental|2|Treosulfan
9921007|NCT00822406|Active Comparator|1|This arm received individualized homeopathic medicine during 6 months (initial phase), and completed three years (second phase)
9921008|NCT00822406|Placebo Comparator|2|This arm received placebo during 6 months. After this period, all patients received individualized homeopathic medicine for three years.
9921009|NCT00822419|Active Comparator|lidocaine|Lidocaine 5% cream 5 gr will be double blindly put on the skin preoperatively
9921010|NCT00822419|Experimental|ketamine|ketamine cream 5% 5gr will be put on the skin preoperatively
9921011|NCT00822419|Sham Comparator|placebo|non-drug similar cream will be put on the skin preoperatively
9921012|NCT00822432||1|
9921013|NCT00822458|Experimental|Arm I|"Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR."
9921014|NCT00822471|Other|Diabetes Self-Management Education|Education intervention with historic self-controls.
9921015|NCT00822484|Active Comparator|ILV-095|6 SC single dose injections
9921016|NCT00822484|Placebo Comparator|Placebo|Placebo
9921017|NCT00822497|Experimental|1|Music-Based Imagery
9921018|NCT00822497|Experimental|2|Music Alternate Engagement
9921019|NCT00822497|No Intervention|Control|Debridement under standard care with no music therapy interventions
9921020|NCT00822536|Active Comparator|1|Bi therapy : aspirin/ clopidogrel
9921021|NCT00822536|Active Comparator|2|Monotherapy: aspirin
9921022|NCT00822549||1|all the patients included in the study received intravenous morphine in PACU and in the wards
9921023|NCT00822562|Active Comparator|Procedure/Surgery|surgery
9921024|NCT00822562|Experimental|Procedure|PRFA or PMCT
9921025|NCT00822575|Active Comparator|A|
9921026|NCT00822575|Sham Comparator|B|
9921027|NCT00822601|Experimental|1|
9921028|NCT00822601|Placebo Comparator|2|
9921029|NCT00822614|Active Comparator|Active Comparator|Current BTP Medication
9921030|NCT00822614|Experimental|Fentanyl TAIFUN|Titration for dose confirmation followed by observation period
9921031|NCT00822627|Experimental|Vaccination group|Vaccination group
9921032|NCT00822627|Experimental|Education/referral|Education/referral
9921033|NCT00822640|Experimental|1|Columbus Knee Prosthesis with rotating Platform
9921034|NCT00822640|Active Comparator|2|Columbus Knee Prosthesis with fixed platform
9921035|NCT00822653|Experimental|Calf Muscle Pump Stimulation|Subjects serve as self-control. Six weeks of dialysis data without intervention will be compared to six weeks post intervention
9921036|NCT00822666|Active Comparator|1|patients homozygous for the 2C19*1 genetic variant
9921037|NCT00822666|Experimental|2|carriers of the 2C19*2 genetic variant (homozygous or heterozygous)
9921038|NCT00822705|Active Comparator|ORAL GLP-1, TABLET|
9921039|NCT00822705|Active Comparator|Oral PYY3-36|
9921040|NCT00822705|Active Comparator|Oral GLP-1 plus oral PYY3-36|
9921041|NCT00822705|Placebo Comparator|4|
9921042|NCT00822731|Experimental|Lymphoma|patients diagnosed as lymphoma
9921043|NCT00822744|Experimental|SSR411298 10 mg|SSR411298 10 mg, one capsule once daily for 8 weeks
9921044|NCT00822744|Experimental|SSR411298 50 mg|SSR411298 50 mg, one capsule once daily for 8 weeks
9921045|NCT00822744|Experimental|SSR411298 200 mg|SSR411298 200 mg, one capsule once daily for 8 weeks
9921046|NCT00822744|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg, one capsule once daily for 8 weeks
9921047|NCT00822744|Placebo Comparator|Placebo|Placebo (for SSR411298), one capsule once daily for 8 weeks
9921048|NCT00822783|Active Comparator|Omalizumab|
9921049|NCT00822783|Placebo Comparator|Placebo|
9921050|NCT00822796|Experimental|A|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
9921051|NCT00822796|Active Comparator|B|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management
9921052|NCT00822809|Experimental|A|"Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.~Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter."
9921053|NCT00822809|Other|B|Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.
9921054|NCT00822822||A|Health History Process
9921055|NCT00822835|Active Comparator|ILV-095|6 SC single dose injections
9921056|NCT00822835|Placebo Comparator|Placebo|Placebo
9921057|NCT00822848|Experimental|Sorafenib, Epirubicin, Ifosfamide|
9921058|NCT00822861|Experimental|Dose level No.1|TPI ASM8 1 mg BID
9921059|NCT00822861|Experimental|Dose level No.2|TPI ASM8 2 mg BID
9921060|NCT00822861|Experimental|Dose level No.3|TPI ASM8 4mg BID
9921061|NCT00822861|Experimental|Dose level No.4|TPI ASM8 8 mg Die
9921062|NCT00822874|Experimental|in-vitro maturation of oocytes|
9921063|NCT00822887|Experimental|Vandetanib|Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
9921064|NCT00822913|Experimental|Botulinum A toxin|Botulinum A toxin intravesical injection
9921065|NCT00822965||Patient Knowledge Assessments|Questionnaires + Phone Interview
9921066|NCT00822978|Active Comparator|ACHN-490 Injection|ACHN-490 Injection in escalating doses
9921067|NCT00822978|Placebo Comparator|2|Placebo is normal saline
9921068|NCT00822991|Active Comparator|Group of CE-US|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
9921069|NCT00822991|Active Comparator|Group of B-mode US|screening by conventional B-mode US every 3-5 months
9921070|NCT00823004|Active Comparator|1|A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
9921071|NCT00823004|Active Comparator|2|MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
9921072|NCT00823017|Experimental|1|Patient-preferred music
9921073|NCT00823017|Experimental|2|Relaxation Music
9921074|NCT00823017|Placebo Comparator|3|Standard of Care
9921075|NCT00823030|Placebo Comparator|Placebo|Placebo instillation: 20 ml of normal saline instilled intravesically
9921076|NCT00823030|Experimental|experimental arm|The experimental instillation will include 8 ml of 2% lidocaine, 3 ml of sodium bicarbonate, and 9 ml of normal saline.
9921077|NCT00823056|Placebo Comparator|1|
9921078|NCT00823056|Active Comparator|2|
9921079|NCT00823121|Active Comparator|frozen-embryo transfer|In this group all embryos are cryopreserved and two months later embryo transfer will perform.
9921080|NCT00823121|Active Comparator|fresh embryo transfer|In this arm fresh embryo transfers are performed on day 2 or 3.
9921081|NCT00823147|Experimental|Pain Catastrophizing Induction Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress.~Subsequent blood draws occur per protocol time points:~25 minutes following IV placement (BASELINE)~15 minutes post catastrophizing induction (stress experiment)~90 minutes (1.5 hours) post-induction~150 minutes (2.5 hours) post-induction~210 minutes (3.5 hours) post-induction~270 minutes (4.5 hours) post-induction"
9921082|NCT00823147|No Intervention|Control Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them.~Blood draws and saliva samples gathered per protocol time points:~25 minutes following IV placement (BASELINE- T1)~25 minutes following baseline T2~115 minutes (1 hour 55 min) post baseline T3~175 minutes (2 hours 55 min) post baseline T4~235 minutes (3 hours 55 min) post baseline T5~295 minutes (4 hours 55 min) post baseline T6"
9921083|NCT00823160|Active Comparator|1: Sternotomy|Patients who are randomized to a sternotomy after the finding of blood in the pericardial sac.
9921084|NCT00823160|Active Comparator|2: Subxyphoid window|Patients who receive a subxyphoid window after the finding of blood in the pericardial sac.
9921085|NCT00823173|Experimental|Topical ESBA105|ESBA105 applied as eye drops
9921086|NCT00823186|Experimental|Phyxol,cancer,intra vascular flow|weekly cisplatin plus paclitaxel for 3 cycles as neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer followed by radical hysterectomy and pelvic lymphedectomy
9921087|NCT00823225|Other|A: Standard therapy|
9921088|NCT00823225|Experimental|B: Urokinase|
9921089|NCT00823238|Active Comparator|systemic|
9921090|NCT00823238|Active Comparator|inhaled|
9921091|NCT00823251|Experimental|IlluminOss device|IlluminOss bone-pin device
9921092|NCT00823277||1|Overweight and obese Children (BMI SDS > 90th percentile according to Danish BMI sheets) 5-20 Years of age. Recruited from the Paediatric department, University Hospital Holbaek, Region Zealand, Denmark, University of Copenhagen
9921093|NCT00823316|Experimental|1|at a dose of 1x1,000,000 hMSC/kg
9921094|NCT00823316|Experimental|2|at a dose of 5x1,000,000 hMSC/kg
9921095|NCT00823342|Placebo Comparator|Group A|CLEVUDINE 30 mg qd + TENOFOVIR Placebo
9921096|NCT00823342|Active Comparator|Group B|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
9921097|NCT00823342|Placebo Comparator|Group C|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
9921098|NCT00823355|Experimental|BCX1777|
9921099|NCT00823368||Arbaclofen followed by Placebo|
9921100|NCT00823368||Placebo followed by Arbaclofen|
9921101|NCT00823381|Experimental|Resveratrol|
9921102|NCT00823381|Placebo Comparator|Placebo|
9921103|NCT00823381|Active Comparator|Calorie Restriction|
9921104|NCT00823394||Windsor Village United Methodist Church|Questionnaire + Body Measurements + Self-help Materials
9921105|NCT00823407|Other|MDA|
9799162|NCT01651936|Experimental|Base Study: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
9921106|NCT00823420|Experimental|in-vitro maturation of oocytes|
9921107|NCT00823433|Experimental|Oral Penicillin|2 grams of oral penicillin V given within 4 hours of delivery
9921108|NCT00823446|Experimental|Revera Wound Care|
9921109|NCT00823446|Placebo Comparator|Normal Saline|
9921110|NCT00823485|Active Comparator|2|drainage of hemorraghia
9921111|NCT00823485|Experimental|1|Actylise
9921112|NCT00823498||African American Parents|
9921113|NCT00823498||African American Youth|African American Youth between ages of 12-15 Years Old
9921114|NCT00823511||Female Partners|Female partners of HIM Study participants
9921115|NCT00823524|Experimental|donor NK cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
9921116|NCT00823550|Experimental|A|entecavir 0.5 mg QD
9921117|NCT00823550|Active Comparator|B|lamivudine 100 mg QD
9921118|NCT00823576|Active Comparator|1|"Group witness: one receiving a single bolus of analgesic~Seepage simple person the end of intervention of 200mg of ropivacaïne 0,5 % at the level of zones it"
9921119|NCT00823576|Active Comparator|2|Group catheter: receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
9921120|NCT00823589|Experimental|pathological group|pathological group
9921121|NCT00823589|Experimental|healthy aged|healthy aged
9921122|NCT00823602|Experimental|1|"GnRH antagonist ganirelix 0.25 mg fromm 6th ovarian stimulation"
9921123|NCT00823602|Active Comparator|2|GnRH agonist, suprefact, stimulation with a standard long protocol
9921124|NCT00823628|Active Comparator|iopromide|
9921125|NCT00823628|Experimental|iodixanol|
9921126|NCT00823641|Experimental|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
9921127|NCT00823667|Active Comparator|Phase 1 Usual care|
9921128|NCT00823667|Active Comparator|Phase 2 Intervention|
9921129|NCT00823693|Active Comparator|Bimosiamose Cream|
9921130|NCT00823693|Placebo Comparator|Placebo Cream|
9921131|NCT00823732|Active Comparator|Phase 2 Intervention|GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
9921132|NCT00823732|No Intervention|Phase I Usual Care|GROUP I (usual care): Patients receive standard care.
9921133|NCT00823745|Experimental|1|[14C]-PF-00868554
9921134|NCT00823758||1|Parents of children under 8 years of age who have ever given their children an over- the-counter medication.
9921135|NCT00823758||2|Adolescents who are 13 to 20 years of age who have ever heard of over-the-counter medication.
9921136|NCT00823758||3|Adults (21 years of age or older) who have used over-the-counter medication in the past 2 years.
9921137|NCT00823758||4|Primary care physicians will be Family Practitioners or General Internist, with an active Texas license, who devote at least 50% of their time to clinical practice.
9921138|NCT00823758||5|Pharmacists holding a PharmD degree and licensure in the state of Texas and work at least half-time in a community pharmacy setting.
9921139|NCT00823771||Reviewed by radiation oncologist|
9921140|NCT00823771||Reviewed by general practitioner|
9921141|NCT00823784|Experimental|1THD group|Series of 135 patients with 3rd degree Hemorrhoids treated by THD device under spinal anaesthesia
9921142|NCT00823784|Active Comparator|2 stapler group|135 patients with 3rd degree hemorrhoids will be treated by staple hemorrhoidopexy
9921143|NCT00823810|Experimental|Colorectal cancer|
9921144|NCT00823849|Experimental|1|
9921145|NCT00823849|Experimental|2|
9921146|NCT00823849|Experimental|3|
9921147|NCT00823849|No Intervention|4|Control Group
9921148|NCT00823862|Experimental|Active (SD-101)|SD-101 in cohorts of escalating doses
9921149|NCT00823875|Experimental|1|
9921150|NCT00823875|Experimental|2|
9921151|NCT00823875|Experimental|3|
9921152|NCT00823875|Other|4|Control Group
9921153|NCT00823927||1|Alveolar macrophage proteomes from HIV-seropositive smokers with emphysema
9921154|NCT00823927||2|Alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.
9921155|NCT00823940|Placebo Comparator|Cohort A1|Dose escalation: 5 - 100mg and placebo in 4 planned doses
9921156|NCT00823940|Placebo Comparator|Cohort A2|Dose escalation: 100-600mg and placebo in 4 planned doses
9921157|NCT00823940|Other|Cohort B1|Glucagon challenge test
9921158|NCT00823940|Active Comparator|Cohort B3|Glucagon challenge test + selected dose of GSK1362885
9921159|NCT00823953|Placebo Comparator|Placebo|placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
9921160|NCT00823953|Active Comparator|Momordica charantia|"Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.~The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3."
9921161|NCT00824057|Experimental|1|
9921162|NCT00824083||1|sarcoma survivors
9921163|NCT00824083||2|healthy subjects
9996668|NCT01502124|Active Comparator|Lyophilized|
9667517|NCT03486704|Experimental|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
9921164|NCT00824109|Other|Single Arm Study|Consecutive patients meeting the selection criteria
9921165|NCT00824122||1|Children greater than 6 months receiving at least one dose of Vancomycin and Red Man Syndrome
9921166|NCT00824122||2|Children greater than 6 months receiving at least one dose of Vancomycin and has not had Red Man Syndrome
9921167|NCT00824135|Experimental|1|
9921168|NCT00824148|Experimental|Real-time glucose monitoring|Use of Guardian REAL-Time Continuous Glucose Monitoring System, (Medtronic Minimed, Northridge, CA) for 1 month, followed by observation for 2 months.
9921169|NCT00824148|Active Comparator|Self-monitoring of plasma glucose|Conventional self-monitoring of plasma glucose by finger-prick sampling for 1 month, followed by 1 month observation.
9921170|NCT00824174||Questionnaire|1 questionnaire, about 15-20 minutes.
9921171|NCT00824187|Experimental|Arm 1|
9921172|NCT00824187|Placebo Comparator|Arm 2|
9921173|NCT00824200|Experimental|Behavioral and Exercise Therapy (M-BET)|Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
9921174|NCT00824200|Active Comparator|Drug Therapy w/ Behavioral Placebo|alpha-adrenergic antagonist medication with a placebo behavioral intervention
9921175|NCT00824200|Active Comparator|Combination Therapy|Combination therapy: MBET and alpha-adrenergic antagonist medication
9921176|NCT00824239|Active Comparator|1. Intermittent sedation|
9921177|NCT00824239|Active Comparator|2. Daily interruption of sedation|
9921178|NCT00824304||Fe, Zn, Fe+Zn, Placebo|placebo comparator
9921179|NCT00824317|Placebo Comparator|1|Placebo
9921180|NCT00824317|Experimental|2|methylphenidate
9921181|NCT00824330|Other|Control Phase; Exercise Phase|"Participants act as their own control.~Control Phase:~Participants will not change their activity during the 3 month control phase (defined as no strength training and less than 30 minutes brisk walking/moderate exercise per week, no vigorous exercise) Baseline measures will be obtained.~Exercise Phase:~This phase will consist of a Titration phase followed by an Intervention Phase. During the Titration phase, under the guidance of a trainer, subjects will increase their number of steps by 20% per week until they have reached 10,000 steps or 3 months have passed. During the Intervention Phase subjects will continue to walk 10,000 steps (or the number of steps they reached in the Titration phase)."
9921182|NCT00824343|Experimental|Single P276-00 arm|This is a single experimental arm study
9921183|NCT00824356|Active Comparator|GSK1004726 (1000mg)|1000mg aqueous suspension
9921184|NCT00824356|Placebo Comparator|Placebo|Intranasal spray
9921185|NCT00824356|Active Comparator|GSK1004723 (200mg)|200 mg aqueous suspension
9921186|NCT00824395||1|Individuals with diabetes
9921187|NCT00824395||2|Individuals without diabetes
9921188|NCT00824447|Placebo Comparator|Placebo control|Placebo control
9921189|NCT00824447|Active Comparator|Grass pollen extract, twice weekly|Grass pollen extract, 9,500 BU, given twice weekly
9921190|NCT00824447|Active Comparator|Grass pollen extract daily|Grass pollen extract, 9,500 BU, given daily
9921191|NCT00824447|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen extract, 19,000 BU, given daily
9921192|NCT00824486|Active Comparator|TIPP|Injury prevention education using TIPP materials
9921193|NCT00824486|Experimental|Safe Home Model|Injury prevention education using safe home model
9921194|NCT00824499|Experimental|DPA|Regional complex intervention based on the Chronic Care Model
9921195|NCT00824499|No Intervention|VR|
9921196|NCT00824551|Experimental|Hyperbaric Oxygen Therapy|2 HBOT treatments
9921197|NCT00824551|Active Comparator|2|Standard care and treatment
9921198|NCT00824577||250~300 patients|heart rate variability, heart function and Kt/V
9921199|NCT00824590|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
9921200|NCT00824590|Experimental|normal renal function|Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function
9921201|NCT00824603||primary care provider|attending insulin CME Training
9921202|NCT00824629|Experimental|1|Afterloading embryo transfer procedure
9921203|NCT00824629|Active Comparator|2|Direct embryo transfer procedure
9921204|NCT00824642|Experimental|Group 1|Applied Acu-TENS prior to exercise
9921205|NCT00824642|Experimental|Group 2|Applied Acu-TENS prior to and during exercise
9921206|NCT00824642|Placebo Comparator|Group 3|Applied placebo TENS prior to exercise
9921207|NCT00824681|Experimental|1|Sound Of Family Together (S.O.F.T.) Music Program
9921208|NCT00824681|Active Comparator|2|Non-Therapy Related Activities (NTRA)
9921209|NCT00824694|Active Comparator|Intervention|The intervention will consist of targeted SMBG, provider training and patient education-all of which are focused on normalizing the most significant glucose abnormalities at any given time. SMBG will alternate between 2 strategies: glucose profiling and target monitoring. Intervention PCP's will use 380 View to identify a patient's most significant glucose elevations(s) and devise a treatment plan that includes drug type, dose increases, monitoring times, goal for the target, and stop criteria.
9935794|NCT03206099||Probands|Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
9935795|NCT03206086|Experimental|Group|Eltrombopag
9921210|NCT00824694|Active Comparator|Control Arms|Subjects will repeat the dose titration cycle under the guidance of a case manager until the target is reached, maximal recommended doses of medications are used, or a stop criterion is met. They will then resume glucose profiling to identify the next target. This process is repeated until all targets reach their optimal value. Control patients will monitor and be treated in the customary manner.
9921211|NCT00824707|Experimental|anti-virus therapy|100 HCC patients will be allocated to receive anti-virus therapy.
9921212|NCT00824707|Active Comparator|conventional therapy|100 patients will undergo conventional therapy
9921213|NCT00824759|Placebo Comparator|placebo|
9921214|NCT00824759|Active Comparator|oxygen|
9921215|NCT00824785|Active Comparator|Arm A EOX|EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
9921216|NCT00824785|Active Comparator|Arm B EOX + panitumumab.|EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
9921217|NCT00824798||haemophiliacs A and B|haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.
9921218|NCT00824811|Experimental|Group 1: Cyclosporine eye drops|Cyclosporine Eye Drops (Restasis) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
9921219|NCT00824811|Experimental|Group 2: Lubricant Eye Drops|Lubricant Eye Drops (Refresh Endura) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
9921220|NCT00824837|Experimental|A|New larger pore membrane
9921221|NCT00824837|Active Comparator|B|Standard haemodialysis membrane
9921222|NCT00824863|Experimental|one arm|All 10 patients receive ketoconazole 2% foam in the uncontrolled study.
9921223|NCT00824889|Other|1|Healthy volunteer
9921224|NCT00824889|Other|2|atopic dermatitis patient
9921225|NCT00824889|Other|3|contact dermatitis patient
9921226|NCT00824889|Other|4|psoriasis patient
9921227|NCT00824889|Other|5|lichen planus patient
9921228|NCT00824889|Other|6|GVH patient
9921229|NCT00824889|Other|7|melanoma patient
9921230|NCT00824902|Experimental|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
9921231|NCT00824928||Observational|Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
9921232|NCT00824967|No Intervention|1- The reference group|one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that...
9921233|NCT00824967|Other|2- The intervention group|Training and valuation of the treating personnel
9921234|NCT00824980|Experimental|IP10.C8 Gel|
9921235|NCT00824980|Placebo Comparator|Placebo Gel|
9921236|NCT00825006|No Intervention|Control|Dual site pacing (LV tip electrode and RV tip electrode)
9921237|NCT00825006|Experimental|Triple site pacing|Triple site pacing(LV tip electrode,RV tip electrode and RV ring electrode)
9921238|NCT00825019|Experimental|1|
9921239|NCT00825019|Placebo Comparator|2|
9921240|NCT00825019|Active Comparator|3|paroxetine
9921241|NCT00825032|Active Comparator|1: comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
9921242|NCT00825032|Experimental|2: UEET + PR|Experimental program consisting in additional 15 daily sessions of unsupported UEET over and above the same PR program used for control patients.
9921243|NCT00825045|Experimental|Treatment with risperidone|Gradual titration of risperidone according to clinical response
9921244|NCT00825058|Experimental|1|
9921245|NCT00825058|Placebo Comparator|2|
9921246|NCT00825058|Active Comparator|3|
9921247|NCT00825071|Active Comparator|Group D|Dexamethasone group : This group received 8 mg dexamethasone
9921248|NCT00825071|Active Comparator|Group O|Ondansetron Group: received 4 mg ondansetron
9921249|NCT00825071|Placebo Comparator|Group P|(Group P) received normal saline (Placebo)
9921250|NCT00825084|Experimental|single dose cohort-Japanese group|Japanese healthy subjects
9921251|NCT00825084|Experimental|single dose cohort-Western group|Western healthy subjects
9921252|NCT00825084|Experimental|multiple dose cohort-Japanese group|Japanese healthy subjects
9921253|NCT00825084|Experimental|multiple dose cohort-Western group|Western healthy subjects
9921254|NCT00825097|Experimental|Neurotomy Group|8 patients undergoing a selective tibial neurotomy under general anesthesia
9921255|NCT00825097|Active Comparator|BTX Group|8 patients undergoing a botulinum toxin injection in the calf muscles under EMG-control
9921256|NCT00825110||No treatment|confirmed diagnosis of colorectal carcinoma
9921257|NCT00825123|Experimental|Ivabradine|
9921258|NCT00825123|Active Comparator|Metoprolol|
9921259|NCT00825123|Placebo Comparator|Placebo|
9921260|NCT00825136|Active Comparator|relaxation|The patients of this arm practice on-line muscle relaxation for 8 weeks.
9921261|NCT00825136|Experimental|relaxation & biofeedback|The patients of this arm practice on-line muscle relaxation plus finger temperature biofeedback for 8 weeks.
9921262|NCT00825149|Experimental|A: R/R FL: Obinutuzumab Low Dose + CHOP|Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m^2), vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
9921263|NCT00825149|Experimental|B: R/R FL: Obinutuzumab High Dose + CHOP|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
9921264|NCT00825149|Experimental|C: R/R FL: Obinutuzumab Low Dose + FC|Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
9921265|NCT00825149|Experimental|D: R/R FL: Obinutuzumab High Dose + FC|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 4 weeks on Days 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
9921266|NCT00825149|Experimental|E: First-Line FL: Obinutuzumab + Bendamustine|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
10213383|NCT04151940||Observational (PET/CT scan)|Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.
10213384|NCT04139564|Experimental|EaseVRx group|Each subject will be asked to complete a 56-day program using the EaseVRx virtual reality headset with assigned modules each week. Each week, subjects will be asked to complete 7 modules (one per day), each approximately 5 minutes in duration, for a total of 56 modules across the program.
10213385|NCT04139564|Active Comparator|Active control group VR Sham|Each subject will be asked to complete a program accessible via VR that includes 2d visual wildlife scenes similar to some EaseVRx content
10213386|NCT04134208|Experimental|Diagnostic (fluciclovine F18, PET-CT)|Within 4 weeks before starting SST, patients receive fluciclovine F18 IV then undergo a PET-CT scan over 30 minutes. Within 22-28 weeks after starting SST, patients receive fluciclovine F18 IV and undergo a second PET-CT scan over 30 minutes.
10213387|NCT04132960|Experimental|HER2 status|"Three cohorts of advanced breast cancer patients:~Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)~Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)~Cohort 3: HER2 non-expressing (IHC0+)"
10213388|NCT04126096|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive beta lactam containing antibiotics during surgery (other than penicillin) in order to determine Negative Predictive Values and Non-Irritant Concentrations.
10213389|NCT04118894||Foot and Ankle Devices|The study subjects included are those treated with one or more approved or cleared Wright Medical products included in this study.
10213390|NCT04118569|Experimental|Narrative Intervention Group|Patients in the narrative intervention group will participate in an interview and the resulting narrative will be uploaded to the electronic medical record. This group will also complete outcome measures (questionnaires) and exit interview.
10213391|NCT04118569|No Intervention|Usual Care Group|Patients in the usual care group will complete outcome measures (questionnaires) and exit interview only.
10213392|NCT04116710|Experimental|Phase 1: HS-130 + HS-110 (viagenpumatucel-L)|Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
10213393|NCT04113187|Experimental|Propranolol arm|
10213394|NCT04113187|Placebo Comparator|Placebo arm|
9996669|NCT01502124|Experimental|Liquid|
9996670|NCT01502137|Experimental|ESRD patients|
9996671|NCT01502137|Experimental|Healthy subjects|
9996672|NCT01502150||Pediatric Proton Therapy Patients|Data collection of MDACC patients under the age of 18 treated with proton radiotherapy. Proton dosimetry data collection, corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.
9996673|NCT01502163|No Intervention|Control|"No prewarming~Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)~Passive insulation with Thermoflect™ material.~All fluids administrated intraoperative will be warmed."
9996674|NCT01502163|Active Comparator|Group passive prewarming|"Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
9996675|NCT01502163|Active Comparator|Group Active prewarming|"Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
9996676|NCT01502176||Atrial fibrillation patients|All patients discharged from hospital with a diagnose of atrial fibrillation
9996677|NCT01502189|Experimental|Representational approach|The Representational approach as described in the detailed description.
9996678|NCT01502202|Active Comparator|Study arm|Pemetrexed plus Cisplatin plus Gefitinib
9996679|NCT01502202|Placebo Comparator|Placebo arm|Pemetrexed plus Cisplatin plus Placebo
9996680|NCT01502215|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hemoglobin is lower than 9 g/dL. Intervention: Other: Red blood cell transfusion
9996681|NCT01502215|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hemoglobin is lower than 7 g/dL Intervention: Other: Red blood cell transfusion
9996682|NCT01502241|Active Comparator|Radiotherapy|6 weeks standard partial brain treatment.
9996683|NCT01502241|Experimental|Temozolomide|Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007
9996684|NCT01502254|Experimental|Copy of audio recording|Patients receive a copy of the audio recorded information about the clinical trial directly after the clinical visit. This makes it possible to repeat the information before a decision is made to participate in the clinical trial or not.
9996685|NCT01502254|No Intervention|No copy of audio recording|Patients in the control arm receive no copy of the audio recording.
9996686|NCT01502267|No Intervention|Group 1|This group will not receive IVIG and B cell depleting agents
9996687|NCT01502267|Experimental|Group 2|This group will receive IVIG and B cell depleting agents
9667518|NCT03486704|Active Comparator|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
9996688|NCT01502280|Experimental|5-ALA/Gliolan® /5-Aminolevulinic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)
9996689|NCT01502280|Placebo Comparator|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
9996690|NCT01502319||All subjects|Group/Cohort label is not applicable to this umbrella protocol. The Consortium funds specific research teams who will determine the number of group(s)/cohort(s) relevant to their study.
9996691|NCT01502345|Experimental|PUUV DNA Vaccine|This group will receive Puumala Virus DNA Vaccine only
9996692|NCT01502345|Experimental|HTNV + PUUV|This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
9996693|NCT01502345|Experimental|HTNV DNA Vaccine|This group will receive Hantaan Virus DNA Vaccine only
9996694|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV)|low dose (no adjuvant)
9996695|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|low dose (with adjuvant)
9996696|NCT01502358|Experimental|Tetravalent dengue Vaccine (TVDV) with Vaxfectin® (high-dose)|high dose (with adjuvant)
9996697|NCT01502384||healthy relatives|healthy 1st degree relatives of PD patients
9996698|NCT01502397||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing rituximab-containing chemotherapy
9996699|NCT01502449|Experimental|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program over 8 weeks that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
9996700|NCT01502449|Active Comparator|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
9996701|NCT01502475||Veteran Attitudes toward CAM|
9996702|NCT01502527|Experimental|Treatment with Femarelle|An open labeled , twice daily treatment with Femarelle
9996703|NCT01502553|Experimental|Blood Pressure, Heart Rate, Monitor|"Device Comparison Test DUT: Transtek Blood Pressure Monitor, LS-802 Refrence Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Groups/Cohorts: Blood Pressure & Heart Rate Monitor"
9921267|NCT00825149|Experimental|F: First-Line FL: Obinutuzumab + CHOP|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
9921268|NCT00825188|Active Comparator|eplerenone|
9921269|NCT00825188|Active Comparator|amlodipine|Amlodipine 5-10mg daily times 8 weeks
9921270|NCT00825201|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation given IP on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9921271|NCT00825214|Active Comparator|1|Use of zapperclick on mosquito bite
9921272|NCT00825214|Placebo Comparator|2|use of inactivated zapperclick on mosquito bite
9921273|NCT00825240||Cancer Survivorship Study|Survey of colorectal cancer patients within one year from treatment end.
9921274|NCT00825279|Active Comparator|1-BMS|Bare Metal Stent (Euca STS Flex)
9921275|NCT00825279|Experimental|2-DES|Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer
9921276|NCT00825292|Active Comparator|2|HDNBI colonoscopy followed by standard white light colonoscopy
9921277|NCT00825292|Active Comparator|1|standard white light colonoscopy followed by HDNBI colonoscopy
9921278|NCT00825331||1|patients for elective catheterization without special risks
9921279|NCT00825331||2|patients for elective catheterization with special risks
9921280|NCT00825331||3|patients for PCI without GP IIb/IIIa
9921281|NCT00825331||4|Patients for PCI with GPIIb/IIIa and emergencies
9921282|NCT00825383|Active Comparator|1|High Fiber Diet
9921283|NCT00825383|Active Comparator|2|Moderate Fiber Diet
9921284|NCT00825396|Experimental|C-KAD Ophthalmic Solution|
9935018|NCT04267731|Placebo Comparator|Placebo|Cellulose 0.75g per day
9799163|NCT01651936|Placebo Comparator|Base Study: Placebo|Participants received placebo BID orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
9921285|NCT00825422|Experimental|A|first bolus of 20 ml of ropivacaine(5mg/ml) and continuous infiltration (8ml/h)of ropivacaine (2mg/ml)
9799164|NCT01651936|Experimental|Safety Extension: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Safety Extension was to last up to 76 weeks.
9799165|NCT01651949|Active Comparator|Females|Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
9799166|NCT01651949|Experimental|Heterosexual Males|Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
9799167|NCT01651949|Experimental|Men who have Sex with Men|Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
9799168|NCT01652001|Experimental|Malic Acid 1%|"Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).~Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A."
9799169|NCT01652001|Placebo Comparator|Control|Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
9799170|NCT01652040|Experimental|RT+Tp|Resistance training using electrical stimulation and ankle weights and Testosterone patches
9799171|NCT01652040|Experimental|Tp|Applying Testosterone patches
9799172|NCT01652287|Active Comparator|BB-12 supplemented yogurt|Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
9799173|NCT01652287|Placebo Comparator|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
9799174|NCT01652469|Experimental|A: Erlotinib|Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
9799175|NCT01652469|Experimental|B: Docetaxel|Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
9799176|NCT01652495|Active Comparator|methylprednisolone acetate group|Single intrabursal injection of methylprednisolone acetate
9799177|NCT01652495|Active Comparator|Triamcinolone acetonide group|Single intrabursal injection of Triamcinolone acetonide
9799178|NCT01652573|Experimental|Nasal calictonin|Subjects will received nasal calcitonin once daily
9799179|NCT01652573|Placebo Comparator|Saline Nasal spray|Patients will receive saline nasal spray once daily
9799180|NCT01652664|Experimental|Travoprost|Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
9799181|NCT01652664|Active Comparator|Timolol|Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
9799182|NCT01652690||Denosumab|Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
9799183|NCT01652703|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
9799184|NCT01652703|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
9799185|NCT01652703|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9799186|NCT01652703|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
9799187|NCT01652703|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9799188|NCT01652703|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
9799189|NCT01652716|Experimental|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
9799190|NCT01652716|Active Comparator|Exenatide twice daily (BID)|Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks
9799191|NCT01652729|Experimental|Exenatide once weekly suspension|Exenatide once weekly suspension 2mg subcutaneous injection
9799192|NCT01652729|Active Comparator|Sitagliptin 100mg|Overencapsulated Sitagliptin 100mg oral tablet once daily
9799193|NCT01652729|Placebo Comparator|Placebo|Placebo oral capsule once daily
9799194|NCT01652872|Active Comparator|Hb-Based Titration Group|Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.
9921286|NCT00825422|Placebo Comparator|B|first bolus of 20 ml of physiological saline solution(9%) and continuous infiltration (8ml/h)of physiological saline solution(9%)
9921287|NCT00825435|Experimental|1|Coronary CT angiogram plus Standard of care (CTA+SOC)
9921288|NCT00825435|No Intervention|2|Standard of Care (SOC)
9921289|NCT00825448|Experimental|2|patient in hospital a week before the date of surgery for the treatment of his addiction alcohol
9921290|NCT00825448|No Intervention|1|no treatment of his addiction alcohol during a week before the date of surgery
9921291|NCT00825461||1|Anorexia with tube feeding
9921292|NCT00825461||2|Anorexia without tube feeding
9921293|NCT00825461||3|Control
9921294|NCT00825474|Experimental|survival rate|therapeutic effect of partial hepatectomy or TACE plus PEI for small hepatocellular carcinoma
9921295|NCT00825487|Experimental|ARQ 621 treatment|
9921296|NCT00825526|Experimental|Early Intervention, MBSR therapy|Group that receives Mindfulness Based Stress Reduction Therapy immediately after randomization
9921297|NCT00825526|Active Comparator|Delayed Treatment Arm, MBSR Therapy|Group that receives Mindfulness Based Stress Reduction Therapy within 3 months of randomization
9921298|NCT00825578|Active Comparator|1|Upper-lobe predominant emphysema
9921299|NCT00825578|Active Comparator|2|Non-upper lobe predominant emphysema
9921300|NCT00825591|Active Comparator|1|Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.
9921301|NCT00825591|Placebo Comparator|2|
9921302|NCT00825604|No Intervention|Without PCI|Optimized medical treatment, physical training and smoking cessation
9921303|NCT00825604|Active Comparator|With PCI|optimized medical treatment, physical training and smoking cessation with complimentary treatment with percutaneous coronary intervention(PCI)
9921304|NCT00825617|Experimental|HRT|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
9921305|NCT00825643||Insulin detemir|
9921306|NCT00825656|Experimental|1|Sinol-M
9921307|NCT00825656|Active Comparator|2|Sinol
9921308|NCT00825669|Active Comparator|survival rate (TACE)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
9921309|NCT00825669|Active Comparator|survival rate (TACE plus laser ablation)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
9921310|NCT00825695|Active Comparator|flavanol-rich cocoa|
9921311|NCT00825695|Placebo Comparator|flavanol-poor cocoa|
9921312|NCT00825708|Active Comparator|rTMS|rTMS session
9921313|NCT00825708|Sham Comparator|SHAM|sham session
9921314|NCT00825721|Active Comparator|1.3% (low dose)|
9921315|NCT00825721|Active Comparator|2% (medium dose)|
9921316|NCT00825721|Active Comparator|2.6% (high dose)|
9921317|NCT00825721|Placebo Comparator|Placebo|
9921318|NCT00825760|Other|1|Single treatment
9921319|NCT00825760|Other|2|12 treatments, once weekly
9921320|NCT00825773|Active Comparator|Excel|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
9921321|NCT00825773|Sham Comparator|Cypher|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
9921322|NCT00825799||Major Depressive Disorder|Adults with major depressive disorder who are experiencing a current depressive episode.
9921323|NCT00825799||Healthy controls|Individuals without any Axis I psychiatric diagnosis who are matched to depressed subjects by age and sex.
9921324|NCT00825838|Experimental|1|Oral ingestion of 6mg chili pepper extract
9921325|NCT00825838|Placebo Comparator|2|Oral ingestion of 0 mg chili pepper extract (matching placebo)
9921326|NCT00825851|Active Comparator|continuous smoking|subjects smoke 20 cigarettes per day
9921327|NCT00825851|Active Comparator|smoking cessation and NRT|subjects quit smoking and use transdermal nicotine patch
9921328|NCT00825851|Placebo Comparator|smoking cessation and placebo patch|subjects quit smoking and use placebo patch
9921329|NCT00825851|No Intervention|never smokers|subjects being never smokers and who refrain from smoking
9921330|NCT00825864|Active Comparator|1diclofenac drops treatment|four times a day for 3 months
9921331|NCT00825864|Active Comparator|2dexamethasone drops|
9921332|NCT00825903|Experimental|1|Aquatic based exercise
9921333|NCT00825929||1|Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)
9921334|NCT00825942|Experimental|C-KAD Ophthalmic Solution|
9921335|NCT00825968||Data collection group|Patients having procedures done at the electrophysiology Laboratories at the Ross Heart Hospital at The Ohio State University Medical Center.
9935019|NCT04267731|Experimental|Low dose|0.25g VMK223 per day
9935020|NCT04267731|Experimental|Middle dose|0.5g VMK223 per day
9935021|NCT04267731|Experimental|High dose|0.75g VMK223 per day
9935022|NCT04266093||Cohort 1|Subjects who have received treatment on an NCI GMB or GMB gene therapy protocol.
9935023|NCT04263311|Experimental|Community Health Workers (CHW) treatment group|There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
9935024|NCT04263311|No Intervention|Control group|There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes
9935025|NCT04262167|Experimental|Low Dose LSCs (cohort 1) n = 4 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 100 million Lung Spheroid Stem Cell (LSC) infusion.
9935026|NCT04262167|No Intervention|Usual Care (Cohort 1) n = 2 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
9935027|NCT04262167|Experimental|High Dose LSCs (Cohort 2) n = 12 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 200 million LSC infusion.
9935028|NCT04262167|No Intervention|Usual Care (Cohort 2) n = 6 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
9935029|NCT04258566|Experimental|Suspected hepatic malignancy|Malignancy determination of new onset hepatic lesion
9935030|NCT04258332|Other|High Salt Diet then Low Salt Diet|"The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure.~The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg)."
9935031|NCT04258332|Other|Low Salt Diet then High Salt Diet|"The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg).~The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure."
9935032|NCT04257552|Active Comparator|Attention Control Group|If randomized to the attention control arm participants will receive discharge instruction from the postpartum nurses per usual care. Study investigators will ask them to provide us with an SMS number. This will enable collection of self-reported breast feeding duration as well as texts on general infant care. The infant care texts are educational in nature and no data will be collected. Participants will receive a total of two texts on general infant care in the first month postpartum. This increased attention to the control arm mirrors the attention received by the Healthy Beyond Pregnancy arms and seeks to isolate the effect of the intervention from a general increased level of contact with providers. Participants that answer 80% of the infant feeding questions will receive a financial compensation.
9935033|NCT04257552|Active Comparator|Pre-Scheduled Postpartum Visit:|If randomized the the usual care with pre-scheduled visit arm, participants will schedule their postpartum visit with the study coordinator and receive discharge information per usual care. Participants that answer 80% of the infant feeding questions (collected via text messaging) will receive a financial compensation.
9935796|NCT03206060|Experimental|1/Lu-177-DOTATATE|Lu-177-DOTATATE is administered IV every 8 (+/- 2) weeks, for a total of 4 administrations. A Ga-68-DOTATATE PET and F-18-FDG-PET, as well as CT/ MRI for RECIST monitoring, will be obtained post 2 administrations and post 4 administrations. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection.
9996704|NCT01502566|Experimental|Educational Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries. This intervention will be applied at the Brazilian National Vaccination Day
9996705|NCT01502566|No Intervention|Control group|This group will receive no intervention
9996706|NCT01502592|Experimental|Cryoablation alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
9996707|NCT01502592|Experimental|Ipilimumab alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
9996708|NCT01502592|Experimental|Ipilimumab & Cryoablation|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
9996709|NCT01502605|Experimental|5-ALA|This arm will receive the investigational agent, 5-ALA.
9996710|NCT01502618|Experimental|Focus Group|The focus group participants for this study will be Black Young Men who have Sex with Men (B-YMSM) ages 16-24 years (inclusive) who are diagnosed as HIV-positive and receive medical care at one of the two participating AMTUs or their community partners.
9996711|NCT01502670|Experimental|Lung Nodule|
9996712|NCT01502683|Experimental|Off-pump No Clamp|Off-pump coronary artery bypass patients randomized to no clamp for proximal anastomoses.
9996713|NCT01502683|Experimental|Off-pump Partial Occluding Clamp|Off-pump coronary artery bypass patients randomized to partial occluding clamp for proximal anastomoses.
9996714|NCT01502683|Experimental|On-pump Single Cross Clamp|On-pump coronary artery bypass patients randomized to single cross clamp for cardioplegic arrest and proximal anastomoses.
9996715|NCT01502683|Experimental|On-pump Double Clamp|On-pump coronary artery bypass patients randomized to cross-clamp for cardioplegic arrest and partial-occluding clamp for proximal anastomoses. This strategy involves the application of two clamps.
9998254|NCT01516489|No Intervention|Stage 1 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
9921336|NCT00825981||coronary artery bypass graft|patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass
9921337|NCT00826033||Therapy monitoring|
9921338|NCT00826072||ALI|patients with acute lung injury at 24h after cardiac surgery
9921339|NCT00826072||Control|patients without acute lung injury 24h after cardiac surgery
9921340|NCT00826085|Experimental|Thermodox in combination with hyperthermia|Single arm study
9921341|NCT00826098|Experimental|1 (PRP)|Total knee replacement with PRP
9921342|NCT00826098|No Intervention|2 (non-PRP)|Total knee replacement without PRP
9921343|NCT00826124|Active Comparator|I|Two epidural steroid injections two weeks apart based on history and physical exam alone
9921344|NCT00826124|Active Comparator|II|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
9921345|NCT00826137|Experimental|A|Treated with prebiotics.
9921346|NCT00826137|Placebo Comparator|B|Placebo treated.
9921347|NCT00826163|Active Comparator|stable COPD|Postbronchodilator FEV1> or = 50% predicted
9921348|NCT00826163|Sham Comparator|Asthma|Postbronchodilator FEV1 > or = 50% predicted
9921349|NCT00826215|Experimental|1|Electroacupuncture treatment
9921350|NCT00826215|Sham Comparator|2|Sham laser acupuncture
9921351|NCT00826293|Active Comparator|True Stabilization Group|Patients will be randomized to one of the two treatment groups (true stabilization vs. sham stabilization). Patients will be exercising with a belt that is expected to reduce impingement of the rotator cuff tendons.
9921352|NCT00826293|Sham Comparator|Sham Stabilization|Patients receive sham stabilization. The sham procedure imitates the treatment without any true effect.
9921353|NCT00826306|Experimental|Video-based education arm|Subjects receiving the video-based educational material
9921354|NCT00826306|Active Comparator|Written education arm|Subjects receiving the written educational material
9921355|NCT00826319||Bioimpedance sub-study cohort|Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
9921356|NCT00826319||Ethnic enrichment cohort|Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
9921357|NCT00826319||Original CanPreddict cohort|The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
9921358|NCT00826332|Active Comparator|Abdominal|Transabdominal ultrasound guided embryo transfer
9921359|NCT00826332|Active Comparator|Vaginal|Transvaginal ultrasound guided embryo transfer
9921360|NCT00826345|Experimental|Acupuncture/Moxibustion|Diagnostic Acupuncturists assessments will inform acupuncture/moxibustion treatment prescriptions for persons with HIV/AIDS experiencing distal peripheral neuropathy. This protocol is tailored specifically for the subject's unique diagnosis according to the symptoms being reported at each diagnostic acupuncture (DA) session.
9921361|NCT00826345|Placebo Comparator|Placebo Acupuncture / Moxibustion|Sham/placebo Arm: Points will be administered away from the classic/traditional true point location.
9921362|NCT00826358|Experimental|A|ABT-143 capsules 5/45mg
9921363|NCT00826358|Active Comparator|B|ABT-335 45mg and rosuvastatin 5mg
9921364|NCT00826371|Experimental|1|
9921365|NCT00826397|Experimental|Acupuncture Arm|Patients in the treatment arm will receive acupuncture administered twice weekly for six weeks and will be allowed to take pain medication as necessary.
9921366|NCT00826397|Sham Comparator|Control Arm|The control patients will receive a form of sham acupuncture, which will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks.
9921367|NCT00826410|Experimental|subcutaneous drain|"Use of subcutaneus suction drain (Redon) after laparotomy"
9921368|NCT00826436||8 subjects for Cohort 1|
9921369|NCT00826436||8 subjects for Cohort 2|
9921370|NCT00826475|Experimental|Mindfulness|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
9921371|NCT00826475|Active Comparator|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
9921372|NCT00826488|Other|observational|Observational
9921373|NCT00826501|Active Comparator|1|Endoscopic cyst-gastrostomy with a neurolytic block along with oral/transdermal analgesic therapy
9921374|NCT00826501|Active Comparator|2|Surgical cyst-gastrostomy with neurolytic block and pain managed by only oral/transdermal analgesic
9921375|NCT00826553|Experimental|GABA agonist|
9921376|NCT00826553|Experimental|Alpha 2 agonist|
9921377|NCT00826566|Active Comparator|1|500 mg caffeine capsules per day
9921378|NCT00826566|Placebo Comparator|2|500 mg placebo capsules
9921379|NCT00826579|Experimental|Colon cancer|Colon cancer patients of all stages
9921380|NCT00826592|Experimental|Video-based education arm|Subjects receiving the video-based educational material
9921381|NCT00826592|Active Comparator|Written education arm:|Subjects receiving the written educational material
9921382|NCT00826605||Urobilinogen increase|Increase in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
9921383|NCT00826605||Weight Loss at Term|Weight loss since previous prenatal appointment after 37 weeks gestation
9921384|NCT00826631|Active Comparator|1|Fast food intake, doubling of caloric intake, in combination with sedentary behavior (no exercise)
9921385|NCT00826631|No Intervention|2|Control group, parallel
9921386|NCT00826644|Experimental|Belotecan plus Cisplatin|
9921387|NCT00826644|Active Comparator|Etoposide plus Cisplatin|
9921388|NCT00826657|Placebo Comparator|placebo|Receive placebo (sugar pill) during the intervention. Received a 1000 mg vitamin B12 injection at the end of the study.
9921389|NCT00826657|Active Comparator|Vitamin B12|Received 500 micrograms vitamin B12 per day during the study Received a 1000 mg vitamin B12 injection at the start of the study
9800401|NCT01686750|Experimental|Integrated care centers|"Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.~HIV voluntary counseling and testing & staging~Risk reduction services including free condoms, needle and syringe exchange, opiate substitution therapy~Substance abuse counseling~Sexually transmitted infection screening and treatment~Access to free antiretroviral therapy and adherence support~Peer community outreach"
9921390|NCT00826670|Experimental|Topical decolonization|
9921391|NCT00826670|Placebo Comparator|Placebo|
9921392|NCT00826683|Other|Control group of healthy subjects|Control group of healthy subjects : simple blood analysis of EPCs
9921393|NCT00826683|Active Comparator|COPD|COPD: one initial blood sample and simple clinical follow-up
9921394|NCT00826683|Active Comparator|NSCLC|NSCLC: one initial blood sample and usual clinical follow-up
9921395|NCT00826709|Experimental|Arm 1|2 Nasal swabs
9921396|NCT00826709|Experimental|Arm 2|2 Nasopharyngeal swabs
9921397|NCT00826709|Experimental|Arm 3|Nasal wash or aspirate
9921398|NCT00826735|Experimental|Guided imagery|The experimental group received a relaxation focused guided imagery intervention to use through the remainder of pregnancy plus a physiologic guided imagery intervention during the third stage of labor. These interventions were scripted and prerecorded on CDs.
9921399|NCT00826761|Active Comparator|1|High dose Lb. casei
9921400|NCT00826761|Active Comparator|2|Low dose Lb. Casei
9921401|NCT00826761|Placebo Comparator|3|
9921402|NCT00826774|Active Comparator|Ususal Care|
9921403|NCT00826774|Experimental|Breif Lifestyle Counseling|
9921404|NCT00826774|Experimental|Enhanced Brief Lifestyle Counseling|
9921405|NCT00826813|Experimental|stenting|The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
9921406|NCT00826826|Active Comparator|Amiodarone|
9921407|NCT00826826|Placebo Comparator|Placebo|
9921408|NCT00826839|Experimental|OCP/MDL|Oral contraceptive pills/microdose lupron
9921409|NCT00826839|Experimental|E2/antagonist|Estradiol patch/gonadotropin-releasing hormone antagonist
9921410|NCT00826878|Experimental|Tivozanib (AV-951)|
9921411|NCT00826904||Lean|Healthy, pregnant women with BMI of 20 - 26 kg/m2
9921412|NCT00826904||Obese|Healthy, obese pregnant women with BMI 30 - 38 kg/m2
9921413|NCT00826917||Objective 1: XI VOCALTM in 3D fetal volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
9921414|NCT00826917||Objective 2: XI VOCALTM in 3D placental volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
9921415|NCT00826917||Objective 3: Comparison between 2 ultrasound machine|"intramachine reliability for (i)fetal, (ii)gestational sac and (iii)placenta volumetry measurement for (a)multiplanar and (b)VOCALTM:- group 1:Accuvix; group 2:Voluson 730~intermachine reliability for fetal, gestational sac and placenta volumetry measurement for (a)multiplanar and (b)VOCALTM for Accuvix and Voluson 730"
9921416|NCT00826917||Objective 4:3D volumetry in fetuses at risk of Hb Bart's|Measurement of fetal, gestational sac and placenta volume per CRL quotient using multiplanar technique:- group 1: affected; group 2: unaffected
9921417|NCT00826930|Experimental|1A|0.5 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
9517801|NCT03302832|Active Comparator|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
9921418|NCT00826930|Experimental|2A|0.75 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
9921419|NCT00826930|Experimental|3A|1.0 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
9921420|NCT00826930|Experimental|4A|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - phenytoin only or none
9921421|NCT00826930|Experimental|1B|0.5 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
9921422|NCT00826930|Experimental|2B|0.75 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
9921423|NCT00826930|Experimental|3B|1.0 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
9921424|NCT00826930|Experimental|4B|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - any except phenytoin-only or none
9921425|NCT00826969|Active Comparator|1|Ciclesonide 320µg
9921426|NCT00826969|Placebo Comparator|2|Placebo
9921427|NCT00826995|Experimental|Video-based education arm:|Subjects receiving the video-based educational material
9921428|NCT00826995|Active Comparator|Written education arm:|Subjects receiving the written educational material
9921429|NCT00827021|Experimental|ESAs 1 low dose|
9921430|NCT00827021|Active Comparator|ESAs 2 high dose|
9921431|NCT00827034|Other|A|A: Warfarin alone
9921432|NCT00827034|Other|B|B: Dimebon and Warfarin co-administration
9921433|NCT00827047|Active Comparator|Total Hemihepatic Vascular Exclusion|Patients with HCC received Total Hemihepatic Vascular Exclusion in hepatectomy.
9921434|NCT00827047|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy.
9921435|NCT00827047|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
9921436|NCT00827086||1|Patients with non-infectious Uveitis
9921437|NCT00827086||2|Patients with scleritis
9921438|NCT00827138|Experimental|DCC-2036|This is a single arm study
9921439|NCT00827151|Active Comparator|Estrogen and lifestyle|
9921440|NCT00827151|No Intervention|Lifestyle|
9921441|NCT00827164|Experimental|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
9921442|NCT00827164|Other|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
9921443|NCT00827177|Experimental|ARQ 197 in combination with sorafenib|
9921444|NCT00827190|Experimental|1|ILS-920
9921445|NCT00827203|Experimental|Cohort|
9921446|NCT00827216|Placebo Comparator|Physiologic saline|
9921447|NCT00827216|Active Comparator|Erythromycine|
9921448|NCT00827229|Other|LaborPro, active Labor, Vaginal Examination|
9921449|NCT00827268|Other|Arm 1|Repeated probes every 8 hours of treatment (1/week)
9921450|NCT00827281|Experimental|1|DCS-augmented CBT for smoking cessation
9921451|NCT00827281|Placebo Comparator|2|Placebo-augmented CBT for smoking cessation
9921452|NCT00827294|Experimental|Self-delivered mirror therapy|All participants were directed to self-deliver mirror therapy for 20 minutes per day.
9921453|NCT00827307|Experimental|Combination|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.
9921454|NCT00827307|Active Comparator|Conctrol|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
9921455|NCT00827333|No Intervention|Phase I-Usual Care|
9921456|NCT00827333|Active Comparator|Phase 2 - Intervention|
9921457|NCT00827346|Active Comparator|Group 1|600-mg double dose
9921458|NCT00827346|Active Comparator|Group 2|600/600-mg double loading dose (first dose 600 mg given immediately upon arrival at the hospital and the second dose 600 mg, 3 hours after the first loading dose for a total of 900 mg
9921459|NCT00827346|Active Comparator|Group 3|Clopidogrel 900mg
9921460|NCT00827346|Active Comparator|Group 4|First dose 600 mg given immediately upon arrival at the hospital and the second dose 300 mg, 3 hours after the first loading dose for a total of 900 mg
9921461|NCT00827385||hypertensive|
9921462|NCT00827385||normotensive|
9921463|NCT00827411|Experimental|1: Monitoring Arm|"First randomization:~Monitoring Arm: dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay (VerifyNow)."
9935797|NCT03204188|Experimental|Treatment|Ibrutinib Fludarabine Pembrolizumab is given daily until disease progression or intolerable side effects
9921464|NCT00827411|Active Comparator|2: Conventional Arm|"First randomization:~Conventional Arm: fixed dose regiment of both aspirin and clopidogrel in all patients following DES implantation according to international guidelines"
9921465|NCT00827411|Experimental|3: Pursuit Arm|"Second randomization after one year of follow-up:~Pursuit Arm: Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year"
9921466|NCT00827411|Active Comparator|4: Interruption Arm|"Second randomization after one year of follow-up:~Interruption Arm: Interruption of clopidogrel therapy."
9921467|NCT00827424|Experimental|1|This arm will receive Lifestyle counseling by applying a modified PACE protocol
9921468|NCT00827424|No Intervention|2|Subject in this arm will be recruited but will receive no intervention
9921469|NCT00827437|Other|1|
9921470|NCT00827450|Placebo Comparator|Ctl|control isocaloric diet; no coffee
9921471|NCT00827450|Placebo Comparator|HF|Hypercaloric. high fructose diet; no coffee
9921472|NCT00827450|Experimental|C1|Hypercaloric, high fructose diet; caffeine-free, torrefied coffee
9921473|NCT00827450|Experimental|C2|Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee
9921474|NCT00827450|Experimental|C3|Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
9921475|NCT00827463|Experimental|NFS and iron in the first quater|first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery.
9921476|NCT00827463|Experimental|No NFS and iron in the first quater|second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy
9921477|NCT00827476|Experimental|ovarian transplantation|tissue will be used for xenotransplantation or in vitro culture
9921478|NCT00827489|Experimental|HTC-867|
9921479|NCT00827489|Placebo Comparator|Placebo|
9921480|NCT00827515|Experimental|One|
9921481|NCT00827515|Experimental|Two|
9921482|NCT00827515|Experimental|Three|
9921483|NCT00827515|Experimental|Four|
9921484|NCT00827528|Experimental|SIS graft|this group will use a biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
9921485|NCT00827528|Active Comparator|2|this group will use a traditional repair on correction of anterior vaginal wall prolapse.
9921486|NCT00827554|Experimental|LMWH plus TACE|50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks
9921487|NCT00827554|Active Comparator|TACE alone|50 HCC patients randomly assigned to receive TACE without LMWH
9921488|NCT00827580|Experimental|Eniluracil|
9921489|NCT00827593|Active Comparator|Standard behavioral weight loss|University-based behavioral weight loss treatment
9921490|NCT00827593|Active Comparator|Weight Watchers|Weight Watchers program
9921491|NCT00827593|Active Comparator|Combined Treatment|University-based behavioral weight loss treatment followed by Weight Watchers
9921492|NCT00827619|Other|1|single arm non-randomized post-market study
9921493|NCT00827645||Uterine artery embolization|Women with symptomatic uterine fibroids scheduled for uterine artery embolization
9921494|NCT00827658|Active Comparator|Hypothenar Palm block|Hypothenar Palmar block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
9921495|NCT00827658|Active Comparator|Volar Wrist Block|Volar Wrist block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
9921496|NCT00827671|Other|Pre-operative chemotherapy|
9921497|NCT00827684|Active Comparator|Response or stable disease|will receive Temsirolimus
9921498|NCT00827684|Experimental|Progression|Will receive a combination of Temsirolimus and Irinotecan
9921499|NCT00827710|Active Comparator|1|patients who received point-of-care report cards and were listed on provider performance report card
9921500|NCT00827710|Active Comparator|2|Patients who received point-of-care diabetes report cards but were not listed on provider performance report card
9921501|NCT00827710|Active Comparator|3|Patients who did not receive point-of-care report card but who were listed on provider performance report card
9921502|NCT00827710|No Intervention|4|Patients who did not receive point of care report card and who did were not listed on provider performance report card
10213395|NCT04107116|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
9996716|NCT01502696|Experimental|PEG IFN alfa-2b|
9996717|NCT01502696|No Intervention|Observation|
10213396|NCT04107116|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by their local oncologists.
10213397|NCT04101526|No Intervention|Pre-Intervention Qualitative Interviews|Qualitative interviews will be conducted with breast cancer survivors, survivors' caregivers, cancer support group leaders and clinicians regarding sleep disturbance in breast cancer survivors and preferences for an intervention for sleep disturbance.
10213398|NCT04101526|Experimental|Videoconference Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Behavioral: New Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference
10213399|NCT04101526|No Intervention|Waitlist control group|No intervention until 6 weeks after the baseline assessment, at which point participants complete a follow-up assessment and then are offered the new CBT-I intervention.
10213400|NCT04098666|Experimental|metformin users|Extended release metformin 500 mg tablets up to 2,000 mg (4 tablets) a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
10213401|NCT04098666|Placebo Comparator|metformin non-users|Placebo tablets identical to dxtended release metformin 500 mg tablets up to 4 tablets a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
10213402|NCT04097262|Experimental|Own-Price Elasticity|"The price of fruit will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
9921503|NCT00827723||Alcoholic|Alcoholic cirrhotic patient with resectable hepatocellular carcinoma
9921504|NCT00827723||Viral|Viral cirrhotic patient with resectable hepatocellular carcinoma
9921505|NCT00827736|Experimental|Botox injection|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
9921506|NCT00827736|Active Comparator|ISDN ointment|application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter
9921507|NCT00827762||Phenylketonuria|Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.
9921508|NCT00827788|Active Comparator|iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
9921509|NCT00827788|Active Comparator|iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
9921510|NCT00827801||Group 1|MDASI-HF questionnaire provided to Doctor for symptom management.
9921511|NCT00827801||Group 2|MDASI-HF questionnaire collected not provided to Doctor.
9921512|NCT00827814|Experimental|Dutasteride|
9921513|NCT00827840|Experimental|1. Paliperidone ER|New antipsychotics
9921514|NCT00827840|Active Comparator|2 Risperidone|
9921515|NCT00827853|Experimental|1|Conventional angioplasty balloon post-dilation of nitinol self expanding stents
9921516|NCT00827853|Experimental|2|Cryoplasty balloon post-dilation
9921517|NCT00827866|Other|1|Counselor-Initiated Tobacco Quit Line Group QL where the counselor contacts the client with a standardized intervention protocol)
9921518|NCT00827866|Other|2|Self-Paced Tobacco Quit Line Group which leaves the calling up to participants
9921519|NCT00827879|Experimental|Strength at Home Couples Group|PTSD-Focused Cognitive Behavioral Therapy for Couples
9921520|NCT00827879|Placebo Comparator|Supportive Group Therapy|Supportive therapy for couples
9921521|NCT00827892|Experimental|1|
9921522|NCT00827892|Placebo Comparator|2|
9921523|NCT00827905||Hospitalized|Patients admitted to the hospital
9921524|NCT00827957|Active Comparator|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
9921525|NCT00827957|Active Comparator|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
9921526|NCT00827970|Experimental|1 Screening|Individuals receiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
9921527|NCT00827970|No Intervention|2 Control|Control group receiving usual care
9921528|NCT00828035|Other|1, REL|rel group : patients with light endoscopic robot
9921529|NCT00828035|Active Comparator|2, AO|AO group : Patients with surgery assistant
9921530|NCT00828048||Pancreatic Cyst|Pancreatic Cyst
9921531|NCT00828087|Experimental|Everolimus Arm|Everolimus Eluting Coronary Stent System
9921532|NCT00828087|Active Comparator|non drug eluting stent Arm|cobalt chromium balloon expandable stent
9921533|NCT00828126||PET-CT Scan|
9921534|NCT00828152|Experimental|1|Internet-delivered CBT. Contact with therapist thru an e-mail system. 12 weeks.
9921535|NCT00828152|Placebo Comparator|2|On line discussion group.
9921536|NCT00828165|Experimental|ARRY-300|
9921537|NCT00828165|Placebo Comparator|Placebo|Placebo
9921538|NCT00828217|Experimental|with APA|Children have adapted physical activity during their hospitalization
9921539|NCT00828217|No Intervention|without APA|Children don't have adapted physical activity during their hospitalization
9921540|NCT00828230|Experimental|1|2mg rectal budesonide per day for 8 weeks
9799195|NCT01652872|Experimental|Fixed Dose Group|Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was > 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to < 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.
9799196|NCT01652885|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
9799197|NCT01652976|Experimental|Treatment Arm|Dasatinib and mFOLFOX6
9799198|NCT01653028|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9799199|NCT01653132|Experimental|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
9799200|NCT01653132|Placebo Comparator|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
9799201|NCT01653158|Experimental|CP-751,871 combined with docetaxel|
9799202|NCT01653262|Experimental|Brivaracetam|"The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily.~Based on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed.~At the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks."
9799203|NCT01653288|Experimental|Coping Coach|Receive access to Coping Coach online intervention at baseline for use (self-guided, with email reminders) over the next 6 weeks.
9799204|NCT01653288|Experimental|Coping Coach Waitlist Control|Treatment as usual from baseline to 12 week follow-up assessment. Then receive access to Coping Coach intervention after 12 week follow-up for use (self-guided, with email reminders) over the next 6 weeks.
9799205|NCT01653327|Active Comparator|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
9799206|NCT01653327|Placebo Comparator|Placebo|The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline.
9799207|NCT01653405|Experimental|Intervention Group|VA patients treated at anticoagulation clinics at 8 sites in VISN 1. The intervention included a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
9799208|NCT01653405|No Intervention|Control Group|VA patients treated at anticoagulation clinics at 116 sites outside of VISN 1.
9799209|NCT01653418|Experimental|V-BEAM + Stem Cell Infusion|Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
9799210|NCT01653509|Experimental|Test patch|Patch containing acyclovir applied to cold sore
9799211|NCT01653509|Placebo Comparator|Placebo patch|Patch without acyclovir applied to cold sore
9799212|NCT01653587|Active Comparator|Transradial approach|Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis
9799213|NCT01653587|Active Comparator|Transfemoral approach|Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis
9799214|NCT01653704|Experimental|active management of crises scenario|participants assigned to actively manage a crisis scenario
9799215|NCT01653704|Active Comparator|Observer role in crisis scenario|Observational role in management of crises scenario
9799216|NCT01653743|Experimental|MSJ-0011|
9799217|NCT01653743|Active Comparator|urinary hCG|
9799218|NCT01653782|Experimental|kUNDALINI YOGA|"Guided kundalini yoga sessions specific for low back pain for 1 hour, twice a week (120 minutes of instructor-led yoga) for 6 weeks. Cd recording for home practice recommended once per day.A written self care pamphlet The Back book"
9799219|NCT01653782|Active Comparator|Self care advice to stay active|Evidence based advice from caregiver to stay active and exercise
9799220|NCT01653782|Active Comparator|Exercise|"Guided exercise at a gym focusing on strength training. Twice a week during 6 weeks. A written self care pamphlet The Back book"
9800402|NCT01686750|No Intervention|Standard services|In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
9800403|NCT01686828|Experimental|Acyline & placebo gel & placebo pill|Acyline (300mcg/kg) + placebo transdermal gel + placebo pill daily
9800404|NCT01686828|Experimental|Acyline & Testosterone 1.25g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (1.25g) daily + placebo pill daily
9800405|NCT01686828|Experimental|Acyline & Testosterone 5g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (5g) daily + placebo pill daily
9800406|NCT01686828|Experimental|Acyline & Testosterone & Letrozole|Acyline (300mcg/kg) + Testosterone gel (5g) daily + letrozole (5mg) daily
9800407|NCT01686932|Experimental|Vildagliptin followed by Sitagliptin|Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
9800408|NCT01686932|Experimental|Sitagliptin followed by Vildagliptin|Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
9921541|NCT00828230|Placebo Comparator|2|One application of placebo foam once daily for 8 weeks
9800409|NCT01686958|Experimental|MR-Guided Transurethral US Ablation|MR-Guided Transurethral US Ablation of Prostate Tissue
9800410|NCT01687036|Other|Cryoablation|Cryoablation
9800411|NCT01687088||chronic migraineurs|At least 8 migraine days per week and headache at least 15 days per month.
9800412|NCT01687088||controls|No significant headache or disability as defined by migraine disability scale.
9800413|NCT01687101|Experimental|STOPAIN topical gel|STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
9800414|NCT01687114|Experimental|cranberry juice|27% cranberry juice
9800415|NCT01687166|Experimental|Blazer Open-Irrigated Ablation Catheter|Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system
9800416|NCT01687166|Active Comparator|FDA Approved Open-Irrigated Ablation Catheter|FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.
9800417|NCT01687179|Experimental|"Sirolimus and Hydroxychloroquine"|"Subjects will take Sirolimus at an initial dose of 2mg followed by dose adjustment to keep Sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial. In addition to Sirolimus subjects will receive Hydroxychloroquine at 200 mg daily for 6 months. Once safety is established at the lower dose (Sirolimus and Hydroxychloroquine 200 mg), subjects enrolled henceforth will receive Sirolimus and Hydroxychloroquine 400 mg (200 mg twice a day) for 6 months."
9800418|NCT01687218|Active Comparator|Group 1|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
9800419|NCT01687218|Active Comparator|Group 2|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
9800420|NCT01687218|Active Comparator|Group 3|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
9800421|NCT01687218|Active Comparator|Group 4|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
9800422|NCT01687218|Active Comparator|Group 5|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
9800423|NCT01687218|Active Comparator|Group 6|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
9800424|NCT01687244|Experimental|rAd-IFN Dose 1x10^11vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
9800425|NCT01687244|Experimental|rAd-IFN dose 3x10^11 vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
9800426|NCT01687257|Experimental|SOF+RBV|Participants will receive SOF+RBV for 48 weeks.
9800427|NCT01687257|Experimental|Observation, then SOF+RBV|Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
9800428|NCT01687270|Experimental|SOF+RBV|Participants will receive sofosbuvir+RBV for 24 weeks.
9800429|NCT01687283|Experimental|fluticasone propionate|1 mg BID inhalation via nebulizer
9800430|NCT01687283|Active Comparator|budesonide suspension|2 mg BID inhalation via nebulizer
9800431|NCT01687296|Experimental|fluticasone Nebules/placebo tablet|2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily
9996718|NCT01502722|Experimental|Group 1 - Crossover|This group will drink water in the 1st study.
9517802|NCT03302832|Experimental|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
9517803|NCT03302819|Experimental|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
9799221|NCT01653847|Active Comparator|Group 1: Tacrolimus with MMF.|This group will receive a standard dose Tacrolimus and MMF. This will follow standard of care protocol at Northwestern Memorial Hospital's Comprehensive Transplant Center.
9799222|NCT01653847|Active Comparator|Group 2: Tacrolimus with Everolimus|This group will receive a low dose Tacrolimus with concentration controlled Everolimus
9799223|NCT01653847|No Intervention|Donors|One time blood samples will be collected from kidney donors to recipients in this study
9799224|NCT01653912|Experimental|GSK2110183, carboplatin and paclitaxel|Subjects will be treated with a maximum of six doses of carboplatin + paclitaxel in combination with continuous daily GSK2110183 followed by single agent GSK2110183 at the single-agent MTD of 125 mg or above oral daily.
9799225|NCT01653964|Experimental|Molecular breast imaging|Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
9799226|NCT01654068|Experimental|Radiation Therapy to Local Spine Metastasis|Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
9799227|NCT01654107|Experimental|Persistence Targeted Smoking Cessation|Persistence Targeted Smoking Cessation - 8 weeks counseling + 12 weeks nicotine lozenge
9799228|NCT01654107|Active Comparator|Clearing The Air|Clearing the Air Smoking Cessation intervention - 8 weeks counseling + 12 weeks nicotine lozenge
9799229|NCT01654224|Active Comparator|High Dose Inactivated Influenza Vaccine|For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
9799230|NCT01654224|Active Comparator|Standard Dose Inactivated Influenza Vaccine|For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
9799231|NCT01654250|Experimental|Active|NWP09
9799232|NCT01654250|Placebo Comparator|Placebo|Placebo
9799233|NCT01654263|Experimental|Group IA: Pneumococcal vaccine-naive, age 55 - 64|Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults
9799234|NCT01654263|Experimental|Group IB: Pneumococcal vaccine-naive, age 65 - 74|Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults
9799235|NCT01654263|Experimental|Group IIA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
9799236|NCT01654263|Experimental|Group IIAA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
9799237|NCT01654263|Experimental|Group IIB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
9799238|NCT01654263|Experimental|Group IIBB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
9799239|NCT01654276|Experimental|Febuxostat|Adult patients (age > 21 years) with gout and hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women) requiring uric acid lowering therapy.
9799240|NCT01654289|Experimental|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
9799241|NCT01654289|Experimental|Exercise|The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
9799242|NCT01654289|No Intervention|Wait-list control|"Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as experimental participants."
9799243|NCT01654302|Active Comparator|Synera|lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium chloride, wood flour, water and filter paper.
9921542|NCT00828243||Genetic association|Infants with and without neonatal respiratory distress syndrome undergo surfactant gene sequencing to identify genomic variants associated with neonatal respiratory distress syndrome
9921543|NCT00828243||Nutrient|To newborn infants with respiratory distress syndrome, we administer stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based comparison of surfactant phospholipid and protein turnover.
9921544|NCT00828269|No Intervention|1|Liver tissue biopsy
9921545|NCT00828282|Experimental|1|
9921546|NCT00828334|Experimental|Transcatheter PDA Coil|Transcatheter occlusion of Patent Ductus Arteriosus (PDA) with the flex and medium Nit-Occlud PDA.
9921547|NCT00828373|Placebo Comparator|Placebo|
9921548|NCT00828373|Active Comparator|Lidocaine|
9921549|NCT00828386|Experimental|Induction chemotherapy + concurrent chemoradiotherapy|"Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):~Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion~Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by~5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.~The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks)."
9921550|NCT00828386|Active Comparator|Concurrent radiochemotherapy alone|Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
9921551|NCT00828399|Experimental|Glutamine|
9921552|NCT00828399|Placebo Comparator|Whole protein|
9921553|NCT00828425||1|Diabetic patients with retinopathy
9921554|NCT00828438|Experimental|Lorcaserin 10mg|
9921555|NCT00828477|Active Comparator|1|Xibrom (bromfenac)
9921556|NCT00828477|Active Comparator|2|Nevanac (nepafenac)
9921557|NCT00828490||Pediatric Asthmatics|Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma
9921558|NCT00828490||Antipsychotic Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months
9921559|NCT00828490||Bipolar Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months.
9921560|NCT00828490||Opioid Therapy|"Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months:~Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code"
9921561|NCT00828490||Fraud and Abuse|Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months
9921562|NCT00828490||Pediatric Antipsychtotic Therapy|Medicaid beneficiaries <18 years of age with at least 3 antipsychotic Rx's in the past year.
9921563|NCT00828503|Active Comparator|1 Certican + Valganciclovir|Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
9921564|NCT00828503|Active Comparator|2 Valganciclovir alone|Valganciclovir will be added alone.
9921565|NCT00828581|Experimental|Lorcaserin|
9921566|NCT00828594|Experimental|Phase 1: RAD001 plus sorafenib|
9921567|NCT00828607||liver mass|The group will comprise any patients with an unknown liver mass at the time of diagnostic imaging.
9921568|NCT00828620||PET-CT|Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
9921569|NCT00828646|Experimental|BMS-708163 - Panel 1|(Age 20-45 years)
9921570|NCT00828646|Experimental|BMS-708163 - Panel 2|(Age 20-45 years)
9921571|NCT00828646|Experimental|BMS-708163 - Panel 3|(age 65 or above)
9921572|NCT00828646|Experimental|BMS-708163 - Panel 4|(age 65 or above)
9921573|NCT00828659|Placebo Comparator|Placebo|
9921574|NCT00828659|Active Comparator|Active Comparator #1|
9921575|NCT00828659|Active Comparator|Active Comparator #2|
9921576|NCT00828659|Active Comparator|Active Comparator #3|
9921577|NCT00828659|Experimental|Lorcaserin Dose #1|
9921578|NCT00828659|Experimental|Lorcaserin Dose #2|
9921579|NCT00828659|Experimental|Lorcaserin Dose #3|
9921580|NCT00828685|Active Comparator|Operative (CRPP)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized.
9921581|NCT00828685|Active Comparator|Operative (ORIF)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized
9921582|NCT00828698||Acute Myocardial Infarction patients|
9921583|NCT00828724|Experimental|Lorcaserin 10mg|
9921584|NCT00828737|Experimental|Arm 1|
9921585|NCT00828763|Experimental|1|[14C]-GSK1349572 administered as a single oral dose
9921586|NCT00828776|Experimental|1|Heparin Cristália
9921587|NCT00828776|Active Comparator|2|Heparin - Roche
9921588|NCT00828802|Experimental|Cohort 1|Lenalidomide (5mg) and Decitabine
9921589|NCT00828802|Experimental|Cohort 2|Lenalidomide (10 mg) and Decitabine
9921590|NCT00828802|Experimental|Cohort 3|Lenalidomide (15 mg) and Decitabine
9921591|NCT00828802|Experimental|Cohort 4|Lenalidomide (20 mg) and Decitabine
9921592|NCT00828802|Experimental|Cohort 5|Lenalidomide (25 mg) and Decitabine
9921593|NCT00828828||Sarcoidosis|Sarcoidosis patients who are assigned to receive influenza vaccine
9921594|NCT00828828||Healthy Controls|Healthy controls who are assigned to receive influenza vaccine
9921595|NCT00828854|Experimental|treatment|Continued treatment with same AI at labeled dose and schedule, plus Entinostat (5mg PO every week)
9921596|NCT00828867|Experimental|Cohort 1|100mg
9921597|NCT00828867|Experimental|Cohort 2|200mg
9921598|NCT00828867|Experimental|Cohort 3|400mg
9921599|NCT00828867|Experimental|Cohort 4|800mg
9921600|NCT00828867|Experimental|Cohort 5|1500mg
9921601|NCT00828867|Experimental|Cohort 6|2000mg
9921602|NCT00828867|Experimental|Cohort 7|800mg with food
9921603|NCT00828867|Experimental|Cohort 8|3000mg
9921604|NCT00828867|Experimental|Cohort 9|4000mg
9921605|NCT00828880||DRX9000|
9921606|NCT00828906|Experimental|1|DuoTrav
9921607|NCT00828919|Experimental|Treatment|Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study
9921608|NCT00828932|Experimental|Lorcaserin 10mg|
9921609|NCT00828971|Experimental|Arm 1|
9921610|NCT00828971|Active Comparator|Arm 2|
9921611|NCT00828997|Other|Prevenar vaccine|all participants are immunized with a dose of pneumococcal conjugate vaccine
9921612|NCT00829023|Experimental|betadine, DuraPrep, ChloraPrep|surgical skin preparation solution
9921613|NCT00829062|No Intervention|Glucose sensor|Children who have assented to wear a 72 hour physician ordered continuous glucose monitor.
9921614|NCT00829075|Experimental|I|only r-FSH TREATMENT
9921615|NCT00829075|Experimental|II|only HP-hMG TREATMENT
9921616|NCT00829075|Experimental|III|r-FSH plus HP-hMG TREATMENT
9921617|NCT00829101||1 One-stage repair|A consecutive group of children born with unilateral cleft lip and palate from the south region of Sweden, in all 10 children, who have had a primary palatal surgery at 12 months of age.
9921618|NCT00829101||2 Two-stage repair, early closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 12 months of age.
9921619|NCT00829101||3 Two-stage repair, delayed closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 36 months of age.
9921620|NCT00829114|Active Comparator|1|ART/COC group
9921621|NCT00829114|Active Comparator|2|COC group
9921622|NCT00829127|Experimental|1|
9921623|NCT00829127|Placebo Comparator|2|
9921624|NCT00829140|Placebo Comparator|Placebo BID|
9921625|NCT00829140|Experimental|Lorcaserin 10mg BID|
9921626|NCT00829153|Experimental|U clip|Anastomosis with U clips
9921627|NCT00829153|Active Comparator|2|Prolene anastomosis
9921628|NCT00829192|Experimental|1|Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months
9921629|NCT00829192|Placebo Comparator|2|Placebo implant administered subcutaneously every 60 days for 24 months
9517804|NCT03302819|Experimental|Imaging characteristics and performance|Patients attending the symptomatic clinic
9921630|NCT00829218|Active Comparator|1 - Glutamate challenge|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
9921631|NCT00829218|Placebo Comparator|2- Placebo|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
9921632|NCT00829231|Experimental|Arm 1|
9921633|NCT00829231|Experimental|Arm 2|
9921634|NCT00829231|Experimental|Arm 3|
9921635|NCT00829257|Experimental|Fine particle steroid inhaler|HFA-BDP plus Fluticasone/Salmeterol Combination
9921636|NCT00829257|Active Comparator|Coarse Particle Inhaler|FP plus Fluticasone/Salmeterol combination
9921637|NCT00829270||mitochondrial diseases diagnosis|
9921638|NCT00829322|Experimental|Treatment group|
9921639|NCT00829322|Placebo Comparator|Control group|
9921640|NCT00829335||HCC patients|According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
9921641|NCT00829348|No Intervention|Statins, counseling|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
9921642|NCT00829348|Experimental|Statins, Counselling, SMS|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
9921643|NCT00829361|Other|Telemedicine|
9921644|NCT00829400|Experimental|Posit Science|Brain Fitness, Insight, and Aristotle Cognitive Software Training Suites Targeting 100 hours of training
9921645|NCT00829400|Active Comparator|Nintendo Brain Age|Brain Age 2 Nintendo DS Portable Device for home or office use, targeting 100 hours of training
9921646|NCT00829465|Active Comparator|control|
9921647|NCT00829465|Experimental|therapy|
9921648|NCT00829478|Placebo Comparator|1|Usual Care
9921649|NCT00829478|Experimental|2|Intervention
9921650|NCT00829517|Active Comparator|STI kiosk|computer-assisted provision of screening for chlamydia
9921651|NCT00829517|Experimental|contraceptive kiosk|computer-assisted provision of hormonal contraception
9921652|NCT00829543|Experimental|sacroiliac injection|an open label study designed to evaluate the efficacy and safety of guide-free sacroiliac injection in refractory sacroiliac pain due to spondyloarthropathies
9921653|NCT00829556|Experimental|1|
9921654|NCT00829556|No Intervention|2|Standard Surgical skin preparation
9921655|NCT00829569|Experimental|Intralipid with/without Omegaven|Lipid infusion with/without marine n-3 fatty acids
9921656|NCT00829582|Experimental|ETI-204|ETI-204, Anthim
9921657|NCT00829582|Sham Comparator|placebo|
9921658|NCT00829595|Experimental|1|IBD, on both an anti-TNF agent and an immunomodulator
9921659|NCT00829595|Experimental|2|IBD, not on any immunosuppressive medications
9921660|NCT00829595|Active Comparator|3|Healthy, non-IBD, not on immunosuppressive medications (control arm)
9921661|NCT00829608|Experimental|Human Papillomavirus Vaccine|There are 9 participants currently being followed in the faculty sponsor's clinic that carry the clinical and histologic diagnosis of RRP. The 9 participants meet one or more of the following criteria: Surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and rapid regrowth of papilloma disease with airway compromise.
9921662|NCT00829634|Other|l-methamphetamine|
9935034|NCT04257552|Experimental|Healthy Beyond Pregnancy|Healthy Beyond Pregnancy is a web platform with an electronic survey that assesses a participant's self-identified postpartum concerns. Participants are then presented with 3 educational videos that reflect their self-identified needs from the survey. The Healthy Beyond Pregnancy generates an individualized passport for postpartum care. This passport for care lists the women's self-identified postpartum needs as well as issues that should be prioritized based on her health history.The individualized passport for postpartum care will be printed out and given to participants. After the participant schedules her postpartum visit, she will receive a print out that includes the date and time of her appointment, a copy of the commitment statement as well as a reminder of the monetary incentive she will receive if she fulfills her commitment and attends her postpartum visit.
9935035|NCT04251897|Active Comparator|Standard care mattress|Patient will have 2 days to familiarize with the novel support surface. Patient will be on standard care mattress. They will be turned over every 2 hours for 3 days.
9935036|NCT04251897|Experimental|Novel support surface|"After the standard care mattress, the same patient will be placed on novel support surface. They will be turned over every 2 hours for 3 days.~Patient will then continue with the novel support surface and turned every 3 hours for 3 days.~They will then continue with the novel support surface and turned every 4 hours for 3 days."
9935037|NCT04251195|Experimental|Cognitive Intervention|
9935038|NCT04251195|Active Comparator|Active Control Intervention|
9935039|NCT04250714||Treatment patients|Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use
9935040|NCT04250311|Experimental|MMH-407|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
9935041|NCT04250311|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
9935042|NCT04249245||Parkinson Patients|"These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris).~They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015."
9935043|NCT04249245||Control Subjects|"They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned.~If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group."
9935044|NCT04247282|Experimental|A/arm A|M7824 (Days 1, 15)
9935045|NCT04247282|Experimental|B/arm B|M7824 + TriAd vaccine (ETBX-011, ETBX-051 and ETBX-061) (Days 1)
9935046|NCT04247282|Experimental|C/arm C|M7824 + TriAd vaccine (Day 1) + N-803 (Day 1)
9921663|NCT00829647|Experimental|combination dasatinib plus lenalidomide|dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily
9921664|NCT00829660|Active Comparator|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
9921665|NCT00829660|Placebo Comparator|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
9921666|NCT00829699|Experimental|1|Euinsulinemic (low insulin infusion) Euglycemic (normal blood glucose levels) glucose clamp with lipid (fat) infusion
9921667|NCT00829699|Experimental|2|Euinsulinemic Hyperglycemic (high glucose levels) glucose clamp with lipid infusion
9921668|NCT00829699|Experimental|3|Hyperinsulinemic (High dose insulin) euglycemic glucose clamp with lipid infusion
9921669|NCT00829699|Experimental|4|Hyperinsulinemic hyperglycemic (high glucose level) glucose clamp with lipid infusion
9921670|NCT00829725|Active Comparator|screws-internal fixation|3-4-screws-internal fixation
9921671|NCT00829725|Experimental|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
9921672|NCT00829751|Active Comparator|ReNu Multiplus|Purevision lenses will be soaked in ReNu Multiplus
9921673|NCT00829751|Active Comparator|OptiFree RePlenish|PureVision lenses will be soaked in OptiFree RePlenish
9921674|NCT00829816|Experimental|Dimebon|20 mg dimebon by mouth 3 times per day
9921675|NCT00829816|Placebo Comparator|Placebo|20 mg placebo by mouth 3 times per day
9921676|NCT00829842|Placebo Comparator|1|Placebo
9921677|NCT00829842|Experimental|2|
9921678|NCT00829855||1|Patients with hypertensive (systolic blood pressure ≥160 mmHg) acute pulmonary edema, evaluated within 120 minutes after admittance.
9921679|NCT00829855||2|The same patients from group 1 followed-up at 48 to 96 hours.
9921680|NCT00829881|Placebo Comparator|1|Participants will receive a placebo capsule, administered orally, once per study visit.
9921681|NCT00829881|Experimental|2|Participants will receive a betahistine capsule, administered orally, once per study visit.
9921682|NCT00829894|Experimental|1|Risperidone 1 mg Tablet
9921683|NCT00829894|Active Comparator|2|Risperdal® 1 mg Tablet
9921684|NCT00829907|Experimental|1|Orm-12741
9921685|NCT00829920||Bladder cancer|Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
9921686|NCT00829946|Experimental|2|
9921687|NCT00829959||Genetic Counseling|Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).
9921688|NCT00829972||1|children undergoing adenotonsillectomy
9921689|NCT00829972||2|children undergoing elective procedures other than adenotonsillectomy
9921690|NCT00830011|Active Comparator|standard care|Medical care including medication for neuropathic pain
9921691|NCT00830011|Active Comparator|CBT|
9921692|NCT00830050|Experimental|Arm 1|
9921693|NCT00830050|Placebo Comparator|Arm 2|
9921694|NCT00830089|Experimental|TAP block|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
9921695|NCT00830089|No Intervention|Standard care|No TAP block is given. Care is otherwise identical to arm 1
9921696|NCT00830141||1|50 children with GH deficiency
9921697|NCT00830141||2|50 children with ISS
9921698|NCT00830141||3|50 children with FTT
9921699|NCT00830141||4|50 children with obesity
9921700|NCT00830141||5|50 children without short stature or obesity will serve as controls
9921701|NCT00830193|Active Comparator|N-acetylcysteine|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Patients randomized to the experimental arm received intravenous normal saline plus NAC 10 grams IV (5 g pre and 2.5 g at 6 and 12 hours post-exposure) for a total of 3 doses.
9921702|NCT00830193|Placebo Comparator|Placebo|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g in 100 cc D5W (pre-CT dose) or 2.5 g in 50 cc D5W (post-CT doses). The placebo was D5W and was colour and consistency matched by pharmacy. Patients randomized to placebo received intravenous normal saline plus 3 doses of placebo.
9921703|NCT00830245|Experimental|Erlotinib|Erlotinib 150mg/day (if no negative conversion --> increment to 250mg/day)
9517805|NCT03302819|Experimental|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
9799244|NCT01654302|Placebo Comparator|Inactive Patch|placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients.
9799245|NCT01654380|Experimental|Part A, Cohort A; LY2605541|Healthy participants received 5.1 milliunits/minute (mU/min) in Period 1, 10.2 mU/min in Period 2, and 15.3 mU/min in Period 3, administered intravenously (IV) over 8 hours. All periods were separated by a minimum 6-day washout period
9799246|NCT01654380|Active Comparator|Part A, Cohort A; Insulin Glargine|Healthy participants received insulin glargine (30 milliunits/meter squared/minute [mU/m^2/min]) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period
9799247|NCT01654380|Experimental|Part A, Cohort B; LY2605541|Healthy participants received 15.3 mU/min in Period 1, 37.0 mU/min in Period 2, and 74.1 mU/min in Period 3, administered IV over 8 hours. All periods were separated by a minimum 6-day washout period.
9799248|NCT01654380|Active Comparator|Part A, Cohort B; Insulin Glargine|Healthy participants received insulin glargine (60 mU/m^2/min) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period.
9799249|NCT01654380|Experimental|Part B; LY2605541|Participants with T1DM received 15.3 mU/min in 1 of 4 study periods, administered IV up to 8 hours and received 74.1 mU/min in 1 of 4 Periods, administered IV up to 10 hours. Each dose was separated by a minimum 6-day washout period.
9799250|NCT01654380|Active Comparator|Part B; Insulin Glargine|Participants with T1DM received 1 insulin glargine dose per study period (10 and 20 mU/m^2/min) administered IV over 8 hours in 2 of 4 study periods. Each dose was separated by a minimum 6-day washout period.
9799251|NCT01654445|Experimental|TNK-tPA Tenecteplase|This is an open-label trial, all patients will receive tenecteplase.
9799252|NCT01654523|Other|Treatment arm|Open trial with no randomization
9799253|NCT01654536|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg
9799254|NCT01654536|Active Comparator|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg
9799255|NCT01654549|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
9799256|NCT01654549|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
9799257|NCT01654601|Experimental|A Group|"1.1st Administration - DWCZP tablet 100mg Mutiple dose~2.2nd Administration - Clozaril tablet 100mg Mutiple dose"
9799258|NCT01654601|Experimental|B Group|"1.1st Administration - Clozaril tablet 100mg Mutiple dose~2.2nd Administration - DWCZP tablet 100mg Mutiple dose"
9799259|NCT01654666|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
9799260|NCT01654666|Active Comparator|Control group|Treatment:Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
9799261|NCT01654666|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
9799262|NCT01654796|Active Comparator|Low Field Magnetic Stimulation|Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
9799263|NCT01654796|Placebo Comparator|Sham (LFMS)|Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
9799264|NCT01654796|Other|Crossover Arm|Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
9799265|NCT01654861|Experimental|HDIVC|Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
9921704|NCT00830271|Experimental|Vicryl plus/Monocryl plus|"Vicryl plus and Monocryl plus is the active comparator arm. These are the active sutures, coated with triclosan antiseptic, being used in the closure of skin and subcutaneous tissues after breast cancer surgery."
9921705|NCT00830271|Placebo Comparator|vicryl/monocryl|"Plain Vicryl or Monocryl suture currently the standard which are not coated with triclosan, serve as the control."
9921706|NCT00830297|Active Comparator|1 Insulatard (long-acting insulin)|
9921707|NCT00830297|Active Comparator|2 Conventional treatment|
9921708|NCT00830323|Experimental|1|
9921709|NCT00830323|Experimental|Arm 2|
9921710|NCT00830323|Active Comparator|Arm 3|
9921711|NCT00830349|Experimental|1|Risperidone 1 mg Tablets
9921712|NCT00830349|Active Comparator|2|Risperdal® 1 mg Tablets
9921713|NCT00830401|No Intervention|1|One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
9921714|NCT00830401|Active Comparator|2|One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.
9921715|NCT00830414|Experimental|1|
9921716|NCT00830414|Active Comparator|2|DEPO-PROVERA®
9921717|NCT00830427|Experimental|PF-00610355|
9921718|NCT00830427|Experimental|PF - 00610355|
9921719|NCT00830427|Placebo Comparator|Placebo|
9921720|NCT00830453|Experimental|Hyperbaric oxygen|Hyperbaric oxygen, 1.5 atmospheres absolute, 60 minutes door-to-door, 60 daily sessions.
9921721|NCT00830466|Experimental|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
9921722|NCT00830479|Active Comparator|Open Surgery|
9921723|NCT00830479|Active Comparator|Endoscopic Surgery|
9921724|NCT00830492|Active Comparator|2|In group A (n=100), the patients were stimulated conventional. They desensitized with buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg and ovarian stimulation would commence with 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
9921725|NCT00830492|Experimental|clomiphen/gonadotropin/GnRH antagonist|Patients in group B ( n=100 ) were stimulated clomiphene citrate ( ) 100 mg from cycle day three through seven and continuous gonadotropin stimulation with of r_FSH 75 IU daily from cycle day 5. Ultrasound in two group was performed on 8 cycle day. In group B 0.25 mg GnRH antagonist (Ganirelix , Organon ,Netherland ) daily was started with dominant follicle ≥14mm and in this day 75 IU human menopoasl gonadotropin (HMG) (Menogon, ferring, pharmacenticals , Germany ) increased to the initial gonadotropin . LH assessment on the day of starting antagonist was performed and if LH was >15 IU/L , cycle was cancelled. Human chorionic gonadotropin 10000 IU ((pregnyl, Organon, Oss, the Netherlands ) was given when 1 to 3 follicles reached 18 mm
9921726|NCT00830505|Experimental|1: fluticasone/salmeterol|2 puffs twice a day for 2 weeks
9921727|NCT00830505|Active Comparator|2: fluticasone|2 puffs twice a day for 2 weeks
9921728|NCT00830531|Experimental|1|Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
9921729|NCT00830531|Placebo Comparator|2|Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
9921730|NCT00830544|Experimental|1|Experimental chemotherapy using neoadjuvant approach
9921731|NCT00830570||1|Historical control group. Patients in this group are drawn from the same plan populations as the intervention group, but they are identified during the 1-year period prior to the start of patient enrollment in the intervention group. The historical control group is closely matched with the intervention group on demographic characteristics, practice patterns, and benefit plan features that may affect resource utilization.
9921732|NCT00830570||2|Concurrent control group. Patients in this group are drawn from different set of plan populations, but they initiate warfarin treatment during the same time period as patients in the intervention group. Outcomes data for the concurrent control group will be used to evaluate whether any differences between the intervention group and the historical control group can be attributed to changes in clinical practice over time. Baseline data for the concurrent control group will help validate the incidence assumptions used in the calculation of statistical power. This use of baseline population norms is an effective means of limiting bias in quasi-experimental studies.
9935047|NCT04243577|Experimental|Experimental Sensors|This arm will include the use of the experimental wearable sensors we are developing.
9935048|NCT04243577|Active Comparator|Conventional Sensors|This arm will include the use of the conventional sensors: regular snap on sEMG electrodes and IOPI device bulb.
9935049|NCT04242953|Experimental|SCO-120|
9921733|NCT00830570||3|Active study group. For plans participating in the active arm of the study, enrollment is offered to every patient who initiates warfarin therapy during the enrollment period (beginning in July 2007) and who meets the eligibility criteria. Patients are identified for the active study group if they have a warfarin pharmacy claim and no prior warfarin claims during the preceding 180 days. Only patients who remain eligible for the pharmacy benefit throughout the study period are included in the final sample.
9921734|NCT00830583|Other|1|pompe's disease suspected patient
9921735|NCT00830609|Active Comparator|A|Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).
9921736|NCT00830609|Experimental|B1|After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
9921737|NCT00830609|Experimental|B2|If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
9921738|NCT00830622|Experimental|1|Cell Phone Intervention: participant receives weekly SMS text message from the health care worker.
9921739|NCT00830622|No Intervention|2|SOC: Participant receives standard of care support but not weekly SMS text messages from the health care worker.
9921740|NCT00830648|Experimental|1|
9921741|NCT00830661|Active Comparator|LIFT|those subjects receiving the Ligation of Intersphincteric Fistula Track procedure
9921742|NCT00830661|Active Comparator|Plug|those subjects randomized to the receive the placement of the porcine anal fistula plug
9921743|NCT00830674|Experimental|KRN23|Single IV or SC administration on day 1
9921744|NCT00830674|Placebo Comparator|Placebo|Single IV or SC administration on day 1
9921745|NCT00830687|Other|Targon FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
9921746|NCT00830700|Experimental|CATMH intervention|Child telemental health service delivery intervention
9921747|NCT00830700|No Intervention|augmented TAU/PCP|Augmented treatment as usual with primary care physician
9921748|NCT00830713|Experimental|MKTP treatment|subject will undergo MKTP
9921749|NCT00830726||1|Healthy volunteers
9921750|NCT00830726||2|Patients with symptomatic heart failure and EF < 40%
9921751|NCT00830726||3|Patients with symptomatic aortic valve stenosis
9921752|NCT00830726||4|Patients with Acute Coronary syndromes prior to surgical intervention
9921753|NCT00830726||5|Patients with refractory stable angina requiring surgical intervention.
9921754|NCT00830726||6|Patients with pulmonary hypertension and preserved systolic left ventricular function.
9921755|NCT00830778|Experimental|PG anastomosis|Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
9921756|NCT00830778|Active Comparator|PJ anastomosis|Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
9921757|NCT00830843|Active Comparator|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
9921758|NCT00830843|Experimental|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
9921759|NCT00830856|Experimental|1|Early initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and within 72hrs of diagnosis were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
9935050|NCT04242953|Placebo Comparator|Matching Placebo|
9996719|NCT01502722|Experimental|Group 2 - Crossover|This group will drink Pineapple Soda in the 1st study
9921760|NCT00830856|Experimental|2|Delayed initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and after completion of high dose fluconazole for 10 weeks, the patients in this group were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
9921761|NCT00830882|Experimental|1:levosalbutamol|2 puffs four times a day for 2 weeks
9921762|NCT00830882|Active Comparator|2: racemic salbutamol|2 puffs four times a day for 2 weeks
9921763|NCT00830882|Placebo Comparator|3: Placebo|2 puffs four times a day for 2 weeks
9921764|NCT00830895|Experimental|RAD001|RAD001 10mg/day
9921765|NCT00830908|Experimental|LaserComb|Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
9921766|NCT00830921||1|"Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept."
9921767|NCT00830934|Active Comparator|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
9921768|NCT00830934|Experimental|Group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
9921769|NCT00830973||Active Study Group|The active study group consists of 50 year or older postmenopausal women taking tamoxifen for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet all inclusion criteria, and are enrolled members for Medco clients agreeing to participate.
9921770|NCT00830986||1|Computer Assisted Total Knee Arthroplasty
9921771|NCT00830986||2|Conventional Instrumented Total Knee Arthroplasty
9921772|NCT00830999|Experimental|Positive energy balance|Comparison between isocaloric and hypercaloric diets with no exercise performed in any trials
9921773|NCT00830999|Experimental|Energy balance with exercise|Comparison between an isocaloric diet without exercise and a hypercaloric diet with a sufficient amount of exercise performed to match the excess calories consumed resulting in both trials being in net energy balance.
9921774|NCT00830999|Experimental|Negative energy balance|Comparison between isocaloric and hypocaloric diets with no exercise performed in any trials
9921775|NCT00830999|Experimental|Negative energy balance with exercise|Comparison between consuming an isocaloric diet without exercise and consuming the same amount of calories as in the isocaloric trial but with exercise performed resulting in net negative energy balance in the exercise trial.
9921776|NCT00831012|Experimental|Group 1|Group 1 will consist of healthy participants receiving an immunization of 10^3 PFU rDEN3delta30/31-7164
9921777|NCT00831012|Experimental|Group 2|"Group 2A will consist of healthy participants who will receive an immunization of 10^5 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2A participants will be enrolled if less that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42.~Group 2B will consist of healthy participants who will receive an immunization of 10^1 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2B participants will be enrolled if more that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42."
9921778|NCT00831025|Experimental|1|Depigmented and polymerized allergen extract of Olea europaea pollen for subcutaneous injection.
9921779|NCT00831025|Placebo Comparator|2|Placebo for subcutaneous injection.
9921780|NCT00831064|Active Comparator|1. 4L PEG only|4L PEG PO
9921781|NCT00831064|Active Comparator|2. 2L PEG plus bisacodyl|2L PEG PO + 4 tablets bisacodyl PO
9921782|NCT00831064|Active Comparator|3. NaP|90 cc NaP PO
9921783|NCT00831064|Active Comparator|4. PSMC plus Mg-citrate|PSMC plus 300 cc Mg-citrate PO
9921784|NCT00831077|Active Comparator|14C-ORM-14540|
9921785|NCT00831077|Active Comparator|14C-ORM-12741|
9921786|NCT00831103|Experimental|EPB-348 1000 mg|EPB-348 1000 mg dosed once daily for seven days
9921787|NCT00831103|Experimental|EPB-348 2000 mg|EPB-348 2000 mg dosed once daily for seven days
9921788|NCT00831103|Experimental|EPB-348 3000 mg|EPB-348 3000 mg dosed once daily for seven days
9921789|NCT00831103|Active Comparator|Valacyclovir|Valacyclovir 1000 mg dosed three times daily for seven days
9921790|NCT00831116||LipiScan|Subjects who have at least one native coronary artery imaged with the LipiScan CIS.
9921791|NCT00831142||Prostate Cancer|Males with prostate cancer, referred for biopsy or radical prostatectomy
9996720|NCT01502722|Experimental|Group 3 - Crossover|This group will drink Pineapple Diet Soda in the 3rd study
9996721|NCT01502735|Experimental|DENV-1 PIV (high dose)|
9996722|NCT01502735|Experimental|DENV-1 PIV (low dose)|
9996723|NCT01502748|Experimental|Endovascular Sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study
9996724|NCT01502774|Experimental|Cyclosporin|Injection of Cyclosporin A : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
9996725|NCT01502774|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
9996726|NCT01502800|Experimental|Part 1 (ARQ 761)|"ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.~Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:~1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2"
9996727|NCT01502800|Experimental|Part 2 Arm A|"The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.~Beginning dose level will be 390 mg/m2."
9996728|NCT01502800|Experimental|Part 2 Arm B|"ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
9996729|NCT01502800|Experimental|Part 2 Arm C|"ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
9996730|NCT01502826||Group A|less insulin-resistant
9996731|NCT01502826||Group B|severely insulin-resistant
9996732|NCT01502839||OEF/OIF Veterans|Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
9996733|NCT01502852||OEF/OIF Veterans with TBI|
9996734|NCT01502852||Family Members and Friends|Family Members and Friends of OEF/OIF Veterans with TBI
9996735|NCT01502852||Community Mental Health Center Providers|Community Mental Health Center providers working with OEF/OIF Veterans with TBI
9996736|NCT01502878|Active Comparator|Nut challenge|Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
9996737|NCT01502878|Placebo Comparator|Nut challenge: Placebo|See intervention
9996738|NCT01502878|Experimental|Nut oral desensitization|Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
9996739|NCT01502891|Active Comparator|Decision aid|DEPRESSION CHOICE decision aid is provided to clinician to share with patient
9996740|NCT01502891|No Intervention|Normal care|
9996741|NCT01502904|Active Comparator|Cypher group|
9799266|NCT01654887|Experimental|Lung Ultrasound|LUS first with the option of obtaining CXR second
9996742|NCT01502904|Experimental|Nobori group|
9996743|NCT01502904|Active Comparator|Pravastatin group|
9996744|NCT01502904|Active Comparator|Pitivastatin group|
9996745|NCT01502904|Active Comparator|Non-ARB group|
9996746|NCT01502904|Experimental|ARB group|
9996747|NCT01502930|Experimental|IRT|Imagery Rehearsal Therapy
9996748|NCT01502930|Active Comparator|CONT|Stress reduction and positive imagery
9996749|NCT01502930|No Intervention|REG|Registration only
9996750|NCT01502943|Experimental|Phlegm and blood stasis Syndrome G|
9996751|NCT01502943|Placebo Comparator|Phlegm and blood stasis control G|
9996752|NCT01502943|Experimental|Qi deficiency and blood stasis G|
9996753|NCT01502943|Placebo Comparator|Qi deficiency and blood stasis control G|
9996754|NCT01502969|Placebo Comparator|Placebo|Children receiving placebo (cell culture medium in absence of virus)
9996755|NCT01502969|Active Comparator|Rotavirus vaccine|Rotavin-M1, 10e6.3ffu/dose, 2 doses
9996756|NCT01502982|Experimental|Chemoimmunotherapy|
9996757|NCT01502995|Active Comparator|With laser light|Trial of walking tasks using laser light on walker.
9996758|NCT01502995|Active Comparator|Without laser light|Trial of walking task without laser light on walker.
9996759|NCT01503008|Experimental|Sustained Behavior Change system support|
9996760|NCT01503008|Active Comparator|Control|
9996761|NCT01503034||Study cohort|This cohort is made up of pregnant women with a breast cancer diagnosed between 2000 and 2014.
9996762|NCT01503034||Compared cohort|This cohort is made up of non-pregnant women with a breast cancer diagnosed between 2000 and 2009.
9996763|NCT01503047|Experimental|CLA group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
9998255|NCT01516489|Experimental|$5 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
9921792|NCT00831155|Active Comparator|1|Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
9921793|NCT00831155|No Intervention|2|Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
9921794|NCT00831194|Experimental|Diet plan and PDA|
9921795|NCT00831207||G1|15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ < 350 cells/mm3.
9921796|NCT00831207||G2|31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).
9921797|NCT00831207||G3|43 HIV-1+ individuals undergoing HAART with TF.
9921798|NCT00831207||G4|20 normal individuals who served as controls for serum cytokines.
9921799|NCT00831220||1|Patients with a COPD exacerbation
9921800|NCT00831220||2|Patients with stable COPD
9921801|NCT00831220||3|Smokers or former smokers
9921802|NCT00831220||4|Never smokers
9921803|NCT00831246|Experimental|1|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
9921804|NCT00831246|Sham Comparator|2|Patients are given standard post-op care with clear liquid diet as tolerated .
9921805|NCT00831259||1|Incidence of silent stroke in patients with PFO
9921806|NCT00831259||2|Incidence of silent stroke in patients without PFO
9921807|NCT00831285|Experimental|tortilla with high amylose flour|
9921808|NCT00831285|Experimental|barley tortilla with low amylose flour|
9921809|NCT00831285|Experimental|barley tortilla with low amylose flour and soluble fibre|
9921810|NCT00831285|Experimental|barley tortilla with low amylose flour and insoluble fibre|
9921811|NCT00831285|Active Comparator|glucose|
9921812|NCT00831285|Experimental|barley tortilla with low amylose flour and low soluble fibre|
9921813|NCT00831298|Other|1|Behavioral Questionnaire Sleep Recordings Genetic analysis
9921814|NCT00831337|Experimental|Liver cirrhosis compensated|VSL3 supplemented twice daily for 28 days
9921815|NCT00831337|Experimental|Liver cirrhosis decompensated|VSL3 supplemented twice daily for 28 days
9921816|NCT00831337|Experimental|Control group|VSL3 supplemented twice daily for 28 days
9921817|NCT00831350|Experimental|ranibizumab|
9921818|NCT00831363||1|minimal invasive approach
9921819|NCT00831363||2|traditional transgluteal approach
9921820|NCT00831376|Experimental|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
9921821|NCT00831376|Active Comparator|2: racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
9921822|NCT00831376|Placebo Comparator|3: Placebo|Patients will be asked to take two puffs four times a day for 2 weeks
9921823|NCT00831402|No Intervention|Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY)|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
9921824|NCT00831402|Active Comparator|Arm with iodized vitamin|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
9921825|NCT00831467|Experimental|CV9103|CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23
9921826|NCT00831506|Experimental|A|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
9921827|NCT00831506|Experimental|B|digoxin once daily (0.125 mg QD) plus Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
9921828|NCT00831519||Macrosomial, GD|
9921829|NCT00831519||Macrosomial, control|
9921830|NCT00831545|Experimental|Subjects with melanoma|
9921831|NCT00831545|Experimental|Subjects with breast cancer|
9921832|NCT00831545|Experimental|Subjects with non-small cell lung cancer|
9921833|NCT00831597|Experimental|Bendamustine with rituximab|All patients received combination bendamustine with rituximab
9921834|NCT00831610|Other|STUDY|"Female healthy volunteers (25 to 55 years old) with normal weight.~Morbid Obese women waiting for bariatric surgery.~Post-bariatric female patients, 25 to 55 years old, MORE than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Skin Evaluation before the abdominoplasty.~Group 3, submitted to anchor-line abdominoplasty without flap undermining."
9921835|NCT00831610|Other|CONTROL|Group 3: Post-bariatric female patients, 25 to 55 years old, LESS than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Who will be submitted to abdominoplasty after the study period.
9921836|NCT00831623|Experimental|Proton radiation therapy|Single arm
9921837|NCT00831636|Experimental|Open label CP-4055|Phase I: Dose escalation Phase II: Fixed dose
9921838|NCT00831649|Experimental|natalizumab|
9921839|NCT00831688|Active Comparator|1|Local overpressure treatment
9921840|NCT00831688|Placebo Comparator|2|Placebo treatment
9921841|NCT00831714||Group 1|
9921842|NCT00831714||Group 2|
9921843|NCT00831727|Experimental|Expressive Writing|
9921844|NCT00831727|Placebo Comparator|Control|
9935051|NCT04237012|Experimental|Dextenza|Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed
9935052|NCT04237012|Active Comparator|Over the counter Artificial tears|Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert
9935053|NCT04236986|No Intervention|Baseline [11C]PBR28 PET Scan|Subjects will complete a 120-minute baseline [11C]PBR28 PET scan.
9935054|NCT04236986|Experimental|Post-LPS [11C]PBR28 PET Scan|Subjects will complete a second120-minute [11C]PBR28 PET scan 3-hours after LPS administration (1.0ng/kg; IV)
9998342|NCT01517360|Experimental|Oxytocin+Social Cognitive Skill Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
9998343|NCT01517386||paravertebral anesthesia|patients scheduled for elective unilateral thoracic surgery under paravertebral block and general anesthesia
9998344|NCT01517399|Other|Test drug administration|All drugs except vitamin K will be administered as a single dose once by itself as a reference treatment and once with tivantinib
9998345|NCT01517425||Cases|Subjects previously enrolled in the Scripps Genebank Study
9998346|NCT01517425||Controls|Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort
9998347|NCT01517451|Experimental|Radiation with Androgen Deprivation Therapy (ADT)|This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT (stereotactic body radiation therapy). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens.
9998348|NCT01517464|Experimental|SGT-94|Dose escalation of experimental therapeutic SGT-94 to assess safety
9998349|NCT01517477|Experimental|First Arm: One iStent|Device: One iStent
9998350|NCT01517477|Experimental|Second Arm: Two iStents|Device: Two iStent devices
9998351|NCT01517477|Experimental|Third Arm: Three iStents|Device: Three iStent devices
9998352|NCT01517490||Type 1 Insulin Pump|Patients with type 1 diabetes starting insulin pump treatment
9998353|NCT01517490||Type 1 conventional therapy|Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.
9998354|NCT01517490||Type 2 Bariatric surgery|Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.
9998355|NCT01517490||Type 2 conventional|Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.
9998356|NCT01517490||Type 1 insulin pumpe follow-up|Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.
9998357|NCT01517490||Healthy|Healthy volunteers.
9998358|NCT01517503|Experimental|Cognitive Therapy (CT)|Cognitive Therapy (CT)
9998359|NCT01517503|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT)
9998360|NCT01517516||Functional Pain Conditions and Inflammatory bowel disease|Cyclical Vomiting Syndrome, Irritable Bowel Syndrome, Inflammatory Bowel disease (Ulcerative colitis and Crohns)and Vulvodynia (vestibulodynia)
9528746|NCT03208361|Experimental|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
9998361|NCT01517516||Inflammatory Bowel Disease|Subjects diagnosed with Crohn's Disease or Ulcerative Colitis.
9998362|NCT01517542|Experimental|Nutritional counseling|It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.
9998363|NCT01517542|No Intervention|Usual diet|It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits
9998364|NCT01517555|Experimental|Liraglutide|
9998365|NCT01517555|Placebo Comparator|Placebo|
9998366|NCT01517568|Experimental|Liraglutide|
9998367|NCT01517581||Malignant Disease with no visualized BAT|Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.
9998368|NCT01517607||Mesalazine|
9998369|NCT01517620|Experimental|Total Glucosides Paeony, Capsules|
9936005|NCT02835222|Active Comparator|Standard of Care - Cytarabine and daunorubicin|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
9936006|NCT02831049|Experimental|1|alcohol retrieval / alcohol extinction
9936007|NCT02831049|Active Comparator|2|soft-drink retrieval / alcohol extinction
9936008|NCT02831049|Active Comparator|3|alcohol retrieval / soft-drink extinction
9936009|NCT02830724|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
9936010|NCT02830724|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
9936011|NCT02830308||Adults with known or suspected endocrine or metabolic dissorde|Adults with known or suspected endocrine or metabolic dissorders
9936012|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 three times a week"
9936013|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®) plus Onivyde chemo|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~IV Onivyde® 70 mg/m2 over 90 minutes followed by IV leucovorin (LV) 400 mg/m2 over 30 minutes or according to local standard, followed by IV fluorouracil (5-FU) 2400 mg/m2 over 46 hours, every 2 weeks.~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 twice a week and following the chemotherapy dosing."
9936014|NCT02821832|Other|Arm A|Expected high risk of relapse
9936015|NCT02821832|Active Comparator|Arm B|Expected low risk of relapse
9936016|NCT02821832|Experimental|Arm C|Expected low risk of relapse
9936017|NCT02821806||Cohort 1|Healthy Volunteers
9936018|NCT02821767||1|Individuals with various diagnosed and undiagnosed ocular conditions
9936019|NCT02815592|Experimental|Experimental Arm 1|BMS-986012/Cisplatin/Etoposide
9936020|NCT02815592|Experimental|Experimental Arm 2|BMS-986012/Carboplatin/Etoposide
9936021|NCT02815592|Experimental|Experimental Arm 3A|BMS-986012/Platinum/Etoposide
9936022|NCT02815592|Active Comparator|Active Comparator Arm 3B|Platinum/Etoposide
9936023|NCT02810405||1/Patient Samples|Patients treated at NCI with available tissue samples
9936024|NCT02802423|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.
9936025|NCT02802384||Cases|People with active Paget's Disease of Bone
9936026|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
9936027|NCT02798523|Experimental|Group A|Following collection of a 3-mm skin punch biopsy sample and a preinfusion whole-blood sample, volunteers will receive a single intravenous dose of 250 milligrams (mg) of methylprednisolone sodium succinate infused over 15 minutes, and a single application of topical methylprednisolone 0.1% to a small area (2 x 2 cm) of the skin. Whole blood samples will then be obtained serially, at 2 and 4 hours after the start of drug administration. A second skin punch biopsy will be performed 4 hours after the start of drug administration, in the area of skin where topical methylprednisolone was applied.
9998370|NCT01517620|No Intervention|no intervention|
9936028|NCT02798523|Experimental|Group B|Following collection of a pre-infusion whole- blood sample, volunteers will receive a single intravenousdose of 250 milligrams (mg) of methylprednisolone sodium succinate infused over 15 minutes. Whole-blood samples will then be obtained serially, at 1 and 2 hours after the start of drug administration.
9998371|NCT01517633|Experimental|A device for identifying between amniotic fluid and urine|
9998372|NCT01517646|No Intervention|Fat Reduction|
9998373|NCT01517685|Experimental|Flax Oil and then Fish Oil|All people in the study will use the flax seed oil and then the fish oil.
9998374|NCT01517711|Experimental|Tramadol ER|
9476131|NCT03574740||Entire population|All patients included in this retrospective study. These patients were analyzed following their tobacco smoking habits.
9998375|NCT01517711|Placebo Comparator|Sugar pill|
9998376|NCT01517724|Experimental|Bortezomib consolidation|Bortezomib administered once a week 1.3mg/sq m; maximum of 8 cycles (each cycle is 4 weeks)
9998377|NCT01517789|Experimental|Patients|
9476132|NCT03574701|Experimental|A: Vitamin A and Olfactory Retraining|Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
9476133|NCT03574701|Experimental|B: Vitamin A|Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
9476134|NCT03574701|No Intervention|C: Standard of Care|Group C: This study group will receive only standard of care .
9476135|NCT03574688|Experimental|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
9528747|NCT03208361|Active Comparator|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
9998378|NCT01517802|Experimental|Abiraterone acetate|Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
9998379|NCT01517815|Experimental|No overweight patient|Patient with weight less than or equal to 120kg
9998380|NCT01517815|Experimental|Overweight patients|Patient with weight more than 120kg
9998381|NCT01517828|Experimental|Ketamine Arm|Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
9998382|NCT01517828|Active Comparator|Midazolam Arm|Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
9998383|NCT01517841||Chronic kidney disease|Patients with chronic kidney disease (20% or less kidney function remaining. Patients with end stage renal disease who are currently receiving dialysis.
9998384|NCT01517854|Active Comparator|Revatio|
9998385|NCT01517854|Placebo Comparator|Placebo|
9998386|NCT01517906|Experimental|Cognitive behavioral counseling|
9998387|NCT01517906|Active Comparator|Supportive therapy|
9998388|NCT01517919|Experimental|Intervention: Peer Led Self-Management|Intervention: Peer Led Self-Management (PLSM) involves the DSME program followed by 12 months of peer-led ongoing self-management support
9998389|NCT01517919|No Intervention|Diabetes Self-Management Education|Control: Diabetes Self-Management Education (DSME) involves 12 sessions of self-management training including diabetes education, one-on-one sessions, bi-weekly phone contacts, and preparation for a clinic visit.
9998390|NCT01517932|Experimental|Group-DEX|Patients in this arm received dexmedetomidine 0.2 microgram per kg i.v. during 10 minutes 1 hour before the end of surgery
9998391|NCT01517932|Placebo Comparator|Group-PLB|Patients in this arm received saline placebo 0.05 ml per kilogram i.v. during 10 minutes 1 hour before the end of surgery
9998392|NCT01517958||Respiratory Distress Group|Neonates 28 weeks GA or greater with respiratory distress
9998393|NCT01517958||Control Group|Neonates 28 weeks GA or greater without respiratory distress.
9998394|NCT01517971||Ancillary-correlative (whole-genome expression)|RNA extracted from archived tumor tissue samples are analyzed for whole-genome expression profiling by Gene Profiling Array cGMP U133 P2 and RT-PCR.
9998395|NCT01517997|Experimental|Drug Coated Balloon (DCB) Arm|Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.
9998396|NCT01517997|Active Comparator|Drug Eluting Stents (DES) Arm|Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.
9998397|NCT01518010|Experimental|GamePlay|
9998398|NCT01518023||Cancer gastrectomy|Patients previously submitted to partial/total gastrectomy for gastric cancer
9998399|NCT01518023||Colorectal cancer operation|Patients previously submitted to right colectomy or rectosignoidectomy for cancer
9998400|NCT01518023||Bariatric patients|Morbidly obese participants who underwent antiobesity Roux-en-Y gastric bypass
9998401|NCT01518036|Experimental|Low dose|
9998402|NCT01518036|Experimental|High dose|
9998403|NCT01518062|Experimental|Low dose|
9998404|NCT01518062|Experimental|Medium dose|
9998405|NCT01518062|Experimental|High dose|
9998406|NCT01518075|Experimental|Non invasive mechanical ventilation|Evaluation of breathing swallowing interaction under non invasive mechanical ventilation
9998407|NCT01518075|Active Comparator|Spontaneous Breathing|Evaluation of breathing swallowing interaction without non invasive mechanical ventilation
9998408|NCT01518088|Experimental|Low dose dietary fiber|
9998409|NCT01518088|Experimental|High dose dietary fiber|
9998410|NCT01518088|Placebo Comparator|No added fiber|
9998411|NCT01518101|Experimental|Vildagliptin/Metformin followed by Liraglutide+Metformin|In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
9998412|NCT01518101|Experimental|Liraglutide + Metformin followed by Vildagliptin/Metformin|In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
9998413|NCT01518114|Experimental|Exercise Training|"Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.~Exercise prescription will be based upon cardiopulmonary test done at baseline."
9998414|NCT01518114|Active Comparator|Best Medical Care|Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.
9998415|NCT01518127|Experimental|stem cell group|intravitreal injection of autologous bone marrow stem cells
9998416|NCT01518140|Experimental|VapoTherm|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
9998417|NCT01518140|Experimental|BiPAP|"Participants receive air through bilevel positive airway pressure (BiPAP) for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
9998418|NCT01518140|Experimental|Non-Rebreather Mask|"Participants receive air through Non-Rebreather Mask for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using bilevel positive airway pressure (BiPAP)."
9998419|NCT01518166|Experimental|Trial period A|
9998420|NCT01518166|Experimental|Trial period B|
10034852|NCT01800526|Experimental|Oral N-acetylcysteine (NAC)|Eligible subjects who did not participate in Intravenous NAC or subjects who are at least 4 weeks after participation in Intravenous NAC, will be given Oral NAC at a dose of 2400mg daily, in two equally divided doses, for 4 weeks. Subjects will have blood drawn prior to beginning the phase and weekly for 4 weeks. At each visit interim medical events and adverse events will be collected.
10034853|NCT01800526|Experimental|Intravenous N-acetylcysteine (NAC)|"For part 1, Eligible subjects who did not participate in Oral NAC or subjects at least 4 weeks after oral NAC will receive IV NAC 150 mg/kg over 8 hours. At least four weeks after the first infusion, the subject will receive IV NAC 300 mg/kg over 8 hours.~For part 2, Eligible subjects with sickle cell disease and hospitalization for VOC within the past 2 years, who now present in VOC will be enrolled. Subjects will receive IV NAC 75 mg/kg over 1 hour every 6 hours for 5 days or discharge, whichever occurs earlier."
10034854|NCT01800539|Experimental|Provider Education Model (PEM)|condition wherein providers will receive specially structured training during their typical home visits based by Kennedy Krieger Institute (KKI) staff
10034855|NCT01800539|No Intervention|Treatment-as-Usual (TAU)|condition wherein providers continue with their existing practices
10034856|NCT01800565|Other|pubertal progression|A collection of first voided urine sample for the measurement of LH.
10034857|NCT01800578||Bispectral Index Group|
10034858|NCT01800591|No Intervention|Control Arm|No other financial incentive other than for enrollment, 6-month weigh in, and completion.
10034859|NCT01800591|Experimental|Delayed gratification|In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
9480623|NCT05262595|Active Comparator|Arm 4|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
9998421|NCT01518179|Experimental|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
9998422|NCT01518179|Other|Control|Routine follow up and treatment
9998423|NCT01518205|Experimental|LDL-apheresis and TT|"The patient of the experimental Arm, in addition to Traditional Therapy (TT), will undergo a cycle of 10 LDL-apheresis session.~Apheretic treatment scheme: 10 apheretic session carried out as follow: first and second apheresis with a 3 days interval (i.e. 2 treatment in one week), then one session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
9998424|NCT01518205|No Intervention|Traditional Treatment|"All patients will receive the traditional treatment for the ulcer healing Standardized medication.~All lesions taken into consideration will be treated in a standardized way, with a different approach according to the presence of a possible infection.~The evolution of lesions might be documented by means of mapping the same by drawing their profiles on an Opsite film.~antibiotics therapy (according to antibiogram). Anti-platelet therapy. Statin therapy."
9998425|NCT01518218|Experimental|laying-on-of-hands|Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
9998426|NCT01518218|No Intervention|control group|Patients of this arm did not receive any alternatives other than conventional treatment.
9998427|NCT01518231|Experimental|cell transplantation|The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
9998428|NCT01518231|No Intervention|Convention therapy|The control group just receive drug therapy.
9998429|NCT01518283|Experimental|Cabazitaxel|Drug: Cabazitaxel 10 mg/m2
9998430|NCT01518296|Experimental|Patients referred to urodynamic test|Patients that are referred to urogynecology and the pelvic reconstruction unit undergoes a physical gynecological examination and a urodynamic test, During which the degree of pelvic organs prolapse is evaluated with full and empty bladder.
9998431|NCT01518335|Experimental|Platelet Rich Plasma|Patients receive Platelet rich plasma injection + standard of care therapy(bandaging or boot and crutches) + non-NSAID pain medicine
9998432|NCT01518335|Placebo Comparator|Placebo/Standard of Care|Patient receives Placebo Comparator: Placebo/Standard of Care [saline injection + standard of care (bandaging or boot and crutches)] + non-NSAID pain medicine
9998433|NCT01518348|Experimental|Patch Test|
9998434|NCT01518387|Experimental|Arm 1|750-2250mg/day, tid, 8 weeks
9998435|NCT01518400||Eligible Population|Cancer Survivors of all ages (Must be diagnosed with cancer at 21 years or younger)
9998436|NCT01518413|Experimental|Combination Therapy|Three to 6 patient will be enrolled at each dose level and dose escalations will proceed in the absence of dose-limiting toxicity attributed to therapy, first with dose escalation of sorafenib and then, if tolerated, escalation of irinotecan.
9998437|NCT01518426|Experimental|Extraction of P300 ERPs|Extract P300 ERPs with Emotiv EEG headset
9998438|NCT01518439|Experimental|neuromuscular patients|neuromuscular patients with cough inefficiency in a stable respiratory state upon inclusion
9998439|NCT01518452|Experimental|working memory training|Cogmed JM working memory training
9936029|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
9936030|NCT02789657|Experimental|Optimal- 18 weeks|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
9998440|NCT01518452|Experimental|delayed working memory training|Cogmed JM working memory training after 8 weeks waiting
9998441|NCT01518465|Experimental|Arm I (5000 IU dalteparin)|Patients receive a prophylactic dose of dalteparin SC on days 1-28; lenalidomide PO on days 1-21; and low-dose dexamethasone PO on days 1, 8, 15, and 22.
9998442|NCT01518465|Experimental|Arm II (200 IU/kg dalteparin)|Patients receive a therapeutic dose of dalteparin SC on days 1-21 and lenalidomide PO and low-dose dexamethasone PO as in Arm I.
9998443|NCT01518478|Other|20 Non-atopic|Non-atopic, healthy control.
9998444|NCT01518478|Other|20 ADEH- (mild to severe AD)|Atopic Dermatitis without previous or current Eczema Herpeticum.
9936031|NCT02789657|Experimental|Sub-optimal with AC|12 weeks (4 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post 12 weeks, initiation of doxorubicin and cyclophosphamide for 4 cycles (6 weeks), followed by surgery.
9936032|NCT02789657|Experimental|Optimal with AC|Less than 18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab, followed by initiation of doxorubicin and cyclophosphamide. Post treatment, patients will undergo surgery.
9936033|NCT02789657|Experimental|Sub-optimal no AC|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
9936034|NCT02788227|Experimental|Boosted Group|Group randomized at Month 18 to receive booster vaccination
9936035|NCT02788227|Experimental|Non-boosted Group|Group randomized to no booster at Month 18
9936036|NCT02784210|Experimental|Methylprednisolone|3 day course of intravenous methylprednisolone 1000 mg/day
9936037|NCT02784210|Experimental|prednisone|3-day course of oral prednisone 1250 mg/day
9936038|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
9936039|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
9936040|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
9936041|NCT02773030|Experimental|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
9936042|NCT02773030|Experimental|Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
9936043|NCT02773030|Experimental|Cohort D: CC-220 in combination with Dexamethasone - Part 2|Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle
9998445|NCT01518491|Experimental|NanoDOX Hydrogel plus VAC|NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
9998446|NCT01518491|Active Comparator|VAC Alone|Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
9998447|NCT01518504|Experimental|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
9998448|NCT01518504|Sham Comparator|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
9998449|NCT01518543||ASTUS|Patient candidate for an arthrodesis in the following joints:Ankle,1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid, and whose surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA.
9998450|NCT01518569|Placebo Comparator|placebo|normal saline, same amount, iv
9998451|NCT01518569|Active Comparator|ulinastatin|5000 unit/kg iv
9998452|NCT01518582||Radiculopathy Cervical|Radiculopathy, Cervical
9998453|NCT01518595|Placebo Comparator|placebo|Patients will receive placebo tablets twice daily for 3 months.
9998454|NCT01518595|Active Comparator|bosentan|pts. will receive bosentan for 3 months
9998455|NCT01518621|Active Comparator|Radiotherapy alone|Total brain irradiation, 3Gy x10
9998456|NCT01518621|Experimental|Radiation plus erlotinib|Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation
9998457|NCT01518634|Experimental|Imipramine treatment|
9998458|NCT01518634|Placebo Comparator|Placebo|
9480624|NCT05262556|Experimental|TQ Formula + Nivolumab + Ipilimumab|
9936044|NCT02773030|Experimental|Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.~Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA.~Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle."
9936045|NCT02773030|Experimental|Cohort F: CC-220 with DEX and bortezomib - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle."
9936046|NCT02773030|Experimental|Cohort G1: CC-220 in combination with CFZ and DEX - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects > 75 years old, the DEX dose will be 20 mg
9936047|NCT02773030|Experimental|Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg
9936048|NCT02773030|Experimental|Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2|Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
9936049|NCT02773030|Experimental|Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above).~Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle."
9936050|NCT02773030|Experimental|Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle. Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle."
9936051|NCT02773030|Experimental|Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible|Part 2
9936052|NCT02773030|Experimental|Cohort C: CC-220 Monotherapy in RRMM|Part 2
9936053|NCT02771236||Affected Participants|Participants with inherited eye diseases
9936054|NCT02771236||Unaffected family members|Family members without eye disease
9936055|NCT02769975||Case Only|Children ages 0-18 with known or suspected endocrine or metabolism disorders.Family members ages 0-100. They may participate in the DNA part of the study
9936056|NCT02769962|Experimental|1/Phase I|EP0057 + olaparib
9936057|NCT02769962|Experimental|2/Phase II|EP0057 + olaparib at MTD/RP2D
9936058|NCT02769949||Family members|Family members (adult and pediatric; affected and unaffected) may be enrolled for the purpose of determining the molecular lesion(s) responsible for genetic disorders.
9936059|NCT02769949||Genetic disorders|subjects with genetic disorders
9936060|NCT02767986||Spanish-speaking Latinas|Women who speak Spanish as their primary language
9936061|NCT02759835|Experimental|Arm 1|osimertinib followed by LAT followed by osimertinib
9936062|NCT02759835|Experimental|Arm 2|LAT followed by osimertinib
9936063|NCT02759744|Experimental|1|ultrasound image-guided focal ablation
9936064|NCT02759731|Experimental|Arm 1|Baricitinib starting at a dose of 2mg daily for 12 weeks. If the response at 12 weeks is a CR and there has not been a DLT, the dose will be remain at 2mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks, the dose will be decreased to 1mg daily, and will continue at this dose as tolerated. If there has been DLT at this dose (1 mg), patients will be taken off treatment.
9936065|NCT02759731|Experimental|Arm 2|If the response is a PR or stable disease (from cohort 1), the dose will be increased to 4mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks will have a dose reduction back to 2mg daily. For patients who experience cGVHD progression at any time within the first 12 weeks on 2mg daily, the dose can be increased to 4mg daily until 24 weeks.
9936066|NCT02755584||Healthy Volunteers|between the ages of 20-39 years and 70 years old and older
9936067|NCT02755220|Experimental|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
9936068|NCT02748707|Experimental|Arm 1|Celecoxib 200mg twice daily for 21 days
9936069|NCT02748707|Experimental|Arm 2|Erlotinib 150 mg once daily for 21 days
9936070|NCT02748707|Experimental|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
9480625|NCT05262504||EDOF IOL Group|Patients who were implanted with the novel wavefront shaping extended depth of focus IOL
9936071|NCT02748707|Sham Comparator|Arm 4|Control group with no drug
9480626|NCT05262504||Multifocal IOL group|Patients who were implanted with the multifocal IOL
9528809|NCT03207217|Experimental|Phase II Efficacy|
9936072|NCT02743468||Healthy Volunteers|Healthy Volunteers
9936073|NCT02741440||Affected Participants|Twenty-five (25) participants with molecularly-confirmed SCA7
9936074|NCT02729727|Other|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
10214116|NCT01044069|Experimental|Pts with B Cell Acute Lymphoblastic Leukemia|This is a phase I study. Patients with CD19+ ALL (CR, relapsed, MRD, or refractory) are eligible for enrollment. B-ALL patients in first CR will be enrolled but only treated if they develop MRD or a frank relapse, while patients with MRD or with documented relapsed/refractory disease are eligible for immediate treatment. The T cell doses originally proposed in this study were based on doses administered safely in prior autologous T cell adoptive therapy trials but the dose has been modified based on the toxicities observed in patients with morphologic evidence of disease. Patients will be treated with different doses of T cells depending on the amount of disease at the time of T cell infusion. Patients in Cohort 1 (<5% blasts in the BM) will continue to receive 10^6 19-28z+ T cells/kg as previously. Patients in Cohort 2 (≥5% blasts in the BM) will receive the reduced dose of 1x106 19-28z+ T cells/kg).
10214117|NCT00988260|Experimental|Ganirelix 0.125 mg|
9936075|NCT02719899||1|Healthy Volunteers
9936076|NCT02715388|Experimental|Silicon oil removal 3D visualization|
10214118|NCT00988260|Experimental|Ganirelix 0.25 mg|
10214119|NCT00988260|Experimental|Ganirelix 0.5 mg|
10214120|NCT00984321|Experimental|Psychoeducational Intervention Group|
10214121|NCT00984321|Experimental|Expressive Writing Intervention|
10214122|NCT00984321|Active Comparator|Control Group|
10214123|NCT00974571|Experimental|1|montelukast
10214124|NCT00974571|Active Comparator|2|cetirizine
10214125|NCT00974571|Placebo Comparator|3|placebo
10214126|NCT00972738|Experimental|1|montelukast
10214127|NCT00972738|Active Comparator|2|loratadine
10214128|NCT00972738|Placebo Comparator|3|placebo
10214129|NCT00968201|Experimental|1|Montelukast
10214130|NCT00968201|Placebo Comparator|2|Placebo
10214131|NCT00968149|Experimental|1|Montelukast
10214132|NCT00968149|Placebo Comparator|2|Placebo
10214133|NCT00967577|Experimental|J591|
10214134|NCT00963469|Experimental|1|montelukast
10214135|NCT00963469|Active Comparator|2|loratadine
10214136|NCT00963469|Placebo Comparator|3|placebo
10214137|NCT00960141|Experimental|1|montelukast
10214138|NCT00960141|Active Comparator|2|loratadine
10214139|NCT00960141|Placebo Comparator|3|placebo
10214140|NCT00943683|Experimental|1|Montelukast
10214141|NCT00943683|Placebo Comparator|2|Placebo
10214142|NCT00943397|Experimental|1|Montelukast
10214143|NCT00943397|Active Comparator|2|Usual Care
10214144|NCT00937937|Experimental|Arm I|Patients receive dinaciclib IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
10214145|NCT00935519|Other|ceramic bearing|Survival rate of THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
10214146|NCT00911547|Experimental|1|Montelukast + Beclomethasone
10214147|NCT00911547|Experimental|2|Montelukast + Placebo inhaler
10214148|NCT00911547|Experimental|3|Placebo tablet + Beclomethasone
10214149|NCT00911547|Placebo Comparator|4|Placebo tablet + Placebo inhaler
10214150|NCT00909909|Active Comparator|A|3DCRT/IMRT lumpectomy bed boost followed by accelerated whole breast irradiation (AWBI)
10214151|NCT00909909|Active Comparator|B|Accelerated whole breast irradiation (AWBI) followed by 3DCRT/IMRT lumpectomy bed boost
10214152|NCT00899379|Experimental|Treatment Sequence 1|Placebo-Rizatriptan-Rizatriptan-Rizatriptan
10214153|NCT00899379|Experimental|Treatment Sequence 2|Rizatriptan-Placebo-Rizatriptan-Rizatriptan
10214154|NCT00899379|Experimental|Treatment Sequence 3|Rizatriptan-Rizatriptan-Placebo-Rizatriptan
10214155|NCT00899379|Experimental|Treatment Sequence 4|Rizatriptan-Rizatriptan-Rizatriptan-Placebo
10214156|NCT00899379|Experimental|Treatment Sequence 5|Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan
10214157|NCT00898677|Experimental|1|rizatriptan 5 mg
10214158|NCT00898677|Experimental|2|rizatriptan 10 mg
10214159|NCT00898677|Active Comparator|3|sumatriptan 100 mg
10214160|NCT00898677|Placebo Comparator|4|placebo
10214161|NCT00897949|Experimental|Rizatriptan 10 mg|
10214162|NCT00897949|Experimental|Rizatriptan 5 mg|
10214163|NCT00897949|Placebo Comparator|Placebo|
10214164|NCT00897104|Experimental|1|Rizatriptan
10214165|NCT00897104|Experimental|2|Sumatriptan
10214166|NCT00897104|Placebo Comparator|3|Placebo
10214167|NCT00817817|Experimental|Group 1|
10214168|NCT00817817|Experimental|Group 2|
10214169|NCT00809588|Experimental|Melanoma Vaccine|GM-CSF Vaccine
10214170|NCT00803790|Experimental|Sequence 1- alendronate+vitamin D combination then alendronate|Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.
10214171|NCT00803790|Experimental|Sequence 2 alendronate then alendronate+vitamin D combination|Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
10214172|NCT00803790|Experimental|Sequence 3 alendronate+vitamin D combination then vitamin D|Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.
9936077|NCT02711137|Experimental|Part1/Treatment Group A : 8mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
9936078|NCT02711137|Experimental|Part1/Treatment Group A : 12mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
9936079|NCT02711137|Experimental|Part1/Treatment Group A : 16mg QD INCB057643|"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA.~Treatment Group A included solid tumors and lymphoma"
9936080|NCT02711137|Experimental|Part1/Treatment Group B : 8mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF
9936081|NCT02711137|Experimental|Part1/Treatment Group B : 12mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF.
9936082|NCT02711137|Experimental|Part1/Treatment Group C : 8mg QD INCB057643|Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group C (TGC), based on protocol-specific criteria. Treatment Group C includes subjects with MM
9936083|NCT02711137|Experimental|Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort|Initial cohort dose of INCB054763 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group A (TGA), based on protocol-specific criteria. Part 2 Treatment Group A expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
9936084|NCT02711137|Experimental|Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort|Initial cohort dose of INCB057463 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group B (TGB), based on protocol-specific criteria. Part 2 Treatment Group B expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.
9936085|NCT02711137|Experimental|Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg|Initial cohort dose of INCB057643 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Gemcitabine) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies where Gemcitabine is relevant
9936086|NCT02711137|Experimental|Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Paclitaxel) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
9936087|NCT02711137|Experimental|Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Rucaparib) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.
9998459|NCT01518647|Experimental|Group Therapy|ACT given as conventional group therapy in groups of 7-8 patients 3,5 hours each session, 9 sessions during 3 month
9998460|NCT01518647|Experimental|Workshop|ACT given as a one-day workshop with 15 patients with a following individual consultation
9998461|NCT01518647|Active Comparator|Standard treatment|Standard treatment is one single advisory consultation given 2 weeks after randomization
9998462|NCT01518660|Experimental|Training|
9998463|NCT01518660|No Intervention|Control|
9998464|NCT01518686|No Intervention|one arm|observational study, no cohort, single group of different ages
9998465|NCT01518712|Experimental|Treatment Sequence AB|
9998466|NCT01518712|Experimental|Treatment Sequence BA|
9998467|NCT01518725|Experimental|Vitamin D Supplementation|The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day.
9998468|NCT01518725|Placebo Comparator|Gel-like Substance|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
9998469|NCT01518738|Experimental|breath attention training|
9998470|NCT01518738|Active Comparator|working memory attention training|
9998471|NCT01518738|No Intervention|no training|
9998472|NCT01518764|Experimental|Red Wine Polyphenols|Red Wine Polyphenols 600mg/day (capsules)
9998473|NCT01518764|Placebo Comparator|placebo|placebo (capsules)
9998474|NCT01518777|Other|Half-dose isotope for NuclearStressTest|"Intervention is Nuclear stress test of the heart. Single-arm of this study Half-dose of isotope for Nuclear stress test is group of study subjects who will do Research Nuclear stress test with half-dose of isotope that normally used for routine Nuclear stress test. Isotope is the tracer CZT (cadmium zinc telluride) that used for Nuclear stress test routinely to see the function of arteries of the heart. Patients with suspected Coronary Artery Disease who meet entry criteria undergo a research nuclear stress test using a decreased dose of isotope, using a new camera."
9998475|NCT01518790|Experimental|Polyethylene glycol 3350|
9998476|NCT01518803|Active Comparator|Mediterranean-style breakfast|
9998477|NCT01518803|Active Comparator|Western-style breakfast|
9998478|NCT01518816||preterm labor cases|Group A: 35 pregnant women diagnosed with preterm labor(Preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation < 2cm and effacement< 50%) which will deliver within one week maximum after hospitalization.
9998479|NCT01518816||control group|Group B: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit.
9998480|NCT01518829||Patients with hepatocellular carcinoma|Patients with hepatocellular carcinoma who will undergo locoregional therapy
9998481|NCT01518829||patients with chronic liver disease|patients with chronic liver disease, as a control group
9998482|NCT01518842|Experimental|test group intravitreal stem cell|"Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.~Intervention: Biological: intravitreal injection of autologous bone marrow stem cells"
9998483|NCT01518855|Experimental|Arm 1|Adalat CR 20-40mg od + Diovan 40-80mg od
9998484|NCT01518855|Active Comparator|Arm 2|Norvasc 2.5-5mg od + Diovan 40-80mg od
9998485|NCT01518881|Experimental|TKM-100201|
9998486|NCT01518881|Placebo Comparator|Placebo|
9998487|NCT01518894|Experimental|PF-04958242|
9998488|NCT01518894|Placebo Comparator|Placebo|
9998489|NCT01518907|Experimental|AA4500 0.0029 mg in 1 mL|
9998490|NCT01518907|Experimental|AA4500 0.0145 mg in 5 mL|
9998491|NCT01518907|Experimental|AA4500 0.0145 mg in 1 mL|
9998492|NCT01518907|Experimental|AA4500 0.0435 mg in 5 mL|
9998493|NCT01518907|Experimental|AA4500 0.0435 mg in 1 mL|
9998494|NCT01518907|Experimental|AA4500 0.116 mg in 5 mL|
9998495|NCT01518907|Experimental|AA4500 0.116 mg in 1 mL|
9998496|NCT01518907|Experimental|AA4500 0.232 mg in 5 mL|
9998497|NCT01518907|Experimental|AA4500 at 0.232 in 1 mL|
10214173|NCT00803790|Experimental|Sequence 4- vitamin D then alendronate+vitamin D combination|Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
10214174|NCT00792506|Experimental|ITF2357|Eligible patients had to be treated with weekly single doses of ITF2357 according to the above mentioned treatment plan.
10214175|NCT00773357|Experimental|Guanfacine|guanfacine 3mg/day
10214176|NCT00773357|Placebo Comparator|Placebo|placebo control
9998498|NCT01518907|Experimental|AA4500 0.464 mg in 5 mL|
10214177|NCT00773357|Experimental|Carvedilol|Carvedilol 50 mg/day
10214178|NCT00745108|Experimental|Tibolone 1.25 mg|
10214179|NCT00745108|Experimental|Tibolone 2.5 mg|
10214180|NCT00745108|Active Comparator|CE/MPA|
10214181|NCT00725491|Experimental|1|ganirelix
10214182|NCT00725491|Active Comparator|2|triptorelin
10214183|NCT00725374|Active Comparator|Arm 1|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with tibolone
10214184|NCT00725374|Placebo Comparator|Arm 2|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with placebo
10214185|NCT00724789||Observational Cohort|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone/ganirelix followed by in vitro fertilization or intra cytoplasmatic sperm injection.
10214186|NCT00724789||Historical Controls|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone in a long protocol with a gonadotropin releasing hormone agonist followed by IVF or ICSI
10214187|NCT00711607|Experimental|1|Group 1: NOMAC-E2 (days 1-24 and day 35)
10214188|NCT00711607|Placebo Comparator|2|Group 2: NOMAC-E2 (days 1-24) followed by Placebo (day 35)
9998499|NCT01518907|Experimental|AA4500 0.464 mg in 1 mL|
9998500|NCT01518920|Experimental|PF-04958242|
9998501|NCT01518920|Placebo Comparator|Placebo|
9998502|NCT01518933|Experimental|Silibilin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
9998503|NCT01518933|Placebo Comparator|Saline|Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
9998504|NCT01518959|Placebo Comparator|Placebo|no treatment
9998505|NCT01518959|Active Comparator|Cholecalcipherol|Treatment with 180 000 IU cholecalcipherol monthly
9998506|NCT01518985|Placebo Comparator|Placebo|Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
9998507|NCT01518985|Experimental|Bendavia|Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
9998508|NCT01518998|Placebo Comparator|Placebo|Take one double-blind capsule filled with a placebo tablet in the every morning
9998509|NCT01518998|Active Comparator|Fimasartan 60mg|Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
9998510|NCT01518998|Active Comparator|Fimasartan 30mg|Take one double-blind capsule filled with Fimasartan 30mg in the every morning
9998511|NCT01518998|Active Comparator|Amlodipine 5mg|Take one double-blind capsule filled with Amlodipine 5mg in the every morning
9998512|NCT01518998|Active Comparator|Amlodipine 10mg|Take one double-blind capsule filled with Amlodipine 10mg in the every morning
9998513|NCT01518998|Experimental|Fimasartan 60mg/ Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
9998514|NCT01518998|Experimental|Fimasartan 60mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
9998515|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
9998516|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning
9998517|NCT01519011|Experimental|1: A, B, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
9998518|NCT01519011|Experimental|2: B, C, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
9998519|NCT01519011|Experimental|3: C, A, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
9998520|NCT01519011|Experimental|4: B, A, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
9998521|NCT01519011|Experimental|5: A, C, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
9998522|NCT01519011|Experimental|6: C, B, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
9998523|NCT01519011|Experimental|Extension|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
9998524|NCT01519024||Women with breast hypertrophy|Fourteen women with breast hypertrophy
9998525|NCT01519024||Women without breast hypertrophy.|Fourteen women without breast hypertrophy for de control group (CG).
9998526|NCT01519037|Active Comparator|calcimimetic agent (cinacalcet)|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or the placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
9998527|NCT01519037|Placebo Comparator|Placebo|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
9998528|NCT01519102|Active Comparator|CHO-independent partial insulin bolus with closed-loop|
9998529|NCT01519102|Active Comparator|CHO-dependent full insulin bolus combined with closed-loop|
9998530|NCT01519115|Active Comparator|Usual care|usual care of one physical therapy visit in hospital after ACF surgery
9528810|NCT03207217|Experimental|Phase II Acceptability|
9998531|NCT01519115|Experimental|Early physical therapy intervention|early physical therapy program instructed and followed at home for 6 weeks
9998532|NCT01519128|Experimental|Treatment sequence AB|In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1. In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11.
9998533|NCT01519128|Experimental|Treatment sequence BA|In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11. In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1.
9998534|NCT01519154|Active Comparator|Propofol|Propofol 10 mg/h as maintenance infusion
9998535|NCT01519154|Experimental|Ketamine-Propofol|Additional Ketamine at induction, Propofol 5 mg/h as maintenance infusion
9998536|NCT01519180||Control group|Healthy volunteers
9998537|NCT01519180||Idiopathic gastroparesis|Idiopathic gastroparesis
9998538|NCT01519193|Experimental|Narrative Exposure Therapy|
9998539|NCT01519193|No Intervention|No treatment control|
9998540|NCT01519219||Hepatic Irradiation|
9998541|NCT01519232||Liver Irradiation|patients already scheduled to undergo liver irradiation
9936088|NCT02711137|Experimental|Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Abiraterone + Prednisone) in Castration Resistant Prostrate Cancer
9936089|NCT02711137|Experimental|Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Ruxolitinib) in Myelofibrosis.
9936090|NCT02711137|Experimental|Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg|Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Azacitidine) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
9936091|NCT02709226|Experimental|1/Radiation|Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
9936092|NCT02707042|Other|Group A|Control
9936093|NCT02707042|Other|Group B|Amoxicillin
9936094|NCT02707042|Other|Group C|Azithromycin
9936095|NCT02706652||all patients|all eligible patients
9936096|NCT02706639||SVAS group|Children or adults must:be between the ages of 0-85; have clinical features of SVAS; SVAS-like condition; have genetic testing results that imply affected status (SVAS has decreased penetrance)
9936097|NCT02706639||WS group|Children or adults must: be between the ages of 0 and 85 have a presumed or confirmed diagnosis of WS; have a parent/guardian available to provide consent and assist in answering medical questions
9936098|NCT02706639||WS region gene changes|Children or adults must: be between the ages of 0-85; have clinical or research genetic testing that reports gene variation in one or more genes in the WS region (ELN variants alone will be considered in the SVAS category but other changes to the region that include ELN plus other genes may be grouped in this category).
9936099|NCT02703584|Experimental|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
9936100|NCT02703584|Placebo Comparator|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
9936101|NCT02694783|Experimental|Treatment Arm|ex vivo generated polyomavirus-specific T cells from HLAmatched donor
9936102|NCT02692924||NICHD Fetal Growth Studies Singletons and NICHD Fetal Growth Studies Dichor|Analysis of stored ultrasound data collected from the NICHD Fetal Growth Studies - Singletons and NICHD Fetal Growth Studies - Dichoronic Twins
9936103|NCT02692885||Healthy Volunteers|Individuals known to have brown adipose tissue, identified by PET/CT following participation/scanning in other clinical studies
9936104|NCT02692885||Surgical Patients|Individuals undergoing planned, clinically-indicated surgeries
9936105|NCT02692872||1|We plan to perform genetic screening of up to 2,000 individuals of African ancestry, an ethnic group with a high prevalence of alpha thalassemia.
9936106|NCT02692846||Control participants with connective tissue disease|Not have a diagnosis of WS. Have a clinical or molecular diagnosis of connective tissue disease, between the ages of 1 and 70 years old
9936107|NCT02692846||Unaffected Control participants|Not have a diagnosis of WS or other connective tissue disease, between the ages of 1 and 70 years old
9936108|NCT02692846||WS participants|Have diagnosis of WS, between the ages of 5 and 70 years old. Be able to tolerate blood pressure measurements.
9936109|NCT02689466||cervical dystonia|clinically documented cervical dystonia (focal cervical or segmental with neck involvement) established by history and physical/neurological examination, at least 18 years old.
9936110|NCT02689466||healthy volunteers|age and sex matched healthy volunteers, at least 18 years old.
9936111|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
9936112|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
9936113|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency.
9936114|NCT02679144|Experimental|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
9936115|NCT02669251|Experimental|Phase 1b|Phase Ib dose escalation
9936116|NCT02669251|Experimental|Phase 2|MTD po bid on days 1-28
9936117|NCT02669225|Experimental|Rested Wakefulness|RW PET/MR Scanning Sessions
9936118|NCT02669225|Experimental|Sleep Deprivation|SD PET/MR Scanning Sessions
9936119|NCT02669212|Other|1|MRI RadiofrequencyCoils, TMS
9936120|NCT02664402||Adults|English speaking, physician diagnosed with a life threatening illness.
9936121|NCT02662907|Experimental|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
9936122|NCT02662907|Other|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
9936123|NCT02659956||Individuals without known CNS disease|Family members of patient participants
9936124|NCT02659956||Patient controls|a target population of 50 patient controls will also be enrolled. These individuals will have diseases that share clinical, imaging, or biological features with MS.
9936125|NCT02659956||Patients with multiple sclerosis|Up to 150 adults (age >= 18) with MS, diagnosed by applicable consensus criteria, and by the best judgment of the investigators, at the time of enrollment.
9936126|NCT02659930|Experimental|1/Group 1|Pomalidomide and liposomal doxorubicin given at escalating doses to patients with KS requiring systemic therapy
9936127|NCT02659930|Experimental|2/Group I; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS requiring systemic therapy
9936128|NCT02659930|Experimental|3/Group II|Pomalidomide with liposomal doxorubicin given at escalating doses in to patients with advanced KS or KS and concurrent KSHV-associated MCD or KICS requiring systemic therapy
9936129|NCT02659930|Experimental|4/Group II; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS or KS with concurrent KSHV-associated MCD or KICS requiring systemic therapy
9936130|NCT02656381||Anterior Uveitis|Participants with AU at entry
9936131|NCT02656381||Intermediate Uveitis|Participants with IU at entry
9936132|NCT02656381||Other|Participants not fitting above criteria
9936133|NCT02656381||Posterior/Pan Uveitis|Participants with non-infectious posterior or pan-uveitis
9936134|NCT02649868|Experimental|1|Treatment of hepatic tumors using bead embolization.
9936135|NCT02649868|Experimental|2|Treatment of hepatic tumors using bead embolization
9936136|NCT02639325||Patients|Patients who have solitary primary or recurrent brain tumor with associated seizures.
9936137|NCT02639312||1|hemifacial microsomia
9936138|NCT02639312||2|mandibular prognathism
9936139|NCT02639299||Healthy volunteer|healthy, malaria-na(SqrRoot) ve US adults
9936140|NCT02639273|Experimental|Drug|single dose nalmefene
9936141|NCT02639273|Placebo Comparator|Placebo|single dose placebo
9936142|NCT02639260|Experimental|Cohort A|3,000 mg/day
9936143|NCT02639260|Experimental|Cohort B|10,000 mg/day
9936144|NCT02630459|Placebo Comparator|Double Blind Treatment Phase (DBTP): Placebo|Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
9936145|NCT02630459|Experimental|DBTP: Erenumab 28 mg QM|Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
9936146|NCT02630459|Experimental|DBTP: Erenumab 70 mg QM|Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
9936147|NCT02630459|Experimental|DBTP: Erenumab 140 mg QM|Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
9936148|NCT02630459|Experimental|Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM|Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board [IRB] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.
9936149|NCT02630459|Experimental|CHU Sub-Study: Two 70 mg/mL AI/pens|A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study
9936150|NCT02630459|Experimental|CHU Sub-Study: One 140 mg/mL AI/pen|A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study
9936151|NCT02630043|Experimental|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
9936152|NCT02629107||Healthy Volunteers|Healthy volunteers, age 18-34.
9936153|NCT02622035|Experimental|1|Gain frame; Anger
9936154|NCT02622035|Experimental|1b|high visual perception load high interactive
9936155|NCT02622035|Experimental|2|Gain frame; Fear
9936156|NCT02622035|Experimental|2b|high visual perceptual load
9936157|NCT02622035|Experimental|3|Loss frame; Anger
9936158|NCT02622035|Experimental|3b|low visual preceptual load
9936159|NCT02622035|Experimental|4|Loss frame; Fear
9936160|NCT02621021|Experimental|1/ACT TIL|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2)
9936161|NCT02621021|Experimental|2/ACT TIL + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2) + pembrolizumab
9936162|NCT02617966||Affected|Participants with retinal disease
9936163|NCT02617966||Unaffected|Healthy volunteers
9936164|NCT02610465||1|Computed Tomography (CT) images
9936165|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
9936166|NCT02595957||Cascade Testing|Family members of individuals who have received secondary genomic findings after exome/genome sequencing
9936167|NCT02595957||Secondary findings recipients|Individuals who have received secondary genomic findings after exome/genome sequencing
9936168|NCT02594215|Experimental|Experimental|Experimental
9936169|NCT02594202||1|Adults (= 18 years of age) with biopsy-proven or suspected prostate cancer
9936170|NCT02586857|Experimental|Cohort 1|ACP-196 200 mg administered orally (PO) twice per day (BID)
9936171|NCT02586857|Experimental|Cohort 2|ACP-196 400mg administered orally (PO) once per day (QD).
9936172|NCT02586597|Experimental|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
9936173|NCT02586597|Experimental|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
9936174|NCT02586597|Sham Comparator|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
9936175|NCT02583646||normal weight|Girls age 8-14 below 85% in respect to weight for their age group
9936176|NCT02583646||overweight|Girls age 8-14 at or above 85% in respect to weight for their age group
9936177|NCT02579967|Experimental|1/ IOC Arm-Closed with amendment L (07/05/2019)|Immunosuppression Only Conditioning Arm
9936178|NCT02579967|Experimental|2/ RIC Arm - Closed with Amendment L (07/05/2019)|Reduced Intensity Conditioning Arm
9936179|NCT02579967|Experimental|3/ MAC Arm-Closed with amendment L (07/05/2019)|Myeloablative Conditioning Arm
9936180|NCT02579967|Experimental|4/RIC-MMF Arm|Reduced Intensity Conditioning with MMF duration de-escalation design
9936181|NCT02579967|No Intervention|5/Donor Arm|Donor
9936182|NCT02578875||Sample|Discarded patient samples and autopsy material
9936183|NCT02575976|Experimental|comprehensive CR|education and exercise-based cardiac rehabilitation
9936184|NCT02575976|Active Comparator|exercise-based CR|Exercise-based cardiac rehabilitation
9936185|NCT02575976|Other|wait list control|no cardiac rehabilitation
9936186|NCT02573324|Experimental|ABT-414, Radiation and Radiation/Temozolomide (TMZ)|ABT-414 is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. ABT-414 is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
9936187|NCT02573324|Placebo Comparator|Placebo, Radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
9936188|NCT02565004||1|Patients who were enrolled on protocol 09-C-0079, or family members of patients who were enrolled on protocol 09-C-0079
9936189|NCT02565004||2|Individuals found to harbor a germline APC promoter 1B variant not previously enrolled in Cohort l.
9936190|NCT02564991||Healthy Controls|125 non-substance abusing controls (NSAC)
9936191|NCT02564991||Individuals with Alcohol Use Disorder|This group includes individuals who enrolled NIAAA alcohol treatment.
9936192|NCT02564978|Experimental|Minocycline|Oral administration of minocycline.
9936193|NCT02559778|Active Comparator|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
9476136|NCT03574675|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
9936194|NCT02559778|Active Comparator|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.
9936195|NCT02545868|Experimental|Group A: OCR + Vaccines|Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
9936196|NCT02545868|Other|Group B: Vaccines (Optional OCR in Extension)|Participants will receive immunizations (TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH) on Day 1 until Week 12 of the immunization period. Participants who complete the 12-week immunization study period will have the option to receive two single infusions of OCR 300 mg, on Day 84 and Day 98, and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
9936197|NCT02544022||1/Phase 1 Focus Group|Patients with NF1 who have PNs and report experiencing pNF related pain and parents of these patients. (completed)
9936198|NCT02544022||2/Phase 1 Patients|Patients with NF1 who have pNFs(completed)
9936199|NCT02544022||3/Phase 1 Parent|Parents of patients in cohort 2 (completed)
9936200|NCT02544022||4/Phase 2 Patients|Patients with NF1 who have pNFs and recent pNF-related pain
9936201|NCT02544022||5/Phase 2 Parents|Parents of patients (ages 8-17 years) enrolled in cohort 4
9936202|NCT02544009||1|16 subjects who previously participated in the Biggest Loser study
9936203|NCT02543996||Affected or unaffected cohorts (including genetic carriers or non-carriers as|Affected or unaffected cohorts (including genetic carriers or non-carriers as reference biospecimens)
9936204|NCT02543983|Experimental|1|Participants will be administered open-label intravenous ketamine.
9936205|NCT02535702|Experimental|Attentional Bias Task|Subjects will briefly see two images side by side on a screen. Immediately after, a dot appears on the left or on the right. The subjects task is to press the left or right button, following the position of the image (left or right). Images can contain food-related items. We will also show short 1-minute food-related movies. Subjects will be asked to fast for three hours before this task begins.
9936206|NCT02535702|Experimental|Cue Reactivity Task|In this task subjects will view pictures of various items on the screen in front of them. Subjects will rate the items by how much they would like to have them. Subjects will choose how much they want the item by pressing a button.
9936207|NCT02535702|Experimental|Delay Discounting Task|Subjects will be asked to imagine whether they would receive money now or money later (in the future). The future money option may be several days from now or as far out as 6 weeks from now. For example, a s ubject may see a $100 option in 6 weeks or a $10 option now. Subjects will not receive actual money for participation in this task
9936208|NCT02535702|Experimental|Motivational Reward Task|Subjects will make a choice among some items presented on the screen in front of them. One of the items will be the winner item. The other items will be loser items. Each time a subject is presented with various items, they will choose the item they think is the winner item. Subjects will start with bonus points at the beginning of the task, so they can add more points to this amount as they continue to choose winner items.
9476137|NCT03574675|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
9800529|NCT01690520|Active Comparator|Arm I (standard of care)|"CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit."
9800530|NCT01690520|Experimental|Arm II (experimental)|"CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm."
9800531|NCT01690546|Experimental|BUP/VLNXT to VIVITROL|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
9800532|NCT01690663|Placebo Comparator|Bupivacaine 0.25% mixed with 1ml normal saline|Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)
9800533|NCT01690663|Active Comparator|Bupivacaine 0.25% with 1mg dexamethasone (1ml)|Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)
9800534|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 2mg dexamethasone|Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)
9800535|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml|Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml
9800536|NCT01690923|Experimental|Nasal Mask First, then Pillows Mask|"Nasal mask is used for 7 nights, then followed by Pillows mask for 7 nights.~[Nasal mask=Mirage Activa, Micro, FX; Pillows mask=Swift FX]"
9800537|NCT01690923|Experimental|Pillows Mask, then Nasal Mask|Pillows mask for 7 nights, then followed by Nasal mask is used for 7 nights. [Nasal mask=MMirage Activa, Micro, FX; Pillows mask=Swift FX]
9800538|NCT01690988|Experimental|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
9800539|NCT01690988|Placebo Comparator|Normal saline (placebo)|Intravenous normal saline
9800540|NCT01690988|Experimental|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
9800541|NCT01691014||adalimumab|
9800542|NCT01691014||Etanercept|
9800543|NCT01691014||infliximab|
9800544|NCT01691014||Certolizumab|
9800545|NCT01691027|Experimental|Visuo-motor training for low vision|All participants undergo training on scotoma awareness, Line and Circle Tracing and Video games
9800546|NCT01691092|Experimental|Ketamine|All subjects will receive ketamine
9803207|NCT04421560|Experimental|Pembrolizumab + Ibrutinib + Rituximab|"Phase 1b~Dose escalation will occur using a standard 3+3 dose-escalation approach, beginning at dose level I (560 mg daily) and potentially escalating to dose level 2 (840mg) with rules for escalation and de-escalation.~Ibrutinib: orally 2x daily~Pembrolizumab: 200 mg intravenously every 3 weeks~Rituximab/biosimilar: 375mg/m^2 intravenously once per week for 4 weeks (4 total doses).~Phase 2~Participants will receive Pembrolizumab, Rituximab and Ibrutinib at the pre-determined dosage level established in Phase 1b.~Ibrutinib: orally maximum tolerated dose from phase 1 daily (560 mg or 840mg)~Pembrolizumab: 200 mg intravenously every 3 weeks~Rituximab/biosimilar: 375 mg/m^2 intravenously once per week for 4 weeks (4 total doses)."
9803208|NCT04420182|Other|COVID-19 Virtual Care at Home|"VIRTUES COVID-19 Care at Home Platform~The components of the platform will include:~Vital sign monitoring, including O2 saturation with a home-based pulse oximeter, temperature and respiratory rate performed three times per day (a notification to do this will be sent from the app), with the option of doing assessments more frequently if needed. Study patients will be provided monitoring devices to collect this data.~Symptom logs will be entered by the patients.~Feedback to the patient by the local COVID-19 care team for any action:~Two-way communication between the patient and the COVID-19 care team~Ability for team members to see all prior notes in order to have continuity of care~Reports of these interactions are transmitted to the patient's health record~Current information on COVID-19 as per the Public Health Agency of Canada"
9803209|NCT04417166|Experimental|Pembrolizumab and Radiotherapy|"Induction Phase:~Standard Involved Field Radiation Therapy (IFRT) and pembrolizumab. Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 6 cycles. IFRT will start at first cycle of Pembrolizumab and will be delivered concurrently.~Patients with complete remission (CR), partial response (PR) and stable disease (SD) after Induction Phase will continue with pembrolizumab maintenance.~Maintenance Phase:~Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle up to 34 cycles or until disease progression or unaccepted toxicity"
9803210|NCT04413344|Active Comparator|Active|
9803211|NCT04413344|Placebo Comparator|Placebo|
9803212|NCT04409080|Experimental|Part A and Part B|Part A: Single ascending dose Part B: Preferred dose
9803213|NCT04408196||Patients|100 patients admitted to an inpatient rehabilitation facility
9803214|NCT04408196||Caregivers|100 caregivers of patients admitted to an inpatient rehabilitation facility
9803215|NCT04404465||Control Group|Participants undergoing electrophysiologic (EP) study or ablation for supraventricular tachycardia (SVT) with no history of AF and does not meet criteria of At Risk Group or AF Group
9998542|NCT01519258|Active Comparator|PSV|Patients will be ventilated with the a conventional mode of ventilation called Pressure Support Ventilation (PSV) for 15 minutes. Mechanical ventilator settings will be set to match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
9476138|NCT03574662|Experimental|Frailty assessment in Advanced heart failure|Subjects with advanced heart failure defined as current or recent (within the last 3 months) New York Heart Association (NYHA) class III or IV symptoms.
9476139|NCT03574649|Experimental|NANT NSCLC Combination Immunotherapy regimen|
9476140|NCT03574649|Active Comparator|Standard of Care|
9800547|NCT01691105|No Intervention|Academic Detailing (AD)|Standard of care for patients who are smokers and admitted to the hospital.
9800548|NCT01691105|Experimental|AD + Integrated Tobacco Order Set|Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
9800549|NCT01691248|Active Comparator|Fidaxomicin|200 mg Fidaxomicin tablet once daily for no longer than 40 days
9800550|NCT01691248|Placebo Comparator|Placebo|Placebo tablet once daily for no longer than 40 days
9800551|NCT01691313|Experimental|vanoxerine 200mg|vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
9800552|NCT01691313|Placebo Comparator|placebo|placebo to match vanoxerine oral capsule
9800553|NCT01691313|Experimental|vanoxerine 300mg|vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
9800554|NCT01691313|Experimental|vanoxerine 400mg|vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)
9800555|NCT01691326|Experimental|6 months to < 36 months of age group|Participants at 6 months to < 36 months of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone® (Pediatric Dose).
9800556|NCT01691326|Experimental|3 years to < 9 years of age group|Participants at 3 years to < 9 years of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone®.
9800557|NCT01691339|Experimental|Fluzone vaccine (Group 1)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
9800558|NCT01691339|Experimental|Fluzone Intradermal vaccine (Group 2)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone Intradermal vaccine intradermally
9800559|NCT01691339|Experimental|Fluzone vaccine (Group 3)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
9800560|NCT01691339|Active Comparator|Fluzone High-Dose Vaccine (Group 4)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone High-Dose vaccine intramuscularly
9800561|NCT01691378|Experimental|WtoH Intervention|Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
9800562|NCT01691378|Other|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
9800563|NCT01691430|Active Comparator|2 cranberry capsules|Experimental: 2 cranberry capsules
9800564|NCT01691430|Placebo Comparator|2 placebo capsules|Experimental: 2 placebo capsules qd
9800565|NCT01691482|Active Comparator|Albuterol/salbutamol followed by ipratropium|Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
9800566|NCT01691482|Active Comparator|Ipratropium followed by albuterol/salbutamol|Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium
9800567|NCT01691508|Experimental|Mepolizumab|Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20
9800568|NCT01691508|Experimental|Placebo|Placebo subcutaneous once every 4 weeks upto Week 20
9800569|NCT01691521|Experimental|Mepolizumab IV|Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
9800570|NCT01691521|Experimental|Mepolizumab SC|Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
9800571|NCT01691521|Placebo Comparator|Placebo|Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
9800572|NCT01691534|Experimental|TMC207, PA-824, pyrazinamide and clofazimine (J-PA-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazamine 100mg Days 4-14
9800573|NCT01691534|Experimental|TMC207, PA-824 and pyrazinamide (J-PA-Z)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14
9800574|NCT01691534|Experimental|TMC207, PA-824 and clofazimine (J-PA-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
9800575|NCT01691534|Experimental|TMC207, pyrazinamide and clofazimine (J-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
9800576|NCT01691534|Experimental|pyrazinamide (Z)|pyrazinamide 1500mg Days 1-14
9800577|NCT01691534|Experimental|clofazimine (C)|Clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
9800578|NCT01691534|Active Comparator|Rifafour|Rifafour e-275 mg dosed by weight
9800579|NCT01691560|Experimental|5% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
9800580|NCT01691560|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
9998543|NCT01519258|Experimental|NAVA|Patients will be ventilated with NAVA for 15 minutes. Nava level will be titrated prior to randomization, to deliver the same peak of airway pressure obtained with the active comparator, PSV. The resulting tidal volume should match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
9998544|NCT01519297|Other|Single arm intervention|Irbesartan 150 mg orally for one dose
9998545|NCT01519310|Active Comparator|Group 1|Group 1 (Antibiotics/probioitic):
9998546|NCT01519310|Active Comparator|Group 2|Group 2 (Antibiotics/no-probiotic):
9998547|NCT01519310|Active Comparator|Group 3|Group 3 (no-Antibiotics/probiotic):
9998548|NCT01519336|Active Comparator|A danoprevir|
9998549|NCT01519336|Placebo Comparator|B darunavir|
9998550|NCT01519336|Experimental|C danoprevir/darunavir|
9998551|NCT01519349|Experimental|Cohort 1|Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
9998552|NCT01519349|Experimental|Cohort 2|Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
9998553|NCT01519349|Experimental|Cohort 3|Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
10214189|NCT00703014||Mothers Corifollitropin Alfa 150 µg|Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
9998554|NCT01519375||1|Patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis, 18 years or older
9998555|NCT01519388|Experimental|neuromuscular patients|Neuromuscular non invasively ventilated patients in stable at the time of the study
9998556|NCT01519401|Active Comparator|3 mg drospirenone and 20 µg ethinyl-estradiol|
9998557|NCT01519401|Active Comparator|3 mg drospirenone and 30 µg ethinyl-estradiol|
9998558|NCT01519440||blunt|Blunt expansion of the primary incision was derived by placing the index fingers of the operating surgeon into the incision and pulling the fingers apart laterally and cephalad.
9998559|NCT01519440||sharp|Sharp expansion of the primary incision was developed by cutting laterally and cephalad using bandage scissors
9800581|NCT01691560|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
9998560|NCT01519479|Experimental|Palliative Care Consultation|Participant will get one palliative care consultation while in the hospital. The participants desire for subsequent palliative care visits will be determined and mutually agreed upon at the initial consultation.
9998561|NCT01519479|Active Comparator|Control|Usual care for HF patient which may include a palliative care consult if ordered by treating physician.
9998562|NCT01519492|Experimental|AFN-12520000|100 mg tablet
9998563|NCT01519505|Experimental|Lifestyle counseling|"Complete lifestyle counseling including~Individual intervention, OR~Group intervention"
9998564|NCT01519505|No Intervention|Usual health care|Usual health care, including self-administered information by leaflets
9998565|NCT01519531|Experimental|VIA-3196|
9800582|NCT01691560|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
9998566|NCT01519531|Placebo Comparator|Placebo|Multiple, ascending dosing groups (cohorts) will be evaluated.
9998567|NCT01519544|Active Comparator|Temazepam|50 subjects are instructed to take 7.5mg temazepam by mouth prior to going to sleep for one night only.
9998568|NCT01519544|Active Comparator|Acetazolamide|50 subjects are instructed to take 125mg of acetazolamide by mouth prior to going to sleep one night only.
9998569|NCT01519557|Experimental|DAR-100A|DAR-0100A is a dopamine D1 full agonist, the active component of the racemic mixture DAR-0100
9998570|NCT01519557|Placebo Comparator|Placebo|Intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
9998571|NCT01519583|Experimental|Basic Pedometry Intervention|Basic pedometry intervention: Participants will have a goal of obtaining 10,000 steps/day (with no direction with regards to walking intensity/speed/cadence)
9998572|NCT01519583|Experimental|Enhanced Pedometry Intervention|Enhanced pedometry Intervention: Participants will have the goal of obtaining 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min);
9998573|NCT01519583|Placebo Comparator|Control Group|Control group: Will maintain their usual activity and return for follow-up measures
9998574|NCT01519596|Experimental|Arm I (physical activity)|Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
9998575|NCT01519596|Active Comparator|Arm II (usual care)|Patients undergo usual care for 4 weeks.
9998576|NCT01519609|Active Comparator|Moviprep|Moviprep bowel preb
9998577|NCT01519609|Active Comparator|Phosphoral|Bowel prep
9998578|NCT01519622||Sick elderly in community|
9998579|NCT01519687|Experimental|Levotofisopam|All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
9998580|NCT01519726|Experimental|Morbidly obese patients|
9998581|NCT01519739|Experimental|MediGuide Arm|
9998582|NCT01519752|Experimental|Oxiconazole Nitrate Cream 1%|
9998583|NCT01519752|Active Comparator|Oxiconazole Nitrate Cream 1% (Oxistat®)|
9998584|NCT01519752|Placebo Comparator|Placebo|
9998585|NCT01519830|Experimental|Verum|Iron Carboxymaltose (Ferinject)
9998586|NCT01519830|Placebo Comparator|Placebo|0.9% NaCl solution
9998587|NCT01519843|Active Comparator|Real|Real tDCS
9998588|NCT01519843|Placebo Comparator|sham|Sham tDCS
9998589|NCT01519856||tablet|
9998590|NCT01519895|No Intervention|Existing care|routine existing care
9998591|NCT01519895|Experimental|Telephone intervention|in addition to provide telephone intervention support
9998592|NCT01519973|Other|Evaluation of technology in SPECT|Evaluation of the accuracy of SPECT with new technologies for attenuation correction (AC), scatter correction (SC) and resolution recovery (RR) for assessment of myocardial perfusion using Rb-82 PET as the gold standard.
9998593|NCT01519986|Experimental|Low fat Meal|50,000 UI vitamin D3 with low fat meal
9998594|NCT01519986|Experimental|Medium fat meal|50,000 UI vitamin D3 with medium fat meal
9998595|NCT01519986|Experimental|High fat meal|50,000 UI vitamin D3 with high fat meal
9998596|NCT01519999|Experimental|Shared Decision Making|
9998597|NCT01519999|No Intervention|Comparison (control)|
9998598|NCT01520012|Experimental|Sequence 1|
9998599|NCT01520012|Experimental|Sequence 2|
9998600|NCT01520012|Experimental|Sequence 3|
9998601|NCT01520012|Experimental|Sequence 4|
9998602|NCT01520012|Experimental|Sequence 5|
9998603|NCT01520025|Experimental|18F-FDG PET imaging|Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.
9998604|NCT01520051|Experimental|Mepolizumab|
9998605|NCT01520051|Placebo Comparator|Saline|
9998606|NCT01520077|Other|Vytorin|"Subjects will receive Vytorin for 24 weeks. At 24 weeks if regrowth greater or equal than 20%, subjects will be randomized 1/1 to either stop or continue vytorin. Subjects will be follow for additional 24 weeks.~Subjects that at 24 weeks don't meet the 20% regrowth will be dropped out of the study."
9998607|NCT01520103|Experimental|Vinorelbin and Everolimus|
9998608|NCT01520103|Other|standard therapy|Vinorelbin
10034860|NCT01800591|Experimental|Immediate gratification|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be told that they can weigh in again any time before the study ends when they think they have lost 5% of their initial body weight. If they did meet their 5% goal, they will begin receiving a bi-weekly premium discount during the next pay period for a total duration of 12 months. Subjects that do not meet the 5% cut off during a weigh in are allowed to re-weigh themselves as many times as they like although they are encouraged to do so when they think they have met their target weight. Their premium goes back to normal price after this 12-month discount ends.
10214190|NCT00703014||Mothers recFSH 200 IU|Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
10034861|NCT01800591|Experimental|Financial incentive with frequent feedback|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be asked to weigh in on the IncentaHEALTH scales everyday they are at work. These subjects will participate in a daily lottery with the possibility of winning the same amount as the discount in Arms 2 and 3 over the course of the study. The subject can choose to select or be designated a two digit number that ranges from 00 to 99. Each day a lottery will be held and the subject will be given a 1% chance of matching both digits or an 18% chance of matching one digit. In order to get the lottery winnings, the subject must meet a weight goal that consistently decreases to accumulate to a 5% weight loss by the 6 month mark. After 6 months, the subject will receive the lottery winnings if they maintain that target weight (initial weight minus 5%) until the end of the 12-month study.
10034862|NCT01800604|Experimental|Pain Self-Management Arm #1|Pain Self-Management Intervention #1
10034863|NCT01800604|Experimental|Pain Self-Management Arm #2|Pain Self-Management Intervention #2
10214191|NCT00702988||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) (60 μg, 120 μg and 180 μg)
10214192|NCT00702988||Experimental Group 2|150 IU recFSH
10034864|NCT01800604|Experimental|Pain Self-Management Arm #3|Pain Self-Management Intervention #3
10034865|NCT01800604|Experimental|Pain Self-Management Arm #4|Pain Self-Management Intervention #4
10034866|NCT01800617|Experimental|Liothyronine, Sodium|
10034867|NCT01800630|Experimental|Gemcitabine HCl Oral Formulation (D07001-F4)|Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.
10034868|NCT01800643|Other|Orally Busulfan PK|Evaluate the Pharmacokinetics of orally busulfan
10034869|NCT01800643|Other|Intravenously Busulfan PK|Evaluate the Pharmacokinetics of intravenously busulfan
10034870|NCT01800656|Experimental|Ligate and let go|"Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy."
9936209|NCT02535702|Experimental|NSPRD Task|During the MRI scan, subjects will get small electric shocks through electrodes placed on one of their toes. The shocks feel like an elastic band snapping against the skin. Right after a shock, subjects will see a dot on the computer screen. Subejcts will press a button to rate the intensity of the shock.
9936210|NCT02535702|Experimental|Reasoning Task|Subjects will identify changes in various shapes when they are displayed on the screen in front of them. Some changes of the shapes may be that they were rotated, enlarged, or multiplied. Subjects will choose the changes in the shapes by pressing a button.
9936211|NCT02535702|Experimental|Self-control Task|During the MRI scan, subjects will do a task that requires close concentration. Subjects will be asked to respond quickly to images on the computer screen, during which they will hear distracting noises. The subject will be able to remove the distraction in order to complete the task. During some sub-study sessions, subjects will start with no money ($0) and may be able to earn up to $40 if they do not remove the distraction. At other sub-study sessions, subjects will start with $40 and may lose between 25 to $1 each time they remove the distraction. Subjects cannot lose more than $40 in these sessions. Compensation for this sub-study is up to $40 per session, depending on their performance.
9936212|NCT02535702|Experimental|Spinner Task and MID Task (monetary incentive delay task)|The Spinner task requires the subject to participate in a game of chance while lying in the MRI scanner. Subjects will be asked to respond by pressing a button. The MID task is a reaction time task. The MID Task tests how quickly a subject can press a button to hit a target on the screen in front of them. If the subject presses the button as soon as the target appears, the subject will score points. Subjects should try to score as many points as you can.
9936213|NCT02531893||Irritable youth|Participants meet full DMDD criteria for IBT and either full DMDD or one of two core DMDD criteria for CBT.
9936214|NCT02531880|Experimental|1|Patients will be given the study drug
9936215|NCT02522611|Experimental|Resiniferatoxin|Schedule a maximum of 3 periganglionic DRG injection(s) at contiguous level(s) to treat targeted DRG responsible for chronic CIBP
9936216|NCT02520609||Healthy volunteers|Healthy volunteers
9936217|NCT02520609||Patients with metabolic syndrome without NAFLD|Patients with metabolic syndrome without NAFLD
9936218|NCT02520609||Patients with NAFLD|Patients with NAFLD
9936219|NCT02520154|Experimental|Treatment (carboplatin, paclitaxel, and pembrolizumab)|"NACT: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~ADJUVANT THERAPY: Beginning 3-6 weeks after surgery, paclitaxel IV over 1 hour on days 1, 8, and 15, patients receive carboplatin IV over 1 hour on day 1, and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity."
9936220|NCT02517398|Experimental|MSB0011359C (M7824)|
9936221|NCT02511028|Experimental|ferumoxytol|A 510 mg dose (17 mL) of ferumoxytol diluted in 50 mL of 0.9% normal saline will be intravenously infused over 17 minutes
9936222|NCT02511015||Family Member Control Subjects|Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
9936223|NCT02511015||Healthy Control Subjects|Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
9936224|NCT02511015||Parkinson Subjects|Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
9936225|NCT02511002||1|Post influenza infection
9936226|NCT02507687|Experimental|Bimatoprost Sustained-Release (SR)|Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
9936227|NCT02507687|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Assigned Primary Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
9936228|NCT02505984|Active Comparator|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
9936229|NCT02505984|Placebo Comparator|Placebo|Sub-group of participants receiving placebo nasal spray
9936230|NCT02504905|Experimental|PAR-CD|CD and age/sex matched HV control
9936231|NCT02504905|Experimental|PAR-WC|WC and age/sex matched HV control
9998609|NCT01520116|Experimental|Stage 1 - Arm 1 - Dose 1|
9936232|NCT02504879||Melorheostosis patients|Patients aged > 18 years with possible and confirmed melorheostosis.
9936233|NCT02504879||Relatives of patients with melorheostosis|Relatives of patients with melorheostosis may be included for genetic testing only.
9936234|NCT02504866|Experimental|AET|Aerobic exercise will be performed on an elliptical trainer at a vigorous intensity
9936235|NCT02504866|No Intervention|Control|Wait-list control that performs no exercise for first 12 weeks; randomized to an exercise intervention (either AET or RET) after 12 weeks
9998610|NCT01520116|Experimental|Stage 1 - Arm 2 - Dose 2|
9998611|NCT01520116|Experimental|Stage 1 - Arm 3 - Dose 3|
9998612|NCT01520116|Experimental|Stage 1 - Arm 4 - Dose 4|
9998613|NCT01520116|Placebo Comparator|Stage 1 - Arm 5 - Vehicle|
9998614|NCT01520116|Experimental|Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1|
9998615|NCT01520116|Experimental|Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1|
9476141|NCT03574636|Active Comparator|OCT guidance|"Firehawk stent implantation will be performed with Optical Coherence Tomography guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
9936236|NCT02504866|No Intervention|Healthy Volunteer|Healthy volunteers will perform specific measures for a single study visit
9936237|NCT02504866|Experimental|RET|Rapid reciprocal exercise will be performed on an elliptical trainer at light to moderate intensity
9936238|NCT02504853||Affected Genetic|Have a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs).
9936239|NCT02504853||Affected Non-Syndromic Food|Individuals with a clinical history of immediate hypersensitivity reaction to foods and sensitized to food allergen(s) as evidenced by SPT or allergen-specific IgE testing.
9936240|NCT02504853||Allergic GI Disease|Individuals with a diagnosis or clinical suspicion of eosinophilic esophagitis (EoE), as determined by the principal investigator (PI) or associate investigators (AIs).
9936241|NCT02504853||Unaffected Relative/Healthy Volunteer|Unaffected relatives are relatives of affected; unaffected by food allergy or the genetic condition under study. Healthy volunteers are not related to affected and serve as controls.
9936242|NCT02504840||healthy volunteers|healthy volunteers
9936243|NCT02504840||patient controls|Participants with diseases that share features with MS.
9936244|NCT02504840||patients with suspected or confirmed multiple sclerosis|Participants with definite, probable, or possible MS.
9936245|NCT02484417|Experimental|Cohort 1: RSV A2 10^5 PFU/dose|Challenge 4 subjects with low dose and proceed to larger cohort after safety review.
9998616|NCT01520116|Active Comparator|Stage 2 - Arm 3 -Timoptic 0.5% BID|
9998617|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
9998618|NCT01520142|Experimental|Treatment|
9998619|NCT01520142|Placebo Comparator|Placebo|
9998620|NCT01520155||Systemic lupus erythematosus with renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
9998621|NCT01520155||Systemic lupus erythematosus without renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
9998622|NCT01520155||Non-autoimmune kidney disease|Patients with non-systemic, non-autoimmune kidney disease
9998623|NCT01520194||psychosocial burden|122 women attending reproductive health clinics were interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
9998624|NCT01520194||economic burden|Medical records of 102 patients diagnosed with genital warts were reviewed in the six BEMFAM's participating reproductive health clinics
9998625|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
9998626|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
9998627|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
9998628|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
9998629|NCT01520259||cases|Women from the cohort with gallbladder cancer
9998630|NCT01520259||cohort|Women from Chile screened for gallbladder cancer with and without gallstones
9998631|NCT01520259||controls|Women from the cohort with gallstones
9998632|NCT01520285|Active Comparator|Zanidip|tablets
9998633|NCT01520285|Placebo Comparator|Control Drug|Felodipine sustained-release tablet (5mg/tablet)
9998634|NCT01520298|Placebo Comparator|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
9998635|NCT01520298|Active Comparator|Acetaminophen treatment|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
9998636|NCT01520311|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
9998637|NCT01520337||patients undergoing outpatient colonoscopy|
9998638|NCT01520350|Experimental|Mood stabilizer + Aripiprazole|
9998639|NCT01520350|Placebo Comparator|Mood stabilizer + placebo|
9998640|NCT01520376|Active Comparator|Counselling|People receiving a psychiatric evaluation after screening (HADS test > 12 points) and revised at 1 and 6 months
9998641|NCT01520376|No Intervention|Usual care|People after screening (HADS test > 12 points) and send to their primary care physician
9998642|NCT01520389|Experimental|MM-151 Dose Escalation|MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
9998643|NCT01520389|Experimental|MM-151 Expansion in KRAS wild type colorectal cancer|MM-151 given weekly
9476142|NCT03574636|Active Comparator|IVUS guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
9998644|NCT01520389|Experimental|MM-151 + irinotecan|MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
9998645|NCT01520415|Active Comparator|bupivacaine|
9998646|NCT01520415|Placebo Comparator|saline|
9998647|NCT01520428|Active Comparator|Motivational Interviewing, CBT and E-mail support|
9998648|NCT01520428|Active Comparator|E-Mail-support|
9998649|NCT01520441|Experimental|BOTOX Injection|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
9998650|NCT01520467|Experimental|Anastrozole|stratification according to the rare disease. Oral administration of Anastrozole (1mg/day) for 18 months
9998651|NCT01520467|Placebo Comparator|Placebo|stratification according to the rare disease. Oral administration of 1 placebo tablet /day for 18 months
9998652|NCT01520480||Non-pathological fracture|Non pathological subtrochanteric femur fractures
9998653|NCT01520480||Pathological fracture|Pathological subtrochanteric fractures
9998654|NCT01520493|Experimental|Exercise|All patients are subject to this Arm.
9998655|NCT01520571|Active Comparator|Non-Computer Assistance TKA|Non-Computer Assistance TKA
9998656|NCT01520571|Experimental|Computer Assistance TKA|Computer Assistance TKA
9998657|NCT01520584|Active Comparator|vitamale|
9998658|NCT01520584|Placebo Comparator|sham pill|
9998659|NCT01520597||Case|Patient with culture-proven listeriosis
9998660|NCT01520597||Control|Patient above the age of 18 years with medical background and clinical features compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp > 38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile symptom leading to empiric amoxicillin prescription.
9998661|NCT01520610||CTT|Patients with cardiopathy of tako TSUBO.
9998662|NCT01520610||SCA|Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.
9998663|NCT01520610||Surgical stress|patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.
9998664|NCT01520623|Other|Allografted patients|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
9998665|NCT01520636|Placebo Comparator|group 1: standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
9998666|NCT01520636|Experimental|group 2: experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
9998667|NCT01520649|Experimental|NSI-189 Phosphate|There will be 3 ascending cohorts. The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
9998668|NCT01520649|Placebo Comparator|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
9998669|NCT01520662|Experimental|Wellness Portal Intervention|Wellness Portal Intervention: patients have access to the portal in the course of the study.
9998670|NCT01520662|No Intervention|Wellness Portal Control|Control patients don't have access to the Wellness Portal in the course of the study.
9998671|NCT01520675|Active Comparator|Surgery|Patients will be randomized to surgery
9998672|NCT01520675|Active Comparator|Endotherapy|Patients will be randomized to endoscopic therapy
9998673|NCT01520701|Active Comparator|Ialuset® application|Arm with application to the skin Ialuset ® cervical during radiotherapy
9998674|NCT01520701|Experimental|bandage skin Hydrosorb|Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy
9998675|NCT01520740|Active Comparator|Collateral Ventilation Positive (CV+)|
9998676|NCT01520740|Active Comparator|Collateral Ventilation Negative (CV-)|
9998677|NCT01520753|Experimental|BIAsp 70|
9998678|NCT01520753|Experimental|BIAsp 70 + BIAsp 50|
9476143|NCT03574636|Active Comparator|QCA guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
9528811|NCT03207230|Experimental|Standard|All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.
9998679|NCT01520766|Experimental|glass fiber|
9998680|NCT01520766|Experimental|titanium|
9998681|NCT01520779||Patients with recurrence|Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
9998682|NCT01520779||Patients with no recurrence|Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
9998683|NCT01520792|Experimental|Paracetamol|
9998684|NCT01520805|Experimental|CPI-613|CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
9998685|NCT01520818|Experimental|BIAsp 50 or 70|
9998686|NCT01520818|Active Comparator|BHI 30|
9998687|NCT01520831|Experimental|BIAsp 30|
9998688|NCT01520831|Experimental|BIAsp 50|
9998689|NCT01520831|Experimental|BIAsp 70|
9998690|NCT01520831|Active Comparator|Insulin aspart|
9998691|NCT01520844|Other|Cohort study|Blood sampling
9998692|NCT01520857|Active Comparator|Spinal anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. spinal anesthesia
9998693|NCT01520857|Active Comparator|General Anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. general anesthesia
9998694|NCT01520883||DEcisional conflict|
9998695|NCT01520896|Experimental|Part 1 - A|Single dose NKTR-118 25 mg on Day 1 only
9998696|NCT01520896|Active Comparator|Part 1 - B|Ketoconazole 400 mg once daily on Days 4 to 8
9998697|NCT01520896|Active Comparator|Part 1- C|Ketoconazole 400 mg plus NKTR-118 25 mg on Day 7
9998698|NCT01520935||Cohort Group|
9998699|NCT01520948|Experimental|Exercise-based behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
9998700|NCT01520948|Placebo Comparator|Behavioral control|Mirrored Star Drawing
9998701|NCT01520961||Hueter Anterior Approach|
9998702|NCT01520961||posterolateral approach|
9998703|NCT01520974|Active Comparator|Probiotic tablet|
9998704|NCT01520974|Placebo Comparator|Placebo tablet|Comparison tablet without the probiotic bacteria
9998705|NCT01521000|No Intervention|Observation|Observation arm will continue to be followed with serial L-Dex and water volume displacement methods.
9936246|NCT02484417|Experimental|Cohort 2: RSV A2 10^5 PFU/dose|Challenge 12 subjects with the low dose and proceed to high dose after safety review.
9936247|NCT02484417|Experimental|Cohort 3: RSV A2 10^6.3 PFU/dose|Challenge 12 subjects with the high dose
9936248|NCT02484404|Experimental|P1 Durvalumab+C|Ph I Durvalumab + cediranib dose escalation
9936249|NCT02484404|Experimental|P1 Durvalumab+O|Ph I Durvalumab + olaparib dose escalation
9936250|NCT02484404|Experimental|P1 Durvalumab+O+C|Ph I Durvalumab + olaparib + cediranib dose escalation
9936251|NCT02484404|Experimental|P2 Durvalumab+C|Ph II Durvalumab + cediranib at RP2D
9936252|NCT02484404|Experimental|P2 Durvalumab+O|Ph II Durvalumab + olaparib at RP2D
9936253|NCT02484404|Experimental|P2 Durvalumab+O+C|Ph II Durvalumab + olaparib + cediranib at RP2D
9936254|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
9936255|NCT02471378||Pregnant Women 15-25 years old|Malaria-infected pregnant Women
9936256|NCT02471365||Healthy Volunteers|Non-pregnant and non-nursing females between 35 and 74 who usesa high number (e.g., 15 or more products a day) of consumer products.
9936257|NCT02471352||1/ Skin disease or at risk|Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease
9936258|NCT02471352||2/ Healthy Volunteers|Healthy Volunteers
9936259|NCT02470091|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
9936260|NCT02465138|Placebo Comparator|Placebo|Normal Saline will be administered prior to procedure.
9936261|NCT02465138|Active Comparator|Toradol|Intravenous ketorolac prior to ERCP
10214193|NCT00702845|Experimental|corifollitropin alfa 100 µg|Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
10214194|NCT00702845|Active Comparator|recFSH 150 IU|Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
10214195|NCT00702806|Experimental|Org 36286 120 μg + Puregon® 150 IU|On Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 120 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
10214196|NCT00702806|Experimental|Org 36286 180 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 180 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
10034871|NCT01800656|Active Comparator|Snare polypectomy|Subjects are submitted to endoloop-assisted snare colorectal polypectomy
10214197|NCT00702806|Experimental|Org 36286 240 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 240 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
10214198|NCT00702806|Active Comparator|Puregon® 150 IU|On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
10214199|NCT00702624||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
10214200|NCT00702624||recFSH 150 IU|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
10214201|NCT00702585|Experimental|Org 36286 7.5 µg|Org 36286 7.5 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
10214202|NCT00702585|Experimental|Org 36286 15 µg|Org 36286 15 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
10214203|NCT00702585|Experimental|Org 36286 30 µg|Org 36286 30 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
10214204|NCT00702585|Experimental|Org 36286 60 µg|Org 36286 60 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
10214205|NCT00702585|Placebo Comparator|Placebo|Placebo to Org 36286 administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
10214206|NCT00702546||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. But in base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
10214207|NCT00702546||recFSH 150 IU|In this follow-up study, no medication or investigational product was administered. However, in base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
10214208|NCT00702520||Corifollitropin alpha 100 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily subcutaneous (SC) injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous luteinizing hormone (LH) and follicle stimulating hormone (FSH) was confirmed by estradiol (E2) and progesterone (P) measurements, a single dose of corifollitropin alpha 100 μg was administered in participants weighing <= 60 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recombinant follicle stimulating hormone (recFSH) injections (maximally 200 IU) up to and including the day of administration of human chorionic gonadotprophin (hCG). No study medications were administered in the present P05783 study (38834, NCT00702520).
9936300|NCT02460783|Experimental|5-2 CR|Healthy living diet for 5 days/week; Calorie Restriction(530 Kcal in the form of a shake) for 2 days/week
9936301|NCT02460783|Active Comparator|Healthy Living|Healthy living diet for 7 days/week
9936302|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders.
9936303|NCT02446626|Active Comparator|1|Patients with Lyme disease, post treatment
9936304|NCT02446626|Active Comparator|2|Patients with post-Lyme disease complaints at least 12 months from initial treatment
9936305|NCT02446626|Active Comparator|3|Acute erythema migrans patients (possible positive control)
9936306|NCT02446626|Active Comparator|4|Lyme Arthritis patients (possible positive control)
9936307|NCT02446626|Active Comparator|5|Healthy Volunteers (negative control)
9936308|NCT02445248|Experimental|CTL019|Single arm
9936309|NCT02440425|Experimental|Combination Therapy|Combination Therapy: Pembrolizumab (experimental use) and Paclitaxel (standard use). All trial treatments will be administered on an outpatient basis. One cycle equals 21 days. The first cycle is 28 days with Pembrolizumab given on day 8 in order to determine paclitaxel tolerance.
9936310|NCT02438969||Cohort 1|Treatment-seeking or non-treatment-seeking individuals with AUD and ELS exposure
9936311|NCT02438969||Cohort 2|Treatment-seeking or non-treatment-seeking individuals with AUD without ELS exposure
9936312|NCT02438969||Cohort 3|Healthy volunteers with ELS exposure
10034872|NCT01800682|Experimental|Tramodol Extended-release (ER), 25 milligram (mg)|Tramodol ER, 25 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
9936313|NCT02438969||Cohort 4|Healthy volunteers without ELS exposure
9936314|NCT02437110|Experimental|ALS|20 participants with ALS and a level of HERV-K >1000 copies/ml
9936315|NCT02435810||Family Member|A family member of a patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
9936316|NCT02435810||Patient|Patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
9936317|NCT02435472|Experimental|Arm A: Exercise|Arm A will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test (CPET) performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing. Archival biopsy tissue samples from before and after the intervention will also be requested.
9998706|NCT01521000|Other|Intervention-garment sleeve|If the L-Dex is outside the normal range, or has increased 10 units from baseline, the patient will then be randomized to wear a compression sleeve (20 to 30 mm of Hg) daily for 4 weeks or observation (no sleeve). After 4 weeks, L-Dex measurements and water volume displacement will be reassessed in the treatment group.
9998707|NCT01521013|Active Comparator|Supported self-care|
9998708|NCT01521013|Active Comparator|Unsupported self-care|
9998709|NCT01521052|Experimental|elderly depressed patients|Twenty seven (27) patients aged 68 years or above, currently suffering from a major depressive episode, who did not respond to treatment with at least one antidepressant medications in the recommended dosage and duration, or could not tolerate at least two antidepressants.
9998710|NCT01521065|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
9998711|NCT01521078|Experimental|Intervention|Provided access to the Check Your Drinking University version (CYDU).
9998712|NCT01521078|No Intervention|Control|No invention control group
9998713|NCT01521130|No Intervention|Healthy Control|Healthy Control
9998714|NCT01521130|No Intervention|BECTS, no medication|BECTS, no medication
9998715|NCT01521130|Experimental|Levetiracetam Higher dose|Levetiracetam Higher dose
9998716|NCT01521156|Active Comparator|1 = Control product|
9998717|NCT01521156|Experimental|2 = Tested product|
9998718|NCT01521169|Active Comparator|1 = Tested product dose 1|
9998719|NCT01521169|Active Comparator|2 = Tested product dose 2|
9998720|NCT01521169|Sham Comparator|3 = Control product|
9998721|NCT01521182|Active Comparator|1 = Tested product|
9998722|NCT01521182|Placebo Comparator|2 = Control product|
9998723|NCT01521195|Experimental|Patients on veno-arterial (VA) ECMO|
9998724|NCT01521208|Active Comparator|LUCAS, Continuous chest compressions|Mechanical continuous chest compressions performed by LUCAS device (also during defibrillation)
9998725|NCT01521208|Active Comparator|Manual chest compressions|Manual chest compression is performed, chest compressions halted during defibrillation
9998726|NCT01521221|Experimental|Patients|Patients with autonomic failure.
9998727|NCT01521221|Experimental|Healthy subjects|Control group
9998728|NCT01521234|Experimental|Feedback group|For participants assigned to the feedback group, physiotherapists will receive a summary of patients' walking activity for the previous week as a tool to guide goal planning. Physiotherapists will use the information as a 'homework checker' to determine if patients are complying with an assigned walking program. In the case of non-compliance, the physiotherapist will discuss a coping strategy for better integrating walking activity into the patients' day. In the event that the patient is meeting their specific sub-goals for walking activity, the physiotherapist will re-evaluate these sub-goals and suggest more challenging goals.
9998729|NCT01521234|No Intervention|No-feedback group|For participants assigned to the control group, physiotherapists will not receive accelerometer-based feedback of daily walking activity. However, physiotherapists will still discuss the achievement of walking goals with their patients. This is usual care around goal planning.
9998730|NCT01521247|No Intervention|Control group|Usual care.
9998731|NCT01521247|Other|Asthma Transition Program|Asthma Transition Program
9998732|NCT01521273|Experimental|high iron bean with native phytic acid concentration|
9998733|NCT01521273|Experimental|normal iron bean with native phytic acid concentration|
9998734|NCT01521273|Experimental|high iron bean partially dephytinized|
9998735|NCT01521273|Experimental|normal iron bean partially dephytinized|
9998736|NCT01521273|Experimental|high iron bean totally dephytinized|
9998737|NCT01521273|Experimental|normal iron bean totally dephytinized|
9998738|NCT01521286||Group A|Subjects presenting with HZ episode.
9998739|NCT01521312|Experimental|Saxagliptin|Saxagliptin 5 mg (tablet) at BREAKFEAST
9998740|NCT01521312|Placebo Comparator|placebo pill|at BREAKFEAST
9998741|NCT01521325|Experimental|Amatuximab infusion|Subjects will receive one infusion of radiolabeled amatuximab.
9998742|NCT01521351||carotid thermal heterogeneity|Patients that have carotid thermal heterogeneity detected by MR
9998743|NCT01521351||no carotid thermal heterogeneity|Patients that DONT have carotid thermal heterogeneity detected by MR
9998744|NCT01521351||carotid artery disease|Patients with detected carotid artery disease by ultrasound
9998745|NCT01521351||no carotid artery disease|Patients with no carotid artery disease detected by ultrasound
9998746|NCT01521377|Placebo Comparator|Placebo|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin.
9998747|NCT01521377|Active Comparator|Moxifloxacin Positive|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose oral tablet moxifloxacin (400mg) on day 10.
9998748|NCT01521377|Experimental|GSK573719 Supra-therapeutic dose|Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
9998749|NCT01521377|Experimental|GSK573719/Vilanterol Therapeutic dose|Single inhalation from GSK573719/Vilanterol (125/25 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
9998750|NCT01521377|Experimental|GSK573719/Vilanterol Supra-therapeutic dose|Single inhalation from GSK573719/Vilanterol (500/100 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
9998751|NCT01521390|Other|Treatment Arm|Subjects receive one inhalation from each intervention
9998752|NCT01521403|Active Comparator|Metronidazole|Metronidazole 3x500 mg per day for 10 days
9998753|NCT01521403|Placebo Comparator|Placebo|Placebo 3x1 tablet per day for 10 days
9998754|NCT01521416||Cohort Group|
9998755|NCT01521429||MPS I|Mucopolysaccharidosis I (Hurler, Scheie, Hurler-Scheie)
9998756|NCT01521429||MPS II|Mucopolysaccharidosis II (Hunter)
9998757|NCT01521429||MPS VI|Mucopolysaccharidosis VI (Maroteaux-Lamy)
9998758|NCT01521442|Experimental|Arm 1|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
9998759|NCT01521442|Other|Arm 2|12-week delay before beginning Mindful Yoga Therapy treatment which will consist of 12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
9998760|NCT01521455|Experimental|HCP0910|Fluticasone /salmeterol 250/50 combination capsule
9998761|NCT01521455|Active Comparator|Seretide Diskus|Seretide 250 Diskus
9998762|NCT01521481|Experimental|Triple inguinal nerve block|Ropivacaine 5 mg/ml
9998763|NCT01521481|Active Comparator|Unilateral subarachnoid anesthesia|Bupivacaine 10 mg/ml
9998764|NCT01521520||Clinical Type 1 Diabetes|This group will be subdivided into individuals with recent onset clinical type 1 diabetes (within 6 months of diagnosis), latent autoimmune diabetes of the adult, and longer standing type 1 diabetes.
9998765|NCT01521520||High Risk Pre-Type 1 Diabetes|High risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
9998766|NCT01521520||Low Risk Pre-Type 1 Diabetes|Low risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes but no islet autoantibody markers (GAD, IAA, or IA-2).
9998767|NCT01521520||Normal Control|Normal control is based on history with no known history or family history of type 1 diabetes.
9998768|NCT01521533|Experimental|NOX-A12|
9998769|NCT01521572|Experimental|Salbutamol|Short-acting bronchodilator for use in humans released by the Ministry of Health, widely used worldwide for the treatment of chronic obstructive pulmonary disease.
9998770|NCT01521585|Experimental|SEN0014196 50 mg oral tablet|
9998771|NCT01521585|Experimental|SEN0014196 200 mg oral tablet|
9998772|NCT01521585|Placebo Comparator|Placebo tablet|
9998773|NCT01521611|Experimental|Targeted radiotherapy|Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
9998774|NCT01521624|Active Comparator|Case|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
9998775|NCT01521624|No Intervention|Control|Subjects provided only advice for lifestyle modification with no drug intervention
9998776|NCT01521637|Experimental|NMES|The 'NMES' arm will be treated with NMES.
9998777|NCT01521637|Sham Comparator|No NMES|The 'No NMES' arm of the experiment will be sham-treated with NMES. The device will be installed, but not used.
9998778|NCT01521650|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
9998779|NCT01521650|No Intervention|Control|No intervention. What has been the standard procedure so far
9998780|NCT01521676|Experimental|breast cancer|blood and tumor sample
9998781|NCT01521689|Experimental|Rituximab|Consolidation treatment with sub cutaneaous low doses of Rituximab
9998782|NCT01521702|Experimental|Neoadjuvant chemotherapy|After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).
9998783|NCT01521702|Active Comparator|surgery|surgery
9936318|NCT02435472|No Intervention|Arm B: Usual Care|"Arm B will receive print material with physical activity guidance which includes general physical activity information (e.g., Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a heart rate monitor, an individualized aerobic exercise program based on their cardiorespiratory fitness test results, and opportunity to consult with study exercise physiologist (one-time)."
9936319|NCT02435472|Active Comparator|Arm C: Exploratory|Arm C is a non-randomized control group of men without cancer, which will receive all baseline and 16 week follow-up assessments (except tissue procurement) will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing.
9936320|NCT02435472|Active Comparator|Observational Non-Randomized Group|There is also a non-randomized observational component to the study where biospecimens and survey data will be collected and one CPET will be administered. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research.
9476144|NCT03574623|Experimental|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
9528812|NCT03207269|Experimental|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
9936321|NCT02431923||EVD Close Contacts|At least one of the following:-Household contact of survivor at time of or since EVD event-Sexual contact with survivor since EVD event-Other selected contacts
9936322|NCT02431923||EVD Survivors|Subject listed on the Ministry of Health registry for Ebola survivors
9936323|NCT02431923||Non Contact Controls|Selected Controls
9936324|NCT02423070||Cohort 1|Heart and Lung Transplant patients
9936325|NCT02423057|Experimental|1|TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
9936326|NCT02423031||Caregivers|caregivers of pediatric patients with cancer and other serious illnesses
9936327|NCT02423031||pediatric patients|pediatric patients with cancer and other serious illnesses
9936328|NCT02417766||Family Members|Family members to the patients
9936329|NCT02417766||Patient|Patients here at NIH
9936330|NCT02417740||Adult with absence of Portal Hypertension|Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination.
9936331|NCT02417740||Adult with presence of Portal Hypertension|Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg).
9936332|NCT02417740||Minors likely to have the absence of Portal Hypertension|Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination.
9936333|NCT02417740||Minors likely to have the presence of Portal Hypertension|Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5).
9936334|NCT02417714||Body CT group|100 subjects for a body CT
9936335|NCT02417714||Chest Ct Group|100 subjects for a chest CT
9936336|NCT02415387|Experimental|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
9936337|NCT02415387|Placebo Comparator|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
9936338|NCT02407405|Experimental|1|Selumetinib 50 mg BID daily
9936339|NCT02404870|Experimental|Admission 1 or 2|Canagliflozin
9936340|NCT02404870|Placebo Comparator|Admission 2 or 1|Placebo
9936341|NCT02400216||Group A|Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)
9936342|NCT02400216||Group B|Patients with minimal fibrosis (Ishak score 0-1).
9936343|NCT02392442|Experimental|1 - Endotoxin|6 hour lavage post endotoxin
9936344|NCT02392442|Experimental|2 - Endotoxin|24 hour lavage post endotoxin
9936345|NCT02392442|Experimental|3 - Endotoxin|48 hour lavage post endotoxin
9936346|NCT02392442|Placebo Comparator|4 Placebo comparator|6 hour control lavage
9936347|NCT02390765||All participants|All participants in the study will be evaluated as one group
9936348|NCT02390752|Experimental|Phase I|take oral drug daily for a 28 day cycle
9936349|NCT02390752|Experimental|Phase II|take oral drug daily for a 28 day cycle
9936350|NCT02379429||1/ Participants|Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention
9936351|NCT02379429||2/Healthy Volunteers|Healthy volunteers from whom blood, saliva and urine samples are easily obtainable.
9528313|NCT03211819|Experimental|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.~Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
9528314|NCT03211819|Active Comparator|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
9528315|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
9998784|NCT01521715|Experimental|Pazopanib|800 mg (2x400mg) pazopanib per day
9998785|NCT01521728|Active Comparator|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
9998786|NCT01521728|Active Comparator|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
9998787|NCT01521728|Active Comparator|Stretching/Range-of-Motion Exercise|"In ALS, stretching and range of motion are routinely recommended for the prevention of frozen shoulder syndrome and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
9998788|NCT01521741||Breast Cancer|
9998789|NCT01521754||Perspective|Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
9998790|NCT01521754||Retrospective|Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
9998791|NCT01521767|Experimental|A|4 mg tolterodine extended release capsules, administered with water and under fasting condition.
9998792|NCT01521767|Experimental|B|4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
9998793|NCT01521767|Experimental|C|4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
9998794|NCT01521767|Experimental|D|4 mg MPB-RR1, administered without water and under fed condition.
9998795|NCT01521767|Experimental|E|4 mg MPB-RR1, administered with water and under fasting condition.
10034873|NCT01800682|Experimental|Tramodol ER, 50 mg|Tramodol ER, 50 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
10034874|NCT01800682|Experimental|Tramodol ER, 100 mg|Tramodol ER, 100 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
10034875|NCT01800695|Experimental|Arm A|ABT-414 in combination with radiation and temozolomide
10034876|NCT01800695|Experimental|Arm B|ABT-414 in combination with temozolomide
10034877|NCT01800695|Experimental|Arm C|ABT-414 monotherapy
10034878|NCT01800708|Active Comparator|Triamcinolone acetonide|The study group will receive an intraoperative intracameral injection of triamcinolone acetonide
10034879|NCT01800708|Active Comparator|Prednisolone syrup|The control group will receive prednisolone syrup postoperatively
10034880|NCT01800721|Experimental|Experimental Condition SNAP|"Behavioral Intervention SNAP HIV training and peer outreach~Participants learn skills for sexual health and peer outreach which includes talking with network members about HIV testing and prevention."
10034881|NCT01800721|Active Comparator|SNAP Control Condition|"SNAP Control~Participants receive information on HIV/STDs as well as healthy eating and nutrition instruction."
10034882|NCT01800734|Other|Clamp-Mixed Meal Arm|Twenty adults patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
10034883|NCT01800747|Active Comparator|Direct antibiotic treatment|The doctor gives to parents an antibiotic prescription for their son's respiratory infection which he should start immediately.
10034884|NCT01800747|No Intervention|No antibiotic treatment|The doctor does not give to parents an antibiotic prescription for their son's respiratory infection.
10034885|NCT01800747|Experimental|Delayed antibiotic prescription|The doctor gives to parents an antibiotic prescription for their son's respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improve.
10034886|NCT01800760|Experimental|No groups|
10034887|NCT01800773|Experimental|Written Exposure Therapy|Written exposure treatment is a 5 session treatment in which participants write about their trauma event in a specified manner.
10034888|NCT01800773|Active Comparator|Cognitive Processing Therapy|cognitive processing therapy will be included as the evidence-based treatment for PTSD in this study.
10034889|NCT01800799|Experimental|UTI (WBC>10 per high power field)|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
9998796|NCT01521806|Experimental|Low dose|15 g of fiber per day will be added to snack foods
9528316|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
9998797|NCT01521806|Experimental|High dose|30 g of fiber per day will be added to snack foods
9998798|NCT01521806|Placebo Comparator|No fiber|Snack foods without fiber will be given
9528317|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
9998799|NCT01521819|Experimental|Iray plus Lucentis|open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.
9998800|NCT01521832|Experimental|Dose Group A|
9998801|NCT01521832|Experimental|Dose Group B|
9998802|NCT01521832|Experimental|Dose Group C|
9998803|NCT01521832|Experimental|Dose Group D|
9998804|NCT01521832|Experimental|Dose Group E|
9998805|NCT01521832|Experimental|Dose Group F|
9998806|NCT01521832|Experimental|Dose Group H|
9998807|NCT01521832|Experimental|Dose Group I|
9998808|NCT01521832|Experimental|Dose Group J|
9998809|NCT01521832|Experimental|Dose Group K|
9998810|NCT01521832|Experimental|Dose Group L|
9998811|NCT01521910|Experimental|Low protein diet|
9998812|NCT01521910|Active Comparator|Normal protein diet|
9998813|NCT01521936|Experimental|Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.
9998814|NCT01521936|Experimental|Arm II (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8.
9998815|NCT01521962|Experimental|SYR-322 (Alogliptin) QD|SYR-322 25 mg, orally.
9998816|NCT01521962|Placebo Comparator|Insulin|injection
9476145|NCT03574623|Active Comparator|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
9998817|NCT01521975|Experimental|HBeAg Negative Hepatitis|HBeAg Negative Hepatitis patients.
9998818|NCT01521988|Active Comparator|Atrial flutter ablation|RF atrial flutter ablation
9998819|NCT01521988|Experimental|Atrial flutter ablation and pulmonary vein isolation|RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
9998820|NCT01522001|No Intervention|Hospital-based|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 to 3 individual consultations with nurse specialized in cardiac rehabilitation~Examination by cardiologist 8-12 weeks after discharge."
9998821|NCT01522001|Active Comparator|Shared care Model|"First visit at cardiac ambulatory approximately 14 days after discharge includes examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
9998822|NCT01522014|Active Comparator|Ceramic on Ceramic|Subjects received a ceramic on ceramic bearing total hip replacement.
9998823|NCT01522014|Active Comparator|Ceramic-on-Highly Crosslinked Polyethylene|
9998824|NCT01522027|Experimental|Nerve stimulator|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
9998825|NCT01522040|Active Comparator|Magnesium|Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
9998826|NCT01522040|Placebo Comparator|Control|Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
9998827|NCT01522053|Experimental|Catheter-over-needle|Patients will receive a catheter placed by a catheter-over-needle method.
9998828|NCT01522053|Active Comparator|Catheter-through-needle|Patients will receive a catheter placed by the traditional catheter-though-needle method.
9998829|NCT01522066|Experimental|Perineural catheter|Local anesthetic will be delivered through an indwelling perineural catheter
9998830|NCT01522066|Active Comparator|Single-shot block|Local anesthetic will be delivered by the conventional, single-shot method.
9998831|NCT01522079|Experimental|Air stacking|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position.
9998832|NCT01522092|Experimental|escitalopram|escitalipram tablets 5mg, 10 mg and 20 mg, once a day for 12 months
9998833|NCT01522105|Experimental|1|i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage
9998834|NCT01522118|Experimental|HIFU|(high intensity focused ultrasound)
9998835|NCT01522144|Experimental|Asthma clinical decision support|decision support compared to no decision support in a cluster-randomized trial by practise
9998836|NCT01522157|Active Comparator|All test patients|All test patients are given low-fat, low-carbohydrate and mediterranean diet, in randomised order on different days.
9998837|NCT01522222|No Intervention|Control|half of the study subjects will receive standard of care during their open heart surgery.
9998838|NCT01522222|Experimental|Treatment|half of the study subjects will receive the prescribed ventilatory support during open heart surgery.
9998839|NCT01522261|Active Comparator|Mechanical Bowel Prep|Patients randomized to complete a Mechanical Bowel Prep. (complete bowel cleansing) and fleet enemas prior to surgery.
9998840|NCT01522261|Active Comparator|No Mechanical Bowel Prep.|Patients randomized to complete two fleets enemas only prior to surgery.
9998841|NCT01522274|Active Comparator|Moderate intensity exercise|Brisk walk on treadmill for 56 minutes 3x per week.
9998842|NCT01522274|Active Comparator|Health education|Attend health education sessions 3x per week.
9998843|NCT01522287|Active Comparator|BT STEPS alone|"Subjects assigned to BT STEPS without coaching will receive computer assisted Cognitive Behavior Therapy. They will receive a welcome and orientation call from the project manager and up to three automated reminder e-mails if there is no activity in the BT Steps website for 5 days. E-mails will describe most recent step the participant used and what to expect in upcoming steps. The focus of reminder messages is on the patients progress through BT STEPS."
9998844|NCT01522287|Active Comparator|BT Steps with non-therapist coaching|Subjects randomized to BT STEPS with coaching will receive computer assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching, encouragement and support via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session. Coaches will be supervised by the CBT therapist, and may consult with the CBT clinician as needed.
9998845|NCT01522287|Active Comparator|BT STEPS with therapist coaching|Subjects randomized to BT STEPS with therapist coaching will receive computer-assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching and support from a CBT therapist via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session.
9998846|NCT01522313||Patients|Data of patients anesthetized in the years 2006 to 2012 (Hospital stay: January 2006 - June 2012) will be analysed in the study.
9998847|NCT01522326|Experimental|Metoclopramide|150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
9998848|NCT01522326|Active Comparator|Ibuprofen|150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
9998849|NCT01522352|Experimental|pericardial aortic valves|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
9998850|NCT01522365|Active Comparator|Abutment-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
9998851|NCT01522365|Active Comparator|Implant-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
9998852|NCT01522378|Experimental|Biv-ICD|Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
9936352|NCT02379416|Experimental|treatment|The starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
9936353|NCT02371681|Experimental|1|TB drugs
9936354|NCT02363335|Placebo Comparator|Placebo|Randomized, double blind, placebo-controlled cross-over study
9936355|NCT02363335|Experimental|Roflumilast|Randomized, double blind, placebo-controlled cross-over study
9936356|NCT02363335|Experimental|Roflumilast/Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
9936357|NCT02363335|Experimental|Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
9936358|NCT02363296|Experimental|EEG phase-triggered PAS|TMS triggered to a specific phase of the EEG mu rhythm
9936359|NCT02362438|Experimental|10X|Highest dose in the escalation scheme
9936360|NCT02362438|Experimental|1X|Lowest dose in the escalation scheme
9936361|NCT02362438|Experimental|3.3X|2nd dose increase in escalation scheme
9936362|NCT02362438|Experimental|5X|3rd dose increase in escalation scheme
9936363|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
9936364|NCT02356159|Experimental|1/Phase 1: Dose escalation arm|Induction chemotherapy, then palifermin at escalating doses, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
9936365|NCT02356159|Experimental|2/ Phase II arm|Induction chemotherapy, then palifermin at the MTDdetermined in Phase 1, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
9936366|NCT02343120|Experimental|Zanubrutinib|Participants were administered up to 320 mg total daily dose of zanubrutinib until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up
9936367|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
9936368|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
9936369|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
9998853|NCT01522430|Experimental|Renal angiography followed by renal sympathetic denervation|Catheter based therapy for renal denervation using the Simplicity (TM) catheter (Ardian/Medtronic)
9998854|NCT01522430|Sham Comparator|Renal angiography alone|Renal selective angiography using standardized method: Local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
9998855|NCT01522482|Experimental|High saturated fat meal|
9480627|NCT05262491|Experimental|Study treatment|Participants receive BL-B01D1 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
10214209|NCT00702520||Corifollitropin alpha 150 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing >= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
10214210|NCT00702351|Experimental|Arm 1|150 µg Org 36286 (corifollitropin alfa)
9936372|NCT02339012||20-34|healthy individuals ages 20-34 years
9936373|NCT02339012||35-49|healthy individuals ages 35-49 years
9936374|NCT02339012||50-64|healthy individuals ages 50-64 years
9936375|NCT02339012||65-79|healthy individuals ages 65-79 years
9936376|NCT02339012||80+|healthy individuals ages 80 years and older
9936377|NCT02338986||Healthy Volunteers|Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases
9936378|NCT02327897||asthmatic|
9936379|NCT02327897||non-asthmatic|
9936380|NCT02327884||Group 1|Healthy Volunteers matched with Sjogren's Syndrome patients
9936381|NCT02327884||Group 2|Family Members, affected and unaffected
9936382|NCT02327884||Group 3|any other cause salivary gland dysfunction
9936383|NCT02322177||1|Participants are women with inborn errors of metabolism who have been pregnant
9936384|NCT02317887|Experimental|Group 1|1e9 vg/eye
9936385|NCT02317887|Experimental|Group 2|1e10 vg/eye
9936386|NCT02317887|Experimental|Group 3|1e11 vg/eye
9936387|NCT02317887|Experimental|Group 4|1e11 vg/eye
9936388|NCT02317887|Experimental|Group 5|Not to exceed 3e11 vg/eye
9936389|NCT02317887|Experimental|Group 6|Not to exceed 6e11 vg/eye
9936390|NCT02317328||Affected participants|Participants with ocular conditions
9936391|NCT02317328||Healthy Volunteers|Healthy volunteers
9936392|NCT02315612|Experimental|Arm 1|dose escalation of CD22-CAR
9936393|NCT02315612|Experimental|Arm 2|dose expansion of CD22-CAR
9936394|NCT02315599||1|Patients screening for, participating in, or have participated in a POB gene therapy clinical trial and have received/or be scheduled to receive a genetically engineered cellular therapy.
9936395|NCT02315586||1|Participants will be enrolled at the NIH Clinical Center.
9936396|NCT02315586||2|IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program
9936397|NCT02311374|Sham Comparator|Phase 2|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM-12 PM).
9936398|NCT02311374|Sham Comparator|Phase I|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9 AM-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM 12 PM).
9936399|NCT02311335||1|Dyslipidemia patients
9936400|NCT02311322||Children with growth disorders|Children with growth disorders
9936401|NCT02311322||Family members of subjects with growth disorders|Family members of subjects with growth disorders
9936402|NCT02309593||PROFEMUR® Xm Femoral Stems|Single study group either previously implanted or will be implanted with the following combination of components: PROFEMUR® Xm Femoral Stems, with any type of Acetabular Shells.
9936403|NCT02304458|Experimental|Treatment (nivolumab, ipilimumab)|See Detailed Description
9998856|NCT01522482|Experimental|Saturated fatty acid and fish oils meal|Equivalent to two portions of oily fish
9998857|NCT01522482|Active Comparator|High unsaturated fat meal|Provided a fatty acid profile representative of a typical UK diet
9998858|NCT01522495|Experimental|SPY Imaging|SPY Imaging Prior to Amputation or Debridements (50 participants)
9998859|NCT01522495|No Intervention|No SPY Imaging|Amputation or Debridements as Standard of Care (50 participants)
10034890|NCT01800799|Experimental|Recurrent UTI|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
10034891|NCT01800799|No Intervention|Normal control|Normal control
10034892|NCT01800825|Active Comparator|Clindamycin|Clindamycin 300mg orally twice daily for five days
10214211|NCT00702351|Experimental|Arm 2|100 µg Org 36286 (corifollitropin alfa)
10214212|NCT00702338||corifollitropin alfa + recFSH Mothers|Eligible participants in Stage 1a of base study P05693 (NCT00697255) were administered injection(s) with subcutaneous (SC) corifollitropin alfa (15mcg) and daily SC injections with recFSH (50 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then to be followed for safety and efficacy on the current follow-up (FU) study (P05713) according to standard practice (no treatment administered).
10214213|NCT00702338||corifollitropin alfa + hCG Mothers|Eligible participants in Stage 1b of base study P05693 (NCT00697255) were administered injection(s) with SC corifollitropin alfa (30 mcg) and daily SC injections with hCG (200 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then followed for safety and efficacy on the current FU study (P05713) according to standard practice (no treatment administered).
9998860|NCT01522495|Experimental|Validation Against Angiogram|"Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention.~(30 participants)"
9998861|NCT01522495|Experimental|Establishing Normal Values|To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
9998862|NCT01522508||propofol/remifentanil|patients receive standardized propofol and changing remifentanil concentrations
9998863|NCT01522508||sevoflurane/remifentanil|patients receive standardized sevoflurane and changing remifentanil concentrations
9998864|NCT01522521|Experimental|1.|
9998865|NCT01522521|Placebo Comparator|2.|
9998866|NCT01522534|Experimental|Blind block with mepivacaine|Blind block with mepivacaine and intravenous morphine
9998867|NCT01522534|Active Comparator|Morphine|Intravenous Morphine and placebo blind block
9998868|NCT01522547|Experimental|Cohort 1: 0.5 mg pomalidomide|0.5 mg pomalidomide orally daily for 84 days
9998869|NCT01522547|Experimental|Cohort 2: 1.0 mg pomalidomide|1.0 mg pomalidomide orally daily for 84 days
9998870|NCT01522547|Experimental|Cohort 3: 2.0 mg pomalidomide|2.0 mg pomalidomide orally daily for 84 days
9998871|NCT01522547|Experimental|Cohort 4: 3.0 mg pomalidomide|3.0 mg pomalidomide orally daily for 84 days
9998872|NCT01522547|Experimental|Cohort 5: 4.0 mg pomalidomide|4.0 mg pomalidomide orally daily for 84 days
9998873|NCT01522560|Placebo Comparator|Control Group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
9998874|NCT01522560|Active Comparator|Feedback group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
9998875|NCT01522573||EUS guided ERCP procedure group|Subjects who will undergo Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP) procedures for their pancreatico-biliary conditions.
9998876|NCT01522586|Experimental|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
9998877|NCT01522586|Placebo Comparator|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
9998878|NCT01522599|Active Comparator|ARDS-Net strategy (Control)|
9998879|NCT01522599|Experimental|ECCO2-R with 4 mL/Kg Vt (Treatment)|
9998880|NCT01522612|Experimental|5-fluorouracil/leucovorin plus cetuximab|
9998881|NCT01522612|Active Comparator|5-fluorouracil/leucovorin alone|
9998882|NCT01522625|Experimental|TDF|tenofovir disoproxil fumarate (TDF) 300mg
9998883|NCT01522625|Placebo Comparator|Placebo|
9998884|NCT01522638||ADOA|This group includes subjects diagnosed with autosomal dominant optic atrophy
9998885|NCT01522638||Healthy subjects|
9998886|NCT01522664|Experimental|Single group|
9998887|NCT01522677|Experimental|PDT|Participants receive neoadjuvant 5-ALA and PDT.
9998888|NCT01522716|Experimental|Mesenchymal stromal cell treatment|
9998889|NCT01522729|Experimental|Fentanyl|
9998890|NCT01522729|Experimental|Placebo|
9998891|NCT01522742||Healthy control subjects|Healthy control subjects matched to psoriasis patients on traditional cardiovascular risk factors will be studied at baseline.
9998892|NCT01522742||Psoriasis patients starting etanercept|Patients with moderate to severe psoriasis with or without arthritis who are about to be started on etanercept (enbrel) by their treating clinicians will be studied at baseline and 3 months after etanercept therapy.
9998893|NCT01522768|Experimental|Afatinib and Paclitaxel|This is a multi-institution, open-label, non-randomized, Phase II evaluation of oral afatinib daily and intravenous paclitaxel (weekly, 3 weeks on, 1 week off) in patients with trastuzumab refractory HER2-positive metastatic or recurrent esophagogastric adenocarcinoma. An initial biopsy prior to the start of therapy is required for the correlative studies evaluating the biologic effects of afatinib. It will be obtained for all patients whose tumors are feasible to biopsy. At the site investigator's discretion, a second biopsy will also be obtained. At the discretion of the MSK Principal Investigator, select participants who show response on this study and then progress may be asked to have an optional third biopsy.
9476146|NCT03574623|Active Comparator|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
9476147|NCT03574610|Experimental|Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
9998894|NCT01522794|Experimental|NOX-H94|Single dose of NOX-H94
9998895|NCT01522794|Placebo Comparator|Placebo|Single dose of placebo control
9998896|NCT01522807|Experimental|100 mg PF-05190457|Three fasted treatments and fed with the short-duration osmotic capsule
9998897|NCT01522807|Experimental|100 mg PF - 05190457|Three fasted treatments and fed with the long-duration osmotic capsule
9998898|NCT01522820|Experimental|Cohort 1a (vaccine therapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.
9998899|NCT01522820|Experimental|Cohort 1b (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.
10214214|NCT00702273||150 µg Corifollitropin Alfa|Participants from the base study P05787 (NCT00696800), received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (Org 36286) on menstrual cycle Day 2/3 (Day 1); 7 daily SC injections from Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG). Daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started, for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
9998900|NCT01522820|Experimental|Cohort 1c (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.
9998901|NCT01522820|Experimental|Cohort 1d (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.
9998902|NCT01522820|Experimental|Cohort 2 (vaccine therapy with or without immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.
9998903|NCT01522833||Cohort A|EGFR Wild Type patients
9998904|NCT01522833||Cohort B|EGFR mutation patients
9998905|NCT01522846||Heparin|
9998906|NCT01522859|No Intervention|standard care|A standardised home based programme of specialist respiratory assessment and monitoring provided by the local Community Respiratory Team (CRT) and General Practitioner (GP) for a period of six months.
9998907|NCT01522859|Experimental|Telehealth monitoring|Daily monitoring of patient's health status using a small telecommunications device.
9998908|NCT01522872|Experimental|Monotherapy TH-302 Dose Escalation|
9998909|NCT01522872|Experimental|TH-302 and Dexamethasone Dose Expansion|
9998910|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Bortezomib|
9998911|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Pomalidomide|
9998912|NCT01522885|Active Comparator|KatGuide|Chest tube insertion is performed by using the KatGuide
9998913|NCT01522885|Active Comparator|Conventional group|Chest tubes are inserted by using conventional method (forceps) for large bore chest tube insertion.
10034893|NCT01800825|Placebo Comparator|placebo|This will be an identical placebot
9998914|NCT01522898|Active Comparator|Medical Rate Control|Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
9998915|NCT01522898|Experimental|AV nodal ablation|AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.
9998916|NCT01522911|Other|atrial and brain natriuretic peptide|Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
9998917|NCT01522989|Experimental|PD-0332991, 5-FU and oxaliplatin|PD-0332991 with 5-FU and oxaliplatin
9998918|NCT01523002|Active Comparator|Arm A: Metoprolol DDI and Pyramax 90-day re-dosing|Subjects will take 1 day of metoprolol followed by a 7 day wash out period; then 2 days of Pyramax followed by 1 day of Pyramax + metoprolol and then a 87 day follow-up period. Subjects will then receive Pyramax once daily for three days followed by a 40 day follow-up period and a study completion evaluation.
9998919|NCT01523002|Active Comparator|Arm B: Pyramax 60-day re-dosing|Subjects will take Pyramax once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take Pyramax once daily for 3 days followed by a 40 day follow-up period.
9998920|NCT01523015|Experimental|Combined therapy|The combined modality therapy will be consisted of preoperative chemoradiotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil, 45Gy) for type I i II cancer or preoperative chemotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil) for type III cancer and followed by surgery.
9998921|NCT01523015|Active Comparator|Surgery|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
9998922|NCT01523028|Experimental|Coffee, bread and honey|200 mL coffee + 2 bread rolls + honey
9998923|NCT01523028|Experimental|Coffee, bread and peanut butter|200 mL coffee + 1 bread roll + peanut butter
9998924|NCT01523028|Experimental|200 mL black coffee|
9998925|NCT01523041|Experimental|BIAsp 70 clinical trial formulation|
9998926|NCT01523041|Experimental|BIAsp 70 final formulation|
9998927|NCT01523041|Experimental|BIAsp 50 final formulation|
9998928|NCT01523054|Experimental|Metoprolol- Toprol XL|Metoprolol extended release (CR/XL) tablet 200 mg once daily
9998929|NCT01523054|Active Comparator|Metoprolol- Lopressor|Metoprolol immediate release (IR) tablet
9998930|NCT01523067|Active Comparator|Vasomera (PB1046)|
9998931|NCT01523067|Placebo Comparator|0.9% Sodium Chloride|
9998932|NCT01523080|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA.
9998933|NCT01523080|Experimental|Acetaminophen extended release Gel tabs 650 mg|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
9998934|NCT01523093|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) orally disintegrating tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
9998935|NCT01523093|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron 8 mg Orally Disintegrating Tablets Manufactured By OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc, USA)
9998936|NCT01523106|Active Comparator|Carnitine|Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months
9998937|NCT01523106|Placebo Comparator|Placebo|Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.
9998938|NCT01523119|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) Orally Disintegrating Tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
9998939|NCT01523119|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron Orally Disintegrating Tablets 8 mg Manufactured By Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, USA)
9998940|NCT01523132||Breast cancer patients|Female breast cancer patients without metastasis and locally advanced disease
9998941|NCT01523145|Experimental|Intervention|
9998942|NCT01523145|Experimental|Control gruop|
9476148|NCT03574584|Experimental|NNC0165-1562 + Semaglutide|Participants will receive NNC0165-1562 and semaglutide once weekly for 20 weeks.
9476149|NCT03574584|Experimental|Placebo (NNC0165-1562) + Semaglutide|Participants will receive placebo (NNC0165-1562) and semaglutide once weekly for 20 weeks.
9998943|NCT01523158|Other|Immunotherapy|Open label study of changes to cellular responses following immunotherapy
9998944|NCT01523197|Other|ventilator|The comparison of the curative effect on OS between BiPAP and auto-trilevel ventilations
9998945|NCT01523210||upper limb spasticity|patients suffering from upper limb spasticity and are treated with botulinum toxin
9998946|NCT01523223|Experimental|Treatment (DLI)|Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.
9998947|NCT01523236|Experimental|Investigational Test Product|Mometasone furoate anhydrous 50 mcg/actuation Nasal Spray (Teva)
9998948|NCT01523236|Active Comparator|Reference Listed Drug|Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray (Schering)
9998949|NCT01523236|Placebo Comparator|Placebo|Saline Placebo Nasal Spray
9998950|NCT01523249||Scanned and palpated|Healthy, pregnant, term women delivering at BC Women's Hospital and expecting to have neuraxial anesthesia.
9998951|NCT01523262|Active Comparator|Preconditioning and normal treatment|
9998952|NCT01523262|Placebo Comparator|normal treatment|Standard treatment
9476150|NCT03574558|Experimental|MD-Logic Switch Advisor|MD-Logic Switch Advisor Algorithm for personalized automated determination of insulin pump settings for subjects with type 1 diabetes switching from MDI to pump therapy and vice versa
9936404|NCT02296684|Experimental|Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475|"MK-3475 will be given intravenously once approximately 2-3 weeks prior to standard of care surgery.~Adjuvant therapy will be dictated by surgical pathology and occurs after standard of care surgery and will consist of:~risk-based intensity modulated radiation therapy consisting of 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)once-daily fraction size (total of 30 fractions)~optional image-guided radiation therapy~risk-based cisplatin administered intravenously on Days 1, 22, and 43 of treatment course~MK-3475 will be given intravenously once every 3 weeks for a maximum of 6 doses if participant is considered high-risk based on 's surgical pathology from standard of care surgery shows high risk features (positive margins or extracapsular extension). These doses of MK-3475 will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
9936405|NCT02296684|Experimental|Cohort 2: Neoadjuvant MK-3475|-MK-3475 will be given once intravenously and then given again 21 days after dose 1 (14-24 days before standard of care surgery
9936406|NCT02290392||1|African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.
9936407|NCT02286830|Active Comparator|zoledronic acid|treatment with zoledronic acid for 4 years
9936408|NCT02286830|Placebo Comparator|no treatment|treatment with zoledronic acid withheld after two years
9936409|NCT02281747||affected with arthritis|arthritis may be either rheumatoid, osteoarthritis, or ankylosing spondylitis
9936410|NCT02281747||unaffected with arthritis|in some analyses, the comparison is by arthritis status. in other analyses, it is within arthritisstatus by clinically relevant subgroups.
9936411|NCT02268253|Experimental|Tagraxofusp (SL-401)|
9936412|NCT02264678|Experimental|Module 1 Part A|Module 1 Part A: ascending doses of ceralasertib in combination with carboplatin AUC5 will be administered to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD).
9936413|NCT02264678|Experimental|Module 1 Part B|Module 1 Part B: patients with advanced lung adenocarcinoma with low expression of ATM will receive ceralasertib and carboplatin, at the dose, frequency and schedule recommended from Module 1 Part A.
9936414|NCT02264678|Experimental|Module 2 Part A1|Module 2 Part A1: ascending doses of ceralasertib will be administered alone to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD) to take into Module 2 Part A2.
9936415|NCT02264678|Experimental|Module 2 Part A2|Module 2 Part A2: ascending doses of ceralasertib will be administered in combination with olaparib to patients to define the dose, frequency and schedule of ceralasertib and olaparib to take into Module 2 Part B.
9936416|NCT02264678|Experimental|Module 2 Part B1|Module 2 Part B1: Patients with second line 'ATM deficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
9936417|NCT02264678|Experimental|Module 2 Part B2|Module 2 part B2: Patients with second line 'ATM proficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
9936418|NCT02264678|Experimental|Module 2 Part B3|Module 2 Part B3: Patient with second or third line breast cancer with BRCA mutations (somatic or germline), excluding HER2 positive breast cancer will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
9936419|NCT02264678|Experimental|Module 2 Part B4|Module Part B4: Patients with second or third line triple negative breast cancer with no known BRCA mutations. This expansion will be enriched for patients with disease harbouring a HRR-related gene mutation (HRRm) will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
9936420|NCT02264678|Experimental|Module 3 Part A|Module 3 Part A: cohort escalation of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients to define the dose, frequency and schedule of ceralasertib and durvalumab to take into Module 3 Part B. Additionally, Module 3 Part A will include a serial tumour biopsy cohort to evaluate the Proof of Mechanism of ceralasertib in HNSCC and NSCLC patients.
9936421|NCT02264678|Experimental|Module 3 Part B|Module 3 Part B: cohort expansions of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients at dose, frequency and schedule from Module 3 Part A.
9936422|NCT02264678|Experimental|Module 2 Part B5|Patients with BRCA mutant or RAD51C/D mutant (either germline or somatic) or HRD-positive status epithelial ovarian, fallopian tube, or primary peritoneal cancer according to local testing. Patients must be platinum sensitive and previously progressed on a licensed PARPi. The cohort will be split into 2 groups: Cohort 1 - without intervening chemotherapy following progression on a PARPi, Cohort 2 - with intervening chemotherapy following progression on a PARPi. Patients will receive ceralasertib and olaparib, at the RP2D dose, frequency and schedule established from Module 2 Part A2.
9936423|NCT02262832|Other|Leptin study drug|Administration of study drug SQ BID
9936424|NCT02262806|Other|Leptin therapy|leptin administered via SC injections BID
9936425|NCT02257892||Patients|Affected patients, with symptoms or genetic mutation
9936426|NCT02257892||Unaffected/healthy relatives|Relatives without symptoms or genetic mutation
9936427|NCT02257866||Healthy Volunteers|Patients without known auto immune diseases
9936428|NCT02257866||Vasculitis|Patients with known or suspected vasculitis age 5 or older
9936429|NCT02257853|No Intervention|Control Group|No intervention group
9936430|NCT02257853|Experimental|Intervention|Receives stress reduction intervention introduction with daily practice
9936431|NCT02249975|Experimental|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
9936432|NCT02247388|Experimental|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
9936433|NCT02247388|No Intervention|Standard Care|Standard Care
9936434|NCT02242968||Healthy Volunteers|Male and Female healthy volunteers between aged 18 and 65 years.
9936435|NCT02233868|Experimental|Phase I|PET scan with [11C]PBR28 followed by PET scan with FDG and MRI.
9998953|NCT01523288||Prader-Willi patients|
9998954|NCT01523288||Control group|Control group for ultrasound scan
9998955|NCT01523314|Experimental|dexamethasone - Cyclodextrin|
9998956|NCT01523314|Active Comparator|Avastin/Laser|
9998957|NCT01523327||A|40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
9998958|NCT01523327||B|40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
9998959|NCT01523340||Erlotinib treatment|
9998960|NCT01523353|Active Comparator|Exercise Intervention|4 week personalised exercise program on a static bicycle.
9998961|NCT01523353|No Intervention|Control Arm|Patients having standard preoperative preparation and advice.
9998962|NCT01523405||1|
9998963|NCT01523418||Group 1|
9998964|NCT01523431|Active Comparator|Standard FOLFIRI for wild/hetero UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
10214215|NCT00702273||200 IU RecFSH|Participants from the base study P05787 (NCT00696800), received a single SC injection of placebo Corifollitropin Alfa on menstrual cycle day 2/3 (Day 1); 7 daily SC injections with 200 IU recFSH from Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Multiple daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
10214216|NCT00702234||Women/Expectant Mothers - Corifollitropin Alfa 150 µg|In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
9998965|NCT01523431|Experimental|Reduced Dose of CPT-11 for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 90 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
9998966|NCT01523431|Active Comparator|Standard FOLFIRI for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
9998967|NCT01523444|No Intervention|Treatment as Usual|
9998968|NCT01523444|Active Comparator|computer Screening & Brief Advice|All participants receiving care at the site assigned to the computer-facilitated screening and brief advice (cSBA) condition will receive the cSBA intervention as part of their care at that clinic.
9998969|NCT01523444|Experimental|computer Screening & Brief Advice Plus|All participants receiving care at the site assigned to the cSBA+ condition will receive the cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider as part of care at that clinic.
10214217|NCT00702195||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)
10214218|NCT00702195||Experimental Group 2|Placebo
10214219|NCT00702195||Experimental Group 3|all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)
10214220|NCT00702195||Experimental Group 4|150 IU Puregon®
10214221|NCT00697255|Experimental|corifollitropin alfa + recFSH|Eligible participants will receive a subcutaneous (SC) injection of corifollitropin alfa (Stage 1a: 15mcg, Stage Ib/II: 30 mcg) the first, second, or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient, the participant will receive a second or third dose of corifollitropin alfa (Stage 1a: 15 mcg, Stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm, the participant will start daily SC injections with FSH (Stage 1A: 50 IU, Stage II: 75 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
10214222|NCT00697255|Experimental|corifollitropin alfa + hCG|Eligible participants will receive a SC injection of corifollitropin alfa (Stage Ia:15 mcg, Stage Ib/II: 30 mcg) the first, second or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient the participant will receive a second or third dose of corifollitropin alfa (Stage IA: 15 mcg, stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm the participant will start daily SC injections with hCG (Stage Ib/II: 200 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
10214223|NCT00696878|Experimental|Corifollitropin alfa 150 µg|Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after [rec]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.
9936436|NCT02233868|Experimental|Phase II|After 3 weeks of abstinence or non-abstinence, PET scan with [11C]PBR28 followed by PET scan with FDG and MRI are repeated.
9936437|NCT02233829|Active Comparator|Evening MRI/PET/Raclopride/IV Methylphenidate Session|The PET [11C] raclopride scan will be done between 5-7 PM. After iv catheters are inserted blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plus-infusion method for [11C]raclopride and the administration of intravenous MP (0.5 mg/kg) forty-five minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
9936438|NCT02233829|Active Comparator|Morning MRI/PET/Raclopride/IV Methylphenidate Session|Morning Session [11C]raclopride PET scan: To be started between 7-8 AM. After iv catheters are inserted, genetic blood samples are drawn and then blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plusinfusion method for [11C]raclopride and the administration of intravenous MP (0.25 mg/kg) fortyfive minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
9936439|NCT02231840||Not treatment-seeking participants|Individuals who meet current or past DSM 5 criteria for AUD but are not seeking treatment. Healthy volunteers and other volunteers.
9936440|NCT02231840||Treatment-seeking Patients|Individuals who meet current DSM 5 criteria for AUD and are seeking treatment for it.
9936441|NCT02225171||Physicians|15 physicians each will be interviewed from the specialties of reproductive endocrinology and obstetrics/gynecology.
9936442|NCT02225119||Affected|Participants with macular disease
9936443|NCT02225119||Unaffected|Healthy volunteers
9936444|NCT02211768|Experimental|1/FDG and FLT PET scans|Subjects will undergo FDG-PET and FLT-PET scans at least one day apart
9936445|NCT02211768|Other|2/FDG-PET scan|Subjects will undergo FDG-PET scan
9936446|NCT02211755|Experimental|1|Starting doses are clofarabine at 1 mg/m2 IV on days 1 through 5 of a 21-day cycle, and bortezomib at 0.8 mg/m2 subcutaneously on days 1 and 4 of a 21-day cycle.
10214224|NCT00696800|Experimental|150 µg Corifollitropin Alfa|Participants received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (org 36286) on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
10214225|NCT00696800|Active Comparator|200 IU recFSH|Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
10214226|NCT00647933|Experimental|Org 36286 15 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 15 μg.
10214227|NCT00647933|Experimental|Org 36286 30 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 30 μg.
10214228|NCT00647933|Experimental|Org 36286 60 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 60 μg.
10214229|NCT00647933|Experimental|Org 36286 120 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 120 μg.
10214230|NCT00641771|Experimental|1|MK0217A
10214231|NCT00641771|Placebo Comparator|2|Placebo
10214232|NCT00628745||Observational|
10214233|NCT00616967|Active Comparator|Arm I|Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
10214234|NCT00616967|Experimental|Arm II|Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
10214235|NCT00598208|Experimental|1|60 µg Org 36286 (corifollitropin alfa)
10214236|NCT00598208|Experimental|2|120 µg Org 36286 (corifollitropin alfa)
9936447|NCT02203526|Experimental|Arm 1-A (original study design - prior to Amendment G)|TEDD-R (cycle 1) with ibrutinib; TEDDI-R with cytarabine (cycles 2-6)
9936448|NCT02203526|Experimental|Arm 1-B (original study design-prior to Amendment G)|TEDDI-R with cytarabine
9936449|NCT02203526|Experimental|Arm 2 (Dose Escalation; prior to Amendment 06/04/2021)|TEDDI-R with cytarabine, and isavuconazole
10214237|NCT00598208|Experimental|3|180 µg Org 36286 (corifollitropin alfa)
10214238|NCT00598208|Active Comparator|4|Follitropin beta injection
9936450|NCT02203526|Experimental|Arm 3 (Dose Expansion; prior to Amendment 06/04/2021)|TEDDI-R with cytarabine and isavuconazole
9936451|NCT02203526|Experimental|Arm 4 (Dose Expansion; Amendment 06/04/21)|TEDDI-R, cytarabine or methotrexate, isavuconazole, ibrutinib for 10 days
9936463|NCT02193425|Experimental|PET FDG &amp; MRI Scans|The test-retest reproducibility of the gender and aging effects on FC measures (lFCD, C, L and S) acquired in RS and TS conditions.
9936464|NCT02190266||Patients|Patients with confirmed refractory and/or disseminated coccidioidomycosis.
9936465|NCT02190253||Organ transplant recipients|Recipients of either liver, kidney, liver and kidney, and small bowel transplants
9936466|NCT02190253||Waitlist patients|Patients on waitlist for liver, kidney or intestinal transplantation
9936467|NCT02181569||Treatment seeking participants with alcohol dependence|Treatment seeking individuals with alcohol dependence who are admitted into a 28-day inpatient treatment program.
9936468|NCT02169310|Experimental|1|up to 40 adult TBI patients between the ages of 18 and 60
9936469|NCT02169310|Active Comparator|2|up to 40 adult healthy volunteers between the ages of 18 and 60
9936470|NCT02162732|Experimental|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
9936471|NCT02156115||healthy volunteers|healthy volunteers
9936472|NCT02156115||lymphatic patients|lymphatic patients
9936473|NCT02156115||relatives|relatives
9936474|NCT02156102||Microbiome with active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants with active leg ulcers and sickle cell disease.
9936475|NCT02156102||Microbiome with no active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants without active leg ulcers but do have sickle cell disease.
9936476|NCT02156102||Non-microbiome participants|We will recruit but not obtain microbiome samples from participants with sickle cell disease
9936477|NCT02154035||Group 1|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
9936478|NCT02154035||Group 2|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
9936479|NCT02154022||1|Patients with cancer who are currently enrolled in IRB approved NIH Intramural Research Program clinical trial
9936480|NCT02153957|Experimental|1|enhanced PA home intervention group for the first 12 weeks; followed by 12 weeks of PA maintenance on their own.
9936481|NCT02153957|Active Comparator|2|usual physical activity (no intervention) for 12 weeks; followed by the enhanced PA home intervention for 12 weeks.
9936482|NCT02147405||ARV naive|Patients that have not started or have ever been on ARV therapy.
9936483|NCT02147405||IRIS|Patients that are on medication but are possibly experiencing an IRIS event.
9936484|NCT02146378||Vyndaqel|
9936485|NCT02146170||Single group|Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET
9936486|NCT02139397|Experimental|DFMO and Bortezomib|Subjects will take DFMO by mouth 2 times a day for each day of a 21 day cycle and Bortezomib will be given by IV push on days 1, 4, and 8 of each 21 day cycle.
9936487|NCT02133196|Experimental|1/High-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus high-dose Aldesleukin
9936488|NCT02133196|Experimental|2/Low-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus low-dose Aldesleukin
9936489|NCT02124057||Healthy female control|Age-matched healthy control women
9936490|NCT02124057||Healthy male control|Age-matched healthy control men
9936491|NCT02124057||Other Motor Neuron Disease Patients|Male participants with other motor neuron disease
9936492|NCT02124057||SBMA Patients|Men with genetically confirmed SBMA
9936493|NCT02124057||SMBA|SBMA carrier women
9936494|NCT02119611|Other|Single-arm|Therapy
9936495|NCT02116764||Cross Sectional|3 years after Transplant
9936496|NCT02116764||No Transplant|These patients were diagnosed with CGD but have not been transplanted
9936497|NCT02116764||Prospective|Prior to Transplant Conditioning
9936498|NCT02116764||Retrospective|1 year after Transplant
9936499|NCT02108080||Inpatient AUD|This group includes individuals who are in the alcohol use treatment.
9936500|NCT02108080||Outpatient|This group includes individuals who are not seeking treatment for alcohol use disorder.
9936501|NCT02108054|Experimental|1|People with alcohol use disorder
9998970|NCT01523470|Active Comparator|stepwise withdrawal of NIV|On the day of decision of withdrawal (day0), the duration of non-invasive ventilator (NIV) will be decreased to 16 hours. On the following day (day1), the duration of NIV will be further decreased to 12 hours. The duration will be further decreased to 8 hours at night on the following day (day 2), and it will be stopped on the day after (day 3). Vital signs and blood gases will be monitored for a total of 5 days after withdrawal is planned (day 0 to day 5).
9998971|NCT01523470|Experimental|immediate withdrawal of NIV|The patient will have immediate withdrawal of non-invasive ventilator (NIV). Vital signs and blood gases will be monitored for 2 more days after NIV is stopped (day 0-2).
9998972|NCT01523483|Experimental|Progesterone|Patients in this arm will receive two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
9998973|NCT01523483|Placebo Comparator|placebo|Patients will receive two placebo capsules placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
9998974|NCT01523509|Experimental|Contrast|All subjects will be in one group who will have a control radiograph of teeth before applying the Sodium Iodide contrast agent topically between the teeth (the intervention) when another radiograph will be taken to test for the presence of contrast in a cavity.
9998975|NCT01523522|Active Comparator|myoblast injection|autologous myoblast
9998976|NCT01523522|Placebo Comparator|saline solution injection|saline solution injection in anal sphincter
9998977|NCT01523535|Placebo Comparator|normal sleep|Subjects have 8 hours of sleep opportunity per night
9998978|NCT01523535|Experimental|cycles of sleep restriction|subjects are exposed to bouts of reduced sleep duration. The sleep loss is the intervention (experimental challenge).
10034894|NCT01800851|Experimental|no weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
10034895|NCT01800851|Experimental|weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
10034896|NCT01800851|Other|lean body mass|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
10034897|NCT01800864|Other|Normal|Normal weight subjects
10034898|NCT01800864|Other|Over weight /obese subjects|Overweight and obese subjects
10034899|NCT01800929|Experimental|N6|The N6 system comprises an investigational sound processor, remote assistant and fitting software
10034900|NCT01800929|Active Comparator|N5|The current commercially-available cochlear implant system Performance of N5 will be compared to performance with N6 using a within-subject design.
10034901|NCT01800942|Placebo Comparator|Placebo|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
10034902|NCT01800942|Experimental|Azithromycin|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
10034903|NCT01800955|Experimental|resistive capacitive diathermy|in the resistive capacitive diathermy protocol patients are administered the resistive capacitive diathermy treatment for a thirty minutes session, three times per week for a total of ten sessions
10034904|NCT01800955|Sham Comparator|sham placebo group|"The sham treatment is administered with the resistive capacitive diathermy device set on on but not active (not supplying energy) with the same type of application, the same frequency and duration of experimental diathermy group"
10034905|NCT01800981||Debrase|Patients previously treated with Debrase for burn debridement
10034906|NCT01800981||Standard of Care|Patients previously treated with local Standard of Care for burn debridement
10034907|NCT01800994||asthma, COPD|patients with asthma and COPD treated with inhalation devices
10034908|NCT01801020|Experimental|temperature measuremts|A temporal artery measurement will be taken from two points a strait line across the forehead and an additional measurement behind the earlobe. In addition tympanic temperature will be measured.
10034909|NCT01801046|Experimental|Treatment (chemotherapy, G-PBSC)|INDUCTION CHEMOTHERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-3 and cytarabine IV on days 1-7. HMMACT: Patients receive G-PBSC on day 9.
9936502|NCT02108054|Experimental|2|People without alcohol use disorder
9936503|NCT02108041||Physicians that interact with the black/High SES avatar patien|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American.
9936504|NCT02108041||Physicians that interact with the black/Low SES avatar patient|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American.
9936505|NCT02108041||Physicians that interact with the white race/high SES avatar|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian.
9936506|NCT02108041||Physicians that interact with the white race/low SES avatar p|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian.
9936507|NCT02108028||Cohort 1A / Initial Young Adults with Children|Young adults who have a child(ren) and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
9936508|NCT02108028||Cohort 1B / Comparison Young Adults with Children|Young adults who have children and are 18- 39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
9936509|NCT02108028||Cohort 2A / Initial Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
9936510|NCT02108028||Cohort 2B / Comparison Independent Young Adults|Young adults who live independently and are 18-39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
9936511|NCT02108028||Cohort 3A / Initial Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site. COMPLETE
9936512|NCT02108028||Cohort 3B / Comparison Young Adults No Children, Not Independent|Young adults with no children, not living independently who are 18-39 diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at a participating site.
9936513|NCT02108028||Cohort 4 / Non-patient participants|Family members, friends, or health care providers of patient participant. COMPLETE
9936514|NCT02107989|Experimental|healthy volunteers|healthy volunteers
9936515|NCT02107989|Experimental|Patients|Patients
9936516|NCT02107976|Experimental|Stage 1|Upon admission, diabetic subjects maywill discontinue their oral hypoglycemic medications and/or insulin regimen per investigators discretion. Oral hypoglycemic agents and/or insulin doses will be adjusted and may be supplemented with a correction scale and/or and transitioned to a basal-bolus insulin regimen. In order to achieve optimal glycemic monitoring and for safety reasons, subjects may be fitted with a Dexcom continuous glucose monitor (CGM) upon inpatient admission. CGM will be used to supplement, rather than replace, fingerstick glucose measurements. CGM monitoring will include a sensor fitted subcutaneously, a wireless transmitter that allows for remote glucose monitoring by the research team.
9936517|NCT02107976|Experimental|Stage 2|Subjects may be considered for arm stage 2 inpatient study no less than 8 weeks duration from arm stage 1 study. Once the RBC vitamin C concentrations are optimal (>30 uM), subjects may be re-admitted to Clinical Center metabolic unit and undergo the same protocol as described above in arm stage 1. Oral vitamin C and E supplementation may be discontinued on admission. The inpatient diet, glucose monitoring and sampling scheme will be the same as described for the first inpatient study.
9936518|NCT02105766|Experimental|male donor - female recipient|The first cohort of patients will be male donor - femalerecipients to see if this new regimen will yield higher rate of durable donor leukocyte chimerism. We will also measure anti-A, anti-B, and/or other red cell antibody titers from this initial cohort to determine the feasibility of transplanting patients with pre-existing antibodies (major ABO mismatch or other anti-donor red cell antibody)
9936519|NCT02105766|Experimental|patients with preexisting antibodies|patients with preexisting antibodies (major ABO mismatch or otheranti-donor red cell antibody). The primary endpoint forthis group will be different than the first cohort. It is very likely that red cell aplasia (6 months to 2 years posttransplant) and prolonged duration of red cell transfusion are expected in this second group, thus a later time point to determine treatment success is justified.
9936520|NCT02089789||CDG|Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
9936521|NCT02077894||Affected participants|Participants with an eye disease.
9936522|NCT02077894||Unaffected family members|Unaffected family members.
9936523|NCT02066415|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
9936524|NCT02066415|Experimental|Erenumab 70 mg|Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
9936525|NCT02066415|Placebo Comparator|Erenumab 140 mg|Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
9936526|NCT02064764|Active Comparator|Cryoablation only|Pulmonary vein isolation
9936527|NCT02064764|Experimental|Cryoablation and renal nerve denervation|Pulmonary vein isolation plus renal nerve denervation
9998979|NCT01523548|Experimental|Carbon Monoxide|Inhaled Carbon Monoxide therapy administered over 16 weeks
9998980|NCT01523561|No Intervention|usual care|The participants in the no intervention group were informed that they should continue living as usual
9998981|NCT01523561|Experimental|dance intervention|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
9998982|NCT01523574|Placebo Comparator|Control Group|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
9998983|NCT01523574|Experimental|Vitamin e|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
9998984|NCT01523600|Experimental|Whole body vibration training|
9998985|NCT01523600|Active Comparator|Wellness group|
9998986|NCT01523626|Other|Conventional imaging|The control group will be evaluated with X-rays, ultrasonography and selective CT scanning.
9998987|NCT01523626|Other|Immediate total body CT|The intervention group will receive a 'total body' CT scan from head to pelvis. Conventional radiography and FAST will be completely omitted.
9998988|NCT01523639|Active Comparator|Metformin|FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles
9998989|NCT01523639|Placebo Comparator|Placebo|FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles
9998990|NCT01523652||Nadroparin/control (phase 1)|patients affected by benign pelvic gynaecologic diseases were enrolled and treated with nadroparin for prophylactic anticoagulation; patients untreated with nadroparin were as control group.
9998991|NCT01523652||Nadroparin (phase 2)|patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. All these patients underwent laparotomy;
9998992|NCT01523678|Experimental|Filgrastim|
9998993|NCT01523691|Experimental|repeated sleep restriction and recovery|
9998994|NCT01523691|Experimental|control sleep|
9998995|NCT01523730|Active Comparator|Repetitive Transcranial Magnetic Stimulation (rTMS)|
9998996|NCT01523730|Placebo Comparator|Sham rTMS|
9936528|NCT02063464||Cohort 1|Subjects w/ovarian, primary peritoneal or fallopian tube ca who are not currently on therapy and are screening for trials, being seen in consultation, or presenting for enrollment on a trial.
9998997|NCT01523769|No Intervention|Control|Control group, the cord was not milked
9998998|NCT01523769|Experimental|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery
9998999|NCT01523795|Experimental|Motion-controlled video gaming|Participants played motion-controlled video games that involved at least throwing, hitting, or dancing motions using a Wii or Xbox 360 console for one hour
9999000|NCT01523795|Active Comparator|Traditional video gaming|Participants played traditional (handheld gamepad controller-based) video games using a Playstation 3 console for one hour
9999001|NCT01523795|Active Comparator|Television watching|Participants watched television via Netflix instant streaming for one hour
9999002|NCT01523847|Experimental|MBVD (Myocet+BVD)|"2 MBVD courses, after early restaging with PET scan (PET-2)~The subsequent treatment will be planned as follows:~-Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).~-Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional."
10214239|NCT00597805||1|Patients scheduled for a total, anterior or posterior pelvic exenteration
10214240|NCT00537914|Other|1|single-arm non-comparative somatropin safety study (PASS)
10214241|NCT00519857|Active Comparator|1|Tibolone
9936529|NCT02055248||Subjects with Moebius or related syndromes and their family me|Subjects with Moebius or related syndromes and their family members and healthy volunteers.
9936530|NCT02055222||Lung disease (IPF) and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
9936531|NCT02055222||Lung disease COPD and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
9936532|NCT02055222||Normal Volunteers- Non-smokers, and Smokers|50 smoking and 30 non-smoking controls
10214242|NCT00519857|Placebo Comparator|2|Placebo
10214243|NCT00461032|Experimental|1|montelukast
10214244|NCT00461032|Placebo Comparator|2|Placebo
10214245|NCT00442338|Experimental|Montelukast 7 mg|Montelukast 7 mg IV administration
10214246|NCT00442338|Experimental|Montelukast 14 mg|Montelukast 14 mg IV administration
10214247|NCT00442338|Active Comparator|Aminophylline 250 mg|Aminophylline 250 mg IV drip administration
10214248|NCT00431093|Experimental|1|tibolone
10214249|NCT00431093|Active Comparator|2|low-dose estradiol/noresterone
10214250|NCT00394069|Experimental|Montelukast sodium|Participants receive montelukast sodium for 14 days.
10214251|NCT00293995|Other|Laparoscopic repair|Laparoscopic repair, with closure of contralateral patent processus vaginalis
10214252|NCT00293995|Other|Open repair|Open repair
10214253|NCT00289874|Experimental|1|montelukast
10214254|NCT00289874|Placebo Comparator|2|placebo
9999003|NCT01523860|Experimental|1|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.
9936533|NCT02055209||1|Adults only, all genders, US-born African American
9936534|NCT02019706|Experimental|Imaging|All subjects will be imaged
9936535|NCT02019654||1|Mild or moderate TBI within the past 30 days
9528813|NCT03207269|Active Comparator|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
9936536|NCT02015078||African Americans|Targets are family members attending African American family reunions.
9936537|NCT02015013|Experimental|Filgrastim|ICL and healthy volunteers will be given 10 g/kg daily for 5 days administered according to a vialbased algorithm to reduce wastage and increase the G-CSF dose given to lighter- Filgrastim weight donors to improve CD34+ yields
9936538|NCT02015013|Experimental|Plerixafor|ICL and healthy volunteers will be given 0.24 mg/kg as a single dose (maximum dose: 40mg) 11 hours prior to apheresis
9936539|NCT02014246||1|Participants with confirmed or suspected movement disorder or dementia diagnosis and their affected and unaffected family members will be potential candidates for the study, well as unrelated, healthy individuals (known as control samples.
9936540|NCT02014246||2|We plan to enroll 12,000 study subjects (10,000 patients, 1,000 asymptomatic family members, 1,000 neurological normal controls) for this study
9936541|NCT02009800|No Intervention|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
9936542|NCT02009800|Experimental|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
9936543|NCT02008292|Experimental|physostigmine and amphetamine|There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
9936544|NCT01993719|Experimental|1/Arm 1 (CLOSED)|Standard preparative regimen + Young TIL Cells
9936545|NCT01993719|Experimental|1/Arm 1P|Standard preparative regimen + Young TIL Cells + possible retreatment with standard preparative regimen + Young TIL Cells +pembrolizumab
9936546|NCT01993719|Experimental|2/Arm 2 (CLOSED)|Lower dose preparative regimen + Young TIL Cells
9936547|NCT01993719|Experimental|3/Arm 1N|Standard preparative regimen + Young TIL Cells
9936548|NCT01981538||Adult informal caregivers|Subjects will be eligible for this protocol if they are adult informal caregivers that are family members or friends of a patient enrolled in a cancer treatment study at the NIH Clinical Center
9936549|NCT01976715||HIV-1|Subjects (greater than or equal to 18 years) with human immunodeficiency virus type 1 (HIV-1) who have documented virologic failure.
9936550|NCT01969825|Experimental|Massage|Professional Swedish massage less than 15 minutes prior to semen collection for intrauterine insemination.
9936551|NCT01969825|No Intervention|No massage|Normal protocol for semen collection prior to intrauterine insemination.
9936552|NCT01967563||overweight and class I obese adult male volunteers|Adult Male Subjects will be recruited to determine the effects on energy expenditure of transitioning from an energy-and macronutrient-balanced standard baseline diet to a eucaloric ketogenic diet
9936553|NCT01961557|Experimental|There is a single study arm in this feasibility study|All participants will be evaluated using the different configurations of the EA-KAFO (see Table 1 in the protocol), which includes the configuration that contains the Active Motorized KAFO and the configuration that contains the Powerwalk Knee Exoskeleton. Each subject will serve as their own control to assess the effect of each configuration of the EA-KAFO interventions.
9936554|NCT01953016||immunodeficiency|Individual of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.
9936555|NCT01952574|Placebo Comparator|Placebo|"Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
9936556|NCT01952574|Experimental|Erenumab 7 mg QM|"Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
9936557|NCT01952574|Experimental|Erenumab 21 mg QM|"Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
9936558|NCT01952574|Experimental|Erenumab 70 mg QM|"Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
9936559|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg PFS|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
9936560|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg AI/Pen|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
9936561|NCT01952171||Congenital Heart Disease|Congenital Heart Disease
9936562|NCT01950624||Down syndrome cohort|Individuals who have a diagnosis of complete trisomy 21, translocation down syndrome and Mosaic Down syndrome
9936563|NCT01950572||1/Eligible cancer diagnosis|Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
9936564|NCT01950520|Experimental|Cohort 2|Interventions, in random order, will be administered during one of the six one-day stays
9936565|NCT01950520|Experimental|Cohort 3|Interventions, in random order, will be administered during one of the four overnight inpatient stays
9936566|NCT01950520|Experimental|Low Temperature 1st|Low temperature before 27c (Cohort 1 only)
9936567|NCT01950520|Experimental|Low Temperature 2nd|Low temperature after 27c (Cohort 1 only)
9936568|NCT01934660||Group 1|Healthy volunteers
9936569|NCT01934660||Group 2|Subjects diagnosed with diabetes
9936570|NCT01934660||Group 3|Subjects diagnosed cardiovascular disease
9936571|NCT01933620||Patient|Patients who might become colonized or infected with a multi drug-resistant organism
9936572|NCT01927783||Group 1|Healthy Volunteer
9936573|NCT01927783||Group 2|Focus Group- Neighborhood and Physical Activity
9936574|NCT01927783||Group 3|Focus Group
9936575|NCT01927783||Group 4|Focus Group- Mobile App
9936576|NCT01927783||Group 5|Consent for Cooking Survey Focus Group
9936577|NCT01927783||Group 6|Community Organization Survey focus Group
9936578|NCT01925196||C9ORF72|Participants with C9ORF72 mutation
9936579|NCT01919099||Post-transplant|Patients receiving allogenic stem cell transplants at the NIH CC
9936580|NCT01915225||1/ Cohort 1|Subjects with or without solid tumors in whom diagnostic, preventative, or therapeutic intervention is being performed
9936581|NCT01915212|Experimental|HSV529|1 x 107 pfu/dose of HSV529 in 10 mM L-histidine buffer containing 50 mM potassium glutamate, 160 mM sodium chloride, and 10% (w/v) sucrose
9936582|NCT01915212|Placebo Comparator|Placebo|Sodium Chloride 0.9%
9936583|NCT01905865||Parent|Persons aged 18 years or older who have a child with an undiagnosed medical condition, who have applied to the Undiagnosed Diseases Network, and have been assigned to the NIH.
9936584|NCT01905826||Patient Relatives|Blood relatives of enrolled patients.
9936585|NCT01905826||Patients|Patients with known mutations in GATA2 or those with clinical and laboratory characteristics strongly consistent with GATA2 deficiency.
9936586|NCT01900132|Experimental|1/All Subjects|Healthy Volunteers and patients
9936587|NCT01888913||Adult Women|Adult Women aged 18-50
9936588|NCT01878045||American Indians with type 2 diabetes|previously enrolled in OH95-DK-N037
9936589|NCT01875601|Experimental|A|NK cell infusion (dose escalation)
9936590|NCT01875601|Experimental|B|NK cell infusion + escalating doses of rhIL15
9936591|NCT01875588||DOD|Participants that are from IDCRP
9936592|NCT01875588||HIV negative controls|Participants that do not have HIV infection
9936593|NCT01875588||HIV positive|Participants that have HIV infection
9936594|NCT01867411||ex-smokers|former smokers who have quit
9936595|NCT01867411||never smokers/vapers|never smoked/vaped nicotine
9936596|NCT01867411||non-treatment seeking smokers/vapers|smokers/vapers not interested in quitting nicotine
9528814|NCT03207269|No Intervention|Control no snack|No snack will be consumed prior to bed.
9936597|NCT01867411||Treatment seeking smokers/vapers|smokers/vapers interested in quitting nicotine
9936598|NCT01867333|Experimental|1|Enzaluatmide alone
9936599|NCT01867333|Experimental|2|Enzaluatmide with PSA-TRICOM
9936600|NCT01867320|Experimental|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
9936601|NCT01862731||1/Control Volunteers|Healthy controls
9936602|NCT01862731||2/Volunteers with Pain|Subjects with Chronic Idiopathic Patellofemoral Pain
9936603|NCT01862718|Experimental|1|Ablation plus radiation
9936604|NCT01862107||Healthy Volunteer|Any healthy volunteer getting a lumbar puncture done for either clinical care or research purposes.
9936605|NCT01862107||Patient|Any patient getting a lumbar puncture done for either clinical care or research purposes.
9936606|NCT01861106|Active Comparator|Arm A|10/10 HLA Matched Related Donor or Unrelated Donor or 9/10 HLA with DQ mismatch Transplant
9936607|NCT01861106|Active Comparator|Arm B|9/10 or 8/10 HLA Match Related Donor or Unrelated Donor or Haploidentical Donor Transplant
9936608|NCT01861106|Active Comparator|Arm C (combined with Arm B per Amendment N)|Haploidentical Related Donor Transplant
9999004|NCT01523912|Experimental|gastric RFA|Ablation of gastric dysplastic mucosa
9999005|NCT01523925|Experimental|Combined dCIT with FET|Combined distributed constraint induced therapy with functional electrical therapy
9999006|NCT01523925|Experimental|Combined BAT with FET|Combined bilateral arm treatment with functional electrical therapy
9999007|NCT01523925|Active Comparator|Control intervention group|Control intervention
9999008|NCT01523925|Experimental|dCIT|distributed constraint induced therapy
9999009|NCT01523925|Experimental|BAT|bilateral arm treatment
9999010|NCT01523938|Experimental|Hypnotherapy|
9999011|NCT01523938|No Intervention|No Hypnotherapy|
9999012|NCT01523951||Healthy volunteers|
9999013|NCT01523990|Experimental|Panel I (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
9999014|NCT01523990|Placebo Comparator|Panel I (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
9999015|NCT01523990|Experimental|Panel II (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
9999016|NCT01523990|Placebo Comparator|Panel II (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
9999017|NCT01523990|Experimental|Panel III (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
9999018|NCT01523990|Placebo Comparator|Panel III (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
9999019|NCT01523990|Experimental|Panel IV (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
9999020|NCT01523990|Placebo Comparator|Panel IV (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
10214255|NCT00250458|Experimental|1|Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate
9999021|NCT01523990|Experimental|Panel V (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
9999022|NCT01523990|Placebo Comparator|Panel V (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
9999023|NCT01523990|Experimental|Panel VI (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
9999024|NCT01523990|Placebo Comparator|Panel VI (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
9999025|NCT01523990|Experimental|Panel VII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
9999026|NCT01523990|Placebo Comparator|Panel VII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
9999027|NCT01523990|Experimental|Panel VIII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
9999028|NCT01523990|Placebo Comparator|Panel VIII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
9999029|NCT01523990|Experimental|Panel IX (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
10214256|NCT00250458|Placebo Comparator|2|matching placebo
10214257|NCT00245570|Experimental|1|Montelukast - Salmeterol - Placebo
10214258|NCT00245570|Experimental|2|Montelukast - Placebo - Salmeterol
10214259|NCT00245570|Experimental|3|Salmeterol - Montelukast - Placebo
10214260|NCT00245570|Experimental|4|Salmeterol - Placebo - Montelukast
10214261|NCT00245570|Experimental|5|Placebo - Montelukast - Salmeterol
10214262|NCT00245570|Experimental|6|Placebo - Salmeterol - Montelukast
10214263|NCT00229970|Experimental|1|Placebo
10214264|NCT00229970|Experimental|2|MK0476 7 mg injection
10214265|NCT00229970|Experimental|3|MK0476 14 mg injection
10214266|NCT00092131|Experimental|1|Montelukast - Placebo
10214267|NCT00092131|Experimental|2|Placebo - Montelukast
10214268|NCT00092118|Experimental|1|Montelukast
10214269|NCT00092118|Placebo Comparator|2|Placebo
10214270|NCT00092092|Experimental|Montelukast→Placebo|Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.
10214271|NCT00092092|Experimental|Placebo→Montelukast|Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.
10214272|NCT00092092|Active Comparator|Budesonide→Placebo|Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.
10214273|NCT00092092|Active Comparator|Placebo→Budesonide|Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.
9999030|NCT01523990|Placebo Comparator|Panel IX (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
9999031|NCT01523990|Experimental|Panel X (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
9999032|NCT01523990|Placebo Comparator|Panel X (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
9999033|NCT01523990|Experimental|Panel XI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
9999034|NCT01523990|Placebo Comparator|Panel XI (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
9999035|NCT01523990|Experimental|Panel XII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.
9999036|NCT01523990|Experimental|Panel XIII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.
9999037|NCT01523990|Experimental|Panel XIV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.
9999038|NCT01523990|Experimental|Panel XV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.
9999039|NCT01523990|Experimental|Panel XVI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.
9999040|NCT01524003|Experimental|Cryotherapy after VIA triage|Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.
9999041|NCT01524003|Active Comparator|Colposcopy and biopsy|Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
9999042|NCT01524016|Experimental|68Ga-DOTATATE, PET/CT scan|We will perform 68Ga-DOTATATE PET/CT scanning on subjects
9999043|NCT01524029||Breast Cancer Screening Patients|Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
9999044|NCT01524029||Diagnostic Patients|Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
9999045|NCT01524042|Experimental|group 2|study group:double pants group
9999046|NCT01524055|Other|Air|Air as insufflation gas during single-balloon enteroscopy.
9999047|NCT01524055|Other|CO2|CO2 as insufflation gas during single-balloon enteroscopy.
9999048|NCT01524068|Experimental|Arm A - Standard Steroid Treatment|
9999049|NCT01524068|Experimental|Arm B - Experimental Treatment|
9999050|NCT01524081|Experimental|APPE - antibiotic prophylaxis|Patients indicated for emergent appendectomy with antibiotic prophylaxis
9999051|NCT01524081|Experimental|GERD - antibiotic prophylaxis|Patients indicated for emergent surgery due to gastroduodenal perforation with antibiotic prophylaxis.
9999052|NCT01524081|Experimental|ILEUS - antibiotic prophylaxis|Patients indicated for emergent due to small bowel obstruction with antibiotic prophylaxis
9999053|NCT01524081|Placebo Comparator|APPE - placebo|Patients indicated for emergent appendectomy without antibiotic prophylaxis. Placebo (saline) was administrated.
9999054|NCT01524081|Placebo Comparator|GERD - placebo|Patients indicated for emergent surgery due to gastroduodenal perforation without antibiotic prophylaxis. Placebo (saline) was administrated.
9999055|NCT01524081|Placebo Comparator|ILEUS - placebo|Patients indicated for emergent due to small bowel obstruction without antibiotic prophylaxis. Placebo (saline) was administrated.
9999056|NCT01524094|Experimental|Arm A: CRS plus postop intraperitoneal chemotherapy.|Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
9999057|NCT01524094|Active Comparator|Arm B: Systemic chemotherapy alone|Systemic chemotherapy alone
9999058|NCT01524107||Urgent Caesarian Section|
9999059|NCT01524107||Elective Caesarian Section|
9999060|NCT01524120||Crohn's disease (CD)|Patients with CD and mucosal healing on endoscopy.
9999061|NCT01524120||Crohn's disease|Patients with CD and mucosal healing on endomicroscopy.
9999062|NCT01524120||Ulcerative colitis (UC)|Patients with UC and mucosal healing on endoscopy.
9528815|NCT03207529|Experimental|Treatment (alpelisib, enzalutamide)|Patients receive alpelisib PO and enzalutamide PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9528816|NCT03207425|Experimental|Mild hepatic impairment group|
9999063|NCT01524120||Ulcerative colitis|Patients with UC and mucosal healing on endomicroscopy.
9999064|NCT01524146||Photodynamic therapy|Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
9999065|NCT01524159|Placebo Comparator|placebo group|This group will receive placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
9999066|NCT01524159|Active Comparator|bromelain group|Bromelain Group This group will receive bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
9999067|NCT01524172|Active Comparator|Standard Mental Health Treatment|Trauma-informed evidence supported mental health treatment
9999068|NCT01524172|Experimental|Yoga Based Psychotherapy Group|Yoga Based Psychotherapy will be used as an adjunct mental health interventions
9999069|NCT01524185|Experimental|FamilyLive|Multi-therapist group intervention for families with a history of intergenerational neglect and trauma exposure
9999070|NCT01524185|Active Comparator|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
9999071|NCT01524237|Experimental|10 mg LY2140023 + ketamine|Single oral dose of 10 mg LY2140023 followed by intravenous (IV) ketamine during one of the crossover periods
9999072|NCT01524237|Experimental|20 mg LY2979165 + ketamine|Single oral dose of 20 mg LY2979165 followed by IV ketamine during one of the crossover periods
9999073|NCT01524237|Experimental|40 mg LY2140023 + ketamine|Single oral dose of 40 mg LY2140023 followed by IV ketamine during one of the crossover periods
9999074|NCT01524237|Experimental|60 mg LY2979165 + ketamine|Single oral dose of 60 mg LY2979165 followed by IV ketamine during one of the crossover periods
9999075|NCT01524237|Experimental|160 mg LY2140023 + ketamine|Single oral dose of 160 mg of LY2140023 followed by IV ketamine during one of the crossover periods
9999076|NCT01524237|Placebo Comparator|Placebo capsules + ketamine|Single oral dose of placebo capsules followed by IV ketamine during one of the crossover periods
9999077|NCT01524237|Placebo Comparator|Placebo tablets + ketamine|Single oral dose of placebo tablets followed by IV ketamine during one of the crossover periods
9999078|NCT01524250|Experimental|oral prednisone|1250mg oral prednisone daily for 3 days
9999079|NCT01524250|Active Comparator|IV methylprednisolone|1000mg IV methylprednisolone daily for 3 days
9999080|NCT01524315|Experimental|Supplementation|6 ml Vitamin-B1-ratiopharm in 100 ml normal saline, intravenous, preoperative
9999081|NCT01524315|Placebo Comparator|Placebo|100 ml normal saline, intravenous, preoperative
9999082|NCT01524341|Experimental|Cohort 1|10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
9999083|NCT01524341|Experimental|Cohort 2|10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days
9999084|NCT01524354|Active Comparator|Control|Patients received maintenance of anesthesia with continuous infusion of propofol according to recommendations of the manufacturer.
9999085|NCT01524354|Active Comparator|cerebral state index|Patients received continuous infusion of propofol with rate maintaining cerebral state index (CSI) between 40 and 60 points.
9999086|NCT01524367|Placebo Comparator|saline group|We administrate the saline single bolus (0.01ml/kg,intravenously) at time of oral cavity sealing.
9999087|NCT01524367|Experimental|dexmedetomidine group|We administrate the dexmedetomidine single bolus (1ug/kg, intravenously) at time of oral cavity sealing.
9999088|NCT01524380|Active Comparator|Ginkgo biloba extract, antioxidant|Active treatment with Ginkgo biloba extract
9999089|NCT01524380|Placebo Comparator|Placebo|Treatment with placebo
9999090|NCT01524393||IVF pregnancy|
9999091|NCT01524406|Experimental|HPP593|
9999092|NCT01524406|Placebo Comparator|Placebo|
9999093|NCT01524419||women after vaginal birth|
9999094|NCT01524432|Experimental|Drug loaded microcapsules socks|Study medication
9999095|NCT01524432|Placebo Comparator|No drug loaded microcapsules socks|Placebo medication
9999096|NCT01524445||bortezomib retreatment|bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
9999097|NCT01524458|Experimental|POEM|To perform myotomy using endoscopy through a long submucosal tunnel
9999098|NCT01524471|Experimental|POEM|Endoscopic Myotomy
9999099|NCT01524484||Anesthesia staff Interviewees|Staff entering quality data into the electronic anesthesia record are interviewed regarding working conditions and record layout
9999100|NCT01524484||Anesthesia records|Anesthesia records (all types of procedures) are checked for correct reporting of defined events
9999101|NCT01524497|Active Comparator|Trazodone|
9999102|NCT01524497|Placebo Comparator|Placebo|
9999103|NCT01524510|Experimental|MRA|All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA
9999104|NCT01524562||Rakai Community Cohort|HIV Patients
9999105|NCT01524562||Rakai HIV Care Program|HIV Patients
9999106|NCT01524575|No Intervention|ERCC1 high expression|Patients with ERCC1 high expression tumors will be treated at discretion of investigator
9999107|NCT01524575|Experimental|ERCC1 low expression|Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
9999108|NCT01524601|Experimental|Rosuvastatin|Rosuvastatin treatment for 4 weeks
9999109|NCT01524614|Experimental|Nasal mask with no PEEP|Nasal mask with PEEP 0, then add PEEP 5, and 10
9999110|NCT01524614|Experimental|Nasal mask with PEEP|Nasal mask with PEEP 5, then add PEEP 10
9999111|NCT01524614|Experimental|Face mask with no PEEP|Face mask with PEEP 0 then add PEEP 5, 10
9999112|NCT01524614|Experimental|Face mask with PEEP|Face mask with PEEP 5, then add PEEP 10
9999113|NCT01524640|Experimental|Killed oral cholera vaccine|"Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
9999114|NCT01524640|Placebo Comparator|Placebo|"Non biologic placebo~Ingredients Per 1.5 ml dose~Starch 60mg~Red color[1mg/ml] 10 µl~Yellow color [1mg/ml] 5 µl~Xanthum Gum (1% solution) 300 µl~Water for Injection Upto 1.5 ml~All the above ingredients are of pharmaceutical grade.~Non-biological placebo of above composition has been used in 2010 for Randomized, double-blind, placebo controlled trial to evaluate the safety and immunogenicity of orally administered, killed, bivalent whole-cell , cholera vaccine, Shanchol in Bangladeshi Adults and Children. This study involving 330 subjects was carried out at International Center for Diarrheal Disease Research Bangladesh (ICDDR,B) located in Dhaka, Bangladesh with Dr. Firdausi Qadri as Principal Investigator (NCT01042951). There were no safety concerns associated with this placebo in this study and the report of this study has been submitted to the National Regulators in Bangladesh and the World Health Organization."
9999115|NCT01524653|Experimental|Rosuvastatin First, Placebo Last|This arm will receive rosuvastatin during the first treatment period followed by placebo in the second treatment period after washout.
9999116|NCT01524653|Experimental|Placebo First, Rosuvastatin Last|This arm will receive placebo during the first treatment period followed by rosuvastatin in the second treatment period after washout.
9999117|NCT01524705|Experimental|Insulin Glargine, metformin, exenatide|Approximately 60 Type 2 DM participants will be instructed on an AHA/ADA meal plan. Insulin Glargine, metformin and exenatide will used as a combination strategy to control individual HBA1Cs between 6.7 and 7.3% throughout the trial.
9999118|NCT01524705|Active Comparator|glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
9999119|NCT01524718|Experimental|Imaging with two X-ray image intensifiers|There is no change in the procedure except for the imaging technique, while in the first group the X- ray image intensifier serves in the two planes, and being moved from one plane to the other, and in the second group the two devices are static in the same position, one in the AP plane and the other as the axial plane.
9999120|NCT01524718|No Intervention|Imaging with one X-ray image intensifier.|The X- ray image intensifier serves in the two planes, and being moved from one plane to the other
9999121|NCT01524731|Placebo Comparator|Placebo|Placebo group
9999122|NCT01524731|Active Comparator|4 mg dexamethasone|4 mg dexamethasone group
9999123|NCT01524731|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg group
9999124|NCT01524744|Active Comparator|Pimecrolimus ointment 0.1 %|This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
9999125|NCT01524744|Active Comparator|Adcortyle|Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
9999126|NCT01524757|Experimental|pantoprazol|
9999127|NCT01524757|Placebo Comparator|placebo|
9999128|NCT01524809|Experimental|Treatment period 1|
9999129|NCT01524809|Experimental|Treatment period 2|
9999130|NCT01524835||Live lung donors|Live lung donors who participated in donation from 1993 through 2006
9999131|NCT01524848|Other|Open label|Single arm pazopanib
9999132|NCT01524861|Placebo Comparator|Placebo|30 subjects receive placebo (placebo group)
9999133|NCT01524861|Experimental|alpha-lipoic acid|30 subjects receive alpha-lipoic acid, 400 mg/day per os bis in die (800 mg/day)(ALA group)
9528817|NCT03207425|Experimental|Moderate hepatic impairment group|
9936609|NCT01861106|Active Comparator|Arm D (Deleted this arm per amendment I)|Umbilical Cord Blood Transplant
9936610|NCT01861106|No Intervention|Arm E (Deleted this arm per amendment O)|Donor
9936611|NCT01861093|Experimental|1|at least one
9936612|NCT01859299||Affected|Participants with various types of uveitis
9936613|NCT01859299||Healthy controls|Participants without uveitis
9936614|NCT01851447||Fragile Sarcolemmal Muscular Dystrophy|patients with early adulthood or late onset of a genetic disorder FSMD (LGMD 2B-F, I, L, MM, BMD and MMD3)
9936615|NCT01851434||healthy volunteers|age- and sex-matched to the participants with unilateral optic neuritis and a brain MRI suggestive of MS
9936616|NCT01851434||Patients with unilateral optic neuritis|Recruitment will proceed until 10 participants with a brain MRI suggestive of MS (obtained at any time point during the study) have completed the study.
9936617|NCT01851395||1/Thoracic|Patients with histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma
9936618|NCT01851395||2/Genitourinary|Patients with genitourinary malignancies
9936619|NCT01851395||3/ACT|Patients treated with an adoptive cellular therapy
9936620|NCT01851395||4/Ovarian|Patients with ovarian cancer
9936621|NCT01851395||5/Epithelial|Patients with breast, colorectal, pancreatic, stomach or biliary cancer.
9936622|NCT01851382||Cohort 1|Healthy volunteers.
9936623|NCT01851369|Experimental|1|combination treatment with oral TRC102 and oral TMZ for days 1-5 of 28-day cycles
9936624|NCT01842399|Placebo Comparator|Placebo Comparator|2x/day orally
9936625|NCT01842399|Experimental|Resveratrol 1|75 mg, 2x/day orally
9936626|NCT01842399|Experimental|Resveratrol 2|150 mg, 2x/day orally
9936627|NCT01842386|Experimental|Rituximab|Adults (=18 years of age) with anticytokine autoantibodyassociated diseases who are refractory to conventional treatment and who test negative for the human immunodeficiency virus (HIV)
9936628|NCT01841957|Experimental|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
9936629|NCT01841957|Active Comparator|DSBCS|Delayed Sequential Bilateral Cataract Surgery
9936630|NCT01838512||Cohort 1|Participants with relapsed/refractory multiple myeloma (RRMM) followed up for up to 5 years
9936631|NCT01838512||Cohort 2|Participants with newly-diagnosed multiple myeloma (NDMM) followed up for up to 8 years
9936632|NCT01834001||1/Untreated prostate cancer|Patients with untreated prostate cancer
9936633|NCT01834001||2/Radiotherapy treated prostate cancer|Patients with prostate cancer who have already received definitive radiotherapy and have experienced biochemical failure
9936634|NCT01829724||Healthy volunteer|The control groups for each participant cohort will consist of up to 50 individuals spanning Objectives 1 and 2, for a total recruitment of up to 100 healthy volunteers within the same age range.
9936635|NCT01829724||Individuals with childhood-onset brain or peripheral injury|The childhood-onset brain injury group 120 individuals spanning the three objectives.
9936636|NCT01812694|Active Comparator|Enhanced Standard Care|Standard prenatal care plus education
9936637|NCT01812694|Experimental|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
9936638|NCT01809288||1|Healthy African, African-American, and white women between 30 and 65 years of age who are federal employees or contractors.
9936639|NCT01805869||Healthy volunteers|Male or female ages 16-50
9936640|NCT01802567|Experimental|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
9936641|NCT01799538|Experimental|1|Nebullizer
9936642|NCT01799538|Active Comparator|2|Inhaler
9936643|NCT01795586|Experimental|Dose Escalation|Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
9936644|NCT01783509||LGMD|Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
9936645|NCT01780168||Inborn errors of metabolism/mitochondrial disease|Patients with inborn errors of metabolism including those with mitochondrial disease
9936646|NCT01780142||asthmatics|Subjects with confirmed diagnosis of asthma without other lung disease followed for collection of clinical data &amp; specimens
9936647|NCT01780142||non-asthmatic healthy volunteers|Healthy volunteers in whom asthma has been ruled out and without other lung disease followed for comparison to asthmatics
9936648|NCT01778569||Group 1|Patient with a diagnosis of chronic plaque psoriasis, psoriatic arthritis, or pustular psoriasis
9936649|NCT01778543||Coloboma|Participants with Coloboma and their family members.
9936650|NCT01778504||Probands|Children, adolescents, and adults
9936651|NCT01778504||Relatives of Probands|1st, 2nd, and 3rd degree relatives
9936652|NCT01747213|Experimental|BNC|Bisnorcymserine tartrate
9936653|NCT01747213|Placebo Comparator|Placebo|microcrystalline celluose
9936654|NCT01736293||Affected Patients|Participants with ABCA4-related retinopathies.
9936655|NCT01734369||Healthy Control Subjects|Military service members active duty or no longer in duty, military contractors, and civilians working for the military. Controls should be without a recognized autoimmune or chronic muscle disease.
9936656|NCT01734369||Myositis Subjects|Diagnosis of myositis during military service or service as a military contractor or civilian working for the military with polymyositis, dermatomyositis, or inclusion body myositis.
9936657|NCT01730131||Control Patients at Risk for PML|Participants with impaired immune function from any cause and considered at risk for PML
9936658|NCT01730131||Healthy Volunteers|Healthy volunteers without impaired immune function
9936659|NCT01730131||PML Patients|Participants with PML
9936660|NCT01730092||Healthy Volunteers|Enroll up to 120 healthy volunteers, in order to obtain approximately 55 evaluable healthy volunteers matched to pulmonary arterial hypertension subjects for age and gender
9936661|NCT01730092||Pulmonary Arterial Hypertension Subjects|150 subjects with pulmonary arterial hypertension; male or female, age equal to 18-99 years
9936662|NCT01721720||1|children and adolescents and adults with ADHD
9936663|NCT01712672||1|Healthy participants
9936664|NCT01712620|Experimental|Group A|Spironolactone
9936665|NCT01712620|Placebo Comparator|Group B|Placebo
9936666|NCT01702922||1/Active Cancer Parents|Must have been in a partnership at the time child was diagnosed with cancer &amp; must have been diagnosed at least 3 months prior to enrollment on this study &amp; be currently receiving treatment
9936667|NCT01702922||2/Complete Cancer Parents|Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
9936668|NCT01702922||3/NF1 Parents|Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
9936669|NCT01696734|Experimental|Treatment (domperidone)|Patients receive domperidone PO TID or QID. Treatment continues in the absence of disease progression or unacceptable toxicity.
9936670|NCT01678222||SNP|individuals who are homozygous for either the major or minor variant of both SNPs
9936671|NCT01676805||1|Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy
9936672|NCT01676805||2|Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy
9936673|NCT01661959||Non-Operative|
9936674|NCT01661959||Operative|
9936675|NCT01661010||Control|Family members can serve as control group
9936676|NCT01661010||Sex-linked genes|Patients previously identified through outside research or diagnostic labs as having sex-chromosome variants causing deletion/duplication of sex-linked genes or entire sex chromosomes.
9936677|NCT01660984||Parents/caregivers|Parents or caregivers of study patients to assess their psychosocial experiences and needs.
9936678|NCT01660984||Patients|Children and adults with MTC and MEN2B, other non-tumor manifestations of MEN2, and patients with MEN2 who do not demonstrate MTC. Characterize the biology and manifestations of their disease.
9936679|NCT01660451|Experimental|Copanlisib (indolent NHL)|Part A: Participants in this arm will be patients with indolent NHL.
9936680|NCT01660451|Experimental|Copanlisib (aggressive NHL)|Part A: Participants in this arm will be patients with aggressive NHL.
9936681|NCT01660451|Experimental|Copanlisib (indolent B-cell NHL)|Part B: Participants in this arm will be patients with indolent B-cell NHL.
9936682|NCT01659151|Experimental|Combination Therapy|Combination Chemotherapy and Immunotherapy. The combination of vemurafenib followed by lymphodepletion with chemotherapy, Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) infusion, and High Dose Interleukin-2 (IL-2).
9936683|NCT01658917||Primary|Patients greater than or equal to 18 years of age who have premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis
9936684|NCT01656564||Healthy Controls|Individuals with no known history of HIV
9936685|NCT01656564||Healthy Controls - Questionnaire Group|Individuals with no known history of HIV
9936686|NCT01656564||HIV|Individuals who acquired HIV in early life
9936687|NCT01639950||Adults Group 1|Adults patients with cancer or neurofibromatosis 1 (NF1)
9936688|NCT01639950||Adults Group 2|Adults with sickle cell disease (SCD)
9936689|NCT01639950||Children|Children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
9936690|NCT01639950||Parents|Parents of children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
9936691|NCT01634048|Experimental|High protein low calorie meal replacements|Meal replacements with added protein powder(1.34g pro/kg).
9936692|NCT01634048|Sham Comparator|Normal protein, low calorie meal replacement group|The control group will have standard meal replacements (0.8g protein/kg body weight).
9936693|NCT01633411||Cohort A|Subjects in Cohort A will receive 6 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
9936694|NCT01633411||Cohort B|Subjects in Cohort B will receive 8 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
9936695|NCT01633411||Cohort C|Subjects in Cohort C will receive 10 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
9936696|NCT01633021||Diabetes|Self/Family member affected by type-2 diabetes (plus self-referred family-members)
9936697|NCT01633021||Heritable Cancer Screen-Positive|Person who has screened-positive for heritable cancers on genetic tests (plus referred family-members)
9936698|NCT01633021||Sickle Cell (Trait/Disease/Related)|Self/Family member affected by Sickle Cell Trait or Sickle Cell Disease (plus self-referred family-members)
9936699|NCT01631617|Active Comparator|1A/Cephalexin|Cephalexin + Placebo bleach
9936700|NCT01631617|Active Comparator|1B/TMP/SMX|TMP/SMZ DS 800 /160 orally every 12 hours for 14 days
9936701|NCT01631617|Active Comparator|1C/Doxycycline 100|Doxycycline 100 mg orally every 12 hours for 56 days
9936702|NCT01631617|Active Comparator|1D/Doxycycline 20|Doxycycline 20 mg orally every 12 hours for 56 days
9936703|NCT01631617|Active Comparator|2A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
9936704|NCT01631617|Placebo Comparator|2B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
9936705|NCT01631617|Placebo Comparator|2C/Placebo capsules + Dilute bleach|Placebo capsules + dilute bleach study bath liquid
9936706|NCT01631617|Placebo Comparator|2D/Placebo capsules + Placebo bleach|Placebo capsules + placebo study bath liquid
9936707|NCT01631617|Active Comparator|3A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
9936708|NCT01631617|Placebo Comparator|3B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
9936709|NCT01629108||1|Healthy volunteers aged 5 to 80
9936710|NCT01624220|Experimental|Hypofractionated Radiation|"All patients receive CT-guided spinal SBRT using IMRT to maximize conformality of treatment plan to target volume, while sparing normal structures. Dose given to tumor and number of treatments received determined by patient's doctor.~In second stage, characterize tolerance of esophagus to hypofractionated radiation doses through prospective constraint relaxation and toxicity monitoring. Data collected from Group 1 in first stage will give data on dose delivered to esophagus. Second stage of protocol will begin accrual once Group 1 has filled. Dose constraints used for Groups 3 allow higher dose. Dose constraints for Group 4 represent modest increase of esophageal dose maximums."
9936711|NCT01624220|Experimental|ExacTrac Positioning System|Analysis performed of ExacTrac positioning system with and without fiducial guidance. Four dimensional CT datasets for simulation will allow use of data from this portion of protocol to characterize degree to which organ at risk (OAR) motion is relevant at each spinal level. 20 patients accrued in two groups of 10, with 10 patients in each rostral-caudal position in the spine (Group 1: T4-T12, Group 2: L1-L5). Imaging done with fiducial markers for this study will not impact patient management. Patients will treated with standard dose constraints to normal tissues.
9936712|NCT01621594|Experimental|1|Subjects with Clinical indication for a coronary CT angiography exam
9936713|NCT01621581|Experimental|Single Arm|AAV2-GDNF vector will be delivered to each patient
9936714|NCT01617408||1|Neurologically normal subjects aged 18 to 50 years old
9936715|NCT01617395||GEMS cohort|Individuals at risk for developing MS
9936716|NCT01617395||Healthy Volunteer Cohort|Healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS
9936717|NCT01617395||MS Patients Cohort|MS patients whose first-degree relatives are enrolled in this study
9936718|NCT01590069|Experimental|Treatment (aerosolized aldesleukin)|Patients receive aerosolized aldesleukin QD on days 1-21. Courses repeat every 28 days in the absence of disease progression of unacceptable toxicity.
9936719|NCT01581580|Other|treatment arm|patients with Parkinson's Disease, dysonia, and essential tremor
9936720|NCT01581554||Patients with HBeAg negative chronic hepatitis B|Patients with HBeAg negative chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
9936721|NCT01581554||Patients with HBeAG positive chronic hepatitis B|Patients with HBeAg positive chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
9936722|NCT01573390||1|Healthy participants.
9936723|NCT01572662|Experimental|Fludarabine + Busulfan|"Fludarabine administered by vein at dose of 40 mg/m2 in 100 ml of normal saline (NS) on Days -6 through -3.~First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies."
9936724|NCT01572506|Active Comparator|Group 1|Age 70 and older with unexplained anemia
9936725|NCT01572506|Active Comparator|Group 2|Age 70 and older with iron deficient
9936726|NCT01572506|Active Comparator|Group 3|Age 70 and older without anemia
9936727|NCT01572506|Active Comparator|Group 4|Age 18 - 50 without anemia
9936728|NCT01572480|Experimental|A - (closed)|Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)
9936729|NCT01572480|Experimental|B|Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1-21 of the 28-day cycle); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle)
9800583|NCT01691612|Experimental|D. pteronyssinus allergens|Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments
9800584|NCT01691690|Experimental|IV Acetaminophen|Patients will receive pre-medication with oral midazolam Participants of this experimental arm of the study will receive Acetaminophen IV to evaluate opioid-sparing effect and pain score reduction..
9528818|NCT03207425|Experimental|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
9936730|NCT01571752||CMU|Current marijuana users
9800585|NCT01691690|Placebo Comparator|Saline placebo infused intraoperatively|For this arm Morphine will be administered to manage pain.
9800586|NCT01691768|Experimental|Intervention|1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of Quality Improvement methodology to promote reliable service delivery
9800587|NCT01691768|Active Comparator|Control|monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
9999134|NCT01524861|Experimental|L-acetil-carnitine|30 subjects receive L-acetyl carnitine, 500 mg per os bis in die (1000 mg/day) (LAC group)
9999135|NCT01524874|Active Comparator|Powder D3 Capsule - 2,000 IU per Cap|Vital Nutrients
9999136|NCT01524874|Active Comparator|Chewable D3 Tablet - 2,000 IU per Tab|Integrative Therapeutics Inc.
9800588|NCT01691781|Experimental|lisinopril|Lisinopril - open-label, 2.5-40mg daily
9800589|NCT01691794|Active Comparator|Atazanavir, 150 mg + Ritonavir, 100 mg (weight:15 to <20 kg)|Participants with baseline weight of 15 to <20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
9999137|NCT01524874|Active Comparator|Liquid D3 Drop - 2,000 IU per Drop|Biotics Research
9999138|NCT01524926|Experimental|Crizotinib in Anaplastic large cell lymphoma|
9999139|NCT01524926|Experimental|Crizotinib in Inflammatory myofibroblastic tumor|
9999140|NCT01524926|Experimental|Crizotinib in Papillary renal cell carcinoma type 1|
9999141|NCT01524926|Experimental|Crizotinib in Clear cell sarcoma|
9999142|NCT01524926|Experimental|Crizotinib in Alveolar soft part sarcoma|
9999143|NCT01524926|Experimental|Crizotinib in Alveolar rhabdomyosarcoma|
9999144|NCT01524939|Experimental|Investigational product|
9999145|NCT01524952|Experimental|Active|cTEMS
9999146|NCT01524965|Experimental|Immediate mobilisation|
9999147|NCT01524965|Active Comparator|Standard mobilisation|
9999148|NCT01525004|Active Comparator|Standard dose trivalent inactivated influenza vaccine|
9936731|NCT01571752||Cohort 1 - HIV Positive|HIV positive adults
9936732|NCT01571752||Cohort 1 - NIH Negative|HIV negative adults
9936733|NCT01571752||Cohort 2 Seeds-Wave 0|HIV positive adults
9936734|NCT01571752||Cohort 2 Wave 1|HIV negative adults or HIV positive adults
9936735|NCT01571752||Cohort 2 Wave 2|HIV negative adults or HIV positive adults
9936736|NCT01571752||COSU|Current opioid/stimulant users
9936737|NCT01571752||COSU-NTS|Non-treatment seekers
9936738|NCT01571752||COSU-TS|Treatment seekers
9936739|NCT01571752||NDU|Non-drug-users
9936740|NCT01571752||Unclassified|
9999149|NCT01525004|Experimental|High-Dose trivalent inactivated influenza vaccine|
9999150|NCT01525017|Experimental|Combig-DC Cancer Vaccine|Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.
9999151|NCT01525043|Active Comparator|Naproxen|
9999152|NCT01525043|Experimental|Synera single patch applied for 12 hrs/day|
9999153|NCT01525043|Experimental|Synera sinlgle patch applied for 4hrs twice daily|
9999154|NCT01525056|Other|imaging with ct, mri and pet scans|ct,mri and pet scans pre and post radiation
9936741|NCT01568697||Healthy Volunteers|Healthy volunteers (with/without periodontal disease)
9936742|NCT01568697||Immune deficient patients|Subjects with known genetic immune deficiency
9936743|NCT01568697||Subjects with severe periodontitis of suspected genetic etiology and their family|Subjects with severe periodontitis of suspected genetic etiology and their family members
9936744|NCT01568671||1|Male 18-35 White 18.5-25.0 (Phase 1)
9936745|NCT01568671||2|Male 18-35 White 18.5-25.0 (Phase 2)
9936746|NCT01568671||3|Male 18-35 White 30.0-40.0
9936747|NCT01568671||4|Female 18-35 White 18.5-25.0
9936748|NCT01568671||5|Male 55-75 White 18.5-25.0
9936749|NCT01568671||6|Male 18-35 African American 18.5-25.0
9936750|NCT01568658||Affected probands|Affected probands over age 4 weeks and onwards with known or suspected inherited neurological disorders of childhood onset
9936751|NCT01568658||Healthy volunteers|Healthy volunteers will be recruited for the imaging procedures in order to establish baseline and age-range matched data on the healthy, maturing muscle, spinal cord volume and dynamic breathing
9936752|NCT01568658||Single patient on Idebenone|Single patient on IND expanded access of Idebenone
9936753|NCT01568658||Unaffected family members|Families of affected probands with known or suspected inherited neurological disorders of childhood onset
9936754|NCT01563874||Cohort 1|This study involves a broad panel of lymphoma and lymphoid samples, which were previously procured under multiple protocols at the NIH, and for which there is excess tissue available for research.
9936755|NCT01553214|Other|Donors|volunteer healthy donors willing to receive G-CSF and dexamethasone and undergo leukapheresis
9936756|NCT01539863|Experimental|Treatment at regular intervals|Participants will be scheduled to receive the intervention, maintenance care, i.e. care on a regular basis throughout the study period.Care may consist of manual treatment but also of e.g. advice concerning exercises, ergonomic adaptation and stress management
9936757|NCT01539863|Active Comparator|Treatment as needed|Participants will receivethe intervention, i.e.care only when requested by them, i.e. when experiencing a relapse or deterioration
9936758|NCT01534598|Experimental|Single Arm|FdCyd + THU administered on an intermittent schedule in 21-day cycles per dose escalation table. THU will be administered orally at a fixed dose of 3000 mg 30 minutes prior to FdCyd.
9936759|NCT01529593|Experimental|Temsirolimus + Metformin|Starting dose of Temsirolimus 25 mg by vein weekly. Metformin titrated over 3 weeks at 500 mg by mouth daily. Four weeks of treatment constitute 1 cycle. Cycle one (1) however, will be 6 weeks long to allow for metformin titration.
9936760|NCT01524822||Artillery personnel|exposure to a significant number of concussive evolutions, specifically, exposure to 400 or more within a career, will be considered experienced by the investigators.
9936761|NCT01524822||Breachers|exposure to a significant number of breaching blasts, specifically, exposure to 400 breaching blasts or more within a career, will be considered experienced by the investigators
9936762|NCT01524822||Companions|The criterion is met by a person who has both some historical knowledge of the participant and routine interactions outside a work environment.
9936763|NCT01524822||Unexposed|People not exposed to repeated blasts
9936764|NCT01524549||WT for CYP2J2*7 and heterozygous for EPHX2 K55R|SNP
9936765|NCT01524549||WT for CYP2J2*7 and homozygous for EPHX2 K55R|SNP
9936766|NCT01524549||WT for EPHX2 K55R and heterozygous for CYP2J2*7|SNP
9936767|NCT01524549||WT for EPHX2 K55R and homozygous for CYP2J2*7|SNP
9936768|NCT01524549||WT for EPHX2 K55R and WT for CYP2J2*7|SNP
9936769|NCT01516125||Screening only - no intervention|
9999155|NCT01525095||Candida Positive Patients|Symptomatic adult patients, confirmed via concordant diagnostic blood culture and species identification and subsequent second blood culture results and species identification that are Candida positive
9999156|NCT01525095||Candida Negative Patients|Hospitalized adult patients, confirmed via concordant diagnostic blood culture with subsequent species identification and subsequent second blood culture with subsequent species identification that are Candida negative
9999157|NCT01525108|Experimental|Home-based blood pressure monitoring|
9999158|NCT01525108|Active Comparator|Usual care|
9999159|NCT01525121|Experimental|Expiratory Rib Cage Compression|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
9999160|NCT01525121|No Intervention|Control|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
9999161|NCT01525147|Experimental|YHB1411-2: Level 2|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
9999162|NCT01525147|Experimental|YHB1411-2: Level 3|The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.
9999163|NCT01525147|Experimental|YHB1411-2: Level 4|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
9999164|NCT01525147|Experimental|YHB1411-2: Level 5|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
9999165|NCT01525147|Experimental|YHB1411-2: Level 1|All investigational products are YHB1411-2(This level is pilot study).
9999166|NCT01525199||Case|
9999167|NCT01525199||Control|
9476151|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
9476152|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
9999168|NCT01525212|Experimental|Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075|
9999169|NCT01525212|Experimental|Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075|
9999170|NCT01525212|Experimental|Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075|
9999171|NCT01525212|Experimental|Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075|
9999172|NCT01525264|Experimental|Culturally Relavent Education|Education about improving diet using a DVD with Korean role models and native Korean language.
9999173|NCT01525264|Active Comparator|Healthy Wife Intervention|Intervention group of couples who received education about importance of a Healthy Diet. It was an attention control group
9999174|NCT01525277||left subclavian vein|CVC implanted in the left subclavian vein
9999175|NCT01525277||right subclavian vein|CVC implanted in the right subclavian vein
9800590|NCT01691794|Active Comparator|Atazanavir, 200 mg + Ritonavir, 100 mg (weight: 20 to <40 kg)|Participants with baseline weight of 20 to <40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
9800591|NCT01691794|Active Comparator|Atazanavir, 300 mg + Ritonavir, 100 mg (weight: ≥ 40 kg)|Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
9800592|NCT01691820|Experimental|Group S+|Cytomegalovirus (CMV) seropositive subjects aged between 10-17 years at enrollment in the study.
9800593|NCT01691820|Experimental|Group S-|Cytomegalovirus (CMV) seronegative subjects aged between 10-17 years at enrollment in the study.
9936770|NCT01511614|Active Comparator|active tDCS|(1) anodal left-dlPFC + cathodal right-vmPFC stimulation, with anode over the left dlPFC and cathode over the right-vmPFC; (2) cathodal left-dlPFC + anodal right-vmPFC stimulation, in which polarity is reversed between the two electrodes
9999176|NCT01525290|Experimental|intravenous tissue plasminogen activator|Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
9999177|NCT01525290|Placebo Comparator|Placebo|Intervention drug: placebo
10034910|NCT01801059|Active Comparator|Arm I education CRC and CRC screening|Educational intervention: Patients receive CRC and CRC screening information from an educational video and received a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
10214274|NCT00092053|Placebo Comparator|Placebo|Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
9800594|NCT01691820|Experimental|Missing serostatus Group|Subjects with no confirmed serostatus, aged between 10-17 years at enrollment in the study.
9800595|NCT01691833|Experimental|Vitamin D|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
9800596|NCT01691833|Placebo Comparator|Placebo|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
9800597|NCT01691833|No Intervention|Normovitaminosis|Patients with normovitaminosis( levels greater than or equal to 30ng/ml) will receive no intervention.
9800598|NCT01691859|Experimental|Mepolizumab|Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
10214275|NCT00092053|Experimental|ibandronate 100 mg|Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
10214276|NCT00092053|Experimental|ibandronate 150 mg|Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
10214277|NCT00092014|Experimental|Alendronate 70 mg|Alendronate sodium, 70 mg, orally once weekly for up to 24 months
10214278|NCT00092014|Active Comparator|Risendronate 35 mg|Risendronate, 35 mg, orally once weekly for up to 24 months
10214279|NCT00090142|Experimental|1|Montelukast - Placebo
10214280|NCT00090142|Experimental|2|Placebo - Montelukast
10214281|NCT00085930|Experimental|EBV specific CTLs w/out lymphodepletion|Escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells administered to patients with Neuroblastoma.
10214282|NCT00043108|Experimental|Treatment|Thoracic RT (50.4 Gy/1.8 Gy Fx) Paclitaxel (50mg/m2/weekly X 6) Carboplatin (AUC 2/weekly X 6)
9800599|NCT01691885|Experimental|A/B|Placebo followed by Fluticasone Furoate Vilanterol Combination
9800600|NCT01691885|Placebo Comparator|B/A|Fluticasone Furoate Vilanterol Combination followed by Placebo
9800601|NCT01691898|Experimental|Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab|For the first 2 cycles, RTX 375 milligrams per square meter (mg/m^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
10214283|NCT05225727|Experimental|Intervention|Students randomized to the intervention group will receive Me & You Tech in place of their standard health education.
10214284|NCT05225727|No Intervention|Control|Students assigned to the standard care condition will receive their usual health education which usually includes knowledge-based content on violence prevention taught from the state textbook
10214285|NCT05225701|Experimental|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules. The duration of the intervention program may vary between users; however, the participant will have access permits for a maximum period of 12 weeks. In order to monitor the participant's progress, each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists) to get an a weekly personalized synchronous assistance and psychological counseling.
10214286|NCT05225701|Active Comparator|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules. The duration of the intervention program may vary between users; however, the participant will have access permits for a maximum period of 12 weeks. All modules are sequential, allowing the user to go step by step. This arm does not have personalized online assistance.
9999178|NCT01525303|Experimental|Exercise-Start (ES)|The ES group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches. In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 1. The exercise prescription will increase to 25 minutes in Week 2, and 30 minutes in Week 3. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
9999179|NCT01525303|Experimental|Exercise-Middle (EM)|The EM group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches.In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 5. The exercise prescription will increase to 25 minutes in Week 6, and 30 minutes in Week 7. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
9999180|NCT01525355||EUS prior to ERCP|
9999181|NCT01525368||cognitive intervention group|
9999182|NCT01525368||active control group|
9999183|NCT01525394|Experimental|Lenvatinib Capsules|
9999184|NCT01525394|Active Comparator|Moxifloxacin tablets|
9999185|NCT01525394|Placebo Comparator|Placebos|
9999186|NCT01525433|No Intervention|Control|
9999187|NCT01525433|Active Comparator|Low Intensity Information (DVD)|A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
9999188|NCT01525433|Active Comparator|High Intensity Information (Promotora)|A higher intensity information program consisting of the video plus a 'promotora' or lay-community health educator led-intervention at the participant's home to encourage cervical cancer screening.
10034911|NCT01801059|Experimental|Arm II education and patient activation intervention|Educational intervention administered: Patients receive patient activation intervention comprising CRC and CRC screening information and communication skills training intervention by educational video and brochure, and they also receive a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
10034912|NCT01801072|Active Comparator|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days.
10034913|NCT01801072|No Intervention|No levetiracetam|No levetiracetam
10034914|NCT01801085||FOLFOX4|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
10034915|NCT01801085||XELOX|Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
10034916|NCT01801137|Experimental|Afinitor|Treatment by Afinitor 10 mg per day
10034917|NCT01801150|No Intervention|lifestyle and diabetes treatment|Counseil about lifestyle and current diabetes treatment
10034918|NCT01801150|Experimental|CPAP nasal treatment|Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device
10034919|NCT01801163|Experimental|Sorafenib plus Stereotactic Radiotherapy|Single agent Sorafenib x 2 weeks followed by Stereotactic Radiotherapy, then Sorafenib until disease progression.
10034920|NCT01801176|Experimental|Initial monitoring group|
10034921|NCT01801189|Experimental|Pregabalin|Single, 300 mg pre-operative oral dose of Pregabalin.
10034922|NCT01801189|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose.
10034923|NCT01801202|Experimental|Hair removal|hair removal treatment using 805nm LightSheer Duet HS handpiece
10034924|NCT01801228|Experimental|Eplerenone|oral daily treatment with doses 100 to 400 mg
10034925|NCT01801228|Active Comparator|Spironolactone|oral daily treatment with doses 100 to 400 mg
10034926|NCT01801254|Experimental|STRIDES|Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
10034927|NCT01801254|Sham Comparator|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior. Stimuli used and durations of training sessions for this protocol are identical to those used in the treatment condition.
10034928|NCT01801267|Experimental|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV).
10034929|NCT01801267|Active Comparator|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision.
10034930|NCT01801293|Experimental|Intervention Arm|One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning.
9999189|NCT01525446|Experimental|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
9999190|NCT01525459||Glioma patients|
9999191|NCT01525485||Electrical Stimulation|Participants will have a dedicated visit with a pelvic floor physical therapist during which instructions on usage and technique for the Minnova unit will be given. The electrical parameters selected will be: 10 Hertz frequency, 5-second on/10=second off cycle, and a pulse width of 0.4 milliseconds. The bipolar square will be delivered over a range that varies from 0 to 100 milliamps, depending on the maximum current intensity comfortably tolerated by the patient. The participant will perform each treatment session for 20 minutes twice daily for 8 weeks. Participants will be asked to keep a log recording the dates, times, and duration of each treatment session.
9999192|NCT01525485||Interstim device|Participants assigned to the sacral neuromodulation group will undergo InterStim device placement by one of the three Urogynecologists at OUHSC using a staged implant technique according to manufacturer's specifications.
9999193|NCT01525498||1 day catheter removal|Participants randomized to group 1 will have their catheter removed 1 day after surgery.
9999194|NCT01525498||2 day catheter removal|Participants randomized to group 2 will have their catheter removed 2 days after surgery.
9999195|NCT01525511|Experimental|Group A|Primaquine only followed by Dihydroartemisinin-piperaquine and followed by Primaquine together with Dihydroartemisinin-piperaquine.
9999196|NCT01525511|Active Comparator|Group B|Primaquine only followed by Primaquine together Dihydroartemisinin-piperaquine and followed by Dihydroartemisinin-piperaquine only.
9999197|NCT01525524|Sham Comparator|Sham Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
9999198|NCT01525524|Active Comparator|Active Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the transcranial Direct Current Stimulation device. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 30 minutes.
9999199|NCT01525537|Experimental|SPI guided arm|sufentanil was adjusted to SPI level
9999200|NCT01525537|Active Comparator|Standard practise|Sufentanil was given at standard practise
9999201|NCT01525576|No Intervention|Control group|No offer of booster program.
9999202|NCT01525576|Experimental|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
9999203|NCT01525654|Active Comparator|Partners|Patients who are matched with support partners and have a billing diagnosis of RA (714.0) or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) or the Patient-Centered Outcomes Initiative (PACO)
9999204|NCT01525654|No Intervention|Controls|Controls will be BRASS patients who continue to receive regular care without being matched with a peer support partner.
9999205|NCT01525680|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
9999206|NCT01525680|Placebo Comparator|Prolonged Exposure therapy with placebo|
9999207|NCT01525693||Diagnosed within 6 months|No (test) intervention to be adminisitered
9999208|NCT01525706|Experimental|Ethanol and Paclitaxel Injection|All patients will receive at least one treatment with alcohol and paclitaxel.
9999209|NCT01525719|Experimental|RAD001|
9999210|NCT01525732|Other|POEM|Per Oral Endoscopic Myotomy
9999211|NCT01525758|Experimental|SI000413 400mg|tablet, SI000413 200mg bid
9999212|NCT01525758|Experimental|SI000413 600mg|tablet, SI000413 200mg tid
9999213|NCT01525758|Experimental|SI000413 800mg|SI000413 200mg, 2T bid
9999214|NCT01525758|Placebo Comparator|placebo|placebo 2T tid for 8 weeks
9999215|NCT01525771|No Intervention|No intervention|Single-center, open-label, prospective, single-arm, phase I-II study
9999216|NCT01525784||Rt-CGMS|Using Rt-CGMS, approved by ministry of health as part f clinical care
9999217|NCT01525784||Control|Not approved or suggested for RtCGMS. Other acceptabl means of therapy
9999218|NCT01525797||Control|
9999219|NCT01525797||Rejection|
9936771|NCT01511614|Sham Comparator|sham tDCS|To simulate the experience of tDCS stimulation, current is ramped on and turned off at the beginning and end of the tDCS session. An additional sham option is to have the current ramp up and down only at the beginning of the sham session, and not at the end. This second sham is supported in the literature as an effective blinding technique, which subjects cannot distinguish from active stimulation. One of these sham options will be used for data that will be analyzed together, to be determined based on equipment capabilities and preliminary analysis of blinding efficacy in our cross over design. We will assess the efficacy of sham condition by providing participants and the investigator with a questionnaire on the MRI/tDCS session, wherein they will report whether they thought the tDCS session was active or sham. The MRI operator (or other non protocol personnel) will control active/sham conditions.
9936772|NCT01511588||HH patients|Clinical patients with hypogonadotropic hypogonadism (HH)
9936773|NCT01505062|Experimental|SAR421869 (Cohort 1)|Starting dose of SAR421869 given through one subretinal injection.
9936774|NCT01505062|Experimental|SAR421869 (Cohort 2)|Escalating dose of SAR421869 given through one subretinal injection.
9936775|NCT01505062|Experimental|SAR421869 (Cohort 3)|Escalating dose of SAR421869 given through one subretinal injection.
9936776|NCT01505062|Experimental|SAR421869 (Cohort 4)|Maximum tolerated dose (MTD) of SAR421869 given through one subretinal injection.
9936777|NCT01505062|Experimental|SAR421869 (Cohort 5)|MTD of SAR421869 given through one subretinal injection.
9936778|NCT01500447||Central Precious Puberty|CPP subjects
9936779|NCT01500447||Hypogonadotropic Hypogonadism|IHH, KS, GnRH Deficiency, BAM syndrome (arhinia), HA, CDP subjects
9936780|NCT01498276||General Population|Members of the general population
9936781|NCT01498276||Members of under-resourced communities|Participant recruited from under-resourced communities in the Washington, DC area in the Southeastern US
9936782|NCT01498263||Alzheimers related dementias (family)|Enrollment was open to family members of persons diagnosed with Alzheimers (/related dementia) in specific communities around Memphis, TN.
9936783|NCT01498263||Inherited inflammatory condition (family)|Enrollment open to family members of persons diagnosed with inherited inflammatory conditions. Participation at NIH or remote (internet/phone); request referral of family for remote participation.
9936784|NCT01498263||Inherited metabolic conditions (family)|Enrolls family members of persons diagnosed with inborn errors of metabolism / mitochondrial disorders. Study at NIH or remote (internet/phone); request family-referrals for remote participation.
9936785|NCT01498263||Inherited neurodegenerative disorders (family)|Open to family members of persons diagnosed with genetically-defined neurodegenerative conditions. Study at NIH or (internet/phone); request referral of family members for remote participation.
9936786|NCT01498263||Typically developing (family) = Healthy Volunteers|Open to parents of typically-developing child/ren <18yrs (*when age-matched child is full-time resident of parent's home). Study at NIH; request family-referrals for remote participation.
9936787|NCT01498263||Undiagnosed conditions (family)|Enrollment open to family members referred in from the Undiagnosed Disease Network. Participation at NIH or remote (internet/phone); request referral of family members for remote participation
9936788|NCT01496625||Cohort 1|Participants with age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases.
9936789|NCT01496625||Cohort 2|Participants without any retinal diseases.
9936790|NCT01496599||Healthy Volunteers|Subjects without PD diagnosis
9936791|NCT01496599||Parkinsons Disease subjects|Subjects fitting the MSD Clinical Diagnostic Criteria for PD
9936792|NCT01496599||Prodromal Parkinson disease|Subjects fitting the MDS prodromal criteria for PD
9936793|NCT01495598|Experimental|1/Phase 1|Up to six subjects will initially be treated with pomalidomide 5mg daily for 21 days of a 28 day cycle
9936794|NCT01495598|Experimental|2/ Phase 2|15 HIV positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mgdaily for 21 days of a 28 day cycle
9936795|NCT01469247|Experimental|Radiation Therapy|Starting dose of 24 Gray (Gy) in 2 Gy fractions.
9936796|NCT01468883|Active Comparator|M|Modified radical mastectomy
9936797|NCT01468883|Experimental|X|Excisional biopsy plus radiation
9936798|NCT01446133|Experimental|Untreated 65 +|"Patients with untreated SLL/CLL with indications for treatment that are age 65 or older.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
9999220|NCT01525810||Subjects treated with Peginterferon Lambda-1a (BMS-914143)|Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
9999221|NCT01525823|Experimental|BMS-754807 + Metformin|
9936799|NCT01446133|Experimental|Prior Treatment Any Age|"Patients of any age with previously treated CLL/SLL and recurrent disease.~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
9936800|NCT01445509|Experimental|Arm 1|Group 1 will receive dasatinib and bevacizumab together at the start of study in a dose escalation fashion
9936801|NCT01445509|Experimental|Arm 2|Group 2 will be randomized as to which agent they receive for cycle one. Cycles 2 and beyond are treated using both agents.
9936802|NCT01445483||1/Cohort 1|KPS>70; Age =65; controlled primary tumor and no extracranial metastases
9936803|NCT01445483||2/Cohort 2|KPS>70 and at least one of the following: age >65, uncontrolled or synchronous primary disease, or extracranial metastases
9936804|NCT01445483||3/Cohort 3|KPS<70
9936805|NCT01445314||1/Patients|Infants, children, adolescents, and adults who have taken neurobehavioral assessments as part of a past, current, or future IRB-approved protocol.
9936806|NCT01445288||1|Pediatric Patients with Central Nervous System Tumors
9936807|NCT01443910||behavior, supportive|receiving information about behavior with supportive provider communication
9936808|NCT01443910||behaviors, directive|receiving information about behavior with directive provider communication
9936809|NCT01443910||genetics, directive|receiving information about genetics with directive provider communication
9936810|NCT01443910||genetics, supportive|receiving information about genetics with supportive provider communication
9936811|NCT01443468||1|Patients within a family with a known TP53 mutation who are positive for that mutation.
9936812|NCT01443468||2|Patients within a family with a known TP53 mutation who are negative for that mutation.
9936813|NCT01443468||3|Unaffected family members.
9999222|NCT01525836|Experimental|combination treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
9999223|NCT01525836|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.
9936814|NCT01443468||4|Patients who meet clinical LFS criteria but haven't had TP53 testing.
9936815|NCT01443468||5|Patients within a family with an negative/unknown TP53 mutation.
9936816|NCT01441089||1/ Patients with cancer, other tumors, or possible genetic tumor|Patients enrolled on IRB approved NIH Intramural Research Program (IRP) therapeutic clinical trials
9936817|NCT01439165|Experimental|Adacel® Vaccine Group|Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)
9936818|NCT01439165|Active Comparator|Td Adsorbed Vaccine Group|Participants randomized to receive Subjects randomized to receive a Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine.
9936819|NCT01434368||children age 8-17 years admitted to pilot brain imaging studies|children age 8-17 years admitted to pilot brain imaging studies
9936820|NCT01434368||healthy adults|healthy adults ages 25 - 35 years at the time of enrollment
9936821|NCT01434368||typically developing children ages 12/13- 17 years|typically developing children ages 12 or 13 - 17 years
9936822|NCT01434368||typically developing children ages 8 - 17 years|typically developing children ages 8 - 17 years
9936823|NCT01434368||typically developing children with evidence of advanced bone age|typically developing children (with evidence of advanced bone age relative to chronologic age); age 8 or ages 12-13
9936824|NCT01432847||Affected|Participants affected by ocular diseases/conditions.
9936825|NCT01432847||Healthy Volunteers|Age, gender, and ethnicity-matched to participants with ocular conditions.
9936826|NCT01425892||incomplete sjogren's|patients who meet criteria as incomplete sjogren's
9936827|NCT01425892||primary sjogren's|patients who meet criteria for classification for primary sjogren's
9936828|NCT01425892||secondary sjogren's|patients who meet classification criteria for secondary sjogren's
9936829|NCT01422694||Healthy control|Healthy volunteers will be recruited to serve as controls
9936830|NCT01422694||Other Inflammatory Diseases|Subjects with Other Inflammatory Diseases
9936831|NCT01422694||Patients with Spondyloarthritis|Subjects with confirmed or probable SpA will be identified predominantly by physician referral.
9936832|NCT01419561|No Intervention|1|Evaluation for Alternative Causes of KICS Symptoms
9936833|NCT01419561|No Intervention|2|Natural History/Observation Arm
9936834|NCT01419561|Experimental|3|High dose zidovudine + valganciclovir
9936835|NCT01419561|Experimental|4|Rituximab with or without liposomal doxorubicin
9936836|NCT01419561|Other|5|Standard and alternative rational therapies
9936837|NCT01417533||GNE|Patients with a diagnosis of GNE myopathy
9936838|NCT01417533||GNE-Related Diseases|Patient with a GNE related disease
9936839|NCT01417533||non-GNE|Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
9936840|NCT01399411||AHS Cohort|licensed pesticide applicators and their spouses from Iowa and North Carolina already enrolled in the Agricultural Health Study (AHS)
9936841|NCT01399385|Experimental|Group 1|Group 1 will consist of subjects with a 10-year total CHD risk <10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
9936842|NCT01399385|Experimental|Group 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
9936843|NCT01399385|Experimental|Group 3|Group 3 will consist of subjects with a 10-year total CHD risk >20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
9936844|NCT01399385|Experimental|Group 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
9936845|NCT01391962|Experimental|Part I|Patients will be randomized to receive cediranib (30 mg) or sunitinib malate (37.5 mg) orally, once a day in 28-day cycles
9936846|NCT01391962|Experimental|Part II|At the time of disease progression patients will cross over to the other treatment arm after a 2-week wash-out period.
9936847|NCT01386437||Fungal infections|Patients with or without inherited or acquired abnormalities of immune function manifesting mucocutaneous and/or invasive fungal infections
9936848|NCT01386424||Healthy Volunteers|Healthy Volunteers
9936849|NCT01375530||1|Healthy adults 18 years old or older
9936850|NCT01370278|Active Comparator|Normal Saline|Normal saline sprayed into stent/airway tubes then suctioned out through bronchoscope.
9936851|NCT01370278|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate sprayed into stent/airway tubes then suctioned out through bronchoscope.
9936852|NCT01362803|Experimental|Arm 1|Phase 1: AZD6244 PO BID x 28 DAYS
9936853|NCT01362803|Experimental|Arm 2|Phase 2: AZD6244 PO BID x 28 DAYS
9936854|NCT01352975||Group 0|participants without AMD (no large drusen or advanced AMD in either eye)
9936855|NCT01352975||Group 1|participants with large drusen in study eye and no large drusen or advanced AMD or GA in fellow eye
9936856|NCT01352975||Group 2|participants with bilateral large drusen with or without retinal pigment epithelial hypo/hyperpigmentary changes
9936857|NCT01352975||Group 3|participants with large drusen in study eye and advanced AMD (CNV and GA) in fellow eye
9936858|NCT01352975||Group 4|participants with findings of RPD
9936859|NCT01352962|Experimental|Arm 1|Standard of Care plus escalating doses of Lenalidomide
9936860|NCT01352962|Experimental|Arm 2|Lenalidomide Lead for 14 days + standard of care +lenalidomide MTD
9936861|NCT01350648||HBV and HCV Co-infection|HBV and HCV Co-infection
9936862|NCT01350648||Hepatitis B|Hepatitis B alone
9936863|NCT01350648||Hepatitis C|Hepatitis C alone
9936864|NCT01350648||HIV and HBV and HCV Tri-Infection|HIV and HBV and HCV Tri-Infection
9936865|NCT01350648||HIV and HBV Co-infection|HIV and HBV Co-infection
9936866|NCT01350648||HIV/HCV Co-Infection|HIV and HCV Co-infection
9936867|NCT01326715|Active Comparator|mangafodipir|see protocol
9936868|NCT01324206||Healthy Volunteers|Healthy Volunteers 18 years or older
9936869|NCT01323322||HANDLS|A fixed cohort as an area probability sample of Baltimore City from August 2004 through November 2009.
9936870|NCT01319565|Experimental|1/ACT|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin
9936871|NCT01319565|Experimental|2/ACT + TBI|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin + TBI
9936872|NCT01316783||Healthy Volunteers|African ancestry and whites (who will serve as a comparison group)
9936873|NCT01313442||1/ Cohort 1|Subjects with a diagnosis of cancer
9936874|NCT01306084||1|NIH campus employees who have recently recovered from COVID-19
9936875|NCT01306084||2|Clinical Center health care workers and ancillary staff who have close patient contact and possible exposures to SARS-CoV-2
9936876|NCT01306084||3|Healthy and immunocompromised subjects who have or are suspected to have a viral infection
9936877|NCT01306084||4|Healthy and immunocompromised subjects exposed to someone who has a viral infection or is suspected of having a viral infection
9936878|NCT01306084||5|Healthy subjects who grew up in dengue endemic areas.
9936879|NCT01306084||6|Healthy subjects with a history of viral hepatitis
9936880|NCT01306045|Active Comparator|A/ Erlotinib|Erlotinib
9936881|NCT01306045|Active Comparator|B/ AZD6244|AZD6244
9936882|NCT01306045|Active Comparator|C/ MK-2206|MK-2206
9936883|NCT01306045|Active Comparator|D/ Lapatinib|Lapatinib
9936884|NCT01306045|Active Comparator|E/Sunitinib|Sunitinib
9936885|NCT01306045|Other|F/ NOS|NOS (not otherwise specified)
9936886|NCT01306019|Experimental|1|Gene Therapy
9936887|NCT01294332|Experimental|Exercise|Aerobic exercise performed for 12 weeks
9936888|NCT01293448|Experimental|Intervention|CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
9936889|NCT01287156||1|Subjects with diagnosed or suspected TBI or postconcussive syndrome
9936890|NCT01287000||1|Workers and volunteers engaged or potentially engaged in oil spill clean-up operations in the Gulf of Mexico
9936891|NCT01282021||Region 1|Northern part: Gonder, Gojam, Tigray
9936892|NCT01282021||Region 2|Southern Ethiopia: Bale, Sidamo, Gambela
9936893|NCT01282021||Region 3|Northeastern and Southeastern Ethiopia
9936894|NCT01276470||Antisynthetase Neative|Subjects with myositis without antisynthetase syndrome
9936895|NCT01276470||Antisynthetase Positive|Subject with myositis with antisynthetase syndrome
9936896|NCT01276470||Healthy Control|Subjects without autoimmune disease
9936897|NCT01273168|Experimental|1|Z-endoxifen will be administered orally once a day in 28-day cycles
9936898|NCT01273129|Experimental|1|Patients 8 years of age or older with drug resistant epilepsy or tumor related epilepsy
9936899|NCT01266577|Other|One Arm|Subjects receive the same scan
9936900|NCT01266044|Experimental|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
9936901|NCT01266044|Active Comparator|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
9936902|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
9999224|NCT01525888|No Intervention|control|continue with treatment with angiotensin converting enzyme inhibitor or angiotensin blocker during all study period
9999225|NCT01525888|Experimental|drug stop|temporary stop of angiotensin converting enzyme inhibitor and angiotensin blocker treatment at least 72 hours before coronary angiography and renew of treatment 72 hours after angiography
9999226|NCT01525901|Experimental|Insulin-Like Growth Factor-1 (IGF-1)|Injection
9999227|NCT01525901|Placebo Comparator|Normal saline|Injection
9999228|NCT01525914||dutasteride, active surveillance|men with favorable risk prostate cancer on surveillance treated with dutasteride
9999229|NCT01525940|Other|Colon capsule and CT-colonography|PillCam Colon Capsule Endoscopy (Given® Diagnostic System) ingestion first and CT-colonography about 10-12 hours post-ingestion
9999230|NCT01525966|Experimental|Treatment (carboplatin and nab-paclitaxel)|Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once weekly. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
9999231|NCT01525979|Experimental|Task-Related UAT|Therapist conducted unilateral arm training Task-related unilateral arm training
9999232|NCT01525979|Experimental|Task-Related BAT|Therapist conducted bilateral arm Training Task-related bilateral arm training
9999233|NCT01525979|Experimental|Task-Related UAT coupling BAT|Therapist conducted task-related unilateral training for 45 minutes, followed by task-related bilateral arm training for another 45 minutes during each training session
9999234|NCT01525979|Experimental|Robot-assisted UAT|Robot-assisted unilateral arm training
9999235|NCT01525979|Experimental|Robot-assisted BAT|Robot-assisted bilateral arm training
9999236|NCT01525992|Experimental|Community Pharmacy-based Program|
9999237|NCT01525992|Active Comparator|Usual care|
9999238|NCT01526005||Active agent (nicotine patch)|
9999239|NCT01526005||Placebo patch|
9999240|NCT01526018||Novel bottle|
9999241|NCT01526031|Experimental|BV1|1:10,000 bee venom (BV) acupuncture plus physiotherapy
9999242|NCT01526031|Experimental|BV2|1:30,000 bee venom (BV) acupuncture plus physiotherapy
9999243|NCT01526031|Placebo Comparator|NS|Normal saline injection plus physiotherapy
9999244|NCT01526044|Experimental|Freestyle group|Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
9999245|NCT01526044|Active Comparator|AccuChek group|Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
9999246|NCT01526070||Patients with Exudative Age-Related Macular Degeneration|Patients with eAMD who received intravitreal thearpy
9999247|NCT01526083|Other|Single dose of Warfarin on day 3|Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID
9999248|NCT01526083|Other|Single dose of Warfarin|
9999249|NCT01526096|Active Comparator|Standard ASCT (Grp 1)|Standard autologous stem cell transplantation (ASCT)
9999250|NCT01526096|Experimental|Depletion of T-cells after ASCT (Grp 2)|Standard ASCT followed by treatment with basiliximab to remove certain immune cells (called regulatory T-cells or Tregs) from the blood
9999251|NCT01526096|Experimental|Depletion of T-cells before ASCT(Grp 3)|Blood collected for an ASCT will be processed using a special cell sorting machine (CliniMACS device) to remove Treg cells before the stem cells are infused back into the body during stem cell transplant.
9999252|NCT01526109|Experimental|strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
9999253|NCT01526109|Placebo Comparator|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
9999254|NCT01526109|Experimental|whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
9999255|NCT01526122|Experimental|G0041(75/100mg)|
9999256|NCT01526122|Active Comparator|Clopidogrel & Aspirin|
9999257|NCT01526161|Experimental|Inhaled Fluticasone propionate and salmeterol|inhaled fluticasone propionate 100 micrograms and salmeterol 50 m
9936903|NCT01264679|Experimental|Ferumoxytol|When a participant has persistent or recurrent IDA (defined as hemoglobin <12.0 grams [g]/deciliter [dL] and with either transferrin saturation <40% or ferritin <100 nanograms/milliliter), the participant will begin a 7-week treatment period. Participants will receive 2 IV injections of ferumoxytol 7.0 milligrams (mg) iron/kilogram (maximum of 510 mg/dose), the first dose administered on Day 1 and the second on Days 3 through 9 of the Treatment Period.
9936904|NCT01264055||1|Adults with idiopathic bronchiectasis
9936905|NCT01254903|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
9936906|NCT01251900||Patients|Hispanic women, over the age of 18, with breast cancer will be eligible.
9936907|NCT01247597||Controls|People without pathogenic DICER1 germline variation
9936908|NCT01247597||DICER1 (cases)|People with pathogenic DICER1 germline variation or history of DICER1-associated tumors
9936909|NCT01237093|Experimental|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda for 12 weeks
9936910|NCT01237093|Experimental|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish for 12 weeks
9936911|NCT01237093|Experimental|4. Meat and fish and soda|weight maintaining diet with meat, fish, and soda for 12 weeks
9936912|NCT01237093|Experimental|5. Fish, no meat or soda|weight maintaining diet with meat, fish, and soda for 12 weeks
9936913|NCT01237093|Experimental|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat for 12 weeks
9936914|NCT01237093|Experimental|7. No meat, fish, or soda|no fish, and no soda (vegetarian) for 12 weeks
9936915|NCT01237093|Experimental|8. Soda, no meart or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda) for 12 weeks
9936916|NCT01237093|Experimental|Meat and fish, no soda|weight maintaining diet with meat and fish but no soda for 12 weeks
9936917|NCT01231932||Cancer survivors|Individuals recently completed primary treatment for cancer
9936918|NCT01231932||Individuals receiving cancer treatment|Individuals receiving cancer treatment
9936919|NCT01231932||Individuals with cancer|Individuals with cancer
9936920|NCT01224704|Experimental|Lean: hypertonic first|Lean: Hypertonic solution at day 6 and water deprivation at day 10
9936921|NCT01224704|Experimental|Lean: water deprivation first|Lean: Water deprivation at day 6 and hypertonic solution at day 10
9936922|NCT01224704|Experimental|Obese: hypertonic first|Obese: Hypertonic solution at day 6 and water deprivation at day 10
9936923|NCT01224704|Experimental|Obese: water deprivation first|Obese: Water deprivation at day 6 and hypertonic solution at day 10
9936924|NCT01224691||Asmathics|Asmathics
9936925|NCT01224691||Non-Asmathics|Non-Asmathics
9936926|NCT01222741||Healthy Voluntary|Healthy voluntary
9936927|NCT01222741||Patients|affected patient
9936928|NCT01222741||relatives|family member to patient
9936929|NCT01218854|Experimental|B-NASS|Block assisted needle angle selection system
9936930|NCT01218854|Experimental|L-NASS|laser assisted needle angle selection system
9936931|NCT01218854|Experimental|MD-NASS|mobile-device assisted needle angle selection system
9936932|NCT01212055||Cohort 1|Patients with DOCK8 deficiency, LAD-1, or GATA2 Deficiency
9936933|NCT01212029|Experimental|1/All Subjects|Imaging studies related to functional brain activation
9936934|NCT01212003||Active TB|subjects with active TB as determined by smear, culture, or biopsy or have appropriately documented clinically suspicious active TB without definitive microbiology confirmation
9936935|NCT01212003||Latent TB|subjects with documented evidence of a positive PPD skin test or Interferon Gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB
9936936|NCT01200953||Confirmed or suspected exposure|Confirmed or suspected exposure to biodefense select agent, to agent of bioterrorism concern, to naturally-occurring pathogen in the environment, to EID agent, or to an individual
9936937|NCT01200953||Confirmed or suspected infection|Confirmed or suspected infection by biodefense select agent, by agent of bioterrorism concern, by naturally-occurring pathogen in the environment, or by emerging infectious disease agent
9936938|NCT01200953||Healthcare worker or healthy volunteer|Healthcare worker or healthy volunteer involved in simulation drills or exercises evaluating the Clinical Center admission, care, and infection control processes
9936939|NCT01200953||Healthcare worker surveillance|Healthcare worker surveillance of medical staff involved in the medical care of patients in the above 2 categories
9936940|NCT01200680||chordoma cohort|Chordoma patients
9936941|NCT01191853||Healthy volunteers|Healthy volunteers will have blood drawn before and after seasonal flu vaccination
9936942|NCT01176006|Active Comparator|Group A|10/10 HLA Matched Related or Unrelated Donor Transplant
9936943|NCT01176006|Active Comparator|Group B|9/10 HLA Matched Related or Unrelated Donor Transplant
9936944|NCT01176006|Other|Group C|Donor
9936945|NCT01176006|No Intervention|Group D|Family Interview
9936946|NCT01175993|Active Comparator|Eliptical training|Home base exercise
9999258|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and placebo|inhaled fluticasone propionate 100micrograms twice daily + placebo
9936947|NCT01174121|Experimental|1/CD8+ Enriched TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young CD8+ enriched TIL + high-dose aldesleukin (CLOSED)
9936948|NCT01174121|Experimental|2/Unselected TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin (CLOSED)
9936949|NCT01174121|Experimental|3/Unselected TIL + Pembro Prior to Cells|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
9936950|NCT01174121|Experimental|4/Unselected TIL + Pembro at POD|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab within 4 weeks of progressive disease for up to 8 doses every 3 weeks
9936951|NCT01174108|Experimental|1|Target doses: CD34+ cells 8 x 106/kg; CD3+ cells 2 x 107/kg
9936952|NCT01174108|No Intervention|2|Donor
9936953|NCT01168271||Children Ages 0-3 years|Children aged 0-3 years in Ouelessebougou
9936954|NCT01168271||Febrile Hospitalized Children|Febrile hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Toure Hospital in Bamako
9936955|NCT01168271||Non-Hospitalized Children|Febrile non-hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Toure Hospital in Bamako
9936956|NCT01168271||Pregnant Women + Newborns|Pregnant women presenting for antenatal consultations and delivery and their newborns
9936957|NCT01164241||1|Eczema
9936958|NCT01164241||2|unaffected relatives
9936959|NCT01164241||3|healthy volunteers
9936960|NCT01164241||4|other allergic phenotypes
9936961|NCT01155388|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
9936962|NCT01155388|Active Comparator|Oral Iron|Participants will receive oral iron: 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
9936963|NCT01151124|Experimental|CTX0E03 DP|human neural stem cell product, once only injection, increasing doses
9936964|NCT01150721||1/PNMI|Adult patients with Pulmonary Nontuberculous Mycobacterial Infection
9936965|NCT01150721||2/Healthy Volunteers|Healthy Volunteer adults
9936966|NCT01150708||Chiari 1 with syringomyelia|Chiari I malformation with syringomyelia.
9936967|NCT01150708||Chiari 1 without syringomyelia|A Chiari I Malformation without syringomyelia is defined as descent of the cerebellar tonsils > 5 mm below the foramen magnum 79 without associated syringomyelia.
9936968|NCT01150708||Syringomyelia without chiari|A syrinx or syringomyelia is defined as an intramedullary cyst that extends / length > 1spinal segment.
9936969|NCT01148381||controls|healthy non-smoking, participants with no substance use disorders
9936970|NCT01148381||psychiatric disorders|individuals with other psychiatric disorders
9936971|NCT01148381||smokers|healthy individuals with nicotine use disorder
9936972|NCT01148381||substance use disorders|healthy individuals with other substance use disorders
9936973|NCT01148381||treatment seeking individuals|treatment seeking individuals with substance use disorders
9936974|NCT01145196||Affected|Participants affected by Paquenil induced retinal toxicity
9936975|NCT01145196||Unaffected|control participants without Plaquenil induced retinal toxicity
9936976|NCT01143558|Experimental|1|All cohorts undergo the same intervention with the study device.
9936977|NCT01143532||Kidney transplant donor of black African descent.|Kidney transplant donor of black African descent.
9936978|NCT01143532||Kidney transplant recipient of black African descent|Kidney transplant recipient of black African descent.
9936979|NCT01143519||FLT1 C-677T|SNP
9936980|NCT01143519||MDM2 rs2279744|SNP
9936981|NCT01143519||p53 rs1042522|SNP
9936982|NCT01143519||RMM1 rs1465952|SNP
9936983|NCT01143519||TLR8 rs3761624|SNP
9936984|NCT01143480||ABCA1|SNP or allele of interest
9936985|NCT01143480||APOE|SNP or allele of interest
9936986|NCT01143480||APOL1|SNP or allele of interest
9936987|NCT01143480||CD14|SNP or allele of interest
9936988|NCT01143480||CD44|SNP or allele of interest
9936989|NCT01143480||IRGM|SNP or allele of interest
9936990|NCT01143480||ITIH3|SNP or allele of interest
9936991|NCT01143480||ITIH4|SNP or allele of interest
9936992|NCT01143480||MyD88|SNP or allele of interest
9936993|NCT01143480||TIRAP|SNP or allele of interest
9936994|NCT01143480||TLR4|SNP or allele of interest
9936995|NCT01143480||TLR5|SNP or allele of interest
9936996|NCT01143480||TNFa|SNP or allele of interest
9936997|NCT01139476||AHS BEEA participants|A subset of 1990 AHS cohort members who are male private pesticide applicators, living and over 50 years of age at the time contact, cancer free, and who completed AHS Phases IIII.
9936998|NCT01139476||Non-AHS BEEA participants|A group of 225 age-, race-, and countymatched, non-AHS controls, who have not lived or worked on a farm as an adult, or held a job applying pesticides.
9936999|NCT01137435|Experimental|Study Group|
9937000|NCT01132937||Healthy Controls|Accrual Ceiling: 20. Healthy, uninjured, subjects are used to match to those suspected of head injury. 10 subjects have been enrolled to date in the PET arm
9937001|NCT01132937||Suspected of Head Injury|Accrual Ceiling: 1000. Subjects enrolled with 48hrs of suspected head injury in emergency department of local hospitals, Suburban Hospital Center or Washington Hospital Center
9937002|NCT01132924||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
9937003|NCT01132885||Adults with WS or genetic abnormalities|Adults with Williams syndrome or genetic abnormalities in chromosome 7q11.23
9937004|NCT01132885||Children with WS or genetic abnormalities|children ages 5-17 with Williams Syndrome or genetic abnormalities in chromosome 7q11.23
9937005|NCT01132885||Parents|Parents of children with 7q11.23 CNV will undergo blood draws
9937006|NCT01132885||Unaffected Siblings|Siblings of children with 7q11.23 CNV
9937007|NCT01132885||Unrelated children|Typically developing children ages ages 5-17
9937008|NCT01132859||1|Volunteers of 18 years of age or older willing to donate blood and tissue specimens and participate in imaging studies to evaluate the components of the immune system
9937009|NCT01130545||Volunteers|Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)
9937010|NCT01130519|Experimental|1|All patient will be receiving fixed starting dose of bevacizumab (10 mg/kg IV every 2 weeks) and erlotinib (150 mg/day PO)
9937011|NCT01125228||Arm 1|Zidovudine 200mg by mouth every 4hr
9937012|NCT01125228||Arm 2|-Zidovudine 200mg by mouth every 4hr -Alpha Interferon 1 million units once a day, escalating
9937013|NCT01125228||Arm 3|-Alpha Interferon 1 million units once a day, escalating
9937014|NCT01123499||Healthy Volunteers|Any healthy volunteers that are eligible to donate blood.
9937015|NCT01109420||1/ Cohort 1|Affected with non-medullary thyroid cancer
9937016|NCT01109420||2/Cohort 2|Non-affected members of families with non-medullary thyroid cancer
9937017|NCT01109394||1/Cohort 1|Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit.
9937018|NCT01109394||2/Cohort 2|Human samples, specimens and data collected on IRB approved protocols that are now closed
9937019|NCT01109394||3/Cohort 3|Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer.
9937020|NCT01109238||Process Feasibility|
9937021|NCT01105858||Volunteers|Adult volunteers &amp; family members recruited from the Phoenix metropolitan area
9937022|NCT01095003|Experimental|Vinflunine plus Capecitabine|"Patients received (in combination with capecitabine)~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks."
9937023|NCT01095003|Active Comparator|Capecitabine single-agent|Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
9937024|NCT01087346|Active Comparator|Control|Information about child health
9937025|NCT01087346|Experimental|Family Environment Information|Information about family environment factors in children's obesity risk
9476153|NCT03574519|Experimental|Non-contingent incentives and weekly feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive weekly updates about their performance.
9476154|NCT03574519|Experimental|Non-contingent incentives and daily feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive daily updates about their performance.
9937026|NCT01087346|Experimental|Gene times Family Environment Information|Information about interactions between genetic and family environment factors in children's obesity risk
9937027|NCT01087346|Experimental|Genetic Information|Information about genetic factors in child obesity risk
9937028|NCT01087333||1|Patients with hematologic malignancies or solid tumors.
9937029|NCT01087333||2|Normal Donors who are defined as individuals without a diagnosis of or history of any cancer.
9937030|NCT01087320||Genetic Disorders|Patients or family probands with genetic cause of disorders that are intractable or difficult to identify with existing technique.
9937031|NCT01087307||1|Biologic and environmental samples anonymously obtained from adult volunteers for use in laboratory assay evaluation
9937032|NCT01087294|Experimental|1A/T cell Arm (closed)|Dose escalation of CAR+ T cells based on the patients actual body-weight
9937033|NCT01087294|Experimental|1B/T memory stem cell arm|Dose Escalation with 5 dose levels of CAR+ T memory cells based on the patients actual body-weight
9937034|NCT01087294|Other|2/Donor arm|Leukapheresis
9937035|NCT01087281||1|Neurologically normal healthy volunteers in good general health.
9937036|NCT01087281||2|Patients with unilateral or bilateral focal lesions of prefrontal, parietal, occipital or temporal cortex, or amygdala.
9937037|NCT01071577||Healthy Volunteers|Healthy volunteers wanting to donate BMSC for allogeneic use
9937038|NCT01071577||Patients|Patients donating BMSC for autologous use
9937039|NCT01064817|Experimental|PRM-151|PRM-151 (recombinant human serum amyloid P, recombinant human pentraxin 2)
9937040|NCT01064817|Placebo Comparator|Placebo|Placebo
9937041|NCT01059786|Experimental|Arm 1|Rituximab + Bendamustine at 70 mg/m2 for initial tolerability study (closed)
9937042|NCT01059786|Experimental|Arm 2|Rituximab + bendamustine at 90 mg/m2 for initial tolerability study (closed)
9937043|NCT01059786|Experimental|Arm 3|Rituximab + Bendamustine (at the tolerated dose)
9937044|NCT01059786|Active Comparator|Arm 4|Rituximab + Pentostatin
9937045|NCT01051635|Experimental|Cohort A|LMP400 administered IV daily for 5 days per dose escalation table.
9937046|NCT01051635|Experimental|Cohort B|LMP776 administered IV daily for 5 days per dose escalation table.
9937047|NCT01036971||1|potential research subjects
9937048|NCT01036685||379-bench-control|healthy control who will only do behavioral tasks
9937049|NCT01036685||379-bench-other-psych-diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who will only dobehavioral tasks
9937050|NCT01036685||379-bench-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who will only do behavioral tasks
9937051|NCT01036685||379-bench-user|someone with a DSM-V substance use disorder on a substance other than nicotine who will only do behavioral tasks
9937052|NCT01036685||379-control|healthy control who can do MRI and tDCS
9937053|NCT01036685||379-other-psych -diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who can do MRI and tDCS
9937054|NCT01036685||379-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who can do MRI and tDCS
9937055|NCT01036685||379-user|someone with a DSM-V substance use disorder on a substance other than nicotine who can do MRI and tDCS
9937056|NCT01036581|Experimental|MR Methodology Development and Evaluation|Methodology development and evaluation consists of pulse sequence development, testing, and parameter optimization. For each method we develop or evaluate, we may recruit up to 40 participants to come in for up to 4 visits each. Each participant will be scanned for up to 2 sessions per visit, not to exceed 4 total scan hours per visit.
9999259|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and Montelukast|inhaled fluticasone propionate 100micrograms twice daily + Montelukast
9999260|NCT01526174|Experimental|First Arm|Determine safety of intratympanic injection
9999261|NCT01526174|Experimental|Second Arm|Efficacy evaluation of 4 intratympanic injections
9999262|NCT01526187||Sub-Saharan Africa|
9999263|NCT01526187||Asia|
9937057|NCT01036581|Experimental|TMS-fMRI Experiment 1|To evaluate the relationship between BOLD activation and MEP and establish a BOLD activation marker of cortical excitability. Participants will start with a set of two short task-based EPI scans and anatomical scan. RMT will then be determined. Participants will undergo a single-pulse TMS-fMRI scan with stimulation intensities relative to the RMT over the motor cortex and/or the DLPFC. In total, six (6) intensities will be tested, 80% 100%, 105%, 110%, 115%, and 120% relative to the RMT. The fMRI design will be event-related. Each intensity (event type) will be presented 50 times. The order of the intensities will be randomized, and the inter-stimulus-interval (ISI) will range from 12s to 20s (centered at 16s plus random jittering in between, about 0.06Hz). The highest intensity of stimulation will be 120% RMT. EMG recordings in the corresponding hand muscle will be simultaneously acquired during the scan. Total approximate time required for this experiment is about 6-8 hours.
9937058|NCT01036581|Experimental|TRPMS Experiment 1|To evaluate the prolonged effect of TPRMS on motor cortex excitability and help interpret and design subsequent experiments investigating the effect of TRPMS on BOLD signal. The experiment design consists of four groups, each group will include 10 participants (8 completers/group). For TRPMS stimulation sessions, our test conditions will be a 10 stimuli-session (approximately 2min), 50 stimuli-session (approximately 7min), 100 stimuli-session (approximately 14min), and 150 stimuli-session (20min) for each of the four groups, respectively. Therefore, the outcome will be measured with the spontaneous motor unit potentials (sMUPs) in the contralateral abductor pollicis brevis muscle (APB). After the stimulation session, we will measure sMUPs continuously for another 20min to observe the prolonged effect of the TRPMS stimulation and to compare these four conditions. The total approximate time required for this experiment is about 2-2.5 hours.
9937059|NCT01036581|Experimental|TRPMS Experiment 2|To evaluate cortical excitability changes caused by TRPMS measured with simultaneous TMS-fMRI. Participants will undergo a baseline TMS/fMRI session to get a measurement of baseline cortical excitability in the form of single-pulse TMS induced BOLD activation and determine motor hot-spot and RMT. We will then conduct an event-related single-pulse TMS/fMRI session with TMS stimulus at 120% RMT, 50 events with jittered inter-stimulus-interval (ISI) averaging 16s. Simultaneous EMG recording will be gathered from the corresponding hand muscle. Next we will use TRPMS to stimulate the left motor cortex over the hot-spot : 20-min application of TRPMS, 100ms duration, 0.2Hz (one stimulus every 5s), total 240 stimuli. Then we will evaluate the modulatory effect of the TRPMS stimulation via a second TMS/fMRI session with a similar procedure as the baseline session using the RMT determined at baseline. Total time for this experiment is about 5-6 hours.
9937060|NCT01031407||Group 1|Healthy Volunteers
9937061|NCT01031407||Group 2|Individuals with Autism Spectrum Disorders
9937062|NCT01031407||Group 3|Parents of Healthy Volunteers, or Individuals with Autism Spectrum Disorders
9937063|NCT01031160||U.S. high school students|U.S. high school students who were in 10th grade in the 2009-2010 school year.
9937064|NCT01026220|Experimental|Regimen I (consolidation therapy)|Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
9937065|NCT01026220|Experimental|Regimen II (consolidation therapy)|Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
9937066|NCT01026220|Experimental|Induction: all patient|All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.
9937067|NCT01021033||Chronic stroke patients|Chronic stroke patients
9937068|NCT01019343|Placebo Comparator|Healthy Volunteers|Healthy Volunteers
9937069|NCT01019343|Active Comparator|Movement Disorder|Subjects diagnosed with movement disorder
9937070|NCT01011712||1|patients without known or not fully characterized immunodeficiency, who have severe, persistent, or treatment-refractory viral infections
9937071|NCT01005654||1/ Cohort 1|Subjects with endocrine neoplasm or pre or potentially malignant condition of the endocrine system, scheduled to have surgery or biopsy
9937072|NCT00978003||1/Healthy Volunteers|Adults age 18-55.
9937073|NCT00977977|Experimental|Combination of Rituximab plus cyclosporine|2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months. Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued.
9937074|NCT00967785|Active Comparator|Treatment Arm|Neutropenia and infections
9937075|NCT00961714|Experimental|OsseoFix|Osseofix is an titanium expandable device similar to a vascular stent that is placed in the fractured vertebral body to provide a structure in which bone cement (polymethylmethacrylate) is inserted. It is intended to be used in the thoracolumbar spine between levels T6 through L5.
9937076|NCT00943514||1|chronic or recurring respiratory infections including pulmonary nontuberculous mycobacterial disease
9937077|NCT00943514||2|Relatives
9937078|NCT00942981||healthy volunteers|healthy volunteers
9937079|NCT00942981||patients|patients with schizophrenia, schizoaffective disorder or other psychotic disorders aged18-60
9999264|NCT01526187||Latin America|
9999265|NCT01526200||CEIOUS|One hundred and twenty-seven consecutive patients -77 males and 50 females, mean age of patients was 61 years (median 65 years; range 29-85 years)- underwent liver resection using intraoperative ultrasound and contrast-enhanced intraoperative ultrasound.
9937080|NCT00936325||Healthy volunteers|healthy volunteers to act as controls.
9937081|NCT00936325||Patients with SCLS|patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome.
9999266|NCT01526226|Experimental|HFNC|High flow nasal cannula
9999267|NCT01526226|Active Comparator|nCPAP|Nasal CPAP
10214287|NCT05225701|No Intervention|waiting list|Participants on the waiting list will be assigned to the intervention after 2 months after randomization and will join the Transdiagnostic guided internet-delivered intervention with synchronous assistance.
10214288|NCT05225688||PASC patients|Non-hospitalized covid-19 patients with Post-acute Sequelae of COVID-19
9937082|NCT00936325||Relatives|relatives of patients who have systemic capillary leak syndrome.
9999268|NCT01526239|Experimental|Intervention group|Intervention consisted of a pamphlet about the benefit of CRC-S, given to patients prior to their PCP visit and a reminder note about CRC screening to be given to their physician during the encounter.
9999269|NCT01526239|No Intervention|Control group|Control group will not receive the pamphlet regarding colorectal cancers.
9999270|NCT01526265|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
9999271|NCT01526265|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
9999272|NCT01526265|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
9999273|NCT01526265|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
10034931|NCT01801306|Other|NeMoProbe|The NeMo System is used for intracranial pressure (ICP) and brain temperature monitoring, as well as the determination of the brain tissue oxygenation saturation (SbtO2) and cerebral blood flow. The sensors for NIRS are implemented into a conventional brain tissue probe for ICP monitoring (NeMo Probe).
9937083|NCT00924196||Biologic parents of children and adults with NFI|Biologic parents of children and adults with NFI will be evaluated at one time point, using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
9937084|NCT00924196||Children and adults with NFI|Children and adults with NFI whose tumor and non tumor related manifestations will be longitudinally evaluated. Closed to enrollment
10034932|NCT01801319|Active Comparator|Stimulation|Libra Deep Brain Stimulation System is implanted and activated post implantation
10214289|NCT05225688||Healthy controls|Non-hospitalized covid-19 patients without residual symptoms
10214290|NCT05225675|Experimental|ARGX-117|Intravenous administration of ARGX-117
10214291|NCT05225675|Placebo Comparator|Placebo|Intravenous administration of placebo
10214292|NCT05225649|Experimental|Behavior Change Intervention|Participants will receive health coaching, patient-directed behavior change support by mobile health, and usual clinical care.
9937085|NCT00924196||Unaffected siblings of children and adults with NFI|Unaffected siblings of children and adults with NFI will be evaluated at one time point using a Neuropsychological Test Battery and QOL Assessment. Closed to enrollment
10214293|NCT05225649|No Intervention|Control|Participants will receive usual clinical care.
10214294|NCT05225636|Active Comparator|Radial access|The ischemic stroke treatment will be performed through the radial artery (as first option)
10214295|NCT05225636|Active Comparator|Femoral access|The ischemic stroke treatment will be performed through the femoral artery (as first option)
10214296|NCT05225623|Experimental|Intervention|16-week behavioural weight loss classes
10214297|NCT05225623|Other|Waitlist Control|Participants in this arm will receive their treatment as usual for Psoriatic Arthritis and receive BWLT after the intervention group.
10214298|NCT05225597|Active Comparator|epinephrine|In the epinephrine group, 0.2 mL of epinephrine (1:5000 solution) was used immediately after making the clear corneal incision during cataract surgery
10214299|NCT05225597|Active Comparator|carbachol|In the carbachol group, a 0.5 ml dose of 0.01% carbachol solution (Miostat®, Alcon Laboratories, Inc., Fort Worth, TX) was given intracamerally immediately after viscoelastic matter removal following IOL implantation
10214300|NCT05225597|No Intervention|control|The control group was given neither epinephrine nor carbachol. Standard cataract surgery was performed
10214301|NCT05225571||cervical myofascial pain syndrome|The participants who diagnosed as cervical myofascial pain syndrome aged 18-64 years. The pain must last at least 3 months.
9999274|NCT01526265|Experimental|Collaborative Rewards|"Same as USUAL CARE arm, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
9999275|NCT01526278|Other|Maxmarvil®|single-arm study
9999276|NCT01526317|Experimental|1|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
9999277|NCT01526317|Experimental|2|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
9999278|NCT01526317|Experimental|3|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
9999279|NCT01526317|Experimental|4|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
9999280|NCT01526317|Experimental|5|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
9999281|NCT01526317|Experimental|6|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
9999282|NCT01526330|Experimental|Group A|
9999283|NCT01526330|Experimental|Group B|
9999284|NCT01526330|Experimental|Group C|
9999285|NCT01526330|Placebo Comparator|Group D|
9999286|NCT01526369|Active Comparator|Paclitaxel and Trastuzumab|Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
9999287|NCT01526369|Experimental|Paclitaxel, Trastuzumab and Lapatinib|"Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)~+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal."
9999288|NCT01526382|Active Comparator|intervention arm|patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
9999289|NCT01526382|Placebo Comparator|control arm|Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
9999290|NCT01526395|No Intervention|Unmodified ECT|Data will be collected on patients receiving ECT in its unmodified form prior to the introduction of low dose propofol sedation.
9999291|NCT01526395|Active Comparator|Low Dose Propofol|Subjects will be given low dose propofol prior to ECT.
9999292|NCT01526421|Experimental|monetary reinforcer|
9999293|NCT01526421|No Intervention|no reinforcer|
9999294|NCT01526434||Certolizumab Pegol treatment|Patients with RA who begin therapy with Certolizumab Pegol (CZP) will be consecutively included in accordance with the selection criteria. The choice of medical treatment is made independently by the physician before evaluating the possible participation of the patient in the protocol.
9999295|NCT01526447|Experimental|Craniosacral Therapy (CST)|Each participant of the experimental group receives 8 Craniosacral Therapy units once a week of 45 minutes.
9999296|NCT01526447|Sham Comparator|Sham Craniosacral Therapy (SHAM)|Each participant of the sham group receives 8 sham therapy units once a week of 45 minutes.
9999297|NCT01526460|Active Comparator|Atorvastatin|Atorvastatin 80 mg
10214302|NCT05225558|Experimental|Combination therapy - Vancomycin IV plus Delpazolid 800 mg, PO, BID|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration."
10214303|NCT05225558|Placebo Comparator|Monotherapy - Vancomycin IV plus Placebo of Delpazolid|"Intravenous vancomycin dosed as per 2020 IDSA guideline~Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L.~Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration."
10214304|NCT05225532|Experimental|LA group|Patients randomized to procedure performed in the left atrium
10214305|NCT05225532|Active Comparator|RA group|Patients randomized to procedure performed in the right atrium
10214306|NCT05225519|Experimental|Experimental arm|Usage of a long-sleeved white shirt impregnated with a long-infrared irradiating bioceramic for a period of 12 weeks.
10214307|NCT05225519|Placebo Comparator|Placebo arm|Usage of a long-sleeve white shirt (similar to the one in the experimental arm) but with no long-infrared technology for a period of 12 weeks.
10214308|NCT05225493||Hospital|Medical specialists in hospitals and their patients aged 18 years and older in the participating hospitals who are diagnosed there with an HIV indicator condition.
10214309|NCT05225493||Primary care|General practitioners and their patients aged 18 years and older in the participating general practices who are diagnosed there with an HIV indicator condition.
9999298|NCT01526460|Active Comparator|Rosuvastatin|Rosuvastatin 40 mg
9999299|NCT01526460|Placebo Comparator|No statin loading dose|No statin loading dose
9999300|NCT01526473|Experimental|AVX901|AVX901 at 4 x 108 IU intramuscularly, given every 2 weeks for a total of three doses.
9999301|NCT01526486|Experimental|Videoscopic (Minimally invasive)|Patients in this arm will have the procedure done through the three port minimally invasive approach.
9999302|NCT01526486|Active Comparator|Open (traditional approach)|Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
9999303|NCT01526499|Experimental|TC|Docetaxel plus Cyclophosphamide
9999304|NCT01526499|Active Comparator|T|Docetaxel
9999305|NCT01526512|Experimental|metroCX|metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
9999306|NCT01526525|Placebo Comparator|TK|In TK group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point in both hands, the needles were not inserted in the skin but they were put atop the skin and were secured by adhesive tape. For 30min in the E/A stimulator ITO ES-160 the indicator light was on but no electrical current was applied. Thereafter the E/A device deactivated and after the awakening of the patients, it was connected in ST36 and LI4 points for 30min with the same technique. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36. The patients were told that they may or may not feel electrical current because of its very high frequency.
9999307|NCT01526525|Active Comparator|TKE|In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
9999308|NCT01526564|Active Comparator|ALC|ALC
9999309|NCT01526564|Placebo Comparator|Placebo|
9999310|NCT01526590|Experimental|Definity|Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
9999311|NCT01526616|Active Comparator|Metformin|850 mg/day twice a day
9999312|NCT01526616|Active Comparator|Metformin plus spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
9999313|NCT01526642|No Intervention|Long Term Oxygen Therapy|
9999314|NCT01526642|Active Comparator|Non Invasive Ventilation|
9999315|NCT01526655|Active Comparator|Abdominal total hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
9999316|NCT01526655|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
9999317|NCT01526681||RANGER: Avance Nerve Graft|Processed Human Nerve Graft
9999318|NCT01526681||Historical Control for Standard Treatment|Literature review for outcomes from standard treatments, i.e. Autogenous Nerve Graft.
9999319|NCT01526681||MATCH Arm: Contemporary Control|Addendum 1: Autogenous Nerve Graft and Nerve Tube Conduit
9999320|NCT01526681||Sensation-NOW Arm: Breast Neurotization|Addendum 2: Post-mastectomy autologous breast reconstruction with or without neurotization
9999321|NCT01526694|Experimental|treatment with BDT|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
9999322|NCT01526707|Experimental|inhaled steroid|inhaled steroid treatment for 7 days
9999323|NCT01526720||Group A: Diabetic|Newly diagnosed type 2 diabetic patients (i.e. diagnosis made no more than 6 months before recruitment)
9999324|NCT01526720||Group B: Relatives|Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes
9999325|NCT01526746|Experimental|End Stage Renal Disease, dialysis|eGFR <15 ml/min/1.73m^2
9999326|NCT01526746|Experimental|Severe renal impairment|eGFR < 29 ml/min/1.73m^2
9999327|NCT01526746|Experimental|Healthy controls|eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
9999328|NCT01526759|Experimental|pectin|10 gram high gelling-high viscous fiber, added to a drink
9999329|NCT01526759|Placebo Comparator|control|10g gelatin, added to a drink
9999330|NCT01526772||Patients who have undergone RYGB|Patients who have undergone RYGB and have been referred for an EGD
9999331|NCT01526798|Experimental|Therlite hemodialysis|
9999332|NCT01526798|Active Comparator|Control group hfHDF|Control group hfHDF
9999333|NCT01526811||AAA patients|Subjects presenting with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and requiring endovascular treatment with Endurant™ Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional study
9999334|NCT01526824|No Intervention|Control arm, clopidogrel without Lovaza|These patients will be receiving standard of care therapy with either standard dose (75mg daily) or high dose (150mg daily) clopidogrel +/- aspirin based on physician discretion.
9999335|NCT01526824|Experimental|Clopidogrel plus Lovaza|This is the study arm of the trial, in which patients will be receiving either a standard dose (75mg daily) or high dose (150mg daily) clopidogrel with or without aspirin as well as therapy with daily Lovaza.
9999336|NCT01526837|Experimental|bevacizumab (Avastin)|Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
9999337|NCT01526850|Experimental|allogenic mesenchymal stem cells (MSCs)|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
9999338|NCT01526850|Active Comparator|Control group|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
9999339|NCT01526863|Placebo Comparator|Placebo|
9999340|NCT01526863|Active Comparator|HA egg|
9999341|NCT01526876|Experimental|Single Arm drug study|The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
9999342|NCT01526915|Experimental|Bone curettage + PRF|Bone curettage and PRF insertion
9999343|NCT01526915|Other|Bone curettage alone|Bone curettage without PRF insertion
9999344|NCT01526941|Experimental|Treatment period 1|
9999345|NCT01526941|Experimental|Treatment period 2|
9999346|NCT01526954|Experimental|TissuGlu Surgical Adhesive|Experimental Arm: standard of care plus TissuGlu Surgical Adhesive and no drains
10034933|NCT01801319|Sham Comparator|No Stimulation|The Libra DBS System is implanted and not activated
9999347|NCT01526954|No Intervention|Control- Standard of Care|Control Arm: standard of care plus drains and no TissuGlu Surgical Adhesive
9999348|NCT01526967||New moldable user|Subjects presenting with peristomal lesions with a traditional barrier and for whom a ConvaTec Moldable Technology™ Skin Barrier is used as a replacement.
9999349|NCT01526967||New osomate|Subjects for whom a ConvaTec Moldable Technology™ Skin Barrier is used as the first long-term (within 7 days of ostomy surgery) system following surgery and have intact peristomal skin.
9999350|NCT01526980|Experimental|Treatment period 1|
9999351|NCT01526980|Active Comparator|Treatment period 2|
9999352|NCT01527019|Experimental|Cephalosporin oral suspension|130 research subjects on cephalosporin oral suspension (test) 400 mg once daily
9999353|NCT01527019|Experimental|Cephalosporin capsules|130 research subjects on cephalosporin capsules (test) 400 mg once daily
9999354|NCT01527019|Active Comparator|Norfloxacin|130 research subjects on norfloxacin (test) 400 mg twice daily
9999355|NCT01527058|Experimental|68Ga-BNOTA-PRGD2 PET/CT scanning|Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
9999356|NCT01527084|Other|Group A|undergo surgery between days 10 - 15 after PCD
9999357|NCT01527084|Other|Group B|"continued with PCD beyond 15 days and indications for surgery in them will be,~Persistent sepsis or symptoms~Worsening of clinical condition~Failure to thrive~Complications of SAP or PCD"
9999358|NCT01527097|Experimental|Atorvastatin|
9999359|NCT01527097|Placebo Comparator|Placebo|
9999360|NCT01527123|Experimental|GSK2585823|External Preparation
9999361|NCT01527136|Experimental|Treatment (entolimod)|Patients receive entolimod IM or SC on days 1, 4, 8, and 11. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
9999362|NCT01527175|Active Comparator|supraclavicular|supraclavicular: supraclavicular approach for subclavian venous catheterization
9999363|NCT01527175|Placebo Comparator|infraclavicular|infraclavicular: infraclavicular approach for subclavian venous catheterization
9999364|NCT01527188|Experimental|100IR|
9999365|NCT01527188|Experimental|300IR|
9999366|NCT01527188|Experimental|500IR|
9999367|NCT01527188|Placebo Comparator|Placebo|
9999368|NCT01527201|Experimental|Treatment Group|Worn out cartilage will be surgically treated.
9999369|NCT01527201|No Intervention|Control Group|Worn out cartilage will be observed, but will not be treated surgically.
9999370|NCT01527214|Experimental|CT scan and education|All general practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital.Randomized 1:1. In the intervention group, GPs continue to refer to the lung cancer fast track when indicated. In addition, they are allowed to refer directly to a rapid chest CT scan in cases where they find reasons to examine the patient for lung diseases without having sufficient suspicion of lung cancer to refer the patient to the lung cancer fast track. The GPs will be offered special training related to the diagnosis of lung cancer in general practice before the new referral option is introduced. This will be done by offering training sessions and written material.
9999371|NCT01527214|No Intervention|Control|Cluster eligibility: all practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital. Randomized 1:1. Control arm continues with the usual referral pattern
9999372|NCT01527227||children of mentally ill|This research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population
10034934|NCT01801332|Experimental|intensive arm|Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days + intensive enteral nutrition by feeding tube for 14 days
10034935|NCT01801332|Active Comparator|control arm|"Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days +  classical  oral alimentation for 14 days"
10034936|NCT01801345|Other|Rested|Subjects will perform the scenario, once during a normal workday (rested)
10034937|NCT01801345|Active Comparator|Fatigued|Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued).
10034938|NCT01801371|Experimental|68Ga-BNOTA-PRGD2|In patients in suspicion of glioma, single bolus of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be intravenously injected 30 minutes before brain PET/CT to determine 68Ga-BNOTA-PRGD2 uptake in tumor and brain.
10034939|NCT01801384|Experimental|Original contingent vouchers schedule|Women will receive an abstinence-contingent voucher-based incentives intervention (Contingency Management) for smoking cessation and relapse prevention.
10034940|NCT01801384|Experimental|Revised contingent vouchers schedule|Women receive abstinence-contingent voucher-based incentives (Contingency Management) intervention designed to further increase cessation and relapse prevention rates.
10034941|NCT01801384|Sham Comparator|Non-contingent vouchers schedule|This serves as a control condition wherein women earn incentives independent of smoking status.
10034942|NCT01801397|Other|Teriparatide|one arm study. All patients receive teriparatide
10037245|NCT01823315|Experimental|Methotrexate Single-coure chemotherapy|Regimen: Methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5. If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen.
9937086|NCT00924027|Experimental|1/Radiation Therapy|Radiation therapy given as HDR Brachytherapy.
9937087|NCT00923507||Patients|Patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstr(SqrRoot)(Delta)m macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL).
9937088|NCT00923442||1|Patients (from birth to 75 years old) diagnosed with any hematologic malignancy or pre malignant condition
9937089|NCT00923221||1/Patient samples|blood samples from patients with diagnosed prostate cancer
9937090|NCT00923104||1/healthy volunteers|healthy volunteers
9937091|NCT00923104||2/patients|subjects with breast cancer, ductal carcinoma in situ, and adenocarcinoma of prostate
9937092|NCT00923065||Consults|Individuals being seen as a consult.
9937093|NCT00923065||Donors|Donors of cellular products.
9937094|NCT00923065||Genetic Follow-Up|Individuals with a known/suspected germline genomic research incidental pathogenic or likely pathogenic variant, and/or who require CLIA confirmation.
9937095|NCT00923065||Patients|Individuals being enrolled for the treatment or follow-up of their disease.
9937096|NCT00923026||A/Gene Therapy|Patients who have received gene therapy
9937097|NCT00923026||B/Non-Gene Therapy|Patients who have not received gene therapy
9937098|NCT00923013|Experimental|1|Cladribine with immediate Rituximab
9937099|NCT00923013|Active Comparator|2|Cladribine with Rituximab delayed by at least 6 months after Cladribine if and when minimal residual disease is detected
9937100|NCT00923013|Experimental|3|Non-randomized group receving Cladribine with immediate Rituximab (before rather than after the 1st of the 5 daily doses of cladribine on day 1)
9937101|NCT00900198||1/Standard|Standard
9937102|NCT00900198||2/Standard and Preclinical Models|Standard and Preclinical Models
9937103|NCT00900198||3/Preclinical Models|Preclinical Models
9937104|NCT00900198||4/Preclinical Models, Pediatric|Preclinical Models, Pediatric
9937105|NCT00895271||Healthy Volunteers|Up to 50 subjects as healthy controls
9937106|NCT00895271||Immunodeficiency|Up to 150 subjects with poorly defined, rare inherited immunodeficiency or immunodysregulation disorders
9937107|NCT00887939||1|Affected physical urticaria
9937108|NCT00887939||2|Healthy volunteer
9937109|NCT00887939||3|Unaffected relative
9937110|NCT00867269||Blood Relatives|Blood Relatives of ICL subjects
9937111|NCT00867269||Household Contacts|Household contacts of ICL subjects
9937112|NCT00867269||ICL Subjects|Patients with confirmed idiopathic CD4 lymphocytopenia
9937113|NCT00862433|Experimental|Arm 1|Determine optimal fat content of meal for optimal absorption of vitamin E
9937114|NCT00862433|Experimental|Arm 2|Determine optimal dose of vitamin E.
9937115|NCT00862433|Experimental|Arm 3|Investigate the relationship between vitamin C status and vitamin E turnover
9937116|NCT00862433|Experimental|NAFLD sub-study|Investigate the relationship between fatty liver disease and vitamin E turnover.
9937117|NCT00852943||Patients|Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation or mast cell homeostasis or activation, will be eligible for enrollment.
9937118|NCT00852111||Patients|Prostate cancer patients
9937119|NCT00837122||Control|Control subjects are nondiabetics ethnically matched to patients
9937120|NCT00837122||T2D|Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
9937121|NCT00814827||Group 1|Patients with nontuberculous mycobacteria (NTM) alone.
9937122|NCT00814827||Group 2|Patients with non-NTM opportunistic infection, either with or without concurrent NTM infection.
9937123|NCT00814827||Group 3|Patients with pulmonary mycobacterium tuberculosis (MTB).
9937124|NCT00814827||Group 4|Patients with disseminated mycobacterium tuberculosis (MTB).
9937125|NCT00814827||Group 5|Blood Specimen Donors.
9937126|NCT00806364||1|Blood, skin, stool/rectal swabs, buccal mucosa and bone marrow aspirate samples from approximately 250 healthy volunteer donors
9937127|NCT00804154|Experimental|Single Arm|advanced cancer patients with pain
9937128|NCT00794352||Healthy Volunteer|Healthy patients with NO inflammatory and/or demyelinating/dysmyelinating diseases of the CN
9937129|NCT00794352||Patient Cohort|Patients who present with CNS white matter injury (including inflammatory and/or demyelinating/dysmyelinating diseases of the CNS)
9937130|NCT00789009||Group 1|Consist of HIV positive patients recruited from the Washington DC metropolitan area who will receive long-term care for their HIV infection through the NIAID/CCMD HIV clinic
9937131|NCT00789009||Group 2|Patients with known or suspected HIV infection, referred to a NIAID/CCMD investigator for reasons such as testing to diagnose or exclude HIV disease or assistance with HIV-related problems.
9937132|NCT00787423||COHORT 1|Individuals from 18 to 75 years of age who are current heroin users seeking treatment for addiction and who spend most of their time in Baltimore city.
9937133|NCT00776412||HIV Negative|Healthy Volunteer Cohort
9937134|NCT00776412||HIV Positive INR|HIV Positive INR Cohort
9937135|NCT00776412||HIV Positive Standard|HIV Positive Standard Cohort
9937136|NCT00775853||Individuals at risk for developing PD|Individuals who may be at risk for developing PD because of genetic risk, olfactory dysfunction, symptomatic rapid eye movement sleep behavior disorder, or orthostatic hypotension
9937137|NCT00774254|Experimental|A|
9937138|NCT00767312||Patients|HIV-infected patients who are 18 years of age or older, have been enrolled in another NIH protocol.
9937139|NCT00739362|Experimental|Active|Active tDCS stimulation
9937140|NCT00739362|Sham Comparator|Sham|Sham/no-stimulation
9937141|NCT00720785|Experimental|1|NK Cell Infusion (cell /kg pt wt)
9937142|NCT00720785|Experimental|2|1.3 mg/m2/dose administered as a 3 to 5 second bolusintravenous injection
9937143|NCT00719719||Drug Anaphylaxis|Drug Anaphylaxis
9937144|NCT00719719||Food Anaphylaxis|Food Anaphylaxis
9937145|NCT00719719||Idiopathic Anaphylaxis|Idiopathic Anaphylaxis
9937146|NCT00719719||Venom Anaphylaxis|Venom Anaphylaxis
9937147|NCT00713492|Experimental|1|Alcohol
9937148|NCT00702533||Healthy volunteers|Healthy volunteers between 18 and 60 years of age
9937149|NCT00702533||patients with gastric acid secretory disorders|18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.
9937150|NCT00687115|Other|Overfeeding|an inpatient overfeeding arm in which obesity resistant individuals are prescribed a 150% increase in a weight maintenance calorie diet for 6 weeks which (by random assignment) is either low in protein (6%) content. Overfeeding or Overfeeding Low Pro or with normal (20%) protein content
9937151|NCT00687115|Other|Weight Loss|a weight loss arm in which obese individuals are placed on a 50% decrease from a weight maintenance calorie diet for 6 weeks which (by random assignment) is either a standard 50% decrease in energy intake with all macronutrients held at the same percentage (20% protein, 50% carbohydrate, 30% fat) or a 50% decrease in energy intake with the same absolute protein content (in grams) as the weight maintaining diet while on our clinical research unit then followed as outpatients monthly for 10 months
9937152|NCT00669188|Experimental|Information Type 1|genetic risk information
9937153|NCT00669188|Sham Comparator|Information Type 2|information absent
9937154|NCT00663611|Experimental|Study I and IB|Each involve six subjects &amp; are designed to test the hypothesis that pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will yield a reasonable pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher than that in Study I. Study I and IB will be done first before proceeding to Study II
9937155|NCT00663611|Experimental|Study II|Is a randomized, double-blinded, placebo-controlled 12 week study involving 26 subjects divided into 2 groups: Group A and Group B. Group A will involve 13 subjects receiving pulsatile GH or placebo infusion for 4 weeks with 8 week washout after intervention. Group B will involve 13 subjects receiving conventional once a day subcutaneous infusion of GH or placebo for 4 weeks with 8 week washout after intervention.
9937156|NCT00655096||Affected participants|Adults and children with either diagnosed or un-diagnosed ocular conditions.
9937157|NCT00655096||Disease free control|Adults and children without any ocular disorders.
9937158|NCT00655096||Unaffected relative|Unaffected first degree relative of a genetic ocular disease participant.
9937159|NCT00646022||Arm 1|Participants who undergo extended evaluation for disease at NIH
9937160|NCT00646022||Arm 2|Participants who do not undergo extended screening or evaluation for disease at NIH
9937161|NCT00606346||Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
9937162|NCT00606346||No Biologics|Treatments will be prescribed according to investigator judgement.
9937163|NCT00605878||Grouo 3|Healthy (pediatric) controls
9937164|NCT00605878||Group 1|Healthy (adult) volunteers
9937165|NCT00605878||Group 2|AD patients
9937166|NCT00605878||Group 4|Patients diagnosed with the primary immunodeficiency hyperIgE syndrome (HIES)
9937167|NCT00605878||Group 5|Patients diagnosed with the primary immunodeficiency Wiskott-Aldrich Syndrome (WAS)
9937168|NCT00605878||Group 6|Patients diagnosed with the combined immunodeficiency associated with DOCK8 mutation (DOCK8)
9937169|NCT00601003|Experimental|Nifurtimox|
9937170|NCT00598351||Patients|Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.
9937171|NCT00594672||AREDS participants|Participants who were enrolled in the AREDS or AREDS2 protocol and successfully completed the final AREDS or AREDS2 follow-up visit.
9937172|NCT00568243||1|normal adult volunteers and patients with eye movement problems
9937173|NCT00567567|Active Comparator|Consolidation Arm A: single myeloablative consolidation|Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.
9937174|NCT00567567|Experimental|Consolidation Arm B: tandem myeloablative consolidation|Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.
9937175|NCT00557726||1|Patients with a variety of infections and inflammatory diseases.
9937176|NCT00542230||Healthy Volunteers|Healthy Volunteers
9937177|NCT00542230||Sickle Cell Trait|Patient with sickle cell trait or disease
9937178|NCT00533182||Immunocompromised|Immunocompromised individuals
9937179|NCT00533182||Non-Immunocompromised|Non-immunocompromised individuals
9937180|NCT00533182||Pregnant|Pregnant women
9937181|NCT00523627||Healthy Volunteers with normal glucose regulation|Healthy volunteers with normal glucose regulation
9937182|NCT00508547||Guselkumab|Participants will receive guselkumab as prescribed by the physician according to standard of care for psoriasis.
9937183|NCT00508547||Infliximab|Participants will receive infliximab as prescribed by the physician according to standard of care for psoriasis.
9937184|NCT00508547||Ustekinumab|Participants will receive ustekinumab as prescribed by the physician according to standard of care for psoriasis.
9937185|NCT00508547||Biological Therapies|Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by physician for psoriasis. Participants will not receive any intervention as a part of this study.
9937186|NCT00508547||Conventional Systemic Agents|Participants will receive conventional systemic agents as prescribed by the physician for psoriasis. Participants will not receive any intervention as a part of this study.
9937187|NCT00508547||IL-17 Inhibitor|Participants will receive an IL-17 inhibitor as prescribed by the physician according to standard of care for psoriasis.
9937188|NCT00500994|Experimental|fMRI study|subjects receiving MRI
9937189|NCT00495300||1|Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program
9937190|NCT00475761||Breast Cohort|Primary clinical- patients referred to diagnostic breast biopsy
9937191|NCT00471302||1|Healthy adults in a malaria endemic area in Mali
9937192|NCT00471250||1|Healthy Volunteers
9937193|NCT00471250||2|NIH patients with known or suspected susceptibility to infection.
9937194|NCT00469339||cohort of Mexican-American households|cohort of Mexican-American households
9937195|NCT00453505|Experimental|1|Healthy adults
10214310|NCT05225480|Experimental|intervention arm|"The illness perception conversation will be delivered in one session during around 15 minutes. The conversation will be based on responses to the eight item Brief illness perception questionnaire and a rating of the most relevant item made by the patient on the same day.~The aim of the conversation will be to get an overview of the patient's illness perceptions concerning their knee OA and what is deemed the most maladaptive perceptions by the participant. Participants will be invited to elaborate on their thoughts concerning these perceptions.Although any maladaptive perceptions will be corrected if natural during the conversation, the conversation will not lead to any active attempts of changing illness perceptions. Rather, the conversation focusses on giving patients time and opportunity to express knee pain related perceptions and worries concerning their knee pain."
9937196|NCT00453505|Sham Comparator|1a|Healthy Volunteers
9937197|NCT00453505|Experimental|2|Healthy Volunteers
9937198|NCT00453505|Sham Comparator|2a|Healthy Volunteers
9937199|NCT00453505|Experimental|3|Healthy Volunteers
9937200|NCT00453505|Sham Comparator|3a|Healthy Volunteers
9937201|NCT00453505|Experimental|4|Healthy Volunteers
9937202|NCT00453505|Sham Comparator|4a|Healthy Volunteers
9937203|NCT00451022||Cohort 1|Subjects previously participating in gene transfer or other immunotherapy studies at the NCI or extramural sites receiving therapeutic agents as part of a multi-site trial.
9937204|NCT00450788||Golestan Cohort|Cohort of adults from Golestan region in Iran
9937205|NCT00450450|Experimental|Arm I|Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.
10214311|NCT05225480|Active Comparator|control arm|"The control conversation will be delivered in one session during around 15 minutes. In order to create two similar conversational settings where the only difference is the actual content of the conversations. The conversation will be based on responses to an eight item questionnaire concerning motivation for research participation and - similar to the illnes perception conversation - a rating of the most relevant item made by the patient.~The aim of the conversation will be to get an overview of the patient's motivation for research participation and let them elaborate on their thoughts concerning their motivation."
10214312|NCT05225467||Main group|All participants taking part in this study are subsequently categorized in this group
10214313|NCT05225428|Experimental|QUALITATIVE ASSESSMENT|"This part of the research study involves watching a brief educational video about genetic testing for inherited cancer risk (about 8 minutes) before completing a short interview by video or telephone with trained researchers. This interview will be digitally recorded for later review.~It is expected that about 20 people will take part in this part of the research study.~In the larger part of the study that will happen after this part of the study, it is expected 1000 people will participate."
10214314|NCT05225428|Experimental|RCT-VERDI|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
10214315|NCT05225428|Experimental|RCT-Genetic Counseling|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
10214316|NCT05225389|Experimental|CT1812|Investigational Drug
10214317|NCT05225376|Experimental|Establishment of physical activity sessions for pregnant women|All the women will receive the studied intervention
10214318|NCT05225350|No Intervention|Controls|In the first arm the patients received care consistent with regional guidelines. Treatment as usual.
10214319|NCT05225350|Experimental|Dietary Intervention|In the second arm the patients received care consistent with regional guidelines in combination with the intensive dietary intervention for three months
10214320|NCT05225324||Equfina 50 mg|Participants who will be prescribed with Equfina 50 mg tablets, orally within the scope of the approved label for Korea under the medical judgment of the investigator will be observed prospectively for 24 weeks.
10214321|NCT05225311||Patients with Fetal Ebstein's Anomaly or Tricuspid Valve Dysplasia|Patients will be followed for life-long outcomes.
10214322|NCT05225298|Active Comparator|Static frequency|Test based screening for SARS-CoV-2 every two weeks
10214323|NCT05225298|Active Comparator|Dynamic frequency|Test based screening for SARS-CoV-2 ranging from once a week to once every four weeks anchored to county COVID-19 case rates
10214324|NCT05225285|Experimental|VACC|This group will receive the inactivated Coronavac/Butantan vaccine.
10214325|NCT05225285|Active Comparator|BNTC|This group will receive the immunizing BNT162b2 (Pfizer).
10214326|NCT05225285|Active Comparator|ADU|This group of adults participants will receive the inactivated Coronavac/Butantan vaccine.
10214327|NCT05225272||Patients undergoing on-pump cardiac surgery|The investigators aim to conduct a bidirectional (prospective and retrospective) observational, cohort study including on-pump cardiac surgery patients.
10214328|NCT05225246||Readmission group|Patients who had heart surgery and returned unplanned to the University Hospital Basel within 30 days of leaving the hospital (outpatient or inpatient)
10214329|NCT05225246||control group|Patients who had heart surgery and did not return unplanned to the University Hospital Basel within 30 days of leaving the hospital (outpatient or inpatient)
10214330|NCT05225233|Experimental|Active tDCS with Cognitive Training|Participants will receive active tDCS stimulation with their cognitive training during a one-hour session each day which includes 20 minutes of stimulation at the beginning of a 46-minute task training session. Ten sessions will be completed over three weeks.
10214331|NCT05225233|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 seconds, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
10214332|NCT05225194||COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by SAS-CoV-2.
9999373|NCT01527240|Experimental|Ciclosporin A|Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
9999374|NCT01527240|Placebo Comparator|Placebo|Injectable Saline Solution.
10214333|NCT05225194||Non-COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by other etiologies than SARS-CoV-2.
10214334|NCT05225194||Family controls|Family controls of participants with ARDS (either due to COVID-19 or other etiologies) without history of COVID-19 or hospitalization in the last 12 months.
10214335|NCT05225181|Experimental|sequential training|first perform physical exercise followed by cognitive training
10214336|NCT05225181|Experimental|simultaneous training|perform physical exercise and cognitive tasks simultaneously
10214337|NCT05225181|Active Comparator|control group|perform body stretching and health education courses
10214338|NCT05225155||Control|Women without thrombophilia, submitted to in vitro fertilization techniques
10214339|NCT05225155||Untreated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, without treatment with enoxaparin
10214340|NCT05225155||Treated Thrombophilia|Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, and treated with enoxaparin
10214341|NCT05225142|Experimental|Modified minimally invasive surgery alone|Modified minimally invasive surgery alone for access and debridement of intrabony defect. This approach maximises wound stability. No application of regenerative biomaterial.
10214342|NCT05225142|Active Comparator|Modified minimally invasive surgery with enamel matrix derivative|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative (regenerative biomaterial)
9937206|NCT00450450|Active Comparator|Arm II|Patients undergo conventional allogeneic bone marrow transplantation on day 0.
9937207|NCT00445627||Healthy Lean Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
9937208|NCT00445627||Overweight Obese Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
9937209|NCT00445627||Type 1 Diabetes|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
9937210|NCT00442195||1|Healthy Volunteers
9937211|NCT00428987||lean|Normal weight men and women over the age of 18 years with BMI greater than 18.5 and less than 25, who are reasonably healthy
9937212|NCT00428987||obese|Obese men and women over the age of 18 years with BMI greater than 30, who are reasonably healthy
9937213|NCT00428987||overweight|Overweight men and women over the age of 18 years with BMI greater than 25 and less than 30, who are reasonably healthy
9937214|NCT00410241||A1|Self-referred individuals 45-65 at enrollment, 25% of whom had coronary artery disease
9937215|NCT00410241||A2|Individuals 45-65 at enrollment who self-identified as African, African-American, or Afro-Caribbean
9937216|NCT00410241||A3|Adults aged 18-65 at the time of enrollment, including subjects of both sexes, who have been identified as likely to return for follow up
9937217|NCT00410241||B|Family members of Group A1, A2, or A3
9937218|NCT00404560||healthy blood relatives|relatives not ill with a known or suspected infection susceptibility syndrome
9937219|NCT00404560||Patients|patients who either have, or are suspected of having, an infection or infection susceptibility in order to further characterize such conditions
9937220|NCT00397280||1|Any healthy donors meeting inclusion/exclusion criteria
9937221|NCT00397111||Healthy Volunteer|Healthy Volunteer/control group
9937222|NCT00397111||Major Depressive Disorder|Individuals with Major Depressive Disorder
9937223|NCT00392821|Experimental|RAD001 and Sorafenib|RAD001 and Sorafenib
9937224|NCT00378742||Participants|Participants with inherited eye diseases or relative of affected participant
9937225|NCT00369421||Healthy Volunteers|Healthy Volunteers
9937226|NCT00369421||Patients|Patients with unique disorders
9937227|NCT00369421||Unaffected family members|Unaffected family members of patients
9937228|NCT00368446||1|Normal
9937229|NCT00368446||2|Patients with Genetic Disorders of Mucociliary Clearance
9937230|NCT00362843||healthy volunteers|healthy volunteers
9937231|NCT00362843||patients|Patients with Fragile X Syndrome
9937232|NCT00361829||Ecologic/Community|Married women, infants, caregivers, Japanese-American, Argentine-American
9937233|NCT00359684||Cystinosis|Patients with a diagnosis of cystinosis
9937234|NCT00359580||AGDB|Those individuals who are listed in the Fisher Family History and other genealogy books ordatabases will be included in the AGDB.
9937235|NCT00353782||Dyslipidemia|Dyslipidemia
9937236|NCT00353158|Active Comparator|A|Subjects currently on or previously on chronic voriconazole or subjects who are scheduled to begin voriconazole
9937237|NCT00353158|Experimental|B|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
9937238|NCT00352924||Cohort of Agricultural Workers|Cohort of Agricultural Workers
9937239|NCT00346164|Experimental|Arm A: No adjuvant treatment|Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
9937240|NCT00346164|Experimental|Arm B: Low risk; adjuvant radiotherapy|Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
10214343|NCT05225142|Active Comparator|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Modified minimally invasive surgery access and debridement of intrabony defect combined with local application of enamel matrix derivative and bone replacement graft (regenerative biomaterial)
10214344|NCT05225090|Other|Smartphone App Intervention|Cancer patients taking at least one oral anti-cancer drug or oral medication to manage a chronic condition in conjunction with any cancer treatment will receive messages through the Medisafe App.
9999375|NCT01527253|Experimental|Active Diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations containing important amounts of specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics)
9999376|NCT01527253|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations but lacks the specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics).
9999377|NCT01527266|Experimental|carbohydrate mouth rinse fasted|sucrose mouth rinse in the fasted state
9999378|NCT01527266|Experimental|carbohydrate mouth rinse fed|sucrose mouth rinse fed state
9999379|NCT01527266|Placebo Comparator|Placebo mouth rinse fed|placebo (non-caloric sweetened drink) in the fed state
9999380|NCT01527266|Placebo Comparator|Placebo mouth rinse fasted|placebo (non-caloric sweetened drink) in the fasted condition
9999381|NCT01527279|Placebo Comparator|Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
9999382|NCT01527279|Experimental|Antazoline|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
9999383|NCT01527305|Experimental|Paliperidone palmitate|
9999384|NCT01527318|Experimental|Fibrate Treatment|Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
9999385|NCT01527331|No Intervention|control group|usual care
9999386|NCT01527331|Experimental|Video decision aid arm|
9999387|NCT01527409|Experimental|Experimetal Arm|"Providing tailored health care program, which provides various information related to exercise, diet, and posttraumatic growth.~Tailored health partnership program consists of three strategic areas (exercise, diet, and posttraumatic growth). Those areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients who participate in the tailored health partnership program will be received tailored manual and workbook for tele-coaching that help them to lead their healthy life.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life."
9999388|NCT01527409|No Intervention|Control Arm|"Providing usual care. Also, patients will be provided a workshop for health education that is dealt with ten areas (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation).~Twelve month later, patients will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth."
9999389|NCT01527448|Experimental|Atypical antipsychotic treatment|Quetiapine XR is given to postpartum women diagnosed with bipolar disorder II. Starting dose is 50mg, maximum dose is 300mg/day.
9999390|NCT01527461||Lung Cancer Patients|diagnosed lung cancer patients .
9999391|NCT01527461||COPD Patients|COPD patients, not diagnosed with lung cancer.
9999392|NCT01527539|Experimental|BIAsp 30|
9999393|NCT01527552|Experimental|Formulation A|
9999394|NCT01527552|Experimental|Formulation B|
10214345|NCT05225077|Active Comparator|Dapagliflozin 10mg group|Dapagliflozin 10 mg once a day for 1 month after the procedure.
10214346|NCT05225077|No Intervention|Non-intervention group|No intervention.
10214347|NCT05225064|No Intervention|Control|No vaccine or mask promotion, but access to vaccines increased to match access in intervention villages
10214348|NCT05225064|Experimental|Village-level vaccine clinics with monetary, non-monetary, or no incentive|Villages are cross-randomized to no incentive, guaranteed cash, a cash lottery, or food for receiving the vaccination
10214349|NCT05225064|Experimental|Household-level vaccination with monetary, non-monetary, or no incentive|Villages are cross-randomized to no incentive, guaranteed cash, a cash lottery, or food for receiving the vaccination
10214350|NCT05225064|Experimental|Village-level vaccination without incentive, plus mask promotion|Individuals are encourage to attend village-level vaccine clinics but not given any incentive. Mask distribution and reinforcement activities are conducted in villages at a similar time as vaccine promotion.
10214351|NCT05225064|Experimental|Village-level vaccination without incentive|Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
10214352|NCT05225025|Experimental|ROSE Intervention|
10214353|NCT05225025|Active Comparator|Standard of Care|
9999395|NCT01527565|Experimental|Formulation A|
9999396|NCT01527565|Experimental|Formulation B|
9999397|NCT01527604|Active Comparator|Avenanthramide-enriched oat muffin|
9999398|NCT01527604|Placebo Comparator|Refined flour muffin|
9999399|NCT01527617|Active Comparator|Cranberry beverage|
9999400|NCT01527617|Placebo Comparator|Non-cranberry beverage|
9999401|NCT01527630|Experimental|Formulation A|
9999402|NCT01527630|Experimental|Formulation B|
9999403|NCT01527643|Experimental|Formulation A|
9999404|NCT01527643|Experimental|Formulation B|
9999405|NCT01527656|Experimental|Formulation A|
9999406|NCT01527656|Experimental|Formulation B|
9999407|NCT01527669|Experimental|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
9999408|NCT01527669|Experimental|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
9999409|NCT01527695|Experimental|AZD3241|AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
9937241|NCT00346164|Experimental|Arm C: Intermediate & High risk; adjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
9937242|NCT00346164|Experimental|Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
9937243|NCT00344331||Patients with a diagnosis of Niemann-Pick type C (NPC) of either sex and any age|Participants may range from neurologically asymptomatic to severe and may have liver disease or unrelated comorbidities, but must be stable enough to safely travel and tolerate medical evaluations.
9937244|NCT00344188||1|This population of patients are referred from their physicians both regionally and nationally.
9937245|NCT00342927||Volunteers|Volunteers for a genetic study of diabetes and nephropathy
9937246|NCT00342888||Childhood Leukemia Cases|Cases were diagnosed at 9 hospitals in Northern California
9476155|NCT03574519|Experimental|Contingent incentives and weekly feedback|Participants will receive payment for meeting their daily goals and will receive weekly updates about their performance.
9937247|NCT00342888||Matched Controls|Controls were matched on age, gender and race/ethnicity from birth certificates in Northern California
9937248|NCT00342797||Retinoblastoma cohort|Retinoblastoma patients treated at two hospitals in New York and one hospital in Boston from 1914-2006 who survived at least one year after their retinoblastoma diagnosis.
9937249|NCT00342732||non-diabetic volunteers|non-diabetic volunteers aged 18-65 who are healthy as determined by medical history, physical examination, and laboratory tests
9937250|NCT00342667||1|patients with preterm labor/contractions and preterm premature rupture of membranes
9937251|NCT00342654||1|Participants from two large, nutritional intervention trials that were conducted in Linxian, China between 1985-1991.
9937252|NCT00342589||Healthy Volunteers|Individuals exposed to environmental or person- to-person sources of organisms, including healthy volunteers, health care professionals, patient families, or other patients in health care facilities
9937253|NCT00342589||Patients|Patients immunosuppressed with acute pneumonia and are undergoing or have undergone a clinically indicated procedure to obtain a respiratory sample for diagnostic purposes.
9937254|NCT00342550||Pregnant Women|Pregnant women aged 15 and older between 20 and 35 weeks with singleton gestation
9937255|NCT00342446||Patients with Infertility|Patients of all races with primary or secondary infertility, including women with recurrent miscarriages.
9937256|NCT00342277||Pregnant Women|Consecutive pregnant women admitted with either: Preterm labor/delivery/PROM. Termdelivery without labor/spontaneous labor /chorioamnionitis/failed labor leading to c-section
9937257|NCT00342264||1|The study cohort will be comprised of underground, and surface workers (excluding administrative workers) who have been employed in the candidate non-metal mines for at least one year during the period between the date of dieselization of each mine and December 31, 1996.
9937258|NCT00341939||1/Cancer Patients|Cancer patients previously enrolled on IRB approved clinical trials at NCI
9937259|NCT00341874||1|Subjects with hearing loss consisting of both nonsyndromic and syndromic forms of deafness of genetic etiology
9937260|NCT00341679||Family Members|Family members need to be blood relatives of the proband with the diagnosis of an autoimmune disease
9937261|NCT00341679||IIM Patient|Adult and pediatric patients with diagnosis of myositis or a related autoimmune or rheumatic disorder (by Bohan and Peter criteria, American College of Rheumatology, or other criteria).
9937262|NCT00341679||Normal volunteers|gender and race-matched to a subset of autoimmune subjects as controls. Should be without any autoimmune disease.
9937263|NCT00341523||1|Chinese adults at high risk for esophageal cancer
9937264|NCT00341497||Cohort|Persons seen at dental clinics at 6 Veterans Affairs Medical Centers who had clinically visibleoral lesions
9937265|NCT00341276||1|First, several hundred cases of esophageal cancer and gastric cancer (both cardia and body) ascertained in Taiyuan at the Shanxi Cancer Hospital.
9937266|NCT00341237||polymorphisms|Specimens are available to investigators in coded form to anonymously screen for the presence of single-nucleotide polymorphisms (SNPs) and other mutations in DNA.
9937267|NCT00340899||Pregnant women|Pregnant women with gestational age between 6 and 22 weeks
9937268|NCT00340405||Tin Miners in China at risk of lung cancer|Tin Miners in China at risk of lung cancer
9937269|NCT00340171||Pregnant women and infants|pregnant women with singleton pregnancy and their newborns
9937270|NCT00340132||Adult volunteers|Volunteers aged 18-55 who are healthy as determined by medical history, physical examination, and laboratory tests
9937271|NCT00340028||Women in Early Pregnancy|Women enrolled in the University of North Carolina's Right from the Start study are followed while trying to become pregnant and through 9 weeks of pregnancy
9937272|NCT00340002||Pregnant women|Pregnant women aged 18 years and older
9937273|NCT00339924||Physicians|Currently practicing, board certified general internists, both allopathic and osteopathic, whose offices are in the United States.
9937274|NCT00339911||1/ single cohort|Healthy NCI Frederick Cancer Research and Development Center employees
9937275|NCT00339495||Non-Screening|Participants received their usual care
9937276|NCT00339495||Screening|Participants received trial-provided screening examinations for prostate, lung, colorectal, and ovarian cancer
9937277|NCT00339482||American Indians|Residents of the Gila River Indian Community
9937278|NCT00339287||Healthy volunteers|Healthy adult volunteers at least 18 years of age.
9937279|NCT00339235||Non-pregnant women|Non-pregnant women aged 18 years and older
9937280|NCT00339235||Pregant women|Pregnant women aged 18 years and older
9937281|NCT00331331||Patients|Participants with appropriate ocular disorders who were previously enrolled as part of the MUST study and patients who participate in other intramural NIH studies and agreed to participate in this study.
9937282|NCT00326482||Prior Liver Biopsy|HIV+ historical liver biopsy history
9937283|NCT00326482||Prospective Liver Biopsy with ARV|HIV+ taking c/ARV medications
9937284|NCT00326482||Prospective Liver Biopsy without ARV|HIV+ not taking c/ARV medications
9937285|NCT00314119||1|Men and women between 20 and 50 years of age diagnosed with NF1 and their biological parents are eligible for this study.
9937286|NCT00302146||Asymptomatic|Unaffected at-risk individuals with or without a first degree family member with parkinsonism, GD with and without a family history of PD, Gaucher carriers with and without a family history of PD.
9937287|NCT00302146||Control|Controls will include subjects without GBA mutations, with sporadic PD and healthy volunteers who do not have a family history of parkinsonism or Gaucher disease.
9937288|NCT00302146||PD|Subjects with parkinsonism to better characterize the parkinsonian phenotype (e.g.,GD/PD, Sporadic PD, Gaucher carrier PD).
9937289|NCT00271622||healthy volunteers|healthy volunteers
9937290|NCT00271622||individuals with risk for psychiatric disorders or neurodevelopmental disorders|individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders.
9937291|NCT00250159||1/CAH Patients Managed at the NIH|Patients with Congenital Adrenal Hyperplasia (CAH).
9937292|NCT00250159||2/CAH Patients Managed by Outside Physicians|Patients with Congenital Adrenal Hyperplasia (CAH) followed by home physician post visit at NIH.
9937293|NCT00250159||3/Relatives of Patients|Relatives (mostly parents) of patients will be genotyped. This is often necessary to establish the genotype of the patient.
9937294|NCT00250159||4/FMPP Patients|Patients with Familial Male-Limited Precocious Puberty (FMPP).
9937295|NCT00250159||5/Patients with Androgen Excess of Unknown Etiology|Patients with Androgen Excess of Unknown Etiology followed by home physician post visit at NIH.
9937296|NCT00246857||patients referred by physician with a suspected inherited immune deficiency|patients referred by physician with a suspected inherited immune deficiency
9937297|NCT00242723||1/Cohort 1|Subjects with potentially malignant or suspicious lesions, or biopsy proven thoracic cancers or thoracic metastases from cancers of non-thoracic origin
9937298|NCT00233272||Healthy Volunteers|Healthy volunteers over a wide age-range
9937299|NCT00182858||1|Participants will be 18 years or older that are Healthy Volunteers or have been identified by the investigator and/or physician to have a condition of interest for exploratory studies related to the participant s illness or other feature that offers the possibility of creating information that leads to scientifically useful and important studies.
9999410|NCT01527695|Experimental|Placebo|AZD3241 placebo bid for 8 weeks
10214354|NCT05225012|Experimental|PrEliMS Intervention|"We will ask participants to complete the anxiety/depression questionnaires and visual analogue scales once a week throughout the participants involvement in the study (estimated to be 9 weeks). The baseline will be established over a period of the first three weeks (before participants start the intervention). Participants will also be asked to complete a second set of questionnaires (secondary measures) before starting the intervention, to assess quality of life, stress, the impact of MS, MS-related self-efficacy and fatigue.~The procedure will then repeated with newly recruited participants, and the newly refined workbook will be used. Participants within this phase will also be invited to feedback interviews a week after completion of the intervention."
10214355|NCT05224999|Experimental|nivolumab|
10214356|NCT05224960|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|UC-MSCs plus standard of care (SOC).
10214357|NCT05224960|Placebo Comparator|Placebo|Placebo plus SOC.
10214358|NCT05224947|Experimental|Infant formula A|
9937300|NCT00156767||Bone Marrow Transplant|Patients enrolled in an NCI protocols for bone marrow transplant for breast cancer using prednisone treatment.
9937301|NCT00156767||Cirrhosis|Adults on NIDDK protocol 91-DK-0213 with evidence of chronic liver disease with class A or B cirrhosis secondary to viral hepatitis
9937302|NCT00156767||Critical Care|Patients with a diagnosis of sepsis by the primary clinical provider in the Emergency room of ICU
9937303|NCT00156767||Healthy Volunteer|Healthy adult volunteers
9937304|NCT00156767||Known Adrenal Insufficiency|patients with known diagnosis of Adrenal Insufficiency
9937305|NCT00156767||Nephrotic Syndrome|Adults enrolled in NIDDK protocols with diagnosis of nephrotic syndrome
9937306|NCT00156767||Post Surgical Treatment for Cushings|Patients with transient adrenal insufficiency secondary to successful surgical treatment of cushing's syndrome
9937307|NCT00128973||Healthy Volunteers|Healthy adult M/F 18-85 y/o.Hgb>=11.Wt>110 lbs.No heart,lung,kidney,bleeding disorders.No hep BorC since age 11. No IV drug use.No exposure to the AIDS virus.Not pregnant.
9937308|NCT00128973||Patients|Patients with abnormalities of immune function
9937309|NCT00128973||Relatives of Patient:|Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and first cousins to a patient.
9937310|NCT00128960||1|Participants with different types of diseases and conditions who have undergone an allogeneic (donor) stem cell transplant.
9937311|NCT00118586||Muscle tension dysphonia|Increased phonatory muscle tension in the paralaryngeal and suprahyoid muscles onpalpation
9937312|NCT00118586||Normal Volunteers|Normal vocal function refers to normal voice quality with a negative history of voice orlaryngeal disorders
9937313|NCT00118586||Spasmodic dysphonia|A diagnosis of adductor or abductor SD will be based on voice testing and fiberoptic nasolaryngoscopy conducted during the initial interview
9937314|NCT00118586||Vocal Tremor|Vocal tremor during vocalization that primarily involves laryngeal structures
9937315|NCT00114647||1|Healthy Volunteers
9937316|NCT00114647||2|HIV
9937317|NCT00111384||Group A|Affected participants, must have a correct clinical diagnosis of NF1.
9937318|NCT00111384||Group B|Unaffected individuals greater than 2 years of age who are relatives of participants.
9937319|NCT00109174|Other|One arm|Subjects receive the same test
9937320|NCT00106925||1|allogeneic stem cell transplant recipients
9937321|NCT00106925||2|Donors
9937322|NCT00104325||1|white blood cells obtained through cytapheresis by healthy males and females 18 years and older
9937323|NCT00102544|Experimental|All cohorts (prostate biopsy percutaneous biopsy and ablation)|This study will consist of comparison of tracked imaging with near-simultaneous actual imaging .
9937324|NCT00098072|No Intervention|Pilot|Pilot
9937325|NCT00097474|Experimental|Combination|Both HC 30 and ML 5 will be administered
9937326|NCT00097474|Experimental|Hydrocortisone|30mg Hydrocortisone will be administered
9937327|NCT00097474|Experimental|Melatonin|5 mg Melatonin will be administered
9937328|NCT00097474|Placebo Comparator|Placebo|Placebo
9937329|NCT00092235||Cohort 1|Patients who have undergone an allogeneic stem cell transplant and are diagnosed withcGVHD
9937330|NCT00092235||Cohort 2|Pediatric patients who have undergone an allogeneic stem cell transplant and arediagnosed with cGVHD
9937331|NCT00092235||Cohort 3|Patients who have undergone an allogeneic stem cell transplant and choose to submitbiopsy, blood and urine samples only
9937332|NCT00092235||Cohort 4|Patients who have undergone an allogeneic stem cell transplant and are not diagnosed withcGVHD
9937333|NCT00092222|Active Comparator|Active Treament 3|Patients not responding to high- dose zidovudine and valganciclovir alone may be treated with botezomib plus high- dose zidovudine and valganciclovir
9937334|NCT00092222|Active Comparator|Active Treatment 1|Single agent sirolimus for patients where targeted oncolytic virotherapy seems suboptimal
9937335|NCT00092222|Active Comparator|Active Treatment 2|EPOCH chemotherapy with rituximab may be utilized to rescue such patients, with the intent of stabilizing suchpatients
9937336|NCT00092222|Active Comparator|Active Treatment 4|Rituximab with liposomal doxorubicin (R-Dox) followed by consolidation or lmaintenancel therapy with dose escalating interferon-alpha
9937337|NCT00092222|Active Comparator|Active Treatment 5|High dose zidovudin and valganciclovir
9937338|NCT00092222|Active Comparator|Natural History|Observation Only
9937339|NCT00091871||Affected family members|Family members with peripheral blood eosinophilia
9937340|NCT00091871||Unaffected family members|Family members without peripheral blood eosinophilia
9937341|NCT00090662||Healthy volunteer|Healthy volunteer
9937342|NCT00086567||patients|Patients in first remission from treatment of FIGO stage III/IV primary peritoneal, fallopian tube, or epithelial ovarian carcinoma
9999411|NCT01527708||Keratoconus Group (KCG)|Keratoconus group (KCG) included patients with progressive keratoconus.
9999412|NCT01527708||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
9999413|NCT01527708||Normal Group (NG)|Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.
9999414|NCT01527721|Experimental|CxL group|Volunteers of this group received CxL treatment.
9999415|NCT01527721|Experimental|tCxL group|Volunteers of this group received CxL combined with t-PRK treatment
9999416|NCT01527734|Placebo Comparator|Placebo|
9999417|NCT01527734|Experimental|Tetrodotoxin, TTX|
9999418|NCT01527747|Placebo Comparator|Placebo|Placebo arm
9999419|NCT01527747|Experimental|Saxagliptin|Active drug arm
9999420|NCT01527773||COPD cohort|Cohort of patients with proven COPD
9999421|NCT01527786|Experimental|SNRI treatment|Participants are undergoing pharmacotherapy treatment with Desvenlafaxine (SNRI).
9999422|NCT01527799||Subjects with Sickle Cell Anemia|Subjects with Sickle Cell Anemia, 10-21 years of age
10214359|NCT05224947|Experimental|Infant formula B|
10214360|NCT05224934|Experimental|Ultra-hypofractionated radiotherapy|Patients receive ultra-hypo-fractionated radiotherapy with 25Gy to 50Gy in five fractions, followed by surgery done at 1 to 2 months post-RT
10214361|NCT05224869|Experimental|Patients with prostate cancer|Patients undergo hydrogel rectal spacer placement on day 1. Two-seven days after hydrogel placement, patients undergo CT simulation of radiation treatment planning. Seven-ten days after CT simulation, patients undergo SBRT in 5 fractions over 1 week. One month after completing SBRT, patients undergo brachytherapy. One month after brachytherapy, patients undergo post-implant dosimetry scan
10214362|NCT05224856|Experimental|CT-P63 and CT-P66|
10214363|NCT05224856|Placebo Comparator|Placebo|
9999423|NCT01527799||Healthy controls|Healthy controls, 10 to 21 years of age
9999424|NCT01527812|Experimental|Above the femoral nerve|In Group I we will inject the local anaesthetic below the fascia iliaca and above the femoral nerve.
9999425|NCT01527812|Experimental|Below the femoral nerve|In Group II we will inject the local anaesthetic below the femoral nerve and above the fascia of the iliopsoas muscle.
9999426|NCT01527812|Experimental|Circumferential|In Group III a circumferential spread will be achieved with multiple injections.
9999427|NCT01527825|Active Comparator|Single dose|Trivalent Influenza Vaccine (seasonal)
9999428|NCT01527825|Experimental|Double dose TIV|Trivalent Influenza vaccine (seasonal) Two doses will be administered at enrolment
9999429|NCT01527825|Experimental|Two dose TIV|Trivalent Influenza vaccine (seasonal) Participants will receive two doses of TIV, one month apart
9999430|NCT01527838|Experimental|Single FT1050 treated UCB Unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
9999431|NCT01527864|Experimental|pegylated endostatin|
9999432|NCT01527864|Placebo Comparator|Control|
9999433|NCT01527877|Experimental|BKM120|
9999434|NCT01527903|Active Comparator|Propofol|
9999435|NCT01527903|Active Comparator|Midazolam|
9999436|NCT01527929|Experimental|Cohort A|Normal renal function - Cabazitaxel administered once every 3 weeks
9999437|NCT01527929|Experimental|Cohort B|Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
9999438|NCT01527929|Experimental|Cohort C|Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
9999439|NCT01527968|Active Comparator|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
10214364|NCT05224830||Presence of Hyperventilation Syndrome (HVS+)|Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS +- : Nijmegen questionnaire score > 23/64
10214365|NCT05224830||No presence of Hyperventilation Syndrome (HVS-).|Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS - : Nijmegen questionnaire score < 24/64
10214366|NCT05224791||Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
10214367|NCT05224791||Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption."
10214368|NCT05224726|Experimental|PRP Treatment|PRP preparation will be applied on uterine incision after its closure.
10214369|NCT05224726|No Intervention|Control|Normal Cesarean delivery stages.
10214370|NCT05224687||Daptomycin are dosed solely by pharmacists|Daptomycin at two institutions are dosed solely by pharmacists
10214371|NCT05224687||daptomycin protocol is not used and dose by the provider|daptomycin PTD is optional or not utilized at the other institutions.
10214372|NCT05224661||Adult patients with AML in complete remission undergoing alloHCT|Adult patients with AML in complete remission undergoing alloHCT
10214373|NCT05224635||subjects presenting to the emergency room|Chart review will include subjects presenting to the emergency room from the 1st of November 2021 through 1st of July 2024.
10214374|NCT05224609|Experimental|Cohort 1|Moderate hepatic impairment group
10214375|NCT05224609|Experimental|Cohort 2|Severe hepatic impairment group
10214376|NCT05224609|Experimental|Cohort 3|Normal hepatic function
10214377|NCT05224570||Gunshot wounds admitted in ICU|patient with Gunshot wounds admitted to ICU
10214378|NCT05224557||New onset HFrEF AA patients|
10214379|NCT05224557||New onset HFrEF Caucasian patients|
9937343|NCT00084305||Family|Family members of patients with pulmonary fibrosis
9937344|NCT00084305||Healthy Volunteers|Healthy Volunteers
9937345|NCT00084305||Pulmonary Fibrosis|Patients with pulmonary fibrosis
9937346|NCT00083512||1/Glioblastoma multiforme patients|Patients with histologically confirmed supratentorial Glioblastoma multiforme
9937347|NCT00082706|Experimental|5-FU, Leucovorin, Gemcitabine + Cisplatin|5-FU continuous infusion over Days 1 - 5; Leucovorin once a day as a short infusion on Days 1 - 5; Cisplatin infusion over a few hours (usually 2-4 hours) once a day on Days 1 - 5; Gemcitabine infusion over 30 minutes on Days 1 & 5 only.
9937348|NCT00081523||Patients|Individuals with known or suspected sickle cell disease
9937349|NCT00078078||Methylmalonic Acidemia|Individuals with methylmalonic acidemia
9937350|NCT00077909||Group 1|Patients with Infectious Pneumonia
9937351|NCT00077909||Group 2|Patients with Non-Infectious Pneumonia
9937352|NCT00076830||Enrolled Cohort|All patients enrolled, as this is a evaluation/diagnostic study
9937353|NCT00073801||Chronic Pelvic Pain and Endometriosis|Women with chronic pelvic pain and endometriosis found at study surgery
9937354|NCT00073801||Chronic Pelvic Pain and No Endometriosis|Women with chronic pelvic pain and NO endometriosis found at study surgery
9937355|NCT00073801||Healthy Volunteers|Women without no chronic pelvic pain and no symptoms of endometriosis
9937356|NCT00073060||NIH Platelepheresis Donors|75, Apheresis Study Group - donation procedures use same devices as leukapheresis donors, also requiring citrate infusion
9937357|NCT00073060||NIH Research Leukapheresis Donors|75, Apheresis Study Group - donation procedures use same devices as plateletpheresis donors, also requiring citrate infusion; citrate administered may be twice as great as during plateletpheresis.
9937358|NCT00073060||NIH Whole Blood Donors|150 age, gender, race-matched donors - CONTROL GROUP
9937359|NCT00071786||Group 1|All study participants fall into one group for this observational family study regardless of diagnosis.
9937360|NCT00071526||Diabetes Type I|Subjects with Type I diabetes mellitus
9937361|NCT00071526||Diabetes Type II|Subjects with Type II diabetes mellitus
9937362|NCT00071526||Healthy Volunteers|Healthy Volunteers
9937363|NCT00071045||1|patients undergoing allogeneic stem cell transplantation
9937364|NCT00071045||2|HLA compatible donors
9937365|NCT00068159||1|Untreated-NYHA Class I HH subjects without conventional therapy for HH
9937366|NCT00068159||2|Treated- NYHA Class I HH subjects with conventional phlebotomy and/or iron chelationtherapy
9937367|NCT00068159||3|Age-gender matched healthy HH control volunteers
9937368|NCT00068003||1/Cancer Patients|Patients with a current diagnosis of cancer
9937369|NCT00068003||2/Healthy Volunteers|Healthy volunteers
9937370|NCT00067821||Patients|Must have a brain tumor, or residual abnormality that is measurable or evaluable on standard MRI or CT
9937371|NCT00067054||1|Sample collection only
9937372|NCT00065676|Experimental|1 gram quercetin|1 gram quercetin with 6 hour OGTT
9937373|NCT00065676|Experimental|2 grams quercetin|2 gram quercetin with 6 hour OGTT
9937374|NCT00065676|Experimental|placebo|placebo with 6 hour OGTT
9937375|NCT00061568|Experimental|1|donor
9937376|NCT00061568|Experimental|2|recipient
9937377|NCT00060775||Non-Targets|Characterized by temperament - no behavioral inhibition
9937378|NCT00060775||Targets|Characterized by temperament - high/low behavioral inhibition
9937379|NCT00060541||Patients|Patients age 4 or older seeking care from, or being referred to the Surgical Neurology Branch for evaluation and management of neurosurgical conditions
9937380|NCT00059748||Patients affected with autoinflammatory diseases|Subjects with known or suspected diagnosis of NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still s disease, Behcet s disease, JDM, and other autoinflammatory diseases.
9937381|NCT00055224|Experimental|Threat conditions|acoustic startle and shock device
9937382|NCT00055172||Non-sibling relative|18 years of age or older
9937383|NCT00055172||Patients (index cases)|Patients (index cases), 6 months of age or older
9937384|NCT00055172||Siblings|Siblings, 6 months of age or older
9937385|NCT00055055||Healthy Volunteers|A healthy individual who has not used any NSAIDS, with no infectious disease, or severe trauma within 8 weeks of enrollment, doesn't have a first degree relatives with RA, SLE, SSc or IIM
9937386|NCT00055055||Parent of Proband|Biological mother or father of the proband who is willing to enroll in the study
9999440|NCT01527968|Active Comparator|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
9999441|NCT01527968|Placebo Comparator|Placebo|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
9999442|NCT01527981|Experimental|CBT-AD|Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.
9999443|NCT01527994|Experimental|Aprepitant 125 mg|Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
9999444|NCT01527994|Placebo Comparator|Placebo|Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
9999445|NCT01528007|Placebo Comparator|Placebo pill.|
9999446|NCT01528007|Active Comparator|50mg Naltrexone when needed|
9999447|NCT01528020|Experimental|Dialectical Behavior Therapy|
9999448|NCT01528020|Active Comparator|Inidividual and Group Supportive Therapy|
9999449|NCT01528059|Active Comparator|Billroth II|After stomach resection, the remnant stomach is connected to the jejunum.
9999450|NCT01528059|Active Comparator|Roux en Y|After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.
9999451|NCT01528098||PEG plus bisacodyl|Those who taken PEG 4L + bisacodyl 10mg
9999452|NCT01528098||PEG 4L|Those who taken PEG 4L alone
9999453|NCT01528137|Experimental|Treatment (immunomodulator)|Patients receive talactoferrin PO BID for 12 weeks. Courses repeat every 14 weeks in the absence of disease progression or unacceptable toxicity.
9999454|NCT01528163|Experimental|Cabazitaxel|Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel
9999455|NCT01528163|Active Comparator|Methotrexate|"Methotrexate is the historical control and has been widely used in SCCHN for palliation.~This medication is an antimetabolite and antifolate drug. It acts by inhibiting the metabolism of folic acid."
9999456|NCT01528176|Other|(CKD) stages III-V and non -CKD patients|We recruited patients with wide range of eGFR
9999457|NCT01528189|Placebo Comparator|Standard glucose management|
9999458|NCT01528189|Active Comparator|Hyperinsulinemic normoglycemic clamp|
9999459|NCT01528202|No Intervention|Baseline placebo|measures taken before administration of placebo
9999460|NCT01528202|Placebo Comparator|Placebo|Placebo intervention given after 'baseline placebo' arm
9999461|NCT01528202|No Intervention|baseline cherry juice|measures taken before the cherry juice intervention
9999462|NCT01528202|Experimental|cherry juice|trial where cherry juice is taken following the 'baseline cherry juice' arm
9999463|NCT01528241|Experimental|ABP688|Elderly MDD patients and demography matched healthy volunteer
9999464|NCT01528267|Active Comparator|Autologous blood|Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
9999465|NCT01528267|Sham Comparator|Saline|Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
9999466|NCT01528280|Experimental|Shiftwork|The comparison will consider nightworkers versus dayworkers.
9999467|NCT01528306|Experimental|HP802-247|
9999468|NCT01528306|Placebo Comparator|Placebo (Vehicle)|
9999469|NCT01528358||Early Sepsis Critically Ill Patients|Patients who are admitted to ICU with a diagnosis of early sepsis.
9999470|NCT01528358||Non-septic Critically ill patients|Patients who are critically ill and admitted to ICU without diagnosis of sepsis.
9999471|NCT01528371|Active Comparator|Midazolam|Intravenous administration of midazolam at dose of 0.02mg/kg
9999472|NCT01528371|Placebo Comparator|NSS|Intravenous administration of saline solution at dose of 0.004ml/kg as a placebo drug
9999473|NCT01528410|Experimental|ALFApump removal of ascites|Removal of ascites
9999474|NCT01528410|Active Comparator|Large volume paracentesis for removal of ascites|Removal of ascites
9999475|NCT01528423||Men 16 - 18yrs|
9999476|NCT01528423||Men 30 - 32 yrs|
9999477|NCT01528423||Men 70 yrs +|
9999478|NCT01528423||Women 16 - 18 yrs|
9999479|NCT01528423||Women 30 - 32 yrs|
9999480|NCT01528423||Women 70 yrs +|
9999481|NCT01528436|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
9999482|NCT01528436|Active Comparator|Placebo Umbilical Cord Blood and Rehabilitation|Placebo Umbilical Cord Blood infusion and Active Rehabilitation
10214380|NCT05224531|Experimental|CS1 480 mg dose group|480 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
10214381|NCT05224531|Experimental|CS1 960 mg dose group|960 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
10214382|NCT05224531|Experimental|CS1 1920 mg dose group|1920 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
10214383|NCT05224518|Experimental|home-based elastic band training group|The interventional group received 12 weeks of home-based elastic band training, three days a week, with progressive, medium-intensity exercise.
10214384|NCT05224518|Active Comparator|stretching exercises group|The control group received home stretching exercises three days a week for 12 weeks.
10214385|NCT05224479|Active Comparator|Traditional workflow triage|Radiologists follow standard triage of chest radiographs.
10214386|NCT05224479|Active Comparator|Machine learning workflow triage|Radiologists follow machine learning triage of chest radiographs.
10214387|NCT05224479|Sham Comparator|Random workflow triage|Radiologists follow randomly ordered triage of chest radiographs.
10214388|NCT05224466||A|defined as patients survived on PD for more than 10 years
10214389|NCT05224466||B|defined as patients survived on PD for 5-10 years
9999483|NCT01528449|Experimental|retrospective|archived specimens from blood donors whose units have already been released and transfused into recipients will be tested. Attempts will be made to contact and obtain follow up specimens from both the donor and recipient of units initially testing positive for B.microti. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
9999484|NCT01528449|Experimental|prospective, real time|specimens from current blood donors will be tested and those testing positive for B.microti will not be released and the units will be disgarded, and the donors notified and deferred from future blood donation. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
9999485|NCT01528462||Expedited Treatment of Sleep Disorders|Please see below.
9999486|NCT01528475|Active Comparator|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs, initiation of an intravenous infusion of cold saline, and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
9999487|NCT01528475|No Intervention|Usual pre-hospital care|Patients in this arm will receive usual post-resuscitation care by paramedics. Usual post-resuscitation care does not include initiation of cooling in the pre-hospital setting.
9999488|NCT01528488|Experimental|EVOZAC|EVOZAC should be sprayed to the skin of the total face three times per day.
9999489|NCT01528488|Placebo Comparator|Physiological saline|Physiological saline should be sprayed to the total face three times per day.
9999490|NCT01528501|Experimental|I|
9999491|NCT01528514|Active Comparator|Curcuminoids|
9999492|NCT01528514|Placebo Comparator|Placebo|
9999493|NCT01528540|Placebo Comparator|Placebo|This group will contain a placebo for antioxidant cocktail and pregabalin
9999494|NCT01528540|Experimental|Antioxidant plus pregabalin|This group will contain antioxidant cocktail and pregabalin
9999495|NCT01528553|Active Comparator|Staples|Old implant type
9999496|NCT01528553|Active Comparator|8plate|New implant type
9999497|NCT01528566|Experimental|Tai Chi|
9999498|NCT01528566|Placebo Comparator|Attentation control|
9476156|NCT03574519|Experimental|Contingent incentives and daily feedback|Participants will receive payment for meeting their daily goals and will receive daily updates about their performance.
9999499|NCT01528579|Active Comparator|Neck Specific exercises|Neck Specific exercises from a structured frame of exercises
9999500|NCT01528579|Active Comparator|Behavioral approach|Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
9999501|NCT01528579|Active Comparator|Prescribed physical activity|Prescribed physical activity from a physiotherapist without neck specific exercises
9999502|NCT01528618|Experimental|gemcitabine and cisplatin|gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
9999503|NCT01528618|Active Comparator|5-Fluorouracil and cisplatin|5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
9999504|NCT01528631|Placebo Comparator|Control Product|200 ml water with 50g of sucrose
9999505|NCT01528631|Active Comparator|Product 1|200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
9999506|NCT01528644|Experimental|Iron in beads|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
10214390|NCT05224466||C|defined as patients survived on PD within 5 years
10214391|NCT05224440|Experimental|Sponsorship Initiative|TSMV receives a VA certified and volunteer sponsor (1-on-1) approximately 6 months prior to military discharge. Sponsorship continues for approximately 6 months after military discharge.
10214392|NCT05224440|No Intervention|Transition as Usual|TSMVs transition to civilian life as usual.
10214393|NCT05224388||Critically ill, prophylactic dose regimen|Prophylaxis of deep vein trombosis in critically ill patients
10214394|NCT05224388||Critically ill, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in critically ill patients
10214395|NCT05224388||Covid, prophylactic dose regimen|Prophylaxis of deep vein trombosis in Covid patients
10214396|NCT05224388||Covid, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in Covid patients
10214397|NCT05224336|Experimental|Psilocybin|Participants will receive 25mg oral psilocybin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
10214398|NCT05224336|Placebo Comparator|Niacin|Participants will receive 100mg oral niacin one day to two weeks after baseline psychophysical and fMRI testing. Psychophysical and fMRI testing will then be employed one day to two weeks after drug administration.
10214399|NCT05224310|Active Comparator|Pectoral nerve block|Starting from the lateral third of the clavicle and moving distally and laterally to the midaxillary line. The pectoral major and minor muscles will be identified and 10 mL of bupivacaine 0.25% will be injected between the 2 muscles, and then move the ultrasound probe towards the axilla until the serratus anterior is identified above the second, third, and fourth ribs then injection of 20 mL of bupivacaine 0.25% after negative aspiration into the fascial plane between pectoralis minor and serratus anterior muscles.
10214400|NCT05224310|Active Comparator|Serratus anterior plane block|"Aiming to find the serratus anterior muscle the investigator will identify the fifth rib in the midaxillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) will be detected using ultrasound.~The investigator will penetrate the serratus anterior muscle by a 23 GA, 35 mm needle in-plane to ultrasound probe from supero-anterior to postero-inferior to inject deep to it."
10214401|NCT05224284|Other|BPA level|BPA (Bisfenol A) in blood and ejaculate samples
9937387|NCT00055055||Primary Unaffected Dizygous Twin|Dizygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
9937388|NCT00055055||Primary Unaffected Monozygous Twin|Monozygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
9937389|NCT00055055||Primary Unaffected Non-twin Sibling|Sibling of the same biological parents, same gender, within 5 years of age of the proband who does not meet criteria for one of the rheumatic diseases
9937390|NCT00055055||Proband|Proband should have documented evidence that he/she meets criteria for adult and juvenile forms of systemic rheumatic disorders
9937391|NCT00055029||Affected males and family members|Up to 500 participants, including a minimum of 150 males diagnosed with XLRS
9937392|NCT00051857||1/Healthy Controls|Subjects 5 years old and up with musculoskeletal impairment, pathology, or variant.
9937393|NCT00051857||2/Healthy Volunteers|Subjects 5 years old and up without musculoskeletal impairment, pathology, or variant.
9937394|NCT00050752||1 / Patients|Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
9937395|NCT00050752||2 / Family Members|Family members (related by blood) of patients who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
9937396|NCT00050752||3 / Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)
9937397|NCT00050310||Acute Infection (confirmed or suspected)|adults and children with acute anthrax infection
9937398|NCT00050310||AVA Recipient/Healthy Volunteer|healthy adults who have received AVA vaccine
9937399|NCT00050310||Recovered|adults and children in recovering phase of anthrax infection
9937400|NCT00050310||Suspected Exposure|adults and children with suspected exposure to anthrax
9937401|NCT00047996||Group1|Clinical Center Patients, Healthy Volunteers
9937402|NCT00047853|Experimental|Acoustic startle|loud noises with MEG only
9937403|NCT00047853|Experimental|Threat of shock|threat of electric shock
9937404|NCT00046202||normal subjects|subjects in whom no disorder of cholesterol is suspected related to affected individuals
9937405|NCT00046202||subjects suspected of cholesterol disorder|subjects in whom a disorder of cholesterol metabolism is suspected
9937406|NCT00046189||1|Patients with XP
9937407|NCT00046189||2|Family members from XP families with known DNA repair gene mutations
9937408|NCT00046059||ADHD|Children aged 7-17 with ADHD and their families.
9937409|NCT00044304|Experimental|Imatinib|open label imatinib mesylate treatment
9937410|NCT00044304|Experimental|Ruxolitinib|open label ruxolitinib treatment
9937411|NCT00044174||Depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as exhibiting depressive symptoms
9937412|NCT00044174||Non-depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as not exhibiting depressive symptoms
9937413|NCT00044122||Adult Relatives|Relatives of patient with mastocytosis
9937414|NCT00044122||Adults with Mastocytosis|Adults with documented mastocytosis
9937415|NCT00044122||Pediatric Patients with Mastocytosis|Pediatric patients with documented mastocytosis
9937416|NCT00044122||Pediatric Relatives|Pediatric relatives of patients with mastocytosis
9937417|NCT00043472||1|Eligible women at least one intact ovary who have signed written, informed consent that they will undergo screening as per protocol.
9937418|NCT00043472||2|Eligible women with at least one intact ovary who have signed written, informed consent that they will undergo risk reducing surgery
9937419|NCT00042614||Controls|Matched to patients for age, gender and race
9937420|NCT00042614||Patients|Who have had heart transplants, awaiting, or controls screened.
9937421|NCT00040222||1|Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study.
9937422|NCT00039689||HIV chronic infection|For example, an individual infected with HIV-1 for an indeterminate amount of time.
9937423|NCT00039689||HIV early infection|For example, a negative HIV antibody immunoassay within 6 months of a positive HIV antibody assay and confirmatory test (as defined by current CDC criteria).
9937424|NCT00039676||Standard|People that have blood or lymph node cancer, or a family history of leukemia or lymphoma.
9937425|NCT00034216||Healthy Volunteers|Healthy volunteers 18 years of age and older
9937426|NCT00034216||Participants|Participants with cancer 18 years of age and older
9937427|NCT00033774||1|Eligible healthy volunteers 18 and older
9937428|NCT00033137||Family Members|A relative of a patient with a confirmed or suspected diagnosis of BHD (related by blood)
9937429|NCT00033137||Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis(Spouses have been removed from the inclusion criteria for this study. This closed cohort has been created for spouses previously enrolled on study.)
9937430|NCT00033137||Patients|Patients with phenotype or genotype suggestive of Birt Hogg Dub(SqrRoot)(Copyright) and/or Renal tumor histology consistent with BHD
9937431|NCT00032513||CAEBV|Patients with chronic active Epstein-Barr virus.
9937432|NCT00032513||Hydroa vaccineforme|Patients with EBV hydro vaccineforme.
9937433|NCT00029965||Galactosialidosis|Galactosialidosis
9937434|NCT00029965||GM1 gangliosidosis|GM1 gangliosidosis
9937435|NCT00029965||GM2 gangliosidosis|GM2 gangliosidosis
9937436|NCT00029965||Sialidosis|Sialidosis
9937437|NCT00029445||Family members|Family members of individuals with innate control over HIV
9937438|NCT00029445||Long term nonprogressors|Individuals with innate control over HIV
9937439|NCT00028340||1/Breast Cancer and High-Risk Patients|Pre- or postmenopausal women who have or have previously had invasive or noninvasive breast cancer of epithelial origin, or women without breast cancer but at an increased risk of breast cancer.
9937440|NCT00028340||2/Normal Volunteers|Pre- or postmenopausal women who are not at an increased risk for breast cancer.
9937441|NCT00028080||Lyme Disease|Participants who have been diagnosed with or are strongly suspected to have Lyme disease.
9937442|NCT00027326||1/Patients|Candidate for or currently receiving radiotherapy
9937443|NCT00027274||1|All families with a member who has one of the relevant syndromes.
9937444|NCT00027183||1|Healthy Volunteers
9937445|NCT00027183||2|Cystic Fibrosis subjects
9937446|NCT00026884||Family Members|Family members (related by blood) of patients who have or are suspected of having a malignant disease or an inherited genitourinary malignant disorder
9937447|NCT00026884||Patients|Patients with biopsy-proven malignant diseases; or patients suspected of having a malignant disease; or patients who have or who are suspected of having an inherited genitourinary malignant disorder
9937448|NCT00026754||Cohort 1|Patients
9937449|NCT00026754||Cohort 2|Healthy Volunteers
9937450|NCT00026702||All|Subjects at least three years old
9937451|NCT00026663||1/Patients with Cancer|Cancer patients providing samples for research studies
9476157|NCT03574480|Experimental|Control|Advice on healthy diet and physical activity recommendations
9937452|NCT00026663||2/Normal Volunteers|Normal Volunteers providing samples for research studies
9937453|NCT00026650||1/Cohort 1|Patients who have received radiotherapy in the ROB and may or may not be officially entered on a clinical protocol.
9937454|NCT00026559|Experimental|Threat Conditions|threat of shock and auditory startle
9937455|NCT00025935||Children/adolescents with ADHD|Children/adolescents with ADHD
9937456|NCT00025935||Children/Adolescents with DMDD or subthreshold DMDD|Children/Adolescents with DMDD or subthreshold DMDD
9937457|NCT00025935||Children/adolescents with MDD|Children/adolescents with MDD
9937458|NCT00025935||Healthy volunteer adults|Healthy volunteer adults
9937459|NCT00025935||Healthy volunteer children/adolescents|Healthy volunteer children/adolescents
9937460|NCT00025935||Parents of children/adolescents with DMDD or subthresdhold DMD|Parents of children/adolescents with DMDD or subthresdhold DMDD
9937461|NCT00025714||Patients|Patients who have agreed to undergo brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
9937462|NCT00024804||1|Subjects with known or suspected bone disease and disorder of mineral metabolism.
9937463|NCT00024635||Adult Healthy Volunteers|Adult Healthy Volunteers
9937464|NCT00024635||Adult Patients|Adult patients with mood and anxiety disorders
9937465|NCT00024635||Minor Healthy Volunteers|Minor Healthy Volunteers
9937466|NCT00024635||Minor Patients|Minor patients with mood and anxiety disorders
9937467|NCT00024635||Parents of Minor Healthy Volunteers|Parents and guardians of minor healthy volunteers
9937468|NCT00024635||Parents of Minor Patients|Parents and guardians of minor patients with mood and anxiety disorders
9937469|NCT00024622||Healthy volunteers|Healthy volunteers.
9937470|NCT00024622||Patients - Parkinsons|Patients with Parkinsons
9937471|NCT00024622||Patients - schizophrenia spectrum disorders|Patients - schizophrenia spectrum disorders
9937472|NCT00024479||suspected or confirmed rheumatic disease|autoimmune, autoinflammatory, or degenerative conditions
9937473|NCT00023049||1|patients with known SNHL and/or peripheral vestibular dysfunction
9937474|NCT00023036||1|Patients with known or suspected nonsyndromic SNHL associated with EVA
10214402|NCT05224206|Active Comparator|Sham iTBS/Active iTBS|Intermittent Theta Burst Stimulation (iTBS) or realistic sham iTBS will be applied to the left DLPFC. Both sessions will be one week apart.
10214403|NCT05224206|Active Comparator|Active iTBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 weeks.
10214404|NCT05224167|Active Comparator|Group A|patients of this group will receive 5 mg of Melatonin 12 hours and 5 mg 2 hours prior to surgery
10214405|NCT05224167|Active Comparator|Group B|patients of this group will receive 1 mg/kg of Hydroxizin 12 hours and 1 mg/ kg 2 hours prior to surgery
10214406|NCT05224128|Experimental|Imatinib Drug|Standard medication of liver fibrosis + Imatinib 200 mg 1 time a day.
10214407|NCT05224128|Placebo Comparator|Placebo|Standard medication of liver fibrosis + placebo as a control group.
10214408|NCT05224089|Experimental|Liposomal Bupivacaine/Bupivacaine HCL|20mL 1.3% Exparel (266mg) + 60mL 0.25% bupivacaine (150mg) + 20mL normal saline. Total 100mL divided into 10mL syringes, 30 mL left TAP, 30mL right TAP, 20mL left rectus, 20mL right rectus.
10214409|NCT05224089|Active Comparator|Regular Bupivacaine Arm|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL of normal saline. Total 100mL divided into 10mL syringes, 30mL left TAP, 30mL right TAP, 20mL left rectus, 20mL right rectus.
10214410|NCT05224063|Experimental|Individualized CEN-targeted rTMS|Individualized CEN-targeted rTMS will combine neuronavigated rTMS and single pulse TMS-EEG to identify the region of the dlPFC making the strongest connection with the parietal node of the CEN. First, regions of the dlPFC strongly connected to the parietal CEN will be identified by applying single TMS pulses in grid-like fashion to ROIs within the dlPFC. For each anatomical dlPFC subunit probed with TMS, the TMS-EEG response will be quantified in the parietal region of the CEN. The dlPFC subunit that demonstrates the strongest TMS-EEG response in parietal cortex will be chosen for rTMS. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
10214411|NCT05224063|Active Comparator|Neuronavigated rTMS|Neuronavigated rTMS will be delivered using neuro-navigation based on participants' own MRI images to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
10214412|NCT05224063|Active Comparator|Scalp-targeted rTMS|Scalp-targeted rTMS will be delivered using standard BEAM F3 targeting methodology to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
9937475|NCT00023036||2|Patients with nonsyndromic EVA
9937476|NCT00023036||3|unaffected siblings and parents of affected family members
9937477|NCT00023036||4|Other unaffected relatives; included if there is more than one sibship with affected family
9937478|NCT00023023||Adults and children subjects|The NIH and SH components will enroll and follow only adult (age (Bullet)18) blood donor or recipient subjects. CNMC will enroll and follow children between the ages of 6 months and 18 years.
9937479|NCT00018889||1|Patients age 2 years and older with a clinical or suspected diagnosis of movement disorder
9937480|NCT00018057|Experimental|Active|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
9937481|NCT00018057|Placebo Comparator|Control|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
9937482|NCT00018044||Patient Relatives|Blood relatives of enrolled patients
9937483|NCT00018044||Patients|Patients with mycobacterial infections
9937484|NCT00017914||Healthy Volunteer|Healthy subject who has not received anti-inflammatory medications and should not has undergone surgery or any major trauma within the 8 weeks prior to enrollment.
9937485|NCT00017914||Myositis Patient|Patient should have documented evidence that he/she meets criteria for an idiopathic inflammatory myopathy (IIM)
9937486|NCT00017914||Non-Myositis Patient|Patients with other myopathies/autoimmune diseases/complications similar to myositis patients. Close relatives of IIM patients (affected or unaffected siblings, children, parents, grandparents)
9937487|NCT00013559||Family|Parents and/or siblings of patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
9937488|NCT00013559||Patients|Patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
9937489|NCT00012545||Healthy Pregnant Volunteers|Pregnant women whose babies are at risk for sickle cell anemia will be identified and referred to the NIH Research Coordinator for evaluation and entry into the study.
9937490|NCT00011648||non-SCD|200 Men and Women without a diagnosis of sickle cell disease 18 years of age or older
9937491|NCT00011648||SCD|1000 Men and Women with a diagnosis of sickle cell disease
9937492|NCT00009243||Patients|Patients with acute stroke symptoms
9937493|NCT00007150|Other|1/HH patients|HH patients
9937494|NCT00006518||1|Patients with HIV infection, KSHV infection, or with cancer
9937495|NCT00006319||ADA deficient SCID|Patients with ADA deficient SCID
9937496|NCT00006319||Wiskott-Aldrich syndrome|Male patients with Wiskott-Aldrich syndrome
9937497|NCT00006177||Adult bipolar patients|Adult bipolar patients
9937498|NCT00006177||Adult Extended Relatives of BD probands|Adult Extended Relatives of BD probands
9937499|NCT00006177||Bipolar Children and Youth|Bipolar Children and Youth
9937500|NCT00006177||Child/Adolescent Extended Relatives of BD probands|Child/Adolescent Extended Relatives of BD probands
9937501|NCT00006177||Children with ADHD only (controls)|Children with ADHD only (controls)
9937502|NCT00006177||First degree relatives of BD patients|First degree relatives of BD patients
9937503|NCT00006177||Healthy volunteer adults (parents or not)|Healthy volunteer adults (parents or not)
9937504|NCT00006177||Healthy volunteer children and youth|Healthy volunteer children and youth
9937505|NCT00006150||Affected adults and children|Confirmed or suspected history of a Hyper IgE syndrome
9937506|NCT00006150||Relatives|Family members of subjects with confirmed or suspected history of a Hyper IgE syndrome
9937507|NCT00005927||Hyperaldosteronism and cushing participants|Subjects with Hyperaldosteronism and cushing. Adults, pediatric subjects and family members (DNA collection only for family members).
9937508|NCT00005917||Chediak-Higashi Syndrome|Confirmed or suspected patients with Chediak-Higashi Syndrome.
9937509|NCT00005909||Alkaptonuria|Patients with confirmed or suspected alkaptonuria
9937510|NCT00005902||1|250 subjects with von Hippel-Lindau (VHL) disease.
9937511|NCT00004850||HBV positive|HBV positive subjects
9937512|NCT00004850||HCV positive partners|HCV positive partner subjects
9937513|NCT00004850||HCV postive|HCV positive subjects
9937514|NCT00004847|Experimental|Adults or children with suspected PHEO/PGL|Patients are adults or children of any age with known, sporadic or familial PHEO/PGL
9937515|NCT00004738||Family Members|At least 2 family members of a patient with a confirmed diagnosis of Chiari I malformation.
9937516|NCT00004738||Patients|Patient with a confirmed diagnosis of Chiari I malformation who has a family member with syringomyelia or Chiari I malformation
9999507|NCT01528644|Experimental|Iron in capsule|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
9999508|NCT01528644|Experimental|Iron in beads in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
9937517|NCT00004577||Healthy Volunteer|Any healthy, male or female volunteer 18 years of age and older.
9937518|NCT00004571||Healthy volunteers|Healthy subjects from the community
9937519|NCT00004571||Schizophrenia|Patients with schizophrenia and psychosis
9937520|NCT00004571||Williams Syndrome|Individuals with copy number variation in the Williams Syndrome Region.
9937521|NCT00004568||Inherited Neurological Patients|Includes individuals and families with a known or unknown inherited neurological condition.
9937522|NCT00003838|No Intervention|Donor|Donor
9937523|NCT00003838|Experimental|Recipient|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days followed by a PBPC graft targeted to deliver >5x10^6 CD34+ cells/kg
9937524|NCT00001987||Healthy Volunteers|Healthy Volunteers
9937525|NCT00001987||Patients with severe insulin resistance|patients with severe insulin resistance manifesting with acanthosis nigricans, hyperinsulinemia, type A and B insulin resistance syndromes, and patients with lipodystrophy.
9937526|NCT00001979||Patients|Patients with known or suspected immunologically-mediated kidney diseases or immunologically-mediated diseases with potential for kidney disease.
9937527|NCT00001975||Group 1|Patients will be those already diagnosed with TSC (definite or possible)
9937528|NCT00001971||Healthy individuals|Healthy individuals who have recovered from liver diseases or who are healthy volunteers
9937529|NCT00001971||Patients|Liver disease patients
9937530|NCT00001888||1|Asthmatics
9937531|NCT00001888||2|Research Volunteers
9999509|NCT01528644|Experimental|Iron in capsule in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
9999510|NCT01528657|Experimental|Ventricular Pace Suppression (VpS)|The function Ventricular Pace Suppression (VpS) is activated
9999511|NCT01528657|Experimental|Intrinsic Rhythm Support (IRSplus)|The function Intrinsic Rhythm Support (IRSplus) is activated
9999512|NCT01528670||Skull Base|
9999513|NCT01528670||Lower GI|
9999514|NCT01528670||Prostate|
9999515|NCT01528670||Pelvic Region|
9999516|NCT01528670||Head-and-Neck|
9999517|NCT01528670||Upper GI|
9999518|NCT01528670||Brain|
9999519|NCT01528670||Other|
9999520|NCT01528683|Experimental|Carbon Ion Radiotherapy|
9999521|NCT01528722|Sham Comparator|Saline sham injection|Sham wash and injection with normal saline (09%)
9999522|NCT01528722|Active Comparator|Bupivacaine|Bupivacaine injection/wash treatment arm
9999523|NCT01528748||Chronically Depressed, Alcohol Dependent|Participants who have been formally diagnosed with a clinical diagnosis of Chronic Depression and Alcohol Dependence.
9999524|NCT01528761|Experimental|Prosocial Behavior Physical Activity|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
9999525|NCT01528761|Active Comparator|Healthy Aging (HA)|Behavioral: Healthy Aging (HA) The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
9999526|NCT01528774||Melanoma|Patients with histologically confirmed melanoma
9999527|NCT01528774||Prostate|Patients with histologically confirmed prostate cancer
9999528|NCT01528774||Solid tumors - other|Patients with histologically confirmed solid tumor cancers other than melanoma and prostate
9999529|NCT01528774||Benign Hematologic Conditions|Patients diagnosed with non-cancerous hematologic conditions
9999530|NCT01528774||Healthy Volunteers|Family members of patients undergoing treatment at Comprehensive Cancer Centers of Nevada, or other healthy volunteers
9999531|NCT01528800|Placebo Comparator|Placebo|Microcrystalline Methylcellulose
9999532|NCT01528800|Active Comparator|Vitamin K1|Vitamin K1
9999533|NCT01528813|Active Comparator|Er:YAG + amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
9999534|NCT01528813|Placebo Comparator|Amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
9999535|NCT01528826|Experimental|NVBOX regimen|Vinorelbine plus oxaliplatin
9476158|NCT03574480|Experimental|Intervention|"Advice on healthy diet and physical activity recommendations~Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
9999536|NCT01528839|Placebo Comparator|Pill|
9999537|NCT01528839|Experimental|L-Thyroxine as addon|
9999538|NCT01528852|Experimental|CHX Cord application|Chlorhexidine cord application for 10 days
9999539|NCT01528852|Active Comparator|Control|Same liquid as intervention without the chlorhexidine used for cord cleaning for 10 days once daily
9999540|NCT01528852|No Intervention|Dry Cord care|Use current recommended keep cord dry
9999541|NCT01528865|Experimental|Study Drugs|The medications to be used in this study are Lamivudine (EPIVIR®) and Tenofovir disoproxil fumarate (VIREAD®), medications already used in people with certain other types of viruses [but not HERV-K(HML2)] in their body. Treatment will last 16 weeks. This is an experiment combining these two drugs and has been issue an Investigational New Drug (IND) Exemption by the FDA.
9999542|NCT01528904||Hyperthyroid pregnant women|hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination.
9999543|NCT01528904||Hypothyroid pregnant women|hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
9999544|NCT01528904||Healthy pregnant women|uncomplicated pregnancies in healthy women, older then 35 years, directed for cordocentesis due to age, because of missed karyotyping in previous period of pregnancy
9999545|NCT01528930|Experimental|Amikacin for inhalation|"Drug: Amikacin~Amikacin is provided for inhalation via nebulization.~500 mg of amikacin is administered once daily using the Pari-Boy N/Long Life Nebulizer.~Administration time is approximately 20 minutes.~Amikacin will be administered for 2 years."
9999546|NCT01528943|Experimental|Prostacyclin|Treatment with prostacyclin
9999547|NCT01528943|Placebo Comparator|Isotonic saline|Treatment with isotonic saline
10034943|NCT01801410|Active Comparator|Misoprostol|Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
10034944|NCT01801410|Active Comparator|Foley Catheter|Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
9476159|NCT03574467||Bobath Approach Applied to Patient with Brain Tumors|
9476160|NCT03574467||Bobath Approach Applied to Patient with Stroke|
9476161|NCT03574428|Active Comparator|Cohort 1|GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo
9476162|NCT03574428|Active Comparator|Cohort 2|GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo
9476163|NCT03574428|Active Comparator|Cohort 3|GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo
9476164|NCT03574428|Active Comparator|Cohort 4|GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo
9999548|NCT01528995|Active Comparator|sacral nerve modulation|Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
9999549|NCT01528995|Active Comparator|anal bulking agents|anal injection with Permacol after positive PNE test. Randomized controlled trial.
9999550|NCT01528995|Active Comparator|Anal bulking agents|Anal injection with Permacol after negative PNE test. cohort study.
9999551|NCT01529008|Experimental|Core decompression/PREOB® implantation|
9999552|NCT01529008|Placebo Comparator|Core decompression/placebo implantation|
9999553|NCT01529021||humanoid robot distration|The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.
9999554|NCT01529021||control|standard care procedures were used during the vaccination
9999555|NCT01529047|Experimental|In-person PFI|In-person personalized feedback intervention
9999556|NCT01529047|Experimental|Web-based PFI|Web-based personalized feedback intervention
9999557|NCT01529047|No Intervention|Assessment Only|Complete online survey assessments only.
9999558|NCT01529073|Experimental|Nitazoxanide|
9999559|NCT01529086||Group 1|"Subjects on Dutasteride that meet the following criteria:~. A rise in PSA from nadir at any time post-nadir~. PSA change from baselin >0.2 mg/ml at any time post-baseline~. Abnormal DRE at any time post-baseline~. Free-PSA <12% at any time post-baseline~. At least one of the above 4 criteria~Subjects on Dutasteride that do not meet the above criteria"
9999560|NCT01529086||Group 2|"Subjects on placebo treatment that meet the following criteria:~Change from baseline PSA between 0.0 and 0.35 (ie, 0.0 ≤ change from baseline PSA < 0.35) at any time post-baseline. Note that in REDUCE PSA was recorded to the nearest 0.1.~Abnormal DRE at any time post-baseline~Change from baseline PSA ≥ 0.35 at any time post-baseline~Change from baseline PSA ≥ 0.75 at any time post-baseline~PSA ≥ 2.5 at any time post-baseline~PSA ≥ 4.0 at any time post-baseline~Percent Free PSA < 12% at any time post-baseline~At least one of the above 7 criteria.~Subjects on placebo that do not meet the above criteria"
9999561|NCT01529099|Experimental|Sigma HP Partial Knee|Partial knee replacement
9999562|NCT01529125||Kwashiorkor|HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
9999563|NCT01529125||Marasmus|HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
9999564|NCT01529125||Control|HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
9999565|NCT01529138|Experimental|Temsirolimus|An ester of the macrocyclic immunosuppressive agent sirolimus.
9999566|NCT01529138|Experimental|Axitinib|An oral, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3.
9999567|NCT01529151|Active Comparator|OMT Group|Participants will receive Osteopathic Manipulative Treatment (OMT) with the objective of treating diagnosed somatic dysfunction and this will entail the use of specific indirect and direct techniques, including soft tissue, inhibitory, myofascial release, articulatory and high-velocity / low-amplitude (HVLA) techniques.
9999568|NCT01529151|Active Comparator|VRT Group|Participants will receive Vestibular Rehabilitation Therapy (VRT), which includes balance exercises in sitting and standing positions that include gaze stabilization, kinesthetic and proprioceptive retraining.
9999569|NCT01529151|Active Comparator|OMT - VRT Group|Participants will receive both Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT).
9937532|NCT00001876||Combo|Patients with rheumatoid arthritis and biopsy-proven pulmonary fibrosis.
9937533|NCT00001876||pulmonary fibrosis|Patients with biobsy-proven idiopathic pulmonary fibrosis only.
9937534|NCT00001876||rheumatoid arthritis|Patients with rheumatoid arthritis only.
9937535|NCT00001853||Healthy volunteers|Healthy adult African Americans born in the United States, with American born parents or born in Africa with African born parents.
9937536|NCT00001850||Children|with reproductive disorders
9937537|NCT00001850||Men|with reproductive disorders
9937538|NCT00001850||Woman|with reproductive disorders
9937539|NCT00001846||research donors|healthy volunteers (age 18 years or greater) who donate blood for in vitro research purposes
9937540|NCT00001823||A/Surgery Branch Protocol Candidates|Patients suspected of having, or with biopsy proven, malignant disease being evaluated for or treated on NCI Surgery Branch protocols
9937541|NCT00001813||1|Subjects with clinical and/or laboratory documentation of typical features or suggestiveclinical features of XP, CS, TTD, or overlap syndromes
9937542|NCT00001813||2|Family members of patients with XP, CS, TTD, or overlap syndromes
9937543|NCT00001813||3|Healthy Volunteers
9999570|NCT01529151|No Intervention|Control Group|
9999571|NCT01529164|Experimental|treatment|
9999572|NCT01529177|Experimental|Metformin / clomid / hCG|"Metformin 1000 mg orally to be given daily for one week then twice daily for 2 weeks then 3 times daily for 6 months.~After 3 months from starting metformin the participant will receive 2 more medications in addition to metformin:~Clomid 50 mg orally per day and 5000 IU human chorionic gonadotrophin (hCG ) IM once per week for three months."
9999573|NCT01529177|Experimental|Clomid / hCG|Clomid 50 mg per day will be administered orally and human chorionic gonadotrophin ( choriomon ) 5000 IU will be administered IM once per week. Both medications will be given for 6 month.
9999574|NCT01529190|Active Comparator|pregabalin 300mg|Group 1 patients will receive a single dose of 300 mg pregabalin, 1 hour before the surgical incision; group 2 patients will receive a placebo dose. Pain intensity will be assessed with the numeric rating scale. The consumption of tramadol in 24 hours after surgery and the time for the first complementation dose will be registered. Blood samples will be collected by 6 hours and 24 hours after surgical incision, for IL-6 dosage, and maintained at -70 celsus degree
9999575|NCT01529190|Placebo Comparator|sugar pill|group 2 will receive a placebo dose, 1 hour before tue surgical icnision
9999576|NCT01529216|Experimental|Electrical signal ON|Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
9999577|NCT01529216|Sham Comparator|Sham|"Subjects randomized to this group (Group B) will have their device in turned off mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study."
9999578|NCT01529229|Experimental|Desloratadine + Prednisolone|Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.
9999579|NCT01529229|Active Comparator|Dexchlorpheniramine + Betamethasone|Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.
9999580|NCT01529242|Experimental|Desloratadine + Prednisolone|desloratadine 0,5 mg/ml + prednisolone 4 mg/ml - oral solution
9999581|NCT01529242|Active Comparator|Dexchlorpheniramine + Betamethasone|dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution
9999582|NCT01529255|Experimental|ROADMAP|
9999583|NCT01529255|Active Comparator|SOC (Standard of Care)|
9999584|NCT01529281|Experimental|BCAA|Branched chain amino acid
9999585|NCT01529281|Placebo Comparator|Asparmate|Placebo control containing no protein or carbohydrate
9999586|NCT01529294|Experimental|Iloperidone|Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet
9999587|NCT01529307|Experimental|TAS266|
9999588|NCT01529320|Experimental|Adventan® (metilprednisolona aceponato 0,1%)|
9999589|NCT01529359|Placebo Comparator|Placebo|Probiotics Excipients
9999590|NCT01529359|Experimental|Lactibiane Tolerance|Probiotics combination
9999591|NCT01529372|Experimental|Percutaneous renal denervation|
9999592|NCT01529398|Active Comparator|sensorimotor training (SMT)|
9999593|NCT01529398|Active Comparator|Resistance training (RT)|
9999594|NCT01529398|Sham Comparator|Control group (CG)|
9999595|NCT01529411|Experimental|Vinflunine|"Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min)~+ best suportive care, with regards clinical practice."
9999596|NCT01529411|Other|Best suportive care|Best suportive care
9999597|NCT01529437|Active Comparator|Sublingual immunotherapy|Subjects will take sublingual immunotherapy who have dust mite and timothy grass allergies
9999598|NCT01529437|Placebo Comparator|placebo arm|The placebo arm will be double blinded and is an important control in SLIT therapies
9999599|NCT01529463||Disease Management|
9999600|NCT01529476|Experimental|Nemonoxacin 500 mg|
9999601|NCT01529476|Active Comparator|Levofloxacin 500 mg|
9999602|NCT01529489|Active Comparator|Interval physical training Control group|
9999603|NCT01529489|Experimental|Resisted/Aerobic physical training group|
9999604|NCT01529489|Active Comparator|Aerobic/resisted physical training group|
9999605|NCT01529489|Experimental|Interval physical training group|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
9999606|NCT01529528|Placebo Comparator|Placebo of CWP-0403 100mg|Placebo of CWP-0403 100mg
9999607|NCT01529528|Experimental|CWP-0403 200mg|CWP-0403 200mg
9999608|NCT01529528|Experimental|CWP-0403 100mg|CWP-0403 100mg
9999609|NCT01529541|Active Comparator|Sitagliptin|Sitagliptin 100mg
9999610|NCT01529541|Experimental|CWP-0403|CWP-0403 100mg
9999611|NCT01529554|Active Comparator|Everolimus|Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)
9999612|NCT01529554|Placebo Comparator|Placebo|Placebo comparator with identical composition of tablets except everolimus
9999613|NCT01529567|Active Comparator|CBT without exposure|
9999614|NCT01529567|Experimental|CBT with exposure|
9999615|NCT01529580|Experimental|1 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 1 week before your child begins active treatment with their interventionist.
9999616|NCT01529580|Experimental|2 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
9999617|NCT01529580|Experimental|3 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
9999618|NCT01529619|Experimental|Rivastigmine 18 mg|During the 16-week titration period patients received daily rivastigmine 4.5mg patch for the first 4 weeks, rivastigmine 9mg patch for the next 4 weeks, rivastigmine 13.5mg patch for the next 4 weeks and then rivastigmine 18mg patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
9999619|NCT01529658|No Intervention|No hypothermia|After clamping of the renal vessels, no ice slush will be used.
9999620|NCT01529658|Experimental|Hypothermia|saline ice slush around kidney for 10 minutes.
9999621|NCT01529671|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
9999622|NCT01529671|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
9999623|NCT01529671|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
9999624|NCT01529671|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
9999625|NCT01529671|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
9999626|NCT01529684|Experimental|OSI-906|"Two Parts:~Part A: 14C-labeled OSI-906~Part B: (Optional) OSI-906 (non-labeled)"
9999627|NCT01529697|Active Comparator|Active Feedback|In this arm patients will receive monthly review and education on inhaler technique and use based on a computer download of their last month of inhaler use
9999628|NCT01529697|Placebo Comparator|Control|In this arm patients will be reviewed monthly, however will not have information from INCA device to tailor inhaler education.
9999629|NCT01529710|Experimental|Mirazid|Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®). It originates from Myrrh a medicinal herb that has been used for thousands of years. Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
9999630|NCT01529710|Active Comparator|Praziquantel|Tablets
9999631|NCT01529788|Active Comparator|Lateral orbital injection of Botox Cosmetic or Dysport|Lateral orbital injection of either Botox Cosmetic, 10 units or Dysport, 30 units as a single dose in a randomized (right or left sides) double blind fashion in 90 consecutive subjects
9999632|NCT01529840|Experimental|Low dose 33 mcg/kg/day|
9999633|NCT01529840|Experimental|High dose 66 mcg/kg/day|
9999634|NCT01529892|Experimental|methamphetamine EM|Extensive metabolizer will be give a single oral 5 mg of duterium labeled methamphetamine
9476165|NCT03574415|Experimental|Japanese_DWP14012 Amg|DWP14012 Amg, tablets, orally, single and multiple administration
9999635|NCT01529892|Experimental|methamphetamine PM|Poor Metabolizers will be give a single oral 5 mg of duterium labeled methamphetamine
9999636|NCT01529918|Experimental|web-intervention group|Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version
9999637|NCT01529918|No Intervention|paper-based group|Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based
9999638|NCT01529931|Experimental|Maintenance|This arm receives Hair2Go treatments once a month for 6 months
9999639|NCT01529944|Experimental|Low dose 33 mcg/kg/day|
9999640|NCT01529944|Experimental|High dose 66 mcg/kg/day|
9999641|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 25 mg|Nemonoxacin Malate Sodium Chloride 25 mg
9999642|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 50 mg|Nemonoxacin Malate Sodium Chloride 50 mg
9999643|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 125 mg|Nemonoxacin Malate Sodium Chloride 125 mg
9999644|NCT01529957|Placebo Comparator|placebol|placebol
9999645|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 250 mg|Nemonoxacin Malate Sodium Chloride 250 mg
9999646|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 500 mg|Nemonoxacin Malate Sodium Chloride 500 mg
9999647|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 650 mg|Nemonoxacin Malate Sodium Chloride 650 mg
9999648|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 750 mg|Nemonoxacin Malate Sodium Chloride 750 mg
9999649|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1000 mg|Nemonoxacin Malate Sodium Chloride 1000 mg
9999650|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1250 mg|Nemonoxacin Malate Sodium Chloride 1250 mg
9999651|NCT01529970||parkinson's disease, young onset|
9999652|NCT01529970||Normal|
9999653|NCT01530009|Active Comparator|Amoxicillin|A liquid preparation of amoxicillin will be administered during the study through a nasoduodenal catheter after random patient assignment.
9999654|NCT01530009|Placebo Comparator|Placebo|A liquid placebo will be administered via a nasoduodenal catheter to patients based on random assignment.
9476166|NCT03574415|Experimental|Japanese_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
9999655|NCT01530022|Other|LCM 300 mg/CBZ-IR 600 mg|Crossover sequence of experimental treatment and active comparator
9999656|NCT01530022|Other|CBZ-IR 600 mg/LCM 300 mg|Crossover sequence of active comparator and experimental treatment
9999657|NCT01530035|Active Comparator|soccer training intervention|
9476167|NCT03574415|Experimental|Japanese_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
9999658|NCT01530035|Other|strength training intervention|
9999659|NCT01530035|No Intervention|control group|elderly men with no change in daily activities
9999660|NCT01530035|No Intervention|active soccer control group|veteran soccer players with a 40 year history of continues soccer playing
9999661|NCT01530048|Experimental|U200|
9999662|NCT01530048|Active Comparator|U100|
9999663|NCT01530061|Experimental|Preschool Children age 4-6 years|Preschool children participate in eating either an egg breakfast or a bagel breakfast.
9999664|NCT01530061|Experimental|Teenagers 14-17 years of age|Teenagers participate in eating either an egg breakfast or a bagel breakfast.
9999665|NCT01530074|Experimental|Study Group|
9999666|NCT01530126|Active Comparator|B-TCP +buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
9999667|NCT01530126|Experimental|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
9999668|NCT01530126|Experimental|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
9999669|NCT01530139|Placebo Comparator|Level 0|Level 0: Control group - participants will receive non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
9999670|NCT01530139|Experimental|Level 1|Level or Group 1: participants will receive personalised dietary advice based on their dietary intake data alone.
9999671|NCT01530139|Experimental|Level 2|Level or Group 2: participants will receive personalised dietary advice taking their dietary intake and phenotypic data ( obesity-related phenotypes and clinical biomarkers) into account.
9999672|NCT01530139|Experimental|Level 3|Level or Group 3 : participants will receive personalised dietary advice taking their dietary intake, phenotypic (obesity-related markers) and genotypic data into account.
9999673|NCT01530165|Other|Standard|Pre diabetics randomized to control arm will receive standard life style advice which is given to all pre diabetics seeking medical advice.
9999674|NCT01530165|Experimental|life style intervention arm|This arm would be given aggressive life style intervention in comparison to standard (control) arm. The intervention would consist of nutritional and physical activity advice.
9999675|NCT01530191||Abdominal|- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
9999676|NCT01530191||Vaginal|- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
9999677|NCT01530204|Active Comparator|Physical Therapy|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
9999678|NCT01530204|Active Comparator|Cognitive Behavioral Therapy for Pain|8-12 session pain-focused Cognitive Behavioral Therapy
9999679|NCT01530204|Active Comparator|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
9999680|NCT01530230|Other|Oxytocin 5 units|
9999681|NCT01530230|Other|Oxytocin 10 units|
9999682|NCT01530269|Experimental|PET/CT imaging with C11-Sodium Acetate|
9999683|NCT01530282|Experimental|measurement of respiratory mechanics|Invasive method: two catheters will be inserted to measure reference respiratory mechanics Non_invasive method: airway pressure measured during a 150-200 ms occlusion at the beginning of inspiration.
9999684|NCT01530295|No Intervention|contol|control group
9999685|NCT01530295|Other|chemotherapy|neoadjuvant chemotherapy
9999686|NCT01530308|Active Comparator|Investigational medicinal product|Haloperidol 1 mg twice daily at 12am and 20pm
9999687|NCT01530308|Placebo Comparator|Placebo group|Placebo 1 mg twice daily at 12am and 20pm
9999688|NCT01530321|Experimental|High dose spinal manipulation|18 visits for spinal manipulation
9999689|NCT01530321|Experimental|Moderate dose spinal manipulation|12 visits for spinal manipulation and 6 visits for light massage
9999690|NCT01530321|Experimental|Low dose spinal manipulation|6 visits for spinal manipulation and 12 visits for light massage
9999691|NCT01530321|Other|High dose massage|18 visits for light massage
9999692|NCT01530347|Experimental|Easy Check versus reference glucometer and blood ketone meter|Collection of paired measurements of capillary blood glucose using reference method (approved glucometer)and blood beta Hydroxybutyrate (approved ketone meter) and data generated by the non invasive study device
9999693|NCT01530360|Experimental|cerebral oximetry + treatment guideline|Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline
9999694|NCT01530373|Experimental|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
9999695|NCT01530373|Active Comparator|clonidine|oral clonidine 0.1 mg daily for 3 weeks
9999696|NCT01530386|Experimental|Lacosamide|300 mg/day
9999697|NCT01530412|No Intervention|Control Group|Patients are randomized to the control group and are assessed pre rehabilitation and post rehabilitation after which they proceed to the intervention group.
9999698|NCT01530412|Experimental|Pulmonary Rehabilitation|Patients undergo an active seven week pulmonary rehabilitation programme. Assessments occur pre rehabilitation, post rehabilitation, at three months and at one year.
9999699|NCT01530425||Phase 1 assessments|Regency Wheelchairs and APDK 12-inch wide wheelchairs
9999700|NCT01530425||Phase 2 assessments|Hope Haven and APDK 14-16 inch wide wheelchairs
9999701|NCT01530425||Phase 3 assessments|Motivation and Whirlwind wheelchairs
9999702|NCT01530438|Other|ALS patients without cognitive disorders|Amyotrophic lateral sclerosis without cognitive disorders
9999703|NCT01530438|Other|ALS patients with cognitive disorders|Amyotrophic lateral sclerosis with cognitive disorders
9999704|NCT01530438|Other|ALS patients + frontal-temporal dementia|Amyotrophic lateral sclerosis plus frontal-temporal dementia
9999705|NCT01530451|Experimental|A: Drug/ Placebo|Initial phase on Desmopressin and then cross over to placebo on the second phase
9999706|NCT01530451|Experimental|B: Placebo/ Drug|Initial phase on Placebo and then cross over to Desmopressin on the second phase
9999707|NCT01530490|No Intervention|Hemoes|
9999708|NCT01530490|Experimental|Cabergoline|cabergoline
9999709|NCT01530503|Experimental|capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food
9999710|NCT01530503|Experimental|capecitabine plus mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion Mitomycin 6 mg/m2 day 1
9999711|NCT01530516|Active Comparator|Full brackets plus Forsus springs|Standard of care - Class II springs used after le el and alignment.
9999712|NCT01530516|Experimental|Xbow plus full brackets|Alternative treatment - First use the Xbow appliance and then full brackets after Class II occlusion has been corrected.
9999713|NCT01530529|Experimental|PF-05180999 Immediate-Release|
9999714|NCT01530529|Experimental|PF-05180999 Modified-Release 1|
9999715|NCT01530529|Experimental|PF-05180999 Modified-Release 2|
9999716|NCT01530529|Experimental|PF-05180999 Modified-Release 1 With Food|
9999717|NCT01530542|Experimental|Treatment A|
9999718|NCT01530542|Experimental|Treatment B|
9999719|NCT01530542|Experimental|Treatment C|
9999720|NCT01530542|Experimental|Treatment D|
9999721|NCT01530542|Experimental|Treatment E|
9999722|NCT01530555|Experimental|Treatment arm|"Rabbit ATG, Thymoglobuline (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months, with later tailing according to individual patient response. Aim to maintain trough whole blood CSA levels between 150 and 250 ng/ml."
9999723|NCT01530568|Active Comparator|Smear|Routine microbiology based diagnostics for TB
9999724|NCT01530568|Experimental|GeneXpert|Arm that will receive the Xpert test
9999725|NCT01530581|Experimental|G-BM Transplant|
9999726|NCT01530581|Other|G-PB Transplant|G-PB Transplant
9999727|NCT01530594|Active Comparator|Lenalidomide|Lenalidomide/Low dose Dex (LLD)
9937544|NCT00001778||healthy volunteers|At least 18 years old and have no history of any medical illness that may confound study results or make participation in this protocol impossible
9937545|NCT00001778||individuals seropositive for HTLV|Positive HTLV-1 ELISA followed by a positive Western Blot
9937546|NCT00001778||individuals with indeterminate HTLV sero-status|Positive HTLV ELISA but a Western Blot that only partially fulfills criteria
9937547|NCT00001756||Healthy Volunteers|Healthy Volunteers
9937548|NCT00001756||Patients|Patients have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, orimmunologic condition.
9937549|NCT00001727||1|Subjects with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome.
9937550|NCT00001721||Patients|Patients diagnosed with SLOS
9937551|NCT00001645||Diarrhea GI Parasite|Subjects infected with a GI parasite
9937552|NCT00001645||Echinococcus|Subjects infected with echinococcus
9937553|NCT00001645||Intestinal Worm|Subjects infected with parasitic intestinal worm
9937554|NCT00001645||Malaria|Subjects infected with malaria
9937555|NCT00001645||Parasitic Infection|Subjects infected with a parasitic infection that is not included in the other cohorts
9937556|NCT00001620||Subjects undergoing screening|Adults and children being screened for an active NHLBI protocol
9937557|NCT00001604||1|Subjects with a family history of stuttering
9937558|NCT00001595||Patients with pituitary tumors or hypothalmic defects|Patients with pituitary tumors or hypothalmic defects
9937559|NCT00001594||Children with OI|Children with OI
9937560|NCT00001582||1|Suspected or known disorder of the immune system or cancer; or, known or potential carrier of autoimmune disorder or immunodeficiency disease.
9937561|NCT00001539||healthy volunteers|healthy individuals who have never had Lyme disease
9937562|NCT00001539||Lyme arthritis|patients with suspected Lyme arthritis
9937563|NCT00001539||multiple sclerosis controls|patients diagnosed with multiple sclerosis who have never been diagnosed with Lyme disease
9937564|NCT00001539||OspA vaccine|patients who received two doses of the OspA vaccine
9937565|NCT00001539||PTLDS|presumed PTLDS
9937566|NCT00001539||PTLDS for screening|patients suspected of PTLDS for screening
9937567|NCT00001539||recovered controls|patients who were diagnosed with Lyme disease, treated, and fully recovered
9937568|NCT00001539||seropositive controls|patients who are seropositive for Lyme disease, but have no manifestations/symptoms and have never been treated for Lyme disease
9937569|NCT00001532||1|Subjects with pulmonary disease or possible pulmonary disease and Relatives
9937570|NCT00001532||2|Healthy
9937571|NCT00001529||Group 1|Healthy volunteers
9937572|NCT00001521|Experimental|Investigational 1|boys/flutamide, letrozole, and reduced hydrocortisone dose or conventional treatment (with hydrocortisone and fludrocortisone ) until the age of 14
9937573|NCT00001521|Experimental|Investigational 2|girls/flutamide, letrozole, and reduced hydrocortisone dose, the Letrozole will discontinue at 13 y.o. and continue flutamide until 2 years after menarche or when final height is reached, whichever occurs first
9937574|NCT00001506||Patients|With dermatologic diseases and systemic diseases with cutaneous manifestations
9937575|NCT00001505||1/Single Cohort|Healthy individuals (including employees and other patients) and patients with selected skin or other diseases
9937576|NCT00001503||1/All Patients|Patients who were previously enrolled on a CCR protocol and need follow-up by CCR Investigators.
9937577|NCT00001486||Normal Controls|Male and female adult healthy volunteers
9937578|NCT00001486||Parents|Parents of Probands and siblings for the purposes of DNA collection
9937579|NCT00001486||Probands|Adult Subjects with Schizophrenia Spectrum Disorders
9937580|NCT00001486||Siblings|Adult siblings of Probands
9937581|NCT00001481|Placebo Comparator|Group 1, Hormone and Placebo Group|8 weeks of hormonal addback plus 4 weeks of placebo
9937582|NCT00001481|Active Comparator|Group 2, Continued Replacement Group|12 weeks of hormone addback
9937583|NCT00001471||Healthy Volunteers|Healthy Volunteers
9937584|NCT00001471||HIV-infected|HIV-infected individuals
9937585|NCT00001471||ICL|Idiopathic CD4 lymphopenia
9937586|NCT00001467||Blood relatives|blood related family members of proband
9937587|NCT00001467||Proband|person initially ill/studied/diagnosed
9937588|NCT00001465||LAM|Patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research
9937589|NCT00001456||HPS|HPS patients of any gender and ethnicity age 1-80 years
9937590|NCT00001456||HPS Symptom Questionnaire|Includes both patients and family members or caregivers.
9937591|NCT00001452||1|families with PPNAD and/or Carney complex
9937592|NCT00001406||1|Volunteers with elevated eosinophil counts in the peripheral blood or tissues; or a relative of a volunteer with eosinophilia
9937593|NCT00001405||Healthy Volunteers|Healthy Adult Volunteers
9528318|NCT03212001||Informal caregiver (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
9937594|NCT00001405||Patients|Pts with PID or other blood disorder or clinical history consistent with PID or other blood disorder. Pts are able to volunteer as patient for research collection only per PI discretion.
9937595|NCT00001403||Proteus Syndrome|Patients with Proteus syndrome (PS) and other overgrowth disorders hypothesized to be in the AKT/PI3K pathway
9937596|NCT00001393||Subjects|Individuals with focal segmental glomerulosclerosis (FSGS)
9937597|NCT00001392||Study Cohort|Subjects with known or suspected forms of sclerosing glomerular or chronic, fibrosing tubulointerstitial kidney diseases
9937598|NCT00001379|Experimental|1|Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the designated schedule,as tolerated. Patients continue taking interferon for 1 year beyond CR. Patients who progress may crossover to receive EPOCH-R.
9937599|NCT00001379|Experimental|2|EPOCH-R every 3 weeks for up to 8 cycles, based on response.
9937600|NCT00001373||Affected|Patients with auto-inflammatory disorders
9937601|NCT00001373||Family Members|Family members of patients
9937602|NCT00001373||Healthy Volunteers|Healthy Volunteers
9937603|NCT00001372||1|Longitudinal cohort study with affected SLE patients
9937604|NCT00001372||2|Patient relatives
9937605|NCT00001372||3|Unrelated healthy volunteers
9937606|NCT00001367||family members|Family Members who are 2 years old or older of people with a neurological disorder
9937607|NCT00001367||healthy volunteers|healthy volunteers age 18 and older
9937608|NCT00001367||patients|subjects with neurological disorders who are 2 years old or older
9937609|NCT00001360||1|Normal volunteer participants aged 18-65 who are in good general health.
9937610|NCT00001355||Healthy Volunteer|Healthy Volunteer to serve as controls
9937611|NCT00001355||Patient|Patients known to have or suspected of having an immune defect significantly or primarily involving the phagocytes
9937612|NCT00001355||Patient Relatives|blood relatives of patients
9937613|NCT00001352||Genetic Relatives|Controls
9937614|NCT00001352||Healthy Volunteers|Controls
9937615|NCT00001352||Patient Population|Adult patients with cryptococcosis no predisposing conditions except ICL
9937616|NCT00001351||Immediate family members of patients|immediate family members of patients with inflammatory conditions may be evaluated under this protocol
9937617|NCT00001351||Patients|Inflammatory conditions associated with, but not limited, to acute and chronic infections or presumed infections, and congenital or acquired immunologic disorders
9937618|NCT00001350||1|ALPS patients and relatives of all ages
9937619|NCT00001345||1|Members of families that have had relatives diagnosed with a disease of mineral metabolism. Participants will be asked to give blood samples for DNA extraction.
9937620|NCT00001337|Experimental|Arm A|EPOCH + Rituximab every 3 weeks for 6 cycles.
9937621|NCT00001316||Individuals with HIV|Individuals with HIV
9937622|NCT00001316||Individuals without HIV|Individuals without HIV
9937623|NCT00001309|Other|Pharmacokinetics and Biodistribution of Ascorbic Acid|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
9937624|NCT00001281||HIV Infected Individuals|HIV infected Individuals
9937625|NCT00001281||HIV Uninfected Individuals|HIV uninfected Individuals
9937626|NCT00001281||Individuals with/without Immunodeficiencies|Individuals with/without immunodeficiencies
9937627|NCT00001281||Individuals with/without infectious diseases|Individuals with/without infectious diseases of interest
9937628|NCT00001276||Patients with hypoglycemia|Patients with hypoglycemia due to diverse etiologies.
9937629|NCT00001265||Healthy Volunteers|Patients with no disease
9937630|NCT00001265||Patients with muscle disease|Patients with known or suspected Idiopathic Inflammatory myopathies (IIM)
9937631|NCT00001258||1|Patients with schizophrenia spectrum disorder
9937632|NCT00001258||2|normal volunteers
9937633|NCT00001254||Patients|Patients will Zollinger-Ellison Syndrome
9937634|NCT00001252||healthy volunteer|Normal/healthy volunteers
9937635|NCT00001252||Impaired volunteer|volunteers with impairments of the neuromusculoskeletal system.
9937636|NCT00001248||healthy volunteers|Healthy volunteers for technique development and comparison with the patient populations.
9937637|NCT00001248||MS/CIS/RIS population|Patients with a diagnosis of MS or who have typical imaging abnormalities associated with MS.
9937638|NCT00001248||Non-MS comparison population|Patients with disorders of the CNS, to include patients with diseases that share mechanisms of tissue damage with MS
9937639|NCT00001247||1|Individuals with schizophrenia-spectrum illness from the community.
9937640|NCT00001246||1|Our studies include data from typically developing youth, and individuals with a range of psychiatric presentations from behaviorally-defined (e.g. Childhood-Onset Schizophrenia, Autism Spectrum Disorder) as well as genetically-defined (e.g. Sex Chromosome Aneuploidy) groups. Participants span a wide age range (from 3 years of age upwards).
9937641|NCT00001244||General Population|MD referred or self-referred
9999728|NCT01530594|Experimental|Bortezomib/Lenalidomide|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
9937642|NCT00001242||Study Cohort|Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo- pseudohypoparathyroidism, or suspicion of these or related disorders
9937643|NCT00001238||Disease Category I|Patients, biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is known, including VHL and HPRC
9937644|NCT00001238||Disease Category II|Patients and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is not yet known
9937645|NCT00001238||Disease Category III|Patients and biologic family members with a urologic malignant disease of suspected, but not proven genetic etiology
9937646|NCT00001231||Healthy Women|The purpose of this protocol is to allow for the careful screening of healthy volunteers for participation in research protocols.
9937647|NCT00001231||premenopausal depressed women patients|The purpose of this protocol is to allow for the careful screening of patients for participation in research protocols.
9937648|NCT00001230||1|Patients that have, or are suspected of having, one of the filarial infections affecting humans
9937649|NCT00001223||CF Patients|cystic fibrosis patients
9937650|NCT00001223||CF Relatives|relatives of cystic fibrosis patients
9937651|NCT00001215||Control|healthy volunteers
9937652|NCT00001215||Family Member|a family member of a documented proband
9937653|NCT00001215||Patient|the participant on initial screening must be found to have or be a carrier of a documented lysosomal storage disorder
9937654|NCT00001208||Patients|Patients will be eligible for participation if they have a movement disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
9937655|NCT00001205||1|Male and female subjects aged 3-75 years with likely or definite neurocysticercosis (NCC) diagnosis
9937656|NCT00001204||1|Longitudinal sequential cardiologic studies utilizing noninvasive techniques in homozygous patients with well-characterized LDL receptor defects
9937657|NCT00001186||Cohort 1|Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.
9937658|NCT00001186||Cohort 2|Young adults with cancer (YACers) acting as counselors at Camp Fantastic and are enrolled in another NIH protocol.
9937659|NCT00001184||1|Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study.
9937660|NCT00001183||Group 1|Pulmonary Patients
9937661|NCT00001177||healthy volunteers|healthy females
9937662|NCT00001177||patients|females with menstrually-related mood or behavioral difficulties
9937663|NCT00001174||Healthy Volunteers|Healthy volunteers
9937664|NCT00001174||Patients|Patients with bipolar disorder
9937665|NCT00001168||Dyslipidemia|Dyslipidemia
9937666|NCT00001163||1|primary clinical; volunteers come from all U.S.
9937667|NCT00001160||thyroid cancer|Patients with thyroid cancer
9937668|NCT00001160||thyroid nodules|Patients with thyroid nodules
9937669|NCT00001159||Thyroid disorders|Patients with thyroid disorders
9937670|NCT00001154||Patients|Subjects with new and undefined dyslipidemia
9999729|NCT01530607|Active Comparator|cyclophosphamide|Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
9999730|NCT01530607|Experimental|Goserelin (Zoladex)|Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
9999731|NCT01530620|Experimental|Propiverine hydrochloride ER|45 mg
9999732|NCT01530620|Active Comparator|Propiverine hydrochloride IR|15 mg
9999733|NCT01530646|Placebo Comparator|Control|Carbohydrate & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of maltodextrin (no protein) for 14 days. Weight loss.
9999734|NCT01530646|Experimental|Whey|Whey protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of WPI for 14 days. Weight loss.
9999735|NCT01530646|Experimental|Soy|Soy protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of SPC for 14 days. Weight loss.
9999736|NCT01530672|Experimental|ANC clients|
9999737|NCT01530685|Experimental|Glycabiane, gelule|
9999738|NCT01530685|Placebo Comparator|Placebo|
9999739|NCT01530698|Experimental|single step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for single-step antigen loading and TLR activation (TriMix-DC)
9999740|NCT01530698|Active Comparator|two step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for antigen loading and separately for TLR activation
9999741|NCT01530711|Experimental|terlipressin|
9999742|NCT01530724|Experimental|low fat diet|Weight-loss diet strategy
9999743|NCT01530724|Experimental|low carb diet|Weight-loss diet strategy
9999744|NCT01530737|Placebo Comparator|Control Group|
9999745|NCT01530737|Experimental|Active Antithrombin Group|
9999746|NCT01530750||Post cardiac surgery|
10034945|NCT01801423|Experimental|Hydroxyurea|Study investigators propose to enroll 60 children with SCA and an elevated TCD measurement between 5 and 12 years of age in this one arm feasibility study of hydroxyurea therapy, with follow-up of at least 12 months per subject. The study intervention will include HU to begin at ~ 20 mg/kg/day(range 17.5 - 26 mg/kg/day). No dose escalation will occur. Given the success of the first year of enrollment and the favorable response of TCD measurement after 3 months on HU therapy, the study investigators have participants as an internal pilot. The definitive phase III trial will now compare low dose HU therapy to the result of no treatment arm from the STOP Trial.
10034946|NCT01801462|Experimental|Simulation-based ultrasound training|The initial training is provided on a high-fidelity Virtual-Reality (VR) simulator (Scantrainer, Medaphor). The VR simulator provides images obtained from real patients and haptic feedback from the ultrasound probe. The basic gynecologic and advanced gynecologic modules are selected for training purposes. When all modules are passed on the VR simulator, the participants receive 30 minutes of training on the low-fidelity simulator (BluePhantom) to allow participants to review the functions, they just trained, using real ultrasound equipment.
10034947|NCT01801462|No Intervention|Control|Participants randomized to the control group receive traditional clinical introduction locally in the departments. This may include observation and supervised practice and the different types of clinical training provided by each department are gathered through the department's head of education and registered.
10034948|NCT01801488||AVM Patients|Patients receiving surgical intervention for an intracranial arterial-venous malformation.
10034949|NCT01801488||Ruptured Aneurysm|Patients receiving surgical intervention for a ruptured intracranial aneurysm.
10034950|NCT01801488||Unruptured Aneurysm|Patients receiving surgical intervention for an unruptured intracranial aneurysm.
10034951|NCT01801501||Critical Care Patients|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock
10034952|NCT01801527|Experimental|Telerehabilitation group|
10034953|NCT01801527|No Intervention|Control group|Information about usual care
10034954|NCT01801540|Experimental|0% arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
10034955|NCT01801540|Other|5 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
10034956|NCT01801540|Other|10 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
10034957|NCT01801540|Other|0 % arabinose meal Starch|A meal containing two bons with butter and cheese, The and water
10034958|NCT01801540|Other|5 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
10034959|NCT01801540|Other|10 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
10034960|NCT01801553|Active Comparator|spinal manipulation intervention group|Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
10034961|NCT01801553|Sham Comparator|Spinal manipulation control group|Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation
10034962|NCT01801566|Active Comparator|Conventional implant loading protocol|Single implant-retained mandibular overdenture
10034963|NCT01801566|Experimental|Immediate loading implant protocol|Single implant-retained mandibular overdenture
10034964|NCT01801605|Active Comparator|on|active session
10034965|NCT01801605|Placebo Comparator|off|fictive session
10034966|NCT01801631|Experimental|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
10034967|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
10034968|NCT01801644|Experimental|gemcitabine plus cisplatin|gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied
10034969|NCT01801657||Bronchiectasis,stable|A patient was defined as stable if there was no exacerbation for the previous 4 wk
9999747|NCT01530763|Experimental|Ceftaroline fosamil|
9999748|NCT01530763|Active Comparator|Ceftriaxone|
9937671|NCT00958464||1|MRI protocol on 2 separate occasions
9937672|NCT00958490|Active Comparator|First walking group|Group walking at 2 months postop
9937673|NCT00958490|Active Comparator|Second group walking|Group walking at 3 months postop
9937674|NCT00958503|Placebo Comparator|Placebo|Placebo
9937675|NCT00958503|Active Comparator|Thiamphenicol|Active comparator
9937676|NCT00958516|Experimental|LEO 29102 cream|
9937677|NCT00958529|Experimental|inulin|0, 5, 10 g inulin
9937678|NCT00958542|Experimental|Surgical Arm|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
9937679|NCT00958542|No Intervention|Non-Surgical Arm|Non-Surgical No intervention - Includes patients who have either refused to have surgery or have not been recommended to have surgery at this point. These patients will continue to be monitored closely, however, will not receive any other intervention.
9937680|NCT00958607|Active Comparator|Self-Directed Program|
9937681|NCT00958607|Active Comparator|Stroke Support Person|
9937682|NCT00958607|No Intervention|Standard Care|"Participants in this arm receive Standard Care which consists of being given a copy of the Heart& Stroke Foundation's stroke resource titled Let's Talk About Stroke"
9937683|NCT00958620|Active Comparator|Active ESWT|
9937684|NCT00958620|Sham Comparator|Sham ESWT|
9937685|NCT00958633|Active Comparator|8 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s)and will be randomized to one of two treatment arms for up to 52 weeks:~Group 1 patients randomized to the 8 week arm will discontinue antidepressant treatment after 8 weeks, as recommended in current clinical practice guidelines. The antidepressant will be tapered in a double-blind manner beginning at 6 weeks, and will be substituted with placebo by 8 weeks.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
9937686|NCT00958633|Active Comparator|52 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s) and will be randomized to one of two treatment arms for up to 52 weeks:~Group 2 patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
9937687|NCT00958646|Experimental|Osteopathic Manipulation|Standardized OMT procedure
9937688|NCT00958646|Placebo Comparator|Placebo|Light touch placebo procedure
9937689|NCT00958659||Ancillary-Correlative (gene expression profiling)|Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
9937690|NCT00958685|Experimental|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
9937691|NCT00958685|Experimental|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
9937692|NCT00958698|Experimental|Arm I (nurse-assisted intervention module)|Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads patients through WRITE Symptoms? intervention module, with personalized support and advice. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management.
9937693|NCT00958698|Experimental|Arm II (self-directed intervention module)|Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms? intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms? intervention module over approximately 4 weeks. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management.
9937694|NCT00958698|Active Comparator|Arm III (standard care from local provider)|Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.
9937695|NCT00958750|Active Comparator|5% MTF|5% minoxidil topical foam used once daily
9937696|NCT00958750|Active Comparator|2% MTS|2% minoxidil topical solution twice daily use
9937697|NCT00958763|Experimental|Motivational Interviewing, Single - MIS|
9937698|NCT00958763|Experimental|Motivational Interviewing, Group - MIG|
9937699|NCT00958763|Other|Usual Care Group - UCG|
9937700|NCT00958802|Placebo Comparator|Arm A|Chondrocyte culture with FBS medium
9937701|NCT00958802|Experimental|Arm B|Chondrocyte culture with PRP
9937702|NCT00958815||HIV-seronegative with no CVD risk factors|Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference <102cm (men) and <88cm (women).
9937703|NCT00958815||HIV+ with CVD risk factors|35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.
9937704|NCT00958867|Experimental|1|Six-month, twice-weekly aerobic training (AT) program
9937705|NCT00958867|Experimental|2|Six-month, twice-weekly resistance training (RT) program
9937706|NCT00958867|Active Comparator|3|Six-month, twice-weekly stretch & relax (S & R; control) program
9937707|NCT00958906|Experimental|Intravitreal infliximab|
9937708|NCT00958932|Experimental|Speech recognition (TEAM intervention)|
9937709|NCT00958932|Active Comparator|Speech recognition (Usual care)|
9937710|NCT00958945||FloSeal - Knee - control|100 Historical Control Patients, knees - no FloSeal (retrospective)
9937711|NCT00958945||FloSeal - Knee - 5ml|100 Patients, knees - 5mL FloSeal (retrospective)
9937712|NCT00958945||FloSeal - Knee - 10ml|100 Patients, knees- 10mL FloSeal (prospective)
9937713|NCT00958945||FloSeal - Hip - Control|100 Historical Control patients, hips-no FloSeal (retrospective)
9937714|NCT00958945||FloSeal - Hip - 5ml|100 retrospective patients, hips-5mL of FloSeal (retrospective)
9937715|NCT00958958|Other|Quality improvement program|"There are multifaceted Interventions for the clinic hospital team Including~Distribution of educational materials~Case manager~Reminders~Practical training"
9937716|NCT00958958|No Intervention|Hospital standard treatment|Hospital standard treatment
9937717|NCT00958997||Type 1 diabetic subjects|Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician
9937718|NCT00958997||Healthy control subjects|Age-weight-BMI matched to the subjects with type-1 diabetes
9937719|NCT00959010|Experimental|Omega 3 Premium|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA
9937720|NCT00959010|Placebo Comparator|Placebo|capsules containing middle chain triglycerides
9937721|NCT00959062|Experimental|clonidine|
9937722|NCT00959062|Placebo Comparator|placebo|
9937723|NCT00959075|Experimental|Oral thiamin supplementation|Vitamin B1 (Oral thiamin) 100mg BID for 6 months
9937724|NCT00959075|Placebo Comparator|Sugar pill|oral placebo 1 tablet BID for 6 months
9937725|NCT00959088||1|HIV-infected individuals with suspected TB co-infection.
9937726|NCT00959101|Experimental|A|
9937727|NCT00959101|Experimental|B|
9937728|NCT00959101|Active Comparator|C|
9937729|NCT00959127|Experimental|ARRY-438162 (MEK 162)|
9937730|NCT00959153|Experimental|Kidney stones|Kidney stones
9937731|NCT00959179||Device therapy patients for CHF.|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
9937732|NCT00959179||ICD and CRT-D patients|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
9937733|NCT00959205|Active Comparator|Angiography|Conventional fluoroscopically guided activation mapping
9937734|NCT00959205|Experimental|CARTO 3D|CARTO (3D Electroanatomic imaging)
9937735|NCT00959218|Experimental|Dronabinol|
9937736|NCT00959218|Placebo Comparator|Placebo|
9937737|NCT00959257||Asthma|Asthma patients on inhaled corticosteroids
9937738|NCT00959257||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
9937739|NCT00959296||Patients with a device implant|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
9937740|NCT00959309|Experimental|Intervention|
9937741|NCT00959309|Active Comparator|Control|
9937742|NCT00959335|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
9937743|NCT00959335|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
9937744|NCT00959348||Asthma|Asthma patients on inhaled corticosteroids
9937745|NCT00959348||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
9937746|NCT00959361|Experimental|pharmaceutical care|consultation with the pharmacists
9937747|NCT00959361|No Intervention|control|usual care without consultation with the pharmacists
9937748|NCT00959387|Experimental|Induction TP chemotherapy followed by CRT|paclitaxel 175mg/m2 as a 3-h infusion on Day 1, and cisplatin 80mg/m2 as a 2-h infusion on Day 1 three weekly followed by concurrent chemoradiotherapy based on cisplatin. All patient were given adequate hydration and antiemetics. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
9937749|NCT00959400|Experimental|Fentanyl Transdermal|
9937750|NCT00959413||A|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1,000 copies/ml
9937751|NCT00959413||B|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1,000 copies/ml or less
9937752|NCT00959413||C|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1,000 copies/ml
9937753|NCT00959413||D|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1,000 copies/ml or less
9937754|NCT00959426|Experimental|PF-04620110|
9937755|NCT00959426|Placebo Comparator|Placebo Comparator|
9937756|NCT00959439|Experimental|1|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
9937757|NCT00959439|Active Comparator|2|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
9937758|NCT00959452|Experimental|Psychotherapy|
9937759|NCT00959465|Experimental|Cohort 1/Dose Level A|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
9937760|NCT00959465|Experimental|Cohort 1/Dose B|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
9937761|NCT00959465|Experimental|Cohort 2/Dose C|A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.
9937762|NCT00959478|Experimental|Educational tool & Carbon Monoxide Alarm|"Parents will be randomly assigned into a control and intervention group. Both groups will complete a computer based survey at enrollment and at their home visits occuring two weeks and approximately six months following enrollment. Participants will be given the following materials at enrollment.~Intervention:~Fast Facts about Carbon Monoxide Educational Tool~Kidde Nighthawk Carbon Monoxide Alarm~Control:~- Central Ohio Poison Control Center Flyer"
9937763|NCT00959491||Colonoscopy indication|All outpatients referred to colonoscopy according to inclusion criteria in the specified period time of one year .
9937764|NCT00959517|Experimental|CQ|
9937765|NCT00959517|Experimental|CQ+PQ|
9937766|NCT00959517|Experimental|CQ + AS|
9937767|NCT00959517|Experimental|SP|
9937768|NCT00959517|Experimental|SP + PQ|
9937769|NCT00959517|Experimental|SP + AS|
9937770|NCT00959530|Experimental|lingualized|complete denture fabricated by lingualized occlusion scheme
9937771|NCT00959530|Placebo Comparator|Full Bilaterally Balanced Articulation|complete denture fabricated by Full Bilaterally Balanced Articulation scheme
9937772|NCT00959543|Other|waterpolo players|30 throwing shoulders of waterpolo players
9937773|NCT00959543|Other|controle group|15 healthy patients (non waterpolo players); 30 shoulders
9937774|NCT00959569|Experimental|esmolol|the study group will receive esmolol (1-3 mg/kg)
9937775|NCT00959569|Placebo Comparator|normosaline|normosaline (same ml of the study drug)
9937776|NCT00959582|Experimental|1|18-F-FDG PET/CT imaging
9937777|NCT00959595|Experimental|EMLA cream|
9999749|NCT01530776|Experimental|Healthy Lifestyle Group|Participants randomized to this condition will receive information and strategies to help them eat healthier and be more active during and after pregnancy. They will get this information about eating and activity through handouts, text messages, Facebook updates, and in-person visits and phone calls from a health coach.
9999750|NCT01530776|No Intervention|Usual Care|This condition is meant to represent standard clinical care provided to pregnant and postpartum mothers at Temple University.
9999751|NCT01530802|Experimental|Uterine artery clipped|Both uterine arteries are temporarily clipped by Yasargil clips during laparoscopic myomectomy.
9999752|NCT01530802|No Intervention|Control group|Conventional laparoscopic myomectomy is performed. (No intervention to temporarily occlude uterine arteries is made)
9999753|NCT01530815|Experimental|Bupivicaine Infusion|We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain
9999754|NCT01530828||Premature infants|Weight less than 1000 grams, age 1 - 16 days.
9999755|NCT01530841|Experimental|AVAPS|Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated
9999756|NCT01530841|Active Comparator|Bilevel pressure|Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode
9999757|NCT01530854||Septic|
9999758|NCT01530854||Healthy|
9999759|NCT01530893|Experimental|Intervention group A: flavanones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
9999760|NCT01530893|Experimental|Intervention group B: isoflavones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
9999761|NCT01530893|Experimental|Intervention group C: Flavan-3-ols|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
9999762|NCT01530893|Experimental|Intervention group D: Anthocyanins|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
9999763|NCT01530906|Experimental|rTMS|"patients included in this arm will receive 10 sessions of transcranial magnetic stimulation (10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC).~Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)"
9999764|NCT01530906|Placebo Comparator|rTMS SHAM|Transcranial magnetic stimulation SHAM Intervention: Repetitive transcranial Magnetic Stimulation SHAM Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol
9999765|NCT01530919||Parathyroid surgery|Database of patients who have undergone minimally invasive radioguided parathyroidectomy
9999766|NCT01530958|Experimental|ATSM + Health Coach and CKD Registry|
9999767|NCT01530958|Active Comparator|CKD Registry|
9999768|NCT01530958|Active Comparator|ATSM + Health Coach|
9999769|NCT01530958|Placebo Comparator|Usual Care (no interventions)|
9999770|NCT01530971|No Intervention|room air|no supplemental oxygen in intraoperative period
9999771|NCT01530971|Experimental|Oxygen|Supplemental 3LPM oxygen via canula
9999772|NCT01530984|Experimental|Ipilimumab alone|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance).
9999773|NCT01530984|Experimental|Ipilimumab with GM-CSF|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance). GM-CSF 250 mcg/m2 SQ will be administered on days 1-14 in Cycles 1-6 and then every 3 months for 14 days beginning on the day of ipilimumab administration during the maintenance therapy phase
9999774|NCT01531010|Active Comparator|Pressure-limited ventilation|
9999775|NCT01531010|Active Comparator|Volume-targeted ventilation|
9999776|NCT01531023||ESBL producing E. coli bacteria|Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
9999777|NCT01531023||Non-ESBL E.coli urinary tract infection|E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
9999778|NCT01531036|Experimental|shear wave imaging|Single arm study evaluating breast 3D elastography by means of shear wave propagation into breast tissue.
9999779|NCT01531049|Experimental|Varenicline|A varenicline treatment group (with motivational interview technique combined with varenicline and placebo transdermal patch). Intervention with Nicorette 15mg /16 h patch
9999780|NCT01531049|Experimental|Nicotine cutaneous patch 15mg|Intervention with Varenicline for 12 weeks. Nicotine cutaneous patch 15mg/16h
9999781|NCT01531049|Experimental|Nicotine cutaneous patch 10mg|Intervention with Placebo transdermal patch for 8 weeks. Nicotine cutaneous patch 10mg/16h
9999782|NCT01531049|Placebo Comparator|Placebo cutaneous patch|No active medication.One transdermal patch/16 h.Total duration was 8 weeks.
9999783|NCT01531062|Experimental|Nigella sativa|Nigella sativa extracts, 300 mg twice daily
9999784|NCT01531062|Placebo Comparator|Placebo|
9999785|NCT01531075|Experimental|ENGERIX-B|
9999786|NCT01531075|Experimental|Sci-B-Vac|
9999787|NCT01531088|No Intervention|Usual care|Recommendations made by consultant pharmacists as part of their federally-mandated medication regimen review process
9999788|NCT01531088|Experimental|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events
9999789|NCT01531101|Experimental|Individual PDT with TW|Individual Psychodynamic psychotherapy with transference work (TW).
9999790|NCT01531101|Active Comparator|Individual PDT without (TW)|Individual Psychodynamic psychotherapy without focus on transference work (TW).
9999791|NCT01531114|Active Comparator|Prasugrel loading dose|Patients will be randomized to this arm to receive loading dose of prasugrel
9999792|NCT01531114|No Intervention|ticagrelor loading dose|Patients will be randomized to this arm to receive loading dose of ticagrelor
9999793|NCT01531127||Combined Therapy|ADHD Medication and Learning Strategies Treatment
9999794|NCT01531127||ADHD Medication Treatment|Control group
9999795|NCT01531140|Active Comparator|Polyethylene glycol|Polyethylene glycol p.o.(Fortrans):60 ml/kg for 2 days
9999796|NCT01531140|Experimental|PEG + Bisacodyl|Polyethylene glycol p.o.(Fortrans): 30 ml/kg for 2 days + Bisacodyl p.o.: 10-15 mg/day
9999797|NCT01531140|Experimental|Sennosides|Sennosides: 1tbl/8kg/day for 2 days (1 tbl=8,6 mg sennosides B)
9999798|NCT01531166||Chronic hepatitis B|
9999799|NCT01531179|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
9999800|NCT01531179|Placebo Comparator|Control|Placebo for 3 months
9999801|NCT01531192|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
9999802|NCT01531192|Active Comparator|Nystatin|50000 unit/3 times a day
9999803|NCT01531218|Active Comparator|azithromycin|azithromycin 500mg
9999804|NCT01531218|Placebo Comparator|placebo|placebo 500mg
9999805|NCT01531231||YOUNGER HEALTHY NO CORONARY ARTERY DISEASE (CAD)|- Whether an association between typical daily experiences and recovery time varies with age; this group will be compared to the older comparison group and to previous data collected from those subjects who participated in the Long QT Syndrome study (LQTS).
9999806|NCT01531231||OLDER HEALTHY SUBJECTS NO CORONARY ARTERY DISEASE (CAD)|- Determine whether daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD when comparing CAD patients with healthy patients
9999807|NCT01531231||HIGH RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether emotion assessed randomly throughout the day is associated with myocardial ischemia
9999808|NCT01531231||LOW RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether typical daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD
9999809|NCT01531244|Experimental|Treatment (targeted gene therapy and ILI)|Patients receive melphalan and dactinomycin via ILI. Patients then receive CRAd 3/5-delta via ILI.
9999810|NCT01531257||Kidney Transplant Recipients|The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types. We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
9999811|NCT01531283|Experimental|decaylated ghrelin|UAG (4.0 µg/kg/hr)
9999812|NCT01531283|Experimental|acyl ghrelin|AG (1.0 µg/kg/hr)
9999813|NCT01531283|Experimental|combined acyl and desacyl ghrelin|the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
9999814|NCT01531283|Placebo Comparator|saline|saline
9999815|NCT01531309|Experimental|Mild Hepatic Impaired Participants|Mild hepatic impaired participants will receive a single sublingual dose of AGO178, 1 milligram (mg) on Day 1.
9999816|NCT01531309|Experimental|Moderate Hepatic Impaired Participants|Moderate hepatic impaired participants will receive a single sublingual dose of AGO178, 1 mg on Day 1.
9999817|NCT01531309|Experimental|Healthy Participants Matched by Aged, Gender and Body Mass Index (BMI)|Healthy participants matched by aged, gender and BMI will receive a single sublingual dose of AGO178, 1 mg on Day 1.
9999818|NCT01531322|Experimental|Group 1|Adults aged 18 through 55 years (before the fifty sixth birthday)
9999819|NCT01531322|Experimental|Group 2|Children aged 3 through 5 years (before the sixth birthday)
9999820|NCT01531322|Experimental|Group 3|Infants aged approximately 2 months (42 to 98 days)
9999821|NCT01531348|Experimental|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
9999822|NCT01531361|Experimental|Arm I (vemurafenib and sorafenib tosylate)|Patients receive vemurafenib PO BID and sorafenib tosylate PO BID on days 1-28.
9999823|NCT01531361|Experimental|Arm II (vemurafenib and crizotinib)|Patients receive vemurafenib as in Arm I and crizotinib PO QD or BID on days 1-28.
9999824|NCT01531400|Experimental|music|Investigators played self-selected background music in the music group
9937778|NCT00959595|Placebo Comparator|Placebo cream|A placebo cream identical in appearance and consistency to the experimental cream
9937779|NCT00959608|Active Comparator|Basic|Basic program participants receive 10-15 minute PCP weight management counseling at approximately four month intervals for up to 24 months and weight management materials.
9937780|NCT00959608|Experimental|Basic Plus|Half of study participants are randomly assigned to Basic Plus program, where in addition to receiving the same intervention as the Basic program participants, the Basic Plus participants also receive counseling from a lifestyle coach at the primary care provider's office (monthly in year 1 and bimonthly in year 2).
9937781|NCT00959621|Active Comparator|ASA|The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.
9937782|NCT00959621|Active Comparator|Klexane|Clexane (enoxaparine) 40 mg sc
9937783|NCT00959621|Active Comparator|Aspirin and Enoxaparine|
9937784|NCT00959634|Experimental|1|Dose 1 BID
9937785|NCT00959634|Experimental|2|Dose 2 BID
9937786|NCT00959634|Placebo Comparator|3|Placebo BID
9937787|NCT00959686|Experimental|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
9937788|NCT00959712|No Intervention|Control|Subjects are given a pedometer and step count log in which to record their daily step counts for 1 year.
9937789|NCT00959712|Active Comparator|ECA Interaction|"Subjects are given pedometers and step count logs in which to record their daily steps for 1 year. Subjects are also given a tablet computer and instructed to interact with the ECA (Embodied Conversational Agent) Tanya every day for 2 months."
9937790|NCT00959725|Experimental|Intravitreal infliximab.|
9937791|NCT00959738|Other|A|diverting loop ileostomy with rod
9937792|NCT00959738|Other|B|diverting loop ileostomy without rod
9937793|NCT00959777|Experimental|DA-3031|
9937794|NCT00959777|Active Comparator|filgrastim|
9937795|NCT00959790|Experimental|High vegetable dose|Consumption of 200 grams of vegetables daily, for four weeks.
9937796|NCT00959790|Experimental|Low vegetable dose|Consumption of 50 grams of vegetables daily, for four weeks.
9937797|NCT00959790|Active Comparator|Weight loss interventio|Consumption of - 1000 kcal daily, for four weeks to be used as a positive control for the vegetables interventions.
9937798|NCT00959803|Experimental|Single dose|3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.
9937799|NCT00959803|Experimental|Multiple dose|3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.
9937800|NCT00959816|Experimental|Single Dose (Part 1)|
9937801|NCT00959816|Experimental|Multiple Dose (Part 2)|
9937802|NCT00959829|Placebo Comparator|silence|"The control group listened silence and was evaluated the same things."
9937803|NCT00959855|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation classes based on the British Thoracic Society guidelines will be undertaken for two hours for 16 sessions within an eight week period.
9937804|NCT00959855|No Intervention|Pulmonary Rehabiliation|The control group will be assessed in the same time frame without participating in the rehabilitation class. They will avail of the next available class after the 12 month assessment.
9937805|NCT00959881|Experimental|Donepezil plus placebo|
9937806|NCT00959881|Experimental|Donepezil plus begacestat|
9937807|NCT00959933|Experimental|1|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
9937808|NCT00959933|Active Comparator|2|Rebetol 200 Capsules (Schering Corporation, U.S.A.)
9937809|NCT00959959|Experimental|650 mg TOK-001|
9937810|NCT00959959|Experimental|1300 mg TOK-001|
9937811|NCT00959959|Experimental|1950 mg TOK-001|
9937812|NCT00959959|Experimental|975 mg TOK-001|
9937813|NCT00959959|Experimental|975 mg TOK-001, supplement|
9937814|NCT00959959|Experimental|1950 mg TOK-001, split dose|
9937815|NCT00959959|Experimental|2600 mg TOK-001|
9937816|NCT00959959|Experimental|2600 mg TOK-001, split dose|
9937817|NCT00959972|Experimental|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
9937818|NCT00959972|Experimental|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
9937819|NCT00959998|Active Comparator|Relaxation acupressure|
9937820|NCT00959998|Experimental|High Intensity Stimulating Acupressure|
9937821|NCT00959998|Experimental|Low Intensity Stimulating Acupressure|
9937822|NCT00960024|Experimental|Individual Placement and Support-vocational rehabilitation|
9937823|NCT00960024|Active Comparator|Vocational rehabilitation available at study site|
9937824|NCT00960037|Experimental|Vitamin D|Vitamin D3 supplementation based on baseline 25(OH)D level
9937825|NCT00960037|Placebo Comparator|Placebo|
9937826|NCT00960089|Experimental|LIQUICURE|Medical Device
9937827|NCT00960102|Active Comparator|bilateral cochlear implant|
9937828|NCT00960102|Active Comparator|cochlear implant and hearing aid|
9937829|NCT00960102|Active Comparator|bilateral hearing aid|
9937830|NCT00960128||A|Adult cohort
9937831|NCT00960128||B|Paediatric cohort
9937832|NCT00960167|Experimental|Dose Level I|42 Gy in 12 fractions.
9937833|NCT00960167|Experimental|Dose Level II|49 Gy in 14 fractions.
9937834|NCT00960167|Experimental|Dose Level III|56 Gy in 16 fractions.
9937835|NCT00960167|Experimental|Dose Level IV|63 Gy in 18 fractions.
9937836|NCT00960180|Experimental|1|
9937837|NCT00960180|Placebo Comparator|2|
9937838|NCT00960219|Experimental|DAAOI-1|
9937839|NCT00960219|Placebo Comparator|placebo|
9937840|NCT00960232|Experimental|Vitamin D|vitamin D 40.000 IU per weel
9937841|NCT00960232|Placebo Comparator|Placebo|Placebo
9937842|NCT00960245|Experimental|1|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
9937843|NCT00960245|Active Comparator|2|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
9937844|NCT00960258|Experimental|Arm 1|
9937845|NCT00960271||NON SMALL CELL LUNG CANCER|Non small cell lung cancer, with clinical N2 disease, otherwise operable.
9937846|NCT00960284|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
9937847|NCT00960284|Experimental|Arm II|Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
9937848|NCT00960310|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
9937849|NCT00960310|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
9937850|NCT00960336|Experimental|single arm|
9937851|NCT00960349|Other|Treatment A|Cediranib 20mg + Cisplatin + S-1
9937852|NCT00960349|Other|Treatment B|Cediranib 20mg + Cisplatin + Capecitabine
9999825|NCT01531400|No Intervention|no music (control)|Investigators played no music in the music group
9999826|NCT01531413|Experimental|Oxygen Insufflation|At the end of the laparoscopic appendectomy we will desufflate the abdomen of CO2 then reinsufflate with oxygen to washout the CO2 leaving an oxygen rich environment
9999827|NCT01531426||NIRS continuous monitoring|
9999828|NCT01531452|Experimental|treatment|oxaliplatin+s1
9999829|NCT01531465|Other|HFNC to NCPAP|Infants who are currently on HFNC.
9999830|NCT01531465|Other|NCPAP to HFNC|Infants who are currently on NCPAP.
9999831|NCT01531478||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
9999832|NCT01531491|Experimental|Hypercapnia group|Respiratory rate will be 10/min and the rebreathing tube will be connected between the y-piece of corrugated tube and the tracheal tube to maintain the partial pressure of the end-tidal carbon dioxide at around 50 mmHg during emergence after propofol anesthesia.
9999833|NCT01531491|Experimental|Hypocapnia group|No rebreathing tube (Nothing) will be connected. Respiratory rate will be 10/min and the tidal volume will be modulated to maintain the partial pressure of the end-tidal carbon dioxide at around 30 mmHg during emergence after propofol anesthesia.
9476168|NCT03574415|Experimental|Caucasian_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
9937853|NCT00960362|Placebo Comparator|A|
9937854|NCT00960362|Experimental|B|Intravenous cohort 1; 0.01 mg/kg
9937855|NCT00960362|Experimental|C|Intravenous cohort 2; 0.1 mg/kg
9937856|NCT00960362|Experimental|D|Intravenous cohort 3; 0.6 mg/kg
9937857|NCT00960362|Experimental|E|Intravenous cohort 4; 3.0 mg/kg
9937858|NCT00960362|Experimental|F|Intravenous cohort 5; 10 mg/kg
9937859|NCT00960362|Experimental|G|Intravenous cohort 6; 30 mg/kg
9937860|NCT00960401||cardiac counseling|10 left sided breast cancer patients 10 right sided breast cancer patients
9937861|NCT00960401||coronary artery evaluation|10 left sided breast cancer 10 right sided breast cancer
9937862|NCT00960414|Experimental|SHINE A|
9937863|NCT00960414|Active Comparator|SHINE B|
9937864|NCT00960453|Other|Sitagliptin 25mg|Repeated administrations for 4 days
9937865|NCT00960453|Other|Sitagliptin 50mg|Repeated administrations for 4 days
9937866|NCT00960453|Other|Sitagliptin 100mg|Repeated administrations for 4 days
9937867|NCT00960466|Active Comparator|Usual Care Arm|The usual care group will receive their Chemotherapy or Radiotherapy as normal.
9937868|NCT00960466|Experimental|DT&PL arm|"During the second week of radiotherapy/second cycle of chemotherapy, patients in the Distress Thermometer and Problem List (DT&PL) arm of the study will complete the DT&PL (estimated 15 minutes to complete) with the trained radiographer/nurse.~The DT&PL assessment will be repeated at the end of therapy fractions/cycles. This will elicit concerns about post-therapy issues and facilitate continuity of care between the cancer team and primary care. Depending on the duration of therapy, therapists may choose to use the DT&PL at other points during patient care. A copy of the DT&PL will be stored in the medical record to track the frequency of use and to check that those assigned to usual care were not monitored with the DT&PL."
9937869|NCT00960479|Experimental|1|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
9937870|NCT00960479|Active Comparator|2|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
9937871|NCT00960492|Experimental|Arm 1|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent during the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase.
9937872|NCT00960492|Experimental|Arm 2|XL184 will be initiated during the maintenance phase with TMZ
9937873|NCT00960492|Experimental|MTD Expansion|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
9937874|NCT00960518|Placebo Comparator|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
9937875|NCT00960518|Experimental|TACE+adefovir|patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
9937876|NCT00960544|Experimental|Capecitabine|Capecitabine - Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
9937877|NCT00960557|Experimental|Combretastatin A1 Diphosphate|
9937878|NCT00960583|Experimental|Exercise program|"Exercise program comprising muscle strengthening, cardiovascular training and stretching exercises.~Program duration : 12 weeks Sessions frequency : twice per week Session duration : 1h30"
9937879|NCT00960583|Active Comparator|Routine follow-up|Routine follow-up after functional multidisciplinary rehabilitation by attending physician (Advice to stay active)
9937880|NCT00960609||caval confluence HV involvement|Patients carriers of primary or metastatic tumour with direct contact or invasion of one HV at the caval confluence.
9937881|NCT00960635|Active Comparator|calcitriol|
9937882|NCT00960635|Placebo Comparator|pill without agent|
9937883|NCT00960648||Xience/Promus|Active prospective registration of patients receiving everolimus eluting stent
9937884|NCT00960648||Cypher|Retrospective historical controls that received sirolimus-eluting stent
9937885|NCT00960674|Experimental|Tactile massage|A gentle form of massage given once a week for three weeks
9937886|NCT00960674|Experimental|Relaxation|Relaxation (by the use of a CD with relaxation exercises used at least once a week for 10 weeks)
9937887|NCT00960713||The RITAI cohort|Every patient treated by rituximab off-label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (South of France) is eligible for the study, whatever the dose and planned infusions number. The enrolment is definitive when the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Department of Pharmacology Pharmacovigilance unit and to Health Authorities (AFSSAPS). Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco-immunological studies.
9937888|NCT00960726|Experimental|NOV-002|
9937889|NCT00960739|Experimental|Topotecan / 131-iodine MIBG association|"The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). *~Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. *~A dosimetry is performed during hospitalization.~A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. *~Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG.~If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled."
9937890|NCT00960765||Roux-En-Y Gastric Bypass|
9937891|NCT00960765||Gastric Banding|
9937892|NCT00960765||Sucessful Response to RYGB|
9937893|NCT00960765||Failed Response to RYGB|
9937894|NCT00960791|Experimental|1|14C-labelled AZD1656
9937895|NCT00960817|Active Comparator|1. Routine treatment|Control group
9937896|NCT00960817|Experimental|2. Dipyridamole treatment|Group that receives Dipyridamole treatment
9937897|NCT00960830|Placebo Comparator|mirtazapine|
9937898|NCT00960830|Placebo Comparator|mirtazapine, sugar pill|
9937899|NCT00960882|Experimental|DMMET-01|
9937900|NCT00960908||Resolute|Prospective recruitment of Resolute arm will start in March 2009
9937901|NCT00960908||Endeavor|The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
9937902|NCT00960921|Experimental|Iron group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of iron sucrose, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
9937903|NCT00960921|Placebo Comparator|Saline group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of normal saline, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
9937904|NCT00960960|Experimental|Part 1 (Cohort 1-2): Pictilisib 60 mg +Paclitaxel +Bevacizumab|Pictilisib 60 mg will be administered orally (PO) once daily (QD) for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 milligrams per meter square (mg/m^2) intravenously (IV) on Days 1, 8, and 15 and bevacizumab 10 milligrams per kilogram (mg/kg) IV on Days 1 and 15 of each 28-day cycle. In Cohort 1 (Part 1), pictilisib will be evaluated with paclitaxel only; participants in Cohort 1 (Part 1) will be eligible to receive bevacizumab starting at Cycle 2. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937905|NCT00960960|Experimental|Part 1 (Cohort 3): Pictilisib 100 mg+ Paclitaxel + Bevacizumab|Pictilisib 100 mg will be administered PO QD for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937906|NCT00960960|Experimental|Part 2 (Arm A: Cohort 1a): Pictilisib 165 mg + Paclitaxel|Pictilisib 165 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity
9937907|NCT00960960|Experimental|Part 2 (Arm A: Cohort 2a): Pictilisib 250 mg + Paclitaxel|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9999834|NCT01531504|Other|Hysterectomy|candidate for a conventional laparoscopic-assisted
9937908|NCT00960960|Experimental|Part 2 (Arm A: Cohort 3a): Pictilisib 330 mg + Paclitaxel|Pictilisib 330 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937909|NCT00960960|Experimental|Part2(Arm B:Cohort 1b):Pictilisib 200mg+Paclitaxel+Bevacizumab|Pictilisib 200 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937910|NCT00960960|Experimental|Part2(Arm B:Cohort 2b):Pictilisib 250mg+Paclitaxel+Bevacizumab|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937911|NCT00960960|Experimental|Part2(Arm B:Cohort 3b):Pictilisib 260mg+Paclitaxel+Bevacizumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937912|NCT00960960|Experimental|Part2(Arm C:Cohort 1c):Pictilisib 180mg+Paclitaxel+Trastuzumab|Pictilisib 180 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937913|NCT00960960|Experimental|Part2(Arm C:Cohort 2c):Pictilisib 260mg+Paclitaxel+Trastuzumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
9937914|NCT00960960|Experimental|Part 3: Pictilisib 260 mg + Letrozole|Pictilisib 260 mg will be administered PO QD continuously with letrozole 2.5 mg PO QD for each 28-day cycle. Study treatment will continue until disease progression or unacceptable toxicity.
9937915|NCT00960973|Experimental|Vitamin K|Vitamin K supplementation (menatetrenone 30 mg, 3 times a day for 4 weeks)
9476169|NCT03574415|Experimental|Caucasian_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
9476170|NCT03574415|Experimental|Korean_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
9476171|NCT03574415|Experimental|Korean_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
9476172|NCT03574415|Placebo Comparator|Placebo|DWP14012 placebo-matching tablets
9476173|NCT03574402|Experimental|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
9937916|NCT00960973|Placebo Comparator|Placebo control|Placebo control
9937917|NCT00961012|Experimental|Intervention|"Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a settling time of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the randomization/ allocation envelope."
9937918|NCT00961012|No Intervention|Control group|"Experimenter A reminds the subject to remain immobile.~For both intervention and control group. After the five-minute period, experimenter A calls experimenter B to return. Experimenter B takes a pressure reading, measures the trunk displacement, obtains spirometry readings, and takes a measure of discomfort."
9937919|NCT00961025|Placebo Comparator|Placebo|
9937920|NCT00961025|Experimental|DA-1229|DA-1229
9937921|NCT00961038|Experimental|Arm 1|
9937922|NCT00961038|Experimental|Arm 2|
9937923|NCT00961038|Placebo Comparator|Arm 3|
9937924|NCT00961103||SMA II and SMA III|patients with SMA II and SMA III
9937925|NCT00961129||patients with colorectal cancer|patients with colorectal cancer in any stage or survivors
9937926|NCT00961155|Active Comparator|cyklezonid|children will receive 160 mcg once daily cyklezonid for 3 months
9937927|NCT00961155|Active Comparator|montelukast sodium|children will receive 5 or 10 mg montelukast sodium for 3 months
9937928|NCT00961155|Placebo Comparator|placebo|children will receive placebo for 8 weeks out of allergy season to house dust mite
9937929|NCT00961155|Active Comparator|formoterol|children will receive formoterol aerolzol 12mcg twice daily for 3 months
9937930|NCT00961168|Experimental|Lung-Protective Ventilation|Lung-Protective Ventilation comparing volume vs. pressure control
9937931|NCT00961194|Placebo Comparator|placebo|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
9937932|NCT00961194|Experimental|dose of ketamine tested = 0.35 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
9937933|NCT00961194|Active Comparator|dose of ketamine tested = 0.7 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
9937934|NCT00961194|Active Comparator|dose of ketamine tested = 1.4 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
9937935|NCT00961207|Active Comparator|Aliskiren in Macroalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.
9937936|NCT00961207|Active Comparator|Aliskiren Microalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks
9937937|NCT00961246|Active Comparator|general health information group|participants received general health information
9937938|NCT00961246|Experimental|individually-tailored intervention|participants received individually-tailored intervention
9937939|NCT00961272||HIV-infected, pre-menopausal women|
9937940|NCT00961324|Experimental|IDeg|
9937941|NCT00961324|Experimental|IGlar|
9937942|NCT00961337|Experimental|Vaccination township|Shinwu township was randomly designated as intervention township which freely vaccinated on grade 1-4 and 5-9 students.
9937943|NCT00961337|No Intervention|Control townships|Guanyin township was designated as control township which only provide free vaccination on grade 1-4 students.
9937944|NCT00961363|Experimental|Sitagliptin|Sitagliptin
9937945|NCT00961363|Placebo Comparator|Placebo|Placebo
9937946|NCT00961376|Active Comparator|Cohort A|PBMC re-infusion
9937947|NCT00961376|Experimental|Cohort B|CD25 depletion
9937948|NCT00961389||delirious patients|minimal any positive CAM-ICU score during ICU admission
9937949|NCT00961389||non-delirious patients|without any positive CAM-ICU score during ICU admission
9937950|NCT00961467|Experimental|RMPT (Arm A -thalidomide 50 mg/day)|
9800602|NCT01691898|Experimental|Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
9937951|NCT00961467|Experimental|RMPT (Arm B - thalidomide 100 mg/day)|
9937952|NCT00961480|Active Comparator|Treatment A|50 mg sitagliptin and 500 mg metformin as individual tablets
9937953|NCT00961480|Experimental|Treatment B|sitagliptin/metformin 50 mg/500 mg tablet
9937954|NCT00961480|Active Comparator|Treatment C|50 mg sitagliptin and 1000 mg metformin as individual tablets
9937955|NCT00961480|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
9937956|NCT00961480|Active Comparator|Treatment E|50 mg sitagliptin and 850 mg metformin as individual tablets
9937957|NCT00961480|Experimental|Treatment F|sitagliptin/metformin 50 mg/850 mg tablet
9937958|NCT00961493|Experimental|1|
9937959|NCT00961493|Active Comparator|2|
9937960|NCT00961506|Experimental|LESS cholecystectomy|LESS cholecystectomy
9937961|NCT00961506|Active Comparator|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
9937962|NCT00961558|No Intervention|Observation arm|Patient will not to undergo any form of Assisted Reproductive Technologies for a period of 6 months
9937963|NCT00961558|Other|Surgery Arm|Patients will have varicocelectomy within 1 month of assessment and will not undergo any form of Assisted Reproductive Technologies for a period of 6 months after surgery
9937964|NCT00961597|Experimental|Meniscus repair with PRP|Meniscus repair for tears extending into the red/white region with PRP
9937965|NCT00961597|Active Comparator|Meniscus repair without PRP|
9937966|NCT00961610||Internet support group Intervention|
9937967|NCT00961610||Control group|
9937968|NCT00961727||PEWS System of Care|
9937969|NCT00961740|Other|Cognitive Behavioral Therapy|Design: 49 children (aged 8-12)with obesity was recruited, the children were randomly assigned to a group that started a cognitive behavioural intervention immediately after recruitment, and another group that received the same treatment after a 12-week wait list condition. For further description of the treatment, see summary. Arm 1 (this arm) started receiving a cognitive behavioural intervention immediately after randomization.
9937970|NCT00961740|Other|12-weeks waitlist condition|After an initial pre-assessment no contact were made before assessment after 12-weeks and start of intervention after this assessment. After the 12-week waitlist condition the families were offered the same familibased cognitive behavioral intervention as in arm one.
9937971|NCT00961753|Experimental|Optimized Ibuprofen|
9937972|NCT00961753|Active Comparator|Standard Ibuprofen|
10214413|NCT05224063|Sham Comparator|Sham rTMS|Sham rTMS will be delivered for one session to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
9937973|NCT00961766|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010 or matching placebo
9937974|NCT00961766|Placebo Comparator|Placebo|Participants may be randomized to escalating doses of BG00010 or matching placebo
10214414|NCT05224050|Active Comparator|Heart Rate Variability Biofeedback (HRVB)|Participants will be provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
10214415|NCT05224050|Sham Comparator|Breathing awareness training (BAT)|The sham condition will consist of the exact same treatment; however, instead of engaging in resonance breathing, participants will be asked to follow a pacer, which will be set at pace of a 9-17 breaths per minute, consistent with typical breathing.
9937975|NCT00961779|Placebo Comparator|Placebo (Normal saline infusion)|
9937976|NCT00961779|Experimental|NNZ-2566|NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
9937977|NCT00961831|Experimental|Arm 1|
9937978|NCT00961831|Experimental|Arm 2|
9937979|NCT00961844|Experimental|DC vaccine + Temozolomide|Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.
9937980|NCT00961857|Active Comparator|Treatment A|Individual Tablets of 50 mg sitagliptin and 500 mg metformin
9937981|NCT00961857|Experimental|Treatment B|Sitagliptin/metformin 50 mg/500 mg tablet
9937982|NCT00961857|Active Comparator|Treatment C|Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
9937983|NCT00961857|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
9937984|NCT00961870|Experimental|Healthy postmenopausal women|Forearm vibration will be applied in women without postmenopausal osteoporosis
9937985|NCT00961870|Experimental|Osteoporotic postmenopausal women|Forearm vibration will be applied in women with postmenopausal osteoporosis
9937986|NCT00961870|Experimental|Healthy young adult women|Forearm vibration will be applied in healthy young adult women
9937987|NCT00961870|Experimental|Healthy young adult men|Forearm vibration will be applied in healthy young adult men
9999835|NCT01531517|Experimental|Pedyphar|Ointment
10214416|NCT05224037|Experimental|Study group|This is a single-arm study. All the participants will undergo examinations with 2 devices
9937988|NCT00961883|Experimental|1|Thirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
9937989|NCT00961883|Experimental|2|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
9937990|NCT00961883|Experimental|3|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
9937991|NCT00961883|Experimental|4|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
9937992|NCT00961909|Experimental|1active|
9937993|NCT00961909|Placebo Comparator|1placebo|
9937994|NCT00961909|Experimental|2active|
9937995|NCT00961909|Placebo Comparator|2placebo|
9937996|NCT00961922|Experimental|Neurofeedback|Children in this group receive 30 sessions of neurofeedback
9937997|NCT00961922|Sham Comparator|Placebo feedback|The children in this group receive 30 sessions of placebo feedback, based on muscular tension.
9937998|NCT00961922|No Intervention|Siblings|The siblings will be tested 1 time, they will function as a healthy control group.
9937999|NCT00961974|No Intervention|Standard Care|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
9938000|NCT00961974|Experimental|Care Plus|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
9938001|NCT00961974|Experimental|Care Ultra|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
9476174|NCT03574402|Experimental|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
9476175|NCT03574402|Experimental|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9476176|NCT03574402|Experimental|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9938002|NCT00961987|Experimental|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
9938003|NCT00961987|Active Comparator|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
9938004|NCT00962026|Experimental|Rilonacept|
9938005|NCT00962117||Obese/Non-obese|
9938006|NCT00962130|Experimental|Blood Glucose Measurement|Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed.
9938007|NCT00962143|Active Comparator|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
9938008|NCT00962143|Experimental|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
9938009|NCT00962156|Experimental|HES 130/0.4|Volume expansion
9938010|NCT00962156|Active Comparator|Ringer acetate|Volume expansion
9938011|NCT00962169|Experimental|Quality improvement program|
9938012|NCT00962169|Experimental|Electronic patient device (EPD)|
9938013|NCT00962182|Experimental|Enzyme treatment|Enzyme for 12 weeks
9938014|NCT00962182|Placebo Comparator|Placebo control|Placebo enzyme for 12 weeks
9938015|NCT00962182|Experimental|Enzyme + gluten|Enzyme and 500 mg gluten b.i.d. for 12 weeks
9938016|NCT00962195|Experimental|purple sweet potato juice|Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks
9938017|NCT00962195|Placebo Comparator|Control juice|Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks
9938018|NCT00962221||subclinical hypothyroidism|Patients with subclinical hypothyroidism
9938019|NCT00962234||Metabolism|Lung cancer patients who exhibit abnormalities in lipid measures.
9938020|NCT00962273|Experimental|Pandemic Stress Vaccine - Interactive|
9938021|NCT00962273|Active Comparator|Pandemic Stress Vaccine - Didactic|
9938022|NCT00962273|No Intervention|Wait list|Some participants are assigned to an eight week waiting condition prior to the course commencing.
9938023|NCT00962286|Experimental|Furosemide, obesity, glomerular hyperfiltration|
9938024|NCT00962299|Active Comparator|Beclomethasone|Inhaled corticosteroids
9938025|NCT00962299|Placebo Comparator|Placebo|Placebo Comparator
9938026|NCT00962312|Experimental|Capecitabine and Lapatinib|
9938027|NCT00962325|Experimental|Activity behaviors counseling|
9938028|NCT00962325|No Intervention|Standard care control|6 weeks of standard preoperative care
9938029|NCT00962338||lap. inguinal herniorrhaphy|Patients undergoing planned lap. inguinal herniorrhaphy
9938030|NCT00962351|Other|Metal-on-Polyethylene|
9938031|NCT00962351|Other|Metal-on-Metal, 28mm femoral head|
9938032|NCT00962351|Other|Metal-on-Metal, 36mm femoral head|
9999836|NCT01531517|Active Comparator|Panthenol|Ointment
9999837|NCT01531530|Experimental|Vaccine-recipients|
9999838|NCT01531530|Placebo Comparator|Placebo|
9999839|NCT01531543|Experimental|VAC-laparostomy|Primary use of Vacuum Assisted Closure (VAC) laparostomy after surgical revision because of severe peritonitis
9999840|NCT01531543|No Intervention|Primary abdominal closure|The abdominal wall is primary closed after the surgical revision because of severe peritonitis
9999841|NCT01531569|Experimental|BeneFlax|BeneFlax given as a single oral dose to assess pharmacokinetics
9999842|NCT01531582|Experimental|Children with Angelman Syndrome|Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
9999843|NCT01531595|Experimental|Chemotherapy plus bevazicumab|
9999844|NCT01531621||mCRC treatments|All used treatments for metastatic colorectal cancer
9999845|NCT01531634|Active Comparator|Dynamic Cognitive Intervention Group|Twelve Meetings of Dynamic Cognitive Intervention.
9999846|NCT01531634|No Intervention|No Additional Intervention|
9999847|NCT01531647|Active Comparator|Period 1 Control|
9999848|NCT01531647|Experimental|Period 2 danoprevir/ritonavir|
9999849|NCT01531660|Experimental|training|step up jogging program
9999850|NCT01531712|Experimental|QT + QRT|"Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy)."
9999851|NCT01531751|Experimental|High Cut-off Hemodialysis|
9999852|NCT01531777|Experimental|Apatinib 500mg|500mg,p.o.,qd
9999853|NCT01531777|Experimental|Apatinib 750mg|750mg,p.o.,qd
9999854|NCT01531790|Experimental|Endostar plus pemetrexed/carboplatin|21 days as one cycle, for a total of 4-6 cycles
9999855|NCT01531816|Experimental|Single Arm: Study Intervention|Cycle ergometry and/or Interactive video-game
9999856|NCT01531829|Experimental|Low dose (50mg/2h) rt-PA plus LMWH|Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
9999857|NCT01531829|Active Comparator|LMWH|Low molecular weight heparin
9999858|NCT01531842|Experimental|Topical antibiotic|Patients will be randomized in a 1:1 fashion to receive a drop of topical antibiotic before and after the intravitreal injection in the +ABX arm (in addition to the typical prep with betadine).
9999859|NCT01531842|Other|No Antibiotic Arm|No topical antibiotics in the -ABX arm (only the typical prep with betadine)
9999860|NCT01531855|Other|Insulin dose|Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
9999861|NCT01531868|Other|Auditory qualitative|
9999862|NCT01531868|Other|Auditory absolute risk|
9999863|NCT01531868|Other|Auditory relative risk|
9999864|NCT01531868|Other|Visual qualitative|
9999865|NCT01531868|Other|Visual relative risk|
9999866|NCT01531868|Other|Visual absolute risk|
9999867|NCT01531907||Obese|Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2
9999868|NCT01531907||Lean|Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2
9999869|NCT01531920|Other|alcohol + placebo|Part A alcohol + placebo
9999870|NCT01531920|Other|alcohol + perampanel|Part A : alcohol + perampanel
9999871|NCT01531920|Other|perampanel + alcohol|Part B: perampanel + alcohol
9999872|NCT01531920|Other|placebo + alcohol|Part B: placebo + alcohol
9999873|NCT01531933|Experimental|DLBS3233|
9999874|NCT01531933|Placebo Comparator|Placebo of DLBS3233|
9999875|NCT01531972|Experimental|SEP-228432 (Cohort 1)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days; followed by (steady state) at a dose of 200 mg orally once per day for 5 days.
9999876|NCT01531972|Experimental|SEP-228432 (Cohort 2)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
9999877|NCT01531972|Experimental|SEP-228432 (Cohort 3)|Subjects will receive 40 mg of SEP-228432 (titration) 40 mg of SEP 228432 orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
9999878|NCT01532011|Experimental|Erlotinib + Pralatrexate|"Dose escalation group starting dose: Erlotinib 75 mg by mouth daily for a 28 day cycle. Starting dose of Pralatrexate 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
9999879|NCT01532024|Experimental|Healthy Volunteers|Delivery of intrapulmonary NAP Dose escalation from 5 mcgs to 80mcgs
9999880|NCT01532024|Experimental|Pulmonary Infiltrate in ICU|Delivery of NAP (80mcgs) to ventilated patients with pulmonary infiltrates
9999881|NCT01532024|Experimental|Patients with Bronchiectasis|Delivery of NAP (80mcgs) to patients with bronchiectasis
9999882|NCT01532037|Experimental|Guided Self Help|Participant receives usual care and 4, 45 minute sessions with a therapist to support them to complete the cognitive behavioural therapy based workbook for fatigue in Multiple Sclerosis.
9999883|NCT01532037|Experimental|Pure Self Help|Participant receives usual care and cognitive behavioural therapy based self help work book for fatigue in multiple sclerosis to complete alone
9999884|NCT01532037|Placebo Comparator|Treatment as Usual|Participants receive usual care from healthcare professionals
9999885|NCT01532050|Other|Mandibular Advancement Device (MAD)|Mandibular Advancement Device (MAD)
9999886|NCT01532063|Other|INTUBATION|Subjects intubed in Intensive Care Unit
9999887|NCT01532076|Experimental|cellularized composite graft augmentation|lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
9999888|NCT01532076|Active Comparator|Control acellular composite graft augmentation|open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
9999889|NCT01532102|Experimental|AP611074 5% gel|Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42
9999890|NCT01532102|Placebo Comparator|Placebo gel|Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42
9999891|NCT01532115|Experimental|BIA 9-1067|
9999892|NCT01532115|Placebo Comparator|Placebo|
9999893|NCT01532115|Active Comparator|moxifloxacin|
9999894|NCT01532180|Experimental|THN Therapy|
9999895|NCT01532193|Experimental|Hipoxia|The low oxygen tension group
9999896|NCT01532193|No Intervention|Control group|Conventional culture conditions
9999897|NCT01532206|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning performed with Blood pressure cuff insufflation
9999898|NCT01532206|No Intervention|Standard of care|Standard of care
9999899|NCT01532219|Experimental|Internet-delivered Psychodynamic Treatment|Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
9999900|NCT01532219|Active Comparator|Internet-delivered structured support|Participants in the active control condition will receive a structured support treatment via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail.
9999901|NCT01532232||placebo|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
9999902|NCT01532232||varenicline|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
9999903|NCT01532245|Active Comparator|two-lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
9999904|NCT01532245|Active Comparator|one lung ventillation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
9999905|NCT01532245|Active Comparator|one lung ventilation (OLV) with PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2Opositive end-expiratory pressure (PEEP) were alternated
9999906|NCT01532258|No Intervention|Control Group|No intervention provided. These participants will receive access to the Go! Foods for You program after the research trial has been completed (12 weeks after registration).
9999907|NCT01532258|Active Comparator|GFFY-1 without weekly MA support|Utilization of the 8-week online nutrition program Go! Foods for You without weekly contact from staff at the medical provider's office.
9999908|NCT01532258|Active Comparator|GFFY-2 with weekly MA support|Utilization of the 8-week online nutrition program combined with weekly contact from the staff at the medical provider's office.
9999909|NCT01532271||Concussed|Patients with recent concussion
9999910|NCT01532271||Matched controls|Athletes with no recent concussion
9999911|NCT01532284|Experimental|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
9999912|NCT01532284|No Intervention|No Polar Body Biopsy|
9999913|NCT01532297|Active Comparator|HD treated with standard dialysate|
9999914|NCT01532297|Active Comparator|post-dilution oHDF with standard dialysate|
9999915|NCT01532297|Experimental|pre-dilution oHDF with citrate dialysate|
9999916|NCT01532297|Experimental|HD treated with citrate dialysate|
9999917|NCT01532297|Experimental|post-dilution oHDF with citrate dialysate|
9999918|NCT01532297|Active Comparator|pre-dilution oHDF with standard dialysate|
9999919|NCT01532323|Experimental|Oral disorder children|Oral disorder children aged 2 to 15 years
9999920|NCT01532323|Active Comparator|Control group|No oral disorder children aged 2 to 15 years
9999921|NCT01532336|Experimental|NVC-422 Solution, 0.3%|Dosed for 10 days
9999922|NCT01532336|Placebo Comparator|NVC-422 Vehicle Solution|Dosed for 10 days
9999923|NCT01532375|Experimental|Kochujang(32g)|
9999924|NCT01532375|Placebo Comparator|placebo(32g)|
10034970|NCT01801657||Bronchiectasis,exacerbations|Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
10034971|NCT01801670||MF patients for blood & biopsy|Participants who are cared for at Boston Medical Center will first be assessed by physicians of the CTCL multi-specialty clinic if vorinostat, administered per standard of care, is an appropriate therapy for their CTCL. The decision to invite patients to participate in this study is (1) separate from the above described clinical decision to utilize vorinostat, and (2) will be offered subsequent to the clinical decision to utilize vorinostat. Vorinostat (Zolinza) will be administered as follows: each subject will receive each month for the first 3 months (cycle 1 to 3) 3 capsules of vorinostat 100 mg po daily. For months 4-6 (cycles 4 to 6), subjects will receive each month for 4 capsules of vorinostat 100 mg po daily.
10034972|NCT01801683|Other|Intervention: PEARLS (evidence based reports)|Intervention was modified academic detailing method, performed by sixth-year medical students/academic detailers.Each mentor chose two patients from real life who represented diagnostic, therapeutic or prognostic challenge. The students formed an answerable question, using PICO, and wrote report according to PEARLS.
10034973|NCT01801683|No Intervention|Control group of GPs|GPs not mentors who do not receive academic detailing intervention using PICO/PEARLS.
10034974|NCT01801696|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
10034975|NCT01801696|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
10034976|NCT01801722||NT-proBNP,ejection fraction ,COPD stage.|The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
10034977|NCT01801748|Experimental|oral wheat challenge|
10034978|NCT01801761||develop group|previous COPD study
10034979|NCT01801761||validation group|consecutive COPD patients from outpatient clinics
10034980|NCT01801774|Placebo Comparator|Dexamethasone|Dexamethasone 0.1%/Tobramycin 0.3% eye drop 4 times per day for 28 days
10034981|NCT01801774|Active Comparator|Triamcinolone|Subtenon 20-mg Triamcinolone injection
10034982|NCT01801787|Experimental|verum tDCS|left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
10034983|NCT01801787|Sham Comparator|sham tDCS|left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
10034984|NCT01801800||Aneurysmal subarachnoid haemorrhage|Speckle-tracking images in Echocardiography
10034985|NCT01801813||Neurosurgery for brain tumor patients|Collecting pre-operative and per-operative data, neuro-radiological data and post-operative complications
10034986|NCT01801826||Treatment|Treatment with CryoTouch IV device
10034987|NCT01801839||SIRS,sepsis,normal|"SIRS~(1) temperature > 38 centigrade or < 36 centigrade; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000/μL or < 4000/μL , or > 10% immature cells.~sepsis~SIRS + infection.~normal~not SIRS and have no infection."
10034988|NCT01801852|Experimental|NKT cells|NKT cells treatment plus regular treatment
10034989|NCT01801878|Experimental|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
10214417|NCT05224024|Active Comparator|Retzius-repairing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-repairing technique as prostate cancer patients with robot assisted radical prostatectomy.
10214418|NCT05224024|Placebo Comparator|Retzius-sparing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-sparing technique as prostate cancer patients with robot assisted radical prostatectomy.
10214419|NCT05223998|Experimental|Full-thickness skin microcolumns Implantation|implantation of FTSM on open wound
10034990|NCT01801878|Active Comparator|Normal saline|Normal saline inject to the half of irradiated breast
10034991|NCT01801891|Active Comparator|Control group|Patients randomised to the control group will, in addition to their routine compression bandaging, be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The stimulators given to the control group will be set to provide minimal stimulation resulting in no visible muscular contraction.
10034992|NCT01801891|Experimental|VASGARD stimulator|Patients randomised to this group, in addition to their routine treatment with compression bandaging, will be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The intervention group stimulators will be capable of causing muscular contraction with a maximum force ranging from 30-40% of voluntary contractions.
9938033|NCT00962364||AMI|Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
9938034|NCT00962364||ICM|Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
9938035|NCT00962364||DCM|Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
9938036|NCT00962377|Other|AlloMap Molecular testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
9938037|NCT00962377|Active Comparator|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in the monitoring of asymptomatic heart transplant patients for acute cellular rejection
9938038|NCT00962403|Experimental|Yoga treatment|
9938039|NCT00962403|No Intervention|Waitlist|Waitlist control, no active treatment, treatment as usual, active treatment offered after waitlist control period. This study began as a single arm treatment trial and then transitioned to a randomized controlled trial.
9938040|NCT00962416|Active Comparator|1|Biolimus eluting Stent (Biomatrix)
9938041|NCT00962416|Active Comparator|2|Bare metal stent (Gazelle)
9938042|NCT00962442|Active Comparator|nutritional support + N-Acétylcysteine|N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
9938043|NCT00962442|Placebo Comparator|nutritional support + placebo|placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
9938044|NCT00962455|Experimental|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
9938045|NCT00962455|Active Comparator|Usual practice|Usual practice regarding spirometry execution in family practice
9938046|NCT00962468|Experimental|Pathway|A care pathway will be implemented in this experimental group.
9938047|NCT00962468|No Intervention|Usual care|Usual care will be provided.
9938048|NCT00962481|Active Comparator|Bimosiamose|
9938049|NCT00962481|Placebo Comparator|Placebo|
9938050|NCT00962494|Experimental|online workshop|
9938051|NCT00962533|Experimental|ROADMAP Group (Group I)|"Patients were to take telbivudine 600 mg orally daily from Baseline.At Week 24, patients in Group I were split into Group I-A or Group I-B based on their virologic load:~Group I-A: This group of patients was those with HBV DNA ≥300 copies/mL at Week 24 and adefovir was to be added at Week 28;~Group I-B: This group of patients was those with HBV DNA <300 copies/mL at Week 24. Telbivudine monotherapy was to be continued until there was a viral breakthrough (confirmed by two examinations with at least 1 month interval with compliance factor excluded) and then adefovir was to be added;~The total treatment duration was 104 weeks."
9938052|NCT00962533|Active Comparator|SOC (Standard of Care) Group (Group II)|patients were to take telbivudine 600 mg monotherapy from Baseline until Week 104. If viral breakthrough (defined as HBV DNA 1 log10 above nadir) was confirmed (by two examinations with at least a 1 month interval with compliance factor excluded), adefovir 10 mg daily was to be added.
9938053|NCT00962546||CTA/CTP|Patients undergo CTA/CTP imaging prior to cerebral angiography
9938054|NCT00962611|Experimental|Copanlisib|
9938055|NCT00962637|Experimental|1|Androxal™ 12.5 mg
9938056|NCT00962637|Experimental|2|Androxal™ 25 mg
9938057|NCT00962637|Active Comparator|3|AndroGel®
9938058|NCT00962637|Placebo Comparator|4|Placebo
9938059|NCT00962663|Experimental|ICA-105665|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
9938060|NCT00962663|Active Comparator|Ibuprofen|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
9938061|NCT00962663|Placebo Comparator|Placebo|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
9938062|NCT00962676||immunocompromised group|
9938063|NCT00962676||non-immunocompromised group|
9938064|NCT00962689||Chronic Rhinosinusitis|Patients with chronic rhinosinusitis as defined by American Academy of Otolaryngology-Head and Neck Surgery and American Rhinologic Society guidelines
9938065|NCT00962689||Control Group|Patients undergoing endoscopic sinus surgery for diseases other than chronic rhinosinusitis (i.e., access to pituitary gland, etc)
9938066|NCT00962702|Experimental|Exclusion of Left Atrial Appendage|Exclusion of Left Atrial Appendage
9938067|NCT00962715|Experimental|TIV|TIV (Influenza Vaccine Trivalent Inactivated) alone
9938068|NCT00962715|Experimental|TIV + PEGrIFN-α|TIV + Pegylated Interferon
9938069|NCT00962715|Experimental|TIV + IFNα|TIV + Interferon
9938070|NCT00962767|Experimental|a|2 doses of gemtuzumab ozogamicn administered at monthly intervals
9938071|NCT00962767|Active Comparator|b|2 years maintenance therapy with intermittent ATRA plus 6-Mercaptopurine (6-MP) and methotrexate (MTX)
9938072|NCT00962806|Active Comparator|Exercise|8 week intensive exercise group
9938073|NCT00962806|Other|Control Lifestyle counseling|Lifestyle counseling without intensive exercise
9938074|NCT00962819||cross-sectional|College-aged students who were immunized with MMR.
9938075|NCT00962845|Experimental|Hydroxychloroquine|Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patients will undergo resection of their tumors. HCQ will be given to the patients up to the day of the operation but not resumed postoperatively.
9938076|NCT00962897||Surgical Bypass Group|Those patients that underwent bypass of blockage in the thigh with surgery.
9938077|NCT00962897||Stent-graft group|Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
9938078|NCT00962910|Experimental|Pathway|A care pathway will be implemented in this experimental group.
9938079|NCT00962910|No Intervention|Usual Care|Usual Care will be provided.
9938080|NCT00962936|Experimental|CT-011|
9938081|NCT00962962|Other|Low-Amount/Moderate Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
9938082|NCT00962962|Other|High-Amount/Moderate-Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
9938083|NCT00962962|Other|High-Amount/Vigorous-Intensity Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
9938084|NCT00962962|Other|Low-Amount/Moderate-Intensity Exercise + Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The CLI sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
9938085|NCT00962975|Experimental|Single Arm|
9938086|NCT00963040|Experimental|Syntocinon®|
9938087|NCT00963040|Placebo Comparator|Sterile water|
9938088|NCT00963066|Active Comparator|Pressure Support ventilation|
9938089|NCT00963066|Experimental|NAVA flow triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with flow triggering
9999925|NCT01532401|Experimental|chlorure de sodium|
9476177|NCT03574402|Experimental|Arm5: X396|Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
9938090|NCT00963066|Experimental|NAVA EMG triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram
9938091|NCT00963079|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
9938092|NCT00963079|Active Comparator|Fresh blastocyst transfer|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
9938093|NCT00963118|Placebo Comparator|placebo|Rice powder based nutrition bar
9938094|NCT00963118|Experimental|Angelica keiskei|Angelica keiskei (green leafy vegetable) based nutrition bar
9938095|NCT00963118|Experimental|Glycine max|Glycine max (black soybeans) based nutrition bar
9938096|NCT00963118|Experimental|Angelica keiskei + Glycine max|Angelica keiskei (green leafy vegetable) and glycine max (black soybeans) based nutrition bar
9938097|NCT00963131|Experimental|antioxidant tablets|the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
9938098|NCT00963131|Placebo Comparator|placebo tablets|the control arm received placebo tablets for 3 months or until the resolution of the disease
9938099|NCT00963183|Experimental|A|Drug: AZD5423
9938100|NCT00963183|Placebo Comparator|B|Drug: Placebo
9938101|NCT00963196|Active Comparator|One unsuccessful trial|Patients with one unsuccessful previous antidepressant trial
9938102|NCT00963196|Active Comparator|One successful trial|Patients with one previous successful antidepressant trial
9938103|NCT00963196|Active Comparator|No previous trial|Patients with no prior antidepressant therapy
9938104|NCT00963209|Experimental|Tamoxifen|
9938105|NCT00963222|Active Comparator|with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
9938106|NCT00963222|Placebo Comparator|with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
9938107|NCT00963222|Active Comparator|without atherosclerosis/ vitamin A|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
9938108|NCT00963222|Placebo Comparator|without athrosclerosis/ placebo|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive placebo
9938109|NCT00963261|Experimental|psycho-oncological intervention|stepped care psycho-oncological intervention
9938110|NCT00963261|No Intervention|control group|
9938111|NCT00963274|Experimental|bortezomib + romidepsin|Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks. In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
9938112|NCT00963287|Experimental|bascial prescription|Decoction ,two times a day,one bag of decoction one time
9938113|NCT00963287|Placebo Comparator|low does of bascial decoction|Decoction ,two times a day, one bag decoction of one time
9938114|NCT00963313||Adalimumab, injection|Adalimumab, one injection every fourteen days during 24 weeks.
9938115|NCT00963339||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
9938116|NCT00963352||Patients operated for colon cancer|
9938117|NCT00963365|Experimental|AZD6765 oral solution|Active
9938118|NCT00963365|Experimental|AZD6765 IV infusion|Active
9938119|NCT00963365|Placebo Comparator|Placebo to AZD6765 oral solution|Placebo
9938120|NCT00963365|Placebo Comparator|Placebo to AZD6765 IV infusion|Placebo
9938121|NCT00963391|Experimental|ABHS use|Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). Proper safety measures were followed. Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
9938122|NCT00963391|No Intervention|No treatment|Centers assigned to the control group received no hand hygiene recommendations other than to continue with current hand hygiene practices and no further information on hand hygiene other than the general information received before trial initiation was provided.
9938123|NCT00963404|Experimental|Tumor-boost|Image-guided tumorboost of the bladder cancer.
9938124|NCT00963417|Active Comparator|Triptorelin plus tamoxifen|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.
9999926|NCT01532401|Placebo Comparator|Methylcellulose|
10034993|NCT01801904|Experimental|Panitumumab|
9938125|NCT00963417|Experimental|Triptorelin plus exemestane|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.
9938126|NCT00963443|Experimental|Arm 1|
9938127|NCT00963443|Active Comparator|Arm 2|
9938128|NCT00963443|Active Comparator|Arm 3|
9938129|NCT00963443|Placebo Comparator|Arm 4|
9938130|NCT00963495|Experimental|Clioquinol|Patients will take Clioquniol at various doses depending on which dose level they come into the study at. Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
9938131|NCT00963534|Experimental|lenalidomide, bendamustine, rituximab|
9938132|NCT00963573|Experimental|loratadine/betamethasone oral solution|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
9938133|NCT00963586||HNC Maastricht|Patients treated for HNC in the University Hospital Maastricht/MAASTRO clinic, the Netherlands
9938134|NCT00963586||HNC Groningen|Patients treated for HNC in the University Medical Center Groningen, the Netherlands
9938135|NCT00963612|Other|Single Arm|"In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver BOLD-MRI before hepatic resection."
9938136|NCT00963625|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
9938137|NCT00963625|Active Comparator|Fresh blastocyst transfer.|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
9938138|NCT00963651||Suspicion of pulmonary nodules|Eligible participants will include those referred for x-ray computed tomography (CT) of the chest for suspicion of a pulmonary nodule or other unrelated reasons.
9938139|NCT00963664|Experimental|Interferon and lovastatin treatment|Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
9938140|NCT00963690|Experimental|CloSys HD with standard compression|CloSys Arm
9938141|NCT00963690|Active Comparator|Standard compression alone|Manual compression arm
9938142|NCT00963703|Experimental|Rituximab|
9938143|NCT00963716|Experimental|Hot biopsy|Hot biopsy i.e. Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
9938144|NCT00963716|Active Comparator|Cold biopsy|Cold biopsy i.e. Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
9938145|NCT00963729|Experimental|Arm I|Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9938146|NCT00963729|Experimental|Arm II|Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
9938147|NCT00963742|Experimental|Lenstec Softec HD IOL implantation|390 eyes of 390 study subjects all receiving the investigational IOL; IOL implanted after surgical removal of cataract
9938148|NCT00963755||Primary prostate cancer|Patients referred with a suspicion of prostate cancer based on elevated PSA and rectal examination in whom a prostate biopsy is planned and radical prostatectomy is envisioned in the event of a positive biopsy finding
9938149|NCT00963755||Prostate cancer relapse|Patients previously treated for prostate cancer and being investigated for biochemical relapse, (mostly in the Urology and Radiation Therapy Department, but not exclusively), for whom surgical or radiation therapy is envisioned in the event of a positive FCH-PET finding
9938150|NCT00963768|Experimental|Cohort 1|JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
9938151|NCT00963768|Experimental|Cohort 2|JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
9938152|NCT00963768|Experimental|Cohort 3|JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
9938153|NCT00963768|Experimental|Cohort 4|JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
9938154|NCT00963768|Experimental|Cohort 5|JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
9999927|NCT01532466|Experimental|Rocuronium, fentanyl-induced cough, normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
9999928|NCT01532466|No Intervention|Normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
9999929|NCT01532479||Treatment Group|Subjects with ORN treated with Hyperbaric Oxygen Therapy
9999930|NCT01532479||Postive Control Group|Subjects treated with Hyperbaric Oxygen Therapy that have not had head or neck radiation therapy
9999931|NCT01532479||Negative Control Group|Subjects who have had head and neck radiation that have not had Hyperbaric Oxygen Therapy
9999932|NCT01532492||Rotator cuff repair group|Patients undergoing an arthroscopic rotator cuff repair
9999933|NCT01532492||DRC without rupture|Disorders of the rotator cuff without rupture
9800603|NCT01691898|Experimental|Cohort C (FL): RTX + Polatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
9999934|NCT01532492||Shoulder instability|Shoulder instability
9999935|NCT01532518|Experimental|Cohort 3|Nepadutant low dose for 7 days followed by Nepadutant high dose for additional 7 days
9999936|NCT01532518|Experimental|Cohort 2|Nepadutant medium dose for 7 days followed by Nepadutant high dose for additional 7 days
9999937|NCT01532518|Experimental|Cohort 1|Nepadutant low dose for 7 days followed by Nepadutant medium dose for additional 7 days
9999938|NCT01532531|Experimental|Collateral Meridian Therapy|"The CMT group patients received, according to the CMT protocol described previously, CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
9999939|NCT01532531|No Intervention|Control (CT) group|Patients in the CT group received electronic lead-patches applied on the treatment points, which was identical to what the CMT patients received, also for 6 minutes, though no electric stimulation was applied.
9999940|NCT01532544|Experimental|Integrilin and Ilomedin given as continous infusion|
9999941|NCT01532544|Placebo Comparator|Standard treatment daily doses of low molecular weight heparin|Standard treatment daily doses of low molecular weight heparin.
9999942|NCT01532583||Patients operated on with the TOT|
9999943|NCT01532596|Experimental|Mindfulness-Based Stress Reduction|A standardized 8-week mindfulness meditation training program
9999944|NCT01532596|No Intervention|Wait-List|
10034994|NCT01801943|Experimental|Cognitive Remediation Therapy Group|30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
9938155|NCT00963781|Experimental|Six months DAPT|All patients will be assigned to 6 months of DAPT
9938156|NCT00963794|Other|Electromagnetic measurement|Electromagnetic measurement to detect rectal cancer.
9938157|NCT00963833||Group 1|
9938158|NCT00963846|Placebo Comparator|placebo|
9938159|NCT00963846|Experimental|huperzine 0.2 mg BID|
9938160|NCT00963846|Experimental|huperzine 0.4 mg BID|
9938161|NCT00963846|Experimental|huperzine 0.8 mg BID|
9938162|NCT00963898|Experimental|Mental Retardation|
9938163|NCT00963950|Experimental|Intervention group|transvaginal cholecystectomy
9938164|NCT00963950|Active Comparator|laparoscopic cholecystectomy|Laparoscopic cholecystectomy (4 port)
9938165|NCT00963963|Active Comparator|health promotion materials|Parents receive health promotion booklets
9938166|NCT00963963|Active Comparator|attention-controlled parent print materials|Booklets on adolescent sexuality and health
9938167|NCT00963963|Experimental|audio-CD parent education|audio-CDs on parenting practices
9938168|NCT00963976|Experimental|Target systolic BP < 150 mmHg|Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.
9938169|NCT00963976|Active Comparator|Target systolic BP < 180 mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
9938170|NCT00964015|Active Comparator|Starch group|Patients randomized to the Starch group will receive Voluven (6% Hydroxyethyl Starch 130/0.4) for their intravenous bolus and fluid resuscitation requirements.
9938171|NCT00964015|Active Comparator|Saline group|Patients randomized to the Saline group will receive 0.9% Normal Saline for their intravenous fluid bolus and resuscitation requirements
9938172|NCT00964041|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before any assessments, for eight weeks.
9938173|NCT00964041|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before any assessments, for eight weeks.
9938174|NCT00964054|Experimental|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
9938175|NCT00964054|Active Comparator|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
9938176|NCT00964067|Active Comparator|Treadmill group|Interval exercise performed on treadmills, supervised
9938177|NCT00964067|Active Comparator|Exercise groups|Supervised and organised in groups of ten
9938178|NCT00964067|Active Comparator|home-based exercise|Interval training at home, free choice of modality
9938179|NCT00964080|Experimental|Study of MBP-426/leucovorin/5-FU|Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
9938180|NCT00964093|No Intervention|No intervention|
9938181|NCT00964106|Experimental|Probe drugs|"Caffeine 100 mg CYP1A2 Pioglitazone 15 mg CYP2C8 Flurbiprofen 40 mg CYP2C9 Omeprazole 20 mg CYP2C19 Dextromethorphan 45 mg CYP2D6 Midazolam 3 mg (Part 1, Part 2 Cohorts B and C)~1 mg (Part 2 Cohort A) CYP3A4/5 Rosuvastatin 10 mg OATP1B1"
9999945|NCT01532609|Experimental|Intervention|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
9938182|NCT00964106|Experimental|Default Inhibitors|A Ketoconazole 400 mg once-daily Day 1 through Day 9 CYP3A4 B Fluconazole 400 mg x1 dose on Day 1 200 mg once-daily Day 2 through Day 9 CYP2C9 C Rifampin 600 mg x1 dose on Day 1 and Day 8 OATP1B1
9938183|NCT00964132|Experimental|NRX194204|
9938184|NCT00964145||Nulliparous female patients|Nulliparous female patients ages 21-70 years old.
9938185|NCT00964184|Experimental|Drug|1 gm metformin per day
9938186|NCT00964184|Other|control|lifestyle intervention
9938187|NCT00964197|Experimental|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
9938188|NCT00964236||Sapropterin|Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
9938189|NCT00964236||Control|Healthy individuals without phenylketonuria (PKU).
9938190|NCT00964249|Experimental|LABA|After randomization subject will inhale either 12.5 microgram or 25 microgram GW642444M once daily for 7 days.
9938191|NCT00964249|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
9999946|NCT01532609|No Intervention|Standard care|No additional training or service is provided for standard care group service providers or clients.
9999947|NCT01532622|Active Comparator|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days.
9938192|NCT00964262|Experimental|SR Exenatide (PT302)|Intervention: Drug: SR Exenatide (PT302)
9938193|NCT00964275|Experimental|Arm I|Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
9938194|NCT00964275|Active Comparator|Arm II|Patients only undergo standard diagnostic methods.
9938195|NCT00964288|Other|Period 1|
9938196|NCT00964288|Other|Period 2|
9938197|NCT00964288|Other|Period 3|
9938198|NCT00964288|Other|Period 4|
9938199|NCT00964301|Experimental|Intervention Group|Participants, caregivers and school nurse will attend telemedicine education sessions at school.
9938200|NCT00964301|Active Comparator|Usual care|Usual care participant will receive routine care from their primary care provider.
9938201|NCT00964314|Experimental|five elements music|Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
9938202|NCT00964314|Active Comparator|western music|Listening western music based on conventional therapy in China.
9938203|NCT00964314|No Intervention|Without music|no music therapy will be done in the arm.
9938204|NCT00964340|Placebo Comparator|Placebo|The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
9938205|NCT00964340|Active Comparator|0.5g SRT2104|The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
9938206|NCT00964340|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
9938207|NCT00964379|Active Comparator|intraperitoneal colostomy|
9938208|NCT00964379|Active Comparator|extraperitoneal colostomy|
9938209|NCT00964405|Experimental|LAMA|After randomization subject will inhale either GSK233705 50, 100 or 200 microgram once daily for 7 days.
9938210|NCT00964405|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
9938211|NCT00964418|Experimental|IDeg|
9938212|NCT00964418|Active Comparator|IGlar|
9938213|NCT00964457|Active Comparator|Capecitabine, oxaliplatin|
9938214|NCT00964457|Active Comparator|capecitabine, oxaliplatin and cetuximab|capecitabine, oxaliplatin ane cetuximab
9938215|NCT00964483|Experimental|DASH materials|Participant randomized to a 12-week, group-based lifestyle intervention using modified DASH materials and intervention delivery approaches to help them adopt the DASH diet. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium.
9938216|NCT00964483|Active Comparator|Delayed intervention|"The intervention participants will receive an NHLBI brochure entitled Your Guide to Lowering Blood Pressure. They will then receive the modified DASH materials and the intervention at the end of the study, following the intervention group's completion of the study."
9938217|NCT00964522|No Intervention|Standard care|The arm A is the one of standard education and care.
9938218|NCT00964522|Active Comparator|Nurse education and care program|The arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation.
9938219|NCT00964535|Experimental|Budesonide/formoterol Easyhaler|
9938220|NCT00964535|Experimental|Charcoal and Budesonide/formoterol EH|
9938221|NCT00964535|Active Comparator|Symbicort Turbohaler|
9938222|NCT00964535|Active Comparator|Charcoal and Symbicort Turbohaler|
9938223|NCT00964561|Experimental|Ciprofloxacin and Valortim|First two subjects to receive treatment arm of Ciprofloxacin and Valortim. Total of sixteen volunteers to be randomized to receive Ciprofloxacin and Valortim.
9938224|NCT00964561|Experimental|Placebo Antibiotic and Valortim|Randomized such that four subjects to receive Placebo Antibiotic and Valortim.
9938225|NCT00964561|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that 4 subjects to receive Placebo Antibiotic and Placebo Valortim.
9938226|NCT00964574|Experimental|APIDRA + LANTUS basal|The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12
9938227|NCT00964587|Active Comparator|Usual Care|Packet of standard print patient education materials on CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA).
9938228|NCT00964587|Experimental|Self Study|One 90-minute educational session. Print materials and DVDs for self-study
9938229|NCT00964587|Experimental|Group Problem-Solving Training|One 90-minute education session. Group problem-solving training (eight, 90-minute sessions)
9938230|NCT00964587|Experimental|Individual Problem-Solving Training|One 90-minute education session. Individual problem-solving training (eight, 60-minute sessions)
9938231|NCT00964600|Experimental|TAP blockade|bilateral TAP blockade at the end of cesarean delivery
9938232|NCT00964600|No Intervention|No TAP|These patients would have usual analgesic drugs after cesarean
9938233|NCT00964639|Placebo Comparator|Saline|
9938234|NCT00964639|Active Comparator|Naropin|
9938235|NCT00964652|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
9938236|NCT00964665|Experimental|Group 1 ABF656 900ug Q2w|
9938237|NCT00964665|Experimental|Group 2 ABF656 900ug Q4w|
9938238|NCT00964665|Experimental|Group 3 AB656 1200ug Q4w|
9938239|NCT00964665|Experimental|Group 4 ABF656 1500ug Q4w|
9938240|NCT00964665|Active Comparator|Group 5 Pegasys® 180µg qw|
9938241|NCT00964691|Active Comparator|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
9938242|NCT00964691|Active Comparator|IPTp with Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
9938243|NCT00964704|Experimental|Single Arm|
9938244|NCT00964717|Active Comparator|Chiropractic|Real Chiropractic treatment
9938245|NCT00964717|Sham Comparator|Sham Chiropractic|stimulation utilizing 'activator' thumper
9938246|NCT00964717|No Intervention|No treatment|No add on therapy - patients lay down for a period of 15 minutes without any treatment or intervention
9938247|NCT00964730|Experimental|Talampanel|
9938248|NCT00964730|Placebo Comparator|Placebo|
9938249|NCT00964730|Other|Moxifloxacin|
9938250|NCT00964756|Experimental|Gene therapy|
9938251|NCT00964769|Experimental|Pneumococcal polysaccharide vaccine|The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
9938252|NCT00964808|Experimental|Buprenorphine|Double dummy; Group A: Active Buprenorphine and placebo oxycodone
9938253|NCT00964808|Experimental|Oxycodone|"Double Dummy:~Group B: Placebo Buprenorphine and Active Oxycodone"
9938254|NCT00964821||Flu vaccine|Patients and normal volunteers who have received a flu vaccine
9938255|NCT00964821||Non-vaccine|Patients and normal volunteers who have not received the flu vaccine
9938256|NCT00964834|Experimental|Doxycycline and Valortim|Randomized such that sixteen volunteer subjects to be renadomized to receive Doxycycline and Valortim
9938257|NCT00964834|Experimental|Placebo Antibiotic and Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Valortim.
9938258|NCT00964834|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Placebo Valortim.
9938259|NCT00964847|Active Comparator|Blood pressure education/walking program|
9938260|NCT00964847|Active Comparator|Combined intervention|
9938261|NCT00964847|Experimental|Yoga Exercise Program|
9938262|NCT00964873|Experimental|1 Part 1|
9938263|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 1)|
9938264|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 2)|
9938265|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 3)|
9938266|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 4)|
9938267|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 5)|
9938268|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 6)|
9938269|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 7)|
9938270|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 8)|
9938271|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 9)|
9938272|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel A)|
9938273|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel B)|
9938274|NCT00964951|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
9476178|NCT03574402|Experimental|Arm6: X396|Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
9476179|NCT03574402|Experimental|Arm7: Pyrotinib Maleate|Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
9938275|NCT00964951|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
9938276|NCT00964951|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
9938277|NCT00964951|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
9938278|NCT00964951|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
9938279|NCT00964964|Experimental|SIBA 3W|
9938280|NCT00964964|Experimental|SIBA OD|
9938281|NCT00965003|Experimental|MRI scan with surface coil|Patients with known laryngeal cancer, with suspected cartilage involvement by conventional computed tomography scanning, who undergo high resolution magnetic resonance imaging enhanced with a surface coil placed over the larynx.
9938282|NCT00965016|Sham Comparator|No Hypothermia, No intervention, ECMO|No hypothermia used during ECPR
9938283|NCT00965016|Active Comparator|Hypothermia, intervention, ECMO|Hypothermia + intervention
9938284|NCT00965016|Active Comparator|Hypothermia, no intervention, ECMO|Hypothermia without intervention after ECMO
9938285|NCT00965042|Experimental|Ceftobiprole|Ceftobiprole 500 mg by 2 hour intravenous infusion every 8 hours for 7 days
9938286|NCT00965107|Experimental|Thiopental|Thiopental for induction of anaesthesia.
9938287|NCT00965107|Active Comparator|Propofol|Propofol for induction of anaesthesia.
9938288|NCT00965120|Placebo Comparator|1|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).
9938289|NCT00965120|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).
9938290|NCT00965133|No Intervention|Normal daily activity|
9938291|NCT00965172|Experimental|Caphosol|Caphosol (calcium phosphate)
9938292|NCT00965172|Active Comparator|Baking Soda|Control Group (standard of care)
9938293|NCT00965198||Clearlink Arm, EUH|Standard catheter access device at Emory University Hospital
9938294|NCT00965198||VLINK Arm, EUHM|Novel, silver-coated catheter access device at Emory University Hospital Midtown
9938295|NCT00965198||Clearlink, EUM|Standard catheter access device at at Emory University Hospital Midtown
9938296|NCT00965198||VLINK Arm, EUH|Novel, silver-coated catheter access device at Emory University Hospital
9938297|NCT00965224|Experimental|standard therapy + vaccination|
9938298|NCT00965224|No Intervention|standard therapy|
9938299|NCT00965289|Experimental|HDT combined with rituximab before ASCT|The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
9938300|NCT00965302|Active Comparator|Intensive medical management of Type 2 DM|Intensive medical management of Type II diabetes will include visits every three months for a year with an endocrinologist, with lifestyle counseling, weight management, regular exercise, and glucose control forming the core of the medical therapy.
9938301|NCT00965302|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as part of a bariatric surgical program emphasizing healthy dietary choices, regular exercise, and glucose control.
9938302|NCT00965328|Active Comparator|hemofiltration at 4L/h|Hemofiltration was started at 4L/h and crossed over to 2L/h after 60 minutes of hemofiltration
9938303|NCT00965328|Active Comparator|hemofiltration at 2L/h|hemofiltration was started at 2L/h and crossed over to 4L/h after 60 min
9938304|NCT00965354||Influenza diagnosis|Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
9938305|NCT00965367|Experimental|Acustimulation|
9938306|NCT00965367|No Intervention|Standard treatment group|
9938307|NCT00965393|Placebo Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of placebo (saline).
9938308|NCT00965393|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of bradykinin receptor antagonist (HOE-140).
9938309|NCT00965406|Placebo Comparator|glucose insulin potassium (GIK)|Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
9938310|NCT00965406|Experimental|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
9938311|NCT00965406|No Intervention|Control group|No intervention and patients were treated with updated international recommendations of acute coronary syndrome.
9938312|NCT00965432|Placebo Comparator|Placebo|
9938313|NCT00965432|Active Comparator|STX107|
9476180|NCT03574402|Experimental|Arm8: AZD3759|EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
9476181|NCT03574402|Experimental|Arm9: Pirotinib|"Patients with EGFR20ins mutation positive receive Pirotinib.~This arm was divided into three groups:~Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2."
9938314|NCT00965445||cardiac surgery with CPB|
9938315|NCT00965471|Experimental|managed group|
9938316|NCT00965471|Placebo Comparator|control group|
9938317|NCT00965510|Experimental|Care Coordination|Patients receive care coordination to improve their diabetes.
9938318|NCT00965510|No Intervention|control|patients with type II diabetes receive usual health care
9938319|NCT00965536||1|Seroquel
9938320|NCT00965536||2|Seroquel Prolong
9938321|NCT00965549|Experimental|Lantus + Apidra basal plus one|"Before randomization (common with arm 2):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day"
9938322|NCT00965549|Active Comparator|NovoMix 30 Biphasic|"Before randomization (common with arm 1):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)"
9938323|NCT00965588|Experimental|Vaccine (UB 311)|
9938324|NCT00965601|Active Comparator|CTB Group|Subjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
9938325|NCT00965601|No Intervention|Usual Care|Subjects will not receive any type of intervention
9938326|NCT00965653|Experimental|1|
9938327|NCT00965653|Active Comparator|2|
9938328|NCT00965666|Experimental|Open Label|
9938329|NCT00965705|Active Comparator|Guided Self Help|
9938330|NCT00965705|Active Comparator|Cognitive Behavioral Therapy|
9938331|NCT00965705|Active Comparator|Dialectical Behavioral Therapy|
9938332|NCT00965744|Experimental|Vessel sealing system LigaSure (VS group)|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
9938333|NCT00965744|No Intervention|Conventional hand-tied method (CH group)|Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
9938334|NCT00965770||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
9938335|NCT00965783|Experimental|1|Sleep time restriction
9938336|NCT00965783|Experimental|2|Sleep time extension
9938337|NCT00965796|Experimental|Lidocaine, pain intensity and Saline|(2 mg/kg/h) and patients of group 2 (n = 20) received 0.9% saline infusion throughout the surgical procedure
9938338|NCT00965809|Experimental|ACTIVE THC|Subjects will take 5MG of THC in 6 drops of olive oil orally.
9938339|NCT00965809|Placebo Comparator|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
9938340|NCT00965822|Active Comparator|1|
9938341|NCT00965822|Placebo Comparator|2|
9938342|NCT00965835||DS|Those with Down syndrome
9938343|NCT00965835||Non-DS|Healthy controls
9938344|NCT00965861||1|The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
9938345|NCT00965874|Experimental|Magnesium Sulfate high dose infusion|9 g Magnesium sulfate infusion over 30 minutes
9938346|NCT00965874|Active Comparator|Magnesium Sulfate low dose infusion|4.5 magnesium sulfate infusion over 30 minutes
9938347|NCT00965874|Placebo Comparator|placebo|serum salin
9938348|NCT00965887|Active Comparator|1|MK0974 Ethanolate
9938349|NCT00965887|Active Comparator|2|MK0974 Hydrate
9938350|NCT00965900|Active Comparator|Endoscopic band ligation|Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
9938351|NCT00965900|Active Comparator|Propranolol|start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
9938352|NCT00965900|Active Comparator|EBL+Propranolol|"EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment~start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
9938353|NCT00965913|Experimental|Three Interventions on Lower Back|Three treatments were applied on the lower back, according to treatment sequence, daily for 21 days
9938354|NCT00965926|Experimental|Low dose group|3 way cross-over. Fasting, normal diet and high-fat diet
9938355|NCT00965926|Experimental|High dose group|3 way cross-over. Fasting, normal diet and high-fat diet
9938356|NCT00965965|Experimental|Experimental patient education document|
9938357|NCT00965965|Active Comparator|Traditional patient education document|
9938358|NCT00965978|Experimental|Low dose group|Receives low dose of ONO-5920/YM529 with and without food
9938359|NCT00965978|Experimental|High dose group|Receives high dose of ONO-5920/YM529 with and without food
9938360|NCT00965991|Active Comparator|Metformin|
9938361|NCT00965991|Active Comparator|Glyburide|
9999948|NCT01532622|Placebo Comparator|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
9999949|NCT01532661||observational study|haemorrhagic trauma received rFVIIa
9999950|NCT01532674|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy and scaling and root planing
9999951|NCT01532674|Active Comparator|scaling and root planing|Only scaling and root planing
9999952|NCT01532713|Experimental|non-block side|
9999953|NCT01532726||Eslicarbazepine Acetate (ESL)|ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
9999954|NCT01532739|Experimental|Cognitive training|
9999955|NCT01532739|No Intervention|No cognitive training|
9999956|NCT01532765|Active Comparator|Epiretinal Membrane Surgery without ILM peel|
9999957|NCT01532765|Active Comparator|Epiretinal Membrane Surgery with ILM peel (ICG assisted)|
9999958|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery without ILM peel|
9999959|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery with ILM peel (ICG assisted)|
9999960|NCT01532791||mtDNA mutation|m.3243 A>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
9999961|NCT01532791||Control|controls (people not maternally related to mutation carriers) Preference is for married in relatives
9999962|NCT01532804|Experimental|Arm A|FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
9999963|NCT01532804|Experimental|Arm B|Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)
9999964|NCT01532843|Active Comparator|PegIFN alfa-2b + nucleos(t)ide analogue|Peginterferon alfa-2b 1.5 μg/kg per week s.c. for 48 weeks in addition to standard nucleos(t)ide analogue treatment
9999965|NCT01532843|No Intervention|Nucleos(t)ide analogue|Continuation of Nucleos(t)ide analogue mono-therapy
9999966|NCT01532856|Active Comparator|Group A induction therapy|Thalidomide + Cyclophosphamide + Dexamethasone
9528819|NCT03207295|Experimental|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
9999967|NCT01532856|Active Comparator|Group B induction therapy|thalidomide + dexamethasone
9999968|NCT01532856|Active Comparator|Group C induction therapy|thalidomide + melphalan + prednisone
9999969|NCT01532882|Experimental|Diosmin|
9999970|NCT01532882|Placebo Comparator|Placebo|
9938362|NCT00966004|Experimental|YM178 group|oral
9938363|NCT00966004|Placebo Comparator|Placebo group|oral
9938364|NCT00966004|Active Comparator|tolterodine group|oral
9938365|NCT00966017||DS|Those with Down syndrome
9938366|NCT00966017||Non-DS|Healthy controls
9938367|NCT00966030|Experimental|1|MK0974 Tablet
9938368|NCT00966030|Active Comparator|2|MK0974 Liquid filled capsule
9938369|NCT00966056|Active Comparator|Mitomycin C|Cases recruited into this arm receive topical application of mitomycin c (1mg/ml)following surgical synechiolysis
9938370|NCT00966056|Active Comparator|Teflon septal splint|Cases recruited into this arm receive insertion of teflon internal nasal septal splint following surgical synechiolysis
9938371|NCT00966069|Active Comparator|Healthcare worker visit|"Healthcare worker performs home visit when study child has acute respiratory illness to collect a respiratory swab (nasopharyngeal swab).~At the healthcare worker home visit, the HCW will collect the nasopharyngeal swab, and a parent will collect an anterior nasal swab. The HCW swab is to be returned immediately to the laboratory, and the parent collected swab was placed in a post box for return to the laboratory by surface mail."
9938372|NCT00966069|Experimental|Parent collection|Home collection of respiratory swab (anterior nose) and mailed return when study subject has an acute respiratory illness.
9999971|NCT01532895||Hydromorphone HCI OROS|
9999972|NCT01532947|Experimental|post restoration|
9999973|NCT01532947|No Intervention|no post restoration|no post placement
9999974|NCT01532960|Experimental|9 Peptides from Her-2/neu, CEA, & CTA, peptide-tet, poly-ICLC|9 class I MHC-restricted synthetic peptides (100 mcg each peptide) derived from breast cancer associated proteins, a class II MHC-restricted tetanus derived peptide (200 mcg), plus polyICLC (1 mg).
9999975|NCT01533012|Experimental|Pressure difference|Peak inspiratory pressures difference between two lungs
9999976|NCT01533012|No Intervention|FOB evaluation|FOB evaluation for the optimal position of tubes
9999977|NCT01533025|Active Comparator|bone-tendon Achilles allograft group|the group which underwent anterior cruciate ligament reconstruction using bone-tendon Achilles allograft
9999978|NCT01533025|Active Comparator|free tendon Achilles allogarft group|the group which underwent anterior cruciate ligament reconstruction using free tendon Achilles allograft
9999979|NCT01533051||Chronic hepatitis B|
9999980|NCT01533064||Psychiatric Outpatients|
9999981|NCT01533090|Active Comparator|polyethylene glycol (PEG)|
9999982|NCT01533090|Experimental|PEG low volume with bisacodyl|
9999983|NCT01533129|Active Comparator|Daily testosterone transdermal gel|
9999984|NCT01533129|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
9999985|NCT01533142||surgical methods|Different methods are used among hospitals in Helse-Vest, and this allows us to compare different clinical and biological effects following bariatric surgery different methods) among a homogeneous population in the western part of Norway (Vestlandet
9999986|NCT01533142||Morbid obesity|
9999987|NCT01533155|Active Comparator|NKTR-118/ Quinidine|One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)
9999988|NCT01533155|Placebo Comparator|NKTR-118/ Placebo|One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)
9999989|NCT01533155|Active Comparator|NKTR-118/ Quinidine/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)
9999990|NCT01533155|Placebo Comparator|NKTR-118/ Placebo/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)
9999991|NCT01533194|Experimental|Treatment (wild-type reovirus)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
10034995|NCT01801943|Experimental|Walking Intervention Group|60 minutes of walking and 30 minutes of reading stimulation three times a week
9938373|NCT00966082|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
9938374|NCT00966082|Active Comparator|endoscopic band ligation+Propranolol|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval, with propranolol
9938375|NCT00966095||men scheduled for prostate biopsy|
9938376|NCT00966108||Healthy subjects|
9938377|NCT00966108||Glaucoma patients|
9938378|NCT00966121|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
9938379|NCT00966121|Active Comparator|EBL+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
9938380|NCT00966134||probands|
9938381|NCT00966147|Experimental|Lidco group|All patients monitored by the lidco system and treated to optimize oxygen delivery
9938382|NCT00966160|Active Comparator|PI|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
9938383|NCT00966160|Active Comparator|NNRTI|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
9938384|NCT00966199|Experimental|Hypertensive elderly|community dwelling hypertensive elderly from general practices
9938385|NCT00966212|No Intervention|health promotion materials|
9938386|NCT00966212|Active Comparator|print parent education|
9938387|NCT00966225|Experimental|One gram LIP-01 per day|One gram LIP-01 per day for 12 weeks
9938388|NCT00966225|Experimental|Two grams LIP-01 per day|Two grams LIP-01 per day for 12 weeks
9938389|NCT00966225|Experimental|0.333 grams LIP-01 per day|0.333 grams LIP-01 per day for 12 weeks
9938390|NCT00966251|Experimental|CT-011|
9938391|NCT00966290|Experimental|ACC group|Anticoagulant clinic-based shared-care group
9938392|NCT00966290|Active Comparator|UC group|Usual care group
9938393|NCT00966303|Experimental|Cardiac Rehabilitation|9 patients with cardiomyopathy in functional class III or IV, submitted to an 8-week program with exercises and respiratory muscle training.
9938394|NCT00966316|Experimental|pathway|aspirin，Chinese herbs；acupuncture；rehabilitation；health education；
9938395|NCT00966329|Experimental|to switch from the NNRTI/PI to maraviroc|to switch from the NNRTI/PI to maraviroc
9938396|NCT00966329|Active Comparator|to continue with the same approach|to continue with the same approach
9938397|NCT00966342|Other|Vaccine|Everyone gets licensed Influenza vaccine
9938398|NCT00966368|Experimental|IDeg E|
9938399|NCT00966368|Experimental|IDeg M|
9938400|NCT00966381|No Intervention|Control|The minimal care group will receive standard public health information on nutrition from the American Heart Association twice during the 16-week intervention. Upon completion of the endpoint measurement (20 wks postpartum), they will be given all intervention materials.
9938401|NCT00966381|Experimental|Exercise Group|The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 wks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-wk exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
9938402|NCT00966394||ADHD medication|Children with ADHD and pharmacologic treatment
9938403|NCT00966394||ADHD without medication|Children with ADHD without pharmacologic treatment
9938404|NCT00966394||healthy|Healthy children ASA1
9938405|NCT00966407||Healthy Young Adults|College-age (18-35 years) participants recruited from Howard University, East Carolina University, and University of Massachusetts, Amherst, University of Calgary, Winston-Salem University
9938406|NCT00966420|Experimental|mucosa resection|
9938407|NCT00966459|Other|1|
9938408|NCT00966472|Experimental|Erlotinib + Rosuvastatin|To determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
9938409|NCT00966485|Active Comparator|80 mg ASA dose|6 months post stent on 80 mg ASA
9938410|NCT00966485|Active Comparator|500 mg ASA dose|6 months posr stent on ASA alone
9938411|NCT00966498|Experimental|1|This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
9938412|NCT00966511||Lung resection candidates|Study participants will be patients who are candidates for lung resection (lobectomy or greater)
9938413|NCT00966524|Experimental|Video|Teaching tracheal intubation to medical students using video-guided feedback during the procedure.
9938414|NCT00966524|Active Comparator|Standard|Teaching tracheal intubation to medical students using direct visualization feedback during the procedure.
9938415|NCT00966563|Active Comparator|Mangafodipir treatment|Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
9938416|NCT00966563|Placebo Comparator|NaCl 0.9%|
9938417|NCT00966576|Experimental|Brinzolamide/Timolol Maleate Fixed Combination|
9938418|NCT00966589|Sham Comparator|conservative treatment|physiotherapy
9938419|NCT00966589|Active Comparator|surgery|laparoscopic hernioplasty (TEP)
9938420|NCT00966602|Experimental|Treatment Period 1|
9938421|NCT00966602|Experimental|Treatment Period 2|
9999992|NCT01533220|Experimental|Test group|"Naphazoline Hydrocloride (1.0mg) + Pheniramine Maleate (0.2mg) + Panthenol(5.0mg).~02 drops in each nostril every 12 hours for 3 days"
9938422|NCT00966602|Experimental|Treatment Period 3|
9938423|NCT00966615|Experimental|Balance group|peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product
9938424|NCT00966615|Active Comparator|Control group|conventional PD solution
9938425|NCT00966628|Active Comparator|Ringer's lactate|
9938426|NCT00966628|Experimental|Hypertonic sodium lactate|
9938427|NCT00966667||cancer survivor|cancer survivor
9938428|NCT00966680||1|Observational study comparing the speed of general versus spinal anesthesia during emergency cesarean
9938429|NCT00966706|Experimental|Arm I|Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9938430|NCT00966706|Experimental|Arm II|Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9938431|NCT00966732|Experimental|yoga condition|assigned to start the yoga program right away
9938432|NCT00966732|No Intervention|wait-list control condition|This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
9938433|NCT00966745|Active Comparator|milrinone|milrinone infusion
9938434|NCT00966745|Placebo Comparator|placebo|
9938435|NCT00966758|Other|1|
9938436|NCT00966771||IUD|Women presenting for emergency contraception who select the copper IUD
9938437|NCT00966771||Oral levonorgestrel|Women presenting for emergency contraception who select oral levonorgestrel
9938438|NCT00966810|Experimental|CML allogeneic stem cell transplantation|Patients with chronic myeloid leukemia suitable for allogeneic stem cell transplantation with a matched related donor.
9938439|NCT00966836|Experimental|Pre-emptive everolimus|
9938440|NCT00966836|Experimental|Prophylaxis mycophenolate|
9938441|NCT00966836|Experimental|Prophylaxis Everolimus|
9938442|NCT00966836|Active Comparator|Pre-emptive mycophenolate|
9938443|NCT00966888|Experimental|Arm I|Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
9938444|NCT00966888|Active Comparator|Arm II|Patients receive standard of care and observation only.
9938445|NCT00966901|Experimental|Three Treatment Sites UV Exposed|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
9938446|NCT00966914|Placebo Comparator|Placebo|Placebo in combination with cisplatin and either paclitaxel or docetaxel
9938447|NCT00966914|Active Comparator|Tavocept (BNP7787)|Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
9938448|NCT00966927||subjects with spina bifid|subjects with spina bifid between 14 and 21 years old referred to Unit for Care of Spina Bifid Hospital of Parma
9938449|NCT00966966|Experimental|1|SAM-531_gemfibrozil
9938450|NCT00967031|Experimental|Lapatinib + capecitabine|lapatinib 1250mg/day + capecitabine 2000mg/m2/day
9800604|NCT01691898|Experimental|Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
9938451|NCT00967057|Experimental|Arm I (induction therapy)|Patients receive idarubicin IV over 1 hour on days 1 and 2; oral dexamethasone twice daily on days 1-5 and 15-19; intrathecal (IT) methotrexate on days 1 and 8; vincristine sulfate IV on days 3, 10, 17, and 24; and pegaspargase intramuscularly (IM) on days 3 and 17 or asparaginase IM on days 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25.
9938452|NCT00967057|Experimental|Arm II (induction therapy)|Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.
9938453|NCT00967070|Experimental|Both Treatments Applied on Lower Back|Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
9938454|NCT00967083||family caregivers of lung cancer patients|In this 2-year pilot study, we plan to screen family caregivers of lung cancer patients within 4 to 6 weeks after the a new visit to the thoracic clinic. We will screen spouses, adult children, and other family members using the HAD-18 to determine their level of anxiety and depressive symptoms at enrollment.
9938455|NCT00967096|Experimental|1|The primary clinical endpoint to be assessed in this study will be the proportion of Rifaximin doses successfully administered. Because of mucositis, compliance with oral agents, even those that are well tolerated in other settings, may be limited in the early post-transplant period. Thus, it will be important to demonstrate the feasibility of administering Rifaximin to BMT patients before embarking on larger scale studies. Secondary outcomes will include AGVHD, event-free survival, overall survival, non-relapse mortality, neutrophil and platelet engraftment.
9938456|NCT00967109|Active Comparator|Allowed drop in hemoglobin to 4,5-5,5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
9938457|NCT00967109|Experimental|Allowed drop in hemoglobin to 5,5-6,5 mmol/L|Transfusion with red blood cells to level between 5.5-6.5 mmol/L
9938458|NCT00967122|No Intervention|No Arm|
9938459|NCT00967135|Experimental|Pregabalin|Study subjects will be randomized to receive on the morning of surgery, at least 30 minutes before induction, a 150 mg oral dose of pregabalin. Patients will then receive a 150 mg oral dose of pregabalin on the evening of the surgery. Subsequently, patients will receive a 150 mg oral dose of pregabalin twice daily on the following four postoperative days.
9938460|NCT00967135|Placebo Comparator|Placebo|Study subjects will be randomized to receive a matching placebo on the morning of surgery, at least 30 minutes before induction. Patients will then receive a placebo on the evening of the surgery. Subsequently, patients will receive a placebo twice daily on the following four postoperative days.
9938461|NCT00967148|Experimental|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
9938462|NCT00967148|Active Comparator|Standard of care|The control arm will receive a subcutaneous injection of 4,500 U of tinzaparin daily beginning with the first postoperative dose and continued for the duration of hospitalization.
9938463|NCT00967161|Experimental|Evolution Medial Pivot Knee|20 Patients will receive the EMP Knee Implant
9938464|NCT00967161|Active Comparator|Triathlon PS Knee|20 Patients will receive the Triathlon PS Knee
9938465|NCT00967174|Experimental|Three Treatments Applied to Lower Back|Treatments were applied on the lower back, according to treatment sequence, daily for 21 days.
9938466|NCT00967187|Experimental|MPC-4326 200 mg BID X 14 Days|
9938467|NCT00967187|Experimental|MPC-4326 300 mg BID X 14 Days.|
9938468|NCT00967213|Experimental|Ranibizumab|three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
9938469|NCT00967252||atorvastatin 10 mg or equivalent dose|Patients already taking atorvastatin 10 mg or equivalent dose in another statin who is undergoing high risk surgery
9938470|NCT00967252||atorvastatin 20 mg or equivalent dose|Patients already taking atorvastatin 20 mg or equivalent dose in another statin who is undergoing high risk surgery
9938471|NCT00967252||atorvastatin 40 mg or equivalent dose|Patients already taking atorvastatin 40 mg or equivalent dose in another statin who is undergoing high risk surgery
9938472|NCT00967252||atorvastatin 80 mg or equivalent dose|Patients already taking atorvastatin 80 mg or equivalent dose in another statin who is undergoing high risk surgery
9938473|NCT00967252||non-statin group|Patients who are not taking or cannot take a statin drug who is undergoing high risk surgery
9938474|NCT00967265|Experimental|Introduction seminar|Psychoeducation for patients on waiting list
9938475|NCT00967265|Active Comparator|Usual care|Usual care
9938476|NCT00967278||Off-Pump|Patients with coronary artery disease undergoing elective off-pump CABG
9938477|NCT00967304|Experimental|1 Discontinue OAT or AAA|"Patients classified as being at low risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding."
9999993|NCT01533220|Active Comparator|Comparator group|"Naphazoline Hydrocloride (0.5mg)~02 drops in each nostril every 12 hours for 3 days"
9999994|NCT01533233|Experimental|nonintubated anesthesia|Thoracoscopic lobectomy using nonintubated anesthesia
9999995|NCT01533233|Active Comparator|intubated general anesthesia|Thoracoscopic lobectomy using intubated general anesthesia
9999996|NCT01533272|Experimental|Tenofovir, emtricitabine, Maraviroc|New postexposure prophylaxis (it is a combination drug)
9999997|NCT01533272|Active Comparator|Tenofovir, emtricitabine, lopinavir/r|Standard prophylaxis (it is a combination drug)
9999998|NCT01533285|Other|Group 1|Treatment AB: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment B (typhoid vaccination) administered [Period 2]
9999999|NCT01533285|Other|Group 2|Treatment BA: Treatment B (typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
10000000|NCT01533285|Other|Group 3|Treatment AC: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment C (TSST+Placebo vaccination) administered [Period 2]
10000001|NCT01533285|Other|Group 4|Treatment CA: Treatment C (TSST+Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
10000002|NCT01533285|Other|Group 5|Treatment AD:Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment D (TSST+typhoid vaccination) administered [Period 2]
10000003|NCT01533285|Other|Group 6|Treatment DA:Treatment D (TSST+typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
10000004|NCT01533298|Experimental|CombiflexOmega peri|
10000005|NCT01533298|Active Comparator|SmofKabiven peripheral|
10000006|NCT01533324|Experimental|S-1 combined with LV|S-1 combined with LV
10000007|NCT01533350||group1|women with a ultrasonographic homogeneous echo endometrium in the late follicle phase
10000008|NCT01533350||group2|"women with a ultrasonographic  triple-line endometrium in the late follicle phase"
10000009|NCT01533363|Active Comparator|Stapled hemorrhoidopexy|surgical procedure to treat hemorrhoids
10000010|NCT01533363|Active Comparator|Milligan Morgan|surgical procedure to treat hemorrhoids
10000011|NCT01533376|Experimental|Timolol|Participants in this group will receive topical timolol
10000012|NCT01533376|Placebo Comparator|Placebo|Participants in this group will receive Preservative free artificial tear gel.
10000013|NCT01533389|Experimental|Silodosin|8mg QD
10000014|NCT01533389|Placebo Comparator|Placebo|8mg QD
9476182|NCT03574402|Experimental|Arm10: Nimotuzumab plus gemcitabine and carboplatin|"Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
9476183|NCT03574402|Experimental|Arm11: Nimotuzumab plus pemetrexed and cisplatin|"Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m^2, iv gtt. on day 1. Cisplatin 75mg/m^2, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
9476184|NCT03574402|Experimental|Arm12: Pirotinib|"Patients with rare EGFR mutation receive Pirotinib.~This arm was divided into two groups:~Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1."
9476185|NCT03574402|Experimental|Arm13: Avitinib|Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
9476186|NCT03574402|Experimental|Arm14: Sintilimab|Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
9476187|NCT03574402|Experimental|Arm15: Sintilimab|"Patients with TMB≥10 mut/Mb，1%≦PD-L1<50% without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
10000015|NCT01533402|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
10000016|NCT01533402|Experimental|Internet CBT|Internet-delivered cognitive behavioural therapy with therapy support
10034996|NCT01801943|Experimental|Combination Group|30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
10000017|NCT01533415|Active Comparator|Active CES treatment|Out of the total population of 150 participants,75 of them will be assigned to the active treatment group. Because this is a double-blind study it is unknown which members will belong to this group until completion of the study.
10000018|NCT01533415|Sham Comparator|Sham CES treatment|Of the 150 participants in this study, half of them will be assigned to the sham treatment group. Because this is a double-blind study, it is unknown which members will be assigned to this group until the completion of the study.
10000019|NCT01533441|Placebo Comparator|placebo low VKA|
10000020|NCT01533441|Placebo Comparator|Placebo high VKA|Microcrystalline cellulose
10000021|NCT01533441|Active Comparator|Vitamin K2 Low VKA|
10000022|NCT01533441|Active Comparator|Vitamin K2 high VKA|
10000023|NCT01533454|No Intervention|Control|Control participants will attend a 4-month structured weight-loss program and attend subsequent follow-ups at 4-month intervals upon completion of the program.
10000024|NCT01533454|Experimental|Incentives|Incentive arm participants will be offered an additional program (in addition to the COMM program) where they can earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
10000025|NCT01533467|Other|Perineal device used|Use of the perineal device during delivery
10000026|NCT01533467|No Intervention|No intervention|Controls, delivered as normal
10000027|NCT01533480|Active Comparator|Zirgan, Adenovirus conjunctivitis,|Zirgan
10000028|NCT01533480|Placebo Comparator|genteal gel|0.3% Hypromellose gel (genteal gel)
10000029|NCT01533519|Experimental|NPY/placebo|This arm gets NPY first then placebo (saline). The placebo is 0.9% USP-grade saline without NPY.
10000030|NCT01533519|Experimental|placebo/NPY|This arm gets placebo (saline) first then NPY.
10000031|NCT01533532|Experimental|KLH-2109, low dose|
10000032|NCT01533532|Experimental|KLH-2109, medium dose|
10000033|NCT01533532|Experimental|KLH-2109, high dose|
10000034|NCT01533532|Placebo Comparator|placebo|
10000035|NCT01533545|Active Comparator|Plain mepivacaine|
10000036|NCT01533545|Active Comparator|Mepivacaine with epinephrine|
10000037|NCT01533558||caspofungin|caspofungin dosing
10000038|NCT01533571|Active Comparator|Immediate implant + xenogenic graft|Treatment with immediate implant and GBR using xenogenic bone graft material
10000039|NCT01533571|Active Comparator|Immediate implant + allogenic graft|Treatment with immediate implant and GBR using allogenic bone graft material.
10000040|NCT01533623|Other|mandibular advancement device treatment|Patients diagnosed with sleep-disordered breathing that receive treatment with a titratable, duobloc mandibular advancement devices
10000041|NCT01533649|Experimental|A/R intervention|The A/R intervention will accommodate 10 study subjects who will participate in an epilepsy-specific counseling intervention.
10000042|NCT01533649|Experimental|Relaxation|The relaxation group will accommodate 10 study subjects who will participate in a condition unspecific supportive relaxation intervention.
10000043|NCT01533649|No Intervention|Usual care|10 Potential study subjects who are not interested in participating in either intervention will be asked to provide data as a usual care control group.
10000044|NCT01533662|Experimental|phenylephrine|patients more than 60 years receiving 100micrograms of phenylephrine infusion (2 groups 60-75 years and more than 75 years)
10000045|NCT01533662|Placebo Comparator|placebo|patients more than 60 years receiving saline infusion (2 groups 60-75 years and more than 75)
10000046|NCT01533675|Experimental|Hydrogen peroxide|
10000047|NCT01533675|Active Comparator|Saline|
10000048|NCT01533727|Experimental|Group A|Autologous CIK Transfusion plus Chemotherapy
10000049|NCT01533727|Active Comparator|Group B|chemotherapy alone
10000050|NCT01533766|Experimental|CombiflexOmega|
10000051|NCT01533766|Active Comparator|SmofKabiven|
10000052|NCT01533792|Experimental|Supra/subgingival therapy|The experimental group received supra and subgingival scaling associated with oral hygiene orientation (OHO)
10000053|NCT01533792|Active Comparator|Control group|Control group received only supragingival scaling with OHO too.
10000054|NCT01533805|Experimental|Pilates with stabilization|This group will do pilates exercises with a focus on control of segmental stabilization of the lumbar spine neutral.
10000055|NCT01533805|Active Comparator|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine.
10000056|NCT01533818|Active Comparator|Amoxicillin|This is an active intervention
10000057|NCT01533818|Placebo Comparator|Sugar Syrup|
10000058|NCT01533844||Neonates|Neonates with CDAD
10000059|NCT01533857|Experimental|Black tea|black tea
10000060|NCT01533857|Placebo Comparator|placebo|
10000061|NCT01533870|Experimental|NKTR-118|Single dose NKTR-118 25 mg on Day 1 only
10000062|NCT01533870|Active Comparator|Rifampin|Rifampin 600 mg once daily on Days 4 to 12
10000063|NCT01533870|Active Comparator|Rifampin/ NKTR-118|Rifampin 600 mg plus NKTR-118 25 mg on Day 13
10000064|NCT01533896|No Intervention|Control|Parents and children in the control group received routine primary care during the well child visit.
10000065|NCT01533896|Experimental|Grow Nicely|Grow Nicely multimedia program.
10000066|NCT01533909||Cancer patients|As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
10000067|NCT01533961|Experimental|SCYX-7158|In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
10000068|NCT01533961|Placebo Comparator|Placebo of SCYX-7158|In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158
10000069|NCT01533987|Experimental|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
10000070|NCT01533987|Placebo Comparator|Placebo|The placebo consists of microcrystalline cellulose,dicalcium phosphate, magnesium stearate, and FD & C yellow #6.
10000071|NCT01534000|Active Comparator|CT guided group|For Patients with chest pain randomised to this arm, clinical decision will be based on the results of a Cardiac computed tomographic angiography (CCTA)
10000072|NCT01534000|No Intervention|Control group|Patients with chest pain randomised to the control group will be evaluated using the standard functional-based strategy with either a treadmill stress-test or SPECT (single-photon emission computed tomography). A Cardiac CT will will be performed, but will be blinded for initial clinical evaluation.
10000073|NCT01534026|Active Comparator|Aspirin|Current dose of aspirin for 12 weeks
10000074|NCT01534026|Experimental|Withdrawal arm|Withdrawal of aspirin for 12 weeks
10000075|NCT01534039|Active Comparator|Sur-Fit Natura/FormaFlex|Subject will be on Surfit Moldable for 2 weeks then crossover to Formaflex
10000076|NCT01534039|Active Comparator|FormaFlex/Sur-Fit Natura|Subject will be on Formaflex for 2 weeks then crossover to Surfit Moldable
10000077|NCT01534091|Active Comparator|Pedometer with supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
10000078|NCT01534091|Active Comparator|Pedometer without supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
10000079|NCT01534091|No Intervention|Control group|Overweight & obese children not participating in an intervention.
10000080|NCT01534117|Active Comparator|Platelets/DDAVP|Fall on ASA/Plavix that sustained head trauma requiring administration of platelets and/or DDAVP
10000081|NCT01534117|No Intervention|No Platelets|Those that sustain head trauma NOT requiring platelet transfusion. The investigators are evaluating platelet function in those not requiring platelet transfusion
10000082|NCT01534130|Experimental|acupuncture|
10000083|NCT01534130|Sham Comparator|sham acupuncture|
10000084|NCT01534169|Experimental|Isotonic Na chloride|The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.
10000085|NCT01534221|Active Comparator|Study group two|Endeavor resolute drug eluting stent
10000086|NCT01534221|Active Comparator|Study group three|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
10000087|NCT01534221|Active Comparator|Study group four|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
10000088|NCT01534221|Active Comparator|Study group five|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
10000089|NCT01534221|Active Comparator|Study group one|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
10000090|NCT01534234|Experimental|SonR group|SonR CRT Optimization
10000091|NCT01534234|Active Comparator|ECHO group|Echocardiographic Optimization
10000092|NCT01534247|Experimental|CAZAVI|CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
10000093|NCT01534247|Active Comparator|Metronidazole|Metronidazole (500 mg)
10000094|NCT01534247|Active Comparator|CAZAVI+metronidazole|CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)
10000095|NCT01534286|Active Comparator|Theramine|Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
10000096|NCT01534286|Placebo Comparator|Theramine-like Placebo|Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.
10000097|NCT01534299||Renal Denervation Treatment|All patients treated with renal denervation procedure will be enrolled as part of this single arm registry
10000098|NCT01534312|Experimental|CGMP protein|Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
10000099|NCT01534312|Active Comparator|Standard oral 5ASA maximal dose|Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
10034997|NCT01801943|Experimental|Healthy Living Group|60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.
10034998|NCT01801956|Active Comparator|Motivational interviewing|A one hour motivational interview
10034999|NCT01801956|Experimental|Physical activity|Four motivational interviews, free membership of a sport club, virtual arena to upload training data from a GPS-watch
10035000|NCT01801969||Rehabilitation service|"Centralized or Decentralized rehabilitation~Size of municipality"
10214420|NCT05223959|Experimental|CaPE Intervention|CaPE is a manualized intervention consisting of 12 one-to-one psychoeducation sessions, one session per week. Each session will last for 60 minutes. All sessions will be delivered by a trained therapist who will receive two months training from senior therapists before starting intervention.
10214421|NCT05223959|No Intervention|Treatment as Usual|Treatment as usual (TAU) will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.
10214422|NCT05223946|Active Comparator|Passive Microwave Radiometry|Diagnostic Test: Passive Microwave Radiometry The MWR2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases.
10214423|NCT05223946|Experimental|SCENAR|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
10214424|NCT05223933|Experimental|Intervention fokontany|
10214425|NCT05223933|No Intervention|Control fokontany|
10214426|NCT05223920|Experimental|Bomedemstat|All patients will be dosed with bomedemstat daily for 169 days with additional treatment continuing in patients deriving clinical benefit.
10214427|NCT05223907|Experimental|Group Etomidate|Etomidate will be used for general anesthesia
10214428|NCT05223907|Experimental|Group Propofol|Propofol will be used for general anesthesia
10214429|NCT05223881|Experimental|Cystic Fibrosis|Patients who are diagnosed with Cystic Fibrosis.
10000100|NCT01534325|Experimental|Study arm|The Arm who uses the real study device Daily use of SD device
10000101|NCT01534325|Sham Comparator|Control Arm|Daily use of Sham comperator
10000102|NCT01534325|Experimental|Staudy2 arm|Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
10000103|NCT01534338|Experimental|Mindfulness Meditation|The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
9476188|NCT03574402|Experimental|Arm16: Sintilimab|"Patients with KRAS and TP53 mutation, 1%≦PD-L1<50%, TMB<10 mut/Mb without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
10000104|NCT01534338|Active Comparator|Sleep Education|The sleep education condition is founded on knowledge acquisition. In the sleep seminar condition, a trained health educator will provide didactic presentations on sleep, sleep hygiene, sleep problems, and potential solutions to sleep problems in a group-based setting. Active components of sleep education include increasing knowledge of sleep biology, identifying characteristics of healthy and unhealthy sleep, sleep problems, and self-monitoring of sleep behavior. Participants attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. The health education condition is comparable to MAPs in terms of time, attention, group support, and participant expectancy of a benefit in sleep parameters.
10000105|NCT01534364|No Intervention|control|Ad libitum alimentation
10000106|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
10000107|NCT01534377|Experimental|Interpersonal Psychotherapy|Adolescents will receive Interpersonal Psychotherapy for the treatment and prevention of depression.
10000108|NCT01534377|Experimental|Enhanced Care|Adolescents will receive the Enhanced care model or care that they would typically receive in community setting to treat and prevent depression.
10000109|NCT01534390|Experimental|Use of in-line microfilters|
10000110|NCT01534390|No Intervention|Standard therapy without the use of in-line microfilters|
10000111|NCT01534429||chronic post-herniorraphy pain|patients with severe chronic post-herniorraphy pain
10000112|NCT01534442|Active Comparator|Atropin|Atropin
10000113|NCT01534442|Placebo Comparator|Placebo|Saline
10000114|NCT01534455|Experimental|Lapatinib + 1,23 mg Eribulin|
10000115|NCT01534455|Experimental|Lapatinib + 1,76 mg Eribulin|
10000116|NCT01534468|Experimental|Group 1: Previous H7N7 ca LAIV recipients|Participants in Group 1 will have previously received an H7N7 ca LAIV. In this study, they will receive one intramuscular (IM) injection of the H7N7 vaccine at study entry.
10000117|NCT01534468|Experimental|Group 2: Previous H7N3 ca LAIV recipients|Participants in Group 2 will have previously received an H7N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
10000118|NCT01534468|Experimental|Group 3: Previous H2N3 ca LAIV recipients|Participants in Group 3 will have previously received an H2N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
10000119|NCT01534468|Experimental|Group 4: Vaccine-naive participants|Participants in Group 4 will have not previously received a LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
10000120|NCT01534494|Experimental|psilocybin|
10000121|NCT01534507||Healthy Volunteer 1 (Group 1)|For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1
10000122|NCT01534507||Group 2 for study 2|Patients with diarrhoea due to irritable bowel syndrome
10000123|NCT01534507||Group 3 for study 2|Patients with constipation due to irritable bowel syndrome
10000124|NCT01534507||Group 4 for study 2|Patients with mixed bowel habit due to irritable bowel syndrome
10000125|NCT01534507||Group 5 for study 2: Healthy volunteer 2|Healthy participants to act as control
10000126|NCT01534546|Active Comparator|arm A postoperative Oxaliplatin/capecitabine（XELOX）|"postoperative Oxaliplatin/capecitabine（XELOX） patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.~capecitabine：1000 mg/m2 ，bid, d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
10000127|NCT01534546|Experimental|arm B: postoperative Oxaliplatin/S-1（SOX）|"postoperative Oxaliplatin/S-1（SOX） patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.~S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
10000128|NCT01534546|Experimental|Arm C：postoperative Oxaliplatin /S-1（SOX）|"Postoperative Oxaliplatin /S-1（SOX） patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.~Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)"
10000129|NCT01534559|Experimental|Outpatient Medicine Management Clinic|Consented patients will attend two outpatient clinic appointments to receive help with any (potential) medicine-related problems
10000130|NCT01534559|No Intervention|Control|Patients will receive the normal care provided by the hospital
10000131|NCT01534572|Experimental|Probiotics_Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
10000132|NCT01534572|Experimental|Probiotics_Bifidobacterium|Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium.
10000133|NCT01534702|Experimental|Treatment|
10000134|NCT01534715|Experimental|IMGN529|Dose escalation study, dosing done every 3 weeks.
10000135|NCT01534741|Active Comparator|Dialyser|FX CorDiax 60 dialyzer
10000136|NCT01534741|Active Comparator|FXDialyser|FX 60 dialyzer
10000137|NCT01534754|Active Comparator|Mesalazine|Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
10000138|NCT01534754|Active Comparator|Lactobacillus casei|Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
10000139|NCT01534754|Active Comparator|Mesalazine plus Lactobacillus casei|Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
10000140|NCT01534754|Placebo Comparator|Placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
10000141|NCT01534780|Experimental|fixation with Protack|
10000142|NCT01534780|Experimental|fixation with Securestrap|
10000143|NCT01534780|Experimental|fixation with Glubran|surgery
10000144|NCT01534793||HoLEP|Holmium Laser Enucleation of the Prostate
10000145|NCT01534806|Experimental|ketorolac|
10000146|NCT01534806|Placebo Comparator|Placebo|Placebo IV push
10000147|NCT01534832|Experimental|Smoke clearance|Smoke clearance device active
10000148|NCT01534845|No Intervention|only Radiotherapy|fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy
10000149|NCT01534845|Active Comparator|CCRT with Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles).
10000150|NCT01534858|Experimental|Partial and full thickness burns with split thickness grafts|
10000151|NCT01534871|Experimental|Exercise|Subjects enrolled in the exercise arm will receive the study intervention.
10000152|NCT01534871|No Intervention|Control|Subjects in the control arm will receive standard of care (e.g. medication and medical supervision) for rheumatoid arthritis. These subjects will not participate in the exercise intervention.
10000153|NCT01534884|Active Comparator|MabThera|rituximab
10000154|NCT01534884|Active Comparator|CT-P10|rituximab
10000155|NCT01534923||Pts having colorectal cancer screening|The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).
10000156|NCT01534936||Schizophrenic outpatients with affective symptoms.|
10000157|NCT01534949|Experimental|CT-P10|rituximab
10000158|NCT01535027|Active Comparator|Teriparatide|18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)
10000159|NCT01535027|Active Comparator|Teriparatide and Raloxifene|9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months
9476189|NCT03574402|Experimental|Arm17: Sintilimab plus pemetrexed and cisplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m^2 iv gtt. Q3W on day1. Cisplatin 75mg/m^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
10000160|NCT01535027|Active Comparator|Teriparatide and Alendronate|9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months
10000161|NCT01535066|Experimental|Arm I|Patients receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
10000162|NCT01535066|Sham Comparator|Arm II|Patients receive sham acupuncture twice weekly for 6 weeks and then once weekly for 6 weeks.
10000163|NCT01535066|No Intervention|Arm III|Patients are assigned to a waiting list for 12 weeks with standard follow-up care.
10000164|NCT01535079|Placebo Comparator|Placebo|
10000165|NCT01535079|Experimental|V0498TA01A 15 mg|
10000166|NCT01535079|Experimental|V0498TA01A 25 mg|
10000167|NCT01535079|Experimental|V0498TA01A 35 mg|
10000168|NCT01535079|Other|Strefen|Positive control
10000169|NCT01535092|Experimental|silibinin|Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
10000170|NCT01535092|Placebo Comparator|Placebo|Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
10000171|NCT01535105||Obese Adolescents|
10000172|NCT01535144|Experimental|degradable metallic device|
10000173|NCT01535144|Active Comparator|non-degradable metallic device|
10000174|NCT01535157|Experimental|Fenretinide/LXS + Ketoconozale|One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.
10214430|NCT05223881|Active Comparator|Healthy Normal|Patients in this arm will be a sibling of patients who have been diagnosed with Cystic Fibrosis.
10214431|NCT05223842|Experimental|Family Promoting Positive Emotions Group|Each dyad (mother and their child) will receive 8 sessions of promoting positive emotions intervention with a clinician for 8 weeks.
10214432|NCT05223842|Active Comparator|Written Information Group|Mothers will be sent written information and resources on depression for 8 weeks over email.
10214433|NCT05223829|Experimental|Brexanaolone|In this single-arm study, participants will be administered brexanolone as a continuous IV infusion over 20 hours (titrated up to 90mcg/kg/hour).
10214434|NCT05223777|Active Comparator|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument. As such, the focus of the study does not relate to the safety and efficacy of the device, which has already been established. Instead, the current IRB proposal investigates whether there are long-term benefits to patient outcomes that differ between KINCISE-guided versus mallet THA.
10214435|NCT05223777|Placebo Comparator|Traditional Mallet|A traditional mallet will be used during surgery in this group.
10000175|NCT01535170|Experimental|bovine Lactoferrin|"Lactoferrin and placebo will be masked as drug A and B in the factory. Randomization will be stratified by center and patients will be randomized into A or B groups by a random-number table sequence after informed consents are obtained. No patients, research nurses, investigators, or other medical staffs in RCC will be aware of the assignment during the study period.~Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17]. Drug administration will begin within 24 hours after RCC admission and will last for 6 weeks or until discharge. Medication and nutritional support will be prescribed as the medical routine."
10000176|NCT01535170|Placebo Comparator|Placebo|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control.
10000177|NCT01535183|Experimental|Irinotecan|
10000178|NCT01535196|Experimental|25-OH-D3 vitamin|180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
10000179|NCT01535196|Placebo Comparator|MCT oil|9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol
10000180|NCT01535209|Experimental|SBRT to resection cavity|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
10000181|NCT01535209|Active Comparator|WBRT|30Gy in 10 fractions over 12 days to whole brain
10000182|NCT01535248||All ERCP Patients|All patients that will be approached for this study will be undergoing ERCP as part of their medical care.
10000183|NCT01535300||Elective pediatric surgery|
10000184|NCT01535313|Active Comparator|Manual (Hospital Systems TRAP Needle)|Bone marrow biopsy with a standard manual system
10000185|NCT01535313|Experimental|Powered|
10000186|NCT01535339||Phase I - Normative|Athletes who does not participate in contact sport with no recent concussion
10000187|NCT01535339||Phase IIa - Concussed|Athletes with recent concussion
10000188|NCT01535339||Phase IIa - Control|Athletes with no recent concussion
10000189|NCT01535339||Phase IIb - Athletes|Athletes with no recent concussion
10000190|NCT01535352|Experimental|Internet-facilitated CBT|Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
10000191|NCT01535352|Active Comparator|Coach-facilitated Treatment as Usual|Participants in the FUC condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
10000192|NCT01535404|Active Comparator|Right ventricular apex pacing|
10000193|NCT01535404|Experimental|Left ventricular apex pacing|
10000194|NCT01535417|Experimental|GCSB|
10000195|NCT01535417|Active Comparator|Celebrex|
10000196|NCT01535456|Experimental|F-FLT PET scan, 5-azacitidine treatment|F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
10000197|NCT01535469|Experimental|CrAg Screening and Fluconazole|Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.
10000198|NCT01535482|Experimental|Cognitive Therapy|A cognitive therapy protocol specifically designed to target suicidal ideation in older adults.
10000199|NCT01535482|Active Comparator|Enhanced Usual Care|Enhanced usual care consists of the usual care that individuals receive for suicide prevention, plus assessment and referral services provided by project staff, and weekly phone calls provided by study therapists.
10000200|NCT01535495|Experimental|Complete laser|Patients who have had complete panretinal photocoagulation laser treatment and active retinal neovascularization
10000201|NCT01535495|Experimental|Laser naive|"Patients who have not had panretinal photocoagulation laser treatment and active retinal neovascularization without so called high-risk characteristics"
10000202|NCT01535521|Other|SPT in patients with MAD|
10000203|NCT01535547|Experimental|isavuconazole and tacrolimus|
10000204|NCT01535586|Active Comparator|CPAP|participants will be treated with continuous positive airway pressure (CPAP) for 12 weeks
10000205|NCT01535586|Active Comparator|MAD|Participants will be treated with a mandibular advancing device for 12 weeks
10000206|NCT01535612|Experimental|PaQ™ insulin infusion device|PaQ™ insulin infusion device which delivers rapid acting insulin.
10000207|NCT01535625|Other|Momo stent|Patients with PCI
10000208|NCT01535651|Experimental|TOP Program plus Text messaging|Boys and Girls Club members who participate in TOP over 9 months will receive regular text messages in addition to TOP
10000209|NCT01535651|No Intervention|TOP Program alone|Boys and Girls Club participants will participate in TOP for 9 months
10000210|NCT01535677|Experimental|1|5 mg dapagliflozin and 850 mg Glucophage in fasted state
10000211|NCT01535677|Experimental|2|dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted
10000212|NCT01535677|Experimental|3|5 mg dapagliflozin and 850 mg Glucophage in fed state
10000213|NCT01535677|Experimental|4|dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state
10000214|NCT01535690|Experimental|laser and methilene blue|After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler (Profi III Bios, Dabi Atlante, Ribeirão Preto, São Paulo, Brazil) for 1 hour. Specific tips were used (Perio sub, Dabi Atlante, Ribeirão Preto, São Paulo, Brazi). PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl (Photon Laser III - PL7336, DMC, São Carlos -São Paulo, Brazil) was applied (660 nm, 100 mW, 9 J, 90 seconds per site, 320 J/cm2).
10000215|NCT01535716|Experimental|ECOM group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
10000216|NCT01535716|Active Comparator|standard management group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
10000217|NCT01535742|Experimental|Ambu Aura-i size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
10000218|NCT01535742|Experimental|air-Q size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
10000219|NCT01535742|Experimental|Ambu Aura-i size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
10000220|NCT01535742|Experimental|air-Q size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
10000221|NCT01535755|Active Comparator|protocol group|This group patients are weaned as the protocol which the investigators described.
10000222|NCT01535755|Other|clinicians' order group|This group patients are weaned as the clinicians' order.
10000223|NCT01535768|Experimental|Intervention Group|Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
10000224|NCT01535768|No Intervention|Control Group|"Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates.~(If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)"
10000225|NCT01535781|Placebo Comparator|Placebo|Patients are given saline instead of tranexamic acid in the placebo group
10000226|NCT01535781|Active Comparator|Tranexamic Acid|Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.
10000227|NCT01535794||18-26 year old men who have sex with men|
10000228|NCT01535820|Experimental|Treatment sequence AB|
10000229|NCT01535820|Experimental|Treatment sequence BA|
10000230|NCT01535833|Other|Robotic sacral colpopexy|To assess subjects with stage 2 pelvic organ prolapse undergoing robotic sacral colpopex
10000231|NCT01535846|Experimental|Conscious food tasting intervention|Instead of focusing on dieting rules to restrict food intake, paying attention to sensory stimulation allow the recognition of internal cues of hunger and satiety which can be helpful to facilitate a more internalized regulation of food intake among restrained eaters. In the experimental group, the conscious food tasting intervention will be conducted by a registered dietitian into small groups of ten to twelve women during six weekly 2-hour workshops. Workshops will be taking place in a well-ventilated room to insure that there are no extraneous odours or noises that may hamper the activities involving senses.
10000232|NCT01535846|No Intervention|Control|
10000233|NCT01535859|Experimental|Cabergoline|
10000234|NCT01535859|Placebo Comparator|Placebo|
10000235|NCT01535872|Experimental|DHEA treatment|
10000236|NCT01535872|No Intervention|No treatment|
10000237|NCT01535885|Experimental|Multi-Virus CTLs|The treatment plan delivers a single dose of Multi-Virus CTL to all patients enrolled on study.
10000238|NCT01535898||Pts having an MRI|This is a technology assessment protocol. The study is designed to assess the utility of the technology using a limited number of participants.
10000239|NCT01535989|Experimental|intravenous|dose escalation
10000240|NCT01536002|Experimental|Pharmacokinetics|Propofol pharmacokinetics
10000241|NCT01536028|Active Comparator|BIAsp 30|
10000242|NCT01536028|Experimental|BIAsp 50|
10000243|NCT01536028|Experimental|BIAsp 70|
10000244|NCT01536028|Active Comparator|IAsp|
10000245|NCT01536054|Experimental|Treatment (vaccine, sirolimus, GM-CSF)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Patients also receive sirolimus PO QD on days 1-14 OR 15-28 OR 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive an additional course of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine only followed by ALVAC(2)-NY-ESO-I (M)/TRICOM vaccine SC 8 weeks after completion of course 4.
10000246|NCT01536080||Reflux esophagitis (RE)|
10000247|NCT01536080||Non-erosive reflux disease (NERD)|
10000248|NCT01536080||Functional heartburn (FH)|
10000249|NCT01536106|Experimental|Treatment|Implantation of bone marrow derived mononuclear cells
10000250|NCT01536106|Placebo Comparator|Placebo Control|Infusion of autologous peripheral blood
10000251|NCT01536132|Active Comparator|Levosimendan|levosimendan at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
10000252|NCT01536132|Placebo Comparator|Placebo|placebo (same appereance than levosimendan in colour) at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
9476190|NCT03574402|Experimental|Arm18: Sintilimab plus Gemcitabine and carboplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
10000253|NCT01536158|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
10000254|NCT01536158|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
10000255|NCT01536210|Experimental|YY-162|"YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)~1T/Three times a day(Tid) for 8 weeks, PO medication"
10000256|NCT01536210|Placebo Comparator|Placebo|Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
10000257|NCT01536223|Active Comparator|PF group|the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy
10000258|NCT01536223|Experimental|TPF group|TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy
10000259|NCT01536236|Active Comparator|Subthreshold programming|During one of the first 2 weeks of the trial the subject will be randomized to a subthreshold stimulation arm. They will be blinded and receiving therapy, but will it will be delivered at a level (subthreshold) that they will not feel the stimulation.
10000260|NCT01536236|Placebo Comparator|Placebo or Stimulation off arm|During one of the first two weeks of the study, the patient will be randomized to a no stimulation arm. They will be blinded and will not be receiving therapy.
10000261|NCT01536236|Active Comparator|Optimal stimulation programming|During the third week of the trial period, all subjects will receive optimal stimulation.
10000262|NCT01536249|Experimental|Dexpramipexole single dose & 12 Doses Cimetidine|300 mg Dexpramipexole Oral Dose (to be taken in conjunction with multiple doses of Cimetidine at 400 mg per dose)
10000263|NCT01536249|Experimental|Dexpramipexole single Dose|300 mg Dexpramipexole Oral Dose
10000264|NCT01536288|Active Comparator|Rhodiola crenulata-placebo sequence|Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
10000265|NCT01536288|Active Comparator|Placebo-Rhodiola crenulata sequence|Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
10000266|NCT01536301|Active Comparator|Morphine|The patients in this arm will have post-operative analgesia including morphine (patient controlled analgesia).
10000267|NCT01536301|Experimental|Oxycodone|The patients in this arm will have post operative analgesia including oxycodone (patient controlled analgesia).
10000268|NCT01536327||Observation|Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
10000269|NCT01536353|Experimental|AGSAV301|
10000270|NCT01536353|Active Comparator|Exforge 10/160|
10000271|NCT01536431|Experimental|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
10000272|NCT01536431|Active Comparator|Pro insulin peptide & saline|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
10000273|NCT01536431|Placebo Comparator|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls)
9528319|NCT03212001||Healthcare providers (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
10000274|NCT01536444|Experimental|Micrografting|
10000275|NCT01536470|Experimental|Noradrenaline|Continuous infusion of noradrenaline to maintain arterial blood pressure management in high-risk surgical patients
10000276|NCT01536470|Experimental|Ephedrine chorhydrate|Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline)using intravenous bolus of Ephedrine chorhydrate
10000277|NCT01536483|Experimental|Butyrate|"New born with a birth weight <1000g: Seven enemas of butyrate will be performed every 2 days from PND5~New born with a birth weight >1000g: Seven enemas of butyrate will be performed every day from PND5"
10000278|NCT01536483|No Intervention|Therapeutic Abstention|The protocol will pretend enema: instillation in the diaper the product under consideration, to make the two indistinguishable processes (time, odor, wicking diaper ...)
10000279|NCT01536509|Experimental|Telehealth Behavioral Treatment|
10000280|NCT01536509|Active Comparator|Education Only|
10000281|NCT01536522|Active Comparator|Nutritional Approach for Asthma|individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
10000282|NCT01536522|Placebo Comparator|Standard American Diet|patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
10000283|NCT01536522|Active Comparator|Alternate Day Diet|"patients will consume a regular Standard American Diet for 4 weeks and then provided a regulated dosed quantity of low caloric value shakes. they will consume this on alternating days"
10000284|NCT01536522|Active Comparator|Whole Lung Allergen Challenge|patients with or without asthma will be given controlled doses of specified allergens
10000285|NCT01536548|Experimental|Skin drawing|
10000286|NCT01536548|Active Comparator|No skin drawing|
10000287|NCT01536600||BIAsp 30 users|
10000288|NCT01536613||BIAsp 30 users|
10000289|NCT01536626||BIAsp 30 users|
10000290|NCT01536639||BIAsp 30 users|
10000291|NCT01536652||BIAsp 30 users|
10000292|NCT01536665|Experimental|Low|
10000293|NCT01536665|Experimental|Medium|
10000294|NCT01536665|Experimental|High|
10000295|NCT01536678|Active Comparator|Test formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2..
10000296|NCT01536678|Active Comparator|Reference formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2.
10000297|NCT01536691|Experimental|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
10000298|NCT01536691|Active Comparator|ondansetron, aprepitant, dexamethasone|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
10000299|NCT01536717|Active Comparator|Bupivacaine hydrochloride 0.5%|Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics. Bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
10000300|NCT01536717|Placebo Comparator|Sodium chloride 0,9%|
10000301|NCT01536730|Experimental|Homework Intervention Strategy|
10000302|NCT01536730|No Intervention|Control|
10000303|NCT01536743|Experimental|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
10000304|NCT01536756|Experimental|Exercise Intervention -- Physical Rehabilitation Program|
10000305|NCT01536756|Other|Wait List Control Group|
10000306|NCT01536769||Parkinson patients|Parkinson patients, symptom onset > 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases
10000307|NCT01536769||Control subjects|No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases
10035001|NCT01802008|Active Comparator|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
10000308|NCT01536782|Active Comparator|Bolus|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
10000309|NCT01536782|Active Comparator|Gravity|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
10000310|NCT01536782|Active Comparator|Pump|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
10000311|NCT01536808|Experimental|Type 2 Diabetes Mellitus|
10000312|NCT01536834|Experimental|Medical Device|The Investigational device is a liquid in a delivery system for the treatment of verrucas
10000313|NCT01536847|Placebo Comparator|Control Test Drink|Control drink
10000314|NCT01536847|Experimental|Experimental Test Drink 1|Control drink containing ingredient 1
10000315|NCT01536847|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
10000316|NCT01536964|Experimental|Morphine|the effect of morphine on prasugrel absorption will be tested
10000317|NCT01536964|Placebo Comparator|Saline|
10000318|NCT01536977|Experimental|Supportive care (BBT-I)|"Patients complete the BBT-I, comprising the following modules: 1) What to expect in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) A review of the Spielman Model of insomnia; 3) A discussion (based on the Spielman Model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) An introduction to the concept and practice of Stimulus Control Therapy; 5) An introduction to Sleep Scheduling Specifically modified for cancer patients; 6) Sleep Compression; and 7) Concomitant Medications and Substance Use."
10000319|NCT01536990||Stroke|Medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction secondary to stroke.
10000320|NCT01537003|Experimental|Promogran and Low EPA|Patients with low EPA will be treated with PROMOGRAN and standard of care for vlu compression
10000321|NCT01537003|Active Comparator|Low EPA and compression|Patients with Low EPA will only get standard of care for VLU which is compression.
10000322|NCT01537003|Active Comparator|High EPA and compression|Patients with high EPA will get standard of care for VLU which is compression.
10000323|NCT01537003|Experimental|Promogran High EPA|patients with HIGH EPA will then be treated with PROMOGRAN and standard of care for VLU compression
10000324|NCT01537016|Experimental|Promogran and High EPA|Wound with high EPA will be treated with promogran and covered with a secondary dressing that is standard of care
10000325|NCT01537016|Experimental|Promogran and Low EPA|Wounds with low EPA will be treated with Promogran and covered with a secondary which is standard of care
10000326|NCT01537016|Active Comparator|High EPA and standrad of care|Wounds with high EPA will get standard of care as in line with current practice as they is no other test currently available for EPA
10000327|NCT01537016|Active Comparator|Low EPA and standard of care|Low EPA wounds will be treated with the standard of care for diabetic foot ulcers.
10000328|NCT01537055|Experimental|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy
10000329|NCT01537055|Active Comparator|levofloxacin-based triple therapy|levofloxacin-based triple therapy for 10 days
10000330|NCT01537094|Active Comparator|Vitamin C low dose|vitamin C 250 mg oral once daily
10000331|NCT01537094|Active Comparator|Vitamin C high dose|vitamin C 1,000 mg oral once daily
10000332|NCT01537094|Placebo Comparator|Placebo|Placebo oral once daily
10000333|NCT01537107|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10000334|NCT01537146|Active Comparator|Femoral Block|
10000335|NCT01537146|Active Comparator|Local Infiltration Anagesia|
10000336|NCT01537159||Acute Myelogenous Leukemia (AML)|Patients who have been diagnosed with AML
10000337|NCT01537172|Experimental|ONO-4053|E Experimental Intervention Drug: ONO-4053
10000338|NCT01537172|Placebo Comparator|Placebo|
10000339|NCT01537224|Other|neurostimulation|
10000340|NCT01537237||intra-procedure 3DATG|Patients who will undergo intra-procedure 3DATG rotational angiography to guide their ablation procedure
10000341|NCT01537237||pre-procedure CT|Patients who will undergo pre-procedure CT scan to guide their ablation procedure
10000342|NCT01537250|Active Comparator|Nemonoxacin 750 mg|Nemonoxacin 750 mg 2 tablets.
10000343|NCT01537250|Active Comparator|Nemonoxacin 500 mg|Nemonoxacin 500 mg 3 tablets
10000344|NCT01537250|Active Comparator|Levofloxacin 500 mg|Levofloxacin 500 mg
10000345|NCT01537263||Ultrasound Perfusion Imaging|Patient with subarachnoid hemorrhage.
10000346|NCT01537276|Experimental|real-time fluoroscopy|evaluating the tubal patency and pathology under fluoroscopy real-timely
10000347|NCT01537276|No Intervention|respective image|evaluating the tubal patency and pathology by Two supine and two oblique static images.
10000348|NCT01537289|Experimental|Pigtail catheter|
10000349|NCT01537289|Active Comparator|Traditional chest tube|28-French chest tube
10000350|NCT01537328|Experimental|Progressive Treatment|Progressive intervention will involve the early initiation of intensive rehabilitation using progressive exercise and faster progression to functional strengthening exercises.
10000351|NCT01537328|Active Comparator|Traditional treatment|Traditional intervention represents the synthesis of previously published total knee arthroplasty rehabilitation programs.
10000352|NCT01537341|Active Comparator|Traditional Treadmill|Participants will follow the same guidelines as the split belt component but will complete the intervention on a traditional, single belt/speed treadmill.
10000353|NCT01537341|Experimental|Split-belt|Participants will walk on a custom-built split-belt treadmill comprised of two separate belts, each with its own motor, that permitted the speed of each belt (i.e. each leg) to be controlled independently.
10000354|NCT01537354|Active Comparator|Survanta®|Survanta® (Beractant, Abbot Laboratories, Columbus, OH) Surfactant will be administered by respiratory therapist not involved in patient's care.
10000355|NCT01537354|Active Comparator|Curosurf®|Curosurf® (Cornerstone Therapeutics, Inc., Cary, NC Surfactant will be administered by respiratory therapist not involved in patient's care.
10000356|NCT01537380|Experimental|Cefazoline|
10000357|NCT01537445||Patients with pancreastransplantation|All patients undergoing pancreas transplantation.
10000358|NCT01537458||Isolated TI repair|Patients that underwent isolated tricuspid valve repair
10000359|NCT01537471|Other|Placebo|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. On one of three visits, a subject will receive placebo. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
10000360|NCT01537471|Experimental|Meclizine|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
10000361|NCT01537484|Experimental|Swedish Massage|Swedish massage for one hour, once per week, for eight weeks. At week 10, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), and 50% will be randomized to Usual Care.
10000362|NCT01537484|Active Comparator|Light Touch Bodywork|Light-touch bodywork for one hour, once per week, for eight weeks. At week 10, 50% of the patients will be randomized to a maintenance dose (one hour of light-touch massage every two weeks, and 50% will be randomized to Usual Care.
10000363|NCT01537484|Other|Usual Care|Those initially randomized to the usual care control will be rolled into the Swedish massage intervention (one hour of Swedish massage, once/week for eight weeks) at week 25. At week 34, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), while 50% will be randomized back to Usual Care.
10000364|NCT01537497|Experimental|100 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
10000365|NCT01537497|Experimental|250 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
10000366|NCT01537497|Experimental|600 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
10000367|NCT01537497|Placebo Comparator|Placebo|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
10000368|NCT01537510|Active Comparator|Usual Care|
10000369|NCT01537510|Experimental|Clinician intervention only|This arm will entail the development and deployment of alerts and access to a SmartSet at the time of a well child visit with a child between the ages of 6-12 years with a BMI ≥ 95th percentile.
10000370|NCT01537510|Experimental|Clinician intervention plus Direct-to-parent communication|Parents of children enrolled in this intervention arm will receive mailings, text messages and a series of 4 calls with a health coach to encourage behavior change in addition to the intervention received by the clinicians.
10000371|NCT01537523|Experimental|community-care program|receive intervention for 12 weeks
10000372|NCT01537523|No Intervention|control|
10000373|NCT01537536|Experimental|EndoTAG-1|Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
10000374|NCT01537562|Active Comparator|Delayed IUC insertion|Patients randomised to delayed, routine, insertion had their IUC inserted at 3-4 weeks (day 21-35 after mifepristone treatment
10000375|NCT01537562|Active Comparator|Early IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment.
10000376|NCT01537575|Placebo Comparator|saline solution|
10000377|NCT01537575|Experimental|intravenous immunoglobulins|
10000378|NCT01537588|Active Comparator|Standard|ACL reconstruction with autograft harvest of STG from ACL-deficient leg
10000379|NCT01537588|Experimental|Autograft harvest of STG from ACL-deficient leg|Autograft harvest of STG from leg contralateral to ACL-deficient leg
10000380|NCT01537588|No Intervention|Normal matched|
10000381|NCT01537601|Other|Antibiotic prophylaxis alone|Children will be on antibioprophylaxis and will not have a circumcision.
10000382|NCT01537601|Experimental|Circumcision and antibiotic prophylaxis|Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis
10000383|NCT01537614|Experimental|COLIMYCINE injectable|
10000384|NCT01537614|Experimental|COLIMYCINE inhalation|
10000385|NCT01537627|Active Comparator|Low-intensity training (LT)|
10000386|NCT01537627|Active Comparator|High-intensity training (HT)|
10000387|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 1|SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection
10000388|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 2|SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection
10000389|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 4|Dose Level 4
10000390|NCT01537653|Placebo Comparator|Placebo|Placebo
10000391|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 1|Dose Level 1
10000392|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 2|Dose Level 2
10000393|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 3|Dose Level 3
10000394|NCT01537679|Other|Meditation Intervention|
10000395|NCT01537679|Other|Relaxation Intervention|
9938478|NCT00967304|No Intervention|2 Observation arm|"Men and patients classified as being at high risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding."
9938479|NCT00967317|Experimental|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
9938480|NCT00967317|Active Comparator|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
9938481|NCT00967356|Experimental|A|AZD5985
9938482|NCT00967356|Placebo Comparator|B|Placebo
9938483|NCT00967382|No Intervention|Control|"Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
9938484|NCT00967382|Active Comparator|dalteparin sodium|"Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
9938485|NCT00967395|Experimental|Healing|patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject.
9938486|NCT00967395|Sham Comparator|Sham healing|Same design of room as with the healing, while in this case a student is behind the screen
9938487|NCT00967395|No Intervention|Control|Business as usual in the third arm
9938488|NCT00967408|Experimental|Rehabilitation + Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
9938489|NCT00967408|Placebo Comparator|Rehabilitation + Placebo|Rehabilitative treatment + Non active Placebo tablets for 6 months
9938490|NCT00967421|Experimental|BAC 0.5|BAC level 0.5 g/dL (drink + placebo pill)
9938491|NCT00967421|Experimental|BAC 1.0|BAC level 1.0 g/dL (drink + placebo pill)
9938492|NCT00967421|Placebo Comparator|placebo|BAC level 0,0 g/dL (placebo drink+ placebo pill)
9938493|NCT00967434|Active Comparator|Group A- atorvastatin in pre and postop|Atorvastatin 80 mg administered daily for at least 7 preoperative days, 80 mg on day of surgery and 80 mg daily for up to 7 postoperative days.
9938494|NCT00967434|Active Comparator|Group B- Atorvastatin postop|Placebo administered for up to 7 preoperative days, atorvastatin 80 mg administered on day of surgery and daily for up to 7 postoperative days.
9938495|NCT00967434|Placebo Comparator|Group C- Placebo|Patients receive placebo daily for up 7 preoperative days, placebo on day of surgery and placebo daily for up to 7 postoperative days.
9938496|NCT00967460|No Intervention|Control group: No intervention|No intervention, regular childcare program
9938497|NCT00967460|Experimental|Intervention group|Promoting unstructured spontaneous PA through an adaptation of the built environment and the provision of a supportive social environment
9938498|NCT00967512|Experimental|cenersen, idarubicin, cytarabine|cenersen, idarubicin, cytarabine
9938499|NCT00967512|Placebo Comparator|placebo, idarubicin, cytarabine|placebo, idarubicin, cytarabine
9938500|NCT00967525|Experimental|1|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
9938501|NCT00967538|Experimental|Etanercept|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
9938502|NCT00967564||001|epidemiologic study QoL assessment
9938503|NCT00967590|Experimental|1|
9938504|NCT00967590|Placebo Comparator|2|
9938505|NCT00967603|No Intervention|observation|no therapy until progression
9938506|NCT00967603|Experimental|sunitinib|sunitinib until progression or for a maximum of 6 months
9938507|NCT00967629|Other|Sevelamer Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
9938508|NCT00967629|Other|Calcium Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
9938509|NCT00967642|No Intervention|standard treatment|glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
9938510|NCT00967642|Other|Intravenous Insulin|intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
9938511|NCT00967681|Experimental|A|Oncoxin, a nutritional supplement
9938512|NCT00967681|Placebo Comparator|B|
9938513|NCT00967707|Active Comparator|Gabapentin + venlafaxine|
9938514|NCT00967707|Active Comparator|Gabapentin + donepezil|
9938515|NCT00967720||Barriers, Adherence, Asthma|
9938516|NCT00967733|Active Comparator|High ALA-Low Linoleic|
9938517|NCT00967733|Placebo Comparator|Low ALA-Low Linoleic|
9938518|NCT00967733|Active Comparator|High ALA-High Linoleic|
9938519|NCT00967733|Placebo Comparator|Low ALA-High Linoleic|
9938520|NCT00967759|Experimental|Decongex Plus|
9938521|NCT00967759|Active Comparator|Bronpheniramine isolated|
9938522|NCT00967759|Active Comparator|Fenilefrine isolated|
9938523|NCT00967772|Experimental|Naftopidil|
9938524|NCT00967837|Experimental|Diabetes with non healing wounds|To determine and monitor progress of diabetic patients with non healing wounds that have failed conventional 60 day treatment respond to pulsatile intravenous insulin therapy in improving and completing healing in non healing wounds
9938525|NCT00967850|Experimental|Intravitreal Bevacizumab|Intravitreal injections of bevacizumab
9938526|NCT00967850|Active Comparator|Visudyne|Photodynamic Therapy with Visudyne
9938527|NCT00967902|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
9938528|NCT00967902|Active Comparator|Taxus® Liberté® Stent|Commercially available product
10000396|NCT01537692|Experimental|BDP HFA Nasal Aerosol 80 mcg/d|single dose, intranasal aerosol
10000397|NCT01537692|Experimental|BDP HFA Nasal Aerosol 320 mcg/d|single dose, intranasal aerosol
10000398|NCT01537692|Active Comparator|BDP HFA Inhalation Aerosol 320 mcg/d|single dose, orally inhaled aerosol
10000399|NCT01537705|Experimental|Neuron012703|Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
10000400|NCT01537718|Experimental|REPLY 200 implanted patients|REPLY 200 implanted patients
10000401|NCT01537731||hysterectomy|Patient who previously underwent vaginal or laparoscopic hysterectomy
10000402|NCT01537744|Experimental|oral 5-azacitidine + romidepsin|oral 5-azacitidine in combination with romidepsin
10000403|NCT01537757|Experimental|Part 1, Panel A - Severe Renal Impairment Group|
10000404|NCT01537757|Experimental|Part 1, Panel B - Healthy Control Group to Match Panel A|
10000405|NCT01537757|Experimental|Part 2, Panel C - Moderate Renal Impairment Group|
10000406|NCT01537757|Experimental|Part 2, Panel D - Healthy Control Group to Match Panel C|
10000407|NCT01537757|Experimental|Part 2, Panel E - Mild Renal Impairment Group|
10000408|NCT01537757|Experimental|Part 2, Panel F - Healthy Control Group to Match Panel E|
10000409|NCT01537770|Active Comparator|Vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
10000410|NCT01537770|Sham Comparator|lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
10000411|NCT01537796|Experimental|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
10000412|NCT01537796|Experimental|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
10000413|NCT01537796|Experimental|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
10000414|NCT01537809|Active Comparator|D3 600 IU/ daily|Subjects randomized to 600 IU/day of vitamin D3 taken orally for six months.
10000415|NCT01537809|Active Comparator|D3 1000 IU/ daily|Subjects randomized to 1000 IU/day of vitamin D3 taken orally for six months.
10000416|NCT01537809|Active Comparator|D3: 2000 IU/daily|Subjects randomized to 2000 IU/day of vitamin D3 taken orally for six months.
10000417|NCT01537822|Experimental|hysteroscopic morcellator|Women, randomized into getting a treatment with the hysteroscopic morcellator.
10000418|NCT01537822|Active Comparator|Resectoscope|Women, randomized into getting a treatment with the resectoscope.
9938529|NCT00967915|Experimental|Frenotomy|Group of neonates that will receive frenotomy for tongue-tie
9938530|NCT00967915|Sham Comparator|No frenotomy|Group of infants that will undergo sham procedure (no frenotomy performed)
9938531|NCT00967928|Experimental|Single arm|All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
9938532|NCT00967967|Other|Mometasone furoate and desloratadine|Mometasone and desloratadine treatment
9938533|NCT00967980|Active Comparator|1. Femoral Nerve Block|Patients will be randomized with a computer program to receive a femoral catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
9938534|NCT00967980|Active Comparator|2. Psoas Compartment Catheter|Patients will be randomized with a computer program to receive a psoas compartment catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
9938535|NCT00968006|Experimental|Treatment|Sitagliptin 100 mg once daily for 4 weeks
9938536|NCT00968006|No Intervention|Control|No change in anti-diabetic treatment regimen for at least 4 weeks.
9938537|NCT00968045|Placebo Comparator|Placebo|100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.
9938538|NCT00968045|Experimental|Study drug|Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start
9938539|NCT00968110|Experimental|Xolair|All patients will receive Xolair treatment for 16 weeks.
9938540|NCT00968136||a short-term trial of the ketogenic diet|
9938541|NCT00968136||long-term trial of the ketogenic diet.|
9938542|NCT00968162|Experimental|Dose de-escalation|
9938543|NCT00968175|Active Comparator|Group 1: CPN + analgesic therapy|Receives ultrasound guided celiac plexus neurolysis (CPN) in addition to standard analgesic therapy
9938544|NCT00968175|No Intervention|Analgesic therapy alone|Will not receive ultrasound guided celiac plexus neurolysis (CPN); only standard analgesic therapy for pain management
9938545|NCT00968188|Experimental|Active intervention|Highly interactive, motivational, culturally tailored, online HIV prevention.
9938546|NCT00968188|Active Comparator|Information only|Medically fact based online intervention.
9938547|NCT00968214||Single group|DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
9938548|NCT00968266|Experimental|Group intervention|"In short, the intervention consists of two group sessions moderated by a pharmacist. During these sessions, patients' self-perceived needs to take medication ('necessity beliefs'), concerns about taking medication ('concern beliefs'), and practical barriers are discussed. To explore a patient's individual ambivalence regarding his/her beliefs and barriers, the pharmacist uses Motivational Interviewing techniques. In between the sessions, participants make a homework assignment about their own beliefs and barriers, and eight weeks after the second session, a follow-up call to the individual patients is made by the pharmacist.~Patients in the experimental arm also receive a brochure about the DMARDs they currently use (see: control arm)"
9938549|NCT00968266|Active Comparator|Control arm: usual care|In the control arm, patients receive a brochure about the DMARDs they are currently using.
9938550|NCT00968279||Atrial Fibrillation|
9938551|NCT00968292|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
9938552|NCT00968292|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
9938553|NCT00968305||Children with asthma|African American children with clinically diagnosed stable asthma
9938554|NCT00968318|Other|Rate of seroma formation|Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion
9938555|NCT00968331|Experimental|REVLIMID plus RITUXIMAB|"Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles."
9938556|NCT00968357|Experimental|SCV-07|Cohort 1: SCV-07 0.1 mg/kg. Cohort 2: 1.0 mg/kg per day administered SC
9938557|NCT00968370|Active Comparator|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
9938558|NCT00968370|Other|Hospital management|Hospital management: all children admitted at the hospital will be managed with injection Ceftriaxone and other micronutrients for the total duration of hospitalization as per approved protocol.
10000419|NCT01537848||post-operative collection|patients suffering from a post-operative abdominal collection
10000420|NCT01537861|Experimental|Arm 1|"Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.~Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.~Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.~PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen."
10000421|NCT01537874|Experimental|Motivational Interview Intervention|Motivational interviewing session (1 hour in home) plus 2 follow-up phone calls
10000422|NCT01537874|Other|Usual Best Practices|Standard care delivered using informational materials
10000423|NCT01537939|Other|Walking|Quasi-experimental design with one-group, post-test only
10000424|NCT01537978|Experimental|Video game play|Changes in upper limb; strength, active range of motion, electromyographic activity as well as heart rate response.
10000425|NCT01537991|Experimental|Group 1A|Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
10000426|NCT01537991|Experimental|Group 1B|Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
10000427|NCT01537991|Experimental|Phase II|All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.
10000428|NCT01538004||BpTRU readings in private office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
10000429|NCT01538004||BpTRU readings in open office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an open office area The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
10000430|NCT01538017|Active Comparator|Collagenase injection|Injection of collagenase obtained from Clostridium Histolyticum in contracture string
10000431|NCT01538017|Active Comparator|Percutaneous needle fasciotomy|PNF ad modum Lermusiaux and Debeyre
10000432|NCT01538030||Amniotic Fluid Volume > 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1
10000433|NCT01538030||Amniotic Fluid Volume < 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less.
10000434|NCT01538043|Active Comparator|local mud packs and thermal-mineral bath|50 patients with primary knee OA will be treated with daily local mud packs and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
10000435|NCT01538043|No Intervention|regular routine ambulatory care|50 patients, the control group, will continue regular routine ambulatory care
10000436|NCT01538056|Experimental|Fenestrated procedure|Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
10000437|NCT01538069|No Intervention|Control group|
10000438|NCT01538069|Experimental|Exercise group|
10000439|NCT01538069|Experimental|CPAP group|
10000440|NCT01538069|Experimental|Exercise and CPAP group|
10000441|NCT01538082||Patients without stress|Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
10214436|NCT05223764||Fertility preservation population|all women who underwent oocyte cryopreservation cycles for oncological purposes from January 2001 to December 2017 at Fertility Center of Humanitas Research Hospital, Rozzano (Milano), Italy
10214437|NCT05223725|Experimental|dose escalation|initial phase, increasing dose
10214438|NCT05223725|Experimental|low dose|second phase, fixed dose 5x10(11) vp
10214439|NCT05223725|Experimental|high dose|second phase, fixed dose 2x10(12) vp
10214440|NCT05223725|No Intervention|control|second phase, blinded, randomized with no intervention delivered but with testing and monitoring.
10214441|NCT05223712||Development Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
10214442|NCT05223712||Development Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
10214443|NCT05223712||Validation Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
9938559|NCT00968383|Active Comparator|Optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification
9528820|NCT03207295|Placebo Comparator|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
9938560|NCT00968383|Experimental|PCI with optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting
9938561|NCT00968396|Experimental|Stem Cell Collection + Transplantation|Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m^2 IV over 30 minutes daily on Days -2 and -1.
9938562|NCT00968409|Other|FFNP-PET/CT Imaging|All subjects will receive an injection of F-18-FFNP followed by PET/CT imaging, laboratory testing and safety testing.
9938563|NCT00968422|Experimental|Low dose ABT-384|
9938564|NCT00968422|Experimental|Mid dose ABT-384|
9938565|NCT00968422|Experimental|High dose ABT-384|
9938566|NCT00968422|Placebo Comparator|Placebo|
9938567|NCT00968435|Experimental|(IMRT) + cisplatin + bevacizumab + cetuximab|This is a single-institution, non-randomized, phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab + cetuximab.
9938568|NCT00968448|Active Comparator|Training|respiratory muscle training (pressure threshold loading)
9938569|NCT00968448|Sham Comparator|sham training|training with low resistance
9938570|NCT00968461|Experimental|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
9938571|NCT00968487|Experimental|Lyophilized Plasma|
9938572|NCT00968487|Active Comparator|Fresh Frozen Plasma|
9938573|NCT00968500||Parents Who Have Lost a Child to Cancer|The overall goal of the proposed cross-sectional study is to obtain information necessary to the development of an effective Meaning-Centered Grief Intervention for parents who lost a child to cancer. In order to identify a subset of parents with whom we will conduct qualitative interviews with a subset of participants to address Aims 1 and 2, we will first screen participants to determine their levels of Prolonged Grief Disorder symptoms using a quantitative assessment (PG-13). The screening measure (PG-13) and the additional questionnaires included in the quantitative battery of measures will be analyzed to achieve Aim 3.
9938574|NCT00968513|Active Comparator|Usual Care|(N=150) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
9938575|NCT00968513|Experimental|Brief Treatment|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization.
9938576|NCT00968513|Experimental|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
9938577|NCT00968552||Patients undergoing stent placement|Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care.
9938578|NCT00968565|Experimental|Citrate|Sodium citrate will be infused as the blood enters the ECMO circuit and calcium chloride will be infused as the blood leaves the ECMO circuit and enters the patient
9938579|NCT00968578|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
9938580|NCT00968578|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
9938581|NCT00968591|Experimental|RAD001|
9938582|NCT00968604|Experimental|BikDD Nanoparticle|BikDD Nanoparticle starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
9938583|NCT00968630|Experimental|Treatment (HIV-specific immune reconstitution after HCT)|Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, +365, and +730, and then annually thereafter as feasible.
9938584|NCT00968643|Active Comparator|Arm I (control)|Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
9938585|NCT00968643|Experimental|Arm II|Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
9938586|NCT00968695|Experimental|Albumin|The subjects will be receiving albumin 20% infusions
9938587|NCT00968721||IBD patients|
9938588|NCT00968734|Experimental|Low fat meal|
9938589|NCT00968734|Experimental|Hight fat meal|
9938590|NCT00968747|Experimental|Fasting (Healthy).|Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
9938591|NCT00968747|Experimental|Fasting (NAFLD)|Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
9938592|NCT00968747|Experimental|Hypocaloric diet (NAFLD)|Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
9938593|NCT00968747|Experimental|Oral carbohydrate challenge|Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
9938594|NCT00968760|Experimental|CD19-specific T cell Infusion without IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 1 - low dose of T cells without IL-2.~Group 3 - higher dose of T cells without IL-2."
9938595|NCT00968760|Experimental|CD19-specific T cell Infusion with IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 2 - higher dose of T cells with IL-2.~Group 4 - higher dose of T cells with IL-2."
9938596|NCT00968773|Experimental|The Rebound hernia repair device with no fixation|Competent adults who have a unilateral, bilateral inguinal hernia that is primary in nature.
9938597|NCT00968773|Active Comparator|Standard Hernia Mesh using fixation|Competent adults who have a unilateral or bilateral inguinal hernia that is primary in nature.
9938598|NCT00968786|No Intervention|no home monitoring|no automated measuring devices for patients use at home
9938599|NCT00968877|Active Comparator|Cholecalciferol|
9938600|NCT00968877|Placebo Comparator|Placebo|
9938601|NCT00968903|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
9938602|NCT00968903|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
9938603|NCT00968916|Experimental|1|"Level 1:~15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 2:~25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 3:~35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 4:~50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal"
9938604|NCT00968929|Experimental|r-SK group|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
9938605|NCT00968929|Active Comparator|UK group|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
9938606|NCT00968955|Active Comparator|Local infiltration with ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
9938607|NCT00968955|Placebo Comparator|Local infiltration with saline|Local infiltration with saline (150 ML) (placebo)
9938608|NCT00968994|Experimental|exSALT SD7™ Wound Dressing|The exSALT™ SD7 Wound Dressing provides an antimicrobial barrier that inhibits microbial growth in the dressing. The exSALT™ SD7 Wound Dressing consists of 3 layers: two non-adherent polyethylene mesh wound contact layers and one absorbent core made of polyester. All three layers are silver coated. The concentration of silver on the exSALT™ SD7 Wound Dressing is approximately 0.4 mg/cm2 (2.5% w/w).
10214444|NCT05223712||Validation Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
10214445|NCT05223712||Test Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
10000442|NCT01538082||Patients with stress|Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
10000443|NCT01538095|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
10000444|NCT01538108|Experimental|NMB's PTA Balloon catheter with paclitaxel|
10000445|NCT01538108|Active Comparator|Standard Angioplasty Balloon|
10000446|NCT01538121||Cases-Early Severe Preeclampsia|Patients with severe preeclampsia before 34 weeks of gestation
10000447|NCT01538121||Controls|Patients with normal pregnancies at term.
10000448|NCT01538134||Cases|Patients with ultrasonographic diagnosis of fetal growth restriction.
10000449|NCT01538134||Control|Patients with normal pregnancies at term.
10000450|NCT01538147||Cases|Patients with Severe preeclampsia
10000451|NCT01538147||Control|Patients with normal pregnancies at term
10035002|NCT01802008|Active Comparator|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
10035003|NCT01802021|Experimental|Qingshu-Yiqi-Tang+standard therapy|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.~1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD."
10035004|NCT01802021|No Intervention|1st line doublet chemotherapy|1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
10035005|NCT01802047|Experimental|Electric Pump Modality|Each mother follows all 3 electric pump modalities in a randomized order.
10035006|NCT01802099|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
10035007|NCT01802099|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
10035008|NCT01802112|Placebo Comparator|Maltodextrins|15 grams of maltodextrins per day dissolved in water during 21 days
10035009|NCT01802112|Experimental|Resistant maltodextrins|15 grams of resistant maltodextrins per day, dissolved in water during 21 days
10035010|NCT01802125||Basic science (SNP array analysis)|Tissue samples are analyzed using laboratory biomarker analysis for LOH and SNP array profiling using microarray and immunohistochemistry.
10035011|NCT01802138|Experimental|Activated T-lymphocyte|"This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.~If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated."
10035012|NCT01802164|Experimental|1|Conventional abdominal wall closure with mesh implantation
10035013|NCT01802164|No Intervention|2|Conventional abdominal wall closure without mesh implantation
10035014|NCT01802177|Experimental|UVB excimer light|Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
10035015|NCT01802177|No Intervention|No treatment (covered)|
10035016|NCT01802190||Deafness patients|Deafness patients
10035017|NCT01802229|Active Comparator|Suture|Umbilical port-site closure with simple suture of the fascia.
10035018|NCT01802229|Experimental|Prophylactic mesh|Umbilical port-site closure with mesh placement
10214446|NCT05223712||Test Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
10214447|NCT05223686|Experimental|Human CD19-CD22 Targeted T Cells Injection|Single administration：1.0×10^6 CAR+T, 3.0×10^6 CAR+T，6.0×10^6 CAR+T
10214448|NCT05223660|Experimental|Low dose KT07|KT07 single dose (4 capsules) followed by multiple doses for 5 days (tid)
10214449|NCT05223660|Experimental|High dose KT07|KT07 single dose (6 capsules) followed by multiple doses for 5 days (tid)
10214450|NCT05223660|Placebo Comparator|Low dose placebo|Placebo single dose (4 capsules) followed by multiple doses for 5 days (tid)
10214451|NCT05223660|Placebo Comparator|High dose placebo|Placebo single dose (6 capsules) followed by multiple doses for 5 days (tid)
10214452|NCT05223647|Experimental|Chemo-immunotherapy plus thoracic radiotherapy|"Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.~Thoracic radiotherapy of 30 Gy/10 fractions between 2nd and 3rd carboplatin/etoposide/durvalumab course."
9938609|NCT00968994|Active Comparator|Xeroform® Petrolatum Dressing|Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
9938610|NCT00969007|Experimental|Lifestyle counseling|
9938611|NCT00969020|Active Comparator|Telemedicine|RRS via telemedicine. By developing the concept of Remote Rehabilitation Support (RRS) the investigators will try to bring preoperative education of the patient, dissemination of information and postoperative support to a new level.
9938612|NCT00969020|No Intervention|Standard|The standard procedure for THA used under The Lundbeck Center for fast track hip and knee surgery
9938613|NCT00969033|Experimental|CS-1008 with irinotecan|CS-1008 and irinotecan
9938614|NCT00969033|Active Comparator|irintoecan|irinotecan alone
9938615|NCT00969046|Experimental|Bolus|20 min bolus infusion
9938616|NCT00969046|Experimental|CIV-1d|1 day continuous infusion
9938617|NCT00969046|Experimental|CIV-5d|5 day continuous infusion
9938618|NCT00969059|Placebo Comparator|PLACEBO|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive placebo for 28 days.
9938619|NCT00969059|Experimental|Active|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive 7.5 mg twice daily (bid) GW856553 for 28 days.
9938620|NCT00969072|Experimental|GI198745|
9938621|NCT00969085|Experimental|Curcumin|
9938622|NCT00969111|Experimental|Postop Non-High Risk|Proton to 66.6 CGE
9938623|NCT00969111|Experimental|Postop High Risk|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
9938624|NCT00969111|Experimental|Salvage Non-High Risk|Proton to 70.2 CGE
9938625|NCT00969111|Experimental|Salvage High Risk|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
9938626|NCT00969137|Active Comparator|Nicotine|Intravenous Nicotine
9938627|NCT00969137|Placebo Comparator|Saline|Saline infusion
9938628|NCT00969163|Experimental|1|2.5 mg testosterone gel
9938629|NCT00969163|Experimental|2|300 ug testosterone gel
9938630|NCT00969163|Placebo Comparator|3|placebo gel
9938631|NCT00969176|No Intervention|paracetamol|not applicable, since all included cases will receive intravenous paracetamol
9938632|NCT00969189||Children|between 10 and 30 kgs
9938633|NCT00969189||Infants|between 5 - 10 kg
9938634|NCT00969202|Experimental|Stereotactic Radiosurgery using NovalisTx|Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
9938635|NCT00969215|Experimental|Laser treatment|Half of each subject's scar will be treated with a fractional CO2 laser.
9938636|NCT00969215|No Intervention|No treatment|Half of each subject's scar will not be treated.
9938637|NCT00969254|Experimental|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
9938638|NCT00969254|Active Comparator|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
9938639|NCT00969267|Experimental|Stimulation A|with needle A stimulation
9938640|NCT00969267|Active Comparator|Stimulation B|with stimulation
9938641|NCT00969267|Sham Comparator|Stimulation C|without needle
9938642|NCT00969306|Active Comparator|Chloroquine|Patients receive Chloroquine
9938643|NCT00969319||Group 1|
9938644|NCT00969345|Sham Comparator|Control Group|Stretching exercises performed twice a day for 10 minutes (4 months)
9938645|NCT00969345|Active Comparator|Respiration Group|Respiratory Yoga exercises performed twice a day for 10 minutes (4 months)
9938646|NCT00969371|Experimental|Lenstec Tetraflex IOL implantation|patients in Study arm received TetraFlex Lens
9938647|NCT00969371|Active Comparator|Control IOL|commercially approved PCIOL implanted
9938648|NCT00969384|Experimental|waist circumferences|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
9938649|NCT00969384|Experimental|Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
9938650|NCT00969397|Experimental|Topical Antiangiogenic|Topical Antiangiogenic Agents
9938651|NCT00969397|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
9938652|NCT00969410|Experimental|AV-299 administered IV (monotherapy)|Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if <= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If >= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
9938653|NCT00969423|Experimental|5 mm equipment|5 mm videoscopic equipment
9528821|NCT03207412|Experimental|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
9938654|NCT00969423|Experimental|10 mm|Use of standard 10 mm VATS equipment
9938655|NCT00969449|Experimental|Arm 1|
9938656|NCT00969449|Active Comparator|Arm 2|
9938657|NCT00969462|No Intervention|Doxorubicin|Single arm
9938658|NCT00969475|No Intervention|Control|Half of each subject's wound will not be treated.
9938659|NCT00969475|Experimental|Laser resurfacing|Half of each subject's wound will be treated with a fractional CO2 laser.
9938660|NCT00969488|Experimental|high protein diet group|"Women in high protein diet will be stimulate to consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group. The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats). The experimental groups will also receive six cans of sardine to increase the women's commitment to the study.~Both women group will receive a nutritional plan based on an 1800 kcal diet."
9938661|NCT00969488|Active Comparator|normal protein diet group|The control group will receive a diet to lose weight with norma protein intake and will receive 2kg of pasta to increase the women's commitment to the study. The nutritional plan based on an 1800 kcal diet.
9938662|NCT00969514||Robotic cystectomy|Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO
9938663|NCT00969527|Experimental|A|Oncoxin + Viusid
9938664|NCT00969527|Placebo Comparator|B|
9938665|NCT00969566|Experimental|Metformin+Sitagliptin|Initial combination of metformin and sitagliptin
9938666|NCT00969592|Active Comparator|insulin glulisine, insulin aspart|insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp
9938667|NCT00969592|Active Comparator|insulin aspart, insulin glulisine|insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp
9938668|NCT00969605|Active Comparator|Pressure support ventilation|
9938669|NCT00969605|Active Comparator|Adaptive support ventilation|
9938670|NCT00969631|Experimental|Metformin-CC|
9938671|NCT00969631|Active Comparator|Laparoscopic ovarian diathermy (LOD)|
10000452|NCT01538173|Experimental|HES group|Application of twice a day 250ml HES 6% for three days postoperatively.
9938672|NCT00969644|Active Comparator|GH|
9938673|NCT00969644|Active Comparator|Pegvisomant|
10000453|NCT01538173|Active Comparator|NaCl group|Application twice a day 500ml 9% NaCl for three days postoperatively.
10000454|NCT01538186||PCI without treating the side branch|
10000455|NCT01538186||PCI with treating the side branch|
10000456|NCT01538225|Experimental|first sativex, second placebo|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)
10000457|NCT01538225|Experimental|first placebo, second sativex|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)
10000458|NCT01538238|Experimental|pazopanib|pazopanib 800mg qd
10000459|NCT01538251|Experimental|Propionyl-L-carnitine|modified release tablets 500 mg
10000460|NCT01538251|Placebo Comparator|Placebo|Modified release tablet 500 mg
10000461|NCT01538277|Experimental|Contact Force arm|the real-time contact force will be known to the operator
10000462|NCT01538277|Active Comparator|Standard|Standard ablation arm
10000463|NCT01538303||measurement absolute flow and resistance|
10000464|NCT01538316|Active Comparator|Quercetin supplement|
10000465|NCT01538316|Active Comparator|Genistein supplement|
10000466|NCT01538316|Placebo Comparator|Placebo|
10000467|NCT01538329|Experimental|Amantadine|Patients with amantadine
10000468|NCT01538329|Placebo Comparator|Placebo|Patients with amantadine placebo
10000469|NCT01538342|Other|chronic plaque psoriasis|3 biopsies: 2 lesional and 1 non-lesional
10000470|NCT01538342|Other|pustular psoriasis|3 biopsies: 2 lesional and 1 non-lesional
10000471|NCT01538342|Other|erythrodermic psoriasis|3 biopsies: 2 lesional and 1 non-lesional
10000472|NCT01538342|Other|atopic dermatitis|2 biopsies: 1 lesional and 1 non-lesional
10000473|NCT01538342|Other|healthy patients|1 biopsy of healthy skin.
10000474|NCT01538355|Experimental|Prolonged fasting|Patients undergo an initial 7-day fasting episode.
10000475|NCT01538355|Experimental|Ketogenic low glycemic load treatment|Patients receive a ketogenic low glycemic load treatment from the outset of the study.
10000476|NCT01538355|Experimental|Control diet|Patients stay on their regular diet.
10035019|NCT01802242|Experimental|Active Radiation Treatment (Cohort 2)|
9938674|NCT00969683|Active Comparator|Double lumen tube without a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
9938675|NCT00969683|Experimental|Double lumen tube with a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
9938676|NCT00969696|Active Comparator|Galatamine|Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
9938677|NCT00969696|Placebo Comparator|Sugar Pill|Sugar Pill
9938678|NCT00969735|Active Comparator|Cryoablation|Deflectable over-the-wire cryoablation balloon catheter (Arctic Front®, Cryocath Technologies)
9938679|NCT00969735|Active Comparator|Radiofrequency ablation|Open irrigation ablation catheter (Navistar® Thermo-cool®, Biosense Webster Inc).
9938680|NCT00969787|Experimental|DWP05195|
9938681|NCT00969800|Experimental|Active Cleverin Gel|Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
9938682|NCT00969800|Sham Comparator|Inactive Cleverin Gel|Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
9938683|NCT00969813|Experimental|Normal hepatic function|
9938684|NCT00969813|Experimental|Mild hepatic impairment|
9938685|NCT00969813|Experimental|Moderate hepatic impairment|
9938686|NCT00969826|Experimental|GCPGC 30 μg/kg|Ten volunteers were administered GCPGC 30 μg/kg or placebo (active:placebo=8:2)
9938687|NCT00969826|Experimental|GCPGC 100 μg/kg|Ten volunteers were administered GCPGC 100 μg/kg or placebo (active:placebo=8:2)
9938688|NCT00969826|Experimental|GCPGC 300 μg/kg|Ten volunteers would be administered GCPGC 300 μg/kg or placebo (active:placebo=8:2)
9938689|NCT00969826|Experimental|Neulasta 100 μg/kg|Eight volunteers were administered Neulasta 100 μg/kg
9938690|NCT00969839|Experimental|Intramedullary Fixation System|Humeral fractures to be treated with the Intramedullary Fixation System
9938691|NCT00969852|Experimental|Sertraline|Single Arm
9938692|NCT00969865||Individualized Managment Group|Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
9938693|NCT00969865||Standard Management Group|Participants who receive standard of care.
9938694|NCT00969891||AML patients in induction treatment|
9938695|NCT00969904|Active Comparator|1|
9938696|NCT00969904|Placebo Comparator|2|
9938697|NCT00969917|Experimental|IPI-504|IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
9938698|NCT00969930||healthy controls|
9938699|NCT00969930||BD type I patients|
9938700|NCT00969943||Cocaine-dependent Men|
9938701|NCT00969943||Cocaine-dependent Women|
9938702|NCT00969943||Control Men|
9938703|NCT00969943||Control Women|
9938704|NCT00969956||Group A|150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
9938705|NCT00969956||Group B|150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
9938706|NCT00969956||Group C|150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
9938707|NCT00969956||Group D|50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)
9938708|NCT00969969|Active Comparator|Arthrodesis|Fusion
9938709|NCT00969969|Experimental|Cartiva|Synthetic Cartilage Implant
9938710|NCT00969982|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
9938711|NCT00969982|Active Comparator|misoprostol|Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
9938712|NCT00969995||migraine1|50 subjects with migraine without aura
9938713|NCT00969995||migraine 2|50 subjects with migraine with aura
9938714|NCT00969995||tension|50 subjects with tension headache
9938715|NCT00969995||cluster|50 subjects with cluster headache
9938716|NCT00969995||Healthy|50 healthy subjects
9938717|NCT00970008|Active Comparator|Massage 30 min - 2x wk for 4 wks & 1x wk for 4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
9938718|NCT00970008|Active Comparator|Massage 60 min - 2x wk for 4 wks & 1x wkly for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
9938719|NCT00970008|Active Comparator|Massage 30 min sessions - 1x/wk for 8wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
9938720|NCT00970008|Active Comparator|Massage 60 min sessions - 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
9938721|NCT00970008|No Intervention|Usual Care Control|Continue on usual care for eight (8) week period.
9938722|NCT00970021|Placebo Comparator|Water with artificial colour|Placebo
9938723|NCT00970021|Active Comparator|Extract of agaricus blazei Murill|Agaricus blazei Murill
9938724|NCT00970034||AF|Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
9938725|NCT00970034||SR|Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
9938726|NCT00970047||Pregnant females|Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.
9938727|NCT00970060|Experimental|Exercise program|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
10000477|NCT01538381|Experimental|Afatinib|Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
9938728|NCT00970086|Experimental|transversus abdominal plane block|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%."
9938729|NCT00970099|Active Comparator|Exercise|12 week exercise regimen
9938730|NCT00970099|Placebo Comparator|non-exercise|Normal lifestyle routine with no exercise for 12 weeks.
9938731|NCT00970112|Placebo Comparator|Placebo|Placebo 1 hour before surgery
9938732|NCT00970112|Experimental|Etoricoxib|Etoricoxib 1 hour before surgery
9938733|NCT00970112|Experimental|Dexamethaone|Dexamethasone 1 hour before surgery
9938734|NCT00970125|Experimental|Cancer subjects|
9938735|NCT00970138|Experimental|A 850|apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9938736|NCT00970138|Experimental|B 425|apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9938737|NCT00970138|Placebo Comparator|C pla|placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9938738|NCT00970177|Experimental|low dose of antigen + low dose of adjuvant|
9938739|NCT00970177|Experimental|high dose of antigen + high dose of adjuvant|
9938740|NCT00970177|Experimental|high dose of antigen|
9938741|NCT00970229|Experimental|Assess [123I]MNI-420 and SPECT Imaging|To assess [123I]MNI-420 and SPECT Imaging in PD, HD subjects and similarly aged healthy subjects.
9938742|NCT00970255|Active Comparator|Frenotomy|
9938743|NCT00970255|Sham Comparator|Sham Frenotomy|
9938744|NCT00970333|Experimental|assess [18F]-FEPPA PET imaging|
9938745|NCT00970346|Experimental|Inhaled OligoG CF-5/20|
9938746|NCT00970372||Involuntary patients|Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
9938747|NCT00970372||Voluntary patients|Voluntary patients on the same wards. Most patients have dual-diagnosis.
9938748|NCT00970385|Active Comparator|CHOP 21|"Induction therapy CHOP every 21 days:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
9938749|NCT00970385|Experimental|VIP/ABVD arm|"VIP cycle:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD cycle:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD)."
9938750|NCT00970398|No Intervention|Reference group|Human milk breastfeeding
9938751|NCT00970398|Active Comparator|Control formula|Standard infant formula, with no Osteopontin supplemented.
9938752|NCT00970398|Active Comparator|Formula with 50% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.
9938753|NCT00970398|Active Comparator|Formula with 100% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.
9938754|NCT00970411|Experimental|KRN951|
9938755|NCT00970437|Active Comparator|CBASP|CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
9938756|NCT00970437|Placebo Comparator|SYSP|The comparator for CBASP is SYSP, a system of supportive psychotherapy, an active but less specific, manualized control treatment. SYSP - defined as non-interpersonal and non-cognitive-behavioral therapy - resembles supportive clinical management, client-centered therapy, counseling, and psychoeducation about depression. There is no specific explanatory mechanism for treatment effect offered to the patient and it does not focus on specific themes.
9938757|NCT00970450|Experimental|Paracetamol|
9938758|NCT00970450|Experimental|Paracetamol/Tropisetron|
9938759|NCT00970450|Placebo Comparator|Saline|Proband will receive Saline
9938760|NCT00970450|Active Comparator|Tropisetron|Proband will receive Tropisetron alone
9938761|NCT00970463||GH|Patients with GHD
9938762|NCT00970463||Pegvisomant and Somatostatin analogues|Acromegaly
9938763|NCT00970515|Experimental|Laparoscopic approach|group A: Laparoscopic approach
9938764|NCT00970515|Active Comparator|Open approach|group B: Open anterior approach
9938765|NCT00970528|Experimental|Arm 1|
9938766|NCT00970528|Active Comparator|Arm 2|
9938767|NCT00970541|Active Comparator|Cinnamon Supplementation|A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E> 20:1) will be consumed before meals, three times per day.
9938768|NCT00970541|Placebo Comparator|Placebo|A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
9938769|NCT00970554|Active Comparator|Patching only|
9938770|NCT00970554|Experimental|Patching plus telescope group|
9938771|NCT00970567|Other|Arm 1|stop after positive ketone bodies in urine
9938772|NCT00970567|Other|Arm 2|stop after positive ketone bodies in blood, normal therapy
9938773|NCT00970567|Other|Arm 3|stop after positive ketone bodies in blood, additional therapy
9938774|NCT00970580|Experimental|BIIB022 in Combination with Paclitaxel and Carboplatin|BIIB022 in Combination with Paclitaxel and Carboplatin
9938775|NCT00970619|No Intervention|Conventional anticoagulation therapy|Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 [23], CBO 2008 [24]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
9938776|NCT00970619|Experimental|Ekos Endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
9938777|NCT00970645|Active Comparator|traditional mediastinoscopy/thoracoscopy|Traditional Mediastinoscopy used to detect or stage lung cancers.
9938778|NCT00970645|Active Comparator|EBUS/EUS|Minimal invasive technique for staging/detecting lung cancer.
9938779|NCT00970658|Experimental|Salonsip|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
9938780|NCT00970658|Active Comparator|Sabiá|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
9938781|NCT00970697|Experimental|becaplermin gel|application of a continuous thin layer of becaplermin gel (Regranex Gel®) during 8 weeks. The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment.
9938782|NCT00970697|Active Comparator|Duoderm Hydrogel™|application of a continuous thin layer of hydrogel dressing (Duoderm Hydrogel®), during 8 weeks. Duoderm Hydrogel™ is a sodium carboxymethylcellulose aqueous-based gel, similar in composition to becaplermin excipient.
9938783|NCT00970710|Experimental|Lifestyle counseling|VACOPP (Vaasa Childhood Obesity Primary Prevention Study): Intensified lifestyle counseling including physical activity and nutritional information beginning during maternity health care and continuing during child health care clinic visits.
9938784|NCT00970723|Experimental|intensive treatment|with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected
9938785|NCT00970723|Active Comparator|conventional treatment|in accordance with national guidelines
9938786|NCT00970749||history of chlamydia infection|Women who self-reported a history of cervical infection with Chlamydia trachomatis
9938787|NCT00970749||no history of chlamydia infection|Women who self-reported no history of cervical infection with Chlamydia trachomatis
9938788|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.1 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
9938789|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.15 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
9938790|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.2 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
9938791|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.1 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
9938792|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.15 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
9938793|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.2 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
9938794|NCT00970762|Active Comparator|Vecuronium 0.1 INT, 0.025 MNT|Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
9938795|NCT00970775|Experimental|1. AZD2423|
9938796|NCT00970775|Placebo Comparator|2. Placebo|
9938797|NCT00970788|No Intervention|verbal group|Verbal description of goals of care.
9938798|NCT00970788|Experimental|Video group|Video decision aid.
9938799|NCT00970827|Active Comparator|1|Leg postconditioning
9938800|NCT00970827|Active Comparator|2|Arm postconditioning
9938801|NCT00970827|Placebo Comparator|3|Control group
9938802|NCT00970840|Experimental|LNS-20gM or LNS-P&L|
9938803|NCT00970879|Experimental|cotrimoxazole (high)|CD4 cell count≥350/mm3
9938804|NCT00970879|Active Comparator|mefloquine|CD4 cell count≥350/mm3
9938805|NCT00970879|Experimental|cotrimoxazole (low)|CD4 cell count<350/mm3
9938806|NCT00970879|Active Comparator|mefloquine & cotrimoxazole|CD4 cell count<350/mm3
9938807|NCT00970905|Experimental|Aprepitant & Ondansetron|
9938808|NCT00970918|Experimental|1|
9938809|NCT00970931|Placebo Comparator|placebo|
9938810|NCT00970931|Experimental|chlortalidone-amiloride|
9938811|NCT00970957|Experimental|Central RVO - Macular edema - Avastin|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
9938812|NCT00970957|Sham Comparator|Central RVO - Macular edema - Sham|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
9938813|NCT00970957|Experimental|Branch RVO - Macular edema - Avastin|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
9938814|NCT00970957|Sham Comparator|Branch RVO - Macular edema - Sham|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
9938815|NCT00970970||Von Hippel Lindau|Adult patients with Von Hippel-Lindau disease
9938816|NCT00970983|Active Comparator|QUART|Patients in this arm will receive quadrantectomy, axillary dissection and radiotherapy (the current standard therapy).
9938817|NCT00970983|Experimental|QURT (SN-)|Patients will receive quadrantectomy, sentinel node investigation and radiotherapy. Selective axillary dissection will be performed if sentinel node is positive.
9938818|NCT00970996|Experimental|Biochemotherapy|Abraxane with Cisplatin, Temozolomide, interleukin-2 and interferon a2b
9938819|NCT00971009|Experimental|OPPC service|A practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
9938820|NCT00971009|Experimental|WebChoice IHCA|WebChoice is an interactive health communications application (IHCA) that in addition to offer a practice-integrated nurse administered online patient-provider communication (OPPC) service, allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
9938821|NCT00971009|No Intervention|Control group|The control group receives usual care
9938822|NCT00971022||Low-income Populations|
9938823|NCT00971061|Experimental|MSPI|Molteno single-plate implant
9938824|NCT00971061|Active Comparator|AVI|Ahmed valve implant
9938825|NCT00971074|Experimental|Hylan G-F 20|Single injection of Hylan G-F 20 into the affected knee.
9938826|NCT00971074|Sham Comparator|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
9938827|NCT00971087|Other|Biopsy|subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
9938828|NCT00971087|Other|screening|subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram
9938829|NCT00971100|Experimental|low dose of antigen + low dose of adjuvant|
9938830|NCT00971100|Experimental|high dose of antigen + high dose of adjuvant|
9938831|NCT00971100|Experimental|high dose of antigen|
9938832|NCT00971113|Experimental|sc-FOS+Sideritis euboea group|Jelly supplemented with short chain fructooligosaccharides and Sideritis euboea extract
9528320|NCT03212001||Administrators and Decision Makers (observations, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
9800605|NCT01691898|Experimental|Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
9800606|NCT01691898|Experimental|Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
9800607|NCT01691950||Reconstruction|Those who have undergone limb reconstruction following lower limb trauma
9938833|NCT00971113|Placebo Comparator|placebo group|Jelly without short-chain fructooligosaccharides and Sideritis euboea
9938834|NCT00971126|Experimental|Single Group Assignment|
9938835|NCT00971139|Experimental|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
9528321|NCT03212001||Technician (observation, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
9528322|NCT03212040|Active Comparator|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
9800608|NCT01691950||Healthy volunteers|Healthy volunteers for control
9800609|NCT01692119|Experimental|regular, pharmacy-based intervention|providing medication in weekly dosing aids and regular contacts with the local pharmacy
9800610|NCT01692119|No Intervention|usual care|usual care
9800611|NCT01692197|Experimental|E7070 + Idarubicin + Cytarabine|E7070 400 mg/m2 IV over 1 hour on day 1 and day 8 (+/- 2 days on Day 8 only) followed by, Idarubicin 8 mg/m2 IV over 1 hour daily for 3 days (days 9-11) and Cytarabine 1.0 g/m2 IV over 24 hours daily on day 9-12 (age <60 years) or days 9-11 (age > 60 years). Dexamethasone 10 mg IV daily for 3-4 days with cytarabine.
9800612|NCT01692275|Active Comparator|Medical Care + Chiropractic Care|Medical care plus chiropractic manipulative therapy
9800613|NCT01692275|Active Comparator|Conventional Medical Care Only|Conventional medical care only
9800614|NCT01692301|Experimental|LCZ696 (sacubitril/valsartan)|Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
9800615|NCT01692301|Active Comparator|Olmesartan|Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
9800616|NCT01692340|Experimental|Isotopically labeled lycopene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
9800617|NCT01692340|Experimental|Isotopically labeled phytoene|We will administer 3.2 mg isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
9800618|NCT01692340|Experimental|Isotopically labeled phytofluene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
9800619|NCT01692496|Experimental|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
9800620|NCT01692626|Experimental|Pimecrolimus on Left vs. Placebo on Right|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
9938836|NCT00971139|No Intervention|Control group|Patients receiving usual care
9938837|NCT00971152|Active Comparator|450 IU daily dose of gonadotrophin|
9938838|NCT00971152|Experimental|600 IU daily dose of gonadotrophin|
9938839|NCT00971165|Active Comparator|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
9938840|NCT00971165|Experimental|losartan|Oral losartan up to 100 mg daily, once a day, for 18 month
9938841|NCT00971191|Experimental|treatment|Patients treated with brief exposure to PF-00299804 prior to surgical resection
10000478|NCT01538381|Other|Observation|No treatment only observation
10035020|NCT01802242|Other|Prior Radiation Treatment (Control Cohort)|Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
9938842|NCT00971217|Experimental|Exercise|"Participants will engage in 2 exercise sessions each week for 10 weeks. Each session will last 50 minutes and will commence with a 5 minute warm up on the bike or treadmill and conclude with a 5 minute cool down. The participants will be required to exercise on their own without interference from others. Participants will wear heart rate monitors to ensure that they are exercising to moderate intensity (70-80% of age predicted maximum heart rate).~Exercise: Aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines."
9938843|NCT00971217|Experimental|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a web-site specifically aimed at young men once per week and complete the set cognitive-behavioural tasks.
9938844|NCT00971217|Experimental|Combined Exercise/Online CBT|Participants will simultaneously par-take in both the exercise and the online CBT conditions already outlined.
9938845|NCT00971217|No Intervention|Control|Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
9938846|NCT00971230|Experimental|FTC/TDF- Daily|FTC/TDF dosed daily
9938847|NCT00971230|Experimental|FTC/TDF-Intermittent|FTC/TDF dosed intermittently
9938848|NCT00971230|Placebo Comparator|Placebo-Daily|Placebo dosed daily
9938849|NCT00971230|Placebo Comparator|Placebo-Intermittent|Placebo dosed intermittently
9938850|NCT00971256||Bladder cancer patients|Bladder cancer patients from one Beaumont Urologist.
9938851|NCT00971308|Experimental|BMS-824393 (Panel 1)|
9938852|NCT00971308|Experimental|BMS-824393 (Panel 2)|
9938853|NCT00971308|Experimental|BMS-824393 (Panel 3)|
9938854|NCT00971308|Experimental|BMS-824393 (Panel 4)|
9938855|NCT00971308|Experimental|BMS-824393 (Panel 5)|
9938856|NCT00971347|Active Comparator|Nutrition brochure|Control participants will receive only a nutrition brochure, Finding Your Way to a Healthier You, based on a USDHHS/USDA publication, Dietary Guidelines for Americans 2005.
9938857|NCT00971347|Experimental|Chewing gum + nutrition brochure|Participants in the experimental arm will be instructed to incorporate gum chewing in their diet with a goal of at least 90 minutes per day. The schedule is 20 minutes each after breakfast, lunch and dinner plus 10 minutes mid-morning, mid-afternoon and 1 to 2 hours after dinner. Experimental participants also will be told to chew gum instead of unplanned eating in response to hunger, cravings, preoccupation with eating, or negative feelings.
9938858|NCT00971360||Conversion disorder|
9938859|NCT00971360||Healthy control|
9938860|NCT00971373|Experimental|Exp Scrubs|antimicrobial impregnated scrubs
9938861|NCT00971373|No Intervention|Non-antimicrobial scrubs|Non-antimicrobial scrubs
9938862|NCT00971386|Other|Normal Healthy Subjects|Normal healthy subjects without history, signs-symptoms or diagnosis of heart failure
9938863|NCT00971386|Other|Chronic Ambulatory Heart Failure|Diagnosis of Chronic Heart Failure and currently on optimal medical therapy
9938864|NCT00971386|Other|Acute Heart Failure|Patients admitted to the hospital with acute congestive heart failure.
9938865|NCT00971399|Experimental|RMS|ramosetron 0.1mg q.d. SL on D1-5
9938866|NCT00971399|Active Comparator|ODS|ondansetron 8mg, b.i.d SL on D1-5
10000479|NCT01538394|Experimental|Varenicline & nicotine patches|"Combined therapy by using Varenicline plus nicotine patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus placebo transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
10000480|NCT01538394|Placebo Comparator|Varenicline & placebo patches|"Monotherapy by using Varenicline plus placebo patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus nicotine transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
10000481|NCT01538407|No Intervention|Control group|No intervention group
10000482|NCT01538407|Active Comparator|Strength training group|The knee extension strength training intervention period is 12 weeks with training sessions three times per week.
10000483|NCT01538420|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
10000484|NCT01538420|Placebo Comparator|Placebo|Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
9938867|NCT00971438|Experimental|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
9938868|NCT00971438|Active Comparator|Repeat examination after observation|Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)
9938869|NCT00971451|Experimental|knee joint cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
9938870|NCT00971451|Experimental|TENS|continuous TENS for duration of the 1 hour exercise session
9938871|NCT00971451|No Intervention|No intervention|no modality intervention; just exercise
9938872|NCT00971464|Experimental|Eccentric viewing|"Eccentric viewing is the use of a retinal locus other than the anatomical fovea for fixation in cases when there is central vision loss. This other area (or areas) is called the preferred retinal locus (PRL). In eccentric viewing the patient is aware that they are looking to the side or using their side vision. Most patients with a dense central scotoma will develop eccentric viewing naturally over time. It is thought, however, that, in many cases the naturally developed PRL is not in the ideal position. The four components of eccentric viewing that will be taught are: 1) The optimal direction for eccentric viewing 2) Using large objects to teach eccentric viewing 3) Repetitive practicing of the technique and 4) Maintaining the eye in the eccentric viewing position."
9938873|NCT00971464|Active Comparator|CCTV arm|A CCTV is an electro-optical device mainly used for reading, but which can also be used for writing or viewing pictures. It is comprised of a video camera which faces downwards towards the reading material and which inputs the image to a digital monitor. Magnification is variable over a large range. By means of a zoom lens and the brightness, contrast, and image polarity (black letters on white or white on black) can be controlled to provide the best combination of viewing conditions for an individual user. The significant advantages of CCTV over optical magnifiers are that it provides high levels of magnification with a greater field of view (compared to the equivalent optical device), allows reading at a more normal viewing distance of about 40 - 50 cms and allows binocular viewing.
9938874|NCT00971477|Experimental|Teledermatology|Online Telemedicine Group
9938875|NCT00971477|Active Comparator|Usual Care|Conventional in-office care
9938876|NCT00971490|Experimental|Group 1|
9938877|NCT00971490|Placebo Comparator|Group 2|
9938878|NCT00971490|Sham Comparator|Group 3|
9938879|NCT00971503|Sham Comparator|saline injection|
9938880|NCT00971503|Experimental|Autologous bone marrow implantation|
9938881|NCT00971516|Active Comparator|Diabetes|compare cytokines between diabetes and non diabetes patients
9938882|NCT00971516|Active Comparator|Implants|Compare implant healing phases
9938883|NCT00971529||lifestyle|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups (smoking with tea filters or regular filters).
9938884|NCT00971529||tea filter|The investigators then recruited 59 volunteers with longer smoking history and stronger desire for quitting smoking for smoking cessation test using the tea filter.
9938885|NCT00971542|Experimental|low dose of antigen + low dose of adjuvant|
9938886|NCT00971542|Experimental|high dose of antigen + high dose of adjuvant|
9938887|NCT00971542|Experimental|high dose of antigen|
9938888|NCT00971555||Late preterm|Late preterm infants admitted to the NICU
9938889|NCT00971568||Urine sample|To prepare for SELDI-TOF we will use 15 samples. Each sample (25ul) will be analyzed with the Luminex 100 IS (MiraiBio, South San Francisco, CA) using a LINCOplex cytokine/che-
9938890|NCT00971581|Experimental|FDC KETOPROFEN+OMEPRAZOLE|One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks
9938891|NCT00971594|Experimental|WL+AEX|Weight loss plus aerobic exercise
9938892|NCT00971607|Active Comparator|1|Sevoflurane
9938893|NCT00971607|Placebo Comparator|2|Oxygen
9938894|NCT00971646||OAB|Patients with overactive bladder syndrome
9938895|NCT00971646||Osteoporosis|Patients with osteoporosis
9938896|NCT00971659|Experimental|insulin glargine + exenatide + metformin|
9938897|NCT00971659|Experimental|Insulin glargine + sitagliptin + metformin|
9938898|NCT00971659|Active Comparator|insulin glargine + metformin|
9938899|NCT00971672||Toddlers from Jewish origin|Toddlers from Jewish origin aged 18 to 36 months
9938900|NCT00971672||Toddlers from non Jewish origin|Toddlers aged 18 to 36 months belonging to non Jewish (Arab) population
9938901|NCT00971685|Experimental|Lenalidomide plus Dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
9938902|NCT00971698||Sickle Cell Patients|Patients with homozygous Sickle Cell Anemia
9938903|NCT00971698||Sickle Cell Thalassemia|Patients with Sickle Cell Thalassemia
9938904|NCT00971711|Experimental|Probiotic|To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).
9938905|NCT00971724|Placebo Comparator|Placebo|Treatment with placebo for 15 days
9938906|NCT00971724|Experimental|Prednisolone 7.5 mg daily|Treatment with prednisolone 7.5 mg daily for 15 days
9938907|NCT00971724|Experimental|Prednisolone 15 mg daily|Treatment with prednisolone 15 mg daily for 15 days
9938908|NCT00971724|Experimental|Prednisolone 30 mg daily|Treatment with prednisolone 30 mg daily for 15 days
9938909|NCT00971724|Experimental|Prednisolone 75 mg|Treatment with prednisolone 75 mg for a single day
9938910|NCT00971724|Experimental|Prednisolone 15 mg twice daily|Treatment with prednisolone 15 mg twice daily for a single day
9938911|NCT00971763|Experimental|R-GCVP|"Up to 6 x 21 day cycles of R-GCVP:~Gemcitabine 750mg/m^2 days 1 & 8 (increasing to 875mg/m^2 for cycle 2 & 1g/m^2 for subsequent cycles if tolerated satisfactorily)~Cyclophosphamide 750mg/m^2 day 1~Vincristine 1.4mg/m^2 day 1 (capped at 2mg)~Prednisolone 100mg/day days 1-5~Rituximab 375mg/m^2 day 1~Neulasta 6mg day 9"
9938912|NCT00971802|Experimental|Cohort 1|Healthy volunteers - PF-03882845 versus Placebo
9938913|NCT00971802|Experimental|Cohort 2|Healthy volunteers - PF-03882845 versus Placebo
9938914|NCT00971802|Experimental|Cohort 3|Healthy volunteers - PF-03882845 versus Placebo
9938915|NCT00971802|Experimental|Cohort 4|Healthy volunteers - PF-03882845 versus Placebo
9938916|NCT00971815|Active Comparator|escitalopram|A pill containing Escitalopram
9938917|NCT00971815|Placebo Comparator|placebo|a placebo pill
9938918|NCT00971854|Experimental|60 Hz stimulation|Experimental reduced frequency pallidal stimulation
9938919|NCT00971854|No Intervention|130 Hz stimulation|Current standard pallidal stimulation setting
9938920|NCT00971880||Patients receiving blood transfusions|All the patients with blood disorders that require blood transfusions
9938921|NCT00971893||Methylprednisolone Group|
9938922|NCT00971906|Experimental|low dose of antigen + low dose of adjuvant|
9938923|NCT00971906|Experimental|high dose of antigen + high dose of adjuvant|
9938924|NCT00971906|Experimental|high dose of antigen|
9938925|NCT00971958|Active Comparator|Mogen Clamp|
9938926|NCT00971958|Active Comparator|Plastibell|
9938927|NCT00971958|Active Comparator|AccuCirc|AccuCirc is a device approved by the FDA for circumcision of male infants up to ten days of life.
9938928|NCT00971971|No Intervention|Control|Traditional SLED
9938929|NCT00971971|Experimental|Profiling|dialysate temperature reduction with Na and ultrafiltration (UF) profiling
9938930|NCT00971984||Alpha thalassemia patients|Patients diagnosed with alpha thalassemia mutations and anemia
9938931|NCT00972036|Experimental|Unresectable colon cancer patients with liver metastases|This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
9938932|NCT00972049|Experimental|1|Capsule administered once orally
9938933|NCT00972049|Placebo Comparator|2|Capsule administered once orally
9938934|NCT00972062|Placebo Comparator|Placebo cream|Cream base used in compounding medications into cream media
9938935|NCT00972062|Experimental|Herbal Cream|Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications
9938936|NCT00972075|Experimental|Circadin|Circadin is 2 mg of prolonged release melatonin
9938937|NCT00972075|Placebo Comparator|Placebo|
9938938|NCT00972101|Experimental|Regimen 1: No TBI|High Dose Chemotherapy without Total Body Irradiation (TBI)
9938939|NCT00972101|Experimental|Regimen 2: TBI|High Dose Chemotherapy with Total Body Irradiation (TBI)
9938940|NCT00972114|Experimental|CABG combined cardiomyoplasty|Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
9938941|NCT00972114|Active Comparator|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
9938942|NCT00972114|Active Comparator|CABG alone|Coronary artery bypass graft surgery alone
9938943|NCT00972140|Experimental|Formoterol-HFA|Formoterol-HFA pMDI 12µg twice daily
9938944|NCT00972140|Active Comparator|Formoterol-DPI|Formoterol-DPI 12µg twice daily
9938945|NCT00972179|Active Comparator|AMG 157|Six subjects in each cohort (cohorts 1 to 6) will receive AMG 157 for a total of 36 subjects.
9938946|NCT00972179|Placebo Comparator|AMG 157 Placebo|Two subjects in each cohort (cohorts 1 to 6) will receive placebo, for a total of 12 subjects.
9938947|NCT00972192|Active Comparator|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and counseling immediately after the baseline interview. Patients underwent phlebotomy and serologic testing and results were disclosed the following day with post-test counseling (before they were discharged from the hospital).
9938948|NCT00972192|No Intervention|HIV testing post-discharge|Participants who were randomized to the control group were given a referral card and an appointment, by the interviewers, to return for free HIV testing and counseling at Mulago hospital one week after discharge. Participants who returned had their transport reimbursed.
9938949|NCT00972218|Experimental|Enteropathic spondyloarthritis|Patients have concomitant inflammatory spinal symptoms and inflammatory bowel disease.
9938950|NCT00972231||Thalassemia Group|Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia
9938951|NCT00972231||Sickle Cell Group|Patients with Sickle Cell Anemia and Sickle Cell Thalassemia
9938952|NCT00972257|Active Comparator|Drug: Dorzolamide/Timolol|
9938953|NCT00972257|Active Comparator|Treatment with Brimonidine/Timolol|
9938954|NCT00972270|Experimental|IMPELLA LP 2.5|
9938955|NCT00972270|Active Comparator|Intra-Aortic Balloon Pump|
9938956|NCT00972296||Persons with hemophilia with ankle pain|
10000485|NCT01538433||biopsy-proven IgA nephropathy|
9528323|NCT03212040|Active Comparator|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
9938957|NCT00972348|Experimental|Access to Personal Health Record|Full access to the Personal Health Record including lists of diagnoses, medications and laboratory values.
9938958|NCT00972348|Active Comparator|No access to the PHR|No access to the PHR but patients will complete surveys.
9938959|NCT00972387|Active Comparator|Order 1|Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
9938960|NCT00972387|Active Comparator|Order 2|Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
9938961|NCT00972387|Active Comparator|Order 3|Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
9938962|NCT00972387|Active Comparator|Order 4|Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
9938963|NCT00972413|Experimental|Group I|
9938964|NCT00972413|Experimental|Group II|
9938965|NCT00972413|Experimental|Group III|
9938966|NCT00972426|Experimental|Treatment A Group|Mikelan LA + Xalatan
9938967|NCT00972426|Active Comparator|Treatment B Group|Timoptol XE + Xalatan
9938968|NCT00972452|Experimental|Exercise|5-10d exercise training
9938969|NCT00972491|Other|0 sec, 60 sec, 90 sec|LMA will be inserted at 0, 60, and 90 seconds after eyelash reflex disappears
9938970|NCT00972556|Experimental|GMTA|
9938971|NCT00972556|Active Comparator|20% FC|
9938972|NCT00972569|Active Comparator|BNP with PDE-V|BNP (Nesiritide) will be infused starting at 0.0025 g/Kg/min IV for 3 hours, if tolerated increased to 0.005 g/kg/min for 45 hours without bolus with PDEV inhibition, they will also receive Sildenafil 12.5 mg at timepoints 0,12, 24 and 36 hours
9938973|NCT00972569|Active Comparator|BNP (Nesiritide) will be infused at 0.005 u/Kg/min IV for 48 h|BNP (Nesiritide) will be infused at 0.025 ug/Kg/min IV for 3 hours then 0.005ug/kg/min 45 hours without bolus. No PDE-V is given.
9938974|NCT00972569|No Intervention|standard care|Patients randomized to this group will continue to receive therapy at the discretion of the heart failure specialist who is managing the patient (with the exception of BNP and low dose dopamine). Blood and Urine will be collected after the patient has been randomized for 48 hours
9938975|NCT00972582|Experimental|Leucine|
9938976|NCT00972647|No Intervention|Unguided|Fluoroscopy images taken without laser beam guidance
9938977|NCT00972647|Experimental|Laser guided|Fluoroscopy images taken with laser beam guidance
10035021|NCT01802255|Experimental|Inhalatory sedation|Sevoflurane given via AnaConDa for sedation minimum 48 hours
9938978|NCT00972660|Active Comparator|Control group|"Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)"
9938979|NCT00972660|Experimental|Mesenchymal stem cell (MSC)|"Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
9938980|NCT00972673|Experimental|arm 1|In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.
9938981|NCT00972673|Placebo Comparator|arm 2|In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.
9938982|NCT00972686|Experimental|GSK2126458|GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
9938983|NCT00972699|Experimental|Mentor Mothers Intervention|In the intervention arm, participants will receive the Department of Health-delivered Prevention of Mother to Child Transmission (PMTCT) program plus the Project Masihambisane mentor mothers support program. HIV positive mentor mothers, who have been through the PMTCT program, will be recruited and trained to deliver the intervention to pregnant mothers living with HIV.
9938984|NCT00972699|No Intervention|Control|Mothers living with HIV in the standard of care control clinics will receive the Department of Health-delivered PMTCT program.
9938985|NCT00972712|Experimental|A|Bortezomib and Tipifarnib
9938986|NCT00972764||Control|
9938987|NCT00972764||Laryngomalacia Cases|
9938988|NCT00972790|Sham Comparator|Control Group|The patients in the control arm will receive sham nerve blocks with 20 ml of saline + epinephrine 1:200,000, in a manner identical to that described for the treatment group.
9938989|NCT00972790|Active Comparator|Intervention Group|The patients in the intervention group will receive bilateral scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000.
9938990|NCT00972803|Experimental|pistacia Mutica|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
9938991|NCT00972803|Placebo Comparator|placebo|The subjects were asked to use a mouthwash containing Placebo twice a day for 4 days.
10000486|NCT01538446|Experimental|1: Monitoring Arm|Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
10000487|NCT01538446|Active Comparator|2: Conventional Arm|Conventional Arm: fixed dose of prasugrel 5 mg
9528324|NCT03212079|No Intervention|Control|The participant will self motivate hi/herself to increase physical activities.
9528325|NCT03212079|Experimental|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
9938992|NCT00972803|Active Comparator|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
9938993|NCT00972829|Experimental|Crestor|Crestor 10 or 20 milligrams
9938994|NCT00972829|Active Comparator|Ezetimibe|Ezetimibe 5 or 10 milligrams
9938995|NCT00972855|Experimental|Bicalutamide|Bicalutamide 50 mg Tablet
9938996|NCT00972855|Active Comparator|Casodex®|Casodex® 50 mg Tablet
9938997|NCT00972868|Experimental|COPD|Thirty adult (> 18 years of age) patients in acute hypercapnic respiratory failure resulting from COPD and requiring Noninvasive Positive Pressure Ventilation (NPPV)
9938998|NCT00972907|Experimental|Treatment|Nifedipine coated suppositories BID.
10000488|NCT01538459|Active Comparator|Bupivacaine|50 randomized participants in group receive 20cc 0.25% bupivacaine injected perineurally for interscalene nerve block.
10000489|NCT01538459|Experimental|Dexamethasone and Bupivacaine|50 randomized participants in group will 8 mg(2cc of 4mg/cc solution) Dexamethasone added to 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection. Injected perineurally for interscalene nerve block pre-operatively.
10000490|NCT01538485|Experimental|Cholecalciferol|
10000491|NCT01538511|Experimental|BIAsp 70|
10000492|NCT01538511|Experimental|BIAsp 30|
10000493|NCT01538550|Experimental|Flexible sigmoidoscopy|70,000 men and women at age 50-74 years are randomised from the population registry to be invited to have a screening examination using flexible sigmoidoscopy once-only
10000494|NCT01538550|Experimental|iFOBT|70,000 men and women at age 50-74 years randomised from the population registry to be invited to have a screening examination biennially using an immunochemical test for fecal occult blood testing (iFOBT).
10000495|NCT01538576||Insulin aspart users|
10000496|NCT01538589||Insulin aspart users|
10000497|NCT01538602||PCOS patients|
10000498|NCT01538602||Healthy volunteers|
10000499|NCT01538641|Experimental|1|
10000500|NCT01538654||'enteral protein tube feeding in obese|protein sparing modified fast with a defined enteral formula by tube
10000501|NCT01538667|Experimental|Arm 1|
10000502|NCT01538667|Experimental|Arm 2|
10000503|NCT01538667|Experimental|Arm 3|
10000504|NCT01538667|Experimental|Arm 4|
10000505|NCT01538693|Active Comparator|escitalopram oxalate|Exercise testing with escitalopram oxalate dose
10000506|NCT01538693|Active Comparator|cyproheptadine|exercise testing with cyproheptadine dose
10000507|NCT01538693|Placebo Comparator|placebo|exercise testing with placebo dose
10000508|NCT01538706|Experimental|Hospital-based home care|Patients were included if below the age of 18, had been diagnosed with any type of cancer at least one month prior to inclusion, on intravenous anticancer therapy with a curative intent, and the parent was fluent in speaking and reading Danish. Patients living within a radius of 50 kilometres from the hospital were assigned to the home care program. Moreover, patients were assigned to one of three groups according to the geographical distance from the hospital and timing of the inclusion period: (1) home care group if participating in the program, (2) historical standard care group for an eight-month period before the program started regardless of their residence distance from the hospital, and (3) concurrent standard care group if living more than 50 km from the university hospital.
10000509|NCT01538758|Active Comparator|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
10000510|NCT01538758|Active Comparator|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
10000511|NCT01538771|Placebo Comparator|Control group|Received same volume of saline
10000512|NCT01538771|Active Comparator|Darbepoetin group|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning & conventional treatment
10000513|NCT01538823||Group 1|Enrollment of surgical patients at Barnes Jewish Hospital (BJH) with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy.
10000514|NCT01538823||Group 2|Surgical patients at BJH with non urological cancers
10000515|NCT01538823||Group 3|Surgical patients at BJH with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy
10000516|NCT01538823||Group 4|Surgical patients at BJH with non urological cancers
10000517|NCT01538823||Group 5|Healthy volunteers with no history of cancer or renal disease
10000518|NCT01538823||Group 6|Patients at BJH/Washington University School of Medicine under post procedure surveillance for RCC recurrence and patients under treatment for metastatic disease.
10000519|NCT01538823||Group 7|Patients with a presumptive diagnosis of bladder cancer or prostate cancer
10000520|NCT01538836|No Intervention|Weight maintenance|Weight maintenance with normal protein intake
10000521|NCT01538836|Active Comparator|Weight loss with normal protein intake|
10000522|NCT01538836|Experimental|Weight loss with protein supplementation|
10000523|NCT01538849|Experimental|YH4808 A mg (Twice daily)|YH4808 A mg (Twice daily, Oral administration)
10000524|NCT01538849|Experimental|YH4808 B mg (Once daily)|YH4808 B mg (Once daily, Oral administration)
10000525|NCT01538849|Experimental|YH4808 B mg (Twice daily)|YH4808 B mg (Twice daily, Oral administration)
10000526|NCT01538849|Experimental|YH4808 C mg (Once daily)|YH4808 C mg (Once daily, Oral administration)
10000527|NCT01538849|Active Comparator|Esomeprazole 40mg (Once daily)|Esomeprazole 40mg (Once daily, Oral administration)
10000528|NCT01538875|Experimental|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes (Maximum number of doses: 3).
10000529|NCT01538875|Active Comparator|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
10000530|NCT01538888|Experimental|WHOLE BODY VIBRATION|SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY
9528326|NCT03212079|Experimental|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
9528327|NCT03211780|Experimental|Ultrasound|
9528328|NCT03211988|Other|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
9528329|NCT03211884|Experimental|Problem-solving therapy|Couched within Bandura's social-cognitive theory, self-management refers to the process by which individuals accept responsibility for and take action to change their behaviors, obtain knowledge related to their situation (e.g., behavioral manifestations of a TBI) through increased awareness and use of effective personal resources (e.g., skill in every-day problem-solving). This ultimately enhances the caregivers' confidence that they can cope with caregiving and behavior-related stressors in the care recipient.
9528330|NCT03211884|No Intervention|Usual Care|Usual care was defined as various military caregiver organizations, support groups and services available to all family caregivers of combat Veterans (e.g., Military OneSource; Operation We Are Here; Veterans Administration Program of Comprehensive Assistance for Family Caregivers; American Red Cross Military and Veteran Caregiver Network; Project New Hope; Wounded Veteran Family Care; Women for Wounded Warriors).
9528331|NCT03211767|Active Comparator|Aged garlic extract|2 capsules per day containing aged garlic extract
9938999|NCT00972920|Active Comparator|Blind TAP block|"TAP block technique as first described by McDonnell. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Identification of triangle of Petit just above iliac crest and between external oblique and latissimus dorsi muscles. Insertion of regional anaesthesia needle perpendicular to skin, and its advancement until sensation of two 'pops' indicating advancement of needle through both external oblique and internal oblique muscle layers.~After confirmation of negative aspiration the local anaesthetic is injected slowly, (1mg/kg of levobupivacaine), concentration 2.5 mg/mL. Repeat procedure bilaterally (to a maximum dose of 2mg/kg of levobupivacaine)."
9939000|NCT00972920|Active Comparator|Ultrasound-guided TAP block|"Technique as described by Hebbard. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Ultrasound probe covered with sterile sheath.~Identification of triangle of Petit with USS probe perpendicular to skin. Insertion of regional anaesthesia needle transversely to the probe, using in-plane (IP) technique, moving posteriorly. Advancement of the needle under ultrasound control until its tip is located between internal oblique and transversus abdominis muscle layers."
9939001|NCT00972933|Experimental|Ipilimumab|Induction ipilimumab 10 mg/kg IV day 0, 21 (baseline, week 3) Maintenance Ipilimumab 10 mg/kg IV days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
9939002|NCT00972946|Experimental|Administration of labelled cells|MRI scanning before and after administration of iron-labelled cells
9939003|NCT00972946|Experimental|Administration of Endorem|MRI scanning before and after intravenous administration of Endorem
9939004|NCT00972972|Active Comparator|dietary supplement|Extracts of bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.)
9939005|NCT00972972|Placebo Comparator|placebo dietary supplement|Placebo juice extracts
9939006|NCT00972985|Experimental|modafinil|All healthy control subjects receive modafinil in this crossover design
9939007|NCT00972985|Experimental|methylphenidate|All healthy control subjects receive methylphenidate in this crossover design
9939008|NCT00972985|Experimental|lorazepam|All healthy control subjects receive lorazepam in this crossover design
9939009|NCT00972985|Placebo Comparator|placebo|All healthy control subjects receive placebo in this crossover design
9939010|NCT00972998|Experimental|Healthy individuals|
9939011|NCT00973011|Experimental|A|
9939012|NCT00973037||CYP2D6|CYP2D6 genotype
9939013|NCT00973050|Experimental|Bicalutamide (test)|Bicalutamide Tablet, 50 mg
9939014|NCT00973050|Active Comparator|Casodex® (reference)|Casodex® Tablet, 50 mg
9939015|NCT00973063|No Intervention|conventional gloving|
9939016|NCT00973063|Experimental|routine sterile gloving|
9939017|NCT00973076|Experimental|AZD8055|AZD8055 will be administered orally
9939018|NCT00973089|No Intervention|Complete caries removal|Control group
9939019|NCT00973089|Other|Incomplete caries removal|Test group
9939020|NCT00973115|Experimental|Simvastatin CR 20mg- morning administration|
9939021|NCT00973115|Active Comparator|Simvastatin CR 20mg- evening administration|
9939022|NCT00973128|Experimental|Group 1|Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)
9939023|NCT00973128|Active Comparator|Group 2|Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.
9939024|NCT00973154|Active Comparator|Prednisone|Drug
9939025|NCT00973154|Placebo Comparator|Placebo|
9939026|NCT00973167|No Intervention|Control|Remains sedentary with normal lifestyle
9939027|NCT00973167|Experimental|Treatment|Receive LMHFV treatment for 18 months.
9939028|NCT00973180|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
9939029|NCT00973180|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
9939030|NCT00973193|Experimental|panitumumab|
9939031|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Adefovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Adefovir for a period of 48 weeks.
9939032|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Tenofovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Tenofovir for a period of 48 weeks.
9939033|NCT00973219|No Intervention|no treatment|50 HBeAg negative chronic hepatitis B patients with low viral load will not receive treatment during a period of 48 weeks
9939034|NCT00973232|Experimental|Part A, Arm A|
9939035|NCT00973232|Experimental|Part A, Arm B|
9939036|NCT00973232|Active Comparator|Part A, Arm C|
9939037|NCT00973232|Active Comparator|Part A, Arm D|
9939038|NCT00973232|Experimental|Part B, Arm E|
9939039|NCT00973232|Active Comparator|Part B, Arm F|
9939040|NCT00973232|Active Comparator|Part B, Arm G|
10000531|NCT01538901|Experimental|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann & Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
10000532|NCT01538901|Active Comparator|imiquimod 5% cream|250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.
10000533|NCT01538914|Experimental|PVB|Postoperative pain is controlled with local analgesics delivered via PVB.
10000534|NCT01538914|Active Comparator|PCA|Postoperatve pain is controlled with intravenous PCA.
10000535|NCT01538927|Experimental|Fibrin Sealant|One quadrant surgically elevated will be closed with fibrin sealant
10000536|NCT01538927|Placebo Comparator|Suture|The surgically elevated flap is closed with non resorbable sutures.
10000537|NCT01538940|Active Comparator|HIV+, CD4<200, ID vaccine|
10000538|NCT01538940|Active Comparator|HIV+, CD4<200, IM vaccine|
10000539|NCT01538940|Active Comparator|HIV+, CD4>=200, ID vaccine|
10000540|NCT01538940|Active Comparator|HIV+, CD4 >=200, IM vaccine|
10000541|NCT01538940|Other|HIV-, ID vaccine|
10000542|NCT01538940|Other|HIV-, IM vaccine|
10000543|NCT01538953|Experimental|Handwashing|participants received weekly, in-home handwashing promotion and soap as needed
10000544|NCT01538953|Experimental|handwashing and water treatment|
10000545|NCT01538953|Experimental|Water treatment with sodium hypochlorite|
10000546|NCT01538953|Experimental|Water treatment with flocculent-disinfectant|participants received a supply of flocculent-disinfectant product and instruction to use it to treat drinking water
10000547|NCT01538953|No Intervention|Control|
10000548|NCT01538979|Experimental|BM32 low dose|7 subcutaneous injections of 20 micrograms over two grass pollen seasons
10000549|NCT01538979|Experimental|BM32 high dose|7 subcutaneous injections of 40 micrograms over two grass pollen seasons
10000550|NCT01538979|Placebo Comparator|Placebo|7 subcutaneous injections over a time span of two pollen seasons
10000551|NCT01538992|Experimental|renal denervation|in this group percutaneous renal denervation with Standard steerable Mariner Radiofreqency ablation Catheter (5F or 7F)
10000552|NCT01538992|No Intervention|medical thrapy|medical treatment
10000553|NCT01539018|Active Comparator|Sorafenib alone.|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
10000554|NCT01539018|Experimental|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily continuously and UFT 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
10000555|NCT01539031|Experimental|10 mg group|
10000556|NCT01539031|Active Comparator|23 mg group|
10000557|NCT01539044|Active Comparator|IB-neostigmine|subject will be given intermittent bolus of rocuronium during the surgery and reversal of neostigmine at the end of surgery at TOF 2
10000558|NCT01539044|Experimental|CI-Sugammadex|subject will be given continuous infusion of rocuronium and reversal of sugammadex at the end of surgery at PTC 1-2
10000559|NCT01539057|Experimental|Intravenous Fibrinogen|Fibrinogen will be administered until an expected plasmatic value of 2.9 g / L is achieved.
10000560|NCT01539057|Placebo Comparator|Saline Serum|the same dose in volume of saline dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of saline dilution
10000561|NCT01539096|Sham Comparator|Sham tDCS plus CIMT|Subjects in this group will be trained on Constraint induced movement therapy (CIMT) for the hand while concurrently receiving placebo noninvasive brain stimulation (tDCS). They will be receiving Sham tDCS: placebo noninvasive brain stimulation. They will be provided treatment for 3 days a week for 5 weeks for 1 hr each day at the Cleveland Clinic. They would be asked to use affected hand in daily activities for 5 hrs everyday at home while wearing a mitt on their unaffected hand.
10000562|NCT01539096|Experimental|tDCS plus CIMT|Patients with stroke affecting the hand will receive Constraint-induced movement therapy (CIMT) concurrent with tDCS: noninvasive brain stimulation. TDCS will be applied to areas of the brain responsible for movement of the affected hand. This combination of tDCS and CIMT will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
9939041|NCT00973245|Experimental|Arm 1|
9528332|NCT03211767|Placebo Comparator|Placebo|2 capsules per day without aged garlic extract
9939042|NCT00973245|Experimental|Arm 2|
9939043|NCT00973245|Active Comparator|Arm 4|
9939044|NCT00973245|Experimental|Arm 3|
9939045|NCT00973258|Experimental|Nutritional Intervention|Nutritional intervention
9939046|NCT00973258|Experimental|Physical Exercise|Physical exercise training intervention
9939047|NCT00973258|Experimental|Cognitive Training|Cognitive training intervention
9939048|NCT00973258|Experimental|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
9939049|NCT00973258|Placebo Comparator|Control Group|Participants will receive their usual diet and placeboes.
9939050|NCT00973271|Experimental|290 mg DCCR|
9939051|NCT00973271|Experimental|435 mg DCCR|
9939052|NCT00973271|Active Comparator|135 mg fenobric acid|
9939053|NCT00973271|Placebo Comparator|Placebo|
9939054|NCT00973297|Experimental|Falls prevention|
9939055|NCT00973297|No Intervention|Control group|Routine rehabilitation treatment
9939056|NCT00973310|Experimental|Combined Treatment arm|All the patients received oral erlotinib and concurrent radiation therapy
9939057|NCT00973323|Experimental|Arm 1|
9939058|NCT00973323|Experimental|Arm 2|
9939059|NCT00973323|Experimental|Arm 3|
9939060|NCT00973323|Active Comparator|Arm 4|
9939061|NCT00973336|Experimental|Calcium and vitamin D|Intervention
9939062|NCT00973336|No Intervention|No treatment (control)|
9939063|NCT00973375||Endeavor group and Excel group|Endeavor group: measurements from the vessels implanted Endeavor stent(s). Excel group: measurements from the vessels implanted Excel stent(s).
9939064|NCT00973401||Diabetic individuals|
9939065|NCT00973414|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before CSEA
9939066|NCT00973414|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after CSEA
9939067|NCT00973414|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before CSEA
9939068|NCT00973414|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after CSEA
9939069|NCT00973453|Other|Slow regimen|
9939070|NCT00973453|Other|Intermediate regimen|
9939071|NCT00973453|Other|Fast regimen|
9939072|NCT00973466||HIV-infection|All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
9939073|NCT00973492||patients with functional insulinotherapy|There is only one group in this study. The participants will attend a functional insulinotherapy class.
9939074|NCT00973505||CYP19|CYP19 genetic polymorphism
9939075|NCT00973518||Alzheimer's Disease subjects|Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
9939076|NCT00973518||Healthy Control subjects|Age & gender-matched subjects determined to be healthy.
9939077|NCT00973531|Other|Ambulatory APAP and SMT|Subjects placed on the APAP machine
9939078|NCT00973531|Other|Titration Polysomnogram with CPAP and SMT|Subjects placed on CPAP machine
9939079|NCT00973544||control|drains would be removed when daily discharge will be below 20 cc for 2 consecutive days
9939080|NCT00973544||study|drains will be removed on post operative day (POD) 10
9939081|NCT00973557||Taking Bevacizumab|Patients who are currently being treated for cancer by the drug Bevacizumab.
9939082|NCT00973570|Experimental|"Intervention group"|"The intervention group benefits from the TABADO program"
9939083|NCT00973570|No Intervention|"Control group"|"The control group not benefit from any specific intervention other than the treatment and education usually available"
9939084|NCT00973583|Active Comparator|vitamin D|
9939085|NCT00973583|Placebo Comparator|placebo|
9939086|NCT00973609|Active Comparator|Fluoropyrimidine + Bevacizumab|Standard therapy
9939087|NCT00973609|Experimental|Bevacizumab monotherapy|
9939088|NCT00973609|Experimental|No maintenance treatment|
9939089|NCT00973635|No Intervention|Traditional training|"Patients of subjects with no detailed curriculum for handoff skills during non-intervention months.~Learners provided a brief outline of how to perform discharge summaries (handout).~Learners given two core articles describing some of the communication issues regarding handoff safety.~Handoff teaching left to discretion of the subintern's team (typically the see one, do one, teach one method).~No feedback given to these subinterns on their performance of their handoff skills."
9939090|NCT00973635|Experimental|Intervention|Group that receives educational intervention.
9939091|NCT00973661|Experimental|Electronic tools|
9939092|NCT00973661|No Intervention|Usual care|
9939093|NCT00973687|Placebo Comparator|10 mg/mL Unsweetened Formulation|no prior vomiting
9939094|NCT00973687|Experimental|1 mg/mL Ora Sweet Formulation|no prior vomiting
9939095|NCT00973687|Active Comparator|10 mg/mL Unsweetened with prior vomiting|with prior vomiting
9528333|NCT03211728|Experimental|experimental group|
9528334|NCT03211728|Placebo Comparator|placebo group|
9528335|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy
9528336|NCT03211741|Other|open label|
9528337|NCT03211598|Other|TACE with Surefire|Subjects enrolled in the study will have their TACE procedure with the Surefire Infusion System.
9939096|NCT00973687|Experimental|1 mg/mL Ora Sweet with prior vomiting|with prior vomiting
9939097|NCT00973713|Experimental|RAD001 10mg/d|
9528338|NCT03212183|Experimental|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
9939098|NCT00973726|Other|Glucose|Subjects are given an oral glucose tolerance test.
9939099|NCT00973791|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before spinal anesthesia
9939100|NCT00973791|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after spinal anesthesia
9939101|NCT00973791|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before spinal anesthesia
9939102|NCT00973791|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after spinal anesthesia
9939103|NCT00973830|Experimental|Carve-In|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling with a nurse or medical assistant from their clinic. Counseling focuses on behavioral changes patients can make to improve their diabetes.
9939104|NCT00973830|Experimental|Carve-Out|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling over-the-phone with a diabetes health educator stationed in Chicago, IL. Counseling focuses on behavioral changes patients can make to improve their diabetes.
9939105|NCT00973830|No Intervention|Control|Patients in this arm receive standard care. They receive no Diabetes Guide or brief counseling sessions
9939106|NCT00973882|Experimental|Carboplatin-Etoposide|
9939107|NCT00973908|Active Comparator|VSL#3|Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
9939108|NCT00973908|Placebo Comparator|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
9939109|NCT00973934|Experimental|Magnetic Seizure therapy (MST)|Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
9528339|NCT03212183|Other|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
9528340|NCT03212092|Experimental|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
9528341|NCT03212092|Placebo Comparator|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
9528342|NCT03211936|Active Comparator|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.~PEEP 4 cmH2O~Use ultrasound"
9528343|NCT03211936|Experimental|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.~PEEP titrated~Use ultrasound~Impedance tomography~Best PEEP for less collapse"
9528344|NCT03211910|Placebo Comparator|Standard Care of Treatment|Participants will be treated with standard of care treatment.
9939110|NCT00973934|Active Comparator|Right Unilateral Electroconvulsive Therapy|
9939111|NCT00973947|Other|Control|Immobilisation: Standard headrest plus individual customised mask (orfit)
9939112|NCT00973947|Other|TRial Arm|Immobilisation: Customised headrest plus individual customised mask (orfit)
9939113|NCT00973986|Active Comparator|CYP3A4*1/*1|
9939114|NCT00973986|Active Comparator|CYP3A4*1/*1G|
9939115|NCT00973986|Active Comparator|CYP3A4*1G/*1G|
9939116|NCT00973999|Experimental|Injection into salivary gland|
9939117|NCT00974012|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
9939118|NCT00974012|Active Comparator|Depakote®|500 mg Extended Release Tablet
9939119|NCT00974025|Experimental|Vitamin C|High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks
9939120|NCT00974025|Placebo Comparator|Placebo|Placebo will be given in two-daily doses for four weeks
9939121|NCT00974038|Experimental|CBT, SP|cognitive behavioral therapy, supportive psychotherapy
9939122|NCT00974064||A-Healthy Non smokers|Healthy nonsmokers. Defined as non-smokers by self report and urine cotinine levels consistent with a nonsmoker (urine cotinine <5 ng/mL).
9939123|NCT00974064||B-Healthy smoker|"Healthy current smokers. Subjects categorized as healthy according to criteria under Collection (#1204012331) protocol."
9939124|NCT00974064||C-Healthy smoker to quit|Healthy smokers willing to quit. Defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL).
9939125|NCT00974064||D-Current smoker w. COPD|Current smokers with COPD. COPD as defined by the GOLD criteria and currently smoking as defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL)
9939126|NCT00974064||E-Current COPD smoker to quit|Current smokers with COPD willing to stop smoking. Subjects have COPD as defined by the GOLD criteria
9939127|NCT00974077|Other|Wait List Control|Patients do ot receive psychotherapy. The wait list control group will be assessed according to study protocol and offered MBCT after 6 month
9939128|NCT00974077|Experimental|Mindfulness Based Cognitive Therapy|The published protocol of MBCT will be used. This is an eight week group program. Participants learn mindfulness techniques but also cognitive techniques to prevent new depressive episodes
9939129|NCT00974103|Experimental|Chiropractic treatment, exercise|Chiropractic treatment and exercise
9939130|NCT00974103|Experimental|Exercises|Exercise advise
9939131|NCT00974129||Patients with Infantile Hemangiomas|
9939132|NCT00974155|Experimental|EMC (Early Medication Change)|
9939133|NCT00974155|Active Comparator|TAU (Therapy As Usual)|
9939134|NCT00974168|Active Comparator|A|Radiation Cumulative BED ≤ 100 Gy2
9800621|NCT01692626|Experimental|Pimecrolimus on Right vs. Placebo on Left|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
9939135|NCT00974168|Active Comparator|B|Cumulative BED ≤ 130 Gy2
9800622|NCT01692730|Experimental|Enhanced Web Assisted Intervention|Enhanced Web Assisted Tobacco Intervention. An enhanced and highly interactive website for cessation.
9800623|NCT01692730|Active Comparator|Basic Web Assisted Intervention.|Basic Web Assisted Tobacco Intervention. A basic website for cessation comparable to those for general adult populations, including established evidence-based cessation information and features.
9800624|NCT01692743|No Intervention|Standard of Care|Participants undergo usual follow up (routine and as needed office visits and telephone calls) and receive educational fact sheets from the Crohn's and Colitis Foundation of America.
9939136|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (10 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
10035022|NCT01802255|Active Comparator|Intravenous sedation|Midazolam given intravenously for sedation minimum 48 hours
9528345|NCT03211910|Active Comparator|SacralSaver|SacralSaver
9800625|NCT01692743|Experimental|Weekly Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
9800626|NCT01692743|Experimental|Home Monitoring Every Other Week|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
9800627|NCT01692756|Experimental|Kenalog or Placebo|Kenalog® (40mg) or saline placebo injection 1-2 days after ACL injury and 12-14 days later.
9800628|NCT01692756|Experimental|Kenalog then placebo|Subjects will initially receive 40mg injection of Kenalog® 1-2 days after injury and saline placebo at 12-14 days post injury.
9800629|NCT01692756|Experimental|Kenalog only|Subjects will receive two consecutive (40 mg) intra-articular injections of Kenalog®
9800630|NCT01692756|Placebo Comparator|Placebo|subjects will receive two consecutive intra-articular saline placebo injections at the same time periods.
9800631|NCT01692782|Experimental|SEP-225289 4mg|SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses
9800632|NCT01692782|Experimental|SEP-225289 8mg|SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses
9800633|NCT01692782|Placebo Comparator|Placebo|4 capsules of placebo
9800634|NCT01692938||No Retinal Disease|
9800635|NCT01692938||Retinal Disease|
9800636|NCT01692951||Lung adenocarcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
9800637|NCT01692951||Control matched to adenocarcinoma|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
9939137|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (30 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
9939138|NCT00974194|Experimental|SinglePort CCK|CCK using Triport
9939139|NCT00974194|Active Comparator|LS CCK|CCK using three or four trocars
9939140|NCT00974272|Experimental|Exenatide|
9939141|NCT00974272|Placebo Comparator|Placebo|
9939142|NCT00974285|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
9939143|NCT00974285|Placebo Comparator|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
9939144|NCT00974298||Elbow replacement|There are no other arms other then an uncemented total elbow replacement.
9939145|NCT00974324|Experimental|treatment|endostar combined with CHOP regimen
9939146|NCT00974337||Shock|"Preterm VLBW infants with shock (BP <3rd centile for gestation and birth weight with at least one of the following:~Prolonged capillary refill time (>3sec)~Reduced urine output (<1 mL/kg/hr)~Metabolic acidosis (Base deficit >5)"
9939147|NCT00974337||No shock|Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
9939148|NCT00974402|Experimental|Patients with PTSD Symptoms|Patients with Post-Traumatic Stress Disorder (PTSD) symptoms willing to undergo Cognitive Behavioral Therapy in a primary care setting.
9939149|NCT00974428|Active Comparator|Wobenzym® N and placebo|Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day
9939150|NCT00974428|Active Comparator|Wobenzym® N|Wobenzym® N 4 tablets three times per day
9939151|NCT00974428|Placebo Comparator|Placebo|Placebo 4 tablets three times per day
9939152|NCT00974441|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
9939153|NCT00974441|Active Comparator|Depakote®|500 mg Extended Release Tablet
9939154|NCT00974454|Active Comparator|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
9939155|NCT00974454|Placebo Comparator|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
9939156|NCT00974467|Experimental|After The Injury website|
9939157|NCT00974467|Other|Usual care|Treatment as usual
9939158|NCT00974506|Active Comparator|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine therapy by general practitioner
9939159|NCT00974506|Active Comparator|Routine care therapy|Routine care therapy by general practitioner
9939160|NCT00974519|Active Comparator|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
9939161|NCT00974519|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
9939162|NCT00974519|Placebo Comparator|Placebo|Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
9939163|NCT00974532|Active Comparator|Subjects with normal kidney function|eGFR > 60 ml/min/m²
9939164|NCT00974532|Experimental|CKD late Stage 3 and Stage 4|eGFR 15-40 ml/min/m²
9939165|NCT00974558|Experimental|fan directed to cheeks|Blow draft of air generated by fan across cheeks
9939166|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin|Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941
9939167|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin+Bevacizumab|Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.
9939168|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin|Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\n
9939169|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin+Bevacizumab|Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\n
9939170|NCT00974610||Breast|
9939171|NCT00974610||Lung|
9939172|NCT00974610||Melanoma|
9939173|NCT00974610||Pancreatic|
9939174|NCT00974610||Colorectal|
9939175|NCT00974623||Spinal Fusion|Patients who undergo a planned spinal fusion procedure requiring approved bone grafting materials (e.g., bone grft substitutes, allograft or autograft).
9939176|NCT00974636|Experimental|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
9939177|NCT00974636|Placebo Comparator|Ususal Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
9939178|NCT00974649|No Intervention|Included in questionnaire study|
9939179|NCT00974662|Experimental|WST11|Treatment with WST11-mediated VTP
9939180|NCT00974688|Active Comparator|Group 1|
9939181|NCT00974688|Active Comparator|Group 2|
9939182|NCT00974701|Experimental|Patients to undergo PillCam procedure|Patients presenting to ER with acute overt upper GI bleeding
9939183|NCT00974714|Experimental|1|Oral L-arginine 2 g twice a day, for 14 weeks
9939184|NCT00974714|Placebo Comparator|2|oral placebo twice a day for 14 weeks
9939185|NCT00974727|Experimental|Gardening Program|
9939186|NCT00974727|No Intervention|Control|Subjects received the standard of care for the summer.
9800638|NCT01692951||Lung squamous cell carcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
9800639|NCT01692951||Control matched to squamous cell|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
10000563|NCT01539109|Experimental|Rehab and tDCS|Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
10000564|NCT01539109|Sham Comparator|Rehab and sham tDCS|Patients in this group will receive Sham tDCS: placebo noninvasive brain stimulation, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase
10000565|NCT01539122|Active Comparator|TM Glenoid|Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
10000566|NCT01539122|Active Comparator|Cemented Glenoid|Cemented glenoid shoulder replacement component
10000567|NCT01539161|Experimental|Reveal XT plus SOC|Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
10000568|NCT01539161|Active Comparator|Standard of Care|Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.
10000569|NCT01539174|Experimental|Treatment (monoclonal antibody, combination chemotherapy)|Patients receive rituximab IV on days 0, 1, 4, 8, and 15 of course 1; days 1, 8, and 15 of course 2; and day 1 of all subsequent courses. Patients also receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
10000570|NCT01539187|Experimental|VizAblate intervention|VizAblate System with subject serving as her own control
9800640|NCT01692964||InflammaDry|Patients suspected of having dry eye will be tested with the InflammaDry.
9800641|NCT01693029|Experimental|HX575 epoetin alfa|HX575, recombinant human epoetin alfa
9800642|NCT01693029|Active Comparator|US-licensed epoetin alfa|US-licensed recombinant human epoetin alfa
10000571|NCT01539200|Placebo Comparator|Control|
10000572|NCT01539200|Active Comparator|Oral Nutritional Supplement (ONS) and JDR|
10000573|NCT01539213|Experimental|AIN457|secukinumab (AIN457)
10000574|NCT01539252|Active Comparator|Single dialyzer|Single dialyzer
10000575|NCT01539252|Experimental|Double dialyzer|Two dialyzers in parallel
10000576|NCT01539265|Experimental|silodosin, arm 1|
10000577|NCT01539265|Experimental|silodosin, arm 2|
10000578|NCT01539265|Placebo Comparator|placebo|
10000579|NCT01539278|Active Comparator|Observation, no surgery (control)|Patients have been diagnosed with mild OSA, no intervention is done; enrolled patients may be randomly or nonrandomly placed in this group
10000580|NCT01539278|Experimental|Surgery (adenotonsillectomy)|Patients who have been diagnosed with mild OSA. Patient may be randomly assigned or non-randomly choose to be in this group; all undergo adenotonsillectomy
10000581|NCT01539304|Experimental|CITUS Dry Syrup|Pranlukast dry syrup 10%
10000582|NCT01539304|Placebo Comparator|Placebo|Placebo
10000583|NCT01539343|Experimental|Antimicrobial Lock Solution|Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
10000584|NCT01539356||preterm infants|"preterm infants receiving blood transfusion~preterm infants with neonatal sepsis."
10000585|NCT01539369|Experimental|High fibre diet|
10000586|NCT01539369|Active Comparator|Healthy eating diet|
10000587|NCT01539382|Experimental|Cerebral oxygenation intervention|Cerebral oxygenation levels for people in this group will be monitored and maintained above 60%. If levels decrease to below 60%, a protocol is followed to guide possible interventions to increase cerebral oxygenation levels above 60%
10000588|NCT01539382|No Intervention|Cerebral oxygenation control|Cerebral oxygenation levels for people in this group will be masked and thus doctors and care staff will not use the cerebral oxygenation levels to make any interventions. If the cerebral oxygenation levels drop to below 40%, the cerebral oxygenation levels will be unmasked so that doctors can follow the protocol to increase levels to above 60%.
10000589|NCT01539395||Inactive Disease|Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
10000590|NCT01539395||Active Disease|Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
10000591|NCT01539395||Active Disease - Steroid Therapy|Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
10000592|NCT01539408|Active Comparator|Misoprostol|400 mcg of sublingual misoprostol in one dose
10000593|NCT01539408|Active Comparator|Manual vacuum aspiration (MVA)|Standard surgical treatment (MVA)
10000594|NCT01539421|Experimental|Exercise Intervention|Use of Wii computer for enhanced exercise in COPD patients.
9528822|NCT03207412|Experimental|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
9800643|NCT01693068|Experimental|Pimasertib|
10000595|NCT01539434|Experimental|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
10000596|NCT01539434|Active Comparator|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
10000597|NCT01539460|Experimental|minimally invasive surgery|There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis
10000598|NCT01539473|Experimental|TR-701 FA with Tyramine|TR-701 FA 200 oral with Tyramine
10000599|NCT01539473|Placebo Comparator|Placebo-controlled with Tyramine|Placebo-controlled with Tyramine
10000600|NCT01539551||1|sepsis and septic shock patients
10000601|NCT01539564|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
10000602|NCT01539564|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
10000603|NCT01539577||OZURDEX®|OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.
10000604|NCT01539603|Experimental|DEB-BMS|Drug eluting balloon + Bare metal stent
10000605|NCT01539603|Active Comparator|Drug eluting stent|conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
10000606|NCT01539616|Experimental|ZYH7 4mg|ZYH7 4mg
10000607|NCT01539616|Experimental|ZYH7 8mg|ZYH7 8mg
10000608|NCT01539616|Experimental|ZYH7 16mg|ZYH7 16mg
10000609|NCT01539616|Active Comparator|Fenofibrate 160mg|Fenofibrate 160mg
10000610|NCT01539629||Pulse Width|One group reflecting two different pulse widths.
10000611|NCT01539655|Experimental|vandetanib then vandetanib + omeprazole|Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2
10000612|NCT01539655|Experimental|vandetanib + omeprazole then vandetanib|Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2
10000613|NCT01539655|Experimental|vandetanib then vandetanib + ranitidine|Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2
10000614|NCT01539655|Experimental|vandetanib + ranitidine then vandetanib|Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2
10000615|NCT01539668||Pap sampling|Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
10000616|NCT01539681||Group 1|
10000617|NCT01539707|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 5 mg of solifenacin succinate.
10000618|NCT01539707|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
10000619|NCT01539720|Experimental|Levonorgestrel Intrauterine System|Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
10000620|NCT01539720|Active Comparator|Ulipristal acetate|Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
10000621|NCT01539733|Experimental|Olanzapine|
10000622|NCT01539733|Active Comparator|Haloperidol|
10000623|NCT01539746|Experimental|TAVI without predilation|
10000624|NCT01539746|Active Comparator|Standard TAVI procedure|
10000625|NCT01539772||Becker|"BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.~."
10035023|NCT01802268|Active Comparator|Sirolimus|Conversion from Tacrolimus to Sirolimus
10035024|NCT01802268|Active Comparator|Tacrolimus|Maintenance on tacrolimus
9939187|NCT00974740|Placebo Comparator|atorvastatin matching placebo|atorvastatin matching placebo
9800644|NCT01693068|Active Comparator|Dacarbazine|
9800645|NCT01693120|Experimental|Ablation|Phased RF ablation
9800646|NCT01693185|Experimental|Remifentanil|remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
9800647|NCT01693185|Active Comparator|midazolam and meperidine|a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)
9800648|NCT01693250|Experimental|fitbit ultra|Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
9800649|NCT01693250|Active Comparator|Pedometer|After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
9800650|NCT01693523|Experimental|Minocycline|Minocycline 100 mg by mouth two times a day (200 mg/day). Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
9800651|NCT01693523|Placebo Comparator|Placebo|Matching placebo capsules by mouth twice a day. Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
9800652|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.1 mg/kg Q2W)|Participants will receive intravenous (IV) infusion of MEDI4736 (durvalumab) 0.1 mg/kg every 2 weeks (Q2W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800653|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 0.3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800654|NCT01693562|Experimental|Escalation Cohort (MEDI4736 1 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 1 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800655|NCT01693562|Experimental|Escalation Cohort (MEDI4736 3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800656|NCT01693562|Experimental|Escalation Cohort (MEDI4736 10 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800657|NCT01693562|Experimental|Escalation Cohort (MEDI4736 15 mg/kg Q3W)|Participants will receive IV infusion of MEDI4736 15 mg/kg every 3 weeks (Q3W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800658|NCT01693562|Experimental|Exploration Durvalumab 20 mg/kg (Q4W)|Participants will receive IV infusion of MEDI4736 20 mg/kg every 4 weeks (Q4W) in the dose-exploration phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800659|NCT01693562|Experimental|Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800660|NCT01693562|Experimental|Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W)|Participants with non-SCCHN human papilloma virus positive (Non-SCCHN HPV+) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9939188|NCT00974740|Experimental|atorvastatin|40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months
9939189|NCT00974753|Placebo Comparator|PPV-MP + Placebo (Saline drops)|PPV-MP= pars plana vitrectomy membrane peel
9939190|NCT00974753|Active Comparator|PPV-MP + Ketorolac 0.5%|PPV-MP= pars plana vitrectomy membrane peel
9939191|NCT00974753|Placebo Comparator|PhacoVit-MP + Placebo (Saline drops)|PhacoVit-MP= phacovitrectomy membrane peel
9939192|NCT00974753|Active Comparator|PhacoVit-MP + Ketorolac 0.5%.|PhacoVit-MP= phacovitrectomy membrane peel
9939193|NCT00974766|Active Comparator|Low-dose glucocorticoid|Low-dose steroid
9939194|NCT00974766|Active Comparator|High-dose glucocorticoid|High-dose steroid
9939195|NCT00974779|Experimental|HCO dialyzer|Hemodialysis with the HCO1100 hemodialyzer membrane with high molecular weight cut off.
9939196|NCT00974779|Active Comparator|Placebo|Regular dialysis using a polyamide high-flux hemodialyzer
9939197|NCT00974805|Experimental|Seretide 500 Accuhaler|Seretide 500 Accuhaler one inhalation BD
9939198|NCT00974831|Experimental|AA Drink|Amino Acid Drink Mixture
9939199|NCT00974831|Placebo Comparator|Glucose drink|
9939200|NCT00974857|Active Comparator|Study group|"Pre-dialytic overhydration(OH) will be estimated by Body Composition Monitor (BCM) at least once a month.~If OH is positive, dry weight will be reached by ultrafiltration without regard to the level of blood pressure.~If OH is negative and:~Systolic blood pressure(SBP)< 100 mmHg with/or intradialytic hypotension episodes(IDHE) and/or clothing and/or erythrocytosis(htc>36%);dry weight will be increased.~SBP normal(100-150 mmHg) w/o IDHE and clothing and erythrocytosis;dry weight will not be changed.~SBP normal(100-150 mmHg) with IDHE and/or clothing and/or erythrocytosis;dry weight will be increased.~SBP>150 mmHg captopril test(CT)will be done. If CT is positive, ACEI/ ARBs will be used and dry weight will be increased if IDHE and/or clothing and/or erythrocytosis(htc>36%) are present.~If CT is negative, BCM measurement will be repeated and if same,ABPM will be performed for confirmation."
9939201|NCT00974857|Other|Control Group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
9939202|NCT00974883||Suspected GCA|Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis
9939203|NCT00974883||Training cohort|Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes
9939204|NCT00974896|Experimental|AMG 479 + Sorafenib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
9939205|NCT00974896|Experimental|AMG 479 + Erlotinib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
9939206|NCT00974909|Active Comparator|Treatment group|Treatment group
9939207|NCT00974909|Sham Comparator|sham group|Sham group
9939208|NCT00974935|Experimental|Cohort 1|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01 mcg intramuscular.
9939209|NCT00974935|Experimental|Cohort 2|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.1 mcg intramuscular.
9939210|NCT00974935|Experimental|Cohort 3|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.5 mcg intramuscular.
9939211|NCT00974935|Experimental|Cohort 4|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 2.5 mcg intramuscular.
9939212|NCT00974935|Experimental|Cohort 5|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 10 mcg intramuscular.
9939213|NCT00974935|Experimental|Cohort 6|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular.
9939214|NCT00974935|Experimental|Cohort 7|Two doses of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular 21 days apart.
9800661|NCT01693562|Experimental|Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with non-small-cell lung cancer (NSCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800662|NCT01693562|Experimental|Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W)|Participants with hepatocellular carcinoma (HCC Total) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800663|NCT01693562|Experimental|Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with advance cutaneous melanoma (ACM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800664|NCT01693562|Experimental|Expansion UM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with uveal melanoma (UM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800665|NCT01693562|Experimental|Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with gastroesophageal cancer (GEC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800666|NCT01693562|Experimental|Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with triple-negative breast cancer (TNBC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800667|NCT01693562|Experimental|Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with pancreatic adenocarcinoma (PAC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800668|NCT01693562|Experimental|Expansion UC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with urothelial carcinoma (UC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800669|NCT01693562|Experimental|Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with glioblastoma multiforme (GBM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800670|NCT01693562|Experimental|Expansion OC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with ovarian cancer (OC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800671|NCT01693562|Experimental|Expansion STS Cohort (MEDI4736 10 mg/kg Q2W)|Participants with soft- tissue sarcoma (STS) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800672|NCT01693562|Experimental|Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with small-cell lung cancer (SCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9939215|NCT00974948|Active Comparator|Neurolysis|Patients will undergo EUS followed by EUS-guided, bilateral neurolysis with bupivicaine and absolute alcohol.
9939216|NCT00974948|No Intervention|Conventional therapy|EUS will be performed with no celiac plexus neurolysis.
9939217|NCT00974961|Active Comparator|Levobupivacaine|Lumbar puncture with Levobupivacaine for spinal anesthesia
10000626|NCT01539785|Active Comparator|Secondary cytoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction.
10000627|NCT01539785|Experimental|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique.
10000628|NCT01539798|Experimental|Oral Saline|Ingestion of 0.9% saline solution
10000629|NCT01539798|Active Comparator|Intravenous Saline|Intravenous infusion of 0.9% saline solution
10000630|NCT01539824|Experimental|IMM-101 plus SBRT|The treatment regimen with IMM-101 (Mycobacterium obuense) will be every 2 weeks for the first three doses with the last of these doses being on the same day as the radiotherapy by CyberKnife treatment on a liver lesion targeted by the Principal Investigator. Following a rest of 4 weeks, patients will again receive IMM-101 every 2 weeks for the next 3 doses followed by a further 4 weeks rest. Thereafter, IMM-101 will be given at 4 week intervals for up to 12 months or until patient withdrawal for any reason
10000631|NCT01539876|Other|Fine Needle aspiration will be done X5:|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
10000632|NCT01539889|Experimental|DFH-12 PulmoBind|DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
10000633|NCT01539902|Experimental|Human Umbilical Cord derived MSCs|
10000634|NCT01539902|Placebo Comparator|Cyclophosphamide|
10000635|NCT01539915|Experimental|BCT194|
10000636|NCT01539928||lung cancer or high suspicion of lung cancer|After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
10000637|NCT01539941|Experimental|Medication Integration Protocol|
10000638|NCT01539954||Youth 9-18 years of age|
10000639|NCT01539993||1|
10000640|NCT01540019|Experimental|Paullinea cupana|50mg of Paullinia cupana as capsule, twice daily
10000641|NCT01540032|No Intervention|Control|
10000642|NCT01540032|Experimental|Diet|
10000643|NCT01540058|Experimental|test-guided strategy|"Treatment considered as the standard at the time of patient inclusion based on the primary cancer suspected by the BioTheranostics Cancer Type ID test molecular analysis"
10000644|NCT01540058|Active Comparator|Empiric strategy|Gemcitabine/Cisplatin
10000645|NCT01540084|Active Comparator|conventional group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary.
10000646|NCT01540084|Experimental|cocktail group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 1% propofol at the rate of 1 mg/kg/hr was administered. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
10000647|NCT01540110|Experimental|Docetaxel + cyclophosphamide|
10000648|NCT01540123|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
10000649|NCT01540123|Experimental|Berry drink standardised to contain 500mg of polyphenols|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
10000650|NCT01540136|Experimental|Nedaplatin|Nedplatin combine with IMRT
10000651|NCT01540136|Active Comparator|Cisplatin|Cisplatin combine with IMRT
10000652|NCT01540149||ICD implant|
10000653|NCT01540175||Participants|Participants enrolled on the study will have blood samples obtained.
10000654|NCT01540188|No Intervention|Starndard care arm|Participants of the standard care arm are control groups of IDUs and family members. They do not attend intervention sessions.
10000655|NCT01540188|Experimental|Intervention arm|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
10000656|NCT01540201|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
10000657|NCT01540201|Experimental|1:1 group|inspiratory time : expiratory time = 1:1
10000658|NCT01540214||POP surgery|All women who present with POP at the outpatient clinic of our centre and who will undergo prolapse repair surgery will be asked informed consent for participation in this study
10035025|NCT01802294|Experimental|Parenting Program|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly sessions. Program is manualized.
10000659|NCT01540227||Syphilis Patients|Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.
10000660|NCT01540240|Active Comparator|standard dosage zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
10000661|NCT01540240|Active Comparator|low dosage zidovudine|
10000662|NCT01540253|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive PI3K inhibitor BKM120 PO QD and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10000663|NCT01540279||Cohort one with abdominal wall closure with Monocryl|
10000664|NCT01540279||Cohort two with abdominal wall closure with Monocryl plus|
10000665|NCT01540292|Experimental|MSC|Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.
10000666|NCT01540305|Active Comparator|Transcranial Magnetic Stimulation|Actual transcranial magnetic stimulation of supplementary motor areas bilaterally.
10000667|NCT01540305|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation over the supplementary motor areas.
10000668|NCT01540318|Experimental|Abdominal Ultrasound|"Patients in the experimental arm will receive a Focused Assessment with Sonography for Trauma (FAST) which includes the use of abdominal ultrasound."
10000669|NCT01540318|No Intervention|No Abdominal Ultrasound|
10000670|NCT01540331|Experimental|PNT treatment|all subjects enrolled in the study, that underwent PNT treatment
10000671|NCT01540344|Experimental|Treatment Arm|"FOLFOX/FOLFIRI + cetuximab (6 cycles)~CRS and HIPEC~FOLFOX/FOLFIRI + cetuximab (6 cycles)"
10000672|NCT01540357|Active Comparator|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
10000673|NCT01540357|Active Comparator|Treatment after waiting time|Treatment was performed after completion of the active arm.
10000674|NCT01540383|Experimental|Intensive aphasia therapy group|Group starts intensive integrative aphasia therapy within 3 workdays (or as soon as possible) after baseline exam
10000675|NCT01540383|Other|Waiting list control group|Group starts intensive integrative aphasia therapy after a waiting period of at least three weeks
10000676|NCT01540396|Active Comparator|75 Gram OGTT|The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
10000677|NCT01540396|Active Comparator|100 gram OGTT|A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
10000678|NCT01540422||CABG w/saphenous vein grafts harvested using endoscopy|Those who have CABG surgery with saphenous vein grafts harvested using endoscopic techniques
10000679|NCT01540435|No Intervention|Postoperative Arm (Arm A)|"FOLFOX:~Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery."
10000680|NCT01540435|Experimental|Perioperative Arm (Arm B)|"Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.~FOLFOXIRI + bevacizumab:~bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively."
10000681|NCT01540448|Active Comparator|No-3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography but the surgeon was able to view the 3D reconstruction only after surgery.
10000682|NCT01540448|Experimental|3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography and the surgeon was able to view 3D reconstruction before and during laparoscopic colorectal resection.
10000683|NCT01540461|Experimental|Arm: Brivanib|
10000684|NCT01540500|Experimental|Steady State PK Group|
10000685|NCT01540526|Experimental|Safety cohort|6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
10035026|NCT01802294|No Intervention|Wait-list control|Wait-list control group. Program delivered 3 months after posttest.
10035027|NCT01802307|Experimental|Focal Therapy|
10035028|NCT01802359||Mirodenafil|
10035029|NCT01802372|Active Comparator|WHO CVD Risk Assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health Insurance and the WHO CVD Risk Assessment package for 12 months.
9528823|NCT03207451|Experimental|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
9939218|NCT00974961|Active Comparator|Bupivacaine|Lumbar puncture with Bupivacaine for spinal anesthesia
9939219|NCT00974987|Experimental|Treatment group|BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment) and TMZ(temozolomide) treatment
9939220|NCT00975013||Bone Density Study Group|Morbidly obese, (BMI >40 kg/m2, or 35 kg/m2 with comorbidities) female patients who have given consent to undergo additional testing including bone densitometry, and lab testing preoperatively and at 6 and 12 months after undergoing elective laparoscopic roux-en-Y gastric bypass.
9939221|NCT00975026|Active Comparator|Massages|Chair massage for 30 minutes once a week.
9939222|NCT00975026|Active Comparator|Massages + Stretches|Chair massage for 30 minutes once a week in addition to stretching exercises, to be done twice daily for 20 minutes.
9939223|NCT00975026|No Intervention|No Intervention|
9528346|NCT03211468|Experimental|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
9528347|NCT03211468|No Intervention|Control Group|No participation in intervention program.
9528348|NCT03211572|Experimental|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
9528349|NCT03211494|Active Comparator|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
9528350|NCT03211494|Active Comparator|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
9939224|NCT00975039|Experimental|WST11|Treatment with WST11-mediated VTP
9528351|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
9528352|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
9528353|NCT03211637|Experimental|INTERVENTION GROUP|This group comprises 6 healthcare units equipped with a Family Health Strategy, where patients are seen by coordinating nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
9528824|NCT03207451|Experimental|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
9939225|NCT00975052|Active Comparator|A|Sitagliptin alone
9939226|NCT00975052|Active Comparator|B|Metformin alone
9939227|NCT00975052|Experimental|C|Sitagliptin and metformin concomitantly
9939228|NCT00975052|Placebo Comparator|D|Placebo
9939229|NCT00975065|Experimental|Galvus group|"the combination of metformin plus Vildagliptin:~vildagliptin 50 mg bid plus metformin 1500mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy."
9939230|NCT00975065|Active Comparator|Diabex group|"metformin alone arm:~metformin 1500mg plus metformin 500mg or 1000mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy"
9939231|NCT00975078|Experimental|adrenal insufficiency|
9939232|NCT00975104|Experimental|AMG 745 0.3 mg/kg|0.3 mg/kg AMG 745
9939233|NCT00975104|Experimental|AMG 745 1.0 mg/kg|1.0 mg/kg, AMG 745
9939234|NCT00975104|Placebo Comparator|Placebo|Placebo
9939235|NCT00975104|Experimental|AMG 745 3.0 mg/kg|3.0 mg/kg, AMG 745
9939236|NCT00975117|Placebo Comparator|Placebo|
9939237|NCT00975117|Experimental|Spermotrend|
9939238|NCT00975169||TZDs User|
9939239|NCT00975182|Experimental|A|
9939240|NCT00975234|Experimental|Skeletal myoblasts|Patients who are receiving skeletal myoblasts
9939241|NCT00975234|Placebo Comparator|Placebo|Revascularisation surgery
9939242|NCT00975247|Active Comparator|Received Booklet|Patients who have received colonoscopy preparation booklet
9939243|NCT00975247|No Intervention|Did not receive booklet|Patients who did not receive colonoscopy preparation booklet
9939244|NCT00975273|Experimental|Breathing Training|Patients will receive biofeedback assisted breathing training
9939245|NCT00975273|Active Comparator|Breathing Awareness|Patients will receive biofeedback assisted breathing awareness training.
9939246|NCT00975299|Experimental|Arm 1|
9939247|NCT00975299|Experimental|Arm 2|
9939248|NCT00975312|Experimental|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.
9939249|NCT00975325|Active Comparator|"Yohimbine, Yohimbine Spiegel"|
9939250|NCT00975325|Active Comparator|Yohimbine Yocon-Glenwood|
9939251|NCT00975338||Prospective LIFEspan|LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
9939252|NCT00975338||Prospective Non-LIFEspan|LIFEspan youths with Spina Bifida
9939253|NCT00975338||Retrospective Non-LIFEspan|Non-LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
9939254|NCT00975338||LIFEspan Staff|All staff affiliated with the LIFEspan model of linked transition care
9939255|NCT00975338||Caregivers|Parents of participating youths
9939256|NCT00975351|Experimental|IV dose of 5-methyltetrahydrofolic acid|IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
9939257|NCT00975364||blood sampling|Consented volunteers provide a one-off blood sample
9939258|NCT00975377|No Intervention|No hair removal|Patients randomized to the no hair removal cohort will not undergo any preoperative hair removal.
9939259|NCT00975377|Active Comparator|Hair clipping|Patients in the clipping cohort undergo hair removal at the surgical site. Hair removal will occur on the day of surgery immediately prior to the scheduled operation.
9939260|NCT00975390|Experimental|1|Carbohydrate ingestion
9939261|NCT00975390|Experimental|2|Carbohydrate and protein ingestion
9939262|NCT00975390|Experimental|3|Carbohydrate and caffeine ingestion
9939263|NCT00975403|Experimental|Dead space breathing|
9939264|NCT00975403|Sham Comparator|Room air breathing|
9939265|NCT00975429|Experimental|WST11 - 4mg (TOOKAD® Soluble)|4mg/kg Treatment with WST11-mediated VTP
9939266|NCT00975429|Experimental|WST11 - 6mg|6mg/kg Treatment with WST11-mediated VTP
9939267|NCT00975442|Experimental|Eccentric training|
9939268|NCT00975442|Placebo Comparator|Forearm band|
9939269|NCT00975455||Subjects with hematuria|
9939270|NCT00975468|Active Comparator|Pressure-Controlled Ventilation|The patients' lungs ventilation will be initiated with a peak airway pressure that provided a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
10000686|NCT01540526|Experimental|Pharmacodynamic cohort|PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
10000687|NCT01540539|Experimental|Dosing cohort 1|
10000688|NCT01540539|Experimental|Dosing cohort 2|
10000689|NCT01540539|Experimental|Dosing cohort 3|
10000690|NCT01540539|Experimental|Dosing cohort 4|
10000691|NCT01540539|Experimental|Dosing cohort 5|
10000692|NCT01540539|Experimental|Dosing cohort 6|
10000693|NCT01540539|Experimental|Dosing cohort 7|
10000694|NCT01540539|Experimental|Dosing cohort 8|
10000695|NCT01540552||Budesonide Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Budesonide.
10000696|NCT01540552||Placebo Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Placebo.
10000697|NCT01540578||Observational|Archived cell samples are analyzed for replication timing by flow cytometry, microarray, and single-cell fluorescence in situ hybridization (FISH) assays. Replication-timing results among cases and controls are also analyzed.
10214453|NCT05223647|Active Comparator|Chemo-immunotherapy|Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
10000698|NCT01540591|Placebo Comparator|control|Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
10000699|NCT01540591|Experimental|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
10000700|NCT01540604|Experimental|CRD007 10 mg tablet|
10000701|NCT01540617||Persons with low back pain|
10000702|NCT01540617||Healthy persons|
10000703|NCT01540643||Abdominal aortic aneurysm|
10000704|NCT01540656|Active Comparator|Group 1|This group will receive immediate TMNS treatment beginning at baseline and ending at the 6 week point of the study.
10000705|NCT01540656|Active Comparator|Group 2|This group will receive delayed TMNS treatment beginning at the 6 week point of the study and ending at 12 weeks.
10000706|NCT01540669|Active Comparator|Polydextrose, low dose|Polydextrose, low dose
10000707|NCT01540669|Active Comparator|Polydextrose, medium dose|Polydextrose, medium dose
10000708|NCT01540669|Active Comparator|Polydextrose, high dose|Polydextrose, high dose
10000709|NCT01540669|Placebo Comparator|Placebo powder|Placebo powder
10000710|NCT01540708|Experimental|SERETIDE Rotacaps|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used.
10214454|NCT05223634||oral and/or nasal specimen samples|After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected
10214455|NCT05223621||Turner|patients with Turner syndrome
10214456|NCT05223621||POI|patients with primary ovarian failure
10214457|NCT05223595|Experimental|dose escalation|Gentuximab at a dose of 8 mg/kg or 12 mg/kg based on body weight + Almonertinib at a dose of 110mg for one 28-day cycle
10214458|NCT05223569|Experimental|Metaverse-assisted home OCT monitoring model|"Participants will receive a home monitoring set, which includes a HoloLens2 headset, a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester. For each home service, participants will undergo the following:~HoloLens2-assisted online instruction provided by a virtual specialist~Visual acuity self test using a smartphone~Self-testing OCT imaging~HoloLens2-assisted online consultation"
10214459|NCT05223569|Active Comparator|Hospital-based monitoring with a staff-administrated OCT|Participants will be instructed to come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators every month.
10214460|NCT05223556||Shaoguan Diabetic cohort|Patients with diabetes ages 30-80 were enrolled in Shaoguan Diabetic Eye Screening Programme, who will receive diabetic retinopathy screening both in a remote diagnostic imaging site and in a tertiary hospital
10214461|NCT05223530||Prevention of Pre-eclampsia and Intrauterine Growth Restriction (PREDO)|"The PREDO study is a cohort study that was started in 2005 in the Helsinki metropolitan area and Northern Karelia. In 2005-2009, it recruited a total of 4,777 women in the early pregnancy. Almost all subjects participated in stress monitoring during pregnancy. In addition, some mothers participated in either genetic, ultrasound, or drug research to develop methods for predicting and preventing pre-eclampsia and fetal growth retardation, and for identifying related factors.~Some key objectives have been to determine whether the physical and mental well-being of the pregnant women could be relevant with hereditary factors for the course of pregnancy and the subsequent physical and mental development and health of the child.~The previous follow-up phases have been performed 2 weeks and 6 months after the birth in 2006-2011 and at the age of approximately 2-6 and 7-12 years. More than 2,500 families participated in the most recent follow-up phase. Now it is 11-17 years of follow-up."
10214462|NCT05223530||Finnish Gestational Diabetes Prevention (RADIEL)|"The RADIEL study is a randomized multicenter study that was launched in 2008 in Helsinki, Espoo, Vantaa and Lappeenranta. Between 2008 and 2011, we recruited a total of 729 women for gestational diabetes prevention research. Subjects either planned to become pregnant or were in early pregnancy at the time of the study. Subjects were randomized to either receive diet and exercise intervention (active group) or to continue with normal counseling follow-up (control group). Study visits occurred every three months before pregnancy (if recruited before pregnancy), once in each trimester of pregnancy, and at 6 weeks, 6 months, and 12 months after delivery. The effectiveness of the intervention was measured with a variety of metrics.~In 2013-2017, we invited mothers and children who participated in the RADIEL study to a 5-year follow-up of the project, and nearly 350 mother-child pairs participated. Now it is 11-17 years of follow-up."
9939271|NCT00975468|Placebo Comparator|Volume Controlled Ventilation|The patients' lungs will ventilated with a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
9939272|NCT00975494|Active Comparator|sildenafil|sildenafil 50 mg three times/day
9939273|NCT00975494|Placebo Comparator|Placebo|Placebo
9939274|NCT00975520|Active Comparator|Radiation Therapy|Investigational Treatment
9939275|NCT00975520|Other|Observation|Observation
9939276|NCT00975533|Experimental|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
9939277|NCT00975533|Active Comparator|Control|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
9939278|NCT00975559||Normal volunteers|Normal study volunteers with no prior history of coronary artery disease
9939279|NCT00975559||Apical Ballooning Syndrome|Women who have had a documented Apical Ballooning event as shown by coronary angiogram
9939280|NCT00975559||Coronary Endothelial Dysfunction|Patients who have been diagnosed with Endothelial Dysfunction via a coronary angiogram with acetylcholine challenge
9476191|NCT03574376|Active Comparator|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
9528825|NCT03207451|Experimental|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
9939281|NCT00975559||Myocardial Infarction|Women diagnosed with a Myocardial Infarction who subsequently had a Percutaneous Intervention
9939282|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|
9939283|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|
9939284|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 30 μg|
9939285|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|
9939286|NCT00975572|Placebo Comparator|Placebo control|
9939287|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|
9939288|NCT00975663|Experimental|1|Optimized TDM of tacrolimus and MMF dosing
9939289|NCT00975663|Active Comparator|2|Current tacrolimus and MMF dosing strategies
9939290|NCT00975702|No Intervention|No RIPC Group|This group is the control group or the comparator group with RIPC
9939291|NCT00975702|Experimental|RIPC Group|In this group deceased donors will receive Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet of the lower limb prior to organ recovery.
9939292|NCT00975728|Experimental|Group 1 Product 825 (2-servings day)|30 subjects drinking 2 servings day of Product 825 for 8 weeks
9939293|NCT00975728|Experimental|Group 1 Product 824 (2 servings-day)|30 subjects drinking 2 servings-day of Product 824 for 8 weeks
9939294|NCT00975728|Experimental|Group 2 Product 825 (1 serving-day)|30 subjects drinking 1 serving-day of Product 825 for 8 weeks
9939295|NCT00975728|Experimental|Gruop 2 Product 824 (1 serving-day)|30 subjects drinking 1 serving-day of Product 824 for 8 weeks
9939296|NCT00975741|Experimental|Monodose device|Mometasone furoate 400 µg DPI capsules administered through a monodose device.
9939297|NCT00975741|Active Comparator|Multidose device|Mometasone furoate 400 µg DPI capsules administered through a multidose device
9939298|NCT00975754|Experimental|1|Pulmicort pMDI
9939299|NCT00975754|Experimental|2|Budesonide pMDI
9939300|NCT00975754|Experimental|3|Budesonide pMDI + Aerochamber Zero-stat spacer
9939301|NCT00975754|Experimental|4|Pulmicort repulses via Spira Nebuliser
9939302|NCT00975754|Experimental|5|Pulmicort Turbohaler
9939303|NCT00975767|Experimental|MGCD265+erlotinib|
9939304|NCT00975767|Experimental|MGCD265+docetaxel|
9939305|NCT00975793|No Intervention|Standard Care|Randomised allocation of standard care at the clinician's discretion in accordance with current best practice.
9939306|NCT00975793|Experimental|Early Goal Directed Therapy|Randomised allocation of early goal-directed therapy (EGDT).
9939307|NCT00975819|Experimental|Sirolimus|
9939308|NCT00975832||women with polycystic ovary syndrome|
9939309|NCT00975832||women without polycystic ovary syndrome|
9939310|NCT00975832||women from 18-40 years of age|
9939311|NCT00975845||BioCleanse Tibialis Tendon Allograft|Tibialis Tendon allograft from donor 18-65 years old
9939312|NCT00975858|Active Comparator|Percutaneous Coronary Intervention|
9939313|NCT00975858|Experimental|Off Pump Coronary Artery Bypass Surgery|
9939314|NCT00975910|Placebo Comparator|Saline|
9939315|NCT00975910|Active Comparator|Lidocaine|
9939316|NCT00975936|Experimental|[14C]-GSK706769|Single dose of 50µg [14C]-GSK706769 containing 250 nCi
9939317|NCT00975936|Experimental|[14C]-GSK706769 + Ketoconazole|An oral, 5-day repeat dose of 200 mg Ketoconazole (Q12) with a concomitant single oral dose of 50 µg [14C]-GSK706769 containing 250 nCi on day 3.
9939318|NCT00975949||Fluconazole Group|These subjects received fluconazole in our NICU fluconazole prophylaxis study during 1998-2000
9939319|NCT00975949||Placebo Group|These subjects received a placebo during our NICU fluconazole prophylaxis study during 1998-2000
9939320|NCT00975962|Experimental|Thrombolysis + Remote perconditioning|"Remote perconditioning (rIPerC) undertaken in ambulance on rute to hospital in case of suspected stroke.~The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC."
9939321|NCT00975962|Active Comparator|Thrombolysis|Thrombolysis without pretreatment with remote perconditioning
9939322|NCT00975988||TYKERB® tablets|There is only one group. This group includes patients administrated TYKERB® tablets
9939323|NCT00976001|Other|Follow-up at an out-patient stroke unit|Information, measurement of handicap, further rehabilitation efforts, drug therapy for secondary prevention of stroke.
9939324|NCT00976001|Other|Follow-up with the general practitioner|
9939325|NCT00976040|Experimental|Early antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy within 7 days of enrollment.
9939326|NCT00976040|No Intervention|Standard antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy approximately 4 weeks after enrollment.
9939327|NCT00976053|Active Comparator|SPECT myocardial perfusion imaging|
9939328|NCT00976053|Active Comparator|PET myocardial perfusion imaging|
9939329|NCT00976066|Experimental|GSK1521498|Subjects will receive a dose of the experimental compound GSK1521498
9939330|NCT00976066|Active Comparator|Naltrexone|Subjects will receive a dose of the licensed pharmaceutical product, Naltrexone
9939331|NCT00976079|Experimental|Active TENS|Active TENS therapy for 4 weeks plus standard physical therapy for same time period.
9939332|NCT00976079|Placebo Comparator|Placebo TENS|Placebo TENS for 4 weeks plus standard physical therapy for same time period.
9939333|NCT00976079|No Intervention|Control Group|No TENS, standard physical therapy for 4 weeks.
9939334|NCT00976092|Experimental|Prasugrel + Bivalirudin|60 mg prasugrel plus bivalirudin
9939335|NCT00976092|Active Comparator|Clopidogrel + Heparin|clopidogrel as loading and heparin
9939336|NCT00976105|Active Comparator|Part A: Zolpidem or placebo|This part is designed to examine the acute effects of up to 10mg of a known hypnotic sedative drug (Zolpidem) on cognitive and mood changes sensitve to sedation and tiredess.
9939337|NCT00976105|Experimental|Part B: GSK1521498 or placebo|At least 15 hours after Part A is completed subjects will enter Part B of the study.
9939338|NCT00976118|Placebo Comparator|placebo|
9939339|NCT00976118|Experimental|oral masitinib (AB1010)|masitinib (AB1010) 3 or 6 mg/kg/day
9939340|NCT00976131|Placebo Comparator|Arm A|Cycle 3 of doxorubicin with Coenzyme Q10, Cycle 4 with Coenzyme Q10 Placebo
9939341|NCT00976131|Experimental|Arm B|Cycle 3 of doxorubicin with Coenzyme Q10 Placebo, Cycle 4 with Coenzyme Q10
10000711|NCT01540708|Active Comparator|SERETIDE Diskus|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler
9800673|NCT01693562|Experimental|Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W)|Participants with microsatellite instability (MSI)-high cancer will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800674|NCT01693562|Experimental|Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with nasopharyngeal carcinoma (NPC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
9800675|NCT01693614|Experimental|DLBCL Cohort|Diffuse large B-cell lymphoma cohort
9800676|NCT01693614|Experimental|MCL Cohort|Mantle cell lymphoma cohort
9800677|NCT01693614|Experimental|FL Cohort|Follicular lymphoma cohort
9800678|NCT01693900|Experimental|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area.
9800679|NCT01693900|Active Comparator|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
9800680|NCT01694108|Experimental|BCG-vaccine (SSI)|"Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block-randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. < 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e-crf).~Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute CG vaccine in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician."
9800681|NCT01694108|No Intervention|No Intervention|Control children will be treated as usual, since no suitable placebo exists.
9800682|NCT01694121|Experimental|MEN Count|3 session HIV intervention including a) HIV risk reduction, inclusive of gender equity and healthy relationship counseling and b) case management support for stable employment and housing.
9800683|NCT01694121|Active Comparator|Comparison|An attention comparison program similar to the MEN Count intervention in structure (3 one-on-one sessions delivered over 60-90 days) but focused on stress reduction and healthy lifestyle.
9800684|NCT01694186|Sham Comparator|sham injection|sham injection
9800685|NCT01694186|Experimental|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
9800686|NCT01694199|Active Comparator|Active study device with PRFE|This study arm receives pulsed radiofrequency energy (PRFE) from an active test device.
9800687|NCT01694199|Sham Comparator|Sham study device with no PRFE|This study arm receives no pulsed radiofrequency energy (PRFE) from a sham test device.
9800688|NCT01694420|Experimental|Quad FDC|FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
9800689|NCT01694433|Experimental|Calcipotriene Cream|The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
9800690|NCT01694433|Placebo Comparator|Placebo|The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
9800691|NCT01694485|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800692|NCT01694485|Experimental|Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800693|NCT01694485|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800694|NCT01694485|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800695|NCT01694485|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800696|NCT01694563|Other|Atrial Fibrillation|Patients with non-paroxysmal atrial fibrillation (persistent or longstanding persistent)who are scheduled to undergo elective concomitant open, on-pump cardiac surgical procedure and the Maze IV ablation procedure. This single arm registry is designed to monitor the AtriCure Synergy Ablation System for continued safety and efficacy during the peri-procedural and long term phase during commercial use.
10000712|NCT01540721|Experimental|Experimental paracetamol formulation|Experimental formulation
10000713|NCT01540721|Active Comparator|Marketed paracetamol|Marketed formulation
10000714|NCT01540734|Active Comparator|Marketed paracetamol|marketed formulation
10000715|NCT01540734|Experimental|Experimental paracetamol formulation|Experimental formulation
10000716|NCT01540747|Experimental|Inofolic plus|178 patients
10000717|NCT01540747|Active Comparator|Inofolic|180 patients
10000718|NCT01540760|Experimental|MCAF5352A|
10000719|NCT01540760|Placebo Comparator|Placebo|
10000720|NCT01540786|Experimental|Part 1: OAB subjects|
9939342|NCT00976144|Experimental|GSK573719, GW642444, GSK573719+GW642444, placebo|This is a four-way cross-over study. Subjects, healthy volunteers, will receive a single dose of GSK573719 (500ug), GW642444 (50ug), GSK573719 (500ug)+GW642444 (50ug) administered concurrently, or placebo at each of the four treatment periods. There is a minimum wash-out period of seven days between doses. On enrolment into the study, subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start.
9939343|NCT00976157||Ventilator-associated pneumonia|
9939344|NCT00976170|Experimental|1|
9939345|NCT00976222|Other|1 Arm Ranibizumab|
9939346|NCT00976235|Experimental|IMT|
9939347|NCT00976261|Experimental|GSK1614235|Glucose lowering agent under investigation.
9939348|NCT00976261|Active Comparator|Sitagliptin|Glucose lowering comparator
9939349|NCT00976261|Placebo Comparator|Placebo|Placebo to match GSK1614235 and placebo to match Sitagliptin
9939350|NCT00976287|Active Comparator|Conserved Therapy|Conserved Therapy
9939351|NCT00976287|Experimental|Interventional Therapy|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
9939352|NCT00976300|Experimental|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
9939353|NCT00976300|Active Comparator|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).
9939354|NCT00976313||1|male patients
9939355|NCT00976313||2|female patients
9939356|NCT00976326|Experimental|A: Healthy volunteers|
9939357|NCT00976326|Experimental|B: Subjects with mild liver impairment|
9939358|NCT00976326|Experimental|C: Subjects with moderate liver impairment|
9939359|NCT00976326|Experimental|D: Subjects with severe liver impairment|
9939360|NCT00976365|Experimental|THL-P|Solution for study only.
9939361|NCT00976365|Placebo Comparator|Sugar pill|THL-p
9939362|NCT00976378|Experimental|0.05 mg/kg NOX-A12|
9939363|NCT00976378|Experimental|0.15 mg/kg NOX-A12|
9939364|NCT00976378|Experimental|0.45 mg/kg NOX-A12|
9939365|NCT00976378|Experimental|1.35 mg/kg NOX-A12|
9939366|NCT00976378|Experimental|2.7 mg/kg NOX-A12|
9939367|NCT00976378|Experimental|5.4 mg/kg NOX-A12|
9939368|NCT00976378|Experimental|10.8 mg/kg NOX-A12|
9939369|NCT00976378|Experimental|5.4 mg/kg NOX-A12 plus apheresis|
9939370|NCT00976417||1. Patients in the control group|
9939371|NCT00976417||2. Patients in the intervention group|
9939372|NCT00976430|Experimental|Therapy for Parkinson's disease|Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
9939373|NCT00976443|Placebo Comparator|Placebo (normal saline)|Gastric injections of normal saline
9939374|NCT00976443|Active Comparator|BTA 100 U|Gastric injections of botulinum toxin A, 100 Units
9939375|NCT00976443|Active Comparator|BTA 300 U|BTA 300 U, gastric injections under EUS guidance
9939376|NCT00976469|Experimental|Dose A (3.75 µg HA antigen, 0.25 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.
9939377|NCT00976469|Experimental|Dose B (7.5µg HA antigen, 0.5 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.
9939378|NCT00976534|Experimental|1|
9939379|NCT00976534|Placebo Comparator|2|
9939380|NCT00976547||Tinnitus patients|Group of 48 tinnitus patients
9939381|NCT00976586||Patients wiht Incontinentia Pigmenti|Patients wiht Incontinentia Pigmenti
9939382|NCT00976612||Nilotinib|Patients who receive nilotinib with failure to both imatinib and sunitinib
9939383|NCT00976625|No Intervention|1|Control group without intervention. Treatment group with aortic valve replacement.
9939384|NCT00976625|Other|2|
9939385|NCT00976638|Active Comparator|Chromogenic Arm|Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
9939386|NCT00976638|Active Comparator|Molecular Arm|Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
10000721|NCT01540786|Experimental|Part 2: Healthy subjects|
10000722|NCT01540786|Experimental|Part 2: OAB subjects|
10000723|NCT01540799|Experimental|Treatment|
10000724|NCT01540799|Other|Other|Stimulation not able to be felt
10000725|NCT01540812||V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud|Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5
10000726|NCT01540877|Experimental|Capsaicin application|application of 0.6%
10000727|NCT01540877|Experimental|Local anesthetics application|application of EMLA
10000728|NCT01540877|Experimental|Combined application of 1. capsaicin 2. local anesthetics|application of 1. capsaicin 0.6% and 2. EMLA
10000729|NCT01540877|Experimental|Combined application of 1. local anesthetics and 2. capsaicin|application of 1. EMLA and 2. capsaicin 0.6%
10000730|NCT01540890||withdrawal|patients who undergo an opioid withdrawal
10000731|NCT01540890||opioids|patients on opioid medication without withdrawal
10000732|NCT01540890||opioid-free|patients with chronic pain without opioid medication
10000733|NCT01540903|Experimental|Group 1 10,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.
10000734|NCT01540903|Experimental|Group 2 25,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.
10000735|NCT01540903|Placebo Comparator|Controls - saline|4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.
10000736|NCT01540916|Experimental|Hyperventilation|Minute ventilation will be increased of about 30% of baseline value, through an increase in respiratory rate
10000737|NCT01540916|Experimental|Hypoventilation|Minute ventilation will be decreased of about 30% of baseline value, through a decrease in respiratory rate
10000738|NCT01540929||Study Group|DoD Smallpox Screening Form 600 (2 part format)
10000739|NCT01540942|Active Comparator|Nutrition treat|perioperative nutrition support until the patients get the normal nutrition or disease remission
10000740|NCT01540942|Active Comparator|bowel resection|bowel resection until the patients get the normal nutrition or disease remission after bowel resection
10000741|NCT01540955|Experimental|Group Intervention program|
10000742|NCT01540955|No Intervention|Wait-list control group|The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.
10000743|NCT01540968|Experimental|Nutrition & physical exercise|
10000744|NCT01540968|No Intervention|Control|
10000745|NCT01540994|Experimental|SBRT|Stereotactic Body Radiation Therapy
10000746|NCT01541007|Active Comparator|Standard Cabazitaxel Schedule|Cabazitaxel 25 mg/m2 every three weeks
10000747|NCT01541007|Experimental|Weekly cabazitaxel schedule|cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
10000748|NCT01541020||Healthy individuals|
10000749|NCT01541020||Individuals with low back pain|
10000750|NCT01541033||Autism with FAH|Children diagnosed with autism with first degree relatives that have autoimmune disorders.
9480628|NCT05262478||Alpha-D cervical disc prosthesis|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
9939387|NCT00976651|Active Comparator|Recombinant FSH|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
9939388|NCT00976651|Experimental|human chorionic gonadotropin|"Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.~Histology and gene expression is studied on the endometrium"
9939389|NCT00976690|Active Comparator|1|Azathioprine : 2mg/kg/day
9939390|NCT00976690|Active Comparator|2|Mesalazine : 4g/day
9939391|NCT00976729|Placebo Comparator|Placebo i.v.|
9939392|NCT00976729|Experimental|0.03 mg/kg i.v.|
9939393|NCT00976729|Experimental|0.09 mg/kg i.v.|
9939394|NCT00976729|Experimental|0.25 mg/kg i.v.|
9939395|NCT00976729|Experimental|0.5 mg/kg i.v.|
9939396|NCT00976729|Experimental|1.0 mg/kg i.v.|
9939397|NCT00976729|Experimental|2.0 mg/kg i.v.|
9939398|NCT00976729|Placebo Comparator|Placebo s.c.|
9939399|NCT00976729|Experimental|0.25 mg/kg s.c.|
9939400|NCT00976729|Experimental|0.5 mg/kg s.c.|
9939401|NCT00976742|Experimental|Endurance Exercise Training|
9939402|NCT00976755|Experimental|Arm A: Everolimus|"Everolimus:~10mg daily"
9939403|NCT00976768|Experimental|FOLFIRI arm|Patients receiving FOLFIRI
9939404|NCT00976794|Experimental|lithium plus carbamazepine|combination of the two drugs in standard dosage
9939405|NCT00976794|Active Comparator|lithium plus valproate|combination of the two drugs in standard dosage
9939406|NCT00976807|No Intervention|Control|
9939407|NCT00976807|Experimental|Intervention|Pulmonary Rehabilitation
9939408|NCT00976833|Active Comparator|Usual Care|Usual Care
9939409|NCT00976833|Other|Standardized Rehabilitation|Intervention arm to receive Standardized Rehabilitation Therapy
9939410|NCT00976846|Experimental|Baxter Xenium XPH 210|Device: Baxter Xenium XPH 210 dialyzer
9939411|NCT00976859|No Intervention|Waitlist control group|
9939412|NCT00976859|Experimental|Imagery Modification|Via a internet research patients collect data on skin renewal which is discussed afterwards; in a guided imagery modification the patients imagines the process of skin renewal and the building of new skin cells
9939413|NCT00976872|Active Comparator|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
10000751|NCT01541033||Autism without FAH|Children diagnosed with autism without first degree relatives that have autoimmune disorders.
10000752|NCT01541033||Control|Typically developing children
9528826|NCT03207451|Experimental|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
9939414|NCT00976872|Placebo Comparator|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
9939415|NCT00976885||Subjects with normal health|
9939416|NCT00976885||Subjects with Stroke|
9939417|NCT00976924|Experimental|Andon|Andon blood glucose test strips with test meter
9939418|NCT00976924|Active Comparator|Lifescan|Lifescan blood glucose test strips with test meter
9939419|NCT00976963|Active Comparator|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediatley
9939420|NCT00976963|Active Comparator|TMP/SMX|Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab (TMP/SMX) Take one twice daily for 3 days for urinary tract infection
9939421|NCT00976976|Experimental|DXP|
9939422|NCT00977002|Experimental|PPNIV|Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
9939423|NCT00977002|Active Comparator|O2I|Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
9939424|NCT00977015|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
9939425|NCT00977015|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
10000753|NCT01541046|Experimental|Biogaia L. reuteri DSM 17938|Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10^8 cfu),5 drops, once per day for 21 days.
10000754|NCT01541046|Placebo Comparator|Probiotic Placebo|Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
10000755|NCT01541059|Placebo Comparator|Placebo|Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
10000756|NCT01541059|Experimental|Ropivacaine|Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.
10000757|NCT01541072|Experimental|Pegfilgrastim|
10000758|NCT01541072|Active Comparator|Filgrastim|
10000759|NCT01541085||Darunavir/Ritonavir (DRV/r)|
10000760|NCT01541085||Efavirenz (EFV)|
10000761|NCT01541098|Active Comparator|Licensed Plasma|
10000762|NCT01541098|Experimental|Lyophilized Plasma|
10000763|NCT01541111|Other|Magnesiun, pain relief, sugar pills|Magnesiun 75mg po each 12h pain relief Sugar pills po each 12h
10000764|NCT01541124|Experimental|Morphine, Pain intensity|For cancer pain treatment, World Health Organization recomends tritation of opioids associated with non steroidal antiinflamatory drugs. This study compares the analgesic effect with diferents dosages in 63 patients with cancer pain.
10035030|NCT01802372|Sham Comparator|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline,and usual care.
10000765|NCT01541137|Active Comparator|diclofenac + IV-PCA|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine boluses, from the 2nd postoperative morning the patients were given oral diclofenac 75 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
10000766|NCT01541137|Active Comparator|parecoxib/ valdecoxib + IV-PCA|oral valdecoxib 40 mg, a 44-hour iv-infusion parecoxib 80 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine, From the 2nd postoperative morning valdecoxib 40 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
10000767|NCT01541137|Active Comparator|patient controlled epidural analgesia|At the induction of anesthesia the PCEA-patients were given IV paracetamol 1g and an epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses, IV paracetamol 1g x 4 for the first 24 hours and thereafter 1g x 3 orally, PCEA was discontinued and paracetamol was replaced with ibuprofen 600 mg x 3 and oral oxycodone
10000768|NCT01541150|Active Comparator|patient suffering pedophilia|This group is the active comparator because patients suffering pedophilia with neuropsychological questionnaires
10000769|NCT01541150|Placebo Comparator|control group|This group is the placebo comparator
10000770|NCT01541163||Acute Ischemic Stroke|Patients with acute ischemic stroke admitted within 12 hours after onset.
10000771|NCT01541176|Experimental|Absence of corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
10000772|NCT01541176|Active Comparator|Corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
10000773|NCT01541189|Experimental|valsartan|After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.
10000774|NCT01541202|Placebo Comparator|Placebo|placebo in addition to standard therapy
10000775|NCT01541202|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
10000776|NCT01541228|Active Comparator|Group I|Patients with actinic keratosis (AK) on the left and right sides of face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
10000777|NCT01541228|Active Comparator|Group II|Patients with actinic keratosis (AK) on the left and right sides of the face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
10000778|NCT01541241||copper IUD used|"Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.~Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding."
10000779|NCT01541267|Active Comparator|C - A - B|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
10000780|NCT01541267|Active Comparator|B - A - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
10000781|NCT01541267|Active Comparator|A - B - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
10000782|NCT01541293|Experimental|Intrauterine Lidocaine|The experimental arm will receive 100mg lidocaine (5mL of 2% concentration) instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
10000783|NCT01541293|Placebo Comparator|Intrauterine Saline|Placebo arm will receive 5mL of normal saline instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
9800697|NCT01694641|Experimental|time-lapse morphokinetic evaluation|"Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention."
9800698|NCT01694641|No Intervention|standard embryo monitoring|Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.
9800699|NCT01694667|Active Comparator|Omega-3 Fatty Acids|Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA
9800700|NCT01694667|Placebo Comparator|Placebo|Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
9800701|NCT01694706|Experimental|Reference|faldaprevir medium, fasted
9800702|NCT01694706|Active Comparator|Test 1|faldaprevir medium, fed
9800703|NCT01694706|Active Comparator|Test 2|faldaprevir medium + omeprazole medium
9800704|NCT01694771|Experimental|Olodaterol and Tiotropium|2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
9800705|NCT01694771|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
9800706|NCT01694966|Active Comparator|Methylene Blue MMX® 200mg|Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
9800707|NCT01694966|Active Comparator|Methylene Blue MMX® 100mg|Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
9800708|NCT01694966|Placebo Comparator|Placebo|Oral dose, 8 Placebo tablets over a 4hr schedule
9800709|NCT01695044|Experimental|Arm 1: PSMA ADC|Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
9800710|NCT01695135|Experimental|Abiraterone acetate plus prednisone|
9800711|NCT01695135|Experimental|Placebo plus prednisone|
9800712|NCT01695239|Experimental|Ixekizumab Q2W|Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
9800713|NCT01695239|Experimental|Ixekizumab Q4W|Administered by 80 mg SC injection every 4 weeks (Q4W).
9800714|NCT01695239|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
9800715|NCT01695239|Active Comparator|Adalimumab Q2W|Administered by 40 mg SC injection Q2W.
9800716|NCT01695291|Placebo Comparator|Placebo|Participants randomized to placebo will receive pills that are identical in appearance to the study drug but contain no active medication.
9800717|NCT01695291|Experimental|Minocycline Augmentation|Those randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline (minimum 50 mg/day and maximum 200 mg/day). After randomization, participants will receive child proofed bottles that contain enough study medication until the next visit with an additional 3 days coverage in case of scheduling issues. All participants will have a minocycline level drawn at week 12 to confirm treatment adherence. Minocycline is FDA-approved in those ages 8 and above for treatment of infections and acne and has a favorable risk-benefit profile.
9800718|NCT01695304|Experimental|Intervention Arm|Households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water.
9800719|NCT01695304|No Intervention|Control Arm|Households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
9800720|NCT01695330|Experimental|Subcutaneous bortezomib|
9800721|NCT01695369|Active Comparator|Senofilcon A|Senofilcon A; Comfilcon A
9800722|NCT01695369|Experimental|Comfilcon A|Comfilcon A; Senofilcon A
9800723|NCT01695473|Experimental|Neoadjuvant BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in operating room (OR) scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
9800724|NCT01695668|Experimental|Lotemax|Loteprednol Etabonate 0.5%
9800725|NCT01695668|Active Comparator|Restasis|Cyclosporine
9800726|NCT01695746||C.E.R.A.|Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months). Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information. Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
9800727|NCT01695772|Experimental|Bevacizumab|
9800728|NCT01695954|Experimental|Arm A|Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.
9800729|NCT01695954|Experimental|Arm B|Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.
9800730|NCT01695993|No Intervention|Arm 1 - Standard Care Only|Patients will receive standard care only
9800731|NCT01695993|Other|Arm 2 - Expectancy-neutral Arm|"Patients receive:~Expectancy-neutral handout~Expectancy-neutral MP3~Acupressure bands"
9800732|NCT01695993|Experimental|Arm 3 - Expectancy-enhancing Arm|"Patients receive:~Expectancy-enhancing handout~Expectancy-enhancing MP3~Acupressure bands"
9800733|NCT01696032|Experimental|SGI-110 + Carboplatin|Stage 1 was a safety lead-in stage with a dose escalation design. Participants were evaluated with the combination of SGI-110 (guadecitabine) plus carboplatin (G+C), given as 28-day treatment cycles: guadecitabine administered subcutaneous (SC) daily on Days 1-5, at a starting dose of 45 mg/m2/day in Cohort 1, followed by carboplatin intravenous (IV) based on a targeted dose of area under the curve (AUC) 5 on Day 8. After dose limiting toxicities were noted, guadecitabine dose was reduced to 30 mg/m2/day for subsequent cycles for 4 participants. Cohort 2 received 30 mg/m2/day guadecitabine and carboplatin IV AUC 4.
9800734|NCT01696032|Experimental|SGI-110 + Carboplatin or TC|Stage 2 was an open-label, randomized, controlled trial. Eligible participants were randomly assigned in a 1:1 ratio to receive either (1) G+C combination treatment in 28-day cycles at 30 mg/m2 SC once daily on Days 1-5 and carboplatin IV AUC 4 on Day 8, or (2) treatment of choice (TC) of topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel, or gemcitabine based on recommended dosing in 28-day cycles; participants initially randomized to TC were able to cross over to receive 30 mg/m2 G+C due to disease progression.
9800735|NCT01696045|Experimental|Ipilimumab 3 mg/kg|Ipilimumab (3 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
9800736|NCT01696045|Experimental|Ipilimumab 10 mg/kg|Ipilimumab (10 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
9800737|NCT01696058|Experimental|Olodaterol andTiotropium|2 puffs Olodaterol from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
9800738|NCT01696058|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
9800739|NCT01696071|Experimental|Treatment A|2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
9800740|NCT01696071|Experimental|Treatment B|2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
9800741|NCT01696084|Experimental|Arm A (CPX-351)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
9800742|NCT01696084|Active Comparator|Arm B (7+3)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
9800743|NCT01696188|Experimental|In-plane group|This group will receive an interscalene catheter placed with in-plane approach.
9800744|NCT01696188|Experimental|Out-of-plane group|This group will receive an interscalene catheter with an out-of-plan approach.
9800745|NCT01696214|Placebo Comparator|Ipratropium|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
9800746|NCT01696214|Placebo Comparator|Theophylline|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
9800747|NCT01696214|Placebo Comparator|Montelukast|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
9800748|NCT01696214|Placebo Comparator|fluticasone 250 mg/salmeterol 50mg|Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
9800749|NCT01696279|Experimental|Lanthanum Carbonate|Participants will receive lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided and mixed equally between in three meals.
9800750|NCT01696279|Active Comparator|Calcium Carbonate|Participants will receive calcium carbonate orally at a total daily dose adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
9800751|NCT01696357||Adolescents with asthma|Ages 13-17 with an asthma diagnosis-both symptomatic and non-symptomatic- and with currently prescribed asthma medication.
9800752|NCT01696357||Adolescents without asthma|Ages 13-17 without an asthma diagnosis and without any other respiratory condition that presents with asthma-like symptoms.
9800753|NCT01696396|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800754|NCT01696396|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800755|NCT01696396|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
9800756|NCT01696396|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M)for 108 weeks."
9800757|NCT01696643|Experimental|CB-5945|0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
9800758|NCT01696643|Placebo Comparator|Placebo|Placebo, administered orally, BID for 52 weeks
9939426|NCT00977028|Experimental|Tumescent Lidocaine with liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
9939427|NCT00977028|Experimental|Tumescent Lidocaine No Liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
9939428|NCT00977041|Experimental|Neurofeedback|See Intervention description below.
9939429|NCT00977054|Experimental|DFPP and Peg-IFN + RBV|Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight < 75 kg, 1,000 mg/day and body weight >= 75 kg, 1,200 mg/day)
9939430|NCT00977054|Active Comparator|Peg-IFN + RBV|Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight < 75 kg, 1,000 mg/day and body weight >=75 kg, 1,200 mg/day)
9939431|NCT00977067|Experimental|A|
9939432|NCT00977093|Experimental|Perfusion CMR examination|All patients will undergo perfusion CMR examination, single-photon emission computed tomography, and conventional invasive coronary angiography.
9939433|NCT00977119||Capecitabine|Women with breast cancer receiving capecitabine as treatment for their breast cancer.
9939434|NCT00977132|Experimental|Lenalidomide|Lenalidomid in combination valproic acid
9939435|NCT00977145|Experimental|intratumoral IFN-gamma plus MELITAC 12.1,|intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1, an emulsion of a mixture of 12 class I MHC-restricted melanoma-derived peptides (12-MP) and a class II MHC-restricted tetanus toxoid-derived helper peptide (Peptide-tet).
9939436|NCT00977158||Throat Swab|Infants who have been diagnosed with cystic fibrosis
9939437|NCT00977210|Experimental|OXi4503|
9939438|NCT00977223|Experimental|Aprepitant|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
9939439|NCT00977223|Placebo Comparator|placebo|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
9939440|NCT00977236|Experimental|Orthokeratology lenses|Children wearing orthokeratology at night for partial correction and spectacles at daytime for residual refractive error will be study group
9939441|NCT00977236|Other|Single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
9939442|NCT00977249|Active Comparator|varenicline|"Varenicline for 12 weeks.~The treatment schedule for varenicline is:~Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks"
9939443|NCT00977249|Placebo Comparator|placebo|Placebo for 12 weeks
9939444|NCT00977262|Experimental|Healthy control subjects, High saturated fat shake|
9939445|NCT00977262|Experimental|Healthy control subjects, High Monounsaturated fat shake|
9939446|NCT00977262|Experimental|Healthy control subjects, High Polyunsaturated fat shake|
9939447|NCT00977262|Experimental|Healthy obese subjecs, High saturated fat shake|
9939448|NCT00977262|Experimental|Healthy obese subjects, High monounsaturated fat shake|
9939449|NCT00977262|Experimental|Healthy obese subjects, High polyunsaturated fat shake|
9939450|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Saturated fat shake|
9939451|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Monounsaturated fat shake|
9939452|NCT00977262|Experimental|Obese diabetes type 2 subjects, High polyunsaturated fat shake|
9939453|NCT00977288|Experimental|1|MK0859 10 mg + placebo
9939454|NCT00977288|Experimental|2|MK0859 40 mg + placebo
9939455|NCT00977288|Experimental|3|MK0859 100 mg + placebo
9939456|NCT00977288|Experimental|4|MK0859 300 mg + placebo
9939457|NCT00977288|Experimental|5|MK0859 10 mg + atorvastatin 10mg
9939458|NCT00977288|Experimental|6|MK0859 40 mg + atorvastatin 10mg
9939459|NCT00977288|Experimental|7|MK0859 100 mg + atorvastatin 10mg
9939460|NCT00977288|Experimental|8|MK0859 300 mg + atorvastatin 10mg
9939461|NCT00977288|Placebo Comparator|9|Placebo + atorvastatin 10mg
9939462|NCT00977288|Placebo Comparator|10|Placebo
9939463|NCT00977301|Experimental|fosamprenavir/ritonavir/olanzapine|single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID
9939464|NCT00977301|Active Comparator|single dose olanzapine|Single dose of 10 mg olanzapine
9939465|NCT00977327|Other|Intraoperative MR|Use of intraoperative MR during resection of intraaxial tumor, Glioma
9939466|NCT00977327|Other|Intraoperative Ultrasound|Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
9939467|NCT00977340|Experimental|Imagery Rehearsal Treatment|Imagery Rehearsal Treatment; 1 session on-site and 4 weeks of individual daily training; following principles Krakow and Zadra (2006)
9939468|NCT00977340|Experimental|Confrontation|Confrontation with nightmare content, until fear reaction habituates; 1 session on-site and 4 weeks of individual daily training
9939469|NCT00977340|Placebo Comparator|Imagination|Imagination of a safe and pleasant site; 1 session on-site and 4 weeks of individual daily training
9939470|NCT00977353|Experimental|sarcosine|sarcosine
9939471|NCT00977353|Active Comparator|citalopram|citalopram
9939472|NCT00977366|Active Comparator|Hydrochloric acid infusion|
9939473|NCT00977366|Placebo Comparator|Saline|
9939474|NCT00977405|No Intervention|Control|Primary closure after standard washing of wound with chlorhexidine solution
9939475|NCT00977405|Experimental|Collatamp G|Primary closure of wound with collatamp G in subcutaneous layer
9939476|NCT00977418|No Intervention|No intervention|Seniors undergo all testing but remain current lifestyle
9939477|NCT00977418|Experimental|Training|Groups will undergo either physical or mental training. Physical training is 1 hour aerobic training 3 times per week for 12 weeks. Mental training is 1 hour Strategic Memory Advanced Reasoning Training 3 times per week.
9939478|NCT00977444|Experimental|kondrium|intraarticular injections once month
9939479|NCT00977444|Experimental|kondrium f|
9939480|NCT00977444|Active Comparator|corticosteroid|intraarticular injections once month
9939481|NCT00977496||Nasal Swab|New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
9939482|NCT00977587|Active Comparator|Saccharomyces Cerevisiae CNCM I-3856|2 weeks of treatment with Saccharomyces Cerevisiae CNCM I-3856 1 capsule twice a day, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).
9939483|NCT00977587|Placebo Comparator|placebo|"Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~Calcium phosphate, Dibasic 472.0 mg~Maltodextrin DE14 112.1 mg~Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
9939484|NCT00977600|Experimental|GT4P-F|GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
9939485|NCT00977600|Experimental|GT4P-API|GT4P-API was supplied as an odorless, colorless, tasteless oil in 125 ml bottles. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-API was taken orally and washed down with 100 ml of water. GT4P-API was stored at ambient temperature, away from light.
9939486|NCT00977600|Active Comparator|Ammonul|Ammonul® was supplied as single-use glass vials of 10% sodium phenylacetate and 10% sodium benzoate for intravenous injection. Ammonul® was diluted before use with sterile dextrose injection 10% to a concentration of 9 mg/ml. Once diluted it was kept at room temperature and used within 24 hours. The dose was 2.75 g/m2 and was administered as an intravenous infusion over a 120-minute period. Ammonul® was stored at 25°C, within a range of 15-30°C.
9939487|NCT00977600|Active Comparator|Buphenyl|Sodium phenylbutyrate or Buphenyl® was supplied as a white powder in 250 g bottles. The required amount of powder (equivalent to 3 g/m2 of PBA) was weighed out, mixed in 100 ml of water, and administered orally. Doses were calculated on a weight/volume basis and corrected for sodium content and purity. Buphenyl® was stored at ambient temperature.
9939488|NCT00977626|Experimental|Part 1 AZD2423 or Placebo|AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days
9939489|NCT00977626|Experimental|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
9939490|NCT00977626|Experimental|Part 3 - AZD2423|AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
9939491|NCT00977652|Active Comparator|Active stimulation|Percutaneous posterior tibial nerve stimulation
9939492|NCT00977652|Sham Comparator|sham stimulation|Inefficient percutaneous posterior tibial nerve stimulation
9939493|NCT00977678||Open access gastroscopy|Patients referred to open access gastroscopy
9939494|NCT00977678||Conventional outpatient gastroscopy|Gastroscopy after preceding appointment
9939495|NCT00977717||FOLFOX|Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
9939496|NCT00977730|Active Comparator|Protandim|
9939497|NCT00977730|Placebo Comparator|Sugar pill|
9939498|NCT00977756||Group G|Participants will receive a medication regimen including RAL + ATV + RTV.
9939499|NCT00977756||Group H|Participants will receive a medication regimen including RAL + TDF.
9939500|NCT00977756||Group I|Participants will receive a medication regimen including ETV + DRV + RTV.
9939501|NCT00977756||Group J|Participants will receive a medication regimen including MVC + ATV + RTV.
9939502|NCT00977756||Group K|Participants will receive a medication regimen including MVC + LPV + RTV.
9939503|NCT00977756||Group L|Participants will receive a medication regimen including MVC + RAL + ETV.
9939504|NCT00977756||Arm M|Participants will receive a medication regimen of DRV
9939505|NCT00977756||Arm N|Participants will receive a medication regimen of DRV
9939506|NCT00977756||Arm O|Participants will receive a medication regimen of unboosted ATV
9939507|NCT00977756||Arm P|Participants will receive a medication regimen of RPV
9939508|NCT00977756||Arm Q|Participants will receive a medication regimen of RPV
9939509|NCT00977795|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
9939510|NCT00977821|Active Comparator|fresh|Embryo transfer with fresh oocytes
9939511|NCT00977821|Experimental|Frozen|Embryo transfer with vitrified oocytes
9939512|NCT00977834||Group 1|Patients with lymphoma or lung cancer
9939513|NCT00977834||Group 2|Caregivers
9939514|NCT00977847|Experimental|Interactive Voice Response Practice|"The introductory letter to patients will allow them an opportunity to opt-out of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR."
9939515|NCT00977847|Experimental|Wireless Tablet PC Practice|Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
9939516|NCT00977847|Experimental|Internet Portal Practice|Patients in this practice will receive the informational letter either by email or mail one month before their scheduled visit. It will have directions to access the MFHP website and how to transfer data through the hospitals secure internet portal (Patient Gateway). About 1/3 of patients are signed up to use this service. Those who do not have a Patient Gateway account will be provided with directions on how to establish this service. Patients will be required to have a Gateway account to ensure that the MFHP data file is sent securely to the correct EHR record. Patients in this arm will receive an initial email or letter with a single follow-up reminder sent 2 weeks later. For patients who participate, the completed family history data will be transmitted to the patient's EHR.
9939517|NCT00977847|Active Comparator|Usual Care Physician Assesment Practice|Usual standard family history assessments will be conducted by physicians during the patient visit. This arm will allow us to account for any temporal trends in family history assessment.
9939518|NCT00977873|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
9939519|NCT00977873|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
9939520|NCT00977886|Placebo Comparator|Placebo|
9939521|NCT00977886|Experimental|ELB353|
9939522|NCT00977912|Experimental|"Milk containing B. Lactis"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
9939523|NCT00977912|Placebo Comparator|"Milk containing placebo"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
9939524|NCT00977925|Experimental|Fibrin Pad|
9939525|NCT00977925|Active Comparator|Standard of Care|
9939526|NCT00977951|Experimental|Intradermal avotermin|
9939527|NCT00977951|Placebo Comparator|Placebo (vehicle)|
9939528|NCT00977964|Experimental|Milk Based Protein Formula Process A|
9939529|NCT00977964|Experimental|Milk Based Protein Formula Process B|
9939530|NCT00977964|Experimental|Milk Based Protein Formula Process C|
9939531|NCT00977964|Experimental|Milk Based Protein Formula Process D|
9939532|NCT00977964|Experimental|Milk Based Protein Formula Process E|
9939533|NCT00977964|Experimental|Milk Based Protein Formula Process F|
9939534|NCT00978055|Experimental|1|Liothyronine Sodium Tablets, 50 mcg
9939535|NCT00978055|Active Comparator|2|Cytomel® Tablets, 50 mcg
9939536|NCT00978081|Experimental|Arm I|Patients receive oral aminolevulinic acid and then undergo continuous photodynamic therapy 4-6 hours later.
9939537|NCT00978081|Experimental|Arm II|Patients receive aminolevulinic acid as in arm I and then undergo fractionated photodynamic therapy 4-6 hours later.
9939538|NCT00978133|Active Comparator|Skin Staples|Skin closure with skin staples
9939539|NCT00978133|Experimental|Dermabond|Closure of abdominal wound with dermabond (2-octylcyanoacrylate)
9939540|NCT00978146|Experimental|Desmoid tumor|Patients with desmoid tumors
9939541|NCT00978159|Active Comparator|esomeprazole|esomeprazole 20 mg
9939542|NCT00978159|Active Comparator|Famotidine|famotidine 40 mg
9939543|NCT00978198|Experimental|Part 1|single administration
9939544|NCT00978198|Experimental|Part 2|multiple administration
9939545|NCT00978211|Experimental|DOTA-TOC|Treatment arm
9939546|NCT00978224|Experimental|A|Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
9939547|NCT00978224|Placebo Comparator|B|Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
9939548|NCT00978237|Active Comparator|EFV and Fixed combinations of analogues|EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
9939549|NCT00978237|Experimental|LPV/r and combination of analogues.|
9939550|NCT00978263|Experimental|Glargine|Initial basal Insulin therapy was according to the dose administrated at bedtime in the last day hospitalization. basal Insulin doses were titrated every 3 days to achieve target FPG values between 80 and 130 mg/dl.
9939551|NCT00978263|Experimental|metformin-based Oral Antidiabetic Drugs|Subject in metformin-based OAD group was visited every two weeks in the first month and the every four weeks for another five months. The subjects will start with Metformin 425mg bid, The dosage was titrated (up to 850mg bid) based on the fasting blood glucose every two weeks. If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.
9939552|NCT00978302|Placebo Comparator|Placebo (vehicle)|
9939553|NCT00978302|Experimental|Avotermin|
9939554|NCT00978315|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
9939555|NCT00978315|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
9939556|NCT00978328||001|oxycodone immediate release (OXYRX) Characteristics of pts. receiving prescription medications containing OXYRX
9939557|NCT00978354|Active Comparator|Furosemide|Furosemide intravenous continuous infusion
9939558|NCT00978354|Placebo Comparator|Normal Saline|Normal saline titrated continuous intravenous infusion
9939559|NCT00978367|Experimental|Drug, intradermal avotermin (Juvista)|
9939560|NCT00978367|Placebo Comparator|Placebo (vehicle)|
9939561|NCT00978393|Experimental|A|
9939562|NCT00978393|Experimental|B|
9939563|NCT00978393|Experimental|C|
9939564|NCT00978393|Experimental|D|
9939565|NCT00978393|Experimental|E|
9939566|NCT00978393|Experimental|F|
9939567|NCT00978406||Healthy volunteers|Healthy volunteers
9939568|NCT00978471|Experimental|experimental arm thiotepa|4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.
9939569|NCT00978471|Other|Reference arm|4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.
9939570|NCT00978484|Active Comparator|Static Virtual Reality|Exposure Therapy using a still computer image
9939571|NCT00978484|Experimental|Dynamic Virtual Reality|Virtual Reality Exposure Therapy using full, immersive Virtual Reality
9939572|NCT00978523|Experimental|Treatment with AR-12|This is a single-agent, open-label, Phase 1, dose-escalation study in adult patients with advanced or recurrent solid tumors or lymphoma. Patients will receive orally administered AR-12 once daily for 28 consecutive days. The first dosing cycle will be followed by at least a 7 day off-treatment period; however, no off-treatment period will be scheduled between subsequent treatment cycles
9939573|NCT00978536|Other|group 1|MS with cortical cognitive troubles
9939574|NCT00978536|Other|group 2|MS with subcortical cognitive troubles
9939575|NCT00978536|Other|group 3|MS in the early stage of the disease when cognitive troubles are absent or inconspicuous
9939576|NCT00978575|Active Comparator|Intravenous iron|
9939577|NCT00978575|Active Comparator|Oral iron|
9939578|NCT00978575|Placebo Comparator|Isotonic Sodium and placebo tablets|
9939579|NCT00978588|Experimental|HES 130/0.4|
9939580|NCT00978588|Active Comparator|5% albumin|
9939581|NCT00978601|Experimental|Multimodal analgesic protocol group|Women who received the multimodal analgesic protocol during minimally invasive myomectomy.
9939582|NCT00978601|No Intervention|No use of multimodal analgesic protocol group|Women who did not receive the multimodal analgesic protocol during minimally invasive myomectomy.
9939583|NCT00978614|Experimental|Neramexane, Placebo, Moxifloxacin|
9939584|NCT00978640|Experimental|fasting and exercise|36 h fast and 1 h ergometer cycling 50% VO2max
9939585|NCT00978640|Experimental|exercise|1 h ergometer cycling 50% VO2max
9939586|NCT00978653|Experimental|Allopurinol|Hyperuricemic (uric acid (UA)>7 mg/dL), nondiabetic CKD patients without any comorbidity, age<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
9939587|NCT00978666||Healthy controls|Healthy comparison adolescent females
9939588|NCT00978666||Anorexia Nervosa|Adolescent females currently ill with Anorexia Nervosa, restricting type
9939589|NCT00978679|Experimental|Orthokeratology|Myopic children wearing orthokeratology at night will be the study group
9939590|NCT00978679|Other|Others|Myopic children wearing single-vision spectacles in the daytime will serve as control group
9939591|NCT00978692|Experimental|Toric orthokeratology lenses|Children wearing toric ortho-k lenses at night for correcting astigmatism and myopia will be the study group
9939592|NCT00978692|Other|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive error will be serve as control group
9939593|NCT00978718|Placebo Comparator|Arm I|Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
9939594|NCT00978718|Experimental|Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily|Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
9939595|NCT00978718|Experimental|Arm III: 400 μg Se as high-Se baker's yeast daily|Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
9939596|NCT00978783|Active Comparator|speaking valve|
9939597|NCT00978783|Active Comparator|Positive end expiratory pressure|
9939598|NCT00978796|Active Comparator|Sitagliptin|Patients will receive sitagliptin for 4 weeks and then cross over to sugar pill
9939599|NCT00978796|Placebo Comparator|Sugar pill|Subjects will receive sugar pill for 4 weeks and then cross over to active sitagliptin
9939600|NCT00978809|Active Comparator|Semont|BPPV patients treated by Semont maneuver by a physical therapist.
9939601|NCT00978809|No Intervention|control|healthy volunteers.
9939602|NCT00978809|Active Comparator|Epley maneuver|BPPV patients treated with Epley maneuver by a physical therapist.
9939603|NCT00978822|Experimental|Clevidipine butyrate injectable emulsion|
9939604|NCT00978835|Experimental|Nurse case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
9939605|NCT00978835|Active Comparator|Nurse Education|Didactic, non-interactive education by a nurse on general health topics.
9939606|NCT00978848||Women seeking emergency contraception|Women seeking emergency contraception
9939607|NCT00978848||Women seeking urine pregnancy testing|Women seeking urine pregnancy testing
9939608|NCT00978861|Experimental|whitening|30% Hydrogen peroxide
9939609|NCT00978887|Experimental|A|Retorna (facial cream)
9939610|NCT00978887|Placebo Comparator|B|Placebo (facial cream)
9939611|NCT00978900|Active Comparator|Acesulfame K|
9939612|NCT00978900|Active Comparator|Sucralose|
9939613|NCT00978900|Active Comparator|Aspartame|
9939614|NCT00978900|Active Comparator|Glucose|
10000784|NCT01541306||achondroplasia or hypochondroplasia|Children or adults with achondroplasia or hypochondroplasia
9939615|NCT00978900|Active Comparator|Fructose|
9939616|NCT00978900|Placebo Comparator|Water|
9939617|NCT00978913|Experimental|DC vaccination and Cyclophosphamide|
10000785|NCT01541319||Randomized to <= 10day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
10000786|NCT01541319||Randomized to >= 21day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
10000787|NCT01541319||Randomized but not transfused|Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
10000788|NCT01541319||Healthy volunteers|
10000789|NCT01541332|Experimental|Pomalidomide + PLD + Dexamethasone|Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
10000790|NCT01541436|Active Comparator|Capsaicin, UV-B, RIPC|
10000791|NCT01541436|Sham Comparator|Capsaicin, UV-B|
10000792|NCT01541449||RA patients treated with plaquenil|
10000793|NCT01541449||Patients who do not use plaquenil|
10035031|NCT01802398||No treatment|Observational cohort study of older (age≥60 years) adults who present to an emergency department with syncope (otherwise known as fainting)
10035032|NCT01802424|Experimental|The Friends program|Youth with increased levels of anxiety are thought to regulate their fear by recognizing bodily cues, learning relaxation, regulating thoughts and feelings and expose themselves to situations and objects that activate their anxiety.
10035033|NCT01802450|Experimental|Dasatinib (Sprycel)|Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib
9939618|NCT00978939|Experimental|Aggressive Drainage Arm|Patients will drain up to 1 liter of pleural fluid everyday
9480629|NCT05262465|Experimental|MST for unfit|"Induction chemotherapy can use azacytidine combined with low-dose cytarabine, or azacytidine combined with BCL / 2 inhibitor, and infuse modified peripheral blood hematopoietic stem cells after chemotherapy.~Consolidation chemotherapy used azacytidine combined with low-dose cytarabine. After chemotherapy, modified peripheral blood hematopoietic stem cells were infused and repeated for 3 courses."
9939619|NCT00978939|Active Comparator|Standard Drainage Arm|Patients will drain up to 1 liter of pleural fluid every other day
9939620|NCT00978952|Experimental|Investigational Group|Use of Large Diameter Advanta™ V12 Covered Stent.
9939621|NCT00978965||All patients|
9939622|NCT00978978|Active Comparator|Propofol, endoscopies, liver diseases|Propofol, endoscopies, liver diseases
9939623|NCT00978978|Active Comparator|midazolam and fentanyl, endoscopies, liver diseases|Control: midazolam and fentanyl, endoscopies, liver diseases
9939624|NCT00979043|Active Comparator|Dietary weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
9939625|NCT00979043|Active Comparator|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
9939626|NCT00979043|Active Comparator|Dietary weight-loss & exercise|Participants received both the dietary weight-loss and exercise interventions for 18-months
9939627|NCT00979043|No Intervention|Health lifestyle control|The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
9939628|NCT00979056|Experimental|Rifaximin|
9939629|NCT00979056|Placebo Comparator|Lactose|
9939630|NCT00979095||Multiple hernia|Patients with more than 3 primary hernias
9939631|NCT00979095||Control group|Patients without hernias
9939632|NCT00979108|Active Comparator|Standard exercise|Subjects will be instructed in neck and postural exercises.
9939633|NCT00979108|Experimental|Over-door traction and exercise.|Subjects will receive traction utilizing an over-the-door traction unit in addition to neck and postural exercises.
9939634|NCT00979108|Experimental|Mechanical traction and exercise|Mechanical cervical traction will be utilized in addition to neck and postural exercises.
9939635|NCT00979160|Experimental|Dasatinib|Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
9939636|NCT00979173|Experimental|AC480|Patients who are not on enzyme inducing anti-epileptic drugs (EIAEDs) and are scheduled to undergo salvage surgical resection treated with preoperative AC480 at 300 mg BID followed by post-surgical AC480 at 300 mg BID.
9939637|NCT00979225|Experimental|Medication report|Medication reports delivered to providers at the point of care
9939638|NCT00979225|Experimental|Med. report plus care manager notices|Medication reports delivered to providers at the point of care and notices sent electronically to care managers
9939639|NCT00979225|No Intervention|Control|
9939640|NCT00979264|No Intervention|Control|Standard quality improvement approaches available through participation in Get With the Guidelines - Heart Failure.
9939641|NCT00979264|Active Comparator|Intervention|Enhanced and/or intensive quality improvement approaches, coupled with standard approaches available through participation in Get With the Guidelines - Heart Failure.
9939642|NCT00979290||Separate anti-TB drugs|
9939643|NCT00979290||Fix-dosed combination anti-TB drugs|
9939644|NCT00979316|Experimental|BMS-708163 (800 mg)|
9939645|NCT00979316|Experimental|BMS-708163 (200 mg)|
9939646|NCT00979316|Placebo Comparator|Placebo|
9939647|NCT00979316|Active Comparator|Moxifloxacin|
9939648|NCT00979329||mRCC or GIST treated with sunitinib/sorafenib|
9939649|NCT00979342|Experimental|Cervical Block, 6 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 2cc at 12:00, 10cc at 3:00, 10 cc at 9:00, 5 cc at 4:00, 5 cc at 8:00, and 5 cc at 6:00.
9939650|NCT00979342|Experimental|Cervical Block, 2 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 10 cc at 4:00, and 10 cc at 8:00.
9939651|NCT00979342|Experimental|Ibuprofen q. 8 hours|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg every 8 hours, for the first 24 hours and then PRN.
9939652|NCT00979342|Experimental|Ibuprofen PRN|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg PRN.
9939653|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 1)|
9939654|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 2)|
9939655|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 3)|
9939656|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 4)|
9939657|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 5)|
9939658|NCT00979381||1|Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks
9939659|NCT00979381||2|patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
9939660|NCT00979381||3|healthy volunteers
9939661|NCT00979394||Patients with type 2 diabetes|
9939662|NCT00979433|Experimental|Bubble CPAP|All neonates randomised to bubble CPAP will be put on Bubble CPAP following initial extubation in first week of life.
9939663|NCT00979433|Other|Conventional CPAP|All neonates randomly allocated to conventional/ventilator derived CPAP.
9939664|NCT00979446|Experimental|Guided|
9939665|NCT00979446|Active Comparator|Self-directed|
9939666|NCT00979472|Experimental|with urgency|
9939667|NCT00979472|Experimental|without urgency|
9939668|NCT00979511|Experimental|1 Hi-Calcium milk & exercise|
9939669|NCT00979511|Experimental|2 Hi-calcium milk with passive exercise|
9939670|NCT00979511|Experimental|3Low-Calcium with exercise|
9939671|NCT00979511|Experimental|4 Low-calcium milk with passive exercise|
9939672|NCT00979524|Experimental|Comprehensive Mental Health Services|Intervention group participants will receive an array of mental health education and services based on their level of need. Study participants will fall into low, moderate, or elevated risk based on results of baseline screening. Services will be provided to each group as specified below. Low risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) education activities to promote knowledge and change attitudes around mental health; Moderate risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Short-term mental health services delivered by the LCSW-C, (c) Depression prevention intervention, (d) Education activities to promote knowledge and change attitudes around mental health; High risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Mental health treatment services, (c) Education activities to promote knowledge and change attitudes around mental health.
9939673|NCT00979524|Active Comparator|Usual Care (Employment Training Services)|"Newly enrolling Westside YO members will receive usual care services, which constitute a moderate level of mental health services and supports. The usual care services related to mental health at the Westside will include (1) the ACASI screen for all newly enrolling Westside YO members, (2) the initial visit with a LCSW-C, and (3) mental health training for Westside Case Advocates. More extensive mental health educational activities and services (e.g., additional sessions with LCSW-C, SOS Club) provided to the intervention group will not be available at the Westside YO Center during the initial study period. Also, Eastside Case Advocates will receive more extensive and ongoing mental health training."
9939674|NCT00979537|Experimental|Test: Nisoldipine ER Tablets, 40 mg|Nisoldipine Extended-release Tablets, 40 mg
9939675|NCT00979537|Active Comparator|Reference: Sular Tablets 40 mg|Sular Tablets, 40 mg
9939676|NCT00979589|Active Comparator|Combination Clopidogrel and asprin|
9939677|NCT00979589|Placebo Comparator|Asprin and placebo|
9939678|NCT00979641|Experimental|chemoterapy|docetaxel/paclitaxel + bevacizumab
9939679|NCT00979667|Experimental|Oseltamivir|
9939680|NCT00979667|Experimental|Zanamivir|
9939681|NCT00979667|Placebo Comparator|Placebo of Oseltamivir|
9939682|NCT00979680|Active Comparator|High-dose Radiotherapy|
9939683|NCT00979680|Active Comparator|Chemo-radiotherapy|
9939684|NCT00979693|Experimental|Full Dose|Participant will receive 25 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with each session scheduled seven to 14 days apart.
10214463|NCT05223504||Observed patients|Adult patients (≥18 years) admitted with an acute medical disease and who are scheduled for discharge to their own homes within five days from inclusion.
9480630|NCT05262452|Experimental|CureHIFUPanc|Patients diagnosed with locally advanced/borderline resectable pancreatic cancer through biopsy and CT/MRI imaging and planned to undergo anti-cancer treatment using FOLFIRINOX
9480631|NCT05262439|Experimental|New generation CPAP mask|The intended purpose of mask systems is to provide airflow from a CPAP device, through tubing, and to the patient. The air acts as a pneumatic splint to keep the airway open and prevent collapse during sleep. The masks to be used in this study are released masks approved and released.
9480632|NCT05262413|Experimental|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
9480635|NCT05262361|Experimental|Office based Vergence and Accommodative Therapy immediately after enrollement|This arm will start immediately after baseline assessment. The participant will have two sessions of one hour each for 6 weeks (12 office-based vergence and accommodative therapy sessions). The first outcome measurement will be attained by a masked optometrist. Then, the participant will have 2 more weeks of therapy (4 office-based vergence and accommodative therapy sessions). The second and final outcome measurement will be attained. Assessments include a masked optometric vision exam, objective eye movement recordings and an functional MRI scan.
9480636|NCT05262361|No Intervention|Office based Vergence and Accommodative Therapy Delay 6 weeks post enrollment|This arm will start with a 6 week delay (no vision therapy) after baseline assessment to evaluate natural recovery. After 6 weeks, the first outcome assessment will be attained by a masked optometrist. The participant will have two sessions of one hour each for 8 weeks (16 office-based vergence and accommodative therapy sessions). The second and final outcome measurement will be attained. Assessments include a masked optometric vision exam, objective eye movement recordings and an functional MRI scan.
10000794|NCT01541462|Active Comparator|Pressure support|Patients randomized to the pressure support arm will wean using pressure support ventilation. The level of pressure support will be decreased by 2 cm H2O every 6 hours. The maximum decrement in pressure support permitted in one day will be 6 cm H2O.
10000795|NCT01541462|Active Comparator|Spontaneous Breathing|Patients randomized to spontaneous breathing arm will be disconnected from the ventilator and allowed to breathe spontaneously through the tracheostomy. Duration of the trial will be increased sequentially as tolerated.
10000796|NCT01541475|Experimental|Escitalopram + Bupropion|
10000797|NCT01541475|Active Comparator|Escitalopram|
10000798|NCT01541488|Experimental|BI 1021958|Single rising dose (SRD) part
10000799|NCT01541488|Experimental|BI 1021958 (Food effect)|Food effect part (FE)
10000800|NCT01541488|Placebo Comparator|Placebo to BI 1021958|Matching placebo as drinking solution and tablets
10000801|NCT01541501||Pachymetry|All recruited volunteers in present study, that underwent pachymetry measurement with four different instruments
10000802|NCT01541527||severe, moderate and mild HA patients|one Arm: biological collection of 300 severe, moderate and mild HA patients
10000803|NCT01541540|Experimental|e-Counseling plus Usual Care|
10000804|NCT01541540|Active Comparator|e-Info Control plus Usual Care|
10000805|NCT01541566||Home blood pressure telemonitoring|Patients regularly monitoring their blood pressure at home with an electronic validated upper arm device, transmitting blood pressure values at monthly intervals to the doctors office through the Internet.
10000806|NCT01541566||Conventional blood pressure measurement|Blood pressure measured only in the doctor's office during quarterly visits, without regular home blood pressure monitoring.
10000807|NCT01541579|Experimental|Treatment Arm|Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
10000808|NCT01541579|Placebo Comparator|Placebo-control group|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
10000809|NCT01541592|Active Comparator|Saturated fat|Palm oil (rich in the saturated fat palmitate)
10000810|NCT01541592|Active Comparator|Monounsaturated fat|Olive oil (rich in the monounsaturated fat oleate)
10000811|NCT01541592|Active Comparator|Polyunsaturated fat|Safflower oil (rich in the polyunsaturated fat linoleate)
10000812|NCT01541605|Active Comparator|methylphenidate|
10000813|NCT01541605|Placebo Comparator|placebo|
10000814|NCT01541618||Tysabri Group|Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
10000815|NCT01541631|Experimental|HIV-1 co-infected with schistosoma mansoni|HIV-1 patients co-infected with Schistosoma mansoni
10000816|NCT01541631|No Intervention|HIV-1 positive individuals with negative S. mansoni|HIV-1 positive individuals with negative Schistosoma mansoni
10000817|NCT01541631|Experimental|Schistosoma mansoni positive but HIV-1 negative|Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals
9480637|NCT05262335|Experimental|Experimental: Experimental group 1|Initial treatment: Anlotinib + Oxaliplatin + Capecitabine. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
9939685|NCT00979693|Active Comparator|Active Placebo|The participant will receive 4 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with sessions scheduled seven to 14 days apart.
9939686|NCT00979706|Active Comparator|HAART|Patients assigned to this arm will receive standard HAART
9939687|NCT00979706|Experimental|HAART + Immunotherapy|Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
9939688|NCT00979719|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
9939689|NCT00979719|Placebo Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, & Fuchs, 2007) Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.
9939690|NCT00979719|No Intervention|Passive Control Group (PCG)|patients are asked to answer the questionnaires only
9939691|NCT00979758|Sham Comparator|Atorvastatin|Atorvastatin routine dose
9939692|NCT00979758|Placebo Comparator|Intensive Atorvastatin|Atorvastatin Intensive dose
9939693|NCT00979758|Active Comparator|Atorvastatin+Transplantation|Atorvastatin routine dose+ Mononuclear cells Transplantation
9939694|NCT00979758|Experimental|Intensive Atorvastatin+Transplantation|Atorvastatin intensive dose+ Mononuclear cells Transplantation
9939695|NCT00979771|Experimental|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
9939696|NCT00979771|Placebo Comparator|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
9939697|NCT00979784|Active Comparator|1|
9939698|NCT00979784|Experimental|2|
9939699|NCT00979797|Experimental|Maternal & Child Health|Community-based interventions to promoto Maternal and Child Survival in collaboration with GoB, Donors and NGOs.
9939700|NCT00979823|Experimental|Early SimCare Diabetes Group|This group will receive an email web-link to 3 simulated learning cases each month for 6 months. After 6 months (18 total learning cases), they will then complete 4 simulated assessment cases, a diabetes knowledge survey, and a satisfaction survey.
9939701|NCT00979823|Active Comparator|Delayed SimCare Diabetes Group|Beginning in the spring of 2011, residents in this group will receive an email web-link to complete 4 simulated assessment cases and a diabetes knowledge survey. They will subsequently be sent 3 learning cases a month for 6 months and a satisfaction survey to complete.
9939702|NCT00979836|Experimental|Calcium Dobesilate|
9939703|NCT00979836|Placebo Comparator|Placebo|The placebo is a capsule with the same presence of experimental drug.
9939704|NCT00979849|Experimental|A|AZD8683
9939705|NCT00979849|Placebo Comparator|B|Placebo
9939706|NCT00979862|Experimental|Treatment cediranib maleate, cilengitide)|"Part A (dose finding): Patients receive cediranib maleate PO once daily on days 1-28 and cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Part B (dose expansion): Patients are assigned to 1 of 2 groups according to prior anti-VEGF therapy (yes vs no). Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A."
9939707|NCT00979914|Experimental|Patient education programme|Patients with osteoarthritis who were referred to the patient education programme.The patients followed the patient education programme.
9939708|NCT00979914|No Intervention|Control|Patients randomized to control group
9939709|NCT00979927|Placebo Comparator|Saline|
9939710|NCT00979927|Active Comparator|SPC3649|
9939711|NCT00979966|Experimental|A|Temsirolimus
9939712|NCT00979966|Experimental|B|Sunitinib
9939713|NCT00979979||HCV patients|HCV patients with detectable viremia; all sera are tested both by Abbott RealTime HCV genotype II test and by direct HCV sequencing both at 5'UTR and NS5B
9939714|NCT00979979||Non-HCV patients|Patient without evidence of HCV infection (negative both for anti-HCV and HCV RNA); all sera are both tested by Abbott RealTime HCV genotype II test and by direct HCV sequencing at 5'UTR and NS5B
9939715|NCT00980031|Placebo Comparator|Lactose Tablet|Compounded capsule using Lactose Monohydrate Powder
9939716|NCT00980031|Active Comparator|Eplerenone|25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.
9939717|NCT00980070|Experimental|Positioning Device|use of positioning device
9939718|NCT00980070|Active Comparator|Control|institutional standard of care
9939719|NCT00980083|Placebo Comparator|Placebo|
9939720|NCT00980083|Active Comparator|Exendin(9-39)|
9939721|NCT00980109|Placebo Comparator|placebo oseltamivir|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
9939722|NCT00980109|Active Comparator|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
9939723|NCT00980109|Placebo Comparator|placebo inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
9939724|NCT00980109|Active Comparator|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
9939725|NCT00980135|Experimental|Arm 1|
9939726|NCT00980135|Experimental|Arm 2|
9939727|NCT00980135|Other|Arm 3|
9939728|NCT00980161||Peg-IFN + RBV with SVR|HCV patients receiving peginterferon alfa-2a and ribavirin with sustained virologic response
9939729|NCT00980161||Peg-IFN + RBV without SVR|HCV patients receiving peginterferon alfa-2a and ribavirin without sustained virologic response
9939730|NCT00980187|Active Comparator|Hydrochlorothiazide|
9939731|NCT00980187|Experimental|Indapamide SR|
9939732|NCT00980213||sunitinib|advanced renal cell cancer patients treated with sunitinib as first-line therapy
9939733|NCT00980239|Experimental|Group 1|Group 1 = Irinotecan + Bevacizumab
9939734|NCT00980239|Experimental|Group 2|Group 2 = Irinotecan, Bevacizumab + Oxaliplatin
9939735|NCT00980239|Experimental|Group 3|Group 3 = Irinotecan, Bevacizumab + Cetuximab
9939736|NCT00980252|Experimental|CBT|UK-based intervention
9939737|NCT00980304|Experimental|Rituximab in combination with ICE as salvage therapy|
9939738|NCT00980356|Active Comparator|Vildagliptin, 50 mg, peroral|
9939739|NCT00980356|Placebo Comparator|Placebo pill|
9939740|NCT00980369||Chronic anal fissures|Group A: with vertical incision Group B: with parallel incision
9939741|NCT00980369||Parallel incision, vertical insicion|
9939742|NCT00980408|Placebo Comparator|Sugar pill, behavioral glutamic acid|Placebo condition for D-Cycloserine
9939743|NCT00980408|Placebo Comparator|Sugar pill, fMRI, glutamic acid|Placebo condition for D-Cycloserine, fMRI
9939744|NCT00980408|Placebo Comparator|Sugar pill, memantine, behavioral|Placebo condition Memantine, behavioral
9939745|NCT00980408|Placebo Comparator|Sugar pill, memantine, fMRI|Placebo condition Memantine, fMRI
9939746|NCT00980408|Active Comparator|D-Cycloserine behavioral|
9939747|NCT00980408|Active Comparator|D-Cycloserine, fMRI|
9939748|NCT00980408|Active Comparator|Memantine, behavioral|
9939749|NCT00980408|Active Comparator|Memantine, fMRI|
9939750|NCT00980421|Experimental|IT|Iron Tablet group (12.5 mg/d) + Placebo Biscuit
9939751|NCT00980421|Experimental|IZ|Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
9939752|NCT00980421|Experimental|IB|Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
9939753|NCT00980421|Placebo Comparator|CO|Placebo Tablet + Placebo Biscuit
9939754|NCT00980434||1|patients with neurological symptoms
9480638|NCT05262335|Experimental|Experimental: Experimental group 2|Initial treatment: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
9939755|NCT00980434||2|patients without neurological symptoms
9939756|NCT00980447|Experimental|UMN-0501 45µg|Recombinant H5N1 vaccine 45µg
9939757|NCT00980447|Experimental|UMN-0501 90µg|Recombinant H5N1 vaccine 90µg
9939758|NCT00980447|Experimental|UMN-0501 135µg|Recombinant H5N1 vaccine 135µg
9939759|NCT00980473|Active Comparator|Iridoplasty|
9939760|NCT00980473|Active Comparator|Control (Medication)|
9939761|NCT00980486||BMI <30|BMI <30
9939762|NCT00980486||BMI 30-39|BMI 30-39
9939763|NCT00980486||BMI >40|BMI >40
9939764|NCT00980512|Experimental|Parent Training|Parent Training of foster parents
9939765|NCT00980512|No Intervention|Control|Control group
9939766|NCT00980525||IL-1 genotype positive|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
9939767|NCT00980525||IL-1 genotype negative|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
9939768|NCT00980551|Experimental|Topotecan/Vincristine with subtenon Carboplatin|
9939769|NCT00980577|Active Comparator|NS|stimulating catheter will be inserted using stimulator
9939770|NCT00980603|Active Comparator|docetaxel|
9939771|NCT00980603|Experimental|doctaxel plus cisplatin|
9939772|NCT00980603|Experimental|docetaxel plus S-1|
9939773|NCT00980616|Experimental|Ropivacaine, serum, adrenalin|235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.
9939774|NCT00980616|No Intervention|No infiltration|B: no infiltration
9939775|NCT00980694|Experimental|Ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
9939776|NCT00980707|Experimental|inhaled corticosteroid|All asthmatics will start inhaled corticosteroids.
9939777|NCT00980733|Active Comparator|Fortified Yoghurt|Yoghurt with fortification of Micronutrients, yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
9939778|NCT00980733|Placebo Comparator|Yoghurt|Plain Yoghurt same as in fortified arm but without fortification
9939779|NCT00980733|No Intervention|Control|Non blinded group given no intervention
9939780|NCT00980759|Experimental|EFI(Extended-Field Irradiation)|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
9939781|NCT00980759|Experimental|Pelvic RT|Pelvic Irradiation with chemotherapy(cisplatin)
9939782|NCT00980824|Experimental|therapy|Cognitive behavioural therapy. Six sessions of structured focused therapy.
9939783|NCT00980824|Active Comparator|Standard treatment|referral to specialised or generic mental health service
9939784|NCT00980850|Experimental|Groups A1 and A2|Baxter vaccine
9939785|NCT00980850|Experimental|Groups B1 and B2|GSK vaccine
9939786|NCT00980863|Active Comparator|Lifestyle intervention to increase physical activity|
9939787|NCT00980863|No Intervention|waiting control group|
9939788|NCT00980876|Active Comparator|Cipro HC|Reference product
9939789|NCT00980876|Experimental|Ciprofloxacin HCl and Hydrocortisone|Test product
9939790|NCT00980889|Active Comparator|steel|Insertion of Metalic Steel Stent, Wallstent® in malignant distal bile duct obstruction
9939791|NCT00980889|Active Comparator|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
9939792|NCT00980915||At risk for Acute Lung Injury|"Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI~Cases-High risk patients that do develop Acute Lung Injury"
9939793|NCT00980941|Experimental|Soup with no added starch|
9939794|NCT00980941|Experimental|Soup + 50 g of whole grain starch|
9939795|NCT00980941|Experimental|Soup + 50 g of high amylose corn starch|
9939796|NCT00980941|Experimental|Soup + 50 g of regular corn starch|
9939797|NCT00980941|Experimental|Soup + 50 g maltodextrin starch|
9939798|NCT00981006|Experimental|human cardiac stem cell therapy|single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
9939799|NCT00981032|Experimental|Pre-visit Summary|Patients in this arm will receive a pre-visit summary prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
9939800|NCT00981032|Experimental|Clinical Decision Sharing Tool|Patients in this arm will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
9939801|NCT00981071||A platoon with TB outbreak|
9939802|NCT00981097||Specimen Collection|Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma.
9528354|NCT03211637|Active Comparator|CONTROL GROUP|This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
9528355|NCT03212105|Active Comparator|60 Second Video|The mindfulness intervention is a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
9528356|NCT03212105|Other|Educational Pamphlet|The educational pamphlet contains information about pain and stress, which patients will be able to read within 60 seconds.
9528357|NCT03211754|Experimental|Obese patients|Treatment for 8 weeks
9939803|NCT00981110|Active Comparator|Mepore Self-adhesive absorbent dressing|Mepore Self-adhesive absorbent dressing
9939804|NCT00981110|Experimental|AQUAGEL Ag Hydrofiber Wound Dressing|AQUAGEL Ag Hydrofiber Wound Dressing
9939805|NCT00981123||1|
9939806|NCT00981136|Active Comparator|SILS|Single Incision Laparoscopic Surgery (SILS) where a single incision in the umbilicus is all that is used to remove the appendix. The specific methods (staple/tie/port use/etc) will vary depending on surgeon.
9939807|NCT00981136|Active Comparator|3 port|Standard laparoscopic appendectomy with 3 ports and intracorporeal stapling.
9939808|NCT00981162|Experimental|Treatment (sorafenib tosylate and everolimus)|Patients receive everolimus PO once daily and sorafenib tosylate PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9939809|NCT00981201|Experimental|Celecoxib + Placebo|
9939810|NCT00981201|Experimental|Celecoxib + Celecoxib|
9939811|NCT00981201|Active Comparator|Placebo + Celecoxib|
9939812|NCT00981201|Placebo Comparator|Placebo + Placebo|
9939813|NCT00981240|Experimental|Dose escalation|Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
9939814|NCT00981266|Other|Augmentation|"The study population will consist of women aged 22 or over who are undergoing primary breast augmentation.~The Augmentation cohort will include candidates for general breast enlargement, post-lactational involution and/or asymmetry."
9939815|NCT00981266|Other|Augmentation Revision|"The study population will consist of women aged 22 or over who are undergoing augmentation revision.~The Augmentation Revision cohort will include candidates with previous augmentation with silicone-filled or saline-filled implants."
9939816|NCT00981279||HIV seroposite patients|Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
9939817|NCT00981318|Other|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid|single arm
9939818|NCT00981331|Experimental|Subtalar joint manipulation|Each subject in this group will recieve a subtalar joint manipulation to their symptomatic ankle
9939819|NCT00981331|Sham Comparator|Sham Manipulation|Each subject in this group will recieve a sham subtalar joint manipulation to their symptomatic ankle
9939820|NCT00981383|Experimental|Treatment|Omega-3 Fatty Acid Supplement, 1.9 g ω-3 FAs daily
9939821|NCT00981383|Placebo Comparator|Placebo|Matching placebo, less than 0.12 g ω-3 FAs daily
9939822|NCT00981422||Glaucoma patients|POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
9939823|NCT00981422||Healthy|healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation
9939824|NCT00981487|Experimental|Fed|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
9939825|NCT00981487|Experimental|Fasting|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
9939826|NCT00981500||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
9939827|NCT00981500||gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
9939828|NCT00981500||sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy
9939829|NCT00981513|Active Comparator|Influenza vaccination|Live attenuated influenza vaccine (seasonal and pandemic strains) by nasal spray
9939830|NCT00981513|Placebo Comparator|Saline placebo|Saline nasal spray
9939831|NCT00981539|Active Comparator|treatment : receives pre operative enema|one arm will receive pre operative enema
9939832|NCT00981539|No Intervention|no enema|this group will not receive pre operative enema
9528358|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
9528359|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
9939833|NCT00981552|Other|Cervix Cancer|Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
9939834|NCT00981565|Active Comparator|Operative|
9939835|NCT00981565|Active Comparator|Conservative|
9939836|NCT00981591|Experimental|Inhaled Iloprost|
9939837|NCT00981591|Placebo Comparator|Inhaled Placebo|
9939838|NCT00981604|Active Comparator|SILS Cholecystectomy|Single Incision Laparoscopic Cholecystectomy
9939839|NCT00981604|Active Comparator|Standard Laparoscopic Cholecystectomy|4 port laparoscopic cholecystectomy
9939840|NCT00981643|Experimental|Multiple Sclerosis, Meditation group|Multiple Sclerosis, Meditation instruction and practice group
9939841|NCT00981643|No Intervention|Multiple Sclerosis, Control group|Multiple Sclerosis, Control group
9939842|NCT00981643|Experimental|Peripheral Neuropathy, Meditation group|Peripheral Neuropathy, Meditation instruction and practice group
9939843|NCT00981643|No Intervention|Peripheral Neuropathy, Control group|Peripheral Neuropathy, Control group
9939844|NCT00981695|Experimental|Vaccinees|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
9939845|NCT00981695|No Intervention|Controls|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
9939846|NCT00981708|Experimental|Treatment|Lenalidomide, Dexamethasone and cyclophosphamide
9939847|NCT00981721|Experimental|1|cediranib 20mg
9939848|NCT00981721|Experimental|2|cediranib 30mg
9939849|NCT00981773|Experimental|Immediate switch|"Continue current boosted protease inhibitor~Switch NRTI backbone to maraviroc 150 mg bid"
9939850|NCT00981773|Active Comparator|Continue current antiretroviral therapy|Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.
9939851|NCT00981786|Active Comparator|Brinzolamide/Timolol therapy|Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops
9939852|NCT00981786|Active Comparator|Brimonidine/Timolol therapy|Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops
9939853|NCT00981838|Experimental|1|Rituximab (375 mg/m2).
9939854|NCT00981851|Active Comparator|beta 2 agonist + anticholinergic aerosol|
9939855|NCT00981851|Placebo Comparator|placebo inhalation|
9939856|NCT00981864|Experimental|Concurrent Boost RT|
9939857|NCT00981877|Active Comparator|1|This group will receive S. Boulardii Probiotic and Oral rehydration as needed
9939858|NCT00981877|Active Comparator|2|This group will receive a mixed Probiotic preparation and oral rehydration as needed
9939859|NCT00981877|Placebo Comparator|3|This group will receive a placebo, and oral rehydration as needed
9939860|NCT00981890|Experimental|Sunitinib|
9939861|NCT00981903|Experimental|VTE Treatment Group|
9939862|NCT00981903|No Intervention|Control|
9939863|NCT00981929|Active Comparator|Tramadol|CYP2D6 metric
9939864|NCT00981929|Active Comparator|Omeprazole, losartan, caffeine|CYP2C19, CYP2C9 and CYP1A2 metrics
9939865|NCT00981929|Active Comparator|Tramadol, omeprazole, losartan and caffeine|CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics
9939866|NCT00981955|Active Comparator|75mg caffeine|
9939867|NCT00981955|Active Comparator|50mg l-theanine|
9939868|NCT00981955|Active Comparator|75mg caffeine and 50mg l-theanine|
9939869|NCT00981955|Placebo Comparator|0mg caffeine/l-theanine|
9939870|NCT00981968|Experimental|Japanese Cohort|Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.
9939871|NCT00981968|Experimental|Western Cohort|Single oral dose of sitaxentan sodium in 10 healthy subjects.
9939872|NCT00981981|Placebo Comparator|Control|Wheat bran cereal
9939873|NCT00981981|Active Comparator|3g high MW|Cereal containing 3g high molecular weight oat beta glucan
9939874|NCT00981981|Active Comparator|4g medium MW|Cereal containing 4g oat beta glucan with medium molecular weight
9939875|NCT00981981|Active Comparator|3g medium MW|Cereal containing 3g oat beta glucan with medium molecular weight
9939876|NCT00981981|Active Comparator|4g low MW|Cereal containing 4g oat beta glucan with low molecular weight
9939877|NCT00981994|Experimental|Electronic Decision Support|Use of electronic decision support to provide the treatment algorithm for providers managing patients with acute respiratory infections.
9939878|NCT00981994|Experimental|Paper Decision Support|Use of paper based tools to provide the treatment algorithm for providers managing patients with acute respiratory infections.
9939879|NCT00981994|No Intervention|Usual Care|Usual Care
9939880|NCT00982046|Active Comparator|ACUVUE OASYS|Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
9939881|NCT00982046|Active Comparator|AIR OPTIX AQUA|Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
10000818|NCT01541631|No Intervention|HIV-1 and Schistosoma mansoni negative|Individuals with no HIV-1 and S. mansoni infections
10000819|NCT01541657|No Intervention|Control Group|This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
10000820|NCT01541657|Experimental|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
10000821|NCT01541657|Experimental|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
10000822|NCT01541657|Experimental|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
10000823|NCT01541670|Experimental|Open-label Dose-Escalation Arm|Conducted in an ascending dose manner, subjects will be assigned to single- or multiple-dose administration of the investigational product
10000824|NCT01541683|Experimental|Halls|every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
10000825|NCT01541683|Other|no Halls|Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
10000826|NCT01541696||Group B|subjects in this group will receive Micronutrient Supplements only.
10000827|NCT01541696||Group C|Subjects in this Group will receive Micronutrient Supplements plus Zinc.
10000828|NCT01541709|Experimental|Imatinib|
10000829|NCT01541774|Experimental|Phoenix Atherectomy System|
10000830|NCT01541800||Patients|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
10000831|NCT01541813||iron overloads except C282Y homozygosity|Patients with an iron overloads except C282Y homozygosity
10000832|NCT01541839|Experimental|Septal Stapler|This group will have closure of their nasal septal flaps via septal stapler.
10000833|NCT01541839|No Intervention|Control (Suture)|This arm will have closure of their nasal septal flaps as routinely performed with suture passed in a quilting fashion.
10000834|NCT01541852|Active Comparator|Losmapimod|7.5mg tablet twice daily
10000835|NCT01541852|Placebo Comparator|Placebo|One tablet twice daily
10000836|NCT01541904|Experimental|Arm A. PRO-118/Placebo 0.015%,0.020%|
10000837|NCT01541904|Experimental|Arm B. PRO-118/Placebo 0.015%,0.020%|
10000838|NCT01541904|Experimental|Arm C. PRO-118/Placebo 0.015%,0.020%|
10000839|NCT01541904|Experimental|Arm D. PRO-118/Placebo 0.015%,0.020%|
10000840|NCT01541904|Placebo Comparator|Arm E PRO-118/Placebo 0.015%,0.020%|
10000841|NCT01541943|Experimental|HL-040XC|Once daily, administered orally, 8 week
10000842|NCT01541943|Active Comparator|Atorvastatin|Once daily, administered orally, 8 week
10000843|NCT01541943|Active Comparator|Losartan|Once daily, administered orally, 8 week
10000844|NCT01541943|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
10000845|NCT01541956|Active Comparator|metformin up titration|metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
10000846|NCT01541956|Experimental|vildagliptin add on to metformin|Vildagliptin 50 mg twice daily + Metformin 500mg twice daily
10000847|NCT01541982||virtual and classic autopsy|"Goldstandard: A group of patients in which virtual and classic autopsy is performed."
10000848|NCT01541982||virtual autopsy only|"Intervention: A group of patients in which for various reasons virtual autopsy only is performed."
10000849|NCT01541995||virtual and classic autopsy|Patients where contrast medium enhanced post mortem CT and classic autopsy will be performed.
10000850|NCT01541995||virtual autopsy only|Patients where only contrast medium enhanced post mortem CT will be performed.
10000851|NCT01542008|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the CAE intervention.
10000852|NCT01542008|Active Comparator|broad non-individualized education (EDU)|This arm will receive the EDU intervention.
10000853|NCT01542047|Experimental|Carboplatin AUC5 + escalating pazopanib|Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21
10000854|NCT01542060||BIAsp 30 users|
10000855|NCT01542073|Experimental|68Ga-BNOTA-PRGD2 cardiac PET/CT scanning|We will perform 68Ga-BNOTA-PRGD2 cardiac PET/CT scanning on myocardial infarction patients to determine its value.
10000856|NCT01542086|Active Comparator|Myocardial SPECT|
10000857|NCT01542086|Experimental|64-channel coronary CT angiography (CCTA)|
10000858|NCT01542099|Active Comparator|Single lumen tube|Single lumen tube intubation during remifentanil infusion
10000859|NCT01542099|Active Comparator|Double lumen tube|Double lumen tube intubation during remifentanil infusion
10000860|NCT01542112|Experimental|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
10000861|NCT01542112|Experimental|No treament|Usual routine in the department
10000862|NCT01542138|Active Comparator|Niacinamide|4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.
10000863|NCT01542138|Active Comparator|Desonide|Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation
10000864|NCT01542138|Placebo Comparator|Placebo|Humectant placebo cream
10000865|NCT01542151|Active Comparator|Morning|Women randomized to a labor induction in the morning between 0600 and 1000.
10000866|NCT01542151|Experimental|Evening|Women randomized to a labor induction begun in the evening between 1700-2100
10000867|NCT01542177||Pancreatic cancer|
10000868|NCT01542190|Active Comparator|ketorolac tromethamine|
10000869|NCT01542190|Placebo Comparator|Dextrano 70 / Hypromellose|
10000870|NCT01542203||Breast Cancer, Various BMIs|18 female breast cancer patients who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI > 35 kg/m2).
10000871|NCT01542216|Placebo Comparator|Yoga and Stretching Group|Patients undergo yoga and stretching exercises
10000872|NCT01542216|Active Comparator|Nutrition and Exercise Group|Patients are provided with nutrition, cardiovascular exercise and strength exercise consultations
10000873|NCT01542242|Experimental|Liraglutide|Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
10000874|NCT01542268|Active Comparator|pentoxifylline|
10000875|NCT01542268|Placebo Comparator|pentoxifylline placebo|
10000876|NCT01542281|Experimental|Nutritional supplementation and prehab|The first group (pre-hab) will receive both nutritional supplementation and a prehabilitation program.
10000877|NCT01542281|Active Comparator|Prehab exercise|
10000878|NCT01542294|Experimental|treatment|s1+oxaliplatin
10000879|NCT01542320|Experimental|Probiotic|Lactobacillus reuteri DSM 17938
10000880|NCT01542320|Placebo Comparator|Placebo|Solution without the active probiotic Lactobacillus reuteri
10000881|NCT01542346|Experimental|wound closure with subcutaneous adaption|
10000882|NCT01542359|Experimental|Yoga|"The integrated yoga program was designed to: 1) include the three primary elements of yoga as most commonly practiced in western cultures (physical postures, breath control and meditation); and 2) be appropriate for those without any prior yoga experience and with pre- and Stage I hypertension. The yoga program was designed by Eddie Stern, Founder and Director of Ashtanga Yoga New York (AYNY) in consultation with Drs. Hagins and Rundle, and are in large part congruent with the yoga program we studied previously (see Preliminary Studies). The yoga class includes: instruction on yogic principles regarding moral precepts (yamas and niyamas); active postures requiring mild-moderate physical exertion; conscious control of the breath in synchrony with active postures; and meditation. We expect approximately 10-15 minutes of the integrated yoga program to consist of isolated practice of meditation (occurring independently of the moving postures, typically in seated or lying positions)."
10000883|NCT01542359|Active Comparator|Conventional Exercise|Conventional exercise such as standing toe touch with arm swings, curl ups, push ups, leg lifts, etc. All done at a relatively slow rate which will be non-aerobic and at an average rate across the session of 3 METs
10000884|NCT01542385|Active Comparator|Immediate stenting|the stent selection (bare metal vs drug eluting) and implantation will be performed as recommended by current practice guidelines.
10000885|NCT01542385|Experimental|Delayed stenting|participants randomised to delayed stenting will be treated with GPIIb-IIIa inhibitors for 12-18 hours after reperfusion followed by anticoagulation for until the control angiogram, expected no sooner than 18-24 hours after the index reperfusion.
10000886|NCT01542411||recurrent pregnancy loss|
10000887|NCT01542411||thrombophilia, aspirin|
10000888|NCT01542411||heparin|
10000889|NCT01542424||BIAsp 30 users|
10000890|NCT01542424||IDet users|
10000891|NCT01542437|Experimental|BIBW 2992|Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
10000892|NCT01542450|Experimental|Treatment period 1|
10000893|NCT01542450|Active Comparator|Treatment period 2|
10000894|NCT01542463||IDet users|
10000895|NCT01542476||IDet users|
10000896|NCT01542489||IDet + IAsp users|
10000897|NCT01542489||IDet + HI users|
10000898|NCT01542515||Osteoarthritis of the carpometacarpal joint of the thumb|The group of patients enrolled in this study all have the diagnosis of carpometacarpal arthritis of the thumb. The patients did not respond favorably to non-operative management including oral anti-inflammatory medications, corticosteroid injections, and thumb splinting. Operative management was therefore recommended using the technique of meniscal allograft arthroplasty.
10000899|NCT01542554|Experimental|Low glycaemic index diet|
10000900|NCT01542554|Active Comparator|Usual diabetic diet|
10000901|NCT01542567|Active Comparator|diclofenac|suppositories to prevent BCG side effects
10000902|NCT01542567|Placebo Comparator|placebo suppositories|
10000903|NCT01542593|Experimental|Ureteral catheterization|"During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
10000904|NCT01542606|Experimental|color status|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
9939882|NCT00982046|Active Comparator|Biofinity|Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
9939883|NCT00982059||All|All patients enrolled in the study will be undergoing the same procedures.
9480639|NCT05262335|Experimental|Experimental: Experimental group 3|Initial treatment: Anlotinib + Standard first-line chemotherapy Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
9939884|NCT00982085||Soldiers|Soldiers: The soldiers who respond the questionnaires
9939885|NCT00982098|Experimental|Early Rehabilitation|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).~Patients will be instructed to carry on exercises at home for the following 11 months."
9939886|NCT00982098|No Intervention|Counseling and home-based exercises|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: Patients will be instructed to carry on pelvic floor exercises at home for the year after prostatectomy."
9939887|NCT00982124|Experimental|Treatment Arm (only)|Zoledronic acid infusion
9939888|NCT00982176||1|
9939889|NCT00982202|Experimental|PGZ|
9939890|NCT00982202|Placebo Comparator|Placebo|
9939891|NCT00982241|Active Comparator|normal fluid intake|1500 ml /day (+/- 300 ml) for 2,5 days
9939892|NCT00982241|Active Comparator|high fluid intake|2400 ml/day (+/- 300 ml )for 2,5 days
9939893|NCT00982241|Active Comparator|low fluid intake|fluid intake 900 ml/day (+/- 300ml) for 2,5 days
9939894|NCT00982254|Experimental|Oral Insulin|oral insulin capsule formulation
9939895|NCT00982254|Active Comparator|Subcutaneous Insulin|Subcutaneous injection of regular human insulin
9939896|NCT00982267|Experimental|SU014813|
9939897|NCT00982293|Active Comparator|Active fields|
9939898|NCT00982293|Sham Comparator|Inactive device|"Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be on."
9939899|NCT00982332|Active Comparator|betamethasone|patients treated with a single intramuscular injection of betamethasone
9939900|NCT00982332|Placebo Comparator|isotonic sodium chloride solution|
9939901|NCT00982358|Placebo Comparator|Placebo|
9939902|NCT00982358|Active Comparator|Valsartan|
9939903|NCT00982371||Controls|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; NO clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
9939904|NCT00982371||Type 2 Diabetes|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
9939905|NCT00982384|Experimental|Disease management|Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
9939906|NCT00982384|Active Comparator|Best care|Best care according to clinical guidelines for COPD patients
9939907|NCT00982436|Experimental|Neoadjuvant/Concomitant Chemoradiation|Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin
9939908|NCT00982449|Active Comparator|4 mCi of I-FIAU|GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-4.
9939909|NCT00982449|Active Comparator|2 mCi of I-FIAU|GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-2.
9939910|NCT00982462|Placebo Comparator|Corn oil placebo|Micro-encapsulated powder containing corn oil placebo.
9939911|NCT00982462|Experimental|Long-chain polyunsaturated fatty acids|Micro-encapsulated powder containing 1:1 ratio of the omega-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and the omega-6 fatty acid, arachidonic acid (ARA) from algal and fungal sources, respectively.
9939912|NCT00982475|Active Comparator|PVI with robotic navigation|
9939913|NCT00982475|Placebo Comparator|PVI manually|
9939914|NCT00982501|Experimental|WS® 1442 900 mg|
9939915|NCT00982501|Experimental|WS® 1442 1800 mg|
9939916|NCT00982501|Active Comparator|Nordic walking training 2x30 min|
9939917|NCT00982501|Active Comparator|Nordic walking training 4x45 min|
9939918|NCT00982514||Standard dose asparaginase|Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
9939919|NCT00982514||Reduced dose asparaginase|Children who receive reduced dose asparaginase according to NOPHO ALL 2008
9939920|NCT00982527|Placebo Comparator|Placebo|Saline blinded infusion
9939921|NCT00982527|Active Comparator|Fenoldopam|Drug infusion
9939922|NCT00982540|No Intervention|preemptive|Patients with persistent fever and neutropenia despite appropriate antibacterial therapy
9939923|NCT00982566|Experimental|Sequence I|
9939924|NCT00982566|Experimental|Sequence II|
9939925|NCT00982566|Experimental|Sequence III|
9939926|NCT00982566|Experimental|Sequence IV|
9939927|NCT00982566|Experimental|Sequence V|
9939928|NCT00982566|Experimental|Sequence VI|
9939929|NCT00982566|Experimental|Sequence VII|
9939930|NCT00982566|Experimental|Sequence VIII|
9939931|NCT00982566|Experimental|Sequence IX|
9939932|NCT00982566|Experimental|Sequence X|
9528360|NCT03211689|Experimental|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
9528361|NCT03211689|No Intervention|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
9939933|NCT00982566|Experimental|Sequence XI|
9939934|NCT00982566|Experimental|Sequence XII|
9939935|NCT00982566|Experimental|Sequence XIII|
9939936|NCT00982566|Experimental|Sequence XIV|
9939937|NCT00982566|Experimental|Sequence XVI|
9939938|NCT00982566|Experimental|Sequence XV|
9939939|NCT00982579|Experimental|Vaccinees|Vaccinated at 20 weeks of age (n=24)
9939940|NCT00982579|No Intervention|Controls|No experimental vaccine (n=24)
9939941|NCT00982605||non small cell lung cancer|cancer patients
9939942|NCT00982618|Experimental|LIDOCAINE group|LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
9939943|NCT00982618|Experimental|Epidural Group|Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
9939944|NCT00982618|Active Comparator|PCA group|Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.
9939945|NCT00982631|Experimental|temsirolimus/PLD|temsirolimus (Torisel) with pegylated liposomal doxorubicin (PLD,Doxil,Caelyx);a dose escalating study in a 3+3 design
9939946|NCT00982670||Systemic lupus erythematosus|Patients should fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus
9939947|NCT00982670||Normal control|Age- and sex-matched health volunteers will serve as controls.
9939948|NCT00982709|Active Comparator|Exercise Types|comparing two different exercise programs for PD
9939949|NCT00982722|Experimental|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
9939950|NCT00982722|Active Comparator|calciumcarbonate|calcium carbonate 500 mg x 2
9939951|NCT00982748|Active Comparator|Group B|Study participants in this arm attend yoga breathing classes once per week over the span of one chemotherapy cycle.
9939952|NCT00982748|Experimental|Group A|Participants in this study arm attend weekly yoga breathing classes during two consecutive cycles of chemotherapy
9939953|NCT00982787|Experimental|1|
9939954|NCT00982787|Placebo Comparator|2|
9939955|NCT00982800|Placebo Comparator|Placebo Sugar Pill|"Patients are stratified based on their initial pain score in the recovery room. patients with a pain numeric rating scale of greater than or equal to 7/10 are stratified to the high group. then randomized to receive gabapentin 200 mg tid x 9 doses, or placebo x 9 doses. Patients with a pain score equal to or less than 6/10 are stratified to the low group, then randomized to receive gabapentin 200mg tid x 9 doses or placebo x 9 doses.~All patients receive Acetaminophen 1gm every 6 hours for 3 days, Celecoxib 400mg as a loading dose then 200mg twice a day for 3 days. Patients also receive patient controlled analgesia (PCA) of hydromorphone for 24 hrs, then are transitioned to oxycodone 5-15 mg every 2 hours as needed."
9939956|NCT00982800|Active Comparator|Gabapentin 200 mg tid x 9 doses|
9939957|NCT00982826|Experimental|1|ABT-072 tablet single ascending dose
9939958|NCT00982826|Experimental|2|Placebo tablet
9939959|NCT00982826|Experimental|3|ABT-072 tablet administered under non-fasting conditions.
9939960|NCT00982826|Experimental|4|ABT-072 tablet administered under fasting conditions
9939961|NCT00982826|Experimental|5|ABT-072 tablet multiple ascending dose
9939962|NCT00982839|Active Comparator|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
9939963|NCT00982839|Experimental|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
9939964|NCT00982852||Acute|Patients in acute need for angioplasty or left heart catheterization.
9939965|NCT00982852||Chronic or non-acute|Patients will planned angioplasty or left heart catheterization.
9939966|NCT00982891|Experimental|Morphine, low dose, in addition to conventional treatment|Morphine dose titration
9939967|NCT00982904|Experimental|Fexinidazole|
9939968|NCT00982904|Placebo Comparator|Placebo|
9939969|NCT00982917|Experimental|teachers taught curriculum|Teachers taught Stamp-in-Safety curriculum
9939970|NCT00982917|Experimental|teachers do not learn curriculum|Teachers are not taught Stamp-in-Safety curriculum
9939971|NCT00982969||TB suspected|Soldiers who are clinically suspected with tuberculosis
9939972|NCT00983008|Experimental|Protected Time Group|Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.
9939973|NCT00983021|Experimental|A|
10000905|NCT01542619|Experimental|rVIIa-FP|
10000906|NCT01542619|Placebo Comparator|Placebo (0.9% normal saline)|
10000907|NCT01542658||uterine myoma|
10000908|NCT01542671|Experimental|Intervention|Lifestyle counseling at baseline, six, twelve months; Food and exercise log recording and feedback, motivational phone calls monthly for 12 months, 4 tailored mailings on lifestyle change, and weekly mailings on weight loss, exercise, and healthy eating for first 12 months. Maintenance mailings biweekly for six months and then monthly during the second year.
10000909|NCT01542671|Placebo Comparator|Control|Lifestyle counseling at baseline, six and twelve months similar to intervention group, and infrequent non-tailored pamphlets.
10000910|NCT01542697|Active Comparator|Magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline at the end of surgery before closure
10000911|NCT01542697|Placebo Comparator|normal saline|intraperitoneal nebulisation of 5 ml of normal saline after end of surgery before closure
10000912|NCT01542710|Experimental|Glaucoma fixed Combination Medications|
10000913|NCT01542723|Experimental|LMWH|750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
10000914|NCT01542723|No Intervention|No intervention|750 patients with an arthroscopy of the knee will be randomized to receive no treatment.
10000915|NCT01542762|Experimental|LMWH|750 patients with lower leg cast immobilization will be randomized tot receive treatment with a LMWH.
10000916|NCT01542762|No Intervention|No intervention|750 patients with lower leg cast immobilization will be randomized tot receive no treatment with LMWH.
10000917|NCT01542775|Placebo Comparator|Control|
10000918|NCT01542775|Active Comparator|Exercise|
10000919|NCT01542801|Active Comparator|Norfloxacin|norfloxacin 400 mg once daily administration
10000920|NCT01542801|Experimental|Ciprofloxacin|Ciprofloxacin 750 mg per week
9939974|NCT00983021|Experimental|B|
9939975|NCT00983021|Active Comparator|C|
9939976|NCT00983021|Experimental|D|
9939977|NCT00983034|Active Comparator|Membranous nephropathy|Patients with primary membranous nephropathy diagnosed by biopsy
9939978|NCT00983034|Active Comparator|IgA nephropathy|Patients with IgA nephropathy diagnosed by biopsy
9939979|NCT00983034|Active Comparator|Focal segmental glomerulosclerosis|Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
9939980|NCT00983047|Active Comparator|Docetaxel|The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.
9939981|NCT00983047|Experimental|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2,efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD.No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment:Dose of 200mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxic."
9939982|NCT00983112|Experimental|Evicel|
9939983|NCT00983112|Placebo Comparator|Placebo|
9939984|NCT00983125|Experimental|clonidine|
9939985|NCT00983125|Other|no clonidine|
10000921|NCT01542814||Fujifilm 3Dimensional Mammography|Group of subjects being given Fujifilm 3D Mammography Imaging
10000922|NCT01542814||2D FFDM|Group of Subjects receiving FujiFilm or other FDA Approved 2D Mammography Imaging
10000923|NCT01542827|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
10000924|NCT01542827|Experimental|Biofreeze|Biofreeze topical gel containing 3.5% menthol
10000925|NCT01542866|Experimental|Home Monitoring Test|Health management tool (HMT) for measuring vision impairment
10214464|NCT05223426|Experimental|Cognitive training followed by usual care|Usual care and cognitive training for 6 weeks, followed by usual care (only) for 6 weeks.
10214465|NCT05223426|Experimental|Usual care followed by cognitive training|Usual care (only) for 6 weeks, followed by cognitive training and usual care for 6 weeks.
10214466|NCT05223387|Experimental|Study Group|Anthogyr Axiom TL REG and corresponding Multi-Unit abutments
10214467|NCT05223387|Active Comparator|Control Group|Anthogyr Axiom BL REG and corresponding Multi-Unit abutment
10214468|NCT05223374||Assess the time to diagnosis from initial concern by EAC utilizing Canvas Dx|Time from initial concern to diagnosis when using Canvas Dx as part of the diagnostic process (Reported time to diagnosis)
9939986|NCT00983138|Experimental|recombinant asparaginase|
9939987|NCT00983151|Experimental|Active|
9939988|NCT00983151|Placebo Comparator|Placebo|
9939989|NCT00983164|No Intervention|group I|group I - controls
9939990|NCT00983164|Experimental|group II|group II - patients with hepatitis C without treatment
9939991|NCT00983164|Experimental|group III|group III - patients with hepatitis C treated weekly with pegylated interferon combined with daily ribavirin
9939992|NCT00983177|Active Comparator|colchicine|
9939993|NCT00983177|Placebo Comparator|Lactose capsule|
9939994|NCT00983190|Other|Single Group Assignment|
9939995|NCT00983203|Experimental|FID 114657|FID 114657
9939996|NCT00983203|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
9939997|NCT00983229|Active Comparator|CTrach|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of CTrach (sizes 3,4 or 5), establishment of ventilation.~Direct evaluation of laryngeal view through CTrach~Tracheal intubation through CTrach LMA~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
9939998|NCT00983229|Active Comparator|Intubating Laryngeal Mask Airway (ILMA)|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of ILMA (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through ILMA using fibrescope~Tracheal intubation through ILMA using fibrescope.~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
9939999|NCT00983229|Active Comparator|I-gel|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through I-gel using fibrescope~Tracheal intubation through I-gel using fibrescope~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
9940000|NCT00983255|Experimental|SAD/ Part A|Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.
9940001|NCT00983255|Experimental|MAD / Part B|Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.
9940002|NCT00983255|Experimental|Bioavailability / Part C|TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.
9940003|NCT00983255|Experimental|Venous Tolerability/ Part D|IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,
9940004|NCT00983268|Experimental|Treatment Arm|
9940005|NCT00983320|Experimental|medication|quetiapine
9940006|NCT00983320|Placebo Comparator|placebo|placebo
9940007|NCT00983333|Experimental|Web-based communication tool for health care professionals|
9940008|NCT00983333|Experimental|Web-based communication training tool for patients|
9940009|NCT00983333|No Intervention|Usual care for patient participants|
9940010|NCT00983398|Experimental|Treatment (mannitol, melphalan, carboplatin, STS)|Patients receive mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats every 4-6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9940011|NCT00983411||Healthy and OHS subjects|10 healthy subjects: 20 to 60 years old 10 patients with Obesity hypoventilation syndrome: 20 to 70 years old treated with nocturnal non invasive ventilation for at least three months.
9940012|NCT00983424|Experimental|Treatment arm|Cyclosporine A + nab-paclitaxel
9940013|NCT00983450|Experimental|study group|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
9940014|NCT00983450|Experimental|CONTROL|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
9940015|NCT00983463||Obese, bariatric surgery, liver biopsy|Obese subjects approved and scheduled for bariatric surgery at Vanderbilt University Medical Center
9940016|NCT00983463||Normal BMI, abdominal surgery, liver biopsy|Normal weight subjects having elective abdominal surgery at Vanderbilt University Medical Center.
9940017|NCT00983463||Liver transplantation donors and recipients|All livers made available for implantation or explantation will be eligible.
9940018|NCT00983502||Integrative Medicine|Patients of MD practitioners trained in Complementary and Alternative Medicine
9940019|NCT00983502||Naturopath Doctors|Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
9940020|NCT00983502||Chronic Fatigue Specialists|Patients of MD's who specialize in treating Chronic Fatigue and related conditions
9940021|NCT00983502||Control Group|Patients treated by primary care MDs in practice-based research networks
9940022|NCT00983554|No Intervention|Placebo|
9940023|NCT00983554|Experimental|Anastrazole and Testosterone|
9940024|NCT00983554|Experimental|Dutasteride and Testosterone|
10000926|NCT01542879|Experimental|WB-DW-MR scan|simultaneous WB-DW-MR scan and 18-F FDG PET scan
10000927|NCT01542892|Experimental|Supplement|
10000928|NCT01542892|Sham Comparator|Placebo|
10000929|NCT01542892|Experimental|Exercise|
10000930|NCT01542905|Experimental|Korean Red Ginseng|
10000931|NCT01542905|Placebo Comparator|Placebo|
10000932|NCT01542918|Experimental|Study intervention|Lenalidomide Plus Rituximab
10000933|NCT01542931|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
10000934|NCT01542931|Experimental|TPF induction chemotherapy|Induction chemotherapy before surgery: docetaxel, cisplatin, and 5-fluorouracil.
10000935|NCT01542944|Experimental|TevaGastrim|treatment with TevaGastrim for allogeneic stem cell collection
10000936|NCT01542970|Placebo Comparator|Placebo|Placebo for both L. reuteri and omega-3 fatty acids.
10000937|NCT01542970|Experimental|L. reuteri and placebo|Active Lactobacillus reuteri and placebo for omega-3 fatty acids
10000938|NCT01542970|Experimental|Omega-3 fatty acids and placebo|Placebo for L. reuteri and active for omega-3 fatty acids
10000939|NCT01542970|Experimental|L. reuteri and omega-3 fatty acids|Active L. reuteri and active omega-3 fatty acids
10000940|NCT01542983|Active Comparator|Treatment-as-usual|Treatment as usual for fatigue and insomnia
10000941|NCT01542983|Active Comparator|Behavioral treatment|Brief behavioral treatment for insomnia and bright light Light and BBTI combined treatment for insomnia and fatigue
10000942|NCT01543009|No Intervention|Emla + no additional intervention|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) without warming
10000943|NCT01543009|Experimental|Emla + Local Warming|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) plus warming with a heating pad at 40°C for 5 minutes
10000944|NCT01543022|Experimental|Symphony system|
10000945|NCT01543035|Experimental|Etravirine switch|Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
9480640|NCT05262322||All Participants (Group 1; Retrospective)|All participants' data will be collected retrospectively from medical records 12 months prior to the date of diagnosis of a first ischaemic stroke attributable to nonvalvular AF
9528362|NCT03212066|Experimental|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
10000946|NCT01543048||Women with CIN3 treated by conization|
10000947|NCT01543061|Active Comparator|New study eye drop|One month of contact lens wear with use of the Test study eye drops
10000948|NCT01543061|Placebo Comparator|No Eyedrop|One month of contact lens wear with no eye drop use
10000949|NCT01543061|Active Comparator|BLINK Contacts Lubricating eye drop|One month of contact lens wear with use of the Control study eye drops
10000950|NCT01543100|Experimental|monoclonal gamopathy|"Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.~Patient's age ≥18 yo,~Patients having signed the specific consent of the study."
10000951|NCT01543113|Other|melanoma|melanoma
10000952|NCT01543126||pleural effusion|patients with pleural effusion
10000953|NCT01543139|Experimental|Valproate+Cytidine-+Creatine-|The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate
10000954|NCT01543139|Active Comparator|Valproate+Cytidine-|The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate
10000955|NCT01543139|Active Comparator|Valproate|The subjects with bipolar depression, treated with valproate
10000956|NCT01543165|Experimental|Group 1|Sequential intravenous administration of ketorolac and nefopam
10000957|NCT01543165|Active Comparator|Group 2|Sequential intravenous administration of ketorolac and morphine
10000958|NCT01543165|Placebo Comparator|Group 3|Intravenous administration of ketorolac
10000959|NCT01543191|Experimental|PUR118|
10000960|NCT01543191|Placebo Comparator|Placebo|
10000961|NCT01543217|Active Comparator|Control|Ususal care.
10000962|NCT01543217|Active Comparator|Intervention|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
9940025|NCT00983554|Experimental|Testosterone|
9940026|NCT00983567|Experimental|Teen web|Main web - with all components
9940027|NCT00983567|Active Comparator|Minimal teen web|Teen web minus behavioral components
9940028|NCT00983593|Experimental|Group Therapy|Group therapy following the Mind-Body Bridging program.
9940029|NCT00983606||1|32 to 35 WGA Infants less than six months of age by RSV season peak.
9940030|NCT00983632|Experimental|vagus stimulation|electrical vagus stimulation to X.nerve on neck
9940031|NCT00983658|Experimental|huMAb OX40L|
9940032|NCT00983658|Placebo Comparator|Placebo|
9940033|NCT00983671||children with asthma|children with diagnosed asthma, age 6-18 years
9940034|NCT00983671||cystic fibrosis|children with cystic fibrosis, age 6-18 years
9940035|NCT00983671||chronic lung disease|children with chronic lung disease, also known as bronchopulmonary dysplasia, age 6-18 years
9940036|NCT00983671||pneumonia|children with clinical signs of pneumonia, age 6-18 years
9940037|NCT00983684|Experimental|Intra-operative radiotherapy|A single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
9940038|NCT00983684|Active Comparator|Post-operative radiotherapy|Standard post-operative radiotherapy.
9940039|NCT00983697|Experimental|FDG PET/CT|Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
9940040|NCT00983710|Experimental|1|Participants will receive a new patient education program designed to help men manage side-effects related to treatment for localized prostate cancer. The intervention will be targeted to low health literacy men.
9940041|NCT00983710|Active Comparator|2|Usual care, including a booklet on coping with localized prostate cancer. After the 6-month primary outcome data are collected, control group men will be offered the opportunity to cross-over and receive the new educational intervention.
9940042|NCT00983736|Experimental|Active|
9940043|NCT00983736|Placebo Comparator|Placebo|
9940044|NCT00983762||MIS knee arthroplasty|Persons scheduled for Minimally Invasive Surgery Mini-Incision (MIS) Total Knee Arthroplasty (TKA)
9940045|NCT00983762||Unicompartmental knee arthroplasty|Persons scheduled for Unicompartmental knee arthroplasty
9940046|NCT00983762||Standard knee arthroplasty|Persons scheduled for Standard Para-patellar surgery TKA
9940047|NCT00983762||Heathly knee subjects|Persons with healthy knees
9940048|NCT00983775|Experimental|healthy low dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.
9940049|NCT00983775|Experimental|healthy high dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
10000963|NCT01543230|Experimental|CoMplete™ Acetabular Hip System (CoM)|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
10000964|NCT01543243|Experimental|Group 1|"Group 1: immediate effects: T0, Stochastic resonance whole-body vibration A intervention, immediate T1 (one minute after Stochastic resonance whole-body vibration B intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration intervention, immediate T3 (one minute after Stochastic resonance whole-body vibration intervention)~long term effect: T4, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T5, 16 days wash-out period; T6, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T7"
10000965|NCT01543243|Experimental|Group 2|"Group 2: immediate effect: T0, Stochastic resonance whole-body vibration B intervention, immediate T1 (one minute after intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration A intervention, immediate T3 (one minute after intervention)~Long term effect: T4, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T5, 16 days wash-out period;T6, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T7"
10000966|NCT01543256|Active Comparator|Metal stents|The WallFlex Biliary Fully Covered Stent System is being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
10000967|NCT01543256|Active Comparator|Plastic Stents|Plastic stents per Investigator preference are being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
10000968|NCT01543269|Active Comparator|ZYT1 tablets|ZYT1 tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
10000969|NCT01543269|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
10000970|NCT01543282|Active Comparator|EUS 22 gauge needle|EUS 22 g needle is the most common needle used in clinical practice. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
10000971|NCT01543282|Experimental|EUS 25 gauge needle|25 gauge needle is usually used less frequently but nowadays is increasingly used and is as well a valid option. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
10000972|NCT01543295||Known Positive Syphilis Infection|Individuals known to have a clinical diagnosis of Syphilis
10000973|NCT01543295||High Risk for Syphilis Infection|Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis.
10000974|NCT01543295||Pregnant Women (High Risk and Low Risk)|"1st or 3rd trimester from either High Risk (see description above) or Low Risk population.~Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
10000975|NCT01543308||coronary heart disease|
10000976|NCT01543308||healthy control group|
10000977|NCT01543321|Experimental|Tetrabenazine group|Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
10000978|NCT01543321|Placebo Comparator|Plagebo group|Patients will receive a buccal tablet identical to the experimental product
10000979|NCT01543334||Patients|Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
10000980|NCT01543347|Experimental|Temocillin|Treatment group
10000981|NCT01543360|Active Comparator|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein).
10000982|NCT01543360|Active Comparator|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein).
10000983|NCT01543373|Experimental|CRE8 arm|
10000984|NCT01543373|Active Comparator|Vision/Multilik8 arm|
10000985|NCT01543386|Other|curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
10000986|NCT01543399|Experimental|Tibolone use|climacteric women will use Tibolone for 30 days
10000987|NCT01543399|Placebo Comparator|Placebo use|climacteric women will use placebo for 30 days
10000988|NCT01543412|Experimental|FOLFIRI|Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
10000989|NCT01543438|No Intervention|Control|current standard of care
10000990|NCT01543438|Experimental|Intervention Group|receives video prescription
10000991|NCT01543464|Experimental|Vaccine+adjuvants+temozolomide treatment|Experimental arm
10000992|NCT01543477||Single group|
10000993|NCT01543516||Patients with Asthma|"Affected patients~-20 Patients suffering from asthma with an eNO over 30 bbp"
10000994|NCT01543516||Healthy Subjects|"Non-affected patients~-20 matched controls not suffering from asthma"
10000995|NCT01543529|Active Comparator|RO4917838 + non-alcoholic drink|
10000996|NCT01543529|Experimental|RO4917838 + alcohol|
10000997|NCT01543529|Placebo Comparator|RO4917838 placebo + alcohol|
10000998|NCT01543529|Placebo Comparator|RO4917838 placebo + non-alcoholic drink|
10000999|NCT01543542|Other|Radiation Therapy Treatment|Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
10001000|NCT01543555|Experimental|Atorvastatin active|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
10001001|NCT01543555|Placebo Comparator|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
10001002|NCT01543620||Patients with cystic fibrosis treated with aminoglycosides|
10001003|NCT01543620||Patients with cystic fibrosis not treated with aminoglycosides|
10001004|NCT01543646||Liver Biopsy patients|All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
10001005|NCT01543672|Experimental|SBRT group A|escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)
10001006|NCT01543672|Experimental|SBRT group B|Escalate the MLD in patients with ≥ 2 lung metastases
10001007|NCT01543711||Breast cancer survivors|Women treated for breast cancer, without signs of recurrence or metastasis
10001008|NCT01543724|Experimental|Lithium|
10001009|NCT01543737|Active Comparator|Single injection hyaluronic acid|3ml hyaluronic acid (DUROLANE)
10001010|NCT01543737|Active Comparator|Three injection hyaluronic acid|2ml hyaluronic acid (HYALGAN)
10001011|NCT01543750|Experimental|Study Medication|4-aminopyridine 10mg twice daily for 8 weeks
10001012|NCT01543750|Experimental|Placebo|placebo twice daily for 8 weeks
10001013|NCT01543763|Experimental|Panobinostat with PC124871|
10001014|NCT01543789|Experimental|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity
9940050|NCT00983775|Experimental|type 1 diabetes mellitus|16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
9940051|NCT00983788|Experimental|Bezafibrate|
9940052|NCT00983788|Placebo Comparator|Placebo|
9940053|NCT00983840|Experimental|Family Eats|8-session program on health eating
9940054|NCT00983840|Active Comparator|Family eats- plain|Family eats without role model stories and goal setting
9940055|NCT00983866|Experimental|Tailored Telephone Counseling|
9940056|NCT00983866|No Intervention|Standard Trial Recruitment Procedures|
9940057|NCT00983944|Experimental|Arm I (EPOCH-R)|Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9940058|NCT00983944|Experimental|Arm II (R-VACOP-B)|Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.
9940059|NCT00983970|Experimental|Interactive video cycling|Interactive video cycling arm utilized the Gamebike that interfaced a Sony Play Station 2 with a stationary bicycle and a 42 inch flat screen TV. The Gamebike has a handle bar mounted game controller allowing the participant to play most Sony Play Station 2 raced-based video games. The Gamebike reads the participants' speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks.Participants were told that they could exercise at any intensity or duration that they desired, and reading materials were provided for those who did not chose to exercise for the full 60 minute session.
9940060|NCT00983970|Active Comparator|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device.
9940061|NCT00983996|Experimental|1|Alendronate Sodium Tablets, 10 mg
9940062|NCT00983996|Active Comparator|2|Fosamax Tablets, 10 mg
9940063|NCT00984035||Prospecitive Analysis|Patients currently receiving cisplatin as treatment for their cancer.
9940064|NCT00984035||Restrospective Analysis|Patients that have previously received cisplatin as treatment for their cancer.
9940065|NCT00984048||FOLFOX, XELOX or FOLFIRI +/- bevacizumab|Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.
9940066|NCT00984087|Experimental|Active rTMS treatment|
9940067|NCT00984100|Experimental|Notes Transvaginal Cholecystectomy|Patients who undergo a NOTES Transvaginal cholescystectomy.
9940068|NCT00984113|Experimental|A-Patients with mild renal impairment|
9940069|NCT00984113|Experimental|B-Healthy subjects matched to Group A|
9940070|NCT00984113|Experimental|C-Patients with moderate renal impairment|
9940071|NCT00984113|Experimental|D-Healthy subjects matched to Group C|
9940072|NCT00984113|Experimental|E-Patients with severe renal impairment|
9940073|NCT00984113|Experimental|F-Healthy subjects matched to Group E|
9940074|NCT00984152|Active Comparator|1|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
9940075|NCT00984152|Active Comparator|2|TDF/FTC + Efavirenz (Atripla) Once-Daily
9940076|NCT00984178|No Intervention|Control group|standard treatment
9940077|NCT00984178|Experimental|Bone marrow mononuclear progenitors|intracoronary transplantation of bone-marrow mononuclear progenitor cells
9940078|NCT00984178|Experimental|GCSF|progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
9940079|NCT00984178|Experimental|GCSF plus bone marrow mononuclear cells|combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
9940080|NCT00984191|Experimental|99mTc positive|99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
9940081|NCT00984191|Experimental|99mTc Negative_Neck dissection|99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
9940082|NCT00984191|Experimental|99mTc Negative_No neck dissection|99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
9528363|NCT03212066|No Intervention|Wait-List Control|Business as usual
9940083|NCT00984217|Experimental|Panitumumab|Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).
9940084|NCT00984230|No Intervention|Breastfeeding (Reference)|
9940085|NCT00984230|Active Comparator|Basic starter formula: BSF|
9940086|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics + OS|
9940087|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics|
9940088|NCT00984243|Experimental|Photodynamic Therapy|PHOTODYNAMIC THERAPY (PDT)
9940089|NCT00984269|No Intervention|No Tourniquet|Patients undergoing hand/wrist surgery without the use of a tourniquet.
9940090|NCT00984269|Experimental|Tourniquet|Patients undergoing hand/wrist surgery with the use of a tourniquet.
9940091|NCT00984347|Active Comparator|Oxytocin induction|women in need for induction of labor due to medical indications, will receive continuous IV oxytocin
9940092|NCT00984347|Active Comparator|Breast Stimultion|nipple stimulation with a breast pump, calibrated at the lowest suction strength,operated alternately: 15 min one breast, 15 min second breast, 15 min rest, till appearance of regular uterine contractions (3 contractions in 10 min). the manipulation will continue for 3 hours of regular contractions.
9940093|NCT00984360|Experimental|A118G|
9940094|NCT00984360|Experimental|Wild-type|
9940095|NCT00984386|Experimental|Intradermal Zesteem|
9940096|NCT00984386|Placebo Comparator|Placebo|
9940097|NCT00984399|Experimental|vaginal 17β-estradiol, questionnaire , symptom checklist|This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
9940098|NCT00984412|Experimental|AATT|
9940099|NCT00984425|Experimental|Lapatinib and Sorafenib 1° level of dose|Lapatinib 750 mg/die + Sorafenib 200 mg bid
9940100|NCT00984425|Experimental|Lapatinib and Sorafenib 2° level of dose|2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
9940101|NCT00984425|Experimental|Lapatinib and Sorafenib 3° level of dose|3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
9940102|NCT00984425|Experimental|Lapatinib and Sorafenib 4° level of dose|4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid
9940103|NCT00984438|Experimental|BCNU wafter followed by chemotherapy|Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year
9940104|NCT00984477|Experimental|1|AZD5122 oral suspension (part A and B)
9940105|NCT00984477|Placebo Comparator|2|Placebo oral suspension (part A)
9940106|NCT00984477|Experimental|3|AZD5122 oral and IV infusion (part B)
9940107|NCT00984503|Experimental|Intradermal Juvista|
9940108|NCT00984503|Placebo Comparator|Placebo|
9940109|NCT00984503|Experimental|Intradermal and topical Juvista|
9940110|NCT00984503|Placebo Comparator|Intradermal and topical placebo|
9940111|NCT00984516|Experimental|Intradermal Juvidex|
9940112|NCT00984516|Placebo Comparator|Placebo (vehicle)|
9940113|NCT00984529||1|Cardiologist´s office patients
9940114|NCT00984555||A1 (Inoculation with 7 timepoints)|Semen exposure via inoculation, Vaginal swabs at 7 time points
10001015|NCT01543789|Active Comparator|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
10001016|NCT01543802|Experimental|Pazopanib|
10001017|NCT01543815|Experimental|WBT-WEB|Well-Being Therapy based on Web Mobile technology
10214469|NCT05221944||Patients on antithrombotic therapy|The study aimed to investigate if perioperative bleeding complications were more common in patients on antithrombotic therapy. We retrospectively reviewed patients with IC/BPS who underwent hydrodistension during January 2010 and May 2021. Patients with and without antithrombotic drugs were identified and grouped and their medical records were reviewed.
10214470|NCT05221944||Patients without antithrombotic therapy|Patients without antithrombotic drugs were identified as controls
9528364|NCT03211676|Active Comparator|Theranova-500|
9528365|NCT03211676|Sham Comparator|Elisio-21H|
9940115|NCT00984555||A2 (Inoculation with 4 timepoints)|Semen exposure via inoculation, Vaginal swabs at 4 time points
9940116|NCT00984555||B1 (intercourse with 7 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 7 time points
9940117|NCT00984555||B2 (Intercourse with 4 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 4 time points
9940118|NCT00984581|Experimental|Intradermal avotermin|
9940119|NCT00984581|Placebo Comparator|Placebo|
9940120|NCT00984607|Experimental|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring.
9940121|NCT00984633|Experimental|0.6 mg/kg intubation dose + sevoflurane|
9940122|NCT00984633|Experimental|0.9 mg/kg intubation dose + sevoflurane|
9940123|NCT00984633|Experimental|0.6 mg/kg intubation dose + propofol|
9940124|NCT00984633|Experimental|0.9 mg/kg intubation dose + propofol|
9940125|NCT00984646|Experimental|Intradermal Prevascar|
9940126|NCT00984646|Placebo Comparator|Placebo (vehicle)|
9940127|NCT00984685||depression|Patients diagnosed with depression before April 15, 2009
9940128|NCT00984724|Experimental|Standard Treatment|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Referral to Quitline.
9940129|NCT00984724|Experimental|MAPS-6|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period.
9940130|NCT00984724|Experimental|MAPS-12|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline.
9940131|NCT00984724|Experimental|Standard Treatment + NRT|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
9940132|NCT00984724|Experimental|MAPS-6 + NRT|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
9940133|NCT00984724|Experimental|MAPS-12 + NRT|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
9940134|NCT00984750|Experimental|1|Statin and acetyl-L-carnitine
9940135|NCT00984750|Placebo Comparator|2|Statin and placebo
9940136|NCT00984763|Experimental|Group 1|AMA1-C1/Alhydrogel® + CPG 7909 vaccine given twice two months apart followed by malaria parasite challenge
9940137|NCT00984763|No Intervention|Group 2|Control: malaria parasite challenge without prior vaccinations
9940138|NCT00984789|Experimental|Arm 1|
9940139|NCT00984789|Active Comparator|Arm 2|
9940140|NCT00984802|Experimental|Low dose|
9940141|NCT00984802|Experimental|Mid Dose|
9940142|NCT00984802|Experimental|High Dose|
9940143|NCT00984802|Placebo Comparator|Placebo|
9940144|NCT00984828|Experimental|vel 8 - ASCT|8 cycles of velcade with ASCT
9940145|NCT00984828|Active Comparator|vel4 - ASCT|4 cycles of velcade with ASCT
9940146|NCT00984841|Experimental|Tailored letter|Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
9940147|NCT00984841|Active Comparator|Usual Care|Patients in the usual care group were part of a practice wide quality improvement process.
9940148|NCT00984854|Experimental|Intradermal Juvidex|
9940149|NCT00984854|Placebo Comparator|Placebo (vehicle)|
9940150|NCT00984880|Experimental|1|Intravenous solution given as a single ascending bolus dose
9940151|NCT00984880|Experimental|2|Intravenous solution given as a single ascending bolus dose followed by a single infusion
9940152|NCT00984893||Zoledronic acid|
9940153|NCT00984893||Oral Bisphosphonates|
9940154|NCT00984906|Other|Empty Easyhaler type A|
9940155|NCT00984906|Other|Empty Easyhaler type B|
9940156|NCT00984906|Other|Empty Turbohaler|
9940157|NCT00984932|Experimental|Rosuvastatin|
9940158|NCT00984945|Active Comparator|H5 VLP vaccine 5 µg|
9940159|NCT00984945|Active Comparator|H5 VLP vaccine 10 µg|
9940160|NCT00984945|Active Comparator|H5 VLP vaccine 20 µg|
9940161|NCT00984945|Placebo Comparator|Placebo (Formulation buffer)|
9940162|NCT00984958|Other|Bulkamid|Injection with Bulkamid
9940163|NCT00984958|Other|expectance|The expectance arm will after 2 month have the same treatment as the treatment arm
9940164|NCT00984971|Experimental|Tenofovir|
9940165|NCT00984971|Placebo Comparator|HEC Placebo|
9940166|NCT00984971|Other|Open label tenofovir tablet|
9940167|NCT00984984|Experimental|methylprednisolone PO|
9940168|NCT00984984|Active Comparator|methylprednisolone IV|
9940169|NCT00984997|Experimental|Surgery + Radiotherapy + Chemotherapy|"Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.~Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional."
9940170|NCT00985023|Active Comparator|Steel screw fixation|
9940171|NCT00985023|Experimental|Bioabsorbable screw fixation|
9940172|NCT00985036||Glioma|patients who are diagnosed with and are being treated for glioma
9940173|NCT00985036||meningioma|patients who are diagnosed with and are being treated for meningioma
9940174|NCT00985062|Active Comparator|Mild Ovarian Stimulation|
9940175|NCT00985062|Active Comparator|Conventional Ovarian Stimulation|
9940176|NCT00985101||diabetes no complications|
9940177|NCT00985101||diabetes with complications|
9940178|NCT00985179|Experimental|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
9940179|NCT00985179|No Intervention|Waiting control group (WCG)|
9940180|NCT00985218|Experimental|experimental arm|Embryos cultured in SMART System
9940181|NCT00985218|Active Comparator|Control|Embryos cultured in microdrops in dishes
10001018|NCT01543815|Active Comparator|CBT|Cognitive Behavior Therapy
10001019|NCT01543815|No Intervention|CM|Standardized Care Management
10001020|NCT01543841||Advanced Cancer|Patients with histologically confirmed metastatic or unresectable solid tumors will have one tube of whole blood (~6mL) collected at the time of venipuncture for routine sample collection. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
10001021|NCT01543841||Healthy Volunteers|Eligible volunteers will have one tube of whole blood (~6mL) collected. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
10001022|NCT01543854|Experimental|RLX030|RLX030 as intravenous infusion for 20 hours
10001023|NCT01543854|Placebo Comparator|Placebo|Matching placebo as intravenous infusion for 20 hours.
10001024|NCT01543867||Users of somatropin|
10001025|NCT01543880||Users of somatropin|
10001026|NCT01543893|Experimental|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
10001027|NCT01543893|Active Comparator|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
10001028|NCT01543906|Experimental|QLT091001|oral QLT091001 administered once daily for 7 days
10001029|NCT01543932|Experimental|Prasugrel standard dose|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
10001030|NCT01543932|Experimental|high clopidogrel dose|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.
10001031|NCT01543932|Experimental|Ticagrelor standard dose|Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.
10001032|NCT01543945|Experimental|Multimodal antiemetic management group|Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg
10001033|NCT01543945|Active Comparator|Control group|Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv
10001034|NCT01543971|Active Comparator|TXA127|(Group A) TXA127 at 300 mcg/kg once a day for 5 days
10001035|NCT01543971|Active Comparator|Neupogen|(Group B) Neupogen 10 mcg/kg once a day for 5 days
10001036|NCT01543971|Active Comparator|TXA127 and Neupogen|(Group C) both TXA127 (300mcg/kg) and Neupogen (10mcg/kg) together once a day for 5 days
10001037|NCT01543984|Experimental|Tailored Physical Activity|"Health guidance (1,5h) and Tailored Physical Activity (3*50 min/week in 10 weeks)"
10001038|NCT01543984|Other|Reference group|Health Counselling (1,5h)
10001039|NCT01543997|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
9940182|NCT00985244|Active Comparator|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
9940183|NCT00985244|Placebo Comparator|Placebo|Subjects in this group will receive 3 times a week placebo
9940184|NCT00985270|Active Comparator|Rifampicin|
9940185|NCT00985270|Placebo Comparator|Placebo|
9940186|NCT00985283|Experimental|Preventive home visit|receives preventive home visit intervention 4 times over 1 year
9940187|NCT00985283|Active Comparator|comparison group|receives information packets on local services for older adults and health promotion material twice during 1 year
9940188|NCT00985296||Ragweed+ Dust Mite+ CAC w/ DM|
9940189|NCT00985296||Ragweed + Dust Mite + CAC w/Saline|
9940190|NCT00985296||Ragweed + Dust Mite - CAC|
9940191|NCT00985322|Experimental|ACE inhibitor Ramipril|
9940192|NCT00985322|Active Comparator|non-RAS inhibitor antihypertensive therapy|
9940193|NCT00985335|Experimental|External Application of Neem-based Cream|Non Controlled, non-randomized, single group pilot study.
9940194|NCT00985348|Experimental|Treatment 1/Treatment 2|
9940195|NCT00985348|Experimental|Treatment 2/Treatment 1|
9940196|NCT00985361|Experimental|Vitamin D 2000 international units daily|
9940197|NCT00985361|Active Comparator|Vitamin C 500mg daily|
9940198|NCT00985374|Experimental|1|
9940199|NCT00985387||Solifenacin treatment|Male and female OAB patients who were treated with solifenacin
9940200|NCT00985452|Other|Group 2: Intervention|Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
9940201|NCT00985452|Other|Group 3: Intervention/financial incentive|Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
9940202|NCT00985452|Other|Group 1: Control|Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
9940203|NCT00985478|Experimental|A|SLV342 suspension or capsule
9940204|NCT00985478|Placebo Comparator|B|matching placebo
9940205|NCT00985530|Experimental|Arm 1|Tamibarotene + Arsenic Trioxide
9940206|NCT00985556|Experimental|Arm I|Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
9940207|NCT00985556|Experimental|Arm II|Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
9940208|NCT00985569||Lubiprostone|Subjects switching from current bowel medicines to lubiprostone
9940209|NCT00985608|Active Comparator|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
9940210|NCT00985608|Active Comparator|Group A: NCA 600mg +antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
9940211|NCT00985634|Experimental|LeGoo|Subjects in this arm, which is assigned at random, will receive the study device.
9940212|NCT00985634|Active Comparator|Control|Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
9940213|NCT00985647|Active Comparator|3TC 300mg/150mg|Group 1: Participants will be administered 3TC 300 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 150 mg once daily for 10 days
9940214|NCT00985647|Active Comparator|3TC 150mg/300mg|Group 2: Participants will be administered 3TC 150 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 300 mg once daily for 10 days
9940215|NCT00985660|Experimental|Test:|Nisoldipine ER Tablets, 30 mg
9940216|NCT00985660|Active Comparator|Reference|Sular Extended-release Tablets, 30 mg
9940217|NCT00985764||placental previa|
9940218|NCT00985777|Experimental|Phase I Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days and one dose on Day 15.
9940219|NCT00985803|No Intervention|Group Control|
9940220|NCT00985803|Experimental|Endurance|
9940221|NCT00985803|Experimental|Cardiovascular|
9940222|NCT00985816|Active Comparator|L reuteri DSM 17938|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties (Connolly, 2005). The placebo consists of an identical formulation except that the L. reuteri is not present. This dose of the oil formulation with L. reuteri has been shown to induce significant colonisation in infants and is well-tolerated (Abrahamsson et al., 2007; Savino et al., 2007; Indrio et al., 2008).
9940223|NCT00985816|Placebo Comparator|Placebo|
9940224|NCT00985842|Other|Arm 1|Comparison of five different clinically used suspension and socket systems
9940225|NCT00985855|Experimental|Cisplatin, vinorelbine|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.
9940226|NCT00985855|Experimental|Cisplatin, etoposide|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.
9940227|NCT00985881|Experimental|Arm 1: stochastic resonance|Mechanical stochastic resonance
9940228|NCT00985881|Other|Arm 2: current clinical practice|Current clinical practice
9940229|NCT00985894|Experimental|Teledermatology|Online Telemedicine Group
9940230|NCT00985894|Active Comparator|Usual Care|Conventional in-office care
9940231|NCT00985920|Experimental|Tranexamic acid, 1.5 g|1.5 g of tranexamic acid in 50 cc of normal saline solution is given to the patients.
9940232|NCT00985920|Experimental|Tranexamic acid, 3.0 g|3.0 g of tranexamic acid in 50 cc of normal saline is given to the patients.
9940233|NCT00985920|Placebo Comparator|Placebo, saline|50 cc of sterile normal saline solution is given to the patients.
10001040|NCT01543997|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
10001041|NCT01544010|No Intervention|assessment only control group|Assessment at baseline, 12, and 24 months
10001042|NCT01544010|Active Comparator|Minimal Stage Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
10001043|NCT01544010|Active Comparator|Moderate TTM Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Moderate TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance and temptations at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
10001044|NCT01544010|Active Comparator|Full TTM tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Full TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
10001045|NCT01544010|Active Comparator|Enhanced TTM+Addiction Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Enhanced TTM+Addiction Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of addiction levels (# cigarettes/day) stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
10001046|NCT01544036|Experimental|Contrast Enhanced Ultrasound|Renal blood flow before and after exposure to iodinated contrast agent (perflutren) also known as Definity will be measured using contrast enhanced ultrasound (CEUS).
10001047|NCT01544049||Fallopian tube removal|Women who have had one or both fallopian tube(s) removed as method of ovarian cancer prevention.
10001048|NCT01544075|Experimental|PNE+PI|The interventional group who will receive the experimental PNE+PI treatment.
10001049|NCT01544075|Active Comparator|NS|The control group who will receive the neck school treatment.
10001050|NCT01544101|Experimental|Vegan Diet|
10001051|NCT01544101|Placebo Comparator|Supplement|
10214471|NCT05221697|Other|Intervention|Nurse or GP consultation
10214472|NCT05213013|Experimental|Experimental|All registered participants in the control group, will receive inhaler treatment with the toy-type nebulizer in the hospital. Both the parent and the child in the intervention group will be trained on the use of a nebulizer/mask.
9476192|NCT03574376|Active Comparator|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
9476193|NCT03574363|Experimental|KBP-5074 0.25 mg tablet|KBP-5074 0.25 mg tablet QD orally, 84 days
9476194|NCT03574363|Experimental|KBP-5074 0.5 mg tablet|KBP-5074 0.5 mg tablet QD orally, 84 days
9476195|NCT03574363|Placebo Comparator|Placebo tablet|Placebo tablet QD orally, 84 days
9476196|NCT03574350|Experimental|KS in Kangaroo Position (KSKP)|KS is performed while the infant is in Kangaroo Position using a lycra band to maintain the position.
9476197|NCT03574350|Active Comparator|KS in incubator (KSI)|The infant is in the incubator, unclothed with diaper.
9476198|NCT03574324|Experimental|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
9476199|NCT03574324|Other|CCRE+PF|Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy
9476200|NCT03574311|Experimental|Ferric carboxymaltose|Preoperative 1000 mg intravenous single dose as 30 minute infusion
9476201|NCT03574311|Placebo Comparator|Placebo|Preoperative 100 ml saline as 30 minute infusion
10214473|NCT05213013|No Intervention|No intervention|No intervention. All registered participants in the control group, will receive inhaler treatment with the standard nebulizer in the hospital. Both the parent and the child in the intervention group will not be trained on the use of a nebulizer/mask.
10214474|NCT05206617||Limb Girdle Muscular Dystrophy type 2L|At baseline, 1- and 3-year follow up will the outcome measures be assessed. There will be no intervention.
9476202|NCT03574285|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
10214475|NCT05205967||Patients who received the Galleri test|
10214476|NCT05205967||Patient who were eligible to receive the Galleri test but did not|External contemporaneous control cohort
10214477|NCT05203692|Experimental|DS-7011a|"Stage 1: Healthy participants who will be randomized to receive a single intravenous (IV) ascending dose of DS-7011a (starting dose 0.1 mg/kg).~Stage 2: Healthy participants who will be randomized to receive a single subcutaneous (SC) ascending dose of DS-7011a (starting dose will be centered around estimated therapeutic dose confirmed in Stage 1).~Stage 3: Healthy Japanese participants who will be randomized to receive an IV dose of DS-7011a (based on estimated therapeutic dose confirmed in Stage 1)."
10214478|NCT05203692|Placebo Comparator|Placebo|Healthy participants who will be randomized to receive a single dose of placebo.
10214479|NCT05203237|Placebo Comparator|Placebo (Part A)|Placebo administered SC once in healthy participants
10214480|NCT05203237|Experimental|VK2735 (Part A)|Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.
10214481|NCT05203237|Placebo Comparator|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants
10214482|NCT05203237|Experimental|VK2735 (Part B)|Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.
10214483|NCT05202769||Healthy Volunteers|20 healthy volunteers above the age of 18 in a laboratory setting with video clips taken under varying conditions of lighting, distance between the cameras and the participants' faces and with various positions and limb movements involved.
9476203|NCT03574285|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
9476204|NCT03574272|Experimental|Patient Transfer Monitoring System|
9940234|NCT00985933|Experimental|1|180 mg of AZD8529
9940235|NCT00985933|Experimental|2|50 mg AD8529
9940236|NCT00985933|Placebo Comparator|3|Placebo
9940237|NCT00985972||Intervention|Groups of school intervention that involves a combination of the physical activity and nutrition education in subjects 6 to 18 years of age
9940238|NCT00985972||Control|Groups included in the same school communities that serve as reference for individuals involved in intervention.
9940239|NCT00985998|Experimental|Nimotuzumab|
9940240|NCT00986024|Experimental|aerobic exercise|
9940241|NCT00986024|Experimental|strength training|
9940242|NCT00986024|No Intervention|control group|
9940243|NCT00986037|Experimental|IV ABT-308 in asthmatics|ABT-308 single escalating doses in mild to moderate asthmatics
9940244|NCT00986037|Experimental|SC ABT-308 in asthmatics|ABT-308 multiple SQ doses in mild to moderate asthmatics
9940245|NCT00986037|Experimental|IV ABT-308 in healthy volunteers|ABT-308 single escalating IV doses in healthy volunteers
9940246|NCT00986050|Active Comparator|Bare metal stent (BMS)|
9940247|NCT00986050|Active Comparator|Drug eluting stent (DES)|
9940248|NCT00986050|Active Comparator|Abciximab|
9940249|NCT00986050|No Intervention|No abciximab|
9940250|NCT00986063|Active Comparator|Standard of care|AIDS patients taking care with standard of care
9940251|NCT00986063|Experimental|Genetic test|AIDS patients who required highly active antiretroviral therapy(HAART) whom genotype status will be determined before initiation of HAART
9940252|NCT00986076|Experimental|Enoxaparin infusion|"Congenital Cataract Surgery with IOL implantation~Intraocular infusion of Enoxaparin"
9940253|NCT00986076|Placebo Comparator|Balanced Salt Solution Infusion|Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
9940254|NCT00986089||women who have an IUD placed at the time of c-section|
9940255|NCT00986115|Active Comparator|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
9940256|NCT00986115|Placebo Comparator|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
9940257|NCT00986128|Experimental|001|
9940258|NCT00986128|Experimental|002|
9940259|NCT00986141||laser trabeculoplasty|Subjects with POAG and on medical treatment who are undergoing SLT
9940260|NCT00986141||Surgery|Glaucoma laser treatment
9940261|NCT00986167|Experimental|Quetiapine XR|The study population will be patients admitted to the acute psychiatry inpatient wards of St Vincent's or the Alfred and determined by a Psychiatrist to be experiencing a psychotic illness (including mania with psychotic features and drug-induced psychosis) and acting in an aggressive manner (determined by a score of at least 1 on the OAS).
9940262|NCT00986193|Active Comparator|Conventional Aortic Valve Surgery|Insertion of a biological valve
9940263|NCT00986193|Experimental|Transapical Aortic Valve Implantation|Transapical implantation of an Edwards SAPIENtm valve
9940264|NCT00986206||Biomarker testing|Collect serum for biomarker testing for LAP and HE4 and discovery of new biomarkers.
9940265|NCT00986219||Asthma Language between patients and physicians|
9940266|NCT00986271|Other|With and without MODS developement|EVLI was determinated by PiCCO plus system.
9940267|NCT00986284|Experimental|Gefitinib, Neoadjuvant therapy|Patients with EGFR mutation will be recruited and treated with gefitinib.
9940268|NCT00986297|Other|arm one|IGRT
9940269|NCT00986323|Active Comparator|Temeperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
9940270|NCT00986323|Placebo Comparator|Placebo TLA|Placebo TLA treatment
9940271|NCT00986336|Experimental|001|
9940272|NCT00986336|Experimental|002|
9940273|NCT00986336|Experimental|003|
9940274|NCT00986336|Experimental|004|
9940275|NCT00986375|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
9940276|NCT00986375|Active Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
9940277|NCT00986414|Experimental|AFQ056-10mg|
9940278|NCT00986414|Experimental|AFQ056-25mg|
9940279|NCT00986414|Experimental|AFQ056-50mg|
9940280|NCT00986414|Experimental|AFQ056-75mg|
9940281|NCT00986414|Experimental|AFQ056-100mg|
9940282|NCT00986414|Placebo Comparator|Placebo|
9940283|NCT00986466|Experimental|exercise with vitamin D 800 IU/d|
9940284|NCT00986466|Active Comparator|exercise with placebo|
9940285|NCT00986466|Active Comparator|no exercise with vitamin D 800 IU/d|
9940286|NCT00986466|Placebo Comparator|no exercise with placebo|
9940287|NCT00986505|Experimental|Lidocaine|Comparison between intravenous lidocaine and saline infusion
9940288|NCT00986518|Experimental|adaptive cell immunotherapy|
9940289|NCT00986531|Experimental|1|80 mg AZD8529
9940290|NCT00986531|Placebo Comparator|2|Placebo
9940291|NCT00986596|Active Comparator|vitamin D3|vitamin D3 capsule 4000 IU p.o. daily
9940292|NCT00986596|Placebo Comparator|placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
9940293|NCT00986609|Experimental|Arm I|Patients receive MUC-1 peptide vaccine subcutaneously and poly-ICLC vaccine intramuscularly in weeks 0, 4, 8, 12, 52, and 56, in the absence of disease progression or unacceptable toxicity. Patients may receive additional vaccines in weeks 34 and 38 if anti-MUC1 immunity falls below the two-fold enhancement from baseline
9940294|NCT00986687||Vitrified oocytes|
9940295|NCT00986687||Control oocytes|
9940296|NCT00986700|Other|different types of bad time food|Different types of bad time food
9940297|NCT00986752|Active Comparator|Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
9940298|NCT00986752|Experimental|Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
9476205|NCT03574246|Experimental|CHXBNZ|Pharyngeal pack moisturized with chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15 and placed to oropharynx
9476206|NCT03574246|Active Comparator|SF|Pharyngeal pack moisturized with %0,9 NaCl and placed to oropharynx
9476207|NCT03574233||patients who are ready to wean ventilator off|
9476208|NCT03574220|Experimental|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.~Adjuvant Therapy:~Pembrolizumab 200mg IV every 21 days for 6 months"
9940299|NCT00986752|Experimental|Atherectomy|The third randomization arm is Atherectomy.
9940300|NCT00986765|Experimental|Lovenox® , 4000 UI/day (+ Aspegic®)|Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin), 100 mg)
9940301|NCT00986765|Active Comparator|Aspegic ®, 100 mg/day|Aspegic® (Aspirin),100 mg/day
9940302|NCT00986778|Active Comparator|Lamivudine plus Adefovir|
9940303|NCT00986778|Active Comparator|Entecavir|
9940304|NCT00986778|Experimental|Entecavir plus Adefovir|
9940305|NCT00986791|No Intervention|Control group|Treatment as usual
9940306|NCT00986791|Experimental|GSP-A|Gold-Standard-Program for Alcohol cessation intervention (GSP-A): 6-week intensive patient education program with pharmaceutical support
9940307|NCT00986804|Experimental|Level 1|Decitabine 5.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
9940308|NCT00986804|Experimental|Level 2|Decitabine 7.5 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
9940309|NCT00986804|Experimental|Level 3|Decitabine 10.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
9940310|NCT00986804|Experimental|Level 4|Decitabine 15.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
9940311|NCT00986817|Experimental|Terlipressin|
9940312|NCT00986817|Placebo Comparator|Placebo|
9940313|NCT00986843|Experimental|HM30181AK tablet + Irinotecan tablets|HM30181AK tablet + Irinotecan tablets
9940314|NCT00986869||echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
9940315|NCT00986960|Active Comparator|Adrenocorticotropin hormone|Patients receive the hormone
9940316|NCT00986960|Placebo Comparator|Placebo|Patients receive placebo only
9940317|NCT00987012|Experimental|Pomegranate juice|
9940318|NCT00987012|Placebo Comparator|Placebo drink|
9940319|NCT00987025|Experimental|Telehealth|Telehealth participants will be recruited from centers that have a telehealth blood pressure station installed. Participants will be asked to use the station once per week. Blood pressure measures will be monitored by nurse researchers - out of range values will result in appropriate medical recommendations.
9940320|NCT00987025|Active Comparator|Control|Control participants will receive education material.
9940321|NCT00987038|Other|PF-04171327 and Midazolam|
9940322|NCT00987051|Experimental|1|Patients with endometrial cancer
9940323|NCT00987064|Active Comparator|Temperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
9940324|NCT00987064|Placebo Comparator|Placebo TLA|Placebo treatment with TLA (no filtration function)
9940325|NCT00987077|Experimental|Selective Retinatherapy (SRT)|Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
9940326|NCT00987077|No Intervention|control group|Patients randomized to control group achieve no treatment and are followed up for three months.
9940327|NCT00987077|Experimental|crossover|After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.
9940328|NCT00987090|Active Comparator|Alzheimer Disease|subjects who have developed symptoms of Alzheimer Disease aged from 45 to 85 years old
9940329|NCT00987090|Placebo Comparator|Control|subjects without symptoms of Alzheimer Disease aged from 45 to 85 years old.
9940330|NCT00987103|Experimental|Sublingual - Rectal - Oral|Administration order of rank: Sublingual - Rectal - Oral
9940331|NCT00987103|Experimental|Sublingual - Oral - Rectal|Administration order of rank: Sublingual - Oral - Rectal
9940332|NCT00987103|Experimental|Oral - Sublingual - Rectal|Administration order of rank: Oral - Sublingual - Rectal
9940333|NCT00987103|Experimental|Oral - Rectal - Sublingual|Administration order of rank: Oral - Rectal - Sublingual
9940334|NCT00987103|Experimental|Rectal - Sublingual - Oral|Administration order of rank: Rectal - Sublingual - Oral
9940335|NCT00987103|Experimental|Rectal - Oral - Sublingual|Administration order of rank: Rectal - Oral - Sublingual
9940336|NCT00987116|Active Comparator|Starting dose Prednisone Azathioprine|Classical Strategy
9940337|NCT00987116|Active Comparator|Starting dose Prednisone - Azathioprine|Rapid strategy
9940338|NCT00987142|Experimental|CX501|Cultured chimeric skin
9940339|NCT00987142|Active Comparator|Non adherent dressing|Occlusive non adherent dressing
9940340|NCT00987155|Experimental|high intensity interval training|8 weeks of high intensity 4 times 4 interval training at 85-90% of peak heart rate during hybrid cycling
9940341|NCT00987168|Experimental|Sandostatine LP|
9940342|NCT00987181||Angiography high risk|Patients with multiple risk factors, positive non-invasive test, or known pre-existing coronary artery/vascular disease. Patients with diabetes mellitus will be identified, and subject to a sub-group analysis.
9940343|NCT00987181||Angiography Low Risk|Patients with chest pain symptoms, minimal risk factors, and inconclusive evidence of myocardial ischaemia on non-invasive testing.
9940344|NCT00987207|Experimental|cyclosporine|A single bolus of 2.5 mg/kg cyclosporine is administered before aortic cross-declamping
9940345|NCT00987207|Other|Control|No cyclosporine A is administered before aortic cross-declamping
9940346|NCT00987220||Placebo|
9940347|NCT00987220||donepezil (Aricept)|
10001052|NCT01544140|Experimental|midazolam then midazolam + vandetanib|Midazolam alone followed by midazolam in combination with vandetanib
10001053|NCT01544192|Active Comparator|retinal nerve fiber thickness|
9940348|NCT00987233|Experimental|triamcinolone acetonide aqueous nasal spray|
9940349|NCT00987233|Active Comparator|Nasacort® AQ Nasal Spray|
9940350|NCT00987233|Placebo Comparator|Placebo|
9940351|NCT00987246|Experimental|LAS41005|
9940352|NCT00987246|Active Comparator|LAS106521|
10001054|NCT01544192|Active Comparator|Mean Deviation|
9940353|NCT00987246|Placebo Comparator|Placebo|
9940354|NCT00987259||Post MI patients|Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
9940355|NCT00987285|Experimental|Computer Assisted Self Management plus Social Support|an interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media combined with enhanced support in the form of group Diabetes Care Management visits and live follow up phone calls from Diabetes Care Managers
9940356|NCT00987285|No Intervention|Usual care|will receive a health-risk appraisal, interactive CD-ROM program that provides standardized advice on behavior change, but not the hypothesized key intervention processes of goal setting, barriers identification, problem solving, or social environmental support.
9940357|NCT00987285|Experimental|Computer Assisted Self Management|An interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media.
9940358|NCT00987298||Visceral fat mass|The study population will include adult men and women, ages 18 to 90 years. All subjects will be recruited at Oregon Health and Science University (OHSU). Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
9940359|NCT00987311|Active Comparator|1-Test product A|1-Dairy product containing probiotics A (test product A)
9940360|NCT00987311|Active Comparator|2-Test product B|2-Dairy product containing probiotics B (test product B)
9940361|NCT00987311|Sham Comparator|3-Control|3-Dairy product without probiotics (control)
9940362|NCT00987324|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus)
9940363|NCT00987324|Active Comparator|Plain Balloon|plain balloon angioplasty
9940364|NCT00987324|Experimental|Paclitaxel-eluting balloon|SeQuent Please
9940365|NCT00987350|Active Comparator|Trivalent influenza vaccine by needle and syringe|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the standard needle and syringe method
9940366|NCT00987350|Experimental|Trivalent influenza vaccine by jet injection|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the experimental method of jet injection
9940367|NCT00987363|Experimental|Low dose (1x10 E8)|Dose of 1x10 E8 autologous bone marrow-derived mononuclear cells
9940368|NCT00987363|Experimental|Intermediate dose (5x10 E8)|Dose of 5x10 E8 autologous bone marrow-derived mononuclear cells
9940369|NCT00987363|Experimental|High dose (1x10 E9)|Dose of 1x10 E9 autologous bone marrow-derived mononuclear cells
9940370|NCT00987363|No Intervention|Control|Conventional treatment established by the good clinical practice
9940371|NCT00987376|Experimental|1|Prostate cancer patients
9940372|NCT00987428|Experimental|groupe 1|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
9528366|NCT03211650|Experimental|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
9528367|NCT03211650|Active Comparator|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
9940373|NCT00987428|Active Comparator|Groupe 2|usual procedure
10001055|NCT01544192|Active Comparator|Pattern Standard Deviation|
9940374|NCT00987441|Active Comparator|Local anesthetic plus opioid 1|Local anesthetic (ropivacaine 0.125%) plus first opioid dose (sufentanil 0.3 microgram/ml) delivered peridural space
9940375|NCT00987441|Active Comparator|Local anesthetic plus opioid 2|Local anesthetic (ropivacaine 0.125%) plus second opioid dose (sufentanil 0.4 microgram/ml) delivered peridural space
9940376|NCT00987441|Active Comparator|Local anesthetic plus opioid 3|Local anesthetic (ropivacaine 0.125%) plus third opioid dose (sufentanil 0.5 microgram/ml) delivered peridural space
9940377|NCT00987441|Active Comparator|Local anesthetic 1 plus opioid|First local anesthetic dose (ropivacaine 0.0625%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
9940378|NCT00987441|Active Comparator|Local anesthetic 2 plus opioid|Second local anesthetic dose (ropivacaine 0.1875%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
9940379|NCT00987441|Active Comparator|Local anesthetic 3 plus opioid|Third local anesthetic dose (ropivacaine 0.25%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
9940380|NCT00987454|Active Comparator|Erythropoietin|Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.
9940381|NCT00987454|Placebo Comparator|Placebo|Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.
9940382|NCT00987493|Experimental|Treatment with rituximab, bendamustine and lenalidomide|
9940383|NCT00987506||XIENCE V®|Participants receiving XIENCE V® EESS
9940384|NCT00987519||Acute bronchiolitis|Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation.
9940385|NCT00987519||Acute gastroenteritis|Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study.
9940386|NCT00987519||Febrile convulsion|Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection.
9940387|NCT00987519||Control group|Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection.
10001056|NCT01544192|Active Comparator|ganglion cell count|
10001057|NCT01544192|Active Comparator|c/d ratios|
10001058|NCT01544205|Experimental|Emotion network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
10001059|NCT01544205|Active Comparator|Place processing network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
10001060|NCT01544218||YCMC|Youth ages 9-18 with one of four chronic medical conditions - asthma, diabetes, rheumatic or gastroenterologic conditions
10001061|NCT01544231||Patients|Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
10001062|NCT01544244|Experimental|GSC physcial therapy|Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
10001063|NCT01544244|Active Comparator|Standard|Patients in this arm of the study will follow the standard physical therapy sequence.
10001064|NCT01544257|Experimental|OMT|patients under standard medical care plus OMT.
10001065|NCT01544257|No Intervention|Control|patients under standard medical care plus only osteopathic evaluation
10001066|NCT01544270|Active Comparator|Study product containing milk proteins|Yoghurt-like milk-based product
10001067|NCT01544270|Active Comparator|Study product containing probiotics|Yoghurt-like milk-based product
10001068|NCT01544270|Placebo Comparator|Control product|Yoghurt-like milk-based product without supplemented nutrients
10001069|NCT01544283|Experimental|Patch|Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
10001070|NCT01544283|Active Comparator|Subacromial Injection|A single injection will be administered into the subacromial space utilizing triamcinolone acetonide at the baseline visit.
10001071|NCT01544296|Experimental|KHK6188, high dose|
10001072|NCT01544296|Experimental|KHK6188, low dose|
10001073|NCT01544296|Placebo Comparator|Placebo|
10001074|NCT01544374|Experimental|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
10001075|NCT01544374|No Intervention|Control- no intervention|Usual Care
10001076|NCT01544387|Other|Bed Rest|Subjects will have limited activity. Bed Rest
10001077|NCT01544387|Other|Activity|Activity
10001078|NCT01544413|Experimental|Laparoscopic sentinel lymph node biopsy|This is a single armed study. After endoscopic marking using Tc99m HSA and indocyanine green fluid, Laparoscopic sentinel lymph node biopsy was performed and evalute at backtable.
10001079|NCT01544426|Experimental|Office hysteroscopy and endometrial snip|Office hysteroscopy and endometrial snip
10001080|NCT01544426|Active Comparator|Office hyteroscopy|Office hysteroscopy
10001081|NCT01544439|Experimental|Oral stabilization appliance,counselling|The reversible occlusal therapy by stabilizing appliance used by patients in Study Group shall be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. Patients receive oral and written instructions about self-care (counseling), including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
10214484|NCT05202769||ICU patients|Group/Cohort Description: 20 patients above the age of 18 years and able to provide consent, admitted to the ICU with various underlying conditions and comorbidities. Video clips are taken under varying conditions of lighting, positions and with ongoing care and procedures.
10214485|NCT05202249|Experimental|muscle layer fixation group|
10214486|NCT05202249|No Intervention|conventional skin fixation group|
10214487|NCT05202002|Active Comparator|Educational video|Participants will receive an online video clip, explaining the benefits of breastfeeding.
10214488|NCT05202002|Sham Comparator|Control group|Participants will not receive the video clip
10001082|NCT01544439|Placebo Comparator|Non-occluding splint, counselling|The non-occlusive splint (placebo) will also be made by the same dental technician. They differ by the plates did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. As not lead acrylic on the occlusal surfaces of teeth, adequate retention is given by an arch wire in orthodontic buccal surface of teeth. All patients will submitted a counseling approach / self-care. Patients receive oral and written instructions about self-care, including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
10001083|NCT01544452|Other|Total preoperative MR evaluation|Total diagnostic evaluation with MRI of the liver, abdomen, colonography and rectum in one session combined with CT thorax
10001084|NCT01544452|Other|Standard diagnostic evaluation|Standard preoperative diagnostic evaluation for patients with rectal cancer, incl. CT thorax, abdomen and MRI of the rectum and colonoscopy
10001085|NCT01544465|Experimental|Structured physical activity|Rehabilitation evaluation followed by physical therapy for approximately 8 weeks
10001086|NCT01544465|Active Comparator|Sleep hygiene education|Sleep hygiene education consists of educational materials on insomnia published by the American Academy of Sleep Medicine.
10001087|NCT01544504|Experimental|Norepinephrine|Topical norepinephrine
10001088|NCT01544517|Experimental|5d-QCT|5-day eradication regimen consisting in the concomitant administration of esomeprazole 40mg bid + amoxicillin 1g bid + levofloxacin 500mg bid + tinidazole 500mg bid
10001089|NCT01544517|Active Comparator|10-day sequential regimen|5 days of esomeprazole 40mg bid + amoxicillin 40mg bid followed by 5 more days of esomeprazole 40mg bid + levofloxacin 500mg bid + tinidazole 500 mg bid
10001090|NCT01544530|Experimental|Hypothermia (32-33 degree C)|Following randomization, hypothermia will be induced by a combination of cold isotonic fluid and sustained until organ procurement by a central venous catheter
10001091|NCT01544530|No Intervention|Normothermia (36.5 - 37.5 degree C)|Normothermia will be maintained until organ procurement as per current standard of care
10001092|NCT01544543||COPD Exacerbation Cohort|Patients hospitalized for a COPD exacerbation
10001093|NCT01544556||Prineo|An open, prospective, controlled, randomized clinical Study
10214489|NCT05201664||Surgical Extrusion|Patients who receive surgical extrusion treatment in maxillary premolars.
10214490|NCT05201508|Active Comparator|Sutures only|Traditional suture closure of hiatal defect
9940388|NCT00987532|Experimental|parent intervention plus gym lessons|Parent-focused participatory preschool intervention in addition to twice weekly gym lessons over 6 months. The participatory intervention includes parents, teachers and children.
9940389|NCT00987532|Active Comparator|gym lessons only|Twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
9940390|NCT00987571||Carpal Tunnel patients|These patients have documented carpal tunnel syndrome
9940391|NCT00987571||Normal Subjects|These individuals have no carpal tunnel syndrome
9940392|NCT00987597|Experimental|cognitive behavioural approach|specific technique of cigarette exposure and nicotinic treatment adjustment
9940393|NCT00987597|Active Comparator|usual approach|recommendations and nicotinic substitutes
9940394|NCT00987610|Active Comparator|slender guidewire|Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less
9940395|NCT00987610|Active Comparator|normal guidewire|Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch
9940396|NCT00987636|Experimental|R1|Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume <200 mL compared to no add-on treatment.
9940397|NCT00987636|Experimental|R2|High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm).
9940398|NCT00987636|Experimental|R3|Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease.
9940399|NCT00987662|Active Comparator|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add HCZ 12.5 mg.
9940400|NCT00987662|Active Comparator|Amplodipine|Treatment with amlodipine 10 mg for 4 weeks. If BP>135/85 mmHg add hydrochlorothiazide 12.5 mg
9940401|NCT00987688|Experimental|Hypothermia|Early and sustained hypothermia.
9940402|NCT00987688|No Intervention|Normothermia|Standard management
9940403|NCT00987701|Active Comparator|Crystalloid resuscitation|Crystalloid (Ringer's lactate) will be delivered before (15min) or after (15min) neuraxial anesthesia
10214491|NCT05201508|Experimental|Polyglactin mesh|In addition to traditional sutures, key hole polyglactin mesh for hiatal defect closure.
10214492|NCT05199974|Active Comparator|Group A: Linea alba was closed with conventional continuous technique .|Group A: 25 patients included . Linea alba will be closed with conventional continuous technique .
10214493|NCT05199974|Active Comparator|Group B: Linea alba was closed with Modified Smead Jones technique with Far-near near-far technique.|Group B:25 patients included. Linea alba will be closed with Modified Smead jones technique with Far-near near-far technique.
10214494|NCT05199064||Chronic refractory migraine patients|25 patients who were diagnosed as having chronic refractory migraine and were refractory to conventional treatments, such as oral medications, GONB,and botulinum toxin injection were evaluated.All patients received pulsed RFtherapy to the GON from the proximal (C2) level in the pain clinic between September 2020 and September 2021.
10214495|NCT05197530|Experimental|Early RA (<1 year of disease)|In this single center study, early RA subjects (<1 year of disease) who are MTX inadequate responders or experience a flare (see inclusion criteria for detail) on MTX and are starting an anti-TNF therapy will be invited to participate to receive ICG injections at Baseline (prior to the start of medication), week 16 and week 52. NIR-ICG imaging will be done immediately post injection and 1 week later for a total of three injection/imaging visits and three imaging visits without injections. See schedule of events for more detail. Total length of participation will be up to 53 weeks (+3days).
10214496|NCT05197530|Experimental|Established RA (> 10 years of disease)|Patients with symptomatic established RA (>10 years) will be invited to participate in an ICG injections followed by NIR-ICG imaging and NIR-ICG imaging visit 1 week later. Total length of participation will be up to 1 week (+3 days)
10214497|NCT05197348|Experimental|Meaning-Centered Group Psychotherapy (MCP).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis. The investigators will follow the manualized MCP for patients with advanced cancer.
10214498|NCT05197348|Active Comparator|Cognitive Behavioral Psychotherapy (CBT).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis, with the following sessions. The investigators will follow the manualized CBT or patients with advanced cancer.
10214499|NCT05197322|Other|Tumour Mutation Burden high or medium (or MSI-High)|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test should be available and patients will continue their treatment as follows:~TMB-high (defined as ≥20 mutations per Mb) or medium (defined as 6-19 mutations per Mb); FOUNDATIONONE®CDx (or MSI-H if FM1 test is not evaluable):~A further two cycles of pembrolizumab 200 mg IV every 21 days~Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
10214500|NCT05197322|Other|Tumour Mutation Burden low or unevaluable|"Patients will one cycle of pembrolizumab 200 mg IV (a cycle is 21 days). Prior to cycle 2 the result of the FOUNDATIONONE®CDx test should be available and patients will continue their treatment as follows:~TMB-low (defined as ≤5 mutations per Mb); FOUNDATIONONE®CDx (or if FM1 test and PCR are not evaluable):~• Planned surgery to remove the CRC 4 - 6 weeks after last dose of pembrolizumab"
10214501|NCT05196074||Acute hypoxemic respiratory failure patients on VV-ECMO|
10214502|NCT05195697||Mild acute pancreatitis|Patients treated with mild acute pancreatitis during the study period
10214503|NCT05195697||Moderate acute pancreatitis|Patients treated with moderate acute pancreatitis during the study period
10214504|NCT05195697||Severe acute pancreatitis|Patients treated with severe acute pancreatitis during the study period
10001094|NCT01544556||Steristrips|An open, prospective, controlled, randomized clinical Study
10001095|NCT01544608||Subjects who are hospitalized due to acute psychotic episode.|All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
9476209|NCT03574194|Experimental|Methionine-restricted diet|6-10 weeks methionine-restricted diet (MRD) curative intent radiation therapy course of 6 weeks or less.
10001096|NCT01544621||Successful quitters Sustained smokers|Successful quitters
10001097|NCT01544634|Experimental|Propranolol + Low dose Qvar|
10001098|NCT01544634|Active Comparator|Placebo + high dose Qvar|
10001099|NCT01544647|Active Comparator|Usual spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
10001100|NCT01544647|Active Comparator|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
10001101|NCT01544660||Scanning|no treatment
10001102|NCT01544660||scanning|no treatment
10001103|NCT01544673|Active Comparator|Arm A|
10001104|NCT01544673|Placebo Comparator|Arm B|
10001105|NCT01544686|Active Comparator|3M™ Tegaderm CHG IV|Patients receive the 3M Tegaderm CHG IV securement dressing after placement of a central venous catheter.
10001106|NCT01544686|Placebo Comparator|3M™ Tegaderm™ Advanced IV'|Patients receive the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
10001107|NCT01544699|Active Comparator|Real stimulation|real tDCS (well, that's the way it is I am not gonna change it)
10001108|NCT01544699|Sham Comparator|Sham|sham tDCS
10001109|NCT01544712|Active Comparator|Control|Core decompression
10001110|NCT01544712|Experimental|Bone marrow|core decompression plus autologous concentrated bone marrow
10001111|NCT01544725|Experimental|Ketamine-propofol|
10001112|NCT01544725|Active Comparator|Ketamine alone|
10001113|NCT01544738|Experimental|Aponeurotic stimulation group|The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the trunk and upper limb muscles.
10001114|NCT01544738|Active Comparator|Placebo stimulation group|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the Aponeurotic stimulation group.
10001115|NCT01544751|Active Comparator|Low dose Metformin|500 mg twice a day for one year
10001116|NCT01544751|Active Comparator|Metformin|1000 mg twice a day for one year
10001117|NCT01544751|Active Comparator|Atorvastatin|20 mg day
10001118|NCT01544764|No Intervention|Control|This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
10001119|NCT01544764|Experimental|AFIX In-Person Visit|"This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
10001120|NCT01544764|Experimental|AFIX Webinar Visit|"This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
10001121|NCT01544777|Experimental|Both Eyes|Model 751 IOL implanted in both eyes.
10001122|NCT01544777|Experimental|Single eye|Model 751 IOL in one eye
10001123|NCT01544777|Active Comparator|Control|Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
10001124|NCT01544790|Experimental|Robot-assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
10001125|NCT01544790|Active Comparator|Open transthoracic esophagectomy|traditional open transthoracic esophagectomy with gastric conduit formation.
10001126|NCT01544803|No Intervention|Control group|
10001127|NCT01544803|Experimental|Web based self-monitoring|
10001128|NCT01544803|Active Comparator|Web based self-help|
10001129|NCT01544816|Placebo Comparator|Control Food Product|Control food product
10001130|NCT01544816|Experimental|Experimental Food Product 1|Experimental food product 1
10001131|NCT01544816|Experimental|Experimental Food Product 2|Experimental food product 2
10001132|NCT01544829|Active Comparator|Active Comparator: Single serving of theobromine|
10001133|NCT01544829|Active Comparator|Multiple servings of theobromine|
10001134|NCT01544829|Placebo Comparator|Placebo capsules|
10001135|NCT01544842|Active Comparator|Tacrolimus|Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
10001136|NCT01544842|Active Comparator|Triamcinolone|Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
10001137|NCT01544842|Placebo Comparator|Placebo|Orabase paste, three times a day for 3-6 weeks.
10001138|NCT01544855|Experimental|APOE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
10001139|NCT01544868|Other|Energy expenditure measurement|Descriptive measurements
10001140|NCT01544881|Experimental|TI Inhalation Powder|Technosphere Insulin Inhalation Powder using the Gen2C inhaler
10001141|NCT01544881|Active Comparator|RAA|Rapid Acting Analog
10001142|NCT01544894|Active Comparator|raloxifene|60 mg/d for one year.
10001143|NCT01544894|Active Comparator|strontium ranelate|2 g/d for one year.
10001144|NCT01544907|Active Comparator|Conventional PTA only|"Treatment Arm 1- Conventional PTA only~The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.~An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.~At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of >30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation."
10001145|NCT01544907|Experimental|Drug Eluting Balloon (DEB)|"Treatment arm 2 - Conventional Balloon with DEB~A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel."
10035034|NCT01802463||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
10035035|NCT01802463||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
10035036|NCT01802463||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
10035037|NCT01802476|Other|Fixed Sequence Crossover Arm|This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
10035038|NCT01802489|Active Comparator|Amiloride|Amiloride capsules 10mg once per day for 5 months
10035039|NCT01802489|Placebo Comparator|Placebo|Placebo capsules one per day for 5 months
10035040|NCT01802502|Active Comparator|Rifampicin 600 mg|Subjects in this arm receive 600 mg rifampicin intravenously
10035041|NCT01802502|Experimental|rifampicin 750 mg|Subjects in this arm receive 750 mg rifampicin orally
10035042|NCT01802502|Experimental|rifampicin 900 mg|Subjects in this arm receive rifampicin 900 mg orally
10035043|NCT01802528||Obturator externus muscle injection|patients were treated with obturator externus injection
10035044|NCT01802541|Experimental|DAG oil|
10035045|NCT01802541|Placebo Comparator|TAG oil|
10035046|NCT01802593|Experimental|Immunomodulator therapy 26 weeks|IFX 5mg/kg for 76 weeks, continuing immunomodulator for 6 months from first infusion
10035047|NCT01802593|Experimental|Immunomodulator therapy 2 weeks|IFX 5mg/kg induction for 76 weeks, discontinuing immunomodulator on day of second infusion( after 14 days).
10035048|NCT01802619|Placebo Comparator|inhaled nitrogen|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, pure nitrogen (placebo) is mixed with pure O2 or air. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the NO is delivered through the inspiratory limb of the anesthetic or ventilator circuit.
10035049|NCT01802619|Experimental|inhaled nitric oxide|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, 800 ppm NO gas is mixed with pure O2 or air to obtain a final concentration of 80 ppm NO. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the gas is delivered through the inspiratory limb of the anesthetic or ventilator circuit. NO, NO2 and O2 and methemoglobin levels are monitored by an unblinded observer.
10035050|NCT01802645|Active Comparator|Cetuximab/FOLFIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
10035051|NCT01802645|Experimental|Cetuximab/FOLFOXIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
10035052|NCT01802645|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
10035053|NCT01802645|Experimental|Bevacizumab/FOLFOXIRI|"Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
10035054|NCT01802658|Active Comparator|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
10035055|NCT01802658|Placebo Comparator|NACL|NACl 100 ml IV. 3 infusions. Administration 3 times over two years.
10001146|NCT01544933||burst fractures in vertebrae with true ribs|between T1 and T10
10001147|NCT01544933||burst fractures in vertebrae with floating ribs|between T11 and T12
10001148|NCT01544946|Experimental|sucrose po|
10001149|NCT01544946|Placebo Comparator|placebo po|
10001150|NCT01544959|Active Comparator|fentanyl|
10001151|NCT01544959|Experimental|beta-blocker|Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
10001152|NCT01544972|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days
10001153|NCT01544972|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
10001154|NCT01544985|Experimental|sucrose po|88% sucrose solution (Syrup B.P.)
10001155|NCT01544985|Placebo Comparator|placebo po|sterile water
10001156|NCT01545011|No Intervention|standard|conventional respiratory rehabilitation
10001157|NCT01545011|Experimental|IMT|Inspiratory muscle training and conventional respiratory rehabilitation
10001158|NCT01545024||DPP-IV inhibitor|
10001159|NCT01545037|Active Comparator|Probiotic capsules|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.
10001160|NCT01545037|Placebo Comparator|Placebo capsules|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks
10001161|NCT01545050|Experimental|Induction Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
10001162|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(600 IV/200 SC mg)|
10001163|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(300 IV/100 SC mg)|
10001164|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(150 IV/100 SC mg)|
10001165|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(400 SC/200 SC mg)|
10001166|NCT01545050|Experimental|Maintenance Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
10001167|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(100 SC mg)|
10001168|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
10001169|NCT01545050|Experimental|Open Label Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
9476210|NCT03574168|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
10001170|NCT01545089|Experimental|Mattress protector days 1,2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
10001171|NCT01545089|Experimental|Mattress protector days 3,4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
9528368|NCT03211650|Active Comparator|hyaluronic acid|Intra-articular injections of hyaluronic acid
10001172|NCT01545154||Prostate Cancer|
10001173|NCT01545167||African Americans with pancreatitis|pancreatitis
10001174|NCT01545167||African Americans without Pancreatitis controls|people without pancreatitis
10001175|NCT01545180||HTPcap in IC|HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
10001176|NCT01545206||acute STEMI, Primpary PCI|
10001177|NCT01545219|Experimental|Prebiotic|
10001178|NCT01545219|Experimental|Probiotic|
10001179|NCT01545219|Experimental|Synbiotic|
10001180|NCT01545219|Placebo Comparator|Placebo|
10001181|NCT01545245||Treated|Palivizumab treated
10001182|NCT01545245||Untreated|Palivizumab untreated
10001183|NCT01545258|Experimental|Exercise|Exercise training supervised by trained physiotherapists lasting 60 minutes performed 3 times/week.
10001184|NCT01545258|No Intervention|Control|
10001185|NCT01545271|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
10001186|NCT01545271|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
10001187|NCT01545284|Experimental|Acitretin|Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
10001188|NCT01545297|Active Comparator|Propofol-Remifentanil|Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
10214505|NCT05195697||Acute gastrointestinal bleeding|Patients treated with acute gastrointestinal bleeding during the study period
10214506|NCT05195697||Perforated ulcer|Patients treated with perforated ulcer during the study period
10214507|NCT05195697||Older than 70 years|Patients older than 70 years
10214508|NCT05195697||Less than 70 years|Patients younger than 70 years
10214509|NCT05195697||Prothrombotic medications|Patients on prothrombotic medications
10214510|NCT05195697||Frail patients|Patients with increased frailty score
10214511|NCT05195697||Reintervention group|Patients in need of reintervention
10214512|NCT05194124|Experimental|Setmelanotide subcutaneous injection Weekly 20 mg|Patients on 2mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period, and all will be assigned to this arm in the open label period.
10214513|NCT05194124|Experimental|Setmelanotide subcutaneous injection Weekly 30 mg|Patients on 3mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period, and all will be assigned to this arm in the open label period.
10214514|NCT05194124|Experimental|Setmelanotide subcutaneous injection Daily 2 mg|Patients on 2mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period.
9940404|NCT00987701|Active Comparator|Colloid resuscitation|Colloid (6% hydroxyethyl starch ) will be delivered before (15min) or after (15min) neuraxial anesthesia
9940405|NCT00987714|Experimental|Protocolized Care|Algorithm to manage Pulse Pressure Variation, Cardiac Index, and Mean Arterial Pressure will be used in these donors.
9940406|NCT00987714|No Intervention|Standard Care|This is the Organ Procurement Organization current practices.
9940407|NCT00987740|Experimental|Hemolung Respiratory Assist System|
9940408|NCT00987753|Experimental|infusion of L-377202|
9940409|NCT00987766|Experimental|Treatment|Gemcitabine + Oxaliplatin + Erlotinib
9940410|NCT00987779|Experimental|Period I: Tablet(400 mg single dose)|Period I: Tablet in fasting state, Period II: Liquid formulation in fasting state, Period III: Liquid formulation in fed state
9940411|NCT00987779|Experimental|Period I: Liquid formulation(400 mg single dose)|Period I: Liquid formulation in fasting state, Period II: Tablet in fasting state, Period III: Liquid formulation in fed state
9940412|NCT00987792||Group 1|
9940413|NCT00987805|Experimental|Banhasasim-tang|
9940414|NCT00987805|Placebo Comparator|Placebo drug|The placebo of this study is corn-starch granules. It has the same form, color, flavor and amount like experimental herbal extracted formula
9940415|NCT00987818|Experimental|PCT guided antibiotic therapy|
9940416|NCT00987818|Placebo Comparator|Standard antibiotic therapy|
9940417|NCT00987857|Active Comparator|2 yearly endoscopies|Two years endoscopies
9940418|NCT00987857|Experimental|endoscopy at need|Endoscopy only when patient reports symptoms
9940419|NCT00987870|Experimental|BFH772 cream 1%|
9940420|NCT00987870|Placebo Comparator|Placebo to BFH772 cream 1%|
9940421|NCT00987870|Experimental|BFH772 ointment 1%|
9940422|NCT00987870|Placebo Comparator|Placebo to BFH772 ointment|
9940423|NCT00987870|Active Comparator|calcipotriol/betamethasone ointment|
9940424|NCT00987883||Malnutrition cohort|The patients with undernutrition
9940425|NCT00987883||Well nourished cohort|Patient that well nourished and without undernutrition
9940426|NCT00987896|Experimental|Megachannel Application|Colonoscopy with loaded Megachannel is performed
9940427|NCT00987909|Placebo Comparator|Placebo|Solution resembling the active solutions, but without allergen extract
9940428|NCT00987909|Experimental|Cat hair allergen extract, dose group 1|
9940429|NCT00987909|Experimental|Cat hair allergen extract, dose group 2|
9940430|NCT00987909|Experimental|Cat hair allergen extract, dose group 3|
9940431|NCT00987922|Experimental|Hypothermia|
9940432|NCT00987922|No Intervention|Control|
9940433|NCT00987961|No Intervention|Treatment as usual|Participants in this arm will receive the standard detox treatment for individuals hospitalized with opioid dependence.
9940434|NCT00987961|Experimental|Linkage|Participants in this arm will receive a maintenance schedule of Suboxone during their hospital stay, and an appointment with an outpatient Suboxone provider for after their discharge.
9940435|NCT00987974|Experimental|rosuvastatin 3days|8 Subjects will use rosuvastatin 20 mg/day for 3 days
9940436|NCT00987974|Active Comparator|atorvastatin 3 days|8 Subjects will use atorvastatin 80 mg/day for 3 days.pj
9940437|NCT00987974|Placebo Comparator|placebo 3days|8 Subjects will use placebo for 3 days.
9940438|NCT00987974|Experimental|rosuvastatin 7 days|8 Subjects will use rosuvastatin 20 mg/day for 7 days.
9940439|NCT00987974|Active Comparator|atorvastatin 7 days|8 Subjects will use atorvastatin 80 mg/day for 7 days.
9940440|NCT00987974|Placebo Comparator|placebo 7 days|8 Subjects will use placebo for 7 days.
9940441|NCT00987987|Experimental|1|1
9940442|NCT00988026|Experimental|Minocycline 100 mg|Minocycline
9940443|NCT00988026|Active Comparator|Lymecycline 300 mg|Group B: Lymecycline
9940444|NCT00988039|Active Comparator|bPI + 2NRTIs|
9940445|NCT00988039|Experimental|bPI + raltegravir|
9940446|NCT00988039|Experimental|bPI monotherapy|
9940447|NCT00988078|Experimental|Metformin|Metformin 500mg three times a day for six months
9528369|NCT03211559|Active Comparator|AEROBİC EXERCİSE (walking on treadmill)|Patients walked on treadmill for 8 weeks, 3 days in a week,30-40 minutes each.
9940448|NCT00988078|Placebo Comparator|Placebo|1 capsule three times a day for six months
9940449|NCT00988104|Active Comparator|Cognitive Behavioral Therapy|
9940450|NCT00988104|Active Comparator|Supportive Counseling|
9940451|NCT00988182|Experimental|whey protein, 5g|
9940452|NCT00988182|Experimental|whey protein, 10g|
9940453|NCT00988182|Experimental|whey protein, 20g|
9940454|NCT00988182|Experimental|whey protein, 40g|
9940455|NCT00988182|Experimental|water control|
9940456|NCT00988195|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
9940457|NCT00988234|Experimental|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
9940458|NCT00988234|Experimental|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
9940459|NCT00988234|Experimental|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
9940460|NCT00988234|Experimental|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
9940461|NCT00988273||Control|In patients undergoing endoscopy for indications other than Crohn's disease or ulcerative colitis
9940462|NCT00988273||Diseased group|Patients with Crohn's disease or ulcerative colitis undergoing endoscopy.
9940463|NCT00988286|Experimental|CEP|
9940464|NCT00988312|Experimental|s.c. vaccination|vaccine given subcutaneously
9940465|NCT00988312|Experimental|i.v. vaccination|vaccines are given intravenously
9940466|NCT00988338||Trinity Evolution|
9940467|NCT00988364|Active Comparator|Ezetimibe|Randomly chosen participants will receive ezetimibe 10mg daily for 3 months.
9940468|NCT00988364|Active Comparator|Simvastatin|Randomly chosen participants will receive Simvastatin 20mg daily for 3 months.
9940469|NCT00988364|Active Comparator|Vytorin|Randomly chosen participants will receive Vytorin 20/10mg daily for 3 months.
9940470|NCT00988364|Placebo Comparator|Placebo|Randomly chosen participants will receive Placebo tab 1 daily for 3 months.
9940471|NCT00988377|Experimental|10 g whey protein|
9940472|NCT00988377|Experimental|20 g whey protein|
9940473|NCT00988377|Experimental|30 g whey protein|
9940474|NCT00988377|Experimental|40 g whey protein|
9940475|NCT00988377|Experimental|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
9940476|NCT00988390|Other|Intervention, mothers living with HIV|Mothers living with HIV, Cognitive-behavioral intervention delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions)
9940477|NCT00988390|No Intervention|Control, mothers living with HIV|Mothers living with HIV, offered intervention at end of study (18 months after recruitment)
9940478|NCT00988390|No Intervention|Control, non-HIV-infected mothers|Neighborhood control mothers not infected with HIV, did not receive any intervention
9940479|NCT00988403|Experimental|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
9940480|NCT00988403|Experimental|Fructan - 10 grams|Subjects will consume 10 grams of fructan
9940481|NCT00988403|Experimental|Fructan - 12.5 grams|Subjects will consume 12.5 grams of fructan
9940482|NCT00988403|Experimental|5 grams Fructan|"Experimental - 5 grams Fructan~Subjects will consume 5 grams of Fructan."
9940483|NCT00988455|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
9940484|NCT00988468|Experimental|Manual Therapy|Subjects will receive oscillatory (grade 1 & 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
9940485|NCT00988468|Experimental|Therapeutic Exercise|Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
9940486|NCT00988468|Placebo Comparator|Control|Subjects will watch a 15 minute instructional video on a health topic.
9940487|NCT00988494|Experimental|High concentration|DE-105 high concentration
9940488|NCT00988494|Experimental|Low concentration|DE-105 low concentration
9940489|NCT00988494|Placebo Comparator|Placebo|DE-105 placebo
9940490|NCT00988507|Experimental|Ferroquine high dose + artesunate|Ferroquine at 6 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
9940491|NCT00988507|Experimental|Ferroquine medium dose + artesunate|Ferroquine at 4 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
9940492|NCT00988507|Experimental|Ferroquine low dose + artesunate|Ferroquine at 2 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
9940493|NCT00988507|Experimental|Ferroquine alone at medium dose|Ferroquine at 4 mg/kg/d OD alone for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
9940494|NCT00988520|Experimental|0.6 mg/kg intubation dose under sevoflurane|
9940495|NCT00988520|Experimental|0.9 mg/kg intubation dose under sevoflurane|
9940496|NCT00988520|Experimental|continuous dose following 0.6 mg/kg intubation dose + propofol|
9940497|NCT00988520|Experimental|continuous dose following 0.9 mg/kg intubation dose + propofol|
9940498|NCT00988546|Other|1|exam documentation performed using dictation
9940499|NCT00988546|Experimental|2|exam documentation performed using computer based template
9940500|NCT00988572|Experimental|Intervention group|Vestibular rehabilitation, twice a week for 9 weeks
9940501|NCT00988572|No Intervention|Control group|The patients in the control group does nothing, except for normal treatment for their wrist fracture.
9940502|NCT00988585|Placebo Comparator|Olive Oil|Olive Oil 600 mg/day
9940503|NCT00988585|Active Comparator|EPA 1800|1800 mg/day
9940504|NCT00988585|Active Comparator|DHA|DHA 600 mg/day
9940505|NCT00988585|Active Comparator|EPA 600|EPA 600 mg/day
9940506|NCT00988624|Experimental|Period 1|
9940507|NCT00988624|Experimental|Period 2|
9940508|NCT00988624|Experimental|Period 3|
9940509|NCT00988624|Experimental|Period 4|
9940510|NCT00988624|Experimental|Period 5|
9940511|NCT00988650|Active Comparator|North American diet|Control North American diet for five weeks in isocaloric conditions
9940512|NCT00988650|Experimental|Mediterranean diet|Mediterranean diet for five weeks in isocaloric conditions
9940513|NCT00988650|Experimental|weight loss period|Weight loss period of 20-week (minimum 5% reduction in body weight)
9940514|NCT00988650|Active Comparator|Weight stabilizing mediterranean diet|Mediterranean diet for five weeks in isocaloric weight stabilizing conditions
9940515|NCT00988663|Active Comparator|Memantine arm|Patient receiving ECT and Memantine
9940516|NCT00988663|Placebo Comparator|placebo|25 patients receiving ECT will will receive placebo
9940517|NCT00988676||colonoscopy|
9940518|NCT00988689|Experimental|Soup with no added starch|
9940519|NCT00988689|Experimental|Soup + 50 g of whole grain starch|
9940520|NCT00988689|Experimental|Soup + 50 g of high amylose corn starch|
9940521|NCT00988689|Experimental|Soup + 50 g of regular corn starch|
9940522|NCT00988689|Experimental|Soup + 50 g maltodextrin starch|
9940523|NCT00988702|Experimental|Dan Tian Breathing|subjects received one-month's training on the Dan Tian Breathing
9940524|NCT00988702|Active Comparator|Progressive muscle relaxation training|Subjects received one-month's conventional progressive muscle relaxation training
9940525|NCT00988715|Experimental|Treatment (PRIT, transplant)|Patients undergo pretargeted radioimmunotherapy comprising a test dose of BC8-SA conjugate IV on day -22 and 111In-DOTA-biotin IV on day -20, followed by a therapy dose of BC8-SA conjugate IV on day -14 and 90Y-DOTA-biotin IV on day -12. Patients receive fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and then peripheral blood stem cell transplant on day 0. Patients with matched related donors receive cyclosporine IV on days -3 to 56 and taper to day 180 and mycophenolate mofetil PO BID on days 0-27. Patients with matched unrelated donors receive cyclosporine IV on days -3 to 100 and taper to day 180 and mycophenolate mofetil PO TID on days 0-40 and taper to day 96.
9940526|NCT00988728|Experimental|SCH 900435|SCH 900435 (Org 25935): a Glycine Uptake Inhibitor
9940527|NCT00988728|Placebo Comparator|Placebo|
9940528|NCT00988728|Active Comparator|Olanzapine|
9940529|NCT00988754|Active Comparator|A|Medical examination once per year, school and family-based lifestyle intervention including a weekly health lesson, school-affiliation to sports clubs and regularly trainings for teachers and parents
9940530|NCT00988754|No Intervention|B|Medical examination and information on a healthy lifestyle.
9940531|NCT00988767|Experimental|intramuscular injections|Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10
9940532|NCT00988780|Experimental|Maraviroc|"Maraviroc 600mg po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID"
9940533|NCT00988780|Placebo Comparator|Placebo|"Placebo po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID"
9940534|NCT00988793|Active Comparator|Laparoscopic distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
9940535|NCT00988793|Active Comparator|Open distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
9940536|NCT00988806|Active Comparator|Levosimendan|infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours.
9940537|NCT00988806|Placebo Comparator|Placebo|infusion of placebo for 24 hours.
9940538|NCT00988819||No treatment|
9940539|NCT00988845|Experimental|Indole-3-carbinol|
9940540|NCT00988871||Liver transplantation (LT) recipients|LT recipients who had both PICC and CICC at the same time according to the LT protocol of our hospital
9528370|NCT03211559|Experimental|Aerobic Exercise+Clinical Pilates|Patients walked on treamill for 8 weeks, 3 days in a week, 30-40 minutes each. Additionally they did clinical pilates exercise for 8 weeks, 3 days in a week.
9940541|NCT00988897|Experimental|1|"Patients will receive modified FOLFOX-6 regimen:~oxaliplatin 85mg/m2, day 1 (given as a 2-hour infusion)~LV 400mg/m2, day 1 (given as a 2-hour infusion simultaneous to oxaliplatin)~5-FU given as a bolus IV 400mg/m2 dose on day 1 followed by 2400mg/m2 continuous infusion over 46 hours (day 1 and 2)~A cycle is defined as 2 weeks. Patients will receive cycles of modified FOLFOX-6 regimen every 2 weeks up to a maximum of 8 cycles. Use of bevacizumab is at the discretion of the treating physician."
9940542|NCT00988910||Group 1|
9940543|NCT00988910||Group 2|
9940544|NCT00988923|Experimental|group a: Hyperthermia (HT)|HT were treated for 20 minutes per session, a total of 8 sessions with device;
9940545|NCT00988923|No Intervention|group b: No intervention|device was switched in off, only bolus was active
9940546|NCT00988936|Experimental|[F-18]RDG-K5|
9940547|NCT00988949|Experimental|PF-04455242 18 mg|Subjects in this arm will receive a single 18 mg oral dose of PF-04455242 prior to spiradoline challenge
9940548|NCT00988949|Placebo Comparator|Placebo|Subjects in this arm will receive placebo prior to spiradoline challenge.
9940549|NCT00988949|Experimental|PF-04455242 30 mg|Subjects in this arm will receive a single 30 mg oral dose of PF-04455242 prior to spiradoline challenge.
9940550|NCT00988962|No Intervention|High-Risk No Treatment|
9940551|NCT00988962|Experimental|High-Risk Treatment|
9940552|NCT00988962|No Intervention|Low-Risk|
9940553|NCT00988975|Active Comparator|Pelvicol graft|
9940554|NCT00988975|No Intervention|No graft material|No graft material
9940555|NCT00988988|Active Comparator|Steroid Cream|1% steroid cream
9940556|NCT00988988|Active Comparator|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled
9940557|NCT00988988|Active Comparator|placebo|inactive cream
9940558|NCT00989027|No Intervention|No treatment|A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
9940559|NCT00989027|Active Comparator|Treatment|Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.
9940560|NCT00989053|Active Comparator|escitalopram|
9940561|NCT00989053|Placebo Comparator|placebo|
10001189|NCT01545297|Experimental|Dexmedetomidine|Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
10001190|NCT01545310|Experimental|Group 1 (healthy), Group 2 (schizophrenia)|
10001191|NCT01545323|Experimental|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
10001192|NCT01545349|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to subjects with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
10001193|NCT01545349|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
9940562|NCT00989079|Experimental|Cohort 1 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
9940563|NCT00989079|Experimental|Cohort 1 Sequence 2|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
9940564|NCT00989079|Experimental|Cohort 1 Sequence 3|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
9940565|NCT00989079|Experimental|Cohort 2 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
9940566|NCT00989079|Experimental|Cohort 2 Sequence 2|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
9480641|NCT05262322||Subset of All Participants (Group 2; Prospective)|A subset of participants from Group 1 who were initiated on apixaban, edoxaban or rivaroxaban for secondary prophylaxis of stroke will take part in this prospective component of the study, whereby data on their management pathway (treatments and follow-up appointments) and patient-reported outcomes will be collected for 6 months from the date of first dose of DOAC treatment.
9480642|NCT05262309|Experimental|Pamrevlumab|
9940567|NCT00989079|Experimental|Cohort 2 Sequence 3|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.
9480643|NCT05262309|No Intervention|Standard of care|
9940568|NCT00989118|Experimental|Laser treatment|
9940569|NCT00989118|Active Comparator|Endometrioma cystectomy|
9940570|NCT00989131|Experimental|Paclitaxel, micellar (Paclical®)|
9940571|NCT00989131|Active Comparator|Paclitaxel, CrEL (Taxol®)|
9940572|NCT00989170|Experimental|Family Program for the Prevention of Weight Gain|Use of an enhanced Family Program on the prevention of weight gain in families with overweight children.
9940573|NCT00989170|Active Comparator|No enhanced Family Program|
9940574|NCT00989209|Active Comparator|A: myofunctional prior to botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group A, botulinum toxin was applied after myofunctional therapy.
9940575|NCT00989209|Active Comparator|B: myofunctional after botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group B, botulinum toxin was applied before myofunctional therapy.
9940576|NCT00989222|Other|Volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
9940577|NCT00989222|Other|External fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
9940578|NCT00989248|Experimental|comparation VE/VO2 and VE/VCO2|
9940579|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 15 ug & trivalent|120 participants selected by random
9940580|NCT00989274|Active Comparator|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|120 participants selected in random form
9940581|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 7.5 ug|120 participants selected in random form
9940582|NCT00989300|Experimental|Treatment group|patients received clopidogrel 75 mg with rabeprazole 20 mg, omeprazole 20 mg, or placebo in a crossover manner
9940583|NCT00989300|Placebo Comparator|Placebo group|
9940584|NCT00989313||1|
9940585|NCT00989326|Active Comparator|CONTROL group|The patients receive standard of care for 18 months. The CONTROL group patients will be equipped with Home Monitoring. However, the Home Monitoring data will not be used for patient surveillance; i. e. the patient will be followed in the conventional manner.
9940586|NCT00989326|Experimental|ACTIVE group|The patients are followed by Home monitoring only. Every patient must be seen by his physician 18 months after enrolment for regular follow-up. Within this period, the additional Pace Maker follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception or patient/physician call
9940587|NCT00989339|Experimental|Twenty-four Hour TPN and Saline Infusion|Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.
9940588|NCT00989365|Other|Patient cousenling|Improve medicine use Self control asthma crisis Ambient hygiene
9940589|NCT00989378||control|normal healthy men and women
9940590|NCT00989391|Experimental|Cohort 1|Subjects will be assigned to receive either PF-03654764 or placebo.
9940591|NCT00989391|Experimental|Cohort 2|Subjects will be assigned to receive either PF-03654764 or placebo.
10001194|NCT01545362||Staged bilateral total knee arthroplasty|Patients that have bilateral total knee arthroplasty staged within one week
10001195|NCT01545401|Experimental|EMPOWER-PAR Intervention|"The intervention arm receives the EMPOWER-PAR intervention package consisting of:~Chronic Disease Management (CDM) Training Workshops for the staff in the respective clinics~The Global CV Risks Self-Management Booklet (patient self-management tool) to empower patients to self-manage their CV risk factors~Facilitation and support of the staff in these clinics so that they may implement the interventions"
10001196|NCT01545401|No Intervention|Control|"The control arm continues with usual care.~The EMPOWER-PAR intervention package will be made available after the trial ends."
10001197|NCT01545414|Experimental|ICBT|Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
10001198|NCT01545414|Active Comparator|ICONTROL|Internet-based treatment with a focus on relaxation training
10001199|NCT01545414|No Intervention|SMT|Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments
10001200|NCT01545427|Experimental|Gleevec|Gleevec 200 mg bid for 6 months.
10001201|NCT01545427|Placebo Comparator|Placebo|Placebo coated to appear identical to Gleevec.
10001202|NCT01545440|Experimental|lebrikizumab - highest dose|
10001203|NCT01545440|Experimental|lebrikizumab - lowest dose|
10001204|NCT01545440|Experimental|lebrikizumab - middle dose|
10001205|NCT01545440|Placebo Comparator|placebo|
10001206|NCT01545466|Experimental|Mindfulness Based Stress Reduction|Participants will complete an 8 week course in Mindfulness Based Stress Reduction (MBSR), meeting once/week for 8 weeks and having a 4-6 hour retreat after the 6th class
10001207|NCT01545466|No Intervention|Wait-List Control Group|These participants will continue in usual care during the trial and will be offered the intervention of MBSR after the trial is over.
10001208|NCT01545479|Other|Captopril 25mg|To study the renal blood oxygenation, the subjects took captopril (25mg).
10001209|NCT01545492||Tight|"Children born to women in the CHIPS RCT randomized to Tight blood pressure control [target diastolic BP 85mmHg]"
10001210|NCT01545492||Less Tight|"Children born to women in the CHIPS RCT randomized to Less Tight [target diastolic BP 100mmHg]."
10001211|NCT01545505|Other|In remission phase of PTSD|Patients having suffered from PTSD in the past and in remission od PTSD and their parents
10001212|NCT01545505|Other|Activ PTSD|patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
10001213|NCT01545531||Iohexol GFR|
10001214|NCT01545557|Experimental|Hyaluronic acid|
10001215|NCT01545570|Active Comparator|GSK2376497|single dose escalation or multiple-dose titration
10001216|NCT01545570|Placebo Comparator|0.9% sodium chloride|placebo injection
10001217|NCT01545596|Experimental|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
10001218|NCT01545596|No Intervention|No Notification|No additional notification given to anesthesia team apart from the information on their monitors.
10001219|NCT01545609|Experimental|Text messaging|Text messaging
10001220|NCT01545609|No Intervention|No intervention|No intervention
10001221|NCT01545635|Active Comparator|Coagulation factor concentrates|
10001222|NCT01545635|Active Comparator|Fresh Frozen Plasma|
10001223|NCT01545661|Experimental|Sputum induction|Enrolled patients receive sputum induction (using ultrasonic nebulisation with hypertonic saline)
10001224|NCT01545661|Active Comparator|No sputum induction|Enrolled patients randomised to this study arm will receive an observed expectorated sputum collection attempt. Research nurses train study patients on the method of producing sputum spontaneously.
10001225|NCT01545674||Pregnant Women Blood Draw|Pregnant Women with elevated risk of trisomic pregnancy to donate a blood sample through one time blood draw
10001226|NCT01545687|Experimental|Arm I|Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy [RT]) and for 4 weeks after, including weekends.
10001227|NCT01545687|Placebo Comparator|Arm II|Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
10001228|NCT01545713||Renal Transplant Recipients|Patients undergoing living-donor kidney transplant at NMH who have a positive XM-One AbSorber® positive test result.
10001229|NCT01545726|Experimental|QAW039|Eligible patients will receive QAW039 po 450 mg daily dose.
10001230|NCT01545726|Placebo Comparator|Placebo|Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.
10001231|NCT01545739||CRT pacemaker implantation|
10001232|NCT01545752|No Intervention|coventional group|Teaching just by book
10001233|NCT01545752|Experimental|non-interactive CD|Teaching book with non-interactive CD
10001234|NCT01545752|Experimental|interactive CD|Teaching book with interactive CD
10001235|NCT01545778||Tapentadol IR|
10001236|NCT01545778||Oxycodone IR|
10001237|NCT01545791||Insulin detemir users|
10001238|NCT01545804|Experimental|Lenalidomide|
10001239|NCT01545830|Active Comparator|Regular Dose|Intervention: 600 IUs of cholecalciferol taken by mouth daily.
10001240|NCT01545830|Experimental|High Dose D|Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
10001241|NCT01545856||New levodopa users|Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period
10001242|NCT01545869|Experimental|Fractional carbon dioxide laser|
10001243|NCT01545882|Experimental|Degarelix|Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
10001244|NCT01545908|Placebo Comparator|placebo enema|Participants in this arm undergo 6 retention enemas, week 1, week 2, week 3, week 4, week 5, week 6
10001245|NCT01545908|Active Comparator|Fecal transplant from an unrelated donor|Participants in this arm undergo 6 retention enemas,week 1, week 2, week 3, week 4, week 5, week 6,using stool specimen prepared from a healthy, screened donor.
10001246|NCT01545921|Experimental|Arm A|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death"
9940592|NCT00989391|Experimental|Cohort 3|Subjects will be assigned to receive either PF-03654764 or placebo.
9940593|NCT00989404|Experimental|Period|10 mg BID Zanamivir or placebo for 5 days
9940594|NCT00989417|Active Comparator|CONTROL Group - Without Home Monitoring|Patients receiving the standard of care. Due to safety concerns, the patients are followed every 6 months after a first follow-up, which is performed between 1 and 3 months after implantation.
10214515|NCT05194124|Experimental|Setmelanotide subcutaneous injection Daily 3 mg|Patients on 3mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period.
9940595|NCT00989417|Experimental|ACTIVE GROUP With Home Monitoring|After a first follow-up (between 1 and 3 months after implantation), the patients are followed one time per year. Within this period, the additional ICD follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception, Data/IEGM-online analysis on internet site or patient/physician call.
9940596|NCT00989430|Experimental|Prism Adaptation Treatment|Two weeks of prism adaptation treatment followed by 4 weekly assessments and long-term follow-ups at the 3rd and 6th months.
9940597|NCT00989430|No Intervention|Control: Standard Rehabilitation Care|Participants will continue with their standard inpatient rehabilitation care. They will be assessed with cognitive and functional scales for tracking their recovery.
9940598|NCT00989443|Experimental|Cidofovir|
9940599|NCT00989456|Experimental|exercise and education|Supervised physical exercise in groups, plus a self management education programme (patient education).
9940600|NCT00989456|Active Comparator|exercise only|Supervised physical exercise in groups.
9940601|NCT00989469|Experimental|Sorafenib and irinotecan|
9940602|NCT00989482|Experimental|Computer Kiosk Eduction|
9940603|NCT00989495|Experimental|Brace - Randomized|Participants were randomized to be braced
9940604|NCT00989495|No Intervention|Observation - Randomized|Participants were randomized to be observed only
9940605|NCT00989495|Experimental|Brace - preference based|Participants chose to be braced
9940606|NCT00989495|No Intervention|Observation - preference-based|Participants chose to be observed only
9940607|NCT00989508|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
9940608|NCT00989508|Placebo Comparator|Placebo marked PEXSIG|Pre-operative administration of placebo tablets according to dosing schedule
9940609|NCT00989521|Placebo Comparator|placebo|normal saline for inhalation
9940610|NCT00989521|Active Comparator|PUR003|PUR003 for inhalation
9940611|NCT00989534|Experimental|Sleep loss and circadian alignment|Sleep restriction without circadian misalignment
9940612|NCT00989534|Experimental|Sleep loss and circadian misalignment|
9940613|NCT00989547|Active Comparator|A|
9940614|NCT00989547|No Intervention|B|
9940615|NCT00989560|Active Comparator|Active arm|
9940616|NCT00989560|No Intervention|Standard care arm|
9940617|NCT00989599|Experimental|compress of Chamomilla recutita infusion|Patients who developed phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
9940618|NCT00989599|Active Comparator|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
9940619|NCT00989625|Active Comparator|10mg Sumatriptan/60mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
9480646|NCT05262283||2019-2020 season|Injuries in the first 26 games of 2019-2020
9940620|NCT00989625|Active Comparator|30mg Sumatriptan/180mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
9940621|NCT00989625|Active Comparator|85mg Sumatriptan/500mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
9940622|NCT00989638||Women at high risk for breast cancer|
9940623|NCT00989651|Experimental|Regimen I (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive veliparib PO BID on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
9940624|NCT00989651|Experimental|Regimen II (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
9940625|NCT00989651|Experimental|Regimen III (paclitaxel, cisplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1 and IP on day 8, and cisplatin IP on day 1 or 2. Patients also receive bevacizumab and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
9940626|NCT00989677||Rheumatoid Arthritis|
9940627|NCT00989703|Experimental|1|GLPG0259 25/50/75 mg/day for 14 days
9940628|NCT00989703|Placebo Comparator|2|placebo for 14 days
9940629|NCT00989716|Active Comparator|Glyceryl trinitrate transdermal patch|
9940630|NCT00989716|Experimental|Continue or stop pre-stroke antihypertensives|
9940631|NCT00989729|Active Comparator|Methylprednisolone|75 patients will receive a single preoperative dosage of Methylprednisolone
9940632|NCT00989729|Placebo Comparator|Physiological Saline|75 patients will receive a single preoperative dosage of Physiological Saline
9940633|NCT00989742|Active Comparator|Doxycycline|
9940634|NCT00989742|Placebo Comparator|Placebo|
9940635|NCT00989755|Experimental|Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)|Clinics in this group receive Fax to Quit materials and in person training from a Regional Outreach Specialist (ROS). The ROS also provides on-going training/technical assistance and performance feedback.
9940636|NCT00989755|Placebo Comparator|Fax to Quit alone|Clinics in this group receive Fax to Quit materials and can download materials from a website.
9940637|NCT00989794|Experimental|GelrinC|GelrinC one step implantation to the femoral condyle lesion
9940638|NCT00989820|No Intervention|Surgery|This is the standard arm. Surgery without hyperbaric oxygen treatment
9940639|NCT00989820|Experimental|Hyperbaric oxygen therapy with surgery|Intervention arm. Hyperbaric oxygen therapy with surgery.
9940640|NCT00989846||lung disease|patients with various chronic or acute lung diseases
9940641|NCT00989859||Plethysmographic monitoring|Plethysmographic monitoring
9940642|NCT00989885||Obstructive Sleep Apnea|475 patients that sought the CESF to probable diagnosis of some sleep disorder, subsequently diagnosed with Obstructive Sleep Apnea.
9940643|NCT00989898|Active Comparator|Closed-loops at Dinner|Automated closed-loop control starts at 18:00
9940644|NCT00989898|Active Comparator|Closed-loop at Bedtime|Automated closed-loop control starts at 21:00
9940645|NCT00989924||Diabetes mellitus|The Diabetic patient who receives follow-up at NTUH diabetics caring network
9940646|NCT00989976|Other|8.5 h sleep|Subjects will have normal sleep times
9940647|NCT00989976|Other|restricted bedtimes|4.5 h bedtimes
9940648|NCT00990002||Control|A children's milk-based beverage
9940649|NCT00990002||experimental probiotic 1|children's milk-based beverage containing a bioactive ingredient
9940650|NCT00990002||experimental probiotic 2|children's milk-based beverage containing a different bioactive ingredient
9940651|NCT00990015|Experimental|PF-04308515|
9940652|NCT00990015|Placebo Comparator|Placebo|
9940653|NCT00990028|Experimental|Rosuvastatin|20 mg oral during 10 days
9940654|NCT00990028|Placebo Comparator|Placebo|
9940655|NCT00990041||PBMC|
9940656|NCT00990041||periodontitis|
9940657|NCT00990054|Experimental|plerixafor|
9940658|NCT00990067|Other|duloxetine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9940659|NCT00990080|Active Comparator|Group 1|Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
9940660|NCT00990080|Active Comparator|Group 2|Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
9940661|NCT00990119|Experimental|High FLow Therapy|Use of High Flow Therapy for support of Respiratory Insufficiency
9940662|NCT00990119|Active Comparator|NiPPV|
9940663|NCT00990132|Active Comparator|Long term oxygen therapy|LTOT will be established as per current national guidelines
9940664|NCT00990132|Experimental|Home mechanical ventilation|Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.
9940665|NCT00990145|Experimental|Intervention|EDP-322 v. Placebo
9940666|NCT00990158|Active Comparator|Low dose vitamin K + usual warfarin|Low dose oral vitamin K (0.150 mg orally once daily) + warfarin continuation with usual warfarin monitoring
9940667|NCT00990158|Placebo Comparator|Usual warfarin therapy + placebo|Patients continue usual warfarin and take one placebo per day
9940668|NCT00990171||PD-BCM|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
9940669|NCT00990197|Active Comparator|Day 1|Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
9940670|NCT00990197|Active Comparator|Day 2|Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
9940671|NCT00990223|Experimental|Cohort 1|Healthy Volunteers - eplerenone versus placebo.
9940672|NCT00990262||Acute Chest Pain|Patients who presented to the emergency department with acute chest pain, with negative initial biomarkers and normal or non-ischemic ECG
9940673|NCT00990275|Experimental|Post-alcohol|
9940674|NCT00990301|Experimental|Moexipril HCl/ Hydrochlorothiazide 15mg/25mg Tablets|
9940675|NCT00990301|Active Comparator|Uniretic® 15mg/25mg Tablets|
9940676|NCT00990353||Prism adaptation therapy|Patients receive prism adaptation therapy by protocol (Frassinetti et al., 2002)
9940677|NCT00990353||Bromocriptine pharmacotherapy|Patients receive bromocriptine pharmacotherapy by protocol (Barrett et al., 1999)
9940678|NCT00990366|Active Comparator|biliary stent without an antireflux valve|patients with biliary obstruction who need a biliary stent, selected for the stent without an antireflux valve arm
9940679|NCT00990366|Active Comparator|biliary stent with an antireflux valve|patients with biliary obstruction, who need a biliary stent, selected for the stent with an antireflux valve arm
9940680|NCT00990379||Controls|Healthy men and women, 18 years of age or older, who have no history of significant medical conditions.
9940681|NCT00990379||HIV positive|Men and women, 18 years of age or older, who have been diagnosed with HIV infection. Patients may be on or off of ARVs.
9940682|NCT00990379||Parkinson's Disease|Men and women, 18 years of age or older, who have been diagnosed with Parkinson's Disease.
9940683|NCT00990392|Experimental|Polysporin Triple Therapy|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
9940684|NCT00990392|Placebo Comparator|Placebo|Petroleum jelly
9940685|NCT00990405|Experimental|Lansoprazole+Clarithromycin+Amoxycillin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
9940686|NCT00990431|Active Comparator|Carbon dioxide laser treatment|
9940687|NCT00990431|Active Comparator|Erbium:YAG laser treatment|
9940688|NCT00990444|Placebo Comparator|Placebo|Treatment with vehicle capsule containing excipients only, taken in conjunction with standard meal.
9940689|NCT00990444|Active Comparator|Oral Insulin in Dextran|Treatment with fixed insulin dose taken in conjunction with standard meal.
9940690|NCT00990457|Active Comparator|Low-carbohydrate Diet Plus Exercise|Participants will follow a low-carbohydrate weight loss diet plus participate in a supervised exercise training program for 6 months.
9940691|NCT00990457|Active Comparator|Low-Fat, Low-Calorie Diet Plus Exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
9940692|NCT00990496|Experimental|GBM Treatment|
9940693|NCT00990522|Experimental|debridement|monthly vs weekly debridement
9940694|NCT00990535|Experimental|Octreotide-LAR|Patients will receive every 21 days an injection of octreotide-LAR 30 mg until progression is documented.
9940695|NCT00990548||Cardiovascular Service Line patients|Patients admitted to the Cardiovascular Service Line at a major teaching hospital during a consecutive 11-month period.
9940696|NCT00990574|Active Comparator|spinal anesthesia group (SAG)|Participants will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
9940697|NCT00990574|Active Comparator|The WSCG (wiley spinal catheter group)|The WSCG (wiley spinal catheter group) will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
9940698|NCT00990587|Experimental|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
9940699|NCT00990600|Experimental|Simplified one pill regimen|Fixed dose combination of tenofovir + emtricitabine + efavirenz
9940700|NCT00990613|Other|Cohort 1|
9940701|NCT00990613|Other|Cohort 2|
9940702|NCT00990626||1|Schizophrenic outpatients
9940703|NCT00990639|Experimental|candesartan+UDCA group|oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months
9940704|NCT00990639|Placebo Comparator|UDCA group|ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months
9940705|NCT00990678|Experimental|"Strong vitamin D"|Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily
9940706|NCT00990678|Active Comparator|Vitamin D|calcium 400 mg + 10 microgram Vitamin D3, 3 times daily
9940707|NCT00990678|Placebo Comparator|Calcium|Tablet Calcium 400 mg x 3 daily
9940708|NCT00990691|Experimental|Desipramine high dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 50 mg ;~From 26 to 35 kg : 75 mg ;~From 36 to 45 kg : 100 mg ;~> 46 kg : 150 mg."
9528371|NCT03211429|Active Comparator|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
9528372|NCT03211429|Active Comparator|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
9528373|NCT03211429|Active Comparator|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
9528374|NCT03211507||Case|Males with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
9940709|NCT00990691|Experimental|Desipramine low dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 25 mg ;~From 26 to 35 kg : 50 mg ;~From 36 to 45 kg : 75 mg ;~> 46 kg : 100 mg."
9940710|NCT00990691|Placebo Comparator|Placebo|12 patients with Rett syndrome receiving a daily dose of placebo.
9940711|NCT00990717|Experimental|NK-92 cells|Preparation of irradiated NK-92 cells suspended in a saline and plasma solution. NK-92 working cell bank was established from a master cell bank supplied by Conkwest Inc. (San Diego CA).
9940712|NCT00990730||rheumatoid arthritis subjects|60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
9940713|NCT00990730||healthy controls|20 matched controls without rheumatoid arthritis
9940714|NCT00990743|Experimental|SYL040012|
9940715|NCT00990756|Experimental|PF-03526299 1.396 mg|
9940716|NCT00990756|Experimental|PF-03526299 4mg|
9940717|NCT00990795|Experimental|Cyclosporine|Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
9940718|NCT00990795|Placebo Comparator|Placebo|Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
10001247|NCT01545921|Experimental|Arm B|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death"
10001248|NCT01545921|Experimental|Arm C|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death"
10001249|NCT01545921|Experimental|Arm D|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death."
10001250|NCT01545947|Experimental|CC-223/erlotinib concurrent|Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
10001251|NCT01545947|Experimental|CC-223/oral azacitidine concurrent|Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
10001252|NCT01545947|Experimental|CC-223/oral azacitidine sequential|Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
10001253|NCT01545960||Healthy Volunteers|
10001254|NCT01545973||Healthy Volunteers|Human subjects without chronic medical conditions, defined as conditions requiring chronic medication use.
10001255|NCT01545986|Experimental|High Velocity Exercise|The high velocity exercise group performed the concentric contraction phase of resisted exercise in one second or less. This group performed sit to stand exercise, walking, curbs, and stairs as fast as was comfortable without an increased limp. Other exercises were performed at the participant preferred rate.
10001256|NCT01545986|Active Comparator|Low Velocity exercise|The low velocity exercise group performed the concentric contraction phase of resisted exercise in two seconds. This group performed sit to stand exercise, walking, curbs, stairs, and other exercises at the participant preferred rate.
10001257|NCT01545999|Active Comparator|PAS 25|In humans, paired associative stimulation (PAS-25) is a transcranial magnetic stimulation (TMS) protocol that has been shown to result in LTP-like plasticity (PAS-LTP) in the motor cortex (M1). PAS-LTP has been shown to be dependent on the NMDAR and to correlate significantly with performance on a motor learning task.
10001258|NCT01545999|Sham Comparator|PAS 100|To control for non-specific effects of PAS protocol, the investigators will use a modified PAS protocol (PAS-100) that does not result in any neurophysiologic effects. Patients with schizophrenia and healthy controls will be assessed first with the N-back task and then randomized
10001259|NCT01546012|Experimental|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
10001260|NCT01546012|Active Comparator|HYLO-COMOD®:|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
10001261|NCT01546025|Placebo Comparator|Relaxation training|
10001262|NCT01546025|Active Comparator|Brief Motivational Counseling|
10001263|NCT01546051|Experimental|BCI-838 Food Effect Dosing Arm 1|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
10001264|NCT01546051|Experimental|BCI-838 Fasted Dosing (100 & 300 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
9940719|NCT00990808|Experimental|Panel A|Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859
9940720|NCT00990808|Experimental|Panel B|Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
9940721|NCT00990834|Experimental|Statin exposure|Subjects' endpoints will be measured before and after one to eight months of statin exposure.
9940722|NCT00990847|Experimental|Procaterol|Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
9940723|NCT00990847|Active Comparator|Salbultamol|Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
9940724|NCT00990860|Experimental|Sorafenib|
9940725|NCT00990886|Experimental|001|Oxybutynin chloride 15 mg once daily for 12 weeks
9940726|NCT00990886|Placebo Comparator|002|Placebo Once daily for 12 weeks
9940727|NCT00990925|Experimental|Weight Loss Education Group|Involvement in weekly manualized, educational group on nutrition and lifestyle modifications to help with weight loss.
9940728|NCT00990925|Other|Usual Care|Treatment as usual
9940729|NCT00990951|Experimental|Senna alexandrina and associations|Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
9940730|NCT00990977|No Intervention|controls|assessment only
9940731|NCT00990977|Experimental|cases|MBSR including brief information session and assessments
9940732|NCT00990990|Experimental|Cohort 1|
9940733|NCT00990990|Experimental|Cohort 2|
9940734|NCT00990990|Experimental|Cohort 3|
9940735|NCT00990990|Experimental|Cohort 4|
9940736|NCT00990990|Experimental|Cohort 5|
9940737|NCT00990990|Experimental|Cohort 6 (optional)|
9940738|NCT00990990|Experimental|Linezolid Cohort|
9940739|NCT00991003|Experimental|Colon capsule endoscopy and colonoscopy|Patients underwent CCE on day 1 and conventional colonoscopy on day 2
9940740|NCT00991016|Experimental|PF-04805712|
9940741|NCT00991042|Other|cytokine levels|Serum levels of pro-inflammatory cytokines were measured using the Enzyme Linked Immuno Sorbent Assay (ELISA) technique in 23 patients with pain due to herniated disk disease (G1) as well as in 10 control healthy subject
9940742|NCT00991055|Experimental|Pioglitazone|
9940743|NCT00991055|Placebo Comparator|Placebo|
9940744|NCT00991094||Observational (questionnaire)|Patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. Patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.
9940745|NCT00991107|Experimental|HE3286|HE3286 20 mg (10 mg BID)
9940746|NCT00991133|Experimental|Clofarabine|Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.
9940747|NCT00991146|Experimental|canakinumab|
9940748|NCT00991159|Experimental|RN316|
9940749|NCT00991198|Experimental|A|Aria Regimens 0.5% conc
9940750|NCT00991198|Experimental|B|Aria Regimen (5 products) 0.25% conc
9940751|NCT00991198|Placebo Comparator|C|Aria Regimen Control without O2
9940752|NCT00991211|Experimental|Bendamustine + Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
9940753|NCT00991211|Active Comparator|CHOP + Rituximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
9940754|NCT00991224|Experimental|Arm 1|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
9940755|NCT00991224|Experimental|Arm 2|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
9940756|NCT00991224|Experimental|Arm 3|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir >200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
9940757|NCT00991224|Experimental|Arm 4|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of >200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
9940758|NCT00991237|Experimental|Pain reduction|
9940759|NCT00991250|Experimental|SentoClone®|SentoClone®: Specific tumour-reactive lymphocytes located in lymph nodes directly draining primary tumours or metastases are identified and expanded. These lymphocytes are infused to the patient to treat metastatic disease.
9940760|NCT00991250|Active Comparator|Temodal® or Dacarbazine Medac®|"To be decided by each centre as one of the following:~Temodal® (temozolomide)~Dacarbazine Medac® (dacarbazine) The reference treatment regimen should follow the general guiding principles for each of the two reference treatments."
9940761|NCT00991263||Group 1|Tissue blocks from CALGB-9344 and CALGB-9741 are utilized to purify RNA to be tested in the PAM50 assay (a 50-gene quantitative PCR assay, that provides an intrinsic breast cancer subtype diagnosis) and generate risk of relapse (ROR) scores. For more information, see Details section.
9940762|NCT00991328|Active Comparator|Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes|Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
9940763|NCT00991328|No Intervention|Patients with SctO2 less than 60 %.|The study patients will not get any intervention in this arm if the Sct02 falls below 60%
9940764|NCT00991354|Experimental|Group 1|Participants will receive 3 mg of PENNVAX-B vaccine or placebo at Months 0, 1, and 3.
9940765|NCT00991354|Experimental|Group 2|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
9940766|NCT00991354|Experimental|Group 3|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
9940767|NCT00991367|Experimental|A|Cicatrix
9940768|NCT00991367|Placebo Comparator|B|Placebo
9940769|NCT00991380|Experimental|Lifestyle counselling|
9940770|NCT00991380|Active Comparator|Usual Care|
9940771|NCT00991393||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
9940772|NCT00991419|Experimental|A|[18F]4694
9940773|NCT00991432||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
9940774|NCT00991445|Active Comparator|Group MIS|Minimal Invasive Surgery
9940775|NCT00991445|Active Comparator|Conventional Exposure|
9940776|NCT00991471|Experimental|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
9940777|NCT00991471|Experimental|Control: No MDRNSTAT|Control group
9940778|NCT00991484||control group|
9940779|NCT00991484||individuals from hernia-family|
9940780|NCT00991497|Active Comparator|24 hours compression bandaging|
9940781|NCT00991497|Active Comparator|5 days compression bandaging|
9940782|NCT00991523|Experimental|sweetened beverage|
9940783|NCT00991523|Placebo Comparator|placebo control|placebo
9940784|NCT00991536||Chronic respiratory failure|Patients with restrictive pulmonary disorders leading to progressive hypercapnic respiratory failure and requiring nocturnal non-invasive ventilation
9940785|NCT00991549|Experimental|1|interdisciplinary weight loss intervention
9940786|NCT00991549|Active Comparator|2|Small group seminars without interdisciplinary intervention
9940787|NCT00991575||Diabetes, type 1|
9940788|NCT00991588||PCL, posterolateral reconstruction|All patients who are entered into study who receive a PCL and/or posterolateral knee ligament reconstruction
9940789|NCT00991601|Experimental|biopsy arm|patients with tumors in liver and/or pancreas
9940790|NCT00991614||EVOLUTION® Duodenal Stent|
9940791|NCT00991627|Active Comparator|Pharmacological|Patients in this group will receive a basal infusion of ephedrine. Hypotension will be treated for a reduction in systolic blood pressure 20% below baseline values.
9940792|NCT00991627|Experimental|Non-Pharmacological|Patients in this group will undergo uterine lateral displacement through the use of a wedge-shaped cushion placed under their right hip. Hypotension will be treated for a reduction in systolic blood pressure 40% below baseline values.
9940793|NCT00991640|No Intervention|Control|No intervention
9940794|NCT00991640|Experimental|Preceptorships|Preceptorships with e-learning
9940795|NCT00991653||Breast cancer|Diagnosed with breast cancer 1/1/2003 - 31/12/2007.
9940796|NCT00991666|Experimental|1|AMD Patients
9940797|NCT00991666|Active Comparator|2|healthy controls
9940798|NCT00991679||Normal control subjects|Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
9940799|NCT00991679||dry eye patients|Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
9940800|NCT00991692|Experimental|Treatment dosage levels examined|
9940801|NCT00991705|Other|Group B|Atorvastatin (7 days) → Fimasartan + Atorvastatin (7 days)
9940802|NCT00991705|Other|Group A|Fimasartan (7 days) → Fimasartan + Atorvastatin (7 days)
9940803|NCT00991718|Experimental|A|On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.
9940804|NCT00991718|Experimental|B|On Day 1, subjects received a single oral dose of 14C-GDC-0449.
9940805|NCT00991718|Experimental|C|On Days 1-7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.
9940806|NCT00991718|Experimental|D|On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
9940807|NCT00991731|Active Comparator|Faith-based|Faith-based interventions incorporate tenets of the faith-based organization (e.g., religious beliefs, scriptural references) and involve the faith-based organization in the planning of the intervention from beginning to end
9476211|NCT03574155|No Intervention|Control- group|"It is composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium, who will receive preoperative and postoperative guidelines according to the usual routine for the perioperative period of the present institution. Patients and their followers of the control group will participate in a preoperative consultation with the surgeon to discuss the indication of the procedure and its risks, benefits and alternatives to the procedure being indicated, if any.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
9940808|NCT00991731|Active Comparator|Non-faith-based|A curriculum designed for delivery without biblical references. In the traditional teachings of how to increase physical activity.
9940809|NCT00991731|No Intervention|Control|"This group will receive a printed pamphlet Energize Yourself! Stay Physically Active, published by the National Heart Lung and Blood Institute, that encourages participation in at least 30 minutes of daily physical activity all at once or in bouts lasting 10 minutes at a time."
9940810|NCT00991744|Experimental|Liposomal cytarabine|Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL
9940811|NCT00991744|Active Comparator|Intrathecal triple|Intrathecal methotrexate, cytarabine and prednisolone
9940812|NCT00991770|Experimental|Massage Therapy|Massage therapy provided by a certified Massage Therapist
9940813|NCT00991770|Active Comparator|Control|Empathic support conversation
9940814|NCT00991796|Experimental|CS-1008|CS-1008 with carboplatin and paclitaxel
9940815|NCT00991796|Placebo Comparator|Placebo|Placebo with carboplatin and paclitaxel
9940816|NCT00991822|Active Comparator|1|Patients with open angle glaucoma
9940817|NCT00991822|Active Comparator|2|Patients with open angle glaucoma
9940818|NCT00991848|Experimental|Lidocaine|Patients received 240 mg lidocaine diluted in 125 mL 0.9% saline. The solutions were infused over a period of 1 h, once a week, for 4 weeks (T1, T2, T3 and T4).
9940819|NCT00991861|Experimental|LAS41007 o.d.|Once daily
9940820|NCT00991861|Experimental|LAS41007 b.i.d.|Twice daily
9940821|NCT00991861|Active Comparator|LAS106521|
9940822|NCT00991900||Healthy subjects|
9940823|NCT00991913||Delirium|Delirium was determined by CAM-ICU
9940824|NCT00991913||no Delirium|no Delirium was determined by CAM-ICU
9940825|NCT00991926||orlistat plus normo-caloric diet|10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
9940826|NCT00991926||normo-caloric diet|10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days
9940827|NCT00991965||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
9940828|NCT00991978|Experimental|89Zr-bevacizumab PET|89Zr-bevacizumab PET
9940829|NCT00992004|Experimental|Arantal®|Highly bioavailable turmeric extract (food supplement)
9940830|NCT00992004|Placebo Comparator|Placebo|Same capsule without the active ingredients (only excipients)
9940831|NCT00992030|Experimental|ARM A|Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
9940832|NCT00992030|Active Comparator|ARM B|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation
9940833|NCT00992043|Placebo Comparator|exercise and placebo|
9940834|NCT00992043|Experimental|exercise and creatine|
9940835|NCT00992069|Experimental|TMC207 alone and with EFV|Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
9940836|NCT00992082|Active Comparator|Group LIA|Local Infiltration Analgesia
9940837|NCT00992082|Active Comparator|Group M|Intrathecal morphine
9940838|NCT00992121|Other|Part I and 2 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles
9940839|NCT00992121|Other|Part I and 3 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles
9940840|NCT00992147|Experimental|autologous cultured adipocytes|
9940841|NCT00992160|Experimental|Active|Vestipitant 15mg once daily
9940842|NCT00992160|Placebo Comparator|Placebo|Placebo
9940843|NCT00992173|Experimental|Ultratrace Iobenguane I 131|
9940844|NCT00992199|No Intervention|control arm|adjuvant intravenous system chemotherapy
9940845|NCT00992199|Experimental|IP Chemo arm|adjuvant system intravenous chemotherapy combined with adjuvant intraperitoneal chemotherapy
9940846|NCT00992212|Experimental|Group A (Seasonal TIV + 7.5mcg HA+ full dose MF59)|
9940847|NCT00992212|Experimental|Group B (Ajuvanted Seasonal TIV + 7.5mcg HA+ full dose MF59)|
9940848|NCT00992212|Experimental|Group C (7.5mcg HA+ full dose MF59)|
9940849|NCT00992212|Experimental|Group D (7.5mcg HA+ full dose MF59 + Seasonal TIV)|
9940850|NCT00992212|Experimental|Group E (3.75mcg HA+ ½ dose MF59+ Seasonal TIV)|
9940851|NCT00992238|Experimental|Flavoxate Hydrochloride Tablets, 100mg|
9940852|NCT00992238|Active Comparator|Urispas® Tablets, 100mg|
9940853|NCT00992277|Experimental|Facial|Skin rejuvenation treatments
9940854|NCT00992290|Experimental|Lactobacillus GG|
9940855|NCT00992290|Placebo Comparator|Placebo|
9940856|NCT00992316||Pf-04531083|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects
9940857|NCT00992329|Experimental|ciprofloxacin tab1|formulation 1
9940858|NCT00992329|Experimental|ciprofloxacin tab2|formulation 2
9940859|NCT00992329|Experimental|ciprofloxacin tab 3|formulation 3
9940860|NCT00992329|Active Comparator|ciprofloxacin reference|reference product
10001265|NCT01546051|Experimental|BCI-1038, BCI-1206 & BCI-1283|Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
10001266|NCT01546051|Experimental|BCI-838 Fasted Dosing (900 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
10001267|NCT01546064|Active Comparator|Bile duct anastomosis with T-tube|
10001268|NCT01546064|Active Comparator|Bile duct anastomosis without T-tube|
10001269|NCT01546077|Active Comparator|Hydrolocalization technique group|Technique of placement of popliteal perineural catheter using the hydrolocalization technique with ultrasound
10001270|NCT01546077|Active Comparator|Stimulating Catheter technique group|A technique for placement of popliteal catheter with the aid of a neurostimulator
10001271|NCT01546090|Experimental|alprazolam|Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs
10001272|NCT01546090|Placebo Comparator|placebo|placebo capsules were filled with starch
10001273|NCT01546103|Active Comparator|Vitamin D3 supplementation of 1000 IU|
10001274|NCT01546103|Active Comparator|Vitamin D3 supplementation of 5000 IU|
10001275|NCT01546116|Experimental|Adefovir and lamivudine combination|
10001276|NCT01546129|Experimental|Dianatal Obstetric Gel|Standard of care according to the established Guidelines of the Department plus use of Dianatal applied with a vaginal applicator in stage I and stage II of labor
10001277|NCT01546129|No Intervention|Control|Standard of care according to the established Guidelines of the Department.
10001278|NCT01546181||Controls|subjects older than 10 years old, with no know ocular or general disease
10001279|NCT01546181||Age-related macular degeneration|
10001280|NCT01546181||inherited retinal dystrophies|
10001281|NCT01546181||retinal trauma|
10001282|NCT01546181||toxic retinopathies|
10001283|NCT01546181||arterial hypertensive patients|
10001284|NCT01546181||diabetic patients|
10001285|NCT01546181||inflammatory diseases|
10001286|NCT01546220|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
10001287|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
9940861|NCT00992342|Experimental|PF-03893787 5 mg|
10001288|NCT01546233||multidisiplinary self care program|Patient with Lung cancer will be participated in group education with multidisiplinary self care program
10001289|NCT01546233||Conventional education|Lung cancer patient will be received standard education
10001290|NCT01546246|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
9940862|NCT00992342|Experimental|PF-03893787 15 mg|
9940863|NCT00992342|Experimental|PF-03893787 50 mg|
9940864|NCT00992355|Active Comparator|Tobramycin 0.3% - Dexamethasone 0.1%|
9940865|NCT00992355|Active Comparator|Tobramycin-Dexamethasone plus Ketorolac tromethamine|
9940866|NCT00992368|Active Comparator|reduction mammaplasty|submitted to surgery
9940867|NCT00992368|No Intervention|not reduction mammaplasty|not submitted to surgery
9940868|NCT00992381|Experimental|1|PN400
9940869|NCT00992381|Active Comparator|2|Naproxen
9940870|NCT00992420||GRAVITAS Study Arm A|"Tailored clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months"
9940871|NCT00992420||GRAVITAS Study Arm B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months."
9940872|NCT00992420||GRAVITAS Study Arm C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.
9940873|NCT00992472|Experimental|Prochlorperazine suppositories, 25mg|
9940874|NCT00992472|Active Comparator|Compazine® suppositories, 25mg|
9940875|NCT00992485|Experimental|autologous adipose derived stem cell|
9940876|NCT00992524|Active Comparator|Oral Titrated Misoprostol Solution|
9940877|NCT00992524|Active Comparator|Vaginal Misoprostol|
9940878|NCT00992537|Experimental|IDeg|
9940879|NCT00992537|Experimental|IDegAsp|
9940880|NCT00992537|Active Comparator|IAsp|
10001291|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
10001292|NCT01546259|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
10001293|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
10001294|NCT01546272|Experimental|Resorbable staples|Suture using Insorb Resorbable staples
10001295|NCT01546272|Active Comparator|Resorbable wires|Suture using Monocryl resorbable wire
10001296|NCT01546311||lower limb amputees|
10001297|NCT01546324||Pregnant women|Women pregnant following the use of Natera's PGS/PGD testing
10001298|NCT01546350|No Intervention|Control - regular ART treatment|patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.
9940881|NCT00992550|Experimental|Hookah visit, then cigarette visit|4-day inpatient stays for profile of biomarker excretion
9940882|NCT00992550|Experimental|Cigarette visit, then Hookah visit|4-day inpatient stay for profile of biomarker excretion
9940883|NCT00992615|Experimental|Arm 20 cores|
9940884|NCT00992615|Active Comparator|arm 12 cores|
9940885|NCT00992628|Active Comparator|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
9940886|NCT00992628|Active Comparator|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
9940887|NCT00992641|Experimental|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
9940888|NCT00992641|Active Comparator|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
9940889|NCT00992667|Experimental|Asthmatics|Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.
9940890|NCT00992680|Experimental|Group A|Anastomotic Coupler System + standard of care per GOLD
9940891|NCT00992680|No Intervention|Group B|Standard of care per GOLD alone
9940892|NCT00992693|Experimental|Treatment with IV Ribavirin|In this open label treatment study, the investigators intend to treat all subjects who present with a tentative diagnosis of VHF and meet entry criteria with a 10 day course of IV Ribavirin.
9940893|NCT00992745|Experimental|Previous ProstaScint®|Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
9940894|NCT00992745|Experimental|No Previous ProstaScint®|Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
9940895|NCT00992758|Experimental|Treatment, Non-Randomized, Open Label|Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
9940896|NCT00992771|Experimental|Varneicline|
9940897|NCT00992771|Placebo Comparator|Placebo|
9940898|NCT00992797|Experimental|Cholecalciferol|
9940899|NCT00992797|Placebo Comparator|Placebo|
9940900|NCT00992810|Experimental|Lateral-to-Medial Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
9940901|NCT00992810|Experimental|Medial-to-Lateral Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
9940902|NCT00992823|Active Comparator|Group 1:iron weekly supplementation|
9940903|NCT00992823|Active Comparator|Group 2: cycle supplementation|two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
9940904|NCT00992849|Experimental|Bevacizumab|Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.
9940905|NCT00992862|Experimental|Moexipril HCl 15mg Tablets|
9940906|NCT00992862|Active Comparator|Univasc® 15mg Tablets|
9940907|NCT00992888|Experimental|albumin liver dialysis|
9940908|NCT00992888|No Intervention|Standard medial care without dialysis|
9940909|NCT00992901|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
9940910|NCT00992901|Experimental|atropine|To evaluate the effect of neural activation on insulin secretion and glucose metabolism
9940911|NCT00992901|Experimental|GLP-1 and GIP|to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
9940912|NCT00992914|Active Comparator|Lidocaine injection|Stellate Ganglion Injection with Lidocaine
9940913|NCT00992914|Placebo Comparator|saline injection|Superficial subcutaneous injection
9940914|NCT00992940|Experimental|Patient-Controlled Sedation/Analgesia|Patient controls the amount of sedation and analgesia delivered, according to their own requirements.
9940915|NCT00992940|Active Comparator|Anesthetist-Controlled Sedation/Analgesia|Patient sedation and analgesia requirements are delivered by the anesthetist.
9940916|NCT00992953|Experimental|Virtual Reality Therapy|10 Weeks of Virtual Reality Exposure with Stimulus Control, with up to twice a week, 90 min sessions
9940917|NCT00992953|Active Comparator|Treatment As Usual|Traditional Therapy and Psychiatric Medication
9940918|NCT00992979|Experimental|Therapeutic Massage|
9940919|NCT00992979|Active Comparator|Relaxation Control|Relaxation Control Session
9940920|NCT00993005|Experimental|A|Cicatrix
9940921|NCT00993005|Placebo Comparator|B|Placebo
9940922|NCT00993057|Active Comparator|Q1 hour protocol|change of insulin infusion every hour
9940923|NCT00993057|Active Comparator|Q30min protocol|change of insulin infusion every 30 minutes
9940924|NCT00993070|Experimental|Capsaicin|
9940925|NCT00993070|Placebo Comparator|placebo|
9940926|NCT00993083|Experimental|Vaccinated|14 volunteers (2 in lead safety group and 12 in main study group) to receive MVA-NP+M1 via the IM route. Volunteers will then be challenged with Influenza 30 days post vaccination.
9940927|NCT00993083|No Intervention|Control|12 volunteers who will not receive vaccine but will also be challenged with Influenza on day 30
9940928|NCT00993096|Experimental|IDegAsp low|
9940929|NCT00993096|Experimental|IDegAsp middle|
9940930|NCT00993096|Experimental|IDegAsp high|
9940931|NCT00993096|Experimental|BIAsp 30 low|
9940932|NCT00993096|Experimental|BIAsp 30 middle|
9940933|NCT00993096|Experimental|BIAsp 30 high|
9940934|NCT00993109|Experimental|Arm 1|
9940935|NCT00993109|Active Comparator|Arm 2|
9940936|NCT00993122|Active Comparator|ribavirin pre-treatment|patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
9940937|NCT00993122|Active Comparator|combined stardard therapy|patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
9940938|NCT00993161|Experimental|patients|Patients with neuromuscular disorder and controls
9940939|NCT00993161|Experimental|Controls|healthy controls
9940940|NCT00993174|Experimental|Topical anesthesia|Patients undergo strabismus surgery for esotropia using topical anesthesia (instillation of drops plus gel)
9940941|NCT00993174|Active Comparator|Sub-Tenon's anesthesia|Patients undergo surgery for strabismus (esotropia) using sub-Tenon's administration of anesthetic (xylocaine)
9940942|NCT00993213|Active Comparator|Liposuction|Standard of Care with Liposuction
9940943|NCT00993213|Sham Comparator|No Liposuction|Standard of Care without Liposuction'
9940944|NCT00993239|Experimental|Birinapant (TL32711)|
9940945|NCT00993278|Active Comparator|Low-Carbohydrate (Modified Atkins) Diet|
9940946|NCT00993278|Active Comparator|Low-Fat (Heart Healthy) Diet|
9940947|NCT00993304|Experimental|A|
9940948|NCT00993304|Placebo Comparator|B|
9940949|NCT00993330||1|20 healthy subjects between 18 and 40 years
9940950|NCT00993330||2|20 healthy subjects between 41 and 50 years
9940951|NCT00993330||3|20 healthy subjects between 51 and 60 years
9940952|NCT00993330||4|20 healthy subjects between 61 and 70 years
9940953|NCT00993330||5|20 healthy subjects between 71 and 80 years
9940954|NCT00993330||6|20 healthy subjects between 81 and 90 years
9940955|NCT00993343|Active Comparator|Cyclosporine + Methotreaxte|
9940956|NCT00993343|Active Comparator|sirolimus + tacrolimus|
9940957|NCT00993356|Other|Group 2|After a baseline evaluation, patients underwent transsphenoidal surgery (direct surgery group).
9940958|NCT00993356|Experimental|Group 1|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
9940959|NCT00993369||Healthy newborns conceived naturally|
9940960|NCT00993369||Healthy newborns conceived with IVF|
9940961|NCT00993395|Experimental|Peer Mentor Intervention|peer mentor-based disease management focusing on three domains: medical care, recovery, and social stabilization
9940962|NCT00993408|Experimental|ACT-293987 (NS-304) and matching placebo|"Subjects will be randomized to the study following screening.~Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304."
9940963|NCT00993434|Active Comparator|Kid STRIDE Booklet|
9940964|NCT00993434|Placebo Comparator|Safety Booklet|
9940965|NCT00993486|Experimental|L1 (dose 1.0x10E4 T-cells/kg)|
9940966|NCT00993486|Experimental|L2 (dose 5.0x10E4 T-cells/kg)|
9940967|NCT00993486|Experimental|L3 (dose 1.3x10E5 T-cells/kg)|
9940968|NCT00993486|Experimental|L4 (dose 3.2x10E5 T-cells/kg)|
9940969|NCT00993486|Experimental|L5 (dose 7.9x10E5 T-cells/kg)|
9940970|NCT00993486|Experimental|L6 (dose 2.0x10E6 T-cells/kg)|
9940971|NCT00993486|Experimental|L7 (dose 5.0x10E6 T-cells/kg)|
9940972|NCT00993512|Experimental|TPCS2a|No comparative treatment is given in this open-label phase I, dose escalating safety study
9940973|NCT00993525|Experimental|Intravitreal anti-VEGF|Intravitreal injection of 0.5 mg of ranibizumab
9940974|NCT00993538|Experimental|1|
9940975|NCT00993551|Experimental|12 month surgery|Infants will receive primary surgery at age 12 months using Sommerlad technique
9940976|NCT00993551|Experimental|6 month surgery|Infants will receive primary surgery at age 6 months using Sommerlad technique.
9940977|NCT00993577|Experimental|Exercises|Global Postural Reeducation Static Stretching Exercises
9940978|NCT00993590|Experimental|M CHESS group|The intervention group will receive access for 12 months to M-CHESS via a smartphone to: (1) contact their case managers and primary provider; (2) communicate with the managed care organization case managers; (3) communicate with peers; (4) share information about changes in health status; (5) receive reminders to take medications and complete medical follow-up; (6) receive feedback on use of their asthma action plan; (7) receive tailored inquiries and insights regarding attendance or use of asthma resources; and (8) access audio and video versions of asthma educational materials and lower reading level versions of text materials; (9) provide monthly study outcome data monthly for 12 months.
9940979|NCT00993590|Active Comparator|Control group|The control group will receive standard care plus a smartphone for 12 months; they will provide study outcome data monthly for the next 12 months.
9940980|NCT00993603|Experimental|Lifestyle programme.|8 month lifestyle programme.
9940981|NCT00993629|Active Comparator|Arm 1|adjunctive pregnenolone
9940982|NCT00993629|Placebo Comparator|Arm 2|adjunctive placebo
9800759|NCT01696695||Metastatic Colorectal Carcinoma (mCRC) Participants|Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed. The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
9940983|NCT00993642|Experimental|All Participants|
9940984|NCT00993681|Experimental|1|900 subjects will receive a two vaccination regimen with an LT patch
9940985|NCT00993681|Placebo Comparator|2|900 subjects will receive a two vaccination regimen with a placebo patch
9940986|NCT00993707|Active Comparator|0.01% CTX-100 (formerly ETX-100)|
9940987|NCT00993707|Active Comparator|0.03% CTX-100 (formerly ETX-100)|
9940988|NCT00993707|Placebo Comparator|Placebo|
9800760|NCT01696760|Experimental|Arm I (acetylsalicylic acid and PCD)|Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.
9800761|NCT01696760|Experimental|Arm II (enoxaparin and PCD)|Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.
9800762|NCT01696773|Experimental|Tangerine tomato juice|Tangerine tomato juice will be fed
9800763|NCT01696773|Experimental|Red tomato juice|Red tomato juice will be fed
9800764|NCT01696877|Active Comparator|Degarelix|Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg at 14 (±3) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by their urologists according to standard institutional practices, but will require prostate-specific antigen evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
9800765|NCT01696877|Experimental|Cyclophosphamide, GVAX and Degarelix|Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intradermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (2.5 × 108 cells), for a total dose of 5 × 108 cells. On day 14, Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg.
9800766|NCT01696929|Experimental|Tocilizumab|Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
9800767|NCT01696942|Experimental|Cimzia treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
9800768|NCT01696942|Active Comparator|Mesalamine treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.
9800769|NCT01696955|Experimental|Arm I (cetuximab and tivantinib)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9800770|NCT01696955|Experimental|Arm II (cetuximab)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9800771|NCT01696968|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
9800772|NCT01696968|Active Comparator|Lung Screening|"Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as smokers undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial."
9800773|NCT01696981|Active Comparator|Colorectal Screening|Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
9800774|NCT01696981|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
9800775|NCT01696994|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
9800776|NCT01696994|Active Comparator|Ovarian Screening|Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
9800777|NCT01697319|Experimental|BMN 110 at 2.0 mg/kg/week|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 144 weeks.
9800778|NCT01697345|Experimental|Vaginal Testosterone|Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).
9800779|NCT01697358|Active Comparator|SCS + OMM|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
9800780|NCT01697358|Active Comparator|OMM alone|The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan
9800781|NCT01697449||Cohort|
9800782|NCT01697462||Cohort|
9800783|NCT01697501|Experimental|Chronic hepatitis B patients|
9940989|NCT00993720|Experimental|type 1 DM with betacell function: Liraglutide|
9940990|NCT00993720|Experimental|type 1 DM without betacell function: Liraglutide|
9940991|NCT00993720|No Intervention|type 1 DM without betacell function: Insulin|
9940992|NCT00993733|Experimental|CVVHDF on-line|CVVHDF using a central water treatment plant, providing dialysate directly to the patient. They will perform a continuous veno-venous haemodiafiltration.
9940993|NCT00993733|Experimental|classical CVVHDF|CVVHDF using a mobile generator with dialysate bags. They will perform a continuous veno-venous haemodiafiltration.
9940994|NCT00993746|Active Comparator|Bupivacaine plus lidocaine|Group 1: bupivacaine 20 ml plus lidocaine 10 ml
9940995|NCT00993746|Experimental|Bupivacaine alone|Group 2: bupivacaine 30 ml
9940996|NCT00993759|No Intervention|No treatment|
9940997|NCT00993759|Experimental|3804-250A lotion|
9940998|NCT00993785|Experimental|OTW Catheter System|
9940999|NCT00993811|Experimental|Circumcision|Males undergoing circumcision
9941000|NCT00993837|Experimental|conversion|
9941001|NCT00993850|Other|Bipolar disorder education|Psychoeducation
9941002|NCT00993850|Other|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia
9941003|NCT00993863|Placebo Comparator|Placebo|
9941004|NCT00993863|Experimental|ADL5859 30 mg|
9941005|NCT00993863|Experimental|ADL5859 100 mg|
9941006|NCT00993863|Experimental|ADL5859 200 mg|
9941007|NCT00993863|Active Comparator|ibuprofen 400 mg|
9941008|NCT00993876|Experimental|Selective serotonin reuptake inhibitor (SSRI)|citalopram
9941009|NCT00993876|Experimental|Serotonin-norepinephrine reuptake inhibitor (SNRI)|reboxetine
9941010|NCT00993876|Active Comparator|IPT|interpersonal psychotherapy
9941011|NCT00993889|Experimental|VR during Physical Therapy|The subject will receive virtual reality during painful physical therapy sessions.
9941012|NCT00993889|Experimental|VR background pain|The subjects receives virtual reality, not during a physical therapy procedure, another time of the day for background pain.
9941013|NCT00993889|Experimental|No VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
9941014|NCT00993902|Sham Comparator|Single IUI|Single IUI will be carried on after 36-38 hours of HCG administration
9941015|NCT00993902|Active Comparator|Double IUI|
9941016|NCT00993941|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
9941017|NCT00993941|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein.
9941018|NCT00993980|Experimental|1|qigong
9941019|NCT00993980|Active Comparator|2|exercise therapy
9941020|NCT00993993||"group early intervention"|
9941021|NCT00993993||"group late intervention"|
9941022|NCT00994006|Active Comparator|Magnesium oxide tables|Subjects will be instructed to take Magnox 520 qd
9941023|NCT00994006|Active Comparator|Magnesium citrate tablets|Subjects will be instructed to take magnesium diasporal tablets t.i.d.
10214516|NCT05194124|Placebo Comparator|Placebo subcutaneous injection Daily|Patients will be randomized 1:1 to receive either QD or QW placebo during the double blind period (and setmelanotide in the other formulation).
10214517|NCT05194124|Placebo Comparator|Placebo subcutaneous injection Weekly|Patients will be randomized 1:1 to receive either QD or QW placebo during the double blind period (and setmelanotide in the other formulation).
10214518|NCT05188157|Other|control group|conventional physiotherapy
10214519|NCT05188157|Experimental|mirror therapy group|conventional physiotherapy and mirror therapy
10214520|NCT05184933|Experimental|Dipping vs non-dipping HTN|"Participants will wear an ambulatory blood pressure monitor (SpaceLabs, Inc.) which will take their blood pressure in 20-30-minute intervals for 24-48 hours to determine blood pressure dipping status.~All participants in this arm will complete the experiments in this order:~At-home polysomnography;~Constant Routine protocol;~Rested Wakefulness Trial AND Overnight Sleep Trial (Randomized crossover);~Sleep Regularization Trial"
10214521|NCT05183308||patients treated with Vitamin D|
9941024|NCT00994032|Active Comparator|vertebroplasty|
9941025|NCT00994032|Active Comparator|Medical Treatment|
9941026|NCT00994045|Active Comparator|Fresh Frozen Plasma|
9941027|NCT00994045|Experimental|Fibrinogen concentrate|
9941028|NCT00994058|Experimental|Intevention with Inhibitor|
9941029|NCT00994084|Active Comparator|Lifestyle modification|This arm receives the intervention program that includes structured physical activities and nutrition and behavior lessons
9941030|NCT00994084|Placebo Comparator|Control|This arm receives no intervention
9941031|NCT00994097|Experimental|A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed|NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology
9941032|NCT00994097|Active Comparator|B: cisplatin/gemcitabine or cisplatin/pemetrexed|Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology
9941033|NCT00994136|Experimental|Normal saline|In the intervention group the use of heparin as locking solution in the catheter lumen (or lumina) when the catheter is not longer in use is omitted. Catheters are locked under positive pressure with normal saline in stead injecting an extra volume of heparinised saline (100IU/ml).
9941034|NCT00994136|No Intervention|Heparin lock|
9941035|NCT00994149|Experimental|Diazoxide|Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
9941036|NCT00994149|Placebo Comparator|Ora-plus|Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
9941037|NCT00994162|Experimental|Negative Pressure Wound Therapy|Application of NPWT therapy to the wound
9941038|NCT00994227|Experimental|surgery|
10001299|NCT01546350|Experimental|Test - PGD|patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
10001300|NCT01546363||Validation|
10001301|NCT01546363||Testing|
10001302|NCT01546376||HIV-cancer patients who recived RT|
10001303|NCT01546389|Experimental|Cohort 3, Group E|Cohort 3 (High Dose, Low Aliquot), Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose); 5 subjects
10001304|NCT01546389|Experimental|Cohort 1, Group A|Cohort 1 (Medium Dose, Medium Aliquot), Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose); 5 subjects.
10001305|NCT01546389|Experimental|Cohort 1, Group B|Cohort 1 (Medium Dose, Medium Aliquot), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose); 5 subjects
10001306|NCT01546389|Experimental|Cohort 3, Group F|Cohort 3 (High Dose, Low Aliquot), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose); 5 subjects
10001307|NCT01546389|Experimental|Cohort 2, Group D|Cohort 2 (Medium Dose, Low Aliquot), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose); 5 subjects
9800784|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycle 1|Participants were administered intravenous (IV) fosaprepitant at the following weight-adjusted doses: participants 4 months to <12 years old were administered 5 mg/kg (not to exceed 150 mg); participants 1 to <4 months old were administered 2.5 mg/kg; participants 0 to <1 month old were administered 1.25 mg/kg. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
10001308|NCT01546389|Experimental|Cohort 2, Group C|Cohort 2 (Medium Dose, Low Aliquot), Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose); 5 subjects
10001309|NCT01546415|Experimental|Desferasirox|
10001310|NCT01546428|Experimental|INC280|
10001311|NCT01546441|Experimental|interprofessional assessment|patients receive an interprofessional assessment in a team environment
10001312|NCT01546441|Active Comparator|usual care|Usual care in family practice
10001313|NCT01546467|Experimental|Cognitive remediation|30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
10001314|NCT01546467|No Intervention|Wait list control group|Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
10001315|NCT01546480||Pain patients|Patients with unexplained chronic abdominal pain 12 months after elective cholecystectomy
10001316|NCT01546480||Operated painfree Patients|Painfree patients 12 months after elective cholecystectomy
10001317|NCT01546480||Nonoperated painfree patients|Painfree patients with no previous abdominal operation
10001318|NCT01546493|Experimental|Controls|Asymptomatic control subjects with no deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
10214522|NCT05183308||patients treated with Vitamin D and Clodronic Acid|
10214523|NCT05182645|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
10214524|NCT05182645|Active Comparator|waiting control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.
10214525|NCT05174078|Experimental|Medically-Tailored Meals (MTM)|Medically-tailored meals delivered to participants' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
10214526|NCT05174078|Experimental|Produce Box and Recipes|Weekly produce box delivered to participants' homes and access to recipes via the internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
10214527|NCT05174078|No Intervention|Standard of Care|Matched controls from the same base population as participants in the intervention arms. Controls will identified from the electronic medical record (EMR).
10214528|NCT05169905|Experimental|Pooled Pediatric Group|Healthy non-pregnant girls 9-17 years of age receive a single dose of RSV MAT vaccine at Day 1 and a single dose of dTpa vaccine at Day 31 (first vaccination schedule), or a single dose of dTpa vaccine at Day 1 and a single dose of RSV MAT vaccine at Day 31 (second vaccination schedule) and are followed-up until end of study (180 days post-RSV MAT vaccine administration).
10214529|NCT05169905|Experimental|Pooled Adult Group|Healthy non-pregnant adult women 18-49 years of age receive a single dose of RSV MAT vaccine at Day 1 and a single dose of dTpa vaccine at Day 31 (first vaccination schedule), or a single dose of dTpa vaccine at Day 1 and a single dose of RSV MAT vaccine at Day 31 (second vaccination schedule) and are followed-up until end of study (180 days post-RSV MAT vaccine administration).
10214530|NCT05169866|Experimental|Intravenous Nifekalant|Patients randomized to Nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours. If the patient has a recurrence of atrial fibrillation, the maintenance dose can be increased (up to 0.8 mg/kg/h) according to the patient's condition, or receive a bolus of 3mg/kg again at 2 hours intervals. Nifekalant is administered for 24 hours unless meeting the criteria for discontinuation.
10214531|NCT05169866|Active Comparator|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours. If the patient has a recurrence of atrial fibrillation, the dosage can be adjusted according to the patient's condition, but the total dosage administered within 24 hours should not exceed 2g. Amiodarone is administered for 24 hours unless meeting the criteria for discontinuation.
10214532|NCT05160740|Experimental|ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group
10214533|NCT05160740|Placebo Comparator|No ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group
9941039|NCT00994253|Experimental|Aliskiren|"Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day.~Patients will be assigned to the treatment arm containing aliskiren. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + aliskiren 150-300mg"
9941040|NCT00994253|Active Comparator|Hydrochlorothiazide|"HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day.~Patients will be assigned to the treatment arm containing HCTZ. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + HCTZ 12.5-25mg"
9480647|NCT05262283||2020-2021 season|Injuries in the first 26 games of 2020-2021 in the new post-COVID season
9941041|NCT00994266|Experimental|A|Diamel
9941042|NCT00994266|Placebo Comparator|B|Placebo
9941043|NCT00994305|Active Comparator|N-acetylcysteine|N-acetylcysteine 600 mg bid po 0-7 PO
9941044|NCT00994305|Sham Comparator|control|No treatment: standard care provided. No N-acetylcysteine administration.
9941045|NCT00994331|Active Comparator|Group A-CT Coregistration|5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
9941046|NCT00994331|Active Comparator|Group B-Angiographic|5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
9941047|NCT00994331|Active Comparator|Group C-Standard Angiography|5 subjects with standard angiography in a conventional PCI (Group C)
9941048|NCT00994344|Experimental|Darunavir/ritonavir|to switch from the triple therapy based regimens to Darunavir/ritonavir
9941049|NCT00994344|Active Comparator|Lopinavir/ritonavir|to switch from the triple therapy based regimens to Lopinavir/ritonavir
9941050|NCT00994357|Experimental|Real-time Continuous Glucose Monitoring|Real-time Continuous Glucose Monitoring at five times for up to 6 days during pregnancy, and during delivery, in addition to standard monitoring and treatment.
9941051|NCT00994357|Active Comparator|Control group|Standard monitoring and treatment of diabetic patients during pregnancy.
9941052|NCT00994370||liver cancer|Patients referred for SIRT will be considered for this investigation. These patients will predominantly have stage IV colorectal metastases with liver dominant metastases or hepatocellular carcinoma. A team of oncologists, interventional radiologists, radiation oncologists and oncologic surgeons will determine that the patients are not candidates for surgical resection or ablative therapy. The patients will then be screened to confirm the patient's eligibility to receive standard of care SIRT treatment. SIRT treatment and imaging studies included in this investigation are standard of care for the patients' liver dominant disease.
9941053|NCT00994396|Placebo Comparator|Placebo pill|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos
9941054|NCT00994396|Experimental|Vitamin D|4000 IU vitamin D3 (cholecalciferol) per day for 6 months.
10001319|NCT01546493|Experimental|Symptomatics|Subjects with bilateral cam deformity and unilateral symptoms. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
10001320|NCT01546493|Experimental|Asymptomatic|Asymptomatic subjects with cam deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
10001321|NCT01546506|Experimental|Midodrine|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
10001322|NCT01546506|No Intervention|No treatment|
10001323|NCT01546545||Enrollment Group|Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.
10001324|NCT01546558|Experimental|Metformin, Ranolazine|"Single cohort, 2-period study:~Period 1, metformin 1000 mg bid on Days 1-5~Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10"
10001325|NCT01546597|Experimental|Metformin, Ranolazine|"Single cohort, 4-period study:~Period 1, metformin 500 mg bid on Days 1-5~Period 2, metformin 850 mg bid on Days 6-10~Period 3, metformin 500 mg bid + ranolazine 1000 mg bid on Days 11-15~Period 4, metformin 850 mg bid + ranolazine 1000 mg bid on Days 16-20"
10001326|NCT01546610|Experimental|intervention foot orthoses|Ethyl vinyl acetate (EVA) insole with medial arch support and bar retrocapital
10001327|NCT01546610|Placebo Comparator|placebo insole|Foot orthose with support retrocapital and support of medial arch insole intervention
10035056|NCT01802671|Experimental|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways: a web tool named TEO (Emotional Therapy Online) and SMS that will send to the patients' mobile phone with reminders and reinforcements.
10035057|NCT01802671|Active Comparator|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment and information
10035058|NCT01802671|Experimental|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT.
10214534|NCT05156099||ScanNav Anatomy PNB unaided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance without the device.
10214535|NCT05156099||ScanNav Anatomy PNB-aided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance with the device.
10214536|NCT05155631|Experimental|Cognitive Behavioral Treatment Arm|"Subjects in the Cognitive Behavioral Treatment Arm will undergo 8-10 weeks of remote cognitive behavioral therapy. Subjects will complete modules on their phones and will be monitored by study coordinators for support and treatment completion."
10214537|NCT05155631|No Intervention|Usual Care Arm|"Subjects in the Usual Care Arm will undergo 8-10 weeks of continued lifestyle. Subjects will be asked to report any new medications or lifestyle changes to study coordinators throughout the 8-10 weeks."
10214538|NCT05153395|Experimental|Insulin|Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
10214539|NCT05137600|Experimental|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
10001328|NCT01546662|Experimental|E-RH-06 - Low Dose|1 Capsule twice daily
10001329|NCT01546662|Experimental|E-RH-06 - High Dose|2 capsules twice daily
9800785|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 150 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 3 mg/kg (not to exceed 150 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
9941055|NCT00994474|Active Comparator|Fractional carbon dioxide laser treatment|
9941056|NCT00994474|Active Comparator|Fractional Er:YAG laser treatment|
9941057|NCT00994487|Experimental|Breastfed child|Female, normal weight, 3 to 5 year old children, exclusively breastfed from birth to 3 months of age
9941058|NCT00994487|Active Comparator|Bottle Fed Child|Female, normal weight, 3 to 5 year old children, exclusively bottle fed from birth to 3 months of age
9941059|NCT00994500|Experimental|Treatment (vorinostat, bortezomib)|Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9941060|NCT00994513|Active Comparator|ALA|alpha lipoic acid 1200 mg/day
9941061|NCT00994513|Placebo Comparator|Placebo|placebo 1200 mg/day
9941062|NCT00994526|Placebo Comparator|Ham|
9941063|NCT00994526|Experimental|Ham + calcium|
9941064|NCT00994526|Experimental|Ham + vitamin E|
9941065|NCT00994552|Active Comparator|Pressure support ventilation|Pressure support ventilation
9941066|NCT00994552|Active Comparator|Pressure control ventilation|Pressure control ventilation
9941067|NCT00994565|No Intervention|Usual care|
9941068|NCT00994565|Active Comparator|Activity monitoring and distance counseling|
9941069|NCT00994578|No Intervention|Internet Only|Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
9941070|NCT00994578|Experimental|CHESS|Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
9941071|NCT00994578|Experimental|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
9941072|NCT00994578|Experimental|CHESS/COPE|Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
9941073|NCT00994591|Experimental|Pharmacokinetic dosing|
9941074|NCT00994617|Experimental|Combination Therapy|Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
9941075|NCT00994617|Active Comparator|Monotherapy|Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
9941076|NCT00994630||BP I patients manic phase|
9941077|NCT00994656||posterior spinal fusion subject|Subject will have a history of either idiopathic or neuromuscular scoliosis who is now scheduled to have a posterior spinal fusion.
9941078|NCT00994669||healthy control male|
9941079|NCT00994669||lung cancer male|
9941080|NCT00994721||pancreatic cancer|resected pancreatic cancer
9941081|NCT00994734|No Intervention|clinic administration of mifepristone|
9941082|NCT00994734|Experimental|home administration of mifepristone|
9941083|NCT00994747|Active Comparator|Group EEEEEEE|Infant is fed Enfamil from 0.5-7.5 months of life
9941084|NCT00994747|Experimental|Group ENEEEEE|Infant is fed Enfamil during 0.5-1.5 months of life, Nutramigen from 1.5-2.5 months of life and then Enfamil 2.5-7.5 of life.
9941085|NCT00994747|Experimental|Group EENEEEE|Infant is fed Enfamil 0.5-2.5 months of life, Nutramigen from 2.5-3.5 months of life and then Enfamil from 3.5 to 7.5 months of life
9941086|NCT00994747|Experimental|Group EEENEEE|Infant is fed Enfamil from 0.5-3.5 months of life, Nutramigen from 3.5-4.5 months of life and then Enfamil from 4.5-7.5 months of life.
9941087|NCT00994747|Experimental|Group ENNNEEE|Infant if fed Enfamil from month 0.5-1.5 months of life, Nutramigen from 1.5 to 3.5 months of life and then Enfamil again 3.5-7.5 months of life.
9941088|NCT00994747|Experimental|Group NNNNNNN|Infant is fed Nutramigen from 0.5-7.5 months of life.
9941089|NCT00994773|Experimental|Simvastatin|Simvastatin orally
9941090|NCT00994773|Experimental|Simvastatin and tenofovir|Simvastatin combined with tenofovir
9941091|NCT00994773|Experimental|Simvastatin and entecavir|Simvastatin combined with entecavir
9941092|NCT00994786|Experimental|pregabalin|
9941093|NCT00994786|Placebo Comparator|Placebo|
9941094|NCT00994799||ranibizumab group|patients receiving intravitreal ranibizumab for diabetic macular edema
9941095|NCT00994799||laser|patients receiving macular grid-pattern laser therapy
9941096|NCT00994812|Experimental|Metformin|
9941097|NCT00994825|Placebo Comparator|Placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
9941098|NCT00994825|Experimental|Levosimendan|Levosimendan
9941099|NCT00994838|Active Comparator|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
9941100|NCT00994838|No Intervention|standard diet|
9941101|NCT00994851|Experimental|SENNA+ CASSIA|Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days
9941102|NCT00994851|Placebo Comparator|Placebo|Daily administration (capsule) of placebo at bedtime, during 30 days
9528375|NCT03211507||Controls|Males with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
9528376|NCT03211455|Placebo Comparator|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
9528377|NCT03211455|Experimental|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
10001330|NCT01546662|Placebo Comparator|Placebo ;|Placebo Comparator
10001331|NCT01546701|Experimental|Buprenorphine|Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
10001332|NCT01546701|Active Comparator|Morphine|Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
10001333|NCT01546714||AAWSW/AAWSWM|African American Women Who Have Sex with Women/African American Women Who Have Sex with Women and Men
10001334|NCT01546727|Experimental|Family Behavioral Treatment|This intervention will provide nutritional counseling for a health diet, parent training in effective child behavioral management strategies, and stimulus control of the home environment delivered via group based clinic visits and individual home visits on alternate weeks
10001335|NCT01546727|Active Comparator|Motivational Interviewing|This intervention will shared information with parents about their child's weight and use motivational interviewing to elicit changes parents would like to make to their child diet and activity patterns.
10001336|NCT01546727|No Intervention|Standard of Care|Participants in this arm will be followed over time and be assessed on the primary and secondary outcomes at the same time points as the two treatment arms
10001337|NCT01546740||Glaucoma patients|all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma.
10001338|NCT01546753|Experimental|Walnut Protein Powder|146 weeks for active treatment subjects
10001339|NCT01546753|Placebo Comparator|Oat Powder|184 weeks for placebo
10001340|NCT01546766||Subjects with diabetes|(Subjects that have been diagnosed with diabetes).
10001341|NCT01546766||Control volunteers|(Subjects with no history of ocular problems).
10001342|NCT01546766||Subjects with retinal conditions|(Subjects with a history of retinal disorders except diabetes).
10001343|NCT01546779|Experimental|lung function|
10001344|NCT01546792|No Intervention|Usual care control|Leaflet on exercise and diet
10001345|NCT01546792|Experimental|Lifestyle intervention|Exercise training (mixture of supervised and non-supervised) Dietary advice Behaviour change counselling (physical activity, diet)
10001346|NCT01546805|Placebo Comparator|Placebo|
10001347|NCT01546805|Experimental|Zinc Group|
9528378|NCT03211169|Experimental|Pediatric Biopsy Forceps directed biopsies|Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
9528379|NCT03211169|Active Comparator|Cholangioscopy-directed biopsies|Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.
9528380|NCT03211338|Active Comparator|Preterm labor placentas and progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
10001348|NCT01546844|Experimental|Care4Life|Text message and online interactive component to help patients with self-management.
10001349|NCT01546844|No Intervention|Standard of Care|Patients enrolled in this arm will receive their normal standard of care from their physician for treatment of type II Diabetes Mellitus.
10001350|NCT01546870||pediatric heart transplant recipients|
10001351|NCT01546896|Experimental|buspirone+alprazolam|
10001352|NCT01546896|Active Comparator|alprazolam|
10001353|NCT01546896|No Intervention|healthy controls|
10001354|NCT01546909|Experimental|TETRAVAC-ACELLULAIRE|
10001355|NCT01546935|Experimental|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
10001356|NCT01546961|Experimental|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
10001357|NCT01546974|Experimental|HME filter|
10001358|NCT01546974|Experimental|Heated humidificator MR 730 Fisher & Paykel|
10001359|NCT01546987|Active Comparator|ADT + GnRH agonist + dose escalated radiation|Patients receive standard androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation therapy (RT).
10001360|NCT01546987|Experimental|ADT + GnRH agonist + dose escalated radiation + TAK-700|Patients receive the same standard ADT with a GnRH agonist and oral antiandrogen. In addition, patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO twice daily (BID) for 2 years.
10001361|NCT01547013||COHORT 1|"Critical Controls: Twenty five (25) critically injured subjects with NO severe traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. (Critical CONTROLS)"
10001362|NCT01547013||COHORT 2|"Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with severe leg injuries presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT)"
10214540|NCT05137600|Experimental|Midazolam|Midazolam is a sensitive CYP3A index substrate
10214541|NCT05137600|Experimental|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites
10001363|NCT01547013||COHORT 2A|"Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL severe leg injuries. Unilateral injuries include patients who meet the inclusion criteria for a severe lower extremity injury for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg."
10001364|NCT01547013||COHORT 2B:|"Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a severe leg injury. Bilateral injury patients include patients with at least one lower extremity injury classified as severe based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort."
10001365|NCT01547013||COHORT 2C|Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
10001366|NCT01547026|Active Comparator|Psycho-education|Patients receive a 10 min. psycho-education on positive health effects of sports
10001367|NCT01547039||Carotid endarterectomy (CEA)|Patients undergoing carotid endarterectomy
10001368|NCT01547052|Experimental|DBT for children|Dialectical Behavior Therapy adapted for children
10001369|NCT01547052|Active Comparator|Enhanced Supportive-Educational Therapy|Enhanced Treatment-As-Usual, including supportive-educational model, cognitive-behavioral skills and parent management training
10001370|NCT01547078|Active Comparator|Licensed Plasma|
10001371|NCT01547078|Experimental|Lyophilized Plasma|
10001372|NCT01547091|Experimental|UC-MSCs Treatment|Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.
10001373|NCT01547091|Active Comparator|DMARDS|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).
10001374|NCT01547091|Active Comparator|UC-MSC+DMARDS|Patients will be treated in combination with UC-MSC and DMARDS.
10001375|NCT01547104|Active Comparator|Glimepiride-ratiopharm|Glimepiride (1-4mg) as add on therapy
10001376|NCT01547104|Experimental|Trajenta|Linagliptin 5 mg as add on therapy
10001377|NCT01547143|Experimental|IST and/or alloHCT|Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.
10001378|NCT01547156|No Intervention|Control group|Control group received usual care
10001379|NCT01547156|Experimental|Telemonitoring group|Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
10001380|NCT01547169|Placebo Comparator|Saline|
10001381|NCT01547169|Experimental|Low Dose Insulin Detemir (10IU bid)|
10001382|NCT01547169|Experimental|High Dose Insulin Detemir (20IU bid)|
10001383|NCT01547182|Active Comparator|Weight Loss|Caloric restriction
10001384|NCT01547182|Experimental|Weight Loss and Aerobic Training|Caloric restriction and walking
10001385|NCT01547182|Experimental|Weight Loss and Resistance Training|Caloric restriction and lifting weights
10001386|NCT01547195|Experimental|Group-swimming|
10001387|NCT01547195|Active Comparator|Control-walk|
10001388|NCT01547208|Experimental|Group A|Patients will be randomized to a VT ablation procedure immediately after an appropriate ICD shock
10001389|NCT01547208|Active Comparator|Group B|Patients will wait until an arrhythmic storm to undergo a VT ablation procedure
10001390|NCT01547221|Active Comparator|3% boric acid|control
10214542|NCT05137548|Experimental|ATI-2173.|ATI-2173
10001391|NCT01547221|Experimental|1% clotrimazole ear drop|3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.
10001392|NCT01547260|Experimental|Lenalidomide|Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
10001393|NCT01547260|Experimental|gemcitabine|Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II. Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
10001394|NCT01547273|Experimental|bone graft inside socket only|bone graft inside socket only
10001395|NCT01547273|Experimental|bone graft inside and outside socket|bone graft inside and outside socket
10214543|NCT05137548|Experimental|Tenofovir Disoproxil Fumarate|Tenofovir disoproxil fumarate
10214544|NCT05127824|Experimental|HLA-A2 postive|The study will include 21 participants over the 18 years of age with newly diagnosed, clinically localized clear cell renal cell carcinoma, planned for surgical resection with curative intent. Participants receiving vaccine much be HLA-A2 positive.
10214545|NCT05127824|No Intervention|HLA-A2 negative|Up to 21 additional participants who screen as HLA-A2 negative will be enrolled as non-treatment controls. These participants will not be required to undergo blood collection or study procedures
10214546|NCT05126758|Active Comparator|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
10001396|NCT01547273|Experimental|no bone graft|no bone graft
10001397|NCT01547312|Experimental|Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV|800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
10001398|NCT01547312|Experimental|Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV|100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
10001399|NCT01547312|Experimental|Main Pt.1: 800 mg Grazoprevir|800 mg Grazoprevir.
10001400|NCT01547312|Experimental|Procedural Pilot|Optimization of FNA procedure.
10001401|NCT01547325|Experimental|NanoDOX Hydrogel|
10001402|NCT01547325|Placebo Comparator|Placebo Hydrogel|
10001403|NCT01547338||Breast reconstruction patient|Unilateral breast reconstruction patients
10001404|NCT01547351||ARMS Questionnaire Group|Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire. These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
10001405|NCT01547364|Placebo Comparator|Caudal Saline|
10001406|NCT01547364|Active Comparator|Caudal Dextrose|
10001407|NCT01547377|Experimental|zinc and selenium supplementation|Patients received 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation during 4 months
10001408|NCT01547377|Placebo Comparator|rosuvastatin + placebo|Patients received 10 mg rosuvastatin concomitantly placebo pills similar zinc and selenium supplementation
10001409|NCT01547416|Experimental|combined general/epidural anesthesia|epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. Epidural analgesia was maintained using the patient-controlled analgesia technique.
10001410|NCT01547416|Active Comparator|General anesthesia|Patients allocated to general anesthesia group did not receive epidural anesthesia.
10001411|NCT01547429|Experimental|Intraocular Lens Implantation for the Treatment for Aphakia|Implantation of an Artisan intraocular lens to correct aphakia in Adults. No other information is needed to describe this section
10001412|NCT01547442|Experimental|Artisan Aphakia Intraocular Lens|Implantation of an Artisan intraocular lens to correct aphakia in children
10001413|NCT01547455|Experimental|Atorvastatin|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
10001414|NCT01547455|Placebo Comparator|Control|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
10001415|NCT01547481||Parkinson's Disease Cohort|Individuals Diagnosed with Parkinson's Disease
10001416|NCT01547481||Essential Tremor cohort|Individuals Diagnosed with Essential Tremor
10001417|NCT01547481||Rapid Eye Movement Disorder Cohort|Individuals Diagnosed with Rapid-Eye Movement Behavior Disorder (RBD). Eligible individuals will have been diagnosed with RBD based on a sleep study prior to entering the study. This study does not pay for or support a sleep study.
10001418|NCT01547481||Healthy Control group|Individuals are healthy, without a known neurologic disease.
10001419|NCT01547481||Progressive Supranuclear Palsy Cohort|Individuals diagnosed with Progressive Supranuclear Palsy (PSP).
10001420|NCT01547481||Parkinsonism - Undifferentiated|Individuals with any form of Parkinsonism, not meeting any of the above cohorts.
10001421|NCT01547494|Placebo Comparator|Dietary Supplement|
10001422|NCT01547494|Experimental|Vegan Diet|
10001423|NCT01547507|Active Comparator|KimVent Turbo-Cleaning Closed Suction System Kimberly clark|
10001424|NCT01547507|Active Comparator|Airway Medix Closed Suction System|
9476212|NCT03574155|Experimental|Experimental Group|"Composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium who will receive preoperative counseling and education through a pre-defined protocol after preoperative consultation with the surgeon. The counseling session will take place with at least one companion. The purpose of this session is to supplement, re-emphasize and strengthen the perioperative guidelines. An illustration (explanatory folder) will be used to demonstrate the location of the surgery, how the scar will be and on which sites of the abdomen and organs the surgery will cover. All this counseling and education will be applied at the same time to the patient and her companion. At the end of the intervention, a space will be left open for both the patient and the companion to ask questions and questions.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
9476213|NCT03574142|Experimental|Epanova|Epanova® capsule, per oral
10001425|NCT01547520|Experimental|meperidine|25 mg of meperidine is injected intramuscularly before EGD
10001426|NCT01547520|Placebo Comparator|placebo|placebo was given intramuscularly before EGD
10001427|NCT01547533||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating
10001428|NCT01547546|Experimental|Single Arm|
10001429|NCT01547559|No Intervention|part1:blank control|NO maintain drugs with Hp negative patients.
10001430|NCT01547559|Experimental|part1:teprenone 1|maintain treatment with Teprenone for Hp negative patients
10001431|NCT01547559|Experimental|part1:EAC-T|eradication of Hp with triple treatment
10001432|NCT01547559|Experimental|part1：EA-EMC-T|eradication of Hp with sequential therapy
9476214|NCT03574103|Active Comparator|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction as dietary weight loss strategy.
9476215|NCT03574103|Experimental|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
9476216|NCT03574103|Experimental|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
9476217|NCT03574090|Experimental|amoxicillin clavulanate|1000 mg amoxicillin and potassium clavulanate equivalent to 200mg of clavulanic acid. administered topically and dissolved in 500 ml 0.9% Physiological Serum.
9476218|NCT03574090|Active Comparator|Physiological Saline|500 milliliters of 0.9% Physiological Serum.
9476219|NCT03574077|Experimental|Instant messaging|AWARD advice + NRT sampling + Active referral + Instant Messaging (IM)
9476220|NCT03574077|Active Comparator|SMS messaging|AWARD advice + NRT sampling + Active referral + SMS messaging
9476221|NCT03574064|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
9476222|NCT03574064|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
9476223|NCT03574064|Experimental|GLP-2+GIP|GLP-2+GIP
9476224|NCT03574064|Placebo Comparator|Placebo|Placebo
9476225|NCT03574051|Experimental|Probiotic|Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days
9476226|NCT03574025||Cardiac Arrest Questionnaire|Children who will survive 3 months after Cardiac Arrest
10001433|NCT01547559|Active Comparator|part1：T-T|Teprenone as maintain drugs for Hp positive patients
10001434|NCT01547559|Experimental|part2:GGA group|Geranylgeranylacetone plus diclofenac sodium for patients with rheumatic diseases
10001435|NCT01547559|No Intervention|part2:control group|diclofenac sodium only for patients with rheumatic diseases
10001436|NCT01547572|Experimental|Study group|The study group will get a video and leaflet on enhanced recovery.
10001437|NCT01547572|No Intervention|Control group|The control group will receive a leaflet only.
10001438|NCT01547585|Placebo Comparator|Control|- Isocaloric control muffins
10001439|NCT01547585|Experimental|Low Dose Soy|- Isocaloric muffins containing low dose of soy
10001440|NCT01547585|Experimental|High Dose Soy|- Isocaloric muffins containing high dose soy
10001441|NCT01547611|Active Comparator|Customary treatment|Group A (physiotherapy as usual), customary treatment. The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
10214547|NCT05126758|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
10214548|NCT05123612|Experimental|Fiber|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day.
10214549|NCT05123612|Experimental|Fermented Foods|Participants will be asked to consume 6 servings of fermented foods per day.
10214550|NCT05123612|Experimental|Fiber + Fermented Foods|Participants will be asked to increase their usual dietary fiber intake by 20 grams/day and to consume 6 servings of fermented foods per day.
10214551|NCT05123612|No Intervention|Comparator|Participants will receive usual care for pregnancy and postpartum.
10214552|NCT05113303||navigation assisted knee revision surgery|
10214553|NCT05113303||manual procedure|
10001442|NCT01547611|Experimental|structured behavioural medicine program|Group B (extended physiotherapy treatment), customary treatment (please see above) plus a standardised and structured behavioural medicine program. The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
10001443|NCT01547624|Experimental|Neck Specific exercises|3 months of neck specific exercises for 30 patients.
10001444|NCT01547624|No Intervention|Waiting list|Thirty patients on the waiting list for 3 month before they have their intervention
10001445|NCT01547624|No Intervention|Healthy controls|Forty healthy controls. Comparisons between forty included WAD patients and 40 healthy controls matched for age and gender will be investigated at baseline.
10001446|NCT01547637|Experimental|Ultrasound Guided|Ultrasound guided obturator nerve block will be performed after induction of general anesthesia. The anterior and posterior divisions of the obturator nerve will be identified with ultrasound. A stimulating needle will be inserted under direct ultrasound visualization. The anterior division will be blocked first. When adductor twitches are present at less than or equal to 0.5 mA, 10 ml of 2% lidocaine will be injected. Next, the needle will be re-directed under direct ultrasound visualization towards the posterior branch of the obturator nerve. After twitches < 0.5 mA are achieved then 10 mL of 2% lidocaine will be injected when the needle tip is visualized in proximity of the posterior branch.
10001447|NCT01547637|Experimental|Anatomic landmark|Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
10001448|NCT01547650||SIADH, CSWS, CDI, PP, DIH, HF|CSWS (cerebral salt wasting syndrome), SIADH (syndrome of inappropriate ADH) , CDI (central diabetes insipidus), PP (primary polydipsia), DIH (drug-induced hyponatremia), HF (heart failure with hyponatremia)
10001449|NCT01547676|Experimental|Arm A (unclamped partial nephrectomy)|Patients undergo unclamped partial nephrectomy. Some patients may undergo unclamped partial nephrectomy with controlled hypotension.
10001450|NCT01547676|Active Comparator|Arm B (clamped partial nephrectomy)|Patients undergo clamped partial nephrectomy.
10001451|NCT01547689|Experimental|Human Umbilical Cord Derived MSC|
10001452|NCT01547702|Experimental|Treatment|This group will have access to the Teacher Help for ADHD intervention program during the randomized controlled trial.
10001453|NCT01547702|No Intervention|Waitlist Control|This group will not receive the intervention until all data collection is complete for their study cohort.
10001454|NCT01547884||1|Latent TB positive with helminth positive
10001455|NCT01547884||2|Latent TB positive with helminth negative
9800786|NCT01697579|Experimental|Fosaprepitant 1.2 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 60 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 1.2 mg/kg (not to exceed 60 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
9800787|NCT01697579|Experimental|Fosaprepitant 0.4 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 20 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 0.4 mg/kg (not to exceed 20 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
10001456|NCT01547897|Active Comparator|NOX-E36|
10001457|NCT01547897|Placebo Comparator|Placebo|
10001458|NCT01547910|Experimental|Fish oil|Children will receive fish oil capsules according to age as described in the protocol
10001459|NCT01547910|Placebo Comparator|Placebo|Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
10001460|NCT01547923|Experimental|A : pre-therapeutic screening for DPD deficiency|Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
10001461|NCT01547923|Other|B : no pretherapeutic research of DPD deficiency|For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
10001462|NCT01547949|Experimental|tart cherry juice|
10001463|NCT01547949|Placebo Comparator|cherry flavored fruit drink|
10001464|NCT01547962|Experimental|Split-mouth design: Treatment|
10001465|NCT01547962|Active Comparator|Split-mouth design: Control|
10001466|NCT01547988|Experimental|Balance Training Intervention|The Balance Training Intervention group received 24 training sessions over three months that included perturbation as well as dual-task exercises.
10001467|NCT01547988|No Intervention|Reference Group|
10001468|NCT01548001|Experimental|Iguratimod monotherapy|
10001469|NCT01548001|Experimental|Iguratimod and MTX combination|
10001470|NCT01548001|Active Comparator|MTX monotherapy|
10001471|NCT01548027|Experimental|No intervention|no injection of local anesthetic agents
10001472|NCT01548027|Experimental|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
10001473|NCT01548027|Experimental|TAP block group|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
10001474|NCT01548066|Experimental|Sodium valproate|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
10001475|NCT01548066|Placebo Comparator|Control|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
10001476|NCT01548079|No Intervention|Control|Untreated controls
10001477|NCT01548079|Active Comparator|Ursodeoxycholic acid|Oral ursodeoxycholic acid 20 mg/kg/day in three weeks
10001478|NCT01548092|Experimental|Autologous SVF|Intralesional application
10001479|NCT01548105||Prolapse and Smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and have been smoking more than one pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
10001480|NCT01548105||Prolapse and non smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
10001481|NCT01548105||No prolapse and smoker|Patients in this arm, have been determined not to have prolapse and smokes more than 1 pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
10001482|NCT01548105||No prolapse and non smoker|Patients in this arm have been determined not to have prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
10001483|NCT01548118|Experimental|Adult Group 1, HPV vaccine 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
10001484|NCT01548118|Placebo Comparator|Adult Group 1, Placebo 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
10001485|NCT01548118|Experimental|Adult Group 2, HPV vaccine 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
9528381|NCT03211338|Active Comparator|Term labor placentas and progesterone|IMC cells taken from term labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
10001486|NCT01548118|Placebo Comparator|Adult Group 2, Placebo 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
10001487|NCT01548118|Experimental|Children Group 1, HPV vaccine 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
10214554|NCT05097014|Active Comparator|CHF5993|pMDI fixed combination product of beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF) and 10 µg of glycopyrronium (G)
10001488|NCT01548118|Placebo Comparator|Children Group 1, Placebo 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
10001489|NCT01548118|Experimental|Children Group 2, HPV vaccine 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
10001490|NCT01548118|Placebo Comparator|Children Group 2, Placebo 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
10001491|NCT01548131|Experimental|Psychoeducative group therapy|Psychoeducative group therapy
9528382|NCT03211338|Active Comparator|Preterm labor placentas without progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
10001492|NCT01548131|No Intervention|Control|Women screened for fear of childbirth were taken cared by primary health care nurses and if needed referred to specialized care in hospital
10001493|NCT01548144|Experimental|Crizotinib + Pazopanib - Group A|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
10001494|NCT01548144|Experimental|Crizotinib + Pemetrexed - Group B|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
9528383|NCT03211338|Active Comparator|Term labor placentas without progesterone|IMC cells taken from term labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
9528384|NCT03211338|Active Comparator|Term placentas from progesterone treated pregnancies|IMC cells taken from term labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
9528385|NCT03211338|Active Comparator|Preterm placentas from progesterone treated pregnancies|IMC cells taken from preterm labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
10001495|NCT01548144|Experimental|Pazopanib + Pemetrexed - Group C|"Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Expansion group starting dose: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion group starting dose: MTD from Phase 1."
10214555|NCT05097014|Active Comparator|CHF1535|pMDI fixed combination product beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF)
10214556|NCT05097014|Placebo Comparator|Matched placebo|Matched placebo pMDI
10214557|NCT05096507||Study group|People age 65 years and older undergoing primary hip fracture surgery
10214558|NCT05091294|Active Comparator|Group S:33|120-second local anesthesic (% 0,5 Bupivacaine) injection time
9528386|NCT03211338|Active Comparator|Term placentas not treated with progesterone in pregnancy|IMC cells taken from term placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
9528387|NCT03211338|Active Comparator|Preterm placentas not treated with progesterone in pregnancy|IMC cells taken from preterm placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
9528388|NCT03211338|Active Comparator|Term postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
9528389|NCT03211338|Active Comparator|Preterm postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
9528390|NCT03211338|Active Comparator|Term postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
9528391|NCT03211338|Active Comparator|Preterm postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
9528392|NCT03211182|Experimental|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
9528393|NCT03211182|No Intervention|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
9941103|NCT00994864|Other|adjuvant FOLFOX (1 pre-operative cycle)|One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
9941104|NCT00994877||Septic Patients|
9941105|NCT00994877||Healthy Control|
9941106|NCT00994903|Placebo Comparator|Placebo|Placebo tablets (Inert calcium lactate)
9941107|NCT00994903|Experimental|Simvastatin|40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
9941108|NCT00994955|Experimental|selective retina therapy (SRT)|Focal laser treatment with an SRT-Laser which selectively affects the retinal pigment epithelium while sparing the photoreceptor layer.
9941109|NCT00994981|Experimental|magnesium|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
9941110|NCT00994981|Placebo Comparator|normal saline|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
9941111|NCT00994994|Active Comparator|Tranexamic acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
9941112|NCT00994994|Placebo Comparator|Placebo|same volume of normal saline was given.
9941113|NCT00995033|Experimental|NicVAX conjugate vaccine|
9941114|NCT00995033|Placebo Comparator|Placebo|Biological
9941115|NCT00995046|Active Comparator|usual prophylaxis regimen|All patients will receive their usual prophylaxis regimen during the first 6 months
9941116|NCT00995046|Experimental|individually tailored prophylaxis regimen|All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.
9941117|NCT00995059|Experimental|Arm 1|CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
9941118|NCT00995098|Experimental|Early enteral nutrition|Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
9800788|NCT01697579|Placebo Comparator|Placebo Control-Cycle 1|Participants were administered IV normal saline at volume to match age and weight specific doses of fosaprepitant. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
9941119|NCT00995098|Active Comparator|Control: Parenteral Nutrition|Twenty patient will be enrolled into this arm. PN administration will start within 24 hours after admission and continue for 7 days after admission.Parenteral nutrition will be administered through subclavian central venous catheter.
9941120|NCT00995124|Experimental|NeutraLice Lotion|Single application of head lice product.
9941121|NCT00995124|Experimental|NeutraLice Advance|single application of head lice product
9941122|NCT00995124|Active Comparator|Moov Head Lice Solution|Single application for head lice with 10 min application time.
9941123|NCT00995137|Experimental|relapse B-Lineage ALL|"All patients meeting the eligibility criteria.~Intervention: NK Cell Infusion"
9941124|NCT00995150|Experimental|LNG20|LNG20 levonorgestrel-releasing intrauterine system
9941125|NCT00995150|Active Comparator|Mirena|Levonorgestrel-releasing intrauterine system for contraception
9941126|NCT00995176||1|Women residing in areas from defined geographic areas with high HIV prevalence and poverty
9941127|NCT00995176||2|Men residing in areas from defined geographic areas with high HIV prevalence and poverty
9941128|NCT00995189|Experimental|OFR|Opti-Free RepleniSH contact lens care solution used for 30 days
10001496|NCT01548144|Experimental|Crizotinib + Pazopanib + Pemetrexed - Group D|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
10001497|NCT01548157|Experimental|HCP1007|HCP1007
10001498|NCT01548157|Active Comparator|omarco and crestor|Rosuvastatin plus Omega-3
10001499|NCT01548170|Active Comparator|Sunitinib 50mg|Sunitinib 50 mg administered as a single dose.
10001500|NCT01548170|Experimental|Sunitinib 37.5mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
10001501|NCT01548170|Experimental|Sunitinib 37.5 mg + Ketoconazol 400 mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
10001502|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
10001503|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 400mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
10001504|NCT01548183|Experimental|Lifestyle counseling|Weekly SMS assessing risky sexual encounters and providing feedback including concern, goal-setting and tools to reduce risk
10001505|NCT01548183|No Intervention|Usual care|Usual care includes ED provider counseling as per normal clinical care
10001506|NCT01548196|Other|standard percutaneous nephrostomy|Standard PCN
10001507|NCT01548196|Other|double-J ureteral stent,|double-J ureteral stent,
10001508|NCT01548196|Other|open-ended ureteral catheter|open-ended ureteral catheter
10001509|NCT01548196|No Intervention|no nephrostomy or ureteral stent/catheter.|no nephrostomy or ureteral stent/catheter.
10001510|NCT01548209|Experimental|Group D|A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
10001511|NCT01548209|Placebo Comparator|Group P|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
10035059|NCT01802684|Experimental|OPTIMOX-aflibercept|"Induction therapy (sequence #1)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)~Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)~Duration : 6 cycles (3 months) Second phase (sequence #2B)~Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)~Duration : until PD or limiting toxicity Reintroduction (sequence #3)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)~Regimen : aflibercept + fluoropyrimidine~Duration : until PD or limiting toxicity"
10035060|NCT01802697|Experimental|IdeS|Intravenous infusion
10035061|NCT01802697|Placebo Comparator|PBS Buffer|Intravenous infusion
10035062|NCT01802736|Active Comparator|Standard Positive Prevention Counselling|"Standard positive prevention counseling which includes alcohol reduction and sexual risk behavior counseling provided in the clinic by the clinic medical counselors on the day of enrollment and at month 3 visit.~Although there is awareness of the need to engage and include PLWHA in HIV prevention, there are little practical efforts devoted towards this engagement even in developed countries. One of the major reasons is the lack of a well-defined standard positive prevention package that needs to be delivered to PLWHA. The approach proposed by Kennedy et al modified to suit the local setting and involves a simpler understandable classification of the goals, interventions and expected outcomes of the treatment."
10035063|NCT01802736|Experimental|Alcohol Motivational intervention counselling plus SPP|
10214559|NCT05091294|Active Comparator|Group F:34|15-second local anesthesic(% 0,5 Bupivacaine) injection time
10214560|NCT05082285|Experimental|ABCWY-2Gen low dose Group|Participants receive 3 doses of the MenABCWY-2Gen low dose vaccine.
10214561|NCT05082285|Active Comparator|MenB+MenACWY-TT Group|Participants receive 3 doses of both the meningococcal group B (MenB) vaccine and the meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine.
10214562|NCT05082285|Experimental|ABCWY-2Gen high dose Group|Participants receive 3 doses of the MenABCWY-2Gen high dose vaccine in.
10214563|NCT05082285|Experimental|ABCWY-1Gen Group|Participants receive 3 doses of the MenABCWY-1Gen vaccine.
10214564|NCT05076552|Experimental|Phase 1: Dose Escalation|In Phase 1, participants will receive TACH101 in a 48 hour single-dose lead-in period followed by repeated dosing on a 3-day on/4-day off schedule in each 28 day cycle.
10214565|NCT05076552|Experimental|Phase 1b: Dose Expansion|"In Phase 1b, participants will receive TACH101 at the RP2D identified in Phase 1 on a 3-day on/4-day off schedule. Two cohorts of participants will be enrolled:~Participants with gastrointestinal cancers~Participants with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC)."
10214566|NCT05073614|Other|patients with chronic gastritis|patients with symptomatic chronic gastritis will undergo upper endoscopy, gastric biopsies will be obtained to establish giagnosis of chronic gastritis, detection of h.pylori and assessment of heparanase expression.
10214567|NCT05072717|Experimental|Patients with a meniscal tear requiring surgery|Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an arthroscopic imaging system.
10214568|NCT05072704|Active Comparator|Control group|Sufentanil IV injection
10214569|NCT05072704|Experimental|OFA group|Dexmedetomidine IV infusion
10214570|NCT05069727|Active Comparator|Group 1, Regular Protocol|Participants will bolus (insulin), based on carbohydrate content in each meal
10001512|NCT01548235||BIAsp 30 users|
10001513|NCT01548248||Levemir® users|
10001514|NCT01548261||Health people.|
10001515|NCT01548300||Enrolled participants|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The participants will be nonsmokers with cardiometabolic disease, that are not taking anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS is not allowed.
10001516|NCT01548313||Pregnant women from Ljubljana region|Women at 3rd trimester of pregnancy living in the Ljubljana region.
10001517|NCT01548313||Pregnant women from Izola region|Women at 3rd trimester of pregnancy living in the Izola region.
10001518|NCT01548313||Pregnant women from Murska Sobota region|Women at 3rd trimester of pregnancy living in the Murska Sobota region.
10001519|NCT01548326|Active Comparator|Atorvastatin|will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
10001520|NCT01548326|Placebo Comparator|Placebo|will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
10001521|NCT01548365|No Intervention|Control Group|routine care for the selection, placement and maintenance of venous access devices (VAD).
10001522|NCT01548365|Experimental|Infusion Therapy Nursing Expert|Patients in this group will receive the infusion therapy nursing expert (ITNE) service.
10001523|NCT01548378|Experimental|High Dose|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
10001524|NCT01548378|Experimental|Middle Dose|Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
10001525|NCT01548378|Experimental|Low Dose|Patients in this treatment group will receive 4mg NL003 in D0、14、28
10001526|NCT01548378|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
10001527|NCT01548391|Experimental|HX-1171 20 mg (20mg 1T)|
10001528|NCT01548391|Experimental|HX-1171 40 mg (20mg 2T)|
10001529|NCT01548391|Experimental|HX-1171 80 mg (20mg 4T)|
10001530|NCT01548391|Experimental|HX-1171 160 mg (20mg 8T)|
10001531|NCT01548391|Experimental|HX-1171 300 mg (200mg 1T, 20mg 5T)|
10001532|NCT01548391|Experimental|HX-1171 600 mg (200mg 3T)|
10001533|NCT01548391|Experimental|HX-1171 1200 mg (500mg 2T, 200mg 1T)|
10001534|NCT01548391|Experimental|HX-1171 1500 mg (500mg 3T)|
10001535|NCT01548391|Experimental|HX-1171 2000 mg (500mg 4T)|
10214571|NCT05069727|Experimental|Group 2, Simplified protocol|Participants will bolus (insulin), based on three sets of meal set of meals announcement
10001536|NCT01548430|Experimental|TTP4000 1.0 mg/kg|Administered subcutaneously
10001537|NCT01548430|Experimental|TTP4000 3.0 mg/kg|Administered subcutaneously
10001538|NCT01548430|Placebo Comparator|Placebo|Administered subcutaneously
10001539|NCT01548443|Experimental|Medifoam H|"A group which treated with medifoam H on the wound."
10001540|NCT01548443|Active Comparator|Duoderm THIN|"A group which treated with  Duoderm THIN  on the wound"
10001541|NCT01548456||Intramedullary nailing|Subjects with a femur fracture who undergo operative fixation with an intramedullary nail
10001542|NCT01548456||Open Reduction Internal Fixation|Subjects with a femur fracture who undergo open reduction internal fixation with a dynamic compression plate
10001543|NCT01548469|Active Comparator|Perio Total Care toothpaste|A Group which use Perio Total Care toothpaste during participation.
10001544|NCT01548469|Experimental|Bio Mineral toothpaste|A Group which use Bio Mineral toothpaste during participation.
10001545|NCT01548482|Experimental|Treatment (trebananib, temsirolimus)|Patients receive trebananib IV over 60 minutes and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10001546|NCT01548495||Responded to rHuEPO treatment|response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
10001547|NCT01548495||IR to rHuEPO treatment|No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
10001548|NCT01548495||Responded to high level rHuEPO|Responded to more than 80,000UI of rHuEPO treatment
10214572|NCT05058274||Single arm|All participants
10214573|NCT05053620||Single arm|All patients.
10214574|NCT05046353|Experimental|D-serine|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
10214575|NCT05046353|Placebo Comparator|placebo|Subjects will receive 16 sessions of auditory remediation paired with either D-serine or Placebo in a 1:1 D-serine 120 mg/kg:placebo ratio.
10214576|NCT05044650|Experimental|KOVIR|Standard dose, 3 capsules/time x 3 times/day x 14 days combined with background treatment
10214577|NCT05044650|No Intervention|NON-KOVIR|Only background treatment
10214578|NCT05043376|Active Comparator|Standard of care|In this arm patients will receive the standard COVID-19 care as per the hospital guidelines.
10214579|NCT05043376|Experimental|BLIS K12|In this arm patients will receive the BLIS K12 as add-on to the standard COVID-19 care
10214580|NCT05041426|Experimental|Letermovir|Participants who are CMV seropositive (CMV R+) will receive letermovir prophylaxis for 6 months, and participants who are CMV donor seropositive/recipient seronegative (CMV D+/R-) will receive letermovir prophylaxis for 12 months. Letermovir will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If letermovir is co-administered with cyclosporine A, the dosage of letermovir will be decreased to 240 mg once daily.
10214581|NCT05041426|Active Comparator|Valganciclovir|Historical controls will be lung transplant recipients for idiopathic pulmonary fibrosis from 2010-2019 who are CMV R+ or CMV D+/R-. CMV prophylaxis in the historical controls was with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
10214582|NCT05027399|Active Comparator|Intervention Group|Consultations will be carried out via video call, every 15 days for a period of 3 months, with a total of 6 telephone consultations that will have in order to clarify doubts about the CI, the monitoring of possible clinical signs of instability and help in adapting or creating strategies for better adherence to therapy.
9528394|NCT03211325|Experimental|Healthy|"Two sequences of ten healthy volunteers each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
9528395|NCT03211325|Experimental|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
9528748|NCT03208335|Experimental|rh-endostatin combination|Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.
9800789|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from the 5 mg/kg fosaprepitant arm in Cycle 1 were administered fosaprepitant 5 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5- hydroxytryptamine 3 (5-HT3) antagonist with or without dexamethasone. Participants 1 year or less were required to receive ondansetron in all cycles as the 5-HT3 antagonist.
9800790|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from Cycle 1 fosaprepitant arms (3, 1.2, or 0.4 mg/kg) or Cycle 1 control arm were administered fosaprepitant 3 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5-HT3 antagonist with or without dexamethasone.
9803216|NCT04404465||At Risk Group|"Participants with no prior diagnosis of AF and have:~two or more of the following criteria:~Age >65 years of age~A diagnosis of hypertension~A diagnosis of diabetes~A diagnosis of sleep apnea~A body mass index (BMI) ≥30~Stable heart failure (HF) with preserved or reduced ejection fraction (New York Heart Association Class I, II or III)~Chronic kidney disease (CKD) not requiring dialysis~AND/ OR~More than 5% premature atrial complex (PAC) burden on ambulatory ECG monitoring (e.g. holter, ZioPatch, Lifewatch, etc.)"
9803217|NCT04404465||AF Group|Participants who have a history of non-valvular AF or Atrial Flutter (AFL) documented on ECG or ambulatory monitoring within 1 year of enrollment
9803218|NCT04400578|Experimental|TRICIN|"If a patient is eligible~local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application~Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application~Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application"
9803219|NCT04396288|Experimental|Healthy volunteers|
9803220|NCT04394585|Experimental|Smart phone app group|Patients used smart phone app based human coaching program for 3 months postoperatively.
9803221|NCT04394585|Active Comparator|Nutritional consultation group|Patients have two consulting with clinical nutritionist at 1 month and 3 months postoperatively.
9803222|NCT04394325|Experimental|Group A) Intervention group|Group A) an intervention group (n=80) who will receive the standard care and information (oral and written) + the digital information tool.
9803223|NCT04394325|No Intervention|Group B) Control group|Group B) a control group (n=80) who will receive standard care and information (oral and written).
9803224|NCT04392180||Caregivers|"Caregivers who care for a child that is both under 3 years of age and has experienced acute pain.~This cohort will participate in a qualitative interview about pain assessment, treatment, and response to treatment in their child."
9803225|NCT04391803|Experimental|Pipeline™ Flex Embolization Device with Shield Technology™|This is a prospective, single-arm study in which subjects have consented and deployment of the Pipeline™ Flex Embolization Device with Shield Technology™ is attempted.
9803226|NCT04388839|Experimental|Arm A - First Strike|Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
9803227|NCT04388839|Experimental|Arm B - Second Strike - Maintenance|Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
9803228|NCT04388839|Experimental|Arm C - Adaptive Therapy|Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
9803229|NCT04388839|Active Comparator|Arm - D Conventional Therapy|Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
9803230|NCT04386057|Experimental|Safety Lead-In Cohort|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis.~Test the safety of study drugs in combination and define dose levels.~LY3214996~HCQ"
9803231|NCT04386057|Experimental|LY3214996 and HCQ Combination|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis. Combined dosage per determined Lead-In Cohort~LY3214996~HCQ"
9803232|NCT04386057|Experimental|LY3214996-Monotherapy|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days.Treatment will be administered on an outpatient basis.~-LY3214996"
9941129|NCT00995189|Active Comparator|RNM|ReNu MultiPlus contact lens care solution used for 30 days
9941130|NCT00995241|Experimental|Raltegravir 800 mg / 24 hours|Raltegravir 800 mg / 24 hours
9941131|NCT00995254|No Intervention|Control group|Control group will ONLY receive SHI after completion of the study
10001549|NCT01548495||No rHuEPO treatment|
9941132|NCT00995254|Experimental|Intervention group|Intervention group will receive smoking hygiene intervention (SHI) at three individualized contacts.
9941133|NCT00995267|Experimental|behavioral intervention|Behavioral intervention arm comprises 5 joint parent-child school-based nutritional activities in which nutritional information was combined with Adler's behavioral concepts. and a 5-session parental workshop.
9941134|NCT00995267|No Intervention|control arm|
9941135|NCT00995280|Active Comparator|1|Single lumen needle use in oocyte retrieval
9941136|NCT00995280|Active Comparator|2|Double lumen needle with follicle flushing during oocyte retrieval
9941137|NCT00995293|Experimental|Docetaxel Cisplatin 5-Fluorouracil (DCF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Docetaxel 60mg/m² on day 1~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
9941138|NCT00995293|Experimental|Cisplatin 5-Fluorouracil (CF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
9941139|NCT00995306|Active Comparator|1|Civamide Cream 0.075%
9941140|NCT00995306|Active Comparator|2|Civamide Cream 0.01%
9941141|NCT00995319||radiation patients|cancer patients with radiotherapy concerning the head and neck area/oral cavity
9941142|NCT00995332|Experimental|ATRA+valproc acid+low-dose cytarabine|
9941143|NCT00995358|Experimental|vaccination|
9941144|NCT00995384|Other|CT scan|CT Scan for endocarditis patients. All patients receive intervention.
9941145|NCT00995397|Experimental|Dexchlorpheniramine 1% lotion|
10214583|NCT05027399|No Intervention|Control Group|Will be composed by the participants who will have no intervention and will continue to monitor according to the institution's routine.
10214584|NCT05011162|Other|Digital Acceptance and Commitment Therapy (ACT) Arm|Pragmatic
10214585|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514|Participants will receive ABBV-514.
10214586|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514 + Pembrolizumab|Participants will receive ABBV-514 in combination with pembrolizumab.
10214587|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion.
10214588|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514 + Pembrolizumab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with pembrolizumab
10214589|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514 + Budigalimab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with budigalimab.
10214590|NCT05005351|Active Comparator|Digital Acceptance and Commitment Therapy (ACT) Arm 1|
10214591|NCT05005351|Active Comparator|Digital Acceptance and Commitment Therapy (ACT) Arm 2|
10214592|NCT05005351|Active Comparator|Digital Symptom Tracker Arm|
10214593|NCT04996316||Clinical staff (interview, training, survey)|Before implementation, some participants will complete usability testing of the interface in the electronic health record and MammoScreen. Participants participate in interviews over 30 minutes at baseline, then undergo training sessions over 20 minutes monthly prior to MammoScreen launch. Clinical staff also participate in interviews over 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the first month of the maintenance phase.
10214594|NCT04996316||Patients (interview, MammoScreen)|Patients participate in interviews over 1 hour. Patients medical records are reviewed. Patients use the MammoScreen at enrollment. Some Patients will also participate in interviews up to 1 hour, each during years 3-5.
10214595|NCT04987372|No Intervention|Classical protocol|"Fentanyl Max. 15µg/kg IV Per-operative~Ultiva (Remifentanyl) 0.02-0.1µg/kg/h IV Post-operative~Paracetamol 4x1g /24h IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in cas of break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
10214596|NCT04987372|Active Comparator|Multimodal protocol|"Lyrica (Pregabalin) 75mg PO 2 hours before the operation~Dexdor (Dexmedetomidine) 0.8µg/kg/h IV Per-operative / Post-operative~Ketalar (Ketamine) Bolus (0.5mg/kg) + 0.3mg/kg/h IV Per-operative until stop propofol~Linisol (Lidocain) Bolus (1.5mg/kg) + 1.3mg/kg/h IV Per-operatiive until 12h post-op~Magnesium Sulphate Induction (25mg/kg) + 25mg/kg weaning ECC IV Per-operative~Fentanyl 2.5µg/kg IV Per-operative~Paracetamol 4x1g /24u IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in case of Break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
10214597|NCT04981067|Other|Sciatic nerve block using same or decreased concentration of local anesthetic|If the sciatic nerve block in the previous participant was successful, the concentration of local anesthetic would be maintained or decreased 0.05% in the next patient based on a random assignment.
9941146|NCT00995397|Active Comparator|Dexchlorpheniramine 1% cream|
9941147|NCT00995423|Active Comparator|CoroflexTM|highly flexible CoroflexTM Please-Stent features
9941148|NCT00995423|Active Comparator|TAXUS|Paclitaxel-eluting stent
9941149|NCT00995462|No Intervention|Control|
9941150|NCT00995462|Experimental|Small-group seminar for 2 years|
9941151|NCT00995462|Experimental|Small-group seminars for 1 year followed by email intervention|
9941152|NCT00995514||Clopidogrel|Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype
9941153|NCT00995514||Prasugrel|Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician
9941154|NCT00995540|Placebo Comparator|Placebo|Placebo subcutaneous injection tid for 12 weeks
9941155|NCT00995540|Active Comparator|100 mg INGAP Peptide tid|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
9941156|NCT00995540|Active Comparator|200 mg INGAP Peptide tid|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
9941157|NCT00995579||Healthy college volunteers|
9941158|NCT00995592|Experimental|Mentor mothers|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
9800791|NCT01697592|Experimental|Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
9941159|NCT00995592|No Intervention|Control|Control cases were visited and their infants were weighed 4 times over one year period. After one year, mothers were provided Philani nutrition intervention program.
9941160|NCT00995605|Experimental|Groups SAD|AMAP102 or Placebo as single ascending doses in five groups
9941161|NCT00995605|Experimental|Groups MAD|AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups
9941162|NCT00995618|Experimental|Tranilast|Tranilast tablets
9941163|NCT00995618|Active Comparator|Febuxostat|Febuxostat tablets
9941164|NCT00995618|Experimental|Combination|Tranilast plus febuxostat
9941165|NCT00995631|No Intervention|Premenopausal, Control|Premenopausal women randomized to Control (delayed liposuction surgery)
9941166|NCT00995631|Active Comparator|Premenopausal, Surgery|Premenopausal women randomized to surgery (femoral lipectomy)
9941167|NCT00995631|No Intervention|Postmenopausal, Control|Postmenopausal women randomized to Control (delayed liposuction surgery)
9800792|NCT01697592|Experimental|Omarigliptin 25 mg/Glinides (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
9800793|NCT01697592|Experimental|Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
9800794|NCT01697592|Experimental|Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
9800795|NCT01697592|Experimental|Omarigliptin 25 mg/α-GIs (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
9800796|NCT01697592|Placebo Comparator|Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
9800797|NCT01697592|Placebo Comparator|Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
9800798|NCT01697592|Placebo Comparator|Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
9800799|NCT01697592|Placebo Comparator|Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
9800800|NCT01697592|Placebo Comparator|Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.
9800801|NCT01697696|Experimental|NVA237 dose 1|NVA237 dose 1
9800802|NCT01697696|Active Comparator|Long-acting beta 2-agonist (LABA)|QAB149
9800803|NCT01697709|Placebo Comparator|Placebo|Placebo medication
9800804|NCT01697709|Experimental|quetiapine|Quetiapine treatment
9800805|NCT01697748|Placebo Comparator|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
9800806|NCT01697748|Active Comparator|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
9800807|NCT01697956|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 42 day (6 week) Treatment Period.
9800808|NCT01697956|Placebo Comparator|Placebo Nasal Aerosol|Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 42 day (6 week) Treatment Period.
9800809|NCT01697969|Experimental|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop once daily in both eyes for 14 days
9800810|NCT01698008|Experimental|Mobile application Diabetes Doctor|The intervention group will send in blood glucoses once a month using the mobile phone app, Diabetes Doctor. All subjects will be evaluated at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After 3 months, a Diabetes Quality of Life (QOL) survey will be completed. A Usability and Satisfaction of Diabetes Doctor (USDD) survey will also be obtained. At the 3 month visit, they will also be given the chance to discontinue the mobile app and switch to standard of care. At 6 months, all mobile app users will complete the USDD and satisfaction and QOL survey. If they are not using the mobile app, then they will complete the QOL survey.
9941168|NCT00995631|Active Comparator|Postmenopausal, Surgery|Postmenopausal women randomized to surgery (femoral lipectomy)
9941169|NCT00995657|Active Comparator|High dose ICS|Fluticasone Propionate 250mcg bid
9941170|NCT00995657|Active Comparator|Low dose ICS|Fluticasone propionate 50mcg bid
10001550|NCT01548508|Experimental|Functionnal ElectroStimulation (FES)|
10001551|NCT01548508|Sham Comparator|SHAM|
10001552|NCT01548521|Experimental|Oxytocin|
10001553|NCT01548534|Placebo Comparator|DHA-free arm|Dietary supplementation with vegetable oil.
10001554|NCT01548534|Experimental|DHA arm|Dietary supplementation with fish oil.
10001555|NCT01548547|Experimental|LP mastery learning group|
10001556|NCT01548547|Active Comparator|IV mastery learning group|
10001557|NCT01548560|Experimental|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
10001558|NCT01548560|Placebo Comparator|Placebo Gel|Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
10001559|NCT01548560|Experimental|Dapvirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
10001560|NCT01548560|Placebo Comparator|Vaginal Film|Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
9528396|NCT03211325|Experimental|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
9528397|NCT03211403|Experimental|SHR4640 2.5mg|6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo
9528398|NCT03211403|Experimental|SHR4640 10mg|6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo
9528399|NCT03211403|Experimental|SHR4640 20mg|6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo
9528400|NCT03211065|Experimental|Immunoglobulin therapy|Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.
9528401|NCT03211364|Active Comparator|Angular mobilization|Angular mobilization of the shoulder joint in the frontal plane.
9528402|NCT03211364|Active Comparator|Angular mobilization with soft tissue techniques|Angular mobilization performed in the scapular plane. Additional soft tissue techniques to eliminate limitations created by tensed muscles in order to perform capsular stretch.
9528403|NCT03211364|Placebo Comparator|Scapular mobilization|Scapular mobilization without glenohumeral movement.
9528404|NCT03211221|Active Comparator|Active rTMS|Active stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System. Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.
9528405|NCT03211221|Placebo Comparator|Sham rTMS|Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp. This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS.
9528749|NCT03208179|Active Comparator|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
9528750|NCT03208179|Experimental|IPTp-DP|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit
9528751|NCT03208179|Experimental|IPTp-DPAZ|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.
9528752|NCT03207646|Experimental|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
9528753|NCT03207646|No Intervention|Control|Standard-of-care alone.
9528754|NCT03207698|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
9528755|NCT03207698|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
9528756|NCT03207698|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Metformin for treating furcation defect
9528757|NCT03207724|Experimental|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
10001561|NCT01548586|Active Comparator|Anodal tDCS|
10001562|NCT01548586|Active Comparator|Cathodal tDCS|
10001563|NCT01548586|Placebo Comparator|Placebo type tDCS|
10001564|NCT01548612|Experimental|Sodium nitroprusside|
10001565|NCT01548612|Placebo Comparator|Placebo|Glucose solution 5%
10001566|NCT01548625||Healthy middle-aged human volunteers|
10001567|NCT01548664|Experimental|Nintendo Wii FitTM|Fifteen minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
10001568|NCT01548664|Active Comparator|Lower extremity exercise|Fifteen minutes of lower extremity exercises that addressed balance, posture, weight shifting and strengthening were provided bilaterally, following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area
10001569|NCT01548677|No Intervention|observation|18 weeks
10001570|NCT01548677|Experimental|Herceptin (trastuzumab)|18 weeks
10001571|NCT01548703|Experimental|BCI-838 Dosing Arm 1|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
10001572|NCT01548703|Experimental|BCI-838 Dosing Arm 2|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
10001573|NCT01548703|Experimental|BCI-838 Dosing Arm 3|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
10001574|NCT01548729|Experimental|Patient with cystic fibrosis|Patients with end-stage cystic fibrosis
9941171|NCT00995683|Experimental|half sodium lactate|infusion of 0.5 ml/kg/day during 48 hours
9941172|NCT00995683|Active Comparator|isotonic sodium chloride|infusion of 0.5 ml/kg during 48 hours
9941173|NCT00995696|Experimental|PhaST|Group receiving PhaST IVR phone calls.
9941174|NCT00995696|No Intervention|Usual Care|Group NOT receiving IVR phone calls.
9941175|NCT00995735||Transgastric|Patients submitted to Transgastric NOTES surgery
9941176|NCT00995735||Transvaginal|Patients submitted to Transvaginal surgery
9941177|NCT00995787|Experimental|AZD1656|
9941178|NCT00995787|Placebo Comparator|Placebo|
9528406|NCT03211247|Experimental|Viaskin Peanut 250 mcg|
9941179|NCT00995800|Active Comparator|Fluticasone propionate / Formoterol fumarate|
9941180|NCT00995800|Placebo Comparator|Fluticasone propionate / Formoterol fumarate placebo|
9941181|NCT00995826|Placebo Comparator|placebo|
9941182|NCT00995826|Experimental|CS-8958 DPI|
9941183|NCT00995839|Experimental|continuous terlipressin|
9941184|NCT00995839|Experimental|vasopressin|
9941185|NCT00995839|Experimental|terlipressin bolus dose|
9941186|NCT00995852|Active Comparator|bilateral|"Treatment arm B - incomplete bilateral treatment of in total two lobes (contralateral).~The study will only use Intrabronchial Valves™"
9941187|NCT00995852|Active Comparator|unilateral|Treatment arm A - unilateral treatment with complete closure of the worst lobe of the lungs
9941188|NCT00995878|Active Comparator|Focused Ultrasound (MRgFUS)|
9941189|NCT00995878|Active Comparator|Uterine Artery Embolization (UAE)|
9941190|NCT00995917|Experimental|Vitamin K acupoint injection|Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
9941191|NCT00995917|Sham Comparator|Saline Injection|Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
9941192|NCT00995969|Placebo Comparator|Placebo only|Subjects will apply placebo cream to both target lesions
9941193|NCT00995969|Active Comparator|Active plus placebo|Subjects will apply CT 327 to one target lesion and placebo to the other target lesion
9941194|NCT00995995||All patients|
9941195|NCT00996008|Placebo Comparator|Placebo only|Subjects will apply placebo cream to all 4 target lesions
9941196|NCT00996008|Active Comparator|Active plus placebo|Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
9941197|NCT00996021|Experimental|Arm 1|This is a three way crossover study with 3 periods. Subjects will receive a single dose of either GSK1349572 250 mg suspension, placebo suspension or moxifloxacin 400 mg tablet in each of the three periods. The order in which the treatments are given will be randomized. There is a screening visit within 30 days prior to the first dose of study drug and a follow-up visit within 10-14 days after the last dose of study drug.
9941198|NCT00996060|Experimental|Hydralazine and Valproic Acid|Starting dose of Hydralazine is 25 mg orally daily, days 1-28. (See Intervention for Dose Escalation Schema) Valproic acid 250 mg orally three times per day for days -14 through -8, then 500 mg orally three times per day daily for days -7 through 28, with the dose titrated to keep the serum level between 0.4 and 0.7 mM.
9941199|NCT00996073|Active Comparator|Autograft|Lumbar Interbody Fusion with Autograft
9941200|NCT00996073|Experimental|Low Dose|Lumbar Interbody Fusion with NeoFuse-Low Dose
9941201|NCT00996073|Experimental|High Dose|Lumbar Interbody Fusion with NeoFuse-High Dose
9941202|NCT00996086||CRT device-recipients|
10001575|NCT01548781|Experimental|Viscous Resistance & Abduction Loading|The intervention for the experimental group entails practicing reaching utilizing the robotic device, ACT3D, with the experimental element of horizontal viscosity in combination with abduction loading.
10001576|NCT01548781|Active Comparator|Abduction Loading|The intervention for the active comparison group entails practicing reaching utilizing the robotic device, ACT3D, with only abduction loading.
10001577|NCT01548794|Active Comparator|Bupivacaine(Group B)|spinal anesthesia
10001578|NCT01548794|Experimental|Bupivacaine+Lidocaine (Group BL)|spinal anesthesia
10001579|NCT01548794|Active Comparator|Local Infitration Anesthesia(Group LI)|local infiltration anesthesia
10001580|NCT01548820||Chronic HBV Egyptian patients|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
10001581|NCT01548859|Active Comparator|Midazolam|Used for maintenance anaesthesia (0.2 mg/kg/saat continuous infusion)
10001582|NCT01548859|Active Comparator|Sevoflurane|Used for the maintenance for anaesthesia (% 0.5-8 end tidal concentration)
10001583|NCT01548872|Active Comparator|crystalloid cardioplegia solution|After aortic cross clamp 30ml/kg will be administered
10001584|NCT01548872|Active Comparator|HTK solution|After aortic cross clamp 50ml/kg will be administered
10001585|NCT01548911|Experimental|Treatment (monoclonal antibody therapy)|Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
10001586|NCT01548924|Experimental|Priming Phase|The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
9528407|NCT03211247|Experimental|Viaskin Peanut 100 mcg|
9528408|NCT03211247|Placebo Comparator|Placebo|
10001587|NCT01548924|Experimental|Treatment Phase|The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
10001588|NCT01548937|Experimental|I-123 ADAM|I-123 ADAM Serotonin transporter imaging
10001589|NCT01548950|Other|Single-arm study|Preoperatively, sildenafil until development of pulmonary congestion (1-4 weeks). On treatment pulmonary congestion (dyspnea and need for increasing diuretics) occurs when there is a substantial decrease in pulmonary vascular resistance, which may be confirmed noninvasively by Doppler-echocardiography. At that moment, patient will be assigned to surgery. If pulmonary congestion is not observed, bosentan will be added on top of sildenafil, and the patient will be kept on treatment for 10-12 months. In this case, a new cardiac catheterization will be performed before surgery. In both cases (short-term and medium-term treatment) patients will be kept on treatment for six months following surgery, and then re-catheterized.
9528409|NCT03211260|Experimental|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
9941203|NCT00996099|Active Comparator|CGM-eMPC|
9941204|NCT00996099|Other|Control|
10001590|NCT01548963|Experimental|Perioperative glycemia control|Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
10001591|NCT01548963|Active Comparator|Postoperative glycemia control|Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
10001592|NCT01548976||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
10001593|NCT01548989||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
10001594|NCT01549028|Experimental|Mobile-based PR program.|Home based mobile PR program for 3 months.
10001595|NCT01549054|Experimental|10-mg dose of E5501 2G tablet|
9528410|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
9528411|NCT03211130|Experimental|SystemCHANGE™|
9528412|NCT03211130|Active Comparator|Attention-Control|
9528413|NCT03211052|Experimental|TAK-700 + LHRH agonist + Prostatectomy|Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
9528414|NCT03211052|Other|Prostatectomy|Prostatectomy only-Within 28 days of randomisation
9528415|NCT03211104|Experimental|curcumin|"Curcumin extracted from curcuma longa linn.~formulation : curcumin powder 240mg/capsule~general name : Diferuloylmethane~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
9528416|NCT03211104|Placebo Comparator|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
9528417|NCT03211143|Experimental|A|"TR group~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
9528418|NCT03211143|Experimental|B|"RT group~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
9941205|NCT00996112||Historical|
9941206|NCT00996112||Prospective|
9941207|NCT00996138|Other|Arm 1|Dose ranging
9941208|NCT00996138|Other|Arm 2|Dose ranging
9941209|NCT00996177|Experimental|IONSYS|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
9941210|NCT00996177|Active Comparator|Patient-Controlled Analgesia|IV Morphine Patient-Controlled Analgesia (IV PCA)
9941211|NCT00996190|Active Comparator|Phenylephrine Intermittent Bolus|Bolus syringe will contain 120 micrograms/mL of phenylephrine. Infusion solution bag will contain placebo (saline solution).
9941212|NCT00996190|Active Comparator|Phenylephrine Continuous Infusion|Infusion solution bag will contain 120 micrograms/mL of phenylephrine. Bolus syringe will contain placebo (saline solution).
10001596|NCT01549054|Experimental|10-mg dose of E5501 cyclodextrin oral solution|
10001597|NCT01549054|Experimental|10-mg dose of E5501-P21% powder|
10001598|NCT01549054|Experimental|10-mg dose of E5501 lipid-based oral|
10001599|NCT01549080||research|biological research on the effects of yisuishengxuegranule
10001600|NCT01549080||clinical research|clinical research on thalassemia
10001601|NCT01549093|Experimental|Endostar -Continued Pumping into+GC|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
10001602|NCT01549093|Active Comparator|Endostar -injecting into +GC|Endostar that is injecting into vein with Gemcitabine -Carboplatin
10001603|NCT01549093|Active Comparator|GC|Gemcitabine -Carboplatin
10001604|NCT01549106|Experimental|IPI-145|
10001605|NCT01549106|Placebo Comparator|Placebo|
10001606|NCT01549119|Experimental|Low dose VAC-3S|
10001607|NCT01549119|Experimental|Medium dose VAC-3S|
10001608|NCT01549119|Experimental|High dose VAC-3S|
10001609|NCT01549119|Placebo Comparator|Placebo|
10001610|NCT01549119|Experimental|Double-dose VAC-3S|
10001611|NCT01549145|Experimental|NIMBUS multifunctional stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
10001612|NCT01549158|Experimental|Torasemide PR 10 mg|
10001613|NCT01549158|Active Comparator|Furosemide-IR 40 mg|
10001614|NCT01549158|Active Comparator|Torasemide-IR 10 mg|
10001615|NCT01549171||Iloprost|This is the study group with 1 uM Iloprost.
10001616|NCT01549171||Control|This is the control group with vehicle (normal saline) only.
10001617|NCT01549197||ICU staff and relatives|
10001618|NCT01549249|No Intervention|vitrectomy|
10001619|NCT01549262|Active Comparator|Standard Incubator|
10001620|NCT01549262|Experimental|ESD Time-lapse Monitoring system|
10001621|NCT01549288|Experimental|modified Atkins diet|
10001622|NCT01549288|Other|control arm|the control arm continues the anti-epileptic drugs without any added dietetic input
10001623|NCT01549301|Experimental|Group D 10 i.v.|Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
10001624|NCT01549301|Experimental|Group C 5 i.v.|Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
10001625|NCT01549301|Experimental|Group B 10 s.c.|Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
10001626|NCT01549301|Experimental|Group A 5 s.c.|Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
10001627|NCT01549327|Active Comparator|Routine Care|Participants who are randomized to the active comparator arm will receive routine care, which is the care routinely provided to the participant's patient population at the study centre.
10001628|NCT01549327|Experimental|Routine Care plus OIN|OIN (Oncology Interactive Navigator) is the intervention. Participants who are randomized to routine care plus OIN will receive routine care and have unlimited access to the website for the study duration.
10001629|NCT01549353|Experimental|chewing gum|
10001630|NCT01549366|Experimental|Aspen Spinous Process Fixation Device|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
10001631|NCT01549366|Active Comparator|Pedicle Screws|Subjects randomized to the pedicle screw group will have polyaxial top loading pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
10001632|NCT01549379|Active Comparator|Surgical patients|This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
10001633|NCT01549379|Active Comparator|Chemoradiation Patients|This group will consist of 15 patients with locally advanced HNSCC with lymph nodes ≥3 cm in which chemoradiotherapy is the primary treatment as per standard of care. This group will be composed of patients with a primary malignancy originating in the nasopharynx, oropharynx, hypopharynx or larynx. Pre-treatment DCE-CT of neck will be obtained. The standard therapy, radiation and chemotherapy, will be administered and the patients will have standard follow up. A post-treatment DCE-CT of neck will be obtained 8-10 weeks after treatment along with standard CT neck.
10001634|NCT01549418|Active Comparator|Aspirin|Patients with at least one large polyps taking aspirin in dose 75 mg daily for 21 days (7 days before and 14 days after polypectomy)
10001635|NCT01549418|Placebo Comparator|Placebo|Patients with at least one large polyps taking placebo daily for 21 days (7 days before and 14 days after polypectomy)
9528419|NCT03211078|Experimental|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
9528420|NCT03211013|Experimental|Immediate Oxytocin|Participants randomly assigned to this arm will receive OT nasal spray (24 IU) at laboratory visit 1 and placebo nasal spray at visit 2. The order will be masked for participants and study staff.
9941213|NCT00996229|Experimental|Caloric restriction + placebo supplementation|
9528421|NCT03211013|Placebo Comparator|Delayed Oxytocin|Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
9528422|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage <5%
9528423|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
9528424|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage >15%
9528425|NCT03211351|Experimental|Liposic|Liposic was applied to one eye of patients in this group
9941214|NCT00996229|Experimental|Omega-3 supplementation|
9941215|NCT00996229|Placebo Comparator|Placebo supplementation|
9941216|NCT00996229|Experimental|Resveratrol supplementation|
9941217|NCT00996242|Experimental|L-lysine|
9941218|NCT00996255|Experimental|Dose-Escalation|
9941219|NCT00996268|Experimental|Part A|Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836.
9941220|NCT00996268|Experimental|Part B|Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo.
9941221|NCT00996294|Experimental|surgery|patients will be submitted to biliopancreatic diversion or gastric bypass
9941222|NCT00996320|Experimental|Intervention Schedule|Interns on the intervention schedule work the a modified ICU schedule averaging about 60 hours per week over 4 weeks, with maximum scheduled shift length 16 hours.
9941223|NCT00996320|No Intervention|Traditional Schedule|Interns on the traditional schedule work the usual ICU schedule averaging about 80 hours per week over 4 weeks, with maximum shift length 30 hours.
9941224|NCT00996359|Experimental|Irradiated allogeneic lymphocytes after Total Body Irradiation|
9941225|NCT00996385|Experimental|Velcade plus Eloxatin|Six 20-day cycles
9941226|NCT00996398|Experimental|Cold water immersion|14°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
9941227|NCT00996411|Experimental|Salvinorin A|
9941228|NCT00996424|Experimental|Acetylcysteine|Inhalation with N-Acetylcysteine
9941229|NCT00996424|Placebo Comparator|normal saline|Inhalation with normal saline solution
9941230|NCT00996463|Active Comparator|IL SSG|Intralesional sodium stibogluconate
9941231|NCT00996463|Experimental|ETC+MWT|Electro-thermo-coagulation with subsequent moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
9941232|NCT00996463|Experimental|MWT|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
9941233|NCT00996515|Experimental|Cohort 5|Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18
9941234|NCT00996515|Experimental|Cohort 4|Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18
9941235|NCT00996515|Experimental|Cohort 3|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17
9941236|NCT00996515|Experimental|Cohort 2|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16
9941237|NCT00996515|Experimental|Cohort 1|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15
9941238|NCT00996528|Experimental|Philani Intervention Program|
9941239|NCT00996528|No Intervention|Standard Care|No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
9941240|NCT00996541|Experimental|Intervention|
9941241|NCT00996541|Placebo Comparator|Control|
9941242|NCT00996554|Experimental|Double-Layer-Suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
9941243|NCT00996554|Active Comparator|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).
9941244|NCT00996567|Experimental|Cetuximab (Erbitux)|
9941245|NCT00996619||People undergoing GI tract endoscopy|
9941246|NCT00996645|No Intervention|Feedback report only|This arm will receive performance feedback reports but no worksheet to facilitate goal-setting and action plans.
9941247|NCT00996645|Experimental|Goal-Setting Worksheet|This arm will receive a theory-informed worksheet to facilitate the development of goals and action plans in response to the performance feedback reports.
9941248|NCT00996671|Experimental|Dose Escalation Cohorts|single dose administration escalating doses starting at 20 mg and continue escalation; the highest dose in this study will not exceed the mean Day 1 exposure in male dogs at the NOAEL dose (6 mg/kg/day).
9941249|NCT00996671|Experimental|Food effect Cohort|Dose to be selected based on emerging safety and PK data; subjects will be given FDA standard high fat meal followed by single dose of study drug.
9941250|NCT00996684|Experimental|microplasmin, intravitreal injection|Subjects will receive one intravitreal injection of microplasmin on Day 0.
9941251|NCT00996684|Placebo Comparator|Placebo|Subjects will receive one intravitreal injection of the placebo on Day 0.
9941252|NCT00996697|Active Comparator|Triple therapy|Symbicort and tiotropium
9941253|NCT00996697|Placebo Comparator|Combination therapy|Symbicort and placebo
9941254|NCT00996723|Other|1|
9941255|NCT00996749|Experimental|Treatment (omega-3 fatty acid)|Patients receive long-term omega-3 PUFA supplementation PO.
9941256|NCT00996762|Experimental|Part 1-3|2-period crossover, Period 1 (D1-7) will receive either the commercial formulation or the alternative formulation. Period 2 (D1-7) will receive the formulation not received in Period 1. There will be 3 parts with 3 different alternative formulations. Subjects will only participate in one part.
9941257|NCT00996788|Experimental|Rebamipide|Rebamipide 100 mg tid for 28 days
9528426|NCT03211351|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
9528427|NCT03210987|Active Comparator|patient case presentation Bedside|In the bedside presentation group, patient case presentation and discussions will be at bedside with direct involvement of the patient as needed.
9528428|NCT03210987|Active Comparator|patient case presentation Outside-the-room|In the outside the room condition, case presentation and discussions will take place outside without the patient being present. After the case presentation and discussions the team will enter the room and give the patient a short summary of the medical situation, complete the medical information and examine the patient, as needed, and discuss the next steps.
10001636|NCT01549431|Experimental|Combo of Panobinostat and Carfilzomib|A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week.
9528429|NCT03210922|Experimental|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
9528430|NCT03210922|No Intervention|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
9528431|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
10001637|NCT01549444||Group 1|Babies of mothers that have diabetes and/or hypertension and babies that are small for dates
10001638|NCT01549444||Group 2|Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age
10001639|NCT01549457|No Intervention|Non-intervention|Participants will only receive standard of care
10001640|NCT01549457|Experimental|Cell phone intervention arm|Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH or 4 months of RIF) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH or months of RIF) without weekly SMS text messages via mobile phone.
10001641|NCT01549470|Experimental|Study vaccine|Participants in this arm will receive a total of three doses of study vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection (dose strength 4 mg/mL) and will be administered by IM injection in the deltoid muscle.
10001642|NCT01549470|Placebo Comparator|Placebo vaccine|Participants in this arm will receive a total of three doses of a placebo vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection and will be administered by IM injection in the deltoid muscle.
10001643|NCT01549483||Asthma|asthmatic subjects
10001644|NCT01549483||Asymptomatic AHR|Asymptomatic subjects with airway hyperresponsiveness
10001645|NCT01549483||Control|Healthy controls, without airway hyperresponsiveness
10001646|NCT01549496|Experimental|boceprevir|boceprevir 800 mg tid
10001647|NCT01549509|Experimental|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
10001648|NCT01549535|Active Comparator|Group A (study group)|Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope System™ extended view colonoscopy.
10001649|NCT01549535|Active Comparator|Group B (control group)|Group B (control group) will undergo a PeerScope System™ extended view colonoscopy followed immediately by a Standard view colonoscopy.
10001650|NCT01549561|No Intervention|Services As Usual|Foster care services as usual
10001651|NCT01549561|Experimental|Parent and Youth Training|16 Weeks of Parent Training in group context with 5 to 10 relative and non-relative foster caregivers; Youth training with skills coaches
10001652|NCT01549561|Experimental|Parent Training|16 weeks of parent training with 5 to 10 relative and non-relative foster caregivers
10001653|NCT01549574|Experimental|crizotinib/crizotinib+esomeprazole crossover|Each subject in this study will receive two treatments (A and B) separated by at least 14 days of washout period. Treatment A is a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule. Treatment B consists of 40 mg daily esomeprazole dose from Day 1 to Day 5 and a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5.
10001654|NCT01549600|Experimental|psyllium|5.1 g psyllium husk in at least 8 ounces of water
10001655|NCT01549600|Active Comparator|Microcrsytalline Cellulose|1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day
10001656|NCT01549626|Active Comparator|defatted flaxseed flour|30 grams per day of defatted flaxseed flour
10001657|NCT01549626|Active Comparator|golden flaxseed flour|30 grams per day of golden flaxseed flour
10001658|NCT01549626|Active Comparator|whole brown flaxseed flour|30 grams per day of whole brown flaxseed flour
10001659|NCT01549639||General Anaesthesia|Patients undergoing general anaesthesia using Marsh model target controlled infusion in effect site mode.
10001660|NCT01549678|Experimental|Intervention foot orthoses|Ethyl Vinil Acetate EVA insole shaped in the cast of the patient's foot.
10001661|NCT01549678|Placebo Comparator|Placebo insole|EVA flat insole.
10001662|NCT01549691|Experimental|zopiclone|zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
10001663|NCT01549691|Experimental|alprazolam|given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
10001664|NCT01549691|Placebo Comparator|placebo|Placebo given night before operation and the morning of operation
10001665|NCT01549704|Other|Arm RP|first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
10001666|NCT01549704|Other|Arm PR|first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
10001667|NCT01549717|Experimental|Elective cardiac surgery patients|Patients undergoing elective cardiac surgery
10001668|NCT01549730|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with cervix cancer
10001669|NCT01549743|Experimental|Celecoxib|
10001670|NCT01549743|Experimental|Rebamipide|
10001671|NCT01549743|Experimental|Celecoxib plus Rebamipide|
10001672|NCT01549756||Qualitative Research|Experiential/opinion based research
10001673|NCT01549769|Experimental|Bardoxolone Methyl 20 mg|
9941258|NCT00996814|Experimental|Proactive Ethics Intervention|These patients have an ethics consultant involved in their care beginning on the fifth day of treatment in the ICU
9941259|NCT00996814|No Intervention|Usual Care|These patients receive usual care in the ICU.
9941260|NCT00996853||Total vaccinated cohort|The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.
9941261|NCT00996866|Placebo Comparator|Placebo|Half of subjects will be randomized to the placebo group.
9941262|NCT00996866|Active Comparator|Vitamin D3|This is the study group that receives Vitamin D supplementation.
9941263|NCT00996879|Experimental|Midazolam + BMS-791325|
9941264|NCT00996905|No Intervention|Beginner Conventional (BC)|Beginner level (residents) doing epidural insertions the conventional way (ie. no ultrasound scanning)
9941265|NCT00996905|Experimental|Beginner Ultrasound (BU)|Beginner level (residents) doing epidural insertions with the help of ultrasound scanning.
9941266|NCT00996905|No Intervention|Experienced Conventional|Experienced level (fellows) doing epidural insertions the conventional way.
9941267|NCT00996905|Experimental|Experienced Ultrasound|Experienced level (fellows) doing epidural insertions with the help of ultrasound scanning.
9941268|NCT00996957|Experimental|ACE-041|Patients assigned to 1 of 9 possible dosing groups
9941269|NCT00996983|Experimental|A|
9941270|NCT00997009|Experimental|Arm A|chemotherapy plus cetuximab
9941271|NCT00997009|Active Comparator|Arm B|chemotherapy
9941272|NCT00997022|Experimental|Sorafenib|Daily sorafenib taken orally
9941273|NCT00997048|Experimental|Laying open|
9941274|NCT00997048|Active Comparator|Sinus excision|
9941275|NCT00997061||HYCAMTIN|
9941276|NCT00997074|Experimental|ibuprofen|the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
9941277|NCT00997074|No Intervention|placebo|this group will receive 2 placebo tablets together with the misoprostol
9941278|NCT00997087|Placebo Comparator|Sugar Pill, Placebo|
9941279|NCT00997087|Active Comparator|Flumazenil|
9941280|NCT00997100|Other|ABR-215757|
9941281|NCT00997165||Metabolic syndrome (MS)|Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
9941282|NCT00997165||MS with sleep apnea|Metabolic syndrome with sleep apnea
9941283|NCT00997165||MS with Liver steatosis|Metabolic syndrome with liver steatosis
9941284|NCT00997178|Experimental|Non-surgical periodontal therapy|Non-surgical periodontal therapy consisted of scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
9941285|NCT00997178|Other|Delayed non-surgical periodontal therapy|No periodontal treatment for 6 months
9941286|NCT00997191|Active Comparator|Laser Group|Focal / grid Laser photocoagulation in diabetic macular edema
9941287|NCT00997191|Experimental|Triamcinolone group|Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
9941288|NCT00997191|Experimental|Bevacizumab group|Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
9941289|NCT00997256|Experimental|Verum|Neurapas balance, film-coated tablets
9941290|NCT00997256|Placebo Comparator|Placebo|Film-coated sugar-pill
9941291|NCT00997269|Experimental|CoQ-10 supplementation|
9941292|NCT00997269|Placebo Comparator|CoQ-10 placebo supplementation|
9941293|NCT00997282|Experimental|OPC-262 2.5 mg|orally administered once daily for 24 weeks
9941294|NCT00997282|Experimental|OPC-262 5 mg|orally administered once daily for 24 weeks
9941295|NCT00997282|Placebo Comparator|Placebo|orally administered once daily for 24 weeks
9941296|NCT00997295||Heat moisture exchanger (HME)|This group was submitted to general anesthesia with low flow gas and heat moisture exchanger
9941297|NCT00997295||Low flow gas (LFG)|This group was submitted to general anesthesia with only low flow gas
9941298|NCT00997295||Humidity of the respiration|"Heat and moisture group:~The first group (G1)will be submitted to low flow gas anesthesia and heat and moisture exchanger (HME)~Control group:~The second group(G2)Will be submitted to low flow gas anesthesia"
9476227|NCT03574012|Active Comparator|Control Group (general health information, fitness tracker)|Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.
9476228|NCT03574012|Experimental|Intervention Group (individualized information, tracker)|Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.
9941299|NCT00997295||HME and LFG|
9941300|NCT00997308|Experimental|AZD1446 Low|Low dose of AZD1446
9941301|NCT00997308|Experimental|AZD1446 High|High dose of AZD1446
9941302|NCT00997308|Placebo Comparator|Placebo|
9941303|NCT00997347|Experimental|64-70 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days
9941304|NCT00997347|No Intervention|57-63 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)
9941305|NCT00997360|Experimental|1|PKI-179
9941306|NCT00997399|Experimental|LBH589|
9941307|NCT00997412|Experimental|MA|MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
9941308|NCT00997412|Active Comparator|AZA|AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
9941309|NCT00997451|Experimental|Behavioral Self-Management|Cognitive-behavioral self-management
9941310|NCT00997451|Active Comparator|Symptom Monitoring|
9941311|NCT00997451|No Intervention|Standard Medical Care|
9941312|NCT00997477|Experimental|Formoterol and Budesonide|
9941313|NCT00997490|Experimental|Verum|Neurapas balance, film-coated tablet
9941314|NCT00997490|Placebo Comparator|Placebo|
9941315|NCT00997529|Experimental|1|
9941316|NCT00997542|Active Comparator|Allopurinol|
9941317|NCT00997542|Placebo Comparator|Placebo|
9941318|NCT00997568||TEE Procedure|Patients who have been scheduled for a TEE procedure by their physician
9941319|NCT00997581|Experimental|apremilast|Experimental treatment for acute gout
9941320|NCT00997581|Active Comparator|indomethacin|Medication currently used for the treatment of acute gout
9941321|NCT00997607|Experimental|Ebola vaccine only|Participants will receive only the Ebola vaccine or a placebo injection.
9941322|NCT00997607|Experimental|Marburg vaccine only|Participants will receive only the Marburg vaccine or a placebo injection.
9941323|NCT00997607|Experimental|Ebola and Marburg vaccine|Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
9941324|NCT00997633||Peritoneal carcinomatosis|Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment
9941325|NCT00997646||Patients in hospitalist-run ward|Patients was admitted from ER to a hospitalist-run ward.
9941326|NCT00997646||Patients in conventional ward|Patients was admitted from ER to a non hospitalist-run ward.
9941327|NCT00997659|Experimental|chromium picolinate|
9941328|NCT00997685|Experimental|Capecitabine plus oxaliplatin，mCRC|
9941329|NCT00997711|Experimental|Cypher|Sirolimus-eluting stent
9941330|NCT00997724|Experimental|a-VATS|Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
9941331|NCT00997737|Experimental|DB, VI and FV|Breathing exercises
9941332|NCT00997750|Experimental|Lornoxicam|Lornoxicam 8mg/day and 12mg/day for 15 days
9941333|NCT00997763|Active Comparator|XIENCE V|everolimus-eluting stent
9941334|NCT00997763|Active Comparator|CYPHER|Using Cypher stent
9941335|NCT00997776|Experimental|Exercise|High intensity lower extremity exercise
9941336|NCT00997776|Sham Comparator|Attention control|lower extremity TENS
9941337|NCT00997789|Experimental|Rebamipide, Serum concentration, Tablet|The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)
9941338|NCT00997802|Other|CT colonography and optical colonoscopy|
9941339|NCT00997815|Experimental|Botulinum toxin A|The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.
9941340|NCT00997815|Placebo Comparator|Placebo|Using normal saline
9941341|NCT00997828|Experimental|everolimus-eluting stent|everolimus-eluting stent
9941342|NCT00997828|Active Comparator|coronary artery bypass graft surgery|coronary artery bypass graft surgery
9941343|NCT00997841|Active Comparator|POC algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following Point of Care based algorithm
9941344|NCT00997841|Active Comparator|conventional algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following conventional coagulation management algorithm
9941345|NCT00997854|Active Comparator|Group 1 Bolus Feeds|This group will receive feeds administered by bolus method over no more than 30 minutes per feed.
9941346|NCT00997854|Experimental|Group 2- Slow Infusion Feeds|This group will receive feeds administered by slow infusion over pump for 2 hours.
9941347|NCT00997867|Active Comparator|Catheter 0-1cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 0-1cm past the needle tip. The patient will be called the following day by research staff to assess their post-surgical pain.
9941348|NCT00997867|Active Comparator|Catheter placed 5-6cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 5-6cm past the needle tip. Patients will be called the following day by research staff to assess their post-surgical pain.
9941349|NCT00997880|Experimental|Rosuvastatin calcium 40mg|high-dose (40mg rosuvastatin)
9476229|NCT03573999|Active Comparator|Mannitol 20%|Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.
9476230|NCT03573999|Experimental|Hypertonic saline 7.5%|Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening
9476231|NCT03573986|Experimental|Arm A|
9528432|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
9941350|NCT00997880|Active Comparator|Rosuvastatin calcium10mg|low-dose statin (10mg rosuvastatin)
9941351|NCT00997906|Experimental|Arm I|Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
9941352|NCT00997906|Experimental|Arm II|Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
9941353|NCT00997919|Experimental|A|
9941354|NCT00997919|Experimental|B|
9941355|NCT00997945|Experimental|1|ZD4054 (Zibotentan) 10mg
9941356|NCT00997958|Experimental|CellCept|Administered in tablet form twice daily one hour after eating.
9941357|NCT00997971|Experimental|Modilac Rose 1|Infant formula with partially hydrolysed rice protein
9941358|NCT00997997||Group 1|
9941359|NCT00998036|Experimental|Temsirolimus, cisplatin, erlotinib|Cisplatin and temsirolimus will be administered weekly on days one and eight of a three week cycle. Erlotinib will be taken by mouth daily.
9941360|NCT00998062||1|Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
9941361|NCT00998075|Active Comparator|1|Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule
9941362|NCT00998075|Active Comparator|2|Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
9941363|NCT00998075|Active Comparator|3|Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
9941364|NCT00998088|Experimental|Erythropoietin|
9941365|NCT00998088|No Intervention|Control arm|
9941366|NCT00998088|Experimental|cell saver|
9941367|NCT00998088|Experimental|drain|
9941368|NCT00998088|Experimental|Erythropoietin and cell saver|
9941369|NCT00998088|Experimental|Erythropoietin and drain|
9941370|NCT00998114|Experimental|Exercise and diastolic dysfunction|Aerobic exercise for 30-45 minutes five times a week for six months
10001674|NCT01549782|Active Comparator|Fiber supplement|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
10001675|NCT01549782|Placebo Comparator|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
10001676|NCT01549808|Experimental|group 2|"Participants:~100 patients will be included in the observation phase of this project, and another 100 in the intervention phase, according to the following criteria: Patients hospitalized in Unit 4141, at Rigshospitalet or ICU at Slagelse, who have been intubated for more than 48 hours, age ≥18, and after positive confirmation from relatives that the patient before the hospitalization was able to read and understand instructions.~The research is divided in 3 phases:~An 8 month observation phase.Current practice relatede to mobilize is measured.~An 2 month implementation phase and third: an 8 month intervention phase. The effect is measured as the difference in the functional level between the observation phase and the intervention phase related to primary and secondary outcome.~The effect of the intervention is described by using following test:~walking distance,ADL function, capability to sit and stand"
10001677|NCT01549847|Experimental|L-carnitine and piracetam|
10001678|NCT01549847|Placebo Comparator|Placebo|
9941371|NCT00998153|Experimental|1|RRFT
9941372|NCT00998153|Active Comparator|2|Usual care
9941373|NCT00998166|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Chemotherapy infusion on Day 1 of a 3-week cycle
9941374|NCT00998179|Active Comparator|Acu-TENS|Application of Acu-TENS prior to exercise
9941375|NCT00998179|Placebo Comparator|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine) prior to exercise
9941376|NCT00998218|Experimental|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) for 4 weeks
9941377|NCT00998218|Placebo Comparator|Sugar pill|Placebo comparator BID for 4 weeks.
9941378|NCT00998231|Active Comparator|Major Depressive Episode (MDE)|20 subjects with major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
9941379|NCT00998231|Active Comparator|Control|20 subjects without major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
9941380|NCT00998244|Experimental|Very Low Carbohydrate Diet|Very Low Carbohydrate Diet
9941381|NCT00998244|Active Comparator|Low Fat Diet|Low Fat Diet
9941382|NCT00998257||Group 1|
9941383|NCT00998270|Active Comparator|Autologous arm|
9941384|NCT00998270|Experimental|Allogeneic arm|
9941385|NCT00998283|Experimental|Cohort 1|Administration of HM10460A 5μg/kg or Placebo
9941386|NCT00998283|Experimental|Cohort 2|Administration of HM10460A 15μg/kg or placebo
9941387|NCT00998283|Experimental|Cohort 3|Administration of HM10460A 45μg/kg or placebo
9941388|NCT00998283|Experimental|Cohort 4|Administration of HM10460A 135μg/kg or placebo
9941389|NCT00998283|Experimental|Cohort 5|Administration of HM10460A 350μg/kg or placebo
9941390|NCT00998348|No Intervention|Comparison Group|The comparison group will receive children's picture books (1 per month for the duration of the 8-month program).
9941391|NCT00998348|Experimental|Parenting Program|The parenting program is an 8-month obesity prevention intervention for parents with preschool-age children.
9941392|NCT00998361|Experimental|Stem Cell Transplant|All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
9941393|NCT00998387||medical ICU|admitted to medical ICU at Seoul National University Hospital longer than 24 hours
9941394|NCT00998413|Experimental|Multifaceted intervention|Multifaceted intervention:physical exercise, nutrition, and behavioural intervention.
9941395|NCT00998413|No Intervention|Control|standard usual care
9941396|NCT00998439|Experimental|Paclitaxel coated balloon catheter|
9941397|NCT00998439|Active Comparator|uncoated balloon catheter (POBA)|
9941398|NCT00998452|No Intervention|MOVE!|Participants will receive the usual VA MOVE! Program. These elements include a baseline assessment, brief clinic counseling session about weight, printed targeted health information on weight management and behaviors, and opportunities to participate in group sessions at the VA site and telephone follow-up from MOVE! clinic staff.
9941399|NCT00998452|Active Comparator|MOVE*VETS|Participants will receive the same MOVE! program as the control group plus 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from volunteer veteran peer counselors.
9528433|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
9941400|NCT00998465||Obese, hypertension|Obese patients with hypertension and a body mass index 40-50 kg/m2
9941401|NCT00998465||Control|Control subjects without hypertension and body mass index < 30 kg/m2
9941402|NCT00998465||Obese, normotension|Obese patients without hypertension and a BMI between 40-50 kg/m2
9941403|NCT00998478|Experimental|Activity prescription|
9941404|NCT00998478|No Intervention|Normal Curriculum|Followed normal curriculum including physical education
9941405|NCT00998504|Placebo Comparator|placebo|starch pill
9941406|NCT00998504|Active Comparator|resVida|synthetic pill containing 75 mg of resveratrol
9941407|NCT00998530||African American HIV+|African American women with HIV and infected with Trichomonas
9941408|NCT00998530||Caucasian HIV-|Caucasian women who are HIV negative and infected with Trichomonas
9941409|NCT00998530||African American HIV-|African American women who are HIV negative and are infected with Trichomonas
9941410|NCT00998543||Smallpox Vaccine (LISTER Strain) Group|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04 (NCT 00258947).
9941411|NCT00998556|Experimental|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
9941412|NCT00998556|No Intervention|Control Group|The control group will receive standard therapy for heart failure. Part of this therapy are ACE inhibitors. Since ACE inhibitors are potentially harmful for the baby when getting into the breast milk, it is necessary to stop lactation in the control group as well.To stop lactation, application of bromocriptine (2.5mg/day) for up to one week.
9941413|NCT00998569|Experimental|Neurocognitive Enhancement|neurocongnitive enhancement
9941414|NCT00998569|Other|Wait List|no intervention
9941415|NCT00998595|Experimental|Promotora|This group receives additional education and proactive follow-up by removing barriers to already existing services and reminders by a lay community health workers (Promotora)
9941416|NCT00998595|No Intervention|Standard of Care|These subjects receive the routine standard of postpartum care
9941417|NCT00998608|Experimental|HR|risperidone 2mg/d + haloperidol 2mg/d
9941418|NCT00998621||Hepatitis C infection|
9941419|NCT00998621||Hepatitis C + HIV infections|
9941420|NCT00998634|Experimental|LITHIUM CARBONATE 150 and/or 300 mg|
9941421|NCT00998634|Placebo Comparator|PLACEBO|
9941422|NCT00998647||with modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
9941423|NCT00998647||without modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
9941424|NCT00998673|Experimental|Arm 1|
9941425|NCT00998673|Other|Arm 2|
9941426|NCT00998686|Experimental|dutogliptin/PHX1149T|
9941427|NCT00998686|Active Comparator|sitagliptin|
9941428|NCT00998699|Active Comparator|XOMA 052|
9941429|NCT00998699|Placebo Comparator|Placebo|
9941430|NCT00998712||1|Black women in the third trimester of a pregnancy complicated by gestational diabetes.
9941431|NCT00998712||2|Black women in the third trimester of a normal, uncomplicated pregnancy.
9941432|NCT00998712||3|White women in the third trimester of a pregnancy complicated by gestational diabetes.
9941433|NCT00998712||4|White women in the third trimester of a normal, uncomplicated pregnancy.
9941434|NCT00998725||HIV+ARV+|
9941435|NCT00998725||HIV+ARV-|
9941436|NCT00998725||HIV negative|
9941437|NCT00998751|Experimental|masitinib (AB1010)|oral masitinib 7.5 mg/kg/day
9941438|NCT00998777|Experimental|Shoulder Strengthening|The shoulder strengthening program is a 6-week intervention aimed to improve shoulder and scapular stabilizer strength and scapular kinematics. The program includes 10 exercises: shoulder flexion, Ys,Ts,Ws, Throwing Acceleration, Throwing Deceleration, Low Rows, Dynamic Hug, IR @ 90, and ER @ 90. The program also includes 2 stretches: sleeper stretch and corner stretch.
9941439|NCT00998803||Immunocompromised participants|Immunocompromised (<= 21 years of age) due to cancer, receipt of stem cell transplant, human immunodeficiency virus (HIV) or Sickle cell disease
9941440|NCT00998816|Placebo Comparator|Placebo capsules|one placebo capsule will be administered 1 hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12h BID for 10 days following lateral thoracotomy.
9941441|NCT00998816|Active Comparator|pregabalin capsules|Pregabalin capsules (150mg) will be administered one hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12 hours (BID) for 10 days following lateral thoracotomy.
9941442|NCT00998829||Study population|The group comprises the entire study population
9941443|NCT00998842||healthy subjects|five male, five female, ages 18-64
9941444|NCT00998855||Adolescents|Post pubertal, sedentary lean and obese Hispanic adolescents
9941445|NCT00998894||decision-support alerts|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will be generated for clinicians.
9941446|NCT00998894||routine practice|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will not be generated for clinicians.
9941447|NCT00998907|Active Comparator|PDS II|PDS II® loop suture is used for abdominal wall closure
9941448|NCT00998907|Experimental|PDS plus|"antibacterial coated PDS plus is used for abdominal wall closure"
9941449|NCT00998920|Experimental|10mg BID|S-equol capsule, oral, single dose
9941450|NCT00998920|Experimental|20 mg BID|
9941451|NCT00998920|Experimental|40mg BID|
9941452|NCT00998920|Experimental|80 mg BID|
9941453|NCT00998920|Experimental|160 mg BID|
9941454|NCT00998920|Placebo Comparator|Placebo|
9941455|NCT00998933|Experimental|1|
9941456|NCT00998959|Experimental|Mindfulness based stress reduction and problem solving therapy|
9941457|NCT00998959|Other|Psychoeducation|
9941458|NCT00998972|No Intervention|control|control arm without any specific intervention
9941459|NCT00998972|Experimental|N-acetylcysteine|administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death
9941460|NCT00998998|Experimental|1|6 or 12 month old infants with iron deficiency anemia assigned to receive home stimulation program via weekly home visits over 1 year
9941461|NCT00998998|Active Comparator|2|6 or 12 month old infants with iron deficiency anemia assigned to surveillance (weekly visits to monitor health and iron supplement) over 1 year
9941462|NCT00998998|Experimental|3|Nonanemic infants identified at 6 or 12 months assigned to receive home stimulation program via weekly home visits over 1 year
9941463|NCT00998998|Active Comparator|4|Nonanemic infants identified at 6 and 12 months assigned to surveillance (weekly visits to monitor health) over 1 year
9941464|NCT00999024||Healthy subjects|20 healthy subjects will be included
9941465|NCT00999024||COPD Patients|20 Patients with Grade IV COPD will be included
9941466|NCT00999050|Experimental|diabetic pts <35BMI|All patients will be in a single arm receiving bypass surgery to assist with diabetes management
9941467|NCT00999076||Sputum with positive AFB smear|
9941468|NCT00999089|Active Comparator|CCAB|Conventional Coronary Artery Bypass
9941469|NCT00999089|Active Comparator|OPCAB|Off-Pump Coronary Artery Bypass
9941470|NCT00999089|Active Comparator|PACAB|Pump-Assisted Coronary Artery Bypass
9941471|NCT00999115|Experimental|Allogenic ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million in case of incomplete fistula closure following week 12 assessment.
9941472|NCT00999128|Experimental|Part 1|
9941473|NCT00999128|Experimental|Part 2|
9941474|NCT00999180|Active Comparator|Btx-A and Kinesiotherapy|The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
9941475|NCT00999180|Placebo Comparator|Saline and Kinesiotherapy|The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
9941476|NCT00999193|Active Comparator|Conservative Treatment|
9941477|NCT00999193|Experimental|ORIF w. locking plate, no luxation|
9941478|NCT00999193|Experimental|Hemiarthroplasty, no luxation|
9941479|NCT00999206|Experimental|1|
9941480|NCT00999206|Experimental|2|
9941481|NCT00999206|Experimental|3|
9941482|NCT00999206|Active Comparator|4|
9941483|NCT00999219|Experimental|FK199B-first group|
9941484|NCT00999219|Experimental|Zolpidem-first group|
9941485|NCT00999232|Experimental|Erythromycin|
9941486|NCT00999232|Placebo Comparator|Placebo|
9941487|NCT00999245|Other|High Demand / Low Infusion|PCA dosing plan
9941488|NCT00999245|Other|Low Demand / High Infusion|PCA plan for Low Demand / High Infusion
9941489|NCT00999258|Active Comparator|sirolimus|the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
9941490|NCT00999258|No Intervention|tacrolimus|
9941491|NCT00999271||Healthy subjects|30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
9941492|NCT00999284|Placebo Comparator|Placebo|Sham infusion of sodium chloride 0.9%
9941493|NCT00999284|Active Comparator|Low dose arm|Infusion of 0.3 mg/kg/h ZK200775 over 4 hours
9941494|NCT00999284|Active Comparator|High dose arm|Infusion of 0.75 mg/kg/h ZK200775 over 4 hours
9941495|NCT00999297|Placebo Comparator|Sugar pill (Placebo o mg/d)|0 mg/d sugar pill
9941496|NCT00999297|Active Comparator|Dihydrocapsiate|Drug 3 mg/d or 9 mg/d including Placebo
9941497|NCT00999297|Active Comparator|3 mg/d or 9 mg/d Dihydrocapsiate|Drug including Placebo
9941498|NCT00999310||Klinefelter syndrome|
9941499|NCT00999310||Control men|
9941500|NCT00999310||Control women|
9941501|NCT00999310||parents of Klinefelter groupe|
9941502|NCT00999323||coronary artery disease|patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
9941503|NCT00999336|Active Comparator|Group H|Healthy subjects matched to the renal impairment groups
9941504|NCT00999336|Experimental|Group A|Patients with mild renal impairment
9941505|NCT00999336|Experimental|Group B|Patients with moderate renal impairment
9941506|NCT00999336|Experimental|Group C|Patients with severe renal impairment
9941507|NCT00999349|Experimental|Silymarin (LEGALON)|
9941508|NCT00999349|Placebo Comparator|Placebo|
9941509|NCT00999362||Early kidney-transplant recipients|Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.
9941510|NCT00999362||stable kidney transplant recipients|Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation
9941511|NCT00999375|Experimental|Group A|
9941512|NCT00999375|Active Comparator|Group B|
9941513|NCT00999427|Experimental|A|The randomly selected group of subjects who will receive the intervention. The radiologist performing the transrectal prostate biopsy on these subjects will have a gauze soaked with Povidone-iodine over his/her index finger, and will insert this into the rectum. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin to the other. This will be allowed to dry for 2 minutes before proceeding with the biopsy.
9941514|NCT00999427|No Intervention|B|The randomly selected group of subjects who will receive the standard of care biopsy without any added intervention.
9941515|NCT00999440|Experimental|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done.Patients who start with any opiate and then switch to methadone, move to methadone follow up
9941516|NCT00999453|Experimental|LDL-cholesterol 70 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
9941517|NCT00999453|Active Comparator|LDL-cholesterol 100 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
9941518|NCT00999479|Experimental|Monophasic OCP|Patients randomized to this study arm will receive combined oral contraceptive pills. Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages
9941519|NCT00999479|Placebo Comparator|Placebo|Patients assigned to this arm will use non-hormonal, barrier contraceptives to prevent pregnancy.Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages.
9941520|NCT00999505|Active Comparator|Amantadine|Amantadine 200mg twice a day
9941521|NCT00999505|Placebo Comparator|Placebo|Placebo capsules twice a day
9941522|NCT00999531|Experimental|1|GS-9411 9.6 mg
9941523|NCT00999531|Experimental|2|GS-9411 4.8 mg
9941524|NCT00999531|Experimental|3|GS-9411 2.4 mg
9941525|NCT00999531|Placebo Comparator|4|Saline Placebo
9941526|NCT00999557|Experimental|Arm I|Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
9941527|NCT00999557|Placebo Comparator|Arm II|Patients apply topical placebo solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
9941528|NCT00999570||Patients operated by AR trained surgeons|patients who had their total knee replacements performed by surgeons who have completed a fellowship training in adult reconstruction surgery
9941529|NCT00999570||Patients operated by non-AR surgeons|patients who had their total knee replacements performed by orthopaedic surgeons who did not complete an adult reconstruction fellowship training
9941530|NCT00999583|Experimental|EPO|five injections maximum of 40000 UI EPO
9941531|NCT00999583|Active Comparator|Control|Classical take care
9941532|NCT00999635|Experimental|Custom made insole|Custom made functional moulded insole
9941533|NCT00999635|Active Comparator|Prefabricated Insole|Prefabricated accommodative moulded insole
9941534|NCT00999648|Experimental|Manual therapy|Myofascial trigger point pressure release
9941535|NCT00999648|Placebo Comparator|Control|Placebo myofascial trigger point pressure release
9941536|NCT00999700|Experimental|ARM A|Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
9941537|NCT00999700|Active Comparator|ARM B|RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
9941538|NCT00999739|Experimental|two vaccines|people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
10001679|NCT01549899|Active Comparator|In-person CBT of Insomnia|CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
10001680|NCT01549899|Active Comparator|Internet CBT of Insomnia|The I-CBTi protocol was developed by the National Center for Telehealth and Technology with the first author (DJT) serving as the subject matter expert, and administered on the afterdeployment.org website. The information and instructions for I-CBTi were identical to in-person CBTi; however, their mode of delivery in I-CBTi is considerably different due to the constraints of its automated, online format. The lessons were presented as audio recordings accompanied by visual graphics and animations and several lessons, had interactive components such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
10001681|NCT01549899|No Intervention|Minimal Contact|Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
10035064|NCT01802749|Active Comparator|chemotherapy|"Combination chemotherapy with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days."
10214598|NCT04981067|Other|Sciatic nerve block using increased concentration of local anesthetic|If the sciatic nerve block in the previous participant was not successful, the concentration of local anesthetic would be increased 0.05% in the next patient.
10214599|NCT04964050|Experimental|Treatment sequence TRR|Participants will receive Capozide (T) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
10214600|NCT04964050|Experimental|Treatment sequence RTR|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by Capozide (T) in period 2 followed by ACE-Hemmer-Ratiopharm (R) in period 3.
10214601|NCT04964050|Experimental|Treatment sequence RRT|Participants will receive ACE-Hemmer-Ratiopharm (R) in period 1 followed by ACE-Hemmer-Ratiopharm (R) in period 2 followed Capozide (T) by in period 3.
10214602|NCT04961905|Experimental|Single tablet fist, fasted|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
10214603|NCT04961905|Experimental|FDC fist, fasted|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
10214604|NCT04961905|Experimental|Single tablet fist, fed|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
9528434|NCT03211195|Experimental|Sotagliflozin - Commerical|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
10214605|NCT04961905|Experimental|FDC fist, fed|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
10214606|NCT04936321|Active Comparator|Sleep Education + CBT for Pain|Participants will receive access to internet-delivered sleep education during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
10214607|NCT04936321|Experimental|CBT for Insomnia + CBT for Pain|Participants will receive access to internet-delivered CBT for insomnia during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
10214608|NCT04928118||Impella protected Percutaneous coronary intervention (PCI)|Patients undergoing Impella protected PCI as deemed necessary by interventional cardiologist - VCU Medical Center case based standard of care
9528435|NCT03211195|Active Comparator|Sotagliflozin -Development|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
9528436|NCT03211273||Patient cohort|Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
9528437|NCT03211039|Other|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
9528438|NCT03211039|Other|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
9528758|NCT03207685|Other|All Subjects|This is a single arm study With a device intervention of Additional Seizure Monitoring
9941539|NCT00999739|Experimental|One vaccine|people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
9941540|NCT00999752|Active Comparator|Arm A|Nebivolol to reach blood pressure control
9941541|NCT00999752|Active Comparator|Arm B|Hydrochlorothiazide for blood pressure control
9941542|NCT00999765||Bipolar Disorder - stable|
9941543|NCT00999778|Active Comparator|Caregiver Education Intervention|10 1:1,one hour sessions weekly for 10 weeks with parent and interventionist. Behavioral education strategies will be targeted
9941544|NCT00999778|Active Comparator|Caregiver-Mediated Intervention|One hour 1:1 with parent, child and interventionist, each week, for 10 weeks social communication and joint engagement strategies will be targeted
9941545|NCT00999791|Active Comparator|Avastin|
9941546|NCT00999791|Active Comparator|Diclofenac|
9941547|NCT00999817|Other|A|Single 30 mg dose of dextromethorphan
9941548|NCT00999817|Experimental|B|Single 45 mg dose of PF-00299804 plus a single 30 mg oral dose of dextromethorphan
9941549|NCT00999856|Active Comparator|Cohort 1|In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
9941550|NCT00999856|Active Comparator|Cohort 2|Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
9941551|NCT00999856|Active Comparator|Cohort 3|Cohort 3 only differs in the used photometer from cohort 2.
9941552|NCT00999856|Active Comparator|Cohort 4|Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
9941553|NCT00999856|Active Comparator|Cohort 5|The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.
9941554|NCT00999869|Experimental|Botulinum toxin A|At first visit, patients will be randomized by blocked randomization into 2 sides of scalp. Experimental side will be injected with botulinum toxin A ( Botox) 2 units per 6.05 cm2 of lesion ( Concentration 2 units of Botox per 0.1 ml of normal saline ).
9941555|NCT00999869|Active Comparator|Triamcinolone acetonide|At visit0, patients will be injection with triamcinolone acetonide concentration at 10 mg/ml on the comparison side
9941556|NCT00999882|Experimental|AZD8055|Dose escalation
9941557|NCT00999895||Antipsychotic outpatients with schizophrenia|Switched treatment of antipsychotic outpatients with schizophrenia
10001682|NCT01549912||Rotator cuff tear|
10001683|NCT01549938|Active Comparator|Treatment|20,000 IU cholecalciferol capsule
10001684|NCT01549938|Placebo Comparator|Placebo|Microcellulose capsule
10001685|NCT01549990||Sevoflurane group|donors who went through donor nephrectomy under general anesthesia with sevoflurane
10001686|NCT01549990||desflurane group|donors who went through donor nephrectomy under general anesthesia with desflurane
10001687|NCT01550016||Febrile Patients|Observation of patients with possible dengue fever in the early phase of disease
10001688|NCT01550029|Experimental|Counseling/Mood Management|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
10001689|NCT01550029|Active Comparator|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle."
10001690|NCT01550042||Intensive observation cohort|Patients > 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
9528759|NCT03207880|Experimental|MLPT|Multi-level pregnancy test
9528760|NCT03207828|Experimental|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
10001691|NCT01550055|Experimental|CMAB009 plus Irinotecan|
10001692|NCT01550055|Active Comparator|Irinotecan-only and sequential-CMAB009|
10001693|NCT01550068|Experimental|Experimental Arm|Echocardiographic screening
10001694|NCT01550068|No Intervention|Control Arm|No echocardiographic screening
10001695|NCT01550081|Active Comparator|Rate of perceived exertion|Exercise intensity controlled by Borg
10001696|NCT01550081|Active Comparator|Heart rate monitor|Exercise intensity controlled by heart rate monitors
10001697|NCT01550107|Active Comparator|Allopurinol|Allopurinol 600mg tablets
10001698|NCT01550107|Placebo Comparator|Lactose tablets|Placebo Lactose tablets
10214609|NCT04928092||Active research group|Patients undergoing intravascular imaging guided, low contrast PCI procedure as part of standard care
10214610|NCT04925765|Experimental|Virtual Reality Session|All participants in this study will complete a 1 hour virtual reality session.
9941558|NCT00999960|Active Comparator|1: without simulator|without simulator
9941559|NCT00999960|Experimental|2: with simulator|with simulator
9941560|NCT00999973|Active Comparator|Mitomycin c 0.02%|
9941561|NCT00999973|Placebo Comparator|Placebo|
9941562|NCT00999986|No Intervention|placebo|
9941563|NCT00999986|Active Comparator|cyclophosphamide|
9941564|NCT00999999|Active Comparator|Standard|Standard dural closure
9941565|NCT00999999|Experimental|Experimental|Experimental dural closure, adding of Investigational Medicinal Product (IMP)
9941566|NCT01000038|Experimental|Wii-Fit Intervention|Intervention: Subjects in this arm participate in Wii-Fit exercises
9941567|NCT01000038|Active Comparator|Walking Intervention|Intervention: Subjects in this arm participate in walking
9941568|NCT01000077||Discarded Operating Room Tissue|The purpose of this research study is to use the discarded (tissue that would normally be thrown out) tissue from your surgery in order to obtain cells that can be grown in a laboratory to study how to use cells like these to fix sick and diseased organs. We will test if these cells can be used to build new and healthy tissues. This technique is called tissue engineering. In this study we will be comparing cells obtained from different individuals.
9941569|NCT01000077||Discarded Placenta|During a standard surgery or delivery of a baby unneeded tissue is usually discarded. We would like to explore the opportunity to grow the cells of these discarded tissues in the laboratory. The cells will be placed in special dishes and supplemented with a mixture of salts and nutrients that were designed to allow the cells to survive outside the body and grow. This procedure is called tissue culture of cells. We will attempt to isolate a population of cells from the tissue culture and study them in the laboratory.
9941570|NCT01000090||Acromegaly patients, somatostain analogues|
9941571|NCT01000090||Acromegaly patients, surgery|
9941572|NCT01000103|Active Comparator|1: Real rTMS treatment|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
9941573|NCT01000103|Sham Comparator|2: Sham rTMS treatment|Simulation of rTMS
9941574|NCT01000116|Active Comparator|Fibrin glue|
9941575|NCT01000116|Active Comparator|Tacks|
9941576|NCT01000142|No Intervention|Treatment as Usual Control Group|
9941577|NCT01000142|Sham Comparator|Light Touch Group|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
9941578|NCT01000142|Experimental|Standard OMT Group|
9941579|NCT01000168|Experimental|Treadmill therapy|"Patients assigned to the Treadmill therapy group received daily 30 minutes specific walking training on treadmill with body weight support alternatively overground, and 30 minutes functional training, treated by a physiotherapist."
9941580|NCT01000168|Active Comparator|Conventional walking therapy|Patients assigned to the comparative conventional walking therapy group received daily 30 minutes specific traditional walking training overground and 30 minutes functional training, treated by a physiotherapist.
9941581|NCT01000181||Patients undergoing carotid endarterectomy|
9941582|NCT01000194|Experimental|High polyunsaturated fat meal|A high fat milkshake containing 55g of fat, mainly PUFA
9941583|NCT01000194|Experimental|High monounsaturated fat meal|A high fat milkshake containing 55g of fat, mainly MUFA
9941584|NCT01000194|Experimental|High saturated fat meal|A high fat milkshake containing 55g of fat, mainly SFA
9941585|NCT01000207|Experimental|1|Dose ranging
9941586|NCT01000207|Experimental|2|Dose ranging
9941587|NCT01000220|Active Comparator|Omeprazole|
9941588|NCT01000220|Placebo Comparator|placebo|
9941589|NCT01000233|Active Comparator|Phytine (Phytate)|300 mg tid* 24 months
9941590|NCT01000233|Placebo Comparator|Placebo|
9941591|NCT01000246|Experimental|influenza vaccine day 4|influenza vaccine day 4 of chemotherapy
9941592|NCT01000246|Experimental|influenza vaccine day 16|influenza vaccine day 16 of chemotherapy
9941593|NCT01000246|Active Comparator|influenza vaccine|influenza vaccine in patients with heartfailure
9941594|NCT01000259||Ancillary-Correlative|Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
9941595|NCT01000298|Placebo Comparator|Placebo|
9941596|NCT01000298|Experimental|Amoxicillin|
9941597|NCT01000298|Experimental|cefdinir|cefdinir
9941598|NCT01000350|Experimental|Exercise Post Saline|Saline infusion 1L hours before exercise test
9941599|NCT01000350|Placebo Comparator|Placebo|Placebo given prior to exercise test
10214611|NCT04905862||Hemodialyzed patients|Hemodialyzed patients vaccinated with BNT162b2 - mRNA vaccine against COVID-19
10214612|NCT04905862||Patients treated with peritoneal dialysis|Patients treated with peritoneal dialysis vaccinated with BNT162b2 - mRNA vaccine against COVID-19
10214613|NCT04905862||Patients without chronic kidney disease|Patients without chronic kidney disease vaccinated with mRNA BNT162b2 - vaccine against COVID-19
10214614|NCT04905862||Kidney transplant recipients|Kidney transplant recipients vaccinated with mRNA vaccine against COVID-19
10214615|NCT04899167|Experimental|4 years after kidney transplantation|Patients 4 years after KT (N=10); 5 with estimated (e) glomerular filtration rate (GFR) ≤35 mL/min/1.73m2, and 5 with estimated (e) glomerular filtration rate (GFR)>35 mL/min/1.73m2.
10214616|NCT04899167|Experimental|7 years after kidney transplantation|Patients 7 years after KT (N=10); 5 patients with eGFR ≤35 mL/min/1.73m2, and 5 with eGFR>35 mL/min/1.73m2.
10214617|NCT04898309|Experimental|Study stage 1: GNR-038, 50 МЕ/ kg|Recombinant C1 esterase inhibitor
10214618|NCT04898309|Experimental|Study stage 1: GNR-038, 100 МЕ/ kg|Recombinant C1 esterase inhibitor
10214619|NCT04898309|Experimental|Study stage 1: Berinert®, 20 МЕ/ kg|Human C1 esterase inhibitor
10214620|NCT04898309|Experimental|Study stage 1: Placebo|Placebo
10214621|NCT04898309|Experimental|Study stage 2: GNR-038 in selected dose|Recombinant C1 esterase inhibitor
10214622|NCT04898309|Experimental|Study stage 2: Berinert®, 20 МЕ/ kg|Human C1 esterase inhibitor
9941600|NCT01000363||Spanish speaking group|Diabetes medical group visits will be held at the Grady North DeKalb satellite clinic the third Thursday of the month starting in October 2009. There will be two cohorts of patients- English speaking patients and Spanish speaking patients. Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.
9941601|NCT01000363||English speaking group|"Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.~This visit will only focus on the patient's diabetes care. Each patient will continue to see their regular physician for their health care.~All of the services that will be provided at the medical group visit are standard of care and are the same that the patient will receive in a one-on-one visit. However, this format will allow the patient to been seen by the physician and receive diabetes education in one visit."
9941602|NCT01000402|Other|Psychopharmacotherapy|No specific arms; Treatment decision based on available guidelines
9941603|NCT01000415|Experimental|Cisplatin plus gemcitabine|Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
9941604|NCT01000441|Active Comparator|arm 1 (2d anti-TNF):|infliximab, etanercept, adalimumab
9941605|NCT01000441|Active Comparator|arm 2 (other biotherapy)|abatacept, rituximab or tocilizumab
9941606|NCT01000519|Active Comparator|Aerobic Training|50 minutes of aerobic training, 18 sessions within 2 months period
9941607|NCT01000519|Experimental|Progressive Resistance Training|50 minutes of progressive resistance training consisting of nine resistance exercises, each conducted 3 sets of 10 repetitions. 18 sessions over 2 months period.
9941608|NCT01000532||Pacemaker therapy|
9941609|NCT01000545|Placebo Comparator|placebo gelcaps + best medical treatment|Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
9941610|NCT01000545|Active Comparator|SLX 500LRU/day + best medical treatment|Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
9941611|NCT01000545|Active Comparator|SLX 1000LRU/day + best medical treatment|Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
9941612|NCT01000545|Active Comparator|SLX 2000LRU/day + best medical treatment|Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
9941613|NCT01000571||H1N1 pandemic influenza vaccine recipient|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
9800811|NCT01698008|No Intervention|Standard of Care|The standard of care arm will not use the mobile application Diabetes Doctor to communicate with their physician about their blood sugars. They will attend clinic visits and have evaluations initially, and at 3 and 6 months. They will also receive a HbAIc at each visit. They will do the same QOL survey at 3 months. At 6 months, they will be given the QOL survey.
10001699|NCT01550133|Experimental|Not Learned: Non-nutritive bev to Nutritive bev|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid and act as a control for the learned effects.
9800812|NCT01698268|Experimental|TAP Group|Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine.
10001700|NCT01550133|Experimental|Not Learned: Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid and act as a control for the learned effects.
9800813|NCT01698268|Active Comparator|Local Infiltration Group|Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine.
9800814|NCT01698320|Placebo Comparator|Placebo MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
9800815|NCT01698320|Experimental|Albuterol MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
9800816|NCT01698333|Experimental|122-0551|
9800817|NCT01698463|Other|Identify Patients at Risk/Exercise Prescription|The intervention was delivered in two visits and two follow-up phone calls. Physician identifies that the patient is at risk of falls or fractures Visit one: individualized exercise prescription by a physiotherapist. Visit two: motivational interviewing (behavioural counselling) by kinesiologist Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
9800818|NCT01698502||Trained|Healthy, Endurance trained (Maximal oxygen uptake (VO2max), ml*min-1*kg-1>60), 20-30 year, BMI: 18,5-25kg/m2, males.
9800819|NCT01698502||Untrained|Healthy, sedentary (Maximal oxygen uptake (VO2max), ml*min-1*kg-1<50), 20-30 year, BMI: 18,5-25kg/m2, males.
9800820|NCT01698528|Experimental|Intervention Group|The experimental arm will be provided with a tablet computer with a newly designed software to help manage his or her diabetes care. This arm will communicate with his or her provider through the tablet computer to initiate and titrate basal insulin dose based on the 303 protocol. The individuals in this arm will also track their glucose values and medication adherence using the tablet computer by documenting when medication was taken or insulin was injected.
9800821|NCT01698528|No Intervention|Control Group|The individuals in the control group will receive usual care from the study Clinic as they always have. These individuals will be tracking their diabetes in the same way they have been by communicating with their health care provider and his or her office via fax/phone/e-mail. These individuals will not be provided with a tablet computer.
9800822|NCT01698554|Experimental|bimatoprost formulation A solution|Bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
9800823|NCT01698554|Active Comparator|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
9800824|NCT01698554|Placebo Comparator|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
9800825|NCT01698554|Placebo Comparator|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
9800826|NCT01698684|Placebo Comparator|Placebo|
9800827|NCT01698684|Experimental|Avanafil 100 mg|
9800828|NCT01698684|Experimental|Avanafil 200 mg|
9800829|NCT01698710|Experimental|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
9800830|NCT01698775|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
9800831|NCT01698775|Active Comparator|Placebo to omarigliptin (Phase A) → Glipizide (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
9800832|NCT01698801|Experimental|Lenalidomide plus dexamethasone|Lenalidomide plus low-dose dexamethasone
9800833|NCT01698814|Experimental|AL-4943A|AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
9800834|NCT01698814|Placebo Comparator|AL-4943A Vehicle|AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
9800835|NCT01698879|Experimental|Single arm, three cohorts|Idarubicin, cytarabine, Mylotarg.
10001701|NCT01550133|Experimental|Not Learned: Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage and act as a control for the learned effects.
10001702|NCT01550133|Experimental|Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
10001703|NCT01550133|Experimental|Learned: Non-Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of non-nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage to determine if cephalic phase response changes with learning.
10001704|NCT01550133|Experimental|Learned: Nutritive solid to Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid to determine if cephalic phase response changes with learning.
10001705|NCT01550133|Experimental|Learned: Nutritive beverage to Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive beverage to determine if cephalic phase response changes with learning.
10001706|NCT01550133|Experimental|Not Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
10001707|NCT01550146|Experimental|Dexamethasone, 0.1 mg/kg|The patients in the Dexamethasone group get iv 0.1 mg/kg dexamethasone preoperative.
10001708|NCT01550146|Placebo Comparator|Placebo|In the Placebo group the patients get 0.1 ml/kg normal saline.
10001709|NCT01550172|Experimental|Sleep Behavioral Therapy A and NHMS|Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
10001710|NCT01550172|Active Comparator|Sleep Behavioral Therapy B and NHMS|Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
10001711|NCT01550185|Experimental|Treatment (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
10001712|NCT01550198||Newborns|"Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)"
10001713|NCT01550211||Students|Healthy students from Bar-Ilan University
10001714|NCT01550211||Schizophrenic patients' relatives|Healthy family members (parents or siblings) of the schizophrenic participants (chronic and naive)
10001715|NCT01550211||Naive schizophrenic patients|Naive patients with a diagnosis of schizophrenia, a history of only one psychotic episode and un-medicated
10001716|NCT01550211||Chronic schizophrenia patients|Chronic patients with a diagnosis of schizophrenia and a history of more than one psychotic episode
10001717|NCT01550250|Experimental|Immediate Night-time Compression|Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system. Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period. A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks. From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
10001718|NCT01550250|Active Comparator|Delayed Group: Standard Care|Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance. Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week. Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
10001719|NCT01550276|Experimental|Suboccipital soft tissue inhibition|The SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
10001720|NCT01550276|Experimental|Occiput-atlas-axis global manipulation|The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
10001721|NCT01550276|Experimental|The combination of both treatments|
10001722|NCT01550276|Placebo Comparator|control group|
10001723|NCT01550302|No Intervention|Controls|Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
10001724|NCT01550302|Active Comparator|Superficial Cervical Plexus Block|Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.
10001725|NCT01550354|Active Comparator|Propofol group|Intravenous administration of propofol 2 mg/kg before intubation
9800836|NCT01699022|Experimental|Injection Cyclofem|"Injection of Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
9800837|NCT01699087|Experimental|PRK ALLEGRETTO|Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
9476232|NCT03573973|Experimental|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
9800838|NCT01699178|Experimental|Oral testosterone undecanoate|Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
9800839|NCT01699178|Active Comparator|Transdermal testosterone gel (AndroGel)|Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
9800840|NCT01699373|Experimental|Ultrasound-assisted|Pre-procedural ultrasound scan performed
9800841|NCT01699373|No Intervention|Manual Palpation|
9800842|NCT01699503|No Intervention|No Screening|Subjects who are randomized into the non-screening arm will receive the usual standard of care.
9800843|NCT01699503|Experimental|Screening Group|Subjects who are randomized into the screening arm of the study will be screened by the MIS. Subjects with MIS score of less than 5 points will be referred to the Collaborative Dementia Care Program for a subsequent diagnostic assessment, counseling and management.
9800844|NCT01699542|Active Comparator|Metal Stent|The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.
9800845|NCT01699542|Active Comparator|Bougie Dilation|Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.
9800846|NCT01699607|Experimental|amphetamine|There is only one arm to the study. All subjects will receive amphetamine at 0.5mg/kg prior to the second PET scan.
9800847|NCT01699685|Placebo Comparator|Sequence A|Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
9800848|NCT01699685|Active Comparator|Sequence B|Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
9800849|NCT01699698|Experimental|Test subject|
9800850|NCT01699750|Experimental|Air Optix Aqua|Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
9800851|NCT01699750|Active Comparator|Acuvue Oasys|Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
9800852|NCT01699763|Experimental|Subjects with and without Diabetes|All testing and lancing were performed by the study staff; Subjects with and without Diabetes did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using three Blood Glucose Monitoring Systems (BGMS): Contour® NEXT LINK BGMS; OneTouch® UltraLink® BGMS; Nova Max Link® BGMS.
9800853|NCT01699789|Active Comparator|Resources for Services|The Resources for Services condition offers time-limited technical assistance to individual agencies, coupled with outreach from a community engagement specialty, to participate in structured reviews of components of the Quality Improvement Program Intervention as implemented by the Resources for Services Expert Team.
9800854|NCT01699789|Experimental|Community Engagement and Planning|The Community Engagement and Planning arm supported 4 months of planning for the Community Engagement and Planning Council consisting representatives of all assigned programs in biweekly 2 hour meetings to fit trainings in the Quality Improvement Program to the community and develop strategies across programs to collaborate as a network. The CEP Council developed a written plan for training and monitoring and supported implementation of the training plan. CEP sites were provided with enrolled client lists.
9800855|NCT01699815|Active Comparator|Preemptive group|The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
9800856|NCT01699815|Active Comparator|Closure group|The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.
9800857|NCT01700036|Experimental|Treatment arm|Alpha-1-Antitrypsin (AAT) for the treatment of Steroid Refractory Acute Graft vs Host Disease.
9800858|NCT01700049|Experimental|Open Label oral vismodegib|This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
9800859|NCT01700140|Experimental|SyB D-0701: high dose group|
9800860|NCT01700140|Experimental|SyB D-0701: low dose group|
9800861|NCT01700140|Placebo Comparator|placebo group|
9941614|NCT01000584|Other|1|Group A: One dose of the licensed H1N1 vaccine and one dose of the seasonal influenza vaccine given concurrently
9941615|NCT01000584|Other|2|Group B: One dose of seasonal influenza vaccine given 3 weeks after administration of one dose of the licensed H1N1 vaccine
9941616|NCT01000597|Other|Treatment Y|Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
9941617|NCT01000597|Other|Treatment Z|A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
9941618|NCT01000623|Experimental|Arm I|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
9941619|NCT01000623|Active Comparator|Arm II|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
9941620|NCT01000623|Active Comparator|Arm III|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
9941621|NCT01000623|Active Comparator|Arm IV|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
9941622|NCT01000688|Experimental|vildagliptin treatment first, acarbose treatment second|
9941623|NCT01000688|Experimental|acarbose treatment first, vildagliptin treatment second|
9941624|NCT01000740|Experimental|1|Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
9941625|NCT01000740|No Intervention|2|Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
9941626|NCT01000740|No Intervention|3|Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being
9941627|NCT01000766||Acute drug-induced liver injury|
9941628|NCT01000779|Active Comparator|Endoscopic Variceal Ligation|endoscopic therapy to obliterate varices
9941629|NCT01000779|Active Comparator|Propranolol|drugs to decrease portal pressure
9941630|NCT01000792|Experimental|Levocetirizine|Levo 5 mg o.d.
9941631|NCT01000831|Active Comparator|Adjuvanted Arepanrix 2 doses|Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart
9941632|NCT01000857|Experimental|Open label treatment with 2-period crossover design|"Group 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days.~Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days.,~PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period."
9941633|NCT01000870|Experimental|Access MNI-513 and PET Imaging|
9941634|NCT01000896|Experimental|AZD0530 + carboplatin and paclitaxel|AZD0530 in combination with carboplatin and paclitaxel
9941635|NCT01000935|Active Comparator|Platelet Rich Plasma|The platelet concentrate extracted from patient's own blood (PRP) will be applied to the surgical site after completion of the repair.
9941636|NCT01000935|No Intervention|Surgical repair (standard-of-care)|Patients will have a rotator cuff repair without the PRP application.
9941637|NCT01000948|Experimental|ZD4054|The study had only one arm: intervention
9941638|NCT01001013|Experimental|LC15-0444 200 mg|LC15-0444 200 mg
9941639|NCT01001013|Experimental|Pioglitazone 30 mg|Pioglitazone 30 mg
9941640|NCT01001013|Experimental|LC15-0444 200 mg + pioglitazone 30 mg|LC15-0444 200 mg + pioglitazone 30 mg
9941641|NCT01001026|Other|1|Adults: One doses of H1N12009 vaccine
9941642|NCT01001026|Other|2|Children: Two doses of H1N12009 vaccine given 3 weeks apart
9941643|NCT01001039||control|Patients seen in the Otology clinic who have not had sinus surgery in the past 2 months or a history of sinusitis in the last 6 months.
9941644|NCT01001039||cases|Patients seen in the Rhinology Clinic with a complaint of facial pain. They must have evidence of chronic sinusitis.
9941645|NCT01001117|Experimental|Laser treated|Eye treated with LensAR Laser System
9941646|NCT01001117|Active Comparator|Control Eye|Contralateral eye treated with conventional phaco-emulsification
9941647|NCT01001130||fluticasone furoate group|Korean patients administered fluticasone furoate according to the Prescription information
9941648|NCT01001143|Experimental|Dose Level 1|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 100 mg/m2 PO daily for each 28 day cycle."
9941649|NCT01001143|Experimental|Dose Level 2|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 200 mg/m2 PO daily for each 28 day cycle."
9941650|NCT01001143|Experimental|Dose Level 3|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 300 mg/m2 PO daily for each 28 day cycle."
9941651|NCT01001182||Non interventional|Patients with RA diagnosis receiving any treatment for RA (DMARDS or biologics)
9941652|NCT01001260||No Aspirin Treatment|
9941653|NCT01001260||81 mg Aspirin Treatment|
9667574|NCT03416010|Active Comparator|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
9941654|NCT01001260||325 mg Aspirin|
9941655|NCT01001273|Experimental|Study Group|Hyperinsulinemic Normoglycemic Clamp will be started at the time of surgery (before incision) and will be continue for 3 days.
9941656|NCT01001273|No Intervention|Control Group|Patients in the control group will receive standard care.
9941657|NCT01001286|Active Comparator|Youth Club|The intervention will be compared to a waitlist comparison group. The group will enter NFE after the four-month posttest. During the four months, the youth will be offered a biweekly recreational youth club. The club will be led by Jordanian university student volunteers out of community-based organizations. Club activities will take place approximately every two weeks, including games, sports, arts and crafts, cultural activities, and trips. The Club will not include any significant education components or youth empowerment methodology--the hypothesized active ingredients of QS NFE.
9941658|NCT01001286|Experimental|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
9941659|NCT01001312|Experimental|Daxor Blood Volume Analysis|Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
9941660|NCT01001312|Active Comparator|Clinical volume status assessment|Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.
9941661|NCT01001364|Experimental|Formoterol/Budesonide|
9941662|NCT01001364|Active Comparator|Foraseq|
9941663|NCT01001455||blood pressure monitor|Cuff circumference:22cm-36cm
9941664|NCT01001455||stethoscopy|Cuff circumference: 22cm-36cm
9941665|NCT01001468|Experimental|VB-201 20 mg|
9941666|NCT01001468|Experimental|VB-201 80 mg|
9941667|NCT01001468|Placebo Comparator|Placebo|Single daily dose of oral placebo
9941668|NCT01001481||001|
9941669|NCT01001507|Experimental|Integrated HIV/FP services|Family planning services are integrated into HIV care and treatment services at this facility.
9941670|NCT01001507|No Intervention|Standard (non-integrated), referral-based, services|Patients from the HIV care and treatment clinic will be referred for family planning services, and will not receive FP services by the HIV care provider
9941671|NCT01001533||Children sedated by DEX|All pediatric patients (1 month to 18 years of age) eligible for Radiology Sedation Service for CT scan and Nuclear Medicine Scan procedure.
9941672|NCT01001585|Experimental|slow induction with sevoflurane|Only children with a BIS greater than 95 prior to inhalation of sevoflurane will be included in the study. Inductions will be done using a tight fitting mask with continuous monitoring of end tidal gas concentrations. During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached. Inspired sevoflurane will be increased only after end tidal concentration of sevoflurane is constant for at least one minute. Each induction (except for the patients requiring very low doses of sevoflurane) will take approximately 10 minutes.
9941673|NCT01001611|Experimental|CKD-501 0.5mg|
9941674|NCT01001611|Placebo Comparator|Placebo|
9667575|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
9667576|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
9941675|NCT01001624|Experimental|A|Melanil facial cream
9941676|NCT01001624|Active Comparator|B|Hydroquinone 2% cream
9941677|NCT01001637|Active Comparator|curcumin|
9941678|NCT01001637|Placebo Comparator|Placebo|
9941679|NCT01001650|Experimental|Group 1|4 doses of 7,500 PfSPZ/immunization.
9941680|NCT01001650|Experimental|Group 2|4 doses of 30,000 PfSPZ/immunization
9941681|NCT01001650|Experimental|Group 3|4 doses of 135,000 PfSPZ/immunization
9941682|NCT01001650|Experimental|Group 4|4 or 6 doses of 135,000 PfSPZ/immunization.
9941683|NCT01001663|Experimental|FemoSeal®|Closure device for femoral artery access closure
9941684|NCT01001663|Active Comparator|Manual compression|Conventional manual compression
9941685|NCT01001676|Active Comparator|Conventional Balloon Angioplasty|
9941686|NCT01001676|Experimental|Drug Eluting Balloon Angioplasty|
9941687|NCT01001689|Experimental|Nutritional counseling + exercise groups|Women in this arm will receive 2 telephone consultations on nutritional health during pregnancy, be invited to 2 evening meetings with nutritional topics and have access to a password protected internet site with topics related to nutrition and fitness in pregnancy. They will also be enrolled in an exercise group which will meet twice weekly, and be encouraged to exercise on their own 1-2 times each week.
9941688|NCT01001689|No Intervention|control|Women in this arm of the study will receive routine pregnancy care.
10001726|NCT01550354|Active Comparator|Alfentanil group|Intravenous administration of alfentanil 14 μg/kg before intubation
10001727|NCT01550354|Active Comparator|Rocuronium group|Intravenous administration of rocuronium 0.3 mg/kg before intubation
10001728|NCT01550380|Experimental|All participants|
10001729|NCT01550406|Active Comparator|Tachocomb|Tachocomb will be applicated on the cut surface of distal pancreatectomy
10001730|NCT01550406|Active Comparator|PGA|PGA will be applicated on the cut surface of distal pancreatectomy
10001731|NCT01550406|No Intervention|Control|No mesh will be applicated on the cut surface of distal pancreatectomy
10001732|NCT01550419|Experimental|Atorvastatin(50 characters)|
10001733|NCT01550419|Placebo Comparator|Placebo(50 characters)|
10001734|NCT01550432|Experimental|High-Dose Glutathione|2,260 mg/day
9528439|NCT03210857|Experimental|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
9528440|NCT03210636|Experimental|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
9528441|NCT03210805|Experimental|Supplementation|Omega-3 Polyunsaturated Fatty Acids
10001735|NCT01550432|Experimental|Low-Dose Glutathione|1,130 mg/day
10001736|NCT01550432|Experimental|High-Dose N-Acetylcysteine|1,200 mg/day
10001737|NCT01550432|Experimental|Low-Dose N-Acetylcysteine|600 mg/day
9528442|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
10001738|NCT01550432|Placebo Comparator|Placebo|Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.
10001739|NCT01550445|No Intervention|steroid withdrawal|The clinical outcome after kidney transplantation, under the immunosuppression of steroid withdrawal starting at 3 months post-transplantation using tacrolimus, mycophenolate mofetil, and basilixumab should be analyzed.
10001740|NCT01550458|Experimental|Mibefradil|
10001741|NCT01550458|Placebo Comparator|Placebo|
10001742|NCT01550497|Experimental|Home Exercise Group|Perform home exercises of unsupervised spinal stabilization exercises for 8 weeks
10001743|NCT01550497|Experimental|Weeky Physical Therapy Group|weekly physical therapy of supervised spinal stabilization exercises for 8 weeks
10001744|NCT01550523|Experimental|18-mer oligodeoxynucleotide|
10001745|NCT01550536|Experimental|Training|Sedentary women who exercised <2 hours per week and who had never engaged in a regular exercise program were enrolled in an exercise training intervention, following baseline measurements. See intervention below.
10001746|NCT01550536|No Intervention|Active|Postmenopausal women who exercised >5 hours per week and had been doing so for at least the past 10 years. These women were asked to maintain their normal activity habits for the duration of the study.
9528443|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
9528444|NCT03210597|Experimental|hydro-aerobic|Water aerobics exercise
10001747|NCT01550588|Placebo Comparator|Medication|Anticoagulation, Antiplatelet agent
10001748|NCT01550588|Active Comparator|Device closure|Amplatzer PFO occluder device
10001749|NCT01550601|Other|bariatric surgery 1|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with conservation of gastric antrum.
9528445|NCT03210597|Experimental|hydro-power|Resistance water exercise
9528446|NCT03210597|Experimental|hydro-combined|Water aerobics and resistance water exercise
10001750|NCT01550601|Experimental|bariatric surgery 2|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with ablation of gastric antrum.
10001751|NCT01550614|Experimental|Arm A: Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
10001752|NCT01550614|No Intervention|Arm B|Standard of care angina medication
10001753|NCT01550627|Active Comparator|extra-fluid|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day).
10001754|NCT01550627|Placebo Comparator|non extra fluid (control group)|The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
10001755|NCT01550640|Experimental|remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
10001756|NCT01550640|No Intervention|standard|control standard group
10001757|NCT01550653|Experimental|Liraglutide|"See Intervention"
10001758|NCT01550653|Placebo Comparator|Placebo|"See Intervention"
10001759|NCT01550666|Experimental|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
10001760|NCT01550666|No Intervention|Treatment As Usual|Participants of this group will continue to receive medication follow up at the Center for Health Care Services. They will not be required to do anything additional except to complete assessment visits.
10214623|NCT04895202||Siponimod|Patients administered Siponimod as per Swiss label
10001761|NCT01550679||Smokers or ex-smokers|Smokers or ex-smokers 40-65 years of age with a smoking history of at least 20 pack-years with no diagnosis of COPD or asthma
10001762|NCT01550718|Active Comparator|ESML-Exercise (Physical Activity Program)|ESML-Exercise consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic. Classes are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the class gets individual attention and that all exercises are done safely using proper form.
10001763|NCT01550718|Active Comparator|ESML-SOCIAL (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session. Seminars are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the seminar gets individual attention and that everyone has a chance to bring up any concerns."
10001764|NCT01550718|No Intervention|No Intervention|This arm will receive no intervention during the active treatment period. After the 4 month assessment participants can choose to attend a support group.
10001765|NCT01550770|Experimental|proprofol|
10001766|NCT01550783|Experimental|Group I (home-based HPV screening)|Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
10001767|NCT01550783|Experimental|Group II (clinic-based standard of care screening)|Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.
10001768|NCT01550796|Active Comparator|d-cycloserine|d-cycloserine 250 mg two days per week one hour prior to(cognitive training)
10001769|NCT01550796|Placebo Comparator|Placebo|Placebo pill two days per week 1 hour prior to cognitive training
10001770|NCT01550822|Active Comparator|HEALS|Intervention group which will receive group clinics addressing smoking cessation, healthy eating, physical activity, and the risk factors of stroke.
10001771|NCT01550822|No Intervention|Usual Care|This group will receive usual care for stroke survivors
10001772|NCT01550835|Experimental|Distal Embolic Protection Only|Carotid stenting with distal embolic protection only
10001773|NCT01550835|Active Comparator|Distal embolic protection and aspiration thrombectomy|Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection
10001774|NCT01550848|Experimental|Abraxane and Gemcitabine|Abraxane and Gemcitabine
10001775|NCT01550874|No Intervention|Control Group|Wear the pedometer provided by study everyday with weekly charging and syncing of data.
10001776|NCT01550874|Experimental|Experimental Group|Wear the pedometer provided by the study everyday and also participate in phone-based physical activity behavior-change counselling for 6 months and then check sustainability without further motivational support for another 6 months.
10001777|NCT01550887|No Intervention|Impulsivity evaluation|
10001778|NCT01550900|Experimental|Metformin ER|Participants receive two tablets of Metformin ER 500 mg once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy. Dose will be reached in a gradual escalation scheme to improve gastrointestinal tolerance. If participants experience side effects during dose escalation regimen, they will be reduced to one tablet of 500 mg daily, and may continue taking 500 mg daily for the duration of the study.
10001779|NCT01550900|Active Comparator|Placebo|Control group given matched Placebo once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy.
10001780|NCT01550913|Experimental|Sober Network IPT|Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
10001781|NCT01550913|Other|Treatment as Usual|Participants are assigned to have Treatment as Usual
10001782|NCT01550926|Active Comparator|Arm 1|60 mg orlistat
10001783|NCT01550926|Active Comparator|Arm 2|120 mg orlistat (2 X 60 mg capsules)
10001784|NCT01550926|Experimental|Arm 3|orlistat experimental formulation
10001785|NCT01550939|No Intervention|Time Comparison between the Lenstar and IOLMaster|
10001786|NCT01550978|Experimental|Study Group|Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
10001787|NCT01550978|No Intervention|Control Group|Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator
10001788|NCT01551004|Experimental|Cohort A|8 subjects (6 active, 2 placebo) receive a single oral dose of 100 mg CRS3123 or placebo
10001789|NCT01551004|Experimental|Cohort B|8 subjects (6 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo
10001790|NCT01551004|Experimental|Cohort C|8 subjects (6 active, 2 placebo) receive a single oral dose of 400 mg CRS3123 or placebo
10001791|NCT01551004|Experimental|Cohort D|8 subjects (6 active, 2 placebo) receive a single oral dose of 800 mg CRS3123 or placebo
10001792|NCT01551004|Experimental|Cohort E|8 subjects (6 active, 2 placebo) receive a single oral dose of 1200 mg CRS3123 or placebo
10001793|NCT01551017||c-treatment|test group
10001794|NCT01551017||standard cooling|comparison group
10001795|NCT01551043|Experimental|Arm 1|
10001796|NCT01551069|Active Comparator|HCQ|HCQ 200~400mg, once daily, oral administration
10001797|NCT01551069|Other|Placebo|HCQ-placebo, once daily, oral administration
10001798|NCT01551108|Active Comparator|Mobile phone intervention: minimal|Intervention: limited behavioral strategies
10001799|NCT01551108|Experimental|Mobile phone intervention: intensive|Intervention: advanced behavioral strategies
10214624|NCT04889794|Experimental|Exposed FMGs to GPS intervention|Patients who are followed by FMGs exposed to the GPS intervention. They will receive the GPS intervention.
10214625|NCT04889794|No Intervention|Non exposed FMGs to GPS intervention|Patients who are part of the FMGs not exposed to the GPS intervention. They will receive the usual care and services.
10214626|NCT04889040|Experimental|RO7496998 (AT-527)|Orally administered, 550 mg twice daily (BID) for 5 days
9528447|NCT03210688|Active Comparator|High dose prednisolone|Prednisolone 1 mg/kg/day
9528448|NCT03210688|Experimental|Alfacalcidol and low dose prednisolone|Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
9528449|NCT03210623|Experimental|group A|subjects applying the stent retriever(TonbridgeMT)
9528450|NCT03210623|Active Comparator|group B|subjects applying Solitaire™
9528451|NCT03210727|Other|single arm|This arm will be used to pilot test the Ready to CARE program (with the caregivers) and measure outcomes (in the patients).
9528452|NCT03210584||Imaging measurements|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Multimodal evaluation is conducted on ex vivo human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
9528453|NCT03210662|Experimental|Treatment (EBRT, pembrolizumab)|Beginning on day 1, patients undergo fractionated EBRT daily for 5 consecutive days a week for up to 12 or 22 treatments. Patients also receive pembrolizumab IV over 1 hour on day 2. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
9528454|NCT03210675|Other|Study group|Will have a PSG at home every 6 months (± 1 month) from the age of 6 months until the age of 3 years.
9528455|NCT03210675|Other|Standard Care Group|Will have a single PSG at home which will give a reference in the Down Syndrome population of 3 years old and will be used as reference to the study group
9528456|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
9528457|NCT03210779|Active Comparator|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
9528458|NCT03210779|Placebo Comparator|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
9528459|NCT03210909|Experimental|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
9800862|NCT01700179|Experimental|ACH-0143102 plus ribavirin daily|ACH-0143102 225 mg loading dose on Day 1 followed by 75 mg maintenance dose on Days 2-84. Weight-based RBV(as per label) for Days 1-84.
9800863|NCT01700192|Experimental|MK-8237|MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).
9800864|NCT01700192|Placebo Comparator|Placebo|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
9800865|NCT01700205|Active Comparator|Type of Formula: CMF|Infants are randomized to feed standard cow milk formula during first year of life
9800866|NCT01700205|Experimental|Type of Formula: EHF|Infants are randomized to feed extensively hydrolyzed infant formula during first year of life
9800867|NCT01700335|Experimental|SyB L-1101|"In Cohort 1, SyB L-1101 1200 mg/day group, Participants were administered 1200 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~In Cohort 2, SyB L-1101 1800 mg/day group, Participants were administered 1800 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~For both Cohorts, the treatment period of 14 days constitutes 1 cycle, and the treatment was allowed for up to 8 cycles."
9800868|NCT01700387|Experimental|OnabotulinumtoxinA + Topiramate|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with topiramate. During the first month of the treatment period, subjects will titrate as follows:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
9800869|NCT01700387|Placebo Comparator|OnabotulinumtoxinA + Placebo|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with placebo. During the first month of the treatment period, subjects will titrate as follows:~Week 1: 1 tab qhs Week 2: 1 tab bid Week 3: 1 tab q am + 2 tabs qhs Week 4: 2 tabs bid"
9800870|NCT01700517|Sham Comparator|control group|Spinal anesthesia with 0.5% isobaric bupivacaine, in isolation. Punctures in the femoral and popliteal areas were made to mask the femoral and sciatic block, respectively, with no infusion of any medication.
9800871|NCT01700517|Experimental|Femoral nerve block|In addition to the spinal anesthesia, block of the femoral nerve guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. The technique used was femoral area puncture, at the level of the crural fold of skin, with a 0.5% (125mg) ropivacaine associated to 75 mcg of clonidine.
9800872|NCT01700517|Experimental|sciatic nerves block|In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
9800873|NCT01700530|Experimental|Statin|Statins (40mg/day)for an average of 12 weeks
9800874|NCT01700530|Experimental|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
9800875|NCT01700530|Active Comparator|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk) for 12 weeks
9800876|NCT01700621|Experimental|measles-rubella and rotavirus vaccines|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
9800877|NCT01700621|Active Comparator|measles-rubella vaccine|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age
9800878|NCT01700673|Experimental|Myeloablative BMT|Azacitidine and sargramostim after myeloablative stem cell transplant
9800879|NCT01700673|Experimental|Non-myeloablative BMT|Azacitidine and sargramostim after non-myeloablative stem cell transplant
9800880|NCT01700673|Experimental|Standard consolidation|Azacitidine and sargramostim after standard consolidation
9800881|NCT01700725|Experimental|Nasal Irrigation - Saline|nasal irrigation using saline plus routine care for symptoms of CRS and fatigue
9800882|NCT01700725|Experimental|Nasal Irrigation - Xylitol|Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
10214627|NCT04889040|Placebo Comparator|Placebo|The dose and regimen of the placebo will match that of AT-527.
10214628|NCT04882046|Other|patients diagnosed by a clinician who suspects leptospirosis|
10214629|NCT04878679|Experimental|"Strength training + WB-EMS"|Strength training combined with WB-EMS : 2 times/week for 20 minutes
10214630|NCT04878679|Experimental|Cardiovascular training + WB-EMS|Cardiovascular training, using rowing machine, combined with WB-EMS : 2 times/week for 20 minutes
10214631|NCT04878679|Active Comparator|Control group|No physical activity
10214632|NCT04875754|Experimental|Group 1: ICM-203 (Low dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e12 vg (n=6) or placebo (n=2) into the target knee at Day 1
10214633|NCT04875754|Experimental|Group 2: ICM-203 (Medium dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 2x10e13 vg (n=6) or placebo (n=2) into the target knee at Day 1
10214634|NCT04875754|Experimental|Group 3: ICM-203 (High dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e13 vg (n=6) or placebo (n=2) into the target knee at Day 1
10214635|NCT04855929|Experimental|ANV419 single agent, Q2W|
10214636|NCT04855929|Experimental|ANV419 in combination with CPI or Immunostimulatory agent, Q2W|
9941689|NCT01001728|Active Comparator|Prone Position|Patients will lie on their fronts on an in-house designed board comprising an arm positioning device registerable to the couch-top, together with a styrofoam/ memory foam mattress. The ipsilateral breast will drop through an aperture in the mattress. The distance from the nipple to the superior, inferior and lateral aspects of the aperture will be recorded along with the distance of the nipple from the couch-top. Arms will be extended as far as possible above the head and the position of the arm immobilisation handles recorded. The head will be turned to the contralateral side. The contralateral breast will be pulled laterally such that it is as flat as possible beneath the patient. Measurements will be taken in order to relate the position of the bi-lateral tattoos to the orthogonal lasers. A fourth tattoo will be marked on the patient's back in line with the A-P laser. The position will be reproduced at treatment using measurements from the tattoo to the laser.
9941690|NCT01001728|Active Comparator|Supine position|For the supine position, patients will be positioned on a customized supine breast board co-registerable to the couch-top to CT and the treatment machines. Arms will be placed above the head in supports. Arm and head position will be recorded along with the angle of the board (which is adjusted such that the sternum is parallel to the couch-top). Tattoos will be marked bi-laterally and medially in a defined relationship to orthogonal lasers. The position will be reproduced at treatment using the above measurements, tattoos and lasers.
9941691|NCT01001754|Experimental|PEG-rIL-29 at 120 µg|
9941692|NCT01001754|Experimental|PEG-rIL-29 at 180 µg|
9941693|NCT01001754|Active Comparator|Peginterferon alfa-2a at 180 µg|
9941694|NCT01001780|Experimental|Pentostatin, Cyclophosphamide, Rituximab|
9941695|NCT01001819||1|Chronic Rhinosinusitis w/o nasal polyps
9941696|NCT01001819||2|No sinus disease
9941697|NCT01001845|No Intervention|Lifestyle counseling|
9941698|NCT01001845|Active Comparator|vit E|200mg 2 times per day for 3 weeks
9941699|NCT01001845|Experimental|Milk Thistle extract|1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks
9941700|NCT01001845|Experimental|vit E + Milk Thistle Extract|200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks
9941701|NCT01001858|Active Comparator|Domiciliary group|In this group OSA diagnosis was performed at patient's home by mean of non-attended RP. All follow-up visits were conducted by a trained nurse in patient's home.
9941702|NCT01001858|Active Comparator|Hospital Group|In this group diagnosis was made by in-hospital PSG. Follow-up was performed at hospital by a specialist Physician
9941703|NCT01001858|Active Comparator|Mixed Group|In this group diagnosis was made by home RP, and follow-up at hospital
9941704|NCT01001871|Experimental|Vitamin/mineral fortificant with iron|
9941705|NCT01001871|Placebo Comparator|Vitamin/mineral fortificant without iron|
9941706|NCT01001884|Experimental|counseling|caregiver psychoeducational consultation program (CPCP)
9941707|NCT01001897|Experimental|misoprostol|400 micrograms of misoprostol inserted buccally or vaginally prior to IUD insertion
9941708|NCT01001897|Placebo Comparator|Placebo|Troches identical to experimental drug inserted buccally or vaginally prior to IUD insertion
9941709|NCT01001936|Experimental|1|
9941710|NCT01001949|Experimental|Wheat Bran Extract|
9941711|NCT01001949|Placebo Comparator|placebo|
9941712|NCT01001962|Active Comparator|Metformin|527 Patients treated with Metformin 850x2mg titrated to 1000x2mg Daily oral
9941713|NCT01001962|Active Comparator|Empagliflozin|527 Patients treated with empagliflozin 10mg titrated to 25 mg Daily oral
10214637|NCT04855760|Experimental|REL-1017 25 mg|Participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT).
10214638|NCT04852198|Active Comparator|OAGB|149 patients receiving one anastomosis gastric bypass (OAGB) with a Biliopancreatic-limb of 150cm
10214639|NCT04852198|Active Comparator|RYGB|149 patients receiving Roux-en-Y gastric bypass (RYGB) with a Biliopancreatic-limb of 150cm
10214640|NCT04848402|Experimental|On-Body Delivery System (OBDS)/Multiple Bolus Injector|On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).
10214641|NCT04848402|Experimental|Single Auto Injector|Single auto injector used to administer placebo SC.
10214642|NCT04840264|Experimental|1st Line Therapy|Docetaxel 25mg/m2, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m2, ivdrip 180 min, D1, D15; 5Fu 1200mg/m2, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
10214643|NCT04840264|Experimental|2nd Line Therapy|Docetaxel 25mg/m2, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m2, ivdrip 180 min, D1, D15; 5Fu 1200mg/m2, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
10214644|NCT04840264|Experimental|3rd or later Line Therapy|Docetaxel 25mg/m2, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m2, ivdrip 180 min, D1, D15; 5Fu 1200mg/m2, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.
10214645|NCT04839042|Experimental|SC-Ad6-1 Low Dose Intramuscular|Low Dose SC-Ad6-1, I.M., single-dose (Day 1)
10214646|NCT04839042|Experimental|SC-Ad6-1 Medium Dose Intramuscular|Medium Dose SC-Ad6-1, I.M., single-dose (Day 1)
10001800|NCT01551121||intervention group|"Patient in the intervention group will have camera installed in their room. These cameras can either work in visible or infrared range. They are physically linked to a server that will store and analyze images in real-time. The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy"
10001801|NCT01551121||non-equipped group|"Patient in the non-equipped group will have usual care"
9528460|NCT03210649|Experimental|CKD-519 400mg(PartⅠ: 1day)|CKD-519 400mg(100mg x 4tabs) or placebo
10001802|NCT01551134|Active Comparator|Open fundoplication|Fundoplication performed with open surgery
10001803|NCT01551134|Experimental|Lap fundoplication|Primary fundoplication performed by laparoscopic surgery
10001804|NCT01551147|Experimental|Experimental 200 mg dose|
10001805|NCT01551147|Active Comparator|Active Comparator|
10001806|NCT01551147|Placebo Comparator|Placebo Comparator|
10001807|NCT01551160|Experimental|Medical Emergency Team|A communication and team-working initiative
10001808|NCT01551225|Active Comparator|Escitalopram|17 or 18 Patients with IBS and panic disorder treated with Escitalopram.
10001809|NCT01551225|Placebo Comparator|Placebo tablets to Escitalopram|17 or 18 Patients with IBS and panic disorder treated with placebo.
10001810|NCT01551238|Experimental|Protein intake of 5 energy percent|
10001811|NCT01551238|Experimental|Protein intake of 30 energy percent|
10001812|NCT01551251||Advanced NSCLC with high TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
10001813|NCT01551251||Advanced NSCLC with low TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
10001814|NCT01551277|Placebo Comparator|Control Group|
10001815|NCT01551277|Experimental|BREATH STACKING|
10001816|NCT01551290|Placebo Comparator|Group I: Placebo|Participants in Group I receive placebo
10001817|NCT01551290|Experimental|Group II: Infliximab|Participants in Group II receive 5 mg/kg infliximab
10001818|NCT01551316|Experimental|MN-221|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
10001819|NCT01551316|Experimental|PLACEBO|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
9528461|NCT03210649|Experimental|CKD-519 400mg(PartⅡ: 14days)|CKD-519 400mg(100mg x 4tabs) or placebo
9528462|NCT03210792|Active Comparator|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
10001820|NCT01551329|Experimental|Drug: Ketamine|
10001821|NCT01551342||Cystoscopic surveillance, TURT or Cystectomy|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.
10001822|NCT01551368|Experimental|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
10001823|NCT01551368|Placebo Comparator|Placebo|Same as for nimodipine but an identical placebo will be self-administered.
10001824|NCT01551381|Experimental|EV-077|Oral administration
10001825|NCT01551381|Placebo Comparator|Placebo|Oral administration
10001826|NCT01551394|Experimental|Meropenem|"Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.~Treatment duration is 11 ± 3 days."
10001827|NCT01551394|Active Comparator|Standard of care|"The two accepted therapeutic options are:~ampicillin + gentamicin (SOC regimen 1) and~cefotaxime + gentamicin (SOC regimen 2)."
10001828|NCT01551433||Pts scheduled for Ivor Lewis esophagectomy|During the operation, once the gastric conduit has been mobilized and positioned, and once the anastomotic site has been identified by the surgeon, the assigned RSA will provide the Wipox instrument to the fellow (the primary surgeon will be blinded to the result) who will then obtain one measurement from the anastomotic site.
10001829|NCT01551446|Experimental|Bardoxolone Methyl 20mg|
10001830|NCT01551459|Active Comparator|Arm 1: Dacarbazine|Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
10001831|NCT01551459|Experimental|Arm 2: Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity.
10001832|NCT01551485|Experimental|Zolpidem|
10001833|NCT01551485|Placebo Comparator|Placebo|
10001834|NCT01551498|Placebo Comparator|Placebo|subject takes one oral placebo lozenge, three times per day
10001835|NCT01551498|Active Comparator|Anatabloc Supplement|subject takes one oral Supplement lozenge, three time per day
10001836|NCT01551511|Experimental|delta-9-tetrahydrocannabinol (namisol)|
9476233|NCT03573973|Sham Comparator|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
9941714|NCT01002027|Active Comparator|CBT-counselling with Nurse|CBT-counselling with Maternal Health Nurse, adjunctive to management by general medical practitioner
9941715|NCT01002027|Active Comparator|CBT-Counselling by Psychologist|CBT-counselling with Psychologist, adjunctive to management by general medical practitioner
9941716|NCT01002027|No Intervention|Routine management|Ongoing management by general medical practitioner
9941717|NCT01002040|Active Comparator|One Dose Influenza vaccine|Arepanrix H1N1 Influenza vaccine (one dose)
9941718|NCT01002040|Active Comparator|Two Doses Influenza vaccine|Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)
9941719|NCT01002053||Diabetics with peripheral neuropathy|Patients with diabetes and peripheral neuropathy.
9941720|NCT01002079|Experimental|BMS-708163|
9941721|NCT01002079|Other|Rifampin|
9941722|NCT01002079|Experimental|Rifampin + BMS-708163|
9941723|NCT01002092|Active Comparator|Chemotherapy|
9941724|NCT01002092|Experimental|Endostar plus Chemotherapy|
9941725|NCT01002131||Digital Volume tomography|three-dimensional digital imaging using cone beam tomography (CBCT)
9941726|NCT01002157|Experimental|Vitamin K2 supplementation|
9941727|NCT01002157|Placebo Comparator|Placebo control|
9941728|NCT01002183|No Intervention|single arm|Fos-clin/Arte
9941729|NCT01002196|Experimental|stimulus fading procedures|
9941730|NCT01002196|Active Comparator|guidance of defocused communication|
9941731|NCT01002209|Sham Comparator|Sham Hyperbaric Oxygen Treatment|
9941732|NCT01002209|Experimental|Hyperbaric oxygen treatment (HBO)|
9941733|NCT01002222|Experimental|MCS-2|
9941734|NCT01002261||Liver cirrhosis / healthy subjects|10 patients with liver cirrhosis and 10 sex and age-matched healthy subjects
9941735|NCT01002261||Liver cirrhosis and healthy subjects|Patients with liver cirrhosis and healthy subjects
9941736|NCT01002274|Experimental|MCS-2|2 soft-gel capsules Qd for 40 weeks
9941737|NCT01002313||normal control|
9941738|NCT01002313||Patient treatment group|Treatment with prednisone
9941739|NCT01002326|Experimental|Cognitive-Behavioral Therapy|
9476235|NCT03573934|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2) injection
9476236|NCT03573934|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP) injection
9476237|NCT03573934|Experimental|GLP-2+GIP|GLP-2+GIP injection
9941740|NCT01002365|Active Comparator|Post op care|
9941741|NCT01002365|Active Comparator|Oxygen administration- different %|
9941742|NCT01002378|Experimental|Arm 1|
9941743|NCT01002378|Experimental|Arm 2|
9941744|NCT01002378|Experimental|Arm 3|
9941745|NCT01002391|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
9941746|NCT01002391|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
9941747|NCT01002404|Active Comparator|angled tipped guide wire|angled tipped guide wire used to deep biliary cannulation
9941748|NCT01002404|Active Comparator|straight tipped guidewire|straight guide wire used to deep biliary cannulation
9941749|NCT01002417|Placebo Comparator|Placebo|Both the phase 2b and phase 3 parts of the study have the placebo arm.
9941750|NCT01002417|Active Comparator|MCS-2 15 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
9941751|NCT01002417|Active Comparator|MCS-2 30 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
9941752|NCT01002430|Experimental|Gene therapy|
9941753|NCT01002430|No Intervention|Control|Control patients will have electroanatomic mapping procedure but no gene injections.
9941754|NCT01002443|Active Comparator|H. pylori eradication|
9941755|NCT01002443|Placebo Comparator|placebo|
9941756|NCT01002469|Experimental|sodium [1-13C] acetate|
9941757|NCT01002495|Experimental|Cohort 1|Eight endocardial injection for a total dose of 1mg VM202
9941758|NCT01002495|Experimental|Cohort 2|Eight endocardial injections for a total dose of 2mg VM202
9941759|NCT01002495|Experimental|Cohort 3|Twelve endocardial injections for a total dose of 3mg VM202
9941760|NCT01002521||Cases|Persons With Diabetes (PWD) who have current non-healing ulcer(s)
9941761|NCT01002521||Controls|Persons With Diabetes (PWD) with no current ulcers and no history of ulcers
9941762|NCT01002534|No Intervention|baseline|visit 1
9941763|NCT01002534|Active Comparator|Vardenafil|nasal instillation of Vardenafil ( visit 2 or 3)
9941764|NCT01002534|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
9941765|NCT01002560||Malignant melanoma tumour tissue|
9941766|NCT01002560||Benign pigmented lesions & other skin cancers|Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
9941767|NCT01002586|Experimental|Wii-Fit arm|Half hour daily, five days a week, for 8 weeks
9941768|NCT01002586|Active Comparator|Walking arm|Half hour daily, five days a week, for 8 weeks
9941769|NCT01002599|Experimental|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
9476238|NCT03573934|Placebo Comparator|Placebo|Placebo injection
9941770|NCT01002599|Active Comparator|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
9941771|NCT01002625|Experimental|1. PF-04457845 followed by placebo|PF-04457845 followed by placebo
9941772|NCT01002625|Experimental|2. Placebo followed by PF-04457845|Placebo followed by PF-04457845
9941773|NCT01002638|Experimental|Occlusive Dressing|
9941774|NCT01002638|Active Comparator|Surgery|
9941775|NCT01002651|Experimental|Wheat Bran Extract (high dose)|
9941776|NCT01002651|Experimental|Wheat Bran Extract (low dose)|
9941777|NCT01002651|Placebo Comparator|placebo|
9941778|NCT01002664|Active Comparator|MCS-2|Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
9941779|NCT01002664|Placebo Comparator|Placebo|Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
9941780|NCT01002677|Experimental|Curriculum|
9941781|NCT01002677|Active Comparator|Self-directed|
10214647|NCT04839042|Experimental|SC-Ad6-1 High Dose #1 Intramuscular|High Dose #1 SC-Ad6-1, I.M., single-dose (Day 1)
10214648|NCT04839042|Experimental|SC-Ad6-1 High Dose #2 Intramuscular|High Dose #2 SC-Ad6-1, I.M., single-dose (Day 1)
10214649|NCT04839042|Experimental|SC-Ad6-1 Multiple Dose Intramuscular|Multiple Dose SC-Ad6-1, I.M., multiple-dose (Day 1 and Day 22)
10214650|NCT04839042|Experimental|SC-Ad6-1 Low Dose Intranasal|Low Dose SC-Ad6-1, I.N., single-dose (Day 1)
10214651|NCT04839042|Experimental|SC-Ad6-1 Medium Dose Intranasal|Medium Dose SC-Ad6-1, I.N., single-dose (Day 1)
10214652|NCT04839042|Experimental|SC-Ad6-1 High Dose #1 Intranasal|High Dose #1 SC-Ad6-1, I.N., single-dose (Day 1)
10214653|NCT04839042|Experimental|SC-Ad6-1 High Dose #2 Intranasal|High Dose #2 SC-Ad6-1, I.N., single-dose (Day 1)
10214654|NCT04839042|Experimental|SC-Ad6-1 Multiple Dose Intranasal|Multiple Dose SC-Ad6-1, I.N., multiple-dose (Day 1 and Day 22)
9476239|NCT03573895|Experimental|Foam-Roller|
9476240|NCT03573895|Experimental|Neuromuscular Stretching|
9476241|NCT03573895|Experimental|Pasive stretching|
9941782|NCT01002690|Experimental|Etoricoxib|10-13 days treatment with etoricoxib
9941783|NCT01002703|Experimental|RBP|Lenalidomide and Bendamustine and Prednisone
9941784|NCT01002768|Experimental|IDeg|
9941785|NCT01002768|Experimental|IGlar|
9941786|NCT01002794|Experimental|Arthroscopic partial meniscectomy|Standard arthroscopic partial meniscectomy - NGD 1
9941787|NCT01002794|Experimental|Exercise Therapy|Supervised neuromuscular- and strength training
10214655|NCT04836585|No Intervention|Care As Usual|Participants in the control condition are followed by their RLS psychiatrists during the study as per usual care.
10214656|NCT04836585|Experimental|eMBC Intervention|Participants in the intervention arm are followed by their RLS psychiatrists during the study at clinically appropriate intervals with the addition of eMBC.
10214657|NCT04824651||Solid cancer|objective : 800 participants for adult cohort, 100 for pediatric cohort (solid cancer and malignant hemopathy)
9941788|NCT01002807|Other|FDC of dapagliflozin/metformin XR|
9941789|NCT01002807|Other|FDC of dapagliflozin/reduced mass metformin XR|
9941790|NCT01002807|Other|dapagliflozin and Glucophage® XR|
9941791|NCT01002833|Experimental|PfA|Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
9941792|NCT01002833|Experimental|PfB|Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
9941793|NCT01002833|Active Comparator|NF54|Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
9941794|NCT01002846|Experimental|traditional acupuncture|Procedure : ST 36 and PC 6 are selected, subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth
9941795|NCT01002846|Sham Comparator|sham acupuncture|Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
9941796|NCT01002859|Active Comparator|cyclosporin|Intravenous cyclosporin injection.
9941797|NCT01002859|Placebo Comparator|Pacebo|Intravenous injection of NaCl solution.
9941798|NCT01002872|Active Comparator|Lanthanum Carbonate|
9941799|NCT01002872|Placebo Comparator|Placebo|
9941800|NCT01002898|Experimental|lopinavir/ritonavir|
9941801|NCT01002911|Experimental|Aggressive Antibiotic therapy|Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
9941802|NCT01002911|Active Comparator|Conventional Antibiotic Therapy|Preoperative intravenous antibiotics
9941803|NCT01002937||Tumour tissue, renal cell carcinoma|> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
9941804|NCT01002963|Experimental|PF-04418948 30 mg|
9941805|NCT01002963|Experimental|PF-04418948 100 mg|
9941806|NCT01002963|Experimental|PF-04418948 300 mg|
9941807|NCT01002963|Experimental|PF-04418948 1000 mg|
9941808|NCT01002963|Experimental|PF-04418948 3000 mg|
9941809|NCT01002963|Experimental|PF-04418948 4500 mg|
9941810|NCT01002963|Experimental|PF-04418948 6000 mg|
10214658|NCT04824651||Solid organ transplantation|objective : 700 participants for adult cohort, 50 for pediatric cohort
10214659|NCT04824651||Allogeneic hematopoietic stem cell transplantation|objective : 350 participants for adult cohort, 50 for pediatric cohort
10214660|NCT04824651||Chronic renal failure|Patients with chronic renal failure stage 4, 5 who receive dialysis or not. objective : 350 participants for adult cohort, 30 for pediatric cohort
9941811|NCT01003002||PD Cohort|The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
9941812|NCT01003015|Experimental|Arm 1|
9941813|NCT01003028|Experimental|Limited|Limit the maximum plasma concentration target to 9.8 ng/ml
9941814|NCT01003028|Active Comparator|Control|Use 20 ng/ml as max plasma concentration
9476242|NCT03573895|No Intervention|Control|
9941815|NCT01003041||lifestyle counseling|in the future parents will be advised to expose their infants to phonetic sounds in order to develop their phonetic categories in the future
9941816|NCT01003054|Experimental|Autologous Transplantation|Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
9941817|NCT01003093|Experimental|Antigen group + high adjuvans|The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.
9941818|NCT01003093|Experimental|Antigen group|The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.
9941819|NCT01003093|Experimental|Antigen + low adjuvans group|The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.
9941820|NCT01003119|Experimental|A CHESS|Those in the ACHESS arm will also be given a smart-phone with access to the ACHESS system (the intervention) for a full 12 months. The ACHESS intervention includes: 1) the Core CHESS system that has been tested in several diseases, 2) a proactive computer-based relapse prevention system, 3) data transfer from the phone to a computer accessible by the patient's counselor/care manager, and 4) systems for the patient to maintain contact with his/her Care Manager
9941821|NCT01003119|No Intervention|Usual Care|Those randomized into the Usual Care group will receive usual medical care.
9941822|NCT01003132|No Intervention|Treatment As Usual|Treatment as usual as determined by the clinical team responsible for the individual's care
9941823|NCT01003132|Active Comparator|Acceptance and Commitment Therapy|Up to 10 sessions of Acceptance and Commitment Therapy plus treatment as usual
9941824|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0|"15 μg HA (0.5 mL) per injection, 1 injection~50 adults (aged 18~60 years) were assigned to receive one injection of H1N1 vaccine"
9941825|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|"15 μg HA (0.5 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
9941826|NCT01003145|Experimental|H1N1 vaccine of 30 μg HA on Day 0 and 21|"30 μg HA (1 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
9941827|NCT01003158|Experimental|Monotherapy part|AZD8931 monotherapy
9941828|NCT01003158|Experimental|Combination part|AZD8931 plus paclitaxel
9941829|NCT01003171|Experimental|MCS-2|
9941830|NCT01003197||complication group < III|
9941831|NCT01003197||complication group >= III|
9941832|NCT01003223|Experimental|PKM modeling with graphical report|
9941833|NCT01003236|Placebo Comparator|placebo|1 tablet 3 times daily
9941834|NCT01003236|Experimental|Milk Thistle extract|1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day
9941835|NCT01003262|Experimental|Emergency Department Observation|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
9941836|NCT01003262|Active Comparator|Unstructured, inpatient evaluation|
9941837|NCT01003314|Experimental|Group 1|
9941838|NCT01003314|Experimental|Group 2|
9941839|NCT01003327|Other|I-gel inserted first|The I-gel airway is insewrted first, then the LMA-Unique
9941840|NCT01003327|Other|LMA-Unique inserted first|LMA-Unique airway is inserted first, then the I-gel
9941841|NCT01003340|Experimental|Wee Wheezers asthma education|6 lesson asthma education delivered at home by Community Health Workers
9941842|NCT01003366|Experimental|bevel down|approaching the IJV with the needle bevel facing down
9941843|NCT01003366|Active Comparator|bevel up|approaching the IJV with the needle bevel facing up
9941844|NCT01003392||Normal|Normal volunteers, with no diagnosed chronic disease.
9941845|NCT01003392||Coronary artery disease|Group of patients with diagnosed coronary artery disease.
9941846|NCT01003392||Diabetes|Diabetic patients.
9941847|NCT01003405|Experimental|KUC-7483|
9941848|NCT01003431|Experimental|1|RotaTeq™ + DTwP
9941849|NCT01003431|Active Comparator|2|Rotarix™ + DTwP
9941850|NCT01003431|Active Comparator|3|RotaTeq™ + DTaP
9941851|NCT01003444|Experimental|Cohort 1|Muscle biopsy in healthy volunteers
9941852|NCT01003457||detrusor overactivity|
9941853|NCT01003470|Experimental|acupuncture|
9941854|NCT01003470|Active Comparator|rehabilitation|
9941855|NCT01003470|Active Comparator|acupuncture and rehabilitation|
9941856|NCT01003483|Experimental|Orlistat|The dose of 120 mg orlistat was taken three times daily and the dose remained constant throughout the study period.
9941857|NCT01003483|Experimental|Metformin|The dose of metformin was increased step - wise, from 500 mg once daily for the first week to 500 mg twice daily for the next week, and to 500 mg three times daily for the remaining study period .
9941858|NCT01003509|No Intervention|study, control|Control: Only modified shouldice repair performed Study: Modified Shouldice + Moloney repairs performed
9941859|NCT01003509|No Intervention|modified shouldice and double|one arm is only modified shouldice, other one is double
9941860|NCT01003522|Other|Treatment Arm A|Stenting of central lesion and subsequent standard palliative treatment and dyspnoea symptom control
9941861|NCT01003522|Other|Treatment Arm B|Standard palliative treatment and standard dyspnoea symptom control.
9941862|NCT01003535||[123I]5-IA-85380 SPECT|
9941863|NCT01003548|Active Comparator|Static culture|Embryos individually cultured in microdrops of 40 microliters of G-IVFplus series V
9941864|NCT01003548|Experimental|Smart plataform|Embryos culture in dynamics microfluidic culture system
9941865|NCT01003561|Experimental|ultrasonographic exam|
9941866|NCT01003574|Other|Control Arm|Control arm will receive standard care for risk of cardiac sequelae - a mailed, tailored (neither generic nor targeted) print summary of individualized information about the survivor's treatment, late effects risks, and recommended follow-up and lifestyle modifications.
9941867|NCT01003574|Other|Test Arm|Test arm will receive standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
9941868|NCT01003587|Experimental|District health information package|
9941869|NCT01003587|No Intervention|No Intervention|
9941870|NCT01003600||Questionnaire|This study is a cross-sectional survey study to be administered to adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens Cancer Center (QCC) at Queens Hospital between 6 months and 2 years ago and have no evidence of disease at the time of study enrollment.
9941871|NCT01003613|Active Comparator|Tranilast|CAT with FG and Tranilast and MMC 0.02%
9941872|NCT01003613|Placebo Comparator|Control|CAT with FG and MMC 0.02%
9941873|NCT01003626|Experimental|IFP Measurement|Tumor interstitial fluid pressure (IFP) assessments
9941874|NCT01003652||Harmonic Focus /conventional haemostasis|
9941875|NCT01003652||Harmonic Focus|
9941876|NCT01003652||new surgical device|
9941877|NCT01003652||Harmonic Focus / conventional haemostasis|Harmonic Focus group refers to the use of ultracision shears for haemostasis and conventional haemostasis group refers to the tie-and-clamp technique in total thyroidectomy
9941878|NCT01003665||Intensive Care treatement|ASA status 3 or 4 patients with invasive blood pressure measurement on the intensive care unit
9941879|NCT01003678|Experimental|Level 1|1 mg daily for 5 consecutive days followed by 23 days off drug
10001837|NCT01551511|Placebo Comparator|Placebo|
10001838|NCT01551524|Experimental|Intravenous Erwinia|
10001839|NCT01551537||Cohort Group|Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka.
10001840|NCT01551576||photoacoustic imaging (PAI)|Men seen in the urology clinic for elevated PSA and/or abnormal digital rectal exam (DRE) will be offered PAI at the time of transrectal ultrasound guided biopsy, which is standard of care. In addition, patients with a biopsy proven prostate cancer may also be approached for this PAI scan
10001841|NCT01551589|Experimental|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
10214661|NCT04824651||Autoimmune and autoinflammatory systemic diseases|Systemic lupus erythematosus ,Systemic Vasculitides,... objective : 750 participants for adult cohort, 130 for pediatric cohort
10214662|NCT04824651||Multiple sclerosis/ Neuromyelitis optica diseases|MS defined by Mac Donald et al. 2017 and Neuromyelitis optica defined by Wingerchuk et al. 2015 ; objective : 600 participants for adult cohort
10214663|NCT04824651||Chronic inflammatory rheumatism|Ankylosing spondylitis and rheumatoid polyarthritis objective : 600 participants for adult cohort
10214664|NCT04824651||Hypogammaglobulinemia|objective : 300 participants for adult cohort
10214665|NCT04824651||Obese non diabetic|BMI ≥ 30 objective : 1400 participants for adult cohort, 100 for pediatric cohort
9800883|NCT01700725|No Intervention|Control Group|Control group subjects continue to use routine care only
9800884|NCT01700816|Experimental|Bright light therapy|2500 Lux gaze directed every morning from 8 am until 8:30 am
9476243|NCT03573882|Other|Voxelotor|Participants will receive voxelotor (GBT440) at the highest dose (either 900 mg or 1500 mg) deemed safe by the Data Safety Monitoring Board (DSMB).
9476244|NCT03573869|Experimental|Cryoballoon ablation|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
9800885|NCT01700816|Placebo Comparator|Sham light|<1000 Lux gaze directed every morning from 8 am until 8:30 am
9476245|NCT03573869|No Intervention|Standard treatment|Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment
9476246|NCT03573843|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization , resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner, plus the use of a mobile device without installed delirium prevention software (placebo).
9476247|NCT03573843|Experimental|Experimental|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously, plus the use of software installed on a mobile device designed to support the prevention of delirium (Prevention software).
9800886|NCT01700829|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
9941880|NCT01003691|Experimental|Arm 1|
9941881|NCT01003704||General Anesthesia only|
9941882|NCT01003704||Peripheral nerve block|
9476248|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
9476249|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging >ypT1-2N0 as poor response.
9800887|NCT01700829|Active Comparator|Ketamine|0.5 mg/kg, I.V. (in the vein)
9800888|NCT01700907|Active Comparator|group DES|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
9800889|NCT01700907|Active Comparator|group SEVO|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
9800890|NCT01700959|Active Comparator|Melatonin|Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime.
9800891|NCT01700959|Placebo Comparator|Placebo|Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime.
9800892|NCT01700985|Experimental|122-0551|
9800893|NCT01700985|Placebo Comparator|Vehicle|
9800894|NCT01701011|Experimental|PRCI-monitoring|Coping intervention, Daily Record Keeping, Questionnaires
9800895|NCT01701011|No Intervention|Routine care control|Questionnaires
9800896|NCT01701011|No Intervention|Monitoring control|DRK and Questionnaires
9800897|NCT01701024|Active Comparator|ACYC|ACYC active, topically applied to the face for 12 weeks
9800898|NCT01701024|Placebo Comparator|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
9800899|NCT01701037|Experimental|Dabrafenib and Trametinib|Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
9800900|NCT01701063|Experimental|Treatment-Naive or Prior Partial/Null Response|telaprevir + Peginterferon alfa-2b + Ribavirin
9800901|NCT01701102|Active Comparator|Mepivacaine 37.5 mg|
9800902|NCT01701102|Active Comparator|Mepivacaine 30 mg plus fentanyl 10 µg|
9800903|NCT01701102|Active Comparator|Mepivacaine 27 mg plus fentanyl 10 µg|
9800904|NCT01701102|Active Comparator|Mepivacaine 24 mg plus fentanyl 10 µg|
9800905|NCT01701115|Experimental|Low Dose (20 mL) Local Anesthetic|Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.
9800906|NCT01701115|Active Comparator|Control Dose (40 mL) Local Anesthetic|Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine
9800907|NCT01701193|Placebo Comparator|Physiological saline- Laparoscopic|Participants receiving intraperitoneal administration of physiological saline at the time of laparoscopic myomectomy.
9800908|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparoscopic|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of laparoscopic myomectomy.
9800909|NCT01701193|Placebo Comparator|Physiological saline- Laparotomy|Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy (laparotomy).
9800910|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparotomy|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy (laparotomy).
9800911|NCT01701245|No Intervention|Standard of care|No intervention, standard of care
9800912|NCT01701245|Active Comparator|GammaCore|Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
9800913|NCT01701258|Active Comparator|CSA/MDD-amisulpride|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
9800914|NCT01701258|Placebo Comparator|CSA/MDD-placebo|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.
9941883|NCT01003704||spinal|
9941884|NCT01003717||Endeavor|Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
9941885|NCT01003730|Active Comparator|1|High tidal volume (15mL/kg PBW0 with low PEEP (3cm H2O
9941886|NCT01003730|Active Comparator|2|Low tidal volume (6mL/kg PBW) and high PEEP (3cm H2O)
9941887|NCT01003730|Active Comparator|3|low tidal volume (6mL/kg PBW) and high PEEP (10cm H2O)
9941888|NCT01003756|Experimental|Knee Intervention|Patients undergoing Total Knee Replacement. Exercise 8-10 weeks preoperatively
9941889|NCT01003756|No Intervention|Knee Control|Patients undergoing Total Knee Replacement. Receives standard instructions
9941890|NCT01003756|Experimental|Hip Intervention|Patient undergoing Total Hip Replacement. Exercise 8-10 weeks preoperatively
9941891|NCT01003756|No Intervention|Hip Control|Patients undergoing Total Hip Replacement. Receives standard instructions
9941892|NCT01003795||Promus|Patients treated with at least one Promus, everolimus-eluting, Stent
9941893|NCT01003808|Experimental|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
9941894|NCT01003834|Placebo Comparator|Control|Screening only
9941895|NCT01003834|Active Comparator|Assessment|Screening plus assessment
9941896|NCT01003834|Experimental|Computer Intervention|Screening, assessment, and computer-delivered intervention
9941897|NCT01003834|Active Comparator|Therapist Intervention|Screening, Assessment, and therapist-delivered intervention
9941898|NCT01003847|Active Comparator|fenofibrate|
10214666|NCT04824651||Diabetic (type I and II) obese or not|objective : 1400 participants for adult cohort, 100 for pediatric cohort
10214667|NCT04824651||People living with HIV-1|objective : 1400 participants for adult cohort
9800915|NCT01701258|Active Comparator|CSA/RES-amisulpride|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
9800916|NCT01701258|Placebo Comparator|CSA/RES-placebo|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.
9800917|NCT01701258|Active Comparator|MDD-amisulpride|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
9800918|NCT01701258|Placebo Comparator|MDD-placebo|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.
9800919|NCT01701258|Active Comparator|Control-amisulpride|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
9800920|NCT01701258|Placebo Comparator|Control-placebo|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.
9800921|NCT01701271|Experimental|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Androgenetic Allopecia in several types apply on the scalp drops of the hair loss prevention lotion
9800922|NCT01701362|Active Comparator|pregabalin|
9800923|NCT01701362|Placebo Comparator|placebo|
9800924|NCT01701375|Experimental|Arm 1|"PD 0332991 will be given orally days 1,2,3~Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6~Mitoxantrone will be given over 2 hour infusion day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
9800925|NCT01701401|Experimental|LDV/SOF 12 weeks|LDV/SOF administered for 12 weeks
9800926|NCT01701401|Experimental|LDV/SOF+RBV 12 weeks|LDV/SOF+RBV administered for 12 weeks.
9800927|NCT01701401|Experimental|LDV/SOF 24 weeks|LDV/SOF administered for 24 weeks
9800928|NCT01701401|Experimental|LDV/SOF+RBV 24 weeks|LDV/SOF+RBV administered for 24 weeks.
9941899|NCT01003847|Active Comparator|fatty acid|drug
9941900|NCT01003847|Active Comparator|Placebo|
9941901|NCT01003860||0.5% Ropivicaine (150 mg)|
9941902|NCT01003860||0.75% Ropivicaine (225 mg)|
9941903|NCT01003873||Bypass gastric|First arm is represented by obese patients that will be studied before and after a gastric bypass. They will be studied before surgery as well as 1 month and 6 months after surgery.
9941904|NCT01003873||Lifestyle intervention|The second group is represented by obese patients that will be studied before lifestyle intervention, 6 months after the beginning of the intervention and after a time that will allow patients to lose the same amount of weight that patients that had been through surgery had lost one month after surgery.
9941905|NCT01003873||Control subjects|The third group is a control group of normal weight people that will be studied at one time and after 6 months with stable weight.
9941906|NCT01003925||Usual Care|Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
9476250|NCT03573778|Experimental|iHEAL|10-18 visits (over 6 months) with a Registered Nurse
9476251|NCT03573778|Active Comparator|Usual Care|Information about Community Services
10001842|NCT01551589|Active Comparator|Elective Nodal Irradiation (ENI)|Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
10001843|NCT01551602|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
10001844|NCT01551602|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
10001845|NCT01551602|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
10001846|NCT01551602|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
10001847|NCT01551602|Active Comparator|MN-10-T SD|Single administration of MN-10-T
10001848|NCT01551602|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
10001849|NCT01551602|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
10001850|NCT01551602|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
10001851|NCT01551602|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
10001852|NCT01551602|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
10001853|NCT01551602|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
10001854|NCT01551615|Experimental|Metformin then metformin + vandetanib|Metformin alone followed by metformin in combination with vandetanib
10001855|NCT01551628|Experimental|Recombinant Human Arginase 1 Peg5000|
10001856|NCT01551641|Experimental|VEGF decressed|patients will receive concurrent chemoradiotherapy only
10001857|NCT01551641|Experimental|thalidomide|patients will be given thalidomide concurrent chemoradiotherapy
10001858|NCT01551641|Experimental|without thalidomide|patients will receive concurrent chemoradiotherapy only
10001859|NCT01551654|Placebo Comparator|Placebo Acu-TENS|No Electrical output was coming out from the TENS unit
10001860|NCT01551654|Experimental|TENS over acupuncture points|A constant mode of electrical stimulation at 2 pulses per second and pulse width at 200µs for 45 minutes. Intensity was set to just initiate muscle contraction.
10001861|NCT01551667||Cases / bacteraemia|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
10001862|NCT01551667||Controls|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients does not have bacteraemia.
10001863|NCT01551680|Experimental|Concurrent whole brain radiotherapy and iniparib|
10001864|NCT01551706|Active Comparator|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract (350 mg) per day
10001865|NCT01551706|Placebo Comparator|Exicipient pill|
10001866|NCT01551719|No Intervention|Standard Procedure (phase I)|Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
10001867|NCT01551719|Experimental|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
10001868|NCT01551732|Active Comparator|Anger Control Therapy|10 session manualized cognitive behavioral anger control therapy
10001869|NCT01551732|Experimental|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with an interactive biofeedback videogame.
10001870|NCT01551771|Experimental|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
10001871|NCT01551771|Placebo Comparator|GW824575 matched-placebo|Placebo
10001872|NCT01551784||1|
9941907|NCT01003925||Conjoint Analysis Group|Patients randomized to the experimental group will meet the research staff to complete the conjoint analysis software and post-test measures. The post-test measures include preparedness for decision-making, personal uncertainty, osteoarthritis knowledge, arthritis self-efficacy, and satisfaction with the results of the conjoint analysis program. The in-person visit takes approximately 60 minutes to complete. Four weeks after the in-person visit, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (i.e. global pain assessment, arthritis self-efficacy, personal uncertainty, and osteoarthritis knowledge).
9941908|NCT01003951|Experimental|Acupuncture|Each patient will receive two acupuncture treatments each week for four consecutive weeks. At the end of four weeks, the intervention will be complete.
9476252|NCT03573726|Other|Technically N/A, Crossover Design|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
9480648|NCT05262270|Experimental|Drug intervention (XR-NTX+XR-BUP)|"The study intervention is three doses of 380mg XR-NTX (Weeks 0, 3 and 6) and two doses of 300mg XR-BUP (Weeks 0, 4).~Drug: XR-NTX XR-NTX: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Extended Release Injectable Naltrexone Arm: Experimental~Drug: XR-BUP XR-BUP: 2 subcutaneous injections administered Week 0, 4. Other Names: Extended Release Injectable Buprenorphine Arm: Experimental"
9528463|NCT03210792|Experimental|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
9941909|NCT01003977||Xience V|Patients treated with a Xience V everolimus-eluting stent
9941910|NCT01004016|Placebo Comparator|Placebo|
9528464|NCT03210870|Other|Intervention|In-person nutritional education classes
9941911|NCT01004016|Experimental|KPS-0373|
9941912|NCT01004055|Experimental|Procellera™ Wound Dressing|
9941913|NCT01004055|Active Comparator|ACTICOAT™|
9941914|NCT01004055|Active Comparator|Mepilex® Ag|
9941915|NCT01004068|Experimental|SET-diet plus clomiphene|Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
9941916|NCT01004068|Active Comparator|Clomiphene citrate|One month of observation followed by one-cycle of clomiphene citrate therapy
9941917|NCT01004068|Experimental|SET plus diet|Lifestyle modifications for two months.
9941918|NCT01004094|Experimental|simple goal setting|This group will only set a goal.
9941919|NCT01004094|Experimental|goal setting plus action intentions|This group will set goals and form action intentions (plans) to facilitate goal attainment.
9941920|NCT01004094|Experimental|goal setting plus coping intentions|This group will set goals and form coping intentions (plans) to facilitate goal attainment.
9941921|NCT01004094|Experimental|goal setting plus action intentions plus coping intentions|This group will set goals, form action intentions (plans), and form coping intentions (plans) to facilitate goal attainment.
9941922|NCT01004120|Placebo Comparator|MDn|
9941923|NCT01004120|Active Comparator|B-GOS|
9941924|NCT01004133||Subjects 80 years of age or older without chronic diseases.|
9941925|NCT01004198|Experimental|MP4OX - 250|250 mL dose
9941926|NCT01004198|Experimental|MP4OX - 500|500 mL dose
9941927|NCT01004198|Active Comparator|Ringers Lactate solution|500 mL dose
9941928|NCT01004211|Active Comparator|Standard transurethral resection|Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
9941929|NCT01004211|Experimental|Narrow band imaging transurethral resection|The system will be switched to narrow band imaging by simply pushing a button. Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
9941930|NCT01004224|Experimental|BGJ398|
9941931|NCT01004237|Active Comparator|pravastatin|
9941932|NCT01004237|Active Comparator|valsartan|
9941933|NCT01004237|Active Comparator|pravastatin combined with valsartan|
9941934|NCT01004276|Experimental|Improved module|
9941935|NCT01004276|No Intervention|Standard module|
9941936|NCT01004289|Active Comparator|Control|Primary angioplasty and stenting without additional intervention.
9941937|NCT01004289|Experimental|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion.
9941938|NCT01004302|Sham Comparator|Sham surgery|
9941939|NCT01004302|Active Comparator|Active radiosurgery|
9941940|NCT01004315|Experimental|KUC-7483|
9941941|NCT01004315|Placebo Comparator|Placebo|
9941942|NCT01004315|Active Comparator|Tolterodine|
9941943|NCT01004328|Experimental|Intervention Group 1|All participants
9941944|NCT01004341|Other|Family-based weight control|Group-based family therapy for weight loss in children age 8-12 years.
9941945|NCT01004380|Experimental|Farletuzumab|2.5 mg/kg once weekly administered i.v. during the Combination treatment period and 7.5 mg/kg Q3W administered i.v. during the Maintenance period
9528465|NCT03210870|No Intervention|Control|no in-person nutritional education classes
9528466|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
9528467|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
9528468|NCT03210935||Merkel cell carcinoma|
9528469|NCT03210935||Advanced basal cell carcinoma|
9528470|NCT03210935||Cutaneous adnexal carcinomas|
9528471|NCT03210948|Experimental|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
9528472|NCT03210948|Active Comparator|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
9941946|NCT01004419|Experimental|Vandetanib plus fulvestrant|vandetanib by mouth once daily for 28 days plus fulvestrant intra-muscular injection each cycle
9941947|NCT01004445|Experimental|Arm 1|
9941948|NCT01004445|Experimental|Arm 2|
9941949|NCT01004445|Placebo Comparator|Arm 3|
9941950|NCT01004458|Active Comparator|Early treatment group|The experimental group receiving CBT
9941951|NCT01004458|No Intervention|Waiting list group|The waiting list group served as referents during the trial
9941952|NCT01004484|Active Comparator|Yogurt with probiotics and inulin|A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving).
9941953|NCT01004484|Placebo Comparator|Placebo|Acidified dairy snack without yogurt cultures, probiotic or inulin.
9941954|NCT01004497|Experimental|Modified Hyper-CVAD + Dasatinib|Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 & 11 Daunorubicin: 45 mg/m2/day, IV, days 4 & 11 Dexamethasone: 40 mg/day, IV, days 1~4 & days 11~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1~5 Mitoxantrone: 12 mg/m2/day, IV, days 1~2
9941955|NCT01004523||Single group|Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
9941956|NCT01004536|No Intervention|no treatment|The other half of cesarean section wound that is to be left untreated.
9941957|NCT01004536|Experimental|silicone gel|Randomly-designated half of cesarean section wound that is to be subject to application ot silicone gel
9941958|NCT01004549||Bilateral intraocular lens implantation.|
9941959|NCT01004575|Experimental|Kaname|patients that are treated by implanting Kaname Cobalt-Chromium coronary stent
9941960|NCT01004588|Experimental|Protein drink|protein drink
9941961|NCT01004588|Placebo Comparator|Placebo drink|Placebo drink
9941962|NCT01004601|Active Comparator|low dose docetaxel|Low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)
9941963|NCT01004601|Active Comparator|Pemetrexed|Pemetrexed (500 mg/m2 every 3 weeks)
9941964|NCT01004627|No Intervention|Control group - selective duplex|Patients will receive a duplex ultrasound only if specifically requested following physical examination.
9941965|NCT01004627|Experimental|Obligatory Duplex scan|Patients will receive a duplex ultrasound regardless of clinical findings. Arterial and venous duplex ultrasound examination
9941966|NCT01004640||Group 1|"Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.~Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis."
9941967|NCT01004653|Experimental|H1N1 influenza A Vaccine (Split virion), Inactivated|15 μg H1N1 influenza A Vaccine (Split virion), Inactivated
9528473|NCT03210545|Active Comparator|betamethasone - physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated physiological dose during one treatment period.
9528474|NCT03210545|Active Comparator|betamethasone - supra physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated supra physiological dose during one treatment period.
9528475|NCT03210896|No Intervention|Main Group|100 subjects (70 T2D and 30 Controls) consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers.
9667577|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
9941968|NCT01004666||Women with equivocal findings on Mammography, US and/or MRI|Women with equivocal findings on Mammography, US and/or MRI
9941969|NCT01004666||Discrepancy between clinical examination and imaging|Women with discrepancy between clinical examination and breast imaging
9941970|NCT01004666||Women with dense breast|Women with dense breast
9941971|NCT01004666||Women in high risk for Breast Cancer|Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
9941972|NCT01004731|Experimental|Cetuximab in combination with Carboplatin/Gemcitabine|Approximately 30 patients with advanced NSCLC will be enrolled. Patients will receive 3-week cycles of Cetuximab in combination with Carboplatin/Gemcitabine.
9941973|NCT01004757|Active Comparator|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled, aerobic exercise
9941974|NCT01004757|Active Comparator|Low Fat diet|cross over design of three weeks Low Fat diet followed by two weeks LOGI diet always combined with heart rate controlled aerobic exercise
9941975|NCT01004809||Dutasteride|Patients administrated dutasteride with male hair loss
9941976|NCT01004835||Migraine Disease|Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
10001873|NCT01551797|Experimental|Test Sustained Release (SR) Paracetamol (2000 mg)|A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
10001874|NCT01551797|Experimental|Test SR Paracetamol (1500 mg)|A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
10001875|NCT01551797|Active Comparator|Reference Paracetamol (2000 mg)|Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
10001876|NCT01551810|Experimental|Influenza Virus Vaccine|Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
10001877|NCT01551810|Experimental|Influenza Virus Vaccine(Preservative)|Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections
10001878|NCT01551823|Experimental|Team 1|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
10001879|NCT01551823|Experimental|Team 2|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
10001880|NCT01551836|Other|Paracetamol formulation 1|Higher dose level of marketed paracetamol (compared to the other dosage arm)
10001881|NCT01551836|Other|Paracetamol formulation 2|Lower paracetamol concentrations
10001882|NCT01551849||VA-ECMO patients|Patients placed on VA-ECMO support for primary cardiac dysfunction.
10001883|NCT01551875||subjects who are meeting the inclusion criteria|
10001884|NCT01551901|Experimental|Luna Interbody System|
10001885|NCT01551914|Experimental|ultrasonic scissors|
10001886|NCT01551914|Active Comparator|conventional techniques of haemostasis|clips, ligatures, and bipolar coagulation
10001887|NCT01551940|Experimental|Botox|Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %
10001888|NCT01551940|Placebo Comparator|Placebo|Placebo injection : NaCl 0.9 %
10001889|NCT01551953|Experimental|tai chi exercise|
10001890|NCT01551953|Experimental|mind-body breathing|
10001891|NCT01551953|Active Comparator|education|
10001892|NCT01551966|Experimental|video capsule endoscopy|
10001893|NCT01551992|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
10001894|NCT01551992|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
10001895|NCT01552005||Population of patients treated with Saxagliptin|
10001896|NCT01552018|Active Comparator|Saxagliptin|Saxagliptin 5 mg/day
10001897|NCT01552018|Placebo Comparator|Placebo|Placebo
10001898|NCT01552031||Observational group|
10001899|NCT01552044|Experimental|spironolactone|Spironolactone 25mg/day
10001900|NCT01552044|Placebo Comparator|Placebo|placebo tablets
10001901|NCT01552070|Experimental|With recruitment maneuver group|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds. Blood gases were sampled and blood samples taken for culture before, within 2 minutes, 5 minutes, and 30 minutes after intubation. Haemodynamic and respiratory parameters were continuously recorded throughout the study.
10001902|NCT01552070|Active Comparator|Without recuritment maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
10001903|NCT01552096|Placebo Comparator|Placebo|The placebo group (n=30) will receive a submucosal infiltration with 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
10001904|NCT01552096|Active Comparator|lidocaine|will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.
9941977|NCT01004887||Single group|Patients with newly diagnosed high-grade gliomas participating in NCCTG/Alliance or Mayo protocols. Previously collected blood and tissue samples are analyzed via PCR, IHC, flow cytometry, and FISH.
9941978|NCT01004900|Active Comparator|Trabeculoplasty|
9941979|NCT01004900|Active Comparator|Control (Medication)|
9941980|NCT01004926|Experimental|Echelon|
9941981|NCT01004965||Group 1|"Samples are obtained: 1) pretreatment, 2) at the time of documentation of refractory disease in acute myeloid leukemia (AML) patients who do not achieve complete response (CR) after induction therapy, and 3) at the time of first relapse in patients who achieve CR.~Marrow cells are preferentially used for all samples, but peripheral blood is acceptable if marrow is not available and the blood contains 20% or more blasts."
9941982|NCT01005004|Experimental|HuCNS-SC cells|Intracerebral implantation of HuCNS-SC via direct injection during surgery
9941983|NCT01005017|Active Comparator|Percutanous RF lesioning|Radiofrequent lesioning uses a high frequency alternating current to heat tissues leading to thermal coagulation. It produces predictable and accurate lesions of the splanchnic nerves.
9941984|NCT01005017|No Intervention|Optimal medical treatment|
9941985|NCT01005030||PostCEPT Subjects|Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
9941986|NCT01005030||Control Subjects|Non-blood relatives of PostCEPT Subjects matched for age and other demographics
9941987|NCT01005043|Experimental|heavy ion radiotherapy|Heavy ion radiotherapy of osteosarcoma with 60 to 66 GyE (20-22 days). Before and after radiotherapy, but not during radiotherapy, chemotherapy is recommended to standard therapy protocols like EURAMOS 1 which is not part of this study.
9941988|NCT01005069|Experimental|Treatment I|
9941989|NCT01005069|Experimental|Treatment II|
9941990|NCT01005069|Experimental|Treatment III|
9941991|NCT01005069|Experimental|Treatment IV|
9941992|NCT01005069|Placebo Comparator|Placebo|
9941993|NCT01005082|Experimental|Low salt diet plus water therapy|
9941994|NCT01005082|Active Comparator|water therapy alone|
9941995|NCT01005095|Experimental|High dose vitamin D|800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
9941996|NCT01005095|Active Comparator|Low dose vitamin D|800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
9941997|NCT01005121|Experimental|colchicine|patients will receive 2 mg of colchicine daily
9941998|NCT01005147|Experimental|Tranexamic acid arm|
9941999|NCT01005147|Placebo Comparator|Control arm|Will receive a placebo in place of tranexamic acid treatment
9942000|NCT01005160|Experimental|CKD501|
9942001|NCT01005173||Group A|Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
9942002|NCT01005173||Group B|Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
9942003|NCT01005173||Group C|Acetaminophen Overdose Subjects - Hospitalized 90 Subjects
9942004|NCT01005186|Experimental|Active|Active
9942005|NCT01005186|Experimental|Active 2|Active
9942006|NCT01005199|Experimental|Arm A: Sorafenib standard|• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).
9942007|NCT01005199|Experimental|Arm B: Sorafenib + everolimus|• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)
9942008|NCT01005225||Solid tumors|Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
9942009|NCT01005238|Active Comparator|telbivudine|patients in this arm will continue to take telbivudine
9942010|NCT01005238|Experimental|lamivudine|patients in this arm will take lamivudine
9942011|NCT01005264|Active Comparator|non-removable fiberglass|Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus
9942012|NCT01005264|Active Comparator|Stabil-D®|Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole
9942013|NCT01005303|Placebo Comparator|Placebo|
9942014|NCT01005303|Active Comparator|Micronutrient|
9942015|NCT01005342|Experimental|Mixture of fiber|Single intake of a mixture of spray-dried oat drink, rye bran and sugar beet fiber
9942016|NCT01005342|Experimental|Sugar beet fiber|Single intake of sugar beet fiber
9942017|NCT01005342|Experimental|Rye bran|Single intake of rye bran
9942018|NCT01005342|Experimental|Oat bran|Single intake of oat bran
9942019|NCT01005342|Experimental|Spray-dried oat drink|Single intake of spray-dried oat drink
9942020|NCT01005342|Placebo Comparator|Control|Single intake of a meal with no added fiber
9942021|NCT01005368||Group 1|Blood and bone marrow is collected at baseline, 3 months after completion of induction therapy, 2 months after completion of consolidation therapy, 1 year after completion of study treatment, and at disease relapse. Samples are analyzed by FISH for interphase cytogenetics, PCR for IgV_H mutational status, flow cytometry for surface expression of CD38 cells, western blot to assess Mcl-1, Bcl-2, BAK-1, ATM, ZAP-70, and Bar expression, and sequencing for p53 and ATM function.
9942022|NCT01005381|Experimental|Small Particle Size Calcium Carbonate|Subjects are given small particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
9942023|NCT01005381|Active Comparator|Large Particle Size Calcium Carbonate|Subjects are given a large particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
9942024|NCT01005381|Placebo Comparator|Calcium Placebo|Subjects are given two placebo tablets daily, which are identical to the large and small particle size calcium carbonate supplements.
9942025|NCT01005381|Active Comparator|No Vitamin D supplement|Subjects are given calcium carbonate supplement once daily (325 mg/d from supplement).
9942026|NCT01005381|Experimental|Vitamin D supplement|Subjects are given a calcium supplement once daily (325 mg/d from supplement) with 1000 IU/d vitamin D supplement.
9942027|NCT01005394||Navigated TMS|single arm study where all subjects will be studied using the Navigated TMS device
9942028|NCT01005420|Experimental|Blueberry Powder|"A blueberry smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~206.4 Kcals~40.3 g Carbohydrate~11.5 g Protein~0.08 g Fat~0.05 g Sat fat~4.2 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~22.5 g Freeze-dried blueberry powder~5.0 g Imitation vanilla flavor~1.0 g Splenda~16 oz plastic cup with lid~Smoothie total weight - 378.5 g"
9942029|NCT01005420|Placebo Comparator|Placebo|"A placebo smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~201.3 Kcals~40.3 g Carbohydrate~10.7 g Protein~0.08 g Fat~0.05 g Sat fat~4.3 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~5.0 g Benefiber~12.0 g Sugar~4.0 g Artificial blueberry flavor(liquid & powder)~1.5 g Red food color~0.7 g Blue food color~16 oz plastic cup with lid~Smoothie total weight - 373.2 g"
9942030|NCT01005433|Active Comparator|Dexmedetomidine 0.6 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
9942031|NCT01005433|Active Comparator|Dexmedetomidine 0.4 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 4 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
9942032|NCT01005433|Active Comparator|Dexmedetomidine 0.2 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia.
9942033|NCT01005433|Placebo Comparator|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 20 min before induction of anesthesia
9942034|NCT01005446||RSP Device|Post Market Study
9942035|NCT01005472|Experimental|sunitinib malate, temozolomide|
9942036|NCT01005485||Group A|Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
9942037|NCT01005485||Group B|Healthy controls will be recruited from the general medical population, community.
9942038|NCT01005485||Acute Myocardial Infarction|Patients with acute myocardial infarction with or without ST segment deviation.
9942039|NCT01005498|Experimental|Low carbohydrate diet (F)|The group attended to low carbohydrate diet
9942040|NCT01005498|Active Comparator|Traditional diet (K)|The group attended to traditional diet
9942041|NCT01005511|Experimental|Grindcare|24 patients receiving active treatment
9942042|NCT01005511|Placebo Comparator|Placebo treatment|24 patients receive a placebo treatment
9942043|NCT01005550|Experimental|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
9942044|NCT01005550|Experimental|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
9476253|NCT03573713|Experimental|IPT-G (Treatment arm)|This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
9476254|NCT03573713|Other|Control arm (Treatment as usual - Care Group)|This arm will receive assessment only at the beginning of the study (parallel to the start of IPT-G) and then receive the Care Group intervention after 12 weeks together with the IPT-G arm.
9942045|NCT01005550|Experimental|10 mg of ropivacaine|10 mg of ropivacaine are used for the spinal anaesthesia
9942046|NCT01005550|Experimental|12 mg of ropivacaine|12 mg of ropivacaine are used for the spinal anaesthesia
9942047|NCT01005563|Experimental|Arm 1: Beef/Pork|Participants consuming diet with beef/pork as predominate sources of protein
9942048|NCT01005563|Experimental|Arm 2: Soy/Legumes|Participants consuming diet with soy/legumes as predominate sources of protein
9942049|NCT01005628||001|bortezomib Injection into a vein 1.3 mg/m2 twice a week for 21 days
9942050|NCT01005641|Experimental|A|phase II
9942051|NCT01005667|Experimental|BirthTrack Monitor|
9942052|NCT01005667|No Intervention|Control - no BirthTrack Monitor|
10001905|NCT01552096|Experimental|Tramadol|(n=30) will receive a submucosal infiltration with 2 mg kg-1 tramadol in 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
10001906|NCT01552122|Experimental|Odanacatib|
10001907|NCT01552122|Active Comparator|Alendronate|
10001908|NCT01552135||Healthy|Healthy men above 50 years old
10001909|NCT01552148|Active Comparator|Group TAP (US guided)|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
10001910|NCT01552148|Other|Group Control|
10001911|NCT01552161||Patients with negative coronarography.|Subjects who underwent coronary angiography and were classified as having no critical lesions in coronary arteries (a lesion of up to 50% of artery lumen is accepted as non-critical).
10001912|NCT01552161||Patients with positive coronarography|Subjects who underwent coronary angiography and were classified as having critical lesions in coronary arteries (over 50% narrowing of artery lumen).
10001913|NCT01552174||Outpatients attending general ophthalmologic consultation|"Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation~Patients informed of the objectives of the survey and agreeing to participate.~Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up."
10001914|NCT01552187|Placebo Comparator|Placebo|Placebo
10001915|NCT01552187|Active Comparator|Colchicine|Colchicine
10001916|NCT01552200|Experimental|A-Standard Colonoscopy, G-Eye procedure|Standard Colonoscopy,G-Eye procedure
10001917|NCT01552200|Active Comparator|B- G-Eye procedure, Standard Colonoscopy|G-Eye procedure,Standard Colonoscopy
10001918|NCT01552226|Active Comparator|Continuous Preperitoneal Analgesia|Continuous Preperitoneal Analgesia for pain management
10001919|NCT01552226|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia for pain management
10001920|NCT01552239|Experimental|1 Arm|"Stratum A:~R0, primary wound closure~Stratum B:~R0, secondary wound closure~Stratum C:~R1, tertiary wound closure"
10001921|NCT01552252|Placebo Comparator|0% POs-Ca|
10001922|NCT01552252|Active Comparator|0.5% POs-Ca|
10001923|NCT01552252|Active Comparator|1% POs-Ca|
10001924|NCT01552252|Active Comparator|1.5% POs-Ca|
10001925|NCT01552252|Active Comparator|2% POs-Ca|
10001926|NCT01552265||single-group MCI patients|
10001927|NCT01552291|Active Comparator|Glutamin|
10001928|NCT01552291|Placebo Comparator|Placebo|
10001929|NCT01552304|Experimental|Oxygen treatment group|Besides routine care, patients in this group will receive postoperative oxygen therapy with nasal prolong at 3 liters/min during the first 3 nights after surgery.
9528476|NCT03210896|Experimental|Sub Group I|20 subjects from the main group (10 T2D and 10 Controls) to remain after providing the above samples. These patients will stay for an additional 3 hours and provide 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers at the following time intervals: 5, 30, 60, 120 & 180 minutes.
10001930|NCT01552304|Other|Control group|Patients will be managed by the anesthesiologists and surgeons as per routine practice.
10001931|NCT01552317|Experimental|lifestyle counselling|A package of advice and interventions to help participants reduce their salt intake.
9528477|NCT03210896|No Intervention|Sub Group II|5 control subjects consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers. This will be followed by 1 capillary blood sample and 3 breath samples every hour for a total of 5 hours.
10001932|NCT01552317|No Intervention|Normal care|This group will receive the normal care that they would get anyway.
10001933|NCT01552330|Experimental|Group A|Primaquine only followed by Pyronaridine-Artesunate and followed by Primaquine together with Pyronaridine-Artesunate.
10001934|NCT01552330|Active Comparator|Group B|Primaquine only followed by Primaquine together Pyronaridine-Artesunate and followed by Pyronaridine-Artesunate only.
10001935|NCT01552382||cardiac surgical patients|patients undergoing a cardiac surgical procedure
10001936|NCT01552421|Active Comparator|TV NOTES cholecystectomy|Participants randomized to TV NOTES cholecystectomy
10001937|NCT01552421|No Intervention|Laparoscopic cholecystectomy|Participants randomized to laparoscopic cholecystectomy
10001938|NCT01552447|Other|1 application of EpiFix|1 x dehydrated human amnion/chorion membrane
10001939|NCT01552447|Other|2 applications of EpiFix|2 x dehydrated human amnion/chorion membrane
10001940|NCT01552447|Other|Standard of care|Compression bandaging
9528478|NCT03210558|Active Comparator|Group A|Testosterone cream 1% (Andro-Feme® )
9528479|NCT03210558|Placebo Comparator|Group B|Placebo cream
10001941|NCT01552473|Active Comparator|Brain Training Program 1|Training Program focusing on providing educational information of cognitive issues related to TBI
10001942|NCT01552473|Experimental|Brain Training Program 2|Program focuses on strategies to address cognitive issues following TBI
10001943|NCT01552486|Experimental|Chiropractic Spinal Manipulative Therapy|
10001944|NCT01552486|Other|Usual Care|
10001945|NCT01552499|Other|Control|
10001946|NCT01552499|Experimental|Treatment|
10001947|NCT01552512|No Intervention|MSPP Integrated Package|Participants in this arm only receive the standard care offered by the Ministry of Health (MSPP)called the Integrated Package. During the trial, they do not receive Nutributter.
10001948|NCT01552512|Experimental|Nutributter 3 Months, Integrated Package|Participants receive a one-month supply for the first 3 months of the 6-month trial in addition to the Integrated Package.
10001949|NCT01552512|Experimental|Nutributter 6 Months, Integrated Package|Participants receive a one-month supply for each month of the 6-month trial in addition to the Integrated Package.
10001950|NCT01552525||acute kidney injury|Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
10001951|NCT01552538|Experimental|Cyberonics VNS System|Continued stimulation w/Cyberonics VNS
10001952|NCT01552551|Active Comparator|Healthy Steps|Healthy Steps program as currently implemented by the PA Department of Aging
10001953|NCT01552551|Experimental|Healthy Steps with Falls Case Management|Healthy Steps program augmented with research interventionist guidance on seeking physician care and home safety assessment
10001954|NCT01552551|Experimental|Healthy Steps in Motion|Healthy Steps program augmented with Healthy Steps in Motion, a 4-week, twice a week program of group exercise.
10001955|NCT01552564||STEMI patients|Consecutive patients presenting through the PPCI service
10001956|NCT01552577||TBI Group|Adults (civilian or military) with a history of one or more brain injuries / concussions.
9476255|NCT03573687|Experimental|RT on Fat Metabolism|Determine the extent to which a full-body acute RT protocol will affect intra-RT and post-RT SCAAT lipolytic rate, and post-RT whole-body substrate utilization in RT women compared to baseline measures (independent of Aims 2 and 3).
9942053|NCT01005771|Experimental|GF-001001-00 2%|
9942054|NCT01005771|Experimental|GF-001001-00 1%|
9942055|NCT01005771|Experimental|GF-001001-00 0.25%|
9942056|NCT01005771|Placebo Comparator|Placebo|
9942057|NCT01005784|Active Comparator|fixed|
9942058|NCT01005784|Experimental|flexible|
9942059|NCT01005797|Experimental|Expansion A|Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
9942060|NCT01005797|Experimental|Expansion B|Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
9942061|NCT01005797|Experimental|Expansion C|Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
9942062|NCT01005823|Active Comparator|LEO 29102 cream 0.3 mg/g|
9942063|NCT01005823|Active Comparator|LEO 29102 cream 1.0 mg/g|
9942064|NCT01005823|Active Comparator|LEO 29102 cream 2.5 mg/g|
9942065|NCT01005823|Placebo Comparator|LEO 29102 placebo cream|
9942066|NCT01005836|Experimental|Cognitive-behavioral therapy: Anxiety|CBT for child anxiety. Coping Cat.
9942067|NCT01005836|Other|Usual care: Anxiety|Usual clinic care
9942068|NCT01005836|Experimental|Cognitive behavioral therapy: depression|CBT for youth depression. The Primary and Secondary Control Enhancement Training protocol.
9942069|NCT01005836|Other|Usual care: Depression|Usual clinic care for depression
9942070|NCT01005849|Experimental|Protecflor|
9942071|NCT01005849|Placebo Comparator|Placebo|
9942072|NCT01005862|Experimental|PF-04360365|
9942073|NCT01005862|Placebo Comparator|Placebo|single dose administered intravenously
9942074|NCT01005927|Placebo Comparator|No Fructooligosaccharide|0 g fructooligosaccharide added to calcium-containing beverage
9942075|NCT01005927|Active Comparator|3 g Fructooligosaccharide|3 g fructooligosaccharide added to calcium-containing beverage
9942076|NCT01005940|Experimental|Mandibular advancement device|Subject is evaluated when receiving intervention with mandibular advancement device.
9942077|NCT01005940|No Intervention|No mandibular advancement device|Subject is evaluated when not receiving treatment with mandibular advancement device.
9942078|NCT01005953||Professionals treating autistic children|Special educators, occupational therapists, speech pathologists, behavior analysts who work with children on the spectrum.
9942079|NCT01005953||Families with autistic children (3-10)|
9942080|NCT01005979|Experimental|A|
9942081|NCT01005992|Experimental|Laser treated scar|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
9942082|NCT01005992|Active Comparator|Standard scar management|The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
9942083|NCT01006031|Experimental|PegIFN alfa-2a and Ribavirin|HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
9942084|NCT01006044|Experimental|Vaccination|Autologous Dendritic cells loaded with tumor lysate
9942085|NCT01006057|Experimental|ESRD|
9942086|NCT01006057|Experimental|Mild|
9942087|NCT01006057|Experimental|Moderate|
9942088|NCT01006057|Experimental|Normal|
9942089|NCT01006057|Experimental|Severe|
9942090|NCT01006070||Patients with existing spinal fractures|Myeloma patients with documented x-ray evidence of spinal fractures.
9942091|NCT01006070||Patients without spinal fractures|Myeloma patients with bony disease in the spine without existing fractures.
9942092|NCT01006083||Low-risk patients, not on APAs|Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
9942093|NCT01006083||High-risk patients, not on APAs|Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
9942094|NCT01006083||APA for primary prevention|High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
9942095|NCT01006083||APA for secondary prevention|Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
9942096|NCT01006096|Experimental|Erlotinib|
10001957|NCT01552577||Control Group|Healthy adults (civilian or military) with no history of brain injury.
10001958|NCT01552616|Experimental|Activation Treatment|
10001959|NCT01552616|No Intervention|Usual Care|This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.
9942097|NCT01006096|Placebo Comparator|Placebo tablets|
9942098|NCT01006148|Experimental|Bone substitute|Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.
9942099|NCT01006161|Experimental|Low dose SCH 527123|
9942100|NCT01006161|Experimental|Medium dose SCH 527123|
9942101|NCT01006161|Experimental|High dose SCH 527123|
9942102|NCT01006161|Placebo Comparator|Placebo|
9942103|NCT01006174|Experimental|A|Subjects will be assigned to consume 3 grams soybean oil, 8 grams canola oil, and 20 grams butter that is added to a salad.
9942104|NCT01006174|Experimental|B|Subjects will be assigned to consume 8 grams soybean oil, 20 grams canola oil, and 3 grams butter that is added to a salad.
9942105|NCT01006174|Experimental|C|Subjects will be assigned to consume 20 grams soybean oil, 3 grams canola oil, and 8 grams butter that is added to a salad.
9942106|NCT01006187|Active Comparator|Group 1|1 liposomal lidocaine 4% cream .
9942107|NCT01006187|Active Comparator|Group 2|Vapocoolant spray
9942108|NCT01006187|Active Comparator|Group 3|Rubbing adjacent to the injection site
9942109|NCT01006187|Active Comparator|Group 4|Distraction by means of self-selected reading material or internet
9942110|NCT01006200||Structural /dynamic airway obstruction|Obstructive granulation tissue formation after SEMS implantation was defined as granulation tissue obstructing the lumen of the SEMS under bronchoscopic examination.
9942111|NCT01006213|Experimental|Lifestyle counseling vs motivational intervention|
9942112|NCT01006226|Experimental|64Cu-ATSM PET|
9942113|NCT01006239||Biorepository|Patients undergoing surgical resection of a solid tumor.
9942114|NCT01006278||Surgical group with knee pain|patients 18 years of age or greater with a history of knee pain for more than three but less than six months who failed conservative management with the presence of mechanical symptoms including locking, catching, or giving way; positive physical exam findings including joint line tenderness, McMurray's exam, or Steinman's exam; and MRI of the knee positive for meniscus tear in a location correlating with physical examination. Exclusion criteria were as follows: the presence of high grade gonarthrosis including Kellgren-Lawrence grade IV; a history of prior knee surgery or trauma; ligamentous incompetence on examination or MRI; and diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.
9942115|NCT01006278||Group 2|volunteer group
9942116|NCT01006317|No Intervention|Control|Financial coverage of MCH care within the local reimbursement system (CMS).
9942117|NCT01006317|Experimental|Clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
9942118|NCT01006317|Experimental|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
9942119|NCT01006317|Experimental|Financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
9942120|NCT01006330||Elderly medical inpatients|
9942121|NCT01006343|Experimental|Higher Protein (HP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The HP menus will contain 30% protein, 45% carbohydrate, and 25% fat. Subjects in the HP group will be provided with portioned, cooked and frozen pork products as part of their HP menu plan.
9942122|NCT01006343|Experimental|Lower Protein (LP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The LP group menus will contain 18% protein, 57% carbohydrate, 25% fat. The LP group will follow a lacto-ovo vegetarian menu with no striated tissue foods. Subjects in the LP group will be provided with selected, portioned dairy products.
9942123|NCT01006382||Adolescents and young adults with food allergy|Adolescents aged 13-21 years with a diagnosis of food allergy
9942124|NCT01006395|Active Comparator|zoledronic acid|intervention
9942125|NCT01006395|Placebo Comparator|Placebo|
9942126|NCT01006408|Active Comparator|Low Level Laser|Low Level Laser twice a week for 8 weeks
9942127|NCT01006408|Sham Comparator|Placebo and Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
9942128|NCT01006434||Thrombolysis group (Pilot phase)|Patients receiving intravenous thrombolysis for acute ischemic stroke. Pilot phase (100 Patients).
9942129|NCT01006434||Thrombolysis group|Patients receiving intravenous thrombolysis for acute ischemic stroke.
9942130|NCT01006447|Active Comparator|Instructor contact 1 class|
9942131|NCT01006447|Active Comparator|Instructor contact 4 classes|
9942132|NCT01006460|Experimental|Adapt 232|
9942133|NCT01006460|Experimental|Arctic root group|
9528480|NCT03210506|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
9528481|NCT03210506|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
9528482|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
9528483|NCT03210415||Study group|Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
9528484|NCT03210415||Control group|Pregnant women ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
9528485|NCT03210532|Experimental|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
9528486|NCT03210532|Active Comparator|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
9528487|NCT03210532|Active Comparator|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
9528488|NCT03210389|Experimental|lobaplatin+5-FU|Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.
9942134|NCT01006460|Active Comparator|Ginseng group|
9942135|NCT01006460|Placebo Comparator|Placebo group|
9942136|NCT01006473|Experimental|Exercise training group|Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
9942137|NCT01006473|No Intervention|Inactive control group|No intervention
9942138|NCT01006486|Experimental|Anticoagulation clinic|Anticoagulation clinic, including all procedures related to a standardized use of coumarins.
9942139|NCT01006486|Active Comparator|Standard care|Standard use of coumarins, as prescribed by their physicians.
9942140|NCT01006499|Placebo Comparator|Placebo group|Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
9942141|NCT01006499|Active Comparator|Pentoxifylline group|Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
9942142|NCT01006499|Active Comparator|Pentaglobin group|Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
9942143|NCT01006499|Active Comparator|Pentoxifylline plus Pentaglobin group|Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.
9942144|NCT01006525||Insomniacs|Primary insomniacs, ages 21-70, in good general health.
9942145|NCT01006551|Experimental|Ziprasidone|
9942146|NCT01006577|Other|colon j pouch|Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
9942147|NCT01006577|Experimental|side-to-end anastomosis (STE)|Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon is closed with a linear stapler. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
9942148|NCT01006642||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
9942149|NCT01006642||Functional dyspepsia-EPS|Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
9942150|NCT01006642||Functional dyspepsia-PDS|Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
9942151|NCT01006668|Experimental|Sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
9942152|NCT01006668|Active Comparator|Propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary
9942153|NCT01006681|Experimental|Monovalent MF59-Adjuvanted vaccine|
9942154|NCT01006694|Active Comparator|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
9942155|NCT01006694|Experimental|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
9942156|NCT01006720||Sgx 0.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
9942157|NCT01006720||Sgx 0.5|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
9942158|NCT01006720||Sgx 0.75|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
9942159|NCT01006720||Sgx 1.0|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
9942160|NCT01006720||Sgx 1.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
10001960|NCT01552629|Experimental|Group 1 QGE031|QGE031 will be administered as a subcutaneous dose q2 weeks
10001961|NCT01552629|Placebo Comparator|Group 2 Placebo|A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks
10001962|NCT01552629|Experimental|Group 3 Cyclosporine A|Cyclosporine A will be administered (as per label) for atopic dermatitis.
10001963|NCT01552642|Active Comparator|Intervention Group|Intervention Group
10001964|NCT01552642|No Intervention|Control Group|Control Group
10001965|NCT01552655|Other|Dual-time PET/CT|
10001966|NCT01552668|Experimental|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
10001967|NCT01552668|Placebo Comparator|Placebo|
10001968|NCT01552707|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion"
10001969|NCT01552707|Sham Comparator|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest.
10001970|NCT01552733|Experimental|Robotic Therapy|Robotic Therapy using 'Inmotion' device plus standard care. Participants randomised to robotic therapy will receive up to 12 sessions (approximately 1 hour each) performing tasks (including circle drawing, reaching targets and holding/moving against moderate resistance.
10001971|NCT01552733|Placebo Comparator|Standard Care|Rehabilitation therapy according to local guidelines.
10001972|NCT01552759|Experimental|Obese subjects with BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) and the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
10001973|NCT01552759|Experimental|Obese without BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) but who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
10001974|NCT01552759|Experimental|Normal-weight without BED|"Subjects with BMI 20-25 kg/m^2 who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
10001975|NCT01552785||Healthy adults|
10001976|NCT01552798|Experimental|Arm 1|
10001977|NCT01552798|Active Comparator|Arm 2|
10001978|NCT01552798|Placebo Comparator|Arm 3|
10001979|NCT01552811||Type 1 diabetes|
10001980|NCT01552811||healthy controls|
10001981|NCT01552824|Experimental|Vesico-amniotic shunt|In this arm, patients will be randomly selected to undergo vesico-amniotic shunting.
10001982|NCT01552824|Experimental|CYSTO|In this arm, all patients will be randomly selected for fetal cystoscopy.
10001983|NCT01552837|No Intervention|Healthy volunteers|MRI compatible, no present or past DSM-IV diagnosis
10001984|NCT01552837|Active Comparator|patients with Bipolar Disorder|MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder
10001985|NCT01552850|Experimental|Oxycodone Formulation A Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
10001986|NCT01552850|Experimental|Oxycodone Formulation B Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
10001987|NCT01552850|Experimental|Oxycodone Formulation C Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
10001988|NCT01552850|Experimental|Oxycodone Formulation D Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
10001989|NCT01552850|Experimental|Oxycodone Oral Solution|40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
10001990|NCT01552863|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10001991|NCT01552863|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
9528489|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
9528490|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
9942161|NCT01006720||Neo 10|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
9942162|NCT01006720||Neo 25|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
9942163|NCT01006720||Neo 40|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
9942164|NCT01006720||Neo 55|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
9942165|NCT01006720||Neo 70|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
9942166|NCT01006720||Saline|Saline group: Saline as placebo
9942167|NCT01006733|Experimental|Target INR 1.8 and Pharmacogenetic|The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
9942168|NCT01006733|Experimental|Target INR 2.5 and Pharmacogenetic|The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
9942169|NCT01006733|Experimental|Target INR 1.8 and Clinical|The target INR is 1.8. Warfarin initiation is via clinical dosing.
9942170|NCT01006733|No Intervention|Target INR 2.5 and Clinical|The target INR is 2.5. Warfarin initiation is via clinical dosing.
9942171|NCT01006746||ICD patient and Home Monitoring|Patients primo implanted with ICD
9942172|NCT01006759|Experimental|leprosy disability|intervention of a series of cases with leprosy that made treatment in a Clinical Hospital
9942173|NCT01006772|No Intervention|Control Group|Control group patients receive usual clinical practice provided by Stroke Unit at Stobhill Hospital in Glasgow. They receive physiotherapy and early mobilisation as deemed appropriate to treat their oown impairments.
9942174|NCT01006772|Experimental|Experimental group|Intervention Group patients receive custom made solid ankle foot orthosis (AFO)treatment.
9942175|NCT01006785|Experimental|Treatment I|DLBS1425 150 mg three times daily
9942176|NCT01006785|Experimental|Treatment II|DLBS1425 300 mg three times daily
9942177|NCT01006798|Experimental|Cohort 1|three vaccinations of 10^7vp Ad4-H5-Vtn or placebo
9942178|NCT01006798|Experimental|Cohort 2|three vaccinations of the 10^8vp Ad4-H5-Vtn or placebo
9942179|NCT01006798|Experimental|Cohort 3|three vaccinations of 10^9 Ad4-H5-Vtn or placebo
9942180|NCT01006798|Experimental|Cohort 4|three vaccinations of 10^10 Ad4-H5-Vtn or placebo
9942181|NCT01006798|Experimental|Cohort 5|three vaccinations of 10^11 Ad4-H5-Vtn or placebo
9942182|NCT01006811|Experimental|modified Atkins diet|
9942183|NCT01006824|Experimental|1|Capsule Endoscopy
9942184|NCT01006824|Active Comparator|2|Dedicated small bowel contrast radiography
9942185|NCT01006863|Active Comparator|Ephedrine 0.15 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1.5 mg/kg of ephedrine
9942186|NCT01006863|Active Comparator|Ephedrine 0.1 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1 mg/kg of ephedrine
9942187|NCT01006863|Active Comparator|Ephedrine 0.07 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 0.7 mg/kg of ephedrine
9942188|NCT01006863|Placebo Comparator|Placebo|received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
9942189|NCT01006863|Active Comparator|Phenylephrine|received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/kg of phenylephrine
9942190|NCT01006876|Active Comparator|Study Arm|Patients receive continuous Coumadin therapy throughout the study.
9942191|NCT01006876|Active Comparator|Control Arm|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
9942192|NCT01006902||Individuals age 65 or older|Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
9942193|NCT01006915|Experimental|Surgical decompression|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
9942194|NCT01006915|No Intervention|Standard medical care|Standard diabetic care and medical care provided for diabetic sensorimotor polyneuropathy
9942195|NCT01006928||Mothers|Mother of infants in NICU
9942196|NCT01006941|Experimental|Trichuris suis ova|
9942197|NCT01006954|Active Comparator|Flare Up|Flare up protocol in poor responders for IVF/ICSI
9942198|NCT01006954|Experimental|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
9942199|NCT01006993|Experimental|NeuroFlo Treatment|
9942200|NCT01007006|Experimental|TMRDU|Telepharmacy Robotic Medicine Delivery Unit (TMRDU) group will receive TMRDU plus medication management
9942201|NCT01007006|No Intervention|Control|Control arm will receive only medication management, no TMRDU.
9942202|NCT01007019|Experimental|YH4808 30mg|"1.Single dose~2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9942203|NCT01007019|Experimental|YH4808 50mg|"1.Single dose~2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9942204|NCT01007019|Experimental|YH4808 100mg|"1.Single dose~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9942205|NCT01007019|Experimental|YH4808 200mg|"1.Single dose~2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9942206|NCT01007019|Experimental|YH4808 400mg|"1.Single dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9942207|NCT01007019|Experimental|YH4808 100mg(repeat doses)|"1.Repeat doses~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9942208|NCT01007019|Experimental|YH4808 200mg(repeat doses)|"1.Repeat doses~2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)"
9942209|NCT01007019|Experimental|YH4808 400mg(repeat doses)|"1.Repeat dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9528827|NCT03207334|Experimental|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase.
9800929|NCT01701414|Sham Comparator|Standard Care (SC)|The SC group will receive a sham injection of normal saline in order to blind both the participants and the treating physicians. A 7.5-MHz linear transducer will be placed on the side of the affected hip 1cm below the inguinal ligament. 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice.
9800930|NCT01701414|Experimental|Femoral Nerve Block (FNB)|"Participants randomized to the second group, FNB group, will receive an Ultrasound (US) guided femoral nerve block using a Sonosite TitanTM (Sonosite, Inc., Bothell, WA) with a 7.5-MHz linear array transducer. Using this technique, 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The femoral, obturator, and lateral cutaneous nerve are anesthetized with this technique (thus the name 3-in-1 femoral block is often used), providing maximum analgesia to the hip."
9800931|NCT01701505|Experimental|Kovacaine Mist High Dose|400uL of Kovacaine Mist, as 2 sprays of 200uL.
9800932|NCT01701505|Experimental|Kovacaine Mist Mid Dose|200uL of Kovacaine Mist, as 2 sprays of 100uL.
9800933|NCT01701505|Experimental|Kovacaine Mist Low Dose|120uL of Kovacaine Mist, as 2 sprays of 60uL.
9800934|NCT01701973|Other|Group A (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo."
9800935|NCT01701973|Other|Group B (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo."
9800936|NCT01701973|Other|Group C (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo."
9800937|NCT01701999|Experimental|Vaccine|
9800938|NCT01702025|Placebo Comparator|Placebo|"Administer a single dose of placebo (yellow corn meal in a capsule, gelatin ) in Normoxic Conditions.~Following a minimum of 7 days a single dose placebo will be administered (yellow corn meal in a gelatin capsule) in Hypoxic conditions."
9800939|NCT01702025|Active Comparator|Aminophylline|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Hypoxic conditions."
9800940|NCT01702025|Active Comparator|Methazolamide|"Administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
9800941|NCT01702025|Active Comparator|Aminophylline+Methazolamide|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.(Aminophylline+Methazolamide)~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
9800942|NCT01702233|Experimental|Traumeel S inj.|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
9800943|NCT01702233|Active Comparator|Fortecortin/Dexamethasone 8 mg inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
9800944|NCT01702233|Placebo Comparator|Saline inj.|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
9800945|NCT01702246|Experimental|simvastatin|Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months
9800946|NCT01702259|Experimental|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
9800947|NCT01702259|Sham Comparator|Placebo device|Inactive Erchonia GLS device
9800948|NCT01702298|Experimental|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
9800949|NCT01702311|Active Comparator|Bedtime supplementation|Patients in this arm will have acqhs (before meals and at bedtime) and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.
9800950|NCT01702311|No Intervention|no bedtime supplementation|Patients in this arm will have ac (before meals), qhs (at bedtime) and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin bedtime supplementation.
9800951|NCT01702363|Experimental|GSK573719|125mcg
9800952|NCT01702428|Experimental|INV_MMR_L1 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
9800953|NCT01702428|Experimental|INV_MMR_L2 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
9942210|NCT01007019|Experimental|YH4808 600mg|"1.Single dose~2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
10001992|NCT01552863|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10001993|NCT01552863|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10001994|NCT01552863|Experimental|Treatment E|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10001995|NCT01552863|Experimental|Treatment F|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10001996|NCT01552941|Experimental|Vagal Nerve Stimulation|
10001997|NCT01552993|Experimental|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and sucrose
10001998|NCT01552993|Placebo Comparator|placebo|pacifier and sucrose only
10001999|NCT01553006|Active Comparator|cefditoren pivoxil|cefditoren 10 mg/kg/day for 14 days
10002000|NCT01553006|Active Comparator|cefditoren pivoxil high dose|cefditoren 20 MKD were used to compare efficacy of treatment.
10002001|NCT01553019|Experimental|1- R(0) negative|50.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
10002002|NCT01553019|Experimental|2- R(1) micro-positive|54.00 cobalt gray equivalent(CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
10002003|NCT01553019|Experimental|3- R(2) gross positive|59.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
10002004|NCT01553032|Active Comparator|Erbitux®|
10002005|NCT01553032|Active Comparator|Fractionated Radiotherapy|
10002006|NCT01553045||atrial fibrillation, catheter ablation|Patients referred for ablation of atrial fibrillation
10002007|NCT01553097||women with stage I or II BC with adjuvant chemotherapy|"women with Stage I or II BC who~have undergone surgical treatment (biopsy, lumpectomy or mastectomy) and;~will be receiving adjuvant chemotherapy"
10002008|NCT01553097||women with Stage I or II BC without adjuvant therapy|"Women with stage I or II BC who~Have undergone surgical treatment (biopsy, lumpectomy or mastectomy) \~will not be receiving adjuvant chemotherapy"
10002009|NCT01553097||Healthy control|healthy education-age-matched women without cancer
10002010|NCT01553110||Cold Population|Male and female subjects 12 years of age and older with acute nasal discharge fewer then 7 days. Patients must be symptomatic at screening.
10002011|NCT01553110||Allergic Rhinitis|Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
9803233|NCT04386057|Experimental|Cross Over Arm|"Participants who are enrolled to Arm 2 who experience radiologic disease progression on monotherapy will have the option to cross-over to receive treatment with the combination. Crossover will occur at the treating investigator's discretion following consultation and approval from the overall principal investigator. Combined dosage per determined Lead-In Cohort~LY3214996~HCQ"
10002012|NCT01553123|Experimental|Ulipristal with iron|
10002013|NCT01553123|Placebo Comparator|Placebo|Placebo with iron
10002014|NCT01553227|Experimental|ventilator|The overall purpose of this study is to determine the effects of auto-Trilevel ventilation on patients with OSAHS and OHS by comparison with BiPAP ventilation. The following parameters are compared such as apnea hypopnea index, lowest SPO2, arousal index, sleep efficiency, PaCO2, daytime sleepiness and so on.
10002015|NCT01553266||MDET intervention|
10002016|NCT01553266||Control group|Patients who have not received the MDET intervention.
10002017|NCT01553305|Experimental|Supervised exercise programme|Six-weeks supervised high-intensity exercise programme with training sessions twice a week followed by 6-weeks unsupervised exercise programme.
10002018|NCT01553305|No Intervention|Unsupervised exercise programme|
10002019|NCT01553331|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle
10002020|NCT01553331|Active Comparator|ultrasonic dissection|Laparoscopic cholecystectomy made with ultrasonic dissection starting from gallbladder fundus
10002021|NCT01553370|Active Comparator|Alternate Intake-time|
10002022|NCT01553370|Experimental|Immediately post-exercise|
10002023|NCT01553383|Active Comparator|Dental device|"Provent nasal peep valve vs dental device"
10002024|NCT01553383|Active Comparator|CPAP|"continuous positive airway pressure CPAP vs nasap peep valve Provent"
10002025|NCT01553422|Active Comparator|before fluid Therapy|
10002026|NCT01553422|Active Comparator|after fluid Therapy|
10002027|NCT01553435|Placebo Comparator|Dextromethorphan, opioid analgisia, efficacy|
10002028|NCT01553435|Placebo Comparator|Placebo,opioid analgesia, efficacy|
10002029|NCT01553487|Experimental|Excercise|The forearm vibration training
10002030|NCT01553487|No Intervention|Control|Patients will be treated by routine fracture treatment methods (fixation and rest).
10002031|NCT01553500|Experimental|glucomannan|
9528491|NCT03210194|Active Comparator|Standard Neonatal Resuscitation Training|Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
9528492|NCT03210194|Experimental|MP-ICT Neonatal Resuscitation Training|The Multi-platform ICT (MP-ICT) training includes continuous certification in neonatal resuscitation and is being developed for online and offline access, and will be complemented with simulated practices on every site. The platform is being improved and adjusted to the needs of the fieldwork in Ayacucho and Cusco. The adaptations include increasing hosting; ameliorate friendly usability, uploading packages and videos, improvement of examination and certifications, and tests for readiness. The MP-ICT resource will be accessed from remote Peruvian locations through computers, personal portable devices and cell phones. To be granted an MP-ICT Certification the trainee needs to have passed the online theoretical exam, assist to the practice and approve practical skills assessment.
9528493|NCT03210363|Experimental|Guiana population|"Human Biological samples from Guiana population :~Two serum tubes of blood will be collected"
9528494|NCT03210272|Experimental|Single rising dose part|Group of healthy male volunteers receive rising single doses of BI 1358894
9528495|NCT03210272|Experimental|Food effect part|Group of healthy male volunteers receive single doses of BI 1358894 with and without food
9528496|NCT03210402|Active Comparator|Elevated night pacing on|
9528497|NCT03210402|Placebo Comparator|Elevated night pacing off|
9803234|NCT04381936|No Intervention|Standard Care|Patient receives usual hospital care
9942211|NCT01007019|Experimental|YH4808 800mg|"1.Single dose~2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
9942212|NCT01007019|Placebo Comparator|Placebo|
9942213|NCT01007019|Active Comparator|Esomeprazole 40mg|
9942214|NCT01007045||"Clinically likely"|Subjects deemed clinically likely to have DVT based on modified Well's criteria
9942215|NCT01007045||"Clinically unlikely"|Subjects deemed clinically unlikely to have DVT based on modified Well's criteria
9942216|NCT01007058||Response Markers|Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon
9942217|NCT01007084|Experimental|Propranolol|
9942218|NCT01007084|Placebo Comparator|Sugar pill|
9942219|NCT01007175|Experimental|Cohort 1|
9942220|NCT01007175|Experimental|Cohort 2|
9942221|NCT01007175|Experimental|Cohort 3|
9942222|NCT01007175|Experimental|Cohort 4|
9942223|NCT01007175|Experimental|Cohort 5|
9942224|NCT01007188|Active Comparator|1.5PD|average American diet plus 1.5 oz per day almonds
9942225|NCT01007188|Other|Base|average American diet without almonds
9803235|NCT04381936|Active Comparator|Low dose corticosteroids|"First (main) randomisation part A~[This arm is now closed to recruitment]"
9803236|NCT04381936|Active Comparator|Hydroxychloroquine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
9803237|NCT04381936|Active Comparator|Lopinavir-Ritonavir|"First (main) randomisation part A~[This arm is now closed to recruitment]"
9803238|NCT04381936|Active Comparator|Azithromycin|"First (main) randomisation part A~[This arm is now closed to recruitment]"
9803239|NCT04381936|Active Comparator|Convalescent plasma|"First (main) randomisation part B~[This arm is now closed to recruitment]"
9942226|NCT01007188|Active Comparator|3.0PD|average American diet plus 3.0 oz per day almonds
9942227|NCT01007201|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|15 μg HA (0.5 mL) per injection, 2 injections 50 children (aged over 3 years old to 6 years old) and 50 children/teenagers (aged over 6 years old to 18 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
9942228|NCT01007201|Experimental|H1N1 vaccine of 7.5 μg HA on Day 0 and 21|7.5 μg HA (0.25 mL) per injection, 2 injections 50 toddlers (aged over 1 year old to 3 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
9942229|NCT01007214|Experimental|Prostate cancer|A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
9942230|NCT01007227|Other|Lifestyle instruction|
9942231|NCT01007240|Experimental|soft liner with nano particles|the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion.
9942232|NCT01007266|Other|Group A|Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
9942233|NCT01007266|Active Comparator|Group B|Individuals receive conventional treatment for type 2 diabetes
9942234|NCT01007279|Active Comparator|CLOPIDOGREL|
9942235|NCT01007279|Experimental|ROSUVASTATIN|
9942236|NCT01007305|Experimental|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy for benign conditions.
9942237|NCT01007305|Active Comparator|Ovarian conservation|No ovaries or fallopian tubes removed at the time of hysterectomy for benign conditions.
9942238|NCT01007318|Active Comparator|Single port|Single port through the transumbilical incision was made by wound retractor combined with surgical glove and then 3 trocal was inserted to the finger part of the surgical glove. Laparoscopic instrument was working through the single port and resected appendix removed through it.
9942239|NCT01007318|Active Comparator|3 port|3 port laparoscopic appendectomy was done by conventional method
9942240|NCT01007344|Active Comparator|flaxseed|2 muffins and 1 slice of bread for a total of 30g flaxseed per day
9942241|NCT01007344|Placebo Comparator|whole wheat flour|2 muffins and 1 slice of bread containing whole wheat flour per day
9942242|NCT01007357|No Intervention|Body MRI healthy volunteers|Body MRI to optimize sequences in healthy individuals and in disorder subjects
10002032|NCT01553500|Placebo Comparator|placebo|
10002033|NCT01553513||Group 1 - STEMI|Patients with acute cardiovascular event and typical aberrations in the ECG(STEMI) and positive serum markers
10002034|NCT01553513||Group 2 - NSTEMI|Patients with acute coronary syndrome without typical aberrations in the ECG (NSTEMI) or without positive serum markers
10002035|NCT01553513||Group 3 - symptomatic CAD|Symptomatic patients with stable CAD, who are eligible for ICA
10002036|NCT01553513||Group 4 - STEMI|Patients eligible for ICA 6 months after STEMI and revascularization
10002037|NCT01553526||Orsiro DES|
10035065|NCT01802749|Experimental|Chemotherapy and bevacizumab|"Combination chemotherapy AND bevacizumab with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC 5 on day 1 every 4 weeks and Bevacizumab 10 mg/kg i.v. on Day 1 every 2 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks;L~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks.~Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn."
10035066|NCT01802762|Other|NeMo Patch and NeMo Probe|TBI and SAH patients, one arm
10035067|NCT01802801||1|
10035068|NCT01802814|No Intervention|SR-A|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
10035069|NCT01802814|Active Comparator|SR-A + Epratuzumab|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
10035070|NCT01802814|No Intervention|SR-B|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
10035071|NCT01802814|Active Comparator|SR-B + Epratuzumab|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
10035072|NCT01802827||VAT patients|Patients developing Ventilator Associated Tracheobronchitis
10035073|NCT01802827||VAP|Patients presenting ventilator associated pneumonia
10035074|NCT01802827||No ventilator associated infection|patients who do not present ventilator associated infection during their stay in ICU
10035075|NCT01802840|Placebo Comparator|biscuits without soy fiber|biscuits without soy fiber
10214668|NCT04824651||Senior group (free from chronic conditions of interest listed above)|≥75 years objective : 450 participants for adult cohort
10214669|NCT04824651||Control group (free from chronic conditions of interest listed above)|18 to 74 years objective : 1400 participants for adult cohort, 100 for pediatric cohort (from 5 to 17 years old)
10214670|NCT04824651||Control AZ-PF group (free from chronic conditions of interest listed above)|Participants with first dose of Astra-Zeneca vaccine AZD1222 and second dose of Pfizer ARNm vaccine BNT162b2 objective : 200 participants for adult cohort
10214671|NCT04824651||Major sickle cell syndrome|100 for pediatric cohort (from 5 to 17 years old)
10214672|NCT04823923|Other|Patients without renal insufficiency under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
10214673|NCT04823923|Other|Patients without renal insufficiency under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
10214674|NCT04823923|Other|Patients with moderate renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
10035076|NCT01802840|Experimental|biscuits supplemented with soy fiber|biscuits supplemented with soy fiber
10035077|NCT01802853|Experimental|A: RO6811135 s.c.|
10214675|NCT04823923|Other|Patients with moderate renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
10214676|NCT04823923|Other|Patients with severe or terminal stage renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
10035078|NCT01802853|Active Comparator|B: RO6811135 i.v.|
10035079|NCT01802892|Experimental|Ronacaleret 100 mg|Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
10035080|NCT01802892|Experimental|Ronacaleret 400 mg|Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
10035081|NCT01802905|Experimental|Sequenced patients|Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
10035082|NCT01802918|Experimental|Cohort 1|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): ABCD, BACD, BCAD, or BCDA. Where A=Placebo, B= GSK2838232 5mg, C=GSK2838232 10mg, and D=GSK2838232 20mg
10214677|NCT04823923|Other|Patients with severe or terminal stage renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
10214678|NCT04822467|Active Comparator|Standard Wipe|Participants will receive a supply of ethanol-based wipes for daily use
10214679|NCT04822467|Experimental|SQ53 Wipe|Participants will receive a supply of SQ53 wipes for daily use.
10214680|NCT04808973|Experimental|Lamivudine plus Dolutegravir in FDC|Single arm of 3TC+DTG for treatment of pregnant women with HIV infection
9528498|NCT03210233|Experimental|Naive controls|Never received teicoplanin. Blood test, skin testing and challenge testing.
9942243|NCT01007370|Active Comparator|LMA-Fastrach|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)~Tracheal intubation through the LMA-Fastrach~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
9942244|NCT01007370|Active Comparator|I-gel|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)~Tracheal intubation through the I-gel~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
9942245|NCT01007383|Experimental|LEO 27847 oral solution (0.05 mg/mL)|LEO 27847
9942246|NCT01007383|Experimental|LEO 27847 oral solution (0.75 mg/mL)|LEO 27847
9942247|NCT01007383|Placebo Comparator|LEO 27847 oral solution (placebo)|Placebo
9942248|NCT01007409|Active Comparator|Group B|Period 1: fed control → Period 2: fasted control
10002038|NCT01553552||Infected by Schistosoma haematobium|
10002039|NCT01553552||Not infected by Schistosoma haematobium|
10002040|NCT01553565|Active Comparator|Conventional polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed with electrocautery. Submucosal injection of some solution before the removal are not performed.
10002041|NCT01553565|Experimental|Cold polypectomy|
10002042|NCT01553578|Experimental|Arm A (healing touch therapy)|Patients receive 30 minutes of healing touch therapy consisting of magnetic clearing, pain drains, hands in motion/hands still and mind clearing.
10002043|NCT01553578|Experimental|Arm B (guided imagery)|Patients listen to guided imagery audiotapes for 30 minutes.
10002044|NCT01553578|Active Comparator|Arm C (standard care)|Patients receive standard of care.
10002045|NCT01553604|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
10002046|NCT01553604|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
10002047|NCT01553617|Experimental|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
10002048|NCT01553617|Active Comparator|Human serum albumin|Human serum albumin (HSA 50g/L)
10002049|NCT01553630|Active Comparator|RIA bone graft|Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
10002050|NCT01553630|Active Comparator|Surgery without bone graft|Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
10002051|NCT01553643|Experimental|Chinese Herb Huang-Chi-Wu-Wu-Tang|
10002052|NCT01553643|Placebo Comparator|Placebo|
10002053|NCT01553656|Experimental|Cabozantinib capsules and tablets|Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
10002054|NCT01553669|Experimental|reminiscence therapy|Reminiscence therapy is a method of using the memory to protect mental health and improve the quality of life.
10002055|NCT01553669|No Intervention|Control group|The participants assigned to the waiting-list as the control group will be treated as before. After the intervention period, we will conduct reminiscence therapy on them if they ask for.
10002056|NCT01553682|No Intervention|Enhanced Standard-Of-Care|Participants will watch a video about how to prevent STIs and HIV, then do question and answer session. This group will be last 1 hour. It will be led by one African American health educator, and have about 4-8 other young women participants. Participants will be asked to rate the workshop anonymously.
10002057|NCT01553682|Active Comparator|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
10002058|NCT01553682|Experimental|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
10002059|NCT01553695|Active Comparator|general population|
10002060|NCT01553695|Experimental|ADHD Patient|
9528499|NCT03210233|Experimental|High Risk|Received teicoplanin and suffered suspected IgE mediated anaphylaxis. Blood test, skin testing and challenge testing.
9528500|NCT03210233|Experimental|Low Risk|Received teicoplanin previously with no adverse reaction Blood test, skin testing and challenge testing.
9942249|NCT01007409|Active Comparator|Group A|Period 1: fasted control → Period 2: fed control
9942250|NCT01007422||Supportive Care|
9942251|NCT01007461|Experimental|IK-1001|IK-1001 Sodium Sulfide (Na2S) for Injection
9942252|NCT01007461|Placebo Comparator|Placebo|0.9% Sodium Chloride (NaCl)
9942253|NCT01007500|Experimental|Group Dexamethasone|
9942254|NCT01007500|Active Comparator|Group Ondansetron|
9942255|NCT01007513||At risk patient for preterm delivery|Patient referred to the MFM clinic for a risk evaluation for preterm delivery.
9942256|NCT01007539|Experimental|CDP-choline|
9942257|NCT01007539|Placebo Comparator|Placebo (fructose)|
10002061|NCT01553721|Experimental|udenafil|"Phase IIa Experimental : Udenafil Dose 1, Dose 2~Phase IIb Experimental : Udenafil"
10002062|NCT01553721|Placebo Comparator|placebo|"Phase IIa Placebo Comparator : Placebo~Phase IIb Placebo Comparator : Placebo"
10002063|NCT01553760|Experimental|Tri-MICS|
10002064|NCT01553760|Active Comparator|Conventional Phaco|
10002065|NCT01553773|Experimental|Isoflavone|a gel with isoflavones (genistein 4%)
10002066|NCT01553773|Experimental|Estradiol|gel with 17-β estradiol 0.01%
10002067|NCT01553786|Experimental|lenalidomide|lenalidomide + CHOP
10002068|NCT01553799||US check tube|
10002069|NCT01553799||US check tube, Endobronchial|
10002070|NCT01553825||Pathologically diagnosed carcinoma|
10002071|NCT01553838|Experimental|Sequentially MRI guided and TRUS guided biopsy|Targeted MRI guided biopsy according to findings in a multiparametric MRI followed by transrectal guided biopsy
10002072|NCT01553877|Active Comparator|Pushti Packet|
10002073|NCT01553877|Experimental|Rice based Ready to Use Complementary Food Supplements|
10002074|NCT01553877|Active Comparator|Chick-pea based Ready to Use Complementary Food Supplements|
10002075|NCT01553890|Other|Patients diagnosed with scleroderma|patients diagnosed with scleroderma, clinical and lab support
10002076|NCT01553890|Other|No disease|Blood sample, venous blood, about 10 ml will be drawn from participants
10002077|NCT01553903|Experimental|Tamoxifen,|Current hormonotherapy treatment in hormone dependent breast cancer
10002078|NCT01553903|Experimental|Exemestane|Current hormonotherapy treatment in hormone dependent breast cancer
10002079|NCT01553903|Experimental|Anastrozole|Current hormonotherapy treatment in hormone dependent breast cancer
10002080|NCT01553903|Experimental|Letrozole|Current hormonotherapy treatment in hormone dependent breast cancer
10002081|NCT01553929|Experimental|Physical and cognitive activity group|
10002082|NCT01553929|Active Comparator|Physical activity group|
10002083|NCT01553929|Placebo Comparator|control group|
10002084|NCT01553942|Experimental|Afatinib|Afatinib
10002085|NCT01553968|Other|Endurance Trained Subjects|
10002086|NCT01553968|Other|Untrained Subjects|
10002087|NCT01553981|Active Comparator|Tadalafil|Tablet Tadalafil 20 mg every alternate day
10002088|NCT01553981|Placebo Comparator|Placebo|Tablet Placebo every alternate day
10002089|NCT01553994||HPV vaccinated, non-vaccinated|Individuals born between 1989 and 1996. HPV-vaccinated will be compared to non-vaccinated in regards to condyloma status post vaccination.
10002090|NCT01554007||Crohn's disease|Korean patients diagnosed with Crohn's disease
10002091|NCT01554020|Active Comparator|Multiherb product|Herbal product
10002092|NCT01554020|Placebo Comparator|Placebo|Maltodextrin control
10002093|NCT01554033||Huntington's disease patients|Huntington's disease patients and his(/her) family
10002094|NCT01554033||age-sex matched control|age-sex matched control about huntington patients
10002095|NCT01554046|Experimental|couples of first-degree family members|
9528501|NCT03210311|No Intervention|control group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform twice a day upper limb exercises at home. They are advised to use the arm as normal as possible."
9528502|NCT03210311|Active Comparator|intervention group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform upper limb exercises at home twice a day. They are advised to use the arm as normal as possible~Wear a compression sleeve"
9800954|NCT01702428|Experimental|INV_MMR_L3 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
9800955|NCT01702428|Active Comparator|COM_MMR Group|Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively. Pooled analysis is conducted for this group.
9800956|NCT01702454|Experimental|Fluarix Quadrivalent Primed Group|Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
9800957|NCT01702454|Experimental|Fluarix Quadrivalent Unprimed Group|Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
9800958|NCT01702519|Active Comparator|Reference|nicotine transdermal patch with the existing polyisobutylene adhesive
9800959|NCT01702519|Active Comparator|Treatement|nicotine transdermal patch with the alternate polyisobutylene adhesive
9800960|NCT01702532|Experimental|Nicotine Mouth Film|mint nicotine mouth film, buccal administration
9800961|NCT01702532|Active Comparator|Nicotine Lozenge|nicotine lozenge, buccal administration
9800962|NCT01702558|Experimental|Phase 1 (mBC) Cohort 1: T-DM1 + Capecitabine|In Phase 1, Cohort 1 participants (with mBC) will receive trastuzumab emtansine (T-DM1) at a dose of 3.6 milligrams per kilogram (mg/kg) via intravenous (IV) infusion (on Day 1 [on Day 2 for Cycle 1] of each 21-day cycle) along with capecitabine at de-escalating dose levels (starting from 750 milligrams per meter squared [mg/m^2]) via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, disease progression (PD), death, or study end.
9800963|NCT01702558|Experimental|Phase 1 (LA/mGC) Cohort 2: T-DM1 + Capecitabine|In Phase 1, Cohort 2 participants (with LA/mGC) will receive trastuzumab emtansine at a dose of 2.4 mg/kg via IV infusion on Day 1 (on Day 2 of first week) of every week along with capecitabine at MTD (determined in Cohort 1) via tablet orally twice daily on Days 1-14 followed by a 7-day rest period, in each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
9800964|NCT01702558|Active Comparator|Phase 2 (mBC): T-DM1 + Capecitabine|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle along with capecitabine at MTD via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
9800965|NCT01702558|Experimental|Phase 2 (mBC): T-DM1|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle until investigator-assessed PD, unacceptable toxicity, withdrawal of consent, death, or study end.
9800966|NCT01702844|Experimental|nab paclitaxel|Patients will receive nab-paclitaxel once weekly for 3 weeks of every 4 week cycle
9800967|NCT01702961|Other|BEAM+R: Autologous Stem Cell Transplant|Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
9528503|NCT03210441||Group 1|Patients affected by breast cancer and potentially treated with taxane chemotherapy
9528504|NCT03210441||Group 2|Patients affected by breast cancer and not potentially treated without taxane chemotherapy
9528505|NCT03210168|Experimental|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
9528506|NCT03210181|Experimental|Block|Patients will receive superficial cervical plexus block
9528507|NCT03210181|Placebo Comparator|Placebo|Patients will receive normal saline
9800968|NCT01702987|Placebo Comparator|Statin + placebo|9 patients taking statin medications and placebo.
9800969|NCT01702987|Active Comparator|Statin + ubiquinol|12 patients on statins and ubiquinol
9800970|NCT01703000|Experimental|NG PROMUS stent|Single-arm treatment group receiving interventional NG PROMUS study stent
9800971|NCT01703039|Experimental|sertraline + riluzole|sertraline 100 mg po daily and riluzole 50 mg po bid
9800972|NCT01703039|Active Comparator|sertraline + placebo|sertraline 100 mg po daily and placebo
9800973|NCT01703065|Experimental|Cabozantinib in metastatic CRPC|Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
9800974|NCT01703065|Experimental|Cabozantinib in non-metastatic CRPC|Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
9800975|NCT01703091|Experimental|Ramucirumab plus Docetaxel|Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
9942258|NCT01007565|Experimental|periarticular injection, pain level|
9942259|NCT01007578|Experimental|Paclitaxel treatment|Paclitaxel-coated balloon catheter angioplasty treated subjects
9528508|NCT03210467||experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
10002096|NCT01554072|Placebo Comparator|Placebo|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. Patients will be instructed individually on each exercise, performing with supervisor that there be no doubt about execution, thereby minimizing any possible mistake in practice at home. For each day of the year ended data should be recorded in a daily monitoring. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
10002097|NCT01554072|Active Comparator|exercise|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. For each day of the year ended data should be recorded in a daily monitoring. Is also scheduled a visit to the laboratory biweekly in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
10002098|NCT01554085|Experimental|ALS-002158|
10002099|NCT01554085|Placebo Comparator|Placebo|
10002100|NCT01554098|Active Comparator|Strategy : supine first|"This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.~Withdrawal in supine position followed by withdrawal with dynamic position change"
10002101|NCT01554098|Active Comparator|Strategy : dynamic first|This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
9528509|NCT03210467||control group|patients who were untreated ever in immune-active phase took entecavir(ETV) for maintenance treatment.
9528510|NCT03210454|Experimental|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
9528511|NCT03210454|Experimental|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
10002102|NCT01554111|Active Comparator|Picosalax with rectal enema|This arm will receive one satchet of Picosalx and a rectal enema before the sigmoidoscopy for their bowel preparation regimen.
10002103|NCT01554111|Active Comparator|rectal enema|This group of patients will receive only a rectal enema for bowel preparation before their flexible sigmoidoscopy.
10002104|NCT01554111|Active Comparator|Pico-Salax|patient will take one sachet of pico-salax
10002105|NCT01554124|Experimental|Meropenem|"Infants will received Meropenem 40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
10002106|NCT01554137|Experimental|With isokinetic strength training|60 minutes isokinetic strength training on concentric mode
9528512|NCT03210454|No Intervention|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
9528513|NCT03210246|Experimental|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
10002107|NCT01554137|Placebo Comparator|without isokinetic strength training|passive motion 60 minutes
10002108|NCT01554150|Experimental|Method of Levels Cognitive Therapy (MOL)|Participants in this arm will be able to receive therapy over a 3 month period. They will be able to schedule sessions with a therapist as and when they need them.
10002109|NCT01554150|No Intervention|Contact Service|The Contact Service arm is effectively a waiting list control. Participants assigned this arm will remain on the service's waiting list during the 3 months of the therapy phase. These participants will have access to a 'Contact Service' provided by the study therapist, where they are able to contact him if they want further information about the study or their treatment options.
10002110|NCT01554189|Experimental|Panel A (GT1 10 mg)|
10002111|NCT01554189|Experimental|Panel B (GT1 50 mg)|
10002112|NCT01554189|Experimental|Panel C (GT1 100 mg)|
10214681|NCT04804007|Experimental|Maintenance Oral Etoposide|Maintenance daily oral Etoposide.
9528514|NCT03210246|Placebo Comparator|COC + Placebo|COC + Placebo
9528515|NCT03210324|Experimental|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
9528516|NCT03210324|Experimental|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
9528517|NCT03210324|Experimental|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
9528518|NCT03210480|Experimental|Group 1|Lithium sulphate prolonged-release 660 mg
9528519|NCT03210480|Active Comparator|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
9528520|NCT03210493|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
9528521|NCT03210493|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
9528522|NCT03210142|Experimental|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
9528523|NCT03210064|Experimental|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
10002113|NCT01554189|Experimental|Panel D (GT1 200 mg)|
10002114|NCT01554189|Experimental|Panel E (GT3 10 mg)|
10002115|NCT01554189|Experimental|Panel F (GT3 50 mg)|
10002116|NCT01554189|Experimental|Panel G (GT3 100 mg)|
10002117|NCT01554189|Experimental|Panel H (GT3 200 mg)|
10002118|NCT01554189|Experimental|Panel I (GT1a 10 mg)|
10002119|NCT01554189|Experimental|Panel J (GT1a 50 mg)|
10002120|NCT01554189|Placebo Comparator|Placebo Panel|
10002121|NCT01554202|Experimental|Young controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002122|NCT01554202|Experimental|Middle age controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002123|NCT01554202|Experimental|Elderly controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002124|NCT01554202|Experimental|Autosomal dominant forms of early-onset Alzheimer disease|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002125|NCT01554202|Experimental|Subjectif Cognitive Impariment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002126|NCT01554202|Experimental|Mild Cognitive Impairment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002127|NCT01554202|Experimental|Alzheimer Disease patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002128|NCT01554202|Experimental|Non degenerative amnsesic syndrome|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002129|NCT01554202|Experimental|Frontotemporal lobe dementia|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
10002130|NCT01554215|Experimental|Mom Power Intervention Group|Participants that are randomly assigned to be in the intervention group will be invited to learn about parenting and self-care skills information at a community location, facilitated by two trained and experienced clinicians in a group setting. They will benefit from the en-vivo experience of being supported as a parent and will receive feedback and support about their challenges and strengths in parenting.
10002131|NCT01554215|Active Comparator|Mom Power Attentional Control Group|Participants randomly assigned to this group will receive parenting and self-care skills information through the mail weekly.
9667578|NCT03414658|Experimental|Trastuzumab + Vinorelbine|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle"
10002132|NCT01554228||Bariatric Surgery|
10002133|NCT01554254|Experimental|300mcg/kg/day for 28 days|
10002134|NCT01554267|Experimental|Mastectomy Skin Flap SPY Excision|Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
10002135|NCT01554280|Experimental|Oesophageal Stents|Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.
10002136|NCT01554293|Experimental|PBL 1427 capsules|
10002137|NCT01554293|Placebo Comparator|Matching placebo|
10002138|NCT01554306||parkinson's disease, nocturnal hypokinesia, rotigotine|
10002139|NCT01554319|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
10002140|NCT01554319|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
10002141|NCT01554332|Active Comparator|Active stimulation|
10002142|NCT01554332|Sham Comparator|Sham stimulation|
10002143|NCT01554358|Other|Lifestyle counseling|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.
10214682|NCT04804007|No Intervention|Observation|If randomized to Observation, subjects will jump to follow-up.
10214683|NCT04788238|Experimental|Intervention group|Participants in the intervention arm will participate in the dual-task Zumba Gold (DTZ) program. They will be grouped into 10 participants per class.
10214684|NCT04788238|No Intervention|Control group|Participants in the control group will receive health education about dementia risk reduction provided by community health nurses.
10214685|NCT04787692|Experimental|Opioid and Benzodiazepine Naive-patients|Opioid and Benzodiazepine Naive-patients, defined as no medications 30 days prior to surgery
10214686|NCT04787692|Experimental|Opioid and Benzodiazepine Tolerant-patients|Opioid and Benzodiazepine Tolerant-patients, defined as use of medications on most days for 1 or more months (>30 days) prior to surgery
10214687|NCT04778579|Experimental|ARI-0001|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
10214688|NCT04777058||Patients|Patients admitted to the intensive care unit, treated with isavuconazole intravenously for treatment of invasive fungal infections
10214689|NCT04775446||Patients with malignant pleural mesothelioma treated with Nivolumab.|Patients with malignant pleural mesothelioma treated with Nivolumab.
10214690|NCT04771013|Experimental|Daily oral dose of thymic peptides|Patients will receive a daily oral dose of 250 mg of lyophilized thymic peptides dissolved in 50 mL of water (one hour before or two hours after a meal) in addition to the standard treatment, for up to 20 days or until medical discharge.
10214691|NCT04762121||Patients requiring intravenous catheter insertion|Adults (>18 years old) who require intravenous catheter insertion for their operation/procedure
10214692|NCT04760561|No Intervention|Control group (conventional care)|Patients randomized to this arm will receive the conventional positioning interventions provided by the critical care nurses, which will not include self-prone positioning.
10214693|NCT04760561|Experimental|Intervention group (prone position group)|Patients randomized to this arm will receive self-prone positioning.
10214694|NCT04755244|Experimental|evorpacept (ALX148) + venetoclax + azacitidine|"Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine~Phase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine"
9942260|NCT01007604|Active Comparator|Exercise and lifestyle counselling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
9942261|NCT01007604|Experimental|PCD with peristaltic pulse waveform|Daily use for two hours
9942262|NCT01007630|Active Comparator|Rasagiline|0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
9476256|NCT03573687|Experimental|PRO Timing on Fat Metabolism|Assess the differences in overnight and next morning SCAAT lipolytic rate and next-morning whole-body substrate utilization compared to baseline between acute NP and DP consumption trials after a RT bout in RT women.
9942263|NCT01007630|Placebo Comparator|Placebo|0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
9942264|NCT01007669|Active Comparator|Reference|Health check only
9942265|NCT01007669|Experimental|Intervention|Physical activity and Health check
9942266|NCT01007682|No Intervention|Screening for working memory capacity|
9942267|NCT01007682|Experimental|Distressing movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
9942268|NCT01007695|Experimental|All patients|All participants enrolled.
9942269|NCT01007708|Experimental|IDP-108|
9942270|NCT01007708|Placebo Comparator|Vehicle|
9942271|NCT01007734||1|
9942272|NCT01007747|Experimental|Geranium oil|
9942273|NCT01007760|Placebo Comparator|Room air|
9942274|NCT01007760|Active Comparator|Low dose exposure second-hand smoke|
9942275|NCT01007760|Active Comparator|High dose exposure second-hand smoke|
9942276|NCT01007773|Experimental|Dexmedetomidine|In conjunction with conventional sedative and analgesic agents.
9942277|NCT01007773|Active Comparator|Standard of Care|Patients randomized to conventional sedation will have as the main pharmacologic agents to achieve sedation and analgesia propofol and fentanyl, respectively.
9942278|NCT01007799|Placebo Comparator|Placebo|Placebo pills to take for 12 weeks
9942279|NCT01007799|Active Comparator|Vitamin D|Vitamin D supplement for 12 weeks
9942280|NCT01007851|Experimental|GnRH agonist|
9942281|NCT01007851|Placebo Comparator|Saline|
9942282|NCT01007864|Experimental|piribedil|
9942283|NCT01007864|Active Comparator|pramipexole or ropinirole|
9942284|NCT01007877|No Intervention|No break|
9942285|NCT01007877|Placebo Comparator|Placebo Energy Drink|During a 15 minute break, subjects consume a placebo energy drink
9942286|NCT01007877|Experimental|Red Bull Energy Drink|during a 15 minute break, subjects consume Red Bull Energy Drink
9942287|NCT01007903|No Intervention|Usual Care|
9942288|NCT01007903|Experimental|Tai Chi|
9942289|NCT01007929|Experimental|1|14C-AZD1236
9942290|NCT01007955||Severely Obese|Severely obese individuals scheduled to undergo gastric bypass surgery
9942291|NCT01007968|Experimental|HDACi|
9942292|NCT01007981||CRT device|Patients with Cardiac Resynchronization Therapy(CRT) device implanted in the last 5 years will be studied by the new echo modality.Study doesn't involve acute device implantation.
9942293|NCT01008007|Experimental|A|Viusid in combination with the conventional treatment for acute fever of viral etiology
9942294|NCT01008007|Active Comparator|B|Conventional treatment for acute fever of viral etiology
9942295|NCT01008020|No Intervention|Dietary supplement: placebo|
9942296|NCT01008020|Active Comparator|Tea catechin extracts|
9942297|NCT01008033|Experimental|IDP-108|
9942298|NCT01008033|Placebo Comparator|Vehicle|
9942299|NCT01008046|Experimental|combined N-acetyl cysteine - CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
9942300|NCT01008046|Active Comparator|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.
9942301|NCT01008072||without buprenorphine preparation|
9942302|NCT01008072||with buprenorphine preparation|
9942303|NCT01008085|Experimental|Self-expanding stent|Stentys stent
9942304|NCT01008085|Active Comparator|Balloon-expandable stent|VISION/Driver
9942305|NCT01008098|Experimental|PTSD group|
9942306|NCT01008111|Active Comparator|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
9942307|NCT01008111|Placebo Comparator|Dermabond-Placebo Comparator|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
9942308|NCT01008124|Experimental|Liberatory Maneuver|Liberatory Maneuver
9942309|NCT01008124|Placebo Comparator|Placebo Maneuver|Placebo Maneuver
9942310|NCT01008137|Experimental|Group 1: Day 0-PANFLU.1; Day 21-ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
9942311|NCT01008137|Experimental|Group 2: Day 0-ANFLU; Day 21-PANFLU.1|50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
9942312|NCT01008137|Experimental|Group 3: Day 0-PANFLU.1+ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
9942313|NCT01008163|Experimental|1|YY-351, PO, 1T tid. / Placebo, 1T tid.
9942314|NCT01008163|Experimental|2|YY-351. PO, 2T bid. / Placebo 2T qd.
9942315|NCT01008163|Experimental|3|YY-351, PO, 2T tid.
9942316|NCT01008163|Placebo Comparator|4|Placebo, PO, 2T tid.
9942317|NCT01008189|Active Comparator|Self study comparison group|Caregivers and children and adolescents each received three books about coping with grief after the death of a loved one and a syllabus to guide reading
9942318|NCT01008189|Experimental|Family Bereavement Program|12- session group for caregivers and bereaved children and adolescents plus 2 individual sessions
9942319|NCT01008215|Experimental|Algorithm|Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
9942320|NCT01008215|No Intervention|Care as usual|Control group
9942321|NCT01008228|Active Comparator|tube thoracic drainage|drainage performed with tube drainage CH 16 or ch 20
9942322|NCT01008228|Experimental|exsufflation|exsufflation with a specific thoracentesis system
9942323|NCT01008241||Adult Residents of South Florida|Persons 18 years of age or older, residing in Broward or Miami-Dade Counties.
9942324|NCT01008254|Experimental|Musical prompt|
9942325|NCT01008254|Active Comparator|Delayed musical prompt|
9942326|NCT01008254|No Intervention|No musical prompt|
9942327|NCT01008267||SWL under general anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general anesthesia.
9942328|NCT01008267||SWL under general selective anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general selective anesthesia, using a bronchial blocker.
9942329|NCT01008293|Experimental|VSL#3|
9942330|NCT01008293|Active Comparator|Lactulose|30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
9942331|NCT01008306||Renal transplanted children and young adults|"Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006.~Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards."
9942332|NCT01008332|Experimental|Cohort 1|ToleroMune HDM, subjects to receive either active or placebo comparator
9942333|NCT01008332|Experimental|Cohort 2|ToleroMune HDM, subjects to receive either active or placebo comparator
9942334|NCT01008332|Experimental|Cohort 3|ToleroMune HDM, subjects to receive either active or placebo comparator
9942335|NCT01008332|Experimental|Cohort 4|ToleroMune HDM, subjects to receive either active or placebo comparator
9942336|NCT01008332|Experimental|Cohort 5|Toleromune HDM, subjects to receive either active or placebo comparator
9942337|NCT01008345|Experimental|ezetimibe|will receive the active treatment with ezetimibe and statin
9942338|NCT01008345|Placebo Comparator|placebo|
9942339|NCT01008371||Obese|Healthy obese subjects
9942340|NCT01008371||Non-obese|Healthy non-obese subjects
9942341|NCT01008384|No Intervention|placebo|
9942342|NCT01008384|Experimental|Vitamin D3|Vitamin D3 given for 8 weeks
9942343|NCT01008397|Experimental|AHIST for seasonal allergic rhinitis|AHIST for SAR: each green tablet contains 12mg chlorpheniramine tannate.
10002144|NCT01554358|No Intervention|Control|"the subjects in the control group had been educated regarding general principles of healthy lifestyle that benefits T2D and obesity prevention, and also informed about the current evidence showing that the lifestyle intervention is effective in women at high risk for T2D during the run-in period."
10002145|NCT01554384|Experimental|Xpert MTB/RIF|Patients in this arm will receive 1 sputum Xpert MTB/RIF test (point-of-treatment) and 1 sputum sample for MGIT liquid TB culture (regional lab)
10002146|NCT01554384|Active Comparator|Sputum smear microscopy|Patients in this study arm will receive 2 sputum samples for same-day smear microscopy and 1 of the sputum samples will have a MGIT Liquid culture (regional lab).
10002147|NCT01554397|Experimental|Phase II|All patients receive IMRT with concurrent cisplatin 40 mg/m2
10002148|NCT01554397|Active Comparator|Phase III - A|Patients in Phase III, Arm A receive 4-field box RT with concurrent cisplatin 40 mg/m2
10002149|NCT01554397|Experimental|Phase III - B|Patients in Phase III, Arm B receive IMRT with concurrent cisplatin 40 mg/m2
10002150|NCT01554423|Active Comparator|Testing and Counseling|One of the four RCT arms will be comprised of couples randomly assigned to testing and counseling on HIV and associated STI co-infections based on revised procedures developed by the CDC. Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences. Randomized trial studies of behavioral interventions have incorporated testing and counseling as a comparison condition and studies in the US and SSA countries have shown that testing and counseling on its own can help to reduce HIV/STI risk behaviors.
10002151|NCT01554423|Experimental|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
10002152|NCT01554423|Experimental|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present. The six IFCBT sessions are delivered during a 2-week period with two group couples' sessions and one individual couples' session each week.
10002153|NCT01554423|Experimental|BMI + IFCBT|Participants assigned to this experimental arm will receive Brief Motivational Interviewing combined with Integrated Family and Cognitive Behavioral Therapy.
10002154|NCT01554436|Experimental|patients in smoking cessation|patients in smoking cessation
10002155|NCT01554449|Experimental|Serious game|In this group, patients will have a session of conventional retraining with a serious game retraining.
10002156|NCT01554449|Active Comparator|control patients|In this group, patients will have the conventional retraining with an other conventional retrainning session. The difference between both groups of patients is the serious game session for one group and conventional session for the other group
10002157|NCT01554449|Placebo Comparator|controls|For the neurologic assessments, patients are compared to healthy patient (without stroke)
10002158|NCT01554462|Active Comparator|ADHD active|4 month intervention with EPA/DHA in ADHD group
10002159|NCT01554462|Placebo Comparator|ADHD Placebo|4 month dietary intervention with placebo in ADHD group
10002160|NCT01554462|Active Comparator|Active Healthy control|4 month dietary intervention with DHA/EPA in healthy control group
9528524|NCT03210064|Active Comparator|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
9528525|NCT03209947|Experimental|Ulnar nerve ultrasound|
10002161|NCT01554462|Placebo Comparator|Healthy placebo|4 month dietary intervention with placebo in healthy control group
10002162|NCT01554501||Community sample|
9528526|NCT03209830|Experimental|Arm A|OSU6162, drug given to half of the patients after randomization
9528527|NCT03209830|Placebo Comparator|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
9528528|NCT03209739|Active Comparator|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
9528529|NCT03209739|No Intervention|No reminder|No additional reminder will be given
9528530|NCT03209869|Experimental|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
9528531|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
9528532|NCT03209895|Experimental|Joint Health Product|
9528533|NCT03209895|Placebo Comparator|Placebo|
9528534|NCT03209895|Active Comparator|Glucosamine / Chondroitin|
9528535|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
9528536|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
10002163|NCT01554540|Experimental|Cutaneous iontophoresis of Treprostenil|
10002164|NCT01554540|Placebo Comparator|Cutaneous iontophoresis of placebo|
10002165|NCT01554553|Experimental|Posterior crural repair|
10002166|NCT01554553|No Intervention|No posteriorcrural repair|
10002167|NCT01554566|Experimental|honey, no honey|
10002168|NCT01554592|Experimental|Statin withdrawal|Participants will received a placebo for 12 weeks.
9942344|NCT01008436|Active Comparator|Control|Traditional best-practice surgical hemostasis
9942345|NCT01008436|Experimental|Omni-stat Celox|Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis
9942346|NCT01008488|Active Comparator|Antibiotic|
9942347|NCT01008488|No Intervention|No antibiotic|
9942348|NCT01008527|Experimental|Infusion and Peptide Administration|Patients get the study drug Oncovir poly IC:LC with or without CP 870-893. Up to 6 groups of 3 to 10 patients each will be treated in this study. The first group (between 3 and 6 patients) gets peptide vaccine with poly IC:LC. Second, third and fourth groups of 3 to 6 patients receive peptide vaccine with poly IC:LC and the antibody CP 870,893 at increasing doses from 0.01, 0.025 and 0.05 mg/kg. CP 870-893 will be given to 10 patients at a dose of 0.1 mg/kg to patients in the fifth group, and 0.2 mg/kg to the sixth group. The CP 870,893 will be given as an intravenous infusion over 30 minutes and will be given once every 2 weeks for the first 6 infusions. CP-870-893 will then be given every 4 to 6 weeks for 3 injections. The final 3 injections of CP 870,893 will be given every 8 to 12 weeks. These infusions will take place on weeks 1, 3, 5, 7, 9, 11, 17, 21, 25, 33, 41, and 53 for a total of 12 infusions.
9942349|NCT01008566|Experimental|Treatment (cixutumumab, sorafenib tosylate)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9942350|NCT01008592||Group 1|Subjects with chronic idiopathic urticaria exhibiting dermatographism.
9942351|NCT01008631|Experimental|dialysis|Two doses of sodium thiosulfate
9942352|NCT01008631|Experimental|healthy volunteer|One dose of sodium thiosulfate
9942353|NCT01008644|Experimental|Saline|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min.
9942354|NCT01008644|Experimental|Water|The subjects will drink tap water for 2 hours, the volume calculated as 20ml/kg/hour
9942355|NCT01008657|Experimental|"extranodular no touch multipolar RFA"|
9942356|NCT01008657|Active Comparator|intranodular multipolar RFA|
9942357|NCT01008670||Device Implant Recipients|Patients undergoing CRT implantation, or candidates for future CRT devices currently undergoing ICD or pacemaker implantation.
9942358|NCT01008683||Stem cell and and heart transplant patients|Stem cell and and heart transplant patients
9942359|NCT01008709|Placebo Comparator|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur
9942360|NCT01008709|Active Comparator|Aesculap U-Clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur.
9942361|NCT01008735||women with hodgkin lymphoma treated with chemotherapy|
9942362|NCT01008761|Active Comparator|Zithromax, 100 mgmgs; 5mls suspension|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
9942363|NCT01008761|Placebo Comparator|Suspension placebo,|placebo (suspension produced by CDC Edmonton.) given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days.
9942364|NCT01008774|Experimental|A|
9942365|NCT01008774|Active Comparator|B|
9942366|NCT01008774|No Intervention|C|
9942367|NCT01008787|No Intervention|Focus Group|Qualitative interviews examining social support for PA conducted with African American (AA) women recruited from Wheeler Avenue Baptist Church located in Houston used to design Culturally-Appropriate Peer-based Motivational Interviewing (CAPMI) intervention.
9942368|NCT01008787|Active Comparator|Intervention Group 1|CAPMI Intervention: Training + Weekly Partner Questionnaire + Interview + PA Newsletter
9942369|NCT01008787|Active Comparator|Intervention Group 2|Interview + PA Newsletter
9942370|NCT01008800|Experimental|Center-Based classroom intervention|Four days a week for 2.5 hours a day the child will participate in a classroom with peers in an attempt to increase social communication, language abilities, and other skills. Parents will also receive education sessions 1-3 times per month for 1-2 hours each. Treatment will last for 6 months.
9942371|NCT01008800|Active Comparator|Parent Training|Parents are taught strategies on how to interact with their children to increase their skills. Parent training sessions are given 2 times a month at our center and once a month at home for 60-90 minutes each. Treatment will last for 6 months.
9942372|NCT01008813|Experimental|adjuvanted A(H1N1)v influenza vaccine|Two injections at day 0 and day 21
10002169|NCT01554592|Active Comparator|Stable statin therapy|Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
10002170|NCT01554631|Experimental|Arm 1|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken without water
10002171|NCT01554631|Experimental|Arm 2|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken with water
10002172|NCT01554631|Active Comparator|Arm 3|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet 100 mg; Day 1: oral sucrose load plus Glucobay standard tablet 100 mg taken with water
10002173|NCT01554644|Active Comparator|Prontosan Solution and Gel|ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
10214695|NCT04744298|Experimental|TheraPPP Pathway|"The investigators will perform an effectiveness-implementation hybrid study design (type 1) to evaluate the effectiveness and implementation of the TheraPPP pathway.~All mechanically ventilated patients admitted to the ICU will enter the pathway. To evaluate effectiveness the investigators will collect patient data for approximately 27 months. To assess acceptability of the pathway the investigators will conduct a survey and focus groups to clinicians who used the Pathway."
10214696|NCT04741945|Experimental|Metformin|2000 mg/daily metformin for 12 months.
10002174|NCT01554644|Placebo Comparator|Saline Solution and Inert Gel|
10002175|NCT01554657|Experimental|5 Days|
10002176|NCT01554657|Placebo Comparator|7 days|
10002177|NCT01554670|No Intervention|arthroscopic subacromial decompression|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).
10002178|NCT01554670|Active Comparator|decompression+RF micro-tenotomy|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
10002179|NCT01554709|Experimental|CardioGard Cannula|
10002180|NCT01554709|Active Comparator|Reference Cannula|
10002181|NCT01554722|Experimental|in plane needle placement|
10002182|NCT01554722|Experimental|out of plane needle placement|
10002183|NCT01554735|Experimental|lifestyle counselling|exercise and diet counselling for weight loss
10002184|NCT01554748|Other|Patient cohort|TMC total joint arthroplasty
9800976|NCT01703091|Placebo Comparator|Placebo plus Docetaxel|Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
9800977|NCT01703117|Experimental|age matched cohort 50-95 years old|20-22 subjects between the ages of 50-95 will receive riluzole
10002185|NCT01554774||GOLD II|Will be included in this group the patients with COPD stage II
10002186|NCT01554774||GOLD III|Will be included in this group the patients with COPD stage III
10002187|NCT01554774||GOLD IV|Will be included in this group the patients with COPD stage VI.
10002188|NCT01554787|Experimental|Chinese Herb Astragalus membranaceus|
9800978|NCT01703117|Placebo Comparator|24 subjects between 50-95 years old|20-22 subjects between 50-95 will receive placebo
9800979|NCT01703169|Experimental|Eltrombopag|Single arm study. Dose Escalation.
9800980|NCT01703208|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
9800981|NCT01703208|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
10002189|NCT01554787|Placebo Comparator|Placebo|
10002190|NCT01554800|Experimental|ACP-501|
10002191|NCT01554813|Experimental|Influenza split vaccine of 15μg HA|15μg HA/strain/0.5ml/vial
10002192|NCT01554813|Experimental|Influenza split vaccine of 15 μg HA|15μg HA/strain/0.5ml/syringe
10002193|NCT01554813|Active Comparator|Influenza split vaccine|15μg HA/strain/0.5ml/syringe
10002194|NCT01554826|Experimental|Influenza Split Vaccine|7.5μg HA/strain/0.25ml/syringe
10002195|NCT01554826|Active Comparator|Inactivated Influenza Vaccine|7.5μg HA/strain/0.25ml/syringe
10002196|NCT01554839|Experimental|Treatment Group|Treatment group participates in 1 hour online educational tool in addition to baseline and follow up surveys
10002197|NCT01554839|Placebo Comparator|Non Treatment Group|Non Treatment group participates in baseline and follow up surveys
10035083|NCT01802918|Experimental|Cohort 2|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
10035084|NCT01802931|Active Comparator|Session 1 or Session 2|Single dose sessions without ketoconazole co-administration
10214697|NCT04741074|Active Comparator|Semaglutide|This arm will receive semaglutide.
10214698|NCT04741074|Placebo Comparator|Placebo|This arm will receive placebo.
10214699|NCT04733742|Experimental|Conbined treatment group|intravenous tenecteplase bridging with endovascular treatment
10214700|NCT04733742|Active Comparator|Endovascular treatment alone group|endovascular treatment alone
9528537|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
9528538|NCT03210025|Experimental|BF-Methyldopa Tablet 250mg|During the study session, healthy subjects will be administered a single dose of BF-Methyldopa Tablet 250mg after an overnight fast of approximately 10 hours
9528539|NCT03210025|Active Comparator|Metopa Tab 250mg|During the study session, healthy subjects administered a single dose of Metopa Tablet 250mg after an overnight fast of approximately 10 hours
9800982|NCT01703221|Experimental|Omarigliptin 25 mg (Phase A+B)|Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
9942373|NCT01008813|Experimental|non-adjuvanted A(H1N1)v influenza vaccine|Two injection at day 0 and day 21
9942374|NCT01008826|Experimental|glucoraphanin-rich broccoli extract|
9942375|NCT01008826|Experimental|sulforaphane-rich broccoli extract|
9942376|NCT01008839||Old age group of healthy women|Old women over 70 years old
9942377|NCT01008839||young group of healthy women|aged 25-35 years
9942378|NCT01008865|Experimental|Studer Pouch|Studer Pouch orthotopic urinary diversion
9942379|NCT01008865|Experimental|T-Pouch|T-Pouch orthotopic urinary diversion
9942380|NCT01008917|Experimental|single treatment-non randomized study|Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
9942381|NCT01008930|Experimental|PEM Scan|HR PEM images (High Resolution PEMFlex Solo II scan images)
9942382|NCT01008956|Experimental|Single Group|Subjects enrolled in this group will be stratified by age (18 to 40 years and 41 to 64 years)
9942383|NCT01008982|Experimental|single arm|
9942384|NCT01009008|Experimental|Post-mastectomy|Post-mastectomy patients undergoing expander reconstruction
9942385|NCT01009021|Other|Placebo first (scheme 2)|scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode [placebo treatment episode (PTE)] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode [diclofenac treatment episode (DTE)] to the left eye
9942386|NCT01009021|Other|Diclofenac first (scheme 1)|scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode [diclofenac treatment episode (DTE)] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode [placebo treatment episode (PTE)] to the left eye
9942387|NCT01009073|Experimental|Arm A (ABT-263 and erlotinib)|
9942388|NCT01009073|Experimental|Arm B (ABT-263 and irinotecan)|
9942389|NCT01009073|Experimental|Arm C (ABT-263 monotherapy)|
9942390|NCT01009112|Experimental|CBT for Insomnia|"Patients change their sleep times and habits in order to reduce alertness and over thinking when they are trying to sleep. This helps them learn how to sleep overnight in one solid block of time"
9942391|NCT01009112|Experimental|Imagery Rehearsal Therapy|"Patients rescript the narrative of a nightmare to eliminate the distressing elements and create a new pleasant dream scene. They then rehearse this scene in their imagination at least twice each day. This reduces the frequency and intensity of the target nightmare and often reduces other nightmares, too."
9942392|NCT01009112|Experimental|Prolonged Exposure|This behavioral treatment for PTSD involves 1) systematic and repeated exposure to objects and situations that are avoided due to trauma-related distress, 2) prolonged, repeated recounting of trauma memories through visualization, and 3)therapist-guided discussions of thoughts and emotions related to the exposure exercises. The goals of PE are to reduce the anxiety and distress elicited by trauma-related memories and situations, show patients these memories and situations are distinct from the trauma, and teach patients they can tolerate the distress caused by these memories and situations.
9800983|NCT01703221|Active Comparator|Sitagliptin (Phase A) switching to Omarigliptin (Phase B)|Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
9800984|NCT01703221|Placebo Comparator|Placebo (Phase A) switching to Omarigliptin (Phase B)|Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
9800985|NCT01703260|Experimental|Roflumilast + pioglitazone|Roflumilast dose and pioglitazone dose, orally for up to 4 months
9800986|NCT01703260|Experimental|Roflumilast|Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
9800987|NCT01703260|Experimental|Pioglitazone|Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
9800988|NCT01703286|Experimental|Linagliptin 5mg|given once daily over 28 days
9800989|NCT01703286|Active Comparator|Glimepiride|given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
9800990|NCT01703286|Placebo Comparator|Placebo|given once daily over 28 days
9800991|NCT01703507|Experimental|Arm A (Ipilimumab and Whole Brain Radiation Therapy)|Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.
9800992|NCT01703507|Experimental|Arm B (Ipilimumab and Stereotactic Radiosurgery)|Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.
9800993|NCT01703598|Experimental|DBS surgery|Single arm
9800994|NCT01703663|Experimental|EPAP|Provent Sleep Apnea Therapy.
9800995|NCT01703663|No Intervention|control|
9800996|NCT01703702|Experimental|Intervention|Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
9800997|NCT01703702|Experimental|Control|Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
9800998|NCT01703741|Experimental|Testosterone gel (FE 999093)|Subjects received testosterone gel with initial dose as fixed on Day 56 (23 mg, 46 mg or 69 mg) during the 000023 study. The dose could further be down titrated based on serum testosterone levels at Day 90/91 of 000023 study. Testosterone gel was applied daily in morning using an applicator, to the shoulder/upper arm in a contralateral fashion for 6 months.
9800999|NCT01703819|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
9801000|NCT01703819|Placebo Comparator|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
9942393|NCT01009112|Active Comparator|Suportive Care Therapy|This is an active therapy where the focus of the intervention is on helping patients better understand their emotional response to their PTSD and sleep symptoms.
9942394|NCT01009125|Experimental|$2 cash incentive|
9942395|NCT01009125|Experimental|$5 cash incentive|
9942396|NCT01009151|Experimental|Heart Care Self Tracker|Web-based Home Tele-monitoring system
9942397|NCT01009177|Experimental|Bosentan|
9942398|NCT01009177|Placebo Comparator|Placebo|
9942399|NCT01009190|Experimental|ARM A|Carboplatin plus PF-01367338
9942400|NCT01009190|Experimental|ARM A EXPANSION|Carboplatin plus PF-01367338
9942401|NCT01009216|Experimental|ABT-384|
9942402|NCT01009229|Other|1|
9942403|NCT01009255|Experimental|GSK239512|Oral tablets
9942404|NCT01009255|Placebo Comparator|Placebo|Placebo to match GSK239512.
9942405|NCT01009294|Experimental|Ataluren|Ataluren was provided as a vanilla-flavored powder to be mixed with water, apple juice, or milk. Study drug dosing was based on milligrams of drug per kilogram of body weight. The dose level for ataluren was 20 milligrams/kilograms (mg/kg) in the morning, 20 mg/kg at midday, and 40 mg/kg in the evening. Administration within 30 minutes after a meal was recommended. Study drug was taken for up to 50 days.
9942406|NCT01009320||Pacemaker with magnets|Patients with pacemakers who will be tested for magnetic interference with a magnetic drape.
9942407|NCT01009359|Experimental|Arm 1|
9942408|NCT01009359|Experimental|Arm 2|
9942409|NCT01009359|Experimental|Arm 3|
9942410|NCT01009372|Experimental|breaks during laparoscopic surgery|Intraoperative Breaks were instituted in the intervention group. The other group operated conventionally without breaks
9942411|NCT01009385|Active Comparator|prone position|
9942412|NCT01009385|Active Comparator|sitting position|
9942413|NCT01009411||Control|Patients in active phase of labor not augmented
9942414|NCT01009411||Augmented|Augmentation leading to normal progress
9942415|NCT01009411||Caesarean section|Augmentation leading to Caesarean section
9942416|NCT01009424|Experimental|1|R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
9942417|NCT01009424|Experimental|2|R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
9942418|NCT01009424|Experimental|3|R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
9942419|NCT01009424|Experimental|4|R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
9942420|NCT01009424|Experimental|5|R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
9942421|NCT01009424|Experimental|6|R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
10002198|NCT01554852|Active Comparator|Intensive pathway|"The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.~Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):~Induction treatment:~CRD regimen - cyclophosphamide, lenalidomide, dexamethasone~CTD regimen - cyclophosphamide, thalidomide, dexamethasone~CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone~Consolidation treatment (depending on response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~High-dose therapy and stem cell transplant~Maintenance treatment:~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)"
10035085|NCT01802931|Active Comparator|Co-dose Session|Single dose session with ketoconazole co-administration
10035086|NCT01802944|Experimental|10 IU BID|10 IU BID Intranasal Insulin
10035087|NCT01802944|Experimental|20 IU BID|20 IU BID Intranasal Insulin
10035088|NCT01802944|Experimental|PLACEBOS|Saline nasal solution used as placebo
9528540|NCT03210129|Experimental|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
9528541|NCT03210129|No Intervention|Control Group|Patients of the control group will receive standard care alone.
9942422|NCT01009437|Active Comparator|Control Arm - No Ritonavir|Five ER+, HER2- breast cancer patients meeting all study eligibility will be enrolled prior to the start of phase I recruitment to act as controls (no ritonavir will be given-will receive therapeutic conventional surgery) to confirm that anesthesia does not affect EET levels. Core biopsies, surgical tumor/normal tissue and pre- and post- surgery blood samples will be collected for comparison with the treatment group.
9942423|NCT01009437|Experimental|Ritonavir - Escalating Doses (I)|"Standard phase I dose escalation (with therapeutic conventional surgery) will be used with 3 levels of ritonavir given - 200 mg bid, 400 mg bid, and 600 mg bid for the following groups:~ER+, HER2-~ER+, HER2+~ER-, HER2+~ER-, PR+, HER2-~ER-, PR-, HER2-"
9942424|NCT01009437|Experimental|Ritonavir - Maximum Tolerated Dose (II)|Phase II: Once the maximum tolerated dose (MTD) of ritonavir is established, 19 ER+, HER2- patients will be enrolled at MTD during the phase II component along with therapeutic conventional surgery.
9942425|NCT01009450|Active Comparator|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
9942426|NCT01009450|Active Comparator|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
9942427|NCT01009476||001|
9942428|NCT01009476||002|
9942429|NCT01009502|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
9528542|NCT03210103|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
9528543|NCT03210103|Experimental|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
9942430|NCT01009528|Experimental|Intervention|Admission to electronic feedback system
9942431|NCT01009528|No Intervention|control|Control group. No special attention
9942432|NCT01009541|Experimental|Pregabalin controlled release, 82.5 mg|
9942433|NCT01009541|Experimental|Pregabalin controlled release, 165 mg|
9942434|NCT01009541|Experimental|Pregabalin controlled release, 330 mg|
9942435|NCT01009541|Other|Pregabalin immediate release, 150 mg|Reference Treatment
9942436|NCT01009567|Sham Comparator|Control|Receive human albumin 20% infusion
9942437|NCT01009567|Experimental|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
9942438|NCT01009593|Experimental|ABT-869|
9942439|NCT01009593|Active Comparator|Sorafenib|
9942440|NCT01009606|Active Comparator|Arm 1 : Control : usual strategy|
9942441|NCT01009606|Experimental|Arm 2: Comparator : modified strategy|
9942442|NCT01009632|Experimental|Voice rest|
9942443|NCT01009632|Experimental|Resonant voice exercise|
9942444|NCT01009632|Experimental|Spontaneous speech|
9942445|NCT01009658|Active Comparator|MSG first|
9942446|NCT01009658|Placebo Comparator|NaCl first|
9942447|NCT01009671|Experimental|ART 44|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
9942448|NCT01009671|Active Comparator|ART 50|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
9942449|NCT01009684||DNG/EV|Users of the oral contraceptive containing Dienogest and Estradiol valerate
9942450|NCT01009684||Other OCs|Users of oral contraceptives (OCs) containing other progestins and estrogens
9942451|NCT01009749|Experimental|MESA|
9942452|NCT01009749|Active Comparator|MESH|
9942453|NCT01009788|Experimental|TMZ/ABT888|Combination therapy with temozolomide and veliparib
9942454|NCT01009801|Active Comparator|Arm I|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
9942455|NCT01009801|Experimental|Arm II|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
9942456|NCT01009827||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
9942457|NCT01009866|Experimental|MR1-1|All subjects are enrolled onto this arm. All subjects will receive MR1-1.
9942458|NCT01009879|Experimental|Etanercept|
9942459|NCT01009892|Active Comparator|Codeine Sulfate, 30 mg|tablet
9942460|NCT01009892|Active Comparator|Codeine Sulfate, 60 mg|tablet
9942461|NCT01009892|Active Comparator|Codeine Sulfate, 15 mg|tablet
9942462|NCT01009905||A|
9942463|NCT01009944|Experimental|Lisinopril, Atenolol|
9942464|NCT01009957|Experimental|Everolimus|Everolimus + standard therapy for CKD
9942465|NCT01009957|No Intervention|Control|Standard therapy for CKD
9942466|NCT01009970|Experimental|1|R-COMP
9942467|NCT01009996||Coronary bifurcation lesions|
9942468|NCT01010022|Experimental|1|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
9942469|NCT01010022|Active Comparator|2|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
9942470|NCT01010035||type 2 diabetes|patients with diagnosis of Type 2 diabetes mellitus
9942471|NCT01010035||Control|non type 2 diabetes mellitus
9528544|NCT03210038|Active Comparator|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
9528545|NCT03210038|Active Comparator|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
9528546|NCT03210038|Active Comparator|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
9528547|NCT03210038|Active Comparator|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
10002199|NCT01554852|Active Comparator|Non-intensive pathway|"The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.~Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:~Induction treatment~CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated~CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated~Consolidation treatment (depending on participant's response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~Maintenance treatment~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (*for participants recruited under Protocol v5.0 only*)"
9528548|NCT03210051|Experimental|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
9528549|NCT03209986|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
9528550|NCT03209986|No Intervention|control|Standard medication for viral hepatitis and cirrhosis
9801001|NCT01703832|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
10002200|NCT01554865|Active Comparator|conventional diet counselling|counselling given by dietician on diet modification and caloric restriction
10002201|NCT01554865|Active Comparator|partial meal replacement diet|calorie-restricted diet using 1-2 meal replacements
10002202|NCT01554878||knee surgery|
10002203|NCT01554917|Experimental|Iguratimod|
10002204|NCT01554930|Active Comparator|Western therapy|
10002205|NCT01554930|Experimental|Xiyanping injection plus western therapy|
10002206|NCT01554943|Active Comparator|CMF|adjuvant standard CMF given from 1988 to 1996
10002207|NCT01554943|Experimental|EC|Adjuvant EC chemotherapy given from 1988 to 1996
10002208|NCT01554943|Experimental|HEC|High dose epirubicin (HEC) given from 1988 to 1996
10002209|NCT01554956|Experimental|Human Plasminogen|Human Plasminogen Eye Drop treatment
10002210|NCT01554969|Experimental|capecitabine + ganetespib .|Capecitabine oral medication. Ganetespib IV medication
10002211|NCT01554995|Experimental|LCB01-0371|active
10002212|NCT01554995|Experimental|Linezolid|comparator
10002213|NCT01555008|Experimental|Treatment A|
10002214|NCT01555008|Placebo Comparator|LX4211 Placebo|
9801002|NCT01703832|No Intervention|No intervention|no tablet intake and subjects will undergo the natural course
9801003|NCT01703845|Experimental|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
9801004|NCT01703845|Experimental|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
9801005|NCT01703858|Active Comparator|1 BI 113608|powder in the bottle for oral solution, oral administration with 240 mL water
9801006|NCT01703858|Experimental|2 BI 113608|conventional tablet formulation
9801007|NCT01703858|Experimental|3 BI 113608|conventional tablet formulation, fed
9801008|NCT01703858|Experimental|4 BI 113608|conventional tablet after pantoprazole administration
9801009|NCT01703858|Experimental|5 BI 113608|conventional tablet formulation, fasted, 0:30 min before fat breakfast
9801010|NCT01703988|Experimental|Nusinersen 3 mg|3 mg nusinersen on Days 1, 29, 85, intrathecal (IT) injection
10002215|NCT01555021||Treatment as Usual (TAU)|"This group will provide blood samples to be analyzed at a later date for genotyping to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications.Treatment will be initiated based on the attending clinicians decision making absent genotyping results.~All subjects in the group will receive the following assessment instruments for diagnosis: SCID-I/P and the Mini International Neuropsychiatric Interview (MINI)~All subjects in the group will have the severity of their depression measured by the HAM D-17 (physician rating scale), the QIDS-SR-16 (patient rating). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the UKU. ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the TAU group will provide saliva samples for future GWAS analysis."
10002216|NCT01555021||Assay Guided Treatment (AGT)|"This group will provide blood samples for genotyping test to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications . This test result will be available within 3-5 days available to guide clinicians in their choice and dosing of antidepressant medications.~All subjects in the group will have the severity of their depression measured by the Hamilton Depression Rating Scale-17 (physician rating scale), the QIDS-SR-16 (patient rating scale). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the Udvalg for Kliniske Undersogelser (UKU). ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the AGT group will provide saliva samples for future GWAS analysis."
10002217|NCT01555034|Active Comparator|intervention plus therapy|
10002218|NCT01555034|Active Comparator|intervention no therapy|exercise and nutrition
9528551|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
9528552|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
9528553|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
9528554|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
9528555|NCT03209817|Experimental|Red cherry tomato|300 grams of red cherry tomatoes per day for four weeks (each)
9528556|NCT03209817|Experimental|Yellow cherry tomato|300 grams of yellow cherry tomatoes per day for four weeks (each)
9801011|NCT01703988|Experimental|Nusinersen 6 mg|6 mg nusinersen on Days 1, 29, 85, IT injection
9801012|NCT01703988|Experimental|Nusinersen 9 mg|9 mg nusinersen on Days 1 and 85, IT injection
9801013|NCT01703988|Experimental|Nusinersen 12 mg|12 mg nusinersen on Days 1, 29, 85, IT injection
9801014|NCT01704079|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
9801015|NCT01704079|Placebo Comparator|Sugar pill to CTAP101 30 μg|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
9801016|NCT01704196|Active Comparator|Nepicastat|Nepicastat 120mg and 100mg riboflavin (once per day) for 11 weeks
9801017|NCT01704196|Placebo Comparator|Placebo|Placebo capsule containing 100mg riboflavin (once per day) for 11 weeks.
9528557|NCT03209817|No Intervention|Control No tomato|No tomato products consumption
9528558|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.
9528559|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
9528560|NCT03209804|Other|Traditional neurosurgical techniques|Unsimultaneous endovascular interventional embolisation/radiotherapy followed by microsurgical resection, as traditional clinical routines.
9801018|NCT01704261|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
9801019|NCT01704261|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
9801020|NCT01704287|Experimental|Pembrolizumab 2 mg/kg|Participants were initially randomized to receive pembrolizumab 2 mg/kg intravenously (IV) once every 3 weeks (Q3W). With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
9801021|NCT01704287|Experimental|Pembrolizumab 10 mg/kg|Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
9801022|NCT01704287|Active Comparator|Investigator-Choice Chemotherapy (ICC)|Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
9801023|NCT01704287|Experimental|ICC→Pembrolizumab 2 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
9801024|NCT01704287|Experimental|ICC→Pembrolizumab 10 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
9801025|NCT01704456|Experimental|Mindfulness-based cognitive therapy (MBCT)|Women in the MBCT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
9801026|NCT01704456|Experimental|Cognitive Behavioural Therapy (CBT)|Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
9942472|NCT01010048|Experimental|progesterone,tamsulosin,propantheline Bromide and nifedipine|different effect of these drugs use to treat urinary calculus after ESWL
9942473|NCT01010087|Active Comparator|Standard Oseltamivir dose 75 mg bid|Standard dosing
9942474|NCT01010087|Experimental|High Dose Oseltamivir arm 225mg bid|High dose arm of the study
9942475|NCT01010100|Experimental|Arm 1|
9528561|NCT03209804|Experimental|Hybrid operating techniques|A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously
9942476|NCT01010100|Placebo Comparator|Arm 2|
9942477|NCT01010113|Placebo Comparator|Test formula 1|Standard formula with prebiotics
9942478|NCT01010113|Experimental|test product|Infant formula with synbiotics
9942479|NCT01010152|Experimental|Codeine Sulfate|30 mg tablet
9942480|NCT01010152|Active Comparator|Tylenol #3|30 mg tablet
9942481|NCT01010165||septic arthritis|
9942482|NCT01010165||crystal arthritis|
9942483|NCT01010165||rheumatismal disease|
9942484|NCT01010178|Experimental|Macrolid, Theophylline, Corticosteroids|Approved drug in this setting
9942485|NCT01010191|Experimental|Cellulose pill|The active intervention is a sugar pill.
9942486|NCT01010191|No Intervention|No treatment|The control arm is wait list control
9942487|NCT01010256||Subjects diagnosed with CMML|Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
9942488|NCT01010256||Control Group|The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
9942489|NCT01010269|Active Comparator|Vanguard Complete Knee|Vanguard Completed Knee with Microplasty Tibial Tray is designed to hold the tibial knee bearings in a microplsty knee procedure. The Co-Cro-Mo trays are designed with a shorter stem.
9942490|NCT01010269|Active Comparator|Vanguard High Flex RP|VGRD High Flex RP knee is an extension to the exsting Vanguard Knee and has been specifically desinged to facilitate greather than 135 degrees of knee flextion as required by certain patients.
9942491|NCT01010295|Experimental|doxycycline|doxycycline 100 mg twice daily for 3 weeks
9942492|NCT01010308|Experimental|Intervention Group:|"The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement~Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group"
9942493|NCT01010308|No Intervention|Historical control group|Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
9942494|NCT01010308|No Intervention|Angiogenesis marker control group|The angiogenesis marker control group will consist of 6 -10 patients seen in the Dermatology clinic for conditions other than IH and not receiving corticosteroids or beta blockers.
9942495|NCT01010321||all study Population|all
9942496|NCT01010334|Active Comparator|Arm 1|Standard of Care Treatment
9942497|NCT01010334|Experimental|Arm 2|Treatment Arm of a separate protocol (physician discretion)
9942498|NCT01010347|Active Comparator|Splint|Preformed velcro volar splints are compared to traditional circumferential casting.
9942499|NCT01010347|Placebo Comparator|Cast|The circumferential cast is the standard of treatment against which the splint is compared.
9942500|NCT01010373|Experimental|AS101 infusions|In addition to induction chemotherapy AS101 will be given intravenously. The patient will also receive AS101 infusions during the time break till the next chemotherapy course, as long as the patient does not achieve complete remission and the platelet count is <20,000/μl; ANC <1000. AS101 will be administered likewise up to two consolidation or equivalent chemotherapy courses (re-induction or salvage in the event that no CR is achieved following first induction chemotherapy), i.e., total of three chemotherapy courses.
9942501|NCT01010386|Placebo Comparator|atmospheric (20%) oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
9942502|NCT01010386|Active Comparator|physiologic (5%) oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
9942503|NCT01010412|Experimental|Ultrasound|Ultrasound guided nerve localization through direct visualization of the nerves and surrounding structures.
9942504|NCT01010412|Active Comparator|Nerve Stimulation|Standard of Care
9942505|NCT01010425|Experimental|ACP-001, dose-level 1|
9942506|NCT01010425|Experimental|ACP-001, dose-level 2|
9942507|NCT01010425|Experimental|ACP-001, dose-level 3|
9942508|NCT01010425|Experimental|ACP-001, dose-level 4|
9942509|NCT01010438||Adults|Adult patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
9942510|NCT01010438||Children (1-17)|Pediatric patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
9942511|NCT01010451|Experimental|Antimicrobial pulpotomy|Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste
9942512|NCT01010451|Active Comparator|Calcium hydroxide pulpectomy|Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication
9942513|NCT01010464|Experimental|Adhesion Reduction Plan|Lysis of adhesions and application of Seprafilm
9942514|NCT01010464|No Intervention|Standard Management|Standard management and no application of Seprafilm
9942515|NCT01010490|Experimental|Torsional ultrasound|Torsional ultrasound with the INFINITI phacoemulsification system (Alcon Lab, USA)
9942516|NCT01010490|Active Comparator|Longitudinal ultrasound (INFINITI)|Longitudinal ultrasound with the INFINITI phacomachine (Alcon Lab, USA)
9528562|NCT03209856|Experimental|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
9528563|NCT03209856|No Intervention|Routine care|This group will receive the routine care.
9528564|NCT03210077||Entropy Group|General Anesthesia using Entropy Monitoring
9528565|NCT03210077||Control Group|General Anesthesia without Entropy (Control Group)
9528566|NCT03209843|Other|Successfully CTO recanalization|
9528567|NCT03209765|Active Comparator|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
9528568|NCT03209765|No Intervention|No reminder|
9528569|NCT03209622|Experimental|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
9942517|NCT01010490|Active Comparator|Longitudinal ultrasound (LEGACY)|Longitudinal ultrasound with the LEGACY phacomachine (Alcon Lab, USA)
9942518|NCT01010516|Active Comparator|High-dose rosuvastatin|40 mg of rosuvastatin
9942519|NCT01010516|Active Comparator|Stain plus fenofibrate|existing statin plus micronized fenofibrate 200 mg
9942520|NCT01010516|Active Comparator|Statin plus niacin ER/laropiprant|existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
9942521|NCT01010529|Experimental|occupational therapy|
9942522|NCT01010529|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (3 months).
9942523|NCT01010542|Active Comparator|ILV-095|
9942524|NCT01010542|Placebo Comparator|placebo|
9942525|NCT01010581|Experimental|SC12267 (4SC-101) + Methotrexate|
9942526|NCT01010581|Placebo Comparator|Placebo + Methotrexate|
9942527|NCT01010594|Active Comparator|Fruit restricted|Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily.
9942528|NCT01010594|Active Comparator|Fruit ad libitum|Type 2 diabetics are advised to eat at least two pieces of fruits daily
9942529|NCT01010607|Experimental|Vibraton Mirror (VM)|subjects will receive tendon vibration AND mirror therapy
9942530|NCT01010607|Active Comparator|Mirror (M)|Subjects will receive treatment only with Mirror, together with sham vibration (over bone instead of tendon)
9942531|NCT01010607|Sham Comparator|Sham (S)|Opaque board instead of mirror, bone vibration instead of tendon vibration
9942532|NCT01010620||Screening|Screening Assessment battery. Specific to study(or studies) the individual is screening for.
9942533|NCT01010646|Experimental|GP1N IFN alfa-2bXL 27 MUI + Ribavirin|IFN alfa-2bXL 27 MUI, powder and solvent for solution injection
9942534|NCT01010646|Experimental|GP2N IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI, powder and solvent for solution injection
9942535|NCT01010646|Active Comparator|GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections
9942536|NCT01010659|Experimental|Lacrimal Tube|Dacryocystorhinostomy with silicone lacrimal intubation
9942537|NCT01010672|Experimental|Ridaforolimus 40 mg|
9942538|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 1|formulation 1
9942539|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 2|formulation 2
9942540|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 3|formulation 3
9942541|NCT01010698|Active Comparator|cimetidine (or acyclovir) reference|reference product
9942542|NCT01010711|Other|migraine dietary supplement|"the average days of migraine during a 4 week-run-in-period are compared with the average days of migraine during intervention with a specific dietary supplement from week 8 - 12"
9942543|NCT01010724|Experimental|bIAP|Dosage 200 IU bIAP/kg: 1000 IU prior to anaesthesia administered as a bolus followed by intravenous continuous infusion of 5,6 IU/kg/hr for approximately 36 hours.
9942544|NCT01010724|Placebo Comparator|Placebo|
9942545|NCT01010737|Experimental|Multimeric-001 250 mcg|250mcg of Multimeric-001 was administered twice at an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
9942546|NCT01010737|Active Comparator|Adjuvant: Montonide isa 51 VG|Adjuvanted PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
9942547|NCT01010737|Active Comparator|Placebo|PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
9942548|NCT01010737|Experimental|Multimeric-001 500 mcg|500mcg of M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
9942549|NCT01010737|Experimental|Adjuvanted Multimeric-001 500mcg|5000mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
9942550|NCT01010737|Experimental|Adjuvanted Multimeric-001 250mcg|250mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
9942551|NCT01010789|Experimental|Armodafinil|Flexible dose 150-250mg/day
9942552|NCT01010789|Placebo Comparator|Mathing Placebo|
9942553|NCT01010802|Experimental|Erythropoietin|"There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin."
9942554|NCT01010815||UC group|clinically and microscopically confirmed UC patients between the age of 19 and 75 years
9942555|NCT01010815||Control group|normal healthy controls
9942556|NCT01010828|Active Comparator|Tri-Vector Approach|
9942557|NCT01010828|Experimental|Mini Mid-Vastus Approach|
10002219|NCT01555047|Active Comparator|males who were not infected by mycoplasma|100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.
10002220|NCT01555047|Experimental|infected by mycoplasma males|100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.
10002221|NCT01555047|No Intervention|fertile males|50 fertile males were chose as control samples
10002222|NCT01555060|Experimental|Iron supplements|Subjects who are randomized to receive daily iron supplements after donating blood
10002223|NCT01555060|No Intervention|Control|Subjects who are randomized not to receive daily iron supplements after donating blood
10002224|NCT01555086|Experimental|Limited pelvic Lymphadenectomy|
10002225|NCT01555086|Experimental|Extended pelvic Lymphadenectomy|
10002226|NCT01555099|Experimental|AZD5423|New study drug
10002227|NCT01555099|Active Comparator|Budesonide|Comparator to which the new study drug will be compared
10002228|NCT01555099|Placebo Comparator|Placebo|No drug to which both other arms will be compared
10002229|NCT01555112|Experimental|Topical AS101|15% AS101 ointment applied twice a day for treatment of external genital warts.
10002230|NCT01555177||Peri-operative NSTEMI patients|Patients with POMI undergoing cardiac catheterization within 72 hours of first troponin elevation and within 2 weeks of their non-cardiac surgery.
10002231|NCT01555177||Non-surgery related NSTEMI patients|Patients with NSTEMI undergoing cardiac catheterization within 72 hours of symptom onset.
10035089|NCT01802957|Other|St. Paul and Networked Health Centers|An uncontrolled before and after design with baseline and follow-up cross sectional measurements will be used at the overall site level (St. Paul Hospital and the 8 associated HCs). There will be no control unit.
10035090|NCT01802970|Experimental|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
10035091|NCT01802996|Experimental|Arm I|Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
10035092|NCT01802996|No Intervention|Arm II|Only chemotherapy
10035093|NCT01803009|Experimental|One arm|View CRC RAT and view presentation regarding risk of advanced adenoma
10035094|NCT01803022||Low Molecular Weight Heparin|
10035095|NCT01803035|Experimental|1 % LTX-109|LTX-109 topical gel in 1 % strength
10035096|NCT01803035|Experimental|2 % LTX-109|LTX-109 topical gel in 2 % strength
10035097|NCT01803035|Placebo Comparator|Placebo|Placebo gel, containing all ingredients except LTX-109
10035098|NCT01803048||TBI|30 individuals who will be tested at two weeks post-TBI; 30 individuals who will be tested at one month post-TBI; 30 individuals who will be tested at three months post-TBI; 30 individuals who will be tested at six months post-TBI; 30 individuals who will be tested at 12 months post-TBI.
9801027|NCT01704495|Experimental|AZD5069 5 mg|AZD5069 oral capsules self-administered twice daily
9476257|NCT03573687|Experimental|PRO Timing on Markers of Fat Metabolism|Assess the differences in overnight and next morning metabolic biomarkers of fat metabolism compared to baseline between acute nighttime PRO (NP) consumption versus daytime PRO (DP) consumption trials after a RT bout in RT women.
9476258|NCT03573674|Experimental|Cognitive ergonomics Intervention|
9801028|NCT01704495|Experimental|AZD5069 15 mg|AZD5069 oral capsules self-administered twice daily
9801029|NCT01704495|Experimental|AZD5069 45 mg|AZD5069 oral capsules self-administered twice daily
9801030|NCT01704495|Placebo Comparator|Placebo|Placebo oral capsules self-administered twice daily
10035099|NCT01803048||Healthy Control|30 healthy individuals with no history of TBI
10035100|NCT01803061|Experimental|WebCan|Provides computerized PRO to the treating physician at the point of care
10035101|NCT01803061|No Intervention|Usual care|
10035102|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) TEST 1|Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
10035103|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
10035104|NCT01803087|Active Comparator|(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)|BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
10035105|NCT01803087|Active Comparator|CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI|Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
10035106|NCT01803100||Hospitalized inpatients|Inpatients newly admitted into freshly-cleaned rooms.
10035107|NCT01803126||atherosclerosis|No treatment.
10035108|NCT01803139|Active Comparator|Standard breast radiotherapy|The treatment is planned using 2D wedges optimisation on the central CT-planning slice.
10035109|NCT01803139|Experimental|Breast IMRT|The treatment is planned 3D IMRT optimisation using all CT-planning slices.
10035110|NCT01803152|Experimental|Part 1-DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
10035111|NCT01803152|Active Comparator|Part 2-Gemcitabine/DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks;~Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
10035112|NCT01803165||Single shot femoral and sciatic nerve block|Prospective patient study group who present for infrainguinal bypass grafting and will receive single shot femoral and sub gluteal sciatic nerve blocks.
10002232|NCT01555190|Active Comparator|myo-inositol 1500 gr|6 months treatment with myo-inositol 1500 gr
10002233|NCT01555190|Active Comparator|myo-inositol 2000gr + folic acid 200 mcg|
10002234|NCT01555203|Experimental|liveWell: A healthy foundation for life|
10002235|NCT01555216|Active Comparator|Posterior tibial nerve catheter|5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
10002236|NCT01555216|Active Comparator|Single injection PTNB|Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
10002237|NCT01555229|Experimental|Intermittent drainage|Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
10002238|NCT01555229|Active Comparator|Continuous drainage.|Continuous subglottic secretion drainage at -20 mmHg.
10002239|NCT01555242|Experimental|Aneustat (OMN54)|
10002240|NCT01555268|Experimental|Arm A (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.
10002241|NCT01555268|Experimental|Arm B (trebananib, cytarabine)|Patients receive trebananib as in Arm A. Patients also receive cytarabine SC BID on days 1-14 of course 1 and days 1-7 of subsequent courses.
9801031|NCT01704521|Active Comparator|Lead-In|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin
10002242|NCT01555294||community-based cohort|"The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.~In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed."
10002243|NCT01555294||Familial Combined Hyperlipidemia|FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
10002244|NCT01555307|Experimental|Balance group|Typical plus balance exercises
10002245|NCT01555307|Other|Typical group|Typical exercises
10002246|NCT01555320|Placebo Comparator|Qishen Yiqi dripping pills dummy|
10002247|NCT01555320|Experimental|Qishen Yiqi Dripping Pills|
9801032|NCT01704521|Active Comparator|No Lead-in|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin
9801033|NCT01704599|Experimental|Humira then Humira plus 3 B vitamins|"Humira then Humira plus 3 B vitamins~The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject."
9801034|NCT01704651|Experimental|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
9801035|NCT01704651|Placebo Comparator|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
9801036|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
10002248|NCT01555333|Experimental|Arbaclofen|Open Label Study
9942558|NCT01010841|Active Comparator|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
9942559|NCT01010841|Experimental|Low-glycemic-load diet + medical food|Modified Mediterranean-style, low-glycemic-load diet + medical food
9942560|NCT01010893|Experimental|Influenza vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose).
9942561|NCT01010893|Experimental|Influenza vaccination and co-vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
9942562|NCT01010945|Experimental|erlotinib, gemcitabine, nab-paclitaxel|Patients receive the following treatment in 28-day cycles: 1) erlotinib: orally once daily from days 1 through 28 continuous dosing; 2) gemcitabine (following nab-paclitaxel): intravenously over 30 minutes on days 1, 8 and 15 every 28 days; and 3) nab-paclitaxel: intravenously over 30 minutes on days 1, 8 and 15 every 28 days.
9942563|NCT01010958|Experimental|Valproate|Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.
9942564|NCT01010997||Dry AMD|Intermediate AMD subjects
9942565|NCT01010997||Wet - treated AMD|AMD subjects under treatments
9942566|NCT01011010|Other|Single Arm|Single Arm Trial
9476259|NCT03573674|Active Comparator|Stress management Intervention|
9476260|NCT03573674|No Intervention|Passive control|"Passive Control groups receive no intervention at all."
9942567|NCT01011023|Experimental|WITHOUT NASOGASTRIC TUBE|1. Experimental group (EG): without NGT, by removing the NGT at the end of the surgery, once the stomach had been aspirated,
9942568|NCT01011023|Active Comparator|WITH NASOGASTRIC TUBE|2. Control group (CG): with NGT, with radiographic corroboration of correct placement after the surgery. Both groups were given: 5-day fasting because it was the therapeutic gold standard at our hospital and our country, intravenous solutions and antibiotics for 5 days, ranitidine, and analgesics, without use of any antiemetic drug. Once the fasting period ended, in the CG the NGT was clamped and withdrawn, and in both groups oral fluids and diet were started. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
9942569|NCT01011036|Other|1|
9942570|NCT01011036|Other|2|
9942571|NCT01011036|Other|3|
9942572|NCT01011062|Experimental|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
9942573|NCT01011062|Experimental|Losartan + hyperinsulinaemia|
9942574|NCT01011062|Placebo Comparator|Saline|Infusion of Saline as a volume control intervention
9942575|NCT01011088||Early phase|Psychoses within the first 3 months after baby born
9942576|NCT01011088||Delayed phase|Psychoses > 3 months to one year after baby born
9942577|NCT01011114|Active Comparator|Cincalcet|cinacalcet will be titrated as needed to achieve serum phosphorus of > 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mg/l.
9942578|NCT01011114|Placebo Comparator|Control|"subjects will receive placebo pill titrated as needed to achieve phosphorus > 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mEq/l."
9942579|NCT01011127||pravastatin|
9942580|NCT01011127||rosuvastatin|
9942581|NCT01011140||Online Survey|Survey of Palliative care physicians from Latin America and Spain
9528570|NCT03209622|Active Comparator|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
9528571|NCT03209466|Experimental|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
9528572|NCT03209466|Placebo Comparator|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
9528573|NCT03209531|Experimental|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
9528574|NCT03209531|Experimental|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
9801037|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
9801038|NCT01704781|Experimental|Part A: lenalidomide dose escalation|"All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.~Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)"
9801039|NCT01704781|Experimental|Part B: lenalidomide|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
9801040|NCT01704781|Placebo Comparator|Part B: lenalidomide placebo|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide placebo two days prior to and at the day of immunization.
9801041|NCT01704846|Experimental|Treatment sequence 1|Test - Reference - Reference - Test
9801042|NCT01704846|Experimental|Treatment sequence 2|Reference - Test - Test - Reference
9801043|NCT01704976|Experimental|Intervention|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (5 Hz, noise 4) - T1
9801044|NCT01704976|Sham Comparator|Sham group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (1 Hz, noise 1) - T1
9801045|NCT01705080||A - EnligHTN for Severe Resistant HTN|"Office systolic Blood Pressure ≥160 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
9801046|NCT01705080||B - EnligHTN for Resistant HTN|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
9801047|NCT01705080||C - EnligHTN for Resistant HTN & CKD|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated ≥15 GFR <45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
9801048|NCT01705145|Experimental|Ivacaftor|"Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than [<] 14 kilograms [kg]) or 75 mg (for participants weighing greater than or equal to [>=] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..~Part B: Ivacaftor 50 mg (for participants weighing <14 kg) or 75 mg (for participants weighing >=14 kg) q12h for 24 weeks during Part B of the study."
9801049|NCT01705236|Experimental|Fingolimod - Longitudinal Assessment|No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.
9801050|NCT01705288|Active Comparator|Control Group (Standard Laparotomy)|Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.
9801051|NCT01705288|Experimental|Rapid Recovery Group|"Protocol for rapid recovery laparotomy procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital."
9801052|NCT01705496|Experimental|[124I]FIAU|Single dose study of [124I]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.
9801053|NCT01705509|Other|Ranolazine Treatment Arm|All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
9801054|NCT01705574|Experimental|E/C/F/TDF|E/C/F/TDF + ATV placebo + RTV placebo + FTC/TDF placebo
9801055|NCT01705574|Active Comparator|ATV + RTV+ FTC/TDF|ATV + RTV + FTC/TDF + E/C/F/TDF placebo
9801056|NCT01705574|Experimental|Open-Label Extension Phase|After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an unblinding visit at Week 60. Participants who are virologically suppressed at Week 48 during the double-blinded treatment phase will have the option to enter the open-label extension phase. Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+ RTV + FTC/TDF arm will be re-randomized to receive either open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or open-label ATV + RTV+ FTC/TDF.
9942582|NCT01011166|Experimental|IDX184 50 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.
9942583|NCT01011166|Experimental|IDX184 100 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
9942584|NCT01011166|Experimental|IDX184 100 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
9942585|NCT01011166|Experimental|IDX184 150 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
9942586|NCT01011166|Experimental|IDX184 200 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
9942587|NCT01011166|Experimental|IDX184 200 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
9942588|NCT01011192||ke0 of 0.26 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 0.26 min-1 (Asena PK® - Cardinal Health)
9942589|NCT01011192||ke0 of 1.21 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 1.21 min-1 (Primea Orchestra® - Fresenius-Kabi basis)
9942590|NCT01011205|Experimental|Dosing Regimen 1|Advagraf + MMF + Corticosteroids (Bolus)
9942591|NCT01011205|Experimental|Dosing Regimen 2|Advagraf + MMF + Basiliximab + Corticosteroids (Bolus)
9942592|NCT01011205|Experimental|Dosing Regimen 3|Advagraf (5 days delay) + MMF + Basiliximab + Corticosteroids (Bolus)
9942593|NCT01011244|Experimental|ADIPOPLUS|patients with a fistula in Crohn's disease
9942594|NCT01011257|Active Comparator|Aspirin 81 mg, 1 tab twice daily|All participants to take one aspirin (81mg per tab) twice daily.
9942595|NCT01011257|Active Comparator|Clopidogrel 75 mg 1 tab daily|Only stable CAD participants will take Clopidogrel (75mg per tab) daily.
10002249|NCT01555346||High risk pregnant subjects undergoing an invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy scheduled to undergo an invasive procedure for fetal karyotype determination.
10002250|NCT01555346||High risk subjects electing not to undergo invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy who elect not to undergo an invasive procedure for fetal karyotype determination.
10002251|NCT01555359||Patients undergoing stem cell collection|
10002252|NCT01555372|Active Comparator|Hook Plate|20 participants will be enrolled in this group.
10002253|NCT01555372|Experimental|Locking Plates|20 paticipants will be enrolled in this group
9528575|NCT03209453|Experimental|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
9528576|NCT03209453|No Intervention|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
9942596|NCT01011270||Back pain|The aim of this study was to investigate the effect of rehabilitation of the dynamic ;(RDM) in balance and balance of industrial operators. The sample consisted of industrial operators, individuals with low back pain, referred to the industry of Physical Therapy
9942597|NCT01011270||Balance|the treatment with RDM reflected in significant improvement in back pain and postural balance of industrial operators.
9942598|NCT01011296|Experimental|Single IV Dose 1|
9942599|NCT01011296|Experimental|Single IV Dose 2|
9942600|NCT01011296|Experimental|Single IV Dose 3|
9942601|NCT01011322|Experimental|LT-02 Dose 1|0.2g IMP per dose
9942602|NCT01011322|Experimental|LT-02 Dose 2|0.4g IMP per dose
9942603|NCT01011322|Experimental|LT-02 Dose 3|0.8g IMP per dose
9942604|NCT01011322|Placebo Comparator|Sugar pill|placebo matching to 0g of IMP,
9942605|NCT01011348|Other|Placebo vs Q10 100mg vs Q10 300mg|
9942606|NCT01011348|Other|Q10 100mg vs Placebo vs Q10 300mg|
9942607|NCT01011348|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
9942608|NCT01011348|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
9942609|NCT01011426|Active Comparator|Bisacodyl|
9942610|NCT01011426|Placebo Comparator|empty opague capsule|
9942611|NCT01011452|Active Comparator|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
9942612|NCT01011452|Placebo Comparator|Placebo|
9942613|NCT01011478|Placebo Comparator|Group 1: placebo|Patients receive oral placebo once daily for 5 years.
9942614|NCT01011478|Experimental|Group 2: rosuvastatin|Patients receive oral rosuvastatin once daily for 5 years.
9942615|NCT01011491|Experimental|Medifast 5 & 1 Plan|Medifast's 5 & 1 Plan is a meal replacement plan for weight loss and weight maintenance.
9942616|NCT01011491|Active Comparator|Food-based|The food-based arm followed a meal plan of self-selected foods that provided the same number of calories as the Medifast 5 & 1 plan.
9942617|NCT01011517|Experimental|grape seed supplement|Nature's Pearl 650 mg, two capsules daily
9942618|NCT01011517|Placebo Comparator|placebo|placebo
9942619|NCT01011530|Experimental|MLN4924|MLN4924 via IV infusion
9942620|NCT01011543|Active Comparator|Endoscopic approach|CT thorax is done in all patients to localize the exact anatomical site of the disease. This evaluation is followed by fluoroscopy-guided bronchoscopy for BAL (bronchoalveolar lavage) and TBB (transbronchial biopsies). A sputum sample immediately after the endoscopy will be collected if possible.
9942621|NCT01011543|Active Comparator|Induced sputum|Sputum induction after administration of 6-8 mL 3% NaCl aerosol by an ultrasonic nebulizer; sputum will be collected 15-30 minutes after administration of the aerosol. This process will be done twice in every patient.
9942622|NCT01011569||cage|patient who underwent stand alone cage insertion after discectomy
9942623|NCT01011569||plate|patient who underwent plate fixation and autologous ilia bone graft after discectomy
9528761|NCT03207828|Other|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
9942624|NCT01011582||Novel H1N1 influenza|
9942625|NCT01011582||Seasonal influenza|
9942626|NCT01011608|Experimental|Medical Food Supplement|Medical food supplement to be given in divided portions in morning, afternoon and evening
9942627|NCT01011608|Active Comparator|standard hospital food|standard hospital diet
9942628|NCT01011621|Experimental|0.5% prednisolone acetate cream|
9942629|NCT01011621|Active Comparator|0.1% betamethasone valerate cream|
9942630|NCT01011647||Acute coronary conditions|"Patients hospitalized with the following conditions~Unstable angina~Acute myocardial infarction~Congestive heart failure"
9942631|NCT01011660|Active Comparator|A,1,IV|A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV
9942632|NCT01011660|Active Comparator|A,2,IV|A means active; 2 means Amlodipine+Telmisartan; IV means phase IV
9942633|NCT01011660|Active Comparator|A,3,IV|A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV
9942634|NCT01011660|Active Comparator|A,4,IV|A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV
9942635|NCT01011686|Experimental|ANT-SM|autologous adipose-derived stem cell
9942636|NCT01011699|Active Comparator|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
9942637|NCT01011699|Active Comparator|nicotinamide|"Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of nicotinamide dose up to 4 tablets, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
10002254|NCT01555385|Active Comparator|Dietary supplement: high-protein breakfast|high-protein juice
10002255|NCT01555385|Active Comparator|Dietary supplement: high-carbohydrate breakfast|high-carbohydrate juice
10002256|NCT01555385|Placebo Comparator|Dietary supplement: low energy breakfast|low-calorie juice
10002257|NCT01555398|Experimental|Fasting conditions|Investigational product administrated under fasting condition.
10002258|NCT01555398|Active Comparator|Fed conditions|Investigational product administrated 30min after starting a high-fat breakfast.
10002259|NCT01555411||No treatment|
10002260|NCT01555424|Active Comparator|High dose|
10002261|NCT01555424|Active Comparator|Reference dose|
10002262|NCT01555450|Experimental|With Patient Navigator|People in this arm receive the Intervention of a Patient Navigator
10002263|NCT01555450|No Intervention|Control - Without Patient Navigator|People in this arm receive just the usual care of colorectal cancer screening
10002264|NCT01555476|Experimental|A-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
10002265|NCT01555476|Active Comparator|B-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
10002266|NCT01555502||low complications|Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
10002267|NCT01555502||High complications|Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
10002268|NCT01555515|Experimental|EPODURE Low dose|EPODURE pump secreting hEPO 18-25 IU/kg/day
10002269|NCT01555528||Growth Disorders|
10002270|NCT01555580|Experimental|GM-CSF|
10002271|NCT01555593|Experimental|COPD FEV1<70%pred feNO Cardioline Exp'air|COPD subjects with FEV1<70% of predicted value and Forced Expiratory Volume Forced to Forced Vital Capacity ratio (FEV1/FVC) less than 88% (males)or less than 89% (females) of Low Levels of Normality (LLN) entering the respiratory rehabilitation unit will undergo multiflow feNo measure with Cardioline Exp'air by Medi-soft - Sorinnes (B)
10002272|NCT01555606||Moderate to severe plaque psoriasis patients|The group includes adult patients (either male or female) diagnosed with plaque psoriasis for at least 6 months prior to screening with PGA value of greater than or equal to 3. The patients in the group needed are currently receiving treatment with conventional systemic agents, topical therapy and/or phototherapy or biologic therapy
10002273|NCT01555619||CRT-D System|St. Jude Medical (SJM) Promote® Q/Promote® Quadra/Unify Quadra™ CRT-D system.
10002274|NCT01555632|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
10002275|NCT01555632|Experimental|Arm II (atorvastatin calcium)|Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
10002276|NCT01555645|Experimental|Stress management Individual format|The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
10002277|NCT01555645|Experimental|Stress management Group format|Participants will meet for 2 hours every week for a total of 20 hours. In the intervals between the group meetings patients will be asked to do homework. Homework entails practicing problem-solving techniques, keeping a diary, practicing relaxation or physical activities. Each group meeting has a specific subject, i.e. What is stress and stress behaviors, Stress related symptoms, How to manage anger and negative thoughts, Self-registrations and behavioral changes, Future perspectives, Cancer, stress and relations, Expectations and demands, Body, pleasure and sexuality.
9801057|NCT01705587|Experimental|Immediate teriparatide|Open label teriparatide given immediately following surgical repair of fracture
10002278|NCT01555658|Experimental|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Bivalirudin
10002279|NCT01555658|Experimental|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Unfractioned Heparin.
10002280|NCT01555684|Experimental|venoplasty proceedures|Half of the participants receive treatment and the other half do not
10002281|NCT01555684|Placebo Comparator|Control - no treatment|
10002282|NCT01555710|Experimental|Palifosfamide-tris plus Carboplatin and Etoposide|Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
10002283|NCT01555710|Active Comparator|Carboplatin plus Etoposide|Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
10002284|NCT01555736|Active Comparator|preseasonal immunotherapy scheme|
10002285|NCT01555736|Active Comparator|perennial immunotherapy scheme|
10002286|NCT01555749|Experimental|NNC172-2021 low dose / Placebo|
10002287|NCT01555749|Experimental|NNC172-2021 high dose / Placebo|
10002288|NCT01555775|Experimental|P-CHO supplement|This group will drink the P-CHO supplement in the first trial and the fruit milk shake in the second.
10002289|NCT01555775|Experimental|Fruit Milk Sake|This group will drink the fruit milk shake in the first trial and the P-CHO supplement in the second.
10002290|NCT01555788|Experimental|Type 1 diabetic population|The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).
10002291|NCT01555801|Experimental|Submucosal injection combining with EUS|The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
10002292|NCT01555801|Placebo Comparator|ordinary endosonography(EUS)|The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
9476261|NCT03573661|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
9476262|NCT03573635|Other|Supratube|Patient with orotracheal intubation and supratube device
9476263|NCT03573622|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
9801058|NCT01705587|Experimental|Delayed teriparatide|Open label teriparatide given six months following surgical repair of fracture
10002293|NCT01555814|Experimental|Amisulpride|For 4 weeks, all patients will be treated with amisulpride open label.
10002294|NCT01555827|Experimental|Alzheimer Disease|
10002295|NCT01555827|Active Comparator|Control|
10002296|NCT01555840|Other|patients requiring upper GI endoscopy|patients with upper abdominal complaints requiring upper GI endoscopy
10002297|NCT01555853|Experimental|Phase I-Dose Level 0|Abraxane 100 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
10002298|NCT01555853|Experimental|Phase I-Dose Level 1|Abraxane 125 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
9476264|NCT03573622|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
9476265|NCT03573596|Other|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
9528577|NCT03209440|Active Comparator|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
9942638|NCT01011725|Experimental|Postmenopausal Women- Active Agent Group|
9942639|NCT01011725|Placebo Comparator|Postmenopausal Women- Placebo|Placebo
9942640|NCT01011751|Experimental|Cyproterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
9942641|NCT01011751|Experimental|Medroxyprogesterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
9942642|NCT01011751|Experimental|Venlafaxine|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.
9942643|NCT01011764|Active Comparator|SKILLS group|The SKILLS intervention targets a specific set of social skills over 8 bi-weekly sessions. The intervention is delivered to a small group of children with autism at school during lunchtime. The content delivered to the group of young children with autism including lessons developed from a manual by Seattle Children's Hospital Research Foundation. Children are given weekly homework assignments to reinforce the topics discussed in the group sessions.
9942644|NCT01011764|Experimental|ENGAGE group|The ENGAGE intervention targets two social domains, and two learning contexts. The two social domains are peer acceptance and social engagement with peers. The social group will be small and include children with ASD as well as their typical peers. There will be a greater number of typical peers included to model social behaviors and foster friendships. The typical peers will be selected based on results from the friendship survey and teacher nominations. The two learning contexts are direct instruction in a group social skills format during lunchtime and individualized embedded generalization activities in the school day.
9942645|NCT01011777|Experimental|Autologous Muscle Derived Cells|Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
9942646|NCT01011790|Experimental|Stress Management Tool|All subjects will use the Healing Rhythms™ meditation program for 4 weeks.
9942647|NCT01011803|Experimental|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
9942648|NCT01011842|Experimental|radiation therapy arm|
9942649|NCT01011855|Active Comparator|Radiant warmer bed sequence 1|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
9942650|NCT01011855|Active Comparator|Radiant warmer bed sequence 2|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
9942651|NCT01011855|Active Comparator|Radiant warmer bed sequence 3|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
9942652|NCT01011855|Active Comparator|Radiant warmer bed sequence 4|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
10002299|NCT01555853|Experimental|Phase I-Dose Level 2|Abraxane 150 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
10002300|NCT01555853|Experimental|Phase II|Abraxane (dose to be determined in Phase I) IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
10002301|NCT01555866|Experimental|Part 1 Subjects with End Stage Renal Disease (ESRD)|
10002302|NCT01555866|Experimental|Part 1 Healthy Subjects|
10002303|NCT01555866|Experimental|Part 2 Subjects with Mild Renal Impairment|
10002304|NCT01555866|Experimental|Part 2 Subjects with Moderate Renal Impairment|
10002305|NCT01555866|Experimental|Part 2 Subjects with Severe Renal Impairment|
10002306|NCT01555866|Experimental|Part 2 Subjects with no Renal Impairment|
10002307|NCT01555879||All patients|All patients in T3 who have used Abatacept for at least 3 months between 2009-03-17 and 2011-11-30.
10002308|NCT01555918|Experimental|Isavuconazole single oral dose - Part 1|
10002309|NCT01555918|Experimental|Isavuconazole single intravenous (IV) dose - Part 1|
10002310|NCT01555918|Experimental|Isavuconazole multiple oral doses - Part 2|
10002311|NCT01555918|Experimental|Isavuconazole multiple intravenous (IV) doses -Part 2|
10002312|NCT01555970|Experimental|NAC|Patients allocated in this group will receive N-acetylcysteine 1200 mg (one 600 mg capsule twice a day) during the first week of the study. On day 8 this will increase to 4 capsules per day (2400 mg NAC; 2 capsules twice a day). Finally, on day 15 (after 1 week at 2400 mg) the dose will be increased to the target dose of 5 capsules per day (3000 mg; 2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
10002313|NCT01555970|Placebo Comparator|Placebo|Patients allocated in this group will receive one capsule of placebo twice a day during the first week of the study. On day 8 this will increase to 4 capsules per day (2 capsules twice a day). Finally, on day 15 the dose will be increased to the target dose of 5 capsules per day (2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
10002314|NCT01555996|Experimental|Early and intensive OT|
10002315|NCT01555996|Active Comparator|Standard non-pharmacological prevention|
10002316|NCT01556022|Experimental|ADRCs processed by the Celution System|400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
10002317|NCT01556022|Placebo Comparator|Lactated Ringers and Subject's blood|Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
10002318|NCT01556035|Experimental|Lenalidomide treatment|
10002319|NCT01556048|Experimental|IMMEDIATE START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 1 of entry into the study
9528762|NCT03207659|Experimental|Dusting|small stones will be left to pass spontaneously.
10002320|NCT01556048|Placebo Comparator|DELAY START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 12 of entry into the study
10002321|NCT01556074|Experimental|Yoga treatment|
10002322|NCT01556087|Experimental|Distress Tolerance|7 sessions aimed at increasing distress tolerance skills
10002323|NCT01556087|Placebo Comparator|Health Education|7 didactic health education sessions
10002324|NCT01556113|Active Comparator|omega diet carrying CC/CG genotype|Subjects homozygous for the major allele of the rs73049 SNP or heterozygous (CC and CG)
10002325|NCT01556113|Active Comparator|omega diet carrying GG genotype|Subjects homozygous for the minor allele of the rs73049 SNP (GG)
10002326|NCT01556126|Experimental|Amphilimus eluting stent (Cre8)|Sirolimus formulated coronary eluting stent
10002327|NCT01556152|Active Comparator|Treatment Arm 1|
10002328|NCT01556152|Active Comparator|Traetment Arm 2|
10002329|NCT01556152|Placebo Comparator|Treatment Arm 3|
10002330|NCT01556178||Children without central nervous system tumors|Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus
10002331|NCT01556191|Experimental|Gefinitib + Fulvestrant (patient with EGFR mutations)|
10002332|NCT01556191|Active Comparator|Erlotinib (wild type patients)|
10002333|NCT01556191|Experimental|Erlotinib + Fulvestrant (wild type patients)|
10002334|NCT01556191|Active Comparator|Gefinib (patient with EGFR mutations)|
10002335|NCT01556217|Experimental|JNJ-39393406|
10002336|NCT01556217|Placebo Comparator|Placebo|
10002337|NCT01556230||Group I|The first group of subjects, Group I, will be followed in Protocol I and are a group of subjects with an apparent clinically nonfunctioning pituitary lesion who will be studied in a prospective study of conservative non-surgical management.
10002338|NCT01556230||Group II|A second group of subjects, Group II, are subjects who are undergoing surgical intervention for CNFA or radiotherapy for CNFA and these subjects will be studied in a prospectively follow up as part of Protocol II.
10002339|NCT01556282|Experimental|Therasphere|
10002340|NCT01556295||Experimental|
10002341|NCT01556295||Control|
10002342|NCT01556308|Experimental|DM-EBS|
10002343|NCT01556321|Experimental|Green tea, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
10002344|NCT01556321|Placebo Comparator|Placebo, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
10002345|NCT01556321|Experimental|Green tea, overweight|Subjects with a BMI >30 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
10002346|NCT01556321|Placebo Comparator|Placebo capsules, obese|Subjects with a BMI >30 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
10002347|NCT01556334|Experimental|Azithromycin|Azithromycin 1g po
10002348|NCT01556334|Active Comparator|Erythromycin|Erythromycin IV followed by po for a total of 5 days.
10002349|NCT01556373||severe sepsis|patients with severe sepsis
10002350|NCT01556373||Controls|Controls matched to patients on age, sex and cardiovascular risk factors
10002351|NCT01556386||Pharmacogenetic analysis, ALL|
10002352|NCT01556399||Duodenal adenomas|Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
9801059|NCT01705652|Experimental|Nexrutine Surgery Group|Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
9801060|NCT01705652|Experimental|Nexrutine Radiation Group|Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
10002353|NCT01556412||Chronic hepatopathy suspicious of PSC|"All patients with chronic hepatopathy of unknown origin and a high risk of primary sclerosing cholangitis as the underlying disease for chronic hepatopathy.~This group includes all patients with cholestatic hepatopathy (predominantly elevated gamma-glutamyltransferase and alkalic phosphatase) and positive ANCAs (Anti-neutrophil cytoplasmic antibodies) and/or inflammatory bowel disease in medical history.~Other explanations of cholestatic hepatopathy (like pancreatic tumor or cholelithiasis) must not be apparent in patients eligible for this study.~Furthermore, infection oder extrahepatic cholestasis already proven by laboratory results or percutaneous ultrasound, which make endoscopic retrograde cholangiography necessary, are exclusion criteria in this study."
10002354|NCT01556464|Experimental|ACPAP|Patients in the intervention group will be introduced to the auto-adjusting CPAP (ACPAP) (ResMed S9) during the day and placed on it at night with a nocturnal oximetry and ACPAP download to assess its effectiveness and pressure requirements. The intervention is the application of the ACPAP. The patients will be discharged on ACPAP pressure determined by the ACPAP download (95th percentile pressure in absence of significant air leak) and will be scheduled for an outpatient repeat diagnostic PSG and, if indicated, a full night titration study.
10002355|NCT01556464|No Intervention|Control|The control group will receive nocturnal oxygen or no therapy while in the hospital and after discharge at the discretion of the attending physician. They will be scheduled for outpatient repeat diagnostic PSG and then, if indicated, a full night titration study.
10002356|NCT01556477|Active Comparator|azacitidine|
10002357|NCT01556477|Experimental|azacitidine + lenalidomide|
10002358|NCT01556503||Pigmented Lesion|Patients identified as having a concerning pigmented lesion and the physician believes it is appropriate to biopsy to rule out melanoma.
10002359|NCT01556516||Women with Pompe Disease|
10002360|NCT01556529|Experimental|risk profile information|patient gets information on quantitative individual complication risk profile and patient gets standard T2DM DMP care
10002361|NCT01556529|Active Comparator|Control|Control group: patient gets standard T2DM DMP care
10002362|NCT01556542|Active Comparator|standard PTA|nitinol stent implantation
10002363|NCT01556542|Experimental|DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
10002364|NCT01556555||Primary sclerosing cholangitis|Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP.
10002365|NCT01556568|Experimental|MEK162|Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.
10002366|NCT01556607|Active Comparator|Experimental: MDT-637|
10002367|NCT01556607|Placebo Comparator|Placebo|
10002368|NCT01556646|Experimental|Tolvaptan|Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study
10002369|NCT01556659|Active Comparator|Triple antithrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
10002370|NCT01556659|No Intervention|Triple anti-thrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
10002371|NCT01556672|Experimental|adalimumab|All patients will receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
10002372|NCT01556685|Active Comparator|Group 1 Avonex|Approximately 90 subjects treated with IFN beta 1a IM 30μg
10002373|NCT01556685|Active Comparator|Group 2 Jumtab|Approximately 90 subjects treated with IFN beta 1a IM biosimilar
10002374|NCT01556698|Experimental|NVN1000 Gel|NVN1000 Gel topically applied one daily at bedtime for 8 weeks
9528578|NCT03209440|Experimental|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
9942653|NCT01011855|Experimental|Radiant warmer bed sequence 5|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
9528579|NCT03209440|Experimental|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
9528580|NCT03209583||Congenital Heart Disease|subjects have CHD and arrhythmias being treated with an implanted pacing device.
9942654|NCT01011855|Experimental|Radiant warmer bed sequence 6|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
9942655|NCT01011881||patients with pleuritis|
9942656|NCT01011920|Experimental|MTX+ AraC|Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
9942657|NCT01011920|Experimental|Ara-C +Rituximab|Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
9942658|NCT01011920|Experimental|Ara-C + rituximab+thiotepa|Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
9942659|NCT01011920|Experimental|WBRT 36 Gy +/- boost 9 Gy|ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
9942660|NCT01011920|Experimental|BCNU + Thiotepa + APBSCT|Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
9942661|NCT01011959|Active Comparator|1|dose 1 vs. placebo
9942662|NCT01011959|Active Comparator|2|dose 2 vs. placebo
9942663|NCT01011959|Active Comparator|3|dose 3 vs. placebo
9942664|NCT01011959|Active Comparator|4|dose 4 vs. placebo
9942665|NCT01011959|Active Comparator|5|dose 5 vs. placebo
9942666|NCT01011959|Active Comparator|6|dose 6 vs. placebo
9942667|NCT01011972|Experimental|XMT-1107|Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
9942668|NCT01011985||AVF|Initial access is an AVF
9942669|NCT01011985||AVG|Initial vascular access is an AVG
9942670|NCT01011985||TC|Initial vascular access is a tunneled catheter, with or without a maturing AVF or AVG
9942671|NCT01012011||Group 1|
9942672|NCT01012050|Experimental|NV Group|Performed nebulization coupled with noninvasive ventilation
9942673|NCT01012050|Active Comparator|NEB group|Performed nebulization alone.
9942674|NCT01012063|Experimental|group IE|The group IE received iron sucrose and erythropoietin-β (Epo-β) during the operation
9942675|NCT01012063|Placebo Comparator|group C|The group C received saline as same method.
9942676|NCT01012076|Active Comparator|Active Control|The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning. Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to improve the parent's ability to successfully promote the child's social and emotional competency.
9942677|NCT01012076|Experimental|Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to promote the ability of the parent-child dyad to successfully manage shared toy play.
9942678|NCT01012102|Experimental|Group 1|EMD 640744 30μg and Montanide® ISA 51 VG
9942679|NCT01012102|Experimental|Group 2|EMD 640744 100μg and Montanide® ISA 51 VG
9942680|NCT01012102|Experimental|Group 3|EMD 640744 300μg and Montanide® ISA 51 VG
9942681|NCT01012154|Experimental|All patients|
9942682|NCT01012193|Active Comparator|adjunctive cilostazol|adjunctive cilostazol 100mg bid to dual antiplatelet therapy
9942683|NCT01012193|Active Comparator|high maintenance-dose clopidogrel|double dose of clopidogrel 150mg/day
9942684|NCT01012206|No Intervention|Control group|Children in control group obtained no lifestyle counseling (intervention).
9942685|NCT01012206|Active Comparator|Intervention group|Children in the intervention group and their parents were given lifestyle counseling and participated in an intervention program regarding food habits and physical activity.
9942686|NCT01012232|Active Comparator|low volume local anesthetic|bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
9942687|NCT01012232|Experimental|high volume local anesthetic|bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL)
9942688|NCT01012284|Experimental|Panel A|8 patients with moderate hepatic impairment classified as moderate as per the Child Pugh Classification.
9942689|NCT01012284|Experimental|Panel B|8 healthy participants who will match to patients with hepatic impairment in Panel A with regards to sex, age (more or less to 5 years), and body mass index.
9942690|NCT01012310|Experimental|Cohort 1|
9942691|NCT01012310|Experimental|Cohort 2|
9942692|NCT01012310|Experimental|Cohort 3|
9942693|NCT01012310|Experimental|Cohort 4|
9942694|NCT01012349|Experimental|Test|Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)
10002375|NCT01556698|Placebo Comparator|Vehicle Gel|Vehicle Gel topically applied once daily at bedtime for 8 weeks
10002376|NCT01556711||Head Injury|Males and females ages 18 to 80 (the entire age range), who are admitted to the ED, who are suspected of a traumatically induced structural brain
10002377|NCT01556711||Control|"A 'normal' control group will be recruited for comparison and will consist of ED patients (ED normal control group) who have sustained an injury but do not exhibit any trauma above the clavicle and no history of MVA requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope"
10002378|NCT01556737|Experimental|Supplement|
10002379|NCT01556737|Placebo Comparator|Placebo|
9528581|NCT03209427|Active Comparator|Group I|intrathecal injection of 100 μg morphine
9528582|NCT03209427|Active Comparator|Group II|iIntrathecal injection of 200 μg morphine
9528583|NCT03209557|No Intervention|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
10002380|NCT01556789|Experimental|ONT-10 Vaccine|ONT-10 investigational agent
10002381|NCT01556802|Experimental|Minocicline|minocicline 100mg oral twice a day for 5 days
10002382|NCT01556802|Placebo Comparator|Placebo|Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
10002383|NCT01556815|Active Comparator|Group TACE|Patients who undergo TACE
10002384|NCT01556815|Experimental|Group Combination|Patients who are treated with sorafenib combined with TACE
10002385|NCT01556841|Experimental|TroVax®|TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
10002386|NCT01556841|Placebo Comparator|Placebo|
9528763|NCT03207659|Experimental|Basketing|stones will be actively extracted.
9801061|NCT01705691|Active Comparator|Arm 1: Paclitaxel then AC|Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
9801062|NCT01705691|Experimental|Arm 2: Eribulin then AC|Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles, followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
9801063|NCT01705717||cohort|
9801064|NCT01705730||Tocilizumab|Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.
9801065|NCT01705964|Experimental|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
10002387|NCT01556867|Active Comparator|dry cord care|
10002388|NCT01556867|Active Comparator|antiseptic care|
10002389|NCT01556880|Experimental|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
10002390|NCT01556880|No Intervention|Standard usual care|
10002391|NCT01556893|Other|LASIK Flap Arm|This is a single arm study.
10002392|NCT01556919||Mucosal Impedance Probe|
10002393|NCT01556945|Experimental|Group A : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the GlaxoSmithKline (GSK) adjuvant system, number 2 (AS02) and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant concomitantly as separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
10002394|NCT01556945|Experimental|Group B : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
10002395|NCT01556945|Experimental|Group C: FMP1/AS02 + AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with adjuvant AS02 adjuvant alone at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
10002396|NCT01556945|Experimental|Group D : RTS,S/AS02 + AS02|RTS,S malaria vaccine given with the adjuvant AS02 and an adjuvant AS02 alone concomitantly at separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
10002397|NCT01556945|Placebo Comparator|Control cohort|Infectivity controls (unvaccinated). Non-randomized infectivity controls were recruited specifically for the malaria challenge phase of the trial.
10035113|NCT01803165||Retrospective study group|Retrospective chart review will be performed and data collected on patients who have undergone infrainguinal bypass grafting under general anesthesia and without the use of regional or neuraxial anesthesia.
10035114|NCT01803178|Active Comparator|Plant Sterols|Plant Sterols
10035115|NCT01803178|Placebo Comparator|Placebo Product|Placebo Product
10035116|NCT01803191|Experimental|Fosfomycin 3 g|Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy
10035117|NCT01803191|Active Comparator|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg before biopsy
10035118|NCT01803217|Experimental|mode switch to atrial pacing|
10035119|NCT01803217|Active Comparator|atrioventricular hysteresis function|
10035120|NCT01803230|Placebo Comparator|placebo|placebo (dextrose)
10035121|NCT01803230|Experimental|creatine|creatine supplementation
10035122|NCT01803243|Experimental|Leg length correction|The shorter leg in a sample of 15 patients with structural leg length inequality will be corrected by either a shoe insole or a modified shoe with sole lift.
10035123|NCT01803243|Experimental|Control of foot position 1|The foot position in in a sample of 15 patients with hemiplegic cerebral palsy will be controlled by an ankle foot orthosis.
10035124|NCT01803243|Experimental|Control of foot position 2|The foot position in in a sample of 15 patients with diplegic cerebral palsy will be controlled by an ankle foot orthosis.
9528584|NCT03209557|Experimental|SmokeBeat Intervention|"25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.~A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.~A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking."
9528585|NCT03209661|Active Comparator|E-Cigarette 5.4% NBV|Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.
9528586|NCT03209661|Placebo Comparator|E-Cigarette 0% NBV|Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.
9528587|NCT03209661|Placebo Comparator|Menthol Inhaler|Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.
9528588|NCT03209544|Experimental|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
9528589|NCT03209544|No Intervention|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
9528590|NCT03209635|Placebo Comparator|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
9528591|NCT03209635|Experimental|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
9528592|NCT03209700|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
9528593|NCT03209648|Experimental|Debio 1450|In Treatment Period 1, participants will receive single oral dose of Debio 1450 40 mg on Day 1. In Treatment Period 2, participants will receive itraconazole 200 mg, twice daily (BID) orally, on Day 1, followed by itraconazole 200 mg once daily (QD), on Days 2 to 4, and then single oral dose of Debio 1450 40 mg and itraconazole 200 mg on Day 5, followed by a single oral dose of itraconazole 200 mg on Days 6 and 7.
9528594|NCT03209778|Active Comparator|Control group|Control participants without psychiatric nor neurological history
9528595|NCT03209778|Experimental|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
9528596|NCT03209414||Stable coronary artery disease|Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
9528597|NCT03209414||Unstable coronary artery disease|Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
9942695|NCT01012349|Active Comparator|Comparator|Acetylsalicylic acid - (Aspirin - Bayer)
9942696|NCT01012375|Experimental|1|AZD1446 tid
9942697|NCT01012375|Experimental|2|AZD1446 tid
9942698|NCT01012375|Experimental|3|AZD1446 qd
9942699|NCT01012375|Placebo Comparator|4|Matching placebo capsule
9942700|NCT01012401|Experimental|CHESS with Clinician Report + Internet access|An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
9942701|NCT01012401|Active Comparator|Usual care with Internet access|Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
9942702|NCT01012427|Experimental|Patients with 3.0 cm or smaller renal cancer|The interventions in this study are part of clinical care and include percutaneous image-guided biopsy, percutaneous renal tumor cryoablation, CT/MR imaging of the ablation bed, and repeat pathologic sampling of the tumor bed with percutaneous biopsy. The cryoablation is done as the therapeutic intervention in patients with small renal cancer. The CT/MR imaging is done to evaluate the treatment for residual disease after the ablation. The repeat biopsy (e.g. three cores) is done to confirm that the neoplasm has been eradicated. These patients have continued imaging, and if necessary, percutaneous biopsy to ensure no recurrent disease.
9942703|NCT01012453|No Intervention|Hand Eczema in health care workers|
9942704|NCT01012479|Experimental|Candesartan QD + Hydrochlorothiazide QD|
9942705|NCT01012505||20 preterm infants|20 preterm infants without active disease
9942706|NCT01012518|Active Comparator|Conventional PCT|PCT performed without video guidance, as conventionally performed
9942707|NCT01012518|Experimental|Video-assisted PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
9942708|NCT01012531|Active Comparator|highly polymerized allergen extract|
9942709|NCT01012531|Placebo Comparator|Placebo|
9942710|NCT01012544|Active Comparator|stent thrombosis patients|Patients with a history of a stent thrombosis
9942711|NCT01012544|Active Comparator|Patients without a history of a stent thrombosis|Patients without a history of stent thrombosis
9942712|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant|
9942713|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant|
9942714|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted|
9942715|NCT01012557|Active Comparator|Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant|
9942716|NCT01012635||Neurofeedback, tDCS (2 levels), Self-hypnosis, Meditation|
9942717|NCT01012700|No Intervention|intranasal or IV|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
9942718|NCT01012700|Active Comparator|Hiltonol (poly ICLC)|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
9942719|NCT01012752|Active Comparator|modified allergen extract|
9942720|NCT01012752|Placebo Comparator|Placebo|
9942721|NCT01012778|Experimental|Climbup ADHD and Dyslexia Program|"Open label - intervention with pre and post parameters collected~Intervention: Yoga, Meditation, Play therapy for children with ADHD and Dyslexia twice a week in classroom with 6 week and 12 month, primary outcomes in terms of Vanderbilt ADHD scores"
9942722|NCT01012791|Experimental|Zumba exercise group|
9942723|NCT01012791|No Intervention|Non-Zumba exercise group|
9942724|NCT01012830|Experimental|Huperzine A|200 micrograms (mcg) of HuperzineA taken twice daily.
9942725|NCT01012843|Active Comparator|Antibiotic|Patients who received antibiotic treatment after abscess drainage
9942726|NCT01012843|Placebo Comparator|Placebo|Patients who received placebo after abscess drainage
9942727|NCT01012856|Active Comparator|Cognitive-Behavioral Therapy for Depression (CBT)|
9942728|NCT01012856|Experimental|Exposure-Based Cognitive Therapy for Depression (EBCT)|
9942729|NCT01012869|Experimental|everolimus-eluting stent|patients undergoing treatment of a coronary chronic total occlusion (at least 3-months old) using everolimus-eluting stents (Xience, Abbott Vascular) or Promus (Boston Scientific)
9942730|NCT01012882|Experimental|sublingual application of allergen extract|
9942731|NCT01012882|Placebo Comparator|sublingual application of placebo|
9942732|NCT01012908|Experimental|Norzyme|Pancreatic Enzymes - Norzyme (Bergamo)
9942733|NCT01012908|Active Comparator|Creon (Solvay)|Pancreatic Enzymes - Creon (Solvay)
9942734|NCT01012934|Experimental|1|Alendronate Sodium Tablets, 70 mg
9942735|NCT01012934|Active Comparator|2|Fosamax Tablets, 70 mg
9942736|NCT01012960|Placebo Comparator|Placebo|Placebo= normal saline
9942737|NCT01012960|Active Comparator|methylnaltexone|peripheral opioid antagonist
9942738|NCT01012986||2nd Grade|students of 2nd grade
9942739|NCT01012986||4th Grade|students of 4th Grade
9942740|NCT01013012|Active Comparator|Group A|Group A : saline 1 ml + ramosetron 6μg/kg
9942741|NCT01013012|Experimental|Group B|Group B : dexamethasone 4 mg + ramosetron 6μg/kg
9942742|NCT01013025||Patients treated with Vantas implant|Patients were enrolled if they had had a Vantas implant placed for treatment of adenocarcinoma of the prostate, and if the patients were scheduled for explant of the implant, and the physician had difficulty locating the implant.
9942743|NCT01013038|Active Comparator|Conventional percutaneous coronary intervention|
9942744|NCT01013038|Experimental|Thrombus aspiration|
9942745|NCT01013051||Post Gastric Bypass|
9942746|NCT01013051||Obese Controls|age, BMI, gender matched
9942747|NCT01013064|Experimental|Cohort1|
9942748|NCT01013064|Experimental|Cohort2|
9942749|NCT01013064|Experimental|Cohort3|
9942750|NCT01013064|Experimental|Cohort4|
9942751|NCT01013064|Experimental|Cohort5|
9942752|NCT01013064|Experimental|Cohort6|
9942753|NCT01013077|Experimental|Optive|Commercial drop.
9942754|NCT01013077|Experimental|Soothe|Commercial drop.
9942755|NCT01013077|Experimental|New Emulsion|New formulation.
9942756|NCT01013090|Active Comparator|Epidural crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
9942757|NCT01013090|Active Comparator|Epidural colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
9942758|NCT01013090|Active Comparator|Spinal crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
9942759|NCT01013090|Active Comparator|Spinal colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
9942760|NCT01013090|Active Comparator|CSEA crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
9942761|NCT01013090|Active Comparator|CSEA colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
9942762|NCT01013103|Other|Atorvastatin, Ischemic Heart Disease|
9942763|NCT01013103|Placebo Comparator|Atorvastatin vs Placebo Cardiac Surgery|
9942764|NCT01013116|Experimental|modified allergen extract of house dust mites|
9942765|NCT01013116|Placebo Comparator|Placebo|
9942766|NCT01013142|Experimental|MN-221|
9942767|NCT01013142|Placebo Comparator|MN-221 Placebo|
9942768|NCT01013168|Experimental|OncoSorb® column|
9942769|NCT01013220|Experimental|Depression Product Detailing|Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org
9942770|NCT01013220|Placebo Comparator|Depression HEDIS Detailing|Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive
10002398|NCT01556958||Active Wheezing - age 5-12|
10002399|NCT01556958||Active Wheezing - under age 5|
10002400|NCT01556958||No Wheezing|
10002401|NCT01556971|Active Comparator|Botox|The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
10002402|NCT01556971|Placebo Comparator|Saline Solution|A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
10002403|NCT01556984||DSA group|
10002404|NCT01556984||control group|
10002405|NCT01557010|Experimental|Treatment A|
10002406|NCT01557010|Experimental|Treatment B|
10002407|NCT01557010|Experimental|Treatment C|
10002408|NCT01557010|Placebo Comparator|Treatment D|
10002409|NCT01557023|Experimental|dienogest 2 mg/ethynilestradiol 30 mcg;|
10002410|NCT01557023|Active Comparator|Yasmin®|
10002411|NCT01557036||Aneurysms treated with Pipleline|Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device
10035125|NCT01803243|No Intervention|Control|A sample of 15 healthy controls from a simultaneously conducted study (UKBB-Spine-1315-1) will be used for comparative purposes.
9942771|NCT01013233|Experimental|training|Patients in this group start the cognitive training over 6 weeks directly after randomization.
9942772|NCT01013233|Placebo Comparator|control|In this control group begin the training in a cross-over design 7 weeks after randomization.
9942773|NCT01013246|Experimental|Video game play|
9942774|NCT01013259|Placebo Comparator|Placebo|
9942775|NCT01013259|Experimental|Mutaflor|
9942776|NCT01013272|Active Comparator|Entecavir|Ongoing entecavir 0.5mg daily
9942777|NCT01013272|Active Comparator|Lamivudine|Switch to lamivudine 100mg daily
9942778|NCT01013298|Experimental|Video-guided PCT|Patients that will be extubated and re-intubated with the ETT-TVT, and monitored throughout intubation and PCT
9942779|NCT01013311||Cardiac Sarcoidosis|Patients with Cardiac Sarcoidosis who had an ICD implanted
9942780|NCT01013337|Experimental|Arm I (Acupuncture)|Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments).
9942781|NCT01013337|Sham Comparator|Arm II (Placebo)|Patients undergo 10, 20-minute sessions of sham acupuncture treatments over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at non-acupuncture points.
9942782|NCT01013337|No Intervention|Arm III (Control)|Wait-list control patients are contacted by phone at the same frequency as real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
9942783|NCT01013363|No Intervention|No music|Participants will not use the digital music player during their procedure.
9942784|NCT01013363|Experimental|Music|Participants will use the digital music player during their procedure.
9942785|NCT01013376|Experimental|Active|Topical administration of MC-1101
9942786|NCT01013376|Placebo Comparator|Vehicle|Vehicle
9942787|NCT01013389|Experimental|Actifuse ABX|Actifuse ABX bone substitute
9942788|NCT01013389|Active Comparator|INFUSE, plus master granules (MGG)|synthetic bone substitute used in posterolateral instrumented lumber fusion with interbody fusion
9942789|NCT01013402|Experimental|volunteers for insulin hypoglycemia test|None of the subjects had diabetes mellitus or any other metabolic diseases. They were not taking any medicine and they did not have anemia or polycythemia. Also none of the patients had any condition causing hypoxia or any compromise in peripheral circulation.
9942790|NCT01013441|Experimental|Treatment Arm|
9942791|NCT01013454|Experimental|Varenicline transdermal delivery system|
9942792|NCT01013467|Active Comparator|color coded bloodpressure booklet|
9942793|NCT01013480|Active Comparator|STX209|
9942794|NCT01013493||myopic|
9942795|NCT01013493||non myope-healthy|
9942796|NCT01013506|Experimental|Letrozole +/-goserelin, OSI-906 (Arm I )|Patients receive oral letrozole once daily on days 1-28 plus subcutaneous goserelin (the latter for pre-menopausal women only) on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9942797|NCT01013506|Experimental|Letrozole +/- goserelin, OSI-906, erlotinib (Arm II)|Patients receive oral letrozole and subcutaneous goserelin (the latter for pre-menopausal women only) and oral IGF-1R inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9942798|NCT01013532|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
9942799|NCT01013532|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
9942800|NCT01013532|Experimental|Cilostazol|cilostazol plus placebo of aspirin
9942801|NCT01013532|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
9942802|NCT01013545|Experimental|JAE-EMT|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. This intervention condition uses spoken language as the mode of communication. Individual, single word targets will be selected based on the child's level of language production and specific interests. The targets are systematically modeled in response to child actions and attention during play. A sequence of milieu teaching prompts will also be used to elicit targets from the child when use of the target language is functional for the child.
9942803|NCT01013545|Experimental|JAE-AAC|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. The mode of communication introduced in this intervention condition is a developmentally chosen augmentative communication device. These devices are provided with a set of individually selected visual-graphic symbols and a relevant lexicon. The use of the device is taught within natural communicative exchanges within play routines and daily activities.
9942804|NCT01013558|Active Comparator|remifentanil|
9942805|NCT01013558|Placebo Comparator|saline|
9942806|NCT01013571|Experimental|1|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
9942807|NCT01013571|Experimental|2|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
9942808|NCT01013584|Active Comparator|1,000 IU|1,000 IU/day of vitamin D3
9942809|NCT01013584|Active Comparator|5,000 IU|5,000 IU/day of vitamin D3
9942810|NCT01013584|Active Comparator|10,000 IU|10,000 IU/day of vitamin D3
9942811|NCT01013610|Active Comparator|Multiple Dose|
9942812|NCT01013610|Placebo Comparator|Placebo|
10002412|NCT01557049|Experimental|Postural Reeducation Group|The participants, after obtaining a written informed consent, were randomized for one of the two groups: In the Global Postural Reeducation group (GPR), they were submitted 1 time per week, during 12 weeks, at GPR sessions. The duration of sessions was 60 minutes each, with the same physical Therapist of the study. After the intervention, subjects returned to assessment 3 months after, with the blinded assessor. All the 6 postures from GPR were used during the study. All outcomes measurements, in both groups, were validated for Portuguese language and applicable at baseline, 3 months and 6 months after baseline.
10002413|NCT01557049|No Intervention|Control Group|In the control group, no physical intervention was given during the study. After the study, 6 months after, all participants from control group received the same treatment given in GPR group, according to the Unifesp Ethics Committee orientations. All participants, of both groups, have a doctor from the study, if necessary.
10002414|NCT01557062|Other|Polysomnography|
10002415|NCT01557062|Other|Temperature measure|
10002416|NCT01557062|Other|Fibromyalgia Impact questionary|
10002417|NCT01557075|Active Comparator|Atorvastatin group|Atorvastatin 40 mg daily for 12 months after randomization
10002418|NCT01557075|Active Comparator|Pravastatin group|Pravastatin 20mg daily for 12 months after randomization
10002419|NCT01557101|Other|COLON CAPSULE ENDOSCOPY|
10002420|NCT01557101|Other|OPTICAL COLONOSCOPY|
10002421|NCT01557114|Experimental|radiation therapy with Ipilimumab|
10002422|NCT01557127||Group 1|
10002423|NCT01557140|Placebo Comparator|RASi plus placebo|RAS inhibition was optimized and after patients were randomly assigned to receive placebo
10002424|NCT01557140|Experimental|RASi plus carvedilol|RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol
10002425|NCT01557153|Experimental|Amlodipine|
10002426|NCT01557153|Placebo Comparator|Placebo|
10002427|NCT01557179|Experimental|Hyaluronic acid vaginal gel (Hyalofemme)|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
10002428|NCT01557179|Active Comparator|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
10002429|NCT01557192|Active Comparator|Active LFMS treatment|20 minute exposure to the LFMS electromagnetic field treatment
10002430|NCT01557192|Placebo Comparator|Sham LFMS treatment|20 minute exposure to either the sham (inactive) electromagnetic field treatment
10002431|NCT01557218|Experimental|Cucumber|
10002432|NCT01557218|Experimental|Pepper|
10002433|NCT01557218|Experimental|Tomato|
10002434|NCT01557218|Experimental|Vegetable variety|
10002435|NCT01557218|Experimental|Apple|
10002436|NCT01557218|Experimental|Peach|
10002437|NCT01557218|Experimental|Pineapple|
10002438|NCT01557218|Experimental|Fruit variety|
10002439|NCT01557231||No treatment|OA
10002440|NCT01557257|Experimental|40 mg ALO-02 capsule|Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block
10002441|NCT01557257|Experimental|80 mg ALO-02 capsule|Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block
10002442|NCT01557257|Experimental|40 mg OxyContin tablet|Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block
10002443|NCT01557270|Experimental|ropivacaine + dexmedetomidine|This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
10002444|NCT01557270|Active Comparator|ropivacaine + saline|This group represents the current standard of care in peripheral nerve blockade
10002445|NCT01557296|Placebo Comparator|Diabetic diet|Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
10002446|NCT01557296|Active Comparator|Diet food in small particle size|Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
10002447|NCT01557335|Experimental|Clopidogrel (Plavix®) and PA32540|PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
10002448|NCT01557335|Active Comparator|EC aspirin, EC omeprazole, Clopidogrel|
10002449|NCT01557361|Active Comparator|Standard RRT initiation|RRT is initiated >12 hours after eligibility determination. Once a decision is made to start RRT, a dialysis catheter will be placed and RRT initiated as soon as possible.
10002450|NCT01557361|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility.
10002451|NCT01557374|Active Comparator|Maintenance Tocilizumab, Abatacept|No modification in biotherapy dose and administration frequency
10002452|NCT01557374|Experimental|Decrease Tocilizumab, Abatacept|Progressive decrease by predetermined pattern. Progressive injection interval increase (by stage)
10002453|NCT01557387||Patients with pseudopolyps.|No treatment involved in this study.
10002454|NCT01557413|Experimental|Intramedullary nail|Intramedullary nail
10002455|NCT01557413|Experimental|Locked plate|Locked plate
10002456|NCT01557426|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of their skin or soft tissue infection and an ultrasound to an uninfected portion of skin.
10002457|NCT01557439|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
10002458|NCT01557439|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
10002459|NCT01557478|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
10002460|NCT01557478|Active Comparator|Melatonin 20mg|20 mg melatonin gelatin capsule
10002461|NCT01557491|Active Comparator|Straight Incision|incision made perpendicular to scalp surface
10002462|NCT01557491|Active Comparator|Bevelled Incision|Incision made at 45 degrees to scalp surface
10002463|NCT01557608|Experimental|Photon stimulation|
10002464|NCT01557608|Placebo Comparator|Placebo treatment|
10035126|NCT01803256||Scoliosis patients:|15 patients with adolescent idiopathic scoliosis.
10035127|NCT01803256||Control subjects:|15 adolescent healthy control subjects
10002465|NCT01557621|Experimental|Collaborative Population-Based Recall-Phone/Mail Group|Collaborative Pop-Based R/R: Phone/Mail Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
10002466|NCT01557621|Experimental|Collaborative Population-Based Recall-Mail Only Group|Collaborative Pop-Based R/R: Mail-Only Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
10002467|NCT01557621|Active Comparator|Practice-based Recall|Practice-based Recall
10002468|NCT01557634|Experimental|Closed-loop with diluted insulin|Insulin pump therapy using diluted insulin (20 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
10002469|NCT01557634|Active Comparator|Closed-loop with non-diluted insulin|Insulin pump therapy using standard non-diluted insulin (100 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
10002470|NCT01557647|Experimental|inhaled treprostinil|
10002471|NCT01557647|Placebo Comparator|placebo|
10002472|NCT01557660|Experimental|inhaled treprostinil|
10002473|NCT01557673|Active Comparator|NG bolus feeding over 5 min|Tube bolus (TB): feed administered via syringe through NG tube over 5 min.
10002474|NCT01557673|Placebo Comparator|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.
10002475|NCT01557712|Experimental|Ketamine+venlafaxine|one injection of 0.5 mg/kg of kentamine the first day plus venlafaxine (150-375 mg day) during 6 weeks
10002476|NCT01557712|Active Comparator|venlafaxine|venlafaxine (150-375 mg day) during 6 weeks
10002477|NCT01557725||THR/TKR patients|Any patients receiving fast-track THR or TKR in departments participating in the Lundbeck Foundation Centre for fast-track THR and TKR
9476266|NCT03573583|Experimental|Resistance Training group (RT)|"The resistance training intervention will include a full body, resistance training performed three days per week.~The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines"
9476267|NCT03573583|Active Comparator|Successful Aging|The comparator group will meet for stretching and health education classes every 2-5 weeks up to 7 total visits.
9476268|NCT03573570|Experimental|Treatment|110 Fair Price Shops (FPS) in Chidambaram, Tamil Nadu, India will be assigned randomly to receive rice fortified. Rice will be fortified using Fortified Rice Kernels (FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and B12. All households receiving rice from the PDS will receive fortified rice instead of conventional PDS rice, and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. Because a given FPS only receives rice from a single upstream distributor (godown) it should be straightforward to ensure that fortified rice reaches the appropriate treatment FPS and only those FPS.
9476269|NCT03573570|No Intervention|Control|The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
10002478|NCT01557738|Experimental|Acute effects of flavanol consumption|The outcome measurements will be made on all study participants before and 2 hours after consumption of the high flavanol beverage.
10002479|NCT01557738|Placebo Comparator|Low Flavanol Trial; acute effects|Once again, the outcome measurements will be made on all study participants before and 2 hours after consumption of the low flavanol beverage.
10002480|NCT01557738|Experimental|Long-term effects of flavanol consumption|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a high flavanol beverage.
10002481|NCT01557738|Placebo Comparator|Low Flavanol Trial; long-term effects|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a low flavanol beverage.
10002482|NCT01557764|Experimental|Treatment (enzyme inhibitor and monoclonal antibody)|Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
10002483|NCT01557803||Starting ART|Adult patients starting anti retroviral therapy for the first time
10002484|NCT01557816|Active Comparator|Naproxen|
10002485|NCT01557816|Sham Comparator|Placebo|
10002486|NCT01557829|Active Comparator|PEEK interbody cage|Posterior fusion with an interbody spacer (cage) made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is filled with local bone or bone harvested from the iliac crest.
10002487|NCT01557829|Experimental|Valeo OL ceramic cage|Posterior fusion with the Valeo OL cage, a silicon nitride ceramic interbody spacer. The center area of the cage is filled with autograft local bone or bone harvested from the iliac crest.
10002488|NCT01557907|Experimental|Intradermal - BD Research Catheter Set|Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
10002489|NCT01557907|Active Comparator|Subcutaneous - Medtronic Quick-Set|Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
10002490|NCT01557933||ECT|All study subjects have consented to receive ECT.
10002491|NCT01557972||1. Morning HP and NT|Subjects based on HBP were divided into MH and MN patients
10002492|NCT01557972||2. Clinic HP and NT|Subjects based on CBP were divided into CH and CN patients
10002493|NCT01557985|Experimental|Transversus abdominis plane (TAP) Block|All participants in the study will receive a Transverses abdominis plane (TAP) Block in conjunction with their surgery.
10002494|NCT01557998|Other|Control - No intervention|PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
10002495|NCT01557998|Experimental|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
10002496|NCT01557998|Other|HCV+PWID|Control and Experimental Confirmed HCV viremic study subject will receive HCV treatment
10002497|NCT01558011|Experimental|chemotherapy|"Chemotherapy:~Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
10002498|NCT01558024||C1S patients|"18 Patients with venous insufficiency: C1S patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
10002499|NCT01558024||C3 patients|"18 Patients with venous insufficiency: C3 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
10002500|NCT01558024||C5 patients|"18 Patients with venous insufficiency: C5 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
10002501|NCT01558024||Sedentary volunteers|18 healthy volunteers with a sedentary lifestyle (< 2h of physical activity per week)
10002502|NCT01558024||Active volunteers|18 healthy volunteers with an active lifestyle (between 2 and 6 hours of physical activity per week)
10002503|NCT01558024||Athletic volunteers|18 healthy volunteers with an athletic lifestyle (over 6 hours of physical activity per week for at least one year)
10002504|NCT01558037||Main study|Main study patients are enrolled before or at time of solid organ transplant. Qualifying subjects either have tested positive for Cytomegalovirus or have a donor who has tested positive for Cytomegalovirus.
10002505|NCT01558037||Sub study|Subjects are enrolled to this arm who have begun replicating Cytomegalovirus post transplant. These subjects may or may not have been on the main study arm.
9528598|NCT03209414||Non-ST elevation myocardial infarction|Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
10002506|NCT01558050|Experimental|red rice|commercially available red rice nutritionial supplement
10002507|NCT01558050|Placebo Comparator|placebo|placebo capsules
9528599|NCT03209414||ST-elevation myocardial infarction|Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.
9528600|NCT03209596|Experimental|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
9528601|NCT03209596|Active Comparator|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
10002508|NCT01558076||Subjects with sickle cell anemia|60 subjects with sickle cell anemia will be enrolled on the study.
10002509|NCT01558076||30 healthy controls|30 controls without sickle cell anemia or sickle cell trait will be enrolled on the study.
10002510|NCT01558115|Experimental|Denosumab - Group #1|Receive active drug for year 1 and year 2 of the study
10002511|NCT01558115|Placebo Comparator|Placebo - Group #2|Receive placebo for year 1 and active drug for year 2 of the study
10002512|NCT01558141|Active Comparator|Follicular flushing|Flushing follicles with embryo culture media prior to aspiration.
10002513|NCT01558154|Experimental|Chinese herb|Chinese herbs special for depression
10002514|NCT01558154|Experimental|acupuncture|
10002515|NCT01558154|Experimental|Psychotherapy|
10002516|NCT01558154|Experimental|physiotherapy|
10002517|NCT01558167|Experimental|Bendamustine, Rituximab,Lenalidomide|Dose modification treatment plan of lenalidomide
10002518|NCT01558180|Experimental|Telephone Care Management|calls from a registered nurse to educate caregivers about behavioral sleep strategies
10002519|NCT01558180|Placebo Comparator|Usual Care|It's a placebo comparator because individuals in this group will receive an educational handout on behavioral sleep strategies. This handout approximates standard of care.
10002520|NCT01558193|Placebo Comparator|Placebo|Two placebos consumed
10002521|NCT01558193|Active Comparator|Multi-vitamin/mineral|Subjects took multi-vitamin/mineral and placebo fatty acid capsule
10002522|NCT01558193|Active Comparator|Docosahexaenoic acid|Subjects took docosahexaenoic acid capsule and placebo vitamins/minerals
10002523|NCT01558193|Active Comparator|DHA plus vitamins/minerals|Subjects took both fatty acid and vitamin/mineral supplements
10002524|NCT01558206||Patients with impression of PTE|Those with signs and symptoms in favor of pulmonary thromboembolism.
10002525|NCT01558219|Experimental|acitive anticancer drug|single cytostatic agent, cabazitaxel every second week in the treatment of castration resistant metastatic prostate cancer after docetaxel
10002526|NCT01558232|Experimental|Tibion Arm|Arm of the study in which enrolled subacute post-stroke subjects undergo lower extremity physical therapy using the Tibion Bionic Leg.
10002527|NCT01558245|Experimental|Tissue kallikrein group|Patients in this group will be prescribed with intravenous infusion of TK (0.15 PNAU/d, dissolved in 100ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
10002528|NCT01558245|No Intervention|Control group|Patients in control group will receive foundation treatment, including aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
9528602|NCT03209401|Experimental|Niraparib and Carboplatin|"Niraparib will be administered orally, once daily for 21 days of each 21-day cycle in escalating doses depending on cohort patient is assigned to.~Carboplatin will be administered via an injection on Day 2 of a given 21-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
9528603|NCT03209609|Experimental|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
9528604|NCT03209609|Active Comparator|Standard of care vein grafts|Coronary artery bypass vein grafts
10002529|NCT01558258|Experimental|Mindfullness Meditation-based Intervention|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
10002530|NCT01558258|No Intervention|Wait-list control group|The wait-list control condition will control for naturally occurring changes in stress and other outcomes over the six-week intervention period. After the post-treatment assessments have been completed, those assigned to the wait-list control group will be able to participate in the MAP classes.
10002531|NCT01558310|Active Comparator|Group A|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52.The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
10002532|NCT01558310|Placebo Comparator|Group B|Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
10002533|NCT01558323|Experimental|LCQ908 (mild renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with mild renal impairment and will receive a single 40 mg dose of LCQ908.
10002534|NCT01558323|Experimental|LCQ908 (moderate renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with moderate renal impairment and will receive a single 40 mg dose of LCQ908.
10002535|NCT01558323|Experimental|LCQ908 (severe renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with severe renal impairment and will receive a single 40 mg dose of LCQ908.
10002536|NCT01558336|Experimental|Praziguantel|tablet single dose
10002537|NCT01558349||Hospitalized controls|Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
10002538|NCT01558349||Metastatic melanoma|This cohort includes patients with metastatic melanoma.
10002539|NCT01558362|Experimental|123I-CMICE-013|Administration and analysis of alternative MPI radiotracer
10002540|NCT01558375|Placebo Comparator|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
10002541|NCT01558375|Experimental|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
10002542|NCT01558388|Experimental|Vaginal lactobacilli|
10002543|NCT01558388|Placebo Comparator|Placebo|
10002544|NCT01558401|Experimental|Physical activity program Group|The physical activity program consists of 123 sessions over 52 weeks. The initial assessment is followed by 12 weeks of physical activity. After this ten-week period, a second assessment is performed, followed by 3 weeks of rest. This is followed by a further 17 weeks of activities, 4 weeks of activities followed by 4 weeks of rest. Finally, there were 12 more weeks of activities.
10002545|NCT01558414|Experimental|SILS|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
10002546|NCT01558414|Experimental|FSIS|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
10002547|NCT01558414|Active Comparator|Conventional laparoscopy|Cholecystectomy performed by a conventional laparoscopic approach
10002548|NCT01558427|Experimental|Active clinical surveillance|Active monitoring of patients with low volume metastases with Prostate Specific Antigen (PSA) and sequential imaging.
10002549|NCT01558427|Experimental|Salvage treatment of metastases|Surgical or radiotherapy treatment of metastases.
10002550|NCT01558440|Active Comparator|Infant Formula|A diet that is being fed to the young infants
9528764|NCT03207997|Experimental|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC> 75% theoretical and DLCO / VA> 55%) 2 additional unenhanced MR sequences
9528765|NCT03207997|Experimental|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
9528605|NCT03209349|Experimental|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
9528766|NCT03207997|Experimental|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC <50% theoretical or DLCO / VA <35%). 2 additional unenhanced MR sequences
9942813|NCT01013623|Active Comparator|Best Medical Therapy|The best medical therapy group will not initially undergo surgery, but will be treated with the therapy that medical oncologists or surgeons feel is best for the patient. This treatment may include standard or experimental therapies.
9942814|NCT01013623|Active Comparator|Surgery Alone|The surgery alone group will undergo complete resection (surgical removal) of all known disease, if possible. After surgery, patients will be followed regularly and monitored for disease recurrence.
9942815|NCT01013623|Active Comparator|Surgery + BCG|The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
9942816|NCT01013636||Anaplasma|
9942817|NCT01013662|Active Comparator|glycemic control between 180 and 220 mg/dl|
9942818|NCT01013662|Active Comparator|glycemic control for levels between 80 and 110 mg/dl|
9942819|NCT01013675|Experimental|1|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
9942820|NCT01013675|Active Comparator|2|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
9942821|NCT01013688|Experimental|left atrial RF ablation groups|Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall
9942822|NCT01013688|Experimental|Bi-atrial radiofrequency ablation group|In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove
9942823|NCT01013688|No Intervention|Amiodarone group|No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery
9942824|NCT01013714|Active Comparator|Routine Care + Cardiac Sympathetic Denervation (CSD)|"Patients in this arm receive routine care and undergo cardiac sympathetic denervation. The procedure must be scheduled to occur within one month of randomization.~Follow-up Visits~Follow up at 4 weeks after optimization of medical therapy and surgery~All patients are followed at the ICD clinic at 7 months or as needed.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
9942825|NCT01013714|Placebo Comparator|Routine Care|"Patients in this arm remain on prescribed drug regimen and will not undergo CSD.~Follow-up Visits~Medical follow up at 4 weeks after optimization of medical therapy.~All patients are followed at the ICD clinic at 7 months or as needed.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
9942826|NCT01013727|Experimental|Postural Reconstruction|
9942827|NCT01013727|Active Comparator|muscular stretching|
9942828|NCT01013766|Other|AM/PM/BID|Subjects will receive a dose of 100mg in the AM on Day 1, followed by a dose of 100mg in the PM on Day 4, and a dose of 50mg BID on Day 6.
9942829|NCT01013766|Other|PM/AM/BID|Subjects will receive a dose of 100mg in the PM on Day 1, followed by a dose of 100mg in the AM on Day 4, followed by 50mg BID on Day 6.
9942830|NCT01013779|Experimental|Arm A|Conventional radical radiotherapy in this trial means that those patients with microscopic disease receive a dose of 50Gy using daily incremental fractions of 2Gy over 25 fractions and those with macroscopic disease receive 54Gy in 27 fractions.
9942831|NCT01013805|Experimental|Arm 1|Integrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
9942832|NCT01013818|Experimental|HGS1029|
9942833|NCT01013831|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
9942834|NCT01013896|Active Comparator|Cystic Fibrosis Education|This intervention is designed to increase knowledge and enhance the skills needed to optimize CF-management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem-solving training to overcome barriers.
9942835|NCT01013896|Experimental|Motivational Interviewing|The Counselor's overarching goal for the intervention is to motivate and assist the participant to improve his/her adherence to the CF pulmonary medications. The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic-level figures showing the association between adherence and health outcomes.
9942836|NCT01013909|Experimental|Arm 1|
9942837|NCT01013909|Experimental|Arm 2|
9942838|NCT01013909|Placebo Comparator|Arm 3|
9942839|NCT01013909|Placebo Comparator|Arm 4|
9942840|NCT01013909|Active Comparator|Arm 5|
9942841|NCT01013922||No treatment|Patients with a smoking history of 15 pack years or more.
9942842|NCT01013935|Active Comparator|Full CARE+ Spanish computer-counseling group|
9942843|NCT01013935|Active Comparator|Brief risk assessment study group only (control)|
9942844|NCT01013948||N/A (Survey study)|
9528767|NCT03207997|Active Comparator|Control group|2 additional unenhanced MR sequences
9942845|NCT01013974|Experimental|GSK573719 250 microgram (μg) arm|Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
9942846|NCT01013974|Experimental|GSK573719 500 μg arm|Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
9942847|NCT01013974|Experimental|GSK573719 1000 μg arm|Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
9942848|NCT01013974|Placebo Comparator|Placebo|Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
9942849|NCT01014000|Active Comparator|Empirical|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
9942850|NCT01014000|Experimental|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
9942851|NCT01014039|Active Comparator|Flexible Sigmoidoscopy Screening arm|Intervention by flexible sigmoidoscopy screening
9942852|NCT01014039|No Intervention|Control arm|No intervention (no screening)
9942853|NCT01014065||1|Patients with renal cell carcinoma scheduled to receive sunitinib
9942854|NCT01014104|Experimental|Case|Administration of Methylprednisolone
9942855|NCT01014104|Sham Comparator|Control|
9942856|NCT01014117|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days.~A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days."
9942857|NCT01014117|Active Comparator|Placebo and 2.0g SRT2104|This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
10035128|NCT01803295|Experimental|40 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
10035129|NCT01803295|Active Comparator|Standard of care MMC mixed with water|40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
10002551|NCT01558440|Experimental|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
10002552|NCT01558440|Experimental|Diluted F-100|300 ml of water is added to 1000 ml of F-100
10002553|NCT01558453|Experimental|Eloxatin|Oxaliplatin
10002554|NCT01558466|Placebo Comparator|Group A - Placebo|iNO combined with placebo will be administered
10002555|NCT01558466|Active Comparator|Group B- Sildenafil|iNO combined with Sildenafil
10002556|NCT01558479||Case|Has a diagnosis of Parkinson's disease
10002557|NCT01558479||Control|No diagnosis of Parkinson's disease
10002558|NCT01558479||Family Member|Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease
10002559|NCT01558505|Active Comparator|standard PTA|conventional balloon angioplasty
10002560|NCT01558505|Experimental|Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty
10002561|NCT01558531||DEB|paclitaxel-eluting balloon angioplasty
10002562|NCT01558531||conventional PTA|historical conventional balloon angioplasty control group (patients referred to our institution between 2008 and 2009)
10002563|NCT01558557|Experimental|Gluten Free Diet|
10002564|NCT01558570||Schizophrenia|
10002565|NCT01558583|Other|Rating and Ranking Group|A group of individuals from the United States and Australia who complete a rating and ranking task.
10002566|NCT01558583|Other|Discrete Choice Group|A group of individuals from the United States and Australia who complete a discrete choice experiment task.
10002567|NCT01558583|Other|Balance Sheet Group|Individuals from the United States and Australia who will complete an implicit values clarification task
10002568|NCT01558622|Placebo Comparator|dexketoprofen trometamol|Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
10002569|NCT01558622|Placebo Comparator|tramadol hydrochloride|Tramadol Hydrochloride is a well-known centrally acting opioid pain killer.
10002570|NCT01558622|Placebo Comparator|pethidine hydrochloride|Pethidine is a synthetic opioid analgesic which produces a pattern of effects similar to morphine the standard against which opioid analgesics are compared.
10002571|NCT01558622|Placebo Comparator|dexketoprofen trometamol + tramadol hydrochloride|
10002572|NCT01558622|Placebo Comparator|dexketoprofen trometamol + pethidine hydrochloride|
10002573|NCT01558622|Placebo Comparator|vitamin c|
10002574|NCT01558648||Pts having Minimally Invasive esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
10002575|NCT01558648||Pts having open esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
10002576|NCT01558687|Experimental|Group A = Cilengitide Group|Cilengitide + SoC (Temolozomide + Radiotherapy)
10002577|NCT01558687|Active Comparator|Group B = Control Group|SoC (Temolozomide + Radiotherapy)
10002578|NCT01558713|Active Comparator|Group BFS|Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
10002579|NCT01558713|Active Comparator|Group RFS|Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
10002580|NCT01558713|Active Comparator|Group LFS|Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
10002581|NCT01558713|Active Comparator|BupivacaineF|Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY
10002582|NCT01558713|Active Comparator|RopivacaineF|Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.
10002583|NCT01558713|Active Comparator|LevobupivacaineF|Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.
10002584|NCT01558726|Experimental|Case management|
10002585|NCT01558726|Active Comparator|Usual treatment|Usual treatment of the CAPSad
10035130|NCT01803295|Experimental|80 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
10035131|NCT01803308|Experimental|Experimental Part A|"Experimental: Part A: Part A will use a single ascending dose protocol in small, open-label cohorts to determine the starting dose for Part B in the potentially therapeutic range.~Intervention: SB9200"
10035132|NCT01803308|Experimental|Experimental Part B|"Experimental: Part B: Part B will use a multiple ascending dose protocol to further explore the safety, tolerability, pharmacokinetics and pharmacodynamics of SB9200 over 7-14 days of dosing.~Intervention: SB9200 and Placebo"
9528606|NCT03209349|Active Comparator|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
9528607|NCT03209037|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
9528608|NCT03209037|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
9528609|NCT03209245|Active Comparator|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
9528610|NCT03209245|Placebo Comparator|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
9528611|NCT03209258|Other|Goal-directed care bundle|Management policy to receive a goal-directed care bundle that involves the rapid correction (<1 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 7 days or hospital discharge (or death, if sooner)
9528612|NCT03209258|Other|Usual care group|Patients receive the usual management based on local guidelines and hospital's individual policy.
9528613|NCT03209180|Active Comparator|Carvedilol IR (Immediate Release)|Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months
9528614|NCT03209180|Experimental|CarVeDilol-SR (Slow Release)|CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months
9942858|NCT01014117|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
9942859|NCT01014130|Active Comparator|Arm 2|Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
9942860|NCT01014130|Experimental|Arm 1|Hypofractionated radiotherapy (HypoRT) - Investigational
9942861|NCT01014156|Experimental|epoprostenol intraveneously|epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
9942862|NCT01014182||Early PCI|Routine invasive strategy with early PCI performed in STEMI patients within 24 hours from successful fibrinolysis
9942863|NCT01014182||Standard Therapy|Standard therapy in STEMI patients with fibrinolysis and/or conventional ischaemic-guided therapy.
9942864|NCT01014195||Group 1|"Survivors of pediatric leukemia treated on Total Therapy Protocol XV (TOTXV) at St. Jude Children's Research Hospital (SJCRH), who are ≥ 8 years of age and ≥ 5 years from diagnosis.~Intervention: Neurocognitive and behavioral evaluation"
9942865|NCT01014221|Experimental|Acupuncture group|acupuncture administered in 8 sessions over 4 weeks
9942866|NCT01014221|Active Comparator|Steroid group|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
9942867|NCT01014234|Experimental|Rapamycin|Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
9942868|NCT01014234|Active Comparator|cyclosporine|Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
9942869|NCT01014247|Active Comparator|Arm 1|
9942870|NCT01014247|Placebo Comparator|Arm 2|
9942871|NCT01014260|Placebo Comparator|Placebo|placebo
9942872|NCT01014260|Active Comparator|Doxycycline|Doxycycline
9942873|NCT01014273|Active Comparator|Trans-femoral access|Femoral artery PCI access site
9942874|NCT01014273|Active Comparator|Trans-radial access|Radial artery PCI access site
9942875|NCT01014312|Experimental|Depression Care Management (DCM)|Participants will receive Depression Care Management.
9942876|NCT01014312|Active Comparator|Enhanced Care|Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.
9942877|NCT01014325|Experimental|Allergen extract|
9942878|NCT01014325|Placebo Comparator|Placebo|
9942879|NCT01014338|Active Comparator|ACE-inhibitor|
9942880|NCT01014338|Placebo Comparator|Sugar Pill|
9942881|NCT01014364|Experimental|Corticosteroids|Hydrocortisone
9942882|NCT01014364|Placebo Comparator|Control|isotonic saline
9942883|NCT01014416|Experimental|Arm 1|Single dose, Tolvaptan 15mg or Placebo/day
9942884|NCT01014416|Experimental|Arm 2|Single dose, Tolvaptan 30mg or Placebo/day
9942885|NCT01014416|Experimental|Arm 3|Single dose, Tolvaptan 60mg or Placebo/day
9942886|NCT01014429|Experimental|1|
9942887|NCT01014468|Active Comparator|Ranibizumab|Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
9942888|NCT01014468|Active Comparator|Bevacizumab|Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)
9942889|NCT01014481|Experimental|start antiretroviral treatment|the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment
9942890|NCT01014494|Experimental|Active - Adaprev|Adaprev (Class III medical device)
9942891|NCT01014494|No Intervention|Standard Care|No different treatment to normal
9942892|NCT01014507|Active Comparator|A|
10002586|NCT01558765|Experimental|Intervention group|Patients receive integrated rehabilitation
10002587|NCT01558765|No Intervention|Control group|Patients receive usual follow-up care without physical exercise
10002588|NCT01558778|Experimental|Supportive care (whole body vibration)|Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
10002589|NCT01558817|Active Comparator|Informational brochure|Patients receive an informational brochure
10002590|NCT01558817|Experimental|Intervention|Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
10002591|NCT01558830|Placebo Comparator|sugar pill|one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
10002592|NCT01558830|Active Comparator|Ranolazine|500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
10002593|NCT01558843||traumatic brain injury|
10002594|NCT01558843||aneurysmal subarachnoid hemorrhage|
10002595|NCT01558843||intracerebral hematoma|
10002596|NCT01558843||brain tumor|
10002597|NCT01558856|Active Comparator|Unilateral testing|"Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves.~Intervention: Unilateral electrode placement and testing"
10002598|NCT01558856|Experimental|Bilateral testing|"Patients in this group will have bilateral testing for neuromodulation of the sacral nerves.~Intervention: Bilateral electrode placement and testing"
10002599|NCT01558869|Experimental|Arm 1|
10002600|NCT01558882||10 patients|The patients included desire tubal sterilization via the ESSURE technique.
10002601|NCT01558895|Experimental|Conventional Treatment and Infrared ray heat treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
10002602|NCT01558895|Active Comparator|conventional treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
10002603|NCT01558908|Experimental|Intramuscular injection of ERC|
10002604|NCT01558921|Experimental|B: 5x5Gy -> CAPOX -> surgery|experimental group (arm B) M1 scheme
10002605|NCT01558921|Active Comparator|A: 5 weeks chemoradiation -> surgery|control group (arm A) standard long course chemoradiotherapy
10002606|NCT01558934|Experimental|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume. If the therapeutic dose is not reached under 50% methadone reduction conditions, the methadone dose will be further reduced to 0 mg for 2 days followed by reintroduction of 25% of the starting dose on the 3rd day, and on such 3rd day lofexidine titration will resume again.
10002607|NCT01558947|Experimental|chemotherapy with ECX|chemotherapy with ECX
10002608|NCT01558947|Experimental|chemotherapy with XP|chemotherapy with XP
10002609|NCT01558960|Experimental|IVit Treatment group|Intravitreal injections of Melphalan
10002610|NCT01558973||Cocaine dependent|
10002611|NCT01558973||Opioid dependent|
10002612|NCT01558973||Alcohol dependent|
10002613|NCT01558973||Healthy controls|
10002614|NCT01558973||Adolescents|
10002615|NCT01558973||Pathological gamblers|
10002616|NCT01558986|Active Comparator|Treatment Arm|Patients to receive intravenous cefazolin 1 gram within 30 minutes prior to skin incision
10002617|NCT01558986|Placebo Comparator|Placebo Arm|Patients to receive sterile water only within 30 minutes prior to skin incision
10002618|NCT01559025|No Intervention|Insulin therapy|Patients will receive the conventional treatment with insulin
10002619|NCT01559025|Active Comparator|Vildagliptin|Patients will receive vildagliptin besides the conventional treatment with insulin
10002620|NCT01559038||adalimumab|Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
10002621|NCT01559038||DMARD (disease-modifying antirheumatic drugs)|Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
10002622|NCT01559051|Experimental|Intravenous Injection and Inhalation infusion of AD-SVF|AD-SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation
10002623|NCT01559077|Active Comparator|ALN-TTR02|
10002624|NCT01559077|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
10002625|NCT01559103|Experimental|MEDI5117|Intravenous infusion administered over 60 minutes
10002626|NCT01559103|Placebo Comparator|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
10002627|NCT01559142|Active Comparator|IFX TG|
10002628|NCT01559142|Active Comparator|IFX alone|
10002629|NCT01559155||Bullous pemphigoid|Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
10002630|NCT01559155||Other bullous-like auto-immune|Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
10002631|NCT01559155||Control group|Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.
10002632|NCT01559168|Experimental|Prolapse patients recieving UpHold LITE|Non-pregnant female patients >= 50 years who are not considering future pregnancies, who are diagnosed with uterine or vault prolapse with ICS POP-Q score of stage 2 or greater, who are receiving the UpholdTM LITE mesh kit and who agree to be in the study.
9528615|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
9942893|NCT01014507|Experimental|B|
9942894|NCT01014520|Experimental|Gabapentin|Neurontin
9942895|NCT01014520|Experimental|Amitriptyline|Elavil
9942896|NCT01014546|Experimental|Treatment (arsenic trioxide with or without ascorbic acid)|Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
9942897|NCT01014559|Active Comparator|Prolonged release tablet|OxyCodone Naloxone controlled release tablet
9942898|NCT01014559|Active Comparator|Tablet|Oxycodone PR Tablets
9942899|NCT01014598|Experimental|Treatment (cisplatin)|Patients receive cisplatin intra-arterially via isolated lung suffusion over 2 hours. Beginning approximately 2 weeks later (6-8 weeks if indicated for patients with sarcoma undergoing surgery after cisplatin), patients receive standard chemotherapy regimen.
9942900|NCT01014611||Class II NYHA Heart Failure|Fraction of ejection between 40% and 30%
9942901|NCT01014611||Class III NYHA Heart Failure|Fraction of ejection lower than 30%
9942902|NCT01014611||Healthy volunteers|Matched with patients on age and physical activity
9942903|NCT01014637|Active Comparator|Amorolfine 5%|
9942904|NCT01014637|Experimental|RV4104A-cylcopiroxolamine-ciclopirox|
9942905|NCT01014650|Placebo Comparator|IV normal saline|Single IV dose of normal saline as a control for safety and tolerability observations
9942906|NCT01014650|Experimental|IV GLYX-13|Single IV dose of GLYX-13
9942907|NCT01014650|Experimental|SC GLYX-13|Single SC dose
9942908|NCT01014663|Active Comparator|Therapeutic Exercise|
9942909|NCT01014663|Active Comparator|Non-Contact Boxing Training|
9942910|NCT01014676|Active Comparator|Probiotic milk|
9942911|NCT01014676|Placebo Comparator|Standard milk|
9942912|NCT01014702|Experimental|Laser Treatment|
9942913|NCT01014702|Active Comparator|Phacoemulsifcation|
9942914|NCT01014715|Other|Single Arm|Phase II-Preoperative Radiation followed by Lumpectomy
9942915|NCT01014754||NSF|Biopsy-proven diagnosis of NSF
9942916|NCT01014754||Kidney dysfunction plus gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have had a medical imaging procedure using GBCA in the 2 years prior to skin biopsy.
9942917|NCT01014754||Kidney dysfunction without gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have never been exposed to GBCA and have had skin biopsy.
9942918|NCT01014754||Normal kidney function with gadolinium exposure|Those with normal kidney function who have undergone a medical imaging procedure using Gd-based contrast agent (GBCA) in the 2 years prior to a skin biopsy.
9942919|NCT01014754||Normal kidneys without gadolinium exposure|Those with normal kidney function who have never been exposed to GBCA and have had a skin biopsy.
10002633|NCT01559181||Exposure to intrauterine hyperglycemia|The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c.
10002634|NCT01559181||Control group|The control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
10002635|NCT01559194|Active Comparator|Low Fat Diet + Exercise|Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
10002636|NCT01559194|Active Comparator|Low Carbohydrate Diet + Exercise|Subjects were educated about a low carbohydrate diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
10002637|NCT01559207||Patients with VTE|"Group P is composed of all patients with a history of VTE. Group Px is a subgroup of 15 patients from group P. Members of Px are randomly selected from P."
10002638|NCT01559207||Healthy volunteers|"Group T: 15 healthy volunteers with no history of VTE will be included in this group."
10002639|NCT01559220|Experimental|Open Label|DBS Implant and stimulation
10002640|NCT01559233|Experimental|FPlus|
10002641|NCT01559246||Cardiac Arrhythmia|Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
10002642|NCT01559272|Experimental|Panel A|Panel A consists of 2 treatment groups
10002643|NCT01559272|Experimental|Panel B|Panel B consists of 5 treatment groups
10002644|NCT01559272|Experimental|Panel C|Panel C consists of 1 treatment group
10002645|NCT01559272|Experimental|Panel D|Panel D consists of 4 treatment groups
10002646|NCT01559285|Active Comparator|0.375% ropivacaine|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
10002647|NCT01559285|Active Comparator|0.75% ropivacaine|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
10002648|NCT01559285|Active Comparator|0.2% ropivacaine|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
10002649|NCT01559298|Active Comparator|Aspirin + clopidogrel|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d) + clopidogrel (75 mg/d) following the TAVI procedure.
10002650|NCT01559298|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d)
10002651|NCT01559324|Experimental|Bifrontal ECT (BF)|Formula-based low dose BF ECT
10002652|NCT01559324|Experimental|Right unilateral ECT (RU)|Formula-based high-dose RU ECT
10002653|NCT01559337|Other|Nerve repair|the dorsal branch of the proper digital nerve was used as a pedicle nerve for reconstructing PDN defects
10002654|NCT01559350||RGEA group|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
10002655|NCT01559350||SVG group|A saphenous vein grafting in the right coronary artery system during OPCAB
10002656|NCT01559376||Endoscopic radial artery harvest|
10002657|NCT01559376||Conventional open radial artery harvest|
10002658|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with an inspiratory oxygen fraction(FIO2) of 1.0, supplied by a continuous positive airway pressure of 10 centimeters of water(cmH2O), during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled CPAP and 100% oxygen.
10002659|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 31%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, supplied by a continuous positive airway pressure of 10 cmH2O, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 0.3 is used. The intervention associated with this arm is labeled CPAP and 31% oxygen.
10002660|NCT01559402|Experimental|Start O2 100% and CPAP 0, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, without a continuous positive airway pressure, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled No CPAP and 100% oxygen.
10002661|NCT01559415|Experimental|Very Low Calorie Diet|
9528616|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
10002662|NCT01559415|Active Comparator|Low Calorie Diet|1250 kcal diet in which Modifast is given in combination with a normal diet
10002663|NCT01559428|Experimental|Plant sterol-enriched margarine|
10002664|NCT01559428|Experimental|Plant stanol-enriched margarine|
10002665|NCT01559428|Placebo Comparator|Control margarine|
10002666|NCT01559441|Experimental|Beetroot juice|
10002667|NCT01559441|Placebo Comparator|Carbohydrate control drink|
10002668|NCT01559467|Other|Routine clinical care plus early CMR|
10002669|NCT01559467|No Intervention|Routine clinical care|
10002670|NCT01559467|Other|Routine clinical care plus early CTA|
10002671|NCT01559480|Active Comparator|Desogestrel|
10002672|NCT01559480|Placebo Comparator|Placebo|
10002673|NCT01559493||FFR; iFR|Interventional Cardiology, Pressure wire, fractional flow reserve, coronary flow measurement
10002674|NCT01559519|Active Comparator|albumin|cirrhotic patients who underwent tips placement
10002675|NCT01559532||ATK patients|Patients from our institution that underwent cemented TKA for degenerative knee disorders.
10002676|NCT01559545|Active Comparator|Metronidazole|Immediate release metronidazole
10002677|NCT01559545|Experimental|Metronidazole-DRF1|Modified release metronidazole (DRF1)
10002678|NCT01559545|Experimental|Metronidazole-DRF2|Modified release metronidazole (DRF2)
10002679|NCT01559558||cystocele|
10002680|NCT01559584|Experimental|Phototherapeutic|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
10002681|NCT01559584|Active Comparator|Conventional therapy|One monthly injections of intralesional potent corticosteroids
10002682|NCT01559597|Active Comparator|Cold chain|Group vaccinated with tetanus toxoid vaccine kept in cold chain
10002683|NCT01559597|Experimental|CTC|Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain
10002684|NCT01559610|No Intervention|Control Group|Received preoperative guidance by a member of healthcare team with the aid of checklist
10002685|NCT01559610|Other|Group intervention|preoperative guideline by a nurse
10002686|NCT01559636|Active Comparator|Diarrhea|Infants with diarrhea will have blood and stool sample taken and receive zinc and ORS. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
10002687|NCT01559636|Active Comparator|Non-diarrhea|Infants without diarrhea will have blood and stool sample taken and receive multivitamins. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
10002688|NCT01559662|Experimental|Sugared Chewing Gum|Patient asked to chew sugared chewing gum postoperative day 1 to 7, 3 times a day, 45 minutes at a time
10002689|NCT01559662|No Intervention|No Gum|No gum given, routine postoperative care provided
10002690|NCT01559688|Experimental|ART therapy group|Participants in this arm will receive 2-5 sessions of ART therapy, depending on individual progress. Each session will last 60-90 minutes over a 2-week period.
10002691|NCT01559688|Active Comparator|Waitlist|Participants in this group will receive 2 fitness assessment or career counseling sessions. Each session will last 60-90 minutes over a 2-week period. Upon completion of this arm, participants will be offered the choice to start ART therapy.
10002692|NCT01559714||Clinical HCM patients|Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC and ACCF/AHA guidelines
9476270|NCT03573531||Donor Human Milk|Donor Human Milk (processed by a human milk bank) Sampled at two different neonatal units in the United Kingdom Collection of 5 ml of otherwise routinely discarded donor human milk
10002693|NCT01559714||Pre-clinical HCM patients|Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy
10002694|NCT01559727|No Intervention|Control|The patients with symptomatic heart failure were treated with standard treatment.
10002695|NCT01559727|Experimental|15 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
10002696|NCT01559727|Experimental|30 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
10002697|NCT01559727|Experimental|60 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
10035133|NCT01803321|Experimental|Cohort 1|Dose 1
9528617|NCT03209297|Experimental|Direct treatment|Patients receive the TMD treatment immediately
10002698|NCT01559740|Experimental|0.25% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 1 receiving a TAP block with 0.25% bupivacaine with 1:200,000 epinephrine at a dose of 1 mL/kg.
10002699|NCT01559740|Experimental|0.125% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 2 will receive a TAP block with a total dose of 1 mL/kg given at a concentration of 0.125% bupivacaine with 1:200,000 epinephrine.
10002700|NCT01559753|Experimental|8 days of antibiotic treatment|Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
10002701|NCT01559753|Active Comparator|15 days antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.
9528618|NCT03209297|Experimental|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
9528619|NCT03209063||Group 1|90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy.
10002702|NCT01559766||4-6 years old group|
10002703|NCT01559766||7-9 years old group|
9528620|NCT03209063||Group 2|90 Patients having history of two or more miscarriages.
9528621|NCT03209076|Experimental|Robotic|Robotic low anterior resection
9528622|NCT03209076|Active Comparator|Laparoscopic|Laparoscopic low anterior resection
9528623|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
9528624|NCT03209310||Control Group|Children with typical development were included in this study
9528625|NCT03209115|Active Comparator|calcium hydroxide and chlorhexidine|Removal of old root canal filling and placing calcium hydroxide and chlorehexidine as intracanal medication
9528626|NCT03209115|Active Comparator|calcium hydroxide|Removal of old root canal filling and placing calcium hydroxide as intracanal medication
10002704|NCT01559779||Normal glucose tolerance|Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery
10002705|NCT01559818|Experimental|IMM-101|IMM-101 1.0 mg administered intradermally
10002706|NCT01559831|Other|IXIARO|IXIARO, applied according to licensed dose, intramuscular
10002707|NCT01559870||patients with elective cardiac surgery|adult patients who had undergone elective cardiac surgery with CPB
10002708|NCT01559883||all eligible patients|there is only 1 Cohort in which all patients participating in this NIS are included
10002709|NCT01559896|Experimental|intervention and placebo|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
10002710|NCT01559909|Experimental|Socket wall height|
10002711|NCT01559961|Experimental|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
10002712|NCT01559974|Active Comparator|Vitamin D|
10002713|NCT01559974|Placebo Comparator|Placebo|
10002714|NCT01559987|Other|Control|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
9528627|NCT03209323|Experimental|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
9528768|NCT03207971|Active Comparator|SCTG from palatal area with predominance of lamina propria|
10002715|NCT01559987|Other|Test|MTB + Floss
10002716|NCT01559987|Experimental|MTB + Waterpik Ultra Water Flosser High|MTB + Waterpik Ultra Water Flosser High
10002717|NCT01560000|Other|fiber|
10002718|NCT01560013|Experimental|Naltrexone|Treatment with naltrexone for two months together with psycho-social support
10002719|NCT01560026||ovarian preservation|endometrial cancer with ovarian preservation
10002720|NCT01560026||oophorectomy|endometrial cancer without ovarian preservation
10002721|NCT01560039|Active Comparator|Real EEG-NF|10 EEG based neurofeedback sessions modulating the activity of the primary motor cortex
10002722|NCT01560039|Sham Comparator|Sham EEG-NF|10 sessions of Sham EEG_NF of the motor cortex area
10002723|NCT01560039|Active Comparator|Transcrainal Magnetic Stimulation|10 dailt TMS stimulation sessions of M1
10002724|NCT01560052|Active Comparator|oral methylprednisolone|"oral methylprednisolone~Original Cohort:~Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~Low Dose Cohort:~Methylprednisolone group; start at 0.4mg /kg/day with a maximal dose of 32mg/day and a minimum dose of 24mg/day, reducing over 6-9months.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
10035134|NCT01803321|Experimental|Cohort 2|Dose 2
10035135|NCT01803334|Experimental|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
10035136|NCT01803334|No Intervention|Control|If she is randomized to the control group, then she will undergo traditional preoperative counseling by the same team without marking the abdomen.
9528628|NCT03209323|Experimental|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
9528629|NCT03209323|Experimental|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
9528630|NCT03209128||Irradiation prophyllactique cérébrale|
9942920|NCT01014754||Controls|Existing skin tissue from neonatal skin (<6 months) will be used as controls, as they presumably have never been exposed to gadolinium
9942921|NCT01014780||Normal (non-dry) dry eye subjects|These are healthy individuals, age 18 and above, who do not exhibit dry eyes by signs and symptoms
9942922|NCT01014780||Dry eye subjects|These are subjects, age 18 years and above, who do exhibit signs and symptoms of dry eye.
9942923|NCT01014793||Responders to cabergoline|patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
9942924|NCT01014832|Experimental|Uncontrolled diabetes|Uncontrolled diabetes
9942925|NCT01014845|Experimental|Hepatitis E vaccine|Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
9942926|NCT01014845|Placebo Comparator|HBV vaccine|Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
9942927|NCT01014858|Experimental|Donepezil|5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient adjusted to 5mg dose. 10mg does continues for the remainder of the study.
9942928|NCT01014858|Placebo Comparator|Placebo|Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the remainder of the study.
9942929|NCT01014884|Other|Control Group|The control group will receive usual care as provided by your Health Plan.
9942930|NCT01014884|Other|Intervention group|Additional visits will be conducted by a member of the multidisciplinary team (case manager/nurse, social worker and/or pharmacist that will be either face to face or by telephone.
9942931|NCT01014897|Experimental|subcortical|Subcortical stroke patients will receive tDCS stimulation and sham in random order
9942932|NCT01014897|Experimental|cortical|subjects will receive active and sham tDCS in random order
9942933|NCT01014923|Experimental|Intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
9942934|NCT01014923|No Intervention|Control|Parents receive a Department of Transportation booklet on teen driving
9942935|NCT01014949|Other|Control, Diabetes and Metabolic Syndrome|
9942936|NCT01014962|Experimental|Albaconazole 400 mg cohort 1|Albaconazole 400 mg
9942937|NCT01014962|Placebo Comparator|Placebo cohort 1|Placebo once daily
9942938|NCT01014962|Experimental|Albaconozole 400 mg cohort 2|Albaconozole 400 mg every 12 hours
9942939|NCT01014962|Placebo Comparator|Placebo cohort 2|Placebo every 12 hours
9942940|NCT01014962|Experimental|Albaconozole 400 mg cohort 3|Albaconozole 400 mg every 8 hours
9942941|NCT01014962|Placebo Comparator|Placebo cohort 3|Placebo every 8 hours
9942942|NCT01015001|Active Comparator|Active rTMS|1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects
9942943|NCT01015001|Placebo Comparator|Sham rtms|Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region
9942944|NCT01015014|Active Comparator|AN3365|
9942945|NCT01015014|Placebo Comparator|Saline|
9942946|NCT01015027|Experimental|Dose 1|(3:1, active:placebo)
9942947|NCT01015027|Experimental|Dose 2|(3:1, active:placebo)
9942948|NCT01015027|Experimental|Dose 3|(3:1, active:placebo)
9942949|NCT01015027|Experimental|Dose 4|(3:1, active:placebo)
9942950|NCT01015040|Active Comparator|solifenacin succinate tablet (fasting)|
9942951|NCT01015040|Experimental|solifenacin succinate suspension (fasting)|
9942952|NCT01015040|Experimental|solifenacin succinate suspension (fed)|
9942953|NCT01015053|Experimental|Regional block|"An ultrasound-guided rectus sheath block will be performed by the regional block anesthesiologist in the regional block arm."
9942954|NCT01015053|Active Comparator|Wound infiltration|"Local wound infiltration will be performed by the surgeon in the wound infiltration arm."
9942955|NCT01015066|Active Comparator|buprenophine/naloxone|Participants with this arm will receive 4-16 mg/d buprenorphine/naloxone (Suboxone).
9942956|NCT01015066|Experimental|Naltrexone|Participants assigned to this arm will receive 50 mg/d naltrexone.
10002725|NCT01560052|Placebo Comparator|placebo|"Original Cohort:~Matching placebo; Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines; Low Dose Cohort; Matching placebo: Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
10002726|NCT01560065|Other|Normospermic patients|
10002727|NCT01560065|Other|Oligoasthenospermic patients|
10002728|NCT01560065|No Intervention|Control|
10002729|NCT01560091|Placebo Comparator|Group A|Patients will receive ESWL and no medication
10002730|NCT01560091|Active Comparator|Group B|Patients will receive Flomax after ESWL
9942957|NCT01015079||Entire Taiwan women|
9942958|NCT01015092||unselected HIV outpatient attendees|All HIV patients attending for general HIV care at 2 London Hospitals
9942959|NCT01015105||patients with hip fracture|
9942960|NCT01015144||Atorvastatin|
9942961|NCT01015144||No statin|
9942962|NCT01015157|Active Comparator|Standard stapling without reinforcement|Standard Echelon 60 linear stapling with GOLD cartridges
9942963|NCT01015157|Active Comparator|Seamguard gastric stapling line reinforcement|
9942964|NCT01015183|Experimental|Intervention|Received Zinc Sulfate
9942965|NCT01015183|Placebo Comparator|Control|Control group
9942966|NCT01015196|Active Comparator|Idarubicine|
9942967|NCT01015196|Experimental|Daunorubicine|
9942968|NCT01015209|Active Comparator|Cohort 1: 18 healthy subjects|18 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3% (6 subjects per group)
9942969|NCT01015209|Active Comparator|Cohort 2: 12 healthy patients|12 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3%
9942970|NCT01015235|Placebo Comparator|Arm 1: Placebo|Placebo
9942971|NCT01015235|Active Comparator|A2: KAI-1678|Test Drug
9942972|NCT01015235|Active Comparator|A3: Ketorolac|Active Comparator
9942973|NCT01015248|Experimental|Rituximab and Bendamustine|
9942974|NCT01015261|Experimental|Bone Marrow Transplantation|
9942975|NCT01015261|Active Comparator|Chemotherapy|
9942976|NCT01015274||Healthy control male|
9942977|NCT01015313|Experimental|intensive sodium management|
9942978|NCT01015313|No Intervention|standard care|
9942979|NCT01015339|Active Comparator|Cisplatin plus capecitabine|
9942980|NCT01015339|Experimental|Paclitaxel plus Capecitabine|
9942981|NCT01015352|Active Comparator|Arm A|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.
9942982|NCT01015352|Active Comparator|Arm B|"Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND~Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)~12 additional maintenance courses are planned in responders"
9942983|NCT01015365|Other|Surgical revision|Surgical cementless One-stage revision of the chronic infected hip arthroplasty
9942984|NCT01015378||Diverticulitis of the sigmoid colon - first episode|
9942985|NCT01015391|Experimental|T2|
9942986|NCT01015391|Active Comparator|AZA|
9942987|NCT01015404|Experimental|Experimental H|high volume (0.6mL、0.3% Trafermin)
9942988|NCT01015404|Experimental|Experimental L|low volume (0.2mL、0.3% Trafermin)
9942989|NCT01015417|Active Comparator|Amoxicillin clavulanic acid|Postoperative administration of 2g of Augmentin, 3 times daily for 5 days.
9942990|NCT01015417|Other|No medication|no postoperative antibiotics
9942991|NCT01015456|Experimental|1|Oral mycophenolate sodium 1440 mg per day for 12 months
9942992|NCT01015456|Active Comparator|2|Intravenous cyclophosphamide monthly for 6 months
9942993|NCT01015469|Active Comparator|Group A|Conventional laparoscopic Roux-en-Y gastric bypass (Golden Standard)
9942994|NCT01015469|Experimental|Group B|Conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
9942995|NCT01015482|Experimental|Remifentanil|Remifentanil Infusion
9942996|NCT01015482|Active Comparator|Midazolam|Active Placebo
9942997|NCT01015495|Experimental|ranibizumab|
9942998|NCT01015508|Other|High predisposition|High predisposition for weight regain
9942999|NCT01015508|Other|low predisposition|low predisposition for weight regain
9943000|NCT01015508|Other|Medium predisposition|Medium predisposition for weight regain
9943001|NCT01015521|Experimental|Aminoflavone Prodrug|Aminoflavone to treat ER positive breast cancer patients
9943002|NCT01015521|Experimental|Aminoflavone Prodrug with pretreatment|Aminoflavone Prodrug to treat Triple Negative Breast Cancer
9943003|NCT01015547|Experimental|Infliximab plus Methotrexate|infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
9943004|NCT01015547|Experimental|Combination of DMARDs|methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
9943005|NCT01015547|Active Comparator|Methotrexate alone|Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
9943006|NCT01015573|Experimental|healthy subjects|
9943007|NCT01015599|Experimental|HOP'N After-School Program|After-school program with daily physical activity following CATCH guidelines, daily fruit/vegetable snack, and weekly nutrition and physical activity education based on social cognitive theory.
9943008|NCT01015625|Other|A: Surgical Therapy|Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).
9943009|NCT01015625|Other|B: Surgery on Demand|In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.
9943010|NCT01015651|Active Comparator|remifentanil-2|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 2 ng/ml.
10002731|NCT01560091|Active Comparator|Group C|Patients will receive silodosin after ESWL
10002732|NCT01560130|Active Comparator|Shape Up Rhode Island + Online Weight Loss + Incentives|
10002733|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program|
10002734|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|
9528631|NCT03209336|Experimental|A group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated by surgical resection and the radiotherapy is given during the operation after the removal of the tumour.
9528632|NCT03209336|No Intervention|B group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated only by surgical resection and no radiotherapy afer the removal of the tumour.
10002735|NCT01560169||Gluten challenge|Gluten containing or gluten-free study food in established celiac disease patients
10002736|NCT01560169||Observation|Observation in newly diagnosed celiac disease patients
10002737|NCT01560182|Experimental|OTL-200 Gene Therapy|CD34+ cells transduced ex vivo with lentiviral vector encoding ARSA cDNA
10002738|NCT01560195|Experimental|Pegylated rhG-CSF: 100µg/kg|Staged III or IV NSCLC patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
10002739|NCT01560195|Experimental|Pegylated rhG-CSF: 6mg|Staged III or IV NSCLC patients receiving chemotherapy and pegylated rhG-CSF 6mg
10002740|NCT01560195|Placebo Comparator|Placebo|Staged III or IV NSCLC patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF in cycle 2 to 4
10002741|NCT01560221|Experimental|Therapeutic Workplace|Participants will receive all standard services plus the Therapeutic Workplace intervention, in which access to stipend supported training and/or wage subsidies for community employment is contingent upon drug abstinence as verified by urinalysis.
9528633|NCT03209193|Experimental|Sevoflurane|Sevoflurane (2 vol%) use as a maintenance volatile anesthetic drug during the surgery
9528634|NCT03209193|Experimental|Desflurane|Desflurane (6 vol%) use as a maintenance volatile anesthetic drug during the surgery
9528635|NCT03209219|Experimental|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
9528636|NCT03209219|Active Comparator|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
9528637|NCT03209102|Experimental|BPD adolescents|Adolescents suffering from Borderline Personality Disorder. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
9528638|NCT03209102|Experimental|Healthy controls adolescents|Healthy controls adolescents. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
9528639|NCT03209011|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
9528640|NCT03209011|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
9528641|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
10002742|NCT01560221|Active Comparator|Standard Services|Participants will receive methadone treatment or buprenorphine treatment, depending upon medical recommendations of their physicians, slot availability, and their own preferences. Participants who remain in treatment for at least 90 days will have the charge of prostitution that is pending against them dropped.
10002743|NCT01560247||Treatment Group|Subjects in whom a MindFrame Device was employed for restoration of flow and clot removal
10002744|NCT01560273||Aspen Spinous Process Fixation Device|The Aspen device provides supplemental posterior fixation for fusion
10002745|NCT01560299|Active Comparator|group one|This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
10002746|NCT01560299|Active Comparator|group two|methimazole stopped 48-72 hour before radioiodine therapy
10002747|NCT01560299|Active Comparator|group three|
10002748|NCT01560312|Experimental|Renal denervation|Renal denervation (Symplicity® Catheter System™) + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)
10002749|NCT01560312|No Intervention|Medical treatment|"Conventional antihypertensive treatment including spironolactone (if not contraindicated).~One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure."
10002750|NCT01560325|Experimental|CKD-516 inj.|CKD-516 Inj, 3.3~13mg/m2/day, D1, 4, 8, 11 every 3 weeks
10002751|NCT01560338||Pediatric after Cardiac Arrest|Pediatric patients greater than 3 kg. and less than 18 years suffering cardiac arrest who have been given or currently receiving morphine and/or midazolam and receiving hypothermia.
10002752|NCT01560351|Experimental|rTMS|Session of repeated low-frequency Transcranial Magnetic Stimulation
10002753|NCT01560351|Sham Comparator|Placebo|Sessions of sham rTMS
10002754|NCT01560364||Hemofilter|
10002755|NCT01560390|Other|Rémifentanil + Kétamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
10002756|NCT01560390|Other|Rémifentanil + Placebo|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
10002757|NCT01560442||buprenorphine|
10002758|NCT01560442||Methadone Hydrochloride|
10002759|NCT01560455|Active Comparator|single stent|single stent
10002760|NCT01560455|Active Comparator|dual stent|dual stent (culotte)
10002761|NCT01560468|Experimental|ITX 5061|Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.
9528642|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
9528643|NCT03209024|Other|Control|Participants complete a 3-week home blood pressure monitoring regimen using a handwritten logbook to record all blood pressure readings.
9528644|NCT03209024|Experimental|Intervention|Participants complete a 3-week home blood pressure monitoring regimen using a smartphone app and Bluetooth® technology to wirelessly record all blood pressure readings.
9528645|NCT03209154|Experimental|Study Group|Study Group intervention: Therapeutic drug monitoring.
9528646|NCT03209154|Active Comparator|Control Group|Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
9943011|NCT01015651|Active Comparator|remifentanil-4|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 4 ng/ml.
9943012|NCT01015690||unexplained infertility|patients with unexplained infertility
9943013|NCT01015690||healthy controls|women who wish to conceive, no more tha 3 previous cycles, age above 18
9943014|NCT01015690||references|lesbian women with a regular cycle without use of anticonception and not at risk of becoming pregnant
9943015|NCT01015716|Active Comparator|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
9943016|NCT01015716|Experimental|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
9943017|NCT01015729|Active Comparator|1|Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule
9943018|NCT01015729|Active Comparator|2|Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
9943019|NCT01015729|Active Comparator|3|Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
9943020|NCT01015742|Experimental|Experimental|Stem cell Transplant using two unrelated umbilical cord blood units.
9943021|NCT01015755|Experimental|thirst intervention|
9943022|NCT01015794|Experimental|Adrenergic agonist|
9943023|NCT01015846|Experimental|Intervention|
9943024|NCT01015846|Active Comparator|Core stability exercise|Traditional core stability exercise
9943025|NCT01015859|No Intervention|DDD long AV delay|Pacemaker is programmed in DDD mode with long AV delay (250 msec)
9943026|NCT01015859|Active Comparator|AAI SafeR|Pacemaker is programmed in AAI SafeR mode
9943027|NCT01015872|Experimental|CPAP|the subjects introduced with CPAP treatment
9943028|NCT01015898|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
9943029|NCT01015911|Experimental|1|SGN-75
9943030|NCT01015924|Active Comparator|Elastic Stable Intramedullary Nailing|Operative intervention with closed or open reduction and intramedullary stabilization of midshaft clavicle fractures
9943031|NCT01015924|Active Comparator|Plate osteosynthesis|Open reduction and plate fixation of midshaft clavicle fractures
9943032|NCT01015937|Active Comparator|Turmeric|"diabetic nephropathy patient~more than 300 mg/proteinuria"
9943033|NCT01015937|Active Comparator|ACE inhibitor + ATI blocker|"diabetic nephropathy~more than 300 mg/day proteinuria"
9943034|NCT01015950|Experimental|Pumpy'Sup|Lipid-based nutrient supplement
9943035|NCT01015950|Experimental|SCSB|Processed, fortified, cereal-based food blend (SCSB for malnourished children)
9943036|NCT01015950|Experimental|Misola|Locally processed, fortified food blend (Misola)
9943037|NCT01015950|Active Comparator|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, oil) and a multiple micronutrient powder (Mix-Me) are provided to simulate the currently recommended enhanced home-prepared rehabilitation food mixture (farines enrchies) according to the national Mali CMAM protocol."
9943038|NCT01015963||Ancillary-correlative (DNA sample analysis)|Blood samples collected on clinical trial CLB-9871 are examined via ABCC2 and SLC01B3 genotyping using TaqMan analysis. Other genes related to the pharmacokinetics and side effects of docetaxel may be considered for future genotyping. In some cases, panels of drug response SNPs on high-density arrays may be genotyped.
9943039|NCT01015989|Active Comparator|CARE+ Kenya brief computer risk assessment session (control)|
9528647|NCT03209271|Experimental|Body temperature fluid|500ml Ringers Acetate infused over 15 minutes warmed to 38°C
9528648|NCT03209271|Active Comparator|Room temperature fluid|500ml Ringers Acetate infused over 15 minutes cooled to 22°C
9528649|NCT03209206|Experimental|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
9528650|NCT03209206|Placebo Comparator|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
9528651|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
9528652|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
9528653|NCT03209232|Experimental|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
9528654|NCT03209232|Active Comparator|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
9528769|NCT03207971|Active Comparator|SCTG from palatal area with predominance of submucosa|
9943040|NCT01015989|Active Comparator|Full CARE+ Spanish computer-counseling group|
9943041|NCT01016002|Experimental|Intervention|
9943042|NCT01016028||Questionnaire + Sensory Tests + Interview|
9943043|NCT01016041|Experimental|everolimus stent|
9943044|NCT01016041|Active Comparator|paclitaxel eluting|
9943045|NCT01016054|Experimental|A. PLD plus AGS-8M4|Women with platinum resistent ovarian cancer
9943046|NCT01016054|Experimental|B. Carboplatin and gemcitabine plus AGS-8M4|Women with platinum sensitive ovarian cancer
9943047|NCT01016080|Active Comparator|oral glutathione|glutathione, 500 mg, taken orally twice daily
9943048|NCT01016080|Placebo Comparator|placebo capsules|identical-appearing placebo capsules
10002762|NCT01560481|Experimental|Step A: metformin glycinate 620 mg|620mg single dose by mouth
10002763|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg|1240mg single dose by mouth
10002764|NCT01560481|Experimental|Step A: metformin glycinate 2480 mg|2480mg single dose by mouth
10002765|NCT01560481|Active Comparator|Step A: metformin hydrochloride 1000 mg|1000mg single dose by mouth
10002766|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg, food intake|1240mg single dose by mouth after food intake
10002767|NCT01560481|Experimental|Step B: metformin glycinate 620 mg BID|620mg BID for 8 days
10002768|NCT01560481|Active Comparator|Step B: metformin hydrochloride 500 mg BID|500mg tablets BID for 8 days
10002769|NCT01560494|Experimental|STAC curriculum|
10002770|NCT01560494|No Intervention|Conventional Curriculum|
10002771|NCT01560520||Accelerometer|
10002772|NCT01560533|Other|Treated by HIPEC|Patients treated by HIPEC for peritoneal cancer
10002773|NCT01560533|Other|Standard chemiotherapy|Patients treated by standard chemiotherapy for peritoneal cancer
10002774|NCT01560546|Active Comparator|Testim|
10002775|NCT01560546|Placebo Comparator|Placebo|Placebo for 24 weeks
10002776|NCT01560559|Experimental|Single Arm|Peroral endoscopic myotomy
10002777|NCT01560585|Experimental|Open label|All participants will receive Isotretinoin for 24 weeks
10002778|NCT01560598||Reflux esophagitis|those with endoscopically proven reflux esophagitis
10002779|NCT01560598||Normal|those with normal GFS finding (without definite mucosal break at Z-line)
10002780|NCT01560611||High-risk cardiac surgery patient|
10002781|NCT01560637|Experimental|UT-15C|Open label access
10002782|NCT01560650|Experimental|high dose (35ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 35 mL/kg/h.
10002783|NCT01560650|Experimental|low dose (25ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 25 mL/kg/h.
10002784|NCT01560663||Docetaxel Carboplatino|Doses of AUC 5-6 of carboplatin in combination with 75 mg/m2 of docetaxel are easily combined, being myelosuppression the most important toxicity. This combination has been studied in metastatic breast cancer as well as in the neoadjuvant setting. The combination of taxanes and platinum salts is increasingly used as neoadjuvant chemotherapy for TNBC. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.
10002785|NCT01560676|Active Comparator|HEALTH[e]TEEN|8 lessons over 6-8 weeks Education on healthy eating and physical activity Behavioral support for self-monitoring and goal setting
10002786|NCT01560676|Active Comparator|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks Education on healthy eating and coping skills training Behavioral support for self-monitoring and goal setting
10002787|NCT01560689|Active Comparator|BUDESONIDE/FORMOTEROL|
10002788|NCT01560689|Placebo Comparator|control|
10002789|NCT01560702|Active Comparator|Autologous blood|Patients will be injected by autologous blood at the edge of actively bleeding ulcer
10002790|NCT01560702|Other|Epinephrine injection|Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
10002791|NCT01560715|Experimental|Experimental: Test group|Retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200 or visual field less than 20 degrees
10002792|NCT01560728|Experimental|Trauma-Focused CBT|Adapted or modified Trauma-Focused Cognitive Behavioral Therapy
10002793|NCT01560728|No Intervention|Wait list|Monitored while waiting for intervention
10002794|NCT01560741|Active Comparator|Telemedicine Group|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be provided with a ventilator outfitted with a wireless transmitter to allow the remote data collection of compliance and efficacy information. While patient sleeps, data is collected. If abnormalities criteria will be detected, remote titration of ventilator settings will be done to optimise therapy. Patient will be monitored again and data analyzed. This procedure will be repeated until we obtained the optimal ventilator parameters for each patient in this group. Nocturnal oximetry under home mechanical non-invasive ventilation will be carried out after one week and one month of treatment. Subjects also receive pre-arranged telephone calls to assist with progress.
10035137|NCT01803347|Experimental|ASC + fibrin glue|Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.
10002795|NCT01560741|Other|Usual care|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be assessed by a hospital visit scheduled at the end of third month after their initial adaptation. In this hospital visit data provided by the ventilator will be transferred to research team computer so they could evaluate patient compliance and efficacy of ventilation criteria under the parameters used at home present at the time of assessment. If abnormality criteria will be detected, re-titration of ventilator settings will be made. Patients will be encouraged to call their respiratory consultant any time they had a problem or concern.
10002796|NCT01560754|Experimental|Transdermal nicotine patch|Subjects will apply a combination of 7 or 14 mg nicotine transdermal patches until reaching their highest well tolerated dose of 7 to 28 mg/day.
10002797|NCT01560754|Placebo Comparator|Transdermal placebo patch|Subjects will apply a combination of 7 or 14 mg placebo transdermal patches until reaching their highest well tolerated dose.
10002798|NCT01560767|Active Comparator|Femoral Nerve Block|levobupivacaine
10002799|NCT01560767|Active Comparator|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
10002800|NCT01560793|Experimental|VAX161B|Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
10002801|NCT01560806|No Intervention|Conventional Healthcare services|People with high blood pressure detected during screening survey or opportunistically during study period will be referred to receive the conventional health care services for hypertension at district hospital or local commune health station
10002802|NCT01560806|Experimental|Commune Hypertension Management|People with high blood pressure were managed in commune-based hypertension management programme
10002803|NCT01560832||Laboratory (PCR)-confirmed C.difficile infection|patient who has experienced the passage of 3 or more unformed or loose stools [diarrhea] conforming to the shape of a container within a 24-hour period and has a positive laboratory test result confirmed by PCR.
10002804|NCT01560845|Experimental|ABMSCi plus surgery group|Autologous bone marrow stem cells infusion through hepatic artery in open abdominal portal hypertension surgery
10002805|NCT01560845|No Intervention|portal hypertension surgery group|only portal hypertension surgery for this group patients
10002806|NCT01560884|Active Comparator|Group B|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
10214701|NCT04732052|Active Comparator|Active tDCS|Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the stimulation using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The active stimulation condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration a single tDCS session will be 20 minutes.
10214702|NCT04732052|Sham Comparator|Sham tDCS|Sham Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the sham stimulation using two sponge electrodes soaked in a saline solution. The sham stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation for 10s only. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The sham tDCS is identical to the active tDCS except that the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each sham tDCS session will be 20 minutes.
10214703|NCT04731675|Experimental|AMB-05X|"Subjects will receive an injection of AMB-05X once every 2 weeks for 12 weeks (for 6 treatments total).~Based on ongoing review of the available safety, PK, PD, and efficacy data, the Sponsor may either increase or decrease the dose."
10214704|NCT04720612|Experimental|Omalizumab|Participants in this arm will receive the study drug, omalizumab.
10214705|NCT04720612|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
10214706|NCT04688320|Experimental|Recombinant nonimmunogenic staphylokinase|lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.
10214707|NCT04688320|Experimental|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
10214708|NCT04667949|Experimental|Fingolimod|Fingolimod 0.5 mg capsule taken orally once daily
10214709|NCT04661137|Experimental|Carfilzomib-containing Regimen|"Carfilzomib 56 mg/m2 on days 1, 8 and 15. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 80 mg on days 1, 8 and 15."
10214710|NCT04661137|Experimental|Pomalidomide-containing Regimen|"Pomalidomide 4 mg po daily for 21 days. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 60 mg on days 1, 8 and 15."
10214711|NCT04661137|Experimental|Exploratory/Daratumumab-containing Regimen|"Daratumumab on current schedule (16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on).~Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 100 mg on days 1, 8, 15 and 22."
9943049|NCT01016093|Experimental|Intervention|Patients in this arm received zoledronic acid.
9943050|NCT01016093|Placebo Comparator|Control|Patients in this arm received placebo as control group
9943051|NCT01016119|Placebo Comparator|Placebo|In this group we will use Placebo cream, in the early rehabilitations in the upper extremity
9943052|NCT01016119|Experimental|Folrex|In this group we will use Folrex cream, in the early rehabilitations in the upper extremity
9943053|NCT01016145|Active Comparator|First generation antipsychotic|Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
9943054|NCT01016145|Experimental|Second generation antipsychotics|Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone
9943055|NCT01016158|Experimental|umbilical cord serum eyedrops|patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears
10002807|NCT01560884|Active Comparator|Group C|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
9943056|NCT01016184|Active Comparator|vitamin D|
9943057|NCT01016184|Active Comparator|placebo|
9943058|NCT01016197|Active Comparator|Conservative|Four weeks of splinting followed by mobilisation.
9943059|NCT01016197|Experimental|Surgery|Surgical repair of the tendon with a bone anchor followed by four weeks of splinting and then mobilisation.
9943060|NCT01016210|Experimental|60 infertile women|Candidates for IVF-ET treatment
9943061|NCT01016210|No Intervention|control|no treatment
9943062|NCT01016223|Active Comparator|Beclomethasone dipropionate inhaler|
9943063|NCT01016223|Placebo Comparator|Matched inhaler|
9943064|NCT01016249|Active Comparator|Treatment 1. 5% Saline + Epinephrine|Nebulization with 4ml of 5% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
9943065|NCT01016249|Other|Treatment 3. 3% Saline + Epinephrine|Nebulization with 4ml of 3% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
9943066|NCT01016249|Other|Treatment 2 . 0.9% Saline + Epinephrine|Nebulization with 4ml of 0.9% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
9943067|NCT01016275||Iliac lesions TASC A or B|All lesion types belonging to the iliac TASC A or B.
9943068|NCT01016288||22 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 22 G needle
9943069|NCT01016288||25 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 25 G needle
9943070|NCT01016301|Active Comparator|Pharmacist service,|The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
9943071|NCT01016301|No Intervention|Control|Usual care
9943072|NCT01016314|Experimental|Aspen Spinous Process System|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
9943073|NCT01016314|Active Comparator|Pedicle Screw Fixation|Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
9943074|NCT01016327|Experimental|1|
9943075|NCT01016340|Active Comparator|MCS-5|Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
9943076|NCT01016340|Placebo Comparator|Placebo|Group 4: Placebo for 16 weeks
9943077|NCT01016366|Experimental|Lu AA24493|
9943078|NCT01016366|Placebo Comparator|Placebo|
9943079|NCT01016405||Severity of dry eye in patients undergoing cataract surgery|
9943080|NCT01016418|Experimental|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
9943081|NCT01016431|Experimental|Rate adaptive|Patients will have their ICD programmed in a AAI-R mode, with peak atrial rate set at 85% of age-adjusted predicted maximal HR
9943082|NCT01016431|Active Comparator|Control|ICDs will be programmed in the usual VVI backup pacing mode at 40 bpm
9943083|NCT01016444||Albuterol responsive|Those who respond clinically to albuterol.
9943084|NCT01016444||Albuterol unresponsive|Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
9943085|NCT01016470|Placebo Comparator|B|Placebo
9943086|NCT01016470|Experimental|A|VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
9943087|NCT01016496|Experimental|Action observation plus repetition|Observation of actions and repetition of the same actions
9528655|NCT03208959|Experimental|Dose level 1|HTI-1090 tablets will be orally administered on an empty stomach,twice daily, BID i.e., dosing will be 12 hours apart and at approximately the same times each day
9528656|NCT03208959|Experimental|Dose level 2|100% Increment from dose level 1
9528657|NCT03208959|Experimental|Dose level 3|100% Increment from dose level 2
9528658|NCT03208959|Experimental|Dose level 4|100% Increment from dose level 3
9528659|NCT03208959|Experimental|Dose level 5|50% Increment from dose level 4
9528770|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
9943088|NCT01016496|Active Comparator|repetition only|repetition of gestures
9943089|NCT01016509|No Intervention|control|No hyperglycemia patient group
9943090|NCT01016509|Active Comparator|Insulin 1|Conventional insulin treatment
9943091|NCT01016509|Experimental|Insulin|Intensive insulin treatment
9943092|NCT01016522|Experimental|KetoCal|KetoCal tube feeding formula
9943093|NCT01016535||Children, Health Professionals|
9943094|NCT01016548|Experimental|Two doses of vaccine|Second dose is given 21 days after the initial dose. The same dose and route of administration are used.
9943095|NCT01016548|Active Comparator|One dose of vaccine|Given at baseline only.
9943096|NCT01016574|Other|women with stage I or II breast cancer|
9943097|NCT01016587||COPD patients|Not hospitalized COPD patients, degree 2-4.
9943098|NCT01016626|Experimental|CKD-4101 tablet|
9943099|NCT01016626|Active Comparator|Mycophenolate Mofetil capsule|
9943100|NCT01016639|Experimental|Chemoradiotherapy|
9943101|NCT01016665|Placebo Comparator|Placebo|Placebo
9943102|NCT01016665|Other|Tamoxifen|Tamoxifen 20 mg day 26 days
9943103|NCT01016665|Other|Anastrozole|Anastrozole 1mg 26 days
9943104|NCT01016704|No Intervention|Control|
9943105|NCT01016704|Experimental|Incentive|
9943106|NCT01016717|Active Comparator|Omeprazole|Patients will be taking omeprazole tablets 40 mg QD for 30 days
9943107|NCT01016717|Active Comparator|Pantoprazole|Patients will be taking Pantoprazole tablets 40 mg QD for 30 days
9943108|NCT01016730|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9943109|NCT01016743|Active Comparator|Active repetitive transcranial Stimulation|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
9943110|NCT01016795|Active Comparator|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
9943111|NCT01016795|Active Comparator|Cyclophosphamide and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
9943112|NCT01016821|Other|Oxycodone, labour pain|
9943113|NCT01016860|Experimental|OSI-906 and/or irinotecan|Dose Escalation Phase: Treatment for Cycle 1 will commence on Day -3 of a 21-day cycle (3 weeks) when a single dose OSI-906 is given with full pharmacokinetics(PK) sampling at predetermined time points. Irinotecan will be administered intravenously over 90 minutes on Day 1 and Day 8 with full PK sampling on Day 1. The institution of oral dosing of OSI-906 2-4, 8-10, 15-17 (for cycle 1 only) will be given followed by full PK sampling of both drugs on Day 8. Pre-dose samples of OSI-906 will be drawn on Cycle 1 Days 8, 10, 15, 17 and Cycle 2 Days 1, 8, 10, 15 and 17. For Cycle 2 and thereafter, both drugs will be administered starting on Day 1.
9943114|NCT01016886|Experimental|1|
9943115|NCT01016899||Non-melanoma skin cancer|Early stage squamous or basal cell carcinoma
9943116|NCT01016925|No Intervention|Control|
9943117|NCT01016925|Experimental|femoral tunnelized perineural catheter|
9943118|NCT01016951|Experimental|A|AZD9164
9943119|NCT01016951|Placebo Comparator|B|Placebo
10002808|NCT01560884|Active Comparator|Group D|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
10002809|NCT01560884|Active Comparator|Group A|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
10002810|NCT01560897|Experimental|C13|The dose of sodium [1-13C] acetate is calculated according to patient weight (27mg/kg) or (0.33 mmol / kg).
10002811|NCT01560962|Other|PI vs no intervention|In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention.
10002812|NCT01560962|Other|PI vs hygiene|In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash.
10002813|NCT01560962|Other|PI vs azasite|In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days.
10002814|NCT01560962|Other|PI vs tobradex|In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin.
10002815|NCT01561014|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD, 5 days a week and receive fluorouracil IV continuously and erlotinib hydrochloride PO QD on days 1-38. Patients also receive oxaliplatin IV over 2 hours on days 1, 15, and 29.~SURGERY: Within 4-8 weeks after completion of chemoradiotherapy, patients with potentially resectable disease (i.e., complete response, partial response, or stable disease) undergo surgery to remove the tumor.~CONSOLIDATION CHEMOTHERAPY: Within 2-4 weeks after surgery, patients with tumors that demonstrate positive immunohistochemistry for EGFR and/or cyclin D1 (in the pretreatment biopsy or in the residual tumor in the esophagectomy specimen) receive consolidation chemotherapy comprising erlotinib hydrochloride PO QD for 12 weeks."
10002816|NCT01561027|Experimental|CNV1014802|CNV1014802 350mg on prescription (BID) for 21 days
10002817|NCT01561027|Placebo Comparator|Placebo|Placebo 350mg BID for 21 days
10002818|NCT01561040|Experimental|Omega 3, Vitamins A, D3 and E|Dry eye patients that have been screened with elevated osmolarity dispensed EZ Tears supplements containing Omega 3, Vitamins A, D3 and E to evaluate the change in dry eye conditions subjectively and objectively.
10002819|NCT01561066|Sham Comparator|conservative therapy|Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
10002820|NCT01561066|Active Comparator|Application of autologous PRFG|The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.
10002821|NCT01561092|Active Comparator|Escitalopram|
10002822|NCT01561092|Placebo Comparator|Non active drug|
10002823|NCT01561105|Experimental|IMPACT|
10002824|NCT01561105|No Intervention|Care as Usual|Patients received all depression care available to them as part of care as usual in the participating primary care clinics.
10002825|NCT01561118|Experimental|Bicycle-Ergometer Training Group|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions).~In the second part of the study intervention will be prolonged for another 12 weeks."
10002826|NCT01561118|Other|Control|"No intervention during hemodialysis during the first 12 weeks of the study.~In the second part of the study a training program, according to that of the intervention group, will be performed with a performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions)."
10002827|NCT01561131|Active Comparator|Whey protein supplement|Whey protein
10002828|NCT01561131|Active Comparator|Whey protein enriched with calcium supplement|Whey protein enriched with calcium
10002829|NCT01561131|Active Comparator|Soy protein supplement|Soy protein
10002830|NCT01561131|Placebo Comparator|Control supplement|Maltodextrin
10002831|NCT01561170||Chronically venous ulcer|A group of 36 patients
10002832|NCT01561183|Experimental|Indirect pulp capping (IPC)|Indirect pulp capping
10002833|NCT01561183|Experimental|Direct pulp capping (DPC)|Direct pulp capping
10002834|NCT01561183|Experimental|Miniature pulpotomy (MP)|Miniature pulpotomy
10002835|NCT01561183|Experimental|Full pulpotomy (FP)|Full pulpotomy
10002836|NCT01561196|Active Comparator|Ultrasound guided arterial cannulation|The arterial needle is placed using ultrasound monitoring for guiding the operator.
10002837|NCT01561196|Active Comparator|Conventional cannulation|the arterial needle is placed using the traditional method and lidocaine. The operator decides where to place the needle in the forearm
9528660|NCT03208946|Experimental|High-CML diet|An isocaloric, high-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
9528661|NCT03208946|Sham Comparator|Low-CML diet|An isocaloric, low-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
9528662|NCT03208972|Experimental|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
10002838|NCT01561209|Active Comparator|Amitryptiline|Amitryptiline 5 mg before bedtime
10002839|NCT01561209|Placebo Comparator|Placebo|Placebo pill
10002840|NCT01561222|Placebo Comparator|placebo|
9528771|NCT03207984|Active Comparator|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to treat multiple gingival recessions in aesthetic areas
10002841|NCT01561222|Experimental|Calcitriol|
10002842|NCT01561235|Active Comparator|Normal Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 14 E%, Fat: 30 E% and carbohydrate: 56E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
10002843|NCT01561235|Experimental|Medium-high protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 25E%, Fat: 30 E% and carbohydrate: 45E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
10002844|NCT01561235|Experimental|High Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 50 E%, Fat: 30 E% and carbohydrate: 20E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
10002845|NCT01561248|No Intervention|SOC-treatment|Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
10002846|NCT01561248|Experimental|PEG-Solution, daily bowel lavage|Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
10002847|NCT01561274|Active Comparator|2 ml bupivacaine|2 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg of bupivacaine.
9528663|NCT03208972|Active Comparator|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
9528664|NCT03208920|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
9528665|NCT03208920|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
9801066|NCT01705964|Sham Comparator|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
9943120|NCT01017068|Experimental|A1 (glaucoma)|
9943121|NCT01017068|Experimental|A2 (glaucoma)|
9943122|NCT01017068|Experimental|A3 (glaucoma)|
9943123|NCT01017068|Experimental|A1 (normals)|
9943124|NCT01017068|Experimental|A2 (normals)|
9943125|NCT01017068|Experimental|A3 (normals)|
9943126|NCT01017081|Active Comparator|Control|Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay.
9943127|NCT01017081|Experimental|Physiotherapy|"Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission."
9943128|NCT01017094|Experimental|dry dressing|local application
9943129|NCT01017107|Experimental|Activated protein C|
9943130|NCT01017133|Other|Arm I|With 6 weeks prior to surgery, patients undergo fluorine F18 (18F)-EF5 PET at 10 minutes and 90 minutes after injection of 18F-EF5. Patients also undergo fludeoxyglucose F18 (18F-FDG) PET at 1 hour and 3 hours after injection of 18F-FDG.
9943131|NCT01017159|Active Comparator|Subcutaneous immunoglobulin|
9943132|NCT01017159|Placebo Comparator|Saline|
9943133|NCT01017185|Experimental|Oncolytic virotherapy, intratumoral injection of HF10|
9943134|NCT01017198|Experimental|BIIB021 and Food|The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
9943135|NCT01017198|Experimental|BIIB021 and Antacid|Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
9943136|NCT01017211|Experimental|auricular acupuncture protocol|
9943137|NCT01017211|Sham Comparator|sham auricular acupuncture|
9943138|NCT01017276|Experimental|ASP group|
9943139|NCT01017289|Experimental|Quantum|In this single arm study, the Quantum nailing system will be used in all patients.
9943140|NCT01017302|Experimental|1|
9943141|NCT01017302|Placebo Comparator|2|
9943142|NCT01017302|Experimental|3|
9943143|NCT01017302|Placebo Comparator|4|
9943144|NCT01017315|Experimental|No application of baby talcum|control
9943145|NCT01017328||surgery with general anesthesia|
9943146|NCT01017341|No Intervention|No hip protector|no hip protector
9943147|NCT01017354|Experimental|High-dose vitamin D3|monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)
9943148|NCT01017354|Experimental|standard vitamin D + 25(OH)D|standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)
9943149|NCT01017354|Active Comparator|standard vitamin D|standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)
9943150|NCT01017367|Experimental|MDX-1100|MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
9943151|NCT01017367|Placebo Comparator|Placebo|Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
9943152|NCT01017380|Experimental|placebo|identical placebo
9943153|NCT01017393|Experimental|ketamine|epidural ketamine added to the patient controlled epidural analgesia regimen
9943154|NCT01017393|Active Comparator|ketamine free|epidural ketamine NOT added to the patient controlled epidural analgesia regimen
9943155|NCT01017406|Experimental|Plantar fascia stretching exercise|Patient perform plantar fascia stretching 3 times per day
9943156|NCT01017419||Audiology counseling|
9943157|NCT01017445|Experimental|Quadricep strengthening exercise|Quadricep strengthening exercise
9943158|NCT01017458|Experimental|1|MK0773 + placebo injection
9943159|NCT01017458|Active Comparator|2|placebo to MK0773 + testosterone injection
9943160|NCT01017458|Placebo Comparator|3|placebo to MK0773 + placebo injection
9943161|NCT01017471|Experimental|control|carpal tunnel release using standard incision
9943162|NCT01017484|Experimental|DASH|The Dietary Approaches to Stop Hypertension Dietary pattern.
9943163|NCT01017484|Experimental|Control|The typical American diet as estimated from the NHANES survey.
9943164|NCT01017523|Experimental|1 (Couples)|Diabetes self-management education, telephone support and behavior change for couples.
9943165|NCT01017523|Active Comparator|2 (Individual)|Diabetes self-management education, telephone support and behavior change for individuals.
9943166|NCT01017523|Placebo Comparator|3 (Control)|Diabetes self-management education only.
9943167|NCT01017562||condition of joint implant|
9943168|NCT01017588|Experimental|back exercise|strengthening back exercise
9943169|NCT01017614|Experimental|Monofer|"administered as intravenous infusions (A1)~administered as intravenous bolus injections (A2)"
9943170|NCT01017614|Active Comparator|Iron Sulphate|tablets administered orally
9528666|NCT03208790|Experimental|Group A|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 10mg for 3 months.
9528667|NCT03208790|Experimental|Group B|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 5mg for 3 months.
9801067|NCT01706003||Telemedicine Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated via telemedicine for migraine headaches
9528668|NCT03208790|Placebo Comparator|Group 3|patients with oral premalignant lesions will receive placebo buccal tablets for 3 months.
9528669|NCT03208777||control group|taking blood samples from apparently healthy people
9528670|NCT03208777||benign colorectal|taking blood samples from patients
9528671|NCT03208777||malignant colorectal|taking blood samples from patients
9528672|NCT03208764|Experimental|Nitric Oxide treatment|
9528673|NCT03208829|Experimental|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
9801068|NCT01706003||In-Office Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated in the clinician's office for migraine headaches
9801069|NCT01706081|Experimental|Acupuncture|Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.
9801070|NCT01706081|Experimental|Wait-list|Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
9801071|NCT01706146|Other|Non-Coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
9801072|NCT01706159|Experimental|rFXIII|
9801073|NCT01706159|Active Comparator|Placebo|
9801074|NCT01706198|Experimental|FF/VI|fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler
9801075|NCT01706198|Active Comparator|ICS or ICS/LABA maintenance therapy|inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)
9801076|NCT01706250|Experimental|MAXCLARITY II|MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
9801077|NCT01706250|Active Comparator|PROACTIV|Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
9801078|NCT01706263|Experimental|MAXCLARITY II|MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over-the-counter.
9801079|NCT01706328|Experimental|FF/VI Inhalation Powder NDPI|Subjects randomized to the FF/VI 100/25 arm will take an active inhalation of study medication during their morning dosing from their NDPI and will have an inhalation of dummy medication (placebo) as their morning ACCUHALER/DISKUS dose and as their evening dose.
9801080|NCT01706328|Active Comparator|Fluticasone Propionate/Salmeterol Inhalation Powder|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg arm will have an active dose of medication during both their morning and evening treatments from the ACCUHALER/DISKUS and a dummy placebo dose in the morning from their NDPI.
9801081|NCT01706458|Active Comparator|sipuleucel-T|Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
9801082|NCT01706458|Experimental|sipuleucel-T with DNA Vaccine|Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
9801083|NCT01706536|Placebo Comparator|EP-101 Placebo|EP-101 Placebo AM + EP-101 Placebo PM
9801084|NCT01706536|Experimental|EP 101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
9801085|NCT01706536|Experimental|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
9801086|NCT01706536|Experimental|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
9801087|NCT01706536|Experimental|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
9801088|NCT01706549||Posthysterectomy pain|Observational study on posthysterectomy pain
9801089|NCT01706575|Experimental|Pegylated Interferon (Peginterferon) Alfa-2a|Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than <0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
9801090|NCT01706588|Experimental|Diclofenac sodium 5 mg/mL|
9801091|NCT01706588|Experimental|Diclofenac sodium 12.5 mg/mL|
9801092|NCT01706588|Experimental|Diclofenac sodium 25 mg/mL|
9801093|NCT01706588|Experimental|Diclofenac sodium 50 mg/mL|
9801094|NCT01706588|Placebo Comparator|Placebo 1 mL|
9801095|NCT01706666|Experimental|Arm A (bortezomib)|Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
9801096|NCT01706666|Experimental|Arm B (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
9801097|NCT01706666|Experimental|Arm C (bortezomib, lenalidomide)|Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
9801098|NCT01706770|Experimental|enfilcon A|The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
9801099|NCT01706770|Active Comparator|galyfilcon A|The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
9801100|NCT01706822|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy
9801101|NCT01706926|Placebo Comparator|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram [mg] per week) through oral or parenteral route.
9528674|NCT03208829|Active Comparator|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
9528675|NCT03208725||Hospitalized children with severe wasting or kwashiorkor (SWK)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
9528676|NCT03208725||Community reference participants (CP)|Children recruited from the community who are seen a single appointment in the community.
9528677|NCT03208725||Hospitalized children with moderate wasting (MW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
9528678|NCT03208725||Hospitalized children without wasting (NW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
9943171|NCT01017627|Other|Early anemia management|Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
9943172|NCT01017627|Other|case control|"Each case will be data-matched to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm."
9943173|NCT01017640|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID in the absence of disease progression or unacceptable toxicity.
9943174|NCT01017640|Experimental|Arm II (veliparib and mitomycin C)|Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive mitomycin C IV over 10-20 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9943175|NCT01017666|Experimental|Rosiglitazone 8mg PO|Cohort 1
9943176|NCT01017666|Experimental|Midazolam 2mg PO, Warfarin 25mg PO|Cohort 2
9943177|NCT01017679|Experimental|1|Oral Drug gefitinib(Iressa) 500 mg Everyday
9943178|NCT01017679|Active Comparator|2|Oral Drug gefitinib(Iressa) 250 mg Everyday
9943179|NCT01017692||Lumbar Spinal Stenosis|Subjects who have undergone or will undergo an MRI, with symptoms of LSS
9943180|NCT01017757||Renal transplant patients|
9943181|NCT01017770|Experimental|Artemether -lumefantrine|Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
9943182|NCT01017770|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
9943183|NCT01017783|Other|Healthy Choices|
9943184|NCT01017783|Experimental|Diet Substitution A|
9943185|NCT01017783|Experimental|Diet Substitution B|
9943186|NCT01017796|Experimental|A. Experimental|1200mg acetylcysteine and 2g ascorbic acid at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
9943187|NCT01017796|Placebo Comparator|B. Control|200ml 0,9% normal saline IV
9943188|NCT01017809|Other|Oxali/Topotecan|Patients enrolled to NYU 03-67 will be receiving Oxaliplatin 85 mg/m2 IV over 120 minutes on Day 1 and 15 Topotecan 0.4mg/m2/day CIV from D1 to 15 (in addition to the assigned intervention)
9943189|NCT01017835||statin treatment, isolated hypertension|treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
9943190|NCT01017835||placebo treatment, isolated hypertension|treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
9943191|NCT01017848||Adults, nondiabetics|adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction
9943192|NCT01017861||Pregnant, 12th week|Pregnant women in the 12th week of pregnancy.
9943193|NCT01017861||Pregnant, 28th week|Pregnant women in the 28th week of pregnancy.
9943194|NCT01017861||Pregnant, full term|Pregnant women at full term, in hospital for an elective cesarean section.
9943195|NCT01017861||Non pregnant women|Non pregnant women
9943196|NCT01017887||Airseal port for laparoscopic surgery|Airseal access port for laparoscopic surgery with standard ports.
9943197|NCT01017887||Standard Laparoscopy ports|Uses standard laparoscopy ports.
9943198|NCT01017913|Active Comparator|Electrotherapy equipment|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms with two channels.
9943199|NCT01017913|Active Comparator|electrotherapy equipment|The CI was adjusted with 4000 HZ bases frequency, modulation frequency range 20 HZ, ∆F10 HZ, slope 1/1 and quadripolar manner.
9943200|NCT01017913|No Intervention|Control|The patients of the Control group stayed without any treatment in the same period
9943201|NCT01017926|Active Comparator|Triazolam Reference Arm|There will be a clearance period of at least 3 days between the two phases of the study.
9528679|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
9528680|NCT03208543|Experimental|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
9528681|NCT03208894|Experimental|with salbutamol|
9528682|NCT03208894|Experimental|with furosemide|
9528683|NCT03208894|Experimental|both furosemide and salbutamol|
9528684|NCT03208894|No Intervention|no inervention|
9528685|NCT03208816|Other|single arm|symptom management program for chemotherapy patients
9943202|NCT01017926|Experimental|Triazolam Trial Arm|
9943203|NCT01017939|Experimental|Group A: abiraterone + prednisone + dextromethorphan|Group A will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP2D6 using 2 single doses of dextromethorphan hydrobromide as a probe drug.
10002848|NCT01561274|Active Comparator|1.5 ml bupivicaine.|1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 12.5 mg of bupivacaine.
10002849|NCT01561287|Experimental|Dermal Autograft|
9528686|NCT03208712|Experimental|Radium-223 and Atezolizumab|"Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses~Atezolizumab 1200 mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity, or 17 doses"
9528772|NCT03207984|Experimental|Test MG|Root coverage surgery with Mucograft collagen matrix graft to treat multiple gingival recessions in aesthetic areas
9943204|NCT01017939|Experimental|Group B: abiraterone + prednisone + theophylline|Group B will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP1A2 using 2 single doses of theophylline as a probe drug.
9943205|NCT01017978|Other|MRI Scan|MRI scan of soft tissue tumor
9943206|NCT01017991|Experimental|Infant formula with probiotic|Infant formula with probiotic for 0 to 12 months of age
9943207|NCT01017991|Placebo Comparator|Standard infant formula|Infant formula for 0 to 12 months of age
9943208|NCT01018017|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
9943209|NCT01018017|Placebo Comparator|Placebo|The placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
9943210|NCT01018043||001|Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
9943211|NCT01018069|Active Comparator|AEG35156|Patient receive AEG35156 prior to chemotherapy
9943212|NCT01018069|Sham Comparator|Control|Patients receive chemotherapy only
9943213|NCT01018108|Other|I|Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.
9943214|NCT01018121|Experimental|Clinic and Home Behavioral Intervention|
9943215|NCT01018121|Active Comparator|Pediatrician Counseling|
9943216|NCT01018147|Experimental|CT Imaging|Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
9943217|NCT01018160||001|
9943218|NCT01018199|Experimental|Group 1- C-reactive protein (CRP) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating RCP levels
9943219|NCT01018199|Active Comparator|Group 2 - procalcitonin (PCT) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
9943220|NCT01018212|Experimental|A|Cicatrix cream
9943221|NCT01018225|Experimental|darifenacin|
9943222|NCT01018225|Placebo Comparator|Sugar Pill|
9943223|NCT01018238|Placebo Comparator|Placebo arm|
9943224|NCT01018238|Experimental|Cohort 1|
9943225|NCT01018238|Experimental|Cohort 2|
9943226|NCT01018238|Experimental|Cohort 3|
9943227|NCT01018238|Experimental|Cohort 4|
9943228|NCT01018251|Experimental|Arm I|Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
9943229|NCT01018290||Navigated TMS examination|20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles
9943230|NCT01018303|Experimental|Antioxidant-enriched multivitamin supplement|
9943231|NCT01018329|Experimental|I|Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
9943232|NCT01018342|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
9943233|NCT01018342|Active Comparator|2|Macrobid® Capsules 100 mg
9943234|NCT01018355|Experimental|Device closure of PFO|Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
9943235|NCT01018355|Active Comparator|Medical anticoagulative treatment|Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
9943236|NCT01018368|Experimental|VX-770|
9943237|NCT01018368|Experimental|Rifampin|
9943238|NCT01018381|Active Comparator|Conventional Therapy|Conventional therapy is given, including PEIT, TOCE, PEIT + TOCE, TOCE + RFA for hepatocellular carcinoma or Entecavir for hepatitis B virus.
9943239|NCT01018381|Experimental|Conventional Therapy plus MGN-3|
9943240|NCT01018407|Experimental|Discrete Trial Training|Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
9943241|NCT01018407|Experimental|Interpersonal Developmental Approach|Targets Joint Attention and Symbolic Play. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
9943242|NCT01018433|Experimental|T-SIB|Treatment for self-injurious behaviors; study intervention
9943243|NCT01018433|Other|Treatment as Usual|
9943244|NCT01018446|Experimental|Busulfan, Pharmacokinetic|To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.
9943245|NCT01018459|Experimental|Group D: 10^11 vp/mL or placebo|10 subjects will receive 10^11 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
9943246|NCT01018459|Experimental|Group A: 10^9 vp/mL or placebo|10 subjects will receive 10^9 viral particles (vp)/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
10002850|NCT01561287|Experimental|AlloDerm|
10002851|NCT01561326|Experimental|Cognitive-affective barriers counseling delivered by phone|Standard care plus cognitive-affective barriers counseling delivered by phone , i.e., culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence
10002852|NCT01561326|Experimental|cognitive-affective barriers counseling via brochure|Standard care plus cognitive-affective barriers counseling delivered via mail-home print material
10002853|NCT01561326|Active Comparator|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
10002854|NCT01561352|Experimental|Factor VII|
10002855|NCT01561365|Experimental|Emergency|
10002856|NCT01561365|Experimental|Orthopedic residents|
10002857|NCT01561391|Experimental|Continuous infusion|
10002858|NCT01561391|Experimental|Bolus injection|
9528687|NCT03208998|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
10002859|NCT01561391|Experimental|Control|
10002860|NCT01561404|Experimental|Everolimus|Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)
10002861|NCT01561417|Active Comparator|CP-rFVIIa|
10002862|NCT01561417|Experimental|VII25|
10002863|NCT01561430|Experimental|15 mg LY2886721|LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks.
10002864|NCT01561430|Experimental|35 mg LY2886721|LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.
10002865|NCT01561430|Experimental|70 mg LY2886721|LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.
10002866|NCT01561430|Placebo Comparator|Placebo|Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.
10002867|NCT01561456|Experimental|AXL1717|AXL1717
10002868|NCT01561456|Active Comparator|Docetaxel|Docetaxel
10002869|NCT01561482|Experimental|Metformin, Simvastatin|"Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.~They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study."
10002870|NCT01561508|Experimental|GABA|2/3 of participants will be randomized to the GABA treatment group. Dosage will be based on body weight and will be adjusted at each study visit.
10002871|NCT01561508|Placebo Comparator|Placebo|1/3 of participants will receive placebo.
10002872|NCT01561547|Experimental|Kangaroo Mother Care|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sterile water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
10002873|NCT01561547|Active Comparator|Sucrose|Two minutes before the painful procedure and at the moment of the procedure, the infant will be given 24% sucrose by mouth. The volume is determined by body weight and is not important in terms of efficacy, it is the percentage of sweetness that is important.
10002874|NCT01561547|Experimental|Combination Kangaroo Mother Care and Sucrose|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sucrose water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
10002875|NCT01561573|Other|Ultrasound colles fracture|This is a single arm study
10002876|NCT01561586|Active Comparator|A: Weekly cisplatin with RT|Weekly cisplatin 40mg/m2 six cycles concurrent to radiation therapy
10002877|NCT01561586|Experimental|B: Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
10002878|NCT01561599|Placebo Comparator|Normal saline|Placebo
10002879|NCT01561599|Active Comparator|BB3|Small molecule mimetic of hepatocyte growth factor/scatter factor
10002880|NCT01561612|Experimental|Intervention|Breastfeeding promotion according to World Health Organization's Baby Friendly Hospital Initiative
10002881|NCT01561612|No Intervention|Control|Usual care
10002882|NCT01561638|Active Comparator|group p|pulse radiofrequency lesioning
10002883|NCT01561638|Placebo Comparator|sham group|Controlled, conventional
10002884|NCT01561638|Active Comparator|group C|Pulse dose radiofrequency
10002885|NCT01561664|Active Comparator|volunteers|not overweight Volunteers responding to the study criteria
10002886|NCT01561664|Experimental|overweight patients insulin sensitive|overweight patients insulin sensitive responding to the study criteria
10002887|NCT01561664|Experimental|overweight insulin resistant|overweight patients insulin resistant responding to the study criteria
10002888|NCT01561677|No Intervention|apnea/hypopnea index (AHI<5 : no OSAS)|
10002889|NCT01561677|No Intervention|apnea/hypopnea index (5≥AHI<15 : mild OSAS)|
10002890|NCT01561677|No Intervention|apnea/hypopnea index (15≤AHI<30 :moderate OSAS)|
10002891|NCT01561677|Active Comparator|apnea/hypopnea index ( AHI≥30 : severe OSAS treated).|Treated with CPAP
10002892|NCT01561677|Sham Comparator|apnea/hypopnea index ( AHI≥30:severe OSAS untreated).|Treated with sham CPAP (placebo)
10002893|NCT01561729|Experimental|Study group|This is the only arm of the study. All patients enrolled will have a nasogastric or orogastric tube placed. All will be assessed by both the RightSpot pH Indicator and chest radiograph.
10002894|NCT01561742|Experimental|Minocycline|
10002895|NCT01561742|Placebo Comparator|Placebo|
10002896|NCT01561781|Experimental|digoxin then digoxin + vandetanib|Digoxin alone followed by digoxin in combination with vandetanib
10002897|NCT01561794|Experimental|Ciprofloxacin|
10002898|NCT01561820|Active Comparator|Buddy|Participant will be assigned a buddy that will meet with them at the gym for each of their exercise sessions. This person will serve as a source of support and motivation for them and will also help them remember and stick to the goals set for you. This person will also help them maintain their exercise logs and ensure they are correct. The buddy will not be exercising with them, but will just be there with them while you exercise.
9528688|NCT03208998|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
9528689|NCT03208556|Experimental|iPD1 CD19 eCAR T cells|patients will receive a lymphodepletion chemotherapy prior to CAR T cell infusion
10002899|NCT01561820|Placebo Comparator|Non Buddy|Participants will not be assigned a buddy (and are not allowed to bring someone with them as a buddy). They will be asked to exercise on their own and remember the goals set for them. They will also be responsible for filling out their own exercise logs and ensuring they are correct.
10002900|NCT01561846|Active Comparator|regular cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trialy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
9528690|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
10002901|NCT01561846|Experimental|CLA enriched cheese|
10002902|NCT01561859|Experimental|Cognitive enhancement therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups
10002903|NCT01561859|Active Comparator|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
10002904|NCT01561872||intervention group|"Rooms of the patient of the intervention group will be equipped of cameras"
10002905|NCT01561872||reference group|"Patient in the non-equipped group will have usual care"
10002906|NCT01561885|Active Comparator|Patients on Pathway Care|
10002907|NCT01561885|No Intervention|Patients on Usual Care|
10002908|NCT01561924|Experimental|Ex vivo|
10002909|NCT01561937|Experimental|Pre-warfarin treatment (trial part A)|
10002910|NCT01561937|Experimental|Post-warfarin treatment (trial part B)|
10002911|NCT01561950|Experimental|Factor VII|
10002912|NCT01561950|Placebo Comparator|Placebo|
10002913|NCT01562002|Experimental|Bone Marrow mesenchymal stem cell|Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant
10002914|NCT01562002|Active Comparator|Allogenic limbal stem cell Transplant|Stem Cell with Amniotic Membrane Transplant
10002915|NCT01562015|Experimental|Ganetespib|Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
10002916|NCT01562080|Experimental|Dietary supplement|red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid
10002917|NCT01562080|Placebo Comparator|microcrystalline cellulose|
10002918|NCT01562093|Experimental|local nasal steroids|
10002919|NCT01562093|Placebo Comparator|placebo|
10002920|NCT01562106|Experimental|ICG Dye|Fluorescence-guided sentinel lymph node detection
10002921|NCT01562145||Patients with rotator cuff tears|Patients with ultrasound verified rotator cuff tears
10002922|NCT01562145||Healthy controls|Age and gender matched controls with ultrasound verified intact rotator cuff
10002923|NCT01562158|Placebo Comparator|Placebo|
10214712|NCT04660422||Pre-COVID-19 ACP baseline|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~September 15, 2019 - March 14, 2020,"
9528691|NCT03208738|No Intervention|Assessment only|
9528692|NCT03208738|Experimental|VetChange mobile app|
9528693|NCT03208738|Experimental|AFT + VetChange mobile app + supportive accountability tool|
9528694|NCT03208751|Other|Exercise training|All patients were included in the exercise training group
10002924|NCT01562158|Experimental|Low dose|
10002925|NCT01562158|Experimental|Medium dose|
10002926|NCT01562158|Experimental|High dose|
10002927|NCT01562171|Experimental|Cooked Lentils|The study group will be asked to consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
10002928|NCT01562171|Active Comparator|Potato-Based Foods|The control group will be asked to consume one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
10002929|NCT01562184|Active Comparator|Active tDCS|Active tDCS
10002930|NCT01562184|Sham Comparator|Sham tDCS|Sham tDCS
10002931|NCT01562197|Experimental|Axitinib|axitinib treatment arm
10002932|NCT01562197|Experimental|Axitinib plus Lomustine|Axitinib plus Lomustine
10002933|NCT01562210|Experimental|Olaparib, radiation +/- Cisplatin|Olaparib and radiotherapy with or without Cisplatin
10002934|NCT01562223|Experimental|Repeatability Assessment|Gadolinium motexafin gadolinium All participants will undergo two consecutive DCE-MRI and DWI scans per same imaging parameters and subsequent comparison for repeatability.
10035138|NCT01803347|Active Comparator|Fibrin glue|Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.
10002935|NCT01562249|Experimental|Experimental group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients; adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
10002936|NCT01562249|Active Comparator|Instruction Group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients, adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
10002937|NCT01562249|No Intervention|Control group|Inclusion criteria for this group were: adults (age above 18 years); absence of stomatognathic system alterations; absence of alterations in the scapular region; complete permanent dentition (absence/extraction of the third molar was accepted); Skeletal and Angle's Class I facial pattern; and absence of malocclusion. Exclusion criteria were: previous orthodontic treatment; and history of previous oral motor intervention.
10002938|NCT01562262||CTR|Control group
10002939|NCT01562262||ASS|Apnea without complaints group
10002940|NCT01562262||ACS|SAOS Group
10002941|NCT01562288||Observational|Previously collected serum and DNA from peripheral blood mononuclear cell samples are analyzed for HER2-specific antibodies and FcγR genotype by ELISA and PCR.
10002942|NCT01562301|Experimental|Anvirzel + Carboplatin + Docetaxel|Anvirzel administered sublingually. A total of five dose cohorts evaluated (6, 12, 24, 36, 48 mg/m2/day; SL divided into 3 doses given every 8 hrs) with 3 patients per cohort. Patients receive the assigned dose (2, 4, 8, 12, or 16 mg/m2) of Anvirzel three times a day throughout each cycle for a total of 4 cycles of chemotherapy. Cycles occur every 21 days. Patients start with an AUC of 6 for Carboplatin and 75mg/m2 for docetaxel, and on subsequent cycles, modifications at the discretion of the treating team. Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
10002943|NCT01562340|Active Comparator|Pomegranate fruit extract|
10002944|NCT01562340|Active Comparator|Pomegranate juice|
10002945|NCT01562353||Case|Subject has a diagnosis of current prescription opioid dependence (confirmed by the MINI). Subject had no history of dependence on alcohol or illicit or prescription drugs, including opioids, prior to prescription opioid exposure for the treatment of chronic pain.
10002946|NCT01562353||Control|Subject's prescribing physician has reported absence of significant problematic behavior with respect to prescription opioids or other substances while under the physician's care. Subject has a negative urine drug screen for alcohol, illicit drugs, and nonprescribed controlled substances at screening. Subject has no current or past substance abuse or dependence (confirmed by the MINI and medical history).
10002947|NCT01562366|Experimental|Group 1|
10002948|NCT01562366|Active Comparator|Group 2|
10002949|NCT01562392|Experimental|berries and vegetables|subjects include specific berries and vegetables in the diet
10002950|NCT01562392|Placebo Comparator|control product|Control product with equivalent amounts of carbohydrates but without vegetables and berries.
10002951|NCT01562405|Experimental|ACE-011 (sotatercept)|ACE-011, Lenalidomide or pomalidomide, Dexamethasone
10002952|NCT01562418|Experimental|Ergonomic consulting|Ergonomic consulting without biofeedback
10002953|NCT01562418|Experimental|Ergonomic consulting with biofeedback|Ergonomic intervention with biofeedback
10002954|NCT01562418|No Intervention|general instructions|general instructions with no intervention
10002955|NCT01562431|Other|Control|Participants complete the Signal-checklist BUT counselors do not obtain the results of the checklist
10002956|NCT01562431|Other|Intervention|Participants complete the Signal-checklist AND the counselor will get the results of the questionnaire
10002957|NCT01562457|Experimental|Low dose|
10002958|NCT01562457|Experimental|Medium dose|
10002959|NCT01562457|Experimental|High dose|
9528695|NCT03208881||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
9528696|NCT03208634|Experimental|Robotic intervention|Robotic intervention.
9528697|NCT03208647||AA Group|All the patients of AA group met a AA diagnostic criteria；
9528698|NCT03208647||Control Group|The control group were chosen from other departments who were under acute infection (such as pneumonia), acute abdominal emergency (such as appendicitis), cataract surgery;
9528699|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
9528773|NCT03207893|Experimental|GEM+CGM|GEM lifestyle modification & continuous glucose monitoring
9528774|NCT03207893|Active Comparator|Routine Care|Subject's current t2d treatment
9801102|NCT01706926|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
10002960|NCT01562470|Experimental|herbal-based cellulite cream|Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
10002961|NCT01562483|Experimental|delta-9-tetrahydrocannabinol (namisol)|
9528700|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
9528701|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
9528702|NCT03208582|Other|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
9528703|NCT03208686|Other|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
9528704|NCT03208452|Placebo Comparator|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
9528705|NCT03208452|Active Comparator|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
9528706|NCT03208517|Experimental|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
9528707|NCT03208517|Experimental|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
9528708|NCT03208517|No Intervention|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
9528709|NCT03208465|Experimental|Patients with Empagliflozin|
9528710|NCT03208465|Active Comparator|Patients with Sitagliptin|
9528711|NCT03208439|Experimental|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
9528712|NCT03208439|Placebo Comparator|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
9528713|NCT03208491|Experimental|serious games|
9528714|NCT03208491|Active Comparator|usual care|
9528715|NCT03208218|Experimental|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
9528716|NCT03208218|Active Comparator|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
9528717|NCT03208413|Experimental|thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
9528718|NCT03208114|Experimental|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
9528719|NCT03208114|No Intervention|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
9528720|NCT03208257|Experimental|Esmolol|Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
9801103|NCT01706926|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
9943247|NCT01018459|Experimental|Group B: 10^10 vp/mL or placebo|10 subjects will receive 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
9943248|NCT01018459|Experimental|Group C: 5 x 10^10 vp/mL or placebo|10 subjects will receive 5 x 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
9943249|NCT01018472|Experimental|Bifidobacterium infantis|
9943250|NCT01018472|Placebo Comparator|Placebo|
9943251|NCT01018485|Experimental|Botulinum Toxin First Dose|Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A
9943252|NCT01018485|Experimental|Botulinum Toxin Second Dose|20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study
9943253|NCT01018498|Experimental|Restricted FODMAPs diet|Restricted fermentable substrate diet for 1 week
9943254|NCT01018524|Active Comparator|small hernias - suture repair|
9943255|NCT01018524|Active Comparator|small hernias - mesh repair|
9943256|NCT01018524|Active Comparator|large hernias - sublay mesh|
9943257|NCT01018524|Active Comparator|large hernias - onlay mesh|
9943258|NCT01018576|Experimental|Delayed cord clamping|
9943259|NCT01018589|Experimental|A|Cicatrix cream
9943260|NCT01018602|Active Comparator|vildagliptin|
9943261|NCT01018602|Placebo Comparator|inactive pill without active agent|participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
9943262|NCT01018615|Experimental|low dose silymarin and low dose EGCG|
9943263|NCT01018615|Experimental|high dose silymarin and low dose EGCG|
10002962|NCT01562483|Placebo Comparator|Placebo|
10002963|NCT01562496|Experimental|Exercise|Twente patients will perform Aerobic exercise 3 times a week for at least 30 min
10002964|NCT01562496|No Intervention|Control|Fifteen patients will be listed as a control group and will be instructed to continue their previous level of activity throughout the study
10002965|NCT01562509|Active Comparator|Standard implementation strategy|Standard intervention
10002966|NCT01562509|Experimental|Innovative implementation strategy|Implementation tools
10002967|NCT01562522|Experimental|Intervention group|
10002968|NCT01562522|No Intervention|Control group|
10002969|NCT01562535|Experimental|Pronation group|In this group, participants will receive the pronation procedure. The technique is described below
10002970|NCT01562535|Active Comparator|Supination group|Participants in this group will be performed the supination technique. Description below.
10002971|NCT01562561|Experimental|Rep + NPH|
10002972|NCT01562561|Active Comparator|NPH|
10002973|NCT01562574|Experimental|Activated recombinant human factor VII|
10002974|NCT01562574|Placebo Comparator|Placebo|
10002975|NCT01562587|Experimental|Adults|
10002976|NCT01562587|Experimental|Paediatric|
10002977|NCT01562600||Nexium|
10002978|NCT01562626|Experimental|Dose escalation|
10002979|NCT01562639||Nexium|
10002980|NCT01562652|Experimental|Research|
10002981|NCT01562665||All Population|
10002982|NCT01562665||Sample of patients will be invited to complete Quality of Life|
10002983|NCT01562691|Experimental|Nasopore only|Packing using nasopore without airway integrated
10002984|NCT01562691|Active Comparator|nasopore with airway integrated|packing using airway integrated nasopore
10002985|NCT01562691|Active Comparator|airway-integrated Vaseline gauze|Nasal packing using airway-integrated Vaseline gauze
10002986|NCT01562704|Experimental|paracetamol|
10002987|NCT01562704|Placebo Comparator|placebo|
10002988|NCT01562717|Experimental|Ibuprofen|
10002989|NCT01562717|Placebo Comparator|Placebo|
10002990|NCT01562730||No previous cardiovascular disease|Individuals without any history of cardiovascular disease
10002991|NCT01562730||Previous cardiovascular disease|Individuals with history of cardiovascular disease
10002992|NCT01562769||Standard precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
10002993|NCT01562769||contact precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
10002994|NCT01562795|Experimental|group 1|
10002995|NCT01562795|Experimental|group 2|
10002996|NCT01562795|Experimental|group 3|
10002997|NCT01562795|Other|group 4|
10002998|NCT01562821|Experimental|Low dose|
10002999|NCT01562821|Experimental|High dose|
10003000|NCT01562821|Placebo Comparator|Placebo|
10003001|NCT01562834|Experimental|Somatropin|
10003002|NCT01562834|Placebo Comparator|Placebo|
10003003|NCT01562847||Nilotinib|
10003004|NCT01562860|Active Comparator|Carpal Tunnel and Pronator Teres Release|Patients enrolled in this arm of the study will have both surgical procedures performed at the same time
10003005|NCT01562860|Active Comparator|Carpal Tunnel Release only|Patients enrolled in this arm will have only Carpal Tunnel Release performed. In they still have symptoms of median nerve neuropathy, they will be scheduled for an additional procedure to release the pronator Teres in a separate surgery.
10003006|NCT01562912|Active Comparator|Control|Radiofrequency Ablation Procedure. Subjects who are undergoing AF ablation with traditional ablation technology at the same centers by the same operators. Control patients will be enrolled in a 1:2 ratio compared to the PVAC cohort. Intervention is the use of Radiofrequency Ablation.
10035139|NCT01803360|Experimental|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
10035140|NCT01803360|Placebo Comparator|Placebo|Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment
9943264|NCT01018628|Active Comparator|Cohort 1 - Dose Level A (25 mg/day)|Cohort 1 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 25 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 25 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
9943265|NCT01018628|Active Comparator|Cohort 2 - Dose Level B (75 mg/day)|Cohort 2 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 75 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 75 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
9943266|NCT01018628|Active Comparator|Cohort 3 - Dose Level C (250 mg/day)|Cohort 3 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 250 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 250 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
9943267|NCT01018628|Active Comparator|Cohort 4 - Dose Level D (500 mg/day)|Cohort 4 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 500 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 500 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
9943268|NCT01018628|Active Comparator|Cohort 5 - Dose Level E (1000 mg/day)|Cohort 5 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 1000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 1000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
9943269|NCT01018628|Active Comparator|Cohort 6 - Dose Level F (2000 mg/day)|Cohort 6 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 2000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 2000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
10003007|NCT01562912|Experimental|PVAC Ablation Procedure|Intervention is the use of PVAC technology. The PVAC is deployed in the left atrium over a 0.032-inch guidewire inside the PV and advanced until it is wedged within the antrum proximal to the ostium. Energy is delivered through selected electrode pairs with local potentials as well as adjacent electrode pairs, allowing bipolar current to flow to the target electrode(s) from both sides. Each application lasts for 60 seconds. When the temperature does not rise above 50°C within 15 seconds, the application should be discontinued to improve position. The PVAC may be manipulated within the antrum to ablate in a pattern of overlapping circular lesions.
10003008|NCT01562925|Active Comparator|Red Wine|Patients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure
10003009|NCT01562925|Active Comparator|White wine|
10003010|NCT01562925|Active Comparator|Beer|
10003011|NCT01562925|No Intervention|Control|Patients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)
10003012|NCT01562938|Placebo Comparator|Placebo|Placebo
10003013|NCT01562938|Active Comparator|MEDI-557 low-dose|
10003014|NCT01562938|Active Comparator|MEDI-557 high-dose|
10003015|NCT01562951|Placebo Comparator|PLACEBO|Treatment with placebo
10003016|NCT01562951|Active Comparator|ADALIMUMAB|Treatment with Adalimumab
10003017|NCT01562964|Experimental|Hypnotherapy|Hypnotherapy will be conducted at the Royal Brompton Hospital by a qualified practician (DF). Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
10003018|NCT01562964|Active Comparator|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min. Patients will be encouraged to talk about their physical symptoms and any emotional issues, and to discuss how these might be coped with in a better way.
10003019|NCT01562977|Other|no arms|no arms were present for the study, only 2 different cohorts:MCL and LDCGB
10003020|NCT01562990|Experimental|R-CMC544 and R-GEMOX|Treatment with R-CMC544 and R-GEMOX
10003021|NCT01563016|Experimental|Glucose & Depleting|participants will perform in a depleting task and receive a glucose drink
10003022|NCT01563016|Placebo Comparator|Glucose & non-depleting|participants will perform in a non-depleting task and receive a glucose drink
10003023|NCT01563016|No Intervention|Placebo & depleting|participants will perform in a depleting task and receive a placebo drink
10003024|NCT01563016|No Intervention|Placebo & non depleting|participants will perform in a non depleting task and receive a placebo drink
9528721|NCT03208075|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
10003025|NCT01563042|Experimental|Cohort 1 GSK2434735|Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
10003026|NCT01563042|Experimental|Cohort 2 GSK2434735|Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
10003027|NCT01563068|Experimental|Calcipotriene Foam|Calcipotriene foam 0.005% administered under maximal-use conditions to adolescent patients with plaque psoriasis
10003028|NCT01563120|Active Comparator|metformin|metformin up to 2550mg per day
10003029|NCT01563120|Active Comparator|glybenclamide|glybenclamide up to 20mg per day.
10003030|NCT01563133|Other|Lymph nodes, pancreatic masses & cysts|
10003031|NCT01563146||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2006 and May the 31st 2007.
10003032|NCT01563159||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2010 and May the 31st 2011.
10003033|NCT01563211||Patients receiving endocrine treatment for breast cancer|Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer.
10003034|NCT01563211||Patients receiving chemotherapy for breast cancer|Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel).
9943270|NCT01018628|Active Comparator|Cohort 7 - Dose Level G (3000 mg/day)|Cohort 7 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 3000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 3000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
9943271|NCT01018628|Active Comparator|Cohort 8 - Dose Level H (500 mg/day in fed state)|Cohort 8 will be administered at approximately the same time every dosing day and 30 minutes following the start of consumption of a standardized high-fat meal. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The dose of SRT2379 administered to subjects in the fed state is planned to be 500 mg, however this may be modified upwards or downwards following evaluation of safety and pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in the study.
9943272|NCT01018641|Experimental|1|SA3Ag in both stage 1 and stage 2
9943273|NCT01018641|Experimental|2|SA3Ag in stage 1 followed by placebo in stage 2.
9943274|NCT01018641|Placebo Comparator|3|Placebo in both stage 1 and stage 2
9943275|NCT01018641|Experimental|4|SA3Ag in stage 1 and no vaccine in stage 2.
9943276|NCT01018641|Placebo Comparator|5|Placebo in stage 1 and no vaccine in stage 2.
9943277|NCT01018654|Experimental|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
9943278|NCT01018654|Active Comparator|Standard Cognitive-Behavioral Treatment|Standard Cognitive-Behavioral Treatment for Substance Abuse
9943279|NCT01018667||CRT group|
9943280|NCT01018667||OPT group|
9943281|NCT01018693|Experimental|VAK694 AND Immunotherapy (alutard)|
9943282|NCT01018693|Experimental|: VAK694 placebo AND Immunotherapy (alutard)|
9943283|NCT01018693|Experimental|VAK694 placebo AND Immunotherapy (alutard) placebo|
9943284|NCT01018706||STEMI patients treated with PCI|Four hundred patients with STEMI treated with primary PCI or rescue PCI.
9943285|NCT01018719||Left side breast cancer|
9943286|NCT01018719||Right side breast cancer|
9943287|NCT01018745|Experimental|BMS-907351 (XL184)|
10003035|NCT01563224|Experimental|single group, crossover, 3 interventions|
10003036|NCT01563250|No Intervention|Core Laboratory|Patients receiving serial routinely available cardiac biomarker testing in a core laboratory setting using Troponin T. (Roche Centaur)
10003037|NCT01563250|Active Comparator|Point of Care|Patients will receive the Point of Care testing intervention using serial cardiac biomarker testing at the bedside including myoglobin, Troponin I and CK-MB. (Triage Cardiac Panel, Alere)
10003038|NCT01563263|Active Comparator|IC43 100 mcg|IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein
10003039|NCT01563263|Placebo Comparator|Placebo|phosphate buffered saline solution containing 0,9 % NaCL
10003040|NCT01563276||Progressive Supranuclear Palsy|Patients with a diagnosis of probable or possible PSP as defined by the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria.
10003041|NCT01563276||Parkinson's Disease|"Idiopathic PD according to the UK Parkinsons Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)"
10003042|NCT01563276||Healthy Control|
10003043|NCT01563289|Placebo Comparator|placebo|
10003044|NCT01563289|Experimental|Ibuprofen|
10003045|NCT01563315||Adults with CAP admitted to hospital|All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
10003046|NCT01563328|Experimental|Cohort 1|DTG x 5 days followed by BCV + DTG x 10 days
10003047|NCT01563328|Experimental|Cohort 2|DTG x 5 days followed by TVR + DTG x 10 days
10003048|NCT01563341|Experimental|Deep Brain Stimulation|Parkinson's disease patients who would otherwise be undergoing subthalamic nucleus (STN) deep brain stimulation (DBS) will have dual hemispheric stimulation of the STN and globus pallidus interna (GPi).
10003049|NCT01563367|Active Comparator|Iron isomaltoside 1000 (Monofer®)|Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion
10003050|NCT01563367|Placebo Comparator|0,9% sodium saline|Placebo (0.9% sodium saline) - Intravenous infusion
10003051|NCT01563380|Experimental|PRP arm|Platelet-rich plasma was applied over the wound including the capsule, medial and lateral recesses.
10003052|NCT01563380|No Intervention|Control Arm|
10003053|NCT01563393|Other|STAMP using|Relevant to the third part of the study. 30 Children between 1 and 17 years of age from internal medicine department will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale.
10003054|NCT01563393|Other|No STAMP using|Relevant to the third part of the study. Other 30 children that are not screened by dietitian and either not by STAMP
10003055|NCT01563419|No Intervention|Control|dialing up the selected dose of insulin pens without an indicator magnifying window
10003056|NCT01563419|Experimental|Magnifier|dialing up the selected dose of insulin pens clipped on an indicator magnifying window
10003057|NCT01563432|Experimental|febuxostat (TR)|
10003058|NCT01563432|Experimental|febuxostat (RT)|
10003059|NCT01563445|Experimental|activated recombinant human factor VII|
10003060|NCT01563445|Placebo Comparator|Placebo|
10003061|NCT01563458|Experimental|High dose|
10003062|NCT01563458|Experimental|Low dose|
10003063|NCT01563458|Placebo Comparator|Placebo|
10003064|NCT01563471|Experimental|Treatment sequence 1|
10003065|NCT01563471|Experimental|Treatment sequence 2|
10003066|NCT01563471|Experimental|Treatment sequence 3|
10003067|NCT01563471|Placebo Comparator|Treatment sequence 4|
10003068|NCT01563484||low-osmolar contrast media|Patients undergo TACE of low-osmolar contrast media on day 1.
10003069|NCT01563484||iso-osmolar contrast media|Patients undergo TACE of iso-osmolar contrast media on day 1.
10003070|NCT01563497|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
10003071|NCT01563497|Experimental|PF-05089771 TS formulation fasted|Tablets TS formulation- fasted
10003072|NCT01563497|Experimental|PF-05089771 TS formulation fed|Tablets TS formulation- fed
10003073|NCT01563510|Experimental|Laparoscopic operation|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
10003074|NCT01563510|Active Comparator|Open operation|The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
10003075|NCT01563523|Experimental|Activated recombinant human factor VII|
10003076|NCT01563523|Placebo Comparator|Placebo|
10003077|NCT01563562|Experimental|Bardoxolone Methyl 20 mg|
10003078|NCT01563575|Experimental|Intervention Group|fast-track implementation process
10003079|NCT01563575|No Intervention|Control Group|Continue usual routine
10003080|NCT01563588|Experimental|dietary and physical training|12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
10003081|NCT01563588|No Intervention|control|dietary counseling by a dietetician in the anticancer hospital
10003082|NCT01563601|Experimental|Obatoclax mesylate, Carboplatin and Etoposide (CEO)|
10003083|NCT01563601|Active Comparator|Carboplatin and Etoposide (CE)|
10003084|NCT01563614|Experimental|Treatment|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
10003085|NCT01563627|Experimental|Antiepileptic Drug resistant|Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates
10003086|NCT01563627|Experimental|Antiepileptic drug Controlled group|epilepsy well controlled by antiepileptic drugs
10003087|NCT01563640|Placebo Comparator|normal school uniforms|washing only
10003088|NCT01563640|Experimental|insecticide-treated school uniforms|washing and insecticide treatment
10003089|NCT01563653|Experimental|Patients|Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.
10003090|NCT01563692||Paediatric health care workers|NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
10003091|NCT01563692||Non-paediatric health care workers|This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
10003092|NCT01563718|Experimental|PRE-release XR-NTX|Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
10003093|NCT01563718|Active Comparator|POST-release XR-NTX|Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
10003094|NCT01563731|Other|SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l|Highest SBP target. Higher LDL-C target. Control arm
10003095|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l|"Intermediate SBP target. Higher LDL-C target~."
10003096|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Lowest SBP target. Higher LDL-C target
10003097|NCT01563731|Active Comparator|SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l|Highest SBP target. Lower LDL-C target.
10003098|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l|Intermediate SBP target. Lower LDL-C target.
10003099|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C < 1.8 mmol/l|Lowest SBP target. Lower LDL-C target.
10003100|NCT01563744|Experimental|EGD-assisted colonoscopy prep|2 liters of polyethylene glycol instilled through the channel of the endoscope during EGD when colonoscopy expected the following day. Patients follow a clear liquid diet, then ingest an addition 1 liter polyethylene glycol 4 hours prior to colonoscopy. Patients are also given a tap water enema 1 hour prior to colonoscopy.
10003101|NCT01563744|Active Comparator|Standard Colonoscopy Prep|Split-dose polyethylene glycol (2 liters pm prior to colonoscopy, 1 liter 4 hours prior to colonoscopy)), clear liquid diet, metoclopramide 10 mg IV 30 minutes prior to procedure, tap water enema 1 hr prior to colonoscopy
10003102|NCT01563757||Fontan Patients with PLE and PB|Fontan Patients with Protein Losing Enteropathy and Plastic Bronchitis
10003103|NCT01563757||Fontan Patients w/out PLE & PB|Protein Losing Enteropathy and Plastic Bronchitis
10003104|NCT01563757||Glenn Physiology Patients|
10003105|NCT01563757||2 ventricle heart with ASD|2 ventricle heart with Atrial Septal Defect
10003106|NCT01563770|Experimental|Salvia miltiorrhiza extract (Danshen)|p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks
10003107|NCT01563770|Placebo Comparator|placebo|p.o. placebo, twice daily
10214713|NCT04660422||COVID-19 rate|"Two six-month control periods prior to the wide-scale implementation of the intervention, allow us to measure a baseline rate of ACP activity and identify the pre-COVID-19 ACP baseline rate and a COVID-19 ACP baseline rate.~March 15, 2020 - September 14, 2020"
10214714|NCT04660422||ACP rate|ACP rate during the implementation period, which begins December 15, 2020 and continues for six months, to the rates in the previous two control periods December 15, 2020-June 15, 2021
10214715|NCT04657666|Experimental|Nabiximols|"Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Each spray delivers 100 microliters (μL) of nabiximols.~Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks."
10214716|NCT04657666|Placebo Comparator|Placebo|"Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients.~Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks."
10214717|NCT04653571||CASPR2 encephalitis|Cohort of patients with a CASPR2 antibody-associated auto-immune encephalitis.
9943288|NCT01018758|Experimental|palonosetron|
10214718|NCT04649034||86 patients ischemic DCM|A cohort of 86 patients with ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
9943289|NCT01018771|Experimental|Actifuse ABX|Actifuse ABX bone substitute
9943290|NCT01018771|Active Comparator|INFUSE, plus Mastergraft granules|
9943291|NCT01018784|Experimental|MORAb-009|
9943292|NCT01018797|Experimental|INTRASTROMAL CORNEAL RING SEGMENT|Eighteen eyes of 18 patients, 8 men and 10 women, with high levels (> 5 diopters [D]) of postkeratoplasty astigmatism were studied in a nonrandomized, retrospective, observational case series. PK was performed to treat keratoconus in 15 patients, corneal scar after trauma in 2 patients, and Fuchs endothelial dystrophy in 1 patient.
9943293|NCT01018823|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, oral, once daily for 14 days
9943294|NCT01018823|Experimental|Ertugliflozin up to 5 mg|Ertugliflozin up to 5 mg, oral, once daily for 14 days
9943295|NCT01018823|Experimental|Ertugliflozin up to 25 mg|Ertugliflozin up to 25 mg, oral, once daily for 14 days
9943296|NCT01018823|Experimental|Ertugliflozin up to 100 mg|Ertugliflozin up to 100 mg, once daily for 14 days
9943297|NCT01018823|Placebo Comparator|Placebo|Placebo to Ertugliflozin once daily for 14 days
9943298|NCT01018836|Experimental|Riluzole; Radiation Therapy|
9943299|NCT01018849|Active Comparator|Vitamin D (cholecalciferol)|Subjects receive 150,000 IU of Vitamin D3 every 2 months
9943300|NCT01018849|Placebo Comparator|Placebo|Subject will receive a placebo - an exact replica of the Vitamin D3 capsule that does not contain the active ingredient, Vitamin D3
9943301|NCT01018888|Experimental|Keratoprosthesis|
9943302|NCT01018901|Experimental|Arm I|Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.
9943303|NCT01018914|Active Comparator|Prograf with Myfortic|
9943304|NCT01018914|Experimental|Advagraf with Myfortic|
9943305|NCT01018927||Additional MRI images|Prospective review of 100 CMR studies performed on multiple myeloma patients referred for cardiac evaluation by MRI. Three additional MRI images will be performed to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
9943306|NCT01018940||Plavix|
9943307|NCT01018940||Prasugrel|
9943308|NCT01018966|Experimental|Ixabepilone|
9943309|NCT01019005|Experimental|Tibial|
9943310|NCT01019005|Experimental|Wound|
9943311|NCT01019005|No Intervention|Sham|
9943312|NCT01019018|Active Comparator|Stevens cannula|Subtenon with stevens cannula
9943313|NCT01019018|Experimental|Olive tip|Olive tip group
9943314|NCT01019044||Rectal mucosa biopsy|Rectal mucosa samples collection
9943315|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh A|
9943316|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh B|
9943317|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh C|
9943318|NCT01019070|Active Comparator|BMS-650032 in Healthy Subjects|
9943319|NCT01019083|Placebo Comparator|zinc supplementation-Placebo|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
9943320|NCT01019083|Placebo Comparator|Anti Parasite Drug- Placebo|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
9943321|NCT01019083|Experimental|Effect of Arsenic in Dukoral- Control|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
10003108|NCT01563796||TCC positive|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology
10003109|NCT01563796||TCC negative|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.
10003110|NCT01563809|Active Comparator|Low androgens FSH+LH|Patients with androgens below threshold receiving FSH+LH for ovarian stimulation
10003111|NCT01563809|Active Comparator|High androgens FSH+LH|Patients with androgens above threshold receiving FSH+LH for ovarian stimulation
10003112|NCT01563809|No Intervention|High androgens FSH alone|
10003113|NCT01563809|No Intervention|Low androgens, FSH alone|
10003114|NCT01563822|Experimental|follicular fluid group|Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
10003115|NCT01563822|No Intervention|control group|Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.
10003116|NCT01563835|Active Comparator|Epidural (PCEA)|bupivacaine, fentanyl
10003117|NCT01563835|Active Comparator|IV PCA|Intravenous fentanyl patient controlled analgesia
10003118|NCT01563848|Active Comparator|Group 1 (RFA CTI+Reveal)|assessing the incidence of atrial fibrillation in patients with atrial flutter
10003119|NCT01563848|Active Comparator|Group 2 (RFA CTI+Cryo PVI+Reveal)|efficacy of cryoablation in patients with atrial flutter
10003120|NCT01563887|Experimental|DD.com|Participants in this arm will receive the DiabetesDriving.com internet intervention intended to help reduce their risk of being in a future collision.
10003121|NCT01563887|Experimental|DD.com + MI|Participants will receive the DiabetesDriving Internet intervention and two 60 minute Motivational Interview (MI) sessions over the telephone. The MI sessions will take place once before and once following completion of the Internet intervention. This interview will focus on making explicit individual's ambivalence around changing behavior.
10003122|NCT01563900|Sham Comparator|sham-CPAP group|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp).
10003123|NCT01563900|Active Comparator|Auto-titration CPAP|This group will received an auto-titration CPAP, which will have a pressure range of 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
10003124|NCT01563926|Experimental|Somatropin|
10003125|NCT01563939|Active Comparator|Continuous infusion|Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
10003126|NCT01563939|Active Comparator|Demand Bolus|Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.
10003127|NCT01563952|Active Comparator|Non-IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
10003128|NCT01563952|Experimental|IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
10003129|NCT01563952|Active Comparator|Non-IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
10003130|NCT01563952|Experimental|IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
10035141|NCT01803373|Experimental|Treatment Sequence ABC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
10035142|NCT01803373|Experimental|Treatment Sequence ACB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
9943322|NCT01019083|Experimental|zinc supplementation|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
9943323|NCT01019083|Experimental|administration of antiparasitic drugs|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
9943324|NCT01019083|Experimental|Effect of arsenic on Dukoral response|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
9943325|NCT01019109||Titanium rod|Titanium rods used as a part of PSF construct
9943326|NCT01019109||CoCr Rod|Cobalt Chrome rods used as a part of PSF construct
9943327|NCT01019122||Dexa Scan|Eligible patients from 2003 study will receive a follow-up Dexa scan.
9943328|NCT01019161|Experimental|AZD1152|100 mg Lyophile 5 mL Diluent
9943329|NCT01019161|Experimental|C14 AZD1152|AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial.
9943330|NCT01019174|Active Comparator|oral application|oral application Cyclophosphamide
9943331|NCT01019174|Active Comparator|intravenous application|intravenous application Cyclophosphamide
9943332|NCT01019200||Psoriasis|Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
9943333|NCT01019200||Control|Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
9943334|NCT01019213|Placebo Comparator|Septal pacing|Septal lead will be activated.
9943335|NCT01019213|Experimental|His-pacing|His lead will be activated 80 ms before septal lead
9943336|NCT01019226||cardiac MRI|Ischemic cardiomyopathy, non ischemic cardiomyopathy, myocarditis, cardiomyopathy
9943337|NCT01019239|Experimental|Laparoscopic Washout|Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed. Intravenous antibiotics will be continued for a minimum of 72hours and oral antibiotics will be continued for one week. Oral fluids will be commenced on the first postoperative day and diet will be introduced subsequently, depending on clinical status. Early mobilisation will be encouraged.
9943338|NCT01019239|Active Comparator|Conventional Treatment|Operative procedure will be similar to that previously described.Patients randomised to the second arm will undergo standard management (according to local preference) which will consist of Hartmanns Procedure or Primary resection of the diseased segment and anastomosis. Post operative care will be standardised between arms as described in the protocol
9943339|NCT01019265|Experimental|Norspan patch (Buprenorphine TDS)|
9943340|NCT01019265|Active Comparator|TramadolSR tab (Tridol SR tab)|
9943341|NCT01019278|Experimental|Arm I|Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
9943342|NCT01019291|Experimental|NO2|NO2 400 µg/m3
9943343|NCT01019291|Experimental|Formaldehyde|Formaldehyde 100 µg/m3
9943344|NCT01019291|Experimental|NO2 + Formaldehyde|mixture of Formaldehyde and NO2
9943345|NCT01019291|Placebo Comparator|Placebo|
9943346|NCT01019330||Femoral|Subjects receiving femoral artery cardiac catheterization
9943347|NCT01019330||Radial|Subjects receiving radial artery cardiac catheterization
9943348|NCT01019382|Experimental|All patients|All patients entering the trial
9943349|NCT01019395|Experimental|Group 1|Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion.
9943350|NCT01019395|Experimental|Group 2|Group 2: Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion
9943351|NCT01019395|Experimental|Group 3|Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
9943352|NCT01019408|Active Comparator|CQ25|Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
9943353|NCT01019408|Active Comparator|CQ40|Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
9943354|NCT01019421|Experimental|Lu AE58054|
9943355|NCT01019421|Placebo Comparator|Placebo|
10003131|NCT01563965|Active Comparator|Conventional preoperative fast|Patients underwent surgery after 8h fast
10003132|NCT01563965|Experimental|Carbohydrate plus protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil).All the patients fasted for solids at least 8 hours from the operation
10003133|NCT01563991|Active Comparator|Standard fluid volume|Subject receives normal fluid volume during peri-operative period
10003134|NCT01563991|Experimental|Reduced Fluid Volume|Subject receives a reduced fluid volume during the peri-operative period
10003135|NCT01564004|Experimental|Clinical hypnosis|20 minutes tape recorded clinical hypnosis intervention
10003136|NCT01564004|Active Comparator|Neuro-linguistic programming|20 minutes tape recording of nouro-linguistic programming intervention
10003137|NCT01564017|Experimental|Allergovac depot. Group 1|Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
10003138|NCT01564017|Experimental|Allergovac depot. Group 2|Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
10003139|NCT01564017|Experimental|Allergovac depot. Group 3|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
10003140|NCT01564017|Experimental|Allergovac depot. Group 4|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
10003141|NCT01564017|Experimental|Allergovac depot. Group 5|Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
10003142|NCT01564017|Placebo Comparator|Allergovac depot placebo. Group 6|The same scheme of treatment as the active groups
10003143|NCT01564030|Other|Empty stomach|Patients have fasted for 8 hours.
10003144|NCT01564030|Other|Fluid|Patients have fasted for 8 hours, followed by the consumption of 250mL of apple juice.
10003145|NCT01564030|Other|Solid|Patients have fasted for 8 hours, followed by the consumption of their breakfast.
10003146|NCT01564043|Experimental|website and pedometer|
10003147|NCT01564069||IT opioids|Patients with IT pumps receiving IT opioids
10003148|NCT01564069||Systemic opioids|Patients taking oral or transdermal opioids for chronic pain
10003149|NCT01564069||Non-opioid management|Patients managing chronic pain without taking opioids
10003150|NCT01564082|Experimental|ETT first|Patients will have the endotracheal tube (ETT) introduced into the pharynx prior to GlideScope insertion, and then advanced under GlideScope guidance into the trachea.
10214719|NCT04649034||86 patients non ischemic DCM|A cohort of 86 patients with non-ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
9476271|NCT03573531||Preterm Milk|Preterm transitional or mature breast milk Sampled from healthy mothers of preterm babies (born , 37 weeks gestational age) at a neonatal unit in the United Kingdom Collection of 5 ml at a time point of routine expression
10003151|NCT01564082|No Intervention|Control Group|Patients will have the GlideScope introduced into the pharynx. The endotracheal tube (ETT) will then be advanced under direct vision into the mouth/pharynx. The ETT will then be advanced into the trachea under GlideScope guidance.
10003152|NCT01564095|Experimental|Tacrolimus + HTK|Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
10003153|NCT01564095|Placebo Comparator|HTK|Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation
10003154|NCT01564108|Experimental|Ranibizumab|Series of intravitreal injections of Ranibizumab
10003155|NCT01564134|Experimental|HepB 5ug|receive the vaccine with 5ug HBsAg
10003156|NCT01564134|Experimental|HepB 10ug|receive the vaccine with 10ug HBsAg
10214720|NCT04649034||86 patients hypertrophic cardiomyopathy|A cohort of 86 patients with hypertrophic cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 55% or with an apical aneurism diagnosed in an image test
10003157|NCT01564134|Experimental|HepB 20ug|receive the vaccine with 20ug HBsAg
10214721|NCT04643574|Experimental|NeoTIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (fludarabine and cyclophosphamide), Low Dose Irradiation (LDI), ex vivo expanded Tumor Infiltrating Lymphocyte (TIL), enriched for tumor antigen specificity (NeoTIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
10214722|NCT04636840|No Intervention|Control Group|Care as usual-referral to nationwide resources for eating disorders (NEDA)
10214723|NCT04636840|Experimental|Experimental Group A- Mobile App with Social Networking Feature|Access to Space From Body and Eating Concerns program on SilverCloud Health App in addition to access to Private Facebook group for social networking support.
10003158|NCT01564134|Experimental|HepB 60ug|receive the vaccine with 60ug HBsAg
10003159|NCT01564147|Other|Immediate Education therapeutic|Access to the course of immediate therapeutic education
10003160|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
10003161|NCT01564160|Experimental|Arm 1: PCSO-524|PCSO-524
10003162|NCT01564160|Active Comparator|Arm 2: Fish Oil|Fish Oil
10003163|NCT01564173||VT Ablation|Patients undergoing epicardial mapping and ablation procedure for a ventricular tachycardia
10003164|NCT01564186||MulitPoint Pacing|
10003165|NCT01564186||BiV Conventional|
10003166|NCT01564199|Experimental|Treatment A|Salmeterol/fluticasone propionate with concomitant charcoal
10003167|NCT01564199|Experimental|Treatment B|Salmeterol/fluticasone propionate without concomitant charcoal
10003168|NCT01564212|Active Comparator|standard airflow and forced air warming|Subjects will lie on operating room bed with standard airflow and forced air warming.
10214724|NCT04636840|Experimental|Experimental Group B- Mobile App Only|Access to Space From Body and Eating Concerns program on SilverCloud Health App.
10214725|NCT04633889|Experimental|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
10214726|NCT04633889|Placebo Comparator|Placebo|Normal saline (240mL) intravenous infusion over 12 hours
9476272|NCT03573531||Term Milk|Term mature breast milk Sampled from healthy mothers of term babies in the community (e.g. Baby Cafes). Collection of 5 ml expressed for this study
9476273|NCT03573492|Active Comparator|In-Person Education by Ultrasonographer|In-person education of the DVT scanning technique by an RDMS-certified ultrasonographer
9476274|NCT03573492|Active Comparator|Online Education (EM Sono)|Online lectures of DVT scanning technique by an Emergency Ultrasound fellowship director
9943356|NCT01019434|Other|Temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
9943357|NCT01019434|Experimental|Temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
9943358|NCT01019447|Active Comparator|Study group|The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used.
9943359|NCT01019447|Active Comparator|Control group|The control group in which polyglactin 910 antimicrobial sutures will be used.
9943360|NCT01019473|Experimental|AFQ056A|
9943361|NCT01019473|Placebo Comparator|Placebo|
9943362|NCT01019499|Active Comparator|berry products|Berry products
9943363|NCT01019499|Placebo Comparator|control products|Control products
9943364|NCT01019512|Active Comparator|Arm I|Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.
9943365|NCT01019512|Experimental|Arm II|Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.
9943366|NCT01019512|Experimental|Arm III|Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.
9943367|NCT01019525||Mouth Breathing|Children aged between 8-12 years, with clinical diagnosis of mouth breathing
9943368|NCT01019525||Nasal Breathing|Children aged between 8-12 years old, with normal breathing
9943369|NCT01019551|Experimental|ARM A : ART intensification alone|Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
9943370|NCT01019551|Experimental|ARM B : ART intensification + Immunomodulation|Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
9943371|NCT01019564|Experimental|Easy Rub MPS|Complete Easy Rub Formula MPS
9943372|NCT01019564|Active Comparator|Aquify MPS|
9943373|NCT01019577|Experimental|Ixabepilone|
9943374|NCT01019590|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
9943375|NCT01019590|Active Comparator|2|Benicar HCT ® Tablets 40 mg/25 mg
9943376|NCT01019603|Experimental|1|Tazarotene foam 0.1%
9943377|NCT01019603|Active Comparator|2|Tazaroc Gel 0.1%
9943378|NCT01019642|Experimental|Vitamin D|Cholecalciferol, 4,000 IU/d for 6 months
9943379|NCT01019642|Placebo Comparator|Placebo|placebo
9943380|NCT01019655|Experimental|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
9943381|NCT01019655|No Intervention|Control|No intervention other than usual care at the study site
9943382|NCT01019668|Active Comparator|verteporfin PDT, half-dose|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
9943383|NCT01019668|Active Comparator|verteporfin PDT, half-fluence|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
9943384|NCT01019681|Experimental|UBC injection into one leg of PVD pt|25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
9943385|NCT01019733|Experimental|Patients|Children whom will receive intrathecal autologous stem cells
9943386|NCT01019746|Experimental|control propofol administration|
9943387|NCT01019759|No Intervention|No add-on AF-surgery|patient undergoing only scheduled valve and/or coronary bypass surgery
9943388|NCT01019759|Experimental|PV isolation|patient undergoing add-on epicardial microwave energy pulmonary vein isolation
9943389|NCT01019772|Experimental|LBVH0101|
9943390|NCT01019772|Active Comparator|Hiberix|
9943391|NCT01019785|Active Comparator|High dose Vitamin D|
9943392|NCT01019785|Sham Comparator|Low dose Vitamin D|
9943393|NCT01019798|Experimental|open label|
9943394|NCT01019824|Experimental|Low Dose|160 mg dose
9943395|NCT01019824|Experimental|High Dose|320 mg dose
10214727|NCT04625764|Experimental|patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB|
10214728|NCT04622943|Experimental|firearms safety|Children will spend two 30-minute sessions engaged on ShootSafe, an internet-based training program on firearms safety.
10214729|NCT04622943|Active Comparator|nutrition|Children will spend two 30-minute sessions engaged on nourishinteractive.com, an internet-based training program on nutrition and exercise.
10214730|NCT04620369|Experimental|Arm A (rose geranium in sesame oil nasal spray)|Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.
10214731|NCT04620369|Placebo Comparator|Arm B (isotonic nasal saline)|Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.
9943396|NCT01019824|Placebo Comparator|Placebo|Placebo Comparator
9943397|NCT01019837|Experimental|Monovalent MF59- Adjuvanted vaccine|Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular
9943398|NCT01019850|Other|Treatment for All Patients|Patients on study will receive vorinostat orally once daily on days 1 to 14. The starting dose level is 180 mg/M2. The maximum dose is 400 mg. Patients will receive 131- I Metaiodobenzylguanidine on day 3, 1hr after vorinostat dosing. Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg. Peripheral Blood Stem Cell Infusion is planned for 2 weeks after MIBG infusion (day 17). The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing. Patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines.
9943399|NCT01019863|Experimental|Oxaliplatin|oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
9943400|NCT01019876|Experimental|Fludarabine|
9943401|NCT01019876|Experimental|Cyclohosphamide 200|
9943402|NCT01019876|Experimental|Cyclophosphamide 40|
9943403|NCT01019876|Experimental|Cyclophosphamide 30|
9943404|NCT01019889|Experimental|Placebo|Placebo (encapsulated starch + lactose)
9943405|NCT01019889|Experimental|SCRT(Socheongryong-tang )|encapsulated Socheongryong-tang extract
9943406|NCT01019889|Experimental|YPS (Yeongyopaedok-san)|Encapsulated Yeongyopaedok-san extract
9943407|NCT01019915|Other|Heart failure patients. Intervention CRT|CRT implantation in heart failure. Effect of intervention after 6 months of treatment.
9943408|NCT01019941|Other|1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.|
9943409|NCT01019941|Other|1st cycle:Taxotere inj.-> 2nd cycle:CKD-810|
9943410|NCT01019993|Active Comparator|good pulmonary functions (group N)|The patients were allocated if they have forced vital capacity (FVC %) and/or forced expiratory volume in 1 sec (FEV1%) of 80% of predicted or more
9943411|NCT01019993|Active Comparator|pulmonary dysfunction (group PD)|The patients were allocated if they have FVC and/or FEV1 of 50%-79% of predicted
9943412|NCT01020032|Experimental|Music therapy|"Individual receptive music therapy by U sequence method"
9943413|NCT01020045||HIV-seropositive, HIV seronegative|No intervention - biologic samples were collected from both HIV positive and HIV negative subjects
9943414|NCT01020045||Treatment naive subjects|HIV-seropositive subjects naive to antiretroviral therapy. HIV-seronegative subjects otherwise healthy.
9943415|NCT01020058|Active Comparator|Lichtenstein in local anesthesia (LLA)|Patient operated in local anesthesia, with an anterior mesh repair according to Lichtenstein
9943416|NCT01020058|Active Comparator|TEP|Patient receives a totally extraperitoneal laparoscopic repair
9943417|NCT01020071|Other|laser treatment|laser peripheral iridotomy and laser peripheral iridoplasty
9943418|NCT01020084||Control|Subjects with normal salivary flow rate
9943419|NCT01020084||Hyposalivation|Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy.
9943420|NCT01020136|Experimental|Sequence 1 (BABA)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
9943421|NCT01020136|Experimental|Sequence 2 (ABAB)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B-> A -> B
9943422|NCT01020162|Active Comparator|Non-surgical|TENS, amitriptyline, gabapentin.
9943423|NCT01020162|Active Comparator|Surgical intervention|Resection of the ilioinguinal nerve
9943424|NCT01020175|Other|Bone marrow transplantation|Patients received bone marrow transplantation
9943425|NCT01020175|Other|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
9943426|NCT01020201||PONV group|patients with postoperative nausea and vomiting
9943427|NCT01020201||Control group|patients without postoperative nausea and vomiting
9943428|NCT01020214|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
9943429|NCT01020214|Active Comparator|2|Benicar HCT® Tablets 40 mg/25 mg
9943430|NCT01020227|Experimental|Integrative Therapies|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
9943431|NCT01020227|No Intervention|Standard Care|Patients were given no intervention but were contacted at 6 weeks and 6 months for data collection purposes
9943432|NCT01020240|No Intervention|Avaliation|This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
9943433|NCT01020240|No Intervention|Orientation|In this group will be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory and in the second post operatory wil be realize a new interview.
10003169|NCT01564212|Active Comparator|laminar airflow with surgical drapes|Subjects will lie on operating room bed with laminar airflow device on and surgical drapes surrounding bed.
10003170|NCT01564212|Active Comparator|laminar aiflow with forced air warming|Subjects will lie on operating room bed with laminar airflow on and warming forced air.
10003171|NCT01564212|Active Comparator|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow and surgical drapes surrounding bed.
10003172|NCT01564225|Experimental|EDI200|
10003173|NCT01564238|Experimental|High calcium diets (1300 mg or higher)|
10003174|NCT01564238|Experimental|Low calcium diet (800 mg/d)|
10003175|NCT01564251|Experimental|Stage 1 Arm 1: GDC-0575 Monotherapy|Participants will receive escalating doses of GDC-0575, administered orally, for 3 consecutive days, starting on Days 1, 8, and 15 of each 21-day cycle.
10003176|NCT01564251|Experimental|Stage 1 Arm 2a: GDC-0575 + Gemcitabine (750 or 1000 mg/m^2)|Participants will receive gemcitabine 750 milligrams per meter square (mg/m^2) or 1000 mg/m^2, intravenously, on Days 1 and 8 followed by escalating doses of GDC-0575 orally, on Days 2 and 9 of each 21-day cycle.
10003177|NCT01564251|Experimental|Stage 1 Arm 2b: GDC-0575 plus Gemcitabine (500 mg/m^2)|Participants will receive gemcitabine 500 mg/m^2, intravenously, once weekly for approximately 2 consecutive weeks of any 3-week period and escalating doses of GDC-0575 orally approximately 24-hours after each gemcitabine dose.
10003178|NCT01564251|Experimental|Stage 2: GDC-0575 plus Gemcitabine|Participants will receive GDC-0575 in combination with gemcitabine intravenously (1000 mg/m^2 and/or 500 mg/m^2), at or below the MTDs for the combination treatments that are determined during Stage 1.
10003179|NCT01564264|Experimental|Sentinel Node Biopsy|Each participant will have both measurements, the new diagnostic test (sentinel node biopsy) and the gold standard (complete lymphadenectomy)
10003180|NCT01564290|Placebo Comparator|probiotic|Probiotic product with Sacharomices Boulardii
10003181|NCT01564290|Active Comparator|probiotic yogurt|Yogurt with Lactobacilus Rhamnonsus strain spp
10003182|NCT01564303|No Intervention|2. Acetylcysteine group (NAC+S) , aside with the saline, will|2. Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of administration of the contrast agent.
10003183|NCT01564303|Experimental|CAR+S , aside with the saline, carnitne will be adminstrated|Carnitine group (Car+S), aside with the saline, patients will be administrated with 20 mg/kg carnitine over 10 minutes 2 hours prior to the administration of the contrast agent and 8 hours after CT.
10003184|NCT01564303|Experimental|Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with|4. Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the administration of the contrast agent and in the subsequent day.
10003185|NCT01564303|No Intervention|Control group (S) will be treated without any extra agents|Control group ( S ) , which will be treated without any extra agents, just Saline (0.9 %) will be given I.V. at a rate of 1 ml per kilogram of body weight per hour for 12 hours before and 12 hours after administration of the contrast agent.
10003186|NCT01564316||neurodegeneration patients|•neurodegeneration patients and control group include dementia patients visited the part of neurology
10003187|NCT01564329|Experimental|endostar2|CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
10003188|NCT01564329|Experimental|endostar1|CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
10003189|NCT01564342|Other|wounds irrigated with sterile normal saline|Patients in this arm had their wounds irrigated with sterile normal saline
10003190|NCT01564342|Other|wound irrigation with tap water|Patients in the arm had their wounds irrigated with tap water
10003191|NCT01564355|Experimental|Systemic Steroid Group|Will receive post-operative oral steroids for 10 days as per usual protocol.
10003192|NCT01564355|Placebo Comparator|Placebo|Will receive placebo pills for 10 days post-operatively
10003193|NCT01564368|Experimental|Diffusion Weighted-MRI|Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.
10003194|NCT01564381|Experimental|Resveratrol|The capsules will contain 90mg of resveratrol.
10003195|NCT01564381|Experimental|ResA|ResA is a product produced by using patented technology that physically binds resveratrol to arginine, creating a novel conjugate. The capsules will contain 90mg of resveratrol.
10003196|NCT01564381|Placebo Comparator|Placebo|The placebo will be cellulose.
9943434|NCT01020240|Experimental|Guide|in This group wiil be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory, will be realize the orientations and the guide will be give, and in the second post operatory will be realize a new interview.
9943435|NCT01020253|Active Comparator|Alendronate medication|
9943436|NCT01020253|Active Comparator|Alfacalcidol medication|
9943437|NCT01020253|No Intervention|Non-medication|
9943438|NCT01020266|Active Comparator|Electroacupuncture|
9943439|NCT01020266|Sham Comparator|Control|
9943440|NCT01020279|Other|Parallel Group A|Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
9943441|NCT01020279|Other|Parallel Group B|oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
9943442|NCT01020292|Experimental|NFV and Concurrent ChemoRads|
9943443|NCT01020331|Experimental|ACTIVE|
9943444|NCT01020344|Active Comparator|Lung volume reduction surgery|This group will receive lung volume reduction surgery
9943445|NCT01020344|No Intervention|No lung volume reduction surgery|This group will not receive LVRS during the 3 months of the study
9943446|NCT01020357|Active Comparator|caffeine|
9943447|NCT01020357|Placebo Comparator|placebo|
9943448|NCT01020370||Alemtuzumab Group|
9943449|NCT01020370||Interferon Beta-1a SC Group|
9943450|NCT01020383|Experimental|ALX-0081|
9943451|NCT01020383|Active Comparator|GPIIb/IIIa inhibitor|
9943452|NCT01020396|Experimental|1|Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)
9943453|NCT01020396|Active Comparator|2|MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)
9943454|NCT01020409||cardiac surgery with CPB use|Adult patients, who signed the informed consent, intervention: first-time scheduled heart surgery with CPB use.
10003197|NCT01564420||Intrathecal morphine|Patients were randomized for general anesthesia, and allocated in the control group and morphine intrathecal group.
10003198|NCT01564420||Control group|
10003199|NCT01564433|Experimental|Gait trainer treatment|
10003200|NCT01564433|Active Comparator|Conventional group|
10003201|NCT01564446|Experimental|secure message regarding post-discharge medication|Participants will be sent a secure message to confirm compliance with post-discharge medication.
10003202|NCT01564472||PSG Scoring|Retrospective, de-identified PSG studies will be collected and scored by registered polysomnogrpahy technicians. The manually scored studies will be compared to the automatic scoring performed by the new Sleepware Software G3 Autoscoring Algorithm.
10003203|NCT01564498|Placebo Comparator|White potato|Participants will consume 300-500 g of cooked white potatoes per day
10003204|NCT01564498|Experimental|Purple Potato|Participants will consume 300-500 g of cooked purple potato per day
10003205|NCT01564498|Placebo Comparator|Orange carrots|Participants will consume 200-300 g typical varieties of orange carrots during the intervention
10003206|NCT01564498|Experimental|Purple Carrots|Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
10003207|NCT01564511|Experimental|Gait trainer treatment|Roboti gait training by mean of Gangtrainer I
10003208|NCT01564511|Sham Comparator|Conventional group|Convetional physical gait training
10003209|NCT01564550||type 2 diabetes|
10003210|NCT01564550||healthy subjects|
10003211|NCT01564563|Placebo Comparator|Placebo|
10003212|NCT01564563|Experimental|Low dose|
10003213|NCT01564563|Experimental|High dose|
10003214|NCT01564576|No Intervention|Conventional neuromuscular blockade|The dose of rocuronium (medication used for NMB during anesthesia)will be adjusted to maintain a depth of NMB of T1 of 10-20% as assessed by a nerve stimulator. At the end of surgery patients will receive neostigmine 2.5 mg and atropine 1 mg to reverse the effect of rocuronium. Extubation will be performed when train-of-four ratio ≥ 0.9.
10003215|NCT01564576|Experimental|Profound neuromuscular blockade|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
10003216|NCT01564602|Experimental|single port laparoscopic surgery|2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders
10003217|NCT01564615|Experimental|AgION catheter|Patients in this arm received an AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
10003218|NCT01564615|Active Comparator|Non-impregnated polyurethane catheter|Patients in this arm received a non-impregnated polyurethane umbilical catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
10003219|NCT01564641||iDuo G2|iDuo G2 to be implanted in the patient.
10003220|NCT01564667|Experimental|Attention Bias Modification Treatment|Attention bias modification training using a computerized spatial attention task (dot-probe) designed to alter threat-bias attention patterns away from threat.
10003221|NCT01564667|Active Comparator|Attentional Control Training|Attention control training using a computerized spatial attention taks (dot-probe) counter balances training toward and away from threat.
10003222|NCT01564680|Experimental|Lornoxicam|Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
10003223|NCT01564680|Placebo Comparator|Control|Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
10003224|NCT01564680|Experimental|Paracetamol|1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively
10003225|NCT01564719|Experimental|Immediate-intervention arm|This is a holistic health intervention. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
10003226|NCT01564719|Experimental|One-year waitlist arm|This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
10003227|NCT01564719|Experimental|Two-year waitlist arm|This holistic health intervention arm for Cohort 3 was the same as Cohort 2's, only Cohort 3 waited for two years and received the stress management program meQuilibrium rather than Williams LifeSkills.
10003228|NCT01564745|Other|Cough Determinants|
10003229|NCT01564771||Group one|Adults ≥18 years of age with chest X-ray confirmed CAP
10003230|NCT01564797|Active Comparator|Education Intervention|A series of 5 home-based lay health educator-led education sessions (Home Health Parties (HHP)), to educate a Hispanic population about diabetes, management of diabetes, and diet and exercise
10003231|NCT01564797|No Intervention|Control Arm|A delayed intervention where the intervention was delivered after the hA1c level was measured for the second time (3 months after the baseline measurement)
10003232|NCT01564810|Experimental|Arm A|patients received cetuximab in combination with chemotherapy
10003233|NCT01564810|Active Comparator|Arm B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
10003234|NCT01564823|Experimental|Metronidazole + Azathioprine.|Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
10003235|NCT01564823|Active Comparator|Metronidazole + Adalimumab|Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.
10003236|NCT01564836|Experimental|Imatinib treatment discontinuing|
10003237|NCT01564849||chronic rhinitis,|
10003238|NCT01564849||chronic sinusitis|
10003239|NCT01564849||nasal polyps|
10003240|NCT01564849||control rhinitis|
10003241|NCT01564849||control sinusitis|
10003242|NCT01564849||control polyps|
10003243|NCT01564875|Experimental|Simvast CR|"Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.~Placebo with the same appearance and formulation as that of Zocor Tab, 1 tablet once daily to be administered between 6 and 9 p.m."
10003244|NCT01564875|Active Comparator|Zocor|"Placebo with the same appearance and formulation as that of Simvast CR Tab, 1 tablet once daily to be administered between 6 and 9 a.m.~Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m."
10003245|NCT01564888|Placebo Comparator|Patent hemostasis|Patent hemostasis is the technique for radial artery hemostasis after transradial catheterization, with proactive attempt to maintain radial artery hemostasis and radial artery patency.
10003246|NCT01564888|Active Comparator|Ulnar artery compression|Ulnar artery compression will involve radial artery hemostasis using patent hemostasis technique and compression of ulnar artery to the point of occluding flow, in an attempt to augment radial artery flow.
10003247|NCT01564901||Cohort|
10003248|NCT01564927|Experimental|Electroacupuncture to right LI4 and LI11|
10003249|NCT01564927|Sham Comparator|Electroacupuncture to knee caps|Electroacupuncture to knee caps
10003250|NCT01564927|Placebo Comparator|Sham electroacupuncture to LI4 & LI11|
10003251|NCT01564966||Living kidney donors|Those who donate kidneys
10003252|NCT01564979|Experimental|preseptal|
10003253|NCT01564979|Experimental|pretarsal|
10003254|NCT01564992||Parkinson disease|Identification of genes
10003255|NCT01565005||Microcephaly|Microcephaly Intellectual abilities Cranial MRI
10003256|NCT01565005||FANCONI ANEMIA|
10003257|NCT01565018|Experimental|Treatment A - Treatment B|"Treatment A: Test; drug product PR 2.2.1~Treatment B: Reference; drug product PR 2.1.4~Sequence of two single applications of Rotigotine transdermal patches (PR 2.2.1 first) for 24 hours separated by a Washout Period of 5 days."
10003258|NCT01565018|Experimental|Treatment B - Treatment A|"Treatment B: Reference; drug product PR 2.1.4~Treatment A: Test; drug product PR 2.2.1~Sequence of two single applications of Rotigotine transdermal patches (PR 2.1.4 first) for 24 hours separated by a Washout Period of 5 days."
10003259|NCT01565031||controlled asthmatics, down-titration|Adults (age between 18 and 80) with asthma under control (see definitions) during the last 3 months, treated with a combination of ICS and long-acting beta-agonist (LABA).
10003260|NCT01565044|Experimental|" AUTO  Group"|
10003261|NCT01565044|Sham Comparator|" CONTROL  Group"|
10003262|NCT01565057|Experimental|sedimenting meal|To assess whether rates of gastric emptying of a specifically formulated emulsion drink are significantly different from a control drink and that this in turn leads to differences in satiation (cessation in the desire to eat) and satiety (desire to limit further food intake) as measured by visual analogue scale (VAS) satiety questionnaire and blood CCK.
10003263|NCT01565070|Active Comparator|Biofreeze|
10003264|NCT01565070|Placebo Comparator|Placebo|Use of placebo ointment
10003265|NCT01565096|Experimental|Vildagliptin plus Metformin|Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
10003266|NCT01565096|Active Comparator|Glimepirid plus Metformin|Metformin (1000 mg BID) + Glimepiride (individual dosage)
10003267|NCT01565109|Experimental|Single arm study|"Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU~Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks"
10003268|NCT01565122||Cohort|
10003269|NCT01565135|Experimental|Intervention Practices|Intervention offices will adopt a multimodal vaccine program to increase their patients' vaccine rates.
10003270|NCT01565135|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
10003271|NCT01565161|Experimental|Home-Based Health Coaching|Intervention delivered in the home.
10003272|NCT01565161|Active Comparator|Control Arm|Mailed educational materials
10003273|NCT01565174||High activity COMT|Carriers of high activity COMT158Val allele who are expected to show higher THC-induced meso-limbic DA release
10003274|NCT01565174||Low activity COMT|Carriers of low activity COMT 158Met homozygotes are expected to release low amount of dopamine after smoking a cigarette with THC
10003275|NCT01565200|Other|T-DM1|After an imaging phase, the patient will receive T-DM1 iv every 3 weeks until progression or toxicity
10003276|NCT01565213|Active Comparator|CBT cognitive behavioral therapy|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks
10003277|NCT01565213|Active Comparator|MMI Multimodal group intervention|group multimodal intervention
10003278|NCT01565213|Other|CAU|Care as usual given by the GPs
10003279|NCT01565226||Open|open, observational study
10003280|NCT01565239|Experimental|Fiix PT (Fiix-INR) monitoring and dosing of warfarin|The modified prothrombin time, sensitive only to factor II and X activity, will be used to monitor and dose warfarin.
10003281|NCT01565239|Active Comparator|PT (INR) monitoring and dosing of warfarin|The prothrombin time, sensitive to factors II, VII and X activity, will be used to monitor and dose warfarin.
10003282|NCT01565252|No Intervention|Stage 1|"Dietary regimens:~Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant."
10003283|NCT01565252|Experimental|Stage 2|Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
10003284|NCT01565265|Active Comparator|GnRH agonist long protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with decapeptyl, which will be administered from the midluteal phase of the preceding menstrual cycle up to ovulation induction.
10003285|NCT01565265|Experimental|antagonist protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with Cetrotide, which will be administered from the day six up to ovulation induction.
10003286|NCT01565278|Experimental|Soybean oil + Fish oil|Intralipid (0.25 g/kg/TPN day) + Omegaven (0.4 g/kg/TPN day) for a period of 6 months.
10003287|NCT01565278|Active Comparator|Soybean oil (Standard treatment)|Standard treatment: Intralipid (0.25 g/kg/TPN day) for a period of 6 months
10003288|NCT01565304|Experimental|POWER Through Choices|10-session group-based sexual education curriculum
10003289|NCT01565304|No Intervention|Usual services|No intervention
10003290|NCT01565317|Experimental|Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
10003291|NCT01565317|No Intervention|Control Group|Matched control group will be recruited from obese patients with diabetes followed at Joslin Clinic. This group will receive the routine standard diabetes care.
10003292|NCT01565395|Experimental|Xeomin Injections|Fifteen units (0.15 ml) of incobotulinum toxin A injected into each parotid gland and 20 units (0.2 ml) to each submandibular gland for a total dose of 70 units using anatomical landmarks for ALS Twenty units (0.2ml) injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks for PD/parkinsonism
10003293|NCT01565395|Placebo Comparator|Placebo|0.15 ml sterile 0.9% saline injected into each parotid gland and 0.2 ml to each submandibular gland using anatomical landmarks for ALS 0.2ml injected into each parotid gland and 0.3 ml to each submandibular gland using anatomical landmarks for PD/parkinsonism
10003294|NCT01565408|Experimental|NNC0114-0006|
10003295|NCT01565408|Placebo Comparator|Placebo|
10003296|NCT01565447||Children with ALL or LL|Children diagnosed with ALL or LL will be recruited for this study
10003297|NCT01565460||pancreatic/biliary strictures|Sample Collection: Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
10003298|NCT01565473||Parkinson disease patients|
9476275|NCT03573479||Pre-implementation cohort|This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians
9528722|NCT03208075|Experimental|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
10003299|NCT01565473||Healthy normal controls|
10003300|NCT01565486|Other|Ultrasonic coagulation device|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
9801104|NCT01706926|Experimental|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
9801105|NCT01706952|Experimental|Cocaine|"Cocaine 4%. Three cotton neuropatties will be soaked with 4% cocaine. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This intervention will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
9801106|NCT01706952|Active Comparator|Adrenaline|"Adrenaline 1/1.000 Three cotton neuropatties will be soaked with Adrenaline 1/1,000. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
9801107|NCT01706965|Experimental|Kuvan|Kuvan once-daily dosing initiated with 10mg/kg for the first week followed by 20mg/kg for the remaining weeks of the study
9801108|NCT01706965|Active Comparator|Multivitamin|Daily multivitamin tablet
9801109|NCT01706978|Experimental|Soft Tissue Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
9801110|NCT01706978|Active Comparator|Bone Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
10214732|NCT04620252|Experimental|Chewing calcium supplements|"Participants will be given one of 4 different treatments to chew: a negative control group and 3 calcium supplements with different calcium compositions.~Participants will be randomized to determine the sequence of exposure to the different treatments."
10214733|NCT04620252|Experimental|Fluoride rinse|Participants will rinse with an over the counter sodium fluoride rinse for 1 min, either alone or after having chewed with the calcium supplement providing the maximum calcium release in arm 1.
10214734|NCT04603417||Patients|Patients with CRPS diagnosis
10214735|NCT04603417||Controls|Healthy controls with known Neurological Disorders
10214736|NCT04600973|Active Comparator|Surveillance with Technical Assistance|Surveillance will be offered to 3 teams with Technical Assistance (TA) in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported.
9801111|NCT01707004|Experimental|Treatment (donor bone marrow transplant)|"Beginning between days -29 and -22, patients receive decitabine IV over 1 hour daily for 10 days, fludarabine phosphate IV over 30 minutes on days -5 to -2, and busulfan IV over 3 hours on days -5 to -2.~PREPARATIVE REGIMEN: Patients undergo total-body irradiation BID on day -1.~TRANSPLANT: Patients undergo allogeneic bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus PO BID or IV continuously on days 5-180, mycophenolate mofetil PO TID on days 5-35, and filgrastim SC beginning day 5 until ANC >= 1,000/mm^3 for 3 consecutive days."
10214737|NCT04600973|Active Comparator|Surveillance with EBIP Coaching|Surveillance will be offered to 3 teams with Evidence-Based Infection Prevention Bundle (EBIP) coaching in block randomization. Surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention.
10214738|NCT04600973|Active Comparator|Technical Assistance No Surveillance|TA will be offered to 3 teams. TA will have monthly scheduled TA calls (60 minutes each) with each team individually to review and discuss the protocol interventions (as is done in the EBIP group) and allow for a consultation with experts on the peri-operative interventions. Surveillance toolkit will only be used for transmission data collection.
10214739|NCT04600973|Active Comparator|EBIP Coaching No Surveillance|EBIP will be offered to 3 teams. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Surveillance toolkit will only be used for transmission data collection.
10214740|NCT04599725||Pregnant people|
10214741|NCT04574869|Experimental|Cohort 1|
10214742|NCT04574869|Experimental|Cohort 2|
10214743|NCT04574869|Placebo Comparator|Placebo Cohorts 1 and 2|Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
10214744|NCT04574869|Experimental|Cohort 3|
10214745|NCT04574869|Experimental|Cohort 4|
10214746|NCT04574869|Placebo Comparator|Placebo Cohorts 3 and 4|Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
10214747|NCT04548947|Experimental|Cold snare polypectomy with a submucosal injection|The procedure will include a cold snare polypectomy with a submucosal injection done prior to the resection.
10214748|NCT04544280|Experimental|Intervention|
10003301|NCT01565486|Other|Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
10003302|NCT01565512|Placebo Comparator|saline injection|saline injection
10003303|NCT01565512|Active Comparator|Bupivacaine injection|penile block with bupivacaine
9801112|NCT01707030|Experimental|BAI Arm|Receiving a web-based brief intervention for alcohol problems
9801113|NCT01707030|Active Comparator|Usual Care|In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
9801114|NCT01707043|Active Comparator|Taclonex Ointment First|All subjects will use Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas, then switch to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days
9801115|NCT01707043|Active Comparator|Taclonex Scalp Suspension first|All subjects will use Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days, then switch to Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas,
9801116|NCT01707095|Experimental|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
9801117|NCT01707095|Experimental|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
9801118|NCT01707108|Experimental|Dental Implants|Rehabilitation of missing teeth with Dental Implant (MIS Technologies)
9801119|NCT01707147||Patients with Type 2 Diabetes Mellitus|
9801120|NCT01707225|Experimental|Octreotide LAR Depot|Once enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.
9801121|NCT01707238|Experimental|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
9801122|NCT01707238|Active Comparator|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
9801123|NCT01707290|Experimental|Ivacaftor|Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
9801124|NCT01707290|No Intervention|Observational|Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
9801125|NCT01707368||all eligible patients|Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
9801126|NCT01707381|Active Comparator|Timolol Maleate|Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
9801127|NCT01707381|Experimental|BOL-303259-X|BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.
9801128|NCT01707420|Active Comparator|Gabapentin|gabapentin, 20 mg/kg, single dose, 60 min prior to surgery
9801129|NCT01707420|Placebo Comparator|liquid placebo|subjects randomized to the liquid placebo arm will receive a single dose elixir of 0.4 mL/kg given 60 min prior to surgery
9801130|NCT01707472|Experimental|Simtuzumab in HIV Patients|HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
9801131|NCT01707472|Experimental|Simtuzumab in HCV Patients|HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks.
9801132|NCT01707472|Experimental|Simtuzumab in HIV/HCV Co-Infected Patients|HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
9801133|NCT01707654|Other|nerve graft|Simultaneous repair of the infected wound and digital nerve defect in the finger using a bipedicled nerve flap including nerve graft from the dorsal branch of the digital nerve.
9801134|NCT01707667|Experimental|Prucalopride|
9801135|NCT01707667|Active Comparator|PEG 3350|
9801136|NCT01707693|Experimental|Lifestyle Physical Activity Intervention|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
9803240|NCT04381936|Active Comparator|Tocilizumab|"Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment.~(Children with COVID-19 pneumonia are not eligible for this comparison).~[This arm is now closed to recruitment]"
9476276|NCT03573479||PICU Liber8 bundle|After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.
9943455|NCT01020422|No Intervention|Breast hypertrophy|Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
9943456|NCT01020422|Experimental|Reduction Mammaplasty|Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
9943457|NCT01020461|Experimental|Venous blood sampling|To use Accuvein to improve the effectiveness of venous blood sampling
9943458|NCT01020461|Experimental|Peripheral IV catheter placement|To use Accuvein to improve the effectiveness of placing peripheral IV catheter
9943459|NCT01020539|Experimental|Matched Family Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from a related family donor using bone marrow or cord blood stem cells. Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression. Graft-versus-host-disease (GVHD) prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
9943460|NCT01020539|Experimental|Unrelated Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from an unrelated donor using matched bone marrow or cord blood stem cells.Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression and unrelated donor transplant recipients will additionally receive Anti-Thymocyte Globulin. GVHD prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
9943461|NCT01020578||Impaired glucose tolerance|Patients diagnosed with impaired glucose tolerance
9943462|NCT01020578||Control|Patients with normal blood glucose
9943463|NCT01020630|Experimental|Sunitinib|25 mg (2 capsules of 12.5 mg) for oral administration
9943464|NCT01020630|Placebo Comparator|Placebo|2 capsules for oral administration
9943465|NCT01020643|Experimental|controlled sedation using propofol|
9943466|NCT01020656||group 1|patients with no anticoagulants used as the control group
9943467|NCT01020656||group 2|patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
9943468|NCT01020656||group 3|patients treated with aspirin
9943469|NCT01020656||group 4|patients treated with clopidogrel therapy
9943470|NCT01020656||group 5|patients treated with both anticoagulant and aspirin medications
9943471|NCT01020656||group 6|patients treated with both anticoagulant and clopidogrel medications
9943472|NCT01020656||group 7|patients treated with both aspirin and clopidogrel medications
9943473|NCT01020695||PTSD veterans|18 PTSD veterans
9943474|NCT01020695||controls|20 controls
9943475|NCT01020708|Active Comparator|Comparator|Mesalamine enema
9943476|NCT01020708|Experimental|ALTH12-1:4|ALTH12-1:4 experimental treatment dose
9943477|NCT01020708|Experimental|ALTH12-2:4|ALTH12-2:4 experimental treatment dose
10003304|NCT01565525|No Intervention|Bright Futures|This represents 'usual care' in the pediatric office. The anticipatory guidance regarding nutrition is based on the Bright Futures Pocket Guide.
10003305|NCT01565525|Experimental|Maternal focused intervention|Childhood obesity prevention was approached in this arm via anticipatory guidance aimed at maternal eating habits.
10003306|NCT01565525|Active Comparator|Ounce of Prevention|This is a program of anticipatory guidance given to mothers of infants ages 2 weeks to one year which focuses on serving size per age and tips for introducing new foods for the infant.
10003307|NCT01565577|Experimental|Bras A|
10003308|NCT01565590|Active Comparator|Propofol|
10003309|NCT01565590|Experimental|Dexmedetomidine|
10003310|NCT01565629|No Intervention|Waitlist Condition|Children in this condition will withhold from any type of intervention for a period of 12 weeks.
10003311|NCT01565629|Experimental|Computer Assisted CBT|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
10003312|NCT01565681|Experimental|Arm A: ASKP1240 lowest dose|
10003313|NCT01565681|Experimental|Arm B: ASKP1240 second lowest dose|
10003314|NCT01565681|Experimental|Arm C: ASKP1240 third lowest dose|
10003315|NCT01565681|Experimental|Arm D: ASKP1240 fourth lowest dose|
10003316|NCT01565681|Experimental|Arm E: ASKP1240 fifth lowest dose|
10003317|NCT01565681|Experimental|Arm F: ASKP1240 middle dose|
10003318|NCT01565681|Experimental|Arm G: ASKP1240 sixth highest dose|
10003319|NCT01565681|Experimental|Arm H: ASKP1240 fifth highest dose|
10003320|NCT01565681|Experimental|Arm I: ASKP1240 fourth highest dose|
9528723|NCT03208075|Experimental|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
10003321|NCT01565681|Experimental|Arm J: ASKP1240 third highest dose|
10003322|NCT01565681|Experimental|Arm K: ASKP1240 second highest dose|
10003323|NCT01565681|Experimental|Arm L: ASKP1240 highest dose|
10003324|NCT01565681|Placebo Comparator|Arm M: Placebo|Sodium Chloride solution
10003325|NCT01565720|Experimental|Group 1|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole low dose once a day (QD) for 11 days
10003326|NCT01565720|Experimental|Group 2|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole high dose once a day (QD) for 11 days
10003327|NCT01565720|Placebo Comparator|Group 3|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 11 days
10003328|NCT01565720|Active Comparator|Group 4|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 10 days and then moxifloxacin on Day 13
10003329|NCT01565733||NovoMix® 30 users|
10003330|NCT01565746|Experimental|Radium-223 dichloride [50 kBq/kg]|
10003331|NCT01565746|Experimental|Radium-223 dichloride [100 kBq/kg]|
10003332|NCT01565746|Experimental|Radium-223 dichloride [expansion]|
10035143|NCT01803373|Experimental|Treatment Sequence BAC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
10035144|NCT01803373|Experimental|Treatment Sequence BCA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
10035145|NCT01803373|Experimental|Treatment Sequence CBA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
10035146|NCT01803373|Experimental|Treatment Sequence CAB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
10035147|NCT01803386||ALS Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. The ALSFRS-R will also be administered. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
10035148|NCT01803386||Healthy Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
10035149|NCT01803399|Experimental|GSK1322322 1200 mg Arm|Each subject will receive a single dose of GSK1322322 1200 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
10035150|NCT01803399|Experimental|GSK1322322 3000 mg Arm|Each subject will receive a single dose of GSK1322322 3000 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
10035151|NCT01803399|Placebo Comparator|Placebo Arm|Each subject will receive a single dose of GSK1322322 Placebo IV over 60 minutes on Day 1 of one of the 4 treatment periods
9803241|NCT04381936|Active Comparator|Intravenous Immunoglobulin|"First (main) randomisation part A (children only)~[This arm is now closed to recruitment]"
9803242|NCT04381936|Active Comparator|Synthetic neutralising antibodies|"First (main) randomisation part B.~[This arm is now closed to recruitment]"
9803243|NCT04381936|Active Comparator|Aspirin|"First (main) randomisation part C~[This arm is now closed to recruitment]"
9476277|NCT03573453|Experimental|Intermittent|enteral nutrition will be administered via enteral feeding pump as 30-60minutes lasting bolus 6 times per day volume of initial bolus will be 80ml. The volume of bolus will be increased gradually according to tolerance, till the estimated target rate will be reached
9803244|NCT04381936|Active Comparator|Colchicine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
9803245|NCT04381936|Active Comparator|Baricitinib|"First (main) randomisation part D~[This arm is now closed to recruitment]"
9943478|NCT01020721||Glaucoma|South korean patients with primary congenital glaucoma
9943479|NCT01020734|Experimental|transplantation|perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
9943480|NCT01020760|No Intervention|No posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to avoid supine posturing for seven days after surgery, but will not be advised to posture in the face down or prone position.
9943481|NCT01020760|Experimental|Face down posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to posture in the face down or prone position for 50 minutes per hour for seven days.
9943482|NCT01020825||ASCs|Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
9943483|NCT01020825||Fibrin glue|Patients randomized to the control treatment (application of fibrin glue) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
9943484|NCT01020825||ASCs + Fibrin Glue|Patients randomized to the control treatment (application of fibrin glue) + intralesional injection of ASCs in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
9943485|NCT01020851|Experimental|tailored intervention|Participants in this arm will receive 6 monthly telephone calls of a behaviorally tailored intervention based on the transtheoretical model.
9943486|NCT01020851|Active Comparator|attention placebo|Participants in this arm will receive 6 monthly telephone delivered counseling sessions about general health topics
9943487|NCT01020864|Experimental|Chemotherapy|"Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.~Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment."
9943488|NCT01020916|Experimental|Target Temperature 33°C|
9943489|NCT01020916|Active Comparator|Target Temperature 36°C|
9943490|NCT01020942|Experimental|Pretreatment|
9943491|NCT01020942|No Intervention|Control|
9943492|NCT01020955|Active Comparator|NutropinAq and Increlex|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and Increlex (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
9943493|NCT01020955|Placebo Comparator|NutropinAq and placebo|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and placebo for 6 months.
9943494|NCT01020994|Experimental|LAS41003|
9943495|NCT01020994|Active Comparator|LAS189962|
9943496|NCT01020994|Active Comparator|LAS189961|
9943497|NCT01021046|Experimental|GCCT,corneal allograft survival ,DALK|experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue
9943498|NCT01021046|Experimental|FCT,corneal allograft survival ,DALK|control group: deep anterior lamellar keratoplasty using fresh corneal tissue
9943499|NCT01021059|Experimental|1|rh IL-15 daily for 12 days of 42 days cycle.
9943500|NCT01021072|Experimental|MTD|The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
9943501|NCT01021085||Pregnant women|Pregnant women who have conceived via ART and are between days 36 and 56 of gestation
9943502|NCT01021098||Natural History Study|The core Natural History Study of ILI is an observational, longitudinal cohort study using data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ILI. This study aims to describe the clinical history of influenza and other viral respiratory pathogens in a population of US military active duty members and their dependents. The primary focus will be the etiology, natural history and immunology of ILI in otherwise healthy adults and children. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
10035152|NCT01803399|Active Comparator|Moxifloxacin 400 mg Arm|Each subject will receive a single dose of moxifloxacin 400 mg administered orally on Day 1 of one of the 4 treatment periods
10035153|NCT01803425||Synflorix™ cohort|Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
9476278|NCT03573453|Experimental|Continuous|enteral nutrition will be administered via enteral feeding pump for at least 16 hours par day initial rate will be 25ml/hour. The rate will be increased gradually according to tolerance, till the estimated target rate will be reached
9943503|NCT01021098||HIV-Positive Cohort|In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
9943504|NCT01021124||QFT (+) vs QFT (-)|
9943505|NCT01021150|Experimental|Ombrabulin/cisplatin|AVE8062 combined with 75 mg/m2 of cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
9943506|NCT01021163|Placebo Comparator|N-acetylcysteine , saline|
9943507|NCT01021176|Placebo Comparator|0mg 0 spray|No Diltiazem
9943508|NCT01021176|Active Comparator|2mg 2 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 2mg/2 spray Diltiazem
9943509|NCT01021176|Active Comparator|4mg 4 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 4mg/4 spray Diltiazem
9943510|NCT01021176|Active Comparator|8mg 8 spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 8mg/8 spray Diltiazem
9943511|NCT01021189|Experimental|1|AZD1446
9943512|NCT01021189|Placebo Comparator|2|Placebo
9943513|NCT01021202|Experimental|Early tracheostomy|Percutaneous dilation tracheostomy < 72h on mechanical ventilation
9943514|NCT01021202|Experimental|Late tracheostomy|Percutaneous dilation tracheostomy > 10 days on mechanical ventilation
9943515|NCT01021228||group1|continuous volatile anesthesia (sevoflurane) during the liver resection
9943516|NCT01021228||group2|continuous intravenous anesthesia (propofol) during the liver resection
9943517|NCT01021228||group3|preconditioning volatile anesthesia (sevoflurane) 30 minutes before ischemia (inflow occlusion)
9943518|NCT01021241|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner
9943519|NCT01021267|Experimental|Saw palmetto berry extract|Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
9943520|NCT01021280||Type II BS|Adolescents and young adults with type II Bartter syndrome
9943521|NCT01021280||Type IV BS|Adolescents and adults with type IV Bartter syndrome
9943522|NCT01021280||Controls|Age and sex- matched controls
9943523|NCT01021319||Acute ischemic stroke|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset.
9943524|NCT01021358|Experimental|Arm A (ABT-263 and Ketoconozole)|
9943525|NCT01021371|Experimental|Patient interview and communication to GP from hospital|Intervention group: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group about their rehabilitation needs and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus.
9943526|NCT01021371|No Intervention|Control group: Usual practice, no intervention|
9943527|NCT01021384|Other|Problem Solving Education|
9943528|NCT01021397|Experimental|1|Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
9943529|NCT01021397|Placebo Comparator|2|Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
9943530|NCT01021410||Acetaminophen Group|Subjects who completed COMIRB 06-1265 and were assigned to the acetaminophen treatment group for that study.
9943531|NCT01021436|Experimental|Amikacin inhalation solution|Subjects received 125 mg/mL of aerosolized amikacin via the PDDS clinical device at a nominal dose of 400 mg every 12 h for 7-14 days
9943532|NCT01021449||Control|Healthy subjects
9943533|NCT01021449||Schizophrenia|Schizophrenic patients
9943534|NCT01021462|Experimental|Period 1 + Period 2|graded infusion of intravenous glucose
9943535|NCT01021475|Experimental|Usual drug FD therapy + Visceral Manipulation|
9943536|NCT01021475|Active Comparator|Usual drug FD therapy|
9943537|NCT01021488|Experimental|Experimental: Rosuvastatin + enoxaparin arm|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
9943538|NCT01021488|Active Comparator|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
9943539|NCT01021501|Experimental|nifedipine controlled release tablets|Prospective, open, non-randomized, non-controlled study to evaluate the effect and safety of nifedipine controlled release tablets in hypertensive patients on chronic maintenance hemodialysis and the influence of hemodialysis on the plasma concentration of nifedipine
9943540|NCT01021514||Type 2 DM, Healthy control|Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
9943541|NCT01021514||Type 2 DM, Heatlhy control|
9943542|NCT01021527|Experimental|Treatment Sequence 1|A-B-C-C
9943543|NCT01021527|Experimental|Treatment Sequence 2|B-C-A-C
9943544|NCT01021527|Experimental|Treatment Sequence 3|C-A-B-C
9943545|NCT01021527|Experimental|Treatment Sequence 4|A-C-B-C
9943546|NCT01021527|Experimental|Treatment Sequence 5|B-A-C-C
9943547|NCT01021527|Experimental|Treatment Sequence 6|C-B-A-C
9943548|NCT01021566|Experimental|Combined hemoperfusion-hemodialysis|On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
9943549|NCT01021566|Active Comparator|Methadone, conventional treatment for opiate detoxification|On admission thirty patients receive the 10-day methadone treatment regimen.
9943550|NCT01021579|Active Comparator|Metformin plus Simvastatin|PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)
9943551|NCT01021579|Placebo Comparator|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
9943552|NCT01021592||001|
9943553|NCT01021605|Experimental|Hemolung Respiratory Assist System|
9943554|NCT01021631|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hematocrit is lower than 30%
9943555|NCT01021631|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hematocrit is lower than 24%
9943556|NCT01021644|Experimental|aerobic exercise-training|
9943557|NCT01021644|Active Comparator|stretch exercise|
9943558|NCT01021657||Glaucoma|
9943559|NCT01021670||001|Dapoxetine hydrochloride One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
9943560|NCT01021670||002|Alternate care/non-dapoxetine hydrochloride treatment(s) As prescribed or directed
9943561|NCT01021696|No Intervention|Treatment as usual|Control group
9943562|NCT01021696|Active Comparator|Paracetamol|Intervention group
9943563|NCT01021696|Active Comparator|Morphine|Intervention group, individual pain treatment
9943564|NCT01021696|Active Comparator|Buprenorphine plaster|Intervention group, individual pain treatment
9943565|NCT01021696|Active Comparator|Pregabalin|Intervention group, individual pain treatment
9943566|NCT01021709|Experimental|tDCS with alternative electrode montage|Treating major depression with either alternative tDCS electrode montage.
9943567|NCT01021722|Experimental|Modified suture technique|Sutured in a modified manner
9943568|NCT01021722|No Intervention|Historical sphincter group|The outcome of historical sphincter tears
9943569|NCT01021722|No Intervention|Normal primaparous deliveries|Normal deliveries
9943570|NCT01021735|Active Comparator|Anti-TNF therapy|Etanercept or adalimumab by s/c injection
9943571|NCT01021735|Experimental|Rituximab therapy|Rituximab given by IV infusion
9943572|NCT01021774|Active Comparator|Advancement flap surgery|
9943573|NCT01021774|Active Comparator|Collagen plug|
9943574|NCT01021800|Experimental|Cell infusion|
9943575|NCT01021826||Hip and knee replacements recipients|Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
9943576|NCT01021839|Active Comparator|Bovine Carotid Artery Graft|
9943577|NCT01021839|Active Comparator|Expanded Polytetrafluoroethylene Grafts|
9943578|NCT01021865||With type 2 Diabetes|
9943579|NCT01021865||Without type 2 diabetes|
9943580|NCT01021891|Experimental|Non-Diabetic Subj. w/o COPD|Single dose, 30 units
9943581|NCT01021891|Experimental|Non-Diabetic Subj. with COPD|Single dose, 30 units
9943582|NCT01021917||Other Dieters (OD)|Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
9943583|NCT01021917||Take Shape For Life (TSFL)|Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
9943584|NCT01021917||Medifast Direct (MD)|Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.
9943585|NCT01021930|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
9943586|NCT01021930|Active Comparator|Group B: Non-DM|Coronary artery disease without diabetes mellitus
9943587|NCT01021943|Placebo Comparator|Placebo|Half of the subjects will be assigned to receive either spironolactone or placebo for 6 months
9943588|NCT01021943|Active Comparator|spironolactone|Half of the subjects will be randomized to receive spironolactone for 6 months
9943589|NCT01021982||Glaucoma|Glaucoma Patients with visual field defects
9943590|NCT01021982||Retinitis Pigmentosa|Retinitis Pigmentosa Patients with visual field defects
9943591|NCT01021995|Experimental|echinacea|
9943592|NCT01021995|Placebo Comparator|placebo|
9943593|NCT01022008|Experimental|Osteodistraction techniques|Osteodistraction techniques
9943594|NCT01022021|Active Comparator|rituximab|
9943595|NCT01022021|Active Comparator|bendamustine|bendamustine, 90 mg/M2
10003333|NCT01565759|Experimental|Lithium|This will be a short-term longitudinal study of 4 weeks of duration. Twenty (20) healthy male subjects will be recruited and treated with lithium carbonate for 4 weeks. Lithium carbonate (150 mg, 300 mg, 600 mg) will be administered to the recruited subjects. The study will be performed in one centre at Capital District Health Authority - Dalhousie University, Halifax, Nova Scotia, Canada. Lithium serum levels will be tested at day 8, at day 14 and at the end of the treatment. Additional tests may be performed as necessary (as in the case of side effects).
10003334|NCT01565772|Experimental|Radiation, Chemotherapy and Surgery|Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.
10003335|NCT01565785|Experimental|Discharge Prepartion with The FSM-DPI|25 families on each of 2 units will receive the will receive the Family Self-Management-Discharge Preparation Intervention (FSM-DPI). This scripted theory-based intervention is delivered by the study nurse using a e-mobile device. Eight elements of discharge preparation are addressed, the nurse assesses the family status and documents the additional care provided.
10003336|NCT01565785|No Intervention|control group|25 parents on each unit receiving standard of care in discharge preparation.
10003337|NCT01565798|Experimental|Copper Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
10003338|NCT01565798|No Intervention|Standard Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
10003339|NCT01565811||Hepatic pedicle lymph node Involvement|Intervention Type: perihepatic lymphadenectomy(surgical procedure)
10003340|NCT01565824|Experimental|Web-based support|The subjects will get access to a website where they can store blood glucose levels, read specialized information concerning pregnancy and early motherhood, and access a discussion forum for peer support.
10003341|NCT01565824|No Intervention|Usual care|
10003342|NCT01565837|Experimental|Ipilimumab + SART|Patients with oligometastatic but unresectable malignant melanoma will receive induction ipilimumab plus concurrent SART followed by maintenance ipilimumab.
10003343|NCT01565863|Experimental|Progressive Goal Attainment Program|
10003344|NCT01565863|No Intervention|VA employment services|
10003345|NCT01565876|Experimental|study|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
10003346|NCT01565915|Experimental|Perlane-L|Perlane-L treatment
10003347|NCT01565915|Sham Comparator|Non-Treatment|Non-Treatment Arm
10003348|NCT01565967||Autotransfusion|All patients undergoing surgery which requires routine use of an autotransfusion system
10003349|NCT01566006|No Intervention|control group|group receiving the conventional treatment for DN
10003350|NCT01566006|Experimental|cellcept group|additional to the conventional treatment patients will receive cellcept
10003351|NCT01566006|Experimental|carnitine group|aside to the conventional treatment patients will receive carnitine
10003352|NCT01566006|Experimental|PDE5 group|aside to the conventional treatment patients will receive PDE5 inhibitor
10003353|NCT01566019|Experimental|Patients with non curable metastatic cancer|
10003354|NCT01566045|Active Comparator|Core Needle TRUS biopsy (Transrectal ultrasound)|Patient receiving core needle TRUS biopsy (Standard of care biopsy)
10003355|NCT01566045|Experimental|Core Needle MRI/US fusion guided biopsy|Patients receiving Standard of Care core needle TRUS biopsy will then receive the MRI / Ultrasound fusion core needle guided biopsy
10003356|NCT01566058|Experimental|With BB Box|"The mothers in this arm of the study will have access to a BB Box video system to maintain contact with their premature baby."
10003357|NCT01566058|Active Comparator|Without BB Box|"The mothers in this arm of the study will not have access to a BB Box video system to maintain contact with their premature baby. (Standard care)"
10035154|NCT01803438|Active Comparator|AADs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
10035155|NCT01803438|Experimental|Cryoablation procedure|electrical pulmonary veins isolation performed with cryoballoon ablation system
10003358|NCT01566097|Experimental|Intervention group|This study is cluster randomized trial, and the randomization level is physician. Current smokers seen by physician allocated into intervention group were provided with Smoking Cessation Decision Aids along with study questionnaires. The intervention was Smoking Cessation Decision Aids provided to current smokers.
10003359|NCT01566097|No Intervention|Control group|Current smokers seen by physician allocated into control group were provided with only study questionnaires and usual care.
10003360|NCT01566110|Experimental|Diet Intervention Group|
10003361|NCT01566110|No Intervention|Control Group|Subjects assigned to the control group will continue their usual diet. They will receive dietary teaching at each study visit as part of their diabetes management.
10003362|NCT01566123|Experimental|A|Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma
10003363|NCT01566136|No Intervention|Usual care|Current routine rehab care for persons with a hip fracture and CI lacks a well integrated care system within the local hospital network. The usual approach to care at the two sites differ in one major way: patients presenting with a hip fracture to Site 1 receive surgery locally, while those presenting to Site 2 receive surgery at a different hospital because of the absence of an operating suite at this site. Within 2 to 10 days 95% of patients presenting to either site hospital's emergency room with a hip fracture, receive internal fixation or arthroplasty surgery. Patients, including some with mild and moderate CI, are then transferred to in-patient rehabilitation beds at Site 1 or Site 2. Screening of patients for dementia or delirium is not routinely done.
9476279|NCT03573440|No Intervention|no mindful eating education|"Subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
9528724|NCT03208348|Experimental|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
9943596|NCT01022034|Active Comparator|Pexy group|This group of patients with full thickness rectal prolapse will receive standard sacral rectopexy with mesh or sutures
9943597|NCT01022034|Sham Comparator|Non-pexy group|These patients will receive full rectal mobilization from the sacrum but without rectopexy
9943598|NCT01022047|Experimental|Noex|The patients shall use the NOEX drug only once a day (one application in each nostril) during the 12 weeks of treatment
9943599|NCT01022047|Active Comparator|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
9943600|NCT01022060|Experimental|A|Renalof
9943601|NCT01022060|Placebo Comparator|B|Placebo
9943602|NCT01022086||early stage/adjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
9943603|NCT01022086||locally advanced/neoadjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
9943604|NCT01022086||metastatic|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
9943605|NCT01022086||anthracycline-containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
9943606|NCT01022086||non-anthracycline containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
9943607|NCT01022099|Active Comparator|navigated TKA|
9943608|NCT01022099|Other|conventional TKA|
9943609|NCT01022138|Experimental|HER2Bi-armed activated T cells/Cyclophosphamide/biomarker|"HER2Bi-armed activated T cells Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.~Cyclophosphamide After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide~Laboratory biomarker analysis The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored."
9943610|NCT01022151|Placebo Comparator|Placebo [group P]|
9943611|NCT01022151|Active Comparator|Aminophylline 2 mg/Kg [group A2]|
9943612|NCT01022151|Active Comparator|Aminophylline 3 mg/Kg [group A3]|
9943613|NCT01022151|Active Comparator|Aminophylline 4mg/Kg [group A4]|
9943614|NCT01022151|Active Comparator|Aminophylline 5 mg/Kg [group A5]|
9943615|NCT01022151|Active Comparator|Doxapram 1 mg/kg [group D]|
9943616|NCT01022164|Other|fibrin glue|
9943617|NCT01022177|Active Comparator|diabetics|subjects with HbA1c >7,0 and pathological glucose tolerance testing
9943618|NCT01022177|Active Comparator|healthy|healthy subjects with HbA1c <7,0 and negative glucose tolerance testing
9943619|NCT01022216|Active Comparator|V.A.C.® Therapy|Vacuum Assisted Closure device that utilizes controlled negative pressure
9943620|NCT01022216|Experimental|Procellera™ Wound Dressing with V.A.C.® Therapy|Procellera wound dressing used as a primary contact layer on the wound bed, used in conjunction with NPWT
9943621|NCT01022229|Experimental|Compound Natural Health Product|15 study participants who will receive the compound natural health product.
9943622|NCT01022229|Placebo Comparator|Placebo|15 participants will receive placebo natural health product.
9943623|NCT01022255|Experimental|Arm 1|
9943624|NCT01022268||Infection, inflammation or allergy|"Children presenting via any means to St Mary's Hospital; this would include the A&E department, the general and infectious disease wards and the paediatric intensive care unit.~Children needing blood tests for any clinical reason Children who, in the clinical judgement of the doctor assessing them, have presented because of a condition consistent with an infectious, inflammatory or allergic process"
9943625|NCT01022268||controls|children who do not have an infectious, inflammatory or allergic condition, who anyway require blood tests for clinical reasons
10003364|NCT01566136|Experimental|Rehabilitation Model of Care|Staff will be introduced to five components of the Patient-Centred Rehabilitation Model of Care (PCRM-CI) in a one-day workshop prior to implementing the PCRM-CI model. They will then be provided with eight additional educational sessions throughout the year. A manual detailing all aspects of training, including specifics on how to present the material, ideas for stimulating discussion, and case vignettes to illustrate training concepts was developed for our pilot study and will be used here. We also produced a short video on care of elderly with CI in rehabilitation which will be utilized in the training session. The model will be tested over a one year period with a sustainability plan in place developed by the local hospital network and the two study sites.
10003365|NCT01566188|Experimental|omega-3 from vegetal origin|
10003366|NCT01566188|Placebo Comparator|Placebo|
10003367|NCT01566201|Active Comparator|anakinra|
10003368|NCT01566201|Placebo Comparator|placebo|
10003369|NCT01566227|Experimental|number of implants|number of implants (1,2 or 3) used to retained an overdenture
10003370|NCT01566240|Active Comparator|Chemoradiation|Radiotherapy (external beam and brachytherapy) plus concurrent Cisplatin weekly for 5 weeks
10003371|NCT01566240|Experimental|Induction Chemotherapy + Chemoradiation|6 cycles of weekly Paclitaxel and Carboplatin followed by Chemoradiation as per Active Comparator
10003372|NCT01566253|Experimental|PCOA|The PCOA arm receiving oral self administered multimodal analgesic protocol (paracetamol, ketoprofen, morphine) by oral use.
10003373|NCT01566253|Active Comparator|Standard/ IV|The standard/IV arm will be received the analgesic treatment by intravenous use, administered by nursing staff.
10003374|NCT01566266|Experimental|Amoxicillin|
10003375|NCT01566266|Placebo Comparator|Placebo capsules|
10003376|NCT01566279|Other|everolimus|All patients in first part will receive everolimus 10mg q.d.
10003377|NCT01566292|Experimental|BOTOX|
10003378|NCT01566305|Experimental|Buttermilk with added egg yolk|
10003379|NCT01566305|Experimental|Buttermilk without added egg-yolk|
10003380|NCT01566305|Experimental|Skimmed milk with added egg-yolk|
10003381|NCT01566305|Placebo Comparator|Skimmed milk without added egg yolk|
10003382|NCT01566318|Experimental|Problem solving therapy (PST)|6-8 sessions of PST, with booster, delivered over 8 weeks
10003383|NCT01566318|No Intervention|Usual care|Usual agency care, monitored for mental health services
10003384|NCT01566344|Experimental|Routine heart failure therapy plus PVC suppression therapy|
10003385|NCT01566344|No Intervention|Routine heart failure therapy|
10003386|NCT01566357|No Intervention|Fluoride-free toothpaste|
10003387|NCT01566357|Active Comparator|Fluoride toothpaste|
10003388|NCT01566357|Active Comparator|Milk|
10003389|NCT01566357|Active Comparator|Fluoridated milk|
10003390|NCT01566357|Active Comparator|CPP-ACP|
10003391|NCT01566357|Active Comparator|Fluoridated CPP-ACP|
10003392|NCT01566357|Active Comparator|Fluoride mouthrinse|
10003393|NCT01566383|Experimental|Healthy Volunteers|Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.
10003394|NCT01566396|Experimental|A3F|A3F, Fractional RF treatment
10003395|NCT01566422|Experimental|Vancomycin powder|80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
10003396|NCT01566422|No Intervention|Control|80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
10003397|NCT01566474|Experimental|Melatonin + omeprazole|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
10003398|NCT01566474|Active Comparator|omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
10003399|NCT01566487|Experimental|Quetiapine fumarate tablets 300 mg|Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited
10003400|NCT01566487|Active Comparator|Seroquel|Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA
10003401|NCT01566513|No Intervention|Treatment as usual|
10003402|NCT01566513|Experimental|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
10003403|NCT01566513|Experimental|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
10003404|NCT01566513|Experimental|Peer Case Manager|If a participant is randomized into this condition, they are offered the chance to work with a Case Manager, who is trained in strengths-based case management.
10003405|NCT01566552|Other|SINGLE DOSE AMBISOME|
10003406|NCT01566565|Active Comparator|Theophylline|
10003407|NCT01566565|Active Comparator|Bambuterol|
10003408|NCT01566578|Experimental|EGF Cream|
10003409|NCT01566578|Placebo Comparator|Placebo cream|
10003410|NCT01566591|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
10003411|NCT01566591|Active Comparator|Deep TMS Treatment|Deep TMS treatment is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions.
10003412|NCT01566617|Other|Standard Care|(1) group who will receive standard care
10003413|NCT01566617|Other|Standard Care and Pharmaceutical Care|(2) group who will receive standard care and pharmaceutical care
10003414|NCT01566643|Experimental|Hybrid-10|RA3-RACM7: rabeprazole + amoxicillin x 3 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days.
10003415|NCT01566643|Experimental|Hybrid-12|RA5-RACM7: rabeprazole + amoxicillin x 5 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
10003416|NCT01566643|Experimental|Hybrid-14|RA7-RACM7: rabeprazole + amoxicillin x 7 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
10003417|NCT01566656|Experimental|TLI and anti-thymocyte globulin|
10003418|NCT01566669|Placebo Comparator|Normal Saline|Before incision, patients in controlled Group received NS
10003419|NCT01566669|Experimental|parecoxib sodium|Before incision, parecoxib patients received 40mg of parecoxib IV
10003420|NCT01566708|Experimental|treatment group|
9528725|NCT03208270|Experimental|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
10003421|NCT01566708|Active Comparator|waiting list group|
10003422|NCT01566708|Active Comparator|control group|
10003423|NCT01566734|Experimental|Cefazolin|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
10003424|NCT01566734|Experimental|Normal Saline|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients
10003425|NCT01566734|No Intervention|Control|
10003426|NCT01566760|Experimental|Treatment A, Cohort 1|
10003427|NCT01566760|Experimental|Treatment B, Cohort 2|
10003428|NCT01566760|Experimental|Treatment C, Cohort 1|
10003429|NCT01566760|Experimental|Treatment D, Cohort 2|
10003430|NCT01566760|Active Comparator|Treatment E, Cohort 1 and/or Cohort 2|
10003431|NCT01566786|Experimental|activated recombinant human factor VII|
10003432|NCT01566786|Placebo Comparator|Placebo|
10003433|NCT01566799|Experimental|Metformin|Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
10003434|NCT01566812|Experimental|Breast feeding optimization|
10003435|NCT01566812|Active Comparator|Usual/routine care|
10003436|NCT01566825|Active Comparator|Amitriptyline|
10003437|NCT01566825|Placebo Comparator|white 8 mm Lichtenstein®|
10003438|NCT01566851||Patient|Patients with rheumatoid arthritis
10003439|NCT01566864|Experimental|Behavioral: Improve clinic based measurement of blood pressur|
10003440|NCT01566864|Experimental|Behavioral: Provider education system to promote patient-cent|
10003441|NCT01566864|Experimental|Behavioral: Introduce care management system in clinics|
10003442|NCT01566877|Active Comparator|AVI-7288|AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™) that targets Marburg virus nucleoprotein (NP). AVI-7288 is supplied in 5 mL vials containing 5 mL AVI-7288 at a concentration of 50 mg/mL. The dose levels of AVI-7288 will vary in four cohort's.
10003443|NCT01566877|Placebo Comparator|Placebo|Placebo control consists of approximately 150 mL normal saline solution administered by IV infusion over 30 minutes once a day for 14 days.
10003444|NCT01566890|Experimental|Regadenoson ARM|Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
10003445|NCT01566890|Other|Sickle Cell Controls ARM|Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
10003446|NCT01566890|Other|Sickle Cell CEU ARM|Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
10003447|NCT01566890|Other|Healthy Control ARM|Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound
10003448|NCT01566890|Other|Technique Optimization Controls|Healthy volunteers will undergo contrast-enhanced ultrasound.
10003449|NCT01566903||arteriovenous malformations|
10003450|NCT01566903||Arterial stenosis|
10003451|NCT01566903||Post-treatment follow-up|Patient with an arteriovenous malformation for which treatment by embolization or radiosurgery is indicated
10003452|NCT01566916|Active Comparator|Total Hip Arthroplasty performed via direct anterior approach|
10003453|NCT01566916|Active Comparator|Total Hip Arthroplasty using anterolateral approach|
10003454|NCT01566929|No Intervention|IVF only|IVFtreatment
9943626|NCT01022281||Normal Controls|Normal age matched controls without exfoliation
9943627|NCT01022281||Exfoliation Syndrome|Patients with exfoliation syndrome
9943628|NCT01022294|Experimental|Arm 1|Inhalation of nitrousoxide-oxygen during the first experimental session; inhalation of atmospheric air during the second session
9943629|NCT01022294|Experimental|Arm 2|Inhalation of atmospheric air during the first experimental session; inhalation of nitrousoxide-oxygen during the second session
9943630|NCT01022320|Experimental|Surgical outcome|20 consecutive cases of patients who underwent the lateral pharyngoplasty
9943631|NCT01022333|Experimental|DIM group (BRCA1 carriers)|This group will have up to 100 women who are carriers of a BRCA1 deleterious mutation. To ensure safety, women in this group will not be able to participate in the study if they are under medications with warfarin, theophylline, or anticonvulsants; or if they are pregnant, breast-feeding or planning to become pregnant within 6 months of the research project. Women in this group will receive 300 mg per day of Rx Balance BioResponse DIM for six weeks. Supplements will be given free of charge. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be during the six weeks of DIM supplementation (4-6 weeks after the first clinic visit).
9943632|NCT01022333|No Intervention|No DIM group (BRCA1 carriers)|This group will have up to a 100 women who are carriers of a BRCA1 deleterious mutation. This group will not receive DIM. Women that choose not to take DIM will be in this group. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be 4-6 weeks after the first clinic visit.
9943633|NCT01022333|No Intervention|General Control Group|This group will have up to 100 women who do not carry a BRCA1 mutation but who come from BRCA1 carrier family (a family with at least one individual that has tested positive for a BRCA1 mutation). A control subject is considered negative for a BRCA1 mutation if she has been confirmed by direct DNA sequencing to not be a carrier of this gene. A blood sample (20cc) and a urine sample (20cc) will be collected from these women at a single clinic visit.
9943634|NCT01022372||control group|
9943635|NCT01022372||endometriosis group|
9943636|NCT01022372||endometrioma group|
9943637|NCT01022385|No Intervention|12-hour fast|
9943638|NCT01022385|Active Comparator|24-hour low-residual diet and 12-hour fast|
9943639|NCT01022411|Experimental|A|Brown rice
9943640|NCT01022411|Placebo Comparator|B|White rice
9943641|NCT01022437|Experimental|Geranium Oil and component PN-34|
9943642|NCT01022463|Active Comparator|Ivabradine|Crossover study to compare ivabradine and atenolol
9943643|NCT01022463|Placebo Comparator|Atenolol|
9943644|NCT01022476|Experimental|Raltegravir potassium|raltegravir 400 mg twice a day
9943645|NCT01022489|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
9943646|NCT01022489|Placebo Comparator|placebo (sham coil) treatment|
9943647|NCT01022515||patients with pheochromocytoma|Patients with pheochromocytoma / paraganglioma are being followed as recommended according to international standards. No intervention is expected except regular measurement of plasma CgA (as usual) and EM66 (research purpose) levels.
9943648|NCT01022515||Patients with essential hypertension|Patients with essential hypertension will be selected as controls. EM66 and CgA plasma levels will be assessed in these patients after having excluded the presence of a pheochromocytoma / paraganglioma with normal urinary metanephrines / normetanephrines excretion levels.
9943649|NCT01022528|Experimental|Dexamethasone|
9943650|NCT01022528|Placebo Comparator|Saline|
9943651|NCT01022541|Other|This is a single arm study|This is a single arm study
9943652|NCT01022606|Other|Patients with walking limitation|Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording
9943653|NCT01022619||Premature labor|Women at the third trimester of pregnancy with premature contractions and cervical dilation of effacement
9943654|NCT01022619||Control|Women at the third trimester of pregnancy with uncomplicated pregnancy
9943655|NCT01022619||Pre-eclampsia|Women at the third trimester with pre-eclampsia
9943656|NCT01022619||Gestational diabets|Women at the third trimester of pregnancy with gestational diabetes requiring insulin
9943657|NCT01022632|Active Comparator|Fluoxetine|Fluoxetine : 20 mg Once a day in morning after taking food for 6 weeks
9943658|NCT01022632|Experimental|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
9943659|NCT01022632|Experimental|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
9943660|NCT01022645||Levonorgestrel IUD|
9943661|NCT01022645||Copper IUD or Tubal Ligation|
9943662|NCT01022658|Active Comparator|detemir|Insulin detemir at dinner or bedtime
9943663|NCT01022658|Active Comparator|aspart|Insulin aspart before each meal
9943664|NCT01022658|Active Comparator|detemir and aspart|
9943665|NCT01022671|Experimental|Belotecan|Single arm
9943666|NCT01022684||Healthy patients|
9943667|NCT01022697|Active Comparator|A|Glucose drink
9943668|NCT01022697|No Intervention|B|Fasting
9943669|NCT01022710||Group 1|Veterans with sensorineural hearing loss
9943670|NCT01022723||Lung Cancer patients|Lung Cancer (particular focus on non smokers with adenocarcinoma)
9943671|NCT01022723||Patients with Nasopharyneal carcinoma|Patients with Nasopharyneal carcinoma
9943672|NCT01022723||Breast Cancer patients|Breast cancer patients
9943673|NCT01022723||Prostate Cancer patients|Prostate cancer patients
9943674|NCT01022723||Colorectal Cancer patients|Colorectal cancer patients
9943675|NCT01022723||Gastric Cancer patients|Gastric cancer patients
9943676|NCT01022736|Experimental|gabapentin|patients scheduled for cardiac bypass surgery will be administered gabapentin (600mg, orally). Blood will be drawn and plasma gabapentin levels determined 1 hour before surgery, 10 minutes into surgery, 10 minutes before separation from bypass, 30 minutes following bypass, and then before and 2 hours after each dose of gabapentin.
9943677|NCT01022749|Experimental|2|patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
9943678|NCT01022749|Experimental|3|patients with IBD receiving immunosuppressants including TNF blockers (n=100)
9943679|NCT01022749|Experimental|1|patients with IBD not receiving immunosuppressant (n=100)
9943680|NCT01022749|Active Comparator|4|patients with IBD receiving immunosuppressants including TNF blockers (n=20)
9943681|NCT01022775|Experimental|1: Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
9943682|NCT01022775|Active Comparator|2: Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
9943683|NCT01022788|Experimental|Home-based counselling visits by volunteers|Home-based counselling in pregnancy and the first few days of life to encourage women and families to adopt key newborn care behaviours
9943684|NCT01022788|No Intervention|Standard care through existing health system|
9943685|NCT01022814||Pregnant woman|
9943686|NCT01022827|Experimental|posterior shoulder stiffness massage group|The inclusion criteria of patients with glenohumeral internal rotation limitation and posterior shoulder stiffness were: [1] limitation of internal rotation ROM compared to the sound side; [2] mild glenohumeral joint hypomobility according to joint play assessment; [3] stiffness in the posterior shoulder region.
9943687|NCT01022827|Placebo Comparator|posterior shoulder stiffness placebo group|
9943688|NCT01022840|Placebo Comparator|Placebo|Placebo as saline solution
9943689|NCT01022840|Experimental|Low dose|S-Ketamine
9943690|NCT01022840|Active Comparator|High dose|
9943691|NCT01022892||Phase 1 - Pilot phase|Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm.
9943692|NCT01022892||Phase 2 - Blinded from CT Scan|This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study.
9943693|NCT01022905|Experimental|High-risk patients ( 5 cohorts)|
9943694|NCT01022905|Active Comparator|Healthy controls|
9943695|NCT01022918|Experimental|Bevacizumab/Irinoecan|"Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.~Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).~Adjuvant treatment:~Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks."
9943696|NCT01022918|Active Comparator|Stupp|patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
9943697|NCT01022944|Other|Group 2 :|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
9943698|NCT01022944|Other|Group 1|Children with chronic middle ear effusion having adenoidectomy.
9943699|NCT01022957|Experimental|Study group|Neurological, ophthalmological, olfactive exams and cerebral MRI
9943700|NCT01022983|Active Comparator|Levosimendan|
9943701|NCT01022983|Placebo Comparator|Povidon, waterfree etanol, glucosis 5%|
9943702|NCT01023009||eye occlusion|
9943703|NCT01023048|Experimental|PGD testing|
9943704|NCT01023087||Treatment|Patients with sepsis treated with polymyxin E (colistin)
9943705|NCT01023087||Control|Patients with sepsis treated with other, non-nephrotoxic antibiotic medication
9943706|NCT01023100|Experimental|Open label|
9943707|NCT01023113|Experimental|PASCAL laser, PRP in 2-3 sitting at 3 days interval.|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by PASCAL laser
9943708|NCT01023113|Active Comparator|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by conventional laser
9943709|NCT01023126|No Intervention|EO|Exercise three times a week, one under supervision and two freely chosen by the participant
9943710|NCT01023126|Experimental|EGT|Exercise three times a week, one under supervision and two freely chosen by the participant
9943711|NCT01023139|No Intervention|Standard of care (SOC)|No intervention following phase 1 of the study is done during this 2nd phase. Participants will have their height and weights examined at 3 month and 6 month following end of phase 1. During these two visits, they will receive counseling from the physician regarding food choices and exercise maintenance.
9943712|NCT01023139|Experimental|Continuing Behavioral Therapy (CoBT)|This arm follows the end of the phase 1 which incorporates behavioral therapy, nutrition counseling and pharmacotherapy with Sibutramine while medically supervised. Participants randomized to this arm no longer receive medication and will receive behavioral therapy once a month and then evaluated at 3 months and six months for weight loss maintenance.
9943713|NCT01023152|Experimental|Automated cuff-inflator|
9943714|NCT01023165|Experimental|IV bolus insulin, metabolic integrity|Diabetic patients will complete diagnostic testing and complete quality of life questionnaires at baseline and every six months thereafter while enrolled in the study to monitor and assess progress with metabolic integrity and complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months thereafter. Supervising physician may request testing be performed more frequently as deemed medically necessary, testing may include retinal photography, nerve conduction and labs. Meds and medical intervention information is collected weekly at the Intravenous Bolus Insulin treatment sessions. An annual evaluation is performed to review clinical data collected and evaluate progress for analysis and comparison.
9943715|NCT01023191|Active Comparator|Percutaneous insertion|To undergo insertion of catheter using percutaneous technique under local anaesthetic
9943716|NCT01023191|Active Comparator|Open insertion|To undergo insertion of catheter using open technique under general anaesthetic
9943717|NCT01023230|Experimental|DV-601|
9943718|NCT01023243|Placebo Comparator|1 CAre of the Feet for Those at Risk|secular trends for physician documentation in the medical record for care of the feet for high risk patients
9943719|NCT01023243|Active Comparator|Care of the feet for those at risk|the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
9943720|NCT01023243|Active Comparator|Impact of Quality Survey|Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
9943721|NCT01023282|Experimental|ACR325|
9943722|NCT01023282|Placebo Comparator|Placebo|
9943723|NCT01023321|Experimental|1|single ascending doses
9943724|NCT01023321|Placebo Comparator|2|single dose placebo
10003455|NCT01566929|Active Comparator|Weight reduction treatment and IVF|Dietary Supplement: Low calorie diet treatment and then IVFtreatment
9943725|NCT01023321|Experimental|3|multiple dose, 7 or 14 days, oral solution
9943726|NCT01023321|Placebo Comparator|4|multiple dose, 7 or 14 days, oral solution
9943727|NCT01023334|Experimental|Intraocular lidocaine,topical anesthesia,MSICS|experimental group:manual small incision cataract surgery under topical anesthesia with intracameral lidocaine
9943728|NCT01023334|Experimental|intracameral balanced salt solution,topical anesthesia,MSICS|control group:manual small incision cataract surgery under topical anesthesia with intracameral balanced salt solution.
9943729|NCT01023347|Active Comparator|Paclitaxel (Genexol®) and Cisplatin|
9943730|NCT01023347|Experimental|Paclitaxel loaded polymeric micelle (Genexol-PM®) & Cisplatin|
9943731|NCT01023360|Experimental|Clopidogrel and proton pump inhibitors|all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
9943732|NCT01023373|Experimental|B:PTRS|B: the same medical therapy, as previously described in group A, associated with PTRS
9943733|NCT01023373|Active Comparator|A:medical therapy|hypotensive drugs, statins and antiplatelet therapy
10003456|NCT01566942|Active Comparator|FOLFOX|In this group, the patients will receive the adjuvant chemotherapy with mFOLFOX6.
10003457|NCT01566942|Experimental|FOLFIRI|in this arm, patients will receive adjuvant chemotherapy with FOLFIRI regimen for about 8 cycles
9943734|NCT01023399|Experimental|Artesunate + Amodiaquine|"Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: >= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment"
9943735|NCT01023412|Active Comparator|Nutritional product|Oral nutritional supplement containing immuno nutrients
9943736|NCT01023412|Placebo Comparator|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
9943737|NCT01023425|Experimental|switching group|switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately
9943738|NCT01023425|Experimental|naive group|naive patients with AD who initiated therapy with donepezil
9943739|NCT01023438|Experimental|Assisted uptitration|Uptitration of recommended drugs by primary care physician with specialist support
9943740|NCT01023438|Active Comparator|Usual care|Usual communication strategy from cardiologist to primary care physician
9943741|NCT01023464|Other|Period 1|FID 114657 or SootheXP
9943742|NCT01023464|Other|Period 2|FID 114657 or SootheXP
9943743|NCT01023490|Placebo Comparator|Placebo|
9943744|NCT01023490|Active Comparator|Vitamin D|34,500 IU vitamin D per week
9943745|NCT01023503||1|Adults, with a new statin prescription or a change in their stain treatment
9943746|NCT01023529||Prostate cancer|Patients with incurable prostate cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
9943747|NCT01023529||Rectal Cancer|Patients with incurable rectal cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
9943748|NCT01023542|Active Comparator|1|Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.
9943749|NCT01023542|Active Comparator|2|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).
9943750|NCT01023542|Experimental|3|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).
9943751|NCT01023555|No Intervention|0.5cc 2 Bottles|
9943752|NCT01023555|Active Comparator|1cc single bottle|
9943753|NCT01023594|Active Comparator|External stent|Feeding tube insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
9943754|NCT01023594|Active Comparator|Internal stent|short(5cm)internal stent insertion at pancreatojejunostomy site
9943755|NCT01023607|Active Comparator|Group A:|Atorvastatin 20mg
9943756|NCT01023607|Experimental|Group B:|Atorvastatin 60mg
9943757|NCT01023607|Active Comparator|Group C:|Rosuvastatin 10mg
9943758|NCT01023633|Active Comparator|Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)|The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.
9943759|NCT01023633|Experimental|Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)|The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles
9943760|NCT01023646|Other|carbohydrate load|Food challenge - Carbohydrate load
9943761|NCT01023646|Other|Carbohydrate + Protein|Food challenge - carbohydrate + protein
9943762|NCT01023646|Other|Carbohydrate + Fat|Food challenge - carbohydrate + fat
9943763|NCT01023646|Other|Fiber|Food challenge - carbohydrate + fiber
9943764|NCT01023698|Experimental|photocoagulation|Laser photocoagulation
9943765|NCT01023750||Fenofibrate|
9943766|NCT01023763|No Intervention|Usual care|"Nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual (hospital admissions for intravenous treatment).~In control nursing homes that had not completed the training program (intervention period), nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual. The majority of these patients were admitted to hospital for intravenous treatment. A few nursing homes or nursing home departments had sufficient expertise and capacity to provide treatment locally."
9943767|NCT01023763|Other|A training program in iv treatment|"A structured training program in intravenous treatment in nursing homes:~Each of 30 participating nursing homes sequentially received theory and practical training in intravenous treatment. In nursing homes that had completed the training program (intervention period), and had sufficient expertise and capacity, nursing home residents in need of intravenous fluids or antibiotics were treated locally; otherwise they were hospitalized."
9943768|NCT01023802||Neoadjuvant therapy for breast cancer|Women who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.
9943769|NCT01023828||TOBACCO SMOKING|Group of patients with diagnosis of NSCLC and exposure to tabacco smoking
9943770|NCT01023828||WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to wood smoke
9943771|NCT01023828||TABACCO SMOKING AND WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to tabacco smoking and wood smoke
9943772|NCT01023828||WHITOUT EXPOSURE|Patients whit diagnosis of NSCLC and whitout exposure to risk factor
9943773|NCT01023854|Experimental|Continuous Paravertebral block|Continuous Paravertebral block
9943774|NCT01023854|Placebo Comparator|Placebo|Placebo
9943775|NCT01023867|Experimental|Alzheimer's disease group|Patients with Alzheimer's disease treated donepezil
9943776|NCT01023867|Experimental|Mixed Dementia group|Patients with Mixed Dementia treated donepezil
9943777|NCT01023893||End-stage renal disease|
9943778|NCT01023906||18-49 years|Younger
9943779|NCT01023906||50-85 years|Older
9943780|NCT01023919|Active Comparator|Group B: Non-DM|Coronary artery disease with diabetes mellitus
9943781|NCT01023919|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
9943782|NCT01023932||Auditory Neuropathy Patients|
9943783|NCT01023945|Experimental|ASP1941 high dose group|oral
9943784|NCT01023945|Experimental|ASP1941 low dose group|oral
10003458|NCT01566955|Experimental|transgastric adnexectomy|patients are operated transgastric
9943785|NCT01023945|Placebo Comparator|Placebo group|oral
9943786|NCT01023971||Group A|Patients investigated with mfERG and MP-1
9943787|NCT01023971||Group B|Patients investigated by Laser Doppler Flowmetry
9943788|NCT01023984|Active Comparator|TEM - Transanal Endoscopic Microsurgery|TEM under general anesthesia
9943789|NCT01023984|Active Comparator|ESD - Endoscopic Submucosal Dissection|ESD under sedation
9943790|NCT01023997||primary open-angle glaucoma|
9943791|NCT01023997||ocular hypertension patients|
9943792|NCT01023997||normal controls|
9943793|NCT01023997||Exfoliation patients|patients with exfoliation syndrome or exfoliative glaucoma
9943794|NCT01024023|Active Comparator|PPAM Aid|Suitable participants randomised to the treatment arm will receive the non articulated pneumatic early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
9943795|NCT01024023|Active Comparator|AMA Aid|Suitable participants randomised to the treatment arm will receive the articulated early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
9943796|NCT01024049||Asymptomatic LVD|patients over 18 years old with patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history) and asymptomatic left ventricular dysfunction (LVD).
9943797|NCT01024049||healthy controls|individuals over 18 years old free of disease and treatments.
9943798|NCT01024049||patients with cardiovascular risk|patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history)
9943799|NCT01024049||chronic heart failure patients|patient with chronic heart failure
9943800|NCT01024049||acute heart failure patients|acute heart failure patients
9943801|NCT01024075|Placebo Comparator|Saline|Sinufoam is mixed with saline and placed within the ethmoid cavity at the completion of sinus surgery
9943802|NCT01024075|Active Comparator|Dexamethasone|Sinufoam is mixed with dexamethasone and placed within the ethmoid cavity at the completion of sinus surgery
9943803|NCT01024088||GBS PATIENT|
9943804|NCT01024088||CONTROL|
9943805|NCT01024114||Positive MBI scan|Women who are previously enrolled in an MBI study that present with a positive MBI scan.
10003459|NCT01566968||Healthy Volunteers|Adults between ages of 18-75 inclusive who have never smoked and have no history of any respiratory disease for which they are on regular treatment.
9476280|NCT03573440|Experimental|mindful eating education|"After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
9476281|NCT03573388||Optical coherence tomography (OCT)|
9476282|NCT03573362|Experimental|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
9476283|NCT03573362|Active Comparator|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
9476284|NCT03573349|Other|Ketamine|Open-label, non-randomized
9476285|NCT03573284|Experimental|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
10003460|NCT01566968||Asthma|Adults between the ages on 18-75 inclusive who have a physician diagnosis of asthma and have no smoking history or minimal smoking history (less than 10 pack years or in other words less than 20 cigarettes per day for 10 years).
9476286|NCT03573271|Experimental|Micro-coring of facial/neck skin with MCD|Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
10003461|NCT01566968||COPD|Adults between the ages of 18-75 inclusive who have previously been smokers (at least 20 pack years) and have physician diagnosis and spirometry evidence of COPD.
10003462|NCT01566968||Healthy smokers|Adults between the ages of 18-75 inclusive who are currently smokers (at least 10 pack years history)but have no history of any respiratory disease and no evidence of COPD on spirometry.
10003463|NCT01566968||Chronic cough|Adults between ages of 18-75 inclusive who have history of dry cough for at least 8 weeks and have a normal chest x ray and no smoking history or minimal smoking history (less than 10 pack years).
10003464|NCT01566994|Experimental|TTM Tailored|
10003465|NCT01566994|Experimental|Motivational Enhancement Therapy|
10003466|NCT01566994|Experimental|Integrated Treatment|
10003467|NCT01567007|No Intervention|control|session of 15-20 minutes duration. It took place guidelines on physical activity, delivering a manual with general information about physical activity
10003468|NCT01567007|Experimental|Individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise steps. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
10003469|NCT01567007|Experimental|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices.
10003470|NCT01567007|Experimental|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill
10003471|NCT01567046||Correlative studies|Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
10003472|NCT01567072|Experimental|NSAIDs in 7 days|NSAIDs (Ibuprofen) in 7 days
10003473|NCT01567072|Active Comparator|NSAIDs in 3 days|NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
10003474|NCT01567072|Placebo Comparator|Placebo|Only placebo in 7 days
9476287|NCT03573258|Experimental|Fiber|"300 ml of orange juice plus Intervention~6 g of oat beta glucan = FIBER (study A) or~25 g inulin/FOS = FIBER (study B)"
10003475|NCT01567098|Experimental|SILS appendectomy|Single incision laparoscopic appendectomy
10003476|NCT01567098|Active Comparator|3 Ports appendectomy|performing appendectomy through conventional 3 incisions on the abdomen
10003477|NCT01567111|Experimental|Subjects with PA|All study subjects have biochemically confirmed PA and undergo adrenal CT, AVS and MTO-PET to diagnose lateralization of aldosterone production.
10003478|NCT01567124|Other|Olanzapine|Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
10003479|NCT01567124|Other|Clozapine|Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
10003480|NCT01567176|Other|Single Arm|
10003481|NCT01567189|Experimental|Hospital cardiac rehabilitation|The patients will perform physical training sessions in the hospital
10003482|NCT01567189|Active Comparator|Home cardiac rehabilitation|The patients will perform physical training sessions at home
10003483|NCT01567202|Experimental|Arm DC|In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy.
10003484|NCT01567202|Placebo Comparator|Arm Placebo|In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy.
10003485|NCT01567215|Experimental|Granuloma|
10003486|NCT01567228|No Intervention|routine counseling (control group)|Children will receive typical counseling for obesity prevention, dental caries prevention, or school problems per routine standards for pediatrician anticipatory guidance
10003487|NCT01567228|Experimental|CHICA GIS|In randomly assigned experimental clinics, physicians will counsel patients to increase physical activity, seek dental care, or seek academic support services such as tutoring; this counseling will be assisted by an experimental intervention which consist of an electronic medical record that prompts specific counseling in conjunction with a geographic information system. The enhanced electronic medical record will map community resources to support physician counseling and lifestyle modification
10003488|NCT01567241|Placebo Comparator|Relaxation music|
10003489|NCT01567241|Experimental|Clinical hypnosis|
10003490|NCT01567254|Experimental|guided imaginary|7 children receiving auditory guided imagery disk
10003491|NCT01567254|Active Comparator|music|6 children receiving music disk
10003492|NCT01567267|Experimental|Experimental educational intervention|Experimental educational intervention
10003493|NCT01567267|Active Comparator|Standard educational intervention|Standard educational intervention
10003494|NCT01567280||Controlled patients|Asthmatic patients with controlled asthma (according to ACQ score)
10003495|NCT01567280||Partly controlled/Uncontrolled patients|Patients with partly controlled or uncontrolled asthma (according to ACQ score)
10003496|NCT01567319|Experimental|Allergic Subjects|
10003497|NCT01567319|Active Comparator|Atopic Subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
10003498|NCT01567319|Active Comparator|No Atopic Subjects|Healthy volunteers.
10003499|NCT01567332|Experimental|rTMS active|
10003500|NCT01567332|Placebo Comparator|rTMS inactive (sham)|
10003501|NCT01567345|Active Comparator|Intrathecal pump with continuous flow|After placement of the implantable pump, continuous flow is scheduled by physician and the patient can't modify it.
10003502|NCT01567345|Experimental|Intrathecal pump with programmable flow.|After placement of the implantable pump, programmable flow is scheduled by physician and patient can do himself morphine bolus injections for a better control of acute episodes of pain.
10003503|NCT01567358|Experimental|NI-071|
10003504|NCT01567358|Active Comparator|Remicade|
10003505|NCT01567384|Experimental|Combination therapy with OSI and Pemetrexed|
10003506|NCT01567410|Other|traditional Classroom training|one group of nurses receive traditional classroom training to learn about the braden scale and pressure ulcer classification
10003507|NCT01567410|Other|e-learning|one group of nurses receive e-learning as a training method to learn about the braden scale and classification of pressure ulcer
10003508|NCT01567423|Experimental|Artesunate and Amodiaquine (ASAQ)|children receiving fixed-dose combination of artesunate and amodiaquine
10003509|NCT01567423|Active Comparator|Arthemeter and Lumefantrine (AL)|children receiving fixed-dose combination of arthemeter and lumefantrine
10003510|NCT01567449||the case group|The case group referred to SAH patients with aneurysm rebleeding
10003511|NCT01567449||the control group|the control group referred to SAH patients not with aneurysm rebleeding
10003512|NCT01567475|Experimental|Everolimus and rituximab|
9476288|NCT03573258|Placebo Comparator|Placebo|"300 ml of orange juice plus Placebo:~13.5 g maltodextrin = PLACEBO (study A) or~15.5 g maltodextrin = PLACEBO (study B)"
10003513|NCT01567488|Experimental|Everolimus + Octreotide LAR treatment|
10003514|NCT01567501|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
10003515|NCT01567501|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
10003516|NCT01567514|Active Comparator|Glass-ionomer cement lining|Presence of glass-ionomer cement lining in posterior resin composite restorations.
10003517|NCT01567514|No Intervention|No glass-ionomer cement lining|Absence of glass-ionomer cement lining in posterior resin composite restorations
10003518|NCT01567540|Experimental|DPPIV Inhibition|The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).
10003519|NCT01567553||Control group|Only unenhanced MR scanning will be performed in a control group of normal, age-matched subjects and after acceptance of the protocol by an independent ethical committee for the implication of a normal population in such an MRI research project.
10003520|NCT01567553||Experimental group|CIS at presentation (clinically isolated syndromes) will be recruited with MRI evidence of at least two asymptomatic brain MRI lesions. The group will compromise 50 CIS patients. These CIS patients will be included within three months after first clinical presentation.
10003521|NCT01567566|Active Comparator|Local lumbopelvic stabilizers|
10003522|NCT01567566|Experimental|Local lumbopelvic plus hip stabilizers|
10003523|NCT01567592|Experimental|Active Shockwave Therapy|Treatment group. Patients in this group receive actual shockwave therapy.
9476289|NCT03573245||intra-op single dose|intra-operative single dose of tranexamic acid
9943806|NCT01024127||Ancillary-correlative (predictors of AML treatment outcomes)|Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
9943807|NCT01024140|Experimental|Escitalopram|Flexible dose (5-20mg/day) of escitalopram monotherapy.
9943808|NCT01024153|Experimental|Active video game play|
9943809|NCT01024166||Patient|Patient computer system use questionnaire
9943810|NCT01024166||Caregiver|Caregiver computer system use questionnaire
9943811|NCT01024166||Healthcare Provider|Physician and Nurse computer system use questionnaire
10003524|NCT01567605|Experimental|Lidocaine lubricant|In this arm, subjects will use lidocaine lubricant in their normal bowel care routine (rather than standard lubricating jelly).
10003525|NCT01567605|Placebo Comparator|Placebo lubricant|In this arm, subjects will use regular lubricant (AMG MedPro lubricating gel) in their normal bowel care routine.
10003526|NCT01567631|Experimental|intrahepatic Glisson's approach|
10003527|NCT01567631|Active Comparator|classical hepatectomy|
10003528|NCT01567644|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
10003529|NCT01567657|Active Comparator|Pethidin plus midazolam|Initial dose of 25 mg Pethidin iv. plus 1-2 mg Midazolam iv. Additional Bolus of Midazolam (1 mg wise iv.) if needed, until a maximal dose of 7 mg Midazolam iv.
10003530|NCT01567657|Active Comparator|Propofol|Initial dose of Propofol of 50-60 mg iv. for patients 50 years or younger. Initial dose of Propofol of 30-40 mg iv. for patients over 50 years. If needed additional Bolus of 20-30 mg Propofol iv. as usual until sedation is achieved.
10003531|NCT01567670|Active Comparator|Naloxone|nasal spray before binging, naloxone dose 2 mg, maximum daily dose 4 mg
10003532|NCT01567670|Placebo Comparator|nasal spray|nasal placebo (h2o) spray before binging, max sprays / day
10003533|NCT01567683|Experimental|Limtop solution (imiquimod), Vehicle solution for topical use|
10003534|NCT01567709|Experimental|Treatment (alisertib, vorinostat)|Patients receive alisertib PO BID on days 1-7 or days 1-3 and 8-10, and vorinostat PO BID on days 1-14 or days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10003535|NCT01567735|Experimental|TMC435|
10003536|NCT01567748||Hemodynamics Measured|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
10003537|NCT01567774|Active Comparator|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
10003538|NCT01567774|Active Comparator|Rosuvastatin|Patients will receive randomly rosuvastatin (10 mg per day) for 30 days
10003539|NCT01567787|Experimental|Proton Radiation for MPNST|Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
10003540|NCT01567787|Experimental|Proton Radiation for neurofibromas|Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
10003541|NCT01567800|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with prostate cancer
10003542|NCT01567813||Regimen Initiators|Any male health plan member who receives at least one dose of GARDASIL™
10003543|NCT01567813||Regimen Completers|Regimen Initiators who complete the 3-dose vaccination regimen within 12 months
10003544|NCT01567813||Autoimmune cohort|Regimen Initiators who were members of the health plan during the 12-month period prior to their first dose of GARDASIL™
10003545|NCT01567878||ankylosing spondylitis|It will be held ultrasound exam in enthesis and joints in patients with ankylosing spondylitis and healthy subjects
10003546|NCT01567878||Healthy pelople|It will be held ultrasound exam in enthesis and joints of healthy subjects
10003547|NCT01567917||Group A|"Patients who gave a permission to this study and underwent doppler US (Doppler US cohort~- Expected subject no.: 400 patients"
9943812|NCT01024179|Active Comparator|Group B: CTO|Chronic total occlusion
9943813|NCT01024179|Active Comparator|Group A : Non-CTO|"Non-chronic total occlusion :~Fibrous plaque+fibro-calcific plaque + Lipid plaque(<2 quadrants )~Lipid-rich plaque ( ≥2 quadrants )"
9943814|NCT01024192|Experimental|1|Zolpidem 12.5mg tablet at bed time during 12 weeks
9943815|NCT01024257|Experimental|conjunctival autograft plus beta-irradiation|
9943816|NCT01024257|Active Comparator|conjunctival autograft|
9943817|NCT01024270|Experimental|sublingual, oral and vaginal administration of misoprostol|
9943818|NCT01024322||Ciprofloxicine or Vigamox or other.|
9943819|NCT01024322||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
9943820|NCT01024322||Steroid (FML, Pred Forte, Flarex, etc.)|
9943821|NCT01024348|Active Comparator|Tramadex-OD|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
9943822|NCT01024348|Active Comparator|Control group|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
9943823|NCT01024361|No Intervention|Routine|Routine protocol of the service
9943824|NCT01024361|Experimental|CPAP-DR|Infants randomized to this arm will have nasal CPAP installation at delivery room before the 15th minute of life
9943825|NCT01024400|Experimental|vaccine|
9943826|NCT01024413|Experimental|erlotinib|erlotinib 150 mg oral till disease progression
9943827|NCT01024413|Active Comparator|gefitinib|gefitinib 250mg oral till disease progression.
9943828|NCT01024426|Experimental|Health Facility intervention|In the clusters randomized to enhanced health facility-based care, the intervention is designed to address these barriers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
9943829|NCT01024426|Other|Standard of care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
9943830|NCT01024439|Active Comparator|single port|Patients will undergo transumbilical single incision laparoscopic appendicectomy.
9943831|NCT01024439|Active Comparator|conventional Lap|Patients will undergo conventional laparoscopic appendicectomy.
9943832|NCT01024452|Experimental|DAWN AC|
9943833|NCT01024452|Active Comparator|Hamilton Nomogram|
9943834|NCT01024491|Experimental|paroxetine 15mg|Active treatment with daily dose of paroxetine 15mg.
9943835|NCT01024491|Experimental|paroxetine 20 mg|Active treatment daily dose of paroxetine 20 mg
9943836|NCT01024491|Experimental|placebo|placebo
9943837|NCT01024504|Experimental|XELOX/Avastin|Capecitabine Oxaliplatin Bevacizumab
9943838|NCT01024517|Experimental|Single oral dose, solution|
9943839|NCT01024517|Experimental|Single oral dose, solid, fasted|
9943840|NCT01024517|Experimental|Single oral dose, solid, fed.|
9943841|NCT01024543|Sham Comparator|Placebo|Placebo
9943842|NCT01024543|Experimental|Angiotensin II|Angiotensin II
9943843|NCT01024543|Active Comparator|Phenylephrine|Phenylephrine
9943844|NCT01024582|Experimental|accelerated partial breast irradiation|pre-operative radiation of the in situ tumor in the breast
9943845|NCT01024595||Without treatment|
9943846|NCT01024621|Experimental|1|confocal laser endomicroscopy
9943847|NCT01024621|Active Comparator|2|standard endoscopy
9943848|NCT01024634|Other|African American Group|A group of young African American males and females
9943849|NCT01024634|Other|Caucasian Group|a group of young Caucasian men and women
9943850|NCT01024647|Active Comparator|Loss of Reponse Reinduction Responders|Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks
9943851|NCT01024647|Active Comparator|Response loss Reinduction Non-Responders|Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks
9943852|NCT01024647|Active Comparator|Responders|Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks
9943853|NCT01024647|Active Comparator|Non-Responders|Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks
9943854|NCT01024660|Active Comparator|1|5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
9943855|NCT01024660|Placebo Comparator|2|
9943856|NCT01024673||patients with H1N1|patients who are clinical found to be positive for H1N1 will be enrolled
9943857|NCT01024699||XLIF|This group will have the XLIF procedure done.
9943858|NCT01024699||MAS TLIF|This group will have the MAS TLIF procedure done.
9943859|NCT01024725||Not (yet) vaccinated persons|The participants do not want to take the vaccine (available only in the national vaccination campaign) or have not received it yet
9943860|NCT01024725||Vaccinated persons|The participants have taken the vaccine according to the national vaccination campaign
9943861|NCT01024777|Active Comparator|High dose cholecalciferol|Patients in the high dose arm will receive 10,000 international units of cholecalciferol daily.
9943862|NCT01024777|Active Comparator|Low dose cholecalciferol|Patients enrolled in the low dose arm will receive up to 1000 international units of cholecalciferol daily.
9943863|NCT01024790|Experimental|Exercise group|
9943864|NCT01024790|No Intervention|Usual care|
9943865|NCT01024816|Experimental|Restorative yoga intervention|
10003548|NCT01567917||Group B|"Patient who gave a permission to this study, but who did not receive doppler US (Although this group of patients did not undergo doppler US, these patients will be included as group B [simple observation cohort without doppler US examination])~- Expected subject no.: 200 patients"
10003549|NCT01567956|Experimental|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine
10003550|NCT01567956|Placebo Comparator|Placebo|Modified release tablets containing inert substances
10003551|NCT01567969|Experimental|IICAPS|Provision of Intensive In-home Child and Adolescent Psychiatric Service, a six to seven month family-focused in-home psychiatric intervention.
10003552|NCT01567969|Active Comparator|Home-based CTC|Provision of Home-based Child Treatment Coordination, a six to seven month child-focused case management service with monthly in-home visits with the child's parent/legal guardian.
10003553|NCT01567982|Experimental|smokers and nonsmokers|both smokers and nonsmokers will receive same tDCS
10003554|NCT01567995|Experimental|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
10003555|NCT01567995|Other|Vehicle (base cream)|Vehicle (base cream)
10003556|NCT01568060||Infanrix-IPV group|Infants and children who received at least one dose of Infanrix-IPV as a part of routine practice at a private clinic or hospital in korea
10003557|NCT01568086||AFFITOPE AD03 with adjuvant|
10003558|NCT01568086||AFFITOPE AD03 without adjuvant|
10003559|NCT01568099|Experimental|A: AFFITOPE® PD01A + Adjuvant|4 injections of 15µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
10003560|NCT01568099|Experimental|B: AFFITOPE® PD01A + Adjuvant|4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
10003561|NCT01568099|Other|Control|Untreated control group
10003562|NCT01568125||Incretin-related drugs|
10003563|NCT01568151|Active Comparator|Intervention Clinics|Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions(Clinic-directed intervention program)including: 1)provider-directed interventions; 2)office-based systems; and 3) waiting room materials. If the subjects have not undergone colorectal cancer screening after 12 months, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
10003564|NCT01568151|No Intervention|Usual Care Clinics|Subjects recruited at the Usual Care Clinics (Control Clinics) will not receive any study intervention. The results of how many subjects undergo colorectal cancer screening at the Usual Care Clinics will be compared to the number that undergo colorectal cancer screening at the Intervention Clinics.
10003565|NCT01568164|Experimental|Device Treatment|Treatment with the investigational device.
10003566|NCT01568177|Other|abnormal CRT|"40 subjects with microvascular coronary dysfunction (MCD) defined as abnormal CRT.~Visits 1, 2, and 3"
10003567|NCT01568177|Other|Cardiac Syndrome X|20 subjects with symptoms and normal stress tests, no MCD. Visits 1 and 2
10003568|NCT01568177|Other|normal reference controls|40 normal reference controls subjects Visits 1 and 2
10003569|NCT01568190|Experimental|AVANZ|AVANZ Mites
10003570|NCT01568203|Experimental|AMG 579|
10003571|NCT01568203|Placebo Comparator|Placebo|
10003572|NCT01568242|Experimental|Thermoprobe|Determination of vitreous temperature with a thermoprobe
10003573|NCT01568268|Experimental|Palonsetron|
10003574|NCT01568268|Placebo Comparator|Placebo|
9943866|NCT01024816|Active Comparator|Stretching group|
9943867|NCT01024842|Experimental|Low dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu.
9943868|NCT01024842|Experimental|High dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu.
9943869|NCT01024842|Placebo Comparator|Low dose placebo|Individuals will receive three intramuscular injections of low dose placebo
9943870|NCT01024842|Placebo Comparator|High dose placebo|Individuals will receive three intramuscular injections of high dose placebo
9943871|NCT01024868||TAP block|Patients before undergoing laparoscopic or other abdominal surgery
9943872|NCT01024881|Active Comparator|group 1|neutral shoulder position during infraclavicular subclavian catheterization
9943873|NCT01024881|Experimental|group 2|lowered shoulder position during infraclavicular subclavian catheterization
9943874|NCT01024894|Experimental|CYT107|
9943875|NCT01024933|Placebo Comparator|Educational and Behavioral|The Education and Behavioral Contract (Control group) will receive an educational workbook and behavioral contract. Each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
9943876|NCT01024933|Experimental|PASA group-intervention|The PASA group (Positive Affect/Self-Affirmation/Motivational Interviewing) will receive a positive-affect and self-affirmation intervention with motivational interviewing.These patients will also receive an educational workbook and behavioral contract. This is the intervention.
9943877|NCT01024985||multiple sclerosis|
9943878|NCT01024985||neuromyelitis optica|
9943879|NCT01024985||controls|
9943880|NCT01024998|Experimental|2 x 10^8 vector genomes (vg) AAV2-sFLT01|
9943881|NCT01024998|Experimental|2 x 10^9 vector genomes (vg) AAV2-sFLT01|
9943882|NCT01024998|Experimental|6 x 10^9 vector genomes (vg) AAV2-sFLT01|
9943883|NCT01024998|Experimental|2 x 10^10 vector genomes (vg) AAV2-sFLT01|
9943884|NCT01025011||healthy volunteers, anemic patients|healthy volunteers from the eye and gynecology department pregnant patients with anemia
9943885|NCT01025024||POAG group|Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect
9943886|NCT01025024||Normal control|Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease
9943887|NCT01025050|Experimental|Group A|In this group the smallest ring diameter will be applied.
9943888|NCT01025050|Experimental|Group B|In this group the intermediate ring diameter will be applied.
9943889|NCT01025050|Experimental|Group C|In this group the biggest ring diameter will be applied.
9943890|NCT01025063||Lucentis (PRN group)|
9943891|NCT01025063||Lucentis (3 Injections over three months)|
9943892|NCT01025063||PDT (Reduced Fluence) and Lucentis|
9943893|NCT01025102|Experimental|Naropin 0.1%|
9943894|NCT01025115|Experimental|A|Diamel
9943895|NCT01025115|Placebo Comparator|B|Placebo
9943896|NCT01025128|Active Comparator|group A low D|ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
9943897|NCT01025128|No Intervention|group A high D|ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
9943898|NCT01025128|Active Comparator|group B low D|mixed population clinics patients aged 18-39 with lowest vitamin D levels
9943899|NCT01025128|No Intervention|group B high D|mixed population clinics patients aged 18-39 with highest vitamin D levels
9943900|NCT01025141|Experimental|MINISCREW|device
9943901|NCT01025141|Active Comparator|Reference|dental anchorage
9943902|NCT01025167|Experimental|Test|Supportan(R) (500 ml)/disease-specific enteral tube feed for oncologic patients with special key substrates
9943903|NCT01025167|Placebo Comparator|Control|Fresubin(R) energy fibre (500 ml)/a nutritionally complete enteral standard feed (isoenergetic)
9943904|NCT01025180|Other|Procalcitonin level|duration of the antibiotic treatment guided by procalcitonin level
9943905|NCT01025180|No Intervention|physician's appreciation|duration of the antibiotic treatment based on physician's appreciation
9943906|NCT01025206|Experimental|BI-505|
9943907|NCT01025245|Experimental|remifentanil, MgSO4|Experimental 1 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and MgSO4 30 mg/kg IV at the induction followed by intraoperative infusion at 10 mg/kg/hr Drug : remifentanil, MgSO4 Experimental 2 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and normal saline Drug : remifentanil Active comparator : Intraoperative remifentanil infusion at 0.05 ㎍/㎏/min and normal saline Drug : remifentanil
9943908|NCT01025258|Active Comparator|frequent clinic visits|
9943909|NCT01025297|Experimental|CYT107|
9943910|NCT01025323|Active Comparator|Minimal Intervention Group|Participants in this arm receive advice and printed guidelines but no counseling or systematic instruction.
10003575|NCT01568281|Experimental|1|2 way crossover
10003576|NCT01568281|Experimental|2|2 way crossover
10003577|NCT01568281|Experimental|3|2 way crossover
10003578|NCT01568281|Experimental|4|2 way crossover
9943911|NCT01025323|Active Comparator|Enhanced Intervention Group|Participants in this group receive advice and the same printed guidelines as the Minimal Intervention Group, together with dietary and physical activity counseling provided by a dietician and/or coordinator, periodic professional reviews of their progress and systematic instruction.
9943912|NCT01025349|Experimental|metastatic breast cancer|Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
9943913|NCT01025362|Experimental|Lactation counseling|"Intervention arm: The mother and child health centres will implement The Baby-Friendly Initiative to improve their lactation counseling.~Other Names: The Baby Friendly Community Health Service"
9943914|NCT01025362|Active Comparator|Standard care|The comparison group was mother and child health centres which continued offering standard care.
9943915|NCT01025401|No Intervention|Motor manifestations during seizures|
9943916|NCT01025440|Active Comparator|CPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
9943917|NCT01025440|Active Comparator|HFCPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: During HF CPAP 35 L/min wil be administered.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
9943918|NCT01025466|Active Comparator|rivastigmine patch monotherapy|
9943919|NCT01025466|Active Comparator|Combination therapy with memantine|
9943920|NCT01025518|Experimental|resistance training and dietary supplement|
9943921|NCT01025518|Placebo Comparator|Resistance training and placebo ingestion|12 weeks of resistance training and placebo ingestion
9943922|NCT01025531||patients with newly diagnosed Hepatitis C|Hepatitis C patients newly diagnosed
9943923|NCT01025544|Active Comparator|Arm 1|
9943924|NCT01025544|Active Comparator|Arm 2|
9943925|NCT01025557|Experimental|Chocolate milk|
9943926|NCT01025557|Experimental|Milk|
9943927|NCT01025557|Experimental|Infant formula|
9943928|NCT01025557|Experimental|Soy beverage|
9943929|NCT01025557|Experimental|Water|
9943930|NCT01025570|Experimental|Gem/Bos|"Gemcitabine 1000 mg/m2, D1,8,15 of each cycle~Bostutinib 400 mg daily concurrently with Gemcitabine"
9943931|NCT01025583|Active Comparator|group 1 (standard ORS)|Children with acute diarrhea receive standard hypotonic ORS.
9943932|NCT01025583|Active Comparator|Group 2 (hypotonic super-ORS)|Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
9476290|NCT03573245||intra-op dose and additional dose|intra-operative dose of tranexamic acid and additional dose 3 hours after
9943933|NCT01025596|Experimental|CYT107|
9943934|NCT01025661|No Intervention|Waiting list control|The waiting list controls did not receive any intervention during the study period.
9943935|NCT01025674|Experimental|7 Treatment Schools|The Positive Action program was implemented over 6 years, starting with Grade 3, then continuing through Grade 8.
9943936|NCT01025674|No Intervention|7 Control Schools|Standard educational practice
9943937|NCT01025687|Experimental|glucose beverage|
9943938|NCT01025687|Experimental|noncaloric beverage with TV|
9943939|NCT01025687|Experimental|glucose beverage with TV|
9943940|NCT01025687|Experimental|noncaloric beverage|
9943941|NCT01025700|Experimental|Cesemat|
9943942|NCT01025700|No Intervention|Placebo|
9943943|NCT01025713|Experimental|1|GS-9411 2.4 mg
9943944|NCT01025713|Experimental|2|GS-9411 4.8 mg
9943945|NCT01025713|Placebo Comparator|Placebo|Placebo
9943946|NCT01025726|Experimental|Full Intervention|Police Patrolled Walking Program plus Social Marketing Intervention
9943947|NCT01025726|Experimental|Walking Only|Police Patrolled Walking Only Intervention
9943948|NCT01025726|Active Comparator|General Health|General Health Education Intervention
9943949|NCT01025765|No Intervention|Standard care of CHC|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
9943950|NCT01025765|Experimental|Pioglitazone|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
9943951|NCT01025765|Experimental|Acarbose|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
9943952|NCT01025765|Experimental|Metformin|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
10003579|NCT01568294|Experimental|pomalidomide|Patients will receive pomalidomide orally on Days 1-21 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, development of an unacceptable toxicity, voluntary withdrawal, or pomalidomide is in market for the target indication.
9476291|NCT03573245||intra-op dose and perfusion|intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.
10003580|NCT01568333|Experimental|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
10003581|NCT01568346|Active Comparator|MRI|MRI
10003582|NCT01568346|No Intervention|No MRI|No MRI
10003583|NCT01568359||Group 1 - Acromegaly, Group 2 - control|Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)
10003584|NCT01568372|Experimental|Nurse telephone follow-up|This group received a telephone follow-up by a nurse following discharge from the hospital and up until the 10th postoperative day, which is considered as the usual period of healing for a tonsillectomy
10003585|NCT01568372|No Intervention|Standard care group|This group received the standard care which consisted of an informative session before discharge and no follow-up once discharged home.
10003586|NCT01568385|Experimental|TAK-438 20 mg QD|
10003587|NCT01568398|Experimental|TAK-438 20 mg QD|
10003588|NCT01568411|Active Comparator|TD-1211|
10003589|NCT01568411|Active Comparator|TD-1211+ itraconazole|
10003590|NCT01568437|Active Comparator|Conventional management|On the ward, patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg up to every 2 hours or iv morphine. Patients with contraindications to oxycodone will be prescribed oral hydromorphone 1-2 mg instead. This is the current standard of care at Toronto Western Hospital.
10003591|NCT01568437|Experimental|TAP Block+Conventional Management|The TAP block will be performed after the induction, before the surgery, by an anesthesiologist with experience of at least 10 successful TAP blocks.Also patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg(oral hydromorphone 1-2 mg) up to every 2 hours or iv morphine.
10003592|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, fasted)|
10003593|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)|
10003594|NCT01568450|Active Comparator|Oxycontin CR 10mg (Oxycodone 10mg, fasted)|
10003595|NCT01568476|Active Comparator|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
10003596|NCT01568476|Active Comparator|Interneural|sciatic nerve blockade at the site of bifurcation
10003597|NCT01568489|Experimental|HL-009 Liposomal Gel (0.07%)|
10003598|NCT01568489|Experimental|HL-009 Liposomal Gel (0.15%)|
10003599|NCT01568489|Experimental|HL-009 Liposomal Gel (0.30%)|
10003600|NCT01568489|Placebo Comparator|HL-009 Liposomal Gel (Placebo)|
10003601|NCT01568502||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
10003602|NCT01568502||DSCMR|Patients, who underwent Dobutamine Stress Cardiac Magnetic Resonance (DSCMR)
10003603|NCT01568515|Experimental|Electronic Messages|Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months
10003604|NCT01568515|No Intervention|Standard of Care|Control group participants received standard of care at the student health center which included a card with their next appointment written on it.
10003605|NCT01568541|Active Comparator|Children' toothpaste|Children's toothpastes
10003606|NCT01568541|Active Comparator|Regular toothpastes|Regular toothpastes
10003607|NCT01568554||Group 1|Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
10003608|NCT01568554||Group 2 (Not Yet Enrolling)|Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
10003609|NCT01568554||Group 3|"Subjects in Group 3 will participate in the Follow Up Sub-Study. This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit."
10003610|NCT01568567|Active Comparator|Double dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
10003611|NCT01568567|Active Comparator|Single dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
10003612|NCT01568567|Placebo Comparator|Placebo|One stick pack with placebo contains 1.0 g maltodextrin and silicon dioxide
10003613|NCT01568580|Experimental|test drug|GreenGene
10003614|NCT01568749|Active Comparator|Standard paracetamol|Marketed formulation
10003615|NCT01568749|Experimental|Formulation 1|Paracetamol formulation 1
10003616|NCT01568749|Experimental|Formulation 2|Paracetamol formulation 2
10003617|NCT01568749|Experimental|Formulation 3|Paracetamol formulation 3
10003618|NCT01568749|Experimental|Formulation 4|Paracetamol formulation 4
10003619|NCT01568762|Experimental|VAK694|VAK694 was administered as a 1 hour intravenous infusion
10003620|NCT01568762|Placebo Comparator|VAK694 Placebo|VAK694 placebo was administered as a one hour intravenous infusion
10003621|NCT01568762|Experimental|QAX576|QAX576 was administered intravenously as a 2 hour infusion
10003622|NCT01568762|Placebo Comparator|QAX576 placebo|QAX576 placebo was administered as a 2 hour intravenous infusion
10003623|NCT01568775|Experimental|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
10003624|NCT01568788|Experimental|Inactivated Influenza Vaccine|15μg HA/strain/0.5ml/syringe, Hualan Biologicals
10003625|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of Pasteur|15ug HA/strain/0.5ml/syringe, Sanofi Pasteur
10003626|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of GSK|15ug HA/strain/0.5ml/syringe, GSK
10003627|NCT01568801|No Intervention|Control Group|Individuals randomized into the control arm will receive usual community care services referred by the social worker from SGH and AH.
10003628|NCT01568801|Experimental|Intervention Group|Individuals in the intervention group will go through an integrated program of community based health and social care based on intake and ongoing evaluation by the SingaPACE team.
10003629|NCT01568814|Placebo Comparator|High volume PEG|Patients who are scheduled colonoscopy ingest high volume PEG(4L) for bowel preparation.
10003630|NCT01568814|Active Comparator|Low volume PEG with low residual meals|Patients who are scheduled colonoscopy ingest low volume PEG(2L) and have a prepackaged low residual meals for bowel preparation.
10003631|NCT01568840|Experimental|Global Postural Reeducation Group|Global Postural Reeducation
10003632|NCT01568840|Active Comparator|Segmental Exercises Group|Segmental Exercises
10003633|NCT01568879|Experimental|Gout Chronic Disease Management Program|
10003634|NCT01568879|Active Comparator|Usual Care|
10003635|NCT01568931|Active Comparator|Urokinase|Patients will be randomized to to receive local bolus of 200,000 units urokinase
10003636|NCT01568931|Active Comparator|Saline|Patients will be randomized to to receive local bolus of intracoronary saline
10003637|NCT01568957|Experimental|Dual-task gait training|Gait training with simultaneous performance of cognitive tasks for 75% of training session.
10003638|NCT01568957|Active Comparator|Single-task gait training|Gait training (without simultaneous cognitive task performance)
10003639|NCT01568970|Experimental|Return to work follow-up|Regular contact between the patient and his/her caretaker at the rehabilitation center over a 6 month period, including joint communication between patient, caretaker at the rehabilitation center and stake holders such as social security office, general practitioner and workplace.
10003640|NCT01568970|Active Comparator|Standard follow-up|Standard follow-up of the patient after ended rehabilitation by the return-to-work stakeholders, ie. the general practitioner, social security office and the employer. Limited contact between the caretaker at the rehabilitation center and the patient and stakeholders.
10003641|NCT01568983|Placebo Comparator|Control|"12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
10003642|NCT01568983|Active Comparator|Mana-juice|"12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia).~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
10003643|NCT01568983|Active Comparator|Optijuice|"12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
10003644|NCT01568996|Experimental|Low dose BSE-SFN|BSE-SFN will be orally administered at 50 µmol SFN for 28 days.
10003645|NCT01568996|Experimental|Mid dose BSE-SFN|BSE-SFN will be orally administered at 100 µmol SFN for 28 days.
10003646|NCT01568996|Experimental|High dose BSE-SFN|BSE-SFN will be orally administered at 200 µmol SFN for 28 days.
10003647|NCT01569009||Observational|Patients are asked to continue with their normal daily activities.
10003648|NCT01569035|Active Comparator|warfarin|oral anti coagulant
10003649|NCT01569048|Active Comparator|remifentanil|
10003650|NCT01569048|Experimental|dexmedetomidine|
10003651|NCT01569061|Active Comparator|Active Laser Group (ALG)|
10003652|NCT01569061|Sham Comparator|Sham Laser Group (SLG)|
10003653|NCT01569113|Experimental|ellaOne + microgynon 30|
10003654|NCT01569113|Placebo Comparator|placebo + microgynon 30|
10003655|NCT01569139||GPRD MI|Myocardial infarction, as identified in the GPRD data.
10003656|NCT01569139||MINAP MI|Myocardial infarction, as identified in MINAP data.
10003657|NCT01569139||HES MI|Myocardial infarction, as identified in HES data.
10003658|NCT01569165|Experimental|washing after 30 min|washing with water after 30 min following APF treatment
10003659|NCT01569165|Experimental|washing after 15 min|washing with water after 15 min following APF treatment
10003660|NCT01569165|Experimental|immediately washing with water|immediately washing with water after APF treatment
10003661|NCT01569165|Experimental|cleansing teeth with cotton roll|cleansing teeth with cotton roll immediately following APF treatment
10003662|NCT01569165|No Intervention|no fluoride therapy|control group
10003663|NCT01569178|No Intervention|standard care|optimal standard care post myocardial infarction
10003664|NCT01569178|Experimental|Intracoronary Reinfusion of Cells|Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells
10003665|NCT01569204|Active Comparator|BrECAPP|modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
10003666|NCT01569204|Active Comparator|BrECADD|modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
9943953|NCT01025778|Experimental|Remission induction and haplo-SCT|Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.
9943954|NCT01025804||Infants|
9943955|NCT01025856|Active Comparator|high fibre/low glycemic index diet - P A|patients will follow for two months a diet high fibre/low glycemic index without physical activity program
9943956|NCT01025856|Active Comparator|Rich in MUFA diet - PA|Patients will follow for two months a rich in MUFA diet without a physical activity program.
9943957|NCT01025856|Active Comparator|high fibre/low glycemic index diet+PA|Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
9943958|NCT01025856|Active Comparator|Rich in MUFA diet+PA|Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
9943959|NCT01025869|Other|Stent System|Cinatra™ Corolimus Eluting Coronary Stent System
9943960|NCT01025882|Experimental|Regimen 1|Patients undergo a single fraction of margin-intensive stereotactic body radiotherapy (SBRT) on day 1. Patients undergo pancreatoduodenectomy between days 15-43.
9943961|NCT01025882|Experimental|Regimen 2|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients undergo a single fraction of SBRT between days 21-28 followed by pancreatoduodenectomy between days 35-63.
9943962|NCT01025895|Active Comparator|single bundle|acl reconstruction - single bundle technique
9943963|NCT01025895|Experimental|double bundle|acl reconstruction - double bundle technique
9943964|NCT01025908|Experimental|Cognitive Behavioral Therapy|25 panic disorder patients
9943965|NCT01025908|Active Comparator|Supportive psychotherapy|25 panic disorder agoraphobia
9943966|NCT01025921|Placebo Comparator|Inhaled colistin|They will receive inhaled colistin three times daily for 10 days.
9943967|NCT01025921|Placebo Comparator|Inhaled normal saline|Inhaled normal saline three times daily for 10 days
9943968|NCT01025934|Active Comparator|7 days|
9943969|NCT01025934|Active Comparator|20 days|
9943970|NCT01025934|Sham Comparator|sham|
9943971|NCT01025947||Study group|Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted
9943972|NCT01025960|Other|Standard Inspection Colonoscopy|The colonoscope will be inserted rapidly to reach the cecum. Inspection of the large bowel will occur during the withdrawal of the colonoscope.
9943973|NCT01025960|Active Comparator|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
9943974|NCT01025973||Diabetes Mellitus|Patients with type 1, type 2 or gestational diabetes mellitus
9943975|NCT01025973||Normal pregnancy|Patient without diabetes mellitus
10003667|NCT01569217||respiratory muscle dysfunction patients|Neuromuscular patients
10003668|NCT01569217||diaphragmatic dysfunction|patients who present orthopnea, recruitment of accessory muscles, abdominal paradox, respiratory dysfunction or dyssynchronous movement
10003669|NCT01569230|Experimental|Individualized acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
10003670|NCT01569230|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
10003671|NCT01569230|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
10003672|NCT01569230|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
10003673|NCT01569243|Other|Usual care group|Subjects in this group will receive the usual standard of care available at MGH.
10003674|NCT01569243|Experimental|Text messaging group|Subjects in this group will be enrolled to receive text messages aimed at providing bite-sized coaching based on measured step count to help improve activity levels and providing reminder, educational and motivation messages aimed at helping patients to meet their diabetes self-management goals.
10003675|NCT01569256|Active Comparator|Cabergoline administered group|"The patients in this group will have cabergoline (Dostinex tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days) for prevention of OHSS.~All patients were administered long luteal protocol for ovulation induction."
10003676|NCT01569256|No Intervention|Control arm|"The patients in the control group had no manipulation for prevention of OHSS and age-, BMI-matched with the active comparator group.~All patients were administered long luteal protocol for ovulation induction."
10003677|NCT01569269|Experimental|Yoga|See intervention description
10003678|NCT01569269|Experimental|Meditation|See intervention description
10003679|NCT01569269|Experimental|Reiki|see intervention description
10003680|NCT01569269|Active Comparator|Holistic Education|see intervention description
10003681|NCT01569282|Active Comparator|Double bypass|
10003682|NCT01569282|Active Comparator|Stent Strategy|
10003683|NCT01569321|Experimental|Breast cancer|
10003684|NCT01569334|Other|HTC with Cardiac allograft vasculopathy|HTC:heart transplanted recipients
10003685|NCT01569334|Other|HTR without Cardiac allograft vasculopathy|
10003686|NCT01569334|Other|untransplanted|
10003687|NCT01569347||1: Cocaine users|Adults, cocaine users
10003688|NCT01569360|Active Comparator|Corset|the patients are assigned the use of a custome made corset during daytime
10003689|NCT01569360|No Intervention|No corset|the patients do not use a corset during daytime
10003690|NCT01569373||Post allogeneic SCT patients|Patients who have undergone an allogeneic stem cell transplant.
10003691|NCT01569386|Experimental|low intensity physical activity|Daily low intensity physical activity by the half squat
10003692|NCT01569386|Active Comparator|stretch exercise and usual activity|They do whole body stretch exercise for 20 minute in a day
10003693|NCT01569399|Active Comparator|active rTMS|High frequency (10HZ) on the left DLPFC
10003694|NCT01569399|Placebo Comparator|sham rTMS|
10035156|NCT01803451|Experimental|hyperglycemic clamp-Meal tolerance test|these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
10035157|NCT01803451|Experimental|Labeled meal tolerance test|The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
9476292|NCT03573219|Experimental|Healthy participant|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
10035158|NCT01803477|Active Comparator|Picato® 0.05% gel|once daily for two consecutive days
10035159|NCT01803477|Experimental|ingenol mebutate vehicle formulation 1|once daily for two consecutive days
10035160|NCT01803477|Experimental|ingenol mebutate vehicle formulation 2|once daily for two consecutive days
10035161|NCT01803477|Experimental|ingenol mebutate vehicle formulation 3|once daily for two consecutive days
10035162|NCT01803503|Active Comparator|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks. Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities.
10035163|NCT01803503|Experimental|Docetaxel + Sunitinib|"Docetaxel 75mg/m2 day 1, every 3 weeks, preceded by 7 days of sunitinib 12.5mg orally daily during each cycle.~Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities."
10035164|NCT01803516||Breast cancer survivors with radiation-induced Telangiectasias|A quality of life assessment will also be completed by the patient using the Skindex-16 and a subscale of the BREAST-Q Breast Conserving Module questionnaire.
10035165|NCT01803529|Experimental|heat-pack with massage|deep friction massage and standard heat-pack given a maximum of 8 treatments
10035166|NCT01803529|Active Comparator|heatpack only|standard heat-pack given a maximum of 8 treatments
10035167|NCT01803542|Experimental|SBRT|High dose of radiation will be used to treat tumours.
9476293|NCT03573193|Active Comparator|study group:|ridge preservation alveolar ridge socket preserved using alloplastic material beta tri calcium phosphate type
9943976|NCT01025986||Noninfectious Uveitis|
9943977|NCT01025999||RYGB|UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.
9943978|NCT01026025|Experimental|Duet TRS|This is a single arm study.
9943979|NCT01026064|Experimental|Part C- Azithromycin|2 x 250 mg once daily over 3 days
9943980|NCT01026064|Placebo Comparator|Part C- Placebo|Once daily over 3 days
9943981|NCT01026090|Experimental|Dronedarone pre-cardioversion|Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
9943982|NCT01026090|Placebo Comparator|Placebo pre-cardioversion|Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
9943983|NCT01026116|Active Comparator|EC-wP|epirubicin/cyclophosphamide followed weekly paclitaxel
9943984|NCT01026116|Experimental|EP-wP|epirubicin/paclitaxel followed by weekly paclitaxel
9943985|NCT01026129|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia.
9943986|NCT01026129|Experimental|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia.
9943987|NCT01026129|Active Comparator|Lidocaine|Bolus dose of intravenous remifentanil 1mg/kg given once before emergence of general anesthesia.
9943988|NCT01026155|Experimental|Respiratory muscle traininig|Low caloric diet and physical activities + Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
10035168|NCT01803568|Experimental|Exercise in normoglycaemic individuals|
9476294|NCT03573193|Other|control group|ridge preservation (alveolar ridge socket preserved using xenograft material Bio-oss type
9943989|NCT01026155|Active Comparator|Control|Low caloric diet and physical activities
9943990|NCT01026207||Chronic Obstructive Pulmonary Disease|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months, and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.Patients has been underwent one night by polysomnography and one night with portable monitoring.
9943991|NCT01026233|Experimental|1|brentuximab vedotin
9943992|NCT01026246|Experimental|Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
9943993|NCT01026246|Experimental|Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
9943994|NCT01026246|Experimental|Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
9943995|NCT01026259|Experimental|Local incision warming|Local warming applied to surgical incision for 6 treatments beginning in post anesthesia recovery through the second postoperative day.
9943996|NCT01026259|Active Comparator|No warming to surgical incision|Incisions covered with same postoperative dressing as in Arm 1 but without warming treatments.
9943997|NCT01026272||healthy subjects|subjects with no sign of inflammatory disease, or diagnosis of MS
9943998|NCT01026272||Patients with MS|
9943999|NCT01026285||antipsychotic treatment|Risperidone Long-Acting injectable or oral antipsychotics According to label
9944000|NCT01026298|No Intervention|Control Group|8 weeks, no intervention for OSA
9480649|NCT05262270|Placebo Comparator|Placebo|"Matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).~Drug: Placebo (PLB) Injectable Placebo: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Injectable matching (to XR-NTX) placebo Arm: Placebo Comparator - matched Placebo (PLB)~Drug: Placebo (PLB) Injectable Placebo: 2 subcutaneous injections administered Week 0, 4. Other Names: Injectable matching (to XR-BUP) placebo Arm: Placebo Comparator - matched Placebo (PLB)"
9944001|NCT01026298|Active Comparator|CPAP group|8-week randomized-controlled period of CPAP treatment
9944002|NCT01026311|Placebo Comparator|placebo|
9944003|NCT01026311|Active Comparator|Coenzyme Q10|200mg of coenzyme Q10
9944004|NCT01026337||Arm I|"Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo dynamic contrast-enhanced MRI at baseline and after the first 4 weeks of sunitinib malate."
9944005|NCT01026350|Experimental|study group|
9944006|NCT01026363|Experimental|ergocalciferol|Ergocalciferol intervention arm
9944007|NCT01026363|Experimental|calcitriol|calcitriol intervention arm
9944008|NCT01026415|Experimental|1|midazolam +/- brentuximab vedotin
9944009|NCT01026415|Experimental|2|brentuximab vedotin +/- rifampin
9944010|NCT01026415|Experimental|3|brentuximab vedotin +/- ketoconazole
9944011|NCT01026415|Experimental|4|special populations
9944012|NCT01026428|Experimental|Safinamide + Levodopa|
9944013|NCT01026428|Placebo Comparator|Placebo + Levodopa|
9944014|NCT01026441|Other|Treatment for cellulite and circumference reduction|All subjects will be treated with the device
9944015|NCT01026467||Supportive Care (frailty index, geriatric assessment, chemo)|Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy. Patients receive standard-of-care chemotherapy comprising carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses
9944016|NCT01026480||IPAA Patients|Patients who have had their IPAA procedures performed by Dr. Becker
9944017|NCT01026519|Experimental|Dose 1|Active dose
9944018|NCT01026519|Experimental|Dose 2|Active dose
9944019|NCT01026519|Experimental|Dose 3|Active 3
9944020|NCT01026519|Placebo Comparator|Dose 4|Placebo dose
9944021|NCT01026532||Segmental antigen challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
9944022|NCT01026545|Experimental|Cohort 1|
9944023|NCT01026545|Experimental|Cohort 2|
9944024|NCT01026545|Experimental|Cohort 3|
9944025|NCT01026545|Experimental|Cohort 4 (optional)|If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
9944026|NCT01026545|Experimental|Cohort 5 (Japanese)|
9944027|NCT01026545|Experimental|Cohort 6 (Japanese)|
9944028|NCT01026558|Active Comparator|Ceftobiprole (not morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
9944029|NCT01026558|Experimental|Ceftobiprole (morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
9944030|NCT01026571||Bicuspid aortic valve|Collection of patients who are known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
9944031|NCT01026571||Relative|Collection of patients who are a relative to a patient known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
9944032|NCT01026584|Other|drug|
9944033|NCT01026597|Experimental|Cohort 1|Dose 1 versus placebo
9944034|NCT01026597|Experimental|Cohort 2|Dose 2 versus placebo
9944035|NCT01026597|Experimental|cohort 3|Dose 3 versus placebo
9944036|NCT01026597|Experimental|cohort 4|Dose 4 versus placebo
9944037|NCT01026597|Experimental|cohort 5|Dose 5 versus placebo
9944038|NCT01026610|Experimental|LB80380 90 mg|LB80380 90 mg (90 mg + placebo), once daily oral dose
9944039|NCT01026610|Experimental|LB80380 150 mg|LB80380 150 mg (60 mg + 90 mg), once daily oral dose
9944040|NCT01026610|Active Comparator|entecavir 0.5 mg|entecavir 0.5 mg, once daily oral dose
9944041|NCT01026636|Experimental|Ceftobiprole|Ceftobiprole 7mg/kg - 15mg/kg per day as 2h infusion
9944042|NCT01026649|Experimental|2 stage|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
9944043|NCT01026649|Active Comparator|1 stage|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
9944044|NCT01026662||Abdominoplasty|Subjects scheduled for abdominoplasty surgery
9944045|NCT01026675||Pregnant women 6-13 weeks|
9944046|NCT01026688|Experimental|Intervention|
9944047|NCT01026688|Other|Control|
9944048|NCT01026701||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
9944049|NCT01026714|Experimental|flurbiprofen 50mg po|
9944050|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inducer|
9944051|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inhibitor|
9944052|NCT01026727|Experimental|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|MPC-4326 300 mg or 400mg BID plus a 2-3 drug optimized background regimen (OBR)for 24 weeks.
9944053|NCT01026727|Active Comparator|3-4 drug antiretroviral drugs|3-4 commercially available antiretroviral (ARV)drugs for 24 weeks.
9944054|NCT01026740|Experimental|001|Ceftobiprole 500 mg, single infusion over 2 hours
10035169|NCT01803568|Experimental|Exercise in hyperglycaemic individuals|
10003695|NCT01569412|Experimental|Ertumaxomab|Ertumaxomab administration during two treatment cycles will follow a predefined dose escalation scheme, consisting of 5 ascending doses per cycle with each infusion lasting 3 hours.
10003696|NCT01569425|Experimental|Lifestyle counseling|Lifestyle counseling, with high calorie breakfast
10003697|NCT01569425|Active Comparator|Life Counseling|Diet with high calorie dinner
10003698|NCT01569477|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
10003699|NCT01569477|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
10003700|NCT01569490|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
10214749|NCT04544007|Experimental|Administer Poly-ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
10003701|NCT01569490|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
10003702|NCT01569503|Experimental|VSN|VNS therapy
10003703|NCT01569516|Experimental|low dose|1mg, tid
10003704|NCT01569516|Experimental|Moderate dose|2mg,tid
10003705|NCT01569516|Experimental|High dose|4mg,tid
10003706|NCT01569516|Placebo Comparator|Placebo|0 mg, tid
9480650|NCT05262244|Active Comparator|AMD with bevacizumab-800CW|Patients with AMD receive bevacizumab-800CW followed by angiography
10003707|NCT01569581|Experimental|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
10003708|NCT01569581|Experimental|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
10003709|NCT01569581|Experimental|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
10214750|NCT04536623|Experimental|SIESTA-Rehab Protocol|This inpatient rehabilitation floor will be trained to implement the SIESTA-Rehab protocol. Nurses will be empowered to reduce unnecessary disruptions and subjects will be screened for sleep-disordered breathing. Subjects will utilize wearable sensor technology.
10214751|NCT04536623|No Intervention|Standard of Care|This inpatient rehabilitation floor will continue to implement usual care.
10214752|NCT04512742|Other|Leishmania infected-Phlebotomus duboscqi human challenge|There is no clear indication in the medical literature to determine which of the major sand fly vectors of Leishmania major - Phlebotomus papatasi or Phlebotomus duboscqi, will be most effective at transmitting infection to a human host. Both species have a similar mode of feeding and can support L. major development. In our previous study, FLYBITE, no significant difference in biting rates on humans was observed. Based on pre-clinical data , Phlebotomus duboscqi was determined to be the lead candidate for use in this study. If all the 6 participants have developed lesions within the 6-month follow up after Leishmania challenge, the challenge phase of the study is completed. If only 5 participants have developed lesions, then a further 6 participants will undergo Leishmania challenge by P. duboscqi. If only 4 or less subjects in the first cohort develop lesions, then the investigators will switch vector to P. papatasi and a further 6 subjects will undergo Leishmania challenge.
10214753|NCT04510207|Experimental|Investigational Vaccine 1|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP according to the immunization schedule of D0 & D21.
10003710|NCT01569581|Experimental|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
10003711|NCT01569581|No Intervention|0U/0.5ml in infants (6-11 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 6-11 months old on day 0, 28
10003712|NCT01569581|No Intervention|0U/0.5ml in infants (12-23 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 12-23 months old on day 0, 28
10003713|NCT01569581|No Intervention|0U/0.5ml in children (24-35 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1500 children aged 24-35 months old on day 0, 28
10003714|NCT01569581|No Intervention|0U/0.5ml in children (36-71 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1000 children aged 36-71 months old on day 0, 28
10003715|NCT01569620|Active Comparator|Culturally targeted print materials|Best clinical practices plus culturally print materials
10003716|NCT01569620|Active Comparator|Standard print materials|Best clinical practices plus standard print materials
10003717|NCT01569620|Active Comparator|Best clinical practices alone|Best clinical practices alone: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
10214754|NCT04510207|Experimental|Investigational Vaccine 2|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP according to the immunization schedule of D0 & D21.
10214755|NCT04510207|Placebo Comparator|Placebo|Participants will receive 2 doses of Placebo according to the immunization schedule of D0 & D21.
10214756|NCT04510207|Experimental|Investigational Vaccine 1b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP after 3 months following two doses of immunization.
10003718|NCT01569633|Placebo Comparator|Placebo|This group of infant will not receive any medication but sugar water or placebo
10003719|NCT01569633|Active Comparator|Metclopramide|This group of infants will receive Metoclopramide at 0.1mg/kg q8 hrs.
10003720|NCT01569633|Active Comparator|Erythromycin|mediaction used to treat feeding disorder
10003721|NCT01569659|Active Comparator|Standard dose of lurasidone|
10003722|NCT01569659|Experimental|High dose of lurasidone|
10003723|NCT01569672|Active Comparator|Intervention Clinic|Patient Navigator matched with subjects. Patient Navigators will be matched with subjects at the intervention clinics and will assist patients with questions, issues or concerns with their cancer treatment/diagnosis or abnormal test results and followup test or treatments
10003724|NCT01569672|Placebo Comparator|Control Clinics|Subjects are mailed informational/educational materials.
10003725|NCT01569685|Active Comparator|Venlafaxine|6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
9944055|NCT01026753|No Intervention|FOBT by laboratory requisition or directly by PCP|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit.
9944056|NCT01026753|Experimental|FOBT by lab req. or directly from PCP + study magnet|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address.
9480651|NCT05262244|Placebo Comparator|AMD with vedolizumab-800CW|Patients with AMD receive vedolizumab-800CW followed by angiography
9944057|NCT01026766||Non obese/ Warming blankets|
9944058|NCT01026766||Non obese/ Warming intravenous fluids|
9944059|NCT01026766||Obese/ Warming intravenous fluids|
9944060|NCT01026766||Obese/ Warming blankets|
9944061|NCT01026779||Cases of rotavirus gastroenteritis|Patients will be eligible as cases if they have been identified by the investigator's ongoing rotavirus surveillance studies as having been hospitalized with laboratory-confirmed rotavirus gastroenteritis between January 1, 2007 and June 31, 2009. To be eligible as a case, the child must meet the following criteria: 1) immunocompetent; 2) born after April 15, 2006 (to select a population that would have been in the age group eligible for at least 1 dose of RV5 (RotaTeq); and 3) > 2 months of age on the day of admission.
9944062|NCT01026779||Control Subjects|Three controls for each case will be identified using KIDSNET, the state child health registry. Controls will be matched to cases by age and county of residence at birth.
9944063|NCT01026857|Experimental|PLC Colon release tablet 1 g|40 patients each arm
9944064|NCT01026857|Experimental|PLC colon release tablet 2 g|40 patients each arm
9944065|NCT01026857|Placebo Comparator|Placebo PLC colon release tablet 2 g|40 patients each arm
9944066|NCT01026883|Other|Healthy subjects|Hematocrit level of each subject will be assessed by two different techniques
9944067|NCT01026922||SmartPill Participants|It is a single-center study, children aged 8-17 years with severe upper GI symptoms (ie, nausea, vomiting, retching, abdominal pain) referred for antroduodenal manometry (ADM) studies underwent a wireless motility capsule (smartpill) test. The scintigraphic gastric emptying study was done when clinically indicated either at the time of the ADM or at a different time within 1 year of the wireless motility capsule test. In summary, we studied symptomatic adolescents using scintigraphic gastric emptying studies, ADM, and the wireless motility capsule test, with the goal of identifying the diagnostic yield of each test and exploring how they compare in detecting motor abnormalities in the GI tract.
9944068|NCT01026935|Experimental|sutured mesh|200 patients are randomized to inguinal hernia repair with sutured light weight (38g/m2) polypropylene mesh (Lichtenstein repair)
9944069|NCT01026935|Experimental|non-sutured mesh|200 patients are randomized to receive a light weight mesh that adheres to tissues with polylactic micro hooks without sutures
9944070|NCT01026961|Experimental|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
9944071|NCT01026961|Active Comparator|Phenylephrine hydrochloride|Phenylephrine hydrochloride 10mg
9944072|NCT01026987|Experimental|Related Donors: G-CSF & AMD3100|G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.
9944073|NCT01026987|Other|Recipient|Stem Cell Infusion on Day 0
9944074|NCT01027026|Experimental|Group 1 Fast Track Group|The patients are discharged the same day after coronary angiography to the refering Hospital
9944075|NCT01027026|Active Comparator|Group 2: Ordinary care|Ordinary Cardiology care in the Intervention hospital
9944076|NCT01027039||Patients using noise-reducing headphones|Patients using noise-reducing headphones
9944077|NCT01027039||Patients using no headphones|Patients using no headphones
9944078|NCT01027039||Patients using headphones with music|Patients using headphones with music
9944079|NCT01027052|Active Comparator|Hamburger meat patty with Spice Blend|Hamburger meat patty containing spice blend will be consumed on 3 separate occasions
9944080|NCT01027052|Placebo Comparator|Hamburger meat patty with salt|Hamburger meat patty containing salt will be consumed on 3 separate occasions
9944081|NCT01027065|Experimental|Tritherapy: CYT107+ vaccine+ antiviral|
9944082|NCT01027065|Experimental|Bitherapy: CYT107 + antiviral|
9944083|NCT01027078||OSA|patients diagnosed with obstructive sleep apnea who do not have existing cardiovascular disease
9944084|NCT01027078||control|patients without obstructive sleep apnea who are matched in weight and age to the OSA patients
9944085|NCT01027091||patients with positive slope|patients with positive slope in the levels of free serum calcium levels between 6th and 12th postoperative hour
9944086|NCT01027091||patients with negative or no slope|patients with negative or no slope in the levels of free serum calcium levels between 6th and 12th postoperative hour.
9944087|NCT01027117|Active Comparator|Treatment A|Revatio 20 mg intact tablet. This is the reference treatment arm.
9944088|NCT01027117|Experimental|Treatment B|Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce.
9944089|NCT01027117|Experimental|Treatment C|Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP).
9944090|NCT01027130||healthy control|240 female subjects without preeclampsia
9944091|NCT01027130||preeclampsia|120 female subjects with preeclampsia
9944092|NCT01027143|Experimental|omega-3 fatty acids|3 softgels (EPA, DHA) twice daily
9944093|NCT01027143|Placebo Comparator|control|Soybean oil: 3 matched softgel caps twice daily
9944094|NCT01027156|Experimental|High Intensity Exercise|
9944095|NCT01027169|Experimental|Arm 1|subjects with mild hepatic impairment
9944096|NCT01027169|Experimental|Arm 2|subjects with moderate hepatic impairment
9944097|NCT01027169|Experimental|Arm 3|matched subjects with normal hepatic function
9944098|NCT01027182|No Intervention|Raltegravir|
9944099|NCT01027208|Experimental|Ixabepilone|
9944100|NCT01027221|No Intervention|0|primarily resectable pancreatic cancer patients
10003726|NCT01569685|Active Comparator|Sertraline|6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
10003727|NCT01569698||extrarenal replacement therapy|Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
10003728|NCT01569711||Deep brain stimulation|
10003729|NCT01569724|Experimental|bexarotene|
10003730|NCT01569750|Experimental|Ibrutinib|"Part 1 (Dose Escalation): Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) until maximum tolerated dose is achieved.~Part 2: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP."
10003731|NCT01569776|Experimental|New Amino Acid formula|
10003732|NCT01569776|Active Comparator|Control formula|Commercially available Amino Acid infant formula
10003733|NCT01569789|Active Comparator|Ear Stimulation|Comparing cytokine levels pre and post stimulation of the nerve in the ear
10003734|NCT01569789|Placebo Comparator|Calf Stimulation|Comparing cytokine levels pre and post stimulation of the placebo area on the calf
10003735|NCT01569802||screening|
10003736|NCT01569854||statin|
10003737|NCT01569893|No Intervention|Control group|Usual care: treatment as usual
10003738|NCT01569893|Experimental|Self-monitoring for patients with Dibetes mellitus type 2|Self-monitoring for patients with Dibetes mellitus type 2
10003739|NCT01569906||UVB|Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy
10003740|NCT01569906||Controls|Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment
10003741|NCT01569919|Experimental|TroVax®|In this single-arm study, all participants will receive 9 injections of the TroVax® vaccine, plus standard cisplatin and pemetrexed chemotherapy.
10003742|NCT01569932||chemotherapy|Patients will be assessed both before and after they undergo treatment with chemotherapy.
10003743|NCT01569945|Active Comparator|Tablets|Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
10003744|NCT01569945|Active Comparator|human menopausal gonadotropins|Daily Injections
10003745|NCT01569958|Active Comparator|tDCS|
10003746|NCT01569958|Sham Comparator|sham|
10003747|NCT01569971||Adolescents|Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
10003748|NCT01569971||Caregivers|Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
10003749|NCT01569971||Young Adults|Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
10003750|NCT01569984|Experimental|Avastin, SBRT|2 treatments of avastin followed by 6 treatments of SBRT every other day.
10003751|NCT01569997|Other|Intervention group|Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
10003752|NCT01569997|No Intervention|control group|Control group: nursing homes whose residents continue to benefit from usual care
10003753|NCT01570023|No Intervention|Standard Clinical Care|Standard swallowing intervention is that which is identified by the SLP as appropriate to treat the patient's dysphagia and is in common clinical practice. Such treatment would consist of dietary or postural compensatory strategies (i.e., chin down posture while swallowing).
10003754|NCT01570023|Experimental|Standard Clinical Care Plus Isometric Lingual Exercise|Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
10003755|NCT01570049|Experimental|Bendamustine|Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
10003756|NCT01570062|Active Comparator|Indoor Air HEPA Filtration|HEPA filters will be placed in participant's main living area and bedroom. Actual filtration will occur during only one of the two 7-day sampling periods.
10003757|NCT01570062|Placebo Comparator|HEPA Filtration Placebo|For one of two 7-day sampling sessions, HEPA filters placed in participants' homes will be run without an actual filter in the housing unit.
10003758|NCT01570075|Experimental|RFA group|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
10003759|NCT01570075|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
10003760|NCT01570088|Active Comparator|Folic acid|
10003761|NCT01570088|Experimental|L-5-MTHF|
10003762|NCT01570088|Placebo Comparator|Placebo|
10003763|NCT01570101|Experimental|CE Marked Sapheon Closure System in GSV|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
10003764|NCT01570114||covered metallic stent|Endoscopically insertion of fully covered metallic stent on benign colonic strictures
10003765|NCT01570127|Experimental|Individualized Acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
10003766|NCT01570127|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
10003767|NCT01570127|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
10003768|NCT01570127|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
9480652|NCT05262244|Other|Healthy patients with bevacizumab-800CW|Healthy patients, included in fluorescence cancer study receiving bevacizumab-800CW, receive an angiography.
9480653|NCT05262231|Experimental|Experimental|Study group intervention consists 1-session. A session takes approximately 1 hour. The pre-test will be applied just before the intervention. The final test will be administered immediately after the intervention.
9944101|NCT01027221|Active Comparator|0,5 Gy|neoadjuvant Radiation of 0,5 Gy two days before resection
9944102|NCT01027221|Active Comparator|2 Gy|neoadjuvant Radiation of 2 Gy 2 days before resection
9944103|NCT01027221|Active Comparator|5 Gy|neoadjuvant Radiation of 5 Gy 2 days before resection
9944104|NCT01027234|Experimental|1|
9944105|NCT01027234|Placebo Comparator|2|
9944106|NCT01027260|Active Comparator|Itopride 50 mg|
9944107|NCT01027260|Active Comparator|Itopride 100 mg|
9944108|NCT01027260|Placebo Comparator|Placebo|
9944109|NCT01027299|Active Comparator|Standard pacing|Standard pacing settings prescribed by the cardiac surgeon or intensivist after revascularisation.
9944110|NCT01027299|Active Comparator|BiVentricular pacing (BiV).|The group of patients receiving biventricular pacing after cardiac surgery.
9944111|NCT01027312||Glaucoma Patients|Glaucoma patients covering the entire range of visual field loss from none to advanced.
9944112|NCT01027312||Control Group|Aged matched people with no eye diseases.
9944113|NCT01027325|Experimental|High CHO/Low Amylose|55% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 25% Fat
9944114|NCT01027325|Experimental|Low Carbohydrate/Hi Amylose|40% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 40% Fat
9944115|NCT01027325|Experimental|High CHO/High Amylose|55% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 25% Fat
9944116|NCT01027325|Experimental|Low Carbohydrate/Low Amylose|40% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 40% Fat
9944117|NCT01027325|Active Comparator|Baseline|40% Carbohydrate 20% Protein 40% Fat
9944118|NCT01027338|Experimental|Tai Chi Exercise|
9944119|NCT01027338|No Intervention|Usual Care|
9944120|NCT01027377|Experimental|A|Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
9944121|NCT01027377|Experimental|B|Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments
9944122|NCT01027390|Experimental|1 hr training 50% supervision|1 hr training 50% supervision
9944123|NCT01027390|Experimental|3 x 20 min training 50% supervision|3 x 20 min training 50% supervision
9944124|NCT01027390|Experimental|3 x 20 min training initial instructions|3 x 20 min training initial instructions
9944125|NCT01027390|Experimental|10 x 6 min training 50% supervision|10 x 6 min training 50% supervision
9944126|NCT01027390|No Intervention|reference|no training
9944127|NCT01027403||Healthy volunteers|
9944128|NCT01027403||Acute decompensated heart failure|
9944129|NCT01027429|Active Comparator|procaine penicillin and gentamicin|Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
9944130|NCT01027429|Experimental|Amoxicillin and gentamicin|Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
9944131|NCT01027429|Experimental|procaine penicillin, gentamicin, and amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
9944132|NCT01027442|Placebo Comparator|Conventional implant placement method|"The patients in ths group will be treated by conventional, free-hand implant placement"
9944133|NCT01027442|Active Comparator|Computer-guidedimplant placement|In this group, the patients will be treated by implants placed via computer generated SLA guides
9944134|NCT01027455|Placebo Comparator|Dry Cold|Dry (0% relative humidity) and cold (20 degrees Celsius - Room Temperature) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
9944135|NCT01027455|Experimental|Humidification|Humidified (98% relative humidity) and warm (37 degrees Celsius) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
9944136|NCT01027494||Treatment|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, 4 drops in outer ear canal of infected ear(s) while awake 2 times per day for 7 days
9944137|NCT01027494||Healthy|No intervention
9944138|NCT01027520|Experimental|Intervention|Application of Coban dressing
9944139|NCT01027533||Restor +3|patients will be implanted bilaterally with Restor + 3
9944140|NCT01027533||restor +4|Patients will be implanted bilaterally with Restor +4
9944141|NCT01027546|Placebo Comparator|placebo, tranexamic acid|
9944142|NCT01027572|Experimental|Thalamic stimulation|Patients in Vegetative or Minimally Conscious State
9944143|NCT01027611|Experimental|proparacaine HCL 0.5%|
10003769|NCT01570140||Web portal users|T2DM patients in the primary care setting, using the web portal.
10003770|NCT01570153||ADHF patients|
10003771|NCT01570166|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
10003772|NCT01570166|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
10003773|NCT01570179|Experimental|deep block ideal body weight|
10003774|NCT01570179|Active Comparator|deep block real body weight|
10003775|NCT01570179|Experimental|moderate block ideal body weight|
10003776|NCT01570179|Active Comparator|moderate block real body weight|
10003777|NCT01570205|Experimental|XG-102 10 µg/kg|
10003778|NCT01570205|Experimental|XG-102 40 µg/kg|
10003779|NCT01570205|Experimental|XG-102 80 µg/kg|
10003780|NCT01570205|Placebo Comparator|placebo|
10003781|NCT01570218|Experimental|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days.
10003782|NCT01570218|No Intervention|Control|
10003783|NCT01570231|Experimental|bilateral limb ischemic preconditioning (BLIPC)|5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
10003784|NCT01570231|No Intervention|Control group|underwent equivalent medical treatments only
10003785|NCT01570257|No Intervention|control group|These patients receive a shunt with the valve preset and fixed at a Performance level of 1.0, corresponding to an opening/closing pressure of 35-55 mm H2O.
9480654|NCT05262231|No Intervention|No Intervention|No intervention is applied to the control group.
9944144|NCT01027611|Experimental|proparacaine + lidocaine|
9944145|NCT01027611|Experimental|lidocaine gel|
9944146|NCT01027624||Hyperchlesterolaemia|Participants undertreated with hypercholesterolaemia
9944147|NCT01027637|Experimental|Alloderm reconstruction|All patients recieving the intervention Alloderm for breast reconstruction
9944148|NCT01027663|No Intervention|Iron Deficiency Anemia|
9944149|NCT01027663|No Intervention|Hereditary Hemochromatosis|
9944150|NCT01027663|Active Comparator|Iron Supplements|
9944151|NCT01027676|Experimental|study arm|single arm Gefitinib plus vorinostat
9944152|NCT01027689|Active Comparator|Alprazolam commercial immediate release oral tablet|
9944153|NCT01027689|Experimental|Alprazolam test sublingual tablet|
9944154|NCT01027715|Experimental|EEG seizure treatment group|EEG data available to physicians. Treatment based on EEG seizures. Treatment will be dictated by the detailed treatment protocol. Standard antiepileptic medications will be used.
9944155|NCT01027715|No Intervention|Clinical Seizure treatment Group|Seizure treatment in this group will be based on standard care - treating clinical seizures only. While EEG data will be collected in this group, the data will not be available to the treating physicians. A one-hour EEG report will be available to the treating team. Continuous EEG monitoring and treatment will only be allowed if the initial EEG shows status.
9944156|NCT01027728|Experimental|CCX354-C|
9944157|NCT01027741|Experimental|Phone Referral|Participants receive phone referral to cancer control and prevention services.
9944158|NCT01027741|Experimental|Tailored Cancer Communication|Participants will receive phone referral to cancer control and prevention services as well as tailored materials in the mail.
9944159|NCT01027741|Experimental|Cancer Control Navigator|Participants will receive phone referral to cancer control and prevention services as well as a personal cancer control navigator.
9944160|NCT01027741|No Intervention|Control|Participants receive only recommendation to talk to health care professional.
9944161|NCT01027767||Surgery/Radiation Arm|Patients that have had surgery along with radiation therapy
9944162|NCT01027767||Surgery Arm|Patients that have had surgery of a benign lesion.
9944163|NCT01027832|No Intervention|Control arm|no intervention
9944164|NCT01027832|Experimental|Experimental arm|antibiotics
9944165|NCT01027923|Experimental|Dose Level 1|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
9944166|NCT01027923|Experimental|Dose Level 2|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
9944167|NCT01027923|Experimental|Dose Level 3|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
10003786|NCT01570257|Experimental|Intervention group|These patients receive a shunt with the valve preset at a Performance level (PL) of 2.5, corresponding to an opening/closing pressure of 135-155 mm H2O. The PL is allowed to be lowered until clinical improvement occurs.
10003787|NCT01570270|Experimental|regular cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. T
10003788|NCT01570296|Experimental|Gefitinib and BKM120|"Patients with NSCLC who progress on treatment with single-agent EGFR TKI (e.g., gefitinib or erlotinib), and meet the clinical definition of EGFR TKI resistance (Jackman et al., 2010):~A tumour that harbours an EGFR mutation known to be associated with drug sensitivity~Previous objective clinical benefit from treatment with an EGFR TKI~Patients should have systemic progression of disease (by RECIST) while on continuous treatment with gefitinib or erlotinib. Patients that have previously progressed on EGFR TKI (not in the preceding line of treatment) may also be enrolled and will receive gefitinib and BKM120 sequentially.~Patients with any solid tumour-type and activated PI3 kinase pathway and historically known to over express EGFR may also be recruited.~Once the RP2D is reached, an expansion cohort of 40 patients will be accrued for extended safety experience and to ascertain preliminary activity."
10003789|NCT01570374|Experimental|iCBT|Receives treatment.
10003790|NCT01570374|No Intervention|Waiting list control group|The waiting list control group initially receives no treatment, but do weekly screenings. After 9 weeks, the control group receives the same treatment as the other study arm.
10003791|NCT01570400|Experimental|CBM training program variant 1 + iCBT|Cognitive bias modification training program variant 1 combined with iCBT
10003792|NCT01570400|Experimental|CBM training program variant 2 + iCBT|Cognitive bias modification training program variant 2 combined with iCBT
10003793|NCT01570413|Active Comparator|Pelvic Exam|Subjects receive pelvic exam
10003794|NCT01570413|Experimental|No Pelvic Exam|Subjects do not receive pelvic exam
10003795|NCT01570426||Bipolar Disorder|Children, 7- 17 years-old, who meet diagnostic criteria for bipolar disorder, Type 1
10003796|NCT01570426||ADHD/ADD|Children, 7-17 years-old, who meet diagnostic criteria for attention deficit/hyperactivity disorder (ADHD) OR attention deficit disorder (without hyperactivity)
10003797|NCT01570426||Generalized Anxiety Disorder (GAD)|Children, 7-17 years-old, who meet diagnostic criteria for Generalized Anxiety Disorder (GAD)
10003798|NCT01570426||Health Controls|Children, ages 7-17 years-old, without a history of psychiatric diagnosis
10003799|NCT01570452||healthy volunteers|healthy subjects not affected by benign or malignant colonic disease
10003800|NCT01570452||benign colonic tumor patients|patients affected by benign colonic tumor such as adenoma
10003801|NCT01570452||cancer patient I-II stage|Patients affected by colonic cancer in I-II stage
10003802|NCT01570452||cancer patients III-IV stage|Patients affected by colonic cancer in III-IV stage
10003803|NCT01570478|Experimental|Foster® NEXThaler®|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
10003804|NCT01570478|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
10003805|NCT01570504|Experimental|ivermectin multiple doses|A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
10003806|NCT01570504|Active Comparator|1 dose ivermectin|A single 200 mcg/kg dose of ivermectin
10003807|NCT01570517|Experimental|Device implantation|Subjects are implanted with the study device.
10003808|NCT01570530|Active Comparator|Atorvastatin|Patients treated with atorvastatin
10003809|NCT01570530|Other|Without Atorvastatin|Patients treated without atorvastatin
10003810|NCT01570543||orthopedic implants, no treatment|
10003811|NCT01570556|Active Comparator|Patients with positive culture, treatment group|These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
10003812|NCT01570556|No Intervention|Patients with positive culture, observation only|These asymptomatic patients with positive urine culture, will be observed only during the study period.
10003813|NCT01570569|Active Comparator|Omeprazole|
10003814|NCT01570569|Active Comparator|Losartan|
10003815|NCT01570569|Active Comparator|Dextromethorphan|
10003816|NCT01570569|Active Comparator|Caffeine|
9480655|NCT05262218|Experimental|PBF-680|PBF-680 is an Adenosine A1 receptor antagonist formulated in oral gelatine capsules
10003817|NCT01570569|Active Comparator|Midazolam|
10003818|NCT01570582|Experimental|drug effect|"Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.~Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.~Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.~Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is"
10035170|NCT01803581|Experimental|X92001327|the X92001327 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
9480656|NCT05262218|Placebo Comparator|Placebo|Placebo formulated in oral gelatine capsules
9944168|NCT01027936||Normal Healthy Volunteers|
9944169|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training using software packages donated by Posit Science.
9944170|NCT01027962|No Intervention|Control Intervention|Commercially available computer games that do not contain violent stimuli but are appealing to youth between 10 and 19 years of age.
9944171|NCT01027962|No Intervention|Healthy Control Group|No participation in computer activity.
9944172|NCT01028040|Experimental|AZD3043|
9944173|NCT01028066|Active Comparator|Traditional|Traditional nutritional counseling
9944174|NCT01028066|Experimental|Behavioral|Dialogic nutritional counseling
9944175|NCT01028079|Active Comparator|Arm 2|
9944176|NCT01028079|Placebo Comparator|Arm 3|
9944177|NCT01028079|Experimental|Arm 1|
9944178|NCT01028092|Active Comparator|Control|anti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
9944179|NCT01028092|Experimental|CNI-free|Thymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
9944180|NCT01028092|Experimental|Switch|anti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
9944181|NCT01028105|No Intervention|No MRSA screening, Group b|Standard of care
9944182|NCT01028105|Other|MRSA screening, Group a|MRSA preoperative screening
9944183|NCT01028118|Other|Therapy for Women reporting violence|Asking about life experience with violence and Cognitive Behavior Therapy.
9944184|NCT01028144|Experimental|ACT Program|Motivational and Behavioral Skills Physical activity after-school program
9944185|NCT01028144|Active Comparator|General Health|General health education after-school program
9944186|NCT01028157|Placebo Comparator|General Health Control|
9944187|NCT01028157|Experimental|HIV Risk Reduction & Relapse Prevention|
9944188|NCT01028170|Experimental|Furosemide with Hypertonic Saline|Furosemide with 150 mL of 2.4% NaCl
9944189|NCT01028170|Active Comparator|Pulse Furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
9944190|NCT01028183||Extremely Premature Infants|< 30 weeks gestation (N=5000)
9944191|NCT01028183||Premature Infants|30-36 weeks gestation (N=2000)
9944192|NCT01028183||Hospitalized Term Infants|>=37 weeks gestation (N=2000)
9944193|NCT01028183||Healthy Term Infants|>=37 weeks gestation (N=1000)
9944194|NCT01028196||1 - schizophrenia|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with schizophrenia as they routinely attend the clinic or are examined in hospital in a consecutively manner.
9944195|NCT01028196||2 - recurrent depression|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with recurrent depression as they routinely attend the clinic or are examined in hospital in a consecutively manner.
9944196|NCT01028209|Experimental|Assess [18F] PBR06 and PET imaging|
9944197|NCT01028235||Obstructive Dysphagia|Patients who complained of dysphagia, which had an obstructive etiology for their symptoms at the time of endoscopy (ring, mass, stricture, etc)
9944198|NCT01028235||Non-obstructive Dysphagia|Patients whose endoscopy was normal and without any obvious etiology for their symptoms noted.
9944199|NCT01028248|Active Comparator|2.0 mg Ranibizumab|
9944200|NCT01028248|Active Comparator|0.5 mg Ranibizumab|
9944201|NCT01028261|Experimental|ZGN-433|
9944202|NCT01028261|Placebo Comparator|Normal Saline|
9944203|NCT01028274|Placebo Comparator|Placebo|
9944204|NCT01028274|Experimental|Investigational Product 1|
9944205|NCT01028274|Experimental|Investigational Product 2|
9944206|NCT01028287|Active Comparator|ACTH-16 units|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
9944207|NCT01028287|Active Comparator|ACTH-32 units|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
9944208|NCT01028313|Experimental|1|Systemic Therapy
9944209|NCT01028326|Experimental|Group A|Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later
9944210|NCT01028326|Experimental|Group B|Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.
9944211|NCT01028326|Active Comparator|Group C|Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.
9944212|NCT01028339|Active Comparator|Mannitol|
9944213|NCT01028339|Experimental|Hypertonic saline|
9944214|NCT01028365||No treatment|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
9944215|NCT01028404|Experimental|Trial part 1|
9944216|NCT01028404|Experimental|Trial part 2|
9944217|NCT01028417|Experimental|Group 1|Group 1 receives the intervention - insertion of platinum microcoil followed by nodule excision
9944218|NCT01028417|No Intervention|Group 2|Group 2 receives the standard of care - nodule excision, but without the microcoil insertion
9944219|NCT01028430||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
9944220|NCT01028443|Active Comparator|Cyclosporine A 2%|
9944221|NCT01028443|Placebo Comparator|Artificial tears|
9944222|NCT01028456|Placebo Comparator|100 lux|100 lux / 30 minutes day
9944223|NCT01028456|Experimental|Light Therapy 10,000 lux|10,000 lux / 30 minutes a day for 3 months
9944224|NCT01028469|Experimental|Artelon MTP Spacer|Metatarsophalageal hemi-implant
9944225|NCT01028482|Experimental|sertraline, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
9944226|NCT01028482|Placebo Comparator|placebo, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
9944227|NCT01028495|Experimental|gemcitabine and RX-0201|"Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.~RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off."
9944228|NCT01028508|Active Comparator|PHARM|lithium and venlafaxine
9944229|NCT01028508|Experimental|STABLE|ECT + VLF + Li
9944230|NCT01028521|Experimental|CM3.1-AC100|
9944231|NCT01028521|Placebo Comparator|Placebo|
9944232|NCT01028534|Active Comparator|ARB plus increased ARB|angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
9944233|NCT01028534|Active Comparator|ARB plus CCB|angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
9944234|NCT01028534|Active Comparator|CCB plus ARB|calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
9944235|NCT01028547|Active Comparator|dexamethasone 8mg|
9944236|NCT01028547|Placebo Comparator|normal saline|
9944237|NCT01028573|Active Comparator|Group 1|4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
9944238|NCT01028573|Experimental|Group 2|2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
9944239|NCT01028573|Experimental|Group 3|238g of PEG-3350 mixed with 2L of Gatorade
9944240|NCT01028573|Experimental|Group 4|1L of PEG-3350 + Gatorade
9944241|NCT01028586|Active Comparator|Arm 1|Number of Cycles: until progression or unacceptable toxicity develops.
9944242|NCT01028586|Active Comparator|Arm 2|Number of Cycles: until progression or unacceptable toxicity develops.
9944243|NCT01028586|Placebo Comparator|Arm 3|Placebo
9944244|NCT01028599|Experimental|Exercise|
9944245|NCT01028612|Experimental|thermal ablation with external beam radiation|
9944246|NCT01028625|Active Comparator|Cognitive Behavior Therapy|
9944247|NCT01028625|Other|Usual Care|Participants who are randomly assigned to usual care will receive whatever treatment (if any) for depression their own physician may prescribe. In most cases, treatment (if any is provided) is likely to consist of a serotonin reuptake inhibitor (SSRI) antidepressant such as sertraline or citalopram.
9944248|NCT01028638||Renal Cancer|Renal Cancer patients treated with everolimus
9944249|NCT01028664|Experimental|Glaucoma or ocular hypertension patients|
9944250|NCT01028690|Active Comparator|Lactobacillus reuteri|L. reuteri is one species of lactobacillus that naturally inhabits the gastrointestinal tract of humans
9944251|NCT01028690|Placebo Comparator|placebo|Placebo will be delivered in a chewable tablet form (1.5g per dose)
9944252|NCT01028703||Donors|"110 will be cases that undergo uninephrectomy"
9944253|NCT01028703||Controls|"110 controls"
9944254|NCT01028729|Experimental|Endostar with chemotherapy|All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression.
9944255|NCT01028755|Experimental|Arm 1|
9944256|NCT01028768|Experimental|Teduglutide|
9944257|NCT01028781|Other|Thalidomide|Thalidomide was administered and pain reports were recorded over the course of 6 months.
9944258|NCT01028794|Experimental|autologous bone marrow mononuclear cell|On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
9944259|NCT01028794|Experimental|autologous bone marrow mononuclear cells|On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
10035171|NCT01803581|Active Comparator|RID shampoo|The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
9480657|NCT05262192|Experimental|study group|Nutrition education will be given to the experimental group.
9944260|NCT01028807|Experimental|1. Experimental group: Early feeding:|After 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
9944261|NCT01028807|Active Comparator|Control group : Obligatory 5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
9944262|NCT01028833|Experimental|Power mobility|Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
9944263|NCT01028833|No Intervention|Control|Children in the control group will not receive any additional intervention, but will continue to receive the early intervention or other services they were receiving prior to enrollment in this study.
9944264|NCT01028846|Active Comparator|Diazoxide|1-2 mg/kg total dose given intravenously during pancreatic clamp study
9944265|NCT01028846|Placebo Comparator|Placebo|Intravenous normal saline during pancreatic clamp study
9944266|NCT01028859|Experimental|CKD-516 inj|
9944267|NCT01028872|Sham Comparator|Sensar IOL|
9944268|NCT01028872|Active Comparator|Tecnis IOL|
9944269|NCT01028872|Active Comparator|AcrySof IQ|
9944270|NCT01028885|Experimental|Arm I|"Patients undergo MRI and CT scan-based simulation for treatment planning with endorectal balloon target immobilization. The treatment target volumes and surrounding organs at risk are contoured, treatment plan developed and approved.~Patients then undergo 39 fractions of image-guided intensity-modulated radiotherapy over 8 weeks. Patients also undergo weekly MRI scans of the pelvis (in the planned treatment position) during radiotherapy."
9944271|NCT01028924|Experimental|Teduglutide 5 mg|Treatment A, subcutaneous injection
9944272|NCT01028924|Experimental|Teduglutide 20 mg|Treatment B, subcutaneous injection
9944273|NCT01028924|Placebo Comparator|Placebo|subcutaneous injection
9944274|NCT01028924|Active Comparator|Moxifloxacin|400 mg, oral
9944275|NCT01028950|Experimental|YM150 group|
9944276|NCT01028963|Placebo Comparator|Placebo|
9944277|NCT01028963|Active Comparator|Active control|
9944278|NCT01028963|Experimental|Active Study Medication (Group C)|CCX140-B
9944279|NCT01028963|Experimental|Active Study Medication (Group D)|CCX140-B
10003819|NCT01570595|Experimental|Web-Based Intervention|This group will be asked to participate in the online quit smoking program. At their first visit, they will be given an ID number to log in to the quit smoking program, and they will complete their first log in with the research assistant. The online program is made up of 8 separate online sessions that are supposed to be completed approximately once per week. Each sessions is written to take an average reader 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. At the first visit, participants are asked to provide an email address and/or cell phone number so reminders can be sent, by email or text message, to complete the sessions. If participants are late completing a session, they may receive call from clinic staff as a reminder.
10003820|NCT01570595|Active Comparator|Standard Care|"This group will receive standard care for their smoking, including advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
10003821|NCT01570608|Active Comparator|monotherapy arm|patients receiving 3 initial Ranibizumab injections, thereafter as needed
10003822|NCT01570608|Active Comparator|combined treatment arm|
10003823|NCT01570647||Healthy controls|
10003824|NCT01570647||Chronic low back pain|
10003825|NCT01570647||restricted hamstrings|
10003826|NCT01570647||systemic scleroderma|
10003827|NCT01570647||joint hyperlaxity|
10003828|NCT01570660|No Intervention|control group|parallel group without intervention
10003829|NCT01570673|Experimental|Group Urotherapy|Children in this arm wil receive group urotherapy in small groups with other children.
10003830|NCT01570673|Active Comparator|Individual urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
10003831|NCT01570699||2: patients included in METHADOSE study|includes opiate-dependent patients substituted by methadone
10003832|NCT01570699||1: opiate-non dependent patients|Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse
10003833|NCT01570712|Experimental|Housing First Program|
10003834|NCT01570712|Active Comparator|traditional French services|
10003835|NCT01570725|Experimental|1|Virtual reality exposure to a relaxing virtual environment. The virtual experience will be provided using immersive equipment.
10003836|NCT01570725|Experimental|2|Exposure to relaxing music. The music will be selected between classical music tunes.
10003837|NCT01570764|Experimental|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
10003838|NCT01570764|Placebo Comparator|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
10003839|NCT01570777|Experimental|Renal denervation|
10003840|NCT01570777|Other|optimized medication regimen|optimized medication regimen
10003841|NCT01570790|Experimental|Cohort 1|
10003842|NCT01570790|Experimental|Cohort 2|
10003843|NCT01570790|Experimental|Cohort 3|
10003844|NCT01570803|Experimental|Complete SE Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
10003845|NCT01570803|Active Comparator|SMART CONTROL Stent|same to Complete SE
10003846|NCT01570816|Experimental|Experimental|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures
10003847|NCT01570842|Other|Anthropometric Measurements; Tissue Samples|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
10003848|NCT01570881||Delirium,Nondelirium|those with delirium and those without delirium
10003849|NCT01570920|Experimental|walking|a cohort of stroke patients trained during 3 month, based on walking
10003850|NCT01570933|Experimental|NAVAfirst|Starting crossover by NIVnava mode
10003851|NCT01570933|Active Comparator|Cpap first|Start crossover by Cpap on nasal canula
10003852|NCT01570946|Experimental|Lifestyle modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
10003853|NCT01570946|No Intervention|Standard Care|Baseline 30-minute interview delivering personalised diet and exercise advice supplemented with educational material on diabetes.
10003854|NCT01570972|Other|MFG and GCBT|There is a single arm for this study. All participants will be able to participate in MFG and GCBT
10003855|NCT01570985|Active Comparator|Steroid injection Without distension|Group 1 consists of patients receiving Triamcinolone acetonide 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and a total of 4 ml solution.
10003856|NCT01570985|Active Comparator|Steroid with distension|Patients in group 2 will receive intraarticular Triamcinolone Acetonide 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
10003857|NCT01570985|No Intervention|Control|Group 3 will serve as control group and patients in this group could receive any other treatment other than corticosteroid injections or per oral corticosteroid medication. The control group will remain without treatment with corticosteroids, in injection or tablet form till 61 days, which is also the last day of the outcome measurements.
10003858|NCT01570998|Experimental|Treatment (IORT)|Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.
10003859|NCT01571011|Experimental|CURB Intervention|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
10003860|NCT01571011|Experimental|CURB Intervention (Wait List)|Same as the CURB Intervention arm, however, individuals assigned to this arm wait 3 months before receiving the intervention.
10003861|NCT01571024|Experimental|BKM120 + mFOLFOX6|BKM120 + mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.
10003862|NCT01571037|Other|inhaled nebulized Milrinone|"Drug: Inhaled, nebulized, Milrinone~1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation."
10003863|NCT01571050|Experimental|Fresh NaF/SiO2 toothpaste|
10003864|NCT01571050|Placebo Comparator|Purified water|
10003865|NCT01571050|Experimental|Aged NaF/SiO2 toothpaste|
10003866|NCT01571050|Experimental|Fresh MFP/CaCO3 toothpaste|
10003867|NCT01571050|Experimental|Aged MFP/CaCO3 toothpaste|
10003868|NCT01571063|Experimental|Vitamin D3|
10003869|NCT01571063|Placebo Comparator|Placebo|
10003870|NCT01571076|Experimental|Group B - Severe Male Factor|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
10003871|NCT01571076|Experimental|Group B - Advanced Age|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
10003872|NCT01571076|Active Comparator|Group A - Advanced Age|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
10003873|NCT01571076|Active Comparator|Group A - Severe Male Factor|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.
10003874|NCT01571089|Experimental|DBT-inspired exposure treatment|DBT-inspired exposure treatment.
10035172|NCT01803594|Placebo Comparator|Control Shake|Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
10035173|NCT01803594|Active Comparator|PC700, Krill Oil, and Lutein|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)"
10214757|NCT04510207|Experimental|Investigational Vaccine 2b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP after 3 months following two doses of immunization.
10214758|NCT04510207|Placebo Comparator|Placebo-b|Participants will receive a booster dose of Placebo after 3 months following two doses of immunization.
10214759|NCT04509115||Patients given short-acting opioid prescription|Patients not currently using opioids who receive a new short-acting opioid prescription for acute pain will be recruited.
10214760|NCT04503395|Experimental|ESAR|Endovascular Aneurysm Repair + Heli-FX EndoAnchors
10214761|NCT04503395|Active Comparator|FEVAR|Fenestrated EndoVascular Aneurysm Repair
10214762|NCT04497987|Experimental|Bamlanivimab (Part 1)|Participants received single Intravenous (IV) infusion of 4200 milligrams (mg) bamlanivimab.
10214763|NCT04497987|Placebo Comparator|Placebo (Part 1)|Participants received single IV infusion of Placebo.
10214764|NCT04497987|Experimental|Bamlanivimab (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
10214765|NCT04497987|Experimental|Bamlanivimab + Etesevimab (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
10214766|NCT04497987|Placebo Comparator|Placebo Comparator: Placebo (Part 2-Prevention)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
10214767|NCT04497987|Experimental|Bamlanivimab (Part 2 - Treatment)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
10214768|NCT04497987|Experimental|Bamlanivimab + Etesevimab (Part 2- Treatment)|Enrollment for Part 2 was not initiated because the efficacy of Bamlanivimab 4200 mg observed in Part 1 significantly diminished the feasibility of enrolling Part 2.
10214769|NCT04497987|Experimental|Bamlanivimab (Part 3)|"Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~[Participants received single IV infusion of 700 mg bamlanivimab.]"
10003875|NCT01571102|Active Comparator|physiotherapy|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
10003876|NCT01571102|No Intervention|Rest|
10003877|NCT01571102|Active Comparator|Home exercises|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
10003878|NCT01571115|Active Comparator|Insomnia Stretching Exercise|This group will realize stretching exercise
10003879|NCT01571115|No Intervention|Control|This group will not realize any type of intervention.
10003880|NCT01571115|Active Comparator|Insomnia Physical Exercise|This group will realize resistance physical exercise
10003881|NCT01571141|Experimental|Monogin|
10003882|NCT01571141|No Intervention|No intervention|
10003883|NCT01571167|Placebo Comparator|Placebo|
10003884|NCT01571167|Active Comparator|Varenicline 2 mg|
10003885|NCT01571167|Active Comparator|Varenicline 1 mg|
10003886|NCT01571180||Gastric Bypass|Obese patients who have scheduled a gastric bypass
10003887|NCT01571206|Active Comparator|CT-P13|infliximab
10003888|NCT01571219|Experimental|CT-P13|
10003889|NCT01571245||Veterans with PTSD|Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans who are ages 18 to 60 and currently in or about to start treatment for deployment-related Post-Traumatic Stress Disorder (PTSD) at the Central Arkansas Veterans Healthcare System Mental Health Clinics.
10003890|NCT01571258|No Intervention|Control|
10003891|NCT01571258|Experimental|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
9480658|NCT05262192|No Intervention|control group|No intervention will be applied to the control group.
9480659|NCT05262179|Experimental|CTO0101|
10003892|NCT01571271|Experimental|Electrohydraulic lithotripsy|Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method
10003893|NCT01571271|Experimental|Laser Lithotripsy|Laser Lithotripsy: Lithotripsy will be performed using laser method
10003894|NCT01571310|Experimental|Omitted Breakfast|Experimental: The patients in Omitted Breakfast day will omit the breakfast and will continue the fast until noon. Thereafter will eat Lunch at 13;30 and Dinner at 19:00
10003895|NCT01571310|Active Comparator|Breakfast|The patients in Breakfast day will consume breakfast at 8:00 and then lunch at 13;30 and dinner at 19:00
10003896|NCT01571323|Active Comparator|Misoprostol|
10003897|NCT01571323|Active Comparator|Oxytocin|
10003898|NCT01571323|Active Comparator|Oxytocin and Misoprostol|
10003899|NCT01571349||chronic ITP group|ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography
10003900|NCT01571349||acute ITP group|ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography
10003901|NCT01571375||FinnHEMS10|Patients Treated by Helsinki HEMS.
10003902|NCT01571375||FinnHEMS30|PAtients Treated by Tampere HEMS.
10003903|NCT01571388|Experimental|Group 1|Healthy Subjects to receive dacomitinib
10003904|NCT01571388|Experimental|Group 2|Subjects with mildly impaired hepatic function to receive dacomitinib
10003905|NCT01571388|Experimental|Group 3|Subjects with moderately impaired hepatic function to receive dacomitinib
10003906|NCT01571401|Experimental|Supervised PA plus Exercise Counselling|Participants will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, this group will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at fitness centre. In order to achieve the physical activity guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed. In addition to the supervised sessions, traditional exercise counselling will be provided to teach proper technique, how to monitor intensity, and to progress PA safely and effectively to achieve the public health physical activity guidelines
10214770|NCT04497987|Experimental|Bamlanivimab + Etesevimab (Part 3)|"Part 3 of the study is exploratory, conducted to study exploratory objectives and is not reported in this record.~[Participants received single IV infusion of 700 mg bamlanivimab given with 1400 mg etesevimab.]"
9476295|NCT03573167|Active Comparator|In-Person Motivational Interviewing|In-Person Motivational Interviewing (MI) is the standard form of MI treatment delivered in person face to face at the primary care office. MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping participants to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling in-person with the participant for one session of MI lasting approximately 30 minutes.
10003907|NCT01571401|Experimental|Supervised PA plus behavioural counselling|"In addition to the same supervised PA sessions as the SPA group, participants in this group will receive six individual face-to-face behavioural counselling sessions with a physical activity specialist. These counselling sessions will be combined with the supervised PA sessions, and will be provided directly following the supervised PA session. Counselling strategies will be based on the TPB and will target the unique benefits of PA for kidney cancer survivors, strategies for making PA enjoyable, for overcoming barriers, for including social support from family and friends, time management, self-monitoring, goal setting, and planning."
10003908|NCT01571414|Experimental|Arm 1A-EFV and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.
10003909|NCT01571414|Experimental|Arm 1B-EFV and PA-824|Participants will receive EFV on Days 1 to 14, EFV plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 13, 20 to 21, and 42.
10003910|NCT01571414|Experimental|Arm 2A-LPV/r and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
10003911|NCT01571414|Experimental|Arm 2B-LPV/r and PA-824|Participants will receive LPV/r on Days 1 to 14, LPV/r plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 14, 21, and 42.
10003912|NCT01571414|Experimental|Arm 3-RIF and PA-824|Participants will receive PA-824 on Days 1 to 7, RIF on Days 8 to 14, and RIF plus PA-824 on Days 15 to 21. Inpatient study visits will occur at Days 7 and 21.
10003913|NCT01571440|Placebo Comparator|No Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times daily.
10003914|NCT01571440|Active Comparator|12 g Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times daily
10003915|NCT01571466|Experimental|Vaccine group|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
10003916|NCT01571466|Placebo Comparator|Placebo|
10003917|NCT01571479|No Intervention|2-mm mini-instrument (M-LC)|M-LC is three-port laparoscopic cholecystectomy using a 2-mm mini-instrument.
10003918|NCT01571479|No Intervention|conventional instrument(C-LC)|C-LC is conventional three port laparoscopic cholecystectomy
10003919|NCT01571492|Experimental|L2 Paravertebral peripheral nerve block|L2 paravertebral peripheral nerve block catheter will be placed.
10003920|NCT01571492|Active Comparator|Continuous Lumbar plexus peripheral nerve block|Continuous unilateral lumbar plexus peripheral nerve block catheter will be placed.
10003921|NCT01571505|Experimental|IPV vaccination|Randomized IPV vaccination to children at the age of 39 weeks.
10003922|NCT01571505|Placebo Comparator|OPV vaccination|Randomized OPV vaccination to children at the age of 39 weeks.
10003923|NCT01571518|Experimental|early injection|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
10003924|NCT01571518|Sham Comparator|late injection|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
10003925|NCT01571544|Experimental|Thermal suit|Randomly selected half of the patients will use thermal suit prior to anesthesia, during the surgery and post anesthesia care unit.
10003926|NCT01571544|Active Comparator|Conventional clothing|Randomly selected half of the patients will use conventional clothing prior to anesthesia, during the surgery and post anesthesia care unit.
10003927|NCT01571570|Experimental|Treatment A|Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
10003928|NCT01571570|Experimental|Treatment B|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
10003929|NCT01571570|Experimental|Treatment C|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
10003930|NCT01571570|Experimental|Treatment D|Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
10003931|NCT01571570|Experimental|Treatment E|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
10003932|NCT01571570|Experimental|Treatment F|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
10003933|NCT01571570|Experimental|Treatment G|Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
10003934|NCT01571570|Experimental|Treatment H|Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
10003935|NCT01571570|Experimental|Treatment I|Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
10003936|NCT01571583|Experimental|Telaprevir+Peg-IFN-alfa-2a+Ribavirin|Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.
10003937|NCT01571609|Experimental|Carriers|
10003938|NCT01571609|Experimental|Non-carriers|
10003939|NCT01571622|Placebo Comparator|Water before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water
10003940|NCT01571622|Experimental|Whey before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\
10003941|NCT01571648|Experimental|Oral azacitidine|
10003942|NCT01571661|Experimental|Part A Treatment 1|GSK189075A 20mg
10003943|NCT01571661|Experimental|Part A Treatment 2|GSK189075A 50mg
10003944|NCT01571661|Experimental|Part A Treatment 3|GSK189075A 150mg
10003945|NCT01571661|Experimental|Part A Treatment 4|GSK189075A 500mg
10003946|NCT01571661|Experimental|Part A Treatment 5|GSK189075A 1000mg
10003947|NCT01571661|Placebo Comparator|Placebo|Placebo
10003948|NCT01571661|Experimental|Part B Low dose|low dose chosen from Part A
10003949|NCT01571661|Experimental|Part B High Dose|high dose chosen from Part A
10003950|NCT01571674|Experimental|Manipulation + Exercise Group|The treatment received by the manipulation+exercise group will differ from the exercise group for the first week only (two treatment sessions). During the first two sessions, patients in the manipulation+exercise group will receive cervicothoracic spine manipulations and range of motion (ROM) exercises only. Beginning on the third session these patients will receive the same exercise program as the exercise group.
10003951|NCT01571674|Active Comparator|Exercise Group|The exercise group will be treated with a stretching and strengthening program.
10003952|NCT01571687|Active Comparator|antioxidant supplements|800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
10003953|NCT01571687|Placebo Comparator|Placebo|identically appearing placebo
10003954|NCT01571700||Study|Patients with pulmonary hypertension.
10003955|NCT01571700||Control|ASD patients or patients with normal hearts
10003956|NCT01571713||Study|Pediatric patients with pulmonary hypertension
10003957|NCT01571765|Experimental|MNCH programming|protocols and training for data collection, referrals, and management for health district. Training in obstetrics, newborn care and management of sick children for health workers, Increased community health promotion such as training of CHWs, health centre management teams and bednet distribution
10003958|NCT01571765|No Intervention|no added MNCH activities|
10003959|NCT01571791|Placebo Comparator|group SF|either saline infusion and intravenous fentanyl boluses
10003960|NCT01571791|Active Comparator|group KL|ketorolac-lidocaine infusion and intravenous saline boluses
10003961|NCT01571804|Active Comparator|pregabalin 150 mg group|one capsule of pregabalin 150 mg and one placebo capsule
10003962|NCT01571804|Active Comparator|pregabalin 300 mg group|two capsules of pregabalin 150 mg
10003963|NCT01571804|Placebo Comparator|placebo group|to receive two identical placebo capsules
10003964|NCT01571817|Experimental|Study intervention|endoscopically-guided intestinal submucosal transplantation of Isolated Human Pancreatic Islets in a type 1 diabetic patient
10003965|NCT01571843|Experimental|PHPT/ Walking + Forearm exercise|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
10003966|NCT01571843|Placebo Comparator|PHPT/ Walking alone|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
10003967|NCT01571843|Active Comparator|Osteopenia/ Walking + Forearm exercise|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
10003968|NCT01571843|Placebo Comparator|Osteopenia/ Walking alone|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
10003969|NCT01571856|Active Comparator|zinc sulfate|zinc sulphate solution.
10003970|NCT01571856|Placebo Comparator|cornstarch solution|cornstarch powder diluted in distilled water
10003971|NCT01571869|Experimental|1 = Tested product|
10003972|NCT01571869|Placebo Comparator|2 = Control product|
10003973|NCT01571882|Experimental|1 = Tested product 1|
10003974|NCT01571882|Experimental|2 = tested product 2|
9944280|NCT01028976|Placebo Comparator|Placebo|Two tablets, daily, for 8 weeks
9944281|NCT01028976|Experimental|Vitamin C|Two tablets, daily, for 8 weeks
9944282|NCT01028989|Other|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
9944283|NCT01028989|Other|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
9944284|NCT01029002|Experimental|Vitamin D 50000 IU|Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
9944285|NCT01029002|Placebo Comparator|Placebo|Patients randomized to this arm will receive a placebo pill once weekly.
9944286|NCT01029015||Group 1 -OAB|Subjects with overactive bladder (OAB)
9944287|NCT01029015||Group 2 - Insomnia|Subjects with insomnia
9944288|NCT01029015||Group 3 - Normal|Normal Subjects
9944289|NCT01029041|Experimental|Strengthening exercise|This group does global strengthening exercise
9944290|NCT01029041|Experimental|Stretching exercise|This group does global stretching exercise
9944291|NCT01029041|No Intervention|Control|This group does nor do any kind of exercise during the study
9944292|NCT01029067|Active Comparator|Cognitive Remediation|Computerized cognitive remediation (CogPack training). A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with group MCT, eight sessions are administered. Each session lasts approximately 45-60 minutes.
9944293|NCT01029067|Experimental|Metacognitive Training|The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, & Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt. The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions). The eight modules are presented via a video projector using pdf-converted Power-Point slides. Each group session lasts approximately 45-60 minutes. Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy. For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
9944294|NCT01029080||Sepsis|All patients with sepsis defined by actually sepsis guidelines
9944295|NCT01029132|Experimental|non-responder group|patients who did not maintained or improved cognitive function
9944296|NCT01029132|Experimental|responder group|patients who maintained or improved cognitive function
9944297|NCT01029145||1|Bipolar patients that experience a new episode of any type
9944298|NCT01029158|Experimental|1a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
9944299|NCT01029158|Experimental|1b|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
9944300|NCT01029158|Experimental|1c|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
10003975|NCT01571882|Active Comparator|3 = Active control product|
10003976|NCT01571908|Experimental|Magnesium perfusion - Rocuronium|60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously
9480660|NCT05262179|Placebo Comparator|Placebo (Vehicle)|
9944301|NCT01029158|Experimental|1d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
9944302|NCT01029158|Experimental|2a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
9944303|NCT01029158|Experimental|2b|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
9944304|NCT01029158|Experimental|2c|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
10003977|NCT01571908|Active Comparator|Placebo perfusion - Succinylcholine|1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously
10003978|NCT01571921|Experimental|Gamma-Delta Tocotrienol|
10003979|NCT01571921|Active Comparator|TRF|
10003980|NCT01571934||Mild or moderate hemophilia A|Subjects with mild or moderate hemophilia A (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required.
10003981|NCT01571947|Active Comparator|SFA|
10003982|NCT01571947|Active Comparator|MUFA|
10003983|NCT01571947|Active Comparator|PUFA|
10003984|NCT01571947|Active Comparator|CARB|
10003985|NCT01571960|Experimental|Group 1: study vaccine|Participants in this arm will receive a 0.3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 224.
10003986|NCT01571960|Placebo Comparator|Group 1: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 224.
10003987|NCT01571960|Experimental|Group 2: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 303.
10003988|NCT01571960|Placebo Comparator|Group 2: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 303.
10003989|NCT01571960|Experimental|Group 3: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112 and 224.
10003990|NCT01571960|Placebo Comparator|Group 3: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112 and 224.
10003991|NCT01571973|No Intervention|control group|outpatients receiving usual care
10003992|NCT01571973|Experimental|intervention group|outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
10003993|NCT01571999|Experimental|Severe renally impaired subjects|Approximately 9 subjects will complete each treatment arm
10003994|NCT01571999|Experimental|Matched healthy volunteers|Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
10003995|NCT01572012|Experimental|Subcutaneous Administration|Ondansetron + Hylenex administered subcutaneously
10003996|NCT01572012|Experimental|Oral Administration|Ondansetron administered orally
10003997|NCT01572012|Experimental|Intramuscular Administration|Ondansetron administered intramuscularly
10003998|NCT01572012|Experimental|Intravenous Administration|Ondansetron administered intravenously
10003999|NCT01572025|Experimental|DHEA supplementation|
10004000|NCT01572025|Placebo Comparator|Control|
10004001|NCT01572051|Experimental|Group 1A (3month plus phone)|This group will attend to two courses with a 3 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
10004002|NCT01572051|Experimental|Group 1B (3month no phone)|This group will attend to two courses with a 3 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
10004003|NCT01572051|Experimental|Group 2A (2month plus phone)|This group will attend to two courses with a 2 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
10004004|NCT01572051|Experimental|Group 2B (2month no phone)|This group will attend to two courses with a 2 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
10004005|NCT01572051|Experimental|Group 3A (1month plus phone)|This group will attend to two courses with a 1 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
10004006|NCT01572051|Experimental|Group 3B (1month no phone)|This group will attend to two courses with a 1 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
10004007|NCT01572051|Experimental|Group 4A (no course plus phone)|This group will NOT attend to any courses This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
10004008|NCT01572051|Experimental|Group 4B (no course no phone)|This group will NOT attend to any courses This group will NOT receive phone calls This group will only receive printed material This group will be reassessed in 6 months
10004009|NCT01572077|Experimental|FTHA/GDF PET imaging|"This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.~Both groups will undergo FTHA/FDG PET imaging."
10004010|NCT01572090|Active Comparator|Conventional weight loss: CONV-NG|"Obese normoglycemic (NG) patients evidenced by a body fat ≥ 35% in women and ≥ 25% in men and a 2-h oral glucose tolerance test.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
9944305|NCT01029158|Experimental|2d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).
9944306|NCT01029171|Experimental|1|OEP (Otago Exercise Program; home-based balance and strength retraining program)
9944307|NCT01029171|Active Comparator|2|CON (control; usual care)
9944308|NCT01029184|Active Comparator|complete non allergenic cereals|existing commercialized product
9944309|NCT01029184|Experimental|complete non allergenic cereals plus|commercialised product with the addition of a novel ingredient
9944310|NCT01029197|Experimental|CBT Intervention|The CBT intervention includes psychoeducation and coping and social skills delivered in a group format, and exposure therapy delivered in individual sessions
9944311|NCT01029197|Active Comparator|Treatment as Usual|The TAU Condition will receive usual services at the community clinic, which may include medications, individual or group therapy
9944312|NCT01029223|Experimental|ivabradine|
9944313|NCT01029223|Experimental|metoprolol|
9944314|NCT01029223|Placebo Comparator|placebo|
9944315|NCT01029249||ACTG A5257 participants|Participants in this study will also be enrolled in ACTG A5257.
9944316|NCT01029275|Experimental|Arm A|pre-operative medical treatment with Sandostatin
9944317|NCT01029275|No Intervention|Arm B|pituitary surgery as a first line treatment
9944318|NCT01029288|Active Comparator|Statin Choice Decision Aid|Subjects will receive an intervention of Statin Choice Decision Aid and usual care for antihyperglycemic medication discussion with their clinician.
9944319|NCT01029288|Active Comparator|Diabetes Medication Choice Decision Aid|Subjects will receive an intervention of Diabetes Medication Choice Decision Aid and usual care for lipid therapy medication discussion with their clinician.
9944320|NCT01029301|Experimental|Experimental: Endymed study group|
9944321|NCT01029314||Cardiopulmonary bypass surgery|Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
9944322|NCT01029327||Healthy subjects|
9944323|NCT01029379||200 patients,ASA 1|
9944324|NCT01029418|Experimental|AZD6244 and sorafenib|AZD6244+ sorafenib
9944325|NCT01029431|Experimental|1|All subjects will have both Air-Q ILA & PLMA
9944326|NCT01029444|Experimental|Insulin|Brittle diabetic patients or patients with uncontrolled blood sugars will complete blood sugar diaries weekly and have hemoglobin A1c lab tests performed quarterly to evaluate progress in stabilizing blood sugars.
9944327|NCT01029470|Experimental|Luveris|Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.
9944328|NCT01029483|Experimental|Low carbohydrate diet|6 week ad libitum low carbohydrate diet; research diet provided at 120% of estimated energy requirement for weight maintenance; carbohydrate intake limited to 28g/d
9944329|NCT01029483|Active Comparator|High Carbohydrate Diet-ad libitum|High complex carbohydrate diet (55% carbohydrate, 18% protein, 27% fat. 120% of estimated energy needs for weight maintenance provided, participants allowed to eat as much or as little as desired to satisfy appetite
9944330|NCT01029483|Active Comparator|High Carbohydrate Diet-Energy-matched|High carbohydrate diet (55% carbohydrate, 18% protein and 27% fat). Energy intake restricted to ~68% of energy needs for weight maintenance. Participants required to eat all food provided and nothing else
9944331|NCT01029509|Experimental|OPB-31121|OPB-31121 200 mg twice daily for 21 days followed by 7 days of rest
9944332|NCT01029522|Experimental|Lipilou 20mg|
9944333|NCT01029522|Active Comparator|Lipitor 20mg|
9944334|NCT01029561|Active Comparator|CPAP and diet|The patients with severe OSA (AHI>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
9944335|NCT01029561|Active Comparator|Diet|The diet arm wil receive the Conventional diet treatment that usually receive the patients included in the Bariatric Surgery Program
9944336|NCT01029574|Experimental|Rotator cuff repair plus PRP|Conventional arthroscopic repair of rotator cuff with application of PRP.
9944337|NCT01029574|Placebo Comparator|Rotator cuff repair alone|Conventional arthroscopic repair of rotator cuff without application of PRP
9944338|NCT01029600|Active Comparator|Arthroscopic Capsulotomy|Arthroscopic capsular release
9944339|NCT01029600|Active Comparator|Distention with steroid|Arthrographic distention with contrast, saline, steroid and local anaesthetic
9944340|NCT01029613||Rheumatoid arthritis|
9944341|NCT01029626|Other|Endoscopy|If the Glasgow-Blatchford score is zero, the endoscopy is delayed as an outpatient
9944342|NCT01029639|No Intervention|Treatment|Diabetic patients will complete hypoglycemia unawareness questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on low blood sugar incidences reported by subjects requiring heath care intervention other than by the subject themselves.
9944343|NCT01029639|Experimental|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
9944344|NCT01029665||CDH survivors|School age (ages 4-6) Congenital Diaphragmatic Hernia survivors treated at Duke University Medical Center.
9944345|NCT01029678|Experimental|experimental|
9944346|NCT01029743||Group 1|
9944347|NCT01029743||Group 2|
9944348|NCT01029756|Active Comparator|Macintosh Laryngoscope|
9944349|NCT01029756|Active Comparator|Pentax AWS Videolaryngoscope|
9944350|NCT01029769|Active Comparator|initial olanzapin|
9944351|NCT01029769|Active Comparator|initial amisulpride|
9944352|NCT01029769|Active Comparator|early responders|
9944353|NCT01029769|Active Comparator|early non-responders switched|
9944354|NCT01029769|Active Comparator|ealy non-responders non-switched|
9944355|NCT01029821|Other|Low-Molecular-Weight Heparin for DVT|Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
9944356|NCT01029834|Experimental|Intervention- Lifestyle family based|Behavioral family based
9944357|NCT01029834|Active Comparator|Information control|Child intervention only
9944358|NCT01029847|Placebo Comparator|Placebo|
9944359|NCT01029847|Active Comparator|Adalimumab|TNF-alpha inhibitor
9944360|NCT01029938|Active Comparator|Covered stent|The Willis covered stent specifically designed for intracranial vasculature was developed by our institution and the MicroPort Medical Company (Shanghai, China), and coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
9944361|NCT01029938|Active Comparator|Coil|Coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
9944362|NCT01029964|Active Comparator|6-9 years|Age at start of treatment
9944363|NCT01029964|Active Comparator|10-13 years|Age at start of treatment
9944364|NCT01029964|Active Comparator|14-16 years|Age at start of treatment
9944365|NCT01029964|No Intervention|Control 6-9 years|Untreated control group
9944366|NCT01029990|Experimental|Telephone arm|A midwife tries to contact the woman by telephone and offer her an appointment for a PAP-smear
9944367|NCT01029990|Experimental|Self-test arm|
9944368|NCT01029990|No Intervention|Control arm|No intervention other than what is routine in the screening program
9944369|NCT01030016|Experimental|atenolol|subjects received 6 weeks of atenolol
9944370|NCT01030029|Active Comparator|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
9944371|NCT01030029|Placebo Comparator|pstim device without acupuncture|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
9944372|NCT01030042|Experimental|Cetuximab/Irinotecan|Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)
9944373|NCT01030042|Active Comparator|FOLFOX 4|FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab
9944374|NCT01030055|Experimental|TKI258 - bioavailability|
9944375|NCT01030055|Experimental|TKI258 - food|
9944376|NCT01030068|Experimental|Yoga|Yoga plus smoking cessation
9944377|NCT01030068|Active Comparator|Wellness|Health & Wellness classes plus smoking cessation therapy
9944378|NCT01030081|Experimental|Amlodipine (Norvasc®)|
9944379|NCT01030081|Active Comparator|Nifedipine GITS (Adalat® XL 30)|
9944380|NCT01030094||Topiramate|Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
9944381|NCT01030094||Carbamazepine|Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
9944382|NCT01030094||Valproic acid|Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
9944383|NCT01030094||Normal Control|Healthy female participants will be observed in Normal control group.
9944384|NCT01030107||Children with Insufficient Sleep|Children who sleep approximately 9-10 hours/night
9944385|NCT01030120|Active Comparator|etanercept|etanercept 50mg BIW
9944386|NCT01030120|Placebo Comparator|placebo|matching placebo
9944387|NCT01030146|Other|NeilMed® Sinus Rinse™ System|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
9944388|NCT01030159||001|
9944389|NCT01030185|Experimental|NovaShunt's Automated Fluid Shunt|The Automated Fluid Shunt (AFS) Device
9944390|NCT01030211|Active Comparator|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
9944391|NCT01030211|Other|Supportive care|No platelet transfusion for patients with platelet count <20x10^3/uL
9944392|NCT01030224|Experimental|AZD9742 IV Infusion|Active
9944393|NCT01030224|Placebo Comparator|Placebo to AZD9742 IV Infusion|Placebo
9944394|NCT01030237|Experimental|FID 114657|FID 114657
9944395|NCT01030237|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
9944396|NCT01030263|Experimental|CEM|Biopsies obtained with fluorescence-aided confocal endomicroscopy.
9944397|NCT01030263|Other|RFQ|Random four-quadrant biopsies.
9944398|NCT01030276|Experimental|Bright light|
9944399|NCT01030276|Placebo Comparator|"Inactive placebo-light"|
9944400|NCT01030302||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
9944401|NCT01030315|Experimental|Cohort 1|The lowest dose level of HM10760A
9944402|NCT01030315|Experimental|Cohort 2|Second dose level of HM10760A
9944403|NCT01030315|Experimental|Cohort 3|Third dose level of HM10760A
9944404|NCT01030315|Experimental|Cohort 4|Fourth dose level of HM10760A
9944405|NCT01030315|Experimental|Cohort 5|The highest dose level of HM10760A
9944406|NCT01030328|Active Comparator|TriLipix + Atorvastatin|Two tables of TriLipix + Atorvastatin taken once a day by mouth.
9944407|NCT01030328|Placebo Comparator|2|2 sugar pills
9528726|NCT03208270|Active Comparator|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
9944408|NCT01030354|Active Comparator|Dietary Intervention and Higher protein meal replacement|A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass
9944409|NCT01030354|Active Comparator|Dietary Intervention and Standard Protein Meal Replacement|Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
9944410|NCT01030367|Experimental|1|PETN
9944411|NCT01030367|Experimental|2|ISDN
9944412|NCT01030367|No Intervention|3|
9944413|NCT01030380|Experimental|Slendertone Face NMES|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
9944414|NCT01030380|No Intervention|Control Group: No NMES|Control Group: No NMES over the course of 12 weeks.
9944415|NCT01030393|Experimental|intrauterine hCG|"Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.~Intrauterine injection of 500 iu hCG before embryo transfer"
9944416|NCT01030419|Experimental|FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
9944417|NCT01030419|Placebo Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 12-month follow-up testing.
9944418|NCT01030445||Elevated Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation above the mean based on age
9944419|NCT01030445||Decrease Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation below the mean based on age
9944420|NCT01030445||Normal Mean Arterial Blood Pressure|Mean arterial pressure within the standard deviation of the mean based on age
9944421|NCT01030471|Experimental|Lifestyle counseling|
9944422|NCT01030471|No Intervention|Wait list control group|
9944423|NCT01030510|Active Comparator|group R|In group R, remifentanil was infused first before administrating propofol and rocuronium
9944424|NCT01030510|Active Comparator|group P|in group P, remifentanil was administered last after the propofol and rocuronium injection
9944425|NCT01030562||Alternate Arm|Subjects who meet eligibility requirements but do not fit into any of the primary experimental arms.
9944426|NCT01030562||Control Arm|Subjects with an on-time interval between Dose 1 and 2 and an on-time interval between Dose 2 and 3.
9944427|NCT01030562||Experimental/Primary Arm 1|This primary arm will consist of subjects receiving the second dose on time/third dose substantially late.
9944428|NCT01030562||Experimental/Primary Arm 2|This primary arm will consist of subjects receiving the second dose substantially late/third dose on time.
9944429|NCT01030562||Experimental/Primary Arm 3|This primary arm will consist of subjects receiving the second dose substantially late/third dose substantially late.
9944430|NCT01030601|No Intervention|Control|Diabetics undergoing routine cataract surgery
10004011|NCT01572090|Active Comparator|Conventional weight loss: CONV-T2D|"Obese type 2 diabetic (T2D) patients evidenced by a body fat >35% in women and ≥ 25% in men and proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
10004012|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing a sleeve gastrectomy (SG). The Sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach. Via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
10004013|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
10004014|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypass: RYGB-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
10004015|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypss: RYGB-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
10004016|NCT01572103|Experimental|Administration of coffee|Administration of 4 cups of coffee/day for 1 month
10004017|NCT01572103|No Intervention|Coffee abstinence|Total coffee and caffeine containing beverages abstinence
10004018|NCT01572116|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
10004019|NCT01572116|Active Comparator|Lidocaine with Epinephrine + sufentanil|
10004020|NCT01572129|Experimental|Reload|600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
10004021|NCT01572129|Placebo Comparator|Placebo|Placebo arm in addition to the chronic daily dose of 75 mg
10004022|NCT01572142||Parkinson disease group|Subjects with Parkinson disease
10004023|NCT01572155|No Intervention|Sham stimulation|No stimulation of nervus vagus
10004024|NCT01572155|Active Comparator|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
10004025|NCT01572155|Active Comparator|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
10004026|NCT01572168|Experimental|Acupuncture|Eight sessions of weekly acupuncture
10004027|NCT01572181|Experimental|Drugs|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
9801137|NCT01707693|Active Comparator|Information/Attention Comparison|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
10004028|NCT01572220|Other|stress echocardiography|Comparative effectiveness
10004029|NCT01572220|Other|Myocardial SPECT|CER
10004030|NCT01572233|Experimental|Patient with HCV Infection|Personalized Physical Activity and Psycho-Education (PPAPE) Program will be tested on this group.
10004031|NCT01572233|No Intervention|usual care|waiting list group with usual care
9801138|NCT01707992|Placebo Comparator|Placebo-Controlled Phase: Placebo|Participants will receive 2 capsules of placebo (matching to laquinimod 0.6 milligrams [mg]) once daily orally for up to 24 months.
10004032|NCT01572246||Non-cardiac above-the-waist surgery|Subjects with an implanted ICD who present for a non-cardiac above-the-waist surgical procedure involving monopolar electrocautery
10004033|NCT01572246||Cardiac surgery|Subjects with an implanted ICD who present for a cardiac surgical procedure involving monopolar electrocautery
10004034|NCT01572246||Below-the-waist surgery|Subjects with an implanted ICD who present for a below-the-waist surgical procedure involving monopolar electrocautery
10004035|NCT01572259|Experimental|interruption of the growth hormone treatment.|
10004036|NCT01572259|Experimental|Patients traited by grouth hormone|
10004037|NCT01572272||Open|Open group: Data derived from the Capnostream20p and displayed to the medical team. It will allow the treating physician and the nursing team to review the real time data and make clinical decisions based upon it if felt necessary.
10004038|NCT01572272||Masked|Data derived from the Capnostream20p will be recorded; however the medical staff will be masked from it and hence will not use it.
10004039|NCT01572285|Sham Comparator|Sham|Sham arm received a simulation of transforaminal injection using a non-penetrating needle
10004040|NCT01572285|Experimental|Transforaminal|Subjects received TF with infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
10004041|NCT01572311|Experimental|Exercise Intervention Group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of dual-task gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week)
10004042|NCT01572311|Active Comparator|Exercise Control group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week). Note: no dual-task challenges during gait training
10004043|NCT01572324|Experimental|Arterial infusion|
10004044|NCT01572350|Active Comparator|Grid laser|It's a reference standard as the treatment which is currently accepted for NTDDME
10004045|NCT01572350|Experimental|Triamcinolone 4 mg|
10004046|NCT01572350|Experimental|Bevacizumab|
10004047|NCT01572363|Experimental|Sildenafil|All patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
10004048|NCT01572376|Experimental|Bone marrow stem cells|Bone marrow was obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for infusion into the wound.
9944431|NCT01030601|Experimental|Treatment|Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
9944432|NCT01030614|Active Comparator|Dexamethasone group|One hundred five patients were randomized to receive intravenous dexamethasone (8 mg) before laparoscopic cholecystectomy
9944433|NCT01030614|Placebo Comparator|Placebo group|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
9944434|NCT01030640|Placebo Comparator|placebo|formulation without active drug
9944435|NCT01030640|Active Comparator|tanezumab|
9944436|NCT01030679|Experimental|CKD-501 0.5mg|
9944437|NCT01030679|Experimental|CKD-501 1mg|
9944438|NCT01030679|Experimental|CKD-501 2mg|
9944439|NCT01030679|Placebo Comparator|Placebo|
9944440|NCT01030692|Placebo Comparator|Placebo|Placebo capsules as control
9944441|NCT01030692|Active Comparator|Rivastigmine 3 mg|Rivastigmine 3 mg
9944442|NCT01030692|Active Comparator|Rivastigmine 6 mg|Rivastigmine 6 mg
9944443|NCT01030692|Active Comparator|Huperzine A 0.4 mg|Huperzine A 0.4 mg
9944444|NCT01030692|Active Comparator|Huperzine A 0.8 mg|Huperzine A 0.8 mg
9944445|NCT01030731|Experimental|Ceftobiprole (end-stage renal disease subjects).|Ceftobiprole 250mg single dose over 2 hours.
9944446|NCT01030731|Active Comparator|Ceftobiprole (healthy subjects)|Ceftobiprole 250 mg single dose over 2 hours.
9944447|NCT01030744||Gestational Diabetes|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind Diabetes Clinic and are participants in the gestational diabetes educational program.
9944448|NCT01030770|Experimental|Arm A (treatment)|Arm A: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls) (Lucentis®)
9944449|NCT01030770|Placebo Comparator|Arm B (control):|Arm B: Single subconjunctival injection of 0.05mls of 0.9% sodium chloride (Minims Saline®)
9944450|NCT01030809|No Intervention|Usual Care practice|Patients managed according to usual care practices
9944451|NCT01030809|Active Comparator|Treatment Algorithm|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
9944452|NCT01030848||Patients with knee osteoarthritis|
9944453|NCT01030887|Active Comparator|Exercise Programme|This will consist of an 8-week exercise programme, performed twice per week.
9944454|NCT01030887|Placebo Comparator|Usual Care|Standard practice including opportunistic exercise advice and patients' self-directed physical activity
9944455|NCT01030900|Experimental|1|EPOCH + Rituximab + campath every 3 weeks for six cycles
9944456|NCT01030913||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
10004049|NCT01572402|Experimental|Patients with type 2 diabetes|Study group: 40 individuals with type 2 diabetes treated by diet and/or oral hypogylycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent
9944457|NCT01030926|Experimental|A1, first period|
9944458|NCT01030926|Active Comparator|A2, second period|
9944459|NCT01030926|Active Comparator|B1, first period|
9944460|NCT01030926|Experimental|B2, second period|
9944461|NCT01030939|Experimental|Cohort 1: SB-649868|Healthy adult male subjects
9944462|NCT01030939|Experimental|Cohort 2|Healthy adult female subjects
9944463|NCT01030939|Experimental|Cohort 3|Healthy male elderly subjects
9944464|NCT01030939|Experimental|Cohort 4|Healthy female elderly subjects
9944465|NCT01030978|Experimental|Family-based Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
9944466|NCT01030978|Active Comparator|Standard Diet & Activity Education (Control)|
9944467|NCT01030991||HFpEF|HFpEF cohort (observational study)
9944468|NCT01031017|Placebo Comparator|placebo|group taking placebo
9944469|NCT01031017|Active Comparator|study group|group taking progesterone
9944470|NCT01031082||HIV-negative Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
9944471|NCT01031082||HIV-positive Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
9944472|NCT01031108|Other|Type 2 Diabetic Group|The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
9944473|NCT01031108|Other|Otherwise Healthy Cigarette Smoking Group|The Otherwise Healthy Cigarette Smoking Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
9944474|NCT01031147||Magnetic resonance angiography|Three-dimensional time-of-flight magnetic resonance angiography(3D-TOF-MRA) was used to detect the intracranial aneurysms in this study
9944475|NCT01031186|Experimental|Cohort 1, Session 1|In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
9944476|NCT01031186|Experimental|Cohort 1, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
9944477|NCT01031186|Experimental|Cohort 1, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
9944478|NCT01031186|Experimental|Cohort 1, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
9944479|NCT01031186|Experimental|Cohort 1, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
9944480|NCT01031186|Experimental|Cohort 2, Session 1|In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
9944481|NCT01031186|Experimental|Cohort 2, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
9944482|NCT01031186|Experimental|Cohort 2, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
9944483|NCT01031186|Experimental|Cohort 2, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
9944484|NCT01031186|Experimental|Cohort 2, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
9944485|NCT01031199|Experimental|Arm 1|
9944486|NCT01031199|Experimental|Arm 2|
9944487|NCT01031225|Experimental|1|
9944488|NCT01031264||Social drinkers|
9944489|NCT01031290|Experimental|Group A|Active TMS
9944490|NCT01031290|Sham Comparator|Group B|Sham TMS
9944491|NCT01031303|Experimental|Study Group|
9944492|NCT01031316|Experimental|Nondisclosure|
9944493|NCT01031316|Active Comparator|Disclosure|
9944494|NCT01031329||Complicated Acute otitis media Group|"This group was divided into 3 sub-groups.~One sub-group includes treatment failure subjects who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment or reappearance of symptoms within 10 days following the end of antibiotic treatment.~The second sub-group includes subjects with recurrent acute otitis media, who have had new episodes of acute otitis media within the past 6 months or the fourth (or greater) new episode within the past year.~The third sub-group includes subjects with spontaneous otorrhoea if perforation has occurred < 24 hours prior to the visit."
9944495|NCT01031342|Experimental|Early colonoscopy|Colonoscopy performed within 12 hours of presentation
9944496|NCT01031342|Active Comparator|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
9944497|NCT01031355|Experimental|Arm 1|
9944498|NCT01031355|Active Comparator|Arm 2|
9944499|NCT01031355|Active Comparator|Arm 3|
10004050|NCT01572402|Active Comparator|Healthy subjects|Mean and women, age 30-70 years, no diabetes, no metabolic syndrome
10004051|NCT01572441||12-14 year olds|No intervention administered. This is a longitudinal observational study including observation of behaviors and physiological responses.
9944500|NCT01031368|Experimental|Treatment (chemotherapy, G-CSF, cord blood infusion)|"INDUCTION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients receive an infusion of non-HLA matched ex vivo expanded cord blood progenitors on day 6. G-CSF is administered SC on days 0-5 and from day 7 until blood counts recover. Treatment modifications may apply according to response.~CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients also receive G-CSF SC beginning on day 0 and continuing until blood counts recover."
9944501|NCT01031394|Active Comparator|Group 1|1 aerobic and 1 resistance training per week
9944502|NCT01031394|Active Comparator|Group 2|2 aerobic and 2 resistance training each per week
9944503|NCT01031394|Active Comparator|Group 3|3 aerobic and 3 resistance training per week
9944504|NCT01031459||Group 1|
9944505|NCT01031472|Experimental|Part A|Subjects will be randomized in a three way crossover design to either a single dose of GSK2248761 100mg Gelucire capsule administered with food and a single dose of 100mg of formulation 1 or a single dose of 100mg of formulation 3 administered in the fed and fasted state
9944506|NCT01031472|Experimental|Part B|A total of twelve subjects who complete Part A will participate in Part B. Subjects from Part A will be asked to participate on a first come first serve basis until there are 12 subjects, at which time enrolment to Part B will be closed. Part B will be a 2 way cross over study design. Subjects will be randomized to one of a single dose of GSK2248761 100mg Formulation 2 or 4 (based on the evaluation of Part A data) administered with food or in the fasted state. Subjects in Part B will not receive the reference formulation since they previously received this in Part A
10004052|NCT01572454|Experimental|Dexmedetomidine group|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
10004053|NCT01572454|Active Comparator|Remifentanil group|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
10004054|NCT01572519|Experimental|JNJ-40346527|
10004055|NCT01572532|Experimental|Intervention Screening and Treatment|"CHWs will collect urine and vaginal samples for all women enrolled. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison. Vaginal specimens will be collected via sterile self-administered vaginal swabs. The women will be instructed by the CHW to insert a Dacron swab ~4-5 cm into the vagina, allow the swab to stand for 15 seconds, and then rotate 360 degrees prior to withdrawal. The CHW will gently roll out the swab onto a plain glass slide and allow to air dry prior to transport to Sylhet field laboratory.~A midstream urine specimen will be obtained for urine culture. The mother will be instructed to separate the labia and collect 20-30mL of midstream urine into a sterile container which will be immediately refrigerated in a cool specimen box."
10004056|NCT01572532|No Intervention|Control Arm|Standard care will be administered, including antenatal and postnatal care. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison.
10004057|NCT01572545|Experimental|Denosumab|
10004058|NCT01572545|Experimental|Zoledronic Acid|
10004059|NCT01572558|Active Comparator|Appendectomy|Standard surgical treatment, appendectomy
10004060|NCT01572558|Experimental|Conservative, non-surgical treatment|Non-operative treatment with intravenous and oral antibiotics
10004061|NCT01572597|Experimental|Acetylcystein|10-day triple therapy plus N-acetyl-cystein to remove the biofilm.
10004062|NCT01572597|Active Comparator|Metronidazole|10-day triple therapy plus metronidazole (concomitant therapy) as active comparator
10004063|NCT01572610|Experimental|RTA 402|
10004064|NCT01572623|Active Comparator|Antiplatelet before carotid artery stenting|Clopidogrel 600 mg after carotid artery stenting
10004065|NCT01572623|Active Comparator|Statin therapy before carotid artery stenting|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
10004066|NCT01572636||Laronidase use in Hurler Syndrome|Laronidase receiving prior and post transplant
10004067|NCT01572649|Placebo Comparator|Placebo|1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously
10004068|NCT01572649|Experimental|Dose 1|1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously
10004069|NCT01572649|Experimental|Dose 2|1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously
10004070|NCT01572688|Experimental|autologous stem cell transplant|
10004071|NCT01572701|Experimental|20 (±3) mCi of study drug|
10004072|NCT01572753|Experimental|Post-dose fasting 120 mins/50 ml water|
9801139|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 0.6 mg|Participants will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for up to 24 months.
9801140|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 1.2 mg|Participants will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for up to 24 months.
9801141|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 0.6 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 0.6 mg treatment group after 01 January 2016, will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for 24 months.
9801142|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 1.2 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 1.2 mg treatment group prior to 01 January 2016, will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for 24 months.
9944507|NCT01031485|Active Comparator|Spread with milk peptides and plant sterols|
9944508|NCT01031485|Placebo Comparator|Standard spread|
9944509|NCT01031511|Experimental|Treatment Group - CBT|
9944510|NCT01031511|No Intervention|Control Group|
9944511|NCT01031524|Experimental|vaccine|30 µg of PfCS102 formulated in Montanide ISA 720
9944512|NCT01031524|Placebo Comparator|adjuvant|Montanide ISA 720
9944513|NCT01031602||Psych Needs Assessment|Female Sexual Function Index (FSFI), Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire given to underserved and minority women with a gynecologic cancer or premalignant condition.
9944514|NCT01031615|Experimental|Child and Family Traumatic Stress Interv|4-session secondary prevention model that focuses on family communication about symptoms of a child aged 7-16.
9944515|NCT01031615|Active Comparator|Psychoeducational Comparison|4-sessions focused on individual child using psychoeducation and relaxation skills
9944516|NCT01031693|Active Comparator|Group A|Active TMS
9944517|NCT01031693|Sham Comparator|Group B|Sham TMS
9944518|NCT01031719|Experimental|Group A: High Risk Population|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
9944519|NCT01031719|Experimental|Group B: High Risk Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
9944520|NCT01031719|Experimental|Group C: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
9944521|NCT01031719|Experimental|Group D: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
9944522|NCT01031732|Experimental|Two-incision|MIS-2 THA
9944523|NCT01031732|Experimental|Watson-Jones|MIS-WJ
9944524|NCT01031732|Experimental|MIS-AL|
9944525|NCT01031732|Experimental|MIS-PL|
9944526|NCT01031745|Experimental|Contingency|
9944527|NCT01031745|Active Comparator|Control|
9944528|NCT01031758|Other|Group 1|Group 1 is comprised of 6 healthy subjects with HDL-C levels between the 25th and 75th percentile.
9944529|NCT01031758|Other|Group 2|Group 2 is comprised of 6 healthy subjects with high HDL-C levels > 75th percentile.
9944530|NCT01031758|Other|Group 3|Group 2 is comprised of 6 healthy subjects with low HDL-C levels < 25th percentile.
9944531|NCT01031784|Experimental|Holmium-166 microspheres, intra-arterial|intra-arterial administration of holmium-166 microspheres in the liver
9944532|NCT01031797||High SLEDAS|High SLE disease activity score
9944533|NCT01031797||Low SLEDAS|SLE patient with low score
9944534|NCT01031823|Experimental|Social Skills Training|All participants will take part in this arm of the study.
9944535|NCT01031849|Experimental|Kaletra, all patients|Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
9944536|NCT01031862|Other|Healthy Volunteers|12 healthy volunteers
9944537|NCT01031888|Active Comparator|1|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops
9944538|NCT01031888|Active Comparator|2|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops
9944539|NCT01031888|Placebo Comparator|3|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops
9944540|NCT01031888|Placebo Comparator|4|corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops
9944541|NCT01031901|Placebo Comparator|TSC Placebo Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
9944542|NCT01031901|Experimental|TSC 1% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
9944543|NCT01031901|Experimental|TSC 5% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
9944544|NCT01031901|Placebo Comparator|NF1 Placebo Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
9944545|NCT01031901|Experimental|NF1 1% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
9944546|NCT01031901|Experimental|NF1 5% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas
9944547|NCT01031940|Active Comparator|macintosh|
9944548|NCT01031940|Active Comparator|C-MAC|
9944549|NCT01031940|Active Comparator|Airtraq|
9944550|NCT01031966|Active Comparator|H1N1sw monovalent vaccine|
9944551|NCT01031966|Experimental|Thymosin alpha 1 3.2mg|
9944552|NCT01031966|Experimental|Thymosin alpha 1 6.4 mg|
9944553|NCT01031992|Experimental|Group I|First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
9944554|NCT01031992|Experimental|Group II|First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).
9944555|NCT01032005|Placebo Comparator|Fortified salt|Common table salt that has been fortified with iodine only
9944556|NCT01032005|Experimental|Double fortified salt|Common table salt that has been fortified with iron and well as the usual iodine
9944557|NCT01032031|Active Comparator|Green tea + vit C high dose|
9944558|NCT01032031|Placebo Comparator|Placebo|
9944559|NCT01032057|Active Comparator|Gemcitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
9944560|NCT01032057|Active Comparator|chemoradiotherpay with capecitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
9944561|NCT01032083|Active Comparator|Citalopram|An SSRI antidepressant
9944562|NCT01032083|Placebo Comparator|Placebo|
9944563|NCT01032109|Experimental|Bevacizumab|
9944564|NCT01032122|Experimental|rituximab|
9944565|NCT01032148|Experimental|LBH589|LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
9944566|NCT01032161||Delirium|Delirium was determined by RASS-PAEDS
9944567|NCT01032161||no Delirium|no Delirium was determined by RASS-PAEDS
9944568|NCT01032187|Active Comparator|Meglumine antimoniate|20mg/kg/day IV for 20 days
9944569|NCT01032187|Experimental|Anfo B|Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days
9944570|NCT01032213|Placebo Comparator|group C|control group
9944571|NCT01032213|Experimental|group M|magnesium group
9944572|NCT01032252|No Intervention|observational|Control group: followed by monthly falls calenders and four testing periods
9944573|NCT01032252|Experimental|Exercise group|16 week intervention, and followed by monthly fall calenders as well as 4 testing periods
9944574|NCT01032278|Experimental|Cardiac Biomarker Testing|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI), and symptom questionnaires of participants undergoing anthracycline-based chemotherapy.
9944575|NCT01032304|Experimental|Erdosteine|600 mg/day for 12 months
9944576|NCT01032304|Placebo Comparator|Placebo|Placebo for 12 months
9944577|NCT01032317|Other|Single-arm Study|This study was completed prior to the implementation of the requirement for specific identification of study arms. As the requirement was not made retroactive to completed studies, we believe this study to be exempt from the stipulation. Also, per PRS definition, since this is for a single-arm/feasibility study, the data elements are optional.
10004073|NCT01572753|Experimental|Post-dose fasting 60 mins/50 ml water|
10004074|NCT01572753|Experimental|Post-dose fasting 30 mins/50 ml water|
9944578|NCT01032343|Active Comparator|Omega-3 PUFA capsule|
9944579|NCT01032343|Placebo Comparator|Gelatine capsule|
9944580|NCT01032356|Experimental|Dynasplint|Patients will be treated with the current standard of care and the Wrist Extension Dynasplint.
9944581|NCT01032369|Experimental|CBT|with behavioral intervention-CBT.
9944582|NCT01032369|Other|Without CBT|Without behavioral intervention-CBT
9944583|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
9944584|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
9944585|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
9944586|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
9944587|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
9944588|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
9944589|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
9944590|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
9944591|NCT01032421||GNRH|Observational (IVF is not done as part of the study)
9944592|NCT01032434|Experimental|sertraline|sertraline: 50-200mg/day
9944593|NCT01032460|Active Comparator|macintosh|
9944594|NCT01032460|Active Comparator|C-MAC|
9944595|NCT01032460|Active Comparator|Airtraq|
9944596|NCT01032473||GAD|Children between the ages of 7-11 years diagnosed with Generalized Anxiety Disorder (GAD)
9944597|NCT01032473||Control|Children between the ages of 7-11 years free of significant medical or behavioral problems (matched to children diagnosed with GAD based on age, gender, and ethnicity).
9944598|NCT01032486||Azilect|Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
9944599|NCT01032499|Active Comparator|oxytetracycline|
9944600|NCT01032499|Experimental|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
10004075|NCT01572753|Experimental|Post-dose fasting 15 mins/50 ml water|
10004076|NCT01572753|Experimental|Post-dose fasting 120 mins/120 ml water|
10004077|NCT01572753|Experimental|Post-dose fasting 60 mins/120 ml water|
10004078|NCT01572753|Experimental|Post-dose fasting 30 mins/120 ml water|
10004079|NCT01572753|Experimental|Post-dose fasting 15 mins/120 ml water|
10004080|NCT01572766|Active Comparator|FRAX Assessment|FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
10004081|NCT01572766|No Intervention|Control group|Control group receives heel ultrasound and pharmacist counseling
10004082|NCT01572779|Experimental|Intervention|BSM device with bio-feedback
10004083|NCT01572779|Placebo Comparator|Control|The BSM device without feed-back
10035174|NCT01803594|Active Comparator|PC700, Krill Oil, Lutein, and Niacin|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)"
10035175|NCT01803633|Experimental|Cheese|Cheese sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain medium cheddar cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, high oleic sunflower oil, high polyunsaturated fatty acids (PUFA) sunflower oil, and canola oil.
10035176|NCT01803633|Active Comparator|Vegan cheese|Non-dairy cheese alternative sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain vegan cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, cream of tartar, high oleic sunflower oil, high PUFA sunflower oil, and palm oil.
10035177|NCT01803659|Experimental|b-carotene|600 ug RAE/d as b-carotene, 6 d/wk for 3 weeks
10035178|NCT01803659|Active Comparator|retinyl palmitate|600 ug retinol equivalent/d, 6 d/wk for 3 weeks
10035179|NCT01803659|Placebo Comparator|placebo (corn oil)|0 ug RAE/d as corn oil
10035180|NCT01803672|Experimental|health talk and adventure-based training|Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
10035181|NCT01803672|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
10037246|NCT01823315|Experimental|Methotrexate+dactinomycin Single-dose chemotherapy|"Regimen: dactinomycin d 0.6mg/m2, IV, on day1, 2; methotrexate 100mg/m2, IV, on day1 (after Act-d); methotrexate 200mg/m2, IVgtt, on day1 (after methotrexate, 500ml NS, >4h).~If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen."
9944601|NCT01032512|Experimental|IMMUNE-ENHANCING|"40 patients will be instructed to consume 600 ml of the special immune-enhancing formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density)."
9944602|NCT01032512|Sham Comparator|CONTROL|40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.
9944603|NCT01032551|Experimental|Vascular Access Patient Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
9944604|NCT01032551|No Intervention|Usual Care|"The control group (those not randomized to the PtDA) will have usual care. Usual care involves a brief discussion, just prior to the CA procedure, with the treating physician, regarding the patient's eligibility for both vascular accesses, followed by the advantages and disadvantages of both. The details and duration of the discussion is left to the discretion of the treating physician as per their individual standard of care. There will be no access to a formal PtDA in this group."
9944605|NCT01032577||cardiomyopathy, with implant indications|30-50 volunteers age >18, male and female with ability to give informed consent, who are expected to live more than one year, with indication for defibrillator implant and who are not pacemaker dependent.
9944606|NCT01032590|Experimental|Arm I|Arm I (12-week Internet-based weight-loss intervention): After a baseline evaluation, subjects will start a 12 week Internet-based weight-loss intervention.
9944607|NCT01032590|Active Comparator|Arm II|Arm II (wait-list control): Patients are instructed to continue their usual dietary and physical activity routines during a 12-week wait period. After the waiting period, patients receive the Internet-based weight-loss intervention for 12 weeks as in arm I.
9944608|NCT01032616|Experimental|Study Period 1|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
9944609|NCT01032616|Experimental|Study Period 2|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
9944610|NCT01032642|Experimental|thin catheter group|group of women where thin catheter will be used for hysterosalpingography
9944611|NCT01032655|Experimental|sequential, susceptibility guided|single arm
9944612|NCT01032668|Experimental|high dose clopidogrel|
9944613|NCT01032681|Experimental|Group 1|Dose escalation of EMD 521873 monotheraphy 3 doses per cycle
9944614|NCT01032681|Experimental|Group 2|Low dose CPA + Dose escalation of EMD 521873 three doses per cycle
9944615|NCT01032681|Experimental|Group 3|Dose escalation of EMD 521873 monotheraphy 1 dose per cycle
9944616|NCT01032720|Experimental|Ultrasound-guided knee CS injection|Ultrasound will be used to image knee joint and guide needle for intra-articular knee CS injection.
9944617|NCT01032720|Sham Comparator|Sham Ultrasound knee CS injection|CS knee injection will be performed in the same method as the US-guided knee injection but the US machine will be turned off.
9944618|NCT01032772|Experimental|CHOICES Plus Intervention|A two session intervention utilizing a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, and smoking. The interventions will (a) provide norms-based-but personalized-feedback, (b) encourage attendance at a contraceptive counseling visit, (c) encourage participation in the smoking cessation program, (c) increase motivation to change each of the target behaviors, (d) decrease temptation to engage in risk behaviors, (e) increase confidence to avoid risk behaviors, and (f) develop a personalized, tailored change plan.
9944619|NCT01032772|Active Comparator|Information|Women in the information condition receive advice and educational material from the research assistant about women's health and related referrals.
9944620|NCT01032785||Healthy term newborn|Any healthy term newborn born in Wolfson Medical Center
9944621|NCT01032811||Study Participants|St. Jude Children's Research Hospital patients from Leukemia, Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.
9944622|NCT01032824|Experimental|Intervention|Individual telephone counseling intervention.
9944623|NCT01032824|Other|Group Arm|Attention-matched comparison arm
9944624|NCT01032824|Other|Book Arm|Information-matched control arm.
9944625|NCT01032863||Young healthy Indian adults|Persons aged between 25 and 40 years of age who are relatives of patients being treated in Amrita Institute of Medical Sciences (Inpatient or Outpatient) and voluntary blood donors at the same institute who are willing to participate in the study.
9944626|NCT01032876|Experimental|Deep Hypothermic Circulatory Arrest|
9944627|NCT01032876|Experimental|Antegrade Cerebral Perfusion|
9944628|NCT01032902||Known HIV positive|Patients from HIV clinics with documented infections
9944629|NCT01032902||High Risk for Infection with HIV|Patients from defined HIV high-risk populations - i.e. intravenous drug users, or patients presenting with symptoms of sexually transmitted disease.
10004084|NCT01572805|Active Comparator|melatonin 3mg|
10004085|NCT01572805|Active Comparator|melatonin 6mg|
10004086|NCT01572805|Placebo Comparator|placebo|
10004087|NCT01572818|Experimental|Phlebotomy|phlebotomy associated with dietary and lifestyle counseling
9528727|NCT03208127|Experimental|Treatment with Direct Acting Antiviral Fixed Dose Combination|12 weeks of HCV treatment with medically appropriate direct acting antiviral
9528728|NCT03208478|Active Comparator|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
9944630|NCT01032902||Low-Risk for Infection with HIV|"Individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
9944631|NCT01032941|Placebo Comparator|Placebo|Patients in this group will be given placebo 2 packets BID for 8 weeks.
9944632|NCT01032941|Experimental|VSL#3|Patients in this group will be given 2 packets of VSL#3 BID for 8 weeks.
9944633|NCT01032967|Active Comparator|Surgery, esophagectomy|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
9944634|NCT01032967|Active Comparator|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
9944635|NCT01032980||HUMENZA Vaccine Group|Participants vaccinated with HUMENZA according to the recommendations provided in the product leaflet and local recommendations.
9944636|NCT01032980||PANENZA Vaccine Group|Participants vaccinated with PANENZA according to the recommendations provided in the product leaflet and local recommendations.
9944637|NCT01033006|Active Comparator|Arm 1: catheter injection|40 ml of LA through the catheter
9944638|NCT01033006|Active Comparator|Arm 2: transarterial injection|30 ml deep and 10 ml superficial to the artery
9944639|NCT01033006|Active Comparator|Arm 3: catheter and transarterial injection|20 + 10 ml transarterial block and 10 ml through the catheter
9944640|NCT01033058|Active Comparator|usual care|
9944641|NCT01033058|Experimental|intensive statin treatment|
9944642|NCT01033084|Experimental|Sham stimulation / sertraline|In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
9944643|NCT01033084|Sham Comparator|Sham stimulation / placebo pill|"Placebo pills are sugar pills having the same size and shape of the active pills.~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation."
9944644|NCT01033084|Experimental|Active stimulation / Sertraline|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Patients will receive Sertraline 50mg/day."
9944645|NCT01033084|Experimental|Active stimulation / placebo pill|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Placebo pills are sugar pills having the same size and shape of the active pill"
9944646|NCT01033097|Experimental|DNK333 5 mg|
9944647|NCT01033097|Placebo Comparator|Placebo to DNK333 5mg|
9944648|NCT01033097|Experimental|DNK333 25 mg|
9944649|NCT01033097|Placebo Comparator|Placebo to DNK333 25 mg|
9944650|NCT01033097|Experimental|DNK333 100 mg|
9944651|NCT01033097|Placebo Comparator|Placebo to DNK333 100 mg|
9944652|NCT01033097|Active Comparator|Betamethasone 4 mg|
9944653|NCT01033097|Experimental|DNK333 1 mg|
9944654|NCT01033097|Placebo Comparator|placebo 1mg|
9944655|NCT01033149|Other|N-acetylcysteine|open label N-acetylcysteine, flexible dose
9944656|NCT01033162|No Intervention|Usual Care|A group using a Basic ICCS provided by KPNW
9944657|NCT01033162|Experimental|Intervention|A group using an enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
9944658|NCT01033175|Other|COPD patients with ACD|"In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of cases).ACD is defined by low Hb levels (men: <13 mg/dl, women: <12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity."
9944659|NCT01033175|Other|COPD patients without ACD|"Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the controls)"
9944660|NCT01033188|Active Comparator|Single-bundle technique|Anatomic single-bundle technique
9944661|NCT01033188|Active Comparator|Double-bundle technique|Anatomic double bundle technique
9944662|NCT01033201||Lung transplant|All lung transplant patients presenting for screening/surveillance and diagnostic bronchoscopies at Mayo Clinic Florida are eligible for participation.
9944663|NCT01033214|Experimental|TAArget Thoracic Stent Graft|those treated with the investigational device
10004088|NCT01572818|Active Comparator|Lifestyle counseling|dietary and lifestyle counseling
10004089|NCT01572831|No Intervention|standard care|Abx will be determined by the managing physician
10004090|NCT01572831|Experimental|experimental arm|Abx determined by normalization of PCT and basic clinical parameters
10035182|NCT01803685||Surgical treatment|Surgical resection of intracranial arteriovenous malformations.
9801143|NCT01707992|No Intervention|Active Treatment Phase: Off Drug|Participants who were discontinued from treatment with laquinimod 1.2 mg during the placebo-controlled phase due to sponsor decision after 01 January 2016 will continue the active-treatment phase off drug for 24 months.
9801144|NCT01708122|Experimental|Fentanyl|Subjects will receive either 0.5mL or 1 mL of intranasal fentanyl (50mcg or 100mcg)
9801145|NCT01708122|Placebo Comparator|Placebo|Subjects will receive either 0.5mL or 1 mL of intranasal saline as placebo.
9801146|NCT01708161|Experimental|BYL719 + AMG 479|For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
9801147|NCT01708174|Experimental|Sonidegib (LDE225)|600 mg orally for adults and 500 mg/m2 orally for children
9801148|NCT01708174|Active Comparator|Temozolamide (TMZ)|150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
9801149|NCT01708187|Experimental|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
9801150|NCT01708187|No Intervention|Control arm without Clarix™1k graft|Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
9801151|NCT01708213|Experimental|Dermal Filler - Aline HA|Single armed study
9801152|NCT01708278|Placebo Comparator|Sugar chew-Cohort 1|contains 350 mg of vitamin C and 10 mg niacin
9801153|NCT01708278|Active Comparator|Quercetin 1-Cohort 1|Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
9801154|NCT01708278|Active Comparator|Quercetin 2-Cohort 2|Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
9801155|NCT01708278|Active Comparator|Quercetin 3-Cohort 3|Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
9801156|NCT01708278|Placebo Comparator|Sugar chew-Cohort 2|contains 350 mg of vitamin C and 10 mg niacin
9801157|NCT01708278|Placebo Comparator|Sugar Chew-Cohort 3|contains 350 mg of vitamin C and 10 mg niacin
9801158|NCT01708291|Active Comparator|Mindfulness Based Stress reduction|attending 10 weekly sessions and comprised of an eight week mindfulness intervention program, and completing pre- and postevaluation measures on the first and last sessions
9801159|NCT01708291|Placebo Comparator|No Mindfulness based intervention|completing only re- and post-evaluation measures on the first and last sessions
9801160|NCT01708317|Other|ACASI|The group of patients that agreed to participate in the study and answer questions on our Audio-enhanced Computer-Assisted Self-Interview (ACASI)
9801161|NCT01708525|Experimental|Ultherapy®-treated tissue|Heavy water labeled tissue receiving an Ulthera® System Treatment
9801162|NCT01708590|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
9801163|NCT01708590|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
9801164|NCT01708590|Placebo Comparator|placebo|Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
9801165|NCT01708603|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
9801166|NCT01708603|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
9801167|NCT01708603|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
9801168|NCT01708603|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
10004091|NCT01572857||first phase|"This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.~20 patients hospitalized."
10004092|NCT01572857||Second phase|"Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.~30 patients hospitalized."
10004093|NCT01572870||No ABPA nor Aspergillus infection|CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)
10004094|NCT01572870||persistent Aspergillus infection, without ABPA|CF patients with persistent Aspergillus infection, without ABPA.
10004095|NCT01572870||Current or past ABPA infection|CF patients with current or past ABPA
10004096|NCT01572896|Experimental|Taking Charge Experimental Group|
10004097|NCT01572896|Active Comparator|Control Group|
10004098|NCT01572961|Active Comparator|Aspirin|Aspirin
10004099|NCT01572961|Placebo Comparator|Placebo|Placebo
10004100|NCT01572974||No Barrett's esophagus|Subject without columnar lined esophagus
10004101|NCT01572974||Nondysplastic BE|Subject with columnar lined esophagus and absence of dysplasia
10004102|NCT01572974||Low grade dysplastic BE|subject with columnar lined esophagus and presence of low grade dysplasia
10004103|NCT01572974||High grade dysplastic BE|subject with columnar lined esophagus and presence of high grade dysplasia
10004104|NCT01572987|Active Comparator|RFA arm|Under this arm, study patients will undergo radiofrequency ablation.
9528729|NCT03208478|Active Comparator|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
10004105|NCT01572987|Active Comparator|EMR arm|Under this arm, the individuals will undergo endoscopic mucosal resection.
10004106|NCT01573013|Active Comparator|NaFeEDTA treatment, biscuit|Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
10004107|NCT01573013|Active Comparator|EDTA treatment, biscuit|Group receives Na2EDTA enriched biscuit
10004108|NCT01573013|Active Comparator|FeSO4 treatment, biscuit|Group receives 10 mg of iron as FeSo4 per day for 8 months
10004109|NCT01573013|Placebo Comparator|control treatment, biscuit|group receives a biscuit without additional iron
10004110|NCT01573065|Experimental|Single arm|
10004111|NCT01573078||Crohn's disease patient|Outpatients who carry a diagnosis of Crohn's disease made by a gastroenterologist.
10004112|NCT01573091||Heart failure patients|Patients with a CRT device according to current guidelines
10004113|NCT01573104|Experimental|Biomarker group|Patients undergoing CPB having proteomic assays, blood sampling and biomarker assays performed on D0, D1, D2 and D3
9801169|NCT01708629|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
9801170|NCT01708629|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
9801171|NCT01708629|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
9801172|NCT01708629|Placebo Comparator|Placebo|Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
9801173|NCT01708902|Experimental|linagliptin2.5mg / metformin500mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
9801174|NCT01708902|Experimental|linagliptin2.5mg / metformin1000mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
9801175|NCT01708902|Active Comparator|metformin 500mg BID|patient to receive a tablet containing metformin 500mg BID
9801176|NCT01708902|Active Comparator|metformin 1000mg BID|patient to receive a tablet containing metformin 1000mg BID
9801177|NCT01708902|Active Comparator|linagliptin 5 mg QD|patient to receive a tablet containing linagliptin 5mg once daily
9801178|NCT01708915|Active Comparator|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
9801179|NCT01708915|Active Comparator|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
9801180|NCT01708915|Active Comparator|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
9801181|NCT01708915|Placebo Comparator|placebo|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
9801182|NCT01708967|Experimental|Catheter-free method|"We explored success rate, side effects, and vital signs in patients with catether-free method.~Intervention: one-time spray of epinephrine (1cc) plus 4% lidocaine (4cc)"
9801183|NCT01708967|Experimental|Catheter insertion method|We explored success rate, side effects, and vital signs in patients with catether insertion method : use both spray and catheter
9801184|NCT01709032|Experimental|Deferasirox and deferiprone|
9801185|NCT01709084|Experimental|Group 1|Patients will receive fixed dose combination (FDC) tablet of tenofovir disoproxil fumarate/emtricitabine/rilpivirine with a meal, until Week 48.
9801186|NCT01709084|Active Comparator|Group 2|Patients will receive FDC tablet of tenofovir disoproxil fumarate/emtricitabine /efavirenz on an empty stomach at bedtime, until Week 48.
9801187|NCT01709110|Experimental|Teriparatide|"Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
9801188|NCT01709110|Active Comparator|Risedronate|"Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
9801189|NCT01709149|Experimental|CK-2017357|125 mg tablets
9801190|NCT01709149|Placebo Comparator|Placebo|Placebo tablets
9801191|NCT01709162|Experimental|Ipilimumab, 3 mg/kg|Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
9801192|NCT01709162|Active Comparator|Chemotherapy|Participants received the investigator's choice of chemotherapy, administered per package instructions.
9803246|NCT04381936|Active Comparator|Anakinra|"Randomisation for children only with PIMS-TS~(Children with COVID-19 pneumonia are not eligible for this comparison).~[This arm is now closed to recruitment]"
9803247|NCT04381936|Active Comparator|Dimethyl fumarate|"First (main) randomisation part A (UK adults only; early phase assessment)~[This arm is now closed to recruitment]"
10004114|NCT01573117|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
9803248|NCT04381936|Active Comparator|High Dose Corticosteroids|First (main) randomisation part E
9944664|NCT01033253|Experimental|Computerized Tailored Intervention|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
9944665|NCT01033253|No Intervention|Control|Computerized assessments of Transtheoretical Model constructs at 0, 2, 6, and 12 months
9944666|NCT01033266||CPET CPAP|
9944667|NCT01033279|No Intervention|Usual care|Patients followed by usual care at the hospital's anticoagulation clinic
9944668|NCT01033279|Experimental|Self-management|Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms
9944669|NCT01033305|Placebo Comparator|Placebo|
9944670|NCT01033305|Experimental|CyCol™|
9944671|NCT01033318|Experimental|Part 1 A-1|"Part 1; Panel A; Sequence 1:~2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan"
9944672|NCT01033318|Experimental|Part 1 A-2|"Part 1; Panel A; Sequence 2:~Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809"
9944673|NCT01033318|Experimental|Part 1 A-3|Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
9944674|NCT01033318|Experimental|Part 1 A-4|Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
9944675|NCT01033318|Experimental|Part 1 A-5|"Part 1; Panel A; Sequence 5:~Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809"
9944676|NCT01033318|Experimental|Part 1 B-1|"Part 1; Panel B; Sequence 1:~5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food"
9944677|NCT01033318|Experimental|Part 1 B-2|"Part 1; Panel B; Sequence 2:~5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food"
9944678|NCT01033318|Experimental|Part 1 B-3|"Part 1; Panel B; Sequence 3:~5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food"
9944679|NCT01033318|Experimental|Part 1 B-4|"Part 1; Panel B; Sequence 4:~Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food"
9944680|NCT01033318|Experimental|Part 1 B-5|"Part 1; Panel B; Sequence 5:~Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food"
9944681|NCT01033318|Experimental|Part 2 C-1|"Part 2; Panel C; Sequence 1:~50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan"
9944682|NCT01033318|Experimental|Part 2 C-2|"Part 2; Panel C; Sequence 2:~50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809"
9944683|NCT01033318|Experimental|Part 2 C-3|"Part 2; Panel C; Sequence 3:~Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo"
9944684|NCT01033318|Experimental|Part 2 C-4|"Part 2; Panel C; Sequence 4:~50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809"
9944685|NCT01033318|Experimental|Part 2 C-5|"Part 2; Panel C; Sequence 5:~Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809"
9944686|NCT01033344|Placebo Comparator|Placebo|Solution resembling active solution but without peptides
9944687|NCT01033344|Experimental|Group 1|Cat-PAD dose group 1
9944688|NCT01033344|Experimental|Group 2|Cat-PAD Dose group 2
10004115|NCT01573117|Active Comparator|RhinoChill|Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)
10004116|NCT01573130|Experimental|Initial treatment group|Group receives treatment.
10004117|NCT01573130|No Intervention|Waiting list control group|The waiting list control group receives treatment after 9 weeks, before which they do weekly ratings.
10004118|NCT01573143|Placebo Comparator|Sugar pill|Placebo
10004119|NCT01573143|Experimental|Rosuvastatin|Rosuvastatin (20 mg od)
10004120|NCT01573156|Experimental|VTP treatment to small renal mass|
9480661|NCT05262166|No Intervention|Epidural Fentanyl group:|Epidural Fentanyl group: using an epidural catheter technique with epidural catheter set, and at L1-2 insertion level directed up to cover up to T6 sensory level, 5ml of bupivacaine 0.5%plus 50 micrograms fentanyl in a total volume of 40 ml added saline 0.9% (epidural injection of bolus of total Volume of 15 ml of 0.0625%bupivacaine with 1.25Mcg/ml fentanyl) then for next G anaesthesia hours to run in a 3-5 ml/h epidural infusion rate.
9944689|NCT01033370|Other|Open label, non-randomized, pilot study|All subjects who provide consent for trial participation with an acute aortic emergency and elevated BP (systolic blood pressure [SBP] ≥120 mm Hg) requiring IV antihypertensive therapy for up to 48 hours will be administered an infusion of clevidipine to evaluate the efficacy and safety of the IV drug.
9944690|NCT01033396|Experimental|PF-03654764 + Allegra|
9944691|NCT01033396|Experimental|PF-03654764|
9944692|NCT01033396|Active Comparator|Allegra-D|
9944693|NCT01033396|Placebo Comparator|Placebo|
9944694|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^7|Arm 1 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^7 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^7 CFU oral dosage through Day 28.
9944695|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^8|Arm 2 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^8 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^8 CFU oral dosage through Day 28.
9944696|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^9|Arm 3 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^9 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^9 CFU oral dosage through Day 28.
9944697|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^10|Arm 4 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^10 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^10 CFU oral dosage through Day 28.
9944698|NCT01033435||chronic Hemodialysis patients, treated in our unit.|
9944699|NCT01033435||chronic Hemodialysis patients , No intervention|chronic Hemodialysis patients, treated in our unit.
9944700|NCT01033461|Experimental|calcium and probiotic|intervention
9944701|NCT01033461|Experimental|probiotic|intervention
9944702|NCT01033461|Placebo Comparator|placebo|placebo, no intervention
9944703|NCT01033474||donor eggs|
9944704|NCT01033474||infertile patients|
9944705|NCT01033500|Experimental|SIK|Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
9944706|NCT01033513||Literature Only (Control)|The participants on this arm served as the control group. Five types of literature were mailed to the participants in the literature only arm. A letter was included with the materials thanking participants for their participation, requesting that the participants read the literature, and encouraging them to contact the RDs with any questions. The Clinical Study Manager's telephone number was provided for questions about diet or lifestyle changes. The RDs documented all contacts with participants on a phone summary. Other than the delivery of literature and responses to specific questions asked by the participant or the participant's primary caregiver through telephone calls, the RDs had no further interaction with the participant until the conclusion of the participant's trial period.
9944707|NCT01033513||Meals Only|Participants in the meals only arm received a pre-intervention assessment (but no nutrition counseling). The RDs gave the participants in the meals only arm a phone number and encouraged them to phone with questions or problems, especially problems associated with the meals. Subsequently, the meals only participants received seven diagnosis-appropriate therapeutic meals a week, delivered once per week. The meals were specially designed to address the participants' medical diagnoses. They were developed using the ADA MNT protocols for caloric and nutrient content requirements for individuals with the specified diagnoses, in addition to meeting AoA Nutrition Program dietary requirements. The meals were provided primarily in frozen form. However, some shelf-stable and refrigerated components were also included. In conformance with AoA regulations, appropriate meals were also offered to the spouse of any participant receiving a therapeutic meal.
9944708|NCT01033513||MNT Only|The participants in this arm received MNT from the project RDs, who employed the Hyperlipidemia Medical Nutrition Therapy MNT Protocol, developed by ADA (2002). Because ADA had not finalized MNT protocols for hypertension, the RDs followed the protocol for hyperlipidemia for participants diagnosed with either hyperlipidemia or hypertension, with adjustments, as appropriate, to benefit those individuals who were diagnosed with hypertension.All MNT sessions were in the participants' homes, and if a caregiver was required for the individual to participate in the project, every effort was made to include this person in the MNT sessions. The MNT intervention took place over at least three sessions, and, in conformance with the ADA protocol, each participant received individualized counseling and education.
10004121|NCT01573182|Experimental|Donor|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..
10004122|NCT01573195||All prescribing MDs at UWHC|Observational for accept, reject, or accept with modification of Best Practice Alers
10004123|NCT01573208|Experimental|Register|Register
10004124|NCT01573221||stroke|
10004125|NCT01573234|Experimental|MySkin patch|Hydrogel and polyurethane film
10004126|NCT01573234|Active Comparator|Traditional Dressing|
10004127|NCT01573247|Experimental|AKN-028|
10004128|NCT01573286|Experimental|Intestinal Failure in children (>1 year)|Children requiring parenteral nutrition for >30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
10004129|NCT01573286|Experimental|GLP-2 in Infants (<1 year of age)|Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for >50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.
9480662|NCT05262166|Experimental|Intrathecal dexmedetomidine group:|Intrathecal dexmedetomidine plus heavy bupivacaine then general A
10004130|NCT01573299|Active Comparator|Early vertical positioning|
10004131|NCT01573299|Active Comparator|Progressively vertical positioning|
10004132|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.
10004133|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.
10004134|NCT01573338|Experimental|Arm 1|BAY1000394 will be administered in combination with chemotherapy (etoposide and cisplatin or carboplatin) for up to 6 cycles. BAY1000394 will continue beyond Cycle 6 of chemotherapy. Type of chemotherapy for each patient will be decided by the investigator case by case.
10004135|NCT01573377|Experimental|metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
10004136|NCT01573377|Experimental|Ethinylestradiol and Cyproterone Acetate|From the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill.
9480663|NCT05262153|No Intervention|Periodontally healthy|
9803249|NCT04381936|Active Comparator|Empagliflozin|First (main) randomisation part F
10004137|NCT01573403|Experimental|Treatment 1|one dose of DLBS2411 @250 mg
10004138|NCT01573403|Experimental|Treatment II|two doses of DLBS2411 @250 mg
10004139|NCT01573403|Placebo Comparator|Treatment III|
10004140|NCT01573416|Placebo Comparator|Control group|
10004141|NCT01573416|Active Comparator|Intervention group|
10004142|NCT01573468|Experimental|Capecitabine-tesetaxel|21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
10004143|NCT01573468|Active Comparator|Capecitabine-placebo|21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
10004144|NCT01573481|Active Comparator|Pressure support ventilation|"Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure support ventilation mode. The level of the pressure support is the same as the previous day.~During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased)."
10004145|NCT01573481|Active Comparator|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min). During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased).
10004146|NCT01573494|Experimental|Metastatic melanoma patients|Sampling of blood before and after chemotherapy
10004147|NCT01573507|Experimental|sodium lactate infusion|Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
10004148|NCT01573520|No Intervention|usual care|
10004149|NCT01573520|Active Comparator|adherence intervention arm|Monitoring drug adherence to guide treatment
10004150|NCT01573546|Experimental|Aerobic Exercise|
10004151|NCT01573546|Experimental|DASH diet|
10004152|NCT01573546|Experimental|Combined aerobic exercise and DASH diet|
10004153|NCT01573546|Active Comparator|Health education control|
10004154|NCT01573559||ClearView/Predicate|
10004155|NCT01573585|Active Comparator|Usual care|The usual care will consist of strength training, endurance, range of motion, patient education, weight shifting in standing and gait re-training.
10004156|NCT01573585|Experimental|FAST protocol|The Fast muscle activation and stepping training will be the Experimental arm of this trial. This program will be exercises emphasizing speed of movement.
10004157|NCT01573598|Placebo Comparator|Placebo|Dose-matched placebo capsules, oral administration
9803250|NCT04381936|Active Comparator|Sotrovimab|First (main) randomisation part J
9803251|NCT04381936|Active Comparator|Molnupiravir|First (main) randomisation part K
9803252|NCT04381936|Active Comparator|Paxlovid|First (main) randomisation part L
9803253|NCT04379999|Active Comparator|Atorvastatin|Atorvastatin (LIPITOR) 20 milligram tablet daily for 6 weeks
9803254|NCT04379999|Active Comparator|Atorvastatin and Aspirin|Atorvastatin (LIPITOR) 20 milligram tablet and Aspirin 325 mg tablet daily for 6 weeks
9803255|NCT04379076|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
9803256|NCT04379076|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
9803257|NCT04371471||Patient with COVID-19|Patient with clinical signs of CoV-2-SARS infection and signs of severity
9803258|NCT04369365|Active Comparator|Arm A: Azithromycin|weekly oral azithromycin 1500mg for a maximum of 8 weeks
9803259|NCT04369365|Placebo Comparator|Arm B: Placebo|weekly oral placebo for a maximum of 8 weeks
9803260|NCT04356183|Other|Counseling Health As Treatment (CHAT)|CHAT is a control arm designed to reflect traditional clinical counselling.
9803261|NCT04356183|Experimental|Supervised Weight loss and Exercise Training (SWET)|SWET includes supervised aerobic (3x/w) and resistance (2x/w) training plus a weekly weight loss session.
9803262|NCT04339933||BC|Patients who were diagnosed with bladder cancer
9803263|NCT04332887|Experimental|Multidimensional Exercise Program|Patients in this group will receive a 12 week exercise program including: (1) one 20-30 minute individual exercise consultation (teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls); (2) provided exercise booklet, exercise log, exercise video; (3) telephone follow-up once per week for 12 weeks.
9803264|NCT04332887|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
9803265|NCT04329221|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
9803266|NCT04329221|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
9803267|NCT04320498|Active Comparator|control group|The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)
9803268|NCT04320498|Experimental|PRP group|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
9803269|NCT04313231||MDS|"Female and male patients aged 18 years and older~MDS, MDS/MPN diagnosis based on current WHO classification. CCUS and CHIP defined by Valent (Valent, Oncotarget, 2018) and by Stauder (Stauder, Blood, 2018)"
9803270|NCT04313231||control|age-matched healthy persons
9803271|NCT04311268|Experimental|Observational|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
9803272|NCT04308590|Experimental|Relacorilant|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
9803273|NCT04308590|Placebo Comparator|Placebo|Placebo matched to study drug
9803274|NCT04297917|Experimental|Healthy Volunteers with low dose vaccination|5 Healthy Volunteers receiving low dose vaccination
9803275|NCT04297917|Experimental|Healthy Volunteers with high dose vaccination|5 Healthy Volunteers receiving high dose vaccination
9803276|NCT04297917|Experimental|Chronic Hepatitis B participants with low dose vaccination|6 participants with Chronic Hepatitis B infection receiving low dose vaccination
9803277|NCT04297917|Experimental|Chronic Hepatitis B participants with high dose vaccination|6 participants with Chronic Hepatitis B infection receiving high dose vaccination
9803278|NCT04297917|Experimental|Healthy Volunteers who have had COVID-19 AZD1222 vaccine|15 participants who have had 2 doses of COVID-19 AZD1222 vaccine
9803279|NCT04297917|Experimental|Healthy Volunteers who have had Pfizer/Moderna mRNA COVID 19 vaccine|15 participants who have had Pfizer/Moderna mRNA COVID 19 vaccine
9803280|NCT04291508|Active Comparator|IV Acetaminophen-Active|Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight < 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).
9803281|NCT04291508|Active Comparator|IV Vitamin C-Active|Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses)
9803282|NCT04291508|Placebo Comparator|Acetaminophen-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
9803283|NCT04291508|Placebo Comparator|Vitamin C-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
9803284|NCT04291391|Experimental|Lean-normoglycemic (control)|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
9803285|NCT04291391|Experimental|Obese - normoglycemic|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
9803286|NCT04291391|Experimental|obese-glucose intolerant|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
9803287|NCT04291391|Experimental|obese with type 2 diabetes|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
9944709|NCT01033513||Meals and MNT|The participants assigned to the MNT plus meals arm received both of the interventions, as described above.
9944710|NCT01033526|Placebo Comparator|Arm 2|
9944711|NCT01033526|Experimental|Arm 1|
9944712|NCT01033539|Active Comparator|Placebo control|Placebo control without probiotics ATCC PTA 4659
9944713|NCT01033539|Active Comparator|ATCC PTA 4659 Low dose|
9944714|NCT01033539|Active Comparator|ATCC PTA 4659 high dose|
9944715|NCT01033578|No Intervention|Control|Receive hepatectomy and thrombectomy alone, no postoperative adjuvant treatments
9944716|NCT01033578|Experimental|PVIC Group|Portal Vein Infusion Chemotherapy (PVIC): 5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) was continuously infused into portal vein through tube by a infusion pump implanted in operation. Treatment started 2 weeks after the operation and was repeated every 4 weeks for six cycles.
9944717|NCT01033578|Experimental|TACE Group|Transcatheter Arterial Chemoembolization (TACE): 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
9944718|NCT01033578|Experimental|PVIC+TACE Group|Combination of PVIC and TACE. PVIC started 2 weeks after operation and TACE started 6 weeks after operation. Both PVIC and TACE were repeated at 8 weeks intervals for 3 cycles.
10214771|NCT04496804|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an Internet website and one-on-one video chats with a behavioral coach. The Internet website involves content delivered through interactive video courses. The interactive video courses are based on elements of social cognitive theory. Each courses consists of an introduction, the primary content, and a take home message. The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic. A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention, discussion of website material, supportive accountability, and reporting of adverse events/injuries. The chats are conducted face-to-face through Skype. The chats occur 7 times during the first 2 months, 4 times during the second 2 months, and twice during the final 2 months of the intervention.
9944719|NCT01033591|Experimental|Exercise|Supervised exercise + Optimized treatment according to the European Society of Cardiology guidelines
9944720|NCT01033591|Other|Control|Optimized treatment according to the European Society of Cardiology guidelines
9944721|NCT01033604|Experimental|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
9944722|NCT01033604|Active Comparator|Split skin graft alone|Full thickness defects treated with split skin graft alone.
9944723|NCT01033617|Placebo Comparator|Placebo|Saline solution with autologous plasma.
9944724|NCT01033617|Experimental|CD133+ stem cells|Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
9944725|NCT01033630|Placebo Comparator|Placebo|Image-matched placebo of active treatment
9944726|NCT01033630|Active Comparator|D&G 1g|Randomly allocated into three groups, D&G capsule 1g/day
9944727|NCT01033630|Active Comparator|D&G 2g|Randomly allocated into three groups, D&G capsule 2g/day
9944728|NCT01033656|Experimental|Anakinra|experimental drug of study
9944729|NCT01033656|Active Comparator|comparator|comparators:methotrexate, azathioprine, leflunomide or supfasalazine
9944730|NCT01033669||Dry Powder Inhalers|
9944731|NCT01033708|Active Comparator|treatment as usual|Treatment as usual
10004158|NCT01573598|Experimental|Vilazodone 20mg|Vilazodone tablets, 20 mg per day, oral administration
10214772|NCT04496804|Sham Comparator|Wellness for MS (WellMS)|Provides an Internet website and one-on-one video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity. The materials are transformations of brochures provided by the National MS Society, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
10214773|NCT04487691|Experimental|Platelet Lysate|Inhaled nebulized platelet lysate (PL), 2-ml 1x per day for 8 weeks.
10214774|NCT04487691|Active Comparator|Saline|Inhaled nebulized normal sterile saline, 2-ml 1x per day for 8-weeks.
10214775|NCT04484701||PSMA-11 PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
10214776|NCT04479566|Experimental|lithium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
10214777|NCT04479566|Placebo Comparator|calcium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
10214778|NCT04459624|Active Comparator|ESP block|Intervention: Erector Spina Plane Block will administer with 20 ml of % 0.25 bupivacaine
10214779|NCT04459624|Active Comparator|QLB 2 block|Intervention: Quadratus Lumborum Block 2 will administer with 20 ml of % 0.25 bupivacaine
10214780|NCT04458272|Experimental|DS-1001b|
10214781|NCT04456413|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
10214782|NCT04456413|Active Comparator|Best Supportive Care|Patients will receive best supportive care. Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease.
10214783|NCT04441086|Experimental|eMotion|The eMotion intervention is based on feasibility testing of the successful in-person program with critical refinement to improve accessibility. eMotion has undergone subsequent content validity testing with intervention development, self-management, cardiovascular health, and health information technology delivery experts. eMotion teaches a carefully selected repertoire of emotion regulation strategies well suited for aging rural adults following a first cardiac event in tandem with usual cardiac rehabilitation. The intervention helps patients recognize their emotions, balance emotional and physical wellbeing, and implement emotion regulation strategies effectively. Intervention provided in addition to usual cardiac rehabilitation.
9944732|NCT01033708|Experimental|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
9944733|NCT01033760|Experimental|arm 1|darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir
9944734|NCT01033760|Active Comparator|arm 2|darunavir, ritonavir, emtricitabine/tenofovir
9944735|NCT01033799|Sham Comparator|Control Product|
9944736|NCT01033799|Active Comparator|Tested Product|
9944737|NCT01033812||Index Recruiter|Young African American or Latina women who served as index recruiters in ATN 067 and members of their female friendship network members who tested HIV positive based on HIV screening and a confirmatory test result that was conducted in ATN 067.
9944738|NCT01033812||Male Sexual Partners|Any male partner who engaged in at least one episode of oral, vaginal or anal sex during the course of their lifetime with an 084 index recruiter.
9944739|NCT01033838|Active Comparator|laparoscopic-assisted rectosigmoid resection|
9944740|NCT01033838|Experimental|laparoscopic rectosigmoid resection and transrectal retrieval|
9944741|NCT01033877|Experimental|TdaP vaccine|
9944742|NCT01033877|Active Comparator|Td vaccine|
9944743|NCT01033903|Experimental|Misoprostol 800 micrograms intravaginally|
9944744|NCT01033903|No Intervention|expectant managment|
9944745|NCT01033929|Experimental|0.01µg C-Tb|12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
9944746|NCT01033929|Experimental|0.1µg C.Tb|12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
9944747|NCT01033955|Experimental|Drug (Rosuvastatin) Crestor|The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is <18 years, or serum creatinine is greater than or equal to 248 μmol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.
9944748|NCT01033955|Placebo Comparator|Placebo|An identical appearing placebo will be administered to patients in the second study arm.
9944749|NCT01033981||Central America and Caribbean|Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad & Tobago
9944750|NCT01033994|Experimental|AS902330|
9944751|NCT01033994|Placebo Comparator|Placebo|
9944752|NCT01034007|Experimental|Tissue Engineered Vascular Grafts|
10004159|NCT01573598|Experimental|Vilazodone 40mg|Vilazodone tablets, 40 mg per day, oral administration
10214784|NCT04441086|Active Comparator|Healthy living active control|Healthy living strategies based on American Heart Association education. Intervention provided in addition to usual cardiac rehabilitation.
10214785|NCT04441086|No Intervention|Usual care|Usual cardiac rehabilitation with no additional intervention.
10214786|NCT04428307|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
10214787|NCT04428307|Experimental|Arm 2 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
10214788|NCT04428307|Experimental|Arm 3 (client-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
10214789|NCT04424004||MURDOCK Study Participants with valid email address|"Randomized for testing: 1.A randomly selected subset of individuals who consent to participate (N~300-500), will be invited to participate in COVID-19 polymerase chain reaction (PCR) viral testing by at-home collection and return of self-administered nasal swabs. Saliva specimens may replace the nasal swab specimen.~2. The same randomly selected subset of individuals who collect at-home samples for COVID-19 PCR testing (N~300-500), will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies."
10214790|NCT04412525|Experimental|27 gauge needle vitrectomy surgery|
10214791|NCT04412525|Experimental|larger than 27 gauge (23G or 25G) needle vitrectomy surgery|
10214792|NCT04404595|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Phase 1b will include two parts, dose escalation phase (Cohort A) followed by a dose expansion phase (Cohort B & C). Cohort C will evaluate the chosen dose in patients with advanced gastric cancer.
10214793|NCT04404166|Experimental|PINGS 2|
10214794|NCT04404166|No Intervention|Standard of Care|
10214795|NCT04394754|No Intervention|Control|Patients will receive usual care and no digital health device.
10214796|NCT04394754|Experimental|BodyPort|Patients will receive the BodyPort device.
10214797|NCT04394754|Experimental|Noom|Patients will receive a subscription to the Noom platform.
10214798|NCT04394754|Experimental|Conversa|Patients will receive a subscription to the Conversa platform.
10214799|NCT04393948|Experimental|No irradiation|
10214800|NCT04393948|Experimental|100 cGy single lung irradiation|100 cGy single lung radiation
10214801|NCT04393948|Experimental|100 cGy bilateral lung irradiation|100 cGy bilateral lung radiation
10214802|NCT04374877|Experimental|Part A Monotherapy Dose Escalation|The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as monotherapy in up to 42 patients with advanced solid tumors.
9944753|NCT01034046|Active Comparator|Insulin Sensitive Study Participants|Insulin sensitive subjects stratified using fasting insulin levels.
9944754|NCT01034046|Active Comparator|Insulin Resistant Study Subjects|Insulin resistant subjects stratified using fasting insulin levels.
9944755|NCT01034098||Post-menopausal women|Post-menopausal women (without hormone replacement therapy)
9944756|NCT01034124|Placebo Comparator|Water|
9944757|NCT01034124|Active Comparator|Cranberry juice|
9944758|NCT01034150|Active Comparator|Somatosensory stimulation|Active group
9944759|NCT01034150|Placebo Comparator|Control group|Placebo stimulation
9944760|NCT01034189|Experimental|Targeted therapy|Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy
9944761|NCT01034202|Experimental|Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083|
9944762|NCT01034202|Experimental|Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083|
9944763|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.02 mg/kg + placebo|
9944764|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.04 mg/kg + placebo|
9944765|NCT01034202|Experimental|NNC126-0083|
9944766|NCT01034202|Placebo Comparator|Placebo|
9944767|NCT01034215|Active Comparator|Imagery Practice, live trainer|Patients attend a five week training program, with the instructor in the room with them, and actively practice imagery techniques, both in the classroom, and daily, outside of the classroom. Classes are four hours a week for five weeks. Patients practice what they learn for a full 17 weeks, beginning with the first week of class.
9944768|NCT01034215|Active Comparator|"Envision the Rhythms of Life /video"|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD.
9944769|NCT01034215|No Intervention|Waitlist Control Group|No treatment delivery during the 17 weeks of testing live delivery (trainer in the room with patients) vs. distance delivery (trainer delivers program via telemedicine/videoconferencing equipment)
9944770|NCT01034228|Active Comparator|Isoleucine|Glucose ORS with L-Isoleucine
9944771|NCT01034228|Placebo Comparator|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
9944772|NCT01034241|Experimental|Control|Diet consists of 15% dairy protein and low Glycemic Index (GI < 40), 55 En% carbohydrates and 30 En% fat
9944773|NCT01034241|Experimental|High dairy protein|Diet consists of 25% dairy protein and low GI (GI < 40), 45 En% carbohydrates and 30 En% fat
9944774|NCT01034241|Experimental|vegetable protein|Diet consists of 15 En% vegetable protein and low GI (GI < 40), 55 En% carbohydrates and 30 En% fat
9944775|NCT01034241|Experimental|High GI|Diet consists of 15 En% dairy protein and high GI(GI > 60, 55 En% carbohydrates and 30 En% fat
9944776|NCT01034267|Experimental|1|(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
9944777|NCT01034293|Experimental|low feeding frequency (3x)|
9944778|NCT01034293|Experimental|High feeding frequency (14x)|
9944779|NCT01034319|Experimental|Diabetes Genetic Counseling|Subjects will have been genotyped and will received genetic counseling based on their results
9944780|NCT01034319|Placebo Comparator|No Genotyping or Counseling|Patients will not be genotyped and will therefore not receive genetic counseling
9944781|NCT01034332|Experimental|One-cycle induction chemotherapy|TP-HDFL, TP-CCRT, Esophagectomy
9944782|NCT01034345|Experimental|Sirolimus|Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.
9944783|NCT01034345|Active Comparator|Calcineurin inhibitor|Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.
9944784|NCT01034371|Experimental|One-stop hybrid revasularization|
9944785|NCT01034371|Active Comparator|Off-pump coronary artery bypass|
9944786|NCT01034410|Active Comparator|Control|cytarabine 2g/m2 bid Days 4-7
9944787|NCT01034410|Experimental|AS1411-40|AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7
9944788|NCT01034410|Experimental|AS1411-80|AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7
9944789|NCT01034423|Experimental|omega-3 high quality|
9944790|NCT01034423|Experimental|omega-3 low quality|
9944791|NCT01034423|Placebo Comparator|placebo|
9944792|NCT01034436|Placebo Comparator|Low intake of ALA and triacylglycerols|Sunflower oil
9944793|NCT01034436|Experimental|high intake of ALA and triacylglyceroles|Canola and linseed oils
9944794|NCT01034436|Experimental|high intake of ALA and diacylglycerols|Canola and linseed oils
9944795|NCT01034475|Experimental|CPI-613|CPI-240 mg/m2
9944796|NCT01034488|Active Comparator|Heparin sodium - APP|5000UI / mL
9944797|NCT01034488|Experimental|Heparin - Eurofarma|5000 UI/ mL
9944798|NCT01034501|Active Comparator|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
9944799|NCT01034501|Sham Comparator|sham procedure|Not activation of laser device
9944800|NCT01034514|Experimental|4DCT arm|Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.
9944801|NCT01034566|Experimental|Arm I|Patients undergo proton beam radiotherapy 5 days a week for 6 (preoperative patients) or 8 (post-operative patients) weeks in the absence of disease progression or unacceptable toxicity.
9944802|NCT01034605|Experimental|inulin|oligofructose
9944803|NCT01034618|Placebo Comparator|Placebo|
9944804|NCT01034618|Experimental|Intact protein|
9944805|NCT01034618|Experimental|Protein hydrolysate|
9944806|NCT01034644||PRISMS patients|This single group includes all the patients from the PRISMS study
9944807|NCT01034683|Experimental|Esophageal Carcinoma|
9944808|NCT01034722||Western Diet|Volunteer mothers with western diet.
9944809|NCT01034722||Vegetarians|volunteer mothers with vegetarians diet
9944810|NCT01034722||Bedouins|Volunteer mothers who are Bedouins
9944811|NCT01034735|Experimental|Arm A|
9944812|NCT01034735|Experimental|Arm B|
9944813|NCT01034735|Experimental|Arm C|
9944814|NCT01034748|Experimental|1|Single 45 mg oral dose of [14C]PF-00299804
9944815|NCT01034761|Experimental|Pop-up alerts|Providers will receive pop-up alerts in the electronic medical record when prescribing one of the specified medications from the Beers list.
9944816|NCT01034761|No Intervention|Usual care|
9944817|NCT01034774|Active Comparator|ACHN-490 Injection|ACHN-490 Injection will be given either 1 or 5 consecutive days at a dose of 15mg/kg.
9944818|NCT01034774|Placebo Comparator|Placebo is Normal Saline|Placebo will be given either 1 or 5 consecutive days to mask when ACHN-490 Injection is given.
9944819|NCT01034787|Experimental|Open Label CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity.
9944820|NCT01034813||Burn Range of motion|burn patients with hypertropic scar
9944821|NCT01034813||control range of motion|control subjects without scaring
10004160|NCT01573611|Experimental|Grape Powder|
10214803|NCT04374877|Experimental|Part B Indication-specific SRF388 Monotherapy Expansion|Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of SRF388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC, up to 40 patients with HCC, and up to 40 patients with NSCLC.
10214804|NCT04374877|Experimental|Part C SRF388 in Combination with Pembrolizumab|Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of SRF388 in combination with pembrolizumab in patients with advanced RCC or HCC.
10214805|NCT04356495|Sham Comparator|Vitamins|"Patients in this arm will receive a vitamin supplement (AZINC forme et vitalité®) during 10 days"
10214806|NCT04356495|Experimental|Telmisartan|Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days
10214807|NCT04356495|Experimental|Ciclesonide|Patients in this arm will receive ciclesonide (Alvesco® 160 µg ) during 10 days
10214808|NCT04356495|Experimental|interferon β-1b|Patients in this arm will receive interferon β-1b (Extavia® 9,6 MUI/300 µg ) during 5 days
10214809|NCT04355572|Experimental|Vitamin D Supplement|Patients will take vitamin D tablet with 4,000IU daily for 6 months.
10214810|NCT04355572|Placebo Comparator|Placebo|Patients will take placebo for 6 months
10214811|NCT04342546|Experimental|Toxicity test|"For all patients, the NovaGray RILA Breast® test will be performed within 15 days of surgery , 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, within 15 days of starting chemotherapy.~The test consists of a blood sample of 2x4 mL"
10214812|NCT04341376|Experimental|Enhanced First Connections|Enhanced First Connections is a short-term risk assessment and response home visiting referral program. The goal of Enhanced First Connections is to identify family needs and link families to community resources, including evidence based home visiting models. Enhanced First Connections includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation. Women who enroll in Enhanced First Connections are expected to receive between four and eight home visits before being referred to other community resources.
10214813|NCT04341376|No Intervention|Treatment as Usual|Women who receive Treatment as Usual will follow the usual course of clinical care throughout their pregnancy and into the postpartum period, and will be eligible for the typical array of community services that may be offered to them.
10214814|NCT04333290|Experimental|Single Arm: Healthy subjects|The PET radiotracer Myeliviz ([11C]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time. This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution.
10214815|NCT04313478||Low Birth Weight Infants|They were as follows: being at 3 to 9 months' corrected age, gestational age of less than 36 weeks + 6 days, birth weight of 2000 g or less. Infants with any genetic, metabolic, orthopedic congenital abnormalities or chronic diseases and parents' rejection to participate in the study were excluded.
9944822|NCT01034826||life style modification|everyone in this study was advised about their life style, diet, exercise habits.
9944823|NCT01034839||acute myeloid leukemia, adults|Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
9944824|NCT01034852||Surgical ablation|Patients undergoing surgical ablation for Atrial Fibrillation that have failed one or more previous attempts at catheter ablation for Atrial Fibrillation
9801193|NCT01709227|Experimental|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
9803288|NCT04290975|Experimental|Task-shifted arm|In the task-shifted arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a CHW, with a physician consult available to the CHW as needed.
9803289|NCT04290975|Active Comparator|Enhanced usual care arm|In the enhanced usual care arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a physician, with a CHW collecting standardized data to mirror that of the intervention arm.
9803290|NCT04290403|Experimental|Pull ups|Pull-up continence products
9803291|NCT04290403|Experimental|Styled briefs with tapes|Styled briefs with tapes
9803292|NCT04288453|Experimental|Community-based activity program|Engagement in 8-week community-based activity program
9803293|NCT04280354||patients with severe community acquired pneumonia (cases)|Cases: Patients with severe community acquired pneumonia with required ICU admission.
9803294|NCT04280354||patients without pneumonia or sepsis (controls)|Controls: Clinical phenotype of inflammation not due to suspected sepsis; patients with fever >38°C, C reactive Protein (CRP) >100mg/L, no infection focus expected in ≥ 24h.
9803295|NCT04278794|Experimental|Transitional Care Stroke Intervention (TCSI)|Participants randomly assigned to the intervention group will be offered the intervention in addition to usual care provided by in-patient and outpatient stroke rehabilitation services. The TCSI is a 6-month stroke transitional care intervention, provided in addition to usual stroke care, that includes four core components: comprehensive hospital discharge plan, structured home visits and telephone support, monthly intraprofessional case conferences, and linkages to primary care and other healthcare and community services. The TCSI will be delivered by an interprofessional team of care providers at the study site, including an occupational therapist, registered nurse, speech language pathologist, physical therapist, and social worker from a hospital-based outpatient stroke rehabilitation setting.
9803296|NCT04278794|No Intervention|Control|Usual care provided by in-patient and out-patient stroke rehabilitation services.
9803297|NCT04278768|Experimental|Emavusertib (CA-4948) dose escalation|Patients receive emavusertib monotherapy PO BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9803298|NCT04278768|Experimental|Emavusertib dose escalation + Azacitidine|The starting dose level for emavusertib will be 200 mg BID for 21 days (Days 1-21) of a 28-day Cycle. Anticipated emavusertib doses will be 200, 300, 400 mg BID. Azacitidine 75 mg/m2 intravenous (IV) or subcutaneously (SC) will be administered as 7 doses on a 28-day Cycle (e.g., 7 consecutive doses or split doses with weekend break 5-2, starting at Day 1)
9803299|NCT04278768|Experimental|Emavusertib dose escalation + Venetoclax|The starting dose level for emavusertib will be 200 mg BID for 21 days of a 28-day Cycle. Anticipated emavusertib doses will 200, 300, 400 mg BID. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
9803300|NCT04278768|Experimental|Emavusertib monotherapy dose expansion|The Expansion phase will begin once the RP2D from Phase 1 Dose Escalation phase has been identified. There will be 4 Cohorts and patients will be assigned to each Cohort based on baseline disease.
9803301|NCT04272047|Experimental|Knee Control+|Knee Control+ consists of 6 different exercises, with 10 different variations/progressions, and takes 10-15 minutes to complete. In addition, teams are instructed to perform a 5-minute running warm-up before the Knee Control+ exercises. Teams are to carry out the running warm-up and Knee Control+ at all training sessions, and the running warm-up before all matches, during the whole season. Knee Control+ is based on the Knee Control program but with more variations for each exercise making it easier to tailor for the needs in the respective teams.
9803302|NCT04272047|Experimental|Adductor strengthening program|The Adductor strengthening program consists of a single exercise with three levels of difficulty. The exercise is based on the Copenhagen Adduction exercise. Teams are to carry out the Adductor strengthening program as part of their regular warm-up 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
9803303|NCT04272047|Active Comparator|Knee Control|Teams will carry on their normal training and warm-up routines using the Knee Control program with no intervention from the researchers. Knee Control consists of 6 different exercises, with 4 different variations/progressions and 1 pair-exercise.
9944825|NCT01034865||HCC PTS|Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
9944826|NCT01034865||LD|Patients with chronic liver disease without evidence of HCC
9944827|NCT01034878|Experimental|Sunitinib|50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
9944828|NCT01034904||Patients|Patients who have moderate or severe Hemophilia A, living in Canada and who are using Helixate FS either on-demand or prophylaxis
9944829|NCT01034917|Experimental|Etravirine group|To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
9944830|NCT01034917|Active Comparator|Control group|Continue with the same antiretroviral regimen
9944831|NCT01034930|Active Comparator|Retentive Anchors|23 patients will receive as retention system for overdentures Retentive Anchors (Straumann).
9944832|NCT01034930|Active Comparator|Magnets|23 patients will receive Magnets (Straumann) as retention system for overdenture.
9944833|NCT01034930|Active Comparator|Locator System|23 patients will receive Locator System (Straumann) as retention for the mandibular overdenture.
9944834|NCT01034943|Active Comparator|External fixation|Operation with external fixation and optional addition of k-wire
9944835|NCT01034943|Active Comparator|Volar plate|Operation with Synthes volar two column plate (TCP)
9944836|NCT01034956||Facial Soft Tissue Filler Patients|Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years
9944837|NCT01034969||Participants with hereditary angioedema (HAE)|All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor [human]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.
9944838|NCT01034982|Experimental|1|tosylate salt tablet
9944839|NCT01034982|Experimental|2|free suspension
9944840|NCT01034982|Experimental|3|tosylate salt tablet
9944841|NCT01034982|Experimental|4|free suspension
9944842|NCT01034995|Experimental|SSR125543 20 mg|1 capsule of SSR125543 20 mg + 1 capsule of placebo
9944843|NCT01034995|Experimental|SSR125543 50 mg|1 capsule of SSR125543 50 mg + 1 capsule of placebo
9944844|NCT01034995|Experimental|SSR125543 100 mg|2 capsules of SSR125543 50 mg
9944845|NCT01034995|Active Comparator|escitalopram 10 mg|1 capsule of escitalopram 10 mg + 1 capsule of placebo
9944846|NCT01034995|Placebo Comparator|placebo|2 capsules of placebo
9944847|NCT01035008|Experimental|Diagnostic|The investigators are testing a new method called confocal laser endomicroscopy to see if it can detect pre-cancerous abnormalities in the lining of the cysts found in your pancreas. This will involve using a very thin fiber-shaped microscope which will be passed through a needle during the EUS procedure.
9944848|NCT01035021|Active Comparator|group N|Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
9944849|NCT01035021|Active Comparator|group R|Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
9944850|NCT01035034|Experimental|One-stop hybrid coronary revasularization|Percutaneous Coronary Intervention; Coronary Artery Bypass
9944851|NCT01035034|Active Comparator|PCI with stenting|Percutaneous Coronary Intervention
9944852|NCT01035086|Experimental|Boregine|Intervention: Lupinus angustifolius Boregine; 25 g lupin kernel fibre per day over 4 weeks; lupin kernel fibre was incorporated in different food
10004161|NCT01573611|Placebo Comparator|Placebo Powder|
9944853|NCT01035086|Active Comparator|Reference|Intervention: Reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood ingredients); 25 g citrus fibre per day over 4 weeks; the citrus fibre was incorporated in different food
9944854|NCT01035086|Placebo Comparator|Placebo|different food without added fibre
9944855|NCT01035125|No Intervention|Waiting list|
9944856|NCT01035125|Experimental|Self-management program|One week self-management program
9944857|NCT01035164|Experimental|Arm 1|
9944858|NCT01035164|Experimental|Arm 2|
9944859|NCT01035164|Experimental|Arm 3|
9944860|NCT01035177||Control|Women without hip fracture, matched on age to the cases
9944861|NCT01035177||Patient|Female patients aged 60 and older with hip fracture
10004162|NCT01573637|Experimental|Raloxifene hydrochloride 60 mg|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
10035183|NCT01803685||Stereotaxic radiosurgery|Deliver a relatively high dose of focused radiation precisely to the arteriovenous malformations.
10035184|NCT01803685||Endovascular treatment|Deliver embolic materials to the feeding arteries or the nidus by microcatheters
9944862|NCT01035190|Experimental|inhaled Budesonide|
9944863|NCT01035203|Active Comparator|Cognitive behavioural therapy|
9944864|NCT01035203|Experimental|Exercise|Endurance training (walking on a treadmill) 3 x weekly for 4 weeks
9944865|NCT01035216|Experimental|GNKG168|The starting dose will be 0.25 mg/kg. If the dose is tolerable, subsequent cohorts will be enrolled and treated with 0.5, 0.75, 1.0 and 1.5 mg/kg. If 0.25 mg/kg proves to be intolerable, the dose will be reduced to 0.15 mg/kg.
9944866|NCT01035242|Experimental|"association splitting"|Association splitting (6 sessions) delivered by psychologists.
9944867|NCT01035242|Active Comparator|cognitive remediation|CogPack training(6 sessions) delivered by either psychologists or psychology students at an advanced master level.
9944868|NCT01035268|Experimental|surgery by fatty tissue transfer|
9944869|NCT01035268|No Intervention|simple supervision|
9944870|NCT01035281|Experimental|Nabilone|A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
9944871|NCT01035281|Placebo Comparator|Placebo|All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion.
9944872|NCT01035294|Experimental|mindfulness based intervention|
9944873|NCT01035294|Active Comparator|usual care (UC)|
10214816|NCT04313478||Normal Weight Infants|They were as follows: being between 3 and 9 months of age, being full-term, had no complications during delivery. Infants that presented any type of sensory or motor disorder were excluded.
10214817|NCT04309981|Experimental|ARI0002h|Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory region and signal-transduction CD3z that has been humanized
10214818|NCT04303507|Experimental|Chloroquine or Hydroxychloroquine|"In Asia, the participant will receive chloroquine.~In Europe, the participant will receive hydroxychloroquine~Specific drug allocation will be determined by country prior to activation based upon factors such as inventory availability and importation requirements"
10214819|NCT04303507|Placebo Comparator|Placebo|
10214820|NCT04300816|Experimental|CBT-UT|Seven telephone-based sessions of cognitive behavioral therapy for uncertainty tolerance (CBT-UT) delivered over seven weeks.
10214821|NCT04300816|Active Comparator|tCBT|Seven telephone-based sessions of traditional cognitive behavioral therapy (tCBT) delivered over seven weeks.
10214822|NCT04300816|No Intervention|TAU|Participant continues with their lives as they normally would.
9944874|NCT01035307||Genomic and Proteomic Profiling|
9944875|NCT01035320|Experimental|simvastatin + ezetimibe|Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.
9944876|NCT01035359|Active Comparator|external fixation|Operation with external fixation and optional addition of k-wire
9944877|NCT01035359|Experimental|Volar plate|Operation with a Synthes volar two column plate (TCP)
9944878|NCT01035372|Experimental|dried plum|subjects will have 25% by weight (~ 600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder
9944879|NCT01035385|Experimental|FOFLOX4,resectable liver metastasis from CRC|
9944880|NCT01035411|Experimental|1|AZD9668 2X30mg tablet
9944881|NCT01035437|Experimental|HPPH|HPPH
9801194|NCT01709227|Experimental|Peritoneal dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management will be directed by CICU attending and Nephrology service
9801195|NCT01709305|Active Comparator|Metformin + Sitagliptin + Glimepiride|During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
9801196|NCT01709305|Experimental|Metformin + Sitagliptin + Repaglinide|During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
9801197|NCT01709305|Experimental|Metformin + Sitagliptin + Acarbose|During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
9801198|NCT01709305|Experimental|Metformin + Sitagliptin + Gliclazide|During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
9801199|NCT01709383|Active Comparator|Transcranial Direct Current Stimulation|TDCS was applied bilaterally, with the anodal electrode on the left temple and cathodal electrode on the right. TDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period
9801200|NCT01709383|Sham Comparator|Sham Stimulation|Sham tDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
9801201|NCT01709409|Experimental|Curosurf (Group 1)|Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
9801202|NCT01709409|Active Comparator|BLES (Group 2)|Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
9801203|NCT01709422|Active Comparator|Propofol|both midazolam (1mg if aged <= 70 years or 0.5mg in age >70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.
9944882|NCT01035450|Experimental|Everolimus-eluting stent|
9944883|NCT01035450|Active Comparator|Sirolimus-eluting stent|
9944884|NCT01035476|Experimental|Data Card Report|Patients receive detailed reports of acceptance and adherence, with linked recommendations to optimize NIPPV.
9944885|NCT01035476|No Intervention|Standard NIPPV Care|Patients receive routine monitoring and care related to NIPPV.
9944886|NCT01035489|Active Comparator|CRT; RV apical lead placement|Right ventricular apical lead placement in CRT
9944887|NCT01035489|Active Comparator|CRT; RV high posterior septum|High posterior septal lead placement in CRT
9944888|NCT01035515|Experimental|Arm One|Arm 1 of 6 cross-over arms
9944889|NCT01035515|Experimental|Arm Two|Arm 2 of 6 cross-over arms
9944890|NCT01035515|Experimental|Arm Three|Arm 3 of 6 cross-over arms
9944891|NCT01035515|Experimental|Arm Four|Arm 4 of 6 cross-over arms
9944892|NCT01035515|Experimental|Arm Five|Arm 5 of 6 cross-over arms
9944893|NCT01035515|Experimental|Arm Six|Arm 1 of 6 cross-over arms
9944894|NCT01035528|Active Comparator|insulin glargine|antidiabetic treatment with Lantus o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
9944895|NCT01035528|Active Comparator|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
9944896|NCT01035541||P group|Fluid Management according to measurements with PiCCO®
9944897|NCT01035541||C group|Conventional fluid management
9944898|NCT01035554|Active Comparator|Usual Care (UC) + Printed Materials (PM)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
9944899|NCT01035554|Experimental|UC + Self-Paced Program Instruction (SPPI)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
9944900|NCT01035554|Experimental|Home Blood Pressure Monitor (HBPM) + PM|If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) regarding hypertension education and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
9944901|NCT01035554|Experimental|HBPM + SPPI|"If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them.~If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the PM from the National Institutes of Health."
9944902|NCT01035567|Active Comparator|Hybrid revascularization|
9944903|NCT01035567|Active Comparator|Coronary Artery Bypass Grafting|
9944904|NCT01035580|Experimental|curcurim|This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.
9480664|NCT05262153|Active Comparator|Periodontitis III-C|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
9944905|NCT01035593|Active Comparator|Standard of Care (PP + IVIG)|Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
9944906|NCT01035593|Experimental|PP + IVIG + rhC1INH|Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).
9944907|NCT01035619|Experimental|Moxidectin|
9944908|NCT01035645|Experimental|GSK1070806 or placebo|This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
9944909|NCT01035671|Experimental|Low Dose|A0001 (0.5 g BID)
9944910|NCT01035671|Experimental|High Dose|A0001 (0.75 g BID)
9944911|NCT01035671|Placebo Comparator|Placebo|Placebo
9944912|NCT01035775|Experimental|Insertion|Inspection on colonoscope insertion in addition to inspection during withdrawal from the cecum.
9944913|NCT01035775|Active Comparator|Withdrawal|Inspection during withdrawal (usual care) without deliberate inspection during insertion.
9944914|NCT01035801|Experimental|IN105|Prandial Oral Insulin
9944915|NCT01035801|Active Comparator|Insulin Lispro Injection|
9944916|NCT01035983|Experimental|Frovatriptan 2.5 mg|Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.
9944917|NCT01036035|Active Comparator|Treatment B|Study drug
9944918|NCT01036035|Active Comparator|Treatment D|Study drug
9944919|NCT01036035|Placebo Comparator|Treatment E|Placebo
9944920|NCT01036035|Active Comparator|Treatment A|Study Drug
9944921|NCT01036035|Active Comparator|Treatment C|Study Drug
9944922|NCT01036048||cabg disease|pts with saphenous vein graft disease
9944923|NCT01036061|Experimental|GSK618334 low Dose|GSK618334 Low Dose
9944924|NCT01036061|Experimental|GSK618334 Medium Dose|GSK618334 medium dose arm
9944925|NCT01036061|Experimental|GSK618334 High Dose|GSK618334 High Dose Arm
9944926|NCT01036061|Experimental|GSK618334 Placebo|Placebo for all 3 dose levels
9944927|NCT01036087|Experimental|PNC + FEC|"PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and~FEC = 5-fluorouracil, epirubicin, and cyclophosphamide"
9944928|NCT01036139|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
9944929|NCT01036139|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
9944930|NCT01036243|Experimental|Test formula 1|Hydrolyzed formula with probiotics
9944931|NCT01036243|Active Comparator|test formula 2|acidified hydrolyzed formula.
9944932|NCT01036243|Active Comparator|Test formula 3|hydrolyzed formula without probiotics
9944933|NCT01036243|Active Comparator|reference product|standard infant formula
9944934|NCT01036282|Experimental|Computerized Cognitive Remediation|Two arms: 1. Computerized Cognitive Remediation treatment using COGPACK. and 2. PositScience. Each arm is further randomized to either MindReader or no Mindreader.(Social Cognition Training).
9944935|NCT01036282|Experimental|CRT + Social Cognition Training|Two 45-minute sessions of Computerized Cognitive Remediation using COGPACK, one 45-minute discussion session, plus one 45 minute Mind Reader Interactive Guide to Emotions per week for 12 weeks. compared to two 45-minute sessions of PositScience, plus one 45-min Discussion session plus one minute of Mind Reader, Interactive Guide to Emotions
9944936|NCT01036308|Experimental|TypTop|Lupinus albus Typ Top (lupin kernel fibre, dietary fibre content: 83%)
9944937|NCT01036308|Experimental|Soy fibre|Glycine max Hefeng (soy fibre; dietary fibre content: 77%)
9944938|NCT01036308|Experimental|Boregine|Lupinus angustifolius Boregine (lupin kernel fibre, dietary fibre content: 87%)
9476296|NCT03573167|Experimental|Mobile MI|Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
9476297|NCT03573167|No Intervention|Waitlist Control|After consenting to participate in the study, the Waitlist control participants receive no intervention for one (1) month, and then the Waitlist control participants are contacted by the investigators for follow up..
9476298|NCT03573141||Knee OA patients receiving Physical Therapy|Only 1 group was included in this study. Subject's physical activity and sleep quality were assessed at baseline, prior to treatment. Follow up data was collected immediately after a course of physical therapy then again 8 weeks later.
9476299|NCT03573128|Experimental|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
9476300|NCT03573128|Active Comparator|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
9476301|NCT03573102|Active Comparator|control|ACE inhibitor , aspirin , statins will be given once daily
9476302|NCT03573102|Experimental|cases|SGLT2 inhibitors will be given with classic antiproteinuric drugs
9476303|NCT03573076|Experimental|Thulium laser + photodynamic therapy|Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
9476304|NCT03573076|Experimental|RF microneedles + photodynamic therapy|Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
9476305|NCT03573076|Active Comparator|Non-ablative Thulium laser|Non-ablative Thulium laser (NAFL) single treatment
9476306|NCT03573076|Active Comparator|RF microneedles|Radio-frequency microneedles (RF-MN) single treatment
9476307|NCT03573076|No Intervention|Control|Control receiving no intervention
9476308|NCT03573063|Other|Androgen metabolism after starvation|Metabolism changes after 48 hours starvation in healthy women
9476309|NCT03573050|Experimental|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
9476310|NCT03573050|Active Comparator|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
9476311|NCT03573037|Experimental|1-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 1 month after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation.
9476312|NCT03573037|Active Comparator|2-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 2 months after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation
9480665|NCT05262153|Active Comparator|Periodontitis III-C Smoking|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
9944939|NCT01036360||physical activity|
9944940|NCT01036399|Experimental|Revlimid|"Oral Revlimid is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~After this induction phase, the CR, PR and SD will continue Revlimid with the same schedule for other 8 months."
9944941|NCT01036412|Experimental|Chlorhexidine Gel Therapy|Following 2 x 5-minute applications of 2.5 ml in clinic, 2 x 5.0 ml syringes of 1% chlorhexidine gluconate gel, self-administered for a 5-minute application Week 2 & Week 4
9944942|NCT01036633||Control Group no mucositis|Control patients with multiple myeloma who are not currently receiving chemotherapy and who do not suffer from oral mucositis
9944943|NCT01036633||Non-control Group Mucositis|Patients with multiple myeloma suffering from WHO Grade 3/4 Oral Mucositis
9944944|NCT01036646||BSTE-0125-Original Protocol|
9944945|NCT01036646||BSTE-0125.a-Amended Protocol|
9944946|NCT01036659|Active Comparator|Ecallantide in conjunction with Conventional Therapy|
9944947|NCT01036659|Placebo Comparator|Conventional therapy and placebo|
9944948|NCT01036659|No Intervention|Historical Evaluation|
9944949|NCT01036841|Active Comparator|desmopressin tablet|
9944950|NCT01036841|Experimental|desmopressin MELT-formulation|
9944951|NCT01036854|Experimental|Regime 1|Regime 1 will be orally administered once daily in the morning over 6 consecutive days.
9944952|NCT01036854|Active Comparator|Regime 2|Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days
9944953|NCT01036854|Active Comparator|Regime 3|Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.
9944954|NCT01036854|Experimental|Regime 4|Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 & 5- two placebo capsules on each day; Day 6- a single does will be given.
9944955|NCT01036893|No Intervention|oral contraceptives without prucalopride|
9944956|NCT01036893|Active Comparator|oral contraceptives with prucalopride|prucalopride
9944957|NCT01036932|Active Comparator|G-CSF group|Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.
9944958|NCT01036932|Placebo Comparator|Placebo|After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy
9944959|NCT01037023||Patients administrated Topotecan|There is only one group. This group includes patients administrated Topotecan
9944960|NCT01037049|No Intervention|Group 1|Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy
9801204|NCT01709422|Active Comparator|Conventional|both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.
9944961|NCT01037049|Experimental|Group 2|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
9944962|NCT01037101|Active Comparator|IVET+DCS|
9944963|NCT01037101|Experimental|VRET+DCS|
9480666|NCT05262127|Active Comparator|Flash Version of EMDR|Flash methods (e.g. positive engaging focus) are used in addition to the standard EMDR techniques conveyed by video viewed online
9944964|NCT01037101|Experimental|VRET+Placebo|
9944965|NCT01037101|Active Comparator|IVET+Placebo|
9944966|NCT01037101|No Intervention|Wait-List|3 weeks Wait-List
9944967|NCT01037140|Active Comparator|cholecalciferol|
9801205|NCT01709474|Experimental|Vitamin D3 6000 IU|6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
9801206|NCT01709474|Active Comparator|Vitamin D3 400 IU|400 IU/day of vitamin D3 by mouth daily.
9801207|NCT01709500|Experimental|Alirocumab 75 mg/up to 150 mg|Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
9801208|NCT01709500|Placebo Comparator|Placebo|Placebo matched to alirocumab SC injection for 78-week treatment duration.
9801209|NCT01709513|Other|Atorvastatin (statin rechallenge arm)|Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
9801210|NCT01709513|Active Comparator|Ezetimibe|Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
9801211|NCT01709513|Experimental|Alirocumab 75 mg/ up to 150 mg|Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
9944968|NCT01037140|Placebo Comparator|placebo|
9944969|NCT01037205|Active Comparator|DAS181 High Dose|DAS181 Dry Powder 10 mg qd x 3 days
9944970|NCT01037205|Active Comparator|DAS181 Low Dose|DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
9944971|NCT01037205|Placebo Comparator|Lactose Placebo|Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
9944972|NCT01037283|Other|Interpersonal and Social Rhythm Therapy|All participants receive eight sessions of Interpersonal and Social Rhythm Therapy.
9944973|NCT01037296|Other|manual ablation|
9944974|NCT01037296|Experimental|robotic ablation|
9944975|NCT01037322|Active Comparator|cannabidiol in drops|cannabidiol given in drops of olive oil sub lingual 5 mg twice daily
9944976|NCT01037322|Placebo Comparator|placebo in drops|olive oil given in drops sub lingual
9944977|NCT01037335|Placebo Comparator|control group|10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly.
9944978|NCT01037335|Active Comparator|intramuscular morphine|10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly
9944979|NCT01037335|Active Comparator|donor site morphine|5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
10004163|NCT01573637|Placebo Comparator|Lactosa (placebo)|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
10004164|NCT01573663|Experimental|Ambroxol and Levodropropizine|
10004165|NCT01573663|Active Comparator|Ambroxol|
10004166|NCT01573663|Active Comparator|Levodropropizine|
9944980|NCT01037348|Experimental|ranibizumab 0.5mg|
9480667|NCT05262127|Active Comparator|EMDR - alone|Use of standard EMDR techniques conveyed by video online
9944981|NCT01037374|Experimental|Difficult Airway Assessment Form|
9944982|NCT01037387|Active Comparator|Control|Conventional treatment for COPD
9944983|NCT01037387|Experimental|NIMV group|NIMV: Conventional treatment plus noninvasive mechanical ventilation
10004167|NCT01573676||Bariatric surgery patients|Candidates for bariatric surgery.
10004168|NCT01573715|Active Comparator|severe ARDS patients|
10004169|NCT01573715|Active Comparator|control group|
9944984|NCT01037400||Total Knee Replacement Patients|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee replacement surgery with no musculoskeletal injury requiring medical attention in the past 3 months or producing pain in the previous 2 weeks and no inflammatory disease other than osteoarthritis.
9944985|NCT01037426|Other|Study group|Falls before versus after pacemaker implant
9944986|NCT01037439|Active Comparator|Conventional ASV|Current adaptive servoventilation therapy algorithm for non invasive ventilation treatment of Cheyne-Stokes Respiration.
9944987|NCT01037439|Experimental|Modified ASV|Modified adaptive servoventilation algorithm for improved treatment of nocturnal breathing disorders
9944988|NCT01037465|Active Comparator|N-acetylcysteine|N-acetylcysteine
9944989|NCT01037465|Placebo Comparator|Placebo|Placebo
9944990|NCT01037478|Experimental|Resminostat (4SC-201)|oral administration
9944991|NCT01037491|Active Comparator|aspirin|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
9944992|NCT01037491|Active Comparator|clopidogrel|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
9944993|NCT01037504|Experimental|A|Drug: AZD5423
9944994|NCT01037504|Placebo Comparator|B|Drug: Placebo
9944995|NCT01037517|Active Comparator|Successful Mobilizers|Successful Mobilizers are defined as having a peripheral blood CD34 > 10X106/L.
9944996|NCT01037517|Experimental|Poor Mobilizers|Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood [CD34] ≤ 10 X106/L
9944997|NCT01037530|Experimental|Ramipril|
9944998|NCT01037543|Experimental|Cohort 1|1.1 mcg/kg of HM10460A, placebo, or Neulasta
9944999|NCT01037543|Experimental|Cohort 2|3.3 mcg/kg HM10460A, placebo or Neulasta
9945000|NCT01037543|Experimental|Cohort 3|10 mcg/kg of HM10460A, placebo, or Neulasta
9945001|NCT01037543|Experimental|Cohort 4|30 mcg/kg of HM10460A, placebo, or Neulasta
9945002|NCT01037543|Experimental|Cohort 5|90 mcg/kg or HM10460A, placebo, or Neulasta
9945003|NCT01037543|Experimental|Cohort 6|270 mcg/kg of HM10460A, placebo, or Neulasta
9945004|NCT01037556|Experimental|Arm 1: PR104|
9945005|NCT01037582|Experimental|Trial part 1|
9945006|NCT01037582|Experimental|Trial part 2|
9945007|NCT01037595|Experimental|turmeric|turmeric 500 mg tid orally for 8 weeks
9476313|NCT03573011|Experimental|2.0 ± 0.2 MBq/kg [18F]PSMA-11 dosing group|"To define the optimal [18F]PSMA-11 scan protocol, the quality of the PET images from patients that received 2.0 ± 0.2 MBq/kg will be compared to the images from patients that received 4.0 ± 0.4 MBq/kg.~Patients in this study arm will receive 2.0 ± 0.2 MBq/kg for acquiring the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm.~As for the use of radiopharmaceuticals, the ALARA ('as low as reasonably achievable') principle must be applied, this study arm is considered to be the reference."
9476314|NCT03573011|Experimental|4.0 ± 0.4 MBq/kg [18F]PSMA-11 dosing group|Concerning the dose of [18F]PSMA-11, the patients in this study arm will receive 4.0 ± 0.4 MBq/kg for the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm
9476315|NCT03572998|Other|Breast cancer patients|study subject
9476316|NCT03572985|Other|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
9476317|NCT03572985|Other|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
9476318|NCT03572985|Other|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
9476319|NCT03572985|Other|BAC level 0 %|Drink beverages containing non alcohol
9476320|NCT03572959|Active Comparator|comparison group (active control)|0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application. Patients used the medication for 4 weeks , and if extension of treatment was required after that period , patients were instructed to apply miconazole oral gel (JANSSEN-CILAG Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Australia) four times a day for one week to protect from superimposed fungal infections.15
9476321|NCT03572959|Experimental|experimental group|"OLP lesions were irradiated with a 970-nm diode laser (SIRO Laser Advance class III b, SIRONA, Germany) with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly for two months until the resolution of signs for a maximum of ten sessions.11 After each session, patients were advised to have a cold diet and use chlorhexidine oral gel postoperatively twice a day to the lesion for one week."
9476322|NCT03572946|Experimental|target biopsy group|Targeted prostate biopsy
9476323|NCT03572946|Active Comparator|standard biopsy group|Standard prostate biopsy
9476324|NCT03572933|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
9476325|NCT03572933|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
9476326|NCT03572920||Patients with hip/knee arthroplasty.|RAR description by actgraphy Objective sleep evaluation by actigraphy. Subjective sleep quality with sleep diary Pittsburgh Sleep Quality Index (PSQI).
9476327|NCT03572881|Experimental|Asymptomatic|
9476328|NCT03572881|Experimental|Symptomatic|
9476329|NCT03572855|Experimental|Scoliosis Brace|The Peak Scoliosis Brace designed to alleviate pain in adult patients with chronic pain secondary to scoliosis.
9476330|NCT03572842|Other|quantiferon monitor|Test measuring interferon gamma production after T cells and Natural Killers (NK) in vitro stimulation : QuantiFERON Monitor® (QFM)
9476331|NCT03572829|Experimental|Aprepitant|Aprepitant combined with ondansetron and dexamethasone
9476332|NCT03572816|No Intervention|Current standard|"mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
9476333|NCT03572816|Experimental|Intervention|"mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
9476334|NCT03572803|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized using Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds"
9476335|NCT03572803|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized simulating Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds and 3mA each one."
9476336|NCT03572803|Sham Comparator|Control Group|They will receive a treatment of punction sham, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
9476337|NCT03572790|Experimental|Prucalopride|
9476338|NCT03572790|Placebo Comparator|Placebo|
9476339|NCT03572777|Active Comparator|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
9945008|NCT01037595|Placebo Comparator|plasebo|placebo tid orally for 8 weeks
9945009|NCT01037634|Experimental|Oseltamivir|Participants will receive Oseltamivir to treat influenza.
9945010|NCT01037647||Type 2 diabetic men|Men with type 2 diabetes
9945011|NCT01037647||Healthy men|Healthy men
9945012|NCT01037660|Experimental|Metformin|Metformin
9945013|NCT01037673|Experimental|PT progressive exercises|A progressive program of movement and strength exercises for the rotator cuff and scapular muscles combined with mobilisation of the joint capsule when needed
9945014|NCT01037673|Active Comparator|Movement exercises neck and shoulder|General movements for the neck and shoulder,
9945015|NCT01037686|Other|PD, DBS, healthy controls|Patients with idiopathic PD before or after DBS surgery (during on or off-stimulation) and healthy controls.
9945016|NCT01037699|Active Comparator|FSH YOUNGER|
9945017|NCT01037699|Active Comparator|FSH OLDER|
9945018|NCT01037699|Experimental|FSH LH YOUNGER (Recombinant Luteotrophin alfa)|
9945019|NCT01037699|Experimental|FSH LH OLDER|
10004170|NCT01573715|Experimental|moderate SDRA patients|
10004171|NCT01573728|Active Comparator|Low Exercise Arm|Low dose exercise (50 Minutes)
10004172|NCT01573728|Experimental|Public Health Exercise|Public Health dose exercise (150 minutes)
10004173|NCT01573741|Experimental|ketamine,four hours monitoring hydrochloride injection|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
10004174|NCT01573754|Experimental|Hydroxychloroquine|Low-dose hydroxychloroquine 100 mg by mouth twice weekly
10004175|NCT01573754|Active Comparator|Phlebotomy|Phlebotomy 450 mL biweekly
10004176|NCT01573780|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and smac mimetic TL32711 IV over 30 minutes once weekly for 2 weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
10004177|NCT01573793|Active Comparator|Intervention|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
10004178|NCT01573793|Sham Comparator|Control|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
10004179|NCT01573806|Active Comparator|Exenatide|Subjects dosed with exenatide in Phase 2
10004180|NCT01573806|Placebo Comparator|Exenatide vehicle|Subjects dosed with exenatide vehicle in Phase 2
10004181|NCT01573819|Experimental|Cohort 1|A dose of 2mg per day for 10 days
10004182|NCT01573819|Experimental|Cohort 2|A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg
10004183|NCT01573819|Experimental|Cohort 3|a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
10004184|NCT01573832|Experimental|Diabetic Foot Ulcer Intervention|
10004185|NCT01573832|No Intervention|Diabetic Foot Ulcer Usual Care|
10004186|NCT01573832|Experimental|Pionidal Sinus Ulcer Intervention|
10004187|NCT01573832|No Intervention|Pionidal Sinus Ulcer Usual Care|
10004188|NCT01573845|Experimental|Healthy Eating + Eco-Friendly Campaign|
10004189|NCT01573845|Active Comparator|Healthy Eating Campaign|
10004190|NCT01573845|No Intervention|Control/Delayed Intervention|
10004191|NCT01573858|Experimental|Acupuncture treatment 1 plus CC|
10004192|NCT01573858|Active Comparator|Acupuncture treatment 2 plus CC|
10004193|NCT01573858|Active Comparator|Acupuncture treatment 1 plus CC placebo|
10004194|NCT01573858|Active Comparator|Acupucture treatment 2 and CC placebo.|
10004195|NCT01573871|Experimental|Hydrolyzed infant formula|Hydrolyzed infant formula to be fed ad libitum
10004196|NCT01573897||Foot-wound without SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
10004197|NCT01573897||Foot-wound with SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome
10004198|NCT01573923|Sham Comparator|Conventional therapy|only apply for conventional medical therapy without any cell therapy
10004199|NCT01573923|Active Comparator|mesenchymal stem cells|combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
10004200|NCT01573936|Experimental|rehabilitation program|Rehabilitation program from January 2008 through July 2010, which consists of 40-minutes of many therapies for 1-2 days a week
10004201|NCT01573975|Experimental|Seq-Metronidazole|10-day sequential therapy with metronidazole
10004202|NCT01573975|Experimental|Seq-Tetracycline|10-day sequential therapy with tetracycline.
10004203|NCT01573975|Active Comparator|Control|10-day standard triple therapy.
10004204|NCT01573988|Other|non-obese volunteers|Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
10004205|NCT01573988|Other|Obese volunteers|Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.
10004206|NCT01574001|Experimental|Antismoking intervention with minimal early follow-up|"an intervention according to the 5A's model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke"
10004207|NCT01574001|Active Comparator|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
10004208|NCT01574001|Experimental|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
10004209|NCT01574014|Active Comparator|1: CBGT & Hydrocortisone|
10004210|NCT01574014|Placebo Comparator|2: CBGT & Placebo|
10004211|NCT01574027|Placebo Comparator|Placebo|Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
10004212|NCT01574027|Experimental|Vitamin D3 (cholecalciferol)|Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.
9945020|NCT01037712|Experimental|ZELITREX|ZELITREX
9945021|NCT01037712|Placebo Comparator|Placebo|placebo
9945022|NCT01037725|Experimental|AZD5847 oral suspension|Active
9945023|NCT01037725|Placebo Comparator|Placebo to AZD5847|Placebo
9945024|NCT01037738|Active Comparator|ACS - Orthokin|Autologous conditioned serum (ACS) - Orthokin containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF and TGF-ß1, among others) in the liquid blood phase.
9945025|NCT01037738|Placebo Comparator|Placebo|Physiologic solution
9945026|NCT01037751||Interview + Questionnaires|1-on-1 interview + Questionnaires, Part 1 of Study
9945027|NCT01037751||Questionnaires|Questionnaires Only, Part 2 of Study
9945028|NCT01037764|Experimental|alloHCT|alloHCT arm: For HLA-matched sibling HCT, if a patient is 55 years old or less and without co-morbidity, the patient will receive Bu-Cy conditioning therapy and be transplanted with bone marrow cells. Patients who are older than 55 years or with co-morbidity will receive Bu-Flu-ATG conditioning and be transplanted with mobilized peripheral blood hematopoietic cells. For HLA-matched unrelated donor or HLA-mismatched familial donor HCT, the patient will receive Bu-Flu-ATG conditioning and well be transplanted with mobilized peripheral blood hematopoietic cells.
9945029|NCT01037777||presymptomatic carriers|
9945030|NCT01037777||non carrier relatives|
9945031|NCT01037829||Pregnancy women|Comparison of pregnancy outcomes between (Novartis) H1N1 vaccinated women and (Novartis) H1N1 unvaccinated women.
9945032|NCT01037842|Active Comparator|Metformin+Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
9945033|NCT01037842|Placebo Comparator|Metformin+Placebo|placebo three times a day added to metformin 500 mg three times a day
9945034|NCT01037855||Group 1: 6-23 months|
9945035|NCT01037855||Group 2: 2-8 years|
9945036|NCT01037855||Group 3: 9-17 years|
9945037|NCT01037855||Group 4: 18-44 years|
9945038|NCT01037855||Group 5: 45-60 years|
9945039|NCT01037855||Group: >60 years|
9945040|NCT01037868|Experimental|Supportive SMS messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
9945041|NCT01037868|No Intervention|No supportive SMS text message|Patients in the non-intervention group would also receive text messages once every fortnight thanking them for participating in the study and a monthly phone call which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
9945042|NCT01037894|Experimental|Acupuncture|Acupuncture and conventional rehabilitation
9945043|NCT01037894|Active Comparator|Control|Conventional rehabilitation only
9945044|NCT01037920|Experimental|Intervention|subjects in the intervention arm will complete a self-affirmation exercise prior to a physician visit
9945045|NCT01037920|Active Comparator|Control|subjects in the intervention arm will complete a sham exercise prior to a physician visit
9945046|NCT01037933|Active Comparator|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
9945047|NCT01037933|Active Comparator|Non-humor intervention|"A 45-minute non-humorous DVD The A to Z of Steam Railways using a portable DVD player."
9945048|NCT01037946|No Intervention|Standard Care Arm|Families living with HIV, offered intervention at the end of study (24 months after recruitment)
10004213|NCT01574040|Experimental|Staff (and visitors) of the University Medical Centre Utrecht|This is a dynamic study population
9945049|NCT01037946|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
9945050|NCT01037959|Active Comparator|Norfloxacin|Patients with severe cirrhosis treated with norfloxacin
9945051|NCT01037959|Placebo Comparator|Placebo|Patients with severe cirrhosis treated with placebo
9945052|NCT01037972||Whole body vibration|
9945053|NCT01037972||Conventional physiotherapy|
9945054|NCT01037998|Active Comparator|A|Iressa 250 mg daily treatment plus UFUR twice daily treatment
9945055|NCT01037998|No Intervention|B|Gefitinib 250 mg daily treatment
9945056|NCT01038024|Experimental|Antioxidant Supplements|
9945057|NCT01038063|Experimental|Artemether-lumefantrine|Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.
9945058|NCT01038063|Active Comparator|Dihydroartemisinin-piperaquine|Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.
9945059|NCT01038076|Experimental|MedCHEC Tablet Computer & Adherence Care|Patients assigned to the intervention answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates provider and patient reports. Patients may be referred to an Adherence Care Manager on the basis of the reports. In addition, patients will receive standard information about adherence.
9945060|NCT01038076|No Intervention|Adherence Information Only|Patients assigned to the active comparator arm will receive standard information about adherence.
9945061|NCT01038089|Experimental|resveratrol|Resveratrol
9945062|NCT01038102|Active Comparator|PUFA diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%)
9945063|NCT01038102|Active Comparator|SFA diet|Diet high in saturated fat (15 E%)
9945064|NCT01038115|Active Comparator|Cryoballoon|
9945065|NCT01038115|Active Comparator|Radiofrequency|
9945066|NCT01038115|Active Comparator|Cryoballoon + Radiofrequency together|
9945067|NCT01038141|Active Comparator|Milligan Morgan|
9945068|NCT01038141|Active Comparator|Recto Anal Repair|
9945069|NCT01038154|No Intervention|control|Not Receive pravastatin
9945070|NCT01038154|Experimental|Pravastatin|
9945071|NCT01038167|Experimental|Part A|Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
9945072|NCT01038167|Experimental|Part B|Part B will be administered in two periods, separated by a washout. In Period 1, subjects will receive tacrolimus alone. In Period 2, subjects will receive tacrolimus in combination with telaprevir.
9945073|NCT01038180||pacemaker group|
9945074|NCT01038193||aSAH patients|Cognitive assessment
9945075|NCT01038206|Experimental|Family Function Intervention|Familias Unidas Intervention Program
9945076|NCT01038206|No Intervention|Treatment as Usual|The Public School system mandates that all high school students receive at least 5 lessons (55 minutes each) per year of HIV prevention.
9945077|NCT01038219||fever measurements|"1000 estimates and measurements of children's body temperatures will be carried out by parents and nurses in children's emergency and pediatric units as part of the routine work. The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department-- both boys and girls of all ages. A patient might be measured several times.~The measurements will be gathered in the course of one year. Before the routine taking of temperature, the accompanying parent will be asked to estimate the patient's temperature by feeling his forehead (with the back of the hand, the palm, lips). The parent will record his evaluation (without telling the nurse). Afterwards the nurse will do a similar evaluation (excepting the lip test), record it, and then the routine temperature measurement will be taken."
9945078|NCT01038258|Other|No arms|No arms
9945079|NCT01038271|Active Comparator|Standard Palliative Care Group|
9945080|NCT01038271|Active Comparator|Integrated Palliative Care Group|
9945081|NCT01038284|Sham Comparator|Control|
9945082|NCT01038284|Active Comparator|Patient education|
9945083|NCT01038362|Active Comparator|Almonds|National Cholesterol Education Program Step I diet plus almonds for 6 weeks
9945084|NCT01038362|Placebo Comparator|No Almonds|National Cholesterol Education Program Step 1 diet without almonds for 6 weeks
9945085|NCT01038375||Adherence counseling|
9945086|NCT01038375||Usual care|
10004214|NCT01574066|Experimental|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
10004215|NCT01574092|Experimental|Irinotecan plus Cisplatin combination|This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
9945087|NCT01038388|Experimental|Bortezomib, lenalidomide, dexamethasone, vorinostat|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; lenalidomide by mouth once a day on days 1-14; dexamethasone by mouth once a day on days 1, 2, 4, 5, 8, 9, 11, and 12; and vorinostat by mouth on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~After 8 courses, patients may receive maintenance therapy comprising lenalidomide by mouth once a day on days 1-21, dexamethasone by mouth once a day on days 1, 2, 8, and 9, and bortezomib IV over 3-5 seconds or subcutaneously on days 1 and 8. Courses may repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9945088|NCT01038401|Other|HIV-1-infected patients on effective HAART|
9945089|NCT01038401|Other|Non Infected HIV Volunteers|
9945090|NCT01038414|Placebo Comparator|Brief-Duration Counseling|3-Month Duration
9945091|NCT01038414|Active Comparator|Moderate Duration Counseling|6-Month Duration
9945092|NCT01038414|Active Comparator|Extended Duration Counseling|12-Month Duration
9945093|NCT01038440|Placebo Comparator|Control|
9945094|NCT01038440|Active Comparator|EPA 0.5 g/d|
9945095|NCT01038440|Active Comparator|EPA 1.5 g/d|
9945096|NCT01038440|Active Comparator|EPA 3.0 g/d|
9945097|NCT01038440|Experimental|SDA 0.5 g/d|
9945098|NCT01038440|Experimental|SDA 1.5 g/d|
9945099|NCT01038440|Experimental|SDA 3.0 g/d|
9945100|NCT01038440|Experimental|SDA 6.0 g/d|
9945101|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 35 µg|Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day
9945102|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 70 µg|Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day
9945103|NCT01038453|Placebo Comparator|placebo|
9945104|NCT01038466||CHAT trial participants|CHAT trial participants whose data was used in the final data analysis for the CHAT study
9945105|NCT01038479|Active Comparator|Childsmile programme with xylitol|Childsmile program with maternal xylitol consumption;
9945106|NCT01038479|Placebo Comparator|Childsmile programme only|Childsmile programme
9945107|NCT01038492|Experimental|p16 Methylation in Sputum Testing|"Patients tested for smoking-related changes in their breathing~shown a presentation on development of lung cancer~complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic detail~given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits"
9945108|NCT01038505|Active Comparator|Tacrolimus and Myfortic|Immunosuppressive
9945109|NCT01038505|Active Comparator|Tacrolimus and Sirolimus|Immunosuppressive
9945110|NCT01038518||Health2010|Cross-sectional general population study
9945111|NCT01038531|Active Comparator|low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
9945112|NCT01038531|Experimental|APRV|APRV allows spontaneous breathing.
9945113|NCT01038570|Experimental|Oxytocin|
9945114|NCT01038570|Placebo Comparator|Physiological serum|
9945115|NCT01038583||Aspirin|100 mg enteric-coated aspirin
9945116|NCT01038583||Placebo|Placebo
9945117|NCT01038596||osteoarthritic donors|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors
9945118|NCT01038596||healthy donors|age-matched healthy donors
9945119|NCT01038622|Active Comparator|L-arginine|5-day L-arginine treatment (200 mg/kg)
9945120|NCT01038622|Placebo Comparator|placebo|5-day placebo treatment
9945121|NCT01038648|Placebo Comparator|1|Advice life style at baseline only
9945122|NCT01038648|Active Comparator|sitagliptin arm : 2|"100mg/day sitagliptin~advice on life style modification at baseline only"
9945123|NCT01038661|Experimental|First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²|Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
9945124|NCT01038661|Experimental|First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²|Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
9945125|NCT01038661|Experimental|Maintenance treatment: docetaxel (60 mg/m2)|Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
9945126|NCT01038661|Active Comparator|Maintenance treatment: best supportive care (BSC)|BSC until progressive disease
9945127|NCT01038674|Experimental|Anti-IL-20|
9945128|NCT01038674|Placebo Comparator|Placebo|
9945129|NCT01038726|Active Comparator|Exercise Training|
9945130|NCT01038726|Active Comparator|Combined Cognitive/Exercise Training|
9945131|NCT01038726|Active Comparator|Cognitive Training|
9945132|NCT01038726|Active Comparator|Combined Low Intensity Training|
9945133|NCT01038765|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
9945134|NCT01038765|No Intervention|Waiting list control group|3-month waiting list group
9945135|NCT01038791|Active Comparator|usual ventilation|application of usual mechanical ventilation without humidification system
9945136|NCT01038791|Experimental|heated humidifier|mechanical ventilation with heated humidifier
9945137|NCT01038791|Experimental|heat and moisture exchanger|mechanical ventilation with heat and moisture exchanger
9945138|NCT01038817|Active Comparator|fluoride varnish|"Duraphat:~Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)"
9945139|NCT01038817|No Intervention|control|no application on the other side
9945140|NCT01038882|Active Comparator|Midazolam|The patients of this arma receives midazolam before the flexible bronchoscopy to maintain conscious sedation
9945141|NCT01038882|Placebo Comparator|Physiological serum|
9945142|NCT01038895|Active Comparator|Ramipril|10 mg/daily
9945143|NCT01038895|Experimental|Aliskiren|300 mg/ daily
9945144|NCT01038908|Active Comparator|1|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
9945145|NCT01038908|Active Comparator|2|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
9945146|NCT01038934|Experimental|buccal cytobrhsh|healthy young
9945147|NCT01038947|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
9945148|NCT01038960|Experimental|Exercise training|training
9945149|NCT01038960|No Intervention|Not training|No organized training
9945150|NCT01038986||CureXcell treated|Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment
9945151|NCT01038999||A HIV1-infected naive patients|
9945152|NCT01038999||B HIV1-infected patients|in 1st line of ARV therapy for at least 12 months
9945153|NCT01038999||C= control Non infected HIV volunters|
9945154|NCT01039012|Other|Tai Chi plus Standard Care|
9945155|NCT01039012|Other|Standard Care|
9945156|NCT01039025|Experimental|TMC|Topotecan, Melphalan, and Cyclophosphamide
9945157|NCT01039051|Experimental|Diet and Lifestyle counseling|increasing consumption of vegetables and fruits; maintaining energy balance through reducing excessive energy from meat, eggs and brown sugar and increasing energy expenditure from appropriate physical activity, such as doing maternal keep-fit exercises.
9945158|NCT01039077|Active Comparator|Single incision laparoscopic gastric banding|Patients in this group will undergo laparoscopic gastric banding through a single periumbilical incision.
9945159|NCT01039077|Active Comparator|Five port laparoscopic gastric banding|Patients in this group will undergo conventional laparoscopic gastric banding using 5 small incisions.
9945160|NCT01039090|Active Comparator|Per os dopaminergic treatment|
9945161|NCT01039090|Experimental|Continuous Apomorphine infusion|
9945162|NCT01039103|Experimental|Nanocort|PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
9945163|NCT01039103|Active Comparator|Solu-Medrol|Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3
9945164|NCT01039116|Experimental|Level of intervention intensity|"High Intensity: Behavioral Experimental:Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.~Active Comparator: Low-intensity Participants were provided with educational materials 4 times yearly."
9945165|NCT01039129|Experimental|Endoscopic Cholecystectomy|20 patients in this arm will undergo cholecystectomy, or removal of the gallbladder, through this experimental approach. This arm will compose of patients with symptomatic gallstones (cholelithiasis).
9945166|NCT01039129|Experimental|Endoscopic Appendectomy|Participants will with chronic appendicitis will undergo appendectomy through this experimental approach.
9945167|NCT01039129|Experimental|Endoscopic Peritoneoscopy|20 patients in this arm will undergo diagnostic peritoneoscopy with or without biopsy for any indication.
9945168|NCT01039142|Active Comparator|25 mg acitretin|capsule acitretin 25 mg/day will be administered to each patient for a period of 12 weeks
9945169|NCT01039142|Active Comparator|35 mg acitretin|capsule acitretin 35 mg/day will be administered to each patient for a period of 12 weeks
9945170|NCT01039142|Active Comparator|50 mg acitretin|capsule acitretin 50 mg/day will be administered to each patient for a period of 12 weeks
9945171|NCT01039155|Experimental|Treatment (azacitidine, oxaliplatin)|Patients receive azacitidine IV over 15-30 minutes on days 1-5 and oxaliplatin IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9945172|NCT01039168|Active Comparator|Workplace dialogue|Clinical examination and dialogue with supervisor to find solutions to reduce job-person mismatch and facilitate return to work
9945173|NCT01039168|Sham Comparator|Care as usual|No intervention besides of the care as usual being available for the patient
9945174|NCT01039194|Active Comparator|galantamine 8 mg (ER)|
9945175|NCT01039194|Active Comparator|galantamine 16 mg (ER)|
9945176|NCT01039194|Active Comparator|BMS-708163|
9945177|NCT01039233|Experimental|Bicalutamide 50 mg Tablet|
9945178|NCT01039233|Active Comparator|Casodex® 50 mg Tablet|
9945179|NCT01039259||subjects with lip piercing|
9945180|NCT01039259||subjects with tongue piercing|
9945181|NCT01039272||oral cancer|patients with oral squamous cell carcinoma
9945182|NCT01039272||control group|healthy patients without any oral pathology
9945183|NCT01039285|Experimental|Surfactant instillation|2.5 ml/kg of Surfactant will be instilled in the trachea
9945184|NCT01039285|Placebo Comparator|Placebo instillation|2.5 ml/kg of Air will be instilled in the trachea
9945185|NCT01039298|Active Comparator|A|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The Control arm. Surgical boundaries for oral lesions will be defined under regular white light."
9945186|NCT01039298|Experimental|B|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The FV arm (experimental arm). Surgical boundaries for oral lesions will be defined by FV."
9945187|NCT01039311||Optical Coherence Tomography|Examine OCT images and compare them to conventional biopsies in same subject.
10004216|NCT01574118|Experimental|Brief Enhanaced Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting the Trauma memories~Processing the trauma memories~In vivo Exposure homework~*Use of a brief pre-exposure trauma memory retrieval trial~Exposure to video clips related to the patient's trauma~Compound extinction - simultaneously exposing patient to trauma video clips while they listen to their trauma script"
10004217|NCT01574118|Active Comparator|Standard Prolonged Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting of the Trauma memories~Processing the trauma memories~Breathing retraining~In vivo Exposure homework"
10004218|NCT01574118|No Intervention|Delayed Treatment Control|Patients assigned to this arm receive assessment only (Week 0, 3, and 6) prior to receiving standard prolonged exposure therapy using the Foa et al treatment manual.
10004219|NCT01574131|Placebo Comparator|Sugar pill|pill
10004220|NCT01574131|Active Comparator|Fenofibrate|ppar-alpha agonist
10004221|NCT01574196||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
10004222|NCT01574209||Celiac Disease|Patients suffering from coeliac diseases confirmed by small intestinal biopsy
10004223|NCT01574209||IBS patients|Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria
10004224|NCT01574209||Healthy subjects|Healthy subjects as control group
10004225|NCT01574222|Experimental|Arm 1|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling
10004226|NCT01574235||Curative or prophylactic Nivestim® treatment for FN|
9945188|NCT01039324|Experimental|Intermediate Intervention (arm #1)|Care transition reports sent to primary care clinics, care transition letters sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
9945189|NCT01039324|Experimental|Full Intervention (arm #2)|E-mail notices sent to care managers about care transitions plus care transition reports sent to primary care clinics, care transition reports sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
9945190|NCT01039324|Experimental|Control (arm #3)|"Subjects assigned to the control group will receive usual care which is the standard of care coordination currently existent between patients, providers and care managers."
9945191|NCT01039337|Active Comparator|Hip school|This group will receive hip school during the intervention period of 6 weeks.
9945192|NCT01039337|Active Comparator|Hip School and Manual Treatment|This group receives both hip school and manual treatment during the 6 weeks.
9945193|NCT01039337|Active Comparator|Minimal control intervention|An information leaflet including exercises.
9945194|NCT01039363|Experimental|Vorinostat|Vorinostat combined with salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat maintenance
9945195|NCT01039389|Experimental|Collateral promotion; PCI after 6 months|
9945196|NCT01039389|Experimental|Collateral promotion; PCI at baseline|
9945197|NCT01039402||1|Adults ≥ 50 years old
9945198|NCT01039441|Placebo Comparator|instillation of normal saline 50ml under the diaphragm|
9945199|NCT01039441|Experimental|the instillation of 0.5% bupivacaine under the diaphragm|
9945200|NCT01039441|Experimental|CO2 removal by means of a pulmonary recruitment maneuver|
9945201|NCT01039441|Experimental|the instillation of bupivacaine + CO2 removal by maneuver|
9945202|NCT01039454|Placebo Comparator|Placebo|2 way cross over.
9945203|NCT01039454|Active Comparator|Active|2 Way cross over
9945204|NCT01039480||dual therapy (ASS/CLO)|patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
9945205|NCT01039480||clopidogrel users (CLO)|patients with a prescription for clopidogrel
9945206|NCT01039480||aspirin users (ASP)|patients with a prescription for aspirin
9945207|NCT01039493||Patients|
9945208|NCT01039493||Providers|
9476340|NCT03572777|Active Comparator|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.
9476341|NCT03572751||Vascular surgical patients|"Patient subjects are recruited from patients referred for vascular surgical procedure in Tampere University Hospital.~Bed-, wrist- and ECG-sensor monitoring"
9945209|NCT01039506||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 based regimens
9945210|NCT01039532||Basal Bolus regimen|Basal Bolus regimen
9945211|NCT01039532||Biphasic human insulin|Biphasic human insulin
9945212|NCT01039545|Active Comparator|antibiotic|Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
9945213|NCT01039545|Experimental|symptomatic|Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary
9945214|NCT01039558|Active Comparator|lansoprazole + ecabet sodium|
9945215|NCT01039558|Placebo Comparator|lansoprazole + placebo|
9945216|NCT01039597|Experimental|Active study drug|ORE1001 300 mg oral capsules
9945217|NCT01039597|Placebo Comparator|Placebo control|300 mg oral capsules containing placebo material
9945218|NCT01039610|Experimental|Part A|GSK945237 2400mg single dose
9945219|NCT01039610|Experimental|Part B Cohort 1|GSK945237 400 mg QD, 7 Days 4 subjects GSK945237:2 subjects Placebo
9945220|NCT01039610|Experimental|Part B Cohort 2|GSK945237 400 mg QD, 14 Days 4 subjects GSK945237:2 subjects Placebo
9945221|NCT01039610|Experimental|Part B Cohort 3|GSK945237 400 mg BID, 14 Days 4 subjects GSK945237:2 subjects Placebo
9945222|NCT01039610|Experimental|Part B Cohort 4|GSK945237 800 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
9945223|NCT01039610|Experimental|Part B Cohort 5|GSK945237 1200 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
9945224|NCT01039610|Experimental|Part B Cohort 6|GS945237 1600 mg QD, 14 Days 9 subjects GSK945237:3 subjects Placebo
9945225|NCT01039610|Active Comparator|Part C|Linezolid 600 mg BID, 14 Days 9 subjects Linezolid:3 subjects Placebo
9945226|NCT01039610|Active Comparator|Part D|"2 period crossover Period 1: Placebo 1 day; GSK945237 dose to be determined, 5 Days Period 2: Placebo 5 days; moxifloxacin 400 mg single dose~16 subjects"
9945227|NCT01039636|Experimental|FBS0701 - 5 escalating doses|5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
9945228|NCT01039649||Lung Radiation|Patients with tumors in the lung that require radiation therapy
9945229|NCT01039662|Experimental|Oolong tea containing L-arabinose and indigestible dextrin|
9945230|NCT01039662|Placebo Comparator|Oolong tea|
9945231|NCT01039701|Experimental|1|AZD1446 60mg once daily + donepezil 10mg
9945232|NCT01039701|Experimental|2|AZD1446 60mg three times daily + donepezil 10mg
9945233|NCT01039701|Experimental|3|AZD1446 30mg three times daily + donepezil 10mg
9945234|NCT01039701|Placebo Comparator|4|placebo + donepezil 10mg
9945235|NCT01039714||Total Thyroidectomy|
9945236|NCT01039727|No Intervention|care as usual|care as usual
9945237|NCT01039727|Experimental|autosuggestive support|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
9945238|NCT01039727|Experimental|autosuggestive support ++|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
9945239|NCT01039740|Experimental|Responders|Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
9945240|NCT01039740|Experimental|Non-responders|Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
9476342|NCT03572751||Healthy volunteers|"Healthy volunteer subjects will be recruited mainly from the students of Tampere University of Technology.~Bed-, wrist- and ECG-sensor monitoring"
9945241|NCT01039766|Experimental|oxytocin|
9945242|NCT01039766|Placebo Comparator|Placebo|
9945243|NCT01039779|Active Comparator|Lower-extremity exercise training|This training will be tailored by physical therapists for each participant. A series of exercises will be applied to increase the stability of the trunk muscles and to strengthen the leg muscles.
9945244|NCT01039779|Active Comparator|Tai chi exercise|Yang-style tai chi with 18 movements will be taught every week over the 6-month intervention period at a subject's residence by tai chi instructors
9945245|NCT01039818|Active Comparator|Radiodine-200µCi|A subgroup of patients with Graves' Disease and goiter ≥48ml treated with 200µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU, from a randomized controlled trial run at our institution between February 1997 and March 2000, serves as a historical control.
9945246|NCT01039818|Experimental|Radiodine-250µCi|Patients with Graves' Disease and goiter ≥48ml, prospectively assigned to receive 250 µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU.
9945247|NCT01039831||Patients with Parkinson's Disease|Consecutive patient sampling
9945248|NCT01039844|Experimental|Weekly LOC-paclitaxel Injection|LOC-paclitaxel IV by a 1 hour infusion on Day 1, 8, 15, 22 and 29; repeated every 42 days (6 weeks) per cycle.
9945249|NCT01039857|Other|Structured solution focused therapy|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy
9945250|NCT01039857|Experimental|Integrative clarification therapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
9945251|NCT01039870|Experimental|PVB|Paravertebral block initiated at the later part of thoracotomy is used for postoperative pain control
9945252|NCT01039870|Active Comparator|TEA|Thoracic epidural block initiated before the surgical incision is used for postoperative pain control.
9945253|NCT01039883|Experimental|1|Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period.
9945254|NCT01039883|Experimental|2|Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period.
9945255|NCT01039896|Experimental|Group1|SLM0807
9945256|NCT01039896|Experimental|Group2|SLM0807 and HKB0701
9945257|NCT01039909|Placebo Comparator|Placebo|"The Placebo treatment group will be administered 8 placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive placebo approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
9945258|NCT01039909|Active Comparator|2.0g SRT2104|"The 2.0g SRT2104 treatment group will be administered 8 SRT2104 0.25g capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive SRT2104 approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
9945259|NCT01039922||1|Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
9476343|NCT03572725|Active Comparator|Gas tamponade|Gas as intraocular tamponade.
9476344|NCT03572725|Experimental|Air tamponade|Air as intraocular tamponade.
9945260|NCT01039948|Experimental|Phase 2: AV-299 + gefitinib|Phase 2: AV-299 (formerly SCH 900105) administered IV at RP2D (as determined by Phase 1b portion) in combination with gefitinib 250 mg/day orally.
9945261|NCT01039948|Active Comparator|Phase 2: Gefitinib|Phase 2: Gefitinib 250 mg/day, orally.
9945262|NCT01039961|Experimental|1 mg IV|Unit Dose Strength: 0.4 mg/mL
9945263|NCT01039961|Experimental|?mg IV|dose to be determined based on PK of first IV dose
9945264|NCT01039961|Experimental|15 mg (oral)|two 7.5 mg tablets
9945265|NCT01039974|Experimental|Cohorts 1-2|Cohorts 1 and 2 will complete both periods Period 1 GSK962040 single dose Period 2 Ketoconazole repeat dose (10 days), GSK962040 single dose
9945266|NCT01040000|Experimental|NPC-1C/NEO-102|
9945267|NCT01040013|Experimental|Laparoscopy|Laparoscopic Left-Sided Colectomy
9945268|NCT01040013|Active Comparator|laparotomy|Laparotomic Left-Sided Colectomy
9945269|NCT01040026|Experimental|NK cell infusions|10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells
9945270|NCT01040039||HCV+HIV+|
9945271|NCT01040039||HCV+HIV-|
9945272|NCT01040078|Experimental|7.5ug H1N1 vaccine|360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.
9945273|NCT01040078|Experimental|15ug H1N1 vaccine|360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.
9945274|NCT01040078|Placebo Comparator|seasonal influenza vaccine|180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.
9945275|NCT01040091|Active Comparator|HIV-Infected Participants|HIV-infected participants will receive FTC, TDF, and EFV for 60 days by prescription from their physicians. Participants will receive Truvada (FTC/TDF) and EFV for the first 30 days. After Day 30, participants may switch to the TDF/FTC/EFV co-formulation through Day 60 as directed by their physician.
9945276|NCT01040091|Active Comparator|HIV-Uninfected Participants|HIV-uninfected participants will receive Truvada (FTC/TDF) for 30 days.
9945277|NCT01040104||Regular wound healing, young|Regular skin repair, controlled wound healing conditions in young individuals
9945278|NCT01040104||Regular wound healing, aged|Regular skin repair, controlled wound healing conditions in aged individuals
9945279|NCT01040104||Hypertrophic scarring, young|Skin repair with and without hypertrophic scarring in young individuals
9945280|NCT01040104||Hypertrophic scarring, aged|Skin repair with and without hypertrophic scarring in aged individuals
9945281|NCT01040104||Non-diabetic, young|Skin repair in non-diabetic young individuals
9945282|NCT01040104||Non-diabetic, aged|Skin repair in non-diabetic aged individuals
9945283|NCT01040104||Diabetic, young|Skin repair in young diabetic individuals
9945284|NCT01040104||Diabetic, aged|Skin repair in aged diabetic individuals
9945285|NCT01040117|Experimental|Sensory-motor Integration Training|
9945286|NCT01040117|Active Comparator|Conventional neurorehabilitation|
9945287|NCT01040156||LAmb|
9945288|NCT01040156||Cas|
9945289|NCT01040182||ischemic stroke patients|
9945290|NCT01040182||healthy subjects without cerebrovascular disease|
9945291|NCT01040195|Active Comparator|Combination DMARD|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily. All patients will also receive folic acid 5 mg thrice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. In the absence of any contraindication, patients will be randomized into two groups Group 1 to receive Combination Disease Modifying therapy with Sulfasalazine, Methotrexate and hydroxychloroquine (HCQ). Patient will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day.
9945292|NCT01040195|Placebo Comparator|Placebo|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily All patients will also receive folic acid 5 mg twice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. Group 2 patients will receive Sulfasalazine and placebo for methotrexate and hydroxychloroquine.
9945293|NCT01040221|Experimental|Trichuris Suis Ova (TSO)|the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
9945294|NCT01040221|Placebo Comparator|Placebo|placebo dosage received every two weeks.
9945295|NCT01040234||Active pain treatment|Bilateral dual TAP block
9945296|NCT01040247|Experimental|Day 0 Embryo Transfer|Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
9945297|NCT01040247|Active Comparator|Day 2,3 Embryo Transfer|Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization
9945298|NCT01040273|Experimental|Experiment|Anesthetics intraarticular injection
9945299|NCT01040273|Placebo Comparator|Placebo|saline intraarticular injection
9945300|NCT01040286|Experimental|Flurbiprofen Chip|
9945301|NCT01040286|Active Comparator|Chlorhexidine chip|
9945302|NCT01040299|Experimental|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
9945303|NCT01040299|Sham Comparator|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
9945304|NCT01040299|Active Comparator|control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
9945305|NCT01040312||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 with platinum analogues
9945306|NCT01040325|Experimental|Active|358 subjects receive a two vaccination regimen with an LT patch
9945307|NCT01040325|Placebo Comparator|Placebo|358 subjects receive a two vaccination regimen with placebo patch
9945308|NCT01040338||OPRM1 A118G AA genotype|Individuals with the AA genotype at the OPRM1 A118G polymorphism.
9945309|NCT01040338||OPRM1 A118G AG or GG genotype|Individuals with the */G allele at the OPRM1 A118G polymorphism
9945310|NCT01040364||Interna hernia after primary gastric bypass|
9945311|NCT01040377||Inadequate initial weight loss after gastric bypass|
9945312|NCT01040416||Bleeding marginal ulcer after RYGB|
9945313|NCT01040429|Active Comparator|Clonidine capsula|
9945314|NCT01040429|Placebo Comparator|Lactose capsula|
9945315|NCT01040442|Experimental|vibration stimuli|
9945316|NCT01040455|Experimental|lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
9945317|NCT01040455|Placebo Comparator|placebo|placebo once daily for eight weeks
9945318|NCT01040468|Active Comparator|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss
9945319|NCT01040468|Active Comparator|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss
9945320|NCT01040468|Active Comparator|Intensive Lifestyle Modification|Lifestyle intervention for weight loss
9945321|NCT01040481||Malabsorptive distal gastric bypass|
9945322|NCT01040494|Experimental|Aliskiren, add-on|HF patients will be randomized to receive add-on aliskiren 150 mg for 6 months
9945323|NCT01040494|Placebo Comparator|placebo, add-on|patients will be randomized to receive add-on placebo for 6 months
9945324|NCT01040507||primary laparoscopic gastric bypass|
9945325|NCT01040533||Failed / complicated jejunoileal bypass|
9945326|NCT01040546|Experimental|Individualized education|Individualized consultation of health problem, dietary intake and exercise
9945327|NCT01040546|Experimental|Grouped education|Grouped consultation of health problem, dietary intake and exercise
9945328|NCT01040559|Experimental|Idarubicin|Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg
9945329|NCT01040572||Obesity recidivism after gastric bypass|
9945330|NCT01040585||Central America and the Caribbean|Panama, Costa Rica, Honduras, El Salvador and Nicaragua
9945331|NCT01040611|Experimental|Music therapy|This study examined the effectiveness of music therapy on anxiety, depression and physiological responses for patients with tuberculosis.
9945332|NCT01040611|No Intervention|Placebo|No music therapy apply to this arm
9945333|NCT01040650||Normal Controls|Normal Controls
9945334|NCT01040650||Statin associated myopathy|subjects with statin associated myopathy
9945335|NCT01040663|Other|Dash Diet|Subjects receive DASH diet for 4 weeks
9476345|NCT03572686|Sham Comparator|Group Ropivacaine High (RH)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml + N/S 1.6mL.
9945336|NCT01040663|Other|Low GI Diet|Subjects will receive Low GI diet for 4 weeks
9945337|NCT01040663|Other|Western Style Diet|Subjects will receive western style diet for 4 weeks
9945338|NCT01040676|No Intervention|Control Group|"Patients in this (the control group) will be eligible to receive the intervention (see Intervention Group) after 12 weeks (essentially when the trial is over)."
9945339|NCT01040676|Experimental|Intervention Group|Patients in the intervention group will receive automated telephone calls at regular intervals twice a week. The system will be programmed to call them at these intervals until contact. The ATNS system will solicit information from them in a culture specific manner, inquiring as to what foods they are eating each meal, each day, and each month. The ATNS system will then make proactive suggestions regarding low glycemic index foods, giving encouragement and feedback as appropriate.
9945340|NCT01040702|Experimental|ADHD -MPH|adults with ADHD diagnosis who receive a single dose of Methylphenidate
9945341|NCT01040702|Placebo Comparator|ADHD-placebo|adults with ADHD diagnosis who received placebo
9945342|NCT01040702|Experimental|non-ADHD-MPH|healthy adults who received a single dose of Methylphenidate
9945343|NCT01040702|Placebo Comparator|non-ADHD-placebo|healthy adults who received placebo
9945344|NCT01040715|Experimental|TNFa Kinoid dose 1|
9945345|NCT01040715|Experimental|TNFa Kinoid dose 2|
9945346|NCT01040715|Experimental|TNFa Kinoid dose 3|
9945347|NCT01040741||Group 1: 6-23 months|
9945348|NCT01040741||Group 2: 2-8 years|
9945349|NCT01040741||Group 3: 9-17 years|
9945350|NCT01040741||Group 4: 18-44 years|
9945351|NCT01040741||Group 5: 45-60 years|
9945352|NCT01040741||Group: >60 years|
9945353|NCT01040754|Active Comparator|Acupuncture|
9945354|NCT01040754|No Intervention|Waitlist Control|
9945355|NCT01040767|Active Comparator|Class|
9945356|NCT01040767|Active Comparator|Web|
9945357|NCT01040767|No Intervention|Control|
9945358|NCT01040884|Experimental|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
9945359|NCT01040897|Active Comparator|Active Control Arm|At Active Comparative Sites, Pediatric Residents will be trained to address injury prevention issues using The Injury Prevention Program (TIPP) approach
9945360|NCT01040897|Experimental|Health Communication and Obesity Prevention|Pediatric Residents will be training in effective health communication skills and given a toolkit of literacy/numeracy sensitive educational materials to use with families with children age 2 months to18 months during each well child visit
9945361|NCT01040910|Active Comparator|cannabis smoking for IBD|patients with active disease receiving active cannabis for smoking
9945362|NCT01040910|Placebo Comparator|patients smoking non active cannabis|patients with active disease receiving cannabis from which active ingredients have been chemically removed
9945363|NCT01040923||Cardiac CT|All patients in the study will be those presenting themselves for cardiac CT angiography who meet the proper inclusion / exclusion criteria
9945364|NCT01040936|Active Comparator|conventional group|patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
9945365|NCT01040936|Experimental|intensive group|patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
9945366|NCT01040949|Active Comparator|a self help smoking cessation guide|Guia, a culturally relevant self-help smoking cessation guide in Spanish
9945367|NCT01040949|Experimental|couple-based counseling for smoking cessation plus Guia|couple-based counseling for smoking cessation plus Guis, culturally relevant self-help smoking cessation guide for Latinos
9945368|NCT01040962||Falls Risk Assessment, Diabetic Peripheral Neuropathy Patients|
9945369|NCT01040975|Experimental|Motivational Interviewing intervention|Web-based intervention targeting MD communication and Summary Report
9945370|NCT01040975|No Intervention|Control|MD receives Summary Report only
9945371|NCT01040988||Pacemaker|Patients meeting entry criteria with a pacemaker in place.
9945372|NCT01040988||ICD|Patients meeting entry criteria with an ICD in place.
9945373|NCT01041001|Experimental|Cartistem|A single dose of 500㎕/㎠ of cartilage defect
9945374|NCT01041001|Active Comparator|Microfracture treatment|
10004227|NCT01574261|Active Comparator|Inositol|Patients will be randomized to receive Inositol 4 g/die per os for four months of treatment
10004228|NCT01574261|Placebo Comparator|Placebo|Patients will be randomized to receive placebo for four months
10004229|NCT01574274|Active Comparator|SC-PEG|SC-PEG
10004230|NCT01574274|Active Comparator|Oncaspar|Oncaspar
10004231|NCT01574300||Biospecimens and biofluids|"This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.~The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:~tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions~serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response"
10004232|NCT01574313|Experimental|Stellate ganglion block|treated with SGB
10004233|NCT01574313|Active Comparator|Oral medication|treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).
10004234|NCT01574339|Experimental|Treatment Arm|
10004235|NCT01574365|Experimental|RTA402|
10004236|NCT01574365|Experimental|RTA402 Low|
9945375|NCT01041014|Experimental|Professional medical interpreter|Limited English proficient Spanish-speaking patients seen in the treatment arm were provided with the services of a professionally-trained medical interpreter to facilitate communication between the patient and emergency department staff
9945376|NCT01041014|No Intervention|Control, Usual Language Services|Patients randomized to the control arm receive the services of the emergency departments' usual language services (i.e., a telephone language line or ad hoc interpreters).
9945377|NCT01041027|Experimental|Treatment (paclitaxel, carboplatin, radiation therapy)|"CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15."
9945378|NCT01041066|Active Comparator|group L|0.4 mg/kg labetalol
9945379|NCT01041066|Active Comparator|group N|20 ㎍/kg nicardipine
9945380|NCT01041079||Chronic marginal ulcer after RYGB|Patients with intractable or chronic marginal ulcer disease after gastric bypass complaining of abdominal pain, GI bleeding, obstruction, perforation and penetration. Sometimes with other associated diagnosis such as narcotic and tobacco dependence, protein-calorie malnutrition, excessive weight loss, poor pouch emptying syndrome, weight regain, inadequate initial weight loss, severe dumping syndrome among others.
9945381|NCT01041092|Placebo Comparator|sugar pill|
9945382|NCT01041092|Active Comparator|raloxifene hydrochloride|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
9945383|NCT01041105||Gastric bypass after previous Nissen|
9945384|NCT01041131||Failed and/or Complicated VBG|
9945385|NCT01041144|Experimental|Lifestyle counseling|
9945386|NCT01041157|Experimental|1|resistance training
9476346|NCT03572686|Placebo Comparator|Group Ropivacaine Low (RL)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + N/S 1.6mL.
9476347|NCT03572686|Experimental|Group Ropivacaine Low + Dexamethasone (RLD)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + Dexamethasone 8mg (1.6mL).
9476348|NCT03572673|Active Comparator|Flexima 3S|Flexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
9945387|NCT01041183|Active Comparator|group I|0.3 mg IV ramosetron
9945388|NCT01041183|Active Comparator|group II|0.1 mg oral ramosetron
9945389|NCT01041183|Active Comparator|group III|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
9945390|NCT01041196||perforated ulcer after gastric bypass|
9945391|NCT01041222|Experimental|Arm 1|0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
9945392|NCT01041222|Experimental|Arm 2|0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
9945393|NCT01041222|Experimental|Arm 3|1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
9945394|NCT01041222|Experimental|Arm 4|3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
9945395|NCT01041222|Placebo Comparator|Placebo (phosphate buffered saline)|
9945396|NCT01041235|Experimental|ATI-1123|
9945397|NCT01041261|No Intervention|Control arm|Subjects will be issued control study product (Carnation Instant Breakfast, no sugar added)
9945398|NCT01041261|Experimental|Treatment arm|Medical food
9945399|NCT01041313|Active Comparator|Opiate Naive|Subjects who have not taken opiate medication in previous 6 weeks before surgery
9945400|NCT01041313|Active Comparator|Opiate tolerant|Subjects who have taken opiate medications for the 6 weeks before surgery
9945401|NCT01041326|Experimental|Leve 1 Radiation|Subjects in Group 1 will receive 39.6 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
9945402|NCT01041326|Experimental|Level 2 Radiation|Subjects in Group 2 will receive 45 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
9945403|NCT01041326|Experimental|Level 3 Radiation|Subjects in Group 3 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 50.4 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
9945404|NCT01041326|Experimental|Level 4 Radiation|Subjects in Group 4 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 54 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
10004237|NCT01574365|Experimental|RTA402 Medium-low|
9945405|NCT01041339||acute chest pain ST elevation|patients admitted with acute chest pain sharing ST elevation in ER-ECG and elevated troponin
9945406|NCT01041339||controls|asymptomatic patients
9945407|NCT01041352|Active Comparator|Endotracheal group|airway management: endotracheal tube
9945408|NCT01041352|Active Comparator|laryngeal mask group|airway management: laryngeal mask
9945409|NCT01041365||Healthy adolescents|Healthy adolescent African American and Caucasian females, ages 14-18
9945410|NCT01041391||Surgical treatment for Lumbar disc herniation|Patients who had or will have surgery for Lumbar disc herniation
9945411|NCT01041391||Non-surgical treatment for Lumbar disc herniation|Patients that have chosen conservative treatment for lumbar disc herniation
9945412|NCT01041430|Active Comparator|Day Surgery Group|discharge planned on day of surgery, inguinal hernia repair
9945413|NCT01041430|Active Comparator|Inpatient Group|overnight admission at the hospital, inguinal hernia repair
9945414|NCT01041443|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
9945415|NCT01041456||complicated and/or failed BPD|
9945416|NCT01041469||with abnormalities|Down syndrome patients presenting with at least one sign of auto immune abnormality
9945417|NCT01041469||without abnormality|Down syndrome patients without any sign of recognized auto immune condition
9945418|NCT01041482|Experimental|sorafenib|To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.
9945419|NCT01041508|Active Comparator|A|Stratum A are those patients with related stem cell donors.
9945420|NCT01041508|Active Comparator|B|Stratum B are those patients with unrelated stem cell donors.
9945421|NCT01041534||Adjustable Gastric Band (AGB) surgery|Patients who have undergone adjustable gastric band (AGB) surgery at the UWMC or other sites that have agreed to cooperate with our site (letter of cooperation and HIPAA waiver approved by our IRB) between April 1, 2007 and July 1, 2008.
9945422|NCT01041547||Healthy adults|healthy adults with BMI below 32, between ages 19-60 yrs, both males and females
9945423|NCT01041560||Stoke|Hemiplegia with unilateral changes in tone and muscle strength
9945424|NCT01041586|Experimental|BTVA|
9945425|NCT01041599||Diabetic patients|Hypertensive and normotensive patients with type 2 diabetes mellitus
9945426|NCT01041599||Hypertensive patients|Patients with essential hypertension
9945427|NCT01041599||Healthy subjects|Healthy subjects
9945428|NCT01041612|Active Comparator|Group A: C-SEMS, inserted above SO|-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.
9945429|NCT01041612|Active Comparator|Group B: C-SEMS, inserted across SO|-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.
9945430|NCT01041625|Experimental|Apremilast|Apremilast 20 mg PO administered BID over 12 weeks
9945431|NCT01041690|Experimental|Bevacizumab|
9945432|NCT01041729|Experimental|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
9945433|NCT01041729|Active Comparator|Control|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment"
9945434|NCT01041742|Experimental|OPCAB|
9945435|NCT01041755|Experimental|Intravenous infusion of L- Ornithine L- Aspartate|a) 20 g L-ornithine-L-aspartate
9945436|NCT01041755|Active Comparator|Lactose enemas|b) 20% Lactose enemas
9945437|NCT01041768|Active Comparator|antidiabetic medical therapy|
9945438|NCT01041768|Experimental|Bariatric Surgery|
9945439|NCT01041794||1|
9945440|NCT01041820|Experimental|Exercise group|Children will participate in a 10-week moderate to vigorous exercise program
9945441|NCT01041820|No Intervention|non-exercising|Participants will receive no intervention
9945442|NCT01041833|Experimental|atRA group|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
9945443|NCT01041833|Placebo Comparator|Placebo Group|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
9945444|NCT01041846||Decitabine|
9945445|NCT01041872|Active Comparator|Propofol Astrazeneca|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
9945446|NCT01041872|Experimental|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
9945447|NCT01041872|Experimental|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
10214823|NCT04277299|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Solution which is the surgical pathway currently practiced in the study hospital. The ICory-Solution has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
10214824|NCT04277299|No Intervention|Control group|Children in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care. Parents in this group will receive BuddyCare mobile app which is supposed to be as a normal routine in this hospital.
10214825|NCT04265378|Experimental|Stimulation group|Anodal tDCS + intensive cognitive training
9945448|NCT01041872|Experimental|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
9945449|NCT01041872|Experimental|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
9945450|NCT01041872|Experimental|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
9945451|NCT01041885|Experimental|INSTRUCT|INSTRUCT scaffold implantation
10214826|NCT04265378|Sham Comparator|Sham group|Sham tDCS + intensive cognitive training
10214827|NCT04249830|Experimental|Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. Participants will be followed for outcomes for two years.
10214828|NCT04249453||Chronic low back pain with high disability|Veterans with chronic, non-specific LBP and a Roland-Morris Disability Questionnaire (RMDQ) score of >12 (gender-balanced, n1=18)
10214829|NCT04249453||Chronic low back pain with low disability|Veterans with chronic, non-specific LBP and a RMDQ score of 12 (gender-balanced, n2=18)
10214830|NCT04249453||Controls|Asymptomatic veterans with no recent history of LBP (gender-balanced, n3=18)
10214831|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.
10214832|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given IV and temozolomide given orally.
10214833|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
10214834|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
10214835|NCT04233970|Experimental|Intervention group|Participants randomized to the intervention group will receive access to the multi-component, web-based intervention programme. The intervention programme will be developed in line with principles of patient empowerment and based on the Theory of Planned Behaviour.
10214836|NCT04233970|Active Comparator|Control group|Participants randomized to the control group will receive access to the web-based control programme with optimized standard care.
10214837|NCT04232917|Experimental|2LPAPI® arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
10214838|NCT04232917|Placebo Comparator|Placebo arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
10214839|NCT04223258|Experimental|Automatic Oxygen Control|Infants randomized to this arm will be monitored using automatic oxygen control system on the ventilator. When infants oxygen saturation are out of the target range the ventilator will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation int he target range.
10214840|NCT04223258|Active Comparator|Manual oxygen control|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
10214841|NCT04200963|Experimental|IK-175 Single Agent Dose Escalation|Approximately 5 dose escalation steps are planned during the Single Agent Treatment dose escalation phase of the study. (COMPLETE)
9945452|NCT01041911|Active Comparator|Euphorbia 50 mg|This arm subjects will be given 50 mg Euphorbia prostrata
9945453|NCT01041911|Active Comparator|Euphorbia 100 mg|In this arm subjects will be given 100 mg Euphorbia
9945454|NCT01041911|Active Comparator|Euphorbia 200 mg|In this arm subject will be given 200 mg Euphorbia tablets
9945455|NCT01041911|Placebo Comparator|Placebo|In this arm subjects will be given placebo tablets
9945456|NCT01041937|Active Comparator|Cemented Tibia|Assessing the clinical outcomes of the different type of fixation
9945457|NCT01041937|Active Comparator|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
9945458|NCT01041950|Experimental|Lumbar drainage|
9945459|NCT01041950|No Intervention|Control|
9945460|NCT01041963|Active Comparator|Enalapril|
9945461|NCT01041963|Active Comparator|Enalapril plus Losartan|
9945462|NCT01041963|Placebo Comparator|Control|Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker-->hydralazine
9945463|NCT01041989|No Intervention|Standard health counseling at baseline|
9945464|NCT01041989|Experimental|Lifestyle counseling|Multi-domain lifestyle counseling including nutritional guidance, increased physical activity, cognitive training, increased social activity and intensive monitoring of vascular and metabolic risk factors.
9945465|NCT01042002|Experimental|High intensity exercise|
9945466|NCT01042002|No Intervention|Control|
9945467|NCT01042028|Experimental|Phase II: Arm A|Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
9945468|NCT01042028|Active Comparator|Arm B|Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.
9945469|NCT01042041|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.
9945470|NCT01042054|Active Comparator|Epidural|Patients will follow a standard optimised recovery protocol, including epidural analgesia for the first 48 hours postoperatively.
9945471|NCT01042054|Experimental|Wound catheter|Patients will follow a standard optimised recovery protocol, but analgesia in the first 48 hours will be delivered through local anaesthetic wound catheters and additional patient-controlled analgesia, instead of epidural analgesia.
9945472|NCT01042067||Warfarin treatment group|Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
9945473|NCT01042080|Active Comparator|PSV-ET 25|Pressure support ventilation with expiratory trigger set at 25 %.
9945474|NCT01042080|Active Comparator|PSV-ET 50|Pressure support ventilation with expiratory cycling set at 50 %.
9945475|NCT01042080|Experimental|NAVA|NAVA level is adjusted to achieve similar peak inspiratory pressure levels than during PSV.
9945476|NCT01042106|Experimental|DSP-8658|DSP-8658 2.5, 10, 20, 40 mg once daily
9945477|NCT01042106|Placebo Comparator|Placebo|Placebo 2.5, 10, 20, and 40 mg doses once daily
9945478|NCT01042119||Botox|patients who received intravesical injections of botulinum neurotoxin type A
9945479|NCT01042132|Active Comparator|1) IMN and EF/IMN|"Two parts of the study are randomized;~1)initial intramedullary reaming and primary external fixation with secondary intramedullary nailing"
9945480|NCT01042132|Active Comparator|2) TR and RIA|Two parts of the study are randomized; 2)traditional reaming (TR)is compared to a new reaming device, RIA, which is a reamer connected to suction and flushing for prevention of increased intramedullary pressure
9945481|NCT01042184|Experimental|Group A|Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
9945482|NCT01042184|Experimental|Group B: Sequential therapy for 10 days|
9945483|NCT01042184|Active Comparator|Group C: Triple therapy for 14 days|
9945484|NCT01042197|Active Comparator|2|Body surface area: 12 %
9945485|NCT01042197|Active Comparator|1|Body surface area: 6 %
9945486|NCT01042197|Active Comparator|3|Body surface area: 24 %
9945487|NCT01042197|Active Comparator|4|Body surface area: 6 %
9945488|NCT01042197|Active Comparator|5|Body surface area: 12 %
9945489|NCT01042197|Active Comparator|6|Body surface area: 24 %
9945490|NCT01042197|Active Comparator|7|Body surface area: 6 %
9945491|NCT01042197|Active Comparator|8|Body surface area: 12 %
9945492|NCT01042197|Active Comparator|9|Body surface area: 24 %
9945493|NCT01042210||Mothers, preeclampsia|Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h).
9945494|NCT01042210||Newborns, physiological pregnancy-delivery|The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.
9945495|NCT01042210||Newborns, pregnancy with preeclampsia|Newborns from the pregnancies complicated by preeclampsia.
10004238|NCT01574365|Experimental|RTA402 Medium-high|
10004239|NCT01574378|Active Comparator|Control arm|Control arm- conventional method of wound closure
10004240|NCT01574378|Experimental|V-Loc group|V-Loc 90 barbed sutures
10004241|NCT01574391|Active Comparator|EPIDRUM|EPIDRUM DEVICE IS USED TO SITE THE EPIDURALS IN THE PATIENTS RANDOMISED TO THIS ARM
10004242|NCT01574391|No Intervention|Control|This arm is the control where normal technique is used
10004243|NCT01574404|Experimental|Polar Body Biopsy with PGS|Polar Body Biopsy with Pre implantation genetic screening
10004244|NCT01574417|Experimental|Plant stanol-enriched margarine|
10004245|NCT01574417|Placebo Comparator|control margarine|
10004246|NCT01574430|Active Comparator|50% dose PDT|patients in this group was given 50% verteporfin dose PDT
10004247|NCT01574430|Experimental|30% dose PDT|patients in this group was given 30% verteporfin dose PDT
10004248|NCT01574443||epilepsy resection patients|Patients undergoing resection for refractory epilepsy
10004249|NCT01574456||7 patients diagnosed with dementia of the Alzheimer's type|
10004250|NCT01574456||13 patients with mild cognitive impairment|
10004251|NCT01574456||19 healthy controls|
10004252|NCT01574469|Active Comparator|1 = Tested product|
10004253|NCT01574469|Placebo Comparator|2 = Control product|
10004254|NCT01574482|Experimental|1 = Tested product|
10004255|NCT01574482|Placebo Comparator|2 = Control product|
10004256|NCT01574495|Experimental|Error Augmentation-Control|
10004257|NCT01574495|Experimental|Control-Error Augmentation|
10004258|NCT01574508|Experimental|Continuous Subcutaneous Insulin Infusion|CSII
10004259|NCT01574508|Active Comparator|Multiple Daily Insulin Injections|MDI
10004260|NCT01574521||Only father carrier|fetuses whose fathers were HBV carriers whereas mothers negatively.
10004261|NCT01574521||only mother carrier|fetuses whose mothers were HBV carriers whereas fathers negatively.
10004262|NCT01574521||both parents carriers|fetuses whose both parents were HBV carriers
10035185|NCT01803685||Comprehensive treatment|Use two or three methods ( Surgical treatment stereotaxic radiosurgery endovascular treatment ) to cure the intracranial arteriovenous malformations
10035186|NCT01803685||Conservative treatment|Patients refused to any of the treatment above
10035187|NCT01803698|Experimental|Training in the use of IOM charts|"Training family physicians to regularly refer to the Institute of Medicine guideline trajectories and provide feedback about GWG (training in the use of IOM charts) during routine prenatal visits."
10035188|NCT01803698|No Intervention|Usual care|Family physicians providing usual prenatal care.
10035189|NCT01803750||Primary Care Providers|Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.
10035190|NCT01803763|Active Comparator|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
10035191|NCT01803763|Placebo Comparator|Placebo|Fixed dose of Placebo is subcutaneously administered in total 4 monthly doses
10035192|NCT01803776|Experimental|lifestyle counseling|Physical activity and dietary counseling
10035193|NCT01803776|No Intervention|Control|No active intervention
10035194|NCT01803789|Active Comparator|Single Kirschner Wire|Antegrade intramedullary fixation of with a single Kirschner wire.
10035195|NCT01803789|Active Comparator|Double Kirschner Wire|Antegrade intramedullary fixation with double Kirschner wire.
10035196|NCT01803802|Placebo Comparator|Time management|Writing prompts oriented towards objective recounting of previous day
10035197|NCT01803802|Experimental|Sexual schema writing|Expressive writing prompts oriented towards beliefs about sexuality
10035198|NCT01803802|Active Comparator|Trauma writing|Expressive writing prompts oriented towards processing traumatic experiences
10035199|NCT01803828|Active Comparator|Drug Group (Tadalafil)|Tadalafil 20 mg
10035200|NCT01803828|Placebo Comparator|Placebo Group (PLC)|Placebo 20 mg
10035201|NCT01803841|Active Comparator|Transradial access|Coronary angiography and intervention via radial artery approach
10035202|NCT01803841|Active Comparator|Transfemoral access|Coronary angiography and intervention via femoral artery approach
10035203|NCT01803867|Placebo Comparator|rHIgM22|"Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.~Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
9945496|NCT01042210||Mothers, Physiological pregnancy-labour|The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.
9945497|NCT01042249|Experimental|Treatment|Treated with Pelvic Floor Muscle Training in 12 weeks
9945498|NCT01042249|No Intervention|Control|Receives standard rehabilitation after stroke
9945499|NCT01042262|Experimental|Oxygen Group|Subjects received 100% oxygen via nasal cannula (flow =2 L/min)
9945500|NCT01042262|Placebo Comparator|Control Group|Subjects were attached to a nasal cannula without any oxygen flow.
9945501|NCT01042275||TOT|transobturator sling, outside-in (TOT)
9945502|NCT01042275||TVT-O|Tension-free transobturator tape, inside-out (TVT-O)
9945503|NCT01042275||IVS|retropubic Intravaginal Sling (IVS)
9945504|NCT01042275||TVT|retropubic tension-free vaginal tape (TVT)
9945505|NCT01042275||REMEEX|Re-adjustable mechanical external sling (REMEEX)
9945506|NCT01042301|Experimental|Long-term type 1 diabetic patients|Long-term type 1 diabetic patients
9945507|NCT01042301|Active Comparator|control patients|control patients
9945508|NCT01042301|Experimental|diabetic and transplanted patients|diabetic and transplanted patients
9945509|NCT01042301|Experimental|subjects with high risk for diabetes|subjects with high risk for diabetes
9945510|NCT01042301|Experimental|patients with recent type 1 diabetes|patients with recent type 1 diabetes
9945511|NCT01042301|Experimental|patients with Latent Autoimmune Diabetes|patients with Latent Autoimmune Diabetes
9945512|NCT01042314|Experimental|Donepezil and BMS-708163|
9945513|NCT01042327|Experimental|dialyzer comparison|"Stable chronic kidney dialysis patients, currently dialyzing on the main Royal Free hospital dialysis unit will be asked to participate in the study. It is aimed to recruit 15 patients currently dialysing using the Fresenius FX100 dialyzer, who have used Fresenius polysulphone membranes for > 3 months.~During a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility.~Thereafter patients would be switched to dialyse using the ELISIOTM-H dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated"
9945514|NCT01042340|Experimental|Intervention with energy dense formula|Patients were randomised to intervention with the energy dense formula Calogen.
9945515|NCT01042340|No Intervention|Control group|The patients that were randomised to control group were assigned to ordinary treatment.
9945516|NCT01042353|Experimental|E test|
9945517|NCT01042353|Active Comparator|standard culture method|
10214842|NCT04200963|Experimental|IK-175 Single Agent Dose Expansion|A Single Agent Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D.
10214843|NCT04200963|Experimental|IK-175 and nivolumab Combination Dose Escalation|Approximately 2 dose escalation steps are planned during the Combination Treatment dose escalation phase of the study.
10214844|NCT04200963|Experimental|IK-175 and nivolumab Combination Dose Expansion|A Combination Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D.
10214845|NCT04200911|Experimental|RAPA intervention|Sirolimus 1mg orally once a day for 8 weeks
10214846|NCT04198584|Experimental|VC-CBCS Intervention|The VC-CBCS intervention was delivered via WebEx videoconferencing technology and included 14, 2-hour long sessions that involved group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials included a hard copy Patient Workbook and audio-recorded relaxation techniques.
10214847|NCT04198584|No Intervention|Standard of Care (SC)|Participants randomized to SC received no intervention and were followed by medical providers in clinic per clinical practice guidelines and clinicians discretion.
10214848|NCT04190888||Sickle Cell Disease|Patients with sickle cell disease will be followed prospectively
10214849|NCT04182776||Pelvis fracture type II to IV|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
10214850|NCT04178434|Active Comparator|Internet-based CBT intervention|A nine step internet-based intervention with focus on stress and anxiety
10214851|NCT04178434|No Intervention|Treatment as usual|Regular follow-up with two doctor and one nurse appointment
10214852|NCT04177901|Active Comparator|Brachial plexus blockage group|
10214853|NCT04177901|Active Comparator|local anesthesia group|
10214854|NCT04171765|Placebo Comparator|Fixed Dose: Placebo|Participants will receive a fixed dose of placebo matched to BFKB8488A.
10214855|NCT04171765|Placebo Comparator|Individualized Dose: Placebo|Participants will received a dose of placebo matched to BFKB8488A.
10214856|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose A|Participants will receive BFKB8488A.
10214857|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose B|Participants will receive BFKB8488A.
10214858|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose C|Participants will receive BFKB8488A.
10214859|NCT04171765|Experimental|Individualized Dose: BFKB8488A|Participants will receive increasing doses of BFKB8488A up to the highest tolerated dose .
10214860|NCT04168632|Experimental|Intervention|A new 4-week menu plan
10214861|NCT04163614|No Intervention|Control|Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.
10214862|NCT04163614|Experimental|IBPS (Intradialytic Blood Pressure Slope) Arm|IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.
9945545|NCT01042418|Experimental|Whole kernel breakfast|
9945546|NCT01042418|Placebo Comparator|Wheat reference breakfast|
9945547|NCT01042418|Active Comparator|Milled kernel breakfast|
9945548|NCT01042431||Ward population|Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study
10004263|NCT01574534|Experimental|Drug eluting balloon|paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany
10035204|NCT01803893||Embryo culture media|measurement using immunoassay
9945549|NCT01042444|Experimental|Embolic Protection Device|The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
9945550|NCT01042457|Other|Mycophenolate mofetil|
9945551|NCT01042470||control group|female patients without pelvic organ prolapse, stage 0 or I (POP-Q)
9945552|NCT01042470||pelvic organ prolapse|female patients with pelvic organ prolapse stage II or higher (POP-Q)
9945553|NCT01042561|Placebo Comparator|placebo|This group will recieve the current standard of care for infants in the NICU, recieving infant formula that provides less than 400 IU of vitamin D a day.
9945554|NCT01042561|Experimental|Vitamin d|This group will recieve standard of care infant formulas that provide less than 400 IU of vitamin D a day, in addition they will be supplemented with 400 IU of vitamin D3 daily.
9945555|NCT01042587|Active Comparator|bright light|Bright light has been shown to entrain circadian rhythm so our treatment arm will use thirty minutes of early morning exposure to bright blue light for a four week period.
9945556|NCT01042587|Sham Comparator|red light|Low level red light is a weak entrainment stimulus of circadian rhythm. Elders in the control group will be exposed to low level red light as a placebo for thirty minutes daily for four weeks.
9945557|NCT01042626|Experimental|Normocalcemic Hyperparathyroidism|
9945558|NCT01042626|Experimental|Hypercalcemic Hyperparathyroidism|
9945559|NCT01042626|Active Comparator|Healthy subjects|
9945560|NCT01042639|Active Comparator|physical activity once a day|
9945561|NCT01042639|Experimental|physical activity twice a day|
9945562|NCT01042639|No Intervention|control|
9945563|NCT01042652|Active Comparator|Nevirapine|
9945564|NCT01042652|Experimental|Raltegravir|
9945565|NCT01042665||primary open angle glaucoma|"Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included."
9945566|NCT01042665||Ocular Hypertensive group|Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam
9945567|NCT01042691|Experimental|Oxaliplatin|Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment
9945568|NCT01042704|Experimental|Bendamustine, Lenalidomide and Dexamethasone|Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
9945569|NCT01042717|Experimental|Plerixafor|Plerixafor 16 hours
9945570|NCT01042730|Active Comparator|Pitavastatin 1 mg daily|
9945571|NCT01042730|Active Comparator|Pitavastatin 4 mg daily|
10035205|NCT01803893||maternal serum|measurement by immunoassay
9945572|NCT01042743|Experimental|RAP|individuals who underwent robot-assisted surgery for primary right-sied colon cancer
9945573|NCT01042743|Active Comparator|LAP|Individuals who underwent laparoscopic surgery for primary right-side colon cancer
9945574|NCT01042782|Experimental|RAD-MitC|RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
10004264|NCT01574534|Active Comparator|Drug eluting stent|paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA
10004265|NCT01574547||Cat Scratch Colon|Patients with mucosal tears during colonoscopy
10004266|NCT01574547||Control group|Patients without mucosal tears during the colonoscopy
10004267|NCT01574560|Active Comparator|Control Group - Health Education|This group is provided with information regarding secondhand smoke and creating a healthy home environment.
10004268|NCT01574560|Active Comparator|Treatment Group - Counseling|This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
10004269|NCT01574573|Experimental|Obese individuals with weight loss|Self support, group sessions
10004270|NCT01574573|Experimental|Obese individuals without weight loss|self support, group sessions
10004271|NCT01574586|Active Comparator|2-link stent Nobori|Bifurcation stenting
10004272|NCT01574586|Active Comparator|3-link stent Xience|Bifurcation stenting
10004273|NCT01574599|Experimental|Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
10004274|NCT01574599|No Intervention|Conventional Therapy Program|Typical therapy excluding robotics, RFE
10004275|NCT01574625||Mosaic prosthetic heart valve|All patients who were enrolled and implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany) during the previous Mosaic PMA study and who agree to participate in this long-term follow-up study by informed consent.
10004276|NCT01574638|Experimental|Arm 1B|Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
10004277|NCT01574638|Experimental|Arm 1A|Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
10004278|NCT01574638|Experimental|Arm 2A|Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
10004279|NCT01574638|Experimental|Arm 2B|Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
10004280|NCT01574664||Subjects scheduled to undergo lumpectomy|
9801212|NCT01709578|Placebo Comparator|Placebo q2w|Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
10004281|NCT01574677||Screening FIT positive|Patients aged 49-80, with a positive screening FIT, who are referred to colonoscopy, and who meet inclusion criteria.
9801213|NCT01709578|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
10004282|NCT01574690||Heart failure patients|50 subjects (both male and female) Heart failure patients already receiving RHC as part of their usual care
10004283|NCT01574729|Active Comparator|Surgery plus post-surgery chemotherapy|Surgery plus post-surgery chemotherapy
10004284|NCT01574729|Experimental|Surgery combined with rAd-p53 gene therapy|Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy
10004285|NCT01574742|Experimental|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
10004286|NCT01574781||Women with abnormal fetus|Women carrying fetus that is identified as chromosomally abnormal by CVS/Amniocentesis
10004287|NCT01574781||Women experiencing miscarriage|Women identified as miscarrying, prior to any D&C or D&E procedure
10004288|NCT01574781||Born children|The children born from women participating in other cohorts of the study.
10004289|NCT01574781||Male relatives|The male partners (and presumed biological father of any fetuses/children) of women participating in other cohorts of the study or the biological father's brother and/or father.
10004290|NCT01574781||Non-pregnant women|Healthy women who are not pregnant
10004291|NCT01574781||Pregnant women|
10004292|NCT01574794|Experimental|Strengthening Exercises|Recreational older runners recruited from local community
10004293|NCT01574794|Experimental|Stretching Exercises|Recreational older runners recruited from local community
10004294|NCT01574794|No Intervention|Control Group|Recreational older runners recruited from local community
10004295|NCT01574820|Placebo Comparator|placebo|
10004296|NCT01574820|Experimental|rosiglitazone (4 mg)/day|
10004297|NCT01574833|Active Comparator|PEMF|arm that receive PEMF treatment
10004298|NCT01574833|Sham Comparator|Sham|arm that receive sham treatment
10004299|NCT01574846||Vantas|
10004300|NCT01574859||hypopituitarism|group of patients with hypopituitarism
9945575|NCT01042808||1|HIV-1 Infected patients treated with Isentress
9945576|NCT01042821|Active Comparator|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
9945577|NCT01042821|Active Comparator|Group 2|The flap comprised mucosa, submucosa only
9945578|NCT01042834||Air pollution|The subjects will have to live in districts where important atmospheric pollution is established
9945579|NCT01042860|Active Comparator|supplement|lutein supplement
9945580|NCT01042860|Placebo Comparator|placebo|Placebo
9945581|NCT01042873|Other|Intravenous dobutamine|3 hours infusion of dobutamine
9945582|NCT01042886|Experimental|Family plus community focused intervention|
9945583|NCT01042886|Active Comparator|Standard Behavioral Weight Loss Maintenance Intervention|
9945584|NCT01042899|Experimental|Teen Online Problem Solving (TOPS)|Web intervention
9945585|NCT01042899|Experimental|Teen Online Problem Solving---Teen Only|Web Intervention
9945586|NCT01042899|Active Comparator|Internet Resources Comparison|Web Intervention
9945587|NCT01042951|Active Comparator|ShanChol Cholera Vaccine|
9945588|NCT01042951|Placebo Comparator|Placebo|
9945589|NCT01042990|Active Comparator|Home Exercise Only|Participants receive education and instruction on a home exercise program which they do on their own, with intermittent encouragement from study personnel.
9945590|NCT01042990|Experimental|APA|Participants exercise in a gym setting 3x/week for six months, performing gait and balance exercises along with a progressive walking program.
9945591|NCT01042990|Experimental|APA+TM|Participants exercise in a gym setting 3x/week for six months, performing a combined program of adaptive physical activity (gait and balance training) and progressive treadmill walking.
9476349|NCT03572673|Experimental|New 2-piece ostomy appliance|New 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
9945592|NCT01043003|Experimental|Arm I|Patients and caregivers undergo the Bilingual Breast Cancer Educational Intervention (BBCEI) comprising teaching sessions over 50-65 minutes about 4 specific domains (i.e., physical, psychological, social, and spiritual well being) once weekly during month 1 and also undergo evaluation sessions at months 1, 4, and 7. Patients and caregivers receive reinforcement telephone calls every other week.
9945593|NCT01043003|Active Comparator|Arm II|Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
9945594|NCT01043016|Experimental|Photocyanine injection|Patients receive intravenous injection of Photocyanine injection from dosage of 0.1 mg/kg,0.2 mg/kg,0.33 mg/kg,0.5 mg/kg to 0.6 6mg/kg till the dose-limiting effect occur.
9945595|NCT01043042||Hospitalized patients|patients hospitalized at VUH between 4/1/2008 to 10/31/2009
9945596|NCT01043055||Breast Cancer Patients|
9945597|NCT01043055||Healthy Control Group|
9945598|NCT01043068|Experimental|Pain control|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
9945599|NCT01043107||Compuer radiaton group|
9945600|NCT01043107||control group|
9476350|NCT03572647|Experimental|Test ERITROMAX|Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)
9945601|NCT01043120|Experimental|Barusiban|
9945602|NCT01043120|Placebo Comparator|Placebo|
9945603|NCT01043172|Experimental|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
9945604|NCT01043224|Experimental|Clobetasol propionate plus calcipotriol|
9945605|NCT01043250||Risperidone|Receiving risperidone treatment
9945606|NCT01043250||Olanzapine|Receiving olanzapine treatment
9945607|NCT01043250||Aripiprazole|Receiving aripiprazole
9945608|NCT01043276|Experimental|Treatment A|
9945609|NCT01043276|Experimental|Treatment B|
9945610|NCT01043276|Experimental|Treatment C|
9945611|NCT01043276|Experimental|Treatment D|
9945612|NCT01043276|Experimental|Treatment E|
10004301|NCT01574872|Experimental|Aerosal|This arm include all patients treated with Aerosal®
9945613|NCT01043289|Experimental|Bright light therapy|Early morning white light @ 7,000 lux for 60 minutes daily (4.2 x 10^5 lux-min) for 5 weeks
9945614|NCT01043289|Placebo Comparator|Dim red light|Early morning dim red light @ 70 lux for 60 minutes daily (3.0 x 10^3 lux-min) for 5 weeks
9945615|NCT01043302||Surgery+chemotherapy|Primary mass was resected and systemic chemotherapy was performed as an adjuvant treatment
9945616|NCT01043302||Chemotherapy|Only treated with chemotherapy
9945617|NCT01043328||GROUP OSCC|"The study group is composed by patients with a condition that requires a procedure/surgery for oral squamous cell carcinoma treatment.~INTERVENTIONS: Collect blood, saliva and oral tissue."
9945618|NCT01043328||CONTROL GROUP|"Group without oral squamous cell carcinoma but with a condition that requires prosthetic procedure/surgery.~INTERVENTIONS: Collect blood, saliva and oral tissue."
9945619|NCT01043341|Active Comparator|behavioral|the women received a folder about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines.
9945620|NCT01043341|No Intervention|no intervention|the women answered a questionaire about sexual behavior, HPV infection and vaccines
9945621|NCT01043354|Experimental|stage-matched intervention|Transtheoretical Model-based stage-matched intervention
9945622|NCT01043354|Experimental|framing effects intervention|counseling based on prospect theory
9945623|NCT01043354|Active Comparator|attention placebo intervention|counseling about general health topics
9945624|NCT01043367|Experimental|A|Deprexil
9945625|NCT01043367|Placebo Comparator|B|Placebo
9945626|NCT01043380|Experimental|LZ group|
9945627|NCT01043380|Active Comparator|L group|
9945628|NCT01043406|Experimental|Single Arm, Device Implant|
9945629|NCT01043419|Experimental|LENOXe™ (xénon 100 % v/v)|Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia
9945630|NCT01043445|Experimental|GPR119 agonist, 2-oleoyl glycerol|2-oleoyl glycerol; 2g. and vehicle
9945631|NCT01043445|Active Comparator|Oleic acid|oleic acid; 3.2g and vehicle
9945632|NCT01043445|Placebo Comparator|Vehicle|5 ml. of glycerol and 5 ml 96% ethanol
9945633|NCT01043458|Experimental|1|ABT-126 Low Dose
9945634|NCT01043458|Experimental|2|ABT-126 High Dose
9945635|NCT01043458|Experimental|3|Placebo for ABT-126
9945636|NCT01043471|Experimental|Chewing gum|
9945637|NCT01043471|Placebo Comparator|Water|
9945638|NCT01043484|Experimental|A|Bevacizumab + Capecitabine + Radiotherapy
9945639|NCT01043484|Active Comparator|B|Capecitabine + Radiotherapy
9945640|NCT01043510|Experimental|A1, first period|
9945641|NCT01043510|Active Comparator|A2, second period|
9945642|NCT01043510|Active Comparator|B1, first period|
9945643|NCT01043510|Experimental|B2, second period|
10004302|NCT01574872|Placebo Comparator|Placebo|This arm include all patients treated with placebo
10004303|NCT01574885|Experimental|Aerosal|This arm include all patients treated with Aerosal®
9945644|NCT01043536|Experimental|radiotherapy + temozolomide|"Radiotherapy:~dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3~dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3~Chemotherapy:~temozolomide given at the dose of 75mg/m2"
9945645|NCT01043549|Active Comparator|Stimulation|Repetitive transcranial stimulation of the posterior parietal cortex
9945646|NCT01043549|Sham Comparator|Sham stimulation|
9945647|NCT01043575|Experimental|1|Rifapentine
9945648|NCT01043575|Active Comparator|2|Rifampin
9945649|NCT01043588|Other|1 : TURP|Surgery: TransUrethral Resection of the Prostate
9945650|NCT01043588|Other|2 : PVP|Surgery: Photo selective Vaporization of the Prostate
9945651|NCT01043601|Experimental|Inhaled PT005 7.2 µg|
9945652|NCT01043601|Experimental|Inhaled PT005 9.6 µg|
9945653|NCT01043601|Placebo Comparator|Inhaled Placebo|
9945654|NCT01043601|Active Comparator|Formoterol Fumarate 12 µg (Foradil Aerolizer)|
9945655|NCT01043614|Experimental|Peer group education|Small groups of female college freshmen facilitated by peer educators
9945656|NCT01043666|Experimental|YM178 group|oral
9945657|NCT01043666|Placebo Comparator|placebo group|oral
9945658|NCT01043666|Experimental|tolterodine ER group|oral
9945659|NCT01043679|Active Comparator|Seroquel|Efficacy and Safety of Seroquel
9945660|NCT01043679|Active Comparator|Utapine|Efficacy and Safety of Utapine
9945661|NCT01043692|Experimental|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
9945662|NCT01043718|Experimental|More-Intensive|
9945663|NCT01043718|Active Comparator|Less-Intensive|
9945664|NCT01043731||Ginven indication for laparoscopic anterior resection|
9945665|NCT01043744|Experimental|Artemether-Lumefantrine|Receive artemether-lumefantrine with direct observation of am dose on days 0, 1, and 2 of study
9945666|NCT01043744|No Intervention|No treatment|No antimalarial treatment given on day 0.
9476351|NCT03572647|Active Comparator|EPREX|Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
9945667|NCT01043757|Experimental|Control|1) Control Group. Receives daily step goals via emails and has access to the study website to allow them to track their progress. Eligible for check-in incentives.
9945668|NCT01043757|Experimental|Fixed|"Receives control intervention plus are incentivized to attain their daily step goals through daily lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot. Participants who meet their step goal for the day and who upload their data will be entered into the same lottery each day, where the small jackpot is $10 and the large jackpot is $100."
9945669|NCT01043757|Experimental|Ascending|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot.~Participants can increase their daily jackpots by meeting their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $4 and the large jackpot is $40; if they successfully meet their step goal on the first day of the week, the jackpots for the second day increase to $6/$60, and so on such that if they reach their goals each day, the jackpots on day seven will reach $16/$160."
9945670|NCT01043757|Experimental|Decreasing|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Daily drawing procedure same as Ascending condition; structure of incentives is different: Participants can decrease their daily jackpots by failing to meet their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $16 and the large jackpot is $160; if they successfully meet their step goal on the first day of the week, the jackpots will remain at $16/$160; if they do not meet their goal the jackpots will decrease to $14/$140, and so on such that if they fail to reach their goals each day, the jackpots on day seven will decrease to $4/$40."
9945671|NCT01043770|Experimental|Group lifestyle education|Multi-component behaviour change intervention
9945672|NCT01043770|No Intervention|Routine care|Routine care
9945673|NCT01043796|Experimental|Insecticide treated nets and wall liners|
9945674|NCT01043796|Active Comparator|Insecticide treated nets alone|
9945675|NCT01043809|No Intervention|1|Randomly selected schools will not receive handwashing intervention
9945676|NCT01043809|Experimental|2|Randomly selected schools will get standard commercial school-based handwashing promotion
9945677|NCT01043809|Experimental|3|Randomly selected schools will receive standard commercial school-based handwashing promotion program, plus an added level of handwashing promotion (varies by country)
9945678|NCT01043835|Experimental|Laparoscopy-assisted gastrectomy|
9945679|NCT01043835|Active Comparator|Open gastrectomy|
9945680|NCT01043848|Experimental|Early pudendal stimulation|Subjects in this arm will start with the intervention within 2 weeks after SCI
9945681|NCT01043848|Experimental|Late pudendal stimulation|Subjects in this arm will start with the intervention 12 weeks after SCI
9945682|NCT01043848|No Intervention|Control|Subjects in this arm will be treated according to standard therapy but will receive no pudendal stimulation
9945683|NCT01043887|Experimental|Patients with Moderate Hepatic Insufficiency|Patients with moderate hepatic insufficiency (a score of 7 to 9 on the Child-Pugh's scale) received a single 10 mg dose of ridaforolimus.
9945684|NCT01043887|Experimental|Healthy Control Subjects|Healthy control subjects were matched by race, age, gender, and body mass index (BMI) to the patients with moderate hepatic insufficiency. The healthy control subjects also received a single 10 mg dose of ridaforolimus.
9945685|NCT01043900|Placebo Comparator|Sham rTMS|Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
9945686|NCT01043900|Active Comparator|Active rTMS|Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
9945687|NCT01043913|Experimental|Guaraná extract 50mg q12 hours|Guaraná extract pills of 50mg q12 hours for 21 days
9945688|NCT01043913|Placebo Comparator|Placebo 1 tab q12 hours|Placebo pills 1 tab q12 hours for 21 days
9945689|NCT01043952|Active Comparator|Control|"Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
9945690|NCT01043952|Experimental|Bispectral Index Monitor|"Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
9945691|NCT01043965|Active Comparator|Diabetes|Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
9945692|NCT01043965|No Intervention|Control|Control group - normal, healthy individuals.
9945693|NCT01043978|Experimental|Novel nipple|
9945694|NCT01043978|Active Comparator|Coventional nipple|
9945695|NCT01043991|Experimental|EPO|single bolus of EPO, 150 µg
9945696|NCT01043991|Placebo Comparator|Placebo|NaCl
9945697|NCT01044004|Experimental|Post treatment remission armodafinil|Armodafinil 150 mg/day for 13 weeks
9945698|NCT01044004|Placebo Comparator|Post treatment remission placebo|Placebo 150mg/day for 13 weeks
9945699|NCT01044004|Experimental|Chemotherapy armodafinil|Armodafinil 150 mg/day for 13 weeks
9945700|NCT01044004|Placebo Comparator|Chemotherapy placebo|Placebo 150mg/day for 13 weeks
9945701|NCT01044017|Experimental|A|
9945702|NCT01044017|Experimental|B|
9945703|NCT01044017|Placebo Comparator|C|
9945704|NCT01044082|Experimental|controlled cord traction|Controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs.
9945705|NCT01044082|Active Comparator|clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
9945706|NCT01044095|Active Comparator|Autologous prime boost regimen 1|FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)
9945707|NCT01044095|Active Comparator|Autologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)
9945708|NCT01044095|Experimental|Heterologous prime boost regimen 1|FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later
9945709|NCT01044095|Experimental|Heterologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later
9945710|NCT01044108|Experimental|Trial, part 1 (males only)|
9945711|NCT01044108|Experimental|Trial, part 2 (males and females)|
9945712|NCT01044121|Experimental|Mattress Firmness|
9945713|NCT01044134|Experimental|Diet + Water|"Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water)."
10004304|NCT01574885|Placebo Comparator|Placebo|This arm include all patients treated with placebo
10004305|NCT01574898|Active Comparator|Niquitin® Fresh Mint 4 mg|
10004306|NCT01574898|Active Comparator|V0118 - B mg|
10004307|NCT01574898|Experimental|V0474 - C mg|
10004308|NCT01574898|Experimental|V0474 - B mg|
9945714|NCT01044134|Active Comparator|Diet|Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.
9945715|NCT01044147|Experimental|VLM-S|"Participants in this arm receive standard lifestyle coaching, which is delivered on a specified schedule. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
9945716|NCT01044147|Experimental|VLM-M|"Participants in this arm receive modulated lifestyle coaching, where coaching frequency may be adjusted according to whether the participant is meeting program goals for program use and targeted behaviors. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
9945717|NCT01044147|Active Comparator|OGR|Participants in this arm will receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle, but not personalized lifestyle coaching.
9945718|NCT01044186|Experimental|ICL670|
9945719|NCT01044199|Experimental|1: Pre-EP ID|Group of participants receiving PCEC rabies vaccine intradermally with the Pre-Exposure schedule.
9945720|NCT01044199|Active Comparator|2: Pre-EP IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Pre-Exposure schedule.
9945721|NCT01044199|Experimental|3: Booster ID|Group of participants receiving PCEC rabies vaccine intradermally with the Booster schedule.
9945722|NCT01044199|Active Comparator|4: Booster IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Booster schedule.
9945723|NCT01044225|Active Comparator|Cilengitide EMD 121974|A dose of 2000 mg by iv administration 2 weekly.
9945724|NCT01044225|Active Comparator|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
9945725|NCT01044238|Experimental|active medication (methylphenidate)|Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
9945726|NCT01044238|Placebo Comparator|Placebo|Condition randomly assigned to receive placebo, provided to appear identical to active medication
9476352|NCT03572608|Experimental|Acupuncture Treatment|Acupuncture group will receive 3 acupuncture sessions. The first session will be one week before embryo transfer. The second session will be 30 minute before embryo transfer. And the last session will be 30 minute after embryo transfer.
9476353|NCT03572608|No Intervention|Control Group|Control Group will not receive any acupuncture session before or after embryo transfer.
9476354|NCT03572595||Staging|Patients with pathologically proven colorectal cancer presented for pre-operative staging, underwent standard routine conventional radiological imaging i.e MRI , then will be subjected to be imaged by F-18 FDG-PET/CT from skullbase to midthigh, then interpretating the results of the hybrid PET/CT by two nuclear physicians then comparing with other conventional images.
9480668|NCT05262114||Pre-cursor text|A pre-notification text message (SMS) will be sent to eligible people informing them of their imminent invitation to participate in The Who, two days later a brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
9945727|NCT01044251|Placebo Comparator|Placebo|10 days of treatment with placebo in a bid fashion that will look like the study medication.
9945728|NCT01044251|Experimental|Frovatriptan|Frovatriptan 2.5 mg po bid for 10 days
9945729|NCT01044277|Experimental|Group A|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
9945730|NCT01044277|Experimental|Group B|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
9945731|NCT01044277|Placebo Comparator|Group C|Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
9945732|NCT01044316|Active Comparator|Arm 1|
9945733|NCT01044316|Active Comparator|Arm 2|
9945734|NCT01044329|Active Comparator|Intravitreal bevacizumab|
9945735|NCT01044329|Active Comparator|Intravitreal triamcinolone|
9945736|NCT01044342|Experimental|A|Single dose of AZD1446 10 mg
9945737|NCT01044342|Experimental|B|Single dose of AZD1446 80 mg
9945738|NCT01044342|Active Comparator|C|Single Dose of Donepezil 5 mg
9945739|NCT01044342|Placebo Comparator|D|Single dose of placebo to match AZD1446
9945740|NCT01044355|Active Comparator|auto-titrating|Patients being treated for 6 weeks with auto-titrating continuous airway pressure.
9945741|NCT01044355|Active Comparator|Fixed|Patients receiving 6 weeks of treatment with fixed continuous positive airway pressure.
9945742|NCT01044368|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
9945743|NCT01044368|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
9801214|NCT01709578|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
9801215|NCT01709695|Experimental|guanfacine hydrochloride XR|Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
9801216|NCT01709695|Placebo Comparator|Placebo Group|Flexible dose titration of placebo
9801217|NCT01709708|Active Comparator|Marcaine|Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
9801218|NCT01709708|Placebo Comparator|Saline|Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
9801219|NCT01709721|Experimental|Hydromorphone Hydrochloride (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride for the duration of therapy.
9801220|NCT01709721|Active Comparator|Hydromorphone Hydrochloride Titrated Downward/Control (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride titrated downward
9803304|NCT04270500|Active Comparator|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
9803305|NCT04270500|No Intervention|Standard of care (SOC)|Common to both groups as part of the enhanced recovery after surgery (ERAS) protocol as the standard of care in our institution.
9803306|NCT04268771|Experimental|Arm A: DRL_RI|Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with Rituximab, will be enrolled. DRL_RI will be administrated in combination with MTX as two 1000 mg infusions on Day 1 and Day 15
9803307|NCT04268771|Active Comparator|Arm B: US-Rituximab or EU-Rituximab|"Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with rituximab, will be enrolled.~Patients enrolled in Arm -B will continue to receive US-rituximab or EU-rituximab. The rituximab reference product used (US-licensed rituximab [Rituxan] or EU-approved rituximab [MabThera]) should be the same in the prior and the randomized treatment course, respectively."
9803308|NCT04267120|Experimental|Lenvatinib + Pembrolizumab|"Lenvatinib 20 mg/day will be administered orally on a daily basis and pembrolizumab 200 mg will be infused once every 3 weeks.~Subjects may be treated with pembrolizumab for a maximum of 35 cycles or approximately 2 years, but treatment with lenvatinib can continue beyond 2 years if the subject does not meet other treatment discontinuation criteria."
9803309|NCT04265651|Experimental|Infigratinib 0.016 mg/kg|"Dose Escalation:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
9803310|NCT04265651|Experimental|Infigratinib 0.032 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
9803311|NCT04265651|Experimental|Infigratinib 0.064 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
9803312|NCT04265651|Experimental|Infigratinib 0.128 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.~Dose Expansion:~Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose."
9803313|NCT04259125||Acute symptomatic seizures|This is a cohort of 72 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after being diagnosed with seizures. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after seizures are diagnosed, to participate in an optional blood draw at 2-4 months of age, and to complete surveys at 12 & 24 months of age.
9803314|NCT04259125||Control|This is a cohort of 15 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after having an EEG for possible seizures, but found to have a normal EEG. They will be asked to contribute a blood specimen obtained ideally 48-96 hours (though blood collection allowed 24-120 hours) after birth.
9803315|NCT04258085||Screening plus EMR|Individuals in this group are those residing in districts where health facilities have implemented a breast cancer screening program integrated with cervical cancer screening, the Women's Cancer Early Detection Program (WCEDP).
9803316|NCT04253379|Experimental|pediatric epilepsy children|
9803317|NCT04253379|Active Comparator|healthy children|
9945744|NCT01044394|Experimental|same day, reduced volume PEG-ELS prep|Patients with colonoscopies scheduled in the afternoon will complete 2 liters of PEG-ELS solution the morning of their colonoscopy.
9945745|NCT01044420|Experimental|mFOLFIRI|
9945746|NCT01044446|Experimental|Icodextrin|peritoneal dialysate
10004309|NCT01574898|Experimental|V0474 - A mg|
9945747|NCT01044446|Active Comparator|Glucose-based dialysate|peritoneal dialysate
9945748|NCT01044485|Other|lapatinib + docetaxel|"dose level Lapatinib (OD) Docetaxel (q3wks) Systematic Growth factor Minus 0 1250 mg 75 mg/m2 + systematic growth factor support~0, 1250mg 75 mg/m2 No~+1 1500mg 75mg/m2 No~Minus +1* 1500mg 75mg/m2 + systematic growth factor support~+2 1250mg 100mg/m2 No~Minus +2* + systematic growth factor support~+3 1500mg 100mg/m2 No~Minus +3* + systematic growth factor support~Apart within the minus dose levels, G-CSF support should be added only as rescue strategy if severe neutropenia occurred during the first cycle of studied dose.Patients will receive 4 cycles of the association. In case of benefit of the treatment, they should continue the treatment with lapatinib until progression.* patients will be included at level minus X only if 2 DLT out of 6 patients based on febrile neutropenia occurred at level X"
9945749|NCT01044511|Experimental|Home visit|After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse
9945750|NCT01044511|Active Comparator|Standard|Standard contact via Hotline and traditional referring methods
10004310|NCT01574911||healthy adults|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
10004311|NCT01574911||Adults Chronic venous insufficiency|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
10004312|NCT01574911||patients primary lymphedema|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D
10004313|NCT01574924||Medical residents|
10004314|NCT01574937|Experimental|Treatment Arm|Cabozantinib and abiraterone
10004315|NCT01574963||CAD Patients|Patients suffering from CAD requiring coronary artery bypass grafting
10004316|NCT01574963||Control Patients|Patients without CAD
10004317|NCT01574976|Active Comparator|control, no feeback|subjects without ADHD, probabilistic choices without feedback
10004318|NCT01574976|Active Comparator|control, feedback|subjects without ADHD, probabilistic choices with feedback
10004319|NCT01574976|Experimental|ADHD, no feedback|subjects with ADHD, probabilistic choices without feedback
10004320|NCT01574976|Experimental|adhd, feedback|subjects with ADHD, probabilistic choices with feedback
10004321|NCT01574989|Experimental|Active low-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, low-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
10004322|NCT01574989|Experimental|Active high-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, high-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
9945751|NCT01044524|Experimental|1|SLV 334
9945752|NCT01044550|Other|Treatment|Laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury
9945753|NCT01044550|Active Comparator|Control|Assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.
10004323|NCT01574989|Experimental|Sham rTMS/active anodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, anodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
10004324|NCT01574989|Experimental|Sham rTMS/active cathodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, cathodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
10004325|NCT01574989|Sham Comparator|Sham rTMS/Sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, and both interventions will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
10004326|NCT01575002|Experimental|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
10004327|NCT01575002|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham tDCS stimulation.
9480669|NCT05262114||Invitation only|A brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
9480670|NCT05262101|Experimental|TQB2858 injection|TQB2858 injection (1800mg intravenous(iv), on day 1 of every 3 weeks)
9801221|NCT01709747|Experimental|Hydromorphone Hydrochloride|Hydromorphone hydrochloride for intrathecal administration, 12 months safety evaluation
9801222|NCT01709786||Patients with Suspected Hemorrhage|There is a single group of patients in this study -- those with suspected hemorrhage who satisfy the inclusion and exclusion criteria. The same set of measurements will be take from each patients and those measurements will be compared with one another to determine accuracy.
9801223|NCT01709799|Experimental|Cognitive Training plus Exercise|"Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
9801224|NCT01709799|Active Comparator|Cognitive Training plus Exergames|"Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
9801225|NCT01709799|Active Comparator|Cognitive Training|Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.
9801226|NCT01709838|Other|Deferasirox|All patients were treated with 10mg/kg/day deferasirox with dose adjustments after 4 weeks of treatment according to baseline Liver Iron Concentration (LIC).
9801227|NCT01709864|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
9801228|NCT01709864|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.
9801229|NCT01709903|Experimental|QVA149|QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
9801230|NCT01709903|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device
9801231|NCT01709981|Experimental|Colchicine|1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later
9801232|NCT01709981|Placebo Comparator|Placebo|Placebo 1-2 hours prior PCI, followed by placebo 1 hour later
9801233|NCT01710020|Experimental|CP-690,550|
9801234|NCT01710033|Placebo Comparator|Placebo|
9801235|NCT01710033|Experimental|CP-690,550 5 mg BID|
9801236|NCT01710033|Experimental|CP-690,550 15 mg BID|
9801237|NCT01710033|Experimental|CP-690,550 30 mg BID|
9801238|NCT01710046|Experimental|Cohort 1|
9801239|NCT01710046|Experimental|Cohort 2|
9801240|NCT01710137|Active Comparator|Varenicline|"12 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
9801241|NCT01710137|Placebo Comparator|Placebo|"12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
9801242|NCT01710254|Experimental|Regadenoson MRI|Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine
9801243|NCT01710306|No Intervention|Outreach|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: existing OEF/OIF/OND outreach. VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
9801244|NCT01710306|Experimental|Nurse Care Manager (NCM)|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: Study concierge nurse case manager (NCM). VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
9801245|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x4)|2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
9801246|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x6)|2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).
9801247|NCT01710345|Experimental|Sufentanil NanoTab 20 mcg|Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
9801248|NCT01710345|Experimental|Sufentanil NanoTab 30 mcg|Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
9801249|NCT01710345|Placebo Comparator|Placebo NanoTab|Placebo NanoTab as needed every 60 minutes for 12 hours
9945754|NCT01044563|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
9945755|NCT01044563|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
9945756|NCT01044602|Active Comparator|Best Medical Management|Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
9945757|NCT01044602|Active Comparator|Surgical Treatment|Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
9945758|NCT01044615||Mild traumatic brain injury patients|Subjects who have a verifiable diagnosis of mild traumatic brain injury sustained within 24 months prior to enrollment
9945759|NCT01044615||Normal Control|Normal, healthy adults with no history of brain injury.
9945760|NCT01044628|Experimental|Nocturnal oxygen therapy (N-O2)|Oxygen will be delivered overnight to the patients to allow their oxygen saturation to be >90%
9945761|NCT01044628|Sham Comparator|Sham concentrator|Sham therapy with ambient air will be given to the patients at night
9945762|NCT01044654|Experimental|Cohort 1|3 Subjects will receive a single infusion of 0.5-1.0 x 1010 SB-728-T
9945763|NCT01044654|Experimental|Cohort 2|3 Subjects will receive a single infusion of 2.0 x 1010 SB-728-T
9945764|NCT01044654|Experimental|Cohort 3|3 Subjects will receive a single infusion of 3.0 x 1010 SB-728-T
9945765|NCT01044654|Experimental|Cohort 4|Up to 4 HAART failure subjects will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T
9945766|NCT01044654|Experimental|Cohort 5|"Up to 20 subjects with heterozygote CCR5 delta-32 mutation will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T.~Cohort 5 subjects will undergo a structured treatment interruption 2 months following infusion in which their anti-retroviral therapy will be discontinued for 16 weeks. HAART will be reinstituted in subjects whose CD4+ cell counts drop to <350 cells/mm3 and/or whose HIV-RNA increases to >100,000 on three consecutive weekly measurements.~At the end of the STI, subjects with a sustained detectable viral load will be reinstituted on HAART. Subjects with HIV RNA levels below the limit of detection will remain off HAART. Subjects with an undetectable viral load will remain off HAART until HIV RNA levels are detectable or their CD4 count drops below 350 cell/mm3 on three consecutive weekly measurements."
9945767|NCT01044667|Other|Patients taking Myfortic|Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
9945768|NCT01044680|Experimental|Nutriose|17 g NUTRIOSE consumed twice daily for 12 weeks
9945769|NCT01044680|Placebo Comparator|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
9945770|NCT01044719|Active Comparator|10 days|
9945771|NCT01044719|Active Comparator|14 days|
9945772|NCT01044719|Active Comparator|21 days|
9945773|NCT01044810||Simultaneous interruption (Exposure gr)|stopped all drugs in NNRTI-based regimens simultaneously after allergic reactions to NVP-based regimens, and later started EFV-based regimens
9945774|NCT01044810||Naive (Control group)|HIV-1-infected patients who started EFV-based regimens as their initial ARV regimens.
9945775|NCT01044810||staggered interruption (exposure group)|"after having allergic reactions to NVP-based regimens, stopped NNRTIs first, continued the other NRTIs for a period of time, i.e. staggered interruption, and later started EFV-based regimens"
9945776|NCT01044823||Adult RA|
9945777|NCT01044823||pediatric JRA|
9945778|NCT01044836|Experimental|Etanercept|
9945779|NCT01044875|Active Comparator|green laser 532 nm conventional|Current type of laser used for treatment of proliferative diabetic retinopathy
9945780|NCT01044875|Active Comparator|Yellow 577 nm laser|new laser wavelength for treatment of PDR
9945781|NCT01044927|Experimental|Proactive Integrated Care|COPD-specific education, self-management instruction, remote monitoring and enhanced communication with a coordinator
9945782|NCT01044927|Active Comparator|Standard Care Control|No intervention other that measurements taken at 0, 3, 6 and 9 months of the study.
9945783|NCT01044940||Birth asphyxia|Babies suffering from birth asphyxia
9945784|NCT01044940||Blood transfusion|Babies who receives blood transfusion
9945785|NCT01044940||Heart Surgery|Babies who need heart surgery
9945786|NCT01044953||Soccer Players|German professional soccer players
9945787|NCT01044992|Experimental|Drug and radiation|Levodopa and H215O PET
9945788|NCT01045005|Active Comparator|Type 1 Diabetes|Subjects with type 1 diabetes mellitus who are administered oxygen and carbon dioxide
9945789|NCT01045005|Active Comparator|Control Subjects|Healthy volunteers administered oxygen and carbon dioxide via respiratory apparatus
9945790|NCT01045018|Active Comparator|mesalamine 400 mg tablet|
9945791|NCT01045018|Active Comparator|Asacol 400 mg Delayed Release Tablet|
9945792|NCT01045018|Placebo Comparator|Placebo delayed release tablet|
9945793|NCT01045044||Breast cancer, chemotherapy|Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
9945794|NCT01045044||Normal control|Up to 15 normal, healthy women.
9945795|NCT01045070||coronary heart disease|
9945796|NCT01045083|Experimental|1|
9945797|NCT01045109|Experimental|open-label vitamin D3|One arm: open-label receiving vitamin D3 4,000 IU daily
9945798|NCT01045148|Other|CyberKnife Radiosurgery|CyberKnife Radiosurgery
9945799|NCT01045200||Follow-up|Patients curatively operated for rectal cancer
9945800|NCT01045213|Experimental|Proactive Integrated Care|COPD education, self-management education, remote monitoring (Health Buddy, pulse oximeter, pedometer, spirometer) and enhance communication with cell phone contact with a coordinator.
9945801|NCT01045239|Experimental|Micropulse 577 nm yellow diode laser|
9945802|NCT01045239|Active Comparator|532 nm green diode laser|
9945803|NCT01045252||congenital heart disease|Neonates that are enrolled in the NICU and are confirmed of congenital heart diseases.
9945804|NCT01045252||sepsis|Neonates that are enrolled in the NICU and are diagnosed as sepsis.
9945805|NCT01045252||Health|Neonates that are enrolled in the NICU and have no congenital heart diseases and sepsis.
9945806|NCT01045291|Active Comparator|Fusion Pacing OFF|Subjects initially randomized to the Fusion Pacing OFF Arm will receive the Fusion Pacing software download at the implant visit, but the Fusion Pacing software will be programmed OFF. At 4 months subjects in this arm will crossover to the Fusion Pacing ON Arm.
9945807|NCT01045291|Experimental|Fusion Pacing ON|Subjects initially randomized to the Fusion Pacing ON Arm will receive the Fusion Pacing software download at the implant visit, and the Fusion Pacing software will be programmed ON. At 4 months subjects in this arm will crossover to the Fusion Pacing OFF Arm.
9945808|NCT01045304|Experimental|Gencitabine + iniparib twice weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles"
9945809|NCT01045304|Experimental|Gencitabine + iniparib weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles"
9945810|NCT01045317|Experimental|intravenous or oral administration|
9945811|NCT01045330|No Intervention|Usual Care Group|Usual care consists of standard hospital services provided by physicians, nurses, and support staff (e.g., physical therapist, dietitian) in the general surgery units.
9945812|NCT01045330|Experimental|Experimental Group|The intervention consisted of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
9945813|NCT01045343|Active Comparator|Control Arm|
9945814|NCT01045343|Experimental|Integrated Diagnostics Arm|
9945815|NCT01045356||children less than 2 months old|
9945816|NCT01045356||children 2 months to 12 months old|
9945817|NCT01045356||Children > 2 months old and less than or equal to 20 kg|
9945818|NCT01045369|Experimental|Kaletra And Intelence|This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
9945819|NCT01045382|Experimental|Mensenchymal Stem Cells|"Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.~Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.~MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
9945820|NCT01045382|Placebo Comparator|Placebo|"Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.~Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
9945821|NCT01045395|Placebo Comparator|Corn starch, 90mg/d|Corn starch, 90mg/d
9945822|NCT01045395|Experimental|Unique Marine Algae Concentrate (UMAC). 90mg/d|
9945823|NCT01045395|Experimental|Golden brown algae, 90mg/d|
9945824|NCT01045408|Placebo Comparator|Berry|
9945825|NCT01045408|Placebo Comparator|Placebo|
9945826|NCT01045434|Experimental|Omeprazole Magnesium DR 20 mg Capsules|Omeprazole Magnesium DR 20 mg Capsules of Dr Reddys Laboratories Limited
9945827|NCT01045434|Active Comparator|Prilosec 20 mg Tablets|Prilosec 20 mg Tablets of Procter and Gamble
10004328|NCT01575015|Active Comparator|Standard intraoperative support (no CRRT)|
9945828|NCT01045486|Active Comparator|Group A|Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.
9945829|NCT01045486|Placebo Comparator|Group B|Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.
9945830|NCT01045512|Active Comparator|statins, standardised physical training|
9945831|NCT01045512|No Intervention|to continue with current lifestyle|
9945832|NCT01045525|Experimental|Phlebotomy + lifestyle and diet advices|
9945833|NCT01045525|Active Comparator|Lifestyle and diet advices|
9945834|NCT01045538|Experimental|Vorinostat plus XP|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
9945835|NCT01045564|Experimental|A|One dose of study vaccine (GSK 1557484A) on Day 0, Day 182, and Day 364
9945836|NCT01045564|Experimental|B|One dose of study vaccine (GSK 1557484A) on Day 0, Day 91, and Day 364
9945837|NCT01045564|Experimental|C|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
9945838|NCT01045564|Experimental|D|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
9945839|NCT01045564|Experimental|E|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
9945840|NCT01045577|Active Comparator|Masitinib (AB1010)|Masitinib (AB1010)
9945841|NCT01045577|Placebo Comparator|Placebo mactching masitinib|Placebo matching masitinib
9945842|NCT01045590|Active Comparator|glibenclamide + Rosiglitazone|glibenclamide plus rosiglitazone
9945843|NCT01045590|Placebo Comparator|glibenclamide + placebo|
9945844|NCT01045616||Prematurity|
9945845|NCT01045629||SchizoComp|Competence Ability of schizophrenia
9945846|NCT01045629||NonSchizoComp|Competence of Non-schizophrenia
9945847|NCT01045642|Active Comparator|Prilosec 20 mg Tablets|
9945848|NCT01045642|Experimental|Omeprazole Magnesium DR 20 mg Capsules|
9945849|NCT01045655|Experimental|MOMCare intervention|Depression care treatment with study depression care specialist (brief interpersonal psychotherapy or pharmacotherapy)
9945850|NCT01045655|No Intervention|Care Plus|Usual care group; referral to community mental health treatment
9945851|NCT01045668|Active Comparator|Clinical VT ablation|
9945852|NCT01045668|Active Comparator|clinical VT and substrate ablation|
9945853|NCT01045681|Experimental|BVD|Bendamustine, Velcade and Dexamethasone
9945854|NCT01045720|Placebo Comparator|Placebo Comparator|
9945855|NCT01045720|Experimental|ChinesMed|
9945856|NCT01045733|Experimental|IQ Toric IOL|AcrySof IQ Toric intraocular lens (IOL) randomly assigned to one eye, with AcrySof IQ Aspheric IOL with Limbal Relaxing Incision (LRI) procedure in the fellow eye for contralateral implantation.
9945857|NCT01045733|Active Comparator|IQ Aspheric IOL + LRI|AcrySof IQ Aspheric intraocular lens (IOL) with Limbal Relaxing Incision (LRI) procedure randomly assigned to one eye, with AcrySof IQ Toric IOL in the fellow eye for contralateral implantation
9945858|NCT01045746|Experimental|Group 1|T0, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T1, 16 days wash-out period; T2, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T3
10004329|NCT01575015|Experimental|Intraoperative renal support (CRRT)|
9945859|NCT01045746|Experimental|Group 2|T0, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T1, 16 days wash-out period;T2, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T3
9945860|NCT01045772|Experimental|IL-1 trap|
9945861|NCT01045785||aspirin responsive|PFA Col/EPI normal
9945862|NCT01045785||aspirin resistance|PFA Col/epi showed resistance
9945863|NCT01045811|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
9945864|NCT01045811|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
9945865|NCT01045837|Active Comparator|Prednisolone and Gluten free diet|Gluten free diet and prednisolone in the dose of 1 mg/kg/d over a period of 4 weeks.
9945866|NCT01045837|Placebo Comparator|Gluten free diet|Gluten free alone will be given in this group
9945867|NCT01045863|Experimental|PART A: Ascending Cohorts|Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
9945868|NCT01045863|Experimental|PART B: Food effect|Food effect on PF-03382792 PK
9945869|NCT01045863|Experimental|PART C: CSF Cohort|Optional CSF Cohort
9945870|NCT01045876|Experimental|Dexamethasone|
9945871|NCT01045876|Placebo Comparator|Placebo|
9945872|NCT01045889|Experimental|R-CHOP + PBSCT|All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation
9945873|NCT01045902|Experimental|Arm 1|
9945874|NCT01045902|Active Comparator|Arm 2|
9945875|NCT01045915|Experimental|Plasmid AMEP electrotransfer|
9945876|NCT01045928|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21 and rituximab IV on day 1of courses 1, 3, 5, 7, 9, and 11.
9945877|NCT01045941|Experimental|Patients with distal pancreatic cancer|Patients with distal pancreatic cancer amenable to a laparoscopic distal pancreatectomy
9945878|NCT01045980|Experimental|Bioimpedance and Vitamin D|
9945879|NCT01045980|Experimental|Usual care and Vitamin D|Vitamin D3
9945880|NCT01045980|Experimental|Bioimpedance and Placebo|
9945881|NCT01045980|Placebo Comparator|Usual Care and Placebo|
9945882|NCT01046006|Experimental|Bortezomib, Rituximab, Dexamethasone|BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
9945883|NCT01046032|Active Comparator|Metformin|Drug (including placebo)
9945884|NCT01046032|Placebo Comparator|Sugar pill|Drug (including placebo)
9945885|NCT01046045|Active Comparator|Everolimus|before and after everolimus; in other words, comparison of specified outcome before and after treatment with everolimus
9945886|NCT01046045|Active Comparator|Calcineurin-inhibitor immunosuppression|Cyclosporin-based immunosuppression without everolimus
9945887|NCT01046058|Experimental|Panel A: TMC435 150 mg|Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.
9945888|NCT01046058|Experimental|Panel B: TMC435 150 mg|Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.
9945889|NCT01046071|Experimental|transversus abdominis plane block|transversus abdominis plane block with ropivacaine
9945890|NCT01046071|Placebo Comparator|block with saline|20 ml of isotonic saline bilateral
9945891|NCT01046097||Synflorix Group|Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
9945892|NCT01046123|Experimental|Whole brain radiotherapy|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
9945893|NCT01046149|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
9945894|NCT01046149|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
9945895|NCT01046162|Active Comparator|Tafil Tablets 2 mg Pharmacia Upjohn|
9945896|NCT01046162|Active Comparator|Xanax Tablets 2 mg Pfizer LLC|
9945897|NCT01046175|Experimental|Airstacking with manual resuscitator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
9945898|NCT01046175|Active Comparator|Air-stacking with ventilator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a ventilator.
9945899|NCT01046188|Experimental|Web-based Teaching Group|Patients randomized to the intervention group will receive a unique login and password to a link on the Ottawa Fertility Centre website. This will allow them access to a secure site containing required teaching modules. They will then complete an interactive teaching tool that contains the same educational content as the traditional presentation. Patients will be able to access a module that is specific to their stimulation protocol. The teaching tool does not need to be completed all at one time. Once completed, the information can still be accessed as many times as required.
9945900|NCT01046188|Active Comparator|Control group|Participants randomized to the control arm of the study will participate in a traditional didactic teaching session. This session will be carried out by the nurse educator. This session will be attended by up to 10 other couples that may or may not be participating in the study. The nurse educator administering the session will not know which couples are participating in the study. Slides shown and information conveyed will be the same as that provided to the web-based group, however all three stimulation protocols will be presented to the participants regardless of their actual treatment protocol.
9945901|NCT01046201||Obese Children|
9945902|NCT01046214|Experimental|Budeprion XL™|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
9945903|NCT01046214|Active Comparator|Wellbutrin XL®|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
9945904|NCT01046227||Serology after Novel H1N1 vaccination|This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in pediatric haemato-oncology patients.
9945905|NCT01046240|Active Comparator|Intravenous palonosetron|Intravenous palonosetron: control arm (standard treatment)
9945906|NCT01046240|Experimental|subcutaneous palonosetron|subcutaneous palonosetron
9945907|NCT01046266|Experimental|A|
9945908|NCT01046266|Active Comparator|B|
9945909|NCT01046279||Glioma Patient receiving Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
9945910|NCT01046292|Experimental|Ginkgo biloba|
9945911|NCT01046292|Placebo Comparator|Placebo control|
9945912|NCT01046305||Part 1: Interview & Questionnaires|Patients interviews and questionnaires about CML symptoms once.
9945913|NCT01046305||Part 2: Symptoms Rating|Importance of symptoms to CML patients rated by physicians, nurses, patients, and caregivers.
9945914|NCT01046305||Part 3: MDASI-CML Questionnaires|Patients questionnaires about CML symptoms over 1 year using M. D. Anderson Symptom Inventory (MDASI) module (the MDASI-CML)
10004330|NCT01575041|Active Comparator|Sodium|For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
10004331|NCT01575041|Active Comparator|Potassium|For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
10004332|NCT01575041|Placebo Comparator|Placebo|For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
10004333|NCT01575067||blood pressure monitor|Cuff circumference:22cm-42cm
10004334|NCT01575067||stethoscopy|Cuff circumference: 22cm-42cm
10004335|NCT01575119|Experimental|In-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
10004336|NCT01575119|Active Comparator|In-patient|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
10004337|NCT01575119|Experimental|Out-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
10004338|NCT01575119|Active Comparator|Out-patient|Standard of care information, including distributing a patient education brochure, to provide information regarding perioperative smoking
9945915|NCT01046318|Experimental|OPC-262 5 mg|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
9945916|NCT01046331||Adult H1N1|Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection
9945917|NCT01046331||Pediatric H1N1|Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection
9945918|NCT01046357|Experimental|Active|AZD7687 oral suspension
9945919|NCT01046357|Experimental|Placebo|placebo oral suspension
9945920|NCT01046370|Experimental|ARP intervention|
9945921|NCT01046370|No Intervention|No intervention|
9945922|NCT01046383|Experimental|IMN1207|"Dietary Supplement: IMN1207~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
9945923|NCT01046383|Placebo Comparator|Casein|"Dietary Supplement: Casein.~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
9945924|NCT01046409||Main vessel, side branch vessel|
9803318|NCT04252339|Experimental|RLY-1971 - Dose Escalation/Expansion|"Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified~Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified."
9803319|NCT04250727|Experimental|3mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 3mg nicotine concentration.
9803320|NCT04250727|Experimental|6mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 6mg nicotine concentration.
9803321|NCT04247139|Experimental|Commercial Kefir|Commercially produced kefir
9803322|NCT04247139|Experimental|Traditional Kefir|Traditionally grown kefir
9803323|NCT04246619|Experimental|Pregabalin Krka Arm|"ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN.~Investigator can choose on V2:~Total Pregabalin Krka daily dose: 25 mg/day~Total Pregabalin Krka daily dose: 50 mg/day~Total Pregabalin Krka daily dose: 75 mg/day~Total Pregabalin Krka daily dose: 150 mg/day~Total Pregabalin Krka daily dose: 300 mg/day (from Phone call 1 further on)~V3: daily dose should be achieved: MINIMUM dose 150 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day~V4: Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day"
9803324|NCT04246619|Experimental|Dulsevia® Arm|"• ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:~Investigator can choose on V2:~Total Dulsevia® daily dose: 30 mg/day~Total Dulsevia® daily dose: 60 mg/day~V3: daily dose should be achieved: MINIMUM dose 60 mg/day Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day.~V4: Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day."
9803325|NCT04246359|Experimental|RP induction and maintenance|"1. Induction phase:~Rituximab: 375mg / m2, ivd, d1;~Pegylated interferon α-2b: 135 μg (500,000 U), H, d1, 8 Repeated every 21 days, Maximum 6 cycles 2. Maintenance phase:~1) Rituximab: 375mg / m2, ivd, d1; 2) Pegylated interferon α-2b: 135 μg (500,000 U), H, d1,30 Repeated every 2 months, Maximum 12 cycles"
9803326|NCT04241640|Experimental|Nefopam group[|
9803327|NCT04241640|Placebo Comparator|placebo group|
9803328|NCT04239261|Active Comparator|Nutritional therapy|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
9803329|NCT04239261|Placebo Comparator|Placebo|Hydrolyzed gelatin 10.0 grams once daily
9803334|NCT04234139||Retrospective Cohort|Early Liver Transplantation (ELT) for patients who presented with Severe Alcoholic Hepatitis (SAH)
9803335|NCT04234139||Prospective Cohort 1|Early Liver Transplantation (ELT) for patients who present with Severe Alcoholic Hepatitis (SAH)
9803336|NCT04234139||Prospective Cohort 2|Orthotopic Liver Transplantation (OLT) in patient who present with Alcoholic Liver Disease (ALD)
9945925|NCT01046435|Placebo Comparator|Supragingival scaling plus placebo|Plaque control instructions, supra gingival scaling and two placebos
9945926|NCT01046435|Experimental|Root planing plus antibiotics|Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days
9945927|NCT01046448||4C|Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.
9945928|NCT01046461|Experimental|Ramosetron, Aprepitant, Dexamethasone|
9945929|NCT01046474|Experimental|reducing beverages and sugar and increase physical activity|reduction of beverages and sugar and increasing physical activity
9945930|NCT01046474|No Intervention|control -no intervention|
9945931|NCT01046500|Active Comparator|metformin|
9945932|NCT01046500|Active Comparator|myo-inositol|
9945933|NCT01046539|Active Comparator|RDC-0313 + Buprenorphine|Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
9945934|NCT01046539|Placebo Comparator|Placebo|
9945935|NCT01046552|Active Comparator|PES/LC|preoperative ES followed by LC within the same hospital admission
9945936|NCT01046552|Active Comparator|LC/IOES|laparoscopic cholecystectomy with intraoperative ercp under the same anesthesia
9945937|NCT01046578|Experimental|Single Dose 12mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
9945938|NCT01046578|Experimental|Single Dose 18mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
9945939|NCT01046578|Experimental|Single Dose Post Ovulation|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation
9945940|NCT01046578|Experimental|Multi Dose 12mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
9945941|NCT01046578|Experimental|Multi Dose 18mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
9945942|NCT01046578|Experimental|Multi Dose Post Ovulation|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation
9945943|NCT01046578|No Intervention|Control|No intervention given, followed for course of study on a natural cycle
10004339|NCT01575132||Parkinson's Disease, DBS, 10-14 years|
10004340|NCT01575145|Experimental|Quitline facilitation intervention|brief quitline facilitation intervention given
9667579|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
9945944|NCT01046591||Cleft|Those with a repaired cleft palate
9945945|NCT01046591||Comparison|Those without a cleft palate repair
9945946|NCT01046604|No Intervention|No treatment|This is the group of patients that will not undergo any treatment with Lovaza prior to mitral valve repair surgery. This is the 'control' group.
9945947|NCT01046604|Active Comparator|Lovaza treated|This arm will be the group of patients that will be treated with Lovaza prior to undergoing mitral valve repair surgery.
9945948|NCT01046630|Experimental|1|single infusion
9945949|NCT01046630|Active Comparator|2|single infusion
9945950|NCT01046630|Placebo Comparator|3|single infusion
9945951|NCT01046708|Experimental|micronized progesterone|
9945952|NCT01046708|No Intervention|no utrogestan|
9945953|NCT01046721|Active Comparator|Exenatide|subcutaneous administration of Exenatide (0.02ml)
9945954|NCT01046721|Placebo Comparator|0.9% Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
9945955|NCT01046734||Adult Community|
9945956|NCT01046734||Adult Hospital|
9945957|NCT01046734||Children Hospital|
9945958|NCT01046734||Children Community|
9945959|NCT01046747|Active Comparator|Pre-drill|These pins will be pre-drilled
9945960|NCT01046747|Active Comparator|No pre-drill|these pins will not be pre-drilled, but will rely on the self drilling function of the pin for insertion
9945961|NCT01046760||Rolandic Epilepsy|Patients older than seven years old with clinical and electroencephalographic diagnosis of Rolandic Epilepsy
9945962|NCT01046773|Active Comparator|Children with Crohn's disease less than 35 kg|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
9945963|NCT01046773|Active Comparator|Children with Crohn's disease 35 kg or greater|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
9945964|NCT01046786|Active Comparator|Group A|Intraspinal injection of 1.6 million cord blood mononuclear cell
9945965|NCT01046786|Active Comparator|Group B|Intraspinal injection of 3.2 million cord blood mononuclear cell
9945966|NCT01046786|Active Comparator|Group C|Intraspinal injection of 6.4 million cord blood mononuclear cell
9945967|NCT01046786|Active Comparator|Group D|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone
9945968|NCT01046786|Active Comparator|Group E|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone plus 6 week course of oral lithium, titrated to maintain 0.6-1.0 mM serum level
9945969|NCT01046799|Experimental|Entecavir|
9945970|NCT01046838|Placebo Comparator|Placebo|placebo 3 x daily
9945971|NCT01046838|Active Comparator|sildenafil|40 mg sildenafil 3 x daily
9945972|NCT01046851|Active Comparator|Nopan|
9945973|NCT01046851|Placebo Comparator|Placebo|
9945974|NCT01046864|Experimental|Arm 1|
9945975|NCT01046864|Experimental|Arm 2|
9945976|NCT01046864|Experimental|Arm 3|Japanese Population
9945977|NCT01046890|Experimental|darunavir/ritonavir + root of Echinacea purpurea|darunavir/ritonavir + root of Echinacea purpurea
9945978|NCT01046929|Experimental|limonene|
9945979|NCT01046942|Experimental|Clopidogrel+Aspirin, hypercoagulabel|
9945980|NCT01046942|Active Comparator|Aspirin,hypercoagulabel control|
9945981|NCT01046955|Active Comparator|1mg/kg Thymoglobulin|LD kidneys receiving 1mg/kg Thymoglobulin for 7 days starting at the day of surgery.
9945982|NCT01046955|Active Comparator|Campath-1H at 0.3 mg/kg|Recipients of LD kidneys receiving Campath-1H at 0.3 mg/kg once on the day of surgery and again 3 days post-operatively.
9945983|NCT01046955|Active Comparator|Zenapax 1 mg/kg|Recipients of LD kidneys receiving Zenapax 1mg/kg on the day of surgery followed by the same dose every 2 weeks for a total of 5 dosages.
9945984|NCT01046968|Experimental|Lepticore|
9945985|NCT01046981|Experimental|Tumescent Antibiotic Delivery|TAD followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours
9945986|NCT01046981|Experimental|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours.
9945987|NCT01046994|Experimental|surgery|biliopancreatic diversion
9945988|NCT01046994|Active Comparator|standard medical care|patients treated according to the rules of good clinical practice
9945989|NCT01047020||ALL survivors|The study sample for this research will be recruited from participants in an institutionally funded cohort study, St. Jude Life, as well as from active ACT patients that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated group who were followed in the After Completion of Therapy Clinic until age 18 years and a minimum of 10 years after their treatment ended if they were older than age 11 at the end of therapy
9945990|NCT01047020||Comparison Group|Potentially eligible comparison group participants will be recruited from the parent, older sibling, relative or friend population who accompany the ACT patient for follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older) of children in remission, both from the active follow-up cohort (within five years of last treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete the same assessments that the ALL survivor participants will complete. Comparison group participants are frequency matched to potentially eligible participants by race/ethnicity (white, black, other) age group (18 to 29, 30-39, 40-49 years) and gender.
9945991|NCT01047033|Active Comparator|Microcredit only|
9945992|NCT01047033|Experimental|Microcredit plus health education|Thirty minutes of a health education module administered to clients by loan officer at their monthly group meetings over the course of 8 months.
9945993|NCT01047046||SNM device placement|Patients who have undergone a placement of a SNM device to treat refractory OAB. A retrospective chart review will be performed on all patients who underwent a one or two-stage placement of an SNM device, which includes an implantable pulse generator (IPG), for refractory urge incontinence and urgency frequency symptoms. The patients will be those of Dr. Karen Noblett, having their device placed after 2001.
9945994|NCT01047059|Experimental|Trial Intervention|150mg Erlotinib daily, 15mg/kg b.w. Bevacizumab on d1, d22, d43 as medication FDG-PET, FLT-PET and DCE-MRI as diagnostical tools
9945995|NCT01047072|Experimental|Arm I (transplant)|Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
9945996|NCT01047072|Active Comparator|Arm II (nontransplant)|Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
9945997|NCT01047085|Active Comparator|Control group|Control group: Impedance pH measurements of healthy controls are performed to compare the results with the study group.
9945998|NCT01047085|Experimental|Study group|Study group: Pre-operative and post-operative impedance pH measurements are performed to patients in which elective cholecystectomy is planned.
9945999|NCT01047098|Experimental|Iron with meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken with meals
9946000|NCT01047098|Experimental|Iron between meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken between meals
9946001|NCT01047098|Placebo Comparator|Placebo|Prenatal vitamin without iron plus capsule containing calcium carbonate (placebo) taken between meals
9946002|NCT01047111|Active Comparator|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
9946003|NCT01047111|Active Comparator|Sweet Procedure|Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
9946004|NCT01047124|Experimental|Intervention|Specialist mood disorders team: treatment plan according to need
9946005|NCT01047124|No Intervention|Treatment as usual|
9946006|NCT01047137|Placebo Comparator|Control|Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.
9946007|NCT01047137|Experimental|Intervention|Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.
9946008|NCT01047150||Tetrofosmin Rest patients|Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin
9946009|NCT01047150||Sestamibi stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi
9946010|NCT01047150||Tetrofosmin stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin
9946011|NCT01047150||Sestamibi rest patients|Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi
9946012|NCT01047163||Statin|Men aged 65-75yr on Simvastatin therapy presenting with muscle soreness
9946013|NCT01047163||Control|Men, aged 65-75yr not on Statin therapy
9946014|NCT01047176||1|Male or female > 18 year of age with indication to PCI
9946015|NCT01047202|Experimental|Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
9946016|NCT01047202|Experimental|Group 2 : 15 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
9946017|NCT01047202|Sham Comparator|Group 3 : 7.5 μg seasonal trivalent vaccine|60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart
9946018|NCT01047215|Active Comparator|Aripipazole|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
9946019|NCT01047215|Active Comparator|Quetiapine|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
9946020|NCT01047254|Active Comparator|Bupropion|Buproprion 150-300 mg in a flexible dose
9946021|NCT01047254|Placebo Comparator|placebo capsule|Placebo
9946022|NCT01047280|Placebo Comparator|Safflower oil|This arm of the study constitutes the control phase
9946023|NCT01047280|Experimental|Clarinol G-80®|
9946024|NCT01047280|Experimental|G-c9, t11|
9946025|NCT01047371||Patients with Osteoarthrosis|All consecutive patients scheduled for total hip or knee arthroplasty
9946026|NCT01047384|Experimental|Experimental|acupuncture-moxibustion therapy
9946027|NCT01047384|Active Comparator|Regular therapy|Regular therapy
9946028|NCT01047397|Experimental|Group 1|Active Drug
9946029|NCT01047397|Placebo Comparator|Group 2|Placebo
9946030|NCT01047410|No Intervention|Usual care|Patients assigned to the usual care group receive the standard medical care (usual care) during the 15 months lasting study period. Physical training does not form a part of the usual care of renal transplant and dialysis patients. After randomisation, patients assigned to the usual care group receive the advice to meet the 'Nederlandse Norm Gezond Bewegen (NNGB), i.e. the advice to perform 30 minutes of moderately intense physical activity at at least five but preferably all days of the week.
9946031|NCT01047410|Experimental|Exercise intervention|The exercise intervention in this group is identical to the exercise-only group. Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
10004341|NCT01575145|Active Comparator|Stop-smoking intervention|brief review of tips to maintain smoking abstinence, using brochure
10004342|NCT01575158|Experimental|citalopram|citalopram
10004343|NCT01575158|Active Comparator|clomipramnine|clomipramine
9946032|NCT01047410|Experimental|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
9946033|NCT01047423|Experimental|Simvastatin|40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
9946034|NCT01047423|Placebo Comparator|Placebo|Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
9946035|NCT01047449|Active Comparator|SVG harvest - conventional, placebo|
9946036|NCT01047449|Experimental|SVG harvest - no-touch, fish oils|
9946037|NCT01047449|Placebo Comparator|SVG harvest - no-touch, placebo|
9946038|NCT01047449|Active Comparator|SVG harvest - conventional, fish oils|
9946039|NCT01047462|Active Comparator|Laparoscopic lavage|
9946040|NCT01047462|Active Comparator|Primary resection|
9946041|NCT01047488|Active Comparator|Imipramine|Imipramine tablets and placebo capsules to pregabalin
9946042|NCT01047488|Active Comparator|Pregabalin|Pregabalin capsules and placebo tablets to imipramine
9946043|NCT01047488|Experimental|Imipramine plus pregabalin|Imipramine tablets and pregabalin capsules
9946044|NCT01047488|Placebo Comparator|Placebo|Placebo tablets to imipramine and placebo capsules to pregabalin
9946045|NCT01047514|Experimental|Online Chronic Disease Self-management|6 week, online, small group online self-management workshop
9946046|NCT01047566|Experimental|Addition of dronedarone|Addition of Dronedarone to existing rate control medication (beta blocker and/or calcium antagonist)
9946047|NCT01047566|Active Comparator|Dose Increase|Dose increase of existing rate control medication (beta blocker or calcium antagonist or digoxin)
9946048|NCT01047579|Other|Rivastigmine transdermal|
9946049|NCT01047592|Active Comparator|sarcosine|
9946050|NCT01047592|Active Comparator|sarcosine+ BE|
9946051|NCT01047592|Placebo Comparator|Placebo|
9946052|NCT01047605|Experimental|PP1|Neurapas balance
9946053|NCT01047605|Experimental|PP2|Pascoflair 425 mg
9946054|NCT01047605|Placebo Comparator|PL1|P-Tabletten weiß
9946055|NCT01047618||Thromboembolism|
9946056|NCT01047631|Experimental|Functional circuit training and lifestyle counseling|
9946057|NCT01047631|Active Comparator|Health education and independent walking|
9946058|NCT01047644|Experimental|3-month flushing schedule|3-month port-flushing schedule
9946059|NCT01047657|Experimental|weight loss|
9946060|NCT01047657|No Intervention|Control|
9946061|NCT01047670|Experimental|1|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
9946062|NCT01047670|Placebo Comparator|2|placebo
9946063|NCT01047696|No Intervention|Open fire|Households continuing to use an open fire for cooking and heating
9946064|NCT01047696|Experimental|Chimney stove|Households randomized to receive a chimney stove (plancha) for cooking and heating
9946065|NCT01047722|Active Comparator|Patient drinks aspirin in Gatorade.|Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
9946066|NCT01047722|Placebo Comparator|Gatorade Placebo|Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
9946067|NCT01047735|Experimental|Roux-en-Y Gastric Bypass Surgery|Roux-en-Y Gastric Bypass Surgery
9946068|NCT01047735|Experimental|Laparoscopic Adjustable Gastric Banding|Laparoscopic Adjustable Gastric Banding
9946069|NCT01047735|Experimental|Lifestyle/Behavioral Weight Loss|Lifestyle Weight Loss Intervention
9946070|NCT01047748|Active Comparator|intra-fetal injection|Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
9946071|NCT01047748|Active Comparator|intra-amniotic injection|Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion
9946072|NCT01047761|Experimental|exercise|Multimodal exercises that include walking, breathing exercises, dynamic balance, and core strengthening.
9946073|NCT01047774|Experimental|Soy protein|
9946074|NCT01047774|Placebo Comparator|Milk protein|
9946075|NCT01047787||CHF Patients|Congestive Heart Failure Patients
9946076|NCT01047800|Experimental|Counseling group|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
9946077|NCT01047800|No Intervention|Control|Usual management in GI specialty clinic
9946078|NCT01047813||Type 2 diabetes|This group contains 25 participants with type 2 diabetes
9946079|NCT01047813||control group|This group contains 25 participants withput type 2 diabetes. The control group is matched with age, education and lifestyle to the diabetes group.
9946080|NCT01047826|Experimental|M.I.P.O. Group|subjects who have been randomized to the M.I.P.O. group
9946081|NCT01047826|Experimental|Intramedullary Nail group|Subjects who have been Randomized to the I.M. group
9946082|NCT01047852|Experimental|NIV|
9946083|NCT01047852|No Intervention|Control|
9946084|NCT01047891|Experimental|Experimental|
9946085|NCT01047904|Experimental|Iontophoresis-treated|Healthy volunteers will evaluate reliability and performance of Iontophoresis System in delivery of local anesthesia to the TM.
9946086|NCT01047917|Experimental|Meditation DVD|All participants will receive a Meditation DVD to practice at home daily for a total of 4 weeks.
9946087|NCT01047930|Other|AM-Ex; PM-Ex; C|within subject design, with each participant receiving all three conditions
9946088|NCT01047943|Experimental|Psoriasis therapy|
9946089|NCT01047956|Experimental|MethNAC|Methadone and N-acetylcysteine for opioids abstaining
9946090|NCT01047956|Active Comparator|Methadone|Methadone alone
9946091|NCT01047982|Active Comparator|myo-inositol|
9946092|NCT01047982|Placebo Comparator|placebo|acid folic 400 mcg twice per day
9946093|NCT01047995|Active Comparator|Group 1|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
9946094|NCT01047995|Active Comparator|Group 2|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2,~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
9946095|NCT01048008|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
9946096|NCT01048021||Supraclavicular Block|
10004344|NCT01575158|Placebo Comparator|placebo|placebo
10004345|NCT01575171||"Intervention/Nudge"|"Individuals will be analyzed according to their assigned intervention group, to compare the effectiveness of an opt-out EHR decision support system to enhance the prescription of statins to those patients with an elevated LDL-C and to subsequently titrate the medication dose until LDL-C control is obtained. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
10004346|NCT01575184|Experimental|Shoulder traction|The ultrasonographic measurements with shoulder traction
10004347|NCT01575184|Active Comparator|No traction|The ultrasonographic measurements without shoulder traction
10004348|NCT01575210|Experimental|Group A_ washing procedure 1|This group will apply washing technique 1.
10004349|NCT01575210|Experimental|Group B_washing procedure 2|This group will apply washing technique 2.
10004350|NCT01575223|Active Comparator|High volume saline irrigation|Patients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
10004351|NCT01575223|Placebo Comparator|Placebo|Patients in this group will receive low volume saline irrigation (Salinex)
10004352|NCT01575236|Experimental|Guardian|Guardian Laryngeal Mask
10004353|NCT01575236|Experimental|Supreme|Supreme Laryngeal Mask Airway
10004354|NCT01575249||Asymptomatic group|one hundred patients with a negative exercise stress echo for symptoms/ECG/wall motion abnormalities (WMA), negative spirometry test for pulmonary disease, without known CAD or other valvular diseases, in sinus rhythm and with a LVEF>55%
10004355|NCT01575249||Symptomatic group|one hundred patients with symptomatic AS (negative pulmonary tests but positive stress echo or prior CAD or other valvular diseases and a LVEF>55%
10004356|NCT01575262|Experimental|Incentive|Participants use their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of physical activity = 1 point; capped at 30 points per day) over the 12-week intervention period. Points are redeemed for rewards (extrinsic motivation) at week 6 and week 12.
10004357|NCT01575262|Active Comparator|No Incentive|Participants used their PAL card to self-monitor their physical activity levels (intrinsic motivation) over the 12-week intervention period but do not collect points or earn rewards.
10004358|NCT01575288|Placebo Comparator|Maltose|
10004359|NCT01575288|Experimental|High-dose trehalose|
9946097|NCT01048034|Experimental|Azacitidine +/- erythropoetin|
9946098|NCT01048047|Experimental|aliskiren/amlodipine|aliskiren, 300 mg/amlodipine 10 mg
9946099|NCT01048047|Active Comparator|amlodipine|amlodipine 10 mg
9946100|NCT01048086|Experimental|Retinoic Acid|
9946101|NCT01048086|Placebo Comparator|Placebo|
9946102|NCT01048112|Experimental|Repeated dose group|Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
9946103|NCT01048112|Active Comparator|Single dose group|Will receive one dose of Campylobacter jejuni strain CG8421
9946104|NCT01048138|Experimental|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
9946105|NCT01048138|Placebo Comparator|Placebo|5mg IV(in the vein)every 6 hours for 10 days
9946106|NCT01048151|Experimental|Single|TNFerade™ Biologic + Radiation
9946107|NCT01048164|Active Comparator|10 Massages|This group consists of individuals that wear lead aprons, and they will receive ten, 30-minute scheduled massage appointments during the hours the participant is working in the cardiac lab, over a 10 week period.
9946108|NCT01048164|Active Comparator|5 Massages|This group consists of individuals that wear lead aprons, and they will receive five, 30-minute scheduled massage appointments, during the hours the participant is working in the cardiac lab, over a 5 week period. This arm will not receive massages for the first 5 weeks and then will receive their massages during the second 5 week period.
9946109|NCT01048164|No Intervention|Control Group|This group will consist of those individuals that wear lead aprons with no desire to participate in the massage study yet are willing to provide information through questionnaires. They will be given the same questionnaire as those in the two massage therapy arms of the study, at the beginning, middle, and end of study.
9946110|NCT01048177|Experimental|Treatment|
9946111|NCT01048190|Experimental|Infants I-1|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains). Group I-1: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
9946112|NCT01048190|Experimental|Infants I-2|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
9946113|NCT01048190|Experimental|Infant I-3|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
9946114|NCT01048203|Experimental|ABR-215050|
9946115|NCT01048229|Experimental|Rasagiline|
9476355|NCT03572595||Recurrent|"Patients with treated colorectal cancer, suspecting of recurrence , will be subjected to be imaged by F-18 FDG-PET/CT from skull base to midthigh, interpretating the results of the hybrid PET/CT by two nuclear physicians.~Then refer back to the treating physicians , another biopsy will be taken from the suspected recurrence and then results will be compared with hybrid PET/CT images.~comparing the results with histopathology ."
9946116|NCT01048229|Active Comparator|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
9946117|NCT01048268|Experimental|Healthy volunteers|
9946118|NCT01048268|Experimental|Patients with Type 1 diabetes mellitus|
9946119|NCT01048268|Experimental|Patients with type 2 diabetes mellitus|
9946120|NCT01048294|Active Comparator|Standard Light Treatment|30 min of Standard bright light treatment (color 5000K)
9946121|NCT01048294|Experimental|Blue enriched Light treatment 20 min|20 minutes of Blue enriched light treatment (color 17000K)
9946122|NCT01048294|Experimental|Blue enriched light treatment 30 min|30 minutes of Blue enriched light treatment (color 17000K)
9946123|NCT01048307|Experimental|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system)."
9946124|NCT01048307|Placebo Comparator|Saline irrigation (standard care control)|"Saline (control group):~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
9946125|NCT01048320|Other|Treatment|Gemcitabine plus Oxaliplatin in combination with imatinib mesylate
9946126|NCT01048359|Experimental|Brief Intervention|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
9946127|NCT01048359|Active Comparator|Brief advice|This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
9946128|NCT01048359|Experimental|Brief Intervention plus Booster|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.
9946129|NCT01048372||Early HIV infection|HIV infected adults with early evidence of suppressed cell-mediated immunity but whose disease has not progressed far enough to indicate antiretroviral therapy.
9946130|NCT01048372||Control|Healthy adults without HIV infection.
9946131|NCT01048385|Experimental|CoQ10|This group will be treated concomitantly with Coenzyme Q10
9946132|NCT01048385|Placebo Comparator|Control|Treated with capsules containing the vehicle.
9946133|NCT01048398|Experimental|Remifentanil|
9946134|NCT01048398|Active Comparator|Paracetamol|intravenous paracetamol 1g
9946135|NCT01048411|Active Comparator|Naja-comp.|s.c. injection of naja comp (homeopathic remedy) three times a week
9946136|NCT01048411|Placebo Comparator|Placebo|s.c. injection of placebo (NaCl-solution) three times a week
9946137|NCT01048437|No Intervention|Standard transplant education|Missouri Kidney Program's standard Patient Education Program (PEP) transplant module.
9946138|NCT01048437|Experimental|Transplant education with video|Explore Transplant transplant module featuring video
9946139|NCT01048437|Experimental|Transplant education with speakers|Explore Transplant transplant module featuring live guest speakers.
9946140|NCT01048450|Experimental|Treatment|Those who were diagnosed with hallux limitus/rigidus (end stage degeneration at the 1st metatarsal phalangeal joint)
9946141|NCT01048463|Placebo Comparator|EN|The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.
9946142|NCT01048463|Experimental|ENLDEPA|The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
9946143|NCT01048463|Experimental|ENHDPEA|The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
9946144|NCT01048476|Active Comparator|Group L20|Dietary Supplement: 20mg Lutein; daily supplementation one year
9946145|NCT01048476|Active Comparator|Group L10|Dietary Supplement: 10mg Lutein; daily supplementation one year
9946146|NCT01048476|Placebo Comparator|Group Placebo|Dietary Supplement: Placebo, 0 mg Lutein
9946147|NCT01048476|Active Comparator|Active Comparator: Group LZ|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
9946148|NCT01048489|Other|Lifestyle counseling|
9946149|NCT01048489|No Intervention|No counseling|
9946150|NCT01048515|Experimental|Caffeine|
9946151|NCT01048515|Placebo Comparator|Placebo|
9946152|NCT01048528|Experimental|Stress Management|Stress Management and Relaxation Training workshops
9946153|NCT01048528|No Intervention|Wait-list|Wait-list comparison group
9946154|NCT01048554|Other|Temozolomide/Bevacizumab|Patients will be treated with a combination of temozolomide at 75 mg/m2/day for six continuous weeks, followed by a two-week rest period and bevacizumab 10 mg/kg every 2 weeks without interruption. Cycles will be repeated every 8 weeks. Patients will be restaged every 8 weeks.
9946155|NCT01048567|Active Comparator|Lactobacillus acidophilus/rhamnosus|
9946156|NCT01048567|Placebo Comparator|Placebo|
9946157|NCT01048580|Experimental|Perifosine +Capecitabine|One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
9946158|NCT01048619|Experimental|ON 01910.Na|The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
9946159|NCT01048632|Experimental|Oxandrolone|Following clinical evaluation, all patients will be receive oxandrolone in addition to their usual medications. Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
9946160|NCT01048645|Placebo Comparator|P/PC arm|Patients were assigned to receive placebo (P/PC) 1 week prior to treatment until completing two cycles
9946161|NCT01048645|Experimental|RA/PC arm|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two cycles
9946162|NCT01048684|Active Comparator|20% Mannitol 0.7 g/kg (low-dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.
9946163|NCT01048684|Experimental|20% Mannitol 1.4 g/kg (high dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.
9946164|NCT01048710||Tomofix_small|Surgical treatment using TomoFix TM Small
9946165|NCT01048710||Conservative treatment|"In the control group, patients who refused to have surgery will be allowed to be treated using different options of conservative treatment. The frequency of applications depends on the hospital and will therefore be documented in the study. An arthroscopy is not obligatory under this treatment group, but is permitted.~The following conservative treatment methods are allowed:~Physical therapy~Specific exercises for the muscles~Injections into the knee joint~Brace~Medication~No therapy"
9946166|NCT01048736|Active Comparator|Exercise|All treatment groups will receive 4d/wk of exercise
9946167|NCT01048736|Experimental|Exercise + Diet (-250 kcal/d deficit)|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss),
9946168|NCT01048736|Experimental|Exercise + Diet (-600 kcal/d deficit)|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
9946169|NCT01048749|Active Comparator|aquatic vertical supsension|Spinal height measurement using a stadiometer following aquatic vertical suspension
9946170|NCT01048749|Active Comparator|land-based supine flexion condition|Spine height will be measured with a stadiometer following completion of the supine land-based flexion position.
9946171|NCT01048762|Active Comparator|supervised exercise training|Intervention: supervised exercise training and dyspnea counseling in groups for 10 weeks Instruction on home based exercise training
9946172|NCT01048762|Sham Comparator|one instruction on homebased exercises|One instruction on home based exercise training and dyspnea management
9946173|NCT01048801|Active Comparator|Rapid diagnostic test and treatment|
9946174|NCT01048801|Other|Treatment without rapid daignostic test|
9946175|NCT01048814||Ovarian, Peritoneal, Fallopian Cancer|Recurrent, Peristent or Refractory
9946176|NCT01048827|Experimental|experimental|dose-escalation Busulfan
9946177|NCT01048840||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
9946178|NCT01048840||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
9946179|NCT01048853|Experimental|Conservative Surgery|Removal of the pelvic lymph nodes (pelvic lymphadenectomy)
9476356|NCT03572582|Experimental|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
9476357|NCT03572569||Index patients|Patients ≤18 years with primary cardiomyopathy
9946180|NCT01048892|Experimental|Treatment (NTX-010)|
9946181|NCT01048931|Experimental|single-port LAVH|single port LAVH
9946182|NCT01048970|Other|Control arm|Patients will receive nutritional assessment one week prior to treatment until completing two cycles
9946183|NCT01048970|Experimental|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
9946184|NCT01048983|Other|Questionnaires and Phone Calls|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
9946185|NCT01048983|Active Comparator|Curcumin Only|
9946186|NCT01048983|Active Comparator|Armodafinil Only|
9946187|NCT01048983|Active Comparator|Minocycline Only|
9946188|NCT01048983|Active Comparator|Bupropion Only|
9946189|NCT01048983|Active Comparator|Curcumin + Armodafinil|
9946190|NCT01048983|Active Comparator|Curcumin + Minocycline|
9946191|NCT01048983|Active Comparator|Curcumin + Bupropion|
9946192|NCT01048983|Active Comparator|Armodafinil + Minocycline|
9946193|NCT01048983|Active Comparator|Armodafinil + Bupropion|
9946194|NCT01048983|Active Comparator|Minocycline + Buproprion|
9946195|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline|
9946196|NCT01048983|Active Comparator|Curcumin + Armodafinil + Bupropion|
9946197|NCT01048983|Active Comparator|Curcumin + Minocycline + Bupropion|
9946198|NCT01048983|Active Comparator|Armodafinil + Minocycline + Bupropion|
9946199|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline + Bupropion|
9946200|NCT01048996||Non ALI/ARDS|Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
9946201|NCT01048996||ALI/ARDS|Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
9946202|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 1|
9946203|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 2|
9946204|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 3|
9946205|NCT01049048|Placebo Comparator|Control|This group receives placebo chocolate cookies with no vitamin D3 added.
9946206|NCT01049048|Experimental|Vitamin D3|This group receives 2500 IU of Vitamin D3 added to a chocolate cookie daily.
9946207|NCT01049061|Experimental|MORAb-003|
9946208|NCT01049074|Experimental|Verus acupuncture|
9946209|NCT01049074|Sham Comparator|Sham acupuncture|
9946210|NCT01049100|Experimental|operative staging (A)|operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
9476358|NCT03572569||First-degree family members|Parents and siblings of index patients
9946211|NCT01049100|No Intervention|Standard (B)|No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.
9946212|NCT01049113|Experimental|ON 013105|ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.
9946213|NCT01049126||Late stage endometrial cancer|
9946214|NCT01049139|No Intervention|No Supplemental Information|Participants will be administered a standard HIV vaccine trial consent form but no additional information.
9946215|NCT01049139|Experimental|Supplemental information with 1-sided message|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
9946216|NCT01049139|Experimental|Supplemental information with 2-sided messages|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
9946217|NCT01049152||nondiabetic patients|nondiabetic patients with ESRD undergone hemodialysis
9946218|NCT01049152||diabetic patients|diabetic patients with ESRD undergone hemodialysis
9946219|NCT01049165|Active Comparator|Arm 1 (BMS-813160 or placebo)|
9946220|NCT01049165|Active Comparator|Arm 2 (BMS-813160 or placebo)|
9946221|NCT01049165|Active Comparator|Arm 3 (BMS-813160 or placebo)|
9946222|NCT01049165|Active Comparator|Arm 4 (BMS-813160 or placebo)|
9946223|NCT01049165|Active Comparator|Arm 5 (BMS-813160 or placebo)|
9946224|NCT01049165|Active Comparator|Arm 6 (BMS-813160 or placebo)|
9946225|NCT01049165|Active Comparator|Arm 7 [14C] BMS-813160|
9946226|NCT01049165|Active Comparator|Arm 8 (BMS-813160 or placebo)|
9946227|NCT01049165|Active Comparator|Arm 9 (BMS-813160 or placebo)|
9801250|NCT01710358|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50.~At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
9946228|NCT01049178|Experimental|Oral silymarin dose|Dose escalation study
9946229|NCT01049178|Placebo Comparator|placebo|A randomized, double-masked, placebo-controlled cross-over clinical pilot investigation of an inducer of endogenous antioxidant enzymes, silymarin, in humans with atopic asthma.
9946230|NCT01049191||Fracture|Subjects experiencing a prior osteoporotic fracture.
9946231|NCT01049191||Control|These will be age and bone density matched controls to the fracture group.
9946232|NCT01049204|Active Comparator|Group 1|Nadir CD4 count >200 cells/µl blood and randomised to Maraviroc 150mg BD
9946233|NCT01049204|Placebo Comparator|Group 2|Nadir CD4 count >200 cells/µl blood and randomised to placebo twice daily for 24 weeks
9476359|NCT03572556||Patients|Hereditary hemorrhagic telangiectasia patients
9476360|NCT03572556||Controls|Matched for age (+/- 5 ans) and sex.
9801251|NCT01710358|Experimental|Baricitinib|"Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50.~Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
9946234|NCT01049204|Active Comparator|Group 3|Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
9946235|NCT01049204|Placebo Comparator|Group 4|Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks
9946236|NCT01049230|Experimental|Proton beam radiation|Radiation therapy with proton beam
9946237|NCT01049269||1:one group|
9946238|NCT01049282|Experimental|12 TST negative volunteers antigen only|
9946239|NCT01049282|Experimental|12 TST negative volunteers|
9946240|NCT01049282|Experimental|12 BCG vaccinated volunteers|
9946241|NCT01049282|Experimental|12 with Latent TB infection >= 2 years ago|
9946242|NCT01049295|Experimental|oil fish pearls|patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day
9946243|NCT01049295|Placebo Comparator|placebo|patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day
9946244|NCT01049321|Experimental|DASH diet|DASH: Dietary approaches to stop hypertension eating plan
9946245|NCT01049321|Placebo Comparator|Diabetic diet|Diabetic diet: a usual diabetic diet
9946246|NCT01049347|Active Comparator|amitriptyline|
9946247|NCT01049347|Active Comparator|paroxetine|
9946248|NCT01049386|Active Comparator|Sugar absorption test|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
9946249|NCT01049386|Experimental|Sugar absorption test and high-fat breakfast|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine. Subjects will eat a high-fat breakfast together with the sugar drink, to investigate the disturbance caused by fat in intestinal absorption.
9946250|NCT01049399|Placebo Comparator|Placebo|once daily administration of powder for oral suspension.
9946251|NCT01049399|Experimental|NP031112 800 mg|Group dosed with 800 mg once daily for 52 weeks
9946252|NCT01049399|Experimental|NP031112 600 mg|Group treated with 600 mg once daily for 52 weeks
9946253|NCT01049425|Active Comparator|Epirubicin and Cyclophosphamid followed by Docetaxel|4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks
9946254|NCT01049425|Experimental|Combination of Docetaxel and Cyclophosphamid|intravenous infusion on day one every three weeks
9946255|NCT01049438|Experimental|Nasal, body, and systemic decolonization|
9946256|NCT01049451|Experimental|ACTH IM monthly|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
9946257|NCT01049451|Active Comparator|MP IV monthly|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months.
9946258|NCT01049464|Placebo Comparator|5%D/W|The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.
9946259|NCT01049464|Experimental|Magnesium sulphate|The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours
9946260|NCT01049477|Experimental|Music therapy|Experimental arm includes women undergoing cesarean section delivery listening to music before and after c/s. STAI will be completed pre and post operatively.
9946261|NCT01049477|No Intervention|No music group|Subjects will not listen to music before and after c/s. STAI will be completed pre and post operatively.
9946262|NCT01049490|Active Comparator|Intramuscular|15 mcg H1N1 vaccine delivered via intramuscular injection (control)
9946263|NCT01049490|Active Comparator|Intradermal|Intradermal: H1N1 vaccine delivered via intradermal injection: Experimental
9946264|NCT01049516|Other|Minimal Contact Control|
9946265|NCT01049516|Experimental|PE-Massed|
9946266|NCT01049516|Active Comparator|PE-Spaced|
9946267|NCT01049516|Active Comparator|Present-Centered Therapy (PCT)|
9946268|NCT01049529|Placebo Comparator|Placebo group|This group is receiving sunflower oil (the excipient for DHA)
9946269|NCT01049529|Active Comparator|DHA group|This group is receiving the docosahexaenoic acid (DHA) supplement
9946270|NCT01049542|Experimental|Astressin 2B|Healthy volunteers will receive incremental doses of intra arterial Astressin 2B (a selective and potent Urocortin 2 & 3 antagonist). This serves as a dose finding Protocol for Astressin 2B, which will be used in subsequent protocols.
9946271|NCT01049555|Other|Alzheimer and apathy|Alzheimer's disease patients with apathy
9946272|NCT01049555|Other|alzheimer without disease|Alzheimer's disease patients without apathy
9946273|NCT01049555|Other|Case control|subject without apathy neither Alzheimer's disease
9946274|NCT01049568|Experimental|Cell Phone Intervention|
9946275|NCT01049568|No Intervention|Control|"Control group participants will participate in all on-study evaluations, except the intervention exit interviews.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
9946276|NCT01049594||Preterm infants|Delivery at less than 33 completed weeks of gestation
9946277|NCT01049607|Active Comparator|Clamp-Crush technique|
9946278|NCT01049607|Experimental|Stapler hepatectomy|
9946279|NCT01049620|Experimental|Xelox+RAD001|
9946280|NCT01049646|Active Comparator|Angiotensin II|
9946281|NCT01049646|Placebo Comparator|Saline infusion|
9946282|NCT01049659|Other|neuropsychological tests|neuropsychological assessment of children around their second birthday
9946283|NCT01049672|Active Comparator|Alfentanil|Hospice in-patients who require subcutaneous strong opioid administration will be given alfentanil
9946284|NCT01049672|Active Comparator|Diamorphine|Hospice in-patients who require strong opioids will be given diamorphine
9946285|NCT01049685|Active Comparator|Efavirenz Group|Naïve-treatment HIV patients, who started therapy with Efavirenz
9946286|NCT01049685|Active Comparator|Lopinavir/r Group|Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
9946287|NCT01049698|Active Comparator|1. Resistance Training|3 d/wk resistance training
9946288|NCT01049698|Experimental|2. Resistance Training + Diet|Resistance training plus caloric restriction
9946289|NCT01049711||erythropoietin|
9946290|NCT01049724||PRK|Those patients undergoing photorefractive keratectomy
9946291|NCT01049724||LASIK|Those undergoing Laser-assisted insitu keratomileusis
10004360|NCT01575314|Experimental|stapling device|stapling device refer to patients who were randomized to use stapler for dividing lung parenchyma.
10004361|NCT01575314|No Intervention|hand sewn|hand sewn refer to patients who were randomized to use hand suturing for dividing lung parenchyma.
10004362|NCT01575327|Active Comparator|Fixed oxygen flow delivery|Oxygen flow delivery is adjusted by respiratory therapists. Standard medical treatment.
10004363|NCT01575327|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in a closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
10004364|NCT01575340|Experimental|fish oil encapsuled|will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
10004365|NCT01575340|No Intervention|without supplementation|not will receive supplementation or encapsulated fish oil or placebo
10004366|NCT01575353|Active Comparator|Venturi mask|After extubation, patients will receive oxygen therapy through the standard Venturi mask (control)
10004367|NCT01575353|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention)
10004368|NCT01575366|Experimental|Slow tracking training|
10004369|NCT01575366|Experimental|Fast tracking training|
10004370|NCT01575392||Patients coming for creatinine clearance|For this single group study, all patients presenting at the laboratory facility for a 24-hour creatinine clearance and patients in the dialysis population of the Isala Clinics who came for their periodical KT/V control, were informed about the study and asked to participate. Moreover, 20 'healthy' volunteers (including the investigators of this study and staff working at the clinical chemistry department of the Isala clinics) participated in this study.
10004371|NCT01575405|Experimental|Rectal-specific formulation (RF) stage|During this stage, participants will receive seven rectally-administered doses of the rectal-specific formulation (RF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
10004372|NCT01575405|Active Comparator|Vaginal formulation (VF) stage|"During this stage, only one exposure to the vaginal formulation (VF) will be administered (as the seventh dose in the stage), but it will be coupled with six preceding exposures to the Universal HEC Placebo Gel to balance it out against the other three stages in the study.~First and last doses will be administered in clinic, and after the administration of the last dose, various specimens will be collected, including blood, vaginal and rectal fluid, and endoscopic biopsies. Additional blood and fluids will be collected at 2, 4, and 24 hours post seventh dose administration."
10004373|NCT01575405|Active Comparator|Reduced Glycerin Vaginal Formulation (RGVF) stage|During this stage, participants will receive seven rectally-administered doses of the reduced glycerin vaginal formulation (RGVF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
10214863|NCT04149535|Experimental|TAVR with Sentinel|Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.
10214864|NCT04149535|No Intervention|TAVR without Sentinel|Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.
10214865|NCT04140162|Experimental|Dara-Rd followed by Dara-RVd|"Induction regimen with Daratumumab, Lenalidomide and Dexamethasone (Dara-Rd) in all study subjects, weeks 1-24~Consolidation regimen with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (Dara-RVd) in post-induction MRD+ population, weeks 25-36~Maintenance regimen with Daratumumab and Lenalidomide (Dara-R) in all study subjects, weeks 37-88~Maintenance regimen with lenalidomide (R) until progression or intolerance"
10214866|NCT04132219|Experimental|Immediate Intervention Group|"Dyads randomized to the Immediate Intervention Group will receive a Welcome Box at completion of the baseline assessment. The Welcome Box will include two of each of the following: 1) Letters describing the project logistics and the important roles of each dyad member); 2) WiFi-enabled Scales (with instructions to weigh daily); 3) Portion Doctor ®Tableware (with instructions to use the portion plates at least once a day); 4) Fitbit® Inspire Activity Monitors (with instructions to share data with the dyad member and the study office); and 5) Instructions on how to create a secured account on the DUET website and instructions for logging on."
10214867|NCT04132219|Other|Delayed Intervention Group|"Participants assigned to the Delayed Intervention Group will receive a Welcome Box which on the outside is identical (and also is comparably weighted with bottled water) to that given to the Immediate Intervention group. This box would include: 1) Letters describing the project logistics and the important roles of each dyad member; and 2) monthly online study newsletters on topics unrelated to diet and exercise, but still of interest to cancer survivors and dyad members such as coping with stress, reducing exposure to radiation, sun safety, etc. to enhance retention and will be offered the opportunity to receive the online intervention after completing final 6-month assessments."
10214868|NCT04117100||Endoscopic mucosal resection (EMR)|It has become the standard treatment for superficial tumors of the gastrointestinal tract, either flat or sessile: precancerous lesions and superficial cancers with no or low ganglionic risk. The pre-injection of physiological serum detaches the lesion from the deep plane and allows, with great security, the resection of the mucosa, muscularis mucosae with part of the submucosa, whatever the size and location of the lesion. Compared to other techniques, it allows a histological analysis which dictates the subsequent conduct and the possible need for a complementary surgery.
10214869|NCT04117100||Endoscopic mucosal dissection (ESD)|This technique uses submucosal injection and special knives to make a peri-lesional circumferential incision, followed by dissection through the submucosal sub-lesion.
9946292|NCT01049750||type 2 diabetic patients|males; type 2 diabetic patients
9946293|NCT01049763|Experimental|Regimen A|oseltamivir 75 mg single dose
9946294|NCT01049763|Active Comparator|Regimen B|oseltamivir 150 mg single dose
9946295|NCT01049789|Active Comparator|TAU|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement TAU will receive that treatment method.
9946296|NCT01049789|Experimental|COMB|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement COMB will receive that treatment method.
9946297|NCT01049815|Experimental|Sevelamer hydrochloride|
9946298|NCT01049815|Active Comparator|Calcium carbonate|
9946299|NCT01049828||Slightly or Non-Bothered Tinnitus Group|
9946300|NCT01049841|Experimental|perifosine + temsirolimus|This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load.
9946301|NCT01049854|Experimental|Thiotepa/Cyclophosphamide/ATG|Full intensity with TBI
9946302|NCT01049854|Experimental|Busulfan/Melphalan/ATG|Full intensity without TBI
9946303|NCT01049854|Experimental|Busulfan/Fludarabine/Alemtuzumab|Reduced Intensity Chemotherapy
9946304|NCT01049854|Experimental|Fludarabine/Cyclophosphamide/ATG|Reduced Intensity Chemotherapy for Fanconi Anemia
9946305|NCT01049880|Experimental|Ascorbate|
9946306|NCT01049893|Experimental|AC220|Dose finding study. Number of arms dependant upon dose limiting toxicities.
9946307|NCT01049906|Active Comparator|Nerve stimulation and Ultrasound|
9946308|NCT01049906|Active Comparator|Ultrasound without nerve stimulation|
9946309|NCT01049932|Experimental|All subjects|TMC278LA 600mg injected intramuscularly (i/m)
9946310|NCT01049971|Active Comparator|no wound protector|instead of wound protector, a woven drape is applied
9946311|NCT01049971|Experimental|wound protector|after minilaparotomy, wound protector is applied
9946312|NCT01049997||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
9946313|NCT01050010|Other|Dedicated extremity MRI|Structural deterioration radiographic assessed by dedicated extremity MRI
9946314|NCT01050023|Experimental|1 - Active Treatment|Provant device activated to emit RF energy
9946315|NCT01050023|Sham Comparator|2 - Inactive Treatment|Provant device not activated to emit RF energy
9946316|NCT01050036|Experimental|HCT recipients|"Patient with CBF AML will be eligible in his/her 1st complete remission (CR1) status. Patients who have relapsed or have achieved 2nd complete remission should not be included in this study.~1st postremission therapy after CR1 will be performed with high-dose cytarabine (HDAC) chemotherapy, consisting of intravenous cytarabine 3 g/m2 infusion during 3 hours twice a day on days 1, 3, and 5.~After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information."
9946317|NCT01050049||Before guidelines implemented|
9946318|NCT01050049||After guidelines implemented|
9946319|NCT01050075|Experimental|Arm I|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
9946320|NCT01050075|Experimental|Arm II|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.
9946321|NCT01050088|Experimental|Sucrose|5cc sucrose solution
9946322|NCT01050088|Placebo Comparator|Saline|5cc saline p/o
9946323|NCT01050101|Placebo Comparator|High GI low fiber meal|No fiber control meal
9946324|NCT01050101|Active Comparator|Low GI high fiber viscous meal|80:20 ratio of viscous polysaccharide fiber to insoluble non-viscous producing fiber
9946325|NCT01050101|Active Comparator|Low GI high fiber non-viscous meal|20:80 ratio of viscous polysaccharide fiber source to insoluble non-viscous producing fiber
9946326|NCT01050114|Other|ARM 1: onaBoNT-A injection + placebo|onaBoNT-A 200 U (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and placebo oral capsule daily
9946327|NCT01050114|Other|ARM 2: Placebo injection + oxybutynin ER|Placebo injection (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and oxybutynin ER 10 mg capsule daily
9946328|NCT01050127|Experimental|Low dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
9946329|NCT01050127|Experimental|Mid Dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
9946330|NCT01050127|Experimental|High Dose ABT-436|ABT-436 or placebo administered once daily for 14 days.
9946331|NCT01050140|Experimental|fructose|25% dietary energy from fructose
9946332|NCT01050140|Active Comparator|glucose|25% dietary energy from glucose
9946333|NCT01050166||Labeled islets|Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent
9946334|NCT01050244|Experimental|Soy Protein|30g of soy protein from whole soybean soymilk powder given daily for 3 weeks
9946335|NCT01050244|Placebo Comparator|Milk Protein|30g of milk protein from whole milk powder given daily for 3 weeks
9946336|NCT01050270|Other|Ondansetron /acetylcysteine 20.25h|Ondansetron followed by conventional acetylcysteine regimen
9946337|NCT01050270|Other|Placebo/acetylcysteine 20.25h|placebo followed by conventional acetylcysteine regimen
9946338|NCT01050270|Other|Ondansetron/acetylcysteine 12h|ondansetron followed by modified acetylcysteine regimen
9946339|NCT01050270|Other|Placebo/acetylcysteine 12h|placebo followed by modified acetylcysteine regimen
9946340|NCT01050283|Experimental|1|[18F]-FDG-PET/CT (Computed Tomography) Imaging
9946341|NCT01050309|Active Comparator|Cervix|
9946342|NCT01050309|Active Comparator|colon|
9946343|NCT01050309|Active Comparator|Intravenous|
9946344|NCT01050322|Active Comparator|Capecitabine Lapatinib|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
9946345|NCT01050322|Experimental|Vinorelbine Lapatinib|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
9946346|NCT01050322|Experimental|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
9946347|NCT01050335||Surgical resident or attending|
9946348|NCT01050348|Active Comparator|Atorvastatin calcium|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
9946349|NCT01050348|Placebo Comparator|Sugar Pill|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
9946350|NCT01050361|Experimental|EGHEM|The intervention group will be called EGHEM - Echo Guided HEmodyanmic Management - and will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative LVDD grade.
9946351|NCT01050361|No Intervention|SHEM|"The control group will be~called SHEM - Standard HEmodynamic Management - and will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution."
9946352|NCT01050374|Placebo Comparator|1|albendazole + praziquantel
9946353|NCT01050374|Active Comparator|2|mebendazole + praziquantel
9946354|NCT01050400||Observant|Individuals within this group will receive pharmacotherapy according to the established institutional guidelines.
9946355|NCT01050400||Prospective CYP2D6 genetic screening|Individuals within the prospective group will receive their CYP2D6 genotype results prior to pharmacotherapy and their analgesic regimen will be tailored to their genetic results.
9946356|NCT01050413||1|colon cancer, prostate cancer, lung cancer, ovarian cancer
9946357|NCT01050426|Active Comparator|Group 1|UFT/LV + RT
9946358|NCT01050426|Active Comparator|Group 2|UFT/LV + RT + Cetuximab
9946359|NCT01050439|Experimental|UDAlloSCT + Therapy|This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.
9946360|NCT01050452|Placebo Comparator|1|albendazole treatment
9946361|NCT01050452|Active Comparator|2|mebendazole treatment
9946362|NCT01050452|Active Comparator|3|ivermectin treatment
9946363|NCT01050452|Active Comparator|4|albendazole + ivermectin treatment
9946364|NCT01050452|Active Comparator|5|mebendazole + ivermectin treatment
9946365|NCT01050465|Active Comparator|email|Patients randomized to this arm will receive an email health information prescription.
9946366|NCT01050465|Active Comparator|paper|Patients randomized to this arm will receive a paper health information prescription.
9946367|NCT01050478|Experimental|Paliperidone ER|Paliperidone ER: recommended dose: 6 mg/day. Can be 9 mg/day for patients with an acute exacerbation of schizophrenia. A benzodiazepine for sedation and/or rescue medication can be added with a maximum of 7.5 mg/day, at the investigators' discretion.
9946368|NCT01050491|Placebo Comparator|sitaxsentan, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
9946369|NCT01050491|Placebo Comparator|placebo, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
9946370|NCT01050517|Active Comparator|1|albendazole + ivermectin + praziquantel
9946371|NCT01050517|Placebo Comparator|2|albendazole + ivermectin + (1 week later) praziquantel
9946372|NCT01050556|Placebo Comparator|Placebo|Placebo daily
9946373|NCT01050556|Experimental|Folic Acid 400 ug|400 µg folic acid daily
9946374|NCT01050556|Experimental|Folic Acid 800 ug|800 µg folic acid daily
9946375|NCT01050556|Experimental|Creatine|creatine daily
9946376|NCT01050556|Experimental|Creatine + Folic Acid|creatine + folic acid daily
9946377|NCT01050595|Active Comparator|Methylnaltrexone Bromide|
9946378|NCT01050595|Placebo Comparator|Placebo|
9946379|NCT01050608||Sprixx Device Group|Treatment group utilizing multimodal hand hygiene device
10004374|NCT01575418|Experimental|Rectal specific formulation (RF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
9946380|NCT01050608||Standard Hand Hygiene Group|Utilizing wall mounted dispensers and CDC based guidelines.
9946381|NCT01050686|Active Comparator|subcutaneous wound drain|subcutaneous wound drain inserted
9946382|NCT01050686|Experimental|no subcutaneous wound drain|no subcutaneous wound drain inserted
9946383|NCT01050699|Experimental|Dexmedetomidine|Dexmedetomidine plus saline
9946384|NCT01050699|Active Comparator|Usual Care|Midazolam and Fentanyl
9946385|NCT01050712|Experimental|Carbon Monoxide|
9946386|NCT01050712|Placebo Comparator|Synthetic Air|
9946387|NCT01050725||Radiation therapy patients|Individuals receiving radiation therapy as definitive or neo-adjuvant therapy for selected malignancies, including head and neck, lung, esophageal, rectal cervical and prostate cancers.
9946388|NCT01050738|Active Comparator|Intracapsulare position|
9946389|NCT01050738|Active Comparator|Extracapsulare position|
9946390|NCT01050751|Experimental|Lersivirine (new formulation)|
9946391|NCT01050751|Active Comparator|Lersivirine (old formulation)|
9946392|NCT01050777|Experimental|Liposomal Paromomycin|Liposomes containing 10% Paromomycin
9946393|NCT01050777|Experimental|Liposomal meglumine antimoniate|Liposomes containing meglumine antimonate
9946394|NCT01050777|Placebo Comparator|Placebo|
9946395|NCT01050803|Experimental|FDSME group|In the FDSME group, sessions will be held interactive; and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
9946396|NCT01050803|Active Comparator|Control group|
9946397|NCT01050829|Experimental|Arm 1|
9946398|NCT01050829|Active Comparator|Arm 2|
9946399|NCT01050842|Experimental|Arm I|Patients receive oral bicalutamide and oral raloxifene on days 1-28.
9946400|NCT01050868|Experimental|Single Arm|
9946401|NCT01050881||Positive Blood Donors|Blood donors testing positive for HIV, HBV, HCV or HTLV in 2008 and 2009. Donors and patients notified of increased risk of vCJD in 2005.
9946402|NCT01050894||osteoarthritis patients|
9946403|NCT01050920||Blood Collection|
9528775|NCT03207854||Ancillary-correlative (biospecimen collection)|Patients and healthy normal volunteers undergo collection of peripheral blood samples for analysis via flow cytometry, RNASeq, immunohistochemistry, CyTOF experiments, cell cultures, and functional studies of immune cell subsets obtained by FACS. Patients also undergo collection of bone marrow and leukopheresis/leukoreduction specimens, and single cell suspensions and bulk excised tumor biopsies are obtained from routine testing for analysis via immunohistochemistry or CyTOF.
9801252|NCT01710358|Active Comparator|Adalimumab|"Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
9946404|NCT01050933|Experimental|Carbon Monoxide|Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
9946405|NCT01050972|Experimental|Cognitive and physical program|Experimental: Cognitive and physical program. Non randomized residents in the territory of Piedmont (Piemonte) Italy.
9946406|NCT01050985|Experimental|temsirolimus and capecitabine|Treatment with the combination of temsirolimus and capecitabine
9946407|NCT01051011|Experimental|1|
9946408|NCT01051011|Experimental|2|
9946409|NCT01051011|Active Comparator|3|
9946410|NCT01051024|Experimental|A|Diamel
9946411|NCT01051024|Placebo Comparator|B|Placebo
9946412|NCT01051037|Experimental|Arm 1|Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.
9946413|NCT01051050|Other|Mandatory use of surgery wiki|Mandatory participation in journal club wiki which will include adding to and reviewing the information posted on the wiki. Contribution to the wiki will be required at least once during the study period.
9946414|NCT01051050|Other|Voluntary use of surgery wiki|Voluntary participation in the journal club wiki
9946415|NCT01051076|Experimental|Factor VIII and von Willebrand Factor|
9946416|NCT01051089|Experimental|Lifestyle modification|supervised exercise with diet education
9946417|NCT01051089|No Intervention|Control|Control (ordinary care with usual education)
9946418|NCT01051102|Experimental|IDegAsp|
9946419|NCT01051102|Active Comparator|BIAsp 30|
9946420|NCT01051115|Experimental|Dasatinib|Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.
9946421|NCT01051128|Experimental|Spasticity. Baclofen|This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin.
9801253|NCT01710501|Experimental|Grazoprevir 25 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
9801254|NCT01710501|Experimental|Grazoprevir 50 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
9946422|NCT01051141|Active Comparator|CBI in ED with AMET at 3 months|computer brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
9946423|NCT01051141|Active Comparator|CBI in ED with EUC at 3 months|
9946424|NCT01051141|Active Comparator|IBI in ED with AMET at 3 months|
9946425|NCT01051141|Active Comparator|IBI in ED with EUC at 3 months|
9946426|NCT01051141|Active Comparator|EUC in ED with AMET at 3 months|
9946427|NCT01051141|No Intervention|EUC in ED with EUC at 3 months|
9946428|NCT01051154|Active Comparator|Docosahexaenoic acid (DHA)|This group will be receive the DHA supplement
9946429|NCT01051154|Placebo Comparator|Placebo|This group will be receive placebo
9946430|NCT01051167|Experimental|Cetuximab + Folfox-6-regime|"Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h."
9946431|NCT01051180||Doppler|Those patients where the doppler was randomised to be on
9946432|NCT01051180||Non doppler patients|those with no doppler guidance
9946433|NCT01051193|Experimental|TRI476|TRI476
9946434|NCT01051219|Active Comparator|Losartan, daily medication|50 milligrams Losartan to be taken orally daily
9946435|NCT01051219|Placebo Comparator|Placebo|A matched placebo will be given for patients to take once daily
9946436|NCT01051232|Placebo Comparator|Cohort 1|PF-00868554 (filibuvir) 100 mg or placebo
9946437|NCT01051232|Placebo Comparator|Cohort 2|PF-00868554 (filibuvir) 300 mg or placebo
9946438|NCT01051232|Placebo Comparator|Cohort 3|PF-00868554 (filibuvir) 500 mg or placebo
9946439|NCT01051245|Active Comparator|Case management|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
9946440|NCT01051245|Placebo Comparator|Usual care group|Usual care provided by primary care physician and/or specialist. Free access to diabetes educational workshops. Regular delivery of educational brochures (not personally targeted).
9801255|NCT01710501|Experimental|Grazoprevir 100 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
9801256|NCT01710514|Active Comparator|FE 999913 100 mg BID|FE 999913 100 mg vaginal tablet BID
9801257|NCT01710514|Active Comparator|FE 999913 100 mg TID|FE 999913 100 mg vaginal tablet TID
9801258|NCT01710527|Other|Metformin 500mg|Cross over, two treatment, two period, two sequence, cross over, single dose
9801259|NCT01710527|Other|Glucophage 500mg|Cross over, two treatment, two period, two sequence, sigle dose
9801260|NCT01710657|Placebo Comparator|Placebo|Matching placebo for 16 weeks.
9801261|NCT01710657|Experimental|Lacosamide 200 mg/day|Lacosamide treatment of 200 mg/day (100 mg bid (twice daily)) for 16 weeks.
9801262|NCT01710657|Experimental|Lacosamide 400 mg/day|Lacosamide treatment of 400 mg/day (200 mg bid (twice daily)) for 16 weeks.
9801263|NCT01710709|Experimental|Experimental|Aripiprazole, Intramuscular (IM) Depot
9801264|NCT01710787|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
9801265|NCT01710787|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
9801266|NCT01710787|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
9801267|NCT01710800|Placebo Comparator|Placebo arm|Patients will be randomized to receive either PPI or placebo and then undergo a 24 hour pH study with impedance to measure the number of reflux episodes
9801268|NCT01710800|Active Comparator|Esomeprazole|Patients were randomly assigned to receive 40 mg esomeprazole twice daily prior to undergoing a 24 hour pH study with impedance to measure the number of reflux episodes
9801269|NCT01710839|Experimental|Targeted Pan Retinal laser combined with 0.5mg ranibizumab|Cohort 1 (n=24), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses of 0.5 mg ranibizumab followed by PRN treatment with ranibizumab 0.5 mg; after receiving the first loading dose of ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) based on 200° wide field angiography with possibility of a second session of TRP at M4/M7, if non-perfusion persists based on angiogram.The 200°wide field angiography will indicate areas of peripheral ischemia which will be selectively treated, preserving areas of more perfused retina.
9801270|NCT01710839|Active Comparator|Ranibizumab 0.5mg|Cohort 2 (n=6), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses followed by PRN monthly treatment with ranibizumab 0.5 mg.
9801271|NCT01710891|Active Comparator|Direct Laryngoscopy|Patients will undergo their first intubation attempt with direct laryngoscopy using the CMAC device without video assistance. The video monitor with be covered with a hood.
9801272|NCT01710891|Experimental|CMAC|Patients will undergo their first intubation attempt using the CMAC videolaryngoscope using video assistance
9801273|NCT01711177|Sham Comparator|Normal control|Normal patient placebo
9801274|NCT01711177|Sham Comparator|Glaucoma suspect|Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
9801275|NCT01711177|Experimental|Newly diagnosed glaucoma|Treated with Travoprost (0.04%)
9801276|NCT01711216||women received dydrogesterone for irregular menstrual cycle|Adult women received dydrogesterone for irregular menstrual cycle as per standard clinical practice of the treating physician
9801277|NCT01711294|Active Comparator|19 G Flex Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
9801278|NCT01711294|Active Comparator|22 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
9801279|NCT01711294|Active Comparator|19 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
9801280|NCT01711359|Experimental|Baricitinib + MTX|Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
9801281|NCT01711359|Experimental|Baricitinib|Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
9801282|NCT01711359|Active Comparator|MTX|MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
9801283|NCT01711372|Placebo Comparator|Controls who played Groundskeeper game|Controls played a go/no go task on Sifteo cubes to asses for attentional capabilities.
9801284|NCT01711372|Active Comparator|Probands played groundskeeper game|Patients with ADHD played a go/no go task on Sifteo cubes to asses for attentional capabilities
9801285|NCT01711424||OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
9801286|NCT01711619|Experimental|SQS plus OMM|subcutaneous nerve stimulation plus optimized medical management
9801287|NCT01711619|Active Comparator|OMM|optimized medical management
9801288|NCT01711645|Experimental|Adacel® Tdap vaccine|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
9801289|NCT01711658|Placebo Comparator|IMRT + cisplatin + placebo|Intensity Modulated Radiation Therapy (IMRT) with cisplatin and placebo
9801290|NCT01711658|Active Comparator|IMRT + cisplatin + lapatinib|IMRT with cisplatin and lapatinib
9801291|NCT01711736|Experimental|GSK2282512A Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.~Quadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
9946441|NCT01051271|Active Comparator|diphenhydramine|
9946442|NCT01051271|Placebo Comparator|saline|
9946443|NCT01051284|Experimental|Cyberknofe and Gemcitabine|Cyberknife radiation and 6 cycles Gemcitabine
9946444|NCT01051297||VTE -PROSPECTIVE|Patients diagnosed with VTE
9946445|NCT01051297||sleep study group -PROSPECTIVE|patients undergoing sleep study
9528776|NCT03207737|Experimental|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 5-days post baseline testing before beginning a one-year telehealth program.
9946446|NCT01051297||VTE-Retrospective|patients with VTE , chart review
9946447|NCT01051297||OSA-retrospective|PATIENT WITH OSA -CHART REVIEW
9946448|NCT01051297||OSA group -PROSPECTIVE|patients diagnosed with OSA
9946449|NCT01051336|Experimental|TARIS Placebo|
9946450|NCT01051336|Sham Comparator|Sham Procedure|
9946451|NCT01051362|No Intervention|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
9946452|NCT01051375|Experimental|Waitlist Group|The intervention involves completion of a single workshop, provision of psychoeducational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list, within a month of our receiving the referral.
9946453|NCT01051375|No Intervention|Standard of Care|These patients continue to receive the standard of care while awaiting formal assessment.
9946454|NCT01051388|Active Comparator|Group I|Low-dose PPI (Rabeprazole sodium 10 mg)
9946455|NCT01051388|Active Comparator|Group II|High-dose PPI (Rabeprazole sodium 20 mg)
9946456|NCT01051388|Active Comparator|Group III|Non-PPI (Gefarnate)
9946457|NCT01051401|Experimental|Arm I (rosuvastatin)|Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
9946458|NCT01051401|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
9946459|NCT01051427|Active Comparator|Nasal catheter|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
9946460|NCT01051427|Experimental|Surgiflo|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.
9946461|NCT01051479|Experimental|C11-Choline|
10004375|NCT01575418|Active Comparator|Vaginal formulation (VF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
10004376|NCT01575418|Active Comparator|Reduced glycerin vaginal formulation (RGVF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
10004377|NCT01575431||Stable angina|Patients who undergo an elective and successful single or multivessel percutaneous coronary intervention can be considered for the study.
10004378|NCT01575444||Home Based Vaginal Collection|Somali women who are randomized for Home based Vaginal Collection will be given a kit to perform the vaginal sample collection for HPV analysis, with detailed written instructions.
10004379|NCT01575444||Clinic Based Pap Test Collection|30 Somali women who are randomized for Standard Clinic Pap Group will be given a list of clinics that they can attend for cervical cancer screening using pap test. Follow-up will be done on test completion with the clinic at 3 months after enrollment.
10004380|NCT01575457|Experimental|Intervention|The Healthy Futures Program is an interactive, multi-session training program. The intervention participants will participate in College/vocational school, Job, and Career Planning activities with a career coach.
10004381|NCT01575457|Other|Comparison|The Healthy Futures Program is an interactive, multi-session training program. The comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
10004382|NCT01575483||Patients with T2DM|Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled
10004383|NCT01575496|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS.
10004384|NCT01575496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham tDCS.
10004385|NCT01575548|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
10004386|NCT01575548|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
10004387|NCT01575574|Other|GADOXETIC ACID|Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
10004388|NCT01575587|Experimental|Treatment A|
10004389|NCT01575587|Experimental|Treatment B|
9946462|NCT01051505|Experimental|1|
9946463|NCT01051505|Placebo Comparator|2|
9946464|NCT01051531|Experimental|Paliperidone palmitate|
9946465|NCT01051544|Active Comparator|von Willebrand factor-free FVIII concentrates|Patients treated with FVIII concentrates
9946466|NCT01051544|Active Comparator|FVIII/VWF concentrates|Patients treated with FVIII/VWF concentrates
9946467|NCT01051583|Experimental|Avastin , diode laser cyclophotcoagulation|Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
9946468|NCT01051583|Active Comparator|Diode Laser cyclophotocoagulation|Diode laser cyclophotocoagulation to control intraocular pressure
9946469|NCT01051609||Intervention Group|There is only one arm in this trial. Please see interventions for more detailed descriptions.
9946470|NCT01051622|Experimental|PBMC Trafficking|In part B, Patients undergo a blood draw (up to150 mL) and the PBMC's are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
9946471|NCT01051622|Experimental|T Lymphocyte Trafficking|"In part B, Patients undergo a blood draw (up to150 mL) and the T lymphocyte cells are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.~visit."
9946472|NCT01051648|Experimental|Triamcinolone acetenoide|Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery
9946473|NCT01051674|Experimental|High fiber diet|
9946474|NCT01051674|Experimental|Low-carbohydrate diet|
9946475|NCT01051687|No Intervention|control skin patches|no intervention will be given to the patches
9946476|NCT01051687|Active Comparator|botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
9946477|NCT01051700|Experimental|5 mg|GW786034
9946478|NCT01051700|Experimental|10 mg|GW786034
9946479|NCT01051700|Experimental|20 mg|GW786034
9946480|NCT01051700|Placebo Comparator|Placebo|Placebo
9946481|NCT01051713|Experimental|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
9946482|NCT01051713|Experimental|Technology Supported condition|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
9946483|NCT01051713|No Intervention|Self-Guided|Participants in the Self-Guided condition will receive DPP DVDs (3 DVDs and 1 CD) at the beginning of the study. This condition will not receive any direct dietary or physical activity interventions outside of the DVDs. Although Self-Guided participants will be receiving the same 7% weight loss goal as the other two groups, they will not be receiving physical activity or diet goals. The DVDs cover the initial 12-weekly sessions of the DPP, with the sessions portrayed by professional actors. They will also be provided with a supplemental DVD which includes a manual for each of the 12 sessions. They will also be giving the Keeping Track booklets and asked to record their diet and activity daily.
9946484|NCT01051726|Experimental|Aromatherapy group 1|Participants will be given essential oil consisting of (Peppermint, Lavender, Clary Sage and Frankincense) together with a swab to put the oil on.
9946485|NCT01051726|Placebo Comparator|Control group 2|Participants receive a bottle of non essential oil and a swab.
9946486|NCT01051726|No Intervention|Control group 3|Standard maternity care to measure baseline.
9946487|NCT01051752||NTM infection|Patients with NTM infection are generally middle aged or higher aged, white males with COPD or bronchiectasis. They will be recruited from the outpatient clinics of University Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients with NTM disease will be recruited.
9528777|NCT03207737|Active Comparator|Telehealth Only|This group will complete baseline and 5-days post baseline testing before beginning a one-year telehealth program.
9946488|NCT01051765|Experimental|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin: 30mg/m2, d1,d2 every three weeks
9946489|NCT01051804|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
9946490|NCT01051804|Active Comparator|Optive|Optive Lubricant Eye Drops
10004390|NCT01575587|Experimental|Treatment C|
10004391|NCT01575587|Experimental|Treatment D|
10004392|NCT01575600|Active Comparator|10 mL/kg/h lactated Ringer's solution|Group 1, 10 mL/kg/h lactated Ringer's solution
9946491|NCT01051830|Experimental|Interdisciplinary group|Diabetes intervention and rehabilitation program. The rehabilitation program includes geriatric consultation, the rehabilitation program (interventions to improve ROM, muscle strength and endurance, proprioceptive enhancement, balance capacity, aerobic and anaerobic capacity, flexibility, and body composition), and discharge-planning services. The DM intervention includes: dietary and DM education, blood pressure control, dyslipidemia management, a glycemic treatment regimen, and exercises.
9946492|NCT01051830|No Intervention|Control group|Routine care
9946493|NCT01051869|Active Comparator|simple decompression|
9946494|NCT01051869|Active Comparator|anterior subcutaneous transposition|
9946495|NCT01051882|Experimental|MSC-NTF cells IM|Intramuscular administration in early stage patients
9946496|NCT01051882|Experimental|MSC-NTF cells IT|Intrathecal administration in progressive stage patients
9946497|NCT01051895|Experimental|HPV testing|Women randomized to this arm will undergo high risk HPV DNA testing using Hybrid Capture 2®.
9946498|NCT01051895|Active Comparator|Routine colposcopy|Women will be followed in the colposcopy clinic as usual, with no standardized protocol, tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
9946499|NCT01051947|Experimental|Nebivolol|Nebivolol therapy for 2-6 weeks depending on blood pressure readings
9946500|NCT01051947|Experimental|Metoprolol|Metoprolol therapy for 2-6 weeks depending on blood pressure readings
9946501|NCT01051973|Experimental|Cognitive behavior therapy|
9946502|NCT01051973|Active Comparator|Stress management|
9946503|NCT01051999|Experimental|Glutamine|Patients randomized to the glutamine arm will receive 0.7g/kg of oral glutamine powder per day
9946504|NCT01051999|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive 0.7g/kg of oral isonitrogenous L-alanine powder per day
9946505|NCT01052025|Experimental|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
9946506|NCT01052025|No Intervention|Placebo|
9946507|NCT01052051|Experimental|vitamin D3 and calcium carbonate|Daily vitamin D3 2000 IU/day and calcium carbonate 1500mg/day supplementation
9946508|NCT01052051|Placebo Comparator|Placebo for vitamin D3 and calcium carbonate|Placebo for daily vitamin D3 and calcium carbonate
9946509|NCT01052064|Experimental|Transcranial magnetic stimulation|There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
9946510|NCT01052090|Experimental|Lifestyle counseling|
9946511|NCT01052129|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
9946512|NCT01052129|Active Comparator|Anaprox DS 550 mg Tablets|Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
9946513|NCT01052142|Experimental|Lipovaxin-MM|
9946514|NCT01052181|Experimental|Vitamin D supplementation|Cholecalciferol sachets 120,000 IU monthly for 12 months
9946515|NCT01052181|Placebo Comparator|placebo|placebo with same taste, color, odor
9946516|NCT01052220|Experimental|BP Education and Self Regulation of BP|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will received a BP educational session at baseline and were asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI made weekly visits with the intervention participants in the HD unit to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
9946517|NCT01052220|No Intervention|Usual Care|Participants in the usual care group did not receive the intervention but continued to receive their standard care in the hemodialysis unit which involved follow-up by the medical provider and BP medication adjustments as needed. .
9946518|NCT01052233|Active Comparator|Arthroscopic partial meniscectomy|Arthroscopic partial resection of degenerative tear of medial meniscus
9946519|NCT01052233|Sham Comparator|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
9801292|NCT01711736|Active Comparator|Fluarix Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.~Fluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
9801293|NCT01711853|Experimental|Dabigatran Etexilate|patient to receive a capsule containing 75 mg of dabigatran etexilate
9801294|NCT01711866|Experimental|Rotigotine|"First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.~Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.~Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
9801295|NCT01711918|Experimental|Domperidone|Participants will received domperidone at a dose of 10mg given up to three times per day
9801296|NCT01711983|Experimental|Test Device|ASD closure with the GORE® CARDIOFORM Septal Occluder
9801297|NCT01712009|Experimental|Prophylactic naproxen|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
9801298|NCT01712009|Experimental|Prophylactic loratadine|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
9801299|NCT01712009|Other|No prophylactic treatment|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
9801300|NCT01712061|Active Comparator|Arm 1 PF-04634817|
9801301|NCT01712061|Placebo Comparator|Arm 2 Placebo|
9801302|NCT01712074|Experimental|30 mg QD of PF-05212377|
9801303|NCT01712074|Placebo Comparator|Placebo|
9801304|NCT01712178|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
9801305|NCT01712178|Active Comparator|Current formulation adalimumab 40 mg every other week|Current formulation adalimumab 40 mg every other week
9801306|NCT01712204|Placebo Comparator|Placebo|Placebo plus Febuxostat
9801307|NCT01712204|Experimental|AC-201|AC-201 plus Febuxostat
9801308|NCT01712230|Placebo Comparator|Placebo|Monthly placebo injections for 6 months
9801309|NCT01712230|Active Comparator|GnRH agonist|Monthly GnRH agonist injections for 6 months
9801310|NCT01712230|Active Comparator|GnRH agonist + exercise|Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention
9801311|NCT01712256|Experimental|Re-boosting with Vacc-4x|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.
9801312|NCT01712334|Experimental|eRapid Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
9801313|NCT01712334|Active Comparator|Jet Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.
9801314|NCT01712360|Experimental|NAFT500 (pediatric)|Topical once a day for two weeks
9801315|NCT01712360|Experimental|NAFT600 (pediatric)|Topical once a day for two weeks
9801316|NCT01712360|Experimental|NAFT500 (adult)|Topical once a day for two weeks
9801317|NCT01712360|Experimental|NAFT600 (adult)|Topical once a day for two weeks
9801318|NCT01712399|Experimental|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years.
9801319|NCT01712438|Experimental|Human cl rhFVIII|
9801320|NCT01712516|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
9801321|NCT01712516|Active Comparator|QAB149|27.5 ug b.i.d.
9801322|NCT01712516|Active Comparator|NVA237|12.5 ug b.i.d.
9801323|NCT01712516|Placebo Comparator|Placebo|b.i.d.
9801324|NCT01712685|Experimental|Renal Cell Carcinoma|
9801325|NCT01712711|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
9801326|NCT01712711|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
9801327|NCT01712776|Active Comparator|Vapocoolant (Pain Ease Medium Stream )|Application of Vapocoolant (Pain Ease Medium Stream) for 4-10 seconds onto venipuncture site.
9801328|NCT01712776|Placebo Comparator|Nature's Tears Sterile Water|Application of sterile water stream (nature's tears) for 4-10 seconds onto the venipuncture site.
9801329|NCT01712984|Experimental|QIV ID Vaccine Group|Participants will receive the intradermal quadrivalent influenza vaccine
9801330|NCT01712984|Active Comparator|TIV ID1 Vaccine Group|Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
9801331|NCT01712984|Active Comparator|TIV ID2 Group|Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
9801332|NCT01713036|Experimental|Pimasertib|
9801333|NCT01713283|Experimental|SOF+RBV 12 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 12 weeks.
9801334|NCT01713283|Experimental|SOF+RBV 24 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 24 weeks.
9801335|NCT01713348|Experimental|CGM - intervention arm|Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
9801336|NCT01713348|Active Comparator|SMBG - Control arm|Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.
9801337|NCT01713400|Experimental|Ustekinumab|Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
9801338|NCT01713400|Placebo Comparator|Placebo|Placebo, Tacrolimus, and Sirolimus. Placebo: Identical volume to that of ustekinumab. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
9801339|NCT01713530|Experimental|IDegAsp BID+/-OADs|
9801340|NCT01713530|Experimental|IDeg OD plus IAsp +/-OADs|
9801341|NCT01713582|Experimental|AL 10 mg QD 14-21|Participants received 10 mg birabresib/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.
9801342|NCT01713582|Experimental|AL 20 mg QD 14-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801343|NCT01713582|Experimental|AL 40 mg QD 14-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801344|NCT01713582|Experimental|AL 20 mg BID 21-21|Participants received 20 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
9801345|NCT01713582|Experimental|AL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801346|NCT01713582|Experimental|AL 40 mg BID 14-21|Participants received 40 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.
9801347|NCT01713582|Experimental|AL 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801348|NCT01713582|Experimental|AL 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
9801349|NCT01713582|Experimental|AL 160 mg QD 14-21|Participants received 160 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801350|NCT01713582|Experimental|AML de novo 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801351|NCT01713582|Experimental|AML/MDS 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801352|NCT01713582|Experimental|OHM 10 mg QD 21-21|Participants received 10 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
9801353|NCT01713582|Experimental|OHM 20 mg QD 21-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
9801354|NCT01713582|Experimental|OHM 40 mg QD 21-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
9946520|NCT01052246|Experimental|Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser|
9946521|NCT01052246|Active Comparator|Clindamycin 1% + benzoyl peroxide 5%|
9946522|NCT01052259|Experimental|Deoxyspergualin, Treatment,|
9946523|NCT01052285|Placebo Comparator|Placebo|TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
9946524|NCT01052285|Active Comparator|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
9946525|NCT01052285|Experimental|Transversus abdominis plane block|25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
9946526|NCT01052298|Experimental|Arm 1|
9946527|NCT01052298|Experimental|Arm 2|
9946528|NCT01052298|Experimental|Arm 3|
9946529|NCT01052298|Placebo Comparator|Arm 4|
9946530|NCT01052311|Placebo Comparator|Placebo|Placebo pills once daily
9946531|NCT01052311|Active Comparator|Active treatment|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.
9946532|NCT01052337|Active Comparator|propofol|
9946533|NCT01052337|Active Comparator|sevofluorane|
9946534|NCT01052350||Parkinson disease|individuals with Parkinson disease
9946535|NCT01052350||healthy control|individuals without Parkinson disease
9946536|NCT01052363|Experimental|CA4P + Avastin|
9946537|NCT01052363|Experimental|Avastin + CA4P|
9946538|NCT01052389|Experimental|Aripiprazole|Aripiprazole (N05AX12)
9946539|NCT01052389|Experimental|Olanzapine|Olanzapine (N05AH03)
9946540|NCT01052389|Experimental|Haloperidol|Haloperidol (N05AD01)
9946541|NCT01052402|Experimental|Dose A|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose A) followed by a heterologous booster vaccination (Dose A) on Day 360
9946542|NCT01052402|Experimental|Dose B|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose B) followed by a heterologous booster vaccination (Dose B) on Day 360
9801355|NCT01713582|Experimental|OHM 80 mg QD 21-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
9801356|NCT01713582|Experimental|OHM 40 mg BID 21-21|Participants received 40 mg birabresib/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
9801357|NCT01713582|Experimental|OHM 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
9801358|NCT01713582|Experimental|OHM 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801359|NCT01713582|Experimental|OHM 120 mg QD 5-7|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.
9946543|NCT01052415|No Intervention|Standard care|Service providers and HIV patients, offered intervention at the end of study
9946544|NCT01052415|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
9946545|NCT01052441||CT Scan|Subjects with typical or atypical chest pain suspected of coronary artery disease and referred for an elective invasive coronary angiography (ICA), and scheduled to undergo CCTA before ICA or after ICA, if no intervention has been performed.
9946546|NCT01052454|No Intervention|Wait list|Women assigned to the waitlist have the opportunity of taking the MBSR program at no cost following final study assessment
9946547|NCT01052454|Experimental|Mindfulness-based stress reduction|Women in the MBSR arm attend eight weekly MBSR classes
9946548|NCT01052506|Placebo Comparator|Placebo|Single dose of saline solution (8 cohorts IV; 1 cohort SC)
9946549|NCT01052506|Experimental|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
9946550|NCT01052519|No Intervention|obese control|
9946551|NCT01052519|Active Comparator|obese goal-directed|
9946552|NCT01052519|Active Comparator|non-obese goal directed|
9946553|NCT01052532||Mitral Regurgitation pre&post operation|Patients with severe Mitral Regurgitation without evidence of ischemia are tested prior to surgery and after valve repair.
9946554|NCT01052558|Active Comparator|Cataract Surgery Only|
9946555|NCT01052558|Experimental|Treatment with Cataract Surgery & Stents|Ab interno trabecular micro-bypass stent surgery
9946556|NCT01052571|Active Comparator|Without Steroids|Group I patients receiving lumbar transforaminal epidural injections with an injection of local anesthetic (lidocaine 1% or bupivacaine 0.25%
9946557|NCT01052571|Active Comparator|steroids|Group II patients will receive lumbar transforaminal epidural injections with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
9946558|NCT01052584|Experimental|Chloroquine-P. vivax|P. vivax randomized to receive chloroquine 3-day regimen
9946559|NCT01052584|Experimental|Artemether-Lumefantrine: P. vivax|
9946560|NCT01052584|Experimental|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
9946561|NCT01052597|Placebo Comparator|Placebo|
9946562|NCT01052597|Experimental|Curcumin|
9946563|NCT01052610|Active Comparator|Active group|Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract
9946564|NCT01052610|Placebo Comparator|Placebo group|Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator
9946565|NCT01052623|Experimental|Growth hormone-testing (GH/IGF-1-testing)|"Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.~The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days."
9517202|NCT03308383|Experimental|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
9946566|NCT01052636|No Intervention|Control group|Patients receive only routine hospital care
9946567|NCT01052636|Experimental|Experimental group|Patients receive regular hospital routine care and interdisciplinary intervention program
9946568|NCT01052649||Healthy volunteers|
9946569|NCT01052675||Pharmacodependance cases|Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
9946570|NCT01052688||Pregnant Women|Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.
9946571|NCT01052727|Other|overnight stay group|Group of patients who rests at least one night in Hospital
9946572|NCT01052727|Other|day-care Group|Group of patients who is discharged tha same day of operation
9946573|NCT01052753||ADHD group|
9946574|NCT01052753||Control group|
9801360|NCT01713582|Experimental|OHM 120 mg QD 7-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle
9801361|NCT01713582|Experimental|OHM/DLBCL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
9801362|NCT01713608|Experimental|OZ439 Dose level 1 (300mg)|• Cohort 1 (12 subjects: 8 Active [A] and 4 on Placebo [P]) Active dose will consist of 300mg OZ439 drinking solution administered once daily for 3 days
9801363|NCT01713608|Experimental|OZ439 Dose level 2|• Cohort 2 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
9801364|NCT01713608|Experimental|OZ439 dose level 3|Cohort 3 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
9801365|NCT01713621|Experimental|OZ439 100mg|Single dose of 100mg of OZ439 administered as an oral suspension
9801366|NCT01713621|Experimental|OZ439 500mg|Single dose of 500mg of OZ439 administered as an oral suspension
9801367|NCT01713660|Other|FS Corneal Incisions|
9801368|NCT01713686|Experimental|Ulthera System Treatment|A single triple-depth Ulthera System treatment of the decolletage delivering treatment at 4.5mm, 3.0mm and 1.5mm depths.
9801369|NCT01713868|Other|Safe Sleep Edu and Breastfeeding mHealth|Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
9801370|NCT01713868|Other|Breastfeeding Edu and Safe Sleep mHealth|Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
9801371|NCT01713868|Other|Safe Sleep Edu and Safe Sleep mHealth|Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
9801372|NCT01713868|Other|Breastfeed Edu and Breastfeed mHealth|Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging
9801373|NCT01713933|Experimental|Ultherapy™ treatment|Each enrolled subject will receive a bilateral Ultherapy™ treatment of the upper arms
9801374|NCT01713946|Experimental|Everolimus LT target of 3 - 7 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.
9801375|NCT01713946|Experimental|Everolimus HT target of 9 -15 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.
9801376|NCT01713946|Placebo Comparator|Placebo|Participants received placebo plus 1 to 3 antiepileptic drugs.
9801377|NCT01713998|Active Comparator|Group A|Subjects will receive an increased density Ulthera System Treatment over the full face but with the energy turned down to the second highest level of four possible energy settings on one side of the face.
9801378|NCT01713998|Active Comparator|Group B|Subjects will receive an increased density guideline Ulthera System Treatment over the full face but with the energy turned down to the lowest level of four possible energy settings on one side of the face.
9801379|NCT01713998|Active Comparator|Group C|Subjects will receive an increased density guideline Ulthera System Treatment over the full face with the exception that a 4 MHz transducer will be used on the upper face in place of a7 MHz transducer, with the energy turned down to the lowest level of four possible energy settings.
9801380|NCT01714024|Experimental|Healthy Volunteers|Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
9801381|NCT01714024|Experimental|Diabetic Subjects|Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
9801382|NCT01714024|Experimental|Osteopenic Subjects|Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
9801383|NCT01714063||Age 5-6.5|Group 1 will consist of 16 children aged 5-6.5 years
9801384|NCT01714063||Aged 6.6- 8 years|Group 2 will consist of 16 children aged 6.6- 8 years
10004393|NCT01575600|Experimental|30 mL/kg/h lactated Ringer's solution|Group 2, 30 mL/kg/h lactated Ringer's solution
9801385|NCT01714232|Experimental|Study Staff Test BGMSs|All testing and lancing were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems (BGMS): Contour® PLUS BGMS; OneTouch® SelectSimple™ BGMS; Accu-Chek® Performa BGMS; Accu-Chek® Active BGMS; Freestyle Freedom® BGMS.
9801386|NCT01714310|Experimental|Adjunctive fluoxetine|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive fluoxetine at end of study week 4.
9801387|NCT01714310|Placebo Comparator|Adjunctive placebo|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive placebo at end of study week 4.
9801388|NCT01714310|Other|Open Lisdexamfetamine Titration|All participants initially titrated with open-label lisdexamfetamine from baseline to end of study week 4.
9801389|NCT01714323|Other|Standard care|At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
9801390|NCT01714323|Experimental|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
9801391|NCT01714336|Placebo Comparator|placebo|Normal saline will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
9801392|NCT01714336|Active Comparator|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
9801393|NCT01714492||Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|subjects implanted with the Sigma Posterior Stabilizing Rotating Platform TKA including a polyethylene insert with 4 beads
9801394|NCT01714505|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
9801395|NCT01714505|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. The subject will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
9801396|NCT01714544|Experimental|Cloderm Cream|Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
9801397|NCT01714609|Placebo Comparator|Placebo|Subjects randomized to placebo will take two tablets of placebo by mouth twice daily.
9801398|NCT01714609|Experimental|Sorafenib|Subjects randomized to Sorafenib will take Sorafenib 400 mg by mouth twice daily.
9801399|NCT01714635|Experimental|Tecnis Multifocal Intraocular lens #1|A low diopter add multifocal intraocular lens
9801400|NCT01714635|Experimental|Tecnis Multifocal Intraocular Lens #2|A low diopter add multifocal intraocular lens
9801401|NCT01714635|Active Comparator|Monofocal Intraocular Lens|Commercially available monofocal intraocular lens (IOL)
9801402|NCT01714687|Active Comparator|balloon sinus dilation|Balloon sinus dilation will be conducted in-office under local anesthesia.
9801403|NCT01714687|Active Comparator|medical therapy|Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.
9801404|NCT01714726|Experimental|1|MEDI2070 iv infusion
9801405|NCT01714726|Placebo Comparator|2|placebo iv infusion
9801406|NCT01714726|Experimental|open-label|MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
9801407|NCT01714804|Experimental|Prospective|Accell Evo3
9801408|NCT01714921||ICD patients|Patients with an indication for an ICD implantation according to the guidelines treated with a Protecta™, Protecta™ XT or any equivalent following product
9801409|NCT01714947|Experimental|Alisertib|"Part A: [^14C]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1.~Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles)."
9801410|NCT01715064|No Intervention|Control|non-exercise control consisting of movie watching.
9801411|NCT01715064|Experimental|Exercise|1 hour of moderate intensity exercise.
9801412|NCT01715129|Experimental|11.25mg|11.25mg, SC on Day 1 and Day 92
9801413|NCT01715207|Experimental|Atenolol & Aliskiren|Atenolol tablet and Aliskiren 150mg or 300mg tablet by mouth per day for 6month
9801414|NCT01715207|Other|Atenolol|Atenolol tablet(Negative controls, Open-label)
9946575|NCT01052766|Experimental|PET/CT and BH PET/CT|In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
9946576|NCT01052792|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
9946577|NCT01052792|Active Comparator|Anaprox DS 550mg Tablets|Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
9946578|NCT01052805||harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
9946579|NCT01052818||Stage IV NSCLC|Stage IV non small-cell lung cancer patients will be recruited for this protocol
9946580|NCT01052857|Experimental|1|acupuncture daily fo 7 days
9946581|NCT01052857|No Intervention|2|observation
9946582|NCT01052870|Other|androgen receptor gene polymorphism|Medication response will be assessed according to androgen receptor genotype
9946583|NCT01052870|Active Comparator|finasteride|medication for treating androgenetic alopecia in women
9946584|NCT01052883|Experimental|1|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A] then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
9946585|NCT01052883|Experimental|2|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
9946586|NCT01052883|Experimental|3|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C] then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
9946587|NCT01052883|Experimental|4|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
9946588|NCT01052896|Experimental|Gabapentin|Half of the 100 patients enrolled will be placed on Gabapentin therapy to determine if they have improved dyspepsia symptoms.
9946589|NCT01052896|Placebo Comparator|Placebo|Half of the 100 patients will be placed on placebo look-alike of the gabapentin.
9946590|NCT01052909|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
9476361|NCT03572517|Active Comparator|Subarachnoid block|"Subarachnoid block with hyperbaric bupivacaine 0,5% 3ml associate with morphine 50 mcg.~A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
9476362|NCT03572517|Active Comparator|Spinal morphine|"Spinal morphine with morphine 50 mcg. A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
9946591|NCT01052909|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
9946592|NCT01052922|Active Comparator|2 sample InSure|
9946593|NCT01052922|Active Comparator|1 sample OC-Micron|
9946594|NCT01052922|Active Comparator|3 sample g-SENSA|
9946595|NCT01052935|No Intervention|Arm 1|This is a phlebotomy study.
9946596|NCT01052961|No Intervention|Non-intervention arm|patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
9946597|NCT01052961|Active Comparator|oseltamivir, higher dose|oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
9946598|NCT01052974|Placebo Comparator|physiological serum|ropivacaïne controlled by placebo (physiological serum).
9946599|NCT01052974|Active Comparator|ropivacaine|ropivacaïne controlled by placebo (physiological serum).
9946600|NCT01052987|Experimental|Tranilast|Tranilast tablets
9946601|NCT01052987|Active Comparator|Allopurinol|Allopurinol tablets
9946602|NCT01052987|Experimental|Combination|Tranilast plus Allopurinol
9946603|NCT01052987|Active Comparator|High dose Allopurinol|400 mg Allopurinol
9946604|NCT01052987|Experimental|High dose combination|Combination of Tranilast 300 mg and Allopurinol 400 mg
9946605|NCT01053039|Active Comparator|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
9946606|NCT01053039|Placebo Comparator|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
9946607|NCT01053052|Experimental|Sonography with FemVue vs. HSG|FemVue sonography and HSG
9946608|NCT01053065|Active Comparator|Atorvastatin 10 mg/day|Arm composed of 20 patients, receiving atorvastatin 10 mg/day
9946609|NCT01053065|Active Comparator|Atorvastatin 80 mg/day|Arm composed of 20 patients, receiving atorvastatin 80 mg/day
9946610|NCT01053065|Active Comparator|Cholestyramine - Sitosterol|Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day
9946611|NCT01053091|Experimental|Exercise|exercise
9946612|NCT01053091|No Intervention|Control|control
9946613|NCT01053104||capecitabine 2000mg/m2 (Colorectal)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
9946614|NCT01053104||capecitabine 2500mg/m2 (Colorectal)|capecitabine 2500mg/m2 d 1-14, q 3 weekly
9946615|NCT01053104||capecitabine 2000mg/m2 (Breast)|capecitabine 2000mg/m2d 1-14, q 3 weekly
9946616|NCT01053104||docetaxel 75mg/m2 (Breast)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
9946617|NCT01053117|Experimental|Protocolized approach|Protocolized approach to convert catheter to arteriovenous fistula
9946618|NCT01053117|No Intervention|Current Care Model|
9946619|NCT01053130|Experimental|weight loss surgery|laparoscopic sleeve gastrectomy
9946620|NCT01053130|Active Comparator|Lifestyle Intervention|Diet and exercise with or without pharmacotherapy
9946621|NCT01053143|Experimental|Study Group|Participants aged 18 years and older at enrollment.
9946622|NCT01053169||Prophylaxis Cohort|Patients with coagulopathy due to liver disease or other condition requiring correction of coagulopathy who require surgical or diagnostic intervention
9946623|NCT01053169||Treatment Cohort|Patients experiencing acute bleeding perioperatively
9946624|NCT01053182|Active Comparator|Ivor-Lewis|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
9946625|NCT01053182|Active Comparator|Sweet|Esophagectomy via Left Side Thoracotomy
9946626|NCT01053195|Experimental|Lifestyle counseling|In the project areas, lifestyle counseling will be given every three months to individuals having prediabetes and every six months to those with normal glucose levels.
9946627|NCT01053195|No Intervention|Control|No intervention activity will be assigned for participants enrolled from the control areas.
9517203|NCT03308370|Experimental|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
9801415|NCT01715233|Experimental|Metastatic Esophageal, Gastroesophageal & Gastric Cancer|Participants receive Modified Docetaxel 40mg/m2, Leucovorin 400mg/m2 and Fluorouracil 400mg/m2 on day 1, Fluorouracil 1000mg/m2 per day on days 1 and 2 and Cisplatin 40mg/m2 (or Carboplatin) on day 3 in Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
9801416|NCT01715298|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
9801417|NCT01715298|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
9801418|NCT01715415|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
9801419|NCT01715415|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
9801420|NCT01715571|Experimental|Viberect treatment|Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly
9801421|NCT01715805|Other|Placebo + ADT Lead-in|Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
9801422|NCT01715805|Placebo Comparator|Placebo + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
9801423|NCT01715805|Experimental|Cariprazine + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
9801424|NCT01715805|Other|Placebo + ADT (Continued Treatment)|Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
9801425|NCT01715831|Experimental|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
9801426|NCT01715857||Chinese Patients Requiring Surgery with Sevoflurane Anesthesia|Participants who were scheduled for surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (LMA) per approved product information of sevoflurane in China
9801427|NCT01715883|Experimental|Sodium Nitrite|"Sodium Nitrite will be administered at three time points:~At the time of organ procurement, a pre-prepared syringe of sodium nitrite will be added to each of the 2.8 liter bags of Perfadex solution to flush the donor lungs.~At the time of transplant just prior to reperfusion of lungs, the donor lungs are flushed with a cold pneumoplegia solution after the bronchial (1st) anastomosis and with warm pneumoplegia solution after the portal vein (3rd, last) anastomosis. The drug will be added to pneumoplegia solution just prior to both the flushes.~Sodium Nitrite will be delivered intravenously to the recipient immediately prior to lung reperfusion as a single infusion at rate of 4 mL/min for the first 30 min, followed by 2.2 mL/min for the next 60 min."
9801428|NCT01715896|Experimental|Golimumab 50 mg alternating with Placebo|Participants received alternating doses of golimumab 50 milligram (mg) (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
9801429|NCT01715896|Experimental|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
9801430|NCT01715948|Experimental|CROS hearing aid|The CROS uses two hearing aids that fit behind each ear. The hearing aid fitted with a retainer earhook on the side of the poor ear houses a microphone and a transmitter. The hearing aid fitted on the normal ear side houses a receiver that is connected to a slim tube and open ear tip. The CROS does not amplify sound but rather transmits sound from the side of the unaidable ear to the contralateral ear, overcoming the head shadow effect that presents with SSD.
9801431|NCT01715948|Experimental|Bone-anchored hearing device (BAHD)|The BAHD (such as the Baha by Cochlear or Bone-Bridge by MED-EL) also helps to alleviate the negative effect of head shadow and the difficulty with speech perception in noise that present with SSD. Also known as an osseointegrated aural prosthesis, the BAHD is implanted in individuals with SSD to stimulate the ear with the normal cochlea. The BAHD requires that a titanium screw be surgically implanted in the temporal bone on the side of the poor ear. This titanium screw is connected to a percutaneous abutment. An electromechanical sound processor (external transducer) is coupled onto the abutment and can be removed when necessary. Sound can now be routed to the better ear by transcranial bone conduction.
9801432|NCT01716013|Experimental|BondEase|Topical Skin Adhesive
9801433|NCT01716013|Active Comparator|CWCD|Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
9801434|NCT01716039|Active Comparator|MTX 12.5|Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
10004394|NCT01575613|Experimental|Hotspot Targeting|Four hotspot-targeted interventions will be superimposed on ongoing control measures: hotspots will be targeted with a combination of IRS, long-lasting insecticide treated nets (LLINs), larviciding and a focal screening and treatment (FSAT)campaign.
9801435|NCT01716039|Active Comparator|MTX 25 mg|Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
9801436|NCT01716039|Placebo Comparator|Placebo|Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab
9803337|NCT04232852|Active Comparator|Probiotics|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~This group will receive a probiotic mix, which will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule. During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
9803338|NCT04232852|Placebo Comparator|Placebo supplement|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.~Patients of this group will receive an identical capsule of maltodextrin (placebo). During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
9803339|NCT04232683|Experimental|Preoperative Tamsulosin|The study group will receive one oral dose .4mg of Tamsulosin prior to surgery.
9803340|NCT04232683|Placebo Comparator|Preoperative Placebo|The control group will receive one oral dose of placebo pill prior to surgery.
9803341|NCT04231773|Experimental|12.1% Oxygen and Inhaled Nitric Oxide|Moderate level of hypoxia (12.1% Oxygen) and Inhaled Nitric Oxide (40 ppm)
9803342|NCT04231773|Placebo Comparator|12.1 % Oxygen Placebo|Moderate level of hypoxia (12.1 % Oxygen) and Placebo (0 ppm Nitric Oxide)
9803343|NCT04231773|Experimental|13.6 % Oxygen and Inhaled Nitric Oxide|Severe level of hypoxia (13.6% Oxygen) and Inhaled Nitric Oxide (40 ppm)
9803344|NCT04231773|Placebo Comparator|13.6 % Oxygen and Placebo|Severe level of hypoxia (13.6% Oxygen) and Placebo (0 ppm Nitric Oxide)
9803345|NCT04231760|Experimental|Chronic Obstructive Pulmonary Disease|Mild & Moderate COPD to receive either placebo or inhaled nitric oxide (40ppm)
9803346|NCT04231760|Active Comparator|Healthy Controls|Control group to receive either placebo or inhaled nitric oxide (40ppm)
9803347|NCT04230785||AIS before EVT group|This group includes patients with acute ischemic stroke (AIS) before endovascular treatment (EVT)
9803348|NCT04230785||AIS after EVT group|This group includes patients with acute ischemic stroke (AIS) after endovascular treatment (EVT)
9803349|NCT04226872|Experimental|Intervention|"The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet."
9803350|NCT04226872|No Intervention|Control|"The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet. Data collection for outcome variables will be the same as participants in the intervention group."
9803351|NCT04226131|Other|Early Rheumatoid Arthritis (RA)|"Early RA defined as duration of disease/symptoms of less than 6 months (where duration denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic Disease-modifying anti-rheumatic drugs (bDMARD) therapy"
9803352|NCT04226131|Other|Age-, Sex-, BMI-matched Healthy Controls|Healthy Controls.
9803353|NCT04221893|Experimental|Radiation therapy (RT)|Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity. Target prescription dose will be 30 Gy in 5 fractions and each treatment site (up to 5) will undergo standard Department-approved treatment planning, quality-assurance, and delivery protocols
9803354|NCT04216927|Experimental|Nitric Oxide|Intraoperative NO entrained at 20 ppm into the oxygenator of the CPB circuit with standard care
9803355|NCT04216927|Placebo Comparator|Oxygen|Standard CPB without NO administered at any point intraoperatively
9803356|NCT04216316|Experimental|Arm A (pembrolizumab, gemcitabine, carboplatin, M6620)|Patients receive pembrolizumab IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes on day 1 and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab alone IV over 30 minutes on day 1. Cycles repeat every 6 weeks for up to 1 more year in the absence of disease progression or unacceptable toxicity.
9803357|NCT04216316|Active Comparator|Arm B (pembrolizumab, gemcitabine, carboplatin)|Patients receive pembrolizumab, gemcitabine, and carboplatin as in Arm A.
9803358|NCT04212091|Experimental|Part A (Group 1): PGT121.414.LS (3 mg/kg)|Participants will receive 3 mg/kg of PGT121.414.LS by intravenous (IV) infusion at Month 0.
9803359|NCT04212091|Experimental|Part A (Group 2): PGT121.414.LS (10 mg/kg)|Participants will receive 10 mg/kg of PGT121.414.LS by IV infusion at Month 0.
10004395|NCT01575613|No Intervention|Control|Standard of care as determined by the Division of Malaria Control of the Kenyan Ministry of Health
10004396|NCT01575626|Active Comparator|first sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 0%, 7%, 4%
10004397|NCT01575626|Active Comparator|second sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 4%, 7%, 0%
9946628|NCT01053208|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
9946629|NCT01053208|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
9946630|NCT01053234|Experimental|Insulin aspart|
9946631|NCT01053234|Experimental|NPH insulin|
9476363|NCT03572491|Experimental|Allantoic split inactivated seasonal influenza vaccine|A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NYMC X-275 (A/PR/8/34 (M, PB2, PA, NS, NP genes) и A/Michigan/45/2015 (PB1, HA, NA genes)), NYMC X-263В (A/PR/8/34 (PB1, PB2, PA, NS, NP, М genes) и A/Hong Kong/4801/2014 (HA, NA genes)), NYMC BX-35 (B/Lee/40 (NP gene), B/Panama/45/90 (PB2, М genes) и B/Brisbane/60/2008 (HA, NA PB1, PA, NS genes)).
9946632|NCT01053260|Active Comparator|LEARN Program|Participants will receive weekly weight loss counseling based on the LEARN Program for Weight Management.
9946633|NCT01053260|Experimental|LEARN Plus Contingency Management|Participants will receive weekly counseling based on the LEARN Program for Weight Management plus contingency management. Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
9946634|NCT01053273|Active Comparator|Caudal epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
9946635|NCT01053273|Active Comparator|Percutaneous Adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone
9946636|NCT01053299|Active Comparator|No treatment|Every child, without exception, born in the peroid 1.2.1998 - 31.12.2006, still alive, will be called for to take a Xray of their hips aimed at comparing the ultrasound-values taken newborn.
9946637|NCT01053325|Experimental|CTX in HIV-negative women|CTX daily prophylaxis in HIV-negative pregnant women
9946638|NCT01053325|Experimental|CTX in HIV-positive women|CTX daily prophylaxis in pregnant women who are infected with HIV
9946639|NCT01053325|Active Comparator|SP IPT in HIV-negative women|Intermittent Preventive Treatment with SP in HIV-negative pregnant women
9946640|NCT01053325|Active Comparator|IPT SP in HIV-positive women|Intermittent Preventive Treatment with SP in HIV-positive pregnant women
9946641|NCT01053325|Active Comparator|CTX in HIV-positive pregnant women with CD4<350|Daily prophylaxis with cotrimoxazole in HIV-positive pregnant women with CD4<350
9946642|NCT01053338|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
9946643|NCT01053338|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
10004398|NCT01575626|Active Comparator|third sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 7%, 4%, 0%
10004399|NCT01575626|Active Comparator|Propofol|General anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model).Following tracheal intubation, concentration of propofol will be decreased till 0.
10004400|NCT01575639|Experimental|High dose|Oral Prednisolone will be given at dose of 4 mg/kg/day for 14 days
9476364|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
10004401|NCT01575639|Active Comparator|Usual dose|Oral prednisolone will be given at dose of 2 mg/kg/day for 14 days
10004402|NCT01575652|Active Comparator|ACE-I|Group using ACEIs
10004403|NCT01575652|No Intervention|ACE-I, 2|group not using ace-i
10004404|NCT01575665|Experimental|Partial Rebreathing Mask|A novel membrane breathing mask which facilitates a partial rebreathing of expired gas (thereby raising systemic CO2), while allowing a diffusion of oxygen from the atmosphere to the user, through the membranes.
10004405|NCT01575678|Active Comparator|Melatonin|
10004406|NCT01575678|Placebo Comparator|Lactose|
10004407|NCT01575704|Experimental|Sport|
10004408|NCT01575704|Other|Control|
10004409|NCT01575717|Experimental|Vitamin D 4000|Subjects taking 4000 IU of vitamin D
10004410|NCT01575717|Experimental|Vitamin D 2000|Subjects taking 2000IU of vitamin D
10004411|NCT01575717|No Intervention|No Intervention|
10004412|NCT01575730|Active Comparator|Oxaliplatin 37°C, high dose, 30 minutes|
10004413|NCT01575730|Placebo Comparator|Oxaliplatin 41 °C, high dose, 30 minutes|
10004414|NCT01575730|Active Comparator|Oxaliplatin 37°C, low dose, 90 minutes|
10004415|NCT01575743|Experimental|Aerobic Exercise|
10004416|NCT01575743|Other|healthy controls|
10004417|NCT01575782|Experimental|Chloroquine|
10004418|NCT01575795|Active Comparator|Ticagrelor 180mg loading dose|Ticagrelor 180mg loading dose
10004419|NCT01575795|Experimental|Ticagrelor 360mg loading dose|Ticagrelor 360mg loading dose
10004420|NCT01575821|Experimental|Eucalyptus honey ,|75 children
10004421|NCT01575821|Experimental|Labiatae honey|75 children allocated
10004422|NCT01575821|Experimental|Silan date extract (placebo)|75 children allocated
10004423|NCT01575821|Experimental|Citrus honey|75 children allocated
10004424|NCT01575847||Part I|"Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation.~Part 1 20 subjects~Part I~Inclusion Criteria:~Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management.~Exclusion Criteria:~Previous recent history of APAP overdose in the previous 30 days."
10004425|NCT01575847||Part 2|"Part 2~Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making.~Part 2 100 subjects~Part 2~Inclusion Criteria:~Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry.~Exclusion Criteria:~None."
9946644|NCT01053364|Experimental|Implant|
9946645|NCT01053377|Active Comparator|Tamiflu|
9801437|NCT01716104|Experimental|Afalaza (2 tablets twice a day)|
9801438|NCT01716104|Placebo Comparator|Placebo (2 tablets twice a day)|
9801439|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 12 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 12 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 12 weeks. Participants with detectable HCV RNA at TW4 received an additional 12 weeks of study therapy for a total of 24 weeks of treatment.
9801440|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 24 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 24 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 24 weeks.
9801441|NCT01716169|Experimental|Helicoll|"Helicoll will be applied to one chronic wound (approximately 6 months or more duration).~Wound designations of control or Helicoll were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as A or B. Then the envelope was opened which designated whether A or B would receive control or Helicoll."
9801442|NCT01716195|Experimental|Response Adapted Chemoradiation|Paclitaxel 175 mg/m2 + Carboplatin area under curve (AUC) 6 followed by response adapted Radiation Therapy (5 - 6 weeks) + Paclitaxel
9801443|NCT01716208|Experimental|Ofatumumab + Fresh Frozen Plasma|Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).
9801444|NCT01716221|Experimental|Bupropion & Citalopram|100mg Bupropion & 20mg Citalopram taken orally one time per day or 100mg Bupropion & 10mg Citalopram taken orally one time per day or 50mg Bupropion & 20mg Citalopram taken orally one time per day 0r 50mg Bupropion & 10mg Citalopram taken orally one time per day
9801445|NCT01716221|Active Comparator|Bupropion & Placebo|100mg Bupropion & Placebo taken orally one time per day or 50mg Bupropion & Placebo taken orally one time per day
9801446|NCT01716221|Active Comparator|Placebo & Citalopram|Placebo & 20mg Citalopram taken orally one time per day or Placebo & 10mg Citalopram taken orally one time per day
9801447|NCT01716221|Placebo Comparator|Placebo & Placebo|Placebo & Placebo taken orally one time per day
9801448|NCT01716234|Experimental|POS 12 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
9801449|NCT01716234|Experimental|POS 12 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
9801450|NCT01716234|Experimental|POS 18 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
9801451|NCT01716234|Experimental|POS 18 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
9801452|NCT01716234|Experimental|POS 18 TID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
9801453|NCT01716234|Experimental|POS 18 TID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
9801454|NCT01716234|Experimental|POS 12 TID 3 months to <2 Years|Participants aged 3 months to <2 years received posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
9801455|NCT01716455|Experimental|SSP-004184 (Mild Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
9801456|NCT01716455|Experimental|SSP-004184 (Moderate Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
9801457|NCT01716455|Experimental|SSP-004184 (Severe Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
9946646|NCT01053377|Placebo Comparator|Placebo Tamiflu|
9946647|NCT01053390|Active Comparator|epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)|conventional regimen
9946648|NCT01053390|Experimental|Somatotatin|Conventional chemotherapy regimen plus somatostatin
9946649|NCT01053403|Active Comparator|MDMA|
9946650|NCT01053416|No Intervention|observation|
9946651|NCT01053416|Experimental|Yag laser iridotomy|the enrolled eyes will undergo an iridotomy performed by using a Yag-laser
9946652|NCT01053442|Experimental|NaFeEDTA|The maize porridge is fortified with 2.5mg iron as NaFeEDTA
9946653|NCT01053442|Active Comparator|FeSO4|The maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
9946654|NCT01053455||Starting on NCPAP|randomized to start on NCPAP
9946655|NCT01053455||Starting on SiPAP|randomized to SiPAP
9946656|NCT01053468|Experimental|PA Behavior Intervention|Physical Activity Resource Kit
9946657|NCT01053468|Active Comparator|Standard Materials|Receive physical activity handout from the Canadian Public Health Agency
9946658|NCT01053481|Experimental|Vitamin D|Vitamin D supplement
9946659|NCT01053494|Active Comparator|Arm I (WAITLIST CONTROL GROUP)|Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
9946660|NCT01053494|Experimental|Arm II (TOUCH)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks."
9946661|NCT01053494|Experimental|Arm III (TOUCH+)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist."
9946662|NCT01053520|Experimental|Sequence I|
9946663|NCT01053520|Experimental|Sequence II|
9946664|NCT01053520|Experimental|Sequence III|
9946665|NCT01053533|Experimental|Chinese herbal medicines plus western therapy|
9946666|NCT01053533|Active Comparator|western therapy|including supportive therapy and antivirus therapy when necessary
9946667|NCT01053546|Experimental|Arm I (Early exercise group)|Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
9946668|NCT01053546|Experimental|Arm II (Late exercise group)|Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
9946669|NCT01053559|Other|certolizumab pegol|Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
9946670|NCT01053572|Active Comparator|Celestone|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
9946671|NCT01053572|Active Comparator|sodium chloride solution|Group II will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
9946672|NCT01053572|Active Comparator|sodium choride solution|Group III will receive adhesiolysis, local anesthetic, normal sodium chloride solution instead of 10% hypertonic sodium chloride solution and non-particulate Celestone;
9946673|NCT01053572|Active Comparator|Double substitutes|Group IV will receive adhesiolysis, local anesthetic, and 0.9% sodium chloride solution to substitute for the 10% hypertonic sodium chloride, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
9946674|NCT01053585|Active Comparator|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
9946675|NCT01053585|Placebo Comparator|Placebo|Placebo suspension (single dose 90 minutes prior to physiologic measurement)
9946676|NCT01053611|Active Comparator|Group 1 BIS value 30|
9946677|NCT01053611|Active Comparator|Group 2 BIS value 30|
9946678|NCT01053611|Active Comparator|Group 3 BIS value 30|
9946679|NCT01053611|Active Comparator|Group 4 BIS valaue 30|
9946680|NCT01053611|Active Comparator|Group 1 BIS value 50|
9946681|NCT01053611|Active Comparator|Group 2 BIS value 50|
9946682|NCT01053611|Active Comparator|Group 3 BIS value 50|
9946683|NCT01053611|Active Comparator|Group 4 BIS value 50|
9946684|NCT01053611|Active Comparator|Group 1 BIS value 70|
9946685|NCT01053611|Active Comparator|Group 2 BIS value 70|
9946686|NCT01053611|Active Comparator|Group 3 BIS value 70|
9946687|NCT01053611|Active Comparator|Group 4 BIS value 70|
9946688|NCT01053637|Experimental|Hydrocodone/acetaminophen|Patients will receive 0.17 mg/kg hydrocodone component to a max of 10 mg hydrocodone.
9946689|NCT01053637|Placebo Comparator|Sugar water|Placebo
9946690|NCT01053676|Experimental|Arm 1|
9946691|NCT01053676|Active Comparator|Arm 2|
9946692|NCT01053689|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
9946693|NCT01053689|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
9946694|NCT01053702|Experimental|Dose 1|R475
9946695|NCT01053702|Experimental|Dose 2|R475
9946696|NCT01053702|Placebo Comparator|Dose 3|Placebo to match R475 dose
9946697|NCT01053728|Experimental|Cohort 1 : SAR161271 0.3 U/kg|Cross-over design of four formulation of SAR161271 0.3U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
9946698|NCT01053728|Experimental|Cohort 2 : SAR161271 0.6 U/kg|Cross-over design of four formulation of SAR161271 0.6U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
9946699|NCT01053728|Experimental|Cohort 3 : SAR161271 1.2 U/kg|Cross-over design of four formulation of SAR161271 1.2 U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
9946700|NCT01053767|No Intervention|Arm 1|This is a phlebotomy study.
9946701|NCT01053793|Active Comparator|Glucose Standard|
9946702|NCT01053793|Experimental|Potato Variety|
9946703|NCT01053832|Other|Ventricular Pace Suppression- ON|
9946704|NCT01053832|Other|Ventricular Pace Suppression- OFF|
9946705|NCT01053858|Active Comparator|bevacizumab|intravitreal bevacizumab or triamcinolone determined by single physician
9946706|NCT01053858|Active Comparator|triamcinolone|
9946707|NCT01053871|Experimental|1|sedation using propofol
9946708|NCT01053871|Experimental|2|sedation using midazolam with fentanyl
9946709|NCT01053884|Other|Anidulafungin, safety, antifungal drug|single arm study
9946710|NCT01053910|Experimental|Ramipril|Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)
9946711|NCT01053923||MRI Scan|
9946712|NCT01053949|Active Comparator|Drug on 21 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
9946713|NCT01053949|Active Comparator|Drug on 28 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
9946714|NCT01054001|Active Comparator|Early|men with on- demand sildenafil 100mg dosing from the early postoperative period
9946715|NCT01054001|Active Comparator|Delayed|men with on- demand sildenafil 100mg dosing from the delayed postoperative period
9946716|NCT01054014|Experimental|001|JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
9946717|NCT01054014|Experimental|002|JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
9946718|NCT01054014|Experimental|003|JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
9946719|NCT01054027|Experimental|0 Drop|Left eye dose
9946720|NCT01054027|Experimental|1 Drop|Left eye dose
9946721|NCT01054027|Experimental|2 drop|Left eye dose
9946722|NCT01054027|Active Comparator|3 drops|Right eye dose for all groups
9946723|NCT01054040|No Intervention|Standard nutrition cardiac care|Patients will receive standard care of group nutrition counselling and individual counselling if requested
9946724|NCT01054053||1|children born between 06/04/2004 and 17/04/2008 and called to menBvac vaccination and living around Neufchatel en Bray.
9946725|NCT01054092|Experimental|before meal group|ASP1941 will be administered before meal
9946726|NCT01054092|Experimental|after meal group|ASP1941 will be administered after meal
9946727|NCT01054105||Step I: BMPR-2 gene analysis|BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
9946728|NCT01054105||Step-II: Iloprost and Exercise Echo|Illoprost inhalation for 3 months & Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
9946729|NCT01054118|Experimental|001|JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
9946730|NCT01054118|Active Comparator|002|Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
9946731|NCT01054118|Experimental|003|JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
9946732|NCT01054118|Placebo Comparator|004|Placebo Placebo suspension and placebo capsule administered as single doses
9946733|NCT01054235|Experimental|experimental|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
9946734|NCT01054261|Other|Normal|Normal renal function
9946735|NCT01054261|Other|Mild|Mild renal impairment
9946736|NCT01054261|Other|Moderate|Moderate renal impairment
9946737|NCT01054274|Active Comparator|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
9946738|NCT01054274|Experimental|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
9946739|NCT01054287|Experimental|Falls prevention|
9946740|NCT01054287|Placebo Comparator|Usual care|
9946741|NCT01054313|Experimental|Docetaxel + Sirolimus|Starting doses of Docetaxel 30 mg/m^2 IV every 3 weeks + Sirolimus 1 mg daily
9946742|NCT01054326|Experimental|Supervised physical therapy focusing of rotatorcuff exercises|Patients did specific exercises supervised by a physical therapists twice a week during two months. Focus was on early activation of rotator cuff and scapula stabilizers following different phases in a rehabilitation program Assessments before surgery,1 week after as well as 1,2,3 and 6 months after surgery.
9946743|NCT01054326|Active Comparator|Home exercises|Patients did home exercises following a programme during three months. Assessment considering shoulder function and pain was done before surgery, 1w after as well as 1,2,3 and 6 months after surgery,
9946744|NCT01054352|Experimental|001|JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
9946745|NCT01054352|Experimental|002|JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
9946746|NCT01054352|Experimental|003|JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
9946747|NCT01054352|Experimental|004|JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
9946748|NCT01054365||Delayed Discharge Group (DDG)|D/C at least 24 hours after procedure or at usual discharge time (n =200)
9946749|NCT01054365||Early Discharge Group (EDG)|D/C 6 hours after procedure if no indication for extended stay after randomization (n=200)
9946750|NCT01054391|Experimental|NEC Arm|Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
9946751|NCT01054417||Appendicitis|Patients with suspected appendicitis who are to be operated upon by diagnostic laparoscopy
9946752|NCT01054430|Other|Normal|Subjects with normal hepatic function
9946753|NCT01054430|Other|Mild Hepatic Dysfunction|Subjects with mild hepatic impairment
9946754|NCT01054430|Other|Moderate hepatic dysfunction|Subjects with moderal hepatice impairment
9946755|NCT01054469|Placebo Comparator|TAP block with placebo|
9946756|NCT01054469|Active Comparator|TAP block with ropivacaine|
9946757|NCT01054482|Experimental|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
9946758|NCT01054482|Active Comparator|Pre-operative concurrent chemoradiation therapy|
9946759|NCT01054495|Active Comparator|Acupuncture|Needle acupuncture at acupuncture point pericardium 6
9946760|NCT01054495|Sham Comparator|Sham acupuncture|Non-penetrating sham needling at acupuncture point pericardium 6
9946761|NCT01054495|Placebo Comparator|Laser acupuncture|Laser stimulation at acupuncture point pericardium 6
9946762|NCT01054508|Other|Arm 1: Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks)|Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
9946763|NCT01054508|Other|Arm 2: Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks)|Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
9946764|NCT01054521|Experimental|Temperature-controlled RF (TCRF)|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
9946765|NCT01054521|Active Comparator|Bipolar RF (BRF)|The bipolar RF (BRF) probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
9946766|NCT01054534|Other|Placement of interstim lead|Placement of interstim lead using US image fusion technology
9946767|NCT01054547|Placebo Comparator|Liposomal ropivacaine, topical|The topical anesthetics were applied at the region of right and left maxillary lateral incisors at the buccal mucosa.
9946768|NCT01054547|Placebo Comparator|Liposomal ropivacaine, palatal mucosa|Topical formulations were applied at the palatal mucosa at the right canine region and efficacy of topical formulations was accessed through insertion of a 30 gauge needle and injection of anesthetic solution.
9946769|NCT01054638||HIV infected patients: HAART naive or experienced|Patients with a claims diagnosis of HIV infection (HIV, AIDS, or ARC) in the NHI or Impact Databases, according to either of the 3-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 042 HIV disease and V08 Asymptomatic HIV infection status
9946770|NCT01054638||Patients with HIV infection HAART naïve|A naïve subcohort of patients consisting of HAART initiators. Among the primary cohort, we will exclude patients with a dispensing for any HAART in the 6-month baseline period prior to the cohort entry date.
9946771|NCT01054651|Experimental|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
9946772|NCT01054651|Active Comparator|Praziquantel|
9946773|NCT01054664||impaired liver enzymes|
9946774|NCT01054664||normal liver enzymes|
9946775|NCT01054664||hepatitis C antibodies positive|
9946776|NCT01054677|Experimental|Educational intervention on antibiotic prescribing|The participants in this group received an educational intervention.
9476365|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
9517204|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
9946777|NCT01054677|No Intervention|No educational intervention|The participants in this group did not receive the educational intervention
9946778|NCT01054690|Experimental|Silver alloyed urinary catheter|
9946779|NCT01054690|Placebo Comparator|Silicone urinary catheter|
9946780|NCT01054794|Active Comparator|Stimulation ON|
9946781|NCT01054794|Sham Comparator|Stimulation OFF|
9946782|NCT01054833|Experimental|Needleless sling|Needleless® sling
9946783|NCT01054859|Experimental|Treatment A|0.5 g/Kg alcohol plus 200 mg avanafil tablet
9946784|NCT01054859|Active Comparator|Treatment B|0.5 g/kg alcohol
9946785|NCT01054859|Active Comparator|Treatment C|200 mg avanafil tablet
9946786|NCT01054872|Experimental|Monozygotic (MZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
9946787|NCT01054872|Experimental|Dizygotic (DZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
9946788|NCT01054898|Experimental|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
9946789|NCT01054898|Active Comparator|Usual community services|Standard care for abused women in the community
9946790|NCT01054924||U.S. CRC screening population|
9946791|NCT01054937|Experimental|4SC-203|
9946792|NCT01054937|Placebo Comparator|Placebo|
9946793|NCT01054950|Experimental|Education and counseling|Phone calls using behavioral techniques
9946794|NCT01054950|Placebo Comparator|Control|Single phone call
9946795|NCT01054989|Active Comparator|Fat intravenously|Intravenous application of fat
9946796|NCT01054989|Active Comparator|Fat orally|Oral fat load
9946797|NCT01054989|Active Comparator|LPS intravenously|Lipopolysaccharide (LPS; US Standard Reference endotoxin)
9946798|NCT01054989|Placebo Comparator|Glycerol intravenously|Intrevenous glycerol infusion
9946799|NCT01055002|Active Comparator|Artemether/lumefantrine tablets|Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
9946800|NCT01055002|Active Comparator|Atovaquone/Proguanil HCl tablets|Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
9801458|NCT01716455|Experimental|SSP-004184 (End Stage Renal Disease)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
9801459|NCT01716455|Experimental|SSP-004184 (Healthy Elderly Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
9801460|NCT01716455|Experimental|SSP-004184 (Matched Healthy Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
9801461|NCT01716468|Other|Advanced or metastatic cancer|Patients chosen must be diagnosed with advanced or metastatic cancer of the following tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma, sarcoma, non-small cell /small cell lung, genitourinary cancers).All participants will be assigned to a ketogenic diet. There are no randomization to other separate arms since this is a safety and feasibility study.
9801462|NCT01716520|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
9801463|NCT01716520|Experimental|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
9801464|NCT01716520|Experimental|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
9801465|NCT01716533|Other|Recurrence group|Male or female subjects aged 18 years or older at the time of enrollment, who experienced recurrence of Clostridium difficile infection (CDI) after clinical response to antibiotic treatment to treat the initial CDI episode.
9801466|NCT01716533|Other|Sustained response group|Male or female subjects aged 18 years or older at the time of enrollment, who did not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
9801467|NCT01716533|Other|Failure to antibiotic Group|Male or female subjects aged 18 years or older at the time of enrollment, withdrawn due to failure of antibiotic treatment to treat the initial CDI episode.
9801468|NCT01716533|Other|Unclassified Group|Male or female subjects aged 18 years or older at the time of enrollment, who couldn't be classified as sustained response, recurrence, or failure to antibiotic due to missing data.
9801469|NCT01716559||Cohort|
9801470|NCT01716585|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
9801471|NCT01716585|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
9801472|NCT01716663||Experimental: Catheter Ablation|These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
9801473|NCT01716715|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28.
9801474|NCT01716715|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
9801475|NCT01716754|Experimental|QGE031 240 mg every 2 weeks (q2w)|Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.
9801476|NCT01716754|Experimental|QGE031 240 mg q4w|Participants received QGE031 240 mg s.c. q4w for 16 weeks.
9801477|NCT01716754|Experimental|QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
9801478|NCT01716754|Experimental|QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
9801479|NCT01716754|Experimental|QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
9801480|NCT01716754|Experimental|QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
9801481|NCT01716754|Active Comparator|Omalizumab (as per locally approved dosing table)|Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.
9801482|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q2w|Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.
9801483|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q4w|Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.
9801484|NCT01716754|Placebo Comparator|Placebo to QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
9801485|NCT01716754|Placebo Comparator|Placebo to QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
9801486|NCT01716754|Placebo Comparator|Placebo to QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
9801487|NCT01716754|Placebo Comparator|Placebo to QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
9801488|NCT01716754|Placebo Comparator|Placebo to omalizumab|Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.
9801489|NCT01717001||ConforMIS|Patients with ConforMIS implants
9801490|NCT01717001||Standard Total Knee Implant|Patients implanted with standard total knee implant
9801491|NCT01717014|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in open low anterior resection or anterior proctosigmoidectomy
9801492|NCT01717040|Experimental|Pioglitazone|
9801493|NCT01717040|Placebo Comparator|Placebo|
9801494|NCT01717053|Experimental|Abiraterone acetate|Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate.
9801495|NCT01717209|Experimental|Combined nitric oxide and prostacyclin|iNO (20 ppm continuously) and iPGI2 (0.05 micrograms/kg/min continuously)
9801496|NCT01717287|Experimental|Raltegravir Film-coated Tablet|Raltegravir film-coated tablet 400 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
9801497|NCT01717287|Experimental|Raltegravir Chewable Tablet|Raltegravir chewable tablet weight-based dose up to 300 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
9803360|NCT04212091|Experimental|Part A (Group 3): PGT121.414.LS (30 mg/kg)|Participants will receive 30 mg/kg of PGT121.414.LS by IV infusion at Month 0.
9946801|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
9946802|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks
9946803|NCT01055041|Experimental|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
9946804|NCT01055080|Placebo Comparator|Cow's milk formula|
9946805|NCT01055080|Active Comparator|Bovine insulin-free whey based formula|
9946806|NCT01055080|Active Comparator|Whey-based hydrolysed formula|
9946807|NCT01055093||Diabetes Cohort|Prospectively followed cohort of newly diagnosed patients with diabetes mellitus, aged 18-69 years at inclusion into the study
9946808|NCT01055093||Control Cohort|Prospectively followed cohort of glucose tolerant humans, aged 18-69 years at inclusion into the study
9946809|NCT01055119|Active Comparator|Omega-3 fatty acids|
9946810|NCT01055119|Placebo Comparator|Olive oil|
9946811|NCT01055145|Active Comparator|levofloxacin|Levofloxacin 750mg po per day for 3 months
9946812|NCT01055145|Active Comparator|moxifloxacin|Moxifloxacin 400mg po per day for 3 months
9946813|NCT01055158|Experimental|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes.
9946814|NCT01055158|Active Comparator|Control|Enhanced Usual Care
9946815|NCT01055236|Placebo Comparator|hydroxyzine|
9946816|NCT01055236|Placebo Comparator|placebo|starch tablet
9946817|NCT01055249|Other|Group A|Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
9946818|NCT01055249|Other|Group B|Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
9946819|NCT01055275||Cook Iliac Branch Graft|Patients implanted with a Cook Iliac Branch Graft
10004426|NCT01575925|Experimental|4 mg Oral POM + 40 mg Oral DEX|Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
10004427|NCT01575925|Experimental|2 mg Oral POM + 40 mg Oral DEX|Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
10004428|NCT01575938|Experimental|HIV group-based prevention intervention|The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
10004429|NCT01575938|Active Comparator|Diet and nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
10004430|NCT01575938|No Intervention|Standard-of-care|This arm will receive HIV and STI testing and counseling only.
10004431|NCT01575951|Experimental|All patients|All participants enrolled.
10004432|NCT01576029|Active Comparator|Docetaxel|75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
10004433|NCT01576029|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
10004434|NCT01576068|Other|High Risk Customers|Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
10004435|NCT01576081|Experimental|Unilateral orthotic intervention|The HEPHAISTOS orthotic was worn unilaterally for 56days by 11 healthy male subjects.
10004436|NCT01576094|Active Comparator|Milrinone|Milrinone (MR) lactate 1 mg/ml: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission; dose 3, after 2 hours of stability with dose 2, and maintained up to 48 hours. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
10004437|NCT01576094|Active Comparator|Levosimendan|
10004438|NCT01576107|Experimental|Physical activity|Exercise counseling (behavior change techniques)
10004439|NCT01576107|Experimental|Stress-management|Stress-management training
10004440|NCT01576133|Experimental|CAPABLE|Experimental group participants received up to 10 sessions; up to 6 with an OT, and up to 4 sessions with an RN, and ≤ $1200 of safety and functional modifications from a licensed handyman. These sessions happened in coordinated fashion over the course of 4 months.
9801498|NCT01717313|Experimental|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
9801499|NCT01717313|Placebo Comparator|Placebo to Omarigliptin|Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
9801500|NCT01717326|Experimental|A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801501|NCT01717326|Experimental|A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801502|NCT01717326|Experimental|A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
10214870|NCT04117100||Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC)|This is a mucosal thermo-destruction technique. It uses a generator that delivers a sinusoidal current of high frequency to a probe covered with bipolar electrodes in tight network ensuring a uniform diffusion of the thermal effect. The tissue penetration is superficial on 1mm, intended to eradicate the epithelium up to the muscularis mucosae. Circumferential or focal probes are used as a function of the length of the segment to be treated.
9801503|NCT01717326|Experimental|B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801504|NCT01717326|Experimental|B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801505|NCT01717326|Experimental|B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
9801506|NCT01717326|Experimental|B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
9801507|NCT01717326|Experimental|B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
9801508|NCT01717326|Experimental|B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801509|NCT01717326|Experimental|B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
9801510|NCT01717326|Experimental|B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801511|NCT01717326|Experimental|B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
9801512|NCT01717326|Experimental|B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801513|NCT01717326|Experimental|B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
9801514|NCT01717326|Experimental|B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801515|NCT01717326|Experimental|B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
9801516|NCT01717326|Experimental|C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
9946820|NCT01055301|Experimental|treatment|"Ind (1cycle):~bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d & dex 20mg/d PO; cisplatin & dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.~PBSC Coll: at recovery per local standard~Bridging (before/between trans/after Cons):~thal 50mg/d D1-21 & dex 20mg D1,8,15 PO~Tandem Trans (x2):~bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d & dex 40mg/d PO PBSC >/=200x10^6 cells~Cons (1cycle):~same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox~Maint(</= 3 yrs):~D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20"
9946821|NCT01055327||Infants/foetuses w/malformations registered in EUROCAT network|Pregnancies resulting in foetus/infant with malformation registered through participating registers within the EUROCAT network
9946822|NCT01055340|Experimental|Treatment sequence 1|OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo
9946823|NCT01055340|Experimental|Treatment sequence 2|OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min
9946824|NCT01055340|Experimental|Treatment sequence 3|Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min
9946825|NCT01055340|Experimental|Treatment sequence 4|OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min
9946826|NCT01055340|Experimental|Treatment sequence 5|Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min
9946827|NCT01055340|Experimental|Treatment sequence 6|OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo
9946828|NCT01055366|Experimental|Elazop (Azarga)|Elazop Treatment arm
9946829|NCT01055379|Experimental|Rasagiline|
9946830|NCT01055379|Placebo Comparator|Placebo|
9946831|NCT01055392|Experimental|Lithium|Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L). Lithium doses were administered twice a day. Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment. After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
9946832|NCT01055392|Placebo Comparator|Placebo|Identical placebo tablets were administered twice-a-day for two years.
9946833|NCT01055405|Experimental|Sildenafil plus pulmonary rehabilitation|
9946834|NCT01055405|Placebo Comparator|Placebo plus pulmonary rehabilitation|
9946835|NCT01055418|Placebo Comparator|placebo|
9946836|NCT01055418|Experimental|Vitamin C|
9946837|NCT01055431|Placebo Comparator|Control|Control bread
9946838|NCT01055431|Active Comparator|Teff bread|Teff bread
9946839|NCT01055470|Active Comparator|Diclofenac|Tab.Diclofenac 50 mg ,Orally, 12 hrly in morning and in evening after taking food for 3 months.
9946840|NCT01055470|Experimental|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
9946841|NCT01055483|Experimental|LBH589|
9946842|NCT01055509|Experimental|Cognitive Adaptation Training|Cognitive adaptation training and treatment as usual
9946843|NCT01055509|No Intervention|Treatment as ususal|Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives.
9946844|NCT01055522|Experimental|ARM 1: L19IL2 + Dacarbazin|
9946845|NCT01055522|Experimental|ARM 2: L19IL2 + Dacarbazin|
9946846|NCT01055522|Active Comparator|ARM 3: Dacarbazin|DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
9946847|NCT01055535|Experimental|Microplasmin|
9946848|NCT01055548||Parents of babies born before 33 weeks gestation|
9946849|NCT01055561|Experimental|Patients|
9946850|NCT01055561|Experimental|Healthy volunteers|
9946851|NCT01055574||ProDisc-L|Subjects who received single-level ProDisc-L total disc replacement prior to physical capability evaluations
9946852|NCT01055574||anterior lumbar interbody fusion (AILF)|Subjects who received single-level anterior lumbar interbody fusion prior to physical capability evaluations
9946853|NCT01055587||major abdominal surgery|The investigators compare the levels of biomarkers in patients with and without complications in the early postoperative course following major abdominal surgery
9946854|NCT01055587||severe burn injury|The investigators compare levels of biomarkers within the first 20 days in patients with and without complications following severe burn injury
9946855|NCT01055600|Experimental|Study|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
9946856|NCT01055652|Experimental|1|
9946857|NCT01055678|Experimental|All Patients|Single arm study analyzing tumor hypoxia after EF5 injection
9946858|NCT01055691|Experimental|1|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
9946859|NCT01055691|Experimental|2|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
9946860|NCT01055691|Experimental|3|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
9946861|NCT01055691|Experimental|4|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
9946862|NCT01055717|Placebo Comparator|Placebo muffin made with no oats|
9946863|NCT01055717|Active Comparator|Test muffin made with AV-enriched oats|
9946864|NCT01055730||Pulmonary rehabilitation|
9946865|NCT01055743|Experimental|Radical resection + Fluorouracil Implants|
9946866|NCT01055743|Active Comparator|Radical resection|
9946867|NCT01055756|Experimental|Test (Cloratadd D)|Loratadine + Pseudoephedrine sulfate Test
9946868|NCT01055756|Active Comparator|Comparator (Claritin D)|Loratadine + Pseudoephedrine Comparator
9946869|NCT01055795|Experimental|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
9946870|NCT01055808||Type 2 diabetes treated with insulin|
9801517|NCT01717326|Experimental|C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
9801518|NCT01717326|Experimental|D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801519|NCT01717326|Experimental|D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
9801520|NCT01717391|Experimental|Fluorothymidine F 18 PET/CT|Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
9801521|NCT01717456|Active Comparator|Educational-Medical-Behavioral|Educational-Medical-Behavioral intervention includes education, fiber supplements [Metamucil 1-4 packets (3.4-13.6 g)/day], laxatives or anti-diarrheals [Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day], pelvic floor muscle exercises [100 10-second squeezes/day], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments [as needed].
9801522|NCT01717456|Placebo Comparator|Standard Care|Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day], daily diary, and protective pads or garments [as needed].
9801523|NCT01717638|Experimental|B+R246_12_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801524|NCT01717638|Experimental|B+R246_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801525|NCT01717638|Experimental|B+R246_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801526|NCT01717638|Experimental|B246_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801527|NCT01717638|Experimental|B246_18_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801528|NCT01717638|Experimental|B246_24_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801529|NCT01717638|Experimental|B+R234_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801530|NCT01717638|Experimental|B+R234_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801531|NCT01717638|Experimental|B+R234_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801532|NCT01717638|Experimental|B12 14_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 12 and14 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9803361|NCT04212091|Experimental|Part A (Group 4): PGT121.414.LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS by subcutaneous (SC) infusion at Month 0.
9517205|NCT03308344|Experimental|Spouse Trainers (MT-ST)|Participants will engage in a short-form mindfulness training delivered by their peers who underwent an extensive training practicum.
9801533|NCT01717638|Experimental|B18 20_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 18 & 20 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801534|NCT01717638|Experimental|B24 26_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 24 & 26 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
9801535|NCT01717638|Experimental|B48_50|Newly recruited 4 year old naive subjects who received 2 catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, two months apart, in the present study.
9801536|NCT01717742|Active Comparator|tPA and placebo|
9801537|NCT01717742|Experimental|tPA and DNase|
9801538|NCT01717768|Experimental|Part 1: 120 mg BID|Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
9801539|NCT01717768|Experimental|Part 1: 240 mg BID|Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days
9801540|NCT01717768|Experimental|Part 2: 120 mg BID|Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
9801541|NCT01717768|Experimental|Part 3: A-B-C 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
9801542|NCT01717768|Experimental|Part 3: B-C-A 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
9801543|NCT01717768|Experimental|Part 3: C-A-B 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
9801544|NCT01717768|Experimental|Part 4 Cohort 1: 60 mg BID/ 60 mg TID|Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days
9801545|NCT01717768|Experimental|Part 4 Cohort 2: 90 mg BID/ 90 mg TID|Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days
9801546|NCT01717768|Experimental|Part 4 Cohort 3: 180 mg QD|Oral TSX-002 180 mg once daily (QD) for 15 days
9801547|NCT01717768|Experimental|Part 4 Cohort 4: 120 mg BID|Oral TSX-002 120 mg BID for 15 days
9801548|NCT01717859|Other|Tocilizumab|All subjects will receive tocilizumab.
9801549|NCT01717872|Active Comparator|Macintosh laryngoscope blade|A photo of the larynx will be taken with the Macintosh laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the Percent of Glottic Opening (POGO) score by a blinded assessor.
9801550|NCT01717872|Active Comparator|Miller laryngoscope blade|A photo of the larynx will be taken with the Miller laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the percent of glottic opening score by a blinded assessor.
9801551|NCT01717898|Experimental|Abiraterone/prednisone + BEZ235|In Phase I, a dose escalation of BEZ235 will be performed using a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of BEZ235 given in combination with continuous fixed doses of Abiraterone Acetate and prednisone. This BEZ235 dose will be used in the phase II portion of the study.
9801552|NCT01717976|Experimental|Intervention|primary care based nurse telephone support
9801553|NCT01717976|No Intervention|Control|usual care
9801554|NCT01717989||Cohort|Patients with end-stage renal disease (ESRD) treated at small dialysis organizations (SDOs).
9801555|NCT01718028|Experimental|SYSTANE® BALANCE|Propylene glycol 0.6% ocular emulsion, 1 drop in each eye 4 times a day for 30 days
9801556|NCT01718028|Active Comparator|LARMABAK®|Sodium chloride 0.9% saline solution, 1 drop in each eye 4 times a day for 30 days
9803362|NCT04212091|Experimental|Part B (Group 5): PGT121.414.LS + VRC07-523LS (20 mg/kg)|Participants will receive 20 mg/kg of PGT121.414.LS and 20 mg/kg of VRC07-523LS by IV infusion sequentially in this order at Months 0, 4, and 8.
9946871|NCT01055821|Active Comparator|Arm A|Standard of care (SOC)
9946872|NCT01055821|Experimental|Arm B|Vaccine and Standard of care
9946873|NCT01055821|Experimental|Arm C|vaccine and standard of care
9946874|NCT01055847|Experimental|AI 75 mg|Aztreonam for Inhalation 75 mg twice daily
9946875|NCT01055847|Experimental|AI 225 mg|Aztreonam for Inhalation 225 mg twice daily
9946876|NCT01055847|Placebo Comparator|Placebo|Placebo
9946877|NCT01055860||Robotic sacral colpopexy|Our study population will be women who underwent Robotic assisted laparoscopic sacral colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse using a synthetic polypropylene mesh.
9946878|NCT01055899|Experimental|Dose 1|First dose of SC REGN88
9946879|NCT01055899|Experimental|Dose 2|Second dose of SC REGN88
9946880|NCT01055899|Experimental|Dose 3|Third dose of SC REGN88
9946881|NCT01055925|Active Comparator|MPV|
9946882|NCT01055925|Active Comparator|Aquacel|
9946883|NCT01055938|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
9946884|NCT01055938|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
9946885|NCT01055951|Experimental|Solo MicroPump|
9946886|NCT01055964|Experimental|Tacrobell|
9946887|NCT01055964|Active Comparator|Prograf|
9946888|NCT01055990|Other|Heathy,aged 18-60 years,|They are healthy, are 18-60 years of age, did not have a history of infection with the 2009 H1N1 virus, and are appropriate to vaccination, without any interdictions. And they guardians confirmed that they understood the study procedures, provided written informed consent, and agreed to comply with the following visit schedule. Woman participants all are not pregnant,with a negative pregnancy test before vaccination.
9946889|NCT01055990|Experimental|clinically critical H1N1 patients|The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
9946890|NCT01056003||all patients admitting endoscopy for EGD|
9946891|NCT01056029|Experimental|G-202|
9946892|NCT01056042|Experimental|A|Intramuscular depot medroxyprogesterone acetate
9946893|NCT01056042|Active Comparator|B|ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms
9946894|NCT01056055||Suture anchor, Bone tunnel|Suture anchor group: patients who underwent the modified Brostrom procedure using suture anchor technique Bone tunnel group: patients who underwent the modified Brostrom procedure using bone tunnel technique
9946895|NCT01056081|Experimental|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
9946896|NCT01056094|Active Comparator|20mg Lutein|Dietary Supplement: 20mg Lutein; daily supplementation 12 week
9946897|NCT01056094|Active Comparator|10mg Lutein|Dietary Supplement: 10mg Lutein; daily supplementation 12 week
9946898|NCT01056094|Placebo Comparator|0mg Lutein|Dietary Supplement: 0mg Lutein; daily supplementation 12 week
9946899|NCT01056120||ENERGY-Population|"Patient population in standard clinical care, according to the instructions for use and the inclusion / exclusion criteria. Registry patients should be enrolled consecutively to represent a typical set of patients at each site.~The registry will collect clinical data from patients that have given their prior written consent. All data will be anonymized prior to data entry."
9946900|NCT01056133|Experimental|Omega-3 capsules-Fish Oil|Omega-3 fatty acids in the form of fish oil capsules (2g/d)
9946901|NCT01056146|Active Comparator|Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
9946902|NCT01056146|Experimental|I-InTERACT|Participants will receive the internet-based parenting skills program.
9946903|NCT01056172|Active Comparator|A. 24 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.
9946904|NCT01056172|Experimental|B. 16 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.
9946905|NCT01056211|Active Comparator|hypopigmented scars treated with laser|patients with hypopigmented scars treated with Starlux 300 Lux 1540nm Fractional laser hand piece
9946906|NCT01056211|Placebo Comparator|hypopigmented scars treated without laser|patients with hypopigmented scars treated without laser
9946907|NCT01056211|Active Comparator|hypertrophic scars treated with laser|
9946908|NCT01056211|Placebo Comparator|hypertrophic scars not treated with laser|
9946909|NCT01056211|Active Comparator|scars due to grafts and reconstructions treated with laser|scars due to grafts and reconstructions in the head and neck region
9946910|NCT01056211|Placebo Comparator|grafts and reconstructions scars not treated with laser|scars due to grafts and reconstructions in the head and neck region
9946911|NCT01056224|Experimental|1.25 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
9946912|NCT01056224|Experimental|1.5 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
9946913|NCT01056224|Experimental|1.75 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
9946914|NCT01056224|Experimental|1 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
9946915|NCT01056224|Experimental|1.25 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
9946916|NCT01056224|Experimental|1.5 ug/kg normo-tensive 65-75 year olds|"1.5 ug/kg normo-tensive 65-75 year olds~A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old."
9946917|NCT01056224|Experimental|1 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
9946918|NCT01056224|Experimental|1.25 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
9946919|NCT01056224|Experimental|1.5 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
9946920|NCT01056237|Experimental|Multi-target therapy|(Tarcrolimus+mycophenolate mofetil)
9517206|NCT03308344|No Intervention|Wait-list control|Participants will be tested before and after a no-training interval and may receive training at a later time.
9946921|NCT01056237|Active Comparator|Azathioprine|Aza
9946922|NCT01056250|Other|SILS cholangiography|Performing cholangiography in all patients undergoing SILS cholecystectomy.
9946923|NCT01056354||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
9946924|NCT01056354||Novel respiratory virus-1|MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus)
9946925|NCT01056354||Novel respiratory virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
9946926|NCT01056406|No Intervention|Control Group|Overweight and obese pregnant women who are randomly assigned to the control group will receive the current standard of optimal care in addition to 1 nutrition education session with the study nutritionist (a registered dietitian) at 6-16 weeks gestation.
9946927|NCT01056406|Experimental|Nutrition Education Group|Overweight and obese pregnant women randomly assigned to the nutrition education group, in addition to the current standard of optimal care, will receive twice monthly interaction with the study nutritionist (a registered dietitian) from 6-16 weeks gestation through 6 months postpartum.
9946928|NCT01056419|Active Comparator|Total thyroidectomy|
9946929|NCT01056419|Active Comparator|Anti-thyroid drug|
9946930|NCT01056445|Active Comparator|carotid stenting and hemodynamic instability|27 patients undergone carotid stenting
9946931|NCT01056445|Active Comparator|carotid stenting without hemodynamic instability|no hemodynamic instability after carotid stenting
9946932|NCT01056458|Active Comparator|Acupressure acupressure|
9946933|NCT01056458|Sham Comparator|sham acupressure|
9946934|NCT01056471|Experimental|Low dose autologous mesenchymal cells|The dose of infused cells is 10e6 cells/Kg
9946935|NCT01056471|Experimental|High dose|The dose of infused cells is 4*10e6 cells/Kg
9946936|NCT01056471|No Intervention|Placebo Control|
9946937|NCT01056497|Experimental|alpha lipoic acid|
9946938|NCT01056549|Experimental|exenatide subcutaneous injection|Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.
9946939|NCT01056575|Experimental|OC000459|
9946940|NCT01056588|Placebo Comparator|Control Condition|In this condition, participants will receive reinforcement for timely breath samples with no contingency for a specific breath CO level.
9946941|NCT01056588|Active Comparator|CO-Contingent|In this condition, participants will receive reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking.
9946942|NCT01056614|Experimental|Treatment (chemotherapy, PBSC transplant)|Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
9946943|NCT01056627|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
9946944|NCT01056627|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
9946945|NCT01056666|Experimental|Conveen optima urisheaths|
9946946|NCT01056666|Placebo Comparator|absorbent protections|The patient use their usual absorbent protection as comparator. All brands are allowed.
9946947|NCT01056679|Experimental|AVD-Rev|Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
9946948|NCT01056692|Active Comparator|Active compound|OC000459 orally
9946949|NCT01056692|Placebo Comparator|Placebo|Placebo given orally
9946950|NCT01056705|Experimental|Cohort 1: Experiment Infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
9946951|NCT01056705|Experimental|Cohort 2: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
9946952|NCT01056705|Experimental|Cohort 3: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
9946953|NCT01056705|Experimental|Cohort 4: Experiment infants|Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
9946954|NCT01056705|Experimental|Cohort 5: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
9946955|NCT01056731|Experimental|Aliskiren and Aliskiren_HCTZ|aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
9517207|NCT03308344|Experimental|Mindfulness Expert (MT-ME)|Participants will engage in a short-form mindfulness training delivered by an expert mindfulness trainer.
9946956|NCT01056744|Active Comparator|DES|Implantation of a XIENCE® V everolimus eluting coronary stent (drug-eluting stent, DES)
9946957|NCT01056744|Active Comparator|BMS/DEB|Implantation of a Coroflex Blue® coronary stent (bare metal stent, BMS) postdilated with a Sequent Please® paclitaxel-eluting balloon (drug-eluting balloon, DEB)
9946958|NCT01056757|Experimental|Ribavirin|
9946959|NCT01056770|Experimental|Vaccinia-naive group|2.5 * 10^5 pfu/dose
9946960|NCT01056783|Experimental|OC000459|OC000459 100mg twice daily
9946961|NCT01056783|Placebo Comparator|Placebo|
9946962|NCT01056796|Experimental|CAR™ 27|Any patient with a diagnosis of colorectal cancer that has been previously radiated to the pelvic area (6-8 weeks prior to surgery) and that is electively scheduled for an open or laparoscopic total mesorectal excision (TME) and low anterior resection surgery (< 10cm from the anal verge) which requires the creation of an anastomosis, will be offered participation in this study.
9946963|NCT01056809|Active Comparator|Traditional strategy|First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
9946964|NCT01056809|Active Comparator|Alternative strategy|First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
9946965|NCT01056835|No Intervention|control|
9946966|NCT01056848||CK-LX3401|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia.
9946967|NCT01056848||CK-LX3405|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
9946968|NCT01056848||CK-LX3430|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
9946969|NCT01056861||Cervical dystonia (torticollis)|Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
9517208|NCT03308331|Experimental|HIV-1 smokers|
9946970|NCT01056861||Control|age matched controls with out cervical dystonia (torticollis)
9946971|NCT01056874|Active Comparator|Digoxin|
9946972|NCT01056874|Experimental|Digoxin + Maraviroc|
9946973|NCT01056887||Primary Polydip, D. insipidus|
9946974|NCT01056900||Chondron Implantation|This clinical trial was a follow-up study involving 127 patients from 10 hospitals, for whom autologous chondrocyte transplantation was already performed. All the subjects were investigated as a single group
9946975|NCT01056926|Experimental|Nicotine Patch + Denic Smoking|Subjects will wear a nicotine patch and smoke denic cigarettes for 24 hours prior to scan
9946976|NCT01056926|Experimental|Placebo Patch + Denic Smoking|Subjects will wear a placebo patch and smoke denic cigarettes 24 hours prior to scan
9946977|NCT01056926|Experimental|Nicotine Patch + No Smoking|Subjects will wear a nicotine patch and not smoke for 24 hours prior to scan
9946978|NCT01056926|Experimental|Placebo Patch + No Smoking|Subjects will wear a placebo patch and not smoke for 24 hours prior to scan
9946979|NCT01056939|Active Comparator|NAVA|Children randomised in this arm will be treated with neurally adjusted ventilatory assist
9946980|NCT01056939|Active Comparator|Control|Patients randomized to control group will be treated with pressure controlled ventilation (PC) when they are newborns and older children in this group will be treated with pressure regulated volume controlled (PRVC) ventilation.
9946981|NCT01056952|Experimental|Optiflow then CPAP|Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)
9946982|NCT01056952|Experimental|CPAP then Optiflow|Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)
9946983|NCT01056965|Experimental|davunetide (Al-108, NAP) nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with either davunetide 15 mg or placebo. Davunetide and placebo will be administered intranasally with a multi-dispensing, metered nasal spray pump device.
9946984|NCT01056965|Placebo Comparator|Placebo nasal spray|
9946985|NCT01056978||patients|Patients admitted in a palliative care unit
9946986|NCT01056991|Experimental|warming mattress|Patient warmed with electric mattress
9946987|NCT01056991|Active Comparator|warming blanket|Forced air warming blanket
9946988|NCT01057004||all patients|chronical heart failure and EF ≤ 40 %
9946989|NCT01057030|Active Comparator|A1 (BMS-708163)|Healthy Japanese Subjects
9946990|NCT01057030|Placebo Comparator|A2 (Placebo)|Healthy Japanese Subjects
9946991|NCT01057030|Active Comparator|B1 (BMS-708163)|Healthy Non-Japanese Subjects
9946992|NCT01057030|Placebo Comparator|B2 (Placebo)|Healthy Non-Japanese Subjects
9946993|NCT01057043|No Intervention|Waiting list|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
9946994|NCT01057043|Experimental|Cupping|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
9946995|NCT01057056|No Intervention|control group|control group - receiving standard treatment
9946996|NCT01057069|Experimental|HRD; 1x ddAC, 2x tCTC|HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
9946997|NCT01057069|Active Comparator|HRD; 3x CP|HRD tumors; any response to 3x ddAC; 3 courses of CP
9946998|NCT01057069|Active Comparator|non-HRD;3x CP|non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
9517209|NCT03308331|No Intervention|HIV-1 nonsmokers|
9946999|NCT01057069|Active Comparator|non-HRD; response; 3x ddAC|non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC
9947000|NCT01057069|Active Comparator|non-HRD; response; 3x CP|non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
9947001|NCT01057082|Experimental|Juven|Participants in the treatment arm will receive the dietary supplement Juven.
9947002|NCT01057082|Placebo Comparator|Placebo|
10004441|NCT01576133|Active Comparator|Attention visits|Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
9517210|NCT03308331|Active Comparator|Healthy control smokers|
9517211|NCT03308331|No Intervention|Healthy control nonsmokers|
10004442|NCT01576185||Observational (xenograft models)|Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
10004443|NCT01576224|Experimental|Immediate mobilization|Patients start exercises immediately after osteosynthesis.
10004444|NCT01576224|Active Comparator|Later mobilization|Patients are allowed exercises after 14 days.
10004445|NCT01576237||healthy apheresis donors|healthy blood donors for blood cell aphereses
10004446|NCT01576250|Experimental|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
10004447|NCT01576263||Total knee arthroplasty|25 consecutive patients diagnosed for total knee arthroplasty.
10004448|NCT01576263||Total hip arthroplasty|27 patients diagnosed for total hip arthroplasty.
10004449|NCT01576289||Patients undergoing uppper endoscopy|Consecutive patients with and without symptoms of reflux disease who routinely undergo upper endoscopy from November 2011 through May 2012.
10035206|NCT01803919|Experimental|Silver Alloy-Coated Urinary Catheters|Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
10214871|NCT04117100||Per Oral Endoscopic Myotomy (POEM)|"This technique allows a myotomy on the 8 cm of the lower esophagus extended on the gastric side of the cardia, totally endoscopically, after having approached and tunneled the esophageal submucosa.~Less invasive, it gradually replaces the pneumatic dilatation and surgical myotomy of Heller.~It requires a general anesthesia, an expert operator and a trained nursing team, ESD instruments, carbone dioxide insufflation."
10214872|NCT04104178|Active Comparator|Clindamycin|600 mg clindamycin, 3 times daily for 10 days, orally
10214873|NCT04104178|Placebo Comparator|Placebo|Arm consumes placebo capsules identical to clincamycin capsuls from the other arm,3 times daily for 10 days, orally
10214874|NCT04076657|Experimental|Brock String|Participants will receive instruction on Brock String therapy after first clinic visit (<48 hours post) injury, and will complete home therapy exercise twice daily
10214875|NCT04076657|Active Comparator|Standard of Care|Participants will receive standard of care (i.e., no Brock String therapy within the first week post injury) but will be informed they will receive any therapy deemed necessary at follow up visit 7-10 days post injury, consistent with standard of care
10214876|NCT04016896|Experimental|Widowed Elders' Lifestyle after Loss (WELL)|digital monitoring of sleep, meals, physical activity; motivational health coaching; personalized feedback
10214877|NCT04016896|Active Comparator|Enhanced Usual Care|enhanced usual care
10214878|NCT04013932|Experimental|KUPAA Intervention + Standard of Care|Patients will be assigned to a KUPAA group composed of approximately 6 patients (joined by their 6 matched caregivers). Patients will first participate in 1-2 joining sessions with a provider, followed by a 1-day group educational workshop. Participants will then attend weekly family psychoeducation group sessions (~1.5-2 hours) for 12 weeks.
10214879|NCT04013932|No Intervention|Control - Standard of Care|Patients will receive the standard of care.
10214880|NCT04007692||Simple interrupted suture group|Participants will have a simple interrupted suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
10214881|NCT04007692||Triangular suture group|Participants will have a triangular suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
9947003|NCT01057108|Active Comparator|ESRD: FOSTRAP Chewing Gum|
9947004|NCT01057108|Active Comparator|CKD: FOSTRAP Chewing Gum|
9947005|NCT01057108|Placebo Comparator|ESRD Matching Placebo|
9947006|NCT01057108|Placebo Comparator|CKD Matching Placebo|
9947007|NCT01057160|Experimental|intake of rizatriptan 10 mg|
9947008|NCT01057160|Active Comparator|previous used analgesic|
9947009|NCT01057173|Experimental|Transcatheter Aortic Valve Implantation|
9947010|NCT01057173|Active Comparator|Surgical Aortic Valve Replacement|
9947011|NCT01057186||hereditary hypophosphatemia|Norwegian patients with hereditary hypophosphatemia.
9947012|NCT01057186||Hereditary hyperphosphatemia|Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
9947013|NCT01057212|Experimental|Bevacizumab and Ixabepilone|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks. Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule to the remaining 40 patients.
9947014|NCT01057238|Experimental|Intensive Communication|regular family meeting every 5 days.
9947015|NCT01057238|No Intervention|Control|usual care
9947016|NCT01057264|Experimental|HAI Abraxane + Gemcitabine + Bevacizumab|HAI (hepatic arterial infusions) Abraxane with Gemcitabine + Bevacizumab
9947017|NCT01057316|Experimental|Study Group A|
9947018|NCT01057316|Experimental|Study Group B|
9947019|NCT01057316|Experimental|Study Group C|
9947020|NCT01057329||Anorexia nervosa|36 severe AN patients treated with aripiprazole
9947021|NCT01057329||Anorexia|36 severe anorexia nervosa patients treated with olanzapine
9947022|NCT01057329||Attention Deficit Hyperactivity Disorder|30 ADHD patients treated with atomoxetine
9947023|NCT01057329||Depressive disorder|30 depressed patients treated with duloxetine
9947024|NCT01057342|Experimental|Paclitaxel, Carboplatin, ASA404|
9947025|NCT01057355|Experimental|Cyst ethanol lavage|Subjects receiving the study intervention
9947026|NCT01057368|Active Comparator|Mindfulness Based Stress Reduction|
9947027|NCT01057368|Active Comparator|Health Enhancement Program|
9947028|NCT01057368|No Intervention|Wait List Controls|
9947029|NCT01057368|Active Comparator|Long Term Meditators|
9947030|NCT01057407|Experimental|ASP group|
9947031|NCT01057407|Active Comparator|Sevelamer group|
9947032|NCT01057420|Other|Inhalation of 80% Oxygen|Inhalation of 80% Oxygen by nonrebreathing reservoir face masks for 4 hours
9947033|NCT01057459||Ancillary-Correlative (biomarkers and treatment outcomes)|Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
9947034|NCT01057472||Term born babies|Term born babies
9947035|NCT01057472||Preterm babies ready for discharge|Preterm babies ready for discharge
9947036|NCT01057472||Preterm stable babies 1500 grams|Preterm stable babies 1500 grams
9947037|NCT01057485|Experimental|AF ablation and AV node ablation|Patients will receive the combined procedure of AF ablation as well as AV node ablation
9947038|NCT01057485|Active Comparator|AV node ablation|Patient will receive AV node ablation alone
9947039|NCT01057498|Experimental|1a - RNS60 in Healthy Subjects|Single dose administration of nebulized RNS60 testing for bronchoconstriction in healthy human subjects.
9947040|NCT01057498|Experimental|1b: RNS60 in Mild Asthmatics|Single-dose administration of nebulized RNS60 testing for bronchoconstriction in mild asthmatics.
9947041|NCT01057498|Experimental|2e: RNS60 in mild-to-moderate asthmatics|RNS60 in mild-to-moderate asthmatics who are not currently taking a chronic asthma medication.
9947042|NCT01057511|Active Comparator|progesterone|Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally
9947043|NCT01057511|Experimental|Crinone 8%|Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.
9947044|NCT01057524|Active Comparator|Usual Airway Clearance Technique|Two self administered treatment sessions a day and two treatments a day assisted by a Physiotherapist both using the patient's usual airway clearance method.
9947045|NCT01057524|Experimental|High Frequency Chest Wall Oscillation (HFCWO)|Two self administered treatments a day using HFCWO and two treatment sessions a day assisted by a Physiotherapist using their 'usual' airway clearance method.
9947046|NCT01057537|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
9947047|NCT01057537|Active Comparator|Usual Care|Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
9947048|NCT01057550|Active Comparator|Autologous Fascial Sling|Retropubic, bottom up autologous sling
9947049|NCT01057550|Active Comparator|TVT|Standard retropubic TVT
9801557|NCT01718353|Experimental|Docetaxel + Prednisone (Treatment A)|Docetaxel 75 mg/m^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
9801558|NCT01718353|Experimental|Cabazitaxel + Prednisone (Treatment B)|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
9801559|NCT01718483|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
9801560|NCT01718483|Placebo Comparator|Placebo|
9801561|NCT01718509|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
9801562|NCT01718509|Placebo Comparator|Placebo|
9801563|NCT01718522||Intervention Group|Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).
9801564|NCT01718535||CYP2C19 Genotyping|
9801565|NCT01718691|Experimental|SyB L-0501＋rituximab|
9801566|NCT01719003|Experimental|Empagliflozin low dose qd|Empagliflozin low dose once daily
9801567|NCT01719003|Experimental|Empagliflozin high dose qd|Empagliflozin high dose once daily
9801568|NCT01719003|Experimental|OL empa high dose + met 1000 mg bid|Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
9801569|NCT01719003|Experimental|Empagliflozin low dose + met 500 mg bid|Empagliflozin low dose split twice daily + metformin 500 mg twice daily
9801570|NCT01719003|Experimental|Empagliflozin low dose + met 1000 mg bid|Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
9801571|NCT01719003|Experimental|Empagliflozin high dose + met 500 mg bid|Empagliflozin high dose split twice daily + metformin 500 mg twice daily
9801572|NCT01719003|Experimental|Empagliflozin high dose + met 1000mg bid|Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
9801573|NCT01719003|Experimental|Metformin 500 mg bid|Metformin 500 mg twice daily
9801574|NCT01719003|Experimental|Metformin 1000 mg bid|Metformin 1000 mg twice daily
9801575|NCT01719172|Experimental|Veriset™ Hemostatic Patch|Topical hemostat
9801576|NCT01719224|Active Comparator|Elevated body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
9801577|NCT01719224|Active Comparator|supine body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
9801578|NCT01719367|Experimental|Atenolol|Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol.
9517212|NCT03308331|Active Comparator|HIV-1 nonsmokers using nicotine patch|
9801579|NCT01719380|Experimental|LGX818 + cetuximab|
9801580|NCT01719380|Experimental|LGX818 + BYL719 + cetuximab|
9801581|NCT01719653|Active Comparator|MiraLAX 306 g (Day-Prior)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
9801582|NCT01719653|Experimental|MiraLAX 357 g (Day-Prior)|MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
9801583|NCT01719653|Experimental|MiraLAX 306 g (Split-Dose)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
9801584|NCT01719653|Active Comparator|MoviPrep (Split-Dose)|MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
9801585|NCT01719653|Active Comparator|SUPREP (Split-Dose)|SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.
9801586|NCT01719744|Experimental|ENMD-2076|ENMD-2076 capsules, 275 mg once daily, by mouth.
9947050|NCT01057550|Active Comparator|Pelvicol|Retropubic mid urethral sling made from Pelvicol
9947051|NCT01057563|Active Comparator|BMS group|Patients undergoing PCI with BMS implantation
9947052|NCT01057563|Active Comparator|PRE-DEB group|Patients undergoing PCI with BMS implantation after lesion predilation with DEB
9947053|NCT01057563|Active Comparator|POST-DEB group|Patients undergoing PCI with BMS implantation followed by postdilation with DEB
9947054|NCT01057576|Experimental|PMI 5011|An experimental group randomized to PMI 5011
9947055|NCT01057576|Placebo Comparator|Placebo|Placebo
9947056|NCT01057602||Normal community dwelling elders|Individuals age 65 and older who live in the community
9947057|NCT01057615|Experimental|Active Fish Oil + Vitamin C Placebo|Fifteen subjects will take 10 active fish oil capsules per day and 2 vitamin C placebo capsules per day for 3 weeks.
9947058|NCT01057615|Experimental|Fish Oil Placebo + Active Vitamin C|Fifteen subjects will take 10 fish oil placebo capsules per day and 2 active vitamin C capsules per day for 3 weeks.
9947059|NCT01057615|Experimental|Active Fish Oil + Active Vitamin C|Following a 2-week washout period, all subjects from the other two arms (n=30) will take 10 active fish oil capsules per day and 2 active vitamin C capsules per day for 3 weeks.
9947060|NCT01057628|Experimental|ASP1941 group|oral
9947061|NCT01057628|Placebo Comparator|placebo group|oral
9947062|NCT01057641|Experimental|Spacer|"Implantation of a percutaneously implanted interspinous device (spacer)"
9947063|NCT01057641|Other|physiotherapy|The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.
9947064|NCT01057654|Experimental|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
9947065|NCT01057654|Active Comparator|Pravastatin|Pravastatin 40 mg per day
9947066|NCT01057680|Experimental|creatine|This arm will involve creatine supplementation 0.1 g per kg body mass per day while participating in a resistance training program (1 hour per day, 3 days per week).
9947067|NCT01057680|Placebo Comparator|Sugar|This arm will involve placebo (maltodextrin) given every day while the participant does a resistance training program (1 hour per day, 3 days per week).
9947068|NCT01057706|Experimental|9 months of chiropractic care and exercise|chiropractic, exercise
9947069|NCT01057706|Active Comparator|3 months of chiropractic care and exercise|chiropractic, exercise
9947070|NCT01057719|Experimental|Physiotherapy in Spain|Daily inpatient physiotherapy for four weeks in a warm climate
9947071|NCT01057719|Experimental|Physiotherapy in Norway|Daily inpatient physiotherapy for four weeks in a cold climate
9947072|NCT01057732||primary hyperparathyroidism|patients with primary hyperparathyroidism
9476366|NCT03572452|Experimental|McKenzie - method group|Participants will be sent to an experienced MDT therapist for therapy. They are 1) assessed clinically, 2) treated according the MDT-approach which includes home exercise program, consisting i) an educational component, and ii) an active therapy component with directional preference exercises, several times a day with sustained end range positions according to symptom response, and with avoiding aggravating positions. Participants have a maximum of 7 treatment visits. They will also have physiotherapy counselling at study entry about the good prognosis of sciatica.
9517213|NCT03308331|No Intervention|HIV-1 nonsmokers using placebo patch|
9947073|NCT01057732||controls|subjects without primary hyperparathyroidism
9947074|NCT01057758|Placebo Comparator|PLACEBO|Half of the patients will be randomized to the placebo
9947075|NCT01057758|Active Comparator|Simvastatin|Half of the subjects will receive the active drug, Simvastatin.
9947076|NCT01057771|Experimental|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
9947077|NCT01057771|Experimental|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
9947078|NCT01057771|No Intervention|Waiting list control|Waiting list control subjects will be treated exactly like those in active intervention groups, but will not receive interventions.
9947079|NCT01057784||Bariatric Surgery Patients|Patients undergoing bariatric surgery.
9947080|NCT01057784||Reproductive-Age Women - Bariatric Surgery Patients|This subgroup of patients will include 10 reproductive-age women.
9947081|NCT01057797|Experimental|Upper Body Strength Training with Self-Efficacy|16 weeks of upper body strength training combined with an exercise-specific self-efficacy enhancing intervention
9947082|NCT01057797|Active Comparator|Upper body strength training|16 weeks of upper body strength training with weekly health education sessions
9947083|NCT01057797|Sham Comparator|Chair exercise|16 wks of gentle chair exercise with weekly health education
9947084|NCT01057823||Inpatient Elders Age 50 and up|The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
9947085|NCT01057836|Experimental|Neck strength training|
9947086|NCT01057836|Experimental|Neck endurance training|
9947087|NCT01057836|Active Comparator|Stretching|
9947088|NCT01057849|Experimental|Risperidone, Intensive|risperidone and intensive psychosocial intervention
9476367|NCT03572452|Active Comparator|Advice to stay active group|"Participants enrolled into this group will receive physiotherapist's counselling at study entry for at least 60 minutes time about the good prognosis of sciatica, the spontaneous regression of the intervertebral disc herniation and pain tolerance (natural healing). In addition, they will get ergonomic advice and advice to stay normally active. The participants are also told to avoid bed rest and advised to continue their normal routines as actively as possible including exercise activities with limits permitted by their signs and symptoms. A two-page summary booklet related to these items will be given to them."
9476368|NCT03572439|Active Comparator|Cephalad to caudal|Sensory block level check using ice, moving from cephalad to caudal
9801587|NCT01719757|Experimental|Oxycodone/naloxone|Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day
9801588|NCT01719783|Experimental|LAIV H5N2|Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
9801589|NCT01719783|Placebo Comparator|Placebo|two doses of placebo solution intranasal
9801590|NCT01719861|Experimental|Desipramine HCl|Desipramine is a tricyclic antidepressant (TCA).
9801591|NCT01719900|Experimental|Pulse Fibre|The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
9801592|NCT01719900|Placebo Comparator|Control|The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
9801593|NCT01720043|Experimental|All participants|All participants enrolled
9801594|NCT01720069|Active Comparator|Dose 1 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
9801595|NCT01720069|Active Comparator|Dose 2 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
9801596|NCT01720069|Active Comparator|Dose 3 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
9801597|NCT01720173|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9801598|NCT01720225|Experimental|Decitabine|Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
9801599|NCT01720225|Experimental|Azacitidine|Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
9801600|NCT01720251|Placebo Comparator|placebo|SC injections of placebo
9801601|NCT01720251|Experimental|AllerT low dose|SC injections of AllerT 25 or 50 micrograms
9801602|NCT01720251|Experimental|AllerT full dose|SC injections of AllerT 50-100 micrograms
9801603|NCT01720264|Experimental|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
9801604|NCT01720277|Experimental|HD Fluzone Vaccine|NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
9801605|NCT01720277|Active Comparator|SD Fluzone Vaccine|NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
9801606|NCT01720316|Active Comparator|glycine|Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
9801607|NCT01720316|Placebo Comparator|Placebo|placebo, TID dosing, 6 weeks Double-blind
9801608|NCT01720316|Active Comparator|glycine, open-label|glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks
9801609|NCT01720446|Experimental|Semaglutide 0.5 mg|
9801610|NCT01720446|Experimental|Semaglutide 1.0 mg|
9801611|NCT01720446|Placebo Comparator|Semaglutide placebo 0.5 mg|
9801612|NCT01720446|Placebo Comparator|Semaglutide placebo 1.0 mg|
9801613|NCT01720524|Placebo Comparator|placebo|iv placebo of normal saline or 10% dextrose
9801614|NCT01720524|Experimental|sildenafil|Active study drug
9801615|NCT01720602|Experimental|Treatment (vorinostat, AI therapy)|Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
9801616|NCT01720667|Experimental|Intravenous levetiracetam|Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
9801617|NCT01720667|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance
9801618|NCT01720797|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation (PROPEL™) procedure used to achieve rapid orthodontic tooth movement. Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice. Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice, will take place. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
9801619|NCT01720797|Other|Non Micro-osteoperforation|Prior to intervention a swish of 5cc of chlorhexidine for one minute, twice, will take place. Chlorhexidine rinses are to begin twice a day for a week.
9801620|NCT01721044|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
10004450|NCT01576302|Experimental|Diaphragmatic breathing|Training in diaphragmatic breathing as response incompatible with rumination.
9476369|NCT03572439|Active Comparator|Caudal to cephalad|Sensory block level check using ice, moving from caudal to cephalad
9801621|NCT01721044|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
9476370|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
9476371|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
9801622|NCT01721044|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
9801623|NCT01721057|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
9801624|NCT01721057|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
9801625|NCT01721057|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
9801626|NCT01721070|Experimental|SUF NT 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.
9801627|NCT01721070|Experimental|Ketoconazole 400 mg, SUF NT 15 mcg|"Ketoconazole 400 mg administered once daily for three days. One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.~Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
9801628|NCT01721096||XIENCE PRIME - Long Length (LL)|Long Lesion Arm patients (n=323) are treated by at least one Long Size stent (28, 33 and 38 mm length).There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
9801629|NCT01721096||XIENCE PRIME - Core Size|Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
9801630|NCT01721109|Experimental|EVG/COBI/FTC/TDF|Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
9801631|NCT01721161|Experimental|BIIB033|Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses).
9801632|NCT01721161|Placebo Comparator|Placebo|Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
9801633|NCT01721200|Other|Decision Support Tool|This study will examine the efficacy of a web-based educational decision support tool.
9801634|NCT01721200|Other|Usual Care|Usual Care Group will receive their biologic drug teaching from their rheumatologist.
9801635|NCT01721226|Sham Comparator|Control Arm|Participants in the Control Arm will receive standard discharge services according to the standards of care for that facility. In addition, participants in this arm will view an educational video on opiate overdose prevention. Study participants in the Control Arm will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
9801636|NCT01721226|Experimental|CARE tool and cell phone/text messaging|The Intervention Arm will complete the CARE tool device, a technology based HIV-counseling tool, and will receive text message reminders about HIV medical appointments and the importance of taking HIV medications. Study participants in this arm will be followed after release/study enrollment, just like participants in the Control Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
9801637|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 300 mg|Subjects receive Ezogabine/Retigabine 300 mg equally divided TID over Wk 1
9801638|NCT01721317|Placebo Comparator|Titration Phase: Placebo 300 mg|Subjects receive matching Placebo
9801639|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 450 mg|Subjects receive Ezogabine/Retigabine 450 mg equally divided TID over Wk 2
9801640|NCT01721317|Placebo Comparator|Titration Phase: Placebo 450 mg|Subjects receive matching Placebo
9801641|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 600 mg|Subjects receive Ezogabine/Retigabine 600 mg equally divided (200 mg TID) over Wk 3 or until they achieve their optimal tolerated dose as assessed by the Investigator
9801642|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 600 mg|Subjects receive matching Placebo
9801643|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 750 mg|Subjects receive Ezogabine/Retigabine 750 mg equally or unequally divided TID over Wk 4 or until they achieve their optimal tolerated dose as assessed by the Investigator
9801644|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 750 mg|Subjects receive matching Placebo
9801645|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 900 mg|Subjects receive Ezogabine/Retigabine 900 mg equally or unequally divided TID over Wk 5 or until they achieve their optimal tolerated dose as assessed by the Investigator
9947089|NCT01057849|Active Comparator|risperidone, basic|risperidone and basic psychosocial support
9947090|NCT01057849|Experimental|olanzapine, intensive|olanzapine and intensive psychosocial intervention
9947091|NCT01057849|Active Comparator|olanzapine, basic|olanzapine and basic psychosocial support
9947092|NCT01057849|Experimental|aripiprazole, intensive|aripiprazole and intensive psychosocial intervention
9947093|NCT01057849|Active Comparator|aripiprazole, basiv|aripiprazole and basic psychosocial support
9947094|NCT01057875|Experimental|coffee with caffeine|
9947095|NCT01057875|Placebo Comparator|decaffeinated coffee|Starbuck's Grande Pike Roast Decaf
9947096|NCT01057914|Experimental|Supplemention|
9947097|NCT01057914|Experimental|Dietary advice|
9947098|NCT01057914|Experimental|Combination treatment|
9947099|NCT01057914|No Intervention|Usual care|
9947100|NCT01057927|Experimental|OC000459|
9947101|NCT01057927|Placebo Comparator|Placebo|
9947102|NCT01057940||PEJ placement|Patients who have failed conventional DPEJ placement and would otherwise require surgical intervention.
9947103|NCT01057953|No Intervention|Patient|Blood sample for patient included
9947104|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel
9947105|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Half Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength)
9947106|NCT01057966|Experimental|ICAPS AREDS coated tablets - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets
9947107|NCT01057979|Experimental|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
9947108|NCT01057979|Active Comparator|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
9947109|NCT01058031|Experimental|Arm 1|MBSR
9947110|NCT01058044|Experimental|adherence assessment group|evaluation of adherence using MEMS
9947111|NCT01058057|Experimental|Atorvastatin|Atorvastatin 80mg seven days pre-treatment before PCI
9947112|NCT01058083|Experimental|BMS-770767 (Treatment A)|
9947113|NCT01058083|Experimental|BMS-770767 (Treatment B)|
9947114|NCT01058083|Experimental|BMS-770767 (Treatment C)|
9947115|NCT01058083|Experimental|BMS-770767 (Treatment D)|
9947116|NCT01058083|Placebo Comparator|Placebo (Treatment E)|
9947117|NCT01058109|Experimental|calcium group|dietary calcium intake of 1500 mg/d
9947118|NCT01058109|Experimental|calcium-rich diet (1500 mg/d)|calcium intake from food
9947119|NCT01058122||Patients on the ward|
9947120|NCT01058161|Other|Suspects or affected by rheumatoid polyarthritis|
9947121|NCT01058161|Other|stiffening spondylitis with axial and peripheral infringement|
9947122|NCT01058161|Other|polyarthralgies with or without arthritis|Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis
9947123|NCT01058161|Other|Healthy control|
9947124|NCT01058161|Other|not inflammatory control|Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control.
9947125|NCT01058174|Experimental|micafungin|intravenous infusion
9947126|NCT01058174|Active Comparator|standard care|intravenous infusion
9947127|NCT01058187||Control|Marketed cow milk-based infant formula containing DHA and ARA
9947128|NCT01058187||Investigational 1|Cow milk-based infant formula with differing level of ARA from Control formula
9947129|NCT01058187||Investigational 2|Cow milk-based infant formula with a differing level of ARA from Control
9947130|NCT01058200|Active Comparator|vacuum extractor 'iCUP'|new vacuum extractor: sterile disposable plastic cup
9947131|NCT01058200|Sham Comparator|reference vacuum extractor|reference cup of the obstetrical ward: metallic cup
9947132|NCT01058213|Active Comparator|Aerobic training alone|8 weeks of gentle chair (sham) training followed by 8 weeks of interval aerobic training on a stationary bicycle
9947133|NCT01058213|Experimental|Sequential Resistance then Aerobic Training|8 weeks of resistance training of the lower body followed by 8 weeks of interval aerobic training on a stationary bicycle
9947134|NCT01058213|Active Comparator|Concurrent resistance and aerobic training|8 weeks of gentle chair (sham) exercise followed by 8 weeks of concurrent resistance training of the lower body and interval aerobic training on a stationary bicycle
9947135|NCT01058252||Letrozole, recFSH, INVOCell, Monitoring|Infertile couple following MSP with INVO IVF
9947136|NCT01058278|Active Comparator|Prednisone acetate 1%|A topic cortisone-based treatment
9947137|NCT01058278|Active Comparator|diclofenac 0.1%|an non-steroidal anti-inflammatory drug
9947138|NCT01058278|Placebo Comparator|Artificial Tears|Pharmasciences DIN: 02229570
9947139|NCT01058291|Experimental|KW-6500|
9947140|NCT01058291|Placebo Comparator|KW-6500 Placebo|
9947141|NCT01058317|Experimental|Children treated with propranolol|
9947142|NCT01058330|Active Comparator|Plyometric physical training|Individualized plyometric training program to increase strength, coordination, and bone density.
9947143|NCT01058330|No Intervention|Control Group|This group will have no intervention
9947144|NCT01058343|Experimental|IFN-K 1|IFN kinoid dose 1
9947145|NCT01058343|Experimental|IFN-K-2|IFN kinoid dose 2
9947146|NCT01058343|Experimental|IFN-K 3|IFN kinoid dose 3
9947147|NCT01058343|Experimental|IFN-K 4|IFN kinoid dose 4
9947148|NCT01058343|Placebo Comparator|Saline|saline at same dose as IFN K
9947149|NCT01058382||Progesterone Vaginal Suppositories|
9947150|NCT01058382||Intramuscular Progesterone-in-Oil|
9947151|NCT01058408|Experimental|Rad001 with cisplatin|
9947152|NCT01058447|Experimental|1|
9947153|NCT01058460|No Intervention|cytology|Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
9947154|NCT01058460|Experimental|HPV-cytology|Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
9947155|NCT01058473||Sickle Cell Disease|
9947156|NCT01058486|Experimental|Activity-Self Management|
9947157|NCT01058486|No Intervention|Usual Care|
9947158|NCT01058499|Experimental|MBSR|
9947159|NCT01058512|Experimental|Single|single-arm study
9947160|NCT01058525|Active Comparator|nerve block|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000)
9947161|NCT01058525|Experimental|median nerve block after hydro-dissection|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000) after hydro-dissection (glucose 5% solution)
9947162|NCT01058538|Experimental|L19IL2|
9947163|NCT01058551|Experimental|Reveal XT ILR|Implantable Loop Recorder Insertion
9947164|NCT01058603|Active Comparator|D3|
9476372|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
9947165|NCT01058603|Experimental|D5|
9947166|NCT01058629|Experimental|SynergEyes A2 Hybrid Contact Lens|
9947167|NCT01058681|Other|isocaloric|impacts of isocaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
9947168|NCT01058681|Other|hypercaloric|impacts of hypercaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
9947169|NCT01058681|Other|per os and IV glucose during the clamp|impacts of per os glucose on LH pulsatility in euglycemic and hyperinsulinemic clamps
9947170|NCT01058694|Experimental|Weekly SMS, brief message|Weekly SMS received on Monday at 12 noon
9947171|NCT01058694|Active Comparator|Control Group|Receives a phone, but no messages.
9947172|NCT01058694|Experimental|Daily SMS, Brief message|"Receive daily brief message at 12 noon: This is your reminder"
9947173|NCT01058694|Experimental|Daily SMS, Long Message|"Receive a daily long message at 12 noon: This is your reminder + encouragement"
9947174|NCT01058694|Experimental|Weekly SMS, Long Message|"Weekly message sent at 12 noon on Mondays: This is your reminder + encouragement"
9947175|NCT01058720|Experimental|Vitamin D3|Patients would receive 2000 IU of vitamin D3 daily for 12 weeks
9947176|NCT01058733|Other|Internet|New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
9947177|NCT01058746|Active Comparator|pts undergoing pancreatic resection Restrictive arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from 8am to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. After randomization occurs, those patients randomized to the Restricted Arm will continue to receive Normosol or equivalent solution at 6ml/kg/operative hour.
9947178|NCT01058746|Active Comparator|pts undergoing pancreatic resection Liberal arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from midnight to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. Those patients randomized to the Liberal Arm will receive an additional Normosol bolus or equivalent solution equal to (another) 1.5 ml/kg/fasted hour IV (to bring the total to 2 ml/kg/fasted hour) plus an additional bolus of Normosol or equivalent solution 6ml/kg/operative hour to bring the hourly rate to 12ml/kg/operative hour with a maximum of 1000 ml/operative hour.
9947179|NCT01058759|Experimental|Arm B: Enoxaparin|
9947180|NCT01058759|Active Comparator|Arm A: No Enoxaparin|
9947181|NCT01058772|Experimental|INDUCTION of LABOUR|"At enrollment patients assigned to the induction group will be admitted to the obstetric ward and will undergo induction of labour as described in the intervention section.~Once patient's Bishop score exceeds 7 or regular contractions are diagnosed, patients will be transferred to the delivery ward for artificial rupture of membranes (ARM) or Oxytocin augmentation as indicated."
9947182|NCT01058772|No Intervention|EXPECTANT MANAGEMENT|"Patients enrolled in the conservative management arm will be followed up twice weekly for foetal wellbeing by Non-stress test and Biophysical profile. Patients will be followed up to 41+0 weeks.~Patients, who will not deliver by this gestational age, will be admitted for labour induction (see the above protocol). Induction of labour will be offered when non-reassuring foetal status is suspected. All patients in the conservative arm will undergo foetal weight ultrasound estimation prior to induction. Patients with estimated foetal weight over 4000 gr will be offered a C-section."
9947183|NCT01058785|Experimental|Lucanix|Patients will receive injections of Lucanix for each dose cohort.
10004451|NCT01576302|Active Comparator|Muscle relaxation|Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate
10004452|NCT01576315|Experimental|itraconazole|"itraconazole 10 mg/mL oral solution~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
10004453|NCT01576315|Experimental|voriconazole|"voriconazole 40 mg/mL oral suspension :~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
10004454|NCT01576328|Experimental|Cohort 1|MPC dose 1 or Placebo
10004455|NCT01576328|Experimental|Cohort 2|MPC dose 2 or Placebo
10004456|NCT01576328|Experimental|Cohort 3|MPC dose 3 or Placebo
10004457|NCT01576354|Active Comparator|Prolonged-release Fampridine|
10004458|NCT01576354|Placebo Comparator|Placebo|
9476373|NCT03572400|Experimental|Gemcitbine/Durvalumab|"Neoadjuvant CCRT with Gemcitbine/Durvalumab~+Adjuvant Gemcitabine/Durvalumab Total 6 cycles, after that, Durvalumab q4wks up to total 1 year"
9476374|NCT03572387|Experimental|(5-AZA) + (ATRA) combination|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
9476375|NCT03572387|Active Comparator|Lupron only|No treatment after one month of Lupron
9476376|NCT03572361|Experimental|V3-MOMMO|Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer
9947184|NCT01058824|Active Comparator|Lincomycin - Active Comparative - Hard Gelatin Capsule|
9947185|NCT01058824|Experimental|Lincomycin - Study Drug - Hard Gelatin Capsule|
9947186|NCT01058850|Experimental|Rindopepimut (EGFRvIII Vaccine, CDX-110)|
9947187|NCT01058876|Experimental|Usual Cigarette|African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
9947188|NCT01058876|Experimental|Low-yield Cigarette|"African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their usual brand."
9947189|NCT01058889|Experimental|Telemedical device|Patient will receive a blood glucose measurement device and a telemedical device to monitor blood glucose measurements.
9947190|NCT01058889|No Intervention|Treatment as usual|
9947191|NCT01058902|Placebo Comparator|Negative control|Not on aspirin pre operatively, but refuse to enter trial or have a contraindication to aspirin
9947192|NCT01058902|Experimental|Aspirin treatment|group randomised to aspirin
9947193|NCT01058902|Experimental|No aspirin treatment|Randomised to no aspirin
9947194|NCT01058902|Active Comparator|Positive control|Already on aspirin. just observational limb
9947195|NCT01058915|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day for one year
9947196|NCT01058915|Active Comparator|Rosuvaststin 40mg|Rosuvastatin 40mg/day
9947197|NCT01058928||Group ID 7.5|Patients with a tracheal tube ID (internal diameter) 7.5 mm
9947198|NCT01058928||Group ID 8.0|Patients with a tracheal tube ID 8.0 mm
9947199|NCT01058967||major trauma victims|Code 3 patients (highest acuity) admitted to hospital via air ambulance service
9947200|NCT01058980|Active Comparator|Dormant PV conduction|"After PVI, dormant conduction will be evaluated using intravenous adenosine. If dormant conduction is present, the patients will be randomized to two parallel groups:~Group 1: No additional ablation~Group 2: Additional ablation until elimination of dormant conduction."
9947201|NCT01058980|Active Comparator|No dormant PV conduction|If no dormant conduction is documented, patients will be selected in a random fashion to be included in a registry (follow-up as planned for group 1 and 2 above). The registry group will allow for further assessment of the role of dormant conduction as a predictor of AF recurrence by comparing the success rate after ablation in patients without dormant conduction with those of Group 1 and 2.
9947202|NCT01059006|Experimental|PresbyLASIK|Male or female patients with presbyopic symptoms who underwent PresbyLASIK.
9947203|NCT01059019|Sham Comparator|Control|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
9947204|NCT01059019|Experimental|Treatment|20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
9947205|NCT01059032|No Intervention|Unenhanced images|
9947206|NCT01059032|Other|Enhanced images|Enhanced images
9947207|NCT01059045|Experimental|Cryocontact therapy|
9947208|NCT01059045|No Intervention|Control|
9947209|NCT01059058|Active Comparator|Test Group A: MI Paste Plus Group|
9947210|NCT01059058|Active Comparator|Test Group B: Fluoride Varnish Group|
9947211|NCT01059058|Placebo Comparator|Control Group|
9947212|NCT01059097|Active Comparator|High volume surgeons|high volume surgeons performed at least 18 PD/year.
9947213|NCT01059097|Active Comparator|Low volume surgeons|low volume surgeons performed less than 18 PD/year.
9947214|NCT01059110|Experimental|Salicylate ointment|Salicylate ointment under occlusion (pomade M.O Cochon®)
9947215|NCT01059110|Experimental|Imiquimod|Imiquimod : Aldara®
9947216|NCT01059110|Experimental|5-fluoro-uracil|5-fluoro-uracil cream : Efudix®
9947217|NCT01059110|Experimental|Cryotherapy|liquid nitrogen : Cryotherapy
9947218|NCT01059123|Experimental|1:Short treatment|amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
9947219|NCT01059123|Active Comparator|2:Usual treatment|amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.
9947220|NCT01059136|Experimental|1:Spironolactone|Aldosterone blockade on top of standard therapy
9947221|NCT01059136|No Intervention|2:Standard therapy|Standard therapy
9947222|NCT01059149|Experimental|receive real rTMS|For real rTMS, pulses will be delivered at a frequency of 5 Hz for 6s with a 54s interval, with an intensity equal of 90% of the motor threshold as established at Baseline. 20-min real stimulation sessions will be administered 5 days a week for a period of 2 weeks
9947223|NCT01059149|Placebo Comparator|sham rTMS|For sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo procedures will be used administered 5 days a week for a period of 2 weeks.
9947224|NCT01059162|Experimental|IOPtiMate|patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
9947225|NCT01059253|Experimental|Training|15 training sessions
9947226|NCT01059266|Active Comparator|conventional regimen of PURETHAL Grasses|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16)."
9947227|NCT01059266|Experimental|rush regimen of PURETHAL Grasses|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)~Maintenance treatment:~3 monthly doses of 0.5 ml (week 7, 11, 15)."
9947228|NCT01059279||FMF patients|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
9947229|NCT01059279||healthy people|Healthy individuals, that participated in the study of Heller Institute of Medical Research.
9947230|NCT01059331|Experimental|Pregabalin|
9947231|NCT01059331|Placebo Comparator|Sugar pill|
9947232|NCT01059370|Experimental|Autonomic dysrefleksia|Autonomic dysreflexia in SCI when emptying bowels or filling bladder
9947233|NCT01059383|Experimental|VECAM 40/300|
9947234|NCT01059383|Active Comparator|Esomeprazole 20 mg|
9947235|NCT01059396|Experimental|Propranolol|
9947236|NCT01059396|Experimental|carvedilol|
9476377|NCT03572322||Doctors|
9947237|NCT01059396|Placebo Comparator|Placebo|
9947238|NCT01059409|Experimental|Meniscal Allograft|
9947239|NCT01059461|Experimental|Cerebrolysin®, neuroregeneration|Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
9947240|NCT01059474|Experimental|DMPS|We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
9947241|NCT01059487|Other|Traditional Chinese Medicine|Assessing efficacy of treating subjects/patients with Traditional Chinese Medicine (TCM) by administering SF-36v2 and PIQ-6 surveys to subjects/patients to create a baseline and then re-assessing quality of life achieved through TCM treatments by administering follow-up SF-12v2 and PIQ-6 surveys every four weeks
9947242|NCT01059500|Other|Pilot Phase|First 300 patients will be assigned to arm 1 to test the accuracy of the webtool output.
9947243|NCT01059500|Experimental|Webtool output|Phase 2- Intervention, One group will receive the numeric PTP estimate from webtool output, the other groupwill not receive the nemuric PTP estimate
9947244|NCT01059552|Experimental|vorinostat|Dose escalation of vorinostat, cisplatin, pemetrexed and radiation
9947245|NCT01059578|Experimental|Active|GSK206136 once daily
9947246|NCT01059578|Placebo Comparator|Placebo|Placebo once daily
9947247|NCT01059591|Experimental|Active|GSK424887 once daily
9947248|NCT01059591|Placebo Comparator|Placebo|Placebo once daily
9947249|NCT01059604||Pregnant women exposed to sumatriptan, naratriptan, or combo|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination treatment during pregnancy
9947250|NCT01059656|Experimental|1:Pazopanib|Pazopanib 800mg/j
9947251|NCT01059669||Patients|Patients with suspected Chronic Pancreatitis
9947252|NCT01059669||Control group|Healthy controls
9947253|NCT01059708||CO poisoned children|Children, ages 6-16, who have been poisoned by carbon monoxide
9947254|NCT01059721|Experimental|Soft tissue realignment|group cohort label
9947255|NCT01059747||treatment group|
9476378|NCT03572322||Patients|
9947256|NCT01059838|Experimental|single subject|
9947257|NCT01059890|Experimental|Cefotaxime|
9947258|NCT01059890|Experimental|Metrodinazole|
9947259|NCT01059890|Experimental|Ciprofloxacine|
9947260|NCT01059890|Experimental|Fosfocine|
9947261|NCT01059942||Hospitalist physicians/house-staff|Consented Academic Hospitalist and Internal Medicine Residency staff
9947262|NCT01059955|Experimental|Active treatment at day 0 and day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
9947263|NCT01059955|Active Comparator|Active Treatment at Day 0, Sham Treatment at Day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
9947264|NCT01059968||adolescent female endurance athletes|High school female cross country runners in San Diego.
9947265|NCT01059981||1|Dialysis patients
9947266|NCT01059981||2|Trauma patients
9947267|NCT01059981||3|Patients with carbon monoxide poisoning
9947268|NCT01060033|Other|Arm 1|"Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months.~Patients may have one or all of the following sequences in addition to the standard MRI imaging:~MR Spectroscopy~Fat-saturation and Diffusion-Weighted Imaging~Dynamic Contrast Enhancement MRI (MR-DCE)~Diffusion Tensor Imaging (DTI)"
9947269|NCT01060046||Patients with previously implanted biologic mesh|All patients undergoing a repeat operation to repair a recurrent hernia or to revise a surgical site which has been previously repaired using a biologic mesh.
9947270|NCT01060046||Control patients|Any patient undergoing a surgical procedure where fascial biopsy would not compromise the integrity of the procedure.
9947271|NCT01060085||Breast Cancer|Women shown to have DCIS or invasive breast cancer by fine needle aspiration cytology and/or core needle biopsy.
9947272|NCT01060137|Experimental|001|fentanyl matrix Fentanyl transdermal patch 12 - 25mcg/hr can increase with 12 - 25mcg/h based on pain assessment
9947273|NCT01060163|Experimental|group ET|Patients receiving early CABG <=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
9947274|NCT01060163|Placebo Comparator|group EP|Patients receiving early CABG <= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
9947275|NCT01060163|Experimental|group LT|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
9947276|NCT01060163|Placebo Comparator|group LP|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with placebo(saline solution)
9476379|NCT03572296|Placebo Comparator|Placebo|No polyphenols or fibre will be delivered in a low sugar drink.
9476380|NCT03572296|Experimental|Polyphenol and fibre|Blackcurrant extract (800 mg total polyphenols) and pulp (source of fibre) will be delivered in a low sugar drink.
9476381|NCT03572296|Experimental|Fibre|Pulp (source of fibre) will be delivered in a low sugar drink.
9476382|NCT03572270|Experimental|case|PLWH
10004459|NCT01576380|Experimental|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
9476383|NCT03572270|Other|control|HIV negative women, going to medically assisted procreation consultation for male infertility
9947277|NCT01060163|Experimental|group BT|Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
9947278|NCT01060163|Placebo Comparator|group BP|Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)
9947279|NCT01060176|Experimental|High dosage|Tranexamic acid with a loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h
9947280|NCT01060176|Experimental|Medium dosage|Tranexamic acid with a loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h
9947281|NCT01060176|Experimental|Low dosage|Tranexamic acid with a loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h
9947282|NCT01060176|Placebo Comparator|Control|Saline solution
9947283|NCT01060189|Experimental|Ulinastatin|1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
9947284|NCT01060189|Experimental|Tranexamic Acid|15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
9947285|NCT01060189|Placebo Comparator|Placebo|50ml saline solution before skin incision; 50ml saline solution after neutralization
9947286|NCT01060202||Bortezomib|
9947287|NCT01060215|Active Comparator|Infusion|20cc saline infusion into the knee joint
9947288|NCT01060215|No Intervention|No infusion|
9947289|NCT01060228|Other|001|paliperidone ER 1 tablet of 500 mg once daily on Day 1 and Day 15
9947290|NCT01060228|Other|002|divalproex sodium ER 2 tablets of 500 mg once daily from Days 5 through 18
9947291|NCT01060241|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
9947292|NCT01060241|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
9947293|NCT01060267|Active Comparator|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
9947294|NCT01060267|No Intervention|Placebo Group endoscopic therapy|Endoscopic therapy of variceal bleeding.
9947295|NCT01060280|Active Comparator|Education group|Routine clinical practice (includes usual physiotherapy)plus education on active management.
9947296|NCT01060280|Active Comparator|Group GDS physiotherapy|Routine clinical practice (except usual physiotherapy, which is substituted for Group GDS)plus education on active management.
9947297|NCT01060280|Active Comparator|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which will be substituted by Group and Individual GDS) plus education on active management.
9947298|NCT01060293|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
9947299|NCT01060293|Active Comparator|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
9947300|NCT01060293|Active Comparator|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
9947301|NCT01060306||Bare metal stent 1 month|Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation
9947302|NCT01060306||Biodegradable polymer stent 6 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)
9947303|NCT01060306||Biodegradable polymer stent 7 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)
9947304|NCT01060332||diabetics|
10004460|NCT01576393|Experimental|Home-Based family therapy|12 home-based family therapy sessions
10004461|NCT01576393|Active Comparator|Office-based family therapy|12 office-based family therapy sessions
9476384|NCT03572257|Experimental|Quetiapine (0.5 mg/kg TID x 10 days)|This study group will receive treatment with quetiapine after diagnosis of pediatric delirium. Group assignment will be blinded.
9947305|NCT01060358||healthy|Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury.
9947306|NCT01060371||Spinocerebellar Ataxia 1|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
9947307|NCT01060371||Spinocerebellar Ataxia 2|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
10004462|NCT01576393|Placebo Comparator|Women's Health Education|12 womens's health education sessions
10004463|NCT01576419|Experimental|PG201 tablet|
10004464|NCT01576419|Active Comparator|Celecoxib capsule|
10004465|NCT01576432|Experimental|Breastfeeding + skin-to-skin contact|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
9947308|NCT01060371||Spinocerebellar Ataxia 3|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
9947309|NCT01060371||Spinocerebellar Ataxia 6|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
9947310|NCT01060397|Experimental|Extended Brief Intervention|FRAMES motivational interviewing approach
9947311|NCT01060397|Experimental|Control|Usual care
9947312|NCT01060410||Cyclophosphamide,low dose,continuous|
9947313|NCT01060423|Experimental|hepatic TACE with irinotecan eluting beads and iv cetuximab|Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
9947314|NCT01060423|Active Comparator|iv cetuximab and irinotecan|systemic treatment with intravenous cetuximab and irinotecan
9947315|NCT01060449|Other|LV lead low output|"Low output on left ventricular pacing lead.~Intervention: LV stimulus intensity"
9947316|NCT01060449|Other|LV lead high output|"High output on left ventricular lead~Intervention: LV stimulus intensity"
9947317|NCT01060462||001|Pts. w/ neutropenic fever associated w/ hematologic malignancy Itraconazole 200 mg twice daily for 2 days for a total of 4 doses then 200 mg once daily for 12 days. After 14 days of IV administration itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
9947318|NCT01060475|Experimental|A|Low dose LIM-0705 and tacrolimus.
9947319|NCT01060475|Experimental|B|High dose LIM-0705 and tacrolimus.
9947320|NCT01060475|Experimental|C|Placebo LIM-0705 and tacrolimus.
9947321|NCT01060475|Experimental|D|High dose LIM-0705 and placebo tacrolimus.
9947322|NCT01060488|Active Comparator|Group 1:|
9947323|NCT01060488|Active Comparator|Group 2:|
9947324|NCT01060501|Active Comparator|5-FU|Standard arm Systemic drug administration of 5-FU (intravenous)
9947325|NCT01060501|Experimental|5-FU + folinic acid|Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
9947326|NCT01060501|Experimental|5-FU + Interferon-alpha|Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
9947327|NCT01060514|Experimental|Pazopanib + Vinorelbine|
9947328|NCT01060527||IBS-D|
9947329|NCT01060527||IBS-C|
9947330|NCT01060527||Controll|
9947331|NCT01060566|Experimental|VX-770|
9947332|NCT01060566|Experimental|Midazolam|
9947333|NCT01060566|Experimental|Rosiglitazone|
9947334|NCT01060566|Experimental|Fluconazole|
9947335|NCT01060605|Experimental|Rapamycin pre transplant|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
9947336|NCT01060618|Experimental|Maraviroc + Trofile ESTA®|the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response
9947337|NCT01060631||patients with frontal or frontotemporal brain tumor.|
9947338|NCT01060631||patients without supratentorial brain tumor.|
9947339|NCT01060657||conventional (C) group|
9947340|NCT01060657||low dose (L) groups|
9947341|NCT01060683||Group 1: 15 patients|for elective hepatic resection
9947342|NCT01060683||Group 2: 15|for elective hepatic resection
9947343|NCT01060696|Experimental|Hyoscine, Mefenamic acid, Placebo|Blind randomization to three groups. Mefenamic acid group Hyoscine group Placebo group
9947344|NCT01060709||elective colonoscopy and requiring sedation|
9947345|NCT01060722|Experimental|MOD-4023, dose level 1|
9947346|NCT01060722|Experimental|MOD-4023, dose level 2|
9947347|NCT01060722|Experimental|MOD-4023, dose level 3|
9947348|NCT01060735|Experimental|Larger doses of vitamin D supplementation|The subjects enrolled in this arm will be supplemented during the third trimester of pregnancy with 2000IU vitamin D per day
9947349|NCT01060735|No Intervention|Conventional vitamin D supplementation|Regular supplementation during pregnancy with 400IU vitamin D
9947350|NCT01060748|Experimental|ACE527|"First cohort: ACE527 vaccine doses of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis.~Second cohort: ACE527 vaccine dose of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis."
9947351|NCT01060748|Placebo Comparator|Placebo vaccine|"First cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis.~Second cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis."
10004466|NCT01576432|Experimental|Sucrose + skin-to-skin contact|In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
9476385|NCT03572257|Placebo Comparator|Placebo|This study group will receive a placebo treatment after diagnosis of pediatric delirium. Group assignment will be blinded.
10004467|NCT01576432|Experimental|Skin-to-skin contact|In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
10004468|NCT01576432|Active Comparator|Sucrose|In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother
10004469|NCT01576445|Experimental|Mid-vastus approach|
10004470|NCT01576445|Experimental|medial parapatellar approach|
10004471|NCT01576458|Active Comparator|ursodeoxycholic acid|10 pregant women with intrahepatic cholestasis of pregnancy
10004472|NCT01576458|Active Comparator|placebo|10 pregnant women with intrahepatic cholestasis of pregnancy
10004473|NCT01576497|Active Comparator|EUS-FNA with suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA with suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
10004474|NCT01576497|Active Comparator|EUS-FNA without suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
10004475|NCT01576510|Experimental|Prolonged Exposure (PE) treatment.|
10004476|NCT01576510|No Intervention|Trauma exposed healthy controls|Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
10004477|NCT01576562||Study Group - Control Group|VAD implantation (study group) or other cardiothoracic surgery (control group)
10004478|NCT01576601||Hopkins|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
10004479|NCT01576601||Childrens Hospital of Philadelphia|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
9801646|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 900 mg|Subjects receive matching Placebo
9801647|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1050 mg|Subjects receive Ezogabine/Retigabine 1050 mg equally or unequally divided TID over Wk 6 or until they achieve their optimal tolerated dose as assessed by the Investigator
9801648|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1050 mg|Subjects receive matching Placebo
9801649|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1200 mg|Subjects receive Ezogabine/Retigabine 1200 mg equally divided (400 mg TID) over Wk 7 or until they achieve their optimal tolerated dose as assessed by the Investigator
10004480|NCT01576601||Childrens Hospital Boston|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
10004481|NCT01576614||Nurse-Physician Rounding by Phone|"The SICU's practice involves daily morning team rounding at the bedside. The team includes the critical care attending physician (AP), surgical resident physician, and critical care nurse. The AP is physically present in the SICU during these rounds and for the hours between approximately 7am and 7pm. During off-shift hours (7pm-7am), the AP is available by phone as the on-call attending physician. In addition to this on-call availability, the standard of practice in SICU for years has been that the on-call physician proactively places a telephone call to the SICU at least once every evening to perform telephone rounds with the resident physician aeach SICU patient."
10035207|NCT01803919|Other|Conventional Urinary Catheter|Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
10035208|NCT01803932|Experimental|Behavioral intervention|Male-focused group violence prevention intervention
10035209|NCT01803932|No Intervention|Control communities|Communities in which male-focused group prevention activities will not be conducted
10035210|NCT01803945|Placebo Comparator|Placebo Group|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
9801650|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1200 mg|Subjects receive matching Placebo
9801651|NCT01721317|Experimental|Maintenance Phase:Ezogabine/Retigabine|Subjects receive Ezogabine/Retigabine at the daily dose achieved (equally or unequally divided TID) at the end of the Dose-Optimization Phase for 8 Weeks (600 mg, 750 mg, 900 mg, 1050 mg, or 1200 mg)
9801652|NCT01721317|Placebo Comparator|Maintenance Phase: Placebo|Subjects receive matching Placebo
9801653|NCT01721330|Active Comparator|Naltrexone|Active Naltrexone administered twice daily up to a maximum total dose of 100mg/day.
9801654|NCT01721330|Placebo Comparator|Placebo|Naltrexone-masked placebo administered twice daily up to a maximum total dose of 100mg/day.
9801655|NCT01721369||Transient Loss of Consciousness (T-LOC)|Transient Loss of Consciousness (T-LOC). Treatment according to normal clinical practice.
9801656|NCT01721408|Experimental|Group A|
9801657|NCT01721408|Active Comparator|Group B|
9801658|NCT01721447|Experimental|Echo arm|Subjects with atrial fibrillation who are undergoing a TEE procedure will be assessed using Optison echocardiography contrast agent
9801659|NCT01721460|Experimental|Dexmedetomidine during MER|The study is performed in patients undergoing DBS electrode implantation to their STN for the treatment of parkinson's disease. Microelectrode recording (MER) is performed as part of STN electrode implantation surgery, to increase the precision of the stimulating electrode placement. The study includes administration of dexmedetomidine while recording electrical activity at a single location to evaluate the effects of this drug on the MER.
9801660|NCT01721473||cigarette smokers with heavy marijuana use|With heavy marijuana use
9801661|NCT01721473||cigarette smokers with heavy caffeine use|with heavy caffeine use
9801662|NCT01721473||cigarette smokers w/o heavy caffeine and marijuana use|cigarette smokers without the heavy use of marijuana or caffeine
9801663|NCT01721473||non-smokers|not a regular cigarette user
9801664|NCT01721473||cigarette smokers with non-menthol cigarette preference|non-menthol cigarette preference
9801665|NCT01721473||cigarette smokers with menthol cigarette preference|menthol cigarette preference
9801666|NCT01721486|Experimental|Study Group|IV acetaminophen 15 mg/kg (up to 1000 mg) administered intraoperatively over a 15 minute infusion.
9801667|NCT01721486|Active Comparator|Control Group|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30 minutes) prior to induction of anesthesia in the pre-operative area.
9801668|NCT01721564|Experimental|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
9801669|NCT01721603|Experimental|Dabrafenib + Trametinib + gamma knife radiosurgery|
9801670|NCT01721681|Experimental|FACTOR X|"At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X. After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 6 months (26 weeks).~A dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory. Each dose of FACTOR X must not exceed 60 IU/kg."
9801671|NCT01721772|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
9801672|NCT01721772|Active Comparator|Dacarbazine, 1000 mg/m^2|Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
9801673|NCT01721837||Atrial fibrillation and mild to moderate renal impairment|
9801674|NCT01721876|Experimental|Volasertib and Cytarabine|
9801675|NCT01721876|Placebo Comparator|Placebo and Cytarabine|
9801676|NCT01721954|Active Comparator|Control Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab repeated every two weeks until evidence of treatment failure.
9801677|NCT01721954|Experimental|Experimental Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab plus SIR-Spheres microspheres.
9801678|NCT01721967|Experimental|Ranolazine|Ranolazine, 500 mg for 60 days
9801679|NCT01722045|Experimental|Open label IAI|
9801680|NCT01722071|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
9801681|NCT01722071|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
9801682|NCT01722097|Active Comparator|Deep neuromuscular blockade|Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
9801683|NCT01722097|Placebo Comparator|Moderate neuromuscular blockade|Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron
9947352|NCT01060761|Active Comparator|Rehabilitation program|Counselling (supportive conversation with patient and their relatives together) Retreat Weekend (patient and their relatives together)
9947353|NCT01060761|No Intervention|Ususal treatment and support|Usual support and treatment at the hospital, no retreat Weekend.
9947354|NCT01060774|Experimental|Bupivacaine|0.5% bupivacaine/1:200,000 epinephrine
9947355|NCT01060774|Experimental|Lidocaine|2% lidocaine/1:200,000 epinephrine
9947356|NCT01060787||Fluocinolone Acetonide 0.59 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 0.59 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
9947357|NCT01060787||Fluocinolone Acetonide 2.1 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 2.1 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
9947358|NCT01060813|Active Comparator|Exercise + Leucine|Patients will receive leucine 10 g/d po + exercise for 3 months
9947359|NCT01060813|Active Comparator|Leucine without exercise|patients will receive leucine 10 g/d po
9947360|NCT01060826|Experimental|somatostatin, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
9947361|NCT01060826|Placebo Comparator|Placebo, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
9947362|NCT01060839|Experimental|Single session counseling|
9947363|NCT01060839|No Intervention|Standard of care|
9947364|NCT01060852|Experimental|Media Detective|10-lesson elementary school, substance use prevention program developed based upon the Message Interpretation Processing model designed to increase children's critical thinking skills about media messages and reduce intent to use tobacco and alcohol products.
9947365|NCT01060865|Experimental|Aliskiren|only one arm with the experimental drug [aliskiren]
9947366|NCT01060878|Experimental|Dose I|
9947367|NCT01060878|Experimental|Dose II|
9947368|NCT01060878|Experimental|Dose III|
9947369|NCT01060878|Placebo Comparator|Placebo|
9947370|NCT01060904|Experimental|1|brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
9947371|NCT01060904|Experimental|2|brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)
9947372|NCT01060930|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust ~ 300 mcg/m3 - during intermittent exercise
9947373|NCT01060930|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
9947374|NCT01060943|Active Comparator|KOKEN(collagen)|atelocollagen filler
9947375|NCT01060943|Experimental|TheraFill|atelocollagen filler
9476386|NCT03572231||mirabegron|Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice.
9947376|NCT01060956|Active Comparator|Reporting on two bacteria in urine culture|The microbiology laboratory will report on the isolation and susceptibilities of two different bacteria in urine culture
9947377|NCT01060956|Placebo Comparator|"reporting mixed growth"|The microbiology laboratory will report on mixed growth in urine culture
9947378|NCT01060969|Active Comparator|Acetazolamide|acetazolamide 125 mg BID
9947379|NCT01060969|Experimental|Acetazolamide and Tadalafil|Intervention arm
9947380|NCT01060982|Experimental|HIFU treatment|
9947381|NCT01060995||SmartConsent|Subjects receiving SmartConsent informed consent
9947382|NCT01060995||Standard consent|Subjects receiving standard consent
9947383|NCT01061021|Experimental|Integrated Intervention|Five small group + 2 individual counseling behavioral intervention to simultaneously address HIV transmission risk reduction and HIV treatment adherence in men and women living with HIV/AIDS.
9947384|NCT01061021|Active Comparator|Comparison Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
9947385|NCT01061060|Experimental|Beraprost group|Prostaglandin I2
9947386|NCT01061060|Placebo Comparator|Placebo group|
9947387|NCT01061073|Experimental|Omexel|
9947388|NCT01061073|Active Comparator|spasfon|
9947389|NCT01061086||1|Patients over 18 years old admitted to the hospital with Acute Coronary Syndrome.
9947390|NCT01061099|Active Comparator|Stratum A|Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
9947391|NCT01061099|Active Comparator|Stratum B|Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
9947392|NCT01061112||CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
9947393|NCT01061112||CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
9947394|NCT01061112||CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
9947395|NCT01061125||Unblinded|Transtelephonic (TTM) monitoring weekly for 5 months Holter monitor recording at 4 months and at 12 months Implantable Loop Recorder (ILR) weekly reports
9947396|NCT01061125||Blinded|TTM and Holter Monitor conventional follow up Implantable Loop Recorder (ILR) unblinded at 5 months
9947397|NCT01061138||Screening Patients|Female patients scheduled for routine annual screening mammograms
9947398|NCT01061138||Biopsy Patients|Female patients scheduled for routine breast biopsy procedures
9947399|NCT01061164||HIV-infected infants, children, and adolescents|Infants, children, and adolescents with HIV infection who have participated in PACTG 219C and/or select IMPAACT studies.
9947400|NCT01061190|Active Comparator|Propranolol|
9947401|NCT01061190|Placebo Comparator|Placebo|
9947402|NCT01061203|Active Comparator|Grazax|Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
9947403|NCT01061203|Placebo Comparator|Tablet with no active grass|Tablet with no active grass component. One tablet per day administered under the tongue.
9947404|NCT01061216|Experimental|Intradermal insulin infusion (ID)|
9947405|NCT01061216|Active Comparator|Subcutaneous insulin infusion (SC)|
9947406|NCT01061229|Experimental|Homeopathic drug, potency C12|
9947407|NCT01061229|Placebo Comparator|Placebo|
9947408|NCT01061242|No Intervention|Baseline|Post-Intensive Care Unit (ICU) neurocognitive testing and sleep survey performed on patients exposed to ad-lib Medical ICU environment.
9947409|NCT01061242|Experimental|Sleep Promotion Group|Post-ICU neurocognitive testing and sleep survey performed on patients exposed to interventions in the pre-existing MICU sleep quality improvement project.
9947410|NCT01061268|Experimental|BLINK™ tears|
9947411|NCT01061268|No Intervention|No topical artificial tear|
9947412|NCT01061281|Active Comparator|Tecnis MF IOL|
9947413|NCT01061281|Active Comparator|Crystalens AO IOL|
9947414|NCT01061294|Other|Advanced CustomVue™ iLASIK procedure|
9947415|NCT01061307|Experimental|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
9947416|NCT01061320|Active Comparator|alpha tocopherol|
9947417|NCT01061320|Placebo Comparator|placebo|
9947418|NCT01061346|Experimental|High Fat Diet with Fructose|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
9947419|NCT01061346|Experimental|High Fat Diet with Glucose|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
9947420|NCT01061346|Experimental|Low Fat Diet with Glucose|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein.
9947421|NCT01061372|Placebo Comparator|Placebo|
9947422|NCT01061372|Experimental|Pregabalin 150 mg/day|
9947423|NCT01061372|Experimental|Pregabalin 300 mg/day|
9947424|NCT01061398|Experimental|Cardiac CT Arm|Patients referred for stress imaging due to complaints consistent with possible angina, randomized to receive an additional cardiac CT scan.
9947425|NCT01061398|Active Comparator|No CT Arm|Patients with symptoms consistent with possible angina, randomized to receive the type of stress imaging test ordered by their physician.
9947426|NCT01061411|Experimental|Treatment (sunitinib malate, dalteparin)|Patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in week 6 during course 1. In all subsequent courses, patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in weeks 1-6. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9947427|NCT01061424|Active Comparator|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
9947428|NCT01061424|Experimental|community health worker|community health worker provides home visits for education
9947429|NCT01061437|Active Comparator|Arm 1|Standard 14 day, 3-drug regimen
9947430|NCT01061437|Experimental|Arm 2|Concomitant Therapy - 5 day, 4-drug regimen
9947431|NCT01061437|Experimental|Arm 3|Sequential Therapy - 10 day, 4-drug regimen
9947432|NCT01061450|Placebo Comparator|Placebo|Placebo
9947433|NCT01061450|Experimental|Simvastatin|Simvastatin 80 mg/day
9947434|NCT01061463||Exposed group|French coronary interventional cardiologists and cardiologists specializing in cardiac arrhythmias treatments (electrophysiologists), occupationally exposed to X-Rays
9947435|NCT01061463||Unexposed group|French non-interventional cardiologists and non medical workers, not occupationally exposed to X-Rays
9947436|NCT01061489|Experimental|sensory-cognitive training|
9947437|NCT01061489|Experimental|physical fitness|
9947438|NCT01061489|No Intervention|waiting list (control group)|
9947439|NCT01061502|Experimental|Procellera Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 5-7 days, more frequently if needed
9947440|NCT01061502|Active Comparator|Opsite Transparent Adhesive Dressing|Polyurethane film dressing. Dressing changes every 5-7 days, more frequently if needed
9947441|NCT01061541|Experimental|Group A|
9947442|NCT01061541|Active Comparator|Group B|
9947443|NCT01061554|Experimental|Gastric stable emulsion|A gastric stable emulsion vehicle for administration of tri-glyceride based omega-3 oils
9947444|NCT01061554|Active Comparator|Soft gel capsule (TG)|Soft gel capsule for administration of tri-glyceride based omega-3 oils
9947445|NCT01061554|Active Comparator|Soft gel capsules (MPL)|Soft gel capsule for administration of marine phospholipids based omega-3 oils
9947446|NCT01061580|Experimental|CABG plus BMAC Injection|Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
9947447|NCT01061593|Experimental|ATT+Immunoxel|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Immunoxel honey lozenge once per day day
9947448|NCT01061593|Placebo Comparator|ATT+Placebo|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Placebo lozenge made of corn syrup once/day
9947449|NCT01061645|Experimental|MOC31-PE|
9947450|NCT01061658|Experimental|Vaccine - High dosage|
9947451|NCT01061658|Experimental|Vaccine - Lower dosage|
9947452|NCT01061658|Placebo Comparator|Placebo|
9947453|NCT01061749|Experimental|Treatment (selumetinib, cixutumumab)|Patients receive selumetinib PO BID on days 1-28 and cixutumumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9947454|NCT01061762|Experimental|Low Literacy Adherence Counseling|3-counseling sessions for medication adherence improvement tailored for people with poor literacy
9947455|NCT01061762|Active Comparator|Standard Adherence Counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
9947456|NCT01061762|Active Comparator|Health Counseling Comparison|3-sessions of health improvement counseling.
9947457|NCT01061788|Experimental|Everolimus, AMG 479, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
9947458|NCT01061801|Experimental|Emotional expression, patient present|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the presence of the patient (one session).
9947459|NCT01061801|Experimental|Emotional expression, patient absent|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the absence of the patient (3 sessions).
9947460|NCT01061801|Active Comparator|Comparison|Caregivers are asked to talk about their plans for the upcoming week (time management, sessions 1 and 3) and positive aspects of their life (session 2).
9947461|NCT01061814|Experimental|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) SC daily
9947462|NCT01061814|Placebo Comparator|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) SC daily
9947463|NCT01061827||Dementia|
9947464|NCT01061827||Depression|
9947465|NCT01061827||Control|
9947466|NCT01061853|Experimental|T|TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
9947467|NCT01061853|Active Comparator|C|TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL
9947468|NCT01061905|Experimental|Calorie information only|Posting calorie information of sugar-sweetened and zero-calorie beverages prominently on a poster.
9947469|NCT01061905|Experimental|Exercise Equivalent Information|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
9947470|NCT01061905|Experimental|Calorie and Exercise Equivalent information|Posting of both calorie and exercise equivalent information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
9947471|NCT01061918|Active Comparator|Tecnis MF|
9947472|NCT01061918|Active Comparator|ReSTOR|
9947473|NCT01061931|Active Comparator|Arctic Front® catheter|
9947474|NCT01061931|Active Comparator|HD Mesh Ablator® catheter|
9517214|NCT03308331|Active Comparator|Healthy control nonsmokers using nicotine patch|
9947475|NCT01061957||Raltegravir patients|HIV patients who initiated raltegravir due to virological failure
9947476|NCT01061957||Haart naive patients|HIV patients initiating HAART for the first time
9947477|NCT01061983|Experimental|Deep Brain Stimulation|Participants will receive deep brain stimulation.
9947478|NCT01061996|Experimental|1|
9947479|NCT01062022|Active Comparator|Control - Standard of Care|Participation in the study will involve your child completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Your child will be asked to complete the questionnaire during the baseline assessment, and at 6 months, 12 months, and 24 months after the original assessment.
9947480|NCT01062022|Active Comparator|FOCUS-CI|Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
9947481|NCT01062035||ACP (advanced colon polyp) Group|Between the ages of 50 and 60 years old and have an ACP (advanced colon polyp)
9947482|NCT01062035||Control Group|Individuals between the ages of 50 and 60 years old who have had a negative screening colonoscopy.
9947483|NCT01062048||All participants|Participants administered Januvia up to 100 mg once daily as monotherapy or combination therapy with a sulfonylurea or with insulin during the re-examination period (up to 6 years)
9947484|NCT01062087||Local anesthetic|Women who received local anesthetic during surgery in addition to general anesthesia
9947485|NCT01062087||No local anesthetic|Women who did not receive any local anesthetic during surgery, but did have general anesthesia
9947486|NCT01062100|Experimental|nuclear breast imaging|nuclear breast imaging using MBI Gamma camera
9517215|NCT03308331|No Intervention|Healthy control nonsmokers using placebo patch|
9947487|NCT01062139|Experimental|Petasites extract, levocetirizine|Cosalin (Petasites hybridus CO2 extract), Xarlin (levocetirizine) combination therapy group
9947488|NCT01062139|Active Comparator|Cosalin (Petasites hybridus CO2 extract)|Cosalin monotherapy
9947489|NCT01062152|Experimental|Revlimid® in Combination with Telintra ®|Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.
9947490|NCT01062178|Experimental|comparison to biopsy|Comparing contrast enhanced US with biopsy result
9947491|NCT01062191|Experimental|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Nanoflex Powder Dressing applied to joint
9947492|NCT01062191|Active Comparator|Aquacel AG, typical carboxymethylcellulose dressing|Sodium CMC dressing control applied to joint
9947493|NCT01062243|Experimental|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
9947494|NCT01062282||Group 1|
9947495|NCT01062295|Experimental|Siesta-System|Use of Siesta-System
9947496|NCT01062295|Active Comparator|Standard headrest|Use of standard headrest
9947497|NCT01062321||Hepatitis-E, Pregnant & Non-pregnant|Pregnant,Acute Viral Hepatitis, Fulminant Hepatic Failure
9947498|NCT01062334|Experimental|Microdialysis|
9947499|NCT01062347|Experimental|zinc supplementation (20 mg/d, for 7 d)|
9947500|NCT01062360|Experimental|Arm 1|
9947501|NCT01062360|Active Comparator|Arm 2|
9947502|NCT01062360|Active Comparator|Arm 3|
9947503|NCT01062360|Placebo Comparator|Arm 4|
9947504|NCT01062373|Active Comparator|TG-DHA|TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
9947505|NCT01062373|No Intervention|Control|Control: lactating mothers and their newborn with no supplementation given to the mother
9947506|NCT01062373|Experimental|GPL-DHA|GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid
9947507|NCT01062477|Experimental|Study Group 1|Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
9947508|NCT01062477|Experimental|Study Group 2|Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
9947509|NCT01062477|Active Comparator|Study Group 3|Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
9947510|NCT01062490|Experimental|Treosulfan|Patients with myelodysplastic syndrome, (MDS) according to WHO classification (< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation
9947511|NCT01062516|Active Comparator|1|oral esomeprazole 20 mg daily
9947512|NCT01062516|Active Comparator|2|oral famotidine 40mg daily
10004482|NCT01576614||Nurse-Physican rounding by R T P|"Remote Telepresence Robotics (RTP) is a form of telemedicine that enables a fast and direct face-to-face response by a physician, located remotely, and may sometime utilize a mobile robot.~RTP provides the physician the ability to teleconference with patients and other healthcare providers using two way audio visual technology. The sophistication of these devices varies and can range from simple video conferencing to remote robotic control devices with audio visual conferencing capabilities. The robotic capabilities refer to ability of the physician to remotely direct or drive the device from one location to another.~The technology allows clinical experts to provide the right care at the right time and has become an accepted standard of care when used under appropriate circumstances."
10004483|NCT01576627|Experimental|zinc citrate|
10004484|NCT01576627|Active Comparator|zinc gluconate|
10004485|NCT01576627|Active Comparator|zinc oxide|
10004486|NCT01576640|Other|Replapse Prevention Therapy|
10004487|NCT01576653|Active Comparator|No IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
10004488|NCT01576653|Active Comparator|IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
10004489|NCT01576666|Experimental|LDE225 and BKM120 in combination|LDE225 and BKM120 in combination
10004490|NCT01576679|Experimental|tPA|tissue Plasminogen Activator
10004491|NCT01576679|Placebo Comparator|Placebo|Saline
10004492|NCT01576692|Experimental|Treatment|"Participants receive humanized anti-GD2 antibody, chemotherapy, cytokines, and natural killer cells.~Cells for infusion are prepared using the CliniMACS System."
10004493|NCT01576731|Active Comparator|Tenofovir + emtricitabine + lopinavir/r|Standard postexposure prophylaxis combination
10004494|NCT01576731|Experimental|Tenofovir + Emtricitabine + Raltegravir|new postexposure prophylaxis combination
10004495|NCT01576757||Heart failure|Patients with heart failure from any cause will be considered as potential participants given their clinical background meets eligibility criteria.
10004496|NCT01576770|Active Comparator|ethyl chloride vapocoolant spray|"Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch."
10004497|NCT01576770|Experimental|Synera Patch|"The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride."
10004498|NCT01576822|Active Comparator|Low Dose|Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. Participants will be able to attend 9 consecutive sessions, should they wish.
10004499|NCT01576822|Active Comparator|High Dose|Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. A participant may attend visits for 15 consecutive days, should they wish.
10004500|NCT01576848|Experimental|GROUP 1 (OLD-PRO)|test drink contains intrinsically labeled protein alone
10004501|NCT01576848|Experimental|GROUP 2 (OLD-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
10004502|NCT01576848|Experimental|GROUP 3 (YOUNG-PRO)|test drink contains intrinsically labeled protein alone
10004503|NCT01576848|Experimental|GROUP 4 (YOUNG-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
10004504|NCT01576861|Experimental|GH replacement|Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy
10004505|NCT01576861|No Intervention|Control CHF patients under optimized CHF therapy|
10004506|NCT01576887|Placebo Comparator|Placebo|
10004507|NCT01576887|Experimental|Bardoxolone Methyl|
10004508|NCT01576900||Desmopressin monotherapy|Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction
9947513|NCT01062529|Experimental|somatostatin|
9947514|NCT01062542||Breast Cancer Survivors|
9947515|NCT01062542||Pediatric Cancer Survivors|
9947516|NCT01062542||Control group|
9947517|NCT01062594|Active Comparator|Supervised exercise group|
9947518|NCT01062594|No Intervention|Control group - no exercise|
9947519|NCT01062607||1|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start.
9803363|NCT04212091|Experimental|Part B (Group 6): PGT121.414.LS + VRC07-523LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS and 5 mg/kg of VRC07-523LS by SC infusion sequentially in this order at Months 0, 4, and 8.
9803364|NCT04209907|Active Comparator|the group which retrolaminar block will be approved|the retrolaminar block will be made for postoperative analgesia
9803365|NCT04209907|No Intervention|the group which retrolaminar block will not be approved|the retrolaminar block will not be made for postoperative analgesia
9803366|NCT04197700|Other|Personalized Arm|"Personalized Arm: The target MAP will be defined as +/- 5% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements:~Pre-operative anesthesia or surgical consultation;~Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery;~Inpatient measurement the night before surgery;~Pre-anesthetic MAP~The order of the measurements prioritizes outpatient MAPs given that temporary pre-operative discontinuation of anti-hypertensive agents could potentially raise, while fasting and/or fluid restriction pre-operatively could potentially lower resting blood pressure.39 The lower and upper safety limits of personalized MAP targets will be 50mmHg and <90mmHg, respectively."
9803367|NCT04197700|Other|Protocolized Arm|"Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician.~In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician."
9803368|NCT04196868|Experimental|Experimental arm|
9803369|NCT04196868|Placebo Comparator|Control arm|
9803370|NCT04194398||OCS Expand Trial Cohort|All patients previously enrolled in the EXPAND Lung trial.
9803371|NCT04193475||Chest pain|Individuals presenting with chest pain requiring a stress echocardiogram.
9803372|NCT04187742|Active Comparator|LTC Physicians Receive Social Comparison Email|All LTC physicians who receive a social comparison email
9803373|NCT04187742|No Intervention|LTC Physicians Do Not Receive Social Comparison Email|All LTC physicians who do not receive a social comparison email
9803374|NCT04187742|Active Comparator|LTC Physicians Receive Maintenance Certification Email|All LTC physicians who receive a maintenance certification email
9803375|NCT04187742|No Intervention|LTC Physicians Do Not Receive Maintenance Certification Email|All LTC physicians who do not receive a maintenance certification email
9803376|NCT04187742|Active Comparator|LTC Physician Has (or has not) Opened Prior Report|LTC physicians who opened (or has not opened) at least one report receive an email informing them of their report opening status
9803377|NCT04187742|No Intervention|LTC Physician Has (or has not) Opened Prior Report (Control)|LTC physicians who opened (or has not opened) at least one report receive a standard email without report opening status
9803378|NCT04181359|Experimental|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
9803379|NCT04181359|Placebo Comparator|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
9803380|NCT04175691||AIS group|This group includes patients with acute ischemic stroke (AIS).
9803381|NCT04175691||HC group|This group includes healthy controls (HC).
9803382|NCT04172701||LAMA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed long-acting muscarinic antagonists (LAMA) monotherapy between 01 January 2005 and 30 April 2015.
9803383|NCT04172701||ICS/LABA|Chronic obstructive pulmonary disease (COPD) patients who were prescribed a fixed-dose combination (FDC) of inhaled corticosteroid (ICS)/long-acting beta agonists (LABA) between 01 January 2005 and 30 April 2015.
9803384|NCT04168320|Active Comparator|Less favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated less favorable time-Position in immune cycle."
9947520|NCT01062607||2|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period .
9947521|NCT01062620|Experimental|AXL1717|
9476387|NCT03572231||Antimuscarinics|Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
9947522|NCT01062633|Experimental|A, observation|dietary supplement
9947523|NCT01062633|Experimental|B|dietary supplement
9947524|NCT01062633|Experimental|C|dietary supplement
9947525|NCT01062646|Experimental|Multimodal music therapy|Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions.
9947526|NCT01062646|Active Comparator|community treatment as usual|
9947527|NCT01062659||chronic Hepatitis C|Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
9947528|NCT01062685||Shock Cohort|"The SHOCK cohort will meet the American College of Chest physicians/Society of Critical Care Medicine criteria for septic shock, specifically:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Hypotension despite adequate fluid resuscitation:~a. SBP < 90 mm Hg after 20cc/kg crystalloid"
9947529|NCT01062685||Sepsis cohort|"The SEPSIS cohort will to meet:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Absence of refractory hypotension"
9947530|NCT01062685||Non-Infected controls|The third cohort will be comprised of uninfected ED control patients who met the criteria of no suspected infection, no SIRS criteria met and no evidence of hypoperfusion that are age and sex matched on a 1:1 basis with the shock cohort.
9947531|NCT01062698|Active Comparator|IV thrombolysis + thrombectomy|
9947532|NCT01062698|Active Comparator|IV thrombolysis|
9947533|NCT01062711|Other|Control group 0 g protein|Control group in which a placebo drink containing no protein is given following unilateral knee extension exercise
9947534|NCT01062711|Experimental|10g whey|10g whey protein given following unilateral knee extension exercise
9947535|NCT01062711|Experimental|20g whey|20g whey protein given following unilateral knee extension exercise
9947536|NCT01062711|Experimental|30g whey|30g whey protein given following unilateral knee extension exercise
9947537|NCT01062711|Experimental|40g whey|40g whey protein given following unilateral knee extension exercise
9947538|NCT01062711|Experimental|20g soy|20g soy protein given following unilateral knee extension exercise
9947539|NCT01062711|Experimental|40g soy|40g soy protein given following unilateral knee extension exercise
9947540|NCT01062724|No Intervention|Trophamine|This group of neonates will be receive the Trophamine amino acids solution from Pisa laboratories as an active comparator with Primene. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
9947541|NCT01062724|Experimental|Primene 10% from Baxter|This group of neonates will be receive the Primene amino acids solution (10 %) from Baxter laboratories as other active comparator with Trophamine. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
9947542|NCT01062737|Experimental|ASU (Avocado Soybean Unsaponifiable)|
9947543|NCT01062750|Other|adipose tissue derived stromal cells|
9947544|NCT01062776|Placebo Comparator|5 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
9947545|NCT01062776|Placebo Comparator|10 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
9947546|NCT01062776|Experimental|5 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
9947547|NCT01062776|Experimental|10 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
9947548|NCT01062789|Other|Use of an optical breath-hold control device|This is a feasibility study that will use this new device in place of a different bellows-based breath-hold control device for a series patients undergoing CT-guided lung biopsy. The new belt will be used in all patients in our study.
9947549|NCT01062802|Placebo Comparator|Placebo|
9947550|NCT01062802|Active Comparator|Statin group|
9947551|NCT01062815|Experimental|Cycling Parenteral Nutrition|Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
9947552|NCT01062815|Active Comparator|Continuous Parenteral Nutrition|Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.
9476388|NCT03572205|Experimental|CC genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
9517216|NCT03308318||the supratemporalis approach|patients operated upon with zygomaticofacial or craniofacial fractures using the supratemporalis approach
9517217|NCT03308292|No Intervention|Control Group|
9947553|NCT01062828||Gestational age < 32 weeks|Premature infants with gestational age between <32 weeks regardless of birth weight
9947554|NCT01062854|Experimental|Earplugs|Subjects randomized to this arm of the study will wear earplugs during their baseline sleep study (polysomnogram).
9947555|NCT01062854|No Intervention|Comparison group|Subjects randomized to the comparison arm will not wear earplugs during their baseline sleep study.
9947556|NCT01062867|Experimental|ORG25435|Infusion of intravenous anaesthetic agent to induce anaesthesia
9947557|NCT01062906|Placebo Comparator|Control|The control group receives intravenous fentanyl at the induction of anesthesia followed by a continuous infusion of lidocaine during the surgery.
9947558|NCT01062906|Active Comparator|Lidocaine|The Lidocaine group will receive lidocaine as bolus at the induction of anesthesia followed by a continuous infusion of lidocaine until the end of surgery
9947559|NCT01062919|Experimental|Epidural analgesia group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
9947560|NCT01062919|Experimental|Wound Group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
9947561|NCT01062932|Placebo Comparator|Placebo|
9947562|NCT01062932|Active Comparator|Cycloserine|
9947563|NCT01062945|Placebo Comparator|Placebo|
9947564|NCT01062945|Active Comparator|Doxazosin|
9947565|NCT01062958||Arm #1 (Test group)|50 subjects administered Neevo® or Neevo®DHA daily
9947566|NCT01062958||Arm #2 (Control group)|50 subjects administered a prenatal vitamin daily
9947567|NCT01062984|Active Comparator|Continuous Venovenous Hemofiltration|
9947568|NCT01062984|Active Comparator|Continuous Venovenouos Hemodialysis|
9947569|NCT01063010|Placebo Comparator|Placebo|Placebo IV for 90 minutes (+ 15 minutes)
9947570|NCT01063010|Experimental|Bevicizumab|IV infusion over 90 minutes
9947571|NCT01063023|Active Comparator|Arm A - Ortho Tri-Cyclen®|1 to 28 days
9947572|NCT01063023|Active Comparator|Arm B - Ortho Tri-Cyclen®|29 to 56 days
9947573|NCT01063023|Active Comparator|Arm C - Ortho Tri-Cyclen® + BMS-650032|"Ortho Tri-Cyclen®: 57 to 77 days~BMS-650032: 68 to 77 days"
9947574|NCT01063088|Experimental|Vaccination|Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
9947575|NCT01063101|Experimental|BAX 513|Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
9947576|NCT01063101|Placebo Comparator|Capsule (cellulose)|Capsule - one of 5 dose levels (per randomization) - BID
9947577|NCT01063114|Experimental|Proton Beam Radiation|Proton Beam Radiation
9947578|NCT01063127||1|group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
9947579|NCT01063127||2|group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
9947580|NCT01063140||RabAvert|
9947581|NCT01063140||Imovax|
9947582|NCT01063179|Experimental|Arm A: VMPT|Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
9947583|NCT01063179|Active Comparator|VMP|"Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).~No maintenance is scheduled."
9947584|NCT01063192|Active Comparator|Gemcitabine|Arm 1: Gemcitabine alone
9947585|NCT01063192|Active Comparator|GOFL|Arm 2: GOFL (Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
9947586|NCT01063205|Placebo Comparator|Placebo|
9947587|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 1800 mg|
9947588|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 3600 mg|
9947589|NCT01063218|Other|Emollient|Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day
9947590|NCT01063231|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
9947591|NCT01063244|Active Comparator|FoleyBalloon|foley balloon placed in the cervix
9947592|NCT01063244|Active Comparator|foley balloon with weight|foley balloon with weight attached
9947593|NCT01063257|Experimental|Cohort A|Clofarabine treatment at D1-D5
9947594|NCT01063257|Experimental|Cohort B|Clofarabine treatment at D1, D3, D5, D8, D10
9947595|NCT01063270|Active Comparator|Antibiotics|
9947596|NCT01063270|Active Comparator|Antibiotics and Laser treatment|
9947597|NCT01063309||Autosomal recessive CGD|Participants must have autosomal recessive CGD (p47phox, p67phox, or p22phox deficiency) as demonstrated by DHR or genetic screening.
9947598|NCT01063309||CGD carrier|Participants with confirmed as X-linked CGD carriers as demonstrated by DHR or genetic screening.
9947599|NCT01063309||Healthy Volunteer|Healthy volunteers over the age of 18, both male and female. That have not been diagnosed with CGD, Inflammatory Bowel Disease, or another primary disease of the immune system.
9947600|NCT01063309||IFN-gamma treated CGD|Participants with CGD the have been treated with Interferon gamma.
9947601|NCT01063309||Inflammatory bowel disease|Participants with Inflammatory Bowel Disease with a well-recognized granulomatous inflammation, but normal phagocyte function and ROS production. They have not been diagnosed with CGD.
9947602|NCT01063309||Other immune system disorders|Participants with other disorders such as Chediak-Higashi Syndrome, Leukocyte Adhesion Deficiency, myeloperoxidase deficiency, Hyper- IgE (Job's) Syndrome, IRAK4-deficiency, and NEMO-deficiency
9947603|NCT01063309||X-linked Chronic Granulomatous Disease (CGD)|Participants diagnosed with X-linked CGD confirmed by DHR.
9947604|NCT01063361|Experimental|Low glycemic Index Diet|Low glycemic Index Diet, emphasizing pulses
9947605|NCT01063361|Active Comparator|High Cereal Fibre Diet|
9947606|NCT01063374|Active Comparator|low glycemic index, diabetic diet|low glycemic index, diabetic diet
9947607|NCT01063374|Active Comparator|high cereal fibre, diabetic diet|high cereal fibre, diabetic diet
9947608|NCT01063387|No Intervention|Sema4c positive +Common iliac lymph nodes control|"Sema4c Positive & Radical hysterectomy +Pelvic Radiotherapy "
9947609|NCT01063387|Active Comparator|Sema4c positive +Common iliac lymph nodes Experimental|"Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
9947610|NCT01063387|No Intervention|Sema4c Positive + PAN positive control arm|"Sema4c Positive &  Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
9947611|NCT01063387|Experimental|Sema4c positive+ PAN positive Experimental|Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation+ supraclavicular lymph nodes irradiation) '
9947612|NCT01063400||Activity monitoring|
9947613|NCT01063413||Coleman Afterschool Program|Children enrolled in a community center-based after-school program.
9947614|NCT01063413||YMCA Fun Company|Children enrolled in a school-based after-school program.
9947615|NCT01063426|Experimental|Atorvastatin + enoxaparine arm|High dose atorvastatin arm before index surgery+ conventional enoxaparin
9947616|NCT01063426|Active Comparator|Conventional Enoxaprin|Conventional Enoxaparin before 12hr and on 1-7th day after index surgery
9947617|NCT01063439|Experimental|BuEAM: Experimental|BuEAM: Experimental Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day Intervention: Drug: Busulfan, etoposide, cytarabine, and melphalan
9947618|NCT01063452|Experimental|Truvalve|Atkinson Product Design urinary slide valve on the catheter
9947619|NCT01063452|Active Comparator|Control|Drainage bag on the catheter
9947620|NCT01063465|Experimental|Early weightbearing|
9947621|NCT01063465|Experimental|Control group|
9476389|NCT03572205|Experimental|TT genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
9947622|NCT01063478|Experimental|RAD001, Chemotherapy, Radiation|RAD001 + Chemotherapy and Radiation
9947623|NCT01063491|Experimental|Early graft angiography after coronary artery bypass surgery|Treatment of any bypass graft abnormalities that are discovered will be performed if needed
9947624|NCT01063491|No Intervention|No early angiography after coronary artery bypass surgery|
9947625|NCT01063504|Active Comparator|Teriparatide 20 microgram daily for 2 months|
9947626|NCT01063504|Placebo Comparator|Placebo|
9947627|NCT01063530|Experimental|Diammine Silver Fluoride|Application fo diammine silver fluoride in cervical lesions
9947628|NCT01063530|Placebo Comparator|Distilled water|Application of distilled water in cervical lesions
9947629|NCT01063543||patients with blood sample|Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity
9947630|NCT01063556|Experimental|1|
9947631|NCT01063556|Experimental|2|
9947632|NCT01063569|Active Comparator|Oral hydrocortisone|
9947633|NCT01063569|Experimental|Continous subcutaneous hydrocortisone infusion|
9947634|NCT01063582||fighter pilots f-16|This group is made up of pilots from the F-16 Venezuelan military air force stationed in the Base Vicente Landaeta Gil de Barquisimeto, Lara State.
9947635|NCT01063582||aircraft maintenance personnel f-16|Staff responsible for the preparation of aircraft for the flight and maintenance in the hangar at the airbase Vicente Landaeta Gil de Barquisimeto, Lara. Venezuela
9947636|NCT01063608|Experimental|Anti-H1N1v Vaccine|
9947637|NCT01063621|Experimental|KW-6500|
9947638|NCT01063647|Experimental|1|Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)
9947639|NCT01063647|Experimental|2|Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)
9947640|NCT01063647|Experimental|3|Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)
9947641|NCT01063660|Experimental|Treosulfan|Patients with acute myeloid leukaemia (AML) according to WHO classification (> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with < 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation
9947642|NCT01063673||Active runners|Observational follow-up study on 39 runners
9947643|NCT01063686|No Intervention|Insemination cervical cap|
9947644|NCT01063699|Experimental|Lap Kasai|Patients in this arm had their necessary Kasai procedure in a laparoscopic way.
9947645|NCT01063725|Experimental|Femarelle|Women will receive Femarelle twice daily for 12 weeks
9947646|NCT01063725|Placebo Comparator|Placebo|Women will take placebo capsules twice daily for 12 weeks
9947647|NCT01063738|Active Comparator|ICU Recovery Manual & placebo supplement|Patients will receive the standard self-directed rehabilitation package and a placebo nutritional supplement
9947648|NCT01063738|Experimental|ICU recovery manual & amino acid (AA) supplement|Patients will receive the standard self-directed rehabilitation package with the essential amino acid supplement
9947649|NCT01063738|Experimental|PEPSE & placebo supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the placebo nutritional supplement
9947650|NCT01063738|Experimental|PEPSE & AA supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the essential amino acid nutritional supplement
9947651|NCT01063777|Active Comparator|1|
9947652|NCT01063777|Active Comparator|2|
9801684|NCT01722162|Experimental|Arm A: (start levocetirizine after bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily before bed starting on Day 8 of Cycle 1. 5 mg daily before bed Days 1-4 of each cycle starting with cycle 2."
9801685|NCT01722162|Experimental|Arm B: (start levocetirizine before bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily starting 7 days prior to initiation of bevacizumab and capecitabine therapy. 5 mg daily Days 1-14 starting with cycle 2."
9801686|NCT01722266|Placebo Comparator|Placebo|Daily Injection
9801687|NCT01722266|Active Comparator|Liraglutide 1.8mg|Daily Injection
9801688|NCT01722266|Active Comparator|Liraglutide 1.2mg|Daily injections
9801689|NCT01722266|Active Comparator|Liraglutide 0.6 mg|Daily injection
9801690|NCT01722292|Experimental|Phase 1b: LY2940680 + C + E|"Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams [mg] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve [AUC] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle.~Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
9801691|NCT01722292|Placebo Comparator|Phase 2: Placebo + C + E|"Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
9801692|NCT01722292|Experimental|Phase 2: LY2940680 + C+ E|"Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily."
9801693|NCT01722318|Active Comparator|Plecanatide 0.3mg|Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
9801694|NCT01722318|Active Comparator|Plecanatide 1.0mg|Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
9801695|NCT01722318|Active Comparator|Plecanatide 3.0mg|Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
9801696|NCT01722318|Active Comparator|Plecanatide 9.0mg|Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
9801697|NCT01722318|Placebo Comparator|Placebo|Placebo, one tablet by mouth daily for 12 weeks
9801698|NCT01722435||OST completers|Patients who are likely to complete OST during the next 12 or 18 months
9801699|NCT01722487|Experimental|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
9801700|NCT01722487|Active Comparator|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
9801701|NCT01722552|Experimental|adherence feedback|Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was <95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
10004509|NCT01576900||Combination group|"Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP~* Patients will be randomized and assigned to each group at the ratio of 1:1."
9801702|NCT01722552|Active Comparator|standard of care|Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
9803385|NCT04168320|Experimental|Most favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.~SBRT-PATHY will be administered to this arm at an estimated most favorable time-position in immune cycle."
9803386|NCT04166435|Experimental|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
9803387|NCT04163289|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation combined with approved standard of care treatment with nivolumab and ipilimumab.
10004510|NCT01576913|Active Comparator|Music pacing|Exercise testing with music pacing
10214882|NCT04003896|Experimental|Abemaciclib|Abemaciclib will be given as a single oral agent Approximately up to 27 subjects may be enrolled to attain at least 24 evaluable participants. The starting dose will be 200 mg twice daily. Dosing will continue daily for 28 days, this being one cycle. There will be no protocol scheduled hiatus and daily dosing will be continuous unless there is unacceptable toxicity, disease progression, or death.
10214883|NCT03999268|Experimental|Intervention|Participants assigned to the intervention group will receive insulin administration education according to standard procedures plus have access to the I-START app. Over the course of the study period, participants will be able to use I-START as much or as little as they prefer.
9803388|NCT04162938|Experimental|Patient-Centered Electronic App Group|Patients assigned to the intervention group will receive individualized reports regarding patients' HCV disease progress/liver fibrosis staging by a Fibrosis-4 score using the personalized HCV educational app. The individualized report will also include comprehensive knowledge to fill the gap on general HCV information, natural history of the disease, and care and treatment, if there is any, as well as level of interest in receiving HCV care based on patients' response to the short survey questionnaires on the tablet. Patients will also receive the investigators' HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore. Patients will receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
9803389|NCT04162938|No Intervention|Reference Group|Patients assigned to the reference group will receive the investigators' current 'static' standard of care HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore City. Patients will also receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
9803390|NCT04162184|Other|Health Educator Intervention|As the population of focus in this study is diverse, including men and women regardless of pregnancy desire, the primary focus for the intervention for this study will be education, particularly for men. All participants that enroll in the study will be offered the intervention. The study health educator will use the PATH (Parenthood/Pregnancy Attitude, Timing, and How) framework questions to initially guide the conversation. Depending on the participant's desires, the educator will provide education on other topics such as sexually transmitted infections (STIs) and we will also navigate to clinical services as needed. The health educator will use a study manual to guide all intervention activities including engagement. Additionally, the health educator will collect data on intervention outreach, engagement, topics discussed, participant needs and outcomes.
9803391|NCT04154787|Experimental|LNP023|LNP023
9803392|NCT04154787|Active Comparator|Rituximab|Rituximab
9803393|NCT04154150|Experimental|Ketamine + Cognitive Training|
9803394|NCT04154150|Sham Comparator|Ketamine + Sham Training|
9803395|NCT04154072|Active Comparator|NLY01 (2.5 mg)|NLY01 2.5 mg injection
9803396|NCT04154072|Active Comparator|NLY01 (5.0 mg)|NLY01 5.0 mg injection
9803397|NCT04154072|Placebo Comparator|Vehicle|inactive drug, injection
9803398|NCT04151875|Experimental|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
9803399|NCT04151875|Active Comparator|Non-extraction orthodontic treatment|non-extraction orthodontic treatment
10214884|NCT03999268|Active Comparator|Usual Care|Participants in the usual care group will receive insulin administration education according to standard procedures. They will not have access to the I-START app.
10214885|NCT03974828|No Intervention|Non-Contact|Participants in the non-contact group will be monitored by anesthesia control tower clinicians who will utilize AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes predictions, but who will not contact the postoperative provider unless it is clinically necessary for patient safety purposes.
9803400|NCT04150991|Experimental|Fiber intervention|The investigator's targeted supplemental fiber mixture (35 g total) will be composed of 6g of fiber from oligofructose + 10g from resistant maltodextrin + 12g from acacia gum + 4g from whole foods + 3g from RS2; and will be split into three meals each day.
9803401|NCT04150991|Placebo Comparator|Placebo treatment|Maltodextrin will be used as a placebo control, as it is digested in the small intestine and thus does not exert local effects in the colon.
9803402|NCT04149418|Experimental|Yogurt-Control|Consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks, followed by a washout phase for 4 weeks, then consumption of 12 oz. control food (flavored soy pudding, 2 x 6 oz. servings) for 4 weeks.
9947653|NCT01063790|No Intervention|Usual care|Patients undergoing elective inguinal hernia repair attend the pre-admission clinic no later than one week prior to surgery. During this visit they receive one-on-one pre-operative education from a registered nurse. It includes both verbal and written information. Verbal information provided to patients includes procedural information such as the admission process, and post-operative care in the post-anaesthetic care uni and day surgery unit. Post-discharge pain management information is minimal and consists of direction to not wait until the pain is severe before taking prescribed analgesics.
9947654|NCT01063790|Experimental|Individualized Education|
9947655|NCT01063816|Experimental|Arm 1|
9947656|NCT01063842|Experimental|001|tramadol hydrochloride / acetaminophen and placebo 1 tablet of tramadol/acetaminophen in the morning 1 tablet of placebo in the afternoon and evening for 3 days then 1 tablet of tramadol/acetaminophen in the morning evening and 1 tablet of placebo in the afternoon for 4 days then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
9947657|NCT01063842|Active Comparator|002|tramadol hydrochloride /acetaminophen 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
9947658|NCT01063894|Experimental|breakfast cereal|breakfast cereal and milk
9947659|NCT01063894|Placebo Comparator|water|water
9947660|NCT01063920|Experimental|LT-NS001|LT-NS001 1200 mg b.i.d. p.o. for 12 weeks
9947661|NCT01063920|Active Comparator|Naprosyn®|Naprosyn® 500 mg b.i.d for 12 weeks
9947662|NCT01063933|Experimental|Cohort I|Cohort I: >/= 12 years to < 18 years. Peramivir administered daily for five days or until the day of hospital discharge, whichever comes first.
9947663|NCT01063933|Experimental|Cohort II|Cohort II: >/= 6 years to < 12 years
9947664|NCT01063933|Experimental|Cohort III|Cohort III: >/= 2 years to < 6 years
9947665|NCT01063933|Experimental|Cohort V|Cohort V: >/= 91 days to < 181 days
9947666|NCT01063933|Experimental|Cohort VII|Cohort VII: birth to < 31 days
9947667|NCT01063933|Experimental|Cohort VI|Cohort VI: >/= 31 days to < 91 days
9947668|NCT01063933|Experimental|Cohort IV|Cohort IV: >/= 181 days to < 2 years
9947669|NCT01063946|Experimental|[14C]-AVE8062|Single, 30 minute, intravenous infusion of 25 mg/m² of [14C]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
9947670|NCT01063959|Other|Safety|Chart review will evaluate the safety of the two procedures, incidence of complications operatively, hospital stay, and 6-week post-operative periods.
9947671|NCT01063959|Experimental|Weight Loss|Chart review will evaluate weight loss in subjects during the operative, 6-week post-operative, and follow-up of at least 18 months.
9947672|NCT01063959|Other|Insurance versus Private Pay|An insurance company issues an insurance policy to cover specific complications from the gastric bypass or the sleeve gastrectomy surgery which allows the surgeon to offer a fixed price to the patient. Comparison of surgical complications in subjects paying by insurance versus paying personally for the gastric bypass operation.
9947673|NCT01063998||Group 1|Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
9947674|NCT01063998||p 2|Patients diagnosed with renal cancer and normal creatinine.
9947675|NCT01064011|Other|External Ventricular drainage, Intraventricular Thrombolysis|
9947676|NCT01064011|Other|External Ventricular Drainage and Endoscopic Evacuation|
9947677|NCT01064050|Experimental|trachea-bronchial stent (Novatech)|
9947678|NCT01064050|No Intervention|control|
9947679|NCT01064089|Experimental|HSP990|dose escalation
10004511|NCT01576913|No Intervention|No music pacing|Exercise testing without music pacing
10004512|NCT01576926||surgery|patients with obstructive sleep apnea
9947680|NCT01064102|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
9947681|NCT01064102|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
9947682|NCT01064115|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
9947683|NCT01064115|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
9947684|NCT01064128|Active Comparator|conventional laparoscopic hysterectomy|Three or four ports conventional laparoscopic hysterectomy
9947685|NCT01064128|Active Comparator|SPA laparoscopic hysterectomy|Single umbilical incision laparoscopic hysterectomy
9947686|NCT01064141|Experimental|Group 1: Dengue Vaccine Group|Participants will receive CYD Dengue vaccine as Visits 1 and 2.
9947687|NCT01064141|Active Comparator|Group 2: Control Group|Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
9947688|NCT01064141|Experimental|Group 3: Co-administration Group|Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
9947689|NCT01064141|Experimental|Group 4: Sequential Administration Group|Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
9947690|NCT01064154|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
9947691|NCT01064154|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
9947692|NCT01064180|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
9947693|NCT01064180|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
9947694|NCT01064193|Experimental|group 1 : IVF with biopsy|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF
9947695|NCT01064193|Active Comparator|group 2|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
9947696|NCT01064206||Buerger's disease patients|200 thromboangiitis obliterans patients (Buerger's disease or TAO)
9947697|NCT01064206||Control group|200 atheromatous arteritis patients
9947698|NCT01064219|Experimental|intrauterine hCG|intrauterine injection of 100 hCG followed by endometrial biopsy
9947699|NCT01064232|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
9947700|NCT01064232|Active Comparator|Risperdal|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
10214886|NCT03974828|Experimental|Brief contact|PACU and ward providers caring for participants in the brief contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a brief summary of the patient's forecast risk of major adverse events.
9528780|NCT03207906|Active Comparator|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
9801703|NCT01722604|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
9801704|NCT01722604|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
9801705|NCT01722643|Experimental|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
9801706|NCT01722643|Active Comparator|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
9801707|NCT01722669|Experimental|Quercetin|Single dose of quercetin with or without ascorbic acid
9801708|NCT01722669|Active Comparator|Isoquercetin|Single dose of isoquercetin with or without ascorbic acid
9801709|NCT01722734|No Intervention|Control|Patients in the control arm only got a generic health message at the end of the study.
9801710|NCT01722734|Active Comparator|Short Message|Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
9801711|NCT01722734|Active Comparator|Long message|Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
9801712|NCT01722877|Experimental|JetStream Atherectomy|Jetstream NAVITUS System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic disease and thrombus in peripheral vasculature.
9801713|NCT01722994|Experimental|Group 1 Punch Biopsy Wound with chromic gut suture|One of two absorbable sutures is used to close punch wounds.
9801714|NCT01722994|Experimental|Group 2 Punch Biopsy Wound with PDS|This is one of two absorbable sutures used to close punch biopsy wounds.
9801715|NCT01723072|Experimental|1 Omalizumab|omalizumab once a month via subcutaneous injection.
9801716|NCT01723072|Placebo Comparator|2 Placebo|placebo of omalizumab once a month via subcutaneous injection
9801717|NCT01723163|Experimental|Intervention|Abstinence Reinforcement Therapy (ART)
9801718|NCT01723163|Other|Control|Telephone Counseling
9801719|NCT01723228|Experimental|Rasagiline 1.0 mg/day|Rasagiline 1 mg oral tablets once daily for 24 weeks
9801720|NCT01723228|Placebo Comparator|Placebo|Placebo oral tablets once daily for 24 weeks
9801721|NCT01723254|Experimental|PF-06444753|
9801722|NCT01723254|Experimental|PF-06444752|
9801723|NCT01723254|Placebo Comparator|Placebo|Intramuscular
9801724|NCT01723384|Active Comparator|Naltrexone|Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
9801725|NCT01723384|Placebo Comparator|Placebo|Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
9801726|NCT01723397|Active Comparator|Nasaleze spray|"Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
9801727|NCT01723397|Placebo Comparator|Placebo spray|"Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
9801728|NCT01723514|Experimental|Erenumab|Healthy participants and participants with migraine received subcutaneous doses of erenumab on days 1, 29 and 57.
9801729|NCT01723514|Placebo Comparator|Placebo|Healthy participants and participants with migraine received subcutaneous doses of placebo on days 1, 29 and 57.
9801730|NCT01723696|Placebo Comparator|placebo tablet+prenatal vitamin|A daily placebo tablet
9801731|NCT01723696|Active Comparator|Vitamin C +prenatal vitamin|500 mg vitamin C /day
9801732|NCT01723722|Active Comparator|1 (Phenobarbital and Methadone)|"The following is a dosing guide for methadone:~The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.~For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:~NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose~≥16 0.15 mg/kg/dose~Maximum dose of methadone will be 0.15 mg/kg/dose.~After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours.~If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm."
9803403|NCT04149418|Experimental|Control-Yogurt|Consumption of control food (flavored soy pudding, 2 x 6 oz. servings), followed by a washout phase for 4 weeks, then consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks.
9803404|NCT04147689|Experimental|Treated labia majora|Labia majora are treated at Baseline visit (V1) and a touch-up may be performed 4 weeks after Baseline (V2) if needed
9803405|NCT04137289|Experimental|Phase Ia: BI 905711 - dose escalation|
9947701|NCT01064258|Active Comparator|fixed CPAP|subject will sleep with a fixed CPAP device at minimal pressure
9947702|NCT01064258|Experimental|autoCPAP|the subject will sleep connected to an autoCPAP device
9947703|NCT01064271|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
9947704|NCT01064271|Active Comparator|Risperdal®|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
9947705|NCT01064336||Pregnant women on eltrombopag|Any women with eltrombopag exposure during pregnancy that is reported prior to or after knowledge of the pregnancy outcome, substantiated by health care provider, and meeting the enrollment criteria: documentation that eltrombopag is being taken during pregnancy; timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to Eltrombopag for stratification and reporting purposes ); sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered; whether the outcome of pregnancy was known at the time of the report; source of the report (i.e. health care professional, patient); full provider contact information to allow for follow-up (name, address, etc.)
9947706|NCT01064336||Infants|Infants through the first year of life whose mothers were exposed to eltrombopag during pregnancy.
9947707|NCT01064349||Breast cancer patients with brain metastases|Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
9947708|NCT01064375|Experimental|CEA DNA prime (cohort I)|5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
9528781|NCT03207906|Active Comparator|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
9947709|NCT01064375|Experimental|CEA DNA boost (cohort II)|10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
9947710|NCT01064375|Experimental|CEA DNA prime + GM-CSF (cohort III)|5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
9947711|NCT01064388|Experimental|1|
9947712|NCT01064388|Placebo Comparator|2|
9947713|NCT01064427||Chemotherapy group|Breast cancer patients treated by adjuvant chemotherapy after their surgery. The time points of data collection are before the start of the first, second, fourth and sixth cycle of chemotherapy. If patients are treated by radiotherapy after the chemotherapy, there are 2 measurements points pre- and post radiotherapy.The others measurement points are at 12,18 and 24 months after surgery.
9947714|NCT01064427||No chemotherapy group|Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
9947715|NCT01064453||Group 1|
9947716|NCT01064466|Experimental|ETOPOSIDE - Usual|"Etoposide Injection~Combined Chemotherapy~Etoposide Injection + Methotrexate Injection + Topotecan Injection~Usual Approach Group"
9947717|NCT01064466|Experimental|ETOPOSIDE - Study|"Etoposide Capsule~Combined Chemotherapy~Etoposide Capsule + Methotrexate Tablet + HYCAMTIN - Topotecan Capsule~Study Approach Group"
9947718|NCT01064492|Experimental|ABC, ACB, BAC, BCA, CAB, and CBA|
9947719|NCT01064505|Experimental|QPI-1007|
9947720|NCT01064544|Experimental|Starting with light therapy|Starts with 3 weeks of light therapy, followed by a control period
9947721|NCT01064544|Experimental|Ending with light therapy|Ends with 3 weeks of light therapy after a control period.
9947722|NCT01064583|Experimental|flavanol rich cocoa drink (596mg)|dissolved in water, twice daily intervention
9947723|NCT01064583|Experimental|flavanol poor cocoa drink ( 13mg)|dissolved in water, twice daily intervention
9947724|NCT01064596||blood sample|Patient with 4 blood samples to measure anti-Xa activity
9947725|NCT01064609|Active Comparator|2. Biopsy with cryoprobes|Transbronchial cryobiopsy with a cryoprobe.
9947726|NCT01064609|Active Comparator|2.Biopsy with forceps|Transbronchial lung biopsy with conventional forceps.
9947727|NCT01064635|Active Comparator|Letrozole for 3-2 years|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for 3-2 years. Total duration of early adjuvant endocrine therapy: 5 years
9947728|NCT01064635|Experimental|Letrozole for 5 year|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for additional 5 years. Total duration of early adjuvant endocrine therapy: 7 years for patients pretreated with 2 years of TAM and 8 years for patients pre-treated with 3 years of TAM
9947729|NCT01064661|Active Comparator|Blend probiotic of L-NCFM and B-LBi07|Blend probiotic pills of L-NCFM and B-LBi07 BID (2x10^10 cfu total bacteria per day)
9947730|NCT01064661|Active Comparator|Single probiotic of L-NCFM alone|Single probiotic pills of L-NCFM alone BID (2x10^10 cfu total bacteria per day)
9947731|NCT01064674||before renal transplantation|Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department.
9947732|NCT01064700|No Intervention|Baseline|1 week period, in which subjects followed usual schedule, though they were asked to maintain a fairly stable sleep schedule. The baseline period was used for comparison with the experimental intervention.
9947733|NCT01064700|Experimental|Experimental Intervention|Randomized exposure to the 4-week experimental treatments.
9947734|NCT01064726|Experimental|Ibuprofen|
9947735|NCT01064726|Experimental|Fluticasone propionate|
9947736|NCT01064726|Placebo Comparator|Placebo|
9947737|NCT01064752||Minocycline|HIV-1 infected, not on anti-retroviral medication
9947738|NCT01064765||Heart failure|Outpatients with heart failure, age 75 or less, left ventricular ejection fraction 40% or less, english speaking with no known dementia
9947739|NCT01064778|Active Comparator|Low GI|
9947740|NCT01064778|Experimental|High GI|
9947741|NCT01064804||relative bioavailability|
9947742|NCT01064843||4 Imtec mini-dental implants (MDI)|4 Imtec MDI
9528782|NCT03207906|Placebo Comparator|Vehicle|Vehicle solution applied to affected area BID
9947743|NCT01064869|Experimental|Psycho-educational intervention|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
9947744|NCT01064869|No Intervention|usual care|Standard asthma management
9947745|NCT01064895||Active Cohort|Patients receiving the Benephit device and targeted renal therapy.
9947746|NCT01064908||Carotid endarterectomy|Patients who are undergoing elective carotid endarterectomy under local anaesthesia
9528783|NCT03207919|Experimental|Lullaby Project|
9947747|NCT01064921|Experimental|Arm I|Patients receive oral vorinostat on days 0-2 and cisplatin IV on days 7, 21 and 35. Patients undergo radiation therapy 5 days a week beginning on day 7. Patients also receive concurrent oral vorinostat along with the radiotherapy to be given 3 days per week (Monday, Tuesday, and Wednesday). Optional repeat tumor and normal mucosal biopsies will be performed and blood will be drawn for correlative studies.
9947748|NCT01064934|Experimental|Lipid apheresis|Lipid apheresis
9947749|NCT01064934|Active Comparator|Standard care|Standard care
9947750|NCT01064960|Experimental|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
9947751|NCT01064973|Experimental|STX209|STX209 (arbaclofen)
9947752|NCT01064986|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
9947753|NCT01064986|Active Comparator|B|IV Endotoxin plus IV hydrocortisone
9947754|NCT01064999|Experimental|High intensity group|(RT 55Gy + CapOx) + a cycle of Xelox + Surgery
9947755|NCT01064999|Active Comparator|Low instensity group|(RT 50Gy + CapOx) + Surgery
9947756|NCT01065025|Experimental|4SC-205|
9947757|NCT01065038|Experimental|Anagrelide|
9947758|NCT01065038|Active Comparator|Hydroxyurea|
9947759|NCT01065064|Experimental|RESTOR|Patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation.
9947760|NCT01065090||training|one group will receive resistance training and one group the normal physiotherapeutic treatment
9947761|NCT01065090||physiotherapy|one group will receive resistance training and one group the normal physiotherapeutic treatment
9947762|NCT01065103|Experimental|FFR measurement|
9947763|NCT01065116|Experimental|AL Blister-pack|
9947764|NCT01065116|Active Comparator|AL unit dose age specific pre-packs|
9947765|NCT01065129|Experimental|Dose Level 1|"AMD3100 320 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
9947766|NCT01065129|Experimental|Dose Level 2|"AMD3100 440 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
9947767|NCT01065129|Experimental|Dose Level 3|"AMD3100 560 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
10214887|NCT03974828|Experimental|Full contact|PACU and ward providers caring for participants in the full contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.
10214888|NCT03972163|Experimental|SPECTORx Educational Intervention|The program intervention is based on a combination of 3 existing, complementary, educational programs that, together, equip hospice staff to create a comprehensive, patient-centered, medication management care plan.
10214889|NCT03972163|Active Comparator|Attention Control|"As the attention control, we will refer staff in control offices to the National Institute of Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
9947768|NCT01065129|Experimental|Expanded DLT Cohort|After the MTD is determined, patients will be enrolled at the MTD dose of plerixafor. These patients will not receive G-CSF priming but will be treated with plerixafor and azacitidine for 2 cycles.
9947769|NCT01065155||Median central blood pressure|Median central blood pressure, lower median group 1 and higher group 2.
9947770|NCT01065168||endometrioma|ovarian endometrioma undergoing cystectomy
9947771|NCT01065194|Experimental|Levosimendan|Chronic stable heart failure
10214890|NCT03971643|Experimental|IFX-1|Exploratory, Proof of Concept with a total of 15 doses of IFX-1.
10214891|NCT03946228|Experimental|Behavioral Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
9947772|NCT01065194|Placebo Comparator|Placebo|Chronic Stable Heart Failure
9947773|NCT01065207|No Intervention|patient|
9947774|NCT01065220|Experimental|hormone treatment for MtF|"cyproterone acetate~estradiol~alpha-5-reductase-inhibitor"
9947775|NCT01065220|Experimental|hormone treatment for FtM|"testosterone undecanoate~lynestrenol"
9947776|NCT01065233||alcoholic cirrhosis with viral infection|patient with alcoholic cirrhosis with viral infection (300 patients)
9947777|NCT01065233||alcoholic cirrhosis without viral infection|patient with alcoholic cirrhosis without viral infection
9947778|NCT01065246|Experimental|catumaxomab|
9947779|NCT01065259|Experimental|OROS MPH|the group treated by OROS MPH
9947780|NCT01065259|Active Comparator|atomoxetine|the group treated by atomoxetine
9476390|NCT03572205|Experimental|CC genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
9476391|NCT03572205|Experimental|TT genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
9528784|NCT03207919|No Intervention|Control Group|
9801733|NCT01723722|Active Comparator|2 (Phenobarbital and Diluted Deodorized Tincture of Opium)|"The following is a dosing guide for dDTO:~The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.~The starting dose will be determined using a sliding scale in response to the last NAS score before starting.~NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day~≥16 0.8 mg/kg/day~The maximum dose of DTO will be 0.8 mg/kg/day.~After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.~If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm."
9801734|NCT01723826|Experimental|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
9801735|NCT01723904|Experimental|Rotigotine|"- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.~Duration of the Titration Period: Between 1 week and 5 weeks.~- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.~Duration of the Maintenance Period: Between 3 weeks and 7 weeks."
9801736|NCT01724021|Experimental|Arm A|Participants in Arm A received one cycle of rituximab 375 mg/m^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
9801737|NCT01724021|Experimental|Arm B|Participants in Arm B received four cycles of rituximab 375 mg/m^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
9801738|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
9801739|NCT01724060||Gastric banding|Patients due for gastric banding
9801740|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
9801741|NCT01724060||Endobarrier|Patients due to undergo endoscopic Endobarrier insertion
9801742|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
9801743|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
9801744|NCT01724060||Lifestyle|Patients due to be commenced on a lifestyle intervention programme
9801745|NCT01724060||Elective surgery or endoscopy|Patients due to have non bariatric surgery (i.e. cholecystectomy) or an elective diagnostic endoscopy
9801746|NCT01724177|Experimental|Lenalidomide|Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
9801747|NCT01724216|Experimental|pulse sequence software|The central aim of this study is to acquire a set of images and associated technical and clinical information to facilitate regulatory submission of the pulse sequences being studied by GEHC. Segment 1 allows to collect a minimum of 10 subjects then evaluate if additional scans/enrollment needed Segment 2 will allow an additional 90 subjects if data needed
9801748|NCT01724359|Experimental|Paliperidone ER|
9801749|NCT01724489|Active Comparator|Growth Hormone|Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.
9801750|NCT01724489|Placebo Comparator|Placebo|Placebo will be provided by Pfizer Inc. It will appear identical to active growth hormone and will be administered in the same manner.
9801751|NCT01724528|Experimental|Febuxostat|Febuxostat for 7-9 days
9801752|NCT01724528|Active Comparator|Allopurinol|Allopurinol for 7-9 days
9801753|NCT01725126|Experimental|Part A - GSK2890457|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
9801754|NCT01725126|Experimental|Part B - GSK2890457 + Liraglutide|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
9801755|NCT01725126|Experimental|Part C - GSK2890457 + Metformin|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
9801756|NCT01725126|Placebo Comparator|Part A - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
9801757|NCT01725126|Placebo Comparator|Part B - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
9801758|NCT01725126|Placebo Comparator|Part C - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
9801759|NCT01725217|Experimental|MenACWY-CRM|MenACWY-CRM
9801760|NCT01725282|Placebo Comparator|Placebo|Participants received matching placebo tablets once daily before bedtime for 7 weeks.
9801761|NCT01725282|Experimental|Quetiapine 50 mg|Participants received quetiapine extended release (XR) 50 mg tablets once daily before bedtime for 7 weeks.
9801762|NCT01725282|Experimental|Quetiapine 150 mg|After 2 days of up-titration, participants received quetiapine XR 150 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 50 mg tablets once daily for 1 week.
9803406|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 1|
9803407|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 2|
10214892|NCT03946228|No Intervention|Control Condition|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
9801763|NCT01725282|Experimental|Quetiapine 300 mg|After 4 days of up-titration, participants received quetiapine XR 300 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 150 mg tablets once daily for 1 week.
9801764|NCT01725308|Placebo Comparator|Placebo|Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
9801765|NCT01725308|Experimental|FK949E 150 mg|After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
9801766|NCT01725308|Experimental|FK949E 300 mg|After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
9801767|NCT01725308|Experimental|Placebo / FK949E|Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
9801768|NCT01725308|Experimental|FK949E 150 mg / FK949E|After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
9801769|NCT01725308|Experimental|FK949E 300 mg / FK949E|After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
9801770|NCT01725386||Monotherapy|Capecitabine as monotherapy according to prescribing information and normal clinical practice.
9801771|NCT01725386||Combination Therapy|Capecitabine as part of combination therapy according to prescribing information and normal clinical practice.
9801772|NCT01725451|Experimental|Testosterone Unshaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each unshaved axilla in 1 of 6 treatment periods.
9801773|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Spray|Deodorant spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
9801774|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
9801775|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Stick|Deodorant antiperspirant combination stick applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
10214893|NCT03929718|Active Comparator|Standard Therapy|subjects undergoing CTI ablation
9801776|NCT01725451|Experimental|Testosterone Shaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each shaved axilla in 1 of 6 treatment periods.
9801777|NCT01725451|Experimental|Testosterone Shaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to shaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
9801778|NCT01725529|Experimental|TMC435 150 mg|Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
9801779|NCT01725529|Experimental|TMC435 100 mg|Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
9803408|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 3|
9803409|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 4|
10214894|NCT03929718|Experimental|Interventional Therapy|subjects treated with an aldosterone antagonist after CTI ablation
10214895|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: SYD-101 Dose 1|1 drop in each eye at bedtime.
9947781|NCT01065259|No Intervention|control|the normal control with no intervention
9947782|NCT01065272|Active Comparator|Ventolin - Dexamethasone group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
9947783|NCT01065272|Placebo Comparator|Ventolin - Placebo group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
9947784|NCT01065285|Experimental|Evaluation of vaccines against flu|Evaluation of vaccines against flu
9947785|NCT01065298||Group 1:Stem cell Recipient|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
9947786|NCT01065298||Group-2: Controls|Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin >0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.
9947787|NCT01065311|Experimental|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
9947788|NCT01065311|Active Comparator|CBASP|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions.
9947789|NCT01065311|Active Comparator|Treatment-as-usual|"Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
9947790|NCT01065324||Anally inserted enteroscopy group|Anally inserted enteroscopy group
9947791|NCT01065324||Orally inserted enteroscopy group|Orally inserted enteroscopy group
9947792|NCT01065337|No Intervention|control group|patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
9947793|NCT01065337|Active Comparator|bone marrow stem cells intraarterial|bone marrow stem cells administered intraarterial
9947794|NCT01065337|Active Comparator|tissue repair cells intramuscular|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
9947795|NCT01065337|Active Comparator|tissue repair cells intraarterial|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
9947796|NCT01065337|Active Comparator|bone marrow stem cells intramuscular|bone marrow stem cells administered intramuscular
9476392|NCT03572179|Active Comparator|Treatment Group|After finishing orthodontic treatment, all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method
9476393|NCT03572179|No Intervention|Control Group|All patients of this group will follow conventional steps of direct bonding procedure of fixed mandibular retainer
9476394|NCT03572166|Experimental|Arginine Infusion|Arginine Stimulation Test
9476395|NCT03572166|Active Comparator|Hypertonic saline infusion|Hypertonic Saline Infusion Test
9476396|NCT03572140||group A|RAVS IN resistent cases after daclatasvir plus sofosbuvir treatment
9476397|NCT03572140||group B|RAVS IN relapsed cases after daclatasvir plus sofosbuvir treatment
9476398|NCT03572127|Experimental|Non-animal derived diet|High protein diet derived from non-animal sources.
9947797|NCT01065363|Experimental|Lifestyle conseling|
9947798|NCT01065376|Experimental|on the day of hCG|cabergoline administration for 8 days on the day of hCG.
9947799|NCT01065376|Experimental|on the day after oocyte retrieval|cabergoline administration for 8 days on the day after oocyte retrieval
10214896|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: Vehicle|1 drop in each eye at bedtime.
10214897|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
10214898|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: Vehicle|1 drop in each eye at bedtime.
10214899|NCT03918915|Placebo Comparator|Part 1: Vehicle; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
10214900|NCT03903341|Other|idiopathic blepharospasm (BSP) de novo|bold signal in visual pathway
10214901|NCT03903341|Other|Healthy subjects|bold signal in visual pathway
10214902|NCT03882918|Experimental|OV101|once daily at bedtime (gaboxadol)
10214903|NCT03878459|Experimental|Intervention|pioglitazone treatment
10214904|NCT03878459|Placebo Comparator|control|subjects will receive placebo
10214905|NCT03877744|Experimental|Interactive virtual presence|Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
10214906|NCT03877744|Active Comparator|Live technician|Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.
9947800|NCT01065389|Experimental|Prgressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
9947801|NCT01065389|Active Comparator|Unstructured Resistance Exercise|Unstructured Resistance Exercise thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
9947802|NCT01065402|Placebo Comparator|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
9947803|NCT01065402|Experimental|PPB-R-203-Based Meal|"PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. RS intake is associated with several changes in metabolism which may confer some health benefits.~PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition."
9947804|NCT01065415||control group|routine staging work-up with chest CT, PET/CT, and brain MRI
9947805|NCT01065415||study group|routine staging work-up plus whole body MRI for Coregistered MRI/PET
9947806|NCT01065467|Experimental|Treatment|LBH589
9947807|NCT01065493|Experimental|Software Assisted Lifestyle Counseling|
9947808|NCT01065493|Active Comparator|Lifestyle Counseling|Status quo smoking cessation counseling.
9947809|NCT01065519|Active Comparator|1|drug-eluting stent
9947810|NCT01065519|Active Comparator|2|Biolimus A9-eluting Biomatrix stent
9947811|NCT01065532|Active Comparator|1|SeQuent Please Drug-eluting balloon
9947812|NCT01065532|Active Comparator|2|Xience V Drug-eluting stent
9947813|NCT01065545|Experimental|Clofarabine|
9947814|NCT01065584||Standard immunosuppression|Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
9947815|NCT01065584||Immunosuppression without calcineurininhibitors|Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors
9947816|NCT01065610|Experimental|Oxytocin|Intranasal Oxytocin, 24 IU
9947817|NCT01065610|Placebo Comparator|Placebo|
9947818|NCT01065623|Experimental|Arm 1|
9947819|NCT01065636|Experimental|Diet + Resistance Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised resistance exercise training three times a week
9947820|NCT01065636|Experimental|Diet + Aerobic Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised aerobic exercise training three times a week
9947821|NCT01065636|Experimental|Diet + Combined Aerobic/Resistance Exercise|Weekly behavioral/diet-induced weight loss plus combined supervised resistance exercise training and aerobic exercise training three times a week
9947822|NCT01065636|No Intervention|Control Group (No Diet/No Exercise)|No diet No exercise training
9947823|NCT01065649|Experimental|Nortriptyline|20 NERD patients will be treated with nortriptyline 10 mg a day in the first 7 days and 25 mg a day in the following 14 days
9947824|NCT01065649|Placebo Comparator|Placebo|Placebo arm
9947825|NCT01065662|Experimental|Cediranib and Temsirolimus|Please see interventions section.
9947826|NCT01065688|Active Comparator|Roux-en Y|Roux-en Y reconstruction after distal gastrectomy
9947827|NCT01065688|Experimental|Billroth-I|Billroth-I reconstruction after distal gastrectomy
9947828|NCT01065701|Active Comparator|1mcg/kg|1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
9947829|NCT01065701|Active Comparator|2mcg/kg|2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
9947830|NCT01065727|Experimental|mitoxantrone followed by immunomodulator|
9947831|NCT01065727|Active Comparator|natalizumab|
9947832|NCT01065740|Experimental|patient education|individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
9947833|NCT01065740|No Intervention|Usual care|
9947834|NCT01065753|Experimental|Life-style modification|Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
9947835|NCT01065792||1|Patients with HIV-1 infection taking Stocrin
9947836|NCT01065805|Experimental|1|18F-FLT PET
9947837|NCT01065831|Experimental|Lifestyle counseling|This MINT-TLC group will be asked to attend 12 weekly counseling meetings focused on weight loss (if overweight), limiting sodium, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained Lay Health Advisors. Participants will attend weekly group classes targeted at lifestyle changes for the first 12 weeks (intensive phase); followed by three individual MINT sessions conducted monthly for the following three months (maintenance phase). The MINT-TLC sessions aim to help participants make useful therapeutic lifestyle changes (TLC) and develop skills to maintain these changes long-term.
9947838|NCT01065831|Placebo Comparator|Health Education Control Condition|Participants randomized to this control condition will receive traditional, group health education classes for 12 weeks delivered by experts on various health topics unrelated to hypertension such as cancer, health insurance, and depression.
9947839|NCT01065857|Experimental|Citrafleet|The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
9947840|NCT01065857|Active Comparator|Klean Prep|The day prior to the colonoscopy from 16:00h to 20:00h.
9947841|NCT01065857|Experimental|Citrafleet Exploratory|The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
9947842|NCT01065870|Experimental|Group I|Patients with only venous involvement Treated with 6 cycles og GTX and then surgery
9947843|NCT01065870|Experimental|Group II|Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
9947844|NCT01065883|Experimental|community health worker|community health workers will provide education in the home
9947845|NCT01065883|Active Comparator|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
9947846|NCT01065896||Group 1|
9947847|NCT01065909||Diabetes type 2|
9947848|NCT01065909||Chronic Pain|
9947849|NCT01065909||Atrial Fibrillation|
9947850|NCT01065948|Experimental|Patients|
9947851|NCT01065961|Active Comparator|Decadron|Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
9947852|NCT01065961|Placebo Comparator|Saline|subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
9947853|NCT01065974|Active Comparator|Behavior Therapy|"Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring~Stimulus control~Changing eating behaviors~Goal setting~Problem solving~Social support~Cognitive restructuring~Relapse prevention"
9947854|NCT01065974|Experimental|Behavior Therapy + Meal Replacements|The BT +MR condition will implement behavioral treatment strategies in a way that is nearly identical to that of the BT condition. However, participants in this condition also will use MRs during weight loss and weight loss maintenance.
9947855|NCT01065974|Experimental|Nutritrol|"Participants in this condition will be informed about the evidence indicating that the availability, structure and composition of foods they encounter or seek out in their daily lives will play a major role in determining their ability to maintain the weight they lose. We will present the treatment as an opportunity to make numerous changes to their personal food environment involving the variety, energy density, nutritional composition, and portion size of the foods they encounter in every day life.~The Nutritrol condition is comprised of several components:~Food structure~Energy density~Reduce variety of foods high in energy density and increase variety of foods low in energy density~Protein intake~Controlling the personal food environment~Individualized weight loss maintenance prescriptions"
9947856|NCT01065987|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
9947857|NCT01065987|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
9947858|NCT01066013|Experimental|Prospective Antimicrobial de-escalation arm|Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
9947859|NCT01066013|No Intervention|Restrospective control arm|The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
9947860|NCT01066065||Raltegravir Cohort|Patients taking RAL 400 mg BID with Truvada
9947861|NCT01066065||Darunavir Cohort|Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada
9947862|NCT01066078||CRT recipients|
9947863|NCT01066091|Placebo Comparator|mashed potatoes|Mashed potatoes is composed of potatoes and Skim milk powder.
9947864|NCT01066091|Experimental|Mashed potatoes + Oleic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 75% of Oleic Acid
9947865|NCT01066091|Experimental|Mashed potatoes + Palmitic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 39% of saturated fat with 32% of palmitic acid.
10214907|NCT03850067|Experimental|CC-90011 in combination with Cisplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
9801780|NCT01725529|Placebo Comparator|Control|Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.
9801781|NCT01725750|Experimental|Bright White Light (BWL)|"Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box."
9801782|NCT01725750|Active Comparator|Dim Red Light (DRL)|Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
9801783|NCT01725815|Experimental|HARP Intervention|
9801784|NCT01725815|No Intervention|No Intervention: Control|Participants in usual care will continue to obtain any mental health or peer-support services that they would otherwise be receiving.
9801785|NCT01725984||AdVance|Subjects previously implanted with the AdVance Male Sling
9801786|NCT01725984||AdVance XP|Subjects previously implanted with the AdVance XP male sling
9801787|NCT01726023|Experimental|Ceftazidime-Avibactam plus metronidazole|
9801788|NCT01726023|Active Comparator|Meropenem|
9801789|NCT01726036|Active Comparator|Gomco Circumcision Clamp|Gomco circumcision clamp used for neonatal circumcision.
9801790|NCT01726036|Active Comparator|Mogen Circumcision Clamp|Mogen circumcision clamp used for neonatal circumcision.
9801791|NCT01726049|Active Comparator|Sildenafil|Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks
9801792|NCT01726049|Placebo Comparator|Placebo|placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks
9801793|NCT01726270|Experimental|tamsulosin hydrochloride|patients will take drug for 8 weeks in this exploratory study
9801794|NCT01726335|Experimental|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
9801795|NCT01726504|Experimental|electro-acupuncture|"The electric stimulator is applied to bilateral ST25andSP14 with dilatational wave10/50 Hz and electric current0.1-1.0mA.They are given acupuncture with 0.3×50mm or 0.35×75mm needles by inserting30-70mm and twirling lifting andthrusting 3 times.Dosage:The needle arrives the abdominal muscle layer(patients feel painful and acupuncturists feel touching hard).~Bilateral ST37 are given conventional acupuncture with 0.30mm×40mm needles by inserting 25-30mm and twirling lifting and thrusting for 3.Dosage:Local sour and heavy feeling is the appropriate dose.~Every session lasts for 30min/day.The participants are treated continuously for 8 weeks.During 8-week treatment the first 2 weeks,5 sessions per week,and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total."
9801796|NCT01726504|Sham Comparator|sham electro-acupuncture|"The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave, 10/50 Hz and electric current 0.5mA. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. The needle is inserted by 3mm-5mm (the needle can be vertically fixed on the skin).~Bilateral ST37 are given acupuncture with 3mm-5mm (the needle can be vertically fixed on the skin).~Length of Treatment and the treatment sessions are the same as treatment group."
9801797|NCT01726517|Experimental|LDV/SOF 8 Weeks (TN)|Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
9801798|NCT01726517|Experimental|LDV/SOF+RBV 8 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
9801799|NCT01726517|Experimental|LDV/SOF 12 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
9801800|NCT01726517|Experimental|LDV/SOF 12 Weeks (TE)|Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor [PI]+pegylated interferon [PEG]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
9801801|NCT01726517|Experimental|LDV/SOF+RBV 12 Weeks (TE)|Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.
9801802|NCT01726621|Other|Insulin dependent diabetics|Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
9801803|NCT01726673|Experimental|tDCS + robotic arm therapy|Transcranial Direct Current Stimulation (tDCS) 2mA for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
9801804|NCT01726673|Placebo Comparator|tDCS sham + robotic arm therapy|Transcranial Direct Current Stimulation sham condition (0 mA) for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
9801805|NCT01726738|Experimental|BRAF (dabrafenib) and MEK (trametinib) inhibitors|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
9803410|NCT04130906|Active Comparator|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
9947866|NCT01066130|Experimental|Intensive treatment arm|Every second person with psychosocial problems was randomized into this arm. The intervention consisted of personalized, intensive psychosocial treatment provided by a medical social worker on the basis of the patient's problems for up to 2 years after inclusion.
9947867|NCT01066130|Experimental|Minimal treatment arm|Every second patient with psychosocial problems was assigned to this arm. Patients in this arm received minimal social support by a medical social worker.
9947868|NCT01066130|No Intervention|No need for psychosocial treatment|This arm consisted of individuals who did not need psychosocial treatment or measures. The need for such treatment and measures was determined at baseline for all persons included in the study.
10004513|NCT01576965|Experimental|Mechanical Bowel Prep Group|Half of the subjects will be randomized to a group that does mechanical bowel preparation with sodium phosphate enema. Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
10004514|NCT01576965|No Intervention|No Bowel Prep Group|Participants randomly assigned to this group will not have the bowel prep treatment before the surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
10004515|NCT01576978|Active Comparator|postural orientations|The group of postural orientations receive a pamphlet containing information about the sitting, standing and lying postures to be performed at home for 10 weeks.The marking of the note pain will be before and after 10 weeks.
10004516|NCT01576978|Active Comparator|hatha yoga exercises|The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
10004517|NCT01576991||Oocyte collection|This is an observational study; there are no cohorts or groups
10004518|NCT01577004|Experimental|Omega-3 fatty acid supplement|Data obtained after the intervention was compared to baseline data
10004519|NCT01577017|Experimental|Letrozole|Group L will be assigned with Letrozole 5 mg on night on day 5 to day 9 of the cycle
10004520|NCT01577030|Experimental|Dairy|Add 4 daily servings of non-fat dairy to diet for a period of 4 weeks
10004521|NCT01577030|Active Comparator|Fruit|Add 4 daily servings of fruit to diet, remove all dairy from diet for a period of 4 weeks
10004522|NCT01577043|Active Comparator|Racecadotril|intestinal antisecretory
10004523|NCT01577043|Placebo Comparator|cornstach solution|Cornstarch powder diluted in distilled water
10004524|NCT01577056|Active Comparator|Fish oil|
10004525|NCT01577056|Placebo Comparator|Placebo|FH subjects with standard treatment (statin treatment)
10004526|NCT01577082|Experimental|CHF 1535 200/6µg|
10004527|NCT01577082|Active Comparator|BDP 100µg|
9476399|NCT03572127|Active Comparator|Animal derived diet|High protein diet derived from animal sources.
10004528|NCT01577095|Experimental|EA + Rosiglitazone|
10004529|NCT01577095|Placebo Comparator|Rosiglitazone|
10004530|NCT01577121|Placebo Comparator|placebo|
10004531|NCT01577121|Experimental|indomethacin|50 mg/ 6 hours of indomethacin oral use
10004532|NCT01577134|Experimental|Intervention to enhance physical activity|Participants in this arm have high motivation to be regularly physically active. Face-to-face group intervention includes behavior change techniques to enhance physical activity.
10004533|NCT01577134|Active Comparator|Active control intervention|Face-to-face group intervention includes behavior change techniques to enhance volunteering and improve attitudes towards volunteering.
10214908|NCT03850067|Experimental|CC-90011 in combination with Carboplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
9803411|NCT04130906|Sham Comparator|Sham Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
9803412|NCT04129970|Experimental|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
9803413|NCT04122950|Experimental|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
9803414|NCT04122950|No Intervention|Control|Continue with normal daily routine.
9803415|NCT04122924|Experimental|Intervention Group|A three months home-based abdominal muscle training program.
9803416|NCT04122924|No Intervention|Control Group|The control group will have no intervention, and will be asked not to attend any specific supervised abdominal muscle training program during the 3 months intervention period.
9803417|NCT04122274|Sham Comparator|Education Sheet and Sham Intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of the sham intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
9803418|NCT04122274|Experimental|Education Sheet and Decision-based interactive intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of a decision- based interactive concussion education platform intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
9803419|NCT04116749||Non-obese women|body mass index lower than 30 (kg/m^2) at term
9803420|NCT04116749||Obese women|body mass index equal or greater than 30 (kg/m^2) at term
9803421|NCT04113421||Anticoagulation|Inpatients diagnosed with acute PE, in whom clinical providers have elected to prescribe anticoagulation alone for treatment based on clinical grounds at BWH. In this population, a single follow-up contrast-enhanced chest CT will be performed to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
9803422|NCT04112576||HFrEF|Participants that are diagnosed with NYHA class II or III heart failure with reduced ejection fraction.
9803423|NCT04112576||HFpEF|Participants that are diagnosed with NYHA class II or III heart failure with preserved ejection fraction.
9803424|NCT04108221|Experimental|Arm A : c-TAP Block performed by surgeon|c-TAP Block Block performed by surgeon
9803425|NCT04108221|Active Comparator|Arm B : us-TAP Block performed by anesthetist|us-TAP Block by anesthetist
9803426|NCT04094285|Experimental|1|
9803427|NCT04094285|Experimental|2|
9803428|NCT04090567|Experimental|Arm I (olaparib plus cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9803429|NCT04090567|Experimental|Arm II (olaparib plus ceralasertib)|Patients receive olaparib PO BID on days 1-28 and ceralasertib PO QD on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9803430|NCT04086862|Active Comparator|The 1 MHz group|The 1 MHz group will receive therapeutic ultrasound at the 1 MHz setting.
9803431|NCT04086862|Experimental|The 3 MHz group|The 3 MHz group will receive therapeutic ultrasound at the 3 MHz setting.
9803432|NCT04086732|Experimental|Temporomandibular disorder|
9803433|NCT04086732|Experimental|Healthy control|
9803434|NCT04073979|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
9803435|NCT04071652|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
9476400|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
9801806|NCT01726803|Active Comparator|Usual Care|Usual care arm will receive management as recommended by practice guidelines and directed by the primary care provider. The recommended stepped care approach is used with initial management of advice and education only and no referral to physical therapy during the initial 4 weeks.
9801807|NCT01726803|Experimental|Early Physical Therapy with Usual Care|The Early Physical Therapy arm will receive the same advice and education intervention received by the usual care group and will be referred to receive 4 sessions of physical therapy during the first 4 weeks. The physical therapy protocol involves spinal manipulation and exercise.
9801808|NCT01727024|Experimental|Indacaterol (QAB149) Breezhaler®|In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days.
9801809|NCT01727024|Active Comparator|Tiotropium Respimat®|In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.
9801810|NCT01727089|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9801811|NCT01727089|Experimental|Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)|Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9801812|NCT01727141|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
9801813|NCT01727141|Active Comparator|QAB149|27.5 ug b.i.d.
9801814|NCT01727141|Active Comparator|NVA237|12.5 ug b.i.d.
9801815|NCT01727141|Placebo Comparator|Placebo|b.i.d
9801816|NCT01727154||Sipuleucel-T|
9801817|NCT01727180||Chronic kidney disease|
9801818|NCT01727258|Experimental|Mouth Rinse|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
9801819|NCT01727258|Active Comparator|Fluoride Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
9801820|NCT01727258|Active Comparator|Potassium Nitrate Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.
9801821|NCT01727297|Other|REVEAL Implantable Cardiac Monitor|
9801822|NCT01727336|Experimental|Dalantercept 0.9 mg/kg plus axitinib|Subcutaneous (SC) injection of dalantercept 0.9 mg/kg once every 3 weeks and oral axitinib 5 mg BID for continuous dosing.
9801823|NCT01727336|Placebo Comparator|Placebo plus axitinib|Subcutaneous injection of normal saline once every 3 weeks and oral axitinib 5 mg BID for continuous dosing
9803436|NCT04069143|Experimental|Part 1|
9947869|NCT01066169||Healthy volunteers|Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
9947870|NCT01066169||HIV-infected patients|HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1
9947871|NCT01066182|Experimental|DHA supplement|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
9947872|NCT01066182|Placebo Comparator|Sunflower oil capsule|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
9947873|NCT01066195|Experimental|gefitinib|
9947874|NCT01066195|Active Comparator|pemetrexed|
9947875|NCT01066208||WG classification|Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
9947876|NCT01066208||MPA classification|Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
9947877|NCT01066208||CSS classification|Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
9947878|NCT01066208||PAN classification|Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
9947879|NCT01066208||Control Classification|For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
9947880|NCT01066208||WG diagnostic|Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
9947881|NCT01066208||MPA diagnostic|Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
9947882|NCT01066208||CSS diagnostic|Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
9947883|NCT01066208||PAN diagnostic|Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
9947884|NCT01066208||Control diagnostic|Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
9947885|NCT01066208||GCA classification|Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
9947886|NCT01066208||TAK classification|Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
9947887|NCT01066208||GCA diagnostic|Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
9947888|NCT01066208||TAK diagnostic|Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
9947889|NCT01066221||Clostridium difficile patients|observational study
9947890|NCT01066234|Experimental|concurrent chemoradiotherapy|
9947891|NCT01066234|Active Comparator|chemotherapy only|
9947892|NCT01066247|Active Comparator|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
9947893|NCT01066247|Active Comparator|Morphine|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
9947894|NCT01066260|Experimental|Probiotic|
9947895|NCT01066260|Placebo Comparator|Placebo|
9947896|NCT01066273|Experimental|P-Stim device|Receiving the device that is activated
9947897|NCT01066286||core binding factor positive|core binding factor positive acute myeloid leukemia
9947898|NCT01066299|Experimental|oxitocin nasal spray|oxytocin nasal spray
9947899|NCT01066299|Placebo Comparator|placebo|inactive nasal spray
9947900|NCT01066312||Practitioners|Healthcare practitioners who either use, have used or do not use MMT in practice
9947901|NCT01066312||Testees|Healthy adults with no experience with MMT
9947902|NCT01066325|Experimental|NET|This arm will receive two 20-minutes sessions of NET 1 week apart. NET (Neuro Emotional Technique) is a non-invasive stress reduction technique.
9947903|NCT01066325|Active Comparator|Active Controls|This arm will receive two 20-minute sessions of stretching instructions 1 week apart.
9947904|NCT01066325|No Intervention|Inactive Controls|This arm will receive no intervention and no instructions.
9947905|NCT01066338||Normal karyotype|The patients were diagnosed as acute myeloid leukemia with normal karyotype.
9803437|NCT04069143|Experimental|Part 2|
9803438|NCT04069143|Experimental|Part 3|
9803439|NCT04067830|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
9803440|NCT04067830|Experimental|Arm II (RMT + usual care)|Patients use a power lung device to complete 3 sets of 15 RMT exercises over 30 minutes 6 days per week over 2-4 weeks for a minimum of 12 sessions prior to surgery. Patients also receive usual care consisting of attending physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
9803441|NCT04066309|Experimental|Abutment removal|At the time of surgery, customizable healing abutments will be placed on implants. These will be replaced by Pro PEEK Abutments 21 days later to placement of temporary prostheses (loading). The final abutments (Titanium Bases) and final prostheses will be inserted 2 months after loading.
9803442|NCT04066309|Experimental|Final abutment|The final abutments (Titanium Bases) will be placed at the time of the implant placement surgery and will stay at mouth during all period of the study. Temporary and final prosthesis will be placed on Titanium Bases.
9803443|NCT04062097||dabigatran-group|Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
9803444|NCT04062097||VKA-group|Patients under effective treatment with VKA and with intracranial hemorrhage.
9803445|NCT04052841|Experimental|MGD-thermal pulsation group|Undergo a 15-minute Lipiflow treatment lid hygiene, then receive topical eye drops for 3 months.
9803446|NCT04052841|Experimental|MGD-IPL group|Undergo 3 times intense pulsed light therapies for each 3 weeks, then receive topical eye drops for 3 months.
9803447|NCT04052841|Experimental|MGD-manual meibomian gland expression|Warm compresses and lid hygiene per day, lid massage up to four times per day for 15 minutes for 3 months. Then receive topical eye drops for 3 months.
9803448|NCT04052841|No Intervention|Normal health subject group|Normal health subject without intervention.
9803449|NCT04044274|Experimental|IOPstim|
9803450|NCT04040699|Experimental|KN026 combined with KN046|"KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.~KN046 is a PD-L1 - CTLA-4 bispecific antibody."
9803451|NCT04026009|Experimental|CDIFF Ag 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
9803452|NCT04026009|Placebo Comparator|Placebo 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
9803453|NCT04026009|Experimental|CDIFF Ag 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
9803454|NCT04026009|Experimental|CDIFF Ag + AS01B 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF Ag + AS01B adjuvant vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag + AS01B adjuvant vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
9803455|NCT04026009|Placebo Comparator|Placebo 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
9803456|NCT04021030|Experimental|Cognitive Behavioral Therapy (CBT)|
9803457|NCT04007874|Experimental|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
9803458|NCT04007874|Active Comparator|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
9803459|NCT04005079|Experimental|Treatment Group|2% pilocarpine and standard of care post op drops ( Prednisolone acetate and Ofloxacin)
9803460|NCT04005079|Active Comparator|Control Group|Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine
9801824|NCT01727336|Experimental|Dalantercept 0.6 mg/kg|Part 1 dose escalation arm 0.6 mg/kg dalantercept once every 3 weeks
9801825|NCT01727336|Experimental|Dalantercept 0.9 mg/kg|Part 1 dose escalation arm 0.9 mg/kg dalantercept once every 3 weeks
9801826|NCT01727336|Experimental|Dalantercept 1.2 mg/kg|Part 1 dose escalation arm 1.2 mg/kg dalantercept once every 3 weeks
9801827|NCT01727336|Experimental|Dalantercept 1.5 mg/kg|Part 1 dose escalation arm 1.5 mg/kg dalantercept once every 3 weeks
9801828|NCT01727414|Other|OROS-Methylphenidate and placebo for inattentive type pts|Children with ADHD-inattentive type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
9801829|NCT01727414|Other|OROS-Methylphenidate and placebo for combined type pts|Children with ADHD-combined type type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
9801830|NCT01727505|Active Comparator|Sequence A: Conventional-Volume Guarantee|This is a crossover study. Infants will be assigned to one of two sequences. Sequence A consists of a 24-hour period during which the infant receives conventional mechanical ventilation followed by a second 24 hour period during which the infant receives volume guarantee ventilation.
9801831|NCT01727505|Active Comparator|Sequence B: Volume Guarantee-Conventional|This is a crossover study. Infants will be assigned to one of two sequences. Sequence B consists of a 24-hour period during which the infant receives volume guarantee ventilation followed by a second 24 hour period during which the infant receives conventional mechanical ventilation.
9801832|NCT01727700|Placebo Comparator|Placebo|Matching Placebo Once-Daily
9801833|NCT01727700|Experimental|Aripiprazole 5 mg or 10 mg|Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
9801834|NCT01727700|Experimental|Aripiprazole 10 mg or 20 mg|Aripiprazole 10 mg 20 mg Immediate Release Once-Daily
9801835|NCT01727713|Experimental|Aripiprazole|Aripiprazole Immediate Release Once-Daily
9801836|NCT01727726|Placebo Comparator|Placebo + ADT|Matching Placebo and assigned ADT
9801837|NCT01727726|Experimental|Brexpiprazole + ADT|Brexpiprazole, flexible dose and assigned ADT
9801838|NCT01727726|Active Comparator|Seroquel XR + ADT|Seroquel XR, flexible dose and assigned ADT
9801839|NCT01727765|Experimental|Experimental|6 weeks of inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to up to 50% of pre-training maximal inspiratory mouth pressure and will be adapted weekly to reflect the improvement in inspiratory muscle strength
9801840|NCT01727765|Sham Comparator|Sham Comparator|6 weeks of sham inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to 5% of pre-training inspiratory mouth pressure throughout the 6 week period.
9801841|NCT01727791|Experimental|open label|
9801842|NCT01727895|Experimental|Beta-glucan|Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
9801843|NCT01727895|No Intervention|Control group|
9801844|NCT01728077|Experimental|Brivaracetam|At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
9801845|NCT01728116|Experimental|Device (EndoBarrier)|Device for glycemic control
9801846|NCT01728116|Sham Comparator|Sham Procedure|sham procedure
9801847|NCT01728194|Experimental|Escitalopram|Target dose 20mg for 12 weeks
9801848|NCT01728194|Other|Control|Non-psychiatric comparison participants.
9801849|NCT01728246|Experimental|Tramadol/Paracetamol (APAP)|
9801850|NCT01728246|Active Comparator|Non-Tramadol/APAP|
9801851|NCT01728324|Experimental|Randomised 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
9801852|NCT01728324|Experimental|Randomised 16-week arm|BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
9801853|NCT01728324|Experimental|Allocated 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)
9801854|NCT01728337|Active Comparator|Dysport and Xeomin|30 U of Dysport® was injected on the right side of the forehead and 12 U Xeomin® was injected on the left side of the forehead (dose-equivalence 2.5:1).
9801855|NCT01728337|Active Comparator|Xeomin and Dysport|30 U Dysport® was injected on the left side of the forehead and 12 U Xeomin® was injected on the right side of the forehead (dose-equivalence 2.5:1).
9801856|NCT01728376|Experimental|Daptomycin - 12 to 17 year olds|Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
9801857|NCT01728376|Active Comparator|Comparator - 12 to 17 year olds|Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
9803461|NCT04004611|Experimental|Mirikizumab Dose 1|Mirikizumab administered intravenously (IV) and Subcutaneously (SC). Participants >40 kilograms (kg)
9803462|NCT04004611|Experimental|Mirikizumab Dose 2|Mirikizumab administered IV and SC. Participants ≤40 kg
9803463|NCT04004611|Experimental|Mirikizumab Dose 3|Mirikizumab administered IV and SC. Participants ≤40 kg
9528828|NCT03207165|Active Comparator|Left ventricular [LV] +/- Biventricular dysfunction|Assessment of left ventricular [LV] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
9801858|NCT01728376|Experimental|Daptomycin - 7 to 11 year olds|Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
9801859|NCT01728376|Experimental|Daptomycin - 1 to 6 year olds|Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
9801860|NCT01728376|Active Comparator|Comparator - 7 to 11 year olds|Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
9801861|NCT01728376|Active Comparator|Comparator - 1 to 6 year olds|Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
9801862|NCT01728454|Placebo Comparator|Placebo|Following the Stage 1 no treatment baseline assessment period, placebo matching capsules, orally, once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 milligrams (mg)/day separated by an off-drug interval (ODI) in Stage 3.
9801863|NCT01728454|Experimental|Telapristone acetate 6 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
9801864|NCT01728454|Experimental|Telapristone acetate 12 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 12 mg capsules, orally once daily for 18 weeks. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 mg/day separated by an ODI in Stage 3.
9801865|NCT01728584|Experimental|Standard NMB and Standard Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted Train of Four [TOF] ratio of 10%)/Standard insufflation pressure (starting pressure of 12 mmHg).
9801866|NCT01728584|Experimental|Standard NMB and Low Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted TOF ratio of 10%)/Low insufflation pressure (starting pressure of 8 mmHg).
9801867|NCT01728584|Experimental|Deep NMB and Standard Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Standard insufflation pressure (starting pressure of 12 mmHg).
9801868|NCT01728584|Experimental|Deep NMB and Low Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Low insufflation pressure (starting pressure of 8 mmHg).
9801869|NCT01728623|Experimental|E7080|
9801870|NCT01728636|Experimental|Tranexamic Acid|Tranexamic acid 10mg/kg loading dose given pre-incision and 1mg/kg/hr infusion throughout intraoperative period
9801871|NCT01728636|Placebo Comparator|Placebo|Normal saline placebo loading dose 0.5ml/kg and infusion at 0.5ml/kg/hr throughout operative course
9801872|NCT01728779|Experimental|Nelfinavir w/Stereotactic Body Radiation Therapy (SBRT)|Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
9801873|NCT01728792|Experimental|Group 1: TDV SC_2 Doses Day 0|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous (SC) injection, one dose in each arm, Day 0 using a needle/syringe.
9801874|NCT01728792|Experimental|Group 2: TDV IM_2 Doses Day 0|TDV, 0.5 mL, intramuscular (IM) injection, one dose in each arm, Day 0 using a needle/syringe.
9801875|NCT01728792|Experimental|Group 3: TDV IM_2 Doses Days 0 and 90|TDV, 0.5 mL, IM injection, one dose on Day 0 and one dose on Day 90 using a needle/syringe.
9801876|NCT01728792|Experimental|Group 4: TDV SC_2 Doses Day 0|TDV, 0.5 mL, SC injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
9801877|NCT01728792|Experimental|Group 5: TDV IM_2 Doses Day 0|TDV, 0.5 mL, IM injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
9801878|NCT01728805|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
9801879|NCT01728805|Active Comparator|Vorinostat|vorinostat 400 mg once daily
9801880|NCT01728844|Active Comparator|beta-tricalcium phosphate alone|beta-tricalcium phosphate alone
9801881|NCT01728844|Experimental|GFeBGS 0.1%|GFeBGS consisting of beta-tricalcium phosphate + 0.1% recombinant human basic fibroblast growth factor (rh-bFGF)
9801882|NCT01728844|Experimental|GFeBGS 0.3%|GFeBGS consisting of beta-tricalcium phosphate + 0.3% rh-bFGF
9801883|NCT01728844|Experimental|GFeGBS 0.4%|GFeBGS consisting of beta-tricalcium phosphate + 0.4% rh-bFGF
9801884|NCT01729026|Experimental|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
9801885|NCT01729026|Active Comparator|Wait-list, Then Adoption after 3 Months|After 3 months on a wait-list, Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
9801886|NCT01729039|Experimental|gaze stability|standard balance rehabilitation plus vestibular-specific exercises
9801887|NCT01729039|Placebo Comparator|control|standard balance rehabilitation plus placebo eye exercises
9801888|NCT01729156|Other|Healthy controls|Healthy controls receiving 1000 mg metformin twice daily for 3 months
9801889|NCT01729156|Placebo Comparator|Placebo|Placebo
9801890|NCT01729156|Active Comparator|Metformin|"Metformin Sandoz, 1000 mg twice daily for 3 months"
9801891|NCT01729208|Experimental|Dual Focus Soft Contact Lens|Dual Focus Soft Contact Lens
9801892|NCT01729208|Placebo Comparator|Single Vision Soft Contact Lens|Single Vision Soft Contact Lens
9801893|NCT01729247||FeNO|Participants with asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
9801894|NCT01729338|Experimental|Velcade, cyclophosphamide, Revlimid|"INDUCTION (28-day cycles for 8 cycles):~VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15~Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15~Dexamethasone 40 mg PO days 1,8 and 15~MAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):~Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21~Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15"
9801895|NCT01729494|Experimental|Group A|Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
9801896|NCT01729494|Experimental|Group B|Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
9801897|NCT01729494|Active Comparator|Group C|Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
9801898|NCT01729559|Experimental|5000 Units unfractionated Heparin Q 8 hr|Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
9801899|NCT01729559|Active Comparator|30mg enoxaparin Q12 hr|Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
9801900|NCT01729598|Experimental|Valproic Acid|Valproic acid 250 mg or 500mg by mouth twice daily.
9801901|NCT01729598|Placebo Comparator|Placebo|Placebo capsule by mouth twice daily.
9801902|NCT01729728|Experimental|Tapentadol|
9801903|NCT01729819|Experimental|Combination|Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
9801904|NCT01729819|Active Comparator|Tolterodine|Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
9801905|NCT01729845|Experimental|Treatment (decitabine, MEC)|"Patients receive decitabine IV on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).~INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy."
9801906|NCT01729871|Experimental|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
9801907|NCT01729871|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
9476401|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
9801908|NCT01729923|Experimental|Treatment (capecitabine, celecoxib, radiation therapy)|"Patients proceed to surgery, radiation therapy with ADAPT therapy followed by maintenance ADAPT therapy, or ADAPT therapy. Eligible patients undergo surgical resection at baseline or upon achievement of resectable disease after radiation therapy.~RADIATION + ADAPT: Patients undergo radiation therapy 5 days per week and receive capecitabine PO BID and celecoxib PO BID 5 days per week during radiation.~ADAPT: Patients receive capecitabine PO BID on days 1-14 and celecoxib PO BID on days 1-21. Courses repeat every 21 days for up to 3 years in the absence of disease progression or unacceptable toxicity."
9801909|NCT01730040|Active Comparator|Atorvastatin 40 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
9801910|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
9947906|NCT01066351|Experimental|Erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
9947907|NCT01066351|Placebo Comparator|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
9947908|NCT01066377|Experimental|Prebiotic and probiotic mix|Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested). Probiotic: 10^8 - 10^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
9947909|NCT01066377|Placebo Comparator|Maltodextrin/milk powder|
9947910|NCT01066403|Experimental|Pergolide|Patients will be randomly assigned to a sequence of treatments of either pergolide or placebo p.o. under continuous concomitant atypical neuroleptic therapy (stable at least 2 weeks prior trial begin).
9947911|NCT01066416|Placebo Comparator|Medical therapy|Patients undergo surgery 6 months after randomization
9947912|NCT01066416|Experimental|Surgery|Patients undergo surgery at time of randomization
9947913|NCT01066429|No Intervention|Poor prognosis DLBCL|Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3
9947914|NCT01066442|Experimental|BF2.649 ( Pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
9947915|NCT01066442|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
9947916|NCT01066468|Experimental|Gleevec/Glivec|
9947917|NCT01066481|Experimental|PF-01913539 5 mg three times daily|PF-01913539 5 mg three times daily for 6 months
9947918|NCT01066481|Experimental|PF-01913539 20 mg three times daily|PF-01913539 20 mg three times daily for 6 months
9947919|NCT01066481|Placebo Comparator|Placebo|Placebo three times daily for 6 months
9947920|NCT01066494|Experimental|Single-arm|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
9947921|NCT01066507||Breast cancer|Slides containing breast cancer paraffin embedded tissue sections.
9947922|NCT01066533|Experimental|Mineral Trioxide Aggregate(MTA)|MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
9947923|NCT01066533|Experimental|NEC cement|NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.
9947924|NCT01066559|Experimental|High flux polymethylmetacrylate membrane|
9947925|NCT01066559|Active Comparator|Polysulfone membranes|
9947926|NCT01066572|Experimental|Lisinopril|Experimental
9947927|NCT01066572|Placebo Comparator|Placebo|Placebo Comparator
9947928|NCT01066598|Experimental|Rituximab plus prednisone|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d Treat 61 Patients
9947929|NCT01066611|Active Comparator|1|CAL-263
9947930|NCT01066611|Placebo Comparator|2|Placebo
9947931|NCT01066650|Active Comparator|Endeavor Resolute|
9947932|NCT01066650|Active Comparator|Xience V|
9947933|NCT01066663|Experimental|Pyrimethamine|Single daily oral 50 mg dose.
9947934|NCT01066676|Experimental|Dexibuprofen|Dexibuprofen 400 mg powder for oral suspension
9947935|NCT01066676|Active Comparator|Ibuprofen|Ibuprofen 400 mg powder for oral suspension
9947936|NCT01066689|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
9947937|NCT01066689|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
9947938|NCT01066702|Experimental|NeoCart|Autologous cartilagenous tissue implant
9947939|NCT01066702|Active Comparator|Microfracture|surgical intervention
9947940|NCT01066715|Placebo Comparator|Placebo|
9947941|NCT01066715|Experimental|XOMA 052|
9947942|NCT01066728|Active Comparator|Theophylline|Oral loading dose of 6 mg per kilogram of body weight of theophylline followed by a maintenance dose of 2 mg per kilogram every 8 hours plus room air by nasal prongs at 0.5 l/min for 3 days.
9947943|NCT01066728|Experimental|CO2 inhalation|Equivalent loading and maintenance volume of oral normal saline plus CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
9801911|NCT01730040|Experimental|Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
9947944|NCT01066741|Experimental|Homeodent®|Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.
10004534|NCT01577134|Other|Passive control intervention|Waiting-list control group, who receives all information (that the active groups got) via mail after completion of 8.5 months follow-up.
10004535|NCT01577147|Other|sample collection|Ovulation prediction products provided to aid conception
10004536|NCT01577199|Active Comparator|High dose gonadotropins|High dose gonadotropins protocol compared to Low-dose Clomiphene
10004537|NCT01577199|Experimental|Low-dose Clomiphene|clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins
10004538|NCT01577212|Experimental|Individualized dose escalation|Individualized dose escalation on the basis of the dose to the organs at risk.
9801912|NCT01730040|Active Comparator|Atorvastatin 80 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
10004539|NCT01577225|Experimental|OPSITE Post-Op Visible|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Dressing should be used right after surgery and changed as needed.
10004540|NCT01577225|Active Comparator|Tape&Gauze|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.
10004541|NCT01577264||Cimzia treatment|
10004542|NCT01577290|Experimental|Mindfulness training|Group receives mindfulness training.
10004543|NCT01577290|Active Comparator|Discussion group|Group has access to a discussion group.
9801913|NCT01730040|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
10004544|NCT01577303|Experimental|CBM training program variant 1|Attention training towards positive cues using words as stimuli
9803465|NCT04002050|Active Comparator|CBTm Course Intervention|Participants placed in the intervention group will receive the CBTm Course. The CBTm Course consists of 5 classes, 90 minutes each, and held in-person on a weekly basis.
10004545|NCT01577303|Experimental|CBM training program variant 2|Attention training towards positive cues using words and faces as stimuli
10004546|NCT01577303|Experimental|CBM training program variant 3|Attention training towards negative using words as stimuli
10004547|NCT01577303|Experimental|CBM training program variant 4|Attention training towards negative using words and faces
10004548|NCT01577303|Experimental|Control training variant 1|Control training condition using words as stimuli
9801914|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
10004549|NCT01577303|Experimental|Control training variant 2|Control training condition using words and faces as stimuli
10004550|NCT01577316|Experimental|Pregnant Woman|Pregnant Woman
9947945|NCT01066741|Active Comparator|1.4 % Sodium Bicarbonate solution|"Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.~In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis."
9947946|NCT01066754|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets of Dr. Reddy's Laboratories Limited
9947947|NCT01066754|Active Comparator|Allegra|Allegra Tablets 180 mg of Aventis Pharmaceuticals Inc.,
9947948|NCT01066767|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited
9947949|NCT01066767|Active Comparator|Allegra|Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,
9947950|NCT01066806|Experimental|high calcium diet|
9947951|NCT01066806|Active Comparator|normal calcium diet|
9947952|NCT01066845||Patients prescribed Adcirca|all patients prescribed Adcirca during study period
9947953|NCT01066858||Maternal/infant antepartum exposure|"HIV-infected women exposed to TDF during pregnancy~Infants of HIV-infected women exposed to TDF during pregnancy"
9947954|NCT01066858||Maternal/infant postpartum exposure|"HIV-infected women exposed to TDF while breastfeeding~Infants of HIV-infected women exposed to TDF while breastfeeding"
9947955|NCT01066858||Maternal/infant antepartum no exposure|"HIV-infected women not exposed to TDF during pregnancy~Infants of HIV-infected women not exposed to TDF during pregnancy"
9947956|NCT01066858||Maternal/infant postpartum no exposure|"HIV-infected women not exposed to TDF during breastfeeding~Infants of HIV-infected women not exposed to TDF during breastfeeding"
9947957|NCT01066884|Experimental|1|
9947958|NCT01066910|Experimental|Parent-only|
9947959|NCT01066910|Active Comparator|Parent and child|
9947960|NCT01066949|Active Comparator|Support and discussion|The Support and Discussion protocol will consist of two integrated components: (a) brief educational materials presented at the start of each session, and (b) group leader facilitated discussion following presentation of the educational materials.
9947961|NCT01066949|Experimental|Behavioral Self management|Self-Regulation group sessions will be generally highly leader-directed though participants will be regularly encouraged to share their experiences dealing with the dialysis regimen. A consistent attempt will be made to focus all group discussion on self-regulatory principles as they relate to treatment adherence.Session material utilized by group-leaders will be highly structured and detailed across the seven sessions.
9947962|NCT01066962|Active Comparator|darunavir/r + tenofovir/emtricitabine|
9947963|NCT01066962|Experimental|darunavir/r + raltegravir|
9947964|NCT01066975||young and fit|5 healthy subjects, age lower than 30 yrs and high physical fitness
9947965|NCT01066988|Other|Right Eye|ORB Ocular Emulsion or SootheXP
9947966|NCT01066988|Other|Left Eye|ORB Ocular Emulsion or SootheXP
9947967|NCT01067001||2 Way Crossover|2 Way Crossover bioequivalence study
9947968|NCT01067001||Subjects will be randomly divided in to 2 groups.|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.
9947969|NCT01067014||iO-Flex|
10004551|NCT01577316|Experimental|Nonpregnant women|2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
10004552|NCT01577342|Active Comparator|Moxifloxacin 0.5%|1 drop four times daily for 3 days in affected eye post intravitreal injection
10004553|NCT01577342|No Intervention|No antibiotic use|
9947970|NCT01067053|Experimental|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
9947971|NCT01067066|Experimental|TPI 287 + Temodar|Starting dose of TPI 287 90 mg/m^2 IV on Days 1, 8, 15 + Temozolomide (Temodar) PO at 85 mg/m^2 on Days 1-5.
9947972|NCT01067079||Arm 1|
10004554|NCT01577355|Experimental|[C14]-LY2784544|Single 30 mg oral dose containing 100 micro curies of LY2784544
10004555|NCT01577368|Experimental|Piperacillin continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours
9476402|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
9476403|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
9476404|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
10004556|NCT01577368|Active Comparator|Piperacillin intermittent infusion|Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours
10004557|NCT01577394|Experimental|Early stage of dementia|oculomotor measurements
10004558|NCT01577407|Experimental|Nefopam|
9947973|NCT01067092|Experimental|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
10004559|NCT01577407|Placebo Comparator|placebo|
10004560|NCT01577420|Experimental|Group A|Reflexology Sessions: One session per week performed by certified reflexologist for four consecutive weeks.
10004561|NCT01577420|Placebo Comparator|Group B|Placebo Sessions: One session per week performed by research aide for four consecutive weeks.
10004562|NCT01577420|No Intervention|Group C|Control; no foot sessions
10004563|NCT01577433||Control Group|Historical control HeartMate II BTT and DT data
10004564|NCT01577433||Prospective and Retrospectively identified SSI|Prospectively and Retrospectively identified HeartMate II patients where the full length of the velour coated portion of the driveline is tunneled under the skin
10004565|NCT01577446|Experimental|CRT|The CRT group undergoes implantation of a CRT defibrillator
9947974|NCT01067092|Active Comparator|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
9947975|NCT01067118|Active Comparator|Humalog U-100 Insulin|
9947976|NCT01067118|Experimental|LINjeta U-100|
9947977|NCT01067131|Experimental|PEV7C1, intravaginal|Vaccine containing virosomes intravaginally applied
9947978|NCT01067131|Placebo Comparator|PEV7C9, placebo, intravaginal|Placebo vaccine (excipient only) intravaginally applied
9947979|NCT01067131|Experimental|PEV7B2, intramuscular low dose|Intramuscular vaccine low dose of antigen
9947980|NCT01067131|Experimental|PEV7B1, intramuscular high dose|Intramuscular vaccine, high dose of antigen
10004566|NCT01577446|No Intervention|no-CRT|The no-CRT group receives a dual-chamber defibrillator
9947981|NCT01067157|Other|A|"Other = Lifestyle intervention~A: Medical examination before and after inpatient therapy (clinic staff), questionnaires.~Further medical examination and questionnaires after 6 months, 1, 2, 5 and 10 years at home by pediatrics or general practitioner.~The lifestyle intervention includes an age-specific diet (1200-1800 kcal/d), 11 h/wk physical activity (walking, swimming, sports) and behavioural therapy."
9947982|NCT01067170|Experimental|Pneumatic compression stockings|
10004567|NCT01577459|Experimental|TR-701 FA with PSE|TR-701 FA 200 mg oral with PSE
10004568|NCT01577459|Placebo Comparator|TR-701 FA Placebo with PSE|TR-701 FA Placebo 200 mg oral with PSE
9947983|NCT01067183|Experimental|breathing and biofeedback device|This group of physicians were trained in the use of the relaxation breathing technique and the biofeedback device, and then used this portable stress reduction tool on a daily basis with twice weekly visits with the research team. After the 28 day RCT, they were invited to continue to use the device at their discretion during a trial extension from day 28-56 to see if any effect measured was maintained.
9947984|NCT01067183|No Intervention|control arm|This group did not undergo training in the breathing technique and use of the PSMD during the RTC trial day 0-28, but were visited twice weekly by the research team to collect outcome data. During the trial extension Day 28-56, this group did undergo a 1 hr training session with the PSMD and invited to use it at their discretion over the 28 days. Effectiveness outcome data (day 28-56) was collected at day 56.
9947985|NCT01067222|Experimental|BF2.649|
9947986|NCT01067222|Active Comparator|Modafinil|
9947987|NCT01067222|Placebo Comparator|Placebo|
9947988|NCT01067235|Experimental|BF2.649 + Modafinil placebo|
9947989|NCT01067235|Experimental|BF2.649 + Modafinil|
10004569|NCT01577472|Active Comparator|High Dose Clomiphencitrat|450 IU Merional® plus 100mg Serophene®
9476405|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
9476406|NCT03572101||Calgary Patient Cohort|Patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
9476407|NCT03572101||Calgary Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
9476408|NCT03572101||Edmonton Patient Cohort|Patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
9476409|NCT03572101||Edmonton Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
9476410|NCT03572088|Active Comparator|Terlipresssin|Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
9476411|NCT03572088|Placebo Comparator|Control|patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)
9476412|NCT03572075|Experimental|Group A|assessment of symptoms at the first medical examination; standard care protocol; pelvic floor physiotherapy; assessment of symptoms after four months
9476413|NCT03572075|Experimental|Group B|assessment of symptoms at the first medical examination; standard care protocol; assessment of symptoms after four months
9476414|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of >16 weeks.
9476415|NCT03572023|Active Comparator|MINOCA|"This group will include patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).~Integrative characterization of MINOCA patients:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
9476416|NCT03572023|Active Comparator|MI with coronary obstruction|"This group will include patients with myocardial infarction and obstructive coronary arteries.~Characterization of MI patients with coronary obstruction:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
9476417|NCT03572010|Placebo Comparator|FeFum fortified maize test meal|
9476418|NCT03572010|Placebo Comparator|FeSO4 fortified LNS|
10004570|NCT01577472|Active Comparator|Low Dose Clomiphencitrat|150 IU Merional® plus 100mg Serophene®
10004571|NCT01577472|Placebo Comparator|High Dose Placebo|450 IU Merional® plus Placebo
10004572|NCT01577472|Placebo Comparator|Low Dose Placebo|150 IU Merional® plus Placebo
10004573|NCT01577485|Experimental|Probiotic pastille|Test group
9801915|NCT01730040|Experimental|Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
9801916|NCT01730053|Active Comparator|Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
9801917|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
9801918|NCT01730053|Experimental|Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
9801919|NCT01730053|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
9801920|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
9801921|NCT01730053|Experimental|Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
9801922|NCT01730339|Active Comparator|Group 1|
9801923|NCT01730339|Active Comparator|Group 2|
9801924|NCT01730378|Experimental|Prepandrix Group|Subjects in this group received 2 doses of Prepandrix™ vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
9801925|NCT01730378|Active Comparator|Fluarix Group|Subjects in this group received 1 dose of Fluarix™ vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid region of non-dominant arm.
9801926|NCT01730534|Experimental|Dapagliflozin|Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
9801927|NCT01730534|Placebo Comparator|Placebo|Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
9801928|NCT01730586|Experimental|Abraxane|Abraxane 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
9801929|NCT01730729|Experimental|Treatment (cabergoline)|Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9801930|NCT01730846|Experimental|Doxazosin 4mg/day|doxazosin 4mg/day
9801931|NCT01730846|Placebo Comparator|Placebo|placebo control
9947990|NCT01067248||COPD, osteoporosis|The subjects are divided into 6 groups of 20 subjects each, I: COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients without osteoporosis based on T-score and without vertebral fractures, V: healthy controls with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls without osteoporosis based on T-score and without vertebral fractures.
9947991|NCT01067261|Experimental|TMNS and pelvic floor muscle training|This group will receive both the normal pelvic floor muscle training and the TMNS vibration therapy following their radical prostatectomy. Treatment with TMNS will start before the surgery and continue 6 weeks after the surgery.
9947992|NCT01067261|Active Comparator|Pelvic floor muscle training only|This group will receive the normal pelvic floor muscle training after prostatectomy only.
9947993|NCT01067274|Experimental|R1 Arm A : ATRA|"Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum~All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28"
10004574|NCT01577485|Active Comparator|Control pastille|Control group
9476419|NCT03572010|Placebo Comparator|FeSO4 supplement|
10004575|NCT01577511||30 Patients|"Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.~Intervention: Samples and follow up"
10004576|NCT01577524|Active Comparator|Diluted Povidone Iodine Solution|
9476420|NCT03572010|Placebo Comparator|FeSO4 fortified fruit juice|
10004577|NCT01577524|Placebo Comparator|Normal Saline Wash|
9947994|NCT01067274|No Intervention|R1 Arm B : no ATRA|Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum
9947995|NCT01067274|Experimental|R2 Arm 1A : AZACITIDINE and ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
9947996|NCT01067274|Experimental|R2 Arm 1B : AZACITIDINE and No ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
9947997|NCT01067274|Experimental|R2 Arm 2A : ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
9947998|NCT01067274|Experimental|R2 Arm 2B : no ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
9947999|NCT01067287|Active Comparator|Group 1|Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
9801932|NCT01730846|Experimental|Doxazosin 8mg/day|doxazosin 8mg/day
9948000|NCT01067287|Active Comparator|Group 2|Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
9948001|NCT01067300|Active Comparator|Double unit unrelated cord blood transplantation|Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
9948002|NCT01067300|Active Comparator|single unit unrelated cord blood transplantation|Transplantation of a single unrelated cord blood unit at least 24 hours after last chemotherapy
9948003|NCT01067313|Experimental|Dialyzer Ultraflux EMiC2|Dialyzer Ultraflux EMiC2 used in Continuous Hemodialysis
9948004|NCT01067313|Active Comparator|Dialyzer Ultraflux AV1000S|Dialyzer Ultraflux AV1000S used in continuous Hemofiltration
9948005|NCT01067365|Experimental|12.5 mg Androxal|12.5 mg Androxal daily
9948006|NCT01067365|Experimental|25 mg Androxal|25 mg Androxal daily
9948007|NCT01067378|Active Comparator|Expert instructor debriefing|Expert instructor debriefing
9948008|NCT01067378|Experimental|Peer-led debriefing|Peer-led debriefing
9948009|NCT01067391|Active Comparator|tadalafil 20 mg|Oral study medication to be administered once to each participant
9948010|NCT01067391|Placebo Comparator|placebo|oral study medication to be administered once to each study participant
9948011|NCT01067404||2008-09 study TIV recipients|Infants and toddlers who participated in earlier clinical trial (TITRE) to evaluate dosing (0.25mL versus 0.5mL) of trivalent influenza vaccine (TIV)
9948012|NCT01067417|Active Comparator|Hydroxychloroquine|
9948013|NCT01067417|Placebo Comparator|Placebo|
9948014|NCT01067430|Active Comparator|Etoricoxib 90 mg|Subject will take Etoricoxib 90 mg for 14 days
9948015|NCT01067430|Active Comparator|Diclofenac|Film coated tablet 50 mgs given three times a day for 14 days
9948016|NCT01067443|Experimental|Amb+SSG|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
9948017|NCT01067443|Experimental|Amb+Milt|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
9948018|NCT01067443|Experimental|Milt|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
9948019|NCT01067482||Glaucoma patients|
9948020|NCT01067482||Glaucoma suspect group|
9948021|NCT01067482||Normal population|
9948022|NCT01067495|Experimental|Exercise|
9948023|NCT01067547|Experimental|iron sulfate|Oral iron sulfate 300mg tid
9948024|NCT01067547|Active Comparator|intravenous iron sulfate|intravenous iron sulfate 300 mg
9948025|NCT01067599|Active Comparator|Low nicotine|Conventional smokeless tobacco product with 1) NNN plus NNK of <2 μg/gram and nicotine levels of >5 mg/g wet weight
9948026|NCT01067599|Active Comparator|Medium nicotine|Conventional smokeless tobacco product with ) NNN plus NNK of <2 μg/gram and nicotine levels of 3-5 mg/g wet weight.
9948027|NCT01067599|Active Comparator|High nicotine|Conventional smokeless tobacco product with NNN plus NNK of <2 μg/gram and nicotine levels of <3 mg/g wet weight
9948028|NCT01067625|Experimental|TOGA subjects|
9801933|NCT01730872|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
9801934|NCT01730872|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
9801935|NCT01730950|Active Comparator|Bevacizumab|Bevacizumab every 2 weeks
9801936|NCT01730950|Experimental|Bevacizumab + RT|Radiation therapy with bevacizumab every 2 weeks
9948029|NCT01067638|Experimental|tranexamic acid|Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft
9948030|NCT01067651|Active Comparator|Plaster of Paris (POP)|
9948031|NCT01067651|Active Comparator|semi-rigid fiberglass softcast (SRF, 3M Scotchcast)|
9948032|NCT01067664||Patients undergoing IVF with rFSH and GnRH antagonists|
9948033|NCT01067677|Experimental|Metoclopramide|rescue emetic therapy
9948034|NCT01067677|Experimental|Ondansetron|Rescue emetic therapy
9948035|NCT01067677|Experimental|Diphenhydramine|Rescue emetic therapy
9948036|NCT01067677|Placebo Comparator|Saline|Placebo
9948037|NCT01067703|Active Comparator|RIPC|
9948038|NCT01067703|Sham Comparator|CONTROL|
9948039|NCT01067742||Subjects with Mucolipidosis Type IV|
9948040|NCT01067755||Bronchoscopy, lung neoplasm|Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
9948041|NCT01067794||pemetrexed + platinum|Patients with pemetrexed + platinum doublet, with or without additional targeted agents
10004578|NCT01577550|Experimental|i.v. BI 655066|A subject to receive a single i.v. dose of BI 655066
9948042|NCT01067794||gemcitabine + platinum|Patients with gemcitabine + platinum doublet, with or without additional targeted agents
9948043|NCT01067794||taxanes + platinum|Patients with taxanes + platinum doublet, with or without additional targeted agents
9948044|NCT01067794||vinorelbine + platinum|Patients with vinorelbine + platinum doublet, with or without additional targeted agents
9948045|NCT01067794||others + platinum|Patients with other platinum-based doublet, with or without additional targeted agents
9948046|NCT01067807|Experimental|Proellex Formulation 1|25 mg Proellex Gelucire and PEG (original formulation)
9948047|NCT01067807|Experimental|25 mg Proellex Formulation 2|25 mg Proellex coated with MCC
9948048|NCT01067807|Experimental|25 mg Proellex Formulation 3|25 mg Proellex blended with MCC
9948049|NCT01067807|Experimental|50 mg Proellex Formulation 3|50 mg Proellex blended with MCC
9948050|NCT01067820|Experimental|RVX000222, 200 mg daily|
9948051|NCT01067820|Placebo Comparator|Placebo|
10004579|NCT01577550|Placebo Comparator|i.v. placebo|A subject to receive a single i.v. dose of placebo
10004580|NCT01577550|Experimental|s.c. BI 655066|A subject to receive a single s.c. dose of BI 655066
10004581|NCT01577550|Placebo Comparator|s.c. placebo|A subject to receive a single s.c. dose of placebo
10004582|NCT01577576||Upper-body athletes|This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
10004583|NCT01577576||Lower-body athletes|This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
10004584|NCT01577576||Sedentary volunteers|This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.
10004585|NCT01577589|Experimental|A|600 mg ceftaroline fosamil in 50 ml infusion volume
10004586|NCT01577589|Placebo Comparator|B|Placebo in 50 ml infusion volume
10004587|NCT01577589|Experimental|C|600 ceftaroline fosamil in 250 ml infusion volume
10004588|NCT01577589|Placebo Comparator|D|Placebo in 250 ml infusion volume
10004589|NCT01577589|Experimental|E|600 mg ceftaroline in 100 ml infusion volume
10004590|NCT01577589|Placebo Comparator|F|Placebo in 100 ml infusion volume
10004591|NCT01577602|No Intervention|Standard practice|
10004592|NCT01577602|Experimental|Printed list intervention|Providing patients a list of their current medications before they see medical assistant and begin their visit.
10004593|NCT01577602|Experimental|Open ended question intervention|"Medical assistants begin the medication review with a scripted, open ended question (i.e., tell me about your medications)"
10004594|NCT01577602|Experimental|Combined intervention|
10004595|NCT01577615|Experimental|Patterned Experience Group|Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
10004596|NCT01577615|No Intervention|Usual Care Group|In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.
10004597|NCT01577667|No Intervention|Conventional ventilation|Usual ventilation is administered according to the protocols implemented in the unit
10004598|NCT01577667|Experimental|Intellivent|"Intellivent is a ventilatory mode included in ventilator S1, Hamilton Medical. Intervention: the patient is ventilated with the same ventilator than in the conventionnal group; but the ASV-Intellivent ventilation has to be activated via a dedicated key on the ventilator screen.~IntelliVent® activation requires selecting the kind of patient: ARDS, COPD and whether hemodynamic instability exists.~The initial settings are IntelliVent® by default settings (% MV: 110%, PEEP: 5 cm H2O, FiO2: 60% - 100% in case of ARDS).~Therefore modification of these various parameters is automatic. FiO2 and PEP are modified according to SpO2; %MV according to EtCO2."
10004599|NCT01577680|Experimental|Moderate Hepatic Impairment|Approximately 9 subjects will complete each of these treatment arms
10004600|NCT01577680|Experimental|Matched Healthy Volunteers|Matched to the moderate hepatic impairment subjects based on gender, ethnicity, body mass index (+/-15%) and age (+/-5 years) Approximately 9 subjects will complete each of these treatment arms
10004601|NCT01577693|Experimental|0.5 mg novel dose form (test)|0.5 mg novel dose form (test)
10004602|NCT01577693|Other|0.5 mg Soft Gel Capsule|0.5 mg Soft Gel Capsule (reference)
10004603|NCT01577719|Active Comparator|Multimedia Lifestyle Improvement|Multimedia lifestyle intervention
9948052|NCT01067833|Placebo Comparator|Placebo|Placebo
9948053|NCT01067833|Experimental|Dose 1|K201
9948054|NCT01067833|Experimental|Dose 2|K201
9948055|NCT01067833|Experimental|Dose 3|K201
9948056|NCT01067898|Experimental|200 000 IU vitamin D3 every three months|
9948057|NCT01067898|Experimental|100 000 IU vitamin D3 every three months|
9948058|NCT01067898|Placebo Comparator|placebo every three months|
10004604|NCT01577719|Placebo Comparator|Usual Care|usual care
10004605|NCT01577771|Active Comparator|Child|1 dose of Prevnar13 at 2 to 4 years of age
10004606|NCT01577771|Experimental|Toddler 1 dose|Single dose of Prevnar13 at 12-15 months of age
9801937|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
9801938|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
9801939|NCT01731002|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|1 drop to study eye once daily
9801940|NCT01731041|Experimental|Ticagrelor 180mg|Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
9801941|NCT01731041|Active Comparator|Ticagrelor 90mg|Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).
9801942|NCT01731119|Experimental|Flexible Dose Latuda©|Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
9948059|NCT01067911|Active Comparator|1|In this study subjects will consume test meals containing vegetable oils (soy) and butter
9948060|NCT01067911|Active Comparator|2|In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
9948061|NCT01067911|Active Comparator|3|In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
9948062|NCT01067911|Active Comparator|4|In this study subjects will consume test meals containing vegetable oils (canola) and butter
9948063|NCT01067924|Experimental|Motivational interviewing|
9948064|NCT01067924|Active Comparator|Standard of care|
9948065|NCT01067950|Experimental|Isolated Pancreas Transplant|
9948066|NCT01067950|Active Comparator|Intensive Insulin Therapy|
9948067|NCT01067963|Experimental|Behavioral-education/counseling|"Computer assisted education and telephone counseling using motivational interviewing.~Computer assisted education and motivational interviewing"
9948068|NCT01067963|Placebo Comparator|Group talks/social chat|Group session talks on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
9948069|NCT01067989|Experimental|intervention|same treatment for all patients
9948070|NCT01068002||Control, normotensive, pregnancy|Control, normotensive, pregnancy
9948071|NCT01068002||hypertension, pregnancy, no treatment|hypertension, pregnancy, no treatment
9948072|NCT01068002||hypertension, pregnancy, drug treatment|hypertension, pregnancy, drug treatment
9948073|NCT01068015|Experimental|Intervention|This arm receives free circumcision service, POL intervention, intensive HIV counseling and intensive condom promotion.
9948074|NCT01068015|No Intervention|usual|This arm receives no extra HIV prevention services.
9948075|NCT01068028|Placebo Comparator|Placebo for ORM-12741|
9948076|NCT01068028|Experimental|ORM-12741|
9948077|NCT01068041|Placebo Comparator|A|Placebo
9948078|NCT01068041|Active Comparator|B|250mg active ingredient
9948079|NCT01068041|Active Comparator|C|500mg active ingredient
9948080|NCT01068041|Active Comparator|D|1000mg active ingredient
9948081|NCT01068054|Active Comparator|tacrolimus|Tacrolimus arm: active 0.1% tacrolimus eye ointment BID + placebo eye drops QID
9948082|NCT01068054|Active Comparator|cyclosporine|2% cyclosporine eye drops apply QID + placebo eye ointment apply bid
9948083|NCT01068067|Experimental|pharmacogenetics plus SchE guided dosing|
9948084|NCT01068067|Active Comparator|standard dosing|
9948085|NCT01068080||Myocardial fatty acid metabolism, Insulin resistance|"Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT.~Insulin resistance was evaluated by HOMA-IR."
9948086|NCT01068106|Active Comparator|BPLES|Biodegradable polymer limus-eluting stents
9948087|NCT01068106|Active Comparator|PPLES|Permanent polymer limus-eluting stent
9948088|NCT01068119|Experimental|Same-day discharge|Same-day discharge following PCI
9948089|NCT01068132|Experimental|1|Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
9948090|NCT01068145|Experimental|Very low dose SCH 527123|
9948091|NCT01068145|Experimental|Low dose SCH 527123|
9948092|NCT01068145|Experimental|Medium dose SCH 527123|
9948093|NCT01068145|Experimental|High dose SCH 527123|
9948094|NCT01068145|Placebo Comparator|Placebo to match SCH 527123|
9948095|NCT01068145|Experimental|Low dose SCH 527123 (Part 2)|
9948096|NCT01068145|Experimental|Medium dose SCH 527123 (Part 2)|
9948097|NCT01068145|Experimental|High dose SCH 527123 (Part 2)|
9948098|NCT01068145|Placebo Comparator|Placebo (Part 2)|
9948099|NCT01068171|Active Comparator|shoe, plain dressing|post-op shoe with plain occlusive dressing
9948100|NCT01068171|Active Comparator|shoe, collagen|post-op shoe with collagen dressing
9948101|NCT01068171|Active Comparator|boot, plain dressing|air boot with occlusive dressing
9948102|NCT01068171|Active Comparator|boot, collagen|air boot with collagen dressing
9948103|NCT01068171|Active Comparator|monitored air boot, plain dressing|air boot with retention strap to monitor whether boot is removed with occlusive dressing
9948104|NCT01068171|Active Comparator|monitored boot with collagen|air boot with retention strap to monitor whether boot is removed with collagen dressing
9948105|NCT01068184|Experimental|1|
9948106|NCT01068184|Placebo Comparator|2|
9948107|NCT01068197|Experimental|Low glycemic load dietary plan|"The subjects and their parents will be given instructions, and specific examples, to lower the glycemic load of their diets by replacing high-GI sources of carbohydrates with low-GI food sources, replacing energy from carbohydrate with energy from protein and fat, and attempt to balance meals and snacks with low-GI carbohydrate, proteins and low-fat food sources. The objective will be to achieve macronutrient composition for the low-GL diet of 45-50% low-GI carbohydrates, 20-25% protein, and 30-35% fat. All subjects will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized low-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
10004607|NCT01577771|Active Comparator|Toddler 2 dose|2 doses of Prevnar13 2 months apart beginning at 12-15 months of age
10004608|NCT01577771|Experimental|Infants 2+1|Infants receiving Prevnar13 at 6 weeks, 14 weeks and 9 months. Note: This infant immunization schedule is used in many European countries and in South Africa and has been shown to be immunogenic and effective. However, few head-to-head comparisons of the 2+1 and 3+0 schedules have been conducted.
10004609|NCT01577771|Active Comparator|Infants 3+0|Infants receiving Prevnar13 at 6, 10 and 14 weeks
9476421|NCT03571945|Active Comparator|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
9948108|NCT01068197|Active Comparator|Low fat diet|"For the low fat diet, subjects and their parents will be given instructions, and specific examples, to lower the fat content of their diet. The composition of the low-fat diet will be targeted to achieve 55-60% carbohydrates (with no discrimination by their glycemic index), 15-20% protein and 25-30% fat. All recruited children will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized high-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
9948109|NCT01068210|Experimental|Aerobic Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level. The exercise program will consist of three supervised sessions per week. During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
9948110|NCT01068210|Experimental|Resistance Training|A customized and supervised resistance exercise training program that will last 4 months (16 weeks). Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-60 minutes.
9948111|NCT01068210|Experimental|Combined Aerobic and Resistance Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above. At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-90 minutes.
9948112|NCT01068210|Active Comparator|Progressive Stretching Group (Attention-Control)|A customized and supervised progressive stretching program that will last 4 months (16 weeks). The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints. This program will consist of three exercise sessions a week. Each session will last approximately 30-60 minutes.
9948113|NCT01068223|Experimental|001|A:JNJ-39758979/Placebo #1 Single oral dose of JNJ-39758979 600 mg and Placebo
9948114|NCT01068223|Placebo Comparator|002|B: JNJ-39758979 Matching Placebo /Placebo #2 A single dose of 2 different Placebos JNJ-39758979 Matching Placebo and Placebo #2
9948115|NCT01068223|Active Comparator|003|C:Cetirizine/JNJ-39758979 Matching Placebo Single oral dose of 10mg cetirizine and JNJ-39758979 Matching Placebo
9948116|NCT01068236|Experimental|Healthy lifestyle intervention|lifestyle/weight-loss intervention for overweight (95th - 99th percentile) female adolescents (13-15 years of age at study entry) to a usual-care control condition. The intervention will be 20-sessions and combines group visits, individual telephone coaching calls, and tailored pediatric primary care providers (PCP) visits.
9476422|NCT03571945|Active Comparator|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
9948117|NCT01068236|No Intervention|Usual care|In the usual care control condition adolescents and their family will receive individualized feedback from the assessments as well as handouts outlining healthy means of maintaining / reducing weight for adolescents through improving nutrition and physical activity. In addition, these participants will be encouraged to seek any appropriate health care/education services available through Kaiser Permanente or in the community.
9948118|NCT01068275|Active Comparator|Lumbar plexus catheter|
9948119|NCT01068275|Active Comparator|femoral nerve catheter|
9948120|NCT01068275|Active Comparator|single-shot femoral block|
9948121|NCT01068288|Experimental|Expectant Management|Expectant Management
9948122|NCT01068288|Experimental|Operative management|Operative management
9948123|NCT01068301|Other|Second Allogeneic Transplant Procedure Recipient|"Participants with Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Non-Hodgkin lymphoma (NHL) with evidence of bone marrow disease, receiving a second allogeneic transplant procedure.~Intervention: Plerixafor"
9476423|NCT03571932||Intervention Facilities|Includes 18 health facilities
9476424|NCT03571932||Comparison facilities|Infludes 18 health facilities
9476425|NCT03571919|Placebo Comparator|Control|Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.
9476426|NCT03571919|Active Comparator|Lidocaine|Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.
9948124|NCT01068314|Experimental|Repetitive handgrip exercise|After baseline testing and randomization, subjects in this group are instructed to perform the intervention: daily repetitive handgrip exercise with upper arm compression band. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
9948125|NCT01068314|No Intervention|No arm exercise|Time control. Subjects do usual activities without any exercise intervention. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
9948126|NCT01068327|Experimental|Treatment (SRT, radiosensitizer, and chemotherapy)|See Detailed Description
9948127|NCT01068340||SBO Patients|Patients who develop small bowel obstruction requiring or not surgical intervention
9948128|NCT01068340||No SBO Patients|Patients who do not develop small bowel obstruction
9948129|NCT01068353|Placebo Comparator|Placebo|
9948130|NCT01068353|Experimental|Etanercept|
10004610|NCT01577784|Experimental|Pazopanib|800 mg / day of pazopanib in monotherapy
9948131|NCT01068379|Experimental|Cryopexy|the cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
9948132|NCT01068379|Experimental|laser photocoagulation 4 weeks after|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
9948133|NCT01068392|Experimental|OXP|Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.
9948134|NCT01068405|Experimental|Methotrexate|Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
9948135|NCT01068405|Placebo Comparator|Placebo|Patients with digital arthritis receiving placebo at 10mg/week during 12 months
9948136|NCT01068431|Active Comparator|trico bandage|Leg lymphedema stage 2-3
9948137|NCT01068431|Experimental|juxta fit compression device|leg lymphedema stage 2/3
9948138|NCT01068444|Experimental|Pioglitazone|Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
9948139|NCT01068444|Placebo Comparator|Placebo|Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
9948140|NCT01068457||PTPS|Patients with pain after VATS
9948141|NCT01068457||Pain free|Patients reporting no pain late after VAT
9948142|NCT01068470||patients with melanoma or kidney cancer|
9948143|NCT01068483|Experimental|BKM120|Dose escalation followed by dose expansion
9948144|NCT01068522|Experimental|ICP monitoring|Care based upon intracranial pressure.
9948145|NCT01068522|Active Comparator|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
9948146|NCT01068535||Women with Metabolic Syndrome|"Pre-menopausal women with Metabolic Syndrome~Age 35-50 and any 3 of the following:~Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL < 50mg/dL, Fasting glucose ≥ 100mg/dL but <126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure."
9948147|NCT01068535||Non-Metabolic Syndrome (healthy) women|"Non-Metabolic syndrome pre-menopausal women age 35-50~Body Mass Index ≤ 25~Regular menstrual cycles (occur every 24-35 days)~Fasting glucose < 100mg/dL~HDL-C ≥ 50mg/dL~Waist measurement ≤ 35 inches~Fasting triglycerides < 150mg/dL"
9948148|NCT01068561|Experimental|Test group|open-label study of retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200.
9948149|NCT01068574||Single Observational Cohort|
9948150|NCT01068587|Active Comparator|Erlotinib|
9948151|NCT01068587|Active Comparator|Foretinib plus Erlotinib|
9948152|NCT01068639||A|
9948153|NCT01068756|Other|Dapagliflozin/Rifampin|
9948154|NCT01068782|Experimental|Arm 1|
9948155|NCT01068782|Experimental|Arm 2|
9948156|NCT01068782|Experimental|Arm 3|
9948157|NCT01068782|Experimental|Arm 4|
9948158|NCT01068795|No Intervention|enoxaparin fixed|enoxaparin dosage will be fixed during pregnancy
9948159|NCT01068795|Experimental|enoxaparin adjusted|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
9948160|NCT01068808||Nonallergic rhinitis|Nonallergic rhinitis (negative skin prick test)
9948161|NCT01068834||KIF6 tested|Recruited subjects, completing a valid KIF6 test with results
9948162|NCT01068834||KIF6 test naïve|Database matched cohort not receiving a KIF6 test
9948163|NCT01068847|Experimental|1|Receives 2-4 of the drugs listed under Intervention
9948164|NCT01068886|No Intervention|no stent|no stent through pancreatic anastomosis
9948165|NCT01068886|Experimental|stent|stent through pancreatic anastomosis
9948166|NCT01068899||Children|healthy children
9948167|NCT01068899||Adult|healthy adults
9948168|NCT01068925|Experimental|ARM 1|"Arm 1:~GSK1349572 QD for 5 days (Treatment A)."
9948169|NCT01068925|Experimental|ARM 2|ARM 2: TPV/RTV 500/200mg BID (Treatment B).
9948170|NCT01068925|Experimental|ARM 3|ARM 3: GSK1349572 50mg QD and TPV/RTV 500/200mg BID (Treatment C).
9948171|NCT01068938||open angle glaucoma, glaucoma suspects|risk of progression, Latanoprost monotherapy
9948172|NCT01068951|Active Comparator|Mesenchymal stem cells|Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
9948173|NCT01068951|No Intervention|Control|
9948174|NCT01068977|Experimental|Stage I|
9948175|NCT01068977|Experimental|Stage II|
9948176|NCT01068977|Experimental|Stage III|
9948177|NCT01069016|Experimental|Sacral nerve modulation first|"Sacral nerve modulation is applied before the pudendal nerve stimulation. There is no wash-out period (pause) between the two treatments."
9948178|NCT01069016|Experimental|Pudendal nerve stimulation first|"Pudendal nerve stimulation is applied before the sacral nerve modulation. There is no wash-out period (pause) between the two treatments."
9948179|NCT01069029||Combined surgery|Patient which underwent combined surgery of MH and cataract extraction
9948180|NCT01069029||Successive surgery|Patients which underwent the two successive procedures
9948181|NCT01069042|Active Comparator|preserved LVEF under ACEi treatment|preserved LVEF under ACEi treatment
9948182|NCT01069042|Experimental|Poor LVEF group|Poor LVEF under ACEi treatment
9948183|NCT01069055|Placebo Comparator|Placebo Control|Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
9948184|NCT01069055|Active Comparator|Lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
9948185|NCT01069055|Active Comparator|Paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
9948186|NCT01069081|Active Comparator|arm A|docetaxel and cisplatin chemotherapy
9948187|NCT01069081|Experimental|arm B|docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
9948188|NCT01069081|Experimental|arm C|docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.
9948189|NCT01069094|Experimental|progenta 12.5 mg|Progenta (CDB-4124) 12.5 mg capsule
9948190|NCT01069094|Experimental|progenta 25 mg|Progenta (CDB-4124) 25 mg capsule
9948191|NCT01069094|Experimental|progenta 50 mg|Progenta (CDB-4124) 50 mg capsule
9948192|NCT01069094|Active Comparator|Lucron Depot|Lucron Depot, Leuprolide acetate for depot suspension
9948193|NCT01069094|Placebo Comparator|placebo|Placebo capsule
9948194|NCT01069107|Active Comparator|Consume of health services|One year follow-up of patients randomized to two different levels of health care
9948195|NCT01069133|Experimental|Rifaximin|
9948196|NCT01069146|Experimental|Mild therapeutic hypothermia|Sepsis treatment according to standard guidelines plus mild therapeutic hypothermia
9476427|NCT03571906|Experimental|Pre-rehab intervention|"Subjects in the prehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.~Periodic encouragements and consultations will be provided by exercise trainer, physiologist and nurse from the cardiac rehabilitation center. A physician will be available for consultations.~In addition to monitored physical activity, patients will receive nutritional and psychological counseling. This is part of a multi-professional rehabilitation program accepted by the rehabilitation center."
9948197|NCT01069146|No Intervention|Control|Sepsis treatment according to standard guidelines
9948198|NCT01069159|Active Comparator|Propranolol|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
9948199|NCT01069159|Placebo Comparator|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
9476428|NCT03571906|No Intervention|pre-operative usual care arm|"The control group will receive recommendations for a healthy and active lifestyle and physician follow-up~All subjects will undergo a stress test at baseline (post enrollment), and again prior to cardiac surgery."
9476429|NCT03571893|Experimental|Weight Watchers Freestyle (Flex)|Participate in Commercially Available behavioral weight loss program delivered by Weight Watchers International in the community
9476430|NCT03571893|Active Comparator|DIY Personal Plan|Receive informational resources for healthy lifestyle change to promote weight loss
9948200|NCT01069198|Experimental|Intervention group|
9476431|NCT03571880|Experimental|CNSLBP group|
9476432|NCT03571880|Active Comparator|Healthy control group|
9476433|NCT03571867||group Sugammadex|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 2 mg/kg iv sugammadex + 0.01 ml/kg saline in Group S
9476434|NCT03571867||group Neostigmine|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 0.02 mg/kg neostigmin+0.01 mg/kg atropine in Group N.
9948201|NCT01069198|Placebo Comparator|Non-intervention group|Non-intervention group will receive placebo following the same schedule as intervention group.
9948202|NCT01069211||ER expression : Low|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 3 or 4 point of total Allred score.
9948203|NCT01069211||ER expression : Intermediate|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 5 or 6 point of total Allred score.
9948204|NCT01069211||ER expression : High|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 7 or 8 point of total Allred score.
9948205|NCT01069224||RC tear|This study will include a consecutive series of patients who met the study inclusion criteria. Study group patients will be diagnosed RC tear on clinical examination and imaging findings (US and MRI) that will be verified at arthroscopy in order to complete the enrollment.
9948206|NCT01069224||Control group|Control group will include patients suffering from shoulder instability that scheduled for elective surgical repair.
9948207|NCT01069237||OPTI-FREE Replenish|Multi-Purpose Solution for soft contact lenses
9948208|NCT01069237||Clear Care|Lens Care Solution for contact lenses
9948209|NCT01069250||Brain injury|Patients after traumatic brain injury or spontaneous intracranial bleeding
9948210|NCT01069263|Active Comparator|Intravesical DMSO instillation|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
9948211|NCT01069263|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
9948212|NCT01069276||Patients with clinical signs of stroke|Patients with clinical signs of stroke
9948213|NCT01069302|Active Comparator|High loading and high maintenance|Clopidogrel loading 600mg and maintenance 150mg for 7days
9948214|NCT01069302|Active Comparator|High loading and low maintenance|Clopidogrel loading 600mg and maintenance 75mg for 7days
9948215|NCT01069302|Active Comparator|Low loading and high maintenance|Clopidogrel loading 300mg and maintenance 150mg for 7days
9948216|NCT01069302|Active Comparator|Low loading and low maintenance|Clopidogrel loading 300mg and maintenance 75mg for 7days
9948217|NCT01069328|Experimental|Arm 1|
9948218|NCT01069328|Experimental|Arm 2|
9948219|NCT01069328|Experimental|Arm 3|
9948220|NCT01069328|Experimental|Arm 4|
9948221|NCT01069328|Experimental|Arm 5|
9948222|NCT01069328|Experimental|Arm 6|
9948223|NCT01069367|Experimental|Arm:1|
9476435|NCT03571854|Experimental|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
9476436|NCT03571854|Active Comparator|Group VCV|Volume controlled ventilation
9948224|NCT01069393|Active Comparator|Standard DAFNE|Usual DAFNE course taught over 5 consecutive days in one week
9948225|NCT01069393|Experimental|DAFNE 5x1 day|DAFNE course taught 1 day a week for 5 consecutive weeks
9948226|NCT01069406||presence of uterine artery notch|patients with uterine artery notch during the 2nd and 3rd trimester
9948227|NCT01069432||Patients with CLL|Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
9948228|NCT01069432||Normal Volunteers|Normal volunteers who have no history of active or prior hematologic malignancy.
9948229|NCT01069445|Active Comparator|Diet advices|will receive the Optimal Diet for Elderly
9948230|NCT01069445|Experimental|Diet advices + VSL-3|will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
9948231|NCT01069445|Experimental|Diet advices + 5203-L|will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
9948232|NCT01069445|Experimental|Diet advices + Argan oil|will receive the Optimal Diet for Elderly + Argan oil
9948233|NCT01069458|Experimental|The High Protein Diet Group|The high protein diet (25% energy from protein, 55% energy from fat, 20% energy from carbohydrate) will be hypo-caloric and achieved by restricting the amount of sugar containing foods and drinks, reducing the intake of bread, rice, pasta, fruits and fruit-juices and increasing the intake of vegetables (instead of bread, rice, pasta and potatoes) and increasing the amounts of protein (from chicken, fish, and meat) and fat from oil and dressings for lunch and dinner and by choosing nuts and protein-rich yoghurts, egg, cheese, chicken wings, shellfish, fish and fish products as snacks.
9948234|NCT01069458|Active Comparator|The Low Fat Diet Group|The low fat diet (30% energy from fat, 20% energy from protein, 50% energy percent from carbohydrate) will be hypo-caloric and achieved by choosing low-fat diary and meat products, restricting amounts of visible fat and fatty snacks and increasing intake of whole meal bread, muesli, brown rice, whole meal pasta in the main meals and by choosing yoghurt with muesli, oat porridge with milk, fruits and hard bread with jam and soft gout-cheese as snacks.
9948235|NCT01069471|Experimental|HHD O1-EPA plus adjuvant|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
9948236|NCT01069471|Experimental|HHD O1-EPA|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
9948237|NCT01069471|Experimental|LHD O1-EPA adjuvanted|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
9948238|NCT01069471|Experimental|LHD O1-EPA|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
9948239|NCT01069497|Experimental|Intervention Nursing Homes|Comprising 24 nursing homes implementing a specific infection prevention program
9948240|NCT01069497|No Intervention|Usual care Nursing Homes|
9948241|NCT01069536|Active Comparator|2 minutes bolus infusion|
9948242|NCT01069536|Active Comparator|15 minutes slow infusion|
9948243|NCT01069549||subjects with diabetic nephropathy.|"Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.~Subject must be of north Indian origin.~Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study."
9948244|NCT01069549||Subjects without Diabetic nephropathy.|This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
9948245|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948246|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (2mg), CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948247|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (3mg), CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948248|NCT01069601|Experimental|transplanted adults|male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
9948249|NCT01069614|Experimental|Skin stretching device|Skin stretching device
9948250|NCT01069640|Experimental|URLC10-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948251|NCT01069640|Experimental|URLC10-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948252|NCT01069640|Experimental|URLC10-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948253|NCT01069653|Experimental|CDCA1-KIF20A-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948254|NCT01069653|Experimental|CDCA1-KIF20A-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
9948255|NCT01069653|Experimental|CDCA1-KIF20A-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
10004611|NCT01577797|Experimental|CBT-based text messages - Week 1 or 3|One week CBT-based text messages followed by a 1-week washout period (Week 2)
10004612|NCT01577797|Placebo Comparator|Placebo text messages - Week 3 or 1|
10004613|NCT01577823|No Intervention|No foley catheter|
10004614|NCT01577823|Active Comparator|Foley Catheter|
10004615|NCT01577849|Active Comparator|Vitamin D3|
10004616|NCT01577849|Experimental|DP-R206|
10004617|NCT01577862|Active Comparator|Colistin|Colistin alone, 2 million units every 8 hours intravenously or according to renal function
10004618|NCT01577862|Experimental|Colistin plus Rifampicin|Colistin, 2 million units every 8 hours intravenously or according to renal function, plus Rifampicin, 600 mg every 12 hours intravenously
10004619|NCT01577875|No Intervention|control group|histologic prediction only with the narrow band imaging (without magnification)
10004620|NCT01577875|Other|test group|histologic prediction with narrow band imaging plus magnification
10004621|NCT01577888|Experimental|Lithotripsy Treatment|Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
10004622|NCT01577914|Experimental|Carvedilol Tablets USP 12.5 mg|Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
10004623|NCT01577914|Active Comparator|Coreg®|Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
10004624|NCT01577927|Active Comparator|Usual home care|No assistance or care by PT.
10004625|NCT01577927|Experimental|PT-assisted home rehabilitation|Assisted home care is supported by a PT at least 2 times/month. Few brief educational lessons preceeded the training activity that the patient performs by himself at home.
10004626|NCT01577940|Experimental|Infusion of local anesthetic|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours.
10004627|NCT01577940|Placebo Comparator|Infusion of saline|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of saline 5 ml/h 24 hours.
10004628|NCT01577953|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
10004629|NCT01577953|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
9801943|NCT01731171|Experimental|Probiotic Supplement|The probiotic supplement compound will consist of capsules containing approximately 10^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
9801944|NCT01731171|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
9476437|NCT03571815|Experimental|fluoride varnish application|intervention; fluoride varnish application (with 5% Sodium fluoride varnish application on teeth)
9801945|NCT01731470|Experimental|Liposomes|Liposomes
9801946|NCT01731600|Experimental|N8-GP|
9801947|NCT01731678|Experimental|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
9801948|NCT01731691|Experimental|α1 Proteinase Inhibitor in HIV disease|α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
9801949|NCT01731691|Placebo Comparator|Placebo in HIV disease|Placebos weekly for 8 weeks
9801950|NCT01731691|No Intervention|Uninfected controls|Blood collection only for 8 weeks
9801951|NCT01731886|Active Comparator|Arm A|Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by steam cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
9801952|NCT01731886|Active Comparator|Arm B|Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
9801953|NCT01731912|Experimental|Treatment (degarelix acetate, EBRT)|Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
9801954|NCT01731938|Experimental|Fibrin Sealant (FS) Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
9801955|NCT01731938|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
9801956|NCT01731951|Experimental|Arm A: Imetelstat 9.4 mg/kg (Myelofibrosis [MF])|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 milligram per kilogram (mg/kg), intravenously (IV) as 2-hour infusion on Day 1 of each 21-day cycle in Core Phase up to 9 cycles. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
9801957|NCT01731951|Experimental|Arm B: Imetelstat 9.4 mg/kg as Induction + Maintenance (MF)|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 mg/kg, IV as 2-hour infusion on Days 1, 8, and 15 of 21-day cycle in Cycle 1 followed by 9.4 mg/kg on Day 1 of each 21-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
9476438|NCT03571815|Placebo Comparator|control group|application of water on teeth in the control group
9476439|NCT03571737|Active Comparator|Ibuprofen|Ibuprofen 800mg every 8 hours for 3 days
9476440|NCT03571737|Experimental|Ibuprofen & Lidocaine Patch 4%|Ibuprofen 800mg every 8 hours for 3 days and Lidocaine patch 4% 1 patch applied for 12 hours then removed for 12 hours, for 3 days
9476441|NCT03571711||Meropenem therapy in SBP|Patients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
9476442|NCT03571698|No Intervention|Exercise programme only|The treatment group received only exercise programme. The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
9801958|NCT01731951|Experimental|Arm D: Imetelstat 9.4 mg/kg (Blast-phase MF/Acute Myeloid Leukemia)|Participants with blast-phase myelofibrosis/acute myeloid leukemia (MF/AML) received imetelstat 9.4 mg/kg, IV as 2-hour infusion weekly on Days 1, 8, 15, 22 of a 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
9801959|NCT01731951|Experimental|Arm E: Imetelstat 7.5 - 9.4 mg/kg (MF [with Spliceosome Mutation or Ring Sideroblasts])|Participants with MF and spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
9801960|NCT01731951|Experimental|Arm F: Imetelstat 7.5 - 9.4 mg/kg (MF [without spliceosome mutation and ring sideroblasts])|Participants with MF without spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 9.4 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or imetelstat 7.5 mg/kg twice weekly on Days 1, 3 for 2 cycles of 28-day cycle (Cycles 3-4) followed by imetelstat 7.5 mg/kg 3-times-weekly on Days 1, 3, 5 of Cycles 5 and beyond of 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
9801961|NCT01731951|Experimental|Arm G: Imetelstat 7.5 - 9.4 mg/kg (MDS/MPN or MDS with Spliceosome Mutations or Ring Sideroblasts)|Participants with either myelodysplastic syndromes/ myeloproliferative neoplasm (MDS/MPN) or MDS and spliceosome mutations or ring sideroblasts present received 2 cycles of 28-day cycle (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
9801962|NCT01731990|Experimental|Canakinumab (ACZ885)|Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
9801963|NCT01731990|Placebo Comparator|Placebo|Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
9801964|NCT01732107|Experimental|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
9801965|NCT01732263|Experimental|SSP-004184 (Child-Pugh A Liver Impaired)|The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
9801966|NCT01732263|Experimental|SSP-004184 (Child-Pugh B Liver Impaired)|
9801967|NCT01732263|Experimental|SSP-004184 (Child-Pugh C Liver Impaired)|
9801968|NCT01732263|Experimental|SSP-004184 (Matched Healthy Subjects)|
9801969|NCT01732406||Acomegaly with Pegvisomant|Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
9801970|NCT01732406||Acromegaly with somatostatin analog|Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly
9801971|NCT01732406||Active Acromegaly|Patients not on drugs for treatment of acromegaly
9801972|NCT01732419|Experimental|Home-based training|"After the first three supervised training sessions in the hospitals, patients in the home-based training group are instructed to wear a heart rate monitor during exercise training at home. Prescribed exercise exists of two or three exercise sessions per week, of one hour at 70 - 85% of their maximum heart rate.~Once a week the heart rate data is uploaded and evaluated by an exercise specialist together with the patient by telephone."
9801973|NCT01732419|Active Comparator|Centre-based training|Patients in the centre-based training group will perform all trainings sessions under direct supervision of a physical therapist specialized in CR. Training sessions will be performed on an cycle ergometer, starting with a warm up phase of 5 min, followed by 50 min of cycling at 70-85% of the maximal HR and a cooling down period of 5 min. During the training period, physical therapists will record attendance, training duration and actual training intensity. After the 12-week training period patients receive individual advice from their physical therapist on physical activities.
9948256|NCT01069718||Clinical Group|In the Clinical group bottle feedings will be attempted by the bedside nurses, using techniques suggested in the feeding plan. The Infant Feeding Specialist will observe at least one feeding per day to assure that the feeding plan is being adhered to. If, in the judgment of the person feeding the infant, the infant is unable to complete the bottle feeding, the remaining volume will be given via an indwelling gavage tube. During all gavage feedings, both total and partial, infants will be offered a pacifier to suck on.
9948257|NCT01069718||NTrainer Group|"In the NTrainer group, three feedings per day will be given via gavage tube while the infant is receiving NTrainer stimulation. The stimulation will be done by alternating 3 minute epochs of NTrainer stimulation with 3 minutes of sucking on a regular pacifier, up to a total time of 30 minutes.~Every other day, 15 minutes prior to a feeding that is not one of the study sessions, each infant's suck strength and coordination will be measured using the NTrainer device in its NeoSuck RT Assessment mode.~On the day after the study intervention period is completed each infant will be assessed by an investigator unaware of the infant's study group assignment."
9948258|NCT01069731||Infants born at 30 to 36 weeks gestation|Infants will be considered eligible if they are born at 30 to 36 weeks gestation and have no exclusion criteria.
9948259|NCT01069744||Control Group|Control group When neonates are considered ready for oral feedings these feedings will be started with the standard oral feeding protocol for the NICU but without the NTrainer stimulation regimen described previously.
9948260|NCT01069744||NTrainer System|NTrainer Experimental Group When neonates are considered ready for oral feedings these feedings will be started simultaneously with the NTrainer therapy. Control and experimental interventions will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to quiet alert (NIDCAP state 3 or 4). Preterm infants in the experimental group will receive alternating 3-minute epochs of patterned oral somatosensory stimulation and null conditions using the NTrainer© during the tube (gavage) feeding session up to 4 times per day.
9948261|NCT01069757|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
9948262|NCT01069783|Experimental|A3309 low dose|
9948263|NCT01069783|Experimental|A3309 high dose|
9948264|NCT01069783|Placebo Comparator|Placebo|
9948265|NCT01069796|Experimental|Association bevacizumab paclitaxel capecitabine breast cancer|"bevacizumab 10 mg/kg in IV, D1 and D15~paclitaxel 80mg/m2 in IV, D1 to D8 and D15~capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3"
9948266|NCT01069809|Experimental|AGS-004|HIV-1 Immune Therapy
9948267|NCT01069809|Placebo Comparator|Inactive Injection|Inactive Placebo Injection
9948268|NCT01069822|Experimental|1|midazolam + AZD6765 IV solution
9948269|NCT01069822|Active Comparator|2|
9948270|NCT01069835||1|Non-small cell lung cancer patients
9948271|NCT01069848|Experimental|Vedera KXS|
9948272|NCT01069874|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
9948273|NCT01069874|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
9948274|NCT01069887||adult with hematological malignancies|
9948275|NCT01069887||pediatrics with hematological malignancies|
9948276|NCT01069887||pediatrics receiving stem cell transplant|
9948277|NCT01069887||adult receiving stem cell transplant|
9948278|NCT01069913|Active Comparator|BG00012|BG00012 Standard Formulation
9948279|NCT01069913|Active Comparator|BG00012 API|BG00012 API
9948280|NCT01069952|Experimental|Active DBS|Participants will receive deep brain stimulation.
9948281|NCT01069965|Experimental|6. BGP-15|400 mg BGP-15 + Placebo
9948282|NCT01069965|Experimental|5. BGP-15|200 mg BGP-15 BID
9948283|NCT01069965|Experimental|4. BGP-15|200 mg BGP-15 + Placebo
9948284|NCT01069965|Experimental|3. BGP-15|Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening
9948285|NCT01069965|Experimental|2. BGP-15|100 mg BGP-15 + placebo
9948286|NCT01069965|Experimental|1. Placebo|Placebo BID
9948287|NCT01069991|Experimental|Patient education group|Patient education program delivered to high school students with persistent asthma.
9948288|NCT01069991|Experimental|Wait list control group|Control students received no intervention until the one year follow up period was completed.
9948289|NCT01070004|Experimental|Blue light|Exposure to 460-nm monochromatic light (blue light)
9948290|NCT01070004|Experimental|Physical activity|15 minutes of physical activity at a low intensity
9948291|NCT01070017|Experimental|Intervention: DOT-HAART|Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART.
9801974|NCT01732445|Experimental|Supportive care (ruxolitinib phosphate and danazol)|Patients receive ruxolitinib phosphate PO BID and danazol PO TID on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.
9801975|NCT01732458|Experimental|Aprepitant Dose 1: Equivalent to 125 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 125 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered intravenously (IV) immediately prior to anesthesia.
9801976|NCT01732458|Experimental|Aprepitant Dose 2: Equivalent to 40 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 40 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
9801977|NCT01732458|Experimental|Aprepitant Dose 3: Equivalent to 10 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 10 mg in adults Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
9801978|NCT01732458|Active Comparator|Ondansetron|Pediatric participants in the control regimen are administered ondansetron IV on Day 1 immediately prior to induction of anesthesia plus a matching placebo dose to aprepitant as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia.
9801979|NCT01732471|Experimental|Kuvan®|
9801980|NCT01732484|Other|iMics1 NY-60|eyes with implantation of iMics1 NY-60 IOL
9801981|NCT01732484|Other|AcrySof SN60WF|eyes with implantation of AcrySof SN60WF IOL
9801982|NCT01732510|Experimental|Part 1: MK-8226 0.3 mg/kg|MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
9801983|NCT01732510|Experimental|Part 1: MK-8226 1 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
9801984|NCT01732510|Experimental|Part 1: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
9801985|NCT01732510|Experimental|Part 1: MK-8226 10 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
9801986|NCT01732510|Placebo Comparator|Part 1: Placebo (pooled)|Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
9801987|NCT01732510|Experimental|Part 2: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
9801988|NCT01732510|Placebo Comparator|Part 2: Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
9801989|NCT01732536|Experimental|S8 Sinus Implant|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
9801990|NCT01732536|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
9801991|NCT01732549|Experimental|Tasquinimod|1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
9801992|NCT01732549|Placebo Comparator|Placebo|1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
9801993|NCT01732588|Active Comparator|Regimen A - 120mg OZ439 PIB|120mg single dose of OZ439 as powder in bottle (PIB) formulation
9801994|NCT01732588|Experimental|Regimen B - 120 mg OZ439 IR caplet|120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
9801995|NCT01732588|Experimental|Regimen C - 120 mg OZ439 caplet via Enterion capsule|120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
9803466|NCT04002050|No Intervention|Comparison Group|Participants in the comparison group will not receive the intervention during the study, but will be offered intervention once the study has been completed (i.e. 3 month waiting-period). However, in the event that a stressful situation arises while a participant is placed in the comparison group, the participant may seek assistance from the usual mental health supports offered through their respective occupational organizations, EAP programs, and other programs in the community. Following completion of the study, participants in the comparison group will be invited to attend the CBTm Course.
9476443|NCT03571698|Active Comparator|Exercise with NMES standard electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with standard electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
9476444|NCT03571698|Active Comparator|Exercise with NMES large electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
9476445|NCT03571685|Experimental|Sustainable Early Episode Clinic Model of Care|The model of care given in the sustainable early episode clinic study, provides early intense intervention, with an ongoing maintenance phase in an outpatient setting.
9801996|NCT01732640|Experimental|Study Arm|Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
9801997|NCT01732692|Experimental|MOVIPREP (Morning-only dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
9801998|NCT01732692|Other|MOVIPREP (Split-dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.
9801999|NCT01732718|Experimental|Atorvastatin, then Placebo|Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks.
9802000|NCT01732718|Placebo Comparator|Placebo, Then Atorvastatin|Participants first received Placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. After a washout period of 4 weeks, they then received Atorvastatin 40 mg tablets once daily for 6 weeks.
9802001|NCT01732757|Active Comparator|Lastacaft®|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
9802002|NCT01732757|Active Comparator|Pataday™|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
9802003|NCT01732757|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
9802004|NCT01732770|Experimental|Denosumab 60 mg|Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
9802005|NCT01732770|Active Comparator|Zoledronic Acid 5 mg|Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.
9802006|NCT01732783||Metastatic Colorectal Cancer|Participants with wild-type RAS metastatic colorectal cancer who were receiving panitumumab in combination with chemotherapy.
9802007|NCT01732796|Experimental|Allocated 24 weeks BI 207127 + BI 201335|24 weeks of BI 207127 and BI 201335 in combination with Ribavirin
9802008|NCT01732796|Experimental|Randomized 16 weeks BI 7127+BI1335 + RBV|16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV
9802009|NCT01732796|Experimental|Randomized 24weeks BI 7127+ BI1335 + RBV|24 weeks of BI 207127and BI 201335 in combination with RBV
9802010|NCT05317520|Experimental|Intervention group|Cold vapor was applied 3 times in total at 0th,2nd and 6th hours.
9802011|NCT05317520|No Intervention|Control group|No cold vapor was applied at 0th,2nd and 6th hours.
9802012|NCT05317507|Experimental|Randomization order 1|Participants receive placebo at visit 1, 50 mg CBD at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
9802013|NCT05317507|Experimental|Randomization order 2|Participants receive placebo at visit 1, 100 mg CBD at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
9802014|NCT05317507|Experimental|Randomization order 3|Participants receive 50 mg CBD at visit 1, placebo at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
9802015|NCT05317507|Experimental|Randomization order 4|Participants receive 50 mg CBD at visit 1, 100 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
9802016|NCT05317507|Experimental|Randomization order 5|Participants receive 100 mg CBD at visit 1, 50 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
9802017|NCT05317507|Experimental|Randomization order 6|Participants receive 100 mg CBD at visit 1, placebo at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
9802018|NCT05317494||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
9948292|NCT01070017|No Intervention|No DOT-HAART|Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART.
9948293|NCT01070056|Active Comparator|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
9948294|NCT01070056|Experimental|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
9948295|NCT01070069|Active Comparator|Standard EVAR (IntuiTrak)|EVAR using standard vascular exposure for access
9948296|NCT01070069|Experimental|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
9948297|NCT01070069|Experimental|PEVAR (ProstarXL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
9948298|NCT01070082||Adult ICU patients undergoing procedure|
9948299|NCT01070108|Active Comparator|Set 1|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
9948300|NCT01070108|Active Comparator|set 2|2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
9948301|NCT01070108|Active Comparator|set 3|3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
9948302|NCT01070121||RA patients/participants|
9948303|NCT01070134|Experimental|Mindfulness-based Behavioural Therapy (MIBT)|
9948304|NCT01070134|Active Comparator|PT (psychodynamic therapy)|
9948305|NCT01070147|Experimental|Control|The control group will receive a paper-based printed asthma guideline.
9948306|NCT01070160||A|Women with PCOS initiating Metformin and exposure to vaginal progesterone for 6-8 days prior ro Endometrium Biopsy
9948307|NCT01070160||B|Women with PCOS not planning initiating Metformin and exposure to vaginal progesterone for 6-8 days prior to Endometrium Biopsy
9948308|NCT01070160||Women with PCOS who previously initiated metformin|Women with PCOS who initiated metformin at least 3 months prior to enrollment who have completed a 6-10 day course of progesterone
9476446|NCT03571659||two subthreshold parameters|5% and 15% duty cycle (DC)
9476447|NCT03571659||standard ETDRS|early treatment of diabetic retinopathy study
9948309|NCT01070186|Experimental|Treatment|See intervention descriptions
9948310|NCT01070199|Experimental|liquid to liquid,|
9476448|NCT03571620|Placebo Comparator|Vehicle|
9948311|NCT01070199|Experimental|liquid to solid,|
9948312|NCT01070199|Experimental|solid to liquid|
9948313|NCT01070199|Experimental|solid to solid|
9948314|NCT01070212|Experimental|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
9948315|NCT01070212|Experimental|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
9948316|NCT01070212|Experimental|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
9948317|NCT01070225|Experimental|Hydrocortisone and Propranolol|Participant administered 10 or 20mg propranolol orally. Participants meeting the parameters are randomised to receive 400mg Hydrocortisone intravenously. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered 500mcg Ipratropium Bromide via nebuliser; visit end
9948318|NCT01070225|Placebo Comparator|Placebo and propranolol|identical to other arm but participant receive placebo injection as opposed to hydrocortisone
9948319|NCT01070251|Active Comparator|Existing state-sponsored PA program|standard children-focused gym lessons approach
9948320|NCT01070251|Active Comparator|Participatory intervention plus state-sponsored PA program|Participatory parent-focused intervention over nine months in addition to state-sponsored PA program
9948321|NCT01070264|Experimental|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
9948322|NCT01070277|Placebo Comparator|Placebo arm|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
9948323|NCT01070277|Experimental|Tinidazole and Albendazole treatment|Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days
9948324|NCT01070290|Experimental|1|ARQ 197
9948325|NCT01070290|Active Comparator|2|Investigator's choice of oxaliplatin, capecitabine or irinotecan
9948326|NCT01070342||Chidren ages 6 to 18|Children ages 6 to 18 years will be available for participation in this multicenter study. Subjects will be enrolled from community based general pediatric clinics and other well-child care areas within participating hospitals and clinics of the four participating sites. Enrollment will continue until a total of 85 subjects from each age category (6-<12 years and ≥12- <18 years) successfully complete the study.
9948327|NCT01070355|Placebo Comparator|Placebo|2 capsules twice daily
9948328|NCT01070355|Active Comparator|Eicosapentaenoic acid free fatty acid|2g daily (2 x 500mg capsules twice daily)
9948329|NCT01070368|Experimental|Food challenge, skin test|Skin test by two extract commercial, and in-house extract. and open challenge with wheat (except in patient with history of wheat anaphylaxis: assume as challenge positive)
9948330|NCT01070407|Experimental|Arm A, group 1|4 volunteers
9948331|NCT01070407|Experimental|Arm A, group 2|4 volunteers
9948332|NCT01070407|Experimental|Arm A, group 3|5 volunteers
9948333|NCT01070407|Experimental|Arm B, group 5|4 volunteers
9948334|NCT01070407|Experimental|Arm B, group 6|4 volunteers
9948335|NCT01070407|Experimental|Arm B, group 7|5 volunteers
9948336|NCT01070407|Experimental|Arm C, group 9|5 volunteers
9948337|NCT01070407|Experimental|Arm C, group 10|5 volunteers
9948338|NCT01070407|Experimental|Arm C, group 11|4 volunteers
9948339|NCT01070420|Active Comparator|FFR via central venous line|
9948340|NCT01070420|Experimental|FFR via peripheral vein|
9948341|NCT01070446|Experimental|1|This study involves children with CF who will take a water soluble vitamin supplement of choline bitartrate, 2 gm per day with meals.
9476449|NCT03571620|Experimental|1.0% Q301 Cream|
9476450|NCT03571620|Experimental|1.4% Q301 Cream|
9948342|NCT01070459|Placebo Comparator|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
9948343|NCT01070459|Experimental|Aerobic exercise group|The patients continues their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heart rate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week training programme 4 information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
9948344|NCT01070459|Experimental|Follow-up first aerobic exercise group|
9948345|NCT01070459|Placebo Comparator|Follow-up control group|
9948346|NCT01070459|Experimental|Follow-up second aerobic exercise group|
9948347|NCT01070485|Experimental|Radium-223 dichloride (Xofigo, BAY 88-8223)|Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
9948348|NCT01070498|Experimental|Trichuris suis ova (TSO)|
9948349|NCT01070511|Experimental|Tadalafil|
9948350|NCT01070511|Placebo Comparator|Placebo|
9948351|NCT01070524|Experimental|CHF 5188 pMDI|
9948352|NCT01070524|Active Comparator|Budesonide extrafine pMDI|
9948353|NCT01070524|Active Comparator|Seretide(r) Evohaler(r)|
9948354|NCT01070563||Usual|CT angiography is performed 6 hours after the clinical diagnosis of brain death.
9948355|NCT01070563||TCD|When the diagnosis of brain death is made, TCD is performed and then every 2 hours until the flow patterns compatible with brain death are found. Then a CT angiography is performed.
9948356|NCT01070576||normal fracture healing|group in which normal fracture healing has occured
9948357|NCT01070576||atrophic|patients in which an atrophic non-union occured
9948358|NCT01070576||hypertrophic|patients in which a hypertrophic non-union occured
9948359|NCT01070589||Group 1: Obese|BMI>30
9948360|NCT01070589||Group 2: control|Group 2:Normal weight (BMI <25). age and gender matched.
9948361|NCT01070602|Experimental|anterior corneal incision|
9948362|NCT01070628|Experimental|Stalevo (levodopa/carbidopa/entacapone)|"125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.~150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively."
9948363|NCT01070628|Active Comparator|Sinemet (levodopa/carbidopa)|150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively
9948364|NCT01070641|Active Comparator|Carvedilol|Each patient will receive Carvedilol 12.5mg QD
9948365|NCT01070641|Active Comparator|Esophageal Variceal Band Ligation|Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
9948366|NCT01070654|Experimental|40/30 Recruitment Manoeuvre|Patients with respiratory failure that will be first ventilated for 30 minutes according to standardized baseline protective ventilation and after that will receive the recruitment manoeuvre
9948367|NCT01070667|Experimental|Dronedarone|Patients will receive 400 mg of dronedarone per day for 3 months.
9948368|NCT01070667|Placebo Comparator|Placebo|Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
9948369|NCT01070680|Active Comparator|dexmedetomidine|sedative medicine
9948370|NCT01070680|Placebo Comparator|sodium chloride 0,9%|
9948371|NCT01070706|Experimental|Paclitaxel, Gemcitabine, Sunitinib|Paclitaxel, Gemcitabine, Sunitinib
9948372|NCT01070719||Relapsing form of MS treated with natalizumab|Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.
9948373|NCT01070732|Experimental|Paracetamol|All patients will receive one single dose of 1000mg paracetamol.
9948374|NCT01070745|Experimental|Indomethacin for resistant PDA|Treatment with second course of indomethacin
9948375|NCT01070745|Experimental|Ibuprofen for resistant PDA|Ibuprofen as second course of therapy
9948376|NCT01070797|Experimental|Group A|Group A is for CMV seropositive donors.
9948377|NCT01070797|Experimental|Group B|Group B is for CMV seronegative donors.
9948378|NCT01070823||Relapsing Multiple Sclerosis|Participants receiving or considering treatment with Tysabri® (natalizumab).
9948379|NCT01070836||natalizumab|US participants with relapsing MS receiving commercial natalizumab
9948380|NCT01070849|Active Comparator|a) educational booklet|
9948381|NCT01070849|Active Comparator|b) IRENA|
9948382|NCT01070849|Experimental|c) RÜCKGEWINN|
9948383|NCT01070862|Experimental|thalidomide + dexamethasone|Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
9948384|NCT01070862|Active Comparator|Vincristin, Adriamycin, Dexamethasone|
9948385|NCT01070862|Experimental|thalidomide, melphalan, endoxan, dexamethasone|
9948386|NCT01070862|Active Comparator|melphalan, endoxan, dexamethasone (MCDex)|
9948387|NCT01070862|Experimental|Thalidomide, Dexamethasone|
9948388|NCT01070862|No Intervention|watch and wait|
9948389|NCT01070875|Active Comparator|UFH 5000 U three times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous three times a day.
9948390|NCT01070875|Active Comparator|UFH 5000 U two times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
9948391|NCT01070901||Organ transplant recipients|
9948392|NCT01070927|Experimental|cohort 1|
9948393|NCT01070927|Experimental|cohort 2|
9948394|NCT01070940|Placebo Comparator|Isotonic saline infusion|
9948395|NCT01070940|Active Comparator|Intravenous L-NMMA dose 2|
9948396|NCT01070940|Active Comparator|Intravenous L-NMMA dose 3|
9948397|NCT01070940|Active Comparator|Intravenous L-NMMA dose 1|
9948398|NCT01071005|Experimental|Test|Lorelin Depot - Bergamo
9948399|NCT01071005|Active Comparator|comparator|Lupron Depot® - Abbott
9948400|NCT01071018|Experimental|QOD Schedule|QOD Schedule, MK2206 every other day
9948401|NCT01071018|Experimental|QW Schedule|QW Schedule, MK2206 once weekly
9948402|NCT01071031|Experimental|Group 1|Low Dose HIV-v with water for injection
9948403|NCT01071031|Experimental|Group 2|Low Dose HIV-v with adjuvant
9948404|NCT01071031|Experimental|Group 3|High Dose HIV-v with water for injection
9948405|NCT01071031|Experimental|Group 4|High Dose HIV-v with adjuvant
9948406|NCT01071031|Placebo Comparator|Group 5|Control group: adjuvant only or water for injection only
9948407|NCT01071057|Active Comparator|Naloxone/morphine|Naloxone (12 µg/ml) mixed in a single infusion with morphine (1 mg/ml). The study solutions will be prepared by a pharmacist and diluted in saline to produce equal volumes to ensure proper blinding.
9948408|NCT01071057|Placebo Comparator|saline/morphine|Patients will be randomly assigned to one of two groups (Naloxone/morphine or saline/morphine) using computer-generated random numbers. On arrival to the PACU patients will be started on IV PCA and randomized study drug
9948409|NCT01071109|Experimental|Therapeutic Massage|
9948410|NCT01071109|No Intervention|No therapeutic massage|
9948411|NCT01071122|Experimental|Arm 1|
9948412|NCT01071122|Active Comparator|Arm 2|
9948413|NCT01071122|Active Comparator|Arm 3|
9948414|NCT01071135|Experimental|Quetiapine XR|
9948415|NCT01071148||Subgroup 1: Age < 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
9948416|NCT01071148||Subgroup 2: 42 > Age ≥ 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
9948417|NCT01071161|Experimental|Azithromycin|
9948418|NCT01071161|Placebo Comparator|Placebo|
9948419|NCT01071174|Placebo Comparator|Placebo Ring|Vaginal Ring containing no drug substance
9948420|NCT01071174|Experimental|Dapivirine Ring|Dapivirine Vaginal Ring 25mg
9948421|NCT01071187|Experimental|Varenicline|Treatment with varenicline with 0,5mg daily on day 1-3, 1mg daily on day 4-7 and 2mg daily on day 8-84.
9948422|NCT01071187|Placebo Comparator|Placebo|
9948423|NCT01071265|Placebo Comparator|Sham RIPC|Inflation of thigh pneumatic tourniquet to <15 mmHg
9948424|NCT01071265|Active Comparator|Active RIPC|300 mmHg inflation of thigh pneumatic tourniquet for three cycles of 5 minutes each with 5 minutes of no inflation between cycles.
9948425|NCT01071291|Experimental|Arm A|Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2
9948426|NCT01071291|Experimental|Arm B|Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2
9948427|NCT01071304|Experimental|All Participants|In Part 1, all participants received a single oral dose of 2 mg midazolam on Day -2. On Days 1-5, all participants received daily single oral doses of ridaforolimus 40 mg ( 4 x 10 mg tablets). On Day 5, all participants received a single oral dose of 2 mg midazolam coadministered with the dose of ridaforolimus. Participants had the option to continue into Part 2 of this study.
9948428|NCT01071369|Active Comparator|Xylocaine|0.5% Xylocaine
9948429|NCT01071369|Active Comparator|Xylocaine and Celestone|0.5% Xylocaine with 6 mg of non-particulate Celestone.
9948430|NCT01071408|Experimental|Stroke Prevention Program + Usual Care|Stroke Prevention Care Program + Usual Care. The Stroke prevention care program is in addition, not a substitute for usual care. Persons randomized to this arm are eligible to all care, including care by stroke specialists, while enrolled in the intervention.
9948431|NCT01071408|No Intervention|Usual care|
9948432|NCT01071421||Control Group (B): Other Infections|Other infections admitted to the hospital
9948433|NCT01071421||Community Acquired Pneumonia (Group A)|Patients admitted to hospital with Community Acquired Pneumonia defined by respiratory symptoms, fever and lung infiltrates
9948434|NCT01071447|Active Comparator|Rheumatologist-led clinic|Rheumatologist-led clinic: The subjects are seeing a rheumatologist after six months and after 12-months of intervention and have the possibility to contact the rheumatology clinic
9948435|NCT01071447|Experimental|Nurse-led clinic|The subjects are seeing a rheumatology nurse after six months and a rheumatologist after 12 months of intervention and have the possibility to contact the rheumatology nurse during the intervention.
9948436|NCT01071460|Other|SFA Stenting|
9948437|NCT01071473|Other|Exercise Group|Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
10004630|NCT01577979|Experimental|Reminder/Recall Strategy|The experimental group will consist of patients randomly selected from participating clinics. Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging. Text messages will be used to notify parents that their child is due for an immunization or well-care visit. Parents will be able to reply with one of three response options. Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method. The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
10004631|NCT01577979|No Intervention|Usual Care|The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
10004632|NCT01577992|Experimental|Group 1: MSA disease|determination of objective and subjective pain threshold before and after levodopa intake
10004633|NCT01577992|Experimental|Group 2: Parkinson disease|determination of objective and subjective pain threshold before and after levodopa intake
10004634|NCT01577992|Other|Group 3: healthy volunteers.|one determination of objective and subjective pain threshold without treatment
10004635|NCT01578018|Other|Lung Cancer|Diagnostic
10004636|NCT01578018|Other|Lung Disease|Diagnostic
10004637|NCT01578057|Experimental|tasimelteon + placebo ethanol|
10004638|NCT01578057|Experimental|ethanol + placebo tasimelteon|
10004639|NCT01578057|Experimental|tasimelteon + ethanol|
10004640|NCT01578057|Experimental|placebo tasimelteon + placebo ethanol|
9948438|NCT01071499|Active Comparator|1|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
9948439|NCT01071499|Active Comparator|2|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
9948440|NCT01071499|Active Comparator|3|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
9948441|NCT01071525|Active Comparator|Niacin|Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\Laropiprant.
9948442|NCT01071525|No Intervention|Control|Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.
9948443|NCT01071551|Experimental|Lifestyle and health promotion|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
9948444|NCT01071551|Active Comparator|Physical activity only|Children allocated to this group will attend physical activity classes only.
9948445|NCT01071564|Experimental|Treatment (RO4929097 and vismodegib)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO QD beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9948446|NCT01071629|Active Comparator|Combined interval and strength training|CHF Pts randomly designed at the combined interval and strength training group
9948447|NCT01071629|Active Comparator|Aerobic interval training|CHF Patients that randomly designed to participate at the interval training group
9948448|NCT01071642|No Intervention|continue ace-i and arb's versus dicontinue|
9948449|NCT01071642|Active Comparator|group b|
9948450|NCT01071642|Active Comparator|group c|
9948451|NCT01071655|Experimental|2|"Patients with zero favorable genotype: BVZ + XELIRI.~Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.~Patients with two favorable genotypes : BVZ + FUOX."
9948452|NCT01071655|Active Comparator|1|BVZ + XELOX
9948453|NCT01071668||GEM-2 Cohort|Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
9948454|NCT01071681||Group 1|
9948455|NCT01071694||Group 1|
9948456|NCT01071707||Confirmed Diagnosis of IPF|Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
9948457|NCT01071707||No diagnosis of IPF|Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
9948458|NCT01071720|Other|CKD-501 1mg (fed-fasted group)|CKD-501 1mg should be administered following a high-fat, high-caloric diet(fed condition) in one period and on an empty stomach(fasting condition) in the other period.
9948459|NCT01071720|Other|CKD-501 1mg (fasted-fed group)|CKD-501 1mg should be administered on an empty stomach(fasting condition) in one period and following a high-fat, high-caloric diet(fed condition) in the other period.
9948460|NCT01071733||ultrasound wrist|
9948461|NCT01071733||ultrasound finger|
9948462|NCT01071733||ultrasound ankle|
9948463|NCT01071746||Acute decompensation of cirrhosis|acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
9948464|NCT01071759||pregnancy|
9948465|NCT01071772|Experimental|euglycemia|
9948466|NCT01071772|Experimental|hyperglycemia|
9948467|NCT01071785|No Intervention|usual diet|no dietary or drug intervention. Patients followed their usual diet.
9948468|NCT01071785|Experimental|guar gum|guar gum
9948469|NCT01071811|No Intervention|Control group|Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.
9948470|NCT01071811|Experimental|Pedometer group|Received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps.
9948471|NCT01071824|Active Comparator|Transverse coloplasty pouch (Short limb)|The short limb is the standard technique of transverse coloplasty pouch.
9948472|NCT01071824|Experimental|Transverse coloplasty pouch (Long limb)|The long limb relates to straight coloanal anastomosis.
9948473|NCT01071837|Active Comparator|Re-Irradiation|33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
9948474|NCT01071837|Experimental|Re-Irradiation + APG101|66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion
9948475|NCT01071863||Rheumatoid Arthritis (RA) Patient Group|Patients with RA who have been refered for biological drug treatment
9948476|NCT01071863||Control Group|20 people of same age and sex as the RA patient cohort
9948477|NCT01071876|Experimental|BF2.649|BF2.649 capsules dosed at 5mg, 10 mg, 20mg
9948478|NCT01071876|Placebo Comparator|Placebo|Capsules of Placebo containing lactose with low, medium and high dosage
9948479|NCT01071889|Other|Brotizolam|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo
9948480|NCT01071889|Other|Zolpidem|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo.
9948481|NCT01071928|Experimental|Docetaxel and ASA404 in Combination|
9948482|NCT01071967|Experimental|Community-based nurse care management|Participants randomized to receive the intervention worked with a nurse care manager who provided them with a comprehensive set of geriatric and chronic disease preventive services.
9948483|NCT01071967|No Intervention|Usual care|Participants randomized to the control group received usual care without the involvement of a nurse care manager.
9948484|NCT01071980|Active Comparator|Specific resistance training|3 x 20 min a week of specific resistance training for 20 weeks
9948485|NCT01071980|No Intervention|Control|Control group
9948486|NCT01072019|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
9948487|NCT01072019|Active Comparator|MRI generated patient specific custom cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
9948488|NCT01072045|Active Comparator|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
9948489|NCT01072045|Active Comparator|Prednisone|Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
9948490|NCT01072058|Other|TNF blockers|
9948491|NCT01072071|No Intervention|Control group|Patients will be receiving standard of care ICU treatment of their underlying disease according to internationally accepted guidelines and recommendations.
9948492|NCT01072071|Experimental|Furosemide group|patients will be receiving standard of care ICU treatment of their underlying condition according to international guidelines and recommendations. In addition, furosemide will be administered in continuous infusion as per protocol in order to achieve a preset target diuresis that is adjusted according to haemodynamic tolerance.
9948493|NCT01072097|Active Comparator|Atorvastatin|6 months atorvastatin 20mg/day treatment
9948494|NCT01072097|Placebo Comparator|Placebo|6 months placebo treatment
9948495|NCT01072110||Group 1: Patients with diarrhea undergoing endoscopy|Standard video colonoscope.
9948496|NCT01072110||Group 2: Patients with diarrhea undergoing endoscopy.|Confocal laser endomicroscopy (CLE).
9948497|NCT01072162|Experimental|Arm B|25 mg powder for oral suspension single dose fasted.
9948498|NCT01072162|Experimental|Arm C|25 mg powder for oral suspension administered with a meal
9948499|NCT01072162|Experimental|Arm D|25 mg powder for oral suspension administered 2 hours prior to meal
9948500|NCT01072162|Experimental|Arm E|25 mg powder for oral suspension administered 2 hours after to meal
9948501|NCT01072162|Other|Arm A|Commercially available eltrombopag 25 mg tablet
9948502|NCT01072175|Experimental|Arm Part A|Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction
9948503|NCT01072175|Experimental|Arm Part B|GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose
9476451|NCT03571594|Experimental|ONO-5788 Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
9476452|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
9948504|NCT01072175|Experimental|Arm Part C|GSK2118436 + GSK1120212 cohort expansion for safety and efficacy
9948505|NCT01072214|Experimental|1.6 mg|The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
9948506|NCT01072214|Experimental|TBD COHORT 2|Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
9948507|NCT01072214|Placebo Comparator|Placebo|Subjects will receive placebo (drops without drug).
9948508|NCT01072214|Experimental|TBD COHORT 3|Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
9948509|NCT01072227||Single Group|
9948510|NCT01072240||Cohort|
9948511|NCT01072253||eye amputated|lost an eye
9948512|NCT01072266|Experimental|INCB028060|Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
9948513|NCT01072279|Experimental|Burundi: T24|
9948514|NCT01072279|Experimental|Burundi: TNFP|
9948515|NCT01072279|Experimental|Burundi: T18|
9948516|NCT01072279|No Intervention|Burundi: Control|
9948517|NCT01072279|Experimental|Guatemala: PROCOMIDA|
9948518|NCT01072279|Experimental|Guatemala: no family ration|
9948519|NCT01072279|Experimental|Guatemala: LNS|
9476453|NCT03571594|Experimental|ONO-5788 Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
9476454|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
9476455|NCT03571594|Experimental|ONO-5788 Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
9476456|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
9476457|NCT03571594|Experimental|ONO-5788 Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
9948520|NCT01072279|Experimental|Guatemala: Sprinkles|
9948521|NCT01072279|Experimental|Guatemala: reduced family ration|
9948522|NCT01072279|No Intervention|Guatemala: control|
9948523|NCT01072292|Experimental|CBT-I|CBT-I
9948524|NCT01072292|Active Comparator|Wellness Education|Wellness Education
9948525|NCT01072305|Experimental|Intermittent pneumatic compression (IPC)|IPC from induction of general anesthesia to completion of skin closure.
9948526|NCT01072305|Placebo Comparator|control|IPC - placebo from induction of general anesthesia to closure of the skin
9476458|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
9948527|NCT01072318|Experimental|Letrozole, DFS|Efficacy evaluation of extended letrozole after 5 year fareston use
9948528|NCT01072370|Active Comparator|Treatment Group 1|
9948529|NCT01072370|Sham Comparator|Treatment Group 2|
9948530|NCT01072383|Experimental|BT061|receiving BT061 (active compound)
9948531|NCT01072383|Placebo Comparator|Placebo|receiving a placebo
9948532|NCT01072422|Experimental|counseling based on answers in TTQ|40 participating primary health care nurses will be randomly assigned to this arm. Each nurse will identify 5 consecutive patients with COPD who smoke (n = 200 total patients). The nurses will ask the patients to fill in the assessment protocol, TTQ. The nurses will then provide an intervention to each patient in the form of individual treatment on the basis of that patient's answers to the TTQ.
9948533|NCT01072435|Active Comparator|patient-controlled sedation|PCS
9948534|NCT01072435|Active Comparator|target-controlled infusion|TCI
9948535|NCT01072461|Active Comparator|Train Paretic Hand and Arm Separate|Eight three hour training sessions of robotically facilitated hand and arm training in complex virtual environments, using activities that train the fingers in isolation and other activities that train the arm in isolation.
9948536|NCT01072461|Experimental|Train Paretic Hand and Arm Together|
9948537|NCT01072461|Experimental|Train Both Hands Together in VE|
9948538|NCT01072474|Experimental|Capnography|Arm with capnographic monitoring
9948539|NCT01072474|Placebo Comparator|Standard|Standard monitoring.
9948540|NCT01072487|Experimental|Capnography|Arm with capnographic monitoring
9948541|NCT01072487|No Intervention|Standard|Standard monitoring.
9948542|NCT01072513|Other|Semen analysis|Analysis of semen before and after proton radiation therapy.
9948543|NCT01072552||Treated|Palivizumab treated
9948544|NCT01072552||Untreated|Palivizumab untreated
10004641|NCT01578070|Experimental|ViscoGel® and 0.2μg Act-HIB®|
9948545|NCT01072565|Active Comparator|SMBG Only|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
9948546|NCT01072565|Active Comparator|SMBG and CGM|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
9948547|NCT01072578|Experimental|1|
9948548|NCT01072578|Experimental|2|
9948549|NCT01072591|Experimental|1|
9948550|NCT01072591|Placebo Comparator|2|
9948551|NCT01072604|Experimental|Arm 1|
9948552|NCT01072604|Experimental|Arm 2|
9948553|NCT01072604|Active Comparator|Arm 3|
9948554|NCT01072604|Active Comparator|Arm 4|
9948555|NCT01072695|Experimental|Arm 1|
9948556|NCT01072695|Experimental|Arm 2|
9948557|NCT01072695|Experimental|Arm 3|
9948558|NCT01072721|Other|Fibrosis group|a single arm with the two interventions (elastometry and biopsy)
9948559|NCT01072734|Experimental|Vaccine group|single group: all included patients will receive the vaccine
9948560|NCT01072747|Experimental|heparin of bovine origin|Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
9948561|NCT01072747|Active Comparator|heparin of porcine origin|APP Pharmaceuticals
9948562|NCT01072760|Experimental|K wire|
9948563|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 1|Participants will receive the TetraVax-DV admixture 1 vaccine.
9948564|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 2|Participants will receive the TetraVax-DV admixture 2 vaccine.
9948565|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 3|Participants will receive the TetraVax-DV admixture 3 vaccine.
9948566|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 4|Participants will receive the TetraVax-DV admixture 4 vaccine.
9948567|NCT01072786|Placebo Comparator|Placebo|Participants will receive the placebo.
9948568|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 5|Participants will receive the TetraVax-DV admixture 5 vaccine.
9948569|NCT01072799|Experimental|Low dose H1N1|
9948570|NCT01072799|Experimental|Mid dose H1N1|
9948571|NCT01072799|Experimental|High dose H1N1|
9948572|NCT01072799|Placebo Comparator|Placebo|
9948573|NCT01072812|Experimental|Posiphen® tartrate capsules|
9476459|NCT03571594|Experimental|ONO-5788 Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
9476460|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
9476461|NCT03571594|Active Comparator|Octreotide Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
9948574|NCT01072825||transgender people starting hormone treatment|
9948575|NCT01072838|Other|Dose Escalation|
9948576|NCT01072851|Experimental|Multimedia educational tool|Multimedia education tool - A culturally competent video explaining the importance of and the process of colorectal cancer screening
9948577|NCT01072851|Experimental|Print educational tool|Print media - A culturally competent printed brochure explaining the importance of and the process of colorectal cancer screening
9948578|NCT01072851|Active Comparator|No intervention|Usual and customary waiting room process - Usual and customary office waiting period with access to standard nationally generated colorectal cancer screening informational material in the waiting room and/or exam room.
9948579|NCT01072864|Experimental|5 g of walnuts|
9948580|NCT01072864|Experimental|20 g of walnuts|
9948581|NCT01072864|Experimental|30 g of walnuts|
9948582|NCT01072864|Experimental|40 g of walnuts|
9948583|NCT01072890|Experimental|Temsirolimus and Pazopanib|
9948584|NCT01072903||IBS|Subjects with IBS
9948585|NCT01072903||Healthy|Healthy Controls
9948586|NCT01072916||IBS|Subjects with IBS-D
9948587|NCT01072916||Healthy|Healthy Subjects
9948588|NCT01072942|Experimental|Arm 1|
9948589|NCT01072942|Placebo Comparator|Arm 2|
9948590|NCT01072955|Experimental|heparin of bovine origin|5.000UI/mL bottle with 5mL
9948591|NCT01072955|Active Comparator|heparin of porcine origin|5000 USP Heparin Units / mL vial with 10 mL vial
9948592|NCT01072968|Experimental|BF2.649|BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
9948593|NCT01072968|Placebo Comparator|Placebo|Capsules of placebo containing lactose with low, medium and high dosage
9948594|NCT01073007|Experimental|Simvastatin|Simvastatin 40 mg daily for 3 months.
9948595|NCT01073007|Placebo Comparator|Placebo|
9948596|NCT01073033|Experimental|oral supplement1|Oral supplement for pregnant and lactating mothers
9948597|NCT01073033|Active Comparator|oral supplement 2|Oral supplement for pregnant and lactating mothers
9948598|NCT01073033|No Intervention|Reference|No oral supplementation during pregnancy and lactating.
9948599|NCT01073046||Place Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is placed (Rusch® distributed by Teleflex Medical Srl)
9948600|NCT01073046||No Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is not placed
9948601|NCT01073059|Experimental|Valproic acid|
9948602|NCT01073072|Experimental|Tutomesh|Technique of abdominal wall reconstruction strengthened by Tutomesh®
9948603|NCT01073072|Active Comparator|conventional repair|Conventional technique to repair incisional or abdominal wall hernias
9948604|NCT01073085|Experimental|Web-based coaching|"Those in the coaching arm will benefit from e-mails with advice, information, support for smoking cessation. These mails will be adapted to their personal profile."
9476462|NCT03571581|Experimental|Mindfulness Training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
9948605|NCT01073085|Active Comparator|Self-help guide|"Those in the active comparator arm will be allowed to download a self-help guide with step-by-step advice for smoking cessation."
9948606|NCT01073111|Active Comparator|zotarolimus-eluting stents (ENDEAVOR®)|
9948607|NCT01073111|Active Comparator|sirolimus-eluting stents (CYPHER SELECT® PLUS)|
9948608|NCT01073111|Active Comparator|everolimus-eluting stents (PROMUS®)|
9948609|NCT01073124|Active Comparator|Normal Saline|Normal Saline injected intraarticularly into the knee joint
9948610|NCT01073124|Experimental|Dilute Methylene Blue Dye|1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee
9948611|NCT01073137||Diabetic Subjects|
9948612|NCT01073137||Non diabetic subjects|
9948613|NCT01073176|Experimental|TEAMS|TEAMS has been designed to promote executive skills, memory and fine motor control, and includes game-like activities that allow for increases in task complexity.
9948614|NCT01073189|Experimental|Intra-Renal Fenoldopam|Intra-Renal Fenoldopam: Patients randomized to this wing will undergo placement of Angiodynamics Benefit catheter and receive intra-renal infusion of fenoldopm mesylate
9948615|NCT01073189|Active Comparator|Diuretic Control|Patients in the control group will be randomized to receive intra-venous diuretics as a comparator control
9948616|NCT01073202|Active Comparator|ursodeoxycholic acid|
9948617|NCT01073202|Placebo Comparator|identical-appearing placebo|
9948618|NCT01073215|Active Comparator|Group Condition|
9948619|NCT01073215|Experimental|Self-Guided Condition|
9948620|NCT01073241|Active Comparator|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP.
9948621|NCT01073241|Experimental|ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
9948622|NCT01073280||undeterminated neurological disease, cerebral endoscopy|patients without neurological diagnosis that require cerebral , meningeal diagnosis
9948623|NCT01073306|Experimental|Dengue Virus Subtype 2 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
9948624|NCT01073306|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
9948625|NCT01073319|Placebo Comparator|Placebo|Matching oral placebo capsule as control.
9948626|NCT01073319|Active Comparator|Rivastigmine 3 mg|
9948627|NCT01073319|Active Comparator|Rivastigmine 6 mg|
10004642|NCT01578070|Experimental|0.2μg Act-HIB®|
10004643|NCT01578070|Experimental|ViscoGel® and 2μg Act-HIB®|
10004644|NCT01578070|Experimental|2μg Act-HIB®|
10004645|NCT01578070|Active Comparator|10μg Act-HIB®|
10004646|NCT01578083||Cognitive Impairment|With self-report cognitive impairment.
10004647|NCT01578083||No Cognitive Impairment|Without self-report cognitive impairment.
10004648|NCT01578096|No Intervention|Diabetes education|Group-based diabetes education delivered to participants through community health workers
10004649|NCT01578096|Experimental|Diabetes education plus stress management|Group-based diabetes education plus stress management delivered to participants through community health workers
10004650|NCT01578109|Experimental|Treatment (sorafenib tosylate and transplant)|Patients receive sorafenib tosylate PO BID beginning at least 30 days after completion of induction therapy and/or transplant and no more than 120 days after transplant continuing for up to 2 years after transplant in the absence of disease progression or unacceptable toxicity.
10004651|NCT01578122|Experimental|25mmHg ECS|Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
10004652|NCT01578122|Active Comparator|35mmHg ECS|Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
10004653|NCT01578135||Phase I|
10004654|NCT01578135||Phase II|
10004655|NCT01578148|Experimental|Noxipoint Therapy|
10004656|NCT01578148|Active Comparator|Physical Therapy|
10004657|NCT01578161|Experimental|Dexmedetomidine0.25|dexmedetomidine 0.25 microg.kg(-1),(Group D0.25) ivs. for 10min.
10004658|NCT01578161|Experimental|Dexmedetomidine0.5|dexmedetomidine 0.5 microg.kg(-1),(group D0.5) ivs. for 10min.
10004659|NCT01578161|Experimental|Dexmedetomidine1.0|dexmedetomidine 1 microg.kg(-1) ivs. for 10min.
10004660|NCT01578161|Placebo Comparator|NormalSaline|Normal saline 10ml ivs. for 10min.
10004661|NCT01578174|Placebo Comparator|Control|
10004662|NCT01578174|Active Comparator|Dexmedetomidine|
10004663|NCT01578200|Experimental|Lanthanum carbonate|Patients are given Lanthanum Carbonate oral administration after meals three times per day in total daily dose of 750-2250mg.
10004664|NCT01578200|Active Comparator|Calcium Carbonate|Patients are given Calcium carbonate oral administration after meals three times per day in total daily dose of 3.0g.
10004665|NCT01578213|Experimental|Imatinib|
10004666|NCT01578226||Decompensated cirrhotic patients|Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)
10004667|NCT01578252|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
10004668|NCT01578252|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
10004669|NCT01578265|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
10004670|NCT01578265|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
10004671|NCT01578291|No Intervention|No intervention|Parents given routine information by the medical staff.
10004672|NCT01578291|Active Comparator|Parental information|Parents are provided with an educational brochure of the study and the expectations of the discomfort.
10004673|NCT01578291|Active Comparator|Play Therapy|Child and the parents will spend time in the office with the child life therapist undergoing play therapy.
10004674|NCT01578304|Experimental|Imidafenacin|
10004675|NCT01578304|Active Comparator|Fesoterodine|
10004676|NCT01578343|Experimental|Vorinostat-FND|Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
10004677|NCT01578356||Radical Retropubic prostatectomy (RRP)|Men who underwent open radical prostatectomy in the past at our centre.
10004678|NCT01578356||Robot-assisted laparoscopic prostatectomy (RALP)|Men who undergo robot-assisted laparoscopic prostatectomy at our centre.
10004679|NCT01578369|Experimental|Exercise group|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
10004680|NCT01578369|No Intervention|Control|Usual care
10004681|NCT01578382||Hypertensive ischemic leg ulcer|"Twenty consecutive patients with Martorell HYTILU as defined in:~Arch Dermatol 2010;146:961-968"
10004682|NCT01578382||Calciphylaxis|"Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:~Vasa 1998;27:137-143"
10004683|NCT01578382||Venous ulcer (controls)|"Twenty subjects with venous ulcers (CEAP C4-6) as described in:~J Vasc Surg. 2004 Dec;40(6):1248-52"
10004684|NCT01578395|Experimental|N-acetylcysteine|This arm consists of 30 patients who will receive 1200mg n-acetylcysteine dissolved in 50ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
10004685|NCT01578395|Experimental|Ascorbic acid|This arm consists of 30 patients who will receive 3000 mg ascorbic acid dissolved in 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
10004686|NCT01578395|Placebo Comparator|Sodium Chloride (NaCl)|This arm consists of 30 patients who will receive 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
9948628|NCT01073332|Placebo Comparator|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
9948629|NCT01073332|Experimental|Arginine antioxidant supplements|Dietary Supplement: Niteworks
9948630|NCT01073345||Major hepatic resection|Patients undergoing resection of > 2 liver segments
9948631|NCT01073345||Minor hepatic resection|Patients undergoing resection of </= 2 liver segments
9948632|NCT01073345||Control group|Patients undergoing exploratory laparotomy for hepatobiliary disease without resection (e.g. due to inoperable disease)
9948633|NCT01073358|No Intervention|Group A: No routine hilar lymphadenectomy|Resection of colorectal liver metastases without routine hilar lymphadenectomy
9948634|NCT01073358|Experimental|Group B: Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases.
9948635|NCT01073371|Active Comparator|liposome-encapsulated 3% prilocaine|
9948636|NCT01073371|Active Comparator|3% plain prilocaine|
9948637|NCT01073371|Active Comparator|3% prilocaine with 0,03IU/mL felypressin|
9948638|NCT01073384|Experimental|BDP 3 mg|1 mg TID
9948639|NCT01073384|Experimental|BDP 6 mg|2 mg TID
9948640|NCT01073384|Experimental|BDP 9 mg|3 mg TID
9948641|NCT01073384|Experimental|BDP 12 mg|4 mg TID
9948642|NCT01073397|Experimental|Behavioral|Weekly Integral Yoga sessions lasting 90 minutes for 10 weeks with home practice.
9948643|NCT01073397|Active Comparator|Health and Wellness Classes|Weekly classes on health and wellness lasting 90 minutes for 10 weeks, with additional home practice
9948644|NCT01073397|No Intervention|Waitlist|This group receives usual care for 10 weeks and is then randomized to one of the study arms.
9948645|NCT01073423|Experimental|Yoga|
9948646|NCT01073423|Active Comparator|Music Therapy|
9948647|NCT01073436||Discontinuation|Subjects who agree to discontinue their tyrosine kinase inhibitor(TKI)therapy, namely,imatinib mesylate, dasatinib, or nilotinib,and then followed to see if they can maintain a durable remission.
9948648|NCT01073488|Experimental|EMONC: Community mobilization, HBLSS and Facility Improvement|The intervention group received training in community mobilization activities, Home Based Life Saving Skills (HBLSS) and facility improvement.
9948649|NCT01073488|No Intervention|Control|The control group did not receive an intervention, but collected outcome data through a baseline maternal/newborn birth registry.
9948650|NCT01073501|Placebo Comparator|Placebo|Placebo versus pregabalin
9948651|NCT01073501|Experimental|Pregabalin|Placebo versus pregabalin
9948652|NCT01073527|Active Comparator|Hypertonic saline-salbutamol combination|NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
9948653|NCT01073527|Placebo Comparator|normal saline-salbutamol combination|Standard treatment normal saline 4cc with salbutamol 0.5cc
9948654|NCT01073540|Experimental|Arm 1|
9948655|NCT01073540|Active Comparator|Arm 2|
9948656|NCT01073553|Experimental|Arm 1|
9948657|NCT01073553|Active Comparator|Arm 2|
9948658|NCT01073579||Sabril®|All patients in the U.S. who are prescribed Sabril must participate in this patient registry in order to receive Sabril.
9948659|NCT01073592||CNV patiens|
9948660|NCT01073644||Sunitinb malate|
9948661|NCT01073670|Active Comparator|Acetaminophen|Participants received a loading dose of acetaminophen (2600 mg) at induction followed by 1300 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
9948662|NCT01073670|Experimental|Indomethacin|Participants were given 100 mg of indomethacin at induction and then 50 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
9948663|NCT01073670|Experimental|Combination|Participants were given a loading dose of 1300 mg of acetaminophen and 50 mg of Indomethacin followed by 650mg of acetaminophen and 25 mg of indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
9948664|NCT01073683|Experimental|larynx preservation|Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
9948665|NCT01073696|Active Comparator|granisetron IV|
9948666|NCT01073696|Experimental|granisetron patch|
9948667|NCT01073709|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
9948668|NCT01073709|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
9948669|NCT01073722|Active Comparator|Left double lumen tube|Traditionally, single lung ventilation is obtained with a double lumen tube (DLT). In our institution a polyvinyl DLT (Broncho-cath, Mallinckrodt,) without carinal hook, is used. This type of tube exists of a tube with two lumen with two distal cuffs. One lumen (called the bronchial lumen) extends some distance further, has a slight curvature and has a small blue cuff. The other lumen (called the tracheal lumen) has a larger cuff. A DLT tube exists in four sizes and one can choose in a left or a right configuration. Almost always, we use a left sided DLT. A DLT has a much larger diameter than a standard single lumen endotracheal tube
10004687|NCT01578408|Active Comparator|Uncemented HA Coated Corail stem|Surgery with an inversed hybrid arthroplasty with an uncemented hydroxyapatite coated Corail stem and a cemented Marathon cup (DePuy).
9948670|NCT01073722|Active Comparator|EZ-blocker|The EZ-blocker (EZB) is a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. It is intended for use in combination with a standard single lumen tube. After the EZB is advanced trough the distal end of the single lumen tube, both extensions spread out and find their way in the left and right main stem bronchi. The place where the two extensions are attached to the shaft now rests on the carina. Fiber optic bronchoscopy should be used for proper positioning. After placement of the EZB, one of the cuffs can be inflated to obtain lung separation under direct visual inspection with fiber optic bronchoscopy.
9948671|NCT01073735||Cancer Survivors|Examine the construct validity, short-term stability, internal consistency and item-response performance of a health-related needs assessment self-report instrument for adult childhood cancer survivors.
9948672|NCT01073748|Active Comparator|asthmatic subjects|Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
9948673|NCT01073748|Other|Healthy children|Children with no asthma as control group.
9948674|NCT01073761|Experimental|Everybody|All Subjects will receive the same intervention
9948675|NCT01073774|Experimental|Side by Side|
9948676|NCT01073774|Active Comparator|couples control condition|
9948677|NCT01073787|Active Comparator|Normal saline|
9948678|NCT01073787|Experimental|Normal saline and possible medication|
9948679|NCT01073800|Active Comparator|atorvastatin 80 mg|active treatment
9948680|NCT01073800|Placebo Comparator|placebo|
9948681|NCT01073813|Active Comparator|Minocycline 100mg|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
9948682|NCT01073813|No Intervention|No treatment|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
9948683|NCT01073826|Active Comparator|Tocilizumab|Infusion of Tocilizumab and sport intervention
9948684|NCT01073826|Active Comparator|Sitagliptin|Intake of Sitagliptin and sport intervention
9948685|NCT01073826|Placebo Comparator|Placebo|Intake of placebo and sport intervention
9948686|NCT01073839|Experimental|Cisplatin plus Gemcitabine|Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.
9948687|NCT01073852|Placebo Comparator|Placebo|Patients will be taking placebo medication throughout study.
9948688|NCT01073852|Active Comparator|Hydroxychloroquine|Patients will be taking hydroxychloroquine throughout study.
9948689|NCT01073891|Active Comparator|Arm 1|
9948690|NCT01073891|Experimental|Arm 2|
9948691|NCT01073891|Experimental|Arm 3|
9948692|NCT01073904|Experimental|Arm 1|
9948693|NCT01073904|Active Comparator|Arm 2|
9948694|NCT01073917|Other|Spontaneous Breathing|Patients will be breathing spontaneously during anesthesia
9948695|NCT01073917|Other|Pressure controlled ventilation|Patients in the PPV group will be ventilated by pressure control (tidal volume 8-10 ml/kg, frequency 10-14, I:E 1:1, no PEEP, target CO2 4.5 kPa).
9948696|NCT01073917|Other|Pressure Support Ventilation|The patients in the PSV group will breathing spontaneously on the ventilator with assistance by inspiratory support pressure. The support pressure will be adjusted to achieve a tidal volume of 8-10 ml/kg.
9948697|NCT01073956|Placebo Comparator|Inactive electrotherapy|Inactive electrotherapy is applied to the painful points
9948698|NCT01073956|Active Comparator|Ultrasound|Ultrasound electrotherapy is applied to the painful points
9948699|NCT01073956|Active Comparator|Monopolar radiofrequency|Monopolar radiofrequency electrotherapy is applied to the painful points
9948700|NCT01073969|Placebo Comparator|Control cereal|grain-based ready to eat cereal that does not contain active wheat bran extract
9948701|NCT01073969|Active Comparator|low dose|grain-based ready to eat cereal containing a low dose of wheat bran extract
9948702|NCT01073969|Active Comparator|High dose|grain-based ready to eat cereal that contains a high dose of wheat bran extract
9948703|NCT01073982|Placebo Comparator|cherry flavored fruit drink|
9948704|NCT01073982|Experimental|tart cherry juice|
9948705|NCT01073995|Active Comparator|Kenalog and Sensorcaine|"The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:~Intervention:~Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc"
9948706|NCT01073995|Placebo Comparator|Saline|Saline injections will be used to mimic the Steroid dose
9948707|NCT01074021|Experimental|Nimotuzumab plus chemoradiotherapy|
9948708|NCT01074021|Placebo Comparator|placebo plus chemoradiotherapy|
9948709|NCT01074060|Experimental|Arm I|"MOBILIZATION: Patients receive cyclophosphamide IV. Patients also receive filgrastim subcutaneously (SC) daily beginning approximately 24 hours later.~TREATMENT/APHERESIS: Beginning 10 days after cyclophosphamide, patients receive plerixafor IV over 30 minutes followed by filgrastim SC on each day of apheresis."
9948710|NCT01074073|Other|Lithium/Lurasidone|Schizophrenia Patients
9948711|NCT01074086|Experimental|RAD 001|RAD 001 in day 1 and day 7 from 10 mg to 50 mg
9948712|NCT01074112||Abdominal Trauma|Patients with mechanism of injury that could produce abdominal bleeding
9948713|NCT01074112||Female Abdominal Pain|Female patients of child bearing age complaining of abdominal pain
9948714|NCT01074112||Difficult Vascular Access|Patients whom vascular access is needed but difficult
9948715|NCT01074112||Abdominal Aortic Anuerysm|Patients who complain of or are suspected of having an abdominal aortic aneurysm
9948716|NCT01074112||Pulseless Electrical Activity|Patients whom are in cardiac arrest and no pulse can be determined yet they show an electrical rhythm on the monitor
9948717|NCT01074112||Kidney Stones (Hydronephrosis)|Patients who complain of flank pain
9948718|NCT01074112||Plueral Effusion|Patients with a history of renal or hepatic problems and complain of difficulty breathing of an unknown etiology
9948719|NCT01074112||ETT placement|field intubated patients who need another means of verifying tube placement
9948720|NCT01074112||Transcutaneous Pacing|Patients who are being externally paced and need a method of determining mechanical capture
9948721|NCT01074112||Paramedic Discretion|Patients in whom the paramedic feels that an ultrasound study would provide useful data in their treatment
9948722|NCT01074138|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
9948723|NCT01074151||Pregnant patients exposed to Cymbalta|Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning on or after the first day of the last menstrual period
9948724|NCT01074203|Experimental|Nitazoxanide arm|All patients will receive nitazoxanide
9948725|NCT01074320||Breast cancer patients on AIs|Breast cancer patients beginning Aromatase Inhibitor therapy
9948726|NCT01074359|Experimental|A0001|A0001 (0.75 g BID)
9948727|NCT01074359|Placebo Comparator|Placebo|Placebo
9948728|NCT01074372|Experimental|Cohort 1|Dose 1 versus placebo
9948729|NCT01074372|Experimental|Cohort 2|Dose 2 versus placebo
9948730|NCT01074372|Experimental|Cohort 3|Dose 3 versus placebo
9948731|NCT01074372|Experimental|Cohort 4|Dose 4 versus placebo
9948732|NCT01074385|Other|Immediate Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions, about a week apart. Subjects will then be asked to complete a questionnaire 1-2 weeks after completing therapy sessions and one month after completing therapy sessions.
9948733|NCT01074385|Other|Wait List Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
9948734|NCT01074411|Experimental|Treatment (bortezomib, carboplatin)|Patients receive bortezomib IP and carboplatin IP on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9948735|NCT01074476|Experimental|1|Glucosamine sulphate tablets
9948736|NCT01074476|Placebo Comparator|2|Placebo tablets
9948737|NCT01074528|Experimental|mindfulness based stress reduction|8-week mindfulness based stress reduction program
9948738|NCT01074528|No Intervention|control group|patients who have to wait before entering the MBSR program or who do not want to follow this program
9948739|NCT01074541|Active Comparator|Group 1|UV intensity 10 MIN
9948740|NCT01074541|Active Comparator|Group 2|UV intensity 5 MIN
9948741|NCT01074541|Active Comparator|Group 3|UV intensity 1 MIN
9948742|NCT01074541|Active Comparator|Group 4|UV intensity 20 MIN
9948743|NCT01074567|Experimental|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
9948744|NCT01074580||Deterioration, Crohn's disease|Patients > 18 years old with a deterioration of Crohn's disease defined by CDAI >150 and requiring treatment with systemic steroids or TNF alfa inhibitors
9948745|NCT01074593|Experimental|Test|Bergamo - Interferon beta-1a
9948746|NCT01074593|Active Comparator|Comparator - Merck Serono|Merck Serono - Interferon beta-1a
9948747|NCT01074606|Experimental|Toric|AcrySof Toric Intraocular Lens (IOL)
9948748|NCT01074619|Experimental|1|Memantine
9948749|NCT01074619|Placebo Comparator|2|Placebo
9948750|NCT01074645|No Intervention|Placebo|Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
9948751|NCT01074645|Active Comparator|Tenofovir disoproxil fumarate (TDF)|Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
9948752|NCT01074671|Other|No control arm|There is no control arm as part of the study design.
9948753|NCT01074697|Active Comparator|Fosaprepitant dimeglumine|
9948754|NCT01074697|Placebo Comparator|Saline water|
9948755|NCT01074710|Experimental|C13-URA|administered C13-URA 50, 100, 200mg in same subjects
9948756|NCT01074710|Placebo Comparator|Placebo|2 same subjects
9948757|NCT01074723|Experimental|b-cryptoxanthin|
9948758|NCT01074723|Experimental|phytosterols|
9948759|NCT01074723|Experimental|b-cryptoxanthin plus phytosterols|
9948760|NCT01074749|Active Comparator|Optisense lead|Patients with an Accent pacemaker and an OptiSense atrial lead
9948761|NCT01074749|Active Comparator|Tendril lead|Patients with an Accent pacemaker and a Tendril atrial lead
9948762|NCT01074762|No Intervention|Routine general practice care|In the comparison group, doctors were free to choose any treatment and change it over time. The study coordinating centre did not contact comparison practices after the end of recruitment (late 1991) until 1995.
9948763|NCT01074775|Experimental|Challenge group|Recipients of three challenge infections with oral M bovis
9948764|NCT01074788|Experimental|mind body intervention group|
9948765|NCT01074801|Active Comparator|Closed-loop|Subcutaneous insulin delivery to be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
9948766|NCT01074801|Active Comparator|Control arm|Subcutaneous insulin delivery to be administered according the standard insulin pump settings
9948767|NCT01074827|Experimental|Treadmill group|Specific gait training on treadmill
9948768|NCT01074827|Experimental|Strength training group|Eight weeks of intensive strength training
9948769|NCT01074840|Active Comparator|Peanut|Peanut flour will be given in increasing amounts.
9948770|NCT01074840|No Intervention|Control|Subjects will be enrolled who meet the inclusion/exclusion criteria and followed as matched controls. These subjects will not receive any treatment.
9948771|NCT01074853|Experimental|Propranolol|Chronic dose escalation of propranolol over period of 6 to 8 weeks.
9948772|NCT01074853|Placebo Comparator|Placebo|Matched placebo used for dose escalation period of 6 to 8 weeks
9948773|NCT01074866|No Intervention|Pressure support|Non invasive ventilation under pressure support (PS)
9948774|NCT01074866|Active Comparator|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally Adjusted ventilatory Assist
9948775|NCT01074879|Experimental|Whey protein|20 g whey protein + 20 g carbohydrates
9948776|NCT01074879|Experimental|Milk protein|20 g milk protein + 20 g carbohydrates
9948777|NCT01074879|Active Comparator|Carbohydrates|40 g carbohydrates
9948778|NCT01074892|Active Comparator|MPA 10 mg per oral cyclic for 6 months|The peroral treatment is used 10 days each month
9948779|NCT01074892|Active Comparator|MPA 10 mg per os continuous 6 months|Per oral MPA 10 mg is taken daily for 6 months
9948780|NCT01074892|Active Comparator|LNG-IUD for 6 months|Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months
9948781|NCT01074905|Active Comparator|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
9948782|NCT01074905|Active Comparator|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
9948783|NCT01074905|Experimental|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
9948784|NCT01074918|Experimental|Potassium Magnesium Citrate|
9948785|NCT01074918|Active Comparator|Potassium Chloride|
9948786|NCT01074957|Active Comparator|Incentive Spirometry|Incentive Spirometry group (IS) was oriented to take a deep breathing through Voldyne 5000TM (Sherwood Medical; St Loius, MO, USA) from Functional Residual Capacity (FRC) to Total Lung Capacity (TLC).
9803467|NCT03999749|Experimental|Induction Phase, Maintenance Phase|"Induction Phase: 2 induction treatment cycles of 42 days (6 weeks) each, of which the first cycle of 6 weeks is the DLT period.~Maintenance Phase: Consists of treatment cycles of 84 days (12 weeks) each, and may extend up to 1 year."
9803468|NCT03998579|Experimental|Individualized exercise|The intervention group get a referral to physiotherapist in Primary Health Care in Stockholm County Council, close to where they live. Within the third week after discharge, the patients begin twelve weeks of biweekly exercise. The physical exercise is individually targeted aerobic and strength exercises, based on international recommendations for persons with cancer disease. The program is approved by resposible surgeons.
9803469|NCT03998579|Active Comparator|Active control group|Oral and written information of a home-based exercise programme and information of supportive techniques to improve physical activity
9803470|NCT03984084||externally recruited participants|Self-referred affected and non-affected participants responding to advertisements
9803471|NCT03984084||In-house patients|Patients seeking treatment in the outpatient clinic of the Max-Planck-institute of Psychiatry
9803472|NCT03979742|Experimental|MC001|UCBMNC (MC001) transplant+Locomotor training
9803473|NCT03979742|Other|No treatment|No surgery, no transplant, locomotor training only
9803474|NCT03979482||PAH patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
9803475|NCT03979482||Sedentary healthy patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. Healthy but sedentary subjects.
9803476|NCT03964233|Experimental|Dose Escalation - BI 907828 + BI 754091|All neoplasms
9803477|NCT03964233|Experimental|Dose Expansion - Cohort 1 BI 907828 + BI 754091|
9803478|NCT03964233|Experimental|Dose Expansion - Cohort 2 - BI 907828 + BI 754091|
9803479|NCT03964233|Experimental|Dose Escalation - BI 907828 + BI 754091 + BI 754111|All neoplasms
9803480|NCT03958695|Active Comparator|Tunable-tension transobturator tape (TTT)|
9803481|NCT03958695|Active Comparator|Transobturator mid-urethral tape (TOT)|
9803482|NCT03957304|Experimental|Dexmedetomidine 1 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 1 mcg/kg (max 100 mcg or 1 mL).
9803483|NCT03957304|Active Comparator|Dexmedetomidine 2 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 2 mcg/kg (max 100 mcg or 1 mL).
9803484|NCT03957304|Active Comparator|Dexmedetomidine 3 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 3 mcg/kg (max 100 mcg or 1 mL).
9803485|NCT03957304|Active Comparator|Dexmedetomidine 4 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 4 mcg/kg (max 100 mcg or 1 mL).
9803488|NCT03952312|Experimental|"OncoTool Intervention"|
9803489|NCT03952312|Active Comparator|"Oncotool Control"|
9803490|NCT03951779|Experimental|Subjects with unexplained but suspected cardiac dyspnea|Subjects with unexplained but suspected cardiac dyspnea who are being scheduled for right heart catheterization will undergo an exercise cardiac magnetic resonance imaging (eCMR).
9803491|NCT03943030|Experimental|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
9803492|NCT03943030|No Intervention|Group control|The group will not receive pulmonary rehabilitation intervention. Patients will be guided and maintain their daily and routine lives normally during the evaluation process. However, a baseline evaluation will be performed, which will be repeated after 9 weeks: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes commonly used in the assistance to assess PR will also be measured.
9803493|NCT03924791|Experimental|Transforaminal Epidural Injection|Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3
9803494|NCT03924791|No Intervention|Oral pain medication|Patients will receive oral pain medication according to general practitioner guidelines.
9803495|NCT03920774||Familial Dysautonomia|Patients diagnosed with familial dysautonomia, a genetic disorder that affects the development and survival of nerve cells in the autonomic nervous system. It primarily affects neurons that control involuntary actions like regulation of blood pressure and breathing. It also affects the sensory nervous system and the perception of pain, heat and cold.
9948787|NCT01074957|Active Comparator|Exercise group|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
9948788|NCT01074957|Active Comparator|Breath-Stacking|Breath-Stacking group (BS) performed successive inspiratory efforts using a facial mask adapted to an unidirectional valve
9948789|NCT01074970|Active Comparator|Arm A: Cisplatin Monotherapy|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
9948790|NCT01074970|Active Comparator|Arm B: Combination Therapy|"Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles~Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles"
9948791|NCT01074983||Written standard of care|
9948792|NCT01074983||Usual practice pattern|
9948793|NCT01074996|Active Comparator|S-1,|Subjects will receive S-1 until progression
9948794|NCT01074996|Experimental|S-1 plus Leucovorin|patients will receive S-1 plus Leucovorin until progression
9948795|NCT01075022|Experimental|Vitamin D|
9948796|NCT01075022|Placebo Comparator|Placebo|
9948797|NCT01075035||Normal Healthy Controls|Individuals with no history of Traumatic Brain Injury.
9948798|NCT01075035||Civilian TBI|Civilians who have had a Traumatic Brain Injury
9948799|NCT01075035||Military TBI|Combat military veterans who have had a Traumatic Brain Injury
9948800|NCT01075061|Other|healthy volunteers|healthy volunteers
9948801|NCT01075061|Other|Kallmann|Kallmann syndrome patients
9948802|NCT01075061|Other|Congenital Mirror Movement|patients with CMM
9948803|NCT01075113|Experimental|Arm A|Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally. Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
9948804|NCT01075113|Experimental|Arm B CLOSED|Reduced Dose 200mg Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally). Cohort B has been closed. Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib. The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
10004688|NCT01578408|Active Comparator|Cemented Lubinus SPII stem (control arm)|Surgery with a totally cemented option with a Lubinus SPII stem and a IP cup (Link).
10004689|NCT01578421|Other|FX 100 dialyzer|
10004690|NCT01578421|Other|Polyflux 210 H dialyzer|
10004691|NCT01578421|Other|FXCorDiax 100 dialyzer|
10004692|NCT01578434|Active Comparator|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
10004693|NCT01578434|Active Comparator|Vitamin D|Vitamin D: 6 lakh IU single im dose
10004694|NCT01578434|Active Comparator|Vitamin D and Calcium|vitamin D and Calcium: combination of above two
10004695|NCT01578447|Other|Depo-SubQ Provera 104 in Uniject|
10004696|NCT01578447|Other|Intramuscular DMPA|
10004697|NCT01578460|Active Comparator|Control Group|Participants will self-select which group they wish to participate in at time of consent. The control group will use standard glucose meter testing to monitor their glucose levels.
10004698|NCT01578460|Experimental|Continuous Glucose Monitor (CGM) Group|Participants will self-select which group they wish to participate in at time of consent. The CGM group will utilize the iPro2 CGM to monitor their glucose levels during their 28, 32, and 36 week of gestation.
10004699|NCT01578473|Active Comparator|Vitamin D and E|Oral Vitamin D and E alone in men with penile curvature due to PD.
10004700|NCT01578473|Active Comparator|Testosterone Pellets and Vitamin D and E|Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.
10004701|NCT01578512|Experimental|Face-to-Face|8 sessions of weekly group behavioral weight loss treatment
10004702|NCT01578512|Experimental|Web-based|Participants receive one group face-to-face session followed by 7 web-based lessons, reporting of key behaviors, and feedback on progress.
10004703|NCT01578512|Active Comparator|Single Session|Single session behavioral weight loss
10004704|NCT01578525|No Intervention|standard care|Standard care (by German definition), traditional care by physician and nurse on the ward
10004705|NCT01578525|Other|Intensified standard care|Intensified standard care: traditional care by physician and nurse, additional pharmaceutical care by a pharmacist during hospitalization
10004706|NCT01578538|Active Comparator|mesh used repair|mesh used hernia repair will be perform
10004707|NCT01578538|Active Comparator|nonmesh|nonmesh hernia repair techniques will be used
10004708|NCT01578564|Experimental|SOR-C13|
10004709|NCT01578590|Experimental|Subjects will consume lean minced meat|Subjects will perform resistance exercise and consume a piece of meat (135 grams, 35 g of protein)
10004710|NCT01578590|Active Comparator|Subjects will consume a milk beverage|Subjects will perform resistance exercise and consume a milk protein beverage
10004711|NCT01578603|Experimental|sugar substituted chewing gum A|
10004712|NCT01578603|Experimental|Sugar substituted chewing gum B|
9948805|NCT01075139|Experimental|Brief Motivational Intervention|Subjects in this condition met one-on-one with a counselor for 30 minutes. Subjects received personalized feedback regarding their current physical activity levels and fruit/vegetable intake. Counselors used a motivational interviewing style to try to help resolve ambivalence about changing their current behaviors.
9948806|NCT01075139|Active Comparator|Educational information|Subjects in this condition received general educational information about the benefits associated with physical activity and fruit/vegetable intake.
9948807|NCT01075165|Experimental|Silicone Spray|Apply spray silicone
9948808|NCT01075165|Placebo Comparator|Saline Spray|Apply Saline Spray
9948809|NCT01075230|Active Comparator|Standard TKA|
9948810|NCT01075230|Active Comparator|Standard TKA with PRP|
9948811|NCT01075269||Conventional open thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
9948812|NCT01075269||Robotic thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
9948813|NCT01075295|Experimental|Lifestyle Intervention|
9948814|NCT01075295|Active Comparator|TAU|
9948815|NCT01075308|Experimental|SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
9948816|NCT01075334|Experimental|Porimore arm|Infertile men will receive 'Porimore' tablets for a period of time in which three intrauterine insemination cycles will be performed.
9948817|NCT01075334|Active Comparator|Folate and Zinc|
9948818|NCT01075386||Grade 2|Patients with Endometrial cancer of Grade 1 differentiation
9948819|NCT01075386||Benign|Patients without endometrial cancer
9948820|NCT01075386||Grade 1|Patients with Endometrial cancer of Grade 2 differentiation
9948821|NCT01075386||Grade 3|Patients with Endometrial cancer of Grade 3 differentiation
9948822|NCT01075425|Experimental|Arm I|Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9948823|NCT01075464|Experimental|A|
9948824|NCT01075464|Experimental|B|
9948825|NCT01075477||Cohort|
9948826|NCT01075490|Placebo Comparator|prematurely born, bupivacaine, placebo|
9948827|NCT01075490|Experimental|prematurely born, bupivacaine, clonidine|
9948828|NCT01075490|Placebo Comparator|term neonate, bupivacaine, placebo|
9948829|NCT01075490|Experimental|term neonate, bupivacaine, clonidine|
9948830|NCT01075503|Experimental|retrograde infraclavicular|Patients were received retrograde infraclavicular brachial plexus block.
9948831|NCT01075503|Active Comparator|interscalene|Patients were received interscalene brachial plexus block.
9948832|NCT01075503|Active Comparator|supraclavicular|Patients were received supraclavicular brachial plexus block.
9948833|NCT01075529|No Intervention|fluoxetine|
9948834|NCT01075542|Experimental|Toric intraocular lens|Bilateral Toric intraocular lens implantation in cataract surgery
9948835|NCT01075542|Other|Monofocal intraocular lens|Bilateral Monofocal intraocular lens implantation in cataract surgery
9948836|NCT01075555|Active Comparator|sorafenib|sorafenib
9948837|NCT01075555|Experimental|sorafenib + pravastatine|sorafenib + pravastatine
9948838|NCT01075581|Active Comparator|Topical administration|An an intranasal injection of saline will be used as control, and thereafter cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
9948839|NCT01075581|Experimental|Intranasal injection|An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
9948840|NCT01075594||1|Patients with dyslipidemia on lipid lowering therapy
9948841|NCT01075620|Experimental|PFC sigma RP|Posterior stabilized rotating platform knee (press Fit Condylar Sigma rotating-platform, Depuy, Warsaw, Indiana)
9948842|NCT01075620|Active Comparator|LCS RP|non posterior stabilized Low Contact Stress Rotating-Platform; Depuy, Warsaw, Indiana
9948843|NCT01075633|Experimental|Fecal occult blood testing|Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
9948844|NCT01075633|Active Comparator|Colonoscopy|Colonoscopy with sedation.
9948845|NCT01075659|Experimental|LHN1548|Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
9948846|NCT01075659|Active Comparator|2019706|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
9948847|NCT01075659|Active Comparator|2020005|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
9948848|NCT01075698|Active Comparator|Non-ARB group|
9948849|NCT01075698|Active Comparator|ARB group|
9948850|NCT01075711||NIS in-house doctors|This group will be assigned to general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months. Three subjects are expected per in-house doctor therefore altogether, 1000 in-house doctors will be obtained or appointed for the observation study.
9948851|NCT01075711||NIS specialists|This group will be assigned to specialists (rheumatologist) with an observation period of 9 months. Ten subjects per rheumatologist are expected therefore altogether, 500 rheumatologists will be obtained or appointed for the observation study.
9948852|NCT01075724|Active Comparator|Forced air|Forced Air Warming
9948853|NCT01075724|Experimental|Resistive HotDog Warming|Warming by resistive Warming
9948854|NCT01075737||Subjects with Multiple Sclerosis|Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged >21 years.
9948855|NCT01075737||Caregivers|Caregivers (aged >21 years) for MS subjects.
9948856|NCT01075750||Normal Saline|Patients receiving Normal Saline during and after the renal transplantation.
9948857|NCT01075750||Elomel Isoton|Patients receiving Elomel Isoton during and after renal transplantation
9948858|NCT01075776|Experimental|CNP|Infusion of CNP prior to IR injury
9948859|NCT01075776|Placebo Comparator|Saline|Effect of saline infusion prior to IR injury
9948860|NCT01075789|Placebo Comparator|Placebo|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
9948861|NCT01075789|Active Comparator|Lignocaine|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
9948862|NCT01075789|Active Comparator|Pre/post intervention evaluation group|This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.
9948863|NCT01075802|Experimental|Tamoxifen|Dose escalation of tamoxifen in patients with low endoxifen levels
9948864|NCT01075867||Control group|Before ELIPS implementation 12 months follow-up
9948865|NCT01075867||Treatment group|After ELIPS implementation 12 months follow-up
9948866|NCT01075893||Adenomatous polyp|Patients who have begun the polyp-cancer sequence (ie. are in polyp surveillance after excision of a prior adenomatous polyp) will be used to test those patients at higher risk of colorectal.
9948867|NCT01075893||Patients at normal risk of cancer|Patients found to have endoscopically and histological normal mucosa.
9948868|NCT01075893||Ulcerative colitis|Patients who are under surveillance for known ulcerative colitis will be used to test those patients at higher risk of colorectal.
9948869|NCT01075906|Experimental|Colchicine|Colchicine Sprinkle Capsules, 0.3 mg - dose administered according to age range on Day 1
9948870|NCT01075906|Experimental|colchicine at steady state|colchicine sprinkle capsules 0.3 mg - dose administered according to age range on Day 15 following once daily dosing of colchicine on Days 2 - 14
9948871|NCT01075919|Active Comparator|DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA
9948872|NCT01075919|Active Comparator|EPA-rich fish oil|1 g EPA-rich fish oil containing 300 mg EPA + 200 mg DHA
9948873|NCT01075919|Placebo Comparator|Placebo|1 g Olive oil
9948874|NCT01075932|Active Comparator|1 g DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA plus 1 g olive oil
9948875|NCT01075932|Active Comparator|2 g DHA-rich fish oil|2 g DHA-rich fish oil containing 900 mg DHA + 180 mg EPA
9948876|NCT01075932|Placebo Comparator|Placebo|2 g olive oil
9948877|NCT01075945|Experimental|Dihydroartemisinin- piperaquine|orally tablets
9948878|NCT01075945|Active Comparator|artemether- lumefantrine|oral tablets
9948879|NCT01075997|Experimental|A cell phone tips|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone. The group will be asked to check blood sugar on a schedule determined by their providers. The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed. The group will have the A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
9948880|NCT01075997|Active Comparator|B no cell phone tips|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider. The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed. The group will have A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
9948881|NCT01076062|No Intervention|Expectant management (EM) arm|Standard of care: routine clinic appointments until they deliver, fetal heart rate and contraction monitoring during their 41st week if not delivered. Also if they have not gone into labor the subjects will be scheduled for an induction by 42 weeks.
9948882|NCT01076062|Experimental|Induction of Labor (IOL) arm|Elective induction of labor at 39 weeks.
9948883|NCT01076101||Sisters who have a diagnosis of SLE|Sisters who have a diagnosis of SLE
9948884|NCT01076101||Unaffected Sisters|Sisters of SLE patients who do not have a diagnosis of SLE
9948885|NCT01076114||Control|Patients with no evidence of glaucoma or as a suspect with normal intraocular pressure, normal cup to disc ratio with no other ocular pathology and a normal ophthalmic exam.
9948886|NCT01076114||Glaucoma Suspect|Patients with abnormal cup to disc ratio or increased intraocular pressure (>21mm/Hg) with an otherwise normal ophthalmic exam.
9948887|NCT01076127|Experimental|Ketllebell group|Basic ketllebell training 3 x 20 min a week for 8 weeks
9948888|NCT01076127|Sham Comparator|Control group|Control group. Receives a health examination before and after the intervention period, and are advised to stay active.
9948889|NCT01076140|Active Comparator|Nebivolol|Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
9948890|NCT01076140|Active Comparator|Lisinopril|20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
9948891|NCT01076218||Diabetes|Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps
9948892|NCT01076257|Experimental|Constraint-induced Movement Therapy|
9948893|NCT01076257|Other|Transditional rehabilitation|
9948894|NCT01076309||Tamsulosin|Patients taking tamsulosin
9948895|NCT01076309||Non-tamsulosin|Patients not taking tamsulosin.
9948896|NCT01076322|Experimental|Treatment-A sequence|Meptin® Swinghaler / Ventolin® MDI
9948897|NCT01076322|Experimental|Treatment-B sequence|Ventolin® MDI / Meptin® Swinghaler
9948898|NCT01076387|Active Comparator|open radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
9948899|NCT01076387|Active Comparator|robotic-assisted radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
9948900|NCT01076413|Experimental|skill-based exercise|2 times per week for 12 weeks. warm-up, stretching, strengthening, and skill-based exercises. Pre-gait and gait activities including stepping patterns and walking patterns and treadmill training at various walking speeds
9948901|NCT01076413|Active Comparator|aerobic exercise training|warm-up, strengthening and aerobic conditioning (treadmill walking)
9948902|NCT01076426|Experimental|Probiotics|probiotics treatment
9948903|NCT01076426|Placebo Comparator|Placebo|
9948904|NCT01076439|Active Comparator|Olopatadine Nasal Spray (Patanase)|
9948905|NCT01076439|Active Comparator|Fluticasone Furoate Nasal Spray (Veramyst)|
9948906|NCT01076439|Placebo Comparator|Saline Nasal Spray (Placebo)|
9948907|NCT01076465|Experimental|Lifestyle counselling|Educational intervention, monitoring of clinical status, monitoring of treatment adherence
9948908|NCT01076465|Active Comparator|Comparator|Usual care
9948909|NCT01076478|Placebo Comparator|Arm 1|2 tablets BID
9948910|NCT01076478|Experimental|Arm 2|100 mg Cilostazol (2 tablets BID)
9948911|NCT01076478|Experimental|Arm 3|200 mg Cilostazol (2 Tablets BID)
9948912|NCT01076530|Experimental|Arm I|Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
9948913|NCT01076556|Experimental|Treatment (rituximab, cyclophosphamide, alvocidib)|Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).
9948914|NCT01076569||Ancillary-Correlative (molecular analysis)|Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
9948915|NCT01076582|Experimental|Arm 1|
9948916|NCT01076582|Active Comparator|Arm 2|
9948917|NCT01076595||Group 1|
9948918|NCT01076621||A|
9948919|NCT01076634|Experimental|IDeg 100 U/mL|
9948920|NCT01076634|Experimental|IDeg 200 U/mL|
9948921|NCT01076673|Experimental|PBSC and Hyaluronic Acid|Peripheral blood stem cells and hyaluronic acid injections
9948922|NCT01076673|Active Comparator|Hyaluronic Acid|Hyaluronic Acid
9948923|NCT01076699|Active Comparator|Group taking 0.075 mg RVX-100|This group is taking 0.075 mg RVX-100
9948924|NCT01076699|Active Comparator|Group taking 0.125 mg RVX-100|This group is taking 0.125 mg RVX-100
9948925|NCT01076699|Active Comparator|0.250 mg RVX-100|This group is taking 0.250 mg RVX-100
9948926|NCT01076699|Placebo Comparator|placebo|This group is taking a placebo
9948927|NCT01076712|Experimental|Physiotherapy Interventions|Physiotherapy Interventions including strengthening exercise, balance training, gait training with visual cue, gait training with treadmill.
9948928|NCT01076712|Other|Education|Education
9948929|NCT01076725|Active Comparator|Standard technique group|In the standard technique group(n = 63), the PLMA was inserted by index finger insertion technique.
9948930|NCT01076725|Experimental|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
9948931|NCT01076738||single group study|
9948932|NCT01076751||CRPC patients|
9948933|NCT01076777|Experimental|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
9948934|NCT01076777|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
9948935|NCT01076790|Active Comparator|Dexmedetomidine|Analgo-sedative, adjuvant of propofol anesthesia
9948936|NCT01076803|Experimental|Lanreotide (acetate)|
9948937|NCT01076829|Active Comparator|Spice patty|hamburger meat cooked with spice mixture
9948938|NCT01076829|Placebo Comparator|salt patty|Subjects consume salt containing hamburger meat
9948939|NCT01076842|Active Comparator|A Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
9948940|NCT01076842|Active Comparator|B Exenatide|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
9948941|NCT01076842|Active Comparator|C Levemir+Exenatide|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
9948942|NCT01076855||Elderly with mild dementia|>70 years old and presence of a carer
9948943|NCT01076868|Experimental|Primaquine|Primaquine 14 days
9948944|NCT01076881|Experimental|combined aerobic and resistance training|
9948945|NCT01076881|Active Comparator|resistance training alone|
9948946|NCT01076894|Active Comparator|epidural anesthesia|
9948947|NCT01076894|Active Comparator|intercostal anesthesia|
9948948|NCT01076907|Experimental|Warm water loading of sigmoid colon|Warm water loading of sigmoid colon and irrigation when spasms occur.
9948949|NCT01076907|Placebo Comparator|Control|No water loading, only air and waiting for spasms to subside.
9948950|NCT01076920|Experimental|Intervention arm|
9948951|NCT01076933|Experimental|rTMS|rTMS sessions
9948952|NCT01076933|Sham Comparator|control|sham rTMS (control)
9948953|NCT01076946||TLVBS|patients with transient left ventricular ballooning
9948954|NCT01076998|Experimental|Lubricant eye drop|Lubricant eye drop
9948955|NCT01076998|Active Comparator|Refresh PM Ointment|Refresh PM Ointment
9948956|NCT01077011|Experimental|Lubricant eye drop|Lubricant eye drop
9948957|NCT01077011|Active Comparator|GenTeal Gel|GenTeal Gel
9948958|NCT01077037|Experimental|Decision Aid|Receives Decision Aid
9948959|NCT01077037|No Intervention|Control|Patient receives usual care.
9948960|NCT01077089||Transported TBI patients|Traumatically brain injured patients undergoing in-hospital transport.
9948961|NCT01077102|Experimental|Eccentric exercise training|
9948962|NCT01077102|Active Comparator|Concentric exercise training|
9948963|NCT01077115|Experimental|Laparoscopic cholecystectomy|
9948964|NCT01077115|Active Comparator|Open cholecystectomy|
10004713|NCT01578616||3 / non-CAD, ACS with or without TCFA|ACS patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
10004714|NCT01578616||non-CAD, ACS without TCFA, ACS with TCFA|Acute coronary syndrome (ACS) patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
10004715|NCT01578629|Active Comparator|Healthy Volunteers|Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.
10004716|NCT01578629|Active Comparator|Hyperlipidemic|hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.
9948965|NCT01077167|Experimental|1|
9948966|NCT01077180|Experimental|Rheos Device|
9948967|NCT01077180|Active Comparator|Medical Management|
9948968|NCT01077206|Active Comparator|Simvastatin 80mg|
9948969|NCT01077206|Active Comparator|Simvastatin 40mg|
9948970|NCT01077232||Psoriasis Patients|Patients with moderate to severe plaque psoriasis
9948971|NCT01077245|Experimental|MIYA-BM|MIYA-BM Fine Granules (CBM588)
9948972|NCT01077245|Placebo Comparator|Placebo|Placebo Fine Granules (without CBM588)
9948973|NCT01077336||Hospitalized patients with candidemia|
9948974|NCT01077349|Experimental|high volume hemofiltration|
9948975|NCT01077349|Active Comparator|standard care|
9948976|NCT01077388|Experimental|Dietician electronic counseling|This arm will receive care and supportive emails and phone calls from a study dietician for about 6 months. We will also provide a blood pressure monitor, a pedometer, and a scale with instructions for using them at home.
9948977|NCT01077388|No Intervention|Self Care|This arm will continue to get care as usual from their regular doctor. They will also get a blood pressure monitor and a scale at the end of the study.
9948978|NCT01077427|Active Comparator|Gemcitabine + Capecitabine|
9948979|NCT01077427|Experimental|Gemcitabine + Cisplatin + regional hyperthermia|
9948980|NCT01077440||Men - age 18+|
9948981|NCT01077453|Experimental|Arm I (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
9948982|NCT01077453|Experimental|Arm II (1.0 mg letrozole)|Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
9948983|NCT01077453|Experimental|Arm III (0.25 mg letrozole)|Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
9948984|NCT01077453|Experimental|Arm IV (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO once daily for 6 months.
9803496|NCT03916029|Active Comparator|Facilitator|120 hours training for local community members delivered on-country face-to-face during 6 4-day weeks and over a 3-6 month period. Certificate II modules in Aboriginal Primary Health Care, ear and hearing health skills development (otoscopy, tympanometry, and hearScreen) and employment as Ear Health Facilitators to the end of the trial.
9803497|NCT03916029|No Intervention|Control|No Facilitator. Brief 6-monthly 2 to 3 hour in-service training via zoom for health professionals.
9803498|NCT03914443|Experimental|Cohort A|"Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
9803499|NCT03914443|Experimental|Cohort B|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
9948985|NCT01077466|Experimental|Natalizumab|24 patients: 12 with secondary progressive multiple sclerosis 12 with primary progressive multiple sclerosis
9948986|NCT01077479|Experimental|Metformin|
9948987|NCT01077492||Suspected mediastianl lymph nodes|Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
9948988|NCT01077505|Experimental|albiglutide|albiglutide 50mg weekly
9948989|NCT01077531|Active Comparator|Otelixizumab|Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
9948990|NCT01077531|Placebo Comparator|Placebo|Matching placebo for intravenous infusion
10004717|NCT01578642|Other|Single Arm open label|EndoStim LES Stimulation System
10004718|NCT01578668|Experimental|Erlotinib, pemetrexed, cisplatin|
10004719|NCT01578668|Experimental|erlotinib|
9803500|NCT03914443|Experimental|Cohort C|"Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
9803501|NCT03914443|Experimental|Cohort D|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
9803502|NCT03909321|No Intervention|Control group|The Control group will not be submitted to intervention and will be instructed not to engage in any kind of structured physical exercise training and to keep the life activities identified at baseline.
9803503|NCT03909321|Experimental|Beach tennis training group|The Beach Tennis (BT) group will perform two sessions per week of the Beach Tennis training. This intervention will last 12 weeks.
9803504|NCT03908567|Placebo Comparator|Placebo|Nasal spray solution without active ingredient
9803505|NCT03908567|Experimental|1 mg AM-125|Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.
9803506|NCT03908567|Experimental|10 mg AM-125|Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.
9803507|NCT03908567|Experimental|20 mg AM-125|Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.
9803508|NCT03908567|Experimental|Oral 16 mg betahistine|Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.
9803509|NCT03904264|Experimental|Hearing Aid Study|Measure the reduction in tinnitus handicap when mild amplification through receiver-in-the-canal hearing aids is provided to adults with bothersome tinnitus and normal hearing thresholds.
9803510|NCT03904264|No Intervention|VA Clinician Interviews|Document the opinions, procedures, and rationale used clinically to make decisions regarding fitting mild amplification for tinnitus on Veterans with bothersome tinnitus and normal hearing thresholds. The data for this arm of the study will be collected via telephone interview.
9803511|NCT03899103|Experimental|Repeated Courses of Rituximab Only|First course Course Rituximab at Randomization. Prophylactic 2nd and 3rd course rituximab re-administration will be done at 8 months and 16 months of follow-up if B cell count normalize.
9803512|NCT03899103|Active Comparator|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
9803513|NCT03897205|Experimental|Imlifidase|Subjects randomized to imlifidase treatment will receive one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
9803514|NCT03897205|Active Comparator|Plasma Exchange|Subjects randomized to plasma exchange (PE) treatment will receive 5-10 sessions of PE, as judged by the investigator. Immunoadsorption (IA) may replace PE, at the discretion of the investigator.
9803515|NCT03896152|Experimental|Arm 1|approximately 2 year Treatment with low LNP023 dose
9803516|NCT03896152|Experimental|Arm 2|approximately 2 year Treatment with higher LNP023 dose
9803517|NCT03895515||Fiasp®|Participants with type 1 diabetes who have switched to a basal-bolus insulin regimen with Fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin.
9948991|NCT01077557||No HIV infection|Subjects without HIV infection (Group 1) are adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. A 3:1 match of subjects without HIV infection to a subject with HIV infection will occur. Each member of the comparator group without HIV infection will be matched on gender, month/year of IHCIS enrolment, and duration of enrollment to the respective study subject with HIV infection.
9948992|NCT01077557||HIV infection with no antiretroviral (ARV) drug exposure|HIV infection with no ARV drug exposure (Group 2) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have no pharmacy dispensing for ARV drugs.
9948993|NCT01077557||HIV infection with ARV drug exposure|HIV infection with ARV drug exposure (Group 3) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have at least one pharmacy dispensing for an HIV antiretroviral drug.
9948994|NCT01077570||Repaglinide|
9948995|NCT01077609||Allergic rhinitis (AR) & Flixonase|Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate
9948996|NCT01077609||AR & prescription for intranasal steroid other than Flixonase|Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase
9948997|NCT01077635||HIV-1 infected children aged 6 ≤ 18 years|HIV-1 infected children aged 6 ≤ 18 years currently or having ever been exposed to FPV/RTV; this is the indicated group for the licensed dose in the paediatric population.
9948998|NCT01077648||Women diagnosed with advanced breast cancer|Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System
9948999|NCT01077661||Patients administrated Nebivolol|There is only one group. This group includes patients administrated Nebivolol
9949000|NCT01077674||Entropy - BIS|Patients undergoing surgery in sevoflurane anaesthesia.
9949001|NCT01077726|Experimental|1|
9949002|NCT01077752|Experimental|1|Patients with continuous ropivacaine preperitoneal infusion
9949003|NCT01077752|Active Comparator|2|Patients with intravenous lidocaine infusion
9949004|NCT01077752|Placebo Comparator|3|Patients without local anesthetics
9949005|NCT01077765|Experimental|treatment|treatment
9949006|NCT01077791|Experimental|original cognitive therapy|
9517218|NCT03308292|Experimental|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
9949007|NCT01077791|No Intervention|no intervention|
9949008|NCT01077882|Placebo Comparator|current therapy|
9949009|NCT01077882|Experimental|current therapy with educational program|
9949010|NCT01077895|Experimental|CVVH with fluid removal|
9949011|NCT01077895|Active Comparator|CVVH without fluid removal|
9949012|NCT01077908|Experimental|ACT plus standard therapy|Adoptive Cellular Therapy (ACT) prepared using Multimer or Gamma Catch Selection in combination with standard best available antiviral drug therapy
9949013|NCT01077908|Active Comparator|Best available antiviral drug therapy|
9949014|NCT01077934||Injured Extremity without compartment syndrome|
9949015|NCT01077934||Injured extremity with compartment syndrome|
9949016|NCT01077947|Active Comparator|Functional anesthetic discography|"The patients disc levels for surgical treatment will be based exclusively on their Functional anesthetic discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~Patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery by research personnel. Patients will be asked to complete questionnaires before their discography and at every follow-up visit."
9949017|NCT01077947|Active Comparator|Provocative Discography|"The patients disc levels for surgical treatment will be based exclusively on their Provocative Discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~The control disc, in the case provocative discography group must appear normal on the MRI - must have preserved disc height and central disc signal intensity on T-2 weighted images. The provocative discography will be performed using the standard IASP criteria. The patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery."
9949018|NCT01077999|Active Comparator|Carboplatin + paclitaxel + radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
9949019|NCT01077999|Experimental|Carboplatin+ paclitaxel+ panitumumab+ radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
9949020|NCT01078012|Active Comparator|Trained counselling|Comparison of outcomes before intervention vs. 2 months after
9949021|NCT01078025||transvaginal hybrid cholecystectomy|
9949022|NCT01078025||laparoscopic cholecystectomy|
9949023|NCT01078038|Active Comparator|Cypher|Sirolimus-eluting stent
9949024|NCT01078038|Active Comparator|Xience V|Everolimus-eluting stent
9949025|NCT01078051|Active Comparator|Optimal medical therapy|optimal medical therapy
9949026|NCT01078051|Active Comparator|drug-eluting stent|Cypher, xience, Endeavor, Taxus
9949027|NCT01078064||Study group|Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.
9949028|NCT01078129|Active Comparator|behavior therapy - CRT|behavior program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions) by means REHACOM® software
9949029|NCT01078129|Sham Comparator|non-CRT|no intervention
9949030|NCT01078142|Experimental|Single arm|Bendamustin, Rituximab, Temsirolimus
9949031|NCT01078181|Active Comparator|banded gastric bypass|Banded gastric bypass (circular anastomosis 21mm) using the A.M.I. B-Band (Soft Gastric Bypass Band)
9949032|NCT01078181|Active Comparator|non-banded gastric bypass|non-banded gastric bypass (circular anastomosis 21mm)
9949033|NCT01078194||Weight regain / weight loss failure|Weight regain of more than 10 kg from or weight loss of less than 50% EWL 18 months after lap. gastric bypass
9949034|NCT01078272|Experimental|Remote Ischemic Preconditioning (RIPC)|Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
9949035|NCT01078272|Placebo Comparator|Sham Remote Ischemic Preconditioning|Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.
9949036|NCT01078285||Control|
9949037|NCT01078285||Intervention Arm|
9949038|NCT01078311||HCC patients on Sorafenib|
9949039|NCT01078324||Ischemic colitis|Ischemic colitis, Diverticulosis
9949040|NCT01078428|Active Comparator|Silicone gel|Gel containing silicone gel
9949041|NCT01078428|Placebo Comparator|Vaseline|Gel containing petrolatum gel
9949042|NCT01078480|Experimental|Arm sling treatment|Displaced midshaft fracture of the collar bone treated with an arm sling
9949043|NCT01078480|Experimental|Operation|Displaced midshaft fracture of the collar bone treated with operation using a pre contoured titanium plate and screws.
9949044|NCT01078506||Hong Kong Chinese|Without a history of known intracranial pathologies.
9949045|NCT01078519|No Intervention|Massages baths|doulas, massages and baths
9949046|NCT01078519|Active Comparator|Combined spinal-epidural anesthesia|local anesthetics in low doses with opioids
9949047|NCT01078532|Experimental|SMART PHR|Patients receive the active PHR
9949048|NCT01078532|Other|Passive PHR|Usual PHR Care
9949049|NCT01078597||Patients with early Rheumatoid Arthritis|Patients , aged 18 years or over, diagnosed with Rheumatoid Arthritis, with evidence of disease activity within the last year.
9949050|NCT01078610||Psoriatic arthritis patients|
9949051|NCT01078636||EMCI (only cohort recruiting in this study)|Newly recruited early amnestic Mild Cognitive Impairment patients; estimated enrollment 200
9949052|NCT01078636||LMCI (not recruiting in this study)|Late Mild Cognitive Impairment patients; approximately 400 LMCI participants anticipated to follow from the original ADNI study
9949053|NCT01078636||CN (not recruiting in this study)|Cognitively Normal patients; approximately 200 CN participants anticipated to follow from the original ADNI study
9949054|NCT01078649|Experimental|Debio 1143 (AT-406)|Open label study. All patients participating in the study will receive Debio 1143 (AT-406).
9949055|NCT01078701|Experimental|GHB11L1|Dose levels: 6.0 log10 TCID50/volunteer, 6.5 log10 TCID50/volunteer and 7.0 log10 TCID50/volunteer
9949056|NCT01078701|Placebo Comparator|SPGN buffer|SPGN buffer administration by liquid nasal spray
9949057|NCT01078714|Experimental|Bumetanide|
9949058|NCT01078714|Placebo Comparator|Control|
9949059|NCT01078740||Non-CF subjects|Rectal tissue obtained from study subjects without cystic fibrosis (CF) as part of scheduled colonoscopy/biopsies performed for clinical care
9949060|NCT01078740||CF subjects|"Rectal tissue obtained from study subjects with cystic fibrosis (CF) in one of three ways:~Rectal biopsy as part of scheduled colonoscopy/biopsies performed for clinical care~Sigmoidoscopy/biopsy added onto a scheduled, unrelated procedure or surgery performed under general anesthesia~Sigmoidoscopy/biopsy performed for the sole purpose of obtaining rectal tissue for the current study"
9949061|NCT01078766|Experimental|CIMT+HABIT|"Form of summer camp, for six hours per day for 10 consecutive work days."
9949062|NCT01078779|Experimental|Chloroquine|
9949063|NCT01078779|Placebo Comparator|Placebo|
9949064|NCT01078792||COPD exacerbation|Patients admitted to hospital with COPD exacerbation
9949065|NCT01078818|Experimental|IV trivalent saccharose hydroxide ferrous|
9949066|NCT01078818|Active Comparator|Oral ferrous fumarate|
9949067|NCT01078818|Placebo Comparator|Oral and intravenous Placebo|
9949068|NCT01078831||ARDS / ALI patients|
9949069|NCT01078870|Experimental|A|
9949070|NCT01078870|Experimental|B|
9949071|NCT01078870|Experimental|C|
9949072|NCT01078883||Lung cancer|Patients with primary stage IIIb and IV lung cancer
9517219|NCT03308279||Asinthomatic|The only group evaluated
9517220|NCT03308266||CLP children with pain-related TMD|
9517221|NCT03308266||CLP children with no TMD|
9517222|NCT03308266||CLP children with painfree TMD|
9517223|NCT03308253|Other|Standard of Care|Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
9949073|NCT01078948|Experimental|Active 2mA tDCS|The stimulator will be used to deliver anodal stimulation to the left prefrontal cortex and cathodal stimulation to the right prefrontal cortex. The placement of the anode is proposed to enhance activity in the left frontal cortex; the cathode aims to reduce activity in the right prefrontal cortex.
9949074|NCT01078948|Sham Comparator|Sham tDCS|The system setup is identical to that of active tDCS; however, the stimulator will be turned off after 30 seconds.
9949075|NCT01078961|Experimental|Dose Escalation|
9949076|NCT01078987|Active Comparator|Group 1|One to three 5-day course of plasma exchange (plasmapheresis)
9949077|NCT01078987|Active Comparator|Group 2|One to three 5-day course of plasma exchange (plasmapheresis)
9949078|NCT01078987|No Intervention|Group 3|No intervention taken
9949079|NCT01078987|Active Comparator|Group 4|One to three 5-day course of plasma exchange (plasmapheresis)
9949080|NCT01079000|Active Comparator|Control - usual care (UC)|Usual care after an ED visit for asthma will include the provision of discharge instructions/plan, and action plan, and verbal instructions for follow-up with their PCP, and a faxed copy of the ED chart to the patient's PCP.
9949081|NCT01079000|Experimental|Opinion leader (OL) guidance to patients' PCPs|In addition to UC, OL guidance will be provided to the patients' PCP. A letter signed by an influential, respected, and local clinical leader (Respirologist) will encourage follow-up within two weeks and provide management suggestions.
9949082|NCT01079000|Experimental|Care manager education to patients|In addition to UC and OL guidance provided to the patients' PCP, care manager self-management education will be provided to patients. A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
9949083|NCT01079013|Experimental|treosulfan|
9949084|NCT01079052|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
9949085|NCT01079052|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
9949086|NCT01079065|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
9949087|NCT01079065|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
9949088|NCT01079078|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
9949089|NCT01079078|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
9949090|NCT01079091|Experimental|ADVOS (Hepa Wash)|"Treatment with the liver support system Hepa Wash"
9949091|NCT01079104|Active Comparator|Control|Standard Medical Therapy
9949092|NCT01079104|Experimental|Hepa Wash|"Treatment with the liver support system Hepa Wash"
9949093|NCT01079117|Active Comparator|Sevre-Long™|slow release oral morphine
9949094|NCT01079117|Active Comparator|Methadone|Methodone
9949095|NCT01079169|Experimental|Cranberry capsule|
9949096|NCT01079169|Placebo Comparator|Placebo capsule|
9949097|NCT01079208|Placebo Comparator|standard starter infant formula|standard starter infant formula
9949098|NCT01079208|Experimental|test starter formula|test infant formula
9949099|NCT01079208|Experimental|test starter formula with synbiotics|starter formula with synbiotics and adapted protein levels
9949100|NCT01079221|Experimental|Knee extensor exercise training|High intensity aerobic knee-extensor exercise training
9949101|NCT01079247|Active Comparator|Liberal|Maintain hemoglobin at 10-11 g/dL
9949102|NCT01079247|Active Comparator|Restrictive|Maintain hemoglobin at 7-8 g/dL
10004720|NCT01578681|Active Comparator|Airway clearance, bronchiectasis|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
10004721|NCT01578681|Placebo Comparator|bronchiectasis, stretching|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
10004722|NCT01578694|Other|Patient Group|The patient group has been diagnosed by the surgeon as having femoro-acetabular impingement (FAI) of the hip and will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
10004723|NCT01578694|Other|Control healthy volunteers|The control group has not been diagnosed with any hip problems, but will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
10004724|NCT01578720|Other|IVT injection once every 8 weeks after 3 initial monthly doses|"Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).~Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit."
10004725|NCT01578733|Experimental|protein intake|different levels of protein intake
10004726|NCT01578746|Active Comparator|Direct lateral approach|Patient operated using direct lateral approach.
10004727|NCT01578746|Active Comparator|Anterior approach|Patient operated using anterior approach.
10004728|NCT01578759|Experimental|Salpingectomy group|Participants in this group will have their fallopian tubes removed.
10004729|NCT01578759|No Intervention|No Salpingectomy Group|Participants in this group will not have their fallopian tubes removed.
10004730|NCT01578811|Placebo Comparator|Placebo|
10004731|NCT01578811|Experimental|SK-MS10 160mg t.i.d|
10004732|NCT01578811|Experimental|SK-MS10 320mg t.i.d|
10004733|NCT01578824|Active Comparator|Healthy Control|
10004734|NCT01578824|Active Comparator|Vitamin D resistant Rickets|Vitamin D resistant Rickets patients
10004735|NCT01578837|Experimental|Ginseng|Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule
10004736|NCT01578837|Placebo Comparator|Wheat Bran|100 % Natural Wheat Bran capsule
10004737|NCT01578863|Active Comparator|Intervention program|6 months intervention program to lose weight in obese children. Behavioral, emotional, physical, familial and demographic questioners will be fulfilled at the beginning and at the end of the program.
10004738|NCT01578863|No Intervention|Untreated obese children|Behavioral, emotional, physical, familial and demographic questioners will be fulfilled twice in a 6 month program.
10004739|NCT01578863|No Intervention|Normal weight children|Behavioral, emotional, physical, familial and demographic questioners will fulfill twice in the 6 month period.
10004740|NCT01578876|Experimental|CSWT for 3 month|A group
10004741|NCT01578876|Experimental|CSWT for 1 month|B group
10004742|NCT01578876|No Intervention|Control group|C group
10004743|NCT01578889|Experimental|Group 1: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine administered as 0.5 mL by intramuscular (IM) injection in both the left and right deltoids using the Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
9949103|NCT01079260|Active Comparator|Standard ONS|
9802019|NCT05317481|Experimental|BE-SMART-DR|Participation will include research clinical/behavioral interviews and symptom self-ratings, magnetic resonance imaging (MRI) scanning, actigraphy wearables, and use of smart phones for ecological momentary assessment (EMA). Subjects will participate in 12 weekly sessions with a research therapist with the first, middle and last sessions in person, remaining sessions offered by secure video or audio telecommunication and 6-month in person follow-up.
9802020|NCT05317481|Active Comparator|control comparator condition|
9802021|NCT05317468|Experimental|Video|Patients will complete contraceptive counseling using a video-based platform. Patients and counselors will have an audio and video connection.
9802022|NCT05317468|Experimental|Telephone|Patients will complete contraceptive counseling on a telephone call. Patients and counselors will have an audio connection only.
9802023|NCT05317455|Placebo Comparator|Placebo|capsule with excipient only, no active drug.
9802024|NCT05317455|Active Comparator|Dichloroacetate|sodium salt of dichloroacetate, 1000mg
9802025|NCT05317429|Experimental|Treatment|Carbohydrate-rich meal
9802026|NCT05317429|Active Comparator|Control|Carbohydrate-rich meal
9802027|NCT05317390|No Intervention|Retrospective clinical validation of DystoniaNet|Retrospective studies will (1) clinically validate the diagnostic performance of DystoniaNet compared to a normal neurological state (normative test), and (2) develop and test DystoniaNet extensions in comparison with other neurological and non-neurological conditions (differential test).
9802028|NCT05317390|Experimental|Prospective clinical validation of DystoniaNet|Prospective randomized studies will validate DystoniaNet performance for accurate, objective, and fast diagnosis of dystonia in the actual clinical setting.
9802029|NCT05317377|Active Comparator|Structured Exercise|Structured hand exercises will be applied in 45-minute sessions (16 sessions total), 2 days a week, over 8 weeks in addition to participants' routine physical activities.
9802030|NCT05317377|Experimental|Leap Motion Based Exergame (LMBE)|"ErgoActive and HandROM exercise apps focusing on hand exercises and fine motor skills will be applied in 45-minute session (16 sessions total), 2 days a week, over 8 weeks in addition to participants' routine physical activities."
9802031|NCT05317364|Active Comparator|Topical vaginal estrogen group|Estradiol vaginal cream 0.01% 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g estradiol vaginal cream 0.01% will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy
9802032|NCT05317364|Placebo Comparator|Placebo group|Placebo cream, 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g of placebo cream will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy.
9802033|NCT05317351|Active Comparator|"Standard Colonoscopy (SC)"|"Subjects enrolled to arm 1 (SC) will undergo colonoscopy using a standard colonoscope."
9802034|NCT05317351|Active Comparator|"Artificial Intelligence Aided Colonoscopy (GI Genius™) (AI)"|"Subjects enrolled to arm 2 (AI) will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)"
9802035|NCT05317351|Experimental|Combined Artificial Intelligence (GI Genius™) and G-EYE® Colonoscopy (AG)|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
9802036|NCT05317338|Experimental|Intervention group|Participants randomized to this group will be enrolled to a multicomponent training for 5-7 consecutive days and will continue to receive usual hospital care. The training program consists of strength, balance and gait exercises performed within the hospital.
9802037|NCT05317338|No Intervention|Control group|Participants randomized to the control group will receive only the usual hospital care and rehabilitation, without performing multicomponent exercises.
9949104|NCT01079260|Experimental|High Energy, Low volume ONS|High energy, low volume ONS
9949105|NCT01079273|Active Comparator|Vaccine|All Subjects enrolled in this study will receive the study vaccine (single-arm)
9949106|NCT01079286|Experimental|nelfinavir and temsirolimus|dose escalation
9949107|NCT01079312|Active Comparator|Propofol infusion|Anaesthesiologist's managed intravenous infusion of propofol 10mg/ml
9949108|NCT01079312|Active Comparator|Patient-controlled sedation|self-administration of propofol and remifentanil mixture during ERCP
9949109|NCT01079338|Experimental|caffeine|
9949110|NCT01079364|Experimental|Insulin glargine + Insulin glulisine|Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
9949111|NCT01079364|Active Comparator|Premixed insulin|twice daily premixed insulin (before breakfast and evening meal).
9949112|NCT01079377||Adolescent Surgical Candidates|Adolescents at the Center for Adolescent Bariatric Surgery, Columbia University Medical Center
9949113|NCT01079377||Obese Treatment-Seeking Adolescents|Obese Treatment-Seeking Adolescents, Maxcor Program for Overweight Education and Reduction (POWER) Program
9949114|NCT01079377||Normal-Weight Adolescents|Normal-Weight Adolescents
9949115|NCT01079416||Capsule endoscopy|Study device
9949116|NCT01079416||Esophagogastroduodenoscopy|Gold standard
9949117|NCT01079429||MGUS or SMM|Patients with Monoclonal gammopathy of undetermined significance or smoldering myeloma
9949118|NCT01079442|Active Comparator|Treatment arm: coffee|coffee administration
9949119|NCT01079442|Placebo Comparator|Water arm|The control drink consists of 100 ml warm water
9949120|NCT01079455|Active Comparator|HA|Coxarthrosis
9949121|NCT01079455|Active Comparator|Corticosterone|Coxarthrosis
9949122|NCT01079455|Placebo Comparator|Bupivacaine|Coxarthrosis
9949123|NCT01079468||Total Hip Arthroplasty|
9949124|NCT01079468||Total Hip Resurfacing Arthroplasty|
9949125|NCT01079481|Experimental|taxol plus everolimus|
9949126|NCT01079494|Active Comparator|intervention group|physician-pharmacist teamwork
9949127|NCT01079494|No Intervention|control|physician only team
9949128|NCT01079507||adult acute lymphoblastic leukemia|Patients were diagnosed as adult acute lymphoblastic leukemia.
9949129|NCT01079533|Active Comparator|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
9949130|NCT01079533|Experimental|Minimal Cue and TLC|Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
9480672|NCT05262062|Experimental|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.Once the position of ease was identified, it was held for 20 to 30 seconds."
9802038|NCT05317325|Experimental|Experimental Group|Autologous DCs pulsed with HOCl-oxidized autologous tumor lysate (OCDC) vaccine is administered in prime phase and personal neoantigen-sensitized DC(NeoDC) vaccine is administered in boost phase.
9802039|NCT05317312|Experimental|MR-107A-02 1.25 mg twice in a 24 hour period|Oral tablet, one day of dosing
9802040|NCT05317312|Experimental|MR-107A-02 5 mg twice in a 24 hour period|Oral tablet, one day of dosing
9802041|NCT05317312|Experimental|MR-107A-02 15 mg twice in a 24 hour period|Oral tablet, one day of dosing
9802042|NCT05317312|Placebo Comparator|Placebo twice in a 24 hour period|Oral tablet, one day of dosing
9802046|NCT05317260||Chronic hepatitis B patients without hepatic steatosis|Patients with chronic hepatitis B will be defined as the non-steatosis group if they had histological evidence of visible lipid droplets in hepatocytes less than 5%.
9802047|NCT05317260||Chronic hepatitis B with steatosis but no steatohepatitis|Patients with chronic hepatitis B will be categorized as the steatosis but not steatohepatitis group if they had histological evidence of visible lipid droplets in hepatocytes more than 5% in the absence of steatohepatitis feature.
9802048|NCT05317260||Chronic hepatitis B patients with steatohepatitis|Patients with chronic hepatitis B will be classified as the steatohepatitis group if they had histological evidence of steatosis, hepatocyte ballooning, mixed lobular acute and chronic inflammation, and intra-acinar perisinusoidal fibrosis according to Brunt's classification.
9802049|NCT05317234|Experimental|children with cerebral palsy|Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
9802050|NCT05317221||All patients|The is only 1 arm: all breast cancer patients undergoing surgery.
9802051|NCT05317195|Experimental|NP-1|Nicotine Pouch 1.0 (variant NP-1)
9802052|NCT05317195|Experimental|NP-2|Nicotine Pouch 1.0 (variant NP-2)
9802053|NCT05317195|Experimental|NP-3|Nicotine Pouch 1.0 (variant NP-3)
9802054|NCT05317195|Experimental|NP-4|Nicotine Pouch 1.0 (variant NP-4)
9802055|NCT05317195|Active Comparator|Velo-NP|Velo® Ice Cool
9802056|NCT05317195|Active Comparator|Zyn-NP|Zyn® Cool Mint Mini Dry
9802057|NCT05317182|Active Comparator|Analogic-Analogic|Occlusal splints made by conventional impression and conventional fabrication.
9802058|NCT05317182|Active Comparator|Analogic-Digital|Occlusal splints made by conventional impression and digital design and fabrication.
9802059|NCT05317182|Active Comparator|Digital-Digital|Occlusal splints performed by intra-oral scanner and digital design and fabrication.
9802060|NCT05317156|Experimental|Prone position-Cold vapor group|Cold vapor will be applied to the prone position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
9949131|NCT01079546||Sq.CC of head and neck TASMC|
9949132|NCT01079546||hadassa Jerusalem|
9949133|NCT01079546||sheba hospital|
9949134|NCT01079546||rambam Haifa|
9949135|NCT01079546||belinson Petah Tikva|
9949136|NCT01079546||Nazeret|
9949137|NCT01079546||soroka beer sheva|
9949138|NCT01079559|Active Comparator|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery. All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
9949139|NCT01079559|Experimental|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
9949140|NCT01079572|Experimental|web-based|The patient will undergo xrays at the closest PACs enabled imaging centre and will login and answer questions online. The surgeon will review the images and patient responses and determine whether the patient needs to be seen more urgently or a per routine.
9949141|NCT01079572|Active Comparator|in-person|Patients will attend their follow-up appointments in-person as per usual
9949142|NCT01079624|Experimental|GIP two doses and GLP-1 one dose|Intervention with infusion of GIP or GLP-1 intravenously
9949143|NCT01079624|Placebo Comparator|Saline infusion|Control
9949144|NCT01079637|Experimental|Midfoot Fusion Bolt|
9517224|NCT03308253|Experimental|Antibiotic Impregnated Beads|Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
9949145|NCT01079637|Experimental|Cast treatment|
9949146|NCT01079650||children suffering from abdominal or testicle pain|
9949147|NCT01079676|Experimental|Filgrastim|
9949148|NCT01079676|Active Comparator|Granulokine|
9949149|NCT01079715|Experimental|Propranolol|Oral Propranolol administration is the experimental arm of this study
9949150|NCT01079715|No Intervention|Control|Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group
9949151|NCT01079754|Experimental|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
9949152|NCT01079754|Active Comparator|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
9949153|NCT01079767|Other|Temsirolimus|Temsirolimus
9949154|NCT01079780|Experimental|Arm I|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride over 60-90 minutes on day 1.
9949155|NCT01079780|Experimental|Arm II|Patients receive ramucirumab IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm I.
9949156|NCT01079793|Experimental|ixabepilone|Adjuvant therapy
9949157|NCT01079819|Active Comparator|A1 (BMS-708163)|
9949158|NCT01079819|Placebo Comparator|A2 (Placebo)|
9949159|NCT01079819|Active Comparator|B1 (BMS-708163)|
9949160|NCT01079819|Placebo Comparator|B2 (Placebo)|
9949161|NCT01079845|Experimental|Low-glycemic Load Diet|
9949162|NCT01079845|Active Comparator|Low-fat Diet|
9949163|NCT01079858|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
9949164|NCT01079871|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
9949165|NCT01079897|Active Comparator|Atopiclair|
9949166|NCT01079897|Experimental|EHK02-01|Ectoine containing cream
9949167|NCT01079910|Experimental|Experimental toothpaste|0.1% isopropylmethylphenol and 1150ppm fluoride
9949168|NCT01079910|Other|Marketed toothpaste|NaF/Silica toothpaste containing 1150ppm fluoride
9949169|NCT01079923|Active Comparator|Single High Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects .
9949170|NCT01079923|Active Comparator|Daily Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects.
9949171|NCT01080066||Non-Interventional Study|
9803518|NCT03887481|Experimental|Active HD-tDCS + Language/Cognitive Intervention(s) first|Participants will receive active HD-tDCS + Language/Cognitive Intervention(s) first and then receive Sham + Language/Cognitive Intervention(s) after a three-month washout period.
9949172|NCT01080079|Active Comparator|Group A -Terbinafine HCl|Terbinafine HCl
9803519|NCT03887481|Experimental|Sham + Language/Cognitive Intervention(s) first|Participants will receive Sham + Language/Cognitive Intervention(s) first and then receive active HD-tDCS + Language/Cognitive Intervention(s) after a three-month washout period.
9803520|NCT03885362|Experimental|Dexcom G6 and Abbott Freestyle Libre|"Participants will have a Dexcom G6 sensor and Abbott FreeStyle Libre sensor inserted in the abdomen and upper arm respectively. Participants will be asked to swipe the FreeStyle Libre reader across the sensor a minimum of every 8 hours. Participants will be asked to continue their usual regimen of self-monitoring capillary blood glucose (SMBG).~During haemodialysis, a dialysis circuit blood sample will be drawn at 0 (pre-dialysis) 30, 60, 90, 120, 150, 180, 210 and 240 minutes and immediately after dialysis. Samples from the circuit will be analysed on the YSI glucose analyser. Participants will be asked to change the FreeStyle Libre sensors at day 14. The blinded CGM data will be uploaded at the time of each sensor change by the research team."
9803521|NCT03879447||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
9803522|NCT03879447||Lumbar spondylolisthesis group|Lumbar spondylolisthesis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
9803523|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1|
9803524|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib|
9803525|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1|
9803526|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1+Oxaliplatin|
9803527|NCT03877510|Experimental|Open Label IPX203|Subjects will receive IPX203 140 mg, IPX203 210 mg, IPX203 280 mg, or IPX203 350 mg for approximately 9 months. The dose and dosing frequency will be determined by the investigator.
9803528|NCT03870230|Experimental|POAG MD<10dB|patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
9803529|NCT03870230|Experimental|POAG MD>10dB|patients with primary open angle glaucoma with MD in visual field more than 10dB
9803530|NCT03870230|Experimental|NTG MD<10dB|patients with normal tension glaucoma with MD in visual field less than or equal 10dB
9803531|NCT03870230|Experimental|NTG MD>10dB|patients with normal tension glaucoma with MD in visual field more than 10dB
9803532|NCT03870230|Experimental|OHT|patients with ocular hypertension
9803533|NCT03870230|Experimental|controls|healthy, age and sex matched, control subjects
9803534|NCT03868904||OCS Lung INSPIRE Trial|
9803535|NCT03866967|Experimental|AK105|Subjects receive AK105 200 mg intravenously (IV) once every 2 weeks (Q2W) until progression.
9803536|NCT03864848|Experimental|Treatment|Treatment with the Mitral Touch Implant for Epicardial Annuloplasty.
9803537|NCT03861871|Experimental|Fenfluramine Hydrochloride|
9803538|NCT03856216|Experimental|Group I (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
9803539|NCT03856216|Experimental|Group II (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
9803540|NCT03851380||Treatment Resistant Major Depression|Patients with treatment resistant major depression
9803541|NCT03851380||COVID Stress|Veterans with COVID-19-related distress
9803542|NCT03828136|Experimental|ACDF with Novum Vitrium® Cervical Interbody Device|A resorbable cervical interbody cage.
9803543|NCT03828136|Active Comparator|ACDF with Allograft|Structural allograft made from structural corticocancellous allograft bone.
9803544|NCT03821467|Experimental|Healthy subjects|Dual beam Doppler Fourier-domain OCT (DOCT) Dynamic Vessel Analyzer (DVA) Optical coherence tomography (OCT)
9803545|NCT03816163|Experimental|zolbetuximab +nab-paclitaxel + gemcitabine|Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
9803546|NCT03816163|Active Comparator|nab-paclitaxel + gemcitabine|Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
9803547|NCT03813199|Experimental|ABX464 50mg + methotrexate|"Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks~+ methotrexate"
9803548|NCT03813199|Experimental|ABX464 100mg + methotrexate|"Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks~+ methotrexate"
9803549|NCT03813199|Placebo Comparator|Placebo + methotrexate|"Participants will receive two capsules of matching placebo once daily for 12 weeks~+ methotrexate"
9803550|NCT03812276||Study Group|Neodent Acqua GM Helix dental implants will be placed. Multiple implants may be placed in a single subject.
9803551|NCT03811587|Experimental|Treatment group|Diabetes type 2 patients will take a fasting mimicking diet of 5 consecutive days a month, for a duration of 12 months. Besides this, they will receive usual diabetes care from the general practitioner.
9803552|NCT03811587|No Intervention|Control group|Diabetes type 2 Patients will have no intervention, they will receive usual diabetes care from the general practitioner.
9803553|NCT03809234|Experimental|Ondansetron with Tariquidar|The participants will receive an IV ondansetron infusion with tariquidar. Participants will receive either 8mg or 16 mg of iv ondansetron, with 4mg/kg tariguidar.
9803554|NCT03809234|Placebo Comparator|Ondansetron with Placebo|The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
9949173|NCT01080079|Active Comparator|Group B - Terbinafine HCl|Terbinafine HCl
9949174|NCT01080079|Active Comparator|Group C - Terbinafine HCl|Terbinafine HCl
9949175|NCT01080079|Active Comparator|Group D Terbinafine HCl|Terbinafine HCl
9949176|NCT01080079|Active Comparator|Group E|Terbinafine HCl
9949177|NCT01080079|Placebo Comparator|Group F - Placebo|Placebo application
9949178|NCT01080092|Experimental|breathing technique group|technique as a stress management technique, reinforced by biofeedback
9949179|NCT01080092|Placebo Comparator|no breathing technique|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
9949180|NCT01080105|Experimental|AIM + surveillance|Participants will receive access to the AIM website and calls from a motivational coach for 12 weeks plus an additional year of surveillance and optional coach support.
9949181|NCT01080105|Experimental|AIM intervention|Participants will receive access to the AIM web based intervention and calls from a motivational coach for 12 weeks
9949182|NCT01080105|Active Comparator|Educational website|Participants will be given access to a static website with depression prevention related materials and handouts.
9949183|NCT01080144|Experimental|Critical Flicker Frequency|Critical Flicker Frequency Procedure
9949184|NCT01080157||Volunteers 18+, at risk for diabetes|
9949185|NCT01080170||Anastrazole|Newly diagnosed, non-metastatic, hormone-receptor positive breast cancer patients, who have undergone lumpectomy, have been advised to not require chemotherapy, but will need to undergo radiation therapy and will be initiating therapy with anastrazole.
9949186|NCT01080170||Control group - 2|Healthy controls.
9949187|NCT01080183|Experimental|Feedback form|patients receive feedback regarding their prms in addition to doctor receiving report
9949188|NCT01080183|No Intervention|usual care|patients do not receive feedback form prior to the encounter, clinicians continue to receive patient reported measures prior to the appointment
10004744|NCT01578889|Placebo Comparator|Group 1: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.5 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
9803555|NCT03804580|Experimental|osimertinib|All patients recieve osimertinib
9803556|NCT03803995|Other|Mapping and Pacing the His Bundle|All patients will be in this arm. Mapping and Pacing the His Bundle will be performed.
9803557|NCT03795493|Experimental|Intervention Group|Standard chemotherapy treatment and oncology care plus short-term diet and exercise intervention.
9803558|NCT03795493|No Intervention|Control Group|Standard chemotherapy treatment and oncology care.
9803559|NCT03781765|Active Comparator|Methylphenidate|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
9803560|NCT03781765|Active Comparator|Atomoxetine|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
9803561|NCT03781752|Experimental|Methylphenidate|Youth with ADHD
9803562|NCT03772626|Experimental|Heated humidified high-flow|Heated Humidified High-flow Nasal Cannula
9803563|NCT03754244|Experimental|TQB3456|p.o. qd
9803564|NCT03749629|Active Comparator|CANMAT + GeneSight Psychotropic Test guided tx|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the pharmacogenomic test GeneSight®. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
9803565|NCT03749629|Placebo Comparator|CANMAT alone|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) alone.
9803566|NCT03749421||Prosigna Assay|"Biopsy specimen will be subject to molecular profiling via the Prosigna PAM-50 assay~The results of Prosigna assay will be provided to the study team in a standardized report.~This report will include the patient's intrinsic subtype, ROR score, and general risk (high, intermediate, low)."
9803567|NCT03729544|Experimental|Alert|On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
9803568|NCT03729544|No Intervention|No Alert|No provider notification
9949189|NCT01080235|Active Comparator|1|Control. Forty-two residency programs randomly assigned and stratified according to size, affiliation, geographic location, and presence of geriatrics fellowship. Twenty-one in the control arm. This group will use PIM as a data collection tool during baseline and follow-up time (i.e. audit of 50-75 charts, survey from 50-75 patients, and one system survey). They will not see the summary results of the data collected; they will not be required to complete a quality improvement plan based on the summary data. Local researchers will collect the data. Individual trainees will not do data collection or audits. At both baseline and follow-up, trainees will complete pre and post test surveys of 1) geriatric and 2) quality improvement knowledge, skills, and attitudes.
9949190|NCT01080235|Other|2|There are 21 residency programs in intervention arm who will 1) use PIM as a data collection tool (local researchers will audit 50-75 charts, survey 50-75 patients, and complete one system survey); 2) Each trainee will audit of up to five patient charts; collect 5 patient surveys; and complete the system survey as a group; 3) Summary data from these data streams will be reviewed by group; then they will design and implement a quality improvement plan; 4) At follow-up, local researchers will re-audit same 50-75 charts, collect surveys from same 50-75 patients, and complete one system survey. At baseline and follow-up, trainees and faculty will complete surveys of geriatric and quality improvement knowledge, skills, and attitudes.
9949191|NCT01080274||positive ergometry|positive ergometry as specified by a cardiologist on site.
9949192|NCT01080274||negative ergometry.|negative ergometry as specified by cardiologist on site.
9949193|NCT01080274||patients with positive stress test|100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
9949194|NCT01080287||Migraineurs with & w/out auras having orthostatic intolerance|Subjects between ages 18 and 65, having ICHD-II classification of migraine with or without aura, having symptoms of orthostatic intolerance
9949195|NCT01080287||Migraineurs with or without auras|Subjects between ages 18 and 65 having ICHD-II classification of migraine with or without auras
9949196|NCT01080313||Patients with head and neck cancer|
9949197|NCT01080339||Physical Activity and Nutrition|Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
9949198|NCT01080339||Nutrition Education Only|Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group
9949199|NCT01080352|Experimental|Vitamin C treatment|"Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.~5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20."
9949200|NCT01080365|Experimental|1|Commercial Tablet
9949201|NCT01080365|Experimental|2|Clinical Tablet
9949202|NCT01080378|Other|Higher Birth Weight|3447g to 3879g
9949203|NCT01080378|Other|Lower Birth Weight|2624g to 2964g
9949204|NCT01080378|Other|Normal Birth Weight|2965g to 3446g
9949205|NCT01080404|Experimental|Bariatric surgery (overall study)|A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
9949206|NCT01080404|Experimental|Bariatric surgery (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
9949207|NCT01080404|Active Comparator|CPAP (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
9949208|NCT01080417|Active Comparator|Cellcept® 250 mg Capsule|
9949209|NCT01080417|Experimental|Mycophenolate Mofetil Capsule 250 mg|
9949210|NCT01080443|Active Comparator|Cellcept® 250 mg Capsule|
9949211|NCT01080443|Experimental|Mycophenolate Mofetil Capsule 250 mg|
9949212|NCT01080456|Active Comparator|Prograf® Capsule 1 mg|
9949213|NCT01080456|Experimental|Tacrolimus Capsule 1 mg|
9949214|NCT01080469|Active Comparator|Prograf® Capsule 1 mg|
9949215|NCT01080469|Experimental|Tacrolimus Capsule 1 mg|
9949216|NCT01080482|Active Comparator|Prograf® Capsule 5 mg|
9949217|NCT01080482|Experimental|Tacrolimus Capsule 5 mg|
9949218|NCT01080495|Other|TEE (transesophageal echcardiography)|all patients get TEE and all parameters (radial strain, fractional shortening and fractional area change) are evaluated
9949219|NCT01080508||10 Asa I & II patients|
9949220|NCT01080521||Observational (cognitive function during chemotherapy)|Patients receive standard chemotherapy. Treatment repeats for 6 courses. Patients complete neurocognitive evaluations (Patient Assessment and Own Functioning scale and HeadMinder Custom Research Tool) and quality-of-life assessments (Hospital Anxiety and Depression Scale, FACT-O, and FACT/GOG-Ntx subscale) at baseline, before the fourth course of chemotherapy, at 3 weeks after the sixth course of chemotherapy, and at 6 months after the sixth course of chemotherapy.
9949221|NCT01080534|Active Comparator|Prograf® Capsule 5 mg|
9949222|NCT01080534|Experimental|Tacrolimus Capsule 5 mg|
9949223|NCT01080547|Active Comparator|Conventional Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
9949224|NCT01080547|Active Comparator|FTMD Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
9949225|NCT01080547|Active Comparator|Conventional Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
9949226|NCT01080547|Active Comparator|FTMD Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.
9949227|NCT01080560|Active Comparator|NEORAL® Capsule 100 mg|
9949228|NCT01080560|Experimental|Cyclosporine 100 mg Capsule|
9949229|NCT01080586|Active Comparator|NEORAL® Capsule 100 mg|
9949230|NCT01080586|Experimental|Cyclosporine 100 mg Capsule|
9949231|NCT01080599|Experimental|conventional pubic approach|
9949232|NCT01080599|Experimental|inguinal approach|
9949233|NCT01080612|Experimental|330 mg pregabalin controlled release: 400 to 500 calories|
9949234|NCT01080612|Experimental|330 mg pregabalin controlled release: 600 to 750 calories|
9949235|NCT01080612|Experimental|330 mg pregabalin controlled release: 800 to 1000 calories|
9949236|NCT01080612|Other|300 mg pregabalin immediate release|
9949237|NCT01080638|Experimental|Abciximab IC bolus|After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
9949238|NCT01080638|Active Comparator|Abciximab IV bolus and 12hr continuous|
9949239|NCT01080651|Active Comparator|CYP2C19 extensive metabolizer|
9949240|NCT01080651|Active Comparator|CYP2C19 poor metabolizer|
9949241|NCT01080664|Experimental|Regimen 1|Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
9949242|NCT01080664|Experimental|Regimen 2|Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle
9949243|NCT01080690|Active Comparator|EGD|In this arm EGD will be performed before EUS
9949244|NCT01080690|Active Comparator|EUS|In this arm, EUS will be performed before EGD.
9949245|NCT01080703|Experimental|Lower extremity strengthening|
9949246|NCT01080781||Group 1|normal pressures in right auricle (<10 mmHg) /and or pulmonary artery (<35 mmHg)
9949247|NCT01080781||Group 2|high pressures in right auricle (> 10 mmHg) /and or pulmonary artery (>35 mmHg)
9949248|NCT01080820|Placebo Comparator|Placebo + Viread|
9949249|NCT01080820|Active Comparator|Viread|
9949250|NCT01080820|Experimental|CMX157 + Viread|
9949251|NCT01080833|Active Comparator|ERCP mechanical simulator practice|Trainees who are offered ERCP Mechanical Simulator (EMS) training in addition to routine training (study group)
9949252|NCT01080833|No Intervention|No ERCP mechanical simulator practice|Trainees undergoing routine ERCP training only (control group).
9949253|NCT01080846|Experimental|600 mcg of sublingual misoprostol|
9949254|NCT01080859||BAS|Patient's receiving BAS
9949255|NCT01080859||EES|Patients receiving EES
9949256|NCT01080872||Titanium-NO coated stent|Patients receiving titanium-nitride-oxide coated stents during the intervention.
9949257|NCT01080872||Everolimus eluting stent|Patients receiving everolimus eluting stents during the intervention.
9949258|NCT01080885|Experimental|Busy Bodies/Better Bites|Healthy Eating/Physical Activity Intervention
9949259|NCT01080885|Active Comparator|Healthy Spots/Safe Tots|Injury Prevention and Safety Intervention
9949260|NCT01080898||DMLA patients|patients > 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
9949261|NCT01080911|Experimental|spinal morphine 0.05 mg|spinal morphine 0.05 mg plus 0.5% heavy marcaine 3.5 ml
9949262|NCT01080911|Active Comparator|spinal morphine 0.1 mg|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
9949263|NCT01080924|Experimental|Low frequency ultrasound spectroscopy|Low frequency ultrasound spectroscopy after broncholysis
9949264|NCT01080937||Patient with acute heart failure|Hospitalized patient, whatever the mode of initial admission with acute heart failure
10004745|NCT01578889|Experimental|Group 2: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 250 mcg IL-12 pDNA adjuvant, and divided into two 0.55 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
10004746|NCT01578889|Placebo Comparator|Group 2: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.55 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
10004747|NCT01578889|Experimental|Group 3: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1,000 mcg of the IL-12 pDNA adjuvant and divided into two 0.75 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
10004748|NCT01578889|Placebo Comparator|Group 3: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.75 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
10004749|NCT01578889|Experimental|Group 4: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
10004750|NCT01578889|Placebo Comparator|Group 4: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.9 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
10004751|NCT01578915||Cases|Women with 4 or more sexual partners during the past year
10004752|NCT01578915||Controls|Women with only one sexual partner during the past year
10004753|NCT01578928|Experimental|SOM230|subjects with varying degrees of renal impairment along with subjects without renal impairment
10004754|NCT01578941|Placebo Comparator|Placebo|
10004755|NCT01578941|Active Comparator|Treximet|
10004756|NCT01579019|Active Comparator|1000 mg 24 weeks|
10004757|NCT01579019|Active Comparator|1000 mg 26 weeks|
10004758|NCT01579019|Experimental|1500 mg 24 weeks|
10004759|NCT01579019|Experimental|1500 mg 26 weeks|
10004760|NCT01579032||CKD patients|
10004761|NCT01579058|Active Comparator|bisoprolol|bisoprolol 5mg qd
10004762|NCT01579058|Placebo Comparator|placebo|placebo
10004763|NCT01579071|Experimental|CO2 sufflation group|
10004764|NCT01579071|Experimental|Room air sufflation group|
10004765|NCT01579097|Active Comparator|compounded ternary parenteral nutrition|compounded ternary Parenteral Nutrition admixture
10004766|NCT01579097|Experimental|Oliclinomel N4 formulation|Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
10004767|NCT01579110|Experimental|prednisolone + levamisole|
10004768|NCT01579110|Active Comparator|Prednisone|
10004769|NCT01579123|Active Comparator|Laser atherectomy|
10004770|NCT01579123|Active Comparator|Angioplasty|
10004771|NCT01579136|No Intervention|Control group|This group will not get a home blood pressure monitor.
10004772|NCT01579136|Experimental|Home monitors|This group will be given a home blood pressure monitor to use.
10004773|NCT01579149|Experimental|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg)
10004774|NCT01579149|Placebo Comparator|Placebo|
10004775|NCT01579175|No Intervention|Standard postoperative care|
10004776|NCT01579175|Experimental|Chewing gum arm|Sugar free (extra, spearment) chewing gum given to the patient to chew during waking hours every four hours for 15 minutes
9949265|NCT01080950||fever zinc vit. d|patients with fever but without sepsis
9949266|NCT01080950||sepsis zinc vit. d|patients with sepsis
9949267|NCT01080963|Active Comparator|Daptomycin|
9949268|NCT01080963|Active Comparator|Cefuroxime|
9949269|NCT01080989|Other|health screening and clinical diagnosis and treatment for p|The study project can be divided into two parts: (1) health screening for the community and (2) clinical diagnosis and treatment for patients at National Referral Hospital (NRH) in Solomon islands.
9949270|NCT01081002|Active Comparator|Anesthesia (=A) with lidocaine 10%|3 min before sedation 4 puffs of terbutaline diluted lidocaine solution (Xylocaine ® 10% spray, Astra Zeneca, London, UK) will be sprayed on the pharynx
9949271|NCT01081002|Placebo Comparator|A with diluted gentian root solution|3 min before sedation 4 puffs of highly diluted gentian solution will be sprayed on the pharynx
9949272|NCT01081028||Group One: Patients enrolled between Sep2009 and Nov2011|Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
9949273|NCT01081028||Group Two: Patients enrolled between Dec2012 and mid-2016|Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
9949274|NCT01081054|Other|Ambulatory Treatment|Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.
9949275|NCT01081054|Active Comparator|Hospital treatment|Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.
9949276|NCT01081067||Control|Routine cow milk-based infant formula
9949277|NCT01081067||Investigational|Cow milk-based infant formula containing probiotics
9949278|NCT01081093|Experimental|Biventricular pacing|
9949279|NCT01081106|Other|Low-Level Laser Therapy|
9949280|NCT01081119|Experimental|Project CHOICE|Middle school receives Project CHOICE
9949281|NCT01081119|No Intervention|No Project CHOICE|Middle school does not receive Project CHOICE
9949282|NCT01081158|Experimental|Treatment-naïve 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days."
9949283|NCT01081158|Experimental|Treatment-experienced: 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days"
9949284|NCT01081158|Experimental|Treatment-naïve: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
9949285|NCT01081158|Experimental|Treatment-experienced: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
9949286|NCT01081184||primary Sjögren syndrome|
9949287|NCT01081184||Healthy volunteers|
9949288|NCT01081223|Experimental|TVI-Brain-1|Biological/Vaccine: Cancer vaccine plus immune adjuvant, plus activated white blood cells
9949289|NCT01081236||Compensated liver cirrhosis|
9949290|NCT01081236||Decompensated liver cirrhosis|
9949291|NCT01081275|Active Comparator|CI Therapy|CI therapy involves repetitive practice with the more-affected hand on typical daily living activities (such as stacking objects, pouring, moving objects) for 3.5 hours per day, along with physical restraint of the better hand to keep it from assisting, and home practice exercises.
9949292|NCT01081275|Active Comparator|CAM treatments|CAM treatments are holistic physical treatments designed to work on the entire body to improve quality of life and overall health. This study will use yoga, relaxation exercises, aquatherapy (pool therapy), and massage.
9949293|NCT01081288|Active Comparator|Women aged 47-49 invited for breast screening|
9949294|NCT01081288|Active Comparator|Women aged 71-73 invited for breast screening|
9949295|NCT01081314|Experimental|Standard DBT + PTSD Protocol|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team) plus a modified version of Prolonged Exposure therapy for PTSD.
9949296|NCT01081314|Active Comparator|Standard DBT|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
9949297|NCT01081327||Patients receiving Warfarin|
9949298|NCT01081340|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building reciprocal social ties between the intervention group members
9949299|NCT01081340|Active Comparator|Home visit|Home visits focused on preventable infant injuries
9949300|NCT01081353|Experimental|Arm 1|
9949301|NCT01081353|Active Comparator|Arm 2|
9949302|NCT01081353|Active Comparator|Arm 3|
9949303|NCT01081353|Active Comparator|Arm 4|
9949304|NCT01081379||pre-conception immunity|pre-conception immunity- pregnant women with CMV seropositive
9949305|NCT01081379||primary CMV infection|primary CMV infection- pregnant women with primary CMV infection (defined as CMV IgG sero-conversion, the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies).
9949306|NCT01081392|Experimental|LPS sequence 1|Nebulizers A then B then C
9949307|NCT01081392|Experimental|LPS sequence 2|Nebulizers B then C then A
9949308|NCT01081392|Experimental|LPS sequence 3|Nebulizers C then A then B
9476463|NCT03571529|Active Comparator|Robotic rehabilitation|"Active Comparator: Robotic rehabilitation~Protocol with EMG-driven hand exoskeleton (Hand of Hope):~Warm-up: 10 min passive mode 2 min resting~Training: According to residual muscle power:~10 min active-assistive, 2 min resting, 10 min Active-assistive or~5 min active, 2 min resting, 15 min active assistive or~10 min active, 2 min resting, 10 min active and~10 min window cleaning game Robotic rehabilitation will be applied 5 times a week; Totally 15 sessions (3 weeks). Conventional physiotherapy also will be performed to the robotic rehabilitation group."
9949309|NCT01081392|Experimental|LPS sequence 4|Nebulizers A then C then B
9949310|NCT01081392|Experimental|LPS sequence 5|Nebulizers C then B then A
9949311|NCT01081392|Experimental|LPS sequence 6|Nebulizers B then A then C
9949312|NCT01081405|Experimental|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
9949313|NCT01081418|Experimental|Standard care|Standard care comprised a treatment network consisting of open and closed inpatient wards, day-clinics, an outpatient centre, and eight private psychiatrists. Each patient was treated by a private psychiatrist or by a psychiatrist in the outpatient centre. Home visits were possible, but office visits were the general rule. Patients were allowed to use all treatment offers in the outpatient centre. Outside office hours, patients could refer themselves to the psychiatric hospital. Psychosocial treatments as supportive therapy, psychoeducation, psychotherapy, and family intervention were provided infrequently and in a less intensive and unsystematic way, and only in the minority of cases. This 'standard of care' definition is in accordance with other studies.
9949314|NCT01081431|Experimental|Lenalidomide|
9949315|NCT01081444|Active Comparator|1|Active rTMS
9949316|NCT01081444|Placebo Comparator|2|sham rTMS
9949317|NCT01081457|Active Comparator|ON|Stimulator switched ON
9949318|NCT01081457|Sham Comparator|OFF|Stimulator switched OFF
9476464|NCT03571529|Active Comparator|conventional physiotherapy|"Conventional Physiotherapy will be performed to the both group 5 sessions a week and totally 15 sessions (3 weeks).~Conventional physiotherapy will include neurophysiological approaches. Each session will last around 1,5 hours."
9476465|NCT03571503||Integrative Korean medicine treatment|Herniated lumbar disc (HLD) patients with radiating leg pain in the integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed.
9949319|NCT01081483|Active Comparator|ABT-072 Tablet|ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3
9949320|NCT01081483|Placebo Comparator|Placebo|Placebo Tablet, QD, single doses, groups 1-3
9949321|NCT01081535|Experimental|ketorolac|
9949322|NCT01081535|Experimental|fentanyl|
9949323|NCT01081548|Experimental|Generic|
9949324|NCT01081548|Active Comparator|Lipitor|
9949325|NCT01081561|Active Comparator|Cross-linking|Corneal collagen cross-linking with riboflavin and UVA light
9949326|NCT01081561|Active Comparator|Cross-linking plus INTACS|Corneal collagen cross-linking with riboflavin and UVA light plus INTACS
9949327|NCT01081574|Experimental|10 mg Bilastine once daily for 7 days|10 mg Bilastine dispersible oral tablet
9949328|NCT01081587|Experimental|Nutritional Support Team|
9949329|NCT01081587|Active Comparator|Usual care|
9949330|NCT01081600||AUY922|Patients with HER2 positive breast cancer which has become trastuzumab resistent.
9949331|NCT01081613||AUY922|Patients with estrogen receptor (ER) positive, hormone therapy refractory breast cancer.
9949332|NCT01081639|Experimental|Gonal-f|
9949333|NCT01081639|Active Comparator|Puregon|
9949334|NCT01081652|Experimental|Crinone 8% group|Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally
9949335|NCT01081652|Active Comparator|Intramuscular progesterone group|Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily
9949336|NCT01081691|Experimental|001|CNTO 5825 0.1 mg/kg single dose Intravenously (IV) or matching placebo
9949337|NCT01081691|Experimental|002|CNTO 5825 0.3 mg/kg single dose IV or matching placebo
9949338|NCT01081691|Experimental|003|CNTO 5825 1 mg/kg single dose IV or matching placebo
9949339|NCT01081691|Experimental|004|CNTO 5825 3 mg/kg single dose IV or matching placebo
9949340|NCT01081691|Experimental|005|CNTO 5825 10 mg/kg single dose IV or matching placebo
9949341|NCT01081691|Experimental|006|CNTO 5825 For atopic patient:10 mg/kg single IV dose or matching placebo
9949342|NCT01081691|Experimental|007|CNTO 5825 For atopic patient: 3 mg/kg single dose SC or matching placebo
9949343|NCT01081704|Experimental|001|ustekinumab Single dose of 45 mg subcutaneous injection
9949344|NCT01081704|Experimental|002|ustekinumab Single dose of 90 mg subcutaneous injection
9949345|NCT01081717||001|golimumab as prescribed
9949346|NCT01081717||002|anti-TNF biologics as prescribed
9949347|NCT01081717||003|non-anti-TNF biologics as prescribed
9949348|NCT01081717||004|systemic non-biological treatments as prescribed
9949349|NCT01081717||005|general population non-treated cohort
9949350|NCT01081730||001|ustekinumab as prescribed
9949351|NCT01081730||002|anti-TNF biologics as prescribed
9949352|NCT01081730||003|non-anti-TNF biologics as prescribed
9949353|NCT01081730||004|systemic non-biological treatments as prescribed
9949354|NCT01081730||005|general population non-treated cohort
9949355|NCT01081743|Experimental|Social worker|
9949356|NCT01081743|No Intervention|Control|Control group is followed-up as usually (usual care)
9949357|NCT01081756|Experimental|Subjects treated with r-hCG|Subjects treated with r-hCG
9949358|NCT01081756|Active Comparator|Subjects treated with urinary hCG|Subjects treated with urinary hCG
9949359|NCT01081808|Other|Armed Activated T Cells|Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
9949360|NCT01081821|Experimental|001|single dose NJ-39758979/ matching placebo Single oral dose of JNJ-39758979 (either 50 100 300 600mg) or Placebo
9949361|NCT01081821|Experimental|002|multi-dose JNJ-39758979 /matching placebo JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
9949362|NCT01081847|Active Comparator|Group A|Montanide ISA 720 Dose by peptide 50ug
9949363|NCT01081847|Active Comparator|Group B|Montanide ISA 51 Dose by peptide 50ug
9802061|NCT05317156|Experimental|Supine position-Cold vapor group|Cold vapor will be applied to the supine position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
9949364|NCT01081847|Active Comparator|Group C|Montanide ISA 720 Dose by peptide 100ug
9949365|NCT01081847|Active Comparator|Group D|Montanide ISA 51 Dose by peptide 100ug
9949366|NCT01081847|Placebo Comparator|Group E|Control Group. no peptide. Isotonic saline solution
9949367|NCT01081860||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
9949368|NCT01081860||Trigger finger|Patients with trigger fingers
9949369|NCT01081860||Dupuytren Contracture|Patients with Dupuytren
9949370|NCT01081860||Trauma to the hand|Patients with an acute trauma to the hand
9949371|NCT01081899|Experimental|The LCP-I Program.|The Italian version of the Liverpool Care Pathways version 11 for hospital) Programme.
9949372|NCT01081899|No Intervention|standard healthcare practices|No specific interventions are planned in the control wards.
9949373|NCT01081925||Congestive heart failure|Patients suffering from sudden worsening of congestive heart failure
9949374|NCT01081938|Experimental|1|Insulin Glargine + Insulin Glulisine
9949375|NCT01081938|Active Comparator|2|Insulin Glulisine
9949376|NCT01081964|Active Comparator|Levofloxacin 500mg|Levofloxacin 500mg once daily for 7 days
9949377|NCT01081964|Experimental|Zabofloxacin 5 days|Zabofloxacin 400mg for 5 days
9949378|NCT01081964|Experimental|Zabofloxacin 3 days|Zabofloxacin 400mg for 3 days
9949379|NCT01081977|Active Comparator|Early Cord Clamping Group|Early Cord Clamping Group (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate).
9949380|NCT01081977|Experimental|Delayed Cord Clapming Group|Delayed Umbilical Cord Clamping Group (Clamping of Umbilical Cord within 2 minutes of shoulder delivery of neonate).
9949381|NCT01081990|Placebo Comparator|Placebo Pill|
9949382|NCT01081990|Experimental|Flexeril|
9949383|NCT01082003|Other|Permanent Implant|Trental and Vitamin E for 6 months
9949384|NCT01082003|Other|Tissue Expander|Trental and Vitamin E for 6 months
9949385|NCT01082016|No Intervention|Control|Monitor sleep in ICU without attempts at promotion
9949386|NCT01082016|Experimental|Sleep promotion|Measure sleep in ICU with sleep promotion program in effect
9949387|NCT01082029|Experimental|Lansoprazole|
9949388|NCT01082029|Placebo Comparator|Placebo|
9949389|NCT01082042||Standard Care|Individuals who attended the local falls group
9949390|NCT01082042||Intervention group|Individuals who undertook the 12 week exercise (Nintendo WiiFit) intervention
9949391|NCT01082055||Currently receiving antiarrythmic drugs|
9949392|NCT01082094|Experimental|ACRX-100|"Cohort 1 = Low dose~Cohort 2 = Middle dose~Cohort 3 = High Dose"
9949393|NCT01082107|Other|Solar disinfection of drinking water|
9949394|NCT01082120|Experimental|1|AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15
9949395|NCT01082120|Experimental|2|Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15
9949396|NCT01082146|Experimental|Lurasidone|LURASIDONE 40mg
9949397|NCT01082172|Experimental|Thoracic Stent Graft|Thoracic Stent Graft implanted device
9949398|NCT01082185|Other|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
9949399|NCT01082224|Experimental|Waitlisted with HCC-Exception Points|Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
9949400|NCT01082237|Active Comparator|escitalopram|All subjects will receive escitalopram (ESC), brand name Lexapro (Forest Laboratories, Inc., New York) throughout the study. Dosing will start at 5 mg/d, be titrated to 10 mg after 4 days, and continue at 10 mg/d thereafter; an additional dose titration to 20 mg will be pursued at week 8 for those not significantly better (<50% improvement on IDS-30 at week 8 visit) and as tolerated.
9949401|NCT01082250|Other|Reference Formulation|Dosed 12.5% drugload 3X40mg
9949402|NCT01082250|Other|Test Formulation|25% Drugload 1X120mg
9949403|NCT01082263|Other|Midazolam/Lurasidone|Schizophrenia patient
9949404|NCT01082276|Other|Rifampin/Lurasidone|Healthy Normal Subject
9949405|NCT01082302|Active Comparator|oral intake of green tea beverage|Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
9949406|NCT01082302|Experimental|Polyphenon E 15% ointment|3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
9949407|NCT01082341|Experimental|Fy(+)|14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
9949408|NCT01082341|Active Comparator|Fy(+) control|Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
9949409|NCT01082341|Active Comparator|Fy(-)|Six Fy(-) volunteers will be exposed to infective mosquito bites.
9949410|NCT01082393|Active Comparator|topical tacrolimus|
9949411|NCT01082393|Active Comparator|topical pimecrolimus|
9476466|NCT03571503||Doin with integrative Korean medicine|Herniated lumbar disc (HLD) patients with radiating leg pain in the Doin (conduction exercise) with integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed, plus Doin (conduction exercise) for 1 session of the 2 sessions/day of acupuncture.
9949412|NCT01082393|Active Comparator|local steroids|
9949413|NCT01082393|Placebo Comparator|cold cream|
9949414|NCT01082406|Experimental|Trial part 1|
9949415|NCT01082406|Experimental|Trial part 2|
9949416|NCT01082419|Other|Group A|healthy volunteers
9949417|NCT01082419|Other|Group B|patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
9949418|NCT01082419|Other|Group D|patients with cirrhosis
9949419|NCT01082419|Other|Group E|patients with liver tumour and surgery indication
9949420|NCT01082419|Other|Group F|patients with reversible liver diseases and with acute left cardiac insufficiency
9949421|NCT01082419|Other|Group C|patients with non cirrhotic hepatopathy
9949422|NCT01082419|Other|Group G|patients with reversible liver diseases and with biliary cholestasis
9949423|NCT01082445|Experimental|N-acetylcysteine|50 patients that receive 600 mg of acetylcysteine for 3 times a day.
9949424|NCT01082445|Placebo Comparator|Placebo|50 subjects taking placebo pills 3 times a day
9949425|NCT01082471|Experimental|M6G|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
9949426|NCT01082471|Active Comparator|Morphine|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
9949427|NCT01082484|Experimental|Treprostinil|Treprostinil iontophoresis (250, 25 and 2.5 microM)
9949428|NCT01082484|Experimental|Iloprost|Iloprost iontophoresis (200, 20 and 2 microM)
9949429|NCT01082484|Placebo Comparator|NaCl 0.9%|
9949430|NCT01082497|Experimental|Mindfulness|
9949431|NCT01082497|Active Comparator|Education|8 - weekly workshops on affect consciousness for all staff
9949432|NCT01082510|Active Comparator|BCG maintenance therapy|
9949433|NCT01082510|Experimental|UFT maintenance therapy|
9949434|NCT01082523|Active Comparator|Text message reminders|
9949435|NCT01082523|No Intervention|Control|
9949436|NCT01082536||One ventricle pts, bypass, perfusion|1. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
9949437|NCT01082536||One ventricle pts, bypass only|Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion
9949438|NCT01082536||One ventricle pts, no bypass/perfusion|Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.
9949439|NCT01082536||Two ventricle pts, bypass, perfusion|Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
9949440|NCT01082536||Two ventricle pts, bypass only|Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.
9949441|NCT01082536||Two ventricle pts, no bypass/perfusion|Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.
9949442|NCT01082562|Experimental|Arm 1 - BMS-844421|
9949443|NCT01082562|Placebo Comparator|Arm 2 - 0.9% sodium chloride injection solution|
9949444|NCT01082562|Experimental|Arm 3 - BMS-844421|
9949445|NCT01082562|Placebo Comparator|Arm 4 - 0.9% sodium chloride injection solution|
9949446|NCT01082562|Experimental|Arm 5 - BMS-844421|
9949447|NCT01082562|Placebo Comparator|Arm 6 - 0.9% sodium chloride injection solution|
9949448|NCT01082562|Experimental|Arm 7 - BMS-844421|
9949449|NCT01082562|Placebo Comparator|Arm 8 - 0.9% sodium chloride injection solution|
9949450|NCT01082562|Experimental|Arm 9 - BMS-844421|
9949451|NCT01082562|Placebo Comparator|Arm 10 - 0.9% sodium chloride injection solution|
9949452|NCT01082562|Experimental|Arm 11 - BMS-844421|
9949453|NCT01082562|Placebo Comparator|Arm 12 - 0.9% sodium chloride injection solution|
9949454|NCT01082562|Experimental|Arm 13 - BMS-844421|
9949455|NCT01082562|Placebo Comparator|Arm 14 - 0.9% sodium chloride injection solution|
9949456|NCT01082562|Experimental|Arm 15 - BMS-844421|
9949457|NCT01082562|Placebo Comparator|Arm 16 - 0.9% sodium chloride injection solution|
9949458|NCT01082601||Optimal Medical therapy|Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.
9949459|NCT01082627|Experimental|Somatostatin+common daily practice|
9949460|NCT01082627|Placebo Comparator|common daily practice|
9949461|NCT01082653|Experimental|Safety|infusion of autologous bone marrow-derived stem cells
9949462|NCT01082666|Experimental|Continuous control|Continuous control of cuff pressure using a pneumatic device
9949463|NCT01082666|Active Comparator|Manual control|Manual control of cuff pressure is a routine practice in ICU patients
9949464|NCT01082679|Other|methadone via specialty care|
9949465|NCT01082679|Other|Suboxone via specialty care|
9949466|NCT01082679|Other|Suboxone via primary care|
9949467|NCT01082692|Experimental|3mg DNA/dose|Subjects will receive a 4 dose series of PENNVAX-B containing 3mg of DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8 and Week 16.
10004777|NCT01579188|Experimental|GV1001|The adjuvant GM-CSF is administered first as an intradermal injection followed in 10-15 minutes by the GV1001 peptide injected into the same site.
10004778|NCT01579188|Placebo Comparator|Placebo|Placebo
10004779|NCT01579201|Experimental|Carbetocin|
10004780|NCT01579227||1-TOP group 1|TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
10004781|NCT01579227||TOP group 2|TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
10004782|NCT01579227||OTOP group-1|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
10004783|NCT01579227||OTOP group-2|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
10004784|NCT01579227||TAM Group 1|TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
10004785|NCT01579227||Normal Skin|Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
10004786|NCT01579240|Experimental|program visits|visits to intervention program
10004787|NCT01579279|Experimental|ABT-652 6 mg|ABT-652 capsules - twice daily
10004788|NCT01579279|Experimental|ABT-652 12 mg|ABT-652 capsules twice daily
10004789|NCT01579279|Experimental|ABT-652 12 mg - 18 mg|ABT-652 capsules twice daily
10004790|NCT01579279|Placebo Comparator|Placebo|Placebo capsules twice daily
10004791|NCT01579279|Active Comparator|Duloxetine|Duloxetine capsules once daily
10004792|NCT01579292|Experimental|Physical Activity and Diet Intervention|5-month physical activity and diet intervention which includes 6 in-person sessions, mobile app, and pedometer
10004793|NCT01579292|Active Comparator|Pedometer only|Pedometer only
10004794|NCT01579331|Experimental|Dynamic Contour Tonometry|All recruited volunteers in present study, that underwent diurnal GAT tonometry (3 measures) and 5 DCT measurements.
10004795|NCT01579344|Active Comparator|Thyroid carcinoma, Radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy
9949468|NCT01082705|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
9949469|NCT01082705|Experimental|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine administered once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
9949470|NCT01082718|Experimental|Pregnant women|Pregnant women with P. falciparum malaria
9949471|NCT01082718|Active Comparator|Non pregnant women|Non pregnant women with P. falciparum malaria
9949472|NCT01082731|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
9949473|NCT01082731|Active Comparator|Artemether- Lumefantrine|Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
9949474|NCT01082744|Active Comparator|Continuous paravertebral block with ropivacaine|
9949475|NCT01082744|Experimental|Continuous paravertebral block with ropivacaine and sufentanil|
9949476|NCT01082770|Active Comparator|TEGO|TEGO needle free access devices will be used in patients randomised to this arm
9949477|NCT01082770|Placebo Comparator|Control|Patients will continue to receive current standard of practice, ie a 'bung' cap at the end of the hemodialysis line
9949478|NCT01082783||patients with acute media infarct|
9949479|NCT01082783||controls with cardiovascular risks|
9949480|NCT01082796|Other|CYP2C19 EMs group|cyp2c19*1/*1 carriers
9949481|NCT01082796|Other|CYP2C19 PMs group|cyp2c19*2/*2 or *2/*3
9949482|NCT01082809|No Intervention|Sunitinib|Sunitinib, 37.5 mg orally once daily continuously, comprising a 4-week cycle
9949483|NCT01082822|Sham Comparator|standard of care|In the first step, the patient was periodontally treated until the inflammation was eliminated through control of bacterial biofilm and oral hygiene for about 6 months. Then the rigid fixed appliances were placed on the diseased teeth, reverse beveled open-flap surgery was performed in the buccal and palatal maxillary sides of the periodontitis-caught teeth to allow granulation tissue debridement and proper root preparation. The roots were completely scaled, and 17%EDTA was applied for 2 minutes to demineralize the root surfaces and bone wall defects, the flap was sutured.
9949484|NCT01082822|Experimental|PDLSC cell sheet transplantion|Periodontal ligament stem cell derived cell sheet or pellet with carrier such as Bioss was implanted into periodontal defect area at post surgical treatment.
10004796|NCT01579344|No Intervention|Thyroid carcinoma, without radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy
9949485|NCT01082822|Experimental|the bio-ss implantation|implantation of Bioss at post surgical treatment
9949486|NCT01082835||the group of Jiangzhuo Qinggan prescription|
9949487|NCT01082835||the group of irbesartan|
9949488|NCT01082848|Experimental|aripiprazole|
9949489|NCT01082848|Placebo Comparator|placebo|
9949490|NCT01082861|Experimental|HPV&HBV vaccin|HPV&HBV vaccin
9949491|NCT01082861|Experimental|HPV vaccination|HPV vaccination
9949492|NCT01082861|Experimental|HBV vaccination|HBV vaccination
9949493|NCT01082887|Experimental|TIL-Ad-INFg|
9949494|NCT01082900|Experimental|Prophylactic CPAP intervention|Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
9949495|NCT01082900|Active Comparator|No Intervention|Provision of standard care in the Delivery Room
9949496|NCT01082913|Experimental|Sacral Surface Electrical (SSE)|
9949497|NCT01082913|No Intervention|control|
9949498|NCT01082926|Experimental|Arm I|Patients receive intratumoral GRm13Z40-2 therapeutic allogeneic lymphocytes over 10 minutes on days 1 and 3 and intratumoral aldesleukin over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity.
9949499|NCT01082978|Experimental|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
9949500|NCT01082978|Experimental|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
9949501|NCT01082978|No Intervention|Usual standard of care|Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.
9949502|NCT01082991|Other|prevention|
9949503|NCT01083004|Active Comparator|Indocyanine green arm|
9949504|NCT01083004|Active Comparator|Brilliant blue|
9949505|NCT01083017||chlorthalidone|
9949506|NCT01083017||motivational invervention|motivational interview(s) vs. repeated calls vs. no particular intervention
9802062|NCT05317156|No Intervention|Prone position-Control group|Patients in the prone position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
9949507|NCT01083017||standardized anti-hypertensive treatment|
9949508|NCT01083030|Placebo Comparator|Conventional PTA|Angioplasty of SFA with uncoated balloon catheters
9949509|NCT01083030|Active Comparator|Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters
9949510|NCT01083043||Type 2 Diabetes Mellitus|
9949511|NCT01083056||Epimacular Gliosis Without Macular Hole|
9949512|NCT01083056||Epimacular Gliosis With Macular Hole|
9949513|NCT01083069||COOL|Patients after therapy with mild hypothermia
9949514|NCT01083069||UnCool|Patients without therapy with mild hypothermia due to non-operational cooling-devices
9949515|NCT01083095|Active Comparator|3 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
9949516|NCT01083095|Active Comparator|6 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
9949517|NCT01083095|Active Comparator|9 +/- 1 bite|Volunteers were exposed to mosquito biting for 15 min
9949518|NCT01083108|Active Comparator|Non-surgical Arm|Low-calorie Diet
9949519|NCT01083108|Experimental|Surgical Arm|Roux-en-Y Gastric Bypass
9949520|NCT01083134||percentage of stenosis|
9949521|NCT01083147||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
9949522|NCT01083212|Experimental|1|Gemfibrozil day 1-5 + AZD1656 day 4, 1 week without, Placebo day 1-5 + AZD1656 day 4
9949523|NCT01083212|Experimental|2|Placebo day 1-5 + AZD1656 day 4, 1 week without, Gemfibrozil day 1-5 + AZD1656 day 4
9949524|NCT01083225|Experimental|Client feedback|
9949525|NCT01083225|Active Comparator|Treatment as usual|
9949526|NCT01083238|Experimental|1|AZD5069 following a 10-hour fast
9949527|NCT01083238|Experimental|2|AZD5069 30 minutes after the start of a high fat meal
9949528|NCT01083251|Experimental|Peg + Vitamin D|Treatment arm with vitamin D will be treated first with vitamin D supplement for 3 months before the initiation of antiviral therapy. Vitamin D levels will be measures at baseline and three months after. The serum vitamin D-25-OH levels should be > 32 ng/ml before the initiation of antiviral treatment). HBV DNA levels will be also measure at baseline and after 3 months of mono therapy with vitamin D
9949529|NCT01083251|Active Comparator|Peginterferon|
9949530|NCT01083251|Active Comparator|Sebivo|Nucleotide Analog Telbivudine 600 mg daily
9949531|NCT01083251|Active Comparator|entecavir + vitamin d|baraclude 1 mg x1/ day + vitamin d
9949532|NCT01083264|Experimental|Arm 1|
9949533|NCT01083264|Experimental|Arm 2|
9949534|NCT01083264|Experimental|Arm 3|
9949535|NCT01083277|Experimental|variable ventilation|A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
9949536|NCT01083277|Other|conventional ventilation|This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
9949537|NCT01083290|Experimental|Order of strenghts; 25 mg, 50 mg, 100 mg|
9949538|NCT01083290|Experimental|Order of strenghts; 50 mg, 100 mg, 25 mg|
9949539|NCT01083290|Experimental|Order of strenghts; 100 mg, 25 mg, 50 mg|
9949540|NCT01083303|Experimental|weaning at 1500 g|weaning infants from an incubator at 1500 g
9949541|NCT01083303|Active Comparator|weaning at 1600 g|weaning infants from an incubator at 1600 g
9949542|NCT01083329|Placebo Comparator|placebo|for 16 weeks
9949543|NCT01083329|Active Comparator|nicotinic acid|"for 16 weeks :~week 1 = 375 mg per day,~week 2 = 500 mg per day,~week 3 = 750 mg per day,~week 4 = 1000 mg per day,~week 5 = 1500 mg per day,~weeks 6 to 16 = 2000 mg per day."
9949544|NCT01083355||Mechanical ventilation|Critical care patients
9949545|NCT01083381|Active Comparator|treatment group|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.
9949546|NCT01083381|Placebo Comparator|Control group|Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
9949547|NCT01083394|Active Comparator|conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.
9949548|NCT01083394|Experimental|PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.
9949549|NCT01083407|Experimental|0.12% Chlorhexidie Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
9949550|NCT01083407|Placebo Comparator|Toothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
9949551|NCT01083420|Active Comparator|Dexamethasone|Dexamethasone 0.01% mouthwash
9949552|NCT01083420|Experimental|Minocycline|Minocycline 0.2% mouthwash
9949553|NCT01083446|Active Comparator|A|Nutritional intervention, standard Israeli breakfast
9949554|NCT01083446|Active Comparator|B|Nutritional Intervention, fast
9949555|NCT01083459||PCV13 immunized|Children who receive the 13-valent pneumococcal conjugate vaccine
9949556|NCT01083459||PCV13 unimmunized|PCV13 unimmunized Household members of PCV13 immunized children
9949557|NCT01083498|Experimental|Ablative fractional laser|"In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
9949558|NCT01083498|No Intervention|Control|"In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
9949559|NCT01083511||Symptomatic|Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
9949560|NCT01083524|Experimental|Group 1|Dichloroacetate Sodium 3.0 mg/kg, BID
9949561|NCT01083524|Experimental|Group 2|Dichloroacetate Sodium 6.25 mg/kg, BID
9949562|NCT01083524|Experimental|Group 3|Dichloroacetate Sodium 12.5 mg po bid
9476467|NCT03571490|Active Comparator|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
9476468|NCT03571490|Placebo Comparator|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
9476469|NCT03571464|Experimental|Immediate use GGRO Mobile App|The group starts using the GGRO Mobile App immediately after the first assessment (T1) for 15 days.
10004797|NCT01579357|Other|A|Capecitabine in week 1,2,4,5,7 and 8 Cetuximab in week 3 to 9 Oxaliplatin in week 7
9802063|NCT05317156|No Intervention|Supine position-Control Group|Patients in the supine position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
9802064|NCT05317130||This is an observational study.|The cohort will consist of elite Para athletes (athletes with an impairment).
9802065|NCT05317117|Other|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|All participants will be tested with two investigational IVDs at the point of care, the NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and the NxTek™ Malaria P.f/P.v RDT, in addition to comparator tests and the standard of care (microscopy). The investigational tests will not be used to determine any treatment or case management.
9802066|NCT05317104|Experimental|Aerobic Exercise Group|"Intervention group will be included in a program consisting of warm-up, loading and cool-down periods. Maximum Heart Rate (MHR) method will be used to determine the intensity of aerobic exercise training. Since moderate aerobic exercise training was aimed, exercise training will be given in 55-74% of MHRs. Exercise training will be started at mild-moderate intensity. Afterwards, within the limits that the person can tolerate and does not cause complications, with 5-10 minute increments every 1-2 weeks, the person will progress without muscle pain, injury, respiratory distress or fatigue due to overload. Polar H9 Heart Rate Sensor, which will be worn on the chest, will be used to monitor heart rate during exercise training.~Aerobic exercise training will be given in accordance with the procedures determined on the treadmill in the laboratory environment, with a program consisting of 6-week."
9802067|NCT05317104|No Intervention|Control Group|No intervention will be made other than evaluations. However, in order for the participants in this group to achieve the same health gains, they will remain under follow-up and control to apply the same aerobic exercise training program after the study is completed.
9802068|NCT05317091|Experimental|Laughter yoga practice|Laughter yoga for nurses The experimental group was divided into three groups as 18-17-16 people. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday Saturday between 20:00-21:00.laughter yoga for nurses-Deep breathing exercises Deep breathing exercises (5 minutes), Warm-up exercises (10 minutes) laughter yoga for nurses-Childish games Childish games (10 minutes), Laughter exercises (15 minutes).
9802069|NCT05317091|Experimental|Laughter yoga session parts-1|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
9802070|NCT05317091|Experimental|Laughter yoga session parts-2|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
9802071|NCT05317091|Experimental|Laughter yoga session parts-3|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
9802072|NCT05317091|Experimental|Laughter yoga session parts-4|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
9802073|NCT05317078|Experimental|Part 1: AMG 794 Monotherapy Dose Exploration|Participants with claudin 6-positive advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) or epithelial ovarian cancer (EOC) will be treated in up to 8 multiple ascending cohorts with additional participants optionally enrolled in dose exploration cohorts with target dose levels that have previously been shown to be safe and tolerable.
10004798|NCT01579357|Other|B|Capecitabine in weeks 1,2,4,5,7, and 8 Cetuximab in weeks 1,8 and 9 Oxaliplatin in week 7
9802074|NCT05317078|Experimental|Part 2: AMG 794 Monotherapy Dose Expansion|Participants with claudin 6-positive advanced/metastatic NSCLC or EOC will be treated with the OBD of AMG 794 identified in Part 1.
9802075|NCT05317052|Experimental|Massage|Massage therapy
9802076|NCT05317052|Experimental|Music|Music therapy
9802077|NCT05317052|No Intervention|Control|Control
9802078|NCT05317039|Experimental|Group A|Group A will be treated with the buccal plate repositioning technique and grafted with SCPC.
9802079|NCT05317039|Active Comparator|Group B|Group B will be similarly managed and grafted using DFDBA
9802080|NCT05317026|Experimental|V-SBRT|Vertebroplasty followed by Stereotactic Body Radiation Therapy (SBRT)
9802081|NCT05317026|Other|SBRT|SBRT is the actual standard of care.
9802082|NCT05317013|Experimental|Group A - 100 mg CBD|100 mg CBD per day
9802083|NCT05317013|Experimental|Group B - 300 mg CBD|300 mg CBD per day
9802084|NCT05317013|Placebo Comparator|Group C - Placebo|Placebo
9802085|NCT05317000|Active Comparator|Arm A: 5-azacytidine|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Dexamethasone will be reserved for patients who are not controlled by the initial regimen.~A single cycle of 5-azacytidine will be administered and the patient scheduled for surgery in the period of day 16 through day 18."
9802086|NCT05317000|Active Comparator|Arm B: Nivolumab|"Nivolumab will be administered at a dose of 240 mg IV day 1 and day 15. Treatment must be given on a Monday or Tuesday.~No premedication will be given. Patients will be observed following the initial dose of nivolumab per institutional Surgery will be scheduled in the period of day 16 through day 18."
9802087|NCT05317000|Experimental|Arm C: Combination 5-azacytidine and Nivolumab|"Patients will receive 5-azacytidine 75mg/m2 IV daily x 5. Treatment must begin on a Monday. 5-azacytidine will be given prior to nivolumab on day 2.~Patients will receive anti-emetic premedication with prochlorperazine 10 mg IV, a 5HT3 antagonist per institutional guidelines, aprepitant or fos-aprepitant, and prn lorazepam on day 1. Day 2-5 patients will receive prochlorperazine 10 mg IV. Subsequent day 5HT3 antagonist therapy will be determined per institutional guidelines, as recommendations vary based on the half-life of the agent chosen. PRN lorazepam can be used days 2-5.~Nivolumab will be administered at a dose of 240 mg IV day 2 and day 16. No additional premedication will be given on day 16. Dexamethasone will be reserved for patients whose nausea and/or emesis is not controlled by the initial regimen. Surgery will be scheduled in the period of day 17 through day 18."
9802088|NCT05316987|Other|Active vitiligo patients|NBUVB
9802089|NCT05316961|Experimental|PEMF group|"Participants will receive active pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 1.5 mT, 10Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
9802090|NCT05316961|Sham Comparator|Sham group|"Participants will receive sham pulsed electromagnetic field therapy two times a week for eight weeks. The options of the appliance will be adjusted to 0 mT, 0Hz on one leg for 10 minutes. A total of 16 sessions will be given to each participant. Each session will last for 10 minutes. Participants will be positioned in sitting on a chair comfortably. They will receive intervention at Prince of Wales hospital.~3 sets of 10 repetitions of the eccentric exercises are carried out once daily for 6 weeks and after 6 weeks, the patients are instructed to carry out 3 sets of 10 repetitions, 3 times per week for 6 more weeks. The intensity of the exercise should be such that pain, or discomfort, is experienced in the last set of 10 repetitions."
9802091|NCT05316935|Experimental|GnRHa + letrozole group|Patients will be stratified into EEC group and EAH group. Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
9949563|NCT01083537|Experimental|Cisplatin|"Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
9949564|NCT01083537|Experimental|Paclitaxel|"Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
9949565|NCT01083550|Experimental|DA intervention|Decision aid exposure + usual care
9949566|NCT01083550|No Intervention|Control|Usual care
9949567|NCT01083563||RA inadequate response to methotrexate|Individuals with rheumatoid arthritis who have had an inadequate response to methotrexate and will be starting on an anti-TNF agent.
9949568|NCT01083563||RA inadequate response to anti-TNF.|Individuals with rheumatoid arthritis who have had an inadequate response to an anti-TNF and will be be given a rituximab infusion.
9949569|NCT01083589|Experimental|Imatinib Mesylate + Docetaxel|Imatinib Mesylate (Gleevec) Oral 400 mg daily + Docetaxel (Taxotere) 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
9476470|NCT03571464|Active Comparator|Delayed use GGRO Mobile App|Delayed use GGRO Mobile App group started using the App 15 days after the first assessment (T2).
9949570|NCT01083719|Experimental|FDG-PET|A comparison of FDG-PET versus MRI based target volume delineation in glioblastoma and the role of FDG-PET/CT in the alteration of MRI based target volumes.
9949571|NCT01083745||IVF patients - 1|Poor responders
9949572|NCT01083745||IVF patients - 2|Good responders
9949573|NCT01083784|Experimental|Prophylactic group|the group that used prophylactic anticonvulsants (valproate, clonazepam)
9949574|NCT01083784|No Intervention|Control group|control group
9949575|NCT01083797|Other|dexmedetomidine, chloral hydrate|sedation with dexmedetomidine or chloral hydrate on separate occasions in the same patients
9949576|NCT01083823|Active Comparator|Self-reported mood swings|Participants who self-identify as experiencing severe mood swings that interfere with life.
9949577|NCT01083823|Active Comparator|Healthy|Participants who self-identify as not experiencing mood swings in the past or at present and who deny past / present problems with substance use.
9949578|NCT01083862|Experimental|Educational Intervention - Video & Text|"Educational Intervention - Video & Text describing Living with Coronary Artery Disease."
9802092|NCT05316935|Experimental|Diane-35 + metformin group|Patients will be stratified into EEC group and EAH group. Then every 12 weeks, an hysteroscope will be used to evaluate the endometrial condition, and the pathological findings will be recorded.
9802093|NCT05316922|Experimental|TSH suppression during irradiation|"From 14 days beforehand and throughout their RT, patients in the experimental arm will receive L-thyroxine in the morning, starting with 1-2 μg/kg, and adjusting the dose every 3 days to ensure TSH < 0.3 μIU/mL before RT beginning. The 0.3 μIU/mL threshold is just below normal range not causing hyperthyroidism, and is defined as mild TSH suppression. Based on hormone status, L-thyroxine doses will be gradually increased to patients' individual minimum TSH-suppressive dose before starting RT, maintained throughout the treatment, then rapidly tapered off and stopped. During radiation treatment course will be checked twice a week for serum FT3, FT4, TSH assays in order to maintain TSH < 0.3 μIU/mL, possibly without exceeding normal levels of FT3 and FT4. Once a week patients will also have a full visit and any other blood examination according to protocol in use and Institutional practice."
9802094|NCT05316922|No Intervention|Any TSH suppression during irradiation|Patient in the standard arm will perform radiotherapy treatment without any TSH suppression. At the end of radiation they will do serum FT3, FT4, TSH assay and then, after one year from RT, thyroid ultrasound + serum FT3, FT4, TSH assay.
9802095|NCT05316909|Experimental|Baby doll with remote controlled jaw|In this arm, standardized patients will use the Newborn Oral Assessment and Latch Simulator (NORALSim) to demonstrate and teach newborn positioning and attachment in the simulation.
9802096|NCT05316909|Active Comparator|Standard care/doll|In this arm, standardized patients will use a cloth doll/standard treatment to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
9802097|NCT05316896|Experimental|Internal perturbation|The people included in this group did 6 internal perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
9802098|NCT05316896|Experimental|Eksternal perturbation|The individuals included in this group performed 6 external perturbation exercises with 10 repetitions in each session. The patients performed a total of 60 perturbation exercises in one session. Perturbations were chosen according to the patient's tolerance, from easy to difficult. Treatment protocols of stroke individuals were determined according to their functional levels. 6 of the exercises given below were chosen according to the levels determined at the beginning of the study and were progressed by getting more difficult.
9802099|NCT05316883|Other|clozapine treatment|Open label clozapine will be given to all participants in clinical doses adjusted to sideeffects and clinical effect
9802100|NCT05316870|Experimental|Intervention group|The standardized anticoagulation management program of atrial fibrillation in primary medical institutions was implemented for the patients with atrial fibrillation in the intervention group.
9802101|NCT05316870|Other|Control group|The current general practitioner management mode was continued for the patients with atrial fibrillation in the control group.
9802102|NCT05316857|Other|Orelabrutinib + Rifampin|"Orelabrutinib is a white, round, uncoated table,Subjects take high dose orelabrutinib in the first day and the tenth day.~Rifampin is a capsule,Subjects take 600mg QD rifampin in the third day to the eleventh."
9802103|NCT05316857|Other|Orelabrutinib + Itraconazole|"Orelabrutinib is a white, round, uncoated table,Subjects take low dose orelabrutinib in the first day and the eighth day.~Itraconazole is a capsule,Subjects take 600mg QD rifampin in the third day to the tenth."
9802104|NCT05316844||Office Employees Group|Office Employees with neck pain
9802105|NCT05316831|Experimental|Group A|Group A CLL patients: Previously immunized with PCV13, in this study receiving PCV13 followed by PPSV23
9949579|NCT01083862|Active Comparator|Educational Intervention - Text Only|"Educational Intervention - Text Only describing Living with Coronary Artery Disease."
9949580|NCT01083875|Experimental|0.5% amlexanox oral rinse|Patients treated with an oral rinse containing the active 0.5% amlexanox
9949581|NCT01083875|Placebo Comparator|Vehicle|Patients treated with an oral rinse containing no active
9949582|NCT01083888|Experimental|1 group|Participants received a single oral dose of ASP1517 on Days 1 and 8
9949583|NCT01083914||OPCAB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
9949584|NCT01083914||CPB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
9949585|NCT01083914||MECC|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
9949586|NCT01083927|Active Comparator|Rotational Narrow Strip Graft|Technique of surgery
9949587|NCT01083927|Active Comparator|Full Graft|Surgical technique
9949588|NCT01083940|Experimental|Reminders to providers|
9949589|NCT01083940|No Intervention|usual care|
9949590|NCT01083953|Experimental|Sevoflurane|1 arm will receive sevoflurane at varying concentrations at which extubation is attempted according to the Dixon up and down method
9949591|NCT01083953|Experimental|Desflurane|1 arm will receive desflurane at varying end tidal concentration at which extubation will be attempted according to Dixon up and down method
9949592|NCT01083966|Experimental|Avastin|IA Avastin
9949593|NCT01083992|Other|Galvus + vitamin D|Galvus in combination with vitamin D
9949594|NCT01083992|Other|Galvus|vitagliptin as monotherapy
9949595|NCT01084031|Experimental|propofol|
9949596|NCT01084044|Experimental|ulinastatin|
9949597|NCT01084044|Active Comparator|saline solution|
9949598|NCT01084044|Placebo Comparator|Sugar pill|
9949599|NCT01084057|Experimental|Arm I (Cohort A)|Patients receive oral vorinostat once daily on days 1-14 and ixabepilone IV over 3 hours on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9949600|NCT01084057|Experimental|Arm II (Cohort B)|Patients receive oral vorinostat once daily on days 1-7 and 15-21. Patients also receive ixabepilone IV over 3 hours on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9949601|NCT01084070|Experimental|Early oral feeding|
9949602|NCT01084070|Active Comparator|Traditional Care|
9949603|NCT01084096|Active Comparator|Intervention|Eligible women at high risk for preterm birth will be identified and four 6 mg doses of dexamethasone will be administered before delivery.
9949604|NCT01084096|No Intervention|Control|Control arm will not receive a specific intervention for comparison.
9949605|NCT01084109|Active Comparator|1|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
9949606|NCT01084109|Active Comparator|2|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
9949607|NCT01084187|Active Comparator|vardenafil on demand|four sexual attempts with 20 mg vardenafil during next four weeks
9949608|NCT01084187|Placebo Comparator|placebo|placebo of vardenafil during four weeks
9949609|NCT01084187|Active Comparator|daily vardenafil|10 mg of vardenafil each day during four weeks
9949610|NCT01084200|Experimental|Propofol|anesthesia maintenance with propofol and remifentanil
9949611|NCT01084200|Experimental|Sevoflurane|Sevoflurane and Remifentanil for anesthesia maintenance
9949612|NCT01084200|Experimental|Sevoflurane+Propofol|Sevoflurane+Propofol for anesthesia maintenance
9949613|NCT01084213|Active Comparator|IPTp with SP|Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
9949614|NCT01084213|Experimental|IST using RDTs|Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.
9949615|NCT01084226|Active Comparator|Sterol|Additional plant sterols incorporated in the rye bread
9476471|NCT03571438|Experimental|CK2(CX4945) and ATM(Ku 60019)|Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
9949616|NCT01084226|Placebo Comparator|control|No added plant sterol in the identical-looking rye bread
9949617|NCT01084291|Experimental|DEN1 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
9949618|NCT01084291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
9949619|NCT01084304||Active|Use of ovulation tests to aid conception
9949620|NCT01084304||Control|No ovulation tests to aid conception
9949621|NCT01084317||asthmatic children|patients under 18 age, with newly diagnosed asthma
9949622|NCT01084343|Active Comparator|Panel 1|Subjects in this panel receive the low dose of vaccine (10 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
9949623|NCT01084343|Active Comparator|Panel 2|Subjects in this panel receive the high dose of vaccine (50 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
9949624|NCT01084356||hand|patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
9949625|NCT01084356||thyroid|patients admitted for Tc thyroid scan
9949626|NCT01084356||parathyroid|patients investigated for parathyroid adenoma
9949627|NCT01084356||sentinel node|patients who are due to sentinel node biopsy
9949628|NCT01084369|Experimental|Testosterone, Vardenafil|All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
9949629|NCT01084395|Experimental|Adolescent Safer Sex Intervention|
9949630|NCT01084395|Experimental|Parent Safer Sex Intervention|
9949631|NCT01084395|Other|Adolescent Health Promotion Control|
9949632|NCT01084395|Other|Parent Health Promotion Control|
9949633|NCT01084408|Active Comparator|Sequent®Please|
9949634|NCT01084408|Active Comparator|Taxus™Liberté™|
9949635|NCT01084421|Experimental|Computer based intervention|Participants receive content about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general.
9949636|NCT01084421|No Intervention|Wait list control group|Participants will receive the computer based intervention at 3 months follow-up
9949637|NCT01084434|Experimental|Probiotic group|Group of 25 volunteers consuming probiotic product once a day for 7 weeks
9949638|NCT01084434|Experimental|Prebiotic group|Group of 25 volunteers consuming prebiotic product once a day for 7 weeks
9949639|NCT01084434|Experimental|Synbiotic group|Group of 25 volunteers consuming synbiotic product once a day for 7 weeks.
9949640|NCT01084434|Placebo Comparator|Placebo group|Group of 25 volunteers consuming placebo product once a day for 7 weeks
9949641|NCT01084447|Placebo Comparator|control group|In placebo muscular training group the respiratory exercise was used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA) no load.
9949642|NCT01084447|Active Comparator|trained group|In trained group the respiratory exercise used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)the load was initially set at 40% of the maximal inspiratory pressure.
9802106|NCT05316831|Experimental|Group B|Group B CLL patients: Previously immunized with PPSV23, in this study receiving PCV13 followed by PCV13
9476472|NCT03571438|Active Comparator|Sunitinib|Treatment of cell culture with Sunitinib
9476473|NCT03571438|Active Comparator|Pazopanib|Treatment of cell culture with Pazopanib
9802107|NCT05316831|Active Comparator|Group C|Group C controls: Previously immunized with PCV13, in this study receiving PCV13
9802108|NCT05316831|Active Comparator|Group D|Group C controls: Previously immunized with PPPSV23, in this study receiving PCV13
9802109|NCT05316818|Experimental|Triplet regimen (FOLFOXIRI)|The treatment planned consisted of irinotecan 160 mg/m² in 250 ml of NaCl 0.9% over 1 hr, followed by 85 mg/m² oxaliplatin in 250 ml dextrose 5% given concurrently with a 400 mg/m² leucovorin intra venous infusion in 250 ml dextrose 5% for 120 min, followed by 2400 mg/m² for 44-hr continuous infusion
9802110|NCT05316818|Active Comparator|standard duplet regimen (FOLFOX or FOLFIRI)|Regimen consisted of 180 mg/m² intravenous infusion of irinotecan for 60 min OR 85 mg/m² oxaliplatin day 1 only followed by a 200 mg/m² intra venous infusion of leucovorin for 120 min, a 400 mg/m² intravenous bolus of fluorouracil, and a 600 mg/m² continuous infusion of fluorouracil for 22 hr to be repeated on day 2
9802111|NCT05316792|Active Comparator|knee osteoarthritis|In patients with knee osteoarthritis, the thickness of the femoral articular cartilage will be measured with portable USG before and immediately after walking.
9802112|NCT05316792|Active Comparator|healthy volunteers|Femoral articular cartilage thickness will be measured with portable USG before and immediately after walking in healthy volunteers.
9802113|NCT05316766|Experimental|Intervention|Will receive intervention through the multi-user touch surface
9802114|NCT05316766|Active Comparator|Treatment as usual|This will receive conventional therapy
9802115|NCT05316753|Experimental|Schiller Defigard HD- 7 - DGHD7|Device: Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard HD- 7 - DGHD7, Schiller Medical, France) with adult pads (0-21-0003 Schiller) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 200J, 200J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 min post-shock), otherwise after the 3rd shock Other Name: DGHD7
9802116|NCT05316753|Active Comparator|LIFEPAK 15, Physio-Control - LP15|"Device: Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with escalating selected energy: 150J, 360J, 360J. The third shock is combined with MAP (Manual Pressure Application). The protocol is stopped at successfull cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock.~Other Name: LP15"
9802117|NCT05316727||Vaping|At least weekly vape use over the past 3 months of the subjects unspecified product
9802118|NCT05316727||Non vapers|No previous history of vape use and no current history of smoking tobacco for controls
9802119|NCT05316714|Experimental|IPP Nanofat Grafting|Nanofat surgical grafting in albuginea penile tunica
9802120|NCT05316688|Experimental|Diagnostic (tozuleristide, surgery, NIR imaging)|Beginning 1 hour before surgery, patients receive tozuleristide IV over 1-5 minutes. Patients then surgical resection per standard of care and undergo Canvas NIR imaging.
9802121|NCT05316675|Active Comparator|Group 1|:(25)patients will be treated by oral isotretinoin; 0.5 -1 mg/kg/day in two divided doses for 6 months.
9802122|NCT05316675|Active Comparator|Group 2|:(25) Patients will be treated by oral isotretinoin; 0.5 -1 mg/kg/day for seven days each month for 6 pulses.
9802123|NCT05316675|Active Comparator|Group 3|:(25) Patients will be treated by oral isotretinoin; 0.1-0.2 mg/kg/day for 6months
9802124|NCT05316675|Active Comparator|Group 4:|(25) Patients will be treated by oral isotretinoin;20mg /day for one month then the dose increased in monthly steps to reach the standard dosing for 6 months
9802125|NCT05316662||Semaglutide|Participants with T2D will be assessed for clinical parameters associated with the once-daily use of oral semaglutide who have not previously been treated with injectable glucose-lowering medication in routine clinical practice.
9802126|NCT05316649||HPB group|Adult patients undergoing for elective liver or pancreas surgery at Department of Surgery, University Hospital Hradec Kralove, Czech Republic.
9802127|NCT05316636|Experimental|Group A|Vibrational forces from onset of treatment, from weeks 0-6; then, no vibrational forces during the rest of the treatment
9802128|NCT05316636|Experimental|Group B|From weeks 0-6, no vibrational forces. Vibrational forces starting at 6 weeks after treatment onset and applied for 6 weeks until week 12
9802129|NCT05316636|Active Comparator|Group C|Control, no vibrational forces
9802130|NCT05316623|Sham Comparator|Control group|Simulated TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
9802131|NCT05316623|Experimental|Intervention group|Real TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
9802132|NCT05316610|Experimental|Body Confident Athletes|Participants in the intervention condition will take part in an in-person program consisting of five sessions over five weeks.
9802133|NCT05316610|No Intervention|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
9802134|NCT05316597|Experimental|Terpenes On|"Forest bathing intervention with no filtration of terpenes from inhaled air (terpenes on)"
9802135|NCT05316597|Active Comparator|Terpenes Off|"Forest bathing intervention with filtration of terpenes from inhaled air (terpenes off)"
9949643|NCT01084460||EUS-suspected gastric GISTs|In this retrospective study, 50 patients with EUS-suspected gastric GISTs, less than 3 cm were enrolled and had EUS follow-up at least two times over a period of more than 24 months.
9949644|NCT01084473|Experimental|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
9949645|NCT01084473|Active Comparator|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
9949646|NCT01084473|Placebo Comparator|Placebo|The study subjects will be given a saline infusion.
9949647|NCT01084486|Experimental|Metformin, Adiponectine, Arterial Compliance|
9949648|NCT01084512||Healthy group|control subjects
9949649|NCT01084512||Paraplegic group|Paraplegic subjects
9949650|NCT01084512||Tetraplegic group|tetraplegic subjects
9949651|NCT01084525|Experimental|OTO-104 (steroid) 3 mg|
9949652|NCT01084525|Placebo Comparator|Placebo|
9949653|NCT01084525|Experimental|OTO-104 (steroid) 12 mg|The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
9949654|NCT01084564||1|moderate to severe uncontrolled asthma
9949655|NCT01084577|Active Comparator|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
9949656|NCT01084577|Active Comparator|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
9949657|NCT01084590|Experimental|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
9949658|NCT01084590|Active Comparator|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
9949659|NCT01084616||Vaginal Dryness|
9949660|NCT01084616||Non-vaginal dryness|
10004799|NCT01579370|Active Comparator|Quaternary ammonium|Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
10004800|NCT01579370|Experimental|Bleach|Rooms will be terminally cleaned using bleach-containing products.
10004801|NCT01579370|Experimental|Quaternary ammonium and UV-C light|Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
10004802|NCT01579370|Experimental|Bleach and UV-C light|Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.
10004803|NCT01579383|Experimental|Part A, Cohorts A - H|ALD403/Placebo
10004804|NCT01579383|Experimental|Part A, Cohort I|ALD403/Placebo
9476474|NCT03571438|Active Comparator|Temsirolimus|Treatment of cell culture with Temsirolimus
10004805|NCT01579383|Experimental|Part B|ALD403/Placebo/Sumatriptan
10004806|NCT01579396|Experimental|septeX|septeX CVVH for 12h after cardiac surgery
10004807|NCT01579396|Other|standard therapy|standard therapy according to local practice
10004808|NCT01579409|Other|1-25th percentile of the PNNS score|
10004809|NCT01579409|Other|75-100th percentile of the PNNS score|
10004810|NCT01579422|Experimental|social cognitive training|
10004811|NCT01579435|Experimental|Therapeutic tDCS|6 patients with essential tremor
10004812|NCT01579435|Experimental|Physiopathological tDCS|6 patients with essential tremor
10004813|NCT01579448|Experimental|Vaccine to past vaccinated participants|The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.
10004814|NCT01579448|Active Comparator|Vaccine to past placebo recipients|The second arm includes subjects, who received two placebo doses, five years prior. Arm two will receive a primary immunization series consisting of one Shanchol™ dose at baseline and one at day fourteen
10004815|NCT01579448|Placebo Comparator|No intervention to past placebo recipients|The third arm includes subjects, who received two placebo doses, five years prior. This third arm will not receive any intervention and will serve to represent a baseline immune response by vaccine naïve individuals exposed to natural exposure.
10004816|NCT01579461|Experimental|mild hepatic impairment|
10004817|NCT01579461|Experimental|moderate hepatic impairment|
10004818|NCT01579461|Experimental|healthy volunteers (matched with mild hepatic)|
10004819|NCT01579461|Experimental|healthy volunteers (matched with moderate hepatic)|
10004820|NCT01579500|Active Comparator|botulinum toxin A|
10004821|NCT01579500|Placebo Comparator|normal saline|
10004822|NCT01579526|Experimental|FP01 Dose 1|Drug
9949661|NCT01084642||survey|Participants will be asked to complete a survey as a one time assessment.
9949662|NCT01084681|Active Comparator|SILK Artery Reconstruction Device|One arm will receive only the commercially available SILK Artery Reconstruction Device [flow diverter] (no intracranial coils are to be used in association with the SILK device).
9949663|NCT01084681|Active Comparator|Coils|The other arm will be treated with commercially available intracranial coils: the coils can be used with eventual balloon remodeling and/or stents when necessary.
9949664|NCT01084746|Active Comparator|PC-based tailored intervention|
9949665|NCT01084746|Active Comparator|Printed educational materials|
9949666|NCT01084746|No Intervention|No patient intervention|Patients will not receive a patient-directed intervention.
9949667|NCT01084811||chronic rhinosinusitis with nasal polyps|
9949668|NCT01084811||chronic rhinosinusitis without nasal polyps|
9949669|NCT01084811||Control group|
9949670|NCT01084824|Active Comparator|Liquid nitrogen and canthardin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
9949671|NCT01084824|Placebo Comparator|Liquid nitrogen and placebo|Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
9949672|NCT01084850||Diabetes Type II|Patients with type 2 Diabetes Mellitus
9949673|NCT01084850||Control|Patients with no diabetes
9949674|NCT01084863|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
9949675|NCT01084863|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
9949676|NCT01084876|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
9949677|NCT01084876|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
9949678|NCT01084889||symptomatic genital descensus|"Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention.~Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally."
9949679|NCT01084902|Experimental|latnoprost|once daily
9949680|NCT01084902|Active Comparator|Brinzolamide|two times daily
9476475|NCT03571425|Placebo Comparator|Oral Placebo|Placebo drink
9949681|NCT01084915||SAGB VC group|Retrospectively patients with a SAGB-VC gastric band are inventorized. They will also be interviewed and BAROS scores will be taken.
9949682|NCT01084928|Experimental|Intervention Arm (Diet and Exercise)|The lifestyle intervention will include a 16-week intervention period, followed by an 8 week, less intensive maintenance period.
9949683|NCT01084941|Experimental|Lifestyle intervention|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
9476476|NCT03571425|Active Comparator|Oral Protein|Protein drink, ingested orally
9476477|NCT03571425|Active Comparator|Enteral Protein|Protein drink, administered via enteral tube
9949684|NCT01084941|Active Comparator|Standard of care group|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
9949685|NCT01084967||Healthy lean control group|"The healthy lean controls consisted of age-, sex- and geography-matched young volunteers, or golden standard lean controls from China Cardiometabolic Disease and Cancer Cohort Study (4C Study).~Healthy volunteers:~BMI:18.5-22.9kg/m2;~Age:14-30 years old;~To be proved normal by the examinations of liver and kidney function,blood lipids profile,FBG, PBG, fasting insulin and HbA1c.~Controls from 4C Study:~17.0≤BMI≤23.0kg/m2 and waist circumference <85cm for males and <80cm for females;~1.8≤LDL-c≤3.4mmol/l;~FBG<6.1, PBG<7.8;~HOMA-IR<2.5;~BP <140/90mmHg;~eGFR>60mL/(min·1.73 m2), ALT<40IU/L, AST<40IU/L;~Excluding the history of hyperthyroidism, digestive system diseases, malignant tumors, infectious diseases (hepatitis B) and other systemic wasting diseases; Severe dysfunction of heart, lung and kidney;~Not using antihypertensive, hypoglycemic and lipid-lowering drugs；~No history of smoking."
9949686|NCT01084967||obesity group|"BMI ≥30kg/m2;~Age:14-30 years old; obesity group 4000, lean healthy control group 4000"
9949687|NCT01084980|Experimental|Tacrolimus|
9949688|NCT01084993|Active Comparator|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
9949689|NCT01084993|Active Comparator|Heparin|70 U/kg or standard practice
9949690|NCT01085019|Experimental|Dietary supplement: Cinnamon|
9949691|NCT01085019|Experimental|Dietary supplement: Oregano|
9949692|NCT01085019|Experimental|Dietary supplement: Ginger|
9949693|NCT01085019|Experimental|Dietary supplement: Rosemary|
9949694|NCT01085019|Experimental|Dietary supplement: Black pepper|
9949695|NCT01085019|Placebo Comparator|Dietary supplement: Placebo|
9949696|NCT01085032|Experimental|Arm A|Behavioral Counseling and Nicotine Patch
9949697|NCT01085032|Placebo Comparator|Arm B|Behavioral counseling and placebo patch
9949698|NCT01085058|Experimental|A: lenograstim|total group
9949699|NCT01085071|Active Comparator|Normal-high potassium (NHP)|A potassium target of 4.5 mmol/L.
9949700|NCT01085071|Active Comparator|Normal-low potassium (NLP)|A potassium target of 4.0 mmol/L.
9949701|NCT01085110||Persistent Pain patients|Patients with persistent postherniotomy pain after laparoscopic operation and pain related impaired daily function
9949702|NCT01085123|Experimental|1|PET 1: baseline, PET 2: 10 mg Zomig® Rapimelt, PET 3: 5 mg ZOMIG® Rapimelt, PET 4 2.5 mg ZOMIG® Rapimelt
9949703|NCT01085149|Experimental|study group|simvastatin will be inserted to sockets
9949704|NCT01085149|No Intervention|control|sockets will be left to healing without material in socket
9949705|NCT01085175|Experimental|Cohort 1|Low risk Heart Failure patients
9949706|NCT01085175|Experimental|Cohort 2|High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing
9949707|NCT01085188|Experimental|Assertive Continuing Care (ACC)|Behavioral intervention comprised of the community reinforcement approach plus case management delivered in home and other community settings to youth and their caregivers.
10004823|NCT01579526|Experimental|FP01 Dose 2|Drug
10004824|NCT01579526|Experimental|FP01 Dose 3|Drug
10004825|NCT01579526|Active Comparator|Comparator|Drug
9949708|NCT01085188|Experimental|Contingency Management (CM)|Using a prize drawing system (no, low, medium and large value prizes) with adolescents could earn escalating prize drawing opportunities by completing verifiable pro-social activities and providing negative urine test and breath alcohol test results.
9949709|NCT01085188|Experimental|ACC + CM|This arm is the combination of arms 1 and 2.
9949710|NCT01085188|Active Comparator|Usual Continuing Care (UCC)|UCC consists of a discharge recommendation to seek aftercare services at nearest treatment provider to where the patient lived. This service primarily consisted of outpatient group counseling.
9949711|NCT01085227||Patients carrier of a LRRK2 mutation|
9949712|NCT01085227||Asymptomatic relatives of LRRK2 patients|
9949713|NCT01085240|Other|Start Later|The participants receive the Mission Possible intervention but it is delayed by 3 months.
9949714|NCT01085240|Experimental|Start Now|The participants start the Mission Possible program right away.
9949715|NCT01085253||Parkinson|"without gait impairment~with gait and/or balance impairment~with sleep disorders (RBD)~abnormalities of the brainstem and basal ganglia will be studied in relation with parkinsonism, gait and presence of RBD"
9949716|NCT01085253||PSP|supranuclear palsy patients study the abnormalities with the brainstem and basal ganglia and relation with the observed neurological signs (eye movements, balance, neuropsychological assessment and parkinsonism)
9949717|NCT01085253||controls|age matched controls
9949718|NCT01085279|Experimental|Non-ablative fractional laser|"In each patient, one side of the face was treated with non-ablative fractional laser in four-five sessions.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
9949719|NCT01085279|Active Comparator|Triple topical therapy|"In each patient, one side of the face was treated with triple topical therapy (Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1%) during 15 weeks.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
9949720|NCT01085292|Experimental|Group A|
9949721|NCT01085292|Experimental|Group B - D|
9949722|NCT01085305|Experimental|PCIT|Provision of Parent-Child Interaction Therapy
9949723|NCT01085305|Active Comparator|TAU|Treatment as usual from other therapists in the same clinics
9949724|NCT01085370|No Intervention|Control Group|standard medical care only
9802136|NCT05316584|Experimental|Remote Monitoring|At the time of a medication dose, participants scan the smart label by tapping it with their mobile device. Participants receive a notification on their device indicating that their medication adherence was updated. Each day a medication is due, patients receive a morning reminder through SMS message notifying them on their medications schedule. If patients fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message. Participants will also complete a patient reported outcome (PRO) 2 assessment at baseline, and then monthly for the entire 12 months of the study through an HTML link sent to patients by SMS message. If nonadherence is present and/or moderate to severe symptoms, an alert will be triggered to the research team. The research team can send the PRO2 survey to patients at any given time, at their discretion, if patients are experiencing a flare or at the time of a change in medication dose.
9949725|NCT01085370|Experimental|Intervention group|2 sessions with early psychological interventions
9949726|NCT01085409||Tinnitus|Patients with tinnitus
9949727|NCT01085409||Artery disease|Subjects with mobility constraints as a results of severe artery disease which in some cases led to leg amputation.
9949728|NCT01085409||Anxiety|Subjects with anxiety complaints
9949729|NCT01085409||Controls|Healthy controls
9949730|NCT01085422|Experimental|Arm A|
9949731|NCT01085448|Other|Low back pain|Individuals with current low back pain.
9949732|NCT01085474||1|1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
9949733|NCT01085474||2|Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
9949734|NCT01085487||Group 1|
9949735|NCT01085487||Group 2|
9949736|NCT01085487||Group 3|
9949737|NCT01085526|Active Comparator|alutard phl prat. treatment group|18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
9949738|NCT01085526|No Intervention|control group|control
9949739|NCT01085526|Active Comparator|alutard phl.prat., treatment group2|basophil activity, basophil biology measured
9949740|NCT01085552|Other|1|Group A consists of 11 Caucasian male subjects Group B consists of 12 Japanese male subjects
9949741|NCT01085565|Experimental|Exablate treatment|
9949742|NCT01085578|Placebo Comparator|Cohort1|CG400549/placebo
9949743|NCT01085578|Placebo Comparator|Cohort2|CG400549/placebo
9949744|NCT01085578|Other|Cohort3|CG400549
9949745|NCT01085604||Low back pain|Individuals with current low back pain attributed to poor trunk neuromuscular control (clinical instability).
9949746|NCT01085617|Active Comparator|B1 - Standard therapy|Standard chemotherapy for precursor B-cell ALL
9949747|NCT01085617|Experimental|B2 - Rituximab|Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction
9949748|NCT01085617|Active Comparator|T1 - Standard therapy|Standard chemotherapy for T-cell ALL
9949749|NCT01085617|Experimental|T2 - Nelarabine|Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction
9949750|NCT01085617|Active Comparator|P1 - standard palifermin|6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)
9949751|NCT01085617|Experimental|P2 - collapsed palifermin|1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)
9949752|NCT01085656|Experimental|OXi4503|Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
9949753|NCT01085669||VEPTR patients|Children treated with VEPTR Implants for severe spinal or thoracic deformities
9949754|NCT01085695|Experimental|1|
9949755|NCT01085695|Experimental|2|
9949756|NCT01085695|Experimental|3|
9949757|NCT01085695|Active Comparator|4|
9949758|NCT01085708|Experimental|1|
9949759|NCT01085708|Experimental|2|
9949760|NCT01085708|Experimental|3|
9949761|NCT01085708|Active Comparator|4|
9949762|NCT01085721|Experimental|Dexchlorpheniramine pseudoephedrine guaifenesin|
9949763|NCT01085721|Active Comparator|Dexchlorpheniramine|
9949764|NCT01085747||Plastic stent|
9949765|NCT01085747||Covered SEMS|
9949766|NCT01085773|No Intervention|Standard written information on exercise|The Control group got the diabetes outpatients clinics standard written information on exercise as a part of the treatment for Type 2 Diabetes and were, like other Type 2 Diabetes patients in the clinic, advised at inclusion to be physically active.
9949767|NCT01085773|Experimental|Exercise on Prescription|In Denmark, Exercise on Prescription have focused on individual behavioral change and an exercise program for 16 weeks. The physical training consisted of both aerobic and strength training and took place in supervised groups
9949768|NCT01085773|Experimental|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
9949769|NCT01085799|Experimental|Health Education Intervention|Groups of schools receiving the health education intervention
9949770|NCT01085799|No Intervention|Control Schools - Regular curriculum|Groups of schools not receiving the health education intervention
9949771|NCT01085838|Experimental|Cohort 1|The first cohort of 5 patients will start with a dosage of 100 mg erlotinib daily
9949772|NCT01085838|Experimental|Cohort 2|The second cohort of patients will receive 150 mg of erlotinib daily
9949773|NCT01085838|Experimental|Cohort 3|The third cohort of five patients will be enrolled to receive 300 mg of erlotinib daily
9949774|NCT01085851|Experimental|Dexchlorpheniramine 1% lotion|
9949775|NCT01085851|Active Comparator|Dexchlorpheniramine 1% cream|
9949776|NCT01085864||Patients with lung nodules on CT scan.|Patients with lung nodules on CT scan.
9949777|NCT01085877|Active Comparator|Trial part 1|
9949778|NCT01085877|Experimental|Trial part 2|
9949779|NCT01085890|Experimental|Motivational interviewing group|The participants in this arm had 2 group seminars with information on hypertension and related lifestyle factors. They participated in 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
9949780|NCT01085890|No Intervention|Treatment as usual|Participants in this group received treatment as usual for their high blood pressure, but no informational seminars and no extra visits with motivational interviewing and blood pressure measurement.
9949781|NCT01085929|Active Comparator|Incision and Drainage|Abscess underwent incision and drainage
9949782|NCT01085929|Active Comparator|Ultrasound guided needle aspiration|Ultrasound was used to identify the abscess location. A needle was introduced into the abscess cavity and aspiration of the contents were attempted.
9949783|NCT01085942||Asymptomatic rotator cuff tear|Subjects identified with an asymptomatic rotator cuff tear
9949784|NCT01085955||Acute Peripartum|pregnant women who have recently given birth and diagnosed with peripartum cardiomyopathy
9949785|NCT01085955||Healthy Peripartum|Healthy pregnant women who have recently given birth, used as controls
9949786|NCT01085955||Healthy, non-pregnant women|Healthy non-pregnant women without cardiac disease, used as controls
9949787|NCT01085955||New Non-ischemic CMP|Women 18-60 years old who have been diagnosed with non-ishemic cardiomyopathy within the last 6 months and have an ejection fraction less than OR equal to 45% by echocardiogram.
9949788|NCT01085981|Active Comparator|GRAS ingredients cream|"The study will be placebo controlled double blind study which will require two office visits after informed consent and sensitivity testing done with the study cream on the day of recruitment.~On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit Then placebo or active cream will be applied and the pt restudied. the same process is repeated another day with the second arm cream."
9949789|NCT01085981|Placebo Comparator|placebo cream then doppler study|
9949790|NCT01085994||Procalcitonin-guided group|
9949791|NCT01085994||Routine practice group|
9949792|NCT01086007||Pain patients|Patients with pain related sexual dysfunction after laparoscopic inguinal hernia repair
9949793|NCT01086007||Non-pain patients|Patients with no pain related sexual dysfunction after laparoscopic inguinal hernia repair
9949794|NCT01086020|Active Comparator|atorvastatin|patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years
9949795|NCT01086020|Experimental|atorvastatin and ezetimibe|patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years
9949796|NCT01086046|Active Comparator|Heparin|Heparin injection 10 IU/kg/hr within 24h
9949797|NCT01086046|Experimental|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days"
9949798|NCT01086059||Cohort 1 - Exposure cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have used adalimumab in the first trimester of pregnancy for any length of time from the date of conception.
9949799|NCT01086059||Cohort 2 - Matched Diseased Comparison Cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have not used adalimumab or any TNF antagonist in pregnancy.
9949800|NCT01086059||Cohort 3-Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used adalimumab or any TNF antagonist at any time in pregnancy nor have they been exposed to any known human teratogen during pregnancy.
9949801|NCT01086059||Cohort 4 - Registry Group|Pregnant women who have used adalimumab for any length of time following the first day of the last menstrual period until the end of pregnancy who do not meet Cohort 1 inclusionary criteria.
9949802|NCT01086072||Myocardial Infarction - STEMI|
9949803|NCT01086072||Myocardial Infarction - NSTEMI|
9949804|NCT01086085|Experimental|A|
9949805|NCT01086085|Experimental|B|
9949806|NCT01086085|Experimental|C|
9476478|NCT03571412|Experimental|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
9949807|NCT01086085|Experimental|D|
9949808|NCT01086098||All paced patients|
9949809|NCT01086111||PMSF|type 2 diabetes patient receiving a protein sparing diet
9949810|NCT01086111||sleeve gastrectomy|type 2 diabetes patient receiving a gastric bypass
9949811|NCT01086111||RYGBP|type 2 diabetes patient receiving a gastric bypass
9949812|NCT01086124||Echocardiography 1 month|Patients will all have an echocardiography 1 month post myocardial infarction and 3 months post myocardial infarction
9949813|NCT01086163||Omacor dose titration|"Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:~survived first-time AMI more than 12 months ago~stable medical treatment during the last 3 months (except removal of Plavix)~Ethnicity: Caucasians~Males, 50 - 60 yrs~non-diabetics~excluded are those who eat more than one meal of fish / week~excluded are those who take omega-3 supplements of any sorts"
9949814|NCT01086176||Patient-control|
9949815|NCT01086202||Tornier Reversed Shoulder Arthroplasty Medial Offset|
9949816|NCT01086202||Lateral offset arthroplasty|
9949817|NCT01086241|Active Comparator|A: routine 2D mammogram|Subject receives regular 2D mammogram.
9949818|NCT01086241|Active Comparator|B: Routine Mammogram + tomosynthesis|Routine Mammogram and tomosynthesis
9949819|NCT01086254|Experimental|Iniparib/ Gemcitabine/ Cisplatin|"Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.~Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion."
9949820|NCT01086254|Active Comparator|Gemcitabine/ Cisplatin|Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
9949821|NCT01086280||Patients exposed to Saxagliptin|
9949822|NCT01086280||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
9949823|NCT01086293||Patients exposed to Saxagliptin|
9949824|NCT01086293||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
9949825|NCT01086306||Patients exposed to Saxagliptin|
9949826|NCT01086306||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
9949827|NCT01086319||Patients exposed to saxagliptin|
9949828|NCT01086319||Patients exposed to oral antidiabetic drugs (not saxagliptin)|
9949829|NCT01086332|Experimental|phase 1/2|An escalating study of gemcitabine when combined with 1250 mg of nelfinavir twice daily. Dose of gemcitabine is increased for new subjects based on the experiences and tolerance of prior subjects. When the maximum tolerated dose is identified, a recommended phase 2 dose will be assigned and further subjects will receive that dose.
9949830|NCT01086345|Experimental|Arm I|Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
9949831|NCT01086397||1|
9949832|NCT01086436|Experimental|Rotavirus Group|Subjects will receive Rotarix™
9949833|NCT01086436|Placebo Comparator|Placebo Group|Subjects will receive placebo.
9949834|NCT01086449|Experimental|Group A|
9949835|NCT01086462|Experimental|GSK2239633|Single dose infusion of study drug over 15 minutes
9949836|NCT01086488|Experimental|Nasopharyngeal Carcinoma|A: Experimental B: Active Comparator
9949837|NCT01086514|Experimental|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|In this study we will perform Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) on patients with newly diagnosed breast cancer using a dedicated research system, derived from a standard digital mammography unit and review workstation (Senographe DS and SenoAdvantage) modified to deliver the required dual energy paired exposures and visualization of combined images.
10004826|NCT01579539|Experimental|Patients|Patients with moderate to severe thyroid-associated ophthalmopathy
10004827|NCT01579552|Experimental|Intervention Group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
10004828|NCT01579552|Active Comparator|attention control group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
10004829|NCT01579591|Experimental|VSL#3 PROBIOTIC PREPARATION|
10004830|NCT01579591|Placebo Comparator|Placebo|
10004831|NCT01579604|Experimental|Surgical arm|"Nerve reconstruction:~Early nerve transfer (around 6-9 months post cervical spine injury) will be performed in this group of patients."
10004832|NCT01579604|No Intervention|Non-surgical (or observed)|Patients in this group will receive standard of care and be observed for up to two years post injury.
10004833|NCT01579617|Experimental|BUtiful|Intervention arm, 'BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved', has 8 website sessions focused on pregnancy and STI prevention
10004834|NCT01579617|Other|DIVAS|Attention control arm, 'DIVAS. Diversity, Individuality, Vitality, Activity and Strong', has 8 website sessions focused on general health and nutrition
10004835|NCT01579630|Experimental|Pemetrexed 500mg/m2 iv|
10004836|NCT01579630|Experimental|Pemetrexed 500 mg/m2 i.v. and Gefitinib 250 mg|
10004837|NCT01579643|Experimental|LALAK|
10004838|NCT01579643|Active Comparator|Penetrating Keratoplasty (KP)|
10004839|NCT01579656|Experimental|Salba|25g of ground Salba baked into a bran muffin
10004840|NCT01579656|Experimental|Poppy|25g of ground poppy seeds baked into a bran muffin
10004841|NCT01579656|Experimental|Flaxseed|25g of ground flaxseed baked into a bran muffin
10004842|NCT01579656|Experimental|Sesame|25g of ground sesame seeds baked into a bran muffin
10004843|NCT01579656|Placebo Comparator|Wheat Bran|Bran muffin matched for total available carbohydrates, total dietary fibre and calories
10004844|NCT01579682|Experimental|Psychotherapy|Family-Based Therapy (12 sessions)
10004845|NCT01579682|Experimental|Family-Based Therapy with Intensive Family-Focused Treatment|The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
10004846|NCT01579695||Exposed Group will receive Tesamorelin|
9949838|NCT01086527|Experimental|SLCO2B1{NM_007256.2}:c.[935G>A] + [=]|Individuals in this group will be homozygous for SLCO2B1{NM_007256.2}:c.[935G>A].
9949839|NCT01086553|Experimental|A|9mg budesonide OD
9949840|NCT01086553|Active Comparator|B|3mg budesonide TID
9949841|NCT01086566|Experimental|Multiple Boost Group-15 mcg|25 healthy adults who have previously received both Clade 1 and Clade 3 vaccines as a participant in study DMID 05-0043 will receive a single dose of 15 mcg of A/Indonesia/5/05.
9949842|NCT01086566|Experimental|Primed Group-15 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 15 mcg of A/Indonesia/5/05.
9949843|NCT01086566|Experimental|Unprimed Group-90 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 90 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
9949844|NCT01086566|Experimental|Unprimed Group-15 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 15 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
9949845|NCT01086566|Experimental|Primed Group-90 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 90 mcg of A/Indonesia/5/05.
9949846|NCT01086579|Experimental|Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)|IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).
9949847|NCT01086579|Active Comparator|Control Arm PES|Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.
9949848|NCT01086592|Active Comparator|Control|
9949849|NCT01086592|Experimental|Strengthening exercise|Strong progressive strengthening exercises of lower limbs.
9949850|NCT01086592|Experimental|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
9949851|NCT01086592|Experimental|Electrotherapy+weights|
9949852|NCT01086657|Experimental|Group 1|Inactivated H5N1 Vaccine at Enrollment and inactivated H5N1 Vaccine at Week 24
9949853|NCT01086657|Experimental|Group 2|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 4
9949854|NCT01086657|Experimental|Group 3|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 8
9949855|NCT01086657|Experimental|Group 4|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 12
9949856|NCT01086657|Experimental|Group 5|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 16
9949857|NCT01086657|Experimental|Group 6|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 24
9949858|NCT01086683|Experimental|Intervention group|
9949859|NCT01086683|No Intervention|Control group|Wait list control group: The control group received usual care including clinical control visits but no systematic rehabilitation activities.
9949860|NCT01086696|Experimental|1|subjects with tumor types typically treatedwith taxanes
9949861|NCT01086696|Experimental|2|subjects with tumor types typically treatedwith taxanes
9949862|NCT01086722|Experimental|"karolinska cocktail"|The karolinska cocktail contains dextromethorphan, caffeine, losartan and omeprazol
9949863|NCT01086735|Experimental|donor lymphocyte infusion|Donor T-cell transduction
9949864|NCT01086774|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
9949865|NCT01086787||Non heart failure patients|Patients without heart failure undergoing open chest surgery
9949866|NCT01086787||Orthopedic patients|Patients without heart failure undergoing orthopedic surgery
9949867|NCT01086787||Heart failure patients|Patients with heart failure undergoing open chest surgery.
9949868|NCT01086800|Other|HLSE plus PAP|
9949869|NCT01086800|Other|HLSE plus Oxygen|
9949870|NCT01086800|Other|Healthy Lifestyles and Sleep Education|
9949871|NCT01086813|Experimental|1|
9949872|NCT01086826|Active Comparator|RT+CDDP/5-FU|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy."
9949873|NCT01086826|Experimental|RT+CETUXIMAB|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
9949874|NCT01086826|Active Comparator|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):~DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion"
9949875|NCT01086826|Experimental|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RADIOTHRAPY:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
9949876|NCT01086839|Experimental|sodium chloride 6%|"Cross-Over! experimental (days 1 - 28), then Wash-Out (28 days),then placebo comparator (days 57 - 85)."
9949877|NCT01086839|Placebo Comparator|sodium chloride 0,9%|"Cross-Over! placebo comparator (days 1 - 28), then Wash-Out (28 days),then experimental (days 57 - 85)."
9949878|NCT01086865|Active Comparator|Petivit BC|
9949879|NCT01086865|Experimental|Apetiviton BC|
9949880|NCT01086878|Experimental|Cotrimoxazole|
9949881|NCT01086891|Experimental|1|Patients with chronic obstructive pulmonary disease who show arterial oxygen desaturation to effort.
9949882|NCT01086891|Experimental|2|Patients with interstitial lung disease who show arterial oxygen desaturation to effort
9949883|NCT01086917|Experimental|Group 1|to receive a dose of 2,500 PfSPZ Challenge
9949884|NCT01086917|Experimental|Group 2|to receive a dose of 10,000 PfSPZ Challenge
9949885|NCT01086917|Experimental|Group 3|to receive a dose of 25,000 PfSPZ Challenge
9949886|NCT01086930|Experimental|Intervention Group|"In addition to standard care participants in Group A will receive:~• One hour of extra hand training five times per week for 8 weeks using the ReJoyce Workstation.~The training will be supervised by a therapist and provided to the target hand. The hand exercises will be incorporated into computer games and will involve the following tasks using different manipulanda:~reaching~grasping~manipulating~pulling~rotating~releasing"
9949887|NCT01086930|Other|Standard Care Group|Participants in the control group will not receive any training on the instrumented workstation or electrical stimulation to the hand or upper limb. They will however continue to receive standard care as well as three 15-minute specific hand activity sessions per week specifically devoted to the practice of hand activities in a one-to-one format with a therapist (as per the treatment received by the experimental group).
9949888|NCT01086943|Experimental|device arm|
9949889|NCT01086982|Experimental|Octreotide acetate LAR 30 MG|Test
9949890|NCT01086982|Active Comparator|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|
9949891|NCT01087008|Experimental|Zoledronate acid|
9949892|NCT01087008|Other|No treatment control|
9949893|NCT01087021|Experimental|cabazitaxel|"At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.~An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion."
9949894|NCT01087034||Milwaukee brace|Children with an infantile scoliosis requiring Milwaukee bracing
9949895|NCT01087034||Cheneaux brace|Children with an infantile scoliosis requiring Cheaneaux bracing
9949896|NCT01087047||Physiological modifications|Pregnant women who attend the routine ultrasound control in our institution before 14 weeks of pregnancy
9949897|NCT01087047||MRI and acoustic|Women undergoing an MRI for obstetrical purpose
9949898|NCT01087060||cysts surgically removed|
9949899|NCT01087060||cysts under surveillance|
9949900|NCT01087073|Experimental|Patient Activation|Patient knowledge in diabetes self-management behaviors and clinical measures (HbA1c, LDL, HDL, BMI, BP) are tracked at baseline, 10-weeks (post-program), 3 months (post-program) and 6 months (post-program).
9949901|NCT01087073|Experimental|Provider Training Evaluation|Pre-post surveys are conducted at each training session to assess overall satisfaction with the curriculum, knowledge of SDM, and understanding of techniques to promote its use in the healthcare setting.
9949902|NCT01087073|Experimental|Quality Improvement Evaluation|We measure quality improvement efforts through biannual staff experience surveys and one-on-one provider and clinic staff interviews.
9949903|NCT01087073|Experimental|Community Outreach Evaluation|"Pre-post surveys will be disseminated at nutrition tours (Save-A-Lot, Walgreens, 61st Street Farmers Market) to assess change in knowledge of healthy eating behaviors and proper nutrition. Surveys will also assess participant satisfaction of the tours.~Interviews will also be performed with community stakeholders to assess the costs/benefits of the collaboration and overall feedback on involvement."
9949904|NCT01087073|No Intervention|Global Evaluation of the Intervention|A chart review will be performed in order to evaluate our intervention to improve diabetes processes of care and clinical outcomes among our target population. Chart abstractions will be performed on medical records obtained from our six intervention clinics. In addition, chart abstractions from two University of Illinois at Chicago clinics and three FQHCs located on the West Side of Chicago will serve as control data.100 charts will be randomly selected from each clinic per year of the intervention. The chart review will contain charts from adult diabetes patients over a seven year period that matches the duration of the Improving Diabetes project.
9949905|NCT01087086|Experimental|Crononutrition|"Dietary pattern:~Personalized diet~Caloric restriction (-30% Total energy intake)~High adherence to the Mediterranean Diet~Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat)~Low glycemic index/load~Increased antioxidant capacity of the diet"
9949906|NCT01087086|Placebo Comparator|American Heart Association|"Dietary pattern:~Personalized diet~Caloric diet (-30% Total energy intake)~Macronutrients distribution according to the American Heart Association (AHA) guidelines"
10004847|NCT01579695||Control Group will not receive Tesamorelin|
9949907|NCT01087099|Experimental|Albendazole|Treatment with albendazole
9949908|NCT01087112|Active Comparator|Child Health Centre care|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
9949909|NCT01087112|Experimental|Mother-Infant Psychoanalytic tmt|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief that the infant understands verbal communication. The analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
9949910|NCT01087125||Pregnant RA patients with abatacept exposure during pregnancy|
10004848|NCT01579708|Experimental|Program SI! educational intervention|
9949911|NCT01087138|Experimental|Exercise|exercise class 3x's/week
9949912|NCT01087138|Experimental|exercise and calcium intake|exercise class 3x's/week and 1500mg calcium/day
9949913|NCT01087138|No Intervention|usual exercise and calcium|usual exercise and calcium intake
10004849|NCT01579708|No Intervention|Control|
9949914|NCT01087164|Experimental|Compliance|Parents will be randomized to receive high or no compliance condition where those in the experimental group will be asked about whether or not they will protect their daughter from cervical cancer or for males, their son from genital warts.
9949915|NCT01087164|Experimental|Message sidedness|Parents will be given either a one-sided verbal message or a two-sided verbal message about the HPV vaccine.
9949916|NCT01087177|Experimental|Exposure to Pedialink CEASE Trained Site|Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
9949917|NCT01087190|Experimental|INH treatment group|"randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)~INH 300 mg po qd for 9 months"
9949918|NCT01087190|No Intervention|Control group|"randomly allocated to control group in renal transplant recipients with ELISPOT (+)~no treatment"
9949919|NCT01087190|No Intervention|Observation group|"allocated to observation group in renal transplant recipients with ELISPOT (-)~no treatment"
9949920|NCT01087203|Experimental|Tanezumab|
9949921|NCT01087203|Placebo Comparator|Placebo|
9949922|NCT01087216|Active Comparator|Group Laser = Arm As A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
9949923|NCT01087216|Placebo Comparator|Bras B : the control group|patient to accept habitual treatment of corticoid
9949924|NCT01087229|Experimental|equimolar oxygen-nitrous oxide mixture|"equimolar oxygen-nitrous oxide mixture~Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture."
9476479|NCT03571412|Experimental|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
9476480|NCT03571360|Other|Pembrolizumab|Pembrolizumab 200 mg i.v., every 3 weeks, maximum of 2 years
9949925|NCT01087229|Placebo Comparator|Placebo|Patients randomized to this arm will have the placebo.
9949926|NCT01087242|Placebo Comparator|controlled group|Tang-min Lin analogue 6g,tid,po
9949927|NCT01087242|Experimental|Tang-min Lin pill|Tang-min Lin pills 6g,tid,po
9949928|NCT01087255|No Intervention|Usual Care|Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
9949929|NCT01087255|Experimental|Electronic Pillbox Monitoring System|Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
9476481|NCT03571347|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
9949930|NCT01087359|Active Comparator|LPS + melatonin night|
9949931|NCT01087359|Placebo Comparator|LPS + placebo night|
9949932|NCT01087359|Active Comparator|LPS + melatonin day|
9949933|NCT01087359|Placebo Comparator|LPS + placebo day|
9949934|NCT01087359|Experimental|LPS night|
9949935|NCT01087359|Experimental|LPS day|
9949936|NCT01087385||Troponin T elevation|
9949937|NCT01087385||No troponin T elevation|
9949938|NCT01087398|Experimental|Intervention|
9949939|NCT01087411|Experimental|Motivational Interviewing and omega 3|This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
9949940|NCT01087411|Experimental|Motivational interviewing and placebo|This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
9949941|NCT01087411|Experimental|Control and omega 3|This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
9949942|NCT01087411|Placebo Comparator|Control and placebo|This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
9949943|NCT01087424|Experimental|R mini CHOP|Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
9949944|NCT01087437|Experimental|gastrolith calcium treatment|
9949945|NCT01087450||Stage1|1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
9949946|NCT01087450||Stage 2 Randomized, blinded trial|Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment
9949947|NCT01087463|Experimental|single arm|In this single arm study, the Quantum nailing system will be used in all patients.
9949948|NCT01087476|Experimental|doxycycline hyclate|Patients will be randomly assigned to receive either a sub-microbial dose of doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
9949949|NCT01087515|Other|Blood donation|
10004850|NCT01579721|Experimental|SILS-group|20 patients undergoing Single Incision Laparoscopic Surgery
10004851|NCT01579721|No Intervention|CLS-group|20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
9949950|NCT01087554|Experimental|Arm A: Vorinostat + Sirolimus|"Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
9949951|NCT01087554|Experimental|Arm B: Vorinostat + Everolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
9949952|NCT01087554|Experimental|Arm C: Vorinostat + Temsirolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
9949953|NCT01087567|Experimental|Intensive insulin regimen|A weight based, basal bolus will be given for 12 weeks.
9949954|NCT01087567|Active Comparator|Routine Care|Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
9949955|NCT01087580|Experimental|Chemotherapy alone, no radiation therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days~B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel"
9949956|NCT01087580|Experimental|Chemotherapy with Radiation Therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel~GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
9949957|NCT01087593|Experimental|Treatment with transdermal 17β-estradiol|
9949958|NCT01087593|Placebo Comparator|Control|
9949959|NCT01087632|Experimental|Armolipid Plus|Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg
9949960|NCT01087632|Placebo Comparator|Placebo|Placebo matching Armolipid plus
9949961|NCT01087645|Experimental|Trial part 1|
9949962|NCT01087645|Experimental|Trial part 2|
9949963|NCT01087658|Experimental|Glutamine and calcium magnesium|"Glutamine 10g p.o. 3-times a day beginning at day -2 for 7 consecutive days during each chemotherapy cycle. 1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
9949964|NCT01087658|Active Comparator|Calcium magnesium|"1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
9949965|NCT01087671|Other|Open-lable study with one arm|
9949966|NCT01087684|Active Comparator|Argon laser trabeculoplasty|Patients received standard argon laser treatment
9949967|NCT01087684|Active Comparator|Selective laser trabeculoplasty|Patients received a standard selective laser treatment
9949968|NCT01087697|Experimental|Implanted with NUC|Patients who have been implanted with the Neo-Urinary Conduit
9949969|NCT01087710|Experimental|novel nutritional formula|
9949970|NCT01087710|Active Comparator|Control nutritional product|1 8oz serving per day for 12 weeks
9949971|NCT01087749|Experimental|Chronic Kidney Disease|Propranolol, Losartan, and Eprosartan will be administered to patients who have been diagnosed with Chronic Kidney disease and have a glomerular filtration rate (GFR) below 40ml/min.
9949972|NCT01087749|Experimental|Healthy Volunteers|Propranolol, Losartan, and Eprosartan will be administered to healthy volunteers without chronic kidney disease.
9949973|NCT01087840|Experimental|Raltegravir, NPEP|"Drug: Raltegravir Tablet 400mg taken orally, twice daily with or without food for 28 days along with Truvada 1 tablet taken orally daily for 28 days.~Arms: Raltegravir/Truvada"
9949974|NCT01087853|Active Comparator|Phase A1: Plasmalyte|Plasmalyte
9949975|NCT01087853|Active Comparator|Phase A2: 0.9% Saline|0.9% Saline
9949976|NCT01087853|Active Comparator|Phase B1: PlasmaVolume|PlasmaVolume
9949977|NCT01087853|Active Comparator|Phase B2: Voluven|Voluven
9949978|NCT01087866|Experimental|Metformin|
9949979|NCT01087866|Active Comparator|Insulin|
9949980|NCT01087879|Active Comparator|Oral contraceptive pill|9 weeks treatment with contraceptive pill.
9949981|NCT01087879|Active Comparator|Contraception vaginal ring|9 weeks treatment with vaginal ring.
9949982|NCT01087879|Active Comparator|Transdermal contraceptive patch|9 weeks treatment with a transdermal contraceptive patch.
9949983|NCT01087892|Active Comparator|Dietary supplement Probiotic drink|"Double blind~Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days"
9949984|NCT01087892|Placebo Comparator|Dietary supplement probiotic placebo drink|"Double blind~'placebo' is actually a control product~Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days"
9949985|NCT01087983|Experimental|Lapatinib + Sirolimus|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Sirolimus starting oral dose 1 mg daily.
9949986|NCT01087983|Experimental|Lapatinib + Metformin|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Metformin Starting oral dose 1000 mg daily.
9949987|NCT01088009|Experimental|early add-on|
9949988|NCT01088009|Active Comparator|SOC|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
9949989|NCT01088009|Other|De-novo combination|patients in this arm will receive oral lamivudine 100mg and adefovir 10mg for 104 weeks
9949990|NCT01088022|Experimental|Aprepitant, Palonosetron, dexametasone|
9949991|NCT01088022|Placebo Comparator|Placebo, Palonosetron, Dexamethasone|
9949992|NCT01088035|Experimental|Carboplatin|
9949993|NCT01088061||lean women with PCOS|
9949994|NCT01088061||Obese women with PCOS|
9949995|NCT01088061||lean control women|
9949996|NCT01088061||Obese control women|
9949997|NCT01088074|Active Comparator|Histoacryl Tissue Adhesive|Histoacryl Blue (HAB) Tissue Adhesive (n-butyl-2 cyanoacrylate; B. Braun Corp., Melsungen, Germany). Histocryl is a FDA-approved sterile liquid skin adhesive that has been utilized as a substitute for sutures for wound closure for approximately 40 years.
9949998|NCT01088074|Active Comparator|Dermabond|Dermabond High Viscosity Tissue Adhesive (2-ocytl cyanoacrylate; Ethicon, Somerville, NJ). Dermabond is also a FDA-approved liquid bonding agent that has been utilized for wound closure for approximately 10 years and proven as effective as sutures.
9949999|NCT01088074|Active Comparator|Staples|Visistat 35W Stapler (Teleflex Corp, Limerick, PA). The FDA-approved Weck staple system with stainless steel staples has been proven over years of use and remains the standard accepted closure approach due to speed of insertion as well as removal.
9950000|NCT01088074|Active Comparator|Running Subcuticular with Monocryl|Monocryl 4-0 Suture (Ethicon, Somerville, NJ). Monocryl is an FDA-approved absorbable, synthetic, suture indicated for soft tissue approximation.
9950001|NCT01088087|Placebo Comparator|Colostrum|
9950002|NCT01088087|No Intervention|Sugar pill|
9950003|NCT01088100||Patients with POCD - cases|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
9950004|NCT01088100||Patients without POCD - controls|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
9950005|NCT01088113||Tai Chi|Healthy subjects with Tai Chi practice
9476482|NCT03571347|Other|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
9950006|NCT01088113||Qigong|Healthy subjects with Qigong practice
9950007|NCT01088126|Active Comparator|Focal ablation|PV isolation + CFAE-targeted focal ablation
9950008|NCT01088126|Active Comparator|Linear ablation|PV isolation + CFAE-guided linear ablation
9950009|NCT01088139|No Intervention|Control|
9950010|NCT01088139|Experimental|Nutritional Supplementation|
9950011|NCT01088152|Active Comparator|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for celiac disease in primary care
9950012|NCT01088152|Experimental|Celiac School|Structured education using problem-based learning at 10 sessions
9950013|NCT01088165|Experimental|Adalimumab treatment group|
9950014|NCT01088165|Active Comparator|Fumaric acid esters treatment group|
9950015|NCT01088178|Experimental|Immediate Postplacental|Within 10 minutes from delivery of placenta
9950016|NCT01088178|Experimental|Early Postpartum|After 10 minutes from delivery of placenta but within 48hrs from delivery
9950017|NCT01088178|Experimental|Interval|After 6 weeks postpartum
9950018|NCT01088191|Active Comparator|Hyaluronan Alone|Hyaluronan Alone
10004852|NCT01579734|Placebo Comparator|Placebo|1 tablet day for 5 years
9517225|NCT03308240|Experimental|Magic Therapy Group|"Medical student magicians who have completed MagicAid training will provide the therapy.~Three or four tricks will be performed per patient at the discretion of the magician to cater to patient age and cognition capabilities. Patients in the experimental group may be given the opportunity to learn a magic trick that has been presented to them as well."
9950019|NCT01088191|Experimental|MSB-CAR001|Single Dose of MSB-CAR001 Combined With Hyaluronan
9950020|NCT01088204|Active Comparator|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
9950021|NCT01088204|Experimental|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
9950022|NCT01088230|Experimental|Botox®|this group will receive an injection of botox in the wrist flexors and forearm pronators
9950023|NCT01088230|Placebo Comparator|Saline|This group will receive an injection of saline solution in the same muscle groups as the treatment group (wrist flexors and pronators).
9950024|NCT01088256|Active Comparator|etoricoxib, peripheral hyperalgesia|14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
9950025|NCT01088256|Active Comparator|etoricoxib, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
9950026|NCT01088256|Placebo Comparator|placebo, peripheral hyperalgesia|14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
9950027|NCT01088256|Placebo Comparator|placebo, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days
9950028|NCT01088269||AF|Hypertensive patients in AF
9950029|NCT01088269||Non-AF|Hypertensive Patients
9950030|NCT01088282|Active Comparator|Implantation of difractive multifocal IOL|
9950031|NCT01088282|Sham Comparator|Implantation of monofocal IOL|
9950032|NCT01088308|Experimental|Single Arm|All Patients underwent Intervention.
10004853|NCT01579734|Active Comparator|Tamoxifen|Tamoxifen 5 mg, (1 tablet) day for 5 years
10004854|NCT01579760|Experimental|aflibercept every 2 months|
10004855|NCT01579760|Experimental|aflibercept monthly|
10035211|NCT01803945|Active Comparator|AVE8112|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
10035212|NCT01803958|Experimental|partial breast irradiation|38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days
9950033|NCT01088321||Patients initiating abatacept|
9950034|NCT01088321||Patients initiating other biologic disease-modifying drugs|
9950035|NCT01088321||Pts initiate non-biologic disease-modify anti-rheumatic drugs|
9950036|NCT01088334||IVTE, follow-up|no malignancy at basal screening, no extensive screening
9950037|NCT01088334||IVTE, screening|No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women
9950038|NCT01088347|Experimental|Advanced cervical cancer patients|
9950039|NCT01088360||Patients with rheumatoid arthritis initiating abatacept|
9950040|NCT01088360||Pts with RA initiating other biologic disease-modifying drugs|
9950041|NCT01088360||Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs|
9950042|NCT01088373|Experimental|Azacitidine, Lenalidomide|
9950043|NCT01088386||Patients|All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program
9950044|NCT01088425||Spontaneous|Mothers with children conceived after spontaneous cycle
9950045|NCT01088425||Vitrificatíon|Mothers with children conceived after vitrification cycle
9950046|NCT01088425||slow- rate freezing|Mothers with children conceived after slow- rate freezing cycle
9950047|NCT01088477||Breast cancer patients with acquired anti-hormonal resistance|
9950048|NCT01088490||critically ill|Critically ill patients admitted to ICU
9950049|NCT01088516|Experimental|Aluvia-based HAART|Study regimen: ZDV/3TC (combivir) + 2 Aluvia Tabs all PO BID to start at 14-30 weeks gestational age (GA) and continue through labor and as long as the mother breastfeeds
9950050|NCT01088542|No Intervention|No intervention|Communities in the no intervention arm received no intervention from the project and continued to implement prevention services as usual.
9950051|NCT01088542|Experimental|Communities That Care Intervention|Communities randomly assigned to the experimental condition received 5 years of training and technical assistance (from 2003 to 2008) to implement the Communities That Care (CTC) prevention system in their communities. They also received 5 years of funding to support a full-time community coordinator and 4 years of seed money to implement tested and effective prevention programs selected as a result of their CTC process.
9950052|NCT01088555|Active Comparator|Control group|Healthy subjects with no history of kidney stones, heart liver or kidney disease, not pregnant /lactating.
9950053|NCT01088555|Active Comparator|Stone formers|History of calcium containing kidney stones, hypercalciuria on previous urine tests, no heart /liver / kidney disease, not pregnant/lactating
9950054|NCT01088568|Experimental|TICL group|
9950055|NCT01088568|Active Comparator|LASIK group|
9950056|NCT01088581|No Intervention|Observation group|No adjuvant chemotherapy after resection
9950057|NCT01088581|Active Comparator|Adjuvant group|Adjuvant chemotherapy after resection
9950058|NCT01088594|Experimental|1|pioglitazone 45 mg
9950059|NCT01088594|Experimental|2|Rosiglitazone 8 mg
9950060|NCT01088594|Placebo Comparator|3|Placebo
9950061|NCT01088607|Experimental|UDCA Withdrawal and Reinstitution|Each study subject will undergo serial UDCA withdrawal and reinstitution.
9950062|NCT01088620|Experimental|Panitumumab plus pemetrexed and cisplatin (PemCisP)|
9950063|NCT01088620|Active Comparator|Pemetrexed and cisplatin (PemCis)|
9950064|NCT01088633|Other|Exhaled particle analysis|
9950065|NCT01088659|Experimental|1|
9950066|NCT01088659|Experimental|2|
9950067|NCT01088685|Experimental|Experimental Blister Patch|Experimental Hydrogel Blister patch
9950068|NCT01088685|Active Comparator|Marketed Pflaster|Scholls Blasen Pflaster
9950069|NCT01088724|Experimental|chemotherapy|
9950070|NCT01088750|Other|surgery alone|watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL
9950071|NCT01088750|Experimental|CVP Chemotherapy|3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)
9950072|NCT01088763|Experimental|Arm I|"GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~GROUP B: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients may also receive concurrent oral dexamethasone twice daily on the days of gamma-secretase inhibitor RO4929097 administration.~Once the MTD or recommended phase II dose of RO4929097 plus dexamethasone in children with solid tumors, including CNS tumors, or lymphoma has been identified, this dose is used for patients with relapsed-refractory T-ALL (phase 2 portion of the study) to evaluate RO4929097 in combination with dexamethasone using one of the studied schedules."
9950073|NCT01088776|Experimental|Supplement|
9950074|NCT01088776|Placebo Comparator|Control|
9950075|NCT01088802|Experimental|Dose de-escalating radiation therapy with chemotherapy|This protocol combines selective radiation therapy dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks) in patients with HPV-associated cancers of the oropharynx
9950076|NCT01088815|Experimental|Gemcitabine, nab-paclitaxel, GDC-0449|Gemcitabine and nab-Paclitaxel in combination with GDC-0449 (Vismodegib)
9950077|NCT01088828||Group A|"Foetuses with clubfoot identified in utero (n=15). Of these:~around 10 will be born with clubfoot and will form most of Group B,~around 5 will be born without clubfoot and will form part of group C."
9950078|NCT01088828||Group B|Neonates affected by clubfoot (n=10)
9950079|NCT01088828||Group C|Control group of unaffected neonates (n=10)
9950080|NCT01088828||Group D|Young adults having completed treatment (n=5)
9950081|NCT01088828||Group E|Control group of young unaffected adults (n=5)
9950082|NCT01088841|Active Comparator|75 g glucose + 150 ppm lactisole|
9950083|NCT01088841|Active Comparator|75 g glucose + 300 ppm lactisole|
9950084|NCT01088841|Active Comparator|75 g glucose + 450 ppm lactisole|
9950085|NCT01088841|Placebo Comparator|75 g glucose|
9950086|NCT01088854|Experimental|positive airway pressure|
9517226|NCT03308240|No Intervention|Standard Child Life Therapy Group|Stony Brook Child Life Specialists will provide standard therapies available to all patients, such as pet therapy, art therapy, music therapy.
9517227|NCT03308227||Experimental Group|septic shock patients;
9950087|NCT01088867|Other|Acupuncture|14 weeks of electroacupuncture therapy.
9950088|NCT01088880|Experimental|Canakinumab|
9950089|NCT01088893|No Intervention|observation|
9950090|NCT01088893|Experimental|Everolimus|
9950091|NCT01088906|Experimental|1 ARM|pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
9950092|NCT01088919|Experimental|Dosing Regimen 1|
9950093|NCT01088919|Experimental|Dosing Regimen 2|
9950094|NCT01088919|Experimental|Dosing Regimen 3|
9950095|NCT01088919|Experimental|Dosing Regimen 4|
9950096|NCT01088932|Experimental|SRX246|SRX246
9950097|NCT01088932|Placebo Comparator|Placebo|placebo
9950098|NCT01088945|Experimental|Enhanced Discharge Process|Caregivers of these infants will receive individual coaching in order to enhance their understanding of their infant's problems and enhance their knowledge and skills to care for their fragile infants.
9950099|NCT01088945|Active Comparator|Standard Discharge Process|These infants will receive the hospital's current standard of care for the discharge of fragile infants from the NICU.
9950100|NCT01088958|Experimental|Micronutrient Sprinkles|Sales of Sprinkles in these groups of villages by community vendors
9950101|NCT01088971|Active Comparator|Duolac 7S|
9950102|NCT01088971|Placebo Comparator|starch capsule|
9950103|NCT01089036||survival|ECMO survival patients
9950104|NCT01089036||ECMO non-survival|ECMO non-survivals
9950105|NCT01089049|Experimental|Pre-Menopausal|
9950106|NCT01089049|Experimental|Post-Menopausal|
9950107|NCT01089075|Placebo Comparator|placebo/20 mg hydrocortisone|Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
9950108|NCT01089075|Active Comparator|20 mg hydrocortisone/placebo|Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo
9950109|NCT01089140|Experimental|. Tranexamic acid low dose 10 mg/kg|
9950110|NCT01089140|Experimental|Tranexamic acid 100mg/kg|
9950111|NCT01089140|Placebo Comparator|Saline Placebo|
9950112|NCT01089166|Experimental|Torrent's Metformin tablets 500 mg|
9950113|NCT01089166|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
9950114|NCT01089179|Experimental|Torrent's Metformin tablets 500 mg|
9950115|NCT01089179|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
9950116|NCT01089192|Experimental|Torrent's Metformin tablets 750 mg|
9950117|NCT01089192|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
9950118|NCT01089205|Experimental|Torrent's Metformin tablets 750 mg|
9950119|NCT01089205|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA|
9950120|NCT01089218|No Intervention|control|control without intervention
9950121|NCT01089218|Active Comparator|Amoxicillin/clavulanate|
9950122|NCT01089244||Group A|"Patients with a suspected WHO II low grade glioma, disease progression within~1 year"
9950123|NCT01089244||Group B|Patients with a suspected WHO II low grade glioma, progression free within 1 year
9950124|NCT01089283||LRRK2 mutation|Parkinson patients that carry mutation on LRRK2 gene
9950125|NCT01089283||GBA mutation|Parkinson patients that carry mutation on GBA gene
9950126|NCT01089283||no mutation|Parkinson patients that don't carry mutation on LRRK2 or GBA genes
9950127|NCT01089283||healthy|Healthy volunteers
9950128|NCT01089296|Other|Individually customized physiotherapy|The intervention involves handling the infant and changing its position. It focuses on improving symmetry, muscle balance and movement in infants. The parent who is with the infant during the admission period will carry out the daily intervention after being taught by the physiotherapist.
9950129|NCT01089296|No Intervention|Control|Ordinary follow up in the Neonatal Intensive Care Unit (NICU).
9950130|NCT01089309|Experimental|Aldosteron blokade, Arterial stiffness, Glucose homeostasis|
9950131|NCT01089322|Experimental|Stantardized treament|oral and inhaled corticosteroid plus LABA
9950132|NCT01089335||Papillary thyroid cancer|Patients with preoperatively diagnosed highly differentiated papillary thyroid cancer
9950133|NCT01089335||Tumour of uncertain malignant potential|Thyroid tumours with preoperative cytology indicating follicular neoplasia, or on cytology suspected but not proven malignancy
9517228|NCT03308227||Conrol Group|non-septic shock patients;
9517229|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
9517230|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
9950134|NCT01089348|Experimental|Lactofiltrum|
9950135|NCT01089348|Active Comparator|Control|
9950136|NCT01089374|Other|Partial breast radiation after lumpectomy|Radiation per NSABP B-39/R0413 protocol.
9950137|NCT01089387|Experimental|injection of bone marrow cells|
9950138|NCT01089400||Influenza A/H1N1 patients|
9950139|NCT01089400||Non influenza A/H1N1 patients|
9950140|NCT01089426|Other|Historical controls|A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels > 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases
9950141|NCT01089426|Experimental|Omegaven™|
9950142|NCT01089439|Active Comparator|1: INOMAX|"Nitric oxide by inhalation INOMAX:~active arm treated with nitric oxide"
9950143|NCT01089439|Placebo Comparator|2: Placebo|placebo arm treated with placebo at the same conditions
9950144|NCT01089452|Active Comparator|Perindopril monotherapy|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
9950145|NCT01089452|Active Comparator|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
9950146|NCT01089452|Experimental|Olmesartan/amlodipine FDC|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
9950147|NCT01089530|No Intervention|Standard care|
9950148|NCT01089621|Experimental|Duloxetine|
9950149|NCT01089660|Experimental|Study Group 1|Swine-origin A/H1N1 Vaccine Low-dose
9950150|NCT01089660|Experimental|Study Group 2|Swine-origin A/H1N1 Vaccine High-dose
9950151|NCT01089673||no treatment|retrospective data analysis
9950152|NCT01089686|Active Comparator|Venoplasty (treatment)|Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
9950153|NCT01089686|Sham Comparator|Sham procedure (non-treatment)|Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
9950154|NCT01089699|Active Comparator|Professionally-led online support|Members assigned to 10-week online support group with a professional counsellor.
9950155|NCT01089699|Active Comparator|Peer-led online support|
9950156|NCT01089699|Active Comparator|self-study materials|
9950157|NCT01089712||Patients undergoing cardiac surgery|The patient population for this study consists of all patients undergoing cardiac surgical interventions. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.
9950158|NCT01089738|Experimental|Dosing|Ascending Doses
9950159|NCT01089764|Experimental|Couplelinks.ca Intervention|Intervention arm - Couple participates in the Couplelinks.ca program.
9476483|NCT03571321|Experimental|Ruxolitinib|"Participants will receive ruxolitinib in addition to standard chemotherapy.~Standard Chemotherapy Consists of:~Remission consolidation therapy (lasting 8 weeks)~Interim Maintenance (lasting 8 weeks)~Delayed Intensification (lasting 8 weeks~Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)~Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care."
9950160|NCT01089764|No Intervention|No Intervention|Couple is waitlisted for participation in the Couplelinks.ca program.
9950161|NCT01089803||Patients Treated with Laryngectomy|Patients initially treated with laryngectomy and followed for 12 months after receiving this treatment.
9950162|NCT01089803||Patients Treated with Chemoradiation|Patients treated initially with chemoradiation and followed for 12 months after receiving treatment.
9950163|NCT01089816||All|Anyone presenting with influenza-like-illness
9950164|NCT01089829||CKD Stage 4|eGFR <30
9950165|NCT01089829||CKD Stage 5|Receiving Haemodialysis or Peritoneal dialysis therapy
9950166|NCT01089842|Experimental|Health coaching|
9950167|NCT01089842|No Intervention|Control|
9950168|NCT01089855|Experimental|Carbamazepine|
9950169|NCT01089868||Group A|Patients who suffer from a suspected GBM and will undergo a microsurgical procedure for diagnosis verification. MRI and Positron Emission Tomography (PET) scans are scheduled prior to microsurgery, post microsurgery and after having completed radiochemotherapy and an additional scan after TMZ chemotherapy.
9950170|NCT01089868||Group B|Patients enrolled in Group B suffer from a suspected GBM which cannot be accessed microsurgically either due to a an eloquent location of the tumor, or patient's refusal to undergo surgery. In these patients, diagnosis will be obtained by means of stereotactic surgery. After an initial PET and MRI scan prior to biopsy, patients will be monitored by post radiochemotherapy as well as post 3-months chemotherapy MRI/PET scans.
9950171|NCT01089881||Group 1|patients with BPH
9950172|NCT01089881||Group 2|patients with newly diagnosed prostate cancer
9950173|NCT01089881||Group 3|patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.
9950174|NCT01089894||18F-FLT 1|18F-FLT in differentiating benign from malignant pulmonary nodules
9950175|NCT01089894||18F-FLT 2|18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The chemotherapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
9950176|NCT01089894||18F-FLT 3|18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors (The target therapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
9950177|NCT01089920|Experimental|High dose coffee|High dose of polyphenols from soluble coffee
9950178|NCT01089920|Experimental|Medium dose coffee|Medium dose of polyphenols from soluble coffee
9950179|NCT01089920|Experimental|Low dose coffee|Low dose of polyphenols from soluble coffee
9950180|NCT01089920|Experimental|High dose green tea|High dose of green tea polyphenols from infusion
9950181|NCT01089920|Experimental|Medium dose green tea infusion|Medium dose of green polyphenols from infusion
9950182|NCT01089920|Experimental|Low dose green tea infusion|low dose of polyphenols from an infusion of green tea
9950183|NCT01089933|Experimental|Thoracic PVB + multimodal anesthesia|Thoracic PVB + multimodal anesthesia
9950184|NCT01089933|Active Comparator|Local anesthetic + multi-modal analgesia|Local anesthetic + multi-modal analgesia
9950185|NCT01089959|Other|Esomeprazole|Effect of PPI esomeprazole on acid reflux & related arousals during sleep in patients with GERD.
9950186|NCT01089972||20 gauge group|
9950187|NCT01089972||22 gauge group|
9950188|NCT01089985|Experimental|Serum eye drops|Patient's autologous serum is diluted in saline solution
9950189|NCT01089998|Experimental|Arm 1|
9950190|NCT01089998|Experimental|Arm 2|
9950191|NCT01089998|Experimental|Arm 3|
9950192|NCT01089998|Experimental|Arm 4|
9950193|NCT01090037|Experimental|TRK-100STP|
9950194|NCT01090037|Placebo Comparator|Placebo|
9950195|NCT01090128|Experimental|All patients|All participants enrolled.
10004856|NCT01579786|No Intervention|Acetaminophen|A group All patients will be treated only with drugs used for this type during the operation and post operative pain controlled with usual acetaminophen drug administration (maximum 3 g/day)
10004857|NCT01579786|Experimental|Acetaminophen and acupuncture|B group patients. All patients will receive the standard pharmacological treatment for the operation. Acetaminophen (maximum 3g/day) during all seven days after surgery and patients will be treated with acupuncture the first day after surgery and thirty minutes before the surgical procedure
10004858|NCT01579799|Active Comparator|Dose 0.5|
10004859|NCT01579799|Active Comparator|Dose 7.5|
10004860|NCT01579799|Active Comparator|Dose 3|
10004861|NCT01579799|Active Comparator|Dose 1.2|
10004862|NCT01579825|Experimental|Buffer|
10004863|NCT01579825|No Intervention|Control|
10004864|NCT01579838|Experimental|Eculizumab|Eculizumab will be administrated according to known protocols.
10004865|NCT01579851|Active Comparator|Propofol-Remifentanil|Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
10004866|NCT01579851|Active Comparator|Sevoflurane-Remifentanil|Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
9950196|NCT01090167|Experimental|Clofarabine|
9950197|NCT01090193|Other|obstructive jaundice|
9950198|NCT01090206|Other|Hemophilia, Vitamin D deficiency|"Hemophilia, Rickets - Vitamin D per endocrine consult~Hemophilia, Vitamin D deficient - Vitamin D 2000 units daily plus calcium~Hemophilia, Normal Vitamin D - no intervention - observation only"
9950199|NCT01090219|Experimental|two differents meshes|Heavy-weight versus low-weight polypropylene meshes
9950200|NCT01090232|Experimental|chronic HEV infection|in kidney-transplant recipients with chronic HEV infection
9950201|NCT01090232|Active Comparator|control|the host responses in kidney-transplant recipients without viral infection (controls)
9950202|NCT01090245|Active Comparator|Attendance Information Group|Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
9950203|NCT01090245|Experimental|Attendance Incentive Group|Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
9950204|NCT01090258|Experimental|Automated settings|Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
9950205|NCT01090258|Active Comparator|protocolized settings|Ventilator settings performed by the local respiratory therapists according to the local protocols
9950206|NCT01090271|Experimental|Eccentric training|
9950207|NCT01090284||Heavy weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene heavy weight mesh.
9950208|NCT01090284||Light weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene light weight mesh.
9950209|NCT01090297|Active Comparator|Fixed pressure|
9950210|NCT01090297|Active Comparator|Auto-adjusting pressure|
9950211|NCT01090336||Clopidogrel group|At the discretion of the attending cardiologist patients are treated with clopidogrel (600mg loading and 75mg daily dose)
9950212|NCT01090336||Prasugrel group|At the discretion of the attending cardiologist patients are treated with prasugrel (60mg loading and 10mg daily dose)
9950213|NCT01090349|Experimental|Direct Alerts ON|Direct Alerts in implantable device were turned on
9950214|NCT01090349|Active Comparator|Direct Alerts OFF|Direct Alerts in implantable device were turned off
9950215|NCT01090362||Cohort 1|Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
9950216|NCT01090362||Cohort 2|Cohort completed with 11,351 patients enrolled from 30 countries
9950217|NCT01090362||Cohort 3|Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
9950218|NCT01090362||Cohort 4|Cohort 4 completed with 11,2780 patients enrolled from 35 countries.
9950219|NCT01090362||Cohort 5|Final cohort completed with 12,186 patients enrolled.
9950220|NCT01090375|Experimental|Exercise|
9950221|NCT01090375|Placebo Comparator|Non Exercise|
9950222|NCT01090388||1|Participants voluntarily completed a telephone interview using a questionnaire compiled using validated, patient-centered measures of cancer outcomes and psychosocial status.
9950223|NCT01090401|Experimental|Patients with Linox smart S DX lead|
9950224|NCT01090440|Experimental|Three-way cross- over|Three regimens will be administered in this study: A: GSK1144814 Tablet (100mg) Fasted State; B: GSK1144814 Tablet (200mg) Fasted State and C: GSK 1144814 Tablet (100mg) Fed State (FDA high fat breakfast).
9950225|NCT01090505|Experimental|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2|Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy
9950226|NCT01090505|No Intervention|surgery|Procedure/Surgery: Gastrectomy with D2 dissection
9950227|NCT01090518|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
9950228|NCT01090518|Placebo Comparator|Prolonged Exposure therapy with placebo|
9950229|NCT01090557||RSV positive subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are positive for RSV by Direct Fluorescent Antibody technique and/or viral culture
9950230|NCT01090557||RSV negative subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are negative for RSV by Direct Fluorescent Antibody technique and/or viral culture (usually positive for influenza A & B, parainfluenza, human metapneumovirus or adenovirus)
9950231|NCT01090557||Control group|Children with same age range, ethnic background, and gender distribution as the study group coming for evaluation in the outpatient setting without evidence of viral infection
9950232|NCT01090570|Experimental|PLX3397 25 mg|
9950233|NCT01090570|Experimental|PLX3397 50 mg|
9950234|NCT01090570|Experimental|PLX3397 100 mg|
9950235|NCT01090570|Experimental|PLX3397 200 mg|
9950236|NCT01090570|Experimental|PLX3397 300 mg|
9950237|NCT01090570|Placebo Comparator|Placebo|
9950238|NCT01090583||Cesarean Delivery Patients|
9950239|NCT01090596|Active Comparator|Naproxen-Treated|
9950240|NCT01090596|Placebo Comparator|placebo|
9950241|NCT01090609|Experimental|Stent implantation|Cronus Stent implantation
9950242|NCT01090622|Placebo Comparator|Matching Placebo|
9950243|NCT01090622|Experimental|XPF-001|
9950244|NCT01090648|Experimental|001|etravirine One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
9950245|NCT01090661|Experimental|mipomersen IV (supra-therapeutic dose)|200 mg of mipomersen IV / placebo SC
9950246|NCT01090661|Experimental|mipomersen SC (therapeutic dose)|200 mg of mipomersen SC / placebo IV
9950247|NCT01090661|Active Comparator|moxifloxacin IV|400 mg of moxifloxacin IV / placebo SC
9950248|NCT01090661|Placebo Comparator|placebo|Placebo IV / placebo SC
9950249|NCT01090674||1|Patients with amyotrophic lateral sclerosis.
9950250|NCT01090687||Group I Microcalcifications|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary findings based on microcalcifications will be recruited to have a breast CT scan.
9950251|NCT01090687||Group II Soft tissue findings|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary soft tissue findings, with or without associated microcalcifications, will be recruited to have a breast CT scan.
9950252|NCT01090700|Experimental|001|TMC435 TMC435 150 mg daily for 7 days
9950253|NCT01090700|Other|002|Escitalopram Escitalopram 10 mg daily for 7 days
9950254|NCT01090700|Experimental|003|TMC435 + Escitalopram TMC435 150 mg + escitalopram 10 mg daily for 7 days
9950255|NCT01090713|Active Comparator|Lisdexamfetamine|drug
9950256|NCT01090713|Placebo Comparator|Placebo|Placebo comparator
9950257|NCT01090726|Experimental|Storz videolaryngoscope|Macintosh overview followed by Airtraq overview followed by Storz videolaryngoscope overview and intubation.
9950258|NCT01090726|Active Comparator|Airtraq|Macintosh overview followed by Storz videolaryngoscope overview followed by Airtraq overview and intubation.
9950259|NCT01090778|Other|Norditropin SimpleXx sc bolus injection|Single sc bolus injection of 3 mg growth hormone without interval exercise
9950260|NCT01090778|Other|Norditropin SimpleXx single sc injection|Single sc bolus injection of 3 mg growth hormone with interval exercise
9950261|NCT01090778|Other|Norditropin SimpleXx contin. sc infusion|Continuous sc infusion of 3 mg growth hormone without interval exercise
9950262|NCT01090778|Other|Norditropin SimpleXx cont. sc infusion|Continuous sc infusion of 3 mg growth hormone with interval exercise
9950263|NCT01090804|Experimental|breathing exercise|BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
9950264|NCT01090817|Experimental|Mesenchymal stromal cells|Mesenchymal stromal cells administered weekly for 4 weeks
9950265|NCT01090830|Experimental|Belinostat|This is a one arm, open label study of the investigational medication Belinostat.
9950266|NCT01090856|No Intervention|No pre-dilation side branch|
9950267|NCT01090856|Active Comparator|Pre-dilation side branch|
9950268|NCT01090869|Active Comparator|Physical training, unchanged diet|Daily endurance training equivalent to 600 kcal/day and unchanged habitual diet
9950269|NCT01090869|Active Comparator|Physical training, increased diet|Daily endurance training equivalent to 600 kcal/day, and increased diet by 600 kcal/day.
9950270|NCT01090869|Active Comparator|Diet, unchanged physical activity|Energy-reduced diet by 600 kcal/day, and unchanged sedentary lifestyle
9950271|NCT01090869|No Intervention|Control|Unchanged sedentary lifestyle and diet
9950272|NCT01090882|Sham Comparator|Control|Sham wash, sham injection
9950273|NCT01090882|Experimental|Subperitoneal injection|Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
9950274|NCT01090882|Active Comparator|Topical LA|Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm
9950275|NCT01090895|Active Comparator|Vitamin C|Vitamin C infusion
9950276|NCT01090895|Placebo Comparator|Placebo|Saline solution
9950277|NCT01090908||Ages 6-11 years|
9950278|NCT01090908||Ages 12-17 years|
9950279|NCT01090934|Experimental|high resolution EEG|
9950280|NCT01090934|Active Comparator|Stereo Electroencephalography|
9950281|NCT01090947||Patients referred to CAG.|Sequential design with ProtoCAD and CAG
9950282|NCT01090960|Experimental|A|
9950283|NCT01090986||1|Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV. Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
9950284|NCT01090999|No Intervention|1|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The No Intervention group will undergo a standard, minimal monitoring program."
9950285|NCT01090999|Active Comparator|2|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The active comparator group will undergo an intensive maintenance program after the initial in-hospital rehabilitation program."
9950286|NCT01091012|Other|Sildenafil 20mg oral|
9950287|NCT01091012|Other|Sildenafil 10mg intravenous|
9950288|NCT01091025|Other|CF patients without known diagnose of CFRD|There is only one arm. All patients in the study had the same procedures (ie. an OGTT). Investigators used the screening criteria in parallel to this.
9950289|NCT01091038|Placebo Comparator|Routine Care|Usual care of patients in the ambulatory setting
9950290|NCT01091038|Experimental|Basic Clinical Decision Support|Providers use basic clinical decision support
9950291|NCT01091051|Active Comparator|Ustekinumab|Ustekinumab S/C 45mg or 90mg depending on patient's weight or placebo injection. 10 with PPPP and 10 with PPP will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
9950292|NCT01091051|Placebo Comparator|Placebo|Placebo S/C (Sodium Chloride). 10 with PPPP and 10 with PPP will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
9950293|NCT01091064|Experimental|Early depart|Patients who will be liberated at triage with mild acute viral bronchiolitis
9950294|NCT01091064|No Intervention|Medical visit group|Patients with acute viral bronchiolitis who will wait to be seen by the physician
9950295|NCT01091077|Placebo Comparator|Naringenin|Single dose of naringenin, compared to placebo in the same individual.
9950296|NCT01091090|Experimental|Cognitive behavioral|Subjects with receive a cognitive behavioral intervention for smoking cessation
9950297|NCT01091090|Active Comparator|Control|Treatment as usual
9950298|NCT01091129|Experimental|Treatment|Treatment with the miraDry System in both axilla
9950299|NCT01091142|Experimental|NP001|
9950300|NCT01091142|Placebo Comparator|Placebo|
9950301|NCT01091181|Active Comparator|high incision group|hysterotomy at cesarean performed 2 cm above plica vesicouterina
9950302|NCT01091181|Active Comparator|low incision group|hysterotomy at cesarean performed 2 cm below plica vesicouterina
9950303|NCT01091194|Other|Exercise|Interval-based aerobic exercise
9950304|NCT01091194|No Intervention|Control|No intervention other than regular follow up hospital visits
9950305|NCT01091207|Experimental|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
9950306|NCT01091220|Placebo Comparator|Placebo|0.9% saline
9950307|NCT01091220|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg
9950308|NCT01091233||Paracentesis|Paracentesis as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
9950309|NCT01091272|Experimental|Cohort 1|Single dose 3 period interleaved cross-over with placebo substitution
9950310|NCT01091272|Experimental|Cohort 2|Single dose 4 period interleaved cross-over, placebo substitution, with food effect
9950311|NCT01091272|Experimental|Cohort 3|Single dose 4 period cross-over, placebo insertion, with food effect
9950312|NCT01091272|Experimental|Optional Cohort 4|Single dose 3 period cross-over with placebo substitution
9950313|NCT01091285|Active Comparator|Single Balloon Catheter|Cervix Ripening is achieved by a single balloon catheter. Further induction by cytotec or/amniotomy and pitocin
9950314|NCT01091285|Active Comparator|Double balloon catheter|Cervix Ripening is achieved by a double balloon catheter. Further induction by cytotec or/amniotomy and pitocin
9950315|NCT01091298|Experimental|Group 1|
9950316|NCT01091298|Placebo Comparator|Group 2|
9950317|NCT01091324|Active Comparator|Dextromethorphan|
9950318|NCT01091324|Active Comparator|Silymarin|
9950319|NCT01091324|Placebo Comparator|sugar pill|
9950320|NCT01091337|Experimental|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
9950321|NCT01091337|Active Comparator|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
9950322|NCT01091350|Active Comparator|Diprifusor group|Propofol was infused via Diprifusor TCI (Target-controlled infusion)
9950323|NCT01091350|Experimental|Orchestra group|Propofol was infused via Orchestra TCI
9950324|NCT01091376|Experimental|Concomitant Erlotinib and radiotherapy|Patients received Erlotinib and radiation therapy.
9950325|NCT01091389|Experimental|GP ablation|Thoracoscopic PV isolation with GP ablation
9950326|NCT01091389|Experimental|No GP ablation|Thoracoscopic PV isolation with no GP ablation
9950327|NCT01091402||chronic urticaria|
9950328|NCT01091402||asthma|
9950329|NCT01091402||seasonal allergic rhinitis|
9950330|NCT01091402||normal controls|
9950331|NCT01091415|Experimental|calcium phosphate bone cement|one arm; volar locking plate alone the other arm; calcium phosphate bone cement as well as volar locking plate
9950332|NCT01091441||Patients with heart failure|Patients hospitalized for acute heart failure
9950333|NCT01091467||Patients with HF|Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%
9950334|NCT01091480||Patients with HCM|Patients ≥ 15 years with HCM(sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
9950335|NCT01091493|No Intervention|Non-Antibiotic|Patients will not receive antibiotics, although the study is double-blind.
9950336|NCT01091493|Active Comparator|Antibiotic|Patients will receive in a masked way, moxifloxacin.
9950337|NCT01091506|Experimental|L-methylfolate|L-methylfolate 15mg (a medical food)
9950338|NCT01091506|Placebo Comparator|Placebo|Placebo
9950339|NCT01091532|Experimental|Cohort 1|Subjects will be assigned to receive either UK-396,082 or placebo
9950340|NCT01091532|Experimental|Cohort 2|Subjects will be assigned to receive either UK-396,082 or placebo
9950341|NCT01091532|Experimental|Cohort 3|Subjects will be assigned to receive either UK-396,082 or placebo
9950342|NCT01091532|Experimental|Cohort 4|Subjects will be assigned to receive either UK-396,082 or placebo
9950343|NCT01091545|Other|FFDM+DBT|Single-armed study. Women are their own controls with paired images of digital mammography and breast tomosynthesis.
9950344|NCT01091558||Colonoscopy|Healthy volunteer who is having a screening colonoscopy
9950345|NCT01091558||Ulcerative Colitis|Patients with confirmed ulcerative colitis who are scheduled for endoscopy for medical reasons.
9950346|NCT01091571|Placebo Comparator|Endotoxemia placebo|Endotoxin combined with placebo
9950347|NCT01091571|Experimental|Endotoxemia Dipyridamole|Endotoxin combined with Dipyridamol treatment
9950348|NCT01091584|Active Comparator|intervention group|The intervention is to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse.
9950349|NCT01091584|No Intervention|control group|usual care
9950350|NCT01091597|Active Comparator|usual ablation|Wide-area circumferential ablation of the pulmonary veins
9950351|NCT01091597|Experimental|Box isolation of the pulmonary veins|Single Box lesion set encompassing all four pulmonary veins and the posterior wall of the left atrium.
9950352|NCT01091610||1|all emergency medical staff having suffered an accident during work
9950353|NCT01091610||2|non emergency medical personnel having suffered an injury due to a medical mission, e.g. transported patient having suffered additional injury due to an ambulance accident or collision of an ambulance with another vehicle.
9950354|NCT01091623|Active Comparator|strength training|
9950355|NCT01091623|Active Comparator|endurance training|
9950356|NCT01091623|Active Comparator|combined training|
9950357|NCT01091636|Experimental|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Ovarian Cancer after primary cytoreductive surgery or interval cytoreductive surgery
9950358|NCT01091636|No Intervention|No HIPEC|Primary cytoreductive surgery or interval cytoreductive surgery
9950359|NCT01091649|Active Comparator|A|Low dose ABT-450 capsule and ritonavir capsules (reference).
9950360|NCT01091649|Active Comparator|B|Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)
9950361|NCT01091649|Active Comparator|C|Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).
9950362|NCT01091649|Active Comparator|D|High dose ABT-450 capsule and ritonavir capsules (reference).
9950363|NCT01091649|Active Comparator|E|High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)
9950364|NCT01091688|Experimental|Just-in-Time intervention|"The infants and physicians in the experimental group will receive the Just-in-Time intervention sheets at the time of discharge."
9950365|NCT01091688|No Intervention|Routine discharge care|The infants and physicians in the routine discharge care arm will receive the same information and details as is per normal routine in the nursery.
9950366|NCT01091701|Experimental|Ex vivo cultured adult allogenic MSCs|
9950367|NCT01091701|Placebo Comparator|Plasmalyte-A|
9950368|NCT01091714|Active Comparator|PRN Dry Eye Omega Benefits|4 capsules per day = 2240 mg Omega-3s
9950369|NCT01091714|Active Comparator|Nature's Made|2 capsules per day = 2400mg Omega-3s
9950370|NCT01091714|Active Comparator|Thera Tears|4 capsules per day = 2332mg Omega-3s
9950371|NCT01091727|Experimental|Botulinum toxin A|Botulinum toxin A 300U diluted with sterile saline (1 ml per injection site) and injected into 30 sites of the bladder, sparing the trigone.
9950372|NCT01091727|Placebo Comparator|Placebo|Sterile saline 30 cc injected into 30 sites in the bladder, sparing the trigone.
9950373|NCT01091740|Experimental|ZES resolute (Endeavor Resolute)|
9950374|NCT01091740|Active Comparator|EES (Xience)|
9950375|NCT01091753|Placebo Comparator|morning administration group|
9950376|NCT01091753|Experimental|nocturnal administration group|
9950377|NCT01091766|Active Comparator|bupivacaine|test solution consists of bupivacaine 0.125%
9950378|NCT01091766|Active Comparator|bupivacaine+epinephrine|test solution consists of bupivacaine 0.125% with epinephrine 1:200000
9950379|NCT01091766|Active Comparator|epinephrine|test solution consists of epinephrine 1:200000
9950380|NCT01091779||Hypertensive and normotensive|
10004867|NCT01579864|Active Comparator|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary.
10004868|NCT01579864|Experimental|Rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
10004869|NCT01579877|Experimental|Yukmijihwang-tang|Yukmijihwang-tang: Real herbal extract granule
10004870|NCT01579877|Placebo Comparator|Yukmijihwang-tang_Placebo|Yukmijihwang-tang_Placebo: Placebo herbal extract granule
10004871|NCT01579903|Experimental|Sequence 1|Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
10004872|NCT01579903|Experimental|Sequence 2|Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
10004873|NCT01579929|Experimental|LDE225, Etoposide and Cisplatin|This is a single institution phase I trial of LDE225 combined with etoposide and cisplatin in patients with untreated, newly diagnosed extensive stage small cell lung cancer (ES-SCLC). LDE225 is an oral drug, which will be taken daily by patients. Patient self-reporting via STAR will be used in an evaluation of the extent to which patient-reported toxicity influences dose finding in phase I clinical trials. Specifically, STAR reports will be presented to clinicians in real-time at clinic visits, & clinicians will have an opportunity to either agree or modify the patient self-assessments & use this information in their grading & attribution of toxicities.
10004874|NCT01579942||Patients with Major Depressive Disorder|Patients who have Major Depressive Disorder and are taking a Selective Serotonin Re-uptake Inhibitor (SSRI) as part of another study at our clinic.
10004875|NCT01579942||Healthy Controls|Patient with no history of significant mental health problems.
10004876|NCT01579955||eptacog alpha users|
10004877|NCT01579968||eptacog alpha users|
10004878|NCT01579994|Experimental|Ganetespib (STA-9090) and crizotinib|This protocol is a phase I single arm, open label, single institution study of crizotinib and ganetespib (STA-9090) in patients with ALK+ advanced NSCLC who are crizotinib naïve.
10004879|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and active cholecalciferol|500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
10004880|NCT01580007|Active Comparator|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
10004881|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and placebo cholecalciferol|Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
10004882|NCT01580007|Placebo Comparator|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate Placebo cholecalciferol
10004883|NCT01580033|Experimental|A+C+hib Conjugate Vaccine|600 infants aged 3-5 months, will be vaccinated on day0, 28, 56
10004884|NCT01580033|Active Comparator|Walvax AC vaccine, Pasteur Hib vaccine|300 infants aged 3-5 months, will be vaccinated on day0, 28, 56
10004885|NCT01580046|Experimental|Iodixanol|
10004886|NCT01580046|Active Comparator|iopromide|
10004887|NCT01580085||Pulmonary embolism|Patients who were diagnosed with pulmonary embolism
10004888|NCT01580085||control group|age and sex matched adults with osa and no thromboembolism
10004889|NCT01580111|Experimental|Short storage|Short storage arm: Will receive blood (Packed red blood cells) of 1 (one) to 10 (ten) days in storage.
10004890|NCT01580111|Active Comparator|Long storage arm|Will be transfused with blood ( packed red cells) of storage age 21- 35 days.
10004891|NCT01580124|Active Comparator|PVI alone|Pulmonary vein isolation alone in persistent atrial fibrillation
10004892|NCT01580124|Active Comparator|PVI + Defragmentation + linear lesions|AF ablation continuation aiming for AF termination
9950381|NCT01091792|Experimental|Bevacizumab|Bevacizumab + temozolomide + radiotherapy followed by adjuvant bevacizumab + temozolomide
9950382|NCT01091818|Active Comparator|midazolam|
9950383|NCT01091818|Experimental|dexmedetomidin|
9950384|NCT01091844|Active Comparator|Spontaneous Fill Technique|"We allow the bladder to spontaneously fill, then allow the patient to void and afterward catheterize the patient to check a postvoid residual (spontaneous fill technique)."
9950385|NCT01091844|Active Comparator|Retrograde Fill Technique|"We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void (retrograde-fill technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL."
9950386|NCT01091857|Experimental|Exercise intervention (STRIDE)|
9950387|NCT01091857|Active Comparator|Health and Wellness Control|
9950388|NCT01091870|Placebo Comparator|Placebo: soluble blue pigment|Soluble blue pigment for placebo controlling.
9950389|NCT01091870|Experimental|Sildenafil, 75mg daily|Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
9950390|NCT01091870|Experimental|Sildenafil, 150 mg daily|Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.
9950391|NCT01091883|Experimental|Exablate treatment|Exablate 2000
9950392|NCT01091883|Active Comparator|Radiation|External Beam Radiation
9950393|NCT01091896|No Intervention|1 - no bevacizumab|Patients will not receive bevacizumab before nor during vitrectomy
9950394|NCT01091896|Experimental|2- bevacizumab before vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
9950395|NCT01091896|Experimental|3- bevacizumab after vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
9950396|NCT01091909|Experimental|post-extraction wound healing|53 individuals with diabetes and 29 controls, without diabetes, were followed for 60 days after dental extractions, and were examined after 3, 7, 21, and 60 postoperative days.
9950397|NCT01091922|Placebo Comparator|Low Flavanol|Low flavanol drink containing 23 mg of total flavanols. Macro- and micro-nutrient matched with active comparator
9950398|NCT01091922|Active Comparator|High Flavanols|High Flavanol drink containing 495 mg of total flavanols
9950399|NCT01091935||Lidocaine|"Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes~Consecutive patients from two time periods:~June 15 to August 21, 2009~October 15-Dec 22,2009"
9950400|NCT01091961|Active Comparator|Continuing ACEi/ARB|Patients in this group will continue to take their chronic ACEi/ARB medications up to and including the day of surgery.
9950401|NCT01091961|Active Comparator|Holding ACEi/ARB|Patients in this arm will hold their chronic ACEi/ARB medication at least 24 hours prior to surgery.
9950402|NCT01091987|Experimental|Non-pharmacological approach of insomnia|Non-pharmacological approach of insomnia based on cognitive-behavioural techniques (education on sleep, sleep hygiene, stimulus control, cognitive techniques)
9950403|NCT01092000||Faculty/Staff|
9950404|NCT01092000||Graduate Students|
9950405|NCT01092000||Undergraduate Students|
9950406|NCT01092013|Active Comparator|Operating room training|
9950407|NCT01092013|Active Comparator|Skills lab training|
9950408|NCT01092026|Experimental|cord blood transplant|Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
9950409|NCT01092039|Experimental|XIGO pill|Oral Xigo tablet
9950410|NCT01092039|Placebo Comparator|Placebo|Oral placebo tablet
10004893|NCT01580137||healthy conscripts|non allergic subjects who have not a history of recurrent rhinosinusitis
10004894|NCT01580137||subjects with recurrent rhinosinusitis|subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
9950411|NCT01092052|Experimental|1|
9950412|NCT01092078|Experimental|Motivational Interviewing|Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
9950413|NCT01092078|Experimental|Patient Navigation|Participants in the patient navigation arm will receive patient navigation for colonoscopy.
9950414|NCT01092078|Experimental|PLUS|Both patient navigation for colorectal cancer screening and motivational interviewing for blood pressure control
9950415|NCT01092091|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
9950416|NCT01092130|Experimental|Vitamin D|Patients were randomized by an automated computer system to 2000 IU oral cholecalciferol once daily or control (i.e. no extra medication), in a 1:1 ratio for a period of six weeks. Blood was collected in a sitting position on visits 2-4 and patients were asked to collect 24h urine samples prior to visits 2 and 4. Heart failure medication was maintained unchanged throughout the trial. Changes in diuretic dose were permitted if necessary to treat decompensation or renal dysfunction.
9950417|NCT01092156|Active Comparator|Education on Infant-led latching|
9950418|NCT01092156|No Intervention|Standard education|
9950419|NCT01092169||Sickle cell beta|
9950420|NCT01092221|Experimental|Allopurinol|
9950421|NCT01092221|Placebo Comparator|Placebo|
9950422|NCT01092234|Active Comparator|Traditional ward|
9950423|NCT01092234|Experimental|Observational unit|Organizational change. Innovative organization of in-hospital care
9950424|NCT01092247|Placebo Comparator|Standard diet: Nutritional support|
9950425|NCT01092247|Experimental|Nutritional intervention: Ketogenic diet.|
9950426|NCT01092273||Bimatoprost versus Travoprost|
9950427|NCT01092286|Experimental|neuromuscular warm-up|coaches in this arm use the prescribed warm-up before team practices
9950428|NCT01092286|No Intervention|no warm-up|coaches use their usual warm-up before team practices
9950429|NCT01092299|Experimental|Cohort 1 (2 arms)|Period 1: randomized to either fasting IR or ER1. Period 2: Cross-over to either IR or ER1. Period 3: ER1 in fed conditions.
9950430|NCT01092299|Experimental|Cohort 2 (2 arms)|Period 1: randomized to either fasting IR or ER2. Period 2: Cross-over to either IR or ER2. Period 3: ER2 in fed conditions.
9950431|NCT01092299|Experimental|Cohort 3( 2 arms)|Period 1: randomized to either fasting IR or ER3. Period 2: Cross-over to either IR or ER3. Period 3: ER3 in fed conditions.
9950432|NCT01092299|Experimental|Cohort 4 (2 arms)|Period 1: randomized to either fasting IR or MR4. Period 2: Cross-over to either IR or MR4. Period 3: MR4 in fed conditions.
9950433|NCT01092299|Experimental|Part 2: Extended/Modified release|Extended/Modified release capsule to be determined
9950434|NCT01092299|Placebo Comparator|Part 2: Placebo|
9950435|NCT01092312|Experimental|Signature Knee Guide|Vanguard Knee System with Signature Knee Guide
9950436|NCT01092312|Active Comparator|Conventional Approach|Vanguard Complete Knee System with Conventional Approach
9950437|NCT01092325|Experimental|Cohort 1 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
9950438|NCT01092325|Placebo Comparator|Cohort 1 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
9950439|NCT01092325|Experimental|Cohort 2 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
9950440|NCT01092325|Placebo Comparator|Cohort 2 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
9950441|NCT01092325|Active Comparator|Echo Cohort A CXL-1020|A 4 hour infusion of a fixed dose of CXL-1020 which was studied in Cohort 1 or Cohort 2 which is expected to be well tolerated and have hemodynamic effect
9950442|NCT01092325|Active Comparator|Echo Cohort B CXL-1020|CXL-1020 administered at a fixed rate for the initial 2 hours and at a higher fixed rate for the last 2 hours of a 4 hour infusion at doses which were studied in Cohort 1 or Cohort 2 and expected to be well tolerated and have hemodynamic effects
9950443|NCT01092351|Experimental|Nitrofurantoin|Adult patients with a microbiologically confirmed uncomplicated urinary tract infection
9950444|NCT01092377|Experimental|DHA/EPA capsules and iron tablet|
9950445|NCT01092377|Experimental|DHA/EPA and placebo tablet|
9950446|NCT01092377|Placebo Comparator|placebo capsules & placebo tablet|
9950447|NCT01092377|Experimental|iron tablet and placebo capsules|
9950448|NCT01092390|Experimental|Lovaza|4 grams per day
9950449|NCT01092403|Experimental|ASM-024|ASM-024 once daily by inhalation
9950450|NCT01092403|Placebo Comparator|Placebo|Placebo once daily by inhalation
9950451|NCT01092429||one,two,and three vessels disease; mortality|
9950452|NCT01092455||Citrasate and heparin reduction|Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.
9950453|NCT01092468|Placebo Comparator|Diathermy|Perforator flap elevation using conventional diathermy technique
9950454|NCT01092468|Active Comparator|Harmonic Scalpel|Perforator flap elevation using Harmonic Scalpel
9950455|NCT01092481|Active Comparator|FOLFOX_12 or CAPOX_8|6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
9950456|NCT01092481|Experimental|FOLFOX_6 or CAPOX_4|3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
9950457|NCT01092494||OC use|OC use after postoperative gonadotropin-releasing hormone agonist treatment
9950458|NCT01092494||OC non-use|Only postoperative gonadotropin-releasing hormone agonist treatment
9950459|NCT01092520|Experimental|Gabapentin|
9950460|NCT01092533|Experimental|Mycophenolate sodium + Prednisolone|Mycophenolate sodium 1440 mg/day Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
9950461|NCT01092533|Active Comparator|Prednisolone|Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
9950462|NCT01092572|Experimental|Simvastatin 40 mg/d|simvastatin 40 mg per day taken orally
9950463|NCT01092572|Placebo Comparator|Sugar pill|
9950464|NCT01092611|Other|Group A|Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study
9950465|NCT01092611|Other|Group B|Subjects who were administered placebo in primary studies and who accepted to participate in this study
10004895|NCT01580150|Experimental|Berry meal|Carbohydrate meals with berries
9950466|NCT01092624|Experimental|Pessary and solifenacin|
9950467|NCT01092624|Placebo Comparator|Pessary and placebo|
9950468|NCT01092650|Active Comparator|Smoked|Deuterated Phenanthrene spiked in a study cigarette
9950469|NCT01092650|Experimental|Oral|Deuterated phenanthrene in an oral dose
9950470|NCT01092689|Experimental|PhIP|Prior to surgery, consented subjects will ingest a capsule containing [14C]PhIP. This amount of [14C]PhIP (84 micrograms PhIP; 15.6 micro-curies) is equivalent to that in 2 very well done grilled/barbecued chicken breasts (Sinha 1995); the amount of radioactivity is equivalent to the dose received in a commercial airline flying at 30,000 ft. for 5 h (HPS 2007) or to the amount received during a typical chest x-ray.
9950471|NCT01092715|Experimental|Mobilization|Spinal mobilization and exercises
9950472|NCT01092715|Active Comparator|Massage|Neck massage and exercises
9950473|NCT01092741|Experimental|Gleevec|Gleevec 400 mg by mouth (P.O.) twice daily = 800 mg total daily dose
9950474|NCT01092754|Other|A: Other|
9950475|NCT01092754|Other|B: Other|
9950476|NCT01092793|Active Comparator|Krill|
9950477|NCT01092793|Active Comparator|Fish oil|
9950478|NCT01092793|No Intervention|Control|
9950479|NCT01092806|Active Comparator|Prograf|Patients are treated until steady-state conditions with Prograf and then investigated with clamp
9950480|NCT01092806|Experimental|Advagraf|The patients are treated with Advagraf until steady-state conditions and then investigated with clamp
9950481|NCT01092819||acute ischemic stroke|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion.
9950482|NCT01092845|Experimental|PF-04457845 followed by placebo|
9950483|NCT01092845|Experimental|Placebo followed by PF-04457845|
9950484|NCT01092858|Experimental|Arm 1|
9950485|NCT01092858|Placebo Comparator|Arm 2|
9950486|NCT01092884|Active Comparator|Polypodium leucotomos|Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract
9950487|NCT01092884|Placebo Comparator|Sugar pill|Subjects randomized to this arm will receive oral supplementation with placebo
9950488|NCT01092897||Subjects with PAH treated with Imatinib|
9950489|NCT01092962|Experimental|Mycophenolate mofetil|Mycophenolate mofetil
9950490|NCT01092962|Active Comparator|Cyclophosphamide|Cumulative dose of 148mg/kg of cyclophosphamide in 84 days (2mg/kg/day during 12 weeks)
9950491|NCT01092975|Experimental|1.25 mg phenylephrine|
9950492|NCT01092975|Experimental|2.5 mg phenylephrine|
9950493|NCT01092975|Experimental|5.0 mg phenylephrine|
9950494|NCT01092975|Experimental|10.0 mg phenylephrine|
9950495|NCT01092975|Experimental|20.0 mg phenylephrine|
9950496|NCT01092975|Experimental|40.0 mg phenylephrine|
9950497|NCT01092975|Experimental|60.0 mg phenylephrine|
9950498|NCT01092975|Experimental|80.0 mg phenylephrine|
9950499|NCT01092988|Experimental|Exablate 2100|MR Guided Focused Ultrasound treatment
9950500|NCT01093001|Active Comparator|Lead size|The pacemaker lead will be < or = to 7Fr. The ICD lead will be 9 Fr.
9950501|NCT01093001|Active Comparator|RV Lead position|50 patients will be randomized to RV apex lead placement.
9950502|NCT01093001|Active Comparator|Mid-Septum Lead position|50 patients will be randomized to RV mid-septum lead placement.
9950503|NCT01093001|Active Comparator|CS lead position|50 patients will have lead placed in the CS
9950504|NCT01093040|Experimental|Cohort 1|CAT-354 will be administered by SC injection
9950505|NCT01093040|Experimental|Cohort 2|CAT-354 will be administered by SC injection
9950506|NCT01093040|Experimental|Cohort 3|CAT-354 will be administered by SC injection
9950507|NCT01093053|Experimental|Mind-Body Skills Groups|
9950508|NCT01093053|Active Comparator|Standard Treatment|
9950509|NCT01093079||Laparoscopic partial nephrectomy|
9950510|NCT01093079||Open Partial nephrectomy|
9950511|NCT01093092|Experimental|Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)|Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9950512|NCT01093118|Experimental|TMI-358|Active treatment
9950513|NCT01093118|Placebo Comparator|MMI-467|
9950514|NCT01093131|Active Comparator|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
9950515|NCT01093131|Active Comparator|Intravenous hydration and sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
9950516|NCT01093131|Active Comparator|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
9950517|NCT01093131|Active Comparator|Oral hydration and oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
9950518|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 40 units|
9950519|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 80 units|
9950520|NCT01093170|Experimental|RNA-144101|
9950521|NCT01093209|Sham Comparator|Conventional Laser Therapy|
9950522|NCT01093209|Active Comparator|Interferential Laser Therapy|
9950523|NCT01093248||Heroin-addicted Patients|Heroin-addicted outpatient department (OPD) patients who seek help for methadone maintenance treatment
9950524|NCT01093261|Experimental|Hydrocortisone and fludrocortisone|Patients with glucocorticoid insufficiency
9950525|NCT01093261|Placebo Comparator|Placebo|Patients with glucocorticoid insufficiency
9950526|NCT01093261|No Intervention|Controlled|Adapted glucocorticoid function
9950527|NCT01093274|Active Comparator|Polyethylene glycol|Preparation with Polyethylene Glycol and bisacodyl
9950528|NCT01093274|Experimental|Picolax|Preparation with Sodium Picosulphate and Bisacodyl.
9950529|NCT01093300|Experimental|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion
9950530|NCT01093300|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion
9950531|NCT01093313|Experimental|Attention training|
9950532|NCT01093313|Active Comparator|Cognitive therapy|
9950533|NCT01093339||No treatment|Subjects w/ condition and subjects w/o condition of GERD (gastroesophageal reflux disease)
9950534|NCT01093352|No Intervention|Standard|Standard expose and bond.
9950535|NCT01093352|Experimental|Alveolar-decortication|Following surgical exposure of the impacted canine, additional perforations will be made in the surrounding cortical bone prior to wound closure.
9950536|NCT01093365|Experimental|Schizophrenia|To measure the effects of varenicline on cognition of smokers with schizophrenia.
9950537|NCT01093378||Fertile group|fertile group
9950538|NCT01093378||Infertility group|Fertility troubles
9950539|NCT01093391|Placebo Comparator|BARE METAL STENT|BARE METAL STENT - STENT CRONUS
9950540|NCT01093391|Experimental|DRUG ELUTING STENT|STENT INSPIRON WITH SIROLIMUS
9950541|NCT01093404|Experimental|Thrombus aspiration|Thrombus aspiration is then followed by standard balloon angioplasty (PCI).
9950542|NCT01093404|Active Comparator|Standard balloon angioplasty (PCI)|
9950543|NCT01093430|Experimental|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
9950544|NCT01093430|Active Comparator|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
9950545|NCT01093443|Placebo Comparator|A|Patients undergo a standard treatment with a classical GnRH antagonist protocol.
9950546|NCT01093443|Active Comparator|B|Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
9950547|NCT01093456||chronic kidney disease|ESKD patients treated with peritoneal dialysis
9950548|NCT01093456||Healthy volunteers|healthy volunteers, aged 18 years and above
9950549|NCT01093495|Experimental|CPAP group|Subjects in this group will continue receiving CPAP until no oxygen requirement for 24 hours, then will be weaned off CPAP completely as long as they tolerate. CPAP will be re-instituted if subjects meet failing criteria. Another trial off CPAP will start 24 hours after failure and/or after being on 21% for 24 hours. CPAP will be weaned off directly to room air at all times.
9950550|NCT01093495|Experimental|Nasal Cannula Group|Subjects will be weaned from CPAP (when FiO2 <0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
9950551|NCT01093547|Active Comparator|Dianeal only|Patients in Dianeal during the daily exchanges and randomised to Dianeal during the long-dwell exchange
9950552|NCT01093547|Active Comparator|Dianeal; Extraneal long-dwell exchange|Patients in Dianeal during the daily exchanges and randomised to Extraneal during the long-dwell exchange
9950553|NCT01093560|Experimental|young women with MetS|"Saturated fat (control)~n-3 Polyunsaturated fat (experimental)~monounsaturated fat"
9950554|NCT01093638|Experimental|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with premature infant formula
9950555|NCT01093638|Placebo Comparator|Oral Formulation of Placebo|Oral formulation of placebo fed concomitantly with premature infant formula
10004896|NCT01580150|Active Comparator|Reference meal|Carbohydrate meals without berries
10004897|NCT01580163|Experimental|JITAI combined therapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
10004898|NCT01580163|Experimental|Methadone combined herapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
10004899|NCT01580163|Experimental|JITAI therapy group|The investigator will adopt JITAI combined social support in Shanghai-related community and outside of Shanghai.
10004900|NCT01580176|Experimental|GlucoseMonitor|
9950556|NCT01093664|Experimental|AFFITOPE AD02|
9950557|NCT01093677|Experimental|A|750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.
9950558|NCT01093677|Placebo Comparator|B|Placebo BID for 14 days. Up to 10 subjects.
9950559|NCT01093703|No Intervention|Conventional Therapy|In the conventional therapy group, no medication changes other than the ones needed to achieve target awake average SBP will be undertaken. Time at which patients are taking their BP medications will be recorded.
9950560|NCT01093703|Active Comparator|Intensive Therapy|In the intensive therapy group, BP medications will be adjusted to both control awake average systolic BP to target and to cover the overnight period in an attempt to control nocturnal hypertension.
9950561|NCT01093716|Experimental|rTMS|Compare the change in craving parameters following high frequency rTMS stimulation of right and left DLPFC in patients with alcohol dependence
9950562|NCT01093729|Experimental|Cohort1|HM11260C 0.5mcg/kg or Placebo
9950563|NCT01093729|Experimental|Cohort2|HM11260C 2mcg/kg or Placebo
9950564|NCT01093729|Experimental|Cohort3|HM11260C 4mcg/kg or Placebo
9950565|NCT01093729|Experimental|Cohort4|HM11260C 8mcg/kg or Placebo
9950566|NCT01093729|Experimental|Cohort5|HM11260C 14mcg/kg or Placebo
9950567|NCT01093742|Experimental|cohort 1|HM10560A 0.089 mg/kg or Placebo
9950568|NCT01093742|Experimental|cohort 2|HM10560A 0.179 mg/kg or Placebo
9950569|NCT01093742|Experimental|cohort 3|HM10560A 0.357 mg/kg or Placebo
9950570|NCT01093742|Experimental|cohort 4|HM10560A 0.714 mg/kg or Placebo
9950571|NCT01093781|Experimental|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
9950572|NCT01093807|Placebo Comparator|Placebo|
9950573|NCT01093807|Experimental|Lercanidipine 10 mg|
9950574|NCT01093807|Experimental|Lercanidipine 20 mg|
9950575|NCT01093807|Experimental|Enalapril 10 mg|
9950576|NCT01093807|Experimental|Enalapril 20 mg|
9950577|NCT01093807|Experimental|Lercanidipine 10 mg/Enalapril 10 mg|
9950578|NCT01093807|Experimental|Lercanidipine 10mg/Enalapril 20 mg|
9950579|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril 10 mg|
9950580|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril20mg|
9950581|NCT01093820|Experimental|Epopoetinum beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
9950582|NCT01093833|Experimental|Continuous Glucose Monitoring|Each subject will participate in one experimental intervention. Blood glucose will be measured with the BD continuous glucose monitor (BD CGM), with the Medtronic Guardian CGM and the YSI Glucose Analyzer as controls for 12-14 hours.
9950583|NCT01093859|Experimental|PRX-105 Infusion|
9950584|NCT01093898||No intervention|
9950585|NCT01093911|Experimental|CDP7657|CDP7657 in dose escalating cohorts
9950586|NCT01093911|Placebo Comparator|Placebo|
9950587|NCT01093924|No Intervention|self-guided weight loss maintenance|15-month self-guided weight loss maintenance group will receive monthly reminders to maintain their weight loss and newsletters that contain health information.
9950588|NCT01093924|Experimental|DVD group|15-month weight loss maintenance intervention deliver via DVD.
9950589|NCT01093924|Experimental|face-to-face group|15-month weight loss/weight loss maintenance intervention delivered in a group setting
9950590|NCT01093950||PROSPECTIVE BODY CONTOURING SUBJECTS|"It is anticipated that the participants will undergo body contouring procedures including lipoplasty [internal fat suction removal], abdominoplasty [surgical removal of lower abdominal skin and fat], breast reduction [surgical removal of breast skin, fat, and breast tissue to reduce breast size], breast augmentation [surgical breast enlargement], thigh lift [surgical removal of upper thigh tissue], and brachioplasty [surgical removal of upper arm tissue].~These procedures will be evaluated by pre- and post-operative digital scans, analog measurements, and clinical examinations and photographs."
9950591|NCT01093963|Active Comparator|Lisdexamfetamine|Drug
9950592|NCT01093963|Placebo Comparator|Placebo|Drug
9950593|NCT01093989|Placebo Comparator|Immediate iron|Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
9950594|NCT01093989|Active Comparator|Delayed iron|
10004901|NCT01580189|Active Comparator|Milk|Chocolate milk compared to protein supplement
10004902|NCT01580189|Active Comparator|Whey protein|Whey protein compared to milk
10004903|NCT01580189|Placebo Comparator|Sugar|Maltodextrin compared to treatments
10035213|NCT01803958|Active Comparator|whole breast irradiation|50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week, or other biologically equivalent schedule
9950595|NCT01094002|Experimental|Occupational therapy intervention (OTI)|198 subjects. The OTI schedule consisted of a daily 45-minute session, Monday through Friday, for the duration of hospitalisation. Activities were carried out in a structured manner and varied according to need and day of admission. On the first day, the patient's needs were analysed, including the need for iatrogenic prevention, retraining in basic and instrumental activities of daily living, technical aids, instruct the primary caregiver in patient mobilisation techniques, and social and occupational motivation. All OTI participants received an average of 5 sessions during hospitalisation.
9950596|NCT01094002|No Intervention|Conventional treatment model group|202 subjects. All subjects received medical treatment, nursing care, physical therapy, and social assistance in accordance with the usual practice of the geriatrics unit.
9950597|NCT01094015|Active Comparator|Lidocaine-Prilocaine cream|
9950598|NCT01094015|Placebo Comparator|placebo|
9950599|NCT01094028|Experimental|Saline group|Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
9950600|NCT01094041|Experimental|Gluten free diet|
9950601|NCT01094041|Experimental|Gluten rich diet|
9950602|NCT01094054|Active Comparator|Dietary and lifestyle modification|Patients in this arm will eat meals that are identical in size and caloric composition to those consumed by participants in the other arm who undergo adjustable gastric banding
9950603|NCT01094054|Experimental|Adjustable gastric banding|Subjects will undergo gastric banding as per clinical practice
9950604|NCT01094080|Active Comparator|standard infant formula|infants are fed a commercial formula during the first 4 month of life, according to protocol
9950605|NCT01094080|Experimental|modified infant formula|infants are fed a modified infant formula (modified protein content and fatty acid pattern) during the first 4 month of life, according to protocol
9950606|NCT01094080|Other|breast milk|infants are breast fed
9950607|NCT01094093|Experimental|Part B|Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).
9950608|NCT01094093|Experimental|Part A|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.
9950609|NCT01094132|Other|Review by colposcopy + multispectral digital colposcopy|All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
9950610|NCT01094145|Sham Comparator|Placebo|Stimulator setting is OFF
9950611|NCT01094145|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
9950612|NCT01094158|Experimental|high dose|Aramchol 300 mg daily (high dose)
9950613|NCT01094158|Experimental|low dose|100 mg daily (low dose)
9950614|NCT01094158|Placebo Comparator|Placebo|Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
9950615|NCT01094197||Transfused microchimeric subject|Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
9950616|NCT01094210||G1|500 ppm F Test Toothpaste
9950617|NCT01094210||G2|1100 ppm F Control Toothpaste
9950620|NCT01094236|Experimental|Supervisor Treatment Group|Supervisors watched the CD intervention
9950621|NCT01094236|Experimental|Administrators - Treatment|School administrators got access to the intervention binder with CD's, workbook and worksheets
9950622|NCT01094236|Experimental|Students|3rd grade students at participating study schools
9950623|NCT01094236|Experimental|Supervisor Control Group|Supervisors watched a video on playground equipment safety
9950624|NCT01094236|Experimental|Administrators - Control|Administrators did not have access to any treatment materials.
9950625|NCT01094236|Experimental|School Staff|School staff surveyed at staff meetings
9950626|NCT01094249|Experimental|001|divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
9950627|NCT01094275||wild / normal type allele of CYP2C gene|clopidogrel 75 mg alone.
9950628|NCT01094275||wild / normal type allele of CYP2C|clopidogrel 75 mg + omeprazole 20 mg.
9950629|NCT01094275||Loss of Haplotype CYP2C19|clopidogrel 75mg alone
9950630|NCT01094275||Loss of function haplotype of CYP2C|clopidogrel 75mg + omerprazole 20mg.
9950631|NCT01094314|Active Comparator|sequential medium|
9950632|NCT01094314|Active Comparator|single medium|
9950633|NCT01094340|Other|Thalidoide|CSF
9950634|NCT01094353|Active Comparator|Mini-sling|The minisling Ophira™ is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
9950635|NCT01094353|Active Comparator|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
9950636|NCT01094366|Sham Comparator|No Paracervical Block for Pain Control|Subject will not receive a paracervical block during the procedure
9950637|NCT01094366|Active Comparator|Paracervical Block for Pain Control|Subject will receive a paracervical block during the procedure.
9950638|NCT01094379|Active Comparator|Standard lap chole|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
9950639|NCT01094379|Active Comparator|Single incision lap chole|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
9950640|NCT01094392||treatment every 6th week during 6 months|
9950641|NCT01094392||treatment every 2nd week during 6 months|
9950642|NCT01094405|Experimental|EBV Vaccine|
9950643|NCT01094418||IGT group|IGT diagnosed by endocrinologist
9950644|NCT01094418||DM group|DM diagnosed by endocrinologist and whose primary NCS screening shows SNAP amplitudes of sural and superficial peroneal nerves greater than 10mA DM patients with no previous diagnosis of peripheral polyneuropathy
9950645|NCT01094418||Normal healthy participants|Normal health participants with no previous history of DM, IGT, thyroid disorder, hypercholesterolemia, or other condition associated with peripheral polyneuropathy
9950646|NCT01094444|Experimental|Vitamin K3-lotion|A lotion containing 1.5 mM Vitamin K3.
9950647|NCT01094444|No Intervention|B|Standard lotion without Vitamin K3
9950648|NCT01094457|Active Comparator|standard group|patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
10004904|NCT01580202|Active Comparator|Lamivudine|LAM (100 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
9950649|NCT01094457|Experimental|intensive group|patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
9950650|NCT01094483|Experimental|1|PN400 + ASA
9950651|NCT01094483|Placebo Comparator|2|Placebo + ASA
9950652|NCT01094509|Experimental|Tai Chi|Tai Chi exercises
9950653|NCT01094509|Experimental|Guided autobiography|Autobiographical writing during class sessions and at home
9950654|NCT01094509|Experimental|Qigong|Qigong exercises (exploratory, not part of the original protocol, added to gain experience with this intervention)
9950655|NCT01094509|Active Comparator|Successful aging|Seminars on the theme of successful aging
9950656|NCT01094509|Experimental|Combination|Combination of Tai Chi exercises and autobiographical writing
9950657|NCT01094509|Placebo Comparator|Comparison|No assigned experimental activity (exploratory, not part of the original protocol, added to gain experience with a placebo comparator)
9950658|NCT01094535|Experimental|Secretin|One-arm (open label): Synthetic Human Secretin. Patients will undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations.
9950659|NCT01094587|Active Comparator|Sutured closure|
9950660|NCT01094587|Active Comparator|Sutureless closure|
9950661|NCT01094600|Experimental|Secretin|Single arm (open label).
9950662|NCT01094613|Experimental|Delayed Release 6MP|"6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.~The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP)."
9950663|NCT01094613|Active Comparator|Purinethol|6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
9950664|NCT01094626|Experimental|Experimental|Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
9950665|NCT01094626|No Intervention|Controls|Fifteen subjects will be selected as controls, undergoing MRI without secretin-enhancement and matched for age, sex, race and tumor-type.
9950666|NCT01094639|Placebo Comparator|Supragingival prophylaxis|Plaque removal
9950667|NCT01094639|Active Comparator|Scaling root planing|SRP+oral hygiene
9950668|NCT01094652|Experimental|Whole grain diet|Participants in this group will be given whole grain snacks on school days and food packages consisting of whole grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
9950669|NCT01094652|Active Comparator|Refined grain diet|Participants in this group will be given refined grain snacks on school days and food packages consisting of refined grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
9950670|NCT01094665|Experimental|Focal Laser Thermal Therapy|Thermal therapy delivered to lesion visible on MRI.
9950671|NCT01094678|Experimental|Stent|
9950672|NCT01094756|Active Comparator|Obese group - Group 1|If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
9950673|NCT01094756|No Intervention|Lean group - Group 2|If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
9950674|NCT01094769|Experimental|Moxonidine|
9950675|NCT01094769|Placebo Comparator|Placebo|
9950676|NCT01094795||Patients initiating abatacept|
9950677|NCT01094795||Patients receiving other biologic disease-modifying drugs|
9950678|NCT01094795||Patients with early rheumatoid arthritis (RA)|
9950679|NCT01094795||Patients with prevalent RA identified by hospitalization|
9950680|NCT01094795||General population|
9950681|NCT01094821|Experimental|3 mg ATI-7505|3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
9950682|NCT01094821|Placebo Comparator|Placebo|Placebo capsule three times daily for 9 days followed by transit scintigraphy
9950683|NCT01094821|Experimental|10 mg ATI-7505|10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
9950684|NCT01094821|Experimental|20 mg ATI-7505|20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
9950685|NCT01094834|Experimental|DWP05195|
9950686|NCT01094847|Experimental|Treatment A|DWJ1252 given by oral administration under fasting conditions
9950687|NCT01094847|Active Comparator|Treatment B|DWJ1252 given by oral administration, 30 minutes after a meal
9950688|NCT01094847|No Intervention|Treatment C|mosapride by oral administration 30 minutes before meals
9950689|NCT01094860|Experimental|Continuous Infusion Nelarabine|Starting dose 200 mg/m2 x 5 days
9950690|NCT01094873|Experimental|Arm A, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 14 and 1 dose Ad6NSmut 5 x 10^8vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
9950691|NCT01094873|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 14 and 1 dose Ad6NSmut 5 x 10^9vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
9950692|NCT01094873|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
9950693|NCT01094873|Experimental|Arm A, group 4|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 2 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 12, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
9517231|NCT03308201|Experimental|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
9950694|NCT01094873|Experimental|Arm A, group 5|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 14 and 18, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 28, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
9950695|NCT01094873|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 2 and 6, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 16, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
9950696|NCT01094873|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 4 and 1 dose Ad6NSmut 5 x 10^8vp at week 14.~Patients: 2"
9950697|NCT01094873|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 4 and 1 dose Ad6NSmut 5 x 10^9vp at week 14.~Patients: 2"
9950698|NCT01094873|Experimental|Arm B, group 3|"Interventions: AdCh3NSmut; Ad6NSmut.~1 dose AdCh3NSmut 2.5 x 10^10vp at week 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 14.~Patients: 4"
9950699|NCT01094899|Experimental|Type 1 Diabetics without Neuropathy|Adult male with type 1 diabetes and without peripherical neuropathy
9950700|NCT01094899|Experimental|Type 2 Diabetics without Neuropathy|Adult male with type 2 diabetes and without peripherical neuropathy
9950701|NCT01094899|Experimental|Type 1 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
9950702|NCT01094899|Experimental|Type 2 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
9950703|NCT01094925|Placebo Comparator|Placebo|
9950704|NCT01094925|Active Comparator|Gabapentin 300mg|
9950705|NCT01094925|Active Comparator|Gabapentin 600mg|
9950706|NCT01094938||Repair|
9950707|NCT01094951|Other|ENGAGE|"In stage 1, study investigators will train Neighborhood House caseworkers to screen their clients for depressive symptoms.~In stage 2, study investigators will train Neighborhood House caseworkers to use the ENGAGE intervention in referring their clients to mental health services"
9950708|NCT01094977|Experimental|Low Dose|TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure
9950709|NCT01094977|Experimental|High Dose|TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure
9950710|NCT01094977|Placebo Comparator|Placebo|Normal saline 10 ml before skin incision and infusion according to weight until skin closure
9950711|NCT01095016|Experimental|Meptin swinghaler|
9950712|NCT01095016|Active Comparator|Berotec|
9950713|NCT01095029|Experimental|Off/Off|Pacemaker status: Bilateral Off for four weeks before first PET scann.
9950714|NCT01095029|Experimental|On/On|Pacemaker status: Bilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
9950715|NCT01095029|Experimental|On/Off|Pacemaker status: Unilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
9950716|NCT01095042|Experimental|Control group|30 Asymptomatic Healthy Volunteers Intervention : Observation of emotional behavior in asymptomatic healthy volunteers subjected to stress.
9950717|NCT01095042|Experimental|Experimental group|"Persons reached by digestive pathologies (SII or IBD). Group SII : 30 patients Group IBD: 60 patients (30 patients RCH and 30 patients CD)~Intervention : Observation of emotional behavior in person affected by digestive pathologies subjected to stress."
9950718|NCT01095055|Experimental|Group 1|AdCh63 AMA1
9950719|NCT01095055|Experimental|Group 2|AdCh63 AMA1 followed by MVA AMA1
9950720|NCT01095068|Experimental|physical exercise|Physical exercise
9950721|NCT01095081||Group 1|
9950722|NCT01095107|Other|Control Arm = Decreased Energy Density|Decreased energy density = 35-50 grams of fat per day between meals and snacks
9950723|NCT01095107|Other|Treatment Arm = Increased Energy Density|increased increased energy density : Intake > 50 grams of fat per day between meals and snacks
9517232|NCT03308201|Experimental|Hemay022 and Letrozole|Part two: Hemay022 in combination with letrozole will be taken in OTR dose until disease progression, intolerable toxicity or death.
9517233|NCT03308201|Experimental|Hemay022 and Fulvestrant|Part two: Hemay022 in combination with fulvestrant will be taken in OTR dose until disease progression, intolerable toxicity or death.
9950724|NCT01095133|Experimental|Amiloride|
9950725|NCT01095133|Placebo Comparator|Placebo|
9950726|NCT01095159|Active Comparator|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
9950727|NCT01095159|Active Comparator|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
9950728|NCT01095172|Experimental|Rituximab|"Rituximab 375mg/m2~Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone"
9950729|NCT01095172|Active Comparator|Control group|Low dose tacrolimus with mycophenylate mofetil and continued prednisolone
9950730|NCT01095185|Experimental|Standard therapy + Simvastatin|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)~Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)"
9950731|NCT01095185|Placebo Comparator|Standard therapy + placebo|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).~Placebo"
9950732|NCT01095198|Active Comparator|2nd Reminder Letter|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
9950733|NCT01095198|Experimental|Offer of Vaginal Self Collection|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
9950734|NCT01095211|Active Comparator|B-Vitamins|folic acid, cobalamin, vitamin B6
9950735|NCT01095211|Placebo Comparator|placebo|none of the vitamins (99.5% mannitol)
9950736|NCT01095224|Experimental|rAd35 Env A and rAd5 Env A|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
9950737|NCT01095224|Experimental|rAd35 Env A and rAd5 Env B|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
9950738|NCT01095224|Experimental|rAd35 Env A and rAd35 Env A|Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
9950739|NCT01095224|Experimental|rAd5 Env A and rAd5 Env A|Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
9950740|NCT01095224|Experimental|rAd5 Env A and rAd5 Env B|Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
9950741|NCT01095263|Experimental|Sham then Stimulation|
9950742|NCT01095263|Experimental|Stimulation then Sham|
9950743|NCT01095276|Placebo Comparator|Nebulized saline|patients on mechanical ventilation who were randomized to receive a placebo comparator (vehicle solution for dornase alpha)
9950744|NCT01095276|Active Comparator|dornase alpha|patients on mechanical ventilation who were randomly assigned to receive dornase alpha by in-line nebulization
9950745|NCT01095289||Total Laryngectomized|
9950746|NCT01095302|Experimental|Ombrabulin/ docetaxel/cisplatin|AVE8062 combined with docetaxel and cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
9950747|NCT01095315|No Intervention|standard|parturients were placed back to the supine position immediately after spinal injection following standard protocol of spinal anesthesia
9950748|NCT01095315|Experimental|lateral|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
9950749|NCT01095328|Experimental|intervention|Screening for Q-fever during pregnancy
9950750|NCT01095328|No Intervention|control|No screening for Q-fever during pregnancy
9950751|NCT01095341||THP|THP: patients undergoing parathyroidectomy according to tertiary hyperparathyroidism
9950752|NCT01095341||Other causes|patients with hyperthyroidism not caused by parathyroidectomy
9950753|NCT01095354||Asthma Patients|Spirometry. Bronchodilator with Salbutamol. Induced sputum in > 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
10004905|NCT01580202|Experimental|Entecavir|ETV (0.5 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
10004906|NCT01580215||Main cohort|"Patients of both genders of at least 18 years of age~Who understand and voluntarily sign an informed consent form~FEV1 > 15% predicted and < 45% predicted~RV >180% predicted~Diagnosis of emphysema with CT evidence of hyperinflation~Absence of collateral ventilation according to Chartis Assessment System~Treated with Zephyr Endobronchial Valve (EBV)"
10004907|NCT01580228|Experimental|Dinaciclib|
10004908|NCT01580228|Active Comparator|Ofatumumab|
10004909|NCT01580241||Surgery group|Patients with pancreatic cancer who undergo surgical treatment only
10004910|NCT01580241||Chemotherapy group|Patients with pancreatic cancer who undergo chemotherapy treatment only
10004911|NCT01580241||Neoadjuvant group|Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
10004912|NCT01580241||Adjuvant group|Patients with pancreatic cancer who undergo surgery followed by chemotherapy
10004913|NCT01580254|Active Comparator|IOPIZE© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©
10004914|NCT01580254|Active Comparator|GALAXIA© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©
10004915|NCT01580254|Active Comparator|Latanoprost RATIOPHARM© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©
10004916|NCT01580280|Experimental|Thrust manipulation|
10004917|NCT01580280|Active Comparator|Non-thrust mobilization and exercise|
10004918|NCT01580319|No Intervention|Control|Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
10004919|NCT01580319|Experimental|Exercise|Participants receive a physical exercise plan to play at home
10004920|NCT01580345|Active Comparator|Docosa-hexaenoic Acid (DHA)|
10004921|NCT01580345|Placebo Comparator|Placebo|Corn-Soy Oil
10004922|NCT01580358|Active Comparator|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
10004923|NCT01580358|Placebo Comparator|starch|Starch in the same granule as intervention group for this double-blind trial
10004924|NCT01580371|Experimental|Treatment|CKD-581
10004925|NCT01580384||Cohort|
10004926|NCT01580397|Experimental|INNO-206|
10004927|NCT01580436|Experimental|Tricuspid Valve Annuloplasty|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to concomitant tricuspid valve annuloplasty.
10004928|NCT01580436|No Intervention|Conservative arm|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to mitral valve surgery without concomitant tricuspid valve annuloplasty.
10004929|NCT01580462||Children and Adolescent with type 1 diabetes on CSII|
10004930|NCT01580475|Experimental|Lifestyle (exercise training)|Training, detraining and retraining
10004931|NCT01580514|Active Comparator|Exenatide|"Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
10004932|NCT01580514|Placebo Comparator|Saline|"Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
10004933|NCT01580527|Active Comparator|total parenteral nutrition|
10004934|NCT01580527|Experimental|Early enteral nutrition|
9950754|NCT01095367|Active Comparator|Seprafilm™|Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
9950755|NCT01095367|No Intervention|No Seprafilm™|Subject will undergo debulking surgery without Seprafilm™ placement (standard care). At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
9950756|NCT01095380|Active Comparator|Treadmill training - manual assist (TM)|Participants in the TM group received partial body weight support unilateral or bilateral manual assistance from a trainer for stepping
9950757|NCT01095380|Active Comparator|Treadmill training - electrical stimulation (TS)|Participants in the TS group received partial body weight support and bilateral functional electrical stimulation to assist stepping
9950758|NCT01095380|Active Comparator|Overground Training (OG)|Training over ground with body weight support and electrical stimulation for dorsiflex assistance
9950759|NCT01095380|Active Comparator|Treadmill training - locomat robot (LR)|Treadmill training with partical body weight support and assistance of a robotic gait orthosis for stepping
9950760|NCT01095393||Certolizumab pegol (CZP)|Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
9950761|NCT01095393||Non-biologic DMARD|Subjects with RA receiving treatment with non-biologic DMARD
9950762|NCT01095406|Active Comparator|S1 ventilation|Mechanical ventilation with S1 the thrid hour of ventilation
9950763|NCT01095406|No Intervention|Servo i ventilation|1 hour ventilation in pressure support mode with Servo i
9950764|NCT01095419|No Intervention|Control|Patients were seated in a chair for the same period then those from MT group, but did not receive intervention
9950765|NCT01095419|Experimental|Massage Therapy|Patients in the postoperative period of coronary artery bypass graft surgery, which receive intervention for 3 consecutive days
9950766|NCT01095432||Main Study Group|All subjects who are undergoing a standard of care colonoscopy for flexible sigmoidoscopy and have a history of UC and agree to participate will be in the main study group.
9950767|NCT01095445|No Intervention|Standard of care treatment|Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
9950768|NCT01095445|Active Comparator|Extended therapy|Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.
9950769|NCT01095458|Experimental|Phone based weight management group|Group based weight management program delivered via conference calls
9950770|NCT01095458|Experimental|Clinic based weight management group|Traditional clinical based group weight management program
9950771|NCT01095471|Experimental|PCV13|Initial vaccination with PCV13
9950772|NCT01095471|Experimental|PCV7|Initial intervention with PCV7
9950773|NCT01095484||Rotigotine|Patients who have a documented medical necessity to receive treatment with rotigotine treatment in accordance with standard medical practice.
9950774|NCT01095549|Placebo Comparator|Control group|HD patients who will not receive far infrared therapy in this study.
9950775|NCT01095549|Experimental|Far infrared therapy|In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
9950776|NCT01095575|Active Comparator|group 1|NS preoperatively and MO postoperatively
9950777|NCT01095575|Active Comparator|group 2|MO preoperatively and NS postoperatively
9950778|NCT01095588|Experimental|Avanafil|
9950779|NCT01095588|Placebo Comparator|Placebo|
9950780|NCT01095601|Other|Treatment A|2x100 mg Formulation II avanafil tablet, fasted
9950781|NCT01095601|Other|Treatment B|2x100 mg Formulation II avanafil tablet, fed
9950782|NCT01095601|Other|Treatment C|2x100 mg Formulation I avanafil tablet, fasted
9950783|NCT01095601|Other|Treatment D|1x50 mg Formulation II avanafil tablet, fasted
9950784|NCT01095614||12 women with oral contraception|
9950785|NCT01095614||12 women without any contraception|
9950786|NCT01095627|Other|Metacholine Challenge|Exhaled breath analysis following metacholine challenge
9950787|NCT01095640|Experimental|adapalene 0.3% topical gel (Actavis Mid-Atlaqntic LLC)|
9950788|NCT01095640|Active Comparator|Differin® (adapalene 0.3% topical gel)|
9950789|NCT01095640|Placebo Comparator|Vehicle Control|
9950790|NCT01095679|Experimental|Baclofen|
9950791|NCT01095679|Placebo Comparator|Placebo|Placebo
9950792|NCT01095692|Active Comparator|only surgery|
9950793|NCT01095692|Experimental|surgery + TOT|
9950794|NCT01095705|Active Comparator|Conventional procedure|Local anaesthesia (Lidocaïne)
9950795|NCT01095705|Experimental|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) and Hypnosis
9950796|NCT01095718|Experimental|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
9950797|NCT01095718|Active Comparator|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step.Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance. Then the therapist asks immediately to the patient to do the steps."
9950798|NCT01095718|Active Comparator|Trial and Error|"Trial and Error refers to the regular unstructured learning and is considered as control condition.~Here the patient is encouraged to complete the task. When there is mistake, the therapist corrects it. Verbal cues will only be provided if the patient is unable to find and complete the correct next step or commit mistakes. The therapist use general instruction: Here is task, I will ask you to actions, followed by specific instruction, and I will help you after you have tried."
9950799|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
9950800|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
9950801|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
9950802|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
9950803|NCT01095744||EOAD typical AD|this cohort is constituted with early onset typical AD.
9950804|NCT01095744||LOAD typical|this group is constituted with late onset typical AD
9950805|NCT01095744||atypical AD|this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
9950806|NCT01095744||young controls|under 65
9950807|NCT01095744||old controls|over 65
9950808|NCT01095770|Active Comparator|Ablation Frontiers Ablation|This group will undergo AF ablation using Ablation Frontiers Technology.
9802137|NCT05316584|No Intervention|Control|The standard of care for participants in this study is modeled after the standard of care at all five study sites. Standard of care is based on current evidence-based guidelines including a comprehensive assessment, a guideline-concordant therapy plan, scheduled and as needed clinic visits, scheduled and as needed telephone calls, and administration of educational fact sheets about disease-specific topics when appropriate. Personnel used to provide standard of care at each site will vary and may include nurse coordinators, advanced practice providers, social workers, psychologists, dieticians, pharmacists, and other ancillary staff.
9802138|NCT05316558|Experimental|Body Confident Coaching|Participants in the intervention condition will take part in an online program consisting of five modules over five weeks.
9802139|NCT05316558|No Intervention|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
9803569|NCT03728166|Experimental|Alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
9803570|NCT03728166|No Intervention|No Alert|No notification to the provider.
9803571|NCT03725449|Experimental|Phase I (user testing)|Participants complete telephone-based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability.
9803572|NCT03725449|Experimental|Phase II Group I (mySmartCheck)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive access to mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
9803573|NCT03725449|Experimental|Phase II Group II (standard of care)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
9803574|NCT03723876|Active Comparator|Intervention group|Twelve occasions of Basic body awareness therapy, administered once a week, alongside treatment as usual (such as structured everyday support, medicine, contact with social worker).
9803575|NCT03723876|No Intervention|Control group|No extra intervention except treatment as usual.
9803576|NCT03723811|Experimental|1|SJP002 BID
9803577|NCT03723811|Experimental|2|SJP002 QID
9803578|NCT03723811|Placebo Comparator|Placebo 1|SJP002 Placebo 1
9803579|NCT03723811|Placebo Comparator|Placebo 2|SJP002 Placebo 2
9803580|NCT03721926|Experimental|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
9803581|NCT03721926|Active Comparator|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
9803582|NCT03721393||Group 1: Syncope patients|Patients that have undergone an ARS assessment and diagnosed with orthostatic hypotension or reflex syncope.
9803583|NCT03721393||Group 2: Control patients|Patients that have undergone an ARS assessment and are control subjects.
9803584|NCT03719755|Active Comparator|50% dextrose|Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout
9803585|NCT03719755|Placebo Comparator|Normal Saline|Cystoscopic distention media of normal saline.
9803586|NCT03719326|Experimental|Dose Escalation-Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
9803587|NCT03719326|Experimental|Dose Escalation-Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
9803588|NCT03719326|Experimental|Dose Escalation-Arm C|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
9803589|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 1|The dose given will be determined from the dose escalation part (Arm A).
10004935|NCT01580540||Group A, subjects with colorectal cancer|Subjects between ages 50 and 84 identified to have CRC. Blood and stool specimens are collected and tested after colonoscopy and prior to surgery or other interventions.
10004936|NCT01580540||Group B, subjects without CRC|Subjects between ages 50 and 84 who provide stool and blood specimens prior to colonoscopy.
10004937|NCT01580553|Placebo Comparator|Levocarnitine|
10004938|NCT01580553|Active Comparator|L-carnitine|
10004939|NCT01580566||Group 1 - Control|"Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as control for renal injury subjects."
9802140|NCT05316532||Mechanically ventilated ECCO2R group|Adult, mechanically ventilated critically ill patients with respiratory failure and incapacity to sustain lung protective ventilation
9802141|NCT05316532||Awake spontaneously breathing ECCO2R group|Awake, spontaneously breathing critically ill patients suffering from respiratory exhaustion
9802142|NCT05316519|Experimental|Transcutaneous Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation paired with visuomotor task training
9950809|NCT01095770|Active Comparator|LASSO ablation|This group will undergo atrial fibrillation ablation with traditional LASSO technology
9950810|NCT01095770|Active Comparator|Reveal XT monitoring|This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.
9528829|NCT03207165|Active Comparator|Right ventricular [RV] dysfunction|Assessment of right ventricular [RV] dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
9802143|NCT05316519|Placebo Comparator|Transcutaneous Stimulation (Sham)|Transcutaneous stimulation paired with visuomotor task training
9802144|NCT05316493|Experimental|overweight MA+ILI|enrolled overweight (24kg/m2≤BMI<28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
9802145|NCT05316493|Experimental|overweight LNG-IUS+ILI|enrolled overweight (24kg/m2≤BMI<28kg/m2) patients will be treated with LNG-IUS plus weight management
9802146|NCT05316493|Experimental|obese MA+ILI|enrolled obese (BMI≥28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
9802147|NCT05316493|Experimental|obese LNG-IUS+ILI|enrolled obese (BMI≥28kg/m2) patients will be treated with LNG-IUS plus weight management
9802148|NCT05316480|Experimental|Nimotuzumab|nimotuzumab 200mg/week
9802149|NCT05316467|Experimental|overweight 24kg/m2≤BMI<28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
9802150|NCT05316467|Experimental|BMI≥28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
9802151|NCT05316454|Experimental|Experimental|Patients with hypertension benefit from self-efficacy support in terms of medication adherence and self-efficacy.
9802152|NCT05316454|No Intervention|Control|No change.
9802153|NCT05316428|Experimental|alcohol plus TPN171H|0.5 g/Kg alcohol plus 10 mg TPN171H tablet
9802154|NCT05316428|Experimental|alcohol|0.5 g/kg alcohol
9802155|NCT05316428|Experimental|TPN171H|10 mg TPN171H tablet
9802156|NCT05316415|Experimental|Acemaşiran Music Group|Listening to Acemaşiran music for 40 minutes in successive three days and two times a day (noon and evening) Routine clinical care
9802157|NCT05316415|No Intervention|Control Group|Routine clinical care
9802158|NCT05316402|Experimental|training on the risks associated with sun exposure|power point on the risks associated with sun exposure
9802159|NCT05316389||A Retrospective|A = retrospective cohort including all patients treated at the ICO Angers between January 2017 and September 2021
9802160|NCT05316389||B Prospective|B = prospective including all patients treated at the ICO from February 2022 (2 years of recruitment)
9802161|NCT05316376|Experimental|dd-nabTC|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5, day 1, every 4 weeks)
9802162|NCT05316376|Active Comparator|CONTROL|paclitaxel (175 mg/m2, day 1, every 4 weeks) combined with carboplatin (AUC=6, day1, every 4 weeks)
9802163|NCT05316363|Experimental|OMT Intervention Arm|Patients treated with 4 techniques for 8 minutes in the supine position. OMT systematically administered to address the 4 body regions - cervical spine, thoracic spine, ribs and diaphragm. The techniques utilized for this study include: suboccipital release, diaphragmatic release, rib raising and paraspinal inhibition of the thoracic spine. Each technique administered for approximately 2 minutes.
9802164|NCT05316363|No Intervention|Control|Patients lie supine on the treatment table and rested quietly for a total of 8 minutes.
9802165|NCT05316350|Experimental|Atrial Fibrillation|
9802166|NCT05316350|Experimental|Normal Sinus Rhythm|
9802167|NCT05316337|Experimental|Atrial fibrillation|
9802168|NCT05316337|Experimental|Normal Sinus Rhythm|
9802169|NCT05316324|Experimental|Prepectoral Breast Reconstruction with ADM|
9802170|NCT05316324|Experimental|Prepectoral Breast Reconstruction without ADM|
9802171|NCT05316298|No Intervention|Phase 1: observation|Observation during standard-of-care non-surgical treatment
9802172|NCT05316298|Experimental|Phase 2: Intervention|After unsuccessful standard-of-care non-surgical treatment in phase 1, subjects will undergo treatment by surgical debridement of the diabetic foot ulcer and underlying osteomyelitis, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, followed by postoperative treatment regimen including woundcare, 10 days of antibiotics and offloading.
9802173|NCT05316285|Experimental|Yoga Group|It will consist of students who choose the Yoga for a Healthy Life lesson. For 14 weeks, one day a week and 60 minutes a day, theoretical and practical yoga training will be applied.
9802174|NCT05316285|No Intervention|Control Group|The control group will consist of students who chose the Fashion and Beauty lesson.
9802175|NCT05316272|Experimental|Exercise and placebo|supervised bone-loading exercise 3 days per week and one placebo pill per day for 36 weeks
9802176|NCT05316272|Experimental|Exercise and DHEA|supervised bone-loading exercise 3 days per week and one dose of DHEA (50 milligrams) per day for 36 weeks
9802177|NCT05316272|Experimental|no exercise and DHEA|no supervised bone exercise and one dose of DHEA (50 milligrams) per day for 36 weeks
9802178|NCT05316272|Experimental|no exercise and placebo|no supervised bone-loading exercise and one placebo pill per day for 36 weeks
9803590|NCT03719326|Experimental|Dose Expansion-Ovarian Cancer-Arm 2|The dose given will be determined from the dose escalation part (Arm A).
9803591|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 3|The dose given will be determined from the dose escalation part (Arm B). .
9803592|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 4|The dose expansion will be determined from the dose escalation part (Arm C).
9950811|NCT01095770|Active Comparator|Permanent Pacemaker - dual chamber|This group will be monitored pre and post ablation with a dual chamber permanent pacemaker
9950812|NCT01095783|Experimental|Physiotherapeutic intervention|
9950813|NCT01095783|Other|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
9950814|NCT01095809|Experimental|bevacizumab|intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
9950815|NCT01095809|Experimental|triamcinolone acetonide|intravitreous triamcinolone 2 mg, frequency: 3 months
9950816|NCT01095822|Active Comparator|Aliskiren|25 patients with recently diagnosed hypertension and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
9950817|NCT01095822|Experimental|Aliskiren + Valsartan|25 patients with recently diagnosed hypertension, and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
9950818|NCT01095848|Experimental|0.25ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
9950819|NCT01095848|Experimental|1ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
9950820|NCT01095861|Experimental|FlexTip ETT|FlexTip ETT
9950821|NCT01095861|Placebo Comparator|Control|Standard Flexible ETT Mallinckrodt Hi-Lo cuffed tracheal tube Catalog # 86114 Mallinckrodt, ST. Louis, MO, 63134
9950822|NCT01095900||LIS group)|
9950823|NCT01095900||BT group|
9950824|NCT01095913|Experimental|IC-Green Injections|ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
9950825|NCT01095926|Experimental|Doxorubicin|
9950826|NCT01095939|Placebo Comparator|Control Arm|
9950827|NCT01095939|Experimental|Benazepril|
9950828|NCT01095952|Experimental|AVNS ON|Consulta downloaded with AVNS to provide high frequency bursting during fastly conducted AF. AVNS will be programmed on for five months. The feasibility and safety of the AVNS algorithm to reduce inappropriate shocks will be monitored.
9950829|NCT01095965|Experimental|Lifestyle education|Nutrition education comprised of 4 components: Curriculum (8 weeks), follow-up meetings (4 monthly plus 2-bimonthly), education materials for use at home and vegetable gardening demonstrations.
9950830|NCT01095991|Experimental|1|AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
9950831|NCT01095991|Experimental|2|Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
9476484|NCT03571308|Experimental|R-CHOP + Acalabrutinib|"Open-label non-randomised phase Ib/II study conducted in two stages. Phase I will see two doses of acalabrutinib tested. R-CHOP + acalabrutinib will be given for 6 cycles on a 21 day cycle and then two cycles of acalabrutinib only for a total of 56 days. Acalabrutinib will be introduced at Cycle 2.~Phase II will see the recommended phase 2 dose used on the same treatment regimen."
9950832|NCT01096004|Experimental|1|
9950833|NCT01096004|Placebo Comparator|2|
9476485|NCT03571295|Experimental|videolaryngoscopy|
9950834|NCT01096030|Experimental|Regorafenib|
9950835|NCT01096043|Placebo Comparator|Placebo|Each Strata of the study will have a placebo control. In strata A, the chance of getting active drug is 4 out of 5, in Strata B the chance of getting active drug is 3 ot of 4, and in Strata C, the chance of getting active Drug is 4 out of 5. In the event that a patient is allocated to receive placebo, the treatment may be stopped if the patient's condition fails to improve or worsens during the placebo infusion.
9950836|NCT01096043|Experimental|Strata 1 CXL-1020|Patients assigned to CXL-1020 in strata one will have their dose increased from the initial dose 2 times during the study period. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
9950837|NCT01096043|Experimental|Strata 2 CXL-1020|In strata 2, patients who are assigned to active treatment will receive one of up to 3 possible fixed dose levels of CXL-1020 for a period of 6 hours. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
9950838|NCT01096043|Experimental|Strata 3 CXL-1020|In strata 3, patients assigned to receive CXL-1020 will receive a fixed dose of CXL-1020 for 6 hours, and then the dose may be increased or decreased, based on the investigators assessment of the patient. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
9950839|NCT01096069||Rituximab|Rheumatoid arthritis patients undergoing treatment with rituximab.
9950840|NCT01096082|Placebo Comparator|Placebo|
9950841|NCT01096082|Experimental|Lithium Carbonate|
9950842|NCT01096095|Placebo Comparator|Placebo|Placebo
9476486|NCT03571295|Experimental|direct laryngoscopy|
9950843|NCT01096095|Experimental|Sodium phenylbutyrate|Active drug
9950844|NCT01096108|Experimental|Standard Contest|Smoking abstinence, 1 prize award (month 1)
9950845|NCT01096108|Experimental|Standard Contest plus MAPS|Smoking abstinence, 1 prize award (month 1) plus motivational and problem-solving counseling (MAPS - Counseling phone calls); 20 weeks.
9950846|NCT01096108|Experimental|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
9950847|NCT01096108|Experimental|Extended Contests plus MAPS|Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.
9950848|NCT01096121|Placebo Comparator|2|
9950849|NCT01096121|Experimental|1|Enalapril
9950850|NCT01096134|Experimental|HPV Vaccine|Eligible girls were offered 3 doses of the HPV vaccine
9950851|NCT01096147|Active Comparator|SCS|patients receiving SCS for chronic leg and/or back pain.
9950852|NCT01096212|Experimental|generic sevoflurane|
9950853|NCT01096212|Active Comparator|origianl sevoflurane|
9950854|NCT01096225||vaccinated group|
9950855|NCT01096251|Experimental|CBT|CBT group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of CBT) plus 8 outpatient telephone-based sessions of CBT-oriented psychological support and monitoring with the same CBT inpatient psychotherapists.
9950856|NCT01096251|Experimental|BST|BST group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of BST) plus 8 outpatient telephone-based sessions of BST-oriented psychological support and monitoring with the same BST inpatient psychotherapists.
9950857|NCT01096264|Other|Healthy volunteer|"Healthy volunteer undergoing two imagery evaluation :~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
9950858|NCT01096264|Other|vEDS patients|"vEDS patients undergoing two imagery evaluations:~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
9950859|NCT01096277|Active Comparator|Sitagliptin|100 mg sitagliptin per day for 2 weeks
9950860|NCT01096277|Placebo Comparator|Placebo|1 placebo tablet per day for 2 weeks
9950861|NCT01096277|No Intervention|Healthy Control|Healthy control subjects
9950862|NCT01096303||COPD tobacco and/or marihuana users|COPD patients with history of tobacco and/or marihuana smoking.
9950863|NCT01096329|Active Comparator|Cohort 2|Testosterone Spray (5%) vs Intrinsa® Patch
9950864|NCT01096329|Active Comparator|Cohort 3|Testosterone Spray (1%) vs Intrinsa® Patch
9950865|NCT01096329|Active Comparator|Cohort 1|Testosterone Spray (5%) vs Testosterone Spray (1%)
9950866|NCT01096355|Experimental|Group A|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and 8-10.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
9950867|NCT01096355|Experimental|Group B|"Patients receive oral RO4929097 once daily on days 1-7.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
9950868|NCT01096355|Experimental|Group C|"Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
9950869|NCT01096355|Experimental|Group D|"Patients receive oral RO4929097 once daily on days 1, 8, and 15.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
9950870|NCT01096355|Experimental|Group E|"Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
9950871|NCT01096355|Experimental|Group F|"Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
9950872|NCT01096381||Will receive bevacizumab|
9950873|NCT01096381||Will not receive bevacizumab|
9950874|NCT01096394||Ovarian cancer|Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.
9950875|NCT01096407||Paclitaxel-Induced Myalgias/Arthralgias|
9950876|NCT01096420|Experimental|acupuncture|
9950877|NCT01096420|Active Comparator|topiramate|
9950878|NCT01096433|Experimental|CPAP|The subjects introduced with CPAP treatment
9950879|NCT01096472|Experimental|LAS41003|Once daily
9950880|NCT01096472|Active Comparator|LAS189962|Once daily
9950881|NCT01096472|Active Comparator|LAS189961|Once daily
9950882|NCT01096485|Experimental|Arm 1|
9950883|NCT01096485|Active Comparator|Arm 2|
9950884|NCT01096498|Experimental|Arm 1|
9950885|NCT01096498|Active Comparator|Arm 2|
9950886|NCT01096511||Group 1|
9950887|NCT01096524|Other|Control group standard physiotherapy|Standard pathway of care pre-and post-TKA without using NMES.
9950888|NCT01096524|Experimental|Kneehab|Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
9950889|NCT01096537||Young workers|"Exposed young workers graduated in sectors at risk of occupational asthma (bakery, pastry-making or hairdressing)~Non-exposed young workers graduated in sectors without specific occupational exposure as the sale or the food sectors."
9950890|NCT01096563|Experimental|1|AZD9164
9950891|NCT01096563|Placebo Comparator|2|
9950892|NCT01096576|Experimental|A|
9950893|NCT01096576|Placebo Comparator|B|
9950894|NCT01096615|Active Comparator|Tested product: Lactobacillus paracasei LP-33|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
9950895|NCT01096615|Placebo Comparator|Comparative product : placebo|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
9950896|NCT01096628|Experimental|Chiropractic + Exercise|
9950897|NCT01096628|Active Comparator|Exercise|
9950898|NCT01096641|Other|Fatigued patients: Immediate start CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
9950899|NCT01096641|Other|fatigues patients: delayed CBT (after 6 months)|The fatigued patients on the waiting list will start with CBT after 6 months
9950900|NCT01096641|No Intervention|non-fatiqued controls|Non-fatigued control group. This group is not included in the randomization.
9950901|NCT01096654|Active Comparator|CT-scan|In this group treatment will be based on the outcome of the CT-scan only. Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal. If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
9950902|NCT01096654|Active Comparator|Adrenal Vein Sampling|"This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava.~If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA."
9950903|NCT01096693|Placebo Comparator|Saline Placebo|In this arm, the response in forearm blood flow to incremental doses of Urocortins 2, 3 and Substance P will be studied co infused with saline placebo.
9950904|NCT01096693|Active Comparator|Response to Urocortin infusion in presence of Astressin 2B|This arm studies the response to intra arterial infusion of incremental doses of Urocortins 2, 3 and Substance P in the presence or absence of a selective antagonist - Astressin 2B.
9950905|NCT01096706|Experimental|Nitric Oxide Clamp|Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
9950906|NCT01096706|Placebo Comparator|Saline Placebo|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
9950907|NCT01096706|Experimental|Fluconazole|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
9950908|NCT01096706|Experimental|Aspirin|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
9950909|NCT01096706|Experimental|Combined|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.
9950910|NCT01096719|Experimental|Energy Density|
9950911|NCT01096719|Active Comparator|Lifestyle Treatment|
9950912|NCT01096719|Experimental|Energy Density + Lifestyle Treatment|
9950913|NCT01096732|Experimental|GDC-0449|Study drug.
9950914|NCT01096745|Experimental|Gemcitabine/Cisplatin|
9950915|NCT01096745|Experimental|S-1/Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
9803593|NCT03718065|Experimental|Lofexidine Men|Men will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
9950916|NCT01096758||PKU patients|
9950917|NCT01096758||healthy controls|
9950918|NCT01096797|Experimental|Children undergoing adenotonsillectomy|Children between 2-6 years old undergoing elective adenoidectomy with or without tonsillectomy from the ENT Service of the San Gerardo Hospital.
9950919|NCT01096836|Experimental|Diet counseling|Outcomes of the study may enhance diet counseling
9950920|NCT01096836|Experimental|exercise training|
9950921|NCT01096888|No Intervention|Standard WIC care|Patients randomized to this group will receive standard WIC care and an information packet surround healthy eating and activity topics.
9950922|NCT01096888|Active Comparator|Enhanced WIC weight loss program|Participants randomized into this condition will receive standard WIC care, but will also receive weight loss classes provided through the internet. Topics will cover behavioral weight loss topics, based off the protocols of the Look AHEAD program.
9950923|NCT01096901|Active Comparator|Comprehensive behavioral weight loss|The group will be implemented to induce a 6% weight loss over 3 months. The lessons will follow protocols from the Look AHEAD trial and Diabetes Prevention Program. This behavioral program has been shown to promote long-term weight loss and a reduction in diabetes and cardiovascular risk factors, and is based on the social cognitive theory.
9950924|NCT01096901|No Intervention|Education and Support Control group|Participants in this group will receive support and education about healthy eating and activity with lessons based on the Look AHEAD support and education control condition. Participants will attend monthly closed group meetings and meetings will be designed to promote retention but not weight loss.
9950925|NCT01096914|Active Comparator|Radiofrequency|patients treated with percutaneous radiofrequency ablation
9950926|NCT01096914|Active Comparator|laser|Patients treated with percutaneous laser ablation
9950927|NCT01096927|Experimental|Non operative Treatment group|Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)
9950928|NCT01096940|Experimental|1|AZD1656
9950929|NCT01096940|Experimental|2|Simvastatin
9950930|NCT01096940|Experimental|3|AZD1656 + simvastatin
9950931|NCT01096953|Active Comparator|Telepsychiatry|Psychiatry provided over telehealth network
9950932|NCT01096953|Active Comparator|Face-to-face care|Psychiatry provided in person
9950933|NCT01097031||Continuous Infusion|
9950934|NCT01097031||Intermittent Infusion|
9950935|NCT01097031||Infusion Continuous|
9950936|NCT01097070|Experimental|Bevirimat 200 mg twice daily, 15 days|
9950937|NCT01097070|Experimental|Bevirimat 300 mg once daily, 15 days|
9950938|NCT01097070|Experimental|Bevirimat 400 mg once daily, 15 days|
9950939|NCT01097122|Experimental|Healthy young adult subjects|Forearm vibration will be applied in healthy young adult subjects
9950940|NCT01097135|No Intervention|Standard surgical skin preparation|
9950941|NCT01097135|Active Comparator|Standard Surgical Skin Preparation with Duraprep|standard surgical skin prep
9950942|NCT01097148|Active Comparator|Atracurium, TBW|Dose of atracurium 0.5 mg/kg based on total body weight
9950943|NCT01097148|Active Comparator|Atracurium IBW|dose 0.5 mg/kg based on ideal body weight
9950944|NCT01097161|Experimental|Speech treatment on prosodic basis|Patients receive 20 therapy sessions over a course of 3 months, with one double session per week.
10004940|NCT01580566||Group 2 - stable CAD or non-Q wave MI|Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
10004941|NCT01580566||Group 3 - Acute STEMI without chronic kidney disease|Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
10004942|NCT01580566||Group 4 - Acute STEMI with kidney disease|Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).
10004943|NCT01580579||locally advanced lung cancer|Patients with locally advanced lung cancer who are candidates to chemoradiation
10004944|NCT01580605||Users of somatropin|
10004945|NCT01580631||BE with dysplasia.|Patients having Barrett's esophagus with dysplasia.
10004946|NCT01580631||BE without dysplasia.|Patients having Barrett's esophagus without dysplasia.
10004947|NCT01580644|Experimental|Period 1: formulation 1 oral solution|
10004948|NCT01580644|Experimental|Period 2: formulation 2 capsule|
10004949|NCT01580644|Experimental|Period 3: Selected formulation + food|
10004950|NCT01580644|Experimental|Period 4: Selected formulation at higher dose|
10004951|NCT01580657|Experimental|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
10004952|NCT01580657|Experimental|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
9950945|NCT01097174||CyPass Micro-stent|Patients in whom CyPass Micro-stent implantation was attempted.
9950946|NCT01097200|Other|Elevate meshes|The use of Elevate (American Systems trade mark) meshes for the treatment of pelvic prolapse.
9950947|NCT01097200|Other|Sacrocolpopexy|Sacrocolpopexy for the correction of the prolapse
9950948|NCT01097226|Experimental|Apple flavanols|
9950949|NCT01097239|Experimental|High Intensity Focused Ultrasound|Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
9950950|NCT01097252|Active Comparator|weekly cisplatin|Weekly cisplatin 40mg/m2 during radiation therapy
9950951|NCT01097252|Experimental|tri-weekly cisplatin|cisplatin 75mg/m2 three cycles, every 3 weeks
9950952|NCT01097278|Experimental|Arm I|Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
9950953|NCT01097278|Active Comparator|Arm II|Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
10214909|NCT03850067|Experimental|Nivolumab combination|"When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy.~A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each."
10214910|NCT03844906|Experimental|SAGE-718|
9950954|NCT01097356|No Intervention|common care|HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear
9950955|NCT01097356|Experimental|probiotic drinkers|HPV+, LSIL patients who will drink the study drink for 6 months
9950956|NCT01097369||Anti-rasburicase antibodies|
9950957|NCT01097382|Experimental|AMBIEN CR|AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime
9950958|NCT01097408|Experimental|AZD7295|
9950959|NCT01097408|Placebo Comparator|Matched placebo|
9950960|NCT01097434|Active Comparator|Arm 1|Biodegradable polymer limus-eluting stents
9950961|NCT01097434|Active Comparator|Arm 2|Permanent polymer limus-eluting stent
9950962|NCT01097447||Ciprofloxicine or Vigamox or other|up to qid till epithelialized.
9950963|NCT01097447||Topical Nonsteroidal (Acular, Acuvail, Voltaren Xibrom|up to qid for up to 5-10 days postop
9950964|NCT01097447||Topical steroid (FML, Pred Forte, Flarex|qid for up to 8 weeks
9950965|NCT01097473|Active Comparator|Exercise training|Subjects participate in a once weekly supervised exercise training group, duration of 60 min.
9950966|NCT01097473|No Intervention|Control|Control group receives no intervention
9950967|NCT01097486|Active Comparator|Allograft|Cervical Spinal Fusion with Allograft
9950968|NCT01097486|Experimental|NeoFuse|Cervical Spinal Fusion with NeoFuse
9950969|NCT01097499|Active Comparator|LED application|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
9950970|NCT01097499|No Intervention|No LED application|These patients will receive conventional dental implant treatment without the application of the LED therapy.
9950971|NCT01097512|Experimental|Regimen 1: AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle
9950972|NCT01097512|Experimental|Regimen 2: AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle
9950973|NCT01097525|Active Comparator|Wavefront guided (WFG) PRK|
9950974|NCT01097525|Active Comparator|WFG LASIK|
9950975|NCT01097525|Active Comparator|Wavefront optimized (WFO) PRK|
9950976|NCT01097525|Active Comparator|WFO LASIK|
9950977|NCT01097538|Active Comparator|Body-weight supported treadmill training|Supported treadmill walking
10214911|NCT03844906|Placebo Comparator|Placebo|
10214912|NCT03843008|Experimental|Melatonin Group|Participants will receive 3mg of melatonin at 18:00 (+/- one hour) each evening up to seven days or for the duration of his or her hospital stay.
10214913|NCT03843008|No Intervention|No Melatonin Group|Participants will receive no melatonin for the length of their hospital stay.
10214914|NCT03840616|Experimental|Oteseconazole (VT-1161) 150mg capsule|600mg oteseconazole administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14
10214915|NCT03840616|Active Comparator|Fluconazole 150mg capsule / Placebo|150mg fluconazole administered every 72 hours in 3 sequential doses starting on Day 1, followed by placebo administered once weekly starting on Day 14
10214916|NCT03837977|Active Comparator|nal-IRI, 5-FU and racemic folinic acid|liposomal Irinotecan (naI-IRI) (80mg/m*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days
10214917|NCT03837977|Active Comparator|docetaxel|75mg/m*2 intravenously over 60 minutes) every 21 days]
10214918|NCT03833245|No Intervention|Control|The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.
10214919|NCT03833245|Experimental|Patient Navigation|The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
9950978|NCT01097538|Experimental|Total body recumbent stepper training|Recumbent stepper exercise training
9950979|NCT01097551||Patients with type 1 diabetes|Diabetes duration >= 5 years, age >= 18 and <= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension
9950980|NCT01097551||Healthy subjects|Sex and age-matched control healthy subjects
9950981|NCT01097564||COL4A1 genetic testing|COL4A1 genetic testing
9950982|NCT01097590|Experimental|Active TLA Gut™ column|The active column contain an engineered protein with the ability to specifically bind the inflammatory cells.
9950983|NCT01097590|Placebo Comparator|Placebo TLA Gut™column|The placebo column is identical to the active column except it does not contain the engineered protein that specifically bind the inflammatory cells.
9950984|NCT01097681|Experimental|Normal renal function group|oral
9950985|NCT01097681|Experimental|Mild renal impairment group|oral
9950986|NCT01097681|Experimental|Moderate renal impairment group|oral
9950987|NCT01097720||LTG-exposed|Children exposed to LTG during pregnancy.
9950988|NCT01097720||VPA-exposed|Children exposed to VPA during pregnancy.
9950989|NCT01097720||CBZ-exposed|Children exposed to CBZ during pregnancy.
9950990|NCT01097733||Pre-procedural cardiac CT|CRT patients will undergo pre-procedural cardiac CT to assess for dyssynchrony, scar, and coronary venous anatomy. The CT venogram will be randomize to pre-knowledge to implanting physician or blinded. The CT dyssynchrony and scar assessment will remain blinded to caregivers and patients.
9950991|NCT01097759||LigaSure|LigaSure is a vascular sealing device that can seal the hemorrhoidal plexus during hemorrhoidectomy (surgery)
9950992|NCT01097759||Stapler|Circular stapler that removes excess loose tissue above the anus and interrupts the blood supply during hemorrhoidal surgery
9950993|NCT01097772|Other|Ovation Abdominal Stent Graft System|Implant of Ovation Abdominal Stent Graft System
9950994|NCT01097798|Experimental|Aliviador|
9950995|NCT01097798|Active Comparator|Gelol|
9950996|NCT01097811|Active Comparator|Erythromycin|
9950997|NCT01097811|Active Comparator|Neomycin|
9950998|NCT01097837||Epilepsy|Cohort is comprised of women with epilepsy between 18 and 47.
9950999|NCT01097850|Other|Right|Application of henna paste to right hand/foot plus CeraVe moisturizer
9951000|NCT01097850|Other|Left|Application of henna paste to the left hand/foot plus CeraVe moisturizer
9951001|NCT01097876|Experimental|Active PF-04447943|
9951002|NCT01097876|Placebo Comparator|Placebo PF-04447943|
9951003|NCT01097889|Active Comparator|Treatment Group 1|
9951004|NCT01097889|Experimental|Treatment Group 2|
9951005|NCT01097902|Active Comparator|Ibuprophen 800 mg|Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
9951006|NCT01097902|Placebo Comparator|Placebo|Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
9951007|NCT01097928||Patients undergoing Pulmonary Embolectomy|
9951008|NCT01097941|Active Comparator|LAIV/LAIV|
9951009|NCT01097941|Active Comparator|IIV/IIV|
9951010|NCT01097941|Active Comparator|IIV/LAIV|
9951011|NCT01097967|Active Comparator|CPAP in sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
9951012|NCT01097967|No Intervention|no CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
9951013|NCT01097967|Active Comparator|CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
9951014|NCT01097980|Experimental|Trazodone|Trazodone versus placebo in a randomized, double-blind manner
9951015|NCT01097980|Placebo Comparator|Placebo|Patients received placebo
9951016|NCT01097993|Experimental|1 = Tested product|
9951017|NCT01097993|Active Comparator|2 = Control product|
9951018|NCT01098019|Experimental|Xeomin|Each bottle of Xeomin will be reconstituted with 2 mL of NaCl 0.9 which will give a final concentration of 5 U of botulinum toxin A per 0.1 mL. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum total dose of 200 units (4mL).
9951019|NCT01098019|Placebo Comparator|Placebo|Patients will receive 0.9% mL NaCl alone. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum volume of 4 mL.
9951020|NCT01098045||HIV-infection with fat redistribution (lipoatrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-24 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~No evidence of fat redistribution rated by the investigator."
9951021|NCT01098045||Healthy controls|"No history of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-29.9 kg/m2"
9951022|NCT01098045||HIV-infected with fat redistribution (lipohypertrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 25-29.9 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck."
10004953|NCT01580657|Experimental|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
10004954|NCT01580657|Active Comparator|D. Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
9476487|NCT03571282|Experimental|treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
9476488|NCT03571269|Experimental|OCT-guided group|Detailed methods of OCT examination are the same as above. Whether stenting or not will be decided by the operators according to the underlying mechanisms of culprit lesions. If stenting, OCT will be used to guide and optimize the whole process of PCI. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
9951023|NCT01098045||Dicer Cohort|30 men [HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)] will be recruited for this group.
9951024|NCT01098058|Experimental|CBT plus treatment as usual|
10004955|NCT01580657|Active Comparator|E. General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
10004956|NCT01580657|Active Comparator|F. No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
10004957|NCT01580683|Experimental|Ascorbic acid|
10004958|NCT01580683|Placebo Comparator|Placebo|
10004959|NCT01580709|Active Comparator|Multimodality Approach|Patients in the multimodality arm will undergo a single brushing for routine cytology, a second brush sample for Fluorescence In Situ Hybridization and a cholangioscopy with site-directed biopsies for histology.
10004960|NCT01580709|Active Comparator|Multiple brush samples|In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
10004961|NCT01580722|Other|early|patients underwent < 8 weeks reconstruction after injury
10004962|NCT01580722|Other|delay|patients underwent > 8 weeks reconstruction after injury
10004963|NCT01580735|Experimental|ARQ 197|
10004964|NCT01580748|Experimental|Treatment arm|single arm study
10004965|NCT01580774||Post-discharge phone call|All patients in this group will receive a phone call within 72-hours of being discharged from hospital.
9802179|NCT05316246|Experimental|CD30-positive Relapsed/Refractory NK/T-cell Lymphoma|Brentuximab vedotin will be administered as 1.8 mg/kg IV infusion on Day 1 of each 3-week cycle. PD-1 inhibitor tislelizumab will be administered as 200 mg on Day 1 of each 3-week cycle. Patients will receive maximum of 8 cycles if they do not meet the criteria for removal from the study. Patients will be assessed for overall response using the Revised Response Criteria for Malignant Lymphoma (Lugano 2014). Dedicated computed tomography (CT) scans (neck, chest, abdomen, and pelvis) will be performed at Baseline and at Cycles 2, 4 and 8, and positron emission tomography (PET) scans will be performed at Baseline and at Cycles 4 and 8.
9802180|NCT05316207|Active Comparator|Intervention Group|IG was formed from 40 patients who received routine care, treatment and education services of the clinic after open heart surgery, and whose routine controls were determined by the randomization method. The patients in the IG would call by the researcher at least four times, at the end of the first, second, third and fourth weeks after discharge, to provide education and counseling via tele-nursing. In these phone calls, the current problems of the patient, if any, and the issues that should be paid attention to during the home care process after open heart surgery were explained.It was stated that, unlike the patients in CG, patients in IG would be called by the researcher at least four times at the end of the first, second, third and fourth weeks after discharge to provide education and counseling via tele-nursing.
9802181|NCT05316207|No Intervention|Control Group|The patients in the CG were formed from 40 patients who received routine care, treatment and education services of the clinic after open heart surgery, and who were determined by the randomization method, whose routine controls were made after discharge. No application was made to the patients in the CG by the researcher within the scope of the study. However, the researcher gave the phone number to the patients in the CG in terms of their right to receive ethical and professional care, and it was stated that they could call between 10:00 and 22:00 if needed. The reasons for calling the investigator from the CG were recorded .
9802184|NCT05316168|Active Comparator|isolated adductor canal block (ACB)|Adductor Canal Block with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone.
9802185|NCT05316168|Active Comparator|isolated adductor canal block (ACB) + IPACK|ACB with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone, and iPACK with 20cc 0.5% bupivacaine + 2mg dexamethasone.
9802186|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 1|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
9802187|NCT05316129|Experimental|Intravenous treatment - Dose Level 1|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^5 by Intravenous (IV).
9802188|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 2|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^5. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
9802189|NCT05316129|Experimental|Intravenous treatment - Dose Level 2|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^5 by Intravenous (IV).
9951025|NCT01098058|Active Comparator|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
9951026|NCT01098084|Experimental|Decitabine|
9951027|NCT01098123||Diet counseling, nutritional index|Lightweight as athletes with weight limit
9951028|NCT01098123||nutritional index|Heavyweight athletes without weight limit
9951029|NCT01098136|Active Comparator|Chiropractic treatment|Management for one-sided pelvic pain, as decided by the chiropractor
9951030|NCT01098136|Active Comparator|Conventional health care|Conventional health care for one-sided pelvic pain
9951031|NCT01098136|Active Comparator|Conventional and alternative treatment|Treament of pregnant women with other pelvic pain syndromes.
9951032|NCT01098149|Active Comparator|AFB stand alone|Patients are switched in AFB treatment, without blood volume control.
9951033|NCT01098149|Active Comparator|BD and BVC|Patients are switched into bicarbonate dialysis with Blood Volume Control
9951034|NCT01098175||Control group|open surgery with exposure of the surgical wound to the air.
9951035|NCT01098175||Full peritoneal conditioning|Full peritoneum cavity conditioning will be performed as follows. A continuous flow of less than 0.5 l/min of gas will be instilled in the lowest part of the operating wound. As gas premixed bottles with CO2+ 4% of oxygen and 10% of N2O will be used. This gas will be humidified and at 31-32 °C to be achieved by a commercial humidifier (Fisher and Paykel) programmed in order to maintain 100% relative humidity at 31-32°C upon entrance of the peritoneal cavity.
9951036|NCT01098227||RSV positive subjects|Subjects admitted to Winthrop University Hospital with lower viral respiratory infection and RSV positive status by DFA and/or Viral culture
9951037|NCT01098227||RSV negative subjects|Subjects admitted to Winthrop University Hospital with a lower viral respiratory infection and RSV status negative by DFA and viral culture. these subjects may be positive for other viruses detected by DFA or viral culture (Adenovirus, Influenza A or B, Metapneumovirus or parainfluenza) or not
9951038|NCT01098227||Control group|Children in the same age range without respiratory conditions and who are well enough to perform the test from the out patient setting
9951039|NCT01098292||Healthy Control|"Healthy Control participants do not suffer from any Urological Chronic Pelvic Pain Syndromes or from the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
9951040|NCT01098292||Positive Control|"Positive Control participants do not suffer from any Urological Pelvic Pain Syndromes like Interstitial Cystitis and/or Chronic Prostatitis. However Positive Controls have a history of one of the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
9951041|NCT01098357|Experimental|Biochaperone PDGF-BB low dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
9951042|NCT01098357|Experimental|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
9951043|NCT01098357|Active Comparator|Regranex|Becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson & Johnson) is a topical gel of rhPDGF-BB conditioned in a gel tube.
9951044|NCT01098357|Experimental|Very Low Dose BioChaperone PDGF-BB|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
9951045|NCT01098383|Placebo Comparator|Placebo for AChEI and Choline|
9951046|NCT01098383|Experimental|AChEI and Choline|Acetyl-choline Esterase Inhibitor and Choline supplements
9951047|NCT01098409|Experimental|sodium nitrite 24 hours before|
9951048|NCT01098409|Experimental|sodium nitrite during surgery|
9951049|NCT01098409|Placebo Comparator|0.9% sodium chloride|
9951050|NCT01098448|Active Comparator|Scaling and root planing|scaling and root planing as a solo therapy
9951051|NCT01098448|Experimental|Periodontal surgery|
9951052|NCT01098448|Experimental|systemic antibiotics|
9951053|NCT01098448|Experimental|Local delivery of tetracycline|
9951054|NCT01098448|Experimental|local antibiotic and systemic antibiotics|
9951055|NCT01098448|Experimental|local antibiotics and surgery|
9951056|NCT01098448|Experimental|systemic antibiotics and surgery|
9951057|NCT01098448|Experimental|local and systemic antibiotics and surgery|
9951058|NCT01098513|Experimental|Part A|Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX.
10004966|NCT01580774||Usual care (no phone call)|
9951059|NCT01098513|Experimental|Part B|A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period.
9951060|NCT01098526|Experimental|Cohort 1|Subjects will receive a single dose of GSK1349572 100 mg in Period 1 followed by a washout of at least 6 days. Subjects will then receive GSK1349572 50 mg once a day for 5 days in Period 2. Period 3 will begin immediately after Period 2. In Period 3 subjects will receive GSK1349572 50 mg once a day in the morning and Efavirenz 600 mg once a day at bedtime for 14 days. There will be a screening visit up to 30 days before Period 1 and a follow up visit 7-14 days after the end of Period 3.
9951061|NCT01098552||High-risk radical prostatectomy patients|
9951062|NCT01098552||Primary external beam radiotherapy patients|
9951063|NCT01098552||Primary prostate brachytherapy patients|
9951064|NCT01098552||Hormone refractory prostate cancer patients|
9951065|NCT01098552||Active Surveillance|
9951066|NCT01098552||Prostate biopsy patients|
9951067|NCT01098565|Experimental|Study device arm|
9951068|NCT01098591||Myocardial infarction|Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
9951069|NCT01098591||Ischemic cardiomyopathy|Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
9951070|NCT01098604|Active Comparator|32mm ceramic head group|patients performed with THA using 32mm ceramic head
9951071|NCT01098604|Active Comparator|28mm ceramic head group|patients performed with THA using 28mm ceramic head
9951072|NCT01098617||hemorrhage|The patients who had bleeding induced by endoscopic sphincterotomy
9951073|NCT01098630||Group I (limited participation)|Patients do not complete any questionnaires at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
9951074|NCT01098630||Group II (full participation)|Patients complete the Patient Registration Survey and Patient Questionnaire at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
9951075|NCT01098656|Experimental|lenalidomide|
9951076|NCT01098656|No Intervention|Observation|
9951077|NCT01098695|Experimental|EcoFIT offered|
9951078|NCT01098695|No Intervention|No Feedback or services offered|
9951079|NCT01098721|Placebo Comparator|Group 1|A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.
9951080|NCT01098721|Active Comparator|Group 2|A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.
9476489|NCT03571269|No Intervention|Angiography-guided group|Detailed methods of angiography examination are the same as above. Whether stenting or not and the whole process of PCI will be decided by the operators according to the current treatment standard of angiography. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
9476490|NCT03571243||smokers|no intervention
9476491|NCT03571243||never-smokers|no intervention
9951081|NCT01098734|Placebo Comparator|Group 1|0%; vehicle cream
9951082|NCT01098734|Active Comparator|Group 2|0.5% WBI-1001 cream
9951083|NCT01098734|Active Comparator|Group 3|1.0% WBI-1001 cream
9951084|NCT01098760|Experimental|Arm 1|
9951085|NCT01098773||patients requiring ventilation|
9951086|NCT01098773||patients who weaned permanently|
9951087|NCT01098786||Healthy|
9951088|NCT01098799||Control|Healthy controls
9951089|NCT01098799||Chronic kidney disease-1|Chronic kidney disease not taking dialysis treatment
9951090|NCT01098799||Kidney Transplant|Kidney transplants
9951091|NCT01098825||District VI AAP clinicians|
9951092|NCT01098838|Experimental|Weekly dosing of LCL161|by mouth (oral)
9951093|NCT01098838|Experimental|Comparison of LCL161|tablet versus liquid
9951094|NCT01098838|Experimental|Twice daily dosing of LCL161|by mouth for 4 days followed by a 3-day rest period every week
9951095|NCT01098877|Placebo Comparator|Placebo|
9951096|NCT01098877|Experimental|Cohort 1, 1mg|
9951097|NCT01098877|Experimental|Cohort 1, 3mg|
9951098|NCT01098877|Experimental|Cohort 1, 10mg|
9951099|NCT01098877|Experimental|Cohort 2, 30mg|
9951100|NCT01098877|Experimental|Cohort 2, 100mg|
9951101|NCT01098877|Experimental|Cohort 2, 300mg|
9951102|NCT01098877|Experimental|Cohort 3, 600mg|
9951103|NCT01098877|Experimental|Cohort 3, 900mg|
9951104|NCT01098877|Experimental|Cohort 3, up to 900mg (fed)|
9951105|NCT01098877|Placebo Comparator|Cohort 3, placebo (fed)|
9951106|NCT01098890|Placebo Comparator|Placebo|Placebo will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
9951107|NCT01098890|Active Comparator|tPA (tissue plaminogen activator)|Intraventricular TPA will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
9951108|NCT01098903||Sunitinib|Patients with a malignancy treated with sunitinib
9476492|NCT03571230|Experimental|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 10-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 10d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 10d, clarithromycin 500mg bid for 10d, metronidazole 500mg tid for 10d, tinidazole 500mg tid for 10d, levofloxacin 500mg qd for 10d, furazolidone 100mg bid for 10d, tetracycline 750mg bid for 10d."
9951109|NCT01098916|Experimental|X-rays at home|Home hospitalized elderly patients undergo X-rays at home
9951110|NCT01098916|Active Comparator|Hospital X-rays|Home hospitalized elderly patients undergo X-rays examinations in hospital
9951111|NCT01098929||Congenital Diaphragmatic Hernia (CDH)|Individuals affected with congenital diaphragmatic hernia (CDH)
9951112|NCT01098929||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
9951113|NCT01098942||Surgical|Roux-en-Y gastric bypass surgery
9951114|NCT01098942||Non-surgical|Non-surgical lifestyle weight management
9951115|NCT01098955|Experimental|ACT Group 1|Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.
9951116|NCT01098955|Experimental|MBC Group 2|Motivational and Behavioral Counseling (MBC). Varenicline 2 mg daily for 12 weeks.
9951117|NCT01098968|No Intervention|Normal PE|2 Physical Education sessions / week
9951118|NCT01098968|Experimental|PE Volume|4 Physical Education sessions/week (increased volume)
9951119|NCT01098968|Experimental|PE Volume + Intensity|4 Physical Education sessions/week of high intensity (increased volume and intensity)
9951120|NCT01098981|Experimental|Target group|A combined treatment with transcranial US and systemic tPA
9951121|NCT01098981|Active Comparator|Control group|Systemic tPA alone
9951122|NCT01098994|Other|Haptoglobin 1/1|Individuals with type 1 diabetes and the Haptoglobin 1/1 phenotype
9951123|NCT01098994|Other|Haptoglobin 2/1|Individuals with type 1 diabetes and the Haptoglobin 2/1 phenotype
9951124|NCT01098994|Other|Haptoglobin 2/2|Individuals with type 1 diabetes and the Haptoglobin 2/2 phenotype
9951125|NCT01099007|Active Comparator|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
9951126|NCT01099007|Experimental|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
9951127|NCT01099033||Hiatal/Paraesophageal hernia patients|patients with hiatal or paraesophageal hernias
9951128|NCT01099033||control group|patients without hiatal or paraesophageal hernias who are undergoing crural dissection for heller myotomy, or who are undergoing gastric bypass surgery
10004967|NCT01580787|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
10004968|NCT01580787|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
10004969|NCT01580800||Breast cancer survivors|Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.
10004970|NCT01580813|Experimental|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visi
10004971|NCT01580813|Placebo Comparator|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit
10004972|NCT01580826|No Intervention|raw milk|Infants who were assigned to the raw group received fresh or thawed milk from their own mother, cultured weekly with a semi-quantitative analysis. Raw milk was withheld if it contained any Gram-negative organisms, S. aureus or enterococci.
10004973|NCT01580826|Active Comparator|pasteurized milk|Infants who were assigned to pasteurization received own mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
10004974|NCT01580839|Experimental|intravenous tissue plasminogen activator|
10004975|NCT01580839|Placebo Comparator|Placebo|
10004976|NCT01580852|Active Comparator|Dead Sea Water|
10004977|NCT01580852|Sham Comparator|Pool Water|
10004978|NCT01580865|Active Comparator|Mycophenolate Mofetil (MMF)|MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. .
10004979|NCT01580865|Experimental|Tacrolimus (TAC)|TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter
10004980|NCT01580878|Experimental|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
10004981|NCT01580878|Active Comparator|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
10004982|NCT01580878|Placebo Comparator|Butenafine Vehicle|Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
10004983|NCT01580891|Experimental|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
10004984|NCT01580891|Active Comparator|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
10004985|NCT01580891|Placebo Comparator|Placebo topical cream|Placebo topical cream (Taro Pharmaceuticals Inc.)
10004986|NCT01580917||Diabetic Test|Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration
10004987|NCT01580917||Healthy Controls|Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer
10004988|NCT01580930|No Intervention|Control group|Group had outcome measures collected and were instructed to not change activity and sedentary time behavior
9802190|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 3|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
9802191|NCT05316129|Experimental|Intravenous treatment - Dose Level 3|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^6 by Intravenous (IV).
9802192|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 4|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^6. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
9802193|NCT05316129|Experimental|Intravenous treatment - Dose Level 4|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 3 x 10^6 by Intravenous (IV).
9802194|NCT05316129|Experimental|Intraperitoneal treatment- Dose Level 5|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^7. Intraperitoneal: Infusion will be administered through a thin membrane of the abdominal cavity.
9802195|NCT05316129|Experimental|Intravenous treatment - Dose Level 5|Participants will receive one infusion of Follicle-Stimulating Hormone Receptor T (FSHCER T) cells at a dose of 1 x 10^7 by Intravenous (IV).
9802196|NCT05316116|Experimental|Siltuximab|Siltuximab will be given every 3 weeks, for between 18 and 36 weeks
9802197|NCT05316090|Experimental|study group|Children in study group treated using core stability exercises program in addition to traditional program
9802198|NCT05316090|Active Comparator|control group|Children in the control group treated using traditional physical therapy program.
9802199|NCT05316077||Vectorio® kit|
9802200|NCT05316064|Experimental|probiotic 9 log CFU/day|Intervention consists of daily oral administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
9802201|NCT05316064|Placebo Comparator|placebo|placebo contains primarily carrier without probiotic and it is identical in taste and appearance and appear as light-yellow powder. It is also taken by the participants for 12 weeks.
9802202|NCT05316051|Experimental|35° inverted angle foot orthoses|
9802203|NCT05316051|Experimental|25° inverted angle foot orthoses|
9802204|NCT05316051|No Intervention|Control|
9802205|NCT05316038||Belatacept cohort|Kidney transplanted patients for whom a conversion from Tacrolimus to belatacept has been decided will be included in this cohort.
9802208|NCT05315999|Experimental|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO III)
9802209|NCT05315999|Placebo Comparator|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO III)
9802210|NCT05315986|Experimental|Group 1: Sleep intervention (ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
9802211|NCT05315986|Experimental|Group 2: Sleep intervention (ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
9802212|NCT05315986|Experimental|Group 3: No sleep intervention (Control ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
9802213|NCT05315986|Placebo Comparator|Group 4: No sleep intervention (Control ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
9802214|NCT05315973|Experimental|Sensor group|
9802215|NCT05315960||Qualitative study|Consenting participants will complete a form asking about basic characteristics including age, sex, ethnicity, marital status etc. People living in long-term care and family carers will participate in an individual interview and professional staff will participate in an individual interview or focus group (between 5 and 10 participants) depending on their preference. The interview or focus group is expected to last 30-60 minutes. Sessions will be conducted in-person or online (using MS Teams), depending on preference and COVID-19-related restrictions. All sessions will be audio-recorded and transcribed.
9951129|NCT01099046|No Intervention|medication only|medication = anti-diuretics
9951130|NCT01099046|Active Comparator|medication + water intake|anti-diuretics + water intake (at least 2.0 litters per day)
9951131|NCT01099046|Active Comparator|medication + tympanic tubing|anti-diuretics + tympanic tubing (under local anesthesia)
9951132|NCT01099046|Active Comparator|medication + regular sleep|anti-diuretics + regular sleep (regular sleep program under dark everynight)
9951133|NCT01099059|Active Comparator|Ritalin|receive ritalin depending on weight
9528830|NCT03207152|Experimental|Influenza A/California/04/2009|Participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
9951134|NCT01099059|Experimental|Amantadine|100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
9951135|NCT01099072|Active Comparator|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
9951136|NCT01099072|Experimental|methylphenidate+carnitine|
9951137|NCT01099085|Active Comparator|XP/simvastatin|Capecitabine/cisplatin + simvastatin
9951138|NCT01099085|Placebo Comparator|XP/placebo|Capecitabine/cisplatin + placebo
9951139|NCT01099098||Patients with TB sequelae|
9951140|NCT01099098||People without TB sequelae|
9951141|NCT01099124|Experimental|M2ES combined with chemotherapy|
9951142|NCT01099137|Experimental|Vildagliptin|Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
9951143|NCT01099137|Active Comparator|Sulphonylurea dose-up|Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin
9951144|NCT01099150|Experimental|42 healthy volunteers - crossover|"Acute consumption of three interventions (60 g dark chocolate enriched in flavan-3-ols, 60 g standard dark chocolate, or 60 g white chocolate) on three separate days (at least 2 weeks apart) in random order.~Post-prandial measurements at t = 0 h, t = 2 h and t = 6 h."
9951145|NCT01099163|Experimental|3g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, 100 IU vitamin E
9951146|NCT01099163|Active Comparator|3 g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, vitamin E placebo
9951147|NCT01099163|No Intervention|3 g MCT + vit E placebo|3 g MCT AND other diabetes medication currently prescribed to participant, 100 IU vitamin E placebo
9951148|NCT01099176|Experimental|Atorvastatin|10mg of Atorvastatin
9951149|NCT01099176|Experimental|Fenofibrate|267mg of Fenofibrate
9951150|NCT01099176|Experimental|Fenofibrate and atorvastatin|10mg of Atorvastatin and 267mg of fenofibrate
9951151|NCT01099176|Placebo Comparator|Therapeutic Lifestyle Change|Placebo and Therapeutic Lifestyle Change
9951152|NCT01099189||Observed cohort|All patients recruited. Observed for clinical outcomes
9951153|NCT01099228|Active Comparator|131-I MIBG and 111I-n pentetreotide|131-I MIBG and 111I-n pentetreotide
9951154|NCT01099228|Active Comparator|131-I MIBG and In-111 DOTATATE|131-I MIBG and In-111 DOTATATE
9951155|NCT01099280|Experimental|oxytocin group|2 milliunits/min and doubled every 30 minutes to a maximum of 32 milliunits/min or until four contractions in 10 minutes was achieved
9951156|NCT01099280|Experimental|dinoprostone and oxytocin|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
9951157|NCT01099293||Cirrhosis, w/o hepatic encephalopathy|Patients with liver cirrhosis without hepatic encephalopathy by clinical (West-Haven), neurophysiological tests (PHES) nor Critical Flicker Frequency evidence.
9951158|NCT01099293||Cirrhosis-minimal hepatic encephalopathy|Patients with cirrhosis, without clinical evidence of hepatic encephalopathy (West Haven 0) and with positive tests for both, PHES and CFF.
9951159|NCT01099293||Cirrhosis, Hepatic encephalopathy I|Patients with cirrhosis and clinical evidence of hepatic encephalopathy with a West Haven score of I.
9951160|NCT01099293||Control|Healthy subjects willing to participate in the study
9951161|NCT01099306|Active Comparator|intervention|pharmacist-physician collaborative approach to manage Metabolic syndrome
9951162|NCT01099306|No Intervention|control|physician only team to manage Metabolic syndrome
9951163|NCT01099319|Experimental|Renalof|
9951164|NCT01099319|Placebo Comparator|Placebo|
9951165|NCT01099332|Active Comparator|Gastro-retentive zinc cysteine tablet|Once daily administration by mouth of a gastro-retentive, sustained-release preparation of zinc cysteine with excipients, all G.R.A.S., with adequate water.
9951166|NCT01099332|Placebo Comparator|Identical appearance of placebo with active comparator|Once daily administration of placebo of identical physical appearance to that of active comparator with similar amount of water.
9951167|NCT01099345||Group 1 - OAB with DO+|Subjects that DO+ nocturia
9951168|NCT01099345||Group 2- OAB with DO-|Subjects that DO- nocturia
9951169|NCT01099371|Experimental|exercise|
9951170|NCT01099384|Active Comparator|Behavioral: written self-help materials|Behavioral: written self-help materials
9951171|NCT01099384|Experimental|Group behavioral counseling|Group behavioral counseling, weekend program
9951172|NCT01099410||Group 1|volunteer subjects
9951173|NCT01099423|Active Comparator|Immediate nephrectomy|Surgery followed by Sunitinib
9951174|NCT01099423|Experimental|Deferred nephrectomy|Sunitinib (3 cycles) followed by surgery followed by Sunitinib
9951175|NCT01099436|Experimental|TAC + Zoledronic acid|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)
9951176|NCT01099436|Active Comparator|TAC|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)
9951177|NCT01099462||Children with fever|
9951178|NCT01099488|Other|All subjects|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received a GSK2231392A vaccine, were enrolled for blood withdrawal to support the development of CD8+ T cell immunological detection assays.
9951179|NCT01099501|Active Comparator|Oxepa|Oxepa (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
9951180|NCT01099501|Active Comparator|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
9951181|NCT01099514|Experimental|Nilotinib|Nilotinib 400 mg (2 capsules) PO BID q 28 days
9951182|NCT01099527|Experimental|Everolimus|"Everolimus (RAD001) dose escalation of capecitabine, everolimus~Capecitabine dose escalation of capecitabine, everolimus"
9951183|NCT01099540|Experimental|Pazopanib|
9951184|NCT01099553|Other|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Boston Medical Center
9951185|NCT01099553|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions asking them to watch an educational video on the Center for Digestive Disorders website
9951186|NCT01099566|Experimental|Prasugrel|
9951187|NCT01099566|Placebo Comparator|pills consisting of lactose-starch|
9951188|NCT01099605|Placebo Comparator|Pump device|One arm will have continuous subcutaneous infusion of normal saline.
9951189|NCT01099605|Active Comparator|Bupivacaine|will receive continuous infusion of bupivacaine
9951190|NCT01099657|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis for chronic pain
9951191|NCT01099657|Experimental|Virtual Reality Distraction|Virtual Reality Distraction for Chronic Pain
9951192|NCT01099670|Experimental|7.5 mg NRL001|Nine subjects will receive 7.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
9951193|NCT01099670|Experimental|10 mg NRL001|Nine subjects will receive 10 mg NRL001 in a 2 g suppository; three will receive matching placebo.
9951194|NCT01099670|Experimental|12.5 mg NRL001|Nine subjects will receive 12.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
9951195|NCT01099670|Experimental|15 mg NRL001|Nine subjects will receive 15 mg NRL001 in a 2 g suppository; three will receive matching placebo.
9951196|NCT01099683|Experimental|NRL001|All subjects will receive 10 mg NRL001 in a 2 g rectal suppository
9951197|NCT01099683|Placebo Comparator|Placebo|All subjects will receive placebo
9951198|NCT01099696|Experimental|B. infantis 35624|B. infantis 35624 in white capsules
9951199|NCT01099696|Placebo Comparator|placebo|white placebo capsules (inert)
9951200|NCT01099722|Active Comparator|Inhaler|
9951201|NCT01099722|Active Comparator|inhaler|Symbicort
9951202|NCT01099735||CPAP, Manometry|Patients undergoing Manometry before weight loss surgery
9951203|NCT01099748|Active Comparator|Methadone|Dose of methadone must not change from 1 week prior to study start and through the duration of the study.
9951204|NCT01099748|Experimental|Lersivirine + Methadone|
9951205|NCT01099787||FAP IBS|
9951206|NCT01099800||Mexican/Mexican American families|Parents and children who self-identify as being of Mexican heritage whether US-born or Mexican-born
9951207|NCT01099800||Puerto Rican families|Parents and children who self-identify as Puerto Rican whether US-born or island-born.
9951208|NCT01099813||Inpatients assessed for critical care|Patients admitted to Critical Care Units participating in the ICNARC CMP programme who have been assessed at any time on a ward prior to ICU admission by a critical care decision maker (e.g. the CCOT or any member of the medical staff on duty for the unit)
9951209|NCT01099826|Experimental|lifestyle counseling tailored|
9951210|NCT01099826|Experimental|lifestyle counseling motivational|
9951211|NCT01099826|No Intervention|control|
9951212|NCT01099839|Experimental|one group|"Subjects will receive ASP1941 alone, Miglitol alone and ASP1941 + Miglitol in different order."
9951213|NCT01099878|Active Comparator|Cycling Exercise with Functional Electrical Stimulation|Cycling Exercise with Functional Electrical Stimulation
9951214|NCT01099878|Placebo Comparator|Cycling Exercise|Cycling Exercise
9951215|NCT01099891|Experimental|EGF|
9951216|NCT01099891|Placebo Comparator|Placebo|
9951217|NCT01099904|Experimental|1|Normal Renal Function
9951218|NCT01099904|Experimental|2|Mild Renal Impairment
9951219|NCT01099904|Experimental|3|Moderate Renal Impairment
9951220|NCT01099930|Active Comparator|Non-randomized control group|Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
9951221|NCT01099930|Experimental|Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
9951222|NCT01099943|Experimental|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
9951223|NCT01099943|No Intervention|No education, no implemented decision support tools|Clinics randomized to the control will not participate in the education intervention and implementation of decision support tools.
9951224|NCT01099956||diabetes group|
9951225|NCT01099956||control group|
9951226|NCT01099995|Active Comparator|One HBO session|hyperbaric oxygen therapy one dive at 2 absolute atmosphere (1-hour plateau) - oxygen was delivered via a full face mask - followed by 4 hours of normobaric oxygen therapy
9951227|NCT01099995|Experimental|2 HBO sessions|Two sessions of hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) with oxygen delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
9951228|NCT01100008|Experimental|Magnetic resonance imaging|
9951229|NCT01100021|Experimental|tamsulosin + avanafil|
9480673|NCT05262062|Experimental|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
9951230|NCT01100021|Experimental|Doxazosin + avanafil|
9951231|NCT01100047|Experimental|1|
9951232|NCT01100047|Placebo Comparator|2|
9951233|NCT01100060|Experimental|Group 1|Co-administer the test chloroquine (CQ) formulation (620 mg CQ base) plus microsphere azithromycin (AZ) (2000 mg) on Day 1.
9951234|NCT01100060|Active Comparator|Group 2|Co-administer the individual tablets of CQ 2 x 500 mg (600 mg CQ base) tablets plus AZ IR 4 x 500 mg tablets on Day 1.
9951235|NCT01100099|Experimental|Gluten challenge.|Diagnosis of celiac disease. Before and after a gluten challenge small bowel biopsies will be taken, and blood samples will be drawn for tetramer staining of gluten specific T cells.
9951236|NCT01100125|Experimental|sitagliptin|
9951237|NCT01100125|Active Comparator|insulin dose increase|
9951238|NCT01100164|Experimental|eszopiclone 3 mg|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
9951239|NCT01100164|Active Comparator|zopiclone 7,5mg|Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
9951240|NCT01100177|Experimental|Sunitinib plus radiothery|"Sunitinib at doses of 37.5mg/m2/daily in a continuous dosing during 8 weeks.~After evaluation of efficacy, they will receive Sunitinib 37.5 mg/d and treatment with Radiation therapy (total dose 60 Gy).~After radiation therapy, Sunitinib al 37.5 mg/d will be continued until progression."
9951241|NCT01100190|Experimental|NUVANCE Facial Rejuvenation System|
9951242|NCT01100203|Active Comparator|Treatment|
9951243|NCT01100203|No Intervention|Control|
9951244|NCT01100216|Active Comparator|Nicotine Lozenge|4 mg nicotine lozenge (LOZ
9951245|NCT01100216|Active Comparator|Camel Snus Frost|
9951246|NCT01100216|Active Comparator|Stonewall Spearment Tablet|
9951247|NCT01100216|Active Comparator|Skoal Wintergreen|
9951248|NCT01100281||PSP (Progressive supranuclear palsy)|
9951249|NCT01100281||FTD (Frontotemporal lobar degenerative)|
9951250|NCT01100281||Alzheimer's disease|
9951251|NCT01100294|Experimental|Vaccination with Fluval P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
9951252|NCT01100385|Placebo Comparator|Healthy (placebo)|
9951253|NCT01100385|Active Comparator|Healthy (Ateronon)|
9951254|NCT01100385|Placebo Comparator|Cardiovascular Group (placebo)|
9951255|NCT01100385|Active Comparator|Cardiovascular Group (Ateronon)|
9951256|NCT01100398||NAFLD/NASH prevalence|Any subject between the ages of 18-70 without known fatty liver disease who meet inclusion criteria
9951257|NCT01100411|Active Comparator|Air Optix Aqua|Contact lens material: Lotrafilcon A
9951258|NCT01100411|Active Comparator|Biofinity|Contact lens material: Comfilcon A
9951259|NCT01100411|Active Comparator|Proclear|Contact lens material: Omafilcon A
9951260|NCT01100411|Active Comparator|Acuvue Oasys|Contact lens material: Senofilcon A
9951261|NCT01100411|Active Comparator|Acuvue 2|Contact lens material: Etafilcon A
9951262|NCT01100411|Active Comparator|Purevision|Contact lens material: Balafilcon A
9951263|NCT01100424|Experimental|Contact lens wearers|Contact lens wearers experienced three currently available contact lens/contact lens care combinations in randomized order: balafilcon A + Optifree RepleniSH, balafilcon A + ReNu MultiPlus, and balafilcon A + Unisol 4 saline.
9951264|NCT01100424|No Intervention|Non-lens wearers|Non-lens wearers completed one study visit and served as the control group.
9951265|NCT01100450|Experimental|Resistance Training|
9951266|NCT01100463|Placebo Comparator|Placebo Lotion|
9951267|NCT01100463|Experimental|0.1% Uracil|
9951268|NCT01100489|Experimental|Arm I|Patients undergo breast-conserving surgery consisting of partial mastectomies followed by external beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
9951269|NCT01100515|Experimental|Experimental arm|Hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) followed by 4 hours of normobaric oxygen therapy
9951270|NCT01100515|Active Comparator|Control|6 hours course of normobaric oxygen therapy via a face full mask
9951271|NCT01100541|Experimental|Polymeric plate characteristics|Evaluation, in the volunteers viewpoint, of the polymeric plate characteristics.
9951272|NCT01100554|Experimental|all patients|
9951273|NCT01100580|Active Comparator|water therapy|"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
9951274|NCT01100580|Experimental|low salt diet + water therapy|low salt diet refers to a salt intake of 4 g/day
9951275|NCT01100593|Active Comparator|1.75 inch catheter length|Length of catheter to be used
9951276|NCT01100593|Active Comparator|2.5 inch catheter length|length of catheter to be used
9951277|NCT01100619|Experimental|All subjects|All subjects will receive daily XL184, and two single doses of rosiglitazone, 3 weeks apart
9951278|NCT01100632|Experimental|Treatment|Treatment with the combination of Panax ginseng, vitamins and minerals
9951279|NCT01100632|Placebo Comparator|Placebo|Placebo.
9951280|NCT01100645|Experimental|Test|Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)
9951281|NCT01100645|Placebo Comparator|Placebo|Excipient
9951282|NCT01100671||Healthy patients|
9951283|NCT01100684|Experimental|Treatment|0.5 mg asimadoline bid
9951284|NCT01100684|Placebo Comparator|Placebo|Placebo
9951285|NCT01100697||thoracal lesion|spinal lesion at thoracal level detected at prenatal ultrasound exam
9951286|NCT01100697||lumbar lesion|spinal lesion at lumbar level detected at prenatal ultrasound exam
9951287|NCT01100697||sacral lesion|spinal lesion at sacral level detected at prenatal ultrasound exam
9951288|NCT01100710||healthy volunteers|
9951289|NCT01100736|Experimental|Bosentan|Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy
9951290|NCT01100736|Experimental|Sitaxsentan|Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy
9951291|NCT01100736|Placebo Comparator|Placebo|Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy
9951292|NCT01100775|Experimental|Galantamine, then Placebo|Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
9951293|NCT01100775|Experimental|Placebo, then Galantamine|Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.
9951294|NCT01100788|Placebo Comparator|Placebo|No treatment
9951295|NCT01100788|Experimental|scFOS 5 g|5 g scFOS
9951296|NCT01100788|Experimental|scFOS 8 g|8 g scFOS
9951297|NCT01100801|Experimental|TS-1 with cisplatin|"Chemotherapy injection (60mg/m2 cisplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
9951298|NCT01100801|Experimental|TS-1 with oxaliplatin|"Chemotherapy injection (100mg/m2 oxaliplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
9951299|NCT01100827||EGFR mutation status in patients|
10004989|NCT01580930|Experimental|Exercise|Participants performed 5 days per week, 40 min per session of exercise training under direct supervision of personal trainer.
10004990|NCT01580930|Experimental|Sedentary time reduction|participants were give strategies to reduce sedentary time
10004991|NCT01580930|Experimental|exercise plus sedentary time reduction|Participants completed exercise training (5 days per week, 40 min per session) plus were given sedentary time reduction intervention
10004992|NCT01580943|Active Comparator|Antiplaque Efficacy|"This study was designed as a randomized, two group parallel, double-blind, 3-day non-brushing clinical trial. The sample size (50 participants) was determined using similar studies, making it a convenience sample.~Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds."
10004993|NCT01580943|Active Comparator|Taste and Side Effects|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
10004994|NCT01580956|Other|VARIABLE-PSV ventilatory mode|
10004995|NCT01580956|Other|STANDARD-PSV ventilatory mode|
10004996|NCT01581034|Active Comparator|Padma|
10004997|NCT01581034|Placebo Comparator|Placebo|
10004998|NCT01581047||Amoxicillin/Clavulanic Acid|Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
10004999|NCT01581047||Cefuroxime|Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
10005000|NCT01581060|Experimental|WX-554|
10005001|NCT01581073|Experimental|High Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL. If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL. Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
10005002|NCT01581073|Active Comparator|Low Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
10005003|NCT01581099||Clinical treatment|Diabetic individuals refractory to medical treatment kept under clinical treatment guidelines and lifestyle
10005004|NCT01581099||Surgery|Diabetic individuals refractory to conservative clinical treatment subject to Digestive Adaptations III Surgery.
10005005|NCT01581099||Control|Healthy individuals (normal weight and no cardiovascular risk factors) will be used to evaluate the behavior incretin hormones in healthy individuals, serving as a benchmark to analyze the results obtained in other groups.
10005006|NCT01581112|Experimental|Heavy armpit odour|Subjects with heavy armpit odour.
10005007|NCT01581112|Experimental|Heavy foot odour|Subjects with heavy foot odour.
10005008|NCT01581125|Experimental|Sleep:wake 2|Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
10005009|NCT01581125|Experimental|Sleep:wake 1|Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
10005010|NCT01581151|Active Comparator|Monthly Ranibizumab|"• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term monthly to represent a 30 day interval between treatments."
10005011|NCT01581151|Experimental|Dexamethasone intravitreal implant|"Patients will receive a dexamethasone intravitreal implant injection at day 0.~During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.~During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse."
10005012|NCT01581164||HSCT patients|Patients who have been treated with HSCT
10005013|NCT01581190|Experimental|Bananas versus 6% carbohydrate beverage|
10005014|NCT01581216|Experimental|10 minute walk|10-minute walk and exercises for the upper limbs with 1 lb-dumbbells
10005015|NCT01581216|Experimental|20 minute walk|20-minute walk and exercises for the upper limbs with 1 lb-dumbbells
10005016|NCT01581216|Experimental|30 minute walk|30-minute walk and exercises for the upper limbs with 1 lb-dumbbells
10005017|NCT01581229|Experimental|NPPV|
9951300|NCT01100866|Active Comparator|Group 1|POMELLA™ 2 x 500mg capsule once daily
9951301|NCT01100866|Placebo Comparator|Group 2|POMELLA™ placebo
9951302|NCT01100879|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).
9951303|NCT01100879|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
9951304|NCT01100892|No Intervention|Control group|Observation only. Does not receive once-daily insulin detemir.
9951305|NCT01100892|Experimental|Once-daily insulin detemir|Once-daily insulin detemir
9951306|NCT01100918|Active Comparator|1: Dyssynchrony positive|
9951307|NCT01100918|Active Comparator|2a: Dyssynchrony negative|
9951308|NCT01100918|Active Comparator|2b: Dyssynchrony negative|
9951309|NCT01100957|Active Comparator|Conventional flexible videoscope for intubation|
9951310|NCT01100957|Experimental|Single-patient flexible endoscope|Single-patient flexible video-endoscope used for tracheal intubation in this intervention-arm
9951311|NCT01100970||Unipolar electric needle|
9951312|NCT01100970||Bipolar electric needle|
9951313|NCT01100970||Control|Infants who were born in a vaginal birth
9951314|NCT01100996|No Intervention|fasted control|Volunteers are fasted for 10 hours and subjected to experimental endotoxemia
9951315|NCT01100996|Placebo Comparator|control feeding|Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS
9951316|NCT01100996|Active Comparator|enriched feeding|volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS
9951317|NCT01101009|Active Comparator|Perindopril+amlodipine|
9951318|NCT01101009|Active Comparator|Olmesartan/amlodipine|
9951319|NCT01101048|Placebo Comparator|A|Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
9951320|NCT01101048|Active Comparator|B|Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
9951321|NCT01101074||6-23 months|
9951322|NCT01101074||2-8 years|
9951323|NCT01101074||9-17 years|
9951324|NCT01101074||18-44 years|
9951325|NCT01101074||45-60 years|
9951326|NCT01101074||>60 years|
9951327|NCT01101087|Experimental|Taurolock|
9951328|NCT01101087|Placebo Comparator|Placebo|
9951329|NCT01101113|Experimental|Cinacalcet|stepwise dose of cinacalcet + regular medical medication including vit D
9951330|NCT01101113|Active Comparator|Control|conventional treatment for secondary HPT including vit D and phosphate binder
9951331|NCT01101126|Experimental|Disease Management|Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
9951332|NCT01101126|Active Comparator|Unual care|Care delivered by the primary practitioner with the advice of a consultant pulmonologist
9951333|NCT01101139|Experimental|Experimental|Single injection of Sugammadex 0.25 mg/kg
9951334|NCT01101139|Placebo Comparator|Placebo comparator|Single injection of Saline 0.9%
9951335|NCT01101152|Experimental|Female|
9951336|NCT01101152|Experimental|Male|
9951337|NCT01101204|Active Comparator|M1000 S10 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
9951338|NCT01101204|Active Comparator|M1000 S10 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
9951339|NCT01101204|Active Comparator|M1000 S40 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
9951340|NCT01101204|Active Comparator|M1000 S40 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
9951341|NCT01101204|Active Comparator|M2500 S10 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
9951342|NCT01101204|Active Comparator|M2500 S10 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
9951343|NCT01101204|Active Comparator|M2500 S40 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
9951344|NCT01101204|Active Comparator|M2500 S40 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
9951345|NCT01101204|Placebo Comparator|Therapeutic Lifestyle Change|Only therapeutic lifestyle change
9951346|NCT01101217|Placebo Comparator|placebo|placebo for 6 weeks
9951347|NCT01101217|Active Comparator|zinc|zinc sulfate 220 mg per day orally for 6 weeks
9951348|NCT01101230|Experimental|Almond|
9951349|NCT01101230|Placebo Comparator|Muffin|
9951350|NCT01101243|Active Comparator|Group 1|Body surface area: 88 %
9951351|NCT01101243|Active Comparator|Group 2|Body surface area: 22 %
9951352|NCT01101243|Active Comparator|Group 3|Body surface area: 88 %
9951353|NCT01101243|Active Comparator|Group 4|Body surface area: 88 %
9951354|NCT01101243|No Intervention|Group 5|Body surface area: 0 %
9951355|NCT01101256||Fondaparinux Prophylaxis group|
9951356|NCT01101256||Fondaparinux Therapy group|
9951357|NCT01101269|Experimental|Subjects with diabetic nephropathy|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
9951358|NCT01101269|Active Comparator|Healthy volunteers|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
9951359|NCT01101282|No Intervention|'Usual care'|"Participants will receive 'usual medical care' consisting of the following:~Medical management: Bronchodilators, corticosteroids, antibiotics and supplemental oxygen will be provided (where appropriate) in accordance with Australian and New Zealand COPD management guidelines (COPDX guidelines).~Non-invasive ventilation: if clinically indicated and prescribed in accordance with standardised hospital guidelines.~Physical rehabilitation: Participants will be assessed by a physiotherapist and prescribed appropriate exercises to facilitate a safe and timely discharge. Participants will perform physical rehabilitation according to a standardised protocol with an aim of maximising physical function at discharge.~Other allied health (e.g. occupational therapy, speech pathology, dietician) assessments and interventions, as required."
9951360|NCT01101282|Experimental|'Usual care' plus PEP mask therapy|"This will comprise:~'Usual care'~PEP mask therapy"
9951361|NCT01101347|Experimental|Aneurysm-Embolization System|
9951362|NCT01101360|Active Comparator|Matrix RF followed by Pulse Dye Laser|
9951363|NCT01101373||1|All subjects who received BAC for treatment resistant depression between 2000 and 2009
9951364|NCT01101386||Voriconazole|Pharmacokinetic Monitoring
9951365|NCT01101399|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 4 (week 2).
9951366|NCT01101399|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
9951367|NCT01101412|Experimental|Arm I: Antimicrobial Solution|Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
9951368|NCT01101412|Active Comparator|Arm II: Saline Solution|Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
9951369|NCT01101451|Active Comparator|Arm I (EBRT, IMRT)|Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
9951370|NCT01101451|Experimental|Arm II (cisplatin, EBRT, IMRT)|Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9951371|NCT01101503|Experimental|Intensive multifactorial group|Intensive multifactorial therapy group receive intensive blood glucose, blood pressure and blood lipids control.
9951372|NCT01101503|Experimental|conventional multifactorial therapy group|Conventional multifactorial therapy group receive conventional blood glucose, blood lipids and blood lipids control to the local targets.
9951373|NCT01101529|Placebo Comparator|Standard antiemetic therapy plus placebo|Standard anti-emetic prophylaxis consisting of 1/dexamethasone 6 mg daily during the chemotherapy days and 2/tropisetron (Navoban)5 mg daily during chemotherapy and 2 days after
9951374|NCT01101529|Experimental|aprepitant (Emend)|Aprepitant given orally 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after as an addition to standard antiemetic therapy as in the placebo arm.
9951375|NCT01101555|Experimental|COHORT 1: CUMULATIVE DOSE 1.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 3 days, dose 0.3, 0.5, 0.7, four patients in cohort, one of which is on placebo, escalation increment N/A
9951376|NCT01101555|Experimental|COHORT 2: CUMULATIVE DOSE 3.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.5, 0.7, 1.0, 1.0 four patients in cohort, one of which is on placebo, escalation increment 2.3 fold.
9951377|NCT01101555|Experimental|COHORT 3: CUMULATIVE DOSE 6.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 7 days, dose 0.3, 0.7, 5 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.7 fold.
9951378|NCT01101555|Experimental|COHORT 4: CUMULATIVE DOSE 8.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.7, 1.0, 2 x 3.0 four patients in cohort, one of which is on placebo, escalation increment 1.33 fold.
9951379|NCT01101555|Experimental|COHORT 5: CUMULATIVE DOSE 10MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 10 days, dose 10 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.25 fold.
9951380|NCT01101555|Experimental|COHORT 6: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 15 days, dose 15 x 1.0 six patients in cohort, one of which is on placebo, escalation increment 1.5 fold.
9951381|NCT01101555|Experimental|COHORT 7: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 5 x 3.0 six patients in cohort, one of which is on placebo, escalation increment N/A
9951382|NCT01101568|Experimental|Single Sequence|Simvastatin will be administered on Day 1 and Day 10. Rosuvastatin will be administered on Day 3 and Day 12. GSK1292263 will be administered on Days 6 to 14.
9951383|NCT01101581|Experimental|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab and 90Y-Epratuzumab Tetraxetan target different b-cells. Veltuzumab will be administered in all 4 weekly study drug treatments. 90Y-Epratuzumab Tetraxetan will be administered only on days 8 & 15. The dose of veltuzumab remains the same for all patients.
9951384|NCT01101581|Experimental|90Y-epratuzumab tetraxetan|90Y-epratuzumab tetraxetan will be administered 6 mCi/m2 on days 8 and 15.
9951385|NCT01101607|Active Comparator|Pediatric Emergency Physician|Patients randomized to Pediatric Emergency Physician Group will have their fracture reduced by a Pediatric Emergency Physician
9951386|NCT01101607|Active Comparator|Orthopaedic physician|Patients to be randomized to Orthopaedic physician Group will have their fracture reduced by an Orthopaedic Physician
9951387|NCT01101620|Active Comparator|Levosimendan|
9951388|NCT01101620|Placebo Comparator|Placebo|
9951389|NCT01101633|Active Comparator|1|500 ml beverage containing alginate (3%)
9951390|NCT01101633|Active Comparator|2|330 ml beverage containing alginate (3%)
9951391|NCT01101633|Placebo Comparator|3|500 ml beverage without alginate (placebo)
9951392|NCT01101633|Placebo Comparator|4|330 ml beverage without alginate (placebo)
9951393|NCT01101646|Experimental|001|rabeprazole sodium four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
9951394|NCT01101646|Experimental|002|rabeprazole sodium two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
9951395|NCT01101646|Experimental|003|rabeprazole sodium four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
9951396|NCT01101659|Experimental|001|JNJ-40411813 500 mg as 20 mL of oral suspension single dose
9951397|NCT01101659|Placebo Comparator|002|Placebo 20 mL of oral suspension single dose
9951398|NCT01101659|Other|003|ketamine Ketanest S. vials of 20 ml with 5 mg/ml diluted with saline to 0.02 mg Ketamine per mL and per kg bodyweight of the volunteer
9951399|NCT01101659|Other|004|normal saline infusion 0.5 mL /min over 90 minutes
9951400|NCT01101672|Experimental|Single-port laparoscopic colectomy|
9951401|NCT01101672|Active Comparator|Conventinal laparoscopic colectomy|
9951402|NCT01101685|Active Comparator|Escitalopram|7 days dosing at 10mg per day
9951403|NCT01101685|Placebo Comparator|Placebo|7 days dosing at 10mg daily
9951404|NCT01101698|Active Comparator|Vitamin K2, calcification score changes, vitamin D|90 μg vitamin K2+10μg cholecalciferol
9951405|NCT01101698|Active Comparator|Vitamin D, calcium score changes|10μg cholecalciferol (vitamin D)
9951406|NCT01101711||Patients with subarachnoid hemorrhage|
9951407|NCT01101724|No Intervention|Standard of Care|In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
9951408|NCT01101724|Experimental|Intervention|Mandated Rest.
9951409|NCT01101737|No Intervention|Usual care|Patients not invited to the nurse-led clinic will continue with usual GP care
9951410|NCT01101737|Experimental|Nurse-led blood pressure clinic|Patients randomly allocated to the intervention will be invited to a specialist nurse-led blood pressure clinic.
9951411|NCT01101763||All Subjects|Healthy males
9951412|NCT01101789|Active Comparator|triclosan|triclosan-coated sutures
9951413|NCT01101789|Placebo Comparator|control|sutures without triclosan-coating
9951414|NCT01101802|Active Comparator|Mycophenolate mofetil|Patients were given 1gm bd mycophenolate mofetil for 8 weeks
9951415|NCT01101802|Placebo Comparator|Sugar pill|
9951416|NCT01101815|Active Comparator|Oral Naltrexone + ART|Naltrexone (oral). 50 mg maintenance daily for 48 weeks, plus group drug counseling manual driven, N= 100
9951417|NCT01101815|Active Comparator|Naltrexone Implant + ART|Naltrexone Implant + ART. Monthly maintenance for 48 Weeks plus, group drug counseling manual driven, N=100
9951418|NCT01101893|Experimental|Period 1|In period 1 all subjects will receive Raltegravir 400mg q12h from Day 1 to Day 5
9951419|NCT01101893|Experimental|Period 2|In period 2 all subjects will receive GSK2248761 200mg q24h from Day 1 to Day 5.
9951420|NCT01101893|Experimental|Period 3|Day 1 of Period 3 will be the day after Day 5 of Period 2. Subjects will receive GSK2248761 200mg q24h + raltegravir 400mg q12h from Day 1 to Day 5.
9951421|NCT01101919|Experimental|CP-690,550 Dose Group|
9951422|NCT01101932|Experimental|(Part 1) PF-04308515|
9951423|NCT01101932|Placebo Comparator|(Part 1) Solution Placebo|
9951424|NCT01101932|Experimental|(Part 2) PF-04308515 Tablet|
9951425|NCT01101984|Experimental|DE-089|DE-089 ophthalmic solution
9951426|NCT01101984|Active Comparator|HA|0.1% sodium hyaluronate ophthalmic solution
9951427|NCT01102010|Experimental|Blood transfusion|"Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl)~Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl)"
9951428|NCT01102023|Experimental|solar salt based-diet|
9951429|NCT01102036|Placebo Comparator|Yoghurt without probiotics|Yoghurt without probiotic bacteria
9951430|NCT01102036|Active Comparator|Cultura yoghurt|Cultura yoghurt with L casei F19, acidophilus La5 adn B lactis Bb 12
9951431|NCT01102049|Experimental|self-administered food intake|self-administered food intake according to dietary protocol
9951432|NCT01102062|Experimental|Orange Juice|1 glass (=200mL) of orange juice
9951433|NCT01102075|Experimental|Electroacupuncture|The Electroacupuncture therapy protocol included a total of 12 acupuncture points at the CV12,CV6, bilateral ST25, SP15, SP14,LI4, LI11, ST36, ST44. All acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Abdominal acupuncture points were inserted horizontally 6~6.5cm in depth and the others were inserted vertically 2~2.5cm in depth until patient can feel De-Qi. All acupuncture points were stimulated electrically with a frequency of 24 Hz an intensity of 0.27-1.3mA(tolerable strength) with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks by practitioner who had had 6 years of acupuncture training and 3 more years of clinical experience.
9951434|NCT01102075|Sham Comparator|Sham electroacupuncture procedure|The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
9951435|NCT01102075|No Intervention|Waiting list|No treatment was done for waiting group, but could receive same treatments as Electroacupuncture group after the end of trial.
9951436|NCT01102088|Experimental|Radiation + Chemotherapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.~Chemotherapy Administration: Schedule of chemotherapy, and modifications of chemotherapy drugs during chemoradiation treatment will be at the discretion of the treating medical oncologist per their standard of practice and with consideration to standard chemotherapy drugs in the treatment of esophageal cancer."
9951437|NCT01102114|Placebo Comparator|Placebo Vaccine|
9951438|NCT01102114|Experimental|NicVAX Vaccine|
9951439|NCT01102127||Goiter|Patients with nodular goiter
9951440|NCT01102153||Coolgard|invasive cooling
9951441|NCT01102153||ArcticSun|non-invasive (surface) cooling
9951442|NCT01102179||Chronic kidney disease|"All patients with stage 2-5 (pre-dialysis) chronic kidney disease~One-time blood draw (10 ml)"
9951443|NCT01102192||Myasthenia gravis with thymoma|Myasthenia gravis with thymoma
9951444|NCT01102192||Myasthenia gravis without thymoma|Myasthenia gravis without thymoma
9951445|NCT01102192||Thymoma without Myasthenia gravis|Thymoma without Myasthenia gravis
9951446|NCT01102192||cardiac, or thyroid surgery|cardiac, or thyroid surgery
9951447|NCT01102205||healthy|
9951448|NCT01102205||euthyroid hashimoto|
9951449|NCT01102205||hypothyroid hashimoto|
9951450|NCT01102244|Experimental|Tobradex ST|tobramycin 0.3%, dexamethasone 0.05%
9951451|NCT01102244|Active Comparator|Azasite|azithromycin 1%
9951452|NCT01102283||Stent Group|
9951453|NCT01102296|Active Comparator|male homosexuals|HIV-uninfected male homosexuals will be provided 2 doses of HAV vaccine, which will be administered at baseline and 6th month of follow-up.
10005018|NCT01581229|Active Comparator|Control|
10005019|NCT01581242|Experimental|A|
9951454|NCT01102296|Active Comparator|HIV-infected male homosexuals, group1|HIV-infected male homosexuals will be provided 3 doses of HAV vaccine, which will be administered at baseline, 1st, and 6th month of follow-up.
9951455|NCT01102296|Active Comparator|HIV-infected male homosexuals, group 2|HIV-infected male homosexuals will be provided 2 doses of hepatitis A vaccine, which will be administered at baseline and 6th month of follow-up.
9951456|NCT01102309|Experimental|Experimental Group (EG)|Group assigned to robot plus conventional therapy
9951457|NCT01102309|Active Comparator|Control Group (CG)|Group assigned to conventional therapy only
9951458|NCT01102322||1|
9951459|NCT01102335|Experimental|Telbivudine|
9951460|NCT01102335|Active Comparator|TACE only|
9951461|NCT01102348|Experimental|PEP-uP Protocol (after)|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
9951462|NCT01102348|No Intervention|Standard feeding protocol (before)|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
9951463|NCT01102361|Experimental|Transperineal Biopsy|Biopsy of the prostate using transperineal approach
9951464|NCT01102387|Experimental|LAS41003|
9951465|NCT01102387|Active Comparator|LAS189962|
9951466|NCT01102387|Active Comparator|LAS189961|
9951467|NCT01102400|Experimental|1|
9951468|NCT01102439|Active Comparator|Standard dose clopidogrel|300 mg Loading x 1 day, 75 mg/d x 13 days
9951469|NCT01102439|Experimental|Double dose clopidogrel|600 mg Loading x 1 day, 150 mg/d x 6 days, 75 mg/d x 7 days
9951470|NCT01102439|Active Comparator|Standard dose aspirin|Aspirin 81mg/d x 14 days
9951471|NCT01102439|Experimental|High dose aspirin|Aspirin 325 mg/d x 14 days
9951472|NCT01102452|Placebo Comparator|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
9951473|NCT01102452|Experimental|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
9951474|NCT01102504|Experimental|Tomato extract (Ateronon)|Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.
9951475|NCT01102504|Placebo Comparator|Placebo|Placebo
9951476|NCT01102517|Experimental|VATS group|video-assisted thoracoscopic surgery
9951477|NCT01102517|Other|axillary thoracotomy|Control group
9951478|NCT01102543||Premature babies < 28 GA|
9951479|NCT01102543||Premature babies > 28 & < 32 weeks GA|
9951480|NCT01102556||Surgery Patients/High-risk Patients|Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
9951481|NCT01102569||Pancreatic cancer and Ashkenazi decent|Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.
9951482|NCT01102595|Experimental|1: Temozolomide plus Radiation|"Group 1:~Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy).~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
9951483|NCT01102595|Experimental|2: Temozolomide plus Radiation plus Bevacizumab|"Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles + bevacizumab 10 mg/kg every 15 days.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy) + bevacizumab 10 mg/kg every 15 days.~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
9951484|NCT01102608|Experimental|1|
10005020|NCT01581242|Experimental|B|
10005021|NCT01581242|Experimental|C|
10005022|NCT01581255||Conventional lung protective ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the conventional lung protective ventilation arm of the OSCILLATE trial.
10005023|NCT01581255||High frequency oscillation ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the high frequency oscillation ventilation arm of the OSCILLATE trial.
10005024|NCT01581320|Experimental|DP-R206|
10005025|NCT01581320|Active Comparator|Bonviva|
10005026|NCT01581333|Experimental|Experimental Arm|Empirical antimicrobial treatment discontinuation
10005027|NCT01581333|Active Comparator|Control Arm|Standard empirical antimicrobial treatment discontinuation
9951485|NCT01102621||case-control, head and neck cancer with radiotherapy|The group of exposed individuals had to be patients with disease-free survival interval of at least two years subsequent to treatment for head and neck cancer by means of radiotherapy alone or in combination, in which the auditory system was included in the field of irradiation.
9951486|NCT01102621||case-control, head an neck cancer without radiotherapy|The group of non-exposed individuals (control group) had to be patients who had not undergone oncological treatment that put their hearing at risk and who were age-matched (2 years). This group was formed by individuals who had had pelvic tumors or skin tumors and who had only undergone local surgery to remove their tumors, and by female volunteers from the hospital. All of these individuals were asked whether they would be willing to participate in a study, without knowing in advance whether they had any previous hearing problems or complaints.
9951487|NCT01102634|Experimental|Acu-TENS|Application of TENS over acupuncture points
9951488|NCT01102634|Placebo Comparator|Placebo-TENS|Application of Acu-TENS but with no electricity
9951489|NCT01102647|Experimental|Phytosterol ester|Plant sterol compared with placebo
9951490|NCT01102673|Experimental|PF-04991532|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
9951491|NCT01102673|Placebo Comparator|Placebo|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
9951492|NCT01102686|Experimental|Pyrimethamine|
9951493|NCT01102699|Experimental|Filgrastim, G-CSF|Single s.c. dose of G-CSF (300 microg)
9951494|NCT01102712|Experimental|BTVA|
9951495|NCT01102725||Colorectal Surgery|Subject who are undergoing a colon or rectal resection
9951496|NCT01102751||Vitamin D deficient females|(n =18, mean age 29.1±9.9 yrs)
9951497|NCT01102751||vitamin D sufficient healthy females|(control group; n = 19, mean age 28.5±5.2 yrs)
9951498|NCT01102751||genetically-determined hypophosphatemic rahitis|(n=13, mean age 26.5±15.1 yrs)
9951499|NCT01102816|Experimental|Individualized acupuncture|
9951500|NCT01102816|No Intervention|Routine care|
9951501|NCT01102868|Sham Comparator|Needle in acupuncture point Li11|Acupuncture needle in the acupuncture point Li11
9951502|NCT01102868|Experimental|IMS of musculus pronator teres|Acupuncture needle in musculus pronator teres
9951503|NCT01102881|Placebo Comparator|No fiber|No fiber added to muffins or cereal
9951504|NCT01102881|Experimental|Fiber made from corn starch|Muffins and cereal made with novel corn fiber
9951505|NCT01102881|Experimental|Glucose polymer fiber|Muffins and cereal made from glucose polymer fiber
9951506|NCT01102907||Liquid Meal|
9951507|NCT01102907||Solid Meal|
9951508|NCT01102920|Experimental|Tailored behavioural treatment and CPAP|Tailored behavioural treatment targeting physical activity and eating habits.
9951509|NCT01102920|Active Comparator|CPAP-treatment|CPAP-treatment as usual. Advice about benefits of physical activity and weight loss.
9951510|NCT01102933||Unselected post-myocard infarct patients|Patients diagnosed with MI at Uppsala University Hospital
9951511|NCT01102946|Experimental|PRP plus ranibizumab|Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
9951512|NCT01102946|Active Comparator|PRP|Patients will only be submitted to panretinal photocoagulation
9951513|NCT01102959|Experimental|Photographic Material|Photographic Educational Material on Carbohydrate Counting
9951514|NCT01102985|Experimental|aerobic resistance|12 month aerobic resistance exercise at a fitness center
9951515|NCT01102985|Active Comparator|home based physical activity|national recommendations for physical activity for adults
9951516|NCT01102998||Brain Tumor Survivors|Brain tumor survivors ages 8 to 18 years who are at least 5 years post diagnosis and at least 2 years post active therapy or observation and their parents/guardians will be approached to participate during clinic visits.
9951517|NCT01103011|Experimental|ND0611 dose 1, ND0611 dose 2, placebo|
9951518|NCT01103024|Experimental|AIN457 300mg s.c every 2 weeks|
9951519|NCT01103024|Experimental|AIN457 300mg s.c every 4 weeks|
9951520|NCT01103024|Experimental|AIN457 150mg s.c every 4 weeks|
9951521|NCT01103024|Placebo Comparator|Placebo s.c every 2 weeks|
9951522|NCT01103050|Active Comparator|QAV680 + Cetirizine Placebo|
9951523|NCT01103050|Experimental|QAV680 + Cetirizine|
9951524|NCT01103050|Active Comparator|Cetirizine + QAV680 Placebo|
9951525|NCT01103050|Placebo Comparator|QAV680 Placebo + Cetirizine Placebo|
9951526|NCT01103076|Active Comparator|Polyamide 210 H|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
9951527|NCT01103076|Experimental|HCO 1100|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
9951528|NCT01103102|Active Comparator|Lowest Dose|
9951529|NCT01103102|Active Comparator|Intermediate Dose|
9951530|NCT01103102|Active Comparator|Highest Dose|
9951531|NCT01103102|Placebo Comparator|Placebo Control|
9951532|NCT01103115|Placebo Comparator|Placebo|Subjects in this group will take the placebo tablets
9951533|NCT01103115|Active Comparator|Ca600mg+VitD400IU|subjects receive a daily dose of 600 mg elemental calcium and 400 IU vitamin D3
9951534|NCT01103115|Active Comparator|Ca600mg+VitD800IU|subjects receive a daily dose of 600 mg elemental calcium and 800 IU vitamin D3
9951535|NCT01103154|Active Comparator|Carvedilol|carvedilol 6.25mg per day
9951536|NCT01103154|Active Comparator|N+I|nadolol 40mg per day, ISMN 10 mg per day
9951537|NCT01103193|Active Comparator|remifentanil injected|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
9951538|NCT01103193|Active Comparator|sevoflurane in step up concentration|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
9951539|NCT01103206|Experimental|Control group|Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.
9951540|NCT01103206|Experimental|Primary hyperparathyroidism dose I|Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.
9951541|NCT01103206|Experimental|Primary hyperparathyroidism dose II|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
9951542|NCT01103219|Placebo Comparator|Control|Participants in this group will receive nutrition from birth and during the hospital stay until discharge according to the routines of the participating institutions.
9951543|NCT01103219|Active Comparator|Intervention|The participants in this group will receive increased supply of energy, protein, vitamin A, docosahexaenoic acid, and arachidonic acid from birth and during the hospital stay until discharge.
9951544|NCT01103258|Active Comparator|high ligation and stripping|surgery consisting of high ligation in combination with long saphenous stripping
9951545|NCT01103258|Active Comparator|duplex guided foam sclerotherapy|duplex guided foam sclerotherapy
9951546|NCT01103297|Other|Variable Angle Distal Radius Plate|
9951547|NCT01103310|Experimental|Arm 1|Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT
9951548|NCT01103310|Experimental|Arm 2|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood
9951549|NCT01103336|Experimental|Nicorandil in saline|
9951550|NCT01103336|Placebo Comparator|saline|
9951551|NCT01103375|Experimental|Treatment (enzyme inhibitor, immunotherapy)|Patients receive isotretinoin PO QD on days 1-21 and erlotinib hydrochloride PO QD on days 1-28.
9951552|NCT01103388|Experimental|Rituximab|
9951553|NCT01103388|No Intervention|No Rituximbab|
9951554|NCT01103401|Active Comparator|Tobramycin/Dexamethasone|
9951555|NCT01103401|Active Comparator|Tobramycin/Dexamethasone plus Ketorolac tromethamine|
9802216|NCT05315960||Cross-sectional study|"Procedures:~Consent will be obtained from residents, for those who have mental capacity to give informed consent, or from a nearest relative or caregiver as consultee, for those who lack capacity. Once consent is obtained, the LTC resident will be asked to complete a form asking about their characteristics and a questionnaire about their social connections which is expected to take approximately 15 minutes. The proxy will be asked to complete a sociodemographic form about themselves along with a number of questionnaires regarding the LTC resident's dementia severity, neuropsychiatric symptoms, activities of daily living and quality of life for comparison. Data collection for the proxy is expected to take approximately 30-60 minutes. Anticipated sample size 150 between Canada and the UK."
9951556|NCT01103427|Active Comparator|Internet-based coaching .|"Arm 1. Those in the active comparator arm will benefit from automated internet-based coaching. The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
9951557|NCT01103427|Experimental|SMS based coaching|"Arm 2. The subjects will receive automated coachingby SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
9951558|NCT01103427|Experimental|SMS coaching UNN recruited|Arm 3.The subjects will be recruited from those reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4.
9951559|NCT01103427|Experimental|Craving/Panic function. UNN recruited|"Arm 4. The subjects will in addition to the automated coachingby SMS get a SMS panic/craving function. The subjects will be recruited from subjects reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4."
9951560|NCT01103453|Experimental|Intervention Group|Study group are persons diagnosed as suffering from Mild Cognitive Impairment will undergo a series of 9 sessions on a computer program of a virtual supermarket to improve their Executive and IADL functions.
10005028|NCT01581346|Experimental|exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
9802217|NCT05315947|Experimental|Treatment A-B|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence A-B at pre-specified timepoints.
9951561|NCT01103518|Experimental|Combination 1|Ethinyl Estradiol + Cyproterone acetate
9951562|NCT01103518|Active Comparator|Combination 2|Ethinyl Estradiol + Cyproterone acetate
9951563|NCT01103531|Experimental|Exercise Group|Participants in this group will be scheduled for 24 exercise training sessions over an 8-week period (three times weekly) and will be supervised by a certified exercise physiologist.
9951564|NCT01103531|Active Comparator|Education Group|Participants in this group will meet with a counselor who will present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
9951565|NCT01103544||Patients with advanced / metastatic TCCU after CDDP-failure|
9951566|NCT01103570|Experimental|group 1 cholecystocholangiography|cholangiography via gall bladder
9951567|NCT01103570|Experimental|group2 cystic duct cholangiography|cystic duct cholangiography
9951568|NCT01103583|Experimental|Hydroxyurea|
9951569|NCT01103583|Placebo Comparator|Placebo|
9951570|NCT01103596||HIV-infected patients, 1st wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
9951571|NCT01103596||HIV-infected patients, 2nd wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
9951572|NCT01103609|Experimental|1|twice daily on Day 1 to Day 10, with Warfarin on Day 4
9951573|NCT01103609|Placebo Comparator|2|twice daily on Day 1 to Day 10, with Warfarin on Day 4
9951574|NCT01103622|Experimental|1|twice daily Day 1 to Day 7; digoxin on day 4
9951575|NCT01103622|Placebo Comparator|2|twice daily Day 1 to Day 7; digoxin on day 4.
9951576|NCT01103635|Experimental|Arm I|Patients receive tremelimumab over 1 hour on day 1 and CD40 agonist monoclonal antibody CP-870,893 IV over 30 minutes on days 2, 22, 43, and 64. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
9951577|NCT01103648|Active Comparator|Simvastatin arm|A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
9951578|NCT01103648|Active Comparator|Ezetimibe arm|A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
9951579|NCT01103648|Experimental|Simvastatin-Ezetimibe arm|To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).
9951580|NCT01103661|Other|Numeris-AF Guided Coagulation System|
9951581|NCT01103674|Other|Numeris-AF Guided Coagulation System|
9951582|NCT01103687|Experimental|Ad26.ENVA.01 (rAd26)|Participants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.
9951583|NCT01103687|Placebo Comparator|Placebo Vaccine|Participants will receive the placebo vaccine at baseline.
9951584|NCT01103726|Experimental|Stage 1|
9951585|NCT01103726|Experimental|Stage 2|
9951586|NCT01103739|Experimental|cohort 1|
9951587|NCT01103739|Experimental|cohort 2|
9951588|NCT01103752||Surgery|This group (n=220) consist of patients undergoing hip or knee replacement in a fast-track setup and they are tested 3 times for postoperative cognitive dysfunction.
9951589|NCT01103765|Placebo Comparator|classic strategy|after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
9951590|NCT01103765|Active Comparator|post-dilatation strategy|After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
9951591|NCT01103791|Experimental|Cohort 1|Docetaxel-PNP 20mg/m2
9951592|NCT01103791|Experimental|Cohort 2|Docetaxel-PNP 35mg/m2
9951593|NCT01103791|Experimental|Cohort 3|Docetaxel-PNP 45mg/m2
9951594|NCT01103791|Experimental|Cohort 4|Docetaxel-PNP 60mg/m2
9951595|NCT01103791|Experimental|Cohort 5|Docetaxel-PNP 75mg/m2
9951596|NCT01103791|Experimental|Cohort 6|Docetaxel-PNP 90mg/m2
9951597|NCT01103817|No Intervention|Vitamin D Sufficient|"Sufficient is defined as a 25 OH vitamin D level >50 nmol/l measured at baseline. No clinical intervention will be assigned to this group.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
9951598|NCT01103817|Experimental|Vitamin D Deficient|"Deficient is defined as a 25 OH vitamin D level ≤ 37.5 nmol/l. This group will receive Vitamin D.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
9951599|NCT01103830|Experimental|Group 1|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal."
9951600|NCT01103830|Active Comparator|Group 2|"4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.~Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal."
9951601|NCT01103830|Other|Group 3|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
9951602|NCT01103830|Experimental|Group 4|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal."
9951603|NCT01103830|Experimental|Group 5|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fasting condition."
9951604|NCT01103830|Other|Group 6|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fasting condition.~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
9951605|NCT01103843|Active Comparator|Maintenance Dose Arm|Open label clopidogrel 75 mg daily or prasugrel 10 mg daily
9951606|NCT01103843|Active Comparator|Loading Dose Arm|Clopidogrel 600 mg or Prasugrel 60 mg at time of PCI.
9951607|NCT01103856|Experimental|Patient Mentor Intervention|The patient mentor intervention from TSHC has been adapted to the inpatient setting. Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
9951608|NCT01103856|Placebo Comparator|HIV transmission risk reduction|Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor. We will use a modified version of the RESPECT intervention for our attention control group. Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
9951609|NCT01103908||Pediatric cardiac output (CO) after CPB|Cardiac output measurements made in pediatric patients after cardiopulmonary bypass.
9951610|NCT01103921|Other|Glucose|
9951611|NCT01103921|Other|Fructose|
9951612|NCT01103921|Other|High-Fructose Corn Syrup|
9951613|NCT01103921|Other|Aspartame|No sugar
9802218|NCT05315947|Experimental|Treatment B-A|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence B-A at pre-specified timepoints.
9802219|NCT05315934|Experimental|Upper Body Aerobic Exercise|Participants will perform 30 minutes of arm-crank cycling at a moderate exercise intensity based off the participants perceived RPE13
9802220|NCT05315934|Experimental|Lower Body Aerobic Exercise|Participants will perform 30 minutes of static cycling at a moderate exercise intensity based off the participants perceived RPE13
9802221|NCT05315921|Experimental|OsrhAAT 1 mg/kg IV|
9802222|NCT05315921|Experimental|OsrhAAT 3 mg/kg IV|
9802223|NCT05315921|Experimental|OsrhAAT 10 mg/kg IV|
9802224|NCT05315921|Experimental|OsrhAAT 20 mg/kg IV|
9802225|NCT05315921|Experimental|OsrhAAT 40 mg/kg IV|
9802226|NCT05315921|Experimental|OsrhAAT 60 mg/kg IV|
9802227|NCT05315908|Active Comparator|Automated call|Patients receive up to two automated phone calls in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
9802228|NCT05315908|Active Comparator|Text messaging|Patients receive up to two text messages in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.
9802229|NCT05315895||general population|general population in a specific area and specifc time range.
9802230|NCT05315882||Allogeneic stem cell transplantation|Observational, no interventional
9802231|NCT05315869||Retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix located in the retrocaecal position.
9802232|NCT05315869||Non-retrocaecal group|Patients who underwent surgery for signs of acute appendicitis and had intraoperative finding of the appendix not located in the retrocaecal position.
9802233|NCT05315856||ChAdOx1 vaccine group|AstraZeneca vaccine (chimpanzee adenovirus-vectored vaccine, 0.5 mL [5 × 1010 viral particles] per dose)
9802234|NCT05315856||BNT162b2 vaccine group|Pfizer-BioNTech vaccine (mRNA vaccine; 0.3 mL [30 μg] per dose)
9802235|NCT05315830|Experimental|HER2 Vaccine alone|0.6 μg HER2 Vaccine
9802236|NCT05315830|Experimental|HER2 Vaccine plus Standard of Care Chemotherapy|0.6 μg HER2 Vaccine plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or other Standard of Care Chemotherapy
9802237|NCT05315817|Experimental|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
9951614|NCT01103947|Active Comparator|EcoAnesthesia Mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. This group will receive the EcoAnesthesia Mask first."
9951615|NCT01103947|Active Comparator|Standard mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. Patients in this arm will receive the standard mask first."
9951616|NCT01103986|No Intervention|Control Group|
9951617|NCT01103986|Experimental|motivational/ health literacy education|
9951618|NCT01104012||All patients|Allergy patients, asthma and rhinitis
9951619|NCT01104038|Active Comparator|Nutrition Education/Lifestyle Counseling|Children in this group will receive weekly group nutrition sessions , 30 minutes per week for 12 weeks, identical to those provided for the EXCEL intervention group and delivered by a registered dietician.
9951620|NCT01104038|Experimental|EXCEL|The EXCEL arm is the experimental arm of the study. Participants in this arm will receive supervised physical activity in the form of novel gaming (technology-mediated physical activity, 60 minutes per session, three times per week , for 12 weeks and 12 weeks of group nutrition education sessions.
9951621|NCT01104051||Radiofrequency Ablation|The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
9951622|NCT01104051||Sham|subjects to be blinded,to receive sham procedure; The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
9951623|NCT01104064|Experimental|Real rTMS combined with CIT|
9951624|NCT01104064|Sham Comparator|Sham rTMS combined with CIT|
9951625|NCT01104129||Control Group|Individual who has not had pancreatic cancer/IPMN; surgical resection for lesion of pancreas; history of colorectal, gastric cancer, esophageal, or head-and-neck cancer; administration of chemotherapy less than 1 week prior to enrollment; or an endoscopic procedure conducted less than 1 week prior to enrollment.
9951626|NCT01104129||Diagnosis of Pancreatic Cancer/IPMN|Patients diagnosed with Pancreatic Cancer/Intraductal Papillary Mucinous Neoplasm who are scheduled for surgical resection.
9951627|NCT01104142||MDI|Subject on multiple Daily Injections
9951628|NCT01104142||CSII|Subjects on Continuous Subcutaneous Insulin Infusion
9951629|NCT01104168||Nursing home residents with diabetes|
10214920|NCT03808337|Active Comparator|Standare of Care|Patients with newly diagnosed metastatic non-small cell lung cancer or triple negative breast cancer may be enrolled on protocol prior to receiving any systemic therapy. If these patients are randomized to the standard of care arm (Arm 1), they will initiate appropriate therapy as determined by their oncologist. Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist.
10214921|NCT03808337|Experimental|Stereotactic Body Radiotherapy (SBRT) + Standard of Care|Patients enrolled on Arm 2 of the study will undergo Stereotactic Body Radiotherapy/SBRT to all known metastases seen on imaging studies performed prior to enrollment. Radiotherapy will be given concurrently to all metastatic sites. Minimum BED for ablative SBRT is more than or equal to 48 Gy10. Patients can undergo systemic therapy concurrently with SBRT at the discretion of treating radiation oncologist and medical oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
10214922|NCT03787654|Experimental|electroacupuncture group|Acupoints of bilateral Zhongliao (BL33), Huiyang (BL35) and Sanyinjiao (SP6) are stimulated by Huatuo Brand disposable needles and SDZ-V electronic apparatus.
10214923|NCT03787654|Sham Comparator|sham electroacupuncture group|Sham acupoints 1 cun(≈15mm) horizontally outwardly lateral to BL33 and BL35, and 0.5 cun(≈10mm) horizontally behind SP6 are stimulated superficially with a small electricity current by needles of 0.30×40mm size and SDZ-V electronic apparatus.
9951630|NCT01104181|Experimental|swab and brush or swab and swab|we will determine which collection method is superior
10214924|NCT03787654|Active Comparator|Solifenacin group|subjects will orally take Solifenacin 5-10mg per day.
10214925|NCT03772353|Experimental|Pyrotinib Combined with Letrozole and SHR6390|Data from phase Ib showed the triplet of pyrotinib, SHR6390, and letrozole had an acceptable safety profile and encouraging efficacy, potentially offering a chemotherapy-sparing treatment option for patients with HER2-positive/HR-positive MBC. Based on DLTs and clinical efficacy, pyrotinib 320mg/d, SHR6390 125mg/d, and letrozole 2.5mg/d was declared as RP2D. The pharmacokinetic analysis had not yielded conclusive results and would involve more samples in phase II trial.
9951631|NCT01104194|Experimental|Fish-oil|
9951632|NCT01104194|Placebo Comparator|Placebo|Olive oil capsules, identical in appearance to fish oil capsules
9951633|NCT01104233||The soft spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with soft spreading (using LAP Protector).
9951634|NCT01104233||The rigid spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with rigid spreading.
10214926|NCT03772353|Experimental|Pyrotinib Combined with Fulvestrant and SHR6390|Endocrine therapy of HER2-positive/HR-positive MBC，which are suitable for fulvestrant treatment
10214927|NCT03770780|Experimental|SAGE-718|
10214928|NCT03770780|Placebo Comparator|Placebo|
10214929|NCT03697720|Experimental|Primary Dysmenorrhea|We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
10214930|NCT03696771|Experimental|NJH395|Includes non-breast HER2-positive advanced malignancies
9951635|NCT01104259|Experimental|Treatment (veliparib with cisplatin and vinorelbine tartrate)|Patients receive veliparib PO BID on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV over 1 hour on day 1 and vinorelbine ditartrate IV over 10-20 minutes on days 1 and 8. Treatment repeats every 21 days for 6-10 courses in the absence of disease progression or unacceptable toxicity. Treatment with veliparib alone may continue in the absence of disease progression or unacceptable toxicity.
9951636|NCT01104272|Experimental|Energy Level 1|Subcutaneous Adipose Tissue Treated With Energy Level 1.
9951637|NCT01104298|Active Comparator|Arm A|"Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
10005029|NCT01581359|Active Comparator|GnRHa|Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.
9802238|NCT05315804|Experimental|Amelogenin Group (A)|Amelogenins in gel will be applied in intraosseous periodontal defects, after Minimally Invasive Non Surgical Debridement (MINSD)
10005030|NCT01581359|Placebo Comparator|Physiological serum|physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.
10005031|NCT01581372|Experimental|Pharmacist care|
10214931|NCT03675763|Experimental|Craniosacral therapy|Craniosacral therapy and parent information on how to manage colic.
10214932|NCT03675763|No Intervention|Parent information|Parent information on how to manage colic.
10005032|NCT01581372|No Intervention|Usual care|
10005033|NCT01581385||Carotid endarterectomy|Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery.
10005034|NCT01581398|Experimental|A1(Genotype2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 800mg/day
10005035|NCT01581398|Active Comparator|A2(Genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 800mg/day
10005036|NCT01581398|Experimental|B1(Non-genotype 2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight
10005037|NCT01581398|Active Comparator|B2(Non-genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight.
10005038|NCT01581411|Experimental|IA t-PA|intra-ophthalmic artery injection of tissue plasminogen activator
10005039|NCT01581450|Experimental|Tested drug|Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
10005040|NCT01581450|Active Comparator|Gas Active control|Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
10035214|NCT01803971|Experimental|vascular access in out-of-hospital cardiac arrest patients|Obtention of vascular access according to the current strategy, ie after one unsuccessful attempt to obtain a peripheral venous access, use of an intra osseous device
9802239|NCT05315804|Active Comparator|No-amelogenin Group (B)|Only Minimally Invasive Non Surgical Debridement (MINSD) will be performed
10214933|NCT03655223||Newborn infants born in North Carolina|All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
10214934|NCT03655223||Birthing Mothers in North Carolina|All birthing mothers in North Carolina will have the opportunity to participate in Early Check.
10214935|NCT03653390|Experimental|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
9802240|NCT05315791|Experimental|a: ground into pieces|0~3mm
9802241|NCT05315791|Experimental|b: replace the bone|0~3mm
10214936|NCT03653390|Active Comparator|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
9802242|NCT05315791|Experimental|c: turn inward|0~3mm
9802243|NCT05315791|Experimental|d: ground into pieces|3~5mm
9802244|NCT05315791|Experimental|e: replace the bone|3~5mm
9802245|NCT05315791|Experimental|f: turn inward|3~5mm
9802246|NCT05315778|Experimental|Anti-BCMA CAR T-cells infusion|R/R ITP patients will accept infusion of autologous anti-BCMA CAR T-cells with a total of 1.0-2.0×10e7/Kg. The patients will be follow-up for 6 months post CAR T-cell therapy.
9802247|NCT05315765||Phase 1|Qualitative interviews with patients to generate thematic framework and questionnaire
9802248|NCT05315765||Phase 2|Face validity assessment of questionnaire
9802249|NCT05315765||Phase 3|Completion of questionnaire to refine scale and item list
9802250|NCT05315739|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the gammaCore device (electroCore)
9802251|NCT05315739|Sham Comparator|Sham treatment|Inactive sham vagus nerve stimulation applied by the gammaCore sham device (electroCore)
9802252|NCT05315726|Experimental|Pahse 1|
10214937|NCT03653390|No Intervention|Control|Participant continues with their lives as they normally would.
10214938|NCT03649633|Experimental|Steroids/Vitamin C group|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
10214939|NCT03649633|Placebo Comparator|Control group|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
10214940|NCT03623373|Experimental|Bendamustine/Rituximab/Acalabrutinib/Cytarabine|"Patients will receive (6) 28 day cycles~Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.~Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard~After Cycle 6, patients will undergo leukapheresis"
10214941|NCT03616912|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
10214942|NCT03616912|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
10214943|NCT03616912|Placebo Comparator|Placebo|Placebo administered orally.
9802253|NCT05315726|Experimental|Phase 2: Intervention group|
9802254|NCT05315726|Active Comparator|Phase 2: control group|
9802255|NCT05315713|Experimental|Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) Tiragolumab|Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
9802256|NCT05315713|Experimental|Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IV|Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
9951638|NCT01104298|Experimental|Arm B|"Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.~Route of administration: for intravenous use after reconstitution and further dilution.~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
9951639|NCT01104337|Experimental|Paracetamol 2g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 2g/d
10214944|NCT03603964|Experimental|Guadecitabine|Subjects will receive guadecitabine treatment at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol. Treatment may continue as long as the subject continues to benefit based on investigator judgment.
10214945|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
9951640|NCT01104337|Experimental|Paracetamol 3g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 3g/d
9951641|NCT01104337|Placebo Comparator|Placebo|9 patients on stable warfarin therapy received a 10-day regimen of placebo
9951642|NCT01104363|Experimental|Snow white Plaster 2|Test
9951643|NCT01104363|Active Comparator|Primopattern LC gel + PVS|Control
9951644|NCT01104428|Placebo Comparator|placebo|
9951645|NCT01104428|Experimental|"Drug:ziying"|
9951646|NCT01104467|Experimental|Desmoteplase 70 µg/kg|
9951647|NCT01104467|Experimental|Desmoteplase 90 µg/kg|
9951648|NCT01104467|Placebo Comparator|Placebo|
10005041|NCT01581463|Active Comparator|Liothyronine, Sodium|Healthy adults.
10005042|NCT01581476|Active Comparator|Statin|Participants receive active statin and placebo ACE Inhibitor
10005043|NCT01581476|Active Comparator|Angiotensin-converting enzyme inhibitor|Participants receive active ACE Inhibitor and placebo statin
10005044|NCT01581476|Placebo Comparator|Placebo|Participants receive placebo ACE Inhibitor and placebo statin
10005045|NCT01581476|Other|Combination therapy|Participants receive both active ACE Inhibitor and active Statin
10005046|NCT01581489||Early cord clamping (ECC)|Early cord clamping consisted of early (=< 10 s) clamping of the umbilical cord at birth.
10005047|NCT01581489||Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (>= 180 s) clamping of the umbilical cord at birth.
10005048|NCT01581502||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention
10005049|NCT01581515|Active Comparator|P-E group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
10005050|NCT01581515|Active Comparator|X-P group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
10005051|NCT01581606||Group 1R and 1T AMD Screening|Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
10214946|NCT03582774|Active Comparator|Arm I (standard of care)|Participants receive standard of care SRT.
10005052|NCT01581606||Group 2R and 2T Follow up|Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
10005053|NCT01581632|Other|LipiScan/LipiScan IVUS|valuation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
10005054|NCT01581645|Experimental|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
10005055|NCT01581671||Patients having a first time angiogram|Patients who are coming to the Cardiac Cath Lab to have an angiogram for the first time
10005056|NCT01581697|Experimental|Oat bran|
10005057|NCT01581723|Active Comparator|Monopolar TUR|Monopolar diathermy is used to perform tranurethral resection of bladder tumor
10005058|NCT01581723|Experimental|Biploar TUR|Bipolar diathermy is used to perform transurethral resection of bladder tumor
10005059|NCT01581736|Experimental|Exercise|Proteomics of muscle after a single bout of exercise compared to baseline with U100 Humulin infusion at rate of 80 milliunits(mU)/m^2 surface area.
10005060|NCT01581749|Other|36.25Gy to prostate in 5 fractions|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
10214947|NCT03582774|Experimental|Arm II (68Ga-PSMA-11 PET/CT)|Participants receive 68Ga-PSMA-11 IV and 50-100 minutes later undergo whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the discretion of the treating radiation oncologist.
10214948|NCT03581279|Active Comparator|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
10214949|NCT03581279|Active Comparator|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
10214950|NCT03568058|Experimental|vaccine and anti-PD-1|personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
10214951|NCT03568058|Experimental|anti-PD1 before vaccine|anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
10214952|NCT03568058|Experimental|anti-PD1 and vaccine|anti-PD-1 antibody followed by personalized vaccine therapy
10214953|NCT03568058|Experimental|vaccine|personalized vaccine therapy
9951649|NCT01104506|Active Comparator|Painless plexus|Patient with a painless avulsion of brachial plexus
9951650|NCT01104506|Active Comparator|Healthy|Healthy volunteers
9951651|NCT01104506|Experimental|Painful plexus|Patient with a painful avulsion of brachial plexus
9951652|NCT01104519|Experimental|1|Niaspan - Placebo
9951653|NCT01104519|Experimental|2|Placebo - Niaspan
9951654|NCT01104532|Experimental|Dosing Regimen 1|
9951655|NCT01104532|Experimental|Dosing Regimen 2|
9951656|NCT01104532|Experimental|Dosing Regimen 3|
10214954|NCT03558217|Experimental|Collared Femoral Implant|Participants will have the Corail collared femoral implant used during their surgery.
10214955|NCT03558217|Active Comparator|Collarless Femoral Implant|Participants will have the Corail collarless femoral implant used during their surgery.
9951657|NCT01104532|Experimental|Dosing Regimen 4|
9951658|NCT01104571|Other|Part 1: Control|No peri-operative therapy given
9951659|NCT01104571|Experimental|Part 1: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
9951660|NCT01104571|Experimental|Part 1: lapatinib|Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery
9951661|NCT01104571|Other|Part 2: Control|No peri-operative therapy
9951662|NCT01104571|Experimental|Part 2: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
9951663|NCT01104571|Experimental|Part 2: lapatinib-trastuzumab combination|Lapatinib 1000mg/day p.o. continuously for 28 days, in combination with trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery. Both drugs should start 11 days (+2 or -1 day) before the scheduled surgery.
9951664|NCT01104610|Active Comparator|NIV-PSV without Target Volume|Pressure Support Non Invasive Ventilation without Target Volume
9951665|NCT01104610|Active Comparator|NIV-PSV with Target Volume|Non Invasive Pressure Support Ventilation with Target Volume set
9951666|NCT01104610|Active Comparator|NIV-CPAP|Pressure Support Ventilation in CPAP mode
9951667|NCT01104623||ADHD - Patients|Adults (18-50 years old). All eligible subjects will experience the voice recording procedure followed by the assessment of adult ADHD diagnostics. The diagnostic guidelines for ADHD in adulthood will be accomplished as outlined by expert consensus of the German Society for Psychiatry, Psychotherapy and Neurology, with a semi-structured clinical interview following the DSM-IV-TR criteria and the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002) to assess the severity of ADHD-Symptoms. Childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002). To strengthen the validity of the ADHD diagnosis the reported symptoms were corroborated by second party reports.
9951668|NCT01104623||Healthy Controls|Adults(18-50 years old). All eligible subjects will experience the voice recording procedure followed by the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002. To assess the severity of Non-ADHD, the absence of childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002).
9951669|NCT01104649|Experimental|Riluzole|Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
9951670|NCT01104649|Placebo Comparator|Placebo comparator|Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
10214956|NCT03556293|Active Comparator|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
10214957|NCT03556293|Active Comparator|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
10214958|NCT03556293|Active Comparator|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
10214959|NCT03556293|Active Comparator|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
10214960|NCT03551665|Experimental|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
10214961|NCT03512210|Experimental|MINMON 24 weeks with SOF/VEL 12 Weeks|Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks
10214962|NCT03506412|Experimental|Low Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP levels less than or equal to 0.9 ng/ml
9951671|NCT01104675|Experimental|ENMD-2076 treatment|
9951672|NCT01104714||All patients|As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.
10005061|NCT01581762|Sham Comparator|Conventional 22G Needle|Device: EUS-FNA with conventional 22G Needle
10005062|NCT01581762|Active Comparator|22G Procore Needle|Device: EUS-FNA with 22G Procore Needle which has a reverse bevel at the tip of the needle to enhance tissue collection
9951673|NCT01104727|Active Comparator|Multi port|4-Ports Cholecystectomy (4PC): a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
9951674|NCT01104727|Active Comparator|Single port|"Single-Port Cholecystectomy (SPC): a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
9951675|NCT01104753||Non-interventional post-authorisation safety study|
10214963|NCT03506412|Experimental|High Serum Neprilysin (sNEP) levels|Subjects with baseline sNEP greater than or equal to 0.9 ng/ml
9951676|NCT01104805|Experimental|Therapeutic Education System (TES)|Participants randomized to this arm will replace approximately 2 hours of Standard Treatment with the Therapeutic Education System (TES) (comprised of a web-based version of the Community Reinforcement Approach and contingency management).
9951677|NCT01104805|Other|Treatment-as-Usual (TAU)|Participants randomized to TAU will receive standard treatment offered and prescribed, as usual, in the outpatient substance abuse treatment program.
9951678|NCT01104831|Placebo Comparator|21 degree Cooling|Room temperature water circulated through cryotherapy sleeve.
9951679|NCT01104831|Active Comparator|10 degree cooling|Cooled water circulated through a cryotherapy sleeve.
9951680|NCT01104844|Active Comparator|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
9951681|NCT01104844|Active Comparator|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
9951682|NCT01104844|Active Comparator|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
9951683|NCT01104844|Active Comparator|ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
9951684|NCT01104844|Active Comparator|Ibuprofen high dose|Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
9951685|NCT01104844|Placebo Comparator|placebo|2 Placebo tablets
9951686|NCT01104844|Experimental|Full Dose Strength|Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
9951687|NCT01104857|Experimental|Diaphragm muscle biopsy|Patients admitted to the ICU meeting severe sepsis / septic shock criteria
9951688|NCT01104857|Active Comparator|Elective laparotomy|
9951689|NCT01104883|Experimental|Adductor-Canal-Blockade|Adductor-Canal-Blockade with ropivacaine
9951690|NCT01104883|Placebo Comparator|Adductor-Canal-blockade with saline|Adductor-Canal-blockade with isotonic saline
10214964|NCT03502577|Experimental|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
10214965|NCT03493854|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
10214966|NCT03493854|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
10214967|NCT03422276|Active Comparator|Rehabilitation Discharge Plan|Commission on Accreditation of Rehabilitation Facilities (CARF) standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury, including patient and family education, written discharge care instructions, and telephone follow up from a clinical provider.
10214968|NCT03422276|Active Comparator|Rehabilitation Transition Plan|Approximately 12 scheduled contacts from a TBI care manager 6 months following discharge in addition to the CARF standards for discharge.
10214969|NCT03420768|Experimental|Part 1 BMS-986263 45mg weekly|
10214970|NCT03420768|Experimental|Part 1 BMS-986263 90mg weekly|
10214971|NCT03420768|Placebo Comparator|Part 1 Placebo weekly|
10214972|NCT03420768|Experimental|Part 2 BMS-986263 45mg every 2 weeks|
10214973|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 2 weeks|
10214974|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 4 weeks|
10214975|NCT03420768|Placebo Comparator|Part 2 Placebo every 2 weeks|
9951691|NCT01104896|Active Comparator|Nicotine|One or two 15mg nicotine patch(es) applied from 6am to 10pm according to the patients tobacco dependence measured by the Fagerström scale.
9951692|NCT01104896|Placebo Comparator|Placebo|One or two patch(es) with placebo
9951693|NCT01104909|Active Comparator|Clinical dry weight|Group which the dry weight will be assessed based on clinical examination.
9951694|NCT01104909|Active Comparator|Bioimpedance|Group which the dry weight will be assessed by bioimpedance data.
9951695|NCT01104935|Experimental|trastuzumab monotherapy|"H group (trastuzumab monotherapy group)~Trastuzumab: 1-year treatment~Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times"
9951696|NCT01104935|Active Comparator|trastuzumab and chemotherapy|"H+CT group (combination therapy of trastuzumab and chemotherapy)~Chemotherapy: 12 to 24 weeks~Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration."
9951697|NCT01104948|Experimental|DA-8031|
9951698|NCT01104948|Placebo Comparator|Placebo|
9951699|NCT01104961|Experimental|Contact Lens Packaging Solution #1|Test solution - contact lens packaging solution
9951700|NCT01104961|Experimental|Contact lens packaging solution #2|Test solution - contact lens packaging solution
9951701|NCT01104961|Placebo Comparator|Balanced salt solution|Control solution
9951702|NCT01104987||alendronate|A cross sectional study assessing the prevalence of osteoporosis and vertebral fractures in AS has been conducted during the spring in 2009. Patients with osteoporosis that fulfilled the inclusion criteria and did not have any exclusion criteria for the present trial were asked to join this study.
9951703|NCT01105013|Experimental|tonaftato|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
9951704|NCT01105026|Experimental|bioactive glass|
9951705|NCT01105039||lap. hernia repair|undergoing laparoscopic groin hernia repair
9951706|NCT01105052|Active Comparator|Bibliotherapy|A group receiving a self-help book to work on for six weeks with no therapist support.
9951707|NCT01105052|Experimental|Bibliotherapy with support|A group receiving a self-help book to work on for six weeks, together with brief weekly telephone calls (<15 minutes) from a therapist.
9951708|NCT01105052|No Intervention|Wait-list control group|This group receives no intervention until about five months after the two treatment groups, when participants in this group receive the self-help book without therapist support.
9951709|NCT01105078|Other|Flow rate|Comparison between a flow rate of 2.5/l/min/m2 versus 3.0/l/min/m2
9951710|NCT01105104|Other|MedMinder System|
9951711|NCT01105104|Other|MedMinder System - deactivated|
9951712|NCT01105143|Active Comparator|lifestyle intervention|Multimodal lifestyle intervention to reduce body weight
9951713|NCT01105143|Placebo Comparator|placebo|placebo
9951714|NCT01105156||Gastric Band Patients|
9951715|NCT01105169|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate.
9951716|NCT01105169|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
9951717|NCT01105169|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
9951718|NCT01105169|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
9951719|NCT01105182||Radiofrequency Ablation|
9951720|NCT01105195|Active Comparator|DuraPrep|
9951721|NCT01105195|Active Comparator|ChloraPrep|
9951722|NCT01105208|Experimental|Arm 1|
9951723|NCT01105208|Active Comparator|Arm 2|
9951724|NCT01105221|Experimental|Acupuncture|
9951725|NCT01105221|Active Comparator|Artificial tear drop|
9951726|NCT01105234|Experimental|Calcipotriol ointment|
9951727|NCT01105260||control|group with classical rehabilitation program
9951728|NCT01105260||training|group with an 8 weeks interval training program on wheelchair independence
9951729|NCT01105273|Experimental|HAPLO|
9951730|NCT01105286|Experimental|Calcipotriol ointment|
9951731|NCT01105338|Active Comparator|Green tea drink|Green tea drink
9951732|NCT01105338|Active Comparator|Green tea capsules|Green tea capsules
9951733|NCT01105338|Placebo Comparator|Green tea placebo capsules|Green tea placebo capsules
9951734|NCT01105338|Active Comparator|Lycopene capsules|Lycopene capsules
9951735|NCT01105338|Placebo Comparator|Lycopene placebo capsules|Lycopene placebo capsules
9951736|NCT01105338|Active Comparator|Tomato rich diet|Tomato rich diet
9951737|NCT01105351|Active Comparator|folic acid plus B6 and B12|folic 400 µg plus vitamin B12 plus B6
9951738|NCT01105351|Placebo Comparator|Folic acid|folic acid alone
9951739|NCT01105390|Experimental|Treatment (rilotumumab, cisplatin, pemetrexed disodium)|Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
9951740|NCT01105403|Experimental|CD34+ mobilisation for transplantation|
9951741|NCT01105416|Placebo Comparator|Enhanced Standard Care (ESC)|Standard emergency department care plus informational brochures
9951742|NCT01105416|Experimental|Brief Prevention Intervention (BPI)|Brief Prevention Intervention in the Pediatric ED
9951743|NCT01105429|Active Comparator|BMS-820132 (0.3 mg) or Placebo|
9951744|NCT01105429|Active Comparator|BMS-820132 (1.0 mg) or Placebo|
9951745|NCT01105429|Active Comparator|BMS-820132 (3 mg) or Placebo|
9951746|NCT01105429|Active Comparator|BMS-820132 (10 mg) or Placebo|
9951747|NCT01105429|Active Comparator|BMS-820132 (30 mg) or Placebo|
9951748|NCT01105429|Active Comparator|BMS-820132 (75 mg) or Placebo|
9951749|NCT01105429|Active Comparator|BMS-820132 (150 mg) or Placebo|
9951750|NCT01105429|Active Comparator|BMS-820132 (300 mg) or Placebo|
9951751|NCT01105429|Active Comparator|BMS-820132 (TBD) or Placebo|
9951752|NCT01105442||Bupivacaine|Patients who received bupivacaine + sufentanil
9951753|NCT01105442||Levobupivacaine|Patients who received levobupivacaine and morphine on demand
9951754|NCT01105455|Placebo Comparator|High fiber|High fiber carbohydrate foods with a high / medium glycemic index. Whole wheat bread and/or brown rice are provided to subjects if they wish. Subjects are provided with a list of other recommended carbohydrate foods.
9951755|NCT01105455|Active Comparator|Low GI|Carbohydrate foods with a low glycemic index. Low GI rice and whole grain bread provided to subjects if they wish. Subjects are provided with a list of recommended foods.
9951756|NCT01105468||Mamma Carcinoma, no treatment|
9951757|NCT01105468||Mamma Carcinoma, treatment|
9951758|NCT01105468||No Mamma Carcinoma diagnosed by X-ray|
9951759|NCT01105481|Experimental|amisulpride add-on|
9951760|NCT01105481|Placebo Comparator|placebo add-on|
9951761|NCT01105507|Experimental|canakinumab arm|
9951762|NCT01105520||intralspinal processes|Patients with intralspinal processes
9951763|NCT01105546|Experimental|prophylaxis|prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.
9951764|NCT01105546|Active Comparator|on demand treatment|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
9951765|NCT01105559||Group 1|Participants previously received 3 doses and a booster dose of the investigational vaccine DTaP IPV Hep B PRP-T.
9951766|NCT01105559||Group 2|Participants previously received 3 doses CombAct-Hib™ + Engerix™ B + OPV and a booster dose of CombAct-Hib™ + Oral poliovirus vaccine (OPV) vaccine.
9951767|NCT01105559||Group 3|Participants previously received 3 doses DTaP IPV Hep B PRP-T; a dose of Engerix™ B at birth, and a booster dose of DTaP IPV Hep B PRP-T vaccine.
9951768|NCT01105572|Experimental|Intel Home Health Guide|Participants in the intervention group will receive the use of the Intel Healthguide, an Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback when transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager. Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
9951769|NCT01105572|No Intervention|Case Management Only|All participants in the comparison group, are identified for outreach and assistance by a nurse case manager. Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
9951770|NCT01105585|Experimental|ZCB00 IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens (IOL) randomly assigned to one eye, with AcrySof Natural IQ (SN60WF) IOL in the fellow eye for contralateral implantation
9951771|NCT01105585|Active Comparator|SN60WF IOL|AcrySof Natural IQ (SN60WF) intraocular lens (IOL) randomly assigned to one eye, with Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens in the fellow eye for contralateral implantation
9951772|NCT01105598|Experimental|Cohort 1|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
9951773|NCT01105598|Experimental|Cohort 2|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
9951774|NCT01105598|Experimental|Cohort 3|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
9951775|NCT01105598|Experimental|Cohort 4|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
9951776|NCT01105598|Experimental|Cohort 5|Free-living subjects (18 active/6 placebo) with mild dyslipidemia
9951777|NCT01105611|Experimental|Raltegravir|Raltegravir in combination with Tenofovir/Emtricitabine
9951778|NCT01105611|Active Comparator|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
9951779|NCT01105637|Other|Exercise|
9951780|NCT01105663||Sedated, Intubated, Morphine|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
9802257|NCT05315687|Experimental|Arm I (systemic therapy, Y90 radioembolization)|Patients receive systemic therapy. Beginning 1-6 weeks after starting systemic therapy, patients also undergo Y90 radioembolization.
9951781|NCT01105663||Sedated, Intubated, Midazolam|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
9951782|NCT01105676|Experimental|single group single arm study|Open no masking is used. All involved know the identity of the intervention assignment
9951783|NCT01105715||Rheumatoid Arthritis (RA) Case Subjects|"Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA~Have currently active disease as assessed by Clinical Disease Activity Index (CDAI) score of >10~Have > or = 3 swollen joints"
9951784|NCT01105715||Control Subjects|"Age, sex, and 5-year age categories matched to cases~No historical diagnosis of RA and other primary autoimmune or inflammatory disorders"
9951785|NCT01105728|Experimental|Study arm|Endoscopic resection
9951786|NCT01105741||Active Crohn's disease - single arm|Active Crohn's disease, a decision is made to start treatment with adalimumab.
9951787|NCT01105780|Experimental|001|JNJ-41443532 250mg tablet once daily for 1 day
9951788|NCT01105780|Placebo Comparator|002|Placebo Matching placebo
9951789|NCT01105806||cardiopulmonary resuscitation (CPR) video|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative script in advance directive (AD) completion over a 1 month time frame post intervention.
9951790|NCT01105806||cardiopulmonary resuscitation (CPR) narrative script|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative in advance directive (AD) completion over a 1 month timeframe post intervention.
9951791|NCT01105819|Other|Standard oral care with chlorhexidine|The control group will receive a standard oral care. This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed
9951792|NCT01105819|Active Comparator|Lactobacillus plantarum 299|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
9951793|NCT01105832|Experimental|Proximal humeral fracture - intervention|20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
9951794|NCT01105832|No Intervention|Proximal humeral fracture|20 patients will receive standard treatment (physiotherapy)
9802258|NCT05315687|Active Comparator|Arm II (systemic therapy)|Patients receive systemic therapy.
9802259|NCT05315674||Exacerbators|Patients who experience ≥1 inpatient AECOPD
9951795|NCT01105871|Active Comparator|naloxone|4 mg in 10 ml saline iv bolus
9951796|NCT01105871|Placebo Comparator|saline placebo|10 ml of normal saline iv bolus
9951797|NCT01105897||Surgically treated endometriosis patients|Women scheduled for operation on suspected endometriosis in two study hospitals specialized in the surgical treatment of endometriosis between January 2005 - December 2007 (Päijät-Häme Central Hospital) and January 2008 - December 2008 (Helsinki University Hospital).
9951798|NCT01105910|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
9951799|NCT01105910|Active Comparator|Sensitive Eyes|Sensitive Eyes Eye Drops (Bausch & Lomb)
9951800|NCT01105923|Experimental|Receive CDS intervention|Providers in clinics that will receive the CDS alert, as their clinic was randomized into our study.
9951801|NCT01105923|No Intervention|No CDS intervention|
9951802|NCT01105949|Other|Marketed nasal strip|Marketed nasal strip
9951803|NCT01105949|Experimental|NexGen JB Organic PET/PE|NexGen JB Organic PET/PE, prototype nasal dilator strip
10214976|NCT03395288|Experimental|RCT treatment arm|Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
9802260|NCT05315674||Non-exacerbators|Patients without inpatient AECOPD
9802261|NCT05315661|Experimental|Treatment Arm|injected with 3x10^7 cells/2mL of ET-STEM to intraventricular space via an Ommaya reservoir. repeated 3 times at 4 week intervals
9802262|NCT05315648||General anesthesia group|Patients in GA group will receive general anesthesia combined with FNB. All patients received routine anesthesia and surgical protocols. GA will be induced by intravenously administering propofol 2-4 mg/kg, cisatracurium 0.2mg/kg, sufentanil 0.2-0.3 μg/kg and maintained with remifentanil at 0.15-0.2 μg/kg/min and 2%-3% sevoflurane to keep bispectral index (BIS) values at 40 - 60. All the blocks were performed after general anesthesia. The FNB will be performed under aseptic precautions using ultrasound guidance. Ultrasound probe will be placed on the inguinal crease to identify the femoral artery and nerve. Using an in-plane technique, a 10-cm long 18- gauge (G) Tuohy needle (Braun Medical, Melsungen, Germany) will be inserted in the lateral to medial direction towards the femoral nerve. Once the needle tip location was confirmed, 0.375% ropivacaine, 20 ml was injected after negative.
9951804|NCT01105949|Experimental|NexGen AB 2R11|NexGen AB 2R11
9951805|NCT01106001|Active Comparator|Levobupivacaine|Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children
9951806|NCT01106001|Placebo Comparator|Saline|Saline (also saline solution) is a general term referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water but is only sterile when it is placed intravenously, otherwise, a saline solution is a salt water solution.
9951807|NCT01106053|Experimental|Pramipexole|Open-label trial of pramipexole.
9951808|NCT01106066|Experimental|S-1/oxaliplatin/RT|Radiotherapy + 4 dose levels of oxaliplatin/S-1
9951809|NCT01106079|Experimental|Intensive management|
9951810|NCT01106079|Active Comparator|Standard management|
9951811|NCT01106105||control (Body Mass Index < 25)|
9951812|NCT01106105||Obese (Body Mass Index > 35)|
9951813|NCT01106118||Group 1|
9951814|NCT01106131|Experimental|CKD-501 0.5mg|
9951815|NCT01106131|Active Comparator|Pioglitazone 15mg|
9951816|NCT01106144||Acute myeloid leukemia|
9951817|NCT01106170|Experimental|Arm 1|Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
9951818|NCT01106170|Experimental|Arm 2|Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.
9951819|NCT01106183|Active Comparator|Transfer Factor|Transfer factor supplement; 2 capsules per day
10214977|NCT03395288|No Intervention|RCT control arm|Participants in this arm will not use any additional intervention.
9951820|NCT01106183|Placebo Comparator|Sugar pill|
9951821|NCT01106196||MI plus respiratory illness|Patients with an incident myocardial infarction who also have a record of a visit to primary care with a respiratory tract infection
9951822|NCT01106209||Prematurely born infants in the NICU|Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤1500 grams or <30 weeks gestational age at birth
9951823|NCT01106209||Healthy term infants|Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery
9951824|NCT01106209||Infants having surgery at <1 year old|Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life
10005063|NCT01581775|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
10005064|NCT01581775|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
10005065|NCT01581788|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
10005066|NCT01581788|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
10005067|NCT01581801|Other|Gastric Bypass|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo gastric bypass
10005068|NCT01581801|Other|Sleeve Gastrectomy|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo sleeve gastrectomy
10005069|NCT01581814|Active Comparator|Metformin|31 subjects were randomized to receive 500 mg Metformin per 3/die
10005070|NCT01581814|Active Comparator|0.03 mg EE plus 3 mg of DRPS|
10005071|NCT01581814|Active Comparator|Metformin plus Yasmin|
10005072|NCT01581827||Study population|People at high risk of heart failure (from SCREEN-HF study)
10005073|NCT01581853|Other|Lopinavir/ritonavir 800 mg / 200mg|Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
10005074|NCT01581866|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
10005075|NCT01581866|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
10005076|NCT01581879|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
10005077|NCT01581879|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
10005078|NCT01581892|Experimental|Bone marrow stem cells|Bone marrow is obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for mixing with osteogenic matrix.
10005079|NCT01581905|Active Comparator|LH Group|The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
10005080|NCT01581905|Active Comparator|RH Group|The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.
10005081|NCT01581944|No Intervention|No Treatment (Control)|Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.
10005082|NCT01581944|Experimental|2 Doses Goserelin|Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.
10005083|NCT01581944|Experimental|3 Doses Goserelin|Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).
10005084|NCT01581957|Active Comparator|Specific Enteral formulation|
10005085|NCT01581957|Placebo Comparator|Standard enteral formulation|
10005086|NCT01581983|Experimental|Internet Mindfulness Meditation|
10005087|NCT01581983|Experimental|Individual Mindfulness Meditation|
10005088|NCT01581996|Experimental|Lanthanum carbonate treatment|One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
10005089|NCT01582022|Experimental|local anesthetic|local anesthetic agent
10005090|NCT01582022|Placebo Comparator|normal saline|comparator
9951825|NCT01106235|Experimental|Treatment (immunostimulant, autologous lymphocytes, and chemo)|Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.
9951826|NCT01106261|Experimental|Pulmonary metastasectomy|Pulmonary metastasectomy
9951827|NCT01106261|Active Comparator|Active monitoring|Active monitoring
9951828|NCT01106300||Multi-organ failure|Sedated ventilated patients in multi-organ failure
9951829|NCT01106300||Single-organ failure|Sedated ventilated patients in single organ failure
9951830|NCT01106339||A|Patients with somatoform disorders due to DSM-IV
10214978|NCT03395288|Experimental|Observational arm|Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
10214979|NCT03389035|Experimental|CARCIK-CD19|
10214980|NCT03386708|Experimental|hUC-MSC intrauterine injection group|Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)
10214981|NCT03383770|Active Comparator|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A tuohy needle is used."
9951831|NCT01106365|Experimental|prefrontal cortex (PFC)|rTMS with the H-coil to the prefrontal cortex (PFC)
9951832|NCT01106365|Active Comparator|motor cortex|rTMS with the H-coil to the motor cortex
9951833|NCT01106365|Sham Comparator|sham treatment|sham treatment
9951834|NCT01106378||NEVO™ Sirolimus-eluting Coronary Stent System.|Subjects treated during routine clinical practice with the NEVO™ Sirolimus-eluting Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease.
9951835|NCT01106378||CYPHER Select® Plus Coronary Stent|Subjects treated during routine clinical practice with the CYPHER Select® Plus Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease
9951836|NCT01106417|Experimental|NeoFuse|"Anterior Cervical Discectomy and Fusion with NeoFuse.~NeoFuseTM is constituted of STRO-3 immunological selected allogeneic MPCs, which are derived from adult bone marrow mononucleated cells that are culture-expanded and subsequently cryopreserved.~The allogeneic MPCs are formulated in concentrations of nucleated cells in a 5 mL volume and are cryopreserved in 7.5% dimethyl sulfoxide (DMSO)/50% Alpha Modified Eagle's Medium (MEM) and 42.5% ProFreeze®. The final formulation consists of 0.15mL (approximately 10 million MPCs) of thawed NeoFuse™ thawed NeoFuseTM combined with the amount of MasterGraftTM Matrix to fill the PEEK cage per ACDF level."
9951837|NCT01106417|Active Comparator|MasterGraft Granules|"Anterior Cervical Discectomy and Fusion with MasterGraft Granules~MASTERGRAFT® GRANULES are a medical-grade, polyporous resorbable ceramic hybrid composed of 15% hydroxyapatite (HA) and 85% beta-tricalcium phosphate (β-TCP). The combination of these natural bone materials provides surgeons with an osteoconductive, porous implant that improves osteointegration by allowing cells to colonize throughout the implant and optimize the bone healing process"
9951838|NCT01106443|Active Comparator|Total Thyroidectomy - CLND|Total thyroidectomy without central lymph node dissection.
9951839|NCT01106443|Experimental|Total Thyroidectomy +CLND|Total thyroidectomy with central lymph node dissection.
9951840|NCT01106443|Experimental|Hemi-thyroidectomy + CLND|Hemi-thyroidectomy with central lymph node dissection.
9951841|NCT01106443|Active Comparator|Hemi-thyroidectomy - CLND|Hemi-thyroidectomy without central lymph node dissection.
9951842|NCT01106469|Experimental|001|JNJ-41443532 25mg tablet once daily
9951843|NCT01106469|Experimental|002|JNJ-41443532 100mg tablet once daily
9951844|NCT01106469|Experimental|003|JNJ-41443532 250mg tablet once daily
9951845|NCT01106469|Experimental|004|JNJ-41443532 500mg once daily (with 250mg tablets)
9951846|NCT01106469|Experimental|005|JNJ-41443532 1000mg once daily (with 250mg tablets)
9951847|NCT01106469|Experimental|006|JNJ-41443532 1500mg once daily (with 250mg tablets)
9951848|NCT01106469|Placebo Comparator|007|Placebo Matching placebo
9951849|NCT01106482|Active Comparator|Arm 1|
9951850|NCT01106482|Active Comparator|Arm 2|
9951851|NCT01106482|Active Comparator|Arm 3|
9951852|NCT01106482|Active Comparator|Arm 4|
9951853|NCT01106495|Experimental|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. Patients with subclinical atherosclerosis whose serum LDL high than 160mg/ml receive EECP 1- hour session every working day over a 7 week period. Simvastatin is used to decrease cholesterol level for 7 weeks.
9951854|NCT01106495|Active Comparator|Control|Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.
9951855|NCT01106508|Experimental|LEQ506|
9951856|NCT01106521|Experimental|PBSI|PBSI is a form of accelerated partial breast irradiation involving the insertion of 103-palladium stranded seeds under ultra-sound guidance and light sedation after CT planning in lieu of whole breast adjuvant radiotherapy.
9951857|NCT01106547|Experimental|Methylprednisolone|
9951858|NCT01106547|Placebo Comparator|placebo/sodium chloride|
9951859|NCT01106560|Active Comparator|Anterior Approach Group|(AMIS)
9951860|NCT01106560|Active Comparator|Posterior Approach Group|(Posterior)
9951861|NCT01106599|Experimental|A|
9951862|NCT01106612|Experimental|Initial coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
9951863|NCT01106612|Active Comparator|Initial nuclear stress test|Stress radionuclide myocardial perfusion imaging
9951864|NCT01106638|Experimental|Intensive behavioral intervention|Eight session, behavioral intervention targeting HIV-infected smokers
9951865|NCT01106638|Active Comparator|Standard care|Advice to quit, smoking cessation brochure, offer of nicotine patch
9951866|NCT01106664|Placebo Comparator|P|
9951867|NCT01106664|Experimental|E|
9951868|NCT01106703|Experimental|PG102 group|
9951869|NCT01106703|Placebo Comparator|placebo group|
9951870|NCT01106716|Placebo Comparator|A1: Placebo|Placebo
9951871|NCT01106716|Experimental|A2: KAI-1678|Experimental
9951872|NCT01106716|Active Comparator|A3: Lidocaine|Lidocaine
9951873|NCT01106729|Other|Cyanidin 3 glucoside|
9951874|NCT01106742|Experimental|AndoSan, UC|AndoSan as a supplement to 10 UC patents
9951875|NCT01106742|Experimental|AndoSan, CD|AndoSan as a supplement to 10 CD patients.
9951876|NCT01106755|Experimental|hemiparetic gait|gait training on ground level
9951877|NCT01106768||test cohort|Evaluation of oral health needs of children with attention deficit disorder with or without hyperactivity
9951878|NCT01106768||not disorder cohort|children without attention deficit disorder
9951879|NCT01106781||1|Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.
10214982|NCT03383770|Active Comparator|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A facet needle is used."
10214983|NCT03381274|Experimental|Arm A|MEDI9447 and osimertinib
10214984|NCT03381274|Experimental|Arm B|MEDI9447 and AZD4635
10214985|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
10214986|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
10214987|NCT03329599|Experimental|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
10214988|NCT03329599|No Intervention|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
10214989|NCT03327922|Experimental|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
10214990|NCT03327922|Experimental|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
10214991|NCT03291691||Standard of care: SCI|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided sciatic nerve block. N=15.
10214992|NCT03291691||Standard of care: FEM|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
10214993|NCT03291691||Standard of care: ISB|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided interscalene plexus block. N=15.
10214994|NCT03291691||Standard of care: AXP|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided axillary plexus block. N=15.
10214995|NCT03278665|Experimental|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
10214996|NCT03216109|Experimental|Weekly telephone symptom assessment|"Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Symptom assessments will be documented into an encrypted, HIPAA compliant digital platform which provides longitudinal symptom data management and also provides symptom assessment tools for the clinical team in their intervention strategies.~In addition, patients will complete symptom and quality of life surveys at 0, 3, 6 and 9 months."
9951880|NCT01106820|Active Comparator|Resistance training|
9951881|NCT01106820|Active Comparator|Relaxation training|
9951882|NCT01106872|Experimental|Treatment|Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma
9951883|NCT01106885|No Intervention|Enhanced Usual Care|"Adult patients with diabetes and depression.~Report screening results~Notify PCP of screening results (optional per patient)~PCP referrals~Educational materials regarding diabetes, physical activity, and depression"
9951884|NCT01106885|Experimental|Staged Care Management|Adult patients with diabetes and depression
9951885|NCT01106924|Experimental|Probiotic|daily probiotic consumption
9951886|NCT01106924|Placebo Comparator|Placebo|daily placebo consumption
9951887|NCT01106937||Patients with low Factor XIII|Postoperative occurence of pulmonary embolism in patients scheduled to undergo a neurosurgical procedure with laboratory-confirmed low levels of Factor XIII
9951888|NCT01106963||Tibial shaft fractures|Patients had tibial shaft fractures in the last 3 years. All were treated with intramedullary (IM) reamed nails with 2 or 3 interlocking screws.
9951889|NCT01107002|Experimental|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
9951890|NCT01107028||Rehab|Subjects randomized to the Rehab group will have data collected at baseline and then within one week enroll in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
9951891|NCT01107028||Wait|Subjects randomized to the Wait group will have data collected at baseline and wait eight weeks before enrolling in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
9951892|NCT01107041|Experimental|Mobilyze!|
9951893|NCT01107054|Experimental|PF-00610355 450 µg|An orally inhaled dose of PF-00610355 450 µg
9951894|NCT01107054|Experimental|PF-00610355 1200 µg|An orally inhaled dose of PF-00610355 1200 µg
9951895|NCT01107054|Active Comparator|moxifloxacin 400 mg|A single oral dose of moxifloxacin 400 mg on Day 4.
9951896|NCT01107054|Placebo Comparator|placebo|A single oral dose of non-matched placebo on Day 4.
9951897|NCT01107067|Experimental|testosterone replacement therapy|
9951898|NCT01107080||Degradation|30 mastectomy, partial mastectomy, and mammoplasty samples will be analyzed to define the effective post-excision time window in which the device must be used before the results can no longer be evaluated. The mammoplasty specimens are necessary to assess normal tissue outcomes.
9951899|NCT01107080||Reproducibility|25 Partial Mastectomy cases will be analyzed to distinguish between different implementation methods of the technology.
9951900|NCT01107093|Placebo Comparator|Placebo|
9951901|NCT01107093|Active Comparator|CDB-2914|
9951902|NCT01107106||Adolescents|250 postmenarcheal adolescent girls
9951903|NCT01107106||Adults|250 adult women
9951904|NCT01107119|Experimental|Integrated care pathway|"program for~communication and information flow aimed at collaboration between hospitals, general practitioners and home care services~systematic patient follow-up in home care services by using checklists"
9951905|NCT01107119|Active Comparator|usual care|usual care
9951906|NCT01107132||Diabetic Retinopathy|T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)
9951907|NCT01107145|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
9951908|NCT01107145|Experimental|Artemether-Lumefantrine|Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
9951909|NCT01107145|Active Comparator|Chloroquine|Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
9951910|NCT01107158||Group 1|Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
9951911|NCT01107158||Group 2|These patients have uterine dystocia
9951912|NCT01107171|Placebo Comparator|placebo|Tang-min Lin pills analogue
9951913|NCT01107171|Experimental|Tang-min-ling pills high dosage|Tang-min-ling pills, high dosage, 12g, tid po
9951914|NCT01107171|Experimental|Tang-min-ling pills low dosage|low dosage group:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
9951915|NCT01107184|Experimental|Preconditioning|The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
9951916|NCT01107184|Experimental|Postconditioning|The remote ischemic stimulus during cardiopulmonary bypass.
9951917|NCT01107184|Experimental|Pre and postconditioning|The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
9951918|NCT01107184|Sham Comparator|Control|
9951919|NCT01107210||stroke patients|50 patients recruited in the stroke rehabilitation unit in the University Hospital, Leuven, Belgium will be included
9951920|NCT01107223|Experimental|Training to antibiotic prescription|Physicians randomized in the education group attended a two days seminar focussed on evidence-based guidelines on antibiotic use in respiratory tract infections.
9951921|NCT01107223|Placebo Comparator|control|
9951922|NCT01107236|Experimental|IW-6118|
9951923|NCT01107236|Placebo Comparator|Placebo|
9951924|NCT01107236|Active Comparator|Naproxen Sodium|
9951925|NCT01107249|Other|BS Ultraflex or Wallstent stents|All subjects receive a stent of surgeons choice from selected stents.
10005091|NCT01582035|Experimental|Panel 1|TMC647055 in combination with TVR for 10 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
9951926|NCT01107262||Poultry exposed adults|This seroepidemiological study proposes to compare adults with occupational exposure to poultry with non-poultry exposed adult controls for evidence of previous infections with AI viruses.In this study, any person with occupational exposure to poultry i.e. works in poultry production facility or raises a smaller number of poultry on his/her farm will be considered exposed. The questionnaire used in this study will capture poultry exposure data through a group of variables assessing type of occupational setting, length of time of exposure, flock size, type of work performed, and personal protective equipment (PPE) used.
9802263|NCT05315648||Non-general anesthesia group|"Patients in NGA group will receive combined spinal-epidural anesthesia（CSEA）at L3 to L4 interspace with 3.0 ml of 0.5% hyperbaric ropivacaine followed with FNB , and without sedation. The FNB will be performed under aseptic precautions using ultrasound guidance. A high frequency linear ultrasound transducer 5-12 MHz (Sonosite, Inc. Bothell WA 98021 USA) was placed on the inguinal crease to identify the femoral artery and nerve. Using an in-plane technique, a 10-cm long 18- gauge (G) Tuohy needle will be inserted in the lateral to medial direction towards the femoral nerve. Once the needle tip location was confirmed, 0.375% ropivacaine, 20 ml was injected after negative.~If the two times of remedial analgesia are ineffective, change non-general anesthesia to general anesthesia, and the subjects withdrew from the trial."
9951927|NCT01107262||Poultry Non-exposed Adult Controls|Controls, adults who were never exposed to poultry, will be enrolled from urban areas such as the capital Beirut. Controls will be invited to volunteer by word of mouth at public/community sites.
9951928|NCT01107275|Experimental|2 primary ID doses|two doses of rabies vaccines given intradermally on days 0 and 28
9951929|NCT01107275|Experimental|3 primary ID doses|three doses of rabies vaccines given intradermally on days 0, 7, and 28
9951930|NCT01107288|Experimental|Intervention group|Randomized to receive the intervention first
9951931|NCT01107288|Other|Delayed intervention control group|Randomized to wait-list control first
9951932|NCT01107314||trauma patient|SBP less than 90mmHg
9951933|NCT01107340|Other|AMIStem Hip System|Patients who comply with the protocol and received an AMIStem femoral component.
9951934|NCT01107431|Active Comparator|Sucrose with Dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
9951935|NCT01107431|Active Comparator|Sucrose without Dietary Supplement|Consumed 70 grams of sucrose without simultaneously taking the dietary supplement
9951936|NCT01107470||Group A1|Age 18-34y (with short protocol)
9951937|NCT01107470||Group A2|age 35-42y ( with short protocol)
9951938|NCT01107470||Group B1|age 18-34y ( with long protocol)
9951939|NCT01107470||Group B2|age 35-42y ( with long protocol)
9951940|NCT01107483||AC group|asymptomatic carriers
9951941|NCT01107483||CH group|patients with chronic hepatitis
9951942|NCT01107483||HC group|patients with hepatic cirrhosis
9951943|NCT01107483||ACLF group|patients with acute on chronic liver failure
9951944|NCT01107483||healthy control|healthy volunteers
9951945|NCT01107509|Experimental|Neo-adjuvant everolimus|
9951946|NCT01107522|Experimental|Arm A|Single Agent CTO
9951947|NCT01107522|Experimental|Arm B|Combination CTO and Temodar®
9951948|NCT01107522|Experimental|Arm C|Combination CTO, Temodar®, Radiation therapy
9951949|NCT01107548|Experimental|Evidence-based treatment, lifestyle counseling|
9951950|NCT01107561|Experimental|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire.
9951951|NCT01107561|Active Comparator|Surgical airway approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
9951952|NCT01107574|Experimental|Gabapentin and Osteopathic Manipulative Medicine|6 weeks of both Gabapentin 900 mg HS given orally was accompanied with Osteopathic Manipulative Medicine treatment 30 minutes weekly to the tender points of the musculoskeletal system of each patient for 6 weeks.
9951953|NCT01107574|Experimental|Gabapentin|Gabapentin was given orally at 900 mg at HS weekly for 6 weeks.
9951954|NCT01107574|Experimental|Osteopathic Manipulative Medicine|6 weeks of Osteopathic Manipulative Medicine Treatment was applied to the patients tender points in the musculoskeletal system weekly by a 30 minute treatment.
9951955|NCT01107587|Experimental|HRV group|Subjects will receive GSK Biologicals' human rotavirus vaccine 444563.
9951956|NCT01107587|Placebo Comparator|Placebo Group|Subjects will receive placebo.
9951957|NCT01107600|Experimental|Nobel Active®|Immediate implant and socket preservation
9951958|NCT01107613|Experimental|Intervention Arm|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader letter sent to the primary care provider outlining the needs of this patient.
9951959|NCT01107613|No Intervention|Control/Standard Care|All patients will receive prednisone X 10 days and antibiotics X 5 days. This group will receive educational handouts on AECOPD.
9951960|NCT01107639|Experimental|Additional immunotherapy (cetuximab)|All patients in the experimental arm will be given additional immunotherapy (cetuximab) during cycles 1 and 2, during RT and after surgery.
9951961|NCT01107639|Active Comparator|Without additional immunotherapy|Standard therapy without immunotherapy (cetuximab).
9951962|NCT01107678|Experimental|YMCA PAN|YMCA PAN (Physical activity and nutrition)- Consists of organized physical activity and controlled serving sizes of healthy low fat snacks
9951963|NCT01107678|Experimental|YMCA Standard CAre|YMCA standard care - Follow the standard care of the YMCA after school Y-Care program for physical activity and nutrition
9951964|NCT01107691|Experimental|Resistance training|1 set of progressive resistance training per session
9951965|NCT01107691|Experimental|3 sets per session|3 sets of progressive resistance training per session
9951966|NCT01107691|No Intervention|Control|Non exercise control group
9951967|NCT01107704|Experimental|Family Support Intervention|
9951968|NCT01107704|No Intervention|Control Group|
9951969|NCT01107756|Experimental|TAXOTERE (Docetaxel) + GRANOGYTE 34 (Lenograstim)|Taxotere (Docetaxel) is given as background treatment and should be administered by the treating physician in accordance with the prescribing information outlined in the package insert + Granocyte 34 (lenograstim)
9951970|NCT01107769||VISIONAIRE™|Total knee arthroplasty with VISIONAIRE™ patient-matched cutting blocks
9951971|NCT01107769||Standard Instrumentation|Total knee arthroplasty with standard instrumentation
9951972|NCT01107782|Experimental|sildenafil|
9951973|NCT01107782|Placebo Comparator|Placebo control|
9951974|NCT01107808|No Intervention|Control|The adolescents randomized to Standard of care group will receive the medical and behavioral counseling regarding their obesity as a patient of the Children's Center for Weight Management (CCWM). They will not receive any pharmacological treatment for their vitamin D deficiency or insulin resistance. Calcium and vitamin D dietary intake will be determined using a specific food frequency questionnaire at each study visit for all groups. This will be used to determine effect of nutrition counseling.
9951975|NCT01107808|Experimental|Calcium and Vit D|The participants in the vitamin D/calcium group will receive standard of care through the CCWM along with the addition of treatment with ergocalciferol (vitamin D2) and calcium carbonate for their vitamin D deficiency. The vitamin D treatment will be 50,000 IU orally weekly for 8 weeks. This treatment regimen for vitamin D deficiency has been found to be safe to children and adolescents. 32 33The dose of calcium supplementation will be calcium carbonate orally 1200mg daily. This is the daily recommended intake of calcium for adolescents
9951976|NCT01107808|Experimental|Metformin/ Vit D|The participants randomized into the vitamin D/calcium/Metformin treatment group will receive standard of care through the CCWM in addition to treatment for their Vitamin D deficiency with the same doses of ergocalciferol (vitamin D2) and calcium carbonate as previously outlined. Additionally, these participants will receive Metformin ER to treat insulin resistance. The Metformin ER will be started at 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks).
9951977|NCT01107821|Experimental|Engenex™-pump|Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
10005092|NCT01582035|Experimental|Panel 2|TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
9951978|NCT01107860||Group I|
9951979|NCT01107860||Group II|
9951980|NCT01107873||duplex ultrasonography|conduct duplex ultrasonography after caudal block with sevoflurane anaesthesia in children
9951981|NCT01107938|Experimental|10 mg ilaprazole|
9951982|NCT01107938|Experimental|15 mg ilaprazole|
9951983|NCT01107938|Active Comparator|40 mg esomeprazole|
9951984|NCT01107951|Other|Rituximab -dexamethasone|only one arm receive four doses weekly rituximab and four dosis daily dexamethasona
9951985|NCT01107977|Experimental|Iyengar yoga|
9951986|NCT01107977|No Intervention|Waitlist control|
9951987|NCT01107990||Single right ventricles|
9951988|NCT01107990||Single left ventricles|
9951989|NCT01108029|Active Comparator|memantine|memantine 20 mg/day (2 tablets 1 time a day in the morning)
9951990|NCT01108029|Placebo Comparator|placebo|2 tablets (1 time a day in the morning) during 3 months
9951991|NCT01108042|Experimental|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
9951992|NCT01108055|Experimental|pazopanib + paclitaxel|"Cycle of 28 days. Pazopanib: 800mg daily~Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15"
9951993|NCT01108107|Other|Chemotherapy only|Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
9951994|NCT01108107|Other|Chemotherapy + biological treatment|Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.
9951995|NCT01108120|Experimental|continuous intra-femoral thrombolysis group|Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 ~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
9951996|NCT01108120|Experimental|conventional therapy group|Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
9951997|NCT01108133|Experimental|Hydrocortisone, fMRI, Intrusions|10 mg Hydrocortisone are administered one hour before the fMRI experiment. We use the script-driven imagery paradigm to induce intrusive memories during fMRI scanning.
9951998|NCT01108133|Experimental|Dexamethasone, fMRI, Intrusions|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment. (DEX-Test). We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning.
9951999|NCT01108133|Experimental|Placebo, fMRI, Intrusions|Placebo is administered one hour before the fMRI experiment. We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning in patients with posttraumatic stress disorder.
9952000|NCT01108146|Experimental|Arm 1|"Drug: Hydrocortisone 10 mg~Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d"
9952001|NCT01108146|Experimental|Arm 2|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
9802264|NCT05315635||Epidemiology|"Inpatients who initiate treatment for a substance use disorder (SUD) will have to complete self-questionnaires, a clinical psychiatric assessment (MINI) and a cognitive assessment (MoCA).~These participants will be assessed at admission in addiction unit and at discharge, 3 weeks after withdrawal.~Outpatients who begin treatment for an eating disorder (ED) will have to complete self-questionnaires and a clinical psychiatric assessment (MINI) at the beginning of the outpatient treatment program"
9802265|NCT05315622|Experimental|Intervention|Bilateral vertebral manipulation of the T12-L1 vertebra
9802266|NCT05315622|Placebo Comparator|Placebo|Application of slight manual tension to the vertebra without reaching a manipulation thrust
9952002|NCT01108172|Active Comparator|Usual Care|
9952003|NCT01108172|Experimental|Virtual Ward|
9952004|NCT01108198|Active Comparator|mometasone furoate cream|The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo
9952005|NCT01108198|Placebo Comparator|moisturizer|
10005093|NCT01582074||Cases|women with breast cancer
10005094|NCT01582074||Controls|Matched women without breast cancer
10005095|NCT01582113|Experimental|High Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
10005096|NCT01582113|Experimental|Low Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 250 mg of citicoline, of which they will be instructed to take 250 mg daily. This will be done in a double-blind, randomized fashion.
10005097|NCT01582113|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
10005098|NCT01582126|Experimental|Group balance training early start|
10005099|NCT01582126|Experimental|Group balance training late start|
10005100|NCT01582165|Active Comparator|Angina. IMR. Statin.|
10005101|NCT01582165|Placebo Comparator|Angina. IMR. Placebo.|
10005102|NCT01582191|Experimental|Treatment (vandetanib, everolimus)|Patients receive vandetanib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9952006|NCT01108211|Experimental|Treatment Group|This group will receive Vibration Therapy.
9952007|NCT01108211|No Intervention|Observation Group|This group does not receive Vibration Therapy
9952008|NCT01108224|Experimental|Psychosocial support|
9952009|NCT01108224|No Intervention|Control group|
9952010|NCT01108250|Experimental|polypoidal choroidal vasculopathy|patients with polypoidal choroidal vasculopathy
9952011|NCT01108250|Active Comparator|control|control group with no polypoidal choroidal vasculopathy
9952012|NCT01108289|Experimental|Oxytocin in Uniject|Community Health Officers will provide 10 IU Oxytocin in Uniject device IM immediately after delivery of baby
9952013|NCT01108289|No Intervention|PPH Treatment Only|Community Health Officers will be able to treat for PPH only, not provide Oxytocin in Uniject
9952014|NCT01108302|No Intervention|PPH Treatment only|Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject
9952015|NCT01108302|Experimental|Oxytocin in Uniject|Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery
9952016|NCT01108315|Experimental|Intervention|The participant used the web and/or phone-based PRO reporting symptoms to enter symptoms twice a week at minimum.
9952017|NCT01108315|No Intervention|Usual Care|The participants on this arm do not record their symptoms. They report symptoms as they would under usual care.
9952018|NCT01108328|Experimental|PolyGlycopleX (PGX)|5 grams of PGX 3 times per day with each main meal (breakfast, lunch and dinner)
10214997|NCT03216109|No Intervention|Control Arm|Patients randomized to usual clinical care will receive standard of care for thoracic malignancies as provided by the VA Palo Alto Health Care System. Patients will complete outcome surveys at 0, 3, 6, and 9 months.
10214998|NCT03198689|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use
9952019|NCT01108328|Placebo Comparator|Rice flour|5 grams of rice flour 3 times per day at each main meal (breakfast, lunch and dinner)
9952020|NCT01108354||ADHD patients|10 male adult ADHD patients and 10 female adult ADHD patients
9952021|NCT01108354||healthy controls|20 age- and sex-matched healthy volunteers
10214999|NCT03180307|Sham Comparator|no fluorescent imaging|Patient injected with OTL38, but does not undergo fluorescent imaging
10215000|NCT03180307|Experimental|near infrared imaging arm|Patient injected with OTL38 and undergoes near infrared imaging
9952022|NCT01108380|Experimental|1. CD34|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)~In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed."
9952023|NCT01108380|Active Comparator|2. Mononucelar cell|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed."
10215001|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
10215002|NCT03151083|Active Comparator|Phase 1: Implementation As Usual (Implementation Through Rese|SHUTi digital CBTi Program was implemented in VACT primary care using implementation activities executed by the research team between June 2017 and January 2018 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), Single Referral Pathway Not Integrated Primary Care Workflow (Primary care provider contact research team for patient referral over email).
10215003|NCT03151083|Experimental|Phase 2: Primary Care Coached Digital CBTi Implementation (Im|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams June 2018 and January 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a primary care nurse trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Single Referral Pathway Not Integrated Primary Care Workflow.
10215004|NCT03151083|Experimental|Phase 3: Primary Care Mental Health Collaborative Care Implem|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams April 2019 and November 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders, Patient Advertising/Information, patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a peer support specialist working on the primary care mental health collaborative care team, the digital CBTi coach was trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Additional members primary care mental health collaborative care team were educated to provide education about digital CBTi. Multiple referral pathways to digital CBTi: consults to the digital CBTi Coach, warm handoffs to primary care mental health collaborative care team. Digital CBTi coach consults integrated Primary Care Workflow.
10215005|NCT03144583|Experimental|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
10215006|NCT03121469|Experimental|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
10215007|NCT03089541|Experimental|Survey Arm|Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week
10215008|NCT03081897|Experimental|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
10215009|NCT03081897|Active Comparator|SPRANC Control group|General anaesthesia
9952024|NCT01108380|Other|3. Control|Without infusion of G-CSF, patients will be performed just right portal vein embolization
9952025|NCT01108393|Experimental|Agomelatine A|
9952026|NCT01108393|Placebo Comparator|Placebo|
9952027|NCT01108419|Active Comparator|1 = Test Product normal dose|Fermented dairy product containing probiotics - normal dose
9952028|NCT01108419|Active Comparator|2 = Test Product high dose|Fermented dairy product containing probiotics - high dose
9952029|NCT01108419|Sham Comparator|3 = Control Product normal dose|Non-fermented dairy product - normal dose
9952030|NCT01108419|Sham Comparator|4 = Control Product high dose|Non-fermented dairy product - high dose
9952031|NCT01108432|Experimental|Electronic Referrals|Dental practices randomized to the experimental group will have options on how to refer patients to the tobacco cessation website.
9952032|NCT01108432|No Intervention|Routine Referral|Dental practices in this arm will refer patients to the Decide2Quit website by using an information prescription.
9952033|NCT01108484|Experimental|Supervised exercise|Cardiorespiratory and resistance training
9952034|NCT01108484|Experimental|Exercise + diet counseling|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food)
9952035|NCT01108484|Experimental|Exercise + diet counseling + psycho support|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food) + Weekly sessions to modify the behaviour
9952036|NCT01108484|No Intervention|Control|They will keep their usual way of life
9952037|NCT01108536|Experimental|adaptive trans-tibial socket|subjects are fitted with experimental sockets.
9952038|NCT01108562|Placebo Comparator|Control Group|Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
9952039|NCT01108562|Experimental|Lidocaine Group|Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
9952040|NCT01108575|Experimental|Inspiratory muscle strength training|
9952041|NCT01108575|Sham Comparator|Sham Inspiratory muscle strength training|
9952042|NCT01108588|Experimental|Sequence 1|Aspirin - Clopidogrel - Placebo
9952043|NCT01108588|Experimental|Sequence 2|Clopidogrel - Placebo - Aspirin
9952044|NCT01108588|Experimental|Sequence 3|Placebo - Aspirin - Clopidogrel
9952045|NCT01108588|Experimental|Sequence 4|Aspirin - Placebo - Clopidogrel
9952046|NCT01108588|Experimental|Sequence 5|Clopidogrel - Aspirin - Placebo
9952047|NCT01108588|Experimental|Sequence 6|Placebo - Clopidogrel - Aspirin
9952048|NCT01108601|Other|Ringer's Lactate|Each patient will act as their own control with one ear receiving treatment, and the contralateral ear acting as control.
9952049|NCT01108614|Experimental|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
9952050|NCT01108614|No Intervention|Usual|Routine HIV prevention, including health education, counseling and testing, condom promotion.
9952051|NCT01108627|Active Comparator|corticosteroid + long acting beta agonist; steroids|
9952052|NCT01108627|Placebo Comparator|placebo + corticosteroid + long acting beta agonist; steroids|
9952053|NCT01108640||Elective surgical patients|
9952054|NCT01108640||Massive resuscitation patients|
9952055|NCT01108640||surgical patients on pressors|
9952056|NCT01108653|Other|Group 1: Usual care sick-leave management|
9952057|NCT01108653|Other|Group 2: Structuralised sick-leave program|
9952058|NCT01108679||Buprenorphine|Opioid-dependent drug users who are initiating buprenorphine treatment at the Albert Einstein College of Medicine Division of Substance Abuse (DoSA) or at Montefiore's Comprehensive Health Care Center (CHCC).
9952059|NCT01108692|Experimental|Active|Patients will be followed by telecardiology.
9952060|NCT01108692|Active Comparator|Control|Patients will be followed in the conventional manner. They will be equipped with telecardiology but data will not be used for patient surveillance.
9952061|NCT01108744|Active Comparator|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
9952062|NCT01108744|Active Comparator|Mannitol|20% mannitol, dosed by patient's ideal body weight
10215010|NCT03073941|Active Comparator|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
9952063|NCT01108770||HED affected males|
9952064|NCT01108770||Unaffected male controls|
10215011|NCT03073941|Active Comparator|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
10215012|NCT02961582|Experimental|Sacral Neuromodulation|
9952065|NCT01108783|Experimental|Bilastine|
9952066|NCT01108783|Active Comparator|Desloratadine|
10215013|NCT02961582|Other|Personalized Conservative Treatment|
9952067|NCT01108783|Placebo Comparator|Placebo|
9952068|NCT01108848||Berinert|Patients requiring treatment with Berinert®
9952069|NCT01108861|Experimental|Endoprosthesis|GORE VIABAHN® Endoprosthesis
9952070|NCT01108861|Active Comparator|Plain old balloon angioplasty|Plain old balloon angioplasty
9952071|NCT01108900||Patients with erectile dysfunction (ED)|100 ED patients in the study that were switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated
9952072|NCT01108913|Active Comparator|Bimosiamose|
9952073|NCT01108913|Placebo Comparator|Placebo|
9952074|NCT01108926|Experimental|All Subjects|All Subjects will receive the same intervention
9952075|NCT01108939|Experimental|Antimalarial treatment|
9952076|NCT01108939|Sham Comparator|Observation|
9952077|NCT01108965||Extraventricular Drainage|Includes hydrocephalus patients that are in recovery from shunt explanation.
9952078|NCT01108978|Placebo Comparator|Placebo|
9952079|NCT01108978|Active Comparator|Dehypotin|
9952080|NCT01108991|Active Comparator|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
9952081|NCT01108991|Experimental|Physical activity self-management|Cognitive behavioral counseling to increase lifestyle physical activity delivered over five months plus six weeks of COPD self-management education and usual care
9952082|NCT01109017||Norditropin®|
9952083|NCT01109030|Active Comparator|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
9952084|NCT01109030|Placebo Comparator|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks."
9952085|NCT01109082||Adolescents with idiopathic scoliosis|Adolescents with idiopathic scoliosis
9952086|NCT01109095|Experimental|HER.CAR CMV-specific CTLs|Subject will be assigned a dose level at study entry.
9952087|NCT01109121|Active Comparator|Allopurinol|Allopurinol
9952088|NCT01109121|Experimental|Combination 400|Tranilast and Allopurinol
9952089|NCT01109121|Experimental|Combination 600|Tranilast and Allopurinol
9952090|NCT01109134|Experimental|Tirofiban intracoronary bolus-only|Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion
9952091|NCT01109134|Active Comparator|Tirofiban intravenous bolus+infusion|Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion
9952092|NCT01109160|Experimental|Azithromycin|Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
9952093|NCT01109186||kidney-transplanted patients|
9952094|NCT01109199|Experimental|PolyGlycopleX (PGX)|
9952095|NCT01109199|Placebo Comparator|Rice Flour|
9952096|NCT01109212|Experimental|Bindarit|Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
9952097|NCT01109212|Placebo Comparator|Placebo|patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
9952098|NCT01109225|Experimental|Myocardial infarction|"All patients. Patients hospitalized for a first myocardial infarction with known shift of the segment ST revascularized in acute phase by primary angioplasty and dated less than 4 days.~Intervention:~blood sample~MRI~echocardiography~urine sample~pulmonary echography~vascular check~renal echography"
9952099|NCT01109251|Other|Intervention group|Group of patients presenting a non controlled AHT or a masked AHT, benefiting from an optimised caring at visit 0.
9952100|NCT01109251|Other|Control group|Patients presenting a non controlled AHT(persistent AHT, AHT necessiting an adaptation of the treatment by the generalist) with information of the generalist on the necessity of obtaining the tensional control according the HAS recommendations
9952101|NCT01109264|Experimental|Bendamustine Hydrochloride|
9952102|NCT01109264|Active Comparator|Chlorambucil|
9952103|NCT01109277||Healthy term and late-preterm neonates|
9952104|NCT01109290||HED children|
9952105|NCT01109290||HED adults|
9952106|NCT01109290||Control children|
9952107|NCT01109290||Control adults|
9952108|NCT01109303|Active Comparator|TightRope System|Patients are operated on using the TightRope implant by Arthrex.
9952109|NCT01109303|Active Comparator|Screw fixation implant|Patients are operated on using the rigid four-cortices 3,5 mm screw fixation by Synthes.
9952110|NCT01109329|Experimental|HMPV challenge virus|Participants will receive the HMPV challenge virus.
9952111|NCT01109342||Vaccine Recipients|Participants received HIV preventive vaccine VRC-HIV ADV014-00-VP in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
10215014|NCT02961465||Sacral Neuromodulation (SNM)|
10215015|NCT02952508|Experimental|Iopofosine I 131, intravenous administration WM|Iopofosine I 131 in Waldenstroms Macroglobulinemia
9952112|NCT01109342||Placebo Recipients|Participants received a placebo vaccine in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
9952113|NCT01109407||patients with MGUS or SMM|patients with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM)
10215016|NCT02952508|Experimental|Iopofosine I 131, intravenous administration MM|Iopofosine I 131 in Multiple Myeloma
10215017|NCT02952508|Experimental|Iopofosine I 131, intravenous administration CNS Lymphoma|Iopofosine I 131 in Central Nervous System Lymphoma
10215018|NCT02952508|Experimental|Iopofosine I 131 intravenous administration NHL [CLOSED]|Iopofosine I 131 in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma
10215019|NCT02948400|Experimental|Google Cardboard virtual environment|pedestrian safety training using the Google Cardboard device and delivery of a pedestrian virtual environment by mobile smartphone. Note that children in this arm will be trained using an immersive virtual environment delivered by smartphone, which is different from the other arm that is trained using a semi-immersive virtual environment delivered in a kiosk. The intervention is pedestrian safety training for both arms.
9952114|NCT01109446|Experimental|Platelet Rich Plasma|
9952115|NCT01109446|Sham Comparator|Isotonoic Saline Solution|
9952116|NCT01109446|Active Comparator|Steroid (Triamcinolonacetonid)|
9952117|NCT01109459|Experimental|Pediatric vision screening|intervention
9952118|NCT01109459|Active Comparator|Pediatric blood pressure screening|control
9952119|NCT01109459|No Intervention|Primary care providers observation only|Observational
9952120|NCT01109472|Experimental|Patient Tailored Magazine|Patient responses from computer assisted telephone interviews will be used to develop a patient tailored educational magazine.
9952121|NCT01109485|Experimental|Olopatadine|Olopatadine hydrochloride ophthalmic solution 0.1%
9952122|NCT01109498|Experimental|Dose cohort 3 x 10^11gc/kg|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
9952123|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
9952124|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X], 1xE12 gc/kg|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
9952125|NCT01109511|Active Comparator|oxycodone+naloxone|
9952126|NCT01109511|Active Comparator|Control|Oxycodone alone without naloxone
9952127|NCT01109537||RLS Diagnosis|
9952128|NCT01109537||Healthy Controls|
9952129|NCT01109550||with biliary candidiasis|Patients with positive fungal cultures of bile samples.
9952130|NCT01109550||without biliary candidiasis|Patients with negative fungal cultures of bile samples.
9952131|NCT01109563|Active Comparator|Computer Check-In Control|The Computer Check-In gives the participant contact with the research therapist, an assessment of marijuana use and the current impact of use, and a reminder about optional support sessions.
9952132|NCT01109563|Experimental|Marijuana Check-Ins|The MCI, a MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
10005103|NCT01582204|Experimental|124IcG250|This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
9952133|NCT01109589||Children aged 0-2 yrs|
10215020|NCT02948400|Active Comparator|semi-immersive virtual environment|pedestrian safety training using a semi-immersive virtual pedestrian environment kiosk. Note that children in this arm will be trained using a semi-immersive virtual environment delivered in a kiosk, which is different from the other arm that is trained using an immersive virtual environment delivered by smartphone. The intervention is pedestrian safety training for both arms.
10215021|NCT02937831||All Study Participants|
10215022|NCT02918565|Experimental|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
9952134|NCT01109589||Women aged 15-60 yrs|
9952135|NCT01109615|Experimental|Chemotherapy|
9952136|NCT01109628|Experimental|Protein drink|
9952137|NCT01109628|Placebo Comparator|Placebo drink|
9952138|NCT01109667||oral anticoagulant|Patients receiving and not receiving oral anticoagulant therapy.
9952139|NCT01109667||INR Level|Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range.
9952140|NCT01109680|Experimental|14 C labelled Neramexane, capsule|
9952141|NCT01109693|Active Comparator|Continue sertraline|Continue sertraline at the dosage at 3 weeks
9952142|NCT01109693|Active Comparator|Augment with mirtazapine|Add mirtazapine to sertraline
9952143|NCT01109693|Active Comparator|Switch to mirtazapine|Stop sertraline and switch to mirtazapine
9952144|NCT01109706||patient treated by statines|
9952145|NCT01109706||patient without normolipidemic treatment|
9802267|NCT05315609|Experimental|Intervention: Virtual Reality Mindfulness Group|The intervention will be 4-weeks, twice per week, 15-minute/session VR-mindfulness intervention group.
10005104|NCT01582217||SA + 5mg prasugrel|Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
10005105|NCT01582217||ASA + 10 mg prasugrel|Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
9952146|NCT01109732|Experimental|Systematic physical training|Hospital-based SET two days per week for 12 weeks and one home-based exercise session every week. The group-based SET was based on The Norwegian Ullevaal Model, a modified cardiac rehabilitation program, and was slightly adjusted to be applicable to this patient group. Each SET session lasted for 60 minutes and consisted of warm-up exercises, three high-intensity, two moderate-intensity and cool-down exercises, including stretching. The exercises were generally simple aerobic dance movements and walking and involved the use of both upper and lower extremities. The warm-up exercises included large muscle movements that were repeated later in the higher-intensity intervals, but with greater force and a larger range of movement.
9952147|NCT01109732|No Intervention|Treatment as of today|The control group did not receive any additional follow-up regarding exercise at discharge beyond the general advice about the importance of exercise that is routinely provided at the hospital.
9952148|NCT01109745|No Intervention|usual primary care|Number of participating children: 85
9952149|NCT01109745|Experimental|PELICAN Primary care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 85 children
9952150|NCT01109745|No Intervention|usual secondary care|number of participating children: 50
9952151|NCT01109745|Experimental|PELICAN Secondary Care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 50 children
9952152|NCT01109758|Experimental|1|
9952153|NCT01109771|Active Comparator|absorbable fixation left side|
9952154|NCT01109771|Active Comparator|absorbable fixation right side|
9952155|NCT01109784|Experimental|prasugrel|prasugrel per os 10mg/day
9952156|NCT01109784|Active Comparator|clopidogrel|clopidogrel per os 150mg/day
9952157|NCT01109797|Experimental|Transition Social Behavioral Intervention|
9952158|NCT01109797|Experimental|Diabetes Transition Clinic|
9952159|NCT01109823|Active Comparator|patients with normal renal function|Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
9952160|NCT01109823|Active Comparator|patients with hyperfiltration|Patients with hyperfiltration hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
9952161|NCT01109836|Experimental|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
9952162|NCT01109836|No Intervention|Control|Standard stroke care
9952163|NCT01109862|Experimental|THA|Total hip arthroplasty
9952164|NCT01109862|Active Comparator|HAP|Bipolar Hemiarthroplasty
9952165|NCT01109888|Active Comparator|Cetrotide|
9952166|NCT01109901|Other|anterior submuscular transposition|it is kind of surgical method
9952167|NCT01109901|Other|Anterior subcutaneous transposition|it is kind of surgical method
9952168|NCT01109914|Experimental|Renal transplant recipients (MMF)|"Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
10215023|NCT02918565|Experimental|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
10215024|NCT02918565|Experimental|Adaptive Goal Support (AGS)|10 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
10215025|NCT02918565|Experimental|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
10215026|NCT02918565|No Intervention|Control|12 weeks of text message assessments without any feedback
9952169|NCT01109914|Experimental|Renal transplant recipients (CNI)|"Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
10005106|NCT01582217||ASA + 75 mg clopidogrel daily|Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age >75; Wt< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
9952170|NCT01109914|Experimental|Healthy volunteers|"Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).~Intervention: vaccination with Dukoral"
9952171|NCT01109927|Experimental|Insulin treatment|Insulin given as soon as possible after diagnosis
9952172|NCT01109927|No Intervention|Conventional treatment|Diet, oral hypoglycemic agents and insulin first when clinically needed
10005107|NCT01582230|Experimental|Vildagliptin|Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
10005108|NCT01582230|Placebo Comparator|Placebo|Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
10215027|NCT02917213||StudyGroup|"A cohort of 92 patients with first ST elevation acute myocardial infarction (AMI), sinus rhythm, and LV ejection fraction < 45% in the first 24-72 h after symptoms onset.~In the first 24 hours after enrollment a coagulation blood test, a Doppler echocardiogram exam, a Carotid duplex ultrasound exam, a Transcranial Doppler monitoring and a Reveal LINQ insertable cardiac monitoring system will be 1:1 randomly implanted.~A clinical examination (including neuropsiquiatric evaluation), a Doppler echocardiogram exam, a cardiac MRI and a brain MRI will be performed after a week and after 6 months after enrollment."
10005109|NCT01582256||ASD+CNVs|
10005110|NCT01582256||ASD-CNVs|
10005111|NCT01582256||Unaffected siblings of ASD+CNVs|
10005112|NCT01582256||Unaffected siblings of ASD-CNVs|
10005113|NCT01582256||Neurotypicals for ASD+CNVs comparisons|
10005114|NCT01582256||Neurotypicals for ASD-CNVs comparisons|
10005115|NCT01582295|Experimental|Treatment Arm|Cabozantinib ( XL 184)
10005116|NCT01582321|Experimental|Part 1 Male|16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
10005117|NCT01582321|Experimental|Part 1 Female|16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
9952173|NCT01109953||Breath-Hold PET/CT image|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.
9952174|NCT01109966|Active Comparator|Amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
9952175|NCT01109966|Active Comparator|New amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
9952176|NCT01110018|Active Comparator|Period 1|20μg intravenous infusion administered over 30 minutes
9952177|NCT01110018|Active Comparator|Period 2|1000μg Oral dose
9952178|NCT01110018|Active Comparator|Period 3|50μg Intravenous infusion administered over 30 minutes
9952179|NCT01110018|Active Comparator|Period 4|1000μg Inhaled dose
9952180|NCT01110018|Active Comparator|Period 5|100μg Intravenous infusion administered over 30 minutes
9952181|NCT01110031|Experimental|Treatment|Six months treatmet with ofatumumab will be given to subjects with chronic lymphocytic leukemia.
9952182|NCT01110044|Experimental|Group A|Subjects will be administered 251154 vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
9952183|NCT01110044|Active Comparator|Group B|Subjects will be administered no vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
9952184|NCT01110057|Experimental|Active|GW856553
9952185|NCT01110057|Placebo Comparator|Placebo|Placebo
9952186|NCT01110070|Experimental|ChonDux plus microfracture|
9952187|NCT01110070|Active Comparator|Microfracture|
9952188|NCT01110083|Experimental|Arm 1|
9952189|NCT01110096|Experimental|Group A - family camp|Obese families participate in a two week camp with two years follow-up.
9952190|NCT01110096|Other|Group B - family lifestyle school|Families participate in a four day practical course about lifestyle.
9952191|NCT01110109||Continuous Suctioning|Anesthesia staff will suction secretions continuously at 20 mmHg with a safety stop of 5 seconds every 30 minutes.
9952192|NCT01110109||Intermittent Suctioning|Anesthesia staff will suction secretions intermittently using an intermittent suction regulator. The regulator will be set to suction at 100-150 mmHg. The regulator has a preset cycle of intermittent suctioning for 15 seconds with an 8 second pause.
9952193|NCT01110148|Experimental|Video-based informed consent|patients receiving informed consent through video format
9952194|NCT01110148|Active Comparator|traditional informed consent|patients receiving traditional informed consent from the physicians.
9952195|NCT01110161||Visceral fat mass|The study population will include Chinese adult men and women, over the age of 18 years. All subjects will be recruited at Fudan University. Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
9952196|NCT01110213|Experimental|Physical activity|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging leisure time physical activity. Content was based on goal setting theory and decisional balance.
9952197|NCT01110213|Experimental|Fruit and vegetable|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging fruit and vegetable intake. Content was based on goal setting theory and decisional balance.
9952198|NCT01110226|Experimental|Period 1: KML001 15mg plus Cisplatin 75mg/m2|KML001 15 mg orally daily days 1-14 with cisplatin IV on day1
9952199|NCT01110226|Experimental|Period 2: KML001 17.5mg plus Cisplatin 75mg/m2|KML001 17.5 mg orally daily days 1-14 with cisplatin IV on day1
9952200|NCT01110226|Experimental|Period 3: KML001 20mg plus Cisplatin 75mg/m2|KML001 20 mg orally daily days 1-14 with cisplatin IV on day1
9952201|NCT01110265|Placebo Comparator|placebo training|
9952202|NCT01110265|Experimental|attention training|
9952203|NCT01110278||Urge Incontinent Women|Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
9952204|NCT01110278||Control Women|Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.
9952205|NCT01110291||Breast cancer|Twenty patients with verified high risk breast cancer will be included in the study.
9952206|NCT01110304|Active Comparator|Conservative treatment|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed.
9952207|NCT01110304|Active Comparator|Surgical treatment|Patients will undergo surgery to treat their AC joint dislocation.
9952208|NCT01110317|Experimental|001|paliperidone palmitate 100 mg Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1 8 36 and 64.
9952209|NCT01110343|Active Comparator|mindfulness intervention group|Mindfulness intervention is a formatted curriculum based on Mindfulness based stress reduction techniques which have proven effective in reducing stress related to pain, everyday living and medical and psychiatric disorders.
10005118|NCT01582321|Experimental|Part 2 Male|12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
9476493|NCT03571230|Experimental|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
9476494|NCT03571230|Other|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
9476495|NCT03571230|Other|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics for rescue therapy: tetracycline 750mg bid and furazolidone 100mg bid for 14d."
9476496|NCT03571217||Diabetic retinopathy cohort|
9476497|NCT03571217||Mild visual impairment cohort|
9476498|NCT03571178|Experimental|Treatment|Patients who will receive physical therapy
9476499|NCT03571165|Experimental|Intervention|The intervention group received information on accessing My Tools 4 Care - In Care for 2 months.
9476500|NCT03571152|Experimental|Educational videos|Subjects allocated in this arms will receive the educational videos.
9476501|NCT03571139||Diabetics type 2 with and without diabetic retinopathy|Patients with diabetes mellitus type 2 with and without diabetic retinopathy who needs cataract surgery by phacoemulsification. All patients will undergo OCT angiography examination prior to their cataract surgery and 4 weeks after the cataract surgery.
9476502|NCT03571126|Placebo Comparator|Placebos group|"Patients will be administered with dexamethasone plus tropisetron from D1 to D3.~Patients will also be administrated with placebos from D1-D4"
9476503|NCT03571126|Experimental|Experimental group|Patients will receive a regimen with dexamethasone plus tropisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D4.
9476504|NCT03571113||Development|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
9476505|NCT03571113||Validation|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
9476506|NCT03571100|Active Comparator|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
9476507|NCT03571100|Active Comparator|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
9476508|NCT03571087|Experimental|HL140 5/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
9476509|NCT03571087|Experimental|HL140 10/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
9476510|NCT03571087|Experimental|HL140 20/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
9476511|NCT03571087|Experimental|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg~Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)"
9476512|NCT03571087|Experimental|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)"
9476513|NCT03571087|Experimental|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)"
9476514|NCT03571074||Hypoxia|"Defined as a group of patients with oxygen saturation <94 % irrespective of supplemental oxygen.~If COPD, defined as oxygen saturation <88 % irrespective of supplemental oxygen."
9476515|NCT03571074||Normoxia|"Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation >94 % without supplemental oxygen.~If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation >88 % without supplemental oxygen."
9476516|NCT03571074||Hyperoxia|"Defined as a group of patients with oxygen saturation >98 % in combination of supplemental oxygen.~If COPD, defined as oxygen saturation >92 % in combination of supplemental oxygen."
9476517|NCT03571061|Active Comparator|whole colon water immersion group|whole colon water immersion group: the air supply was turn off until the cecum was reached. For adequate lumen distention to advance the colonoscope tip, warm water which stored in 1L bottles and maintained 37°C with a water bath, was instilled intermittently into the colon through the auxiliary working channel of colonoscope using a footswitch-controlled flushing pump
9476518|NCT03571061|Experimental|sigmoid water immersion group|sigmoid water immersion group: air pump would be turned off and the procedure would be switched from water immersion method to air insufflation method after successful passage through the descending sigmoid junction.
9802268|NCT05315609|No Intervention|No intervention: Waitlist Control Group|These participants will be on a waitlist to receive the VR guided meditation program after data collection has been completed (after the 4 weeks)
9952210|NCT01110343|Active Comparator|conventional parent support group|a 6 week behavioral program, with weekly 1.5 hour sessions with a trained parent mentor, 3 monthly booster sessions and follow-up.
9952211|NCT01110356|Experimental|Ferinject|
9952212|NCT01110356|Placebo Comparator|Saline|
9952213|NCT01110369|Experimental|Resistance exercise training and protein drink|
9952214|NCT01110369|Placebo Comparator|Resistance exercise training and placebo drink|
9952215|NCT01110447|Experimental|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus.
9952216|NCT01110447|Placebo Comparator|Placebo|Placebo sachets contain corn starch
9952217|NCT01110473|Experimental|Monotherapy, once daily|
9952218|NCT01110473|Experimental|Monotherapy, twice daily|
9952219|NCT01110473|Experimental|Combination with Azacitidine|
9952220|NCT01110473|Experimental|IV monotherapy, once daily|
9952221|NCT01110486|Experimental|Monotherapy, once daily|
9952222|NCT01110486|Experimental|Combination with carboplatin|
9952223|NCT01110486|Experimental|Combination with docetaxel|
9952224|NCT01110486|Experimental|Monotherapy, twice daily|
9952225|NCT01110486|Experimental|IV Monotherapy, once daily|
9952226|NCT01110512|Experimental|Flavonid|
9952227|NCT01110512|Active Comparator|Daflon|
9952228|NCT01110525|Experimental|1|AZD1981 + Oral contraceptive
9952229|NCT01110525|Placebo Comparator|2|Placebo + Oral contraceptive
9952230|NCT01110551|Experimental|Group 2: low dose ; ID|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo intradermally on Days 0 and 90.
9952231|NCT01110551|Experimental|Group 1: low dose; SC|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo subcutaneously on Days 0 and 90.
9952232|NCT01110551|Experimental|Group 4: high dose; ID|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo intradermally on Days 0 and 90.
9952233|NCT01110551|Experimental|Group 3: high dose; SC|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo subcutaneously on Days 0 and 90.
9952234|NCT01110564||1|COPD patients
9952235|NCT01110577||Traveling cohort|Overweight patients with or without type 2 diabetes or pre-diabetes
9952236|NCT01110590|Experimental|Arm 1|
9952237|NCT01110590|Experimental|Arm 2|
9952238|NCT01110590|Experimental|Arm 3|
9952239|NCT01110590|Placebo Comparator|Arm 4|
9952240|NCT01110603|Experimental|MK-4827 + carboplatin|
9952241|NCT01110603|Experimental|MK-4827 + carboplatin/paclitaxel|
9952242|NCT01110603|Experimental|MK-4827 + carboplatin/liposomal doxorubicin|
9952243|NCT01110616|Experimental|Sequence 1|MK3134-Lorazepam-Placebo-MK3134-Lorazepam
9952244|NCT01110616|Experimental|Sequence 2|MK3134-Lorazepam-Placebo-Lorazepam-MK3134
9952245|NCT01110616|Experimental|Sequence 3|MK3134-Placebo-Lorazepam-MK3134-Lorazepam
9952246|NCT01110616|Experimental|Sequence 4|MK3134-Placebo-Lorazepam-Lorazepam-MK3134
9952247|NCT01110616|Experimental|Sequence 5|Lorazepam-Placebo-MK3134-MK3134-Lorazepam
9952248|NCT01110616|Experimental|Sequence 6|Lorazepam-Placebo-MK3134-Lorazepam-MK3134
9952249|NCT01110616|Experimental|Sequence 7|Lorazepam-MK3134-Placebo-MK3134-Lorazepam
9952250|NCT01110616|Experimental|Sequence 8|Lorazepam-MK3134-Placebo-Lorazepam-MK3134
9952251|NCT01110616|Experimental|Sequence 9|Placebo-MK3134-Lorazepam-MK3134-Lorazepam
9952252|NCT01110616|Experimental|Sequence 10|Placebo-MK3134-Lorazepam-Lorazepam-MK3134
9952253|NCT01110616|Experimental|Sequence 11|Placebo-Lorazepam-MK3134-MK3134-Lorazepam
9952254|NCT01110616|Experimental|Sequence 12|Placebo-Lorazepam-MK3134-Lorazepam-MK3134
9952255|NCT01110629|Experimental|Arm 1|
9952256|NCT01110629|Placebo Comparator|Arm 2|
9952257|NCT01110642|Experimental|Lovastatin solution|All patients will receive lovastatin solution
9952258|NCT01110655|Experimental|Intravenous hypertonic saline|
9952259|NCT01110655|Experimental|Oral hypertonic saline|
9952260|NCT01110668|Experimental|Nilotinib|
9952261|NCT01110720|Experimental|Davunetide 30 mg BID|
9952262|NCT01110720|Placebo Comparator|Placebo|
9952263|NCT01110759||Under Local Infiltration|
9952264|NCT01110759||Under Peripheral Nerve Block|
9952265|NCT01110772|Experimental|2-octyl cyanoacrylate|As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
9952266|NCT01110772|Active Comparator|iodine povacrylex in isopropyl alcohol|Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
9952267|NCT01110811|Active Comparator|TIF procedure|Transoral Incisionless Fundoplication (TIF)
9952268|NCT01110811|Sham Comparator|Sham procedure|The intervention on the Sham procedure consisted of an upper gastrointestinal endoscopy, or EGD.(esophagogastricduodenoscopy).
9952269|NCT01110824|Experimental|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
9952270|NCT01110824|No Intervention|Control|Control arm without intervention
9952271|NCT01110837|Active Comparator|Allergen|
9952272|NCT01110837|Placebo Comparator|Placebo|
9952273|NCT01110850||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
9952274|NCT01110863||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
9952275|NCT01110928||Norditropin®|
9952276|NCT01110941|Experimental|SOL|single arm
9952277|NCT01110954|Active Comparator|PD L 506 2nd dose|Different dosage
9952278|NCT01110954|Experimental|PD L 506|
9952279|NCT01110980|Experimental|Swallowing therapy|Swallowing therapy in combination with individual dietary counselling
9952280|NCT01110980|Active Comparator|Individual dietary counselling|Swallowing therapy only on indication. (usual care)
9952281|NCT01111019|Experimental|r-hGH (Saizen®)|
9952282|NCT01111032||Treadmill test|
9952283|NCT01111045|Active Comparator|Arm 1|0.03 mg/ml BMP-7, single intraarticular knee injection
9952284|NCT01111045|Active Comparator|Arm 2|0.1 mg/ml BMP-7, single intraarticular knee injection
9952285|NCT01111045|Active Comparator|Arm 3|0.3 mg/ml BMP-7, single intraarticular knee injection
9952286|NCT01111045|Placebo Comparator|Arm 4|1 ml placebo, single intraarticular knee injection (control)
9952287|NCT01111071||STEMI|patients with discharge diagnosis of ST elevation myocardial infarction
9952288|NCT01111071||nSTEMI|patients with discharge diagnosis of non ST elevation myocardial infarction
9952289|NCT01111071||unstable angina|patients with discharge diagnosis of unstable angina
9952290|NCT01111097|Active Comparator|Cohort 1|Subjects are given a dose of Dichloroacetate 4mg/kg twice a day for 30 days
9952291|NCT01111097|Active Comparator|Cohort 2|Subjects are given a dose of Dichloroacetate 12.5mg/kg twice a day for 30 days
9952292|NCT01111136|Experimental|stress intervention|Stress intervention.
9952293|NCT01111188|Experimental|all subjects|Subjects will receive PD 0332991 plus bortezomib. The dose of each agent will be dependent on the time point the subject enters the trial.
9952294|NCT01111201||questionnaires|There will be four versions of the questionnaire, each slightly modified to be more specific toward the treatment paradigms in the respective target patient population (Breast Cancer/ Lymphoma/Autologous Bone Marrow Transplant/ Allogeneic Bone Marrow Transplant). All questionnaire versions will consist of seven sections.
9952295|NCT01111214||group 1|Hospitalized children ≤14 years of age with invasive pneumococcal disease
9952296|NCT01111253|Active Comparator|Conservative strategy with antibiotics|"Hospital admission~Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration~Adequate pain relief~Oral intake as tolerated~Daily monitoring"
9952297|NCT01111253|No Intervention|Liberal strategy without antibiotics|"Admission only if discharge criteria are not met~No initial antibiotics~Intravenous fluids only for those not tolerating oral liquids~Adequate pain relief~Oral intake as tolerated~Daily monitoring when admitted to the hospital~Self-monitoring at home (Patient diary with temperature and VAS pain score until full recovery)"
9952298|NCT01111279|Placebo Comparator|Placebo|
9952299|NCT01111279|Experimental|gpASIT+TM|
9952300|NCT01111279|Experimental|gpASIT+TM/adjuvant|
9952301|NCT01111344|Experimental|Glizigen + Viusid|
9952302|NCT01111344|Placebo Comparator|Placebo|
9952303|NCT01111396||Patient with ALL under chemotherapy|This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.
9952304|NCT01111409|Experimental|VFIX|
9952305|NCT01111422|No Intervention|Control|Age and sex matched peritoneal dialysis patients
9952306|NCT01111422|Experimental|N-acetylcysteine|N-acetylcysteine in stable peritoneal dialysis patients
9952307|NCT01111435||Individuals with Multiple Sclerosis|
9952308|NCT01111448|Experimental|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle
9952309|NCT01111487|Active Comparator|Group I|This group will use a pressure level of 10 cmH2O.
9952310|NCT01111487|Active Comparator|Group II|This group will use a pressure level of 15 cmH2O.
9952311|NCT01111500|Active Comparator|external rotation immobilization|Patient will wear an external rotation brace to immobilize the injured arm.
9952312|NCT01111500|Active Comparator|internal rotation immobilization|Patient will wear an internal rotation brace to immobilize the injured arm.
9952313|NCT01111513|Active Comparator|Continuous femoral block|Patients receive a continuous femoral block for 48 hours and they have patient controlled analgesics.
9952314|NCT01111513|Active Comparator|Single dose femoral block|Patients receive a single dose femoral block and have patient controlled analgesics.
9952315|NCT01111513|Active Comparator|Patient controlled analgesics|Patients do not receive a femoral block. They only have patient controlled analgesics.
9952316|NCT01111578||New enteral feeding tube|
9952317|NCT01111591|No Intervention|2. Bile duct cancer - control|Bile duct cancer patients do not administration of COX inhibitor
9952318|NCT01111591|Experimental|3. Pancreas cancer - experimental|Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
9952319|NCT01111591|No Intervention|4. Pancreas cancer - control|Pancreas cancer patients do not administration of COX inhibitor
9952320|NCT01111591|Experimental|Bile duct cancer - experimental|Bile duct cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
9952321|NCT01111617|Experimental|Real-Time fMRI|Real-Time fMRI
9952322|NCT01111630|Experimental|once weekly|
9952323|NCT01111630|Active Comparator|three times weekly|
10215028|NCT02902757|Experimental|Treatment (FDG PET/CT)|Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
9952324|NCT01111643||I|
10215029|NCT02780206|Experimental|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
10215030|NCT02756702||All-Poly|All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components
9952325|NCT01111656|Active Comparator|1|Interferon beta-1b 250ug subcutaneously every other day
9952326|NCT01111656|Experimental|2|Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
9952327|NCT01111669|Experimental|Tranexamic Acid|Patients in the tranexamic acid (TA) group will receive a bolus of TA, prepared according to patient weight (15mg / kg loading dose). The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation for the duration of the operation.
9952328|NCT01111669|Placebo Comparator|Normal Saline|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution as the intervention group. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of normal saline for the duration of the operation.
9952329|NCT01111682|Active Comparator|Mannitol|0.9% normal saline infusion and boluses of mannitol
9952330|NCT01111682|Active Comparator|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
9952331|NCT01111695|Experimental|Honey and ionic silver dressing|
9952332|NCT01111708|Experimental|Close Rectal-Ileo Pouch Anal Anastomosis|
9952333|NCT01111708|Active Comparator|Conventional Ileo Pouch Anal Anastomosis|
9952334|NCT01111708|Active Comparator|Ileo Neo Rectal Anastomosis|
9952335|NCT01111721|Experimental|Project POWER Intervention Group|Intervention group participants will attend the Project POWER intervention sessions, complete a pre-intervention assessment and participate in 3, 6, and 12 month follow-up interviews when they will be asked to provide urine specimens for STI testing. The intervention consists of eight bi-weekly, 1.5 hour sessions. Intervention group participants will also attend one booster group session four weeks after the intervention before being released. Intervention participants will receive booster phone calls from a nurse-interventionist at 2, 6, and 10 weeks after release from prison. Booster phone calls will reinforce intervention content and support participant efforts to reduce risky sex behaviors and make healthy choices.
9952336|NCT01111721|Active Comparator|NC DOC Standard of Care for STIs|Control group participants will receive the North Carolina Department of Correction standard of care for Sexually Transmitted Infections, complete one interview in prison and participate in 3, 6, and 12 month follow up interviews when they will be asked to provide urine specimens for STI testing.
9952337|NCT01111734|Experimental|Treatment Group|The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
9952338|NCT01111734|Experimental|Control|40 healthy age-matched peers with undergo the same baseline testing as the NAC subjects as well as baseline fMRI. They will not engage in any follow up visits.
9952339|NCT01111747|Experimental|PRP|In this group PRP will be used in the patellar tendon donor site.
9952340|NCT01111747|Sham Comparator|Control|In this group PRP will not be aded to the patellar tendon donor site
9952341|NCT01111799|Experimental|Clomiphene citrate + IUI + endometrial biopsy|Clomiphene citrate + IUI + endometrial biopsy
9952342|NCT01111799|No Intervention|Clomiphene citrate + IUI|
9952343|NCT01111799|Experimental|gonadotrophines + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
9952344|NCT01111799|No Intervention|gonadotrophines + IUI|
9952345|NCT01111799|Experimental|natural cycle + IUI + endometrail biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
9952346|NCT01111799|No Intervention|natural cycle + IUI|
9952347|NCT01111812||weight measurements|This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center.
10005119|NCT01582321|Experimental|Part 2 Female|12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
10005120|NCT01582360||antiinfectiva: vancomycin|80 patients Completed.
9952348|NCT01111864|Experimental|MixMe powder (iron & micronutrients)|
9952349|NCT01111864|Placebo Comparator|MixMe powder (micronutrients, no iron)|
9952350|NCT01111864|Experimental|Sprinkles (iron and micronutrients)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Iron 12.5 mg; Zinc 5 mg
9952351|NCT01111864|Placebo Comparator|Sprinkles (micronutrients, no iron)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Zinc 5 mg
9952352|NCT01111890|Experimental|Azarga|Azarga (brinzolamide 1% / timolol 0.5%)
9952353|NCT01111890|Active Comparator|Cosopt|Cosopt (dorzolamide 2% / timolol 0.5%)
9952354|NCT01111903|Experimental|lenalidomide|Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
9802269|NCT05315583|Other|Group with collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
9802270|NCT05315557|Experimental|Terlipressin|Terlipressin 1mg/24 hours
9802271|NCT05315557|Active Comparator|Vasopressin|Vasopressin 0.03 U/hour
9952355|NCT01111929|Active Comparator|Counseling for LAM|"Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.~Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires."
9952356|NCT01111929|Experimental|Counseling for LAM+ LNG-EC|LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills
9952357|NCT01111942|Active Comparator|radiation and weekly carboplatin|
9952358|NCT01111942|Other|conservation surgery|
9952359|NCT01111968|Experimental|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
9952360|NCT01111968|Experimental|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
9952361|NCT01111968|Experimental|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
9952362|NCT01111968|Experimental|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
9952363|NCT01111968|Experimental|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
9952364|NCT01111968|Experimental|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
9952365|NCT01111968|Experimental|pandemic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
9476519|NCT03571061|Placebo Comparator|carbon dioxide (CO2) insufflation|carbon dioxide (CO2) insufflation group: carbon dioxide (CO2) was insufflated through out the whole procedure for advancement and inspection when needed.
9476520|NCT03571048|Active Comparator|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
9802272|NCT05315544|Experimental|CSI pVAD|
9802273|NCT05315531|Experimental|Water Intake|3-week intervention period during which articipants will be asked to increase their daily plain water consumption to at least 2.5 L/d of water for males and 2L/d for females.
9952366|NCT01111968|Experimental|pandemic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
9952367|NCT01111968|Experimental|pandemic vaccine 13|15µg of A/H1N1 with no adjuvant
9952368|NCT01111968|Placebo Comparator|placebo group 14|placebo
9802274|NCT05315518|Experimental|single shade universal resin composite (omnichroma) with blocker|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
9952369|NCT01112007||prehypertension|Subjects with prehypertension, that is, individuals with systolic blood pressure in the range of 120-139 mmHg or diastolic BP between 80-89 mmHg.
9952370|NCT01112020|Experimental|CHG Catheter Dressing Patch|
9952371|NCT01112020|Active Comparator|Biopatch|Biopatch Protective Disk with CHG
9952372|NCT01112020|Active Comparator|Tegaderm CHG|Tegaderm CHG IV Securement Dressing
9952373|NCT01112033||chronic HCV infection|The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
9952374|NCT01112046|Experimental|Endoscopic submucosal dissection|
9952375|NCT01112046|Active Comparator|Laparoscopic resection|
9952376|NCT01112085|Experimental|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
9952377|NCT01112085|Experimental|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
9952378|NCT01112098|Experimental|Educational Pamphlet and letter|Letter invites patient to self-schedule a DXA; educational pamphlet includes information about DXA scans
9952379|NCT01112111||75 PCOS Patients - step up regime|Group A will be comprised of 75 patients and these will receive a low dose step stimulation regime
9952380|NCT01112111||75 PCOS patients -step down regime|Group B will be comprised of 75 patients who will receive a step down regime of stimulation
9952381|NCT01112111||75 PCOS patients - sequential regime|Group C will be comprised of 75 patients who will be treated using a sequential stimulation regime
9952382|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (600 mg, bolus)|
9952383|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (75 mg daily)|
9952384|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (600 mg, bolus)|
9952385|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (75 mg, daily)|
9952386|NCT01112150|Active Comparator|Pumping group|Patients in this arm will get a pumping session 2-3 times a day .
9952387|NCT01112150|Active Comparator|No pumping|These patients will not receive pumping but only classical treatment clinically indicated (diuretics, oxygen, Digoxin, Nitrates, ACE inhibitors etc, as necessary)
9952388|NCT01112163|Experimental|Enhanced external counter pulsation|One session of enhanced external counter pulsation (60 minutes)
9952389|NCT01112189|Experimental|Patients with stem cells|Patients that receive the stem cells treatment
9952390|NCT01112189|Active Comparator|Compressed sleeve treatment|Patients that will receive the compressed sleeve treatment
9952391|NCT01112215|Active Comparator|azathioprine|
9952392|NCT01112215|Active Comparator|Enteric-coated Mycophenolate Sodium|
9952393|NCT01112254|Experimental|MRI±biopsy|a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI ± biopsy results.
9952394|NCT01112254|No Intervention|Standard care|The patients will be operated without additional exams
9952395|NCT01112280|Experimental|cap-assisted chromoendoscopy|To the tip of the colonoscope, transparent cap is fitted and applied. In addition, panchromoendoscopy using indigocarmine solution is preformed in this group.
9952396|NCT01112280|No Intervention|Standard colonoscopy|Neither transparent cap nor chromoendoscopy is applied in this group and standard colonoscopy is performed.
9952397|NCT01112319|Experimental|Elf_care|The trial group will receive with Elf_Care unit (Hot-Cold & Electrotherapy) during physiotherapy treatment ( 28 minutes twice a week)
9952398|NCT01112319|Active Comparator|control group|The control group will receive before physiotherapy COLD HOT or Electrotherapy treatment depends on the patient and physiotherapy prefer.
9952399|NCT01112371|Experimental|Contractubex|
9952400|NCT01112371|No Intervention|Non treatment|
9952401|NCT01112384|Experimental|SB939|
9952402|NCT01112397|Experimental|1|AZD1480 until Maximum Tolerated Dose (MTD) is reached
9952403|NCT01112397|Experimental|2|AZD1480 dose expansion of MTD
9952404|NCT01112436|Placebo Comparator|control group (group C)|control group will receive no medication preoperatively and during operation
9952405|NCT01112436|Active Comparator|periarticular injecion group (group I)|patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
9952406|NCT01112449|Experimental|Low dose selenized-yeast|200 µg/day of selenized-yeast (SY)
9952407|NCT01112449|Experimental|selenomethionine|The second group will receive 200 µg/day of selenomethionine (SM)
9952408|NCT01112449|Placebo Comparator|Placebo|no active medication.
9952409|NCT01112449|Experimental|High dose selenized-yeast|The fourth group will receive 285 µg/day of selenized-yeast (SY).
9952410|NCT01112462|Experimental|Tablet|Paracetamol 500 mg/Phenylephrine 5 mg tablet
9952411|NCT01112462|Active Comparator|Sachet|Paracetamol 1000 mg/Phenylephrine 10 mg sachet
9952412|NCT01112488|No Intervention|Control|usual care
9952413|NCT01112488|Experimental|multidisciplinary intervention|Patient engagement Programme
9952414|NCT01112540|Placebo Comparator|Placebo Group|
9952415|NCT01112540|Experimental|Morphine|
9952416|NCT01112553||Treximet|All migraine subjects will receive Treximet during a migraine episode at Visit 2.
9952417|NCT01112605||otherwise healthy persons|healthy persons, no major trauma or surgery of ankle or calves, no bone or muscle disease, age 18-60
9952418|NCT01112631||Stage II patients post surgery|Stage II patients treated with surgery alone
9952419|NCT01112631||Stage III patients post surgery|Stage III patients treated with surgery and PORT
9952420|NCT01112644|Experimental|OXN PR|Different daily doses; intake every 12 hours
9952421|NCT01112644|Placebo Comparator|PLA|Different daily doses; intake every 12 hours
9952422|NCT01112709|Experimental|SCT|This arm is a long-term, Social Cognitive Theory (SCT)-based intervention, emphasizing self-regulation and other SCT strategies to optimize training, with faded contact.
9952423|NCT01112709|Active Comparator|Control|"This arm will be the control condition; a Standard intervention with minimal contact."
9952424|NCT01112722|Active Comparator|Apitox, purified honeybee toxin, injections|active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'
9952425|NCT01112722|Placebo Comparator|histamine injection|the histamine injection produces a similar local effect of pain and erythema as the active drug
9952426|NCT01112761|Experimental|Healthy Subjects|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
9802275|NCT05315518|Active Comparator|single shade universal resin composite(GC solare sculpt) with chameleon effect|One-shade universal resin composite (GC solare sculpt) gives very natural appearance, High gloss retention over time, time saving regarding to layering technique, wide shade matching range (chameleon effect) and delivering lifelike aesthetic restorations. These features can be offered by supra-nano spherical filler which have controlled refractive index, records excellent esthetic properties in small and medium class IV restorations.
9952427|NCT01112761|Experimental|Athletes with history of concussion|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
9952428|NCT01112774|Experimental|tDCS/Spinal cord injury|Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
9952429|NCT01112774|Experimental|tDCS/Healthy subjects|Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
9952430|NCT01112787|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene Foam 0.1%,
9952431|NCT01112787|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam.
9952432|NCT01112787|Active Comparator|Sodium Laural Sulfate|Subjects will be exposed to patches containing Sodium Laural Sulfate.
9952433|NCT01112787|Placebo Comparator|Distilled Water|Subjects will be exposed to patches containing Distilled Water.
9952434|NCT01112800||Participants|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH) between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT, rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375 mg/m2.
9952435|NCT01112813|Experimental|Lithium|Lithium Carbonate, 0.4-0.8 mmol/L for 2 months
9802276|NCT05315505|Experimental|Home-based pulmonary rehabilitation|"Participants will undergo an initial respiratory rehabilitation program for 8 weeks, which may be in a home or hospital context, according to clinical criteria defined in the technical guidance of the general health department 14/2019 - Pulmonary Rehabilitation Programs in Primary Health Care.~At the end of the 8 weeks, the groups will be randomly divided, with one part receiving the maintenance respiratory rehabilitation program."
9802277|NCT05315505|Active Comparator|Usual care|"Participants will undergo an initial respiratory rehabilitation program for 8 weeks, which may be in a home or hospital context, according to clinical criteria defined in the technical guidance of the general health department 14/2019 - Pulmonary Rehabilitation Programs in Primary Health Care.~At the end of the 8 weeks, the groups will be randomly divided, with one part receiving the usual care."
9802278|NCT05315492|Experimental|Intervention communes|CCC intervention
9802279|NCT05315492|No Intervention|Control communes|Standard care
9802280|NCT05315479|Experimental|N1539|N1539 (Meloxicam IV) 0.6 mg/kg (maximum 30 mg) Q24H
9802281|NCT05315466|Experimental|Non-surgical treatment|Different types of non-surgical treatments
9802282|NCT05315466|Experimental|Surgical treatment|Surgical treatment for spinal stenosis
9802283|NCT05315453|Experimental|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention administered over telehealth
9952436|NCT01112826|Experimental|Capecitabine|Capecitabine 650 mg/m2 bid
9952437|NCT01112826|No Intervention|Standard treatment|Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
9952438|NCT01112839|Active Comparator|Less Intensive Group|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
9952439|NCT01112839|Experimental|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
9952440|NCT01112852|Active Comparator|EVL + vasoconstrictor|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
9952441|NCT01112852|Experimental|EVL + PPI|Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5
9952442|NCT01112878|Placebo Comparator|Sugar Pill|"Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
9952443|NCT01112878|Active Comparator|Clonidine|"Dosage: 0.2 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
9952444|NCT01112878|Active Comparator|Gabapentin|"Dosage: 600 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
9952445|NCT01112891|Experimental|1|
9952446|NCT01112891|Experimental|2|
9952447|NCT01112891|Experimental|3|
9952448|NCT01112943|Experimental|Acupuncture|Acupuncture on predefined points once a week for 20 minutes over the seven week pulmonary rehabilitation course
9952449|NCT01112943|Active Comparator|Pulmonary Rehabilitation|A seven week exercise and educational class run twice a week using international guidelines.
9952450|NCT01112943|No Intervention|Control|Three assessments over the same time frame of three months but without intervention
9952451|NCT01112956||STD clinic patients|Patients attending sexually transmitted Disease clinics. If the initial testing result reported to the patient is confirmed by the Western Blot test, no follow-up specimens will be collected. If the initial testing result reported to the patient is different from the result by the Western Blot test, patients will be asked to provide a follow-up specimen 3-4 months after initial testing.
9952452|NCT01112956||Pregnant women|Women recruited from prenatal clinic. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
9952453|NCT01112956||Men who have Sex with men (MSM)|Men recruited from a clinic for MSM with high risk for HIV infection. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
9952454|NCT01112969|Experimental|Internet-based supportive coaching OSCAR|Arm 1: Internet-based supportive coaching OSCAR
9952455|NCT01112969|Other|Waiting list control group (treatment as usual, TAU)|
9952456|NCT01112995|Experimental|Probiotic|subjects will be given a pill formulation of a probiotic Lactobacillus rhamnosus to be taken once a day.
9952457|NCT01112995|Placebo Comparator|Sugar pill|placebo identical to the active product will be given
9952458|NCT01113021|Experimental|LLLT and Physical Strength training in Humans|
9952459|NCT01113034|Active Comparator|DAS181 Dry Powder 10 mg qd x 3 days|
9952460|NCT01113034|Placebo Comparator|Lactose Placebo|
9952461|NCT01113047|Experimental|Non responder Olmesartan/Amlodipine|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
9952462|NCT01113060||CAD patients|Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
9952463|NCT01113073|Experimental|Elective open heart surgery|Patients who had undergone elective open heart surgery
9802284|NCT05315440|Active Comparator|control group|"The treatment of control group will be organized according to the classic protocol currently in use in our Institute which consists of:~30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation."
9802285|NCT05315440|Experimental|experimental group|30 minutes of passive and active assisted mobilization guided by the therapist associated with instrument assisted soft tissue mobilization, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
9802286|NCT05315427||Evaluation of the impact of music therapy on the pain of patients|One music therapy session
9952464|NCT01113086|Experimental|Left active anodal DLPFC|We will place the anodal electrode on the left dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
9952465|NCT01113086|Experimental|Right active anodal DLPFC|We will place the anodal electrode on the right dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
9952466|NCT01113086|Placebo Comparator|Sham tDCS|Sham tDCS: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds.
9952467|NCT01113086|Other|Open-Label Arm|In addition to this study we will have an open label arm in which subjects who received sham stimulation through the course of the study will have the opportunity to receive active stimulation free of charge. The same parameters and identical procedures as is done in the original study will be used. Data will be collected as an open label, which will therefore provide additional information. Data obtained from this open label portion of the study will be kept separate.
9952468|NCT01113099|Experimental|Academic detailing of physicians|
9952469|NCT01113099|No Intervention|Usual care|
9952470|NCT01113112||Biobehavioral factors|Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
9952471|NCT01113125|Experimental|Fucicort|
9952472|NCT01113125|Placebo Comparator|Fucidin|
9952473|NCT01113138|No Intervention|Baseline|
9952474|NCT01113138|Active Comparator|Mablet|
9952475|NCT01113138|Active Comparator|Magnesium sulfate|
9952476|NCT01113151|No Intervention|Washout|
9952477|NCT01113151|Active Comparator|Mablet|
9952478|NCT01113151|Placebo Comparator|Placebo|
9952479|NCT01113164|Experimental|Ondansetron, Placebo, Sertraline|LL-carriers receiving ondansetron compared to either placebo or sertraline, will result in a significant reduction in alcohol consumption.
9952480|NCT01113164|Experimental|Sertraline, Placebo, Ondansetron|SL and SS-carriers receiving sertraline compared to either placebo or ondansetron, will result in a significant reduction in alcohol consumption.
10005121|NCT01582360||antiinfectiva: meropenem|80 patients recruiting
10215031|NCT02703493|Experimental|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
9952481|NCT01113177||Distraction splint therapy|All JIA patients with asymmetric mandibular growth due to unilateral TMJ arthritis are offered non-surgical functional orthodontic splint therapy with a distraction splint. Mandibular growth is thereafter evaluated in the affected side compared with the mandibular growth in the healthy side of the same individual.
9952482|NCT01113190|Active Comparator|CBI in ED with AMET at 3 months|computer-delivered brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
9952483|NCT01113190|Active Comparator|CBI in ED with EUC at 3 months|computer-delivered brief intervention (CBI) at baseline with enhanced usual care-EUC at 3 months
9952484|NCT01113190|Active Comparator|IBI in ED with AMET at 3 months|intervener-delivered brief intervention (IBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
9952485|NCT01113190|Active Comparator|IBI in ED with EUC at 3 months|intervener-delivered brief intervention (IBI) at baseline with enhanced usual care-EUC at 3 months
9952486|NCT01113190|Active Comparator|EUC in ED with AMET at 3 months|enhanced usual care (EUC) at baseline with adapted motivational enhancement therapy-AMET at 3 months
9952487|NCT01113190|Active Comparator|EUC in ED with EUC at 3 months|enhanced usual care (EUC) at baseline with EUC at 3 months
9952488|NCT01113203|Experimental|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
9952489|NCT01113229|Experimental|Misoprostol|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two misoprostol tablets taken orally (400µg) following cord clamp
9952490|NCT01113229|Placebo Comparator|PLACEBO|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two placebo tablets taken orally following cord clamp.
9952491|NCT01113242||A:|Patients with idiopathic PD and with MMSE < à 26
9952492|NCT01113242||B:|Patients with idiopathic PD and with MMSE ≥ à 26
9952493|NCT01113255|Active Comparator|CHRONIC REPIRATORY FAILURE|
10215032|NCT02678403|Experimental|1 - TENS group|The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
9952494|NCT01113255|Active Comparator|ACUTE RESPIRATORY FAILURE|
9952495|NCT01113268|Other|1:cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
9952496|NCT01113281|Experimental|VPM1002 in three dosages|
9952497|NCT01113281|Active Comparator|BCG|
9952498|NCT01113294|Experimental|ablation|
9952499|NCT01113307||Hard to heal wounds|
9952500|NCT01113320|Placebo Comparator|Placebo|
10215033|NCT02678403|Sham Comparator|2 - SHAM group|SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
10215034|NCT02668822|Experimental|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
10215035|NCT02668822|Placebo Comparator|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
10215036|NCT02668783|Experimental|ENG-E2 125 μg/300 μg|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
10215037|NCT02668783|Placebo Comparator|Placebo|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of placebo. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
10215038|NCT02652923|Experimental|Part 1 - volunteers|Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.
10215039|NCT02652923|Experimental|Part 2 - patients|Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.
10215040|NCT02648061||After cardiac arrest syndrome (ACAS)|adult patients after out-of-hospital cardiac arrest
10215041|NCT02616146|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
10215042|NCT02616146|Active Comparator|LNG-EE 150 μg/30 μg|Participants will receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle will consist of one tablet per day for 21 days, followed a 7-day tablet-free interval.
10215043|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
10215044|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
10215045|NCT02538510|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10215046|NCT02524288|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9952501|NCT01113320|Active Comparator|Safinamide|
9952502|NCT01113333|Experimental|SAR113945|SAR113945, single dose according to dose escalation design
9952503|NCT01113333|Placebo Comparator|Placebo|0.9% saline solution, single dose
9952504|NCT01113346|Experimental|Filtrum-STI|
9952505|NCT01113346|Placebo Comparator|Placebo|
9952506|NCT01113359||study group|hypertensive patients
9952507|NCT01113359||control group|healthy volunteer
9952508|NCT01113372|Experimental|Clopidogrel 3 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 3 months.
9952509|NCT01113372|Active Comparator|Clopidogrel 12 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 12 months.
9952510|NCT01113411|Active Comparator|Intensive Rehabilitation|
9952511|NCT01113411|Active Comparator|Standard Rehabilitation|
9802287|NCT05315414|Experimental|Single tooth restorations|A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.
9802288|NCT05315401|Experimental|Probiotic 9 log CFU/day|The intervention consists of daily administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
9802289|NCT05315401|Placebo Comparator|Placebo|placebo contains primarily carrier and without probiotic. The placebo are identical in taste and appearance and appear as a light-yellow powder.
9952512|NCT01113424|Experimental|NRT-2|2 mg single-dose of a new NRT product
9952513|NCT01113424|Active Comparator|GUM-2|2 mg single-dose of a marketed nicotine gum
9952514|NCT01113424|Experimental|NRT-4|4 mg single-dose of a new NRT product
9952515|NCT01113424|Active Comparator|GUM-4|4 mg single-dose of marketed nicotine gum
9952516|NCT01113437|Experimental|Omalizumab|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
10005122|NCT01582360||antiinfectiva: flukonazol|80 patients
9802290|NCT05315401|Experimental|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week
9802291|NCT05315388|No Intervention|Group 1. Regular therapy group|Group without intervention during the study period no changes will be made in their daily routine. They will receive a weekly intervention operationalized for psychosocial risk.
9952517|NCT01113437|Placebo Comparator|Placebo|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
10005123|NCT01582360||antiinfectiva: cefotaxim|80 patients
10005124|NCT01582360||antiinfectiva: benzylpenicilline|80 patients
10005125|NCT01582360||antiinfectiva: tazobactam piperacillin|80 patients recruiting
10005126|NCT01582360||antiinfectiva: cloxacillin|80 patients
10005127|NCT01582360||antiinfectiva: ciprofloxacin|80 patients
10005128|NCT01582373|Experimental|Cognitive-behavioral couple therapy|The goals of CBCT are to enable participants to: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of their sexual functioning, reduce their sexual distress and increase their sexual satisfaction; (5) consolidate skills.
10005129|NCT01582399|Experimental|Arm A: ASKP1240 intravenous (IV) infusion|
10005130|NCT01582399|Experimental|Arm B: ASKP1240 subcutaneous (SC)|
10005131|NCT01582412|Experimental|Isavuconazole and digoxin|Isavuconazole three times per day (TID) on Days 15 and 16, and once daily (QD) on Days 17 thru 26. Digoxin single dose on Days 1 and 19.
10005132|NCT01582425|Experimental|Isavuconazole and methadone|Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
10005133|NCT01582464||Older Adults in a Senior Community|Residents of a Continuing Care Retirement Community (CCRC) that is a part of The Be Group (previously known as Southern California Presbyterian Homes), with no exclusion other than being able to communicate in English and provide consent to participate.
10005134|NCT01582516|Experimental|Delta24-RGD|Intracerebral slow continuous infusion of study drug in increasing dose
10005135|NCT01582542|Experimental|Desmopressin|
10005136|NCT01582555|Experimental|saline irrigation|a control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation;
10005137|NCT01582555|Experimental|intervention arm (group B),|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
9952518|NCT01113489|Experimental|beclomethasone dipropionate suspension for nebulization|
9952519|NCT01113489|Placebo Comparator|placebo|
9952520|NCT01113515|Placebo Comparator|Placebo|Placebo gel
9952521|NCT01113515|Experimental|Galnobax 20% QD|Esmolol Hydrochloride (Galnobax) 20% gel once daily
9952522|NCT01113515|Experimental|Galnobax 20% BID|Esmolol Hydrochloride (Galnobax) 20% gel twice daily
9952523|NCT01113515|Experimental|Galnobax 14% BID|Esmolol Hydrochloride (Galnobax) 14% gel twice daily
9952524|NCT01113528|Experimental|Regenerative therapy|
9952525|NCT01113528|Placebo Comparator|Sugar pill|
9952526|NCT01113554|Experimental|Arm I|Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
9952527|NCT01113567|Placebo Comparator|Diet and lactose-free milk|Lactose-free milk
9952528|NCT01113567|Active Comparator|Diet and whole milk|Whole milk with lactose
9952529|NCT01113606|Active Comparator|Obagi Nu-Derm System (ONDS)|
9952530|NCT01113606|Active Comparator|Standard of Care|
9952531|NCT01113619|Experimental|RP-G28|Study Drug RP-G28
9952532|NCT01113619|Placebo Comparator|Placebo|Study Drug Placebo
9952533|NCT01113645||Cerebral perfusion evaluation|All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores. Hemodynamic monitoring by CT perfusion scan, as well as by trans-cranial Doppler.
9952534|NCT01113658|Experimental|SNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
9952535|NCT01113671|Placebo Comparator|Placebo|
9952536|NCT01113671|Experimental|d-alpha-tocopheryl acetate|
9952537|NCT01113697||Clinical Investigator Collaborative (CIC) Asthma study cohort|Participants will be healthy volunteer research subjects with allergic asthma who will have an allergen inhalation challenge at CIC sites across Canada.
9952538|NCT01113697||Western Red Cedar Asthma study cohort|Participants will be volunteer research subjects with Western Red Cedar asthma, who will have a plicatic acid inhalation challenge at The Lung Centre at Vancouver General Hospital.
9952539|NCT01113697||Environmental Exposure Unit (EEU), Kingston General Hospital|Subjects will be over 19 years of age so that they qualify for studies involving allergen challenge.
9952540|NCT01113736|Experimental|Human Peritoneal Membrane: AlloMEM™|For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
9952541|NCT01113762|Experimental|resurfacing|a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint
9952542|NCT01113762|Experimental|large head THA|a standard stemmed THA but with a large metal head, and a metal-metal articulation
9952543|NCT01113762|Active Comparator|28 mm ceramics-polyethylene|a standard 28 mm head uncemented THA
9952544|NCT01113762|Active Comparator|28 mm metal-polyethylene THA|a standard stemmed uncemented THA
9952545|NCT01113775||presence of right ventricle dysfunction|
9952546|NCT01113775||absence of right ventricle dysfunction|
9952547|NCT01113788||imaging|imaging with usual catheter/fluoroscopy, no cartosound
9952548|NCT01113827|Active Comparator|150mg olive extract|
9952549|NCT01113827|Active Comparator|50mg olive extract|
9952550|NCT01113827|Placebo Comparator|Placebo control|
9952551|NCT01113840|Placebo Comparator|Control|Control group continues with their daily activity as they were prior to randomization. Receive bi-weekly follow-up phone calls to assess health status and encourage adherence with protocol.
9952552|NCT01113840|Active Comparator|Exercise|Exercise classes three times per week in a controlled, supervised environment.
9952553|NCT01113866||heart failure|
10215047|NCT02504203|Active Comparator|Intervention: BCG and OPV at home visits|Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
9952554|NCT01113905||Radiation Only|
9952555|NCT01113905||Radiation and Chemotherapy|
9952556|NCT01113918||Obsity PCOS Women|"Polycystic ovary syndrome (PCOS) was diagnosed according to the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM) case definition which requires presentation of signs and/or symptoms of a minimum of 2 of the following 3 criteria: polycystic ovary morphology (PCOM), oligomenorrhea or amenorrhea (Oligo-An), androgen excess (HA).~Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m2). Obesity was defined as BMI≥25 kg/m2, according to the Asia-Pacific definition."
10215048|NCT02504203|No Intervention|Control: No vaccines at home visits|For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.
10215049|NCT02489942||Jardiance|Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg
10215050|NCT02482532|Experimental|tvs-CTL Vaccine|Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
9952557|NCT01113918||Non-obesity PCOS Women|The subjects BMI were less than ≥25 kg/m2 and out of criteria of PCOS by European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM).
10215051|NCT02477644|Experimental|Olaparib|Tablets per os 300 mg
10215052|NCT02477644|Placebo Comparator|Placebo|Tablets per os 300 mg
10215053|NCT02466321|Experimental|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
10215054|NCT02465398|Other|Fracture device|Patient were treated with an Anatomical Shoulder Fracture device.
10215055|NCT02438904|Experimental|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
9952558|NCT01113944|Active Comparator|Program 1|Program 1
9952559|NCT01113944|Active Comparator|Program 2|Program 2
10035215|NCT01803984||Patient with migraine with aura|Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
10215056|NCT02420860|Experimental|Treatment (elotuzumab, lenalidomide)|Patients receive elotuzumab IV over 2-4 hours on days 1, 8, 15, and 21 of courses 1-2 and on day 1 of each subsequent course. Patients also receive lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9476521|NCT03571048|Experimental|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
9476522|NCT03571035|Experimental|Example|Mandibular movements recordings by a mono vision system.
10215057|NCT02420613|Experimental|Arm I (vorinostat, radiation therapy, temsirolimus)|"CHEMORADIOTHERAPY PHASE: Patients receive vorinostat QD and undergo radiation therapy QD for 30 fractions over 6-7 weeks.~MAINTENANCE PHASE: Four to six weeks after the completion of radiation therapy, patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity."
9952560|NCT01113970|Experimental|Single Arm|open label, single arm, unblinded
9952561|NCT01113996|No Intervention|Standard treatment - usual care|
9952562|NCT01113996|Experimental|Protein supplementation|
9952563|NCT01113996|Experimental|Protein supplementation and strength training|
9952564|NCT01114009|Experimental|Lung recruitment maneuver|The maneuver briefly increases the alveolar pressure to open recruitable lung (50 cmH2O), sustained with adequate positive end-expiratory pressure(PEEP) after lung recruitment, to avoid derecruitment.
9952565|NCT01114009|Active Comparator|Lung protective strategy|Lung protective strategy group received lung protective strategy without recruitment maneuver
9952566|NCT01114022|Active Comparator|Active comparator|cylindrical PVC cuff
9952567|NCT01114022|Experimental|Experimental 1|cylindrical polyurethane cuff
9952568|NCT01114022|Experimental|Experimental 2|conic PVC cuff
9952569|NCT01114022|Experimental|Experimental 3|conic polyurethane cuff
9952570|NCT01114035|Experimental|Patients|intestinal epithelial dysplasia
9952571|NCT01114035|Other|Control|Children without intestinal epithelial dysplasia
9952572|NCT01114061|Experimental|InsuPatch|The arm with the treatment: using the insupatch device to heat the insulin infusion site.
9952573|NCT01114074||Factor XII deficiency|Patients deficient in coagulation factor XII
9952574|NCT01114074||Factor XI Deficiency|Patients deficient in coagulation factor XI
9952575|NCT01114074||Prekallikrein deficiency|Patients deficient in prekallikrein
9952576|NCT01114074||HMWK deficiency|Patients deficient in high molecular weight kininogen (HMWK)
9952577|NCT01114074||Control group|Healthy controls
9952578|NCT01114087|Experimental|1|Patients presenting with chronic myeloid leukaemia or malignant GIST and receiving for the first time a treatment by imatinib, a tyrosin-kinase inhibitor, preceded or not by hydroxyurea therapy for less than one month.
9952579|NCT01114100|Active Comparator|sertraline, panic education|treatment with sertraline after panic education
9952580|NCT01114100|Placebo Comparator|placebo after panic education|treatment with placebo after panic education
9952581|NCT01114100|No Intervention|care as usual|patient received no diagnosis an no panic education, they had a 24 weeks follow up with a visit at 12 weeks and 24 weeks to evaluate their complaints
9952582|NCT01114113|Active Comparator|non-trigger meal|"Measurement of intestinal transport eating a non-trigger meal."
9476524|NCT03571009|Experimental|utilization of PAAS|conventional treatment utilization of PAAS
9952583|NCT01114113|Active Comparator|"trigger meal baseline"|"Measurement of intestinal transport after eating a trigger meal."
9952584|NCT01114113|Placebo Comparator|"trigger meal with placebo"|Measurement of intestinal transport with blinded placebo
9952585|NCT01114113|Active Comparator|"trigger meal with enzymes (blinded)"|Measurement of intestinal transport with blinded active enzyme capsule
9952586|NCT01114126|Experimental|Neu-P11 2mg|
9952587|NCT01114126|Experimental|Neu-P11 5 mg|
9952588|NCT01114126|Experimental|Neu-p11 20 mg|
9952589|NCT01114126|Experimental|Neu-P11 50 mg|
9952590|NCT01114126|Placebo Comparator|Placebo|
9952591|NCT01114152|Experimental|1|Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8)
9952592|NCT01114152|Placebo Comparator|2|placebo given (2 subjects in each dose group)
9952593|NCT01114165|Experimental|SeptiFast Test|Pathogen detection by SeptiFast Test as an adjunct to traditional microbiological assessments including blood culture
9952594|NCT01114165|Active Comparator|Only Conventional Diagnostics|Pathogen detection only by conventional microbiological assessments, e.g. blood culture
9952595|NCT01114178||claudicants|patients referred for a treadmill test
9952596|NCT01114191|Experimental|Arm 1|
9952597|NCT01114230|Experimental|Dose Level 1|
9952598|NCT01114230|Experimental|Dose Level 2|
9952599|NCT01114230|Experimental|Dose Level 3|
9952600|NCT01114230|Experimental|Dose Level 4|
9952601|NCT01114230|Experimental|Dose Level 5|
9952602|NCT01114230|Experimental|Dose Level 6|
9952603|NCT01114230|Experimental|Dose Level 7|
9952604|NCT01114230|Experimental|Dose Level 8|
9952605|NCT01114230|Experimental|Dose Level 9|
9952606|NCT01114256||Fine needle aspiration (FNA) biopsies|Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
9952607|NCT01114282|Experimental|VELCADE with pralatrexate|Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
9952608|NCT01114295|Experimental|Overt Obscure Gastrointestinal Bleeders|The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.
9952609|NCT01114347|Experimental|Cranberry|Patients randomized to this arm will recieve one gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water.
9952610|NCT01114347|Placebo Comparator|Placebo|The patients randomized to this arm will recieve one placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
9952611|NCT01114386||COPD patients, CHF patients|COPD and CHF patients with smoking history (> 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.
9952612|NCT01114399|Experimental|Standard Broccoli|Standard Broccoli
9952613|NCT01114399|Experimental|High Glucosinolate Broccoli|High Glucosinolate Broccoli
9952614|NCT01114399|Experimental|Peas|Peas
9952615|NCT01114412||Patients|Patients with overactive bladder syndrome
9952616|NCT01114412||Healthy volunteers|Healthy volunteers
9952617|NCT01114451|Experimental|Early Staple Removal|Skin staple removal on post-operative day #3
9952618|NCT01114451|Experimental|Delayed Staple Removal|Skin staple removal on post-operative day 7-10
9952619|NCT01114464||young women with breast cancer|
9952620|NCT01114490|Experimental|Part 1 - Group 1|Moderate Hepatic Patients
9952621|NCT01114490|Experimental|Part 1 - Group 2|Healthy Subjects
9952622|NCT01114490|Experimental|Part 2 - Group 1|Mild Hepatic Patients
9952623|NCT01114490|Experimental|Part 2 - Group 2|Healthy Subjects
9952624|NCT01114542|Experimental|IDeg 0.4 U/kg|
9952625|NCT01114542|Experimental|IDeg 0.6 U/kg|
9952626|NCT01114542|Experimental|IDeg 0.8 U/kg|
9952627|NCT01114542|Active Comparator|IGlar 0.4 U/kg|
9952628|NCT01114542|Active Comparator|IGlar 0.6 U/kg|
9952629|NCT01114542|Active Comparator|IGlar 0.8 U/kg|
9952630|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
9952631|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→OC slow→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
9952632|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→tablet→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
9952633|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→OC slow→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
9952634|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→tablet→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
9952635|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→OC fast→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
9952636|NCT01114594||PKD|Patients with Autosomal Dominant Polycystic Kidney Disease
9952637|NCT01114594||non-PKD CKD|Patients with non-Polycystic Chronic Kidney Disease
9952638|NCT01114607|Experimental|Treatment sequence ABCDE|Eligible subjects will be randomized in sequence ABCDE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
9952639|NCT01114607|Experimental|Treatment sequence ABDEC|Eligible subjects will be randomized in sequence ABDEC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
9952640|NCT01114607|Experimental|Treatment sequence ABECD|Eligible subjects will be randomized in sequence ABECD and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
9952641|NCT01114607|Experimental|Treatment sequence ABCED|Eligible subjects will be randomized in sequence ABCED and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= a film coated tablet of GSK1605786 GSK formulation 500 mg once daily and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
9952642|NCT01114607|Experimental|Treatment sequence ABDCE|Eligible subjects will be randomized in sequence ABDCE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
10035216|NCT01803984||Patient with migraine without aura|patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
9802292|NCT05315388|Experimental|Group 2A: Vitamin N therapy group - metropolitan park environment|Group with periodic outings to a neighborhood or metropolitan natural park (once a week) for approximately 2 hours for a minimum period of six months.
9952643|NCT01114607|Experimental|Treatment sequence ABEDC|Eligible subjects will be randomized in sequence ABEDC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
9952644|NCT01114607|Experimental|Treatment sequence BACDE|Eligible subjects will be randomized in sequence BACDE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
9952645|NCT01114607|Experimental|Treatment sequence BADEC|Eligible subjects will be randomized in sequence BADEC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
9952646|NCT01114607|Experimental|Treatment sequence BAECD|Eligible subjects will be randomized in sequence BAECD and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
9952647|NCT01114607|Experimental|Treatment sequence BACED|Eligible subjects will be randomized in sequence BACED and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
9952648|NCT01114607|Experimental|Treatment sequence BADCE|Eligible subjects will be randomized in sequence BADCE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
9952649|NCT01114607|Experimental|Treatment sequence BAEDC|Eligible subjects will be randomized in sequence BAEDC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
9952650|NCT01114659||Women with PCOS|
9952651|NCT01114659||Normal Control|
9952652|NCT01114685|Active Comparator|Effects of taking AlgaeCal-1|Following a bone health plan with Algae-cal-1 supplement
9952653|NCT01114685|Active Comparator|Effects of taking AlgaeCal-2|Following a bone-health plan while consuming AlgaeCal 2
9952654|NCT01114711||Frovatriptan|All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
9952655|NCT01114750|Active Comparator|Oral Insulin in Dextran Matrix|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
9952656|NCT01114750|Placebo Comparator|Placebo|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
9952657|NCT01114763||Metabolic syndrome|40 men with metabolic syndrome
9952658|NCT01114763||Control|40 physically active men
10035217|NCT01803997|Other|STRIDE|12 cooking classes offered over 6 weeks (approximately 2 classes/week)
9952659|NCT01114776||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
9952660|NCT01114776||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
9952661|NCT01114776||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
9952662|NCT01114776||Controls|
9952663|NCT01114802|Experimental|Project Onward website + social network|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
9952664|NCT01114802|Active Comparator|Project Onward website|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy.
9952665|NCT01114841|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene foam 0.1%
9952666|NCT01114841|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam
9952667|NCT01114854|Other|Topiramate IR followed by Topiramate ER|Dosing with IR followed by dosing with ER
9952668|NCT01114932||BMI-I|Patients with BMI values between 18.5-24.9
9952669|NCT01114932||BMI-II|Patients with BMI values between 25-29.9
9952670|NCT01114932||BMI-III|Patients with BMI values between 30-49.9
9952671|NCT01114958|Experimental|IA Cisplatin / IV Thiosulfate|Single-arm study
9952672|NCT01114984||10% after breast biopsy|Incidence Post-operative pain after breast surgery.
10215058|NCT02420613|Experimental|Arm II (vorinostat, temsirolimus)|Patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
10215059|NCT02409342|Active Comparator|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
9952673|NCT01114984||20% after lumpectomy|Incidence Post-operative pain after breast surgery
9952674|NCT01114984||30% after simple mastectomy|Incidence Post-operative pain after breast surgery
9952675|NCT01114984||50% after mastectomy with reconstruction|Incidence Post-operative pain after breast surgery
9952676|NCT01114984||50% after radical mastectomy|Incidence Post-operative pain after breast surgery
9952677|NCT01114984||50% after radi mastectomy+reconstruction|Incidence Post-operative pain after breast surgery after radical mastectomy with reconstruction
10005138|NCT01582568||Certolizumab|Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
9952678|NCT01114984||40% after cosmetic augmentation|Incidence Post-operative pain after breast surgery
9952679|NCT01114984||40% after breast reduction|Incidence Post-operative pain after breast surgery
9952680|NCT01115010|Experimental|Stiffening wire only if difficulty|Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
9952681|NCT01115010|Experimental|Stiffening wire #1 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
9952682|NCT01115010|Experimental|Stiffening wire #2 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.
9952683|NCT01115023|Experimental|iron group|This group received an iron cooking pot for daily household cooking as an intervention
9952684|NCT01115023|No Intervention|Aluminium group|the subjects in this group were asked to continue cooking in the aluminium pot and not to cook in the iron pot if they possessed one.
9952685|NCT01115036|Experimental|panobinostat|
9952686|NCT01115049|Experimental|Experimental mouthwash|The experimental mouthwash (Buccagel®, Curaden Healthcare, Saronno, Italy) was made up of: purified water, dicaprylyl-ether, coco-caprylate caprate, xylitol, glyceryl-stearate, ceteareth-20, ceteareth-12, cetyl-palmitate, cetearyl-alcohol, chlorobutanol, aroma, hexetidine, methylparaben, propylparaben, sodium saccharin, citric acid and colorant C.I. 16255.
9952687|NCT01115049|Active Comparator|Chlorexidine-based mouthwash|A conventional commercial mouthwash (Curasept® ADS 0.20%, Curaden Healthcare, Saronno, Italy) made up of: water, xylitol, propylenglycol, Peg-40 of hydrogenated ricin oil, ascorbic acid, chlorhexidine digluconate, aroma, poloxamer 407, sodium metabisulfite, sodium citrate and colorant C.I. 42090.
9952688|NCT01115062|Experimental|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg)
9952689|NCT01115062|Experimental|LMX-4 Cream|LMX-4 (liposomal lidocaine 4%) cream
9952690|NCT01115062|Placebo Comparator|Placebo Patch|Placebo Patch
9952691|NCT01115075|Experimental|Dietitian|Recruitment of dietitians and senior level or graduate level dietetics students who are not restrained eaters. This group is skilled in identifying and accurately recording food than individuals not trained in dietetics.
9952692|NCT01115088|Experimental|Aspartame|Food or beverages containing Aspartame in comparison to Stevia or Sucrose
9476525|NCT03571009|No Intervention|Conventional care|conventional treatment only
9952693|NCT01115088|Experimental|Sucrose|Food or beverages containing Sucrose in comparison to Aspartame or Stevia
9952694|NCT01115088|Experimental|Stevia|Food or beverages containing Stevia in comparison to Aspartame or Sucrose
9952695|NCT01115114|Placebo Comparator|Treatment as Usual (TAU)|Study Intervention 1 Treatment as usual (TAU) will be psychiatry follow-up at local Community Mental Health Clinic at least every 3 months.
9952696|NCT01115114|Active Comparator|IMBED|Study Intervention 2 A Primary Care Provider (PCP) will be located within the community mental health clinic one day weekly to specifically run a Metabolic Syndrome Clinic.
10215060|NCT02409342|Experimental|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
10215061|NCT02394535|Experimental|Treatment (chemotherapy, radiation therapy)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 and capecitabine PO BID on days 1-5 (Monday-Friday). Patients also undergo radiation therapy QD on days 1-5 (Monday-Friday). Treatment continues for 51/2 weeks in the absence of disease progression or unacceptable toxicity.
9952697|NCT01115114|Active Comparator|Liaison|Study Intervention 3 A Medical Case Manager(MCM) will be assigned to a patient who is identified on the basis of routine screening to need medical follow-up for metabolic syndrome.
9952698|NCT01115127|Active Comparator|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
9952699|NCT01115127|Active Comparator|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
9952700|NCT01115127|Active Comparator|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
9952701|NCT01115140|Active Comparator|Group A1|metformin plus placebo
9952702|NCT01115140|Experimental|Group A2|metformin plus folic acid
9952703|NCT01115140|Active Comparator|Group A3|placebo plus folic acid
9952704|NCT01115140|Placebo Comparator|Group A4|placebo cp, 2 cps daily
9952705|NCT01115140|No Intervention|Group B|observation
9952706|NCT01115153|Experimental|Antibiotic prophylaxis|Rate of Wound infection in patients with gangrenous appendicitis with single doses of antibiotic (before surgery)
9952707|NCT01115153|Active Comparator|Antibiotic treatment, wound infection|Rate of Wound infection in patients with gangrenous appendicitis with five days antibiotic therapy (after surgery)
9952708|NCT01115179|Active Comparator|Propofol|Propofol anesthesia
9952709|NCT01115179|Active Comparator|Control|Anesthesia with isoflurane alone
9952710|NCT01115179|Active Comparator|Solvent|Anesthesia with isoflurane together with the solvent of propofol (intralipid)
9952711|NCT01115192|Experimental|Group A|Patients with chronic blepharitis, that will be treated with blephacura
9952712|NCT01115192|Experimental|Group B|Patients with chronic blepharitis that will be treated with diluted baby shampoo
9952713|NCT01115205|Experimental|Supervised walking groups|Patients included in walking groups, under the supervision of a qualified personal trainer.
9952714|NCT01115205|Active Comparator|Controls|Patients receiving the standard counselling procedures of the Verona Diabetic Clinic.
9952715|NCT01115218||Glaucoma patients|
9952716|NCT01115257|Other|group 1|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with vitrectomy
9952717|NCT01115257|Other|panretinalphotocoagulation (group 2)|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with panretinalphotocoagulation
9952718|NCT01115270||Hydrocephalus Patients|Those patients diagnosed with Normal Pressure Hydrocephalus.
9952719|NCT01115270||Normal Participants|Individuals who are not diagnosed with Normal Pressure Hydrocephalus.
9952720|NCT01115296|Active Comparator|'L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
9952721|NCT01115296|Placebo Comparator|Placebo|Placebo
9952722|NCT01115322|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
9952723|NCT01115322|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
9952724|NCT01115322|Experimental|Tazarotene Foam with UVA , UVB, and visible light irradiation|Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation
9952725|NCT01115322|Placebo Comparator|Vehicle Foam without irradiation|Subjects will be exposed to Vehicle Foam Patch without irradiation
9952726|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
9952727|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB and visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
9952728|NCT01115322|Sham Comparator|No Treatment without irradiation|Subjects will be exposed to a Blank Patch without irradiation
9952729|NCT01115322|Sham Comparator|No Treatment with UVA and UVB irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB irradiation
9952730|NCT01115322|Sham Comparator|No Treatment with UVA and UVB and visible light irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation
9952731|NCT01115335|Active Comparator|Gomco|NMC performed using a Gomco clamp
9952732|NCT01115335|Active Comparator|Mogen clamp|NMC performed using a Mogen clamp
9952733|NCT01115335|Active Comparator|Plastibell|NMC performed using a Plastibell device
9952734|NCT01115361|Experimental|PPFP in child immunization|Women attending immunization services for their infant will receive educational brochures, group education and individual counseling on the benefits of the health timing and spacing of births,, pregnancy risk and return to fertility during the extended postpartum period (12 months), and referral to family planning services for those who are interested.
9952735|NCT01115361|No Intervention|Control - Standard of care|The control arm will receive standard of care infant immunization services.
9952736|NCT01115374|Active Comparator|manual lymphatic drainage|Application of manual lymphatic drainage
9952737|NCT01115374|Experimental|low frequency sound waves|Application of low frequency sound waves
10005139|NCT01582581|Active Comparator|Telephonic CBT|Computer guided, cognitive behavioral therapy (CBT) delivered by a clinician-administered telephone intervention.
10005140|NCT01582581|Sham Comparator|Wait List Control|Randomized wait list control with measurement of study outcomes at week 0, 3 and 5 after the initiation of waiting.
10005141|NCT01582607|Active Comparator|Group B|subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%
10005142|NCT01582607|Active Comparator|Group R|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%
10005143|NCT01582607|Active Comparator|Group LB|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%
10215062|NCT02385110|Experimental|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Dexamethasone by vein on Days 1-7 of the induction phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week during the maintenance phase. Participants who have evidence of budding relapse during the maintenance phase may revert back to receiving Etoposide.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
10005144|NCT01582607|Active Comparator|Group RF|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl
10005145|NCT01582607|Active Comparator|Group BF|subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
10005146|NCT01582607|Active Comparator|Group LBF|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
10005147|NCT01582633|Experimental|0.1 ml ID dose|Dose of 0.1 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
10005148|NCT01582633|Experimental|0.2 ml ID dose|Dose of 0.2 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
10005149|NCT01582633|Experimental|0.5 ml IM dose - needle-free|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
9952738|NCT01115387||ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who have at least one parent with age related maculopathy.~These individuals with ARM-affected parents and relatives have a substantially higher risk (6-12 fold) of developing ARM than the general population. They will be followed prospectively with fundus photography every two years and questionnaires (distributed over six month intervals) to assess external risks for ARM development in order to investigate genotype-phenotype correlations of early onset clinical features of ARM."
9952739|NCT01115387||Partners/Spouses of ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who are the spouses/partners of individuals with ARM affected parents.~We will invite the partners or spouses to participate in order to compare their risk of developing ARM with those individuals with an increased risk of ARM based on a positive family history."
9952740|NCT01115387||ARM affected individuals and relatives.|"Individuals who have experienced vision loss from ARM and have at least one brother or sister who also has experienced vision loss from ARM can participate in the study. They also need to have at least one adult child (from 49 to 65 years old) who wishes to participate in this study.~We will allow for additional recruitment to compensate for additional family members (such as parents, aunts and uncles) who wish to participate as well as to address potential drop out and those who may be deemed ineligible based on review of their medical and/or eye records. As many as 4000 individuals in this group will be allowed to enroll."
9952741|NCT01115413||young maternal age|maternal age of < 18 years
10215063|NCT02385110|Experimental|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2 of the Induction phase. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week during the maintenance phase.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
10215064|NCT02371447|Experimental|VPM1002BC Induction|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
9952742|NCT01115413||adult maternal age|maternal age >/= 18 years
9952743|NCT01115426|Other|anti-angiotensin II drugs|Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
9952744|NCT01115439||falciparum malaria|Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection
9952745|NCT01115465|Other|Macroplastique|Macroplastique will be used for the treatment in an open-label, five year, post-market study
10215065|NCT02359864|Experimental|Cohort One|An initial 15 patients will be enrolled in the first treatment scheme (5 daily fractions of 2 Gy) and will be followed for 12 months after completion of treatment to assess safety and any toxicity/adverse events associated with treatment. 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events.
9952746|NCT01115478|Active Comparator|Vitamin A|
9952747|NCT01115478|Active Comparator|Zinc|
9952748|NCT01115478|Active Comparator|Vitamin A + Zinc|
9952749|NCT01115478|Placebo Comparator|Placebo|
9952750|NCT01115504|Experimental|Thiamine|Thiamine tablets of 300mg are prescribed for 1 months
9952751|NCT01115504|Placebo Comparator|Plascebo|Tablets of 300mg placebo are prescribed for 1 months
9952752|NCT01115530|No Intervention|1|Control inpatient GEM rehabilitation and continue twice weekly low level walking/stretching to control for time/interaction with intervention/exercise groups
9952753|NCT01115530|Experimental|2|Resistance exercise (2x/week)
9952754|NCT01115530|Experimental|3|Nutritional (amino acid metabolite) supplement twice daily
9952755|NCT01115530|Experimental|4|Resistance exercise (2x/week) and nutritional (amino acid metabolite) supplement twice daily
9952756|NCT01115543|Active Comparator|calcitriol|The subjects were randomized to receive calcitriol in a dose-escalating fashion for up to 24 weeks.
9952757|NCT01115543|Experimental|alfacalcidol|
9952758|NCT01115595|Active Comparator|Intervention|injection by Mite extract with standard allergic medication (oral antihistamine and/or topical nasal steroid)
9952759|NCT01115595|Other|Control Group|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid
10215066|NCT02359864|Experimental|Cohort Two|"The second treatment arm will not be used until the last patient in the first dose arm has completed all follow up. At that point patients~#16-30 will be enrolled in the second dose arm (10 daily fractions of 2 Gy). 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events."
10215067|NCT02337686|Experimental|Treatment (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day -21 and day -1, and then undergo surgery on day 0. After 2-3 weeks or recovery from surgery, patients continue to receive pembrolizumab IV over 30 minutes every 3 weeks. Courses repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
10215068|NCT02316834|Experimental|BMN 673|
10215069|NCT02293655|Placebo Comparator|MPH Discontinuation|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will receive placebo (qAM)."
9802293|NCT05315388|Experimental|Group 2B: Vitamin N therapy group - forest forest environment|Group with periodic outings to a forest environment (once a week) for a time of approximately 2 hours for a minimum period of six months
9802294|NCT05315375||Corpectomy|surgical procedure using expandable cage
9952760|NCT01115608|Experimental|Pharmacist follow-up|"The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of consultation. Written information concerning drugs used will be supplied."
9952761|NCT01115608|No Intervention|Control group|The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.
10215070|NCT02293655|Active Comparator|Sustained MPH|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will continue their optimal MPH dose (qAM)."
10215071|NCT02293005|Experimental|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
9952762|NCT01115621|Active Comparator|Glutenfree diet|Glutenfree diet during the first year of life
9952763|NCT01115621|No Intervention|Control - normal diet|
9952764|NCT01115634|Experimental|Fibroblast|Injection of autologous cultured fibroblast
9952765|NCT01115647|Experimental|Ready-to-Use Therapeutic Foood (RUSF)|"Caretakers will receive weekly RUSF, 350g, and will be advised to feed it(50 g d-1 or 3 tablespoons/day) in one meal or on demand. These are pre-defined quantities. However, minimum quantities required for a timely (≤15 days) recovery from moderate malnutrition will be determined during the pilot phase.~Besides supplementary food, parents will be provided with the usual nutrition counsels prevailing currently in the health services.Children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
9952766|NCT01115647|Active Comparator|CSB++|"Caretakers will receive weekly CSB++ (450g) rations. Parents will be advised to feed the CSB++ (65g d-1 diluted in 370 g water) in one meal or on demand. These are pre-defined quantities. However, minimum quantities of CSB++ required for a timely (≤15 days) recovery from moderate malnutrition in the area will be determined during the pilot phase. Besides supplementary foods, parents will be provided with the usual nutrition counsels prevailing currently in the health services, i.e. to keep on breastfeeding, to increase diet diversity and to feed frequent snacks.~Feeding practices will be also assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
10215072|NCT02292368|Experimental|Acupuncture - One Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
10215073|NCT02292368|Experimental|Acupuncture - Different Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
10215074|NCT02275546|Experimental|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
10215075|NCT02275546|Experimental|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
10215076|NCT02162329|Other|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
10215077|NCT02162329|Experimental|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
9802295|NCT05315349|Experimental|Patient requiring cardiac surgery for myocardial revascularization|
9802296|NCT05315310|Experimental|REAL Training|Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
9952767|NCT01115647|Active Comparator|Children Centered Counseling (CCC)|"The counsellor will spend 1 hour daily (during the 3 first days and then weekly) within the household for identifying enhancing and blocking factors and adapt consequently the treatment strategies in agreement with the caretakers.~As in the other study arms, children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be also assessed in each arm, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members.There will be no dietary supplements intervention, outside normal practices in Burkina."
9952768|NCT01115686|Active Comparator|Branched-chain aminoacids|Branched-chain aminoacids are natural constituents of the food. Branched-chain aminoacids will be orally administered in the form of capsules.
9952769|NCT01115686|Placebo Comparator|placebo|The placebo will be orally administered in the form of capsules
9952770|NCT01115712|Active Comparator|Pioglitazone 30 mg|Pioglitazone 30 mg
9952771|NCT01115712|Placebo Comparator|Placebo|Placebo
9952772|NCT01115725||Gonal-f® prefilled pen|
9952773|NCT01115751|Experimental|LY2780301|"Part A: daily dosing~Part B (if determined as needed by pharmacokinetic, pharmacodynamic, and safety data): twice daily dosing~Part C: Dose and frequency as determined by Parts A and B of the study."
9952774|NCT01115777||Pediatric patients treated with radiotherapy|
9952775|NCT01115790|Experimental|Prexasertib|
9952776|NCT01115842|Experimental|Vitamin D|The patients will be given Vitamin D - 4000IU per day for 5 days (Day 1 through 5)
9952777|NCT01115842|No Intervention|control|
9952778|NCT01115868|Experimental|Group 2 - 2 doses of Prevascar and placebo|
9952779|NCT01115868|Experimental|Group 1 - 2 doses of Prevascar and placebo|
9952780|NCT01115868|Experimental|Group 3 - 2 doses of Prevascar and placebo|
9952781|NCT01115868|Experimental|Group 4 - 2 doses of Prevascar and placebo|
9952782|NCT01115894|Experimental|active medication + psychotherapy|
9952783|NCT01115894|Experimental|placebo + psychotherapy|
9802297|NCT05315297|Experimental|PEMF device|
9802298|NCT05315297|Sham Comparator|Sham PEMF device|
9802299|NCT05315284|Other|Patients with fresh non-comminuted fracture mid-shaft clavicle|
9952784|NCT01115894|Experimental|active medication+brief supportive counseling|
9952785|NCT01115894|Experimental|placebo + brief supportive counseling|
9952786|NCT01115907|Experimental|Freedom SOLO stentless valve implant|Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
9952787|NCT01115920|Experimental|Arm 1|Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
9952788|NCT01115920|Experimental|Arm 2|Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
9952789|NCT01115920|Experimental|Arm 3|Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
9952790|NCT01115920|Experimental|Arm 4|Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
9952791|NCT01115920|Experimental|Arm 5|Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
9952792|NCT01115946|Experimental|single-add first group|single administration first, then concomitant administration
9952793|NCT01115946|Experimental|combi-add first group|concomitant administration first, then single administration
9952794|NCT01115959|Active Comparator|valproic acid|Valproic acid given orally 400mg twice daily
9952795|NCT01115959|Placebo Comparator|placebo|Placebo twice daily for one month
9952796|NCT01115972|Experimental|single-add first group|single administration first, then concomitant administration
9952797|NCT01115972|Experimental|combi-add first group|concomitant administration first, then single administration
9802300|NCT05315258|Experimental|Cutaneous melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
9802301|NCT05315258|Experimental|Uveal melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
9952798|NCT01115985|Experimental|single-add first group|single administration first, then concomitant administration
9952799|NCT01115985|Experimental|combi-add first group|concomitant administration first, then single administration
9952800|NCT01116011|Experimental|AZD7268|
9952801|NCT01116011|Placebo Comparator|Placebo|
9952802|NCT01116050|Placebo Comparator|Placebo|
9952803|NCT01116050|Experimental|MISOPROSTOL|
9952804|NCT01116063|Experimental|Single arm open label|All patients will receive the study drugs and will be evaluated
9952805|NCT01116076|Experimental|DECISION+ Program|Exposure to the Decision+ Program
9952806|NCT01116076|No Intervention|Control|Usual Care
9952807|NCT01116089|Active Comparator|PARI LC® PLUS nebulizer|
9952808|NCT01116089|Active Comparator|PARI eFlow® rapid electronic nebulizer|
9952809|NCT01116115|Active Comparator|Standard vegetable oil based formula|
9952810|NCT01116115|Active Comparator|InFat™ based infant formula|
9952811|NCT01116115|No Intervention|Breast-fed|
9952812|NCT01116128|Experimental|D-MP|
9952813|NCT01116154|Experimental|Arm I|Patients receive oral vorinostat twice daily on days 1-14 and oral lenalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9952814|NCT01116167|Experimental|Letrozole -Berberine|
9952815|NCT01116167|Active Comparator|Letrozole|
9952816|NCT01116167|Active Comparator|Berberine|
9952817|NCT01116180|Active Comparator|Candesartan|
9952818|NCT01116180|Placebo Comparator|Placebo|
9952819|NCT01116206|Experimental|Prucalopride|prucalopride 2- milligram (mg), orally once daily for 12 weeks
9952820|NCT01116206|Placebo Comparator|Placebo|Matching placebo, orally once daily for 12 weeks
9952821|NCT01116219|Active Comparator|Stratum mut EGFR|"Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~Erlotinib 150 mg p.o. daily until progression."
9952822|NCT01116219|Active Comparator|Stratum wtEGFR|"Cohort 1:~Induction chemotherapy with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.~Cohort 2:~Induction chemotherapy with~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~o Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
9952823|NCT01116245|Experimental|Low Dose|5x10^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
9952824|NCT01116245|Experimental|Middle Dose|3.3x10^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
9952825|NCT01116245|Experimental|High Dose|1x10^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
9952826|NCT01116245|Placebo Comparator|Placebo|normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
9952827|NCT01116258|Experimental|1|
9952828|NCT01116258|Placebo Comparator|2|
9952829|NCT01116271|Experimental|1|Selumetinib (AZD6244) in combination with irinotecan
9476526|NCT03570996|Active Comparator|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
9952830|NCT01116284|Experimental|Revision of gastric bypass|A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.
9952831|NCT01116297|Experimental|Imaging with S-FLARE imaging system|3 patients to be imaged by S-FLARE imaging system.
9952832|NCT01116310|Experimental|Fitogyn|4 weeks with placebo followed by 16 weeks with Fitogyn, both taking two capsules per day during the breakfast.
9952833|NCT01116310|Placebo Comparator|Placebo|20 weeks with placebo, taking two capsules per day during the breakfast.
9952834|NCT01116336|Experimental|Erlotinib and Green Tea Polyphenon E|Patients will receive erlotinib, at pre-defined dose level, with polyphenon E.
9952835|NCT01116349|Active Comparator|Surgical treatment|Patients included in the surgical group will have surgery to treat the fracture.
9952836|NCT01116349|Active Comparator|Conservative treatment group|Patients included in the conservative group will be taken to a plaster room where a Hanging Support System(HSS) brace will be installed by a qualified technician.
9952837|NCT01116362|Other|secondary repair|secondary closure beyond the first week.the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
9952838|NCT01116362|Other|primary repair|during first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
9952839|NCT01116375||Obese children with OSA|To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR
9952840|NCT01116388|Other|test product|product free of gluten and casein
9952841|NCT01116388|Other|control product|product containing gluten and milk protein
9952842|NCT01116453|Experimental|Acupuncture|
9952843|NCT01116453|Active Comparator|Usual Care|usual care followed by delayed acupuncture
9952844|NCT01116479|Active Comparator|Haemoglobin (<6.0 mmol/l)|Blood transfusion thresholds:Haemoglobin < 6.0 mmol/l (9.9 g/dL)
9952845|NCT01116479|Experimental|Haemoglobin (< normal range)|Blood transfusion threshold: Haemoglobin < 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males
9952846|NCT01116492|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
9952847|NCT01116492|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
9952848|NCT01116505|No Intervention|gluten-containing diet|
9952849|NCT01116505|Active Comparator|Active comparator, gluten-free diet|
9952850|NCT01116518|Active Comparator|physiotherapy|
9952851|NCT01116518|Active Comparator|acromioplasty|
9952852|NCT01116518|Active Comparator|acromioplasty and rotator cuff reconstruction|
9952853|NCT01116531|Active Comparator|Duloxetine and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
10215078|NCT02162329|Other|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.~After 8 week follow up visit, Wait-List Group offered meditation program."
10215079|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
10215080|NCT02157844||COPD|Subjects with diagnosis of COPD
10215081|NCT02157844||OSA|Subjects with diagnosis of OSA
10215082|NCT02157844||controls|Gender, age, BMI matched controls
10215083|NCT02140944||Pre-Transplant Cohort|HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant
9952854|NCT01116531|Active Comparator|Pregabalin and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
9952855|NCT01116557|Other|THERMOCOOL® group|Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
9952856|NCT01116557|Active Comparator|PVAC® group|Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®
9952857|NCT01116570|Experimental|Physical training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
9952858|NCT01116570|Other|control|None intervention
9952859|NCT01116583|Active Comparator|Gabapentin|Gabapentin group
9952860|NCT01116583|Placebo Comparator|Placebo|Placebo group
9952861|NCT01116622|Experimental|Daily oral erlotinib and bexarotene capusles|Open label dose-ranging trial
9952862|NCT01116635|Experimental|50mg dose loading per vial of doxorubicin|
9952863|NCT01116635|Experimental|75mg dose loading per vial of doxorubicin|
9952864|NCT01116674||Glycemic Control|Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of > 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is > 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
9952865|NCT01116713|Active Comparator|Dexamethasone group|This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.
9952866|NCT01116713|Placebo Comparator|Placebo group|Patients of these group received homologated placebo 60 minutes before skin incision.
10005150|NCT01582633|Active Comparator|0.5 ml IM - needle and syringe|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by needle and syringe
10215084|NCT02140944||Post-Transplant Cohort|HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant
10215085|NCT02131597|Experimental|Treatment (guadecitabine)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 4-8 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 3 courses are taken off therapy after 6 courses. Patients may continue to receive treatment after 24 courses if the investigator determines it is in the patient's best interest.
10215086|NCT02131584|Experimental|Supportive care (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
10215087|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)|Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.
10215088|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)|De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
10215089|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)|Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
9802302|NCT05315232||Qualitative assessment|Survey (using validated quality of life assessment questionnaires) and one to one interviews of people and family members living with Glanzmanns Thrombasthenia
9802303|NCT05315232||Bleed diary|Daily bleed diary completion over 12 weeks
9802304|NCT05315219|Experimental|Endoscopic Thyroidectomy Bilateral Areola Approach|
10215090|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
10215091|NCT02077166|Experimental|Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
10215092|NCT02077166|Experimental|Phase 2: Enrolled at Lenalidomide Dose 20 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
10215093|NCT02077166|Experimental|Phase 2: Enrolled at Lenalidomide Dose 25 mg|Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
10215094|NCT02073981||Parkinson Disease|
10215095|NCT02067741|Experimental|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
10215096|NCT02067741|Experimental|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
10215097|NCT02027935|Experimental|Treatment (T cells, chemo, aldesleukin, ipilimumab)|Beginning 48 to 72 hours prior to T cell infusion, patients receive cyclophosphamide IV over 30-60 minutes. Patients then receive autologous CD8+ melanoma-specific T cells IV over 30-60 minutes on day 0, aldesleukin SC BID on days 0-13 and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
10215098|NCT01965132||Biologic or targeted synthetic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biolsimilars) or a targeted synthetic DMARD
10215099|NCT01953263|Experimental|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
10215100|NCT01907789|Experimental|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
10215101|NCT01907789|Experimental|Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
10215102|NCT01907789|Experimental|Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
10215103|NCT01891344|Experimental|Ovarian cancer|rucaparib
10215104|NCT01859221|Experimental|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
10215105|NCT01859221|Experimental|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
10215106|NCT01847274|Active Comparator|Niraparib|2:1 Ratio administered once daily continuously during a 28 day cycle.
10215107|NCT01847274|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle.
10215108|NCT01799733|Active Comparator|LWT+AM BWL|Late-wake therapy in combination with morning bright white light
10215109|NCT01799733|Placebo Comparator|EWT+PM BWL|Early-wake therapy in combination with evening bright white light
10215110|NCT01778764||retrospective cohort|retrospective follow-up of patients treated since 2006
10215111|NCT01778764||prospective cohort|patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
10215112|NCT01670656|Experimental|NOMAC-E2 700/300 mcg|NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
9802305|NCT05315219|No Intervention|Open Thyroidectomy|
10215113|NCT01670656|Experimental|NOMAC-E2 900/300 mcg|NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
10215114|NCT01670656|Experimental|ENG-E2 100/300 mcg|ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
10215115|NCT01670656|Experimental|ENG-E2 125/300 mcg|ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
10215116|NCT01670656|Placebo Comparator|Placebo|Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
10215117|NCT01648751|Experimental|Vaginal estrogen|Patients in the experimental group will receive vaginal estrogen cream
10215118|NCT01648751|Placebo Comparator|Placebo cream|Patients in the comparison group will receive placebo vaginal cream
10215119|NCT01593111|Experimental|Environmental Intervention|If randomized to this part of the study the patient will receive an individualized homebased program. In addition to general handouts provided to at Visit 3, subjects in this arm will also receive home-based education by Intervention Counselors about how indoor allergens can affect asthma and the importance of strategies for removing allergens. The goal of the intervention is to provide the patient with the knowledge and skills necessary to remove allergens from their home, and to assist them with those clean up measures. Some of the measures implemented will be specifically based on data we have previously collected from them in the clinic and from their previous home visit, while others will be general to reduce all allergen level.
10215120|NCT01593111|No Intervention|Control Group|If assigned to this group the patient will receive general health/safety related counseling. At the counselor visit following randomization, the patient will receive handouts related to general health and safety issues. They will also have visits by the Home Evaluators for assessment of the home and collection of dust samples identical to those in the treatment group (week 28 and week 44).
10215121|NCT01501955|Active Comparator|Stanmore|25 patients will have the Stanmore prosthesis
10215122|NCT01501955|Experimental|Metaphyseal Hip Prosthesis|25 patients will have the Metaphyseal Hip Prosthesis (MHP) prosthesis
10215123|NCT01498770||Asenapine|
10215124|NCT01498770||Aripiprazole|
10215125|NCT01498770||Quetiapine|
10215126|NCT01498770||Risperidone|
10215127|NCT01498770||Olanzapine|
10215128|NCT01498770||Ziprasidone|
10215129|NCT01498770||Iloperidone|
10215130|NCT01498770||Paliperidone|
10215131|NCT01498770||Lurasidone|
10215132|NCT01498770||Clozapine|
10215133|NCT01498770||Amisulpride|
10215134|NCT01498770||Sertindole|
10215135|NCT01498770||Zotepine|
10215136|NCT01495741||Asenapine|Participants prescribed asenapine
10215137|NCT01495741||Risperidone Comparator|Participants prescribed risperidone
10215138|NCT01495741||Olanzapine Comparator|Participants prescribed olanzapine
10215139|NCT01335399|Active Comparator|Lenalidomide + Dexamethasone|
10215140|NCT01335399|Experimental|Lenalidomide + Dexamethasone + Elotuzumab|
10215141|NCT01277211|Experimental|ENG-EE (NuvaRing)|Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
10215142|NCT01277211|Active Comparator|DRSP-EE|Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.
10215143|NCT01273077||Evaluation of Rotarix Program|All infants in Nova Scotia DHA 9 and PEI born after October1, 2010 until September 30, 2012 will be eligible for Rotarix immunization as part of the publicly funded immunization program. New Brunswick will serve as the non-intervention control location.
10215144|NCT01273077||Retrospective Surveillance|All laboratory- confirmed cases of rotavirus gastroenteritis and all cause diarrhea admitted to the trial hospitals from 2008-2010 will be entered in the database.
10215145|NCT01273077||Prospective Surveillance|Will begin on December 1, 2010. Data will be collected to identify hospitalizations for all cause diarrhea and rotavirus gastroenteritis at all 3 sites through the first two consecutive rotavirus seasons following vaccination.
10215146|NCT01273077||Safety Intussusception|Each trial hospital will identify cases of severe diarrhea and intussusception in Rotarix vaccine recipients through the first two consecutive rotavirus seasons following vaccination.
10215147|NCT01273077||ED Rotavirus Snap Shot Study|During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted in year one. In year 2 and 3 of the project:, systematic stool sampling will be carried out for cases of gastroenteritis in children < 5 years of age presenting to the ED departments.
10215148|NCT01273077||KAB Questionnaire for HCP and Parents|Data will be collected by a validated survey given to Parents, Healthcare providers and Program organizers throughout the 2 year program.
10215149|NCT01267812|Experimental|Treatment (bortezomib and rituximab)|Doses of bortezomib given is 1.3 mg/m2 weekly x 4 weeks given every 3 month x 8 cycles. Doses of RITUXAN given is 375 mg/m2 give weekly x 4 weeks given every 6 month for 4 cycles.
10215150|NCT01244828|Experimental|Asenapine|Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
10215151|NCT01207492|Experimental|Nilotinib|Nilotinib 200 mg taken as 400 mg twice daily, continuously
10215152|NCT01181778||All Qualified Participants|All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment
10215153|NCT01047540|Experimental|Dose regimen 1|
10215154|NCT01047540|Experimental|Dose regimen 2|
10215155|NCT01047540|Experimental|Dose regimen 3|
9952867|NCT01116726|Experimental|Motivational interviewing and enhanced community services|Motivational interviewing sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries, provided shortly after childbirth, and at 6, 12, and 18 months. Enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ECC through public service announcements and brochures.
9952868|NCT01116726|Active Comparator|Enhanced community services|Enhanced community services will involve development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
9952869|NCT01116752|Active Comparator|Strict control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive strict glycemic control (80-140 mg/dL)
9952870|NCT01116752|Active Comparator|Conservative control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive conservative control (190-220 mg/dL).
9952871|NCT01116765|Experimental|experimental group|Infants in the experimental group receive an oral stimulation program consisting of stimulation of the oral structures during 10 consecutive days
9952872|NCT01116765|Other|control group|Infant in the control group receive no stimulation only non nutritive sucking during feeding
9952873|NCT01116778|Experimental|eN-Lac® Capsules|
9952874|NCT01116778|Other|Placebo Capsules|
9952875|NCT01116791|Experimental|CRS+HIPC|Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment
9952876|NCT01116804|Other|inoperable liver cancer patients|
9952877|NCT01116817|Experimental|LPV/r monotherapy 400/100 mg twice daily, orally administered|LPV/r monotherapy 400/100 mg twice daily, orally administered
9952878|NCT01116817|Active Comparator|Lumbar puncture|LPV/r 400/100 mg twice daily + 2 NRTI, orally administered.
9952879|NCT01116830|Placebo Comparator|Placebo|
9952880|NCT01116830|Experimental|RO4917838|
9952881|NCT01116843|Experimental|PF-00299804|Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
9952882|NCT01116843|Placebo Comparator|Placebo arm|Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
9952883|NCT01116856|Experimental|Nutrition|This groups will follow a diet.
9952884|NCT01116856|Experimental|Nutrition + resistance training|In this group, nutrition and resistance training will be combined.
9952885|NCT01116856|Experimental|Nutrition + aerobic training|In this group nutrition and aerobic training will be combined.
9952886|NCT01116856|Experimental|Nutrition + mixed training|In this group the nutrition will be combined with 50% of resistance training plus 50% of aerobic training.
9952887|NCT01116869||MBC patients|300 MBC patients, each of whom will provide a series of at least 3 blood draws (baseline, 3-4 weeks and 6-8 weeks after the initiation of the systemic therapy) for CTC analysis, will be enrolled. All MBC patients will be followed for a maximum of 36 months for disease progression and survival.
9952888|NCT01116869||Benign disease volunteers|100 Benign disease volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
9952889|NCT01116869||Healthy volunteers|100 Healthy volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
9952890|NCT01116908|No Intervention|Control|
9952891|NCT01116908|Active Comparator|LifeStraw Family|
10035218|NCT01803997|Other|SPARK|12 physical activity classes offered over 6 weeks (approximately 2 classes/week)
10035219|NCT01804010|Active Comparator|Ivabradine|Single and repeated oral administrations of 3 doses of ivabradine
9952892|NCT01116947|Active Comparator|Intervention Arm|1. Treatment Arm (CASES) will receive high protein meals during thrice weekly hemodialysis in-center (each meal includes ~50 g of protein, ~850 Cal, and phos/protein ratio <10 mg/g) PLUS dietary counseling to continue similar high protein intake with low phosphorus to protein ratio and to avoid foods with high preservative content. Fosrenol 1.0 to 1.5 g per meal will be prescribed (use of pill crusher will be recommended) and will be titrated based on bi-weekly phosphorus levels.
9952893|NCT01116947|Active Comparator|Control Arm (CONTROLS)|2. Control Arm (CONTROLS) will receive salad boxes in-center (no protein, low calorie) and routine dietary counseling and will continue pre-existing phosphorus binder regimen.
9952894|NCT01116960||Faculty; MD|Full time Faculty members working with the Department
9952895|NCT01116960||CRNAs|Full time CRNAs working within the department
9952896|NCT01116960||Residents|Residents working within the department
9952897|NCT01116973|Other|CICC comparison with PICC|All patients will be having CVP reading taken from the CICC
9952898|NCT01116973|Other|PICC group|The transition to the PICC, a 5.0-French, 18-gauge double lumen PICC (BARD, Power PICC Solo Catheter with Tip Location Stylet; Salt Lake City, UT) will be inserted
9952899|NCT01116999|Experimental|Tracheal intubation|
9952900|NCT01117025|Active Comparator|Circumferential PVI|
9952901|NCT01117025|Active Comparator|Circumferential PVI+renal denervation|
9952902|NCT01117038|Experimental|enalapril and avanafil|
9952903|NCT01117038|Experimental|amlodipine and avanafil|
9952904|NCT01117064|Active Comparator|NMTD adjustment testing|We will determine effective NMTD device settings for reducing AHI.
9952905|NCT01117064|Active Comparator|CPAP vs NMTD device|We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
9952906|NCT01117064|Active Comparator|NMTD efficacy and tolerability|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
9952907|NCT01117116|Active Comparator|fluticasone propionate and salmeterol|
9952908|NCT01117116|Active Comparator|budesonide and formoterol|
9952909|NCT01117129|Experimental|A|
9952910|NCT01117129|Placebo Comparator|B|
9952911|NCT01117142||CLL/SLL|Chronic lymphocytic leukemia/small lymphocytic lymphoma
9952912|NCT01117142||Healthy Volunteers|Healthy Volunteers
9952913|NCT01117142||MBL|Monoclonal B-cell lymphocytosis
9952914|NCT01117142||MCL|Mantle Cell Lymphoma
9952915|NCT01117194|Experimental|shoulder training, rehabilitation robot|
9952916|NCT01117194|No Intervention|control group|
9952917|NCT01117220|Placebo Comparator|2|
9952918|NCT01117220|Active Comparator|1|
10005151|NCT01582646|Other|first period with terbutaline and second period with placebo|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
10005152|NCT01582646|Other|first period with placebo and second period with terbutaline.|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
10005153|NCT01582659|No Intervention|No ekstra counseling|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made.
10005154|NCT01582659|Active Comparator|2 counseling sessions|Standardized information about childhood constipation is given and the child receives PEG 3350. 2 additional follow up appointments by telephone are made.
10005155|NCT01582659|Active Comparator|Web access|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made but the family are given access to a website with information about childhood constipation.
10005156|NCT01582672|Experimental|AGS-003 + Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
10005157|NCT01582672|Active Comparator|Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
10005158|NCT01582685|Experimental|Exercise Group|The intervention is a structured walking program which will be performed partly in the Pavilion Physical Therapy clinic and partly at home. The participant will be instructed in how hard to exercise, how long to exercise, and how many times in a week to exercise. You will also be instructed in how to exercise safely.
10005159|NCT01582685|No Intervention|No Exercise|These participants will receive standard of care follow up.
10005160|NCT01582698|Experimental|Seropersistence evaluation + 2nd booster vaccination|Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
10005161|NCT01582711|Active Comparator|3HP Directly Observed Therapy (DOT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) under Directly Observed Therapy (DOT)
10035220|NCT01804010|Placebo Comparator|Placebo|Placebo administration
10035221|NCT01804023||Healthy women|
9952919|NCT01117233|Experimental|Single IV Dose 1|
9952920|NCT01117233|Experimental|Single IV Dose 2|
9952921|NCT01117233|Experimental|Single IV Dose 3|
9952922|NCT01117233|Experimental|Single IV Dose 4|
9952923|NCT01117233|Experimental|Single IV Dose 5|
9952924|NCT01117246|Experimental|Treated bone metastasis|Patients with bone metastasis causing pain.
9952925|NCT01117272||PCOS group|Who met the 2003 Rotterdam criteria.
9952926|NCT01117272||Mild hyperprolactinaemia group|Who were diagnosed with prolactin levels above the upper limit of normal (24.29 ng/ml) and under 100 ng/ml.
9952927|NCT01117272||Control group|Without PCOS and with normal prolactin levels.
9952928|NCT01117285|Active Comparator|3-day post-graduate course|3-day post-graduate course on the use of the COTiD program in clinical practice
9952929|NCT01117285|Experimental|Combined implementation strategy|The combined implementation strategy
9952930|NCT01117298|Experimental|Tadalafil|
9952931|NCT01117298|Placebo Comparator|Placebo|
9952932|NCT01117363|Experimental|Rye porrige breakfast|
9952933|NCT01117363|Active Comparator|Refined wheat reference bread breakfast|
9952934|NCT01117376|Active Comparator|Erythromycin|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
9952935|NCT01117376|Active Comparator|Methylnaltrexone|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
9952936|NCT01117389||Mothers of Childhood cancer survivors|Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the After Completion of Therapy (ACT) clinic at SJCRH. Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the ACT clinic surviving childhood cancer will be asked to complete a questionnaire which queries sociodemographic, medical, and psychological variables which may relate to HPV vaccination.
9952937|NCT01117389||Acquaintance control Group|"Mothers or female primary caregivers ( with daughters aged 9-17) and young adult females aged 18-26 referred for study participation by participants from the ACT clinic. Participants have daughters aged 9-17 years or young adult females aged 18-26 at the time of study enrollment For those acquaintance controls electing to complete the paper-and-pencil questionnaire, the study team will send it to them in the mail along with a pre-addressed, stamped, return envelope. For those electing to complete the on-line questionnaire, the participant's email address will be collected and a secured link to our on-line questionnaire will be sent to them in an email.~A supplemental community control sample (meeting the inclusion and exclusion criteria outlined above) will also be utilized via the subject pool in the Department of Psychology at The University of Memphis."
9952938|NCT01117415||Gall Bladder Surgery|Who have symptomatic cholelithiasis and wish to undergo laparoscopic cholecystectomy for treatment.
9952939|NCT01117441|Active Comparator|R1 control arm|see detailed protocol description
9952940|NCT01117441|Experimental|R1 experimental arm|see detailed protocol description
9952941|NCT01117441|Active Comparator|R2 control arm|see detailed protocol description
9952942|NCT01117441|Experimental|R2 experimental arm|see detailed protocol description
9952943|NCT01117441|Active Comparator|R-HR control arm|see detailed protocol description
10005162|NCT01582711|Experimental|3HP Self Administered Therapy (SAT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)
10005163|NCT01582711|Experimental|3HP SAT with SMS Reminders|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.
10005164|NCT01582724|Experimental|Self-care acupressure|1
9952944|NCT01117441|Experimental|R-HR experimental arm|see detailed protocol description
9952945|NCT01117467|Experimental|Solo|Students will perform their simulation scenario solo and receive feedback within the group
9952946|NCT01117467|Experimental|Paired|Students will be paired with one of their peers for this simulation scenario
9952947|NCT01117493|Other|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
9952948|NCT01117493|Experimental|Expert Patient Programme|Receives a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
9952949|NCT01117519|Active Comparator|unbalanced infusion solution|
9952950|NCT01117519|Active Comparator|balanced infusion solution compound|
9952951|NCT01117532|Experimental|EFT|Four 90 minute group EFT classes
9952952|NCT01117532|No Intervention|No Treatment|
9952953|NCT01117545|Experimental|EFT|Six sessions of EFT (Emotional Freedom Techniques)
9952954|NCT01117545|No Intervention|Wait List|One month wait period
9952955|NCT01117571||open label|iUni® Unicompartmental Knee Resurfacing Device
9952956|NCT01117597|Active Comparator|low RF exposure level|Intervention with low RF exposure level SAR 1.5 W/kg
9952957|NCT01117597|Sham Comparator|sham RF exposure|Intervention with sham RF exposure
9952958|NCT01117597|Active Comparator|high RF exposure level|intervention with high RF exposure level SAR 6W/kg
9952959|NCT01117610|Active Comparator|epidural injection (group I)|patients in Group I will receive epidural injection of 0.1% ropivacaine 10 ml before skin incision.
9952960|NCT01117610|Placebo Comparator|epidural injection group (group C)|control group will receive no medication preoperatively and during operation
9952961|NCT01117636|Experimental|Arm 1|
9952962|NCT01117636|Active Comparator|Arm 2|
9952963|NCT01117636|Placebo Comparator|Arm 3|
9952964|NCT01117649|Experimental|1|hyper-oncotic colloid
9952965|NCT01117649|Active Comparator|2|iso-oncotic colloid
9952966|NCT01117649|Active Comparator|3|crystalloid
9952967|NCT01117662|Experimental|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
9952968|NCT01117662|Placebo Comparator|Control|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
9952969|NCT01117675|Other|Arm I|Arm I: HIV-infected patients controlled through Virtual Hospital
9952970|NCT01117675|Other|Arm II|Arm II: HIV-infected patients controlled through Standard Care
9952971|NCT01117688|Active Comparator|B - without SGW|Ureteroscopy without SGW in place.
9952972|NCT01117688|Active Comparator|A - with SGW|Ureteroscopy with SGW in place.
9952973|NCT01117701|Experimental|A - with SGW|Measurement of the forces needed to passage the ureteroscope in the ureter with a SGW in place.
9952974|NCT01117701|Experimental|B - without SGW|Measurement of the forces needed to passage the ureteroscope in the ureter without a SGW in place.
9952975|NCT01117714|Active Comparator|EUS/EBUS with FNA|EUS/EBUS staging will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. If present and accessible, at least one lymph node from each accessible station will be aspirated with a separate fine needle using routine FNA and cytological techniques. If multiple lymph nodes are present in a single station, the largest lymph node from that location will be sampled. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the staging procedures will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
9952976|NCT01117714|Active Comparator|Surgical Mediastinoscopy|Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
9952977|NCT01117740||Thoracoscopy Group|
9952978|NCT01117740||Indwelling Pleural Catheters|
9952979|NCT01117753|Experimental|OPT-A|OPT-A is an outpatient family-based treatment for co-occurring substance use and internalizing disorders
9952980|NCT01117753|Active Comparator|Treatment as Usual|Treatment as usual in a community based mental health center
9952981|NCT01117779||Kidney lesions amenable to cryoablation|Kidney lesions treated with cryoablation.
9952982|NCT01117805|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based telephone counseling intervention designed for African American women with asthma.
9952983|NCT01117805|No Intervention|usual care|Usual care at the University of Michigan Health System is based on the guidelines as recommended by the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP-EPR3): Diagnosis and Treatment of Asthma and is coordinated so that all patients receive the same action plan, educational materials and instructions in use of devices.
9952984|NCT01117818|Active Comparator|A: AFFITOPE AD02|
9952985|NCT01117818|Active Comparator|B: AFFITOPE AD02|
9952986|NCT01117818|Active Comparator|C: AFFITOPE AD02|
9952987|NCT01117818|Active Comparator|D: Placebo control|
9952988|NCT01117844|Experimental|Proton radiation|
9952989|NCT01117896|Experimental|Adult vs Pedi manikin CC quality|"The primary objective is to determine whether chest compression deterioration occurs at the same rate in pediatric and adult manikins. The primary endpoint will be the difference in mean number of effective compressions per minute in each manikin at times 1, 2, 5 and 10 minutes.~Another objective is to identify the correlation between the anaerobic threshold and the deterioration of compressions in each manikin. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each manikin."
9952990|NCT01117896|Experimental|Stepstool use|A third main objective is to determine the effect of the stepstool use on the quality of chest compressions and metabolic demand. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each experimental group.
10005165|NCT01582724|No Intervention|Usual care|2
10005166|NCT01582737||Group 1|Patients treated with Xarelto for the purpose of prevention of ischemic stroke and systemic embolism
10005167|NCT01582750||Local advanced rectal cancer EUS|
10005168|NCT01582763||GBS|Guillain-Barré syndrome >1000, follow-up 1-3 years
10005169|NCT01582763||NC|Normal controls (NC)
9952991|NCT01117909|Sham Comparator|"Laying of hands plus standard therapy"|Subjects will lie on their back as if they were receiving the joint mobilization treatment and the therapist will place their hands in a position as if to perform the mobilization but no movement will occur. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
9952992|NCT01117909|Experimental|Standard therapy with joint mobilization|This group will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session, in addition to standard therapy. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
9952993|NCT01117922|Experimental|Intervention|After consent, subjects will be assigned to either a usual care group (no intervention) or an intervention group (targeted interconceptional interventions).
9952994|NCT01117922|Other|Usual Care Group|This group will receive usual care.
9952995|NCT01117935|Experimental|Arm I|Patients undergo hypofractionated intensity modulated radiotherapy once daily, 5 days a week, for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with intermediate- and high-risk disease may also receive concurrent and adjuvant or long-term androgen deprivation therapy for up to 36 months.
9952996|NCT01117961|No Intervention|control|
9802306|NCT05315206|Experimental|Citicoline Treated Group, TC Group|In a group of patients with open angle glaucoma (OAG), Citicoline in oral solution (10 ml / day) will be administered for 12 months (Citicoline Treated Group, TC Group)
9802307|NCT05315206|Placebo Comparator|Placebo Treated Group, TP Group|in another group of patients with open angle glaucoma (OAG) will be administered Placebo (Containing all excipients of Citicoline in oral solution) (10 ml / day) for 12 months (Placebo Treated Group, TP Group)
9952997|NCT01117961|Experimental|Intervention|Lifestyle intervention delivered during pregnancy
9952998|NCT01117974|Experimental|Liposuction|
9952999|NCT01118000|Experimental|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
9802308|NCT05315193|Experimental|Structured In-patient and Home plan|Structured In-patient and Home plan
9802309|NCT05315193|Placebo Comparator|Conventional therapy|Conventional protocol as per guidelines
9953000|NCT01118078||Biomarker (DNA methylation, gene expression, RT-PCR)|Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
9953001|NCT01118104|Other|Pulmonary vocational rehabilitation|
9953002|NCT01118130||Case|MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
9953003|NCT01118130||Control|MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
9953004|NCT01118156||Mental Health Clinicians|MH Clinicians at the Denver and Grand Junction VA Medical Centers
9953005|NCT01118169||Veterans|
9953006|NCT01118182||Traumatic Brain Injury (TBI)|Veterans with a positive history of TBI
9953007|NCT01118182||No Traumatic Brain Injury (TBI)|Veterans with a negative history of TBI
9953008|NCT01118195||TBI and Suicidal Behavior|
9953009|NCT01118195||TBI and No Suicidal Behavior|
9953010|NCT01118208|Experimental|Blister Packaging|Patients will receive all prescription medications on blister pack cards.
9953011|NCT01118208|Active Comparator|Dispense as Usual|Patients will receive all prescription medications in standard pill bottles.
9953012|NCT01118234|Experimental|Rituximab|Treatment with Rituximab 375 mg/m² every 3 months for 24 months
9953013|NCT01118234|No Intervention|Observation|Observation for 24 months
9953014|NCT01118247|Experimental|pure Ti|Cup and stem partly coated with pure titanium
9953015|NCT01118247|Active Comparator|pure Ti and HA|Cup and stem partly coated with pure titanium, and fully coated with HA.
9953016|NCT01118260|Active Comparator|TIVA|Total intravenous anaesthesia (TIVA) with propofol and remifentanil
9953017|NCT01118260|Active Comparator|Spinal|Spinal anaesthesia with bupivacaine and fentanyl
9953018|NCT01118286||Group 1|
9953019|NCT01118364|Experimental|cigarette with cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)"
9953020|NCT01118364|Other|cigarette without cannabis|"a cigarette tobacco trade mark Drum"
9953021|NCT01118390|Experimental|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
9953022|NCT01118390|Active Comparator|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
9953023|NCT01118403|Experimental|Sultamicillin, Antibiotic Prophylaxis|Sultamicillin, Antibiotic Prophylaxis
9953024|NCT01118403|Placebo Comparator|Placebo|Physiologic Sodium Chloride Solution
9953025|NCT01118416|Experimental|intervention condition|Participants randomized to the intervention condition will undergo 4 one-hour sessions of motivational interviewing (MI), during which their sexual risk taking and substance use patterns will be discussed with a trained counselor with the goal of reducing instances of unprotected anal sex and substance use.
9953026|NCT01118416|Active Comparator|Education condition|Participants randomized to the education condition will undergo 4 one-hour sessions during which they will view video segments and discuss sexual risk taking and substance use with a health educator, with the goal of reducing instances of unprotected anal sex and substance use by making informed decisions.
9953027|NCT01118429|Experimental|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
9953028|NCT01118429|Placebo Comparator|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
9953029|NCT01118481||Pressure and flow velocity|
9953030|NCT01118481||Pressure only|
9953031|NCT01118494||CKD patients|People who have been diagnosed with CKD，and been in the stage of 3 or 4.
9953032|NCT01118507||TRISOMY|mothers of a trisomic fetus 21
9953033|NCT01118507||NORMAL KARYOTYPE|mothers of DISOMIQUE foetus 21
9953034|NCT01118533|Experimental|metallic blades|laryngoscope blade material
9953035|NCT01118533|Active Comparator|plastic laryngoscope blades|Laryngoscope Blade Material
9953036|NCT01118546||controls 2|patient without CAD, not on aspirin and without history of hypersensitivity
9953037|NCT01118546||case of hypersensitivity|patient with CAD on aspirin, with a history of hypersensitivity
10215156|NCT01047540|Experimental|Dose regimen 4|
10215157|NCT01047540|Placebo Comparator|Placebo|
9953038|NCT01118546||controls 1|patient with CAD on aspirin, without history of hypersensitivity
9953039|NCT01118559|Experimental|fast-fed sequence group|drug is administered in a fasted condition first, and fed-condition study follows
9953040|NCT01118559|Experimental|fed-fast sequence group|drug is administered in a fed condition first, and fasted-condition study follows
10215158|NCT01044160||Oncology Group|The study will recruit from outpatient clinics with procedures designed to obtain a representative sample of research participants, in terms of diagnosis and time since diagnosis.
9953041|NCT01118572|Experimental|YM177 group|
9953042|NCT01118572|Active Comparator|etodolac group|
9953043|NCT01118572|Placebo Comparator|placebo group|
9953044|NCT01118585|Other|TIF Procedure|Intervention: Transoral incisionless fundoplication procedure using the EsophyX device. During general anesthesia the EsophyX device is introduced trans orally into the stomach and used to created a 270 degree, 3cm in length, wrap at the distal end of the esophagus to treat GERD.. .
9953045|NCT01118598|Placebo Comparator|placebo arm|this group will receive placebo as per protocol
9953046|NCT01118598|Active Comparator|tredaptive|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
10215159|NCT01044160||Control Group|The study will first identify a large cohort of children who are willing to participate, and then call them back individually as they are found to match participants in the cancer group.
10215160|NCT01044056|Active Comparator|Levonorgestrel/ethinylestradiol oral contraceptive pill|Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
10215161|NCT01044056|Active Comparator|Norelgestrominum and ethinylestradiol contraceptive patch|Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
10215162|NCT01044056|Active Comparator|Etonogestrel and ethinylestradiol contraceptive vaginal ring|Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
10215163|NCT01005056||Marvelon®|Single arm study. All participants receive Marvelon® according to the approved dosage and administration method.
10215164|NCT00967746|Experimental|ENG-MIUS low|Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm
10215165|NCT00967746|Experimental|ENG-MIUS intermediate|Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm
9953047|NCT01118637|Experimental|Immediate|Assigned immediately after baseline assessment to receive step 1 treatment (web-based self-help)
9953048|NCT01118637|No Intervention|Wait list|Assigned to wait list for 10 weeks before receiving step 1 treatment.
9953049|NCT01118676|Experimental|Cilengitide with standard radiochemotherapy|Cilengitide (4 dose levels are defined :12, 18, 27 et 40 mg /hour) concomitant with radiotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction) and cisplatin and vinorelbine based chemotherapy.
9953050|NCT01118689|Experimental|MLN0128|
9953051|NCT01118702|Active Comparator|001|Concerta one 54mg tablet once
9953052|NCT01118702|Active Comparator|002|Ritalin-SR 3-20mg tablets once
9953053|NCT01118702|Active Comparator|003|Novo-Methylphenidate ER-C one 54mg tablet once
9953054|NCT01118754|Experimental|DE-101 ophthalmic suspension high dose|
9953055|NCT01118754|Experimental|DE-101 ophthalmic suspension low dose|
9528831|NCT03207321||Intervention|In 15 intervention villages, a balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma' - was offered daily to pregnant women and children under six years of age during 1987-1990. The meal provided on average 500 kcal energy and 20-25g of protein to women and half of those amounts to children.
9953056|NCT01118754|Placebo Comparator|DE-101 ophthalmic suspension vehicle|
9953057|NCT01118793||double dosing of Clopidogrel|
9953058|NCT01118806||medical residents, vit d|vitamin
9953059|NCT01118806||levels of vitamin d|resident
9953060|NCT01118819|Experimental|Clostridium novyi-NT spores|
9953061|NCT01118858||Case|Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive impulsive, or inattentive type (ADD).
9953062|NCT01118858||Control|Healthy subjects: Age and gender matched subjects who do not meet any of the exclusion criteria
9953063|NCT01118871|Active Comparator|Standard of care|
9953064|NCT01118871|Experimental|NRTI sparing arm|
9953065|NCT01118884|Experimental|sedation|20 healthy uncooperative children aged 36-96 months were examined in a cross-over study design , each patient served as his/her own control. Each patient was assigned randomly to received 1 of 2 drug regimens for initial sedation session and the other regimen administered at second session which was one week later.
9953066|NCT01118897|Experimental|Neoadjuvant chemoradiation|All patients will receive concurrent chemoradiation. Chemotherapy will consist of Inj. Gemcitabine 300mg/mt2 weekly throughout the course of Radiotherapy. Radiotherapy will be delivered using Tomotherapy to a dose of 57Gy/25# over 5 weeks
9953067|NCT01118910|Experimental|Vusion ointment|
9953068|NCT01118923|No Intervention|Washout|
9953069|NCT01118923|Active Comparator|Mablet|
9953070|NCT01118923|Placebo Comparator|Placebo|
9953071|NCT01118936|No Intervention|Washout|
9953072|NCT01118936|Active Comparator|Mablet|
9953073|NCT01118936|Placebo Comparator|Placebo|
9953074|NCT01119014|Experimental|Aripirazole|
9953075|NCT01119014|Experimental|Quetiapine prolong|
9953076|NCT01119027||Surgeons|Surgeons and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience. .
9953077|NCT01119027||Trainee Surgeons|Surgeon and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience.
9953078|NCT01119053|Sham Comparator|Arm I|In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
9953079|NCT01119053|Experimental|Arm II|Within this space of time, study participants obtain the VNS therapy at once.
9953080|NCT01119066|Experimental|Total Body Irradiation, Thiotepa and Cyclophosphamide|Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
9953081|NCT01119066|Experimental|Busulfan, Melphalan and Fludarabine|Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)
9953082|NCT01119066|Experimental|Clofarabine, Melphalan and Thiotepa|Clofarabine (20mg/m2/ day x 5) (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
10005170|NCT01582763||IC|Infectious controls (IC)
9953083|NCT01119066|Experimental|Melphalan, Fludarabine and Thiotepa|Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
9953084|NCT01119079|Placebo Comparator|Standard labor epidural protocol|Standard labor epidural protocol
9953085|NCT01119079|Experimental|10ml Normal Saline prior to lidocaine|
9953086|NCT01119092|Sham Comparator|Sham intervention plus standard treatment|"This group will receive a laying of hands treatment in addition to standard treatment. The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between."
9953087|NCT01119092|No Intervention|Control Group|This group will be individuals who suffer from the same injury but will be instructed to stretch at home 5 days a week for 2 weeks.
9953088|NCT01119092|Experimental|Grade IV AP joint mobilization plus standard treatment|This group will receive 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
9953089|NCT01119144|Experimental|Polycaprolactone / Tricalcium Phosphate|Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
9953090|NCT01119144|Active Comparator|Control|Control group with titanium mesh
9953091|NCT01119157|Experimental|humoral and cellular immune response|
9953092|NCT01119157|Experimental|reactogenicity|
10005171|NCT01582763||OND|Other neurological diseases (OND)
10005172|NCT01582815|Experimental|JNJ-40411813|
10005173|NCT01582815|Placebo Comparator|Placebo|
10005174|NCT01582828|Active Comparator|Epicardial (surgical) ablation|Epicardial Pulmonary vein isolation
10005175|NCT01582828|Experimental|Hybrid|Epicardial (surgical) ablation & Endocardial assessment
10005176|NCT01582841|Experimental|MSI testing|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI following surgery. Those with MSI-H results will receive a genetic counseling informational call.
9528832|NCT03207321||Control|No supplement was provided in 14 control villages.
9528833|NCT03207490|Experimental|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
10005177|NCT01582841|No Intervention|Usual care|These patients will be treated as usual by their oncologist and medical team. These patients receive a follow up letter a year after randomization, alerting them to the availability of clinical Lynch Syndrome screening.
10005178|NCT01582867|Experimental|HD and HDF|During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
10005179|NCT01582867|Experimental|HDF and HD|patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
10005180|NCT01582893|Experimental|HCO1100-P14L|HCO1100 is connected in row with low flux dialyzer P14L
10005181|NCT01582893|Active Comparator|P210H|High flux Filter P210H
10005182|NCT01582906||Control Group|Participants randomised to the control group would receive usual rehabilitation care via the existing referral pathways.
10005183|NCT01582906||Intervention Group|Participants randomised to the intervention group will be offered two rehabilitation appointments at three month intervals. They will complete the screening tool, the Distress (Concerns) Thermometer before the first appointment; this will be reviewed after three months. Appointments will make use of communication skills recognised to promote motivation via self-efficacy. Self efficacy is a person's belief in their ability to achieve a goal. Their sense of mastery will influence their behaviour, their perception of stress and the effort they put into achieving that goal.
10005184|NCT01582919|Experimental|Participant from AMI cohort|
10005185|NCT01582919|Active Comparator|Participant from 3Ccohort|
10005186|NCT01582932|Experimental|Calcipotriene 0.005% Foam|Foam is a vitamin D3 analog (calcipotriene) foam 0.005%. It is applied twice a day for 8 weeks to psoriasis lesions (except the face).
10005187|NCT01582958|Experimental|Treatment|This arm will receive the usual Pulmonary Rehabilitation Program plus OMT, the intervention.
10005188|NCT01582958|Placebo Comparator|placebo|Receives normal pulmonary rehabilitation care plus positioned to receive OMT but OMT is not provided.
9953093|NCT01119170|Placebo Comparator|control starter formula|
9953094|NCT01119170|Experimental|D-lactate probiotics|
9953095|NCT01119183|No Intervention|1|
9953096|NCT01119183|Active Comparator|2|
9953097|NCT01119183|Experimental|3|
9953098|NCT01119196|No Intervention|glucose-based dialysate|most frequently used Standard of Care (SOC) dialysate
9953099|NCT01119196|Other|Icodextrin dialysate|alternate SOC dialysate
9953100|NCT01119209|Active Comparator|Ropivacaine|
9953101|NCT01119209|Placebo Comparator|Saline|
9953102|NCT01119235|Active Comparator|Cohort 1: PF-04531083|
9953103|NCT01119235|Active Comparator|Cohort 2: PF-04531083|
9953104|NCT01119261|Active Comparator|Non-genotype-guided dosing algorithm|
9953105|NCT01119261|Experimental|Genotype-guided dosing algorithm|
9953106|NCT01119274|Active Comparator|Non-genotype-guided dosing algorithm|
9953107|NCT01119274|Experimental|Genotype-guided dosing algorithm|
9953108|NCT01119300|Active Comparator|Standard care|Standard care
9953109|NCT01119300|Experimental|Genotype-guided dosing algorithm|Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
9953110|NCT01119313|Experimental|LAS 41002|
9953111|NCT01119313|Active Comparator|Active|
9953112|NCT01119326|Placebo Comparator|Placebo|Placebo procedure
9953113|NCT01119326|Experimental|Autologous Fat Transfer (AFT) group|Subjects will be registered in the context of either the Early AFT subgroup, or the Delayed AFT subgroup based on the timing of their wound closure: early AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 2-4 weeks of definitive closure (STSG) or healing (secondary closure) and the delayed AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 6 months or more of definitive closure (STSG) or healing (secondary closure
9953114|NCT01119339|Experimental|LAS 41004 dosage 1|
9953115|NCT01119339|Experimental|LAS 41004 dosage 2|
9953116|NCT01119339|Experimental|LAS 41004 dosage 3|
9953117|NCT01119339|Experimental|LAS 41004 dosage 4|
9953118|NCT01119339|Experimental|LAS 41004 dosage 5|
9953119|NCT01119339|Experimental|LAS 41004 dosage 6|
9953120|NCT01119339|Placebo Comparator|Placebo|
9953121|NCT01119339|Active Comparator|Reference|
9953122|NCT01119352|Experimental|1|
9953123|NCT01119352|Placebo Comparator|2|
9953124|NCT01119378|Experimental|Post Menopausal|post menopausal women between the ages 50-70 yrs.
9953125|NCT01119391||Patients undergoing IVF|Women undergoing an in vitro fertilization cycle
9953126|NCT01119404||Metabolic Syndrome|120 men with metabolic syndrome
9953127|NCT01119404||Coronary Heart Disease (CHD)|120 men with angiographically verified CHD
9953128|NCT01119404||Control|80 physically active men
9953129|NCT01119417|Experimental|BQ123|endothelin blocker
9953130|NCT01119417|Placebo Comparator|Saline|IV saline
9953131|NCT01119430|Placebo Comparator|Fluoxetine plus placebo|
9953132|NCT01119430|Active Comparator|Fluoxetine plus DU125530|
9953133|NCT01119469|Experimental|Cognitive Therapy (CT)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include psychoeducation, attention training, cognitive restructuring, behavioral experiments, imagery rescripting and relapse prevention.
9953134|NCT01119469|Experimental|Exposure Therapy (ET)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include change of safety behavior, exposition (in sensu and in vivo), and response prevention.
9953135|NCT01119469|No Intervention|Waiting List (WL)|12 weeks waiting time
9953136|NCT01119482|Other|Vaccination|Healthy volunteers before and after vaccination
9953137|NCT01119521|Experimental|Group A: INH; BCG|6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI) (completed within no more than 7 months) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination.
9953138|NCT01119521|Experimental|Group B: observation; BCG; observation; INH|7 months of observation (run in period) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination followed after 6 months of observation by 6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI).
9953139|NCT01119534|Experimental|Transpulmin|Suppository composed by guaiacol, eucalyptol, menthol and camphor
9953140|NCT01119534|Active Comparator|Comparator 1|Suppository composed by guaiacol
9953141|NCT01119534|Active Comparator|Comparator 2|Syrup composed by guaifenesin
10005189|NCT01582958|No Intervention|Control|This arm receives only pulmonary rehabilitation care.
9953142|NCT01119547|Experimental|Home exercise|The patients is training at home during 6 v. with an individual exercise program.
9953143|NCT01119547|Experimental|Exercise in group|The patients is doing their individual exercise program in a group.
9953144|NCT01119560||Ancillary-Correlative (Questionnaire, saliva & tissue sample)|The biologic mother of the patient is asked to complete a Diet History Questionnaire about diet during pregnancy, and information on demographics, lifestyle factors, medication used during pregnancy, history of breast feeding, and family history of cancer or birth defects. Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen samples are collected from both biologic parents and the patient. Tissue samples previously stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted from samples, amplified and analyzed using real-time PCR quantitation assay, and genotyped using single nucleotide polymorphisms.
9953145|NCT01119599|Experimental|Treatment (RO4929097, surgery, radiation therapy)|See Detailed Description.
9953146|NCT01119612|Active Comparator|Iron|
9953147|NCT01119612|Placebo Comparator|Placebo|
9953148|NCT01119638|Active Comparator|Escitalopram Drug|"Drug:~Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion."
9953149|NCT01119638|Active Comparator|Risperidone Drug|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
9953150|NCT01119651|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
9953151|NCT01119651|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
9953152|NCT01119651|Experimental|Tazarotene Foam & UVA/UVB/visible light|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB and visible light irradiation
9953153|NCT01119651|Placebo Comparator|Vehicle Foam without irradiation,|Subjects will be exposed to Vehicle Foam Patch without irradiation
9953154|NCT01119651|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
9953155|NCT01119651|Placebo Comparator|Vehicle Foam with UVA & UVB visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
9953156|NCT01119651|Sham Comparator|Blank patch without irradiation|Subjects will be exposed to blank patch without irradiation,
9953157|NCT01119651|Sham Comparator|Blank patch with UVA and UVB irradiation|Subjects will be exposed to blank patch with UVA and UVB irradiation
9953158|NCT01119651|Sham Comparator|Blank Patch with UVA & UVB visible light irradiation|Subjects will be exposed to Blank Patch with UVA and UVB and visible light irradiation
9953159|NCT01119664|Experimental|No prior chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously untreated with chemotherapy
9953160|NCT01119664|Experimental|Patients with prior Pemetrexed-based chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously treated with chemotherapy
9953161|NCT01119677|Experimental|Group 1|No dose titration
9953162|NCT01119677|Experimental|Group 2|Fast dose titration
9953163|NCT01119677|Experimental|Group 3|Slow dose titration
9953164|NCT01119690|Active Comparator|Rapeseed oil|
9953165|NCT01119690|Active Comparator|Milk fat|
9953166|NCT01119729||HIV-infected Outpatients|
9953167|NCT01119742|Experimental|Butenafine Hydrochloride 1% A|1
9953168|NCT01119742|Experimental|Butenafine Hydrochloride 1% B|2
9953169|NCT01119742|Active Comparator|Butenafine Hydrochloride 1%|3
9953170|NCT01119742|Placebo Comparator|Vehicle A|4
9953171|NCT01119742|Placebo Comparator|Vehicle B|5
9953172|NCT01119781|Experimental|peginterferon beta-1a|Single dose of peginterferon beta-1a at either 63 or 125 mcg in renal impaired Participants and healthy volunteers
9953173|NCT01119807|Experimental|IV|
9953174|NCT01119807|Experimental|Humeral IO|
9953175|NCT01119807|Active Comparator|Tibial IO|
9953176|NCT01119820|Experimental|Tissue Donation|This study will involve females over 18 who are scheduled to undergo elective surgery. These patients will be screened for participation in this study, which will only involve the collection of discarded tissue.
9953177|NCT01119872|Other|Compliance-guided PEEP group|Positive End-Expiratory Pressure(PEEP) level was set daily, according to the method described by Suter in 1978. Static compliance (Cst) was calculated at different levels of PEEP at a constant tidal ventilation of 6-8 ml/kg of predicted body weight. Cst was determined by dividing tidal volume by the difference between the pressure at the end of inflation hold and the PEEP. The maximum value of Cst in individual patients was considered as the best PEEP.
9953178|NCT01119872|Other|FiO2-driven-PEEP group|"PEEP was set based on the patient fraction of inspired oxygen (FiO2) according to the Positive End-Expiratory Pressure(PEEP) strategy reported in 2000:Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network."
9953179|NCT01119885||001|fentanyl matrix Knee osteoarthritis starting with 12mcg/h (flexible dose)
9953180|NCT01119885||002|fentanyl matrix Hip osteoarthritis starting with 12mcg/h (flexible dose)
9953181|NCT01119924|Active Comparator|Mirtazapine|Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks
9953182|NCT01119924|Placebo Comparator|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
9953183|NCT01119976|Experimental|Group A|Reduced calorie diet and exercise plan that changes with phases of the menstrual cycle
9953184|NCT01119976|Active Comparator|Group B|Different reduced calorie diet and exercise plan based on MyPyramid.gov website
9953185|NCT01119989|No Intervention|weight maintenance diet|
9953186|NCT01119989|Placebo Comparator|weight maintenance + fructose|
9953187|NCT01119989|Experimental|weight maintenance diet + fructose and amino-acid|
9953188|NCT01120002|Placebo Comparator|Placebo pill|
9953189|NCT01120002|Active Comparator|Tamibarotene|
9953190|NCT01120015|Experimental|Diacerein|diacerein 50mg oD first month, 50 mg BD next 2 months
9953191|NCT01120041|Experimental|Prenatal MI - Postpartum MI|Motivational interviewing counseling given during the prenatal and postpartum phases
9953192|NCT01120041|Experimental|Prenatal MI - Postpartum Health Ed|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
9953193|NCT01120041|Experimental|Prenatal Health Ed - Postpartum MI|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
9953194|NCT01120041|Placebo Comparator|Prenatal Health Ed/Postpartum Health Ed|Traditional health education given during the prenatal phase and the postpartum phase
9953195|NCT01120080|Placebo Comparator|Practical Counseling|
9953196|NCT01120080|Active Comparator|Alcohol Intervention Counseling|
9953197|NCT01120106|Active Comparator|levosimendan|levosimendan continuous infusion at a rate of 0.1 mcg/kg<min
9953198|NCT01120106|Placebo Comparator|placebo|saline infusion
9953199|NCT01120119|Experimental|Calcitriol|
9953200|NCT01120119|Placebo Comparator|placebo|
9953201|NCT01120132|Experimental|Cyclosporine low dose , Prednisolone Acetate|Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
9953202|NCT01120132|Experimental|Cyclosporine high dose, Prednisolone Acetate|Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
9953203|NCT01120132|Experimental|Cyclosporine high dose|Administration of a solution of Cyclosporine (high dose) and Placebo
9953204|NCT01120132|Experimental|Cyclosporine low dose|Administration of a solution of Cyclosporine (low dose) and Placebo
9953205|NCT01120132|Active Comparator|Prednisolone Acetate|Administration of a suspension of Prednisolone Acetate and Placebo
9953206|NCT01120132|Placebo Comparator|Placebo|Administration of Placebo
9953207|NCT01120145||Therapeutic efficacy study|Asymptomatic parasitemic pregnant women at 16-26 weeks of gestation will be enrolled into the study and followed weekly for 42 days after the receipt of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy to assess the clearance of parasitemia.
9953208|NCT01120145||Birth outcomes study|Women presenting for delivery will be enrolled and assessed for a history of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy and evidence of malaria infection by placental histology, maternal peripheral parasitemia, maternal anemia and infant cord blood parasitemia.
9953209|NCT01120145||Characterizing molecular markers of SP resistance|Parasitemic outpatients attending the health facility will be tested for parasite molecular markers of sulphadoxine-pyrimethamine resistance.
9953210|NCT01120158|Experimental|1|Paclitaxel/Bevacizumab
9953211|NCT01120171|Experimental|1|Cyclofosfamide/Liposomal-encapsulated doxorubicin
9953212|NCT01120301|Experimental|Transcranial Laser Therapy|
9953213|NCT01120301|Sham Comparator|Sham control procedure|
9953214|NCT01120314|Experimental|Severe renal impairment population|
9953215|NCT01120314|Experimental|Moderate renal impairment population|
9953216|NCT01120314|Experimental|Mild renal impairment population|
9953217|NCT01120314|Experimental|Healthy population|Healthy matched subjects
9953218|NCT01120327|Experimental|Amlodipine|Amlodipine
9953219|NCT01120327|Placebo Comparator|Placebo|Placebo
9953220|NCT01120340|Active Comparator|mesalamine|Posology: mesalamine: 1,6 g/die for ten days every month for 24 months
9953221|NCT01120340|Placebo Comparator|placebo|
9953222|NCT01120366|Active Comparator|SWITCH|Tocilizumab monotherapy
9953223|NCT01120366|Active Comparator|ADD-ON|Tocilizumab plus methotrexate combination
9953224|NCT01120392|Experimental|Treatment group - Nintendo wii.|
9953225|NCT01120392|Active Comparator|conventional - Physical Therapy|
9953226|NCT01120418|Experimental|Besifloxacin Ophthalmic Suspension 0.6%|Topical ocular administration three times daily (TID) for 5 days
9953227|NCT01120431|Active Comparator|Oral rehydration therapy|
9953228|NCT01120431|Experimental|hylenex-facilitated SC hydration|
9953229|NCT01120444|Active Comparator|Subcutaneous delivery of insulin|A bolus dose of insulin will be given subcutaneously just prior to a standardized meal.
9953230|NCT01120444|Experimental|Intradermal delivery of insulin|A bolus dose of insulin will be given intradermally just prior to a standardized meal
9953231|NCT01120457|Experimental|Arm 1: Dose Escalation and Expansion cohort (AML Patients)|"Dose Escalation: BMS-936564 0.3-10 mg/kg solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)~Dose Expansion: BMS-936564 maximum tolerated dose (MTD) based on dose escalation, solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)"
9953232|NCT01120457|Experimental|Arm 2: Dose Expansion cohort (DLBCL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
9953233|NCT01120457|Experimental|Arm 3: Dose Expansion cohort (CLL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
9953234|NCT01120457|Experimental|Arm 4: Dose Expansion cohort (FL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
9953235|NCT01120496|Experimental|hypertonic saline|hypertonic saline (HS)
9953236|NCT01120496|Placebo Comparator|normal saline (NS)|normal saline (NS)
9953237|NCT01120509|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
10215166|NCT00967746|Experimental|ENG-MIUS high|High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm
10215167|NCT00967746|Active Comparator|Multiload|Multiload-cu 375®
10215168|NCT00944216|Experimental|Salkera Emollient Foam Treatment|All participants will receive this intervention.
10215169|NCT00920634||1|Patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction (amenorrhea first grade, anovulatory cycle, polycystic ovary syndrome, oligoamenorrhea) who underwent ovulation induction
9953238|NCT01120522|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
9953239|NCT01120535|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
9953240|NCT01120548|Experimental|Rehabilitation + Ventilation Group|Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.
9953241|NCT01120548|No Intervention|Rehabilitation Only Group|
9953242|NCT01120574|No Intervention|1|Oxygen therapy group.
9953243|NCT01120574|Active Comparator|2|Home mechanical ventilation plus oxygen therapy group.
9953244|NCT01120613|Experimental|chronotherapy|Patients identified with Nocturnal Hypertension, will have one of the blood pressure medications switched from daytime dosing to nighttime dosing
9953245|NCT01120652|Experimental|Mind-Body Skills Training|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices.
9953246|NCT01120652|Active Comparator|Supportive Counseling|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice.
9953247|NCT01120665|Experimental|PLACEBO-CONTROL|PLACEBO + CONTROL TO EXERCISE
9953248|NCT01120665|Experimental|ESTROGEN THERAPY + CONTROL|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + CONTROL TO EXERCISE
9953249|NCT01120665|Experimental|PLACEBO+AEROBIC TRAINING|PLACEBO + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
9953250|NCT01120665|Experimental|ESTROGEN THERAPY + AEROBIC TRAINING|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
9953251|NCT01120678||Neonates assessed for sepsis.|
9953252|NCT01120730|Active Comparator|HES|Fluid resuscitation with HES
9953253|NCT01120730|Placebo Comparator|ringers lactat|Standard treatment
9953254|NCT01120769|Active Comparator|Acetaminophen|
9953255|NCT01120769|Placebo Comparator|Placebo|
10215170|NCT00920361||1|Patients who underwent IVF
9953256|NCT01120795|Experimental|pegylated interferon and ribavirin|Anti hepatitis C agents
9953257|NCT01120821|Experimental|Study drug|Gleevec treatment
9953258|NCT01120847||Veterans with PTSD|No intervention; this is an observational study.
9953259|NCT01120847||Control group w/out PTSD|No intervention; this is an observational study.
10215171|NCT00886691|Experimental|Arm I (bevacizumab and everolimus)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and everolimus PO QD on days 1-28.
10215172|NCT00886691|Experimental|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo PO QD on days 1-28.
10215173|NCT00878462|Experimental|Sequence 1|Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
10215174|NCT00878462|Experimental|Sequence 2|Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
10215175|NCT00878462|Experimental|Sequence 3|Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
10215176|NCT00878462|Experimental|Sequence 4|Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
10215177|NCT00878462|Experimental|Sequence 5|Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
10215178|NCT00878462|Experimental|Sequence 6|Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
10215179|NCT00778999|Active Comparator|Oral Contraceptive|Use of oral contraceptive pills prior to controlled ovarian stimulation
9953260|NCT01120873|Experimental|Metamin 3D|A randomized, double-blinded and placebo-controlled study
9953261|NCT01120912|Experimental|Oral insulin and placebo|
9953262|NCT01120925|Experimental|MNC|Bone marrow derived MNC
9953263|NCT01120925|Experimental|CD133|CD133 derived from Bone marrow
9953264|NCT01120925|Placebo Comparator|Control|Normal saline with 5% Human Serum Albumin
9953265|NCT01120977||Male|
9953266|NCT01120977||Female|
9953267|NCT01121003|Other|Low fructose diet/no exercise|
9953268|NCT01121003|Experimental|high fructose diet/no exercise|
9953269|NCT01121003|Experimental|high fructose diet+exercise|
9953270|NCT01121016|Active Comparator|combination therapy|combination therapy with inhaled budesonide and oral montelukast
9953271|NCT01121016|Placebo Comparator|monotherapy|monotherapy with inhaled budesonide and placebo of montelukast
9953272|NCT01121029|Experimental|Hematopoietic stem cells|
9953273|NCT01121042|Active Comparator|Ondansetron|Ondansetron oral capsule 8mg daily
9953274|NCT01121042|Placebo Comparator|Placebo|Placebo (100% lactose) matched oral capsule
9953275|NCT01121055|Placebo Comparator|Control|Placebo 1T by mouth (po) at night one day before FB and placebo 1T po 30min before the FB
9953276|NCT01121055|Experimental|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
9953277|NCT01121068||Health care workers|
9802310|NCT05315180|Experimental|dose exploration|Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 1-6 subjects treated at the lowest planned dose level. If no DLT is observed, dose escalation will continue to the next planned dose cohort
9953278|NCT01121081|Placebo Comparator|Placebo|sugar pills
9953279|NCT01121081|Experimental|Dunaliella|drug
10005190|NCT01582984|Active Comparator|iMedConsentTM and customized written handout group|iMedConsentTM and a customized written handout
10005191|NCT01582984|Experimental|iMedConsentTM, handout, and standard video g|iMedConsentTM, handout, and standard AAOS video
10005192|NCT01582984|Experimental|iMedConsentTM, handout, video, and formal education|iMedConsentTM, the handout, the video, and a formal education session
10005193|NCT01582997|Experimental|Dose Escalation Part|Dose escalation will be conducted to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 . The dose may be escalated to the overseas recommended phase III dose.
10005194|NCT01583010|No Intervention|Standard Treatment Group|Patients receiving ultrasound guided regional anaesthesia without using Advanced Needle Visualization Technology(R)
10005195|NCT01583010|Active Comparator|ANV ® Group|Patients receiving ultrasound guided regional anaesthesia with using Advanced Needle Visualization Technology(R)
10005196|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Sham rTMS|
10005197|NCT01583023|Experimental|Placebo + Lithium a/o Epival + Active rTMS|
10005198|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Active rTMS|
10005199|NCT01583036|Experimental|Session 1 digoxin alone, Session 2 retigabine plus digoxin|Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.
10005200|NCT01583062|Active Comparator|1|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
9802311|NCT05315180|Experimental|dose expansion|dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 2 groups may be done concurrently
10005201|NCT01583062|Placebo Comparator|2|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
10005202|NCT01583075|Other|Circumferential ablation|
10215180|NCT00778999|No Intervention|Non-Oral Contraceptive|No use of oral contraceptive pills prior to controlled ovarian stimulation
10005203|NCT01583075|Experimental|Single ring ablation|
10005204|NCT01583088|Experimental|phenic nerve stimulation|effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
10005205|NCT01583088|Sham Comparator|sham|sham phenic nerve stimulation
10005206|NCT01583114|Experimental|perindopril|
10005207|NCT01583114|Placebo Comparator|placebo|same form, administration, posology, frequency and duration as perindopril
10005208|NCT01583127|Experimental|School-Wide (SW)-PBIS intervention|SW-PBIS intervention
10005209|NCT01583127|No Intervention|Control|Practice as usual
10005210|NCT01583140|Experimental|Exercise Intervention|Culturally-modified, individually tailored physical activity print materials
10005211|NCT01583140|Active Comparator|Control|Bilingual health education booklets
10005212|NCT01583153|Active Comparator|Hospital Inpatient Rehabilitation (HI)|
10005213|NCT01583153|Active Comparator|Hybrid Home Programme (HO)|
10005214|NCT01583192|Active Comparator|chloride-hexidine soluted in alcohol|"patients will have skin preparation with chloride-hexidine soluted in alcohol prior to their forefoot surgery.~Skin swabs will be taken prior to skin preparation, after skin preparation and after skin closure at the end of the operation"
10005215|NCT01583192|Active Comparator|povidine-jodine soluted in alcohol|skin perparation will be done with povidine-jodine soluted in alcohol prior to forefoot surgery.
10215181|NCT00754520|Experimental|Ceramic On Metal|This arm utilizes the ceramic on metal articulation using the M2a-38™ mm cup.
10215182|NCT00754520|Active Comparator|Metal on Metal|This arm utilizes the metal on metal articulation using M2a-38™ mm cup.
10215183|NCT00725413|Experimental|Arm 1|Healthy premenopausal women requiring a long-term method of contraception
10215184|NCT00651807|Active Comparator|Arm 1|etonogestrel
10215185|NCT00651807|Placebo Comparator|Arm 2|Placebo
10215186|NCT00620464|Active Comparator|Radiopaque Implanon (ro imp)|The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
10215187|NCT00620464|Active Comparator|Implanon (imp)|"Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year."
9802312|NCT05315167|Experimental|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level. PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
9953280|NCT01121120|Experimental|TXA127|300mcg/kg/day administered subcutaneously up to 28 days
9953281|NCT01121120|Placebo Comparator|Placebo|300mcg/kg/day administered subcutaneously up to 28 days
9953282|NCT01121133|Experimental|Arm A (navitoclax and rifampin)|
9953283|NCT01121159||Preoperatively preformed orbital plates|Reconstruction with MatrixMIDFACE Preformed Orbital Plate (Synthes) or Custom-made orbital implant
10215188|NCT00620035|Experimental|Radiopaque Etonogestrel Implant|"Radiopaque Etonogestrel Implant (drug) inserted with the Next Generation Applicator (NGA)~The Radiopaque Implant is a single rod contraceptive implant of 4 cm length and~2 mm in diameter which is placed at the inner side of the non-dominant upper-arm~about 8-10 cm above the medial epicondyle. The Radiopaque Implant contains~approximately 68 mg etonogestrel (ENG) dispersed in a matrix of ethylene vinyl acetate (EVA) copolymer and barium sulfate, surrounded by an EVA membrane. The barium-sulfate provides radio-opacity and allows detection by X-ray.~The ENG dose released from the implant amounts to about 60-70 mcg/day shortly after insertion and decreases to about 40 mcg/day at the start of the second year, and to about 25-30 mcg/day at the end of the third year."
9528834|NCT03207542|Experimental|B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
9528835|NCT03207542|Experimental|T-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
9953284|NCT01121159||Non-preformed orbital plates|Reconstruction with Orbital Floor Mesh Plate or SynPOR Titanium Reinforced Fan Sheet (both Synthes)
9953285|NCT01121198|Experimental|ASP1941 single arm|
9953286|NCT01121198|Experimental|ASP1941 repeated arm|
9953287|NCT01121198|Placebo Comparator|placebo single arm|
9953288|NCT01121198|Placebo Comparator|placebo repeated arm|
9953289|NCT01121237||CKD5, renal anaemia, haemodialysis|CKD5, renal anaemia, haemodialysis receiving recombinant human erythropoietin alfa (biosimilar)
9953290|NCT01121276|Experimental|NN1218, formulation A|
9953291|NCT01121276|Experimental|NN1218, formulation B|
9953292|NCT01121276|Experimental|NN1218, formulation C|
9953293|NCT01121276|Experimental|NN1218, formulation D|
9953294|NCT01121276|Active Comparator|insulin aspart|
9953295|NCT01121289|Experimental|NN1218, formulation A|
9953296|NCT01121289|Experimental|NN1218, formulation B|
9953297|NCT01121289|Experimental|NN1218, formulation B (high)|
9953298|NCT01121289|Experimental|NN1218, formulation C|
9953299|NCT01121289|Experimental|NN1218, formulation D|
9953300|NCT01121289|Active Comparator|insulin aspart|
9953301|NCT01121302|Experimental|1|dose escalating
9953302|NCT01121302|Placebo Comparator|2|placebo
9953303|NCT01121315||1|Diabetes type II patients, according to medical records, prescriptions or lab results, followed for >6 months after diagnosis.
9953304|NCT01121328|Experimental|Autologous cord blood transfusion|Collected cord blood at birth will be transfused for the preterm neonate
10215189|NCT00431431|Experimental|1|tibolone
10215190|NCT00431431|Active Comparator|2|raloxifene
9953305|NCT01121341|Experimental|EVOH|Procedure: Endoscopic vein with an open CO2 system harvesting
9953306|NCT01121341|Active Comparator|OVH|Procedure: Conventional vein harvesting
9953307|NCT01121354|Experimental|Cefazolin 2g (Test)|
9953308|NCT01121354|Active Comparator|Cefazolin 1.5g (Control)|
9953309|NCT01121367||Emphysema-alone|
9953310|NCT01121367||CPFE group|
9953311|NCT01121367||IPF-alone|
9953312|NCT01121367||smokers|
9953313|NCT01121367||nonsmokers|
9953314|NCT01121380|Experimental|Cohort A - 10 mg|
9953315|NCT01121380|Experimental|Cohort B - 20 mg|
9953316|NCT01121380|Experimental|Cohort C - 40 mg|
9953317|NCT01121380|Experimental|Cohort D - 80 mg|
9953318|NCT01121380|Experimental|Cohort E - X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
9953319|NCT01121380|Experimental|Cohort F - 2X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
9953320|NCT01121380|Experimental|Cohort G - 4X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
9953321|NCT01121380|Placebo Comparator|Placebo|In each cohort there is a placebo arm
9953322|NCT01121419||Neuroblastoma|
9953323|NCT01121432||Mediastinal lymphadenopathy|
9953324|NCT01121445|No Intervention|CPAP with heated humidification|Standard of care
9953325|NCT01121471|Placebo Comparator|Safflower Oil|8.0 g/day safflower oil
9953326|NCT01121471|Experimental|CLA 6.4g/day|Conjugated linoleic acid at a dose of 6.4g/day in a supplement with a total of 8.0g oil
9953327|NCT01121497|Experimental|Physostigmine|Colonoscopy sedation with or without physostigmine
9953328|NCT01121523|Experimental|Cue-directed tactile stimulation|
9953329|NCT01121523|Active Comparator|Control group|
9953330|NCT01121588|Experimental|Crizotinib|
9953331|NCT01121601|Experimental|Group COSEAL|
9953332|NCT01121601|Active Comparator|Reference group|
9953333|NCT01121614|Experimental|LOTUS|LOTUS ultrasonic instrument
9953334|NCT01121614|Experimental|Ethicon Harmonic Scalpel|Ultrasonic instrument
9953335|NCT01121614|Experimental|LigaSure|Bipolar feedback vessel sealing device
9953336|NCT01121627|Experimental|Computerized cognitive training|A 12 week computerized cognitive training
9953337|NCT01121640|Other|CA125 every screen, HE4 at confirmatory screen.|CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
10215191|NCT00413764|Experimental|1|tibolone
10215192|NCT00413764|Active Comparator|2|transdermal continuous combined E2-NETA (estradiol-norethisterone)
9802313|NCT05315167|Experimental|Monotherapy Exploration of the recommended dose|Upon completing Phase 1 and depending on data obtained, dose expansion may proceed in Phase 2 with several cohorts enrolled to confirm the tolerability of the RP2D of PRJ1-3024 (determined in Phase 1). PRJ1-3024 is administered orally once daily. The starting dose is determined by clinical effecacy data from Phase 1, and treatment may continue for up to 2 years as long as the subject experiences clinical benefit in the opinion of the Investigator and shows no signs or symptoms of unequivocal progression of disease.
9953338|NCT01121640|Other|CA125 and HE4 at every screen.|CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
9953339|NCT01121679||Patients aged 80 years and older|Patients aged 80 years and older and hospitalized in a cardiology department
9953340|NCT01121692|Experimental|VCT/Women's CoOp|
9953341|NCT01121692|Experimental|Women's CoOp/Men's CoOp|
9953342|NCT01121692|Experimental|Couples CoOp|
9802314|NCT05315154|Experimental|No axillary surgery|
9953343|NCT01121705|No Intervention|A1. standard duration|Patients were randomly assigned in a 1:1 ratio to two treatment arms. In the standard treatment group (A1), patients were treated for 24 weeks irrespective of the HCV RNA status at week 4 with Peg-interferon alfa-2b at a dose of 1.5 mcg per kilogram of body weight weekly in combination with oral ribavirin administered at a dose of 1000 mg/day for patients with a weight <75 kg or 1200 mg/day for those with a weight of ≥75 kg. Patients enrolled in Arm A1 will be treated for standard 24 weeks duration of treatment with standard dosages of PegInterferon alpha 2b and weight-based dosages of ribavirin.
9953344|NCT01121705|Experimental|B 1 I or II|In the variable treatment group, patients with a virologic response at week 4 will receive treatment for 12 weeks and those without a virologic response at 4 weeks treatment for 36 weeks. Patients without RVR will be treated for 24 or 36 weeks and labelled (B1I) or (B1II, respectively Intervention: different durations of treatment for patients without RVR
9953345|NCT01121718|Experimental|ICG Intervention|Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)
9953346|NCT01121731|Experimental|Interferon α-5|
9953347|NCT01121731|Experimental|Interferon α-5 plus Interferon α-2b|
9953348|NCT01121731|Active Comparator|Interferon α-2b (INTRON® A)|
9953349|NCT01121770|Experimental|Arixtra|
9953350|NCT01121783|Active Comparator|Lactisole-Glucose|
9953351|NCT01121783|Active Comparator|Lactisole-water|
9953352|NCT01121783|Placebo Comparator|Water-Glcuose|
9953353|NCT01121783|Placebo Comparator|Water-Water|
10215193|NCT00408863|Active Comparator|Tibolone|Tibolone 2.5 mg/day
9528836|NCT03207204|Active Comparator|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
9802315|NCT05315154|Active Comparator|Sentinel lymph node biopsy|
9802316|NCT05315141||Xiangya Hospital|
9802317|NCT05315141||The Second Xiangya Hospital|
9802318|NCT05315141||The Third Xiangya Hospital|
9802319|NCT05315141||Hunan Provincial People's Hospital|
9802320|NCT05315141||Xiangtan Central Hospital|
9953354|NCT01121796|Active Comparator|Vitamin D|
9953355|NCT01121796|Placebo Comparator|Placebo|
9953356|NCT01121796|Active Comparator|Unique vehicle for Vitamin D supplementation|
9953357|NCT01121809|Other|Raltegravir|Raltegravir 400 mg bid
9953358|NCT01121809|Other|Etravirine|Etravirine 200 mg bid
9953359|NCT01121822|Experimental|Group 1|Participants at age 18 to 59 years
9953360|NCT01121822|Experimental|Group 2|Participants at age 60 years or older
9953361|NCT01121835|Experimental|Insulin glargine|"Administered once a day in the evening, at the same time every day. The starting daily dose is 0.2 U/Kg of body weight or 12 U, at the investigator's decision.~Insulin glulisine is administered for patients of the insulin glargine group requiring insulin glulisine at week 12 (visit 11).~Insulin glulisine is administered prior (10-15 min) to the main meal of the day, which is the meal with highest Post-Prandial Plasma Glucose (PPPG) on the 3 profiles performed before week 12.~Starting dose is of 4 units per day."
9953362|NCT01121835|Experimental|Premixed insulin|administered once a day (in the evening at dinner) or twice a day (in the morning before breakfast and in the evening at dinner). Starting daily dose will be 6 U at breakfast and 6 U at dinner, if administered twice a day or 12 U at dinner if administered once a day
9953363|NCT01121848|Active Comparator|5-FU & LV|"Day 1: LV 400 mg/m2 (given as a 2-hour infusion)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.~This chemotherapy regimen will be administered each two weeks."
9953364|NCT01121848|Experimental|XELOX or modified FOLFOX-6|"XELOX:~Day 1: Oxaliplatin 130 mg/m2 (2 hours infusion)~This chemotherapy regimen will be administered each two weeks.~OR modified FOLFOX-6:~Day 1: Oxaliplatin 85 mg/m2 (given as a 2-hour infusion)~Day 1: LV 400 mg/m2 (given as a 2-hour infusion simultaneous to oxaliplatin)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours (Day 1 and 2)~This chemotherapy regimen will be administered each two weeks."
9953365|NCT01121874|Active Comparator|LRTI|These patients will undergo ligament reconstruction with tendon interposition (LRTI) surgery. They will serve as a control group, against which to compare the investigational surgical technique.
10215194|NCT00408863|Placebo Comparator|Placebo|Placebo
10215195|NCT00403793|Active Comparator|Arm 1|etonogestrel with testosterone undecanoate
10215196|NCT00403793|Placebo Comparator|Arm 2|Placebo
10215197|NCT00159796|Experimental|Arm 1|Asenapine
10215198|NCT00159796|Active Comparator|Arm 2|Olanzapine
10215199|NCT00159796|Placebo Comparator|Arm 3|Placebo
10215200|NCT00159744|Active Comparator|Arm 1|Asenapine
10215201|NCT00159744|Active Comparator|Arm 2|Olanzapine
10215202|NCT00159744|Placebo Comparator|Arm 3|Placebo
10215203|NCT00143182|Experimental|1|Asenapine
9953366|NCT01121874|Experimental|Suture fixation system|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system.
9953367|NCT01121874|Experimental|Suture fixation system + 2 week immobilization|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system, and with a decreased immobilization time from 6 to 2 weeks post-surgery.
9953368|NCT01121887|Active Comparator|Standard treatment|
9953369|NCT01121887|Experimental|Motivational Interviewing|
9953370|NCT01121952|Placebo Comparator|Placebo|Single high-velocity, low-amplitude (HVLA) thrust manipulation towards Tibia, not affecting the dysfunctional talo-crural joint
9953371|NCT01121952|Experimental|Treatment|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation on dysfunctional talo-crural joint
9953372|NCT01121965|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs
9953373|NCT01121965|Experimental|Early vitrectomy|Pars plana vitrectomy with ILM peeling would be employed when visual symptoms occur.
9953374|NCT01121978|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole or vision deterioration occurs
9953375|NCT01121978|Experimental|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
10215204|NCT00143182|Active Comparator|2|Olanzapine
10215205|NCT03705468||Ketamine sedation|Ketamine sedation
9953376|NCT01122004|Active Comparator|Gabapentin|
9528837|NCT03207204|Active Comparator|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
9953377|NCT01122004|Active Comparator|Pregabalin|
9953378|NCT01122017|Experimental|Medial Opening-Wedge Osteotomy|Medial Opening-Wedge Osteotomy (MOWO) is an approach for the correction of malalignment of the knee
9953379|NCT01122043||Endoglide|Patients with moderate degrees of corneal decompensation from a variety of disorders which require DSAEK corneal transplantation surgery, with or without concurrent cataract surgery, to restore visual acuity.
9953380|NCT01122056|Active Comparator|A = Active group|Patients will receive interactive exercise training session from an experienced multiple sclerosis
9953381|NCT01122056|No Intervention|B = Control group (Placebo Comparator)|Patients will receive general advice about benefits/side effects of physical activity in multiple sclerosis.
9953382|NCT01122069||Contrast echocardiography|110 patients with acute non-ST elevation myocardial infarct were examined with contrast echocardiography prior to coronary angiography.
9953383|NCT01122095||Psoriasis|Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
10215206|NCT03705468||Propofol sedation|Propofol sedation
10215207|NCT03705455|Active Comparator|ISAP SMS|ISAP SMS will be sent to enrolled caregivers
10215208|NCT03705455|No Intervention|No ISAP SMS|No ISAP SMS will be sent to enrolled caregivers
10215209|NCT03705442|Placebo Comparator|Placebo|Placebo
10215210|NCT03705442|Experimental|Probiotics|Omni-Biotic 10
9953384|NCT01122095||Control patient|Age matched, without psoriasis or significant inflammatory disease
9953385|NCT01122121|Experimental|Combined Radiotherapy and Hormone Therapy|Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy.
9953386|NCT01122121|Active Comparator|Hormone Therapy alone|Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin.
9953387|NCT01122134||20 adults with severe malaria|20 adult patients admitted with severe malaria
9953388|NCT01122147|Active Comparator|chamomilla tincture mouthwash|Chamomile comprises bisaboloids, matricine and chamazulene, flavonoids, and cumarins having therapeutical anti-inflammatory, analgesic, musculotropic, and spasmolytic action
9953389|NCT01122147|Placebo Comparator|placebo mouth wash|placebo mouthwash is produced with the same taste and smell for using in placebo/ control group.
9953390|NCT01122186|Experimental|Intervention Condition|Eight sessions of Motivational Interviewing and Cognitive Behavioral Skills Training, adapted to target both MA use and medication adherence, as well as sexual risk behaviors and polydrug use.
9953391|NCT01122186|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition. The content will be as follows: 3 sessions focusing on medication adherence; 3 sessions focusing on the dangers of methamphetamine use; 1 session addressing sexual risk; and 1 session addressing poly-substance use.
9953392|NCT01122199|Experimental|Open Label|RAD001+ AMG479
9953393|NCT01122225||Septic shock|
9953394|NCT01122251|Experimental|Lercanidpine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
9953395|NCT01122251|Active Comparator|Lercanidipine or Valsartan|L10, L20, V80, V160
9953396|NCT01122251|Placebo Comparator|Placebo|Placebo comparators of Lercanidipine and Valsartan
9953397|NCT01122290||negative emotion|Children experienced induction of mild negative emotion through a jigsaw with a missing piece (negative emotion group)
9953398|NCT01122290||neutral emotion|Vs. Same task with No missing piece (neutral emotion).
9953399|NCT01122303||SJS|Stevens-Johnson syndrome patients with dry eye
9953400|NCT01122303||Control|Non-autoimmune dry eye patients
9953401|NCT01122329|Placebo Comparator|inactive food packet|
9953402|NCT01122329|Active Comparator|Axona®|
9953403|NCT01122342|Experimental|Vaginal Testosterone|Daily application of vaginal testosterone for 28 days.
9953404|NCT01122355|Active Comparator|niacin arm|
9802321|NCT05315128|Active Comparator|Intralesional methotrexate|Group A 30 patients received intralesional injection of MTX with an insulin syringe into the tumor at a dose ranging between 12.5 mg to 25 mg according to the tumor size every week until complete improvement or for a maximum of 8 sessions.
9953405|NCT01122355|Active Comparator|fenofibrate arm|
9953406|NCT01122368|Experimental|1 Micafungin|IV
9802322|NCT05315128|Active Comparator|Intramuscular methotrexate|Group B 30 patients received systemic MTX (SC, or IM) was injected at a dose of 25 mg every week until clearance or for a maximum of 8 sessions.
9953407|NCT01122368|Placebo Comparator|2 Placebo|IV
9953408|NCT01122407|Experimental|trimethaphan|Trimethaphan infusion doses of 4 mg/min
9953409|NCT01122407|Experimental|Trimethaphan plus L-NMMA|Trimethaphan infusion 4 mg/min L-NMMA (L-NG-monomethyl Arginine citrate) infusion 250 mpg/kg/min A small group of arm 1 will receive both drugs.
9953410|NCT01122420|Experimental|Goal-Setting Tool|
9953411|NCT01122420|Active Comparator|Health Web Sites|
10215211|NCT03705429|Active Comparator|TC-H Chemotherapy|Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.
9953412|NCT01122433|Experimental|C-MAC|After a maximum of three failed intubation attempts using direct laryngoscope the C-MAC video laryngoscope is used as an emergency airway device.
9953413|NCT01122459|Active Comparator|Hartmanns|These patients will receive Hartmanns during anaesthesia
9953414|NCT01122459|Active Comparator|Voluven 6%|
9953415|NCT01122472|Experimental|Lenalidomide|Lenalidomide daily for 3 weeks every 4 weeks for 24 months
9953416|NCT01122472|Placebo Comparator|Placebo|Placebo daily for 3 weeks every 4 weeks for 24 months
10215212|NCT03705429|Placebo Comparator|Paclitaxel(P) + Trastuzumab(T)|Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.
9953417|NCT01122485|Experimental|Low dose group|two tablets per dose (one tablet of investigational drug and one tablet of placebo)
9953418|NCT01122485|Experimental|High dose group|two tablets per dose (two tablets of investigational drug)
9953419|NCT01122485|Placebo Comparator|Control group|two tablets per dose (two tablets of placebo)
9953420|NCT01122498|Experimental|1|
9953421|NCT01122498|Experimental|2|
10215213|NCT03705416||Endoscopic sleeve gastroplasty|All obese patients who will be undergoing an endoscopic sleeve gastroplasty (ESG). As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the endoscopic sleeve gastroplasty patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
9953422|NCT01122498|Experimental|3|
9953423|NCT01122524||Chromosomal Abnormality|Fetus affected by chromosomal abnormality
9953424|NCT01122524||No Chromosomal Abnormality|Fetus not affected by chromosomal abnormality
9953425|NCT01122589|Experimental|Motivation Interviewing/CBT|
9953426|NCT01122589|Active Comparator|Control|Receive a smoking cessation pamphlet and watch a series of six weekly 30-45 minutes general wellness videos.
9953427|NCT01122602|Experimental|Arm 1|
9953428|NCT01122602|Active Comparator|Arm 2|
9953429|NCT01122602|Placebo Comparator|Arm 3|
9953430|NCT01122615|Experimental|Sunitinib + Temsirolimus|Sunitinib 12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle. Temsirolimus 6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
9953431|NCT01122628||DVR-A|Patients with a distal radial fracture treated with a DVR-A locking plate
9953432|NCT01122641|Placebo Comparator|Placebo|
9953433|NCT01122641|Experimental|Vildagliptin|Vildagliptin 50mg bid
9953434|NCT01122654||Control|
9953435|NCT01122654||Experimental 1|
9953436|NCT01122654||Experimental 2|
9953437|NCT01122667|Experimental|Part 1 - Panel A|Subjects with severe renal impairment
9953438|NCT01122667|Experimental|Part 1 - Panel B|Healthy matched control subjects
9953439|NCT01122667|Experimental|Part 2 - Panel C|Subjects with moderate renal impairment
9953440|NCT01122667|Experimental|Part 2 - Panel D|Healthy matched control subjects
9953441|NCT01122667|Experimental|Part 2 - Panel E|Subjects with mild renal impairment
9953442|NCT01122667|Experimental|Part 2 - Panel F|Healthy matched control subjects
9953443|NCT01122693|Active Comparator|standard 2D ultrasound images|
9953444|NCT01122693|Experimental|high-quality 2D ultrasound images|
9953445|NCT01122693|Active Comparator|nerve stimulation techniques|
9953446|NCT01122706|Experimental|Taiji|35 healthy participants will regularly during 12 weeks attend Taiji training classes twice a week for one hour. (Sept. 6th till Nov. 25th 2010).
9953447|NCT01122706|No Intervention|waiting list control group|35 healthy participants are not allowed to attend any Taiji training during the intervention period (Sept. 6th till Nov. 25th 2010).
9953448|NCT01122732||US Group|Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.
9953449|NCT01122732||NS Group|Catheter will be placed using nerve stimulation guidance
9953450|NCT01122745||Catheter Group|Patient will have continuous interscalene block for pain relief placed preoperatively. They will go home with the portable pump. Pain score will be tracked via phone and compared with the control or single short group.
9953451|NCT01122745||Single shot group|Patient will have single shot interscalene block and will go home. Pain will be tracked using phone. Pain will be compared with the catheter group.
9953452|NCT01122758||COPD cohort|"Inclusion criteria:~Patients ≥ 35 years.~Diagnosis of COPD (GOLD PBD FEV1/FVC ratio <0.70).~Being in a stable phase of disease (8 weeks without exacerbation).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Recent exacerbation (<8 weeks).~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
9953453|NCT01122758||Control cohort|"Inclusion criteria:~Patients ≥ 35 years.~Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio >=0.70).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
9953454|NCT01122771|Active Comparator|Ambisome|15mg Ambisome on days 1,3 and 5
10215214|NCT03705416||Surgery (VSG or RYGBP)|All obese patients who will be undergoing either a vertical sleeve gastrectomy or a Roux-en-Y gastric bypass. As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the surgical procedure patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
10215215|NCT03705403|Active Comparator|Control|Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiation therapy and/or SABR (oligometastatic disease)
10215216|NCT03705403|Experimental|Experimental treatment|Standard of Care (SOC SABR (oligometastatic disease) or radiation therapy (diffuse disease) + L19-IL2 up to 6 cycles (Darleukin)
10215217|NCT03705390|Experimental|ILB|ILB subcutaneous injection
10215218|NCT03705377||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360), family service staff (168)
10215219|NCT03705364|No Intervention|Wait List Control Group|Wait list control group
10215220|NCT03705364|Experimental|Fall Management program|Intervention arm
10215221|NCT03705351|Experimental|Treatment|Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.
10215222|NCT03705325|Experimental|Spirobank smart spirometer with VitalFlo mobile app|In this single arm study, all participants will be receive the spirometer and an iPhone 5S (without SIM card) loaded with the VitalFlo app.
10215223|NCT03705312|Placebo Comparator|Guideline-directed medical therapy|Standard guideline-directed medical treatment for heart failure
10215224|NCT03705312|Experimental|Transcatheter Mitral valve repair|MitraClip treatment
10215225|NCT03705299|Experimental|NeuMeDex NICVP (Non-Invasive CVP) vs Standard CVP|Three pressure readings recorded for both NeuMeDex NICVP and central line pressure catheter over a 10 minute period.
10215226|NCT03705260|Active Comparator|Comparator- High Risk|A high risk sub group of those assigned to the comparator arm will be identified by their most recent A1C > 8. Patients in this group will receive usual care from their Primary Care Physician and dietitian.
10215227|NCT03705260|Active Comparator|Comparator- Well Controlled|The low risk sub group from the comparator arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their Primary Care Physician and their dietitian.
10215228|NCT03705260|Experimental|Enhanced Care- High Risk|A high risk sub group of those assigned to the enhanced care arm will be identified by their most recent A1C > 8. Patients in this group will receive the intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
10215229|NCT03705260|Experimental|Enhanced Care- Well Controlled.|The low risk sub group from the enhanced care arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their PCP and their dietitian. If they are found to be poorly controlled through monthly screening for risk, they may have the opportunity to move into the Enhanced Care High Risk group.
10215230|NCT03705221|Experimental|Group programme|Healthy Parent Carers group programme: A group-based peer led manualised programme called Healthy Parent Carers. The programme content is organised into 12 modules, which can be delivered over six longer (4-hour) sessions or 12 shorter (2-hour) sessions.
10215231|NCT03705221|Active Comparator|Online resources|Healthy Parent Carers online resources: Online resources from the Healthy Parent Carers programme, including materials for 12 modules and related videos and audio files to illustrate the content.
10215232|NCT03705208|Experimental|Youth First Curriculum|"The full Youth First curriculum provides holistic training of both emotional resilience and adolescent health concepts. The curriculum is comprised of a 15-session emotional resilience curriculum and a 10-session adolescent health program. The resilience curriculum aims to increase both internal assets (such as self-esteem, coping skills, health knowledge, and conflict-resolution skills) and external assets (such as positive bonds with peers and family).~The adolescent health curriculum provides in-depth training in physical health and wellness topics such as sexual and reproductive health, common diseases, nutrition, gender equality, and substance use.~The curriculum is imparted by school teachers are trained and certified by CorStone."
9953455|NCT01122771|Experimental|Ambisome + Miltefosine|Ambisome 5mg + miltefosine 10 days
9953456|NCT01122771|Experimental|Ambisome +paromomycin|AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
9953457|NCT01122771|Experimental|Miltefosine + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
9953458|NCT01122797||Alcoholic liver disease|Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
9953459|NCT01122797||Controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.
9953460|NCT01122823|Experimental|On-line workshop|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
9953461|NCT01122836|Experimental|Massage Dose 1|This arm receives weekly 60-minute massage for 4 weeks after a 4-week period of no treatment.
9953462|NCT01122836|Experimental|Massage - Dose 2|This arm receives weekly 60-minute massage for 4 weeks.
10215233|NCT03705208|No Intervention|School as usual|This arm is comprised of students attending school as usual and receiving the established government-designed curriculum.
10215234|NCT03705195|No Intervention|No Intervention|All participants in study will complete two matched clamp studies (OGTT + IGII). The first matched clamp without any intervention the second matched clamp with low dose gliclazide
9953463|NCT01122836|Experimental|Massage - Dose 3|This arm receives 2 weekly 30-minute massage for 4 weeks.
9953464|NCT01122836|Experimental|Massage - Dose 4|This arm receives 2 weekly 60-minute massages for 4 weeks.
9953465|NCT01122836|Experimental|Massage - Dose 5|This arm receives 3 weekly 30-minute massages for 4 weeks.
9953466|NCT01122836|Experimental|Massage - Dose 6|This arm receives 3 weekly 60-minute massages for 4 weeks.
9953467|NCT01122875|Experimental|A|
10215235|NCT03705195|Experimental|Low Dose Gliclazide|"The first 8 participants will complete the dose-ranging phase of LOGIC study. Low dose gliclazide is being used a physiological stimulus. In the dose-ranging phase, 4 participants will receive 10mg gliclazide, the remaining 4 will receive 20mg gliclazide. The allocation to 10mg or 20mg will be randomised and unblinded. The study will analyse after the first 8 participants to assess which dose produces the greatest augmentation of insulin secretion when acting synergistically with the incretin effect.~The further 12 participants will complete the study with the identified best dose."
10215236|NCT03705182|Experimental|Interventiongroup|The intervention group will be shown the fluorescent areas on their skin (fluorescence visualization feedback)
10215237|NCT03705182|No Intervention|Control group|The control group will not be shown the fluorescent areas on their skin (no feedback)
10215238|NCT03705143|Placebo Comparator|Treatment as Usual|Participants will receive no additional intervention besides the services they are currently receiving at the MMT clinic.
10215239|NCT03705143|Experimental|Chinese translated LETS ACT|In addition to services participants are currently receiving at the MMT clinic, individuals will attend six group-based one-hour behavioral activation treatment sessions.
10215240|NCT03705130||Group 1|All subjects will wear the 3 contact lenses: Single Vision, Multifocal 1 and Multifocal 2.
10215241|NCT03705117|Experimental|V565|V565 orally three times daily for up to 7 days
10005216|NCT01583205|Experimental|Coping Effectiveness Training|Coping Effectiveness Training -ALS (CET-ALS) is an eight session intervention derived from Coping Effectiveness Training (CET), a manualized intervention based on stress and coping theory. It is designed to strengthen coping skills and alleviate distress for either the patient or care partner following a diagnosis of ALS.
10005217|NCT01583231|No Intervention|No Prewash|Level 1: participants will be swabbed, then application of brushless scrub, swabbed again
10005218|NCT01583231|Experimental|Prewash|Level 2: participants will be swabbed, perform a wash with soap and water for 1 minute, dry, apply brushless scrub, swabbed again
10005219|NCT01583244||Patients with active rheumatoid arthritis|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
10005220|NCT01583257|Experimental|Active Video Gaming|An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
10035222|NCT01804127|Experimental|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
10035223|NCT01804153|Experimental|Autologous expanded stem cells|Adipose-derived expanded stem cells
10035224|NCT01804192|Experimental|Acu-TENS to LI4 and LI11|"Acu-TENS Group (Experimental Group), subjects received TENS over right L14 and LI11.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
10035225|NCT01804192|Active Comparator|Control group|"Control Acu-TENS Group (Control Group), subjects received TENS over tips of bilateral knee caps.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
9953468|NCT01122888|Experimental|Arm I (course 1)|Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
9953469|NCT01122888|Other|Arm II (course 1)|Patients do not receive treatment and undergo a 2-week rest period.
9953470|NCT01122940|Active Comparator|Epamin: McNeil LA LLC|
9953471|NCT01122940|Experimental|Phenytoin: Laboratorios Pfizer SA DE CV|
9953472|NCT01122953|Experimental|Phenytoin|
9953473|NCT01122953|Active Comparator|Epamin|
9953474|NCT01122966|Other|trabeculectomy|Subjects who have trabeculectomies with intraocular bevacizumab injection
9953475|NCT01122979|Experimental|group 1: insulin glargine + insulin glulisine|insulin glargine once daily + glulisine at meal times
10215242|NCT03705104|Experimental|EPIO (e-health intervention)|Participants will get access to one module every third day (total 9 modules). The app consists of cognitive behavioral pain self-management material, including educational material and relaxation training exercises.
10215243|NCT03705104|No Intervention|treatment as usual|Participants will get treatment as usual during the study. All participants will get access to the app after ended study if interested.
10215244|NCT03705091||Transplant|Incident patients receiving a kidney transplant for end stage kidney disease. Patients will undergo functional magnetic resonance imaging at 2 months, 6 months and 12 months following transplantation.
9528838|NCT03207204|Experimental|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
9953476|NCT01122979|Active Comparator|group 2 NPH insulin + regular insulin|NPH insulin (isophane insulin) (2 or more divided doses) + regular insulin at meal times
9953477|NCT01123005|Experimental|Carbogen arm|
9953478|NCT01123005|Experimental|DCA arm|
9953479|NCT01123031|Active Comparator|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
9953480|NCT01123031|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
9528839|NCT03207204|Experimental|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
9802323|NCT05315089|Experimental|Interventional Group|Virtual reality games +conventional exercises
9802324|NCT05315089|Active Comparator|control Group|Conventional exercises
9802325|NCT05315076|Experimental|Thoracic Manipulation Posterior anterior and conventional therapy|Thoracic Manipulation Posterior anterior and conventional therapy
9953481|NCT01123044|Experimental|corneal stem cell transplant|
9953482|NCT01123044|No Intervention|conservative medical therapy|
9953483|NCT01123096||Stress Urinary Incontinence|Patients with the primary complaint of stress incontinence with minimal or no urge incontinence symptoms. They must be able to read English as the study involves use of validated questionnaires which have only been validated in English.
9953484|NCT01123109|Other|nulliparous females|nulliparous women over the age of 18
9953485|NCT01123122|Active Comparator|Strict glucose control|
9953486|NCT01123122|No Intervention|Standard glucose control|
9953487|NCT01123135|Active Comparator|Vaginal ERT|Vaginal ERT cream 1 gm at bed time 3 times a week
9953488|NCT01123135|Placebo Comparator|Placebo|1gm of placebo at bed time 3 times a week
9953489|NCT01123174|Experimental|ALGOS group|Algorithm of case management over the 6 months following the suicidal gesture (systematic telephone contact, postcards and crisis card)
9953490|NCT01123174|No Intervention|Control group|Treatment as usual (referral back to the general practitioner)
9953491|NCT01123187|Experimental|islet transplantation|Islet transplantation
9953492|NCT01123226|Experimental|Diversified HVLA spinal manipulation|
9953493|NCT01123226|Active Comparator|Trigger point pressure release|
9953494|NCT01123239|Experimental|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches who have been trained to promote patient participation in the medical visit. The coaches, who themselves have diabetes, meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making."
9953495|NCT01123239|Active Comparator|Standard Diabetes Education|Patients receive one-on-one diabetes education sessions before each medical visit. These sessions are purely informational, and do not include the specific patient activation components of the coached care intervention.
9953496|NCT01123252|Active Comparator|Seasonal Affective Rhinitis Group 1|Active Comparator Group
9953497|NCT01123252|Placebo Comparator|Seasonal Affective Rhinitis Group 2|Placebo Group
9953498|NCT01123265||Anti-TNF|
9953499|NCT01123265||Methotrexate|
9953500|NCT01123278|Experimental|Testosterone gel|Testosterone transdermal gel 50 mg/day
9953501|NCT01123278|Placebo Comparator|Placebo gel|Placebo gel
9953502|NCT01123291|Active Comparator|routine follow-up coronary angiography|routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
9953503|NCT01123291|Active Comparator|clinical follow-up|no routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
9953504|NCT01123304|Experimental|MORAb 028|
9953505|NCT01123317|Experimental|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
10005221|NCT01583270|Experimental|Arabinoxylan|Porridge rich in arabinoxylan. 50 g available carbohydrate
10005222|NCT01583270|Experimental|rye kernels|Porridge made from rye kernels. 50 g available carbohydrate
10005223|NCT01583270|Experimental|arabinoxylan and rye kernels|Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate
10215245|NCT03705078|Other|early TIPS|Transjugular portosytemic shunt within 72h
10215246|NCT03705078|Other|Glue obliteration|glue obliteration repeated sessions
10215247|NCT03705065|Experimental|Treatment Group 1|Bupivacaine HCI by instillation into each pectoral pocket.
10215248|NCT03705065|Experimental|Treatment Group 2|Bupivacaine HCI by injection into each pectoral pocket.
10215249|NCT03705052|Other|Intervention|Patients and caregivers were asked to complete a questionnaire
10215250|NCT03705039|Active Comparator|Treatment Group|pulsed ultrasound treatment
9953506|NCT01123330|Experimental|Motivational Interviewing plus DVD|Caregivers watched a 15-minute educational video designed for the project emphasizing the importance of good oral health in children, and how the caregiver can keep children free from tooth decay. The MI interviewer engaged the parent in a discussion of their thoughts and concerns regarding their child's oral health and what changes they wished to make regarding monitoring their child's oral health. Feedback from the child's dental exam was also reviewed. MI+DVD caregivers received a brochure displaying a photo of their child and for those who chose to set specific goals for their child's oral health, those goals were listed on the brochure. Caregivers choosing not to set specific goals were offered a list of 10 project recommendations regarding dietary intake, oral hygiene, and dental check-ups. The session ended with a dialogue regarding possible barriers to implementing the personal plan and how the caregiver planned to overcome those barriers.
9953507|NCT01123330|Active Comparator|DVD only|Caregivers watched the same educational video. At the end of the video, caregivers were given a glossy-printed brochure displaying the project developed recommendations as well as the child's photograph. The brochure was not re-mailed, as it was for the MI+DVD group and caregivers in this condition did not receive any feedback from the dental examination regarding their child's oral health status.
9953508|NCT01123343|Active Comparator|LRI Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for LRI.
9953509|NCT01123343|Active Comparator|Capsulorhexis Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for Capsulorhexis.
9953510|NCT01123408|Experimental|clozapine|During the first 6 weeks clozapine was gradually increased to 500 mg/day and then continued. For the next period, it could vary from 200-800 mg/day;
9953511|NCT01123408|Experimental|Olanzapine|During the first 6 weeks olanzapine was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks olanzapine could vary from 10 to 30 mg/day
9953512|NCT01123408|Active Comparator|Haloperidol|During the first 6 weeks haloperidol was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks the dose could vary from 10 to 30 mg/day
9953513|NCT01123421||With osteoporotic fracture|Approximately 100 postmenopausal women that have been enrolled in a population-based case-control study that have experienced a clinically-diagnosed fracture of thoracolumbar spine or distal forearm due to minimal or moderate trauma based on review on their inpatient and outpatient medical records will be enrolled.
9953514|NCT01123421||Without osteoporotic fracture|Approximately 100 control women will have no history of a prior spine, hip, or wrist fracture.
9953515|NCT01123434||1|Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
9953516|NCT01123447|Active Comparator|Surgery|Isolated ulnar shaft fractures will be treated with open reduction and internal fixation using a limited contact dynamic compression (LC-DC) plate with screws. These will remain at the fracture site for the lifetime of the patient.
9953517|NCT01123447|Active Comparator|Short arm cast|Those individuals randomized to the non-operative treatment group will be treated with a closed reduction and short-arm (below-elbow) cast.
9953518|NCT01123473|Experimental|Lapatinib|Chemotherapy + lapatinib
9953519|NCT01123473|Placebo Comparator|Placebo|Chemotherapy + placebo
10215251|NCT03705039|Placebo Comparator|Control Group|sham ultrasound treatment
10215252|NCT03705013||Baseline Cologuard positive and negative colonoscopy|Those whose Cologuard T0 result was positive and colonoscopy result was negative.
10215253|NCT03705013||Baseline Cologuard positive and no colonoscopy|Those whose Cologuard T0 result was positive and subject declined to complete a colonoscopy per protocol.
10215254|NCT03705013||3-year follow-up Cologuard positive and negative colonoscopy|Those whose Cologuard result at T3 was positive and colonoscopy result at T3 was negative.
10215255|NCT03705013||3-year follow-up Cologuard positive and no colonoscopy|Those whose Cologuard result at T3 was positive and subject declined to complete a colonoscopy per protocol.
10215256|NCT03704987|Active Comparator|Klinefelter|Male patients followed with the diagnosis of klinefelter
10215257|NCT03704987|Active Comparator|Control|healthy male subjects
10215258|NCT03704974||Children of Parents Receiving IY|Children ages 3 to 6 years at start of group with behavior concerns whose parents are referred by their pediatricians for participation in a video-based parent training program from 2014 through 2018.
10215259|NCT03704961|Experimental|classical music|
10215260|NCT03704961|Experimental|Turkish music|
10215261|NCT03704961|Experimental|audiobook|
10215262|NCT03704909|Active Comparator|Group Adrenaline: Group A|All parturients received a prophylactic i.v bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.
10215263|NCT03704909|Active Comparator|Group Ephedrine: Group E|All parturients received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.E
10215264|NCT03704870|Active Comparator|Daily Chest Xray (standard)|
10215265|NCT03704870|Experimental|Chest Xray post chest tube removal only|
9953520|NCT01123486|Experimental|hydromorphone|open label single arm pharmacokinetic-pharmacodynamic study
9953521|NCT01123525|Experimental|Adenosine cardioplegia|Adenosine cardioplegia
9953522|NCT01123525|Active Comparator|Control|Standard hyperkalemic cardioplegia
9953523|NCT01123538|Other|Natural progesterone|Combined menopausal treatment containing natural progesterone
9953524|NCT01123538|Active Comparator|Chlormadinone acetate|Combined menopausal treatment containing chlormadinone acetate
9953525|NCT01123551|Experimental|Nebulized Morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
9953526|NCT01123551|Active Comparator|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
9953527|NCT01123564|Experimental|Lucentis (ranibizumab)|
9953528|NCT01123564|Active Comparator|Laser|
9953529|NCT01123577|Experimental|Intervention|
9953530|NCT01123577|No Intervention|Control|Participants receive usual care by providers.
9953531|NCT01123590||Thymoma|Patients with thymoma
9953532|NCT01123590||Control|Normal controls
9953533|NCT01123616|Active Comparator|non-triclosan-coated|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
9953534|NCT01123616|Active Comparator|triclosan coated suture|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
9953535|NCT01123668||ADHD and non-ADHD Smokers|Those that are defined as regular smokers (10 cigarettes/day or Carbon Monoxide reading of 10 ppm). The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
9953536|NCT01123681||Ventilator associated pneumonia|
9953537|NCT01123681||No pneumonia|
9953538|NCT01123694||Xeroderma Pigmentosum patients|Xeroderma Pigmentosum patients who attend Camp Sundown, a camp for children with this condition.
9953539|NCT01123759|Active Comparator|Tilapia|Subjects are fed 6 oz tilapia once a week for 3 months
9528840|NCT03207204|Experimental|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
9953540|NCT01123759|Active Comparator|Salmon|Subjects fed 6 oz salmon once a week for 3 months
9953541|NCT01123772|Placebo Comparator|Control|Vehicle control
9953542|NCT01123772|Experimental|INO-8875|Active drug
9953543|NCT01123798||Stable controls|Uninjured soldiers to provide normative data for stable physiological status
9953544|NCT01123798||Critical controls|"Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status."
9953545|NCT01123798||Lower extremity trauma|Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort.
9953546|NCT01123811|Experimental|Cetuximab IF|Treatment with combination of Cetuximab and Irinotecan 5-FU
9953547|NCT01123824|Experimental|Sequence clopidogrel 300/75 mg - 600/150 mg|"Period 1:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Period 2:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
9953548|NCT01123824|Experimental|Sequence clopidogrel 600/150 mg - 300/75 mg|"Period 1:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Period 2:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
10005224|NCT01583270|Experimental|semolina|Semoline porridge. 50 g available carbohydrate
10005225|NCT01583309|No Intervention|low-flux hemodialysis|
10005226|NCT01583309|Experimental|online pre-dilution hemofiltration|
10005227|NCT01583309|Experimental|online pre-dilution hemodiafiltration|
9953549|NCT01123837|Active Comparator|D5LR|In the treatment group, a 250cc bolus over 2 hrs of D5LR will be initiated prior to the end of surgery and continued in PACU.Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning
10005228|NCT01583335|Experimental|Improved lifestyle|
10005229|NCT01583335|No Intervention|Control group|The control group was seen at baseline and follow-up, but not in between.
10005230|NCT01583335|No Intervention|Shadow group|The shadow group was followed in registers exclusively
10005231|NCT01583348||Women with gallstones|30 women with symptomatic gallstone disease with an indication for elective cholecystectomy
9953550|NCT01123837|Active Comparator|lactated ringers|In the control group, a 250cc bolus over 2 hrs of LR will be initiated prior to the end of surgery and continued in PACU. Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning.
9953551|NCT01123863||Patient Group|"This study will administer Brigance Preschool Screen -II to 3 year old children with SCD followed at St. Jude Children's Research Hospital~Intervention: Brigance Preschool Screen -II"
9953552|NCT01123863||control group|"The control group will consist of 3-year-old children attending day care in the Memphis area and serve as a population that come from a similar socioeconomic background as the SCD patient population.~Intervention: Brigance Preschool Screen -II"
9953553|NCT01123876|Experimental|Veliparib and FOLFIRI|Veliparib in combination with FOLFIRI regimen.
9953554|NCT01123902|Experimental|hand-held fan|
9953555|NCT01123902|Placebo Comparator|wristband|
9953556|NCT01123915|Experimental|Opal-HIV-Gag(c)|Opal-HIV-Gag(c) administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
9953557|NCT01123915|Placebo Comparator|Diluent|Administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
9953558|NCT01123954|Other|Arm 1|
9953559|NCT01123967|Experimental|PRO+NRT+TC|Proactive outreach (mailed invitation letter followed by telephone outreach) combined with free nicotine replacement therapy (NRT) and telephone counseling (PRO+NRT+TC)to usual care (UC)
9953560|NCT01123967|Active Comparator|Usual Care (UC)|Usual (standard) care - Smoking cessation products: patch, gum, lozenge, inhaler and nasal spray
9953561|NCT01123993|No Intervention|Lifestyle counselling|
9953562|NCT01124019||Random Sample|A random sample of 600 women undergoing screening mammography
9953563|NCT01124019||BIRADS score of 4|An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
9953564|NCT01124032|Experimental|ADHD adults|
9953565|NCT01124032|Experimental|healthy adults|
9953566|NCT01124058|Experimental|Loading|1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose
9953567|NCT01124058|Active Comparator|Maintenance|Re-start same dose as previously stable on
9953568|NCT01124071|Active Comparator|Korean Diet|Provision of 2 Korean meals per day, 6 days per week
9953569|NCT01124071|Active Comparator|Western Diet|Lifestyle counseling, dietary advice, grocery vouchers
9953570|NCT01124084||Health Care Providers|
9953571|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
9953572|NCT01124110|Experimental|Tobacco Tactics Intervention|This intervention contains a website, medications, and nurse counseling.
9953573|NCT01124123|Experimental|Bilastine 20 mg|Single dose 20 mg bilastine oral tablet. Test drug
9953574|NCT01124123|Active Comparator|Bilastine 10 mg|Single dose 10 mg Bilastine endovenous. Control drug
9953575|NCT01124136|Experimental|Neurostimulation + Medication management|Investigational nerve stimulator device implanted to heart plus standard medication therapy.
9953576|NCT01124136|Other|Standard of Care (Control)|Standard of Care treatment is medication management only. Heart failure medications control symptoms and comorbidities, i.e. blood thinners, lipid lowering, and diuretics, and manage heart function, i.e. heart rhythm, rate, and pumping strength.
9953577|NCT01124201|Experimental|Stabilization group|In the Segmental Stabilization group exercises focused on the transversus abdominis and lumbar multifidus muscles.
9953578|NCT01124201|Experimental|Strengthening group|In the Superficial Strengthening group, exercises focused on the rectus abdominis, abdominus obliquus internus, abdominus obliquus externus and erector spinae muscles.
9953579|NCT01124201|Experimental|Stretching group|Stretching group: erector spinae, posterior connective tissues and ischiotibials muscles
9953580|NCT01124214|No Intervention|High Resolution endoscopy (HRE)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN
9953581|NCT01124214|Active Comparator|Endomicroscopy (EM)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN and endomicroscopy esophageal evaluation
9953582|NCT01124227|Sham Comparator|Standard Care|
9953583|NCT01124227|Active Comparator|2 Icodextrin PD changes / day|
9953584|NCT01124227|Active Comparator|1 Icodextrin PD change/day|
9953585|NCT01124253|Experimental|NP plus recombinant human endostatin|
9953586|NCT01124253|No Intervention|vinorelbine plus cisplatin|
9953587|NCT01124266|Experimental|endoscopist only|
9953588|NCT01124266|Experimental|nurse participation|
9953589|NCT01124279|Experimental|AMG 853|
9953590|NCT01124318|Active Comparator|Lactofiltrum|
9953591|NCT01124318|Placebo Comparator|Placebo|
9953592|NCT01124331|Experimental|High Oxygen saturation|Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
9953593|NCT01124331|Active Comparator|Lower oxygen saturation|Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
9953594|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 mg)|Panel 1: Healthy Male Subjects
9953595|NCT01124344|Active Comparator|Placebo or BMS-866949 (10 mg)|Panel 2: Healthy Male Subjects
9953596|NCT01124344|Active Comparator|Placebo or BMS-866949 (30 mg)|Panel 3: Healthy Male Subjects
9953597|NCT01124344|Active Comparator|Placebo or BMS-866949 (45 mg)|Panel 4: Healthy Male Subjects
9953598|NCT01124344|Active Comparator|Placebo or BMS-866949 (60 mg)|Panel 5: Healthy Male Subjects
9953599|NCT01124344|Active Comparator|Placebo or BMS-866949 (90 mg)|Panel 6: Healthy Male Subjects
9953600|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 - 60 mg)|Panel 7: Females
9953601|NCT01124357|Active Comparator|novasure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
9953602|NCT01124357|Other|thermachoice|ThermachoiceTM III thermal balloon ablation
9953603|NCT01124383|Active Comparator|General anesthesia|
9953604|NCT01124383|Active Comparator|Local anesthesia with sedation|
9953605|NCT01124409|Active Comparator|3DCRT with EPID|this patients randomised to this arm will be planned by 3DCRT and during treatment setup error will be identified and corrected by weekly EPID if error >3mm.Weekly CBCT will be done for this arm to note the setup error but will not be corrected.
9953606|NCT01124409|Active Comparator|IGRT with CBCT|The patients randomised to this arm will be planned by 3DCRT and set up error during RT will be verified by CBCT and error corrected if >3mm.Weekly EPID will be done for setup error documentation but no correction based on EPID in this arm.
10215266|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
9953607|NCT01124461||Brain Tumor|Brain neoplasms, malignant
9953608|NCT01124474|No Intervention|Standard fluid management|Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
9953609|NCT01124474|Other|Vigileo model number MHM1|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
9953610|NCT01124487|Experimental|palm olein|
9953611|NCT01124487|Experimental|olive oil|
9953612|NCT01124487|Experimental|lard|
9953613|NCT01124500|Experimental|methylphenidate via transdermal patch compared to placebo|The proposed study is a within-subject, cross-over, randomized and double-blinded pilot trial, designed to evaluate the efficacy and feasibility of sustained-release, long-acting methylphenidate via transdermal patch compared to placebo in fatigued patients with Head and Neck malignancies
9953614|NCT01124513|Active Comparator|Digital Camera|Digital camera images will be taken of a a 2cm^2 area of sun protected skin.
9953615|NCT01124513|Active Comparator|Spectrophotometer|The probe of the protable reflectance spectrophotometer is lightly applied to the sufance of the skin and a reading is taken.
9953616|NCT01124513|Active Comparator|Videodermoscopy|The instrument is put in contact with sun protected skin and an image is taken of a 2 cm^2 area.
9953617|NCT01124526|Experimental|Rituximab, Fludarabine, ciclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)"
9953618|NCT01124539|Experimental|AR-67|
9953619|NCT01124578||Control|Existing used daily change-out device
9953620|NCT01124578||Egret|Extended Use Catheter w/BIOSAFE
9953621|NCT01124591|Experimental|Treatment|Assessment and brief intervention
9953622|NCT01124630|Experimental|CS-1008 with FOLFIRI|Experimental drug CS-1008 in combination with FOLFIRI
9953623|NCT01124656|Experimental|Pioglitazone-Azilsartan QD|(Dependent on glycosylated hemoglobin level at screening)
9953624|NCT01124721|Experimental|Cogmed cognitive training|Computerized working memory, attention and cognitive tasks
9953625|NCT01124721|Active Comparator|Active placebo|Cognitive training, however the training does not increase in difficulty, or does so to a minimal degree.
10005232|NCT01583361|Experimental|Arm A:Neoadjuvant sox|Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.
9953626|NCT01124747|Experimental|ASP1585 and 14C-Labeled ASP1585|
9953627|NCT01124760|Experimental|1|AZD9742
9953628|NCT01124773||Previous HT use and cognition|Women who were aged 50-54 at the time of randomization into the WHI hormone trials.
9953629|NCT01124799|Experimental|001|TMC435 one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening for 9 days
9953630|NCT01124799|Placebo Comparator|002|Placebo placebo dose in the morning at noon and in the evening for 9 days
9953631|NCT01124799|Active Comparator|003|Ciprofloxacin one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg for 9 days
9953632|NCT01124812|Experimental|131I-L19SIP|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy: Treatment dose of 131I-L19SIP RIT is titrated in cohorts of 3 patients.
9953633|NCT01124825|Active Comparator|IGel|Subjects will receive an IGel(TM) airway induction and maintenance of positive pressure ventilation
9953634|NCT01124825|Active Comparator|King Airway|Subject will receive a KING-LTS-D(TM) for induction and maintenance of positive pressure ventilation
9953635|NCT01124851|Experimental|Arm 1|ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days
9953636|NCT01124851|Experimental|Arm 2|ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days
9953637|NCT01124851|Experimental|Arm 3|ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days
9953638|NCT01124877|Other|Open|
9953639|NCT01124890|Placebo Comparator|Conservative|no transfer for early percutaneous coronary intervention after thrombolysis
9953640|NCT01124890|Active Comparator|early PCI|transfer for early percutaneous coronary intervention after thrombolysis
9953641|NCT01124903|Experimental|Dehydration|Multiple measures of hydration status were made when subjects were normally hydrated (euhydrated) and when dehydrated. The diagnostic usefulness of the measures was determined.
9953642|NCT01124929|Active Comparator|Arm 1: Category I treatment for 6 months|Anti-tuberculosis drugs
9953643|NCT01124929|Active Comparator|Arm 2: Category I treatment for 9 months|Anti-tuberculosis drugs,
9953644|NCT01124968|Experimental|eConsulta|Those patients who are offered to use the eConsulta, a web where they can virtually consult with their primary care doctor or nurse.
9953645|NCT01124981|Placebo Comparator|Albumin|
9953646|NCT01124981|Experimental|Haemocomplettan® P|
9953647|NCT01124994|Active Comparator|Mucosectomy|Patients in this arm are undergoing mucosctomy after previous confocal laser endomicroscopy.
9953648|NCT01125007|Active Comparator|toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
9953649|NCT01125007|Experimental|medium toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
9953650|NCT01125020|Active Comparator|gemcitabine and oxaliplatin|
9953651|NCT01125020|Active Comparator|doxorubicin, 5-Fu and cisplatin|
9953652|NCT01125033|Experimental|Vitamin C & Vitamin E.|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
9953653|NCT01125033|Experimental|Vitamin C & Placebo|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
9953654|NCT01125033|Experimental|Vitamin E & Placebo|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
9953655|NCT01125033|Placebo Comparator|Double Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
9953656|NCT01125059|Active Comparator|Methadone Group|0.2 mg/kg IV methadone
9953657|NCT01125059|Placebo Comparator|Placebo Group|5 mL saline bolus
9953658|NCT01125072||entire cohort|patients presenting to the emergency department with chest pain and being admitted to rule out acute coronary syndrome
9953659|NCT01125085|Other|131I-L19SIP RIT in Combination with WBRT|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
9953660|NCT01125111||robotic surgery group|
9528841|NCT03207204|Experimental|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
9953661|NCT01125111||laparoscopic surgery group|
9953662|NCT01125124|Active Comparator|Silver Nitrate 1|Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
9953663|NCT01125124|Experimental|Silver Nitrate 2|Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
9953664|NCT01125124|Experimental|Silver Nitrate 3|Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
9953665|NCT01125137|Experimental|Biopsy|
9953666|NCT01125215|Placebo Comparator|Placebo|Matched gel base of capsaicin nanoparticle
9953667|NCT01125215|Experimental|Capsaicin|0.075% capsaicin nanoparticle gel
9953668|NCT01125241|Experimental|Wuling capsule|
9953669|NCT01125241|Placebo Comparator|Placebo|
9953670|NCT01125254|Experimental|Amlodipine|amlodipine 5mg qd
9953671|NCT01125254|Placebo Comparator|Controls|placebo
9953672|NCT01125267|Experimental|multifamily group-adherence|multifamily group treatment with a focus on improving adherence to antipsychotic medication
9953673|NCT01125267|Active Comparator|multifamily group-standard|multifamily group focused on problems identified by group participants
9953674|NCT01125267|No Intervention|treatment as usual|
9953675|NCT01125280|Experimental|SBO score application|Acute strangulated SBO patients will receive a severity score at emergency admission. According to the score, they will be managed either conservatively or surgically. During surgery, the need of small bowel resection will be evaluated. The endpoint will be to correlate the type and success of treatment with the score in order to validate this new tool in SBO assessment.
9953676|NCT01125319|Other|patients Hemophagocytic lymphohisticytosis group|
9953677|NCT01125319|Other|group control patient|
9953678|NCT01125319|Other|healthy control group|
9953679|NCT01125332|Placebo Comparator|group gel KY|
9953680|NCT01125332|Experimental|group gel lidocaine|
9953681|NCT01125345|Experimental|Hydrophobic IOL|The single piece Acrysof hydrophobic IOL model- SN60WF
9953682|NCT01125345|Active Comparator|Hydrophilic IOL|Rayner Intraocular Lenses Ltd., England, Model C-flex 570C
9953683|NCT01125345|Active Comparator|Hydrophillic IOL|Bausch and Lomb ltd, model Akreos Adapt
9953684|NCT01125371|Experimental|Computerized Brief Alcohol Intervention + IVR|Computer-delivered brief alcohol intervention (CBI) with booster phone calls delivered by IVR+ text messages (TM)
9953685|NCT01125371|Active Comparator|Computerized Brief Alcohol Intervention|Computerized Brief Alcohol Intervention only (CBI)
9953686|NCT01125371|Placebo Comparator|Attention Control|Attention control
9953687|NCT01125384|No Intervention|nurse swabbing|
9953688|NCT01125384|Experimental|"accurate swabbing by a physician"|
9953689|NCT01125397|Experimental|Behavioral Intervention|
9953690|NCT01125397|No Intervention|Control|These participants will be randomized to receive no behavioral intervention prior to bariatric surgery.
9953691|NCT01125410|Experimental|Dequalinium chloride 10mg|
9953692|NCT01125410|Active Comparator|clindamycin vaginal cream 2%|
9953693|NCT01125423|Active Comparator|Subjects with Fibromyalgia|Subjects with Fibromyalgia have skin biopsies taken from the dominant trapezius and palm. Subjects will receive an eight week supply of milnacipran to be titrated 12.5 mg x one day, 12.5 mg twice a day x 2 days, 25mg twice daily for 4 days, then 50mg twice a day x 7 weeks.
9953694|NCT01125423|Other|Control subjects without Fibromyalgia|Subjects without Fibromyalgia have skin biopsies taken from the dominant trapezius and palm.
9953695|NCT01125436|Experimental|Cholecalciferol|Nutritional supplement
9953696|NCT01125436|Placebo Comparator|placebo|
9953697|NCT01125449|Other|Intravenous IVC Intervention|Intravenous ascorbic acid, 1.5g/kg at an infusion rate not to exceed 250mg/min.
9953698|NCT01125462||Subjects previously treated with Gonal-f|Subjects who had undergone at least one treatment cycle with Gonal-f powder and solvent for solution for injection within the past 12 months (equivalent to 75 IU/ml, 450 IU/0.75ml or 1050 IU/1.75 ml)
10215267|NCT03704857|Experimental|Foraminal enlargement with sodium hypochlorite and PDT|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, PDT, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
10215268|NCT03704857|Experimental|Foraminal enlargement with chlorhexidine as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, chlorhexidine as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
10215269|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with AH Plus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
10215270|NCT03704857|Active Comparator|Foraminal enlargement with conventional irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, conventional irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
9953699|NCT01125462||Subjects previously treated with urine-derived FSH|Subjects which had undergone at least one treatment cycle with urine-derived FSH therapy with vials within the past 12 months
9953700|NCT01125488|Experimental|LNG-IUS|LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
9953701|NCT01125488|Active Comparator|GnRH agonist|The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
9953702|NCT01125501|Active Comparator|Protandim|one capsule a day for 30 days of protandim given, followed by a wash out period.
9953703|NCT01125501|Placebo Comparator|Placebo|one capsule a day for 30 days will be given followed by a washout period.
9953704|NCT01125527|Active Comparator|Arm 1|
9953705|NCT01125527|Active Comparator|Arm 2|
9953706|NCT01125553|Experimental|IDegAsp B|
9953707|NCT01125553|Experimental|IDegAsp F|
9953708|NCT01125579||Children aged 6-12|"Children suffering from nervous restlessness, e.g. in agitated depression (ICD 10, F3 and DSM IV affective disorders), aged 6-12 years"
9953709|NCT01125592|Experimental|Footbath|Participants in this arm of the study will receive 4 30 minutes ionic footbath sessions, one each week for 4 weeks.
9953710|NCT01125618|Experimental|MVP village|Wealth stratified and randomly selected households residing in a village exposed to the Millennium Villages Project intervention (or health and development intervention package)
9953711|NCT01125618|Active Comparator|Comparison village|Villages receiving routine services through established programs
10215271|NCT03704857|Experimental|Foraminal enlargement with passive ultrasonic irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, passive ultrasonic irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
9953712|NCT01125631|Experimental|PF-04360365 8.5 mg/kg|
9953713|NCT01125631|Placebo Comparator|Placebo|
10215272|NCT03704844||Patients with renal congestion|
10215273|NCT03704844||Patients without renal congestion|
10215274|NCT03704831||IPACK group|IPACK group
10215275|NCT03704831||Surgical infiltration group|Surgical infiltration group
10215276|NCT03704818|Experimental|Dapagliflozin 5mg|
10215277|NCT03704818|Experimental|Placebo|
9953714|NCT01125644|Experimental|Single Arm|"Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam (patients with definite diagnosis), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology (patients with clinical diagnosis)."
9953715|NCT01125657|Experimental|formualation-A to -B sequence group|
9953716|NCT01125657|Experimental|formulation-B to -A sequence group|
9953717|NCT01125670|Experimental|fast-fed sequence group|
9953718|NCT01125670|Experimental|fed-fast sequence group|
10215278|NCT03704792|Experimental|Adult CLD Group|Only one group of patients in the study: adult patients with chronic liver disease (CLD), all etiologies combined, who will have a FibroScan 530 Compact examination to calculate the CAP value.
9953719|NCT01125683|Experimental|1|2,5 mg once daily
9953720|NCT01125683|Active Comparator|2|single dose of 5 mg
9953721|NCT01125683|Placebo Comparator|3|
9953722|NCT01125683|Experimental|4|60 mg once daily
9953723|NCT01125683|Experimental|5|60 mg three times daily
9953724|NCT01125696|Active Comparator|Standard of Care|
9953725|NCT01125696|Experimental|Tenofovir|
9953726|NCT01125735|Experimental|MIST Therapy|MIST Therapy is a low energy, low intensity ultrasound delivered through a saline mist to the wound bed.
9953727|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
9953728|NCT01125761|Experimental|dexamethasone 0.5 mg and 1.0 mg clemastine cream|
9953729|NCT01125761|Active Comparator|dexamethasone 0,5 mg cream|
9953730|NCT01125787|Experimental|ofatumumab + bendamustine|
9953731|NCT01125839||Spondylitis|Patients who checked spine MRI for back pain
9953732|NCT01125852|Active Comparator|Intervention group|Patients in this group are treated with usual therapeutic endoscopy including endoscopic combination therapy and 72 hours intravenous proton pump inhibitor. Within 24 hours from the therapeutic endoscopy they receive supplementary angiographic embolization.
9953733|NCT01125852|Active Comparator|Control group|Patients in this arm receive standard treatment including therapeutic endoscopy with endoscopic combination therapy followed by 72 hours intravenous proton pump inhibitor.
9953734|NCT01125865|Active Comparator|SEMS|Self-expandable metallic stent will be inserted for the malignant hilar obstruction.
9953735|NCT01125865|Active Comparator|DLS|DoubleLayer plastic stent (Olympus) will be inserted for malignant hilar obstruction.
9953736|NCT01125878|Active Comparator|Starch Composite B|fiber mixture
9953737|NCT01125878|Active Comparator|Starch Composite C|fiber mixture
9953738|NCT01125878|Active Comparator|Starch Composite D|fiber mixture
9953739|NCT01125878|Placebo Comparator|Placebo|Placebo
9953740|NCT01125891|Experimental|gemcitabine and ON 01910.Na|
9953741|NCT01125904|Experimental|crizotinib|
9953742|NCT01125943|Experimental|Acetylcholine|Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab
10215279|NCT03704779|Experimental|Multimodal Mindfulness Activity Program|Students assigned to the intervention will receive 8 weeks of the mindfulness activity intervention.
10215280|NCT03704779|No Intervention|Control Group|Students assigned to the control group will not receive any intervention.
9802326|NCT05315076|Experimental|Muscle Energy Technique (PIR) and conventional treatment|Muscle Energy Technique (PIR) and conventional treatment
9802327|NCT05315063|Experimental|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
9802328|NCT05315063|Experimental|Muscle Energy Technique (PIR)|muscle energy technique
10215281|NCT03704766|Experimental|Inflamed/Infected Joint|Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
9802329|NCT05315050|Experimental|Educational session and Informational Pamphlet|
10215282|NCT03704766|Active Comparator|Normative Control|Patient undergoing procedure unrelated to infection/inflammation
10215283|NCT03704753|Active Comparator|SAPB group A|SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
10215284|NCT03704753|Placebo Comparator|SAPB group B|SAPB single injection (placebo). 30ml of SodiumChloride 0.9 is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
10215285|NCT03704753|Active Comparator|SAPB group C|SAPB single injection and catheter. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery and a multi-holed catheter is left in place. 20ml of Ropivacaine 2mg/ml is injected every 12h through catheter postoperatively.
9802330|NCT05315050|Active Comparator|Informational Pamphlet|
9803594|NCT03718065|Experimental|Lofexidine Women|Women will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
9803595|NCT03718065|Placebo Comparator|Placebo Men|Men will receive matching placebo for five weeks.
9803596|NCT03718065|Placebo Comparator|Placebo Women|Women will receive matching placebo for five weeks.
9803597|NCT03717103|Experimental|IBI188|Part A : Initial dose escalation, Part B : Maintenance dose escalation
9803598|NCT03714828|Experimental|Treatment (talimogene laherparepvec)|The subject participation period will be approximately 48 weeks. This will include a screening visit, 4 injection visits and 5 follow up visits. Total length of study/patient is 8.5 to 10.5 months. TVEC will be administered by injection with a needle directly into one or more tumors.
9803599|NCT03711188|Experimental|IMM-101 (and nivolumab or ipilimumab)|IMM-101 given in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.
9803600|NCT03696199|No Intervention|Traditional Pain Control Care|Standard of care post-operative pain control with oral narcotics
9803601|NCT03696199|Experimental|Regional Anesthesia|Single injection perioperative peripheral nerve block + followed by administration of oral narcotics on a need-based system
9803602|NCT03696199|Experimental|Long-Acting Local Anesthesia|Subcutaneous local cocktail injection + followed by administration of oral narcotics on a need-based system
9803603|NCT03694015|Active Comparator|SUPR (Arm 1)|"Planning according to local protocols. No more than 2 fields; no beam modifying devices, other than multileaf collimators (MLCs). Alternate weighting of beams allowed (ie. 1:2 AP:PA). Review of dosimetry not required, if performed as per institutional standard.~Minimum of kV image matching on unit daily."
9803604|NCT03694015|Active Comparator|VMAT rapid (Arm 2)|"Contouring: GTV based on available imaging (CT sim scan alone-no special imaging), expect to be between 1.5cm and 20cm clinically or from imaging. CTV-optional in all scenarios. If using CTV=GTV +0.5 to 0.7cm adjust to anatomy as follows:~If only bone involved: recommend not to expand past bone; but a 0.5-0.7cm CTV expansion outside of bone into muscle or soft tissue is allowed at RO discretion~If bone and soft tissue involved: 0.5 to 0.7cm CTV expansion is optional, allowed at RO discretion~If spinal metastases: CTV is optional. If used can include whole vertebral body at RO discretion PTV=CTV or GTV+(1 to 1.5)cm at RO discretion. PTV_eval=PTV cropped 0.5cm below skin. OARs: max 2 OARs permitted for VMAT arm. OAR constraints are at RO discretion. If lung/kidneys are within 5cm of PTV, absence of constraints for contours should be noted in treatment plans or dose constraint sheet prior to planning. PTV can be compromised for OAR at RO's discretion. Kidneys considered 1 organ"
9803605|NCT03684785|Experimental|Dose Escalation Phase 1b|Determine the recommended Phase 2 dose of cavrotolimod in combination with pembrolizumab.
9803606|NCT03684785|Experimental|Dose Expansion Phase 2; Merkel cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on an anti-PD-1 / anti-PD-L1 therapy.
9803607|NCT03684785|Experimental|Dose Expansion Phase 2, cutaneous squamous cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and cemiplimab in patients with advanced cutaneous squamous cell carcinoma that have progressed on an anti-PD-1.
9803608|NCT03684785|Experimental|Exploratory Phase 2, Merkel cell carinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
9803609|NCT03684785|Experimental|Exploratory Phase 2, Subcutaneous Dosing Cohort|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with no cutaneous, subcutaneous, or accessible nodal tumor lesions amenable that have progressed on anti-PD-1 / anti-PD-L1 therapy.
9803610|NCT03684785|Experimental|Exploratory Phase 2, Melanoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with locally Advanced or Metastatic Melanoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
9803611|NCT03684785|Experimental|Exploratory Phase 2, Liver Lesion|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with metastatic solid tumors with liver metastases that have progressed on anti-PD-1 / anti-PD-L1 therapy.
9803612|NCT03682393|Experimental|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
9953743|NCT01125943|Experimental|Nitroprusside|Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab
9953744|NCT01125956|No Intervention|Control|This group will receive usual diabetes care through their primary care clinicians.
9953745|NCT01125956|Experimental|Peer counseling|A peer counselor will be assigned to each participant who currently has good diabetes control but had poor control in the past 3 years.
10005233|NCT01583361|Active Comparator|Arm B:Adjuvant SOX|Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
10005234|NCT01583387|Other|1= Intervention|
10005235|NCT01583387|Other|2= Control|
10005236|NCT01583400|Active Comparator|RESPECT-D|The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager
10005237|NCT01583400|Experimental|RESPECT-D-E|RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.
10005238|NCT01583413|Experimental|Opt Out Protocol|
10005239|NCT01583426|Experimental|nab-Paclitaxel|nab-Paclitaxel (125 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
10005240|NCT01583426|Active Comparator|Paclitaxel|Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
10005241|NCT01583465|Experimental|Aquamantys Malleable Bipolar Sealer|In 100 patients randomly assigned, primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of the Aquamantys Malleable Bipolar Sealer with Light.
10005242|NCT01583465|Active Comparator|Standard Treatment|100 patients randomly assigned will undergo primary total hip arthroplasty via the anterior supine intermuscular approach performed with the assistance of standard electrocautery.
10005243|NCT01583478|Active Comparator|incobotulinumtoxinA 20 units|Three patients will be randomly assigned to receive 20 units total of incobotulinumtoxinA to the glabellar region.
10005244|NCT01583478|Active Comparator|incobotulinumtoxinA 40 units|Three patients will be randomly assigned to receive 40 units total of incobotulinumtoxinA to the glabellar region.
10005245|NCT01583478|Active Comparator|incobotulinumtoxinA 60 units|Three patients will be randomly assigned to receive 60 units total of incobotulinumtoxinA to the glabellar region.
10005246|NCT01583478|Active Comparator|incobotulinumtoxinA 80 units|Three patients will be randomly assigned to receive 80 units total of incobotulinumtoxinA to the glabellar region.
10005247|NCT01583478|Active Comparator|incobotulinumtoxinA 100 units|Three patients will be randomly assigned to receive 100 units total of incobotulinumtoxinA to the glabellar region.
9528842|NCT03207204|Experimental|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
9953746|NCT01125956|Experimental|Financial incentives|Patient participants in the financial incentive arm will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
9953747|NCT01125969|Active Comparator|Control|
9953748|NCT01125969|Experimental|Incentive|
9953749|NCT01125969|Experimental|Peer Mentoring|
9953750|NCT01125969|Experimental|Incentives and Peer Mentoring|
9953751|NCT01125982|Active Comparator|Desflurane|Patients will receive Desflurane to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
9953752|NCT01125982|Active Comparator|Propofol|Patients will receive Propofol to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
9953753|NCT01125995|Active Comparator|late CCRT|radiotherapy start on day one of the third cycle of chemotherapy
9953754|NCT01125995|Experimental|Early CCRT|Radiotherapy start on day 1 of 1st cycle of chemotherapy
9953755|NCT01126008|Experimental|weekly docetaxel and cisplatin|
9953756|NCT01126021|Active Comparator|Control|Given access to mental exercises but receives no rewards for use.
9953757|NCT01126021|Experimental|Atomistic|Each individual is awarded for his or her individual participation
9953758|NCT01126021|Experimental|Altruistic|Participants are paired and rewarded according to the other individual's participation.
9953759|NCT01126021|Experimental|Team-based|Teams compete against each other and receive rewards according to relative participation.
9953760|NCT01126034|Experimental|intervention|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~The name and medical record # of the patients involved~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~A reminder of the adverse effect of long-term metoclopramide therapy~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~A request that the physician document the discontinuation trial in the electronic medical record"
9953761|NCT01126034|No Intervention|non-intervention|No intervention letters were sent to subjects in this arm
9953762|NCT01126047|Other|PFT's, eCO, and pulse oximetry|All subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.
9953763|NCT01126073|Placebo Comparator|placebo|
9953764|NCT01126073|Active Comparator|Niacin/Laropiprant 2000mg/40 mg|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will be randomized in the ratio 1:1 to either receive ER niacin/laropiprant or placebo in addition to the statin therapy. Patients in the ER niacin/laropiprant group will receive 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
9953765|NCT01126086|Experimental|Mild impairment|Patients with mild hepatic impairment
9953766|NCT01126086|Experimental|Moderate impairment|Patients with moderate impairment
9953767|NCT01126086|Experimental|Healthy subjects|Matched healthy subjects
10215286|NCT03704753|Active Comparator|SAPB group D|Continious intercostal catheter. 20ml of Ropivacaine 7,5mg/ml is injected through intercostal catheter, which i placed under thoracoscopic visualization. After single injection a continuous infusion of Ropivacaine 2mg/ml is started (weight dependent daily dosage).
10215287|NCT03704753|Active Comparator|SIP group A|SIP single injection 20ml of Ropivacaine 7,5mg/ml is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
10215288|NCT03704753|Placebo Comparator|SIP group B|SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
9802331|NCT05314998|Experimental|Test Arm A: mFOLFIRINOX or Gem/Cap according to transcriptomic treatment specific signature|mFOLFIRINOX-therapy (5-FU, Folinic Acid, Irinotecan, Oxaliplatin) according to individual transcriptomic treatment specific signature or Gem/Cap-therapy (Gemcitabine and Capecitabine) according to individual transcriptomic treatment specific signature
9953768|NCT01126112|Experimental|Panitumumab|Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.
10215289|NCT03704740|Experimental|NBP607-QIV|One or two doses of 0.5mL of NBP607-QIV by intramuscular injection
10215290|NCT03704740|Active Comparator|Agrippal|One or two doses of 0.25mL of Agrippal by intramuscular injection
9953769|NCT01126125|Experimental|Iodized oil to mother|400 mg iodine as iodized oil to breastfeeding mother
9953770|NCT01126125|Active Comparator|Iodized oil to infant|100 mg of iodine as iodized oil to infant
9953771|NCT01126138|Other|Arm A|Vinorelbine plus Capecitabine
9953772|NCT01126138|Other|Arm B|Docetaxel plus Capecitabine
9953773|NCT01126151|Experimental|parent handbook|parent handbook to increase the quantity and quality of communications about alcohol
9953774|NCT01126151|Experimental|parent handbook with boosters|boosters are given to parents at three times (move in, visit weekend; student visits home)
9953775|NCT01126151|Experimental|parent handbook delay|parent handbook is delayed and given after semester has begun
9953776|NCT01126164|Experimental|parent handbook|parent handbook
9953777|NCT01126164|Experimental|peer basics|peer delivered basics
9953778|NCT01126164|Experimental|parent handbook and peer basics|parent handbook and peer basics
9953779|NCT01126177|Placebo Comparator|Placebo|Placebo once daily for 14 days
9953780|NCT01126177|Experimental|SNG001|
9953781|NCT01126203|Experimental|selective laser trabeculoplasty (SLT)|
10215291|NCT03704727|Experimental|probiotic treatment|Probiotic: VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus. Administred orally
10215292|NCT03704714|Experimental|Treatment (nivolumab and R-CHOP)|Participants receive nivolumab IV over 30 minutes on day 1. Participants also rituximab IV on day 2, cyclophosphamide IV on day 2, doxorubicin hydrochloride IV over 3-5 hours on day 2, vincristine sulfate IV over 30 minutes on day 2, and prednisone PO on days 2-6 of course 1 and rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV over 3-5 hours on day 1, vincristine sulfate IV over 30 minutes on day 1, and prednisone PO on days 1-5 of courses 2-6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10215293|NCT03704675|Experimental|Group I (Fasted->Fed)|Group 1 received a single oral dose in a fasting condition in Period 1, followed by a single oral dose after a high-fat diet in Period 2
10215294|NCT03704675|Experimental|Group II(Fed->Fasted)|Group 2 received a single oral dose after a high-fat diet in Period 1, followed by a single oral in a fasting condition in Period 2
10215295|NCT03704662|Other|Stereotactic Body Radiation Therapy|Patients undergo Stereotactic Body Radiation Therapy (25 to 35 Gy over five fractions)
10215296|NCT03704662|Other|Preoperative Fractionated Radiation Therapy and Chemotherapy|Concurrent chemotherapy with radiation treatment (50.4 Gy over 28 fractions).
10215297|NCT03704649|No Intervention|Standard nutrition education|The comparison group for the participatory video intervention.
10215298|NCT03704649|Experimental|Participatory nutrition education|Intervention arm integrates participatory video model to standard girls' club sessions to promote nutrition education.
10215299|NCT03704623|Active Comparator|Paracetamol|Patients will receive IV 1 g of Paracetamol
10215300|NCT03704623|Active Comparator|Parecoxib|Patients will receive 40 mg of Parecoxib IV
10215301|NCT03704597|Active Comparator|7-hour cryotherapy|Standard of care
10215302|NCT03704597|Experimental|2-hour cryotherapy|Experimental treatment
9953782|NCT01126203|Experimental|Argon laser trabeculoplasty (ALT)|
9953783|NCT01126216|Experimental|Reduced RT + Pacitaxel/Cisplatin|63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
9953784|NCT01126216|Active Comparator|Standard RT + 5-Fluorouracil/Cisplatin|70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor
9953785|NCT01126229|Placebo Comparator|Placebo|Dietary Supplement: placebo
9953786|NCT01126229|Experimental|300 mg/d Resveratrol|Dietary Supplement: 300 mg/d Resveratrol
9953787|NCT01126229|Experimental|1000 mg/d Resveratrol|Dietary Supplement: 1000 mg/d Resveratrol
9953788|NCT01126242|Experimental|tape|Group I will be treated with non-elastic adhesive tape around the affected ankle, applied by the 'van Unen-technique'. This technique is an alternative for the 'Coumans- technique'. The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity. Taping is a treatment that involves no loss of time, requires no crutches and is not attended with any ultimate impairment of function.
9953789|NCT01126242|Active Comparator|Lace-up brace|The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
9953790|NCT01126242|Active Comparator|Semi rigid brace|A semi-rigid brace, the M-step® from Medi®, will be applied. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
9953791|NCT01126281|Experimental|Floseal use|
9953792|NCT01126294|Experimental|Melatonin 5 mg|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
9953793|NCT01126294|Experimental|Melatonin 10 mg|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
9953794|NCT01126294|Placebo Comparator|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
9953795|NCT01126307|Active Comparator|verapamil|verapamil 80mg tid
9953796|NCT01126307|Placebo Comparator|placebo sugar pill|placebo tid
9953797|NCT01126320|Experimental|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
9953798|NCT01126320|Active Comparator|Control|routine mechanical ventilator
10005248|NCT01583491|Active Comparator|prf group.peridontal problem|prf insert into surgical site immediate after surgery
9528843|NCT03207204|Experimental|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
9953799|NCT01126346|Experimental|Arm I|Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
9953800|NCT01126385||Transpedicular stabilization|Patients undergoing transpedicular stabilization of the spine
9953801|NCT01126398||Ankle / dist. tibia fracture fixation|
9953802|NCT01126411|No Intervention|control|control group / no immunoadsorption
9953803|NCT01126411|Active Comparator|immunoadsorption|immunoadsorption
9953804|NCT01126450|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9953805|NCT01126463|Experimental|Rhenium Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
9953806|NCT01126476|Active Comparator|small volume strata|12 in small volume strata
9953807|NCT01126476|Active Comparator|large volume strata|12 in large volume strata
10005249|NCT01583491|Placebo Comparator|control group|
10215303|NCT03704571|Experimental|Tailored Group|In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.
9953808|NCT01126502|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive alvespimycin hydrochloride IV over 60 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9953809|NCT01126515||Hyperbaric oxygen|In this open-label feasibility study, all subjects will receive 60 hyperbaric oxygen sessions (100% oxygen, 1.5 atmospheres absolute (atm abs), for 60 minutes), delivered daily, five days per week.
9953810|NCT01126528|Experimental|Vitamin D3|Vitamin D3 (cholecalciferol)
9953811|NCT01126528|Placebo Comparator|Control|Placebo control group
9953812|NCT01126554||Critically ill patients|
9953813|NCT01126567||High Sampling Rate|Samples will be obtained at a high rate
9953814|NCT01126567||Low Sampling Rate|Samples will be obtained at a low rate
9953815|NCT01126606|Experimental|Group 1|Dermacyd Silver Frutal followed by Dermacyd Silver Frutal+PH_DESYLSTY_FR followed by wash out followed by Glycerine Vegetal Soap Granado Traditional
9953816|NCT01126606|Experimental|Group 2|Glycerine Vegetal Soap Granado Traditional followed by wash out followed by Dermacyd Silver Floral followed by Dermacyd Silver Floral + PH_DESYLSTY_FR
9953817|NCT01126632||Cap Assisted Colonoscopy|Patients receiving colonoscopies where scope is fitted with cap
9953818|NCT01126632||Standard Colonoscopy|Patients receiving standard colonoscopy without the cap on the scope
9953819|NCT01126645|Other|local ablation group|Local ablation group: Potentially curative treatment of early HCC includes surgical resection and local ablation (RFA, PEI, BT). Recurrence rates after such approaches are reported to amount to 50% at 3 years and 70% at 5 years. Tumor recurrence may be either due to de novo development of new primary tumors or due to intrahepatic (unrecognized) metastases. Prevention of recurrence after local ablation is an important strategy to improve overall survival. So far, adjuvant chemoembolization and chemotherapy have not proven to be effective in preventing recurrences. There is, however, a strong rationale to assume that sorafenib will be of value in the adjuvant treatment of HCC as sorafenib has a dual mechanism of action (inhibition of tumor proliferation and antiangiogenesis) and has proven efficacy in HCC.
9953820|NCT01126645|Active Comparator|palliative treatment group|"Radioembolization has been reported to be effective in patients with unresectable HCC with preserved liver function from a number of trials. Successful downstaging of disease rendering patients eligible for potentially curative therapies, and even histologically confirmed complete responses of unresectable HCC, have repeatedly been reported providing the rationale to evaluate SIRT+sorafenib in comparison to sorafenib alone.~The impact of cirrhosis as a concomitant disease in most patients with HCC is that it limits the ability of many patients to tolerate chemotherapy and is an independent cause of death in HCC patients. Thus, the historical difficulty in demonstrating an effect of therapy on survival in patients with advanced-stage, unresectable HCC (the majority). A new therapy that is effective in controlling hepatic disease, is less toxic than traditional chemotherapy, and improves the quality of life for patients in the advanced stages of HCC could represent an alternative."
9953821|NCT01126658||All subjects act as their own contral|
9953822|NCT01126684|Active Comparator|Atorvastatin|
9953823|NCT01126684|Placebo Comparator|Placebo|
9953824|NCT01126697|No Intervention|Enhanced standard of care|
9953825|NCT01126697|Active Comparator|Lisinopril|
9802332|NCT05314998|Active Comparator|Control Arm B: mFOLFIRINOX or Gem/Cap according to standard clinical criteria|mFOLFIRINOX-therapy (5-FU, Folinic Acid, Irinotecan, Oxaliplatin) according to standard clinical criteria or Gem/Cap-therapy (Gemcitabine and Capecitabine) according to standard clinical criteria
9953826|NCT01126697|Active Comparator|Coenzyme Q10|
9953827|NCT01126697|Active Comparator|Coenzyme Q10 and Lisinopril|
9953828|NCT01126736|Experimental|Low Dose E7389 in Combination with Pemetrexed|
9953829|NCT01126736|Active Comparator|Pemetrexed|
9953830|NCT01126736|Experimental|High Dose E7389 in Cominbation with Pemetrexed|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
9953831|NCT01126762|Experimental|Dietary advice and grocery store card|Dietary advice to consume low mercury, high DHA fish plus a grocery store gift card to support the purchase of fish
9953832|NCT01126762|Experimental|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
9953833|NCT01126762|Placebo Comparator|Control|General dietary advice not focused on fish intake
9953834|NCT01126775||group non-high-risk|
9953835|NCT01126775||group high risk|
9953836|NCT01126788||PADnet + testing|
9953837|NCT01126788||Parks Flo-lab Test|
9953838|NCT01126814|Experimental|one|
9953839|NCT01126827|Active Comparator|Supportive Psychotherapy|
9953840|NCT01126827|Active Comparator|Mindfulness-Based Cognitive Behavioral Therapy|
9953841|NCT01126840||Questionnaire + Telephone Interview|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete. The phone interview should take 30-45 minutes to complete.
9953842|NCT01126853|Experimental|Vaccination|Receipt of up to 3 series of double dose combination hepatitis A/B vaccine (Twinrix)
9953843|NCT01126866|Experimental|preoperative chemotherapy|
9953844|NCT01126892|Experimental|Nilotinib|
9953845|NCT01126918|Active Comparator|Brochure Condition|Participants in this condition receive an educational brochure about healthy body image via post-mail.
9953846|NCT01126918|Experimental|Group Condition|Participants in this condition attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
9953847|NCT01126944|Experimental|system heart mate II|left ventricular assist device
9802333|NCT05314985|Experimental|Prehab Group / Intervention Group|4 to 8 weeks of preoperative physical therapy training and education intervention before total knee replacement surgery.
9802334|NCT05314985|No Intervention|Control Group|Usual care / no treatment before total knee replacement surgery.
9802335|NCT05314959|Experimental|Physician Awareness|The physician will have access to the pre-visit Control Preference Scale survey results for women assigned to this group
9802336|NCT05314959|Active Comparator|Usual Care|The physician will not have access to the pre-visit Control Preference Scale survey results for women assigned to this group
9802337|NCT05314946|Active Comparator|Percutaneous enteral access|Feeding tube, either gastrostomy (G-) tube or gastrojejunostomy (GJ-) tube (placed by Interventional Radiology) or J-tube (surgically placed)
9802338|NCT05314946|Experimental|No percutaneous enteral access|No feeding tube placed.
9528844|NCT03207477|Experimental|Prematurely born infants|Visual acuity measurement in prematurely born infants included in PREMAVISION study
9953848|NCT01126944|No Intervention|normal medical care|Optimal medical treatment for heart failure according to international guidelines
9953849|NCT01126983|Experimental|Non-Suture|No suture will be used to secure the leads. Benzoin and Steri-Strips will be used like in the other two arms.
9953850|NCT01126996||MenC vaccinated healthy children|Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
9953851|NCT01127009|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
9953852|NCT01127022|Active Comparator|480 mg/d choline intake|480 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [100 mg choline/d]
9528845|NCT03207477|Active Comparator|Term born infants|Visual acuity measurement in term born control infants
9528846|NCT03207360|Experimental|Pain Coping Skills|
9802339|NCT05314933|Active Comparator|Study drug|"Each subject receives either a single dose (SAD) or a multiple dose (MAD) of a 3.5% 2-Deoxyglucose as nasal spray solution.~The starting dose for the first cohort is 3.5 mg/day up to a maximum of 84 mg/day at cohort 6."
9802340|NCT05314933|Placebo Comparator|Placebo|Each subject receives either a single (SAD) or multiple (MAD) dose of placebo. The dose for each cohort is corresponding the amount of solution needed in the verum group.
9802341|NCT05314920|Experimental|transdiagnostic cognitive-behavioural therapy (TD-CBT)|Transdiagnostic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12-week period.
9802342|NCT05314920|Active Comparator|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. Patients will receive 7 sessions (1.5 hr/session) in groups of 8-10 individuals over a 12-week period.
9802343|NCT05314907|Active Comparator|Training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush) and then she collects a self-sample at the health centre as a training.
9802344|NCT05314907|Placebo Comparator|No prior training group|The Health professional shows the woman how to use the self-sampling device (Evalyn Brush).
9802345|NCT05314504|Experimental|Test group|Treatment administration to subjects
9802346|NCT05314504|No Intervention|Control group|After primary endpoint evaluation, eligible subjects will receive treatment at Week 12
9953853|NCT01127022|Experimental|930 mg/d choline intake|930 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [550 mg choline/d]
9953854|NCT01127035|Experimental|SLIT|sublingual immunotherapy biologically standardized
9953855|NCT01127035|Placebo Comparator|placebo|same preparation of SLIT without the allergen
9953856|NCT01127048|Experimental|Prospan Hustenzäpfchen|
9953857|NCT01127048|Placebo Comparator|Placebo|
9953858|NCT01127074|Experimental|KS24.22-vaccination|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated. KS24.22 cells were adjusted to 10E7/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
9953859|NCT01127100|Experimental|Transdermal fentany matrix|Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
9953860|NCT01127100|Active Comparator|gabapentin|Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
9953861|NCT01127113|Active Comparator|SPIO-labelled mononuclear cells|
9953862|NCT01127113|Placebo Comparator|Unlabelled mononuclear cells|
10215304|NCT03704571|Active Comparator|Control Group|In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
9953863|NCT01127113|Active Comparator|SPIO alone|
9953864|NCT01127126|Active Comparator|Bryophyllum|muscle relaxing substance
9953865|NCT01127126|Placebo Comparator|Placebo|control group postmenopausal women suffering from overactive bladder
9953866|NCT01127152|Active Comparator|Automatic relays|Automatic relays of noradrenalin using intensive basis.
9953867|NCT01127152|Active Comparator|Manual relays|Relays of noradrenalin using manual method
9953868|NCT01127178|Experimental|E7016 + TMZ|
9953869|NCT01127191||Military|
9953870|NCT01127204|Active Comparator|arm 1 (reference strategy)|AZT-3TC-LPV/r twice a day
9953871|NCT01127204|Experimental|arm 2 (simplification strategy)|ABC-3TC-EFV once a day
9953872|NCT01127217|Experimental|amlodipine/losartan|
9953873|NCT01127217|Active Comparator|amlodipine|
9953874|NCT01127230||Liposuction patients|Patients who already opted and are scheduled for liposuction.
9953875|NCT01127243|Active Comparator|inpatient LSH|LSH means laparoscopic supracervical hysterectomy
10215305|NCT03704532||Operative treatment|Patients having undergone an operative treatment of achilles tendon rupture
10215306|NCT03704532||Nonoperative treatment|Patients having undergone a nonoperative treatment with functional rehabilitation of achilles tendon rupture
10215307|NCT03704519|Experimental|Men_EPD|Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.
10215308|NCT03704519|Experimental|Men_DEP|Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.
9953876|NCT01127243|Experimental|Day-case LSH|LSH means laparoscopic supracervical hysterectomy
9953877|NCT01127269|Experimental|Insulin Glargine|"Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.~Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm."
9953878|NCT01127282|Experimental|Vitamin|Vitamin(vitamin A 15mg,C 500mg,E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
9953879|NCT01127282|Placebo Comparator|Control|Placebo(digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
9953880|NCT01127295|Other|Tamoxifen, Anastrozole, letrozole, Exemestane|Current hormonotherapy treatment in hormono dependent breast cancer
9953881|NCT01127308|Experimental|[14C]Ertugliflozin|Single dose - oral dosing suspension
10215309|NCT03704519|Experimental|Men_PDE|Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.
10215310|NCT03704519|Experimental|Men_DPE|Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.
10215311|NCT03704519|Experimental|Men_EDP|Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.
10215312|NCT03704519|Experimental|Men_PED|Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.
10215313|NCT03704506|Experimental|treatment group 1|Reyanning mixture+amoxil capsule simulator
10215314|NCT03704506|Experimental|treatment group 2|Reyanning mixture +amoxil capsule
10215315|NCT03704506|Active Comparator|control group|Reyanning mixture simulator +amoxil capsule
10215316|NCT03704493|No Intervention|Image Group|The patients were looking at a static image of a lavender flower while exercising on the treadmill.
10215317|NCT03704493|Experimental|Video Group|The patients were watching a video of a group of amateur runners while exercising on the treadmill.
10215318|NCT03704480|Experimental|Amended ARM A|"One cycle equals 4 weeks (D1=D28);~Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.~Tremelimumab: 300 mg by IV infusion on D1 at cycle 1 only."
10215319|NCT03704454|Experimental|Group A - PYC & Placebo|50 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
10215320|NCT03704454|Experimental|Group B - PYC & Placebo|100 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
10215321|NCT03704454|Experimental|Group C - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 50 mg PYC for the following 4 weeks
10215322|NCT03704454|Experimental|Group D - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 100mg PYC for the following 4 weeks
10215323|NCT03704428|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 dose 1
10215324|NCT03704428|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 dose 2
10215325|NCT03704428|Experimental|Cohort 3|Multiple subcutaneous injections of SHR-1314 dose 3
10215326|NCT03704428|Experimental|Cohort 4|Multiple subcutaneous injections of SHR-1314 dose 4
9953882|NCT01127334||Systolic Heart Failure, Dyssynchrony, CRT-D|Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.
9953883|NCT01127360|Experimental|Bevacizumab|Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
9953884|NCT01127360|Active Comparator|Ranibizumab|Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
9953885|NCT01127386|Experimental|fix dose lenalidomide 25mg, basic cachexia management|dose reduction according to toxicity possible
9953886|NCT01127386|Experimental|CRP-response guided lenalidomide, basic cachexia management|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
9953887|NCT01127386|Experimental|placebo|to generate data about basic cachexia management, no direct comparator for treatment arms efficacy
9953888|NCT01127399||Bariatric, nonasthma|Participants that will have had a bariatric surgery but do not have asthma.
9953889|NCT01127399||Bariatric, asthma|Participants that will have had a bariatric surgery and have been physician diagnosed with asthma prior to the surgery.
9953890|NCT01127399||Control, nonasthma|Healthy participants that who will not be getting a bariatric surgery and who do not have asthma.
9953891|NCT01127399||Control, asthma|Healthy participants that will not be having a bariatric surgery but do have asthma.
9953892|NCT01127412|Active Comparator|Physical activity stimulating program|Advices to stimulate motor activity and motor development at the age of two weeks, two months, four months, eight months and eleven months
9953893|NCT01127412|No Intervention|Control|
9953894|NCT01127425|Active Comparator|1|Intervention: Surgery: laparoscopic sigmoid resection without fast track postoperative care
9953895|NCT01127425|Active Comparator|2|Intervention: Surgery: conventional (open) sigmoid resection without fast track postoperative care
9953896|NCT01127464|Experimental|.3 dose level of DCVax -001|.3 dose level of DCVax plus fixed dose of 1.6 ml Poly ICLC
9953897|NCT01127464|Experimental|1 mg dose level of DCVax -001|1 mg dose level of DCVax -001 plus 1.6 ml of poly ICLC
9953898|NCT01127464|Experimental|3 mg dose level of DCVax-001|3 mg dose level of DCVax-001 plus poly ICLC
9953899|NCT01127464|Placebo Comparator|Placebo|sterile saline
9953900|NCT01127464|Experimental|poly-ICLC alone|1.6 mg of poly-ICLC alone
9953901|NCT01127477|Experimental|1|
9953902|NCT01127529||Subjects with severe congenital protein C deficiency|Registry subjects will be identified by working with Hemophilia Treatment Centers and Thrombosis Centers known to have subjects with severe congenital protein C deficiency, as well as by working with centers that use Ceprotin in emergency care situations.
9953903|NCT01127542|Experimental|Lenalidomide for early stage poor prognosis CLL|
9953904|NCT01127568|Experimental|Propranolol|Propranolol is a beta-blocker (blocking beta- adrenergic receptors) that reduces sympathetic activity. It is a well-known drug typically prescribed to individuals suffering from hypertension, tachycardia, cardiac arrhythmia, tremors, thyroid disease, or migraine.
9953905|NCT01127568|Placebo Comparator|Placebo|The placebo is an inactive capsule that will have no medication effect, but looks exactly like the medication.
9953906|NCT01127620|Experimental|Bilastine|20 mg encapsulated tablets
9953907|NCT01127620|Active Comparator|Cetirizine|10 mg encapsulated tablets
9953908|NCT01127620|Placebo Comparator|Placebo|Encapsulated tablets
9953909|NCT01127672|Active Comparator|control|corticosteroid injection into the origin of the plantar fascia
9953910|NCT01127672|Active Comparator|experimental|platelet rich plasma injection into the origin of the plantar fascia
9953911|NCT01127724|Experimental|group 1- 1000 mcg|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
9953912|NCT01127724|Experimental|Group 2- 100 mcg|Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
9953913|NCT01127724|Experimental|group 3- 2000 mcg|Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
9953914|NCT01127750|Experimental|FTY720|
9953915|NCT01127776|Experimental|Apos System|
9953916|NCT01127776|Placebo Comparator|CONTROL|
9953917|NCT01127789|Experimental|non-invasive brain stimulation|
9953918|NCT01127828|Active Comparator|Probiotic yoghurt (Cultura)|Cultura yoghurt containing: L bulgaricus, S thermophilus
9953919|NCT01127828|Placebo Comparator|Yoghurt with no probiotic|
9953920|NCT01127841|Experimental|Rituximab and Bendamustine|
9953921|NCT01127880|Active Comparator|Ancef 1 gm or Clindamycin 300 mg|Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
9953922|NCT01127880|Placebo Comparator|Placebo|Group B will receive .9% Normal Saline as a placebo.
10215327|NCT03704428|Experimental|Cohort 5|Multiple subcutaneous injections of SHR-1314 dose 5
10215328|NCT03704415|Active Comparator|Extended|Extended sinus surgery including all sinuses
10215329|NCT03704415|Active Comparator|Limited|Limited sinus surgery with partial ethmoidectomy
10215330|NCT03704402||alcohol policy group|High schools that introduced the policy
10215331|NCT03704402||control group|High schools that did not introduce the policy
10215332|NCT03704389|Experimental|Clinical decision support intervention|Participating clinicians will receive any of three clinical decision support nudges within the electronic health record when all eligibility criteria are met within a patient's chart.
10215333|NCT03704363|Experimental|Infliximab|Intravenous infusion(biosimilar infliximab). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
10215334|NCT03704363|Placebo Comparator|Placebo|Intravenous infusion (NaCl intravenous infusion). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98.
10215335|NCT03704337|Experimental|Commercially Available Food Bar|62 g. Food Bar
10215336|NCT03704337|Placebo Comparator|Placebo|25 g. Dextrose
10215337|NCT03704311|Experimental|Single|Evaluation of mitochondrial function after muscle biopsy and follow-up for surgical complications.
10215338|NCT03704272|No Intervention|Control|Families in the control group will receive treatment as usual, which includes reporting to child welfare agencies when appropriate.
10215339|NCT03704272|Experimental|Treatment|SunBrite
9953923|NCT01127906|Other|Randomized cross-over sequence|Randomized unbalanced sequence of incomplete block design with replicates within sequence
9953924|NCT01127919||Low Commitment|Group 1 participants will take a 1-credit hour course that involves exercise training only.
9953925|NCT01127919||High Commitment|Group 2 participants will take a 3-credit hour course that involves exercise training plus an online cognitive component that provides information on fitness and health topics and includes quizzes and other written course work
9953926|NCT01127919||Non-Exercise|Group 3 participants will take the cognitive component of the formal course but will not partake in the formalized exercise program for a period of 35 weeks.
9953927|NCT01127932|Experimental|CBT for suicide|
9953928|NCT01127932|Active Comparator|Enhanced care control group|This group is designed to be an active control which provides detailed information about substance use, suicide risk, and depression without providing any CBT or other specific therapy.
9953929|NCT01127945|Experimental|atorvastatin 80mg|
9802347|NCT05312125|Active Comparator|control group|Children in this group will take routine physiotherapy (stretching, strengthening) program during 6 weeks. 3 days/week.
10215340|NCT03704246|Other|Anti-PD-1|Anti-PD-1 monoclonal antibody HX008 injection with a dose of 200mg (intravenous infusion, every 3 weeks)
10215341|NCT03704233||Cryobiopsy|Transbronchial cryobiopsy is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
10215342|NCT03704220|Other|Single anti-thrombotic treatment|Single anti-thrombotic treatment
10215343|NCT03704181|Experimental|colchicine|colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year
9953930|NCT01127945|Active Comparator|conventional therapy (for heart failure)|
9953931|NCT01127958|Active Comparator|SeQuent Please|PCI with drug-eluting balloon
10215344|NCT03704181|Active Comparator|placebo|"placebo tablet by mouth every 12 hours, for 1 year~pill manufactured to mimic coclchicine 0,5 mg tablet"
9953932|NCT01127958|Active Comparator|Xience Prime|PCI with a drug-eluting stent
9953933|NCT01127984|Experimental|treatment with tissucol|patients treated with tissucol, local application in the pocket of PM / ICD
9953934|NCT01127984|Active Comparator|vacuum drainage system|patients treated with application of vacuum drainage system.
9953935|NCT01127997||study A|post-breakfast meal tolerance test + post-lunch meal tolerance test
9953936|NCT01127997||study B|fasting + post-lunch meal tolerance test
9953937|NCT01128010||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
9953938|NCT01128010||controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
9953939|NCT01128023||PET Rb-82 perfusion imaging|Patients diagnosed with or suspected coronary artery disease requiring evaluation and/or risk stratification will undergo PET Rb-82 perfusion imaging.
9953940|NCT01128023||SPECT perfusion imaging|Patients diagnosed with or suspected coronary artery disease who have undergone SPECT myocardial perfusion imaging.
9953941|NCT01128036||CHF, cardomyopathy|Patients with signs of poor peripheral perfusion due to cardiomyopathy or congestive heart failure
9953942|NCT01128075||naïve subjects|Cohort of RMS patients who initiate disease modifying treatment with Rebif®
9953943|NCT01128075||non-naïve subjects|Cohort of RMS patients who initiate treatment with Rebif® after having failed therapy with other disease modifying drugs on the basis of lack of efficacy, compliance, safety, tolerability or convenience, as per clinical judgment of study investigator
9953944|NCT01128088||PCA and Volulyte|
9953945|NCT01128088||PCA and Hartmann's|
9953946|NCT01128088||Spinal and Volulyte|
9953947|NCT01128088||Spinal and Hartmann's|
9953948|NCT01128101|Experimental|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
10215345|NCT03704155|Experimental|Experimental group (EG)|The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
10215346|NCT03704155|Active Comparator|Control group (CG)|GC was treated with physiotherapy (stretching, balancing training, functional walking training).
10215347|NCT03704142|Experimental|Tweak Focus|Speech understanding and listening effort will be assessed using the Tweak Focus personal sound amplifiers.
10215348|NCT03704142|Experimental|IQ Earbuds|Speech understanding and listening effort will be assessed using the IQEarbuds personal sound amplifiers.
10215349|NCT03704142|Experimental|Sound World Solutions CS50+|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
10215350|NCT03704142|Experimental|Bose Hearphones|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
10215351|NCT03704129|Experimental|"Tutor group"|"After a theoretical part through the administration of a video-tutorial, a 10-point questionnaire will be administered to evaluate the level of learning for each participant. Every single participant will pass the test if he/she correctly answer to >70% of the questions. Those passing the test, will be randomized to two groups.~The interventional group will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself."
10215352|NCT03704129|No Intervention|"No tutor group"|This control group will directly perform the ultrasound examination of the diaphragm. The expert tutor will only show the learners how to use the various functions of the ultrasound, the linear and convex probes both in two-dimensional and in M-mode.
10215353|NCT03704116|Active Comparator|Expedition: Strategic Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
10215354|NCT03704116|Placebo Comparator|Expedition: Informational Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes capped challenge levels.
9528847|NCT03207061|Other|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
9953949|NCT01128127|Experimental|Multifaceted intervention 1|psycho-educational workshop + audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
9953950|NCT01128127|Experimental|Multifaceted intervention 2|audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
9953951|NCT01128127|Active Comparator|Control|usual intervention
9953952|NCT01128140|Experimental|Motivational Enhancement Therapy|
9953953|NCT01128140|Active Comparator|Education|
9953954|NCT01128166||Patients implanted with a CRT-D (Cardiac Resynch. Therapy)|
9953955|NCT01128205||Diagnosed for 6 months or more|
9953956|NCT01128218|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug - 5-aminolevulinic acid. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
9953957|NCT01128257||1|
9953958|NCT01128257||2|
9953959|NCT01128283||Sepsis|Patients with severe sepsis
9953960|NCT01128283||Non-infected|ICU patients without evidence of infection
10005250|NCT01583504|Experimental|High volume saline injection|Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
10005251|NCT01583504|Active Comparator|Control Arm|"Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises.~Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks"
10005252|NCT01583517|Active Comparator|Biliary sphincterotomy|Cutting of the biliary sphincter muscle alone
10005253|NCT01583517|Active Comparator|Dual sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
10005254|NCT01583517|Sham Comparator|Sham|Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
10005255|NCT01583517|Active Comparator|Biliary sphincterotomy - Normal SOM|Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
10005256|NCT01583556||Standard treatment|This study will employ a prospective, non-randomized design. After the questionnaires are filled the patients choose whether or not to schedule a second appointment for evaluation of their fracture: The first group will be scheduled for a second visit (standard treatment) as our daily practice after 1-3 months. They will be contacted after 2-6 months either by phone or email and will complete again some questionnaires (Quick DASH, satisfaction, return to work).
10005257|NCT01583556||Optional follow-up group|The alternative (Optional follow-up group) will be to take a handout describing the recovery and providing instructions for how to contact us should they get off course. The questionnaires will be repeated either by phone or email in 2-6 months.
10005258|NCT01583582|Experimental|Refined peptide concentrate, 1200 mg|Refined peptide concentrate, 1 200 mg, once a day
10005259|NCT01583582|Experimental|Refined peptide concentrate, 2 x 600 mg|Refined peptide concentrate, 600 mg, twice a day
10005260|NCT01583582|Placebo Comparator|Refined peptide concentrate, 0 mg|
10005261|NCT01583621|No Intervention|Placebo|Placebo group
10005262|NCT01583621|Experimental|Supplementation arm 1|cholecalciferol 18000 U/month for 4 months
10005263|NCT01583621|Experimental|supplementation arm 2|cholecalciferol 60000 U/month for 4 months
10005264|NCT01583621|Experimental|Supplementation arm 3|cholecalciferol 120000 U/month for 4 months
10005265|NCT01583634||Healthy volunteers|9 subjects (male and female)
10005266|NCT01583673|Experimental|Amino Acid Formula|Hypoallergenic baby formula
10005267|NCT01583673|Active Comparator|Amino Acid commercial formula|Hypoallergenic commercial amino acid formula
9528848|NCT03207139|Experimental|Ga-68 PSMA ligand|Diagnostic performance of [Ga68] PSMA-11
10005268|NCT01583699|Experimental|Endomicroscopy|All patients included into the study will undergo endomicroscopy of the upper GI-tract.
10005269|NCT01583712|Experimental|Endomicroscopy|All patients included in the study will undergo endomicroscopy of the upper GI-tract including the reachable parts of the small bowel.
10005270|NCT01583725|Experimental|Roux-en-Y Gastric Bypass|30 subjects who plan to undergo Roux-en-Y Gastric Bypass bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
10005271|NCT01583725|Experimental|Gastric Banding (Lap-band)|30 subjects who plan to undergo Gastric Banding bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
10005272|NCT01583725|Experimental|Formula Diet Weight Loss|30 subjects who plan to begin a formula diet to lose weight. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before subjects undertake a 12-week weight loss intervention (T1), at the end of the weight loss intervention (T2) and 18 months after they completed the weight loss intervention(T3).
10005273|NCT01583725|Experimental|No Treatment|30 subjects who do not undergo any treatment for weight loss. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed at baseline (T1) and at 3 months (T2) and 18 months (T3) later.
10005274|NCT01583725|Experimental|Sleeve Gastrectomy Surgery|30 subjects who plan to undergo Sleeve Gastrectomy bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
10005275|NCT01583738|Experimental|V0251|
10005276|NCT01583738|Placebo Comparator|Placebo|
10005277|NCT01583751|Experimental|control|excision and primer repair surgical technique will be perform
10005278|NCT01583777|Experimental|Belinostat|Open Label
10005279|NCT01583790||no group|laparoscopic sleeve gastrectomy
10005280|NCT01583803||Males|
9953961|NCT01128309|Experimental|Stress Reduction Intervention|Stress Reduction Intervention
9953962|NCT01128309|Active Comparator|Active Control Condition|
9953963|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 40mg|
9953964|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 80mg|
9953965|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 40mg|
9953966|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 80mg|
9953967|NCT01128322|Active Comparator|S-Amlodipine 2.5mg|
9953968|NCT01128322|Active Comparator|S-Amlodipine 5mg|
9802348|NCT05312125|Active Comparator|intervention group|Children in this group will take routine physiotherapy (stretching, strengthening) program + backward downhill walking (10 minutes in a day) during 6 weeks. 3 days/week.
9953969|NCT01128322|Active Comparator|Telmisartan 40mg|
9953970|NCT01128322|Active Comparator|Telmisartan 80mg|
9953971|NCT01128322|Placebo Comparator|Placebo|
9953972|NCT01128348|Experimental|patient advocate|"Patient advocate works with patient before, during, and after a visit to asthma doctor.~Patient receives video of asthma education materials"
9953973|NCT01128348|Active Comparator|asthma education|Patient receives video of asthma education materials
9953974|NCT01128374|Experimental|intervention|Therapy
9953975|NCT01128439||1|
9953976|NCT01128478|Other|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
9802349|NCT05309850|Experimental|Usage of tool|Participants get access to the tool and use it regularly
9953977|NCT01128478|No Intervention|Nil-per-mouth regimen|Conventional management
9953978|NCT01128517|Experimental|Bahavioral|Education about complementary food given to mothers
9953979|NCT01128556|Experimental|Bepreve|topical ocular treatment as indicated
9953980|NCT01128582|Active Comparator|Rozerem|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
9953981|NCT01128582|Placebo Comparator|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology
9953982|NCT01128608|Active Comparator|Control Group - Healthy Subjects|Healthy volunteers with normal EGD.
9953983|NCT01128608|Active Comparator|NERD Group|Subjects with NERD. Heartburn symp x2 wk for 3 months. Normal EGD and abnormal 24 hour pH.
9953984|NCT01128634|Other|GSK573719|GSK573719
9953985|NCT01128634|Other|GSK573719/GW642444|GSK573719/GW642444
9953986|NCT01128660||RSD-citizens|Residents of Southern Denmark, who filed more than 9 prescriptions during 2009.
9953987|NCT01128673||Body Cooled|Infants undergoing total body cooling for HIE
9953988|NCT01128673||HIE,Selective Head Cooled|Infants undergoing head cooling for HIE
9953989|NCT01128686||CHB patients who started LAM as an initial antiviral treatment|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation
9953990|NCT01128699|Experimental|ISA+AVI|injection of intraoperative subconjunctival Avastin as an adjunct to Ahmed valve implant
9953991|NCT01128699|Active Comparator|AVI|Ahmed valve implant
9953992|NCT01128712|Other|Group 1|Pregabalin (150mg/day)
9953993|NCT01128712|Other|Group 2|Pregabalin (450mg/day)
9953994|NCT01128725|Other|Group Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
9953995|NCT01128751|Active Comparator|Embol-X|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
9953996|NCT01128751|Active Comparator|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
10005281|NCT01583803||Females|
9953997|NCT01128751|No Intervention|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
9953998|NCT01128764|Experimental|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
9953999|NCT01128764|Active Comparator|CBT for depression|CBT for depression only
9954000|NCT01128777|Experimental|Cognitive behavioral group therapy|Cognitive behavioral group therapy for adolescents and a parallel group for parents
9954001|NCT01128777|Active Comparator|Nondirective supportive group therapy|Nondirective supportive group therapy for adolescents and a parallel group for parents
9954002|NCT01128790|Experimental|remote ischemic preconditioning|4 cycles of 5 mins upper limb ischemia induced by blood pressure cuff inflation 20mmHg above systolic blood pressure
9954003|NCT01128790|Sham Comparator|Sham control|4 x 5 mins of upper limb blood pressure cuff inflation to 10mmHg (non-occlusive)
9954004|NCT01128816|No Intervention|Standard HF therapy|Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
9954005|NCT01128816|Active Comparator|Standard therapy for HF + ASV|Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist
9954006|NCT01128855|Experimental|Cohort 1|3 mg/kg GSK2402968 / placebo
9954007|NCT01128855|Experimental|Cohort 2|6 mg/kg GSK2402968 / placebo
9954008|NCT01128855|Experimental|Cohort 3|9 mg/kg GSK2402968 / placebo
10005282|NCT01583816|Experimental|Resiquimod Gel 0.03% or placebo|Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
9802350|NCT05309850|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease or type 2 diabetes is followed via clinical registries.
9954009|NCT01128855|Experimental|Cohort 4|12 mg/kg GSK2402968 / placebo
9954010|NCT01128868|Active Comparator|Proximal femur locking plate|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc)
9954011|NCT01128868|Other|Trochanteric nail|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
9954012|NCT01128881|Experimental|IMMUNINE|
9954013|NCT01128907||1|Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
9954014|NCT01128907||2|Patients without hematological illness and without Invasive Aspergillosis suspicion.
9954015|NCT01128920|Experimental|Skin and Needle Hygiene Intervention|
9954016|NCT01128920|Experimental|Assessment-Only Condition|
9954017|NCT01128933|Experimental|Hypertensive patients|Hypertensive patients with at least moderate renal artery stenosis
9954018|NCT01128985|Experimental|001|Canagliflozin 50 mg 50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
9954019|NCT01128985|Experimental|002|Canagliflozin 100 mg 100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
9954020|NCT01128985|Experimental|003|Canagliflozin 300 mg 300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
9954021|NCT01128985|Placebo Comparator|004|Placebo matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
9954022|NCT01128998|Experimental|S-1 and Sorafenib|
9954023|NCT01129037|Other|Goal directed fluid management|
9954024|NCT01129050|Experimental|Low-dose Flaxseed Oil|2.2 g ALA (alpha-linolenic acid) per day
9954025|NCT01129050|Experimental|High-dose Flaxseed Oil|6.6 g ALA (alpha-linolenic acid) per day
9954026|NCT01129050|Experimental|Low-dose Fish Oil|1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day
9954027|NCT01129050|Experimental|High-dose Fish Oil|3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day
9954028|NCT01129050|Placebo Comparator|Placebo|4 g or 6 g soybean oil per day
9954029|NCT01129063|Experimental|Sequence clopidogrel 75 / 75 / 300 mg|"Period 1: clopidogrel 75 mg single dose~Period 2: clopidogrel 75 mg single dose~Period 3: clopidogrel 300 mg single dose~Each intake is at around 8:00 AM under fasted conditions."
9954030|NCT01129089|Experimental|LNS-PLW|There will be 48 pregnant or lactating women (PLW) in this arm. They will be randomized to receive cumin flavored LNS-PLW or LNS-PLW with no added flavor on day 2. On day 3, the PLW getting a test-dose of cumin flavored LNS-PLW on day 2 will receive LNS-PLW with no added flavor and the PLW getting a test-dose of LNS-PLW with no added flavor on day 2 will receive cumin flavored LNS-PLW.
9954031|NCT01129089|Experimental|LNS-Child|There will be 48 infant and young children(IYC) in this arm. They will be randomized to receive cardamom flavored LNS-Child or LNS-Child with no added flavor on day 2. On day 3, the IYC getting a test-dose of LNS-Child with no added flavor on day 2 will receive cardamom flavored LNS-Child and the IYC getting a test-dose of cardamom flavored LNS-Child on day 2 will receive LNS-Child with no added flavor.
9954032|NCT01129089|Experimental|MNP-Child|There will be 48 infant and young children(IYC) in this arm. They will receive MNP on day 2 and day 3.
9954033|NCT01129154|Experimental|panitumumab|Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
9954034|NCT01129180|Experimental|Arm I|Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
9954035|NCT01129193|Experimental|Arm I (Hematologic Malignancies)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
9954036|NCT01129193|Experimental|Arm II (Solid Tumors)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
10005283|NCT01583816|Experimental|Resiquimod or placebo|Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
10005284|NCT01583816|Experimental|Resiquimod or vehicle|Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once
9954037|NCT01129219|Experimental|Usual care|Subjects in the control group were asked to maintain their current lifestyle. No restrictions were placed on their exercise activities.
9954038|NCT01129232|Experimental|GAD-alum|GAD-alum administered at 0 and 1 months after inclusion
9954039|NCT01129232|Placebo Comparator|Placebo|
9954040|NCT01129258|Experimental|PF-04991532|
9954041|NCT01129258|Placebo Comparator|Placebo|
9954042|NCT01129271|Experimental|Group clopidogrel fed - fasting|"Period 1:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily"
9954043|NCT01129271|Placebo Comparator|Group placebo fed - fasting|"Period 1:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily~Period 2:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo under fasted conditions, once daily"
10005285|NCT01583816|Experimental|Resiquimod gel 0.01%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
10005286|NCT01583816|Experimental|Resiquimod gel 0.03%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
10005287|NCT01583829|Experimental|Neurofeedback|
10005288|NCT01583829|Experimental|Cognitive Training|
9954044|NCT01129271|Experimental|Group clopidogrel fasting - fed|"Period 1:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily"
9954045|NCT01129271|Placebo Comparator|group placebo fasting -fed|"Period 1:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo in fasted conditions, once daily~Period 2:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily"
9954046|NCT01129297||BMI ≥ 35 kg/m2 and diabetes|BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
9954047|NCT01129297||BMI ≥ 35 kg/m2 with intolerance glucose|BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose> 6 mmol/L and <7 mmol/l and / or> 7.8 mmol/l and <11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
9954048|NCT01129297||BMI ≥ 35 kg/m2 without diabetes|BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
9954049|NCT01129297||BMI <27 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
9954050|NCT01129297||27 < BMI < 35 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
9954051|NCT01129323|Experimental|Reduced-Intensity Preparative Regimen for Allogeneic SCT|Patient in this arm will receive maximally tolerated (reduced) doses of cytotoxic therapy with the goals of suppressing the immune system, and ablate host hematopoiesis to ensure engraftment of the donor's hematopoietic system.
9954052|NCT01129349|Experimental|Oprozomib|Phase I, Dose Escalation, Single Arm, Open Label
9954053|NCT01129375|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
9954054|NCT01129375|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
9954055|NCT01129375|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions"
9802351|NCT05309564|Experimental|Intervention|Intervention with single botulinum neurotoxin injection into masseter.
9954056|NCT01129375|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
10005289|NCT01583829|Active Comparator|Waitlist Control|
10005290|NCT01583842|Experimental|124I-MIBG no-carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
9802352|NCT05309564|No Intervention|Control|No intervention
9954057|NCT01129388|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
9954058|NCT01129388|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
9802353|NCT05308927||Incident patients|Children initiated Norditropin® upon their inclusion in the study but independently from the decision to participate in this study
9954059|NCT01129388|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily"
9954060|NCT01129388|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily"
9954061|NCT01129401|Other|Stonewall Project Participants|
9954062|NCT01129414|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
9954063|NCT01129414|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
9954064|NCT01129414|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Each intake is under fasted conditions"
9954065|NCT01129414|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
9954066|NCT01129427|Experimental|Group clopidogrel - clopidogrel + pantoprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
9954067|NCT01129427|Placebo Comparator|Group placebo - placebo + pantoprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
9954068|NCT01129427|Experimental|Group clopidogrel + pantoprazole - clopidogrel|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions."
10215355|NCT03704103|Experimental|iSage for adjustment of insulin|The provider will prescribe the iSage app to the subject and choose a treatment algorithm within the app to make insulin dose adjustments.
10215356|NCT03704103|No Intervention|Conventional management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet.
10215357|NCT03704090|Active Comparator|Control|Standard non-pharmacological intervention during 5 days after surgery.
10215358|NCT03704090|Experimental|Treatment|Occupational therapy intervention twice a day plus standard non-pharmacological prevention intervention during 5 days after surgery.
10215359|NCT03704077|Experimental|Cohort A: relatlimab + nivolumab + paclitaxel|
10215360|NCT03704077|Experimental|Cohort A: nivolumab + paclitaxel|
10215361|NCT03704077|Active Comparator|Cohort A: ramucirumab + paclitaxel|Standard-of-care
10215362|NCT03704077|Experimental|Cohort B: relatlimab + nivolumab|
10215363|NCT03704077|Active Comparator|Cohort B: nivolumab|Standard-of-care
10215364|NCT03704077|Experimental|Cohort C: relatlimab + nivolumab|
10215365|NCT03704064|Experimental|Stigma + BWL Intervention|Participants in this group will receive the standard behavioral weight loss (BWL) program, which will be combined with a stigma-reduction intervention (more details provided in the Intervention section). All group meetings will be 90 minutes. Beginning at week 5, the 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the monthly and every-other-month weight loss maintenance sessions from weeks 21-72, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically with physical activity.
9954069|NCT01129427|Placebo Comparator|Group placebo + pantoprazole placebo|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions."
9954070|NCT01129453|Experimental|Vaccine-recipients|
9954071|NCT01129453|Placebo Comparator|Placebo|
9954072|NCT01129466|Active Comparator|Supplement A followed by supplement B|
9954073|NCT01129466|Active Comparator|Supplement B followed by Supplement A|
9954074|NCT01129479|Active Comparator|Galantamine|
9954075|NCT01129479|Placebo Comparator|Placebo|
9954076|NCT01129492|Placebo Comparator|Sham Laser|Ten applications of placebo were performed (twice a week) with the same method and Laser equipment, which has a placebo function available with a red ordinary light indistinguishable of the Laser light.
9954077|NCT01129492|Active Comparator|Active Laser|Ten applications of low-level Laser therapy (twice a week) were performed with a continuous wave diode laser device (830nm, beam area of 0.2827cm2), using the punctual method, continuous emission mode, output power of de 50 mW and fluence of 70J/cm2.
9954078|NCT01129518|Experimental|Two Dose MenC Group|Two doses of MenC-CRM197 priming at 3 and 4 months of age.
9954079|NCT01129518|Experimental|Single Dose MenC-CRM197 Group|One dose of MenC-CRM197 priming at 3 months of age.
9954080|NCT01129518|Experimental|Single Dose MenC-TT Group|Single dose MenC-TT priming at 3 months of age
9954081|NCT01129518|Experimental|Control Group|Zero dose MenC priming
9954082|NCT01129544|Experimental|Gene Transfer|open label single arm study
9954083|NCT01129570|Experimental|Siliphos - dose escalation|
9954084|NCT01129596||1|
9954085|NCT01129635|Experimental|CRT Candidate|"Patients with NYHA Class III or IV heart failure; EF ≤ 30% and QRS duration ≥ 120 ms, who are scheduled for CRT surgery.~Intervention: Cardiac Resynchronization Therapy (CRT) implantation"
9954086|NCT01129661|Placebo Comparator|normal saline (0.9%)|
9954087|NCT01129661|Experimental|CSL112|
9954088|NCT01129687||ANSRS group|Patients qualifying for the study.
9954089|NCT01129700|Experimental|short-course CRT-5FU|
9954090|NCT01129713|Active Comparator|Nexium|Comparing 40 mg.once daily in healing erosive esophagitis.
9667580|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle"
9954091|NCT01129713|Active Comparator|Secretol|Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
9954092|NCT01129726|Experimental|Intubation|Transillumination-guided Fiberoptic Intubation
9954093|NCT01129739|Experimental|Human umbilical cord-derived MSCs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle
9954094|NCT01129739|Active Comparator|cyclosporine A (CsA)|CsA at a dose of 5 mg CsA/kg
9954095|NCT01129752||children at risk for depression|children at familial risk for depression
9954096|NCT01129791|Experimental|Raw Milk first|Organic raw cow's milk
9954097|NCT01129791|Placebo Comparator|Pasteurized milk first|Organic pasteurized cow's milk
9954098|NCT01129791|Placebo Comparator|Non-Dairy Milk first|Unflavored soy milk
9954099|NCT01129817|Experimental|Cognitive Functional Therapy|
9954100|NCT01129817|Active Comparator|Manual Therapy and Exercise|
9954101|NCT01129830|Other|Dehydroepiandrosterone|infertile women with low anti mullerian hormone levels
9954102|NCT01129843|Experimental|Directly observed home based daily iron therapy|Village volunteers will provide directly observed home based daily iron supplementation( ferrous sulphate) to enrolled anemic women in the experimental arm
9954103|NCT01129843|Active Comparator|Clinic driven unsupervised daily iron therapy|In the control group of villages, clinic driven unsupervised iron ( ferrous sulphate) supplementation will be offered on monthly basis to anemic women for 3 months
9954104|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, Low Dose|Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA
9954105|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, High Dose|Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA
9954106|NCT01129856|Placebo Comparator|Ocular Iontophoresis Placebo|Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA
9954107|NCT01129895|Experimental|Health promotion|5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
9954108|NCT01129895|No Intervention|Promoting Health|No intervention follow-up only
9954109|NCT01129934|Experimental|Morphine-Promethazine|Pain relief by administration of morphine-promethazine combination
9954110|NCT01129934|Active Comparator|morphine|pain relief by administration of morphine
9954111|NCT01129947|Experimental|DHEA|
9954112|NCT01129986|Experimental|Dermastream|
9954113|NCT01129999|Experimental|Cognitive-Behavioral Therapy|
9954114|NCT01129999|Experimental|Hypnotherapy|
9954115|NCT01130012|Other|Lifestyle, follow-up, early care, standard care high/low risk|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
9954116|NCT01130012|Other|Close follow-up|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
9954117|NCT01130025|Experimental|Innohep®|Long-term treatment with Innohep® only.
9954118|NCT01130025|Active Comparator|Warfarin|Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.
9954119|NCT01130038||Children with DCD and Typical Development|
9954120|NCT01130038||Children with DCD|2 groups Children with DCD and Typical Development
9954121|NCT01130077|Experimental|HLA Restricted glioma antigen peptides plus Poly ICLC|All subjects will receive vaccine plus Poly ICLC will receive 9 injections ( once every 3 weeks)
9954122|NCT01130129|Experimental|Ex-vivo treatment of platelets|Ex-vivo treatment of platelets
9954123|NCT01130155||Mwanza Region|Households, and patients presenting at public health facilities in Mwanza Region
9954124|NCT01130155||Mbeya Region|Households, and patients presenting at public health facilities in Mbeya Region
9954125|NCT01130155||Mtwara Region|Households, and patients presenting at public health facilities in Mtwara Region
9954126|NCT01130181|Experimental|Cholecalciferol|
10215366|NCT03704064|Active Comparator|Standard BWL Intervention|Participants in this group will be provided with 20 weekly behavioral weight loss (BWL) session (described in more detail in the Intervention section), followed by 6 monthly weight loss maintenance sessions and 3 every-other-month sessions (for a total of 29 visits over 72 weeks). All group meetings will be 90 minutes. Beginning at week 5, BWL content in these sessions will last 60 minutes, with an additional 30 minutes devoted to discussing recipes and food preparation.
9954127|NCT01130181|Placebo Comparator|Placebo|
9954128|NCT01130194|Experimental|Experimental|C-MOPP-R chemotherapy, 6 cycles Peripheral blood stem cell mobilization Radioimmunotherapy Autologous Hematopoietic Stem Cell Transplantation
9954129|NCT01130220||Brain Tumor Patient|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
9954130|NCT01130220||Health Care Provider|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
9954131|NCT01130233|Experimental|robotic|robotic assisted rectal resection
9954132|NCT01130233|Active Comparator|laparoscopic|laparoscopic rectal resection
9954133|NCT01130246|Experimental|A-002 500 mg|Once daily oral administration
9954134|NCT01130246|Placebo Comparator|Matched Placebo|Once daily oral administration
9954135|NCT01130285||Non-Lung Cancer, Heavy Smoker|Subjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.
9954136|NCT01130298|Experimental|1|
10005291|NCT01583842|Experimental|124I-MIBG carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
10005292|NCT01583842|Active Comparator|Imaging Only|Participants with high-risk neuroblastoma will receive imaging only without 124I-MIBG
10005293|NCT01583855|Active Comparator|Manual ablation|Patients will have their ablation performed manually.
10005294|NCT01583855|Active Comparator|Ablation using remote catheter system|Ablation for atrial fibrillation using the Amigo remote catheter system
10005295|NCT01583881|Experimental|Renal denervation|Renal denervation
10215367|NCT03704051|Experimental|Breast- versus Bottle-feeding|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
10215368|NCT03704038|Active Comparator|PEEP 5|
10215369|NCT03704038|Active Comparator|PEEP 0|
10215370|NCT03704038|Experimental|PEEP 10|
10215371|NCT03704012|No Intervention|Routine Care|Control Group receives routine care.
10215372|NCT03704012|Experimental|Massage and kinesiotherapy|Intervention Group, receives massage and kinesiotherapy. Behavioral: Protocol of massage therapy and kinesiotherapy. Infants received massage and kinesiotherapy twice a day; 15 minutes each.
10215373|NCT03703999||type 1 diabetic patients freestyle Libre|group of type 1 diabetic patients that will be selected to use Freestyle libre on the basis of clinicians decisions and reimbursement criteria
10215374|NCT03703986||END group|The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.
10215375|NCT03703986||non-END group|The patients in this group had a slight increase of < 2 points or a decrease in NIHSS within 7 days of stroke onset.
10005296|NCT01583881|No Intervention|control|No intervention
10005297|NCT01583907||different dietotherapy strategies|
10005298|NCT01583920|Experimental|Focal salvage HDR prostate brachytherapy|
10005299|NCT01583933|Experimental|Essix retainer|
10005300|NCT01583933|Active Comparator|Hawley retainer|"Hawley retainer is a device composed of an acrylic base with built-in hooks and a labial arch wire 0.022 x0.036 and attached to the teeth. Its metal component consists of two adams hooks positioned from the first permanent molar right to left, a labial bow that progresses from lingual superface to distal of canine to integrate with the acrylic base."
10005301|NCT01583946||Male low past-oriented SWB|
10005302|NCT01583946||Male high past-oriented SWB|
10005303|NCT01583946||Female low past-oriented SWB|
10005304|NCT01583946||Female high past-oriented SWB|
10005305|NCT01583946||Black Female high past-oriented SWB|
10005306|NCT01583946||Black Female low past-oriented SWB|
10005307|NCT01583946||Black male low past-oriented SWB|
10005308|NCT01583946||Black male high past-oriented SWB|
10005309|NCT01583959|Active Comparator|Folic acid 30 mg per week|Patients will be administered 5 mg folic acid for 6 days a week, no tablet on the day they take methotrexate (5 mg x 6 days = 30 mg per week)
10215376|NCT03703973||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.We also measure their preoperative leukocyte telomere length.
9954137|NCT01130311|Experimental|Cholecalciferol (Vitamin D)|Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
9954138|NCT01130311|Placebo Comparator|SALINE, INTRAMUSCULAR INJECTION|NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial
9954139|NCT01130324||VIBATIV treated pregnant women|Women treated with telavancin (any dose or duration) during pregnancy.
9954140|NCT01130363||Fundic Gland Polyps on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have also been prescribed and regularly take a proton pump inhibitor.
9954141|NCT01130363||Fundic Gland Polyp not on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have not been prescribed a proton pump inhibitor.
9954142|NCT01130363||Group 3 (Control Group)|Individuals who are prescribed proton pump inhibitor but are not found to have fundic gland polyps on endoscopic evaluation.
9954143|NCT01130376|Experimental|Vaccine and cytokines|"Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection."
9954144|NCT01130376|Active Comparator|Vaccine alone|"Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0."
9954145|NCT01130376|Active Comparator|Cytokines alone|"Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC."
9954146|NCT01130402||Neck masses|Patients with previously untreated neck masses
9954147|NCT01130415||Patients treated with sacral neuromodulation|
9954148|NCT01130428|Experimental|Intervention group|As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.
9954149|NCT01130441||self-harming group|
9954150|NCT01130441||non-self-harming group -control group|
9954151|NCT01130454|Active Comparator|SCIO Test Group|
9954152|NCT01130454|Placebo Comparator|SCIO Placebo Group|
9528730|NCT03208283|Active Comparator|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
9667581|NCT03414658|Experimental|Trastuzumab + Avelumab + Utomilumab|"This is a crossover arm~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle~Trastuzumab is administered intravenously twice per cycle"
9667582|NCT03411070|Experimental|Treatment (SCOUT reflector surgery)|Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
9954153|NCT01130467||Normal control|
9954154|NCT01130467||pure ADHD|
9954155|NCT01130467||ADHD with comorbidity|
9954156|NCT01130480|Experimental|A|
9954157|NCT01130506|Experimental|Treatment (decitabine, vorinostat, cytarabine)|"INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; vorinostat PO on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.~MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and vorinostat PO on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity."
9954158|NCT01130558|Active Comparator|Ordering template and education|Internal medical residents who were asked to use the insulin order template and received education about basal-bolus insulin ordering.
9954159|NCT01130558|Active Comparator|Education|Internal medical residents who received education about basal-bolus insulin ordering.
9954160|NCT01130571||Non-Small Cell Lung Cancer|
9954161|NCT01130584||Cancer patient|
9667583|NCT03397667|Other|Control|Primary Care
9667584|NCT03397667|Experimental|Intervention|Primary Care plus ABC ANSWERS intervention
9667585|NCT03395340|Experimental|Euxolitinib cream|Investigational cream to 1 location; vehicle cream to 2nd location
9954162|NCT01130636|Experimental|Tamiflu|Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
9667586|NCT03395340|Placebo Comparator|Vehicle cream|Investigational cream to 1 location; vehicle cream to 2nd location
9667720|NCT03161223|Other|B: durvalumab, pralatrexate, romidepsin|Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
9954163|NCT01130649||Epilepsy patients, electronic diary|Cohort of epilepsy patient using an electronic diary system to record all seizures, side effects, and medication compliance
9954164|NCT01130649||Epilpesy patient, no electronic diary|Group of epilepsy patients who are followed using the standard of care, which is a paper diary and routine outpatient follow up visits
9954165|NCT01130662|Experimental|Decitabine Midostaurin combination|
9954166|NCT01130675|Active Comparator|eight ounces of caffeinated coffee for breakfast and lunch|
9954167|NCT01130675|No Intervention|standard care|
9954168|NCT01130688|Experimental|single arm of experimental drug combination|
9954169|NCT01130714|Experimental|Resistance training|Group assigned to complete resistance training during duration of chemotherapy.
9954170|NCT01130714|No Intervention|Control|Usual care.
9954171|NCT01130727|Active Comparator|green tea extract|
9954172|NCT01130727|Active Comparator|Cocoa extract rich in polyphenols|
9954173|NCT01130727|Placebo Comparator|placebo|
9954174|NCT01130727|Placebo Comparator|cocoa extract with low polyphenol|
9954175|NCT01130766|Experimental|stereotactic radiosurgery (SRS)|
9954176|NCT01130766|No Intervention|observation|
9954177|NCT01130779|Experimental|tarceva|continuation of tarceva
9954178|NCT01130792|Experimental|Lactobacillus GG|LGG once daily for 4 weeks
9954179|NCT01130792|Placebo Comparator|Inulin|
9954180|NCT01130805|Experimental|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
9954181|NCT01130818|Experimental|1|single ascending doses
9954182|NCT01130818|Placebo Comparator|2|single dose placebo
9954183|NCT01130818|Experimental|3|single dose, oral solution, 50 mg
9954184|NCT01130818|Experimental|4|single dose, capsules (fasting)
9954185|NCT01130818|Experimental|5|single dose, capsules (fed)
9954186|NCT01130870|Active Comparator|Sensory threshold - Amplitude|Stimulation amplitude set at sensory threshold.
9954187|NCT01130870|Experimental|25% below sensory threshold - Amplitude|Stimulation amplitude 75% of sensory threshold.
9954188|NCT01130870|Experimental|50% below sensory threshold - Amplitude|Stimulation with amplitude set 50% below sensory threshold
9954189|NCT01130909|Experimental|AZD6765 75 mg|
9667721|NCT03161223|Other|C: durvalumab, romidepsin|Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
9954190|NCT01130909|Experimental|AZD6765 150 mg|
9954191|NCT01130909|Active Comparator|Ketamine 0.5 mg/kg|
9954192|NCT01130909|Placebo Comparator|125 mL sterile NaCl 0.9%|
9954193|NCT01130922|Experimental|Moxifloxacin IV|
9954194|NCT01130922|Active Comparator|Moxifloxacin oral|
9954195|NCT01130935||1|
9954196|NCT01130987|Experimental|Comprehensive Handoff Program|Introduction of Computerized tool plus team training
9954197|NCT01131000|Experimental|Ibuprofen|
9954198|NCT01131000|Placebo Comparator|Saline|Normal Saline
9954199|NCT01131039|Experimental|Single|
9954200|NCT01131091|Other|Group A|Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
9954201|NCT01131091|Other|Group B|Subjects with severe renal impairment
9954202|NCT01131091|Other|Group C|Subjects with moderate renal impairment
9954203|NCT01131091|Other|Group D|Subjects with mild renal impairment
9954204|NCT01131091|Other|Group E|Healthy subjects
9954205|NCT01131143|Experimental|Treatment Group 1|Patients will receive a pre-visit, post-referral and post-contact phone call using providers voice
9954206|NCT01131143|Experimental|Treatment Group 2|Patients will receive a previsit, post-referral and post-contact call using a generic voice
9954207|NCT01131143|No Intervention|Treatment Group 3|Patients will be provided usual care with no additional phone calls.
10215377|NCT03703973||control group|We enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
9954208|NCT01131195|Active Comparator|Arm A: bevacizumab and paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle. Both medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug is given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion.
9954209|NCT01131195|Active Comparator|Arm B: bevacizumab, cyclophosphamide and capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily. All three medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug(s) is (are) given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion
10215378|NCT03703960|Experimental|"Group 1 Hypnosis"|
9954210|NCT01131234|Experimental|Treatment (cediranib maleate and RO4929097)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17 (days 1-3, 8-10, 15-17 22-24, 29-31, and 36-38 of course 1 only) and cediranib maleate PO QD on days 1-21 (days 22-42 course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
9954211|NCT01131247|Experimental|ofatumumab + bendamustine|
9954212|NCT01131273|Active Comparator|Methadone maintenance for 12 weeks|Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
9954213|NCT01131273|Active Comparator|buprenorphine-naloxone (Suboxone)|12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling
10215379|NCT03703960|Active Comparator|"Group 2 music"|
9954214|NCT01131364|Experimental|F16IL2 in combination with doxorubicin|
9954215|NCT01131377|Experimental|Acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
9954216|NCT01131377|Placebo Comparator|Placebo|This group will be managed with general metabolic alkalosis treatment such as electrolyte correction, hydration except acetazolamide.
9954217|NCT01131403||BW= using baby wipes and CW= using cotton wool|
9954218|NCT01131403||wet wipe, cotton wool|Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
9954219|NCT01131416|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
9954220|NCT01131416|No Intervention|Conventional|Conventional postoperative feeding schedule
9954221|NCT01131429|Experimental|first-line erlotinib|erlotinib in first-line treatment and docetaxel/cisplatin in second-line treatment
9954222|NCT01131429|Active Comparator|second-line erlotinib|docetaxel/cisplatin in first-line treatment and erlotinib in second-line treatment
10215380|NCT03703960|No Intervention|Control group|
10215381|NCT03703934||Psoriatic Arthritis|Patients with painful psoriatic arthritis
10215382|NCT03703934||Hand Osteoarthritis|Patients with painful nodal non-erosive hand osteoarthritis
10215383|NCT03703934||Healthy Controls|Patients without a painful condition
10215384|NCT03703908|Experimental|Sequential|All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.
9954223|NCT01131442||The patient group|
9954224|NCT01131442||healthy control group|
9954225|NCT01131468|Experimental|N-acetylcysteine|N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
9954226|NCT01131468|No Intervention|Controls|Vancomycine and/or amikacin alone
9954227|NCT01131481|Other|AcrySof MA50BM,AVS Model X-60|AcrySof MA50BM, AVS Model X-60
9954228|NCT01131533|Experimental|Erythropoietin|patients with chronic macular edema associated with diabetic retinopathy
9954229|NCT01131546|Experimental|Levamlodipine besylate (2.5mg)|
9954230|NCT01131546|Experimental|Levamlodipine besylate (5mg)|
9954231|NCT01131546|Active Comparator|Amlodipine maleate (5mg)|
9954232|NCT01131559|Active Comparator|Lisdexamfetamine|Drug
10215385|NCT03703895|Active Comparator|Active Comparator|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule. Subjects will complete up to 4 study visits where Topical AFX5931 will be applied twice daily for 28 days.
10215386|NCT03703895|Placebo Comparator|Placebo Comparator|Placebo Comparator, Topical Placebo. Subjects will complete up to 4 study visits where Topical Placebo will be applied twice daily for 28 days.
9954233|NCT01131559|Placebo Comparator|Placebo|Drug
9954234|NCT01131572|Other|N-acetylcysteine|open label treatment. Each subject receives N-acetylcysteine.
10215387|NCT03703882|Experimental|Dose 1|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day.
10215388|NCT03703882|Placebo Comparator|Placebo|Matching placebo
9954235|NCT01131611|Experimental|CBPT intervention|Standard PT treatment + CBPT
10215389|NCT03703843|Experimental|Active|ARTUS MONO
9954236|NCT01131611|Placebo Comparator|Control-Attention|Standard PT treatment + weekly phone calls
9954237|NCT01131624|Active Comparator|Ferric carboxymaltose|"Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.~subjects with bw <66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening"
9954238|NCT01131624|Active Comparator|Oral Iron|Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
9954239|NCT01131637|Experimental|rhNRG-1|recombinant human neuregulin-1
9954240|NCT01131637|Placebo Comparator|placebo|placebo
9954241|NCT01131650||diabetic retinopathy|
9954242|NCT01131650||diabetica retinopathy prevalence|
9954243|NCT01131702|Experimental|Ranitidine Tablets, 300 mg|Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited
9954244|NCT01131702|Active Comparator|Zantac Tablets, 300 mg|
9954245|NCT01131715||Study group|Patients who are included in the pharmacist follow-up procedure
10215390|NCT03703830|Experimental|Experimental|Cerebellar transcranial current stimulation associated with locomotor training
10215391|NCT03703830|Sham Comparator|Sham comparator|Cerebellar transcranial current stimulation sham associated with locomotor training
9954246|NCT01131728|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
9954247|NCT01131728|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
10215392|NCT03703765|Experimental|Lower limb volume estimation|"Patients referred for a preoperative venous assessment as part of an indication for interventional management, whether by conventional or endovascular surgery, of a chronic venous pathology.~Intervention is measurement of lower limb volume with scanner 3D system before and after surgery or vascular intervention."
10215393|NCT03703752||Adhesive IH|Adhesive IH can further be divided into primary or secondary groups according to the history of abdominal and(or) pelvic surgery
10215394|NCT03703752||non-adhesive IH|Non-adhesive IH means the IH resulting from the abnormality of peritoneal structure.
10215395|NCT03703739|Active Comparator|Reference meal 1|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
9954248|NCT01131741|Experimental|Epinephrine|
9954249|NCT01131741|Placebo Comparator|Control|
9954250|NCT01131754|Experimental|Heparin sol 100U/L|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
9954251|NCT01131754|Active Comparator|saline|peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.
9954252|NCT01131767|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
9954253|NCT01131767|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
9954254|NCT01131780|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
9954255|NCT01131780|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
9954256|NCT01131793|Experimental|RF Guidewire|
9954257|NCT01131806|Active Comparator|MD Flu/Sal|fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
9954258|NCT01131806|Experimental|HD Flu/Sal|fluticasone 250 mcg/salmeterol 25 mcg 2puffs (high dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
10215396|NCT03703739|Active Comparator|Reference 2|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with bean sauce.
10215397|NCT03703739|Experimental|Test meal A|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice cofortified with zinc oxide and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
10215398|NCT03703739|Experimental|Test meal B|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
10215399|NCT03703739|Experimental|Test meal C|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
10215400|NCT03703739|Experimental|Test meal D|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfafe and sodium pyrophosphate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
10215401|NCT03703739|Experimental|Test meal E|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with bean Sauce.
9954259|NCT01131819|Other|1|The novel intervention we propose to use, the Wii Fit, will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects in the study.
9954260|NCT01131832|Experimental|Plant sterol|Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
9954261|NCT01131845|Experimental|Treprostinil diethanolamine|
9954262|NCT01131858|Placebo Comparator|Placebo|Placebo
9954263|NCT01131858|Active Comparator|Vitamin D|Vigantol (cholecalciferol) 4000 IE/day
9954264|NCT01131871|Active Comparator|Standard Behavioral Weight Loss Intervention|
9954265|NCT01131871|Experimental|Enhanced Weight Loss Intervention|
9954266|NCT01131897|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
9954267|NCT01131897|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
9954268|NCT01131910|Experimental|Vaccination against TBE|"Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose~60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose"
9954269|NCT01131923|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
9954270|NCT01131923|Active Comparator|Norvasc Tablets, 10 mg|
9954271|NCT01131936|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
9954272|NCT01131936|Active Comparator|Norvasc Tablets, 10 mg|
9954273|NCT01131949|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
9954274|NCT01131949|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
9954275|NCT01131962|Active Comparator|band ligation group|this group will have immediate control of the hematemesis by endoscopic band ligation.
9954276|NCT01131962|Active Comparator|sclerotherapy group|This group will have immediate control of hematemesis by endoscopic sclerotherapy
9954277|NCT01131975|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
9954278|NCT01131975|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
9954279|NCT01131988|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
9954280|NCT01131988|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
9954281|NCT01132027|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
9954282|NCT01132027|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
9954283|NCT01132040|Experimental|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
9954284|NCT01132040|Active Comparator|Mysoline|Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
10005310|NCT01583959|Active Comparator|Folic acid 10 mg|Patients will be given folic acid 5 mg for two days per week and placebo tablets for four days a week, no tablet on the day they take methotrexate (Folic acid 5mg x 2 days = 10mg per week)
10005311|NCT01583972|Experimental|Vitamin A|50,000 IU vitamin A in edible oil
10005312|NCT01583972|Placebo Comparator|Placebo|edible oil used as diluent for vitamin A
9954285|NCT01132053||PML|These are subjects who have confirmed PML.
9954286|NCT01132053||Control|These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV.
9954287|NCT01132066|Experimental|tDCS|tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation.
9954288|NCT01132066|Placebo Comparator|sham|Sham stimulation will provide identical subjective sensation as anodal tDCS.
10005313|NCT01583998|Active Comparator|e-MBC|Patients will receive e-MBC
10005314|NCT01583998|No Intervention|Treatment as Usual Control|Patients receive standard treatment
10005315|NCT01584011||Middle ear disease|
10005316|NCT01584037||Observational|This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
10005317|NCT01584050|Active Comparator|L-MTHF|
10005318|NCT01584050|Active Comparator|folic acid|
10005319|NCT01584050|Placebo Comparator|placebo (methyl cellulose)|
10005320|NCT01584063|No Intervention|Control|These women received general information about pregnancy and the postpartum period and tips for stress management. This information was delivered during 3 group meetings during pregnancy and 1 group meeting postpartum by trained staff from a local community mental health agency.
10005321|NCT01584063|Experimental|MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
10005322|NCT01584076|Experimental|Donepezil|
10005323|NCT01584102|Experimental|Group 1|
10005324|NCT01584102|Active Comparator|Group 2|
10005325|NCT01584115|Experimental|NY-ESO-1|NY-ESO-1 combined with MPLA vaccine
10005326|NCT01584128||Oxidized regenerated cellulose|Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery.
10005327|NCT01584141||Cases|Asian cases with lymphoid or myeloid neoplasma
10005328|NCT01584141||Controls|Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan
10005329|NCT01584154|Experimental|cryoablation|
10005330|NCT01584154|Active Comparator|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
9954289|NCT01132079|Experimental|Pimecrolimus cream treatment|
9954290|NCT01132079|Active Comparator|Betamethasone valerate cream treatment|
9954291|NCT01132092||Normal hearing (experimental 1)|76 Normal hearing subjects, male and female, adults, , evaluated by new device
9954292|NCT01132092||Normal hearing (experimental 2)|15 Normal hearing subjects, male and female, adults, , evaluated by new device
9954293|NCT01132092||Hearing loss (experimental 3)|15 hearing loss subjects, male and female, adults, evaluated by new device
9954294|NCT01132092||Gold standard 1|15 Normal hearing subjects, male and female, adults, evaluated by gold standard device
9954295|NCT01132092||Gold Standard 2|15 hearing loss subjects, male and female, adults, evaluated by gold standard device
9954296|NCT01132105||Normal subjects|Adults normal hearing and vestibular function subjects
9954297|NCT01132131|Active Comparator|Delegation form|
9954298|NCT01132131|Active Comparator|Regular doctor's consultation|
9954299|NCT01132157|Experimental|Propofol group|
9954300|NCT01132157|Active Comparator|Desflurane group|
9954301|NCT01132170|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
9954302|NCT01132170|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
9954303|NCT01132183|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
9954304|NCT01132183|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
9954305|NCT01132196|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
9954306|NCT01132196|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
9954307|NCT01132209|Active Comparator|Large tissue bites|As control the conventional large bites technique (mass closure) will be applied in with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
9954308|NCT01132209|Experimental|small tissue bites|In the other group of 288 patients the small bites technique will be applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
9954309|NCT01132222|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
9954310|NCT01132222|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
9954311|NCT01132248|Experimental|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
9954312|NCT01132248|Placebo Comparator|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
9954313|NCT01132261|Active Comparator|1|brain preservation diet
9954314|NCT01132261|No Intervention|2|
9954315|NCT01132274|Active Comparator|Conventional catheter ablation|Radiofrequency catheter ablation through fluoroscopic guidance
9954316|NCT01132274|Experimental|Non-fluoroscopic catheter ablation|Radiofrequency catheter ablation guided by the EnSite NavX (St.Jude Medical, St Paul, MN, USA) mapping-system
9954317|NCT01132287|Experimental|1 FID 112903|FID 112903
9954318|NCT01132287|No Intervention|No Intervention|
9954319|NCT01132300|Experimental|Treatment|
9954320|NCT01132339||Enhanced MR (case group)|those with an exposure to gadolinium-based contrast agent
9954321|NCT01132339||Unenhanced MR (control group)|those without an exposure to gadolinium-based contrast agent
9954322|NCT01132339||Unenhanced CT (control group)|those without an exposure to iodine-containing contrast agent
9954323|NCT01132339||Enhanced CT (case group)|those with an exposure to iodine-containing contrast agent
9954324|NCT01132352|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
9954325|NCT01132352|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
9954326|NCT01132365||knee arthroplasty|
9954327|NCT01132391|Experimental|1|Endoanal application
9954328|NCT01132391|Experimental|2|Perianal application
9954329|NCT01132404|Experimental|TAK-448 Dose 1|
9954330|NCT01132404|Experimental|TAK-448 Dose 2|
9954331|NCT01132404|Active Comparator|Leuprorelin|
9954332|NCT01132417||Multidrug resistant (MDR)bacterial strains|
9954333|NCT01132430|Placebo Comparator|Usual care|Standard medical care within 4-6 week period
9954334|NCT01132430|Experimental|Motivational interviewing|Brief MI sessions within 4-6 week period
9954335|NCT01132443|Experimental|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily; clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)
9954336|NCT01132443|Active Comparator|Duac/ formulation 1|Apply topically once daily, Topical Gel (CLN 1%-BPO 5%), methylparaben-preserved
9954337|NCT01132443|Active Comparator|Duac/ formulation 2|Apply topically once daily, Duac Once Daily Gel (CLN 1%-BPO 5%), MPF
9954338|NCT01132456|Experimental|Different patient subset|Patients with dual vessel treatment where each vessel has a lesion with length ≤ 27 mm and reference vessel diameters between 2.25 mm and 4.0 mm.
9954339|NCT01132456|Experimental|38 mm Cohort|Patients with at least one lesion amenable to treatment with a 38 mm length Endeavor Resolute stent. Patients may have one or two lesions, if the two lesions are located in separate target vessels.
9954340|NCT01132469|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
9954341|NCT01132521|Experimental|ulinastatin group|Regular treatments plus ulinastatin. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
9954342|NCT01132521|Placebo Comparator|placebo group|Regular treatment plus placebo. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
9954343|NCT01132534||SE then AFI/NBI|Patients will be randomised to be examined by standard videoendoscopy (SE) then combined AFI/NBI during the esophagogastroduodenoscopy (EGD) examination at same setting.
9954344|NCT01132534||AFI/NBI then SE|Patients will be randomised to be examined by combined AFI/NBI then standard videoendoscopy (SE) during the EGD examination at same setting.
9954345|NCT01132573|Experimental|Treatment (entinostat and clofarabine)|"Patients receive entinostat PO on days 1 and 8 and clofarabine IV over 2 hours on days 3-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity (only for patients >= 60 years of age with newly diagnosed ALL or ABL who are unable or unwilling to tolerate standard multi-agent chemotherapy and patients with relapsed or refractory ALL or ABL).~Patients 40-59 years of age with newly diagnosed ALL receive standard multi-agent induction chemotherapy beginning on day 11. Patients >= 21 years of age in their first relapse with sensitive disease begin initiation of allogeneic transplant after one course of entinostat and clofarabine."
9954346|NCT01132586|Experimental|Treatment (lenalidomide, cytarabine, idarubicin)|"INDUCTION:~COHORT I: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 96 hours on days 5-8, and idarubicin IV over 1 hour on days 5-7.~COHORT II: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 24 hours on days 5-11, and idarubicin as above.~Patients with residual disease on day 18 undergo a second course of induction therapy.~CONSOLIDATION:~COHORT I: Patients receive lenalidomide PO QD on days 1-14, idarubicin IV over 1 hour on days 5-6, cytarabine IV continuously on days 5-7. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.~COHORT II: Patients 2 receive 4 courses of consolidation therapy comprising lenalidomide PO QD on days 1-14 and cytarabine IV every 12 hours on days 5, 7, and 9. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
9954347|NCT01132625|Experimental|AUY922|
9954348|NCT01132638|Active Comparator|Magnesium Pantoprazole|
9954349|NCT01132638|Active Comparator|Magnesium Esomeprazole|
9954350|NCT01132677|Active Comparator|Hyaluronic Acid (HA) Injection|Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
9954351|NCT01132677|Active Comparator|Corticosteroid Injection|Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
9954352|NCT01132703|Placebo Comparator|Matching Placebo|Matching placebo (glyburide excipients without active) is administered as a bolus followed by continuous infusion for 72 hours.
9954353|NCT01132703|Experimental|Glyburide for Injection: Dose 1|Glyburide is administered as a bolus followed by a infusion for 72 hours
9954354|NCT01132703|Experimental|Glyburide for Injection: Dose 2|Glyburide is administered as a bolus followed by a infusion for 72 hours
9954355|NCT01132703|Experimental|Glyburide for Injection: Dose 3|Glyburide is administered as a bolus followed by a infusion for 72 hours.
9954356|NCT01132742||hospitalised children|
9954357|NCT01132768|Active Comparator|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
9954358|NCT01132768|Experimental|Olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.
9954359|NCT01132781|Placebo Comparator|Placebo|200mg twice daily of placebo drug
9954360|NCT01132781|Active Comparator|200mg theophylline|200mg twice daily of slow release theophylline
9954361|NCT01132794|Placebo Comparator|Placebo|Intranasal nasal saline
9954362|NCT01132794|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine
9954363|NCT01132950|Active Comparator|Didactic Educational Counseling|
9954364|NCT01132950|Experimental|Motivation Interviewing|Participant will receive two sessions of personalized motivational interviewing.
9954365|NCT01132963|Experimental|Outdoor Shoes|Patient will be asked to do balance tests while wearing outdoor shoes.
9954366|NCT01132963|Active Comparator|Pillow Paws Slippers|Patient will be asked to complete balance tests while wearing standard hospital issue 'Pillow Paw' slippers on their feet
9954367|NCT01132976|Active Comparator|Goal-based motivational interview|Participants randomised to this group will receive the goal based motivational interview - Personal Concerns Inventory (PCI) in addition to treatment as usual.
9954368|NCT01132976|Other|Treatment as usual|Participants randomly allocated to this group will receive treatment as usual only, ie no specific motivational intervention.
9954369|NCT01133002||VTE management registry|Patients receiving enoxaparin, with or without oral anticoagulation, within Day 0-10 after diagnosis of VTE
9954370|NCT01133015|Experimental|Intermediate lesion|Intermediate lesion will be evaluated by both IVUS and FFR
9476527|NCT03570996|Active Comparator|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
9954371|NCT01133028|Experimental|Combined|This represents a combination of the tolerance training and behavioral management interventions together.
9954372|NCT01133028|Active Comparator|Behavioral management|This represents the behavioral contingency management intervention only.
9954373|NCT01133041|Experimental|NBI observation|
9954374|NCT01133041|Experimental|i-Scan observation|
9954375|NCT01133054|Experimental|low FFR|FFR<0.75
9954376|NCT01133054|No Intervention|high FFR|FFR > 0.75
9954377|NCT01133080|Experimental|Minocycline|
9954378|NCT01133080|Placebo Comparator|Placebo|
9954379|NCT01133106|Experimental|In-person behavioral intervention|behavioral counseling plus antidepressant treatment prescribed by participant's own provider; consisted of orientation session plus 6 counseling sessions in person with a psychosocial nurse practitioner
9954380|NCT01133106|Experimental|Telephone behavioral intervention|This arm is identical to the in-person Arm except that the intervention is delivered by telephone instead of in-person.
9954381|NCT01133106|Active Comparator|Standard care|participants have orientation to the study with the same written materials given those in the experimental arms. Keep a medication log and keep appointments with their own post-stroke provider
9954382|NCT01133119|Active Comparator|Treatment Group 1|
9954383|NCT01133119|Experimental|Treatment Group 2|
9954384|NCT01133132|Placebo Comparator|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
9954385|NCT01133132|Experimental|Intervention|For those subjects randomized to the Survivorship CHESS condition they will receive a smartphone and access to a web based information system that provides access to clinical information about colon cancer treatment, survivorship, exercise planning and tracking functions to allow these subjects to monitor their self defined exercise goals and objectives.
9954386|NCT01133145|Experimental|vascularized transplantation|allogeneic vascularized knee transplantation
9954387|NCT01133197||controls|No hand arthritis
9954388|NCT01133197||CMC Arthritis|Patients with arthritis
9954389|NCT01133210|Experimental|Maraviroc|Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).
9954390|NCT01133210|Placebo Comparator|Placebo|Subjects will receive 12 weeks of treatment with placebo
9954391|NCT01133223|Active Comparator|Thrombectomy|
9954392|NCT01133223|Active Comparator|Usual Care|
9954393|NCT01133236|Experimental|Salt and Fluid|Intervention: Fluid 800 Ml and Salt 2 g per day Control: FLuid and Salt Free
9954394|NCT01133249||Total hip|all consented patients receiving total hip arthroplasty
9954395|NCT01133301|Active Comparator|Naltrexone-Placebo|In the first three weeks of the study, 50 mg Naltrexone will be administrated, the following three three weeks placebo will be administrated.
9802354|NCT05308927||Prevalent patients - finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and finished their growth upon their inclusion. Data collected retrospectively from medical records
9954396|NCT01133301|Placebo Comparator|Placebo-Naltrexone|The first three weeks, placebo will be administrated, the following three weeks 50 mg Naltrexone will be administrated.
9954397|NCT01133327|Experimental|Adapt Carotid Stent System|Intervention with Adapt Carotid Stent System with the FilterWire EZ System
9954398|NCT01133353|Experimental|Tetrabenazine MR|
9954399|NCT01133353|Placebo Comparator|Placebo|
9954400|NCT01133366|Active Comparator|warfarin alone|
9954401|NCT01133366|Experimental|warfarin with mipomersen|
9954402|NCT01133431|Experimental|CKD-501 + Glimepiride -> CKD-501 placebo + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
9954403|NCT01133431|Experimental|CKD-501 placebo + Glimepiride -> CKD-501 + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
9954404|NCT01133444|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
9954405|NCT01133444|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
9954406|NCT01133457|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
9954407|NCT01133457|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
9954408|NCT01133470|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
9954409|NCT01133470|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
9954410|NCT01133483|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
9954411|NCT01133483|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
9954412|NCT01133496|Experimental|Alendronate Sodium|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's
9954413|NCT01133496|Active Comparator|Fosamax|Fosamax Tablets 70 mg of Merck & Company. Inc., USA.
9954414|NCT01133509|Other|gardisil|gardisil
9954415|NCT01133535||Pancreatitis, acute, recurrent|Patients with acute recurrent pancreatitis where the cause is unknown
9954416|NCT01133548|Experimental|1|Testosterone Gel 1.62%
9954417|NCT01133561|Active Comparator|actozone A|Pioglitazone 30 mg tablets daily
9954418|NCT01133561|Placebo Comparator|actozone B|placebo
9954419|NCT01133574|Experimental|A1|Part A, Parallel design Arm 1
9954420|NCT01133574|Experimental|A2|Part A, Parallel design Arm 2
9954421|NCT01133574|Experimental|A3|Part A, Parallel design Arm 3
9954422|NCT01133574|Experimental|A4|Part A, Parallel design Arm 4
9954423|NCT01133574|Experimental|A5|Part A, Parallel design Arm 5
9954424|NCT01133574|Experimental|A6|Part A, Parallel design Arm 6
9954425|NCT01133574|Experimental|A7|Part A, Parallel design Arm 7
9954426|NCT01133574|Experimental|A8|Part A, Parallel design Arm 8
9954427|NCT01133574|Placebo Comparator|A9|Part A, Parallel design Arm 9
9954428|NCT01133574|Experimental|B1-1|Part B, Cross-over design, Arm 1
9954429|NCT01133574|Experimental|B1-2|Part B, Cross-over design, Arm 2
9954430|NCT01133574|Experimental|B2-1|Part B, Cross-over design, Arm 3
9954431|NCT01133574|Experimental|B2-2|Part B, Cross-over design, Arm 4
9954432|NCT01133574|Placebo Comparator|B3|Part B, Cross-over design, Arm 5
9954433|NCT01133587|Experimental|admissions contract|"contract regarding patient-guided admissions"
9954434|NCT01133587|Active Comparator|wait list control|1 year on waiting list
9954435|NCT01133600|Active Comparator|daptomycin|Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is <30ml/min.
9954436|NCT01133600|Active Comparator|vancomycin|Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
9954437|NCT01133613|Experimental|Cohort 1|0.03 mg/ml BMP-7 or placebo via intraarticular knee injection
9954438|NCT01133613|Experimental|Cohort 2|0.1 mg/ml BMP-7 or placebo via intraarticular knee injection
9954439|NCT01133613|Experimental|Cohort 3|0.3 mg/ml BMP-7 or placebo via intraarticular knee injection
9954440|NCT01133652|Active Comparator|VeinViewer|The Veinviewer machine will be used to guide intravenous access.
9954441|NCT01133652|Active Comparator|Ultrasound|The Ultrasound will be used to guide intravenous access.
9954442|NCT01133652|Active Comparator|Conventional IV placement|IV will be placed using conventional technique
9954443|NCT01133691||healthy children aged 6 - 12 years|
9954444|NCT01133717||Control without Sleep Apnea|
9954445|NCT01133717||Subjects with Sleep Apnea|
9954446|NCT01133730|Experimental|Active treatment group|Ultrasound-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
9954447|NCT01133730|Placebo Comparator|Placebo arm|Ultrasound-guided TFP block with 20ml of 5% dextrose solution
9954448|NCT01133743|Experimental|Lenalidomide and Dexamethasone|Lenalidomide target dose of 25 mg PO OD continuously (28-day cycle) using an initial dose escalation period. Oral dexamethasone 12 mg daily on days 1-7, 14 and 21 of each cycle.
9954449|NCT01133769||Surgical vs Non surgical|This is an open, prospective, randomized, dual arm, parallel group clinical study of open reduction and internal fixation (ORIF) or intramedullary nail (IMN) versus non operative treatment for clavicle fracture in polytrauma patients with associated chest injury, with or without additional injuries to the head, abdomen, pelvis and extremities.
9954450|NCT01133782|Experimental|Rapid result|Result of diagnostic PCR panel provided the following day
9954451|NCT01133782|No Intervention|Delayed result|Result of dagnostic PCR panel provided within 10+/-2 days at follow-up visit.
9954452|NCT01133795|Experimental|Midodrine, Albumin|Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
9954453|NCT01133834||patients with meningococcemia|Patients with meningococcemia admitted at the Intensive Care Unit
9954454|NCT01133873|Experimental|1|
9954455|NCT01133873|Placebo Comparator|2|
9954456|NCT01133886|Experimental|Decitabine|
10215402|NCT03703726|Active Comparator|Reference meal|50 g of Commercial Rice was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
10215403|NCT03703726|Experimental|Test meal A|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
10215404|NCT03703726|Active Comparator|Test meal B|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
10215405|NCT03703726|Experimental|Test meal C|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
9954457|NCT01133899|Experimental|GAA-2|2.4 grams of guanidinoacetic acid
9954458|NCT01133899|Experimental|GAA-1|1.2 grams of guanidinoacetic acid
9802355|NCT05308927||Prevalent patients - not finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and did not finish their growth upon inclusion. Data collected both retrospectively and prospectively
9954459|NCT01133899|Experimental|GAA-4|4.8 grams of guanidinoacetic acid
9954460|NCT01133899|Placebo Comparator|PLACEBO|cellulose
9803613|NCT03682393|Placebo Comparator|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
10005331|NCT01584167|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
10005332|NCT01584167|Active Comparator|EMCOOLS Flex.Pads|Passive surface cooling with 10 EMCOOLS Flex.Pads (Emergency Medical Cooling Systems AG, Wien, Austria)
10005333|NCT01584180|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
10215406|NCT03703726|Experimental|Test meal D|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
10215407|NCT03703726|Active Comparator|Test meal E|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
10215408|NCT03703726|Active Comparator|Test meal F|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
10215409|NCT03703713||Hyponatremia|Patients treated for hyponatremia (<125 mmol/L Sodium) in the intensive care department.
10215410|NCT03703700|Experimental|Zishen Yutai pill group|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
10215411|NCT03703700|Placebo Comparator|Placebo group|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
9954461|NCT01133912|Experimental|paclitaxel, gemcitabine, lapatinib|paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day
9954462|NCT01133925|Active Comparator|ODESSA|ODESSA trial (NCT 00693030)Patients were randomized (2:2:2:1) to receive multiple TAXUS Libertè™ vs Cypher Select™ vs Endeavor™ vs Libertè BM stents, in overlap. At 6-months follow-up coronary angiography (QCA), IVUS and Optical Coherence Tomography assessments were made. Data reported in J. Am. Coll. Cardiol. Intv. 2010;3;531-539. DOI 10.1016/j.jcin.2010.02.008.
9954463|NCT01133925|Experimental|Resolute Sprint arm|Zotarolimus Eluting stents (Resolute Sprint) implanted in overlap to treat long coronary lesions
9954464|NCT01133938||Closed reduction < 12 months of age|
9954465|NCT01133938||Open reduction < 12 months of age|
9954466|NCT01133938||Open reduction with concomitant osteotomies > 12 months fo age|
9954467|NCT01133951|Experimental|OAC triple therapy|
9954468|NCT01133951|Placebo Comparator|Placebo|
9954469|NCT01133964|Experimental|milk|skim milk
9954470|NCT01133964|Experimental|casein drink|
9954471|NCT01133964|Experimental|whey drink|
9954472|NCT01133964|Sham Comparator|water|
9954473|NCT01134029|No Intervention|Enhanced Usual Care|Control Group
9954474|NCT01134029|Experimental|Stepped Care|Intervention
9954475|NCT01134094|Active Comparator|Non-Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
9954476|NCT01134094|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
9954477|NCT01134120|Experimental|LY2784544|
9954478|NCT01134146|Experimental|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
9954479|NCT01134159||Xience V|Those who have only received a Xience V stent
9954480|NCT01134159||Taxus Liberte|Those who have received only a Taxus Liberte stent
9954481|NCT01134185|Active Comparator|Group I|Moderate hepatic impairment (grade B)
9954482|NCT01134185|Active Comparator|Group II|Severe hepatic impairment (grade C)
9954483|NCT01134185|Active Comparator|Group III|healthy subjects
9954484|NCT01134211|Other|nelfilcon A / filcon II 3|Nelfilcon A contact lenses worn first, with filcon II 3 contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
9954485|NCT01134211|Other|filcon II 3 / nelfilcon A|Filcon II 3 contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
9954486|NCT01134224|Experimental|NN5401 - low dose|
9954487|NCT01134224|Experimental|NN5401 - medium dose|
9954488|NCT01134224|Experimental|NN5401 - high dose|
9954489|NCT01134224|Active Comparator|biphasic insulin aspart 30 - low dose|
9954490|NCT01134224|Active Comparator|biphasic insulin aspart 30 - medium dose|
9954491|NCT01134224|Active Comparator|biphasic insulin aspart 30 - high dose|
9954492|NCT01134237|Active Comparator|Urokinase|arm of interest
9954493|NCT01134237|Placebo Comparator|Control|Normal saline as a placebo for control arm
9954494|NCT01134289|Active Comparator|lumbar sympathetic block|Unilateral lumbar sympathetic blockade using chirocaine
9954495|NCT01134289|No Intervention|contralateral side|
9954496|NCT01134302|Active Comparator|Arm 1|Hybrid Management
9954497|NCT01134302|Active Comparator|Arm 2|Norwood Management
9954498|NCT01134341|Experimental|Bexarotene (Targretin) & Pralatrexate (Folotyn)|"Bexarotene (Targretin): administered po qd. The initial daily dose of bexarotene will depend on the cohort to which each patient is assigned. Bexarotene will be self-administered except in patients who underwent plasma PK sampling on cycle 1, dose 1 and cycle 1, dose 3, at which time bexarotene was to be administered at the investigational site 1 hour (± 5 minutes) prior to pralatrexate administration.~Pralatrexate (Folotyn): administered weekly via IV push over a minimum of 30 seconds up to a maximum of 5 minutes. One cycle is 4 weeks in duration consisting of weekly dosing of pralatrexate for 3 weeks followed by 1 week of rest. The initial dose of pralatrexate will depend on the cohort to which each patient is assigned."
9954499|NCT01134354||TEFTOM|Patient outcome measure
9667614|NCT03334409|Experimental|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
9954500|NCT01134367||1|Patients with GERD
9954501|NCT01134380||[*1] Genotype - Good responders to Clopidogrel|This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel
9954502|NCT01134380||[*2] genotype with adapted thienopyridine treatment|This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
10215412|NCT03703687|Experimental|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
9954503|NCT01134406|Experimental|Hydros Joint Therapy|Experimental viscosupplement.
9954504|NCT01134406|Experimental|Hydros-TA Joint Therapy|Experimental viscosupplement.
9954505|NCT01134406|Active Comparator|Synvisc-One|Commercial control.
9954506|NCT01134419|Experimental|Computerized Handoff Tool plus training|Computerized handoff tool implemented together with team training for residents
9954507|NCT01134419|Active Comparator|Team training only|No computerized tool
9954508|NCT01134432|Experimental|Prednisolone + Rituximab|
9954509|NCT01134432|Active Comparator|Prednisolone|
9954510|NCT01134445|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
9954511|NCT01134458|No Intervention|Control|Receive primary care and management of CVD according to the discretion of their primary care provider. They will also receive generic educational information concerning CVD at baseline and at study end (at their request). We will collect outcomes at baseline and 3-months.
9954512|NCT01134458|Experimental|Web-based Intervention|Given current risk assessment for CVD based on Health Dialog Cardiac Risk Calculator, recommendations for behavior change, and Health Dialog's Living with Coronary Heart Disease. Can change initial patient risk information provided by the Risk Calculator during the initial visit, noting what they are will work on during the study. Sent monthly email reminders to log onto the system to choose that months' behavioral modules. Given a choice of at least 2 health behavior modules per month (smoking cessation, exercise, diet, and weight) to improve their CVD risk. Information on risk, CVD knowledge, medication management and side effects will be provided to all participants. It will also provide tailored information to help the individual initiate and maintain these behaviors.
9954513|NCT01134471|No Intervention|Control|
9954514|NCT01134471|Active Comparator|Bonewax|Patients treated with the hemostatic bonewax
9954515|NCT01134471|Active Comparator|Ostene|Patients treated with the hemostatic Ostene
9954516|NCT01134484|Experimental|VTD|
9954517|NCT01134484|Active Comparator|TD|
9954518|NCT01134497|Active Comparator|Arm A (control): carboplatin + placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle.
9954519|NCT01134497|Experimental|Arm B: carboplatin + ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
10215413|NCT03703674|Active Comparator|Standard Medical Therapy|Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
10215414|NCT03703674|Experimental|G-CSF + Standard Medical Therapy|"Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.~Drug: G-CSF G-CSF- 5 μg/Kg s.c every 12 hours for 5 consecutive days"
10215415|NCT03703661|Other|Control|primary closure with gauze and adhesive/occlusive dressing
10215416|NCT03703661|Experimental|Negative Pressure|primary closure with gauze and adhesive/occlusive dressing under negative pressure
9954520|NCT01134523|Active Comparator|Group A: EC-T regimen|
9954521|NCT01134523|Experimental|Group B: ET regimen|
9954522|NCT01134536|Experimental|Tapentadol Oral Solution (OS)|
9954523|NCT01134588|Active Comparator|Reference group|This group will fill out paper questionnaires.
9954524|NCT01134588|Experimental|Experimental group|This group will fill out touch-screen questionnaires.
9954525|NCT01134653|Experimental|Jump stretch|Distraction with early mobilization
10215417|NCT03703622|Experimental|Video-debriefing with standard HBB training|Health workers are given standard HBB training according to American Association of Pediatrics (AAP) plus video-debriefing. Filming of the simulated case scenarios will be done and after which the films will be used for debriefing or feedback. Participants will be encouraged to give feedback with the guidance of master trainer and the PI. Teams of three participants(birth attendant, mother and helper) will perform the HBB simulation or scenarios. After each scenario, debriefing is done until all participants have had the opportunity to participate in the simulation exercise. All the participants in this arm will undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick newborn baby who needs resuscitation care. Pre and post-tests will be done to assess performance of all participants.
9954526|NCT01134653|Active Comparator|RICE|Subject receive standard ankle sprain treatment of Rest Ice compression and elevation for one week. This is followed by traditional strength and range of motion therapy. The subject does not receive distraction treatments.
9954527|NCT01134679|Experimental|Phone calls|Disease management with close patient follow-up, using phone calls.
9954528|NCT01134692|Placebo Comparator|Propranolol + Placebo|
9954529|NCT01134692|Active Comparator|Propranolol + Norfloxacin|drug
9954530|NCT01134692|Experimental|Propranolol + Probiotic|VSL#3
9954531|NCT01134718|Experimental|001|TMC435 (F021) one morning dose of 150 mg
9954532|NCT01134718|Experimental|002|TMC435 (G006) one morning dose of 150 mg
9954533|NCT01134718|Experimental|003|TMC435 (G007) one morning dose of 150 mg
9954534|NCT01134744||Chest trauma|chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination
9954535|NCT01134757|Other|house dust mite and alternaria allergy|As the intervention patients with house dust mite or alternaria allergy will undergo a bronchial allergen challenge with mite or alternaria extract. The early asthmatic response (EAR) and the late asthmatic response (LAR) will be measured before and after one year of allergen specific immunotherapy. Except of the challenge no further interventions are planned.
9954536|NCT01134770||Prenatal Cocaine|Use of cocaine at anytime during pregnancy. Subjects may also have used other drugs in combination with Cocaine
9954537|NCT01134770||Prenatal Nicotine-Alcohol-Marijuana|Subjects may have used any of these drugs during pregnancy, alone or in combination. This group has not used cocaine during pregnancy.
9954538|NCT01134770||Drug-Free Pregnancy|"Subjects did not use any of the following drugs during pregnancy:~cocaine, nicotine, alcohol, marijuana."
9954539|NCT01134809||Major abdominal surgery|Patients having major abdominal surgery
9954540|NCT01134822||Idiopathic pulmonary fibrosis (IPF)|
9954541|NCT01134835|Experimental|IMP Pioglitazone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
9954542|NCT01134835|Placebo Comparator|Placebo|Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
9954543|NCT01134848|Active Comparator|Morphine-neostigmine|
9954544|NCT01134848|Active Comparator|Secretin|
9954545|NCT01134861|Active Comparator|Arm 1: Sequential ChemoRT|Vinblastine 6 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 50
9954546|NCT01134861|Experimental|Arm 2: Concurrent STD RT|Vinblastine 5 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 GY/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1
9954547|NCT01134861|Experimental|Arm 3: Concurrent HFX RT|Oral VP-16 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40 (76 mg/day if BSA < 1.7m2) Cisplatin 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36 RT: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1
9954548|NCT01134874|Experimental|Standard weight loss intervention|
9954549|NCT01134874|Experimental|Standard weight loss intervention plus technology|
9954550|NCT01134874|Experimental|Technology only|
9954551|NCT01134926|No Intervention|intra-uterine residua. expectant management|The patients in this arm will not get any treatment and be followed up by US examinations
9954552|NCT01134926|Experimental|Intra-uterine residua. misoprostol|The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
9954553|NCT01134965|Experimental|Digoxin plus Flibanserin|Flibanserin 100 mg tablets once daily for 7 days plus Digoxin 0.5 mg (2 tables of 0.25 mg) as single dose
9954554|NCT01134965|Experimental|Digoxin|Digoxin 0.5 mg as single dose
9954555|NCT01134978|Experimental|Practice Schedules|Subjects are randomly assigned to either a blocked or random practice schedule when learning three 3-D computer mazes. A blocked practice schedule is created when the tasks to be learned are presented in a predictable order, while a random practice schedule has tasks presented in a nonsequential, unpredictable order. Neural activity and behavioral measures will differ for the two practice schedules. For memory and transfer, it is predicted that random practice will be better than blocked practice.
9954556|NCT01134991|Placebo Comparator|Topical Minocycline Foam FXFM244 Placebo|Minocycline Foam FXFM244 Placebo
9954557|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 1%|Minocycline Foam FXFM244, 1%
9954558|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 4%|Minocycline Foam FXFM244, 4%
9954559|NCT01135004||Pneumothorax patients|Primary spontaneous pneumothorax patients undergoing thoracoscopic bullectomy
9954560|NCT01135030|Active Comparator|Posterior referencing|
9954561|NCT01135030|Active Comparator|Anterior referencing|
9954562|NCT01135043|Experimental|education|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
9954563|NCT01135043|Placebo Comparator|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure.
9954564|NCT01135056|Active Comparator|Sorafenib, Multikinase Inhibitor, Tablet|"Sorafenib tosylate:~Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.~Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma."
9954565|NCT01135056|Active Comparator|SIR-Spheres, Microspheres, Device|"SIR-Spheres:~SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.~SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver."
9954566|NCT01135082|Other|1|Receive valent pneumococcal conjugated vaccine in HIV - infected children
9954567|NCT01135082|Other|2|Receive valent pneumococcal conjugated vaccine in HIV negative children
9954568|NCT01135108|Placebo Comparator|A1: Placebo|Placebo
9954569|NCT01135108|Experimental|A2: KAI-1678|Experimental
9954570|NCT01135121||Weaning failure|
9954571|NCT01135121||Weaning succes|
9954572|NCT01135147|Experimental|Diet|Patients treated with diet and physical therapy for the entire 6 months of the study
9954573|NCT01135147|Active Comparator|Surgery|Patients undergoing adenotonsillectomy at some point of the study period
9954574|NCT01135160||TKA/THA|All patients receiving TKA/THA meeting inclusion but not exclusion criteria
9954575|NCT01135173|Active Comparator|Arm A|Motivational and educational intervention, delivered by a trained physician from the SCTS plus written self-help materials.
9954576|NCT01135173|Experimental|Arm B|"Behavioral counseling intervention conducted by a trained physician at the SCTS cessation clinic. Subjects complete homework before the session to facilitate this process. Subjects are asked to identify high-risk situations and difficulties in previous cessation attempts and are walked through a series of suggestions in the event of a slip. Three brief (approximately 10 minute) phone calls are provided to subjects during the 90 day follow-up period. These calls are used to identify early relapse, encourage participants, and provide support. In addition, they are used to review materials and information provided during the sessions."
9954577|NCT01135212|Active Comparator|Fimasartan 60mg|Take one tablet of Fimasartan 60mg once a day in the morning
9954578|NCT01135212|Active Comparator|Fimasartan 120mg|Take one tablet of Fimasartan 120mg once a day in the morning
9954579|NCT01135212|Active Comparator|Candesartan 8mg|Take one tablet of Candesartan 8mg once a day in the morning
9803614|NCT03681912||Implementation Block 1|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 3 months.
9954580|NCT01135225|Active Comparator|PROMUS(TM) Element(TM) Coronary Stent|PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent System
9954581|NCT01135225|Experimental|Evolution Coronary Stent A|Evolution Everolimus-Eluting Monorail Coronary Stent System
9954582|NCT01135225|Experimental|Evolution Coronary Stent B|Evolution Everolimus-Eluting Monorail Coronary Stent System
9954583|NCT01135251|Experimental|dimiracetam|Capsules containing 400 mg of dimiracetam will be administered orally, twice a day for 8 weeks in ascending schedule, contingent on tolerability of the previous dose, as follows: 1 capsule for two weeks (800mg/day), two capsules for the next two weeks (1600mg/day)and 4 capsules for the final 4 weeks (3200mg/day).
9954584|NCT01135251|Placebo Comparator|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day with the same modalities used for the dimiracetam arm: one capsule for 2 weeks, 2 capsules for another 2 weeks and 4 capsules for 4 weeks
10005334|NCT01584180|Active Comparator|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad (Emergency Medical Cooling Systems AG, Wien, Austria)
10005335|NCT01584193|Experimental|US-guided subclavian vein puncture|
10005336|NCT01584193|Active Comparator|Cephalic vein dissection|
9954585|NCT01135264|Active Comparator|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
9954586|NCT01135264|Experimental|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
9954587|NCT01135277||Sepsis|Patients who have been diagnosed with Sepsis within 24 hours of admission
9954588|NCT01135277||Non-Septic|Patients who have not been diagnosed with sepsis within 24 hours of admission
9954589|NCT01135290|Other|B|
9954590|NCT01135290|Active Comparator|A|
9954591|NCT01135303|Experimental|VistaO2 device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
9954592|NCT01135342|Experimental|Diet & Exercise plus Sleep Intervention|Diet and exercise instruction to promote weight loss plus cognitive behavioral therapy for insomnia.
9954593|NCT01135342|Sham Comparator|Diet & Exercise plus Passion and Balance|Diet and exercise instruction to promote weight loss plus sessions that are of general interest, but unrelated to diet, exercise, or sleep.
9954594|NCT01135407||group #1|Parkinson's disease patients at a disease's stage characterized by motor complications
9954595|NCT01135407||group #2|Parkinson's disease patients treated by subthalamic nucleus deep brain stimulation.
9954596|NCT01135407||group #3|healthy controls
9954597|NCT01135433|Experimental|ASP group|ASP1941 and metformin
9954598|NCT01135433|Placebo Comparator|Placebo group|placebo and metformin
9954599|NCT01135446|Experimental|dapagliflozin (0.001 mg)|Cohort 1
9954600|NCT01135446|Experimental|dapagliflozin (0.01 mg)|Cohort 2
9954601|NCT01135446|Experimental|dapagliflozin (0.1 mg)|Cohort 3
9954602|NCT01135446|Experimental|dapagliflozin (0.3 mg)|Cohort 4
9954603|NCT01135446|Experimental|dapagliflozin (1 mg)|Cohort 5
9954604|NCT01135446|Experimental|dapagliflozin (2.5 mg)|Cohort 6
9476528|NCT03570983|Experimental|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
9476529|NCT03570983|Active Comparator|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
9476530|NCT03570970|Experimental|Banapenem C1 group|250mg Once daily for 7
9476531|NCT03570970|Experimental|Banapenem C2group|500mg Once daily for 7
9476532|NCT03570970|Experimental|Banapenem C3group|1000mg Once daily for 7
9476533|NCT03570957|Experimental|MT-2990, Low dose|Single intravenous dose
9476534|NCT03570957|Experimental|MT-2990, Low-middle dose|Single intravenous dose
9476535|NCT03570957|Experimental|MT-2990, High-middle dose|Single intravenous dose
9476536|NCT03570957|Experimental|MT-2990, High dose|Single intravenous dose
9476537|NCT03570957|Placebo Comparator|Placebo|Single intravenous dose
9476538|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
9476539|NCT03570905|Experimental|Sugartong Splint|
9476540|NCT03570905|Experimental|Clam Shell Splint|
9476541|NCT03570879||Power morcellation|Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.
9476542|NCT03570879||Transvaginal extraction|Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.
9476543|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
9476544|NCT03570853|Experimental|Intervention|Participants will receive the 8-week SMART-3RP intervention within a few weeks of enrolling in the study.
9476545|NCT03570853|No Intervention|No Intervention|Participants will not receive the SMART-3RP program and will only complete study questionnaires..
9476546|NCT03570840||obese children and adolescents|
9476547|NCT03570827|Experimental|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
9476548|NCT03570827|Experimental|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
10005337|NCT01584206|Experimental|Ezetimibe|Compare on and off ezetimibe
9954605|NCT01135472|Experimental|Nexium|ARM 1: NEXIUM 40MG ONCE DAILY, ARM 2: NEXIUM 40MG TWICE DAILY, ARM 3: NEXIUM 80MG TWICE DAILY
9954606|NCT01135485||Study group I|Study group I will include children who have undergone stage I palliation employing allograft material for left ventricular outflow tract reconstruction at CHOP during infancy (<1 year of age). Stage I palliation is defined as an operation in which augmentation of the native ascending aorta and aortic arch is performed to bypass atresia or critical obstruction of the left heart structures.
9954607|NCT01135485||Study Group II|Study group II who have undergone stage II palliation in which allograft material is used, but have not undergone antecedent stage I palliation. Stage II palliation is defined as a superior cavopulmonary anastomosis in which the superior vena cava is anastomosed to the ipsilateral pulmonary artery via either the bidirectional Glenn or hemi-Fontan procedures.
9954608|NCT01135485||Control Group|The control group who have undergone palliative or corrective surgery for congenital heart disease during infancy (<1 year of age) not requiring allograft material.
9954609|NCT01135550|Active Comparator|Standard Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
9954610|NCT01135550|Active Comparator|Control Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
9954611|NCT01135563|Experimental|Vinblastine and Sirolimus|The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
9954612|NCT01135576|Placebo Comparator|Placebo juices|Consumption of non-iron fortified fruit juices as part of the usual diet
9954613|NCT01135576|Experimental|Iron fortified fruit juices|Consumption of iron fortified fruit juices as part of the usual diet
9954614|NCT01135589|Experimental|HSCT|
9954615|NCT01135602|Experimental|Topiramate|1 group
9954616|NCT01135615|Other|Sevelamer|
9954617|NCT01135615|Other|calcium acetate|
9954618|NCT01135628|Active Comparator|MHE and diet plus lactobacillus reuteri|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.
9954619|NCT01135628|Active Comparator|MHE and diet|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.
9954620|NCT01135628|Active Comparator|MHE and diet plus nitazoxanide|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.
9954621|NCT01135641|Experimental|Rituximab, ciclosporine and corticosteroids|As soon as the diagnosis of chronic GVHD requiring systemic immunosuppressive therapy is confirmed, patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.Rituximab should be administered within 14 days of starting prednisone. Follow-up dates for response assessment and laboratory tests relate to the date of Rituximab infusion.Patients having a partial response after the 1st cycle of Rituximab will be eligible to receive a second cycle of 4 infusions during 4 weeks. A delay of 8 weeks (from the first infusion of Rituximab) will be observed between the two cycles of Rituximab therapy.Patients who relapse after an initial treatment with one cycle of 4 infusions of Rituximab will be eligible to receive a second cycle of Rituximab therapy.
9954622|NCT01135654|Experimental|Non-Physician Provider|
9954623|NCT01135654|No Intervention|Control|
9954624|NCT01135654|Active Comparator|Primary Care Provider|In clinics randomized to this arm, we will train (and provide technical assistance to) Primary Care providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment.
9954625|NCT01135667|Active Comparator|clopidogrel|clopidogrel 150 mg once daily for 30 days (and then 75 mg for additional 11 months - not study related)
9954626|NCT01135667|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 30 days (and then clopidogrel 75 mg once daily for additional 11 months - not study related)
9954627|NCT01135680|Placebo Comparator|Arm 1|"Cohort A: 9 mL HPN-100 or placebo~Cohort B: 12 mL HPN-100 placebo"
9954628|NCT01135680|Placebo Comparator|Arm 2|"This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.~Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days~Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3~Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days~Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days"
9954629|NCT01135706||Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram with a diagnosis of Pulmonary Hypertension
9954630|NCT01135706||Non Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram without a diagnosis of Pulmonary Hypertension.
9954631|NCT01135732||study group-previous sphincterotomy|
9954632|NCT01135732||control group-not previous sphincterotomy|
9954633|NCT01135745|Experimental|Deep Brain Stimulation Therapy for OCD|Reclaim® DBS Therapy uses thin wires to deliver electric current (stimulation) to a very specific target in the brain. These wires are implanted surgically. They are attached to internal neurostimulators implanted under the skin of the chest below the collarbone, similar to cardiac pacemakers, or in the abdominal wall. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
9954634|NCT01135758|Experimental|ketamine 0.5 mg/kg i.v.|Single administration of ketamine 0.5 mg/kg i.v.
9954635|NCT01135784|Active Comparator|MIGRA-ZEN RELIEF PLUS|Active treatment
9954636|NCT01135784|Placebo Comparator|Placebo for Migra zen plus|Placebo
10005338|NCT01584219||Women after cesarean section|Women after cesarean section
10005339|NCT01584219||pregnancy pathologies|pregnancy pathologies
10005340|NCT01584219||first/second trimester pregnancy|
10005341|NCT01584219||Women after vaginal delivery|Women after vaginal delivery
10005342|NCT01584258|Active Comparator|Laparoscopic Prostatectomy vs prostate SBRT|Patients for whom surgery is considered will be randomised to laparoscopic prostatectomy or prostate SBRT delivered with 36.25 Gy in 5 fractions.
10005343|NCT01584258|Active Comparator|Conventionally Fractionated RT vs Prostate SBRT|Patients for whom surgery is not considered or who refuse surgery will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 2 Gy fractions or SBRT delivered with 36.25 Gy in 5 fractions.
10005344|NCT01584271|Active Comparator|2 Dex-Otic ear drops|Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It
10005345|NCT01584271|Experimental|3 Ear Comfort(TM) ear drops|Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.
10005346|NCT01584271|Active Comparator|1 Otidin(R) ear drops|Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.
9802356|NCT05308420|Active Comparator|PENG block|"Patients scheduled for primary total hip arthroplasty after receiving spinal anesthesia will undergo pericapsular nerve group (PENG) block.~Postoperative multimodal analgesia with paracetamol, etoricoxib and oxycodone"
10005347|NCT01584297|Experimental|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
10005348|NCT01584310|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
10005349|NCT01584310|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
10005350|NCT01584323|Active Comparator|Pomegranate pills|treatment with pomgranate pills to women suffering preterm premature rupture of membranes
10005351|NCT01584323|Placebo Comparator|placebo pills|treatment with placebo to women with preterm premature rupture of membranes
10005352|NCT01584336|Experimental|LATG group|It means the patients who will be enrolled in our study.
10005353|NCT01584362|Experimental|oxfendazole 0.3|administration of a single oral 0.3mg/kg dose of oxfendazole
9802357|NCT05308420|Active Comparator|Intrathecal morphine|"Patients scheduled for primary total hip arthroplasty will receive spinal anesthesia with local anesthetic and morphine administered intrathecally. After onset of spinal anesthesia a sham PENG block will be performed.~Postoperative multimodal analgesia with paracetamol, etoricoxib and oxycodone."
9802358|NCT05305040|Active Comparator|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
9954637|NCT01135797||Patients from phase I-II studies|
9954638|NCT01135836|Experimental|pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
9802359|NCT05305040|Placebo Comparator|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
9954639|NCT01135836|Experimental|intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity
9954640|NCT01135836|Placebo Comparator|Control group|CO2 was removed by passive exsufflation through the port site.
9954641|NCT01135862|Experimental|platelet administered|patients will receive 6 packs of platelets
9954642|NCT01135862|No Intervention|no platelets administered|patients will not receive platelets
9954643|NCT01135875||GBM Patients|GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
9954644|NCT01135875||Normal Controls|Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
9954645|NCT01135888||HED children|
9954646|NCT01135888||HED adolescents|
9954647|NCT01135888||Control children|
9954648|NCT01135888||Control adolescents|
9954649|NCT01135901|Experimental|group programme|Group based behaviour change programme
9954650|NCT01135927|Experimental|A|
9954651|NCT01135927|Active Comparator|B|
9954652|NCT01135940|Experimental|1|2-octylcyanoacrylate (Dermabond) closure
9954653|NCT01135940|Active Comparator|2|Standard staple closure
9954654|NCT01135953|Experimental|ARM 1 - CONTROL|Subject given tDCS every day of the week (5 sessions) at 2 mA.
9954655|NCT01135953|Experimental|Arm 2 - INCREASING|Subjects given increasing intensity during tDCS across the week (Monday 1mA, Tuesday 1.5mA, Wednesday 1.5 mA, Thursday 2 mA, Friday 2mA).
9954656|NCT01135953|Experimental|ARM 3 - CYCLOSERINE|D-cycloserine (100 mg) given on the Monday and Thursday sessions, administering tDCS at 2 mA.
9954657|NCT01135966|Active Comparator|Conventional training|
9954658|NCT01135966|Experimental|Whole body vibration training|
9954659|NCT01135979||Arterio-venous fistulae creation|
9954660|NCT01136005|Experimental|dexpanthenol 5% cream|dexpanthenol 5% cream
9954661|NCT01136005|Active Comparator|cetomacrogol cream|a vehicle
9954662|NCT01136018||intentional lateral caudal approach|
9954663|NCT01136031|Experimental|Paclitaxel and irinotecan|
9954664|NCT01136057||Influenza A Exposure|Participants will include people who have recovered from influenza, received a seasonal influenza vaccine, or have both recovered from influenza and received a seasonal influenza vaccine.
9954665|NCT01136070||Burn Trauma Patients|
9954666|NCT01136083|Experimental|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
9954667|NCT01136083|Active Comparator|Control group|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
9954668|NCT01136096|Experimental|Lifestyle counseling|To promote participants' exercise behaviors with individualized home-based exercise program was designed based on the Health Belief Model and Transtheoretical Model
9954669|NCT01136096|Other|Control|Received oral instruction and written general education information without individualized exercise program
9954670|NCT01136109||Bedside ultrasound only|Bedside ultrasound to determine the dimensions of the inferior vena cava
9954671|NCT01136109||Ultrasound with ventilator changes|Bedside ultrasound to determine the dimensions of the inferior vena cava pre and post ventilator changes.
9954672|NCT01136122|Active Comparator|CPAP Arm|Receive effective CPAP treatment for one month
9954673|NCT01136122|No Intervention|Control Arm|Receive no treatment for one month
9954674|NCT01136135||CARDIAC MRI|
9954675|NCT01136148|Experimental|A Medical and Mental Health Unit|A specialist unit for cognitively impaired older patients admitted as a medical emergency to the acute hospital.
9954676|NCT01136148|Active Comparator|Standard care wards|The standard care provided by the acute hospital for cognitively impaired older patients admitted as a medical emergency.
9954677|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV -|n=12
9954678|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV -|n=12
9954679|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV -|n=12
9954680|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV -|n=12
9954681|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV +|n=12
9954682|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV +|n=12
9954683|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV +|n=12
9954684|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV +|n=12
9954685|NCT01136187|Experimental|Radial approach|Primary percutaneous coronary intervention from the radial approach
9954686|NCT01136187|Active Comparator|Femoral approach|Primary percutaneous coronary intervention from the femoral approach
9954687|NCT01136200|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
9954688|NCT01136200|No Intervention|Control|Patients not receiving infectious disease specialist advice
9954689|NCT01136213||Multiple system atrophy|
9954690|NCT01136213||Idiopathic Parkinson Disease|
9954691|NCT01136213||Volunteers without neuropsychiatric disorder (Control)|
9954692|NCT01136239|Placebo Comparator|Placebo|Placebo (600mg twice daily)
9954693|NCT01136239|Active Comparator|N-acetylcysteine|N-acetylcysteine (600mg twice daily)
9954694|NCT01136252|Experimental|Adalimumab|
9954695|NCT01136278|Experimental|clonidine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
9954696|NCT01136304||Adults with Type 1 Gaucher disease (GD1)|Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.
9954697|NCT01136317|Experimental|Omeprazole|
9954698|NCT01136317|Experimental|Rabeprazole|
9954699|NCT01136317|Placebo Comparator|Placebo|
9954700|NCT01136343|Experimental|lifestyle modified project|education, counseling
9954701|NCT01136343|No Intervention|control|waiting list control
9954702|NCT01136369||OSNA Breast Cancer System|
9954703|NCT01136395|Active Comparator|LD kidney transplantation, ABOi|Living donor (LD) kidney transplantation, ABO incompatible (ABOi); Immunosuppressive treatment: Tacrolimus (Tacr)/ Mycophenolate sodium (MPS), Basiliximab induction, Rtx induction
9954704|NCT01136395|Active Comparator|LD kidney transplantation, ABOc|Living donor (LD) kidney transplantation, ABO compatible (ABOc); Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
9954705|NCT01136395|Active Comparator|DD kidney transplantation|Deceased donor (DD) kidney transplantation, ABO compatible; Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
9954706|NCT01136421|Active Comparator|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
9954707|NCT01136421|Experimental|Magnesium sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
9954708|NCT01136447|Placebo Comparator|Neurostimulation|Block catheter will be introduced using neurostimulation
9954709|NCT01136447|Active Comparator|Ultrasound|Block catheter will be introduced using ultrasound
9954710|NCT01136460||Primary congenital glaucoma|Primary congenital glaucoma patients and their immediate relatives
9954711|NCT01136473||congenital cataract or aphakic glaucoma|children with congenital cataract or aphakic glaucoma
9954712|NCT01136499|Experimental|LBH PANOBINOSTAT|40 mg 3 days per week
9954713|NCT01136512||metformin use|Patients with type 2 diabetes treated with metformin
9954714|NCT01136512||no metformin use|Patients with type 2 diabetes who are not being treated with metformin
9954715|NCT01136525|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
9954716|NCT01136525|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
9954717|NCT01136538|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
9954718|NCT01136538|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
9954719|NCT01136551|Active Comparator|IR formulation|Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)
9954720|NCT01136551|Experimental|CR 1|"CR formulation~Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)"
9954721|NCT01136551|Experimental|CR 2|"CR formulation~Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)"
9954722|NCT01136564|Active Comparator|Paricalcitol|
9954723|NCT01136564|Placebo Comparator|Placebo|
9954724|NCT01136577|Experimental|LEDDYBLOO®|LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
9954725|NCT01136577|Experimental|Double BILITRON®|Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
9954726|NCT01136577|Experimental|Futura®|Future phototherapy device equipped with 8 fluorescent tubes
9954727|NCT01136590|Experimental|tranexamic acid|tranexamic acid will be administered as a bolus (10-mg/kg dose ) or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery
9954728|NCT01136590|Placebo Comparator|placebo|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
9954729|NCT01136603|Experimental|TIGR Mesh|Experimental - TIGR Mesh
9954730|NCT01136603|Active Comparator|Control|Control group - Non absorbable Polypropylene mesh
10005354|NCT01584362|Placebo Comparator|placebo comparator|administration of a single oral dose of placebo
10005355|NCT01584362|Experimental|oxfendazole 1.0|administration of a single oral 1.0 mg/kg dose of oxfendazole
10005356|NCT01584362|Experimental|oxfendazole 3.0|administration of a single oral 3 mg/kg dose of oxfendazole
9954731|NCT01136616||Nasal Fracture|"67 patients admitted for facial fractures and who undergo routine CT scans of the face are to be studied. CT scans are evaluated to assess the position, comminution and displacement of the 5 said buttresses.~The buttresses are graded Grade 1 Simple fracture without displacement Grade 2 Simple fracture with displacement Grade 3 Comminuted fracture without displacement Grade 4 Comminuted fracture with minimal displacement Grade 5 Comminuted fractured with displacement~The septum is graded from Grade 0 Septum is straight Grade 1 Septum is deviated by less than 1 half the distance from the midline to the nasal turbinate Grade 2 Septum is deviated by more than 1 half the distance from the midline to the nasal turbinate Grade 3 Septum is almost touching the nasal turbinate"
9954732|NCT01136629||Subjects with hyper-pigmented spots|Subjects age 21 to 80 year old, who have elected to undergo a plastic surgery will be enrolled. Subjects will be from Chinese, Malay, Indian or Caucasian ancestry. Subjects will be female or male with a hyper-pigmented spots.
9954733|NCT01136694||RA patients who are new bDMARD users|
9954734|NCT01136694||RA patients who are existing DMARD users|
9954735|NCT01136707||Patients with rheumatoid arthritis new to Orencia|
9954736|NCT01136720||patients injected with the Halifax produced 18-FDG|
9954737|NCT01136759|Placebo Comparator|Pregnancy cohort, placebo|Pregnant women will receive placebo gel.
9954738|NCT01136759|Experimental|Lactation cohort, tenofovir gel|Lactating mothers will receive tenofovir gel.
9954739|NCT01136759|Experimental|Pregnancy cohort, tenofovir gel|Pregnant women will receive tenofovir gel.
9954740|NCT01136824||Sarcoma Subjects|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)
9954741|NCT01136837||fragmented QRS positive|fQRS at 48 hours after Primary PCI
9954742|NCT01136850|Active Comparator|SP, chloroquine treatment; bed net|Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
9954743|NCT01136850|Experimental|3 x SP plus azithromycin; bed nets|Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.
9954744|NCT01136863|Active Comparator|felodipine group, active, pill|felodipine and HCTZ treatment group
9954745|NCT01136863|Placebo Comparator|placebo, no treatment, pill|placebo and HCTZ group
9954746|NCT01136889|Active Comparator|PFMT plus routine pessary management|"Women allocated to the intervention group will be invited to attend 5 out-patient appointments over a 16 week period with a trained specialist women's health physiotherapist at the study centre. Women will be taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Tailored advice will be given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise. A prolapse specific Lifestyle Advice sheet will also be given to the women by the physiotherapist."
9954747|NCT01136889|Active Comparator|Lifestyle|Women allocated to the control group will be sent a Lifestyle Advice Leaflet only. They will have no planned intervention after their pessary is fitted, other than routine pessary management according to local protocols. The Lifestyle Advice Leaflet gives instructions on seeking advice, where appropriate, about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause the prolapse to worsen.
9954748|NCT01136902||Type 2 DM|This group includes subjects diagnosed with type 2 diabetes mellitus with none or minimal diabetic retinopathy.
9954749|NCT01136928|Experimental|American ginseng and efavirenz|This is a sequential study. Healthy volunteers will receive efavirenz alone for 14 days followed by efavirenz plus American ginseng for an additional 14 days.
9954750|NCT01136941|Experimental|Treatment|Research participants will be administered Zileuton according to the dose escalation/de-escalation schema provided in the protocol.
10005357|NCT01584362|Experimental|oxfendazole 10|administration of a single oral 10 mg/kg dose of oxfendazole
9954751|NCT01136967|Experimental|Cohort 1 (V600E BRAF negative)|Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.
9954752|NCT01136967|Experimental|Cohort 2 (V600E BRAF positive)|Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.
9954753|NCT01136980|Placebo Comparator|Sham placebo procedure|Sham Procedure: SHAM/PPI's An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach, and the GEJ.
9954754|NCT01136980|Active Comparator|TIF Transoral Fundoplication|Intervention: TIF 2.0/Placebo TIF Transoral Incisionless Fundoplication: A fundoplication of 270 degrees and 3cm in length was created. The EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach.
9954755|NCT01136993||All bi-directional telestroke consultations|
9954756|NCT01137019|Active Comparator|Biolimus-eluting stent|
9954757|NCT01137019|Active Comparator|Everolimus-eluting stent|
9954758|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen|35 healthy volunteers
9954759|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen|35 healthy volunteers
9954760|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
9954761|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen plus ERIG|35 WHO category III patients
9954762|NCT01137045|Active Comparator|SPEEDA with ESSEN IM regimen plus ERIG|35 healthy volunteers
9954763|NCT01137045|Active Comparator|TRCS SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
9954764|NCT01137058|Experimental|U-healthcare|glucose meter and U-healthcare
9954765|NCT01137058|Active Comparator|SMBG group|Diabetic patients who do self monitoring of blood glucose only were categorized into self monitoring of blood glucose (SMBG) group.
9954766|NCT01137058|No Intervention|control|conventional treatment
9803615|NCT03681912||Implementation Block 2|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 6 months.
9954767|NCT01137084|Active Comparator|a steroid immunosuppression protocol|
9954768|NCT01137084|Active Comparator|a steroid-free immunosuppression protocol|without steroid
9954769|NCT01137097|Active Comparator|Lateral sentinel group|Lateral sentinel lymph node biopsy with radioisotope
9954770|NCT01137097|No Intervention|No intervention for lateral neck|No lateral sentinel lymph node biopsy with radioisotope
9954771|NCT01137136||SMAC (SMc AI user Cohort)|All patients who took the AI (Aromatase inhibitor)will be enrolled
9954772|NCT01137149|Active Comparator|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
9954773|NCT01137149|Experimental|Behavioral Acitivation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
9954774|NCT01137188|Experimental|Intervention group|Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks
9954775|NCT01137188|No Intervention|No intervention|Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion
9954776|NCT01137201|Experimental|Mesenteric defects sutured|Closure of the mesenteric defects using running, non-absorbable suture
9954777|NCT01137201|No Intervention|Mesenteric defects not sutured|Non-closure of the mesenteric defects
9954778|NCT01137214|Active Comparator|CPAP|Continuous Positive Airway Pressure
9954779|NCT01137214|Active Comparator|Adaptive Servo-Ventilator|Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
10005358|NCT01584362|Experimental|oxfendazole 20|administration of a single oral 20 mg/kg dose of oxfendazole
10005359|NCT01584362|Experimental|oxfendazole 30|administration of a single oral 30 mg/kg dose of oxfendazole
9954780|NCT01137227||Description|"2137 studies retrieved in 8 databases (Biomed Central, CINAHL, EMBASE, ERIC, PsycInfo, PUBMED, SCOPUS, SPORTDiscus and uploaded in EndNote Web®.~332 studies were excluded as duplicates by EndNote Web®.~1805 titles and abstracts were assessed independently by two researchers (PG/AM): 1541 studies excluded.~264 studies referred for full-text assessment by two independent investigators (PG/AM)~225 studies were excluded according to the eligibility criteria (in case of discrepancies in the assessment of the researchers, studies were reviewed in duplicate)~39 Studies assessed for quality using STROBE~13 Studies were included in the descriptive synthesis"
9954781|NCT01137240||Children with mitochondrial disorders|suffering from gastrointestinal dysfunction
9954782|NCT01137253|Experimental|Trimethaphan|Response to intrabrachial vasodilators during autonomic withdrawal
9954783|NCT01137253|Placebo Comparator|Placebo|Response to intrabrachial vasodilators during saline intravenous (IV) infusion
9954784|NCT01137266|Active Comparator|skin resistence|1) the location with the lowest resistance
9954785|NCT01137266|Active Comparator|irradiation|2) the site that causes an irradiation sensation
9954786|NCT01137266|Active Comparator|random|3) a random stimulation site.
9954787|NCT01137318|Experimental|Cognitive remediation and Behavioral Intervention|
9954788|NCT01137318|Placebo Comparator|Low Level Cognitive Remediation and Behavioral Parent Traning|
9954789|NCT01137331|Experimental|K301|K301 applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
9954790|NCT01137331|Placebo Comparator|Placebo|Placebo applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
9954791|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum WCFS1)|
9954792|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum NIZO3400)|
9954793|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L. plantarum NIZO2877)|
9954794|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum CBS125632)|
9954795|NCT01137357|Active Comparator|Yoghurt with Lactobacillus casei Shirota|
9954796|NCT01137357|Placebo Comparator|Placebo Yoghurt|
9954797|NCT01137383|Experimental|Treatment group|
9954798|NCT01137409||Suspected or Diagnosed with Coronary artery disease|All patients with suspected or previously diagnosed coronary artery disease
9954799|NCT01137448|Experimental|Weight Loss|Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
9954800|NCT01137461|Other|abdominal ultrasound|traditional technique
9954801|NCT01137461|Other|transvaginal ultrasound|new technique
9954802|NCT01137487|Other|residual gastric volume|
9954803|NCT01137487|Other|residual gastric volume not monitored|
9954804|NCT01137513||Chest Pain|Acute Myocardial ischemia
9954805|NCT01137552|Experimental|A|Dose Escalation
9954806|NCT01137552|Experimental|B|Dose Expansion
10005360|NCT01584375|Other|Flat midline head position|
10005361|NCT01584375|Other|Right flat lateral head position|
10005362|NCT01584414||normal samples|
10005363|NCT01584414||premalignant/carcinoma samples|
10005364|NCT01584427|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch.
10005365|NCT01584427|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans
10005366|NCT01584453|Experimental|Sodium Nitrite|
10005367|NCT01584453|Placebo Comparator|Placebo|
10005368|NCT01584492|Experimental|Treatment A|CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
10005369|NCT01584492|Experimental|Treatment B:|CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
10005370|NCT01584492|Experimental|Treatment C|CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
10005371|NCT01584492|Active Comparator|Treatment D|formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
10005372|NCT01584492|Placebo Comparator|Treatment E|placebo pMDI with spacer, 6 inhalations in the morning at the clinic
10005373|NCT01584505|Experimental|CHF5993 HFA pMDI dose 1, BID|CHF5993 HFA pMDI dose 1, BID
10005374|NCT01584505|Experimental|CHF5993 HFA pMDI dose 2, BID|CHF5993 HFA pMDI dose 2, BID
10005375|NCT01584505|Active Comparator|CHF1535 HFA pMDI + Placebo|CHF1535 HFA pMDI BID plus placebo BID
9954807|NCT01137565|Experimental|AMG 853|
9954808|NCT01137565|Placebo Comparator|Placebo|
9954809|NCT01137591|Experimental|APAP and NAC combination|N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill
9954810|NCT01137591|Placebo Comparator|APAP and Placebo combination|N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill
9954811|NCT01137630|Experimental|K40a|K40a is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
9954812|NCT01137630|Experimental|K40b|K40b is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
9954813|NCT01137630|Placebo Comparator|Placebo|Placebo is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
9954814|NCT01137656|Other|Acetylcholine and Blood|This is single arm study. Acetylcholine and blood is infused in brachial artery of non-dominant arm. Blood flow
9954815|NCT01137669|Placebo Comparator|Placebo|10 subjects to receive placebo subcutaneously.
9954816|NCT01137669|Experimental|ZOSTAVAX®|30 subjects to receive 0.65 mL ZOSTAVAX® subcutaneously.
9954817|NCT01137695|Active Comparator|Symlin Naive, Usual Dose|Symlin 120 mcg three times daily in patients not previously treated with pramlintide before the study.
9954818|NCT01137695|Experimental|Symlin Naive, Dose Escalation|Escalation of pramlintide dose to 360 mcg three times daily in patients not taking pramlintide prior to study.
9954819|NCT01137695|Active Comparator|Symlin treated, Usual Dose|pramlintide 120 mcg three times daily in patients who have been treated with pramlintide 120 mcg prior to the trial.
9954820|NCT01137695|Experimental|Symlin Treated, Dose Escalation|pramlintide 360 mcg three times daily in patients previously treated with 120 mcg prior to the study.
9954821|NCT01137708|Experimental|Treatment Sequence 1|
9954822|NCT01137708|Experimental|Treatment Sequence 2|
9954823|NCT01137721||Pre-Hydroxyurea - subjects with SCD|Patients with a diagnosis of HbSS (sickle cell anemia) or HbS/ß0-thalassemia (beta thalassemia) who will be treated with hydroxyurea therapy.
9954824|NCT01137721||Sibling control|Sibling control with no diagnosis of HbSS or HbS/ß0-thalassemia.
9954825|NCT01137721||Observational - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia.
9954826|NCT01137721||Pre-transfusion - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia who will be treated with transfusion therapy.
9954827|NCT01137734|Experimental|Valtech Cardinal Mitral Annuloplasty Ring|All subjects enrolled in the study are implanted with the Valtech Cardinal Mitral Annuloplasty ring.
9954828|NCT01137747|Experimental|Dose Level 0 (starting dose)|"Carfilzomib - 20 mg/m2 days 1 and 2, 27 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 36 mg/m2 for all subsequent doses. If DLT occurs while receiving 36 mg/m2, the dose may be reduced to 27 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
9954829|NCT01137747|Experimental|Dose Level +1|"Carfilzomib - 20 mg/m2 days 1 and 2, 36 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 45 mg/m2 for all subsequent doses. If DLT occurs while receiving 45 mg/m2, the dose may be reduced to 36 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
9954830|NCT01137747|Experimental|Dose Level +2|"Carfilzomib - 20 mg/m2 days 1 and 2, 45 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 56 mg/m2 for all subsequent doses. If DLT occurs while receiving 56 mg/m2, the dose may be reduced to 45 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
9476549|NCT03570827|Experimental|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
9476550|NCT03570775|Experimental|"Neomedlight Sleeping bag phototherapy"|Phototherapy device with LED light + fiber optic mesh
9476551|NCT03570775|Active Comparator|Conventional phototherapy|LU-6T model: phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated.
9476552|NCT03570736|Experimental|Minimal Invasive Surgical Technique|
9954831|NCT01137760|Placebo Comparator|Sugar pill|
9954832|NCT01137760|Experimental|Galactooligosaccharide 2.5 g|
9954833|NCT01137760|Experimental|Galactooligosaccharide 5.0 g|
9954834|NCT01137799|Experimental|001|JNJ-39393406 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
9954835|NCT01137799|Experimental|002|JNJ-39393406 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
9954836|NCT01137799|Experimental|003|JNJ-39393406 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
9954837|NCT01137799|Experimental|004|JNJ-39393406 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
9954838|NCT01137799|Experimental|005|JNJ-39393406 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
9954839|NCT01137799|Placebo Comparator|006|placebo Once daily (single dose)
10215418|NCT03703622|Active Comparator|Standard HBB training only|Health workers are given standard HBB training according to AAP without video-debriefing. All the participants in this arm, like in intervention arm, will also undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick new-born baby who needs resuscitation care only. Pre-and post-tests will be done to assess performance of all participants.
10215419|NCT03703609|Experimental|Tele-yoga|Intervention of doing medical yoga at home (tele-yoga) using (1) an online videoconference system (zoom) for particpating in group-yogaled by a live yoga instructor for 60 minutes twice a week and (2) daily individual yoga for a minimum of 10 minutes using a yoga-app. Participants are provided with a tablet with conference system zoom and yoga app for 12 weeks
10215420|NCT03703609|No Intervention|Individual physical activty advice|The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
10215421|NCT03703596|Experimental|Anlotinib hydrochloric|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
9954840|NCT01137838||Patients with RA and new to abatacept|
9954841|NCT01137838||Patients with RA and new to infliximab|
9954842|NCT01137838||Patients with RA and new to etanercept|
9954843|NCT01137838||Patients with RA and new to adalimumab|
9954844|NCT01137851||New to bDMARD|New to bDMARD RA patients with high and low cost share who continue or discontinue treatment
9954845|NCT01137864|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
9954846|NCT01137864|No Intervention|Control|Patients not receiving infectious disease specialist advice
9954847|NCT01137877|Active Comparator|Infant Formula #1|Milk-based Infant Formula Powder
9954848|NCT01137877|Experimental|Investigational Infant Formula #1|Investigational Milk-based Infant Formula Powder
9954849|NCT01137877|Experimental|Investigational Infant Formula #2|Investigational Milk based infant formula powder
9954850|NCT01137877|Active Comparator|Human Milk|Reference group
9954851|NCT01137903|Other|Patients undergoing medical treatment|"Antibiotic treatment within 90 days with:~Ciprofloxacin Amoxicillin /Clavulanic acid. Trimethoprim /Sulfamethoxazole."
9954852|NCT01137903|Other|Patients undergoing surgical treatment|Conservative surgical Minor amputation 7 days antibiotic after surgical
9954853|NCT01137916|Experimental|drug|Imatinib 800 mg
9954854|NCT01137929||With APN, With VUR, With Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and a renal scar on follow-up DMSA renal scan.
9954855|NCT01137929||With APN, With VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and NO renal scar on follow-up DMSA renal scan.
9954856|NCT01137929||With APN, without VUR, with Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan but who will NOT have VUR by VCUG; however they will have a renal scar on follow-up DMSA renal scan.
9954857|NCT01137929||With APN, Without VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will NOT have VUR by VCUG, NOR will they have a renal scar on follow-up DMSA renal scan.
9954858|NCT01137929||Without APN, With VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also have VUR by VCUG. They will not undergo a second DMSA scan since the first one is normal.
10215422|NCT03703596|Experimental|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
10215423|NCT03703583||Exclusively/predominantly Breastfeeding group|
10215424|NCT03703583||Exclusively/predominantly Formula feeding group|
10215425|NCT03703570|Experimental|KW-6356 Low Dose|Oral administration
10215426|NCT03703570|Experimental|KW-6356 High Dose|Oral administration
10215427|NCT03703570|Placebo Comparator|placebo|Oral administration
10215428|NCT03703557|Experimental|Sorbstar®|Odour sampling: Rub hands with Sorbstar® before and post-surgery
10215429|NCT03703557|Experimental|Dog detection|Odour sampling: Sleep over a night with a compress on the affected breast before and after surgery
10215430|NCT03703544|Experimental|High glycemic index|Subjects will consume locally consumed meals which are high glycemic index for breakfast, lunch snack and dinner will be provided.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
10215431|NCT03703544|Experimental|Low glycemic index|Subjects will consume locally consumed meals which are low glycemic index for breakfast, lunch snack and dinner will be provided. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
10215432|NCT03703531||Patients resuscitated in Istria county|Cardiopulmonary resuscitation performed for OHCA
10215433|NCT03703518|Experimental|Mixed reality|"Mixed reality exercise program using the Microsoft Hololens Roboraid game. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
10215434|NCT03703518|Active Comparator|Conventional exercise group|Conventional exercise program in cervical region based in deep neck flexors and deep neck extensors, isometric contraction during 6-8 seconds. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions.
10215435|NCT03703505|Experimental|AG-348|On Day 1, participants fasting for at least 10 hours the night before will receive oral AG-348 followed by intravenous (IV) [13C6]AG-348, 1 hour post-oral dose.
10215436|NCT03703479|Experimental|A-PRF group|Socket site that will receive A-PRF clot
9954859|NCT01137929||Without APN, Without VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also NOT have VUR by VCUG, NOR a renal scar on follow-up DMSA renal scan.
9954860|NCT01137942||H. pylori eradication failure|Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
9954861|NCT01137955|Experimental|Rifaximin|Antibiotic
9954862|NCT01137955|Placebo Comparator|Placebo|
9954863|NCT01137994|Experimental|Lapatinib plus Chemotherapy|Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
9954864|NCT01137994|Experimental|Trastuzumab plus Chemotherapy|Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
9954865|NCT01138033|Experimental|Part 1|Part 1 - dose escalation; starting dose 80 mg BID
9954866|NCT01138033|Experimental|Part 2|Part 2 - Dose expansion phase of the study at the maximum tolerated dose and schedule identified in Part 1 in patients with tumors known to over express FAK
9954867|NCT01138033|Experimental|Part 3|Part 3 - Characterize the biologically active dose range by analysis of PD markers in skin, hair and in tumor tissue in subjects with solid tumors amendable to biopsy and know to over express FAK
9476553|NCT03570736|Active Comparator|Open Flap Debridement|
9954868|NCT01138033|Experimental|Part 4|Part 4 - Explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM).
9954869|NCT01138033|Experimental|Part 5|Part 5 will investigate the time course, the extent of an apparent change in the PK of GSK2256098 following repeated dosing, and screen for potential CYP3A induction as a possible mechanism of reduced systemic exposure of GSK2256098 at Day 15 and later time points.
9954870|NCT01138059||Acute ischemic stroke patients with unclear onset|
9954871|NCT01138072|Experimental|Treatment A|Simvastatin 20mg (single dose) Day 1
9954872|NCT01138072|Experimental|Treatment B|Atorvastain 20 mg (single dose) Day 3
9954873|NCT01138072|Experimental|Treatment C|Rosuvastatin 10mg (single dose) Day 7
9954874|NCT01138072|Experimental|Treatment X|GSK2248761 200mg single dose Day 10-14, Day 16-17, Day 19-21, Day 23-24
9954875|NCT01138072|Experimental|Treatment D|GSK2248761 200mg + simvastatin 20 mg Day 15
9954876|NCT01138072|Experimental|Treatment E|GSK2248761 200mg + atorvastatin 20 mg Day 18
9954877|NCT01138072|Experimental|Treatment F|GSK2248761 200mg + rosuvastatin 20 mg Day 22
9954878|NCT01138085|Experimental|Dose Escalation|Dose escalation will proceed until unacceptable toxicity is observed. Dose escalation decisions will take into account all available data, including PK data and the safety profile of prior cohorts and will occur following review of these data by the investigator(s), GSK medical monitor, pharmacokineticist, and statistician.
9954879|NCT01138085|Experimental|Expansion Cohorts|"Enrollment into expansion cohort(s) in Part 2A may begin once a recommended dosing regimen(s) is identified in Part 1A utilizing a once daily continuous dosing schedule for both GSK1120212 and GSK2141795. Enrolment to cohorts utilizing this daily dosing schedule may proceed in parallel with enrolment in Part 1B. Expansion cohort(s) will preferentially enroll subjects with treatment-refractory, measurable and biopsiable triple negative breast cancer or BRAF- wild type melanoma. Subjects selected for enrollment into Part 2A or Part 2B will be tested for PTEN deficiency and must agree to provide paired tumor biopsies (at baseline and once while on- treatment). An additional tumor biopsy at the time of disease progression should also be collected if feasible.~In Part 2A and Part 2B, up to 35 additional subjects per tumor type and schedule (i.e., a total of up to 70 subjects per schedule tested) may be enrolled in a two-stage design to better characterize safety, PK and PD."
9954880|NCT01138137|Experimental|All subjects|
9954881|NCT01138176|No Intervention|Standard care|
9954882|NCT01138176|Experimental|Cooling|Reduction of rectal temperature to 33.5 C for 72 hours
9954883|NCT01138202|Experimental|1|boosted LPV/r 400/100 mg BID + 2 NRTI
9954884|NCT01138202|Experimental|2|boosted LPV/r 600/150 mg BID + 2 NRTI
9954885|NCT01138215|Experimental|1|Receive 1 course of VZV vaccine : 2 doses of vaccines with 3 months apart.
9954886|NCT01138228||Normal vision|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
9954887|NCT01138228||Vein Imaging Device|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
9954888|NCT01138241||1|ARV experience (TDF based HAART)
9954889|NCT01138241||2|ARV experience (non TDF based ART)
9954890|NCT01138241||3|ARV Naive
9954891|NCT01138254|No Intervention|control group|ESRD patients will not receive FIR therapy in this study.
9954892|NCT01138254|Experimental|Far infrared therapy|Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
9954893|NCT01138280|Experimental|Heat disinfection|Experimental arm: Heat disinfection link to RO water treatment system and piping system to dialysis machine
9954894|NCT01138280|No Intervention|Conventional RO water treatment|Placebo arm: conventional chemical disinfection link to RO water treatment system.
9954895|NCT01138293|Experimental|motion sensor integrated in a mobile phone|A motion sensor integrated in a mobile phone. The system analyses kind, intensity and duration of physical activity and eating habits.
9954896|NCT01138345||Treatment w/Surgery|Breast Cancer survivors treated with surgery with or without radiation.
9954897|NCT01138345||Treatment w/endocrine therapy|Breast Cancer survivors treated with surgery with or without radiation plus endocrine therapy.
9954898|NCT01138345||Treatment w/ chemotherapy|Breast Cancer survivors treated with surgery with or without radiation and chemotherapy with or without endocrine therapy.
9954899|NCT01138371||Familial hypercholesterolemia|"Heterozygous FH with documented CAD and LDL-C ≥ 200 mg/dL (Documented CAD may be represented as: Lesion(s) on coronary angiography, history of myocardial infarction, CABG, PTCA, progressive angina demonstrated by stress testing, history of other revascularization procedure)~Homozygous FH and LDL-C > 500 mg/dL~Heterozygous FH and LDL-C ≥ 300 mg/dL~On stable LDL apheresis therapy for at least 6 months"
9954900|NCT01138384|Experimental|Foretinib and Lapatinib|Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1.
9954901|NCT01138397|Experimental|Group 1|Participants at 18 to 59 years of age
9954902|NCT01138397|Experimental|Group 2|Participants at 60 years of age or older
9954903|NCT01138410|Experimental|SCIB1|
9954904|NCT01138423|Experimental|Aliskiren|
9954905|NCT01138423|Experimental|Moxonidine|
9954906|NCT01138423|Experimental|Hydrochlorothiazide|
9954907|NCT01138423|Placebo Comparator|Placebo|
9954908|NCT01138449|Experimental|Vitamin A|Vitamin A capsules have retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil
9954909|NCT01138449|Placebo Comparator|Placebo|Placebo capsules contain minute amounts of vitamin E in soybean oil
9954910|NCT01138462|No Intervention|Standard Precautions|control arm, standards precautions for all residents living in the nursing home of control arm, including MRSA carriers
9954911|NCT01138462|Other|Intervention|Intervention arm, standards precautions for all residents living in nursing homes of intervention arm, and topical decolonization for MRSA carriers, including environmental disinfection
9954912|NCT01138488|Experimental|NN5401|
9954913|NCT01138527||Biopsy-proven prostate cancer|Patients with biopsy-proven prostate cancer, planned for radical prostatectomy
9954914|NCT01138540|Active Comparator|Semirecumbent position|Semirecumbent position of patients on mechanical ventilation in the bed of the ICU
9954915|NCT01138540|Experimental|lateral-Trendelenburg position|lateral-Trendelenburg position of patients on mechanical ventilation in the bed of the ICU
9954916|NCT01138553|Experimental|Mifepristone|
9803616|NCT03681912||Implementation Block 3|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 9 months.
9954917|NCT01138566||ESBL- and/or AmpC-(+) or (-)|
9954918|NCT01138579|Experimental|1|
9954919|NCT01138592||Primary Care Patients|Any patient undergoing a telemedicine evaluation involving auscultation of the heart and lungs.
9954920|NCT01138605|Experimental|005|Darunavir 400 mg tablet intake of 2 tablets once daily in combination with ritonavir
9954921|NCT01138605|Experimental|006|Ritonavir Liquid formulation 80 mg/ml taken in combination with Darunavir
9954922|NCT01138605|Experimental|007|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
9954923|NCT01138605|Experimental|008|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
9954924|NCT01138605|Experimental|001|Darunavir Oral suspension 100 mg/ml 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
9954925|NCT01138605|Experimental|002|Darunavir 375 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 20 and 30 kg
9954926|NCT01138605|Experimental|003|Darunavir 450 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 30 and 40 kg
9954927|NCT01138605|Experimental|004|Darunavir 600mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight as of 40 kg
9954928|NCT01138605|Experimental|009|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
9954929|NCT01138618||CHEMPAQ-venous-CHEMPAQ-venous|The two arms only differ in order of kind of blood samples.
9954930|NCT01138618||Venous-CHEMPAQ-Venous-CHEMPAQ|The two arms only differ in order of kind of blood samples.
9954931|NCT01138631|Active Comparator|Embryoscope|
9954932|NCT01138631|No Intervention|Conventional incubator|
9954933|NCT01138670||Cardiac device group|
9954934|NCT01138683|Active Comparator|ultrafiltration group|
9954935|NCT01138683|Active Comparator|diuretics group|
9954936|NCT01138696||Stryker Dacron synthetic graft|
9954937|NCT01138696||Trevira synthetic graft|
9954938|NCT01138709|Experimental|Convexity/Vitala|For all enrolled Subjects, STAGE 1 (Days 1 - 14 equals Convex Product Wear Period followed by, for those who successfully complete Stage I, weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 15 to 21), followed by 8 hours of daily wear time per week (Day 22 to 28), followed by 12 hours of daily wear time (Days 29 to 43).
9954939|NCT01138748|Experimental|Radiation therapy|
9954940|NCT01138761|No Intervention|Physician/resident instruction|This arm is standard of care instruction given to parents/caregivers of children with atopic dermatitis by the dermatologist and/or dermatology resident during a patient visit.
9954941|NCT01138761|Active Comparator|Nurse instruction|Following the usual standard of care instruction by physician/resident (which both the treatment group and the non-treatment group will receive); the dermatology nurse will give enhanced instruction about skin care and medications to the caregivers/parents who were randomized to the treatment group.
9954942|NCT01138774|Placebo Comparator|Control group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
9954943|NCT01138774|Experimental|EPA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
9954944|NCT01138774|Experimental|Lipoic acid group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
9954945|NCT01138774|Experimental|EPA+LA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
9954946|NCT01138787|Active Comparator|Reference spread|"2250 mg PS (as PSE) in spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
9954947|NCT01138787|Placebo Comparator|Placebo spread|"regular light margarine (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
9954948|NCT01138787|Experimental|Test spread|"2250 mg PS in innovatively processed spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
9954949|NCT01138813||1|Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher
9954950|NCT01138839|Placebo Comparator|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery.
9954951|NCT01138839|Experimental|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
9954952|NCT01138852|Experimental|ampicillin-sulbactam|This is the drug used to prevent post-cesarean infection
9954953|NCT01138852|Active Comparator|cefuroxime|This drug was compared to ampicillin sulbactam for prevention of infection
9954954|NCT01138865|Other|1|Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
9954955|NCT01138865|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
9954956|NCT01138878||Patient pre-study group|A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
9954957|NCT01138878||Staff pre-study group|A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
9954958|NCT01138878||Patient intra-study group|A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
9954959|NCT01138878||Post-study staff group|A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
9954960|NCT01138891||Removed breast implants for any reason|
9954961|NCT01138904|Active Comparator|IROX arm: FOLFIRI -> FOLFOX|"IROX arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
9954962|NCT01138904|Active Comparator|OXIR arm: FOLFIRI -> FOLFOX|"OXIR arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
9954963|NCT01138930|Experimental|Berberine|
9954964|NCT01138930|Placebo Comparator|Placebo|
9954965|NCT01138943|Active Comparator|Chlorhexidine alcohol-base mouthrinse|
9954966|NCT01138943|Experimental|non alcohol chlorhexidine mouthrinse|
9954967|NCT01138956|Experimental|Group 1|Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.
9954968|NCT01138956|Active Comparator|Group 2|Pentavalent antimonial, 20mg/kg/day, 28 days
9954969|NCT01138982|Experimental|Mentoring program|Mentor and mentee meet at least every second week, for 2-4 h on every occasion, during 1 year (i.e., for a minimum of two school semesters). Meetings take place outside school and work hours, and the pairs choose activities of their own preferences. No monetary incentives exist, and the mentors are laymen volunteers. The program objective is to establish a safe and supportive relationship, by which the youth is assumed to benefit in social, emotional, and academic development, and as a consequence, be less prone to use alcohol and drugs.
9954970|NCT01138982|No Intervention|Control group|No intervention provided, only brief phone calls to control for attention bias
9954971|NCT01139034|Experimental|shoulder FES treatment|
9954972|NCT01139060|Experimental|Intervention Group|18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression
9954973|NCT01139060|No Intervention|Usual Care|
9954974|NCT01139086||Cardiovascular disease|Diagnosis of cardiomyopathy or ischemic heart disease without heart failure
9954975|NCT01139086||Chronic heart failure|Diagnosis of cardiomyopathy or ischemic heart disease LVEF <40%
9954976|NCT01139086||Control|Age and body built matched with chronic heart failure group
9954977|NCT01139099|Other|Arm|There is no arm in this study.
9954978|NCT01139138|Experimental|Panitumumab + Irinotecan + Everolimus|
9954979|NCT01139151|Experimental|Group 1 - 3 Day Thiarabine|Thiarabine 3 days in a row in each cycle.
9954980|NCT01139151|Experimental|Group 2 - 5 Day Thiarabine|Thiarabine 5 days a row in each cycle.
9954981|NCT01139177|Experimental|Stent placement|
9954982|NCT01139203|Active Comparator|lamivudine|
9954983|NCT01139203|Active Comparator|lamivudine and adefovir|
9954984|NCT01139203|Active Comparator|entecavir|
9954985|NCT01139229|Other|HE group|
9954986|NCT01139229|Other|HS group|
9954987|NCT01139229|Other|SA group|
10005376|NCT01584557|Active Comparator|Tolvaptan, Samsca|Tolvaptan, Samsca, uncoated tablet, 30 mg, once per day, up to 7 days.
9954988|NCT01139242|Other|Body & Soul nutritional intervention|This is a standardized intervention to increase fruit and vegetable consumption among church members through pastoral and peer counseling and church activities/menus.
9954989|NCT01139242|Experimental|Newsletters/peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening among church members out-of-date according to screening guidelines. For those up-to-date, promotion is of increased physical activity.
9954990|NCT01139255|Experimental|Podcasting + mobile media|
9954991|NCT01139255|Active Comparator|Podcasting|
9954992|NCT01139281|Active Comparator|Study Group|The Study Group(SG) received Ginkgo biloba extract(GBE761)(240mg/day)plus cisplatin(CDDP)
9954993|NCT01139281|Placebo Comparator|Control Group(CG)|The Control Group received Placebo plus CDDP
10005377|NCT01584557|Placebo Comparator|sugar pill|placebo, sugar pill
10005378|NCT01584570|Active Comparator|Control|fentanyl 1 mcg/kg before induction
10005379|NCT01584570|Experimental|D 0.5 group|Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium
10005380|NCT01584570|Experimental|D 1.0 group|Dexmedetomidine 1.0 ug/kg + Propofol + Sevoflurane+ Vecuronium
10005381|NCT01584583||blood pressure monitor|Cuff circumference:22cm-36cm
10005382|NCT01584583||stethoscopy|Cuff circumference: 22cm-36cm
10005383|NCT01584596|Experimental|Adapted Diet and Physical Activity|Adapted diet and physical activity guidelines sessions
10005384|NCT01584596|Active Comparator|Adapted Diet|Adapted dietary guidelines sessions
10005385|NCT01584635|Experimental|Peroral Endoscopic Myotomy (POEM)|Peroral Endoscopic Myotomy- a less invasive treatment for patients with Achalasia
10005386|NCT01584661||Compliance with nutritional care|"The Inclusion criteria comprise patients who were treated nutritionally with food enrichment supplements during their hospitalization in Bait Balev and were discharged to their homes with dietary recommendations. Participants who are willing to participate will sign an informed consent form. For patients with cognitive impairment or dementia, as reported in their medical records, their formal primary caregiver or proxy will sign the informed consent form."
10005387|NCT01584674|Experimental|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
10005388|NCT01584674|No Intervention|Control (untreated hemiface)|No treatment will be administered on the control hemiface
9803617|NCT03681912||Implementation Block 4|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 12 months.
9803618|NCT03681912||Implementation Block 5|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 15 months.
10005389|NCT01584687|Experimental|Omalizumab|All patients will receive omalizumab.
10005390|NCT01584700|Other|Renal Artery Denervation|Ontervention
10005391|NCT01584713|Experimental|Adipose derived Stem Cells|
10005392|NCT01584726|Other|magnesium sulfate arm|magnesium sulfate with standard therapy
10005393|NCT01584726|No Intervention|placebo arm|placebo with standard therapy
10005394|NCT01584739|Experimental|AZD8683|
10005395|NCT01584739|Placebo Comparator|Placebo to AZD8683|
10005396|NCT01584752||Fistula patients|Gore-BioA Fistula Plug
10005397|NCT01584765||Rechallenge|positive, negative, indeterminate and intermediate rechallenge subtypes
10005398|NCT01584765||Severe positive rechallenge|Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
10005399|NCT01584778||Behçet patients|
10005400|NCT01584778||Healthy controls|
10005401|NCT01584778||Allergic rhinitis (diseased) controls|
10005402|NCT01584791|Experimental|clopidogrel napadisilate + aspirin|
10005403|NCT01584791|Active Comparator|clopidogrel bisulfate + aspirin|
10005404|NCT01584804|Active Comparator|Monotherapy|Monotherapy with Su-Huang antitussive capsule
10005405|NCT01584804|Placebo Comparator|Sugar pill|Monotherapy with placebo
10005406|NCT01584817|No Intervention|normal education|patients in this arm was educated about bowel preparation on the day of reservation by nurse for 15 minutes and meanwhile a booklet was also sent to them.
10005407|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
10005408|NCT01584830|Experimental|Arm 1|
10005409|NCT01584830|Placebo Comparator|Arm 2|
10005410|NCT01584869|Experimental|capsule endoscopy|
10215437|NCT03703479|No Intervention|control|socket site that will not receive any intervention
10215438|NCT03703453|Experimental|REBOA|Patients undergoing REBOA for medical cardiac arrest
10215439|NCT03703427|Experimental|Capecitabine|
10215440|NCT03703427|Experimental|Vinorelbine|
10215441|NCT03703414||Control|Healthy controls
10215442|NCT03703414||ECT|MDD patients receiving ECT treatment
10215443|NCT03703414||SSRI|MDD patients receiving SSRI treatment
10215444|NCT03703401||Women with recurrent miscarriage and no hydrosalpinx|
10215445|NCT03703401||Women with recurrent miscarriage and concurrent hydrosalpinx|
10215446|NCT03703401||Women with recurrent miscarriage and treated hydrosalpinx|
10215447|NCT03703388|Experimental|Arctigenin 250mg|Arctigenin 250mg will be administered for 28 days.
10215448|NCT03703388|Experimental|Arctigenin 400mg|Arctigenin 400mg will be administered for 28 days.
10215449|NCT03703388|Experimental|Arctigenin 500mg|Arctigenin 500mg will be administered for 28 days.
10215450|NCT03703362|Experimental|Progressive resistance training|Progressive resistance training tested in patients with external snapping hip
10215451|NCT03703349|Experimental|Preoperative oral Magnesium|Magnesium sulfate 8 tablets (8 x 0.4 g) per day, PO, for the 3 days preceding the surgical intervention
10215452|NCT03703349|Placebo Comparator|Control|Placebo oral tablet, for Magnesium Sulfate tablets, PO, for the 3 days preceding the surgical intervention
9954994|NCT01139346|Experimental|oral darinaparsin|open label, single arm, dose escalation
9954995|NCT01139359|Experimental|Single Arm, darinaparsin and CHOP|open label, single arm, unblinded
9954996|NCT01139372|Experimental|FID 115958D|Lubricant eye drop
9954997|NCT01139385||clipless|laparoscopic cholecystectomy performed by harmonic scalpel with closure and division of the cystic duct only by the device
9954998|NCT01139385||traditional|laparoscopic cholecystectomy performed by harmonic scalpel with closure of the cystic duct only by titanium clip
9954999|NCT01139424|Experimental|open label treatment arm|endoscopic suturing
9955000|NCT01139437|Experimental|Adults|Adults ages 18 to 49 years of age. Open label.
9955001|NCT01139437|Experimental|Seropositive children - vaccine|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving the HPIV2 vaccine.
9955002|NCT01139437|Experimental|Seronegative infants and children - low dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of the HPIV2 vaccine.
9955003|NCT01139437|Experimental|Seronegative infants and children - standard dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of the HPIV2 vaccine.
9955004|NCT01139437|Placebo Comparator|Seropositive children - placebo|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving a placebo.
9955005|NCT01139437|Placebo Comparator|Seronegative infants and children - low dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of placebo.
9955006|NCT01139437|Placebo Comparator|Seronegative infants and children - standard dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of placebo.
9955007|NCT01139463||Antipsychotic treatment|Patients were not taking any medications - apart from the prescribed antipsychotic - for a period of 1 month prior to the study with psychotic relapse or newly diagnosed psychotic disorder were recruited from psychiatric inpatient and outpatient clinics of the Split Clinical Hospital.
9955008|NCT01139489|Active Comparator|procalcitonin-guidance|A daily advise to continue or stop antibiotics based on the measurement of the biomarker procalcitonin
9803619|NCT03681912||Sustainment Block 1 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
9955009|NCT01139489|No Intervention|standard-of-care|standard-of-care treatment of ICU infections based upon consensus guidelines and expert opinion
9955010|NCT01139502|Active Comparator|Work rehab with cognitive therapy|Work rehabilitation based on the cognitive therapeutical model
9955011|NCT01139502|Active Comparator|Work rehab with cognitive training|Work rehabilitation with the addition of weekly training of concentration, memory, and executive function
9955012|NCT01139528|Active Comparator|Operative treatment|Closed reduction of the fracture and osteosynthesis with 2-3 intramedullary K-wires (Bouquet method), cast treatment for 7-10 days followed by 5 weeks of buddy-strapping before removal of the K-pins
9955013|NCT01139528|No Intervention|Conservative treatment|No attempt of reduction of the fracture, 7-10 days of cast treatment followed by 5 weeks of buddy-strapping
9955014|NCT01139541|No Intervention|Control|Participants in the control condition will be asked to refrain from using the WalkStations during the study period.
9955015|NCT01139541|Experimental|Individual|In the individual condition, participants will not be part of a team. They will receive weekly email feedback on their Walkstation performance (e.g. number of time slots they signed up for, and number of times they showed up for the time slot.)
9955016|NCT01139541|Experimental|Pairs|In the pair condition, participants will be randomly assigned to a partner. They will receive the same feedback as those in the individual condition, for both themselves AND their partner.
9955017|NCT01139541|Experimental|Groups|In the group condition, participants will be randomly assigned to a group of 5 people. They will receive the same feedback as those in the individual condition, for both themselves AND each member of their group.
9955018|NCT01139567||Standard Care Group|Subjects who will undergo only standard wound care management.
9955019|NCT01139567||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
9955020|NCT01139593||morning dose|women undergoing IVF/ICSi taking their gonadotropin dose in the am
9955021|NCT01139593||evening dose|Women undergoing IVF/ICSI taking their gonadotropin in the evening
9955022|NCT01139606|Experimental|Vibration trainig|
9955023|NCT01139619||1|Inoperable non small cell lung cancer patients. Diagnosed between 2010-05-31 and 2009-06-01.
9955024|NCT01139645|Experimental|Proton Pump Inhibitors|patients were started on Proton Pump inhibitors for 3 months (the whole duration of the study)
9955025|NCT01139645|No Intervention|No Proton Pump Inhibitors|patients are not taking any Proton Pump Inhibitor, and they are matched by age to patients in the experimental group.
9955026|NCT01139684|Experimental|Exercise|
9955027|NCT01139697||Patients with systolic heart failure|Patients with systolic heart failure defined as ejection fraction <45%
9955028|NCT01139723|Experimental|A|
9955029|NCT01139723|Experimental|B|
9955030|NCT01139736|Experimental|Probiotics|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks. VSL#3 was selected for use in this study because (a) it contains three different Bifidobacteria strains (in addition to lactobacilli and streptococci) and the limited evidence available Bifidobacteria as the most effective probiotics in IBS .
9955031|NCT01139749|Active Comparator|Oral isotretinoin|Subjects from treatment arm will be treated with low-dose oral isotretinoin - 20 mg a day, every other day, for six months
9955032|NCT01139749|Active Comparator|salicylic acid and ciclopirox olamine|Subjects from comparison arm will be treated with topical salicylic acid and ciclopirox olamine shampoo
9955033|NCT01139788|Experimental|LY2624587|
9955034|NCT01139827||normal|normal group has no diabetes.
9955035|NCT01139827||IGT|IGT group has impaired fasting glucose or impaired glucose tolerance.
9955036|NCT01139840|Active Comparator|vitamin D2|
9955037|NCT01139840|Active Comparator|vitamin D3|
9955038|NCT01139853|Active Comparator|Nasogastric Tube|10 French Nasogastric Tube inserted before surgery
9955039|NCT01139853|No Intervention|No Nasogastric Tube|
9955040|NCT01139866||Group 1: SABER™-Bupivacaine|Received 5.0 mL SABER™-Bupivacaine in previous C803-017 trial
9955041|NCT01139866||Group 2: SABER™-Placebo|Received 5.0 mL SABER™-Placebo in previous C803-017 trial
9955042|NCT01139892||Surgical management|Surgical clipping will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, bypasses, and other flow-redirecting treatments that do not directly clip the aneurysm will not be included.
9955043|NCT01139892||Endovascular management|Endovascular treatment will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling or stents, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
9955044|NCT01139905|Other|1|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour
9955045|NCT01139918||Cohort A|40 patients with moderate psoriatic arthritis and moderate psoriasis
9955046|NCT01139918||Cohort B|40 patients with mild psoriatic arthritis and moderate psoriasis
9955047|NCT01139918||Cohort C|40 patients with moderate psoriatic arthritis and mild psoriasis
9955048|NCT01139944||Group 1|Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
9955049|NCT01139957||Ancillary-correlative|Patients complete the Health Update Questionnaire annually for up to 5 years. The questionnaire focuses specifically on cancer risk, incidence, and mortality. Patients also receive ongoing communication (e.g., periodic newsletters, copies of study-related publications, etc.) to keep them informed regarding study-related research results, new research findings, new research opportunities for which patients may be eligible, and evolving clinical recommendations regarding hereditary breast/ovarian cancer.
9955050|NCT01140009|Placebo Comparator|Group 1|FLuviral 2010/11Tri-valent Seasonal Influenza Vaccine (TIV)1st; saline placebo 10 days later
9955051|NCT01140009|Placebo Comparator|Group 2|Saline placebo 1st; Fluviral 2010/11 Tri-valent Seasonal Influenza Vaccine (TIV)10 days later
9955052|NCT01140022||Female Patients 18-25 yo|Female patients aged 18-25 who have come to one of the ED or urgent care sites for care, regardless of the presence of CT symptoms.
9955053|NCT01140035|Experimental|Intensive insulin therapy|"Intensive insulin therapy with goal of glucose < 150 mg/dl~Control group with standard insulin therapy with goal of glucose 180 mg/dl"
9955054|NCT01140074|Experimental|Zinc sulfate|Children in active treatment group will be given zinc sulfate 10-20 mg per day orally plus probiotics
9955055|NCT01140074|Placebo Comparator|Placebo|Children will be given placebo plus probiotics
9955056|NCT01140087|Experimental|Interventional|Face Transplantation
9955057|NCT01140100|Active Comparator|propofol-propofol|
9955058|NCT01140100|Experimental|thiopental-propofol|
9955059|NCT01140113|No Intervention|Placebo|this group had undergone to routine coronary artery bypass graft surgery
9955060|NCT01140113|Experimental|Modified Ultrafiltration|patients after weaning from bypass were submitted to ultrafiltration
9955061|NCT01140126|Experimental|Antibody (UB-421)|
9955062|NCT01140139|Experimental|HIV DNA + Hydroxyurea|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption. The patients also received 500 mg of hydroxyurea daily.
9955063|NCT01140139|Experimental|HIV DNA|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
9955064|NCT01140139|Placebo Comparator|Placebo|PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
9955065|NCT01140152||No rejection|Intestinal transplant recipients with no evidence of biopsy proven rejection
9955066|NCT01140152||Rejection|Intestinal transplant recipients who had evidence of biopsy proven rejection
9955067|NCT01140165|Active Comparator|butter|Danish butter
9955068|NCT01140165|Experimental|cheese|
9955069|NCT01140178|Experimental|HPPH|a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.
9955070|NCT01140204|Placebo Comparator|Placebo control|Contrast medium without Paclitaxel
9480674|NCT05262062|Experimental|Integrated Neuromuscular Inhibition Technique|"1. Group c will receive Combination of exercise (strain counter strain , muscle energy & ischemic compression. In ischemic compression patient will receive compression,2. After MTrPs identification, 3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright."
9955071|NCT01140204|Active Comparator|Iopromide Paclitaxel 0.85 mg|Iopromide Paclitaxel 0.85 mg
9955072|NCT01140204|Active Comparator|Iopromide Paclitaxel 4.27 mg|Iopromide Paclitaxel 4.27 mg
9955073|NCT01140204|Active Comparator|Iopromide Paclitaxel 8.54 mg|Iopromide Paclitaxel 8.54 mg
9955074|NCT01140204|Active Comparator|Iopromide Paclitaxel 17.08 mg|Iopromide Paclitaxel 17.08 mg
9955075|NCT01140243|Experimental|test product|Dietary supplement
9955076|NCT01140243|Active Comparator|standart|Dietary supplement
9955077|NCT01140256||SGA infants|SGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
9955078|NCT01140256||AGA|AGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
9955079|NCT01140256||SGA infant|Infants who were born small for gestational age were recruited and zinc stable isotopes were administered at birth and at 6 months.
9955080|NCT01140269|No Intervention|No PCR testing|Control patients will not have PCR testing. This group will have routine testing and treatment as defined by the standard of care.
9955081|NCT01140269|Experimental|PCR testing|PCR will be used in parallel with routine laboratory tests such as culture. Treatment for PCR results will be based on the standard of care. Treatment of the patient will be dependent on the physician's clinical judgment based on existing clinical information including PCR, microbiology, patient physical presentation, and other laboratory results.
9955082|NCT01140282|Active Comparator|Arm I (Control)|Patients refrain from increasing physical activity levels for 16 weeks.
9955083|NCT01140282|Experimental|Arm II (Exercise)|Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.
9955084|NCT01140308|Placebo Comparator|Sugar Pill|Simvastatin 20mg + Placebo
9955085|NCT01140308|Active Comparator|Co Q10|Simvastatin 20mg + CoQ10
9955086|NCT01140321|Experimental|Neridronato|Thalassemia Major or Severe Thalassemia Intermedia
9955087|NCT01140321|No Intervention|Placebo|Thalassemia Major or Severe Thalassemia Intermedia
9955088|NCT01140334|Experimental|Reinforced On-Site Integrated Care (ROIC)|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
9955089|NCT01140334|Active Comparator|Standard On-Site Integrated Care (SOIC).|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week.
9955090|NCT01140373|Experimental|autologous T cells & cyclophosphamide.|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells targeted to Prostate-Specific Membrane Antigen (PSMA) administered one day after pretreatment with cyclophosphamide.
9955091|NCT01140386||hospital pediatric patients 1/1/2000-12/31/2008 documented VTE|Age <18 Hospitalized for greater than or equal to 24 hours VTE documented during hospital admission
9955092|NCT01140399|Active Comparator|Infusional drug treatment|Diuretics or diuretics plus fixed low dose dopamine infusion
9955093|NCT01140399|Experimental|Ultrafiltration|Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion
9955094|NCT01140412|Experimental|Cohort 1|Twice daily regimen
9955095|NCT01140412|Experimental|Cohort 2|Once daily regimen
9955096|NCT01140425|Experimental|PF-00232798 supratherapeutic dose|PF-00232798 supratherapeutic dose
9955097|NCT01140425|Experimental|PF-00232798 therapeutic dose|PF-00232798 therapeutic dose
9803620|NCT03681912||Sustainment Block 2 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
9955098|NCT01140425|Placebo Comparator|Placebo for PF-00232798|Placebo for PF-00232798
9955099|NCT01140425|Active Comparator|Moxifloxacin|Moxifloxacin
9955100|NCT01140438|Active Comparator|Metformin + NPH Insulin|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization insulin treatment will be added in the form of injections of NPH insulin in the evenings.
9955101|NCT01140438|Active Comparator|Metformin + sitagliptin +/-repaglinid|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is > 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
10215453|NCT03703310|Experimental|Patidegib Topical Gel, 2%,|Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
10215454|NCT03703310|Placebo Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
10215455|NCT03703284||LHI Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
10215456|NCT03703284||LHI Non-Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
10215457|NCT03703284||Healthy control|Healthy individuals
10215458|NCT03703271|Active Comparator|chemotherapy|Methotrexate 0.4mg/kg·d, im ,*5d started at the first day of cycle, two weeks a cycle
10215459|NCT03703271|Experimental|study group|hysteroscopic repeat curettage
10215460|NCT03703258|Experimental|Intervention|"The THRIVE app involves 3 weeks of daily activities. Day 1 involves identification of activities to add to a self-care activity list with guidance around selecting activities that increase social contact, reduce alcohol use, and reduce avoidance. They will also complete an active-learning exercise about cognitive distortions and create a stuck point to-do list consisting of their cognitive distortions. In subsequent days, participants will be prompted to complete activities from both lists. They will also have access optional activities on topics such as asking for help, preventing isolation, deciding whether to disclose an assault, coping with negative reactions to disclosure, and thinking in helpful ways about social support. They will be prompted to complete brief daily surveys in the app, which will populate a symptom tracker. Participants in will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use."
10215461|NCT03703258|No Intervention|Assessment-only control|The assessment-only control condition will involve access to a version of the app that includes daily surveys and a symptom tracker populated by these surveys, but without any of the other exercises included in the experimental version of the app. Participants in the control condition will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use.
10215462|NCT03703245||Experimental Dentifrice|Participants were advised to brush their teeth twice daily with a full strip of experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies covering the entire head of the toothbrush for 1 minute.
10215463|NCT03703245||Control Dentifrice|Participants were advised to brush their teeth with control dentifrice containing 0% w/w sodium bicarbonate covering the entire head of the toothbrush for 1 minute.
10215464|NCT03703232|Other|Lower extremity amputees|Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.
10215465|NCT03703219||Mother Touch Program|Forty days of rest period of the mother after delivery, Full body massage, diet and belly binding methods were administered by trained carer.
10215466|NCT03703219||Usual care Program|comparison cohort were followed in usual care under the supervision of health professionals.
10215467|NCT03703206|Experimental|ACB + iPACK|Patients scheduled for TKA will be randomized to receive an adductor canal block with an additional ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK).
10215468|NCT03703206|No Intervention|ACB w/o iPACK|Patients enrolled in this arm will receive the standard of care adductor canal block (ACB) prior to their total knee arthoplasty.
9955102|NCT01140451|Experimental|Ataluren/Ataluren|Participants who received double-blind ataluren during Study 009 will continue to receive open-label ataluren 3 times per day TID: 10 milligram (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
9955103|NCT01140451|Experimental|Placebo/Ataluren|Participants who received double-blind placebo during Study 009 will receive open-label ataluren TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
9955104|NCT01140464|Active Comparator|Enhanced Usual Care|Usual care treatment of depression in primary care settings. Usual care considered enhanced as patients and their parents were given screening results and encouraged to seek care from their primary care doctor and behavioral health services.
9955105|NCT01140464|Active Comparator|Collaborative Care|Collaborative care intervention for depression. Involves care management, evidence based treatments in primary care setting, symptom monitoring and stepped care design
9955106|NCT01140490|No Intervention|Sub-total Parathyroidectomy|
9955107|NCT01140529|Experimental|Dexmedetomidine|
9955108|NCT01140529|Active Comparator|Haloperidol|
9955109|NCT01140529|Placebo Comparator|Placebo|
9955110|NCT01140542|Active Comparator|Roflumilast|500µg, once daily
9803621|NCT03681912||Sustainment Block 3 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
9955111|NCT01140542|Placebo Comparator|Placebo|
9955112|NCT01140555|Experimental|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
9955113|NCT01140581|Experimental|Group A|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks followed by dronedarone 400 mg twice daily for 8 weeks
9955114|NCT01140581|Experimental|Group B|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Two weeks wash-out followed by dronedarone 400 mg twice daily for 6 weeks
9955115|NCT01140581|Experimental|Group C|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Four weeks wash-out followed by dronedarone 400 mg twice daily for 4 weeks
10005411|NCT01584882|No Intervention|Control (Usual care)|Return patients seen within the data collection window in HealthPartners Dental Clinics (new patient exams were excluded) who were documented as using tobacco, specifically cigarettes, at their last dental encounter. Randomization was at the clinic level.
9955116|NCT01140607|Experimental|Cohort 1: normal hepatic function: cabazitaxel|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
9955117|NCT01140607|Experimental|Cohort 2: mild hepatic impairment : cabazitaxel|"cabazitaxel 20mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
9955118|NCT01140607|Experimental|Cohort 3: moderate hepatic impairment: cabazitaxel|"cabazitaxel 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
9955119|NCT01140607|Experimental|Cohort 4: severe hepatic impairment: cabazitaxel|"cabazitaxel 5 mg/m^2 or 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
10215469|NCT03703193|Experimental|Dry needling|The experimental group will receive a single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
10215470|NCT03703193|Active Comparator|Physical Therapy|This group will receive a single session of modulatory interventions targeting modulation of central nervous system.
10215471|NCT03703180||MS|representative cohort of relapsing-remitting MS (n=50) and progressive MS patients (n=50) over the typical age range of 18-65. During two years of follow-up the integrity and function of the visual system will be observed annually with optical coherence tomography, high and low contrast visual acuity and a vision related quality of life questionnaire.
10215472|NCT03703180||Controls|Age and Gender matched healthy controls (n=100) will undergo the same assessments as the MS cohort to build up a representative normative dataset.
10215473|NCT03703167|Experimental|ibrutinib in combination with rituximab and lenalidomide|Ibrutinib will be given day 1-28; Lenalidomide will be given day 1-21; Rituximab will be given on day 1. Rituximab is given for 6 cycles; Lenalidomide is given for 12 cycles; Ibrutinib is continued until disease progression, intolerable toxicity or death.
10215474|NCT03703154||Study Arm|The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
10215475|NCT03703154||Control Arm|Patients in the control arm will remain on the immediate release Tacrolimus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
10215476|NCT03703141|Experimental|Sucralose 48 mg|Sucralose 48 mg in 60 ml of water O.D. for ten weeks
10215477|NCT03703141|Experimental|Sucralose 96 mg|sucralose 96 mg in 60 ml of water O.D. for ten weeks
10215478|NCT03703141|Placebo Comparator|Placebo|60 ml of water as placebo O.D. for ten weeks
10215479|NCT03703115|Active Comparator|Fasting|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet with 2-3 litres of water and non calorie fluids allover the day."
10215480|NCT03703115|No Intervention|Nonfasting|Patients will have usual balanced diet as 3 meals and 2 snacks all over the day. Both groups should take adequate water and non calorie beverages intake daily ( 2-3 liters daily)
10215481|NCT03703089|Experimental|Gemcitabine and Nab-Paclitaxel|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
9955120|NCT01140607|Experimental|Cohort 5: normal hepatic function: cabazitaxel and midazolam|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).~Midazolam is given orally in single dosing on day -1 and day 1 (crossover)"
9955121|NCT01140620|Experimental|ketamine and risperidone|Oral risperidone pretreatment and intravenous ketamine infusion
9955122|NCT01140620|Active Comparator|ketamine and placebo|Oral placebo risperidone pretreatment and intravenous ketamine infusion
9955123|NCT01140620|Active Comparator|saline and risperidone|Oral risperidone pretreatment and intravenous saline infusion
9955124|NCT01140620|Placebo Comparator|saline and placebo|Oral placebo risperidone pretreatment and intravenous saline infusion
9955125|NCT01140620|No Intervention|Patients with Schizophrenia|Patients with schizophrenia will not receive study drug and will not undergo randomisation.
9955126|NCT01140659|Other|Objective measurement of sweat|"We selected 40 patients from February 2007 to May 2009. All participants were randomized into two groups of 20 patients (G3 and G4) and underwent the sympathectomy, being followed for 12 months. We used an objective method for measuring sweat, checking the TEWL (transepidermal water loss) measured by the VapoMeter, and evaluated the quality of life before and after the operation. Also studied were: incidence and intensity of the compensatory hyperhidrosis."
9955127|NCT01140672|Experimental|Cohort 1 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
9955128|NCT01140672|Experimental|Cohort 2 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
9955129|NCT01140672|Experimental|Cohort 3 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)
9955130|NCT01140672|Experimental|Cohort 4 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)
9955131|NCT01140672|Experimental|Cohort 5 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)
9955132|NCT01140672|Experimental|Cohort 6 (N=10) Optional cohort|Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)
9955133|NCT01140698||Term and preterm newborn infants|5 infants of each gestational age of 24-42 weeks
9955134|NCT01140711|Experimental|Gastric bypass|Patients submitted to gastric bypass for treatment of morbid obesity
9955135|NCT01140711|Experimental|Sleeve gastrectomy|Patients submitted to sleeve gastrectomy for treatment of morbid obesity
9955136|NCT01140737|Experimental|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily.
9955137|NCT01140763||Sysmex's 5-blade cutter.|
9955138|NCT01140776||OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
9955139|NCT01140789||Crohn's disease patients|Diagnosis of Crohn's disease by endoscopy, radiology and histology
9955140|NCT01140789||Ulcerative colitis patients|Diagnosis of ulcerative colitis defined by endoscopy, radiology and histology
9955141|NCT01140789||Non-IBD patients|Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.
9955142|NCT01140802||IBD patients|Crohn's disease or ulcerative colitis patients
9955143|NCT01140802||Healthy controls (non-IBD)|Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
9955144|NCT01140802||Relatives of IBD patients|They will be a first degree relative of a IBD patient.
9955145|NCT01140828|Active Comparator|Rabeprazole|Rabeprazole
9955146|NCT01140828|Placebo Comparator|Rabeprazole Placebo|Rabeprazole Placebo
9955147|NCT01140841||Fipamezole ODT|
9955148|NCT01140841||Placebo|
9955149|NCT01140854||Hypertension (case)|Elderly patients 60 years old or older undergoing simple lumbar spine surgery under general anesthesia will receive neurologic/neuropsychometric examinations.
9955150|NCT01140854||Normotension (control)|Middle-aged patients (40-60 years) undergoing simple lumbar spine surgery under general anesthesia as controls to compare their performance to those patients >60 years - will also receive neurologic/neuropsychometric examinations.
9955151|NCT01140893|Experimental|exenatide|55 subjects
9955152|NCT01140893|Placebo Comparator|Placebo|55 subjects
9955153|NCT01140932|Experimental|Intervention|Medical and behavioural intervention
9955154|NCT01140945||Males attending in vitro fertilization clinic|
9955155|NCT01140971|Active Comparator|Misoprostol|Use 25 micrograms vaginal every 6 hours (max dosis 200 micrograms in 48 hours)
9955156|NCT01140971|Active Comparator|Foley|Foley catheter number 14 or 16 was installed intracervical for no more than 48 hours.
9955157|NCT01140984|Experimental|treatment|
9955158|NCT01140997|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
9955159|NCT01140997|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
9955160|NCT01140997|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
9955161|NCT01140997|Active Comparator|Group 4|Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d
9955162|NCT01141010|Sham Comparator|Plain language|Conventional plain language will be given without any psychological intervention
9955163|NCT01141010|Active Comparator|Pre-psycho-language|Prior surgery psychological linguistic intervention
9955164|NCT01141010|Active Comparator|Intra-psycho-language|Intraoperative psychological linguistic intervention
9955165|NCT01141010|Active Comparator|Post-psycho-language|Postoperative psychological linguistic intervention
9955166|NCT01141010|Active Comparator|Combined language|Psychological linguistic intervention will be given in a combination of pre-, intra- and post-operatively
9955167|NCT01141023|Experimental|Datscan SPECT Imaging|Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
9955168|NCT01141036|Active Comparator|propofol|propofol
9480675|NCT05262049|Experimental|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
9803622|NCT03681912||Sustainment Block 4 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
9955169|NCT01141036|Active Comparator|Midazolam|Midazolam
10005412|NCT01584882|Experimental|Tobacco Cessation Tool (CATI Tool)|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a 'CATI'[Computer Assisted Tobacco Intervention] tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
10005413|NCT01584895|Experimental|Rehab|Patients randomized into early cardiac rehabilitation
10005414|NCT01584895|No Intervention|Control|No cardiac rehabilitation until after 6 week post assessment.
10215482|NCT03703063|Experimental|Resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
10215483|NCT03703063|Experimental|Borderline resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
10215484|NCT03703050|Experimental|Cohort 1|Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
10215485|NCT03703050|Experimental|Cohort 2|Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
10215486|NCT03703037||Cohort|"This will be a nested case-control study. Women with low risk pregnancies at or beyond 41 weeks, who will be referred to our Maternal-fetal unit and admitted 1 to 2 days prior to induction of labour according institutional protocol will constitute the cohort.~Then women with intrapartum abnormal fetal heart rate tracings (cases) will be identified and match with controls. The primary outcome will be to obtain odds ratios for the Doppler ultrasound parameters (middle cerebral artery pulsatility index, mean uterine artery pulsatility index and Middle cerebral artery pulsatility index to mean uterine artery pulsatility index ratio) and Ultrasound assessment of amniotic fluid index that would be associated with intrapartum category III fetal heart rate tracing."
10215487|NCT03703037||Cases|"Cases will be patients with abnormal intrapartum cardiotocogram (category III fetal heart rate tracing).~Intervention: Ultrasound and Doppler ultrasound"
10215488|NCT03703037||Controls|"Those will be patients with normal intrapartum cardiotocogram (category I fetal heart rate tracing) or category II that converted into category I after intrauterine resuscitation methods.~Intervention: Ultrasound and Doppler ultrasound"
10215489|NCT03703024|Placebo Comparator|Placebo|Maltodextrin
10215490|NCT03703024|Active Comparator|Low dose|200mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
10215491|NCT03703024|Active Comparator|High dose|400mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
9955170|NCT01141062|Experimental|Treated leiomyomas|Philips MR-guided HIFU
9955171|NCT01141088|Experimental|Bilateral stent-in-stent insertion|The passage of the bilateral metal stent across the stricture, stent-in-stent method.
9955172|NCT01141088|Active Comparator|Bilateral side-by-side insertion|The passage of the bilateral metal stent across the stricture, side-by-side method.
9955173|NCT01141101||MRSA-exposed|The MRSA-exposed group will include 100 MRSA-colonized mothers and their babies
9955174|NCT01141101||MRSA-unexposed|The MRSA-unexposed group will include 100 MRSA-negative mothers and their babies.
9955175|NCT01141114|Experimental|Use of a Patient Navigator|
9955176|NCT01141114|Other|Usual Care|No Intervention - usual care
9955177|NCT01141127|Active Comparator|INTERMITENT ADMINISTRATION|Administration of 10 mg/kg of Tranexamic Acid at the beginning ,the middle and at the end of the intervention
9955178|NCT01141127|Experimental|continuous administration of Tranexamic Acid|Administration of 10 mg /Kg of Tranexamic Acid at the beginning in the priming pump and continuous infusion of 1 mg/KG of Tranexamic Acid until the end of the intervention
9955179|NCT01141140|Other|M-NO-NR|Men (M) non-obese (NO) and non-restrained (NR).
9955180|NCT01141140|Other|M-NO-R|Men (M) non-obese (NO) and restrained (R).
9955181|NCT01141140|Other|M-O-NR|Men (M) overweight or obese (O) and non-restrained (NR).
9955182|NCT01141140|Other|M-O-R|Men (M) overweight or obese (O) and restrained (R).
9955183|NCT01141140|Other|W-NO-NR|Women (W) non-obese (NO) and non-restrained (NR).
9955184|NCT01141140|Other|W-NO-R|Women (W) non-obese (NO) and restrained (R).
9955185|NCT01141140|Other|W-O-NR|Women (W) overweight or obese (O) and non-restrained (NR).
9955186|NCT01141140|Other|W-O-R|Women (W) overweight or obese (O) and restrained (R).
9955187|NCT01141153|Experimental|Oral anticoagulation plus dual antiplatelet therapy|
9480676|NCT05262049|Experimental|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~Hot pack /TENS for 10 minutes~Stretching: Hamstring(10x) and calf (10x)~Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
9955188|NCT01141153|Active Comparator|Dual antiplatelet therapy|
9955189|NCT01141166|Experimental|nutritional and physical rehabilitation plan|
9955190|NCT01141179|Experimental|LEO 27847|
9955191|NCT01141192|Active Comparator|Vitamin D3 supplement|60,000 IU vitamin D3 oral supplement provided every four weeks at weeks 0, 4, 8, and 12 in the form of one 50,000 and two 5,000 IU vitamin D3 supplements in gelcap form.
9955192|NCT01141192|Placebo Comparator|Sugar Pill|Inactive placebo tablets identical in appearance to the active comparator provided every four weeks at weeks 0,4,8,and 12.
9955193|NCT01141218||Never-smokers with lung cancer|
9955194|NCT01141244|Experimental|Treatment (temsirolimus, irinotecan, temozolomide)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and temozolomide PO and irinotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
9955195|NCT01141257|Experimental|Angiocal®|Angiocal®
9955196|NCT01141270|Experimental|AFOLIA|225 IU sc
9955197|NCT01141270|Active Comparator|Gonal-f|225 IU sc
9955198|NCT01141296|Active Comparator|Fenofibrate|
9955199|NCT01141296|Placebo Comparator|sugar pill|
9955200|NCT01141309|Experimental|sorafenib with everolimus|This is a two-stage phase II study combining sorafenib with everolimus in patients with thyroid cancer.
9955201|NCT01141322|Experimental|UDCA treatment|Patients with drug-induced liver injury will be randomly allocated to UDCA treatment group: oral intake ursodeoxycholic acid (UDCA) 13-15 mg/kg BW/day into 3 divided doses after meal till the endpoint or the 8th week. UDCA is 100 mg per tab.
9955202|NCT01141322|Placebo Comparator|Placebo|Patients with drug-induced liver injury will be randomly allocated to placebo group. The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
9955203|NCT01141335|Experimental|PTFE mesh|A Lichtenstein tension-free hernioplasty is performed using PTFE mesh
9955204|NCT01141335|Active Comparator|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using polypropylene mesh
9955205|NCT01141348|Experimental|Special Intervention|
9955206|NCT01141348|Experimental|Delayed Intervention|
9955207|NCT01141361||Peripheral arterial disease patients|Patients with a peripheral arterial disease, defined by an ankle to brachial index below 0.90
9955208|NCT01141387||Patients at the intervention sites|The intervention sites will receive the results of the patient-reported depression severity collected during the phone interviews on a monthly basis. The patients in the intervention arm will be interviewed by phone once per month for 6 months.
9955209|NCT01141387||Patients at the usual care sites|The usual care sites will receive the results of the patient-reported depression severity at the end of the study. Patients in the usual care arm will be interviewed at 3 months and 6 months post study enrollment.
9955210|NCT01141400||depression & initial prescription for an antidepressant|A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
9955211|NCT01141413||RA patients using Remicade®|
9955212|NCT01141413||RA patients using Orencia®|
9955213|NCT01141426|Active Comparator|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
9955214|NCT01141426|Experimental|Intensive Short-Term Dynamic Psychotherapy (ISTDP) Group|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
9955215|NCT01141439||IPDI HFA-BDP MDI|Patients who commenced inhaled corticosteroid therapy as HFA-BDP via MDI
9955216|NCT01141439||IPDI FP MDI|Patients who commenced inhaled corticosteroid therapy as FP via MDI
9955217|NCT01141439||IPDA FP MDI|Patients who had a step up in inhaled corticosteroid therapy as FP via MDI
9955218|NCT01141439||IPDA HFA-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as HFA-BDP via MDI
9955219|NCT01141439||IPDI CFC-BDP MDI|Patients who commenced inhaled corticosteroid therapy as CFC-BDP via MDI
9955220|NCT01141439||IPDA CFC-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as CFC-BDP via MDI
9955221|NCT01141452||IPDA FP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as fluticasone via metered dose inhaler
9955222|NCT01141452||IPDA HFA-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as extra-fine hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
9955223|NCT01141452||IPDA CFC-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
9955224|NCT01141452||IPDI CFC-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
9955225|NCT01141452||IPDI HFA-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
9955226|NCT01141452||IPDI FP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as fluticasone propionate via metered dose inhaler
9955227|NCT01141465||IPDA FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at ≥twice the equivalent BDP-equivalent dose
9476554|NCT03570723|Active Comparator|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
9476555|NCT03570723|Experimental|A glove-loaded Foley's catheter|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
9476556|NCT03570710|Placebo Comparator|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
9955228|NCT01141465||IPDA FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at ≥twice the equivalent BDP-equivalent dose
9955229|NCT01141465||IPDI FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at equivalent BDP-equivalent dose
9955230|NCT01141465||IPDI BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at equivalent BDP-equivalent dose
9955231|NCT01141465||IPDI FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at equivalent BDP-equivalent dose
9955232|NCT01141465||IPDA BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at ≥twice the equivalent BDP-equivalent dose
9955233|NCT01141504|Placebo Comparator|Placebo|Oral placebo capsules similar in color and size to the intervention
9955234|NCT01141504|Active Comparator|PeakATP 250|Oral supplement capsules containing 250 mg/day of PeakATP
9955235|NCT01141504|Active Comparator|PeakATP 400|Oral supplement capsules containing 400 mg/day of PeakATP
9955236|NCT01141504|Active Comparator|PeakATP 400 plus proprietary blend|Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
9955237|NCT01141530||Tissue Bank Samples|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study. All samples studied will be obtained through the UAMS Tissue Bank.
9955238|NCT01141543||cohort 1|Patients in Cohort 1 will be followed with daily Flowcytometric studies to quantify CXCR4 positive cells.The samples will be obtained before the following doses of FLUDARABINE and BUSULFAN. Eighteen hrs (range 18 -20 hrs) after start of the last dose of FUDARABINE andBUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR
9955239|NCT01141543||Cohort 2|Patients in Cohort 2 will receive the second dose of PLERIXAFOR 24 hrs after the first dose. A PB sample for a CBS and Flowcytometry will be drawn prior to the dose. Nine hrs later a further study sample for Flowcytometry will be obtained prior to administration of the second dose of FLUARABINE and BUSULFAN. Flowcytometric studies will be repeated on day 3 and 4. Eighteen hrs (range 18 - 20 hrs) after start of the last dose of FLUDARABINE and BUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR.
9955240|NCT01141543||cohort 3|Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN
9955241|NCT01141543||Cohort 4|Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
9955242|NCT01141556|Placebo Comparator|Placebo|Placebo (NaCl) i.v. intraoperatively, followed by an daily bolus of Placebo (NaCl) i.v. until discharge from ICU (no longer than 13 days)
9955243|NCT01141556|Active Comparator|Selenase|Selenase Bolus 4000 microgram i.v. intraoperatively, followed by an daily bolus of Selenase 1000 microgram i.v. until discharge from ICU (no longer than 13 days)
9955244|NCT01141699||female|Women who live in the Shuang Ho Region of Taipei City. Women can read and write chinese language.
9955245|NCT01141738|Experimental|Caregiver Problem-Solving Intervention|The experimental treatment will provide structured information, guided problem-solving, and training in skills for coping with stress and emotional responses (e.g., relaxation, cognitive reframing, changing negative problem orientation, PS skills).
9955246|NCT01141738|Other|Wait List Control|WLC subjects will be offered an intervention after the 6 month assessment. Both groups will receive standard services provided by the rehabilitation team to CGs of stroke survivors.
9955247|NCT01141764|Experimental|Study Group|"In our study, patients will be scanned with their DBS electrodes turned on and off.~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.~Procedures performed in this study are not part of the standard management of epilepsy."
9955248|NCT01141777|Active Comparator|Spirulina platensis|
9803623|NCT03681912||Sustainment Block 5 Facilitated CoP|Randomized Guided Development of CoPs with an internal facilitator after one year of implementation.
9955249|NCT01141777|Placebo Comparator|Soya bean|
9955250|NCT01141790|Placebo Comparator|Silence|"The control group listened silence and was evaluated the same things."
9955251|NCT01141803|No Intervention|control|
9955252|NCT01141803|Active Comparator|Apples|
9476557|NCT03570710|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
9955253|NCT01141803|Active Comparator|Apple pomace|
9955254|NCT01141842|Experimental|lung cancer|breath samples of patients with confirmed lung cancer
9955255|NCT01141842|Active Comparator|underlying lung disease|patients with underlying lung disease and impairment in lung function
9955256|NCT01141842|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
9955257|NCT01141855|Experimental|Champix plus counselling|varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service
9955258|NCT01141855|Active Comparator|counselling alone|5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).
9955259|NCT01141868|Experimental|Internet Intervention|
9955260|NCT01141868|Experimental|Delayed Intervention|Receive access to the online Internet intervention after completing post-assessments.
9955261|NCT01141881|Experimental|TPA,IVB,F/U|
9955262|NCT01141894|Active Comparator|Routine fluid treatment|Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
9955263|NCT01141894|Experimental|Goal directed haemodynamic treatment|Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
9480677|NCT05262049|Experimental|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy andintermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
9955264|NCT01141920|Active Comparator|3-month counseling induction: routine care|Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
9955265|NCT01141920|Experimental|3-month counseling induction: low threshold|Participants assigned to this treatment arm will receive low threshold counseling. These participants will be scheduled to attend one counseling session per month with their individual counselor for the first 3-months. Participants can attend more counseling sessions if they desire, and they can meet with program supervisors to address crisis situations. They can receive methadone dosing any time during the clinic hours (7:30 am-1:15 pm and 4:00 pm - 6:00 pm)
9955266|NCT01141933|Other|Usual care|Subjects in this group receive the usual treatment only.
9955267|NCT01141933|Experimental|Individual intervention|Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.
9955268|NCT01141933|Experimental|Group intervention|Consisting in a 12 weekly sessions with two therapists. Number of subjects in each group is from 5 to 10. Each session lasts 2 hours.
9955269|NCT01141972|Active Comparator|Supplement|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency
9955270|NCT01141972|Placebo Comparator|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
9955271|NCT01141985|Other|Treated|This is a single arm study.
9955272|NCT01141998|Placebo Comparator|Placebo|
9955273|NCT01141998|Active Comparator|Vitamin D administered orally|
9955274|NCT01141998|Experimental|Vitamin D administered via UVB|
9955275|NCT01142011|Experimental|Belimumab|"The first cycle of Belimumab is a loading cycle of 3 doses over 28 days (days 1, 15, 29).~After the first cycle, additional cycles of belimumab will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles)."
9955276|NCT01142024|Placebo Comparator|saline|saline hydration
9955277|NCT01142024|Experimental|Glutathione|
9955278|NCT01142037|Experimental|Furanocoumarin|Includes participants first refraining from eating foods with furanocoumarins for one week, followed by 2 weeks of increasing furanocoumarin consumption. Participants will be asked to consume cooked parsnips and parsley.
9955279|NCT01142063||Treatment A (Reference fasted)|Treatment A (Reference fasted): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fasted condition.
9955280|NCT01142063||Treatment B (Test fasted)|Treatment B (Test fasted): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fasted condition.
9955281|NCT01142063||Treatment C (Reference fed)|Treatment C (Reference fed): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fed condition.
9955282|NCT01142063||Treatment D (Test fed)|Treatment D (Test fed): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fed condition.
9955283|NCT01142076|Placebo Comparator|placebo|Dose treatment group, 10%
9955284|NCT01142076|Active Comparator|Xinju Xiaogao Prescription|treatment group
9955285|NCT01142102|Experimental|Arm 1|Radiation Therapy
9955286|NCT01142141|Other|Manual therapy, kinesiotherapy|
9955287|NCT01142154|Experimental|oral, liquid solution|
9955288|NCT01142167|Active Comparator|Standard Colonoscopy|Colonoscopy with standard instrument
9955289|NCT01142167|Experimental|Ultra-thin colonoscopy|New prototype scope
9955290|NCT01142180|Active Comparator|TAE group|Patients will be undergone TAE after endoscopic hemostasis.
9955291|NCT01142180|Active Comparator|No TAE group|No TAE procedure will be performed after endoscopic treatment.
9480678|NCT05262036|Experimental|Anti-aging Supplement|Mixture (powder) of NOVOS Core (12 ingredients) + NOVOS Boost (NMN)
9955292|NCT01142206|Active Comparator|Physical Activity|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week.
9955293|NCT01142206|Experimental|Physical Activity & TV Watching|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week and an additional prescription of reducing TV watching to 10 hours per week or less.
9480679|NCT05262036|Placebo Comparator|Placebo excipients|All excipients in powder WITHOUT NOVOS Core
9955294|NCT01142219|Experimental|L-arginine|0.1g/kg/day for 6 months
9955295|NCT01142245|Active Comparator|oral esomeprazole|"Esomeprazole placebo IV loading bolus~Esomeprazole placebo intravenous infusion for 72 hours~Oral Esomeprazole: 80 mg/Day on Day 1, 2 and Day 3, and the drug will be given as 40 mg q12h."
9955296|NCT01142245|Active Comparator|Intravenous Esomeprazole|"Esomeprazole IV loading bolus 80mg~• Esomeprazole intravenous infusion 8mg/hr for 72 hours"
9955297|NCT01142258|Experimental|Trazodone|Study group will receive trazodone 50mg
9955298|NCT01142258|Placebo Comparator|Placebo|Inert pill
9955299|NCT01142271|Experimental|Billroth-I|Patients in this group should be underwent gastroduodenostomy as reconstruction procedure after standard distal subtotal gastrectomy with lymph node dissection.
9955300|NCT01142271|Experimental|Roux en Y|Patients in this group should be underwent jejunojejunostomy and gastrojejunostomy as reconstruction procedure after standard distal gastrectomy.
9955301|NCT01142284|Placebo Comparator|Placebo|Placebo
9955302|NCT01142284|Experimental|Cilostazol|cilostazol
9955303|NCT01142284|Experimental|Probucol|probucol
9955304|NCT01142284|Experimental|Cilostazol + Probucol|cilostazol and probucol
9955305|NCT01142349|Experimental|Lifestyles A|Cognitive Behavioral Therapy for Pain and Insomnia
9955306|NCT01142349|Experimental|Lifestyle B|Cognitive Behavioral Therapy for Pain
9955307|NCT01142349|Active Comparator|Lifestyles C|Osteoarthritis Education
9955308|NCT01142362|Experimental|0.6mg of DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 0.6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
9955309|NCT01142362|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
9955310|NCT01142362|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
9955311|NCT01142401|Experimental|Arm A (fulvestrant)|Patients receive fulvestrant IM on day 1 (days -14, 1, and 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm C.
9955312|NCT01142401|Experimental|Arm B (fulvestrant, bortezomib)|Patients receive fulvestrant as in arm A and bortezomib IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9955313|NCT01142401|Experimental|Arm C (fulvestrant, bortezomib)|Patients receive fulvestrant IV on day 1 and bortezomib IM on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9955314|NCT01142440|Experimental|behavioral intervention|
9955315|NCT01142440|No Intervention|convention dental treatment|
9955316|NCT01142479|Placebo Comparator|herbal A|dilute of (TPE-1) decoction.
9955317|NCT01142479|Experimental|herbal B|TPE-1 decoction (100 ml)
9955318|NCT01142505|Placebo Comparator|Placebo|Patients in the placebo arm will be given an inactive version of the investigational medical product formed of the excipient mannitol (which is coated with the active drug montelukast in the active comparator arm)
9955319|NCT01142505|Active Comparator|Montelukast|Patients in the active arm will be given an active version of the investigational medical product formed of the inactive excipient mannitol with a coating of active drug montelukast.
9955320|NCT01142531||COPD|COPD patients aged 40 or more, with a smoking history of > 10 PY and a post-bronchodilator FEV1/VC < 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.
9955321|NCT01142544||Pediatric ALIEN|All children from 1 month to 18 years old meeting the American-European Consensus Conference definition of acute lung injury
9955322|NCT01142570|Active Comparator|Group 1|Patients will be receive caloric support as dictated by Hariss-Benedict Formula (Group 1)
9955323|NCT01142570|Active Comparator|Group 2|Patients will be receive caloric support as dictated by Indirect Calorimetry (Group 2)
9955324|NCT01142570|Active Comparator|Group 1A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the first(Group 1A)group will receive caloric support calculated by the HARISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight."
9955325|NCT01142570|Active Comparator|Group 2A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight."
9955326|NCT01142570|Active Comparator|Group 3A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the third group will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight."
9955327|NCT01142609|Experimental|Internet (eGetgoing)|Subjects will assigned to use an accredited web-based platform (eGetgoingTM, CRC Health Group, Inc.) to deliver routine substance abuse counseling.
9955328|NCT01142609|No Intervention|Routine on-site|Subjects will attend routine face-to-face individual counseling sessions.
9955329|NCT01142622|Experimental|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
9955330|NCT01142622|Active Comparator|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery
9955331|NCT01142687|Active Comparator|dihydrocapsiate 3 mg|• Group 1: 1 Dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner
9955332|NCT01142687|Active Comparator|dihydrocapsiate 9 mg|• Group 2: 3 Dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
9955333|NCT01142687|Placebo Comparator|Placebo capsule|• Group 3: 3 placebo capsules three times per day within 30 minutes before breakfast, lunch and dinner
9955334|NCT01142700|Experimental|BMS-824393 (10mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
9955335|NCT01142700|Experimental|BMS-824393 (30 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
9955336|NCT01142700|Experimental|BMS-824393 (100 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
9955337|NCT01142700|Placebo Comparator|Placebo|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
9955338|NCT01142700|Other|Peginterferon alfa-2a plus Ribavirin|Weeks 13 - 48
9955339|NCT01142739||Parkinson's Disease patient|levodopa-treated parkinson's disease (PD) patients
9955340|NCT01142739||Non Parkinson's disease controls|Non Parkinson's disease controls
9955341|NCT01142752||Control|Control group of women with uneventful pregnancy
9955342|NCT01142752||Population at risk with preterm birth|Women medically considered at risk for PTB and actually delivering preterm
9955343|NCT01142752||Population at risk without preterm birth|Women medically considered at risk for PTB but with uneventful pregnancy
9803624|NCT03681912||Sustainment Block 1 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
9955344|NCT01142765|Experimental|Group 1|1 dose of AdCh63 MSP1 and 1 dose MVA MSP1 followed by sporozoite challenge
9955345|NCT01142765|Experimental|Group 2|1 dose of AdCh63 AMA1 and 1 dose MVA AMA1 followed by sporozoite challenge
9955346|NCT01142765|Experimental|Group 3|1 dose of AdCh63 AMA1 and 1 dose AdCh63 MSP1 co-administered into separate arms followed by 1 dose of MVA AMA1 and 1 dose MVA MSP1 co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
9955347|NCT01142765|Experimental|Group 4|1 dose of AdCh63 MSP1 and 1 dose AdCh63 ME-TRAP co-administered into separate arms followed by 1 dose of MVA MSP1 and 1 dose MVA ME-TRAP co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
9955348|NCT01142765|Other|Group 5|Non-vaccinated controls for sporozoite challenge
10005415|NCT01584921|Placebo Comparator|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
10005416|NCT01584921|Active Comparator|Low dose Erythropoietin|
10005417|NCT01584921|Active Comparator|High dose Eryhropoietin|
10005418|NCT01584934|Experimental|Sodium oxybate|Patient group receives sodium oxybate as treatment.
10005419|NCT01584934|Placebo Comparator|Placebo|Patient group receives placebo as treatment.
9480680|NCT05262023|Experimental|DNL593 (Healthy Participant)|
10005420|NCT01584947|Placebo Comparator|Placebo lozenge|The patients will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards they start another two weeks treatment with the opposite type of lozenge from the first treatment period.
10005421|NCT01584947|Active Comparator|Bupivacaine lozenge|The patient will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards the patient starts another two weeks treatment with the opposite type of lozenge from the first treatment period.
10005422|NCT01584960|Experimental|Prostate cancer, endurance training|Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
10005423|NCT01584973||cruciate ligament group|
10005424|NCT01584973||control group|
10005425|NCT01584986|Active Comparator|ACP treated|Autologous angiogenic cell precursors (ACPs) were injected into the ischemic gastrocnemius muscle in addition to the conventional treatment.
10005426|NCT01584986|No Intervention|Control|Control patients were treated with the conventional therapy.
10005427|NCT01584999|Active Comparator|Fresh not-leukocyte-reduced RBCs|
9955349|NCT01142778|Experimental|Trastuzumab, Docetaxel, and Bevacizumab|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel along with bevacizumab in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the bevacizumab infusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
9955350|NCT01142778|Active Comparator|Trastuzumab and Docetaxel|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
9955351|NCT01142778|Active Comparator|Trastuzumab and Docetaxel (Standard Regimen)|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of >/=70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
9955352|NCT01142804|Experimental|Enhanced Usual Care Group|Participants received weekly emailed tips of the week to provide support for walking.
9955353|NCT01142804|Experimental|WalkLink Group|Participants received weekly emailed tips of the week, plus evidence-based online fitness walking program.
9955354|NCT01142804|Experimental|WalkLink+ Group|Participants received weekly emailed tips, plus evidence-based online fitness walking program, plus online/in-person social network intervention.
9955355|NCT01142817||HIV Postive Women|Women living with HIV who meet study eligibility criteria
9955356|NCT01142817||Healthy Control Subjects|Women without HIV who meet study eligibility criteria
9955357|NCT01142882|Active Comparator|Traditional Prevention|educator-delivered, small-group HIV & disease prevention education
9955358|NCT01142882|Experimental|Web-based Prevention|self-directed, interactive & customized web-based HIV & disease prevention education
9955359|NCT01142921|Active Comparator|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
9955360|NCT01142921|Experimental|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
9955361|NCT01142934|Other|TegaDerm CHG|TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).
9955362|NCT01142960|Active Comparator|Placebo|Starch
9955363|NCT01142960|Experimental|Lycium Barbarum|Lycium Barbarum supplement
9955364|NCT01142986|Experimental|Low Threshold Stepped Care (LTSC)|Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
9955365|NCT01142986|Experimental|Voucher-Based Stepped Care (VBSC)|Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
9955366|NCT01142986|No Intervention|Routine Stepped-Care (RSC)|Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
9955367|NCT01142999|Active Comparator|Intervention (moisturizer group)|One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.
9955368|NCT01142999|Active Comparator|Control group (no moisturizers)|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
9955369|NCT01143012|Active Comparator|Group eczema education session|One group will attend a group eczema education session. All subjects will answer quality of life questions two times.
9955370|NCT01143012|Active Comparator|Control group|The other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
9955371|NCT01143025|Active Comparator|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
9955372|NCT01143025|Experimental|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
9955373|NCT01143025|Experimental|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
9955374|NCT01143103|Experimental|Respiratory therapy with cough assist|
9955375|NCT01143103|Active Comparator|Usual respiratory therapy|
9955376|NCT01143129|Experimental|dexamethasone|Single dose of dexamethasone (1 mg/kg) at the start of the cardiac surgical procedure
9955377|NCT01143129|Placebo Comparator|Placebo|
9955378|NCT01143194|Experimental|oréVida™ 60mg/day|
9955379|NCT01143194|Experimental|oréVida™ 120mg/day (1)|
9955380|NCT01143194|Experimental|oréVida™ 120mg/day (2)|
9955381|NCT01143194|Placebo Comparator|Placebo|
9955382|NCT01143220||ICD / CRT-D patient|Patients implanted with a single or dual chamber ICD or CRT-D device approved in Japan capable of using the IBP feature.
9955383|NCT01143233|Active Comparator|control formula group|infants are fed a commercial, hydrolysed formula during the first 4 month of life, according to protocol
9955384|NCT01143233|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula with different protein content during the first 4 month of life, according to protocol
9955385|NCT01143233|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula with different protein content with pro- and prebiotics during the first 4 month of life, according to protocol
9955386|NCT01143233|Experimental|intervention formula 3 group|infants are fed hydrolyzed instant formula with different protein content with pro- and prebiotics during the first 4 months of life, according to protocol
9955387|NCT01143233|No Intervention|Reference group|infants are breast fed
9955388|NCT01143285|Experimental|I - Early and active nutritional support.|During the initial consultation, the dietician will answer the questions of the patient and their family. Patients will be seen regularly in follow-up for weight measurement, serum albumin assay, a 1 or 3 day food record and an evaluation of appetite level. Nutritional counselling is then adjusted accordingly and:Balanced meals are continued if weight is stable and appetite is undiminished.Protein and energy fortification is recommended if weight loss is observed or if food intake decreases between 2 consultations leading to total food intake of less than 50% of required food intake. When a patient presents with signs of malnutrition according to the criteria set out by the Authority for Health, oral nutritional support (ONS) is set up, in agreement with the department head. Two 200ml bottles of Fortimel Extra are to be taken every day. If this ONS strategy is insufficient to improve the patient's nutritional status, artificial nutrition should be discussed.
9955389|NCT01143285|No Intervention|II - No nutritional support|Should malnutrition develop in a group II patient, ONS will be ordered. It will consist of two 200ml Fortimel Extra* bottles per day in addition to regular meals. Ideally, the ONS should be taken as a snack outside of meal times so as to not spoil the appetite. If this ONS is insufficient to improve the nutritional status of the patient, artificial nutrition (either enteral or parenteral) will be discussed.
9955390|NCT01143298|Experimental|LEO 27847 oral solution 0.1 mg|LEO 27847 oral solution 0.1 mg
9955391|NCT01143298|Experimental|LEO 27847 tablet 0.10 mg|LEO 27847 tablet 0.10 mg
9955392|NCT01143298|Experimental|LEO 27847 tablet 0.01 mg|LEO 27847 tablet 0.01 mg
9955393|NCT01143311|Other|ARM A|"4 distinct biopsies will be taken~in a non UV-exposed area (inner arm)~in a UV-exposed area (external surface of the forearm)~in a pretumoral region (actinic keratosis)~inside the tumor"
9955394|NCT01143350|Experimental|EHPAD Training and Stimulation|"EHPAD of the group of Training / Stimulation will benefit:~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
9955395|NCT01143350|Placebo Comparator|2- EHPAD control|EHPAD of the reference group, will have their habitual functioning
9955396|NCT01143363|Placebo Comparator|Resting - control|No exercise
9480681|NCT05262023|Placebo Comparator|Placebo (Healthy Participant)|
9955397|NCT01143363|Experimental|Moderate intensity exercise|Moderate intensity exercise (continuous) 1h after breakfast
9955398|NCT01143363|Experimental|High intensity intermittent training|High intensity intermittent training 1h after breakfast
9955399|NCT01143363|Experimental|Short sprint|Short sprint 1h after breakfast
9955400|NCT01143376|Active Comparator|Moderate intensity exercise|Moderate intensity exercise
9955401|NCT01143376|Experimental|High Intensity training|High Intensity intermittent training
9955402|NCT01143376|Experimental|Short springs|short springs training
9955403|NCT01143441|Experimental|Cohort A|Long-Term daclizumab cohort
9480682|NCT05262023|Experimental|DNL593 (Participants with FTD)|
9955404|NCT01143441|Experimental|Cohort B|New Treatment Cohort
9955405|NCT01143441|No Intervention|Cohort C|MS Controls
9955406|NCT01143493||Carrier - Other|
9955407|NCT01143493||Carrier hGR N363S Heterozygote|
9955408|NCT01143493||Carrier hGR N363S Homozygote|
9955409|NCT01143493||Carrier hGR9B A3669G Heterozygote|
9955410|NCT01143493||Carrier hGR9B A3669G Homozygote|
9955411|NCT01143493||Control|
9955412|NCT01143545|Experimental|1|Allogeneic tumor cell vaccine + chemotherapy
9955413|NCT01143584|Experimental|Rapid escalation|Weekly escalation of cabergoline dose in macroprolactinomas Start with 1 mg/week. increase by 1mg/wk every week till 4 weeks. after 4 weeks Cabergoline dose would be increased @1mg/wk every 4 weekly till normalization of prolactin and >50% decrease in tumor volume from baseline.
9955414|NCT01143584|Active Comparator|Conventional escalation|"Conventional escalation of cabergoline~In the Conventional escalation group schedule of cabergoline dosing will be 0.5 mg once a week for 4 weeks. Cabergoline will be incrementally dose adjusted on the basis of individual Prolactin values till amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or till primary endpoint."
9955415|NCT01143597|Active Comparator|Somatosensory stimulation (SS)|Participants in the SS group receive median nerve electrical stimulation applied to the skin of the wrists.
9955416|NCT01143597|Active Comparator|Massed practice + somatosensory stimulation (MP+SS)|Participants in the MP+SS group receive a combined intervention consisting of SS and a skill-based exercise protocol
9955417|NCT01143597|Active Comparator|Conventional resistance training (CRT)|Participants in the CRT group will participate in a weight-based exercise program
9955418|NCT01143623|Active Comparator|Probiotic|
9955419|NCT01143623|Active Comparator|Probiotic-2|
9955420|NCT01143623|Placebo Comparator|Placebo|
9955421|NCT01143662|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per week
9955422|NCT01143662|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per week
9955423|NCT01143662|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per week
9955424|NCT01143662|Active Comparator|Group 4|Pegasys 180mcg per week
9955425|NCT01143740|Experimental|Single Arm|
9955426|NCT01143753|Experimental|RO5212054: Continuous Dosing Cohort|Participants will receive RO5212054 in escalating dose levels.
9955427|NCT01143753|Experimental|RO5212054: New Formulation (F05) Bridging Cohort|Participants will receive RO5212054 as a single dose of new formulation (F05-150 mg film-coated tablet with different ratios of ingredients than F03 to increase bioavailability) and a single dose of current clinical Formulation (F03-150 mg film-coated tablet) in a cross-over manner. Participants will be alternately assigned to receive either F05 or F03 as their first dose, followed by the opposite Formulation as their second dose. Dose of RO5212054 will be decided based on the results of continuous dosing cohort.
9955428|NCT01143805|Experimental|Treatment A: Tasocitinib 10 mg oral tablet|
9955429|NCT01143805|Experimental|Treatment B: Tasocitinib 10 mg IV Infusion|
9955430|NCT01143831|Experimental|All study participants|Three blood collections, one at baseline, one two weeks later, and the final blood collection 4 weeks from baseline, after taking Vitamin K orally for 14 days.
9955431|NCT01143844||Exposed females, ages 11-40|"Prior exposure to alkylating agent chemotherapy and/or radiation therapy~At least 1 year from completion of chemotherapy and/or radiation therapy~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition (other than cancer) known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
9955432|NCT01143844||Unexposed females, ages 40-50|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
9955433|NCT01143844||Unexposed females, ages 11-35|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
9955434|NCT01143857|Active Comparator|Varenicline|
9955435|NCT01143857|Placebo Comparator|Placebo|
9955436|NCT01143909|Experimental|No FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to omitting transfusion of fresh frozen plasma before they undergo an intervention.
9955437|NCT01143909|No Intervention|FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to transfusion of fresh frozen plasma before they undergo an intervention. This is considered standard care.
9955438|NCT01143922||Patients with gastrointestinal tract malignancies|All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound
9955439|NCT01143935||Live patients|All patients undergoing CT scans of the abdomen for non hepatobiliary conditions
9955440|NCT01143935||Autopsy cases|All autopsy cases with no liver disease or trauma.
10005428|NCT01584999|Active Comparator|Fresh RBCs leukocyte-reduced|
9955441|NCT01143948|Active Comparator|15 patient sliding scale regular insulin|
9955442|NCT01143948|Active Comparator|15 patient BBI NPH plus regular insulin|
9955443|NCT01143948|Active Comparator|15 patients BBI Glargine plus Glulisine|
9955444|NCT01143961|Experimental|NBL with one-way valve|NBL performed with one-way valve in ventilator circuit during procedure
9955445|NCT01143961|No Intervention|Standard NBL|Performance of standard NBL with recording of changes in regional ventilation by electrical impedance tomography
9955446|NCT01143974|Experimental|PC Regimen|
9955447|NCT01143987|Experimental|Cinacalcet|Oral cinacalcet
9955448|NCT01144000|Experimental|Daptomycin|High dose Daptomycin in hip, knee and shoulder prosthesis infections
9955449|NCT01144065||Patient with acute MI|Patients with acute MI ( elevated cardiac enzymes + chest pain or typical ECG changes)admitted to the cardiology department at Meir Medical Center
9955450|NCT01144065||Patient with prior cardiovascular disease and/or diabetes|These patients do not have acute coronary syndrome or stroke. Prior cardiovascular disease (CVD) is defined as a history of hospital admission due to acute coronary artery occlusion, percutaneous coronary interventions (PCI), coronary artery bypass grafting, any aortic or peripheral vascular disease that was either symptomatic or required intervention, ischemic or hemorrhagic stroke or transient ischemic attack.
9955451|NCT01144065||Patients without prior cardiovascular disease or diabetes|These patients do not have acute coronary syndrome or stroke Prior cardiovascular disease (CVD) or diabetes
9955452|NCT01144078|Experimental|High Intensity Interval Exercise|This arms receives the High Intensity Interval Exercise intervention
9955453|NCT01144078|Experimental|Traditional Intensity Exercise|This arms receives the Traditional Intensity Exercise intervention
9955454|NCT01144091|Experimental|pentoxyphylline cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
9955455|NCT01144091|Placebo Comparator|placebo cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
9955456|NCT01144091|Experimental|radiology pentoxyphylline|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
9955457|NCT01144091|Placebo Comparator|radiology placebo|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
9955458|NCT01144104|Experimental|Public Service Announcements|Demographically targeted public service announcement
9955459|NCT01144104|Experimental|Interactive Multi-Media Computer Program|Personally tailored information about seeking care for depression based on respondent characteristics
9955460|NCT01144104|Active Comparator|Attention Control Video|Two-minute video focusing on common sleep disorders.
9955461|NCT01144117|Experimental|Erythropoietin|Erythropoietin treated patients contra placebo.
9955462|NCT01144169|Experimental|Hydroxychloroquine (HC)|HC orally for 14 days prior to nephrectomy
9480683|NCT05262023|Placebo Comparator|Placebo (Participants with FTD)|
9955463|NCT01144221|Experimental|Stem cell treatment|Patients treated via stem cell injection
9955464|NCT01144234|Experimental|Invitation letter to male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
9955465|NCT01144234|Placebo Comparator|Information letter|In this arm the pregnant women got an information letter about antenatal care.
9955466|NCT01144247|Experimental|alloreactive CTL arm|
9955467|NCT01144260|Experimental|Bafetinib|
9955468|NCT01144273|Active Comparator|0.5% Ropivacaine|group receiving TAP block (0.5% ropivacaine at TAP plane)
9955469|NCT01144273|Placebo Comparator|normal saline|group receiving placebo (saline) at TAP plane
9955470|NCT01144312|Experimental|pharmacokinetics of fentanyl|
9955471|NCT01144351|Experimental|ELND002|ELND002 sc injection
9955472|NCT01144351|Placebo Comparator|Placebo|placebo injection
9955473|NCT01144390|Experimental|CBT plus MMT|cognitive behavioral therapy for heroin addicts with methadone maintenance treatment
9955474|NCT01144390|Active Comparator|methadone maintenance treatment|methadone maintenance treatment for heroin addicts
9955475|NCT01144429|Active Comparator|100 DPP/mL|Concentration of solution fo s.c. injection: 100 DPP/mL
9955476|NCT01144429|Active Comparator|1000 DPP/mL|Concentration of solution fo s.c. injection: 1000 DPP/mL
9955477|NCT01144429|Active Comparator|5000 DPP/mL|Concentration of solution fo s.c. injection: 5000 DPP/mL
9955478|NCT01144429|Active Comparator|10000 DPP/mL|Concentration of solution fo s.c. injection: 10000 DPP/mL
9955479|NCT01144468||MAP3 Participants|study participants in the MAP.3 study are randomly assigned to either placebo or 25 mg exemestane daily for 5 years. Allocation is blinded. We are following 354 of these study participants and are blinded to treatment allocation.
9955480|NCT01144481||breast cancer with metastasis|female breast cancer patients with metastases to any site
9955481|NCT01144533|Placebo Comparator|Isotonic saline|
9955482|NCT01144533|Experimental|Steroid|
9955483|NCT01144533|Experimental|Hyaluronate|
9955484|NCT01144533|Experimental|Steroid + Hyaluronate|
9955485|NCT01144546|Experimental|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before anesthesia induction
9955486|NCT01144559|Active Comparator|Continuous Infusion|Each subject will have one lower extremity (Right or Left) randomized to receive a perineural catheter with a continuous infusion of local anesthetic and then the outcomes will be measured.
9955487|NCT01144559|Active Comparator|Bolus Administration|The opposite lower extremity (right or left) will be randomized to receive a perineural catheter with the local anesthetic being delivered via a bolus as opposed to continuous as is the case with their other extremity. The outcome measures will then be assessed as described.
9955488|NCT01144572||1|Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
9955489|NCT01144585|Experimental|RIPC|those who receive RIPC and RIPoC before and after CPB
9955490|NCT01144585|Placebo Comparator|Control|this group have same pneumatic cuff around their arm, but it is not inflated.
9955491|NCT01144611|Active Comparator|bIAP|intravenous as a bolus of bIAP (alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
9955492|NCT01144611|Placebo Comparator|placebo|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
9955493|NCT01144650|Placebo Comparator|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
9955494|NCT01144650|Experimental|Dapsone|Patients will receive either a single total dose of 250 mg IV and oral dosage
9955495|NCT01144676|Experimental|Group A1: Dapivirine Vaginal Ring|
9955496|NCT01144676|Placebo Comparator|Group A2: Placebo Vaginal Ring|
9955497|NCT01144676|Experimental|Group B1: Dapivirine Vaginal Ring|
9955498|NCT01144676|Placebo Comparator|Group B2: Placebo Vaginal Ring|
9955499|NCT01144689|Experimental|Mindfulness Training|
9955500|NCT01144689|Active Comparator|Smoking Cessation Therapy|
9955501|NCT01144702|Experimental|artesunate & mefloquine combination|ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to <18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to <9 kg = 1 tablet once daily for 3 days, 9 to <18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
9955502|NCT01144728|Experimental|Single arm Glimepiride+metformin|Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
9955503|NCT01144741||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
9955504|NCT01144741||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
9955505|NCT01144741||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
9955506|NCT01144741||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
9955507|NCT01144741||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
9955508|NCT01144741||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
9955509|NCT01144767|Experimental|Computer-generated advisor|Participants receive sessions with a computer-generated adviser who will provide tailored advice and encouragement to engage in physical activity.
9955510|NCT01144767|Active Comparator|Comparison control condition|Participants will receive live, group sessions on health topics unrelated to physical activity.
9955511|NCT01144806|Active Comparator|Group 1|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
9955512|NCT01144806|Active Comparator|Group 2|Ready to use therapeutic food (RUTF / PlumpyNut)will be provided to parent/care givers of children with severe malnutrition in enrolled in this group
9955513|NCT01144819||STEMI|Patients with STEMI according to ESC STEMI guidelines: Age above 18 years and able to give written, informed consent to participation in the project.
9955514|NCT01144832|Placebo Comparator|placebo capsule|
9955515|NCT01144832|Active Comparator|ebastine|
9955516|NCT01144845||Thoracic surgical patients|Patients with pulmonary malignancies
10005429|NCT01584999|Active Comparator|RBCs with storage longer than 15 days|
10005430|NCT01585012|Experimental|Cervical cap|Collection condom with cervical cap inserted
10005431|NCT01585051|Active Comparator|vitamin D|Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D
10005432|NCT01585051|Placebo Comparator|placebo|administration of 0.9 % NaCl as a placebo
10005433|NCT01585064||DAS28-IOMS|Physicians randomized to the DAS28-IOMS will treat patients according to a protocol aimed at achieving a DAS28 score under 2.4.
10005434|NCT01585064||0SJ-IOMS|Physicians randomized to the 0SJ-IOMS will treat patients according to a protocol aimed at attaining a count of zero swollen joint (28 joints evaluated).
10005435|NCT01585064||Routine Care (RC)|Physicians randomized to the RC group will treat study patients as per routine care and according to their own judgment.
10005436|NCT01585077|Experimental|Naive volunteers|Volunteers without previous exposure to malaria, and negative antibody titers (<1:20) against native protein of P. vivax.
10005437|NCT01585077|Experimental|Pre-immune volunteers|Volunteers with previous exposure to malaria, and positive antibody titers against native protein of P. vivax
10005438|NCT01585090|Experimental|passive ankle dorsi ﬂexion|doing strengthening exercises of PFM in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)
10005439|NCT01585090|Experimental|active ankle plantar ﬂexion with arm up|doing strengthening exercises of PFM in standing position with active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position
10005440|NCT01585090|No Intervention|horizontal standing position|doing strengthening exercises of PFM in standing position with horizontal standing position
10005441|NCT01585103|Experimental|Cytosponge/ brushing|
10005442|NCT01585142|Experimental|BabyNes system formula|
10005443|NCT01585181|Placebo Comparator|Placebo|
10005444|NCT01585181|Experimental|PXVX0200|
10005445|NCT01585220|Experimental|Neuramis|
10005446|NCT01585220|Active Comparator|Restylane®|
10005447|NCT01585233|Experimental|Cohort 1|ASKP1240 lowest dose
10005448|NCT01585233|Experimental|Cohort 2|ASKP1240 low dose
10005449|NCT01585233|Experimental|Cohort 3|ASKP1240 high dose
10005450|NCT01585233|Experimental|Cohort 4|ASKP1240 highest dose
10005451|NCT01585233|Placebo Comparator|Placebo|
10005452|NCT01585259|Active Comparator|Anfibatide|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
10005453|NCT01585259|Placebo Comparator|Placebo|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
10005454|NCT01585285|Experimental|LIMA to SVG Bridge|Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets
10005455|NCT01585285|Active Comparator|Conventional CABG|Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
10005456|NCT01585311||Subarachnoid Hemorrhage patients|SAH patients with hourly eMR values of Heart Rate
10005457|NCT01585337||patients with lumbar fusion|
10005458|NCT01585350|Experimental|Cohort 1|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
10005459|NCT01585350|Experimental|Cohort 2|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
10005460|NCT01585402|Experimental|Etidronate|20 mg/kg oral 14 days on / 10 weeks off study drug
10005461|NCT01585415|Experimental|Single Arm|Two weeks prior to the start of the preparative regimen, patients will begin taking vemurafenib. Patients will then receive lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine, followed by young TIL and high dose aldesleukin
10005462|NCT01585480|Experimental|weight gain prevention intervention|
10005463|NCT01585480|No Intervention|No treatment comparison group|
10005464|NCT01585493|Active Comparator|Treatment as usual|Treatment as usual
10005465|NCT01585493|Active Comparator|Care coordinator|
10005466|NCT01585493|Experimental|CHANGE|
10005467|NCT01585506||Questionnaire responders|
10005468|NCT01585519|No Intervention|(Group 1) Low Apple Diet|
10005469|NCT01585519|Experimental|(Group 2) 2 High Apples|
9480684|NCT05262010|Experimental|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
9480685|NCT05262010|Placebo Comparator|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
9955517|NCT01144858||patients with persistent atrial fibrillation ablation|
9955518|NCT01144871||Male Parent/Guardians|Male Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
9955519|NCT01144871||Female Parent/Guardian|Female Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
9955520|NCT01144884|Other|Single arm trial|"Education:To standardize, treatment education will consist of counsel to stay active. Details will be given to subjects verbally & reinforced in the home booklet.~Posture:Facilitation of proper posture has been show to increase recruitment of the lumbar multifidus & deep neck flexors. Instruction will be given verbally & in writing.~Stretching:Stretching exercises will be targeted to address these common impairments. Patients will be introduced to proper stretching procedures. Each stretch will be held for 30s & repeated two times,each side as applicable. The following stretches will be performed:~Upper trap Anterior/medial Scalene Suboccipital Pectoralis~Muscular Performance: Muscle performance will be trained incorporating components of strength, endurance and motor control. Each of the exercises listed below are outlined based on progressions.~Isometric Cervical Extension Craniocervical flexion Seated Row Seated T Palms Up Seated Side Arm Raises"
9955521|NCT01144897|Experimental|PET Acetate Imaging with Docetaxel|"PET-acetate as an intermediate endpoint in the assessment of response of patients undergoing docetaxel for hormone refractory prostate cancer (HRPC).~Subjects will be treated with docetaxel, 75 mg/m2 every 21 days until disease progression or unacceptable toxicity occurs. Subjects will have two PET acetate scans - one prior to beginning chemotherapy and one approximately 8-9 weeks after chemotherapy has begun."
9955522|NCT01144910||BHR non-atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
9955523|NCT01144910||BHR atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
9955524|NCT01144923|Active Comparator|Conservative treatment|Pharmacotherapy with nortriptyline and/ or gabapentin, physical therapy (e.g. range of motion, therapeutic massage, strengthening exercises), and possibly others (e.g. acupuncture)
9955525|NCT01144923|Experimental|Epidural Steroids|A series of up to 3 epidural steroid injections (ESI)with depo-methylprednisolone
9955526|NCT01144923|Experimental|Combination Treatment|These patients will receive both treatments. They can have up to 3 epidural steroid injections (ESI) with depo-methylprednisolone, and conservative treatment (i.e. pharmacotherapy with nortriptyline and/ or gabapentin, and physical therapy)
9955527|NCT01144936|Experimental|Panel 1: VX-985 Dose 1|
10215492|NCT03703011|Experimental|Interventional|Subjects aged >70 years, hospitalized in the rehabilitation geriatric ward in the Paul Brousse hospital, France, able to walk 10 meters, ready to be discharged, and a Mini mental state examination ≥ 20/30
9955528|NCT01144936|Experimental|Panel 2: VX-985 Dose 2|
9955529|NCT01144936|Experimental|Panel 3: VX-985 Dose 3|
9955530|NCT01144962|Sham Comparator|Control group|Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
9955531|NCT01144962|Active Comparator|Cohort 1|10x10^6 MSC
9955532|NCT01144962|Active Comparator|Cohort 2|30x10^6 MSC
9955533|NCT01144962|Active Comparator|Cohort 3|90x10^6 MSC
9955534|NCT01144975|Active Comparator|XOMA 052|
9955535|NCT01144975|Placebo Comparator|Placebo|
9955536|NCT01145014|Experimental|BI 660848 2 mg|oral drinking solution
9955537|NCT01145014|Experimental|BI 660848 10 mg|oral drinking solution
9955538|NCT01145014|Experimental|BI 660848 20 mg|oral drinking solution
10215493|NCT03702998||HIV-infected individuals +/- HBV/ HCV|"1 All HIV-infected individuals followed up in all public HIV clinics with and without HBV and/or HCV co-infection will be included in the analysis.~1.1 Inclusion criteria for HIV-infected individuals with and without HBV or HCV co-infection: 1.1.1 Positive HIV antibody 1.1.2 At least one visit in one of the HIV clinics 1.1.3 Subjects with positive HBsAg and/or anti-HBc will be regarded as having HBV co-infection 1.1.4 Subjects with positive HCV antibody will be regarded as having HCV co-infection"
9955539|NCT01145014|Experimental|BI 660848 50 mg|oral drinking solution
10215494|NCT03702998||HBV/HCV mono-infected individuals|"2 All HBV and/or HCV-infected individuals followed up in public hospitals will be identified from the Hospital Authority electronic database.~2.1 Inclusion criteria for HBV/HCV mono-infected individuals 2.1.1 Documented diagnosis of hepatitis B or hepatitis C infection, or 2.1.2 Positive HBsAg and/or anti-HBc, or 2.1.3 Positive HCV antibody, and 2.1.4 Negative HIV antibody result, or no record of HIV diagnosis or anti-retroviral therapy prescription"
10215495|NCT03702985|Active Comparator|Capecitabine and Irinotecan without Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
10215496|NCT03702985|Experimental|Capecitabine and Irinotecan with Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) Amifostine: 400mg/m2 per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
10215497|NCT03702959||Betamethasone group 1|Betamethasone Group 1 (5am-11am)
10215498|NCT03702959||Betamethasone Group 2|Betamethasone Group 2 (11am-5pm)
9955540|NCT01145014|Experimental|BI 660848 100 mg|oral drinking solution
9955541|NCT01145014|Experimental|BI 660848 150 mg|oral drinking solution
9955542|NCT01145014|Experimental|BI 660848 200 mg|oral drinking solution
9955543|NCT01145014|Experimental|BI 660848 400 mg|oral drinking solution
9955544|NCT01145014|Experimental|BI 660848 600 mg|oral drinking solution
9955545|NCT01145014|Experimental|BI 660848 10,0 mg|immediate release tablet
9955546|NCT01145014|Experimental|BI 660848 50,0 mg|immediate release tablet
9955547|NCT01145014|Experimental|Placebo|matching placebo (oral drinking solution and IR tablets)
9667615|NCT03334409|Active Comparator|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
9803625|NCT03681912||Sustainment Block 2 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
9955548|NCT01145027|No Intervention|Control group|
9955549|NCT01145027|Experimental|Sensorial Stimulus|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste, in order to trigger the cephalic phase of insulin secretion
9955550|NCT01145040||Partition 1|Overt primary hypothyroidism
9955551|NCT01145040||Partition 2|"Hypothyroidism with full dose levothyroxine substitution therapy (more than 1.75 µg per kg of body mass)"
9955552|NCT01145040||Partition 3|Overt primary hyperthyroidism
9955553|NCT01145079|Experimental|Endeavor arm|
9955554|NCT01145079|Active Comparator|Endeavor resolute arm|
9955555|NCT01145079|Active Comparator|Xience arm|
9955556|NCT01145079|Active Comparator|Cypher arm|
9955557|NCT01145131|Experimental|Beef steak|
9955558|NCT01145131|Experimental|Minced beef|
9955559|NCT01145144|Experimental|DHEA supplementation|DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
9955560|NCT01145144|No Intervention|only induction of ovulation by same long protocol without DHEA|
9955561|NCT01145157|Experimental|Signature Knee Guide|Total Knee Arthroplasty using the Signature Knee Guide with the Vanguard Knee System
9955562|NCT01145157|Active Comparator|Conventional Instrumentation|Total Knee Arthroplasty will be performed using Conventional Instrumentation with the Vanguard Knee System
9955563|NCT01145157|Active Comparator|Computer Assisted Navigation|Total Knee Arthroplasty will be performed using Computer Assisted Navigation with the Vanguard Knee System
9955564|NCT01145170|Experimental|Nimotuzumab|The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
9955565|NCT01145235||Females previously treated with Macrolane in their breasts.|
9955566|NCT01145248|Experimental|Malignant biliary disease|
9955567|NCT01145248|Experimental|Benign biliary disease|
9955568|NCT01145261||Anxiety|Children with anxiety disorders
9955569|NCT01145261||healthy controls|children without anxiety disorders
9955570|NCT01145313||Patients diagnosed with Major Depressive Disorder|Patients diagnosed with MDD who are treated with antidepressants and subsequently augment with atypical antipsychotic therapy.
9955571|NCT01145326|Sham Comparator|Control|Sham-Functional microneedles (no actual microneedles) application, prior to 4% lidocaine gel (LG4) placement.
9955572|NCT01145326|Experimental|Microneedle|Functional microarray (FMA) (microneedles) application, prior to 4% lidocaine gel (LG4) placement.
9955573|NCT01145339|Experimental|Lactase EUF|1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).
9955574|NCT01145339|Active Comparator|Lactase Ref|1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).
9955575|NCT01145365|Active Comparator|Combination Therapy Group|Patients in this arm will have surgically established drainage of their Crohns perianal fistulas and/or abscesses (exam under anesthesia (EUA)) done BEFORE beginning medical therapy with Cimzia.
9955576|NCT01145365|No Intervention|Control Group|Patients in this group will begin medical therapy with Cimzia regardless of status of surgically established drainage.
9955577|NCT01145404|Experimental|Arm A: Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
9955578|NCT01145404|Experimental|Arm B|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
9955579|NCT01145430|Experimental|Treatment (veliparib and liposomal doxorubicin hydrochloride)|Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9955580|NCT01145443||Continuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when a single intensivist was the sole attending physician of record for intervals of 2 weeks (or 1/2 month).
9955581|NCT01145443||Discontinuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when, for intervals of 2 weeks (or 1/2 month), there was a single intensivist who was the primary attending of record during Mondays-Fridays, but cross-covering colleagues took over that role during the weekends.
10005470|NCT01585519|Experimental|(Group 3) 2 Low Apples|
10005471|NCT01585519|Experimental|(Group 4) 2 x 4.4g apple granules|
10005472|NCT01585519|Experimental|(Group 5) 2 x Apple Extract Capsules|
9955582|NCT01145456|Experimental|Treatment (RO4929097 and gemcitabine hydrochloride)|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9955583|NCT01145534|Active Comparator|Glibenclamide|Patients used 5 mg glibenclamide daily for 60 days
9955584|NCT01145534|Experimental|Experimental|Patients ingested the infusion of Cissus verticillata L. prepared as 1 g in 150 mL of hot water for 10 min. This was done daily for 60 days
9955585|NCT01145573|Placebo Comparator|Placebo|Inactive pill taken daily
9955586|NCT01145573|Active Comparator|Calcium|1000mg of calcium taken daily
9955587|NCT01145586|Experimental|Lactase EUF|1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
9955588|NCT01145586|Active Comparator|Lactase Ref|1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days
9955589|NCT01145599||Type-2 diabetes, NPDR|Type-2 diabetic patients with NPDR.
9955590|NCT01145612|Experimental|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
9955591|NCT01145612|Experimental|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
9955592|NCT01145664|Active Comparator|Western therapy|
9955593|NCT01145664|Experimental|Herbal concentrate-granules plus western therapy|
9667616|NCT03332498|Experimental|Pembrolizumab and Ibrutinib|"Pembrolizumab intravenously (IV): 200 mg every 3 weeks (Q3W).~Ibrutinib by mouth (PO): Phase I Dose Escalation at doses of 420 mg daily (cohort 0) and 560 mg daily (cohort 1);. Phase II treatment at Recommended Phase II dose."
9955594|NCT01145664|Experimental|Reduning Injection plus western therapy|
9955595|NCT01145677|Experimental|Topiramate|
9955596|NCT01145690||Internet-based CBT|All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
9955597|NCT01145703|Active Comparator|RDA Vitamin D|
9955598|NCT01145703|Experimental|Vit D repletion + 6M Supplementation|
9955599|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +AEX|
9955600|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +RT|
9955601|NCT01145716|Other|Surgical exploration|Descriptive
9955602|NCT01145729|Active Comparator|Biomarker feedback|Biomarkers of tobacco exposure (laboratory values) delivered to health care provider
9955603|NCT01145729|Placebo Comparator|Usual care (general counseling)|Brochure about pesticides, lead, SHS
9955604|NCT01145742|Experimental|self-management support and BP telemonitoring|collaborative intervention involving home BP monitoring, home behavior change counseling to enhance self management, and intensification of treatment by primary care doctors
9955605|NCT01145742|No Intervention|usual care|usual primary care management of BP. lipids, and glucose
9955606|NCT01145768|Experimental|1|Each cohort will have 9 volunteers that will receive TC-5214
9955607|NCT01145768|Placebo Comparator|2|Each cohort will have 3 volunteers that will receive placebo
9955608|NCT01145781|Active Comparator|Single-freeze cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw.
9955609|NCT01145781|Active Comparator|Double-freeze cryotherapy|Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
9955610|NCT01145807|Placebo Comparator|Placebo|non Transfersome® placebo
9955611|NCT01145807|Sham Comparator|Transfersome® vehicle|Transfersome® vehicle
9955612|NCT01145807|Experimental|TDT 067|TDT 067
9955613|NCT01145820|Experimental|Juice Plus|
9955614|NCT01145820|Placebo Comparator|Placebo|
9955615|NCT01145846|Experimental|Arm I (AI regimen)|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3)
9955616|NCT01145859|Experimental|Arm 1|
9955617|NCT01145872|Experimental|Mindfulness Based Cognitive Therapy|
9955618|NCT01145872|Active Comparator|Health Enhancement Program|
9955619|NCT01145911||Glaucoma patients|Glaucoma patients
9955620|NCT01145924|Active Comparator|EBUS TBNF|single arm trial, patients with enlarged mediastinal nodes will be examine
9955621|NCT01145937|Experimental|PET|"Partial endothelial trepanation in addition to anterior lamellar keratoplasty.~The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature."
9955622|NCT01145937|Active Comparator|DALK|Conventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.
9955623|NCT01145950|Experimental|Group 1|
9955624|NCT01145950|Experimental|Group 2|
9955625|NCT01145963|Experimental|experimental pasta B|Past B
9955626|NCT01145963|Experimental|experimental pasta C|Pasta C
9955627|NCT01145963|Placebo Comparator|Control pasta|Control
9955628|NCT01145976|Active Comparator|CY-ATG(Arm1)|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
9955629|NCT01145976|Experimental|Flu-ATG(Arm2)|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
9955630|NCT01145989|Experimental|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
9955631|NCT01146002|Other|Guanfacine treated.|Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
9955632|NCT01146015|Experimental|1|
9955633|NCT01146028|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
9955634|NCT01146028|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
9955635|NCT01146041|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
9955636|NCT01146041|Active Comparator|exelon|Exelon 1.5 mg capsules of Novartis
9803626|NCT03681912||Sustainment Block 3 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
9955637|NCT01146067|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
9955638|NCT01146067|Active Comparator|Exelon|Exelon 1.5 mg capsules of Novartis
9955639|NCT01146080|Experimental|Promus Element|21 consecutive patients with Promus Element implanted to treat coronary artery lesion
9955640|NCT01146080|Active Comparator|Promus|21 consecutive patients with Promus stent implanted to treat coronary artery lesions
9955641|NCT01146093|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
9955642|NCT01146093|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
9955643|NCT01146106|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
9955644|NCT01146106|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
9955645|NCT01146119|Experimental|Multimeric-001, Adjuvanted|64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
9955646|NCT01146119|Active Comparator|PBS and TIV 15%|32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
9955647|NCT01146119|Placebo Comparator|Placebo, Adjuvanted|32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.
9955648|NCT01146119|Experimental|Co-administration M-001 and TIV 15%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.
9955649|NCT01146119|Experimental|Co administration of M-001 and TIV 50%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.
9955650|NCT01146119|Active Comparator|Co administration of PBS and TIV 50%|24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.
9955651|NCT01146132|Other|Luxembourg diet + wine|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
9955652|NCT01146132|Other|conventional + wine|conventional Diet with red wine
9955653|NCT01146132|Other|conventional|conventional diet without wine
9955654|NCT01146132|Other|Luxembourg diet|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
9955655|NCT01146145|Experimental|treatment|intravenous morphine titration combined to ketamine
9955656|NCT01146145|Placebo Comparator|placebo|morphine titration alone
9955657|NCT01146158|Experimental|surgery Axillary dissection|surgery Axillary dissection
9955658|NCT01146171|Experimental|BMS-844203 (CT-322)|
9955659|NCT01146184|Experimental|Single-Incision Cholecystectomy|Extracting the gallbladder laparoscopically is made difficult through a single incision.
9955660|NCT01146197|Experimental|Amiloride, Indometacin, Eplerenone|Amiloride, indometacin(+Omeprazole), Eplerenone
9955661|NCT01146197|Experimental|Amiloride, Eplerenone, indometacin|Amiloride, Eplerenone, indometacin (+Omeprazole)
9955662|NCT01146197|Experimental|Eplerenone, Amiloride, indometacin|Eplerenone, Amiloride, indometacin (+Omeprazole)
9955663|NCT01146197|Experimental|Eplerenone, Indometacin, Amiloride|Eplerenone, Indometacin, Amiloride
9955664|NCT01146197|Experimental|Indometacin, Eplerenone, Amiloride|Indometacin, Eplerenone, Amiloride
9955665|NCT01146197|Experimental|Indometacin, Amiloride, Eplerenone|Indometacin, Amiloride, Eplerenone
9955666|NCT01146210||Ancillary-correlative|Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
9955667|NCT01146223||Basic science (correlative studies)|Patient mRNA samples from diagnosis are analyzed via quantitative PCR to measure WT1 and VEGF-1 expression.
9955668|NCT01146236|Active Comparator|Sutures|Orthopedic surgical wound closed with sutures
9955669|NCT01146236|Active Comparator|Staples|Orthopedic surgical wound closed with metallic staples
9955670|NCT01146249||1: healthy subject|
9955671|NCT01146249||3: post stroke patients|
9955672|NCT01146249||2: vestibular patients|Vestibular patients with a unique history of peripheric vestibular disorder
9955673|NCT01146249||4: ataxic patients|Patient with proprioception disorder related to peripheral neuropathy
9955674|NCT01146249||5: Old fallers|Old subjects with a history of falls (one or more during the last year)
9955675|NCT01146301|Active Comparator|300 mg Loading dose clopidogrel|
9955676|NCT01146301|Experimental|600 mg Loading dose of clopidogrel|
9955677|NCT01146314|Experimental|Lifestyle intervention|A 6-month 14 session lifestyle intervention led by a psychologist and a dietitian for 90 minutes group sessions. Intervention sessions were help weekly, biweekly, and monthly over the course of 6 months.
9955678|NCT01146327|Experimental|PF-04620110|
9955679|NCT01146327|Placebo Comparator|Placebo Comparator|
9955680|NCT01146340|Experimental|SBRT|SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT
9955681|NCT01146353||CRRT Patients receiving Peramivir|"Eligible patients are male or female patients ≥18 years of age who are hospitalized, undergoing CVVH or CVVHD, and receiving peramivir.~Eligible patients will additionally have the following: blood flow rate will be required to be ≥100 mL/ min with an ultrafiltrate +/- dialysis flow rate greater than or equal to 3000mL/hr, and the continuous renal replacement therapy must be scheduled to run for the full duration of the dosing interval (full 24 hours).~Written informed consent in a form approved by the Northwestern University and the Midwestern University Institutional Review Boards will be granted by the patient."
9955682|NCT01146392||1|Primary care patients with COPD diagnosis
9955683|NCT01146431||Hemodynamic parameters|Hemodynamic parameters will be used as a guide for anesthesia.
9955684|NCT01146431||BIS|Bispectral Index (BIS) will be used as a guide for anesthesia.
9955685|NCT01146444|Experimental|sunscreens with a low, medium, high SPF|sunscreens with a low, medium, and high SPF. UVA and UVB irradiation
9955686|NCT01146444|Experimental|vehicle|Intra-individual application of vehicle in random order; UVA and UVB irradiation
9955687|NCT01146470|Experimental|RGC 200 mg|
9955688|NCT01146470|Experimental|RGC 400 mg|
9955689|NCT01146470|Placebo Comparator|Placebo|
9955690|NCT01146483|Active Comparator|Pantoprazole|two-arm study: 2-period, 2-sequence, cross-over study.Volunteers will be administered either sequence 1 or sequence 2 randomly.
9955691|NCT01146483|Placebo Comparator|Placebo|
9955692|NCT01146509|Experimental|1|
9955693|NCT01146535|Experimental|Interferon-alpha|"Interferon-alpha~150 IU lozenges bid for 5 days"
9955694|NCT01146535|Placebo Comparator|maltose|"maltose~200 mg maltose lozenges bid for 5 days"
9955695|NCT01146548|Experimental|the fluoxetine group|Multiple System Atrophy's patients with fluoxétine
9955696|NCT01146548|Placebo Comparator|the placebo group|Multiple System Atrophy's patients with placebo
10005473|NCT01585532||TB suspects with alternative final diagnosis|
10005474|NCT01585532||Confirmed tuberculosis patients|
10005475|NCT01585545||patients with NSCLC|
9955697|NCT01146587|Experimental|GangTrainer GT1|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period
9955698|NCT01146587|Experimental|Lokomat|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period
9955699|NCT01146587|Active Comparator|Conventional Physiotherapy|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period
9955700|NCT01146626|Active Comparator|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
9955701|NCT01146626|Experimental|Peg+ Ribavirine|Peg+ Ribavirine
9955702|NCT01146639|Experimental|MDCT and additional DynaCT|
9955703|NCT01146678|Experimental|Lantus(insulin glargine)/lixisenatide on-site mix|Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions
9955704|NCT01146678|Active Comparator|lixisenatide + Lantus (insulin glargine)|Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions
9955705|NCT01146691||Standard staffing model|All patients in participating ICUs during the blocks of time when a single intensivist staffs a participating ICU for a 7 day period. The intensivist will be present during daytime hours, and takes call from home afterwards.
9955706|NCT01146691||24-7 shiftwork staffing model|All patients in participating ICUs during the blocks of time when the 24-7 in-hospital intensivist coverage model is in place. This model is enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am. Call rooms will be provided to allow the night shift intensivist to sleep, if the workload permits.
9955707|NCT01146717|Experimental|Exercise|
9955708|NCT01146717|Placebo Comparator|Control group|
9955709|NCT01146730|Experimental|Workcoping and IPS|CBT based counseling and supported employment
9955710|NCT01146730|Active Comparator|Ordinary care by GP or NAV|Ordinary care by GP or The Norwegian Labour and Welfare Administration (NAV)
9955711|NCT01146743|Active Comparator|EUS-guided|EUS-guided gallbladder drainage in acute cholecystitis with high risk patients
9955712|NCT01146743|Active Comparator|percutaneous transhepatic|percutaneous transhepatic gallbladder drainage in acute cholecystitis with high risk patients
9955713|NCT01146756|Experimental|AZD6244 & Thoracic Radiotherapy|AZD6244 in combination with thoracic radiotherapy (RT)- the aim is to determine the recommended phase II dose (RP2D).
9955714|NCT01146769|Experimental|Pelvic floor exercise|
9955715|NCT01146769|No Intervention|Control|
9955716|NCT01146821|No Intervention|Standard care|Standard care
9955717|NCT01146821|Active Comparator|standard care + 0.20gm/kg fish oil|standard care + 0.20gm/kg fish oil
9955718|NCT01146821|Active Comparator|standard care + 0.50 gm/kg fish oil|standard care + 0.50 gm/kg fish oil
9955719|NCT01146847|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish tight glycaemic control
9955720|NCT01146886|Experimental|BI 135585|1 single dose per subject as oral solution in Part 1, or 3 single doses per subject as oral solution and 2 different tablet formulations in Part 2
9955721|NCT01146886|Placebo Comparator|Placebo to BI 135585|1 single dose per subject as oral solution in Part 1
9955722|NCT01146899|Experimental|Provider Alert|Provider receives alert for patient visit
9955723|NCT01146899|No Intervention|No Alert|No alert provided
9955724|NCT01146925|Experimental|CRMD-001-Deferiprone|
9955725|NCT01146925|Placebo Comparator|Placebo|
9955726|NCT01146938|Experimental|hepatic impairment patients|Hepatic impairment patients group Child-Pugh score A or Child-Pugh score B (not Child-Pugh score C)
9955727|NCT01146938|Active Comparator|Healthy volunteers|healthy volunteers group
9955728|NCT01146964|Experimental|Phacoemulsification, Safety, Efficacy|
9955729|NCT01146964|Experimental|MSSICS, Safety, Efficacy|
9955730|NCT01146977|Experimental|Autologous HCT|"5.1.3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~5.1.3.1. If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
9955731|NCT01146977|Active Comparator|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
9955732|NCT01146990||Infants Born to Mothers in the 17P-ES-003 Study|Infants Born to Mothers Who Participated in the 17P-ES-003 Study and whose mothers consented for them to be followed for this study.
9955733|NCT01147016|Experimental|HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy|"HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month~Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care."
9955734|NCT01147081|Experimental|Arm 1|
9955735|NCT01147120|Active Comparator|Progressive Muscle Relaxation|
9955736|NCT01147120|Active Comparator|Clinical Massage Therapy|
9955737|NCT01147133|Experimental|Original|Treatment phase with the original formulation of clopidogrel
9955738|NCT01147133|Active Comparator|Generic|Treatment phase with the generic clopidogrel
9955739|NCT01147159|Other|Skin Prick Test|
9955740|NCT01147185|Other|Intensive training|Locomotor training using a robotic device of at least 50 minutes
9955741|NCT01147185|Active Comparator|Standard training|Locomotor training using a robotic device of maximally 25 minutes
9955742|NCT01147198|Active Comparator|Ready to Use Supplementary Food|Ready to Use Supplementary Food treatment
9955743|NCT01147198|Active Comparator|Premix|Premix Corn Soy Blend-oil treatment
9955744|NCT01147211|Experimental|MK2206 in combination with Gefitinib|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
9955745|NCT01147224||ATEM|A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
9955746|NCT01147237|Experimental|Single arm study|
9955747|NCT01147263||Patients diagnosed with Fibromyalgia|
9955748|NCT01147276|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
9955749|NCT01147289|Experimental|dexalgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose for 3 days, at least
9955750|NCT01147289|Active Comparator|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose for at least 3 days.
9955751|NCT01147315|Experimental|Hybrid bone substitution|Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow
9955752|NCT01147328||1|Patients who did not have their data accessed in the VHR by a provider within 6 months after they consented will be part of the control group
9955753|NCT01147328||2|Patients who had their data accessed in the VHR by a provider within 6 months after they consented will be part of the intervention group
9955754|NCT01147354|Experimental|experimental group|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
9955755|NCT01147354|Placebo Comparator|control group|The patients in this arm took one placebo capsule daily for 12 weeks.
9955756|NCT01147367|No Intervention|Control|no physical activity intervention
9955757|NCT01147367|Experimental|Exercise intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
9955758|NCT01147419|Experimental|bypass|Patients presenting with long occlusion of the superficial femoral artery enrolled in bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery. And the graft will be artificial blood vessel.
9955759|NCT01147419|Experimental|stent|
9955760|NCT01147432|Experimental|PF-04427429|
9955761|NCT01147432|Placebo Comparator|Placebo|
9955762|NCT01147432|Active Comparator|EMLA|
9955763|NCT01147445|Experimental|Cohort 1: 5 mcg dmLT|6 subjects to receive 5 micrograms (mcg) of dmLT vaccine.
9955764|NCT01147445|Experimental|Cohort 4: 100 mcg dmLT|6 subjects to receive 100 mcg of dmLT vaccine.
9955765|NCT01147445|Experimental|Cohort 2: 25 mcg dmLT|6 subjects to receive 25 mcg of dmLT vaccine.
9955766|NCT01147445|Experimental|Cohort 3: 50 mcg dmLT|6 subjects to receive 50 mcg of dmLT vaccine.
9955767|NCT01147445|Experimental|Cohort 5: 50 mcg or 100 mcg dmLT|12 subjects randomized, double-blinded, to receive either 50 mcg or 100 mcg of dmLT vaccine.
9955768|NCT01147484|Experimental|Foretinib|
9955769|NCT01147510|Active Comparator|Monotherapy of medium dose ICS|
9955770|NCT01147510|Experimental|Combination of low ICS and montelukast|
9955771|NCT01147523|Experimental|Vitamin E|Vitamin E, capsules 400 mg daily, for 52 weeks
9955772|NCT01147549|Experimental|1|[C14]AZD9668
9955773|NCT01147562|Other|Lung Cancer Patients|Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
9955774|NCT01147575|Active Comparator|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH respectively the groups were switched for another 6 months (period 2).
9955775|NCT01147575|Placebo Comparator|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
9955776|NCT01147588|Experimental|1|lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg
9955777|NCT01147588|Experimental|2|omeprazole 80 mg + clopidogrel 300/75 mg
9955778|NCT01147588|Experimental|3|esomeprazole 40 mg + clopidogrel 300/75 mg
9955779|NCT01147588|Experimental|4|clopidogrel 300/75 mg alone
9955780|NCT01147614|Active Comparator|specialty mental health care referral|
9955781|NCT01147614|Experimental|Brief Cognitive Behavioral Therapy|
9955782|NCT01147679||bvFTD|This group will include 33 patients who have been diagnosed with behavioral variant frontotemporal dementia by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
9955783|NCT01147679||Alzheimer's disease|This group will include 33 patients who have been diagnosed with clinically probable Alzheimer's disease by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
9955784|NCT01147679||Controls|33 health individuals without clinically significant cognitive impairments will be enrolled in this study.
9955785|NCT01147692|Experimental|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
9955786|NCT01147705|Active Comparator|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks.
9955787|NCT01147705|Placebo Comparator|Placebo|Same number of tablets and appearance as active drug.
9955788|NCT01147718|Experimental|digoxin plus albiglutide|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of albiglutide, followed by a further single dose of 0.5mg digoxin on Day 38.
9955789|NCT01147731|Experimental|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
9955790|NCT01147757|Placebo Comparator|saline|Group S (n = 15): saline
9955791|NCT01147757|Experimental|remifentanil 0.3 mcg/kg/min|Group 0.3 (n = 15): remifentanil 0.3 mcg/kg/min
9955792|NCT01147757|Experimental|remifentanil 0.6 mcg/kg/min|Group 0.6 (n = 15): remifentanil 0.6 mcg/kg/min
9955793|NCT01147757|Experimental|remifentanil 0.9 mcg/kg/min|Group 0.9 (n = 15): remifentanil 0.9 mcg/kg/min
9955794|NCT01147770|Experimental|stop progesterone|
9955795|NCT01147783||SimBaby|
9955796|NCT01147783||Infants (1-12 mo)|
9955797|NCT01147796|Active Comparator|Thrombus|patients with positive TEE (thrombus)
9955798|NCT01147796|Placebo Comparator|No thrombus|patients with negative TEE (no thrombus)
9955799|NCT01147835|Placebo Comparator|Placebo Lollipop|The placebo group will ingest the same herbal lollipop formula without the active ingredient.
9955800|NCT01147835|Experimental|Chinese Licorice Root|The experimental group will ingest the herbal lollipop formula with the active ingredient.
9955801|NCT01147861|Placebo Comparator|Placebo|Subjects will receive 2 placebo tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
9955802|NCT01147861|Other|5mg BID|Subjects will receive 1 x 5mg tablet and 1 placebo tablet in the morning, and 1 x 5mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
9955803|NCT01147861|Other|10mg QD|Subjects will receive 2 x 5mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
9955804|NCT01147861|Other|25mg BID|Subjects will receive 1 x 25mg tablet and 1 placebo tablet in the morning, and 1 x 25mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
9955805|NCT01147861|Other|50mg QD|Subjects will receive 2 x 25mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
9955806|NCT01147887|Experimental|001|Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken.
9955807|NCT01147913|Experimental|Positive Interpretation Training|Four sessions of positive information-processing training for interpretation of ambiguous scenarios relevant to themes of depression.
9955808|NCT01147913|Sham Comparator|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
9955809|NCT01147952|Experimental|12 week exercise training|
9955810|NCT01147952|No Intervention|Conventional Care|
9955811|NCT01147965|Experimental|Ad5 CEA Vaccine|Single arm dose escalation study
9955812|NCT01147978|Experimental|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
9955813|NCT01147978|No Intervention|Usual Procedure|Usual discharge procedure from the ICU
9955814|NCT01148030||Single|3M Skin and Nasal Antiseptic
9955815|NCT01148043|Placebo Comparator|Placebo|
9955816|NCT01148043|Experimental|Hydroxychloroquine|
9955817|NCT01148069|Experimental|Surgery combined with IMRT-IGRT|
9955818|NCT01148095|Experimental|1|AZD2516 (dose escalating)
9955819|NCT01148095|Placebo Comparator|2|Placebo
9955820|NCT01148108|Experimental|Mantle Cell Lymphoma|Patients with relapsed or refractory mantle cell lymphoma
9955821|NCT01148108|Experimental|Diffuse Large B Cell Lymphoma|Patients with relapsed or refractory diffuse large B cell lymphoma
9955822|NCT01148108|Experimental|Multiple Myeloma|Patients with relapsed or refractory multiple myeloma
9955823|NCT01148134||Bcr-Abl positive ALL|
9955824|NCT01148134||Bcr-Abl negative ALL|
10005476|NCT01585571||Control|50 individuals of typical development with no known neuromuscular issues.
9476558|NCT03570710|Active Comparator|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
9955825|NCT01148147|Placebo Comparator|Placebo|Intracoronary Placebo administration
9955826|NCT01148147|Active Comparator|Adenosine|Intracoronary adenosine administration
9955827|NCT01148160||1|Patients with hematologic malignancies who were given voriconazole to treat invasive (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
9955828|NCT01148173|Experimental|Systemic and intrathecal chemotherapy|
9955829|NCT01148186|Experimental|Educational intervention|Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
9955830|NCT01148186|No Intervention|Wait-list group|
9955831|NCT01148199|Active Comparator|Multiple plastic stents|Multiple plastic stents placement after sphincterotomy and stricutre dilation. ERCP repeated every 3 - 4 months during 1-year
9955832|NCT01148199|Experimental|Self-expandable metalic stent|Self-expandable metalic stent after sphincterotomy. Stent removal scheduled for 6 months
9955833|NCT01148238||Diabetes type 1 older than 10 years|Blood samples will be taken from 10 patients with diabetes type 1 older than 10 years and 10 healthy age-and sexmatched controls.
9955834|NCT01148238||Newly diagnosed type 1 diabetes|Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes and 10 healthy age-and sexmatched controls.
9955835|NCT01148238||LADA|Blood samples will be taken from 10 patients with LADA and 10 healthy age-and sexmatched controls.
9955836|NCT01148264|Experimental|olanzapine|
9955837|NCT01148264|Active Comparator|metoclopramide|
9955838|NCT01148277|Active Comparator|Propofol and Remifentanyl|Propofol, colonoscopies, liver diseases, cirrhosis
9955839|NCT01148277|Active Comparator|midazolam and fentanyl|midazolam and fentanyl, colonoscopies, liver diseases
9955840|NCT01148277|Experimental|control midazolam anf fentanyl|midazolam anf fentanyl
9955841|NCT01148290|Active Comparator|Tension free vaginal tape|
9955842|NCT01148290|Experimental|Bulking agent injection|
9955843|NCT01148303|Experimental|Etoricoxib First|This arm will receive etoricoxib for six days, followed by placebo for eight days.
9955844|NCT01148303|Experimental|Etoricoxib Second|This arm will get placebo for eight days before beginning their fast, followed by etoricoxib for six days.
9955845|NCT01148316|Active Comparator|Fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
9955846|NCT01148316|Active Comparator|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
9955847|NCT01148329||Single arm observational study|To evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice
9955848|NCT01148368|Experimental|renal impairment patients|renal impairment patients who eGFR is lower than 30 ml/min/1.73m^2 without hemodialysis
9955849|NCT01148368|Active Comparator|healthy volunteers|healthy volunteers group
9955850|NCT01148394|No Intervention|Traditional|Involves traditional management of patients with preoperative mechanical bowel preparation, no preoperative education, nasogastric tube, delayed feeding and mobilisation, use of drains
9955851|NCT01148394|Active Comparator|Multimodal rehabilitation|Involves preoperative patient education, no preoperative mechanical bowel preparation, no nasogastric tube, early oral feeding and mobilisation, physiotherapy
9955852|NCT01148433||TESTIM® - drug given by prescription|Male patients with Hypogonadism
9955853|NCT01148446|Experimental|R-CHOP|R-CHOP (every 21 days) for six courses Cyclophosphamide: 750 mg/m2, IV, day 1 Doxorubicin: 50 mg/m2, IV, day 1 Vincristine: 1.4 (max 2) mg/m2, IV, day 1 Prednisone: 75 mg/m2, IV, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
9955854|NCT01148446|Experimental|R-mini-CEOP|R-miniCEOP (every 21 days)for six courses Cyclophosphamide: 50 mg/m2, IV, day 1 Epirubicin: 50 mg/m2, IV, day 1 Vinblastine: 5 mg/m2, IV, day 1 Prednisone: 60 mg/m2, IV/PO, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
9955855|NCT01148472|Experimental|Escitalopram|
9955856|NCT01148472|Active Comparator|Duloxetine|
9955857|NCT01148576|Other|control group|patients only with chronic hepatitis B
9955858|NCT01148576|Active Comparator|model group|patients with chronic hepatitis B and hepatic steatosis
9955859|NCT01148576|Experimental|Essentiale group|patients with chronic hepatitis B and hepatic steatosis
9955860|NCT01148576|Experimental|treatment group 2|patients with chronic hepatitis B and hepatic steatosis
10005477|NCT01585571||Adults with CP|50 Individuals with a pediatric diagnosis of spastic, hemiplegic, diplegic or quadriplegic cerebral palsy.
10005478|NCT01585610|Experimental|DVD Program|
10005479|NCT01585610|Active Comparator|Standard Care Printed Materials|
10005480|NCT01585623|Experimental|Segment 1|two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
10005481|NCT01585623|Experimental|Segment 2|SAR302503 500 mg once daily without food in 28-day per cycle
10005482|NCT01585636|Experimental|5 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
10005483|NCT01585636|Experimental|10 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
10005484|NCT01585636|Experimental|20 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
10005485|NCT01585636|Experimental|50 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
10005486|NCT01585636|Experimental|100 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
10005487|NCT01585636|Experimental|200 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
10005488|NCT01585636|Experimental|300 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
10005489|NCT01585636|Experimental|Food effect group|6 Subjects received single, 300 mg SQ109 after high-fat, high-calorie meal.
10005490|NCT01585649|Experimental|XM22, 100 μg/kg BW|
10005491|NCT01585662|Experimental|Naso-pancreatic tube|The patients enrolled in this group will be treated with modified naso-pancreatic tube drainage method.
10005492|NCT01585662|Experimental|Stents|The patients enrolled this group will be treated by placing the stents (at least 2 stents) between gastric and pancreatic pseudocyst.
10005493|NCT01585727|Experimental|TME with neuromonitoring|Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
10005494|NCT01585727|Active Comparator|TME without neuromontoring|Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
10005495|NCT01585740|Active Comparator|Normal Saline|250 patients in this arm assigned to receive normal saline as the study fluid
10005496|NCT01585740|Active Comparator|Ringer's Lactate|250 patients in this arm assigned to receive Ringer's Lactate as the study fluid
10005497|NCT01585753||Arm 1|NRTI and PI
10005498|NCT01585753||Arm 2|Maraviroc + PI
10005499|NCT01585753||Arm 3|maraviroc + NRTI
10005500|NCT01585792|Experimental|TAK-875 25 mg|
9955861|NCT01148602|No Intervention|'Off Clock'|"Stopwatch timers will NOT be used for off clock weeks, so patients presenting with hyperacute stroke will be managed normally without the visual timer."
9955862|NCT01148602|Active Comparator|"'On Clock"|"LED stopwatch-clock timers will be posted for all patients presenting during ON clock weeks. All patients presenting with hyperacute stroke will be managed normally with the addition of a visual stopwatch timer."
9955863|NCT01148615|Experimental|Aflibercept/ docetaxel|"Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks"
9955864|NCT01148628|Experimental|RAD 001 in combination with CaelyxTM|"RAD001 will be given p.o. at increasing doses (no intra-patient)and CaelyxTM will be administered i.v. at a fixed dose.~At each dose level 3 to 6 patients will be entered, according to toxicities observed; the first 3 patients can be treated simultaneously; subsequent patients can be treated after the first 3 have been observed for at least one cycle (4 weeks).~The dose escalation process will be discontinued once the MTD has been achieved and the RD will be evaluated in a subsequent expansion part of the study."
9955865|NCT01148641||LNS-regular|Lipid-based nutrient supplement, regular (peanut) flavor
9955866|NCT01148641||LNS-cinnamon|Lipid-based nutrient supplement, cinnamon flavor
9955867|NCT01148654||1- Preterm Labor 22.0-33.6 weeks gestational age|Pregnant women between 22.0 and 33.6 weeks gestational age presenting to the Hospital of the University of Pennsylvania (HUP) complaining of Preterm labor (PTL), preterm premature rupture of membranes (PPROM), or cervical insufficiency (CI).
9955868|NCT01148654||2- Preterm birth 34-36.6 weeks gestational age|Pregnant women delivering at the University of Pennsylvania between 34.0 and 36.6 weeks gestational age
9955869|NCT01148667|Active Comparator|Infants drink formula added with LGG|Infants have been randomized (1:1) to get casein hydrolysate with or without LGG
9955870|NCT01148667|Placebo Comparator|Infants drink casein hydrolysate without LGG|Infants get extensively hydrolysed casein formula
9955871|NCT01148680|Experimental|immediate registration on islet graft list|"group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
9955872|NCT01148680|Active Comparator|delayed registration on islet graft list|"group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
9955873|NCT01148706|Experimental|ActiSight Needle Guidance System|
9955874|NCT01148719|Active Comparator|Index group|Patients in the index group receive the diagnostic triage instrument. This includes echocardiographic, electrocardiographic and spirometric measurements and blood testing.
9955875|NCT01148719|No Intervention|Control|Participants receive care as usual.
9955876|NCT01148732||Patient needed intubation in emergency department|
9955877|NCT01148758|Experimental|Single Arm|
9955878|NCT01148784|Active Comparator|Quadrupled Hamstring Allograft|
9955879|NCT01148784|Active Comparator|Doubled Tibialis Anterior Allograft|
9803627|NCT03681912||Sustainment Block 4 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
9955880|NCT01148797|Experimental|Canakinumab|
9955881|NCT01148823|Experimental|Postoperative day 1|Dressing was removed on the first postoperative day
9955882|NCT01148823|Experimental|Postoperative day 6|Dressing was removed on the 6th postoperative day
9955883|NCT01148888|Experimental|Magnesium Sulfate|The study will be conducted in the 45 minute interval between the completion of spinal instrumentation and the completion of skin closure. Once the spinal instrumentation is complete and the integrity of the spinal cord pathways is confirmed using SEPs and MEPs, magnesium will be administered for the remainder of surgery.
9955884|NCT01148901|Experimental|Remicade|Infliximab 5 mg/kg was administered as specified in the Summary of Product Characteristics for patients with ankylosing spondylitis
9955885|NCT01148914||Baseline level of biomarkers|
9955886|NCT01148927||Adult acute lymphoblastic leukemia patients|
9955887|NCT01148953|Active Comparator|ALN-TTR01|
9955888|NCT01148953|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
9955889|NCT01148966|Experimental|Treatment (photodynamic therapy)|Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
9955890|NCT01148992|Active Comparator|Lofexidine|
9955891|NCT01148992|Placebo Comparator|Placebo|
9955892|NCT01149005|Experimental|insulin|patients who will get insulin with main meals during Intravenous (IV) antibiotic therapy due to pulmonary exacerbation
9955893|NCT01149018|Experimental|Tetrahydrocannabinol|
9955894|NCT01149018|Placebo Comparator|Placebo|
9955895|NCT01149031|Active Comparator|low level laser therapy, using a probe|"The treatment will be done by using a LLL-probe touching several areas of the vulvar vestibule, according to the selected protocol.~Every patient will be treated twice weekly for 6 weeks."
9955896|NCT01149031|Placebo Comparator|Placebo|The patients will be treated with placebo-probe, according to the same protocol
9955897|NCT01149044|Active Comparator|Upfront Thrombectomy followed by PCI|Upfront manual aspiration thrombectomy followed by PCI
9955898|NCT01149044|Active Comparator|PCI Alone|PCI without upfront manual aspiration thrombectomy
9955899|NCT01149109|Experimental|lomustine (CCNU) + temozolomide (TMZ) and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
9955900|NCT01149109|Active Comparator|temozolomide and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2
9955901|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin with Erlotinib|
9955902|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin without Erlotinib|
9955903|NCT01149135|Active Comparator|Standard light treatment|standard light treatment 5000K; 10 000 lux
9955904|NCT01149135|Experimental|blue enriched light|Blue enriched light with a low intensity (750 lux)
9955905|NCT01149161|Active Comparator|C group|Routine central neck dissection
9955906|NCT01149161|No Intervention|N group|No central neck node dissection
9955907|NCT01149174|No Intervention|transurethral resection alone|Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
9955908|NCT01149174|Active Comparator|intravesical mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
9955909|NCT01149174|Experimental|electromotive mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection
9955910|NCT01149187||IGRA in solitary pulmonary nodules|Inpatients who undergo percutaneous needle biopsy for diagnosis of pulmonary nodules in Seoul National University hospital for six months are going to be included. Patients who are not tolerable for PCNB or do not agree the enrollment of study will be excluded.
9955911|NCT01149200|Experimental|TC-6499|
9955912|NCT01149200|Placebo Comparator|Placebo|
9955913|NCT01149213|Experimental|Transcranial Direct Current Stimulation|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~The patient will receive tDCS every other week during the first three months, then once a month during the next three months."
9955914|NCT01149226|Placebo Comparator|placebo control|
9955915|NCT01149226|Experimental|oral medication chloral hydrate|
9955916|NCT01149252|Placebo Comparator|Psoralait|
9955917|NCT01149265|Experimental|Online support group|
9955918|NCT01149265|Active Comparator|Expressive writing|
10005501|NCT01585792|Experimental|TAK-875 50 mg|
9803628|NCT03681912||Sustainment Block 5 CoP Along|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
9955919|NCT01149278|Active Comparator|high pressure|
9955920|NCT01149278|Placebo Comparator|normal pressure|
9955921|NCT01149291||End stage renal disease patients|
9955922|NCT01149304|Experimental|Group A|Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
9955923|NCT01149304|No Intervention|Group B|Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.
9955924|NCT01149317|Experimental|Acupuncture|Weekly acupuncture treatment for up to 14 weeks
9955925|NCT01149330|Experimental|Adapalene-BPO Gel|
9955926|NCT01149356|Experimental|Arm I|Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9955927|NCT01149356|Active Comparator|Arm II|Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9955928|NCT01149382||islet cell transplant recipients|
9955929|NCT01149395|Experimental|Dexlansoprazole|
9955930|NCT01149408|Experimental|All patients|All participants enrolled.
9955931|NCT01149499|Experimental|Valacyclovir|Test 1000 mg Valacyclovir Tablet
9955932|NCT01149499|Active Comparator|Valtrex|Reference Listed 1000 mg Valtrex Tablet
9955933|NCT01149525|Experimental|1|oral solution of L-Carnitine, 4g per day
9955934|NCT01149525|Placebo Comparator|2|Similar oral solution without L-Carnitine
9955935|NCT01149551||Group 1|
10005502|NCT01585792|Active Comparator|Glimepiride|
10005503|NCT01585792|Placebo Comparator|Placebo|
10215499|NCT03702959||Betamethasone Group 3|Betamethasone Group 3 (5pm-11pm)
10215500|NCT03702959||Betamethasone Group 4|Betamethasone Group 4 (11pm-5am).
10215501|NCT03702946|Experimental|study group|
10215502|NCT03702946|No Intervention|control group|
10215503|NCT03702933||Placebo|starch
10215504|NCT03702933||High Dose|3.5 g/d D-serine adjuvant treatment
10215505|NCT03702933||Low Dose|2.1 g/d D-serine adjuvant treatment
10215506|NCT03702920|Experimental|SMT+ PE-A 5%|PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.
10215507|NCT03702920|Active Comparator|Standard Medical Treatment (SMT)|Standard medical treatment (SMT) will be administered according to institution standards.
10215508|NCT03702907||Normal Cognition|No diagnosis of a cognitive disorder
10215509|NCT03702907||Cognitive Disorder|Diagnosed with a cognitive disorder such as :Mild Cognitive Impairment, Alzheimer's disease, Frontotemporal Dementia, Lewy Body Dementia, Vascular Dementia, or other neurodegenerative condition.
10215510|NCT03702894|Experimental|Clavamox,Coated Tablets, 875 mg + 125 mg|Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
10215511|NCT03702894|Active Comparator|Augmentin®, Coated Tablets, 875 mg + 125 mg|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
10215512|NCT03702881|Experimental|Bonded Spurs associated with posterior build-ups Group|The experimental group will consist of 25 patients treated with bonded spurs associated with build-ups.
10215513|NCT03702881|Active Comparator|Conventional bonded spurs Group|Active comparator group will consist of 25 patients treated with conventional bonded spurs
9955936|NCT01149564|Placebo Comparator|IV ibuprofen|The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
9955937|NCT01149564|Active Comparator|Oral ibuprofen|
9955938|NCT01149577|Experimental|Schizophrenia patients|The study population of 25 schizophrenia patients constituted the active arm of the study.
9955939|NCT01149590|Experimental|CT Calcium Score & Coronary Angiography|CT Scan
9955940|NCT01149590|No Intervention|No CT Scan|No CT Scan
9955941|NCT01149603|Experimental|Implantation of the HeartMate II VAD|Consenting patients who meet the study inclusion and exclusion criteria will be implanted with a HeartMate II ventricular assist device.
9955942|NCT01149629|Active Comparator|Fed Dosing|Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules
9955943|NCT01149629|Active Comparator|Fasted Dosing|Subjects fasted prior to receiving 3 x 100mg capsules
9955944|NCT01149629|Active Comparator|Bioequivalence|Subjects fasted prior to receiving 1x 300mg capsule
9955945|NCT01149629|Active Comparator|TID Dosing|Droxidopa 300 mg given TID
9955946|NCT01149642|Experimental|Oral immunomodulatory solution|The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.
9955947|NCT01149642|Placebo Comparator|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
9955948|NCT01149668|Experimental|PCI-24781|
9955949|NCT01149694|Other|Cohort 1|
9955950|NCT01149694|Other|Cohort 2|
9955951|NCT01149694|Other|Cohort 3|
9955952|NCT01149694|Other|Cohort 4|
9955953|NCT01149707|Experimental|PUR 0110 Rectal Enema 250 mg|Active treatment
9955954|NCT01149707|Experimental|PUR 0110 Rectal Enema 500 mg|Active treatment
9955955|NCT01149707|Experimental|PUR 0110 Rectal Enema 1000 mg|Active treatment
9955956|NCT01149707|Placebo Comparator|Placebo Enema|Placebo comparator
9955957|NCT01149720|Experimental|ARQ 197 Capsule, oral|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
9955958|NCT01149720|Experimental|ARQ 197 Tablet, oral|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
9955959|NCT01149720|Experimental|ARQ 197 Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
9955960|NCT01149746|Experimental|Tamsulosin|0.4 mg Capsule
9955961|NCT01149746|Active Comparator|Flomax®|0.4 mg Capsule
9955962|NCT01149798|Experimental|Abraxane and Cisplatin combination|Abraxane and Cisplatin combination
9955963|NCT01149811||Fipamezole ODT Cohort 1|
9955964|NCT01149811||Fipamezole ODT Cohort 2|
9955965|NCT01149824|Other|Dose Escalating|
9955966|NCT01149837||residual blood donor samples|Protocol describes testing an HTLV-I/II antibody reactive population from this cohort using the InnoLIA HTLV I/II Score line immunoassay
9955967|NCT01149889|Experimental|active stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
9955968|NCT01149928||C/S delivered, wet lung|
9955969|NCT01149928||C/S delivered, healthy infants|
9955970|NCT01149941|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
9955971|NCT01149941|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
9955972|NCT01149954|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
9955973|NCT01149954|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
9955974|NCT01149967|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
9955975|NCT01149967|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
9955976|NCT01149980|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
9955977|NCT01149980|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
10215514|NCT03702855|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
10215515|NCT03702855|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
10215516|NCT03702829|Experimental|Experimental Drug|Inotersen, a transthyretin (TTR) antisense oligonucleotide. Administered subcutaneously weekly. Each dose shall contain 300 mg of active drug. Subsequent visits will occur at 3, 6, 12, 18 and 24 months. Every 2 weeks, blood will be monitored for renal function and platelet count and urine will be tested by dipstick for proteinuria.
10215517|NCT03702816|Experimental|Alzheimer's Disease|"Alzheimer's Disease (N=20)~GE180 PET Scan"
10215518|NCT03702816|Experimental|Parkinson's Disease|"Parkinson's Disease (N=20; 10 with PD-MCI, 10 PD with no cognitive impairment)~GE180 PET Scan"
10215519|NCT03702816|Experimental|Control|"Control Group (N=10)~GE180 PET Scan"
10215520|NCT03702816|Experimental|Mild Cognitive Impairment|"Mild Cognitive Impairment (N=20; 10 florbetapir positive, 10 florbetapir negative)~GE180 PET Scan"
10215521|NCT03702803|Experimental|Galphimia glauca standardized extract|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the experimental group and will be assigned the treatment consisting of hard gelatin capsules with a pharmaceutical formulation prepared with a standardized extract from G. glauca, which will be administered once a day.
10215522|NCT03702803|Active Comparator|alprazolam 1mg|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the control group and will be assigned the treatment consisting of hard gelatin capsules with the drug Alprazolam (1 mg ), which will be administered once a day.
9955978|NCT01149993|Experimental|pre-transplant immunosuppression|subjects in this arm will receive Myfortic 720mg twice daily for 7 days prior to transplantation. Intra-operatively, the donor kidney will receive an infusion of Thymoglobulin, prior to the transplantation.
9955979|NCT01149993|Experimental|pre-transplant induction|subjects in this arm will not receive any pre-transplant immunosuppression. However, the donor kidney will receive an infusion of Thymoglobulin prior to transplantation.
9955980|NCT01149993|Active Comparator|standard of care|subjects in this arm will not receive any pre-transplant immunosuppression, and the donor kidney will not receive an additional dose of Thymoglobulin prior to transplantation. This is the standard of care protocol for Georgetown University Hospital
9955981|NCT01150006||Healthy male participants|
9955982|NCT01150019||Obese Group|
9955983|NCT01150019||Non Obese Group|
9955984|NCT01150032||Osteopenic women|Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)
9955985|NCT01150071||Children born extremely preterm|national cohort of children born before 28 weeks' gestational age or with a birthweight less than 1000 g. 365 eligible survivors
9955986|NCT01150084|Experimental|lunchtime walking|
9955987|NCT01150084|Other|waiting-list control|
9955988|NCT01150136||1|Children with proven CF and known genotype, age 0-17 yr
9955989|NCT01150149|No Intervention|1|
9955990|NCT01150149|Experimental|2|No face touch
9803629|NCT03679312|Experimental|COPD Group|COPD to receive either placebo or inhaled nitric oxide (40ppm)
9955991|NCT01150149|Experimental|3|Surgical face mask
9955992|NCT01150149|Experimental|4|Surgical face mask + no face touch
9955993|NCT01150162|Experimental|Mucosta and Omeprazole|
9955994|NCT01150162|Active Comparator|Omeperazole|
9955995|NCT01150175|Experimental|Autologous bone marrow cells|
9955996|NCT01150175|Placebo Comparator|Plasma|
9955997|NCT01150188|Active Comparator|Amino acids|Amino acid supplementation between meals for eight weeks
9955998|NCT01150188|Placebo Comparator|Placebo|Supplementation of placebo (inert components) between meals for eight weeks
9955999|NCT01150201|Experimental|Aliskiren|Aliskiren
9956000|NCT01150201|Active Comparator|Losartan|ARB
9956001|NCT01150214||DE-MRI|All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
9956002|NCT01150240||Primary Immunodeficiency Disease|Patients with primary Immunodeficiency disease (PID)
9956003|NCT01150253|Experimental|probiotic fermented milk|
9956004|NCT01150253|Placebo Comparator|placebo|
9956005|NCT01150266|Experimental|Alteplase|Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
9956006|NCT01150292|Experimental|DHA - Sunflower oil|400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
9956007|NCT01150292|Experimental|Sunflower oil - DHA|Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
9956008|NCT01150305||1|Patient presenting familial dominant non syndromic hearing loss starting between 4 and 40 years old, over 2 generations
9956009|NCT01150305||2|Healthy volunteer from the same families
9956010|NCT01150318|Experimental|1|Patients treated by 131 iodine for thyroid cancer
9956011|NCT01150331|Experimental|Clonazepam + levetiracetam|Clonazepam IV 1 mg+ levetiracetam IV 2500 mg
9956012|NCT01150331|Active Comparator|Clonazepam + placebo|Clonazepam IV 1 mg + placebo levetiracetam IV
9956013|NCT01150344|Active Comparator|Malarone|"Malarone (atovaquone + proguanil combination):~patients treated with Malarone®"
9956014|NCT01150344|Active Comparator|Riamet|"RIAMET (artemether + LUMEFANTRIN combination):~patients treated with Riamet®"
10005504|NCT01585818|Active Comparator|standard dietary intervention (SDI) arm|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
10005505|NCT01585818|Experimental|LGI intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI. Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
10005506|NCT01585844||Women with sleep apnea|
10005507|NCT01585844||Women without sleep apnea|
10005508|NCT01585857|Experimental|Group 1|2 x 10E6 ASC intra-articular injection (5 ml)
10005509|NCT01585857|Experimental|Group 2|10 x 10E6 ASC intra-articular injection (5 ml)
10005510|NCT01585857|Experimental|Group 3|50 x 10E6 ASC intra-articular injection (5 ml)
10005511|NCT01585870|Experimental|Sorafenib + Eribulin|
10005512|NCT01585883|Experimental|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session.
10005513|NCT01585883|Active Comparator|Standard of care|Patients in this condition will receive usual care as decided by their oncology clinic team or physician.
10005514|NCT01585896|Experimental|Self-help group|The facilitated self-help group, which represents an empirically supported intervention for hoarding (Frost et al., 2011).
10005515|NCT01585909|Other|Septic Shock|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with septic shock
10005516|NCT01585909|Other|SIRS|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with SIRS
10005517|NCT01585909|Other|healthy/controls|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients without SIRS/septic shock
10005518|NCT01585922|Experimental|NPPV|Use the NPPV to treat moderate ARDS
10005519|NCT01585922|Active Comparator|IMV|Use invasive mechanical ventilation in treating the patients allocated to this group.
10005520|NCT01585935|Experimental|Smoflipid|SMOFLIPID will be used for parenteral lipid supply
10005521|NCT01585935|Active Comparator|Intralipid|INTRALIPID will be used for parenteral lipid supply
10005522|NCT01585948||Diabetes Mellitus|All patients undergoing coronary angiography who are diabetics.
10005523|NCT01585948||No diabetes mellitus|All patients undergoing coronary angiography that are non-diabetics.
10005524|NCT01585948||Coronary angiography patients|Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
10005525|NCT01585974||Group 1|
10005526|NCT01586000|Experimental|10 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
10005527|NCT01586000|Experimental|20 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
10005528|NCT01586000|Experimental|40 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
10215523|NCT03702790||Back pain SPECT evaluation|Patients with poorly localized back pain being imaged for clinical decision making
10215524|NCT03702777|Experimental|ASP8302 100mg|Participants will receive ASP8302 100mg capsules orally once daily for up to 4 weeks.
10215525|NCT03702777|Placebo Comparator|Placebo|Participants will receive ASP8302 matching placebo orally once daily for up to 4 weeks.
10215526|NCT03702764||VP-SG 01|Study subjects that present concentric coronary plaques
10215527|NCT03702764||VP-SG 02|Study subjects that present eccentric coronary plaques
10215528|NCT03702738|Experimental|NAC|Patients will be randomized to receive standard TB treatment with N-acetylcysteine 1200 mg BID x 4 months, followed by 2 months of standard TB treatment alone
10215529|NCT03702738|No Intervention|No NAC|Patients will be randomized to receive 6 months standard TB treatment alone
10215530|NCT03702712|Active Comparator|Aerobic Exercise Only|Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
10215531|NCT03702712|Active Comparator|Relaxation Only|Participants in the Relaxation Only arm will complete three separate 20-minute sessions of relaxation using a commercial wearable neurofeedback (headband) device. The device's accompanying software (connected to the headband through Bluetooth) encourages breathing strategies in response to recorded brain wave activity. Real time auditory feedback includes sounds of calm (soft) or loud winds in response to detected brain activity. A visual report of affective states and the user's brain activity is given (alpha and beta waves). Participants will also be asked to take part in 20 minutes of uninterrupted quiet rest in order to match the time of the aerobic only condition.
9956015|NCT01150370|Experimental|Males undergoing circumcision|
9956016|NCT01150383|Active Comparator|group RO (Room air / Oxygen)|RO (Room air / Oxygen): First 6 weeks of exercise training under normoxic conditions (Room air), followed by 6 weeks of exercise training with oxygen supplementation.
9956017|NCT01150383|Active Comparator|group OR (Oxygen / Room air)|OR (Oxygen / Room air): First 6 weeks of exercise training with oxygen supplementation, followed by 6 weeks of exercise training under normoxic conditions (room air).
9956018|NCT01150422|No Intervention|Standard of care for post medical abortion follow-up|Standard of care includes a routine hospital visit two weeks after mifepristone administration. At the hospital visit, the woman will undergo a bimanual and vaginal ultrasound examination. In the event the woman fails to return for the follow-up visit, each hospital will follow their standard procedure for contacting women who fail to attend their follow-up visit, i.e. three efforts to contact the woman. Form 2a will document the results of any clinical examinations, any additional medical abortion-related care given and the abortion outcome. At the follow-up visit, women will also be asked about the acceptability of current medical abortion follow-up procedures and their future preferences.
9956019|NCT01150422|Active Comparator|Alternative follow-up|"At their first clinic visit, women will be asked to provide their phone number for contact purposes. Women will also be asked to complete a semi-quantitative pregnancy test in the clinic and the results of the test will be noted on a study form. After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist.~Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned date two weeks after mifepristone administration. The checklist will indicate that if the woman answers yes to any of the questions, then she should return to the clinic for a follow-up visit. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests."
9956020|NCT01150435||Maintenance Medication D, S- Methadon|
9956021|NCT01150435||Maintenance Medication S- Methadon|
9956022|NCT01150435||Buprenorphine|
9956023|NCT01150435||Buprenorphine+ Naloxone|
9956024|NCT01150448|Experimental|001|Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
9956025|NCT01150448|Experimental|002|Paliperidone palmitate Treatment B Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq patients who do not wish to have multiple blood samples collected will also be assigned to Treatment B
9956026|NCT01150487|Experimental|Sensitized Renal Allograft Recipients|Patients who have antibodies against their donors in their blood.
9956027|NCT01150513|Active Comparator|EC-T|
9956028|NCT01150513|Experimental|TP|
9956029|NCT01150526|Placebo Comparator|Placebo|Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
9956030|NCT01150526|Experimental|CaHMB Pre|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
9956031|NCT01150526|Experimental|CaHMB Pre and Post|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
9956032|NCT01150526|Experimental|HMB Free Acid Gel Pre|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
9956033|NCT01150526|Experimental|HMB Free Acid Gel Pre and Post|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
9956034|NCT01150539|Experimental|Overweight/obese women with PCOS|10 overweight/obese women with polycystic ovary syndrome
9956035|NCT01150552||Poultry exposed individuals|Any individual who had an occupational contact with poultry in the previous five years will be considered exposed. Individuals working on poultry farms, poultry wet markets, or keeping limited numbers of poultry in their backyard, are considered exposed.
9956036|NCT01150552||Non-poultry exposed adult controls|Unexposed individuals must have no occupational exposure to poultry in their lifetime and must also not be exposed to poultry purchased from live bird markets.
9956037|NCT01150565|Experimental|LiRIS low dose|The first dose group of approximately 10 patients receive low dose LiRIS on Day 1 to Day 14.
9956038|NCT01150565|Experimental|LiRIS high dose|The second dose group of approximately 10 patients receive high dose LiRIS on Day 1 to Day 14.
9956039|NCT01150578||Lexi-Echo pilot|Appropriate patients at University of Arizona Medical Center stress imaging laboratory who have a routine regadenoson SPECT nuclear scan will have simultaneous cardiac echo images obtained.
9956040|NCT01150604|Experimental|Self-help course|
9803630|NCT03679312|Experimental|Control Group|Control group to receive either placebo or inhaled nitric oxide (40ppm)
9956041|NCT01150617|Active Comparator|long-acting insulin plus analogues|three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.
9956042|NCT01150617|Active Comparator|long-acting insulin and oral agents|treatment will be once-daily long-acting insulin and oral antidiabetic agents
9956043|NCT01150630|Experimental|adjuvant PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
9956044|NCT01150630|Experimental|perioperative PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
9956045|NCT01150630|Active Comparator|Adjuvant Gemcitabine|Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months
9956046|NCT01150669||Observational|Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.
9956047|NCT01150747||Risk of positive chlamydia|"current, untreated endocervical C. trachomatis infection~mucopurulent cervicitis on pelvic examination~Sexual contact with a male partner recently diagnosed with C. trachomatis, and/or non-gonococcal urethritis"
9956048|NCT01150786|Experimental|selenium|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
9956049|NCT01150786|Placebo Comparator|placebo capsule|The patients in this arm took one placebo capsule daily for 12 weeks.
9956050|NCT01150812|Experimental|1|
9956051|NCT01150825||STEMI|Patients with ST segment elevation myocardial infarction, verified by elevated troponin levels
9956052|NCT01150825||NSTEMI|Patients with non-ST segment elevation myocardial infarction, verified by elevated levels of troponin
9956053|NCT01150851|Active Comparator|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
9956054|NCT01150851|Active Comparator|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
9956055|NCT01150851|Active Comparator|caloric restriction and aerobic exercise|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration, and supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
9956056|NCT01150851|No Intervention|usual diet and usual activity|usual diet and usual activity
9956057|NCT01150864|Active Comparator|Passive Humidifier|The Passive Humidifier (HME)will changed every 24 hours
9956058|NCT01150864|Active Comparator|Active-Passive humidifier|The Active-Passive Humidifier will be changed every 24 hours
9956059|NCT01150864|Active Comparator|Hot Water Humidifier|Hot water humidifier will be set at 36-37 °C
9956060|NCT01150877|Experimental|Experimental Dietary Supplement (e.g., vitamins, minerals)|Experimental arm is supplemented with high-dose of vitamin D.
9956061|NCT01150877|No Intervention|No Intervention|
9956062|NCT01150916|Active Comparator|Heart failure|Patients must fulfill Framingham and/or Boston criteria for heart failure and have systolic or diastolic disfunction in rest echocardiography.
9956063|NCT01150916|Active Comparator|Liver Cirrhosis|Patients must have a biopsy proven diagnosis of liver cirrhosis or the diagnosis established on clinical basis in cases of known etiology of liver disease, peripheral signs of chronic liver disease, esophageal varices at endoscopy and an imaging method with evidence of cirrhosis.
9956064|NCT01150916|Active Comparator|Other causes of ascites|Patients must fulfill stringent diagnostic criteria for the cause of ascites, by clinical criteria, laboratory and imaging tests and histology when appropriate.
9956065|NCT01150916|Active Comparator|Concurrent heart failure and cirrhosis|Patients must fulfill the aforementioned criteria for both conditions.
9956066|NCT01150929|Active Comparator|Fixed bearing|One of the 2 used implants.
9956067|NCT01150929|Active Comparator|Rotating platform|One of the 2 used implants.
9956068|NCT01150942|Experimental|vero cell-derived JE vaccine|vero cell-derived vaccine group
9956069|NCT01150942|Active Comparator|Mouse brain-derived JE vaccine|Mouse brain-derived JE vaccine group
9956070|NCT01150955|Active Comparator|Resveratrol|Dietary supplement of resveratrol 500 mg three times a day over five weeks.
9956071|NCT01150955|Placebo Comparator|Placebo|
9956072|NCT01150968|Experimental|Internal Medicine Residents|All UCSf Internal Medicine residents for 2009-2010
9956073|NCT01150994|No Intervention|Treatment as Usual|
9476559|NCT03570684|Experimental|tie group|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was much easier as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum.
9956074|NCT01150994|No Intervention|Screening Alone|Enhanced screening among ED patients
9956075|NCT01150994|Experimental|Safety Assessment and Follow-up Telephone Intervention|SAFTI: Safety Assessment in the ED combine with a Follow-up Telephone Intervention.
9956076|NCT01151007||Patients with colorectal carcinoma|Patient with colorectal carcinoma operated in Martinique between January 1st, 2007 and December 31st, 2009
9956077|NCT01151033|Experimental|stent implantation|ProNOVA XR Polymer Free Drug Eluting Stent implantation - single arm
9956078|NCT01151059|Other|Group 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
9956079|NCT01151072|Experimental|IDeg i.m. thigh|
9956080|NCT01151072|Experimental|IDeg i.v.|
9956081|NCT01151072|Experimental|IDeg s.c. abdomen|
9956082|NCT01151072|Experimental|IDeg s.c. deltoid|
9956083|NCT01151072|Experimental|IDeg s.c. thigh|
9956084|NCT01151176|Active Comparator|Insulin|Intensive Insulin Therapy
9956085|NCT01151176|Other|Regular Insulin|Sub Cutaneous Regular Insulin
9956086|NCT01151202|Experimental|AG NPP709 syrup|AG NPP709 contains Ivy leaf extract and coptis rhizoma extract
9956087|NCT01151202|Active Comparator|Ivy leaf extract syrup|
9956088|NCT01151228|Placebo Comparator|Zero volume|Patients will not ingest any apple juice prior to the second ultrasound.
9956089|NCT01151228|Experimental|50 mL|Patients will ingest 50 mL apple juice prior to the second ultrasound.
9956090|NCT01151228|Experimental|100 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
9956091|NCT01151228|Experimental|200 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
9956092|NCT01151228|Experimental|300 mL|Patients will ingest 300 mL apple juice prior to the second ultrasound.
9956093|NCT01151228|Experimental|400 mL|Patients will ingest 400 mL apple juice prior to the second ultrasound.
9956094|NCT01151241|Experimental|Early discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
9956095|NCT01151241|Active Comparator|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
9956096|NCT01151254|Active Comparator|PA-Intravenous Sedation|Propofol based total intravenous anesthesia and postoperative sedation
9956097|NCT01151254|Active Comparator|Volatile sedation|Total inhalational anesthesia and postoperative sedation with the AnaConda device
9956098|NCT01151267|Other|Control Arm|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
9956099|NCT01151267|Active Comparator|HSH Group|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
9956100|NCT01151306|Placebo Comparator|Lactose tablet|
9956101|NCT01151306|Active Comparator|Simvastatin 20mg|
9956102|NCT01151319|Experimental|Stage 1.|The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).
9956103|NCT01151319|Experimental|Stage 2|The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.
9956104|NCT01151319|Experimental|Stage 3|Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
9956105|NCT01151319|Experimental|Stage 4|Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).
9956106|NCT01151319|Placebo Comparator|Stage 2 Placebo|Time-course matched to vaccinations (n=2)
9956107|NCT01151319|Placebo Comparator|Stage 3 placebo|Time-course matched to vaccinations (n=2)
9956108|NCT01151319|Placebo Comparator|Stage 4 placebo|Time-course matched to vaccinations (n=2)
9956109|NCT01151384|Experimental|LE-DT|
9956110|NCT01151397|Active Comparator|Peg + Vitamin D + Ribavirin|Peg + Vitamin D + Ribavirin for 3 months
9956111|NCT01151397|Active Comparator|Peg + Ribavirin|Peg + Ribavirin for 6 months
9956112|NCT01151488|Experimental|Resistance Training|16 weeks of moderate intensity resistance training, 3x/week
9956113|NCT01151501|Experimental|noninvasive positive pressure ventilation|
9956114|NCT01151514||nrHA-AKI patients|Patients with hospital-acquired acute kidney injury not referred to the nephrologists
9956115|NCT01151514||lrHA-AKI patients|Patients with hospital-acquired acute kidney injury whao are late referred to the nephrologists
9956116|NCT01151527||Sporadic (idiopathic) or familial interstitial pneumonia|We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
9956117|NCT01151566||Renal Compromise|Those referred for CT scan with identified renal compromise necessitating use of no contrast agent
9956118|NCT01151566||Sensitivity to CT Contrast Agents|Those referred for CT scan with prior demonstration of contrast sensitivity requiring use of no contrast
9956119|NCT01151605|Experimental|obese|20 obese subjects
9956120|NCT01151605|Active Comparator|lean|20 lean subjects
9956121|NCT01151605|Experimental|type 2 diabetes|20 type 2 diabetes
9956122|NCT01151631|Active Comparator|100% occipital nerve stimulation|Stimulation frequency and pulse width will be uniformly held constant at 60 Hz and pulse width at 450 ms. The perception and discomfort amplitude will be defined by increasing the stimulation amplitude in steps of 0.1 V. The amplitude at which the patient starts feeling paraesthesis is called the perception threshold. The threshold at which the patient does not want the voltage to be increased any further because of painful sensations is designated the discomfort threshold. 100% stimulation is defined as stimulation at 90% of the range between perception and discomfort thresholds.
9956123|NCT01151631|Sham Comparator|30% occipital nerve stimulation|30% stimulation means a stimulation level at 30% of the range between perception threshold and 100% stimulation level
9956124|NCT01151644|Active Comparator|VACCINATION OF PATIENTS|
9956125|NCT01151644|Active Comparator|VACCINATION OF HEALTHY CONTROLS|
9956126|NCT01151657|Placebo Comparator|Placebo|Capsules containing maltodextrin.
9956127|NCT01151657|Experimental|Probiotics|Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
9956128|NCT01151670|Experimental|Arm I|Pioglitazone 22.5 mg once daily by mouth
9956129|NCT01151670|Experimental|Arm 2|Pioglitazone 45 mg once daily by mouth
9956130|NCT01151683|Active Comparator|Magnesium|Magnesium chelate 600 mg per day
9956131|NCT01151683|Placebo Comparator|Placebo|Placebo 4 capsules per day
9956132|NCT01151696|Experimental|hydroxyzine|Patients will receive intravenous hydroxyzine 1mg/kg at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
9956133|NCT01151696|Placebo Comparator|Placebo|Patients will receive intravenous placebo at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
9956134|NCT01151709||physicians|primary care practitioners, both family practice and internal medicine physicians from a random sample of providers nationwide
9956135|NCT01151722|No Intervention|no injection|no bevacizumab
9956136|NCT01151722|Experimental|experimental 2|bevacizumab before vitrectomy
9476560|NCT03570684|No Intervention|non-tie group|
9476561|NCT03570671|Experimental|Spasm positive|Ergonovine-induced coronary spasm provocation test positive: defined as transient, total, or sub-total occlusion (>90% stenosis) of a coronary artery with symptoms of myocardial ischemia (angina pain and ischemic ECG change).
9476562|NCT03570671|Placebo Comparator|Spasm negative|Suspected vasospastic angina subjects with negative ergonovine provocation test are considered as reference modality.
9956137|NCT01151722|Experimental|experimental 3|bevacizumab after vitrectomy
9956138|NCT01151735|Active Comparator|C-1-esterase inhibitor 1000 units|1000 units of C-1-esterase inhibitor given at time of prodromal symptoms
9956139|NCT01151735|Active Comparator|1500 units of C-1-esterase inhibitor|treatment with 1500 units of C-1-esterase inhibitor IV at the time of prodromal symptoms to decrease risk of exacerbation of HAE
9956140|NCT01151735|Placebo Comparator|placebo injection|placebo injection given for prodromal symptoms as double blinded therapy
9956141|NCT01151787|Active Comparator|cyclobenzaprine hydrochloride|
9956142|NCT01151787|Placebo Comparator|placebo|
9956143|NCT01151800|Experimental|IVR group|
9956144|NCT01151800|No Intervention|Usual care|
9956145|NCT01151839|Active Comparator|Surgery Alone|
9956146|NCT01151839|Active Comparator|Neoadjuvant chemoradiation followed by surgery|
9956147|NCT01151865|Active Comparator|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
9956148|NCT01151865|Placebo Comparator|Saline placebo|An identical syringe to that in the intervention arm, but which does not contain dexmedetomidine, will be provided. The initial rate of infusion and subsequent adjustments will be the same as in the dexmedetomidine group.
9956149|NCT01151878|Experimental|Glucomannan|glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
9956150|NCT01151878|Placebo Comparator|Placebo|maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
9956151|NCT01151891||Diabetics|Diabetics in the parish of St. James, Jamaica
9956152|NCT01151917||Bilio-pancreatic diversion|Each subject is own control
9956153|NCT01151943|Experimental|Transversus Abdominis Plane (TAP) Block|Patients will receive a bilateral transversus abdominis plane block
9956154|NCT01151943|Active Comparator|Incisional Infiltration of Local Anesthetic|Patients will receive an incisional infiltration with local anesthetic (continuous administration of levobupivacaïne during 48 hours)
9956155|NCT01151956||actinic keratosis patients|patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
9956156|NCT01151969|Experimental|New multicomponent intervention|
9956157|NCT01151969|No Intervention|Usual Care|
9956158|NCT01151982|Experimental|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
9956159|NCT01151982|No Intervention|Usual Care|The kind of care that general practitioners usually provide when not knowing the level and risk profile of depression of the patients
9956160|NCT01151995||Remote plus on-site|Subjects will have remote source document verification performed 2-4 weeks prior to study monitors scheduled visit and any variables that were not able to be verified remotely will be verified on-site.
9956161|NCT01151995||On-site monitoring|Traditional source document verification will be performed when study monitor is on site
9956162|NCT01152008||healthy volunteers|
9476563|NCT03570645|Experimental|dexmedetomidine group|thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine 100 ug every time
9956163|NCT01152034|Experimental|Psychoeducation group therapy|The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations. All participants also received standard psychiatric care as well.
9956164|NCT01152034|Placebo Comparator|Treat as Usual|Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention. Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
9956165|NCT01152047|Experimental|oxytocin, satiety|Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
9956166|NCT01152060||prednisone|
9956167|NCT01152060||prednisone and anti-virus|
9956168|NCT01152073|Placebo Comparator|Placebo|Study participants whose drink formulation contains no active ingredients but will appear and taste similar to the two other formulations. This will form the control formulation
9956169|NCT01152073|Active Comparator|Second Formulation|Study participants' drink formulation will include Red Yeast Rice 600mg, Niacin 12.5mg, Phytosterol esters 650mg, L-Carnitine 150mg, vitamin C 500mg, and Co-Q-10 25mg.
9956170|NCT01152073|Active Comparator|Third Formulation|The third formulation will be identical to the second, but without the Red Yeast Rice.
9956171|NCT01152086|Active Comparator|Hiking first|This group first starts with mountain hiking over 9 weeks followed by a 9 weeks control period.
9956172|NCT01152086|Active Comparator|Control first|This group first starts with the control period (9 weeks) followed by the 9 weeks mountain hiking intervention.
10005529|NCT01586013|Experimental|propofol infusion|Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS <50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
10005530|NCT01586052|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
10005531|NCT01586065|Experimental|CGM|
10005532|NCT01586065|Other|Control|Fingerstick BGs only, no CGM
10005533|NCT01586104|Experimental|Treatment (IMRT)|Patients undergo cardiac-sparing whole lung IMRT.
10005534|NCT01586117|Experimental|Amifostine|intrarectal Amifostine assign to the Amifostine arm
10005535|NCT01586130|Other|isokinetic exercises in eccentric mode|
10005536|NCT01586130|Other|isokinetic exercises in concentric mode|
10005537|NCT01586143|Experimental|transbuccal paracetamol 125 mg|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
10005538|NCT01586143|Placebo Comparator|placebo|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
10005539|NCT01586182|Experimental|Stereotactic Boost|Escalating doses of stereotactic body radiation therapy (SBRT)
10005540|NCT01586208|Active Comparator|40mg/kg intial valproate bolus|Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
10005541|NCT01586208|Active Comparator|20mg/Kg intial bolus valproate|Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
10005542|NCT01586221|Other|Music & Physical Therapy|Subjects will received Music and Physical Therapy in a group setting.
10005543|NCT01586234|Experimental|DSAEK with graft shaping and smoothing|
10005544|NCT01586234|Active Comparator|Standard DSAEK|
10005545|NCT01586247|Experimental|Synbiotic|8g/day gluco-oligosaccharide + 109 CFU/day B. lactis BI07
10005546|NCT01586247|Experimental|Placebo|8g/day maltodextrin
9476564|NCT03570645|Experimental|dexamethasone Group|thoracic paravertebral blocks using a combination of ropivacaine and dexamethasone 10 mg every time
10005547|NCT01586247|Experimental|Prebiotic|8g/day galacto-oligosaccharides (GOS)
10005548|NCT01586247|Experimental|Probiotic|109 CFU/day B. lactis BI07
10005549|NCT01586273|Experimental|MR-HIFU treatment|Subjects undergo a MR-HIFU treatment for pain palliation of bone metastases on their most painful metastasis.
10005550|NCT01586286|Placebo Comparator|Ointment Base|Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
10005551|NCT01586286|Active Comparator|Nifedipine Ointment|Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
10005552|NCT01586299|Experimental|ibuprofen|
10005553|NCT01586299|Active Comparator|acetaminophen|
10005554|NCT01586325|Experimental|Panel 1|Study participants will receive double-blind treatment with JNJ-47910382 30 mg or matching placebo. Participants in each of Panel will be treated sequentially (ie, participants in Panel 1 will be treated before participants in Panel 2, participants in Panel 2 will be treated before participants in Panel 3).
9476565|NCT03570645|Sham Comparator|control group|thoracic paravertebral blocks using only ropivacaine
9476566|NCT03570593|No Intervention|Retrospective Group|
10005555|NCT01586325|Experimental|Panel 2|Study participants will receive double-blind treatment with JNJ-47910382 90 mg or matching placebo. Participants in each of Panel will be treated sequentially.
10005556|NCT01586325|Experimental|Panel 3|Study participants will receive double-blind treatment with JNJ-47910382 200 mg (maxiumum dose) or matching placebo. Participants in each of Panel will be treated sequentially.
10005557|NCT01586351||Patch and ACP Treatment|Patents who get an patch augmentation and ACP injection following an arthroscopic repair of the rotator cuff.
10005558|NCT01586377||CRPS Type 1|Patients with CRPS 1 affecting a single upper limb
10005559|NCT01586377||Healthy volunteers|Volunteers without the diagnosis of CRPS Type 1
10005560|NCT01586390|Experimental|MOK|Adjustable and removable brace made out of Softcast material
10005561|NCT01586390|Active Comparator|WRAP|Softcast ankle cast
10005562|NCT01586403|Experimental|Dose 1|Subjects in cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight
10005563|NCT01586403|Experimental|Dose 2|cohort 2 will receive 7.5 x 106 TIL 1383I TCR transduced T cells per kg body weight.
10005564|NCT01586403|Experimental|Dose 3|Subjects in cohort 3 will receive 2.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
10005565|NCT01586403|Experimental|Dose 4|Subjects will then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
10005566|NCT01586416|Experimental|Behavioral Intervention|Brief behavioral intervention on 2-3 sessions of tailored cognitive-behavioral therapy to support chemotherapy adherence and well-being of patients completing chemotherapy for colon cancer.
10005567|NCT01586429||Epidural|
10005568|NCT01586429||Femoral catheter|
10005569|NCT01586442|Active Comparator|Spironolactone|spironolactone 12.5mg once daily titrated to 25mg once daily
10005570|NCT01586442|Experimental|Eplerenone|Eplerenone 25mg once daily titrated to 50mg once daily
10005571|NCT01586455|Experimental|Group A|related cord blood with ≥3/6 HLA match to the patient and related HPDSC
10005572|NCT01586455|Experimental|Group B|unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
10005573|NCT01586455|Experimental|Group C|unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
10005574|NCT01586455|Experimental|Group D|double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
10005575|NCT01586468|Placebo Comparator|NaCl Solution|
10005576|NCT01586468|Experimental|WF10 0.5 ml/kg BW|
10005577|NCT01586481|Active Comparator|barouk|
10005578|NCT01586481|Experimental|sanidiab|
10005579|NCT01586494|Experimental|Group 1|
10005580|NCT01586494|Experimental|Group 2|
9956173|NCT01152099|Active Comparator|GroupA|"Ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. Multilayer bandage is applied daily during the first four weeks.~The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
9956174|NCT01152099|Experimental|GroupB|"Ambulatory treatment is carried out during one month. Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
9476567|NCT03570593|Experimental|Prospective Group|
9956175|NCT01152125|Experimental|Autologous bone marrow stem cells|
9956176|NCT01152138|Active Comparator|Open Cell Stent|Open cell stent (Driver™ or Integrity™,Medtronic), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
9956177|NCT01152138|Active Comparator|Closed Cell Stent|Closed cell stent (Presillion Plus™, Cordis), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
9956178|NCT01152151|Active Comparator|Postal reminders|Postal reminders
9956179|NCT01152151|Active Comparator|Electronic reminders|Electronic reminders
9956180|NCT01152164||rectal cancer patients|
9956181|NCT01152177|Active Comparator|Electronic reminders|Electronic reminders
9956182|NCT01152177|No Intervention|Usual care|usual care
10005581|NCT01586507|Experimental|Group 1|
10005582|NCT01586507|Experimental|Group 2|
10005583|NCT01586520||Disease positive|Imaging or biopsy evidence of disease
10005584|NCT01586520||Disease negative|No evidence of disease
10005585|NCT01586533|Experimental|Zoenasa-1:4|
10005586|NCT01586533|Active Comparator|Mesalamine Enema|
10005587|NCT01586546|Experimental|Face-to-Face MBM Skills Group|
10005588|NCT01586546|Experimental|Online MBM Skills Group|
10005589|NCT01586546|Other|Waitlist Control I|This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
10005590|NCT01586546|Other|Waitlisted Control II|This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.
10005591|NCT01586559||Control group|Nulliparous women
10005592|NCT01586559||Diastasis|Patients after rectus sheath plication due to diastasis
10005593|NCT01586572|Experimental|mOPV1- Arm A|Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
10005594|NCT01586572|Experimental|mOPV1- Arm B|Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
10005595|NCT01586572|Experimental|mOPV1-Arm C|Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
10005596|NCT01586572|Experimental|Arm D- bOPV1,3|Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.
10005597|NCT01586585||post cardiac surgery patients|
9476568|NCT03570580||Main Group - OSA Scoring|All patients include in this study for whom the four OSA scoring will be evaluated
9476569|NCT03570567|Other|Piranha Treatment|The food impaction will be treated using the Piranha endoscopic device.
10005598|NCT01586598|No Intervention|control group|No intervention will be given to this control group. Spontaneous recovery of mandibular nerve will be assessed for sensory function.
10005599|NCT01586598|Experimental|sensory retraining group|Sensory retraining protocol will be applied this group. Any facilitation of sensory function in mandibular nerve will be assessed.
10005600|NCT01586611|Active Comparator|Gemcitabine|Cycles to be 4 weeks in length Gemcitabine 1000 mg/m2 IV weekly for 3 weeks then one week off
10005601|NCT01586611|Experimental|FOLFOX|Cycles to be 2 weeks in length Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
10005602|NCT01586637|Experimental|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
10005603|NCT01586637|Experimental|Walking|The group walked twice a week during one hour.
10005604|NCT01586650|Experimental|Aerobic training|The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
10005605|NCT01586650|Placebo Comparator|Stretching exercises|The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.
10005606|NCT01586663|Experimental|Experimental Group|Splint group
10005607|NCT01586663|Active Comparator|Control Group|Drug treatment
10005608|NCT01586676|Experimental|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP)
10005609|NCT01586676|Active Comparator|Supervision-as-usual|Supervision-as-usual consists of the typical clinical supervision services provided to clinicians by their supervisors in their community programs.
10005610|NCT01586689|Experimental|Safe Haven|participants assigned to the Safe haven condition and agree to move into the A Safe Haven residential treatment facility
9956183|NCT01152203|Experimental|Bendamustine + Bevacizumab|Bendamustine starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle. Bevacizumab 10 mg/kg by vein on Days 1 & 15 of every 28 day cycle.
9956184|NCT01152229||nuisance bleeding|
9956185|NCT01152229||alarming bleeding|
9956186|NCT01152229||maintenance therapy|
9956187|NCT01152242|Active Comparator|Part 1|Part I of the trial
9956188|NCT01152242|Active Comparator|Part 2|Part II of the trial
9956189|NCT01152255|Experimental|Panel A - MK6186 40 mg|MK6186 40 mg
9956190|NCT01152255|Placebo Comparator|Panel A - Placebo|placebo
9956191|NCT01152255|Experimental|Panel B - MK6186 150 mg|MK6186 150 mg
9956192|NCT01152255|Placebo Comparator|Panel B - Placebo|placebo
9956193|NCT01152255|Experimental|Panel C - MK6186 <=150 mg|MK6186 <=150 mg
9956194|NCT01152255|Placebo Comparator|Panel C - Placebo|placebo
9956195|NCT01152255|Experimental|Panel D - MK6186 <=150 mg|MK6186 <=150 mg
9956196|NCT01152255|Placebo Comparator|Panel D - Placebo|placebo
9956197|NCT01152268||Adolescent Male Participants|"Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being on-treatment for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is Yes or further assessment required, the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm."
9956198|NCT01152281|Active Comparator|Maximal Control|Basic awareness messages with stories of people living with AIDS
9956199|NCT01152281|Experimental|Instrumental|Instrumental messages with stories of people living with HIV
9956200|NCT01152281|Experimental|Empowering|Empowering messages with stories of people living with HIV
9956201|NCT01152281|Experimental|Instrumental and Empowering|Instrumental and empowering messages with stories of people living with HIV
9956202|NCT01152281|Active Comparator|Minimal Control|Basic awareness messages with stories of people who are not infected with HIV
9956203|NCT01152320|No Intervention|Standard of Care|
9956204|NCT01152320|Experimental|Intervention|Spirometry Fundamentals™ CD training program
9956205|NCT01152333|Active Comparator|Exendin (9-39) Acetate|Exendin (9-39) is a synthetic peptide that acts as an antagonist to the GLP-1 receptor. Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length at 600-750 pM/kg/min.
9956206|NCT01152333|Placebo Comparator|Saline|Saline 0.9% will be used as the control infusion.
9956207|NCT01152346|Other|ARM 1|Sequence- Azacitidine followed by Vidaza®
9956208|NCT01152346|Other|ARM 2|Sequence-Vidaza® followed by Azacitidine
9956209|NCT01152372|Other|Arm 1|Beta cell function by frequently sampled intravenous glucose tolerance test
9956210|NCT01152372|Other|Arm 2|Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion
9956211|NCT01152372|Other|Arm 3|Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp
9956212|NCT01152398|Experimental|MVA-BN-HER2|
9956213|NCT01152411|Experimental|Autologous bone marrow stem cells|
9956214|NCT01152424||Acute eosinophilic pneumonia|
9956215|NCT01152424||Community acquired pneumonia|
9956216|NCT01152476|Active Comparator|group SR|
9956217|NCT01152476|Active Comparator|group S|
9956218|NCT01152489|No Intervention|Standard Care|Immunizations are given with standard care of no pain control
9956219|NCT01152489|Active Comparator|Experimental|Vibrating device with cold pack held to arm proximal to injections within the same dermatome; caretakers offered and instructed in use of distraction cards.
9956220|NCT01152489|Sham Comparator|Sham Device|The device without batteries or cold pack held to arm proximal to injections. No formal distraction.
9956221|NCT01152567||ACE|Patients treated for hypertension with ACEs without CVD
9956222|NCT01152567||Candesartan|Patients treated for hypertension with candesartan without CVD
9956223|NCT01152593|Experimental|Intranasal Mupirocin|
9956224|NCT01152606||Cohort|
9956225|NCT01152619|Experimental|1|
9956226|NCT01152619|Experimental|2|
9956227|NCT01152619|Placebo Comparator|3|
9956228|NCT01152619|Placebo Comparator|4|
9956229|NCT01152632|Experimental|specific points of Bladder meridian and Shanjiao meridian|In traditional Chinese acupuncture theory, Bladder meridian and Shanjiao meridian have been considered as the main pathological meridian location of migraine. Meanwhile, specific points on both meridians have been used widely in its treatment for a long time.
9956230|NCT01152632|Experimental|non-specific points of Bladder meridian and Shanjiao meridian|Non-specific points of Shaoyang meridians are also used in cure of migraine. It is conventionally thought to be less effective using non-specific points than specific ones.
9956231|NCT01152632|Active Comparator|specific points of Stomach meridian|Specific points of Stomache meridian for migraine were searched in Chinese ancient data. And this group is set to compare with specific points of Shaoyang meridians for their possible different brain networks.
9956232|NCT01152632|Placebo Comparator|non-acupoints|Three non-acupoints were chosen,two of which were located on the arm and one one the leg.
9956233|NCT01152632|No Intervention|waiting list|
9956234|NCT01152645|Experimental|ARQ 197|
9517234|NCT03308175|Experimental|flat fixed anterior bite plane|"Bands selection will be done for upper 6s. Alginate impressions taken and molar bands are fitted in place into the impressions. Impressions for upper and lower arches are poured with stone plaster. Mounting on simple hinge articulator will be done.~Lingual arches (diameter 1 mm) with anterior acrylic bite plates with thickness enough to separate posterior teeth 4mm .~The acrylic bite planes were in occlusion with the lower anterior teeth and extended sagittally 2-3mm beyond edges of lower incisors.~Finishing ,polishing and cementation into patient's mouth with glass ionomer cement."
9956235|NCT01152658|Placebo Comparator|Nacl Injection|"Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).~NACL0.9% solution will be then injected to the control group in sterile conditions under ultrasound control~double blind procedure~."
9956236|NCT01152658|Experimental|PRGF|1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).2. The enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control.
9956237|NCT01152671|Experimental|Arm 1|
9956238|NCT01152671|Placebo Comparator|Arm 2|
9956239|NCT01152684||HIV-Positive Latinos living in San Diego or Tijuana|This is an exploratory study of Latinos living with HIV in the San Diego-Tijuana US-Mexico border region.
9956240|NCT01152723|Experimental|UNG-GA|New NRT product
9956241|NCT01152723|Experimental|UNG-GB|New NRT product
9956242|NCT01152723|Active Comparator|Nicorette® Gum|Nicorette® Gum
9956243|NCT01152736|Experimental|NSC018|Nicotine
9956244|NCT01152736|Active Comparator|Nicotine Gum|Nicorette® Gum
9956245|NCT01152749|Experimental|UNG-GC-2|2 mg experimental NRT product
9956246|NCT01152749|Experimental|UNG-GC-4|4 mg experimental NRT product
9956247|NCT01152749|Active Comparator|Nicorette® Gum-2|2 mg Nicorette® Gum
9956248|NCT01152749|Active Comparator|Nicorette® Gum-4|4 mg Nicorette® Gum
9956249|NCT01152762|Experimental|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy is the intervention in all selected patients
9956250|NCT01152775|Placebo Comparator|No Media|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
10005611|NCT01586689|Experimental|Usual aftercare|participants assigned to the control condition, and may or may not seek treatment on their own
10005612|NCT01586689|Experimental|Oxford House|participants who were assigned to the Oxford House condition and agree to move into an Oxford House
10005613|NCT01586702|No Intervention|Regular care|Consisting of structured information given at hospital discharge regarding stroke etiology and recommended secondary prevention plus regular outpatient care by general practitioners or family doctors.
9956251|NCT01152775|Experimental|Yes Media Newly Diagnosed Breast Cancer Pts|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
9956252|NCT01152801|Experimental|RAD001|
9956253|NCT01152827|Experimental|RAD001|RAD001 10 mg daily po medication
9956254|NCT01152840|Experimental|RAD001|RAD001 daily po medication
9956255|NCT01152853|Experimental|single arm|PF00299804 treatment arm
9956256|NCT01152879||Home Parenteral Nutrition|Patients receiving home parenteral nutrition
9956257|NCT01152905||Air/TIVA group|The patients received during the anesthesia a mixture of air with 30% oxygen All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
9956258|NCT01152905||Nitrous oxide/TIVA group|The patients received nitrous oxide with 30% oxygen.All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
9956259|NCT01152918|Experimental|Linkage-to-Care Component: Financial Incentive (FI)|HIV test sites will provide financial incentives to encourage linkage to HIV care.
9956260|NCT01152918|Active Comparator|Linkage-to-Care Component: Standard of Care (SOC)|HIV test sites will provide the standard-of-care to their patients for linkage to HIV care.
9956261|NCT01152918|Experimental|Viral Suppression Component: FI|HIV care sites will provide financial incentives to encourage viral load suppression.
9956262|NCT01152918|Active Comparator|Viral Suppression Component: SOC|HIV care sites will provide the standard-of-care to their patients for viral load suppression.
9956263|NCT01152918|Experimental|Prevention for Positives Component: Counseling and SOC|Participants will take part in a computerized HIV risk reduction counseling program and receive SOC for HIV infection.
9956264|NCT01152918|Active Comparator|Prevention for Positives Component: SOC|Participants will receive SOC for HIV infection.
9956265|NCT01152931|Active Comparator|COHORT A= Amodiaquine + Artesunate|Amodiaquine will be administered orally at 10mg/kg daily for 3days. Artesunate 50mg will be administered orally daily for 3days.For subjects >6months< 1 years 4mg/kg daily for 3 days
9956266|NCT01152931|Active Comparator|cohort B= Lumefantrine +Artemether|Artemether 20mg/Lumefantrine 120mg fixed combination administered daily for 3 days
9956267|NCT01152931|Experimental|cohort C = Artesunate + vitamin A|Artesunate 50mg daily for 4days. if >6 months< 1 year 4mg/kg daily for 4days + Vitamin A 5000IU daily for 4days if < 1 year and 10,000IU daily for 4days if > 1 year respectively
9956268|NCT01152931|Experimental|Artesunate, vitamin E oral administration|Artesunate 50mg daily for 4 days.if >6 months< 1 year 4mg/kg daily for 4 days + vitamin E 100mg daily administered orally to the experimental group 4 days.
9956269|NCT01152931|Experimental|cohort E will be given Artesunate and Zinc orally|cohort E will be given Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + zinc gluconate 50mg orally daily for 4 days. if < 1 year 25 mg daily for 4 days
9956270|NCT01152931|Experimental|cohort F= Artesunate and selenium will be given orally|Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + selenium 100ug daily for 4 days. if < 1 year 50ug daily for 4 days.
9956271|NCT01152931|Experimental|cohort G = Amodiaqiune and Vitamin A will be given orally|Amodiaquine 10mg/kg daily for 3 days + vitamin A 5000iu daily for 4 days if < 1 year. 10,000 IU daily for 4 days if > 1 year.
9956272|NCT01152931|Experimental|cohort H = amodiaquine and vitamin E administerd orally|Amodiaquine 10mg/kg daily for 4 days + vitamin E 100 mg daily for 4 days
9956273|NCT01152931|Experimental|cohort I = Amodiaquine and Zinc will be given orally|Amodiaquine 10mg/kg daily for 4 days + zinc 50mg daily 4 days. if < 1 year 25 mg daily for 4 days.
9956274|NCT01152931|Experimental|Cohort J = amodiaquine and selenium will be given orally|Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if > 1 year. 50ug daily for 4 days if < 1 year.
9956275|NCT01152931|Experimental|K= Artesunate+ vitamin A + vitamin E|Tab Artesunate 50mg orally dly x 4 days + Vitamin A, 5000IU orally, dly x 4 days if ≤ 1yr. 10,000IU orally dly x 4days if > 1 yr + vitamin E 100 mg orally dly for 4 days
9956276|NCT01152931|Experimental|L = Artesunate+ Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
9956277|NCT01152931|Experimental|M = Artesunate+ Vitamin A + selenium|Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
9956278|NCT01152931|Experimental|N = Artesunate + Vitamin E + Zinc|Artesunate 50mg daily for 4 days. vitamin E 100mg daily for 4 days. Zinc 50 mg daily for 4 days if > 1 year. 25 mg daily for 4 days if < 1 year.
9956279|NCT01152931|Experimental|O = Artesunate+ Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
9956280|NCT01152957|Experimental|Community Health Worker Model|Care, Attention, Resources, Information, Nutrition and Optimism Project (CARIÑO Project) will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
9956281|NCT01152957|Active Comparator|Enhanced Usual Care|Usual Care and mailing of 4 health education brochures over the year.
9956282|NCT01152970||drug-using youth with violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for an acute violent injury
9956283|NCT01152970||drug-using youth with non-violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for non-violence related care
9956284|NCT01153048|Experimental|Specific education intervention with peer educators|
9956285|NCT01153048|No Intervention|General education session in the health structure|
9956286|NCT01153061|Experimental|Fistula closure with occluder|Patients with benign tracheoesophageal fistulas will be submitted to the correction with the occluder.
9956287|NCT01153074|Experimental|Occluder|The patients with bronchopleural fistulas treated with bronchoscopic deployment of the cardiac septal defects occluder.
9956288|NCT01153100|No Intervention|Standard insulin drip therapy|Standard insulin drip therapy
9956289|NCT01153100|Active Comparator|Insulin drip and glargine|Insulin drip and glargine 0.25 units per kg body weight
9956290|NCT01153113|Experimental|Treatment Arm A|• 5x106 cells per infusion administered ID
9956291|NCT01153113|Experimental|Treatment Arm B|• 1x107 cells per infusion administered ID (Treatment arm B).
9956292|NCT01153126|No Intervention|No Intervention: Usual Care|A group receiving usual care plus 5 reliable websites
9956293|NCT01153126|Experimental|Intervention|A group using the Comprehensive Health Enhancement Support System (CHESS.)
9956294|NCT01153139|Experimental|bilateral theta burst stimulation to the DLPFC|intermittent TBS (iTBS) to the left DLPFC continuous TBS (cTBS) to the right DLPFC
9956295|NCT01153139|Placebo Comparator|Sham stimulation|Sham stimulation with a 45° tilted coil
9956296|NCT01153165|Experimental|Citalopram|Participants will be commenced on Citalopram 20mgs daily
9956297|NCT01153165|Placebo Comparator|Control|Control group - will receive a matched placebo
9956298|NCT01153191|Experimental|Pressurized irrigation|first group-After closure of patients abdominal wall fascia, Hydrostatic irrigation with 3 liters of normal saline with Simpulse Solo irrigation system (Davol) at less than 15PSI will be applied to subcutaneous tissues prior to closure
9956299|NCT01153191|Experimental|Sub Q Antibiotic|second group of patients will receive 2mg/lg of gentamicin in 20 ml of sterile saline injected into the superficial tissues above the ABD wall fascia prior to initial incision
9956300|NCT01153204|Experimental|Group Psychotherapy (GP)|Time-limited group psychotherapy is a technique based on psychodrama, an in-depth method of group psychotherapy. Active methods are used to enable past, present, and future life events to be explored. Sexual issues and their possible solutions are enacted rather than simply discussed. Time-limited group psychotherapy focuses on a central or core issue or a circumscribed area of conflict (psychogenic erectile dysfunction) as the only or major object of intervention efforts.
9956301|NCT01153204|Active Comparator|Sildenafil|Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
9956302|NCT01153204|Active Comparator|Group Psychotherapy (GP) plus Sildenafil|The same as above.
9956303|NCT01153217|Experimental|Abacavir|Switch from tenofovir to abacavir
9956304|NCT01153217|No Intervention|tenofovir|Follow same ART regimen
9956305|NCT01153230||poisoned patient|after patients died the pathological findings evaluated with autopsy
9956306|NCT01153243|Active Comparator|Ergocalciferol|The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
9956307|NCT01153243|Placebo Comparator|Placebo pill|The investigators will give intervention group 12 weeks of placebo pill (in pill every week)
9956308|NCT01153256|Experimental|group M|
9956309|NCT01153256|Placebo Comparator|Group R-0.6|
9956310|NCT01153256|Placebo Comparator|Group R-0.9|
9956311|NCT01153295|Experimental|Positive diagnosis|The diagnosis of IBS is based on the international ROME III criteria, few blod tests, and abscence of danger signals
9956312|NCT01153295|Active Comparator|Diagnosis of exclusion|The diagnosis of IBS is based on normal extended blood tests, screening for celiac sprue and lactose intolerance, stool for ova and parasites and endoscopy with biopsy
9956313|NCT01153308||Bariatric Surgery Patients|Bariatric Surgery patients at UMass Memorial Medical Center
9956314|NCT01153334|Experimental|Early intensive rosuvastatin therapy|
9956315|NCT01153334|Placebo Comparator|Conventional statin therapy|
9956316|NCT01153360|Experimental|T3|triiodothyronine
9956317|NCT01153360|Active Comparator|cyanocobalamin|vitamin B12
9956318|NCT01153373|Placebo Comparator|Minimal Intervention Control|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only. The reports will not be printed or dynamic referrals generated, and all patients will receive treatment-as-usual by their ED providers."
9956319|NCT01153373|Active Comparator|DARSSA Intervention|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
9956320|NCT01153386|Experimental|0.5 mg treprostinil diethanolamine|0.5 mg treprostinil diethanolamine
9956321|NCT01153386|Experimental|2.5 mg treprostinil diethanolamine|2.5 mg treprostinil diethanolamine
9956322|NCT01153386|Experimental|1 mg treprostinil diethanolamine|1 mg treprostinil diethanolamine
9956323|NCT01153399||1|Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics
9956324|NCT01153412|No Intervention|Control Group|Control group no intervention
9956325|NCT01153412|Experimental|Osteopathic Manipulative Treatment|Osteopathic Manipulative medicine group
9956326|NCT01153438||Gastric bypass, Gastric banding|
9956327|NCT01153451|No Intervention|Usual Care|Responsible inpatient and ambulatory physicians assigned to usual care will not receive any email(s) of patients' test results generated from the notification system.
9956328|NCT01153451|Other|Email Notification|Responsible inpatient and ambulatory physicians will receive automated email(s) of patients' tests results finalized post-discharge generated from the notification system. Finalized results will be batched such that no provider will receive more than one email per day.
9956329|NCT01153464|No Intervention|Treatment As Usual|In this arm, participants are not provided any intervention through the study, they are just followed for research purposes at 3m, 6m, 9m, and 12m post baseline as the comparison group.
9956330|NCT01153464|Experimental|Recovery Support Counseling|This group is eligible to receive the telephone based recovery support counseling from paraprofessionals based out of the City of Philadelphia's Department of Behavioral Health.
9956331|NCT01153477|No Intervention|TAU|This group is the control group by which we are comparing our intervention. This group will not receive an intervention from us but will continue to be treated at the Intensive Outpatient facility from which we recruited them.
9956332|NCT01153477|Experimental|Counseling (TMAC-E)|This telephone based intervention includes six factors to improve our extended treatment model: Incentive component; Patient choice; Provision of cell phones to those who need them; Social support and community resources; Positive recovery factors; and Outreach following dropout.
9956333|NCT01153490|Placebo Comparator|Placebo|
9956334|NCT01153490|Active Comparator|Quetiapine ER|
9956335|NCT01153529||Group 1|OEF/OIF Veterans
9956336|NCT01153542|Experimental|VX-770|
9956337|NCT01153542|Experimental|desipramine|
9956338|NCT01153555||Intermediate coronary lesions|"Diagnostic device: FFR~Diagnostic device: IVUS RF~At participating centers, FFR and IVUS are standard of care diagnostic procedures for patients with intermediate (40-80% angiographic stenosis by visual estimate). Both modalities were used regularly for such patients whether or not they are participants in this clinical study. In FIRST, the decision to perform percutaneous coronary intervention (PCI) was left to the discretion of the investigator, and was not dictated by the clinical protocol."
9956339|NCT01153568|Placebo Comparator|Placebo|placebo
9956340|NCT01153568|Experimental|Vitamin D 3|Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg
9956341|NCT01153594|Experimental|Recovery Management Checkups (RMC)|Participants in the RMC group are interviewed quarterly. When they were found to be in need of treatment, the participant was transferred from the interviewer to a linkage manager to receive the intervention (described next). They were also able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
9956342|NCT01153594|No Intervention|Control Group|Participants in the control group are interviewed quarterly. While they do not receive any active intervention from the research team, they are able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
9956343|NCT01153607|Experimental|Arm 1|
9956344|NCT01153607|Experimental|Arm 2|
9956345|NCT01153607|Experimental|Arm 3|
9956346|NCT01153646|Experimental|Cohort 1: 1x10e9 and Cohort 2: 1x10e10 T cells per infusion|Group of patients receiving genetically modified T-cells
9956347|NCT01153659|Experimental|1|
9956348|NCT01153659|Active Comparator|2|
9956349|NCT01153659|Active Comparator|3|
9956350|NCT01153737|Experimental|manual therapy|
9956351|NCT01153737|Active Comparator|TENS|Electric Nerve Stimulation (TENS)
9956352|NCT01153750|Experimental|Glivec and 5-Fluorouracil/Leucovorin|"All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day 0. Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15."
9956353|NCT01153776|Experimental|64-slice CT angiography|64-slice CT angiography
9956354|NCT01153789|Experimental|Patients orthoptic rehabilitation|Children with vertigo-headache and vergence disorders
9956355|NCT01153789|Other|Control Orthoptic diagnostic|Healthy controls
9956356|NCT01153802|Experimental|Healthy Male Volunteers|All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
9956357|NCT01153828||(1) Age <9 months|Age at time of prescription was <9 months
9956358|NCT01153828||(2) 9 months to 6 years|Age at time of prescription was 9 months to 6 years
9956359|NCT01153828||(3) 7 years to 18 years|Age at time of prescription was 7 years to 18 years
9956360|NCT01153828||(4) 19 to 65 years|Age at time of prescription was 19 to 65 years
9956361|NCT01153828||(5) 66 years and older|Age at time of prescription was 66 years and older
9956362|NCT01153854|Experimental|ORS-Raceca In hospital Group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
9956363|NCT01153854|Placebo Comparator|ORS-Placebo in hospital group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and placebo in double blind assigned.
9956364|NCT01153854|Placebo Comparator|ORS-Placebo ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and placebo in double blind assigned and ambulatory (in home) bases.
9517888|NCT03302000|Experimental|Visual stimulation|"Early visual stimulation (EVS) will be implemented by caregivers.~Three phases:~the caregiver will establish eye-to-eye contact with the infant. The caregiver will communicate with the infant talking, singing, changing facial expressions, touching his/her face. Total duration of this part of stimulation is between 2 and 3 minutes~the caregivers will present visual contrast cards at a distance of 15-20 centimetres~the caregiver will present two toys to the infant~Stimulation will last for 28 days (4 weeks) in total, one time a day for 10-15 minutes, all days week."
9956365|NCT01153854|Experimental|ORS-Raceca ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
9956366|NCT01153867|Experimental|Schema Focused Therapy|Participants will receive Schema Focused Therapy
9956367|NCT01153880||Age <9 months definitive|Age at time of prescription was <9 months
9956368|NCT01153880||Age <9 months uncertain|Age at time of prescription was uncertain for <9 months
9956369|NCT01153880||9 months to 6 years|Age at time of prescription was 9 months to 6 years
9956370|NCT01153880||7 to 18 years|Age at time of prescription was 7 to 18 years
9956371|NCT01153880||19 to 65 years|Age at time of prescription was 19 to 65 years
9956372|NCT01153880||66 years and older|Age at time of prescription was 66 years and older
9956373|NCT01153906||Exposed cohort|Females 9-25 years of age, who received at least one dose of Cervarix® as part of their routine health care.
9956374|NCT01153906||Unexposed cohort|Females 9-25 years of age, who did not receive Cervarix®
9956375|NCT01153919|Active Comparator|Arm I|Patients receive romiplostim subcutaneously once weekly for 8 weeks in the absence of disease progression or unacceptable toxicity.
9476570|NCT03570541|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0,375% single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
9956376|NCT01153919|Placebo Comparator|Arm II|Patients receive placebo subcutaneously once weekly for 8 weeks. Patients failing to achieve a platelet count of &gt; 100,000/L cross over to arm I.
9956377|NCT01153932|Experimental|Continuous regimen; 6mg/kg once weekly|Once Weekly
9956378|NCT01153932|Experimental|Intermittent regimen; 6mg/kg twice weekly|Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle
9956379|NCT01153945||Hypothyroid|
9956380|NCT01153945||Non hypothyroid|
9956381|NCT01153945||Healthy subjects|
9956382|NCT01153997|Experimental|A|
9956383|NCT01153997|Experimental|B|
9956384|NCT01153997|Placebo Comparator|C|
9956385|NCT01153997|Placebo Comparator|D|
9956386|NCT01154023|Experimental|stimulus control therapy|Focuses on strengthening the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, and developing a consistent sleep-wake pattern
9956387|NCT01154023|Experimental|sleep restriction therapy|Sleep restriction therapy consolidates sleep by restricting the amount of time spent in bed and limiting sleep to a specific time period .
9956388|NCT01154023|Experimental|multi-component intervention|Combines stimulus control and sleep restriction: strengthen the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, develop a consistent sleep-wake pattern, consolidate sleep by restricting the amount of time spent in bed and limit sleep to a specific time period
10005614|NCT01586702|Active Comparator|Support program|In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
10035226|NCT01804192|Placebo Comparator|Placebo group|Placebo Acu-TENS Group (Placebo Group), subjects received the same protocol as the Acu-TENS group and TENS was applied over right LI4 and LI11 that covered with non-conducting plastics (with the same dimension as the TENS electrodes) Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV.
10035227|NCT01804205|Experimental|Magnesium sulfate group|In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
10035228|NCT01804205|Placebo Comparator|Control group|Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
10035229|NCT01804218|Placebo Comparator|Placebo|Placebo
10035230|NCT01804218|Experimental|Active, nadolol|Active
10035231|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)
10035232|NCT01804244|Experimental|TMC278|All participants will receive a single-dose of TMC278 (1 25-mg tablet [27.5 mg as the hydrochloride salt]) after an overnight fast (going without food) of at least 10 hours before eating a standard breakfast. Study drug will be taken within 10 minutes after completion of a standardized breakfast.
10035233|NCT01804283|Sham Comparator|CON|Patients undergoing double valve replacement (aortic and mitral).
10035234|NCT01804283|Experimental|IPO|Patients undergoing double valve replacement (aortic and mitral) with ischemic postconditioning.
10035235|NCT01804309||Early breast cancer patients|Clinical stage T1-2 N0M0 primary unilateral invasive breast cancer patients
10035236|NCT01804322|Active Comparator|Usual care|usual care according to the practice of participating Epilepsy Centers
10035237|NCT01804322|Experimental|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
10035238|NCT01804335|Experimental|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
10035239|NCT01804348|Experimental|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
10035240|NCT01804361|Experimental|Haporine-S|Moderate to severe dry patients administered with with Haporine-S
10035241|NCT01804361|Active Comparator|Restasis, Cyclosporine 0.05%|Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)
9956389|NCT01154049|Experimental|single arm|3 doses of the vaccine, on days 0, 30 and 60.
9956390|NCT01154062|Experimental|low dose|Pazopanib tablet
9956391|NCT01154114|Experimental|moderate hepatic impaired subjects|Male and female subjects with moderate hepatic impairment defined by a Child-Pugh score of 7-9 will be included. The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.
9956392|NCT01154114|Experimental|normal healthy volunteers|Healthy male and female subjects will be included and will be matched as closely as possible to the group of moderate hepatic impairment subjects for gender, age and body mass index. Each subject will receive daily 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets for 10 consecutive days.
9517889|NCT03302000|Other|standard care|Caregivers will receive an Illustrated Handbook, according to the age range of birth to three months. Assessors will explain all information contained in the handbook after the first assessment and randomisation.
9956393|NCT01154179|No Intervention|Normocaloric feeding|This control group will receive energy and protein intakes as recommended by the use of Schofield equations, as is current practice (100% of requirements)
9956394|NCT01154205||Patients post implantation of ICD or CRTD|
9956395|NCT01154244||Drug naive type II DM|Newly diagnosed type II Diabetes Mellitus
10005615|NCT01586715|Experimental|Autologous Stem Cells|
9956396|NCT01154257|Experimental|Cleaning teeth with toothbrush|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a toothbrush
9956397|NCT01154257|Experimental|Cleaning teeth with foam swab|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a faom swab
9956398|NCT01154270|Experimental|IMRT + C12-boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
9956399|NCT01154309|Experimental|1|Clients are invited to attend 18 group CBT sessions
9956400|NCT01154309|No Intervention|2|Clients receive usual care
9956401|NCT01154348|Experimental|Washout period, S-707106 tablet|14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions
9956402|NCT01154348|Placebo Comparator|Washout, placebo|14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions
9956403|NCT01154348|Experimental|Maintenance, S-707106 tablet plus metformin|14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
9956404|NCT01154348|Placebo Comparator|Maintenance, placebo plus metformin|14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
9956405|NCT01154361|Experimental|Arm A|
9956406|NCT01154361|Active Comparator|Arm B|
9956407|NCT01154387|Active Comparator|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
9956408|NCT01154387|Experimental|TOL101 (Dose A)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
9956409|NCT01154387|Experimental|TOL101 (Dose B)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
9956410|NCT01154400|Experimental|Casein protein hydrolysates|15 g casein protein hydrolysates and 15 g maltodextrin
9956411|NCT01154400|Experimental|Whey protein hydrolysates|15 g whey protein hydrolysates and 15 g maltodextrin
9956412|NCT01154400|Experimental|Casein protein hydrolysates + LEU|15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
9956413|NCT01154400|Experimental|Whey protein hydrolysates + LEU|15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin
9956414|NCT01154413|Experimental|Intensive education of the doctor/nursing team on the protocol|
9956415|NCT01154413|No Intervention|Without intervention in the team|
9956416|NCT01154426|Experimental|Treatment (gemcitabine hydrochloride and ABT-888)|Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease progression or unacceptable toxicity.
9956417|NCT01154439|Experimental|Everolimus|Everolimus mice-regimen
9956418|NCT01154465|Active Comparator|Anatomical guidance puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The preparation of the CVC installation will follow the procedures for disinfection, for skin preparation of the operator, for installation of sterile fields and for local anaesthesia.~The veins will be tracked by simple palpation of the carotid pulse.~The puncture will be made following:~The anterior Boulanger's incision for the internal jugular vein;~When venous aspiration is obtained, the catheter is assembled according to the Seldinger method."
9956419|NCT01154465|Experimental|US-guided puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed. A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein pathway;"
9956420|NCT01154478|Experimental|B group|Diet rich in omega-3 fatty acids
9956421|NCT01154478|Experimental|C group|Diet rich in polyphenols
9956422|NCT01154478|Experimental|D group|Diet rich in polyphenols and in omega-3 fatty acids
9956423|NCT01154478|Placebo Comparator|A group (control group)|diet with low content of omega-3 fatty acids and polyphenols
9956424|NCT01154491|Placebo Comparator|Placebo|Two placebos: placebo for ferric carboxymaltose and placebo for erythropoietin
9956425|NCT01154491|Experimental|FE|Ferric carboxymaltose and placebo for erythropoietin
9956426|NCT01154491|Experimental|EPOFE|Ferric carboxymaltose and erythropoietin
9956427|NCT01154504|Other|clinical treatment|"Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.~Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3)."
9956428|NCT01154504|Experimental|ultrafiltration|"ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).~Diuretic will be withdrawn during ultrafiltration."
9956429|NCT01154504|Experimental|isovolumetric hemofiltration|Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).
9956430|NCT01154530|Active Comparator|Chlorhexidine mouthwash|Participants randomized to chlorhexidine mouthwash prior to gastroscopy
9956431|NCT01154530|No Intervention|No mouthwash|Mouthwash is not performed prior to gastroscopy as is the standard today.
9956432|NCT01154543||HIV positive, gential HSV,Famvir™ 500mg bd, suppressive|
9956433|NCT01154556||HIV1 positive, NNRTI exposure and failure|
9956434|NCT01154569|Active Comparator|Post Roux-en-Y gastric bypass|Post-bypass receiving a single dose of azithromycin
9956435|NCT01154569|Active Comparator|Controls|BMI and sex matched. Have not undergone surgery
9956436|NCT01154582|Experimental|Egg|
9956437|NCT01154582|Experimental|Cottage cheese|
9956438|NCT01154595|Active Comparator|Food-for-Training component|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
9956439|NCT01154595|Experimental|Food-for-Training + RUF (Plumpy Doz(r))|"Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.~In addition, a blanket supplementation with 47g RUF (Plumpy Doz(r)) per day per child is provided."
9956440|NCT01154608|Experimental|pancreatic enzymes|
9956441|NCT01154608|Placebo Comparator|control|
9956442|NCT01154621|Experimental|1|Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers
9956443|NCT01154621|Placebo Comparator|2|Sterile 5% dextrose solution
9956444|NCT01154647|Experimental|selective serotonin reuptake inhibitor|intravenous, acute, 20mg/ml
9956445|NCT01154647|Placebo Comparator|1 ml 0.9 % NaCl|
9956446|NCT01154660|Experimental|Neutral|
9956447|NCT01154660|Active Comparator|Trendelenberg|
9956448|NCT01154712|Active Comparator|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
9956449|NCT01154712|Sham Comparator|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
9956450|NCT01154725|Other|Habitual stoma care|habitual patient education
9956451|NCT01154725|Experimental|Patient education and rehabilitation|patient education and rehabilitation
9956452|NCT01154738|Experimental|Lidocaine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
9956453|NCT01154738|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
9956454|NCT01154764|Experimental|CG100649|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
9956455|NCT01154764|Experimental|CG100649 and ketoconazole|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
9956456|NCT01154790|Experimental|CG100649|By the amount of doses, the groups are classified
9956457|NCT01154790|Active Comparator|Naproxen|By the amount of doses, the groups are classified
9956458|NCT01154790|Placebo Comparator|Placebo|By the amount of doses, the groups are classified
9956459|NCT01154803|Experimental|Ready to Use Therapeutic Food (RUTF)|500 kcal /day for 2 weeks
9956460|NCT01154803|Experimental|Micronutrient Powder (MNP)|2 x 1 g sachets micronutrients /day for 2 weeks
9956461|NCT01154803|No Intervention|no supplement|no supplementation
9956462|NCT01154829|Active Comparator|first choice treatment|Treatment with amisulpride
9956463|NCT01154829|Active Comparator|second choice treatment|treatment with aripiprazole
9956464|NCT01154842||Hemodialysis|Adult hemodialysis patients (age>18 years)
9956465|NCT01154855||Periodontitis|"Patients with severe periodontal disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning~1 per patient at 2nd visit lasting approximately 1 hour."
10005616|NCT01586728|Other|Air - oxygen|One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
9956466|NCT01154855||Healthy patients|"Patients without periodontal (gum) disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning"
9956467|NCT01154868|Other|Healos|
9956468|NCT01154881|Experimental|IDeg 100U/mL 0.4U/kg|
9956469|NCT01154881|Experimental|IDeg 100U/mL 0.6U/kg|
9956470|NCT01154881|Experimental|IDeg 100U/mL 0.8U/kg|
9956471|NCT01154881|Experimental|IDeg 200U/mL 0.6U/kg|
9956472|NCT01154894|Experimental|Placebo-controlled trial|
9956473|NCT01154907||Girls ages 10-12|"In 18 rural schools in Ugu District, South Africa. Undergoing mass-treatment provided by the Department of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
9956474|NCT01154907||Young adult women|"In rural schools in three districts, South Africa. Undergoing mass-treatment provided by the Departments of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
9956475|NCT01154933|Experimental|exenatide 5 mcg|exenatide 5 mcg
9956476|NCT01154933|Experimental|exenatide 10 mcg|exenatide 10 mcg
9956477|NCT01154933|Placebo Comparator|placebo|placebo
9956478|NCT01154946||DAC group|patients who show detrusor after-contraction during voiding cystometrography (CMG)
9956479|NCT01154959|Experimental|Regimen 1|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 3 months (3RHZEM)
9956480|NCT01154959|Experimental|Regimen 2|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin daily for 2 months (2 RHZEM daily / 2 RHM daily)
9956481|NCT01154959|Experimental|Regimen 3|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2RHM thrice weekly)
9956482|NCT01154959|Experimental|Regimen 4|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, ethambutol and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2 RHEM thrice weekly)
9956483|NCT01154959|Active Comparator|Control Regimen|Rifampicin, isoniazid, pyrazinamide and ethambutol thrice weekly for 2 months followed by rifampicin and isoniazid thrice weekly for 4 months (2 RHZE thrice weekly / 4 RH thrice weekly)
9517890|NCT03301987|Experimental|Therapeutic exercise|
9956484|NCT01154972|Experimental|Single arm study - Sentinel Node Localisation|
9956485|NCT01154998||Cases|
9956486|NCT01154998||Controls|
9956487|NCT01155037|Experimental|3.75 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
9956488|NCT01155037|Experimental|7.5 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 7.5µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
9956489|NCT01155037|Active Comparator|3.75 µg of the vaccine on day 0|The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine.
9956490|NCT01155076|Experimental|Vitality product|Proprietary blend of ginseng, cordyceps, and pomegranate
9956491|NCT01155076|Placebo Comparator|Placebo|Placebo
9956492|NCT01155115|Experimental|Primary Ciliary Dyskinesia (PCD) Patients|
9956493|NCT01155115|Experimental|Cystic Fibrosis (CF) Patients|
9956494|NCT01155128|Experimental|Lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
9956495|NCT01155128|Placebo Comparator|lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
9956496|NCT01155206|Experimental|high glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a dose that has been shown to achieve high physiological plasma levels. The IV glucagon will be administered at a rate of 3ng/kg/min.
9956497|NCT01155206|Experimental|low glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a low rate that is designed to mimic basal plasma glucagon concentration. The IV glucagon will be administered at a rate of 0.65ng/kg/min.
9956498|NCT01155232||Forteo (teriparatide)|postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)
9956499|NCT01155232||Forteo (teriparatide) in AFF|women who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)
9956500|NCT01155245||Forteo (teriparatide)|postmenopausal women with osteoporosis
9956501|NCT01155245||Forteo (teriparatide) with AFF|Women with atypical femur fractures
9956502|NCT01155258|Experimental|Arm I|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9956503|NCT01155271|Active Comparator|ERGO|General endurance training on cycloergometer
9956504|NCT01155271|Active Comparator|ERGONIV/ ERGOSPIRO|General endurance training on cycloergometer using ventilatory assistance (ERGONIV) or additional respiratory muscle training (ERGOSPIRO)
9956505|NCT01155297|Sham Comparator|Control Group|At the control group, with 34 subjects, will be performed stretching and metabolic exercises. This group will make the assessments before and the reassessments after the end of the program.
9956506|NCT01155297|Active Comparator|Training group|At the training group, with 34 subjects, will be performed stretching, physical training and resistance. This group will make the assessments before and the reassessments after the end of the program.
9956507|NCT01155310|Experimental|Helium/Oxygen|Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
9956508|NCT01155310|Active Comparator|Air/Oxygen|Air/Oxygen will be administered for a maximum of 72 hours.
9956509|NCT01155349|Experimental|InSight Brain Fitness|
9956510|NCT01155349|Placebo Comparator|No contact-control|
9956511|NCT01155401||1|Patients with acute upper gastrointestinal bleeding
9956512|NCT01155414|Experimental|Investigational infant formula A|Investigational Protein Hydrolysate formula
9956513|NCT01155414|Active Comparator|Hydrolysate based Infant Formula|
9956514|NCT01155414|Experimental|Investigational Infant Formula B|Investigational Protein Hydrolysate Formula
9956515|NCT01155427||entecavir|Patients initiating special antiviral treatments for CHB
9956516|NCT01155427||tenofovir|Patients initiating special antiviral treatments for CHB
9956517|NCT01155427||lamivudine|Patients initiating special antiviral treatments for CHB
9956518|NCT01155427||telbivudine|Patients initiating special antiviral treatments for CHB
9956519|NCT01155427||adefovir|Patients initiating special antiviral treatments for CHB
9956520|NCT01155440|Experimental|LIDOCAINE group|Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
9956521|NCT01155440|Active Comparator|Epidural group|Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
9517891|NCT03301974|Experimental|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
9956522|NCT01155453|Experimental|BKM120 + GSK1120212 DE|Dose Escalation
9956523|NCT01155453|Experimental|BKM120 + GSK1120212 NSCLC patients|Advanced RAS or BRAF mutant NSCLC patients
9956524|NCT01155453|Experimental|BKM120 + GSK1120212 ovarian cancer patients|Advanced RAS or BRAF mutant ovarian cancer patients
9956525|NCT01155453|Experimental|BKM120 + GSK1120212 pancreatic cancer patients|Advanced RAS or BRAF mutant pancreatic cancer patients
9956526|NCT01155492||Subjects with Parkinson's disease|Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
9956527|NCT01155492||Control subjects|Age- and gender-matched subjects who do not have Parkinson's disease
9956528|NCT01155492||Multiple system atrophy.|Men and women with clinically diagnosed multiple system atrophy.
9956529|NCT01155505|Experimental|CC-5013 in combination with Paclitaxel|"Cohorts of 3 evaluable patients will initially be entered within each dose level, sequentially. In each dose level the second and third patient will enter 2 weeks after the first one. The second and third patient may be treated simultaneously, except if a DLT is reported in the first patient, in which case the second and third patient should be treated sequentially, at least one week apart.~Dose escalation will be done when all the patients included in each DL will finish the first treatment cycle. Three additional patients will be sequentially entered (separated by one week each other) if one DLT is observed in cycle 1 among the first 3 patients entered within a dose level. If a DLT is observed in a second patient at this dose level, no further dose escalation will be allowed and the dose level will be considered the MTD.~Once the RD (one level below the MTD) has been defined, additional patients (up to 12) will be treated in order to confirm the safety profile of the combination."
9956530|NCT01155544|Active Comparator|Aripiprazole|
9956531|NCT01155544|Placebo Comparator|Placebo|
9956532|NCT01155557|Active Comparator|Specific Strength Training|10 weeks of specific strength training of neck and shoulder muscles using elastic resistance.
9956533|NCT01155557|Active Comparator|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
9956534|NCT01155596|No Intervention|Control group|Base on positive pressure ventilation with intubation and mechanical ventilator, weaning processes will undergo by Pulmonologists.
9956535|NCT01155596|Experimental|Experimental group|Experimental group is weaning with the support of negative pressure ventilator.
9956536|NCT01155609|Experimental|Supportive care (oral complications management)|Patients receive L-Lysine PO QD until completion of radiotherapy and resolution of mucositis in the absence of disease progression or unacceptable toxicity.
9956537|NCT01155622|Active Comparator|32º Celsius|Endovascular Cooling was set at a target temperature of 32°C
9956538|NCT01155622|Active Comparator|34º Celsius|Endovascular Cooling was set at a target temperature of 32°C
9956539|NCT01155635|Active Comparator|Beta-blocker|Use of Carvedilol with any dose
9956540|NCT01155635|Active Comparator|Non Beta-blocker|No use of Carvedilol
9956541|NCT01155648|Experimental|PSV group.|Chest wall compression plus increase of 10 cmH2O of PSV.
9956542|NCT01155648|Active Comparator|chest wall compression group|Chest wall compression
9956543|NCT01155674||Sepsis patients|Patients presenting sepsis
9956544|NCT01155674||SIRS patients|Patients presenting with the systemic inflammatory response syndrome
9956545|NCT01155674||Healthy subjects|Healthy blood donors
9956546|NCT01155687||Psychosocial counseling|the group received annualized treatment of psychosocial counseling
9956547|NCT01155687||Medication|this group received medical treatment by the local medical doctor
9956548|NCT01155700|Experimental|Omalizumab|Omalizumab treatment
9956549|NCT01155713|Experimental|Arm 1 - TKI258 - bioavailability|
9956550|NCT01155713|Experimental|TKI258 - food effect|
9956551|NCT01155739||procalcitonine monitoring|PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
9956552|NCT01155739||control group|control group: antibiotic use and length of treatment as defined by guidelines
9956553|NCT01155752|Experimental|PULMOZYME|active drug
9956554|NCT01155752|Placebo Comparator|placebo|cross over to placebo
9956555|NCT01155765|Experimental|Prasugrel|Prasugrel per os 10 mg/day
9803631|NCT03679299||Healthy Control|Healthy controls will be recruited from the general population and will be matched based on age, sex, and BMI. They will be assess at two time points, 48 hours apart. At each testing day, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity.
9956556|NCT01155765|Active Comparator|Clopidogrel|Clopidogrel per os 150 mg/day
9956557|NCT01155791|Experimental|combination sodium selenite and docetaxel|
9956558|NCT01155804|Other|Exercice|
9956559|NCT01155804|Other|non-exercice|
9956560|NCT01155817|Experimental|Nilotinib|
9956561|NCT01155843||Asthmatic, chronic stress|
9956562|NCT01155843||Asthmatic, non-stress|
9956563|NCT01155856|Experimental|telemedicine|Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
9956564|NCT01155856|No Intervention|control|The control group will receive usual care and treatment at the hospital until discharge(typically between 5-7 days).
9956565|NCT01155882||Whipple Surgery at the Splenic Artery|Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
9956566|NCT01155895|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
9956567|NCT01155895|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
9956568|NCT01155908|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
9956569|NCT01155908|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
9956570|NCT01155921|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
9956571|NCT01155921|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
9956572|NCT01155934|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
9956573|NCT01155934|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
9956574|NCT01155947|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
9956575|NCT01155947|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
9956576|NCT01155960|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
9956577|NCT01155960|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
9956578|NCT01155973|Experimental|EDUCORE intervention|Use of low risk SCORE table. Use of visual impact images. Handing the patient a pamphlet (advice on how to maintain cardiovascular health plus the low risk SCORE table with the patient's current score marked).
9956579|NCT01155973|Active Comparator|control group|Use of low risk SCORE table; verbally informing the patient of his/her CVR. Giving advice/verbal information on risk factors.
10005617|NCT01586728|Other|Oxygen - Air|One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.
10005618|NCT01586754||With Metabolic Syndrome|
10005619|NCT01586754||Without Metabolic Syndrome|
10005620|NCT01586767|Active Comparator|Proton beam therapy|Subjects treated at Massachusetts General Hospital with proton beam therapy
10005621|NCT01586767|Active Comparator|IMRT|Intensity-modulated radiation therapy at institutions other than Massachusetts General Hospital
10005622|NCT01586780|Experimental|Reference meal|
10005623|NCT01586780|Experimental|Whey protein|
9956580|NCT01155986|Placebo Comparator|Placebo Plaster|Active Comparator
9956581|NCT01155986|Active Comparator|Lidocaine Plaster|
9956582|NCT01156025|Experimental|GV550|(Ganciclovir 1.5 mg/g ophtalmic gel)
9956583|NCT01156025|Placebo Comparator|Placebo|Placebo ophtalmic gel
9956584|NCT01156038|Experimental|Atopy patch test|Atopy patches were applied on healthy volunteer's back for 48 hrs then the patches were removed. Reaction was evaluated 48 and 72 hrs after applying atopy patch test
9956585|NCT01156064||Case (subjects with digestive diseases)|The investigators cases are subjects with confirmed digestive diseases.
9956586|NCT01156064||Control|Healthy individuals aged between 18 and 90 years who are asymptomatic for digestive diseases.
9956587|NCT01156077|Experimental|oral TR-701 FA|Single oral dose of 200 mg TR-701
9956588|NCT01156077|Experimental|IV TR-701 FA|Single IV infusion of 200 mg TR-701 FA
9956589|NCT01156090||Vectibix|patients who received at least one treatment of Vectibix
9956590|NCT01156103|Experimental|SCORES|America SCORES, Bay Area, after-school program
9956591|NCT01156103|No Intervention|Usual care|Standard after-school programming
9956592|NCT01156129|Active Comparator|Arm A: Standard therapy (use of medications)|stool softener
9956593|NCT01156129|Experimental|Arm B: Acupressure bracelets|device - Biobands
9956594|NCT01156129|Experimental|Arm C|Sugar free gum
9956595|NCT01156155||Participants with Rheumatoid Arthritis|Rheumatoid arthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination Bilateral digital xray of hands
9956596|NCT01156155||Osteoarthritis|Osteoarthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination
9956597|NCT01156181|Experimental|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
9956598|NCT01156181|Active Comparator|Control|Embryo transfer without any intervention
9956599|NCT01156194|Active Comparator|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
9956600|NCT01156194|Active Comparator|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
9956601|NCT01156194|Placebo Comparator|Placebo|globules identical to true comparators
9956602|NCT01156207|Experimental|Aliskiren|
9956603|NCT01156207|Placebo Comparator|placebo|
9956604|NCT01156220|Experimental|female|"The healthy female volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2."
9956605|NCT01156220|Experimental|male|"The healthy male volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2"
9956606|NCT01156233|Experimental|Cuff palpation technique|Cuff palpation by the investigator's finger.
9956607|NCT01156233|Experimental|Withdrawing tube technique|Identification of the tube by withdrawing until good quality breath sounds
9956608|NCT01156246|Experimental|1|Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, fasting conditions day 1, visit 3.
9956609|NCT01156246|Experimental|2|Dapagliflozin/metformin tablet, fasting conditions day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 3.
9956610|NCT01156259|Experimental|30 Gy|
9956611|NCT01156259|Active Comparator|40 Gy|
9956612|NCT01156272||Replacement aortic heart valve|ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm
9956613|NCT01156285||AAU|patient with acute attack of anterior uveitis
9956614|NCT01156298||Cohort 1|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date.
9956615|NCT01156298||Cohort 2|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
9956616|NCT01156324|Placebo Comparator|Control|Participants of the routine care control group will each receive a $50 gift certificate at the end of each IVF cycle for which they completed the questionnaires.
9956617|NCT01156324|Experimental|Online Stress Management Group (Upliv)|Personalized online stress management program consisting of weekly sessions which each include relaxation exercises, stress management strategies, and lifestyle modification advice. Participants in Upliv will also be given a set of personal care products as part of the program.
9956618|NCT01156337||low sodium diet 80 mmol/day|
9956619|NCT01156337||moderate sodium intake 120 mmol/day|
9956620|NCT01156389|Active Comparator|Ritonavir plus Pyramax arm|Subjects in arm A will take 7 days of ritonavir followed by 3 days of ritonavir plus Pyramax followed by 7 days of ritonavir followed by 33 days follow-up period (40 days since last Pyramax dosing) and a study completion evaluation.
9956621|NCT01156389|Active Comparator|Pyramax arm|Subjects in arm B will take a three day treatment course of Pyramax, followed by a follow up period of 40 days since last Pyramax dosing and a study completion evaluation.
9956622|NCT01156402|Experimental|Active Intervention: Obesity Prevention|
9956623|NCT01156402|Experimental|Alternative Intervention/control: Oral Health|
9956624|NCT01156441|Experimental|surgical mitral valve repair|Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree. Mitral valve repair will be performed with mitral valve annuloplasty via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia.
9956625|NCT01156441|No Intervention|control: medical management|Clinical observation will be continued without surgery. Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree.
9956626|NCT01156454||Surgery followed by x-ray assessment|After nodes are removed they are taken to radiology to be x-rayed
9956627|NCT01156467|Active Comparator|Control|Infants randomised to this arm will receive a regular nasogastric tube, and the ventilatory care is given as routinely is done.
9956628|NCT01156467|Active Comparator|NAVA|Infants randomised to this arm will receive and Edi-catheter as an oro-/nasogastric tube and the Edi-signal will be monitored and when possible NAVA-ventilation used.
9956629|NCT01156493|Experimental|Protein Hydrolyzed Formula|Infants assigned to this group will receive HP formula when breast milk not available or indicated to receive formula by the attending physician
9956630|NCT01156493|No Intervention|Control|Infants in this group will receive standard prematrue formula when no breast milk available or indicated by the attending physician
9956631|NCT01156519|Other|Salivary cortisol|
9956632|NCT01156584|Experimental|Single arm|Toca 511 vector/ Toca FC prodrug
9956633|NCT01156610|Experimental|Integrated Cessation Counseling|"IVR System: IVR will be used for two purposes: (1) to facilitate access to treatment for low-SES and minority smokers and (2) perform six-month outcome assessment.~Tobacco Treatment Specialist Calls: A tobacco treatment specialist will make four attempts to contact the patient by phone within 14 days. On contacting the patient, the specialist will screen the patient for readiness to quit, provide brief (10 to 15 minutes) counseling tailored to the patient's readiness to quit, and provide information and support for use of medications that could be or were prescribed and about relevant community resources.~NRT: Patients who do not have a contraindication and smoke > 10 cigarettes per day, will be offered a free 6-week kit of generic nicotine patches (2 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches). Individuals who smoke 5-10 cigarettes/day will be offered a 6-week course, starting with the 14 mg patch. Those with a contraindication will not get NRT."
9517892|NCT03301974|Experimental|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
9517893|NCT03301974|Experimental|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
9956634|NCT01156610|Active Comparator|Usual Care|"IVR Call: Similar to the initial IVR call for the intervention arms, the initial control arm call will confirm the participant's identify and provide a brief description of the study (obtaining information about health behaviors), with the opportunity for the individual to accept or decline participation. Following this introduction, the IVR script will confirm smoking status. The phone script will collect specific information about current smoking (cigarettes/day), prior quit attempts, and motivation to quit during the next month. No further contact will be made with patients in the control clinics until the outcome assessment call. In the control practices, the IVR machine will also generate a text note documenting the information obtained for the patients' EHR for use by the patient's health care providers as part of their visit-based best practices."
9956635|NCT01156623|Experimental|With EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, further EBUS-TBNA will be arranged if patients agreed it.
9956636|NCT01156623|No Intervention|Without EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, no EBUS-TBNA will be arranged if patients refused it despite we advised it.
9956637|NCT01156636|Active Comparator|Sildenafil|
9956638|NCT01156636|Placebo Comparator|Placebo|
9956639|NCT01156649|Sham Comparator|Sham PAP therapy|Sham PAP will be used with 30 children, and consists of continuous sub-therapeutic levels of air pressure (approximately 1 cm of water) that are delivered through the nasal interface device.
9956640|NCT01156649|Active Comparator|Treatment group|30 children will receive active treatment PAP, which consists of automatically adjusted air pressures that are delivered through the nasal interface device at levels which effectively treats the obstructive events.
9956641|NCT01156662|Active Comparator|No aspiration|
9956642|NCT01156662|Active Comparator|Thrombus aspiration|
9956643|NCT01156688|Active Comparator|Sublingual Misoprostol|
9956644|NCT01156688|Active Comparator|Buccal misoprostol|
9956645|NCT01156727||SURVEY: 6 months post-deployment|Michigan Army National Guard soldiers 6 months post deployment between August 2011 and December 2013
9956646|NCT01156727||SURVEY: 12 months post-deployment|Michigan Army National Guard soldiers 12 months post deployment between August 2011 and December 2013.
9956647|NCT01156727||INTERVIEWS|Michigan Army National Guard soldiers 12-24 months post deployment between October 2011-April 2014. Also key stakeholders from the B2B program.
9956648|NCT01156740|Active Comparator|Intramuscular benzathine Penicillin G|A single dose of intramuscularly administered intramuscular benzathine penicillin G (IM BPG). The dosing was as follows: IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg
9956649|NCT01156740|Active Comparator|Amoxicillin|A 10-day once daily dose of Amoxicillin was given in an oral form. The first dose was given at the time of randomization, and parents were instructed on giving the remaining doses. Dosing was as follows: 750 mg/QD
9956650|NCT01156779|Experimental|DA-3091|SR-exenatide
9956651|NCT01156779|Placebo Comparator|Placebo of DA-3091|Placebo
9956652|NCT01156818||Children|Age 8-21 years
9956653|NCT01156818||Adult|Age 21-80 years
9956654|NCT01156857|Experimental|A|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
9956655|NCT01156857|Experimental|B|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).
9956656|NCT01156870|Experimental|SAR566658|SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
9956657|NCT01156896|Experimental|Iron intervention|"All study subjects with malaria and all control subjects will receive an iron intervention (supplement or fortification dose of iron).~Control subjects will be studied on only one occasion.~Study subjects with malaria will receive the same iron intervention two weeks later, after the malarial episode has been successfully treated."
9956658|NCT01156909|Experimental|Rituximab|Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
9956659|NCT01156922|Experimental|Rituximab|Rituximab induction two infusions (500 mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
9956660|NCT01156935|Experimental|Laugh yoga|experimental laugh yoga
9956661|NCT01156948|Active Comparator|vaginal misoprostol|vaginal misoprostol was administered to this group of nulliparous women
9956662|NCT01156948|Experimental|oral misoprostol|oral misoprostol
9956663|NCT01156961|Experimental|Single Arm|
9956664|NCT01156974|Experimental|care guide|patients receive education about care goals and work with a care guide to achieve goals
9956665|NCT01156974|Active Comparator|no care guide|patients receive education about care goals and usual care to achieve goals
9956666|NCT01157000|Experimental|001|Canagliflozin On Day 1 all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
9956667|NCT01157013|Experimental|Advanced Hepatocellular Carcinoma|Hepatocellular carcinoma patients not candidates to local and/or curative treatment and an expected overall survival of at least three months and who are susceptible of receiving sorafenib therapy.
9956668|NCT01157026|Experimental|Tocotrienol Rich Fraction plus Tamoxifen|
9956669|NCT01157026|Active Comparator|Placebo plus tamoxifen|
9956670|NCT01157039|Experimental|Dietary Supplement|Arm A: At cycle 2, patients will be randomized to receive for 6 days- Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3
9956671|NCT01157039|Experimental|Dietary supplement|Arm B: At cycle 2, patients will be randomized to receive for 6 days: Glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3.
9956672|NCT01157052|Active Comparator|Ca2+/Mg2+ pre & post cycle 1|Arm A:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1
9956673|NCT01157052|Active Comparator|Ca2+/Mg2+pre & post cycle 2|Arm B:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 2
9956674|NCT01157104|Experimental|IDX320 + PBO → IDX320 + IDX184|400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days
9956675|NCT01157104|Experimental|IDX184 + PBO → IDX184 + IDX320|100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days
9956676|NCT01157104|Placebo Comparator|IDX320 PBO + IDX184 PBO|IDX320 matching PBO + IDX184 matching PBO for 14 days
9956677|NCT01157130|Experimental|Intervention Group|Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
9956678|NCT01157130|No Intervention|Control Group|The control group will receive basic information on physical activity but not be instructed.
9956679|NCT01157143|Experimental|NV1FGF 500 μg|8 intramuscular injections for a total of 500 μg administered in one single administration 3 to 8 days before major amputation
9956680|NCT01157143|Experimental|NV1FGF 2000 μg|8 intramuscular injections for a total of 2000 μg administered in one single administration 3 to 8 days before major amputation
9956681|NCT01157143|Experimental|NV1FGF 4000 μg|8 intramuscular injections for a total of 4000 μg administered in one single administration 3 to 8 days before major amputation
9956682|NCT01157195|Active Comparator|CI therapy|
9956683|NCT01157195|Experimental|Tele-AutoCITE|AutoCITE stands for Automated Constraint Induced Therapy Extender.
9956684|NCT01157208|Experimental|Diet A|This diet is high in omega-3 fatty acids, low in trans fatty acids, and low in omega-6 fatty acids. Subjects are encouraged to eat fatty fish daily (e.g., salmon), to limit vegetable oil intake, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include salmon-salad sandwiches, hummus with olive oil, other bean dips and bean dishes, frozen and canned fish, and blueberry-flax muffins.
9956685|NCT01157208|Experimental|Diet B|This diet is low in trans fatty acids and low in omega-6 fatty acids. Subjects are encouraged to to limit vegetable oil intake, to replace meats and eggs with beans and lean fish/shellfish, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include hummus with olive oil, other bean dips and bean dishes, lean fish and shellfish,and blueberry muffins.
9956686|NCT01157221|Experimental|intervention group|intervention group: end-range mobilization/scapular mobilization treatment approach group
9956687|NCT01157221|Active Comparator|control|
9956688|NCT01157221|Sham Comparator|control-criteria group|
9956689|NCT01157247|Other|Group SNI|Insertion of spinal needle with introducer
9956690|NCT01157247|Other|Group SNI+LA|Local infiltration of lidocaine was applied three minutes after insertion of spinal needle with introducer
9956691|NCT01157247|Other|Group SNI+F|Intravenous fentanyl was applied 3 min before insertion of spinal needle with introducer
9956692|NCT01157247|Other|Group SN|Spinal puncture was performed only with spinal needle without introducer, local anesthetic infiltration or intravenous fentanyl before spinal puncture.
9956693|NCT01157260|Experimental|AST-120|AST-120 administration 2g three times a day
9956694|NCT01157260|No Intervention|Control|Control Chronic Kidney disease stage 3,4
9956695|NCT01157273||High Anxiety (HA) group|13 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores above 41 in STAI-Trait
9956696|NCT01157273||Low Anxiety (LA) group|11 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores below 41 in STAI-Trait
9956697|NCT01157286||level of apnea|patients will be separated depending on the iah(apnea hypopnea index) in mild, moderate and severe
9956698|NCT01157299||Hemodynamic instability|Hypotension and/or evidence of end-organ hypoperfusion
9956699|NCT01157299||Hemodynamic stability|"Normotension and end-organ normoperfusion along with~Vasopressor, vasodilator or inotropic therapy~Edema and/or evidence of hypervolemia"
9956700|NCT01157299||"Hemodinamically normal"|"Normotension and end-organ normoperfusion along with~Non vasopressor, vasodilator or inotropic therapy~Normohydration state~Non Systemic Inflammatory Response Syndrome~Spontaneous breathing and PEEP, or CPAP, equal or less than 5 cm H2O"
9956701|NCT01157312|Experimental|minimal stimulation protocol|5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles
9956702|NCT01157312|Active Comparator|clomiphene citrate(CC)|5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.
9956703|NCT01157325|Active Comparator|Non-neuraxial analgesia|Parturients will not receive neuraxial analgesia
10005624|NCT01586780|Experimental|Whey + 5 amino acids|
10005625|NCT01586780|Experimental|Whey + 6 amino acids|
9956704|NCT01157325|Active Comparator|Neuraxial analgesia|Parturients will receive neuraxial analgesia
9956705|NCT01157338|Active Comparator|diagnostic cardiac catheterization|patients with diagnostic cardiac catheterization
9956706|NCT01157338|Active Comparator|therapeutic cardiac catheterization|patient with angioplasty
9956707|NCT01157390|Experimental|Infant formula|The infants will be fed with Wondersun infant formula with high proportion of palmitic acid at the sn-2 position
9956708|NCT01157390|Active Comparator|Breast feeding|Complete breast feed within the first 3 month
9956709|NCT01157403|Experimental|mesenchymal stem cells|To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM.
9956710|NCT01157442|Experimental|cell phone sms messages|The experimental arm will receive the cell phone SMS text messaging intervention.
9956711|NCT01157442|No Intervention|Control|The control group will receive the standard of care but no SMS text messages.
9956712|NCT01157468||Cases|"The Case group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2:~30 patients with a quiescent lupus~30 patients with an active lupus"
9956713|NCT01157468||Controles|"The Control group is constituted by people coming to give blood to the French Blood Establishment of Martinique."
9956714|NCT01157481|Experimental|Conventional therapy plus nifedipine|
9956715|NCT01157481|Active Comparator|Conventional therapy|
9956716|NCT01157494||children with hemiplegia|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
9956717|NCT01157507|Active Comparator|Botulinum A toxin|Botulinum A toxin intravesical injection.
9956718|NCT01157507|Sham Comparator|Bladder overdistension|Standard treatment: bladder overdistension
9956719|NCT01157507|Placebo Comparator|Placebo|
9956720|NCT01157520||Cesarean|Women scheduled for elective Cesarean section under spinal anesthesia
9956721|NCT01157546|Placebo Comparator|Control|group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
9956722|NCT01157546|Experimental|TAP|group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
9956723|NCT01157572|Active Comparator|Metoprolol|
9956724|NCT01157572|Placebo Comparator|Placebo|
9956725|NCT01157585|Other|drug|
9956726|NCT01157598|Active Comparator|BIS group|
9956727|NCT01157598|Placebo Comparator|non BIS group|
9956728|NCT01157611|Active Comparator|Mentoring program group|type 1 diabetes patients participating in online base mentoring program
9956729|NCT01157611|No Intervention|Control group|type 1 diabetes patients receiving regular clinic visits
9956730|NCT01157624|Active Comparator|oxygen|
9956731|NCT01157624|Placebo Comparator|air supplement|
9956732|NCT01157650|Experimental|Autologous mesenchymal stem cells|Fistulizing Crohn's disease
9956733|NCT01157663|Experimental|Adapted Balance Training group|
9956734|NCT01157663|Active Comparator|Standard Balance training group|Balance training with unipedal standing during 8 weeks
9956735|NCT01157689||Coartem, chloroquine, quinine|All children with a positive malaria test will included. Results will be subanalysed acording to treatment given by routine health staff.
9956736|NCT01157702|Experimental|Vaccine|Vaccination with one dose (0.5 mL) of inactivated influenza vaccine
9956737|NCT01157715|Experimental|0.5 mg cohort|patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
9956738|NCT01157715|Experimental|2.0 mg cohort|patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
9956739|NCT01157728||Relapsing Multiple Sclerosis patients|
9956740|NCT01157728||healthy volunteer|
9956741|NCT01157741|No Intervention|Standard Practice (H-C)|1) Hospital control group (Group H-C): children assigned to this group received the standard hospital-based, outpatient treatment package, which consisted of fortnightly follow-up for growth monitoring, health and nutrition education, and micronutrient supplementation.
9956742|NCT01157741|Experimental|C-C|Community-based follow-up (Group C-C): the standard community-based follow-up package was identical to the one provided to the hospital-based control group, except that the follow-up visits took place at the nearest CNFU rather than the HNFU.
9956743|NCT01157741|Experimental|C-SF|Community-based follow-up plus supplementary food (Group C-SF): children assigned to this group received the same treatment package as those in Group C-C, except that supplementary food (SF) packets and preparation instructions were also provided at the time of each follow-up clinic visit for consumption at home in addition to the children's usual meals.
9956744|NCT01157741|Experimental|C-PS|Community-based follow-up plus psychosocial stimulation (Group C-PS): children assigned to this group received the same treatment package as those in Group C-C, except that they were also provided with psychosocial stimulation (PS).
9956745|NCT01157741|Experimental|C-SF+PS|Community-based follow-up plus SF and PS (Group C-SF+PS): children assigned to this group received the same treatment package as those in the Group C-C, except that they were also provided with both SF and PS, as described above.
9956746|NCT01157754|Experimental|OCP+GnRH antagonist|Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
9956747|NCT01157754|Active Comparator|long GnRH agonist|daily triptorelin starting day 21st of previous cycle
9956748|NCT01157767||breast pts who have undergone surgery|This will be a feasibility study designed to evaluate the compliance of an at-home, directed exercise program and its influence on physical measures during post-operative adjuvant chemotherapy and radiation (if applicable).
10005626|NCT01586780|Experimental|Soy protein drink|
10005627|NCT01586780|Experimental|Soy + 5 amino acids|
10005628|NCT01586780|Experimental|Soy + 6 amino acids|
10005629|NCT01586793|Experimental|High Frequency rTMS|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
10005630|NCT01586793|Experimental|Low Frequency rTMS|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
10005631|NCT01586832||ED Nurses|"Nurses in the emergency department (ED) providing patient care using supplies found in the stocking towers"
10005632|NCT01586845|Experimental|Voclosporin|Voclosporin
10005633|NCT01586845|Active Comparator|Tacrolimus|Tacrolimus
9956749|NCT01157780|Experimental|fish oil|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
9956750|NCT01157780|No Intervention|standard of care|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
9956751|NCT01157793|Experimental|Group 1|
9956752|NCT01157793|Experimental|Group 2|
9956753|NCT01157806|Experimental|radiochemotherapy instead of surgery|
9956754|NCT01157819|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
9956755|NCT01157819|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
9956756|NCT01157858|Active Comparator|Everolimus + octreotide LAR|Octreotide LAR combined with everolimus
9956757|NCT01157858|Active Comparator|Octreotide LAR|Octreotide LAR monotherapy
9956758|NCT01157871|Experimental|placebo|4 administrations at 2-week interval of placebo solution
9956759|NCT01157871|Experimental|NV1FGF 16 mg|4 administrations at 2-week interval of 4mg at each administration
9956760|NCT01157871|Experimental|NV1FGF 32 mg|4 administrations at 2-week interval of 8mg at each administration
9956761|NCT01157884||Kidney Transplantation|
9956762|NCT01157923|Experimental|intervantion group|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor.
9956763|NCT01157923|No Intervention|control group|Regular treatment, No change will be made in the insulin pump setting during the study(unless there is a medical need or any safety concern).
9956764|NCT01157936|Active Comparator|Allopurinol treatment|
9956765|NCT01157936|Placebo Comparator|Placebo|
9956766|NCT01157949|Active Comparator|Study withdrawn|Study withdrawn
9956767|NCT01157949|Placebo Comparator|Withdrawn|Study withdrawn
9956768|NCT01157962|Experimental|Group A Sentinel lymphadenectomy|In group A exclusively sentinel lymphadenectomy is performed
9956769|NCT01157962|Active Comparator|Group B radical pelvine lymphadenectomy|in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.
9956770|NCT01157975|Experimental|Pioglitazone|
9956771|NCT01157975|Experimental|Prednisone|
9956772|NCT01157988|Experimental|ibritumomab tuixetan, response, toxicity|
9956773|NCT01158001|Experimental|Psychotherapy via telemedicine|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in a novel format - interacting with a therapist via videoconferencing.
9956774|NCT01158001|Active Comparator|Face-to-face (in person) psychotherapy|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in the traditional format - in person with a therapist.
9956775|NCT01158014|Experimental|Fibrin Glue, surgery|Conjunctival autograft will be glued using fibrin glue to pterygia bed after removal
9956776|NCT01158014|Active Comparator|Control|Conjunctival autograft will be sutured using 10/0 vicryl sutures to pterygia bed after removal
9956777|NCT01158027||children|
9956778|NCT01158040||Insulin pump|Women suffering from pregestational diabetes mellitus and being treated with insulin pump during pregnancy and delivery
9956779|NCT01158040||IV insulin|Women suffering from pregestational diabetes mellitus and being treated with insulin sub-cutan (SC) during pregnancy and IV insulin during delivery
9956780|NCT01158040||Healthy|Healthy women accepted for delivery in our institute
9956781|NCT01158066|No Intervention|CT cardiac|the patient will undergo cardiac CT
9956782|NCT01158092|Active Comparator|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
9956783|NCT01158092|Active Comparator|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
9956784|NCT01158105|Experimental|Bortezomib|1.6 mg/m2 intravenous infusion will be administered on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles. Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles. This maintenance dose will be administered on days 1 and 15.
9956785|NCT01158131|Experimental|Lifestyle Intervention group|Participants in this group will take part in the lifestyle intervention.
10005634|NCT01586858||RAVE subjects|
9956786|NCT01158131|No Intervention|Post-gestational diabetes mellitus (GDM) Follow-up Group|Participants in this group will not take part in the intervention.
9956787|NCT01158144|Experimental|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
9956788|NCT01158144|Active Comparator|Conctrol|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
9956789|NCT01158170|Experimental|prophylactic cranial irradiation|Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.
9956790|NCT01158170|Active Comparator|Conctrol|Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity
9956791|NCT01158183||Group 1|No intervention
9956792|NCT01158196|Experimental|infra-red diode laser|one session, one dose
9956793|NCT01158209||Assessed cohort|Subjects attending out-patient health services for gynaecological examination.
9956794|NCT01158235|Experimental|LTX-109 (Lytixar)|Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2%LTX-109/placebo and finally group 3: 5%LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
9956795|NCT01158274|Experimental|Treatment|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9956796|NCT01158287|Experimental|Sorafenib 400mg bd, p.o, continuously|
9956797|NCT01158313||Thickener|"Patients with history of swallowing difficulties associated with aging and/or neurological diseases including patients with:~neurodegenerative diseases.~non-progressive neurological diseases including stroke.~older patients including nursing home patients."
9956798|NCT01158326|Active Comparator|Resfenol Solution oral|Acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride active drug
9956799|NCT01158326|Placebo Comparator|Placebo|Placebo oral solution
9956800|NCT01158339|Active Comparator|Arm 1: CBGT|Cognitive Behavioural Group Therapy (CBGT)
9956801|NCT01158339|Experimental|Arm 2: CBGT-ISE|Cognitive Behavioural Group Therapy, with in-Session Exposure (CBGT-ISE).
9956802|NCT01158352|Experimental|Nutritional supplemntation formula|Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
9956803|NCT01158352|Placebo Comparator|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
9956804|NCT01158365|Experimental|Dermacyd (different fragrances)|Day 1 until 30: Investigational Product (Dermacyd) Day 31 until 37: wash-out Day 38 until 67: Glycerine Vegetal Soap Granado Traditional
9956805|NCT01158365|Active Comparator|Glycerine Vegetal Soap Granado Traditional|Day 1 until 30: Glycerine Vegetal Soap Granado Traditional Day 31 until 37: wash-out Day 38 until 67: Investigational Product (Dermacyd)
9956806|NCT01158391|Experimental|NTrainer® Intervention|NTrainer® Intervention - Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
9956807|NCT01158391|Sham Comparator|Control Intervention|Control Intervention - Infants in the Control group will be provided orocutaneous stimulation with a 'quiet pacifier' during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
9956808|NCT01158430|Experimental|ACT group therapy|"Third generation cognitive behavioral therapy~Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours"
9956809|NCT01158430|No Intervention|Control|Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
9956810|NCT01158443|Experimental|Behavioral activation therapy|The Behavioral Activation Program for Energy and Productivity (BA-PEP) is a manualized, 8-session intervention, scheduled to coincide with maintenance armodafinil treatment. It is a structured counseling program with homework, short-term activities and goals, and includes problem-solving, identification of barriers and strategies for their resolution, with an ongoing focus on achieving employment or training.
9956811|NCT01158443|Placebo Comparator|supportive counseling (SC)|Supportive counseling is designed to create an empathic, accepting environment, to direct attention to the patient's feelings and to facilitate acceptance of affective experience using supportive statements, reflective listening and empathic communications.
9956812|NCT01158456||African Americans|Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
9956813|NCT01158456||European American|Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
9956814|NCT01158482||IVC Filter Placement or Removal|Patients undergoing IVC filter placement and/or IVC filter removal at Stanford Medical Center.
9956815|NCT01158508|Experimental|Remote Ischemic Preconditioning|Patients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
9956816|NCT01158560|Experimental|Vitamin D and gargling|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and asked to gargle with tap water twice daily
9956817|NCT01158560|Experimental|Vitamin D and general health advice|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and will receive general health advice in place of gargling advice
9956818|NCT01158560|Placebo Comparator|Placebo and general health advice|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be given general health advice in place of gargling advice.
9956819|NCT01158560|Placebo Comparator|Placebo and gargling|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be asked to gargle with tap water twice daily
9956820|NCT01158586|Experimental|Levobupivacaine|patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl
9956821|NCT01158586|Active Comparator|Ropivacaine|patient controlled epidural analgesia using 0.2% ropivacaine with 2ug/ml fentanyl
9956822|NCT01158599|Other|IXIARO 0,5 ml|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
9956823|NCT01158612|Experimental|Growth hormone|The effect of Growth hormone on the collagen synthesis rate
9956824|NCT01158612|Placebo Comparator|Saline|
9956825|NCT01158625|No Intervention|Morning dosing of antihypertensive drugs|
9956826|NCT01158625|Active Comparator|Nighttime dosing of antihypertensive drugs|
9956827|NCT01158638|No Intervention|Usual Care|Usual Care
9956828|NCT01158638|Active Comparator|10,000 Steps Group|Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
9956829|NCT01158638|Experimental|Web Mediated Step Group|Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
9956830|NCT01158664|Experimental|0.6 mm tread pitch implant|
9956831|NCT01158664|Experimental|0.1 mm tread pitch implant|
9956832|NCT01158690|Experimental|resource card group|The intervention group will receive an envelope with a gift voucher and a resource card (wallet size card with on the one side safety measures and on the other side contact details of resources for violence).
9956833|NCT01158690|Active Comparator|control group|The control group will receive the same envelop with a gift voucher and a letter of thanks.
9956834|NCT01158729|Experimental|ATIII experimental group|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive Antithrombin (Recombinant) prior to initiation of bypass
9956835|NCT01158729|Placebo Comparator|Placebo Controls|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive placebo prior to initiation of bypass
9956836|NCT01158742||1|Caucasians who donated a kidney at Mayo Clinic in Rochester, Minnesota (MN)
9956837|NCT01158742||2|Caucasians who donated a kidney at the University of Minnesota
9956838|NCT01158742||3|African-Americans who donated a kidney at the University of Alabama
9956839|NCT01158755|Active Comparator|Standard dose rifampisin|"Subjects in this arm receive 450 mg rifampicin orally.~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
9956840|NCT01158755|Experimental|High dose rifampisin|"Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
9956841|NCT01158768||Violence, Comorbidity|
9956842|NCT01158781|Experimental|gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition
9517894|NCT03301948|Experimental|Overfeed|Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
9956843|NCT01158794||Study participants|Participants with sickle cell disease and transfusional iron-overload, and non-sickle cell disease (thalassemia major, cancer patients, etc.) and iron overload. Participants with iron overload, defined as too much iron in the body as a consequence of too many blood transfusions.
9956844|NCT01158807||HHT- Brain Arteriovenous Malformation|"Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and~Presence of Brain Arteriovenous Malformation"
9956845|NCT01158807||HHT -NO BAVM|1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
9956846|NCT01158833||spastic diplegia due to Cerebral Palsy|
9956847|NCT01158846|Active Comparator|prasugrel/bivalirudin|60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.
9956848|NCT01158846|Active Comparator|clopidogrel/abciximab|600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.
9956849|NCT01158859|Experimental|Pregabalin|
9956850|NCT01158859|Placebo Comparator|Placebo|
9956851|NCT01158898|Active Comparator|TPI ASM8 low dose|
9956852|NCT01158898|Active Comparator|TPI ASM8 high dose|
9956853|NCT01158898|Placebo Comparator|Placebo|
9956854|NCT01158911||non-diabetic Chronic Kidney disease|
9956855|NCT01158937|Experimental|Extended Meropenem Infusion|Meropenem Infusion over 3 hours
9956856|NCT01158937|Experimental|Bolus Meropenem Infusion|Meropenem infusion over 30 minutes
9956857|NCT01158989||Critically ill|Critically ill subjects were intubated, mechanically ventilated and sedated
9956858|NCT01158989||Ambulatory Group|Subjects were scheduled for an outpatient procedure but were otherwise healthy
9956859|NCT01159002||Critically ill ICU patients|ICU patients with brain injuries who will be receiving a feeding tube.
9956860|NCT01159028|Experimental|BP1001|Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.
9956861|NCT01159028|Experimental|BP1001 in combination with LDAC|AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)
9956862|NCT01159041|Experimental|Family Focused Treatment (FFT)|15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.
9956863|NCT01159041|Active Comparator|Individual Treatment (IP)|15 session individually-based treatment to assist children in understanding the causes of their symptoms.
9956864|NCT01159080|Active Comparator|routine dose tacrolimus and less myfortic|
9956865|NCT01159080|Experimental|reduced dose tacrolimus and conventional myfortic|
9956866|NCT01159093|Experimental|Family Decision Support|Families will receive informational vaccine reminder telephone calls.
9956867|NCT01159093|Experimental|Clinical Decision Support|In this treatment arm, clinicians receive the decision support at the point of care within an electronic health record.
9956868|NCT01159093|Experimental|Family DS+ Clinician DS|Families will receive informational vaccine reminder calls and their clinicians will receive electronic health record-based decision support for immunizations.
10035242|NCT01804374|Experimental|sorafenib and everolimus|This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
10035243|NCT01804387|Active Comparator|Telbivudine plus adefovir|study drugs
10035244|NCT01804387|Active Comparator|Lamivudine plus adefovir|standard drugs
9517895|NCT03301948|Experimental|Energy Balance|Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
9517896|NCT03301922|Experimental|Work-focused metacognitive therapy|Work-focused metacognitive therapy
9956869|NCT01159093|Other|Control|This group will receive regular primary care with no decision support.
9956870|NCT01159119|Experimental|EUR-1066-A|Treatment with Eur-1006-A.
9956871|NCT01159119|Experimental|EUR-1066-B|Treatment with Eur-1066-B
9956872|NCT01159119|Active Comparator|Zenpep|Control Group: Consist of treatment with Zenpep
9956873|NCT01159132|Active Comparator|1|RAL 400 mg OD
9956874|NCT01159132|Active Comparator|2|RAL 800 mg OD
9956875|NCT01159145|Experimental|D961H 10 mg capsule|2 way crossover
9956876|NCT01159145|Experimental|Omeprazole 10 mg tablet|2 way crossover
9956877|NCT01159158|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
9956878|NCT01159158|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
9956879|NCT01159197|Experimental|cognitive behaviorial therapy|
9956880|NCT01159223|Experimental|1|ATV/r 200 mg/100 mg OD
9956881|NCT01159223|Experimental|2|ATV/r 300 mg/100 mg OD
9956882|NCT01159236|Experimental|Group 1: ER-Positive|"Participants with Estrogen Receptor (ER)-Positive breast cancers receive Standard T/FAC or T/FEC chemotherapy before surgery.~T/FAC or T/FEC: Combination chemotherapy with sequential paclitaxel (80 mg/m2) weekly x 12 weeks followed by 5-fluorouracil (500 mg/m2), cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) or epirubicin (100 mg/m2) (FAC or FEC) once every 3 weeks for 4 treatments."
9956883|NCT01159236|Experimental|Group 2: ER-Negative|Participants with ER-negative cancers (randomized between Group 2 & Group 3), Standard T/FAC or T/FEC chemotherapy before surgery.
9956884|NCT01159236|Experimental|Group 3: ER-Negative + Bevacizumab|Participants with ER-negative cancers (randomized between Group 2 & Group 3), T/FEC chemotherapy combined with 10 mg Bevacizumab every 2 weeks during first 3 treatments before surgery.
9956885|NCT01159275|Other|1|First Generic LPV/r 200/50 mg BID, then cross over to Pediatric Aluvia 200/50 mg BID
9956886|NCT01159275|Other|2|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
9956887|NCT01159301|Experimental|Treatment (entinostat, sorafenib tosylate)|Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9956888|NCT01159314|Experimental|Arm A - Baerveldt 250 mm2|Patients receiving Baerveldt 250 mm2
9956889|NCT01159314|Experimental|Arm B - Baerveldt 350 mm2|Patients receiving Baerveldt 350 mm2
9956890|NCT01159327|Experimental|Arm A|Sorafenib maintenance arm
9956891|NCT01159327|No Intervention|Arm B|observation arm
9956892|NCT01159353|Experimental|insulin glulisine + insulin aspart|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
9956893|NCT01159353|Experimental|insulin aspart + insulin glulisine|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
9956894|NCT01159366|Active Comparator|occluded culprit artery|An occluded lesion was defined as a lesion with 100% stenosis or TIMI-flow grade 0 or 1.
9956895|NCT01159366|Active Comparator|non-occluded culprit artery|A non-occluded lesion was defined as a lesion without 100% stenosis or TIMI-flow grade 0 or 1.
9956896|NCT01159379|Experimental|ertapenem, tolerance tests|Patients with IgE-mediated allergy to beta-lactams
9956897|NCT01159392||Brain injury plus acute lung injury|Patients with severe brain injury (Glasgow coma score<13) with acute lung injury (PaO2/FiO2 <300 mmHg)
9956898|NCT01159405|Experimental|99mTc-GP|99mTc-GP with SPECT/CT imaging & whole body scan.
9956899|NCT01159418|Experimental|Panobinostat (LBH589), Carboplatin and Paclitaxel|
9956900|NCT01159457|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Sci-B-Vac vaccination series
9956901|NCT01159457|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Engerix 3-dose vaccination series
9956902|NCT01159470||bacterial infection|children with fever due to bacterial infection
9956903|NCT01159470||viral infection|children with fever due to viral infection
9956904|NCT01159483|Experimental|Cohort A|"Period 1: Participants received 0.01 milligrams (mg) of PF-04958242 or matching placebo, once, orally.~Period 2: Participants received 0.03 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 0.1 mg of PF-04958242 or matching placebo, once, orally."
9956905|NCT01159483|Experimental|Cohort B|"Period 1: Participants received 0.3 mg of PF-04958242 or matching placebo, once, orally (fasted).~Period 2: Participants received 0.6 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 1.0 mg of PF-04958242 or matching placebo, once, orally (fed)."
9956906|NCT01159496|Experimental|Active|
9956907|NCT01159496|Placebo Comparator|Placebo|
9956908|NCT01159509||Infants ages -13 years that had HPS in infancy|
9956909|NCT01159522|Experimental|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
9956910|NCT01159548|No Intervention|Saline|
9956911|NCT01159548|Other|Promethazine 6.25 mg|
9956912|NCT01159548|Other|Promethazine 3 mg|
9956913|NCT01159561|Experimental|Vaccinated|Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
9956914|NCT01159587||Group 1|
9956915|NCT01159587||Group 2|
9956916|NCT01159613||Non Responders|Non Responders
9956917|NCT01159613||RESPONDERS|
9956918|NCT01159626|Experimental|Single dose|
9956919|NCT01159626|Experimental|Multiple dose|
9956920|NCT01159639|No Intervention|aspirin low responders monotherapy|patients with inappropriate response to aspirin assessed by multiple electrode aggregometry
9956921|NCT01159639|Active Comparator|aspirin low responders dual antiplatelet therapy|patients with inappropriate response to aspirin 300 mg therapy after CABG, randomized to receive clopidogrel 75 mg in addition to aspirin
9956922|NCT01159652|Placebo Comparator|Bedtime Placebo|
9956923|NCT01159652|Placebo Comparator|Middle of the Night Placebo|
9517897|NCT03301922|Other|Waiting list|Waiting list
9517898|NCT03301870|Experimental|ATx201 GEL, 2% - intact skin|ATx201 GEL, 2% applied intact skin
9956924|NCT01159652|Experimental|Zolpidem|
9956925|NCT01159652|Experimental|Zaleplon|
9956926|NCT01159678|Experimental|online psychoeducation|
9956927|NCT01159704|Experimental|Network plus HIV Counseling&Education|"Social network peer education model plus HIV testing and counseling; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
9956928|NCT01159704|Active Comparator|HIV Counseling and Education (C&E) only|"HIV testing and counseling C&E; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
9956929|NCT01159730|Experimental|Multiple doses of VB-201|
9956930|NCT01159730|Placebo Comparator|Placebo|
9956931|NCT01159756|Experimental|Travacom|Travacom ophthalmic solution
9956932|NCT01159782|Other|Asthma, Healthy|Asthmatics or Healthy Volunteers
9956933|NCT01159808|Experimental|INX-08189|
9956934|NCT01159808|Placebo Comparator|Placebo|
9956935|NCT01159821|Experimental|001|31001074/paroxetine 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
9956936|NCT01159834||Gardasil, HPV infection|
9956937|NCT01159847|Experimental|Sitagliptin|Patients will receive insulin therapy with sitagliptin.
9956938|NCT01159847|Active Comparator|Insulin|Patients will receive insulin therapy without sitagliptin.
9956939|NCT01159860|Active Comparator|Cryosurgery|One lesion on the patients' trunk or proximal extremities will be treated with cryosurgery.
9956940|NCT01159860|Active Comparator|Curettage|One lesion on one side of the patients' trunk or proximal extremities will be treated by curettage.
9956941|NCT01159873|Experimental|CEP-37251|
9956942|NCT01159873|Placebo Comparator|Placebo|
9956943|NCT01159886|Active Comparator|left lateral|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus position. Then terminal ileal intubation will be attempted.
9956944|NCT01159886|Active Comparator|supine|After confirmation of cecal intubation, patient will undergo randomization to the supine position. Then terminal ileal intubation will be attempted.
9956945|NCT01159925||Possible hepatitis A Cohort|Children with an acute disease characterized by discrete onset of symptoms and jaundice
9956946|NCT01159925||Probable hepatitis A Cohort|Children with an increase in serum levels of transaminase 2.5 times higher than the maximum limit of the normal interval
9956947|NCT01159925||Confirmed hepatitis A Cohort|Children presenting a positive result for Immunoglobulin M for hepatitis A virus
9956948|NCT01159951||Hepatitis Cohort|Subjects suffering with hepatitis
9956949|NCT01159964|Experimental|Cohort 1|Subjects will receive investigational dose-level A (different from dose-levels B and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
9956950|NCT01159964|Experimental|Cohort 2|Subjects will receive investigational dose-level B (different from dose-levels A and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
9956951|NCT01159964|Experimental|Cohort 3|Subjects will receive investigational dose-level C (different from dose-levels A and B). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
9956952|NCT01159977|Experimental|Facilitated small group|Facilitated small groups.
9956953|NCT01159977|Active Comparator|Unstructured protected time|Same time provided as for facilitated small groups, but without structure.
9956954|NCT01159977|Placebo Comparator|Usual practice|No protected time.
9956955|NCT01159990|Experimental|Recombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C|Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
9956956|NCT01159990|Active Comparator|rAd5 gag/pol|Participants will receive one intramuscular injection of rAd5 gag/pol.
9956957|NCT01160003|Experimental|Treatment Period 1|5mg of GW870086X or placebo will be given once daily for 14 days.
9956958|NCT01160003|Experimental|Treatment Period 2|GW870086X (5mg or 8.75mg) or placebo will be given once daily for 14 days. In a randomised dose escalating manor following on from treatment period 1.
9956959|NCT01160003|Experimental|Treatment Period 3|8.75mg of GW870086X or placebo will be given once daily for 14 days.
9956960|NCT01160029|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
9956961|NCT01160029|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
9956962|NCT01160042|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
9956963|NCT01160042|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
9956964|NCT01160055||Cohort A|Subjects with a new episode of Acute Otitis Media (<3 days of onset) who have not yet received antibiotic therapy for the episode.
9956965|NCT01160055||Cohort B|Subjects who have had a diagnosis of Acute Otitis Media within 2-3 days prior to study enrolment and received antibiotic therapy, but remain symptomatic.
9956966|NCT01160068|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
9956967|NCT01160068|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
9956968|NCT01160081||National Health and Nutrition Survey 2006 (ENSANUT 2006)|
9956969|NCT01160094||Patients|ErbB2+ metastatic breast cancer patients
9956970|NCT01160120|Other|1|Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.
9956971|NCT01160133|Experimental|Systane|Systane Lubricant Eye Drops
9956972|NCT01160133|Experimental|Refresh Tears|Refresh Tears Lubricant Eye Drops
9956973|NCT01160146||Lifestyle counseling|"Clinicians provide lifestyle management counseling regarding healthful lifestyle behaviors and daily physical activity.~Logging foods for accountability and counting calories~Close attention to portion control and appropriate serving sizes of foods consumed~Consumption of appropriate calorie and sugar free beverages~Good meal distribution and avoidance of meal skipping~Balance of food groups using the MyPlate concept (USDA Choose My Plate)-inclusion of all food groups with emphasis on fruits, vegetables, whole grains, low-fat dairy products and lean meat/fish/poultry~Increasing physical activity with reasonable, sustainable exercise or activity. Working toward a goal of at least 30 minutes, 5 days per week"
9956974|NCT01160159||Thrombophilia|
9956975|NCT01160159||Healthy volunteers|
9956976|NCT01160172|Experimental|Group A|
9956977|NCT01160172|Experimental|Group B|
9956978|NCT01160172|Experimental|Group C|
9956979|NCT01160172|Experimental|Group D|
9956980|NCT01160172|Placebo Comparator|Group E|
9956981|NCT01160172|Placebo Comparator|Group F|
9956982|NCT01160185||cisplatin|
9956983|NCT01160185||cisplatin + topotecan|
9956984|NCT01160185||cisplatin + paclitaxel|
9956985|NCT01160224|Active Comparator|GW766944|This is the active drug (GW766944)
9956986|NCT01160224|Placebo Comparator|Placebo|Placebo Arm.
9956987|NCT01160263|Other|patients without stiffness|
9956988|NCT01160263|Other|patients with pyramidal stiffness|
9956989|NCT01160263|Other|patients with mixed stiffness|
9956990|NCT01160276|Active Comparator|Cyclosporine|The first group is composed of 14 renal graft recipients under cyclosporine
9956991|NCT01160276|Active Comparator|Tacrolimus|The second group is composed of 14 renal graft recipients under tacrolimus
9956992|NCT01160302|Experimental|Microgranular Curcumin|Consume 4g microgranular curcumin (Curcumin C3 Complex) twice per day
9956993|NCT01160315|Experimental|Arm A (GnRha arm)|IM injection of Triptorelin -Decapeptyl PR 11.25mg- (every 3 months) and Norethisterone acetate- Primolut-Nor 5 mg- per os continuously until the end of the chemotherapy
9956994|NCT01160315|Active Comparator|Arm B (control Arm)|Norethisterone acetate alone, 5mg par day, (ARM B) until the end of the chemotherapy.
9956995|NCT01160328|No Intervention|Control Group|Participants in this group will not receive any treatment.
9956996|NCT01160328|Experimental|Lupron Group|Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels.
9956997|NCT01160328|Other|Lupron & Testosterone Group|Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel).
9956998|NCT01160341|Experimental|Testosteron, secondary hypogonadism|
9956999|NCT01160367|Active Comparator|standard of care health decision making|Patient-family dyads will receive the standard of care for support of patient and family members health care decision making during a clinic appointment.
9957000|NCT01160367|Experimental|TAILORED intervention|Patients and family members who receive the TAILORED Decision Making Intervention
9957001|NCT01160393|Other|Miniaturized bypass system|Miniaturized bypass system and the incidence of atrial fibrillation after cardiac surgery
9957002|NCT01160406||ischemic stroke, no atrial fibrillation|Patients who have suffered ischemic stroke or transient ischemic attack without known atrial fibrillation
9957003|NCT01160419|Other|FLOT|Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles
9957004|NCT01160432|Experimental|Methadone naloxone combination product 2/0,04 mg/ml|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml
9957005|NCT01160432|Active Comparator|Methadone 2 mg/ml|Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).
9957006|NCT01160471||Healthy Volunteers|Adult men and women without a clinical diagnosis of heart failure
9957007|NCT01160471||Patients|Adult men and women with a clinical diagnosis of heart failure
9957008|NCT01160510||Women undergoing mammography|women undergoing mammography at the UVM Breast Cancer Surveillance Consortium site
9957009|NCT01160549||Cases|Women living in rural environments
9957010|NCT01160549||Controls|Women living in more urban environments
9957011|NCT01160588||Sertraline treatment|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and sertraline treatment.
9957012|NCT01160588||Healthy Controls|Healthy control participants will undergo MRI scanning and EEG's.
9957013|NCT01160588||Cognitive Behavioral Therapy|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and talk therapy (CBT).
9957014|NCT01160627|Active Comparator|Standard treatment|Hydration
9957015|NCT01160627|Active Comparator|Combined Acetylcystein and Sodium Bicarbonat|
9957016|NCT01160627|Active Comparator|Sodium Bicarbonate|
9957017|NCT01160627|Active Comparator|Acetylcystein for 2 days|Standard treatment + acetylcystein for 2 days
9957018|NCT01160653|Experimental|1|Gait training and Cognitive Training
9957019|NCT01160653|No Intervention|2|Able Bodied
9517899|NCT03301870|Experimental|ATx201 GEL, 4% - intact skin|ATx201 GEL, 4% applied to intact skin
9517900|NCT03301870|Experimental|ATx201 GEL, 2% - abraded skin|ATx201 GEL, 2% applied to abraded skin
9517901|NCT03301870|Experimental|ATx201 GEL, 4% - abraded skin|ATx201 GEL, 4% applied to abraded skin
9517902|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - intact skin|ATx201 GEL Placebo applied to intact skin
9957020|NCT01160666|Experimental|1: Belilumab|
9957021|NCT01160692|Experimental|Arm 1|
9957022|NCT01160692|Placebo Comparator|Arm 2|
9957023|NCT01160718|Active Comparator|Arm A: Fulvestrant / AZD6244|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid
9957024|NCT01160718|Placebo Comparator|Arm B: Fulvestrant / Placebo|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)
9957025|NCT01160731|Experimental|Cisplatin, Etoposide & Panobinostat|
9957026|NCT01160757|Other|ultrasound|
9957027|NCT01160796|Experimental|Lcr35®|
9957028|NCT01160796|Placebo Comparator|placebo|
9957029|NCT01160809|Experimental|Mosquito repellent and LLINs group vs. LLINs group only|This study is based on two population groups: 1) a group of households that use LLINs alone (control) and 2) a group of households that use both mosquito repellent and LLINs (repellent group).
9957030|NCT01160835|Experimental|Quadriceps-sparing total knee arthroplasty|Quadriceps-sparing arthrotomy with side-cutting instruments
9957031|NCT01160835|Active Comparator|Medial parapatellar total knee arthroplasty|Medial parapatellar arthrotomy with front-cutting instruments
9957032|NCT01160861|Experimental|A|
9957033|NCT01160861|Experimental|B|
9476571|NCT03570541|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL saline single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
9957034|NCT01160861|Experimental|C|
9957035|NCT01160874|Experimental|TDA/H|
9957036|NCT01160874|Other|Sleep apnea patient|
9957037|NCT01160874|Other|Healthy volunteer|
9957038|NCT01160887||Patients with diabetic peripheral neuropathy|
9957039|NCT01160887||Healthy matched controls|
9957040|NCT01160900|Experimental|multivessel revascularization|Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure
9957041|NCT01160913|Active Comparator|Continuous wound infusion above the fascia|
9957042|NCT01160913|Active Comparator|Continuous wound infusion below the fascia|
9957043|NCT01160926|Experimental|AZD6244 + capecitabine + radiotherapy|10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
9957044|NCT01160926|Experimental|Cediranib + capecitabine + radiotherapy|10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
9957045|NCT01160952|Other|long-term group|long-term group refers to prophylaxis by using itraconazole for up to 90 days
9957046|NCT01160952|Other|short term group|short term group refers to prophylaxis by itraconazole for 30 days
9957047|NCT01160965|Active Comparator|0.5% levobupivacaine|Participants given 15mls of 0.5% levobupivacaine as the solution for their epidural top-up
9957048|NCT01160965|Active Comparator|0.75% Rpoivacaine|Participants given 15mls of 0.75% ropivacaine as the solution for their epidural top-up.
9957049|NCT01160978|Active Comparator|Simvastatin 80 mg group|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
9957050|NCT01160978|Experimental|Control Rx|The transplant recipients who have received an organ from non-treated donors.
9957051|NCT01160991|Active Comparator|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
9957052|NCT01160991|Experimental|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
9957053|NCT01160991|Placebo Comparator|Placebo|Placebo capsules are given at 8:00 a.m. Procedures are performed as described above.
9957054|NCT01161004|Experimental|Sugammadex - Nacl 9/00|"Sugammadex - Nacl 9/00:~Patients will first receive sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive Nacl 9/00 5 minutes after the first bolus of sugammadex.~The study is finished 5 minutes after this second injection and care is let to the choice of the anesthesiologist in charge."
9957055|NCT01161004|Experimental|Nacl 9/00 - sugammadex|"Nacl 9/00 - Sugammadex :~Patients wil first receive Nacl 9/00. In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive sugammadex 5 minutes after the first bolus of Nacl 9/00.~Sugammadex is given as: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~The study is finished 5 minutes after the injection of sugammadex and care is let to the choice of the anesthesiologist in charge."
9957056|NCT01161017|Active Comparator|1 Amitriptyline.|Amitriptyline
9957057|NCT01161017|Active Comparator|2 Topiramate|Topiramate
9957058|NCT01161030|Experimental|almonds|1-oz raw almonds: 173 kcal, 4.6 g carbohydrate, 14.6 g fat
9957059|NCT01161030|Placebo Comparator|Control|cheese stick
9957060|NCT01161056||Healthy Control Group|
9957061|NCT01161069|Active Comparator|PF-03049423|Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers
9957062|NCT01161069|Placebo Comparator|Drug|Placebo in oral solution, given once daily for 14 days
9957063|NCT01161082|Experimental|Group 1 with atorvastatin|Dose 1 versus placebo
9957064|NCT01161082|Experimental|Group 2 with atorvastatin|Dose 1 versus placebo
9957065|NCT01161082|Experimental|Group 3 with atorvastatin|Dose 2 versus placebo
9957066|NCT01161082|Experimental|Group 4 with atorvastatin|Dose 2 versus placebo
9957067|NCT01161082|Experimental|Group 5 with atorvastatin|Dose 3 versus placebo
9957068|NCT01161082|Experimental|Group 6 with atorvastatin|Dose 3 versus placebo
9957069|NCT01161082|Experimental|Group 7 without atorvastatin|Dose 3 versus placebo
9957070|NCT01161082|Experimental|Group 8 with atorvastatin|Dose4 versus placebo
9957071|NCT01161095|Experimental|Immediate|LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
9957072|NCT01161095|Active Comparator|Interval|LNG-IUS insertion after 6 weeks postpartum
9957073|NCT01161108|Active Comparator|Group A: Fast Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
9957074|NCT01161108|Active Comparator|Group B: Timed Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
9957075|NCT01161134|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
9957076|NCT01161134|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
10005635|NCT01586884|Experimental|Intervention|"Ten patients undergoing LV lead placement for either initial CRT device implant or revision of an existing system at Lancaster General Hospital who meet the inclusion and exclusion criteria will be screened and approached for enrollment in this safety and feasibility study. Study participants may have ischemic or non-ischemic cardiomyopathy; results for ischemic and non-ischemic patients will be analyzed separately. Any device system from any manufacturer may be used; the choice of device and leads will be at the implanting physician's discretion.~Post implant procedures will be the same as those for any CRT implant. Outpatient follow-up other than the 1-month follow-up will be per the implanting physician's usual practice."
10005636|NCT01586923|Active Comparator|Short-storage RBC|RBC transfusion using packed RBCs stored for 10 days or less.
10005637|NCT01586923|Active Comparator|Prolonged-storage RBC|RBC transfusion using packed RBCs stored for 25 days or more.
10005638|NCT01586936||eptacog alpha users|
10005639|NCT01586949|Experimental|Treatment|Intervention: Daily Challenge
10005640|NCT01586949|No Intervention|Control|Weekly Well-being, an email-based health information delivery service.
10005641|NCT01586988|Experimental|IMAGE Intervention|mothers are provided the IMAGE Parenting and Self-Care intervention
10005642|NCT01586988|No Intervention|Control|Standard care.
10005643|NCT01587053||AVK|patient with AVK treatment
10005644|NCT01587066|Active Comparator|Quetiapine fumarate|
10005645|NCT01587066|Active Comparator|Divalproex sodium|
10005646|NCT01587092|Placebo Comparator|Usual Working Condition Group|Participants assigned to the usual working condition control group will continue to work in their usual environment and accustomed manner. The control group participants will have access to the Workstations at the completion of study.
10005647|NCT01587092|Active Comparator|WorkStation Intervention Group|Participants will be asked to walk for up to 1.5 hours per day on the treadmill. This will be split into two 45 minute sessions per day. Behavioral support will focus on adherence to frequency (attending scheduled sessions). Participants self-select speed of walking and time (they have up to 45 minutes allotted, but may choose less as they like).
10005648|NCT01587131|Experimental|Group 1- DNA prime DNA boost|0.9 mg of FVH1 vaccine delivered ID followed by electroporation on Day 0, Week 15 and Week 27
9476572|NCT03570528||Maxillary Retrusion|CT
10005649|NCT01587131|Experimental|Group 2 - DNA prime Seasonal Vaccine boost|0.9 mg FVH1 vaccine delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
10005650|NCT01587131|Placebo Comparator|Group 3 - sWFI prime Seasonal Vaccine boost|100 microliters of sterile water for injection delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
10005651|NCT01587157|Experimental|capnography|
10005652|NCT01587170||Uninjured control subjects|Uninjured, control subjects who are not taking any of the contraindicated drugs.
10005653|NCT01587170||Spinal-cord injured subjects|Patients who have suffered a spinal cord injury (>1year ago).
10005654|NCT01587183|Other|Educational materials control|Enhanced usual care
10005655|NCT01587183|Active Comparator|Group running style B|Basic running instruction using group based training.
10005656|NCT01587183|Experimental|Group running style A|Form focused running instruction using group based training.
10005657|NCT01587196|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
10005658|NCT01587209||Divers with decompression sickness|The sole group under study is SCUBA divers who have sustained decompression sickness
10005659|NCT01587222|Experimental|Albumin, Midodrine, Octreotide|
10005660|NCT01587248|Active Comparator|Electrocautery|Raising of the flaps with electrocautery
10005661|NCT01587248|Experimental|Harmonic|Dissection with harmonic scalpel in modified radical mastectomy
9957077|NCT01161147|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
9957078|NCT01161147|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
9957079|NCT01161186|Experimental|Nab-paclitaxel,Gemcitabine, and Capecitabine|
9957080|NCT01161199||Untreated non-controllers|
9957081|NCT01161199||Elite controllers|
9957082|NCT01161199||HAART-suppressed|
9957083|NCT01161212|Other|Control group|
9957084|NCT01161212|Other|Intervention group|
9957085|NCT01161238||Lower-limb amputee|Subjects with at least one lower limb amputated at the trans-tibial level
9957086|NCT01161251||Atrial fibrillation patients|Non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
9957087|NCT01161264|Experimental|18-60 YOA|
9957088|NCT01161264|Experimental|≥ 60 YOA|
9957089|NCT01161277|Active Comparator|aripiprazole|
9476573|NCT03570528||Healthy Patients|
9957090|NCT01161277|Active Comparator|haloperidol|
9957091|NCT01161277|Placebo Comparator|suger pill|
9957092|NCT01161316|Active Comparator|Control|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
9957093|NCT01161316|Experimental|Experimental|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
9957094|NCT01161355|Experimental|AZD9668|Tablets and intravenous (IV) dose
10005662|NCT01587261|Placebo Comparator|Placebo|Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
10005663|NCT01587261|Experimental|Vitamin C|Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
10005664|NCT01587287||Corneal power measurement|All recruited volunteers in present study, that underwent corneal power measurement with 8 different instruments
9957095|NCT01161368|Experimental|lapatinib, vinorelbine|"Drug: Lapatinib, Vinorelbine Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
9957096|NCT01161381||Normal|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) < 5.
9957097|NCT01161381||OSAHS patients|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) > 5.
9957098|NCT01161433|Experimental|Intervention|Virtually delivered spirometry quality improvement program
9957099|NCT01161433|No Intervention|Standard of Care|
9957100|NCT01161459|Experimental|Tripterygium wilfordii|120mg/d for 6 months,then decrease to 60mg/d by 30mg/d every month for 12 months
9957101|NCT01161459|Active Comparator|FK506|
9957102|NCT01161485|Active Comparator|HIV Testing and Counseling|HIV Testing and Counseling
9957103|NCT01161485|Active Comparator|Contingency Management (CM)|Contingency management is based on Skinner's principles of operant conditioning in behavioral psychology, dating back to the 1930s (Skinner 1938). The basis of this model is that behavior is learned and reinforced by environmental contingencies that reward or punish.
10005665|NCT01587313|Experimental|Group 1|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 am
10005666|NCT01587313|Experimental|Group 2|ISDN/HYD 2 SR caps crossover to 1 IR cap at 5 pm
10005667|NCT01587313|Experimental|Group 3|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 pm
10005668|NCT01587313|Active Comparator|Group 4|ISDN/HYD 1 IR cap and two SR caps at 8 am crossover to Day 8: BiDil Tablet tid
9957104|NCT01161485|Experimental|CM with Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community.
9957105|NCT01161511|Experimental|1|XmAb5574
9957106|NCT01161550|Experimental|Arm 1|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 25 mg PO BID Days 7-20"
9957107|NCT01161550|Experimental|Arm 2|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 50 mg PO BID Days 7-20"
9957108|NCT01161576|Experimental|Group A|The first dose cohort consists of 6 subjects who received AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (gc) total dose. This is equal to 900,000,000,000 molecules of the drug.
9957109|NCT01161576|Experimental|Group B|The second dose cohort consists of 10 subjects, who will receive AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (gc) total dose. This is equal to 285,000,000,000 molecules of the drug.
9957110|NCT01161602|Experimental|0.2mg Pumosetrag|
9957111|NCT01161602|Experimental|0.5mg Pumosetrag|
9957112|NCT01161602|Experimental|0.8mg Pumosetrag|
9957113|NCT01161602|Placebo Comparator|Placebo|
9957114|NCT01161693|No Intervention|Standard pillow under head|Control (C) - Standard pillow under head (figure 1) as is the usual practice at BC Women's Hospital
9957115|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP|TROOP® elevation pillow (designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table)
9957116|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP-H|Operating table tilted in Trendelenberg position so angle of Troop pillow is parallel to floor (figure 3) until establishment of adequate block and then the bed levelled to horizontal i.e. to the same position as group (HERP) (figure 2)
9957117|NCT01161706|No Intervention|Control|0 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
9957118|NCT01161706|Experimental|8 fluid ounces vegetable juice|8 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
9957119|NCT01161706|Experimental|16 fluid ounces vegetable juice|16 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
9957120|NCT01161719|Experimental|Videoconference|Parent training through videoconference
9957121|NCT01161719|Active Comparator|Control|Parent training through face to face conference
9957122|NCT01161732|No Intervention|Conventional treatment|In the conventional treatment group, indications for aortic valve replacement surgery are development of symptoms, reduced left ventricular systolic function and an increase in aortic jet velocity > 0.5 m/sec during follow-up.
9957123|NCT01161732|Active Comparator|Early Surgery|Early surgery is performed within 2 months of randomization.
9957124|NCT01161758|Active Comparator|Passive cervical mobilisation|Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
9957125|NCT01161758|Placebo Comparator|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique.
9957126|NCT01161758|No Intervention|Non-contact control|Non-contact control, which involved the subject resting in the treatment position without any physical contact between the researcher and the subject.
9957127|NCT01161784|Placebo Comparator|Nutrient drink|
9957128|NCT01161784|Experimental|Probiotics|
9957129|NCT01161810||Post-Burn Rehabilitation|Patients with an acute burn injury who are admitted to the hospital with anticipated length of stay of 5 days or greater
9957130|NCT01161823||Nebivolol|2,5mg or maximum 5mg per day
9957131|NCT01161823||Menoflavon|2 times 1 pill at 40mg Isoflavone per day
9957132|NCT01161836|Experimental|iniparib|"Segment 1: 400 mg [14C]-iniparib single administration~Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy"
9957133|NCT01161901||blood sample|
9957134|NCT01161914|Active Comparator|Cerezyme®|60 U/kg infusion (every 2 weeks for 24 weeks)
9957135|NCT01161914|Experimental|ISU302|60 U/kg infusion (every 2 weeks for 24 weeks)
9957136|NCT01161927|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
9957137|NCT01161927|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
9957138|NCT01161940|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
9957139|NCT01161940|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
9957140|NCT01161966|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
9957141|NCT01161966|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
9957142|NCT01161979|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
9957143|NCT01161979|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
9957144|NCT01162018|Experimental|Acupuncture Arm|
9957145|NCT01162018|Sham Comparator|Sham Acupuncture|Sham Acupuncture
9957146|NCT01162044|No Intervention|No intervention|Subjects will be assessed, but no active intervention given
9957147|NCT01162044|Experimental|Computer game|Subjects will play with computer game while in the Emergency Room
9957148|NCT01162070|Active Comparator|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
9957149|NCT01162070|Experimental|Experimental strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
9957150|NCT01162083||Mitral Valve disease|Patients with mitral valve disease, deemed suitable and ready for elective valve repair or replacement. No significant arrhythmias, other valvular disease or LV dysfunction present. We shall also be recruiting patients undergoing a Mitraclip procedure.
9957151|NCT01162083||COPD|Patients with isolated chronic obstructive pulmonary disease and no cardiac disease.
9957152|NCT01162083||Mixed Lesions|Patients with proven limitation from both cardiac and respiratory disease.
9957153|NCT01162083||CRT|Patients with symptomatic heart failure who have responded to cardiac resynchronisation therapy (biventricular pacemaker).
9957154|NCT01162083||Cardiomyopathy|Heart Failure of primarily myopathic origin, without rhythm disturbance, ongoing ischaemia or significant valvular disease.
9957155|NCT01162148|Experimental|1|conventional
9957156|NCT01162148|Experimental|2|sham IMT
9957157|NCT01162148|Experimental|3|Conventional plus threshold IMT
9957158|NCT01162148|Experimental|4|threshold IMT alone
9957159|NCT01162161||hydrostatic pulmonary edema|patients with a pulmonary edema caused by chronic heart failure
9957160|NCT01162161||toxic pulmonary edema|patients with a pulmonary edema preceded by pneumonia
9957161|NCT01162161||control group|not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)
9957162|NCT01162174|Experimental|100 mg of Oligonol|
9957163|NCT01162174|Experimental|200 mg of Oligonol|
9957164|NCT01162174|Placebo Comparator|0 mg of Oligonol|
9957165|NCT01162200|Other|Stereotactic Body Radiation Therapy|SBRT dose per fraction
9957166|NCT01162213|Experimental|100 mg of Lychee fruit extract|
9957167|NCT01162213|Experimental|200 mg of Lychee fruit extract|
9957168|NCT01162213|Experimental|600 mg of Lychee fruit extract|
9957169|NCT01162213|Experimental|2000 mg of Lychee fruit extract|
9957170|NCT01162226|Experimental|training program|
9957171|NCT01162252|Active Comparator|Mindfulness-Based Stress Reduction|
9957172|NCT01162252|Active Comparator|Living Well|
9957173|NCT01162265||Contacts|Contacts of active cases of tuberculosis
9957174|NCT01162265||new entrants|new entrants from high incidence (>40/100000) countries.
9957175|NCT01162278|Other|single fraction|Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 35Gy in one fraction. Subsequent cohorts of patients will receive an additional 5Gy per treatment to a maximum planned dose of 50Gy in one fraction.
9957176|NCT01162291||movement|healthy subjects, randomised to do flexion and extension movements with their left and right elbow joint after intramuscular application of NaCl 2ml in the right musculus biceps brachii, and 1ml in the left musculus biceps brachii
9957177|NCT01162291||rest|healthy subjects are randomised to rest after intramuscular application of NaCl 1ml in the left and 2ml in the right musculus biceps brachii
9957178|NCT01162330||Babies referred for further hearing tests|Babies referred for further hearing tests after their neonatal hearing screening tests
9957179|NCT01162369||Group 1 - Non-Delirius Patients|
9957180|NCT01162369||Group 2 - Delirious Patients|
9957181|NCT01162395|Experimental|A|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
9957182|NCT01162434||Patients|Up to 8 patients who have received Deep Brain Stimulation for Treatment Resistant Depression at Frenchay Hospital (UK) will be recruited.
9957183|NCT01162434||Healthy volunteers|Up to 16 healthy volunteers, matched to the DBS patients on age, sex, handedness, and education, will be recruited.
9957184|NCT01162447||PCO|Healthy control subjects and patients with polycystic ovarian syndrome will be recruited for the study.
9957185|NCT01162460|Active Comparator|Carbamazepine controlled release|
9957186|NCT01162460|Experimental|Eslicarbazepine acetate|
10005669|NCT01587326|Experimental|Escitalopram|Escitalopram 10 mg/d to 20 mg/d
10035245|NCT01804400|Experimental|QAW039 + Montelukast|
9957187|NCT01162512|Experimental|Physical Activity|Participants will receive 7 weeks of weekly news letters and phone calls. The news letters and phone calls will include information about physical activity and ways to increase physical activity levels. This is in addition the standard medical care.
9957188|NCT01162512|No Intervention|Standard Medical Care|Participants will receive standard medical care
9957189|NCT01162525|Experimental|pTNS treatment|
9957190|NCT01162564||NG-TSM|Patients receiving NG-TSM to repair an abdominal incisional/ventral hernia
9957191|NCT01162577|Experimental|Intervetion|The intervention group received the 5 standard tobacco calls plus 3 weight calls with a weight coach to address weight concerns related to quitting smoking
9957192|NCT01162577|No Intervention|Control|Participants in this arm received only the 5 standard tobacco calls
9957193|NCT01162590|Experimental|Rotarix Group|Subjects will receive Rotarix™.
9957194|NCT01162590|Placebo Comparator|Placebo Group|Subjects will receive placebo.
9957195|NCT01162603|Experimental|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
9957196|NCT01162603|Active Comparator|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.
9957197|NCT01162616|Other|Iron absorption|
9957198|NCT01162629||Osteon|Patients requiring dental implants with deficient alveolar bone height
9957199|NCT01162642|Experimental|Green Tea|4 cups daily of green tea for 6 weeks
9957200|NCT01162642|Placebo Comparator|No Green Tea|4 cups daily of placebo tea for 6 weeks
9957201|NCT01162655|Experimental|Telehealth|Complete CBT group via telehealth
9957202|NCT01162655|Experimental|Internet|Complete Internet-based CBT program
9957203|NCT01162694|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
9957204|NCT01162694|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the uploaded data and receive feedback from their endocrinologist every 2 weeks.
9957205|NCT01162707|Experimental|Pressure Measurement System|CardioMEMS HF Pressure Measurement System
9957206|NCT01162720|Experimental|Short duration tourniquet|Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
9957207|NCT01162720|Active Comparator|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.
9957208|NCT01162746|Experimental|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
9957209|NCT01162746|Active Comparator|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
9957210|NCT01162759|No Intervention|Usual Care|The control group receiving usual care
9957211|NCT01162759|Experimental|Home Blood Pressure Monitoring Group|Intervention group
9957212|NCT01162772||Female Diabetics|female, 25-75 years old, no pregnancy, with/out Hormone replacement therapy T2DM, HbA1c > 7% with metformin mono-therapy
9957213|NCT01162772||Male diabetics|25-75 years, T2DM, HbA1c > 7% with metformin mono-therapy
9957214|NCT01162785|Experimental|First Dose SCH 721015|Part1: 2 Instillations of intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume
9957215|NCT01162785|Experimental|Second Dose SCH 721015|Part 2: Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration of SCH 721015 with Syn3 on same Day 1 and Day 4 regimen at same dose level.
9957216|NCT01162798|Active Comparator|Control|commercially available formula
9957217|NCT01162798|Experimental|Test|test formula
9957218|NCT01162811|No Intervention|Control group|The control group receives conventional care and treatment
9957219|NCT01162811|Experimental|Intervention group|the intervention group receives visualization and relaxation exercises together with structured behavioural attention
9957220|NCT01162824|Other|No endothelial dysfunction|
9957221|NCT01162824|Other|Endothelial Dysfunction|Definition of abnormal epicardial and microvascular vasoreactivity Abnormal epicardial vasoreactivity is defined as a reduction of the baseline coronary diameter ≥75% after glyceryltrinitrate i.c. together with a reproduction of the angina symptoms reported by the patient and/or ischemic ECG-changes. Abnormal microvascular vasoreactivity is defined as the reproduction of the angina symptoms together with ischaemic ECG-changes, but without changes in epicardial vasomotion.
9957222|NCT01162837|Other|All subjects|All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
9957223|NCT01162850|Active Comparator|Polypodium Leucotomos|Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
9957224|NCT01162850|Placebo Comparator|Placebo|Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
9957225|NCT01162876|Experimental|saxagliptin|5 mg daily for 14days
9957226|NCT01162889|Placebo Comparator|Placebo - SC injection|
9957227|NCT01162889|Experimental|Drug dose level 1 - SC injection|
9957228|NCT01162889|Experimental|Drug dose level 2 - SC injection|
9957229|NCT01162889|Experimental|Drug dose level 3- SC injection|
9957230|NCT01162889|Experimental|Drug dose level 4 - SC injection|
9957231|NCT01162889|Experimental|Drug dose level 5 - SC injection|
9957232|NCT01162889|Experimental|Drug dose level 6 - IV Infusion|
9957233|NCT01162889|Experimental|Drug dose level 7 - IV Infusion|
9957234|NCT01162889|Experimental|Drug dose level 8 - IV infusion|
9957235|NCT01162889|Placebo Comparator|Placebo - IV infusion|
9957236|NCT01162889|Experimental|Drug dose level 9 - IV infusion|
9957237|NCT01162902|Experimental|Diltiazem treated group|Diltiazem 180mg treated group
9957238|NCT01162902|Active Comparator|Bisoprolol treated group|Bisoprolol 5mg treated group
9957239|NCT01162902|Active Comparator|Candesartan treated group|Candesartan 32mg treated group
9957240|NCT01162915|Experimental|Safety|Infusion of autologous bone marrow-derived mesenchymal stem cells.
9957241|NCT01162928|Experimental|1|3-chamber-bag combined with Oxepa
9957242|NCT01162928|Active Comparator|2|3-chamber-bag combined with Pulmocare
10005670|NCT01587339||Drug-resistant (or refractory) partial epilepsy of all types|Drug-resistant (or refractory) partial epilepsy of all types
10005671|NCT01587365|Experimental|Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo|BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
10005672|NCT01587365|Experimental|Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo|BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
10005673|NCT01587365|Experimental|Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
10005674|NCT01587365|Experimental|Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
10005675|NCT01587365|Experimental|Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
10005676|NCT01587365|Experimental|Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo|BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
10005677|NCT01587365|Experimental|Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
10005678|NCT01587365|Experimental|Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
10005679|NCT01587378|Experimental|metformin|
10005680|NCT01587378|Placebo Comparator|placebo|
10005681|NCT01587391|Experimental|BI 163538 XX|1 single dose per subject as oral solution
10005682|NCT01587391|Placebo Comparator|Placebo to BI 163538 XX|1 single dose per subject as oral solution
10005683|NCT01587404|Experimental|Constant Catheter Contact Force|No alteration of catheter contact force during recording period
10005684|NCT01587404|Experimental|Variable catheter contact force|change in contact force from low to high after 30seconds of recording.
10005685|NCT01587417|Experimental|BI 187004 CL|1 single dose per subject as oral solution
10005686|NCT01587417|Placebo Comparator|Placebo to BI 187004 CL|1 single dose per subject as oral solution
10005687|NCT01587430|Active Comparator|high dose ARA-C|High dose ARA-C will be applied after two 7+3 induction courses during the first and the second consolidation courses: ARA-C 1 g/m2 bid 1-3 days with idarubicin (8mg/m2 3-5 days)and mitoxantrone (10 mg/m2 3-5 days)
10005688|NCT01587430|Active Comparator|standard dose ARA-C|Standard dose ARA-C will be applied after two 7+3 induction courses the first and the second consolidation courses : ARA-C 100 g/m2 bid 1-7 days with idarubicin (8mg/m2 1-3 days)and mitoxantrone (10 mg/m2 1-3 days)
10005689|NCT01587443||Hemodialysis|
10005690|NCT01587443||Peritoneal dialysis|
10005691|NCT01587469||HIV-infected and -uninfected individuals|HIV-infected and -uninfected individuals with suspected TB infection
10005692|NCT01587482||drug eluting balloon|"In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.~Only the treated patients were included in this cohort."
10005693|NCT01587495|Experimental|Ertapenem|Women diagnosed with postpartum endometritis
10005694|NCT01587508|Active Comparator|meloxicam - Movatec®|
10005695|NCT01587508|Active Comparator|cyclobenzaprine - Miosan®,|
10005696|NCT01587508|Experimental|meloxicam/cyclobenzaprine hydrochloride|
10005697|NCT01587534|Experimental|pancreatic enzyme replacement therapy|The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
10005698|NCT01587534|No Intervention|Placebo|The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
9957243|NCT01162941|Experimental|Steroid dependant ITP|more than 10 mg of prednisolone per day is required to maintain a platelet count above 20X109/L (minimum follow up duration: 3 months after diagnosis)
9957244|NCT01162954|Experimental|DA-6034|
9957245|NCT01162954|Placebo Comparator|Placebo|
9957246|NCT01162967|Active Comparator|Benznidazole|
9957247|NCT01162967|Experimental|Posaconazole, low dose|
9957248|NCT01162967|Experimental|Posaconazole, high dose|
9957249|NCT01162993|Experimental|Spinal Cord Stimulation|Spinal cord stimulation
9957250|NCT01162993|No Intervention|Treatment as usual|Treatment as usual
9957251|NCT01163006|Experimental|polydextrose|
9957252|NCT01163006|Experimental|soluble glucofibre|
9957253|NCT01163006|Placebo Comparator|isocaloric dietary control|
9957254|NCT01163006|Placebo Comparator|full caloric control|
9957255|NCT01163019||Chest pain|Patients who present to the emergency department with a chief complaint of chest pain and have a moderate pre-test probability for an acute coronary syndrome
9957256|NCT01163045|Experimental|neuromonitoring and neurostimulation|
9957257|NCT01163045|Experimental|neurostimulation of recurrent laryngeal nerve|
9957258|NCT01163071|Experimental|ABI-011|
9957259|NCT01163188||Proband|Very low birth weight children (< 32 weeks of gestation) and/ or Very preterm children (< 1500 g birthweight) of the Bavarian Longitudinal Study
9957260|NCT01163188||Controls|Term born children of the Bavarian Longitudinal Study
9957261|NCT01163201|Experimental|Treg Plus CD3+Teff Treatment|Includes dose adjustment of T regulatory (Treg) and CD3+ T effector (CD3+ Teff) cells in recipients of double UCB transplantation
9957262|NCT01163240||pediatric|
9957263|NCT01163305||metastatic colorectal cancer|
9957264|NCT01163331|Experimental|Singing Therapy Group|Singing Therapy Group
9957265|NCT01163344||Dance Therapy Group|This will group will undergo dance therapy once a week for a series of 8 weeks.
9957266|NCT01163344||Physical Therapy Group|This group will undergo physical therapy sessions once a week for a series of 8 weeks
9957267|NCT01163370|Placebo Comparator|control and exercise|this is trained and receives placebo
9957268|NCT01163370|Experimental|creatine|this is non-exercise trained and receives creatine supplementation
9957269|NCT01163370|Experimental|exercise and creatine|this is exercised trained and receives creatine supplementation
9957270|NCT01163370|Placebo Comparator|placebo|this only receives placebo (dextrose)
9957271|NCT01163396|Experimental|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks
9957272|NCT01163409|Experimental|acupuncture|will be made with classic acupuncture needling in traditional points, surpassing the skin
9957273|NCT01163409|Experimental|sham acupuncture|sham acupuncture will be done through a needle and a plastic device attached to skin in traditional acupuncture points.
9957274|NCT01163409|Experimental|exercise training resistance and aerobic|Aerobic exercise for 1 hour and resistance exercises for major muscle groups.
9957275|NCT01163409|No Intervention|healthy lifestyle|Group 4 - will be the control group who receive follow-up and recommendation for physical activity, but without any intervention supervised.
9957276|NCT01163422|Active Comparator|Immediate RVRT|RVRT switched on immediately after pacemaker implant
9957277|NCT01163422|Placebo Comparator|Delayed RVRT|RVRT switched on 4 weeks after pacemaker implant
9957278|NCT01163435|Experimental|high dose dual therapy|group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
9957279|NCT01163435|Experimental|sequential therapy|group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
9957280|NCT01163435|Active Comparator|clarithromycin-based triple therapy|group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
10035246|NCT01804400|Experimental|QAW039 Once a day (q.d.)|
9957281|NCT01163435|Active Comparator|levofloxacin-based triple therapy|group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)
9957282|NCT01163448|Experimental|High-Dose Single-Fraction Image-Guided Radiotherapy|This will assess the feasibility and safety of this approach in men at high-risk for extraprostatic prostate cancer undergoing RP. This initial trial has been designed in a manner intended to emphasize patient comfort and safety.
9957283|NCT01163500|Placebo Comparator|Pill|
9957284|NCT01163500|Experimental|Coenzyme Q10|
9957285|NCT01163513||White population|
9957286|NCT01163513||Indian|
9957287|NCT01163513||Pakistani|
9957288|NCT01163513||Bangladeshi|
9957289|NCT01163513||Other|other South Asian
9957290|NCT01163526||neuroendocrine metastases|15 patients with neuroendocrine metastases
9957291|NCT01163526||colon cancer metastases|15 patients with colon cancer metastases
9476574|NCT03570515|Experimental|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days.
9957292|NCT01163526||HCC treated with cyberknife radiation and chemotherapy|15 patients with HCC treated with cyberknife radiation and chemotherapy
9957293|NCT01163526||HCC treated with Sirsphere embolization and chemotherapy|15 patients with HCC treated with Sirsphere embolization and chemotherapy
9957294|NCT01163552|Experimental|Surgical Debulking and Intrathoracic Hyperthermic Chemotherapy|Patients in this trial will undergo surgical debulking followed by intrathoracic hyperthermic chemotherapy perfusion.
9476575|NCT03570515|Active Comparator|Educational Film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
9476576|NCT03570463||GLA:D Back|Two 1-hour group sessions of patient education 8 weeks of twice-weekly 1-hour supervised group exercise sessions
9476577|NCT03570450|Experimental|Adipose derived Stem Cells - 1.10^6cells/kg|ADSC, single, IV, 1.10^6cells/kg
9957295|NCT01163565|Active Comparator|Ligasure device|
9957296|NCT01163565|No Intervention|Hand ties|
9957297|NCT01163591||Case|Patients with overt diabetic nephropathy as evidenced by ACR greater than or equal to 30mg/mmol on urinalysis and eGFR greater than or equal to 15ml/min/1.73m2 and less than 60ml/min/1.73m2
9957298|NCT01163591||Control|Patients without diabetic nephropathy as defined by the absence of albuminuria (defined by a random spot urinary ACR <2.5 mg/mmol in women or ACR<3.5 mg/mmol in men)and eGFR greater or equal to 90 ml/min/1.73m2
9957299|NCT01163630|Experimental|1|esomeprazole 20mg/ASA 81 mg FDC after a 10-hour fast
9957300|NCT01163630|Experimental|2|esomeprazole 20mg/ASA 81 mg FDC 30 minutes after start of a high-fat, high-calorie breakfast
9957301|NCT01163669||kidney transplant recipients|
9957302|NCT01163682|Active Comparator|Electro-acupuncture|45 minute sessions scheduled once a week for 12 weeks.
9957303|NCT01163682|Sham Comparator|Sham acupuncture|45 minute sessions scheduled once a week for 12 weeks
9957304|NCT01163708|Active Comparator|Navigation alone|Navigation system alone vs Prophecy technique with Navigation system validation
9476578|NCT03570450|Experimental|Adipose derived Stem Cells - 2.10^6cells/kg|ADSC, single, IV, 2.10^6cells/kg
9476579|NCT03570450|Experimental|Adipose derived Stem Cells - 2,5.10^6cells/kg|ADSC, single, IV, 2,5.10^6cells/kg
9476580|NCT03570450|Experimental|Adipose derived Stem Cells - 3.10^6cells/kg|ADSC, single, IV, 3.10^6cells/kg
9476581|NCT03570450|Placebo Comparator|placebo|Placebo
9476582|NCT03570424|Placebo Comparator|Placebo|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
9476583|NCT03570424|Experimental|Whey Protein|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
9957305|NCT01163708|Experimental|Prophecy and Navigation validation|
9957306|NCT01163734|Experimental|Ranolazine|
9957307|NCT01163734|Placebo Comparator|Saline 0.9%|Saline 0.9% and placebo tablet
9957308|NCT01163799|Experimental|Alefacept (ASP0485)|Safety and efficacy of alefacept in combination with alemtuzumab induction and calcineurin inhibitor (CNI) and corticosteroid withdrawal.
9957309|NCT01163812|Experimental|Laparoscopic D2 gastrectomy|
9957310|NCT01163825|Experimental|Nerve Growth Factor|Dose 1
9957311|NCT01163825|Experimental|Nerve Growth Factor 2|Dose 2
9957312|NCT01163838|Placebo Comparator|Placebo|
9957313|NCT01163838|Experimental|RN316: 1 mg/kg every 2 weeks|
9957314|NCT01163838|Experimental|RN316: 2 mg/kg every 4 weeks|
9957315|NCT01163838|Experimental|RN316: 4 mg/kg every 4 weeks|
9957316|NCT01163838|Experimental|RN316: 4 mg/kg every 8 weeks|
9957317|NCT01163838|Experimental|RN316: 8 mg/kg every 8 weeks|
9957318|NCT01163838|Experimental|RN316: 12 mg/kg every 8 weeks|
9957319|NCT01163864|Experimental|affect regulation training|
9957320|NCT01163864|Active Comparator|health and lifestyle|
9957321|NCT01163877|Other|Symptomatic malaria infection|
9957322|NCT01163877|Other|Asymptomatic malaria infection|
9957323|NCT01163877|Other|Hookworm infection|
9957324|NCT01163877|Other|Schistosoma haematobium infection|
9957325|NCT01163890|Experimental|WHI|
9957326|NCT01163890|Active Comparator|Usual Care|
9957327|NCT01163903|Experimental|Pantoprazole and doxorubicin|
9957328|NCT01163929|Experimental|paclitaxel, trastuzumab and everolimus|
9957329|NCT01163942|Active Comparator|No G-CSF, No 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
9957330|NCT01163942|Active Comparator|No G-CSF, yes 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) but they do receive early retreatment in case of no response.
9957331|NCT01163942|Active Comparator|Yes G-CSF, No 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
9957332|NCT01163942|Active Comparator|Yes G-CSF, Yes 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to receive early retreatment in case of no response.
9957333|NCT01163968|Experimental|Weight reduction program|MOMENTUM intervention
9957334|NCT01163981|No Intervention|Blind cannulation|Cannulation without guidance
9957335|NCT01163981|Experimental|Ultrasound guided cannulation|Ultrasound guided cannulation
9957336|NCT01163994|Active Comparator|MEM-ceftriaxone|
9957337|NCT01163994|Active Comparator|MEM-doxycycline|
9957338|NCT01163994|No Intervention|controls|
9957339|NCT01163994|Active Comparator|EM-doxycycline|
9957340|NCT01164020|Placebo Comparator|placebo control|this only receives placebo (dextrose)
9957341|NCT01164020|Experimental|placebo and exercise|this is trained and receives placebo
9957342|NCT01164020|Experimental|creatine supplementation|this is non-exercise trained and receives creatine supplementation
9957343|NCT01164020|Experimental|Creatine and Exercise|this is exercised trained and receives creatine supplementation
9957344|NCT01164033|Active Comparator|A|
9957345|NCT01164033|Experimental|B|
9957346|NCT01164033|Experimental|C|
9957347|NCT01164033|Experimental|D|
9957348|NCT01164046|Active Comparator|vitamin K antagonists|
9957349|NCT01164046|Active Comparator|Low molecular weight heparin|
9957350|NCT01164059|Experimental|atypical antipsychotics|Olanzapine, Quetiapine, or Aripiprazole
9957351|NCT01164059|Active Comparator|typical antipsychotics|Haloperidol or Flupentixol
9957352|NCT01164072||HIGH NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with 7.2 mg nicotine cartridges (high nicotine group).
9957353|NCT01164085|Experimental|Ketorolac|4mg intravitreal injection of ketorolac
9957354|NCT01164111|Experimental|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise. Frequency: 2 times/week
9957355|NCT01164111|No Intervention|Control|Standard preoperative track.: No training intervention. Standard preoperative information.
9957356|NCT01164124|Experimental|Probiotic supplementation|500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
9957357|NCT01164124|Placebo Comparator|Routine feedings|
9957358|NCT01164150|Experimental|Arm B|Radiation: 45 Gy / 25 fractions pelvic radiotherapy using intensity modulated radiotherapy (IMRT) followed by 11 Gy / 2 fractions vaginal vault brachytherapy
9957359|NCT01164150|Other|Arm A Control|Radiation: 45 Gy/25 fraction external beam pelvic radiotherapy delivered using a 3-dimensional planned technique followed by 11 Gy / 2 fractions vaginal vault brachytherapy
9957360|NCT01164163|Experimental|Treatment (Ruxolitinib)|
9957361|NCT01164176|Experimental|RAD001 group|
9957362|NCT01164189|Other|Temozolomide|Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
9957363|NCT01164189|Experimental|Temozolomide + Bevacizumab|"TMZ: Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles~Beva: 10 mg/kg bw IV in 90 minutes on day 1 and 14, 4 week cycles."
9957364|NCT01164215|Experimental|mFOLFOX6|"Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)"
9957365|NCT01164280|Experimental|Pulse Rate Change|Patients are subjected to different pulse rate settings of their neurostimulator. The effect of pulse rate changes on clinical outcome is measured.
9957366|NCT01164293|Experimental|Atopy patch test|Atopy patches were applied on food allergy patient's back for 48 hrs then the patches were removed. Reaction was evaluated at 48 and 72 hrs after applying atopy patch test
9957367|NCT01164306|Experimental|LifeSkills training|
9957368|NCT01164306|Active Comparator|Healthy Lifestyle Behaviors|
9957369|NCT01164319|Active Comparator|Group 1 (no early recurrence)|Patients without atrial fibrillation recurrences through the implantable cardiac monitors during the 3 months post-ablation period.
9957370|NCT01164319|Active Comparator|Group 2 (early AF recurrence)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period.
9957371|NCT01164319|Active Comparator|Group 3 (early recurrence-no reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 would not receive reablation.
9957372|NCT01164319|Active Comparator|Group 4 (early recurrence-early reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 will receive early reablation based on data stored by implanted monitor.
9957373|NCT01164332|Other|Method A|First experimental detection method
9957374|NCT01164332|Other|Method B|Second experimental detection method
9957375|NCT01164345|Experimental|MOZOBIL|treatment with mozobil for autologous stem cell collection
9957376|NCT01164358||study arm I|"patients who have been enrolled in the previous study Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings"
9957377|NCT01164358||study arm II|"patients who have been enrolled in the previous study Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
9957378|NCT01164371||Initial presentation of coronary disease - Stable angina|Patients whose initial symptomatic presentation of coronary disease is stable angina (either diagnosis or symptoms)
9957379|NCT01164371||Initial presentation of coronary disease - ACS|Patients whose initial symptomatic presentation of coronary disease is acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI [nSTEMI] or unstable angina) without prior stable angina or symptoms of stable angina
9957380|NCT01164371||Initial presentation of coronary disease - Coronary death|Patients whose initial symptomatic manifestation of coronary disease is coronary death with no prior diagnosis of stable angina (or symptoms of stable angina) or diagnosis of acute coronary syndrome
9957381|NCT01164371||Initial presentation of coronary disease - None|Patients without symptomatic presentation of coronary disease, either alive or dead from non-coronary cause
9957382|NCT01164397||Dislipidemic Population|People with high levels of total cholesterol, LDL, C-HDL and triglycerides
9957383|NCT01164410||Pediatric Colonoscopy|Patients undergoing colonoscopy in the Department of Pediatric Gastroenterology at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.
9957384|NCT01164423|Experimental|1|Space TGC system with incorporated eMPC advised insulin infusion to establish glycaemic control
10005699|NCT01587547||IVF and ICSI patients|Subjects undergoing IVF or ICSI treatment with a maximum of 2 embryos transferred
10215532|NCT03702712|Experimental|Aerobic Exercise and Relaxation|Participants in the Aerobic Exercise and Relaxation arm will complete the three separate 20-minute aerobic exercise sessions (identical to the aerobic exercise only condition) followed by the same 20-minute neurofeedback-guided mindfulness training (identical to the relaxation only condition).
10035247|NCT01804400|Experimental|QAW039 Twice a day (b.i.d.)|
10215533|NCT03702699||KOA group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
10215534|NCT03702699||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
10215535|NCT03702686|Experimental|FEEDBACK system|Mother / infant dyad will use the FEEDBACK system during a breastfeeding session.
10215536|NCT03702673|Experimental|Treatment A|K-877 CR Tablet A
10215537|NCT03702673|Experimental|Treatment B|K-877 CR Tablet B
10215538|NCT03702673|Experimental|Treatment C|K-877 CR Tablet E
10215539|NCT03702673|Experimental|Treatment D|K-877 IR Tablet
10215540|NCT03702660|Experimental|GIP(3-30)NH2|GIP receptor antagonist
10215541|NCT03702660|Placebo Comparator|Placebo|Placebo (saline infusions)
10215542|NCT03702660|Active Comparator|GLP-1|
10215543|NCT03702660|Experimental|GLP-1 + GIP(3-30)NH2|
10215544|NCT03702647|Experimental|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
10215545|NCT03702647|Placebo Comparator|Normal Saline|30mL of normal saline placed in the POEM tunnel
10215546|NCT03702621|Active Comparator|Liposomal Bupivacaine|"LB (Liposomal Bupivacaine) group - This group will be receiving 20ml EXPAREL (266mg) and 40ml of 0.125% bupivacaine in total, 30ml on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
10215547|NCT03702621|Active Comparator|Standard Bupivacaine|"SB (Standard Bupivacaine) group - This group will be receiving 60ml of 0.25% bupivacaine in total, 30ml on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
10215548|NCT03702595|Experimental|Interventional group|Hip flexors stretching protocol
10215549|NCT03702582|Experimental|Rivaroxaban|"Rivaroxaban: Direct inhibitor of Factor Xa, an enzyme that stimulates the formation of thrombin from prothrombin (A critical step in both the intrinsic and extrinsic aspects of the coagulation cascade)~Dosage form: Per Os (Oral)~Dosage and Frequency: 20 mg every evening with the evening meal (No titration requirements). For patients with decreased glomerular filtration rate (GFR between 15 ml/min and 50 ml/min), dosing will be decreased to 15 mg every evening with the evening meal.~Duration: 30 days (Possibility of continuation after post-operative cardiology clinic visit)"
10215550|NCT03702582|Active Comparator|Warfarin|"Warfarin: Competitive inhibitor of vitamin K epoxide reductase complex 1, an important enzyme in the activation pathway for vitamin K dependent coagulation factors~Dosage form: Per Os (Oral)~Dosage and Frequency: Initial dose of 2 - 5 mg nightly after the evening meal (QHS) with appropriate titration to goal INR 2.0 - 3.0 (Initial dose based on weight, age, gender, co-morbidities and concurrent medications). INR will be checked daily to weekly depending on stability of dosing and medication regimen.~Duration: 30 days (Possibility of continuation after post-operative Cardiology clinic visit)"
10215551|NCT03702556|Active Comparator|Mastectomy without breast reconstruction|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
10215552|NCT03702556|Active Comparator|Breast reconstruction with nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
10215553|NCT03702556|Active Comparator|Breast reconstruction without nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
10215554|NCT03702530|Experimental|Intervention|3x 50 L3 larvae immunisation with albendazole treatment and 2x 50 L3 larvae infection
10215555|NCT03702530|Placebo Comparator|Placebo|3x placebo immunisation with albendazole treatment and 2x 50 L3 larvae infection
10215556|NCT03702517|Experimental|lateral stair walking exercise|The experimental group received 15 minutes of lateral stair walking exercise
10215557|NCT03702517|Active Comparator|traditional physiotherapy|strengthening exercise, balance training and gait training
10215558|NCT03702491|Experimental|Apatinib with SOX(Tegafur,Oxaliplatin)|Patients 3-4 weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
10215559|NCT03702491|Active Comparator|SOX( Tegafur,Oxaliplatin)|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
10215560|NCT03702478||No intervention, cross-sectional study|Questionnaire, cross-sectional study
10215561|NCT03702452|Experimental|Experimental group|Patients in experimental group were graded with modified Barthel index score, and according to the functional score of patients, the corresponding rehabilitation method was selected for functional rehabilitation from functional rehabilitation nursing program,twice a day with 30 min each time, last 1 week.
10215562|NCT03702452|Experimental|control group|Patients in control group were given conventional bedside rehabilitation ,twice a day with 30 min each time, last 1 week.
10215563|NCT03702426|Experimental|Norfloxacin with GM-CSF|Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B
10215564|NCT03702426|Active Comparator|Norfloxacin|Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.
9957385|NCT01164449|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
9957386|NCT01164462|Other|A 2|During the normal opening hours of five testing centers, clients with a rapid finger-stick blood specimen test
9957387|NCT01164462|Other|B group|During evenings and week-ends (i.e. when the centers are closed) only community based with rapid HIV testing
9517903|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - abraded skin|ATx201 GEL Placebo applied to abraded skin
9957388|NCT01164462|Other|A1 group|During the normal opening hours of five testing centers, clients with a conventional test.
9957389|NCT01164488|Experimental|1|
9957390|NCT01164514|Active Comparator|Group 1 - vaccine alone|8 subjects to receive vaccine (10 mcg) alone on Days 0, 29 and 59.
9957391|NCT01164514|Experimental|Group 3 - vaccine + CPG 7909 (250 mcg)|8 subjects to receive vaccine (10 mcg) with 250 mcg of adjuvant on Days 0, 29 and 59.
9957392|NCT01164514|Experimental|Group 2 - vaccine + CPG 7909 (500 mcg)|8 subjects to receive vaccine (10 mcg) with 500 mcg of adjuvant on Days 0, 29 and 59.
9957393|NCT01164514|Placebo Comparator|Group 4 - Placebo|4 subjects to receive normal saline (placebo) on Days 0, 29 and 59.
9957394|NCT01164540|Experimental|1|Oral Treatment
9957395|NCT01164540|Placebo Comparator|2|Oral treatment
9957396|NCT01164553|Experimental|Group 2, 0.5 mL TIV|Naive cohort participants (n=180) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=40) will receive 0.5 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose.
9957397|NCT01164553|Active Comparator|Group 1, 0.25 mL TIV|Naive cohort participants (n=90) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=20) will receive 0.25 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose
9957398|NCT01164566|Experimental|Arm I|Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.
9957399|NCT01164592|Active Comparator|Therapy with adaptive servo ventilation|optimal medical therapy + adaptive servoventilation
9957400|NCT01164592|No Intervention|Optimal medical therapy according to guidelines|optimal medical therapy
9957401|NCT01164618|Experimental|Group 1|The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
9957402|NCT01164618|Experimental|Group 2|The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
9957403|NCT01164631|Experimental|Orthodontic treatment|Snoring patients enrolling for tonsil surgery with maxillary constriction, and/or jaw retrognathism
9957404|NCT01164631|No Intervention|Control Group|Patients enrolled for tonsils surgery
9957405|NCT01164657|Experimental|study group|Randomized to give birth on a birthing seat
9957406|NCT01164657|No Intervention|control group|Randomized to birth in any other position except the birthing seat
9957407|NCT01164670||Men|Men over 70 years old.
9957408|NCT01164670||Women|Women over 70 years old.
9957409|NCT01164683|Experimental|Arm 1|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
9957410|NCT01164683|Active Comparator|Arm 2|Usual care
9957411|NCT01164696||Group 1|
9957412|NCT01164709|Experimental|bortezomib + nelfinavir|escalation 3 by 3 cohorts
9957413|NCT01164735||Correlative studies|Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and expression and chromosome 17 polysomy by FISH and IHC. Clinical information associated with each endometrial carcinoma sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage, and regimen type) is also collected.
9957414|NCT01164748||Sentinel Node Biopsy|All women who has Sentinel Node Biopsy as their primary treatment of the axilla
9957415|NCT01164748||Axillary Lymph Node Dissection|All women who had Axillary Lymph Node Dissection as primary axillary treatment
10005700|NCT01587560|Active Comparator|Pyrocarbon|Patients receiving a shoulder surface replacement implant made of pyrocarbon (the PyroTITAN Humeral resurfacing Arthroplasty)
10005701|NCT01587560|Active Comparator|CoCr|Patients receiving a shoulder surface replacement implant made of Cobalt-Chrome(CoCR) (the TITAN Humeral Resurfacing Arthroplasty)
10005702|NCT01587573||oral lesions|oral lesions suspicious for squamous cell carcinoma with saliva collection prior to clinically driven oral biopsy
10005703|NCT01587586|Active Comparator|PEGASYS 180 µg Q1W + ribavirin* for 48 weeks|Pegasys 180 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses(48)
10005704|NCT01587586|Experimental|P1101 180 µg Q1W + ribavirin* for 48 weeks|P1101 180 µg Q1W(subcutaneous injection)with Ribavirin, multiple doses
10005705|NCT01587586|Experimental|P1101 270 µg Q1W + ribavirin* for 48 weeks|P1101 270 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses
10005706|NCT01587586|Experimental|P1101 450 µg Q2W + ribavirin* for 48 weeks|P1101 450 µg Q2W(subcutaneous injection)+Ribavirin, multiple doses
10005707|NCT01587599|Active Comparator|Pharmaceutical care|
10005708|NCT01587599|Placebo Comparator|Standard care|
10005709|NCT01587625|Experimental|High dose of oxytocin infusion|Oxytocin: High dose infusion
10005710|NCT01587625|Active Comparator|Low dose of oxytocin infusion|Oxytocin: Low dose infusion
10005711|NCT01587638||Hypertensive users of Beta blocker|Patients aged ≥18 years and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time frame in a US Managed care population
10005712|NCT01587664|Experimental|NewBreez ILP|Implantation of a NewBreez ILP
10005713|NCT01587677||Confirmed tuberculosis|
10005714|NCT01587677||Confirmed non-tuberculous mycobacterial infection|
10005715|NCT01587677||Confirmed bronchial carcinoma|
10005716|NCT01587677||Suspected tuberculosis but confirmed alternative diagnosis|
10005717|NCT01587690||Healthy subjects|Self-explanatory
10005718|NCT01587690||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
10005719|NCT01587690||Treated Patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Interferon-beta-1a prior to enrollment
10005720|NCT01587716|Experimental|1. Inhaled GSK2339345/Placebo Single Dose (Cohort 1)|administered three ascending doses of GSK2339345 or placebo as a solution via an aqueous droplet inhaler over four treatment periods, with at least 5 days washout between doses
10005721|NCT01587716|Experimental|2. Inhaled GSK2339345/Placebo Repeat Dose (Cohort 2)|administered a dose of GSK2339345 or placebo, four times a day on two consecutive days. Each subject will receive either GSK2339345 or matching placebo as a solution administered via an aqueous droplet inhaler
10005722|NCT01587729||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
10005723|NCT01587729||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
10005724|NCT01587742||Patients with a diagnosis of any cancer type|All patients of the study population with a diagnosis of any cancer type based on Read codes and ICD-10 codes
10005725|NCT01587742||Patients with a diagnosis of breast cancer|All patients of the study population with a diagnosis of breast cancer based on Read codes and ICD-10 codes
10005726|NCT01587742||Patients with a diagnosis of prostate cancer|All patients of the study population with a diagnosis of prostate cancer based on Read codes and ICD-10 codes
10005727|NCT01587742||Patients with a diagnosis of colon cancer|All patients of the study population with a diagnosis of colon cancer based on Read codes and ICD-10 codes
10005728|NCT01587742||Patients without a diagnosis of any cancer type|All patients of the study population without a diagnosis of any cancer type
10005729|NCT01587755|Other|Topical Treatment Optimizing Program|Optimized care
10005730|NCT01587755|Other|non-Topical Treatment Optimizing Program|Standard care
10005731|NCT01587768||Patients with a definite case of acute liver injury|"The information recorded in the patients' medical record met all the criteria to be classified as idiopathic acute liver injury and the patient presents with at least with one of the following conditions (A+B or A+C):~A - A diagnosis of liver injury (codes listed in tables 1a, 1b, 1c) with a referral to a specialist or hospital.~Together with B - An increase of more than two times the upper limit of the normal range in alanine aminotransferase (ALT) or C - A combined increase in aspartate aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin provided one of them is twice the upper limit of the respective normal range."
10005732|NCT01587768||Patients with a probable case of acute liver injury|The information recorded in the patients' medical file was compatible with idiopathic acute liver injury, but not fulfilling all conditions and criteria to be defined as definite case. For example, patients identified with a READ or ICPC code for acute liver injury with a hospitalization or visit to a specialist but without complete laboratory criteria or patients identified with a READ or ICPC code for acute liver injury without a referral to a hospital/specialist, and with or without complete laboratory data.
10035248|NCT01804400|Active Comparator|Montelukast|
10035249|NCT01804400|Placebo Comparator|Placebo|
9957416|NCT01164761|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
9957417|NCT01164761|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
9957418|NCT01164774|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
9957419|NCT01164774|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
9957420|NCT01164787|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
9957421|NCT01164787|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
9957422|NCT01164800|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
9957423|NCT01164800|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
9957424|NCT01164813|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
9957425|NCT01164813|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
9957426|NCT01164826|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
9957427|NCT01164826|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
9957428|NCT01164852|No Intervention|Expectant management|Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
9957429|NCT01164852|Active Comparator|Interventionist management|Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
9957430|NCT01164878||Before|ELBW infants before change of feeding policy
9957431|NCT01164878||After|ELBW infants after change of feeding policy
9957432|NCT01164904|Experimental|Experimental|Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.
9957433|NCT01164917|Active Comparator|AMG811|All will receive AMG 811, either on Day 1 or Day 85
9957434|NCT01164917|Placebo Comparator|AMG811 Placebo|All will receive placebo, either on Day 1 or Day 85
9957435|NCT01164930|Experimental|Acceptance and Commitment Therapy group|8-week ACT group
9957436|NCT01164930|No Intervention|Wait-list control group|Participants will be offered treatment following wait-list data collection
9517904|NCT03301870|Active Comparator|Negative Irritant Control - intact skin|Negative (low) Irritant Control applied to intact skin
9957437|NCT01164943|Active Comparator|Human FSH|
9957438|NCT01164943|Active Comparator|Recombinant FSH|
9957439|NCT01164969||H. pylori eradication failure|People who are not able to eradicate H. pylori although the appropriate antibiotic therapy taken.
9957440|NCT01165034|No Intervention|Usual care|Best usual practice including general respiratory specialist and primary care
9957441|NCT01165034|Experimental|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
9957442|NCT01165060|Experimental|Bezafibrate|All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
9957443|NCT01165073|Experimental|Naso-gastric tube feeding|
9957444|NCT01165073|Active Comparator|Oral feeding|
9957445|NCT01165099|Experimental|manual acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were manually manipulated during this time. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
9957446|NCT01165099|Experimental|electro acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were either electronically simulated withm2 Hz pulses of 0.5 msec duration for 30 minutes sufficient to cause non-painful muscle contractions. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
9957447|NCT01165099|Sham Comparator|Sham manual or electro acupuncture|Sterile needles were inserted adjacent to the specific acupuncture sites identified for the manual and electro groups to a depth of 1-1.5mm only and insufficient to provoke an unusual sensation and left in position for a 30-60 minutes. Those randomised to 'sham-manual' received no stimulation and those randomised to 'sham-electro' were connected to the electrical stimulator but the current not activated.
9957448|NCT01165099|No Intervention|control group|Following randomisation to be control group, no specific treatment was organised at this time.
9957449|NCT01165125|Other|FF/GW642444 and keto|Ketoconazole (400mcg) administered on Days 1-11, with co-administration of fFF / GW642444 (200mcg/25mcg) on Days 5-11
9957450|NCT01165125|Other|Ketoconazole Placebo to match & FF/GW642444|ketoconazole placebo to match administered on days 1-11. FF/GW642444 (200mcg/25mcg) co-administered on Days 5-11
9957451|NCT01165151|Experimental|Small group|10-member groups
9957452|NCT01165151|Active Comparator|Large group|30-member groups
9957453|NCT01165164|Experimental|FID 115958D|Lubricant eye drop
9957454|NCT01165190||Pioglitazone group|
9957455|NCT01165255||Infants born to women who were exposed to antidepressants|Women ages 12 through 49 (as of delivery date) who were dispensed an antidepressant between 01 January 1995 and 30 September 2004 from the original Bupropion study.
9957456|NCT01165268|Active Comparator|Dapagliflozin (T2DM)|
9957457|NCT01165268|Active Comparator|Dapagliflozin (Healthy Subjects)|
9957458|NCT01165294|Experimental|001|ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
9957459|NCT01165294|Experimental|002|Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
9957460|NCT01165333|Experimental|Dose escalation|In the first part of the trial, a dose-ranging study in ca. 18-21 patients will be done. A standard dose escalation strategy will be used including 3 to 6 patients at each dose level, the first cohort of patients being treated at dose level one Interventions : Cilengitide dose escalation ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
9957461|NCT01165333|Experimental|Cohort extension|An additional 20 patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations Interventions : Cilengitide ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
9957462|NCT01165346|Experimental|Stereotaxic radiation by CyberKnife|Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days
9957463|NCT01165359|Experimental|Part A: ITX 5061|Participants will receive ITX 5061 once a day for 3 days.
9957464|NCT01165359|Placebo Comparator|Part A: Placebo|Participants will receive placebo once a day for 3 days.
9476584|NCT03570424|Experimental|Whey Protein Hydrolysate|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
9957465|NCT01165359|Experimental|Part B: ITX 5061|Participants will receive ITX 5061 once a day for 14 days.
9957466|NCT01165359|Placebo Comparator|Part B: Placebo|Participants will receive placebo once a day for 14 days.
9957467|NCT01165359|Experimental|Part C: ITX 5061|Participants will receive ITX 5061 once a day for 28 days.
9957468|NCT01165359|Placebo Comparator|Part C: Placebo|Participants will receive placebo once a day for 28 days.
9957469|NCT01165372|Experimental|Artesunate 2mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
9957470|NCT01165372|Experimental|Artesunate 4mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 4mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
9957471|NCT01165372|Experimental|DHA-piperaquine|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with dihydroartemisinin-piperaquine once daily according to weight for 3 days.
9957472|NCT01165385|Experimental|Pazopanib and Cisplatin|"Steady state period:Pazopanib will be given 8 days prior to cisplatin~Then pazopanib will be given 400 mg, 600 mg or 800 mg/day, daily and cisplatin 60, 75 or 100 mg/m2 , day 1 - 3 weekly, depending of the dose level"
9957473|NCT01165398||Residents, PAs, mid level providers|Lehigh Valley Health Network residents, physician assistants, and mid level providers who place central lines and attend the central lines simulation course
9957474|NCT01165411||Patients with CVCs and PICC lines placed|This group will have either Standard of Care (control) or Process Improvement infection control changes administered.
9957475|NCT01165437||Suspected Arterial Disease|Patients with known or suspected arterial disease and patients screened using AHA/ACC criteria for P.A.D.
9957476|NCT01165463|Experimental|Clinic-based SOPT basic training|Clinic-based SOPT basic training for 10 hours.
9957477|NCT01165463|Experimental|Home-based SOPT basic training|Home-based SOPT basic training for 10 hours.
9957478|NCT01165463|Active Comparator|Crossword Puzzles Training|Crossword puzzles training for 10 hours in our lab.
9957479|NCT01165463|Experimental|SOPT basic and SOPT booster-training|Clinic-based SOPT basic training and SOPT booster training.
9957480|NCT01165476|Active Comparator|manufacturer #1|treprostinil diethanolamine from manufacturer #1
9957481|NCT01165476|Experimental|manufacturer #2|treprostinil diethanolamine from manufacturer #2
9957482|NCT01165489||Laryngomalacia|Patients with Laryngomalacia
9957483|NCT01165489||Control Group|Patients without Laryngomalacia
9957484|NCT01165502|Experimental|CM3.1-AC100|Compound CM3.1-AC100 s.c.
9957485|NCT01165502|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
9957486|NCT01165515||Healthy young females|20 healthy females, aged between 18 and 35 years
9957487|NCT01165515||Healthy young males|20 healthy males, aged between 18 and 35 years
9957488|NCT01165515||Healthy elderly smokers|20 healthy smokers, aged between 45 and 75 years
9517905|NCT03301870|Active Comparator|Negative Irritant Control - abraded skin|Negative (low) Irritant Control applied to abraded skin
9957489|NCT01165515||Healthy elderly non-smokers|20 healthy non-smokers, aged between 45 and 75 years
9957490|NCT01165515||Healthy young female smokers|20 healthy female smokers, aged between 18 and 35 years
9957491|NCT01165515||Healthy young male smokers|20 healthy male smokers, aged between 18 and 35 years
9957492|NCT01165515||Healthy postmenopausal women|20 healthy postmenopausal women
9957493|NCT01165515||Female CMP Patients|20 female patients suffering from cardiomyopathy (ischemic or dilating)
9957494|NCT01165515||Male CMP Patients|20 male patients suffering from cardiomyopathy (ischemic or dilating)
9957495|NCT01165515||Female CHD patients|30 female patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
9957496|NCT01165515||Male CHD Patients|30 male patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
9957497|NCT01165515||male athlets|20 male athlets
9957498|NCT01165515||female athlets|20 female athlets
9957499|NCT01165528|Active Comparator|Adaptive support ventilation in ARDS|patients of ARDS will be randomized to this arm to receive mechanical ventilation as per ASV protocol
9957500|NCT01165528|Active Comparator|conventional ventilation strategy in ARDS|
9957501|NCT01165567|Experimental|sarpogrelate 300 mg per day|Patients in the sarpogrelate group receive sarpogrelate 300 mg per day for 24 hours before exposure to contrast agent.
9957502|NCT01165567|No Intervention|No sarpogrelate medication|
9957503|NCT01165580|Experimental|Single Arm|
9957504|NCT01165593||Patients with atrial fibrillation|Patients with atrial fibrillation who have received a cardiac CT scan as part of normal care prior to catheter-based treatment of atrial fibrillation.
9957505|NCT01165606|Experimental|Physiotherpy|
9957506|NCT01165619||Hypothalamic Amenorrhea|This group is for pre-menopausal women between the aged 18-40 who have been previously diagnosed with Hypothalamic Amenorrhea. They can be currently diagnosed or may have recovered.
9957507|NCT01165619||Healthy Adult Men|This group is men over the age of 18 who do not have any history of reproductive disorders or chronic disease.
9957508|NCT01165619||Healthy Adult Women|This group is pre-menopausal, regularly menstruating women ages 18-40 who do not have a history of reproductive disorders or chronic disease.
9957509|NCT01165619||Idiopathic Hypogonadotropic Hypogonadism|This group is for adult men and women over the age of 18 who have been diagnosed with Idiopathic Hypogonadotropic Hypogonadism with or without anosmia.
9957510|NCT01165645|Experimental|Arm I|Patients receive oral lopinavir and ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity.
9957511|NCT01165645|No Intervention|Arm II|Patients receive no therapy.
10005733|NCT01587768||Non-cases|Any potential or probable case that was excluded in one of the previous steps and those with insufficient data to determine their case status. Patients presenting normal liver function tests (LFTs), alcohol related problems, gallbladder disease, pancreatic disease, or other liver diseases with clear aetiology such as viral, alcoholic or autoimmune, or presence of other well defined pathology known to cause acute liver injury will be considered non-cases.
9957512|NCT01165658|Experimental|Proton Therapy|The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.
9957513|NCT01165671|Experimental|Experimental Arm|Carbon Ion Radiotherapy to the Macroscopic Tumor 6 x 3 Gy E up to 18 Gy E
9957514|NCT01165671|Active Comparator|Standard Arm|Proton Radiotherapy to the Macroscopic Tumor 5 x 2 Gy E up to 10 Gy E (Standard dose) applied after 48-52 Gy photon radiotherapy
9957515|NCT01165697||Fabry disease biomarker|Neuro-retinal fluorescein angiography (NRFA) exam will be administered once every 6 months for up to 3 years.
9957516|NCT01165710||001|Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
9957517|NCT01165723|Experimental|IV Dose 1: experimental|
9957518|NCT01165723|Experimental|IV Dose 2: experimental|
9957519|NCT01165736|Active Comparator|Intravenous: PF-05186462|
9957520|NCT01165736|Active Comparator|Oral: PF-05186462|
9957521|NCT01165736|Active Comparator|Intravenous: PF-05089771|
9957522|NCT01165736|Active Comparator|Oral: PF-05089771|
9957523|NCT01165736|Active Comparator|Intravenous: PF-05150122|
9957524|NCT01165736|Active Comparator|Oral: PF-05150122|
9957525|NCT01165736|Active Comparator|Intravenous: PF-05241328|
9957526|NCT01165736|Active Comparator|Oral: PF-05241328|
9957527|NCT01165762|Experimental|Immune Tolerance, Kidney transplantation|Induction of immune tolerance in Haplotype matched living donor kidney transplantation.
9957528|NCT01165788||autologous BMT recipients|Lymphoma patients who received an autologous BMT as adults
9957529|NCT01165801|No Intervention|Control Group (CO)|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
9957530|NCT01165814|Active Comparator|Tramadol at fixed intervals|
9957531|NCT01165814|Active Comparator|Tramadol on request|
9957532|NCT01165814|Active Comparator|Naproxen at fixed intervals|
9957533|NCT01165814|Active Comparator|Naproxen on request|
9957534|NCT01165827||Patients with aortic valve procedures|"All consecutive patients from participating hospitals with aortic valve defects who have received one of the following therapies:~surgical aortic valve replacement,~percutaneous transvascular (retrograde) aortic valve implantation~percutaneous transapical aortic valve implantation as principal indication. If the aortic valve insufficiency is concurrent with combination procedures (e.g. coronary artery bypass graft, mitral valve surgery) the aortic valve stenosis must fulfil only the criteria for indication according to the German National guidelines (see: detailed study description)."
9957535|NCT01165853|Other|Glucose|
9957536|NCT01165853|Other|Fructose|
9957537|NCT01165866|Active Comparator|Treatment 1.|Metoclopramide 0.3 mg/kg max 10 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline as a single intravenous dose. Complete blood count,serum electrolytes,renal function,HCO3 level will be requested.Oral fluid will be started thereafter and increased gradually until patient discharge.
9517906|NCT03301870|Active Comparator|Positive Irritant Control - intact skin|Positive (high) Irritant Control applied to intact skin
9517907|NCT03301818|Experimental|Patients undergoing USI repair|
9957538|NCT01165866|Other|Treatment2.|Ondansetron 0.15 mg/kg max 4 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline to be given over 10 minutes,then patient will be kept NPO for one hour after completion of the anti emetic infusion and last episode of vomiting . Oral fluid will be started thereafter and increased gradually until fully tolerated and the patient is ready for discharge
9957539|NCT01165918||Donated embryos|
9957540|NCT01165931|Experimental|Arm 1|
9957541|NCT01165944|No Intervention|Standard diabetes therapy|Standard diabetes therapy with either oral agents or insulin injections
9957542|NCT01165944|Active Comparator|Oral diabetic agents and pramlintide|
9957543|NCT01165944|Active Comparator|Insulin injection with pramlintide|
9957544|NCT01165957||Mobile bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is designed to slide or rotate on the metal baseplate.
9957545|NCT01165957||Fixed bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is locked to the metal baseplate.
9957546|NCT01165970|Active Comparator|Glandosane|After in situ exposition the enamel and dentin samples will demineralize with Glandosane.
9957547|NCT01165970|Experimental|Saliva natura|After in situ exposition the enamel and dentin samples will remineralize with Saliva natura
9957548|NCT01166022|Experimental|Exercise|Muscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
9957549|NCT01166022|No Intervention|Typical Activity|Subjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
9957550|NCT01166048|Placebo Comparator|Milk powder pill|Patients will receive 2 placebo pills per day for a period of 4 weeks.
9957551|NCT01166048|Experimental|Duloxetine|In the experimental arm of the study patients will receive duloxetine, which will be titrated up to a dosage of 120mg over a period of two weeks and continued at this dosage for two weeks.
9957552|NCT01166061|Experimental|Cohort 1|Subjects to receive either active or placebo
9957553|NCT01166061|Experimental|Cohort 2|Subjects to receive either active or placebo comparator
9957554|NCT01166061|Experimental|Cohort 3|Subjects to receive either active or placebo comparator
9957555|NCT01166061|Experimental|Cohort 4|Subjects to receive either active or placebo comparator
9957556|NCT01166061|Experimental|Cohort 5|Subjects to receive either active or placebo comparator
9957557|NCT01166074||SCIG|
9957558|NCT01166087|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
9957559|NCT01166087|Active Comparator|Prozac ® weekly|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
9957560|NCT01166100|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
9957561|NCT01166100|Active Comparator|Prozac ® weekly TM|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
9957562|NCT01166165|Active Comparator|Cholecalciferol|
9957563|NCT01166165|Placebo Comparator|Placebo|
9957564|NCT01166191|Experimental|SCLC|
9957565|NCT01166204|Experimental|Single group|
9957566|NCT01166217|Experimental|ABCE, ACBD, BACD, BCAE, CABE and CBAD|
9957567|NCT01166243|Experimental|Fibrin Pad|Biologic
9957568|NCT01166243|Other|Standard of Care|Procedure
9957569|NCT01166256|Experimental|High-flow nasal cannula|In this arm,patients with acute hypoxemic respiratory failure were treated with high-flow nasal cannula system(Optiflow, Fisher & Paykel, Auckland, New Zealand) to achieve SpO2 >92% or PaO2 >65 mmHg.
9957570|NCT01166256|Active Comparator|Non-invasive ventilation|In this arm, patients with acute hypoxemic respiratory failure is treated with the bi-level positive airways pressure mode (BiPAP Vision, Respironics Inc., Murrysville, PA) S/T mode to achieve SpO2 >92% or PaO2 >65 mmHg.
9957571|NCT01166269|Experimental|Grass-Allergen x 6|This arm will receive 6 injections of allergen.
9957572|NCT01166269|Active Comparator|grass-allergen x 3 and placebo x 3|this arm will receive 3 injections of allergen, and 3 injections of placebo.
9957573|NCT01166269|Placebo Comparator|placebo x 6|this arm will receive 6 injections of placebo.
9957574|NCT01166308|Experimental|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
9957575|NCT01166308|Active Comparator|Standard Treatment: Fractionated Stereotacitc Radiotherapy|Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
9957576|NCT01166321|Experimental|Carbon Ion Radiotherapy Boost|Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging
9957577|NCT01166334|Active Comparator|WebQuit study group|Intervention arm 1 (identity and description withheld to protect integrity of study)
9957578|NCT01166334|Active Comparator|WebQuit control group|Intervention arm 2 (identity and description withheld to protect integrity of study)
9957579|NCT01166360||Patients 2009|Patients undergoing cardiac surgery in 2009
9957580|NCT01166360||Patients 2008|Patients undergoing cardiac surgery in 2008
9957581|NCT01166399||Primiparous women with an obstetric anal sphincter tear|Subjects in this trial will be primiparous women who underwent anal sphincter repair at the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized at the time of delivery as <50% tear through the anal sphincter (modified WHO 3a), >50% (modified WHO 3b), or complete tear through the anal sphincter (4th degree). Subjects in this study will not have receive study interventions.
9957582|NCT01166425|Active Comparator|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID (three times a day) at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID (two times a day) the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
9957583|NCT01166425|Placebo Comparator|placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
9957584|NCT01166451|Experimental|Low-iron|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age.
9957585|NCT01166451|Experimental|High-iron|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age.
9957586|NCT01166464|Experimental|Text Messaging|A text message-based intervention for smoking cessation
9957587|NCT01166464|Placebo Comparator|Control|Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm. This provides a control for staff/program contact time and participant burden.
9957588|NCT01166477|Active Comparator|Triple therapy|The patients who would be allocated to this arm will continue with their triple therapy treatment, based on any protease inhibitor boosted with ritonavir
9957589|NCT01166477|Experimental|Monotherapy|Those patients allocated to this arm will start to take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
9957590|NCT01166490|Experimental|1|ASG-5ME
9957591|NCT01166503||Early Surgery|This group will be made up of subjects whose parents choose to have them undergo corrective surgery at or before age 11 months.
9957592|NCT01166503||Standard Surgery|This group will be made up of subjects who present after age 11 months or whose parents choose to have them undergo corrective surgery between 11-18 months.
9957593|NCT01166516|Other|Treatment with HUD IBV Valve System|Treatment with HUD IBV Valve System in Post-Approval Study
9957594|NCT01166529|Experimental|EUS-CPN|
9957595|NCT01166542|Active Comparator|REOLYSIN, paclitaxel, carboplatin|
9957596|NCT01166542|Placebo Comparator|placebo, paclitaxel, carboplatin|
10005734|NCT01587794||retinal detachment group|Patients who were diagnosed with unilateral rhegmatogenous retinal detachment involving only the superior or inferior half of the retina and who underwent successful scleral buckling procedure or vitrectomy by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study sample.
10005735|NCT01587807|Experimental|Cohort 1|single inhaled dose of GSK1995057 (dose 1) or placebo
10005736|NCT01587807|Experimental|Cohort 2|single inhaled dose of GSK1995057 (dose 2) or placebo
10005737|NCT01587807|Experimental|Cohort 3|single inhaled dose of GSK1995057 (dose 3) or placebo
10005738|NCT01587807|Experimental|Cohort 4|single inhaled dose of GSK1995057 (dose 4) or placebo
9957597|NCT01166555|Experimental|1|
9957598|NCT01166594|Experimental|Bevacizumab|Tested Drug
9957599|NCT01166594|Placebo Comparator|Control|Control - BSS
9957600|NCT01166620||Patients with rheumatoid arthritis new to abatacept.|
9957601|NCT01166620||Patients with rheumatoid arthritis new to etanercept|
9957602|NCT01166620||Patients with rheumatoid arthritis new to adalimumab|
9957603|NCT01166620||Patients with rheumatoid arthritis new to infliximab|
9957604|NCT01166685|Active Comparator|Everolimus-eluting stent|A Xience Prime stent (Everolimus-eluting stent) is implanted in significant coronary lesions.
9957605|NCT01166685|Active Comparator|Bare-metal stent|Implantation of a bare-metal stent
9957606|NCT01166685|Experimental|Biodegradable Polymer-DES|Implantation of a Biodegradable Polymer-DES
9957607|NCT01166698|Experimental|AZD9819|Inhaled suspension
9957608|NCT01166698|Placebo Comparator|Placebo|Inhaled suspension
9957609|NCT01166711|Experimental|Bare Metal Stent (BMS) followed by Drug Eluting Balloon (DEB)|
9957610|NCT01166711|Active Comparator|Drug Eluting Stent (DES)|
9957611|NCT01166776||Umbilical cord|To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
9957612|NCT01166789|Active Comparator|Lubiprostone|Lubiprostone 48ug taken daily for 14 days.
9957613|NCT01166789|Placebo Comparator|Placebo|2 capsules containing a substance with no active ingredient taken daily for 14 days.
9957614|NCT01166815|Active Comparator|Zinc supplemented|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
9957615|NCT01166815|Placebo Comparator|Placebo|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
9957616|NCT01166828|Experimental|1|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
9957617|NCT01166828|Active Comparator|2|TAC participants will have six phone contacts every other week for three months.
9957618|NCT01166841|Experimental|PSVC line clamped|Clamping of the percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
9957619|NCT01166841|No Intervention|Unclamped PSVC|Unclamped percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
9957620|NCT01166854||Muscle weakness|Diffuse Optical Spectroscopy
9957621|NCT01166867||Infant Development|Photo-plethysmography monitoring
9957622|NCT01166880||Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
9957623|NCT01166893||Burn wound|Modulated Imaging and Laser Speckle Imaging
9957624|NCT01166919|Experimental|Medical Tool|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
9957625|NCT01166932|Active Comparator|amoxicillin/clavulanic acid|patients who received amoxicillin/clavulanic acid
9957626|NCT01166932|Active Comparator|ceftriaxone/oxacillin|
9957627|NCT01167010|Experimental|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
9957628|NCT01167010|Active Comparator|Foraseq|Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
9957629|NCT01167010|Active Comparator|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
9957630|NCT01167036|Experimental|FascialEdge tool|A massage tool used to loosen adhesions in the superficial fascia
9957631|NCT01167036|Placebo Comparator|Placebo|Detuned electric point stimulation over the upper trapezius trigger point
9957632|NCT01167049|Experimental|CAPECITABINE|"Single arm:~Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);"
9957633|NCT01167062|Placebo Comparator|Placebo|
9957634|NCT01167062|Experimental|Tamsulosin Hydrochloride OCAS 0.4 mg|
9957635|NCT01167075|Active Comparator|Fresubin Original|
9957636|NCT01167075|Experimental|Intestamin plus Fresubin Original|
9957637|NCT01167088|Experimental|Mitoquinone mesylate tablets (MitoQ)|
9957638|NCT01167088|Placebo Comparator|Matching placebo tablet|
9957639|NCT01167101|Other|Pantoprazole|controls Pantoprazole 40mg qd for 28days
9957640|NCT01167101|Active Comparator|Pantoprazole + Rebamipde|Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days
9957641|NCT01167127|No Intervention|Tablet|OXN tablet, oral BID, flexible dose design
9957642|NCT01167218||verify now assay|subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
9957643|NCT01167231||Group 1|
9957644|NCT01167270|Active Comparator|Parenting Insight|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
9957645|NCT01167270|Placebo Comparator|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the AAP guidelines and the Academy's guide for health supervision, Bright Futures
9957646|NCT01167283|Active Comparator|Electrostimulation|Neuromuscular electrical stimulation
9957647|NCT01167283|Sham Comparator|Sham stimulation|Sham stimulation
9957648|NCT01167296|Active Comparator|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.removed uterine stent was sent for bacterial culture too.
9957649|NCT01167296|Experimental|without Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
9957650|NCT01167309|Active Comparator|Part 1 SAD|four diffferent doses
9957651|NCT01167309|Placebo Comparator|Part 2a MAD|three doses
9957652|NCT01167309|Active Comparator|Part 2b|0.24 mg LEO 27847
9957653|NCT01167309|Active Comparator|Part 2c|0.24 mg LEO 27847
9957654|NCT01167309|Placebo Comparator|Parat 2a MAD|one dose
9957655|NCT01167322|Experimental|NPC-07|Single administration of NPC-07 at a dose of 20mg/kg body weight
9957656|NCT01167335|Experimental|BGG492|
9957657|NCT01167335|Placebo Comparator|Placebo|
9957658|NCT01167361||Children with upper or lower respiratory infections|Respiratory Virus infections in children who are symptomatic with either an Upper Respiratory Tract Infections and/or Lower Respiratory Tract Infections is determined by using a novel highly sensitive and rapid assay for RV detection. An aliquot from the leftover sample remaining after clinical diagnostic testing will be used for FilmArrayTM analysis. Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic studies on this specimen will be performed as ordered and the results will be available to the treating physicians after reporting.
9957659|NCT01167374|Experimental|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
9957660|NCT01167387|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
9957661|NCT01167387|Placebo Comparator|water|The control group will receive plain water with the same volume and timing of treatment.
9957662|NCT01167400|Experimental|Cybercycling|cybercycling for 3 months
9957663|NCT01167400|Active Comparator|Traditional Stationary Biking|Traditional exercise on a stationary bike for 3 months.
9957664|NCT01167413||FIbromyalgia Patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR criteria
9957665|NCT01167439|No Intervention|Mild dysphagia|
9957666|NCT01167439|Active Comparator|Severe dysphagia|
9957667|NCT01167478|Experimental|Caffeine|
9957668|NCT01167491|Other|Disease group|Physiopathology
9957669|NCT01167517|Experimental|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge.
9957670|NCT01167517|Placebo Comparator|Instructions in print format|Breast milk expression instructions provided in print format at the time of hospital discharge.
9957671|NCT01167543||Pediatric patients with symptoms or diagnosis of GER|
9957672|NCT01167543||Control group of pediatric subjects with no symptoms of GER.|
9957673|NCT01167556|Experimental|Family Motivational Intervention|An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
9957674|NCT01167556|Active Comparator|Routine care for parents|Routine care for parents consisting of 2 sessions psycho-education and individual support
9957675|NCT01167647||bronchoscopy patients|
9957676|NCT01167660||Healthy newborn babies|Healthy newborn babies immediately after birth.
9957677|NCT01167660||Sick newborn babies|Sick newborn babies whose medical condition indicates performing coagulation tests.
9957678|NCT01167673|Active Comparator|treatment with study drug|patients receiving study drug for 4 weeks. 3 capsules a day of coltect
9957679|NCT01167673|Placebo Comparator|placebo|patients receiving similar capsules but no active ingredients
9957680|NCT01167686|Experimental|Food supplement|Half of the subjects participating in the trial (91) will recieve four tablets of the food supplement (Gardemont Goldrain Plus) three times a day for seven consecutive days from inclusion.
9957681|NCT01167725|Active Comparator|Arm I|Patients receive standard systemic therapy, at the discretion of patients' oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or FOLFIRI), bevacizumab, or cetuximab. Treatment repeats in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm II.
9957682|NCT01167725|Experimental|Arm II|Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.
9957683|NCT01167738|Experimental|PEXG regimen + metformin|cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
9957684|NCT01167738|Active Comparator|PEXG regimen|cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15
9957685|NCT01167751|Experimental|MNC implantation|Implantation of BM derived MNC
9957686|NCT01167751|Experimental|AC 133 implantation|Implantation of BM derived AC 133
9957687|NCT01167751|Placebo Comparator|Control|Injection of cell carrier
9957688|NCT01167764|Active Comparator|tranexamic acid|tranexamic acid 250mg po 3 times/day for 1 months
9957689|NCT01167764|Placebo Comparator|placebo|placebo po 3 times/day for 1 months
9957690|NCT01167777||male/female|Symtomatic and asymptomatic males and females attending STD, family planning, public health and women's health clinics, or other applicable centers, who are being screened for CT or GC.
9957691|NCT01167803|Active Comparator|Reference - desflurane|The patients in this group will undergo anesthesia using remifentanil associated with desflurane.
9957692|NCT01167803|Experimental|Experimental - xenon|The patients in this group will undergo anesthesia using remifentanil associated with xenon
9957693|NCT01167816|Experimental|azacitabine|
9957694|NCT01167855|Experimental|Intervention|"Telemedicine asthma education sessions~Asthma health assessment via telemonitoring~Provider treatment prompts~School absenteeism~Prescription filling profile"
9957695|NCT01167868|Experimental|FosD|Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects
9957696|NCT01167868|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
9957697|NCT01167894|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
9957698|NCT01167894|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
9957699|NCT01167920|Active Comparator|Virtual Hypertension Clinic Group|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals till the end of the study.
9957700|NCT01167920|No Intervention|Usual Care Group|The Usual Care Group (UCG) patients will be told their BP is not in control and encouraged to work with their physician to improve it. There will be no further structured intervention during the rest of the study.
9957701|NCT01167933|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
9957702|NCT01167933|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
9957703|NCT01167946|Experimental|Group A|will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks
9476585|NCT03570411||HCT Recipient|"All participants who meet eligibility criteria and consent to enrollment on study.~Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.~The amount of blood collected at each visit will be based on age."
9957704|NCT01167946|Active Comparator|Group B|will receive 2 consecutive daily pulses every 3 weeks for 24 weeks
9957705|NCT01167946|Active Comparator|Group C|will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.
9957706|NCT01167959||obesity diabetes, surgical and dietary|
9957707|NCT01167972||1|
9957708|NCT01167985|Experimental|Root canal sealer group+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
9957709|NCT01167985|Experimental|Provisional restoration material+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
9957710|NCT01167985|Experimental|Experimental- Different root canal sealer+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
9957711|NCT01168011|Experimental|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day every day of 21-day cycles.
9957712|NCT01168037||Open repair|Open Surgical Repair (aortic replacement with revascularization of visceral arteries)
9957713|NCT01168037||Endovascular (Windows 1)|Endovascular therapy branched or fenestrated stent-graft
9957714|NCT01168037||Endovascular (Windows 3)|Endovascular therapy branched or fenestrated stent-graft (vascutek anaconda)
9957715|NCT01168050|Experimental|Nilotinib|
9957716|NCT01168063|Experimental|Helicobacter pilory triple treatment|Triple treatment on this arm is based on results of molecular detection of resistance to antibiotics
10005739|NCT01587807|Experimental|Cohort 5|single inhaled dose GSK1995057 (dose 4) with bronchoalveolar lavage (BAL)sampling procedure conducted approximately 30 minutes post GSK1995057 dose
10005740|NCT01587807|Experimental|Cohort 6|high dose of GSK1995057 or placebo followed by an inhaled LPS challenge and BAL sampling procedure.
9476586|NCT03570411||HCT Donor|"Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol~A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant"
10005741|NCT01587820|Experimental|Intra-arterial cisplatin and radiation|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
10005742|NCT01587820|Active Comparator|Intravenous cisplatin and radiation|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
10005743|NCT01587833||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
10005744|NCT01587833||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
10005745|NCT01587846|Experimental|Probiotic/abdominal pain|Children with functional abdominal pain that will receive probiotic.
10005746|NCT01587846|Experimental|Placebo/abdominal pain|Children with functional abdominal pain that will receive placebo.
10005747|NCT01587846|Experimental|Probiotic/constipation|Children with chronic constipation tha will receive probiotic plus lactulose
10005748|NCT01587846|Experimental|Placebo/chronic constipation|Children with chronic constipation that will receive placebo plus lactulose
10005749|NCT01587859||Cohort|Patients submitted to laparoscopic surgery for Type II-IV hiatus hernia
10005750|NCT01587872|Experimental|DBC|Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.
10005751|NCT01587911|Active Comparator|Whey protein|Complete whey protein.
10005752|NCT01587911|Active Comparator|Whey-CMP|Complete whey protein missing the CMP (aka GMP) portion of the peptide.
10005753|NCT01587911|Placebo Comparator|Control|Placebo preload control, matched for energy.
10005754|NCT01587911|Active Comparator|CMP (casinomacropeptide)|Small peptide cleaved from complete whey protein.
10005755|NCT01587911|Active Comparator|MPI|Complete milk protein.
10005756|NCT01587911|Active Comparator|CPI (casein)|Preload containing casein.
10005757|NCT01587937|Experimental|Antibiotic stewardship intervention|Audit-and-feedback intervention to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antimicrobial
10005758|NCT01587937|No Intervention|Control|The pre-intervention period will serve as the control period on each medical and surgical service. The cross-over is uni-directional from control to intervention; all services receive the intervention by the end of the study. This is a stepped wedge design. The order of roll-out is randomized.
10005759|NCT01588002|Active Comparator|A danoprevir+ritonavir|
10005760|NCT01588002|Active Comparator|B efavirenz|
10005761|NCT01588002|Experimental|C combination|
10005762|NCT01588067||Medical|Patients treated for PAD medically or with exercise therapy
10005763|NCT01588067||Endovascular|Patients with PAD treated with endovascular therapy
10005764|NCT01588067||Surgery|Patients with PAD treated with surgery
10005765|NCT01588080|Placebo Comparator|SiPAP|
10005766|NCT01588080|Experimental|Neurally Adjusted Ventilatory Assist|
10005767|NCT01588093|Placebo Comparator|Saline|
10005768|NCT01588093|Active Comparator|Increlex|
10005769|NCT01588132|Experimental|Single dose gourp 1|Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
10005770|NCT01588132|Experimental|Single dose group 2|Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
10005771|NCT01588132|Experimental|Single dose groups 3|Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
10005772|NCT01588132|Experimental|Single dose group 4|Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
10005773|NCT01588132|Experimental|Single dose group 5|Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
10005774|NCT01588132|Experimental|Single dose group 6|Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
9957717|NCT01168063|Active Comparator|Helicobacter pilori standard recommended treatment|H.Pylori Eradication rate with empirical treatment
9957718|NCT01168128|Experimental|Tailored Action Plan|A Tailored Action Plan is an intervention selected to overcome barriers identified before the design and delivery of the intervention.
9957719|NCT01168154|Active Comparator|Lactobacillus Reuterii|
9957720|NCT01168154|Placebo Comparator|Placebo|
9957721|NCT01168167||raltegravir-based cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus raltegravir (n=10 patients) will be offered to participate in this observation arm, but only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
9957722|NCT01168167||standard of care-cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus either a boosted protease inhibitor or efavirenz (n=10 patients) at standard doses will be offered to participate in this observation arm. They will be offered to participate in this trial only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
9957723|NCT01168180|Experimental|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
9957724|NCT01168180|Active Comparator|Ultrasound therapy and hot pack|The participants will receive thirty minutes session of Ultrasound therapy and hot pack for 9 sessions over a period of 3 weeks
9957725|NCT01168193|Other|Patients that underwent surgery|Single arm
9957726|NCT01168206|Placebo Comparator|Placebo|
9957727|NCT01168206|Experimental|TK3|1 capsule, 3 times per day.
9957728|NCT01168245|Experimental|NICE-System NeuroAD|Treatment Group
9957729|NCT01168245|Sham Comparator|Sham-TMS|Control Group
9957730|NCT01168297||Maycoba residents|Pima and non-Pima Mexicans from the village of Maycoba
9957731|NCT01168323|Experimental|Spaced education clinicians - cohort 1|Spaced education clinicians receive four isomorphic cycles of 9 spaced education emails over 36-weeks (0-2 emails per week). Each email contained one question-explanation.
9957732|NCT01168323|No Intervention|Control clinicians - cohort 2|Control clinicians received no intervention
9957733|NCT01168336|Experimental|betahistine|Betahistine 24 mg tablets
9957734|NCT01168336|Experimental|betahistine XR|betahistine 32 mg tablets
10005775|NCT01588132|Experimental|Single dose group 7|Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
9957735|NCT01168336|Placebo Comparator|placebo|
9957736|NCT01168362||High risk group|positive cardiovascular risk group
9957737|NCT01168362||Low risk group|negative cardiovascular risk group
9957738|NCT01168375|Active Comparator|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
9957739|NCT01168375|Active Comparator|conventional therapy plus umbilical cord serum eye drop|
10005776|NCT01588132|Experimental|Single dose group 8|Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
10005777|NCT01588132|Experimental|Multiple dose group 9|Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
10005778|NCT01588132|Experimental|Multiple dose group 10|Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
10005779|NCT01588132|Experimental|Multiple dose group 11|Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
10005780|NCT01588145|Experimental|HM61713|
10005781|NCT01588171|Active Comparator|Bemiparin|A new second generation Low Molecular Weight Heparin
10005782|NCT01588171|Active Comparator|Enoxaparin|A well known Low Molecular Weight Heparin
10005783|NCT01588171|No Intervention|control group|Risky group patients for VTE, but they will not receive any thromboprophylactic drug.
10005784|NCT01588210|Experimental|Glass Ionomer Cement group|a high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany)
9957740|NCT01168388||Movement disorder|
9957741|NCT01168414|Active Comparator|Ganfort|Fixed combination of Bimatoprost and Timolol
9957742|NCT01168414|Active Comparator|Duotrav|Fixed combination of Travoprost and Timolol
9957743|NCT01168453||neutral head position|supine with neutral head position
9957744|NCT01168453||head rotation|supine with 30° head rotation
9957745|NCT01168466|No Intervention|Neurofeedback|Waitlist control group.
9957746|NCT01168466|Experimental|QEEG-based Neurofeedback Training|A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
9957747|NCT01168479|Active Comparator|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
9957748|NCT01168479|Experimental|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
9957749|NCT01168492|Experimental|ketamine|group with triple sedation (ketamine, midazolam, meperidine)
9957750|NCT01168492|Placebo Comparator|placebo|group with conventional sedation and placebo ( midazolam, meperidine and placebo)
9957751|NCT01168505|No Intervention|no iron supplentation|
10005785|NCT01588210|Experimental|Resin Based Fluoride Group|white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein)
10005786|NCT01588210|Placebo Comparator|Resin Based sealant|white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany)
10005787|NCT01588223|Experimental|Lipids|
9476587|NCT03570398|Other|Abdominal CT|
9476588|NCT03570398|Other|Abdominal Ultrasound|
9957752|NCT01168505|Experimental|iron supplement|
9957753|NCT01168531|Placebo Comparator|placebo arm|
9957754|NCT01168531|Active Comparator|pregabalin arm|
9957755|NCT01168531|Experimental|dexamethasone with pregabalin arm|
9957756|NCT01168544|Experimental|loading dose and 50.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
9957757|NCT01168544|Experimental|Loading dose and 25.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
9957758|NCT01168544|Active Comparator|800 IU vit D3/dag|800 IU vit D3/dag
9957759|NCT01168557|Experimental|Stress-Echo and EIT|Patients who routinely undergo stress-echocardiography will additionally be measured by EIT using a rubber belt, which will be placed around their chest
9957760|NCT01168570||SAA monitored group|FMF-Amyloidosis patients receiving colchicine with a purpose to normalize SAA levels
9957761|NCT01168570||Historical control group|FMF-Amyloidosis patients receiving colchicine at a dose determined to stop FMF attacks. obtained from the Fibrillex study
9957762|NCT01168583||Positive Fluid Balance of 2000ml|
9957763|NCT01168583||Negative Fluid Balance of 2000ml|
9957764|NCT01168609||patients with acute myocardial infarction|Acute myocardial infarction (AMI) was defined using the European Society of Cardiology / American College of Cardiology guidelines. Myocardial infarction was detected by the presence of at least two of the following criteria: chest pain lasting more than 30 minutes, typical electrocardiographic changes, and elevated creatinine kinase-MB fraction. Consecutive patients 18 years of age or older who presented within 12 hours after the onset of symptoms were considered for enrollment. Patients who had ST-segment elevation of 1 mm or more in two or more contiguous leads were classified as ST-segment elevation MI.
9957765|NCT01168635|Experimental|Intervention|Virtually-delivered spirometry quality improvement program
9957766|NCT01168635|No Intervention|Standard of Care|
9957767|NCT01168648|Experimental|Yoga as stress management|The intervention consists of following a program of yoga at least three times a week for three months. The yoga program has been designed to reduce stress.
9957768|NCT01168648|Active Comparator|Control group|The group rests without using any specific program for relaxation at least three times a week for three months.
9957769|NCT01168648|Other|Yoga as stress management fewer tests|Eight persons participated in the same intervention as the experimental arm but did not undergo the full range of tests because they did not meet all the inclusion criteria for the study, most commonly because of medication use or body mass index.
9957770|NCT01168661|No Intervention|Control arm|Participants in this arm will be recruited from the group who applied to participate in the study and fulfilled the inclusion criteria but for various reasons (such as time constraints) could not participate.
9957771|NCT01168661|Active Comparator|Cognitive psychotherapy arm|In this arm, participants will attend a group meeting to practice cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
9957772|NCT01168661|Active Comparator|Mindfulness based cog psychotherapy arm|In this arm, participants will attend a group meeting to practice mindfulness based cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
9957773|NCT01168661|Active Comparator|Yoga treatment group|Persons in this arm will practice yoga >= 5 time each week (2 times in a supervised group and the other times on their own).
9957774|NCT01168700|Placebo Comparator|Placebo|Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
9957775|NCT01168700|Experimental|Aged garlic extract (Kyolic ®)|Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
9957776|NCT01168739|Experimental|Quercetin|not necessary, contained in protocol
9957777|NCT01168739|Placebo Comparator|Placebo|not necessary, contained in protocol
9957778|NCT01168752|Experimental|schedule A|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
9957779|NCT01168752|Experimental|schedule B|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as a daily schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
9957780|NCT01168765|Experimental|Intervention group|This is the promotora plus group that will receive the TSSC newsletter and exposure to the media campaign but will also receive monthly visits by promotoras/lay health workers who will review the monthly newsletter with participants, emphasize role model stories, and discuss physical activity and healthful food choices using motivational interviewing strategies.
9957781|NCT01168765|Other|Control group|TSSC Media Campaign only participants who will receive a newsletter and the same exposure to the media campaign intervention as other community members not enrolled in the behavioral intervention.
9957782|NCT01168778|No Intervention|Control|
9957783|NCT01168778|Experimental|Intervention|
9957784|NCT01168791|Experimental|doxorubicin plus palifosfamide-tris|
9957785|NCT01168791|Active Comparator|doxorubicin plus placebo|
9957786|NCT01168804|Experimental|single arm bendamustine bortezomib dexamethasone|single arm combination regimen: bendamustine - bortezomib- dexamethasone
9957787|NCT01168817|Experimental|Arm 1|
9957788|NCT01168817|Active Comparator|Arm 2|
9957789|NCT01168817|Placebo Comparator|Arm 3|
9957790|NCT01168830|Experimental|Investigational device|
9957791|NCT01168843||normal pregnant|
9957792|NCT01168869||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
9957793|NCT01168895|Experimental|Arm 1|
9957794|NCT01168895|Experimental|Arm 2|
9957795|NCT01168947|Experimental|5% dextrose|5% dextrose rinsing fluid
9476589|NCT03570372|Experimental|Intervention group|36 week internet-based CBT with therapist support. Regular online group discussions.
9476590|NCT03570372|Active Comparator|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
9476591|NCT03570359|Active Comparator|Interferon beta 1a|"Part 1- Interferon beta 1a once a day for 3 days via inhalation~Part 2 - Interferon beta 1a once a day for 14 days via inhalation"
9957796|NCT01168960|Other|Cognitive Behavioral Treatment|A single intervention study
9957797|NCT01169012|Other|Single Arm Trial|Single Arm Trial
9957798|NCT01169025|Experimental|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
9957799|NCT01169025|Active Comparator|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
9957800|NCT01169051||Thoracic sugery statins|
9957801|NCT01169051||Thoracic surgery non-statins|
9957802|NCT01169077|Experimental|Group I: 0.25 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 0.25 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
9957803|NCT01169077|Experimental|Group II: 1.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 1.0 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
9957804|NCT01169077|Experimental|Group III: 4.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 4.0 mg, Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
9957805|NCT01169090|Experimental|SK-0403 100 mg QD|
9957806|NCT01169090|Experimental|SK-0403 200 mg QD|
9957807|NCT01169090|Experimental|SK-0403 400 mg QD|
9957808|NCT01169090|Experimental|SK-0403 200 mg BID|
9957809|NCT01169090|Sham Comparator|Placebo|
9957810|NCT01169090|Active Comparator|Sitagliptin 100 mg QD|
9957811|NCT01169129|Active Comparator|surgery+whole-brain irradiation|brain metastases is resected and the patient is submitted to whole-brain irradiation
10005788|NCT01588249|Experimental|Novel formulation of pasteurized maple cough syrup|
10005789|NCT01588249|Placebo Comparator|Placebo|
9957812|NCT01169129|Active Comparator|whole-brain irradiation+radiosurgery|patients will be submitted to whole-brain irradiation and after, they will be submitted to radiosurgery.
9957813|NCT01169142|Active Comparator|Immediate Vitamin D3|Will start Vitamin D3 immediately
9957814|NCT01169142|Active Comparator|Three month delay|Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
9957815|NCT01169155|Active Comparator|Study 3. Adults 20-49 Years of Age|"Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in a linked study, Study 3, with adult participants 20-49 years of age to ensure that the alarms tested will also work for adults in this age group.~This arm will use the alarm signal identified in Study 2 that is significantly associated with Electroencephalography (EEG)-defined awakening and successful completion of simulated escape behaviors by children after awakening from slow wave sleep. A lower frequency tone smoke alarm will evaluate the influence of alarm signal frequency on awakening. A conventional residential tone smoke alarm will be used as a reference stimulus. Both a male and a female voice will be used as alarm stimuli. Note that these will be strangers' voices, and not a mother's voice."
9957816|NCT01169155|Active Comparator|Study 4. Older Adults 60-84 Years of Age|Study 4 of this project will take the voice alarm script in Study 2 and compare it with a low-frequency 520 Hz square wave tone smoke alarm in awakening older adults 60-84 years of age from slow wave sleep and prompting their performance of a simulated escape procedure. Note that this will necessarily be a female stranger's voice, and not a mother's voice, in this older age group. As in Studies 1 and 2, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 4. In order to maintain the same experimental design across these studies, a fourth alarm type will be introduced. This fourth alarm will be a hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm, i.e., the stimulus will begin with the 520 Hz square wave tone in a T-3 pattern followed by the voice script, with this stimulus being repeated until the subject completes the escape procedure.
9476592|NCT03570359|Placebo Comparator|Placebo|"Part 1- placebo once a day for 3 days via inhalation~Part 2 - placebo once a day for 14 days via inhalation"
9476593|NCT03570346|Experimental|Hemay005|6 subjects in each cohort(15mg, 30mg, 60mg) will receive Hemay005
9957817|NCT01169155|Active Comparator|Study 1. Maternal Voice Smoke Alarm Characteristics|"Study 1. Identification of Specific Maternal Voice Smoke Alarm Characteristics Associated With Awakening and Escaping.~Using a randomized, non-blinded, repeated measures, clinical intervention design, Study 1 will identify the critical elements (i.e., use of child's first name and/or behavior commands in message content) in the maternal voice signal that are significantly associated with EEG-defined awakening (and completion of simulated escape behaviors by children after awakening from S4). A conventional residential tone smoke alarm meeting current NFPA 72 National Fire Alarm Code will be used as a reference stimulus to allow comparison of responses to the voice alarm stimuli with responses to a conventional residential tone alarm stimulus."
10005790|NCT01588262|Other|Stressmanagement counselling|
10005791|NCT01588262|No Intervention|Control|
10005792|NCT01588275|Active Comparator|MRA therapy|During 12 months patients will be treated with a bibloc MRA (SomnoDent® MAS, SomnoMed Australia/Europe AG). The MRA will be customized by certified dentists or dental-specialists experienced in the field of dental sleep medicine.
10005793|NCT01588275|Active Comparator|CPAP therapy|"During 12 months patients will be treated with Continuous positive airway pressure (CPAP).Treatment with CPAP prevents upper airway collapse by pneumatically splinting the upper airway during sleep."
9476594|NCT03570346|Placebo Comparator|Placebo|2 subjects in each cohort(15mg, 30mg, 60mg) will receive placebo
10005794|NCT01588288|Experimental|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
10005795|NCT01588301|Experimental|Group 1 : Further invitation by mail|Further invitation to attend for cervical cytology
10005796|NCT01588301|Experimental|Group 2 : Kit for Self-collected vaginal sample|Kit for Self-collected vaginal sample sent at home and then test for Human Papillomavirus (HPV)
10005797|NCT01588301|No Intervention|Group 3: Control|
9957818|NCT01169155|Active Comparator|Study 2. Mother's Versus Stranger's Voice Alarms & Alarm Freq.|"Study 2. Comparison of Mother's Versus Stranger's Voice Smoke Alarms and Alarm Frequency.~Study 2 will take the voice alarm script that was the most successful in Study 1 in awakening and prompting children to perform the simulated escape behaviors, and will compare mother's voice to a female stranger's voice using this script. This will determine whether mother's voice is a critical factor for success of the voice smoke alarm. In addition, a Temporal-Three (T-3) pattern smoke alarm with dominant tones in lower frequency ranges similar to the human voice range will be included as a stimulus in Study 2 to evaluate the influence of alarm signal frequency on EEG-defined awakening (as well as completion of simulated escape behaviors by children after awakening from S4). As in Study 1, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 2. This conventional residential tone alarm has a higher frequency signal than the other T-3 tone alarm."
9957819|NCT01169155|Active Comparator|Study 5. Male Voice and Hybrid Tone/Voice Alarm for Children|Study 5. Children 5-12 Years of Age (Testing Male Voice and Hybrid Tone/Voice Alarm) Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in Study 5 among children 5-12 years of age using the following 4 alarm stimuli: female stranger's voice, male stranger's voice, hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm (from Study 4), and conventional high frequency tone residential alarm. This study arm will allow comparison of a male versus female voice and also evaluate the hybrid low frequency tone/voice alarm among children 5-12 years of age. The same protocol will be used for children in this study arm as was used in Studies 1 and 2.
9957820|NCT01169181|Active Comparator|AMES therapy with rTMS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+rTMS, followed by an EMG test. During the hand-opening phase of the AMES therapy, the subjects assigned to the AMES+rTMS treatment group will be subjected to trains of TMS pulses.
9957821|NCT01169181|Active Comparator|AMES therapy with tDCS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+tDCS, followed by an EMG test. A constant current will be applied throughout the entire 20-minute therapy session with the AMES device.
9957822|NCT01169207||Unaffected|Individuals who do not have IBD
9957823|NCT01169207||Affected|Individuals with IBD
9957824|NCT01169220|Experimental|Split prep|
9957825|NCT01169220|Active Comparator|Whole prep|
9957826|NCT01169233|Other|Shorter Wavelength (green)|
9957827|NCT01169233|Other|Intermediate Wavelength (white w/ green filter)|
9957828|NCT01169233|Other|Longer Wavelength (red)|Placebo
9957829|NCT01169246||Paradym VR, DR and CRT models|
9957830|NCT01169272|Experimental|CRT-SonR 9770|Active implantable defibrillator with ability to cardiac resynchronization therapy
9957831|NCT01169298|Experimental|Lenalidomide|Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
9957832|NCT01169324|Experimental|DBS on|baseline settings
9957833|NCT01169324|No Intervention|DBS off|DBS off
9957834|NCT01169389|Active Comparator|Durolane|
9957835|NCT01169389|Placebo Comparator|Bupivacaine|
9957836|NCT01169402|Experimental|Fluconazole|
9957837|NCT01169415|Experimental|Protracted (30 days), Dexamethasone|Participants will receive a protracted course (30 days) of dexamethasone after surgery.
9957838|NCT01169415|Experimental|Abbreviated (14 days), dexamethasone|Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
9957839|NCT01169428|Active Comparator|Standard Behavioral Weight-Loss Maintenence|"Attention/Education/Support Control~Group designed to control for educational content as well as multiple nonspecific treatment factors (e.g., support, time invested, leader attention, positive expectancy)"
9957840|NCT01169428|Active Comparator|Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss.
9957841|NCT01169454||Monitor then drain|Subjects who are treated with intermittent CSF drainage
10005798|NCT01588314|Active Comparator|gabapentin|
9957842|NCT01169454||Drain then monitor|Subjects who are treated with continuous CSF drainage at set pressure thresholds
9957843|NCT01169480|Experimental|Massage Giver|Participants in the experimental group will be asked to give one 50-minute Swedish massage to another volunteer.
9957844|NCT01169480|No Intervention|Passive Controls|Participants in this arm will wait in a classroom (as usual) and do nothing out of their ordinary routines.
9957845|NCT01169506|Experimental|COPD patients and healthy individuals|
9957846|NCT01169545||Cancer patients over the age of 18|Cancer patients over the age of 18 who are receiving active treatment.
9957847|NCT01169571||Group I - No loading dose|No loading dose to be administered during the loading-dose paradigms
9957848|NCT01169571||Group II - Loading dose over 10 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 10 minutes during the loading-dose paradigms
9957849|NCT01169571||Group III - Loading dose over 20 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 20 minutes during the loading-dose paradigms
9957850|NCT01169584|Experimental|Single Arm - JX-594|Intratumoral injection of JX-594
9957851|NCT01169623|Experimental|Educational Intervention|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
9957852|NCT01169623|Placebo Comparator|CONTROL|55 of head nurses who will not participate in educational intervention will be considered as a control arm
9957853|NCT01169662|Active Comparator|Vegetable/ Fruit juice|450ml active product, 45 ml no added sugar squash (for flavour)
9957854|NCT01169662|Placebo Comparator|Placebo juice|
9957855|NCT01169714|Experimental|Dosing Healthy Adult|Ascending Doses in Healthy Adult Volunteers
9957856|NCT01169714|Experimental|Dosing Healthy Elderly|Dosing in Healthy Elderly volunteers
9957857|NCT01169740||Neonatal jaundice|Infants born between July 1st 2010 and July 31st 2010 and admitted to normal newborn nursery
9957858|NCT01169792||Breast cancer patients|Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
9957859|NCT01169805|Experimental|ONSERAN|
9957860|NCT01169805|Experimental|NASEA|
9957861|NCT01169805|Experimental|ALOXI|
9957862|NCT01169805|Placebo Comparator|normal saline|
9957863|NCT01169818|Experimental|Intervention group|Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
9957864|NCT01169818|Active Comparator|Usual standard of care group|Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician
9476595|NCT03570320|No Intervention|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
9667617|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
9957865|NCT01169857|Experimental|Velcade Therapy|
9957866|NCT01169870|Experimental|Genexol-PM|Genexol-PM 300mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 1 hour on day 1, every 3 week cycle.
9957867|NCT01169870|Active Comparator|Paclitaxel|Paclitaxel 175mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 3 hour on day 1, every 3 week cycle.
9957868|NCT01169883|Active Comparator|Attention Control Group|1) Doctor Asthma Messages delivered over a 10 week time period; 2) Asthma Supervision; and 3) Music Tracks.
9957869|NCT01169883|Experimental|Intervention Group|1) Coping Peer Support delivered over a 10 week time period; 2) Coping Peer Asthma Messages delivered over a 10 week time period; 3) Asthma Supervision; and 4) Music Tracks.
9957870|NCT01169909|Experimental|Ranibizumab treatment|Patients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose.
9957871|NCT01169922|Experimental|SEXUAL PLUS ALCOHOL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction as well as alcohol risk reduction.
9957872|NCT01169922|Active Comparator|INFORMATION-ONLY SEXUAL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction only.
9957873|NCT01169935|Experimental|Administration of Intra-dermal SPIO|MRI scanning before and after intra-dermal injection of SPIO.
9957874|NCT01169935|Experimental|Mantoux, Venesection, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
9957875|NCT01169935|Experimental|Mantoux, Apheresis, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
9957876|NCT01169935|Experimental|Mantoux, Administration of Endorem|Mantoux test then MRI scanning before and after administration of Endorem.
9957877|NCT01169935|Experimental|Mantoux only|Mantoux test then serial MRI scanning.
9957878|NCT01169948||Patients awaiting cardiac surgery|
9957879|NCT01169974||healthy volunteers|
9957880|NCT01170013|Experimental|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
9957881|NCT01170013|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
9957882|NCT01170026|Experimental|Family Check-up/Individual MI|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use plus 2 session Individual Motivational Intervention for the adolescent
9957883|NCT01170026|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
9957884|NCT01170078|Experimental|Arm A: Epoetin Hospira administered IV for three doses|
9957885|NCT01170078|Active Comparator|Arm B: Epogen administered IV for three doses|
9957886|NCT01170130|Experimental|Lidmyd|The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
9957887|NCT01170143|Active Comparator|Trastuzumab QW|Arm A: Trastuzumab 2mg/kg, d1; qw (loading dose 4mg/kg wk1) Paclitaxel 80mg/m2,. d1; qw Carboplatin AUC 2 d1, qw
9957888|NCT01170143|Active Comparator|Trastuzumab Q3W|Arm B: Trastuzumab 6mg/kg, d1(loading dose 8mg/kg wk1) Paclitaxel 175mg/m2,. d1, q3w; Carboplatin AUC 6 ,. d1,q3w
9957889|NCT01170169|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's laboratories limited
9957890|NCT01170169|Active Comparator|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
9957891|NCT01170182|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
9957892|NCT01170182|Active Comparator|Prilosec|Prilosec® 40 mg Merck & Co. Inc
9957893|NCT01170234||Eosinophilic esophagitis (EoE)|Treatment-naïve EoE patients, age 7 -65
9957894|NCT01170260|Active Comparator|Info-only sexual risk reduction|Corresponding intervention gives information only on STDs/HIV
9957895|NCT01170260|Experimental|Sex plus alcohol risk reduction|Corresponding intervention gives info focusing on sex and alcohol risk reduction only
9957896|NCT01170260|Experimental|Sex + alcohol + marijuana risk reduction|Corresponding intervention gives info on sex, alcohol, and marijuana risk reduction
10005799|NCT01588314|Placebo Comparator|placebo|
10005800|NCT01588327||Experimental|Patient taking FDA approved dose of dabigatran
10005801|NCT01588327||Control group|Person not taking any form of anticoagulation.
10005802|NCT01588340|Active Comparator|MRI|The patient will have a rapid noncontrast MRI (magnetic resonance imaging) that will take approximately 15 minutes to complete.
10005803|NCT01588340|Active Comparator|Ultrasound exam|A noncontrast ultrasound examination
10005804|NCT01588379|Experimental|Girls and mothers dance together|African-American girls AND their mom's will participate in the Afro-centric dance program together and also receive weekly newsletter that focuses on health related issues.
10005805|NCT01588379|Experimental|Girls, alone|African-American girls will participate in the Afro-centric dance program alone. Girls and mom's will receive weekly newsletter that focuses on health related issues
10005806|NCT01588379|Active Comparator|No dancing|African-American girls and their mom's will only receive weekly newsletter that focuses on health related issues.
10005807|NCT01588392|Experimental|Short bouts of structured activity|
10005808|NCT01588392|Active Comparator|Unstructured physical activity|
10005809|NCT01588483||giant cell arteritis|patients with biopsy and/or scintigraphy proven GCA
10005810|NCT01588522|Experimental|dose-escalation of compound 31543|compound 31543 Calcitriol, Topical application, 0.25 mL to be applied to each of the four quadrants of the scalp twice daily, morning and night with 10-14 hours between applications
10005811|NCT01588574|Active Comparator|BOTOX (registered trade mark)|
10005812|NCT01588574|Experimental|MT10109|
10005813|NCT01588587||DPP-IV inhibitors|
10005814|NCT01588600|Active Comparator|Control|Breakfast without fiber
10005815|NCT01588600|Experimental|Low-dose|Low-dose of fiber in breakfast
10005816|NCT01588600|Experimental|High-dose|high dose of fiber added to breakfast
10005817|NCT01588626|Experimental|AZD6140|single administration of 90 mg dose of AZD6140
10005818|NCT01588639||Group 1|
10005819|NCT01588665||Pregnant women and pregnant adolescents|
9957897|NCT01170286|Experimental|DBV712 Viaskin|The experimental arm is composed of subjects treated with whole peanut extract on an epicutaneous delivery system (Viaskin patch)
9957898|NCT01170286|Placebo Comparator|Placebo Viaskin|The placebo arm is composed of subjects treated with a placebo formulation on an epicutaneous delivery system (Viaskin patch)
9957899|NCT01170312|Active Comparator|Autologous conditioned plasma|
9957900|NCT01170312|Placebo Comparator|Normal saline|
9957901|NCT01170325|Experimental|Group A|
9957902|NCT01170325|Placebo Comparator|Group B|
9957903|NCT01170338|Experimental|active Chantix|active drug to help smoking cessation
9957904|NCT01170338|Placebo Comparator|sugar pill|
9957905|NCT01170351|Active Comparator|Group-A|Treatment-naive AIH patients consenting to participate
9957906|NCT01170351|Experimental|Group-B|Treatment-naive AIH patients consenting to participate. This group will receive Cyclosporine-A according to a set protocol.
9957907|NCT01170377||Mental Retardation|Patients receiving valproate or not
9957908|NCT01170403||NGT/IFG/DM, MeS/no-MeS|NGT: normal glucose tolerance IFG: impaired glucose tolerance DM : diabetes mellitus MeS: metabolic syndrome no-MeS: no metabolic syndrome
9957909|NCT01170416||12-Lead Body Surface Mapping - Focal VT .|Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
9957910|NCT01170416||12-Lead BSPM - Scar related VT, exit not identified|Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
9957911|NCT01170416||12-Lead BSPM - Scar related VT exit identified|Body surface mapping will be competed on patients with scar related VT where the exit is identified
9957912|NCT01170416||12-Lead BSPM - Supraventricular tachycardia|Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
9957913|NCT01170429|Experimental|I. Procaterol Hydrochloride|Meptin (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
9957914|NCT01170429|Placebo Comparator|II. Procaterol hydrochloride placebo|Meptin placebo (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
9957915|NCT01170442|Experimental|vitamin D3 2000 IU|
9957916|NCT01170442|Experimental|vitamin D3 5000 IU|
9957917|NCT01170442|Placebo Comparator|Placebo|
9957918|NCT01170455|Experimental|Blind Intubation Device|
9957919|NCT01170455|Active Comparator|Direct laryngoscope|
9957920|NCT01170468|Experimental|Vitamin D3|Vitamin D3 5000 IU daily
9957921|NCT01170468|Placebo Comparator|Placebo|Placebo daily
9957922|NCT01170481||papilloedema without glaucoma|
9957923|NCT01170481||papilloedema with glaucoma|
9957924|NCT01170481||glaucoma without papilloedema|
9957925|NCT01170494|Active Comparator|D2 2000 IU daily|
9957926|NCT01170494|Active Comparator|D3 2000 IU daily|
9957927|NCT01170494|Active Comparator|D2 1000 IU + D3 1000 IU daily|
9957928|NCT01170494|Active Comparator|D2 25000 IU Q2wk|
9957929|NCT01170494|Active Comparator|D3 25000 IU Q2wk|
9957930|NCT01170494|Active Comparator|D2 50000 IU Q4wk|
9957931|NCT01170494|Active Comparator|D3 50000 IU Q4wk|
9957932|NCT01170494|Placebo Comparator|placebo daily|
9957933|NCT01170507|Active Comparator|vitamin D3 1000 IU|
9957934|NCT01170507|Active Comparator|Vitamin D3 3000 IU|
9957935|NCT01170507|Active Comparator|Vitamin D3 5000 IU|
9957936|NCT01170507|Placebo Comparator|Placebo|
9957937|NCT01170520|Experimental|rTMS|
9957938|NCT01170559|Experimental|Group 1: ILR Group|Group allocated to receiving an ILR in the A&E department.
9957939|NCT01170559|No Intervention|Group 2: Conventional|Group randomised to conventional lines of investigation
9957940|NCT01170572||Long bone fracture|Patients presenting to accident and emergency during the study period with long bone or clavicle fracture
9957941|NCT01170585|Placebo Comparator|Placebo|randomised to placebo.
9957942|NCT01170585|Active Comparator|Active|randomised to rosuvastatin.
9957943|NCT01170611|Experimental|AAISAFER alone - AAISAFER+PREVENTIVE ALGORITHM - DDD|
9957944|NCT01170637|Active Comparator|Ibuprofen 200 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
9957945|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
9957946|NCT01170637|Active Comparator|Ibuprofen 200 mg BI|Oral administration as a fixed dose combination tablet (BI product)
9957947|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg BI|Oral administration as a fixed dose combination tablet (BI product)
9957948|NCT01170676|Experimental|Puff City GA|Puff City is an NHLBI-funded (C. Joseph, PI; Henry Ford Health System, Detroit, MI), web-based intervention that targets three key asthma management issues in youth: 1) smoking reduction or cessation in those who are smokers, 2) improving adherence to asthma controller medication use, and 3) improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms. Puff City Ga. is a replication study in the rural southeastern United States that adds biological assessments in addition to self-report data.
9957949|NCT01170676|Active Comparator|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
9957950|NCT01170689||Inpatient schizophrenia or schizoaffective disorder|
9957951|NCT01170728||Virtue® Male Sling|Device: Coloplast Virtue® Male Sling
9957952|NCT01170741|No Intervention|Delayed Control Condition|Participants assigned to the delayed treatment control condition will be offered biological testing and the tailored cue-card intervention upon completion of their 3- month follow-up interview. Use of a delayed treatment control group design will permit us to separate intervention effects on HIV risk behaviors from the general effects of participating in the study and completing a detailed HIV risk assessment.
9957953|NCT01170767|Experimental|Avastin|intravitreal injection of bevacizumab
9957954|NCT01170767|Active Comparator|Lucentis|intravitreal injection of ranibizumab
9957955|NCT01170780|Placebo Comparator|Placebo|Saline
9957956|NCT01170780|Active Comparator|Dexamethasone|Corticosteroid (Fortecontin 8 mg)
9957957|NCT01170793|No Intervention|2|no educative telephone coaching (ETC)
9957958|NCT01170793|Experimental|1|with educative telephone coaching (ETC)
9957959|NCT01170806|Active Comparator|Orlistat (Lipiblock) treatment|Lipiblock is a new Orlistat formulation, produce by Germed Pharma, Brazil. Capsule 120mg
9957960|NCT01170806|Active Comparator|Orlistat (Xenical) treatment|Xenical is a innovator Orlistat formulation, produced by Roche
9957961|NCT01170819|Active Comparator|Dinoprostone Vaginal Insert|
9957962|NCT01170819|Experimental|Double Balloon Catheter|
9957963|NCT01170845|Placebo Comparator|Control group|Patients in the control group received saline for 7 days starting at the beginning of surgery
9957964|NCT01170845|Active Comparator|S group|Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery
9957965|NCT01170858|Experimental|Icodextrin group|7.5% icodextrin dialysis solution
9957966|NCT01170858|Active Comparator|glucose solution group|2.5% or 4.25% glucose dialysis solution
9957967|NCT01170871|Experimental|Experimental|Escalating doses of Ixabepilone and Pemetrexed
9957968|NCT01170897|Other|Maximally Tolerated Dose|To identify the maximally tolerated dose (MTD) of PEGPH20.
9957969|NCT01170910|Other|Static incubation|If conservation in static incubation (group 1) is chosen by random selection, the transplant should be carried out while keeping the cold ischemic time (CIT) as short as possible (preferably less than 18 hours). Keep in mind that for reasons of homogeneity for result analysis and for conservation quality, it is recommended that kidneys in group 1 be conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution.
9957970|NCT01170910|Experimental|Pulsatile perfusion|If conservation in a pulsatile perfusion machine (group 2) is chosen by random selection, the kidney will be placed in the perfusion machine within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
9957971|NCT01170923|Experimental|FDG-PET guided|Chemotherapy regimen will be changed depending on metabolic response.
9957972|NCT01170923|Active Comparator|CT guided|Chemotherapy regimen will be changed depending on CT findings (RECIST).
9957973|NCT01170936|Experimental|Canakinumab|
9957974|NCT01170975|Other|Treatment sequence 1|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
9957975|NCT01170975|Other|Treatment sequence 2|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
9957976|NCT01170988|Other|surgical procedure|T-graft bypass or conventional bypass
9957977|NCT01171014|Experimental|High dose probiotic|Bifidobacterium lactis HN019, 10 billion cfu/day
9957978|NCT01171014|Experimental|Low dose probiotic|Bifidobacterium lactis HN019, 1 billion cfu/day
9957979|NCT01171014|Placebo Comparator|Placebo|Placebo
9957980|NCT01171027|Experimental|NOTES(R) Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery techniques
9957981|NCT01171027|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
9957982|NCT01171040||Consecutive patients received echocardiographic examinations|Consecutive patients received echocardiography are willing to participate in this study.
9957983|NCT01171053|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
9957984|NCT01171053|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support
9957985|NCT01171066|Experimental|Tasman CPAP|
9957986|NCT01171079|Experimental|Interceed|
9957987|NCT01171092|Experimental|bortezomib and G-CSF|
9957988|NCT01171105|Experimental|1|AZD5213 (dose escalating)
9957989|NCT01171105|Placebo Comparator|2|Placebo
9957990|NCT01171131||Chronic TBI Patients - Non-penetrating|"Chronic TBI patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
9957991|NCT01171131||Chronic TBI Patients - Blast|"Chronic TBI Blast injury patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
9957992|NCT01171131||Healthy Volunteers|"Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,~No significant medical history~Take no medications (other than birth control pills)~Fever free~No history of head trauma or recent injury/infection~No history of neurological or psychiatric disorders or alcohol or drug dependency."
9957993|NCT01171144||Gastroenteritis Group|All children suffering with gastroenteritis
9957994|NCT01171157||Group 1|Subjects with influenza like illness
9957995|NCT01171170|Active Comparator|carboplatin-paclitaxel-bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
9957996|NCT01171170|Experimental|standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
9957997|NCT01171209|Experimental|IFN-alfa|One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
9957998|NCT01171209|Experimental|Interferon-beta|One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection
9957999|NCT01171222||veteran soccer players from Saarland County, Germany|
9958000|NCT01171248||type 1 diabetes|
9958001|NCT01171248||non-diabetics|
9958002|NCT01171261|Experimental|Jackie Chan Studio Fitness|The Jackie Chan Studio Fitness (J-MAT) cartridge includes four types of activities that use a four panel floor mat made of flexible material that functions as the wireless interface game controller. The celebrity actor and choreographer Jackie Chan is the avatar character in the game that demonstrates and guides users in four types of aerobic and anaerobic game modes.
9958003|NCT01171261|Experimental|XaviX Tennis|XaviX Tennis simulates tennis using a tennis racket controller and an infrared sensor to detect speed and timing of the player's swing of the racquet. The Tennis cartridge includes three playing modes. In Tournament Tour players select from eight different characters with different skills and play opponents in a bracketed tournament. In Exhibition mode players choose a computer opponent or play a tennis match with a friend. The Training Games mode includes a) Serving, b) Target Challenge, c) Serve & Finish, and d) Rally Time.
9958004|NCT01171261|Experimental|XaviX Bowling|XaviX Bowling uses a wireless bowling ball game controller to simulate bowling. The cartridge includes three modes. In Regular Game up to four people can select from 8 preset bowlers with different characteristics. In Tournament Mode up to eight people can play. Challenge Games consists of three games called Against the Clock, Moving Pins, and Panel Crusher.
9958005|NCT01171261|Experimental|XaviX Boxing|XaviX Boxing uses boxing gloves as the game controller and allows players to box against five different computer opponents in Championship and Exhibition modes and to practice boxing skills in Exercise mode. Exercise mode includes Punch Fast, Panel Toucher, Punch the Red Ball, and Combination Training.
9958006|NCT01171274|Active Comparator|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~One class of 90 minutes per week, 10 minutes training at home each day."
9958007|NCT01171274|Active Comparator|Exercise information|"9 weeks of exercises practiced at home.~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
9958008|NCT01171287|Experimental|Aircast Walker|Automobile driving with an Aircast Walker applied to each participant's right lower extremity
10215565|NCT03702400|Active Comparator|Phenylephrine 100 mcg|Phenylephrine will be used at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug to be used whenever systolic blood pressure falls below 10% of baseline.
9958009|NCT01171287|Experimental|Walking cast|Automobile driving with a walking cast applied to each participant's right lower extremity
9958010|NCT01171287|Active Comparator|Running shoe|Automobile driving with a running shoe applied to each participant's right lower extremity
9958011|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 4%|Minocycline Foam FXFM244 - 4%
9958012|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 1%|Minocycline Foam FXFM244 - 1%
9958013|NCT01171339|No Intervention|Control|"Usual care in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
9958014|NCT01171339|Experimental|Intervention arm|"Intervention: Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
9958015|NCT01171352||ICU Dialysis Patients|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
9958016|NCT01171365|Active Comparator|Ciclesonide|Ciclesonide 320 microgrammes twice daily
9958017|NCT01171365|Placebo Comparator|Placebo|Placebo 2 inhalations twice daily
9958018|NCT01171378|Other|Ofatumumab|Single arm study
9958019|NCT01171391|Experimental|VA106483 1mg|
9958020|NCT01171391|Experimental|VA106483 2mg|
9958021|NCT01171391|Experimental|VA106483 4mg|
9958022|NCT01171391|Placebo Comparator|Sugar pill|
9958023|NCT01171404||1|Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
9958024|NCT01171417||Cohort 1|1st-line Faslodex 500 mg
9958025|NCT01171417||Cohort 2|2nd-line Faslodex 500 mg
9958026|NCT01171417||Cohort 3|3rd- line Faslodex 500 mg
9958027|NCT01171417||Cohort 4|patients on exemestane
9958028|NCT01171430|Experimental|MRI WHOLE BODY|
9958029|NCT01171456|Placebo Comparator|Metformin Placebo|
9958030|NCT01171456|Active Comparator|Metformin|
9958031|NCT01171469|Experimental|Dose Level 3|15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
9958032|NCT01171469|Experimental|Dose Level 2|10 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
9958033|NCT01171469|Experimental|Dose Level 1|5 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
9958034|NCT01171482|Experimental|The FM group|Patients in the FM group will be administered 5-FU plus mitomycin
9958035|NCT01171482|Active Comparator|The sorafenib group|Patients in the sorafenib group will be administered sorafenib
9958036|NCT01171495|Experimental|Ensure Plus + Multivitamin/Counselling|
9958037|NCT01171495|Active Comparator|Multivitamin/Counselling|
9958038|NCT01171508||Breast cancer patients|12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.
9958039|NCT01171560|Active Comparator|EZ Blocker|Patients assigned to the EZ group will be intubated using a conventional tube in an adequate size as it is standard of care and single lung ventilation will be provided using the EZ-Blocker.
9958040|NCT01171560|Active Comparator|Double lumen tube|"The patients assigned to the double lume tube group will be intubated using the double lume tube in an adequate size as it is standard of care."
9958041|NCT01171573||Myositis Patients|Cases with myositis PM DM IBM Venepuncture
9958042|NCT01171573||Healthy controls|Control
10035250|NCT01804413|Active Comparator|Pegvisomant-glucagon test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
10215566|NCT03702400|Experimental|Norepinephrine 5 mcg|Norepinephrine will be used at a dose of 5 mcg at a dilution containing 1 mcg / mL to be used whenever systolic blood pressure falls below 10% of baseline.
10215567|NCT03702387|No Intervention|Control Group|Patients in this group will have standard intravenous regional anesthesia (IVRA) performed before the start of their surgery.
10215568|NCT03702387|Experimental|Esmarch Reapplication Group|Patients in this group will have all the standard intravenous regional anesthesia (IVRA) procedures performed before the start of their surgery with one exception: After standard intravenous regional anesthesia (IVRA) is performed, The elastic Esmarch bandage will be reapplied again on the same arm then will be released. then the surgery will be initiated. the only difference between groups is that the Esmarch reapplied group will be applied the esmach two times. First time, at the standard standard intravenous regional anesthesia (IVRA) before the lidocaine injection and second time, after the injection is completed.
10215569|NCT03702361|Experimental|Rapid infusion of Vpriv|Rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive patients with type 1 Gaucher disease
10215570|NCT03702348|Experimental|Resistance exercise group|Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
10215571|NCT03702348|No Intervention|Control group|No intervention during the 12 weeks, being contacted through telephone calls. After the reevaluation at the end of the 12 weeks, this group will perform the same protocol as the experimental group
10215572|NCT03702335|Experimental|Dietary Counselling|Each subject will receive a comprehensive dietary counselling for the first 12-weeks of the study, which will be followed by another 12-weeks without dietary counselling.
10215573|NCT03702335|No Intervention|No Dietary Counselling|Subjects in the control group will be followed for 24-weeks without any dietary counselling.
9958043|NCT01171586|Experimental|SMS Only|"The SMS only group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The SMS only group will also receive a brief printed or web based outline on weight loss resources and information."
9958044|NCT01171586|Experimental|SMS + Phone Counseling|"This group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The group will also receive monthly counseling calls from a Health Coach to discuss barriers and solutions and will receive a brief printed or web based outline on weight loss resources and information."
9958045|NCT01171586|No Intervention|Control|The Control group will receive a binder with an attractive set of Standard Print Materials related to weight loss that is comparable to what one would receive from community resources such as libraries, magazines and national non-profit or governmental organizations such as 5-A Day, American Heart Association and the like.
9958046|NCT01171638||Critical Controls|"Critically injured patients with NO severe traumatic lower extremity injuries to provide normative data for the critically injured physiological status upon arrival at study site"
10005820|NCT01588678|Experimental|DS-3078a|"Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.~Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.~Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects."
10005821|NCT01588691|Active Comparator|Low frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
10005822|NCT01588691|Active Comparator|High frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
10005823|NCT01588691|Placebo Comparator|No stimulation|Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
10005824|NCT01588704|Experimental|Neoadjuvant Bevacizumab|Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.
10035251|NCT01804413|Active Comparator|Insulin tolerance test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
10035252|NCT01804426||Trauma Exposed participants|18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).
10035253|NCT01804439||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
10035254|NCT01804452||Subjects with a diagnosis of PSP or CBD|
10035255|NCT01804478|Experimental|Pneumatic Compression|Both diabetic and control subjects will undergo mild pneumatic compression while tissue oxygenation and blood flow are recorded with a non-invasive NIRS and PPG device
10035256|NCT01804491||Control group|Healthy age matched control subjects
10035257|NCT01804491||Cheilectomy prospective group|"Patients with hallux rigidus treated by the surgery type cheilectomy"
10035258|NCT01804491||Arthrodesis prospective group|"Patients with hallux rigidus treated by the type of surgery arthrodesis"
10035259|NCT01804491||Mixed prospective group|"Patients with hallux rigidus treated by other type of surgery: Arthoplasty, joint resection (Keller-Brandes technique)"
10035260|NCT01804491||Cheilectomy retrospective group|Patients after cheilectomy due to hallux rigidus
10035261|NCT01804491||Arthrodesis retrospective group|Patients after arthrodesis of the metatarsophalageal joint due to hallux rigidus
10035262|NCT01804491||Mixed retrospective group|Patients after other types of surgery due to hallux rigidus: arthroplasty or resection of the first metatarso-phalangeal joint
10215574|NCT03702322|Other|Participants|All participants will undergo each treatment.
10215575|NCT03702296|Other|Intervention|Patients will be provided with ear plugs and eye masks, to be used from 10pm to 6am, for 3 days post-operatively.
10215576|NCT03702296|No Intervention|Control|No ear plugs or eye masks provided.
10215577|NCT03702244|No Intervention|Usual Care|For participants randomized to usual care, the participant's care team will select the specific noninvasive stress test (exercise electrocardiogram, stress nuclear imaging [including PET], stress MR, or stress echocardiogram); OR invasive test: (direct to diagnostic catheterization).
10215578|NCT03702244|Other|Precision evaluation|Participants randomized to a precision strategy will be assigned to either guideline-recommended care without immediately planned testing (low risk) or cCTA with selective FFRct (elevated risk) using a risk tool based on pretest clinical characteristics derived from the PROMISE trial and validated in SCOT-HEART trial. Participants assigned to guideline-recommended care without planned testing will be treated with preventive and antianginal medical treatment per guideline recommendations and clinical judgment and followed without testing.
9958047|NCT01171638||Investigational cohort|"Soldiers with severe traumatic lower extremity injuries in stable or critical physiological status presenting to a participating study site within 12 hours of their injury, to provide data on the acute post-injury phase. This cohort will be made up of:~Patients meeting inclusion criteria for investigational cohort, who have UNILATERAL severe lower extremity injuries~Patients meeting inclusion criteria for investigational cohort, who have BILATERAL severe lower extremity injuries.~Patients meeting inclusion criteria for investigational cohort, who have been clinically diagnosed by the treating provider using that treating providers standards for diagnosing ACS and the patient in addition to be diagnosed with ACS undergoes four-compartment leg fasciotomy."
9958048|NCT01171651|Experimental|JX-594 followed by sorafenib|1e9 pfu (plaque-forming units) total JX-594 dose on each of up to four (4) JX-594 treatment days. Sorafenib is initiated after 3 JX-594 treatments and briefly interrupted if an optional 4th JX-594 treatment is given.
9958049|NCT01171664|Placebo Comparator|Placebo|Placebo containing no active pharmaceutical ingredients
9958050|NCT01171664|Experimental|STAHIST|STAHIST tablet for the symptomatic treatment of Seasonal Allergic Rhinitis
9958051|NCT01171703|Experimental|bypass|femoral-popliteal bypass
9958052|NCT01171703|Experimental|stent|
9958053|NCT01171716|Other|Dietary Protein Intake|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
9958054|NCT01171742|Experimental|IHIO|Intermittent hepatic inflow occlusion (IHIO) by clamping of the portal triad, minimizes blood loss and operation time during liver resection. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. IHIO'll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
9958055|NCT01171742|Sham Comparator|Control|The donor liver parenchyma'll be transected without IHIO.
9958056|NCT01171755|Experimental|Gemcitabine, Ts-1|Gemcitabine : 1000/m2 will be administered on days 1 and 8 at every 3 weeks . TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
9958057|NCT01171768||patients with hemoptysis within 2 weeks|
9958058|NCT01171768||patients without hemoptysis within 2 years|
9958059|NCT01171781|Active Comparator|3 weekly CDDP based CCRT|radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin
9958060|NCT01171781|Experimental|weekly cisplatin based CCRT|radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy
9958061|NCT01171807|Active Comparator|Dexamethasone 21-phosphate encapsulated into red cells|
9958062|NCT01171807|Sham Comparator|Placebo|
9958063|NCT01171833|Experimental|Group A(Sevoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
9958064|NCT01171833|Experimental|Group B(Desflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
9958065|NCT01171833|Experimental|Group C(Isoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
9958066|NCT01171846|Active Comparator|Physiotherapy|
9958067|NCT01171846|No Intervention|Control|Women allocated to the Control group will only receive, by post, the same Lifestyle Advice Sheet as the intervention group.
9958068|NCT01171859|Experimental|Doxycycline + Tauroursodeoxycholic acid|
9958069|NCT01171872||Unaffected|Individuals who do not have IBD
9517908|NCT03301805|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
9958070|NCT01171872||Affected|Individuals who have IBD
9958071|NCT01171885|Placebo Comparator|Placebo|Bilateral superficial cervical block.
9958072|NCT01171885|Experimental|Ropivacaine 0.25%|Bilateral superficial cervical block
9958073|NCT01171885|Experimental|Ropivacaine 0.5%|Bilateral superficial cervical block.
10005825|NCT01588717|Experimental|glycopyrrolate|glycopyrrolate 2 to 6 mg/day
10005826|NCT01588730|Experimental|Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours).
9958074|NCT01171937|Active Comparator|Open-Label Risperidone|Risperidone oral solution (1mg/mL) qd for 8 weeks.
9958075|NCT01171937|Placebo Comparator|Placebo|Placebo
9958076|NCT01171950|Other|All Patients|All patients meeting the patient selection criteria will be treated with the CentriMag device.
9958077|NCT01172002|Experimental|leflunomide group|
9958078|NCT01172002|Active Comparator|Azathioprine group|
9958079|NCT01172015|Experimental|PTI patients|Study NK cells functions, phenotypic changes and transcripts from ITP patients
9958080|NCT01172015|Other|healthy volunteers|Study NK cells functions, phenotypic changes and transcripts from healthy volunteers
9958081|NCT01172028|Experimental|Alimta and Taxotere|Alimta and Taxotere given in combination with dose modifications.
9958082|NCT01172054|Experimental|VAX128|Novel H1N1 Influenza vaccine
9958083|NCT01172054|Placebo Comparator|Placebo|one IM injection
9958084|NCT01172080|No Intervention|control|Participants in this group are monitored for adherence to colonoscopy recommendations.
9958085|NCT01172080|Experimental|intervention|Participants to receive a protocol of reminder letters and a phone call regarding due follow up colonoscopy
9958086|NCT01172106|Placebo Comparator|Encouragement on drug compliance|The intervention for the placebo comparator will be encouragement on drug compliance
9958087|NCT01172106|Experimental|Family psychoeducation|The experimental group will receive weekly sessions of psychoeducation for 12 weeks in addition to receiving drug compliance encouragement
9958088|NCT01172119|Experimental|BioFreedom Standard Dose|
9958089|NCT01172119|Experimental|BioFreedom Low Dose|
9958090|NCT01172119|Active Comparator|Taxus Liberte drug eluting stents|
9958091|NCT01172158||Forgotten ureteral stents|
9958092|NCT01172171|Active Comparator|Melatonin|The randomized patients will receive 10 ml 0,1 mg/ml melatonin intracoronarily and 49 mg intravenously.
9958093|NCT01172171|Placebo Comparator|Isotonic saline|The randomized patients will receive 10 ml isotonic saline (NaCl)and 490 ml intravenously.
9958094|NCT01172210||Bulimia Nervosa|
9958095|NCT01172210||Bulimia Nervosa w/ Alcohol Use Disorder|
9958096|NCT01172210||Healthy Controls|
9667618|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
9667619|NCT03327857|Experimental|Neihulizumab (AbGn-168H)|Intravenous doses of Neihulizumab (AbGn-168H)
9958097|NCT01172223|Experimental|LAPADO|Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks), Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery)
9958098|NCT01172236|Experimental|Lactoferrin|
9958099|NCT01172249|Experimental|Glucosamine-Chondroitin Mantecorp|1 capsule three times daily before meals (drug test - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Mantecorp)
9958100|NCT01172249|Active Comparator|Condroflex|1 capsule three times daily before meals (reference medication - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Condroflex ®).
9958101|NCT01172262||Bothered Tinnitus|Either responds with a Global Tinnitus Scale of Moderately or Severely Bothered. Score >30 on the Tinnitus Handicap Index (THI).
9958102|NCT01172301|Experimental|Oral EAA vs total AA supplement|
9958103|NCT01172314|Experimental|EAA+LEU vs total AA|
9958104|NCT01172314|Experimental|Total AA vs EAA+LEU|
9958105|NCT01172327|Experimental|Multicomponent exercise|This arm is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks.
9958106|NCT01172327|Active Comparator|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks.
9958107|NCT01172340|Experimental|Behavioral and support intervention|one individual counseling session with diet and exercise recommendations plus 16 weeks of group sessions, plus 8 weeks of phone followup
9958108|NCT01172340|Placebo Comparator|wait-listed control group|Controls receive individual counseling session and recommendations, mailed health information, and after post-test measures are offered an abbreviated group-based intervention
9958109|NCT01172379|Experimental|Experimental 1|
9958110|NCT01172379|Experimental|Experimental 2|
9958111|NCT01172379|Experimental|Experimental 3|
9958112|NCT01172379|Placebo Comparator|Placebo Comparator|
9958113|NCT01172392|Experimental|PegIFN + Nucleosidic or Nucleotidic Analog|
9958114|NCT01172392|Active Comparator|Nucleosidic or Nucleotidic Analog|
9958115|NCT01172405|Experimental|Ibuprofen + Caffeine|72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
9958116|NCT01172405|Active Comparator|Ibuprofen|72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.
9958117|NCT01172431|Experimental|Indapamide|Indapamide SR 1.5mg qd
9958118|NCT01172431|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
9958119|NCT01172444|Experimental|Test|Sandoz Mesalamine 1 g Suppository
9958120|NCT01172444|Active Comparator|Reference|Canasa 1 g Suppository
9958121|NCT01172444|Placebo Comparator|Placebo|Sandoz 1 g Placebo Suppository
9958122|NCT01172457|Active Comparator|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
9958123|NCT01172457|Placebo Comparator|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
9958124|NCT01172483|Experimental|multimodal community program|multimodal community program of exercise and education
9958125|NCT01172483|Active Comparator|active control|general practice in primary care and education of chronic disorders
9958126|NCT01172496|Experimental|1 mg tablet; 1mg solution|
9958127|NCT01172496|Experimental|1mg solution; 1mg tablet|
9958128|NCT01172509|Placebo Comparator|sugar pill|placebo administered under double blind conditions
9958129|NCT01172509|Experimental|3 mg of R-baclofen|3 mg of R-Baclofen administered double blind
9958130|NCT01172509|Experimental|10 mg of R-baclofen|10 mg of R-baclofen administered double-blind
9958131|NCT01172509|Experimental|25 mg of R-baclofen|25 mg of R-baclofen administered double blind
9958132|NCT01172509|Placebo Comparator|second sugar pill|the second placebo administered double blind
9958133|NCT01172548|Experimental|imatinib mesylate|
9958134|NCT01172561|Active Comparator|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
9958135|NCT01172561|Experimental|Lay Health Advisor Intervention|The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
9958136|NCT01172574|Experimental|Motor control exercise|Subjects of the exercise group underwent a 3-month (13-week) treatment program directed on 3-weekly 1-hr one-to-one sessions by the researcher who had experience in the specific exercise treatment of the spinal region. During the next 3 months, the subjects were urged to perform the exercises alone at home at least once a day, and compliance was monitored by the activity quota chart given to them at the beginning of each study-month.
9958137|NCT01172574|No Intervention|Control group|The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.
9958138|NCT01172587|Experimental|Lifestyle Counseling|Couples receive behavioral couples therapy for parental drug use.
9958139|NCT01172613||healthy subjects no symptoms|
9958140|NCT01172613||allergic rhinitis patient|
9958141|NCT01172626||epileptic patients|epileptic patients receiving treatment with continuous Sodium Valproate
9958142|NCT01172652|Experimental|ziprasidone|
9958143|NCT01172652|Placebo Comparator|Placebo|
9958144|NCT01172691|Experimental|Placebo and Study|
9958145|NCT01172704|Active Comparator|Care as Usual|Participants randomized to CAU receive the standard care given to patients of the Boston Medical Center who are interested in learning more about HIV/AIDS. Included in this care would be referrals for HIV counseling and testing.
9958146|NCT01172704|Experimental|Skills Building - Motivational Interviewing|Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback & Building Motivation; Session 2: Building Motivation & Skill Selection and Practice; Session 3: Developing Change Plan & Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation & Skill Practice.
9958147|NCT01172717|Experimental|Panitumumab|Single arm study
9958148|NCT01172730||Ultrasound scanning|
9958149|NCT01172743||Diabetes|Individuals with diabetes that fit eligibility criteria.
9958150|NCT01172743||Normal Control|Individuals without history of diabetes.
9958151|NCT01172756|Experimental|Arm 1|
9958152|NCT01172756|Experimental|Arm 2|
9958153|NCT01172756|Experimental|Arm 3|
9958154|NCT01172756|Placebo Comparator|Arm 4|
9958155|NCT01172769|Experimental|Temsirolimus|
9958156|NCT01172782|Placebo Comparator|control group|control group (CG) received 6 mg of hyperbaric bupivacaine and 0.05 mL of saline.
9958157|NCT01172782|Active Comparator|2.5 ug hydromorphone recieved group|the 2.5 μg hydromorphone group (2.5HG) received 1.2 (6 mg) mL of 0.5% hyperbaric bupivacaine and 2.5 μg of hydromorphone in 0.05 mL of saline
9958158|NCT01172782|Active Comparator|5 μg hydromorphone group|5 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 5 μg of hydromorphone in 0.05 mL of saline
9958159|NCT01172782|Active Comparator|the 10 μg hydromorpnone group|the 10 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 10 μg of hydromorphone in 0.05 mL of saline.
9958160|NCT01172795||healthy controls|
9958161|NCT01172795||chronic whiplash patients|
9958162|NCT01172795||Fibromyalgia patients|
9958163|NCT01172834|Experimental|Lifestyle counseling|
9958164|NCT01172860|Experimental|EndoVe treatment|Use of the EndoVe device to safely and effectively ablate rectal tumor tissue
9958165|NCT01172899|Experimental|Laparoscopic adjustable gastric band|
9958166|NCT01172899|Active Comparator|Control group|
9958167|NCT01172925|Experimental|Tiotropium|Inhaler
9958168|NCT01172925|Placebo Comparator|Placebo|Inhaler
9958169|NCT01172951|Active Comparator|OGTT-OGTT-Physical tests|2 successive Oral Glucose Tolerance Tests followed by a physical tests session
9958170|NCT01172951|Active Comparator|OLTT-OLTT-Physical tests|2 successive Oral Lipid Tolerance Tests followed by a physical test session
9958171|NCT01172951|Active Comparator|OGTT-OLTT-Physical tests|Oral glucose tolerance test followed by an oral lipid tolerance test (or vice-versa) followed by a physical tests session
9958172|NCT01172964|Experimental|Arm I|Patients undergo debulking craniotomy and receive injections of HB1.F3.CD neural stem cells directly into brain tissue on day 0. Patients then receive oral 5-fluorocytosine every 6 hours on days 4-10 in the absence of disease progression or unacceptable toxicity.
9958173|NCT01172977||HbA1c ≤ 7|Stroke patients with mild diabetes mellitus HbA1c ≤ 7
9958174|NCT01172977||HbA1c ≥ 7,5|Stroke patients with severe diabetes mellitus HbA1c ≥ 7,5
9958175|NCT01172990|Experimental|Conventional Group|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
9958176|NCT01172990|Active Comparator|Immediate Invasive Group|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines
9958177|NCT01173042|Placebo Comparator|Control|Shake containing heavy whipping cream, glucose and chocolate syrup
9958178|NCT01173042|Experimental|Peanut|Shake containing control (whipping cream, glucose and chocolate syrup) + 3oz of peanuts
9958179|NCT01173042|Experimental|Oil blend|Shake containing control (heavy whipping cream, glucose and chocolate syrup) + oil blend (equivalent to fatty acids provided in 3oz peanuts)
9958180|NCT01173081|Experimental|Teriparatide|Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
9958181|NCT01173081|Placebo Comparator|Placebo Control|Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
9958182|NCT01173094|Experimental|PTA|The patients with short-obstruction in the below-knee artery will be included in this group.
9958183|NCT01173094|Experimental|bypass|The patients with long-obstruction in the below-knee artery will be included in this group.
9958184|NCT01173107|Experimental|MDRD eGFR 10~50 ml/min/1.73m2|
9958185|NCT01173172|Experimental|BNCT, recurrent head and neck cancer|Single arm treated by BNCT only
9958186|NCT01173198|Active Comparator|WAVEFRONT GUIDED LASIK|
9958187|NCT01173198|Active Comparator|WAVEFRONT OPTIMIZED|
9958188|NCT01173224|Experimental|Cohort 2: 20 mg 10 days|Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg).
9958189|NCT01173224|Experimental|Cohort 3: 30 mg 1 day|Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
9958190|NCT01173224|Experimental|Cohort 1: 20 mg, 1 day|Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg).
9958191|NCT01173237|Active Comparator|Tracheal intubation|Endotracheal tube is a airway device used for ventilation or surfactant administration, in preterm babies with SDR surfactant deficiency.
9958192|NCT01173237|Experimental|Proseal laryngeal mask airway|Laryngeal mask airway is a airway device used for ventilation with self-inflating bag or flow-inflating bag. In this study it will be used for surfactant administration, in preterm babies with SDR surfactant deficiency.
9958193|NCT01173250|Active Comparator|stapled ileoanal pouch without diverting ileostomy|
9958194|NCT01173250|Placebo Comparator|stapled ileoanal pouch with diverting ileostomy|
9958195|NCT01173263|Active Comparator|BIS 70|BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
9958196|NCT01173263|Active Comparator|BIS 50|BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)
9958197|NCT01173263|Active Comparator|BIS 35|BIS levels of 35 will be targeted (low frequency EEG activity)
9958198|NCT01173289|Experimental|External Beam Radiotherapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning :~Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
9958199|NCT01173302|Experimental|Post vaccination|All the subjects had been vaccinated with antirabies vaccine.
9958200|NCT01173315|Experimental|Group MV|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg
9958201|NCT01173315|Experimental|Group MVB|Group MVB: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg)plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg)
9958202|NCT01173315|Placebo Comparator|Group P|Group P: starch (placebo
9958203|NCT01173328|Experimental|Pursed-lip Breathing|
9958204|NCT01173354|Experimental|COPD patients only|Free balanced amino acid mixture or free essential amino acid mixture
9958205|NCT01173367|Active Comparator|Aggressive Fever Treatment|
9958206|NCT01173367|Active Comparator|Permissive Fever Treatment|
9958207|NCT01173380|Sham Comparator|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
10005827|NCT01588730|Active Comparator|Static Splint|The control group will be treated with a static splint for a minimum of 6 4 hours each night while sleeping with the end goal of 6-8 hours.
10005828|NCT01588756|Experimental|AcSDKP-NH2 inuline|AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less
9958208|NCT01173380|Active Comparator|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
10005829|NCT01588756|Experimental|AcSDKP-NH2 Cr-EDTA|AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less
9958209|NCT01173393|No Intervention|Standard Treatment|"For patients randomised to hospital cooling:~LMA/ Intubation and ventilation with 100% oxygen~Measure temperature using tympanic probe and record~Insert IV line and administer drugs as per protocol~Fluid challenge with standard temperature saline only as per current guideline (suspected hypovolemia)~Post resuscitation: midazolam 1-5 mg only to maintain LMA/ intubation as needed.~Pancuronium 8 mg only if intubation unable to be maintained with midazolam.~After arrival at the Emergency Department, all patients receive standard care."
9958210|NCT01173406|Sham Comparator|Standard care (SC)|Standard care
9958211|NCT01173406|Active Comparator|Extended education (ME+SC)|Motivational enhancement education + Standard care
9958212|NCT01173419|Active Comparator|VenaCure EVLT NeverTouch|
9958213|NCT01173419|Active Comparator|RF ClosureFAST|
9958214|NCT01173432|Active Comparator|continuous positive airway pressure|using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
9958215|NCT01173432|No Intervention|control|observation for the study period (4 weeks, no CPAP)
9958216|NCT01173458||Blood Draw|"Approximately 1 and one-half teaspoons of blood will be drawn at times specified.~one sample prior to treatment initiation~one sample after completion of treatment~one sample every 6 to 8 weeks during follow up visits~one sample at the time of Relapse"
9958217|NCT01173484||Vomiting-predominant idiopathic gastroparesis|Vomiting with retching and nausea are the most bothersome symptoms
9667620|NCT03326921|Experimental|Treatment (CD4+ and CD8+ HA-1 TCR T cells)|Patients receive fludarabine for 1-3 doses 3-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV over 1 hour.
9958218|NCT01173484||Dyspepsia-predominant idiopathic gastroparesis|Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
9958219|NCT01173484||Regurgitation-predominant idiopathic gastroparesis|Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
9958220|NCT01173510|Experimental|Raltegravir plus tenofovir/emtricitabine|
9958221|NCT01173510|Active Comparator|Efavirenz/Emtricitabine/Tenofovir|
9958222|NCT01173536|Active Comparator|A|
9958223|NCT01173536|Active Comparator|B|
9958224|NCT01173536|Experimental|C|
9958225|NCT01173549|Experimental|001|no intervention Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
9958226|NCT01173549|Experimental|002|Canagliflozin/Placebo Placebo/Canagliflozin Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
9958227|NCT01173562|Experimental|Mebendazole|
9958228|NCT01173575||Bacterial Infection|All Patients with bacterial infection receiving fosfomycin may be included
9958229|NCT01173588|Experimental|Yogurt+fiber+probiotic|Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
9958230|NCT01173588|Placebo Comparator|regular yogurt|yogurt YR had no additional fiber or bifidobacterium
9958231|NCT01173614||Normal subjects|Subjects with two normal eyes.
9958232|NCT01173627|Experimental|A - Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche
9958233|NCT01173627|Active Comparator|B - Actiq 400 mcg|Actiq 400 mcg
9958234|NCT01173640|Experimental|Midazolam Alone|Baseline pharmacokinetics. On Study Visit Day 1, subjects will receive a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
10005830|NCT01588769|Experimental|One arm|3 doses of ALECSAT cell based immunotherapy planned for all enrolled patients
9958235|NCT01173640|Experimental|Single dose resveratrol|On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
9958236|NCT01173640|Experimental|Multiple dose resveratrol|Between Study Visit Days 8 and 15, subjects will take a 1 g dose of resveratrol daily. On Study Visit Day 15, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
9958237|NCT01173666|Placebo Comparator|Drug therapy|Patients will be treated by standard medical therapy.
9476596|NCT03570320|Experimental|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
9958238|NCT01173666|Experimental|Drug therapy + stenting angioplasty|Patients will be treated by standard medical therapy + stenting angioplasty of renal artery.
10005831|NCT01588782|Experimental|Abiraterone acetate|All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.
10005832|NCT01588795|Experimental|Denervation + TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
10005833|NCT01588795|Active Comparator|TMNS|Patients are maintained on standardized anti-proteinuric medications
10005834|NCT01588808|Active Comparator|Immobilization with protein (elderly)|Immobilization with twice-daily protein supplementation - in the elderly
10005835|NCT01588808|Placebo Comparator|Immobilization without protein (elderly)|Immobilization without twice-daily protein supplementation - in the elderly
10005836|NCT01588808|Active Comparator|Immobilization without protein (young)|Immobilization without twice-daily protein supplementation - in the young
10005837|NCT01588847|Experimental|Regional anesthesia|
10005838|NCT01588847|Active Comparator|General anesthesia|
10005839|NCT01588873|Active Comparator|Oral contraceptive pill|
10005840|NCT01588873|Active Comparator|Contraceptive ring|
10005841|NCT01588886||with PPI|CKD with PPI use, follow up at least 5 years began PPI use
10005842|NCT01588886||with or without Pneumonia outcome|Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting.
10005843|NCT01588899|Experimental|MR-HIFU Treatment|Patients in this arm will receive MR-HIFU uterine fibroid treatment
10005844|NCT01588912|Experimental|Telbivudine-Tenofovir roadmap|
10005845|NCT01588912|Active Comparator|Entecavir|
9476597|NCT03570307|Other|drug treatment|Misoprostol for uterine evacuation
10005846|NCT01588925|Experimental|Control group|Cochlear Implantation
10005847|NCT01588925|Active Comparator|Dexamethasone|Cochlear implantation using topical dexamethasone
10005848|NCT01588925|Active Comparator|Dexamethasone+Hyaluronic acid|Cochlear implantation using topical dexamethasone associated with hyaluronic acid
10005849|NCT01588964|Experimental|HIPEC|Surgery plus HIPEC
10005850|NCT01588977||All-Inside TightRope technique|
10005851|NCT01588977||ACL reconstruction with TLS system|
10005852|NCT01588977||Hamstring Tendon Graft Reconstruction of the ACL|
10005853|NCT01589003|Active Comparator|Low GI group|Low Glycaemic index growing up milk
10005854|NCT01589003|Other|High GI group|Hi Glycaemic index growing up milk
10005855|NCT01589016||PUL (pregnancy of unknown location),|
10005856|NCT01589016||EP ( ectopic pregnancies P)|
10005857|NCT01589016||IUP-singleton intrauterine pregnancies|
10005858|NCT01589029|Other|CANAKINUMAB (ILARIS®)|
10005859|NCT01589042||Above the Knee|Patients treated with the Chocolate balloon for a lesion located above the knee
10005860|NCT01589042||Below the Knee|Patients treated with the Chocolate balloon for a lesion located below the knee
10005861|NCT01589055|Active Comparator|Male Smokers|
10005862|NCT01589055|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
10005863|NCT01589055|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
10005864|NCT01589068|Active Comparator|Male Smokers|
10005865|NCT01589068|Active Comparator|Female Smokers (Follicular Phase)|
10005866|NCT01589068|Active Comparator|Female Smokers (Luteal Phase)|
10005867|NCT01589081|Active Comparator|Female Smokers (Luteal Phase)|
10005868|NCT01589081|Active Comparator|Female Smokers (Follicular Phase)|
10005869|NCT01589107|No Intervention|control group|usual care
10005870|NCT01589107|Experimental|Video Arm|
10005871|NCT01589120|No Intervention|control group|Verbal description of goals of care reflecting usual care
10005872|NCT01589120|Experimental|Video Arm|Video intervention group
10005873|NCT01589146|No Intervention|short heparin|
10005874|NCT01589146|Experimental|extended heparin|
10005875|NCT01589159|Experimental|Experimental|
10005876|NCT01589172||Pediatric Brain Trauma Patients|
10005877|NCT01589211|Active Comparator|Brief advice|A brief advice to stop smoking of about 10 min accompanied with self-help material
10005878|NCT01589211|Experimental|Compact cessation course|Cessation intervention of 2 x 120 min in a group setting
10005879|NCT01589211|Active Comparator|Standard cessation course|Cessation course in a group setting over 6 dates
10005880|NCT01589224||Healthy people|
10005881|NCT01589276||Emergency hernia repairs|
10005882|NCT01589276||Elective hernia repairs|
9958239|NCT01173705||Normal weight: abdominal surgery|Lean individuals undergoing elective abdominal surgery
9958240|NCT01173705||Obese: abdominal or bariatic surgery|Obese subjects undergoing elective abdominal or bariatric surgery
9958241|NCT01173744|Experimental|Gamma-3 Nail|
9958242|NCT01173744|Active Comparator|DHS|
9958243|NCT01173757|Experimental|PF-04995274|
9958244|NCT01173770|Experimental|Cohort 1: ADC3680B vs. Placebo|
9958245|NCT01173770|Experimental|Cohort 2: ADC3680B vs. Placebo|
9958246|NCT01173770|Experimental|Cohort 3: ADC3680B vs Placebo|
9958247|NCT01173770|Experimental|Cohort 4: ADC3680B vs. Placebo|
9958248|NCT01173770|Experimental|Cohort 5: ADC3680B vs. Placebo|
9958249|NCT01173770|Experimental|Cohort 6: ADC3680B|
9958250|NCT01173796|Experimental|PMFL ablation|Radio-frequency catheter ablation of the mitral isthmus only
9958251|NCT01173796|Experimental|Repeat PVAI and triggers ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
9958252|NCT01173809|Active Comparator|Control|Patient will continue taking Amiodarone before, during and after catheter ablation (8 weeks post-ablation).
9958253|NCT01173809|Active Comparator|Study|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
9958254|NCT01173822|Experimental|Treatment group|Ultra filtration of residual blood.
9958255|NCT01173822|No Intervention|Control|The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
9958256|NCT01173861|Experimental|Physical activity counseling|Group receives face-to-face physical activity counseling.
9958257|NCT01173861|Active Comparator|Manual|Group receives physical activity manual.
9958258|NCT01173887|Active Comparator|mLSG15|
9958259|NCT01173887|Experimental|mLSG15 + KW-0761|
9958260|NCT01173900|Other|Class-based delivery|All girls attending standard 6 in schools selected for class-based vaccine delivery
9476598|NCT03570307|Other|surgical treatment|dilatation and curettage for uterine evacuation
9958261|NCT01173900|Other|Age-based delivery|All girls born in 1998 attending schools selected for age-based delivery
9958262|NCT01173913|Experimental|ModraDoc001 10 mg capsules|The optimal dose weekly bi-daily oral docetaxel - ModraDoc001 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
9958263|NCT01173913|Experimental|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|Both new oral dosage forms, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets will be investigated to see whether these new formulations have comparable pharmacokinetic characteristics, in terms of systemic exposure to docetaxel, as ModraDoc001 10 mg capsule.
9958264|NCT01173913|Experimental|ModraDoc006 10 mg tablet|The optimal dose weekly bi-daily oral docetaxel - ModraDoc006 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
9958265|NCT01173926|Experimental|IAsp|
9958266|NCT01173926|Experimental|IDeg|
9958267|NCT01173926|Experimental|IDegAsp|
9958268|NCT01173939|Active Comparator|Active comparator: Standard Pravastatin Group|
9958269|NCT01173939|Active Comparator|Intensive Rosuvastatin Group|
9958270|NCT01173965|Active Comparator|Endometrial ablation with microwaves|Endometrial ablation with the use of MEA(microwaves endometrial ablation device)
9958271|NCT01173965|Active Comparator|Endometrial ablation with bipolar diathermy|Endometrial ablation with Novasure(bipolar impedence control system)
9958272|NCT01173978|Experimental|No intervention|Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
9958273|NCT01173978|Experimental|Intervention|Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
9958274|NCT01173991|Experimental|Carbohydrate counting|This group received carbohydrate counting training
9958275|NCT01173991|No Intervention|Controls|This group received standard education
9958276|NCT01174017|Active Comparator|Standard loose Iodine 125 seeds|Prostate brachytherapy implant to be performed with standard format loose Iodine 125 seeds
9958277|NCT01174017|Experimental|AnchorSeed Iodine 125 implant|Prostate brachytherapy implant to be performed with a new design of Iodine 125 seed that has a coating to increase adherence to tissue
9958278|NCT01174056|Experimental|Pioglitazone+zileuton placebo|Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days
9958279|NCT01174056|Experimental|Zileuton+pioglitazone placebo|Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days
9958280|NCT01174056|Sham Comparator|Pioglitazone placebo+zileuton placebo|Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days
9958281|NCT01174069|Experimental|NOTES cholecystectomy|
9958282|NCT01174095||Follow-up Group|"Subjects who received AdGVVEGF121cDNA in either IRB protocol #0794-894 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease or IRB protocol #0297-693 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."
9958283|NCT01174134|Placebo Comparator|Milk-based beverage w/out DHA|
9958284|NCT01174134|Experimental|Milk-based beverage with DHA|
9958285|NCT01174134|Experimental|Milk-based beverage containing DHA at a higher level|
9958286|NCT01174147||Hospital Candida Cases|People who developed a positive blood culture for Candida while hospitalized
9958287|NCT01174199|Experimental|Arm I|Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9958288|NCT01174212|Experimental|Experimental|Patients receiving antibiotics approximately 1 hour prior to incision are considered to be in the experimental group of this study.
9958289|NCT01174212|Other|Control|Control group is to receive no antibiotics until the intraoperative cultures have been obtained.
9958290|NCT01174225|Active Comparator|I|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Flexi T 380(+) IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
9958291|NCT01174225|Active Comparator|II|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Nova T IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
9958292|NCT01174225|No Intervention|III|"Participants who elect for forms of contraception other than a copper IUD will chose which form of contraception they would like to use and be put into one of the groups specified below based on her contraceptive choice. These participants will be observed throughout the study for overall satisfaction and repeat pregnancy rate.~Groups - Participants will be in one of the five following groups Group A - Oral contraceptive pill 28day supply provided after abortion Group B - Medroxyprogesterone acetate (Depo-provera)150mg IM provided after abortion, lasts for 3 months Group C - Ethinyl estradiol and etonogestrel (Nuva ring) provided at time of abortion, lasts for 28 days Group D - Condoms provided at time of abortion Group E - Other"
9958293|NCT01174277||Collection of blood sample|Blood draw
9958294|NCT01174290|Experimental|Haloperidol 1mg IV q6h|
9958295|NCT01174290|Placebo Comparator|D5W 0.2mL IV q6h|
9958296|NCT01174303|Experimental|IDegAsp - BIAsp|
9958297|NCT01174303|Experimental|BIAsp - IDegAsp|
9958298|NCT01174316|Experimental|autotitrating NIV|approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
9958299|NCT01174316|Active Comparator|Standard non-invasive ventilation|approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
9958300|NCT01174329|Experimental|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"Patient regulated (by a remote control) neuro-electrostimulation by Saliwell Crown"
9958301|NCT01174329|Active Comparator|"Automatic neuro-electrostimulation by Saliwell Crown"|No remote control used
9958302|NCT01174355|Experimental|ND0801|
9958303|NCT01174381|Experimental|Lifestyle modification|Lifestyle modification for behavior change related to NCD prevention
9958304|NCT01174394|Experimental|DCEAS|"Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
9958305|NCT01174394|Placebo Comparator|n-CEA|"Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
9958306|NCT01174407||cd35|
9958307|NCT01174420|Experimental|ologen Collagen Matrix|
9958308|NCT01174420|Active Comparator|Mitomycin-C (MMC)|
9958309|NCT01174433|Experimental|Tryton bifurcation stent system|
9958310|NCT01174472|Active Comparator|Conventional Balloon Angioplasty (COBA)|Patients with lesions treated with conventional balloon angioplasty
9958311|NCT01174472|Experimental|Drug Eluting Balloon Angioplasty (DEB)|Patients with lesions treated with Drug Balloon Angioplasty
9958312|NCT01174485|Experimental|exercise|exercise plus liposuction
9958313|NCT01174485|No Intervention|sedentary|physical inactivity plus liposuction
9958314|NCT01174498|Active Comparator|t-VNS sytem Vagus stimulation|Subjects experience a transcutaneous vagal stimulation by the t-VNS device
9958315|NCT01174498|Sham Comparator|Sham transcutaneous stimulation|Sham stimulation with an attached t-VNS device
9958316|NCT01174511|Experimental|A-1 COOL cream|"A research product - A-1 COOL cream contain herbal medicine plants basically :~WATER PETROLATUM~WILD YAM (DIOSCOREA VILLOSA) EXTRACT~SORBITAN SESQUIOLEATE~CALENDULA OFFICINALIS EXTRACT~MINERAL OIL~ARNICA MONTANA EXTRACT~MICROCRYSTALLINE WAX~LICORICE (GLYCYRRHIZA GLABRA) EXTRACT~DECYL OLEATE~DICOCOYL PENTAERYTHRITYL DISTEARYL CITRATE~BEESWAX~ALUMINUM STEARATES"
9476599|NCT03570294|Other|Atosiban|Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.
9958317|NCT01174511|Placebo Comparator|Vaselin ointment|Using the study as placebo.
9958318|NCT01174524|Experimental|gestoden and ethinylestradiol|"Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.~The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients."
9958319|NCT01174563|Experimental|Single Arm|
9958320|NCT01174589|Other|6 weeks of physical training|The 6 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
9958321|NCT01174589|Other|12 weeks of physical exercise|The 12 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
9958322|NCT01174602|Experimental|Exposure Therapy for AN (AN-EX/RP)|Exposure Therapy and Ritual Prevention (AN-EX/RP) includes 12 sessions of confronting feared eating situations without the use of anxiety reducing behaviors.
9958323|NCT01174602|Active Comparator|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT)
9958324|NCT01174641|Experimental|TMS intervention|Trans-cranial magnetic stimulation will be applied at a 1Hz rate for 20min over the ipsilesional posterior parietal cortex of patients showing left neglect after a right hemisphere stroke
9958325|NCT01174641|Placebo Comparator|Placebo TMS|1 Hz trans-cranial magnetic stimulation will be applied over the vertex
9958326|NCT01174654|No Intervention|Referral to community resources|
9958327|NCT01174654|Experimental|Contingency Management|
9958328|NCT01174667|Experimental|Fascial massage|A specific type of fascial massage to release restricted lumbodorsal fascia.
9958329|NCT01174667|No Intervention|No treatment control|Patient will rest quietly without receiving any instruction.
9958330|NCT01174680|Experimental|patients with stable angina pectoris|stable patients, who have been admitted to one of the participating centres for an elective coronary angiography
9958331|NCT01174693|Active Comparator|Clopidogrel|Plavix® 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
9958332|NCT01174693|Experimental|Triflusal|Disgre® 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
9958333|NCT01174706|Experimental|Usual care arm|Patients randomized to this group will receive usual care. Usual care at the three study sites varies but will be defined as whatever information is usually given to patients regarding the prescription medication or over the counter medicine they were prescribed at emergency department discharge.
9958334|NCT01174706|Experimental|Information prescription|Patients randomized to this arm will receive written information from Medline Plus regarding the prescription or over the counter medicine they have been prescribed at ED discharge plus information on their health condition.
9958335|NCT01174706|Experimental|Informationist|Patients in this arm will receive the same information as patients in group 2 but will also be given contact information for a clinical informationist if they have further questions about their prescription medicine or over the counter medicine prescribed at ED discharge.
9958336|NCT01174706|Experimental|practical assistance|Subjects will be offered practical assistance with obtaining prescription such as location of most convenient pharmacy and hours of operation, programs that offer drugs more cheaply, fax prescription from ED to pharmacy
9958337|NCT01174719|Active Comparator|Hydroxyethylstarch|
9958338|NCT01174719|Active Comparator|Humanalbumin|
10005883|NCT01589289|Experimental|Phase 3 RDTs|The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. [To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated].
9958339|NCT01174719|Active Comparator|Ringer lactate|
9958340|NCT01174758||Parkinson's disease|Individuals participating in the study have been diagnosed with idiopathic Parkinson's disease.
9958341|NCT01174771||PSP patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., PSP
9958342|NCT01174771||CBD patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., CBD
9958343|NCT01174771||Age-matched healthy controls|People that have not been diagnosed with any kind of neurologic movement disorder.
9958344|NCT01174797||Patients being evaluated for active ischemia|Subjects with known or suspected CAD who are scheduled to undergo routine exercise MPI or stress echocardiography for the detection of active ischemia are eligible for enrollment.
9958345|NCT01174810|No Intervention|Control|
9958346|NCT01174810|Experimental|Exenatide|
9958347|NCT01174849|Active Comparator|Synflorix|
9958348|NCT01174849|Active Comparator|Prevenar13|
9958349|NCT01174849|Experimental|COMBO|COMBINATION SCHEDULE of comparator vaccine 1 and comparator vaccine 2 Synflorix at 1,2,4 months then Prevenar13 at 6 months.
9958350|NCT01174862||Aspirin responder|Normal aspirin responsiveness in ASPI test (Multiplate)
9958351|NCT01174862||Aspirin non-responder|Reduced aspirin responsiveness in ASPI test (Multiplate)
9958352|NCT01174875||Pregnant mothers, infants and children|Women in their early pregnancy who are attending the first trimester antenatal ultrasound scan at the public maternity units at KK Women's and Children's Hospital (KKH) and National University Hospital (NUH). Only women age 18 years and above who are Singapore Citizens or Singapore Permanent Residents. Participants have to intend to eventually deliver in NUH or KKH and to reside in Singapore for the next 5 years. Willingness to donate cord, cord blood and placenta. The fetus should be racially homogenous with both sets of grandparents of the same ethnicity. Babies born from these mothers will be followed up until the child is at least 14 years of age.
9958353|NCT01174888|Experimental|GROUP I (Dose levels 1-2):|Patients receive midostaurin orally (PO) twice daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9958354|NCT01174888|Experimental|GROUP II (Dose levels 3-6)|Patients receive mitoxantrone hydrochloride IV over 10 minutes, etoposide IV over 1 hour, and cytarabine IV over 6 hours on days 1-6. Patients also receive midostaurin PO twice daily on days 8-21 and bortezomib IV on days 8, 11, 15, and 18. Treatment continues in the absence of disease progression or unacceptable toxicity.
9958355|NCT01174914|Experimental|Naltrexone Low-dose 3mg capsule|Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
9958356|NCT01174914|Active Comparator|Naltrexone Low Dose + ARVs|In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
9958357|NCT01174914|Placebo Comparator|ARV's (continued,standard) plus Placebo|In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
9958358|NCT01174927|Active Comparator|Heroin-dependent patients_1|daily dose of diacetylmorphine (30 mg to 500 mg) in 5 ml
9958359|NCT01174927|Placebo Comparator|Heroin-dependent patients_2|5 ml saline
9476600|NCT03570281|Experimental|Edoxaban group|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
9476601|NCT03570281|Active Comparator|Enoxaparin group|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
9958360|NCT01174940|Experimental|Extracorporeal Photopheresis|Patients will receive 2 ECP treatments on day -10 and day -8 and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
9958361|NCT01174953|Other|Finasteride plus soy|Finasteride and soy
9958362|NCT01174966||Survivor Nonsurvivor|
9958363|NCT01174979|Experimental|Caroverin|
9958364|NCT01174979|Placebo Comparator|Placebo|
9958365|NCT01174992|Experimental|Evicel|
9958366|NCT01174992|Other|Sutures only|
9958367|NCT01175044|Active Comparator|Betadine Lavage|dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000ml of sterile saline irrigation
9958368|NCT01175044|Placebo Comparator|Saline Lavage|2000 ml sterile saline lavage alone
9958369|NCT01175057||Group A|10 patients who undergo home monitoring with the MeDiNa Homebox for 4 weeks and then 4 weeks without the MeDina Homebox
9958370|NCT01175057||Group B|Group B starts without the MeDiNa Homebox for 4 weeks and then undergo Homemonitoring with the MeDiNa Homebox for 4 weeks.
9958371|NCT01175070|Experimental|Pegaptanib|Participants receiving 6-weekly treatment with pegaptanib sodium (Macugen [TM]) for ischaemic diabetic macular oedema over a 30 week period.
9958372|NCT01175096|Active Comparator|RAD001|2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
9958373|NCT01175109|Experimental|Escalating doses of imatinib and LBH589|"Study will incorporate a 3+3 dose escalation design."
9958374|NCT01175122|Experimental|H2N3 MO 2003/AA ca Vaccine|Participants will receive a nasal spray administration of the H2N3 MO 2003/AA ca vaccine on Day 0 and Day 28.
9958375|NCT01175161|Experimental|Immediate postpartum IUD insertion|Women assigned to have the IUD placed 10 minutes to 48 hours postpartum
9958376|NCT01175161|Experimental|6 week postpartum IUD insertion|Women who receive the IUD at the traditional time frame.
9958377|NCT01175187||EPIDURAL FEVER|
9958378|NCT01175187||EPIDURAL WITHOUT FEVER|
9958379|NCT01175187||GROUP 1: EPIDURAL FEVER . GROUP 2 EPIDURAL WITHOUT FEVER|
9958380|NCT01175200|Active Comparator|Prasugrel|
9958381|NCT01175200|Active Comparator|Clopidogrel|
9958382|NCT01175200|Active Comparator|Lansoprazole|proton pump inhibitor
9958383|NCT01175200|Placebo Comparator|Placebo|
9958384|NCT01175239|Experimental|Single infusion of autologous CD34+ cells|
9958385|NCT01175252||Gastroenteritis Cohort|All children suffering with gastroenteritis
9958386|NCT01175265|No Intervention|pulmonary rehabilitation, no breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
9958387|NCT01175265|No Intervention|breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
9958388|NCT01175278|No Intervention|Observation Arm|Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
9958389|NCT01175278|Experimental|Balloon Kypholasty|
9958390|NCT01175278|Active Comparator|Control Arm|Non-surgical Management Treatment Group
9958391|NCT01175291|Active Comparator|Arm A - FOLFOX 7 + MK-0646|
9958392|NCT01175291|Placebo Comparator|Arm B - FOLFOX 7 + Placebo|
9958393|NCT01175304||Workers in a Barcelona tertiary hospital|Workers attending annual medical checkups
9958394|NCT01175330|Placebo Comparator|CABG and intralipid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
9958395|NCT01175330|Active Comparator|CABG and omega-3 fatty acid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
9958396|NCT01175408|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
9958397|NCT01175408|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.
9958398|NCT01175408|Active Comparator|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
10005884|NCT01589328|Experimental|Early Palliative care|"The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
9958399|NCT01175408|Active Comparator|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
9958400|NCT01175421||Patients undergoing sleep study|
9958401|NCT01175447|Experimental|Chemoradiotherapy with S-1|radiation 54Gy over 30 fractions,and concurrent with s-1 on days 1-14 and 29-42
9958402|NCT01175460|Experimental|Chemoradiotherapy|Thoracic radiation 60Gy over 30 fractions.Concurrently, nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 was given on Days 1-14,repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
9958403|NCT01175486|Experimental|Actos|Actos 30 mg for 6 months
9958404|NCT01175486|Active Comparator|Acarbose|Acarbose 50mg tid for 6 months
9958405|NCT01175512|Active Comparator|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
9958406|NCT01175512|Placebo Comparator|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
9958407|NCT01175525|Placebo Comparator|sugar pill|sugar pill dissolved in water to be given 4 times a day 30 minutes prior to meals
9958408|NCT01175525|Active Comparator|Cromolyn|Cromolyn dose of 200mg(dissolved in water) will be given 4 times a day(30 minutes before a meal)
9958409|NCT01175538|Experimental|Lactulose|
10005885|NCT01589328|No Intervention|Contol: usual oncologic care|Patients randomly assigned to usual oncologic care were not scheduled to meet with the palliative care service unless a meeting was requested by the patient, the family, or the oncologist; those who were referred to the service did not cross over to the early palliative care group or follow the specified palliative care protocol.
10005886|NCT01589341||Correlative studies|Archived DNA samples are analyzed (laboratory biomarker analysis) for segmental chromosome aberrations by MLPA, a PCR-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
10005887|NCT01589354|Experimental|Interscalene brachial plexus block|
10005888|NCT01589354|Experimental|Intra-articular injection|
10005889|NCT01589367|Experimental|Arm1_ Metformin|Letrozole with concurrent metformin
10005890|NCT01589367|Placebo Comparator|Arm 2_ Letrole alone|Letrozole with placebo
10005891|NCT01589380|Placebo Comparator|Placebo Arm|Placebo: Capsule that is containing lactate hydrate, identically appearing with fimasartan will be administered to patient in placebo group, once daily. Same placebo drug which was used in phase 3 clinical trial of fimasartan will be provided by Boryoung Phamaceutical company. Dose titration will be done with same criteria of fimasartan group. 30mg form and 60 mg form of placebo will be identical in its morphology.
10005892|NCT01589380|Active Comparator|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
10005893|NCT01589393|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post injury to day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting day 6 post injury.
10005894|NCT01589393|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo 36-48 hours post traumatic injury until day 5, then standard of care (DVT prophylaxis with Enoxaparin) starting on Day 6.
10005895|NCT01589406||group A group B|A:Patients for surgical intervention B:Patients for radiotherapy
10005896|NCT01589419|Experimental|veliparib and capecitabine and radiation|Veliparib on days 1-7, capecitabine and radiation on days 1-5
10005897|NCT01589432|Experimental|ABT-639|
10005898|NCT01589432|Placebo Comparator|Placebo|
10005899|NCT01589432|Active Comparator|Lidocaine|
10005900|NCT01589458|Placebo Comparator|Non-fluoride toothpaste|
10005901|NCT01589458|Experimental|NaF/SiO2 toothpaste|
10005902|NCT01589458|Experimental|MFP/CaCO3 toothpaste|
10005903|NCT01589471|Experimental|Botox-A|Intra-rectal (or intra-colic) injection of 100 U of Botox-A
10005904|NCT01589523|Experimental|GlycoCholic Acid, Study Drug|A Phase III, open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.
10005905|NCT01589536|Experimental|Interventiongroup|A Stationary psychocardiological interval-rehabilitation.
10005906|NCT01589536|No Intervention|controlgroup|The Patients in the control group receive a personal recommendation concerning psychotherapy outpatient counseling and therapy services at home and take therapeutic help.
10005907|NCT01589549|Experimental|Mesenchymal stromal cell therapy|Mesenchymal stromal cell therapy in addition to corticosteroid therapy
10005908|NCT01589549|Active Comparator|Corticosteroid therapy|
10005909|NCT01589562|Active Comparator|Megace 800mg/20ml|Fed condition
10005910|NCT01589562|Experimental|DW-ES(B) 625mg/5ml|Fed condition
10005911|NCT01589575||Spouses|This group of relatives includes the spouses of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
9958410|NCT01175551||Group 1|women screened at Penn OB/GYN Associates or Helen O. Dickens Center with a documented singleton pregnancy less than 18 weeks gestational age
9958411|NCT01175551||Group 2|Nulliparous pregnant women (no previous pregnancy greater than 15 weeks) screened at Penn OB/GYN Associates or Helen O. Dickens Center less than 18 weeks gestational age
9958412|NCT01175564|Experimental|Active|Each cohort will have 9 volunteers that will receive TC-5214
9958413|NCT01175564|Placebo Comparator|Placebo|Each cohort will have 3 volunteers that will receive placebo
9958414|NCT01175577|Active Comparator|Supplement 1|
9958415|NCT01175577|Active Comparator|Supplement 2|
9958416|NCT01175577|Active Comparator|Food-based Intervention|
9958417|NCT01175577|Placebo Comparator|Placebo|
9958418|NCT01175603|Experimental|Cognitive behavioral intervention|Women in the intervention condition will receive 6 two-hour intervention sessions delivered weekly in a group format by the Study Clinician. Each session contains didactic instruction on core content, as well as activities and group discussion. One of the strengths of embedding the MB Course within home visiting is our ability to have home visitors reinforce the material presented by the Study Clinician. The 6-week curriculum is divided into three modules: (a) pleasant activities, (b) thoughts, and (c) relationships with others. Each module has two sessions. These sessions map onto core cognitive-behavioral concepts.
9958419|NCT01175603|No Intervention|Usual home visiting|Women in the control group will receive usual home visiting services and information on postpartum depression.
9958420|NCT01175616|Experimental|Creatine|Open-Label Active Treatment with Creatine 5 grams daily for 8 weeks.
9958421|NCT01175629||Group 1|The Vietnam Era Twin (VET) Registry is a closed cohort composed of 7,369 middle-aged male-male twin pairs both of whom served in the military during the time of the Vietnam conflict (1965-1975). The Registry is a United States Department of Veterans Affairs resource that was originally constructed from military records; the Registry has been in existence for more than 15 years. It is one of the largest national twin registries in the US and currently has subjects living in all 50 states. Initially formed to address questions about the long-term health effects of service in Vietnam the Registry has evolved into a resource for genetic epidemiological studies of mental and physical health conditions. Several waves of mail and telephone surveys have collected a wealth of health-related information on Registry twins. Other data collection efforts have focused on specific sets of twin pairs and conducted detailed clinical or laboratory testing.
9958422|NCT01175642|Experimental|Cognitive remediation|Cognitive remediation
9958423|NCT01175642|Active Comparator|Functional Adaptive Skills Training|Functional and social skills group treatment
9958424|NCT01175642|Active Comparator|Combined Treatment|Combined cognitive remediation and functional adaptive skills training
9958425|NCT01175681|Experimental|treatment|remote ischaemic preconditioning
9958426|NCT01175681|No Intervention|untreated|control
9958427|NCT01175694|Active Comparator|Brachytherapy|Interstitial multicatheter brachytherapy
9958428|NCT01175720|Experimental|test and control|The test and control technique will be tested in a split-mouth design.
9958429|NCT01175733|Experimental|Panitumumab|
9958430|NCT01175746|Experimental|nicardipine|
9958431|NCT01175746|Active Comparator|remifentanil|
9958432|NCT01175759|Experimental|Healthy control group|
9958433|NCT01175759|Experimental|UPRL|
9958434|NCT01175772|Experimental|Metronomic Chemoterapy|Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy
9958435|NCT01175837|Experimental|Short-term fasting prior to systemic chemotherapy|"COHORT I: Patients fast 24 hours before day 1 of course 2 of chemotherapy. If fast is well tolerated, patients may escalate fasting by 12 hours for each subsequent course of chemotherapy for up to 3 courses in the absence of unacceptable toxicity.~COHORT II: Patients fast at the longest fasting regimen found to be safe and tolerable in cohort I before day 1 of each course of course of chemotherapy for up to 4 courses in the absence of unacceptable toxicity."
9958436|NCT01175863|Active Comparator|Intravascular ultrasound|
9958437|NCT01175863|Active Comparator|Fractional flow reserve|
9958438|NCT01175876|Experimental|1|Device: RIPC RIPC consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins Procedure: Carotid Artery Stenting
9958439|NCT01175876|Sham Comparator|2|Procedure: Carotid Artery Stenting
9958440|NCT01175889|Experimental|one side ACE blade|
9958441|NCT01175889|Active Comparator|one side scalpel|
9958442|NCT01175915|Active Comparator|Western therapy|
9958443|NCT01175915|Experimental|Reduning Injection|
9958444|NCT01175915|Experimental|Reduning Injection plus western therapy|
9958445|NCT01175928|Experimental|Peristaltic Pulse PCD|Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
9958446|NCT01175928|Sham Comparator|Sham Device|Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
9958447|NCT01175941|Experimental|NRL001|10 mg NRL001 in a 2 g suppository
9958448|NCT01175941|Placebo Comparator|Placebo|Matched placebo control
9958449|NCT01175954|Experimental|Lacosamide Open-Label|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
9958450|NCT01176019|Experimental|Interactive Video|In addition to standard care, the experimental arm will receive an interactive video designed to inform and educate patients about the choices that exist concerning prenatal screening and diagnosis.
9958451|NCT01176019|No Intervention|Control|A control arm will receive standard care, which is the opportunity to meet with a genetic counselor.
9958452|NCT01176045||Pre-surgical treatment|Patients who are pre & post-surgical treated with ocular lubricants.
9958453|NCT01176045||Non-presurgical treatment|Patients who are only post-surgical treated with ocular lubricants
9958454|NCT01176084|Experimental|low carbohydrate diet|
9958455|NCT01176084|Experimental|diet & exercise|
9958456|NCT01176097|Experimental|6 - 8 cohorts|6 patients in each cohort will receive AZD5658
9958457|NCT01176097|Placebo Comparator|6 - 8 cohorts|2 patients in each cohort will receive placebo
9958458|NCT01176110|Experimental|thermal management with LMA PerfecTemp™|
9958459|NCT01176110|Active Comparator|no specific thermal management|
9958460|NCT01176123|Active Comparator|CBT-I in person|Cognitive behavioral therapy for insomnia delivered in person
9958461|NCT01176123|Experimental|CBT-I via telephone therapy|Cognitive behavioral therapy for insomnia delivered by telephone
9958462|NCT01176136|Experimental|HOPS Intervention|Middle school age children who receive the Homework, Organization, and Planning Skills (HOPS) intervention.
9958463|NCT01176136|No Intervention|Treatment As Usual|Middle school age children randomly assigned to receive treatment-as-usual services available through the school and community.
10005912|NCT01589575||Other relatives|This group of relatives includes the non-spouse relatives of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
10005913|NCT01589588|Experimental|Mask 1|
10005914|NCT01589588|Experimental|Mask 2|
10005915|NCT01589588|Experimental|Mask 3|
9958464|NCT01176149|Experimental|SMBG + intensive education|Patients will receive specific educational interventions to teach them how to perform Self monitoring Blood Glucose (SMBG), how to modify diet and level of physical activity according to blood glucose levels, and the actions to be undertaken in case of abnormal values (hypoglycemia, particularly elevated glucose levels). Patients will be instructed to modify their lifestyle habits (diet, physical activity) in order to reach specific goals (weight reduction, reduction in fat consumption intake, reduction in saturated fat intake, increase in fiber intake, regular physical activity.
9958465|NCT01176149|No Intervention|Usual Care|Usual Care
9958466|NCT01176162||"Group < 28"|• Gestational Age < 28 weeks
9958467|NCT01176162||"Group 28 - < 33"|• Gestational Age : 28 - < 33 weeks
9958468|NCT01176162||"Group 33- < 37"|Gestational Age : 33- < 37 weeks
9958469|NCT01176162||"Group > 37"|Gestational Age > 37 weeks
9958470|NCT01176175|Experimental|50 mg|Progesterone microspheres injectable suspension 50 mg
9958471|NCT01176175|Experimental|100 mg|Progesterone microspheres injectable suspension 100 mg
9958472|NCT01176175|Experimental|200 mg|Progesterone microspheres injectable suspension 200 mg
9958473|NCT01176175|Experimental|300 mg|Progesterone microspheres injectable suspension 300 mg
9958474|NCT01176188|Experimental|Comfort Care|Parental soothing, including tactile and auditory strategies, followed by a quiet period with the application of earmuffs to block auditory stimulation
9958475|NCT01176188|Active Comparator|Usual Care|
9958476|NCT01176201|Experimental|A|400 mg suspension
9958477|NCT01176201|Active Comparator|B|5 x 200 mg immediate release capsule
9958478|NCT01176214|Experimental|early tracheostomy|see study description
9958479|NCT01176214|Active Comparator|late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
9958480|NCT01176227|Placebo Comparator|Kyodophilus matching placebo capsules|
9958481|NCT01176227|Active Comparator|Kyodophilus multi strain probiotic capsules|
9958482|NCT01176253||25 newly diagnosed Type 1 diabetics|25 newly diagnosed Type 1 diabetics within onset of symptoms
9958483|NCT01176253||25 healthy volunteers|25 healthy volunteers (age & sex matched)
9958484|NCT01176279|Active Comparator|Manual and automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of TM BD DTXPlus ™), put the needless connector included in the kit to make the extractions of blood. Connect an arterial blood sampling syringe on the proximal 3-way stopcock key. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
9958485|NCT01176279|Experimental|Automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of BD DTXPlus™), put the needless connector included in the kit to make the extractions of blood. On the proximal 3-way stopcock key put a second identical needless connector: in the intervention group the two 3-way stopcock keys have, each one, a needless connector. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
9958486|NCT01176305||Danish Women 15 to 49 years old.|Free of previous VTE and current use of oral contraceptives.
9958487|NCT01176318|Experimental|erdosteine|standard care plus erdosteine for 10 days
9958488|NCT01176318|Placebo Comparator|placebo|Standard care for exacerbation of COPD plus placebo
9958489|NCT01176331||vitrectomy|
9958490|NCT01176344|Experimental|Vitamin D supplementation|Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly
9958491|NCT01176344|Placebo Comparator|Placebo|The control arm will receive identical inert placebo capsules given once monthly.
9958492|NCT01176357||1|CABG
9958493|NCT01176357||2|Valve surgery
9958494|NCT01176370|Experimental|Implantable Counterpulsation Therapy|The study is a single arm study with up to 20 patients enrolled and implanted with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. There is not a control arm in this feasibility study.
9958495|NCT01176383|No Intervention|Control group|The control group will have a standard NHS cessation clinic experience
9958496|NCT01176383|Experimental|Respiragene test and risk score|Subjects will have a buccal swab taken at first attendance for a 12 gene test of SNP variants associated with risk of lung cancer. From the genetic data and clinical data (any history of COPD, family history of lung cancer in a first degree relative and age) a risk score is calculated from which a lifetime risk of lung cancer if the subject continues to smoke can be calculated. This is expected to be a powerful motivator to encourage smoking cessation.
9958497|NCT01176396|Active Comparator|Caries prevention active intervention|Patients receive CAMBRA related products like CHX, 5000ppm F-toothpaste etc according to their risk level
9958498|NCT01176396|Placebo Comparator|control treatment|Patients receive treatment according to standard of care
9958499|NCT01176409|Experimental|High dose valacyclovir|Valacyclovir 1g po BID
9958500|NCT01176409|Active Comparator|Low dose valacyclovir|Valacyclovir 500mg po BID
9958501|NCT01176409|Placebo Comparator|Placebo|Inert placebo
9958502|NCT01176422||advanced Myelodysplastic Syndrome or acute myeloid leukemia|advanced MDS and AML with/without associated cytogenetic abnormality
9958503|NCT01176487|Experimental|A|A clinical trial using 3-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer
9958504|NCT01176539||Sleep Clinic|
9958505|NCT01176552|Experimental|Study group: GM-CSF, IFN, IL-2|
9958506|NCT01176604|Experimental|Treatment (yttrium Y 90 glass microspheres)|Participants receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0. Participants may receive additional treatments at 4-12 week intervals until all tumors in the liver have been treated in the absence of disease progression or unaccepted toxicity.
9958507|NCT01176643|Active Comparator|standard care plus yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
9958508|NCT01176643|No Intervention|Standard care|
9958509|NCT01176656||SU|T2DM patients with a prescription for a sulfonylurea but no insulin
9958510|NCT01176656||Antidiabetic without SU|T2DM patients with an oral antidiabetic drug other than an SU, and no insulin
9958511|NCT01176656||Insulin|T2DM patients using insulin, with or without other oral antidiabetics
9958512|NCT01176669|Experimental|Apatinib|
9958513|NCT01176682||1|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk factors
9958514|NCT01176695|Experimental|1|fish oil containing lipid emulsion
9958515|NCT01176695|Active Comparator|2|MCT/LCT containing lipid emulsion
9958516|NCT01176708|Experimental|Liver transplanted|10 Liver transplanted patients
9958517|NCT01176708|Experimental|Kidney transplanted|10 kidney transplanted individuals
9958518|NCT01176708|Experimental|Healthy controls|10 healthy controls
9958519|NCT01176721|Active Comparator|t-VNS verum|Active stimulation of the left auricle by t-VNS
9958520|NCT01176721|Placebo Comparator|Sham|Sham-simulation of the left auricle by the t-VNS device.
9958521|NCT01176734|Experimental|active t-VNS|active t-VNS
9958522|NCT01176747|Experimental|BDP/formoterol NEXT DPI|Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
9958523|NCT01176760|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
9958524|NCT01176760|Experimental|Cardia|Truncally vagotomized subjects (due to cardia resection)
9958525|NCT01176760|Experimental|Ctrl|Healthy matched control subjects
9958526|NCT01176799|Active Comparator|Arm A: Control Arm|"Doxorubicin - 60mg/m2 day 1~Cyclophosphamide~-600mg/m2 day1, every 3 weeks x 4 cycles"
9958527|NCT01176799|Experimental|Arm B: Experimental|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
9958528|NCT01176812||Dermal Fillers|Facial Wasting
9958529|NCT01176825|Experimental|CBT|14-week individual cognitive-behavior therapy
9958530|NCT01176825|No Intervention|Treatment As Usual|14-week waitlist control
9958531|NCT01176851|Experimental|Glyco pMDI|Glyco pMDI 100 µg
9958532|NCT01176851|Experimental|Glyco pMDI Charcoal|Glyco pMDI 100 µg + charcoal block
9958533|NCT01176851|Active Comparator|Glyco IV injection|Glyco solution for injection 100 µg
9958534|NCT01176864|Active Comparator|Double-balloon enteroscopy|DBE for suspected or known small-bowel bleeding
9958535|NCT01176864|Active Comparator|Single-balloon enteroscopy|SBE for suspected or known small-bowel bleeding
9958536|NCT01176890|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
9958537|NCT01176890|Experimental|Cardia|truncally vagotomized subjects (due to esophagus resection)
9958538|NCT01176890|Experimental|Healthy controls|Healthy control subjects
9958539|NCT01176903|Experimental|Glyco SD1|Single administration of Glyco pMDI dose level 1
9958540|NCT01176903|Experimental|Glyco SD2|Single administration of Glyco pMDI dose level 2
9958541|NCT01176903|Experimental|Glyco SD3|Single administration of Glyco pMDI dose level 3
9958542|NCT01176903|Experimental|Glyco SD4|Single administration of Glyco pMDI dose level 4
9958543|NCT01176903|Experimental|Glyco SD5|Single administration of Glyco pMDI dose level 5
9958544|NCT01176903|Placebo Comparator|Placebo SP|Single administration of Placebo pMDI
9958545|NCT01176903|Experimental|Glyco MD1|Multiple administration of Glyco pMDI dose level 1
9958546|NCT01176903|Experimental|Glyco MD2|Multiple administration of Glyco pMDI dose level 2
9958547|NCT01176903|Experimental|Glyco MD3|Multiple administration of Glyco pMDI dose level 3
9958548|NCT01176903|Placebo Comparator|Placebo MP|Multiple administration of placebo pMDI
9958549|NCT01176903|Active Comparator|Tiotropium|Multiple administration of tiotropium
9958550|NCT01176929|Experimental|Interventional group|Usual treatment + prevention program of recurrent suicidal acts
9958551|NCT01176929|Active Comparator|Control group|Usual treatment
9958552|NCT01176942|Experimental|Probiotic|
9958553|NCT01176942|Placebo Comparator|Placebo|
9958554|NCT01176994|Experimental|Skin lesions|Individuals with skin lesions whose lesions are not sent for histology by dermatologists
9958555|NCT01177020||Placentas after delivery or abortion|
9958556|NCT01177033||Best endovascular treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
9958557|NCT01177033||Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
9958558|NCT01177072|Experimental|Components-Based Interventions (CBI)|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
9958559|NCT01177072|Experimental|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
9958560|NCT01177072|No Intervention|Wait List Control|Eligible clients will not be provided therapy at enrollment. After the study period has completed, control clients will be re-interviewed. Those that remain eligible due to symptom cutoff scores will be offered therapy. In the interim, controls will receive a phone call once a month; those with indications of possible harm to self or others will be referred to a psychiatrist.
9958561|NCT01177085|Experimental|Mushroom|Mushroom enriched weight loss diet. Participants will be given a personalized diet plan, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
9958562|NCT01177085|Active Comparator|No mushroom diet|Participants will be given a personalized diet plan, without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
9958563|NCT01177111|Experimental|Sunflower seed Oil|
9958564|NCT01177111|Active Comparator|Mustard seed oil|
9958565|NCT01177124|Experimental|MBSR 6 Weeks Program|
9958566|NCT01177124|No Intervention|Usual Care (UC)|
9958567|NCT01177150|Experimental|001|JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
9958568|NCT01177150|Experimental|002|JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
9958569|NCT01177163|Other|001|Placebo one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
9958570|NCT01177163|Experimental|002|JNJ 28431754 100 mg/placebo one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
9958571|NCT01177163|Experimental|003|JNJ 28431754 300 mg/placebo one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
9958572|NCT01177176|Other|Standard Care|Standard tobacco counseling provided to hospital inpatients as part of routine, clinical-guideline compliant care in the study hospital. No post-discharge treatment is offered in this arm.
9958573|NCT01177176|Experimental|Extended Care Management|In addition to Standard Care, subjects in this arm receive Extended Care Management intervention to facilitate the continued use of smoking cessation treatment (counseling and medication use) after hospital discharge. This consists of 3 months of telephone-based contact after discharge.
9958574|NCT01177202|Experimental|Group A|HAC1 Dose = 15ug; Alum Dose = 0
9958575|NCT01177202|Experimental|Group B|HAC1 Dose = 15ug; Alum Dose = 0.75mg
9958576|NCT01177202|Experimental|Group C|HAC1 Dose = 45ug; Alum Dose = 0
9958577|NCT01177202|Experimental|Group D|HAC1 Dose = 45ug; Alum Dose = 0.75mg
9958578|NCT01177202|Experimental|Group E|HAC1 Dose = 90ug; Alum Dose = 0
9958579|NCT01177202|Experimental|Group F|HAC1 Dose = 90ug; Alum Dose = 0.75mg
9958580|NCT01177202|Placebo Comparator|Group G|Saline
9958581|NCT01177202|Active Comparator|Group H|H1N1
9958582|NCT01177215||Digital chest tube|All patients will be treated with the digital chest tube device
9958583|NCT01177241||CLBP|
9958584|NCT01177241||CLBP OU|
9958585|NCT01177306|Experimental|Extended Release Guanfacine|pre and post testing of working memory in subjects whose ADHD has responded to extended release guanfacine. Subjects will be tested before starting study drug and after 6-8 weeks on a stable dose of the study drug.
9958586|NCT01177332|Experimental|Fasted|Two-hour cycling test, fasted condition
9958587|NCT01177332|Other|Glucose-fed|Two-hour cycling test, glucose-fed condition
9958588|NCT01177345||Terminal Disease|Terminal cervical cancer- not treatable
9958589|NCT01177345||Early Disease|Early cervical cancer = meaning treatable with hysterectomy.
9958590|NCT01177345||Advanced Disease|Advanced cervical cancer- treatable with chemotherapy and/or radiation.
9958591|NCT01177358|Experimental|Botulinum Toxin A injection|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 Units (0.1 mL) of Botulinum Toxin A will be injected at three sites along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy."
9958592|NCT01177358|Placebo Comparator|Saline|0.1 mL of normal saline in a placebo vial containing 2 mL of normal saline will be injected along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy.
10005916|NCT01589588|Placebo Comparator|Mask 3, placebo|
10005917|NCT01589614|Experimental|PH-797804 6 mg|Subjects will receive a single 6 mg dose in the fed state
9667621|NCT03324932|Other|AI+denosumab VS only AI|We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.
9667622|NCT03324672|Active Comparator|TRIGGER|
10005918|NCT01589614|Experimental|PH-797804 6 mg + erythromycin 800 mg|Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
10005919|NCT01589627|Experimental|experimental|Patients will be treated with the Standard of Care physical therapy, NSAIDs as well as a Wrist Extension Dynasplint
10005920|NCT01589627|No Intervention|Control|Patients will receive standard of care physical therapy and NSAIDS
10005921|NCT01589640||Blink Tears|Blink Tears is an over the counter artificial tear
10005922|NCT01589640||Blink Gel Tears|Blink Gel Tears is an over the counter artifical tear product
10005923|NCT01589640||Systane Balance|Systane Balance is an over the counter artificial Tear product
10005924|NCT01589666|Experimental|Spray-dried S/D-treated plasma|"Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a universal product."
10005925|NCT01589679|Other|control/ standard of care|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Control subjects will be treated with the Standard of Care during the first 12 weeks, but after the 12 weeks patients will be fit with MTP, which delivers a low-load, prolonged-duration stretch after completion of this study.
10005926|NCT01589679|Experimental|Dynasplint|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Experimental subjects will be immediated treated with the Metatarsal Dynasplint, which delivers a low-load, prolonged-duration stretch for 60 minutes, three times per day.
10005927|NCT01589692|Experimental|Internal Fixation|Open Reduction and Internal Fixation: Internal fixation with a volar locking plating system
9958593|NCT01177371|Experimental|Arm I|"HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day 21 and continuing for 12 months with taper at 9 months. Patients also receive methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at 4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6."
9958594|NCT01177423|Active Comparator|Quicksleeper intraosseous anesthesia|Pulpal and periapical molar and premolar sedation is managed by Quicksleeper intraosseous anesthesia.
9958595|NCT01177423|Active Comparator|Inferior alveolar nerve block|Pulpal and periapical molar and premolar sedation is managed by inferior alveolar nerve block.
9958596|NCT01177436|Experimental|Patients treated for prostatic pathology|Patients treated for prostatic pathology (benign or malign)in the hospital department.
9958597|NCT01177462||hemineglect stroke patients|Stroke patients with hemineglect
9958598|NCT01177462||Control stroke patients|Stroke patients without hemineglect
9958599|NCT01177462||Normal control|Normal subjects
9958600|NCT01177475|Active Comparator|natural milk|
9958601|NCT01177475|Experimental|pasteurized milk|
9958602|NCT01177488|Experimental|BATE-T|Behavioral Activation Therapeutic Exposure done while the patient is at home via videoconferencing technology
9958603|NCT01177488|Active Comparator|BATE-IP|Behavioral Activation Therapeutic Exposure done in the therapist's office
9958604|NCT01177501|Experimental|Topotecan|
9958605|NCT01177514|Experimental|GABAPENTIN|Group of patients treated with oral gabapentin
9958606|NCT01177514|Placebo Comparator|PLACEBO|Group given the placebo capsules
9958607|NCT01177540|Experimental|Arm A|
9958608|NCT01177540|Experimental|Arm B|
9958609|NCT01177566|Active Comparator|pimecrolimus (Elidel)|pimecrolimus twice daily to a chosen target lesion on one side of body
9958610|NCT01177566|Active Comparator|topical medical device cream (Eletone)|topical medical device cream three times daily to a chosen target lesion on one side of the body
9958611|NCT01177579|No Intervention|Aim 1; Biomarkers|Blood concentrations of copper coenzymes will be monitored for 1 year
9667623|NCT03324672|Experimental|TRIGGER+CURETAPE|
9958612|NCT01177579|Experimental|Copper supplement Arm|4 mg or 8 mg copper will be compared in a randomized controlled study
9958613|NCT01177579|No Intervention|Normal Controls|Normal subjects will be used to generate reference measures.
9958614|NCT01177592|Experimental|Guided Therapy|Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
9958615|NCT01177592|No Intervention|Standard Therapy|Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.
9958616|NCT01177605|Placebo Comparator|Vanilla flavored milk-based beverage containing no prebiotics|Vanilla flavored milk-based beverage containing no prebiotics
9958617|NCT01177605|Experimental|Vanilla flavored milk-based beverage containing prebiotics|Vanilla flavored milk-based beverage containing prebiotics
9958618|NCT01177618||Probands|Severe, early-onset COPD subjects that bring the family into the study
9958619|NCT01177618||Relatives|Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
9958620|NCT01177644|Experimental|Active|
9958621|NCT01177657||Gastroenteritis cohort|Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis
9958622|NCT01177657||Hospital control cohort|Children hospitalized for non gastroenteritis causes
9958623|NCT01177657||Neighbourhood control cohort|Children without any symptoms of gastroenteritis or severe gastroenteritis
9958624|NCT01177683|Experimental|Arm 1|Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.
9958625|NCT01177696|Experimental|psychotherapy|"The study aims to evaluate the effectiveness of an intervention of psychotherapy in improving the mental health of caregivers.~This intervention is based on theoretical approaches to care adjusted to cognitive theory, in order to be applied in primary health care centres."
9958626|NCT01177696|No Intervention|Control|
9958627|NCT01177748||Patients on the Stroke Unit|
9958628|NCT01177761|Active Comparator|exercise|endurance,balance, power, resistance type exercise
9958629|NCT01177761|No Intervention|sedentary control|Subjects were instructed to do not relevantly change their lifestyle
9958630|NCT01177774||Recent-onset tics that will persist|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
9958631|NCT01177774||Recent-onset tics that will remit|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
9958632|NCT01177774||Tic-free control subjects|Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.
9958633|NCT01177774||Existing TS/CTD|Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent [Chronic] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.
9958634|NCT01177826||Group 1|Cases
9958635|NCT01177826||Group 2|Controls
9958636|NCT01177839||Intussusception cohort|Subjects with Intussusception
9958637|NCT01177852|Experimental|Notuss® syrup|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
9958638|NCT01177852|Active Comparator|Dropropizine + Pseudoephedrine and brompheniramine|Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
9958639|NCT01177891||Subject index|Population of familial cases of POF : 20 families with at least two subjects with POF nonsyndromic
9958640|NCT01177891||Population Index Related topics|Women, healthy women, men are potential carriers
9958641|NCT01177891||Population control|100 Caucasian women with normal cycles until at least the age of 40 years and a proven fertility
9958642|NCT01177904|Active Comparator|Progesterone 5 Weeks|The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy
9958643|NCT01177904|Other|Control Group : P4 8 weeks|Progesterone will be given until 8 weeks of pregnancy
9958644|NCT01177917|Experimental|Cow milk-based infant formula with prebiotic blend|
9958645|NCT01177917|Placebo Comparator|Marketed Cow milk-based infant formula|
9958646|NCT01177930||Feeding with milk with DHA and ARA|
9958647|NCT01177930||Feeding with milk without DHA and ARA|
9958648|NCT01177982|Active Comparator|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club
9958649|NCT01177982|Experimental|Reduced RBT (r-RBT)|Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
9958650|NCT01177982|Experimental|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
9958651|NCT01177982|Active Comparator|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club Recovery housing CAP short term housing admission Recovery sponsor
9958652|NCT01177982|Active Comparator|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
9958653|NCT01177982|Active Comparator|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
9958654|NCT01177982|Experimental|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
9958655|NCT01177982|Experimental|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
9958656|NCT01177995|Experimental|Social Network|Leaders of labor migrant social networks will be trained to disseminate HIV prevention messages to the members of their social networks. The training will sequentially target ways to increase network members' HIV-related knowledge and norms, attitudes, intentions, and confidence in how to avoid risk. Leaders will be encouraged to have these discussions with network members between and after training sessions.
9958657|NCT01178008|Experimental|Active acupuncture group|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints.
9958658|NCT01178008|Placebo Comparator|Placebo acupuncture group|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
9958659|NCT01178021|Active Comparator|Chloroquine|Standard arm
9958660|NCT01178021|Experimental|Chloroquine/Primaquine|Chloroquine combined with primaquine
9958661|NCT01178034|Experimental|pharmacogenetic warfarin dose|Warfarin maintenance dose on the basis of demographic/pharmacogenetic data
9958662|NCT01178047|Active Comparator|Rasagiline|
9958663|NCT01178047|Placebo Comparator|Placebo|
9958664|NCT01178060|Active Comparator|Personalized Risk Information|Patients received personalized stroke and heart attack risk assessment information.
9958665|NCT01178060|Other|Standard Education|Patients received general risk information on heart attack and stroke.
9958666|NCT01178112|Experimental|Trientine + Carboplatin MTD Group|Trientine starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group.
10005928|NCT01589692|Experimental|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
10005929|NCT01589692|Experimental|Pinning|Percutaneous pinning with any number of Kirschner wires
9958667|NCT01178112|Experimental|MTD Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group
9958668|NCT01178112|Experimental|Carboplatin PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
10005930|NCT01589692|Active Comparator|No Surgery|Closed Reduction and casting: Closed reduction and immobilization with a cast and/or splint
10005931|NCT01589705||polycystic kidney ,no hypertension|The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
9958669|NCT01178112|Experimental|Trientine PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
9958670|NCT01178151|Experimental|afinitor|10mg afinitor daily orally
9958671|NCT01178164|Experimental|Diagnosis of Fabry disease|
9958672|NCT01178177||SOT recipients|solid organ transplant recipients with invasive pulmonary aspergillosis
9958673|NCT01178177||Hematologic disease|Hematologic disease patients with invasive pulmonary aspergillosis
9958674|NCT01178190||lung cancer|
9958675|NCT01178229|Experimental|Physiotherapy|group of bruxist children that received physiotherapy to change the head posture
9958676|NCT01178229|No Intervention|Control|Group of bruxist children that did not receive treatment
9958677|NCT01178242|Experimental|Salivary Gland and Labial Mucous Membrane Transplantation|
9958678|NCT01178255|Experimental|Group 1|
9958679|NCT01178255|Experimental|Group 2|
9958680|NCT01178255|Experimental|Group 3|
9958681|NCT01178255|Experimental|Group 4|
9958682|NCT01178307||Part 1|Patient interview and developmental questionnaires
9958683|NCT01178307||Part 2|Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
9958684|NCT01178307||Part 3|Patient MDASI-GIST Questionnaire
9958685|NCT01178320||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
9958686|NCT01178320||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
9958687|NCT01178346|Experimental|NicVAX|Experimental vaccine
9958688|NCT01178346|Placebo Comparator|Placebo|Placebo vaccine
9958689|NCT01178372|Active Comparator|lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
9958690|NCT01178372|Active Comparator|probiotics|
9958691|NCT01178424|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
9958692|NCT01178424|Active Comparator|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
9958693|NCT01178450|Active Comparator|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
9958694|NCT01178450|Experimental|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
9958695|NCT01178463||I. Obstructive Azoospermia|
9958696|NCT01178463||II. Non-Obstructive Azoospermia Patients|
9958697|NCT01178476|Experimental|Hyposafe Hypoglycemia alarm device|EEG based hypoglycemia detection
9958698|NCT01178476|Active Comparator|Regular glucose control|Regular glucose control group
9958699|NCT01178489||Patients undergoing arthroplasty|Patients undergoing primary, unilateral, total hip or knee arthroplasty under spinal anaesthesia
9958700|NCT01178515|Sham Comparator|Full fat milk|Full fat milk contain 3% fat
9958701|NCT01178515|Experimental|Partially defatted milk|Partially defatted milk contains 2% of fat
9958702|NCT01178515|Experimental|Defatted milk|Defatted milk contains 1% fat
9958703|NCT01178554|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
9958704|NCT01178554|Experimental|Standard Manual Treatment (SMT)|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
9958705|NCT01178554|Experimental|Modular Maual Treatment (MMT)|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems; Chorpita & Weisz, 2004) to help children with primary problems of anxiety, depression, and conduct.
9958706|NCT01178593|No Intervention|Standard Medical Therapy (SMT)|standard medical treatment (care as usual) with supportive talks
9958707|NCT01178593|Active Comparator|Gut focused hypnotherapy|weekly sessions of gut focused hypnotherapy in groups (10 sessions within 12 weeks)
9958708|NCT01178619||AGA|
9958709|NCT01178619||symmetrical IUGR|
9958710|NCT01178619||asymmetrical IUGR|
9958711|NCT01178632|Experimental|Passiflora, Anxiety Disorders|1 tablet Passiflora;Crataegus;Salix; PO;BID
9958712|NCT01178632|Active Comparator|Valeriane, Anxiety Disorder|1 tablet Valeriana officinalis, PO, BID
9958713|NCT01178645|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
9958714|NCT01178658|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
9958715|NCT01178684||1: HIV-pos on d4T with neuropathy|
9958716|NCT01178684||2: HIV-pos on d4T without neuropathy|
9958717|NCT01178684||3: HIV-neg without peripheral neuropathy|
9958718|NCT01178684||4 HIV-pos on d4T with asymtomatic neuropathy|
9958719|NCT01178697|Active Comparator|Intravitreal triamcinolone|
9958720|NCT01178697|Active Comparator|Intravitreal bevasizumab|
9958721|NCT01178710|Experimental|treatment|
9958722|NCT01178710|No Intervention|untreated|control
9958723|NCT01178736||Cancer Screening and Diagnosis|Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
9958724|NCT01178749||Chronic Hepatitis C Infection|patients Receiving 24-week Interferon-α with Ribavirin Treatments
9958725|NCT01178775|No Intervention|1|control design
9958726|NCT01178775|No Intervention|2|education only group
9958727|NCT01178775|Experimental|3|education and education and walking program design
9958728|NCT01178788|Active Comparator|17 alfa hydroxy Progesterone caproate|Women treated with i.m. 17P injection/weekly (Lentogest, IBSA, Italy)
9958729|NCT01178788|Active Comparator|Micronized Progesterone|micronized P 200 mg per vagina /day (Utrogestan, Besins Healthcare, Belgium)
9958730|NCT01178788|Active Comparator|Control|Routine clinical controls
9958731|NCT01178801||liver cancer|Clinical data of patients with liver cancer
9958732|NCT01178840|Other|WC then FC2|The couples will use 4 PATH Woman's Condom then 4 FC2 female condom.
9958733|NCT01178840|Other|FC2 then WC|The couples will use 4 FC2 female condom then 4 PATH Woman's Condom.
9958734|NCT01178866||Clinical course|complicated course group (death within 30 days after surgery or ICU stay > 4 days) and uncomplicated course group (ICU stay ≤ 4 days).
9958735|NCT01178879|Experimental|Telehealth consultation|Telehealth nurse consultation plus treatment as usual
9958736|NCT01178879|No Intervention|Conventional|Treatment as usual
9958737|NCT01178892|Placebo Comparator|Placebo|
9958738|NCT01178892|Experimental|Omega-3|
9958739|NCT01178892|Experimental|Yoga|
9958740|NCT01178892|Experimental|Exercise|
9958741|NCT01178892|Other|Usual Activity 1|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
9958742|NCT01178892|Other|Usual Activity 2|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
9958743|NCT01178905|Other|Mother CMV positive|
9958744|NCT01178918||Healthy volunteers from recipients of H1N1 vaccine|
9958745|NCT01178931|Active Comparator|Oral dydrogesterone|Study group receiving 2x10mg of oral dydrogesterone until a pregnancy test or in the case of pregnancy until 10 week.
9958746|NCT01178931|Active Comparator|Crinone 8% vaginal gel|Control group is receiving vaginal gel, 1x90mg, until a pregnancy test or in the case of pregnancy until 10 week.
9958747|NCT01178957||Type 1 diabetes|
9958748|NCT01178983|Experimental|telebiofeedback|
9958749|NCT01178983|Active Comparator|biofeedback|
9958750|NCT01178996|Experimental|Thymosin alpha 1|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
9958751|NCT01178996|Placebo Comparator|Placebo|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
9958752|NCT01179009|Experimental|ketamine 100-hour infusion|100-hour infusion of ketamine plus a safener (clonidine)
9958753|NCT01179009|Experimental|ketamine 40-minute infusion|40-minute ketamine infusion following a 100-hours +/- placebo (saline) infusion. Participants will also receive a safener (clonidine)
9958754|NCT01179009|Experimental|ketamine IM injections|One-2 weeks after the end of the 96-hour ketamine infusion, subjects assigned to the ketamine maintenance arm will return for ketamine maintenance injections (0.5-5 mg/kg, IM).
9958755|NCT01179009|Experimental|lorazepam IM Injections|Subjects randomized to the lorazepam control arm will also return for IM lorazepam maintenance injections 2 mg IM (range 0.5 - 4).
9958756|NCT01179035|Active Comparator|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
9958757|NCT01179035|Experimental|Transitions Clinic - Parolee Targeted Care|Following randomization, subjects in this arm receive ongoing primary care in a parolee-targeted clinic. Parolee-targeted care includes care from clinicians with a knowledge of the impacts of incarceration on health and experience caring for formerly incarcerated patients, a community health worker that works in medical and social services coordination and chronic disease education, and linkages with community-based organizations serving formerly incarcerated individuals.
9958758|NCT01179061|Experimental|Apelin infusion|6 hour infusion of apelin peptide into circulation
9958759|NCT01179061|Placebo Comparator|Placebo|Infusion of saline into systemic circulation
9958760|NCT01179074|Active Comparator|Oesophageal stent alone|Patients of inoperable oesophageal cancer in this arm underwent oesophageal stenting with self expandable metal stents
9958761|NCT01179074|Active Comparator|Oesophageal stent followed by EBRT|Patients in this arm underwent oesophageal stenting with self expandable metal stents followed by external beam radiotherapy (30Gy/10#/2weeks)
9958762|NCT01179100|Placebo Comparator|Normal Saline|Normal Saline: Calculated and adjusted to match loading dose and infusion rate of lidocaine equivalent adjusted for weight.
9958763|NCT01179100|Active Comparator|Lidocaine|
9958764|NCT01179126|Experimental|complete multivessel revascularization|
9958765|NCT01179126|Active Comparator|stress echo guided revascularization|
9958766|NCT01179139|Active Comparator|Healthy Control|
9958767|NCT01179139|Experimental|CRS|
10005932|NCT01589718|Experimental|0.3mg Pegaptanib Sodium, Macugen|will receive Macugen intravitreal injection prior to surgery
10005933|NCT01589718|Sham Comparator|Sham injection|will receive a sham injection
10005934|NCT01589731||Allergic group|The first group (group A) included 45 patients (17 males; mean age: 46.2 years, SD: 12.2 years) with convincing clinical histories of reproducible adverse reactions to bovine milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.
10005935|NCT01589731||Non Allergic group|The second group (group B) was used as a control for the immunoblotting analysis performed in the first group and included 20 individuals selected based on an evident tolerance to cow's milk, an absence of βs-IgE by ImmunoCAP assay and SPT non-reactivity to β-Lg or TgPolβ-Lg (6 males; mean age: 21.9 years, SD: 17.6 years).
10005936|NCT01589731||Atopic group|The third group (group C) included 49 subjects with atopic respiratory and/or dermatological diseases (19 males; mean age: 28.7 years, SD: 20.6 years) regardless of βs-IgE status. This group was used to compare the ex vivo cell-mediated immunoreactivity between β-Lg and TgPolβ-Lg by comparing the mean ex vivo antigenic challenge results determined using the leukocyte adherence inhibition test (LAIT).
10005937|NCT01589744|Experimental|Suction cup Hemostatic Intra-Uterin|The suction haemostatic cup will be positioned into the uterus, and the aim is to stop haemorrhage
10005938|NCT01589757|Placebo Comparator|Standard Care|Standard care dietary advice to emphasize high fiber foods with a moderate to high GI
10005939|NCT01589757|Experimental|Low GI Diet|Low GI dietary advice in addition to standard care
10005940|NCT01589783||Pregnant or newly post partum women|
10005941|NCT01589783||family practice physicians and obstetricians|
10005942|NCT01589796|Active Comparator|classic TAP|classic US-guided TAP block in a space between iliac crest and the costal margin in the region of the anterior axillary line
10005943|NCT01589796|Active Comparator|Medial TAP|US-guided TAP block in a space between iliac crest and the costal margin within 1 inch lateral to transversus abdominis muscle origination
10005944|NCT01589809|Experimental|Nicotinamide|Comparison is made within-subjects to different doses and no treatment
10005945|NCT01589835|Experimental|Lifestyle counseling|Green prescription with facilitator support
10005946|NCT01589835|Other|Usual care|
10005947|NCT01589848||von Willebrand women|Referred women who may have von Willebrand Disease
10005948|NCT01589861|Experimental|BKM120+Lapatinib|"BKM120 40, 60 or 80 mg/day per os for 28 days cycle~+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle"
10005949|NCT01589874||acute ill patients|
10005950|NCT01589913|Experimental|Treatment as usual plus remote care|"The same treatment as described under treatment as usual plus participation in the intervention ICD-Forum."
10005951|NCT01589913|No Intervention|Treatment as usual|Standard information provided by hospitals on ICD-technology as well as consequences of ICD-implantation plus medical aftercare including cardiology appointments at 1, 3, and 6 months, and one year after ICD-implantation.
10005952|NCT01589952|Experimental|Pegylated Interferon, Entecavir|'Pegylated Interferon, Entecavir' arm will consist of 20 chronic hepatitis B patients who will receive Pegylated Interferon 90 micro gms subcutaneously once weekly in combination with entecavir 0.5 mg orally once daily for 24 weeks
10005953|NCT01589965|Experimental|Treatment group: T5|Small Lottery reward
10005954|NCT01589965|No Intervention|Control group|
10005955|NCT01589965|Experimental|Treatment group T1|High Lottery reward
10005956|NCT01589991|Placebo Comparator|Non-fluoride toothpaste|
10005957|NCT01589991|Experimental|Toothpaste 550 µg F/g (NaF/SiO2)|
10005958|NCT01589991|Experimental|Toothpaste 1100 µg F/g (NaF/SiO2)|
10005959|NCT01589991|Experimental|Toothpaste 1450 µg F/g (MFP/CaCO3)|
10005960|NCT01590030|Experimental|Laparoscopic mesial incision|
10005961|NCT01590030|Active Comparator|Laparoscopic antimesial incision|
10005962|NCT01590043||Control|Healthy 3-18 years old participants
10005963|NCT01590043||Inflammatory bowel disease|3-18 years old patients identified with inflammatory bowel disease
10005964|NCT01590043||Abdominal pain|3-18 years old patients suffering from abdominal pain not related to Inflammatory bowel disease
10005965|NCT01590056||PD patients|PD patients that are treated or are candidates for treatment with STN DBS
10005966|NCT01590108|Experimental|Apelin|Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.
10005967|NCT01590108|Placebo Comparator|Control|Subject will take cardiopulmonary exercise testing with receive placebo
10005968|NCT01590121||Pateints with hereditary haemorrhagic telangiectasia|
10005969|NCT01590134|No Intervention|Control|"Following randomisation,to no active intervention, blood and urine samples will be collected at 6 stated intervals over a 48 hour period~Total number of participants in arm = 6"
10005970|NCT01590134|Active Comparator|Iron control|"Following randomisation, on each of two consecutive mornings, the participant will receive a single dose of ferrous sulphate 200mg. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Total number of participants in arm = 6"
10005971|NCT01590134|Experimental|Dietary supplement|"Following randomisation, on each of two consecutive mornings, the participant will receive the experimental dietary iron supplement. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Toal participants in arm = 6"
10005972|NCT01590147|Experimental|Arm 1 (YST)|Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
9958768|NCT01179152|Active Comparator|Budicort|75 children will receive treatment with Budicort 200 mcg
9958769|NCT01179152|Active Comparator|Symbicort|75 children will receive treatment with Symbicort 160 mcg
9958770|NCT01179152|No Intervention|counselling|75 children who will not treated as their request but will be folowedup
9958771|NCT01179165||Type 2 diabetes age 40-75|Only one diagnostic/observational group
9958772|NCT01179178||COPD-patients|
9958773|NCT01179178||Older adults (65-81 y)|
9958774|NCT01179204||Patiens operated with TKA|
9958775|NCT01179230||PET SPECT|Subjects will have both types of imaging performed, PET and SPECT
9958776|NCT01179243||intensive care patients|no interventions
9958777|NCT01179256|Experimental|CURCUMIN|oral supplementation of curcumin 2000mg
9958778|NCT01179256|Placebo Comparator|PLACEBO|oral PLACEBO TABLET
9958779|NCT01179269|Experimental|Pazopanib plus Paclitaxel|Pazopanib daily and weekly Paclitaxel IV.
9958780|NCT01179282|Placebo Comparator|PLACEBO|PLACEBO NASAL SPRAY
9958781|NCT01179282|Active Comparator|DUST MITE ALLERGEN|Subjects will use dust mite Dermatophagoides pteronyssinus (Dp) extract or placebo nasal spray at home for 2 weeks, with a 1 month washout period followed by 2 weeks of the other nasal spray.
9958782|NCT01179295|Experimental|Arm 1|
9958783|NCT01179295|Experimental|Arm 2|
9958784|NCT01179295|Experimental|Arm 3|
9958785|NCT01179295|Experimental|Arm 4|
9958786|NCT01179308|Active Comparator|General-epidural anesthesia|Epidural and general anesthesia
9958787|NCT01179308|Active Comparator|General anesthesia|General anesthesia alone
9958788|NCT01179321|No Intervention|Control|
9958789|NCT01179321|Experimental|Early nutrition intervention|
9958790|NCT01179360||Imaging group|
9958791|NCT01179373|Active Comparator|TMS, High Frequency|High Frequency TMS with H coil to prefrontal cortex
9958792|NCT01179373|Active Comparator|TMS, Low Frequency|Low Frequency TMS to Prefrontal cortex
9958793|NCT01179373|Placebo Comparator|Sham Stimulation|Sham TMS with H Coil on Prefrontal Cortex
9958794|NCT01179386||methylphenidate|30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
9958795|NCT01179386||no medication|30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.
9958796|NCT01179412|Experimental|2% povidone-iodine|
9958797|NCT01179425|Active Comparator|non-marijuana dependent controls|
9958798|NCT01179425|Experimental|Marijuana-dependent subjects|
9958799|NCT01179451||Post streptococcal reactive arthritis (PSRA)|children who were diagnosed with psra at least one year before the study
9958800|NCT01179464|Active Comparator|Aminobiphosphonates|Aminobiphosphonates
9958801|NCT01179464|Experimental|Aminobiphosphonates and Statin|Aminobiphosphonates and Statin
9958802|NCT01179503|Active Comparator|Calcium only|1200 mg Calcium per day
9958803|NCT01179503|Experimental|Vitamin D plus calcium|2000 IU vitamin D plus 1200 mg calcium per day
9958804|NCT01179529|Experimental|Omalizumab|
9958805|NCT01179542||first trimester|first trimester
9958806|NCT01179542||third trimester|third trimester
9958807|NCT01179542||prgnancies complicated with IUGR|prgnancies complicated with IUGR
9958808|NCT01179542||preeclampsia|preeclampsia
9958809|NCT01179555|Experimental|Pt. 1 Behavioral Activation|"Behavioral Activation (BA) is a behavioral technique to help people overcome avoidant tendencies through goal setting, activity scheduling, and graded task assignment. The key component of BA involves developing an Action Plan, and having the subject document each step of the plan as he or she implements it, reinforcing the steps towards goal attainment. Action Plans are easily applied to diabetes self-care tasks because the latter lend themselves to documentation of simple, step-by-step plans. In this study, a Community Health Educator (CHE) - interventionist will schedule and deliver four 45-60 minute in-home BA sessions within 3 months of randomization (i.e., one session every 2-3 weeks)."
9958810|NCT01179555|Placebo Comparator|Pt. 1 Supportive Therapy|The purpose of Supportive Therapy (ST) is to explore the impact of aging and diabetes on the subject's life. In contrast to the BA intervention, the interventionist does not discuss the importance of dilated eye exams. In subsequent sessions, ST facilitates and deepens knowledge about the subject's life situation in relation to his or her health and other life difficulties. The ST therapist encourages this process and creates an accepting, nondirective, and supportive opportunity for discussion.
9958811|NCT01179581|Experimental|1|single ascending doses
9958812|NCT01179581|Placebo Comparator|2|single dose placebo
9958813|NCT01179581|Experimental|3|multiple dose, 10 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
9958814|NCT01179581|Placebo Comparator|4|multiple dose, capsules, 10 days; scheme to match that of Study Arm 3.
9958815|NCT01179594|Placebo Comparator|A|
9958816|NCT01179594|Experimental|B|
9958817|NCT01179594|Placebo Comparator|C|
9958818|NCT01179594|Experimental|D|
9958819|NCT01179607|Active Comparator|M0002|"Started at 0.3 mg/day and increased every 3 days (to 1, 3 and 6 mg/day)~for hyponatraemic subjects: dose was increased until the evening serum level was between 132 mmol/l and 145 mmol/l;~for normonatraemic subjects the dose was increased until a 500 ml increase in the 24-h urine volume compared with Day-1 was reached.~Once the required response or max dose was achieved, subjects entered a maintenance phase where they remained on the same dose of M0002 or placebo until 15 days."
9958820|NCT01179607|Placebo Comparator|Placebo|
9958821|NCT01179620|Experimental|Certoparin|
9958822|NCT01179633|Active Comparator|Oplon Active Patch|
9958823|NCT01179633|Placebo Comparator|Placebo patch|
9958824|NCT01179646|Active Comparator|Protonix|Protonix 40 mg DR Tablet
9958825|NCT01179646|Experimental|Pantoprazole|Pantoprazole 40 mg DR Tablet
9958826|NCT01179659|Active Comparator|Protonix|Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)
9958827|NCT01179659|Experimental|Pantoprazole 40 mg DR Tablet|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
9958828|NCT01179698|Other|Stryker navigation system|
9958829|NCT01179711|Other|glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
9958830|NCT01179724|Experimental|high dose proton pump inhibitor|
9958831|NCT01179724|Active Comparator|H2 receptor antagonist|
9958832|NCT01179750|No Intervention|No Ultrasonic Coagulating Shears group|the one arm: operated group without using Ultrasonic coagulation shears during gastrectomy;
9958833|NCT01179750|Experimental|ultrasonic coagulation shears group|the other arm: operated group using ultrasonic coagulation shears during gastrectomy
9958834|NCT01179763||Retinal layer thickness analysis|Optical coherence tomography will be conducted to analyze retinal layer thickness (safe examination)
9958835|NCT01179776|Experimental|Ilomedin and standard low dose treatment|
9958836|NCT01179776|Placebo Comparator|Placebo|
9958837|NCT01179789|Active Comparator|Optimal Diet|Diet advices will receive the Optimal Diet for Elderly
9958838|NCT01179789|Experimental|VSL#3|Diet advices + VSL-3: will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
9958839|NCT01179789|Experimental|AISA-5203-L|Diet advices + 5203-L: will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
9958840|NCT01179789|Experimental|Argan oil|Diet advices + Argan oil: will receive the Optimal Diet for Elderly + Argan
9958841|NCT01179802|Experimental|1|single event of a prolonged strenuous endurance exercise (mountain marathon)
9958842|NCT01179815||1|Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
9958843|NCT01179828|Active Comparator|1|Oxycodone 15mg
9958844|NCT01179828|Active Comparator|2|Clobazam 20mg
9958845|NCT01179828|Active Comparator|3|Imipramine 75mg
9958846|NCT01179828|Placebo Comparator|4|Tolterodine 1mg
9958847|NCT01179841|Experimental|Playgroup and Parent Training|"One to two-hour individual therapeutic sessions with parent training in the home or clinic, 1x every week over six months;~parent training/enrichment once a week in our clinic for 20 sessions at 1-2 hours;~a playgroup session for 1-2 hours 2x week for 6 months in our clinic and~Community treatment as usual."
9958848|NCT01179841|Active Comparator|Parent Training|"Parent enrichment sessions once a week for 20 sessions (for 1-2 hours)~Community treatment as usual."
9958849|NCT01179854|Experimental|500 mg|Group of active treatment of Remegal 500 mg
9958850|NCT01179854|Experimental|Remegal 750 mg|Group of active treatment of Remegal 750 mg
9958851|NCT01179854|Experimental|Remegal 1000 mg|Group of active treatment of Remegal 1000 mg
9958852|NCT01179854|Placebo Comparator|Placebo|Placebo
9958853|NCT01179867|Experimental|Electronic Medication Reconciliation|"Electronic medication reconciliation includes:~Electronic retrieval of the community drug list at admission~Generation of discharge prescription using the discharge reconciliation module at discharge~Transfer of information on discontinued and changed medication to respective dispensing pharmacies and prescribing physicians"
9958854|NCT01179867|No Intervention|Usual practice medication reconciliation|Usual practice in dealing with medication reconciliation. This includes viewing the hospital medications through the hospital electronic pharmacy system, and viewing the community drugs in the patient's chart, if it was collected at admission (not always the case). However not all physicians view the community drugs before writing the discharge prescription. The physician will write a paper discharge prescription to be given to the patient, but communications are generally not made directly to the community pharmacist or previous prescribing physicians.
9958855|NCT01179880|Experimental|1|
9958856|NCT01179880|Placebo Comparator|2|
9958857|NCT01179893|Active Comparator|IVIG|Intravenous Immunoglobulin, 2G/Kg, infused over 2 days in the Medical Day Unit of the University Health Network
9958858|NCT01179893|Experimental|PLEX|Patients received one plasma volume plasma exchanges with 5% albumin replacement fluid. Five plasma exchange procedures occurred every second day with breaks over the weekend allowed. Patients treated in the apheresis units at the University Health Network.
9958859|NCT01179906|Experimental|Lifestyle intervention-exercise & diet|Subjects trained for 48 weeks with a personal trainer
9958860|NCT01179945|Experimental|sodium benzoate containing|
9958861|NCT01179945|Active Comparator|non sodium benzoate containing|
9958862|NCT01179958|Experimental|aerobic training|24 weeks of aerobic training, 4 times/week
9958863|NCT01179958|Placebo Comparator|stretching/toning|stretching/toning condition, 24 weeks to parallel the active intervention group
9958864|NCT01179971|Experimental|Fish oil|3g/d
9958865|NCT01179971|Experimental|Gamma-linolenic Acid|3g/d gamma-linolenic acid
9958866|NCT01179971|Experimental|Fish oil plus GLA|1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid
9958867|NCT01179971|Sham Comparator|Olive oil|3 g/d olive oil
9958868|NCT01179997|Active Comparator|Tissue Doppler Imaging (TDI) optimization|Interventricular pacing delay optimized according to Tissue-Doppler echocardiography
9958869|NCT01179997|Active Comparator|Electrocardiographic optimization|Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram
9958870|NCT01180023|Experimental|Sweeping|
9958871|NCT01180023|No Intervention|No sweeping|
9958872|NCT01180062|Active Comparator|Arm 1|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
9958873|NCT01180062|Active Comparator|Active Comparator - Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
9958874|NCT01180062|Active Comparator|Active Comparator - Arm 3|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
9958875|NCT01180075||TDF/FTC/EFV Intensive Sampling-Group A|Patients receiving TDF/FTC/EFV who undergo intensive pharmacokinetic sampling over 24 hours
9958876|NCT01180075||TDF/FTC/ATV/r Intensive Sampling Group A|Patients receiving TDF/FTC/ATV/r who undergo intensive pharmacokinetic sampling over 24 hours
9958877|NCT01180075||TDF/FTC/EFV Sparse Sampling Group B|Patients receiving TDF/FTC/EFV who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
9958878|NCT01180075||TDF/FTC/ATV/r Sparse Sampling Group B|Patients receiving TDF/FTC/ATV/r who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
9958879|NCT01180088|Experimental|ANTERIOR APPROACH|SURGICAL TECHNIQUE
9958880|NCT01180101|Active Comparator|Lifestyle modification group|This group will undergo supervised exercise training 5 days per week and follow hypocaloric diet for 12 weeks. All exercise training sessions will be supervised by an Exercise Physiologist or Research Nurse, and will be conducted in the Exercise Physiology Laboratory at the CCF CRU. Exercise training will consist of walking, running on a treadmill, and stationary cycling on a cycle ergometer. Each exercise session will include a brief standardized warm-up and cool-down that include a series of stretching exercises.
9958881|NCT01180101|Active Comparator|Bariatric Surgery Group|This group will include CKD patients who undergo bariatric surgery.
9958882|NCT01180101|No Intervention|CKD Group (control)|This group will not undergo any form of weight loss intervention
9958883|NCT01180114|Experimental|SUUBI-MAKA|Involves creating and broadening asset ownership opportunities and life options for children (ages 12 to 15 years) orphaned due to AIDS in Uganda.
9958884|NCT01180114|Other|Usual Care|No intervention for asset ownership, development of future planning skills, enhancement of mental health and reduction of risk taking behaviors for children orphaned due to AIDS in Uganda.
9958885|NCT01180140|No Intervention|1|without seamguard
9958886|NCT01180140|Experimental|2|with seamguard
9958887|NCT01180153|Experimental|SOX: advanced BTC or ampullary carcinoma|unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen
9958888|NCT01180166|Experimental|nimotuzumab|Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
9958889|NCT01180179|Active Comparator|Lansoprazole 30mg once daily|Lansoprazole 30mg once daily
9958890|NCT01180179|Active Comparator|Famotidine 40mg once daily|Famotidine 40mg once daily
9958891|NCT01180192|Experimental|oxygen|
9958892|NCT01180205|Active Comparator|T/A|Telmisartan + Amlopidpine
9958893|NCT01180205|Active Comparator|O/HCT|Olmesartan + Hydrochlorothiazide
9958894|NCT01180231|Active Comparator|Moxonidine|
9958895|NCT01180231|Active Comparator|Diet|
9958896|NCT01180231|Active Comparator|Moxonidine and diet|Subjects will be asked to take moxonidine and follow dietary plan designed by a qualified nutritionist for 6 months.
9958897|NCT01180231|No Intervention|Control|Subjects will not be asked to take any interventions.
9958898|NCT01180270||Cervical dystonia|"patients suffering from cervical dystonia~under routine botulinum toxin treatment"
9958899|NCT01180270||healthy volunteers|control group
9958900|NCT01180283|Experimental|lodenafil carbonate (Helleva®)|
9958901|NCT01180309||lingual frenum alterations|individuals each one with their phonological system complete
9958902|NCT01180322|Active Comparator|Arm A|Standard Therapy
9958903|NCT01180322|Experimental|Arm B|"Investigational Therapy Azacitidine Prior"
9958904|NCT01180322|Experimental|Arm C|"Investigational Therapy Azacitidine Concurrent"
9958905|NCT01180322|Experimental|Arm D|"Investigational Therapy Azacitidine After"
9958906|NCT01180335|Active Comparator|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
9958907|NCT01180335|Experimental|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
9958908|NCT01180348|Experimental|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
9958909|NCT01180348|Active Comparator|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
9958910|NCT01180413|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment
9958911|NCT01180426|Experimental|Tosedostat|
9958912|NCT01180452|Other|Single group open label|Prospective Cohort
9958913|NCT01180517|Active Comparator|Drug Eluting Balloon|
9958914|NCT01180517|Active Comparator|Plain Old Balloon Angioplasty (POBA)|
9958915|NCT01180530||A|
9958916|NCT01180543|Active Comparator|Active Comparator: Oplon Active Patch|
9958917|NCT01180543|Placebo Comparator|Placebo Comparator: Placebo patch|
9958918|NCT01180556|Experimental|Probiotics supplementation|Supplementation by probiotics for 4 weeks
9958919|NCT01180556|Placebo Comparator|Placebo|Supplementation of placebo for 4 weeks
9958920|NCT01180569|Experimental|lenalidomide|Eligible patients for this clinical trial will be treated for 6 cycles with lenalidomide at 15 mg daily by mouth on Days1-21 of 28 day cycle, preceded by an escalating schema for safety (5mg daily for 2 weeks; 10 mg daily for 2 weeks; and 15 mg daily for 2 weeks) and then a one week rest).
9958921|NCT01180595|Other|Modular|Trabecular Metal Modular Tibial Total Knee Component
9958922|NCT01180595|Other|Monoblock|Trabecular Metal Monoblock Tibial Total Knee Component
9958923|NCT01180608|Active Comparator|Pregabalin|
9958924|NCT01180608|Placebo Comparator|placebo + pregabalin|
9958925|NCT01180621|Experimental|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
9958926|NCT01180673|Experimental|MINT-TLC|
9958927|NCT01180673|Active Comparator|Control Condition|
9958928|NCT01180686|Active Comparator|Multiple thrust Impulse instrument|This instrument automatically delivers 12 thrusts at the same intensity over the joint involved.
9958929|NCT01180686|Active Comparator|Single impulse Activator IV instrument|This is a manual spring loaded device that delivers one thrust to the joint involved
10005973|NCT01590147|Active Comparator|Arm 2 (CE)|Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.
9958930|NCT01180699|Experimental|influenza vaccine - intradermal|intradermal versus intramuscular
9958931|NCT01180699|Active Comparator|influenza vaccine - intramuscular|
9958932|NCT01180712|Active Comparator|Blaeberry concentrated caspule|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days.~Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)"
9958933|NCT01180712|Placebo Comparator|Placebo capsules containing lactose|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days."
9958934|NCT01180738|Active Comparator|Body weight supported treadmill training|
9958935|NCT01180738|Active Comparator|Overground walking training|
9958936|NCT01180751|Other|[18F]-Fluorodeoxyglucose|Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
9958937|NCT01180764|Experimental|Lovaza|Lovaza 4g po qd
9958938|NCT01180764|Placebo Comparator|Placebo|Matching placebo
9958939|NCT01180803|Experimental|oxygen-saving valves|
9958940|NCT01180803|Active Comparator|continuous oxygen supplementation|
9958941|NCT01180816|Experimental|Temozolomide (Temodar)|
10005974|NCT01590160|Experimental|Cisplatin/Pemetrexed|Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
10005975|NCT01590160|Experimental|Carboplatin/Pemetrexed|Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
10005976|NCT01590173|Experimental|Prednisolone and Heparin during COH for IVF|
10005977|NCT01590173|Active Comparator|COH for IVF|
10005978|NCT01590199|Experimental|RAD001 + SOM230|
10005979|NCT01590225|Experimental|Part A: boceprevir + peginterferon alpha-2b + ribavirin|
10005980|NCT01590225|Experimental|Part B: boceprevir + peginterferon alpha-2b + ribavirin|
10005981|NCT01590251|Experimental|Yoga|Gentle yoga for chronic pain and opioid dependence
10005982|NCT01590251|Active Comparator|Educational Counseling|Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
10005983|NCT01590277|Experimental|ethanol and iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
10005984|NCT01590277|Experimental|placebo ethanol|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
9958942|NCT01180829|No Intervention|Control condition|No interventions text messages sent
9958943|NCT01180829|Experimental|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking
9958944|NCT01180829|Experimental|Consciousness raising text message|A series of 12 text messages, each of which contains text designed to get the person to think about his or her drinking
9958945|NCT01180842|Other|Alternative Treatment|The CF Patient Population receiving the specific yoga study treatment
9958946|NCT01180855|Placebo Comparator|Placebo|Placebo pills prepared by Takeda Pharmaceutical.
9958947|NCT01180855|Active Comparator|Rozerem|Rozerem 8mg
9958948|NCT01180855|Active Comparator|Rozerem + Multi Component Behavior Therapy|Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
9958949|NCT01180868||patients with cancer|patients with hematological malignancies and solid tumors
9958950|NCT01180868||patients with autoimmune dosorders|patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
9958951|NCT01180868||healthy subjects|
9958952|NCT01180907||patients with cancer|
9958953|NCT01180907||patients with autoimmune diseases|
9958954|NCT01180907||healthy subjects|
9958955|NCT01180920||Periodontal disease|11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
9958956|NCT01180920||Healthy periodontium|11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
9958957|NCT01180933|Experimental|fish oil|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA and 150 eicosapentaenoic acid per day from gestational week 22 until delivery
9958958|NCT01180933|Experimental|folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 400 µg folate (methyltetrahydrofolate)per day from gestational week 22 until delivery
9958959|NCT01180933|Experimental|fish oil + folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA, 150 mg eicosapentaenoic acid and 400 µg MTHF per day from gestational week 22 until delivery
9958960|NCT01180933|Placebo Comparator|placebo|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women from gestational week 22 until delivery
9958961|NCT01180946|Active Comparator|Ergocalciferol|Weekly ergocalciferol for 16 weeks
9958962|NCT01180946|Placebo Comparator|Placebo|Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
9958963|NCT01180959|Experimental|Erlotinib + Bevacizumab|Erlotinib 150 mg by mouth once a day. Bevacizumab 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes.
9958964|NCT01181024|Experimental|A: HV ascending dose|
9667722|NCT03161223|Other|D: durvalumab, 5-azacitidine|Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
9958965|NCT01181024|Experimental|B: HV food effect|
9958966|NCT01181024|Experimental|C: Hepatitis C|
9958967|NCT01181037||100 patients, displaced subcapital fracture, T.A.N nail.|100 patients sustained a displaced femoral subcapital fracture, that were operated on with closed reduction and internal fixation with TAN nail.
9958968|NCT01181037||100 patients, displaced subcapital fracture, Bipolar H.A..|
9667723|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
9667724|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
9958969|NCT01181063|Experimental|400/12 μg D94-2BF (60/40) inhaler|
9958970|NCT01181063|Experimental|320/9 μg D94-2BF (20/80) inhaler|
9958971|NCT01181063|Active Comparator|Symbicort 320/9 μg inhaler|
9958972|NCT01181063|Experimental|320/9 μg D94-2F (60/40) inhaler|
9958973|NCT01181063|Experimental|320/9 μg D94-2BF (60/40) inhaler|
9958974|NCT01181115|Experimental|Active treatment|Interferon treatment for MS
9958975|NCT01181154|Placebo Comparator|equivalent volume total (=1000 ml)|Placebo : equivalent volume total (=1000 ml)
9958976|NCT01181154|Experimental|rituximab (Mabthera®)|rituximab (Mabthera®), 1000 mg at day 1 and day 15
9958977|NCT01181180|Experimental|balance treatment|
9958978|NCT01181206|Active Comparator|Arm 1|
9958979|NCT01181206|Active Comparator|Arm 2|
9958980|NCT01181219|Experimental|CXL without epithelial removal|Application of Riboflavin and the consequent UV-irradiation with intact corneal epithelium
9958981|NCT01181219|Active Comparator|CXL with epithelial removal|Corneal epithelial removal prior to Riboflavin and the consequent UV-irradiation
9958982|NCT01181232|Experimental|MR low-dose group|
9958983|NCT01181232|Experimental|MR high-dose group|
9958984|NCT01181232|Active Comparator|IR group|
9958985|NCT01181245|Experimental|FG-3019|All subjects are treated with FG-3019
9958986|NCT01181284||Lisinopril|Participants will be randomized 2 to 1 to receive drug versus placebo.
9958987|NCT01181297|Experimental|Extensively Hydrolyzed Formula with a Probiotic|Extensively Hydrolyzed Formula with a Probiotic
9958988|NCT01181297|Placebo Comparator|Extensively Hydrolyzed Formula without a Probiotic|
9958989|NCT01181310|Experimental|A, B, D, E, C|Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.
9958990|NCT01181310|Experimental|B, C, E, A, D|Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.
9476602|NCT03570268|Experimental|Experimental group: Education group|Participants in the experimental intervention group (education group) received an educational program and tailored home exercises. This intervention consist of multiple, interacting components supported by a handbook and audio-video material designed to teach people the skills, techniques, and strategies for preventing falls, and increase social participation and engagement in inactivity of daily living. . After the educational session, two one hour sessions were spent to teach safe balance exercises that were developed in preceding studies, the patient was invited to perform at home for 2 months.
9667725|NCT03153787|Experimental|Not pregnancy|Vaginal probiotic administration
9958991|NCT01181310|Experimental|C, D, A, B, E|Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.
9958992|NCT01181310|Experimental|D, E, B, C, A|Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.
9958993|NCT01181310|Experimental|E, A, C, D, B|Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.
9958994|NCT01181310|Experimental|A, C, B, E, D|Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.
9958995|NCT01181310|Experimental|B, D, C, A, E|Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.
9958996|NCT01181310|Experimental|C, E, D, B, A|Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.
9958997|NCT01181310|Experimental|D, A, E, C, B|Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.
9958998|NCT01181310|Experimental|E, B, A, D, C|Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.
9958999|NCT01181336|Experimental|Group 2|"FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
9959000|NCT01181336|Experimental|Group 3|"FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
9959001|NCT01181336|Experimental|Group 4|High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
9959002|NCT01181336|Experimental|Group 1|FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
9959003|NCT01181336|Placebo Comparator|Control Group|Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
9959004|NCT01181362|Other|Endoscopy|
9959005|NCT01181375|Experimental|Assays on cervical cancer tissue|
9959006|NCT01181388|Active Comparator|intra-guide-catheter infusion of tirofiban|
9959007|NCT01181388|Experimental|intra-thrombus-aspiration-catheter infusion of tirofiban|
9959008|NCT01181401|Active Comparator|TPF standard|"TPF version 1 (standard)~Induction chemotherapy:~Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
9959009|NCT01181401|Experimental|TPF experimental|"TPF version 2 (experimental)~Induction chemotherapy:~Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
9959010|NCT01181401|Active Comparator|Standard RCT|"Standard RCT:~HART (72 Gy), IMRT or 3D-conformal techniques~with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5"
9959011|NCT01181414|Experimental|Atrioventricular junction ablation|Atrioventricular junction ablation by using radiofrequency energy.
9667726|NCT03138512|Experimental|Part A, Arm A: nivolumab + ipilimumab|
9667727|NCT03138512|Placebo Comparator|Part A, Arm B: nivolumab placebo + ipilimumab placebo|
9959012|NCT01181414|Active Comparator|Drug control of ventricular rate|Drug control of ventricular rate.
9959013|NCT01181427|Placebo Comparator|Single Ascending Dose (SAD)|Healthy volunteers, receiving single ascending doses of ABT-267 or placebo.
9959014|NCT01181427|Placebo Comparator|Multiple Ascending Dose (MAD)|Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor.
9959015|NCT01181427|Active Comparator|Food Effect (FE)|Healthy volunteers, receiving ABT-267, multi-dose, food effect.
9959016|NCT01181427|Placebo Comparator|Antiviral Activity|HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days.
9959017|NCT01181427|No Intervention|Resistance Monitoring|"HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the Antiviral Activity arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected"
9959018|NCT01181440|Experimental|Dermagraft(R) and conventional care|
9959019|NCT01181440|Other|Conventional care only|
9959020|NCT01181453|Experimental|Dermagraft(R)|Weekly application of Dermagraft(R) with standard care
9959021|NCT01181453|Other|Standard care only|Weekly application of standard care
9959022|NCT01181505|Experimental|Tolterodine|
9959023|NCT01181544|Experimental|Heparin dose titration|
9959024|NCT01181557||rectal cancer with stoma|rectal cancer submitted to rectal anterior resection with stomia (RARS). Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month after stoma reconversion
9959025|NCT01181557||rectal cancer without stoma|rectal cancer submitted to rectal anterior resection (RAR) Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month later
9959026|NCT01181557||anterior resection of rectum|patients with rectal cancer submitted to RAR and patients with rectal cancer submitted to RARS
9959027|NCT01181570|Experimental|Adalimumab|
9959028|NCT01181570|Placebo Comparator|Placebo|
9959029|NCT01181583|Experimental|Tailored Internet-delivered CBT|
9959030|NCT01181583|Experimental|Non-tailored Internet-delivered CBT|
9959031|NCT01181583|Active Comparator|Online discussion group|
9959032|NCT01181635|Experimental|Psychotherapy|Short-term pychotherapy and/or psychoeduchative courses.
9959033|NCT01181648||oropharynx cancer survivors|This study has two components. First, we will conduct a cross-sectional survey of 200 oropharynx cancer survivors, diagnosed with HPV+ tumors, who are at least 12 months from their last treatment. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis.
9959034|NCT01181661|Experimental|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
9959035|NCT01181661|Experimental|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
9959036|NCT01181700|Experimental|Treatment A|
9959037|NCT01181700|Experimental|Treatment B|
9959038|NCT01181700|Experimental|Treatment C|
9959039|NCT01181700|Active Comparator|Treatment D|
9959040|NCT01181700|Active Comparator|Treatment E|
9959041|NCT01181700|Active Comparator|Treatment F|
9959042|NCT01181700|Active Comparator|Treatment G|
9959043|NCT01181713||No Antibiotic|No prophylactic antibiotic post intravitreal injection
9959044|NCT01181713||Prophylactic Antibiotic|Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
9959045|NCT01181752||Group A|Baseline/control subjects who are only tested on postoperative day 30
9959046|NCT01181752||Group B|Subjects who will be tested on postoperative day 1 and day 30
9959047|NCT01181752||Group C|"Subjects who cannot proficiently administer the medication on postoperative day 1 will be re-classified as Group C subjects"
9959048|NCT01181765|Experimental|Infliximab infusions (5 mg/kg) at weeks 0, 2, 6, 14 and 22|
9959049|NCT01181791|Experimental|probiotic group|Lactobacillus reuteri will be given at a dose of 1x108 colony forming units (CFU)/day
9959050|NCT01181791|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
9959051|NCT01181817|Other|SCS|patients with Failed back Surgery syndrome treated with SCS
9959052|NCT01181830|Active Comparator|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
9959053|NCT01181830|Placebo Comparator|placebo|administration of 8.1 mmol bid of placebo for 8 weeks
9959054|NCT01181843||Cesearean sections receiving duramorph|
9959055|NCT01181856|Experimental|Group A|Intramuscular immunisation
9959056|NCT01181856|Experimental|Group B|Intradermal immunisation
9959057|NCT01181869||Oxygen therapy|Database of patients on oxygen
9959058|NCT01181869||ventilation|database of patients on ventilatory support
9959059|NCT01181869||Continuous positive airway pressure|Sleep apnoea patients on CPAP
9667728|NCT03138512|Experimental|Part B, Arm A: nivolumab + ipilimumab|
9959060|NCT01181882|Experimental|Fish Oil and Aspirin|
9959061|NCT01181908|Experimental|GSK1144814|Subjects will receive either GSK1144814 or placebo at each treatment arm.
9959062|NCT01181908|Placebo Comparator|placebo|Subjects will receive either GSK1144814 or placebo at each treatment arm.
9959063|NCT01181934|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
9959064|NCT01181934|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
9959065|NCT01181934|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
9959066|NCT01181960||001|Risperidone long acting injectable - New Starts Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
9959067|NCT01181960||002|Risperidone long acting injectable - Continuous Users Patients who have been on Risperidone long acting injectable for at least 6 months before baseline with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
9959068|NCT01181960||003|Paliperidone Palmitate -New and Continuous Users Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
9959069|NCT01181960||004|Other Antipsychotics - New Starts Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
9959070|NCT01181973|Active Comparator|Treatment sequence #1|One 1-mL subcutaneous injection at 30 mg/mL in Period 1 and two 1-mL subcutaneous injections at 15 mg/mL each in Period 2
9959071|NCT01181973|Active Comparator|Treatment sequence #2|Two 1-mL subcutaneous injections at 15 mg/mL each in Period 1 and one 1-mL SC injection at 30 mg/mL in Period 2
9959072|NCT01181999|Experimental|rituximab|
9959073|NCT01182012|Experimental|Lifestyle counseling|Adjust drug treatment to control cardiovascular factor risks. A nurse will implement a lifestyle counseling in order to improve compliance of treatment and a healthy lifestyle.
9959074|NCT01182025|Active Comparator|Western therapy|
9959075|NCT01182025|Experimental|Xiyanping Injection|
9959076|NCT01182025|Experimental|Xiyanping Injection with western medicine|
9959077|NCT01182038|Experimental|Birth seat group|Randomized to birth on a midwife designed birth seat
9959078|NCT01182038|No Intervention|Non-birth seat group|Randomized to birth in any other position except on the midwife designed birth seat.
9959079|NCT01182051|Experimental|Cognitive behavioral therapy|Key treatment ingredients in CBT include psychoeducation, trigger identification, progressive muscle relaxation training, cognitive restructuring, problem solving, in vivo exposure, and relapse prevention (see Appendix I for an outline of the treatment manual).
9959080|NCT01182051|Active Comparator|Relaxation Training|RT will consist of progressive muscle relaxation training, diaphragmatic breathing, and thermal biofeedback.
9959081|NCT01182064||Non infarct|
9959082|NCT01182064||Posttraumatic acute myocardial infarct without coronary injury|
9959083|NCT01182064||Posttraumatic acute myocardial infarct with coronary injury|
9959084|NCT01182077|Experimental|Group 1|ASP015K low dose and midazolam followed by ASP015K high dose and midazolam
9959085|NCT01182077|Experimental|Group 2|ASP015K high dose and midazolam followed by ASP015K low dose and midazolam
9959086|NCT01182090|Active Comparator|Prolapse repair by open approach|Correction of urogenital prolapse by open surgery approach
9959087|NCT01182090|Active Comparator|Prolapse repair by laparoscopic approach|Correction of urogenital prolapse by laparoscopic approach
9959088|NCT01182116|Experimental|J Pouch side to end|Colorectal surgery Function Quality of Life
9959089|NCT01182129|Active Comparator|Swedish Snus Type 1|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
10005985|NCT01590277|Experimental|active iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
10005986|NCT01590277|Experimental|placebo iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
10005987|NCT01590290|Active Comparator|pay for performance|
9476603|NCT03570268|Active Comparator|Control Group: Usual care|Participants allocated to the control group received ongoing usual treatments. In addition, two one hour lessons were spent to teach stretching exercises that the patient was invited to perform at home for 2 months.
9667729|NCT03138512|Placebo Comparator|Part B, Arm B: nivolumab placebo + ipilimumab placebo|
10005988|NCT01590290|No Intervention|no pay for performance|
10005989|NCT01590303|Experimental|Vitamin C|Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
10005990|NCT01590303|Placebo Comparator|placebo|placebo vehicle administered in same fashion as active treatment
10005991|NCT01590316|Experimental|Cerebral NIRS oximetry + treatment guideline based on reading|
10005992|NCT01590316|No Intervention|Blinded cerebral NIRS oximetry|
10005993|NCT01590329|Experimental|Micrografting|
10005994|NCT01590342|Active Comparator|Diclofenac|
10005995|NCT01590342|Placebo Comparator|Placebo|
10005996|NCT01590355|Active Comparator|Radiotherapy plus or minus Chemotherapy|Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease
10005997|NCT01590355|Experimental|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.
10035263|NCT01804504|No Intervention|Control|"Food Frequency Questionnaire(FFQ) and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial."
10035264|NCT01804504|Experimental|Nutrition education|"FFQ and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial.~Do nutrition education"
10035265|NCT01804517||Physician based approach|Patients will be managed as usual at the clinic without the intervention of the nurse.
10035266|NCT01804517||Physician and nurse|Patients will be managed with the help of the nurse for education and follow-up.
10035267|NCT01804530|Experimental|PLX7486-TsOH, Dose escalation and RP2D|Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
10035268|NCT01804543||Angina, Heart Disease|ranolazine 500 mg twice daily for 1 week, then 1000 mg twice daily for 3 weeks
10035269|NCT01804556|Other|Myofascial trigger point injection|Myofascial trigger point injection on gastrocnemius muscle
10035270|NCT01804569|Experimental|moxa|moxibustion treatment 3 times a week for 3 weeks
10035271|NCT01804595|Experimental|Sunscreen|To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
10035272|NCT01804595|Experimental|Text Message Reminders|"As cues to action, this group will receive 60 cellular telephone text-messages on three random mornings per week during the month of May, June, July, August, and September when UV rays are the highest. Using an internet text-messaging service, the messages will be computer generated and sent to Operating Engineers and contain information about weather conditions and various reminders (e.g., Put on sunscreen today or Wow, it's a hot one, you know what to do!)."
10035273|NCT01804595|Experimental|Sunscreen and Text Message Reminders|Just as multimodal interventions such as surgery and radiation can be used to treat skin cancer, multimodal behavioral interventions may reduce sun burning and prevent skin cancer. To determine if the combination of these interventional components results in improvements above and beyond the individual parts, both sunscreen and text messaging interventions will be provided in addition to education.
9959090|NCT01182129|Active Comparator|Swedish Snus Type 2|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
9959091|NCT01182129|Active Comparator|4 mg Nicorette chewing gum|Nicorette is chewed according to instructions in package insert over 30 minutes.
9959092|NCT01182142|Experimental|Capecitabine|All patients will receive capecitabine.
9959093|NCT01182168|Experimental|gemcitabine and cisplatin plus Everolimus|This is a single-institution phase I study of gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) in patients with advanced urothelial cancer.
9959094|NCT01182220||Ultrasound L5/S1 catheter placement|Pt will have back scanned with Ultrasound and L5/S1 interspace localized for epidural placement.
9959095|NCT01182220||Control Group|Patients will have catheter placed after clinically evaluating the back as is done routinely resulting in mid lumbar catheter placement in general.
9959096|NCT01182233|Experimental|Total Skeletal Irradiation|Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.
9959097|NCT01182246|Experimental|AXP107-11|
9959098|NCT01182311||Controls|Never received HBV vaccine and never had HBV
9959099|NCT01182311||HIV vaccinated >= 10 years|Well compensated HIV disease, vaccinated HBV >= 10 years ago
9959100|NCT01182311||Spontaneously recovered >= 10 years|Spintaneously recovered from acute HBV >= 10 years ago
9959101|NCT01182311||Vaccinated >= 20 years|Vaccinated against HBV >= 20 years ago
9959102|NCT01182311||Vaccinated 10 < 15 years|Vaccinated against HBV 10 < 15 years ago
9959103|NCT01182311||Vaccinated 15 < 20 years|Vaccinated against HBV 15 < 20 years ago
9959104|NCT01182363|No Intervention|Control|Usual early intervention services
9959105|NCT01182363|Experimental|Problem Solving Education|
9959106|NCT01182389|Active Comparator|robotic VT Ablation|Robotic VT ablation by substrate elimination
9959107|NCT01182389|Active Comparator|Conventional therapy|review of ICD programming to ensure that detection and therapy will occur appropriately.
9959108|NCT01182402|Experimental|Electronic compliance monitoring|Suboxone treated patients in Kuopio city area get their unsupervised Suboxone doses in electronic compliance monitoring devices during the 4 month study.
9959109|NCT01182467||Crohn's disease|Patients will receieve Radiation: PET-CT scan
9959110|NCT01182506|Experimental|Breast cancer survivors|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
9959111|NCT01182506|Experimental|Collateral source|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
9959112|NCT01182519||Diagnosed with metastatic breast cancer|"The primary objective of this study is to examine the association between urinary PGE-M and the presence or absence of lung metastases in patients with breast cancer. These patients will be subdivided into a set with lung metastases (group 1A; clinically assessed as per guidelines below) versus those with no evidence of lung metastases (group 1B; no known lung metastases). Group #2 (control) will have been treated for early stage breast cancer and will have no known metastases."
9959113|NCT01182519||History of early breast cancer|History of early breast cancer and currently no evidence of disease
9959114|NCT01182532|Active Comparator|Western therapy|
9959115|NCT01182532|Experimental|TCM treatment|
9959116|NCT01182532|Experimental|Western therapy plus TCM treatment|The combination of both western therapy and TCM treatment.
9959117|NCT01182545|Placebo Comparator|The normoventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a tidal volume (TV) of about 8 mL.kg-1 and respiratory rate (R.R) owas adjusted to maintain an end-tidal CO2 (ETCO2) of 4.6-6 kPa throughout the procedure.
9959118|NCT01182545|Active Comparator|The hyperventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a TV of 8 mL.kg-1 with the adjustment of the R.R to maintain an ETCO2 of 4-4.6 kPa, until the end of anaesthesia.
9959119|NCT01182558|Other|Activation of Hypothenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
9959120|NCT01182558|Other|Activation of Thenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
9959121|NCT01182558|Other|Activation of Extensor Digitorum Brevis|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
9959122|NCT01182558|Placebo Comparator|Maintain Relaxation of the Opposite Side|While the muscle of the right side is activated periodically and the compound muscle action potential is tested frequently, the muscle on the left side is maintained at rest and the compound muscle action potential is tested infrequently.
9959123|NCT01182571||heart transplantation|
9959124|NCT01182584||Graves' disease|
9667730|NCT03138512|Experimental|Part B, Arm C: nivolumab + ipilimumab placebo|
9959125|NCT01182584||Healthy volunteers|
9959126|NCT01182597|Active Comparator|IV PPI|Pantoprazole 3.3mg/hr for 72hrs
9959127|NCT01182597|Experimental|Oral PPI|Lansoprazole (Takepron OD) 30mg PO q12h
9959128|NCT01182623||In vivo diagnosis|Patients undergoing colonoscopy where one or more polyps up to 10mm in size are found.
9959129|NCT01182636|Experimental|Investigational Test Product|Adapalene Topical Gel, 0.1%
9959130|NCT01182636|Active Comparator|Reference Listed Drug|Differin® (adapalene 0.1%) Topical Gel
9959131|NCT01182636|Placebo Comparator|Placebo|Gel base only
9959132|NCT01182649|Experimental|EES Group|Patients who received an everolimus eluting stent
9959133|NCT01182649|Active Comparator|SES Gruop|Patients who received a sirolimus eluting stent
10005998|NCT01590368|Other|Marketed electrode|The currently marketed electrodes using the current CE marked adhesive
9959134|NCT01182662|Experimental|Human umbilical cord-derived MSCs and cyclosporin|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months
9959135|NCT01182662|Active Comparator|cyclosporine A|cyclosporine A at a dose of 5 mg CsA/kg
9959136|NCT01182701|Active Comparator|Behavioral intervention|
9959137|NCT01182701|No Intervention|Education support|
9476604|NCT03570242|No Intervention|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
10005999|NCT01590368|Active Comparator|Modified hydrogel|"Electrodes with the new modified adhesive - the test electrodes"
10006000|NCT01590381||personnel in medical training - COURSE 1|
10006001|NCT01590381||personnel in medical training - COURSE 2|
10006002|NCT01590381||personnel in medical training - COURSE 3|
10006003|NCT01590381||personnel in medical training - COURSE 4|
10006004|NCT01590381||personnel in medical training - COURSE 5|
10006005|NCT01590381||personnel in medical training - COURSE 6|
10006006|NCT01590381||personnel in medical training - COURSE 7|
10006007|NCT01590381||personnel in medical training - COURSE 8|
10006008|NCT01590381||personnel in medical training - COURSE 9|
10006009|NCT01590381||personnel in medical training - COURSE 10|
10006010|NCT01590407|Experimental|ALS-002200|
10006011|NCT01590407|Placebo Comparator|Placebo|
10006012|NCT01590420|Experimental|CPAP treatment|1000 patients with 3-years CPAP treatment after a PSG titration
10006013|NCT01590446|Placebo Comparator|Placebo|
10006014|NCT01590446|Active Comparator|BMN 111|
10006015|NCT01590472||Mesothelioma|Individuals who have been diagnosed with mesothelioma
10006016|NCT01590485|Placebo Comparator|Starch capsule|starch with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
10006017|NCT01590485|Active Comparator|Saffron capsule|saffron with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
10006018|NCT01590498||Salvage radiotherapy|local radiation to the prostate and metastasis following biochemical or clinical recurrence
10006019|NCT01590498||observation|did not receive salvage following biochemical or clinical recurrence
10006020|NCT01590511||The study population|Patients in the emergency room or intensive care in acute circulatory failure without ventilatory support.
10006021|NCT01590524|Experimental|CAM group|Subjects receiving the interventions and standard psychological care
10006022|NCT01590524|No Intervention|No-CAM group|Parents receiving only standard psychological care
10006023|NCT01590537||Group 1|
10006024|NCT01590537||Group 2|
10006025|NCT01590576||lower urinary tract symptoms and pelvic organ prolapse|
10006026|NCT01590589||REGISTRY participants|"Individuals~with manifest HD~unaffected but known to carry the HD mutation~unaffected but at risk of carrying the HD mutation~from HD families known not to carry the HD mutation~from outside HD families acting as control research participants (e.g., spouses)"
10006027|NCT01590602||JHD cases|All ages included, but must have an HD age of onset 25 or below
10006028|NCT01590615||Participants with chronic HBV infection|Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
10006029|NCT01590641|Experimental|0.3mg GS-9620|
10006030|NCT01590641|Experimental|1mg GS-9620|
10006031|NCT01590641|Experimental|2mg GS-9620|
10006032|NCT01590641|Experimental|4mg GS-9620|
10006033|NCT01590641|Experimental|0.3mg GS-9620 QW x 2 doses|
10006034|NCT01590641|Experimental|1mg GS-9620 QW x 2 doses|
10006035|NCT01590641|Experimental|2mg GS-9620 QW x 2 doses|
10006036|NCT01590641|Experimental|4mg GS-9620 QW x 2 doses|
10006037|NCT01590654|Experimental|0.3mg GS-9620|
10006038|NCT01590654|Experimental|1mg GS-9620|
10006039|NCT01590654|Experimental|2mg GS-9620|
10006040|NCT01590654|Experimental|4mg GS-9620|
10006041|NCT01590654|Experimental|0.3mg GS-9620 QW x 2 doses|
10006042|NCT01590654|Experimental|1mg GS-9620 QW x 2 doses|
10006043|NCT01590654|Experimental|2mg GS-9620 QW x 2 doses|
10006044|NCT01590654|Experimental|4mg GS-9620 QW x 2 doses|
10006045|NCT01590667|Active Comparator|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
10006046|NCT01590667|Placebo Comparator|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
10006047|NCT01590693|Experimental|Group 2|Children treated with four weeks of below knee walking casts and botulinum toxin A injections
10006048|NCT01590693|Active Comparator|Group 1|Children treated with four weeks of below knee walking casts.
10006049|NCT01590732|Experimental|Treatment (romidepsin, ifosfamide, carboplatin, etoposide)|Participants receive romidepsin IV over 4 hours on days 1 and 4, ifosfamide IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10006050|NCT01590745|Placebo Comparator|Sham Ultrasound regimen|A switch in the transducer circuit allows mock ionisation as a result no ultrasound emitted.
10006051|NCT01590745|Active Comparator|Real Ultrasound therapy|Pulsed mode ultrasound therapy
10006052|NCT01590823|Other|Dabigatran etexilate 110 mg|Single dose of Dabigatran etexilate 110 mg po
10006053|NCT01590836|Experimental|IDeg-->IDegAsp|
10006054|NCT01590849|No Intervention|No hormonal contraception|
10006055|NCT01590849|Active Comparator|Hormonal Contraceptive|healthy women, users of COC containing 20 mcg EE and 3 mg DRSP (Yaz®), 24 days of active pills, 4 days of pill-free interval (n=40).
10006056|NCT01590901|Other|probucol in healthy male subjects|multiple oral doses of probucol in single group of healthy male subjects
10006057|NCT01590914|Experimental|Roux-En Y Gastric Bypass|40 subjects who plan to undergo Roux-En-Y Gastric Bypass bariatric surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
9959138|NCT01182714|Other|removal of catheter|
9959139|NCT01182740||glidescope|
9959140|NCT01182740||storz c-mac|
9959141|NCT01182740||mcgrath vl|
9959142|NCT01182740||ambu pentax aws|
9959143|NCT01182740||macintosh laryngoscope|
9959144|NCT01182740||others|
9959145|NCT01182753|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
9959146|NCT01182753|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
9959147|NCT01182766|Experimental|topiramate|topiramate with brief behavioral enhancement therapy
9959148|NCT01182766|Placebo Comparator|Placebo|Placebo with brief behavioral enhancement therapy
9959149|NCT01182779|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
9959150|NCT01182779|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
9959151|NCT01182792|Experimental|Antioxidant|
9959152|NCT01182792|Placebo Comparator|Control|
9959153|NCT01182818||Observation|all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology
9959154|NCT01182831|Active Comparator|percutaneous fluoro guided celiac plexus neurolysis|
9959155|NCT01182831|Active Comparator|EUS guided neurolysis|
9959156|NCT01182870|Experimental|cholecalciferol|cholecalciferol in doses 800-6000 IU per day
9959157|NCT01182870|Placebo Comparator|placebo|placebo identical looking as cholecalciferol capsules
9959158|NCT01182922|Active Comparator|Doctor's Information Invitation|Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
9959159|NCT01182922|Active Comparator|Gender Preference Invitation|Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
9959160|NCT01182922|Active Comparator|Standard Invitation|Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
9959161|NCT01182935||participants in the 4th Tromsø study|
9959162|NCT01182948|Experimental|Aerobic Exercise|The aerobic training group will use cardiovascular training devices.
9959163|NCT01182948|Experimental|Resistance Exercise|The resistance training group will perform exercises on weight machines and free weights.
9959164|NCT01182961|Experimental|Treadmill +virtual reality training|
9959165|NCT01182961|Active Comparator|Treadmill alone|
9959166|NCT01182961|Active Comparator|standard of care exercise group|
9959167|NCT01182974|Active Comparator|paracetamol treatment|
9959168|NCT01182974|Active Comparator|control- dypirone treatment|
9959169|NCT01182987|Active Comparator|Dementia care management|Patients and family caregivers will be offered dementia care management, which includes detailed comprehensive assessment, education, counseling, referrals to community agencies, collaboration with medical providers and frequent telephone follow-up
9959170|NCT01182987|No Intervention|Usual care|Patients and care family care givers will receive usual support and medical care offered by the health plan.
9959171|NCT01183000|Active Comparator|peritoneal closure|
9959172|NCT01183000|No Intervention|Non closure of the peritoneum|
9959173|NCT01183039|Active Comparator|Ventilatory threshold|Training at the ventilatory threshold
9959174|NCT01183039|Active Comparator|Metabolic threshold|Training at the metabolic threshold
9959175|NCT01183052|Other|Training|20 sessions of training
9959176|NCT01183078|Other|Free-hand technique|Free-hand technique utilized to find screw holes.
9959177|NCT01183078|Other|Wand technique|Wand technique is utilized to find screw holes.
9959178|NCT01183091||First AF ablation|Description of the patients experiencing an AF ablation
9959179|NCT01183117|Experimental|SM-01|
9959180|NCT01183117|Active Comparator|PTA|
9959181|NCT01183130|Experimental|Compliance monitoring in real time|Patients get their opioid substitution medications in electronic compliance monitoring devices and send information of their medication intakes with mobile phone to the clinic every day during the two month study period.
9959182|NCT01183130|Active Comparator|Compliance monitoring|Patients get their opioid substitution medications in electronic compliance monitoring devices. Information of their medication intakes will be reviewed during the weekly visits to the clinic.
9959183|NCT01183156|Active Comparator|Re-invitation letter|
9959184|NCT01183156|Active Comparator|Educational Meeting|
9959185|NCT01183182|Experimental|Needle Guidance|Lung biopsies performed with the needle guidance system.
9959186|NCT01183208|Experimental|Cohort 1 active treatment and placebo|Active treatment and placebo
9959187|NCT01183208|Experimental|Cohort 2 - Active treatment and placebo|Active treatment and placebo
9959188|NCT01183208|Experimental|Cohort 3 Active Treatment and placebo|Active treatment and placebo
9959189|NCT01183247|Active Comparator|Rapamycin|Rapamycin-MMF-tacrolimus
9959190|NCT01183247|Active Comparator|Everolimus|Everolimus - tacrolimus - MMF
9959191|NCT01183247|Active Comparator|Prednisone|tacrolimus - MMF -prednisone
9959192|NCT01183273|Active Comparator|Micro-laparoscopic bypass|
9959193|NCT01183273|Active Comparator|Laparoscopic gastric bypass|
9959194|NCT01183286|Active Comparator|CFFONE|
9959195|NCT01183286|Placebo Comparator|CF website|
9959196|NCT01183299|Active Comparator|High salt intake|
9959197|NCT01183299|Placebo Comparator|Low salt intake|
9959198|NCT01183325|Experimental|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
9959199|NCT01183351|Experimental|Psychosocial intervention|This is a single-group pilot-study
9959200|NCT01183364|Experimental|STA-9090 and Docetaxel|STA-9090 (ganetespib) and Docetaxel
9959201|NCT01183377||1|Female athlete Triad syndrom was based on menstrual disorder,Eating Disorder and bone loss
9959202|NCT01183442|Active Comparator|vitamin D (Oleovit®)|vitamin D drops
9959203|NCT01183442|Placebo Comparator|Placebo|placebo drops
9959204|NCT01183455|Experimental|Aralast NP|Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.
9959205|NCT01183455|Placebo Comparator|Placebo|Participants will receive placebo intravenously once a week for 12 weeks.
9959206|NCT01183494|Experimental|UGT1A1*1/*1|Participants with UGT1A1*/*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
9959207|NCT01183494|Experimental|UGT1A1*1/*28|Participants with UGT1A1*1/*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
9959208|NCT01183507|Active Comparator|NIA intervention|
9959209|NCT01183507|Experimental|TSE intervention|
9959210|NCT01183572|Active Comparator|Folic Acid and Iron|0.4mg of folic acid and 30 mg elemental iron taken daily for 6 months
9959211|NCT01183572|Placebo Comparator|Folic Acid|0.4mg of folic acid taken daily for 6 months
9959212|NCT01183572|Active Comparator|Multivitamins, Folic Acid, and Iron|A multivitamin and micronutrient supplement that constitutes 1 RDA of Vitamins A (2500 IU), B1 (1.4 mg), B2 (1.4 mg), B6 (1.9 mg), B12 (2.6 ug), niacin (18 mg), C (70 mg), E (10 mg), and folic acid (0.4 mg)along with 30 mg of elemental iron taken daily for 6 months.
9959213|NCT01183585|Experimental|1|
9959214|NCT01183598|Experimental|Single Arm|
9959215|NCT01183611|Experimental|A1|health neonates born to mother with positive for both HBsAg and e antigen
9959216|NCT01183611|Active Comparator|A2|health neonates born to mother with positive for both HBsAg and e antigen
9959217|NCT01183611|Experimental|B1|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
9959218|NCT01183611|Active Comparator|B2|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
9959219|NCT01183611|Experimental|C1|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
9959220|NCT01183611|Active Comparator|C2|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
9959221|NCT01183611|Placebo Comparator|C3|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
9959222|NCT01183624|Experimental|Experimental Patch|Herbal Patch
9959223|NCT01183624|Placebo Comparator|Control Patch|Placebo Patch
9959224|NCT01183663|Experimental|Lenalidomide + Bevacizumab|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Bevacizumab starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
9959225|NCT01183663|Experimental|Lenalidomide + Sorafenib|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Sorafenib starting dose: 200 mg by mouth daily for 28 a day cycle.
9959226|NCT01183663|Experimental|Lenalidomide + Temsirolimus|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Temsirolimus starting dose: 15 mg by vein every week for a 28 day cycle.
9959227|NCT01183663|Experimental|Lenalidomide + Oxaliplatin + Leucovorin + 5-fluorouracil|Lenalidomide starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle. Oxaliplatin starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle. Leucovorin 400 mg/m2 by vein on day 1 of a 21 day cycle. 5-fluorouracil 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
9959228|NCT01183676|Experimental|Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
9959229|NCT01183676|Active Comparator|Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
9959230|NCT01183702|Active Comparator|non-LASIK|These participants have NOT had LASIK surgery.
9959231|NCT01183702|Active Comparator|LASIK|These participants have had LASIK surgery.
9959232|NCT01183715|Experimental|Cohort 1|Subjects in Cohort 1 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-05161704 will be administered in Period 4 in the fasted state.
9959233|NCT01183715|Experimental|Cohort 2|Subjects in Cohort 2 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3
9959234|NCT01183754||patients receiving drug-eluting stents|
9959235|NCT01183767|Active Comparator|EGCG|Epigallocatechin-Gallate (EGCG)
9959236|NCT01183767|Placebo Comparator|Placebo|
9959237|NCT01183793|Other|Bras pair|MR-enterography then barium follow through
9959238|NCT01183793|Other|Bras impair|Barium follow-through then MR-enterography
9959239|NCT01183806|Experimental|Rivastigmine and exercise program|Experimental group: Rivastigmine and exercise program: All patients will monthly receive Rivastigmine (Exelon patch). The exercise training program consists of two 40-minute sessions per week for six months and includes aerobic, strength, flexibility and balance training
9959240|NCT01183806|Active Comparator|Rivastigmine|Control group : Rivastigmine All patients will monthly receive Rivastigmine (Exelon patch)
9959241|NCT01183819|Experimental|Space Fortress and Exercise|Participants engage in aerobic exercise 4 times week and Space Fortress sessions 3 times a week for a total of 12 weeks.
9959242|NCT01183819|Active Comparator|Control Games and Exercise|Participants engage in aerobic exercise 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
9959243|NCT01183819|Active Comparator|Control Games and Stretching|Participants engage in stretching/toning exercises 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
9959244|NCT01183832||Concomitant|In this group, anastrazole is concomitant to the radiotherapy
9959245|NCT01183832||Sequential|In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
9959246|NCT01183845|Experimental|Exam with colon capsule|Colon Capsule Endoscopy
9959247|NCT01183871|Active Comparator|good pulmonary functions (group 1)|FVC and/or FEV1 of 80% of predicted or more
9959248|NCT01183871|Active Comparator|mild pulmonary dysfunction (group 2)|FVC and/or FEV1 of 70%-79% of predicted
9959249|NCT01183871|Active Comparator|moderate pulmonary dysfunction (group 3)|FVC and/or FEV1 of 60%-69% of predicted
9959250|NCT01183871|Active Comparator|severe pulmonary dysfunction (group 4)|FVC and/or FEV1 of 50%-59% of predicted
9959251|NCT01183910|Placebo Comparator|Calcium carbonate placebo pill|Placebo medication to treat the appearance of the skin in patients with senile purpura
9959252|NCT01183910|Active Comparator|Nutraceutical|Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
9959253|NCT01183936|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
9959254|NCT01183936|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
9959255|NCT01183962|Other|Vitamin D|Subject receives daily dose of Vitamin D
9959256|NCT01183962|Other|No medicine|Subject does not receive medication
9959257|NCT01184001|Experimental|Sequence 1|
9959258|NCT01184001|Experimental|Sequence 2|
9959259|NCT01184027||G-tube/swallowing intervention|patients will receive G-tube/nutritional and swallowing intervention. As per patient needs
9959260|NCT01184027||G-tube/swallowing counseling|G-tube/ad lib dietary and swallowing counseling. Current standard of care.
9959261|NCT01184027||nutrition/swallowing intervention|Patients will receive active nutrition and swallowing intervention based on patients caloric and swallowing needs.
9959262|NCT01184027||nutrition/swallowing counseling|Patients will have ad lib dietary intake with general nutrition and swallowing counseling.
9476605|NCT03570242|Experimental|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
9476606|NCT03570242|No Intervention|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
9476607|NCT03570242|Experimental|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
9476608|NCT03570216|Experimental|Exercise|All participants will perform 3 exercise sessions: one session to assess their cardiorespiratory fitness, one session on moderate-intensity continuous exercise and one session of high-intensity interval exercise
9476609|NCT03570203||Retrospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of admission.
9476610|NCT03570203||Prospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of recruitment.
9959263|NCT01184040|No Intervention|(A) Non-contingent control|Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
9959264|NCT01184040|Experimental|VIP CM|Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
9959265|NCT01184066|Experimental|ACTS Intervention|The intervention arm are the women who received the ACTS Intervention. It is a 45 minute intervention provided by a breast cancer survivor. The intervention includes a discussion of the patient's attitudes towards chemotherapy, communication strategies with providers, the recommended treatment in accordance with tumor size and tumor characteristics
9959266|NCT01184066|Active Comparator|Usual Care|This group receives care as usual.
9959267|NCT01184092|Experimental|Sequence 1|
9959268|NCT01184092|Experimental|Sequence 2|
9959269|NCT01184092|Experimental|Sequence 3|
9959270|NCT01184092|Experimental|Sequence 4|
9959271|NCT01184092|Experimental|Sequence 5|
9959272|NCT01184092|Experimental|Sequence 6|
9959273|NCT01184105|Experimental|Cohort 1 (pre)|Active treatment or placebo
9959274|NCT01184105|Experimental|Cohort 2 (post)|Active treatment or placebo
9959275|NCT01184131|Experimental|Mentor Training|The group that is randomized into the intervention group to attend Mentor Training Sessions.
9959276|NCT01184131|No Intervention|No Mentor Training|
9959277|NCT01184144|Experimental|pioglitazone|Pioglitazone study drug
9959278|NCT01184144|No Intervention|No drug|"Placebo like comparitor"
9959279|NCT01184157|Experimental|Home|Home-based STI screening using self-obtained vaginal swabs and postal return of samples.
9959280|NCT01184157|Active Comparator|Clinic|Receive STI screening in a clinical setting such as a private physician or clinic.
9959281|NCT01184170|Experimental|Metabolically Normal|"Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
9959282|NCT01184170|Experimental|Metabolically Abnormal|"Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
9959283|NCT01184183||Accuseal patch|
9959284|NCT01184183||Bovine Pericardial patch|
9959285|NCT01184196|Active Comparator|Arm 1|Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
9959286|NCT01184196|Active Comparator|Arm 2|Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.
9959287|NCT01184222|Active Comparator|Arm Active SENGO|The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
9959288|NCT01184222|Placebo Comparator|Arm sham SENGO|The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
9959289|NCT01184235||Autism Spectrum Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Autism Spectrum Disorder
9959290|NCT01184235||Attention Deficit Hyperactivity Disorder|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Attention Deficit Hyperactivity Disorder.
9959291|NCT01184235||Unaffected 1st Degree Relatives|This group will include unaffected, non treated first degree relatives of this study's subjects receiving or anticipating receiving pharmacological intervention.
10006058|NCT01590914|Experimental|Gastric Banding|40 Subjects who plan to undergo Gastric Banding bariatric Surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
9959292|NCT01184235||Mood Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is mood disorder.
9959293|NCT01184261|Experimental|Arm I|Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6.
9959294|NCT01184261|Experimental|Arm II|Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.
9959295|NCT01184274|Experimental|SB939|
9959296|NCT01184287|Experimental|ranpirnase|All patients who do not progress after two cycles of pemetrexed-carboplatin will receive the study drug, ranpirnase
9959297|NCT01184300|Experimental|Rapid Genotyping|Patients randomized to the Rapid Genotyping arm will have their CYP2C19*2 carrier status determined at the time of percutaneous coronary intervention with subsequent alteration in anti-platelet therapy for *2 carriers.
9959298|NCT01184300|No Intervention|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19*2 carrier status will be verified.
9959299|NCT01184313||aortic valve surgery|
9959300|NCT01184339||Standard of Care|Current practice methods for the determination of bacteremia, specific to site practice.
9959301|NCT01184339||Gold Standard ID/AST|"Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed).~Determination of MRSA:S. aureus gold standard and </=11mm OXA DD or </=21mm CFX DD.~Determination of MSSA: S. aureus gold standard and >/=13mm OXA DD or >/=22mm CFX DD."
9959302|NCT01184352||PCI patients treated with Glider Device|
9959303|NCT01184365|Experimental|EnMP-1|The goal of the EnMP-1 is to enable participants, through a behavioural, psycho-educational intervention, to better manage and understand their fatigue. This program is provided in four, two-hour sessions held weekly.
9959304|NCT01184365|Active Comparator|EnMP-2|The goal of the EnMP-2 is to control for group effects
9959305|NCT01184378|Placebo Comparator|control formula|formula containing only vegetable fats
9959306|NCT01184378|Experimental|new formula|new formula with dairy lipids and soluble milk proteins
9959307|NCT01184391|Experimental|Test: Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
9959308|NCT01184391|Active Comparator|Reference: Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
10006059|NCT01590914|Experimental|Formula Diet Weight-Loss|40 subjects will undertake a 12-week liquid formula weight loss plan. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition pre-weight loss and 3 months after a 12-week weight loss plan.
10006060|NCT01590914|Experimental|No Treatment|40 subjects who do not undergo any treatment for weight loss. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition at baseline and after 3 months.
10006061|NCT01590927||20 healthy women|
10006062|NCT01590940||Parietex mesh|Enrolled patients who met criteria for inclusion would have undergone open inguinal hernia repair using the Parietex plug and patch hernia system
10006063|NCT01590966|Experimental|Patients with an active inflammatory joint disease|In total there will be 20 patients included: 5 patients with active rheumatoid arthritis, 5 patients with active early axial spondyloarthritis, 5 patients with active early peripheral spondyloarthritis and 5 patients with active ankylosing spondylitis.
9959309|NCT01184404|Experimental|Treatment|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
10006064|NCT01590992|Experimental|Exposure-based Psychotherapy for Somatic Symptoms|First: 1-2 months waiting period; followed by: exposure-based psychotherapy
9959310|NCT01184404|No Intervention|Control|
9959311|NCT01184430|Active Comparator|advanced hemodynamic monitoring|advanced hemodynamic monitoring with pulse contour analysis ( LiDCO rapid) and goal-directed therapy
9959312|NCT01184430|No Intervention|standard monitoring|hemodynamic monitoring based on the standard operating procedures of our clinic
9959313|NCT01184443|Experimental|Olanzapine|Those who choose to take olanzapine as part of their treatment (standard practice plus medication).
9959314|NCT01184443|No Intervention|Comparison|Those who choose not to take olanzapine as part of their treatment (standard practice).
9959315|NCT01184469||Fresh embryo transfers|Patients who received fresh blastocyst transfer
9959316|NCT01184469||Thawed embryo transfers|Patients who received transfers of frozen/thawed embryos
9959317|NCT01184482|Experimental|Cetuximab and lapatinib|All patients will receive cetuximab by IB weekly and daily doses of lapatinib orally in 3 week cycles with response assessed every 2 cycles.
9959318|NCT01184495|Experimental|Epoetin Bio-Manguinhos|
9959319|NCT01184495|Active Comparator|EPO-BioSimilar|Subcutaneous administration of EPO-BioSimilar
9959320|NCT01184521||pulse CO-oximeter|
9959321|NCT01184534||Questionnaires + Video|
9959322|NCT01184534||Questionnaires|
9959323|NCT01184547|Experimental|COMBEX|Community Based Exercise Program or exercise group and quality of life Intervention- The community-based exercise program consisted of 12 weeks of exercise with a community-based trainer after hospital discharge.
9959324|NCT01184547|Active Comparator|Standard Of Care|Standard of Care group, group with no exercise and quality of life. Intervention- No exercise training received.
9959325|NCT01184560|Experimental|Sibutramine + Orlistat|"A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence"
9959326|NCT01184560|Placebo Comparator|Sibutramine + Orlistat(Placebo)|"Sibutramine : one of components included into Diet Pills. This reduces appetite, normalizes amount of cholesterol in blood, and reduces abdominal fat.~Orlistat : A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence."
9959327|NCT01184573||Mild to Moderate CP|Subjects must have a history compatible with chronic pancreatitis.
9959328|NCT01184573||Healthy Controls|Subjects must be in good health of greater than 18 years of age.
9959329|NCT01184586|Active Comparator|Intervention arm - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (STORZ DUOLITH, 1000 impulses, 0.55-0,8mJ/mm2)
9959330|NCT01184586|Sham Comparator|Control - SHAM ESWT STORZ DUOLITH [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave with modified probe without shockwave transduction (1000 impulses)
10006065|NCT01590992|Active Comparator|Relaxation Therapy|First: 1-2 months waiting period; followed by: relaxation therapy
10006066|NCT01591031|Active Comparator|sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane
10006067|NCT01591031|Active Comparator|rocuronium|anesthesia induction with propofol, remifentanil and rocuronium
10006068|NCT01591057|Experimental|2 Portions|
10006069|NCT01591057|Experimental|5 portions|
10006070|NCT01591057|Experimental|8 portions|
10006071|NCT01591070|No Intervention|vehicle twice weekly|
10006072|NCT01591070|Experimental|tacrolimus once weekly|
10006073|NCT01591070|Experimental|tacrolimus twice weekly|
10006074|NCT01591083|Active Comparator|Double oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
10006075|NCT01591083|Active Comparator|Regular oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
10006076|NCT01591083|Active Comparator|Control group|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
10006077|NCT01591109||Bevacizumab including chemotherapy|Patients treated with bevacizumab including chemotherapy for metastatic liver tumor derived from colorectal cancer before metastasectomy.
10006078|NCT01591109||no adjuvant chemotherapy|Patients with no adjuvant chemotherapy including bevacizumab
10006079|NCT01591122|Experimental|Abiraterone acetate and prednisone|
10006080|NCT01591122|Active Comparator|Placebo and prednisone|
10006081|NCT01591135|Active Comparator|Cisplatin|Chemoradiotherapy with cisplatin and 5-fluorouracil for 2 cycles followed by adjuvant chemotherapy for 2 cycles.
10006082|NCT01591135|Experimental|Paclitaxel|Patients randomized in Arm B will receive chemoradiation with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant chemotherapy with paclitaxel and 5-fluorouracil for 2 cycles.
10006083|NCT01591148|Experimental|Morbidly obese subjects|Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
10006084|NCT01591148|Active Comparator|Control subjects (body mass index 20-25)|Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
10006085|NCT01591174||Functional Dyspepsia with PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
10006086|NCT01591174||Functional Dyspepsia without PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
10006087|NCT01591174||Control Group|Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
10006088|NCT01591187||Cancer|Participants with a diagnosis of cancer.
10006089|NCT01591187||Sickle Cell Disease|"Participants with a diagnosis of sickle cell disease.~Interventions: Text messaging, Questionnaire, Interviews"
10006090|NCT01591200|No Intervention|Control|This arm will receive standard protocol of care alone
10006091|NCT01591200|Experimental|Stem cells high dose|This arm will receive high dose of Allogeneic Mesenchymal Stem Cells
10006092|NCT01591200|Experimental|Stem cells intermediate dose|This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells
10006093|NCT01591200|Experimental|Stem cells low dose|This arm will receive low dose of Allogeneic Mesenchymal Stem Cells
10006094|NCT01591213||Healthy Volunteers|Fourth grade students enrolled in Memphis-area schools.
10006095|NCT01591226|Active Comparator|Caffeine|6mg per kg bodyweight ingested 60min before test
10006096|NCT01591226|Placebo Comparator|Placebo|Sodium chloride and mannitol as placebo are ingested by the athlete
9959331|NCT01184612|Active Comparator|(BSF) MI sessions|5 semi-structured manualised MI sessions was conducted by existing prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual.
9959332|NCT01184612|Active Comparator|(BSF+) MI sessions with supervision|5 semi-structured manualised MI sessions was conducted by ordinary prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual, followed by ongoing Motivational Interviewing training with feedback based on audio taped sessions in peer supervision groups.
9959333|NCT01184612|Active Comparator|(UPI) Usual Planning Interview|5 sessions was conducted by prison staff according to usual working practices, with the exception that content was structured into 5 sessions and audio recorded. The provision of a government decree served as a basis for the intervention, covering planning of prison activities and post release arrangements including strategies for drug use cessation.
9959334|NCT01184625|Experimental|Exercise|
9959335|NCT01184625|No Intervention|No intervention|12 weeks of stable physical exercise level.
9959336|NCT01184638|No Intervention|Local anesthesia|Patients received local anesthesia without any intervention of general anesthetics
9959337|NCT01184638|Active Comparator|Inhalational anesthesia|Patients received sevoflurane anesthesia during general anesthesia
9959338|NCT01184638|Active Comparator|Intravenous anesthesia|Patients received intravenous anesthetic (Propofol) during general anesthesia
9959339|NCT01184651||Girls|Girls with 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) ages 10-13
9959340|NCT01184651||Parents|Parent, guardian, or significant caretaker of girls with CAH
9959341|NCT01184664|Experimental|Varenicline + Active Patch|Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
9959342|NCT01184664|Placebo Comparator|Varenicline + Placebo Patch|Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
9959343|NCT01184677|Placebo Comparator|Group size 4|
9959344|NCT01184677|Experimental|Group size 3|ProSeal LMA size 3 is inserted to the patients of Group size 3.
9959345|NCT01184690|Active Comparator|Single-operator DBE|Single-operator double-balloon endoscopy
9959346|NCT01184690|Active Comparator|Dual-operator DBE|Dual-operator double-balloon endoscopy
9959347|NCT01184716|Active Comparator|Vitamin D fortified bread and milk|
9959348|NCT01184716|No Intervention|Non-fortified bread and milk|
9959349|NCT01184729||Spinal Cord Injury|
9959350|NCT01184768||participants in the 6th tromsø study|
9959351|NCT01184781|Other|A|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
9959352|NCT01184794|Placebo Comparator|Saline|Placebo solution
9959353|NCT01184794|Experimental|levobupivacaine, analgesia|Active drug
9959354|NCT01184807|Other|OPB-51602|
9959355|NCT01184820|Experimental|Arm 1|
9959356|NCT01184820|Experimental|Arm 2|
9959357|NCT01184833||Group 1|
9959358|NCT01184911|Experimental|SP|Asymptomatic parasitemic pregnant women who receive the standard dose of sulfadoxine-pyrimethamine for prevention of placental malaria
9959359|NCT01184924|No Intervention|Control|Usual Care only. Usual care is defined as the care these subjects would like to seek from any health care practitioner or other program they may seek for healthy living. The subjects in this arm will be offered the AF Tai Chi intervention after an 8 week followup data collection
9959360|NCT01184924|Experimental|Tai Chi|Usual care plus Tai Chi. These subjects will be allowed to seek care from any health practitioner or any other programs and will receive the AF Tai Chi program for 8 weeks.
9959361|NCT01184937|Experimental|Patient education program|
9959362|NCT01184937|No Intervention|Standard care|
9959363|NCT01184950|Experimental|Trainer Curriculum|
9959364|NCT01184950|No Intervention|No Curriculum|
9959365|NCT01184963|Other|Controls|Women in reproductive age regular ovulatory cycles
9959366|NCT01184963|Other|PCOS patients|Patients with anovulatory cycles, hyperandrogenism with or without polycystic ovarian appearance
9959367|NCT01184976|Experimental|0.6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
9959368|NCT01184976|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
9959369|NCT01184976|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
9959370|NCT01185002|Experimental|MgC boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered MgC boosts."
10006097|NCT01591226|Active Comparator|Sodium Citrate|sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
9959371|NCT01185002|Experimental|Suprep boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered Suprep boosts"
9959372|NCT01185002|Experimental|Suprep boosts - Reduced dose|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered a reduced dose of Suprep boosts"
9959373|NCT01185041|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
9959374|NCT01185041|Experimental|Watermelon|(6g per day)containing L-citrulline/L-arginine (4/2 g)
9959375|NCT01185054|Experimental|Fluids as Tolerated (FAT) Group|The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
9959376|NCT01185054|Active Comparator|Electrolyte Maintenance Solution (EMS)|The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
9959377|NCT01185067|Active Comparator|grape seed extract capsule|Grape seed extract (MegaNatural BP, Polyphenolics, Inc.) 300 milligram capsules twice daily for six weeks
9959378|NCT01185067|Placebo Comparator|maltodextrin capsule|Maltodextrin capsules (matched for appearance and taste to grape seed extract capsules) twice daily for six weeks
9959379|NCT01185093||Fourth grade students|Each participant will attend two presentations and six hands-on activities led by St. Jude faculty and research staff on topics within their expertise, such as cells and cancer, and healthy living. The pre-test will take place within 7±1 days before the program presentations and before students receive copies of the printed material. Two post-tests will take place. The first post-test will be administered within 7±1 days after the final scheduled program presentation and will be a measure of knowledge acquisition. The second post-test will take place 90±7 days post-intervention and will be a measure of knowledge retention.
9959380|NCT01185119|Active Comparator|GLP-1|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
9959381|NCT01185119|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
9959382|NCT01185132|Experimental|IMRT|Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
9959383|NCT01185132|Active Comparator|3D-CRT|Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
9959384|NCT01185145|Experimental|Mammosite|Accelerated Partial Breast Irradiation using Mammosite RTS
9959385|NCT01185145|Experimental|IMRT|Accelerated partial breast irradiation using IMRT planning technique of external beam radiotherapy
9959386|NCT01185158|Experimental|ZD1839 (IRESSA) 250mg|ZD1839(IRESSA) 250mg orally (po) daily
9959387|NCT01185184|Experimental|1|Subjects will receive in random order, the immediate release tablet containing 10 mg of CP-690,550 and two different controlled-release capsules containing 20 mg of CP-690,550.
9959388|NCT01185197|Experimental|Myfortic plus low-dose steroid|Not necessary
9959389|NCT01185197|Active Comparator|Standard-dose steroid|Not necessary
9959390|NCT01185210|Placebo Comparator|Placebo|Subjects will receive placebo (mix of sugar and salt).
9959391|NCT01185210|Experimental|Alanine - 12.5|Subjects will receive 12.5 grams of alanine
9959392|NCT01185210|Experimental|Alanine - 25|Subjects will receive 25 grams of alanine.
9959393|NCT01185223|Other|Valganciclovir|
9959394|NCT01185223|Active Comparator|Ganciclovir|
9959395|NCT01185236|Experimental|simvastatin/ezetimibe (vytorin) group|vytorin 10/20mg po once daily for 12weeks
9959396|NCT01185236|Active Comparator|atorvastatin group|atorvastatin 20mg po once daily for 12weeks
9959397|NCT01185262|Experimental|Lenalidomida, Rituximab|Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
9959398|NCT01185275||Severe Asthma Patients|Severe asthma patients symptomatic despite high dose inhaled corticosteroid and long acting beta-agonist
9959399|NCT01185314|Other|1|EGFR mutation testing
9959400|NCT01185327||Study|Infants to Israeli Ethiopian-origin Mothers
9959401|NCT01185327||Control|Infants to Israeli non-Ethiopian-origin mothers
9959402|NCT01185379|Active Comparator|Efalex Active 50+|
9959403|NCT01185379|Active Comparator|DHA-rich fish oil|
9959404|NCT01185379|Placebo Comparator|Placebo|
9959405|NCT01185405|Experimental|EA group|Voriconazole dosage adjustment according to the each measurements of voriconazole levels from day 1, using NONMEM program
9959406|NCT01185405|Active Comparator|CA group|Voriconazole dosage adjustment according to the levels from day 5, using predefined protocol
9959407|NCT01185418||risperidone|
9959408|NCT01185418||aripiprazole|
9959409|NCT01185418||haloperidol|
9959410|NCT01185418||amisulpride|
9959411|NCT01185418||lactose|
9959412|NCT01185431|Experimental|Ficus carica (Fig paste)|
9959413|NCT01185431|Placebo Comparator|Control (Placebo paste)|
9959414|NCT01185444|Experimental|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
9959415|NCT01185444|Active Comparator|Hyalgan|the control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
9959416|NCT01185457||Left interscalene block|Left shoulder surgery under left interscalene block and HRV
9959417|NCT01185457||Right interscalene block|Right shoulder surgery under right interscalene block and HRV
9959418|NCT01185470|Experimental|Subjects with Implantable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
9959419|NCT01185496||CGM|Blinded/Unblinded CGM wear in adjunct with SMBG meter diabetes management
9959420|NCT01185535|Active Comparator|2 times topical anesthesia for glottis|
9959421|NCT01185535|Active Comparator|3 times topical anesthesia for glottis|
9959422|NCT01185535|Active Comparator|4 times topical anesthesia for glottis|
9959423|NCT01185574|Experimental|Vitamin D supplementation|The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months.
9959424|NCT01185587||healthy patients with a normal heart|
9959425|NCT01185587||patients with HF without an lCD|
9959426|NCT01185587||patients with HF and an ICD without shock|
9959427|NCT01185587||patients with HF and an ICD with shock|
9959428|NCT01185613|Experimental|Therapy™ Cool Flex Ablation Catheter|
9959429|NCT01185626|No Intervention|Usual care|The gynaecological oncologist (GO) provides care as usual. Currently, hospitals provide follow-up following the Dutch guidelines, meaning that they see their patients on given time points based on the number of years after diagnosis. Most hospitals give their patients leaflets regarding the diagnosis and treatment they receive, however none of them provide personalized information. All information is given during the initial treatment phase, but none of the GOs give additional information during follow-up. None of the GOs is actively screening on psychosocial needs. As this might change in time, we will ask the providers and patients about the type of information they provide, respectively, receive.
9959430|NCT01185626|Experimental|SCP care|After initial treatment, the GO provides the patient with a paper SCP and takes time to discuss all items in the SCP. Each time during follow-up meetings between patient and GO, the patient will receive an updated SCP if applicable. The paper SCP is extracted from the online registration system 'ROGY' (Registrationsystem Oncological GYnaecology) and combines personal patient and disease data with tailored information that is related to the specific situation of this patient. Recurrences, toxicities or additionally involved specialists will be registered in ROGY and automatically updated in the personal SCP.
9959431|NCT01185665|Active Comparator|TENS|FBSS patients treated with TENS
9959432|NCT01185665|Placebo Comparator|Sham-TENS|patients treated with Sham-Tens
9959433|NCT01185678||Group1|
9959434|NCT01185730|Experimental|pulmonary hypertension|cohort of patients with pulmonary hypertension
9959435|NCT01185743|Active Comparator|olanzapine|olanzapine
9959436|NCT01185743|Active Comparator|ziprasidone|ziprasidone
9959437|NCT01185743|Placebo Comparator|Sugar pill|Sugar pill
9959438|NCT01185756|Experimental|ICD implantation|"MIBG for diagnostic purpose:~MIBG scintigraphy for diagnostic purpose"
9959439|NCT01185769|Experimental|High fat|500 mg of tocotrienol will be administered at single dose after consumption of high fat diet
9959440|NCT01185769|Experimental|Low fat|500 mg of tocotrienol will be administered at single dose after consumption of low fat diet
9959441|NCT01185795|Experimental|Cardioviva™ yogurt|
9959442|NCT01185795|Placebo Comparator|Placebo yogurt|
9959443|NCT01185808|Active Comparator|Vitamin D|Vitamin D 5,000IU/day for 6 weeks
9959444|NCT01185808|Placebo Comparator|Placebo|Placebo for 6 weeks.
9959445|NCT01185847|Experimental|A non-squamous|
9959446|NCT01185847|Experimental|A squamous|
9959447|NCT01185847|Active Comparator|B non-squamous|
9959448|NCT01185847|Active Comparator|B squamous|
9959449|NCT01185860|Active Comparator|A|
9959450|NCT01185860|Experimental|B|
9959451|NCT01185860|Placebo Comparator|C|
9959452|NCT01185873|Experimental|1|
9959453|NCT01185899||Suspected ACS patients|Patients presenting with chest pain to the Emergency Department, who are suspected of having ACS, will be asked to participate in the study.
9959454|NCT01185912||Cardiomyocyte apoptosis|Elective aortic valve replacement patience
9959455|NCT01185925|Placebo Comparator|Placebo|Control Group
9959456|NCT01185925|Active Comparator|sildenafil, pde5 inhibitor|treatment group; sildenafil 50 mg three times a day for 1 year
9959457|NCT01185938|Active Comparator|Rosuvastatin|
9959458|NCT01185938|No Intervention|Control|
9959459|NCT01185951|Active Comparator|Achilles tendinopathy|Patients suffering both, insertional and midportion Achilles tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
9959460|NCT01185951|Active Comparator|Patella tendinopathy|Patients suffering patella tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
9959461|NCT01185951|Active Comparator|Epikondylitis|Patients suffering both, lateral (tennis elbow) or medial (golfers' elbow) elbow tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
9959462|NCT01185977|Active Comparator|Fluoxetine|1 week single-blinded placebo lead-in and double-blinded FLX treatment for 8 weeks
9959463|NCT01185977|Placebo Comparator|Placebo (PBO)|Placebo treatment for 9 weeks of study
9959464|NCT01185990||Tinnitus subjects|Subjects with chronic, moderate to severe unilateral tinnitus.
9959465|NCT01185990||Healthy control subjects|
9959466|NCT01186016|Experimental|Genetic Education Session (GES)|The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment.
9959467|NCT01186016|Active Comparator|Nutrition Education Session (NES)|
9959468|NCT01186042||Aging in HIV|20-40 years of age or older than 50
9959469|NCT01186055||Smoking Cessation Counseling|Individuals will receive individual and group counseling for 8 weeks (6 visits) while they quit smoking.
9959470|NCT01186068|Experimental|V-101 Cream 0.01% Concentration|Low dose
9959471|NCT01186068|Experimental|V-101 Cream 0.06% Concentration|Mid-dose
9959472|NCT01186068|Experimental|V-101 Cream 0.1% Concentration|Mid-dose
9959473|NCT01186068|Experimental|V-101 Cream 0.15% Concentration|High dose
9959474|NCT01186068|Placebo Comparator|Vehicle|Cream without an active ingredient
9959475|NCT01186081|Experimental|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
9959476|NCT01186081|Active Comparator|Postoperative chemoradiotherapy|Postoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
9959477|NCT01186094|Active Comparator|Cypher|Sirolimus-eluting stent
9959478|NCT01186094|Active Comparator|Endeavor Resolute|Zotarolimus-eluting Stent
9959479|NCT01186107|Experimental|Endeavor Resolute stent|zotarolimus-eluting stent
9959480|NCT01186107|Active Comparator|Cypher stent|sirolimus-eluting stent
9959481|NCT01186120|Experimental|Biolimus A9-eluting stent|NOBORI stent
9959482|NCT01186120|Active Comparator|Everolimus-eluting stent|PROMUS ELEMENTE stent
9959483|NCT01186146|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
9959484|NCT01186146|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
9959485|NCT01186159|Experimental|Normal Saline|
9959486|NCT01186172|Experimental|Ethanol-lock|Treatment with a combination of ethanol-lock and parenteral therapy
9959487|NCT01186172|Active Comparator|Antibiotic lock|Treatment with a combination of antibiotic-lock and parenteral therapy
9959488|NCT01186185|Experimental|Fludrocortisone|
9959489|NCT01186198||MINI TREK RX 1.20 mm Coronary Dilatation Catheter|
9959490|NCT01186211||Patients presenting for elective TKA|Patients will be advised preoperatively about an accelerated path while in hospital that will share many attributes of the standard TOH care map but with several additions, chosen to help reduce pain and hemarthrosis, both felt to be the major impediments to faster recuperation.
9959491|NCT01186237|Experimental|Early urinary catheter removal|
10006098|NCT01591226|Active Comparator|Caffeine and Sodium Citrate|sodium citrate 120-90min prior test capsules:60min prior test
10006099|NCT01591239|Experimental|Home-Based Intervention|Parents will receive a 1-session training on how to deliver a 3-session intervention across a 3-week period. The intervention program begins with a 3 and a half hour training session delivered by the staff Trainer to the participating parent. At the conclusion of training, the parent will be given the intervention manual and supplemental materials. The trainer will phone the parent shortly before session 1, in between each intervention session, and after the third intervention (four phone calls total) to review the objectives and tasks associated with that week's intervention session and to help prepare for the coming session. At the final phone call between the parent and trainer (after the third week), the trainer will deliver to the parent the follow-up resources.
10006100|NCT01591239|Active Comparator|Educational Group|Parents will receive a 2-hour, education-only psychoeducational curriculum (no parent-led intervention with their teen will occur.
10006101|NCT01591265|Active Comparator|Compensatory Extraction|Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
10006102|NCT01591265|Active Comparator|No Compensatory Extraction|Patients allocated to this group, only the lower FPM tooth will be extracted.
10006103|NCT01591278|Experimental|Pulp dressing agent|
10006104|NCT01591278|Active Comparator|Pulp dressing|MTA
10006105|NCT01591291|Experimental|Ondansetron|
10006106|NCT01591291|Placebo Comparator|Placebo|
10006107|NCT01591304|Active Comparator|Group A|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.
10006108|NCT01591304|Active Comparator|Group B|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.
10006109|NCT01591343|Experimental|Depigoid® (500 DPP/ml)|Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).
10006110|NCT01591395|Active Comparator|Multiport TEP|Adult inguinal hernia patients who randomized to receive multiport endoscopic TEP repair
10006111|NCT01591395|Active Comparator|LESS TEP|Adult inguinal hernia patients who randomized to receive laparoendoscopic single-site TEP repair
10006112|NCT01591421|Experimental|BKM120 and Panitumumab|BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
10006113|NCT01591434|Active Comparator|AQUACEL®|A sterile non-woven sheet of sodium carboxymethylcellulose (NaCMC).
10006114|NCT01591434|Active Comparator|AQUACEL® Extra™|A sandwiched construction of two layers of optimally textiled non-woven fabric, stitch-bonded together using Lyocel (Tencel™ regenerated cellulose) yarns.
10006115|NCT01591486||Hp-negative cohort|"Hp-negative cohort~The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:~negative rapid urease test~negative histology for Hp infection on both initial and follow-up endoscopy~negative serology test~absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus~After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (<160 mg daily) without regular co-prescription of anti-ulcer drugs."
10006116|NCT01591486||Hp-eradicated cohort|Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs.
10006117|NCT01591486||Average-risk cohort|Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.
9959492|NCT01186263|Experimental|99mTc- labeled albumin macroaggregates (MAA)|Diagnostic MAA- SPECT- imaging.
9959493|NCT01186263|Experimental|99mTc- labeled albumin microspheres (B20)|Diagnostic B20- SPECT- imaging.
9959494|NCT01186276|Placebo Comparator|Corn Starch|Corn starch will serve as the control arm.
9959495|NCT01186276|Experimental|Fiber|Fiber will serve as the intervention.
9959496|NCT01186289|Experimental|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
9959497|NCT01186289|Placebo Comparator|placebo|
9959498|NCT01186302|Other|Midlevel provider|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
9959499|NCT01186302|Other|Physician arm|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
9959500|NCT01186315|Active Comparator|Prolonged Exposure therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
9959501|NCT01186315|Experimental|Exposure therapy + VR/ER|prolonged exposure therapy plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
9959502|NCT01186341||Chronic Pain|New or existing patients of the center who are seeking their initial treatment at the Integrative Medicine center for chronic pain (chronic > 3 months) who report their average pain level over the past month to be at least a 4 of 10 on the Visual Analog Scale.
9959503|NCT01186354|Experimental|Receiving results via web-based program|participants will receive genetic risk results for Type 2 diabetes via a web-based program that they access on their own
9959504|NCT01186367|Experimental|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
9959505|NCT01186367|Experimental|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and and as well as the CPET performed at Week 8.
9959506|NCT01186367|Experimental|Progressive Stretching Group (Attention control)|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes).
9959507|NCT01186380||TEE Procedure|patients requiring TEE procedure by their physician
9959508|NCT01186393|Experimental|Control|Arm includes dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). Control diet will be prescribed for weight maintenance.
9959509|NCT01186393|Experimental|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
9959510|NCT01186393|Experimental|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on High Glycemic Index foods.
9959511|NCT01186432|Experimental|Active|ranibizumab sustained delivery implant
9959512|NCT01186445|Experimental|Morphine chlorhydrate|Intracoronary injection of morphine chlorhydrate during reperfusion
9959513|NCT01186445|Placebo Comparator|Saline solution|Intracoronary injection of saline solution during reperfusion
9959514|NCT01186471|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
9959515|NCT01186471|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
9959516|NCT01186471|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
9959517|NCT01186484|Experimental|001|JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
9959518|NCT01186497|Experimental|Treatment sequence AEBDC|
9959519|NCT01186497|Experimental|Treatment sequence BACED|
9959520|NCT01186497|Experimental|Treatment sequence CBDAE|
9959521|NCT01186497|Experimental|Treatment sequence DCEBA|
9959522|NCT01186497|Experimental|Treatment sequence EDACB|
9959523|NCT01186510|Experimental|Lung perfusion|
9959524|NCT01186510|Active Comparator|no lung perfusion|
9959525|NCT01186523|Experimental|400 kcal of exercise/session|400 kcal of exercise/session
9959526|NCT01186523|Experimental|600 Kcal of exercise/session|600 Kcal of exercise/session
9959527|NCT01186523|Experimental|Control, no exercise|No exercise control group
9959528|NCT01186536|Experimental|Whey protein supplementation|Daily whey protein supplementation
9959529|NCT01186536|Experimental|Soy Protein supplementation|Daily soy protein supplementation
9959530|NCT01186536|Experimental|Placebo|Daily carbohydrate placebo supplementation
9959531|NCT01186549|Active Comparator|ephedrine 30 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
9959532|NCT01186549|Active Comparator|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
9959533|NCT01186549|Active Comparator|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
9959534|NCT01186549|Active Comparator|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
9959535|NCT01186549|Placebo Comparator|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
9959536|NCT01186575|Experimental|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
9959537|NCT01186575|No Intervention|Usual Care|Usual care after adult male circumcision (no text messages)
9959538|NCT01186588|Experimental|001|Canagliflozin One 300-mg dose of canagliflozin on Day 1
9959539|NCT01186601|Experimental|Arm 1|
9959540|NCT01186614|Experimental|Novel treatment paradigm|treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
9959541|NCT01186653|Experimental|Symbicort|Symbicort® (budesonide / formoterol, 400 micrograms/9 micrograms one puff bd, dose as per NICE guidelines
9959542|NCT01186653|Active Comparator|Seretide|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
9959543|NCT01186666|Experimental|Non ST-elevation acute coronary syndrome|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
9959544|NCT01186666|Experimental|Stable coronary artery disease|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
9959545|NCT01186679|Experimental|Intralesional|"Surgical transplantation into the lesion site in chronic patients~Direct intrathecal implantation in acute and subacute patients"
9959546|NCT01186679|Experimental|intrathecal|direct into the CSF through lumbar puncture
9959547|NCT01186718||Control Group|Control group = functional symmetric cervical motion.
9959548|NCT01186718||Experimental subject group|Experimental subject group = asymmetric cervical motion
9959549|NCT01186731|Experimental|Liposome Entrapped Docetaxel (LE-DT)|
9959550|NCT01186757|Active Comparator|PF-03715455 1.6mg BID|
9959551|NCT01186757|Active Comparator|PF-03715455 4 mg BID|
9959552|NCT01186757|Active Comparator|PF-03715455 10 mg BID|
9959553|NCT01186757|Placebo Comparator|Placebo|
9959554|NCT01186783|No Intervention|standard treatment|All patients receive established medical therapy according to current guidelines and therapeutic standards.
9959555|NCT01186783|Active Comparator|ivabradine (add-on)|Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
9959556|NCT01186822|Experimental|Lung Flute for BHT|The Lung Flute arm participants were instructed to blow twice in to the Lung Flute device vigorously enough to make the reed oscillate, followed by 5 normal breaths. This was repeated 10 times, followed by 3 huff coughs to complete 1 cycle. Two such cycles were recommended twice a day. One of these cycles was performed under supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD medication regimen was continued in all participants, although the primary physicians of the participants could make medically necessary changes. Chest physical therapy, additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the participants during the study.
9959557|NCT01186822|No Intervention|No intervenstion|No intervention. Same population.
9959558|NCT01186835|Experimental|Combination Botulinum Toxin A and Hyaluronic Acid|One side of face treated with the combination of Botulinum Toxin A and Hyaluronic Acid injections.
9959559|NCT01186835|Active Comparator|Botulinum Toxin A alone|Other side of face treated with =Botulinum Toxin A injection alone.
9959560|NCT01186887|Placebo Comparator|Celecoxib|
9959561|NCT01186887|Placebo Comparator|Placebo|
9959562|NCT01186900|Experimental|Ultrasound-guided needle aspiration|One arm is ultrasound-guided needle aspiration, the other active comparison is traditional open incision and drainage of skin abscess
9959563|NCT01186900|Active Comparator|open incision and drainage|
9959564|NCT01186913||Stratum A: Typical SCID +HCT|"Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
9959565|NCT01186913||Stratum B: Atypical SCID +HCT|"Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
9959566|NCT01186913||Stratum C:SCID +Non-HCT|"Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes:~Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT)~ADA Deficient SCID with intention to treat with gene therapy~X-linked SCID (XSCID) with intention to treat with gene therapy~Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)"
9959567|NCT01186926|Experimental|HGNS Treatment|
9959568|NCT01186952|No Intervention|Optimized usual care|participants will attend one visit with the dietician (30mn) and the physical activity specialist (30mn) when they will be given Canadian guidelines pamphlets for physical activity and food consumption. They will also receive a phone call once a month to discuss about issues in guidelines following.
9959569|NCT01186952|Active Comparator|Diet intervention alone|Participants will attend one visit with the physical activity specialist (30mn) when they will receive the physical activity guidelines. Monthly phone call will be make to discuss about issues in physical activity guidelines following.These individuals will also be enrolled in a supervised caloric restriction program. They will have to visit the dietician once a week for the first months and then twice a month for 3 months. The diet intervention will focus on a low fat diet. At each session participants will be weighed and taken the blood pressure.
9959570|NCT01186952|Active Comparator|diet intervention and exercise program|"Participants will attend diet intervention as described for group 2. They will also follow a supervised exercise program three days per week for 4 months. The exercise training is an interval high intensity aerobic (85-90% heart rate reserve) program with resistance exercises (15RM, 2-3 repetitions). Each session will last one hour. At the end of month 1, 2, and 3, all participants will receive the SWA armband for 7 days to record physical activity and estimate energy expenditure.~At the end of Month 4, all participants will attend a study visit for repeat baseline testing."
9959571|NCT01187056|Experimental|Training, decision making|General practitioners receive training in shared decision-making and risk communication, and use their newly acquired skills in real-life consultations with 7 patients with high cholesterol.
9959572|NCT01187056|Active Comparator|Training, usual practice|The control group GPs will receive 2 hours of training in the primary care guideline for prevention of cardiovascular disease
9959573|NCT01187069|Experimental|Training course for practice nurses in autonomy support|
9476611|NCT03570190||TAVI patients|elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator
9476612|NCT03570164|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
9476613|NCT03570164|Experimental|Desflurane|Anesthesia is maintained with desflurane.
9959574|NCT01187069|No Intervention|Control|Control practices were randomly drawn from among intervention practice applicants and were informed by mail about their status as control practice.
9959575|NCT01187082|Experimental|bladdertraining group|Cognitive training in groups at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
9959576|NCT01187082|Active Comparator|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
9959577|NCT01187108|Placebo Comparator|Placebo pills|
9959578|NCT01187108|Active Comparator|Acetazolamide alone|
9959579|NCT01187108|Active Comparator|N-acetylcysteine alone|
9959580|NCT01187108|Active Comparator|Combination of N-acetylcysteine and acetazolamide|
9959581|NCT01187121||Experimental|Those persons randomized to the Decide Your Time program.
9959582|NCT01187121||Standard Pracitice|Those persons randomized to the standard probationary practice condition.
9959583|NCT01187134|Active Comparator|Intervention group|
9959584|NCT01187134|No Intervention|Conventional CME|Hospitals receive conventional continuing medical education in lecture style twice a year. They receive current publications and recommendations for national and international meetings regarding diagnosis and therapy of sepsis.
9959585|NCT01187147|Experimental|Green Tea|Recruited subjects will be asked to take green tea capsules for 3 months and then stopped for another 3 months.
9959586|NCT01187160|Experimental|Transoral robotic surgery (TORS)|da Vinci® Robotic Surgical System
9959587|NCT01187186|Experimental|Moderate Hepatic Impairment|Subjects with Moderate Hepatic Impairment
9959588|NCT01187186|Experimental|Normal Hepatic Function|Subjects with Normal Hepatic Function
9959589|NCT01187212|Active Comparator|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day (D) 1
9959590|NCT01187212|Experimental|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
9959591|NCT01187225|Active Comparator|Fibrinogen concentrate|
9959592|NCT01187225|Active Comparator|Cryoprecipitate|
9959593|NCT01187238|No Intervention|Arm1-radical radiotherapy alone group|Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone
9959594|NCT01187238|Experimental|Arm2-concurrent chemoradiotherapy group|Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.
9959595|NCT01187251||Group 1 - mp3 users|Subjects who have been using mp3 players for at least 1 hour per day for at least 1 year
9959596|NCT01187251||Group 2 - mp3 non-users|Subjects who does not listen regularly to mp3 music
9959597|NCT01187264|Active Comparator|methotrexate 10 mg|oral methotrexate 10 mg once weekly
9959598|NCT01187264|Active Comparator|methotrexate 25mg|oral methotrexate 25 mg once weekly
9959599|NCT01187277|Experimental|Group A|Group A = conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
9959600|NCT01187277|Active Comparator|Group B|Group B = conventional therapy plus robot-assisted means: 30 min individual physiotherapy plus 20 min robot-assisted gait training and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
9959601|NCT01187290|No Intervention|neoadjuvant chemotherapy|Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
9959602|NCT01187290|Experimental|neoadjuvant chemoradiotherapy|Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
9959603|NCT01187316|Experimental|TENS|
9959604|NCT01187316|Active Comparator|Massage therapy and muscle stretching|
9959605|NCT01187342||Non-striatal lesion group|acute ischemic Stroke in MCA territory of 10-100 cm³ with sparing of striatocapsular structures
9959606|NCT01187342||Striatal lesion group|acute ischemic stroke in MCA/AchA territory with involvement of at least 125 mm³ of striatocapsular structures
9959607|NCT01187420||EEG and Cerebral Vasospasm|Cerebral Vasospasm and role of BIS vista monitor in Subarachnoid Hemorrhage (SAH) patients
9959608|NCT01187459|Experimental|10 ug/day|
9959609|NCT01187459|Experimental|50 ug/day|
9959610|NCT01187472||Treated subjects|Subjects treated on a previous study of locally advanced head and neck cancer
9959611|NCT01187485|Experimental|Androderm® 2.5mg|Study subjects will be randomized to one of the study arms: 2.5 mg of Androderm®.
9959612|NCT01187485|Experimental|Androderm® 5.0 mg|Study subjects will be randomized to one of the study arms: 5.0 mg of Androderm®.
9959613|NCT01187485|Experimental|Androderm® 7.5mg|Study subjects will be randomized to one of the study arms: 7.5 mg of Androderm®.
9959614|NCT01187537|Experimental|Continuous Femoral Nerve Block|
9959615|NCT01187537|Active Comparator|Single-Inj Nerve Block with IV PCA|
9476614|NCT03570138|Experimental|Flash continuous glucose monitoring system|Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
9959616|NCT01187537|Active Comparator|IV PCA|
9959617|NCT01187576|Experimental|Intervention|Multi-professional team intervention with PAR, lifestyle brochure
9959618|NCT01187576|Active Comparator|Conventional treatment|Ordinary recommendations on health behaviours, lifestyle brochure
9959619|NCT01187576|No Intervention|retrospective med history comparison|Treatment as usual (retrospective data collection)
9959620|NCT01187589|Experimental|Pulsehaler|Fully operational Pulsehaler, with protocol enabled
9959621|NCT01187589|Active Comparator|Nebulizer|Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active
9959622|NCT01187602||Women at average risk for ovarian cancer|Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
9959623|NCT01187602||Women with ovarian cancer|Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
9959624|NCT01187602||Increased risk for ovarian cancer|Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
9959625|NCT01187615|Experimental|Arm 1|
9959626|NCT01187615|Experimental|Arm 2|
9959627|NCT01187628|Experimental|Arm 1|
9959628|NCT01187641||colon cancer|patients undergoing treatment for colon cancer
9959629|NCT01187654|Experimental|AC133 recipients|intra coronary injection of bone marrow derived AC133+ cells
9959630|NCT01187654|Experimental|MNC recipients|intra coronary injection of bone marrow derived MNC
9959631|NCT01187654|Active Comparator|control|injection of autologous serum
9959632|NCT01187667||Haloperidol prevention group|ICU patients with a high risk for delirium who are treated with haloperidol for preventive reason.
9959633|NCT01187667||Control group|Historical cohort group of patients (2008-2009)with a determined risk of 50% or more for delirium who were not treated with haloperidol for preventive reason.
9959634|NCT01187680|Experimental|Spraygel|
9959635|NCT01187680|Active Comparator|Control|
9959636|NCT01187693|Other|Shoe lift|
9959637|NCT01187706||gynecological cancer survivors|"Criteria for including: (1)Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. (2)Age from 20 - 70 years old. (3) Agreed to participate in this study.~Criteria for exclusion: Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients."
9959638|NCT01187706||healthy controls|Criteria for including: (1)Not those who suffer from cancer.(2)20-70 years old.(3)Agreed to participate in this study.Criteria for exclusion:Had undergone gynecologic surgical removal of ovaries or uterus were.
9959639|NCT01187719|No Intervention|Control|ARV prophylaxis for PMTCT follows national guidelines.
9959640|NCT01187719|Experimental|phenytoin interaction|ARV prophylaxis for PMTCT follows national guidelines + start phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
9959641|NCT01187732|Experimental|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
9959642|NCT01187732|Active Comparator|Traditional soap and water bath|The control intervention is the traditional bathing assistance as performed in care dependent patients by using tap water, a bowl, towels, washcloths and soap.
9959643|NCT01187745||suspect kidney stones|Patients presenting with flank abdominal pain
9959644|NCT01187758|Experimental|Educational intervention|Multifacet educational intervention that includes workshops, seminars and focus group meetings
9959645|NCT01187758|No Intervention|Control - no intervention|This group did not have any intervention, but their population was screened for carriage of antibiotic resistant bacteria
9959646|NCT01187784|Active Comparator|CBT|Coping Cat cognitive-behavioral therapy protocol
9959647|NCT01187784|No Intervention|Waitlist Control|Treatment as usual
9959648|NCT01187797|Experimental|Intervention|
9959649|NCT01187823|Active Comparator|Nocturnal oxygen therapy|
9959650|NCT01187823|Active Comparator|Adaptive servo ventilation|Bipap® auto SV Advanced
9959651|NCT01187849|Active Comparator|Metformin|
9959652|NCT01187849|Placebo Comparator|Placebo|
9959653|NCT01187862|Other|Basel cocktail|
9959654|NCT01187875|Placebo Comparator|Control|Dextrin Control
9959655|NCT01187875|Experimental|Hi-maize resistant starch 9g|Hi-maize resistant starch 9g
9959656|NCT01187875|Experimental|Novalose 330 resistant starch 9g|Novalose 330 resistant starch 9g
9959657|NCT01187875|Experimental|4.5g Hi-maize and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330
9959658|NCT01187888|Active Comparator|Rasagiline|
9959659|NCT01187888|Placebo Comparator|Sugar pill|
9959660|NCT01187927||Female subjects|Subjects received Cervarix® as per routine practice
9959661|NCT01187940|Experimental|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
9959662|NCT01187940|No Intervention|Placebo|Will receive managment as usual from their local educational and NHS services
9959663|NCT01187966|Placebo Comparator|Placebo|Drug: Placebo
9959664|NCT01187966|Experimental|High Dose (100mg/day)|
9959665|NCT01187966|Experimental|Low dose (50mg/day)|
9959666|NCT01187979|Active Comparator|Control|All eligibly enrolled learners in the intervention schools will receive a prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education. No cash incentives will be paid for meeting milestones
9959667|NCT01187979|Experimental|Cash incentive|All eligibly enrolled learners in the intervention schools will receive a cash incentivised prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education
9959668|NCT01187992|Experimental|Full-dose atorovastatin (80 mg/d)|For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
9959669|NCT01187992|No Intervention|Conventional medical treatment|For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL (2.5 mmol/L).
9959670|NCT01188005|Experimental|OSAS patients|This arm includes the OSAS diagnosed cohort that has been planned to undergo four polysomnographic studies. One standard, one with oxygen supplementation, one with n-CPAP device and one post antioxidants administration
9959671|NCT01188005|No Intervention|Control Group|This group is scheduled to undergo a plain polysomnographic study, whilst plasma cytokine levels will be measured. It will comprise of healthy, non-OSAS volunteers.
9959672|NCT01188018|Active Comparator|Brief Advice|
9959673|NCT01188018|Experimental|Motivational Interviewing|
9959674|NCT01188018|Active Comparator|Health Education|
9959675|NCT01188031|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
9959676|NCT01188031|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
9959677|NCT01188044||Study group|Healthy children
9959678|NCT01188057|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
9959679|NCT01188057|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
9959680|NCT01188070|Sham Comparator|Usual Care Attention Control|Provision of printed educational material and attendance at one group session. This session will focus on nutrition education and flexibility and stretching.
9959681|NCT01188070|Experimental|Psychoeducation plus exercise|Psychoeducation intervention plus an individualized exercise program which will include monitored, individually-prescribed aerobic and resistance exercise.
9959682|NCT01188070|Active Comparator|Psychoeducation|Psychoeducational program to involve group sessions over consecutive weeks. The sessions will use the principles of adult learning, emphasizing active learning, group exercises and discussion, and coaching as well as brief talks to provide content. The curriculum will focus on the strengthening of caregiver self-efficacy through enhancement of knowledge and understanding, the acquisition, strengthening, and practice of caregiving skills, and the development of a more clinical or strategic outlook on the caregiving role.
9959683|NCT01188083|Experimental|Fructose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
9959684|NCT01188083|Experimental|Glucose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
9959685|NCT01188122|Experimental|AnapnoGuard|
9959686|NCT01188135|Experimental|Interactive Voice messaging|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed"
9959687|NCT01188135|No Intervention|Usual care arm|usual care treatment with no interactive phone reminder calls phone
9959688|NCT01188135|Experimental|IVR messaging w/ Psycho-ed. materials|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed. In addition, participants will receive educational material about antidepressant medication."
9959689|NCT01188148|Active Comparator|VPA & Placebo|VPA & Placebo
9959690|NCT01188148|Experimental|VPA & memantine|
9959691|NCT01188161||Normal subjects|Volunteers without a history of dizzyness or vertigo
9959692|NCT01188174|Experimental|Clofarabine|
9959693|NCT01188200|Experimental|Nutritional Formula #M979|nutritional formula
9959694|NCT01188200|Active Comparator|Regular standard meal|standard meal
9959695|NCT01188213|Experimental|Purified MSM|
9959696|NCT01188239||HIGH 6wks LOW 6wks NICOTINE|"Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with ORIGINAL 7.4 mg nicotine cartridges for 6 weeks followed by CATEGORIA 5.2 mg nicotine cartridges for a further 6 weeks (high and low nicotine group)."
9959697|NCT01188252|Experimental|Roniciclib|
9959698|NCT01188265|Experimental|Valproate & dextromethorphan 30 mg|Valproate and dextromethorphan 30 mg per day
9959699|NCT01188265|Experimental|VPA & dextromethorphan 60 mg|VPA & dextromethorphan 60 mg per day
9959700|NCT01188265|Active Comparator|VPA & Placebo|VPA & placebo
9959701|NCT01188278||Patients in CP-CML treated with 2G TKI|Patients in CP-CML treated with 2G TKI (nilotinib or dasatinib) post imatinib failure
9959702|NCT01188291||Sleep Apnea / Hypopnea syndrome|Study group composed of patients with Obstructive Sleep Apnea / Hypopnea syndrome
9959703|NCT01188304|Experimental|1|
9959704|NCT01188304|Placebo Comparator|2|
9959705|NCT01188317|Experimental|1|
9959706|NCT01188317|Placebo Comparator|2|
9959707|NCT01188330|Experimental|WITH Comprehensive Geriatric assessment|Conventional haematological management of patients and Comprehensive Geriatric assessment (CGA) at diagnosis followed by interventions according to disabilities detected and planned monthly follow up by a nurse practitioner during 6 months.
9959708|NCT01188330|Active Comparator|Conventional|Conventional haematological management of patients
9959709|NCT01188382||Healthy elderly|Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease
9959710|NCT01188395||subtypes of bipolar disorders|Bipolar I Disorder with alcoholism Bipolar I Disorder without alcoholism Bipolar II Disorder with alcoholism Bipolar II Disorder without alcoholism
9959711|NCT01188408|Experimental|Liposome Entrapped Docetaxel (LE-DT)|Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
9959712|NCT01188434|Experimental|Integrated Behavioral Treatment|Combined substance abuse, parenting skills, and basic needs intervention
9959713|NCT01188434|Active Comparator|casework treatment as usual|services as usual as referred by child welfare
9959714|NCT01188473|Experimental|NPPV plus standard of care|NPPV initiated early and for a prolonged period of time in addition to standard of care in the management of children admitted to the hospital with status asthmaticus
9959715|NCT01188473|No Intervention|Control: standard of care alone|standard of care in the management of children admitted to the hospital with status asthmaticus
9959716|NCT01188486|Experimental|pulmonary interstitial lymphography|stereotactic body radiation therapy & pulmonary interstitial lymphography
9959717|NCT01188512|Experimental|BPZE1 - Low dose|1,000 colony forming units (cfu) of BPZE1
9959718|NCT01188512|Experimental|BPZE1- middle dose|100,000 colony forming units (cfu) of BPZE1
9959719|NCT01188512|Experimental|BPZE1 - High dose|10,000,000 colony forming units (cfu) of BPZE1
9959720|NCT01188512|Placebo Comparator|Placebo|Formulation buffer
9959721|NCT01188590||Patients undergoing heart surgery|
9959722|NCT01188629|Placebo Comparator|Safety Training|
9959723|NCT01188629|Experimental|Personal Health Partner and Counseling (PHP+C)|
9959724|NCT01188707|Experimental|Belinostat, Erlotinib, NSCLC|
9959725|NCT01188720|No Intervention|Baseline|Assessment only baseline
9959726|NCT01188720|Experimental|Acute exercise|Exercise immediately before sexual activity, three times per week.
9959727|NCT01188720|Active Comparator|General exercise|Exercise not immediately before sexual activity, three times per week.
9959728|NCT01188733|Experimental|Sandostatin LAR 10mg|Sandostatin LAR ( long-acting octreotide) administered every 28 days in a dose of 10mg
9959729|NCT01188733|Experimental|Sandostatin LAR 30mg|Comparison of drug doses
9959730|NCT01188733|Placebo Comparator|Saline|Saline control
9959731|NCT01188746|Experimental|Questionnaire or interview|A pre-experimental design was chosen to examine changes in QoL following a palliative intervention.
9959732|NCT01188759|Experimental|Voriconazole and Anidulafungin Combination|Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.
9959733|NCT01188759|Active Comparator|Voriconazole Monotherapy|Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.
9959734|NCT01188785|Experimental|1 arm|SOC + siG12D LODER
9959735|NCT01188824|Active Comparator|Cilostazol|Pletaal® (Cilostazol) 100 mg, bid p.o.
9959736|NCT01188824|Placebo Comparator|placebo|"Placebo~1 tablet, bid p.o."
9959737|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy|
9959738|NCT01188837|Active Comparator|Full Kinetic Chain Rehabilitation|
9959739|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy with Rehabilitation|
9959740|NCT01188850|Experimental|6mg of DNA/dose|Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
9959741|NCT01188863|Experimental|Solid Oral Dose - 150 mg tablets|
9959742|NCT01188863|Experimental|Solid Oral Dose - 50 mg tablets|
9959743|NCT01188863|Experimental|Liquid Oral Dose|
9959744|NCT01188902|Experimental|walnut|western type diet with 48 g walnut per day
9959745|NCT01188902|No Intervention|control|
9959746|NCT01188915|Experimental|intensive screening|annual breast cancer detection based on mammography, echography and RMI.
9959747|NCT01188941|No Intervention|Standard of Care|
9959748|NCT01188941|Experimental|Assigned a Health System Navigator|
9959749|NCT01188954|Active Comparator|Doxycycline|Doxycyline, family of tetracycline antibiotics, used to scleroses the lymphatic vessels that may have transected during dissection.
9959750|NCT01188954|Placebo Comparator|Normal Saline/Water|The standard care is wetting and suctioning fluids followed with suturing of the groin.
9959751|NCT01188980||NoBE (control)|
9959752|NCT01188980||BE without dysplasia|
9959753|NCT01188980||BE with dysplasia|
9959754|NCT01188993|Active Comparator|septic shock TPT then TEE|Group 1: Each patient will be assessed by both the transpulmonary thermodilution technique and transesophageal echocardiography (TEE)..
9959755|NCT01188993|Active Comparator|septic shock TEE then TPT|Goup 2: Each patient will be assessed by both transesophageal echocardiography (TEE) and the transpulmonary thermodilution technique.
9959756|NCT01189006|Experimental|dextromethorphan|Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study
9959757|NCT01189019|Experimental|Group 1 - 2mg ranibizumab monthly|2mg ranibizumab monthly
9959758|NCT01189019|Active Comparator|Group 2 - 2mg x 3 then PRN|
9959759|NCT01189045|Experimental|Aerobic Program|The Aerobic Program will be the Experimental arm of this trial, where a structured, progressive aerobic exercise will be conducted in a class format
9959760|NCT01189045|Active Comparator|Balance and Flexibility Program|The Balance and Flexibility Program will be a non-aerobic intervention that will act as an Active Comparator. Stretching, balance exercises, yoga- or Tai Chi-style classes will be conducted.
9959761|NCT01189058|Experimental|rTMS and CIMT|This group will receive both rTMS and CIMT.
9959762|NCT01189058|Experimental|rTMS and no CIMT|This group will receive rTMS only.
9959763|NCT01189058|Experimental|Sham and CIMT|This group will receive CIMT and sham rTMS.
9959764|NCT01189058|No Intervention|Sham and no CIMT|This group will receive sham rTMS and no CIMT.
9803632|NCT03679299||Asthma|Individuals experiencing an asthma exacerbation will be recruited from the University of Alberta Hospital Emergency Department. Once discharged, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity. Participants will complete the same assessments at a follow up date 48 hours and 14 days post-discharge, with the addition of a full pulmonary function test, physical activity assessment via a Fitbit, and the completion of two questionnaires: Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire.
9959765|NCT01189084||Observational immunotherapy follow-up|
9959766|NCT01189097|Experimental|dextromethorphan|
9959767|NCT01189149|Experimental|IV fluids|Infants will get IV fluids whem indicated until able to tolerate full oral feedings
9959768|NCT01189149|Experimental|Oro/naso gastric tube feeding|Infants will get oro/naso gastric tube feeding whem indicated until able to tolerate full oral feedings
9959769|NCT01189162|Experimental|NIMV- nasal respiratory support|Infants with RDS will be treateg with nasal intermittent mandatory ventilation
9959770|NCT01189162|Experimental|HFNC- nasal respiratory support with HFNC|Infants with RDS will be treated with nasal respiratory support with high flow nasal canulla
9959771|NCT01189175|Experimental|BI 113823|single oral dose per subject
9959772|NCT01189175|Experimental|BI 113823 + Ketokonazole|after wash-out 5 days ketokonazole with BI 113823 on day 3
9959773|NCT01189188|Experimental|With ultrasound guidance|In this group of patients, ultrasound guidance will be used when drawing blood from the radial artery.
9959774|NCT01189188|Active Comparator|Without ultrasound guidance|In this group of patients, no ultrasound guidance will be used when drawing blood from the radial artery.
9959775|NCT01189214|Experimental|Memantine|
9959776|NCT01189253|Active Comparator|Doxorubicin 75 mg/m² every 3 weeks|Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles
9959777|NCT01189253|Experimental|Trabectedin IV 3 hours|Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression
9959778|NCT01189253|Experimental|Trabectedin IV 24 hours every 3 weeks|Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression
9959779|NCT01189305|Experimental|Behavioral Couples Therapy|
9959780|NCT01189305|Experimental|Individual Drug Counseling|
9959781|NCT01189318|Experimental|Seroquel XR|Patients with MDD receives Seroquel XR.
9959782|NCT01189318|No Intervention|healthy control|
9959783|NCT01189331|No Intervention|CT and FFR|
9959784|NCT01189344|Experimental|Not surgical group|The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.
9959785|NCT01189344|Experimental|Surgical group|The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
9959786|NCT01189357||failed meniscal transplantation|
9959787|NCT01189383|Experimental|IL15-DC Vaccine|Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12.At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
9959788|NCT01189448|Active Comparator|Pyrimethamine/Sulfadiazine|Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
9959789|NCT01189448|Active Comparator|Spiramycine|Spiramycin group : spiramycin 1g tid orally
9959790|NCT01189513|Experimental|SCH 900105|10 mg/kg intravenous Days 1, 8 and 15 of 30 day cycle.
9959791|NCT01189526|Experimental|IVRI|IVRI : intravitreal ranibizumab (0.5mg) injection
9959792|NCT01189526|Active Comparator|Laser|Laser : macular laser photocoagulation
9959793|NCT01189552|Active Comparator|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
9959794|NCT01189552|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
9959795|NCT01189565||Joint Replacement Patients|
9959796|NCT01189578||Recreational cocaine users|Individuals who have used cocaine in the past 3 months, but do not meet DSM-IV-TR diagnostic criteria for Cocaine Dependence.
9959797|NCT01189591|Experimental|Sleep deprivation|Slow-wave sleep deprivation for one night as an experimental treatment for major depressive disorder
9959798|NCT01189643|Experimental|Chemotherapy|This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
9959799|NCT01189656|Experimental|Vaccine+Lamivudine group|Subjects assigned into the experimental and the controlled groups with randomization and double-blindness by a ratio of 2:1
9959800|NCT01189656|Placebo Comparator|Placebo+Lamivudine group|
9959801|NCT01189669|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
9959802|NCT01189669|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
9959803|NCT01189669|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
9959804|NCT01189682|Active Comparator|Tegaderm HP|
9959805|NCT01189682|Placebo Comparator|Tegaderm|
9959806|NCT01189682|Active Comparator|Tegaderm CHG|
9959807|NCT01189695|Experimental|Boosted lopinavir monotherapy|
9959808|NCT01189695|Active Comparator|boosted lopinavir + optimized background regimens (OBRs)|
9959809|NCT01189708|Experimental|Mesh implantation|Ultrapro® Mesh implantation
9959810|NCT01189708|Active Comparator|Standard wound closure without a mesh|Standard wound closure
9959811|NCT01189721|Active Comparator|sevoflurane|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients who are in this group will be infused propofol intraoperatively.
9959812|NCT01189721|Experimental|propofol|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients included this group will be inhaled sevoflurane intraoperatively.
9959813|NCT01189734|Placebo Comparator|laparoscopic common bile duct exploration|
9959814|NCT01189734|Active Comparator|laparoscopic cholecystectomy with intraoperative ES|
9959815|NCT01189773|Experimental|1|Ibuprofen given orally (10 mg/kg, max = 600 mg) and codeine given orally (1 mg/kg, max = 60 mg).
9959816|NCT01189773|Placebo Comparator|2|Ibuprofen given orally (10 mg/kg, max = 600 mg) and placebo given orally ( identical in taste color to codeine preparation).
9959817|NCT01189799|Experimental|Motivational Therapy Aftercare|
9959818|NCT01189799|Other|Dual Recovery Anonymous|Aftercare Treatment as Usual
9959819|NCT01189825|Experimental|Exercise|
9959820|NCT01189838||Low Cyr61|Low Cyr61 immunohistochemical stain in patients' TCC tumor
9959821|NCT01189838||High Cyr61|High Cyr61 immunohistochemical stain in patients' TCC tumor
9959822|NCT01189851|Other|IORT|Treated with Intraoperative Radiation Therapy
9959823|NCT01189864||Ciprofloxicin or Vigamox or other.|
9959824|NCT01189864||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
9959825|NCT01189864||Steroid (FML, Pred Forte, Flarex, etc.)|
9959826|NCT01189877|Experimental|pO2 measurements|In patients meeting eligibility requirements outlined below, comparisons will be made between direct pO2 measurements using a tissue hypoximeter and IHC-assessed expression of hypoxia related proteins (HIF-1α, VEGF, CA IX and GLUT-1) in both normal and tumor tissue.
9959827|NCT01189916|Experimental|Transrectal NOTES appendectomy|These patients will undergo an experimental surgical procedure that uses flexible endoscopic instruments (i.e., inserted through the rectum).
9959828|NCT01189929|Experimental|Gemcitabine and demcizumab With or Without Abraxane®|Gemcitabine and demcizumab With or Without Abraxane®
9959829|NCT01189955|Active Comparator|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
9959830|NCT01189955|Active Comparator|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
9959831|NCT01189968|Experimental|Carboplatin and Pemetrexed plus demcizumab|Carboplatin and Pemetrexed plus demcizumab
9959832|NCT01189968|Experimental|Pemetrexed plus demcizumab|Pemetrexed plus demcizumab
9959833|NCT01189981|Experimental|eHealth intervention|Standard lifestyle counseling. Short Message Service (SMS) encouragements for physical activity,
9959834|NCT01189981|Active Comparator|Lifestyle counseling|Standard lifestyle counseling. No Short Message Service (SMS) encouragements for physical activity.
9959835|NCT01189994|Experimental|Acupuncture|Patients will receive acupuncture treatment in addition to standard care, coming to twelve weekly acupuncture sessions
9959836|NCT01189994|Active Comparator|Orientation|Patients will receive standard care only, coming to three monthly orientation sessions
9959837|NCT01190033|Active Comparator|Neurolysis|In this intervention the neurotome will be connected
9959838|NCT01190033|Placebo Comparator|Neurotome OFF|neurotome not raised
9959839|NCT01190046|Other|Resistance exercise training|Exercise is being used as an experimental tool to determine if remediation of muscle disuse counteracts cellular/molecular defects in muscle structure/function.
10006118|NCT01591525||Uncontrolled Diabetic|Individuals who were previously diagnosed with Type II Diabetes, but have a HgA1C greater than 7.0%
10006119|NCT01591525||Newly diagnosed Type II Diabetic|Individuals who have never been diagnosed with Type II Diabetes, but have an HgA1c greater than 7.0%
10006120|NCT01591525||Newly diagnosised pre-diabetics|Individuals who have never been diagnosed with Type II Diabetes, but have a HgA1C of 6.0%-6.9%
10006121|NCT01591525||Controlled|Diabetic or non-diabetic individuals with RPCG of less than 130 mg/dl.
10006122|NCT01591538||lifestyle condition|
10006123|NCT01591551|Other|Natalizumab (Tysabri) naive|Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.
10006124|NCT01591564|Other|therapy|All participants will receive the intervention.
10006125|NCT01591590|Experimental|All Patients|This is an Interventional, Non Therapeutic arm
10006126|NCT01591603|Experimental|Group 1|
10006127|NCT01591603|Experimental|Group 2|
10006128|NCT01591668|Experimental|0.3mg GS-9620|
10006129|NCT01591668|Experimental|1mg GS-9620|
10006130|NCT01591668|Experimental|2mg GS-9620|
10006131|NCT01591668|Experimental|4mg GS-9620|
10006132|NCT01591668|Experimental|0.3mg GS-9620 QW x 2 doses|
10006133|NCT01591668|Experimental|1mg GS-9620 QW x 2 doses|
10006134|NCT01591668|Experimental|2mg GS-9620 QW x 2 doses|
9959840|NCT01190059|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .
9959841|NCT01190111|Experimental|CYT107 (r-hIL-7)|
9959842|NCT01190137|Active Comparator|400 IU Vitamin D3|
9959843|NCT01190137|Experimental|400 IU Vitamin D2|
9959844|NCT01190163|Experimental|A|
9959845|NCT01190163|Active Comparator|B|
9959846|NCT01190202|Experimental|Overall Study Group (Survey 1)|Subjects at least 6 months of age at the time of Survey 1, conducted at Year 1 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
9959847|NCT01190202|Experimental|Overall Study Group (Survey 2)|Subjects at least 6 months of age at the time of Survey 2, conducted at Year 2 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
9959848|NCT01190202|Experimental|Overall Study Group (Survey 3)|Subjects at least 6 months of age at the time of Survey 3, conducted at Year 3 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
9959849|NCT01190202|Experimental|Overall Study Group (Survey 4)|Subjects at least 6 months of age at the time of Survey 4, conducted at Year 4 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
9803633|NCT03677973|Active Comparator|Active: Dose Escalation|Healthy volunteers will receive AB680 as a single intravenous (IV) infusion at 7 dose levels and as multiple IV infusions at 1 dose level. Assignment to receive AB680 or matching placebo will be random.
9959850|NCT01190241|Experimental|Targeted treatment|Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
9959851|NCT01190280||AC - operation|Patients admitted with acute cholecystitis randomized to operation
9959852|NCT01190280||AC - observation|Patients admitted with acute cholecystitis randomized to observation
9959853|NCT01190280||SGBS - operation|Patients admitted with uncomplicated gallstone disease randomized to operation
9959854|NCT01190280||SGBS - observation|Patients admitted with uncomplicated gallstone disease randomized to observation
9959855|NCT01190280||1983 - stones|Patients that in 1983 were diagnosed with gallstones in a population screening
9959856|NCT01190280||1983 - operation|Patients that were operated for gallstone disease at Haukeland University Hospital, Bergen, Norway, in 1983
9959857|NCT01190280||1983 - controls|Patients that were shown not to have gallstones in a 1983 population screening
9959858|NCT01190280||Gallstone patients|Patients with symptoms from gallstone disease
9959859|NCT01190293|Experimental|All subjects|All Subjects will receive the same intervention.
9959860|NCT01190319|Placebo Comparator|Placebo Beverage|The placebo beverage is matched in energy, macronutrient composition and sensory properties to the active beverage, but is devoid of strawberry polyphenols.
9959861|NCT01190319|Experimental|Strawberry Beverage|The strawberry beverage is matched in energy, macronutrient composition and sensory properties to the placebo beverage, but contains strawberry polyphenols.
9959862|NCT01190332|Placebo Comparator|conventional technique of ERCP|
9803634|NCT03677973|Placebo Comparator|Placebo: Dose Escalation|Healthy volunteers will receive matching placebo as a single IV infusion and as multiple IV infusions. Assignment to receive AB680 or matching placebo will be random.
9959863|NCT01190332|Active Comparator|Rendezvous technique|
9959864|NCT01190345|Experimental|WITH bevacizumab|"bevacizumab 15 mg/kg on day 1 of each cycle : 4 cycles of 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
9959865|NCT01190345|Active Comparator|without bevacizumab|"4 cycles 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV of (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
9959866|NCT01190358|Placebo Comparator|Placebo|Sugar pill
9959867|NCT01190358|Active Comparator|Grape seed extract|300mg of grape seed extract.
9959868|NCT01190371|Other|Artesunate|Confirmation of artemisinin tolerance
9959869|NCT01190384|Experimental|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
9959870|NCT01190384|Active Comparator|Couscous plus Fiber|Soup with added fiber; has a low ORAC value. Subject serving is isocaloric to the experimental Bean soup.
9959871|NCT01190384|Active Comparator|Couscous plus Grape Seed Extract|Control for ORAC value of the Bean soup; for examining the effect of fiber in the bean soup.
9959872|NCT01190397|Experimental|Blephasteam Arm|
9959873|NCT01190397|Active Comparator|warm and moist compresses arm|
9959874|NCT01190423|Experimental|Family Based therapy for young adults|
10006135|NCT01591668|Experimental|4mg GS-9620 QW x 2 doses|
10006136|NCT01591694||FamilyLive|Families with a history of intergenerational trauma (maltreatment, violence exposure, domestic violence, substance abuse, etc.)
9959875|NCT01190488|Experimental|Intervention - Decision Aid|In addition to usual care, patients assigned to the intervention group will also be asked to view and/or read the EOL-PtDA during their hospitalization. The EOL-PtDA can be utilized anytime in the course of their hospitalization (all hospital rooms at UCH have a DVD player). This could be before, during, or after the palliative care team consultation.
9959876|NCT01190488|Active Comparator|Active comparison|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
9959877|NCT01190501|Experimental|complier device|
9959878|NCT01190540|Active Comparator|OSS Phase 1|Thirty-six sites will receive the On Site Support service (OSS) activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 1
9959879|NCT01190540|Active Comparator|OSS Phase 2|Thirty-six sites will receive the OSS activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 2 that will serve as a control group in phase 1 and receive OSS nine months later.
9959880|NCT01190553|Experimental|Treatment|IV amantadine treatment
9959881|NCT01190592|Experimental|Milk|
9959882|NCT01190592|Experimental|Juice|
9959883|NCT01190592|Placebo Comparator|Water|
9959884|NCT01190631|Experimental|Acrysof IQ (SN60WF) IOL|AcrySof IQ SN60WF intraocular lens (IOL) implanted in one eye only during cataract surgery.
9959885|NCT01190657|Experimental|Selbex 50mg (14 days)|
9959886|NCT01190657|Experimental|Selbex 50mg (56 days)|
9959887|NCT01190670|Experimental|Part 1, Group 1|ASP015K, low dose followed by high dose, with oral tacrolimus
9959888|NCT01190670|Experimental|Part 1, Group 2|ASP015K, high dose followed by low dose, with oral tacrolimus
9959889|NCT01190670|Experimental|Part 2|ASP015K high dose with intravenous tacrolimus
9959890|NCT01190683|Active Comparator|cholecalciferol|cholecalciferol 60,000IU/week for first eight weeks followed by 60,000 IU every 15 days for four months along with calcium placebo
9959891|NCT01190683|Active Comparator|Calcium carbonate|two tablets of calcium carbonate daily equivalent to 1 gm of elemental calcium for six months along with vitamin D placebo
9959892|NCT01190683|Active Comparator|oral calcium and cholecalciferol|60,000 IU of cholecalciferol every week for ist eight week and then 60,000IU every 15 days for next four months along with 1 gm of elemental calcium ever day for six months
9959893|NCT01190683|Placebo Comparator|lactose|identical placebos
9959894|NCT01190696|Other|hip spica casting|Patients in the spica cast group treated with skeletal traction and spica cast applied for them
9959895|NCT01190696|Other|titanium elasting nailing|For patients in the Titanium Elasting Nailing group, the nail applied retrogradely in femoral shaft fracture
9959896|NCT01190709|Other|unreamed Intramedullary Nailing|tibial fracture fixed with unreamed Intramedullary Nailing
9959897|NCT01190709|Other|Dynamic Compression Plate|tibial fracture fixed with Dynamic Compression Plate
9959898|NCT01190722|Experimental|etoricoxib|active study drug, coxib
9959899|NCT01190722|Active Comparator|diclofenac|active traditional NSAID control
9959900|NCT01190735|Experimental|Caffeine|Each patient will take pills twice per day containing 100-200 mg of caffeine (as synthetic caffeine alkaloid). Patients will be instructed to take whatever caffeine-containing beverages they are accustomed to taking, without changing their habitual schedule (note that all will be taking <200 mg per day). Caffeine intake will be assessed at each visit. Patients will continue their usual PD medications, without change in dose or timing for the entire duration of the study. Medication will be provided in pre-packaged dosettes.
9959901|NCT01190748|Experimental|A|Galantamine 4 mg Tablet, single dose
9959902|NCT01190748|Active Comparator|B|Reminyl 4 mg Tablet, single dose
9959903|NCT01190761|Experimental|A|Galantamine 4 mg Tablet, single dose
9959904|NCT01190761|Active Comparator|B|Reminyl 4 mg Tablet, single dose
9959905|NCT01190774|Experimental|Dentist behaviour|Patient completes the MDAS which is handed to receptionist who then gives the information to the dentist with patient knowledge
9959906|NCT01190774|Experimental|Dentist behaviour and patient expectancy|Patient completes the MDAS and hands to the dentist
9959907|NCT01190826|Experimental|ASM-024 10 mg|ASM-024 administered once by inhalation at a target dose of 10 mg
9959908|NCT01190826|Experimental|ASM-024 100 mg|ASM-024 administered once at a target dose of 100 mg
9959909|NCT01190826|Placebo Comparator|Placebo|Placebo administered once by inhalation
9476615|NCT03570138|Active Comparator|Standard self monitoring blood glucose system|Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
9959910|NCT01190904||Coronary Artery Disease (≥50%) with or without PCI|We propose to investigate four specific aims using 1,143 diabetic men who have CAD (≥50%) lesion in at least one major epicardial vessel with or without PCI.
9959911|NCT01190917|Active Comparator|Cognitive Behavioral Therapy Group|
9959912|NCT01190917|Active Comparator|Social Play Group|
9959913|NCT01190982|Experimental|LEP-ETU|All patient will have baseline to confirm disease status. The disease progression/response is assessed inaccordance to the RECIST guidelines
9959914|NCT01190995|Experimental|Sucrose|The enrolled neonates will be administered a sterile solution of 24 % sucrose orally for a period of 7 days from enrollment The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure.
9959915|NCT01190995|Placebo Comparator|Placebo|The enrolled neonates will be administered double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
9959916|NCT01191021|Other|Propofol|Volunteers will receive propofol anesthesia on the study day.
9959917|NCT01191060|Experimental|lenalidomide, bortezomib with ASCT|"RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)~Autologous stem cell transplant:~Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)"
9959918|NCT01191060|Experimental|lenalidomide, bortezomib without ASCT|RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
9959919|NCT01191112|Experimental|Peptide Based enteral formula|
9959920|NCT01191125|Experimental|medical food with AN777|
9959921|NCT01191125|Active Comparator|oral nutritional formula|
9959922|NCT01191138|Other|Infracolic Anastamosis|The gastrojejunal anastamosis is done in the infracolic compartment
9959923|NCT01191138|Other|Supracolic Anastamosis|The gastrojejunal anastamosis is done in the supracolic compartment
9959924|NCT01191164|Experimental|Study Arm|
9959925|NCT01191177|Experimental|Lovaza group|Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day
9959926|NCT01191177|Placebo Comparator|Placebo group|Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day
9959927|NCT01191203|Active Comparator|Depo Medroxyprogesterone Acetate|
9959928|NCT01191203|Active Comparator|Copper IUD (CuT360)|
9959929|NCT01191216|Experimental|Arm I|Patients receive oral 1-methyl-d-tryptophan twice daily on days 1-21 and docetaxel IV over 1 hour on day 1 (in course one patients receive 1-methyl-d-tryptophan once daily on days 1 and 3-21).
9959930|NCT01191229|No Intervention|Tecnis One-Piece MF IOL|It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery
9959931|NCT01191229|No Intervention|Crystalens AO|It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO
9959932|NCT01191281|Experimental|Diet/nutrition counsel+food aid|Intervention. Patients enrolled in the intervention group will receive a multi-component intervention that includes dietary and nutritional counseling and food assistance (food aid basket)
9959933|NCT01191281|Active Comparator|dietary/nutritional counseling|Patients enrolled in the comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
9959934|NCT01191294|Experimental|Medical Students|3rd year medical students during their primary care clerkship
9959935|NCT01191307||Shunt Implant|hydropcephalus cohort
9959936|NCT01191307||Cochlear Implant|hearing impaired cohort
9959937|NCT01191307||Spinal Cord Stiumulation|spinal cord injury cohort
9959938|NCT01191307||Vagus Nerve Stimulation|epilepsy cohort
9959939|NCT01191307||Deep Brain Stimulation|dystonia cohort
9959940|NCT01191346||3T MRI|Patients receiving 3T MRI
9959941|NCT01191359|Active Comparator|sublingual administration|oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
9959942|NCT01191359|Active Comparator|vestibular administration|oral immunotherapy with drops applied by single dose containers (200 STU per dose)
9959943|NCT01191372|Placebo Comparator|saline for injection|
9959944|NCT01191372|Experimental|ARC19499 Low Dose|
9959945|NCT01191372|Experimental|ARC19499 Mid Dose|
9959946|NCT01191372|Experimental|ARC19499 High Dose|
9959947|NCT01191385||Group 1|
9959948|NCT01191424|Experimental|CHF1535 NEXT DPI|Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI
9959949|NCT01191424|Active Comparator|Free combination BDP and FF|Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF
9959950|NCT01191450|Active Comparator|Higroton®|Chlorthalidone 25mg - one oral tablet a day in the morning
9959951|NCT01191450|Experimental|Diupress®|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning
9959952|NCT01191463|Experimental|Mung Bean Meals and Guava fruit|Subject in this group will receive, a lunch meal based on 50g of Mung beans together with a local, Vitamin C rich fruit (Guava)
9959953|NCT01191463|Active Comparator|Mung Bean|Subjects in this group will receive a lunch meal based on 50g mung beans but without any vitamin C source.
9959954|NCT01191463|No Intervention|School feeding program|Subjects in this arm, will receive the regular school feeding program as provided by the school authorities
9959955|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in high risk patients|
9959956|NCT01191489|Active Comparator|Non-invasive mechanical ventilation in High Risk Patients|
9959957|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in Low Risk Patients|
9959958|NCT01191489|Active Comparator|Conventional Oxygen Therapy in Low Risk Patients|
9667731|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
9959959|NCT01191502||TECNIS MULTIFOCAL (TMF) INTRAOCULAR LENS|
9959960|NCT01191502||CRYSTALENS HD (CHD) INTRAOCULAR LENS|
9959961|NCT01191515||Near visual outcomes with Monofocal IOL|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
9959962|NCT01191515||Intermediate Visual outcomes|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
9959963|NCT01191554|Experimental|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
9959964|NCT01191554|Experimental|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
9959965|NCT01191567|Active Comparator|Conventional treatment|
9959966|NCT01191567|Experimental|VAC treatment|
9959967|NCT01191580|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy is a brief, manualized therapy that has shown efficacy in treating major depression in several controlled trials including a large trial for depressed HIV-infected individuals and other randomized trials in depressed individuals with other comorbid medical illnesses. Research shows that Interpersonal Psychotherapy improves social skills and functioning. Interpersonal Psychotherapy has shown remarkable flexibility and efficacy across age ranges, cultures, formats, and modes of delivery. We recently obtained promising pilot data in a small open trial on the acceptability and efficacy of individual IPT for depressed breast cancer patients of diverse ethnic background, socioeconomic status, and cancer progression stage.
9959968|NCT01191580|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a brief, manualized form of cognitive-behavioral therapy (CBT) that has been adapted to treat depression in cancer patients, and has shown highly promising results.
9959969|NCT01191580|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy, a relatively unstructured psychotherapy commonly used in clinical practice, focuses on the patient's affect. It builds a strong therapeutic alliance through careful, empathic listening and validating and encouraging toleration of the patient's emotions. It has shown promising results in depressed individuals with cancer and other medical illnesses.
9959970|NCT01191593|Experimental|Adductor-Canal-Blockade with ropivacaine|
9959971|NCT01191593|Placebo Comparator|Adductor-Canal-blockade with saline|
9959972|NCT01191606|Active Comparator|Group A|the exchange of ventilatory mode from volume controlled ventilation to pressure controlled ventilation
9959973|NCT01191606|Active Comparator|Group B|the exchange of ventilatory mode from pressure controlled ventilation to volume controlled ventilation
9959974|NCT01191619|Experimental|McIvor group|groups in which proseal laryngeal mask airway is inserted with McIvor retractor.
9959975|NCT01191632|Active Comparator|Radiation 0,5Gy|"Radiation: one time Radiation with an intensity of 0.5 Gy Group A~Beginning on a weekday 48 hours before surgery"
9959976|NCT01191632|Active Comparator|No radiation|Control group with 0Gy radiation
9959977|NCT01191632|Active Comparator|Radiation 2Gy|"Radiation: one time Radiation with an intensity of~2.0 Gy Group B~Beginning on a weekday 48 hours before surgery"
9959978|NCT01191632|Active Comparator|Radiation 5Gy|"Radiation: one time Radiation with an intensity of~5 Gy Group C Beginning on a weekday 48 hours before surgery"
9959979|NCT01191645|Experimental|Primperan|
9959980|NCT01191645|Active Comparator|Naloxon|
9959981|NCT01191645|Placebo Comparator|Natriumklorid|
9959982|NCT01191645|Experimental|Ultiva|
9959983|NCT01191684|Experimental|Treatment (vaccine therapy)|Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.
9959984|NCT01191697|Experimental|Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine|"Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine for patients with HER2-positive metastatic esophagogastric cancer. Each cycle is 21 days.~Cycle 1, Day 1 Trastuzumab (loading dose) 4mg/kg IV~Cycle 2, Day 1 and all Subsequent Cycles Bevacizumab (7.5mg/kg) IV Trastuzumab (6mg/kg) IV Oxaliplatin (130mg/m2) IV Capecitabine (1200mg/m2) PO (taken Days 1-14 of each cycle)~Patients remained on treatment until disease progression, intercurrent illness that prevented further administration of treatment, unacceptable adverse events, participant decision to withdraw consent or general or specific changes in the participant's condition that rendered the participant unacceptable for further treatment."
9959985|NCT01191710|Experimental|Antagonist group|Antagonist protocol for IVF
9959986|NCT01191710|Active Comparator|Agonist group|Long Agonist protocol for IVF
9959987|NCT01191775|Experimental|PNT2258|PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.
9959988|NCT01191814|Active Comparator|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
9959989|NCT01191814|Active Comparator|Plastic Stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a plastic stent
9959990|NCT01191866||Diabetes mellitus|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh Pediatric Diabetes Clinic
9959991|NCT01191879||acute MI group|Patients presenting with acute ST elevation myocardial infarction, admitted to the intensive cardiac care unit and that are planned for emergency primary PCI
9959992|NCT01191879||Controls|Patients undergoing a non-invasive evaluation of possible myocardial ischemia.
9959993|NCT01191892|Placebo Comparator|Placebo|Carboplatin, Gemcitabine and Placebo
9959994|NCT01191892|Experimental|vandetanib|Carboplatin, Gemcitabine and vandetanib
9959995|NCT01191905|Experimental|High dose CRRT|Clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
9959996|NCT01191905|Active Comparator|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
9959997|NCT01191918|Experimental|donepezil|donepezil plus Lithium
9959998|NCT01191918|Placebo Comparator|Control|Placebo plus Lithium
9959999|NCT01191931||prostate cancer|Patients with histologically proven prostate cancer (positive biopsy) and who are planned to undergo radical prostatectomy.
9960000|NCT01191957|Active Comparator|I. V. Busulphan plus Cyclophosphamide|Conventional conditioning regimen with intravenous (i.v.) Busulphan (Busilvex), 12.8 mg/kg followed by Cyclophosphamide, 120 mg/kg iv.
9960001|NCT01191957|Experimental|I. V. Busulphan plus Fludarabine|Reduced toxicity conditioning regimen with intravenous (i.v.)Busulphan (Busilvex), 12.8 mg/kg plus Fludarabine, 4 x 40 mg/m².
9960002|NCT01191970||Epidural recipients|Subjects who received epidural analgesia during labor
9960003|NCT01191970||Non-epidural recipients|Subjects who did not receive epidural analgesia during labor
9960004|NCT01191983|Experimental|Methoxy polyethylene glycol-epoetin beta|Participants will receive 1.2 mcg/kg methoxy polyethylene glycol-epoetin beta given in monthly doses at each visit. Dose will be measured on the basis of the participants Hb level during the study period. The dose administration will be the nearest possible dose using the prefilled syringes containing 50, 75 and 100 mcg/kg Q4W.
9667732|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
9960005|NCT01191996|Experimental|MIS416|MIS416, immunomodulating microparticle, given intravenously weekly
9960006|NCT01192009|Experimental|Immobilization and Leucine|
9960007|NCT01192009|Placebo Comparator|Immobilization and Placebo|
9960008|NCT01192048||Study Subjects|Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.
9960009|NCT01192061||Normal tension glaucoma group|
9960010|NCT01192061||Control group|
9960011|NCT01192074||Ultrasound of the spine|Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery
9960012|NCT01192087|Experimental|Cetuximab arm|patients receive weekly cetuximab in combination with IMRT and carbon ion boost
10006137|NCT01591694||Yoga Based Psychotherapy|Children with a history of maltreatment and/or violence exposure
10006138|NCT01591694||Biofeedback|Children with a history of maltreatment and violence exposure and their caregivers
10006139|NCT01591694||TST-SA|Trauma Systems Therapy for Adolescent Substance Abuse
10006140|NCT01591707|Experimental|ISC+PRT Intervention|For the duration of at least one school year children will receive 45-90 minutes of intervention in the classroom in an attempt to increase social and communication skills.
10006141|NCT01591707|No Intervention|Instruction As Usual|For the duration of at least one year children will receive the typical classroom instruction
10006142|NCT01591720|Experimental|Tailored Internet-delivered CBT|The intervention is delivered within a primary care clinic.
10006143|NCT01591759|Experimental|Citicoline|8-week treatment of 2,000mg/day of citicoline
10006144|NCT01591759|Placebo Comparator|Placebo|
10006145|NCT01591772||diagnosed with ovarian that recieved chemo|
10006146|NCT01591772||healthy controls|
10006147|NCT01591798|Experimental|Robotic surgery|Proctectomy using robot
10006148|NCT01591798|Active Comparator|Laparoscopic surgery|Conventional laparoscopic rectal resection
10006149|NCT01591811|Experimental|Arm 1 Daily Boost of Radiation Therapy|Arm 1 of treatment, you will be receiving 15 daily radiation fractions of 2.7 Gy (measure of radiation dose) daily for three weeks to the entire breast with a daily concomitant boost of 0.5 Gy
10006150|NCT01591811|Experimental|Arm 2 Weekly Boost of Radiation Therapy|Arm 2 Weekly Boost will receive 15 daily radiation fractions of 2.7 Gy for three weeks to the entire breast with a weekly boost of 2.0 GY.
10006151|NCT01591824|Experimental|POLD TREATMENT|Patients who applies the treatment of resonant oscillation according to the Pold Concept
10006152|NCT01591824|Active Comparator|CONVENCIONAL: column exercise group|Patients who applied the conventional treatment of hospital
9476616|NCT03570125|Experimental|Dietary intervention arm|"group will follow an ad libitum diet but, every two months, will follow a 5 day of fasting mimicking diet (PROLON). The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS).~Prolon will be provided for free by L-nutra or in case of unforeseeable budget constraint at one fifth of its commercial value."
10006153|NCT01591850|Experimental|1 Ketoconazole DDI|
10006154|NCT01591850|Experimental|2 Rifampicin DDI|
9803635|NCT03677739|Experimental|Arm 1 Young melanoma Family Facebook focusing on skin cancer|Participants join a secret Young melanoma Family Facebook Group and view post messages focusing on skin cancer for 12 weeks.
9803636|NCT03677739|Experimental|Arm 2 Healthy Lifestyle Facebook focusing on healthy lifestyle|Participants join a secret Healthy Lifestyle Facebook Group and view post messages focusing on healthy lifestyle for 12 weeks.
10006155|NCT01591850|Experimental|3 ATZ/r DDI|
10006156|NCT01591876|Sham Comparator|Progressive muscle relaxation|As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
10006157|NCT01591876|Active Comparator|Aerobic exercise|Intervention -moderate intensity aerobic exercise.
10006158|NCT01591889|Active Comparator|tindamax|500 mg tablet
10006159|NCT01591889|Active Comparator|tinidazole|500 mg tablet
10006160|NCT01591902|Experimental|EGRIFTA Treatment Grop|Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient
10006161|NCT01591902|Placebo Comparator|Placebo|Placebo-controlled
9476617|NCT03570125|No Intervention|no intervention|Control/Placebo with multivitamin supplementation
9803637|NCT03667170|Experimental|Subjects with MSI-H/dMMR|patients receive KN035 300 mg Subcutaneously biweekly
9803638|NCT03655262|Experimental|1 Session|1 neuro-reinforcement session
10006162|NCT01591915|Experimental|MBSR self care program including weekly sessions|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week. Participants will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 hours.
10006163|NCT01591915|Experimental|MBSR self care program|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week.
10006164|NCT01591915|No Intervention|Standard care|
10006165|NCT01591928||Infants with heterotaxy syndrome|
10006166|NCT01591941|Active Comparator|CON group|Control Group underwent a standard soccer warm-up
10006167|NCT01591941|Experimental|Core-PAC|Experimental took part in the Core position and control movement strategy (Core-PAC) warm-up
10006168|NCT01591967|No Intervention|Control|Control -- no intervention
10006169|NCT01591967|No Intervention|Placebo w/ sham|"Sham intervention with the adjusting tool turned off"
10006170|NCT01591967|Experimental|Activator treatment|Treatment with Activator
10006171|NCT01591980|Experimental|Pregabalin 100 mg|
10006172|NCT01591980|Experimental|pregabalin 150 mg|
10006173|NCT01591980|Sham Comparator|Placebo|
10006174|NCT01591993|Experimental|Test subject|To each subject, the investigators will randomly apply 10% lactic acid on one nasolabial fold, once.
10006175|NCT01591993|Placebo Comparator|Placebo|To each subject, the investigators will apply placebo (0.9% saline solution) on the contralateral nasolabial fold to the lactic acid, simultaneously.
10006176|NCT01592019|Experimental|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
10006177|NCT01592019|Experimental|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
9960013|NCT01192113|Experimental|Group A: Diabetic Peripheral Neuropathy (IV)|
9960014|NCT01192113|Experimental|Group B: Diabetic Peripheral Neuropathy (IM)|
9960015|NCT01192113|Experimental|Group C: Idiopathic Peripheral Neuropathy|
9960016|NCT01192113|Experimental|Group D: Nutritional & Metabolic Peripheral Neuropathy|
9960017|NCT01192113|Experimental|Group E: Compression Peripheral Neuropathy|
9960018|NCT01192165|Experimental|Treatment Group 1|Trametinib plus Docetaxel
9960019|NCT01192165|Experimental|Treatment Group 2|Trametinib plus Erlotinib
9960020|NCT01192165|Experimental|Treatment Group 3|Trametinib plus Pemetrexed
9960021|NCT01192165|Experimental|Treatment Group 4|Trametinib plus Pemetrexed and Carboplatin
9960022|NCT01192165|Experimental|Treatment Group 5|Trametinib plus nab-Paclitaxel
9960023|NCT01192165|Experimental|Treatment Group 6|Trametinib plus Pemetrexed and Cisplatin
9960024|NCT01192217|Active Comparator|VATS group|
9960025|NCT01192217|Active Comparator|Mini-thoracotomy group|
9960026|NCT01192269|Experimental|Docosahexaenoic Acid Supplement|"DHA supplement: Experimental~1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric)."
9960027|NCT01192308|Experimental|40mg QD dose intervention|40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.
9476618|NCT03570112||Pregnant Women with Hep C|SOF/VEL Therapy-sofosbuvir 400mg, velpatasvir 100mg, once daily for 12 weeks at 24 weeks post partum
9960028|NCT01192321|Experimental|Toric T3 - T9|Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
9960029|NCT01192321|Active Comparator|Monofocal|Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.
9960030|NCT01192360|Experimental|Cardiac Patients|In addition to the routine clinical MRI, we will conduct the DCE MR perfusion imaging research component. For this, we will measure native pre-contrast T1 and then inject a tight bolus of gadolinium (0.1mmol/kg) while acquiring high temporal resolution T1-weighted 3D contrast dynamics information over the whole thorax while the patient is holding his / her breath. Overall, the research component will prolong the clinical study by approximately 5 minutes.
9960031|NCT01192360|Experimental|Pulmonary Patients|Patients in this group will receive a full cardiac and pulmonary MRI assessment, with the DCE pulmonary perfusion scan added as described above. Overall, the investigation will take approximately 45 minutes
9960032|NCT01192373|Experimental|High circulating free fatty acids|using Heparin af intralipid infusion for 8 hours
9960033|NCT01192373|Active Comparator|Low circulation free fatty acids|using hyperinsulinaemic euglycemic clamp for 8 hours
9960034|NCT01192438|Experimental|Procedure/surgery|
9960035|NCT01192477|Experimental|Ozone 0.1 ppm|
9960036|NCT01192477|Experimental|Ozone 0.2 ppm|
9960037|NCT01192477|Sham Comparator|Filtered air|
9960038|NCT01192490|Experimental|Lidocaine Arm|This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.
9960039|NCT01192490|Placebo Comparator|Lubricant|Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.
9960040|NCT01192503|Active Comparator|rasagiline|
9960041|NCT01192503|Placebo Comparator|placebo (sugar pill)|
9960042|NCT01192529|Experimental|Experimental Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of Supressi nutritional supplement"
9960043|NCT01192529|Active Comparator|Control Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of T-Diet plus High Protein product"
9960044|NCT01192581|No Intervention|control|routine treatment for brain hypoperfusion
9960045|NCT01192581|Experimental|Vuloven1|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
9960046|NCT01192581|Experimental|Vuloven2|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
9960047|NCT01192581|Experimental|Vuloven3|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
9960048|NCT01192594|Experimental|MAPP Trained Case Managers|Consumers assigned to case managers who receive training in the Milestones of Adjustment Post-Psychosis Recovery Model
9476619|NCT03570099||Prospective Naloxone cohort|The prospective cohort consists of study subjects receiving Naloxone nasal spray in the distribution program.
9960049|NCT01192594|Active Comparator|Non-MAPP trained case managers|Consumers of case managers not trained in the Milestones of Adjustment Post-Psychosis Recovery Model
9960050|NCT01192646|Active Comparator|Home based life saving skills training|Home based life saving skills will done in one the study group and in the control group no training will be done
9960051|NCT01192646|No Intervention|NO HBLSS|No intervention will be given to the control clusters
9960052|NCT01192659||Patients treated with saxagliptin or placebo|Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
9960053|NCT01192659||Patients currently or previously on treatment|Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.
9960054|NCT01192672|Experimental|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
9960055|NCT01192672|Active Comparator|Control Writing|The participants were instructed to write for 30-minute intervals for 4 consecutive days about all of the actions they performed that day for a 24 hour period. The subjects were asked not to write about their feelings or thoughts related to these actions.
9960056|NCT01192672|No Intervention|Usual Care|Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
9960057|NCT01192685|Other|Depressed outpatients treated with TMS|This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial. Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented. Transcranial Magnetic Stimulation (TMS) will be administered to subjects 5 days a week for 6 weeks. Near infrared spectroscopy (NIRS), a spectroscopic method that uses the near infrared region of the electromagnetic spectrum (from about 700 nm to 2500 nm), will be used to assess blood flow in the brain.
9960058|NCT01192711|Experimental|insulin + DID|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections per day of insulin glulisine associated with basal insulin glargine; the DID will be used to estimate the CHO content of the food intended to eat. Insulin doses in this group will be adjusted based on DID calculations and pre-meal BG values.
9960059|NCT01192711|No Intervention|insulin + usual care|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections of insulin glulisine associated with basal insulin glargine. Insulin doses in group B will be adjusted based on SMBG values reviewed during the doctor office visit.
9960060|NCT01192724|Active Comparator|Triple antiplatelet therapy (TAPT) group|3-month use of cilostazol in addition to dual antiplatelet agent
9960061|NCT01192724|Active Comparator|Dual antiplatelet therapy (DAPT) group|Aspirin and clopidogrel (dual antiplatelet therapy, DAPT) for 1 year
9960062|NCT01192763|Experimental|Arm I|Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.
9476620|NCT03570099||Historical control cohort|Data from the historical control cohort will be collected from national registries years 2013-2017.
9476621|NCT03570086||migraineurs without aura|
9960063|NCT01192789|Other|Intervention|Severe Pneumonia Treatment by LHWs with Amoxicillin at 90mg/kg/day for severe pneumonia
9960064|NCT01192789|Other|Control|LHWs refer the severe pneumonia case to local health facility or private practitioner.
9960065|NCT01192802|Active Comparator|1 dose, Albendazole , tablet|
9960066|NCT01192802|Active Comparator|2 doses, albendazole, tablet|1 tablet of 400 mg of albendazole per day for two consecutive days
9960067|NCT01192802|Active Comparator|3 doses albendazole, 400mg, tablet|
9960068|NCT01192841|No Intervention|White coat group|Participants continued their regular practice of wearing their physician white coat.
9960069|NCT01192841|Experimental|Uniform group|Participants were given a clean uniform (scrubs) at the beginning of the day.
9960070|NCT01192854|Experimental|1|
9960071|NCT01192854|Active Comparator|2|
9960072|NCT01192893||OPUS|OPUS is a prospective study of postmenopausal women recruited in the general population between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin (Germany), Kiel (Germany), Paris (Hospital Cochin, France), and Sheffield (UK)). Investigations were approved at each institution according to the Declaration of Helsinki. Written consent was obtained from all subjects. Each center recruited approximately 500 postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79. Ninety-nine percent of subjects were of white ethnicity.
9803639|NCT03655262|Experimental|3 Sessions|3 neuro-reinforcement sessions
9803640|NCT03655262|Experimental|5 sessions|5 neuro-reinforcement sessions
9476622|NCT03570086||health controls|
9803641|NCT03654833|Experimental|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
9960073|NCT01192919||Patients with lung cancer|Patients with lung cancer requiring therapy
9960074|NCT01192932||COPD|COPD patients aged 40 or more, with a smoking history of > 10 pack-years, a post-bronchodilator FEV1/VC < 0.7 and an optimal treatment according to GOLD guidelines will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5 years.
9960075|NCT01192971|Experimental|A 850|Arm 850: Experimental apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patient withdrawal of consent
9960076|NCT01192971|Experimental|B750|B750: apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9960077|NCT01192984|Experimental|KW-0761|
9960078|NCT01192997|Active Comparator|Menveo-Meningitec|Subjects who were primed with Meningitec who will receive Novartis Menveo
9960079|NCT01192997|Active Comparator|MenACWY-TT-Meningitec|Subjects who were primed with Meningitec who will receive GSK MenACWY-TT
9960080|NCT01192997|Active Comparator|Menveo-Menjugate|Subjects who were primed with Menjugate who will receive Novartis Menveo
9960081|NCT01192997|Active Comparator|MenACWY-TT-Menjugate|Subjects who were primed with Menjugate who will receive GSK MenACWY-TT vaccine.
9960082|NCT01192997|Active Comparator|Menveo-NeisVac-C|Subjects who were primed with NeisVac-C who will receive Novartis Menveo
9960083|NCT01192997|Active Comparator|MenACWY-TT-NeisVac-C|Subjects who were primed with NeisVac-C who will receive GSK MenACWY-TT vaccine
9960084|NCT01193023|Active Comparator|Pressure support|"in this arm, pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS)~with ETS +10%~with ETS -10%"
9960085|NCT01193023|Experimental|NAVA|Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.
9960086|NCT01193036||Interview|
9960087|NCT01193036||Symptom Inventory Assessment|
9960088|NCT01193062|Experimental|Cohort 1|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
9960089|NCT01193062|Experimental|Cohort 2|Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo
9960090|NCT01193075||CMT1B|Families/patients with genetically confirmed CMT1B
9960091|NCT01193075||CMT2A|Families/patients with genetically confirmed CMT2A
9960092|NCT01193075||CMT4A|Families/patients with genetically confirmed CMT4A
9960093|NCT01193075||CMT4C|Families/patients with genetically confirmed CMT4C
9960094|NCT01193075||All other CMT|Families/patients with all other forms of CMT or CMT that has not yet been genetically identified
9960095|NCT01193088||CMT1A|Families/people with genetically defined CMT1A
9960096|NCT01193088||Genetically undefined CMT|Families/people with genetically undefined CMT with common causes ruled out.
9960097|NCT01193166|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months
9960098|NCT01193166|Active Comparator|002|olanzapine flexible dosing as prescribed by the study doctor for 12 months
9960099|NCT01193166|Active Comparator|003|paliperidone flexible dosing as prescribed by the study doctor for 12 months
9960100|NCT01193166|Active Comparator|004|aripiprazole flexible dosing as prescribed by the study doctor for 12 months
9960101|NCT01193166|Active Comparator|005|haloperidole flexible dosing as prescribed by the study doctor for 12 months
9960102|NCT01193166|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 12 months
9960103|NCT01193166|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 12 months
9476623|NCT03570073|Active Comparator|Manual vitrification|
9476624|NCT03570073|Experimental|Automatic vitrification|
9476625|NCT03570034||Obalon Balloon System|Obalon Balloon System with moderate intensity Weight Loss Behavioral Modification Program
9480686|NCT05261997|Experimental|Endoscopic group|The patients received intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). After the last ESWL session, the patients are treated with following ERCP within 48h. ERCP was performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy was performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent for drainage and nasopancreatic catheters will be inserted for temporary drainage if necessary. Conservative treatments similar to patients in the control group were given in endoscopic group according to patients' condition.
9480687|NCT05261997|Other|Conservative group|Patients will have pancreatic enzymes (Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table) to control symptoms of exocrine pancreatic insufficiency. The recommended initial dose for adults is (25 000-40 000) IU lipase per meal (40 000 IU for meals and 20 000 IU for snacks), which can be increased until the PEI is relieved. The maximum recommended dose is (75 000-80 000) IU lipase per meal. Actions including drugs(Acarbose Tablets, Glucophage, Glimepirde Tablets) or insulin(Biosynthetic Human Insulin Injection, Tresiba or both) would also be taken for control of diabetes according to patients' glucose levels.
9480688|NCT05261984|Experimental|Former ICU patients|Research subjects with a prior history of ICU treatment within six months.
9480689|NCT05261984|Active Comparator|Age- and sex-matched control group|Research subjects without a prior history of ICU treatment within the last 30 years, age- and sex-matched in a 1:2 ratio to the experimental arm.
9480690|NCT05261971|No Intervention|Medical therapy|One non-steroidal anti-inflammatory drug (400mg etodolac) and one muscle relaxant drug (4 mg thiocolchicoside) were prescribed to the patients in this group.
9480691|NCT05261971|Active Comparator|Hard Splint Therapy|The patients in this group were asked to use a hard splint delivered to them to use at night.
9480692|NCT05261971|Active Comparator|Soft Splint Therapy|The patients in this group were asked to use a soft splint delivered to them to use at night.
9480693|NCT05261945|Experimental|Routine Physical Therapy|"Electrotherapy~Exercises.~Electrotherapy Hot pack Patients will be in prone position and for relaxation pillow will place beneath the abdomen. Then to reduce muscle spasm and to induce vasodilation hot pack will use for 15 minutes. Treatment with hot pack helps in improving and relaxing the muscle spasm and soft tissue elasticity.~TENS TENS will be of 50 Hz, duration of pulse will be<150 microseconds, for 15 minutes to reduce pain.~TENS and Hot Pack will use at the same time for 15 minutes.~Ultrasound Ultrasound's gel will be applied on outer surface of skin with 2-3 mm thickness. Then ultrasound which frequency will be 1MHz applied for 5 min.~• Exercises Passive Range of Motion exercises for 10 minutes~Neck Flexion~Neck Side bending~Neck Rotation~Isometric neck flexion~Isometric neck extension~Isometric neck side bending~These exercises will repeat 3 times within the treatment program."
9480694|NCT05261945|Experimental|Manual Therapy And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 mins, TENS and hot pack for 15 mins, ultrasound for 5 mins.~Manual therapy~Natural Apophyseal Glides The natural apophyseal glides, which will be applied between C2 and C7, will be the Manual Muscle Testings first action. Patients may request to sit and lean on a chair. The oscillatory motions will reapply the mobilization.~Sustained Natural Apophyseal Glides Sustained Natural Apophyseal Glides will be a mixture of mobilization and active gestures/movements.~5 repetitions for 10 minutes of each."
9960104|NCT01193166|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 12 months
9960105|NCT01193179|Experimental|OPC-262|
9667733|NCT03131960|Experimental|VNS + Rehabilitation (1)|Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.
9960106|NCT01193192||Arm #1 (Test Group)|100 subject administered Neevo® or NeevoDHA® daily
9960107|NCT01193192||Arm #2 (Control group)|100 subject administered a prenatal vitamin daily
9960108|NCT01193205|Experimental|20 weeks skills group|Participants receive 20 weeks of Dialectical Behaviour Therapy Skills training, covering 5 modules: mindfulness, interpersonal effectiveness, emotional regulation, distress tolerance, dialectics.
9960109|NCT01193205|No Intervention|Waitlist|Participants on the waitlist condition will be assessed at baseline and symptoms monitored at 10 weeks, 20 weeks and 8 months following baseline assessment. They will then be offered the active treatment.
9960110|NCT01193231||Acuvail 0.45%|Each subject will be randomized to the eye that they will use Acuvail in for 3 days after PRK
9960111|NCT01193231||Systane Ultra Preservative Free Tears|Each subject's contralateral eye (other eye) will use Sytane for 3 days after PRK surgery.
9960112|NCT01193270|Experimental|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate (Aquasol E®) 50 IU/kg.
9960113|NCT01193270|Placebo Comparator|Placebo|Sterile water in volume equal to that of the comparator drug.
9960114|NCT01193296|Experimental|Vildagliptin|
9960115|NCT01193296|Active Comparator|Sitagliptin|
9960116|NCT01193374|Experimental|Parent/child tailored mailed materials|Family provided newsletters tailored to issues and readiness to change. Family receives educational nutrition DVD, pedometers for family activities and child nutrition/physical activity games
9960117|NCT01193374|Active Comparator|Basic information at single time|Family provided with high quality booklet from American Dietetic Association providing the same information that intervention arm received but not tailored.
9960118|NCT01193387|Experimental|IDeg (M) IM1|
9960119|NCT01193387|Experimental|IDeg (M) IM2|
9960120|NCT01193400|Experimental|Clofarabine-Cytarabine|Induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine
9960121|NCT01193413||Non-infected necrosis group|There is no necrosis infection in severe acute pancreatitis.
9960122|NCT01193413||Single drainage group|The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
9960123|NCT01193413||Combined surgery group|If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
9960124|NCT01193426||Cirrhosis patient|All consecutive patients with cirrhosis admitted to the five participating center Patients were hospitalized or treated in an ambulatory setting for treatment of ascites or complications of cirrhosis. Ascitic fluid was obtained by paracentesis according to the usual clinical management for these patients.
9960125|NCT01193439||Patients with high risk|
9960126|NCT01193439||Patients in normal conditions|
9960127|NCT01193452|Experimental|S-1/LV|S-1 combined with Leucovorin
9960128|NCT01193452|Active Comparator|sLV5FU2|5-FU/LV infusion
9960129|NCT01193465|Experimental|humidity|
9960130|NCT01193478|Active Comparator|Cohort 1|GS-5885 (3 mg), once daily or matching placebo, once daily
9960131|NCT01193478|Active Comparator|Cohort 2|GS-5885 (10 mg), once daily or matching placebo, once daily
9960132|NCT01193478|Active Comparator|Cohort 3|GS-5885 (30 mg), once daily or matching placebo, once daily
9960133|NCT01193478|Active Comparator|Cohort 4|GS-5885 ( up to 90 mg), once daily or matching placebo, once daily
9960134|NCT01193478|Active Comparator|Cohort 5|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
9960135|NCT01193478|Active Comparator|Cohort 6 (optional)|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
9960136|NCT01193491|Experimental|IPI-493|
9960137|NCT01193504|Active Comparator|Pred Forte|Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
9960138|NCT01193504|Active Comparator|Lotemax|patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
9960139|NCT01193543|Experimental|calanus oil|calanus oil 1 gram twice daily
9960140|NCT01193543|Placebo Comparator|olive oil|olive oil 1 gram twice daily
9960141|NCT01193569||Standard of Care|Standard of Care for stroke except mechanical therapy
9960142|NCT01193595|Experimental|AVE8062/ bevacizumab|The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.
9960143|NCT01193621|Active Comparator|haloperidol|"0.5, 1, 3 mg of haloperidol will be administered orally every 24 hours for 7 days to 4 healthy subjects in each dose level (a total of 12 subjects).~Dose groups are as follows; D2-receptor occupancy study Group Single Oral Dose No. of subjects~0.5 mg 4~1 mg 4~5 mg 4"
9960144|NCT01193634|Experimental|Paradym RF ICD|Active implantable defibrillators range
9960145|NCT01193699|Experimental|P1101|
9960146|NCT01193712|Other|on-table non-responder|patients who do not show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
9960147|NCT01193712|No Intervention|on-table responders|patients who do show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
9960148|NCT01193725|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
9960149|NCT01193725|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
9960150|NCT01193725|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
9960151|NCT01193738|Active Comparator|active osteopathic compression|osteopathic compression of Pterygopalatine node
9960152|NCT01193738|Placebo Comparator|placebo osteopathic compression|placebo osteopathic compression
9960153|NCT01193751||asphyxiated newborns > 37 weeks of gestation|
9960154|NCT01193764|Experimental|cocoa|unsweetened 100% cocoa (Ghirardelli)
9960155|NCT01193764|Placebo Comparator|placebo|hydrolyzed gelatin powder (Gelita)
9960156|NCT01193790|Experimental|Coblation|
9960157|NCT01193803||Spondylodiscitis control group|Patients needing vertebral biopsy looking for tumoral etiology
9960158|NCT01193803||Prosthetic Joint Infection control group|Patients with primary prosthetic arthrosis surgery
9476626|NCT03570008|Experimental|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
9803642|NCT03654833|Experimental|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
9960159|NCT01193803||Septic arthritis control group|Arthrosic patients needing evacuating articular punction with leucocytes infiltration less than 1000 /mm3
9960160|NCT01193803||Spondylodiscitis case group|Patients suspected of Discitis and/or Vertebral Osteomyelitis is defined by the need of spinal biopsy in infectious context.
9960161|NCT01193803||Prosthetic Joint Infection case group|Patients suspected of Prosthetic Joint Infection defined by the need of surgical revision for diagnostic or therapeutic aiming in infectious context.
9960162|NCT01193803||Septic arthritis case group|Patients suspected of Septic arthritis without prosthesis were defined by the need of synovial punction and/or biopsy
9960163|NCT01193816|Experimental|loxapine|loxapine
9960164|NCT01193816|Placebo Comparator|Placebo|Placebo
9960165|NCT01193829||NSCLC patients|
9960166|NCT01193881|Experimental|Treatment (erlotinib, RO4929097)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9960167|NCT01193894|Experimental|Profermin|
9960168|NCT01193894|Active Comparator|Fresubin|
9960169|NCT01193946||Single-arm design|There is currently considerable debate regarding the accuracy of the estimated average requirement (EAR) and the recommended dietary allowance (RDA) for older people. Very limited data obtained from older individuals are available to support the assumption that age does not affect protein requirement. Existing method like nitrogen balance has inherent limitations that diminish it from being considered a reference method. Indicator amino acid oxidation technique is emerging as an alternative method to measure dietary protein requirement. It is more accurate and less demanding. The current study will be the first time this technique is used with elderly adults and will provide an important foundation for geriatric nutrition research
9960170|NCT01193985|Experimental|Intervention|
9960171|NCT01193998|Active Comparator|Clinician exposed to Model result|
9960172|NCT01193998|Experimental|Clinician blinded to Model result|
9960173|NCT01194024||Intubated within 24hrs of admission|All patients that are admitted to a participating burn center and intubated within 24 hours
9960174|NCT01194037|Experimental|Hanferon (low dose) sc weekly + RBV oral daily|
9960175|NCT01194037|Experimental|Hanferon (high dose) sc weekly + RBV oral daily|
9960176|NCT01194037|Active Comparator|Pegasys 180 ug sc weekly + RBV oral daily|
9960177|NCT01194050||Cohort|
9960178|NCT01194063|Experimental|Omegaven|Administration of intravenous Omega-3 fish oil lipid emulsion 1 g/kg continuous infusion over 12-24 hrs
9960179|NCT01194076|Experimental|5day intensive treatment|
9960180|NCT01194102|Experimental|Stroke Community Wellness Program|"Participants with stroke will attend a 12 week Community Wellness Program. The program consists of a Community Based Exercise Program at the YMCA (2x 1 hour exercise sessions per week with specially trained fitness instructors). They will also attend a 1 hour long Living with Stroke education session one time per week and an independent exercise session in the fitness centre one time per week."
9960181|NCT01194102|Active Comparator|Regular YMCA membership|"The control group will have access to YMCA facilities to use at their discretion but will not attend the Community Based Exercise Program for stroke survivors or the Living with Stroke education program. YMCA staff working with the control group will not receive specialized training in exercise and education for stroke survivors but will be trained on important safety precautions and contraindications to exercise after stroke."
9960182|NCT01194115|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for total of 6 doses; 500 mg metronidazole per oral every 8 hours for total of 6 doses
9960183|NCT01194115|Placebo Comparator|Placebo/standard of care|Placebo pills per oral every 8 hours for total of 6 doses
9960184|NCT01194128|Experimental|Psychoeducatioinal Support|The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
9960185|NCT01194128|Active Comparator|INformation only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. This packet will contain several fact sheets from a nationally-recognized expert source in caregiving (the Family Caregiver Alliance's National Center on Caregiving) and a national information and advocacy group (the National Citizens' Coalition for Nursing Home Reform). The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition."
9960186|NCT01194141|Experimental|Exercise training|Aerobic exercise training 45-60 min/3x/week/12 weeks
9960187|NCT01194167|Experimental|Eltrombopag|Eltrombopag 75 mg per day. Possible escalation to 150 mg per day after day 15 lab results. Possible escalation to 300 mg per day after day 29 lab results.
9960188|NCT01194180|Experimental|Group A|"BCG-naive subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
9960189|NCT01194180|Experimental|Group B|"BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
9960190|NCT01194180|Experimental|Group C|"BCG-experienced subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
9960191|NCT01194180|Experimental|Group D|"BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
9960192|NCT01194193|Experimental|1|
9960193|NCT01194206|Experimental|Arm I|Patients undergo 3 fractions of stereotactic body radiation therapy in 3 fractions delivered within 14 days in the absence of disease progression or unacceptable toxicity.
9960194|NCT01194232|Experimental|Sildenafil|15 subjects will receive 8 week course of Sildenafil administered at a dose of 20 mg per dose three times per day.
9960195|NCT01194284||High-grade osteosarcoma patients|
9960196|NCT01194310||phaco alone|patients w/ diagnosis of open angle glaucoma underwent phaco alone
9960197|NCT01194310||phaco-ELT|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus ELT
9960198|NCT01194310||phaco-Trabectome|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus Trabectome
9960199|NCT01194323||Controls|No complaints or history of heartburn or acid regurgitation; no erosion at EGD; and normal pH monitoring
9960200|NCT01194323||GERD Cases|Patients with esophageal erosion at EGD and abnormal pH monitoring.
9960201|NCT01194336||Huperzine A: 100 ug|
9960202|NCT01194336||Huperzine A: 200 ug|
9960203|NCT01194336||Donepezil: 2.5 mg|
9960204|NCT01194336||Donepezil: 5 mg|
9960205|NCT01194336||Galantamine: 4 mg|
9960206|NCT01194336||Galantamine: 8 mg|
9960207|NCT01194336||Placebo|
9960208|NCT01194388||MicroFx™ PGLA Treated Subjects|
9960209|NCT01194401||Cohort|
9960210|NCT01194492|Other|Albumin kinetics|
9960211|NCT01194505|Active Comparator|ACL, sciatic, femoral, obturator|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
9960212|NCT01194505|Active Comparator|ACL, sciatic nerve block, posterior lumbar plexus block|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
9960213|NCT01194518|Experimental|Lifestyle Intervention Program|
9960214|NCT01194544||population undergoing EGD in health examination.|
9960215|NCT01194557|Active Comparator|rapid diagnostic test|Treatment and diagnosis of malaria in drugs hops using rapid diagnostic tests
9960216|NCT01194557|No Intervention|Presumptive malaria treatment|Presumptive treatment for malaria in drug shops
9960217|NCT01194583||NO NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette without nicotine cartridges (NO nicotine group).
9960218|NCT01194596|Experimental|Spirometry and lifestyle counseling|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
9960219|NCT01194596|No Intervention|Lifestyle counseling|No intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
9960220|NCT01194609|Experimental|Low dose radiation, Immune cell therapy|Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks
9960221|NCT01194648|Other|High Intensity Focused Ultrasound|HIFU, the Intervention
9960222|NCT01194700|Experimental|Evohaler|
9960223|NCT01194700|Experimental|Volumatic spacer|
9960224|NCT01194700|Experimental|Aerochamber Plus|
9960225|NCT01194700|Experimental|Synchro-Breathe|
9960226|NCT01194713|Active Comparator|Sleep deprivation|"13 subjects will undergo full sleep deprivation~these subjects are blind to allocation ntil they enter the study center"
9960227|NCT01194713|No Intervention|Control night|control night of unrestricted sleep in 13 other subjects
9476627|NCT03570008|Active Comparator|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
9960228|NCT01194765|Experimental|Cognitive Behavioural Therapy|
9960229|NCT01194765|No Intervention|Waiting List|
9960230|NCT01194778|Placebo Comparator|placebo|The participants of the placebo group will receive daily 1 placebo sachet containing only sucrose
9960231|NCT01194778|Active Comparator|vitamin K1|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K1.
9960232|NCT01194778|Active Comparator|vitamin K2 - 15 µg|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K2
9960233|NCT01194778|Active Comparator|vitamin K2 - 30 µg|The participants of this group will receive daily 1 sachet containing 30 µg vitamin K2
9960234|NCT01194778|Active Comparator|vitamin K2 - 45 µg|The participants of this group will receive daily 1 sachet containing 45 µg vitamin K2.
9960235|NCT01194791|Experimental|Lenalidomide, Cyclophosphamide and Dexamenthasone|
9960236|NCT01194843|Experimental|Ropivacaine|Ropivacaine administration by local per and post surgery infiltration
9960237|NCT01194843|Active Comparator|Physiological serum|Administration of physiological serum by local per and post surgery infiltration
9960238|NCT01194882|Experimental|Insuman Implantable|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
9960239|NCT01194882|Active Comparator|Insuplant|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
9960240|NCT01194895|Experimental|protective ventilation|
9960241|NCT01194895|Active Comparator|conventional ventilation|
9960242|NCT01194934|Experimental|Group A|Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days
9960243|NCT01194934|Experimental|Group B|Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days
9960244|NCT01194934|Active Comparator|Group C|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group C: 5 µg/kg filgrastim SC every day for 5 days"
9960245|NCT01194934|Experimental|Group D|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days"
9960246|NCT01194947||Study participants|patients 18 or older presenting to the Sheba Medical Center pigmented lesion clinic for skin cancer surveillance. Patients routinely undergo total skin examination that includes clinical and dermoscopic evaluation of skin lesions. Patients also routinely undergo annual total body digital photography that allows identification of new or changing lesions.
9960247|NCT01194986|Experimental|Pilot panel|[11C]AZ12807110 distribution and kinetics
9960248|NCT01194986|Experimental|Main panel|Histamine receptor occupancy reached by AZD5213
9960249|NCT01195012|Other|wait-list control arm|Participants wait-listed to start the behavioral obesity treatment program (Helping HAND) after time two data collection (7 months after baseline).
9960250|NCT01195012|Experimental|Intervention arm|see intervention description
9960251|NCT01195051|Experimental|Electronic medication reconciliation|Providers have access to a new, computer-based application to facilitate documentation and prescribing of outpatient medications in the inpatient setting.
9960252|NCT01195051|No Intervention|Control|
9960253|NCT01195064||COPD+ OSAS- patients|Patients with chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
9960254|NCT01195064||COPD- OSAS+ patients|Patients with obstructive sleep apnea syndrome (OSAS) and without chronic obstructive pulmonary disease (COPD), before planned cardiovascular surgery
9960255|NCT01195064||COPD+ OSAS+ patients|Patients with chronic obstructive pulmonary disease (COPD) and with obstructive sleep apnea syndrome (OSAS), with planned cardiovascular surgery
9960256|NCT01195064||COPD- OSAS- patients|Patients without chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
9960257|NCT01195077|Experimental|Seaweed, Spirulina, Seaweed + Spirulina|"Randomized to:~Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day."
9960258|NCT01195129|Other|MicroVention Hydrogel Coils|FDA approved and in common use for cerebral aneurysm treatment.
9960259|NCT01195129|Active Comparator|Non-hydrogel coils|Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).
9960260|NCT01195142||PCOS-CSAT|Women with PCOS
9960261|NCT01195142||Control-CSAT|Control population consisting of women without PCOS, matched for age and BMI with the PCOS cohort
9960262|NCT01195155|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
9960263|NCT01195155|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
9960264|NCT01195155|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
9960265|NCT01195168||PCOS cohort|Women with PCOS as diagnosed by the NIH criteria
9960266|NCT01195168||Control cohort|Women without PCOS
9960267|NCT01195181|Active Comparator|peginterferon alfa-2a plus ribavirin|patients will receive a fixed dose of 180ug/week of peginterferon alfa-2a plus ribavirin at 15mg/kg/daily.
9960268|NCT01195181|Active Comparator|peginterferon alfa-2b plus ribavirin|patients will receive a weight adjusted dose (1,5ug/kg) from 50 to 150ug/week of peginterferon alfa-2b (standard dose) or a lower dose (1,0ug/kg) at physician discretion (randomization list available only for 100 cases) plus ribavirin at 15mg/kg/daily.
9960269|NCT01195194|Experimental|A- negative pre-transplant ELISPOT|Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml (immunoassay) in the first 3 months, followed by trough levels of 5-10 ng/ml.
9960270|NCT01195194|Experimental|B- Positive pre-transplant ELISPOT|Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml the first 3 months, followed by trough levels of 5-10 ng/ml until the end of the study.
9960271|NCT01195207|Experimental|001|CNTO 3157 or placebo 0.003 mg/kg CNTO 3157 or placebo infusion
9960272|NCT01195207|Experimental|002|CNTO 3157 or placebo 0.01 mg/kg CNTO 3157 or placebo infusion
9960273|NCT01195207|Experimental|003|CNTO 3157 or placebo 0.03 mg/kg CNTO 3157 or placebo infusion
9960274|NCT01195207|Experimental|004|CNTO 3157 or placebo 0.1 mg/kg CNTO 3157 or placebo infusion
9960275|NCT01195207|Experimental|005|CNTO 3157 or placebo 0.3 mg/kg CNTO 3157 or placebo infusion
9960276|NCT01195207|Experimental|006|CNTO 3157 or placebo 1 mg/kg CNTO 3157 or placebo infusion
9960277|NCT01195207|Experimental|007|CNTO 3157 or placebo 3 mg/kg CNTO 3157 or placebo infusion
9960278|NCT01195207|Experimental|008|CNTO 3157 or placebo 10 mg/kg CNTO 3157 or placebo infusion
9960279|NCT01195220|Active Comparator|HIV-T|"Group 1, the control, will be the current standard of care, consenting video and testing for HIV alone (HIV-T).~This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test"
9960280|NCT01195220|Experimental|STI/HIV-T|"Group 2 will add routine STI testing for CT and GC, (STI/HIV-T).~This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED."
9960281|NCT01195220|Experimental|STI/HIV-Plus|"Group 3, in addition to combined STI/HIV testing, will add a behavioral video encouraging safer sex, which is chosen for participants based on their answers to a brief measure on stage of change (STI/HIV-PLUS).~This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes"
9960282|NCT01195233|Other|bioxtra spray and mouth rinse|Drug: BioXtra spray or mouth rinse Patients had been xerostomia due to radiation of head and neck were selected for the study. Gender, age, medical history, VAS, dichotomous questionnaire of xerostomia , and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received BioXtra spray and second group used BioXtra mouth rinse for 2 weeks and then 1 weeks wash -out period and for other 2 weeks drugs is switched . Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and 35 days after first visit.
9960283|NCT01195246|Experimental|HEPLISAV|0.5 mL HEPLISAV
9960284|NCT01195246|Active Comparator|Engerix-B|2.0 mL Engerix-B
9960285|NCT01195246|Active Comparator|Fendrix|0.5 mL Fendrix
9960286|NCT01195259||metformin|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
9960287|NCT01195259||rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
9960288|NCT01195285|Active Comparator|Single-Incision Laparoscopic Cholecsytectomy (SILS)|
9960289|NCT01195285|Active Comparator|Traditional Laparoscopic Cholecystectomy (TLC)|
9960290|NCT01195311|Experimental|INCB024360|
9960291|NCT01195324|Experimental|001|Canagliflozin/Warfarin Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6 followed 14 days later by Treatment B: Tablets oral warfarin 30 mg single dose on Day 1
9960292|NCT01195324|Experimental|002|Canagliflozin/Warfarin Treatment B: Tablets oral warfarin 30 mg single dose on Day 1 followed 14 days later by Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6
9960293|NCT01195337||Study Group|Newsletters, Physical Activity (PA) Prescription Plan, Pedometer
9960294|NCT01195350||stroke|
9960295|NCT01195376|Experimental|BEZ235 Dose Escalation once daily|oral BEZ235 once daily (q.d.)
9960296|NCT01195376|Experimental|BEZ Dose escalation twice daily|oral BEZ235 twice daily (b.i.d.)
9960297|NCT01195389|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
9960298|NCT01195389|Placebo Comparator|Placebo treatment|
9960299|NCT01195402|No Intervention|Control|Subjects do not receive any kind of active intervention.
9960300|NCT01195402|Active Comparator|pulmonary outpatient rehabilitation|Subjects participate in an outpatient pulmonary rehabilitation program
9960301|NCT01195428|Active Comparator|Simvastatin|Simvastatin 40 mg daily.
9960302|NCT01195428|Placebo Comparator|Placebo|Placebo
9960303|NCT01195454|Experimental|Insulin glargine / New insulin glargine formulation|"Period 1: Insulin glargine~Period 2: New insulin glargine formulation~Period 3: New insulin glargine formulation~Period 4: New insulin glargine formulation~Duration of treatment: 1 day at each period"
9960304|NCT01195480|Experimental|Prophylaxis arm|Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
9960305|NCT01195480|Experimental|Pre-emptive arm|In this arm, patients identified at high (> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.
9960306|NCT01195493|Experimental|test mouthrinse|
9960307|NCT01195493|Active Comparator|control group|
9960308|NCT01195519||peritoneal dialysis and hemodialysis patients|peritoneal dialysis and hemodialysis patients
9960309|NCT01195532||Gliclazide/2|60 mg*1 for T 30 mg*2 For R
9960310|NCT01195532||Reference and test drug|Reference: 30 mg *2 Test: 60 mg *1
9960311|NCT01195558||Blind with sleep problems|Blind individuals with no light perception and with sleep-related problems who may suffer from Non-24
9960312|NCT01195571|No Intervention|vaccine administration|Each subject will receive on of four chimera CMV vaccines
9960313|NCT01195610|Experimental|New Nordic Diet|New Nordic Diet
9960314|NCT01195610|Experimental|Average Danish Diet|Average Danish Diet
9960315|NCT01195649||Group 1|
9960316|NCT01195688|Experimental|BI 638683|1 single dose per subject as oral solution
9960317|NCT01195688|Placebo Comparator|Placebo solution|1 single dose per subject as oral solution
9960318|NCT01195714|Experimental|Ofatumumab|
9960319|NCT01195727|Experimental|Group 5A - Apixaban (Low Dose)|"Group 5: 12 years to <18 years;~0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
9960320|NCT01195727|Experimental|Group 5B - Apixaban (High Dose)|"Group 5: 12 years to <18 years;~1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
9960321|NCT01195740|Experimental|Attachment Based Family Therapy|
9960322|NCT01195740|Active Comparator|Enhanced Usual Care|
9960323|NCT01195753|Experimental|Liver Cell Infusion|
9960324|NCT01195766|Experimental|Ofatumumab|Ofatumumab in addition to ESHAP therapy
9960325|NCT01195792|Experimental|2 mg GSK1521498|Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
9960326|NCT01195792|Experimental|5 mg GSK1521498|Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
9960327|NCT01195792|Placebo Comparator|Placebo|Approximately 20 subjects will be randomised to receive matching placebo.
9960328|NCT01195805|Active Comparator|Amiloride|
9960329|NCT01195805|Active Comparator|Spironolactone|
9960330|NCT01195805|Placebo Comparator|Placebo|1 tablet twice a day for 28 days
10006178|NCT01592019|Experimental|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
10006179|NCT01592019|Experimental|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
10006180|NCT01592032|Experimental|Vancomycin antimicrobial-lock|Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
9960331|NCT01195818|Experimental|RAS Inhibitors|RAS Inhibitors
9960332|NCT01195974|Experimental|Period 1|YASMIN + 200 mg GSK2248761 or Placebo
9960333|NCT01195974|Experimental|Period 2|YASMIN + 200 mg GSK2248761 or Placebo
9960334|NCT01195974|Other|Run In Period|YASMIN
9960335|NCT01195987||Hepatitis C with Arthritis|
9960336|NCT01195987||Hepatitis C without Arthritis|
9960337|NCT01196000|Active Comparator|Arm I|Patients undergo standard conventional laparoscopic resection.
9960338|NCT01196000|Experimental|Arm II|Patients undergo robotic-assisted laparoscopic resection.
9960339|NCT01196013|Experimental|Clofarabine|
9960340|NCT01196039|Experimental|A|
9960341|NCT01196039|Placebo Comparator|B|
9960342|NCT01196065|Experimental|Single Arm|
9960343|NCT01196130||Biomarker Assessment|Leftover sample of tumor tissue from a previous procedure used for biomarker testing. Blood drawn for biomarker testing, to check for levels of cytokines, and to check the circulating tumor cells (CTCs). Cancer Symptom Questionnaire completion about cancer symptoms.
10006181|NCT01592032|Experimental|Teicoplanin antimicrobial-lock|Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
10006182|NCT01592032|Experimental|Linezolid antimicrobial-lock|Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
10006183|NCT01592032|Experimental|Daptomycin antimicrobial-lock|Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
9960344|NCT01196169|Experimental|Daptomycin|Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
9960345|NCT01196169|Active Comparator|Vancomycin|Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
9960346|NCT01196195|Experimental|QD kaletra|Once daily kaletra
9960347|NCT01196195|Active Comparator|BID kaletra|twice daily dose of kaletra
9960348|NCT01196221||Patients with 30 to 70% carotid artery stenosis|
9960349|NCT01196234|Experimental|Paclitaxel/Carboplatin/Gefitinib|Paclitaxel/Carboplatin/Gefitinib
9960350|NCT01196234|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel/Carboplatin
9960351|NCT01196260|Experimental|5-fluorouracil plus oxaliplatin|patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin
9960352|NCT01196273||Regional Ruhrgebiets Cohort|
9960353|NCT01196286|Experimental|MFG and CR|Subjects provided with both multifamily psychoeducation (MFG) and cognitive remediation (CR)
9960354|NCT01196286|Active Comparator|MFG|Subjects provided with only multifamily group psychoeducation (MFG)
9960355|NCT01196299||Severe Traumatic Brain Injury Group|The severe traumatic brain injury group are patients admitted to the study with an admission GCS between 3 and 8.
9960356|NCT01196299||Moderate Head Injury Group|The moderate head injury group are patients admitted to the study with an admission GCS from 9 to 12.
9960357|NCT01196299||Mild Head Injury Group|The mild head injury group are patients admitted to the study with an admission GCS from 13 to 15.
9960358|NCT01196299||Healthy Volunteer Group|Healthy volunteers will be selected to match the age distribution of the TBI groups. They must be absent of any abnormal radiological findings.
9960359|NCT01196325||Laser Group|Patients who are clinically indicated for the laser treatment
9960360|NCT01196325||Anti-VEGF Group (Bevacizumab)|Patients who are clinically indicated for the intravitreal injection of Bevacizumab
9960361|NCT01196325||Anti-VEGF Group (Ranibizumab)|Patients who are clinically indicated for intravitreal injection of Ranibizumab
9960362|NCT01196325||Age-matched controls|Group of non-diabetic participants who will be age and gender matched
9960363|NCT01196338|Active Comparator|Non-weightbearing no ROM|"Patients will be placed in a back slab post-op and will remain non-weight bearing with crutches with no range of motion for a total of 6 weeks.~After 6 weeks post-op, they will be placed in a boot orthosis and permitted to weight-bear as tolerated."
9960364|NCT01196338|Experimental|Early weight-bearing and ROM|"Patients will be placed in a back slab post-operatively. At 2 weeks post op they will have the back slab removed and placed in a boot orthosis. At this time they will be permitted to weight-bear as tolerated and perform limited ankle range of motion exercises.~After 6 weeks post op they will start to wean from the boot orthosis."
9960365|NCT01196351|Experimental|Sedentary activity, noncaloric beverage|
9960366|NCT01196351|Experimental|Sedentary activity, glucose beverage|
9960367|NCT01196351|Experimental|Exercise activity, noncaloric beverage|
9960368|NCT01196351|Experimental|Exercise activity, glucose beverage|
9960369|NCT01196364|Experimental|Sedentary activity, noncaloric beverage|
9960370|NCT01196364|Experimental|Sedentary activity, glucose beverage|
9960371|NCT01196364|Experimental|Exercise activity, noncaloric beverage|
9960372|NCT01196364|Experimental|Exercise activity, glucose beverage|
9960373|NCT01196468||Anal/cervical dyplasia|Any patient presenting for care with any degree of anal or cervical dysplasia
9960374|NCT01196468||STI|Any patient presenting for care with any non-HIV sexually transmitted infection
9960375|NCT01196468||Lymphoma|Any patient presenting for care with malignant lymphoma of any histological type
9960376|NCT01196468||Seborrhoeic dermatitis/exanthema|Any patient presenting for care with seborrhoeic dermatitis/exanthema
9960377|NCT01196468||Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia|Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia
9960378|NCT01196481|Experimental|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD + VSL#3
9960379|NCT01196481|Active Comparator|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3-4 weeks till variceal ligation
9960380|NCT01196494|Experimental|intraoperative colon lavage|
9960381|NCT01196494|Active Comparator|stent and deferred surgery|
9960382|NCT01196507|Experimental|Carvedilol|Tablet Carvedilol 12.5 mg BD or maximum tolerated dose
9960383|NCT01196507|Placebo Comparator|Placebo|Placebo tablets 2 to 4 BD
9960384|NCT01196520||BL Cases|Children from East Africa diagnosed with BL
9960385|NCT01196520||HCII Controls|Matched controls from the local health clinics
9960386|NCT01196520||Population Controls|Matched controls from the geographic region
9960387|NCT01196546|Experimental|Vildagliptin/metformin|
9960388|NCT01196559|Experimental|Vinorelbine and Gemcitabine|Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks
9960389|NCT01196572|Experimental|Laser IU|Urethral stricture incised by Holmium laser
9960390|NCT01196572|Active Comparator|Cold knife IU|Urethral stricture incised by knife
9960391|NCT01196585|Experimental|Patients under CT- guided pleural biopsy|Arm A: Patients who go under CT-guided pleural needle biopsy for pleural diseases
9960392|NCT01196585|Experimental|Patients under ultrasonography guided needle biopsy|Arm B: Patients who go under ultrasonography guided cutting needle pleural biopsy for pleural diseases
9960393|NCT01196598|Active Comparator|PFMT group|Women who undergo to three months of a pelvic floor muscle training program.
9960394|NCT01196598|Active Comparator|HE + PFM group|Women who undergo to three months of a hypopressive exercises plus pelvic floor muscle contraction program.
9960395|NCT01196598|Active Comparator|HE group|Women who undergo to three months of a hypopressive exercises program.
9960396|NCT01196598|Active Comparator|Control|Women who undergo to a session for lifestyle advice.
9960397|NCT01196611|Experimental|Function Voice Exercises|Behavioral: Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
9960398|NCT01196611|Experimental|Voice amplification|Behavioral: Voice amplification Patients will use VA over a course of 6 weeks.
9960399|NCT01196624|Active Comparator|TMS TO RT DLPF WITH EXPOSURE|TMS TO RIGHT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
9960400|NCT01196624|Active Comparator|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE
9960401|NCT01196624|Active Comparator|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
9960402|NCT01196624|Active Comparator|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE
9960403|NCT01196637||Thoracic outlet syndrome|These patients have documented thoracic outlet syndrome
9960404|NCT01196637||Normal Subjects|These patients have no thoracic outlet syndrome
9960405|NCT01196650|Active Comparator|1|IN 10 003 formulation A
9960406|NCT01196650|Active Comparator|2|IN 10 003 formulation B
9960407|NCT01196650|Placebo Comparator|3|Placebo capsules
9960408|NCT01196676|Experimental|1|AZD4451
9960409|NCT01196676|Placebo Comparator|2|Placebo
9960410|NCT01196689|Experimental|1|AZD1981 100 mg twice daily for 6 ½ days
9960411|NCT01196702||CVID|Patients with common variable immunodeficiency
9960412|NCT01196702||CVID and granulomatous disease|Patients with CVID complicated with granulomatous inflammation
9960413|NCT01196702||CVID and bronchiectasis|Patients with CVID complicated by bronchiectasis
9960414|NCT01196702||Control on Immunoglobulin|Patients on immunoglobulin long-term who do not have an immunodeficiency
9960415|NCT01196702||Control bronchiectasis|Controls with bronchiectasis not caused by a known immunodeficiency
9960416|NCT01196702||Control with granulomatous disease|Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation.
9960417|NCT01196702||Healthy Controls|
9960418|NCT01196715|Active Comparator|Darbepoetin Alfa|
9960419|NCT01196715|Active Comparator|G-CSF|
9960420|NCT01196715|Active Comparator|Best Supportive Care|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl
9960421|NCT01196728|Experimental|CM3.1-AC100 dose A|Compound CM3.1-AC100 s.c.
9960422|NCT01196728|Experimental|CM3.1-AC100 dose B|Compound CM3.1-AC100 s.c.
9960423|NCT01196728|Experimental|CM3.1-AC100 dose C|Compound CM3.1-AC100 s.c.
9960424|NCT01196728|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
9960425|NCT01196754|Other|sevoflurane|
9960426|NCT01196767|Experimental|ropivacaine|
9960427|NCT01196767|Other|normal saline|
9960428|NCT01196780||Cohort|
9960429|NCT01196845|Other|obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
9960430|NCT01196845|Other|obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
9960431|NCT01196845|Other|non-obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
9960432|NCT01196845|Other|non-obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
9960433|NCT01196884||Asymptomatic ITP patients|
9960434|NCT01196884||ITP patients treated with Rituximab|
9960435|NCT01196884||ITP patients treated with steroids|
9960436|NCT01196897|Experimental|Implantable device|WATCHMAN LAA Closure Technology (Gen 4.0)
9960437|NCT01196910|Active Comparator|Stimulation over the left dorsolateral prefrontal cortex|Group A (fifteen subjects) - treatment by HLPFC coil high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC).
9960438|NCT01196910|Active Comparator|stimulation over the right DLPFC|Group B (fifteen subjects) - Treatment by HLPFC coil high-frequency stimulation over the right DLPFC.
9960439|NCT01196910|Placebo Comparator|Treatment with HLPFC coil simulator mode|Group C (fifteen subjects) - Treatment with HLPFC coil simulator mode (sham).
9960440|NCT01196949|Active Comparator|Manipulative and Rehabilitative Therapy|
9960441|NCT01196949|Active Comparator|Rehabilitative Therapy|
9960442|NCT01196962|Experimental|Internal jugular vein|
9960443|NCT01197001|Experimental|Amlodipine plus Losartan|
9960444|NCT01197001|Active Comparator|Amlodipine, Losartan|
9960445|NCT01197014|Experimental|Amlodipine plus Losartan|
9960446|NCT01197014|Active Comparator|Amlodipine, Losartan|
9960447|NCT01197027|Experimental|Enhanced counseling|5 intensive counseling sessions following acute HIV infection
9960448|NCT01197027|Active Comparator|Standard counseling|Standard HIV counseling following acute HIV infection
9960449|NCT01197040|Experimental|B-Experimental|Experimental
9960450|NCT01197040|Active Comparator|A-Active Comparator|Active Comparator
9960451|NCT01197053|Experimental|100 mcg DBV712 (active)|100 mcg DBV712 administered epicutaneously every 24 hours.
9960452|NCT01197053|Placebo Comparator|Placebo|Placebo will be administered epicutaneously every 24 hours
9960453|NCT01197066|Other|Certolizumab Pegol|Single Arm
9960454|NCT01197079||MSM|Young men (under 26 years of age) who have sex with men
9960455|NCT01197079||Parents|Parents of Boys aged 9 to 18 years
9960456|NCT01197092|Active Comparator|Verum|
9960457|NCT01197092|Experimental|Control|
9960458|NCT01197105|Experimental|Aroeira|
9960459|NCT01197118|Active Comparator|2|chemotherapy alone following radical resection
9960460|NCT01197118|Experimental|1|sequence chemoradiotherapy following radical resection
9960461|NCT01197131||autistic boys|Boys with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician
9960462|NCT01197131||autistic girls|Girls with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician.
9960463|NCT01197131||control boys|"Healthy boys, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger-Syndrome (MBAS)."
9960464|NCT01197131||control girls|"Healthy girls, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger Syndrome (MBAS)."
9960465|NCT01197144|Active Comparator|Adalimumab|Treatment with adalimumab 40 mg sc eow for 4 weeks
9960466|NCT01197144|Placebo Comparator|Placebo|Treatment with placebo s c eow for 4 weeks
9960467|NCT01197144|No Intervention|Healthy Controls|"Healthy volunteers, age ≥18. Will perform all the same pain assessments, blood sampling and baseline fMRI as RA patients~Exclusion criteria:~For fMRI - left handedness and all forms of metallic implants.~Fulfilling ACR criteria for fibromyalgia.~Severe ischemic heart disease.~Concurrent treatment for depression/anxiety with antidepressant drugs.~Concurrent neurological disease.~Other reason as evaluated by the P.I."
9960468|NCT01197157|Placebo Comparator|placebo|"• Group A: comprises 100 chronic hepatitis patients who will receive placebo twice daily orally with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
9960469|NCT01197157|Experimental|Nitazoxanide|"• Group B: comprises 100 CHC patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
9960470|NCT01197170|Experimental|Anastrozole|1 mg PO (by mouth) daily for 28 days.
9960471|NCT01197170|Experimental|Anastrozole + Bevacizumab|Anastrozole 1 mg PO daily and Bevacizumab starting dose 10 mg IV Day 1 of 21 day cycle. Expansion group added when MTD dose of Anastrozole + Bevacizumab found.
9960472|NCT01197170|Experimental|Anastrozole + Everolimus|Anastrozole 1 mg PO daily and Everolimus starting dose 5 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Everolimus found.
9960473|NCT01197170|Experimental|Anastrozole + Sorafenib|Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
9960474|NCT01197170|Experimental|Anastrozole + Erlotinib|Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
9960475|NCT01197196|Experimental|Behavioral weight loss|
9960476|NCT01197196|Active Comparator|Migraine Education|
9960477|NCT01197209|Experimental|Ad-REIC/Dkk-3 Arm|Active arm on Ad-REIC/Dkk-3
9960478|NCT01197222|Active Comparator|EndoClear used|The EndoClear device is used during a laparoscopic abdominal surgery.
9960479|NCT01197222|No Intervention|Control|EndoClear Lens Cleaning Device not used during a laparoscopic abdominal surgery.
9960480|NCT01197235|Experimental|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
9960481|NCT01197235|Placebo Comparator|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
9960482|NCT01197248|Active Comparator|Cystocele Plication|Placement of sutures over the pubocervical fascia during cystocele repair.
9960483|NCT01197248|Experimental|No Plication|Avoid sutures over pubocervical fascia during cystocele repair
9960484|NCT01197261|Active Comparator|OXN PR|Oxycodone Naloxone tablets
9960485|NCT01197261|Placebo Comparator|PLA|
9960486|NCT01197274||Mite-sensitized person|
9960487|NCT01197287|Experimental|QAK423A Arm A|
9960488|NCT01197287|Experimental|QAK423A Arm B|
9960489|NCT01197287|Experimental|QAK423A Arm C|
9960490|NCT01197313|Experimental|Exercise|
9960491|NCT01197339|Experimental|treatment|
9960492|NCT01197339|Sham Comparator|Controls|
9960493|NCT01197352|Experimental|Text message queries with feedback|Weekly prompted queries about drinking behavior with personalized feedback.
9960494|NCT01197352|Active Comparator|Text message queries|Weekly prompted queries about drinking behavior
9960495|NCT01197352|No Intervention|Control|Weekly text reminders to complete final (12 week) instruments
9960496|NCT01197365|Experimental|STUDY GROUP|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
9960497|NCT01197365|Other|CONTROL GROUP|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
9960498|NCT01197391|Experimental|Cohort 1|Dose 1 versus placebo
9960499|NCT01197391|Experimental|Cohort 2|Dose 2 versus placebo
9960500|NCT01197404|Active Comparator|General Health Promotion|
9960501|NCT01197404|Experimental|Affect Management|
9960502|NCT01197443|Experimental|Parent-only Group|Treatment will be administered to parents of the overweight child. Parent-only group treatment will include all of the same skills and techniques to promote weight loss, but the information will be delivered only to the parent. Participation of the children assigned to the parent-only treatment arm will be limited to the baseline and follow-up assessments.
9960503|NCT01197443|Active Comparator|Parent + child Group|The treatment for participants in the parent + child arm will be administered in two separate groups, one for the parents and one for the child.
9960504|NCT01197469|Placebo Comparator|Placebo|Placebo
9960505|NCT01197469|Active Comparator|Tadalafil|
9960506|NCT01197599||Spinal Cord Injury|
9960507|NCT01197599||Able-Bodied Control|
9960508|NCT01197625|Experimental|DC-vaccine|
9960509|NCT01197664|Experimental|Arm I (paricalcitol and chemoradiotherapy)|Patients receive paricalcitol PO daily. Patients also receive standard care chemoradiotherapy with fluorouracil PO.
9960510|NCT01197664|Active Comparator|Arm II (chemoradiotherapy)|Patients receive standard care chemoradiotherapy as in Arm I.
9960511|NCT01197729||STEMI|(ST-Elevation myocardial infarction)
9960512|NCT01197729||NSTEMI|Non-ST-Elevation myocardial infarction
9960513|NCT01197768|Experimental|Nutrition Intervention|The intervention group will receive a full nutrition assessment and a nutrition intervention.
9960514|NCT01197768|No Intervention|Control|This group will receive the nutrition assessment but no intervention from a Registered Dietician. If participant appears to be in danger due to BMI or Caloric intake status, their primary care physician will be notified.
9960515|NCT01197781|Experimental|Period 1|
9960516|NCT01197781|Experimental|Period 2|
9960517|NCT01197807|Active Comparator|Bulb suctioning|Bulb suctioning of mouth and nose immediately after delivery
9960518|NCT01197807|Active Comparator|Wiping|Gentle wiping of mouth then nose with soft cloth
9960519|NCT01197820|Experimental|Arm 1|30 patients with liver tumour and 15 patients with kidney tumour will be enrolled.
9960520|NCT01197846|Experimental|Quetiapine|Quetiapine 300 mg or 600 mg
9960521|NCT01197846|Placebo Comparator|Placebo|
10006184|NCT01592032|Experimental|Tigecycline antimicrobial-lock|Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
10006185|NCT01592084||lipid lowering therapy|those with lipid lowering therapy those without lipid lowering therapy
10006186|NCT01592110|Experimental|Cohort 1|25 mg of risperidone-SABER administered as a SC injection of 0.25 mL (100 mg/mL concentration) in the abdominal region
10006187|NCT01592110|Experimental|Cohort 2|50 mg of ZX003 (risperidone-SABER-DosePro) administered as 0.5 mL (100 mg/mL concentration) via the DosePro Needle-free Delivery System in the abdominal region
10006188|NCT01592110|Experimental|Cohort 3|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL (100 mg/mL concentration) in the abdominal region
10006189|NCT01592110|Experimental|Cohort 4|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL (100 mg/mL concentration) in the abdominal region
10006190|NCT01592123||The participants with septal deviation|
10006191|NCT01592149||Group 1|
10006192|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 0|propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml
10006193|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 2|propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml
10006194|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 4|propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml
10006195|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 0|propofol 1% (Fresenius) plus remifentanil 0 ng/ml
10006196|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 2|propofol 1% (Fresenius) plus remifentanil 2 ng/ml
10006197|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 4|propofol 1% (Fresenius) plus remifentanil 4 ng/ml
10006198|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 0|propofol 1% (B-Braun) plus remifentanil 0 ng/ml
10006199|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 2|propofol 1% (B-Braun) plus remifentanil 2 ng/ml
10006200|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 4|propofol 1% (B-Braun) plus remifentanil 4 ng/ml
10006201|NCT01592188|Active Comparator|MT|Mindfulness training. Participants will be provided with once per week training in mindfulness meditation.
10006202|NCT01592188|Experimental|CBCT|Cognitively-based compassion training. Participants in this arm will be provided with once weekly training on the cognitively-based compassion training program.
10006203|NCT01592201|Experimental|Paliperidone ER|Immediate initiation of Paliperidone ER for a total of 12 weeks
10006204|NCT01592201|Experimental|Antipsychotics and paliperidone ER|Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
10006205|NCT01592214|Experimental|Part 1 #2-XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|4 subjects: 2.0 mg/g concentrations of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 2.4 mg.
10006206|NCT01592214|Placebo Comparator|Part 2 #4-Placebo in 4% Klucel® gel, concentration 0 mg/g|12 subjects: a placebo in 4% Klucel® gel intranasally to both nares in a volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5.
9960522|NCT01197859|Active Comparator|Contamac 74% silicone hydrogel contact lens|Definitive Contact Lens
9960523|NCT01197859|Placebo Comparator|Cooper Vision Biofinity|Biofinity Contact Lens
9960524|NCT01197885|Experimental|IMAB362|Two different doses (antibody / body surface area) of IMAB362 will be administered sequentially.
9960525|NCT01197924||healthy volonteer children|paired for the sex and the age
9960526|NCT01197924||older children followed for a médulloblastome cérébelleux|children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
9960527|NCT01197950|Active Comparator|Manual Acupuncture|Manual stimulation
9960528|NCT01197950|Experimental|Electro Acupuncture|Electrical and manual stimulation
9960529|NCT01197950|No Intervention|Standard care|No acupunture
9960530|NCT01197963|Other|Surgical treatment|Surgical treatment of one arm of the patient population.
9960531|NCT01197963|Other|Medically controlled group|Managed by endocrinologists using current medical therapy such as pills, injections and life style medication.
9960532|NCT01197976|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
9960533|NCT01197976|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
9960534|NCT01197989|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
9960535|NCT01197989|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
9960536|NCT01198015||Rett syndrome girls|The study population (identical to the population in the preliminary research project) consists of a well-defined group of thirteen Dutch RTT girls with complete clinical, molecular, neurophysiological and metabolic work-up.
9960537|NCT01198054|Experimental|Lenalidomine|Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)
9960538|NCT01198080|Experimental|femoral osteonecrosis patients|patientswith femoral head osteonecrosis
9960539|NCT01198119|Experimental|Patient with oral cavity cancer|Patient treated by surgery for the oral cavity cancer
9960540|NCT01198171||Basic science (DNA analysis)|DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
9960541|NCT01198184|Experimental|Treatment (temsirolimus and RO4929097)|Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9960542|NCT01198210|Placebo Comparator|saline|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
9960543|NCT01198210|Active Comparator|ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
9960544|NCT01198210|Active Comparator|dexamethasone|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
9960545|NCT01198210|Active Comparator|dexamethasone-ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
9960546|NCT01198223|Other|drug: garlic extract, nystatin|Drug: garlic extract 40mg/dl or nystatin suspension 100000 iu/ml tid for one month Patients had been clinically with denture stomatitis and confirmed by oral medicine specialist were selected for the study. Gender, age, medical history, erythema types, size, and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received garlic extract and second group used nystatin suspension for 1 month. Each patients was examined at the beginning of the therapy ,and then every 1 weeks up to 1 months .
9960547|NCT01198249|Experimental|amlodipine monotherapy|
9960548|NCT01198249|Experimental|losartan monotherapy|
9960549|NCT01198249|Experimental|HCTZ|
9960550|NCT01198249|Experimental|mlodipine and Losartan and HCTZ|
9960551|NCT01198288|Active Comparator|Standard Care|"Drugs for COPD (as prescribed), oxygen therapy if needed*, check-up by the general practitioner and/or respirologist as usual.~Educational leaflet regarding optimization of oxygen therapy and drugs; Benefits of physical activity and proposal of a programme of exercise training; Energy conservation techniques; Nutritional counselling; Activity of daily Living (ADL) diary; Prevention and management of acute exacerbation~Monthly phone call with the aim of verifying:~the patients' clinical conditions;~the patient's adherence to the pharmacological treatments prescribed~the patient's compliance in filling out the clinical diary and the ADL diary"
9960552|NCT01198288|Experimental|domiciliary rehabilitation|"Same as the standard care group plus 10 (ten) home-based visits supervised by a specifically trained respiratory therapist (education+exercise training) Autonomous home-based programme: The patients will be given instructions and training in order to continue the exercise training programme on the days the respiratory therapist is not visiting them.~Counselling addressed at the outdoor activities."
9960553|NCT01198314|Experimental|LT, withdrawal of immunosuppression|
9960554|NCT01198314|Active Comparator|LT, maintenance of immunosuppression|
9960555|NCT01198340|Active Comparator|With basal local anesthetics|
9960556|NCT01198340|Experimental|Without basal local anesthetics|
9960557|NCT01198353|Experimental|Ziprasidone|During the 12-week study period, patients were prescribed ziprasidone at 20 to 160 mg/day flexibly based on their effectiveness and tolerability. Fifty to one hundred percent of the past antipsychotic dose was maintained in the first week; during next 3 weeks, flexible dosing of 0-100% was used; then, ziprasidone was discontinued. This study included four visits: baseline, week 4, week 8, and week 12. Concomitant benzodiazepines (oral formula or injection) were allowed up to a dose of 4 mg of lorazepam-equivalents per day for anxiety and agitation.
9960558|NCT01198379|Experimental|Aspirin|
9960559|NCT01198379|Placebo Comparator|Sugar pills|Hemodialysis (HD) patients receive placebo not containing aspirin in this study.
9960560|NCT01198392|Experimental|S-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
9960561|NCT01198392|Active Comparator|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
9960562|NCT01198405|Experimental|Enhanced External Counterpulsation|Treatment of Enhanced External Counterpulsation (EECP) with a prespecified protocol on top of guideline-driven standard medical therapy.
9960563|NCT01198405|Active Comparator|Control|Guideline-driven standard medical therapy.
9960564|NCT01198418|Experimental|Internet-based counseling|Completes surveys monthly about their sexual and drug use behaviors as well as receives information designed to help reduce the chances of getting an STI.
9960565|NCT01198418|No Intervention|Survey Alone|Completes surveys monthly about their sexual and drug use behaviors
9960566|NCT01198431|Experimental|Sleep restriction|Each participant will be engaged in three consecutive nights of 4 hours of sleep per night (from 3.00 a.m. to 7.00 a.m.)
9960567|NCT01198431|Placebo Comparator|Normal sleep duration|Each participant will be engaged in three consecutive nights of 9 hours of sleep per night (from 10.00 p.m. to 7.00 a.m.)
9960568|NCT01198444||Group 1|
9960569|NCT01198457||Group 1|
9960570|NCT01198483|Active Comparator|Micro|Microincision cataract surgery
9960571|NCT01198483|Active Comparator|Small|Smallincision cataract surgery
9960572|NCT01198496|Experimental|Blood pressure|"The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.~This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.~BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009."
9960573|NCT01198535|Experimental|Arm A (RO4929097, cetuximab)|Patients in Arm A will receive cetuximab at the standard dose: 400 mg/m2 IV loading dose on Day 1 followed by cetuximab 250 mg/m2 IV weekly. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
9960574|NCT01198535|Experimental|Arm B (RO4929097, cetuximab)|Patients in Arm B will receive cetuximab 200 mg/m2 IV weekly without a loading dose. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
9960575|NCT01198561||repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
9960576|NCT01198613|Placebo Comparator|Placebo|
9960577|NCT01198613|Experimental|ToleroMune Ragweed Regimen 1|
9960578|NCT01198613|Experimental|ToleroMune Ragweed Regimen 2|
9960579|NCT01198613|Experimental|ToleroMune Ragweed Regimen 3|
9960580|NCT01198613|Experimental|ToleroMune Ragweed Regimen 4|
9960581|NCT01198639|Active Comparator|manual administration of iv anesthetics|
9960582|NCT01198639|Experimental|closed-loop administration of iv anesthetics|
9960583|NCT01198652||Belfort-Dildy Obstetric Tamponade Tx|Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.
9960584|NCT01198665|Experimental|RAD001-CHOP|Prospective multicenter open-label phase I/II study Phase I: RAD001 2.5 - 10 mg PO daily D1-14 + CHOP every 3 weeks Phase II: Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be continued until planned 6 cycles or disease progression
9960585|NCT01198704||HCC patients|Patients notified on the national waiting list for hepatic transplant
9960586|NCT01198782|Experimental|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
9960587|NCT01198821|Experimental|Oral sodium bicarbonate and Gemcitabine|
9960588|NCT01198847|Active Comparator|Low intensity arm|Written information about a healthy lifestyle
9960589|NCT01198847|Experimental|High intensity arm|Lifestyle support (PA, sleep, food intake) using MI
9960590|NCT01198886|Placebo Comparator|Successful Aging Program|
9960591|NCT01198886|Experimental|Exercise-Nutrition Program|
9960592|NCT01198899||left ventricular hypertrophy|Patients with left ventricular hypertrophy will be used.
9960593|NCT01198912|Placebo Comparator|placebo|
9960594|NCT01198912|Experimental|doxycycline 100 mg|
9960595|NCT01198925|Active Comparator|extended infusion|
9960596|NCT01198925|Experimental|continuous infusion|
9960597|NCT01198938|Active Comparator|Melatonin|
9960598|NCT01198964||Epileptic Patients|The population of patients with medically refractory epilepsy will already have been recommended clinically for electrode grid placement on the brain and high-level stimulation to map brain function.
9960599|NCT01198990|Experimental|Group 1|"Subjects in will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.~eating/physical activity/positive affect/self-affirmation group."
9960600|NCT01198990|Experimental|Group 2|"Subjects will be randomized to the small change eating strategy and a physical activity goal.~eating/physical activity group. No intervention, just the eating strategy and physical activity components."
9960601|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (8hrs)|
9960602|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (12hrs)|
9960603|NCT01199029|Active Comparator|(Part 1) 5 mg Prednisone|
9960604|NCT01199029|Experimental|(Part 2) X mg PF-04308515|
9960605|NCT01199029|Experimental|(Part 2) Y mg PF-04308515|
9960606|NCT01199029|Active Comparator|(Part 2) 5 mg Prednisone|
9960607|NCT01199029|Active Comparator|(Part 2) 20 mg Prednisone|
9960608|NCT01199081|Experimental|Group A|"Dronedarone 400 mg twice daily for 8 weeks starting from randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
9960609|NCT01199081|Experimental|Group B|"Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
9960610|NCT01199081|Experimental|Group C|"Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
9960611|NCT01199094||Patients with mutation in the Lrp5 gene|Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
9960612|NCT01199107|Experimental|Prolonged Exposure + Exercise|
9960613|NCT01199107|Active Comparator|Prolonged Exposure + Wellness Intervention|
9960614|NCT01199120|Experimental|Omega 3|
9960615|NCT01199133|Active Comparator|Dpte and Dfar Allergen Extract|
9960616|NCT01199133|Placebo Comparator|Placebo tablets|
9960617|NCT01199159|Active Comparator|preoperative misoprostol|400mcg misoprostol given preoperatively
9960618|NCT01199159|Placebo Comparator|Placebo|
9960619|NCT01199172|No Intervention|Control|
9960620|NCT01199172|Experimental|voice hygiene|Subjects will receive training in voice hygiene
9960621|NCT01199172|Experimental|VH + VP|
9960622|NCT01199185|Active Comparator|Tobacco Quitline Group|
9960623|NCT01199185|Experimental|Tobacco Quitline plus Interactive Technology Group|
9960624|NCT01199211||Exercise training, women, marathon.|Other: prospective study with no intervention
9960625|NCT01199224|Experimental|Arm A|
9960626|NCT01199224|Experimental|Arm B|
9960627|NCT01199224|Experimental|Arm C|
9960628|NCT01199224|Experimental|Arm D|
9960629|NCT01199250||Basic science (biomarker analysis)|Previously collected samples are analyzed for biomarker and other laboratory analyses.
9960630|NCT01199276|Experimental|Xenon|60%(1MAC)in oxygen (FiO2 = 0.35-0.45)
9960631|NCT01199276|Active Comparator|Sevoflurane|1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
9960632|NCT01199315|Experimental|1|Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel.
9960633|NCT01199315|Placebo Comparator|2|Oral capsule. Dose single and followed by 5-day repeated dosing.
9960634|NCT01199328|Active Comparator|1|Aspirin 81 mg
9960635|NCT01199328|Active Comparator|2|Esomeprazole 20mg/aspirin 81mg
9960636|NCT01199341|Experimental|Treatment A|AZD1981, low dose, + Warfarin
9960637|NCT01199341|Experimental|Treatment B|AZD1981, high dose, + Warfarin
9960638|NCT01199367|Experimental|Dose escallation|
9960639|NCT01199406|Placebo Comparator|normal saline|80 mL 0.9% NaCl
9960640|NCT01199406|Experimental|Levobupivacaine|80mL 0.125% levobupivacaine
9960641|NCT01199419||PCI|
9960642|NCT01199419||CABG|
9960643|NCT01199432|Experimental|Group B(CEF)|
9960644|NCT01199432|Experimental|Group A(CEFci)|
9960645|NCT01199432|Active Comparator|Group C(EC)|
9960646|NCT01199445|Experimental|triple fortified extruded rice|
9960647|NCT01199445|Other|regular meal|regular vitamin A meal
9960648|NCT01199458|Active Comparator|opioid|Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
9960649|NCT01199458|Placebo Comparator|placebo|Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
9960650|NCT01199497|Experimental|Group 1|Fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
9960651|NCT01199497|Placebo Comparator|Group 2|Placebo
9960652|NCT01199510|Experimental|Standard of Care plus FID 112903|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
9960653|NCT01199510|Active Comparator|Standard of Care only|Post Cataract Standard of Care Regimen
9960654|NCT01199523|Placebo Comparator|Placebo|
9960655|NCT01199523|Experimental|mirabegron high dose|
9960656|NCT01199523|Experimental|mirabegron medium dose|
9960657|NCT01199523|Experimental|mirabegron low dose|
9960658|NCT01199523|Active Comparator|moxifloxacin|
9960659|NCT01199536||1|patients with Helicobacter-positive duodenal ulcer
9960660|NCT01199549||Lycopene group|Mixed age and gender group of healthy volunteers for testing bio-availability of Lycopene containing supplement
9960661|NCT01199549||Resveratrol group|Mixed age and gender group of healthy volunteers for testing bio-availability of Resveratrol containing supplement
9960662|NCT01199549||Laflavon group|Mixed age and gender group of healthy volunteers for testing bio-availability of Soy Isoflavones containing supplement
9960663|NCT01199562||Arm I|Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.
9960664|NCT01199588|Experimental|Nexagon® High Dose|Weekly applications of Nexagon® high dose in addition to compression dressings.
9960665|NCT01199588|Placebo Comparator|Nexagon® Vehicle|Weekly applications of Nexagon® Vehicle in addition to compression dressings.
9960666|NCT01199588|No Intervention|No Investigational Product|Weekly application of compression dressings.
9960667|NCT01199588|Experimental|Nexagon® Low Dose|Weekly applications of Nexagon® low dose in addition to compression dressings.
9960668|NCT01199614|Experimental|open-label PTH(1-84)|open-label PTH(1-84) / variable dosing: 25mcg every other day, 25mcg every day, 50mcg every day, 75mcg every day, 100mcg every day
9960669|NCT01199627|Experimental|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
9960670|NCT01199627|Experimental|B|"Group B: 1st dose: 10mg/kg of TXA (tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
9960671|NCT01199627|Placebo Comparator|C|Placebo
9960672|NCT01199640|Experimental|MLN1202|
9960673|NCT01199653|Active Comparator|Non-operative treatment|Non-operative (conservative) treatment of the clavicle fracture
9960674|NCT01199653|Active Comparator|Operative treatment|Operative stabilization (i.e. ORIF) of the fracture with a plate and screws.
9960675|NCT01199666|Experimental|Text message reminders|
9960676|NCT01199666|Active Comparator|standard of care for MMR, letter reminder for Hep A|MMR: automated phone call appointment reminder Hep A: recall letter, automated phone call appointment reminder
9960677|NCT01199679|Experimental|Endoscopic Mucosal Resection (EMR) Group|
9960678|NCT01199679|Experimental|Banding Group|
9960679|NCT01199692||Age|
9960680|NCT01199692||Gender|
9960681|NCT01199692||Ethnicity|
9960682|NCT01199692||Body Mass Distribution|
9960683|NCT01199692||Dietary Habits|
9960684|NCT01199692||Exercise Habits|
9960685|NCT01199692||Medication Requirements|
9960686|NCT01199692||Disease State Burden|
9960687|NCT01199718|Experimental|CX-4945|CX-4945 oral formulation
10006207|NCT01592214|Active Comparator|Part 2 # 3-XF-73 in 4% Klucel® gel, concentration 0.5 mg/g:|12 subjects: a modified 4% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
10006208|NCT01592214|Experimental|Part 2 #2- XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|12 subjects; a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 2.0 mg/g and volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 3.6 mg on Day 1 and 2.4 mg on Days 2 to 5.
10006209|NCT01592214|Experimental|Part 2 #1- XF-73 in 2 % Klucel® gel, concentration 0.5 mg/g|12 subjects: a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
10006210|NCT01592214|Experimental|Part 1 #1-XF-73 in 2% Klucel® gel, concentration 0.5 mg/g:|4 subjects: 0.5 mg/g concentration of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 0.6 mg.
10035274|NCT01804595|Active Comparator|Education|A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
10035275|NCT01804608|Experimental|Sensorimotor|Sensorimotor, this arm will receive sensorimotor and hip muscle strengthening.
10035276|NCT01804608|Active Comparator|Strength|Strength, this arm will receive only hip muscle strengthening.
10035277|NCT01804621|Experimental|Exercise|Participant received health newsletter with targeted articles about exercise behavior.
10035278|NCT01804621|Experimental|Fruit & Vegetable|Participant received health newsletter with targeted articles about fruit & vegetable consumption.
10035279|NCT01804621|Experimental|Colorectal Cancer Screening|Participant received health newsletter with targeted articles about colorectal cancer screening.
10035280|NCT01804621|Experimental|Mammography|Participant received health newsletter with targeted articles about mammography screening.
10035281|NCT01804634|Experimental|Reduced intensity conditioning|Fludarabine IV infusion over 30 minutes on D-7 to D-3. The dose will be 30 mg/m2/dose (adjusted for renal function). Melphalan: IV infusion over 30-60 minutes, depending on volume, on D-2. The dose will be 100mg/m2.Total body irradiation: 200 cGy AP/PA with 4MV or 6MV photons at 8 12 cGy/min at the point of prescription (average separation of measurements at mediastinum, abdomen, and hips) will be administered in a single fraction on day -1. Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant. Tacrolimus begins on Day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 3 hours every 12 hours. Mycophenolic acid mofetil (MMF) F will be given at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).
10035282|NCT01804647||33 RRMS patients|No study treatments administered
10035283|NCT01804647||9 PPMS patients|No study treatments administered
10035284|NCT01804647||12 SPMS patients|No study treatments administered
10035285|NCT01804647||4 CIS patients|No study treatments administered
10035286|NCT01804660||25 healthy volunteers|No study treatments administered
10035287|NCT01804699||Proband|Probands - Participants diagnosed with ARVC according to the 2010 Task Force Criteria
10035288|NCT01804699||Family|First Degree Family member (blood related mother, father, sister, brother, child) of the proband
9960688|NCT01199757||FF|Cohort of patients receiving fluticasome furoate
9960689|NCT01199757||MF|cohort of patients on mometasone furoate
9960690|NCT01199757||FP|cohort of patients receiving fluticasone propionate
9960691|NCT01199770|Experimental|experimental pasta B, small|small portion experimental pasta B
9960692|NCT01199770|Experimental|experimental pasta C, small portion|small portion experimental pasta C
9960693|NCT01199770|Placebo Comparator|Control pasta, small|small portion Control pasta
9960694|NCT01199770|Other|No Load|Only water
9960695|NCT01199770|Active Comparator|Control pasta, medium|medium portion Control pasta
9960696|NCT01199770|Experimental|experimental pasta B, medium portion|medium portion experimental pasta B
9960697|NCT01199770|Experimental|experimental pasta C, medium portion|medium portion experimental pasta B
9960698|NCT01199783|Experimental|Daptomycin|Infusion of Daptomycin (6 mg/kg bodyweight) once daily
9960699|NCT01199783|Active Comparator|Vancomycin|Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)
9960700|NCT01199809|Experimental|1|
9960701|NCT01199809|Placebo Comparator|2|
9960702|NCT01199835|Experimental|high calcium|Dietary intake of calcium ~ 1500 mg/ d, including ~1200 mg/d from dairy products
9960703|NCT01199835|Active Comparator|Low calcium|Low dietary intake of calcium, i.e. ~ <600 mg/d, including 0-1 portion of dairy products
9960704|NCT01199874|Active Comparator|Primary 1: Rotavirus vaccine 6 and 10 weeks|EPI vaccines + rotavirus vaccine at 6 and 10 weeks
9960705|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 6, 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks
9476628|NCT03570008|Active Comparator|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
9960706|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 10 and 14 weeks
9960707|NCT01199874|Experimental|Primary 2: Rotavirus vaccine withholding breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding
9960708|NCT01199874|Experimental|Primary 2: Rotavirus vaccine with immediate breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding
9960709|NCT01199874|No Intervention|Baseline seroconversion for rotavirus|EPI vaccines
9960710|NCT01199887|Experimental|IW001|Three dose cohorts, 0.1 mg, 0.5 mg, 1.0 mg
9960711|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT|
9960712|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT|
9960713|NCT01199900|Active Comparator|(Part 1) 5 mg Prednisone|5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
9960714|NCT01199900|Experimental|(Part 2) 3 mg PF-04171327|
9960715|NCT01199900|Experimental|(Part 2) 10 mg PF-04171327|
9960716|NCT01199900|Active Comparator|(Part 2) 5 mg Prednisone|
9960717|NCT01199900|Active Comparator|(Part 2) 20 mg Prednisone|
9960718|NCT01199913||desflurane and sevoflurane|Subjects will be randomized to either desflurane or sevoflurane. They will be given the Mini Mental State exam at 1, 6 and 24 hours after the end of anesthesia.
9960719|NCT01199978|Other|Fractionated Proton Radiation|Single arm study, delivering fractionated radiation with a technique (proton therapy) that may be associated with reduced side effects
9960720|NCT01199991||Normative database|
9960721|NCT01200004|Experimental|Azacitidine + Lenalidomide|Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
9960722|NCT01200004|Experimental|Azacitidine + Lenalidomide + Grifola Frondosa|Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
9960723|NCT01200004|Experimental|Expansion Group A|Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
9960724|NCT01200004|Experimental|Expansion Group B|Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
9960725|NCT01200043|Experimental|fructose restriction|Isocaloric fructose restricted diet for 10 days
9960726|NCT01200056|Active Comparator|Atorvastatin 10mg low dose|Atorvastatin 10mg daily for 6 months and compared to atorvastatin 40mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
9960727|NCT01200056|Active Comparator|Atorvastatin 40mg moderate dose|Atorvastatin 40mg daily for 6 months and compared to atorvastatin 10mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
9960728|NCT01200082||Healthy Controls|Male or female, age 19-65, no apparent signs of hepatobiliary diseases
9960729|NCT01200082||Patients with hepatobiliary diseases|Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
9960730|NCT01200108|Experimental|Budesonide high dose via AKITA (1mg/2ml)|
9960731|NCT01200108|Experimental|Budesonide low dose via AKITA (0.5mg/2ml)|
9960732|NCT01200108|Active Comparator|Budesonide high dose via conventional nebulizer (1mg/2ml)|
9960733|NCT01200108|No Intervention|Placebo via AKITA|
9960734|NCT01200121|Experimental|Arm A Bevacizumab|48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
9960735|NCT01200121|Placebo Comparator|Arm B Placebo|26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
9960736|NCT01200134|Experimental|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
9960737|NCT01200147|Active Comparator|Biopsy Arm|
9960738|NCT01200147|Active Comparator|Dilation Arm|
9960739|NCT01200173|Active Comparator|1 = Tested product|
9960740|NCT01200173|Sham Comparator|2 = Control product|
9960741|NCT01200186||Group 1|
9960742|NCT01200186||Group 2|
9960743|NCT01200199||Varicose veins|
9960744|NCT01200212|Experimental|A|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22 + 1800 mg/m2 Capecitabine day 1-14 q22
9960745|NCT01200212|Active Comparator|B|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22
9960746|NCT01200225||Cohort|
9960747|NCT01200251|Experimental|Bimatoprost treated eyelid|one eyelid of the patient was randomized to the treatment arm and given the gel to use
9960748|NCT01200251|No Intervention|control arm - no gel|the other fellow eyelid of the patient did not receive any treatment until month 4 and the patient crossed over to treating both eyelids
9960749|NCT01200264|Experimental|apremilast for all subjects|
9960750|NCT01200277|Experimental|vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
9960751|NCT01200277|Sham Comparator|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
9960752|NCT01200303|Active Comparator|non-cathartic CTC and OC|This is a single arm, open label, prospective test comparison of non-cathartic, CAD-assisted CTC to segmentally unblinded optical colonoscopy (OC). All study subjects receive both tests, starting with CTC, followed by OC within 5 weeks. CTC results are recorded and revealed to endoscopist on a segment-by-segment basis after initial (blinded) OC evaluation; endoscopist can double check / confirm lesion presence after unblinding and this second read serves as reference standard.
9960753|NCT01200316|Experimental|Standard of Care Group|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
9960754|NCT01200316|Experimental|Rocking Motion Group|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
9960755|NCT01200381|Active Comparator|Group A|Automatic anonymous ICD/CRTD follow up (quarterly remote follow ups)
9960756|NCT01200381|Active Comparator|Group B1|Personal ICD/CRTD follow up (phone calls + quarterly remote follow ups)
9960757|NCT01200381|Active Comparator|Group B2|Personal ICD/CRTD follow up (Quarterly visits)
9960758|NCT01200420|Experimental|miravirsen|Dose escalation study with review of safety data following each cohort.
9960759|NCT01200420|Placebo Comparator|saline|Dose escalation study with review of safety data following each cohort.
9960760|NCT01200446|Placebo Comparator|Placebo Docosahexaenoic Acid (DHA)|Eight subjects will take 8 placebo DHA capsules per day for 3 weeks.
9960761|NCT01200446|Experimental|Active Docosahexaenoic Acid (DHA)|Eight subjects will take 8 active DHA capsules per day for 3 weeks.
9960762|NCT01200459|Experimental|Social/Mobile Intervention|Theory-based intervention to promote weight loss utilizing web, mobile phone and social media.
9960763|NCT01200459|No Intervention|Control|"Participants randomized to this group will have access to usual care health information via the SMART study website. This arm will be compared to our intervention group."
9960764|NCT01200472|Experimental|Apremilast capsules|Apremilast in 10 mg capsules
9960765|NCT01200472|Placebo Comparator|Placebo|
9960766|NCT01200537|Active Comparator|Estradiol Patch|This group of patients will receive estradiol patches prior to the IVF cycle.
9960767|NCT01200537|Active Comparator|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
9517909|NCT03301792|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
9960768|NCT01200550||1|
9960769|NCT01200563|Active Comparator|Group 1|Subjects assigned to receive MIST Therapy will be treated 3 times per week. The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
9960770|NCT01200563|Active Comparator|Group 2|Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system. For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
9960771|NCT01200563|Active Comparator|Group 3|Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
9960772|NCT01200576||1|healthy volunteers
9960773|NCT01200615|Other|Explanation about common side effects|50 patients started on SSRI's will be updated about its common side effects
9960774|NCT01200615|Other|Explaning side effects and the nocebo effect|subjects started on SSRI's will be updated about its common side effects and the nocebo effect
9960775|NCT01200615|Other|explanation about the nocebo effect|3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects.
9960776|NCT01200628||Road traffic accident victims|Cohort of patients hospitalized in surgical department after a motor vehicle accident less than 2 weeks
9960777|NCT01200641|Active Comparator|melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
9960778|NCT01200641|Active Comparator|gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
9960779|NCT01200641|Placebo Comparator|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
9960780|NCT01200654|Experimental|MRSA Infections|Methicillin-Resistant Staphylococcus aureus Infections
9960781|NCT01200693|Active Comparator|ZES|Patients with coronary bifurcation lesions treated by Zotarolimus eluting stent
9960782|NCT01200693|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
9960783|NCT01200693|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
9960784|NCT01200706|Active Comparator|Amoxicillin given twice a day|
9960785|NCT01200706|Active Comparator|Amoxicillin given three times a day|
9960786|NCT01200719|Experimental|tACS group|
9960787|NCT01200719|No Intervention|Control group|Patients in the control group followed exactly the same protocol but without receiving the transcranial alternating current stimulation .
9960788|NCT01200732|Active Comparator|Tadalafil|
9960789|NCT01200732|Placebo Comparator|placebo|
9960790|NCT01200745|Active Comparator|capsaicin patch|
9960791|NCT01200745|Placebo Comparator|Hydrogel patch|
9960792|NCT01200784|Experimental|250 mg/d modified release Nicotinamide|
9960793|NCT01200784|Experimental|500 mg/d modified release Nicotinamide|
9960794|NCT01200784|Experimental|750 mg/d modified release Nicotinamide|
9960795|NCT01200784|Experimental|1000 mg/d modified release Nicotinamide|
9960796|NCT01200784|Active Comparator|1000 mg/d immidiate release Nicotinamide|
9960797|NCT01200849|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
9960798|NCT01200849|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
9960799|NCT01200862|Experimental|BGS649 (Part 1)|BGS649 1mg and 0.1mg in hard gelatin capsules. In part 1 there was individualised dosing to titrate the subject's testosterone into the normal range. If the dose was lower than 0.1mg then specific instructions for dilution of an oral solution of BGS649 were provided.
9960800|NCT01200862|Placebo Comparator|Placebo to BGS649 (Part 2)|Matching placebo to BGS649 (0.3 and 0.1mg). 0.3mg placebo capsule given on Day 1 and 0.1mg placebo capsule on other treatment visits (week 1 to 11).
9960801|NCT01200862|Experimental|BGS649 (Part 2)|0.3 or 0.1mg hard gelatin capsules of BGS649 given orally. 0.3mg on Day 1 and 0.1 on all other treatment visits (week 1 to 11).
9960802|NCT01200901|Experimental|Melancolic depression patients|Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).
9960803|NCT01200914|Active Comparator|'PTA without use of the GORE VIABAHN'|Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
9960804|NCT01200914|Experimental|PTA with covered stent|Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
9960805|NCT01200940|Experimental|Phase I - Low-dose sweetener|68 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
9960806|NCT01200940|Experimental|Phase I - Medium-dose sweetener|170 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
9960807|NCT01200940|Placebo Comparator|Phase I Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
9960808|NCT01200940|Experimental|Phase I- High-dose sweetener|250 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test.
9667734|NCT03131960|Active Comparator|Control VNS|Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.
9960809|NCT01200940|Placebo Comparator|Phase II - Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
9960810|NCT01200940|Experimental|Phase II - Diet Soda 1|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
9960811|NCT01200940|Experimental|Phase II - Diet Soda 2|less than or equal to 5 mg/kg sucralose, less than or equal to 50 mg/kg aspartame, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
9960812|NCT01200940|Experimental|Phase II - Water with sucralose and acesulfame-potassium|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
9960813|NCT01200979||pregnant flu vaccinated|pregnant women that choose to receive the seasonal flu vaccine
9960814|NCT01200979||pregnant non-flu vaccinated|pregnant women that do not receive the flu vaccine
9960815|NCT01201005|Active Comparator|Hydroxycobalamin|"Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma) is given as a singel intramuscular injection.~The syringe is covered so it is impossible to see whether it contains any substance"
9960816|NCT01201005|Sham Comparator|needle injection|"The controls receive an intramuscular injection: which is merely an introduction of the needle into the muscle whithout any injection. The syringe is covered so it is not possible to see whether the syringe contains any substance"
9960817|NCT01201018|Experimental|Oshadi DR|
9960818|NCT01201044|Experimental|Gemcitabine, Nedaplatin,BAI plus 3DCRT|"Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year.."
9960819|NCT01201044|Other|Gemcitabine, Nedaplatin, IV Plus 3DCRT|"Gemcitabine 100mg/m2, D1 & D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.~for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year."
9960820|NCT01201070|No Intervention|control group|
9960821|NCT01201070|No Intervention|no treatment|
9960822|NCT01201070|Active Comparator|TREATMENT WITH ANTITHROMBIN|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
9960823|NCT01201083||HIV-|This study measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 105 HIV- recently tested men who have sex with men (MSM) and followed them for a year.
10006211|NCT01592227|Active Comparator|Marketed paracetamol|Marketed paracetamol
10006212|NCT01592227|Experimental|Experimental paracetamol formulation|Experimental formulations
10006213|NCT01592266||AML|patients with AML prior and after treatment
10006214|NCT01592279|Experimental|liraglutide|
10006215|NCT01592279|Active Comparator|Insulin injections|
10006216|NCT01592305|Experimental|S1 P1 TDF + DNV/r|
10006217|NCT01592305|Experimental|S1/S2 P2 DNV/r + ATZ|
9960824|NCT01201083||HIV+ Acutely Infected|This study enrolled and followed 125 acutely infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
9960825|NCT01201083||HIV+ Chronically Infected|This study enrolled and followed 91chronicially infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
9960826|NCT01201096||peptide radioreceptor therapy and liver transplantation|
9960827|NCT01201109||Diabetics|Diabetic patients operated for carpal tunnel syndrome
9960828|NCT01201109||Non-diabetics|Non-diabetic patients operated for carpal tunnel syndrome
9960829|NCT01201122|Experimental|Weight based Mesalamine: Once daily|
9960830|NCT01201122|Experimental|Weight based Mesalamine: Twice daily|
9960831|NCT01201135||Sickle cell disease|
9960832|NCT01201135||hereditary spherocytosis.|
9960833|NCT01201148|Experimental|Oscillating or intermittent tDCS|
9960834|NCT01201161|Experimental|RANI/PPV|Preoperative intravitreal ranibizumab and pars plana vitrectomy
9960835|NCT01201161|Placebo Comparator|PPV|Sham injection and pars plana vitrectomy
9960836|NCT01201174|No Intervention|Patients with Hereditary Spherocytosis|All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
9960837|NCT01201187|Experimental|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
9960838|NCT01201187|Placebo Comparator|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
9960839|NCT01201200||Group 1 - Obstructive Sleep Apnea (OSA)|Fifty-six patients with Obstructive Sleep Apnea
9960840|NCT01201200||Group 2 - Non-OSA Controls|Fifty individuals without OSA with similar age, gender and body mass index (BMI)
9960841|NCT01201200||Group 3 - Treatment|Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure
9960842|NCT01201200||Group 4 - Placebo|Fifteen patients with moderate/severe sleep apnea underwent to placebo
9960843|NCT01201213|Active Comparator|Extradural bupivacaine|Local anesthetic
9960844|NCT01201213|Active Comparator|Extradural levobupivacaine|local anaesthetic
9960845|NCT01201213|Active Comparator|Extradural ropivacaine|local anaesthetic
9960846|NCT01201213|Active Comparator|Intrathecal bupivacaine|local anaesthetic
9960847|NCT01201213|Active Comparator|Intrathecal levobupivacaine|local anaesthetic
9960848|NCT01201213|Active Comparator|Intrathecal ropivacaine|local anesthetic
9960849|NCT01201226|No Intervention|Patients|Perimenopausal women, who will undergo oelvic organ surgery, and will allow harvest of about half an oary for the study purpose
9960850|NCT01201239|Experimental|raltegravir|HIV-infected patients aged over 18 who have failed previous antiretroviral treatment with multi-drug resistant or with multi-drug intolerance are to accept Ral plus OBT.
9960851|NCT01201252||Acute gastroenteritis Group|Suspected/confirmed cases of rotavirus gastroenteritis in children < 5 years of age
9960852|NCT01201278|Experimental|Nasal insulin 8 IU|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
9960853|NCT01201278|Experimental|Nasal insulin 16 IU|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
9960854|NCT01201278|Active Comparator|Subcutaneous insulin lispro 8 U|Subcutaneous insulin lispro (Humalog®) 8 U
9803643|NCT03654833|Experimental|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
9960855|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.4|Fraction of inspired normobaric oxygen of 0.4 (low oxygen group)
10006218|NCT01592305|Experimental|S2 P1 ATZ/r|
9960856|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.7|Fraction of inspired normobaric oxygen of 0.7 (high oxygen group)
9960857|NCT01201304|Experimental|Interoceptive exposure|Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.
9960858|NCT01201304|Placebo Comparator|Expressive writing|Expectancy control intervention.
9960859|NCT01201330||ONJ sufferers|history of jaw osteonecrosis
9960860|NCT01201330||Bisphosphonate exposure|patients with exposure to bisphosphonates
9960861|NCT01201369|Active Comparator|Cypher™ Stent|Participants in the Cypher arm will be randomised to receive a Cypher™ (Cordis, Miami Lake, USA) coronary stent
9960862|NCT01201369|Active Comparator|Xience™ Stent|Patients in the Xience™ arm will receive a Xience™ Stent(Abbott Vascular, Santa Clara, USA.
9960863|NCT01201382|Experimental|IPT-AST|Interpersonal Psychotherapy-Adolescent Skills Training
9960864|NCT01201382|Active Comparator|Group Counseling|Group Counseling
9960865|NCT01201395||Dental caries assessment|
9960866|NCT01201408||Dental Caries assessment|
9960867|NCT01201434|Experimental|Probiotics, Treatment, Food Additive|
9960868|NCT01201447||Questionable occlusal lesions|
9960869|NCT01201460||Glucose testing|Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health.
9960870|NCT01201473||Measure impact of research participation|
9960871|NCT01201499|Active Comparator|Intrathecal morphine|A single shot of intrathecal morphine given before the induction of general anesthesia. Followed by postoperative IV patient-controlled morphine analgesia.
9960872|NCT01201499|Active Comparator|Continuous IV remifentanil|Continuous administration of IV remifentanil during surgery, supported by a single bolus of IV morphine at the end of surgery. Followed by postoperative IV patient-controlled morphine analgesia.
9960873|NCT01201512||Temporomandibular disorders|
9960874|NCT01201525|Experimental|Surgical scar - part 1|Surgical scar - part 1
9960875|NCT01201525|Placebo Comparator|Surgical scar - part 2|Surgical scar - part 2
9960876|NCT01201538|Experimental|Single arm|
9960877|NCT01201551|Active Comparator|healthy subjects without PVD|healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
9960878|NCT01201551|Active Comparator|healthy subjects with PVD|healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
10006219|NCT01592318|Active Comparator|DNV + r reference|
10006220|NCT01592318|Experimental|DNV/r fixed dose combination|
10006221|NCT01592331|Placebo Comparator|Placebo|
10006222|NCT01592331|Experimental|RO5508887|
10006223|NCT01592357|Experimental|Tai Chi|
10006224|NCT01592357|Sham Comparator|Sham Exercise|
10006225|NCT01592422|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every month
10006226|NCT01592422|Active Comparator|Best Supportive Care|Best Supportive Care
9960879|NCT01201564|Active Comparator|intraperitoneal onlay mesh repair|
9960880|NCT01201564|Active Comparator|sublay mesh repair|
9960881|NCT01201577|Active Comparator|Placebo/Probiotic|
9960882|NCT01201577|Active Comparator|Placebo/Prebiotic|
9960883|NCT01201577|Active Comparator|Prebiotic/Probiotic|
9960884|NCT01201577|Placebo Comparator|Placebo/Placebo|
9960885|NCT01201590|Experimental|High Flavanol Cocoa|609mg cocoa flavanols per 24g serving
9960886|NCT01201590|Placebo Comparator|Low flavanol cocoa|13mg cocoa flavanols per 24g serving
10006227|NCT01592448||Usual Care|"Participants will be shown standard (defined as currently commercially available) over-the-counter and prescription medicine bottles and asked questions regarding safety and use. Participants will also be shown additional standard over-the-counter bottles and asked whether these comparison bottles could safely be taken in addition to the primary products shown."
10006228|NCT01592448||Written Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. This flier will be passively hanging within sight of the participant in the room, but no verbal explanation of the flier will be given to the participant. (This is designed to represent a passive education campaign such as posters in drug stores that may be used should these icons be adopted by manufacturers.)"
10006229|NCT01592448||Written + Verbal Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. Research personnel will also verbally go through the flier with the participant and answer any questions in a standardized fashion. (This is designed to represent an active education campaign such as pharmacist counseling that may be used should these icons be adopted by manufacturers.)"
10006230|NCT01592487||Lean BMI|BMI in the 25th - 75th percentile
10006231|NCT01592487||Overweight BMI|BMI in the 85th - 95th percentile
10006232|NCT01592513|No Intervention|Control|
10006233|NCT01592513|Experimental|BIS monitor|"Patients in this group will be monitored by BIS (placement of an electrode over the forehead before sedation).~Patients in this group will receive propofol (boluses of 10-20 mg) to reach a BIS target value of 80-90."
10006234|NCT01592526|Experimental|Untrained, healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
10006235|NCT01592526|Experimental|Well-trained healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
10006236|NCT01592526|Experimental|Untrained, healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
10006237|NCT01592526|Experimental|Well-trained healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
10006238|NCT01592539||Case|Patients with Type 1 Diabetes Mellitus
10006239|NCT01592539||Control|Age and sex matched healthy controls.
10006240|NCT01592552||Neurological Condition|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
10006241|NCT01592552||Control|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
9960887|NCT01201603|Experimental|Orange Juice|Orange Juice reconstituted from frozen concerntrate
9960888|NCT01201603|Placebo Comparator|Orange drink|Sugars matched orange drink
9960889|NCT01201616|Experimental|High fat, low carbohydrate diet|Fats intake 55% , Protein 17% and carbohydrate 28% of total energy
9960890|NCT01201616|Active Comparator|Low fat, high carbohydrate diet|Fat intake 20%, Protein 17% and carbohydrate 63% of total energy intake
9960891|NCT01201642|Experimental|Prednisolone|Prednisolone as 5 mg tablets will be given within 72 h after onset of Bell's palsy as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
9960892|NCT01201642|Experimental|Acute stage acupuncture|Accept acupuncture therapy within 10days after onset of Bell's palsy, do not accept prednisolone therapy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints within 72 h after onset of Bell's palsy. Yifeng (TE17), Hegu (LI4) are punctured 0.5-1.0 cun, the others are punctured 0.1-0.3 cun. and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
9960893|NCT01201642|Experimental|Prednisolone + acute stage acupuncture|Accept prednisolone and acupuncture therapy within 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
10006242|NCT01592578|Active Comparator|Ligation and Cyanoacrylate Group|
10006243|NCT01592578|Experimental|Ligation plus Sclerotherapy and Cyanoacrylate Group|
10006244|NCT01592604|Experimental|Treatment A|Patients receive supportive compressive bandage for 4 weeks
10006245|NCT01592604|Experimental|Treatment B|Below knee walking plaster cast for 4 weeks
10006246|NCT01592617|Experimental|S-488410|
10006247|NCT01592630|Experimental|Ropivacaine|Subjects with TAP catheters attached to the On-Q pump with 0.2% ropivacaine
9960894|NCT01201642|Experimental|Resting stage acupuncture|Accepted acupuncture therapy after 10 days of the onset of Bell's palsy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. Penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints 7 d after enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
9960895|NCT01201642|Experimental|Prednisolone + resting stage acupuncture|Accept prednisolone and acupuncture therapy more than 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Resting stage acupuncture.
9960896|NCT01201642|Other|Other treatment|Do not accept neither prednisolone nor acupuncture therapy. The therapy accepted is different from the five Arms Previously.
9960897|NCT01201668||Persistent Tooth Pain|
9960898|NCT01201681||Post-operativeTooth Pain|
9960899|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Group|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
9960900|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Expansion|Following finding of MTD surface-controlled water soluble curcumin, escalating dose levels
9960901|NCT01201707|Experimental|Treatment of CCSVI with Angioplasty|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will be treated with angioplasty.
9960902|NCT01201707|Sham Comparator|Observation of CCSVI|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will not be treated with angioplasty. These patients will be observed after treatment and compared to those patients who received treatment.
9960903|NCT01201720|Other|Albumin|Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions
9960904|NCT01201733|Experimental|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
9960905|NCT01201733|Active Comparator|Ultrasound therapy and hot pack|The participants will receive a thirty minutes session of Ultrasound therapy and hot pack
9960906|NCT01201746|Experimental|Periodontal Therapy|Scaling Root planing and oral hygiene instructions
9960907|NCT01201746|Placebo Comparator|Delayed treatment|Scaling Root planing and oral hygiene instructions
9960908|NCT01201824|Other|1|
9960909|NCT01201902|Experimental|Group 1 : Low dose with adjuvant|Group 1: 18 ~ 64 years old subjects
9960910|NCT01201902|Experimental|Group 1: High dose with adjuvant|Group 1: 18 ~ 64 years old subjects
9960911|NCT01201902|Active Comparator|Group1 : Plain vaccine|Group 1: 18 ~ 64 years old subjects
9960912|NCT01201902|Experimental|Group 2 : Low dose with adjuvant|Group 2: greater than or equal to 65 years of age
9960913|NCT01201902|Experimental|Group 2 : high dose with adjuvant|Group 2: greater than or equal to 65 years of age
9960914|NCT01201928||Technosphere Insulin Inhalation Powder|
9960915|NCT01201928||Comparator|Based on parent trial
9960916|NCT01201941||Intervention group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will have access to the e-Chasqui system."
9960917|NCT01201941||Simultaneous/historical control group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will not have access to the e-Chasqui system."
9960918|NCT01201954|Active Comparator|sucrose|0,5 ml/kg of sucrose administered 2 minutes prior the procedure
9960919|NCT01201954|Placebo Comparator|sterile water|0,5 ml/kg of sterile water administered 2 minutes prior the procedure
9960920|NCT01201980||1|Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
9960921|NCT01202006|Experimental|Intervention|General practitioners of patients in the intervention group will receive detailed instructions on uptitration of ACE-inhibitors and beta-blockers before the inclusion of participants.
9960922|NCT01202006|No Intervention|Control|Patients in the control group receive care-as-usual. Their general practitioner will not be trained in applying the uptitration protocol.
9960923|NCT01202019|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
9960924|NCT01202019|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
9960925|NCT01202045||systemic sclerosis patients|Every patient will have a rest echocardiography, a stress echocardiography, a right heart catheterization, a blood specimen, and a pulmonary function test.
9960926|NCT01202058|Experimental|NEVO™ SES|"Design Protocol Am3.0 - safety follow-up:~The study population consists of 103 subjects with atherosclerotic coronary artery disease treated with the NEVO™ SES. Candidates for the initial NEVO II Study must have met ALL inclusion criteria and NO exclusion criteria.~Design Original Protocol~Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System."
9960927|NCT01202058|Active Comparator|XIENCE V®/XIENCE PRIME™/PROMUS®|Subjects randomized to treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System
9960928|NCT01202084|Experimental|Formoterol/Fluticasone Eurofarma|formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks
9960929|NCT01202084|Active Comparator|Foraseq®|formoterol + budedonide (12/400 mcg) twice a day per 12 weeks
9960930|NCT01202084|Active Comparator|Fluticasone|fluticasone (500 mcg) twice a day per 12 weeks
9960931|NCT01202097|Experimental|Salmeterol/Fluticasone|
9960932|NCT01202097|Active Comparator|Seretide|
9960933|NCT01202136||Pancreatic cysts|patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts
9960934|NCT01202149|Active Comparator|Elidel Right Side, Hylatopic Plus Left Side|Elidel applied topically on Right Side of body twice a day and Hylatopic plus emollient foam applied topically on Left Side of body three times a day
9960935|NCT01202149|Active Comparator|Elidel Left Side Hylatopic Plus Right Side|Elidel applied topically on Left Side of body twice a day and Hylatopic plus emollient foam applied topically on Right Side of body three times a day
9960936|NCT01202201||Study Cohort|Subjects hospitalized with acute gastroenteritis or rotavirus gastroenteritis
9960937|NCT01202214|Experimental|Active drug|
9960938|NCT01202214|Placebo Comparator|Placebo|
9960939|NCT01202240|Experimental|Tasocitinib (CP-690,550) plus Ketoconazole|
9960940|NCT01202266|Experimental|5 mg PF-05161704 or Placebo|
9960941|NCT01202266|Experimental|15 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
9960942|NCT01202266|Experimental|50 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
9960943|NCT01202266|Experimental|150 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
9960944|NCT01202266|Experimental|xx mg PF-05161704 or Placebo|Planned dose and dosing regimen will be determined based on emerging PK and safety data.
9960945|NCT01202266|Experimental|xxx mg PF-05161704 or Placebo|Dose will be determined based on data from previous 5 arms.
9960946|NCT01202266|Experimental|yy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 6 arms
9960947|NCT01202266|Experimental|yyy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 7 arms.
9960948|NCT01202292|Experimental|Lifestyle counseling|
9667624|NCT03322215|Experimental|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant~Palbociclib:~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.~Fulvestrant:~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
9960949|NCT01202305||HIV negative|
9960950|NCT01202305||HIV positive|
9960951|NCT01202331|No Intervention|J|Stop Annual Treatment
9960952|NCT01202331|No Intervention|K|Stop Biannual Treatment
9960953|NCT01202331|Other|L|Continue Annual Treatment
9960954|NCT01202331|Other|M|Continue Biannual Treatment
9960955|NCT01202331|Experimental|N|Targeted Treatment by Age
9960956|NCT01202331|Experimental|O|Targeted Treatment by Clinical Exam
9960957|NCT01202344|Other|Restenosis|Patients who have restinosis immediately following angioplasty.
9960958|NCT01202344|Other|No Restenosis|Patients who do not have restinosis immediately following angioplasty.
9960959|NCT01202357|Experimental|Case Management (1 year)|
9960960|NCT01202357|No Intervention|Standard Care (1 year)|
9960961|NCT01202370|Experimental|AR-67|Phase 1 study
9960962|NCT01202383|Active Comparator|NADCC tablets|
9960963|NCT01202383|Placebo Comparator|Placebo tablets|
9960964|NCT01202396||ulcerative colitis patients with a pouch|"ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis~comparing patients with versus those without pouchitis~no intervention"
9960965|NCT01202422|Experimental|Pregabalin controlled release, 165 mg|
9960966|NCT01202422|Experimental|Pregabalin controlled release, 330 mg|
9960967|NCT01202422|Other|Pregabalin immediate release, 150 mg|Reference Treatment
9960968|NCT01202435|Experimental|Pregabalin controlled release, 82.5 mg|
9960969|NCT01202435|Other|Pregabalin immediate release, 25 mg|Reference Treatment
9960970|NCT01202448|Active Comparator|DLBCL with risk factor|Patients have any of risk factors for secondary CNS involvement
9960971|NCT01202474|Experimental|insulin glulisine and insulin glargine|insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)
9960972|NCT01202487|Experimental|Pre-treatment with LET|Pre-treatment with Lidocaine Epinephrine Tetracaine solution at least 45 minutes prior to laceration repair with tissue adhesive
9960973|NCT01202487|Placebo Comparator|Pre-treatment with Placebo|Pre-treatment with Placebo solution at least 45 minutes prior to laceration repair with tissue adhesive
9960974|NCT01202500|Other|12 months|
9960975|NCT01202500|Experimental|3 months|
9960976|NCT01202513|Experimental|Bimatoprost application|
9960977|NCT01202526||RYGB patients with type 2 diabetes|Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
9960978|NCT01202526||RYGB patients without type 2 diabetes|Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
9960979|NCT01202552|Experimental|group 1|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
9960980|NCT01202552|Experimental|group 2|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site
9960981|NCT01202552|Experimental|group 3|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
9960982|NCT01202604||Outpatients with bipolar disorder I or II (as per DSM-IV)|The percentage of patients who experience a relapse episode during the first 9 months after a mood event (manic or depressive).
9960983|NCT01202617||Schizophrenic outpatients between 18 & 70 years of age|
9960984|NCT01202630|Experimental|Probiotic|BIO-K+ CL1285
9960985|NCT01202630|Placebo Comparator|Placebo|Placebo
9960986|NCT01202669||Epilepsy patients, EMU stay|
9960987|NCT01202695|Experimental|AVP-21D9|
9960988|NCT01202695|Placebo Comparator|Placebo|
9960989|NCT01202734|Experimental|001|Methylphenidate HCl Period 1: One tablet oral 36 mg once daily single-dose on Day 1 Period 2: Three tablets oral 18 mg once daily single-dose on Day 1 Period 3: Two tablets oral 36 mg once daily single-dose on Day 1. (Each treatment period will be separated by 3-7 days)
9960990|NCT01202786||miRview mets Disclosed|Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
9960991|NCT01202786||Control|Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
9960992|NCT01202799|Experimental|Treatment A|2% w/w diclofenac sodium topical gel
9960993|NCT01202799|Active Comparator|Treatment B|
9960994|NCT01202799|Active Comparator|Treatment C|
9960995|NCT01202812|Experimental|LOVAZA|
9960996|NCT01202812|Placebo Comparator|Placebo capsule|
9960997|NCT01202825|Experimental|001|
9960998|NCT01202825|Placebo Comparator|008|
9960999|NCT01202825|Placebo Comparator|002|
9961000|NCT01202825|Experimental|009|
9961001|NCT01202825|Experimental|003|
9961002|NCT01202825|Placebo Comparator|004|
9961003|NCT01202825|Experimental|005|
9961004|NCT01202825|Experimental|010|
9961005|NCT01202825|Placebo Comparator|006|
9961006|NCT01202825|Experimental|007|
9961007|NCT01202838||Composite Implant|Subject receiving composite implant
9961008|NCT01202851|Experimental|Relaxation Group 1|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
10006248|NCT01592630|Placebo Comparator|Saline|Subjects with TAP catheters attached to the On-Q pump with saline
10006249|NCT01592656|Active Comparator|Non-invasive ventilation (NIV)|30 patients will receive NIV during 6 months = group 1
9961009|NCT01202851|Experimental|Relaxation Group 2|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
9961010|NCT01202851|Other|Waitlist Control Group (WLC)|Participants in this group given the option to take part in one of the two forms of relaxation (off study) after they finish their last questionnaire packet. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
9961011|NCT01202864||Cases|3000 Cases
9961012|NCT01202864||Controls|3000 Controls
9961013|NCT01202890|Experimental|Arm 1|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
9961014|NCT01202916||Congenital Heart Disease|
9961015|NCT01202916||Healthy children|
9961016|NCT01202929||Type I achalasia|classic achalasia: complete esophageal motor failure
9961017|NCT01202929||Type II achalasia|compression achalasia: simultaneous panesophageal pressurization with aperistalsis
9961018|NCT01202929||Type III achalasia|spastic achalasia with aperistalsis: 100% spasm
9961019|NCT01202942|Experimental|Quest|Participants smoke Quest cigarettes level 1 for 10 days, followed by level 2 for 10 days, and finally by level 3 for 10 days.
9961020|NCT01202942|No Intervention|Preferred brand|Participants smoke their preferred brand of cigarettes for the duration of the study.
9961021|NCT01202981||Group 1|Patients who had cataract surgery by the Investigators between July 1, 2007 and June 30, 2008.
9961022|NCT01202981||Group 2|Patients who had cataract surgery by the Investigators between July 1, 2008 and July 1, 2009.
9961023|NCT01203007|Experimental|Tailored diet|Tailored diet according to demonstrated food sensitivity
9803644|NCT03654833|Experimental|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
9961024|NCT01203007|Experimental|Low-antigen content (LAC) diet|Low-antigen content diet
9961025|NCT01203020|Experimental|Allogeneic hematopoietic progenitor cell transplant|Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
9961026|NCT01203033||AML patients|newly diagnosed or relapsed AML patients
9961027|NCT01203085||Pediatric patients|All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.
9961028|NCT01203111|Experimental|Intensive insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)
9961029|NCT01203111|Experimental|insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c <7% at week 12 (end of treatment period 1)
9961030|NCT01203124|Placebo Comparator|1|Placebo given once daily on 7 days
9961031|NCT01203124|Experimental|2|Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6
9961032|NCT01203124|Experimental|3|Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.
9961033|NCT01203124|Experimental|4|Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.
9961034|NCT01203124|Experimental|5|Active treatment once daily on 7 days
9961035|NCT01203137||tricuspid regurgitation, severe|To be included in the present study, the following 3 criteria for severe TR should be met based on the preoperative echocardiography: (1) TR jet > 30% of right atrial area, (2) inadequate cusp coaptation, and (3) systolic flow reversal in the hepatic vein.
9961036|NCT01203150|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
9961037|NCT01203150|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
9961038|NCT01203163||PDT with porfimer sodium|
9961039|NCT01203176|Active Comparator|Post-menopausal symptomatic women|
9961040|NCT01203176|Experimental|Post-menopausal asymptomatic women|
9961041|NCT01203202|Placebo Comparator|PED 0|placebo
9961042|NCT01203202|Experimental|PED 1|PED-1 (clomipramine 15mg)
10006250|NCT01592656|Placebo Comparator|Control group|10 patients will act as control group, they will not be treated with NIV = group 2
9961043|NCT01203202|Experimental|PED-2|PED-2 (Clomipramine 30mg)
9961044|NCT01203215|Experimental|JumpStart|
9961045|NCT01203215|Experimental|Choose to Move|
9961046|NCT01203215|Active Comparator|Wellness|
9961047|NCT01203228|Active Comparator|A|Myeloablative conditioning
9961048|NCT01203228|Experimental|B|Reduced Intensity Conditioning
9961049|NCT01203241|Active Comparator|Conventional ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
9961050|NCT01203241|Active Comparator|Conventional ablation plus left atrial roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
9961051|NCT01203254|Placebo Comparator|Placebo|
9961052|NCT01203254|Active Comparator|Cholestagel|
9961053|NCT01203267|Experimental|paclitaxel plus carboplatin (PCb) Arm|4 cycles of neoadjuvant paclitaxel plus carboplatin
9961054|NCT01203280|Experimental|balance, neck isometric strength and range of motion|
9961055|NCT01203293|Experimental|Cognitive Behavior Therapy|
9961056|NCT01203293|Active Comparator|Treatment as usual|
9961057|NCT01203306|Experimental|Drugs: bevacizumab + octreotide LAR + capecitabine|bevacizumab + octreotide + metronomic capecitabine
9961058|NCT01203332||Alternative Venue Testing (AVT)|Participants recruited for testing through the AVT recruitment method.
9961059|NCT01203332||SSNIT - Index Recruiter|Participants recruited for HIV testing and to bring members of their social and sexual network to the study.
9961060|NCT01203332||SSNIT - Network Member|Participants recruited by someone in their social or sexual network to participate in the study, including HIV testing.
9961061|NCT01203345|Active Comparator|Immune globulin|Lyophilized human immune globulin product
9961062|NCT01203345|Placebo Comparator|Albumin solution|
9961063|NCT01203358|Active Comparator|Surfactant 1|Exosurf Neonatal (Burroughs Wellcome Co.)
9961064|NCT01203358|Active Comparator|Surfactant 2|Survanta (Ross Laboratories)
10006251|NCT01592669|Experimental|passive leg group|bilateral PLR was achieved by raising the patient's legs to a 45 angle.
10006252|NCT01592669|No Intervention|control|supine baseline position
10006253|NCT01592682|No Intervention|Usual care|Household pairs that are assessment only and receive usual care of local in-language smoking cessation resource referral including quitline.
10006254|NCT01592682|Experimental|Smokefree counseling|Household pairs assigned to smokefree counseling intervention, consisting of group education sessions, tobacco exposure lab report, individual follow-up phone calls.
10006255|NCT01592734|Experimental|PEG-only|Polyethylene glycol 4000 only (PEG-only).
10006256|NCT01592734|Active Comparator|PEG-EL|Polyethylene glycol 3350 with electrolytes (PEG-EL).
10006257|NCT01592812|Experimental|electrical stimulation|Evaluation of the effect of calf stimulation on flow and tissue oxygenation
10006258|NCT01592838||Hospitalized Group|Data collection for changes in hospital pattern pre- versus post-rotavirus vaccination, in children ≤15 years old hospitalised for any reason between June 2004 and May 2010.
10006259|NCT01592890|Experimental|[14C]-labeled RO4917523|
10006260|NCT01592903||Patients with symptomatic uterine fibroids.|Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
10006261|NCT01592916||Fibromyalgia|Women with fibromyalgia, aged 20-50 years
10006262|NCT01592916||Healthy controls|Women without severe disease, aged 20-50 years
10006263|NCT01592942|Experimental|glue fixation|Optilene™ mesh 60 g/m2 (B. Braun), fixation Histoacryl™ cyanoacrylate glue (price 14+37 euros)
10006264|NCT01592942|Active Comparator|self-gripping|ProGrip™ mesh 60 g/m2 (Covidien, USA) (price 113 euros)
10006265|NCT01592942|Active Comparator|suture fixation|Ultrapro™ mesh 28 g/m2 (Ethicon, USA) (price 45 euros) fixated by non-absorbable sutures
10006266|NCT01592955|Experimental|EYEOP1 device|cyclocoagulation HIFU
10006267|NCT01592968|Experimental|Arm I (SRS)|Patients undergo SRS on day 1.
10006268|NCT01592968|Experimental|Arm II (WBRT)|Patients undergo WBRT 5 days per week (7 days per week for inpatients) for 2 weeks.
10006269|NCT01592981|Experimental|bortezomib, cyclophosphamide, rituximab|"Bortezomib:1.6 mg/m2 s.c; days 1, 8, 15 of each cycle. Cyclophosphamide:250 mg/m2 oral; days 1, 8, 15 of each cycle. Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days. After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
10035289|NCT01804712|Experimental|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
10035290|NCT01804738|No Intervention|Glucose|Glucose anhydrous 50g dissolved in 250ml water
9961065|NCT01203371|Experimental|Naftopidil|0,25 mg (2 weeks) and 0,50 mg (10 weeks)
9961066|NCT01203371|Active Comparator|Tamsusolin|0,4 mg/day
9961067|NCT01203384|Experimental|CHF5074 1x|oral tablet, multidose
9961068|NCT01203384|Experimental|CHF5074 2x|oral tablet, multidose
9961069|NCT01203384|Experimental|CHF5074 3x|oral tablet, multidose
9961070|NCT01203384|Placebo Comparator|Placebo|placebo, oral tablet, multidose
9961071|NCT01203397|Active Comparator|GROUP 2|
9961072|NCT01203397|Experimental|GROUP 1|
9961073|NCT01203410||Cohort 1|Term infants >2500g birthweight.
9961074|NCT01203436|Experimental|Supplemental Oxygen|Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.
9961075|NCT01203436|Active Comparator|Conventional Oxygen|Conventional oxygenation at a pulse oximetry target of 89% to 94%.
9961076|NCT01203462|Experimental|Bifidobacterium supplemented yogurt|Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
9961077|NCT01203462|Placebo Comparator|Placebo Yogurt|Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
9961078|NCT01203488|Experimental|Experimental|Vitamin A group.
9961079|NCT01203488|Sham Comparator|Control|Sham procedure Control group.
9961080|NCT01203514|Experimental|Trial 1 Experimental|Infants 401-1,000g birthweight
9961081|NCT01203514|Sham Comparator|Trial 1: Sham Comparator|Infants 401-1,000g birthweight
9961082|NCT01203514|Experimental|Trial 2: Experimental|Infants 1,001-1,250g birth weight
9961083|NCT01203514|Sham Comparator|Trial 2: Sham Comparator|Infants 1,001-1,250g birth weight
9961084|NCT01203527||Tamiflu use during first trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
9961085|NCT01203527||Tamiflu use during second trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the second trimester of their pregnancy.
9961086|NCT01203527||Tamiflu use during third trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
9961087|NCT01203527||Tamiflu use in non-pregnant women|This group will consist of twenty-five non-pregnant healthy female volunteers who are being treated with Oseltamivir.
9961088|NCT01203540|Experimental|Naaga in ABAK system|
9961089|NCT01203540|Placebo Comparator|Saline solution|
9961090|NCT01203553||Control Group|The main operation will be performed as planned. For the closure of the abdominal wall, a standard technique will be applied using a running suture of PDS 1 loop. The distance of the sutures to the fascial border is 1cm and the distance between two stitches is not more than 1cm. The total length of suture is at least 4 times the total length of the abdominal incision
9961091|NCT01203553||Treatment Group|The main operation will be performed as planned. Prior to the closure of the abdominal wall a mesh will be implanted in a standardized fashion: A Dynamesh IPOM mesh will be used for the present study. The mesh has a width of 15cm and is tailored to overlap lateral and cranial boarders at least 5cm. The mesh will be placed intra-abdominally and fixed using intra-abdominal stitches using Prolene 2/0 in all four corners. After the initial fixation of the mesh in all quadrants, the boarders of the mesh will be adapted using Prolene 2/0 running sutures. The fixation aims to prevent any intestinal structures to herniate onto the mesh. Afterwards, the abdominal wall is closed as described in the control group.
10006270|NCT01592981|Active Comparator|fludarabine, cyclophosphamide, rituximab|"Fludarabine:40 mg/sq m, oral, days 1,2 and 3 of each cycle. Cyclophosphamide:250 mg/sq m; oral, days 1, 2 and 3 of each cycle. Rituximab: 375 mg/sq m i.v. infusion days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days.After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
10035291|NCT01804738|Active Comparator|Jasmine rice|50g available carbohydrate portion
10006271|NCT01592994|No Intervention|control|control participants received basic messages on the utility of condoms in protecting from HIV and other STIs, and they were informed about local HIV/STI counseling and testing services.
9961092|NCT01203566|Active Comparator|Conventional 3-port laparoscopic appendectomy|Laparoscopic appendectomy will be performed with the standard 3-port technique. The laparoscope is introduced via a 10mm subumbilical port. Dissection will be performed with a 5mm LLQ port and a 5mm RLQ port. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
9961093|NCT01203566|Active Comparator|LESS appendectomy|Two 5 mm ports and a 10mm port will be inserted through a 13mm transumbilical incision. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. Retraction of the appendix would be performed with a flexible curved forceps. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
9961094|NCT01203592|Experimental|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
9961095|NCT01203605||In-patient adult non-cardiac surgery|Consecutive patients admitted to participating centres undergoing elective and non-elective non-cardiac surgery commencing during the seven day study period with a planned overnight stay. All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible.
9961096|NCT01203657|Experimental|Tai Chi|Tai Chi instruction, 2x week in a community senior center setting
9961097|NCT01203657|No Intervention|Wait List Control|This is a wait list control group. There is no active or placebo intervention.
9961098|NCT01203670|Experimental|Soft capsules of Phytalgic|Phytalgic is a food supplement. Its galenic form is soft capsule.
9961099|NCT01203683|Experimental|Active Computer-Based Program|Putatively therapeutic computer program.
9961100|NCT01203683|Placebo Comparator|Placebo computer-based program|Inert computer program.
9961101|NCT01203696|Active Comparator|non-amlodipine|For patient with suboptimal angina control: anti-anginal agent excluding calcium channel blocker
9961102|NCT01203696|Active Comparator|non - amlodipine|For patient with suboptimal BP control: anti-hypertensive agent excluding calcium channel blocker
9961103|NCT01203709|Experimental|Combination treatment|treatment arm
9961104|NCT01203735|Other|Valproic acid, Chemoradiotherapy|
9961105|NCT01203748|Experimental|PVI + Lines Ablation|
9961106|NCT01203748|Active Comparator|PVI Ablation|
9961107|NCT01203748|Experimental|PVI + CFE|
9961108|NCT01203761||Preoperative patients|ENT surgical patients, approximately 1 day before their procedure undertaken
9961109|NCT01203761||Postoperative patients|ENT surgical patients during their postoperative hospitalization
9961110|NCT01203761||Family members|Family members of ENT surgical patients, during the perioperative period
9961111|NCT01203813|Experimental|Physician Intervention|"Physicians randomized to the intervention will receive:~Electronic alerts during office visits for patients with chronic kidney disease~Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
9961112|NCT01203813|No Intervention|Physician Control|Physicians randomized to the control arm will continue to manage their patients with chronic kidney disease according to routine primary care standards.
9961113|NCT01203839|Experimental|Radiation treatment|This is a Phase II single-arm study of PBI with external-beam radiation therapy in which a group of select women with early-stage invasive and noninvasive breast cancer will be given radiation to the partial breast.
9961114|NCT01203891||Healthy brain subjects|The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
9961115|NCT01203904||Pulmicort|
9961116|NCT01203969|Experimental|Single port laparoscopic surgery|
9961117|NCT01203969|Active Comparator|Conventional laparoscopic surgery|
9961118|NCT01203982|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day
9961119|NCT01203982|Active Comparator|Rosuvastatin 40mg|Rosuvastatin 40mg/day
9961120|NCT01203995|No Intervention|Usual Care|
9961121|NCT01203995|Experimental|brief nutrition education|
9961122|NCT01203995|Active Comparator|In Center training|
9961123|NCT01203995|Experimental|Video Conference training|
9961124|NCT01204008|Experimental|CS|conservative discectomy
9961125|NCT01204008|Active Comparator|AS|
9961126|NCT01204021|Experimental|Tai Chi Chih|12 weeks of physical exercise in the form of Tai Chi Chih
9961127|NCT01204021|Active Comparator|Stress Education Control|Stress management education
9961128|NCT01204034|Other|Inuvair|
9961129|NCT01204060|Active Comparator|Nasal allergen challenge|
9961130|NCT01204060|Placebo Comparator|Nasal placebo challenge|
9961131|NCT01204073|Experimental|TAK-441|
9961132|NCT01204086|Experimental|venlafaxine|
9961133|NCT01204086|Experimental|fluoxetine|
9961134|NCT01204112|Experimental|Tasocitinib (CP-690,550) plus Rifampin|
9961135|NCT01204125|Experimental|SAR240550 twice weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 5.6mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions twice weekly (day 1 and day 4; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
9961136|NCT01204125|Experimental|SAR240550 weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 11.2 mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions once weekly (day 1; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
9961137|NCT01204125|Active Comparator|Paclitaxel alone|Paclitaxel will be administered at the dose of 80mg/m2 as a 60-min IV infusion. Patients will receive weekly (day 1) paclitaxel infusions.
9961138|NCT01204138|Placebo Comparator|placebo|Patient randomized to one of two arms, either placebo, or Apremilast
9961139|NCT01204138|Active Comparator|Apremilast|Patients randomized to either placebo or apremilast
9961140|NCT01204151|Experimental|Math intervention|
9961141|NCT01204164|Experimental|TG02 in AL|Single agent TG02 citrate in acute leukemia patients
9961142|NCT01204164|Experimental|TG02 in MM|Single Agent TG02 citrate in multiple myeloma patients
9961143|NCT01204164|Experimental|TG02 + CFZ in MM|TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients
9961144|NCT01204164|Experimental|TG02 + CFZ + DEX in CFZ refractory MM|TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients
9961145|NCT01204177|Experimental|Arm 1|
9961146|NCT01204190|Experimental|Arm 1|
9961147|NCT01204190|Experimental|Arm 2|
9961148|NCT01204190|Experimental|Arm 3|
9961149|NCT01204216|Active Comparator|Aim 1|Subjects in this arm will be 10 people without diabetes as well as 10 people with diabetes and stable glycemic control. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
9961150|NCT01204216|Active Comparator|Aim 2|For Aim 2, 10 additional subjects with diabetes in poor glycemic control will be studied initially and then again in improved glycemic control after at least 8 months (with up to 5 additional subjects entered as needed to ensure 10 completed paired studies) to assess the potential role of MRBC variation in the discordances seen between HbA1c and blood glucose testing. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
9961151|NCT01204229|Experimental|MCID|
9961152|NCT01204229|Experimental|BMI|
9961153|NCT01204268|No Intervention|Propofol group|Patients will receive the total intravenous anesthesia with propofol infusion during the surgery.
9961154|NCT01204268|Active Comparator|Sevo-C group|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
9961155|NCT01204268|Experimental|Sevo-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
9961156|NCT01204281|Experimental|High assistance PAV+|Ventilatory support performed by PAV at 80% assistance (PB 840-plus) FiO2 and PEEP according to routine practice
9961157|NCT01204281|Active Comparator|Assist-control ventilation|Tidal volume, FiO2 and PEEP set according to routine practice
9961158|NCT01204307|Experimental|docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
9961159|NCT01204307|Active Comparator|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
9961160|NCT01204320|Experimental|Paclitaxel-coated Balloon|Paclitaxel-coated Balloon Angioplasty
9961161|NCT01204320|Active Comparator|Paclitaxel-eluting Stent|Paclitaxel-eluting Stent Implantation
9961162|NCT01204333|Experimental|Endovascular thrombolysis|
9961163|NCT01204333|Active Comparator|Standard treatment|
9961164|NCT01204346|Experimental|MBT group|mentalization based treatment program
9961165|NCT01204346|Active Comparator|Treatment as usual group|treatment as usual group
9961166|NCT01204359|No Intervention|follow-up|
9961167|NCT01204372|Experimental|Treatment|Gemcitabine - Trastuzumab - Erlotinib
9961168|NCT01204385||Study Group|
9961169|NCT01204437|Active Comparator|EC standard chemotherapy 4 cycles|
9961170|NCT01204437|Active Comparator|CMF standard chemotherapy 6 cycles|
9961171|NCT01204437|Experimental|Nab-Paclitaxel + Capecitabine 6 cycles|6 cycles of weekly nab-Paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
9961172|NCT01204450|Other|Single Arm Temsirolimus + Valproic Acid|"Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses~Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses"
9961173|NCT01204476|Experimental|Treatment (cixutumumab, octreotide acetate, everolimus)|Patients receive cixutumumab IV over 60-90 minutes and octreotide acetate IM on day 1 and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
9961174|NCT01204489|Experimental|Intensified dietary counseling|The dietary intervention consists of tailored dietary counseling, information leaflets and self-evaluation cards given to the families.
9961175|NCT01204489|Active Comparator|Normal dietary counseling|Public health nurses continue their usual dietary counseling.
9803645|NCT03654833|Experimental|MiST 5 Dostarlimab and Niraparib|Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles, then 1000mg on day 1 of each 42 day cycle.
9961176|NCT01204502|Experimental|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~dose 1 5x104 cells/kg~dose 2 5x105 cells/kg"
9961177|NCT01204515||Girls with IBS|Girls ages 7-12 years who meet Rome III criteria for IBS
9961178|NCT01204515||Healthy Girls (controls)|Girls ages 7-12 years who are otherwise healthy and have no complaints of stomach pain
9961179|NCT01204528|Active Comparator|Paricalcitol 2 microgram/d|
9961180|NCT01204528|Active Comparator|Paricalcitol 1 microgram/d|
9961181|NCT01204528|Placebo Comparator|Placebo|
9961182|NCT01204541||AMD|
9803646|NCT03649958|Active Comparator|HIRREM-SOP or Cereset|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time. This group will have 10 sessions.
9961183|NCT01204541||Young normals|
9961184|NCT01204541||Older normals|
9961185|NCT01204567|Active Comparator|Training follow-up after discharge|Aerobic training Home-program
9961186|NCT01204580|Experimental|Amaryl-M (Glimepiride + Metformin)|"Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets.~Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test."
9961187|NCT01204593|Experimental|Insulin glargine + insulin glulisine|"Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L).~Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) < 180 mg/dL (<10.0 mmol/L) and ideally around 140 mg/dL."
9961188|NCT01204606|Experimental|MMA group|
9961189|NCT01204606|Placebo Comparator|Control group|
9961190|NCT01204619|No Intervention|Conventional training group|in-center conventional training programs + two home visits
9961191|NCT01204619|Experimental|Intensive training group|in-center conventional training programs + an extra structured patient home visits repeatedly and regularly
9961192|NCT01204645||Acute Coronary Syndrome (ACS)|Continuous inclusion at emergency hospitals of patients with acute coronary syndrome (according to ESC/AHA definitions)
9961193|NCT01204645||Follow up|Patients included at 6 or 12 months follow-up visit after an acute coronary event.
9961194|NCT01204645||Coronary|Patients included when undergoing an coronary angiography for suspected or confirmed coronary heart disease
9961195|NCT01204723|Experimental|Behavioral Condition 1|Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
9961196|NCT01204723|Experimental|Behavioral Condition 2|Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
9961197|NCT01204723|Experimental|Behavioral Condition 3|Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
9961198|NCT01204801|Experimental|Thermochemotherapy|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy.
9961199|NCT01204801|Active Comparator|Chemotherapy (control)|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs
9961200|NCT01204827|Experimental|CHBV Sebivo|
9961201|NCT01204840|Active Comparator|Group A - Control group|"Group A (n=10; control group) will receive the patch protocol consisting of the 100ug estrogen patch (Estradot), a Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), and gonadotropin stimulation with 412 IU of recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris)."
9961202|NCT01204840|Experimental|Group B - treatment group|"Group B will consist of 30 subjects. In addition to the same hormone stimulation patch protocol as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection."
9961203|NCT01204866|Experimental|Stage I|Three (3) healthy male or female volunteers aged 18-59 years, not previously exposed to Valortim and who do not have pre-existing allergies
10035292|NCT01804738|Active Comparator|Parboiled basmati rice|50g available carbohydrate portion
9961204|NCT01204866|Experimental|Stage II|Up to 4 healthy male or female volunteers aged 18-59 previously exposed to intravenous (IV) Valortim in PharmAthene Study #0036-08-05
9961205|NCT01204879|Active Comparator|CM for general activities|Standard care plus individual contingency management session for general activities
9961206|NCT01204879|Experimental|CM for exercise-related activities|Standard care plus individual contingency management session for physical activities
9961207|NCT01204892|Active Comparator|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
9961208|NCT01204892|Active Comparator|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
9961209|NCT01204931||Gastroesophageal Reflux Disease (GERD) Cases|"Erosive disease - presence of esophageal mucosal injuries documented endoscopically.~Non-erosive disease - normal esophagogastroduodenoscopy with symptoms"
9961210|NCT01204931||Control Group|normal subjects without symptoms of gastroesophageal reflux disease (GERD)
9961211|NCT01204957|Experimental|Arm 1 Seaweed and Soy Protein|Arm 1 5 g/d Seaweed for 6 wk, then 5 g/d Seaweed and Soy Protein for 1 wk
9961212|NCT01204957|Experimental|Arm 2 Placebo and soy protein|Arm 2 5 g/d Placebo for 6 wk, then 5 g/d Placebo and Soy Protein for 1 wk
9961213|NCT01204970||COPD|COPD Gold class 1-4
9961214|NCT01204970||Transplant|Lung transplant recipients
9961215|NCT01204970||Control|Patients with normal spirometric data
9961216|NCT01204996|Experimental|1|CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
9961217|NCT01204996|Experimental|2|CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
9961218|NCT01204996|Experimental|3|CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
9961219|NCT01204996|Experimental|4|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
10215579|NCT03702218|Experimental|Hep C Ab + NAT - Donor to Naïve Recipient|"HCV Ab and HCV NAT testing at 3 days, week 1, week 2 and monthly for 3 months, at 6 months and 1 year. In approximately 16% of the patients, active hepatis C infection will ensue. For these patients, treatment is as follows.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
9961220|NCT01205009|Active Comparator|Ovitrelle supplemantation|The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
9961221|NCT01205009|No Intervention|no Ovitrelle supplementation|
9961222|NCT01205022|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
9961223|NCT01205074|Experimental|Repeatability|
9961224|NCT01205074|Experimental|COPD|
9961225|NCT01205074|Experimental|Smokers|
9961226|NCT01205074|Experimental|CYP450 1A2 Inhibitors|
9961227|NCT01205074|Experimental|Cirrhosis Beta Blockers|
9961228|NCT01205074|Experimental|Alcohol|
9961229|NCT01205087|Placebo Comparator|Placebo|
9961230|NCT01205087|Active Comparator|OKT3 - 0.2|
9961231|NCT01205087|Active Comparator|OKT3 - 1|
9961232|NCT01205087|Active Comparator|OKT3 - 5|
9961233|NCT01205100|Active Comparator|Biofeedback|Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
9961234|NCT01205100|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
9961235|NCT01205139|Experimental|001|TMC435 150 mg capsule once daily for 11 days
9961236|NCT01205139|Experimental|002|TMC278 25 mg tablet once daily for 11 days
9961237|NCT01205139|Experimental|003|TMC435 + TMC278 150 mg TMC435 capsule + 25 mg TMC278 tablet once daily for 11 days
9961238|NCT01205139|Experimental|004|TMC435 150 mg capsule once daily for 7 days
9961239|NCT01205139|Experimental|005|TDF 300 mg tablet once daily for 7 days
9961240|NCT01205139|Experimental|006|TMC435 + TDF 150 mg TMC435 capsule + 300 mg TDF tablet once daily for 7 days
9961241|NCT01205178|Active Comparator|Tafenoquine|Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
9961242|NCT01205178|Active Comparator|Chloroquine|Dose for first 3 days for Part B & C of the study
9961243|NCT01205178|Active Comparator|Primaquine|once daily for first 14 days
10035293|NCT01804777|Experimental|Amiloride 10 mg, 20 mg, and diet|Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
10035294|NCT01804777|Active Comparator|HCTZ 12.5 mg, 25 mg and diet|HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet
10035295|NCT01804790|Active Comparator|Arm A : Radiotherapy + capecitabine|Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session ; 25 fractions) + capecitabine 800 mg/m² twice daily 5 days/7, excluding weekends), then 6-8 weeks after chemoradiation, surgery with total mesorectal excision (TME), followed by adjuvant chemotherapy for 6 months, either mFolfox6 or capecitabine, depending on the center's choice.
9961244|NCT01205191|Experimental|CBT-ubiquitous|
9961245|NCT01205191|Placebo Comparator|CBT-placebo|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management
9961246|NCT01205191|Active Comparator|CBT-TAU|Cognitive behavioural Therapy provided 'As Usual'
9961247|NCT01205204|Active Comparator|BF25 (Control)|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
9961248|NCT01205204|Experimental|BC15(Study 1)|GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
9961249|NCT01205204|Experimental|BC30(Study 2)|GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
9961250|NCT01205204|Experimental|BC60 (Study 3)|GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
9961251|NCT01205217|Experimental|Arm A|"Lapatinib in combination with epirubicin and cyclophosphamide followed by paclitaxel and lapatinib.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea"
9961252|NCT01205217|Active Comparator|Arm B|"Epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week"
9961253|NCT01205243||ZIAGEN®|Patients administrated ZIAGEN® at the site
9961254|NCT01205256|Experimental|Methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
9961255|NCT01205282|Experimental|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). There will be 14 weeks of active treatment.
9961256|NCT01205282|Placebo Comparator|Placebo|
9961257|NCT01205295||Mental disorders|Preoperative and postoperative screening of mental disorders and efficacy of treatment in hip and shoulder patient.
9961258|NCT01205308|Active Comparator|Stanol ester spread|Vegetable oil based margarine with stanol ester enrichment
9961259|NCT01205308|Placebo Comparator|control spread|Vegetable oil based margarine without stanol ester enrichment
9961260|NCT01205321|Experimental|Arm 1|
10215580|NCT03702218|Experimental|Hep C Ab+ NAT+ Donor to Naïve Recipient|"HCV RNA levels, liver biochemistries, and renal function will be measured 3 days after transplant. HCV Genotype will be determined after HCV RNA is >1,000 IU/mL. HCV RNA levels will be measured weekly after transplant until HCV treatment is initiated.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
10215581|NCT03702218|Active Comparator|Hep C Ab- NAT - Donor to Naïve Recipient|Current standard of care for donor recipient infectious disease matching. No treatment necessary
10215582|NCT03702205|Experimental|Betaine supplementation|The experimental procedure for each athlete includes a 3-week betaine supplementation either 2.5 g or 5 g daily. Betaine will be administered in the form of capsules containing either 0.5 or 1 g betaine. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 5 betaine capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
9961261|NCT01205321|Experimental|Arm 2|
9961262|NCT01205347|Experimental|Simvastatin 80mg|Simvastatin 80mg once a day
9961263|NCT01205347|Active Comparator|Simvastatin 10mg|Simvastatin 10mg once a day
9961264|NCT01205360|Active Comparator|Bupivacaine-Fentanyl (3-15)|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
9961265|NCT01205360|Experimental|Bupivacaine-Fentanyl (4-20)|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
10215583|NCT03702205|Experimental|Placebo treatment|The experimental procedure for each athlete included a 3-week placebo administration. Placebo will be capsules with starch. Placebo will be ingested with at least 250 mL of water. Each athlete will ingest 5 placebo capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
9961266|NCT01205360|Experimental|Bupivacaine-Fentanyl (6-30)|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
9961267|NCT01205373|Experimental|BI 671800 high dose|Oral drinking solution
9961268|NCT01205386||CROSSER|
9961269|NCT01205412||Assessed Cohort|Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
9961270|NCT01205425|Experimental|CT|Procedure of stent implantation will be planed on the basis of both angiography and computed tomography results.
9961271|NCT01205425|Active Comparator|Angio|Procedure of stent implantation will be planned only on the basis of diagnostic coronary angiography.
9961272|NCT01205464|Active Comparator|Doxycycline|Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.
9961273|NCT01205464|Placebo Comparator|Sugar pill|Capsule Placebo, 200 mg, once daily, for 21 days.
9961274|NCT01205477|Experimental|Methylprednisolone|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
9961275|NCT01205477|Placebo Comparator|Placebo|Infiltration of 1 mL of xylocaine
9961276|NCT01205516|Experimental|Methadone|
10215584|NCT03702192|Experimental|single-arm novel anticoagulation|Single-arm clinical study to assess the safety, and effectiveness of a novel anticoagulation protocol to be used in conjunction with the Berlin Heart EXCOR Pediatric Ventricular Assist Device as a bridge to heart transplantation in children with severe heart failure who have failed optimal medical therapy.
9961277|NCT01205516|Active Comparator|Controlled Release Morphine|Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
9961278|NCT01205542|Experimental|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
9961279|NCT01205542|Active Comparator|Reference|Health check and advice to continue ordinary physical activity
9961280|NCT01205555|No Intervention|ultrasound alone group|Patients in the control group will have a standard ultrasound monitoring with HCG administered when the leading follicle reaches 18 mm, and IUI 36 h afterward.
9961281|NCT01205555|Experimental|LH testing combined with ultrasound monitoring|
9961282|NCT01205594|Experimental|ITPR device|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
9961283|NCT01205607|Experimental|ITPR -9 & then -5 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
9961284|NCT01205607|Experimental|ITPR -5 & then _9 mm HG|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
9961285|NCT01205620|Experimental|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
9961286|NCT01205620|No Intervention|No intervention|No intervention will be performed in this control group
9961287|NCT01205633||CNS draining vein abnormalities|
9961288|NCT01205672|Experimental|Metformin|Metformin 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
9961289|NCT01205698|Placebo Comparator|Group 1 - Control A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
9961290|NCT01205698|Experimental|Group 2 - Experimental A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
9961291|NCT01205698|Placebo Comparator|Group 3 - Control B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
10215585|NCT03702153|Experimental|Infected abdominal wall group|A cohort of 40 patients carrying an active chronic mesh infection (mesh sinus, exposed mesh or mesh related enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with synthetic mesh.
9961292|NCT01205698|Experimental|Group 4 - Experimental B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
9961293|NCT01205724|Experimental|A|
9961294|NCT01205724|Experimental|B|
9961295|NCT01205724|Experimental|C|
9961296|NCT01205737|Experimental|TL011|
10215586|NCT03702153|Active Comparator|Clean control group|A cohort of 40 patients with ventral hernias, and submitted to clean ventral hernia repair with synthetic mesh.
9961297|NCT01205737|Active Comparator|MabThera®|
9961298|NCT01205750|Experimental|Glucose clamp|
9961299|NCT01205789||Universal Registry|Subjects who are either not eligible for randomization or for other reasons are not randomized will be consented for the Universal Registry
9961300|NCT01205802|Active Comparator|PTFE group|MHV reconstruction with ringed Goretex
10215587|NCT03702140|Active Comparator|TPTD 6M|
10215588|NCT03702140|Active Comparator|TPTD 6-12M|
10215589|NCT03702140|Active Comparator|TPTD 12-24M|
10215590|NCT03702127|Experimental|TMS in patients with intracranial electrodes|We will administer TMS to neurosurgical patients with intracranial electroencephalography in order to better understand the effects TMS has on the human brain. Participants will receive both active and sham stimulation at varying points during the study.
10215591|NCT03702114||MMG group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
10215592|NCT03702114||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
10215593|NCT03702101||Orofacial pain group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
10215594|NCT03702101||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
10215595|NCT03702075|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-administered program combining self-myofascial release using foam rollers and roller balls and active upper limb neurodynamic exercises. It consisted of three sessions of 50-60 minutes per week for 4 consecutive weeks.
10215596|NCT03702075|No Intervention|Control group|Those patients allocated to the control group received a booklet with information regarding neck pain and explaining basic exercises for active mobilization and stretching with pictures and a short text.
10215597|NCT03702062|Experimental|Observational Arm|Participants will be asked to measure self-assessed 6 minute walk test via the smart phone application twice a week for 2 months after discharge from a heart failure hospitalization, and weekly thereafter for 6 months.
10215598|NCT03702049|Experimental|RN/CHW TBI|Nurse-led Community Health Worker TBI (RN/CHW TBI) program
9961301|NCT01205802|Placebo Comparator|Homograft group|MHV reconstruction with homograft
9961302|NCT01205841|Experimental|Adults|Patients from 16 years of age onwards
9961303|NCT01205841|Experimental|Children|Patients aged 5 to 15 years
9961304|NCT01205854|No Intervention|Conventional clinical and laboratory assessment|
9961305|NCT01205854|Experimental|Conventional assessment plus ultrasonography|
9961306|NCT01205867|Experimental|1|AZD8848 given to BChE deficient subjects and age & gender matched control subjects
9961307|NCT01205880|Active Comparator|vectical ointment and clobex spray|patients were assigned to apply vectical ointment first then clobex spray on one target lesion and also apply clobex spray first then vectical ointment on a different target lesion on the opposite side of the body.
9961308|NCT01205893|Experimental|Reducer|Implant Reducer
9961309|NCT01205893|Sham Comparator|Control|No treatment
9961310|NCT01205906|Experimental|Internet-based guided self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
9961311|NCT01205906|Experimental|Cognitive-behavior group therapy|This well-established, cognitive-behavior group therapy was developed by Hiller and Haerkötter (2005) and consists of 10 weekly group sessions of 90 minutes. The strictly manualized program includes the following components focusing on the special needs of chronic tinnitus patients: Education, relaxation techniques, cognitive restructuring, the role of attentional processes for tinnitus perception, analysis of avoidance behaviors, tinnitus and the health care system as well as relapse prevention. For each session participants receive written materials, exercises and homework assignments to enhance understanding and to transfer the new information into the daily routine.
9961312|NCT01205906|Active Comparator|Discussion forum group|To the participants of the control group the group therapy or the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
9961313|NCT01205919|Experimental|Internet-based self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
9961314|NCT01205919|Active Comparator|Discussion forum group|To the participants of the control group the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
9961315|NCT01205932|Experimental|Arm 1|
9961316|NCT01205932|Experimental|Arm 2|
9961317|NCT01205932|Experimental|Arm 3|
9961318|NCT01205932|Active Comparator|Arm 4|
9961319|NCT01205958|Active Comparator|medication(Zaltoprofen)|
9961320|NCT01205958|Active Comparator|Acupuncture|
9961321|NCT01205958|Active Comparator|Zalprofen plus Acupuncture|
10215599|NCT03702023|Active Comparator|Intervention Group|Patients in the intervention group with receive the study medication 1000mg acetaminophen orally one time prior to their scheduled electrophysiology procedure.
10215600|NCT03702023|Placebo Comparator|Placebo Oral Tablet|Patients in the control group will receive a placebo orally one time prior to their scheduled electrophysiology procedure.
10215601|NCT03701997||EXCOR Pediatric|Pediatric (age 0 - 21) patients who are transplant eligible in need of mechanical circulatory support and are supported with the EXCOR® Pediatric
10215602|NCT03701984|Experimental|lidocaine infusion arm|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
10215603|NCT03701984|Active Comparator|tramadol arm|will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
10215604|NCT03701984|Placebo Comparator|placebo group|will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
10215605|NCT03701971|Experimental|Music Therapy|"a medical examination~Before and after music therapy, patients will have to answer questionnaires :~Before :~Questionnaire 5D itch scale Itchy Quality of Life Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC~• Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC"
10215606|NCT03701971|Active Comparator|Emollient cream|"a medical examination~Before and after music therapy, patients will have to answer questionnaires :~Before :~Questionnaire 5D itch scale~Itchy Quality of Life~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~PGIC~Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~PGIC"
10215607|NCT03701945|Experimental|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to every patient that accepts the intervention and presents an acute exacerbation
10215608|NCT03701932|Experimental|TMS and Lumosity® cognitive retraining|Group will receive TMS and will concurrently engage in cognitive retraining exercises comprised of the Lumosity® battery.
9961322|NCT01205971|Experimental|Motivational Interviewing|Motivational Interviewing to reduce caregiver risk factors for early childhood caries in their children is delivered by Dental Health Advocates (trained public housing residents) in combination with fluoride varnish applications, oral health assessments and referrals for children.
9961323|NCT01205971|Active Comparator|Dental Preventive Services|Fluoride varnish applications, written oral health educational materials regarding early childhood caries prevention, oral health assessments and referrals.
9961324|NCT01205984|Active Comparator|oral methylprednisolone|
9961325|NCT01205984|Placebo Comparator|placebo|
9961326|NCT01205997|Active Comparator|fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
9961327|NCT01205997|Placebo Comparator|placebo|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
9961328|NCT01205997|Active Comparator|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
9961329|NCT01206010|Experimental|Varenicline + Active Tailored Dose|
9961330|NCT01206010|Placebo Comparator|Varenicline + Placebo Tailored Dose|
9961331|NCT01206023||Multiple Sclerosis|Multiple Sclerosis patients
9961332|NCT01206023||Healthy controls|healthy individuals
9961333|NCT01206049|Experimental|Combination chemotherapy + panitumumab|
9961334|NCT01206049|Experimental|Combination chemotherapy + bevacizumab|
9961335|NCT01206075|Other|Mozobil + G-CSF - 001|Up to four patients (splenectomized and non-splenectomized) previously mobilized with G-CSF (previous study), who failed to yield by 2 leukaphereses sufficient CD34+ cells for a future gene therapy procedure, will receive the combination of G-CSF+Mozobil
9961336|NCT01206075|Other|Mozobil|Sixteen or more patients (non-splenectomized and splenectomized) who were not previously mobilized will receive Mozobil alone.
9961337|NCT01206075|Other|Mozobil + G-CSF - 002|Patients who, in this study, fail to mobilize sufficient yields of blood stem cells with Mozobil alone will be invited to be re-mobilized with the combination of Mozobil plus G-CSF.
9961338|NCT01206088|Experimental|nilotinib|
9961339|NCT01206114||Vaccinated persons|The participants have taken one or more doses of 2009 H1N1 vaccine, either as a monovalent vaccine or as a part of a trivalent seasonal 2010-2011 influenza vaccine
9961340|NCT01206114||Not (yet) vaccinated persons|The participants do not want to take any 2009 H1N1 vaccine or have not received any yet
9961341|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group must be lying down facing up 2 hours postoperatively
9961342|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperatively
9961343|NCT01206153|Experimental|metformin|
9961344|NCT01206179|Experimental|non union|Patients with nonunion fracture of long bones
9961345|NCT01206192||Abused Chinese women|
9961346|NCT01206205|Experimental|Lenalidomide, Bortezomib|"3 induction cycles of bortezomib, lenalidomide and dexamethasone (VRD) followed by high dose melphalan and autologous stem cell transplantation.~Two months after haematological recovery, patients will receive 2 consolidation cycles of VRD and maintenance therapy for 1 year with lenalidomide."
9961347|NCT01206218|Active Comparator|Group A|FLOT Regimen
9961348|NCT01206218|Experimental|Group B|FLO Regimen or FLOT Regimen
9961349|NCT01206231||1|Patients with hypercholesterolemia
9961350|NCT01206244||Normal|Normal subjects
9961351|NCT01206244||Dry eye|clinically diagnosed dry eye with aqueous tear deficiency
9961352|NCT01206257||Group 1|
9961353|NCT01206270|Experimental|Testosterone|Testosterone undecanoate 1000mg injection at baseline (0-week), 6-week, 18-week, 30-week
9961354|NCT01206270|Placebo Comparator|Placebo|Injection 4 ml of castor oil at baseline (week-0), week-6, week-18, week-30
10215609|NCT03701932|Active Comparator|TMS and non cognitive computer games|Group will receive TMS while concurrently engaging in selected computer games from several gaming software that includes Play 101 Games and Hoyle Puzzle and Board Games®. They will also be allowed to spend time on gaming activities of their choice in order to keep them engaged
10215610|NCT03701919|Experimental|Botulinum toxin pyloroplasty|Intraoperative laparoscopic intramuscular injection of 100units (10cc) of Botulinum toxin into the pylorus
9803647|NCT03649958|Active Comparator|Cereset 2x|Participants randomized to the Cereset 2x group will be seated in a comfortable zero-gravity chair identical to those in the HIRREM-SOP arm. They will listen to a pattern of musical notes linked to their brain activity patterns, but also receive intermittent very low level electrical stimulation of the scalp linked to brain activity. This group will only have 5 sessions,
10215611|NCT03701919|Placebo Comparator|Normal saline pyloric injection|Intraoperative laparoscopic intramuscular injection of 10cc normal saline into the pylorus
10215612|NCT03701906|Active Comparator|Lactobacillus PS11603 & Bifidobacterium PS10402|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
10215613|NCT03701906|Active Comparator|Placebo|1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
10215614|NCT03701893|Experimental|Lactobacillus PS11610|Lactobacillus PS11610 for couples with genital dysbiosis and infertility. Each dose contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610.Two daily doses for her and one daily dose for him until pregnancy or end of study period (6 months).
10215615|NCT03701880|Experimental|Ivabradine group|an initial dose of 5 mg/12 hours of Ivabradine will be added to beta-blockers (bisoprolol 2.5 mg/day) and ivabradine will be increased until a dose of 7.5 mg/12 hours according to HR. The heart rate target will be at least <70 bpm and not lower than 60 bpm. If HR decreases below 60 bpm, ivabradine and/or beta-blockers doses will be decreased to the previous dose. After discharge, beta-blockers up-titration will be continued during follow-up visit.
10215616|NCT03701880|Active Comparator|Control group|beta-blocker (bisoprolol 2.5 mg/day) and it will be doubled every 2 weeks during the admission according to the stability of HR, blood pressure and tolerability of patients. Ivabradine will be only added after reaching bisoprolol optimal dose (10mg) or maximum tolerated dose and the HR is still above 70 bpm. If HR decreases below 60 bpm, ivabradine dose will be decreased.
10215617|NCT03701867|Experimental|Metabolic Flexibility Tests Group|
10215618|NCT03701854||Heart failure patients with pacemakers|Functional (6-Minute Walking test (6-MWT)) and maximal exercise capacity (Incremental Shuttle Walking test (ISWT)), respiratory (MIP, MEP; Mouth pressure device) and peripheral muscle strength (Dynamometer), pulmonary function (Spirometry) dyspnea (Modified Medical Research Council Dyspnea scale) (MMRC)), and fatigue (Fatigue Severity scale (FSS)) were evaluated in 50 patients.
10215619|NCT03701854||Healthy controls|Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
10215620|NCT03701841||PEG-rhG-CSF primary prophylaxis|Patients receiving chemotherapy who have a overall FN risk >=20% receive PEG-rhG-CSF for primary prophylaxis
10215621|NCT03701841||PEG-rhG-CSF secondary prophylaxis|Patients receiving chemotherapy who had FN or dose-limited neutropenia receive PEG-rhG-CSF for secondary prophylaxis
10215622|NCT03701815|Experimental|Post-stroke|Patients will receive a 12-week lifestyle medicine program.
10215623|NCT03701802||HIV-1 serodiscordant couples|Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
10215624|NCT03701802||Concordant HIV-1 negative couples|Heterosexual couples in which both partners are HIV-1 uninfected
10215625|NCT03701789|Other|Patients with Rheumatoid Arthritis|In-label treatment with Baricitinib
10215626|NCT03701750|Experimental|Experimental Arm|Low Molecular Weight Heparin (enoxaparin sodium) + routine luteal phase support
10215627|NCT03701750|No Intervention|Control Arm|routine luteal phase support
10215628|NCT03701698|Experimental|combination therapy|"There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.~Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.~Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days."
10215629|NCT03701685|Other|nerve grafting|The stumps of digital nerve are connected with nerve graft
10215630|NCT03701672||Opioid Analgesic Treatment|Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs
10215631|NCT03701659|Experimental|TUPKRP+MAB Group|These patient will be treated by TUPKRP and MAB.
10215632|NCT03701659|Active Comparator|MAB Group|These patient will be treated by MAB only.
10215633|NCT03701646||arterial line|Pediatric patients admitted tot he ICU with a medically indicated arterial line.
10215634|NCT03701646||cardiac output|Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
10215635|NCT03701633||Prior to breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
10215636|NCT03701633||After breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
10215637|NCT03701607||PD-L1|
9961355|NCT01206283|Active Comparator|Cerebral perfusion pressure-targeted|15 comatose operated patients after aneurysmal subarachnoid haemorrhage and severe traumatic brain injury respectively were managed postoperatively using cerebral perfusion pressure-targeted therapy according to the American Associations of Neurological Surgeons. Results were categorised into different Glasgow Outcome Scores.
9961356|NCT01206283|Active Comparator|Intracranial pressure-targeted therapy|
9961357|NCT01206309||Controls|Never develop an immune mediated disorder
9961358|NCT01206309||Immune Mediated Disorder|Develop an immune mediated disorder
9961359|NCT01206335|Experimental|OHR/AVR118|Experimental Drug
9961360|NCT01206348|Experimental|Open Label Combination|Solodyn, Ziana, Triaz FC
9961361|NCT01206361||fixed dose prostaglandin combination|
9961362|NCT01206400||pioglitazone vs placebo|15 patients in pioglitazone group and 15 in placebo group
9961363|NCT01206413|Experimental|LGI|Low glycemic index
9961364|NCT01206413|Active Comparator|HGI|High glycemic index
9961365|NCT01206413|Experimental|HB|Home-based exercise
9961366|NCT01206413|Active Comparator|CONTROL|Non-exercisers
9961367|NCT01206543|Experimental|Intraoperative imaging|
9961368|NCT01206569|Experimental|advagraf|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
9961369|NCT01206621||ED patients presenting with dyspnea|
9961370|NCT01206634|Experimental|Regenerative injection therapy|
9961371|NCT01206634|Active Comparator|Exercise|
9961372|NCT01206647|No Intervention|Control arm|The patients randomized to the control arm will continue their current therapy, as individually prescribed. Insulin will be administered via subcutaneous injection and OADs (if applicable) will be administered orally, as individually prescribed.
9961373|NCT01206647|Experimental|Saxagliptin & metformin|Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.
9961374|NCT01206686|Experimental|1 Hour Planning Prompt|
9961375|NCT01206686|Experimental|2 Hour Planning Prompt|
9961376|NCT01206686|Experimental|1 Day Planning Prompt|
9961377|NCT01206686|Experimental|Default Planning Prompt|
9961378|NCT01206686|Active Comparator|Control|
9961379|NCT01206699|Experimental|corticoid|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
9961380|NCT01206699|Placebo Comparator|physiological solution|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
9961381|NCT01206712||T2DM patients treated with LANTUS + MET|T2DM patients treated with LANTUS + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
9961382|NCT01206712||T2DM patients treated with SU + MET|T2DM patients treated with Sulfonylurea (SU) + Metformin(MET)in their routine antidiabetic therapy. These patients do not receive any study specific medication.
9961383|NCT01206712||T2DM patients treated with DPP-4 + MET|T2DM patients treated with Dipeptidylpeptidase 4 inhibitors (DPP-4) + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
9961384|NCT01206712||Healthy subjects|healthy volunteres who do not receive any antidiabetic medication in their routine therapie.
9961385|NCT01206725|Other|. Moderate Intensity Exercise Group|Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
9961386|NCT01206725|Other|Aerobic interval training|Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
9961387|NCT01206790|Experimental|Narrative Exposure Therapy (NET)|
9961388|NCT01206790|No Intervention|Waitinglist Control Group|
9961389|NCT01206829|Active Comparator|Audiological rehabilitation|16 hours of psychosocial rehabilitation course
9961390|NCT01206842|Experimental|social cognition training|
9961391|NCT01206842|No Intervention|treatment as usual|
9961392|NCT01206855|Active Comparator|SOC Treated Side of Incision|One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
9961393|NCT01206855|Active Comparator|MIST Treated Side of Incision|One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
9961394|NCT01206868|Active Comparator|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
9961395|NCT01206868|Sham Comparator|Control|Standard kidney transplantation
9961396|NCT01206933||Detectable HIV RNA and HCV RNA|HIV and HCV co-infected with detectable HIV RNA and HCV RNA
9961397|NCT01206933||Undetectable HIV and Detectable HCV|HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
9961398|NCT01206933||Undetectable HIV and HCV|HIV and HCV infected, Undetectable HIV RNA and HCV RNA
9961399|NCT01206933||Undetectable HCV|HCV(mono-infected,) HCV RNA undetectable
9961400|NCT01206933||Detectable HCV RNA|Monoinfected HCV, detectable RNA
9961401|NCT01206933||Detectable HIV RNA|Monoinfected HIV, Detectable RNA
10006272|NCT01592994|Experimental|RHANI Wives Intervention|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT) and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
10006273|NCT01593007|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
10006274|NCT01593007|Placebo Comparator|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
10006275|NCT01593033|Experimental|Fish oil and Micronutrient Supplementation|
10006276|NCT01593033|Experimental|Micronutrient Supplementation|
10006277|NCT01593033|Placebo Comparator|Placebo|
10006278|NCT01593046|Experimental|Run-in Period|Oral GSK1265744 30mg once daily for 14 days
10006279|NCT01593046|Experimental|Cohort 1|GSK1265744 LAP injection given subcutaneously once a month for 4 months
10006280|NCT01593046|Experimental|Cohort 2|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
10006281|NCT01593046|Experimental|Cohort 3|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
10006282|NCT01593046|Experimental|Cohort 4|GSK1265744 LAP injection given intramuscularly once every 12 weeks.
10006283|NCT01593059||Orsiro DES|
10006284|NCT01593072|Active Comparator|AVI-7537|AVI-7537
10006285|NCT01593072|Other|Placebo|Normal Saline Solution (NSS)
10006286|NCT01593085||patients in palliative cares|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
10006287|NCT01593098||Exposed siblings|Siblings (age >40 and <70) of individuals diagnosed with advanced neoplasm on screening colonoscopy. Advanced neoplasm is defined as adenomas≥10mm size, >25% villous features, severe dysplasia or carcinoma-in-situ
9961402|NCT01206946|Experimental|Antenatal steroids|
9961403|NCT01206946|Placebo Comparator|Normal saline|
9961404|NCT01206959||monitor method|"blood pressure monitor Cuff circumference:22cm-48cm~stethoscopy Cuff circumference: 22cm-48cm"
9961405|NCT01206972|Experimental|Arm 1|
9961406|NCT01206972|Experimental|Arm 2|
9961407|NCT01206972|Experimental|Arm 3|
9476629|NCT03569995|Experimental|Induction+Consolidation chemotherapy|"[Induction phase]~① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation~Complete, partial response or stable disease-> next step~Progressive disease-> eliminated~② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation~Complete response -> consolidation therapy(Rituximab-Cytarabine) progress~Partial response or stable disease-> Rituximab-Methotrexate 2 additional administrations~Progressive disease-> eliminated~③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation~Complete, partial response or stable disease-> consolidation therapy(Rituximab-Cytarabine)~Progressive disease-> eliminated"
9476630|NCT03569969|Experimental|control group|Step1. Under local anesthesia and sedation , the temporal muscle fascia was removed, Step2. After the preparation on the tympanic membrane embedded , foam gel smeary with Dexamethasone was worn.Step3. Then the wound dressing was done with a gas number and a Surgifix. Step4. Patients were discharge from the operating room with an oral administration of Cephalexin capsules.
9961408|NCT01206972|Active Comparator|Arm 4|
9961409|NCT01206998|Experimental|Vaginal progesterone gel|
9961410|NCT01206998|Placebo Comparator|Placebo vaginal gel|
9961411|NCT01207024||knee MRI|knee MRI for all patients undergoing bariatric surgery as usual care
9961412|NCT01207037|Other|Intervention|
9961413|NCT01207050|Experimental|Rozerem (Ramelteon)|The primary drug of interest is a melatonin agonist for the treatment of insomnia.
9961414|NCT01207050|Placebo Comparator|Sugar pill|Control condition.
9961415|NCT01207063|Experimental|Radiotherapy|
9961416|NCT01207076|Experimental|receiving AHN-12 and 90Y-AHN-12|Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).
9961417|NCT01207089|Placebo Comparator|1|
9961418|NCT01207089|Experimental|2|AZD8329
9961419|NCT01207128|Active Comparator|Voriconazole, Micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
9961420|NCT01207128|No Intervention|Voriconazole+Micafungin or Voriconazole+Placebo|Voriconazole+Micafungin or Voriconazole+Placebo
9961421|NCT01207141||rATG induction|Liver transplant recipients who receive induction with rATG prior to transplantation.
9961422|NCT01207141||no rATG induction|Liver transplant recipients who do not receive rATG induction therapy prior to transplantation.
9961423|NCT01207154||BIS guidance|Sedation guided according to a predetermined BIS level
9961424|NCT01207154||Clinical sign guided|Sedation guided by clinical signs
9961425|NCT01207180|Experimental|Follow-up phone call from Nurse|Patients in this are will receive a phone call follow-up from a nurse 1-3 days after their discharge from the ED.
9961426|NCT01207180|Placebo Comparator|Satisfaction survey|This group of patients will receive a phone call from a student who will conduct a brief satisfaction survey of the patient's experience in the ED.
9961427|NCT01207180|Placebo Comparator|Control group|Patients in this group will receive no phone call at 1-3 days.
9961428|NCT01207193|Experimental|bone cyst|Patients with bone cyst defect are injected with mesenchymal cells.
9961429|NCT01207232|Experimental|Time Plan Condition|A basic reminder mailing prompted each subject to write down a planned date and time for getting their flu shot.
9961430|NCT01207232|Experimental|Date Plan Condition|A basic reminder mailing prompted each subject to write down a planned date for getting their flu shot.
9961431|NCT01207232|Active Comparator|Control Condition|A basic reminder mailing prompted each subject to receive a flu shot.
9961432|NCT01207245|Active Comparator|Morning dose of tobramycin|Administration of tobramycin once daily dose in the morning
9961433|NCT01207245|Active Comparator|Evening tobramycin|Evening dose of tobramycin once daily
9961434|NCT01207258|Experimental|Brief Intervention Group|Participants randomly assigned to this group receive a brief motivational enhancement therapy intervention group and are assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
9961435|NCT01207258|No Intervention|Assessed Control Group|This group does not receive the intervention and is assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
9961436|NCT01207258|No Intervention|No Contact Control Group|This group does not receive the intervention and is assessed only at 3 months.
9961437|NCT01207271|Experimental|Cognitive Therapy|
9961438|NCT01207271|Experimental|Dynamic Therapy|
9667735|NCT03113942|Experimental|Pomalidomide group|Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).
9961439|NCT01207284|Experimental|Physical Therapy|Foot and ankle passive and active stretching, muscle strengthening, proprioception training and gait training.
9961440|NCT01207284|No Intervention|Control|
9961441|NCT01207297|Active Comparator|TAC group|Oral tacrolimus (0.04-0.08 mg/kg/d) and prednisone for 12 months.
9961442|NCT01207297|Active Comparator|CYC group|Pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day）for 6 months.
9961443|NCT01207310|Experimental|Pager Arm|Participants in the Pager Arm will be provided with alphanumeric pagers and will receive therapeutic messages on these pagers for 3 months in addition to individual smoking cessation counseling and nicotine patches.
9961444|NCT01207310|Active Comparator|Control Arm|Participants in the Control Arm will receive individual smoking cessation counseling and nicotine patches.
9961445|NCT01207323|Experimental|Dose Escalation (MEHD7945A)|Participants will receive intravenous (IV) infusion of MEHD7945A in escalating doses Q2W until MTD is reached or up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first. Approximately 5 dose levels between 1 and 30 mg/kg will be evaluated.
10006288|NCT01593098||unexposed siblings|Siblings (age >40 and <70) of individuals diagnosed with no polyp on screening colonoscopy who is age and sex matched to case.
9961446|NCT01207323|Experimental|Dose Expansion (MEHD7945A)|Participants will receive IV infusion of MEHD7945A Q2W at or below the MTD (decided from dose escalation part) up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
9961447|NCT01207349||close follow-up by nurse|close follow-up by nurse : patients were visited each tree months
10215638|NCT03701594|Experimental|Yoga-based physical therapy group|The yoga-based physical therapy session will take place in an enclosed, quiet space to minimize outside noise or distraction. The lights will be dimmed, and light, instrumental, calming music will be played throughout. The group will consist of approximately 2-5 individuals depending on the physical capabilities and assistance levels required. The session will consist of an introduction to pranayama (foundational breath-based exercises) followed by asanas, or physical postures, that will be modified according to each individual's physical abilities. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
10215639|NCT03701594|Active Comparator|Seated rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
9961448|NCT01207349||standard follow up|stantdard follow up at one year
9961449|NCT01207362||Young adult|
9961450|NCT01207362||Older adult|
9961451|NCT01207375|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
9961452|NCT01207375|Placebo Comparator|Placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
9961453|NCT01207479|Experimental|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
9961454|NCT01207505|Experimental|Enchancing Emotion Regulation|12 week group 3 week modules: 1) Mindfulness 2) Emotion Regulation 3) Distress Tolerance
10215640|NCT03701594|Active Comparator|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
10215641|NCT03701581|Experimental|Group A: Investigational Treatment|"4-Aminopyridine (FDA-approved drug)~Subjects will not take more than 2 tablets in a 24-hour period~Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.~The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.~Study drug can be taken with or without food.~If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.~Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine)."
9961455|NCT01207518|Experimental|Intervention Group|For the intervention group, there will be a Guide facilitator provided by the project team, normally the Project Manager or their delegate. The role of the Guide facilitator will be to provide basic information about the Guide and to facilitate the use of the web-based tools.
9961456|NCT01207518|Active Comparator|Control Group|The Control Group will be asked to provide immunization rates for the base year and two years of the study, and will be asked about their influenza immunization campaign activities to use as a comparator. They will receive the Guide and web-based tools following completion of the study.
9961457|NCT01207531||Survival Group|
9961458|NCT01207531||Death group|
9961459|NCT01207544|Experimental|fitball program|This group will undergo the fitball program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
9961460|NCT01207544|Active Comparator|Task-oriented program|This group will undergo the task-oriented motor training program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
9961461|NCT01207557|Active Comparator|Standard education only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
9961462|NCT01207557|Active Comparator|Standard Education plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials plus the Ottawa Influenza Decision Aid and tested on their confidence with their immunization decision
9961463|NCT01207609|Experimental|Laparoscopic Gastric Plication|Collect data prospectively on the safety and efficacy of the Laparoscopic Gastric Plication operation for 50 patients with Severe or Morbid Obesity
9961464|NCT01207622|Active Comparator|Atomoxetine|
9961465|NCT01207622|Placebo Comparator|Placebo|
9961466|NCT01207635||Breast Cancer Patients|
9961467|NCT01207661|Experimental|Mesenchymal Injection|Intra Articular injection in Patients with osteoarthritis of knee joint
10215642|NCT03701581|Placebo Comparator|Group B: Placebo|"Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by The University of Iowa Pharmaceuticals, 115 South Grand Avenue G-20, Iowa City, IA 52242. The Investigational Drug Service at the University of Rochester will manage the placebos.~Placebo composition will include:~97% Microcrystalline Cellulose, NF (Avicel Ph 102) 2% Sodium Starch Glycolate, NF~1% Magnesium Stearate, NF~The placebo will be covered in White Opadry, formulation OY-S-9603 and tooled to look similar to the investigational treatment."
10215643|NCT03701542||Group of 22 patients|Group of 22 patients who underwent vitrectomy due to macular hole
9961468|NCT01207700|Experimental|CHW based intervention post ACS|CHW trained and supervised for intervening upon post ACS patients to improve adherence to evidence based care
9961469|NCT01207700|No Intervention|Standard Care|Patients will be followed upto 12 months without a community health worker intervention as per standard practices of the hospital
9961470|NCT01207739|Active Comparator|Doxycycline|
9961471|NCT01207739|Active Comparator|Clarithromycin and hydroxychloroquine|
9961472|NCT01207739|Placebo Comparator|Placebo|
9961473|NCT01207778||preterm ESA recipients|infants 500-1250 grams who received erythropoietin (400 units/kg 3x/week) or darbepoetin (10 micrograms/kg 1x/week), from the first week of life through 35 weeks corrected gestation
9961474|NCT01207778||preterm controls|preterm infants 500-1250 grams who received placebo (sham dosing), from first week of life through 35 weeks corrected gestation
9961475|NCT01207778||term controls|Term infants with normal delivery
9961476|NCT01207791|Other|Minimal screening only (MSO)|Minimal screening
9961477|NCT01207791|Active Comparator|Screening, assessment, and referral (SAR)|
9961478|NCT01207791|Experimental|Brief intervention plus telephone boosters (BI-B)|
9961479|NCT01207804|Experimental|Device|
9961480|NCT01207817||no condition|no condition - healthy volunteers
9961481|NCT01207830|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
9961482|NCT01207856|Active Comparator|group A|specific cognitive rehabilitation
9961483|NCT01207856|Active Comparator|Groupe B : non specific rehabilitation|
9961484|NCT01207856|Other|group C|group C for MRI, neuropsychological and ecological assessments
9961485|NCT01207869|Experimental|Mesenchymal stem cells|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
9961486|NCT01207869|Placebo Comparator|Control|Normal saline
9961487|NCT01207895|Experimental|[18F]-FLT PET scans|
9961488|NCT01207921|Experimental|Arm 1|"Lenalidomide 15 mg/day Cycle 1 (28 days).~If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.~If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day."
9961489|NCT01207947||Group 1|
9961490|NCT01207960|Active Comparator|EMDR|Eye Movement Desensitization and Reprocessing
9961491|NCT01207960|No Intervention|WLC|Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
9961492|NCT01207973|Experimental|BI 113823|5 dose-groups of multiple oral doses of BI 113823
9961493|NCT01207986|Other|CT screening|CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
9961494|NCT01207999||Group A|Subjects diagnosed with invasive cervical cancer
9961495|NCT01208012|No Intervention|Metformin|Patients taking Metformin at individual dose
9961496|NCT01208012|Experimental|Metformin and Liraglutide|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
10215644|NCT03701529|Experimental|Sevoflurane|1.5-2.5 vol% of sevoflurane is used for maintenance of anesthesia.
10215645|NCT03701529|Active Comparator|Propofol|2-5 mcg/ml of propofol is used continuously for maintenance of anesthesia using target-controlled infusion system.
10215646|NCT03701503|Experimental|Obese|"Women age 20-40, with BMI ≥ 25-35 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
10215647|NCT03701503|Active Comparator|Non Obese|"Women age 20-40, with BMI 18,5-23 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
10215648|NCT03701490|Experimental|Prolutex|
9961497|NCT01208025||symptomatic carotid stenosis 30-69%|Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% according to the European Carotid Surgery Trial (ECST) criteria.
9961498|NCT01208064|Experimental|Pazopanib|2 weeks at 600mg and then maintenance at 800mg
9961499|NCT01208064|Placebo Comparator|Placebo|placebo match 2 weeks at 600mg and then maintenance at 800mg
9961500|NCT01208077||Acute CHF|"Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint~Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF~Known history of physician diagnosed CHF~Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up"
9961501|NCT01208077||Acute Stroke Syndrome|"Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint~Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome~Non contrast head CT will be ordered by the treating physician as part of the patient's work up"
9961502|NCT01208077||Acute Systemic Infection|"Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection~Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up"
9961503|NCT01208090|Experimental|Investigational drug - Dose 1|
9961504|NCT01208090|Experimental|Investigational drug - Dose 2|
9961505|NCT01208090|Placebo Comparator|Matching placebo|
9961506|NCT01208116||Subgroups|According to the demographic features, subjects may be divided into some subgroups.
9961507|NCT01208142|Active Comparator|Standard of care|25 Control subjects will only receive SOC (a weekly standardized physical therapy and daily wear of an AFO).
9961508|NCT01208142|Experimental|Dynasplint|25 Patients will receive the standard of care as well as an Ankle Flexion Dynasplint
10215649|NCT03701490|Experimental|Progeffik|
9961509|NCT01208155|Experimental|1|Fostamatinib 50 mg tablet x 2
9961510|NCT01208155|Experimental|2|Fostamatinib 100 mg tablet (batch 1)
9961511|NCT01208155|Experimental|3|Fostamatinib 100 mg tablet (batch 2)
9961512|NCT01208155|Experimental|4|Fostamatinib 100 mg tablet (batch 4)
9961513|NCT01208194|Experimental|MGN1703|Study medication
9961514|NCT01208194|Placebo Comparator|Placebo|
9961515|NCT01208259|Experimental|Binge Eating Disorder/Therapy|
9961516|NCT01208272|Experimental|Binge Eating Disorder/Therapy|
9961517|NCT01208285|Experimental|Group A|approximately 12 male and female subjects with moderate hepatic impairment
10215650|NCT03701477|Experimental|Trans-diagnostic approach|Trans-diagnostic cognitive-behavioral therapy In this arm, patients will participate in 10 sessions of therapy. During each session, specific topics will be discussed and participants will need to complete their homework for the next session. Each session lasts for 120 minutes. Sessions will be held in groups of 5-10 subjects weekly, except the last session that will be held after a two-week interval.
10215651|NCT03701477|Sham Comparator|Control|General relaxation/stress management therapeutic session In this arm, patients will attend a 3-hour meeting in which basic techniques of relaxation and overcoming stress and anxiety will be discussed.
9961518|NCT01208285|Experimental|Group B|approximately 12 healthy male and female subjects
9961519|NCT01208298|Experimental|# 1727|Cold sore Patch
9961520|NCT01208311||Patients with Hepatitis C Cirrhosis|Patients with Hepatitis C Cirrhosis
9961521|NCT01208350|Experimental|1|
9961522|NCT01208350|Experimental|2|
9961523|NCT01208350|Active Comparator|3|
9961524|NCT01208363|No Intervention|Unfortified Toubani|Children in the school will receive, 3 times per week 66g of raw unfortified (no added Fe) cowpea in form of Toubani (a cowpea based snack).
9961525|NCT01208363|Active Comparator|Fortified Cowpea|Study subjects will receive 3 times per week, as part of the school feeding programme 66g of raw fortified cowpea (with added 10mg Fe as NaFeEDTA)in form of Toubani (a cowpea based snack).
10215652|NCT03701464|Experimental|Endoscopic naso-gallbladder drainage|After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
10215653|NCT03701464|Active Comparator|Percutaneous gallbladder drainage|Ultrasound guided，an 18-gauge needle is inserted into the gallbladder，0.035 inch guidewire is coiled into the gallbladder and 9Fr dilator expands the skin,then 8Fr-20cm catheter is placed.
10215654|NCT03701451|Experimental|decitabin and cisplatin induced chemotherapy followed by CC|Treated by demethylated drug decitabine injection combined with cisplatin induced chemotherapy followed by concurrent chemoradiotherapy
10215655|NCT03701438||Idelalisib|Participants currently enrolled in a Gilead-sponsored study, who are currently being treated with 100 or 150 mg of idelalisib twice daily for at least 7 consecutive days prior to receiving an influenza vaccine.
10215656|NCT03701425|Experimental|Mediterranean diet and exercise plan|"Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the distribution of macronutrients: Protein contribution 0.8-1.2 gram, Carbon Hydrates 45-50% Lipids 30% An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
10215657|NCT03701425|Experimental|Mediterranean diet|Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the following distribution of macro nutrients: Protein contribution 0.8-1.2 gram Carbon Hydrates 45-50% Lipids 30%
10215658|NCT03701425|Active Comparator|Only exercise|"An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
10215659|NCT03701425|Active Comparator|Low standard low fat diet|Random assignment, through software, to 4 groups of treatment: consume the low standard low fat diet: according to the definition, with the following distribution of macro nutrients:Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 20%
10215660|NCT03701386|Active Comparator|cesarean hysterectomy|Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
10215661|NCT03701386|Experimental|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade was performed
10215662|NCT03701373|Experimental|S-1 maintenance group|S-1 maintenance
9961526|NCT01208376||unexplained chronic ALT elevation|Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
10215663|NCT03701373|Other|Observation group|Observation without anti-tumor treatment
10215664|NCT03701347|Active Comparator|Reeve's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Reeve's simulators
9961527|NCT01208376||always normal ALT|Control patients: HIV-infected, always normal ALT values
9961528|NCT01208389|Experimental|voretigene neparvovec-rzyl (AAV2-hRPE65v2)|Administration of study agent (AAV2-hRPE65v2) to the previously, uninjected contralateral eye:
9961529|NCT01208428|Active Comparator|Conventional cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy for the treatment of major depression
9961530|NCT01208428|Experimental|Religious cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy, but their religious beliefs will be utilized as a resource in the therapy
9961531|NCT01208441|Experimental|Arm I|"Patients receive oral letrozole once daily on days 1-21. Beginning in course 2, patients also receive oral RO4929097 on days 1-3, 8-10, and 15-18. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Beginning 1 week after completion of neoadjuvant therapy, patients undergo surgery or tumor biopsy. Patients continue to receive oral letrozole once daily during surgery and for an additional 4 weeks."
9961532|NCT01208454|Experimental|Treatment (isotretinoin and vorinostat)|"Patients receive isotretinoin PO BID on days 1-14, PO suspension* of vorinostat QD on days 1-4 of course 1, and capsules of vorinostat PO QD on days 1-4 and 8-11 of course 2 and subsequent courses. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~EXPANSION COHORT 1 (=< 21 years of age): Once the MTD has been determined, patients are treated at that dose level as above.~EXPANSION COHORT 2 (22-30 years of age): Patients receive isotretinoin as above and vorinostat at the MTD on days 1-3 and 8-10."
9961533|NCT01208467||Basic science (DNA analysis)|DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
9961534|NCT01208493|Experimental|high protein preterm infant formula|preterm infant formula with high protein levels
9961535|NCT01208493|Active Comparator|control preterm formula|
9961536|NCT01208506|Experimental|Dose level 1|
9961537|NCT01208506|Experimental|Dose level 2|
9961538|NCT01208506|Experimental|Dose level 3|
9961539|NCT01208506|Experimental|Dose level 4|
9961540|NCT01208506|Experimental|Dose level 5|
9961541|NCT01208506|Experimental|Dose level 6|
10215665|NCT03701347|Active Comparator|Hefler's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Hefler's simulators
10215666|NCT03701347|Experimental|Ida's Model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Ida's simulators
9961542|NCT01208506|Experimental|Dose level 7|
10215667|NCT03701321|Experimental|Phase I (DVd, venetoclax)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, dexamethasone PO on days 1, 8, and 15 of cycles 1-8, and venetoclax PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10215668|NCT03701321|Experimental|Phase II Arm D (DVd, venetoclax)|Patients receive venetoclax PO QD on days 1-21, daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9961543|NCT01208506|Experimental|Dose level 8|
9961544|NCT01208519||Case Control Study 1|To define the impact of antibiotics on new acquisition of MRSA and ESBL-producing gram negative bacteria, a matched case-control study will be done (ratio 1:4). The control group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the corresponding case, with negative cultures at hospital admission. Matching criteria will include: age (±5 years), sex, and total length of hospitalization.
9961545|NCT01208519||Case control study 2|To define individual level of risk related to specific antibiotics, patients acquiring MRSA and ESBL-producing gram negative bacteria will be compared with patients not acquiring antibiotic-resistant strains after starting antibiotic therapy (ratio 1:4). Previously known risk factors or clinically relevant significant variables from the univariate analysis will be considered for inclusion in multivariate logistic regression analysis.
10215669|NCT03701321|Active Comparator|Phase II Arm E (DVd)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10215670|NCT03701256|Experimental|TAP Group|Bilateral ultrasound TAP bloc performed via 20 ml of 2.5% bupivacaine without neuromuscular blocking agents
10215671|NCT03701256|Active Comparator|TRAC Group|Neuromuscular blocking agent: Atracurium 0.1 mg/kg per bolus
10215672|NCT03701243|Experimental|mNT-BBAVF|These patients will receive a modified non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) at elbow for hemodialysis acess.
10215673|NCT03701243|Active Comparator|RCAVF|These patients will receive a radiocephalic arteriovenous fistula (RCAVF) at wrist for hemodialysis acess.
10215674|NCT03701217|Experimental|Eltrombopag treatment|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
10215675|NCT03701217|Active Comparator|Eltrombopag free|Eltrombopag treatment is not performed in this group. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
9961546|NCT01208558|Active Comparator|Diet A and physiotherapy|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people, i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid junk food and juice. In order to match carbohydrate intake between the arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end."
9961547|NCT01208558|Active Comparator|Diet B and physiotherapy|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A.~Other Name: Whole grains Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.~Other Name: Exercise"
9961548|NCT01208558|Active Comparator|Diet A only|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Other Name: No grains"
9961549|NCT01208558|Active Comparator|Diet B only|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.~Other Name: Whole grains"
9961550|NCT01208558|No Intervention|Control|Only follow-up. No intervention.
9961551|NCT01208571|Experimental|Lifestyle counseling|
9961552|NCT01208571|No Intervention|Treatment as usual|
9961553|NCT01208584||Chronic posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A, spinal cord injury (SCI) 12-24 months
9961554|NCT01208584||Acute posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A,SCI 2-6 months,
9961555|NCT01208584||Myelomeningocele patients|Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12) ASIA A
9961556|NCT01208584||Volunteers|Volunteers without any neurological deficits
9961557|NCT01208623||2D|2D digital venography images alone
9961558|NCT01208623||3D|3D rotational venography
9961559|NCT01208623||Combine|combined MDCT angiography/venography
9961560|NCT01208636||Sun exposed people|Sun exposure >3 hours daily for at least 5 days weekly for the last 3 months.
9961561|NCT01208649|Active Comparator|Exenatide|Drug (including placebo)
9961562|NCT01208649|Placebo Comparator|Placebo|
10215676|NCT03701204|Experimental|DynamiCare Rewards|The study will test the feasibility/acceptability and efficacy of DynamiCare Rewards™. DynamiCare Rewards is an iOS/Android app which automates Contingency Management (CM) to help the patient self-monitor and focus attention on his/her behavioral goals (i.e., abstinence) for alcohol or other substance use disorders.
10215677|NCT03701204|No Intervention|Control|Treatment as usual
10215678|NCT03701191|Experimental|Grpup A (Test group)|Inverted periosteal pedicle flap will be carried out
10215679|NCT03701191|Active Comparator|Group B (Control group)|Coronally advanced flap with subepithelial connective tissue graft
9961563|NCT01208675||Mild cognitive impairment|550 patients with mild cognitive impairment or subjective cognitive symptoms at baseline.
9961564|NCT01208675||Healthy elderly subjects|650 elderly subjects, who are cognitively healthy at baseline.
10215680|NCT03701178|Active Comparator|zirconia veneered crowns|we will use zirconia veneered single crowns as a control to evaluate the marginal integrity and fracture and patient satisfaction
10215681|NCT03701178|Experimental|milled BioHpp PEEK|we will use milled BioHPP PEEK single crowns as a intervention to evaluate the marginal integrity and fracture and patient satisfaction
10215682|NCT03701152|Experimental|Negative pressure therapy|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Continuous course
10215683|NCT03701152|Experimental|Investigator|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Splitted course
9961565|NCT01208688|Experimental|FES Therapy|FES Therapy
9961566|NCT01208688|Active Comparator|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
9961567|NCT01208701|Active Comparator|Atorvastatin|
9961568|NCT01208701|Placebo Comparator|Placebo|
10215684|NCT03701139|Experimental|posterior capsulotomy|Primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing during phacoemulsification.
10215685|NCT03701139|Active Comparator|Nd:YAG laser capsulotomy|Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
10215686|NCT03701126|Active Comparator|group A|Transversus Abdominis Plane block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
9961569|NCT01208714|Active Comparator|revascularization|The patients randomized to this treatment will undergo PTA with stenting of the renal artery.
9961570|NCT01208714|Active Comparator|medical therapy|The patients randomized to this treatment will undergo optimal medical therapy
9961571|NCT01208727|No Intervention|Control|22 controls patients without post conditionment
9961572|NCT01208727|Experimental|Intervention|22 posconditioned patients
10006289|NCT01593124|Active Comparator|Imiquimod, 2 doses, vaginally|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
10006290|NCT01593124|Placebo Comparator|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
10215687|NCT03701126|Active Comparator|group B|Caudal block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
10006291|NCT01593124|Active Comparator|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
10006292|NCT01593137|Experimental|Liraglutide + metformin|
10006293|NCT01593137|Active Comparator|glimepiride + metformin|
10006294|NCT01593150|Experimental|Conventional|Conventional treatment Pradaxa prior to DC cardioversion
10006295|NCT01593150|Experimental|TEE|Transesophageal echo prior to DC cardioversion (early DC)
10006296|NCT01593150|Active Comparator|Early versus Late DC cardioversion|Comparing early versus late DC cardioversion. Patients randomized to either early or late DC cardioversion, follow-up time after intervention 12 month.
10006297|NCT01593163|Experimental|EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
10006298|NCT01593163|Other|ST (standard treatment)|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
10006299|NCT01593176||Distal Femur Fracture, LISS Plate|Patients presenting with a distal femur fracture requiring surgical fixation with a Less Invasive Stabilization System (LISS) plate will have placement of RSA beads for analysis.
10215688|NCT03701113|Active Comparator|Milk-based protein matrix (MBPM)|Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
10215689|NCT03701113|Other|CONTROL|Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
10215690|NCT03701100|Active Comparator|Active tDCS|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
10006300|NCT01593189|Experimental|KITS Program|The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
10006301|NCT01593189|No Intervention|Services as usual|Families continued to receive any services that they had been receiving in the community.
10006302|NCT01593267|Active Comparator|Endovascular|Subjects randomized to endovascular coil embolization will be treated by one of two neurosurgeons expert in such treatment. All endovascular coil embolization treatments will be accomplished using accepted techniques.
10215691|NCT03701100|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
10215692|NCT03701087|No Intervention|normal serum vitamin D|normal serum vitamin D
10215693|NCT03701087|Experimental|low serum level of vitamin D|this arm will intake vitamin D 2800 IU daily
10215694|NCT03701087|Placebo Comparator|low serum vitamin D|this arm will intake placebo omega 3
10215695|NCT03701048|Active Comparator|reappoximation of rectus muscle|During Cesarean Section rectus muscle will be reapproximated with interrupted sutures.
10215696|NCT03701048|Active Comparator|no reappoximation of rectus muscle|During Cesarean Section rectus muscle will not be closed.
10215697|NCT03701035|Experimental|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
10215698|NCT03701035|Active Comparator|Non-aerobic Training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
10215699|NCT03701022|Experimental|SHR1210 +Apatinib|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
10215700|NCT03701009|Other|Stone removal (Saline 50ml each time)|After CBD stone removal via lithotripsy, and the cholangiogram showed normal, residual CBD stones were detected by SpyGlass in the first round, if CBD not clean, sterile saline 50ml were intermittently irrigated into the CBD. After that, if bile duct clearance was not achieved, another 50ml saline will be irrigated into CBD again until the clear bile duct determined by SpyGlass.
9961573|NCT01208740|Experimental|Metformin|Metformin pre-treatment and co-administration
9803648|NCT03647085||Group 1 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, persistent atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
9961574|NCT01208740|Placebo Comparator|Placebo|Placebo pre-treatment and co-administration
9961575|NCT01208753|Experimental|Aqueous formulations for formulation selection|50 mg once daily for 3 days of two different aqueous suspensions, with four day wash-out between formulation
9961576|NCT01208753|Experimental|GLPG0555 ascending doses|multiple ascending doses for 13 days, ranging from 100 mg once daily upto a maximum to be determined during escalation (given as once or twice daily)
9961577|NCT01208753|Placebo Comparator|3|once or twice daily for 13 days, matching the scheme of the multiple ascending dose.
9961578|NCT01208766|Active Comparator|R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)|All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
9961579|NCT01208766|Experimental|R1: 1 (2) cycle(s) HDM|All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
9961580|NCT01208766|No Intervention|R2: none|No consolidation, patients will continue to Lenalidomide maintenance.
9961581|NCT01208766|Experimental|R2: 2 cycles of VRD|In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
9961582|NCT01208779||1|Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study
9961583|NCT01208792|Experimental|Disease group|Two hundred patients with PAH will be included: 50 patients with idiopathic PAH (iPAH), 20 with PAH associated with HIV infection, 20 with porto-pulmonary hypertension, 20 with PAH secondary to congenital heart disorders, 40 with SSc, 20 with SLE, 20 with MCTD and 10 with a PAH associated with a Sjögren's syndrome. Two hundred patients without PAH will also be included: 80 patients with SSc and 20 in each of the following groups: HIV infection, porto-pulmonary hypertension, SLE, congenital heart disorders, MCTD and with Sjögren's syndrome.
9961584|NCT01208792|Other|Control group 1|Two hundred healthy blood donors age and sex-matched with patients with PAH, will be included as controls.
9961585|NCT01208792|Other|Control group 2|Twenty patients with proximal chronic thromboembolic pulmonary hypertension (CTPH) will also be included in a control arm of the study.
9961586|NCT01208805||Candidates for dorsal column stimulation|
9961587|NCT01208818|Active Comparator|BD|
10215701|NCT03700983|Experimental|Nutri-PEITC jelly|a single serving of 200 g Nutri-PEITC jelly
10215702|NCT03700957|Experimental|Docosahexaenoic Acid Group|participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days
10215703|NCT03700957|Placebo Comparator|Control Group|participants will recieve placebo
10215704|NCT03700944|Experimental|YOG|The yoga group (YOG) was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week
9961588|NCT01208818|Experimental|C-BD|
9961589|NCT01208818|Experimental|HCO|
9961590|NCT01208818|Active Comparator|Control HD|
9961591|NCT01208831|Experimental|LDE225|
9961592|NCT01208844||Posttraumatic Stress|
10215705|NCT03700944|No Intervention|CON|The control group (CON) had normal life.
10215706|NCT03700931|Experimental|Eating recall condition|Participants receive a questionnaire asking them to write down what they ate the day before at breakfast, between breakfasts and lunch, at lunch, between lunch and dinner, at dinner, and after dinner, reporting for each episode the foods and drinks consumed, place, time of the day and people present (10).
10215707|NCT03700931|Active Comparator|Non-eating recall condition|Participants receive a questionnaire asking them to write down their school, homework (assignment), study, or work-related activities, two at morning, two at afternoon and two at night, of the day before reporting the name of each activity, place, time of the day and people present.
9961593|NCT01208844||Depression|
9961594|NCT01208844||Healthy|
9961595|NCT01208883|Experimental|repetitive per-treatment [18F]FDG-PET for treatment adaptation|
9961596|NCT01208896|Experimental|Rituximab|
9961597|NCT01208948|Active Comparator|Alpha lipoic acid 600 mg|
9961598|NCT01208948|Placebo Comparator|placebo pill|
9961599|NCT01208987|Experimental|Intervention (with Medication History)|these patient visits generated a medication history
9961600|NCT01209013|Experimental|Medlight PDT Balloon|
9961601|NCT01209026|Experimental|FF/GW642444M (200/25mcg)|Inhaled fluticasone furoate (200mcg) /GW642444M (25mcg) combination Days 1- 7; placebo tablet taken orally single dose (po SD) on Day 7.
9961602|NCT01209026|Experimental|FF/GW642444M (800/100 mcg)|Inhaled fluticasone furoate (800mcg) /GW642444M (100mcg) combination Days 1- 7; placebo tablet (po SD) on Day 7.
9961603|NCT01209026|Active Comparator|Moxifloxacin|Inhaled placebo on Days 1-7; moxifloxacin (400mg po SD) on Day 7
9961604|NCT01209026|Placebo Comparator|Placebo|Inhaled placebo on Days 1-7; placebo tablet (po SD) on Day 7.
9961605|NCT01209039|Experimental|Part A, cohort 1 and 2|Part A, Cohorts 1 and 2, will investigate escalating multiple daily doses of GSK1144814 in 19 subjects
9961606|NCT01209039|Experimental|Part A, cohort 3|Cohort 3 will investigate safety, tolerability and PK of a dose of GSK1144814 over a repeat treatment period of 28 days in 18 subjects and a potential drug drug interaction between GSK1144814 and the CYP3A4 sensitive substrate midazolam (in 15 subjects).
10006303|NCT01593267|Active Comparator|Surgical|Subjects randomized to surgical clip occlusion repair will receive treatment from one of two neurosurgeons expert in clip occlusion surgery for ruptured aneurysms.
10006304|NCT01593280|Active Comparator|TAP catheter|Indwelling TAP catheter placed at the end of c-section. It will be dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen OnQ C-block pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The catheters will run at 7cc/hr/side for 50 hrs.
10006305|NCT01593280|Active Comparator|intrathecal morphine|0.3 mg of intrathecal morphine
10006306|NCT01593293|Active Comparator|PemCarbo|Pemetrexed/Carboplatin arm
10006307|NCT01593293|Active Comparator|Pem only|Pemetrexed arm
10006308|NCT01593306|Experimental|cisplatin and paclitaxel with concurrent radiotherapy|weekly cisplatin at 30mg/m2 and paclitaxel at 50mg/m2 are given with concurrent radiotherapy at 2Gy per fraction at 5 fractions per week for 5 weeks followed by either low dose rate (LDR) Intracavitary (I/C) Brachytherapy or supplement Chemoradiotherapy (CRT); if not fit for I/C Brachytherapy
10006309|NCT01593306|Active Comparator|cisplatin with concurrent radiotherapy|weekly cisplatin @ 40mg/m2 is given along with concurrent radiotherapy at 2Gy per fraction with 5 fractions per week for 5 weeks followed by LDR I/C brachytherapy or supplement CRT; if not fit for I/C Brachytherapy
10006310|NCT01593319|Active Comparator|ropivacaine|
10006311|NCT01593319|Placebo Comparator|Natrium chloride|
10006312|NCT01593332|Active Comparator|Rituximab|
10006313|NCT01593332|Active Comparator|Methotrexate|
10006314|NCT01593345|Experimental|Mentor|
10006315|NCT01593345|Active Comparator|Guidebook|
10006316|NCT01593371|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
10006317|NCT01593371|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
10006318|NCT01593397|Experimental|Propofol and Fentanyl administration|Propofol and Fentanyl will be administered to all subjects. All subjects will have blood drawn to determine pharmacokinetic variables. Processed EEG will be used to determine pharmacodynamics. Plasma samples will be used to ascertain adiponectin levels and for DNA sampling for analysis of adiponectin single nucleotide polymorphisms.
10006319|NCT01593410|Experimental|Lenalidomide and dexamethasone|Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
10006320|NCT01593423|Experimental|Homestead Food Production plus small pond aquaculture|
10006321|NCT01593423|Active Comparator|plant-based Homestead Food Production|
10006322|NCT01593423|Sham Comparator|Control|
10006323|NCT01593436|Active Comparator|mindfulness training|mindfulness training for patients with insomnia
10006324|NCT01593436|No Intervention|polysomnography and actigraphy|The intention is to assess the sleep architecture of meditators and non meditators women without menopausal insomnia by polysomnographic , actigraphy, and questionnaires to assess sleep quality and emotional state
10006325|NCT01593449|Active Comparator|American Heart Association|Participants will receive handouts on increasing physical activity derived from the American Heart Association materials on increasing physical activity.
10006326|NCT01593449|Experimental|Dog Walking|The 6-month dog walking intervention involves 5 components to address the individual, interpersonal and community levels of the socio-ecological model: newsletters, pedometers, social networking website, neighborhood dog walks, and invitations to community events.
10006327|NCT01593462|Experimental|Pediatric Small Bowel Crohn's Disease|MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
10006328|NCT01593475|Experimental|Induction chemotherapy followed by CCRT|"In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during RT and CRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy.~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
10006329|NCT01593488|Experimental|Intrathecal liposomal cytarabine|
9961607|NCT01209039|Experimental|Part B|Part B will assess NK1 receptor occupancy following repeated administration of GSK1144814 given once daily until steady state is obtained
9961608|NCT01209052|Experimental|COHORT 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 10mg, to 50mg, and 200mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
9961609|NCT01209052|Experimental|COHORT 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 25mg, to 100mg, and 400mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
9961610|NCT01209052|Experimental|COHORT 3|Placebo controlled, 14-day, once daily, repeat-dose evaluation with one selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohorts 1 and 2.
9961611|NCT01209052|Experimental|COHORT 4|Placebo controlled, 14-day, once daily, repeat-dose evaluation with a higher selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohort 3.
9961612|NCT01209065|Experimental|Part A|Approximately 12 subjects will be enrolled. In the first treatment period, all subjects will receive GSK1349572 50 mg every 24 hours for 5 days. In Period 2, subjects will receive GSK1349572 50 mg every 24 hours in combination with fosamprenavir 700 mg plus ritonavir 100 mg every 12 hours for 10 days. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
9961613|NCT01209065|Experimental|Part B|Approximately 15 subjects will be enrolled and receive three single doses of GSK1349572 approximately one week apart. One will be the current tablet formulation containing micronized drug substance and 2 will be new tablet versions, one containing unmicronized drug substance and one containing an intermediate particle size drug substance. Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
9961614|NCT01209091||No treatment|
9961615|NCT01209104|Experimental|Cohort 1-PK and and safety of GSK1325756 in subjects 40-64y|This arm assesses the pharmacokinetics and safety of a single oral ose of 100mg of GSK1325756 administered to subjects in the age range 40y-64y when administered in the fasted state, in the presence of a high-fat meal and in the presence of a proton-pump inhibitor.
9961616|NCT01209104|Experimental|Cohort 2- PK and safety of GSK1325756 in subjects aged 65y-80y|This arm assesses the pharmacokinetics and safety of a single dose of 100mg of GSK1325756 administered to a group of subjects in the 64y-80y age range in the fasted state
9961617|NCT01209117|Experimental|Periods 1 - 4|Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences.
9961618|NCT01209117|Experimental|Period 5|Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal).
9961619|NCT01209130|Experimental|A|
9961620|NCT01209130|Experimental|B|
9803649|NCT03647085||Group 2 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, paroxysmal atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
9961621|NCT01209156|Experimental|Assess [18F] PBR111 and PET imaging|Evaluation of PET imaging with [18F]PBR111 in HV and AD subjects (Proof of Mechanism)
9961622|NCT01209182|Experimental|Device image reading|Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.
9961623|NCT01209208|Experimental|A|Budesonide
9961624|NCT01209208|Experimental|B|Mesalazine
9961625|NCT01209208|Placebo Comparator|C|
9961626|NCT01209221|Experimental|1|
9961627|NCT01209221|Experimental|2|
9961628|NCT01209221|Placebo Comparator|3|
9961629|NCT01209221|Placebo Comparator|4|
9961630|NCT01209247|Active Comparator|patient treated by fluoroquinolone|patient treated by fluoroquinolone. Nasal, rectal and pharyngeal swabs
9961631|NCT01209247|Placebo Comparator|patient not receiving FQ treatment|reference group of patients not receiving FQ treatment, but hospitalized in the same wards at the same time
9961632|NCT01209273||APD group|which can be 3 to 5 exchanges daily, and up to 20 liters daily( including up to two daytime exchanges)
9961633|NCT01209273||CAPD group|which can be 1 to 4 exchanges daily and up to 16 liters daily(including up to two daytime exchanges)
10215708|NCT03700905|Experimental|Neoadjuvant/adjuvant Nivolumab and Ipilimumab|"Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery~Surgical resection of primary tumor including neck dissection according to standard of care~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only), start within 6 weeks post-surgery~Arm Ia:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months~Arm Ib:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months"
10215709|NCT03700905|Active Comparator|Surgical resection + adjuvant radio(-chemo)therapy|"Surgical resection of primary tumor including neck dissection according to standard of care~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (40mg/m2) in high risk patients), start within 6 weeks post-surgery~Standard follow-up"
9961634|NCT01209312|Experimental|full bolus -20|Will administer full insulin bolus 20 minutes prior to meal
9961635|NCT01209312|Experimental|Full bolus, T0|Will administer full meal bolus at the start of the meal
9961636|NCT01209312|Experimental|1/2 bolus, T-20|Will only give half the insulin dose 20 minutes before meal
9961637|NCT01209312|Experimental|1/2 bolus T0|Will give half the amount of insulin at the time of the meal
9961638|NCT01209338|Active Comparator|sensitized group|One arm will be a sensitized group which would have received cancer health awareness sessions and / or screening earlier at least once in the past.
9961639|NCT01209338|No Intervention|non-sensitized group|The second arm will belong to an area which has never been exposed to any form of cancer awareness or screening activities thus this group is a completely non-sensitized group.
9961640|NCT01209351|Placebo Comparator|Placebo|Placebo
9961641|NCT01209351|Experimental|teduglutide|
9961642|NCT01209364|Experimental|Durolane|intraarticular hyaluronic acid
9961643|NCT01209364|Active Comparator|methylprednisolone|intraarticular injection
9961644|NCT01209377|Experimental|standard|EMDR treatment with bilateral stimulation via eye movement
9961645|NCT01209377|Experimental|fixed|EMDR treatment with eyes fixed
9961646|NCT01209377|Experimental|no focus|trauma exposition without external stimulus
9961647|NCT01209390||Osteochondral lesions|Patients with osteochondral lesions in the knee, the ankle, or other joint
9961648|NCT01209403|No Intervention|No treatment|
9961649|NCT01209403|Active Comparator|Glukose-infusion|Glucose-infusion during hemodialysis
9961650|NCT01209403|Active Comparator|Glucose-insulin infusion|Glucose-insulin infusion during hemodialysis
9961651|NCT01209416|Active Comparator|Ghrelin / Acipimox|Ghrelin infusion and tablet acipimox
9961652|NCT01209416|Active Comparator|Ghrelin / placebo|Ghrelin infusion and placebo tablets
9961653|NCT01209416|Active Comparator|Placebo / Acipimox|saline infusion and tablet Acipimox
9961654|NCT01209416|Placebo Comparator|Placebo / placebo|saline infusion and placebo tablets
9961655|NCT01209429|Experimental|42 hour fast/GH infusion|
9961656|NCT01209429|Experimental|42 hour fast/Placebo infusion|
9961657|NCT01209429|Experimental|12 hour fast/GH infusion|
9961658|NCT01209429|Placebo Comparator|12 hour fast/Placebo infusion|
9961659|NCT01209455|No Intervention|Saline|Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.
9961660|NCT01209455|Active Comparator|Histamine antagonists|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.
9961661|NCT01209455|Active Comparator|Low dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
9961662|NCT01209455|Active Comparator|High dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
10006330|NCT01593501|Active Comparator|High dose vitamin D|50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
9803650|NCT03647085||Group 3 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, atrial flutter at the time of enrollment and are scheduled for an ablation or cardioversion.
9961663|NCT01209468|Active Comparator|oral appliance 2|Patients in treatment arm/group B will have a customized twinblock OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized monobloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the monobloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
9961664|NCT01209468|Experimental|oral appliance 1|Patients in treatment arm/group A will have a customized monobloc OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized twin-bloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the twin-bloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
9961665|NCT01209481|Experimental|Nutritional education|
9961666|NCT01209481|No Intervention|control|
9961667|NCT01209494||Invasive EP Study Group|200 patients are studied before clinically indicated (according to AHA/ACC/ESC guidelines) first ICD implantation or ICD exchange. Invasive EP study is performed to test inducibility of malignant arrhythmia. In addition MAP recordings are performed for measurements of restitution properties. Pacing is done for 12-lead ECG and MAP recordings for analysis of BVR and TWA, if applicable.
9961668|NCT01209494||Noninvasive EP Study Group|"The assignment of patients to the invasive and noninvasive EP groups does not occur by randomization or for intervention.~In the noninvasive EP study group, 500 patients with chronically implanted ICD (>3 month after implantation) are investigated using non-invasive EP study via ICD programmer. Programmed electrical stimulation is performed to test for inducibility of malignant arrhythmia. In addition pacing is done for measurements of BVR from the 12-lead ECG."
9961669|NCT01209507||Chemotherapy every 3 weeks|One treatment of chemotherapy every 3 weeks. Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV. The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
9961670|NCT01209507||Weekly chemotherapy|Chemotherapy will be given three times in a three week cycle. Chemotherapy will be given either Day 1, 8, and day 15 or Day 1,2 and day 8). Chemotherapy will either be 2 doses of 20 mg PO (12 hrs priors and immediately before treatment) or 1 dose via IV. The total dose per cycle will be 20-40 mg approximately for 18 weeks.
9961671|NCT01209546|Active Comparator|Flutter group|In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
9961672|NCT01209546|Active Comparator|PEP group|In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
9961673|NCT01209546|Placebo Comparator|control group|In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
9961674|NCT01209546|Sham Comparator|Group Sham|Exercise with Flutter®VRP1 without the ball inside
10215710|NCT03700866|Experimental|(Functional splinting time)|"Teeth with crown root fracture will be surgically extruded and splinted then the Periotest values will determine when the splint should be removed which will indicate the functional periodontal healing and as well the functional splinting time.~The Periotest readings will be repeated with one week time interval between each series When the Periotest values of the traumatized tooth reach or even approximate the values of the corresponding normal tooth the splint will be removed."
9961675|NCT01209559||air-Q Intubating Laryngeal Airway|
9961676|NCT01209559||LMA FastrachTM or ILMA|
10215711|NCT03700866|Active Comparator|(IADT splinting time)|Teeth with crown root fracture in this group will be surgically extruded and splinted for two weeks according to the international association of dental traumatology (IADT) splinting time two ,weeks splinting, regardless the Periotest score.
9961677|NCT01209572|Experimental|calorimetric chamber|
9961678|NCT01209572|Experimental|Free living conditions|
9961679|NCT01209585||Rheumatoid Arthritis|Subject must have RA with inflamed joint
10215712|NCT03700840|Other|Clinical examination and sample|"Cross-sectional observational study~Measure of 6 indices:~Bleeding on Intergental Brush Index (BOIB)~Gingivitis Score (GI)~Plaque index score (PI)~ICDAS~Salivary test~Individual caries risk assessment~Determination of interdental brushes adapted to each interdental site~Recovery of the interdental brush passed through the 4 sites (between 15-16, 25-26, 35-36, 45-46) on which the interdental biofilm was fixed during the passage in the interdental space.~The interdental brush is immediately put in a sterile tube and then sent in dry ice to maintain the integrity of the genetic material.~Quantitative PCR experiments will be performed and a qualitative and quantitative analysis of the interdental flora will be made."
10215713|NCT03700827|Experimental|Resistance Training Group|Resistance training will consist of 3 whole body circuits per week for 3 weeks lasting approximately 1 hour per session. All major muscle groups will be involved (leg press, bent-over-row, bench press, back squat, dumbbell jump squats, dead-lifts, and weighted abdominal crunches). Each participant will go through each circuit three times with 30 seconds between each exercise and 2 minutes between each set.
9961680|NCT01209585||Osteoarthritis|Subjects must have OA of the knee
9961681|NCT01209585||Pseudo gout|Subjects must have peusdo-gout of knee
9961682|NCT01209611|Experimental|Autologous bone marrow mononuclear cells|Patients received autologous MNC transplantation. Bone marrow aspirates are harvested from the anterior iliac crest of the patients under general or local anesthesia. MNCs are isolated by density gradient centrifugation. The cell suspension was adjusted to a final volume of 6-20 ml with saline. The cell suspension was injected into expanded skin intradermally via a 27-gauge needle (approximately 0.5-1×10^6 cells/cm2).
9961683|NCT01209611|Placebo Comparator|Saline|Patient has intradermally and subcutaneously injection of saline.
9961684|NCT01209637|No Intervention|control|standard care of coronary artery diseases incl. recommended home based exercise 3x/week
9961685|NCT01209637|Active Comparator|Exercise training|exercise training for 4 weeks at 70% of ischemia free individual threshold within a rehabilitation care center
9961686|NCT01209637|Active Comparator|intensive exercise training|intensive exercise training incl. interval training
10215714|NCT03700827|Experimental|Aerobic Training Group|Aerobic interval training will consist of 3 sessions/week for 3 weeks for approximately 45-50 minutes per session depending on exercise energy expenditure. There will be two periods of intervals. The first period will be 3 minutes of high-intensity activity and the second period will be reduced to moderate-intensity for 2 minutes. The speed/incline will change depending on the participants perception or Borg's rating of perceived exertion. Intensity will be measured using Lactate levels after each session.
10215715|NCT03700827|No Intervention|Control Group|The control group must attend sessions but will not exercise.
9961687|NCT01209663|Active Comparator|Ward Care|Protocol based discharge to the surgery ward. Observation and treatment is conducted by ward nurses and general surgeons (current treatment).
9961688|NCT01209663|Experimental|Intermediate Care|Observation and treatment in an intermediate care bed in a minimum of 48 hours after randomization. Daily rounds will be carried out by both general surgeons and intensive care physicians.
10215716|NCT03700814|Experimental|Antibiotics group|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.
9961689|NCT01209676|Experimental|IMCgp100|IMCgp100 will be injected cutaneously or subcutaneously into the metastasis, and peritumoral area if applicable
9961690|NCT01209715|Placebo Comparator|Matching Placebo|Participants will be treated with placebo twice a day for 3 weeks.
9961691|NCT01209715|Active Comparator|Fluticasone/salmeterol|Participants will be assigned to inhaled fluticasone/salmeterol twice a day for 3 weeks.
10215717|NCT03700814|No Intervention|No antibiotics group|Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.
10215718|NCT03700801|Experimental|Triple combination therapy group|triple combination therapy group: Triple oral hypoglycemic therapy based on metformin 0.5mg twice a day, dapagliflozin 10mg per day plus saxagliptin 5mg per day.
9961692|NCT01209728|Experimental|Primary insomnia patients and healthy subjects|Elderly participants, including primary insomnia patients and healthy subjects
9961693|NCT01209741|Active Comparator|1|MK-0974 12MoRT
9961694|NCT01209741|Active Comparator|2|MK-0974 5Mo5C
9961695|NCT01209741|Active Comparator|3|MK-0974 12Mo5C
9961696|NCT01209754||Pregnant Women|Pregnant women exposed to an HIV prevention study agent during pregnancy
9961697|NCT01209754||Infant|Infants resulting from pregnancies where there exists maternal HIV prevention agent exposure
9961698|NCT01209793|Experimental|Dose 1|(3:1, active: placebo)
9961699|NCT01209793|Experimental|Dose 2|(3:1, active: placebo)
9961700|NCT01209793|Experimental|Dose 3|(3:1, active: placebo)
9961701|NCT01209793|Experimental|Dose 4|(3:1, active: placebo)
9961702|NCT01209793|Experimental|Dose 5|(3:1, active: placebo)
9961703|NCT01209806|Active Comparator|simethicone|
9961704|NCT01209806|No Intervention|no simethicone|
9961705|NCT01209845|Experimental|Ketamine|Patients were administered a single sub-anaesthetic i.v. bolus of ketamine (0.2 mg/kg over 1-2 min) in the ED, with continuous monitoring of vital signs, adverse events and psychotomimetic side-effects for 4 h post-administration.
9961706|NCT01209858|Experimental|Experimental 1|
9961707|NCT01209858|Experimental|Experimental 2|
9961708|NCT01209871|Experimental|Treatment (vaccine therapy)|Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.
9961709|NCT01209884||Healthy Elderly sub-group|Healthy males between the age of 80-85 years old who have not experienced chronic disease during their lifetime.
9961710|NCT01209897|Active Comparator|Stage of Change|
9961711|NCT01209897|Experimental|Common Sense Model|
9961712|NCT01209897|Active Comparator|Action Model|
10215719|NCT03700801|Active Comparator|Premixed insulin therapy group|premixed insulin therapy group: The initial total dose is 0.3U-0.5U/Kg, twice a day, subcutaneous injection before breakfast and dinner, adjusted according to the blood glucose level detected by the blood glucose meter
10215720|NCT03700788|Experimental|Clorhexidine|2% Chlorhexidine
10215721|NCT03700788|Active Comparator|Calcium Hydroxide|Calcium Hydroxide
10215722|NCT03700775|Experimental|Telemonitoring intervention|
10215723|NCT03700762||pathologically results|finally proved by pathologically results
10215724|NCT03700762||evaluate by ultrasound gray-scale ratio|the results confirmed by the cut-off value of ultrasound gray-scale ratio
10215725|NCT03700749|Active Comparator|2%chlorhexidine + non-coated suture|2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.
10215726|NCT03700749|Active Comparator|2%chlorhexidine + coated suture|2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.
10215727|NCT03700749|Active Comparator|10% povidone-iodine + non-coated suture|10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.
10215728|NCT03700749|Active Comparator|10%povidone-iodine + coated suture|10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.
10215729|NCT03700723|Experimental|Resusix|The experimental drug (Resusix) will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
9961713|NCT01209910|Experimental|free water|The subjects in this arm will be able to drink water followings study rules.
9961714|NCT01209910|No Intervention|Control|These subjects will be observed during the study.
9961715|NCT01209936|Experimental|deuterium oxide and BC3|Testing of total body water on the BC3 compared to total body water measured by deuterium oxide.
9961716|NCT01209962||Cohort|"The majority of recruited patients will be treated on protocol HUM00004531 A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer."
9961717|NCT01209975||untreated glaucoma patients|We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.
9961718|NCT01209988|Experimental|Tamsulosin 0.4mg|Perioperative tamsulosin 0.4mg daily
9961719|NCT01209988|Placebo Comparator|Control|No medication
9961720|NCT01210014|Placebo Comparator|A|Patients with Recurrent aphthous stomatitis
9961721|NCT01210014|Active Comparator|B|Patients with Recurrent aphthous stomatitis
9961722|NCT01210040|Active Comparator|Folic Acid|2.8mg of Folic Acid given weekly
9961723|NCT01210040|Experimental|Folic Acid and Iron|2.8mg Folic Acid and 60mg Iron given weekly
9961724|NCT01210053|Experimental|Single arm|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
9961725|NCT01210066|Active Comparator|Pain Challenge|Cold pressor test
9961726|NCT01210066|Active Comparator|Pain + Opioid Challenge|IV fentanyl 1mcg/kg followed by cold pressor test
9961727|NCT01210066|Active Comparator|Opioid Challenge|Administration of fentanyl 1mcg/kg of subject weight
9961728|NCT01210092||Macintosh #3 Laryngoscope|
9961729|NCT01210092||Glidescope|
9961730|NCT01210092||Ambu Pentax AWS|
9961731|NCT01210092||McGrath|
9961732|NCT01210092||Airtraq|
9961733|NCT01210092||Storz C-MAC|
9961734|NCT01210105||Macintosh #3 Laryngoscope|
9961735|NCT01210105||Glidescope|
9961736|NCT01210105||Ambu Pentax AWS|
9961737|NCT01210105||McGrath|
10215730|NCT03700723|Active Comparator|FP24 (Frozen Plasma)|The active comparator FP24 will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
10215731|NCT03700710|Active Comparator|Self-Guided Approach|"In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry."
9961738|NCT01210105||Airtraq|
9961739|NCT01210105||Storz C-MAC|
9961740|NCT01210131|Experimental|[18F]HX4|
10215732|NCT03700710|Experimental|Dietitian-led Approach|"In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.~The web platform will be used to share participant dietary and weight data with dietitians."
10215733|NCT03700697|Experimental|Family Stress Module Intervention|Primary care clinicians will use the CHADIS Family Stress Module including the reviewing ACE, Positive Childhood Experiences, and FASS Plus questionnaires at designated child ages; address family stressors revealed using the motivational interviewing teleprompter and refer parents with stressors as indicated using the care coordination functionality.
10215734|NCT03700697|No Intervention|Controls|Control primary care providers will provide care as usual.
9961741|NCT01210157||I Ischemic CMP|Patients with impaired ventricular function caused by coronary artery disease.
9961742|NCT01210157||II CMP|Patients with impaired ventricular function which is not caused by coronary artery disease. Subgroups based on etiology (familial cardiomyopathy, toxic cardiomyopathy, etc.)
9961743|NCT01210196||mild affected Fabry patients|
9961744|NCT01210235|Experimental|FLU-FIT Arm|In this arm, eligible patients aged 50-75 will be offered a FIT kit
9961745|NCT01210235|No Intervention|FLU-Only Arm|In this arm, patients will receive flu shots as usual, without the FLU-FIT intervention.
9961746|NCT01210261|Active Comparator|Autoset S8|Single night auto-titrating CPAP treatment using the reference device (Resmed Autoset S8) with polysomnographic monitoring
9961747|NCT01210261|Experimental|Somnilink SPAP|Single night auto-titrating CPAP treatment using the test device with polysomnographic monitoring
9961748|NCT01210287|No Intervention|Observation|Observation of the HBV reactivation in HBsAg negative/HBcAg positive patients receiving RCHOP without prophylactic anti-HBV treatment.
9961749|NCT01210313||no treatment|
9961750|NCT01210326|Experimental|aspiration|90 patients with non-obstructive azoospermi undergo testicular sperm aspiration
9961751|NCT01210326|Experimental|extraction|90 patients with non-obstructive azoospermi undergo testicular sperm extraction
9961752|NCT01210339|Experimental|1|Treatment A (Clopidogrel 9 days), at least 14 days wash-out, Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days)
9961753|NCT01210339|Experimental|2|Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days), at least 14 days wash-out, Treatment A (Clopidogrel 9 days)
9961754|NCT01210378|Experimental|Nitroglycerin|
9961755|NCT01210391|Experimental|New hydrolyzed infant formula|New, extensively hydrolyzed infant formula
9961756|NCT01210391|Active Comparator|Commercially available infant formula|Commercially available, extensively hydrolyzed infant formula.
9961757|NCT01210404|Experimental|1.0|
9961758|NCT01210417||Trauma victims|All prehospital traumatic patients enrolled by our Helicopter Emergency Medical System (HEMS)
10215735|NCT03700684|Experimental|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
10215736|NCT03700684|Experimental|SpeechVive|Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
10215737|NCT03700684|Active Comparator|Control|Persons with Parkinsons disease do not receive voice intervention
10215738|NCT03700645|No Intervention|PCI and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and receive standard medical treatment according to practice guidelines.
9961759|NCT01210430|Active Comparator|Losartan|
9961760|NCT01210430|Active Comparator|Ascorbic Acid (VItamin C)|
9961761|NCT01210430|Placebo Comparator|Normal Saline|
9961762|NCT01210456|Active Comparator|Physiological Saline and N-Acetylcysteine|
9961763|NCT01210456|Active Comparator|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|
9961764|NCT01210469|Experimental|Strengthening Group|Performed balance training with lower limbs muscle strengthening.
9961765|NCT01210469|Experimental|Stretching Group|Performed balance training with stretching
10215739|NCT03700645|Active Comparator|PCI, standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and in addition to standard medical treatment, receive treatment with allopurinol.
10215740|NCT03700645|No Intervention|CABG and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and receive standard medical treatment according to practice guidelines.
9961766|NCT01210469|No Intervention|Control Group|
10006331|NCT01593501|Active Comparator|Low dose vitamin D|800 IU vitamin D3 every day of an approximate 365-day treatment.
10006332|NCT01593501|Placebo Comparator|Placebo|A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
10006333|NCT01593514|Active Comparator|Group 1 Conjugate-conjugate|Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
10215741|NCT03700645|Active Comparator|CABG standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and in addition to standard medical treatment, receive treatment with allopurinol.
10006334|NCT01593514|Experimental|Group 2 Polysaccharide-conjugate|"Group II will receive one full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.5 mL of MenACWY-PS vaccine will be administered subcutaneously and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
10006335|NCT01593514|Experimental|Group 3 Polysaccharide (subcutaneously)-conjugate|Group III will receive a full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine subcutaneously, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
10006336|NCT01593514|Experimental|Group 4: 1/5th dose Polysaccharide:conjugate|"Group IV will receive one fifth dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.1 mL of MenACWY-PS vaccine will be administered IM and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
10006337|NCT01593527|Experimental|Arm 1|Canakinumab 150 mg s.c.
10006338|NCT01593527|Experimental|Arm 2|Triamcinelone acetonide 40 mg i.m.
10006339|NCT01593540|Experimental|metal-free interdental brushes.|
10006340|NCT01593540|Active Comparator|metal-core interdental brushes|
10006341|NCT01593553|Experimental|ECG screening|Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
10215742|NCT03700632|Experimental|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week.
10215743|NCT03700632|No Intervention|Control|no intervention will be done
10215744|NCT03700593||Single Port Robotic Colorectal Surgery Patients|All patients who undergo a single port robot colorectal surgery.
10006342|NCT01593553|No Intervention|Control group|Standard of care
10006343|NCT01593566|Active Comparator|0.25% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
10006344|NCT01593566|Active Comparator|0.5% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
10006345|NCT01593579||Patients with Melanoma|Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
10006346|NCT01593605|Active Comparator|Dietary Supplement/insulin sensitivity|The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
10006347|NCT01593605|Placebo Comparator|Sugar Pill|Neutral treatment Placebo - one tablet taken twice a day by mouth
10006348|NCT01593605|Active Comparator|Dietary Supplement 2|2nd study supplement contains resveratrol and HMB which may stimulate protein building.
10006349|NCT01593618|Experimental|Web-Based Intervention|UMFollowUp - web-based internet resource for information about their diagnostic histories, recommendations for follow-up care, and tips to enhance their treatment, psychosocial and physical well-being.
10006350|NCT01593618|Active Comparator|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
10006351|NCT01593631|Active Comparator|2 billion lyoph. yoghurt bacteria|
10006352|NCT01593631|Active Comparator|3300 FCC acid lactase|
10006353|NCT01593631|Active Comparator|9000 FCC acid lactase|
10006354|NCT01593631|Active Comparator|Combination of Substances of arm 1 and 2|
9961767|NCT01210482||Temsirolimus|Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)
9961768|NCT01210521|No Intervention|Prior to intervention with Vitamin D|Patients will be analyzed for clinical, serological and immunological parameters before starting the interventional drug, Vitamin D.
9961769|NCT01210521|Active Comparator|Vitamin D Intervention|Patients will be analyzed for clinical, serological and immunological parameters after one month taking Vitamin D.
9961770|NCT01210573||Device adjustment|Advanced or suspected advanced heart failure. Most are anticipated to have severely depressed ejection fraction (<30% and typically <20%), but patients with preserved ejection fraction and either hypertrophy or restrictive cardiomyopathy will also be eligible. Patients pulmonary hypertension, on any therapy (other than diuretics alone), are also felt to be at high risk of developing right heart failure and may also be included. Patients who have already undergone LVAD or cardiac transplant are also considered to have advanced heart failure and are eligible to participate, regardless of the severity of their symptoms at the time of enrollment.
9961771|NCT01210586|Active Comparator|Nicotine Patch|Nicotine Patch for Smoking Cessation
9961772|NCT01210586|Placebo Comparator|Placebo Patch|
9961773|NCT01210599|Experimental|IV infusion of pamidronate vs placebo|
9961774|NCT01210612|Active Comparator|Without Unilateral CAI|
9961775|NCT01210612|Active Comparator|With Unilateral CAI|
9961776|NCT01210638|Active Comparator|Oxymorphone Hydrochloride|Tablet
9961777|NCT01210638|Active Comparator|Opana|Tablet
9961778|NCT01210677|Active Comparator|Prednisone|Prednisone 0.5 mg/Kg per day orally for 3 months
9961779|NCT01210677|Placebo Comparator|Placebo|Matching placebo tablets(s) taken orally per day
9961780|NCT01210742|Experimental|Viscosupplementation with routine management|
9961781|NCT01210742|Active Comparator|Routine management|Routine management for knee OA (NICE guidelines)
9961782|NCT01210755|Experimental|Rivaroxaban then Dabigatran|Cross-over study with 15 days between administration of Rivaroxaban and Dabigatran
9961783|NCT01210755|Experimental|Dabigatran then Rivaroxaban|Cross-over study with 15 days between administration of Dabigatran and Rivaroxaban
9961784|NCT01210833|Active Comparator|Healthy participants|Healthy participants aged from 18 to 60 with no history of hand injuries recruited by convenience sampling.
9961785|NCT01210833|Experimental|Hand Injured participants|Participants with hand injuries aged from 18 to 60 recruited from the outpatients attending the occupational therapy clinic.
9961786|NCT01210846|Experimental|tivozanib|
9961787|NCT01210859||Ureteral stents Detrusitol treatment Lyfestyle outcome|Ureteral stents Detrusitol treatment Lyfestyle outcome
9961788|NCT01210885|Experimental|Group I: Investigational MenABCWY Formulation 1|
9961789|NCT01210885|Experimental|Group II: Investigational MenABCWY Formulation 2|
9961790|NCT01210885|Experimental|Group III: Investigational MenABCWY Formulation 3|
9961791|NCT01210885|Experimental|Group IV: Investigational MenABCWY Formulation 4|
9961792|NCT01210885|Active Comparator|Group V: Active comparator investigational MenB|
9961793|NCT01210885|Active Comparator|Group VI: Active comparator MenACWY|
9961794|NCT01210898|Experimental|Group 1|
9961795|NCT01210898|Experimental|Group 2|
9961796|NCT01210898|Experimental|Group 3|
9961797|NCT01210898|Experimental|Group 4|
9961798|NCT01210898|Experimental|Group 5|
9961799|NCT01210898|Experimental|Group 6|
9961800|NCT01210898|Experimental|Group 7|
9961801|NCT01210898|Experimental|Group 8|
9961802|NCT01210898|Experimental|Group 9|
9961803|NCT01210898|Experimental|Group 10|
9961804|NCT01210898|Experimental|Group 11|
9961805|NCT01210898|Experimental|Group 12|
9961806|NCT01210898|Experimental|Group 13|
9961807|NCT01210911|Experimental|Gemcitabine, erlotinib and metformin|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
9961808|NCT01210911|Placebo Comparator|Gemcitabine, erlotinib and placebo|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. PLacebo will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
9961809|NCT01210924||Pediatric ART patients|
9961810|NCT01210937|Experimental|CEA and TCD monitoring|CEA involves a neck incision and physical removal of the plaque from the inside of the artery.During the surgery, the patient will be monitored by TCD.
9961811|NCT01210950|Experimental|cell and RPR recepients|mesenchymal cells and plasma reach protein are injected to the callus center of short limb
9961812|NCT01210963||SENSIMED Triggerfish|
9961813|NCT01210976|Experimental|levosimendan|
9961814|NCT01210976|Placebo Comparator|placebo|
9961815|NCT01210989|Active Comparator|Hepaguard|
9961816|NCT01210989|Placebo Comparator|Placebo|
9961817|NCT01211002|Active Comparator|radiotherapy combined with EP|the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
9961818|NCT01211002|Experimental|adiotherapy / EP /recombinant human endostatin|recombinant human endostatin: The number of courses is 3 ~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.
9961819|NCT01211015||Control group|healthy control group
9961820|NCT01211015||Disease group|asthma, COPD, ILD, lung malignancy
9961821|NCT01211028|Other|Autologous ASCs|Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.
9961822|NCT01211067||Patients age: 15 - 40 years-old|Patients within the 15 to 40 years-old age-group
9961823|NCT01211067||Patients age: 41 to 60 years-old|Patients within the group-age from 41 to 60 years-old
9961824|NCT01211067||Patients age: older than 61 years-old|Patients within the group-age from 61 years-old and older
9961825|NCT01211080||Threatening hemangioma|The group with cosmetically threatening of functionally threatening hemangiomas warranting active treatment according to our usual criteria (location face, hands, feet with a strong growth tendency and below age of 8 months)
9961826|NCT01211093|Experimental|High frequency whole body vibration|This group will receive a single 10-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
9961827|NCT01211093|Active Comparator|low frequency whole body vibration|This group will receive a single 10-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
9961828|NCT01211093|Active Comparator|Control|This group will stand on the same vibration platform for 10 minutes, but no vibration will be given.
9961829|NCT01211119|Experimental|platelet-rich fibrin, PRF|
9961830|NCT01211132|Active Comparator|Cap arm|
9961831|NCT01211132|Active Comparator|Standard arm|
9961832|NCT01211158|Active Comparator|Propofol alone|Patients receiving propofol alone.
9961833|NCT01211158|Active Comparator|Ketofol|0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
9961834|NCT01211171||Group 1|
9961835|NCT01211210|Active Comparator|A: 5Fu with Radiation|Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks.
9961836|NCT01211210|Experimental|B: FOLFOX with radiation|Patients receive FOLFOX for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFOX
9961837|NCT01211210|Experimental|C: FOLFOX alone|Patients receive FOLFOX for 4 cycles
9961838|NCT01211223|Experimental|Scaling and root planning + placebo + antibiotics|"Scaling and root planning + placebo~Scaling and root planning + metronidazole plus amoxicillin~Metronidazole plus amoxicillin + scaling and root planning"
9961839|NCT01211236|Experimental|Maggot Debridement Therapy|
9961840|NCT01211236|Active Comparator|control|
9961841|NCT01211249|Experimental|GLPG0259 (Part A)|
9961842|NCT01211249|Placebo Comparator|Placebo (Part A)|
9961843|NCT01211249|Experimental|GLPG0259 (Part B)|
9961844|NCT01211249|Placebo Comparator|Placebo (Part B)|
9961845|NCT01211275|Experimental|arm 2|axitinib + cisplatin + premetrexed
9961846|NCT01211275|Active Comparator|arm 1|cisplatin + premetrexed
9961847|NCT01211301|Active Comparator|Food-based, Reduced Energy Diet Plan|
9961848|NCT01211301|Experimental|Medifast 5 & 1 Plan|
9961849|NCT01211314|Experimental|lercanidipine-enalapril fixed combination|uncontrolled hypertensive patients will receive fixed combination therapy
9961850|NCT01211327|Experimental|Cyclosporine A|Cyclosporine A (CsA) 2% eye drops
9961851|NCT01211327|Active Comparator|Dexamethasone|Dexamethasone 0,1% eye drops
9961852|NCT01211353|Experimental|Personalized Drinking Feedback|Personalized feedback on drinking behaviors
9961853|NCT01211353|Active Comparator|Education-Only|Educational information about alcohol
10215745|NCT03700580|Active Comparator|Hydrogel treatment|It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
9961854|NCT01211366|Active Comparator|Conventional Transfusion|Infants will receive PRBCs, crystalloid, and colloid for hemodynamic instability per the usual routine at the discretion of the attending intensive care physician
9961855|NCT01211366|Experimental|Cell Saver|Infants will receive washed cell-saver RBCs for hemodynamic instability in the first 24 hours post-operative period as long as Hgb is < 13 gm/dL and cell-saver is available.
9961856|NCT01211379|No Intervention|FLU-Only Arm|In this arm, primary care patients who got flu shots were only provided with FOBT if the doctor decided to order it.
9961857|NCT01211379|Experimental|FLU-FOBT Arm|In this arm, patients who came in for primary care got a flu shot and were assessed by nurses for eligibility for colorectal cancer screening. Eligible patients were provided with home FOBT.
9961858|NCT01211431|Active Comparator|Reference|Intrathécale morphine is used for post-cesarean pain control
9961859|NCT01211431|Experimental|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
9961860|NCT01211444|Experimental|HGNS System|
9961861|NCT01211457|Experimental|Sapacitabine/decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
9961862|NCT01211457|Experimental|sapacitabine/venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
9802360|NCT05303792|Experimental|Arm A (inotuzumab ozogamicin, chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive inotuzumab ozogamicin IV and IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients >= 70 years of age receive either 2 or 4 cycles of treatment. Patients < 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
9961863|NCT01211470|Experimental|PMX-30063|3 arms of PMX-300063
9961864|NCT01211470|Active Comparator|Daptomycin.|Daptomycin will be administered according to the approved product monograph information for ABSSSI.
9961865|NCT01211496|Active Comparator|High-speed power training|Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
9961866|NCT01211496|Active Comparator|Slow-speed strength training|Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
9961867|NCT01211496|No Intervention|placebo exercise (control group)|Volunteers randomized into the control group (CON) will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
9961868|NCT01211509|Experimental|montelukast sodium|Daily treatment with 10 mg montelukast after diagnosis of fibroproliferative BOS (fBOS) which is the low neutrophilic phenotype within BOS
9961869|NCT01211509|Placebo Comparator|placebo|Lactose monohydricum Ph.Eur.
9961870|NCT01211548||contrast CTA of the CAP|All patients being considered for a complex aortic surgery and undergoing medically indicated contrast enhanced CT aortic angiography of the chest abdomen and pelvis will be includedRaw data from CT coronary angiography will be available from all patients.
9961871|NCT01211561|Experimental|Selenium, selenomethionine|
9961872|NCT01211561|Active Comparator|placebo|
9961873|NCT01211574|Experimental|peer coach|Participants will be coached by a peer between treatment visits.
9961874|NCT01211574|Experimental|mentor|Participants will be coached by a mentor between treatment visits
9961875|NCT01211574|Experimental|Professional|Participants will be coached by an interventionist between treatment visits
9961876|NCT01211587|Experimental|100mg safinamide|Two 50mg tablets of safinamide once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
9961877|NCT01211587|Placebo Comparator|Placebo|Two 50mg tablets of placebo once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
9961878|NCT01211626|Active Comparator|Part A, Group 1 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)
9961879|NCT01211626|Active Comparator|Part A, Group 2 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)
9961880|NCT01211626|Active Comparator|Part A, Group 3 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)
10006355|NCT01593631|Placebo Comparator|Placebo|
10006356|NCT01593644|Experimental|adenosine + dypiridamole|
10006357|NCT01593657|Experimental|Mindful Movement and Breathing program|Mindful Movement and Breathing program implemented in a hospital room or clinic room three times by a yoga instructor: prior to surgery, one day and two days after surgery.
9961881|NCT01211626|Active Comparator|Part A, Group 4 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)
9961882|NCT01211626|Active Comparator|Part A, Group 5 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)
9961883|NCT01211626|Active Comparator|Part B, Group 6 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)
10215746|NCT03700580|Experimental|P1G10 treatment|It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.
10215747|NCT03700554|Experimental|Pleuralvent™|Patients treated with Pleuralvent™ device
9961884|NCT01211626|Active Comparator|Part B, Group 7 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)
9961885|NCT01211626|Active Comparator|Part B, Group 8 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)
10215748|NCT03700554|Active Comparator|Chest tube|Patients treated with Chest tube
10215749|NCT03700528|Experimental|Intervention|This is a single-cohort ACT based intervention.
10215750|NCT03700515|Placebo Comparator|Placebo|Saline infusion
9961886|NCT01211626|Active Comparator|Part B, Group 9 HCV Infected Patient|multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)
9961887|NCT01211652||1|
9961888|NCT01211691|Experimental|Phase 1 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects with heme malignancies will be assigned to one of 11 planned KB004 (dose levels (20mg, 40mg, 70mg, 100mg, 140mg, 190mg, 250mg, 330mg)"
9961889|NCT01211691|Experimental|Phase 2 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects will be assigned to the recommended Phase 2 dose of 250 mg"
9961890|NCT01211704|Placebo Comparator|Placebo, Counceling|Placebo
9961891|NCT01211704|Experimental|Paliperidone Palmitate|Paliperidone Palmitate
9961892|NCT01211717|Experimental|Branched Chained Amino Acids|
9961893|NCT01211717|Placebo Comparator|Cellulose mix|
9961894|NCT01211743|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
9961895|NCT01211743|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
9961896|NCT01211782|Experimental|AC-1204|
9961897|NCT01211782|Placebo Comparator|Placebo|
9961898|NCT01211795|Active Comparator|Topical Ketoprofen gel|
9961899|NCT01211795|Placebo Comparator|Placebo gel|
9961900|NCT01211808|Experimental|Treatment A (BMS-914832)|
9961901|NCT01211808|Experimental|Treatment B (BMS-914832 + diltiazem)|
9961902|NCT01211821|Other|metoprolol|Treatment A
9961903|NCT01211821|Experimental|BMS-914392 + metoprolol|Treatment B
9961904|NCT01211834|Experimental|Tocilizumab 8mg/kg+DMARDs|
9961905|NCT01211834|Placebo Comparator|Placebo+DMARDs|
9961906|NCT01211847|Experimental|DCCR|DCCR Treatment with 290 mg Diazoxide Choline
9961907|NCT01211847|Placebo Comparator|Placebo|Placebo matching DCCR
9961908|NCT01211860|Experimental|DCCR Treatment|DCCR Treatment 290 mg diazoxide choline
9961909|NCT01211912|Experimental|Arm 1 (20 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.
9961910|NCT01211912|Experimental|Arm 2 (34 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.
9961911|NCT01211925|Experimental|critical ischemia|
9961912|NCT01211925|No Intervention|Control|Best medical treatment
10215751|NCT03700515|Experimental|EPO|Erythropoetin infusion (9 IU/kg)
10215752|NCT03700515|Experimental|EPO II|Erythropoetin infusion (20 IU/kg)
10215753|NCT03700502||patients with painful diabetic neuropathy|
10215754|NCT03700502||diabetics with non-pain neuropathy|
10215755|NCT03700502||gender and age matched healthy controls|
10215756|NCT03700489|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
10215757|NCT03700489|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
10215758|NCT03700476|Experimental|Sintilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
10215759|NCT03700476|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
10215760|NCT03700450|Experimental|Cyclophosphamid post Tranplant|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
10215761|NCT03700424|Experimental|Trehalose|Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks
10215762|NCT03700424|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks
10215763|NCT03700398|Experimental|first OE|
10215764|NCT03700398|Other|First WLI|
9961913|NCT01211938|Active Comparator|single-fraction radiotherapy with concomitant 5FU and Hydrea|six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
9961914|NCT01211938|Experimental|hyperfractionated radiotherapy with concomitant Cetuximab|Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
9961915|NCT01211951|Experimental|KCT-0809 ophthalmic solution, low dose|
9961916|NCT01211951|Experimental|KCT-0809 ophthalmic solution, medium dose|
9961917|NCT01211951|Experimental|KCT-0809 ophthalmic solution, high dose|
9802361|NCT05303792|Active Comparator|Arm B (chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, doxorubicin IV on day 4, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients >= 70 years of age receive either 2 or 4 cycles of treatment. Patients < 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
9802362|NCT05303077|Experimental|Study Infant Formula|Infant formula supplemented with omega 3 fatty acids and inactive Bifidobacteria
9961918|NCT01211951|Placebo Comparator|Placebo|
9961919|NCT01211964|Experimental|LEO 22811 oral solution 1.5 mg (fasted state)|
9961920|NCT01211964|Experimental|LEO 22811 single tablet 1.5 mg (fasted state)|
9961921|NCT01211964|Experimental|LEO 22811 single tablet 1.5 (fed state)|
9961922|NCT01212120||All patients|All patients
9961923|NCT01212133||A|
9961924|NCT01212146|Experimental|Probiotic-enriched Artichokes|Artichokes containing approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme
9961925|NCT01212146|Active Comparator|Ordinary artichokes|Ordinary artichokes (probiotic free) of identical shape, texture, and appearance of probiotic-enriched artichokes
9961926|NCT01212198||Korean type 2 diabetic patients|
9961927|NCT01212198||Koreans at high risk for diabetes|
9802363|NCT05303077|Active Comparator|Infant Formula|Infant formula
9802364|NCT05303077|Active Comparator|Breastfeed Active comparator|Infants who are breastfed
9961928|NCT01212198||Korean gestational diabetic patients|
9802365|NCT05302934||Pheno4U|The study will collect data for each patient receiving an Aesculap TKA implant. The data set will be analyzed for critical risk factors among implant and patient data in order to optimize patient-centered therapies.
9802366|NCT05302375|Experimental|iPath*D|An online platform that connects patients screening positive for clinically significant depression in cancer settings to a range of online and inperson evidence-based treatments, facilitated by an interactive DA.
9802367|NCT05302323|Other|Disposable Drapes|group using disposable surgical drapes
9961929|NCT01212211|Experimental|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
9961930|NCT01212211|No Intervention|reference|drug treatment of ten patients will remain unchanged during the three months of inclusion
9802368|NCT05302323|Other|Reusable Drapes|group using reusable surgical drapes
9802369|NCT05302297||Treatment Group (Cemiplimab)|Patients treated with cemiplimab in monotherapy through the Cohort Temporary Authorization for Use (cATU) or patients included in the Nominative Temporary Authorization for Use( nATU) that evolved into the cATU and meeting the inclusion/exclusion criteria of the study.
9803651|NCT03646175|Experimental|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
10006358|NCT01593683|Experimental|Psychological education program|Patients receive the psychological education program upon study enrollment.
10006359|NCT01593683|No Intervention|Waitlist|Participants are assigned to a 16-week wait-list period upon enrollment. Participants are invited to receive the psychological education program following the waitlist period.
9961931|NCT01212237||fMRI Evaluation|"All patients will undergo the following standard imaging and radiotherapy procedures will be performed for each patient:~Standard MRI for radiotherapy treatment planning which takes about 60 minutes.~Radiotherapy treatment simulation with CT.~Radiotherapy treatment planning~Radiotherapy treatment~Routine follow-up every 3 months after the radiotherapy.~Special Procedures.~The following special imaging and radiotherapy procedures will be performed for each patient:~fMRI (30 minutes)~The 3MS examination, administered every 3 months during routine follow-up for one year after the completion of the radiotherapy."
9961932|NCT01212250|Experimental|Carvedilol|Tablet 6.25 mg BD
9961933|NCT01212250|Placebo Comparator|placebo|Placebo tablets 2 BD
10006360|NCT01593709||Cohort 1|Healthy adults; age 18 or older
10215765|NCT03700359|Experimental|Anlotinib/Lobaplatin/Etoposide|EL regimen for 4 cycles followed by Anlotinib Hydrochloride maintenance therapy
10215766|NCT03700359|Active Comparator|Lobaplatin/Etoposide|EL regimen for 4 cycles
10006361|NCT01593735|Experimental|Panel A: GT1, low dose|Participants with genotype 1 (GT1) Hepatitis C Virus (HCV) will receive low dose MK-2748 daily for 7 days.
10215767|NCT03700346|Other|survivors|survivor at ICU discharge muscle microdialysis
10006362|NCT01593735|Experimental|Panel B: GT1, lower dose|Participants with GT1 HCV will receive lower dose MK-2748 daily for 7 days.
10006363|NCT01593735|Experimental|Panel C: GT1, dose based on Panels A+B|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose) and B (lower dose).
10006364|NCT01593735|Experimental|Panel G: GT1, dose based on Panels A+B+C|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), and C.
10006365|NCT01593735|Experimental|Panel H: GT1, dose based on Panels A+B+C+G|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), C, and G.
10006366|NCT01593735|Experimental|Panel D: GT3, low dose (Omitted)|Participants with genotype 3 (GT3) HCV were to receive low dose MK-2748 daily for 7 days. Panel D was omitted from the study design and participants were not enrolled in this panel.
10215768|NCT03700346|Other|Non survivors|death before ICU discharge muscle microdialysis
10215769|NCT03700333|Experimental|S-1 Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Tegafur,Gimeracil and Oteracil Potassium Capsules (S-1)
10215770|NCT03700333|Active Comparator|Pemetrexed Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Pemetrexed
10006367|NCT01593735|Experimental|Panel E: GT3, high dose|Participants with genotype 3 (GT3) HCV will receive high dose MK-2748 daily for 7 days.
10006368|NCT01593735|Experimental|Panel F: GT3, dose based on Panel E|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panel E (high dose).
10006369|NCT01593735|Experimental|Panel I: GT3, dose based on Panels E+F|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose) and F.
10006370|NCT01593735|Experimental|Panel J: GT3, dose based on Panels E+F+I|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose), F, and I.
10006371|NCT01593761|Experimental|Single Arm for CG400549|All the patients will be administered with CG400549.
10006372|NCT01593774|Experimental|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
10006373|NCT01593774|Placebo Comparator|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
10006374|NCT01593800|Experimental|open label probiotics|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
10215771|NCT03700307|Experimental|pulmonary vein isolation|patients will receive circumferential pulmonary vein isolation using cryoballoon ablation
10215772|NCT03700307|Experimental|pulmonary vein and left atrial roof linear isol|patients will receive circumferential pulmonary vein and left atrial roof linear isolation using cryoballoon ablation
10215773|NCT03700294|Experimental|ADCT-601|
9961934|NCT01212263|Experimental|Clomiphene Citrate plus HP uFSH|Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
9961935|NCT01212263|Active Comparator|Step-up HP uFSH|HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter
9961936|NCT01212276|Experimental|Cohort 1|MORAb-028 0.1 mg/kg intravenous
9961937|NCT01212276|Experimental|Cohort 2|MORAb-028 0.2 mg/kg intravenous
9961938|NCT01212276|Experimental|Cohort 3|MORAb-028 0.5 mg/kg intravenous
9961939|NCT01212276|Experimental|Cohort 4|MORAb-028 1.0 mg/kg intravenous
9961940|NCT01212289||Primary cardiac surgery|Pediatric patients receiving primary cardiac surgery
9961941|NCT01212289||Reoperation|Pediatric patients receiving cardiac surgery reoperation
9961942|NCT01212315|No Intervention|Control group|Ordinary sutures (Vicryl / Monocryl) is used for wound closure
9961943|NCT01212315|Active Comparator|Group A|Triclosan coated sutures (Vicryl Plus / Monocryl Plus) is used for wound closure
9961944|NCT01212328|Experimental|Care coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
9961945|NCT01212328|Active Comparator|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
9961946|NCT01212341|Experimental|Singe-dose infusion|Cohort 1: 1x10^6 cells/kg Cohort 2: 1x10^7 cells/kg
9961947|NCT01212341|Experimental|Repeated dose infusion|Cohort 3: 1x10^6 cells/kg Cohort 4: 3x10^6 cells/kg Cohort 5: 1x10^7 cells/kg Cohort 6: 3x10^7 cells/kg
9961948|NCT01212354|Experimental|A - experimental|7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
9961949|NCT01212354|Active Comparator|B - control|7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
9961950|NCT01212367|Experimental|Dose Level 1|
9961951|NCT01212367|Experimental|Dose Level 2|This is a dose de escalation.
9961952|NCT01212380|Experimental|Arm 1|Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
9961953|NCT01212393||Intervention group|reminders
9961954|NCT01212393||current practice group|no intervention
9961955|NCT01212406|Placebo Comparator|Placebo|Olive oil
9961956|NCT01212406|Experimental|Vitamin D|Addition of D-cure (100.000U) to standard care
9961957|NCT01212497|Experimental|Mindfulness meditation coaching|Assess effectiveness of using a virtual computer coach to train mindfulness meditation
9961958|NCT01212510|Other|Tumor markers|measurement of tumor markers ( blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA )
9961959|NCT01212536|No Intervention|Conventional|conventional laryngoscopy for intubation
9961960|NCT01212536|Experimental|Airtraq|laryngoscopy with Airtraq for intubation
9961961|NCT01212549|Active Comparator|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 weeks imiquimod
9961962|NCT01212549|Active Comparator|Cryoimmunotherapy|Cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 5 weeks imiquimod
9961963|NCT01212562||Immunocryosurgery|2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application
9961964|NCT01212575||300 patients|Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
9961965|NCT01212601||1|
10006375|NCT01593826|Active Comparator|Charcoal and Symbicort Turbuhaler|
9961966|NCT01212653|Active Comparator|Golimumab|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
9961967|NCT01212653|Placebo Comparator|Pacebo-controlled|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either Golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
9961968|NCT01212666|Experimental|Adductor-Canal-Block, Ropivacain|25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
9961969|NCT01212666|Placebo Comparator|Adductor Canal Block, Placebo (saline)|25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
9961970|NCT01212679|Experimental|nerve growth factor|Patients who underwent TBI will be chosen to receive NGF randomly.
9961971|NCT01212679|Placebo Comparator|Control|Patients who underwent TBI will be chosen to receive nomral saline randomly.
9961972|NCT01212692|Experimental|Mentally stimulating activities|
9961973|NCT01212692|Active Comparator|Mentally stimulating activities- other|
9961974|NCT01212705|Experimental|ASV|
9961975|NCT01212718|Active Comparator|5-FU|FUFA 5-flurouracil and folinic acid control
9961976|NCT01212718|Active Comparator|Folfiri|5-fluouracil and folinic acid in combination with irinotecan (Folfiri) systemic chemotherapy intensified treatment arm
9961977|NCT01212731||Cohort 1|Subjects with a histological diagnosis of malignancy of the base of skull necessitating irradiation to a minimum of 60 Gy, ECOG PS 0-1 with no evidence of metastatic disease and an estimate life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
9961978|NCT01212731||Cohort 2|Subjects with a histological diagnosis of low grade glioma requiring radiotherapy. ECOG PS 0-1 with no evidence of metastatic disease and an estimated life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
9961979|NCT01212783|Active Comparator|Present-Centered Therapy|Mothers will receive 15 weekly sessions of PCT plus two monthly booster sessions following the 15th session.
9961980|NCT01212783|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus two booster sessions scheduled monthly following the 15th session.
9961981|NCT01212809|Active Comparator|Juvéderm Ultra|Juvéderm Ultra injection
9961982|NCT01212809|Active Comparator|Cosmoderm 1|Cosmoderm 1 injection
9961983|NCT01212822|Experimental|Treatment (bevacizumab, FOLFOX)|"NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab.~ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity."
9961984|NCT01212835|Sham Comparator|no ring|Patients at this group will have RING REMOVED AT THE END OF SURGERY.
9961985|NCT01212835|Active Comparator|RYGBP-Ring|Open Roux-en-Y gastric bypass with a silastic ring which is performed with linear cut stapler 100 mm and a biliopancreatic limb of 60 cm long and a alimentary limb of 100 cm long. All patients will have a 6.5 cm silastic ring located at the middle of the pouch above of the gastroenteroanastomosis.
9961986|NCT01212848|Experimental|TMS|
9961987|NCT01212848|Sham Comparator|Sham|
9961988|NCT01212861|Experimental|Suprachoroidal Dissection Instrument|
9961989|NCT01212913|Experimental|group 1: Basal plus|Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
9961990|NCT01212913|Active Comparator|group 2: Biphasic insulin|Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).
9961991|NCT01212978|No Intervention|Delayed Intervention|These subjects will neither receive a pedometer or access to the motivational software until completion of the study.
9961992|NCT01212978|Active Comparator|Pedometer only|Participants in the this arm will receive a pedometer with instructions to reach a goal of 10,000 steps/day but will not receive access to the motivational software.
9961993|NCT01212978|Experimental|Pedometer + Motivational Software|In this arm, subjects will receive access to both a pedometer and motivational software
10006376|NCT01593826|Active Comparator|Symbicort Turbuhaler|
10006377|NCT01593826|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
10006378|NCT01593826|Experimental|Budesonide/formoterol Easyhaler|
9961994|NCT01213004|Experimental|thoracic (study group 1) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
9961995|NCT01213004|Experimental|abdominal (study group 2) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
9961996|NCT01213017|Experimental|Certolizumab pegol|
9961997|NCT01213030|Active Comparator|10 mCi HX4|Patient will be injected with [F-18] FMISO
9961998|NCT01213030|Active Comparator|10 mCi FMISO|Patient will be injected with [F-18] HX4
9961999|NCT01213056|Active Comparator|Mindfulness Based Cognitive Therapy * (MBCT)|Mindfulness based cognitive therapy aimed to improve coping with, and managing chronic headache pain.
9962000|NCT01213056|No Intervention|Delayed Treatment Control * (DT)|
9476631|NCT03569969|Experimental|Test group|Step1. After sedation and conducting local anesthesia with Lidocaine 2% and inserting the edges of the tympanic membrane and inserting the foam gel into the middle ear, amniotic membranes (produced in Iran tissue product) with a thickness of 100 microns on the tympanic membrane and the foam gel embedded. Step2. Under-layered and short-lived foam gel (manufactured by Ethicon Company) smeary with dexamethasone was covered.
9962001|NCT01213069||all 5000 subjects|this is a purely descriptive study with one group
9962002|NCT01213095|Experimental|Rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
9962003|NCT01213108|Experimental|Örebro prevention program|
9962004|NCT01213108|Active Comparator|Control|Business as usual
9962005|NCT01213121|Experimental|bipolar depression|unmedicated patients with bipolar depression receiving quetiapine treatment
9476632|NCT03569943|Experimental|Robotol|
9962006|NCT01213121|No Intervention|Control|healthy controls matched for age, gender, and body mass index
9962007|NCT01213147|Experimental|clomiphene citrate,pregnancy,poor responders|Woman in clomiphene citrate arm are administered 100mg/day oral from day 3 of menstrual cycle until day 7 of cycle
9962008|NCT01213147|Active Comparator|buserelin,pregnancy,poor responder|women in control arm are administered Buserelin buserelin 50 µg SC twice a day from cycle day 2 of menstrual cycle
9962009|NCT01213160|Experimental|AZD4547|
9962010|NCT01213186|Experimental|Drug: high dose of MSC treatment|Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
9962011|NCT01213186|Experimental|low dose of MSC treatment|Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
9962012|NCT01213186|Placebo Comparator|low dose of MSC|Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
9962013|NCT01213212|Experimental|Caloric restriction|Caloric restriction
9962014|NCT01213212|Sham Comparator|"Diet ad libitum"|"Diet ad libitum"
9962015|NCT01213238|Experimental|Oxaliplatin + Capecitabine + Bevacizumab|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle. Bevacizumab 10 mg/kg by vein on day 1 of a 21 day cycle.
9962016|NCT01213238|Experimental|Oxaliplatin + Capecitabine|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 -14 of a 21 day cycle.
9962017|NCT01213277|Active Comparator|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
9962018|NCT01213277|Active Comparator|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
9962019|NCT01213290|Active Comparator|EUS-FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
10006379|NCT01593865||BIMA Grafting Group|Group consists of patients who received bilateral internal mammary artery grafting for treatment of severe coronary disease since June 2012.
9962020|NCT01213290|Active Comparator|EUS-FNA without stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
9962021|NCT01213303||Blood donors|Evaluation of cardiovascular risk factors, oxidative stress and fatty acid metabolism in a cohort of blood donors
9962022|NCT01213342|Experimental|Treatment Group|This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.
9962023|NCT01213342|Placebo Comparator|Placebo Group|This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.
9962024|NCT01213355|Experimental|Placebo|placebo, plus scopolamine 0.5 mg
9962025|NCT01213355|Experimental|PF-05212377 5 mg, plus scopolamine 0.5 mg;|
9962026|NCT01213355|Experimental|PF-05212377 20 mg, plus scopolamine 0.5 mg;|
9962027|NCT01213355|Experimental|PF-05212377 60 mg, plus scopolamine 0.5 mg;|
9962028|NCT01213355|Active Comparator|donepezil 10 mg, plus scopolamine 0.5 mg.|
9962029|NCT01213368|Experimental|dronedarone 300 mg|Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
9962030|NCT01213368|Experimental|dronedarone 400 mg|Dronedarone, 400mg tablets twice daily, administered with food.
9962031|NCT01213368|Experimental|dronedarone 600 mg|Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
9962032|NCT01213368|Placebo Comparator|placebo|Matching placebo tablets twice daily, administered with food.
9962033|NCT01213381|Experimental|SAR240550|"single cohort: SAR240550~combination cohort: SAR240550 in combination with Gemcitabine and Carboplatin"
9962034|NCT01213394|Experimental|CellCept optimization|
9962035|NCT01213394|Active Comparator|Control|
9962036|NCT01213407|Experimental|Standard therapy plus Trivax|Standard therapy with Surgery, Temozolomide, and Radiotherapy; plus Trivax, 5x10e6 autologous interleukine-12 secreting dendritic cells charged with autologous tumour lysate.
9962037|NCT01213407|Active Comparator|Standard therapy|Surgery, Temozolomide, Radiotherapy
9962038|NCT01213420|Experimental|Aloë Vera FORMULA F-BC-096|
9962039|NCT01213420|Active Comparator|Aloë Vera FORMULA F-BC-096 with modified preservative|
9962040|NCT01213420|Active Comparator|Eucerin Calming cream|
9962041|NCT01213420|Active Comparator|Nivea Cream|
9962042|NCT01213433|Experimental|Amodiaquine+Artesunate|
9962043|NCT01213446|Experimental|Biostate|
9962044|NCT01213459||Cohort A|Women ≥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.
9962045|NCT01213485||Cohort|
9962046|NCT01213498|Active Comparator|Atorvastatin|
9962047|NCT01213498|Placebo Comparator|Unikalk|
9962048|NCT01213511|Active Comparator|MECC Group|Patients operated for elective coronary artery bypass grafting with the use of minimal extracorporeal circulation.
9962049|NCT01213511|Active Comparator|CECC Group|Group of patients undergoing elective coronary bypass grafting with the use of conventional extracorporeal circulation.
9962050|NCT01213537||Patients undergoing clinically indicated CRT implantation|"Patients may be included in the study if they fulfil the following;~Age ≥18 years old~Fulfil the current guidance for the implantation of a CRT device; optimal medical treatment for heart failure, broad QRS complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, LVEF <35%, functional impairment as defined by an NYHA class of III-IV~Clinically stable with no unplanned admission to hospital for preceding 4 weeks~No changes in medications for heart failure in preceding 4 weeks~Able to read and understand patient information sheet and give informed consent~Patients must be excluded from the study if they fulfil they the following;~On positive pressure treatment for known sleep disordered breathing at the time of inclusion~Other known condition (untreated) likely to significantly disturb sleep eg. Restless legs syndrome, pain from any cause etc.~Pregnancy"
9962051|NCT01213550|Experimental|Chlorhexidine|
9962052|NCT01213550|Placebo Comparator|Placebo mouthrinse|
9962053|NCT01213563|Experimental|Actrapid insulin|Intensive glycaemic control Intervention: Actrapid insulin
9962054|NCT01213563|Active Comparator|Actrapid insulin+Gloucose|conventional glycaemic control Intervention: Actrapid insulin+Glucose
9962055|NCT01213602||Femoral block preoperative|In one group (T1) with performance of femoral block before general anesthesia and administration of bolus of local anesthetic through stimulating catheter (combined anesthesia)
9962056|NCT01213602||Femoral block postoperative|In second group (T2) with a administration of local anesthetic through stimulating femoral catheter until awareness of patient (balanced anesthesia).
9962057|NCT01213615||all patients eligible for implantation of a Hancock II Ultra|
9962058|NCT01213628|Experimental|Standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
9962059|NCT01213667|Other|ranibizumab as needed|
9962060|NCT01213680|Active Comparator|1000 mg iron isomaltoside as intravenous infusion|
9962061|NCT01213680|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
9962062|NCT01213693|Experimental|ICS/LABA group|Patients assigned to this arm will take bid 50/500 mcg fluticasone/salmeterol combination
9962063|NCT01213693|Active Comparator|LABA group|Patients assigned to this arm will take bid 50 mcg salmeterol
9962064|NCT01213719|Experimental|creatine|will receive creatine monohydrate (20g/d) throughout 10 days
9476633|NCT03569930|Experimental|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
9962065|NCT01213719|Experimental|betaine|will receive betaine (2g/d) throughout 10 days
9962066|NCT01213719|Placebo Comparator|placebo (dextrose)|will receive dextrose(20g/d)throughout 10 days.
9962067|NCT01213719|Active Comparator|creatine plus betaine|will receive creatine (20g/d) plus betaine (2g/d) throughout 10 days
9962068|NCT01213745|Experimental|Intervention|
9962069|NCT01213745|Experimental|Attention|
9962070|NCT01213745|Active Comparator|Control|
9962071|NCT01213758||Liver tumors|Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
9962072|NCT01213771|No Intervention|Preoperative care 2009|Patients are receiving the usual care
9962073|NCT01213784|Experimental|optimized diabetic control|each participant will be assigned to be optimized in a dedicated diabetic clinic
9962074|NCT01213784|No Intervention|control|participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
9962075|NCT01213797||Suicide attempter and its entourage|"Suicide attempter and its close relatives (who are living under the same roof)~Comparison of the population of the close relations of committing suicide with the data of the Research Institute and Documentation in Economy of Health (IRDES) on the French population (sample of 20.000 people, representative of 95% of the French households)."
9962076|NCT01213849|Experimental|200/100 mcg fluticasone furoate/vilanterol|4 inhalations of 50/25 mcg fluticasone furoate/vilanterol
9802370|NCT05302297||Control Group|Patients treated with other systemic treatments meeting the inclusion/exclusion criteria of the study who initiated at least one systemic treatment for advanced CSCC before start date of the cemiplimab nATU
9802371|NCT05302011|Experimental|Neoadjuvant Pembrolizumab Plus Chemotherapy|Neoadjuvant Pembrolizumab Plus Chemotherapy
9802372|NCT05301920|Experimental|Experimental Group|N=20 60Hz pulse electrical stimulation The clinical trial device performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
9802373|NCT05300711|Experimental|Opportunistic salpingectomy|The participating surgeons will attempt to perform bilateral salpingectomy in addition to the colorectal surgery.
9962077|NCT01213849|Experimental|400/100 mcg fluticasone furoate/vilanterol|4 inhalations of 100/25 mcg fluticasone furoate/vilanterol
9802374|NCT05300711|Active Comparator|Colorectal surgery only|Participants will receive the standard of care, that is colorectal surgery.
9962078|NCT01213849|Experimental|800/100 mcg fluticasone furoate/vilanterol|4 inhalations of 200/25 mcg fluticasone furoate/vilanterol
9962079|NCT01213862|Experimental|intervention and control|"Group I - Intervention: Routine follow-up in a reference health institution with four home visits and four telephone contacts with specialist nurses.~Group II - Control: Routine follow-up with the health team in the reference institution."
9962080|NCT01213875|Experimental|Experimental: Intervention and control|"I: Experimental Routine monitoring by health team in the reference institution, four home visits and four telephone contacts with trained nurses.~II: Control Routine monitoring by health team in the reference institution."
9962081|NCT01213875|No Intervention|Control|
9962082|NCT01213888|Experimental|Arm II|
9962083|NCT01213888|Placebo Comparator|Arm I. Placebo + Pan-Retinal Photocoagulation|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
9962084|NCT01213901|Experimental|1|"Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.~Injections will be given in a random order and the technician will be blinded to the injection.~Each patient will evaluate the comfort of the injection by completing a visual analog scale."
9962085|NCT01213914|Experimental|High-volume hemofiltration at 70ml/kg/hr|Paired randomization into four groups via central randomization center. Group 1: age 18-65 and <40%TBSA Group 2: age 18-65 and >40%TBSA Group 3: age >65 and <40%TBSA Group 4: age >65 and >40%TBSA
9962086|NCT01213914|Active Comparator|Control group|Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.
10006380|NCT01593865||Control Group|This Group consists of historical control patients who received conventional coronary artery bypass grafting (left mammary artery graft only plus great saphenous vein grafts) in the 2010-2012 period, and who are propensity-matched to the BIMA Group patients.
10006381|NCT01593878|Experimental|TV|Test taken with TV on
10006382|NCT01593878|No Intervention|Control|test taken in quiet
10006383|NCT01593930|Experimental|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
10006384|NCT01593930|Experimental|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
10006385|NCT01593930|Experimental|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
10006386|NCT01593930|Experimental|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
10006387|NCT01593943|No Intervention|Control Condition|
9962087|NCT01213979|Active Comparator|1000 mg iron isomaltoside 1000 as intravenous infusion|
9962088|NCT01213979|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
9962089|NCT01213992|Active Comparator|Monofer® 500 mg|500 mg iron isomaltoside 1000
9962090|NCT01213992|Active Comparator|Monofer® 1000 mg|1000 mg iron isomaltoside 1000
9962091|NCT01214005|Experimental|schizophrenia|Smokers with schizophrenia or schizoaffective disorder
9962092|NCT01214005|Other|non-psychiatric|smokers without psychiatric illness
9962093|NCT01214018||Reference|Nearest relatives of brain-dead patients who donated organs
9962094|NCT01214018||Opposition|Nearest relatives of brain-dead patients opposed to organ donation
9962095|NCT01214018||Medical/Legal|Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons
9476634|NCT03569930|Experimental|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
9962096|NCT01214031|Other|Confocal Laser Endomicroscopy Arm|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy.
9962097|NCT01214070|Active Comparator|Arm 1|Group 1 - Combination Treatment
9962098|NCT01214070|Active Comparator|Arm 2|Group 2 - Combination Treatment
9962099|NCT01214070|Active Comparator|Arm 3|Group 3 - Combination Treatment
9962100|NCT01214070|Active Comparator|Arm 4|Group 4 - Combination Treatment
9962101|NCT01214070|Active Comparator|Arm 5|Group 5 - Monotherapy Treatment
9962102|NCT01214070|Active Comparator|Arm 6|Group 6 - Monotherapy Treatment
9802375|NCT05300529|Experimental|Vestibular Rehabilitation Exercises|Vestibular Rehabilitation Exercises focused on eye stabilization and Vestibulo-Oculo Reflex (VOR). Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
9962103|NCT01214070|Active Comparator|Arm 7|Group 7 - Monotherapy Treatment
9962104|NCT01214096|Placebo Comparator|placebo|
9802376|NCT05300529|Sham Comparator|Conventional Rehabilitation exercises|Conventional rehabilitation exercises: stretching and walking. Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
9962105|NCT01214096|Experimental|rhNRG-1|recombinant human neuregulin-1
9962106|NCT01214122|Experimental|Treatment A|AZD9668 - 2 x30mg tablets
9962107|NCT01214122|Experimental|Treatment B|Warfarin - 10 x2.5 mg tablets
9962108|NCT01214135||1|Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).
9962109|NCT01214148|Other|ORSIRO|
9962110|NCT01214226|Active Comparator|Pentoxifylline + Prednisolone|"Pentoxifylline 400 mg prolonged-released tablets 3 time a day [1200 mg/day]~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
9962111|NCT01214226|Placebo Comparator|Placebo + Prednisolone|"Placebo prolonged-release tabled 3 time a day~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
9962112|NCT01214278|Experimental|Supplement 1|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules
9962113|NCT01214278|Experimental|Supplement 2|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)
9962114|NCT01214278|Experimental|Supplement 3|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules
9962115|NCT01214278|Experimental|Supplement 4|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)
9962116|NCT01214304|Placebo Comparator|Lavender Scent|Patients will receive aromatherapy with a fake lavender scent (placebo) which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
9962117|NCT01214304|Experimental|Essential Lavender Oil|Patients will receive essential Lavender Oil which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
9962118|NCT01214343|Experimental|Sorafenib with Low-dose FP|
9962119|NCT01214343|Active Comparator|Sorafenib|
9962120|NCT01214369|Active Comparator|X-tip intraosseous injection|
9962121|NCT01214369|Active Comparator|PDL injection|
9962122|NCT01214382|Experimental|Sertraline|
9962123|NCT01214408|Experimental|GRP-A|
9962124|NCT01214408|Experimental|GRP-B|
9962125|NCT01214447||Low - OSND less than 22|
9962126|NCT01214447||Moderate - OSND score 23-27|
9962127|NCT01214447||Normal - OSND score 28-32|
9962128|NCT01214460||All MET calls|We make an Utstein type analyze to all MET calls
9962129|NCT01214460||All EMS calls|We make an Utstein type analyze to all EMS calls during June 2015
9962130|NCT01214460||All patient in the emergency department|We make an Utstein type analyze to all Emergency visits during June 2015
9962131|NCT01214473|Experimental|Probiotic group|Once daily oral administration of a probiotic preparation (1 billion cells of Lactobacillus plantarum and 150 mg of fructooligosaccharides) for one week to newborn infants
9962132|NCT01214473|Placebo Comparator|Placebo|Once daily oral administration of maltodextrin for one week to newborn infants
9962133|NCT01214486|Experimental|Raltegravir|
9962134|NCT01214499|Active Comparator|Treatment Control|Transmyocardial revascularization (TMR) with Holmium YAG (yttrium aluminium garnet) laser, according to habitual clinical practice in the Department of Cardiovascular Surgery.
9962135|NCT01214499|Experimental|Experimental Treatment|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.
9962136|NCT01214525||Meatotomy|Toilet trained children scheduled for urethral meatotomy for the treatment of urethral meatal stenosis.
9962137|NCT01214538||Control group - culture negative|50 children with pneumococcal culture-negative Acute Otitis Media
9962138|NCT01214538||study group- culture positive|50 children with pneumococcal culture-positive Acute Otitis Media
9962139|NCT01214564|Experimental|1|Up to three days of treatment
9962140|NCT01214577|Experimental|1|Up to three days of treatment
9962141|NCT01214590|Experimental|VascuActive Treatment|
9962142|NCT01214681|Placebo Comparator|Placebo|
9962143|NCT01214681|Experimental|Hi-maize 260|
9962144|NCT01214681|Experimental|Polydextrose|
9962145|NCT01214681|Active Comparator|Hi-maize 260 and polydextrose|
9962146|NCT01214694|Experimental|Active Comparator: Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
9962147|NCT01214694|Experimental|I-InTERACT|Participants will receive a 24 week, 27 session internet-based parenting skills program
9962148|NCT01214694|Experimental|I-InTERACT Express|Participants will receive an abbreviated 7 week, 14 session version of the I-InTERACT parenting skills program.
9962149|NCT01214707||Exercise protocol|No arms are required for this study as all subjects complete the entire protocol
9962150|NCT01214733|Experimental|1|
9962151|NCT01214746|Placebo Comparator|Placebo|
9962152|NCT01214746|Active Comparator|Atorvastatin|
9962153|NCT01214772|Experimental|heparin,pregnancy,IVF failure|Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
9962154|NCT01214785|Active Comparator|Sanitation intervention|
9962155|NCT01214785|No Intervention|Control|
9962156|NCT01214863||T3|Model SN60T3 assigned by AcrySof Toric calculator
9962157|NCT01214863||T4|Model SN60T4 assigned by AcrySof Toric calculator
9962158|NCT01214863||T5|Model SN60T5 assigned by AcrySof Toric calculator
9962159|NCT01214876||Children 1-5 years old|
9962160|NCT01214876||Children 6-10 years old|
9962161|NCT01214876||Adults 25 years and above|
9962162|NCT01214889|Experimental|Study Group A|Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
9962163|NCT01214889|Active Comparator|Study Group B|Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.
9962164|NCT01214902|Experimental|Experimental CIMT|Two month home program that includes restricting the non hemiplegic hand an hour a day during play
9962165|NCT01214902|Active Comparator|Active Play|Two month home program that includes active use of hemiplegic hand during play one hour a day
9962166|NCT01214928|Active Comparator|Cholecalciferol|Cholecalciferol 50,000IU po once weekly for 12 continuous weeks.
9962167|NCT01214928|Placebo Comparator|Placebo|Matching placebo po once weekly for 12 continuous weeks
9962168|NCT01214941|Placebo Comparator|Placebo|
9962169|NCT01214941|Active Comparator|Ticlopidine|
9962170|NCT01214941|Active Comparator|Ticlopidine and itraconazole|
9962171|NCT01214954|Active Comparator|Control group|Standard rehabilitation
9962172|NCT01214954|Experimental|Resistance training|10 weeks of supervised progressive resistance training initiated within the first week after total hip replacement.
9962173|NCT01214967|Experimental|1|Problem Solving Education, a psycho-educational intervention
9962174|NCT01214967|No Intervention|2|Usual care
9962175|NCT01214993|Experimental|Treatment A|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
9476635|NCT03569930|Experimental|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
9962176|NCT01214993|Experimental|Treatment B|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q12h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
9962177|NCT01214993|Placebo Comparator|Treatment C|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive placebo q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
9962178|NCT01215019|Active Comparator|Arm 1|20% Mannitol
9962179|NCT01215019|Active Comparator|Arm 2|3% sodium chloride
9962180|NCT01215045||ReSTOR +4|AcrySof ReSTOR Aspheric +4
9962181|NCT01215058||1|
9476636|NCT03569917|Experimental|patient under Ceftriaxone treatment|
9962182|NCT01215071|Experimental|limited lymphadenectomy|Fields 5, 7, 9, 11, 13, 14 are removed
9962183|NCT01215071|Experimental|extended lymphadenectomy|Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed
9962184|NCT01215084|Experimental|Chinese Subpopulation: Fampridine-PR 10 mg|Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
9962185|NCT01215084|Experimental|Japanese Subpopulation: Fampridine-PR 10mg|Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
9962186|NCT01215084|Experimental|Caucasian Subpopulation: Fampridine-PR 10mg|Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs
9962187|NCT01215136|Active Comparator|Cohort 1|Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance < 60 ml/min AND Karnofsky performance status of 60-70%)
9962188|NCT01215136|Active Comparator|Cohort 2|Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance < 60 ml/min OR Karnofsky performance status of 60-70%)
9962189|NCT01215149|Experimental|Group A|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3
9962190|NCT01215149|Experimental|Group B|Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3
9962191|NCT01215149|Experimental|Group C|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3
9962192|NCT01215149|Experimental|Group D|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3
9962193|NCT01215149|Experimental|Group E|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
9962194|NCT01215149|Experimental|Group F|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
9962195|NCT01215149|Experimental|Group G|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
9962196|NCT01215149|Experimental|Group H|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
9962197|NCT01215149|Experimental|Group I|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
9962198|NCT01215149|Experimental|Group J|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
9962199|NCT01215149|Experimental|Group K|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
9962200|NCT01215149|Experimental|Group L|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
9962201|NCT01215162|Experimental|Single arm study|Patients with stage T1/T2No breast cancer receiving breast conserving treatment
9962202|NCT01215201|Other|Scaling and Root Planing Alone|Control group
9962203|NCT01215201|Experimental|Diode Laser plus Scaling and Root Planing|Diode Laser is used in addition to Scaling and root planing procedure.
9802377|NCT05300503|No Intervention|Control|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the standard video & education session on managing hypertension. They will watch the video at home on their own time. Participants will use a home blood pressure monitor to track their blood pressure (those without a blood pressure cuff will be provided one) for the 3-month intervention period. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160). They will be encouraged to track their blood pressure daily and any symptoms they may be feeling.
9962204|NCT01215214|Experimental|midazolam|period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
9962205|NCT01215266|Active Comparator|Sorafenib|
9962206|NCT01215266|Placebo Comparator|Placebo|
9962207|NCT01215305||Visiting outpatient departments, if symtoms|patients with upper GI symptoms, visiting the outpatient departments of peripheral hospitals in Greece
9962208|NCT01215331|Active Comparator|Insulin|Rapid acting insulin and long acting insulin
9962209|NCT01215331|Experimental|Oral Hypoglycemic Agents|Metformin + glyburide + insulin if needed
9962210|NCT01215383||psychiatric patients|20 in patients and outpatients with schizophrenia, schizoaffective and bipolar disorder based on psychiatrist diagnostic evaluation using DSM-IV criteria, before and at least two months after antipsychotic therapy will be enrolled.
9962211|NCT01215383||healthy volunteers|"Ten healthy volunteers will be checked as controls:~Employee from the hospital staff with no metabolic disease (Diabetes mellitus, hypertension or dyslipidemia) and non-smokers."
9962212|NCT01215396|Placebo Comparator|Carbohydrate Placebo|
9962213|NCT01215396|Active Comparator|Single Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 0.96 g of amino acids."
9803652|NCT03646175|Placebo Comparator|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
9803653|NCT03644563||Follow-up|Those subjects with oncogenic oral HPV infection and/or HPV oncogene serum antibodies from screening.
9962214|NCT01215396|Active Comparator|Double Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 1.92 g of amino acids."
9962215|NCT01215409||Group 1|
9962216|NCT01215448|No Intervention|Lifestyle changes|Lifestyle changes(booklet and audio cassette of recommended diet, physical activity and breathing exercises)
9803654|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet non-menthol|Nicotine 0 mg combined with sweet non-menthol flavor
9962217|NCT01215448|Experimental|Wheatgrass juice & lifestyle changes|Wheatgrass juice & lifestyle changes
9962218|NCT01215474||NSCLC Stadium III-IV|
9962219|NCT01215487||1 - Chronic Myelogenous Leukemia Patients|Patients will be selected from patients referred to the primary hospital site for treatment and assessment. The patients will be approached by the physicians and or the study research nurse to consider participation in the study. Patients may be selected by participating off-site hospital centres and may be enrolled at those collaborating centres.
9962220|NCT01215500|Experimental|Radiation therapy|
9962221|NCT01215539|Experimental|Panitumumab,capecitabine,oxaliplatin|"Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg.~Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 Capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14"
9962222|NCT01215552|Experimental|HT-0712|
9962223|NCT01215565|Experimental|patient treated|patient who receive sunitinib
9962224|NCT01215578|Experimental|patient treated|patient who receive sunitinib (SUTENT)
9962225|NCT01215591|Active Comparator|Gradual wean from Nasal CPAP|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
9962226|NCT01215591|No Intervention|Sudden wean from Nasal CPAP|Usual practice to wean the preterm neonates from nasal CPAP
9962227|NCT01215617|Experimental|Aerobic Interval Training|Patients randomized to training will meet for supervised aerobic interval training three times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
9962228|NCT01215617|Other|Control|Patients will receive standard medical treatment at the University Hospital lung department.
9962229|NCT01215630||Healthy subjects|Men Women Age; 18-75
9962230|NCT01215656|Experimental|Probiotic|follow on formula with the probiotic Lactobacillus fermentum
9962231|NCT01215656|Active Comparator|Control|follow on formula without probiotics
9962232|NCT01215669|Experimental|Group 1: Adult Intradermal (ID) Vaccine|Participants aged 18 to 59 years will be vaccinated with IDflu™ influenza vaccine
9962233|NCT01215669|Active Comparator|Group 2: Adult Intramuscular (IM) Vaccine|Participants aged 18 to 59 years will be vaccinated with Vaxigrip® Influenza vaccine
9962234|NCT01215669|Experimental|Group 3: Elderly Intradermal (ID) Vaccine|Participants aged 60 years or older will be vaccinated with IDflu™ Influenza vaccine
9962235|NCT01215669|Active Comparator|Group 4: Elderly Intramuscular (IM) Vaccine|Participants aged 60 years or older will be vaccinated with Vaxigrip® Influenza vaccine
9962236|NCT01215682|Active Comparator|vit D|
9962237|NCT01215682|Placebo Comparator|placebo|
9962238|NCT01215708|Active Comparator|Nifedipine|nifedipine retard 20mg daily
9962239|NCT01215708|Active Comparator|tamsulosin|tamsulosin 0,4mg
9962240|NCT01215708|Placebo Comparator|placebo|placebo capsule
9962241|NCT01215747|Experimental|Kiacta (eprodisate disodium)|
9962242|NCT01215747|Placebo Comparator|Placebo|
9962243|NCT01215760|Active Comparator|MIRROR|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
9962244|NCT01215760|Active Comparator|Home program|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
9962245|NCT01215773|Experimental|BI 671800 HEA medium dose|Tablet, oral administration with 240 mL of water for each treatment
9962246|NCT01215773|Experimental|BI 671800 HEA high dose|2 Tablets, oral administration with 240 mL of water for each treatment
9962247|NCT01215773|Placebo Comparator|Placebo|Matching to HEA 200 mg tablets, oral administration
9962248|NCT01215799|Experimental|Bafetinib|
9962249|NCT01215825||HD, LD, NIL|HD: the highest daily dose of steroids receiving more than 60 mg/day LD: the highest daily dose of steroids receiving less or equal to 60 mg/day NIL: no steroid use
9962250|NCT01215864|Experimental|TCD-717|
9962251|NCT01215890|Active Comparator|risedronate plus calcium and viamin D|
9962252|NCT01215890|Placebo Comparator|placebo plus clacium and vitamin D|
9962253|NCT01215903|Experimental|Fish gelatin and omega-3|
9962254|NCT01215903|Experimental|Omega-3|
9962255|NCT01216007|Active Comparator|TIVA|TIVA
9962256|NCT01216007|Active Comparator|Inhalational|Inhalational/volatile general anesthetic
9962257|NCT01216020|Experimental|cetuximab plus radiotherapy|Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
9962258|NCT01216020|Active Comparator|cisplatin plus radiotherapy|CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)
9962259|NCT01216046|Experimental|Treatment Arm|Subjects randomized to study drug will take VX-809 for 14 days followed by a 14 day washout. Next subjects will take VX-770 for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 for 14 days.
9962260|NCT01216046|Placebo Comparator|Placebo Arm|Subjects randomized to placebo will take VX-809 placebo for 14 days followed by a 14 day washout. Next subjects will take VX-770 placebo for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 placebo for 14 days.
10006388|NCT01593943|Experimental|CHARM Intervention|CHARM will be conducted via three 30-minute counseling sessions delivered in a rural setting, with the first session being required and the subsequent sessions being optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
10006389|NCT01593956|Other|Concussed athletes|
10006390|NCT01593956|Other|Healthy controls|
10006391|NCT01593969|Active Comparator|Standard RUTF|Standard RUTF given according to National Guidelines
10006392|NCT01593969|Experimental|RUTF/Flax Oil|RUTF/Flax Oil is reformulated RUTF to increase n3 content
10006393|NCT01593969|Experimental|RUTF/Flax Oil plus additional Fish Oil|RUTF/Flax Oil plus additional Fish Oil is RUTF reformulated to increase n3. Fish oil to provide long chain n3
10006394|NCT01593982|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
10006395|NCT01593982|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Active rTMS delivered to the left dorsolateral prefrontal cortex.
10035296|NCT01804790|Experimental|Arm B : Chemotherapy then radiochemotherapy|"Drug: Chemotherapy mFolfirinox~Investigational arm: Neoadjuvant CT mFolfirinox, 6 cycles (ca. 3 months; each cycle = 2 weeks):~oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-fluorouracil (5-FU): 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles).~Then followed by 5 weeks of chemoradiotherapy 50 Gy (2 Gy/session, 5 sessions per week) + capecitabine 800 mg/m² twice daily 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, followed by 3 months of adjuvant chemotherapy, either mFolfox6 or capecitabine depending on the center's choice."
10037247|NCT01823315|Active Comparator|MTX multiple courses chemotherapy|"Regimen: methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5, 2-week intervals. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive at least 1 additional consolidation treatment.~After treatment, all the patients were asked for contraception with condom or oral contraception. Regular hCG surveillance, once a month for 3 consecutive months and once every 3 months for 2 years, was performed. During follow-up period, pelvic ultrasound and pulmonary X ray or CT scan were conducted if needed."
10037248|NCT01823354|Other|Patients|Polysomnography, Assessment of executive functions, Clinical scales, Medical consultation
10006396|NCT01593995|Experimental|EGF ointment|
10006397|NCT01594021|Experimental|High pre-emptive volume loading|
9962261|NCT01216059|Experimental|Intervention group|Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.
9962262|NCT01216059|No Intervention|Control Group|Subjects will receive a weekly text message reminder about pop-culture, sports or weather.
9962263|NCT01216085|Experimental|imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
9962264|NCT01216098|Experimental|Experimental arm - D|Experimental arm - Women randomized to this arm will receive doula support alongside standard care.
9962265|NCT01216098|No Intervention|No intervention - ND|No intervention - Women randomized to this arm will receive standard care alone.
9962266|NCT01216111|Experimental|6 cycles of PC adjuvant chemotherapy|paclitaxel 80 mg/m2 and carboplatin (area under the curve [AUC]= 2) on day 1, 8, 15 every 28 days for six cycles
9962267|NCT01216111|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
9962268|NCT01216137|Experimental|Exercise: Vestibular Rehabilitation|Balance and eye movement training
9962269|NCT01216137|Active Comparator|Exercise Control|Bicycle ergometry and stretching
9962270|NCT01216137|No Intervention|Wait-listed Control|Wait-listed Control
9962271|NCT01216150||aspirin|group treated with aspirin alone
9962272|NCT01216150||aspirin clopidogrel|Goup treated with aspirin and clopidogrel
9962273|NCT01216215||Asthmatic sporadic and familial|
9962274|NCT01216215||Control subjects spradic and familial|
9962275|NCT01216254|Active Comparator|Classic electrocoagulation|Arm of the study where the classic low-frequency electrocoagulation is used during the operation
9962276|NCT01216254|Experimental|High Frequency electrocoagulation|Arm of the study where the tested high-frequency electrocoagulation is used during the operation
9962277|NCT01216267|Active Comparator|lansoprazole|lansoprazole for 7 days
9962278|NCT01216280|Placebo Comparator|2 x 10 mg placebo capsule|2 x 10 mg placebo capsules, administered orally with water, b.i.d.
9962279|NCT01216280|Experimental|10mg Natura-alpha + 10 mg placebo|10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
9962280|NCT01216280|Experimental|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
9962281|NCT01216293|Experimental|Dexlansoprazole 60 mg QD|
9962282|NCT01216293|Active Comparator|Esomeprazole 40mg QD|
9962283|NCT01216293|Placebo Comparator|Placebo QD|
9962284|NCT01216306|Experimental|Television reduction curriculum|Students are taught the television reduction curriculum during the school day and parents are invited to attend after-school meetings to discuss reducing their children's television viewing.
9962285|NCT01216306|No Intervention|Control|Students will be taught the standard preschool curriculum.
9962286|NCT01216358||Arm 1: Combined contraceptive|Initiating an estrogen/progesterone contraceptive
9962287|NCT01216358||Arm 2: Progesterone only contraceptive|Initiating a progesterone-only contraceptive
9962288|NCT01216358||Arm 3 (control): Non-hormonal contraceptive|Initiating or using non-hormonal contraception or not using contraception
9962289|NCT01216371|Active Comparator|Sunitinib|one year adjuvant treatment with sunitinib
9962290|NCT01216371|Placebo Comparator|Placebo|one year treatment with placebo
9962291|NCT01216384|Experimental|BI 671800 active|SRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose. MRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose followed by multiple doses with a PK sampling interval in between.
9962292|NCT01216384|Placebo Comparator|Placebo|3 subjects will receive placebo in each of the 3 doses in the SRD part and 3 doses in the MRD part
9962293|NCT01216423||Incidence of recent stroke in patients with PFO|
9962294|NCT01216423||Incidence of recent stroke in patients without PFO|
9962295|NCT01216436|Experimental|Vaccine plus untransfected DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.
9962296|NCT01216436|Experimental|Vaccine plus GITRL RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.
9962297|NCT01216436|Experimental|Vaccine plus antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.
9962298|NCT01216436|Experimental|Vaccine plus GITRL/ antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.
9803655|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet non-menthol|Nicotine 3 mg combined with sweet non-menthol flavor
9803656|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet non-menthol|Nicotine 12 mg combined with sweet non-menthol flavor
9803657|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet menthol|Nicotine 0 mg combined with sweet menthol flavor
9803658|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet menthol|Nicotine 3 mg combined with sweet menthol flavor
9962299|NCT01216449|Experimental|Intravenous Citalopram|
9962300|NCT01216449|Placebo Comparator|Normal Saline|250mL of 0.9% Sodium Chloride Solution
9962301|NCT01216475|Active Comparator|Femtosecond LASIK|2 lasers refractive procedure
9962302|NCT01216475|Experimental|SMILE|Small incision lenticule extraction (SMILE)
9962303|NCT01216488|Active Comparator|40 ml of Xylocaine|
9962304|NCT01216488|Experimental|25 ml of Xylocaine|
9962305|NCT01216527|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Surgery
9962306|NCT01216527|Active Comparator|control group|only Surgery
9962307|NCT01216540||Patients receiving vancomycin|
9962308|NCT01216553|Active Comparator|hypertonic inhalation + O2|oxygen for 30 minuets after inhalation of 3% saline 4 times daily
9962309|NCT01216553|Active Comparator|Epinephrine & bromhexine nebulized + O2|oxygen for 30 minuets after inhalation of racemic epinephrine with bromhexine 4 times daily
9962310|NCT01216566|Experimental|I. Patients with chronic neck pain|
9962311|NCT01216579|Placebo Comparator|Reference arm|Asthmatic patients managed as per British Thoracic Society guidelines by symptoms and lung function.
9962312|NCT01216579|Active Comparator|Mannitol managed arm|Group of asthmatic patients managed according to their mannitol challenge.
9962313|NCT01216592||COPD|
9962314|NCT01216605|Active Comparator|Oxytocin|
9962315|NCT01216605|Placebo Comparator|Placebo|
9962316|NCT01216618|Experimental|Device|Subject starts with two clamps including device use follows by a clamp without device use
9962317|NCT01216618|No Intervention|Control|Subject starts with clamps without device
9962318|NCT01216644|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
9962319|NCT01216644|Active Comparator|ECF|Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP
9962320|NCT01216657|Experimental|sunitinib|50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
10006398|NCT01594021|Active Comparator|Low pre-emptive volume loading|
10006399|NCT01594034||no treatment|
10006400|NCT01594047|No Intervention|zero/morphine|Patient received a standard balance anaesthesia and morphine for post operative pain.
9962321|NCT01216696|Experimental|Intervention|"Intervention Details:~Drug: ipilimumab~Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first."
9962322|NCT01216709|Experimental|iron drops|
9962323|NCT01216709|Experimental|iron-fortified formula (2.3 mg iron/L)|
9962324|NCT01216709|Experimental|iron-fortified formula (12.4 mg iron /L)|
9962325|NCT01216722|Experimental|Resistance Strengthening|Body weight antigravity positioning and elastic resistance bands are used to provide resistance for strengthening in supine, sitting, and standing in subjects post liver transplant.
9962326|NCT01216722|No Intervention|Usual Care Control|Subjects perform the usual care of progressive ambulation and increased activity post liver transplant
9962327|NCT01216774|Experimental|Low load + fatigue|
9962328|NCT01216774|Active Comparator|High load|
9962329|NCT01216774|Placebo Comparator|Low load|
9962330|NCT01216787|Experimental|Treatment (gamma-secretase inhibitor RO4929097, surgery)|Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Within 35-56 days after completion of therapy, patients with stable or responsive disease undergo surgery. Patients may continue RO4929097 for 28 days after surgery in the absence of disease progression or unacceptable toxicity.
9962331|NCT01216826|Experimental|Everolimus|
9962332|NCT01216839|Experimental|Everolimus|
9962333|NCT01216865|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
9962334|NCT01216865|Active Comparator|Standard Therapy|Any therapy for diabetic foot which is routinely practiced and accepted in China
9962335|NCT01216891|Experimental|Team-based treatment|
9962336|NCT01216904|Placebo Comparator|Placebo patch|
9962337|NCT01216904|Active Comparator|Nicotine patch|
9962338|NCT01216917||Fitness|
9962339|NCT01216917||Whole-body vibration|
9962340|NCT01216917||Control|
9962341|NCT01216930||All colorectal cancer patients|
9962342|NCT01216956|Experimental|Extended release nicotinic acid|
9962343|NCT01216956|Placebo Comparator|Placebo|
9962344|NCT01216982|Active Comparator|Lovaza, omega-3 fatty acid ethyl ester|
9962345|NCT01216982|Placebo Comparator|Placebo|one gram corn oil in a soft gelatin capsule
9962346|NCT01216995|Active Comparator|Dose A|Dose A
9962347|NCT01216995|Placebo Comparator|Placebo|Placebo
9962348|NCT01217008|Experimental|GRNOPC1|Subjects who receive an injection of GRNOPC1
9476637|NCT03569852|Experimental|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
9962349|NCT01217021|Experimental|Assess [18F] MNI-558 and PET imaging|
9962350|NCT01217034|Experimental|TACE with sorafenib|TACE(on demand) with sorafenib till untreatable progression
9962351|NCT01217034|Active Comparator|TACE alone|TACE(on demand) till unreatable progression
9962352|NCT01217086|Active Comparator|CT-P13|
9962353|NCT01217086|Active Comparator|Remicade|
9962354|NCT01217099|No Intervention|methylprednisolone|methylprednisolone pulse azithromycin
9962355|NCT01217099|No Intervention|azithromycin|azithromycin
9962356|NCT01217138|Other|Original epinephrine autoinjector group|Participants were given original epinephrine autoinjector trainer wrapped by a gray sticky paper.
9962357|NCT01217138|Active Comparator|Modified epinephrine autoinjector group|Participants were given the same epinephrine autoinjector trainer wrapped by a gray sticky paper which was modified by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.
9962358|NCT01217151|Sham Comparator|Usual treatment|The hemodynamic management will be performed according to the institution's standard of care, using fluids at the discretion of the anesthesiologist and the ICU specialist.
9962359|NCT01217151|Active Comparator|NICOM|"For volume replacement, crystalloids will be used following the standard procedure according to the anesthesiologist or ICU specialist. Mean arterial pressure and cardiac index will be assessed every 5 minutes, and a volume bolus (250 mL colloid in 10 minutes) will be used to achieve a:~Mean arterial pressure ≥ 65 mmHg (intra and postoperatively), AND~Cardiac index ≥ 2.5 L/min/m2 (intra and postoperatively).~If these cardiovascular parameters are not met after the first colloid infusion, a supplementary bolus will be added. In case of not achieving the target, additional colloid boluses and/or pharmacologic support (norepinephrine in case of persistent hypotension, dobutamine in case of low cardiac output) will be provided according to the protocol"
9962360|NCT01217164|No Intervention|higher protein|
9962361|NCT01217177|Experimental|2.5 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (2.5mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
9962362|NCT01217177|Experimental|5.0 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (5.0mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
9962363|NCT01217177|Experimental|10 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (10mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
9962364|NCT01217203|Experimental|IPH2101 and lenalinomide|
9962365|NCT01217216|Active Comparator|Group-based Intervention|We randomly assigned 30 individuals to a group-based intervention to promote weight loss through dietary restriction and physical activity.
9962366|NCT01217216|Active Comparator|Telephone-based Intervention|We randomly assigned 22 individuals to the telephone-based intervention to promote weight loss through dietary restriction and physical activity.
9962367|NCT01217242||Children with cerebral palsy (CP)|ages 2 to < 10 years who are able to walk with or without an assistive device
9962368|NCT01217255||Brazilian Subject's|Subject's will be recruited from the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paolo (HCFMUSP); Universidade Estadual de Campinas (UNICAMP); Universidade Federal de São Paulo (UNIFESP)
9962369|NCT01217255||Canadian Subject's|Recruited from The Hospital for Sick Children
9962370|NCT01217268|Experimental|Training and supervision of staff|Staff members get training in person centered care by supervision using video-conference kit
9962371|NCT01217281|No Intervention|Control|"Full mouth supra-gingival debridement using hand instruments and ultrasonic scalers, in one session. Patient motivation and oral hygiene instructions Review and prophylaxis at 1 month, 3 months and 6 months after initial treatment session.~Full mouth periodontal therapy provided at the end of the 6month period (supra and sub- gingival full mouth scaling)"
10037249|NCT01823354|Other|Controls|Polysomnography, Assessment of executive functions, Clinical scales Medical consultation
9962372|NCT01217281|Active Comparator|Test/ Non-surgical Periodontal Therapy|"Full mouth periodontal therapy (sub and supra- gingival debridement) provided under local anaesthesia in two half-mouth sessions.~Review and prophylaxis 1 month, 3 months and 6 months after the end of the initial therapy."
9962373|NCT01217294|Sham Comparator|spinal morphine, sham block|"Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as specified by the anaesthetist performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham ultrasound guided fascia iliaca plane block with saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
9962374|NCT01217294|Active Comparator|ultrasound guided fascia iliaca block|"Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
9962375|NCT01217320|Experimental|creatine supplementation|will receive 5g/d of creatine monohydrate throughout the trial
9962376|NCT01217320|Placebo Comparator|placebo|will receive 5g/d of placebo (dextrose) throughout the trial
9962377|NCT01217333|Active Comparator|In-person|Participants in this arm have been randomized to receive Consultation Planning in-person
9962378|NCT01217333|Active Comparator|Telephone|Participants in this arm have been randomized to receive Consultation Planning by telephone.
9962379|NCT01217346||cardiac syndrome X|subjects fulfilling the clinical triad of cardiac syndrome X
9962380|NCT01217359|Experimental|Interferon Alfa-2b|Patients will receive a single dose of interferon
9962381|NCT01217372|Experimental|Lemon supplementation YES|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
9962382|NCT01217372|No Intervention|Lemon supplementation NO|No lemon supplementation
9962383|NCT01217450|Experimental|Treatment (selumetinib, cetuximab)|Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9962384|NCT01217489||Attendees to symptomatic breast clinic|
9962385|NCT01217502|Experimental|Self management|
9962386|NCT01217528|Active Comparator|Group A|"Group A:~VT zone: 350ms~VF zone: 280ms"
9962387|NCT01217528|Experimental|Group B|"Group B:~VT zone: 320ms~VF zone: 250ms"
9962388|NCT01217541|Other|Education and supervision|Personnel in nursing home units get intervention in form of education and supervision
9962389|NCT01217541|No Intervention|Control|Only registering of patient and personnel data in the beginning and the end of the study without any form of intervention.
9962390|NCT01217554||age-matched healthy male participants|age-matched healthy male participants without LBP
9962391|NCT01217554||participants with non specific chronic LBP|male participants with non specific chronic LBP
9962392|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery - s.l.|
9962393|NCT01217567|Experimental|Woman with previous ceasarean section - staples left|
9962394|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery|
9962395|NCT01217567|Experimental|Woman with previous ceasarean section|
9962396|NCT01217580|Experimental|20 ml per side of 0.5% ropivacaine|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
9962397|NCT01217580|Placebo Comparator|20 ml per side of 0.9% sodium chloride|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
9962398|NCT01217593|Experimental|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
9962399|NCT01217593|Active Comparator|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
9962400|NCT01217619|Experimental|Erlotinib|Single-arm
9962401|NCT01217632|Placebo Comparator|FG-3019 Placebo|Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
9962402|NCT01217632|Experimental|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
9962403|NCT01217645|Experimental|150 mg [14C] AZD6765|
9962404|NCT01217658|Experimental|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
9962405|NCT01217658|Active Comparator|AAP Education|Those receiving the control group allocation will be counseled in the American Academy of Pediatrics guidelines regarding Infant Colic (AAP Infant Colic counseling).
9962406|NCT01217671|Experimental|Alpha-1 Antitrypsin|
9962407|NCT01217671|Placebo Comparator|Placebo|
9962408|NCT01217723|Experimental|Thymoglobulin|Thymoglobulin will be administered on Days -2, -1 prior to the transplant and on the day of transplant.
9962409|NCT01217723|Other|No Thymoglobulin|Patients will receive a standard preparative regimen. (i.e. one that does not normally contain Thymoglobulin.)
9962410|NCT01217736|Experimental|VTP-27999|
9962411|NCT01217736|Active Comparator|aliskiren|
9962412|NCT01217736|Placebo Comparator|placebo|
9962413|NCT01217762|Experimental|11 Gy IRay|Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)
9962414|NCT01217762|Experimental|16 Gy IRay|Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)
9962415|NCT01217762|Experimental|16 Gy IRay - Radiation First|16 Gy IRay and Lucentis PRN (N = 13)
9962416|NCT01217762|Experimental|24 Gy IRay|Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)
10006401|NCT01594047|Experimental|ketamine/morphine|patients received a balance anaesthesia supplemented by low dose of ketamine and Morphine by PCA device for postoperative pain
10006402|NCT01594047|Experimental|zero/metadone|patients received a standard balance anaesthesia and methadone by PCA device for postoperative pain
10006403|NCT01594047|Experimental|ketamine/methadone|Patients received a balance anaesthesia supplemented with low dose of ketamine and Methadone by PCA device for postoperative pain
10006404|NCT01594060|Active Comparator|sliding scale|
10006405|NCT01594060|Active Comparator|basal bolus|
10006406|NCT01594086|Experimental|green tea powder|Natural green tea powder
10006407|NCT01594099|Active Comparator|Radiotherapy alone|
10006408|NCT01594099|Experimental|Radiotherapy plus cisplatin|
10006409|NCT01594099|Experimental|Radiotherapy plus liposome paclitaxel|
10006410|NCT01594112||Patient with at least one ID|Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.
10006411|NCT01594138||Suicidal Subjects|Suicidal Subjects
9803659|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet menthol|Nicotine 12 mg combined with sweet menthol flavor
10006412|NCT01594138||Non-Suicidal Control Subjects|Non-Suicidal Control Subjects
10006413|NCT01594177|Experimental|Treatment arm|Afatinib-Trastuzumab (6 weeks) followed by Afatinib*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). *only 11 weeks.
10006414|NCT01594190|Active Comparator|Low Dose Training|15 minutes/day on a weight-bearing treadmill
10006415|NCT01594190|Active Comparator|High Dose Training|2x 30 minutes/day on a weight-bearing treadmill
10006416|NCT01594203||Advanced Soft Tissue Sarcoma|patients with advanced Soft Tissue Sarcoma
10006417|NCT01594229|Experimental|Arm 1|Non-Hodgkin's Lymphoma (NHL)
10006418|NCT01594242|Experimental|Autophagy Induction After Bortezomib|"Subjects will undergo a baseline bone marrow aspirate and biopsy (under sedation if preferred by the subject) and have baseline blood samples (and urine samples if clinically indicated for measurement of their myeloma).~The following week, subjects will undergo a second bone marrow aspirate and biopsy and have additional blood samples taken for research assays prior to starting therapy on treatment day 1 with bortezomib at the standard dose of 1.3 mg/m2. Subjects will receive a second dose of bortezomib on treatment day 4, followed by a third bone marrow aspirate and biopsy on treatment day 4 or 5, along with serial blood samples on treatment days 4 and 5. After completion of the week of study treatment, subjects may continue treatment with the bortezomib-containing regimen planned by their treating oncologist. Active study participation will end after the completion of the week of study treatment."
10006419|NCT01594255|Experimental|AEB071 300 mg|
10006420|NCT01594255|Experimental|AEB071 900 mg|
10006421|NCT01594255|Placebo Comparator|Placebo to AEB071|
10006422|NCT01594255|Active Comparator|Moxifloxacin|
10006423|NCT01594268|Other|Kidney transplantation patient|Kidney transplantation patient; single arm
10006424|NCT01594307||blood pressure monitor|Cuff circumference:13.5cm-22cm
10006425|NCT01594307||stethoscopy|Cuff circumference: 13.5cm-22cm
10006426|NCT01594320|Experimental|Group A|
10006427|NCT01594320|Experimental|Group B|
10006428|NCT01594320|Experimental|Group C|
10006429|NCT01594320|Experimental|Group D|
10006430|NCT01594320|Experimental|Group E|
10006431|NCT01594320|Experimental|Group F|
10006432|NCT01594346|Placebo Comparator|Sugar Pill|
10006433|NCT01594346|Active Comparator|Alpha-Tocopherol|
9962417|NCT01217775|Experimental|PH80 intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
9962418|NCT01217775|Placebo Comparator|Placebo intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
9962419|NCT01217788|Experimental|PH94B intranasal spray|
9962420|NCT01217788|Placebo Comparator|Placebo intranasal spray|
9962421|NCT01217853||SENSIMED Triggerfish|
9962422|NCT01217866||LAVH, techniques|Women aged 35-75 who underwent laparoscopic assisted vaginal hysterectomy via either suture technique vaginally or Enseal coagulation cutting device vaginally
9962423|NCT01217879||Group 1|
9962424|NCT01217905|Experimental|1|
9962425|NCT01217918|Experimental|Cohort 1|PH-797804
9962426|NCT01217918|Experimental|Cohort 2|PH-797804
9962427|NCT01217918|Experimental|Cohotr 3|PH-797804
9962428|NCT01217931|Experimental|Group 1|Pazopanib + possible Bevacizumab
9962429|NCT01217931|Experimental|Group 2|Pazopanib + possible Everolimus
9962430|NCT01217931|Experimental|Group 3|Everolimus + possible Bevacizumab
9962431|NCT01217931|Experimental|Group 4|Everolimus + possible Pazopanib
9962432|NCT01217931|Experimental|Group 5|Bevacizumab + possible Pazopanib
9962433|NCT01217931|Experimental|Group 6|Bevacizumab + possible Everolimus
9962434|NCT01217970|Active Comparator|Ibudilast 20mg BID|Ibudilast 20mg oral BID 7 days
9962435|NCT01217970|Active Comparator|Ibudilast 50mg BID|Ibudilast 50mg oral BID 7 days
9962436|NCT01217970|Placebo Comparator|Placebo|Placebo oral BID 7 days (0mg ibudilast)
9962437|NCT01217996|Other|Intervention Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (intervention).
9962438|NCT01217996|Other|Control Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (control).
9962439|NCT01218074|Active Comparator|Thromboelastography alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.
9962440|NCT01218074|Experimental|Aggregometry+Tromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
9962441|NCT01218152||cancer patients|patients who are seen by oncologists and who are willing to donate an extra blood sample when blood is taken routinely
9962442|NCT01218152||NF1 patients|patients, who have neurofibromatosis type 1 and who have developped an MPNST,donating a blood sample
9962443|NCT01218165|No Intervention|Control Group|without intervention
9962444|NCT01218165|Experimental|Intervention Group|This group receives a probiotic drink daily for 6 week.
9962445|NCT01218178||Sodium bicarbonate plus NAC|Sodium bicarbonate plus NAC
9962446|NCT01218178||Saline hydration plus NAC|Saline hydration plus NAC
9962447|NCT01218191||Subarachnoid hemorrhage|Patients presenting a SAH
9962448|NCT01218217|Experimental|SQ109 75 mg|75 mg SQ109 monotherapy daily
9962449|NCT01218217|Experimental|SQ109 150 mg|150 mg SQ109 daily
9962450|NCT01218217|Experimental|SQ109 300 mg|300 mg SQ109 daily
9962451|NCT01218217|Experimental|SQ109 150 mg + RIF|150 mg SQ109 + RIF standard dose daily
9962452|NCT01218217|Experimental|SQ109 300 mg + RIF|300 mg SQ109 + RIF standard dose daily
9962453|NCT01218217|Active Comparator|RIF Mono|Standard dose Rifampicin monotherapy daily
9962454|NCT01218230|Active Comparator|Intravitreal Pegaptanib|
9962455|NCT01218256|Active Comparator|Hypertrophy resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
9962456|NCT01218256|Active Comparator|Endurance resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
9962457|NCT01218269|Other|no arms|all patients will receive the treatment - there is only one arms
9962458|NCT01218282|Experimental|Home Exercise Training Group A1|Patients assigned to this arm maintain the prescribed walking speed during the training with a metronome
9962459|NCT01218282|Experimental|Home Exercise Training Group A2|Patients assigned to this arm cover a fixed distance in a given period of time.
9962460|NCT01218282|No Intervention|Control|
9803660|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco non-menthol|Nicotine 0 mg combined with tobacco non-menthol flavor
9962461|NCT01218295|Experimental|Respiratory muscle training|Patients assigned to this arm train the respiratory muscles by means of normocapnic hyperpnea.
9962462|NCT01218321||Antiepileptic treatment group|Group of patients treated by antiepileptic medications
9962463|NCT01218334||1|Cardiac Inpatient
9962464|NCT01218334||2|Cardiac Outpatient
9962465|NCT01218334||3|Cardiac Clinic Patient
9962466|NCT01218347|Experimental|Rosuvastatin|rosuvastatin treatment
9476638|NCT03569852|Experimental|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
9962467|NCT01218360||Participants|All participants enrolled
9962468|NCT01218373|Active Comparator|Intervention Group: HOMESWEETHOME services|Monitoring and alarm handling services. eInclusion services. Domotica services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
9962469|NCT01218373|Placebo Comparator|Control Group: No HOMESWEETHOME services|Normal care.
9962470|NCT01218386|Experimental|Study Group|"Start with estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~If day 25 is Monday: 6 days Tuesday: 10 days Wednesday: 9 days Thursday: 8 days Friday: 7 days Saturday: 6 days Sunday: 6 days of Progynova, 2x2 mg per day After this pretreatment: Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation"
9962471|NCT01218386|Active Comparator|Control group|Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation
9962472|NCT01218412|Experimental|Web-based, Mi=Based Intervention|4 session web-based, MI-based intervention.
9962473|NCT01218425|Experimental|Medication|In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.
9962474|NCT01218451|Experimental|Group 1|Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
9962475|NCT01218451|Experimental|Group 2|Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
9962476|NCT01218451|Active Comparator|Group 3|Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
9962477|NCT01218464|Experimental|Conventional plus MSC treatment|Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
9962478|NCT01218464|Experimental|Conventional plus pacebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
9962479|NCT01218490|Experimental|lymphadenectomy|after surgery of the ovarian cancer, patient will have Pelvis and aortic-cava lymphadenectomy
9962480|NCT01218490|No Intervention|no lymphadectomy|after surgery, the patient will not have pelvic and aortic-cave lymphadenectomy
9962481|NCT01218503|Experimental|CHOICES - obese|behavioral weight loss treatment - overweight/obese females
9962482|NCT01218529|Experimental|Whole Brain Radiation Therapy (WBRT) + lapatinib|Whole Brain Radiation Therapy (30Gy in 10 fractions) and lapatinib 1250mg once daily for 2 weeks followed by lapatinib treatment 1500mg once daily for 4 weeks.
9962483|NCT01218568|Experimental|Rifaximin plus lactulose|
9962484|NCT01218568|Active Comparator|lactulose|30-60ml/day
9962485|NCT01218581|Active Comparator|group A|Group A received oral letrozole (2.5 mg/day, Femara, Novartis PharmaServices, Basel, Switzerland)
9476639|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
9962486|NCT01218581|Active Comparator|group B|group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)
9962487|NCT01218607|Placebo Comparator|Placebo|
9962488|NCT01218607|Active Comparator|Active|
9962489|NCT01218620|Experimental|Regimen I (Arm I)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
9962490|NCT01218620|Experimental|Regimen I (Arm II)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
10006434|NCT01594359|Active Comparator|High iron bean|High-iron bean
10006435|NCT01594359|Placebo Comparator|Low iron bean|Low-iron bean
9962491|NCT01218620|Experimental|Regimen II (Arm I)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
9962492|NCT01218620|Experimental|Regimen II (Arm II)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
9962493|NCT01218633|Placebo Comparator|Saline|
9962494|NCT01218633|Active Comparator|GLP-1-(9,36)-amide|
9962495|NCT01218633|Active Comparator|Exendin-9,39 @30pmol/kg/min|
9962496|NCT01218633|Active Comparator|Exendin-9,39 @300pmol/kg/min|
9962497|NCT01218685||Health adults|
9476640|NCT03569826||Observational|There is no intervention being administered. This registry only observes patients through their regular standard of care visits.
9962498|NCT01218685||Health children|
9962499|NCT01218685||Pregnants|
9962500|NCT01218685||Elderly over 65 years old|
9962501|NCT01218685||HIV patients|
9962502|NCT01218685||Kidney transplant|
9962503|NCT01218685||Oncologic patients|
9962504|NCT01218685||Rheumatologic adult patients|
9962505|NCT01218685||Rheumatologic children patients|
9962506|NCT01218737|Experimental|Association|0.3% gatifloxacin and 1.0% prednisolone acetate association in eye drops plus placebo
9962507|NCT01218737|Active Comparator|Isolated ingredients|0.3% gatifloxacin and 1.0% prednisolone acetate isolated eye drops formulations
9962508|NCT01218750|Experimental|edematous tractional epimacular membrane|Diabatic maculopathy comes to the edematous or tractional form. It is believed that epiretinal membranes are comprised from glial components. The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD). In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema. If vitreoschisis is present, a place of dissection is crucial. If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
9962509|NCT01218763||ICD patients|Candidates may come from the investigator's general population, who require DR ICD or CRT-D therapy for primary or secondary ICD indication and meet all study eligibility criteria
9962510|NCT01218789|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
10006436|NCT01594437|Experimental|TCN-202|
9962511|NCT01218815|Experimental|Culprit lesion IRA Revascularization|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
9962512|NCT01218815|Active Comparator|Complete IRA revascularization|Primary PCI of culprit lesion in IRA with DES stent
9962513|NCT01218828|Active Comparator|Standard therapy|Hydration with 0.9% saline per a standard protocol (control group)
9962514|NCT01218828|Experimental|LVEDP-based hydration strategy|LVEDP guided hydration with 0.9% saline (treatment group)
9962515|NCT01218841|Experimental|Fish oil lipid emulsion|Parenteral lipid emulsion composed by fish oil which is rich in the omega-3 polyunsaturated fatty acids eicosapentanoic and docosahexanoic.
9962516|NCT01218841|Active Comparator|MCT/LCT lipid emulsion|Parenteral lipid emulsion containing 50% of medium-chain triglycerides and 50% of soybean oil
9962517|NCT01218880|Experimental|M2ES-A|
9962518|NCT01218880|Experimental|M2ES-B|
9962519|NCT01218880|Experimental|M2ES-C|
9962520|NCT01218880|Experimental|M2ES-D|
9962521|NCT01218893|Active Comparator|15-15-15|This group will receive three times 15 infected mosquito bites under chloroquine prophylaxis, as we know that this dose is protective.
9962522|NCT01218893|Experimental|10-10-10|This group will receive three times 10 infected and 5 uninfected mosquito bites under chloroquine prophylaxis.
9962523|NCT01218893|Experimental|5-5-5|This group will receive three times 5 infected and 10 uninfected mosquitobites under chloroquine prophylaxis.
9962524|NCT01218893|Placebo Comparator|0-0-0|This group will receive three times 15 uninfected mosquitobites under prophylaxis.
9962525|NCT01218906||Cohort Population (Case )|Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
9962526|NCT01218919||Brio DBS System|Eligible subjects in this study will be screened to confirm that they meet the strict guidelines for advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication followed by bilateral surgery to implant the Brio™ deep brain stimulation system
9962527|NCT01218932|Experimental|A|Primaquine only, followed by chloroquine/primaquine, followed by chloroquine only
9962528|NCT01218932|Active Comparator|B|Primaquine alone, followed by chloroquine, followed by chloroquine/primaquine
9962529|NCT01218945||Fat Removal|Patients undergoing surgical fat removal
9962530|NCT01219010|Experimental|001|Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
9962531|NCT01219036|Other|Non-adherent|
9962532|NCT01219036|Other|Adherent|
9962533|NCT01219049|Experimental|Tyrosine 1000 mg / day|Patients receive 1000 mg tyrosine per day.
9962534|NCT01219049|Experimental|Tyrosine 2000 mg / day|Patients receive 2000 mg tyrosine per day.
9962535|NCT01219049|Placebo Comparator|Placebo|Patients receive placebo daily.
9962536|NCT01219062|Placebo Comparator|control|The patient will be performed spinal anesthesia alone, with postoperative PCA
9962537|NCT01219062|Active Comparator|Morphine|The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
9962538|NCT01219062|Active Comparator|bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
9962539|NCT01219088|No Intervention|Controlled group|Spinal anesthesia with 0.5% bupivacaine alone
9962540|NCT01219088|Active Comparator|Femoral nerve block|Spinal anesthesia plus femoral nerve block with 20 mL of 0.25% bupivacaine
9962541|NCT01219088|Active Comparator|Intrathecal morphine|Spinal anesthesia plus 0.1 mg of intrathecal morphine
9962542|NCT01219088|Active Comparator|Periarticular bupivacaine infiltration|Spinal anesthesia plus periarticular infiltration with 20 mL of 0.25% bupivacaine
9962543|NCT01219101|Experimental|clomiphene citrate and ethinyl estradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
9962544|NCT01219101|Active Comparator|clomiphene citrate and placebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
9962545|NCT01219114||1|
9803661|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco non-menthol|Nicotine 3 mg combined with tobacco non-menthol flavor
9962546|NCT01219127|Experimental|Derma-PACE|Pre-treatment evaluations include complete history and physical examination, chemistry and coagulation profiles, detailed past surgical and medical treatments. The local findings of the ulcer are quantitatively assessed using the S(AD) SAD classification (6) including photo-documentation for the size, shape and configuration of the ulcer
9962547|NCT01219140|Experimental|2 POMx Capsules|2 POMx Capsules daily
9962548|NCT01219140|Placebo Comparator|2 placebo Capsules|2 placebo Capsules daily
9962549|NCT01219153|Experimental|Extended high dose letrozole regimen /GnRH antagonist|
9962550|NCT01219153|Active Comparator|Short low dose letrozole regimen /GnRH antagonist|
9962551|NCT01219166||laparoscopic Roux-en-Y-gastric-bypass without cholecystectomy|
9962552|NCT01219166||laparoscopic Roux-en-Y-gastric baypass with cholecystectomy|
9962553|NCT01219179|Experimental|sterile water|Intervention group received sterile water if their sodium value was greater or equal to 150 mEq/liter
9962554|NCT01219192|Experimental|M2ES 15mg|
9962555|NCT01219192|Experimental|M2ES 30mg|
9962556|NCT01219192|Experimental|M2ES 45mg|
9962557|NCT01219192|Experimental|M2ES 60mg|
9962558|NCT01219205|Active Comparator|major branched retinal venous occlusion|
9962559|NCT01219205|Active Comparator|macular branched retinal venous occlusion|
9962560|NCT01219218|Experimental|A|Treatment group. Patients in this group receive actual shockwave therapy.
9962561|NCT01219231|Experimental|Exercise|
9962562|NCT01219231|Placebo Comparator|Placebo|
9962563|NCT01219244|Experimental|Caloric restriction|
9962564|NCT01219244|Experimental|omega-3 supplementation|
9962565|NCT01219244|Experimental|resveratrol supplementation|
9962566|NCT01219244|Placebo Comparator|placebo|
9962567|NCT01219244|Experimental|2nd step: intervention + physical /cognitive training|most effective dietary intervention plus physical and cognitive training
9962568|NCT01219244|Placebo Comparator|2nd step: most effective dietary intervention plus control|most effective dietary intervention plus control
9962569|NCT01219257||SpA patients|The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
9962570|NCT01219270||GFR >= 60|MDRD eGFR 60 or more
9962571|NCT01219270||GFR <60|Under MDRD eGFR 60
9962572|NCT01219283||Control (no PGD)|Receive their planned IVF treatment without PGD. 2 morphologically best embryos are transferred.
9962573|NCT01219283||Case (PGD)|Receive PGD in addition to their planned IVF Cycle. 2 morphologically best PGD normal embryos are transferred.
9962574|NCT01219309|Active Comparator|Omega 3/6 treatment|
9962575|NCT01219309|Placebo Comparator|Placebo|
9962576|NCT01219322|Experimental|intravenous bicarbonate|Intravenous bicarbonate(05meq/cc ) 50 cc will be injected.
9962577|NCT01219322|Placebo Comparator|Intravenous injection of 50 cc normal saline|Injection of volume equivalent of normal saline to compare the establish the effect of same volume as the experimental drug
9962578|NCT01219348|Experimental|Indeolamine 2,3 deoxygenase|To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
9962579|NCT01219374||egg donors|anonymous egg donors
9962580|NCT01219400|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
9962581|NCT01219413|Experimental|aliskiren, placebo, perindopril|
9962582|NCT01219413|Experimental|perindopril, placebo, aliskiren|
9962583|NCT01219426||students from the University of Nantes|To be more than 18 years old (the legal age to gamble in France)
9962584|NCT01219426||pathological gamblers seeking treatment|To be more than 18 years old (the legal age to gamble in France)and pathological gambler
9962585|NCT01219452|Experimental|umbilical cord mesenchymal stem cells|intramuscular injection of umbilical cord mesenchymal stem cell
9962586|NCT01219465|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
9962587|NCT01219478||control|0 metabloil risk
9962588|NCT01219478||1|1 metabloil risk
9962589|NCT01219478||2|2 metabloil risk
9962590|NCT01219478||3|3 metabloil risk
9962591|NCT01219491||Egg donor recipients|
10006437|NCT01594437|Placebo Comparator|Placebo|
9962592|NCT01219517|Experimental|Study Group|All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
9962593|NCT01219530||Gestational Carriers|
9802378|NCT05300503|Experimental|Intervention|Participants will be asked to continue their usual day to day activities and take their current medications as directed. They will be sent a link by email or through MyChart to the educational session described above in the control group section. They will receive an Aetonix aTouchAway platform monitor, which is a disease specific home monitoring device to take home for 3 month intervention period. The device will prompt the participant to check their blood pressure on a daily basis and will send all readings to the UOHI Telehome monitoring program. The telehome monitoring nursing team will monitor the readings for each participant. For hypertensive patients who are not at target with their BP, the telehome monitoring nurse will titrate medications based on an advanced medical directive every 2 weeks. Patients will be provided instructions of when they should seek medical attention (clinical symptoms or SBP <100 or SBP >160).
9802379|NCT05300464|Other|Single arm|All patients perform standard breast screening and also MammoWave exam.
9802380|NCT05300308||transperitoneal pelvic lymph node dissection for treatment of urogenital cancer|patients planned for transperitoneal pelvic lymph node dissection for treatment of urogenital cancer (including prostate or bladder cancer)
9803662|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco non-menthol|Nicotine 12 mg combined with tobacco non-menthol flavor
9803663|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco menthol|Nicotine 0 mg with tobacco menthol flavor
9962594|NCT01219530||Intended Parents|
9962595|NCT01219543|Experimental|Part A|Daily dosing of AZD1480 to the patients with solid tumours excluding HCC
9962596|NCT01219543|Experimental|Part B|BID dosing of AZD1480 to the patients with advanced HCC (Child-Pugh A to B7)
9962597|NCT01219543|Experimental|Part C|BID dosing of AZD1480 to the patients with solid tumours excluding HCC
9962598|NCT01219543|Experimental|Expansion|BID dosing of AZD1480 to the patients with EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available.
9962599|NCT01219556||Group 1|
10006438|NCT01594450|Experimental|biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
10006439|NCT01594450|Active Comparator|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization.
10006440|NCT01594463|Experimental|late ultrasound examination|late examination between 34+1 weeks to 35+6 weeks.
9803664|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco menthol|Nicotine 3 mg combined with tobacco menthol flavor
10006441|NCT01594463|Experimental|early ultrasound examination|early examination between 30+1 weeks to 31+6 weeks
10006442|NCT01594489|Experimental|Aminophylline|Additional Aminophylline therapy to hydration (sodium bicarbonate) and N-acetilcysteine
10006443|NCT01594489|Active Comparator|Control group|Control group treated with hydration (sodium bicarbonate) and N-acetilcysteine
10006444|NCT01594502||Dutasteride Year 2 PCa|Subject assigned to dutasteride, prostate cancer found on Year 2 biopsy.
10006445|NCT01594502||Placebo Year 2 no PCa, Year 4 PCa|Subject assigned to placebo, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
10006446|NCT01594502||Dutasteride Year 2 no PCa, Year 4 PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
10006447|NCT01594502||Placebo, Year 2 and 4 no PCa|Subject assigned to placebo, no prostate cancer found on Year 2 or Year 4 biopsy.
10006448|NCT01594502||Dutasteride, Year 2 and 4 no PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 or Year 4 biopsy.
10006449|NCT01594502||Placebo, Year 2 PCa|Subject assigned to placebo, prostate cancer found on Year 2 biopsy.
10006450|NCT01594541||Patients Treated with CerefolinNAC®|
10006451|NCT01594541||Patients Not Treated with CerefolinNAC®|
10006452|NCT01594554||HCV Patients|A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279).
10006453|NCT01594580|Experimental|Antimicrobial impregnated scrubs|Those randomized to this arm of the study will wear scrubs impregnated with an antimicrobial.
10006454|NCT01594580|Placebo Comparator|Non-impregnated scrubs|Those randomized to this arm of the study will wear scrubs not impregnated with an antimicrobial.
10006455|NCT01594593|Experimental|Acceptance and Commitment Therapy|Group-based behavioral workshop to address cancer-related distress
10006456|NCT01594593|No Intervention|treatment as usual|
9962600|NCT01219569||2. Sevoflurane|Subjects will receive sevoflurane at 1.5% and 2.5% end tidal after steady state maintenance has been achieved and have pupillometry readings taken and every 10 minutes for 30 minute at each drug dose.
9962601|NCT01219569||1.Propofol|1.Subjects will receive propofol infusion and have pupillometry readings taken in both eyes after induction, after steady state maintenance has been achieved and at 30 minutes
9962602|NCT01219582||Group 1|
9962603|NCT01219595|Active Comparator|Part 1|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
9962604|NCT01219595|Other|No treatment|20 non-UTI susceptible women will be enrolled to collect data on the types of E. coli flora present in non-UTI women.
9962605|NCT01219595|Active Comparator|Part 2A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
9962606|NCT01219595|Placebo Comparator|Part 2B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
9962607|NCT01219595|Active Comparator|Part 3A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
9962608|NCT01219595|Placebo Comparator|Part 3B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
9962609|NCT01219608|Active Comparator|Glutamine 0.5 g/kg/day|
9962610|NCT01219608|Active Comparator|Glutamine 1 g/kg/day|
9962611|NCT01219608|Placebo Comparator|Enteral Nutrition|
9962612|NCT01219621|Active Comparator|DDD Long AVD|
9962613|NCT01219621|Experimental|safeR|
9962614|NCT01219647|Experimental|aerobic exercise|Subjects will train on a recumbent cross trainer 20-30 minutes/session for three times/week for six months under supervision of a fitness specialist
9962615|NCT01219647|Active Comparator|stretching|Subjects will particiate in supervised stretching at same frauency, duration and intensity of aerobic exericse arm
9962616|NCT01219686|Experimental|escitalopram 20mg + pindolol 15mg|Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
9803665|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco menthol|Nicotine 12 mg combined with tobacco menthol flavor
9962617|NCT01219686|Active Comparator|Escitalopram 30 mg|Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
9962618|NCT01219686|Active Comparator|escitalopram 20 mg|days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo
9962619|NCT01219699|Experimental|BYL719|In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
9962620|NCT01219699|Experimental|BYL719 + fulvestrant|In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
9962621|NCT01219712|Active Comparator|Preoperative Optimization|"Patients with proximal femur fracture who are > 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management.~The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively.~Hb would be optimized to > 90 g/l~SaO2 > 96%~Stroke volume index (SVI) > 30~Heart rate should ideally be < 80~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal."
9962622|NCT01219712|No Intervention|Standard treatment|Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.
9962623|NCT01219751|Experimental|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
9962624|NCT01219764|Active Comparator|Full Dose|Full dose of Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
9962625|NCT01219764|Experimental|Half dose|Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
9962626|NCT01219790|Experimental|irradiation + zometa|
9962627|NCT01219803|Experimental|High dose GGQL Decoction|
9962628|NCT01219803|Experimental|Mild dose GGQL Decoction|
9962629|NCT01219803|Experimental|Low dose GGQL Decoction|
9803666|NCT03627988|Experimental|Patients with breast cancer|
9962630|NCT01219803|Placebo Comparator|Placebo|
9962631|NCT01219816|Experimental|Patients under 60 years|Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)
9962632|NCT01219816|Experimental|Patients older than 60 years or < =60 years|Vincristine + Aracytine + Dexamethasone
9962633|NCT01219829||Family History patients|Patients with a strong family history of pancreatic cancer or with a genetic syndrome that puts them at risk for pancreas cancer.
9962634|NCT01219829||Recurrence patients|Patients who underwent surgery for pancreatic cancer and developed tumor recurrence after surgery
9476641|NCT03569813|Experimental|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits and behavioral surveillance, and telemedicine visits as needed.
9962635|NCT01219842|Active Comparator|INVASIVE (INV) group|Modern endovascular and/or open revascularization according to the recommendations in the TASC II document.
9962636|NCT01219842|Active Comparator|NON-INVASIVE (NON) group|Patients receiving only best medical treatment (BMT).
9962637|NCT01219868|Experimental|Physician-nurse team|
9962638|NCT01219894||RUTTS Score <30%|Patients with evidence of complete healing of stent at 3 months
9962639|NCT01219894||RUTTS<30%|Group with evidence of incomplete healing of the stent
9962640|NCT01219907|Experimental|Arm I|"VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.~CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.~IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20."
9962641|NCT01219920|Active Comparator|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
9962642|NCT01219920|Experimental|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
9962643|NCT01219946||1|Patients with Chronic Obstructive Pulmonary Disease
9962644|NCT01219972||Allografted patients|"All consecutive patients who underwent an allogeneic blood stem cells transplantation performed at saint Louis hospital during the study recruitment period~if alive at 100 days post-transplant~and who gave informed consent"
9962645|NCT01219998||NGAL Kinetics in neonates|to describe postoperative kinetics of urinary NGAL in neonates and to identify the threshold for accurate prediction of severe AKI requiring RRT in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass
9962646|NCT01220011|Experimental|NO INTERVENTION|
9962647|NCT01220011|Active Comparator|fetoscopic laser|
9962648|NCT01220037|Experimental|Young regular diet|During the time of the study this group will adhere to a standardized regular diet.
9962649|NCT01220037|Experimental|Young low protein diet|During the time of the study this group will adhere to a standardized low protein diet.
9962650|NCT01220037|Experimental|Young high protein|During the time of the study this group will adhere to a standardized high protein diet.
9802381|NCT05300074|Experimental|Training two times per week|Training two times per week. IMT with 5 rounds and 12 repetitions in each round at 60-80% MIP. The primary protocol will end at 6 weeks and the self-administered long-term protocol will end at 6-8 months end of treatment.
9802382|NCT05300074|Experimental|Training five times per week|Training five times per week. IMT with 5 rounds and 12 repetitions in each round at 60-80% MIP. The primary protocol will end at 6 weeks and the self-administered long-term protocol will end at 6-8 months end of treatment.
9802383|NCT05297708||All Participants|he population would be pediatric patients 6 years to <19 years of age who were referred for elevated blood pressure. At the initial clinic visit, the participant will be consented and a thorough history will be taken. An ECHO and non-invasive vascular measurements will be taken (central BP, augmentation index, pulse wave velocity). Patients will have an ambulatory blood pressure monitor (ABPM) placed and be trained to use a home blood pressure monitor (HBP) which will be sent home with them. The monitors in this study are FDA-approved and are being used as indicated. After one day at home, patients will return the ABPM via mail and continue to take measurements with the HBP for 20 days.
9802384|NCT05297513|No Intervention|Standard treatment, no intervention|
9802385|NCT05297513|Experimental|Standard treatment, plus ActiveMatrix|
10006457|NCT01594606|Experimental|Animal-assisted|This group receives the dog training program in which they will be teaching a dog basic obedience skills.
9802386|NCT05297396|Experimental|Slow Tapering of Chronic Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will have their opioid medication doses slowly and gradually reduced every 4 weeks.
9802387|NCT05297396|No Intervention|Continued Opioid Therapy|Subjects who are on a stable dose of daily opioid therapy for at least 6 months will stay on the same dose of opioids they are currently using at the beginning of the study for the entire 12-month duration of the study.
9802388|NCT05297084||Aggressive periodontitis|25 young medically free patients with deep periodontal pockets >5mm
9962651|NCT01220037|Experimental|Elderly|During the time of the study this group will adhere to a standardized high protein diet
9962652|NCT01220050|Experimental|Paricalcitol|
9962653|NCT01220050|Active Comparator|Standard therapy|
9962654|NCT01220063|Other|Radiation + Irinotecan|"Irinotecan will be administered :~- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy~Radiotherapy (RSHF) will be administered :~at D1, D3, D8 and D10~48 Gy, 12 Gy by fractions twice a week"
9962655|NCT01220076|Experimental|Tamoxifene|
9962656|NCT01220089|Active Comparator|Standard maintenance|During months 7 to 18, individuals in the Standard Maintenance condition will receive informational handouts by mail (or e-mail) regarding weight maintenance.
9962657|NCT01220089|Active Comparator|Intensified Maintenance|"During months 7 to 18, individuals in the Intensified Maintenance condition will continue to have monthly in-person visits with the weight loss counselor (Weight Coach)."
9962658|NCT01220115||No treatment|Patients aged 2 to less than 12
9962659|NCT01220115||No treatment patients aged 12 to less than 18|Patients aged 12 to less than 18
9962660|NCT01220115||No treatment Patients greater than 18 years|patients greater than 18 years
9962661|NCT01220141||A|
9962662|NCT01220154|Experimental|Carboplatin Paclitaxel & Bevacizumab|Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
9962663|NCT01220193||Normal cornea|
9962664|NCT01220193||Post laser refractive surgery|
9962665|NCT01220193||Cornea pathology|
9962666|NCT01220193||Cataract surgery|
9962667|NCT01220206|Placebo Comparator|Placebo|2 placebo capsules daily
9962668|NCT01220206|Experimental|one POMx capsule|One POMx capsule, one placebo capsule daily
9802389|NCT05297084||Periodontally healthy individuals|25 young medically free individuals with no periodontal inflammation signs
9962669|NCT01220206|Experimental|2 POMx Capsules|2 POMx Capsules daily
9962670|NCT01220219|Experimental|Pregabalin controlled release, 82.5 mg|
9962671|NCT01220219|Experimental|Pregabalin controlled release, 165 mg|
9962672|NCT01220219|Other|Pregabalin immediate release, 75mg|Reference Treatment
9962673|NCT01220232|Active Comparator|Abacavir/Lamivudine|
9962674|NCT01220232|Experimental|Lersivirine + Abacavir/Lamivudine|
9962675|NCT01220245|Experimental|Heparin-bonded endoluminal fempop bypass|Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
9962676|NCT01220245|Active Comparator|Surgical femoro-popliteal bypass|Surgical femoro-popliteal bypass.
9962677|NCT01220258|Experimental|Azithromycin ophthalmic solution, 1%|
9962678|NCT01220284|Experimental|Satraplatin in combo with vinorelbine|"Escalating doses of satraplatin and oral vinorelbine in subsequent cohorts of 3-6 patients according to the type and severity grade of acute toxicities observed during cycle 1.~The dose escalation process will be discontinued once the MTD is achieved."
9962679|NCT01220310|Experimental|Intervention|Online diabetes workshop observation and learning sessions
9962680|NCT01220323|Active Comparator|direct current stimulation|The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm.
9962681|NCT01220323|Sham Comparator|sham stimulation|
9962682|NCT01220336|Experimental|Health Coaching|
9962683|NCT01220349|Experimental|Echocardiographic 2D strain analysis|
9962684|NCT01220362|Other|Group 1|Bupivacaine 0.125%
9962685|NCT01220362|Other|Group 2|Bupivacaine 0.125%/Fentanyl 2mcg/ml
9962686|NCT01220375|Experimental|1|Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell release from bone marrow and HSC movement into the peripheral circulation.
9962687|NCT01220388|Experimental|L-lysine|11 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
9962688|NCT01220388|Placebo Comparator|placebo|11 days treatment with study drug, order of periods (L-lysine or placebo) being sorted out.
9962689|NCT01220427||Clinical high-risk prostate cancer, radical prostatectomy|
9962690|NCT01220440|Experimental|Methylphenidate, Dexamphetamine, Placebo|The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
9962691|NCT01220479|No Intervention|Control Healthy|
9962692|NCT01220479|No Intervention|Control Diabetic|
9962693|NCT01220479|Experimental|Exercise Diabetic|
9962694|NCT01220479|Experimental|Exercise Healthy|
9962695|NCT01220492|Experimental|conventional plus MSC treatment|participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
9962696|NCT01220492|Experimental|conventional plus placebo treatment|participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
9962697|NCT01220518|Active Comparator|CT-P13|infliximab
9962698|NCT01220518|Active Comparator|Remicade|infliximab
9962699|NCT01220544|Experimental|HaploTransplant with NK cells|Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2
9962700|NCT01220570|Experimental|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
9962701|NCT01220570|Experimental|Ridaforolimus|Ridaforolimus (MK-8669)
9962702|NCT01220570|Experimental|Dalotuzumab|Dalotuzumab (MK-0646)
9962703|NCT01220596|Experimental|Sequential therapy|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
9962704|NCT01220596|Active Comparator|Peginterferon alfa-2a monotherapy|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
9962705|NCT01220622|Active Comparator|Nimodipine|
9962706|NCT01220622|Placebo Comparator|Placebo|
9962707|NCT01220635|Experimental|Skill Group Program|Positive Thoughts and Actions Program
9962708|NCT01220635|Active Comparator|Individual Support Program|Measure of Adolescent Potential for Suicide (MAPS) - modified
9802390|NCT05296850|Experimental|Manual release group|Manual release will perform with plantar fascia and flexor hallucis longus stretching and tissue mobilization. Stretching/mobilization will applied for approximately 3 minutes.
9802391|NCT05296850|Experimental|Kinesio taping group|Two techniques will be used in kinesio taping application; first technique is the gastrocnemius muscle inhibition technique and the plantar fascia ligament correction technique and other technique is the transverse arch ligament correction technique.
9962709|NCT01220648|Experimental|Nilotinib in conjunction with low dose interferon alfa|
9476642|NCT03569813|Active Comparator|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
9962710|NCT01220661|Experimental|One dose|One dose prophylactic antibiotic
9962711|NCT01220674||community dwelling older adults, normal controls|men and women 55 years of age or older who are cognitively intact.
9962712|NCT01220674||community dwelling older adults, mild cognitive impairment|men and women 55 years of age or older who have minimal cognitive decline (MMSE 20-24).
9962713|NCT01220700|Experimental|Triclosane|triclosan coated suture material
9962714|NCT01220700|Active Comparator|Control|ordinary suture material
9962715|NCT01220713|Experimental|Treatment 1--1.5 atm abs|
9962716|NCT01220713|Experimental|Treatment 2--2.0 atm abs|
9962717|NCT01220713|Sham Comparator|Placebo--equivalent to breathing air|
9962718|NCT01220752|Experimental|IMRT + carbon ion boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
9962719|NCT01220765|No Intervention|Standard care|Patients randomized to the standard care group receive standard of care using pulse oximetry
9962720|NCT01220765|Experimental|Capnography|In the intervention group capnography is measured using a cannula under the nose connected to the capnograph. The capnographic device displays respiratory rate, end-tidal carbon dioxide (ETCO2) levels, and continuous waveforms.
9962721|NCT01220778|Experimental|Exercise|
9962722|NCT01220778|No Intervention|Control|
9962723|NCT01220791|Active Comparator|Follicular Medrol|In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
9962724|NCT01220791|Placebo Comparator|No medrol group|Patients will receive only Antagonist protocol for IVF as usual
9962725|NCT01220804||NPDR|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR)
9962726|NCT01220804||Control Population|Healthy volunteers
9962727|NCT01220817|Active Comparator|1 POMx capsule|1 POMx capsule daily
9962728|NCT01220817|Experimental|3 POMx capsules daily|
9962729|NCT01220830|Experimental|RFQMR on Multiple Sclerosis lesions|
9962730|NCT01220843|Placebo Comparator|Placebo|DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal
9962731|NCT01220843|Experimental|Sevelamer carbonate|DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals
9476643|NCT03569787||Patients with hyperprolactinaemia|Patients undergoing subfertility studies with at least one high prolactin reading (>500mU/L).
9962732|NCT01220882|No Intervention|Radiographic skeletal age assessment|Participant group studied will include all pediatric patients presenting to our institution with a unilateral or bilateral SCFE. Patients with metabolic and endocrine conditions will be included.
9962733|NCT01220895|Experimental|ACT (mutlimer selection) plus standard therapy|Adoptive Cellular Therapy prepared using Multimer Selection in combination with standard best available antiviral drug therapy
9962734|NCT01220895|Active Comparator|Best available antiviral drug therapy|
9962735|NCT01220908|Experimental|permanent Coil(s) implant, QOL measure|Coil implantation as treatment. Treatment is permanent implant.
9962736|NCT01220921|Experimental|Lumbar Microdiscectomy|Patients aged 18-80 with symptomatic lumbar disc herniation resulting in single nerve root compression recalcitrant to non-invasive therapies for at least 6 weeks
9962737|NCT01220921|Experimental|Single-Level Lumbar Fusion|Patients aged 18-80 with symptomatic grade I degenerative or isthmic spondylolisthesis with mechanical back pain with or without radiculopathy recalcitrant to non-invasive therapies for at least 3 months
9962738|NCT01220934||Cohort|
9962739|NCT01220960|Experimental|Art Therapy intervention group|For participants who will be part of the art therapy intervention, the art therapy group will be a closed group for eight women with breast cancer who are in treatment and recently have had surgery. The group will meet once a week for two hours over a period of 8 weeks, and will focus on exploring the expressive capabilities of art making in a supportive group. This group will be held in the conference room at the Cedars Breast Clinic. Each week will revolve around a theme that pertains to the experience of women living with breast cancer, and will be guided by the women's needs in the group. A broad range of art materials will be made available and various art techniques explored. No art experience is necessary. The intervention group will also need to fill out simple questionnaires before the art therapy groups starts and after the group finishes
9962740|NCT01220960|No Intervention|Control Group|The group not assigned to the intervention group will be asked to fill out questionnaires at two separate times (before and after the intervention group is run). The Control group will be offered the opportunity to join an open art therapy group upon completing the questionnaires.
9962741|NCT01220986||Right hepatectomy|Intervals from inflow division.
9962742|NCT01221012||men wearing Semipermeable garment|
9962743|NCT01221012||air permeable garment type BP2|
9962744|NCT01221012||air permeable garment type BP3|
9962745|NCT01221012||air permeable garment type MO|
9962746|NCT01221012||air permeable garment type BP1|
9962747|NCT01221025|Experimental|parecoxib|Parecoxib, a water-soluble prodrug of valdecoxib, is a high-selective COX-2 inhibitor that is first available for intravenous administration.
9962748|NCT01221038||group 1|young women not using OC
9962749|NCT01221038||group 2|young women using OC
9962750|NCT01221038||group 3|young men (database)
9962751|NCT01221051|Active Comparator|oxytocin|early cord clamping, administration of oxytocin 10 IU i.v, controlled cord traction, uterine massage after placenta expulsion
9962752|NCT01221051|Placebo Comparator|saline solution|early cord clamping, wait for signs of placenta detachment, encourage the woman to push out placenta by her own effort, uterine massage after placenta expulsion
10006458|NCT01594606|Active Comparator|Dog Walking|This group will walk a different dog each week but will not engage in dog training.
9962753|NCT01221064|Other|Early drainage removal|Patients randomised to early drainage removal arm will have the drain removed in postoperative day 1. Lymph will be punctured on a regular basis
9476644|NCT03569774|Experimental|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
9962754|NCT01221064|Other|Late drainage removal|Patients randomised to late drainage removal arm will have the drains kept until total daily drainage is 30ml and then removed
9962755|NCT01221103|Experimental|DOT|Combination of dexamethasone, ofatumumab and bendamustine
9962756|NCT01221116|No Intervention|1: Type of surgery|Two types of patients are compared (placebo vs levosimendan): CABG - coronary artery bypass grafting and AVR - aortic valve replacement (either with or without CABG - coronary artery bypass grafting)
9962757|NCT01221129||Dietary Restriction|
9962758|NCT01221142|Experimental|Hypothermia|Device: Cincinnati Sub-Zero Hyper-Hypothermia to core temperature of 34C for 24 hours, rewarming rate 0,5/2h until the patient reaches 36,5C
9962759|NCT01221168||Men with or without Prostate Cancer|"Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer.~Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer."
9962760|NCT01221220|Active Comparator|Behavioral Treatment|Six-month, family-based, group, behavioral weight control program
9962761|NCT01221220|Experimental|Behavioral Treatment plus Environmental Strategies|Six-month, family-based, group, behavioral weight control program plus home-based environmental intervention
9962762|NCT01221259|Experimental|Drug E2212|
9962763|NCT01221259|Placebo Comparator|Placebo|
9962764|NCT01221324||Patients after open resection of colorectal cancer|
9962765|NCT01221337|Other|haemodialyzer EVODIAL-haemodialyzer VIE|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
9962766|NCT01221337|Other|haemodialyzer VIE-haemodialyzer Evodial|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
9962767|NCT01221376|Experimental|Imatinib Mesylate|
9962768|NCT01221389|Active Comparator|Colloid Control|Patients will receive 2 units of 250 ml of hydroxyethylated starch solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
9962769|NCT01221389|Active Comparator|Plasma|Patients will receive 2 units of AB+ plasma once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
9962770|NCT01221402|Experimental|Extended-release niacin|
9962771|NCT01221402|Placebo Comparator|Placebo|
10006459|NCT01594619|Experimental|A|Single dose naloxegol 25mg
9476645|NCT03569774|Active Comparator|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
9476646|NCT03569722||Older adults|Older adults, ages 65+
9476647|NCT03569709|Active Comparator|Aerobic Exercise|Sub-threshold aerobic exercise.
9476648|NCT03569709|Placebo Comparator|Stretching|Stretching program that will not raise heart rate.
9962772|NCT01221428|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
9476649|NCT03569709|Placebo Comparator|Rest|Relative rest. Avoid all structured exercise.
10006460|NCT01594619|Active Comparator|B|Diltiazem 240mg once daily day 4-6
10006461|NCT01594619|Active Comparator|C|Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
10006462|NCT01594632|Experimental|Jadelle|Contraception using Jadelle implant
10006463|NCT01594632|Active Comparator|Sino-implant (II)|levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]
10006464|NCT01594645|Experimental|Spermatozoa election using a polscope|AR+ spermatozoa are selected for ICSI using a polscope
10006465|NCT01594645|Active Comparator|Control|Spermatozoa for ICSI are selected based on morphology and motion under conventional light microscopy
10006466|NCT01594658||Foam sclerotherapy|This arm corresponds to ultrasound-guided foam sclerotherapy of superficial venous reflux plus conservative management
10006467|NCT01594658||Conservative|This arm only has medical standard handling (healings performed by the nurse group)
10006468|NCT01594671|Experimental|Tranexamic acid|"Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin"
10006469|NCT01594671|Active Comparator|Habitual haemostasia|The surgical habitual haemostasia.
10006470|NCT01594671|Experimental|Topical Tranexamic acid|Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
10006471|NCT01594684|Active Comparator|drug eluting balloon|treatment with drug eltuing balloon
10006472|NCT01594684|Placebo Comparator|uncoated balloon|treatment with uncoated balloon
10006473|NCT01594684|Active Comparator|double drug eluting balloon|if treatment fails 30 days or later
10006474|NCT01594697|Experimental|metformin|
10006475|NCT01594710||Apparently Health People|
10006476|NCT01594736|Active Comparator|ORSIRO|
10006477|NCT01594736|Active Comparator|XIENCE PRIME DES|
10006478|NCT01594775|Active Comparator|nasal spray|
10006479|NCT01594775|Placebo Comparator|Placebo|
10006480|NCT01594801|No Intervention|Control|Subject continue their routine therapy
10006481|NCT01594801|Experimental|Test|Subjects using the InsuPad device
10006482|NCT01594814||RFA of AVNRT of AVRT|
10006483|NCT01594840|Experimental|Changing chat|Diapers will have tips on them
10006484|NCT01594840|Active Comparator|Control|Normal diapers
10006485|NCT01594866|Placebo Comparator|Escitalopram, 20mg, placebo|escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
10006486|NCT01594866|Experimental|Escitalopram 20mg, escitalopram 10mg|Escitalopram 20mg + Escitalopram 10mg
10006487|NCT01594879|Experimental|Endometrial cancer, LNG-IUS with MPA|
10006488|NCT01594892|Experimental|Dose intensified SBRT|Depending on the modified Mizumoto Score (0-4 points or 5-9 points) patients will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost or with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost, respectively.
10006489|NCT01594905|Experimental|Entecavir 1.0mg + Tenofovir 300mg|All subjects will orally take investigational drugs once daily for 48 weeks.
9962773|NCT01221454|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
9962774|NCT01221454|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
9962775|NCT01221467|Active Comparator|Overnight closed-loop combined with real-time CGM|
9962776|NCT01221467|Active Comparator|Real-time CGM alone|
9962777|NCT01221480||Beta Blocker Use|
9962778|NCT01221480||No beta blocker use|
9962779|NCT01221493|Experimental|Cryo biospy|
9962780|NCT01221519|Experimental|1|AZD1656
9962781|NCT01221519|Experimental|2|AZD1656
9962782|NCT01221519|Experimental|3|AZD1656
9962783|NCT01221532|Experimental|SHHE Peridischarge intervention|Patients receive the Support from Hospital to Home (SHHE) Peridischarge Intervention plus usual care
9962784|NCT01221532|No Intervention|Usual Care|
9962785|NCT01221545|Experimental|A - AZD1656|AZD1656
9962786|NCT01221545|Placebo Comparator|B - Placebo|Placebo
10006490|NCT01594918|Experimental|Cabazitaxel, Mitoxantrone, Prednisone|
9962787|NCT01221558|Experimental|6mg lycopene|
9962788|NCT01221558|Experimental|15mg lycopene|
9962789|NCT01221558|Placebo Comparator|placebo|
9962790|NCT01221571|Experimental|AFM13|IV (intravenous) infusion, dose escalation
9962791|NCT01221584||1|Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
9962792|NCT01221610|Experimental|Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter
9962793|NCT01221610|Active Comparator|Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter
9962794|NCT01221636|Other|Low Metal Abatacept|Reference
9962795|NCT01221636|Experimental|High Metal Abatacept|
9962796|NCT01221701|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus one booster session scheduled 1 month later.
9962797|NCT01221701|No Intervention|typical home visitation|Standard of care in home visitation in which mothers can receive treatment in the community if they choose.
9962798|NCT01221714||Active/Placebo|ACTIVE VITAMIN; PLACEBO OMEGA MAX
9962799|NCT01221714||Active/Active|ACTIVE VITAMIN; ACTIVE OMEGA MAX
9962800|NCT01221714||Placebo/Active|PLACEBO VITAMIN; ACTIVE OMEGA MAX
9962801|NCT01221714||Placebo/Placebo|PLACEBO VITAMIN; PLACEBO OMEGA MAX
9962802|NCT01221740|Experimental|Milnacipran|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
9962803|NCT01221779|Placebo Comparator|sham tDCS|
9962804|NCT01221779|Experimental|anodal tDCS|
9962805|NCT01221792|Active Comparator|carvedilol|Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
9962806|NCT01221792|Placebo Comparator|Sugar Pill|Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
9962807|NCT01221818|Experimental|1|
9962808|NCT01221818|Experimental|2|
9962809|NCT01221818|Experimental|3|
9962810|NCT01221818|Experimental|4|
9962811|NCT01221818|Experimental|5|
9962812|NCT01221818|Experimental|6|
9962813|NCT01221831|Experimental|estetrol dose 1 / P1|
9962814|NCT01221831|Experimental|estetrol dose 1 / P2|
9962815|NCT01221831|Active Comparator|estradiol valerate/dienogest pill|
9962816|NCT01221831|Experimental|estetrol dose 2 / P1|
9962817|NCT01221831|Experimental|estetrol dose 2 / P2|
9962818|NCT01221844|Experimental|Lactoferrin treatment in HT pregnacies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
9962819|NCT01221844|Active Comparator|Ferrous sulfate in HT pregnancies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
9962820|NCT01221870|Experimental|Tesetaxel once every 3 weeks|Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
9962821|NCT01221870|Experimental|Tesetaxel once weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
9962822|NCT01221883|Placebo Comparator|Placebo|Placebo capsule in ER, identical follow up like those in the active arm.
9962823|NCT01221883|Experimental|Diazepam|10 mg of Diazepam mg orally at ER only (a single administration)
9962824|NCT01221896||Hyperparathyroidism|Patients with hyperparathyroidism, prior to surgery.
9962825|NCT01221909|Experimental|Tranexamic acid single dose of 500mg|
9962826|NCT01221909|Placebo Comparator|Saline|
9962827|NCT01221922|Experimental|Acne treatment|Treatment of acne scars
9962828|NCT01221935||Patients initiated on Pristiq as a first line treatment|
9962829|NCT01221935||Patients initiated on Pristiq as a 2nd-line treatment|
9962830|NCT01221935||Patients initiated on a SNRI or SSRI as a first-line treatment|
9962831|NCT01221935||Patients initiated on a SNRI or SSRI as a 2nd-line treatment|
9962832|NCT01221974|Experimental|Essure,Hydrosalpinx, Infertility|
9962833|NCT01221987||Cohort A|Females > 21 years of age, diagnosed with invasive cervical cancer
9962834|NCT01221987||Cohort B|Females > 21 years of age, diagnosed with moderate or severe cervical intraepithelial neoplasia
9962835|NCT01222000|Experimental|right controlled against moisturizing cream|
9962836|NCT01222000|Experimental|left controlled against moisturizing cream|
9962837|NCT01222013|Experimental|Imatinib Mesylate|
9962838|NCT01222026|Active Comparator|Strontium Ranelate|Receiving Strontium Ranelate + Ca/Vitamin-D
9962839|NCT01222026|Placebo Comparator|Placebo|Receiving Placebo + Ca/Vitamin D
9962840|NCT01222039|Experimental|Conventional treatment plus high dose: 3x10e6 cells / Kg.|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
9802392|NCT05296837|Experimental|40mg of oral doxycycline|Arm A will receive 40mg of oral doxycycline pills for 8 weeks
9802393|NCT05296837|Active Comparator|100mg of oral doxycycline|Arm B will receive 100mg of oral doxycycline twice a day for 8 weeks
9802394|NCT05296837|Placebo Comparator|Placebo|Arm C will receive a placebo once a day for 8 weeks
9802395|NCT05296408|Experimental|M+ML|MyoPro paired with motor learning based therapy
9802396|NCT05296408|Active Comparator|ML-alone|motor learning based therapy alone
9802397|NCT05294796|Active Comparator|Short course of antibiotherapy|Patients enrolled in this arm, will receive 8 weeks of antibiotherapy in case of early infection (< 2 week), and 12 weeks of antibiotherapy in case of delayed infection (2-10 weeks)
9962841|NCT01222039|Experimental|Conventional treatment plus low dose: 1x10e6 cells / Kg|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
9962842|NCT01222052|Experimental|Arm A Taxane-containing|3 courses FEC q3weeks followed by 3 courses Docetaxel q3weeks
9962843|NCT01222052|Active Comparator|Arm B standard anthracyclin|6 courses of FEC q3weeks
9962844|NCT01222052|No Intervention|Observation|
9962845|NCT01222065||Glaucoma/Normal|Two groups will be studies: patients with glaucomatous visual field loss and age and gender matched normal patients without visual field loss
9962846|NCT01222143|Experimental|NOVE-HiDAC and Nilotinib|All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
9962847|NCT01222156|Experimental|CGCI navigation|Subjects with CGCI navigation to specific target intracardiac anatomical sites
9962848|NCT01222169|Experimental|larynx assessment under stimulation|
9962849|NCT01222169|Placebo Comparator|Larynx assessment under stimulation|
9962850|NCT01222182||Eligible plan beneficiaries on atorvastatin|A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.
9962851|NCT01222208|Active Comparator|Oral Nutrition|Subjects will receive an oral nutrition regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as pressurized whey protein
9962852|NCT01222208|Placebo Comparator|Peripheral Parenteral Nutrition|Subjects will receive a peripheral parenteral nutrition (PPN) regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as amino acids.
9962853|NCT01222312|Active Comparator|Arm A cisplatin|Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles
9962854|NCT01222312|Experimental|Arm B oxaliplatin|Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles
9962855|NCT01222325|Active Comparator|swl 3000 impulses- 60 imp/min|patients in this group were submitted to extracorporeal shockwave lithotripsy (SWL) 3000 impulses at 60 impulses per minute under general anesthesia. Unique session
9962856|NCT01222325|Active Comparator|swl- 4000 impulses - 90 impulses /min|patients in this group were submitted extracorporeal shockwave lithotripsy (swl) to 4000 impulses at 90 impulses per minute under general anesthesia- unique session
9962857|NCT01222338|Active Comparator|Immunomodulator intervention|Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
9962858|NCT01222338|Placebo Comparator|placebo|Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
9962859|NCT01222364|Active Comparator|Standard Cord Clamping|
9962860|NCT01222364|Experimental|Delayed Cord Clamping|
9962861|NCT01222377|Experimental|Arm I|Patients undergo endoscopic breast surgery.
9962862|NCT01222429|Active Comparator|diet following American Diabetes Association guidelines|Participants will follow diets based on ADA guidelines. This group will also receive weekly nutrition classes.
9962863|NCT01222429|Experimental|vegan diet|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
9962864|NCT01222442|Experimental|1|400 µg AZD3199 + moxifloxacin placebo
9962865|NCT01222442|Experimental|2|1200 µg AZD3199 + moxifloxacin placebo
9962866|NCT01222442|Active Comparator|3|AZD3199 placebo + moxifloxacin 400 mg
9476650|NCT03569696|Experimental|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
9962867|NCT01222442|Placebo Comparator|4|AZD3199 placebo + moxifloxacin placebo
9962868|NCT01222455|Experimental|1|Mild hepatic impairment
9962869|NCT01222455|Experimental|2|Moderate hepatic impairment
9962870|NCT01222455|Experimental|3|Severe hepatic impairment
9962871|NCT01222455|Experimental|4|Matched healthy volunteers with normal hepatic function
9962872|NCT01222468|Active Comparator|nabilone|nabilone 0.5 mg tablets dose-titrated over an 11-week period to a maximum of 3mg po daily. Subjects are allowed to drop back to the previous dose following a dose increase once if required
9962873|NCT01222468|Placebo Comparator|placebo|look-alike 0.5 mg placebo tablets titrated to a maximum daily dose of 3.0 mg daily over an 11-week phase. Subjects are allowed to drop back to the previous dose following a dose increase once during the 11-week phase if required
9962874|NCT01222481||Newly-diagnosed Head and Neck Cancer|
9962875|NCT01222546|Experimental|CH5132799|
9962876|NCT01222559|Experimental|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
9962877|NCT01222559|Active Comparator|Micofracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
9962878|NCT01222611|No Intervention|Standard HAART|ART with 3 drugs including 2 NRTIs plus a ritonavir boosted PI (different to FPV) or a NNRTI
9962879|NCT01222611|Experimental|HAART inlcuding Fos APV/r|ART with 3 drugs including 2 NRTIs plus ritonavir boosted fosamprenavir
9962880|NCT01222624|Experimental|PankoMab-GEX™, 3-weekly|application, q3w
9962881|NCT01222624|Experimental|PankoMab-GEX™, 2-weekly|application q2w
9962882|NCT01222624|Experimental|PankoMab-GEX™, weekly|application q1w
9962883|NCT01222637|Experimental|CetuGEX™, weekly|application weekly
9962884|NCT01222637|Experimental|CetuGEX™ 2-weekly|application biweekly
9962885|NCT01222650|Experimental|KSO-0400 Low Dose|
9962886|NCT01222650|Experimental|KSO-0400 High Dose|
9962887|NCT01222650|Experimental|Silodosin|
9962888|NCT01222650|Placebo Comparator|Placebo|
9962889|NCT01222663|Other|Standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
9962890|NCT01222663|Experimental|Hemoperfusion|standard therapy + 2 sessions of hemoperfusion within the first 24 hours
10006491|NCT01594957|Experimental|LCQ908 (mild hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with mild hepatic impairment and will receive a single dose of LCQ908.
10006492|NCT01594957|Experimental|LCQ908 (moderate hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with moderate hepatic impairment and will receive a single dose of LCQ908.
9962891|NCT01222780|Experimental|Marqibo|"Marqibo® (Vincristine sulfate liposomal) will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.~The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.~Detailed pharmacokinetic studies will be performed during the first treatment cycle"
9962892|NCT01222819|Experimental|IV filgrastim|as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg) in bolus IV injection, as per manufacturer's recommendations.
9962893|NCT01222819|Active Comparator|SC filgrastim|given as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg)
9962894|NCT01222845|Experimental|Pinhead oat porridge|
9962895|NCT01222845|Experimental|Rolled oat porridge|
9962896|NCT01222858|Active Comparator|Internet Education Program|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors.
9962897|NCT01222858|Experimental|Innovative Technology Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback.
9962898|NCT01222897|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
9962899|NCT01222897|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
9962900|NCT01222910|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
9962901|NCT01222910|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
9962902|NCT01222923|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
9962903|NCT01222923|Experimental|1|Risperidone 1 mg ODT tablets of Ranbaxy Laboratories, Ltd
9962904|NCT01222949|Experimental|Asian Healthy Volunteers|Asian males with a body weight ≤ 65 kg (12 subjects) Asian females with a body weight ≤ 65 kg (12 subjects)
9962905|NCT01222949|Experimental|Caucasian Healthy Volunteers|Caucasian males with a body weight ≤ 65 kg (12 subjects) Caucasian females with a body weight ≤ 65 kg (12 subjects) Caucasian males with a body weight > 65 kg (24 subjects)
9962906|NCT01222962|Experimental|fed treatment|18 healthy volunteers administered with a single dose of Eurartesim
9962907|NCT01222962|Experimental|Fasted Treatment|18 healthy volunteers treated with a single dose of Eurartesim
9962908|NCT01222975|Experimental|1|Risperidone orally disintegrating tablets of Ranbaxy Laboratories, Ltd
9962909|NCT01222975|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
9962910|NCT01222988|Other|very low calorie diet program|
9962911|NCT01223014||1|Single cohort of 6 subjects
9962912|NCT01223040|Experimental|SYSTANE® Balance Lubricant Eye Drops|SYSTANE Balance Lubricant Eye Drops dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
9962913|NCT01223053|Active Comparator|Active|Topical ketoprofen 10% Cream
9962914|NCT01223053|Placebo Comparator|Placebo Cream|Placebo Cream
9962915|NCT01223066||Women treated with Macrolane in the breasts|
9962916|NCT01223079|Other|r-hFSH (Gonal F)|Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
9962917|NCT01223079|Other|r-hFSH (Gonal F) and r-hLH (Luveris)|Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm. Patients will then bring 300IU/day of r-hLH until r-hCG administration.
9962918|NCT01223105|Experimental|Slow Freezing|oocytes will be frozen by slow freeze/ rapid thaw
9962919|NCT01223105|Experimental|Vitrification|oocytes will be frozen using rapid freezing/rapid thaw
9962920|NCT01223118|Experimental|Oocyte Vitrification|Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
9962921|NCT01223131|Experimental|Insulin glargine|injection once daily at bedtime
9962922|NCT01223131|Active Comparator|NPH insulin|injection once daily at bedtime or twice daily in the morning and at bedtime
9962923|NCT01223144|Experimental|Patients with essential tremor|Patients with essential tremor
9962924|NCT01223144|Active Comparator|age- and sex-matched control subjects|age- and sex-matched control subjects
9962925|NCT01223157|Experimental|Obese patients|
9962926|NCT01223157|Experimental|Normal weight subjects|
9962927|NCT01223170|Experimental|Enhanced Internet-based intervention|Behavioral: Tailored content Behavioral: Generic Internet-based information Behavioral: Discussion forum Behavioral: Behavioral monitoring
9962928|NCT01223170|Placebo Comparator|Control|Behavioral: Generic Internet-based information Behavioral: Discussion forum
9962929|NCT01223209|Experimental|LTX-315|The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.
9962930|NCT01223222|Placebo Comparator|1% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
9962931|NCT01223222|Active Comparator|2% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
9962932|NCT01223222|Active Comparator|5% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
9962933|NCT01223248|Experimental|stereotactic IGIMRT using a single dose of 24 Gy|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
9962934|NCT01223248|Experimental|stereotactic IGIMRT 27 Gy in 3 fractions|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
9962935|NCT01223274|Experimental|CPAP/PEEP Intervention|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
9962936|NCT01223274|Active Comparator|Control|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
9962937|NCT01223300||Osteoporosis|
10006493|NCT01594957|Experimental|LCQ908 (severe hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with severe hepatic impairment and will receive a single dose of LCQ908.
10006494|NCT01594996||Seroquel XR group|
10006495|NCT01595009|Experimental|Everolimus (RAD001)|Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.
10006496|NCT01595022|Placebo Comparator|Flexi ring FR01|
10006497|NCT01595022|Placebo Comparator|Flexi ring FR20|
10006498|NCT01595022|Placebo Comparator|Ultra low dose LCS|
10006499|NCT01595035|Experimental|counselling|Patients who receive the Pain booklet and support by telephone
10006500|NCT01595035|No Intervention|Control|Standard care
10006501|NCT01595074||Ancillary-Correlative (laboratory biomarkre analysis)|Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.
10006502|NCT01595087|Experimental|Osteodex, infusion|Osteodex
10006503|NCT01595126||Patients with Central Nervous System Tumors|
10006504|NCT01595139||NF-1 without evidence of glioma|
10006505|NCT01595139||NF-1 with evidence of glioma|
10006506|NCT01595152|Active Comparator|solifenacin succinate (10 mg OD)|
10006507|NCT01595152|Active Comparator|fesoterodine (8mg OD)|
9962938|NCT01223313|Experimental|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
9962939|NCT01223326|Experimental|N-acetylcysteine|Intravenous N-acetylcysteine
9962940|NCT01223326|Placebo Comparator|Placebo|Placebo
9962941|NCT01223339|Experimental|Single Dose Japanese Cohort|This will be a single dose Cohort in which Japanese healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin or placebo through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
9962942|NCT01223339|Experimental|Single dose Western cohort|This will be a single dose Cohort in which Western healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
9962943|NCT01223339|Experimental|Multiple Dose Japanese Cohort|This will be a multiple dose Cohort in which Japanese healthy participants will receive once-daily 25 mg ertugliflozin or placebo for 7 days.
9962944|NCT01223391|Experimental|Abdominal binder|Standing with abdominal compression using elastic vs. non-elastic abdominal binders.
9962945|NCT01223391|Placebo Comparator|No abdominal binder|Standing without abdominal compression
9962946|NCT01223430|Experimental|Si-Ni-Tang|
9962947|NCT01223430|Placebo Comparator|Placebo|
9962948|NCT01223443|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
9962949|NCT01223443|No Intervention|Standard medical treatment|
9962950|NCT01223482||Miscarriage with genetic testing|This is a study population of women that have had a miscarriage and had genetic testing performed. The investigators would like to know what their experiences were following their miscarriage and testing.
9962951|NCT01223482||Miscarriage without genetic testing|This cohort is considered the control group. These women have not had genetic testing done, but are asked questions regarding their miscarriage experience.
9962952|NCT01223521|Experimental|Immediate intrauterine contraception|IUD (either Cu-IUD or LNG-IUS) inserted immediately after abortion.
9962953|NCT01223521|No Intervention|Control group|Post-abortal contraception is prescribed by the hospital but on the responsibility of the patient.
9962954|NCT01223534|Active Comparator|Arm A, Standard practice, TST|Participants allocated to screening as stablished by current practice (TST)
9962955|NCT01223534|Experimental|Arm B, Experimental, TST plus QFT-IT|Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.
9962956|NCT01223547|No Intervention|Control group|Participants in this arm continues their usual insulin therapy
9962957|NCT01223547|Active Comparator|Carb counting|Participants in this arm are taught carb counting
9962958|NCT01223547|Active Comparator|Carb counting and bolus calculator|Participants in this arm are taught carb counting and are provided with an integrated glucose meter and bolus calculator.
9962959|NCT01223586||Regression|Patients with regression of plaque volume by statin
9962960|NCT01223586||Non regression|Patients without regression of plaque volume by statin
9962961|NCT01223612|Experimental|Ranibizumab|Intravitreal injection of ranibizumab
9962962|NCT01223612|Active Comparator|Laser|Modified ETDRS laser
9962963|NCT01223625|Active Comparator|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
9962964|NCT01223625|Active Comparator|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
9962965|NCT01223638||Congenital hypothyroidism|Patient which were diagnosed with congenital hypothyroidism
9962966|NCT01223638||Controls|Patients without any endocrine or hearing problems
9962967|NCT01223651|Active Comparator|CGMS at sea level.|To assess reliability of continuous glucose monitoring system at sea level whilst subject undergo's a hyperinsulinaemic glucose clamp study.
9962968|NCT01223651|Active Comparator|CGMS reliability at simulated 8000 feet.|To assess reliability of continuous glucose monitoring system at a simulated altitude of 8,000 feet whilst the participant undergo's a hyperinsulinaemic glucose clamp study.
9962969|NCT01223664|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
9962970|NCT01223664|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
9962971|NCT01223677|Active Comparator|rumination focused CBT|RFCBT-group. This group training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, group discussion, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
9962972|NCT01223677|Active Comparator|rumination focused CBT (online)|The online training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
9962973|NCT01223677|No Intervention|No training control group|No training control group. Participants within this condition received no treatment, but only filled out the outcome measures at each measurement period.
9962974|NCT01223690|Placebo Comparator|Placebo|250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
9962975|NCT01223690|Active Comparator|Clarithromycin|1000 mg of clarithromycin diluted in 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
9962976|NCT01223716|Experimental|Perceptual learning|
9962977|NCT01223716|Experimental|Video Game|
9962978|NCT01223716|Experimental|Occlusion Therapy|
9962979|NCT01223729|Experimental|Acetyl-L-Carnitine|
9962980|NCT01223729|Placebo Comparator|placebo|
9962981|NCT01223742|Experimental|ACETYL-L-CARNITINE|
9962982|NCT01223742|Placebo Comparator|placebo|
9962983|NCT01223755|Experimental|Sirolimus|
9962984|NCT01223755|Active Comparator|conventional therapy|
9962985|NCT01223768|Experimental|Acetyl-L-carnitine|
9962986|NCT01223768|Placebo Comparator|placebo|
9962987|NCT01223781|Experimental|Feedforward stimulation|Prior to any gait condition likely to invoke freez, auditory stimulation is presented
9962988|NCT01223781|Experimental|Feedback stimulation|Once a device identifies freezing, a auditory stimulation is triggered
9962989|NCT01223794||Experimental Group|Fall in higher risk
9962990|NCT01223794||Control Group|Fall in lower risk
9962991|NCT01223807|No Intervention|Control Group|The control group will receive only usual care.
9962992|NCT01223807|Experimental|Diaphragmatic breathing training|The training group will be submitted to a diaphragmatic breathing training program of 4 weeks.
9962993|NCT01223820|Experimental|Capsaicin|
9962994|NCT01223833||tamoxifen|100 postmenopausal women with early breast cancer treated with tamoxifen in the adjuvant setting
9962995|NCT01223833||aromatase inhibitors|200 postmenopausal women with early breast cancer treated with an aromatase inhibitor in the adjuvant setting
9962996|NCT01223859|Experimental|intervention|Interstitial soft palate RF surgery
9962997|NCT01223872||Routine Patient Care|
9962998|NCT01223872||Previously-enrolled REACH Clinic Patients|
9962999|NCT01223872||New REACH Clinic Patients|
9963000|NCT01223885|Experimental|Camel's milk, Cow's milk allergy|
9963001|NCT01223898|Experimental|Nilotinib|
9963002|NCT01223924|Experimental|M2ES 7.5-90mg|M2ES dose escalating
9963003|NCT01223924|Placebo Comparator|Placebo|placebo contract
9963004|NCT01223989|Experimental|group bread|group who received an hypocaloric balanced diet including bread
9963005|NCT01223989|Active Comparator|group without bread|group who received a hypocaloric balanced diet with exclusion of bread
9963006|NCT01224028|Experimental|Tacrolimus group|
9963007|NCT01224028|Placebo Comparator|Placebo|
9963008|NCT01224041|Experimental|Tacrolimus group|
9963009|NCT01224054||Bypass gastric|The mixed surgery which combine the gastric reduction with some degree of disabsorption
9963010|NCT01224054||Biliopancreatic diversion|The mal-absorptive surgery which reduce the intestinal absorption of food
9963011|NCT01224054||Duodenal exclusion|This surgery provides disabsortion by duodenal derivation maintaining an intact stomach
9963012|NCT01224067|Active Comparator|Quetiapine|Quetiapine (dosage 50mg to 300mg + sertraline)Experimental
9963013|NCT01224067|Placebo Comparator|Placebo|Participant will receive placebo for 8 weeks.
9963014|NCT01224080|Experimental|Adiana Device|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
9963015|NCT01224093||First line|
9963016|NCT01224093||Relapsed/refractory|
9963017|NCT01224119|Experimental|Amplex (synthetic bone graft)|
9963018|NCT01224119|Active Comparator|Autograft bone|
9963019|NCT01224132|No Intervention|Probiotics|
9963020|NCT01224132|No Intervention|skim milk powder, dextrose|
9963021|NCT01224184|Active Comparator|Nutrition|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
9963022|NCT01224184|Experimental|Young Women's|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (Principal Investigator (PI): Dr. Wendee M. Wechsberg).
9963023|NCT01224197|Experimental|001|TMC435 100 or 200 mg capsule one single dose
9963024|NCT01224197|Experimental|002|TMC435 100 or 200 mg capsule once daily for 5 days
9963025|NCT01224223||acute asthma exaecerbtion patients|Patients experiencing acute exacerbation of their asthma
9963026|NCT01224223||chronic asthma group|Two groups are being enrolled. The first group is chronic asthma patients with FEV1 below 80% and FEV1/FVC ratio reduced by 5%
9963027|NCT01224249|Active Comparator|Fish and shellfish|
9963028|NCT01224249|No Intervention|Control|Assessment only
9963029|NCT01224275|Experimental|Group antenatal care|The first arm is midwife which allocated to group based antenatal care. They have education in this model of care and follow up meeting to secure the intervention
9963030|NCT01224275|No Intervention|Individual antenaal care|the second arm include midwife which allocated to traditional care as control group.
9963031|NCT01224288|Experimental|DCE-CT Scans|DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
9963032|NCT01224301|Experimental|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have access to school-based flu vaccine clinics and 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
9963033|NCT01224301|Experimental|School based flu vaccine: Low intensity|Interventions: Parents in low intensity schools have access to school-based flu vaccine clinics and less than 3 communications from schools about influenza illness, influenza vaccine, and school based clinics.
9963034|NCT01224301|No Intervention|Standard of Care|Control Schools did not have any in school seasonal influenza vaccine clinics. Parents of children in control schools got no notification from the schools and sought seasonal influenza vaccines for their children as they normally would.
9963035|NCT01224314|Active Comparator|dialysis fluid potassium high|potassium concentration in the dialysis fluid 1 mmol/L higher than usual
9963036|NCT01224314|Active Comparator|dialysis fluid potassium low|potassium concentration in the dialysis fluid 1 mmol/L lower than usual
9963037|NCT01224327|Experimental|umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
9963038|NCT01224327|Active Comparator|Conserved therapy|Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
9963039|NCT01224340|Experimental|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
9963040|NCT01224340|Experimental|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path. The player got points for collected fishes but also credits for time of flying and speed.
9963041|NCT01224340|Experimental|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
9963042|NCT01224353|Placebo Comparator|Thioctacid Oral Placebo Tablet|
9963043|NCT01224353|Active Comparator|Thioctacid Oral Tablet|
9963044|NCT01224366|Experimental|Vildagliptin|
9963045|NCT01224366|Placebo Comparator|Placebo|
9963046|NCT01224379|Other|"Arm1: topping off system"|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
9963047|NCT01224379|Other|Arm 2: monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
9963048|NCT01224392|Active Comparator|Concomitant chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
9963049|NCT01224392|Experimental|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
9963050|NCT01224405|Active Comparator|Treatment arm|ten docetaxel cycles + maintenance androgen deprivation.
9963051|NCT01224405|Experimental|suspension arm|Ten Docetaxel cycles + stop androgen deprivation therapy
9963052|NCT01224405|Experimental|intermittent arm|Intermittent Docetaxel
9963053|NCT01224405|Active Comparator|Continuous arm|Continuous Docetaxel
9963054|NCT01224418|Experimental|Tacrolimus group|
9963055|NCT01224470|Active Comparator|bupivacaine|0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
9963056|NCT01224470|Placebo Comparator|saline|
9963057|NCT01224496|Experimental|Treatment with Chinese herbal concoction|"Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows~Yin deficiency of spleen and kidney~Yang deficiency of spleen and kidney~Deficiency of both Yin and Yang~Stagnation of dampness and poison in the blood~Excessive heat and poison"
9963058|NCT01224509|Experimental|Mifepristone|
9963059|NCT01224509|Active Comparator|Non-treatment|
9963060|NCT01224522|Experimental|Visionaire|the group who will be operated by the use of Visionaire patient matched cutting blocks
9963061|NCT01224522|Active Comparator|Standard Surgical technique|The group who will be operated by means fo standard surgical technique
9963062|NCT01224535|Experimental|Maize porridge with Amaranth|Maize porridge enriched with amaranth grain flour at 70:30 maize/amaranth ratio (80g/day)
9963063|NCT01224535|Active Comparator|Maize flour with multiple micronutrients|Maize porridge fortified with a multiple micronutrient powder (MixMe™)
9963064|NCT01224535|Placebo Comparator|Maize Porridge|Plain maize porridge group
9963065|NCT01224548|Experimental|vegan group|participants from sites of this group will receive vegan nutritional intervention starting from Feb 2011
9963066|NCT01224548|No Intervention|control group|participants from sites of the control group will not receive the same nutritional information until June 2011
9963067|NCT01224561||Constitutional thinness|Women with a a body mass index of less than 16.5 kg/m2
9963068|NCT01224561||Healthy Volonteer|Women with a body mass index between 20 and 25 kg/m2
9963069|NCT01224587|Experimental|1|D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition
10006508|NCT01595165|Placebo Comparator|Control|Control group receiving saline instead of ropivacaine
9963070|NCT01224587|Experimental|2|D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition
9963071|NCT01224587|Experimental|3|D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition
9963072|NCT01224587|Experimental|4|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition
9963073|NCT01224587|Experimental|5|D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition
9963074|NCT01224587|Experimental|6|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition
9963075|NCT01224600||1|patient with newly diagnosed PAD (< 1 year)
9963076|NCT01224613|Active Comparator|Intanza - self-administered|Self-administered intradermal influenza vaccine
9963077|NCT01224613|Active Comparator|Intanza - nurse-administered|Nurse-administered intradermal influenza vaccine
9963078|NCT01224652|Experimental|paclitaxel|Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
9963079|NCT01224652|Experimental|irinotecan|irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle
9963080|NCT01224717|Experimental|PTH134|
9963081|NCT01224717|Placebo Comparator|Placebo|
9963082|NCT01224717|Active Comparator|Forsteo|
9963083|NCT01224730|Experimental|Perifosine 100 mg|Perifosine 100 mg orally daily under Fed and Fasted conditions
9963084|NCT01224743|Placebo Comparator|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
9963085|NCT01224743|Experimental|Blend 2|Blend 2 - combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
9963086|NCT01224743|Experimental|Blend 1|Blend 1 - combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
9963087|NCT01224756|Experimental|Tinoridine HCl 100 mg (2 capsules) TID|
9963088|NCT01224756|Placebo Comparator|Placebo TID|
9963089|NCT01224769||bendamustine +/- rituximab|
9963090|NCT01224808|Experimental|Experimental|
9963091|NCT01224834|Placebo Comparator|1|
9963092|NCT01224834|Experimental|2|
9963093|NCT01224847|Active Comparator|Tetracaine gtt|Pre-Intravitreal injection - 1 gtt Tetracaine topically
9963094|NCT01224847|Active Comparator|Tetraciane gtt + Lidocaine pledget|1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
9963095|NCT01224847|Active Comparator|Cocaine gtt alone|1 gtt pre-IVT injection
9963096|NCT01224860|Experimental|Telmisartan|
9963097|NCT01224860|Experimental|Losartan|
9963098|NCT01224886|Experimental|Sedentary obese|
9963099|NCT01224886|Experimental|Sedentary normal weight|
9963100|NCT01224886|No Intervention|Athletes|
9963101|NCT01224899|Experimental|Surgery|
9963102|NCT01224899|No Intervention|Control|
9963103|NCT01224912|Experimental|Internet Deliviered CBT for Insomnia|Cognitive behavioral self-help method for insomnia via the Internet
9963104|NCT01224938||Asthma patients|Asthmatics of all classes of severity will be included.
9963105|NCT01224938||Healthy control population|A healthy control population will be included to compare with the asthmatics.
9963106|NCT01224951|Active Comparator|Qvar 100|"Patients will be randomized to receive either the active arm (3/4) or a SABA as rescue medication (1/4). The patient will be asked to take Qvar 100 (2puffs) in the morning and in the evening.~Daily dose (400 microgram)."
9963107|NCT01224951|No Intervention|Control|Patients are allowed to use their SABA as rescue medication only. During the last 4 weeks, the patients will receive 400 microgram of Qvar.
9963108|NCT01224964|Active Comparator|Montelukast|
9963109|NCT01224964|Active Comparator|long-acting beta2-mimetic|
9963110|NCT01224977|Other|azithromycin|
9963111|NCT01225042|Experimental|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
9963112|NCT01225042|Placebo Comparator|placebo|Carrier material powder of identical appearance
9963113|NCT01225081|Experimental|ASP group|ASP1941 and pioglitazone
9963114|NCT01225081|Placebo Comparator|Placebo group|placebo and pioglitazone
9963115|NCT01225094|Experimental|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.
9963116|NCT01225094|Placebo Comparator|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
9963117|NCT01225107|Placebo Comparator|Inert Placebo Capsule|
9963118|NCT01225107|Experimental|Cranberry Extract|
9963119|NCT01225120|Experimental|Gait Training|
9963120|NCT01225133|Active Comparator|Complex Ayurvedic Treatment|In the Āyurveda arm treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
9963121|NCT01225133|Active Comparator|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
9963122|NCT01225185||Patients undergoing shoulder surgery|"This observational study will compare cerebral blood flow autoregulation in patients undergoing surgery in either the supine lateral position or the semi-recumbent or beach chair position. The choice of patient positioning is not randomized but based on usual surgical considerations."
9963123|NCT01225198|Placebo Comparator|Placebo Group|Liquid placebo with identical packaging and flavoring to the real supplement.
9963124|NCT01225198|Experimental|Vitamin/Mineral Supplement Group|Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
9963125|NCT01225224|Experimental|ASP015K Single Japanese Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
9963126|NCT01225224|Experimental|ASP015K Single Caucasian Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
9963127|NCT01225224|Placebo Comparator|Placebo Single Japanese Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
9963128|NCT01225224|Placebo Comparator|Placebo Single Caucasian Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
9963129|NCT01225224|Experimental|ASP015K Multiple Group|Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level. ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.
9963130|NCT01225224|Placebo Comparator|Placebo Multiple Group|Participants will receive placebo in three stages, each stage corresponding to a different dosage level. Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.
9963131|NCT01225237|Experimental|ramosetron group|
9963132|NCT01225237|Placebo Comparator|Placebo group|
9963133|NCT01225302|Experimental|Arm A|
10006509|NCT01595165|Experimental|TAP|TAP group receiving ropivacaine total of 150 mg at TAP under US
9802398|NCT05294796|Active Comparator|Long course of antibiotherapy|Patients enrolled in this arm, will receive 12 weeks of antibiotherapy in case of early infection (< 2 week), and until fracture healing of antibiotherapy in case of delayed infection
9963134|NCT01225302|Experimental|Arm B|
9963135|NCT01225328|Experimental|Intervention|Telephone-delivered Behavioral Activation/Problem Solving (BA/PS) intervention
9963136|NCT01225341|Experimental|onabotulinumtoxinA/placebo|Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.
9963137|NCT01225341|Placebo Comparator|Bacteriostatic normal saline/ onabotulnimtoxinA|Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.
9963138|NCT01225367||pulmonary doppler|
9963139|NCT01225406||third line naive|Children on second line or other regimen who switch or start third line regimen
9963140|NCT01225406||third line experienced|children who are on third line regimen
9963141|NCT01225432|Experimental|Gait Training|
9963142|NCT01225445|Experimental|Treatment|ramipril 2.5 mg daily
9963143|NCT01225445|No Intervention|Control|
9963144|NCT01225458|Placebo Comparator|exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
9963145|NCT01225458|Experimental|geriatric follow-up|"250 patients will be included and randomized in the geriatric follow-up arm. They will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients.~About geriatric evaluation Patients randomized in this arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
9963146|NCT01225484|Active Comparator|CFNB, periarticular infiltration|
9963147|NCT01225484|Active Comparator|Intraarticular catheter, periarticular infiltration|
9963148|NCT01225497|Active Comparator|Standard eccentric exercise|Participants randomised to this group shall complete 180 repetitions a day of Alfredsons heel drop protocol. This has been accepted as standard management for mid-portion Achilles pain in the first instance.
9963149|NCT01225497|Experimental|Eccentric exercise as able|Participants randomised to this group shall carry out exactly the same eccentric exercises as per Alfredsons heel drop protocol. However, these individuals will be instructed to do what they can.
9963150|NCT01225510|Experimental|Primary Cohort|
9963151|NCT01225510|Experimental|Exploratory Cohort|
9963152|NCT01225523|Active Comparator|Preoperative chemotherapy followed by surgery|
9963153|NCT01225523|Active Comparator|Perioperative chemotherapy with surgery|
9963154|NCT01225536|Experimental|ARQ 736|
9963155|NCT01225575|Active Comparator|co.don chondrosphere®, 3-7 spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect"
9963156|NCT01225575|Active Comparator|co.don chondrosphere®,10-30spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group B is 10-30 spheroids/cm2 defect"
9963157|NCT01225575|Active Comparator|co.don chondrosphere®,40-70spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group C is 40-70 Spheroids/cm2 defect"
9963158|NCT01225601||Histocytosis|Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)
9963159|NCT01225614|Experimental|bipap ventilation|
9963160|NCT01225614|Active Comparator|Standard care|Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
9963161|NCT01225627|Experimental|Coordinated discharge|Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
9963162|NCT01225627|Placebo Comparator|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
9963163|NCT01225653|Experimental|Latanoprost|Topical treatment with latanoprost
9963164|NCT01225653|Placebo Comparator|Placebo|Placebo arm
9963165|NCT01225679||polysomnography|Overnight supervised polysomnography (Embla System®) was performed in a sleep laboratory, which included capnometry. Arterial blood gas analysis was performed by radial arterial puncture. Ventilatory response to progressive hypercapnia was measured using the Read breathing technique. Briefly, subjects rebreathed into an air tight 5-L bag containing a mixture of 8% carbon dioxide (CO2) and 40% oxygen (O2). The spirometer technology used to monitor ventilation was based on a bi-directional rotating vane principle (flow sensitive). A continuous record of CO2 concentration in the expired gas was obtained by a CO2 analyzer within the circuit. The ventilatory hypercapnic drive was calculated from the slope produced by changes in ventilation (L. min-1) and changes in end-tidal PCO2.
9476651|NCT03569683|Experimental|Interventional Single arm|"Group A- Diode laser biostimulation on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group B- Hyaluronic acid (Gengigel) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group C- Herbal gel (Hiora SG) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery."
9476652|NCT03569670|Experimental|Posterior Stabilized|A posterior stabilized, all-polyethylene tibial component will be used during surgery.
9476653|NCT03569670|Active Comparator|Cruciate Retaining|A cruciate retaining, all-polyethylene tibial component will be used during surgery.
9963166|NCT01225705|Experimental|Raltegravir|45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine
9476654|NCT03569657|Other|A positive psychology workshop|The group intervention implements a manualized treatment protocol outlining the content of each of the four 90 minute sessions. The sessions will include topics such as mindfulness, self-compassion, gratitude and forgiveness, grief and growth, utilizing one's strengths, and resilience; with each session including homework exercises to be practiced between sessions. To assess the outcome measures, participants complete a baseline survey, a survey after the second session (2 weeks), a survey after the final session (4 weeks), and a follow-up survey 3 months after the workshop has ended (4 months).
9963167|NCT01225705|Active Comparator|Atazanavir/ritonavir|45 patients will receive open label atazanavir/ritonavir
9963168|NCT01225744|Experimental|Cetuximab plus Irinotecan, Oxaliplatin and UFT|Cetuximab plus Irinotecan, Oxaliplatin, UFToral
9963169|NCT01225757|Experimental|Echocardiography|These patients will have echocardiography guided fluid management
9963170|NCT01225757|Active Comparator|Traditional fluid management|Fluid management will be guided by monitoring of central venous pressure and urine output.
10006510|NCT01595191|Active Comparator|Music by Mozart|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
10006511|NCT01595191|Active Comparator|Bach Music|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
10006512|NCT01595204|Experimental|Diagnostic Laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
10006513|NCT01595217|Experimental|MRCP and DWI using 3T MRI|MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
10006514|NCT01595217|Experimental|MRCP only using 3T MRI|MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
10006515|NCT01595230|Experimental|Inertervention group_Clips to avoid internal herniation|LRYGB with closure of the defects with simple hernia stapler clips. Aim of this study is to evaluate the benefits and disadvantages of closing the mesenteric defects during gastric bypass in order to avoid internal herniation.
10006516|NCT01595230|No Intervention|Control group|conventional LRYGB without closure of the mesenteric defects
10006517|NCT01595243|No Intervention|control|patient with liver cancer in non-surgical treatment after discharge receive usual care
10006518|NCT01595243|Experimental|patient in experiment|patient in the experimental group will receive seven instances of telephone follow-up or face to face education
10006519|NCT01595256|Experimental|walking group|
10006520|NCT01595256|No Intervention|usual care|
10006521|NCT01595269|Placebo Comparator|Education mode 1 (control)|Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants.
10006522|NCT01595269|Active Comparator|Education mode 2 (static interface)|Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
10006523|NCT01595269|Active Comparator|Education mode 3 (dynamic interface)|Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
10006524|NCT01595295||Hypomethylating Agents|Patients treated with hypomethylating agents
10006525|NCT01595308|Experimental|Pomegranate juice|Pomegranate juice
10006526|NCT01595334|Active Comparator|Study subjects desiring pregnancy|"Study subjects to be treated with rFSH, rLH throughout controlled ovarian hyperstimulation (COH) in appropriate dosages,considering age, body mass index (BMI), ovarian reserve, etc. and GnRH antagonist, cetrorelix in 0.25 mg/d when needed till the desired follicular maturity and the minimum required number of follicles are achieved.~INTRVENTIONS - Monitoring at regular intervals by transvaginal ultrasound and hormonal studies.Once pregnancy established by beta-human chorionic gonadotropin (hCG) and ultrasound will be supported by intervention of adequate luteal support by estrogen (E) + progesterone (P) for 12 weeks of gestation."
10037250|NCT01823367|Experimental|Lifestyle counseling mom only|This intervention, delivered to groups of mothers only, builds upon the evidence-based curriculum used in the Diabetes Prevention Program (DPP) and incorporates into the curriculum detailed education regarding ways to help their children adopt healthier lifestyle behaviors.
10037251|NCT01823367|Experimental|Lifestyle counseling mom and child|The second intervention is delivered to both mothers and children in separate groups using the same parent Diabetes Prevention Program (DPP) curriculum, but adds a group program for children that directly teach these children strategies for eating better and increasing physical activity.
10037252|NCT01823380|Other|Amyotrophic lateral sclerosis|Blood test
9476655|NCT03569644|Other|qualitative study|heterogeneous group of patients
9476656|NCT03569631|Experimental|BPN14770|25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks
9963171|NCT01225770|Experimental|Green tea|Gargling with green tea
9963172|NCT01225770|Active Comparator|water|Gargling with water
9963173|NCT01225796|Experimental|Sodium bicarbonate|This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.
9963174|NCT01225796|No Intervention|Control|This group will not receive any sodium bicarbonate.
9963175|NCT01225809||AD01with or without adjuvant|Patients who have received at least one immunization of AD01 with or without adjuvant during AFF001
9963176|NCT01225874|Experimental|Stratum 3|Patients receive oral dexamethasone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; pegaspargase intramuscularly (IM) on day 4, 5, or 6; cytarabine intrathecally (IT) on day 1; and methotrexate IT on day 8 (some patients also receive methotrexate IT on days 15 and 22).
9963177|NCT01225874|Experimental|Stratum 4|Patients receive oral prednisone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; IM SC-PEG E. coli asparaginase on days 2, 5, 8, 12, 15, and 19; daunorubicin hydrochloride IV over 15-20 minutes on days 8, 15, and 22; and methotrexate IT on days 1 and 8 (some patients also receive methotrexate IT on days 15 and 22).
10006527|NCT01595334|Other|Control subjects desiring pregnancy|"Control subjects selected in randomized way,desiring pregnancy will be treated with gonadotrophins, rFSH and rLH in appropriate dosages considering age, BMI, ovarian reserve, etc. after standard downregulation with GnRH agonist, Leuprolide acetate, 1 mg/d under established 'Long Luteal Suppression Protocol' from the previous cycle.~INTERVENTIONS - Monitoring of response to treatment by hormonal study and sonography evaluation at regular intervals during COH till adequate number of mature follicles of minimum 18 mm mean diameter is achieved, to be followed by hCG trigger and ovum pick-up (OPU) and embryo transfer (ET). Chemical pregnancy by beta-hCG would be confirmed 14 days post-ET. Clinical pregnancy would be confirmed by sonography 6 weeks after ET (visibility of yolk sac and fetal heart-beat). Pregnancy support by E+P for 12 weeks would be provided."
10006528|NCT01595347|Active Comparator|Hyper-oxigenated fatty acid|Hyper-oxigenated fatty acid,Equisetum arvense, Hypericum perforatum
10006529|NCT01595347|Experimental|Olive oil's Cream|Cream with 60% extra virgin olive oil.
10006530|NCT01595360|Placebo Comparator|Placebo|Placebo
10006531|NCT01595360|Experimental|TT-173|TT-173
10006532|NCT01595373|Active Comparator|Ghrelin|Ghrelin
10006533|NCT01595373|Placebo Comparator|Placebo|Ringer acetate is used for placebo.
10006534|NCT01595399|Active Comparator|Atropine, fentanyl and succinylcholine|20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
10006535|NCT01595399|Placebo Comparator|placebo, fentanyl and succinylcholine|an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
10006536|NCT01595412|Active Comparator|Cohort 2|Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
10006537|NCT01595412|Active Comparator|Cohort 1|Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.
10006538|NCT01595425|Experimental|D961H Sachet 20 mg|2 way crossover
10006539|NCT01595425|Experimental|D961HHPMC Capsule 20 mg|2 way crossover
10006540|NCT01595451|Active Comparator|Traditional Acupuncture|Acupuncture will be delivered to 12 points traditionally used to treat chronic low back pain.
10006541|NCT01595451|Placebo Comparator|Non-traditional Acupuncture|You will receive non-traditional acupuncture at 12 points for chronic low back pain.
10006542|NCT01595464|Experimental|Mind-Body Skills Groups|
10006543|NCT01595464|No Intervention|Control Group|
10006544|NCT01595477|Experimental|Mind-Body Skills Groups|
10006545|NCT01595477|No Intervention|Control Group|
10006546|NCT01595490|Experimental|Mind-Body Skills Groups|
9476657|NCT03569631|Placebo Comparator|Placebo|Matching placebo capsules, one capsule taken twice daily for 12 weeks
10006547|NCT01595490|No Intervention|Control Group|
10006548|NCT01595542|Experimental|Intervention|Parents served by experimental school sites received intervention packets including modified vaccine consent form
10006549|NCT01595542|No Intervention|Control|Did not receive intervention materials
10006550|NCT01595555|No Intervention|Wait-list control|Group with no intervention. Only complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
10006551|NCT01595555|Experimental|Stress Free Now|Participate in the 8 week online stress management program Stress Free Now. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
10006552|NCT01595555|Experimental|Stress Free Now + Social Media|Participate in the 8-week Stress Free Now program and a discussion board that provides peer and moderator support. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
10006553|NCT01595568|Experimental|Learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
10006554|NCT01595568|Experimental|Learning to cope with your sensation seeking|Cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
10006555|NCT01595568|Experimental|Learning to cope with your anxiety sensitivity|Cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
10006556|NCT01595568|Experimental|Learning to manage your negative thinking|Cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
10006557|NCT01595594|Active Comparator|Systemic Doxycycline|
10006558|NCT01595594|Experimental|aPDT+ Placebo|
10006559|NCT01595607|Active Comparator|Typical American Diet|Participants will receive a typical American diet for 6 weeks.
10006560|NCT01595607|Experimental|Avocado Diet|Participants will receive a modified typical American diet in which avocado is substituted for foods that contain moderate and high amounts of saturated fat to allow the inclusion of avocado.
10006561|NCT01595633|Active Comparator|Adefovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Adefovir 10mg
10006562|NCT01595633|Experimental|Tenofovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Tenofovir 300mg
9963178|NCT01225913|Other|Asthma observational study arm|Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg/salmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg/formoterol 4.5mcg bid)or Dulera 100-200mcg mometasone/5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.
9963179|NCT01225939|Experimental|1|Single Oral dose AZD8329 tablet (fasting)
9963180|NCT01225939|Experimental|2|Single Oral dose AZD8329 solution (fasting)
9963181|NCT01225939|Experimental|3|Single Oral dose AZD8329 tablet (Fed)
9963182|NCT01225965|Experimental|EIL05, Inhalation|
9963183|NCT01225965|Placebo Comparator|Placebo, 0,9% NaCl|
10006563|NCT01595659|Placebo Comparator|no alcohol and passenger|Blood alcohol concentration (BAC) = 0.00% and risk accepting or averse passenger
10006564|NCT01595659|Experimental|low alcohol dose and passenger|BAC = 0.02% and risk accepting or averse passenger
10006565|NCT01595659|Experimental|moderate alcohol dose and passenger|BAC = 0.05% and risk accepting or averse passenger
10006566|NCT01595672|Active Comparator|EHVCVVH group|Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
10006567|NCT01595672|Active Comparator|Control group|Patients receive conventional treatments recommended by guidelines only.
10006568|NCT01595685|Experimental|Telbivudine|Telbivudine 600 mg Daily Oral
10006569|NCT01595685|Active Comparator|Entecavir|Entecavir 0.5 mg Daily Oral
10006570|NCT01595698|Sham Comparator|Control|
10006571|NCT01595698|Experimental|Physical Exercise|
10006572|NCT01595711||Thoracotomized patients|
10035297|NCT01804803|Experimental|T-SMBG|This group will perform SMBG using a smartphone-connected glucometer implemented with a software for real-time collection and transmission of measured glucose values to the remote server. SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS). A specific algorithm incorporated into the DSS will allow the patients to self-calculate the dose of basal insulin to be administered according to the measured fasting blood glucose levels for consecutive periods of three days. Glucose data and analyses will be made accessible to the patients and medical staff anytime and anywhere via the web. Patients will be also assisted by the diabetes medical team located at or connected with a call center 24-hours/day, 7 days/week.
10035298|NCT01804803|Active Comparator|SMBG|This group will perform SMBG using a regular glucometer and will report glucose data on paper charts (or download data from the glucometer onto the PC) at the planned study visits. Patients will not receive feed-back on their glucose levels nor instructions on how to potentially modify their drug therapy except when undergoing medical visits at the planned intervals. Patients, finally, will not be assisted by the diabetes team/call center.
10035299|NCT01804855|Active Comparator|W82GO|Usual face-to-face care as per the W82GO multidisciplinary treatment intervention (phase 1 for 6 weeks and phase 2 for 46 weeks).
10035300|NCT01804855|Experimental|Smartphone|Usual care for Phase 1 of treatment. Treatment during Phase 2 of intervention using the Reactivate smartphone application only.
10035301|NCT01804868|Experimental|case vignette tutorial|The web tutorial composed of 4 case vignettes.
10035302|NCT01804868|Active Comparator|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation.
10035303|NCT01804894||athletes with lower extremity injury|athletes who were injured during one season of play
10035304|NCT01804907|Experimental|CBT|Cognitive Behavioral Therapy
10035305|NCT01804907|Sham Comparator|Behavioral Modification|Standard sleep hygiene education/desensitization therapy
10035306|NCT01804920|Experimental|D-serine adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
10035307|NCT01804920|Placebo Comparator|Placebo adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
10035308|NCT01804933|No Intervention|conventional neuromuscular blockade|No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement
10035309|NCT01804933|Active Comparator|optimal neuromuscular blockade|Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively
10035310|NCT01804933|Experimental|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
10035311|NCT01804959|Placebo Comparator|Active vs Placebo|In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
10035312|NCT01804959|Active Comparator|60 days of Active vs 120 days of Active|In phase II, subjects from both arms in phase I will receive Vivomixx probiotics 4 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of Vivomixx probiotics vs 120 days of Vivomixx probiotics
10035313|NCT01804972|Active Comparator|Verbal and written infomation|Verbal and written information:Patients will receive both verbal information and written patient information leaflets
10035314|NCT01804972|Experimental|Verbal and electronic information|Patient will receive both verbal information and a web address to access patient information electronically
10035315|NCT01804985|Experimental|De-escalated Treatment|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
10035316|NCT01805011||50 healthy mothers|
10035317|NCT01805050||New Technique|All patients who underwent surgical repair of the anterior instability due an HAGL lesion.
10035318|NCT01805063||Fire suppression|Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
10035319|NCT01805063||Non-fire emergency duty|Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
9476658|NCT03569605|Active Comparator|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
9802399|NCT05294731|Experimental|Part 1 (Dose Finding)|BGB-16673 will be orally administered
9963184|NCT01225978||GeneInsight Clinic (GIC)|The Group/Cohort in this study are geneticists, physicians, and genetic counselors who are using the GeneInsight Clinic (previously known as Patient Genome Explorer) to receive and store genetic test reports and variant update information.
9963185|NCT01226030|Experimental|M2ES 7.5mg|M2ES 7.5mg
9963186|NCT01226030|Experimental|M2ES 15mg|M2ES 15mg
9963187|NCT01226030|Experimental|M2ES 30mg|M2ES 30mg
9963188|NCT01226030|Experimental|M2ES 60mg|M2ES 60mg
9963189|NCT01226056|Experimental|RAD001 in combination with sorafenib|
9963190|NCT01226069|Active Comparator|Glycerine Magnesium Sulphate paste|
9963191|NCT01226069|Active Comparator|Hirudoid cream|Topical Mucopolysaccharide polysulphate
9963192|NCT01226069|Experimental|No application|Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
9963193|NCT01226082|Experimental|Transcranial Direct Current Stimulation|
9963194|NCT01226108|Active Comparator|antinitus patch|One patch per day, Duration: three weeks, Administration: behind the ear
9963195|NCT01226134|Experimental|1.Itopride Group|The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
9963196|NCT01226134|Placebo Comparator|2.Control placebo group|The control group will receive placebo tablets for four weeks
9963197|NCT01226160|Experimental|Face-down posturing group|Postoperative face-down positioning for 10 days after surgery.
9963198|NCT01226160|Active Comparator|Non-posturing group|avoid a face-up position for 10 days after surgery
9963199|NCT01226186|Active Comparator|Nurse dispensed oral morphine solution.|
9963200|NCT01226186|Active Comparator|Self medicated oral morphine solution.|
9963201|NCT01226212|Experimental|Synbiotic|Synbiotic (Synergy 1/B. longum)
9963202|NCT01226212|Placebo Comparator|Placebo|maltodextrose
9963203|NCT01226225|Experimental|Aerobic interval training|
9963204|NCT01226225|Active Comparator|Moderate endurance training|
9963205|NCT01226238|Experimental|Online self-help|Provision of online self-help while waiting for psychotherapy
9963206|NCT01226238|No Intervention|Waiting list alone|Waiting for psychotherapy alone
9963207|NCT01226251||Healthy adults|Subjects consulting a bad breath clinic at the Department of Periodontology, KULeuven
9963208|NCT01226277|Experimental|A|
9963209|NCT01226303|Experimental|standard risk|are defined as those patients with a WBC less than 10x10 9 /L at presentation
9963210|NCT01226303|Active Comparator|high risk|are defined as those patients whose highest treatment WBC is equal to or greater than 10x10 9 /L at presentation
9963211|NCT01226329|Experimental|RQP-MH|Participants in the intervention arm will receive three Patient Activation and Self-Management education sessions, plus a fourth booster session if they show difficulty mastering the content of the first three trainings.
9963212|NCT01226329|Active Comparator|Comparison Group|"Participants in this arm will receive a pamphlet in either Spanish or English called Managing Your Mental Health Care."
9963213|NCT01226342|Experimental|TCEMS|Patients who will receive transcutaneous electrical muscle stimulation
9963214|NCT01226355|Experimental|NOYA|implant NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stents Intervention: Device: stent
9963215|NCT01226355|Active Comparator|Firebird2|implant Firebird2 drug-eluting stents Intervention: Device: stent
9963216|NCT01226394|No Intervention|surveillance|
9963217|NCT01226394|Experimental|laparotomy plus HIPEC.|
9963218|NCT01226407|Experimental|Single Arm for CG200745|any progrossive solid cancer
9963219|NCT01226446|Experimental|Addition of Vitamin D to Peg-interferon plus Ribavirin|
9963220|NCT01226498|Experimental|Fresh blood auto-transfusion|
9963221|NCT01226498|Experimental|Old blood auto-transfusion|
9802400|NCT05294731|Experimental|Part 2 (Dose Expansion)|BGB-16673 will be administered at the recommended Phase 2 dose (RP2D) that was identified in Part 1
9963222|NCT01226524|Experimental|Traditional Chinese Medicine|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
9963223|NCT01226537|Active Comparator|Diabetes Mellitus type 1 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
9963224|NCT01226537|Placebo Comparator|Diabetes mellitus type 1 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
9963225|NCT01226537|Active Comparator|Diabetes type 2 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
9963226|NCT01226537|Placebo Comparator|Diabetes type 2 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
9963227|NCT01226550|Experimental|cytoreductive surgery and HIPEC|
9963228|NCT01226576|Experimental|Treatment|ExAblate Treatment Arm
9963229|NCT01226602|Experimental|1|Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
9963230|NCT01226602|Placebo Comparator|2|Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder
9963231|NCT01226615|Experimental|1|Chondroitin sulphate
9963232|NCT01226615|Placebo Comparator|2|Placebo
9963233|NCT01226641|Experimental|Telemedecine|CPAP treatment with telemedicine system
9963234|NCT01226641|Active Comparator|Standard Care|Standard care, including CPAP
9963235|NCT01226654|Other|MS Patients|All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
9963236|NCT01226654|Other|Healthy Patients|Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
10006573|NCT01595724||Group 1|
10006574|NCT01595737|Experimental|Levosimendan|
10006575|NCT01595737|Placebo Comparator|Placebo|
10006576|NCT01595750|Placebo Comparator|Placebo|
10006577|NCT01595750|Active Comparator|Roflumilast|Roflumilast 500 mcg
10006578|NCT01595763||Deep Vein Thromobosis signs or symptoms|
10006579|NCT01595776|Experimental|single arm: autologous EPCs|
10006580|NCT01595789|Placebo Comparator|Placebo + metformin|
10006581|NCT01595789|Active Comparator|Liraglutide + metformin|
10006582|NCT01595802|Experimental|Subjects without Vasospasm|Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status.
9963237|NCT01226667|Active Comparator|Flexible Dose|flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks
9963238|NCT01226667|Active Comparator|Fixed Dosing|75 mg BID for one week and increased to 150 mg BID for 7 weeks
9963239|NCT01226680|Experimental|Tasocitinib 0.005% QD|
9963240|NCT01226680|Experimental|Tasocitinib 0.003% QD|
9963241|NCT01226680|Placebo Comparator|Vehicle for Tasocitinib|
9963242|NCT01226693|Experimental|Sequence 1|
9963243|NCT01226693|Experimental|Sequence 2|
9963244|NCT01226693|Experimental|Sequence 3|
9963245|NCT01226693|Experimental|Sequence 4|
9963246|NCT01226693|Experimental|Sequence 5|oral, 6mg, single dose
9963247|NCT01226693|Experimental|Sequence 6|oral, 6mg, single dose
9963248|NCT01226758|Experimental|FLU-v with adjuvant|
9963249|NCT01226758|Placebo Comparator|Placebo|Adjuvant only placebo
9963250|NCT01226771|Experimental|"Group A (Loading)"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
9963251|NCT01226771|Experimental|"Group B (Priming)"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
9963252|NCT01226771|Active Comparator|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
9963253|NCT01226784|Active Comparator|Physcial exercise|15 weeks of progressive resistance group exercise, twice/week supervised by physical therapist
9963254|NCT01226784|Active Comparator|Relaxation exercise|15 weeks of relaxation exercise, twice/week supervised by physical therapist
9963255|NCT01226797|Placebo Comparator|Placebo|
9963256|NCT01226797|Active Comparator|PF-04136309|
9963257|NCT01226823|Placebo Comparator|Placebo|obstetrical monitoring plus placebo
9963258|NCT01226823|Experimental|Ursodeoxycholic acid|obstetrical monitoring plus active drug
9963259|NCT01226836|Experimental|Living Well with COPD for Pulmonary Rehabilitation|
9963260|NCT01226849|Experimental|Single Arm|"bortezomib, rituximab, ifosphamide, etoposide, carboplatin~Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended"
9963261|NCT01226862||Hub Hospital|Hub Hospital Cohort: Joint Commission-certified Primary Stroke Centers where patients are treated using hospital-based stroke teams and pathways; these hospital personnel also provide telemedicine consultation to satellite hospitals.
9963262|NCT01226862||Spoke Hospital|Spoke Hospital Cohort: non-stroke center certified sites, where patients are treated at an in-network telestroke community hospital using telemedicine technology with consultation provided by physicians from a hub hospital.
9963263|NCT01226862||Control Hospital|Control Hospital Cohort: non-stroke center certified sites with no telemedicine services.
9963264|NCT01226875|Active Comparator|A (Narrow focus, LP)|A (Narrow focus): stone is in lower pole of kidney and SWL using narrow focus on lithotripter
9963265|NCT01226875|Active Comparator|B (Wide focus, LP)|B: stone is in lower pole of kidney and SWL using wide focus on lithotripter
9963266|NCT01226875|Active Comparator|C (Narrow focus, no LP)|C: stone is in no-lower pole of kidney and SWL using narrow focus on lithotripter
9963267|NCT01226875|Active Comparator|D (Wide focus, no LP)|D: stone is in no-lower pole of kidney and SWL using wide focus on lithotripter
9963268|NCT01226901|Experimental|MK-4827 once daily|MK-4827
9963269|NCT01226927|Active Comparator|Continuous infusion rate|Patients received a continuous infusion of 0.2% ropivacaine at 10.1 mL/hr via their femoral nerve catheter.
10006583|NCT01595802|Experimental|Subjects with Vasospasm|"Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.~Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm."
10006584|NCT01595815|Active Comparator|Conventional ICSI|The couple showed complete fertilization failure after ICSI.
10006585|NCT01595815|Active Comparator|Convention ICSI|The couple showed a low fertilization rates after ICSI.
10006586|NCT01595828|Experimental|Pitavastatin 4mg daily|4 mg tablets of pitavastatin by oral route for a period of 6 months
10006587|NCT01595841|Experimental|Sirolimus|Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
10006588|NCT01595841|No Intervention|Not taking Sirolimus|Participants will not change the standard of care.
10006589|NCT01595867|Placebo Comparator|Treatment A|Placebo
10006590|NCT01595867|Experimental|Treatment B|EMBEDA 30 mg crushed
10006591|NCT01595867|Active Comparator|Treatment C|Morphine Sulfate Controlled Release 30 mg crushed
10006592|NCT01595880|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg
10006593|NCT01595880|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 500mg
10006594|NCT01595893|Experimental|Vitamin D3|
10006595|NCT01595893|Placebo Comparator|Placebo|
10006596|NCT01595906|Experimental|The experiment subjects|"The subjects will undergo:~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, during which the subjects walk on a treadmill at 5km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH). Core (rectal) and skin temperatures and heart rate will be monitored continuously.~Three consecutive days including 3 scenarios:~Without a helmet b.With a helmet c.With a ventilated helmet During the experiment days the subjects will be exposed to the following protocol : A 5 minute sitting, performing cognitive tests on a computer for 15 min, 120 min walking on a treadmill at 5km/h on a 2% incline, at the end of the effort the same cognitive tests will be repeated for extra 15 min, 155 min in total."
10006597|NCT01595919|Experimental|1% Milk|
10006598|NCT01595919|Experimental|Regular Cola|
10006599|NCT01595919|Experimental|Diet cola|
10006600|NCT01595919|Experimental|Orange juice|
10006601|NCT01595919|Placebo Comparator|Water|
10006602|NCT01595932|Placebo Comparator|placebo|
10006603|NCT01595932|Experimental|α-galactosidase|
10006604|NCT01595945|Other|Gastric bypass|Subjects with planned gastric bypass surgery are followed-up in regard of resting metabolic rate.
10006605|NCT01595945|Other|Caloric restriction|Caloric restriction calculated by an online weight management program (based on subject's starting weight, start BMI, age, target weight and time span). Subjects are followed-up in regard to resting metabolic rate.
10006606|NCT01595958|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
10006607|NCT01595958|Active Comparator|Control|usual care of cardiac arrest
10006608|NCT01595971|Experimental|continuing education|RESPIRANET is a multifaceted intervention directed at professionals of the Family Health Teams in the inner cities.Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
10006609|NCT01595971|Placebo Comparator|Usual Care|usual care
10006610|NCT01595984|Active Comparator|Cyclosporin + Mycophenolate mofetil|
10006611|NCT01595984|Experimental|Everolimus + mycophenolate mofetil|
10006612|NCT01595997|Placebo Comparator|Placebo|
10006613|NCT01595997|Experimental|DLX105|
10006614|NCT01596010|Experimental|New formulation|
10006615|NCT01596010|Active Comparator|Old formulation|
10006616|NCT01596023|Experimental|NIOV Ventilator|Breathe NIOV Ventilator under various volume augmentation settings
10006617|NCT01596036|Experimental|Early Appointment|Patients will receive an early appointment (within 10 days) from the time of their anticipated hospital discharge
10006618|NCT01596036|Placebo Comparator|Standard Referral|Patients will receive an appointment to cardiac rehabilitation at 5 weeks from the date of their anticipated hospital discharge. A routine referral to cardiac rehabilitation will also occur in parallel. Consequently, it is possible that some patients will attend cardiac rehabilitation earlier than their assigned 5 week appointment.
10006619|NCT01596049||Self-fixating Mesh|patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.
10035320|NCT01805063||Sedentary shift|Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
10035321|NCT01805076|Other|Arm 1 (control)|Patients undergo a clinical breast examination and mammography with ultrasound of the breast and regional nodes followed by breast conserving surgery.
9963270|NCT01226953|Active Comparator|Arm 1|
9963271|NCT01226953|Active Comparator|Arm 2|
9963272|NCT01226966||A|
9963273|NCT01226992|Experimental|Fecal Transplant|2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
9963274|NCT01226992|Active Comparator|Oral Vancomycin Taper|2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
9963275|NCT01227070||Asthmatic|
9963276|NCT01227070||Healthy Control|
9963277|NCT01227083||1|Asthma control test check AQLQ(Asthma Quality of Life Questionnaire)after being cAQOL(Computerized Asthma specific quality of life)
9963278|NCT01227083||2|Asthma control test check cAQOL(Computerized Asthma specific quality of life)after being AQLQ(Asthma Quality of Life Questionnaire)
9963279|NCT01227096||Electro-acupuncture, Control|
9963280|NCT01227096||Preconditioning, No preconditioning|
9963281|NCT01227109||With infection|This group consist of cancer patients with a bacterial infection
9963282|NCT01227109||Without infection|This is a group of cancer patients without infection
9963283|NCT01227148|Experimental|Tightly glucose conntrol|
9963284|NCT01227148|Active Comparator|Conventional glucose control|
9963285|NCT01227161||ultrasonography children|American Society of Anesthesiologists (ASA) I-II children between the age 0-7, undergoing elective urological surgery, such as inguinal hernia repair, orchiopexy, ureteroneocystostomy
9963286|NCT01227174|Experimental|Propofol sedation|Patients will be undergo procedural sedation using propofol.
9963287|NCT01227226|Active Comparator|Refresh tears|Allergan's Refresh tears artificial tear
9963288|NCT01227226|Active Comparator|Systane Ultra|Alcon's Systane Ultra artificial tear
9963289|NCT01227226|Active Comparator|Visine|Visine artificial tear
9963290|NCT01227226|Active Comparator|Blink tears|AMO's blink tears artificial tear
9963291|NCT01227239|Experimental|1|
9963292|NCT01227291|Experimental|SYL040012|SYL040012 Ophthalmic drop administration
9963293|NCT01227304|Experimental|Test of volume responsiveness using crystalloids|
9963294|NCT01227317||Acute dyspnea in ED|Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
9963295|NCT01227330|Experimental|Medication adherence intervention|Receives 12-week behavioral feedback intervention to improve adherence to statin medication
9963296|NCT01227330|No Intervention|Control|No intervention
9963297|NCT01227330|Active Comparator|Attention-control|Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol
9963298|NCT01227343||Female Smokers|Healthy females who smoke 10-30 cigarettes per day for the past 2 years and meet criteria for nicotine dependence.
9963299|NCT01227343||Female Non-smokers|Healthy females who do not currently smoke cigarettes.
9963300|NCT01227343||Male Smokers|Healthy males who smoke 10-30 cigarettes per day for the past 2 years and who meet criteria for nicotine dependence.
9963301|NCT01227343||Male - Non-Smokers CLOSED|WE ARE NO LONGER RECRUITING MALE NON-SMOKERS
9963302|NCT01227356|Experimental|imatinb + pegIntron|
9963303|NCT01227369||Bisphosphonates|Korean postmenopausal osteoporosis patients with bisphosphonate treatment
9963304|NCT01227408|Experimental|Metronomic Chemotherapy|Doxorubicin will be administered as an intravenous bolus, careful intravenous injection. PPX will be administerd as an intravenous 10 mins. infusion. Capecitabine and methotrexate will be taken orally twice a day. Cyclophosphamide will be taken orally once a day.
9963305|NCT01227460|Experimental|Sitagliptin|
9963306|NCT01227460|Placebo Comparator|Sugar Pill|
9963307|NCT01227473|Experimental|mindfulness prediabetes education group|The mindfulness-based diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with instruction in mindfulness.
9963308|NCT01227473|Active Comparator|conventional prediabetes education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
9963309|NCT01227486||Obese patients for planned surgery and endotracheal intubation|
9963310|NCT01227538||Stimulated urinary C peptide|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
10037253|NCT01823393|Experimental|Heparin|injection of unfractionated heparin (50 IU / kg)
10037254|NCT01823393|Placebo Comparator|NaCl|without heparin
10006620|NCT01596075|Experimental|Oral Cannabidiol|Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
10006621|NCT01596101||acute burns|
10006622|NCT01596101||rehab patients|
10006623|NCT01596114|Experimental|Stop treatment|TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
10006624|NCT01596140|Experimental|Vemurafenib + Oral Everolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
10006625|NCT01596140|Experimental|Vemurafenib + Intravenous Temsirolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
10006626|NCT01596153|Placebo Comparator|Placebo|BID
10006627|NCT01596153|Active Comparator|Go Live Rx Probiotic|BID
10006628|NCT01596166|Experimental|Metoclopramide, Ketorolac|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Ketorolac 0.5 mg/kg (max 30 mg) IV"
10006629|NCT01596166|Placebo Comparator|Metoclopramide, Placebo|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Placebo (normal saline)"
10006630|NCT01596179|Experimental|Interactive navigational support|Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
10006631|NCT01596179|Active Comparator|control arm|Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
10006632|NCT01596192||Patients with acute GVHD|Patients after allogeneic hematopoietic cell transplantation who have developed acute GVHD
10006633|NCT01596205|Experimental|Robot intervention|Participants were given baseline assessments and randomly assigned into 3 groups; 24 with robot assisted cognitive training group (Robot intervention group), 24 with experienced behavioral therapist group (Conventional intervention group), and 37 without cognitive training (Control group).It was explained that there was a waiting list, therefore, participants in control group had an opportunity to participate in cognitive training program after a delay of 12 weeks for the intervention.
10006634|NCT01596205|Active Comparator|Conventional intervention|conventional cognitive training group - pen and pencil with experienced behavioral therapists
10006635|NCT01596205|No Intervention|Control group|
10006636|NCT01596218|Experimental|Treatment Arm|Treatment Arm for all participants - Brentuximab vedotin
10006637|NCT01596244|Experimental|Microclinics training|Diabetic, pre-diabetic, or those with family members who are diabetic/pre-diabetic who participated in a 4 month long intervention with a focus on disease management, health behavior change, and social network supports in order to improve chronic disease risk factors.
10006638|NCT01596257|Active Comparator|bulk SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
10006639|NCT01596257|Experimental|fractionated SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
10006640|NCT01596270|Experimental|Once daily dosing|escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose
10006641|NCT01596270|Experimental|Twice daily dosing|escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose
10006642|NCT01596296|Active Comparator|Transcervical foley catheter|
10006643|NCT01596296|Active Comparator|Dinoprostone|
10006644|NCT01596309|Placebo Comparator|control group, placebo|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added
10006645|NCT01596309|Experimental|Intervention group, cocoa extract|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
10006646|NCT01596322||UARTO|
10006647|NCT01596348||RA patients|Patients with Rheumatoid Arthritis
10006648|NCT01596387|Experimental|Propofol|20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
10006649|NCT01596400|Experimental|Sancuso Arm|
10006650|NCT01596400|Active Comparator|IV Granisetron Arm|IV
10006651|NCT01596413|Experimental|Sancuso Arm|Transdermal Patch 34.3mg graniestron per patch, size 52cm2 Dose: 3.1mg/24 hrs
10006652|NCT01596413|Active Comparator|IV Granisetron|"Aqueous solution for IV administration~1 mg/mL ampoules Dose: 0.01mg/kg (maximum 1 mg)"
10006653|NCT01596426|Experimental|Sancuso Arm|patch
10006654|NCT01596426|Active Comparator|IV granisetron|IV
10006655|NCT01596465|Active Comparator|Control|Control arm
10006656|NCT01596465|Active Comparator|Intervention|Intervention arm
10006657|NCT01596478|Active Comparator|Treatment As Usual|The standard treatment usually provided at the clinic.
10006658|NCT01596478|Active Comparator|Cognitive Motivational Behavior Therapy|An approach that addresses motivation to change gambling and behavioral patterns related to gambling.
10006659|NCT01596478|Active Comparator|12-week wait list|Participant will start treatment 12 weeks from day of consent.
10006660|NCT01596491||patients with peripheral nerve injury|10 patients with neuropathic pain, because of peripheral nerve injury will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
10006661|NCT01596491||patients with postherpetic neuralgia|10 patients with neuropathic pain, because of postherpetic neuralgia will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
10006662|NCT01596517|Experimental|Korean CHC|Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
10006663|NCT01596530|Active Comparator|AZD8931|AZD8931
10006664|NCT01596530|Placebo Comparator|Placebo|Placebo
10006665|NCT01596543|Experimental|sleep deprivation|The research contains only one arm. The subjects will be tested with no sleep deprivation (which will be used as a control measurement) and with partial and complete sleep deprivation.
10006666|NCT01596556|Experimental|smokers|This arm consists of smokers.
10006667|NCT01596556|Active Comparator|non-smokers|non-smoking participants in the study
10006668|NCT01596569|Active Comparator|Active TMS and Cognitive Intervention|"Active TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
10006669|NCT01596569|Sham Comparator|Sham TMS and Cognitive Intervention:|"Sham TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
10006670|NCT01596608|Experimental|Magnetic Seizure Therapy|
10006671|NCT01596634|Experimental|Supportive care (bovine lactoferrin)|Patients receive bovine lactoferrin PO (rinse or tablet) TID for 1 month. Treatment continues in the absence of unacceptable toxicity.
10006672|NCT01596647|Experimental|TKI258 (dovitinib)|dovitinib, 5 days on / 2 days off dose schedule
10006673|NCT01596660|Experimental|Bupivacaina|20 cc of bupivacaine 0.5% in 20 cc de saline solution and it is infiltrated 20 cc each side.
10006674|NCT01596660|Placebo Comparator|saline solution|20 cc of saline solution 0.9% to infiltrate each side.
10006675|NCT01596673|Experimental|BCAD Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet)."
10006676|NCT01596673|Experimental|CDBA Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet (matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet."
10035322|NCT01805076|Experimental|Arm 2 (experimental)|Patients undergo a clinical breast examination, mammography with ultrasound of breast and regional nodes and breast MRI followed by breast conserving surgery or mastectomy.
10035323|NCT01805102||maternal serum|measurement by immunoassay
10035324|NCT01805115|Experimental|Oral misoprostol|The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
10035325|NCT01805115|Experimental|Sublingual misoprostol|The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
10006677|NCT01596673|Experimental|DACB Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
10006678|NCT01596673|Experimental|ABDC Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
10006679|NCT01596686|Active Comparator|sodium picosulphate and magnesium citrate (Picoprep)|
10006680|NCT01596686|Active Comparator|polyethylene glycol (Fortrans)|
10006681|NCT01596712|Experimental|QGE031 Dose 1|QGE031 Dose 1: subcutaneous injection, single dose
10006682|NCT01596712|Experimental|QGE031 Dose 2|QGE031 Dose 2: subcutaneous injection, single dose
10006683|NCT01596712|Experimental|QGE031 Dose 3|QGE031 Dose 3: subcutaneous injection, single dose
10006684|NCT01596712|Placebo Comparator|Placebo|Placebo to QGE031 : subcutaneous injection, single dose
10006685|NCT01596725|Experimental|Group A|
10006686|NCT01596725|Experimental|Group B|
10006687|NCT01596725|Experimental|Group C|
10006688|NCT01596725|Experimental|Group D|
10006689|NCT01596725|Experimental|Group E|
10006690|NCT01596725|Experimental|Group F|
10006691|NCT01596738|Experimental|Tranexamic Acid group|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
10006692|NCT01596738|Placebo Comparator|Placebo group|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
10006693|NCT01596764|Placebo Comparator|Treatment A|Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
10006694|NCT01596764|Placebo Comparator|Treatment B|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under loperamide-induced obstipation condition.
10006695|NCT01596764|Active Comparator|Treatment C|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
10006696|NCT01596764|Active Comparator|Treatment D|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), MNTX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of methylnaltrexone.
10006697|NCT01596777|Placebo Comparator|Treatment A|Administration of LOP placebo (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under placebo condition.
10006698|NCT01596777|Placebo Comparator|Treatment B|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under loperamide-induced obstipation condition.
10006699|NCT01596777|Active Comparator|Treatment C|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX 12 mg sc. (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after subcutaneous administration.
10006700|NCT01596777|Active Comparator|Treatment D|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX IR (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of immediate release capsule.
10006701|NCT01596777|Active Comparator|Treatment E|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX ER (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of extended release capsule.
10006702|NCT01596790|Other|CTC assay|Detection & characterization of viable CTC in the peripheral blood.
10006703|NCT01596803|Active Comparator|vitamins minerals|VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)
10006704|NCT01596803|Placebo Comparator|Placebo|Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle
10006705|NCT01596816|Experimental|Boost by CyberKnife|
10006706|NCT01596816|Experimental|Boost by linear accelerator|
10006707|NCT01596829|Active Comparator|Probiotic|Probiotic consumption during and after course of antibiotic
10006708|NCT01596829|Placebo Comparator|Placebo|Placebo consumed during and after course of antibiotic
10006709|NCT01596855|Experimental|FG-4592|Active Drug
10006710|NCT01596855|Active Comparator|Epoetin alfa|Standard of care
10006711|NCT01596868|Active Comparator|Gemcitabine and Cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT..
10006712|NCT01596868|Active Comparator|docetaxel and cisplatin|Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
10006713|NCT01596881||Multiple Sclerosis Patients|Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
10006714|NCT01596881||Healthy Normal Subjects|Volunteers with healthy eyes.
10006715|NCT01596894|Experimental|Azithromycin + Metronidazole|Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
10006716|NCT01596894|Active Comparator|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
10006717|NCT01596907|Active Comparator|Ephedrine and caffiene|"Drug treatment:~ephedrine sulfate 25-mg with caffeine 200-mg per capsule to be given three times per day 4 hours apart for 6 months after gastric bypass surgery. Weight loss rate, resting energy expenditure, fat free mass will be measured during the treatment."
10035326|NCT01805115|Experimental|Vaginal misoprostol|The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
10006718|NCT01596907|Placebo Comparator|placebo|one placebo capsule will be taken three times per day 4 hours apart, identical to the instructions for the active drug for approximately 6 months following gastric bypass surgery. Weight loss rate, resting energy expenditure and fat free mass will be measured during the treatment.
10006719|NCT01596920|Active Comparator|Grafix®|
10006720|NCT01596920|Placebo Comparator|Control (non-adherent dressing)|
10006721|NCT01596933|Experimental|omega-3 fatty acid supplementation|omega-3 fatty acid supplementation (echium oil)
10006722|NCT01596933|Placebo Comparator|standard nutritional support|sunflower oil supplementation
10006723|NCT01596946|Active Comparator|Contact tracing mode test at clinic|Conventional mode of contact tracing where the partners were asked by either the index patient or demanded by the counsellor to attend a clinic for C. trachomatis testing. The date of testing for chlamydia of the study subject i e a sexual partner to a chlamydia infected index patient was noted. Those partners being C trachomatis positive were referred to the STD-clinic for contact tracing and following the same study arm a the index patient.
10006724|NCT01596946|Experimental|Self-sampling at home|The intervention: Self-sampling of sexual partners to infected index patient for chlamydia by urine test or vaginal sampling at home. They sent the kit tube to a microbiological laboratorium for analysis. The test kit was sent by post by the counsellor at the STD-clinic or distributed via the index patient. The partner in this arm was informed about the test result from the STD-clinic and those tested C trachomatis positive were given an appointment for treating and contact tracing as soon as possible. Their partners were not randomised but following the same mode. The days from the counselling conversation with the index patient to the date of testing was measured and compared with partners tested following arm 1 mode.
10006725|NCT01596959|Active Comparator|ECI CONTACT-ACTIVE|Irrigated Radiofrequency ablation performed using the ECI contact data
10006726|NCT01596959|Placebo Comparator|ECI CONTACT-INACTIVE|irrigated RF ablation performed to the right atrium without the use of ECI contact data
10006727|NCT01596985|Experimental|Ablation using the PlasmaJet system|"Origin of cyst invagination is identified after lysis of adhesions between ovary and adjacent broad ligament, leading to characteristic chocolate fluid evacuation. Surgeon then attempts to turn cyst completely inside out via original invagination site of diameter averaging 1 to 2cm. Ablation of cyst's inner surface is performed using the PlasmaJet system in coagulation mode set at 40, at distance averaging 5mm from tip of handpiece, and with exposure time limited to 1 to 2s on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and corresponding peritoneal implants on adjacent broad ligament. When cyst reversion is not feasible, surgeon progressively exposes cyst interior to guide plasma beam at an angle perpendicular to the inner surface."
10006728|NCT01596985|Active Comparator|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
10006729|NCT01596998|Active Comparator|Levobupivacaine without epinephrine|
10006730|NCT01596998|Experimental|Levobupivacaine with epinephrine|
10006731|NCT01597011||Fibrin sealant group|Patients who have undergone laparoscopic inguinal hernia repair with fibrin sealant for mesh fixation
10006732|NCT01597011||Tissue-penetrating fixation group|Patients who have undergone laparoscopic inguinal hernia repair with the use of tacks, staples or sutures for mesh fixation
10006733|NCT01597024|Experimental|Phase 1: Breakfast Study|
10006734|NCT01597024|Experimental|Phase 2: fMRI Study|
10006735|NCT01597037|Active Comparator|High complexity, high feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
10006736|NCT01597037|Active Comparator|High complexity, low feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
10006737|NCT01597037|Active Comparator|Low complexity, high feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
10006738|NCT01597037|Active Comparator|Low complexity, low feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
10006739|NCT01597063||low risk pregnancies|
10006740|NCT01597076|Experimental|60-240 mL/day|60 -240 mL/day dose group
10006741|NCT01597102||Liver transplantation|Patients with liver failure and liver transplantation
10006742|NCT01597115|Active Comparator|Duplex|Patients in this group will be examed by duplex ultrasonography at 2 and 4 weeks after surgery
10006743|NCT01597115|No Intervention|physical exam|According to the K/DOQI guideline, patients will be examed by vascular access surgeon at 2 and 4 weeks after surgery
10006744|NCT01597154|Experimental|Lifestyle counselling|Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
10006745|NCT01597154|No Intervention|Control|Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
10006746|NCT01597167|Experimental|Magnesium sulfate crossover|IV infusion of magnesium sulfate followed by 5-day washout period and crossover to 5% dextrose (placebo)
10006747|NCT01597167|Placebo Comparator|Placebo crossover|IV infusion of 5% dextrose with 5 day washout and crossover to magnesium sulfate
10006748|NCT01597206|Experimental|Removable partial denture Group|Patients with a reduced posterior dental arch will be randomized into one of 2 Groups Group A will receive a removable partial denture prosthesis
10006749|NCT01597206|Active Comparator|Reduced Posterior Dental Arch Group|Patients with a reduced posterior dental arch and not receiving any Intervention will be compared to the removable partial denture group
10006750|NCT01597219|Experimental|Reduced intensity haploidentical transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
10006751|NCT01597219|Experimental|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
10006752|NCT01597232|Experimental|Transfusion trigger based on WCPTS|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCPTS.
10006753|NCT01597232|Active Comparator|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively.
10006754|NCT01597232|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience.
10035327|NCT01805115|Experimental|Control|The no-misoprostol group did not administer the medication of misoprostol before the procedure
10035328|NCT01805128|Experimental|schizophrenia|child with a DSM-IV diagnosis of schizophrenia
10035329|NCT01805128|Experimental|autism spectrum disorder|child with a DSM-IV diagnosis of autism spectrum disorder
10035330|NCT01805128|Experimental|Healthy|child having no DSM-IV diagnosis of schizophrenia spectrum disorder or autism
10035331|NCT01805167|Other|subjects with a cochlear implant|
10035332|NCT01805193||Suspected coronary heart disease|
10035333|NCT01805206|Experimental|iFABP Monitored|Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
10035334|NCT01805219||healthy subjects|
10035335|NCT01805232|Experimental|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
10035336|NCT01805232|Active Comparator|quinine|quinine infusion 80 mg/kg every 8 hours
10035337|NCT01805245|Experimental|Mindfulness Based Stress Reduction|
10035338|NCT01805245|Active Comparator|Health Education Control|
10035339|NCT01805258|Experimental|Intervention 2: Nevirapine|HIV and Tuberculosis co-infected patients on standard dose nevirapine (Intervention) based ART and Rifampicin based ATT.
10035340|NCT01805258|Active Comparator|Intervention 2: Efavirenz|HIV and Tuberculosis co-infected patients on standard dose Efavirenz(Intervention)based ART and Rifampicin based ATT.
10035341|NCT01805310|Other|Bowel Preparation|Women randomized to the bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one. They will also be placed on a clear liquid diet on preoperative day number one.
10035342|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
10035343|NCT01805336|Other|Arm A|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by traditional tests + executive function by virtual reality tests.~One week later, Assessment 2 : attentional function by virtual reality tests + executive function by traditional tests."
10035344|NCT01805336|Other|Arm B|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by virtual reality tests + executive function by traditional tests.~One week later, Assessment 2 : attentional function by traditional tests + executive function by virtual reality tests."
10035345|NCT01805349|Other|X-Rays|patients with digital arthrosis and hip/knee arthrosis will practice hand X-rays
10035346|NCT01805362|Active Comparator|MORNING|patients continue to take their treatments (RAS blockers and diuretics) on awaking
10035347|NCT01805362|Experimental|EVENING|Patients take their treatments(RAS blockers and diurectics)at bedtime
10035348|NCT01805388|Experimental|Regeneration Treatment Group|RTC with Triple Antibiotic Study Drug
10006755|NCT01597297|Experimental|Fampridine-PR|Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
10006756|NCT01597297|Placebo Comparator|Placebo|Matched placebo twice daily (every 12 hours) for up to 24 weeks.
10006757|NCT01597310|Experimental|Warfarin|25 mg Warfarin, Treatment Period 1 & Treatment Period 2
10006758|NCT01597310|Experimental|Dexpramipexole|150 mg BID Treatment Period 2
10006759|NCT01597323||Treatment Group|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
10006760|NCT01597336|Active Comparator|Saline only flush of abscess|Saline alone used to flush abscess
10006761|NCT01597336|Experimental|Saline plus tPA flush of abscess|Saline plus tPA used for abscess flush
10006762|NCT01597362|Other|Veress needle technique|
10006763|NCT01597362|Other|Direct trocar technique|
10006764|NCT01597362|Other|Open technique|
10006765|NCT01597401|Experimental|Aes-103 300 mg to 1000 mg (Group A)|Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
10006766|NCT01597401|Experimental|Aes-103 2000 mg to 4000 mg (Group B)|Group B will consist of six subjects receiving an initial dose of either Aes 103 (2,000 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (4,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
10006767|NCT01597401|Experimental|Top Dose Expansion (Group C)|Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
10006768|NCT01597427|Sham Comparator|Clonidine|Administration of 2 μg/kg of intravenous clonidine.
10006769|NCT01597427|Placebo Comparator|Placebo|Injection of placebo solution.
10006770|NCT01597453|Other|Lifestyle counseling|There are no different arms, NOR-SYS is an observational study
10006771|NCT01597466|Experimental|Epidrum|Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
10006772|NCT01597466|Active Comparator|Loss of resistance technique|
10006773|NCT01597518|Experimental|Riluzole|
10006774|NCT01597518|Placebo Comparator|Placebo|
10006775|NCT01597531|Active Comparator|Liraglutide only|
10006776|NCT01597531|Active Comparator|Orlistat only|
10006777|NCT01597531|Active Comparator|Liraglutide + Orlistat|
10006778|NCT01597544|No Intervention|CISC instruction post-operatively|For those patients that are randomized to CISC instruction before surgery, instruction will begin on post-operative day one. One of the nurses from the hospital gynecology unit will teach and supervise the patients until they feel comfortable with the technique or until catheterization is no longer required (e.g. when the patient passes her voiding trial on two separate occasions). This is the protocol currently in use at our institution.
10006779|NCT01597544|Active Comparator|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
10006780|NCT01597570|Experimental|FASTSEAL® Bioabsorbable VCD|Fastseal® Bioabsorbable Vascular Access Closure System
10006781|NCT01597570|Active Comparator|Perclose® ProGlide SMC System|Perclose® ProGlide Suture-Mediated Closure System
10006782|NCT01597609|Experimental|Cohort A|- 600 Kcal deficit, Sibutramine placebo
10006783|NCT01597609|Experimental|Cohort B|- 600 Kcal deficit, Sibutramine 10 mg once daily
10006784|NCT01597609|Experimental|Cohort C|- 600 Kcal deficit, Moderate exercise (The energy expenditure will be equivalent to 30 minutes of brisk walking/5 times week i.e. ~1,000 Kcal/week) /sibutramine placebo
10006785|NCT01597648|Experimental|Sequence 1|Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast Washout Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
10006786|NCT01597648|Experimental|Sequence 2|"Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.~Washout Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast"
10006787|NCT01597661||Malformed and population-based sample of non-malformed infants|Infants with any of a wide range of malformations are identified at tertiary care and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using approaches that include reviewing lists of discharge diagnoses available in medical records; contacting newborn nursery and/or labor and delivery rooms; reviewing admission/discharge lists; and reviewing clinic and surgical logs. A population-based random sample of non-malformed newborns in Massachusetts is also included. Information gathered on each subject includes name, address, telephone number, diagnostic information, and date of birth.
10006788|NCT01597700|Experimental|Acotral® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 day.
10006789|NCT01597700|Active Comparator|Zetia® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 days.
10006790|NCT01597713|Experimental|Part 1, level 1-7 escalating doses|
10006791|NCT01597713|Experimental|Part 2, cross-over|
10006792|NCT01597726|Active Comparator|Misoprostol|
10006793|NCT01597726|Experimental|Laminaria|
10006794|NCT01597739|Experimental|JNJ-40346527|
10006795|NCT01597739|Placebo Comparator|Placebo|
9963311|NCT01227590|Experimental|Pharmacokinetics single-arm|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
9963312|NCT01227603|Experimental|Nifedipine-candesartan FDC|Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
9963313|NCT01227603|Active Comparator|Nifedipine and candesartan|Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
9963314|NCT01227603|Active Comparator|Nifedipine|Each subject received one dose of nifedipine GITS 60 mg orally.
9963315|NCT01227603|Active Comparator|Candesartan|Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.
9963316|NCT01227642|Experimental|pre-implant transrectal ultrasound images and planning|Transrectal ultrasound session will be performed at a separate session prior to the implant.
9963317|NCT01227694|Experimental|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
9963318|NCT01227720|Experimental|A NSL2L|Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg
9963319|NCT01227720|Active Comparator|B Lozenge|Marketed Nicotine Lozenge 2 mg
9963320|NCT01227720|Experimental|C NSL4M|Experimental NRT (M) 4 mg
9963321|NCT01227720|Active Comparator|D Lozenge|Marketed Nicotine Lozenge 4 mg
9963322|NCT01227720|Experimental|E NSL4L|Experimental NRT (L) 4 mg
9963323|NCT01227720|Experimental|F NSL4H|Experimental NRT (H) 4 mg
9963324|NCT01227733||Breast Tumor|Breast Tumor Blocks
9963325|NCT01227746||Tumor biopsies|
9963326|NCT01227759|Experimental|Verum|
9963327|NCT01227759|No Intervention|Untreated|
9963328|NCT01227759|Placebo Comparator|Vehicle|
9963329|NCT01227772|Experimental|Weekly Cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
9963330|NCT01227772|Experimental|2-weekly cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
9963331|NCT01227772|Experimental|3-weekly cohort|The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
9963332|NCT01227798|Placebo Comparator|Placebo|100 mM sodium Chloride and 25 mM sodium phosphate at pH 7.0 +/- 0.2
9963333|NCT01227798|Active Comparator|Infergen|15mcg subcutaneous injection at fill volume of 0.5mL
9963334|NCT01227811|Active Comparator|Enablex(R) 15 mg , single dose|
9963335|NCT01227811|Experimental|Darifenacin 15 mg tablets, single dose|
9963336|NCT01227837|Sham Comparator|placebo|use of placebo in control group
9963337|NCT01227837|Experimental|omega 3|use of omega 3 2 gr/day for 6 months
10006796|NCT01597752|Experimental|1|"Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)~Positive control~Negative control"
10006797|NCT01597765|Experimental|Curcuminoids|The administrate curcuminoids is intervention for 30 patients
10006798|NCT01597765|Experimental|Vitamin E|The vitamin E is intervention for 30 patients
10006799|NCT01597804|Experimental|"Supportive care (Bathing Bundle)"|"Patients undergo preoperative preparation with the Bathing Bundle comprising CHG 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery."
10006800|NCT01597817|Active Comparator|chitosan coated textile|Chitosan coated cotton long sleeved t-shirts and pants.
10006801|NCT01597817|Placebo Comparator|chitosan free cotton textile|Chitosan free cotton long sleeved t-shirts and pants.
10006802|NCT01597830|Experimental|active shoe|
10006803|NCT01597830|Sham Comparator|Control|
10006804|NCT01597882||Case managed patients|Patients aged 65 years and over receiving community case management.
10006805|NCT01597895|Active Comparator|Maraviroc|
10006806|NCT01597895|Experimental|Maraviroc + Boceprevir|
10006807|NCT01597895|Experimental|Maraviroc + Telaprevir|
10006808|NCT01597921||Breast cancer patient receiving RT|Total dose:2Gy/Fx
10006809|NCT01597934|Active Comparator|Group A:|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
10006810|NCT01597934|Experimental|Group B|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
10006811|NCT01597947|Experimental|Arm A|
10006812|NCT01597947|Placebo Comparator|Arm B|
10006813|NCT01597960|Active Comparator|Yoga 12 week programme|Usual care (standard cardiac rehabilitation programme) plus yoga intervention.
10006814|NCT01597960|No Intervention|Usual care|Usual care (standard cardiac rehabilitation programme) only.
10006815|NCT01597986|Experimental|Isavuconazole and oral contraceptive|Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.
10006816|NCT01597999|Other|No treatment|Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
10006817|NCT01598012|Experimental|Ayurved Siriraj Prasaplai|
10006818|NCT01598012|Placebo Comparator|placebo|
10006819|NCT01598038|No Intervention|Afinitor|"The recommended dose of Afinitor is 10 mg everolimus once daily, at fixed hour.Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.~In case of frail patients, treatment could be initiated at a lower daily-dose (5mg/d for example) and then increase if tolerance is acceptable."
10006820|NCT01598051||Group 1|Patients treated with Xarelto under practical manner for SPAF.
10006821|NCT01598077|Experimental|Dose escalation and dose expansion|
10006822|NCT01598142|Other|experienced assistant group|experienced endoscopist with an experienced assistant.
10006823|NCT01598142|Other|new trained assistant group|same experienced endoscopist with a new trained assistant
10006824|NCT01598155|Experimental|Supragingival biofilm control|
10006825|NCT01598155|Experimental|Supra- and subgingival biofilm control|
10006826|NCT01598168|Experimental|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
10006827|NCT01598181|Experimental|active tDCS|
10006828|NCT01598181|Sham Comparator|sham tDCS|tDCS fades out after 20 sec. administered double blind by coded program.
10006829|NCT01598220|Experimental|Computer-assisted cognitive remediation therapy|
10006830|NCT01598220|Placebo Comparator|attentional task|
10006831|NCT01598233|Experimental|Intragastric balloon|Patients submitted to six-month intragastric balloon
10006832|NCT01598246||Extubation Success|Patients who do not require re-intubation, upto 72 hours after a planned extubation in the pediatric intensive care unit.
10006833|NCT01598246||Extubation failure|Patients who required re-intubation within 72 hours after a planned extubation in pediatric intensive care unit. To be further classified as early <12 hour and late 12-72 hour, extubation failures.
10006834|NCT01598259|Experimental|melatonin|Subjects will receive melatonin
10006835|NCT01598259|Placebo Comparator|placebo|
10006836|NCT01598272|Experimental|Vitality product AM + Vitality product PM|"Dietary Supplement:~Proprietary blend of ginseng, cordyceps, and pomegranate + proprietary blend of broccoli seed, red orange, and grape seed taken twice a day for 8 weeks."
10006837|NCT01598272|Placebo Comparator|Placebo|Dietary Supplement: Placebo Placebo taken twice a day for 8 weeks
10006838|NCT01598324||escitalopram responders no augmentation|Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
10006839|NCT01598324||Ziprasidone augmentation|Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
10006840|NCT01598324||Placebo augmentation|Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.
10006841|NCT01598337|Active Comparator|Aspirin alone|
10006842|NCT01598337|Experimental|Tirofoban|Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
10006843|NCT01598337|Experimental|Clopidogrel|Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
10006844|NCT01598337|Experimental|Prasugrel|Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
9963338|NCT01227850||Parenteral nutrition patients.|
9963339|NCT01227863|Experimental|Test|Dexamethasone + neomycyn + polimixyn B
9963340|NCT01227863|Active Comparator|Comparator|Dexamethasone + neomycyn + polimixy B
9963341|NCT01227876|Experimental|Test|Ster ® (prednisolone 1% ophthalmic suspension - União Química)
9963342|NCT01227876|Active Comparator|Comparator|Pred Fort ® (prednisolone 1% ophthalmic suspension - Allergan)
9963343|NCT01227915|Experimental|Test|tobramycin 0.3% + dexamethasone 1% - União Química Lab
9963344|NCT01227915|Active Comparator|Comparator|tobramycin 0.3% + dexamethasone 1% - Alcon Lab
9963345|NCT01227941|Experimental|Part A: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination. Dose escalation/confirmation in participants with advanced solid tumors
9963346|NCT01227941|Experimental|Part B: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination at 1 or 2 dose levels of MK-4827 to be determined from the results of Part A. Ovarian Cancer Cohort
9963347|NCT01228006|Experimental|Treatment|NatusGerin
9963348|NCT01228006|Placebo Comparator|Control|Gelatin capsules identical to drug test
9963349|NCT01228032|Experimental|Intervention|
9963350|NCT01228032|No Intervention|Control|referral only
9963351|NCT01228045|Experimental|Trastuzumab in Combination with TS-ONE and cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
9963352|NCT01228058||Adult trauma patients|Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
9963353|NCT01228097||Gastric Bypass|Participants who receive gastric bypass surgery.
9963354|NCT01228097||Principally Restrictive Surgery|Participants who receive gastric banding or sleeve gastrectomy surgery.
9963355|NCT01228097||Weight Stable|Participants who remain weight stable.
9963356|NCT01228110|Active Comparator|Corticosteroid group|This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
9963357|NCT01228110|Placebo Comparator|Placebo group|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
9963358|NCT01228123|Active Comparator|CVVH arm|
9963359|NCT01228123|Active Comparator|IHD arm|
9963360|NCT01228136|Active Comparator|Tranexamic acid|
9963361|NCT01228136|Placebo Comparator|Placebo|
9963362|NCT01228162|Experimental|general anaesthesia|patients receiving general anaesthesia and rocuronium bromide for muscle relaxation
9963363|NCT01228162|Active Comparator|spinal anaesthesia|patients receiving spinal anaesthesia without muscle relaxation
9963364|NCT01228188|Experimental|Idiopathic Full Thickness Macular Hole|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
9963365|NCT01228201|Experimental|Aerboic interval training|
9963366|NCT01228201|Active Comparator|Moderate continuous training|
9963367|NCT01228214|Experimental|Amiloride,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
9963368|NCT01228214|Placebo Comparator|Placebo,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
9963369|NCT01228227|Active Comparator|ROSUVASTATIN|
9963370|NCT01228227|Experimental|ATORVASTATIN|
9963371|NCT01228240|Experimental|Metformin, Apo-metformin|
9963372|NCT01228253|No Intervention|1|Safe voluntary.
9963373|NCT01228253|No Intervention|2|patient with psychotrauma but without PSTD and without any psychiatric trouble at the time of inclusion
9963374|NCT01228253|No Intervention|3|patient with psychotrauma and PTSD (post-traumatic stress disorder) and in full remission at the time of inclusion
9963375|NCT01228253|No Intervention|4.3|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
9963376|NCT01228253|Sham Comparator|4.2|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
9963377|NCT01228253|Experimental|4.1|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
9963378|NCT01228266|Experimental|autologous mesenchymal stem cell|A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months
9963379|NCT01228279|Active Comparator|DIANEAL|One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
9963380|NCT01228279|Active Comparator|EXTRANEAL|The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
9963381|NCT01228292|Active Comparator|Standard Anticoagulation|Hemodialysis is performed using standard anticoagulation using unfractionated heparin if no contra-indications for the use of heparin exist. If contra-indications for heparin exist a heparin coated hemofilter (Evodial) will be used. The use of unfractionated heparin or no heparin (with coated hemofilter) is a decision to be taken before every hemodialysis.
9963382|NCT01228292|Experimental|Citrasate|Hemodialysis is performed with Citrasate
9963383|NCT01228305|Experimental|Acetaminophen|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
9963384|NCT01228305|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
9963385|NCT01228331|Active Comparator|Arm I intensification (cytarabine)|"LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
10006845|NCT01598363|Experimental|Digoxin 0.5mg, Bardoxolone Methyl 20mg and 60mg|
10006846|NCT01598363|Experimental|Rosuvastatin 20mg, Bardoxolone Methyl 20mg and 60mg|
9963386|NCT01228331|Active Comparator|Arm II intensification (clofarabine)|"LR-S patients receive clofarabine* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
9963387|NCT01228331|Active Comparator|Arm III reinduct.(doxorubicin hydrochl.)|"LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
9963388|NCT01228331|Active Comparator|Arm IV reinduct.(daunorubicin hydrochl.)|"LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
9963389|NCT01228344||Artemether-lumefantrine|
9963390|NCT01228357|Experimental|SSRI treated group|SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
9963391|NCT01228357|Active Comparator|non-SSRI treated group|non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
9963392|NCT01228370|Experimental|Silodosin|Silodosin 8mg once a day for 12 weeks
9963393|NCT01228409|Other|Low dose Acitretin (17.5 mg)|
9963394|NCT01228422||1|test interferon - blausiegel
9963395|NCT01228422||2|reference interferon - Roferon A (Roche)
9963396|NCT01228448|Experimental|Participants 1-39|PET Scan done right after one radiation treatment is complete and will take 15-20 minutes. After undergoing their first PET scan, participants will have the option to undergo 1-2 additional scans throughout radiation treatment in the same manner as the first scan.
9963397|NCT01228461||AYA with Fatigue and Hodgkin Lymphoma|
9963398|NCT01228474|Experimental|SET|Single embryo transfer
9476659|NCT03569605|Experimental|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group, behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
9476660|NCT03569592|Experimental|Overdose Prevention Intervention|The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
9963399|NCT01228474|Active Comparator|DET|Double embryo transfer
9963400|NCT01228487||Acute knee pain|Patients with a history of knee pain < 6 months. The radiologic and arthroscopic OA stadium is less or equal II°. n=20.
9963401|NCT01228487||Chronic knee pain|Clinical manifestation of knee joint OA, radiological and arthroscopic III° or more. n=20
9963402|NCT01228487||Control group|Patients coming for post- primary repair of the cruciate ligament, having no inflammation and no sign of OA. n=10
9963403|NCT01228500|Experimental|Experimental Arm (Internal Control)|"One-half of ulcer receives negative pressure wound therapy~One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy"
9963404|NCT01228539|Experimental|TARGET|Affect regulation psychotherapy for PTSD
9963405|NCT01228539|Active Comparator|Prolonged Exposure|Cognitive behavioral therapy for PTSD with trauma memory exposure
9963406|NCT01228552|Active Comparator|Topical, intra-oral ketoprofen gel|
9963407|NCT01228552|Placebo Comparator|Placebo gel|
10006847|NCT01598376|Active Comparator|5/0 gauge vicryl suture|Patients randomly assigned to 5/0 gauge test everting suture
10006848|NCT01598376|Active Comparator|7/0 gauge vicryl suture|Patients randomly assigned to 7/0 gauge test everting suture
9963408|NCT01228565|Placebo Comparator|Placebo|Radiotherapy+Erbitux+Placebo
9963409|NCT01228565|Experimental|OTD70DERM|Radiotherapy+Erbitux+OTD70DERM®
9963410|NCT01228578|Experimental|Multivitamins (B,C,E)|
9963411|NCT01228578|Placebo Comparator|Placebo|
9963412|NCT01228604|Experimental|Methylphenidate|
9963413|NCT01228617|Experimental|A1 Short, no buffer|Nicotine / not yet marketed
9963414|NCT01228617|Experimental|A2 Short, low buffer|Nicotine / not yet marketed
9963415|NCT01228617|Experimental|A3 Short, high buffer|Nicotine / not yet marketed
9963416|NCT01228617|Experimental|B1 Long, no buffer|Nicotine / not yet marketed
9963417|NCT01228617|Experimental|B2 Long, low buffer|Nicotine / not yet marketed
9963418|NCT01228617|Experimental|B3 Long, high buffer|Nicotine / not yet marketed
9963419|NCT01228617|Active Comparator|R = Nicotine Gum|Nicorette® Gum
9963420|NCT01228630|Experimental|Cloratadd-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to comparator drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
9963421|NCT01228630|Active Comparator|Allegra-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to test drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
9963422|NCT01228643|Experimental|Norzyme®|
9963423|NCT01228643|Active Comparator|Creon®|
9963424|NCT01228656|Experimental|-mometasone furoate associated with salicylic acid|
9963425|NCT01228656|Active Comparator|-mometasone furoate|
9963426|NCT01228669|Experimental|A|
9963427|NCT01228669|Experimental|B|
9963428|NCT01228669|Placebo Comparator|C|
9963429|NCT01228682||Patients who are treated with Samsca.|
9963430|NCT01228695||steroid treatment|
9963431|NCT01228708|Active Comparator|Intervention|Patients from half the GP practices in Ringkoebing-Skjern municipality that participates in an active implementation of a guideline for COPD
9963432|NCT01228708|No Intervention|Control group|Patients from the half of the GP practice in Ringkoebing-Skjern that do not participate in the active implementation of a guideline for COPD. The GPs are however in postgraduate training groups with intervention groups GPs
9963433|NCT01228708|No Intervention|External control|Patients with GP practice in neighboring county Ikast-Brande where there have been no information or contact at all from the investigators
9963434|NCT01228760|Experimental|Dose level 1|
9963435|NCT01228760|Experimental|Dose level 2|
9963436|NCT01228760|Experimental|Dose level 3|
9963437|NCT01228760|Experimental|Dose level 4|
9963438|NCT01228760|Experimental|Dose level 5|
9963439|NCT01228760|Experimental|Dose level 5A|
9963440|NCT01228760|Experimental|Dose level 6|
9963441|NCT01228760|Experimental|Dose level 7|
9963442|NCT01228760|Experimental|Dose level 8|
9963443|NCT01228760|Experimental|Dose level 9|
9963444|NCT01228760|Experimental|Chemotherapy-naïve subjects|
9963445|NCT01228760|Experimental|Chemotherapy exposed subjects|
9963446|NCT01228773|Experimental|A|"Providing tailored web-based care program(Health Navigation®), which provides various information related to the CRF.~Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue etc."
9963447|NCT01228773|Other|B|Attention control arm: Providing usual care for CRF. Three months later, as attention control, they will be provided tailored web-based care program(Health Navigation®), which provides various information related to the CRF.
9963448|NCT01228786||Group A|~ 20 sporadic PHPT patients
9963449|NCT01228786||Group B|~10 normocalcemic euthyroid patients (control tissue)
9963450|NCT01228799|Active Comparator|Trabeculectomy|Trabeculectomy with Mitomycin C
9963451|NCT01228799|Active Comparator|Canaloplasty|Canaloplasty with implant of suture
9963452|NCT01228812||RA patients|Patients with Rheumatoid Arthritis
9963453|NCT01228812||Healthy subjects|Healthy subjects matched for age and sex
10006849|NCT01598389|Experimental|Low energy-dense preload|
10006850|NCT01598389|Experimental|High energy-dense preload|
10006851|NCT01598389|Experimental|No preload|
10006852|NCT01598402|No Intervention|No prophylactic treatment|When a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics).
10006853|NCT01598402|Experimental|prophylactic treatment|Administration of prophylactic amoxicillin/clavulanic acid suspension, 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT. If a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics)
10006854|NCT01598415|Experimental|SAR113945|TDU11685 selected dose
10006855|NCT01598415|Placebo Comparator|Placebo|
10006856|NCT01598441|Experimental|iloprost|Iloprost nebuliser solution 500 ng/kg inhaled
10006857|NCT01598441|Placebo Comparator|distilled water|aerosolized distilled water 1-2 ml
10006858|NCT01598454|Experimental|Racotumomab|
10006859|NCT01598467|Other|Women with pelvic organ prolapse|Women with pelvic organ prolapse (simplified POP-Q > stage 1)
10006860|NCT01598480|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze.
10006861|NCT01598480|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
10006862|NCT01598493|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze
10006863|NCT01598493|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
10035349|NCT01805388|No Intervention|Control Non-study Drug Group|RTC on contralateral tooth with no study drug
10035350|NCT01805401|Experimental|Left OFC Group|Anode applied to the left OFC and cathode applied to the right OFC
10006864|NCT01598519|Experimental|study group|1500 students are randomized to receive a universal suicide intervention apart from usual school psychology classes. Furthermore, high risk of suicidal students screened in study group will receive an indicated suicide intervention in addition to usual school psychology classes.
10006865|NCT01598519|No Intervention|control group|1500 students are randomized to receive usual school psychology classes. High risk of suicidal students screened in control group will receive usual psychology classes.
10006866|NCT01598558|Experimental|64Cu-DOTA|Subjects will be injected with less than 14 mCi of 64Cu-DOTA-Rituximab. This is a slow infusion, done over 20 minutes.
10006867|NCT01598571|Experimental|Fostamatinib 50 mg tablet|
10006868|NCT01598571|Experimental|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose|
10006869|NCT01598584|Placebo Comparator|placebo plus gemcitabine|we design placebo plus gemcitabine as control arm
10006870|NCT01598584|Experimental|Mirtazapine plus gemcitabine|We design Mirtazapine plus gemcitabine as experimental arm
10006871|NCT01598597||Cohort|
10006872|NCT01598623|Experimental|Oxytocin+ Non Specific Counselling|
10006873|NCT01598623|Experimental|Oxytocin + Social Skills training|
10006874|NCT01598623|Placebo Comparator|Placebo + Non Specific Counselling|
10006875|NCT01598623|Experimental|Placebo + Social Skills Training|
10006876|NCT01598636|Experimental|Lateral Tibial Tunnel technique|
10006877|NCT01598649|Experimental|Lupin protein|Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol
10006878|NCT01598649|Active Comparator|Milk protein|Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules
10006879|NCT01598649|Active Comparator|Milk protein and arginine|Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day
9476661|NCT03569579|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO.~Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
10006880|NCT01598675|Active Comparator|Control|Symmetric Gait. Dual-belted treadmill belts moving at the same belt speeds during training
10006881|NCT01598675|Experimental|Gait Asymmetry|Error Augmentation. Belts of a dual-belted treadmill may move at different belt speeds to amplify spatiotemporal gait asymmetry during training
10006882|NCT01598675|Experimental|Gait Symmetry|Error Minimization. Belts of a dual-belted treadmill may move at different belt speeds to encourage spatiotemporal gait symmetry during training
10006883|NCT01598688|Active Comparator|Blood collection immediately after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
10006884|NCT01598688|Experimental|Blood collection five minutes after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
10006885|NCT01598714|Other|Darco shoe|Darco walking shoe provided
10006886|NCT01598714|Other|Podalux Shoe|Podalus shoe
10006887|NCT01598714|Other|Standard dressing shoe|Standard dressing shoe
10006888|NCT01598727|Experimental|Fluobeam(TM) Imaging System (Fluoptics)|Single arm observational pilot study
10006889|NCT01598766|Experimental|Diagnostic Coil|This coil is a lightweight, flexible coil which can be used for many pediatric MRI exams
10006890|NCT01598805|Experimental|roll out of eAlerts|Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
10006891|NCT01598818||Visual acuity|Comparison of best visual acuity and refraction using the First Sight Refractive System with autorefraction in subjects with refractive error.
10006892|NCT01598844||High risk patients with aortic stenosis|Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.
10006893|NCT01598844||High risk patients with AI|Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.
10006894|NCT01598857|Experimental|Blisibimod|
10006895|NCT01598857|Placebo Comparator|Placebo|
10006896|NCT01598870||Patients with cirrhosis and ascites|Patients requiring diagnostic and/or therapeutic paracentesis.
10006897|NCT01598883|Other|ACT after initial heparin bolus less than 450|If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
10006898|NCT01598883|Active Comparator|ACT after first intervention less than 450|
10006899|NCT01598909|Active Comparator|Arnica ointment|
10006900|NCT01598909|Placebo Comparator|Placebo ointment|
10006901|NCT01598909|No Intervention|Control|
10006902|NCT01598935|Placebo Comparator|Control|placebo
10006903|NCT01598935|Active Comparator|High protein intake|Nutrition - High protein
9963454|NCT01228825||CABG without CPB|Patients undergoing coronary artery bypass graft (CABG) without Cardiopulmonary bypass ( CPB)
9963455|NCT01228825||CABG with CPB|Patients undergoing coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)
9963456|NCT01228838|Experimental|NGX-1998, 10% w/w capsaicin|
9963457|NCT01228838|Experimental|NGX-1998, 20% w/w capsaicin|
9963458|NCT01228838|Placebo Comparator|Placebo liquid|
9963459|NCT01228851|Experimental|Balance Training|Balance training using Wii Fit Balance Board
9963460|NCT01228864|Experimental|Brody Belt|
9963461|NCT01228864|Active Comparator|Conventional Urinary Drainage bag|
9963462|NCT01228877|Experimental|Exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
9963463|NCT01228890|Experimental|CATCH-IT 2-R Arm|Primary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
9963464|NCT01228890|Active Comparator|Attention Monitoring Psycho-education (AMPE) Arm|
9963465|NCT01228916|Experimental|Tobacco Cessation and Secondhand Smoke Reduction|Community based interventions to raise awareness regarding secondhand smoke exposure, clean indoor air laws, smokefree homes, risks of tobacco use and benefits of cessation; include talks, healthcare provider training, radio public service announcements and talk shows, tleevision interviews, cessation classes and individual sessions, health fairs, community marches for smokefree spaces, materials and resources for assisting in tobacco use cessation, estsablishing smokefree homes, adhering to smokefree laws
9963466|NCT01228916|No Intervention|Delayed Intervention Control|Assessment only during comparison period (no interventions will be provided over and above any secular trends in communities); delayed intervention will be provided at end of 1 year comparison period
9963467|NCT01228942|Other|Platinum Sensitive|Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
9963468|NCT01228942|Other|Platinum resistent|single agent based on Coxen prediction model
9963469|NCT01228955||Yoga Group|Group will enter a 10 week yoga class
9963470|NCT01228981||Type-2 Diabetic Retinopathy|
9963471|NCT01228994|Active Comparator|Baclofen 30 mg/day|Baclofen medication
9963472|NCT01228994|Placebo Comparator|Placebo pill|placebo pill
9963473|NCT01228994|Active Comparator|Baclofen 60 mg/day|Baclofen medication high dose
9963474|NCT01229007|Experimental|Biostate|
9963475|NCT01229020||COPD patients|Patients diagnosed with COPD, by the pulmonologist at the institute,who are referred to undergo ventilation/perfusion scans.
9963476|NCT01229033|Active Comparator|Ablation|Ablation of atrial tachycardia
9963477|NCT01229033|Active Comparator|Cardioversion|Cardioversion of atrial tachycardia
9963478|NCT01229046|Active Comparator|ticarcillin-clavulanate|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
9963479|NCT01229059||lipid infusion in untrained humans|healthy lean humans before and after lipid infusion
9963480|NCT01229059||lipid infusion in athletes|endurance trained atheletes
9963481|NCT01229072|Experimental|1|Heparin Blausiegel
9963482|NCT01229072|Active Comparator|2|Liquemine
9963483|NCT01229085|Experimental|Test|mometasone 0,1% + salicylic acid 5%
9963484|NCT01229098|Experimental|LEO 80185|
9963485|NCT01229137||Right Ventricular Cohort|Right Ventricle wtih SRD-1 conversion
9963486|NCT01229137||Left Ventricular Cohort|Left Ventricle with SRD-1 conversion
9963487|NCT01229137||Right Atrium Cohart|Right atrium cohort with SRD-1 conversion
9963488|NCT01229189|Experimental|Maternal and Neonatal Intervention Arm|Pregnant women will be individually randomized; a daily dose of vitamin D in 4000 IU will be given to Intervention group, started at 20-22 weeks of pregnancy till the time of delivery. The infants of this group will further stratify into two groups, one group will receive 400 IU of Vitamin D for 6 months as Intervention.
10006904|NCT01598935|Active Comparator|Low protein intake|Nutrition - Low protein
10006905|NCT01598935|Active Comparator|Medium protein intake|Nutrition - Medium protein
9802401|NCT05294458|Experimental|Cotadutide solution for injection|"Period 1, subcutaneous injection of cotadutide solution~Period 2, subcutaneous injection of cotadutide solution~Period 3, subcutaneous injection of cotadutide solution"
9802402|NCT05288543|Experimental|Single Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (25 mg), Cohort 2 (50 mg), Cohort 3 (100 mg), Cohort 4 (200 mg), Cohort 5 (300 mg), Cohort 6 (400 mg), Cohort 7 (500 mg) and Cohort 8 (600 mg)
9802403|NCT05288543|Experimental|Multiple Ascending Dose Phase|Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (100 mg), Cohort 2 (300 mg) and Cohort 3 (500 mg)
9963489|NCT01229189|Placebo Comparator|Maternal and Neonatal Control Arm|
9963490|NCT01229202|Active Comparator|standard of care|standard of care for trabeculectomy surgery
9963491|NCT01229202|Active Comparator|bevacizumab arm|
9963492|NCT01229241|Other|levobupivacaine|
9963493|NCT01229241|Other|ropivacaine|
9963494|NCT01229280|Experimental|Darisec(R) 7.5 mg|
9963495|NCT01229280|Active Comparator|Enablex(R) 7.5 mg|
9963496|NCT01229293|Experimental|Resurfacing Total Hip Arthroplasty|A hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint. Articular surface replacement ASR, DePuy posterolateral approach used (RTHA)
9963497|NCT01229293|Active Comparator|Standard Total Hip Arthroplasty (THA)|A standard 28 mm head uncemented THA
9963498|NCT01229306|Experimental|reisolation of all PV and additional anterior line|
9963499|NCT01229306|Placebo Comparator|reisolation of all pulmonary veins|
9963500|NCT01229319|Experimental|cryo + imiquimod to Left|Cryotherapy alone to Right arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Left arm
9963501|NCT01229319|Experimental|Cryo + imiquimod to Right|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
9963502|NCT01229332|Placebo Comparator|Carbidopa|
9963503|NCT01229332|Placebo Comparator|Placebo|
9963504|NCT01229345|Experimental|Breakfast & exercise|
9963505|NCT01229345|Experimental|Breakfast & no exercise|
9963506|NCT01229345|Experimental|No breakfast & exercise|
9963507|NCT01229345|No Intervention|No breakfast & no exercise|
9963508|NCT01229358|Experimental|Silver Eluting Dressing|Acticoat Absorbant™ applied as post-operative dressing
9963509|NCT01229358|Active Comparator|Standard Guaze|Standard dry gauze applied as post-operative dressing
9963510|NCT01229384|Experimental|Positive Airway Pressure Nebulization|Will administer nebulized medications using Positive Airway Pressure Nebulization
9963511|NCT01229384|Active Comparator|Standard Nebulization|Current standard of administering nebulized medications without positive airway pressure
9963512|NCT01229475|Active Comparator|Stepwise approach|Stepwise approach for repeat AF ablation
9963513|NCT01229475|Active Comparator|Linear ablation|Linear ablation for repeat procedure in patients with recurrent atrial fibrillation
9963514|NCT01229488|No Intervention|No Arms|Project was withdrawn before starting
9963515|NCT01229514||Exposure to anesthesia|
9963516|NCT01229514||Normal controls|
9963517|NCT01229540|No Intervention|Lifestyle counseling|
9963518|NCT01229553|Experimental|Decolonization group|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
9963519|NCT01229566|Active Comparator|Active Comparator|Active comparator
9963520|NCT01229566|Placebo Comparator|Placebo|Placebo control
9963521|NCT01229566|Experimental|AKR-963|Investigational drug
9963522|NCT01229579|Experimental|Zinc Supplement|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc
9963523|NCT01229579|Placebo Comparator|Placebo|2.5 ml supplement syrup daily without elemental zinc
9963524|NCT01229592|Experimental|Ethanol|Every three day lock using Ethanol in all the lumen of the Catheter
9963525|NCT01229592|Active Comparator|Heparine|Every three day lock using Heparine in all the lumen of the Catheter
9963526|NCT01229605|Experimental|Single Arm|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
9963527|NCT01229618|Experimental|1|0.14 ml/kg bw - hyperpolarized pyruvate
9963528|NCT01229618|Experimental|2|0.28 ml/kg bw - hyperpolarized pyruvate
9963529|NCT01229618|Experimental|3|0.43 ml/kg bw - hyperpolarized pyruvate
9963530|NCT01229631|Placebo Comparator|Supplementation with non-active|Subjects will be supplemented with placebo capsules (3 capsules am & 3 capsules pm)
9963531|NCT01229631|Active Comparator|Dietary supplementation with Juice plus+|Subjects will be supplemented with Juice plus+ capsules (3 capsules am & 3 capsules pm)
9963532|NCT01229670|Experimental|aerobic intermittent group|aerobic intermittent group
9963533|NCT01229670|Experimental|aerobic continuous group|aerobic continuous group
9963534|NCT01229670|No Intervention|control|home exercise group
9963535|NCT01229683||Shoulder Surgery|Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas.
9963536|NCT01229696|Active Comparator|At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
9963537|NCT01229696|Active Comparator|5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
9963538|NCT01229709|Experimental|Mindfulness Based Tinnitus Reduction|
9963539|NCT01229709|No Intervention|Tinnitus Counseling Only Control|Control group subjects will have had treatment as usual (TAU) care from the UCSF Audiology Clinic which includes Tinnitus Counseling (TC) at least three-months prior to enty into the study.
9476662|NCT03569579|Experimental|Group 1(Treatment B/Treatment A)|"Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
9476663|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
9963540|NCT01229748|Experimental|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth.(Liddle, 2002) considered in the U.S. and abroad as an empirically supported Best Practice treatment for teen substance abuse and delinquency (USDHHS 2002; Drug Strategies 2003; NIDA 1999; Rigter et al 2004).
9963541|NCT01229748|Experimental|Family Motivational Interviewing|Motivational Interviewing (MI; Miller 1983; Miller & Rollnick 1991), is a client-centered treatment designed to strengthen clients' commitment and empower them to change their substance use behavior (Miller & Rollnick 2002).
9963542|NCT01229748|Other|Standard Care|The standard care condition will represent typical services for teens with alcohol problems in the community: assessment and referral for treatment
9963543|NCT01229761|Active Comparator|infant cotrimoxazole|
9963544|NCT01229761|Placebo Comparator|infant placebo|
9963545|NCT01229761|Active Comparator|exclusive breastfeeding for 6 months|
9963546|NCT01229761|Active Comparator|exclusive breastfeeding for 12 months|
9963547|NCT01229774|Experimental|Etoricoxib|
9963548|NCT01229774|Active Comparator|Diclofenac|
9963549|NCT01229800|Active Comparator|Split dose PEG|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
9963550|NCT01229800|Active Comparator|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
9963551|NCT01229813|Active Comparator|bevacizumab and erlotinib (KRAS WT)|
9963552|NCT01229813|Active Comparator|bevacizumab (KRAS WT)|
9963553|NCT01229813|Active Comparator|bevacizumab (KRAS mutated)|
9963554|NCT01229813|Active Comparator|low dose capecitabine (KRAS mutated)|
9963555|NCT01229839|Experimental|infusion group|Infusion of anticancer agent followed by Embolization
9963556|NCT01229839|Experimental|lipiodol chemotherapy group|Infusion of mixture of anticancer agent and lipiodol followed by Embolization
9963557|NCT01229852|Experimental|Active DSF-rTMS|Active rTMS treatment.
10006906|NCT01598948|Experimental|Mipomersen|Patients randomized to this arm will receive mipomersen 200 mg weekly
10006907|NCT01598948|No Intervention|Control|patients randomized to this arm will receive no additional drug
10006908|NCT01598961|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
10006909|NCT01598961|Active Comparator|T1/Tc amplitude group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
10006910|NCT01598961|Experimental|No neuromuscular blockade group|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
10006911|NCT01598974|Experimental|Traditional Acupuncture|Participants will receive acupuncture over 6 30-minute sessions.
10006912|NCT01598974|Experimental|Laser Acupuncture|Participants will receive laser acupuncture over 6 30-minute sessions.
10006913|NCT01598974|No Intervention|Wait-List|Subjects will be put on a 6 week wait-list and receive vouchers for acupuncture at a local clinic.
10006914|NCT01599000|Active Comparator|Efficacy arm|Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
10006915|NCT01599000|Experimental|Effectiveness arm|Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
10006916|NCT01599013|Other|Vinflunine plus Gemcitabine|
10006917|NCT01599013|Other|Vinflunine plus Carboplatin|
10006918|NCT01599039||breast cancer patients with SN|1. Breast cancer patients with sentinel node biopsy (n=25)
10006919|NCT01599039||breast cancer patients with AD|2. Breast cancer patients with axillary dissection (n=25)
9476664|NCT03569540|Experimental|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
10006920|NCT01599039||colo-rectal patients|3. Colo-rectal patients as control group (n=25)
10006921|NCT01599052||Brain Tumour Patients|Newly diagnosed brain tumour patients aged between 5 and 13 years
10006922|NCT01599052||Cystic Fibrosis patients|Patients diagnosed with Cystic Fibrosis aged between 5 and 13 years
10006923|NCT01599052||Healthy control group|Healthy children aged between 5 and 13 years
10006924|NCT01599065||Magnet|group treated by disabling ICD during procedure
10006925|NCT01599065||Off-On|Group having ICD turned off during the procedure
10006926|NCT01599078|Placebo Comparator|Placebo|
10006927|NCT01599078|Active Comparator|Paclitaxel|
10006928|NCT01599091||Fibroblast's donors|Patients undergoing tooth extraction will be asked permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for further basic research.
10006929|NCT01599117|Placebo Comparator|Placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
10006930|NCT01599117|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
10006931|NCT01599130|Active Comparator|entecavir|patients continue to use entecavir
10006932|NCT01599130|Experimental|peg-interferon|patients switch to sequential peg-interferon α-2a
10006933|NCT01599143|Experimental|Mindfulness-based Stress Reduction group|All eligible participants attend a 3-hour weekly session, for 8 consecutive weeks, to learn meditation and simple Hatha Yoga techniques, and incorporate them into their daily lives.
10006934|NCT01599156|Experimental|Reflexology|reflexology treatment, x2-3/week for 12 weeks
10006935|NCT01599169|Experimental|B-Back® verum|
10006936|NCT01599169|Placebo Comparator|B-Back® placebo|
10006937|NCT01599182||High-Risk Prostate Cancer|
10006938|NCT01599182||Intermediate-Risk Prostate Cancer|
10035351|NCT01805401|Experimental|Right OFC Group|Anode applied to the right OFC and cathode applied to the left OFC
10035352|NCT01805401|Sham Comparator|Sham tDCS|
10006939|NCT01599195||adults|adults audiodoc use to evaluate for carotid or femoral bruit
10006940|NCT01599208|Experimental|Single-pulse online stimulation|Online single-pulse online stimulation at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
10006941|NCT01599208|Experimental|Repetitive online stim., 400ms, 10Hz|Repetitive online stimulation for 400ms at 10Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
10006942|NCT01599208|Experimental|Repetitive online stim., 400ms, 20Hz|Repetitive online stimulation for 400ms at 20Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
10006943|NCT01599208|Experimental|Repetitive offline stimulation at 10Hz|Repetitive offline stimulation at 10Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
10006944|NCT01599208|Experimental|Repetitive offline stimulation at 20Hz|Repetitive offline stimulation at 20Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
10006945|NCT01599208|Experimental|Repetitive offline stimulation with iTBS|Repetitive offline stimulation with Intermittent Theta Burst Stimulation (iTBS) comprising 3 pulses at 50Hz, repeated at 5Hz for 2-second stimulation trains with 8-second breaks for 192 seconds. Stimulation will be given at 90% of motor threshold to either the right or the left MTL in comparison to sham condition.
10006946|NCT01599221||Subjects with EBA2|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
10006947|NCT01599247||Suicidal ideation/behavior|
10006948|NCT01599260|Experimental|Resistance Exercise|Subjects will participate in a 16 week long resistance exercise program which will consist of 2 30-minute individually supervised sessions per week.
10006949|NCT01599273|Experimental|Triam inj|
10006950|NCT01599273|No Intervention|observation group|
10006951|NCT01599299||Ultrasound, internal jugular vein|All patients who will need a central venous access (into the right jugular vein) preoperative are included.
10006952|NCT01599312|Other|Classic Macintosh laryngoscope|Classic Macintosh laryngoscope (Karl Storz, Tuttlingen, Germany)
10006953|NCT01599312|Other|McGrath®|McGrath® (Aircraft Medical Ltd, Edinburgh, UK)
10006954|NCT01599312|Other|C-MAC®|C-MAC® (Karl Storz, Tuttlingen, Germany)
10006955|NCT01599312|Other|GlideScope® Cobalt|GlideScope® Cobalt (Verathon Medical, Bothell, WA, USA)
10006956|NCT01599338|Experimental|Liraglutide|Single Arm study. T2DM patients are studied before and after 3 months of Liraglutide treatment (1.2 mg/day).
10006957|NCT01599351|Active Comparator|Prone|Patients were in prone position along the ERCP procedure.
10006958|NCT01599351|Active Comparator|Left lateral decubitus|Patients were in left lateral decubitus along the ERCP procedure.
10006959|NCT01599364|Experimental|Switch|Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
10006960|NCT01599364|No Intervention|continue|Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone
10006961|NCT01599377|Experimental|Cohort 1|
10006962|NCT01599377|Experimental|Cohort 2|
10006963|NCT01599390||Influenza Group|
10006964|NCT01599403|Active Comparator|Paravertebral Block|Patients will receive 1 or 2 paravertebral catheters for ongoing infusion of local anesthestic
10006965|NCT01599403|No Intervention|Patient Controlled Anesthesia|Standard usual care
10006966|NCT01599403|Experimental|Epidural Block|"Intervention:~Patients will have epidural catheters placed for the infusion of local anesthetic solution to control pain (if qualified for this approach and randomized here)"
9476665|NCT03569540|Placebo Comparator|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
10006967|NCT01599403|Active Comparator|Intercostal Nerve Block|Patients will receive intercostal catheters for the infusion of local anesthetic solution to control pain(if qualified for this arm and randomized here)
10006968|NCT01599416|Active Comparator|U-relax Group|Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
10006969|NCT01599416|Placebo Comparator|Placebo Group|Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep
10006970|NCT01599455||Inpatient|Youths admitted for inpatient rehabilitation training
10006971|NCT01599455||Outpatient|Youths visiting outpatient clinics
10006972|NCT01599455||Urodynamic study|Youths who undergo scheduled urodynamic study
10006973|NCT01599468|Experimental|tranexamic acid, post partum hemorrhage|
10006974|NCT01599468|Placebo Comparator|placebo|
10006975|NCT01599481|Experimental|Intervention|Standard Care (IAPT Therapy) + Individual Career Management (ICM)
10006976|NCT01599481|Active Comparator|Control|Standard Care (IAPT Therapy)
10006977|NCT01599507|Experimental|FG-4592|Active Drug
10006978|NCT01599507|Placebo Comparator|Placebo|
10006979|NCT01599533|Other|abdominal aortic aneurysms|
10006980|NCT01599546||Full Term children|born >36 weeks, currently age 6 +/- 6 months
10006981|NCT01599546||Preterm children|born <35 weeks, age 6 +/- 6 months at the beginning of the study.
10006982|NCT01599559|Experimental|observation|Follow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
10006983|NCT01599559|Active Comparator|mediastinal irradiation|Radiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.
10006984|NCT01599572|Experimental|30mg/day zinc supplementation|30mg/day of zinc supplement provided for 3 months to zinc deficient elderly
10006985|NCT01599598|Active Comparator|Progressive Muscle Relaxation|A stress intervention where subjects will learn to regulate stress based on the tensing and releasing of the major muscle groups in the body, accompanied with relaxed breathing techniques.
10006986|NCT01599598|Active Comparator|Coherence Advantage|A stress intervention where subjects will learn to regulate stress by focusing on breathing and mindfulness techniques while recognizing physiological coherence by way of a portable biofeedback device.
10006987|NCT01599611||Exposed group|Children age 5-10 years old who had a total serum bilirubin > 450 umol/L in the neonatal period
10006988|NCT01599611||Non-exposed group|Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence
10006989|NCT01599624|Experimental|iPad-based SRTS|
10006990|NCT01599624|Experimental|iPad-based PMR program|
10006991|NCT01599663|Experimental|Intervention units|"A time period before the clinicians will be educated, trained and guided in the pain management algorithm, pre-test data will be collected in four ICU units.~The clinicians in three of the ICU units will be educated, trained and guided in the pain management algorithm. The algorithm will then be used to assess and treat pain in all consecutive ICU patients. Post-test data will be collected a time period after the intervention is implemented."
10006992|NCT01599663|No Intervention|Control unit|The clinicians in the fourth ICU (control unit) will not be educated, trained and guided in the pain management algorithm. They will continue to assess and treat pain in all consecutive ICU patients as before. The unit, which will be used as a comparison unit, will collect the same post-test data at the same time as data in intervention ICUs were collected.
9476666|NCT03569527|Active Comparator|Kiwifruit|Treating chronic constipation with 2 kiwifruit (6g fiber) per day
10006993|NCT01599676|Sham Comparator|Not essential amino acid|"Non essential amino acid:~The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive 1 unit of an equivalent quantity of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity) isonitrogenous to 10 g of citrulline, once in the morning for 12 weeks."
10006994|NCT01599676|Experimental|Citrulline|The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive citrulline 10 g/day orally in the morning for 12 weeks.
10006995|NCT01599689|Experimental|Mirrors Intervention|Patients allocated to Mirrors will receive a structured, protocol-driven bedside mirrors intervention as part of their postsurgical ICU care. This intervention will commence as soon as all anaesthetic agents have been switched off and the patient is awake following surgery unless considered clinically inappropriate.
10006996|NCT01599689|No Intervention|Standard Care|Patients allocated to Standard Care will receive the usual postsurgical ICU care that does not include the use of mirrors.
10006997|NCT01599702|Experimental|Group A Monofer|Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
10006998|NCT01599702|Experimental|Group B Monofer|Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg.. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
10006999|NCT01599715|Other|Instructional DVD Intervention|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once
10035353|NCT01805414|Experimental|Intervention Breakfast|40-45g carbs (300-350 kcal)
10035354|NCT01805414|Active Comparator|Control Breakfast|These patients received the usual hospital breakfast which contained 40-45 g carbs.
10007000|NCT01599715|Other|Bladder Health Class Intervention|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
10007001|NCT01599728|Other|Patients with heart failure|Assessing the response to infusion of intra-arterial Urocortin 2, 3 and Substance P in patients with heart failure
10007002|NCT01599728|Other|Healthy controls|Assessing response to intra-arterial infusions of Urocortin 2, 3 and Substance P in age and sex-matched healthy volunteers as controls.
10007003|NCT01599767|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
10007004|NCT01599767|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
10007005|NCT01599780||Full-Term Children|≥37 weeks gestation; 18 months old at the start of the study
10007006|NCT01599780||Preterm Children|<33 weeks gestation; 18 months old at the start of the study
10007007|NCT01599819|Experimental|Cohort 1|Low dose of ADVATE followed by low dose of BAX 855
10007008|NCT01599819|Experimental|Cohort 2|High dose of ADVATE followed by high dose of BAX 855
10007009|NCT01599845||Nanoparticle exposed|
10007010|NCT01599871|Experimental|Intervention|Inhaled corticosteroids and long-acting beta agonist + theophylline (Slophylline capsules 100 mg/Theo-dur Retard 100 mg b.i.d.)
9476667|NCT03569527|Active Comparator|Psyllium fiber|Treating chronic constipation with 24g psyllium fiber (6g fiber) per day
10007011|NCT01599871|Placebo Comparator|Control|inhaled corticosteroids and long-acting beta agonist + Placebo
10007012|NCT01599884|Active Comparator|N-acetylcysteine|N-acetylcysteine, 1800 mg twice daily
10007013|NCT01599884|Placebo Comparator|Sugar pill|Identical to active drug
10007014|NCT01599897|Experimental|2 µg ID93 + 2 µg GLA-SE|Low dose and antigen and low dose of adjuvant.
10007015|NCT01599897|Experimental|10 µg ID93 + 2 µg GLA-SE|High dose of antigen and low dose of adjuvant.
10007016|NCT01599897|Experimental|2 µg ID93 + 5 µg GLA-SE|Low dose of antigen and high dose of adjuvant.
10007017|NCT01599897|Experimental|10 µg ID93 + 5 µg GLA-SE|High dose of antigen and high dose of adjuvant.
10007018|NCT01599897|Active Comparator|2 µg ID93 alone|Low dose of antigen alone.
10007019|NCT01599897|Active Comparator|10 µg ID93 alone|High dose of antigen alone.
10007020|NCT01599923|Experimental|Alacramyn|
10007021|NCT01599936|Experimental|Anascorp|Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
10007022|NCT01599949|Experimental|Ibrutinib|
10007023|NCT01599962|Experimental|Cinacalcet|
10007024|NCT01599962|Placebo Comparator|Sugar pill|
10007025|NCT01599975|Active Comparator|Group A: 2 tabs of 18 mg Concerta daily|20 subjects to receive active study drug in a blinded fashion x 2 weeks, then washout x 2 weeks, then cross over to receive matched placebo x 2 weeks.
10007026|NCT01599975|Placebo Comparator|Group B: Matched placebo, 2 tabs daily|Group B to receive matched placebo x 2 weeks, then washout x 2 weeks, then cross over to receive active drug in a blinded fashion x 2 weeks.
10007027|NCT01599988|Active Comparator|Milk protein isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
10007028|NCT01599988|Active Comparator|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
10007029|NCT01600001|Experimental|Drug:KWA-0711 dose 1|
10007030|NCT01600001|Experimental|Drug:KWA-0711 dose 2|
10007031|NCT01600001|Experimental|Drug:KWA-0711 dose 3|
10007032|NCT01600001|Experimental|Drug:KWA-0711 dose 4|
10007033|NCT01600001|Placebo Comparator|Drug: Placebo|
10007034|NCT01600027|Placebo Comparator|Group B|received 1 ml/kg bupivacaine 0.25%.
10007035|NCT01600027|Active Comparator|group BD|received 1 ml/kg bupivacaine 0.25% with dexmedetomidine 2 μg/kg
10007036|NCT01600040|Other|Proton Radiation Therapy|This is a single arm study; all participants will receive proton radiation therapy.
10007037|NCT01600079||Vaccinated Cohort|Participants vaccinated with at least one dose of ZOSTAVAX™
10007038|NCT01600079||Unvaccinated Comparison Cohort|Participants who are not yet vaccinated with any zoster vaccine
10007039|NCT01600118|Active Comparator|ESWT|Extracorporeal shockwave therapy
10007040|NCT01600118|Placebo Comparator|ESWT Placebo|No extracorporeal shockwave therapy
10035355|NCT01805427||patients treated with efavirenz|HIV-infected on stable HAART regimen with efavirenz
10035356|NCT01805427||patients treated with atazanavir|HIV-infected patients on stable HAART regimen with atazanavir
10035357|NCT01805427||patients treated with darunavir|HIV-infected patients on stable HAART regimen with darunavir
10007041|NCT01600131|Experimental|Caregiver education and support|problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.cidrr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
10007042|NCT01600131|Other|Standard Care|Caregivers receiving standard of care
10007043|NCT01600144||data collection|
10007044|NCT01600157|Experimental|Laparoscopic Nephrectomy|
10007045|NCT01600183|Active Comparator|casting|subjects with MTA will be treated with cast for 20 weeks. casting is replaced during every study visit.
10007046|NCT01600183|Experimental|UNFO-s|subjects with MTA will be treated with the UNFO-s device for 12 weeks - will be worn day and night during first 6 weeks and only at night during next 6 weeks
10007047|NCT01600196|Experimental|Resection arm|Liver resection Plus Thrombectomy
10007048|NCT01600196|No Intervention|Best support care arm|Best supportive care
10007049|NCT01600209||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.
10007050|NCT01600235|Experimental|Phenylephrine|Phenylephrine induced-hypertension arm
10007051|NCT01600235|No Intervention|Conventional treatment|Control arm
10007052|NCT01600248|Other|Treatment arm|This is an open-label pilot study with no control group. Participants pre-treatment scores are compared to their post-treatment scores.
10007053|NCT01600261||eye exam|
10007054|NCT01600274|Experimental|Diena|Dienogest-Ethinyl Estradiol (test product) tablet
10007055|NCT01600274|Active Comparator|Valette®|Dienogest-Ethinyl Estradiol (reference product) tablet
10007056|NCT01600300|Placebo Comparator|Sham|Treatment with inactivate Tesmac device
10007057|NCT01600300|Active Comparator|Tesmac|Treatment with active Tesmac device
10007058|NCT01600313|Experimental|treatment, control|
10007059|NCT01600339|Experimental|CABAZITAXEL|cabazitaxel at a starting dose of 25 mg/m
10007060|NCT01600365|Active Comparator|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
10007061|NCT01600365|Placebo Comparator|Ophthalmic gel (placebo)|ophthalmic gel (placebo)in the study eye
10007062|NCT01600391|Active Comparator|Usual Care|A task specific-based intervention that does not include use of visual cues to influence quality or adaptability of gait.
10007063|NCT01600391|Experimental|Overground visual cue training|Overground visual cue training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
10007064|NCT01600391|Experimental|Treadmill visual cue training|Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). Walking training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
10007065|NCT01600404||antimuscarinic treatment|antimuscarinic treatment
10007066|NCT01600404||no antimuscarinic treatment (control)|
10007067|NCT01600417||clinical suspicion of lumbar instability|
10007068|NCT01600430|Active Comparator|Oral Vitamin D--200 IU/day|Cholecalciferol 200 IU given orally once per day
10007069|NCT01600430|Placebo Comparator|Placebo|Identical-appearing treatment that does not contain the test drug given orally four times per day.
10007070|NCT01600430|Active Comparator|Oral Vitamin D--800 IU/day|Cholecalciferol 800 IU given orally once per day
10007071|NCT01600443|Experimental|LoFric - SC - SCCM|Study period 1: LoFric Study period 2: SpeediCath Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
10007072|NCT01600443|Experimental|LoFric - SCCM - SC|Study period 1: LoFric Study period 2: SpeediCath Compact Male Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
10007073|NCT01600443|Experimental|SC - SCCM - LoFric|Study period 1: SpeediCath Study period 2: SpeediCath Compact Male Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
10007074|NCT01600443|Experimental|SC - LoFric - SCCM|Study period 1: SpeediCath Study period 2: LoFric Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
10007075|NCT01600443|Experimental|SCCM - LoFric - SC|Study period 1: SpeediCath Compact Male Study period 2: LoFric Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
10007076|NCT01600443|Experimental|SCCM - SC - LoFric|Study period 1: SpeediCath Compact Male Study period 2: SpeediCath Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
10007077|NCT01600456|Active Comparator|Choice: Prolonged exposure (PE)|"Participants randomized to choice who choose prolonged exposure (PE)."
10007078|NCT01600456|Active Comparator|Choice: PE plus sertraline|"Participants randomized to choice who choose PE plus sertraline."
10007079|NCT01600456|Active Comparator|No choice: Prolonged exposure (PE)|"Participants randomized to no choice who are then randomized to PE."
10007080|NCT01600456|Active Comparator|No Choice: PE plus sertraline|"Participants randomized to no choice who are then randomized to PE plus sertraline."
10007081|NCT01600469|Experimental|DAOI-B|
10007082|NCT01600469|Placebo Comparator|Placebo|
9963558|NCT01229865|Experimental|VB-111|antiangiogenic and vascular disruptive agent
9963559|NCT01229904|Experimental|Arm 1|patients with PTSD are randomized to either entering immediately a 6 week treatment with music therapy, or being in the delay group that enters the treatment arm after 6 weeks. This is a delayed entry RCT.
9963560|NCT01229969|Experimental|NeuroCom EquiTest® System|Measure balance assessment (test for Sensory Organization Test (SOT) and Limit of Stability (LOS).
9963561|NCT01229969|Experimental|Wii Fit|Determine if the Wii Fit is valid and feasible in detecting balance problems in older adults
9963562|NCT01229995|Active Comparator|Prefabricated Abutment|
9963563|NCT01230008||Radiotherapy in mediastinal lymphoma|Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
9963564|NCT01230008||Radiotherapy in mediastinal lymphoma|Radiotherapy will no be administered in patients treated with R-CHOP
9963565|NCT01230008||Radiotherapy in primary mediastinal lymphoma|Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
9963566|NCT01230034|Experimental|Imidapril|10 and 20 mg/day, pill
9963567|NCT01230034|Active Comparator|Ramipril|5 and 10 mg/day, pill
9963568|NCT01230047|Experimental|Psychoeducational Course|In this arm, clients receive the psychoeducational course.
9963569|NCT01230047|No Intervention|Treatment-as-usual/Waiting list|Clients assigned to this condition will receive treatment-as-usual (TAU) and be placed on a waiting list.
9963570|NCT01230073|Active Comparator|ICD traditional follow-up|ICD with traditional follow-up in the outpatient clinic
9963571|NCT01230073|Active Comparator|Home-Monitoring|Home-Monitoring
9963572|NCT01230086|Active Comparator|ICD implantation only|ICD Implantation without testing of defibrillation threshold testing
9963573|NCT01230086|Active Comparator|Modified upper limit of vulnerability testing|"Modified testing of upper limit of vulnerability"
9963574|NCT01230086|Active Comparator|VF-Induction|traditional VF-induction with T-Wave shock
9963575|NCT01230099|Experimental|Supportive Information Team Group|Protocolized information and support meetings led by palliative care clinicians
9963576|NCT01230099|No Intervention|Usual Care Group|
9963577|NCT01230138|Experimental|FP187 - TID|FP187 250mg TID (total daily dose of 750mg)
9963578|NCT01230138|Experimental|FP187- BID|FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
9963579|NCT01230138|Experimental|FP187-LD-BID|FP187 250mg BID (total daily dose of 500mg)
9963580|NCT01230138|Placebo Comparator|Placebo|Placebo treatment
9963581|NCT01230138|Experimental|Open, flexible dosing treatment arm|Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
9963582|NCT01230151|Active Comparator|Clinical|Stimulation settings predetermined clinically (Clinical)
9963583|NCT01230151|Experimental|Model|stimulation settings derived from a patient-specific computer-based model (Model)
9963584|NCT01230190|Active Comparator|Probiotic mixture|participants daily ingest a selected probiotic mixture for a period of 3 months
9963585|NCT01230190|Placebo Comparator|Placebo mixture|controls daily ingest a placebo mixture for a period of 3 months.
9963586|NCT01230203|Other|Computed tomography scan versus color duplex ultrasound|
9963587|NCT01230216|Active Comparator|intensive blood pressure control|systolic blood pressure less than 120 mmHg
9963588|NCT01230216|Active Comparator|standard blood pressure control|systolic blood pressure less than 140 mmHg
9963589|NCT01230229|Active Comparator|Stenting|Active treatment group
9963590|NCT01230229|Placebo Comparator|Conservative treatment|Best medical treatment
9963591|NCT01230255|Experimental|Percutaneous catheter decompression|Ultrasound guided percutaneous catheter drainage of free intra-peritoneal fluid or blood
9963592|NCT01230255|Active Comparator|Open abdominal decompression|Surgical treatment of elevated intra-abdominal pressure through traditional open abdominal decompression
9963593|NCT01230268|Experimental|Mulberry fruit extract|Daily 1000 mg oral Mulberry fruit extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
10007083|NCT01600508|Active Comparator|Traditional stoma care|Being discharged from a hospital with a stoma is a challenge to the patient's quality of life in many aspects. Optimal stoma function and care is essential to keep quality of life best possible. Videoconference can be a useful tool to help patients cope with stoma problems without travelling long distances to a surgical outpatient clinic.
10007084|NCT01600508|Experimental|Videoconference Stoma Consultations|Videoconference Stoma Consultations
10007085|NCT01600521|Active Comparator|Paeoniflorin + Polypeptides (PAE + CCPI)|Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties. Polypeptides (3,000 - 10,000 dalton) in Cervus & Cucumis polypeptide injection (CCPI), the extract from Sika deer (Cervus nippon Temmick) bones and muskmelon (Cucumis melo L) seeds, are the active ingredients with bone healing, pain relieving, and anti-inflammation properties. PAE was administrated orally 600 mg twice a day for at least 12 months. CCPI was administered intravenously 8~12 mL daily with 250 mL 5% dextrose injection solution or 0.9% NaCl IV solution for 2 weeks, discontinued 1 week, and restarted for another 2 weeks.
10007086|NCT01600521|Active Comparator|Methotrexate (MTX) + Leflunomide (LEF)|DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months. MTX dose: 7.5 mg ~ 10mg / week, LEF dose: 10 mg ~ 20mg daily.
10007087|NCT01600521|Active Comparator|MTX + LEF + CCPI|The DMARDs and CCPI were administrated as in the above two groups.
10007088|NCT01600534|Experimental|Lifestyle counseling|Participants obtain access to an internet-based educational intervention.
10007089|NCT01600534|Other|Usual Care Lifestyle counseling|Self directed educational intervention
10007090|NCT01600547||fall clinic population|women, aged + 65 years
10007091|NCT01600547||control fallers|randomly selected community aged matched female controls with a fall episode
10007092|NCT01600547||control non fallers|randomly selected community aged matched female controls, with out fall episodes
10007093|NCT01600560||Social media|
10007094|NCT01600573|Experimental|pazopanib plus weekly topotecan|pazopanib in combination with weekly topotecan
10007095|NCT01600599|Active Comparator|IV & topical TA|patients in this group will receive both intravenous & topical tranexamic acid
10007096|NCT01600599|Placebo Comparator|IV tranexamic acid & Topical Saline|
10007097|NCT01600612|Active Comparator|Oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
10007098|NCT01600612|Active Comparator|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
10007099|NCT01600612|Active Comparator|misopristol|600 ug of misopristol sublingually will be given intravenously to patients with atonic postpartum hemorrhage
10007100|NCT01600625|Experimental|Minocycline treatment group|
10007101|NCT01600651|Sham Comparator|Recruitment maneuver (RM) sham group|when recruitment maneuver sequence precedes a sham evaluation period
10007102|NCT01600651|Sham Comparator|Sham Recruitment (RM) maneuver group|a group in which patients receive a sham sequence before the RM sequence
10007103|NCT01600664|Experimental|interactive computer game|"Participants will be using the interactive computer game- My Diabetic Friend, installed on Intel-powered convertible classmate PC."
9476668|NCT03569527|Active Comparator|Prune|Treating chronic constipation with 100g dried plums (6g fiber) per day
9476669|NCT03569501|No Intervention|nutritional guidance|routine care (all arms with nutritional guidance per routine care)
9476670|NCT03569501|Active Comparator|oat grains|90 mg oat, per day.
10007104|NCT01600664|Active Comparator|Convertible PC|Participants will be using the convertible classmate PC without the interactive computer game
10007105|NCT01600690|No Intervention|Continue statin regimen|Patients randomized to this arm will continue their usual statin regimen and dose, without any intervention.
10007106|NCT01600690|Experimental|Statin withdrawal|Patients randomized to this arm will stop statin treatment for 5 days.
10007107|NCT01600742|Active Comparator|WBRT, placebo|
10007108|NCT01600742|Experimental|WBRT and concurrent vorinostat|
10007109|NCT01600768|Active Comparator|intermittent infusion|
10007110|NCT01600768|Experimental|extended infusion|
10007111|NCT01600781|Active Comparator|NutriniDrink/Fortini group|this group will receive 2 bottles of NutriniDrink/Fortini MF unflavoured daily (200 ml each) and standard dietary counselling for a period of 6 weeks.
10007112|NCT01600781|No Intervention|control group|this control group will only receive standard dietary counselling
10007113|NCT01600794||male/female, immunity or others factor infertility, IVF|
10007114|NCT01600807|Experimental|Gemcitabine, Erlotinib, OSI-906|Experimental treatment arm
10007115|NCT01600807|Active Comparator|Gemcitabine, Erlotinib|Standard treatment arm
10007116|NCT01600820|Experimental|1 = Tested product 1|
10007117|NCT01600820|Experimental|2 = tested product 2|
10007118|NCT01600820|Placebo Comparator|3 = Control product|
10007119|NCT01600833||Obese women|BMI>25
10007120|NCT01600833||Non obese women|BMI<25
10007121|NCT01600859|Experimental|E2609|
10007122|NCT01600859|Placebo Comparator|Placebo for E2609|
10007123|NCT01600872||Gruop 1|
10007124|NCT01600872||Group 2|
10035358|NCT01805453|Active Comparator|Arm A: Losartan|Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason
9963594|NCT01230281|Experimental|Black bean seed coat extract|Daily 1000 mg oral Black bean seed coat extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
9963595|NCT01230294||control|participants without structural heart disease
9963596|NCT01230294||CHF|patients with chronic heart failure of the left ventricle affecting the right heart
9963597|NCT01230294||PAH|patients with pulmonary arterial hypertension without left ventricular dysfunction
9963598|NCT01230320|Experimental|Simplified (S) technique|"Complete dentures fabricated according to a simplified technique, divided into the following four sessions:~Maxillary and mandibular casts will be obtained from irreversible hydrocolloid impressions made in stock trays.~Record bases will be adjusted according to vertical dimension and centric relation measurements, without facebow transfer. Casts will be mounted in a semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationships.~Insertion of finished dentures."
9963599|NCT01230320|Active Comparator|Conventional (C) technique|"Complete dentures fabricated according to a conventional technique:~Initial impression and the obtainment of custom trays;~Final impression with border molding using compound;~Facebow transfer;~Determination of maxillomandibular relationship;~Try-in of anterior teeth;~Try-in of posterior teeth;~Insertion of finished dentures."
9963600|NCT01230359|Experimental|Vitamin B6 and magnesium|
9963601|NCT01230359|Placebo Comparator|Tang powder group|
9963602|NCT01230385|Experimental|Lersivirine 500 mg QD fasted (wet granulated tablet)|
9963603|NCT01230385|Experimental|Lersivirine 500 mg QD fed (wet granulated tablet)|
9963604|NCT01230385|Experimental|Lersivirine 750 mg QD fasted (wet granulated tablet)|
9963605|NCT01230385|Experimental|Lersivirine 750 mg QD fed (wet granulated tablet)|
9963606|NCT01230385|Active Comparator|Lersivirine 500 mg QD fasted (dry granulated tablet)|
9963607|NCT01230411|Placebo Comparator|placebo|IV saline administration as placebo
9963608|NCT01230411|Experimental|Ibuprofen|IV ibuprofen
9963609|NCT01230437||asthmatic patients taking montelukast|asthma with or without rhinitis
9963610|NCT01230450|Experimental|Single-incision Mini-slings (SIMS- Ajust)|AjustTM has polypropylene fixing anchors (one is fixed and the other adjustable) which are anchored onto the obturator membrane. The pulley like system enables adjustment of the tension once the arms have been anchored. Once in place, the anchors rest at right angles to insertion which is claimed to reduce the chances of anchor dislodgment
9963611|NCT01230450|Other|standared med urethral sling (SMUS)|standard med urethral sling (SMUS)TVT-O, was done as originally described by Deleval et al.
9963612|NCT01230463|Active Comparator|15 mg ketorolac IV|
10007125|NCT01600898||Asymptomatic BMPR2 mutation carriers|Asymptomatic BMPR2 mutation carriers
10007126|NCT01600937|No Intervention|Control|Standard care including physician recommendations for daily PA
10007127|NCT01600937|Experimental|Exercise|Theoretical & practical exercise counseling including 2 sessions/ per wk for 1 month of supervised exercise training
10007128|NCT01600963|Experimental|Arm A|
10007129|NCT01600963|Placebo Comparator|Arm B|
10007130|NCT01600976|Experimental|Group 1|10 patients with moderate hepatic impairment (CPB [Child-Pugh score 7 to 9])
10007131|NCT01600976|Experimental|Group 2|10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (± 5 years) and body mass index (BMI) (± 15%)
10007132|NCT01600976|Experimental|Group 3|up to 4 patients with severe hepatic impairment (CPC [limited to Child Pugh score 10 to 12])
10007133|NCT01600989||Patients with severe sepsis / septic shock|30 Adult patients (age > 18years), with severe sepsis or septic shock as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference guidelines at the time of admission to ICU.
10007134|NCT01600989||Healthy volunteers|Healthy volunteers
10007135|NCT01601002|Experimental|Mirtazapine|Mirtazapine in dosage of 7.5 mg to 45 mg/day
10007136|NCT01601015|Experimental|Manual therapy|Manual therapy of Suboccipital soft tissue Inhibition treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
10007137|NCT01601015|Experimental|Occiput-atlas-axis joint manipulation|Is bilaterally administered. The aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction
10007138|NCT01601015|Experimental|Combined treatment|The group receiving combined treatment received the two previous techniques exactly with the same sequence.
10007139|NCT01601015|Placebo Comparator|Control group|Control group not receive treatment and stayed in this position for 10 minutes
10007140|NCT01601028|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o.
10007141|NCT01601028|Placebo Comparator|Placebo|Placebo
10007142|NCT01601041||urinary tract infection|urinary tract infection in male patients with neurogenic bladder dysfunction due to spinal cord injury managed by intermittent catheterization
10007143|NCT01601041||control group|less than three urinary tract infections / year
10007144|NCT01601054|Active Comparator|Anterior lumbar interbody fusion|Anterior lumbar interbody fusion using a tantalum cage. Cage will be inserted through a left sided retroperitoneal approach.
10007145|NCT01601054|Active Comparator|Posterior instrumentation alone|Posterior pedicle screw instrumentation
10007146|NCT01601093|Experimental|High dose|Ceftazidime 3g
10007147|NCT01601093|Experimental|Low dose|Ceftazidime 2g
10007148|NCT01601093|Active Comparator|CFP/SUB|Cefoperazone and sulbactam sodium for injection(2:1)
10007149|NCT01601106|Active Comparator|Liposomal prednisolone|
10007150|NCT01601106|Placebo Comparator|Placebo control|
10007151|NCT01601119||Rebif cohort|Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
10007152|NCT01601119||Other DMT cohort|Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
10007153|NCT01601145|Experimental|lozenges with Lactobacillus brevis CD2|Randomized group using lozenges for 6 weeks.
10007154|NCT01601145|Placebo Comparator|lozenges|Randomized group using lozenges for 6 weeks.
10007155|NCT01601158|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
10007156|NCT01601171||Patients|"Patients with reproductive disorders with or without cleft lip/palate will be recruited for:~completion of medical questionnaire and review of medical records~family tree (including questions on reproductive disorders and cleft lip/palate)~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing~hearing test~bone density~brain MRI~kidney, testicular/ovarian ultrasound"
10007157|NCT01601171||Family members|"Family members of Patients will be recruited for:~completion of medical questionnaire~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing"
10007158|NCT01601184|Experimental|combination of vismodegib with temozolomide|"In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive~- Arm A: the combination of vismodegib (150 mg/day continuously) with temozolomide (150 mg/m2 during Cycle 1 [day 1 to day 5/ 28 day-cycle] and 200 mg/m2 during subsequent cycles) (6 patients)"
10007159|NCT01601184|Active Comparator|temozolomide alone|In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive Arm B: temozolomide alone (150 mg/m2 day1 to day 5/ 28 day-cycle during Cycle 1 and 200 mg/m2 day 1 to day 5/ 28 day-cycle during subsequent cycles) (3 patients).
10007160|NCT01601184|Other|vismodegib alone|Considering the rarity of the disease, the few therapeutic options available and the promising results reported with vismodegib in adult medulloblastoma : the Sponsor will consider (on case by case basis) the enrolment of patients previously treated by temozolomide in a 3rd independent and parallel study arm
10007161|NCT01601197|Experimental|Tactile stimulation|Ipsilateral limb will be rubbed immediately before, during and after immunization injection(s)
10007162|NCT01601197|No Intervention|No tactile stimulation|There will be no tactile stimulation of ipsilateral limb before, during and after immunization injection(s)
10007163|NCT01601210|Placebo Comparator|Placebo|
10007164|NCT01601210|Active Comparator|2 grams of creatine|
10007165|NCT01601210|Active Comparator|4 grams of creatine|
10007166|NCT01601210|Active Comparator|10 grams of creatine|
10007167|NCT01601223||Surgical mechanically-ventilated|Surgical patients undergoing invasive mechanical ventilation for general anesthesia
10007168|NCT01601249|Experimental|Polscope based embryo grading|Embryos for transfer will be selected based on highest polscope scores, unless are not grade 1-2 by conventional morphology
10007169|NCT01601249|Active Comparator|Morphology based embryo grading|Conventional embryo grading and decision making
10007170|NCT01601262|Experimental|Open label|
10007171|NCT01601301|Experimental|PRECICE System|
10007172|NCT01601314|Experimental|magnesium sulphate|The patients who are going to receive Magnesium Sulphate
10007173|NCT01601314|Placebo Comparator|Control|Patients who are going to receive Sodium Chloride 0.9%
10007174|NCT01601327|Other|hypogonadism, treatment|77 patients with idiopathic hypogonadotropic hypogonadism were treated with testosterone gel, testosterone enanthate or human chorionic gonadotropin
10007175|NCT01601327|No Intervention|Control group|42 healthy controls
10007176|NCT01601340|Active Comparator|HQK-1001|
10007177|NCT01601340|Placebo Comparator|Placebo|
10007178|NCT01601353|Experimental|Treatment|Injection of adipose derived cells into penis
10007179|NCT01601353|No Intervention|Control|No intervention through 9 months
10007180|NCT01601366|Experimental|LNG-IUS (Mirena)|"Group I the LNG-IUS group where they will have a LNG IUS (mirena) inserted for them"
10007181|NCT01601366|Active Comparator|Combined oral contraceptives|"Group II COCs group where they will receive low dose combined oral contraceptive pills for 6 months"
10007182|NCT01601392|Experimental|Anodal tDCS|
10007183|NCT01601392|Active Comparator|Cathodal tDCS|
10007184|NCT01601392|Sham Comparator|Sham|
10007185|NCT01601457|Experimental|Activated recombinant human factor VII|
10007186|NCT01601457|Placebo Comparator|Placebo|
10007187|NCT01601483|Experimental|MC-1101 1% Ophthalmic Solution|
10007188|NCT01601483|Placebo Comparator|Vehicle control|
10007189|NCT01601509|Active Comparator|nasal spray with tramazoline and dexamethazone|
10007190|NCT01601509|Placebo Comparator|Placebo|
10007191|NCT01601548|Experimental|Intervention Arm|Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention. Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
10007192|NCT01601548|No Intervention|Control Arm|No intervention is administered. Health-related quality of life questionnaires will be completed.
10007193|NCT01601561|Experimental|High-dose insulin|
10007194|NCT01601561|No Intervention|Control|
10007195|NCT01601574|Experimental|Modified Weight Watchers program|
10007196|NCT01601574|Active Comparator|Standard Diabetes Counseling group|
10007197|NCT01601587|No Intervention|Treatment as usual|Patients will receive treatment as usual
10007198|NCT01601587|Other|Introduction Seminar|Psychoeducational group
10007199|NCT01601613|Experimental|rFVIIa|
9963613|NCT01230463|Active Comparator|30 mg ketorolac IV|
9963614|NCT01230476|Experimental|Cetuximab and chemotherapy|2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy
9963615|NCT01230515||Caregiver|Family members will be asked to complete a demographic survey, an assessment of the patient's current pain, and a series of questionnaires including: Caregiver Pain Medicine Questionnaire, the Stressful Caregiving Adult Reactions To Experiences of Dying Scale, and the Caregivers' Self Efficacy in Pain Management Questionnaire. Upon completion of the questionnaires, patients and caregivers will be interviewed separately.
9963616|NCT01230515||Hospice staff|Hospice staff will be asked to complete the Pain Knowledge and Attitudes survey. They will also complete the Technology Acceptance Model (TAM) questionnaire to assess the perceived utility of an opioid titration order sheet to help manage pain control. A demographic survey will also be completed.
9963617|NCT01230515||Referring physician|Referring physicians will be asked to complete the Pain Knowledge and Attitudes survey as well as the TAM questionnaire and Demographic Survey.
9963618|NCT01230515||Patient|Demographic information includes education, marital status, number in household, and employment status will be obtained from patient. Clinical data will be obtained from the patient's medical records. Information to be obtained will include information about the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription. The patient will also take a pain assessment survey.
9963619|NCT01230541|Placebo Comparator|Placebo|Placebo
9963620|NCT01230541|Active Comparator|Udenafil|Udenafil daily tablet
9963621|NCT01230580|Experimental|Protease Inhibitor Monotherapy|Ritonavir-boosted protease inhibitor
9963622|NCT01230580|Active Comparator|Control|Standard-of-care triple-therapy regimen
9963623|NCT01230606||overnight|Subjects that stay overnight at the hospital.
9476671|NCT03569501|Experimental|oat grains and DHA tablets|90 mg oat and 500 mg DHA oral tablets, per day.
9476672|NCT03569501|Active Comparator|DHA tablets|500 mg DHA oral tablets, per day.
9476673|NCT03569462|Experimental|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
9963624|NCT01230606||Next Day Discharge|Subjects that are discharged on the same day of the procedure.
9963625|NCT01230619|Experimental|RV568 treatment group|
9963626|NCT01230619|Placebo Comparator|Placebo treatment group|
10007200|NCT01601613|Placebo Comparator|placebo|
10007201|NCT01601639|Active Comparator|Argon Plasma Coagulation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
10007202|NCT01601639|Active Comparator|Endoscopic Band Ligation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
9476674|NCT03569462|Active Comparator|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
9963627|NCT01230632|Experimental|Dietary Supplement|3 days high fat food
9963628|NCT01230645|Experimental|RV568 treatment group|
9963629|NCT01230645|Placebo Comparator|Placebo treatment group|
9963630|NCT01230671|Experimental|Yoga|Patients in this arm will receive yoga therapy
9963631|NCT01230671|Placebo Comparator|No yoga|Patients will not have yoga in this arm
9963632|NCT01230684|Other|Endoleak imaging|In the single arm all participants are recieving both imaging techniques; CEUS and CTA
9963633|NCT01230697||Sofanenib and Hypophosphatemia|Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib
9963634|NCT01230723|Active Comparator|Arm 1|Everolimus-Eluting Stent
9963635|NCT01230723|Active Comparator|Arm 2|Zotarolimus-Eluting-Stent
9963636|NCT01230736|Experimental|DuoTrav|One drop in study eye(s) once daily for 8 weeks
9963637|NCT01230762|Experimental|001|dapoxetine 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
9963638|NCT01230775|Experimental|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
9963639|NCT01230775|Placebo Comparator|Placebo|"Week 1:~x1 tablet/d of Placebo will be administered in week 1.~Placebo:~x1 tablet/d of placebo will be administered in week 2.~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
9963640|NCT01230840|Placebo Comparator|placebo|Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
9963641|NCT01230840|Experimental|wheat dextrin|wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
9963642|NCT01230853|Active Comparator|Active Comparator: A|
9963643|NCT01230853|Placebo Comparator|Placebo Comparator A|
9802404|NCT05288543|Placebo Comparator|Part A (Placebo)|Placebo tablets identical to IPG7236 tablets Dosage form: Tablet Route of Administration: Oral
9802405|NCT05282550|Active Comparator|Trazodone First|Trazodone (50 mg at bedtime) and then placebo after a 4-week washout period.
9963644|NCT01230853|Active Comparator|Active Comparator: B|
9963645|NCT01230853|Placebo Comparator|Placebo Comparator B|
9963646|NCT01230866|Other|Proton Radiation Hypofractionation|5 fractions (7.6 Gy(RBE) x 5)
9963647|NCT01230866|Active Comparator|Proton Radiation Standard Fractionation|44 fractions (1.8 Gy(RBE) x 44)
9963648|NCT01230905|Other|MPI nuclear scan|Nuclear MPI for CAD for prostate cancer subjects undergoing treatment and development of normal comparison.
9963649|NCT01230918|Experimental|Diagnostic Imaging|A single dose of 800 to 1100 mBq of 99mTc-NC100692 radiopharmaceutical will be injected. Serial cardiac nuclear imaging will be done over a 3 hour period.
9963650|NCT01230944|Active Comparator|Laparoscopic Nissen|Laparoscopic Nissen fundoplication
9963651|NCT01230944|Active Comparator|Open Nissen|Open (conventional) Nissen fundoplication
9963652|NCT01230970|Experimental|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
9963653|NCT01230983|Experimental|Treatment 1: (No HD MTX / No Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, IT methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
10007203|NCT01601665||Toric High Cylinder Power IOL|Toric high cylinder power intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
10007204|NCT01601665||Monofocal IOL|Monofocal intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
10007205|NCT01601678|Active Comparator|Peroral Endoscopic Myotomy POEM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the POEM therapy group
10007206|NCT01601678|Active Comparator|Laparoscopic Heller Myotomy LHM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the LHM therapy group.
10007207|NCT01601717|Placebo Comparator|Sugar pill|
10007208|NCT01601717|Active Comparator|RTI-336|
10007209|NCT01601730|Placebo Comparator|Placebo|
10007210|NCT01601730|Active Comparator|Modafinil 200 mg + Escitalopram 20 mg|
10007211|NCT01601730|Active Comparator|Modafinil 200 mg|
10007212|NCT01601730|Active Comparator|Escitalopram 20 mg|
10007213|NCT01601743|Active Comparator|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
10007214|NCT01601743|Active Comparator|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
10007215|NCT01601743|Active Comparator|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
10007216|NCT01601756|Experimental|navigated revision total knee arthroplasty|revision total knee arthroplasty with the aid of a navigation system
10007217|NCT01601756|Active Comparator|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
10007218|NCT01601769|Active Comparator|Colposcopy|a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
10007219|NCT01601769|Experimental|Vitom|The VITOM system, consisting of the VITOM scope, xenon light source, HD camera system, AIDA HD documentation system, 1 monitor, and a mechanical support arm (all Karl Storz, Tuttlingen, Germany) is used for video exocolposcopy.
10007220|NCT01601795|Active Comparator|Sevoflurane|During cardiopulmonary bypass, sevoflurane will be administered through a vaporizer integrated into heart-lung-machine.
10007221|NCT01601795|Active Comparator|Isoflurane|During cardiopulmonary bypass, isoflurane will be administered through a vaporizer integrated into heart-lung-machine.
10007222|NCT01601808|Placebo Comparator|Gemcitabine and Placebo|Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
10007223|NCT01601808|Experimental|Gemcitabine and vandetanib|Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
10007224|NCT01601834|Experimental|Cohort 1: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
10007225|NCT01601834|Experimental|Cohort 2: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
10007226|NCT01601886||Before SUPPORT|01/03-06/05
10007227|NCT01601886||During SUPPORT recruitment|07/05-02/09
10007228|NCT01601886||After SUPPORT|03/09-06/10
10007229|NCT01601899|Active Comparator|ARM A|Stavudine (d4T) 30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
10007230|NCT01601899|Active Comparator|ARM B|Stavudine (d4T) 20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
10007231|NCT01601899|Active Comparator|ARM C|TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
10007232|NCT01601912||Atomoxetine NRI|We will modulate endogenous adrenergic pain inhibitory mechanisms by using a selective norepinephrine reuptake inhibitor (NRI).
10007233|NCT01601912||Citalopram SSRI|We will modulate serotonergic pain inhibitory mechanisms by using a selective serotonin reuptake inhibitor (SSRI)
9963654|NCT01230983|Active Comparator|Treatment 2: (No HD MTX / Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, dexrazoxane hydrochloride (Zinecard or DZR), IT methotrexate /cytarabine, radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
9963655|NCT01230983|Active Comparator|Treatment 3: (HD MTX / No Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, leucovorin calcium (LCV), HD methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
9963656|NCT01230983|Active Comparator|Treatment 4: (HD MTX / Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, HD methotrexate /cytarabine, dexrazoxane hydrochloride (Zinecard or DZR), radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
9963657|NCT01230996|Experimental|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
10007234|NCT01601925|Experimental|neck extended group|We measured the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck.
10007235|NCT01601938|Experimental|Selenium|500 mcg of selenium (10mL) daily for 7 days
10007236|NCT01601938|Placebo Comparator|Placebo|Placebo 10 mL (delivered from biosyn) for 7 days
10007237|NCT01601951||Hip Osteoarthritis|
10007238|NCT01601951||Knee Osteoarthritis|
10007239|NCT01601964||Follow-up or medical treatment.|medical treatment
10007240|NCT01601964||Surgical treatment|Surgical treatment
10007241|NCT01601990|Placebo Comparator|Placebo|
10007242|NCT01601990|Experimental|LC15-0444|
10007243|NCT01602003|Experimental|LC15-0444 25 mg bid|LC15-0444 25 mg bid(twice daily)added on Metformin therapy
10007244|NCT01602003|Experimental|LC15-0444 50 mg qd|LC15-0444 50 mg qd(once daily) added on Metformin therapy
10007245|NCT01602003|Active Comparator|Sitagliptin 100mg qd|Sitagliptin 100 mg qd (once daily) added on the Metformin therapy
10007246|NCT01602029|Active Comparator|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
10007247|NCT01602029|Active Comparator|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
10007248|NCT01602029|Placebo Comparator|Placebo|Placebo added to TAU
10007249|NCT01602029|Active Comparator|Odansetron Plus Simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
10007250|NCT01602055|Experimental|Azivol|
10007251|NCT01602055|Active Comparator|Zithromax|
10007252|NCT01602081||LIFT+Biodesign|
10007253|NCT01602094||Adequate antimeales antibody levels|ELISA test OD > 0.1
9476675|NCT03569423|Experimental|Transepithelial PRK|Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
10007254|NCT01602094||Inadequate measles antibody levels|ELISA test OD < 0.1
10007255|NCT01602107|No Intervention|Control|Participants in the control group will not receive therapist-supervised intervention. An exercise sheet briefly describing pelvic floor muscle exercises will be provided, as would be the standard practice from most physicians.
10007256|NCT01602107|Experimental|Pelvic Floor Therapy|Participants in the experimental group undergo and assessment and treatment by a registered physiotherapist. Treatments will include two sessions of biofeedback training, therapist-assisted strengthening exercises, and will a prescribed home exercise program to strengthen their pelvic floor muscles.
10007257|NCT01602133|Experimental|one intervention arm|
10007258|NCT01602146||ultramarathon runner|People who do the Mont Blanc ultramarathon (31/08/12 to 02/09/12)
10007259|NCT01602159|Active Comparator|Open Bypass Surgery|Open Bypass Surgery
10007260|NCT01602159|Active Comparator|Angioplasty and Stenting|
10007261|NCT01602185|Experimental|memantine|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
10007262|NCT01602185|Experimental|dextromethorphan|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
10007263|NCT01602185|Placebo Comparator|placebo|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
10007264|NCT01602211|Experimental|Arm I (INSPIRE internet full program access)|Participants receive full access to the INSPIRE internet site comprising an individually tailored program with a greeting home page with links to each target area, a 'My Health Action Plan' health care guideline for transplant survivors, self-care tips and tool pages for each complication and major issues for HCT survivors, a section for each complication (mood, energy, heart health, strengthening bones, second cancers), resource pages, opportunities to send secure messages with questions or comments on any topic, opportunities to request additional assistance or information, mobile texting options, and social media links (Twitter/Facebook/Pinterest) maintained and monitored by the Social Media Specialist.
10007265|NCT01602211|Experimental|Arm II (delayed program access control)|Participants receive annotated website links to existing transplant and cancer survivor sites, followed by delayed access to the INSPIRE internet program after 1 year.
10007266|NCT01602237||Bakery workers|
10007267|NCT01602250|Placebo Comparator|levobupivacaine placebo|levobupivacaine placebo
10007268|NCT01602250|Experimental|levobupivacaine Intralipid®|levobupivacaine Intralipid®
10007269|NCT01602250|Experimental|ropivacaine Intralipid®|ropivacaine Intralipid®
10007270|NCT01602250|Placebo Comparator|ropivacaine placebo|ropivacaine placebo
10007271|NCT01602276|Experimental|Active Stimulation|Transcranial direct current stimulation using Anodal or Cathodal stimulation over the area of interest
10007272|NCT01602276|Sham Comparator|Sham Stimulation|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.
10007273|NCT01602289|Experimental|LY2875358|Part A. LY2875358 will be administered intravenously (IV) at escalating doses (700 mg up to 2000 mg) on Day 1 and Day 15 of a 28-day cycle, until any discontinuation criterion is met.
10007274|NCT01602289|Experimental|LY2875358+Erlotinib|Part B1. Erlotinib will be administered orally at 150 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B1 was added per protocol amendment in January, 2013.)
10007275|NCT01602289|Experimental|LY2875358+Gefitinib|Part B2. Gefitinib will be administered orally at 250 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B2 was added per protocol amendment in January, 2013.)
10007276|NCT01602302|Experimental|single arm ( bDMARD withdrawal )|single arm (bDMARD withdrawal)
10007277|NCT01602328|Active Comparator|AC607|Treatment with AC607
10007278|NCT01602328|Placebo Comparator|Placebo|Treatment with Placebo
10007279|NCT01602354||Gram-negative Septic shock|Patients affected by Gram-negative septic shock
10007280|NCT01602406|Experimental|LJM716 in combination with trastuzumab|
10007281|NCT01602432||High Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is ≥ 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~Based on this method, the model includes 5 predictive variables as follows:~Site of cancer: classified as very high-risk (+2 points) or high-risk (+1 point).~Platelet count: (>350 x 109/L) (+1 point)~Hemoglobin level (<100 g/L) and/or use of erythropoiesis stimulating agents (+1 point)~Leukocyte count (> 11 x 109/L)(+1 point).~body mass index (≥ 35 Kg/m2) (+1 point)."
10007282|NCT01602432||Low high Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is < 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~In order to confirm the patient low risk status, we will draw a blood sample to determine serum levels of D- dimer and soluble P selectin in patients of this low risk group according to Ay et al. (2010). If levels of D-dimer are ≥ 1.44 µg/mL and/or soluble P selectin ≥ 53.1 ng/mL, we will add one point for each one of the increased biochemical marker and the total score recalculated."
10007283|NCT01602445||Cancer patients|All cancer patients with a diagnosed acute symptomatic VTE episode.
10007284|NCT01602458|Other|Silicone Only Therapy (SOT)|Mepiform™ silicone will be utilized by SOT group.
10007285|NCT01602458|Other|Silicone Pressure Garment Therapy (SPGT)|Mepiform™ silicone and custom compression garments fabricated by Barton Carey™ will be utilized by SPGT group.
10007286|NCT01602497|Active Comparator|rTMS intervention group|The rTMS intervention group undergo ten session of real TMS therapy.
10007287|NCT01602497|Placebo Comparator|Sham group|Patients will undergo ten session of sham rTMS.
10007288|NCT01602523|Active Comparator|budesonide/formoterol|budesonide/formoterol 160/4.5 mcg (Symbicort)
10007289|NCT01602523|Placebo Comparator|Placebo|Symbicort placebo
10007290|NCT01602536|Experimental|Twitter|Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
10007291|NCT01602536|Active Comparator|Control|Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.
10007292|NCT01602575|Experimental|mindfulness treatment|Mindfulness based stress reduction is the intervention in this single arm trial
10007293|NCT01602588|Experimental|Arm B|Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.
10007294|NCT01602588|Active Comparator|Arm A: SCRT alone|Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy
10007295|NCT01602601||Cohort 1|Patients will have a single blood draw for the analysis of antibodies induced by idursulfase. Samples will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro.
10007296|NCT01602627|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9476676|NCT03569423|Active Comparator|Alcohol assisted PRK|Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
10007297|NCT01602640|Experimental|Morphine|
10007298|NCT01602640|Active Comparator|Fentanyl and Midazolam|Control
10007299|NCT01602653|Active Comparator|1|the first group of patients received an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
10007300|NCT01602653|Active Comparator|2|The second grouop of patients received 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
10007301|NCT01602705|Placebo Comparator|Usual care|
10007302|NCT01602705|Active Comparator|Usual care + feedback of practice performance|
10007303|NCT01602705|Active Comparator|Usual care + feedback + health psychology intervention|
10007304|NCT01602718|No Intervention|Physical Function/Activity|"cross-sectional comparison study of physical function/activity, frailty and inflammation measures in prevalent home Dx and prevalent in-center hemodialysis patients.~Subjects: Forty-five prevalent home dialysis patients will be recruited and tested once for all outcome measures. Forty-five prevalent in-center hemodialysis patients will be identified from prevalent patients in the University of Utah in-center dialysis system who are matched for gender, age, comorbidities and time on dialysis as the home dialysis patients who have been tested. Consenting patients will be tested for all outcome measures once and compared to the home dialysis group."
10007305|NCT01602718|No Intervention|Incident Patients|"Study 2: is a longitudinal cohort study of incident patients starting either home dialysis or in-center hemodialysis.~Consenting patients will be tested upon initiation of dialysis therapy and every 6 months for 18 months to track physical functioning /activity, frailty and inflammation over time."
10007306|NCT01602718|Other|Independent Home Exercise|pilot study of independent home exercise training in home dialysis (PD only) patients. Consenting patients will be tested at baseline, then randomized into exercise training or usual care (no prescribed change in activity levels) and retested after 3 months.
10007307|NCT01602757|Experimental|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
10035359|NCT01805453|Placebo Comparator|Arm B: Placebo|Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
10035360|NCT01805466|Experimental|EVADO|"The E.V.A.D.O. system is made of the following components:~The ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.~The HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).~Paediatric circuits with 3/8 tubing for both arterial and venous lines."
10035361|NCT01805466|Active Comparator|Conventional CPB|conventional cardiopulmonary by-pass (CPB) system
10037255|NCT01823406|Experimental|Type 1 Diabetes no complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
10037256|NCT01823406|Experimental|Type 1 Diabetes with microalbuminuria|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
10037257|NCT01823406|Experimental|Type 1 Diabetes with advanced complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
10037258|NCT01823406|Experimental|Aged and sex matched healthy control volunteers|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
10037259|NCT01823419||7-9 year olds|Typically developing 7- to 9-year-olds will be enrolled and tested.
10037260|NCT01823432||BAV Cohort|Patients with bicuspid or unicuspid aortic valves, regardless of surgical status.
10037261|NCT01823445|Experimental|Xylitol disk|Daily use of 8 disks containing 0.5 grams xylitol each for two weeks. The disks adhere to gum tissue with a food grade adhesive backing and slowly dissolve. The disks are applied one on each side of the mouth in the morning after breakfast, again at midday, and four are applied, two on each side, at bedtime.
9963658|NCT01231009|Active Comparator|Corticosteroids|Patients receive for 7 days intravenous corticosteroids, dexamethasone, and they continue receiving for 7 days corticosteroids per os
9963659|NCT01231009|Placebo Comparator|Vestibular exercises|Patients perform for 15 days certain vestibular exercises under suspicion of an expert physiotherapist
9963660|NCT01231061|Experimental|Arm A: SBRT|
9963661|NCT01231061|Experimental|Arm B: Radiosurgery|
9963662|NCT01231074|Experimental|Psychotropic/metformin (PIW)|"Inclusion Criteria:Psychotropic/metformin (PIW) Cohort: Children aged 10-17 years on psychotropic* medication with reported weight gain defined by 1 of the following: 1. >5% weight increase from the start of medication to 3 months on medication 2. Crossing into the 95th percentile for BMI 3. Crossing into the 85-95th percentile plus one obesity related complication~The subject will have to be on one of these medications in addition to the criteria above to be eligible for the study: haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, fluphenazine, loxapine, mesoridazine, thiothixene or trifluoperazine"
9963663|NCT01231074|Experimental|Obese/metformin (OME)|Obese/metformin (OME) cohort: Children 10-17 years old with BMI >95th percentile and fasting insulin level>21.7U/L
9963664|NCT01231100|Experimental|HCUE-guided care|Hand-carried ultrasound echocardiography
9963665|NCT01231100|No Intervention|Standard care|
9963666|NCT01231113|Active Comparator|artesunate-amodiaquine arm|A co-blistered pack of amodiaquine and artesunate.The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
9963667|NCT01231113|Experimental|Dihydroartemisinin-piperaquine arm|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
9963668|NCT01231126|Placebo Comparator|spontaneous vaginal deliveries|
9963669|NCT01231126|Placebo Comparator|elective caesarians|
9963670|NCT01231126|Experimental|induced vaginal delivery by misoprostol|
9963671|NCT01231126|Experimental|caesarians section with induction attempt|
9963672|NCT01231139|Experimental|Paracetamol|Paracetamol dissolved in 0.9% Sodium Chloride
9963673|NCT01231139|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride
10007308|NCT01602770||Group 1|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
10007309|NCT01602783|Experimental|11C Acetate Imaging|11C acetate imaging
10007310|NCT01602796|Experimental|School-based intervention|
10007311|NCT01602796|No Intervention|Control|
10007312|NCT01602822|Other|Atazanavir, Ritonavir, Truvada|Open Label
10007313|NCT01602848|Experimental|Intervention enrollee|HIgh risk fee for service Medicaid recipients identified as eligible by the New York State Dept of Health and enrolled in the intensive care management and coordination intervention
10007314|NCT01602848|No Intervention|Eligible, not enrolled|Medicaid fee-for-service patients who are identified as eligible for the intervention but are not enrolled. These patients receive usual services provided by Medicaid.
10007315|NCT01602861|Experimental|Spironolactone|
10007316|NCT01602861|Placebo Comparator|Placebo|
10007317|NCT01602874|Experimental|A. Tigecycline|
10007318|NCT01602874|Active Comparator|B. Ceftriaxone regimen|
10007319|NCT01602887|Active Comparator|Reference|This is the reference formulation
10007320|NCT01602887|Experimental|NF1|This is a test formulation
10007321|NCT01602887|Experimental|NF2|This is a test formulation
10007322|NCT01602887|Experimental|SOL|This is a test formulation
10007323|NCT01602900|Experimental|GSK356278|Investigational drug
10007324|NCT01602913||Patients with diagnosis of Type II Diabetes|Patients indicating T2DM after the index date (ICD-9-CM 250.x), or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date
10007325|NCT01602913||Patients without diagnosis of Type II Diabetes|Patients not indicating T2DM
10007326|NCT01602926|Experimental|conventional surgery arm|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
10007327|NCT01602926|Experimental|minimally invasive technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal
10007328|NCT01602939|Experimental|2CDA+IFN|
10007329|NCT01602952|Experimental|Radotinib|"Phase 1 : 200mg/kg or 1200mg/m^2~Phase 2 : 400mg Bid"
10007330|NCT01603004||everolimus, sunitinib or traditional chemotherapy|A total of 30 patients with well differentiated pancreatic NETs who have known liver metastases and who are planned to initiate therapy with either targeted (everolimus or sunitinib) or traditional cytotoxic chemotherapy will be recruited for this study. We plan to recruit approximately 10 patients for each therapy (everolimus, sunitinib, cytotoxic chemotherapy). Evidence of metastatic disease will be determined at the discretion of the oncologist based on available imaging, surgical and pathologic evidence.
10007331|NCT01603017|Placebo Comparator|Placebo - no therapy|Patients who were blinded but did not receive therapy
10007332|NCT01603017|Experimental|MRI therapy|Patients receiving MRI therapy but blinded to it
10007333|NCT01603030|Experimental|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
10007334|NCT01603030|Active Comparator|moxifloxacin 0,5% + Prednisolone 1%|1 drop of each bottle, BID, 15 days
10007335|NCT01603069|Active Comparator|AZD3241, 300 mg|AZD3241 300 mg BID
10007336|NCT01603069|Active Comparator|AZD3241, 600 mg|AZD3241 600 mg BID
10007337|NCT01603069|Placebo Comparator|Placebo|Placebo to AZD3241
10007338|NCT01603095||Growth measurements|Approximately 500 patients will be enrolled. Patients from birth to <= 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.
10007339|NCT01603108|Experimental|Rifaximin Arm|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
10007340|NCT01603108|Placebo Comparator|Placebo Control Arm|Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
10007341|NCT01603134|Experimental|Allopurinol 300 mg Tablets USP|Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India
10007342|NCT01603134|Active Comparator|Zyloprim®|Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA,
10007343|NCT01603147|Placebo Comparator|Saline|A total of 10 subjects will receive placebo
10007344|NCT01603147|Experimental|ch-mAb7F9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively.
10035362|NCT01805479|Placebo Comparator|stretching-flexibility|This group will use a stretching and flexibility program designed to utilize minimal levels of aerobic capacity. It was chosen in place of a education-based control group due to the high level of personal interaction that is found in the active arm.
10007345|NCT01603160||Emergency Department Staff|"Interventions put in place in the Emergency Department will effect most staff who work in the ED, but different sub-groups will be approached for participation in specific aspects of the study:~All ED attending and resident physicians and ED nurses will be invited to complete the SCD Attitudes survey.~Select ED Staff will be invited to be members of the QI team and will be invited to participate in the FMECA.~Members of the QI team will be invited to participate in a focus group."
10007346|NCT01603173|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
10007347|NCT01603173|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
10007348|NCT01603186|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
10007349|NCT01603186|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
10007350|NCT01603199|Experimental|Primary biliary cirrhosis (Non-cirrhotic)|
10007351|NCT01603199|Experimental|Primary biliary cirrhosis (Cirrhotic)|
10007352|NCT01603212|Experimental|Vemurafenib + IL-2 + Interferon Alfa-2b|Starting dose of Vemurafenib 720 mg by mouth twice daily. Three dose levels of Vemurafenib evaluated in combination with interferon and IL-2. These doses are 480 mg, 720 mg and 960 mg. IL-2 given by continuous venous infusion at starting IL-2 dose of 7 million IU/m2 daily for 4 days (total of 96 hours, days 2-5) starting day 2. IL-2 dose levels are 5MU/m2/day, 7MU/m2/day and 9MU/m2 day. Doses of interferon remain constant at 5 MU/m2 subcutaneously daily for 5 days starting Day 1.
10007353|NCT01603225||Autism|Individuals with autism will have either Anodal, Cathodal, or Sham Transcranial Direct Current Stimulation (tDCS).
10007354|NCT01603238|Experimental|[14C]-LC15-0444|A single oral dose of [14C]-LC15-0444 50 mg , containing 4.9 MBq [14C] (batch number 110372/C/01).
10007355|NCT01603251|Active Comparator|Artemether-Lumefantrine|
10007356|NCT01603251|Experimental|Artemether-Lumefantrine + single dose Ivermectin|
10007357|NCT01603251|Experimental|Artemether-Lumefantrine + repeated dose Ivermectin|
10007358|NCT01603264|Experimental|A|PF-05280014
10007359|NCT01603264|Active Comparator|B|Trastuzumab-EU
10007360|NCT01603264|Active Comparator|C|Trastuzumab-US
10007361|NCT01603290||Hospitalized Leukemia Patients|leukemia patients with chemotherapy during hospitalization
10007362|NCT01603303|Other|Usual Care + Education Materials|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
10007363|NCT01603303|Experimental|Luvena Group|Luvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
10035363|NCT01805479|Active Comparator|aerobic exercise group|aerobic activity targeting 60% peak heart rate for 12 weeks is the active group.
10035364|NCT01805492|Experimental|Intervention|Dr. Dean Ornish Program for Reversing Heart Disease
10035365|NCT01805492|No Intervention|Control|Non-intervention controls retrospectively matched to intervention participants
10035366|NCT01805505|Experimental|Transvaginal ultrasound-guided embryo transfer|Transvaginal ultrasound-guided transfer of two day-3 embryos
10007364|NCT01603303|Experimental|Hyalo-Gyn Group|Hyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
10007365|NCT01603329|Experimental|Comprehensive incentives + comprehensive communication|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
10007366|NCT01603329|Experimental|Comp incentives + comp communication + non-white paper|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.
10007367|NCT01603329|Experimental|Focused incentives + focused com for oral diabetes medication|Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.
10007368|NCT01603329|Experimental|Foc incentives + foc comm for Diabetes + non-white paper|Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.
10007369|NCT01603329|Experimental|Focused incentives + focused comm for hypertension meds|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.
10007370|NCT01603329|Experimental|Foc incentives + comm for hypertension meds + non-white paper|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.
10007371|NCT01603329|Experimental|Focused incentives + focused comm for cholesterol meds|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.
10007372|NCT01603329|Experimental|Foc incentives +comm for cholesterol meds + non-white paper|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.
10007373|NCT01603329|Experimental|Comprehensive communiation|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
10007374|NCT01603329|Experimental|Comprehensive communication + non-white paper|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.
10007375|NCT01603329|Experimental|Control Arm|Physicians and their patient adherence is tracked, but they receive no intervention.
10007376|NCT01603342|Experimental|clopidogrel|
10007377|NCT01603342|Placebo Comparator|Placebo|
10007378|NCT01603381|Experimental|CBT-I|Cognitive Behavioral Therapy for Insomnia
10007379|NCT01603381|No Intervention|Monitor Only (M.O.)|
10007380|NCT01603433|Experimental|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
10007381|NCT01603446|Experimental|MELAS Patients|Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
10007382|NCT01603446|No Intervention|Control Group|Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects
10007383|NCT01603472||Subjects on Parenteral Nutrition|cases are those on Parenteral Nutrition >6 weeks for intestinal failure.
9963674|NCT01231165|Experimental|Amiloride,nitrates,clopidogrel,aspirin,statins|Comparative Efficacious Research
9963675|NCT01231165|Active Comparator|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
9963676|NCT01231178|Active Comparator|Alginate based beverage|
9963677|NCT01231178|Placebo Comparator|Control beverage|
9963678|NCT01231191|Active Comparator|IV Acetaminophen|Intraoperative IV acetaminophen administered
9963679|NCT01231191|Placebo Comparator|IV Placebo|Intraoperative IV normal saline administered
9963680|NCT01231204|Placebo Comparator|Placebo Infusion|Patients will be randomized to receive a continuous infusion of Normal Saline via a Paravertebral Nerve Block.
9963681|NCT01231204|Active Comparator|Ropivicaine 0.4% Infusion|Patients will be randomized to receive a continuous infusion of 0.4% Ropivicaine via a Paravertebral Nerve Block.
9963682|NCT01231217|Other|green (or white) tea|Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee
9963683|NCT01231217|Other|coffee|Patients are recommended to drink coffee but are not allowed to consume any tea
9963684|NCT01231243|Active Comparator|35% hydrogen peroxide control|The tooth bleaching will be performed using a high hydrogen peroxide concentration (35%) without light-activation with LED/light device
9963685|NCT01231243|Active Comparator|20% hydrogen peroxide|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) without light activation with a LED/laser device
9963686|NCT01231243|Experimental|35% hydrogen peroxide + light|The tooth bleaching will be performed with a high hydrogen peroxide concentration (35%) associated with LED/laser light activation
9963687|NCT01231243|Experimental|20% hydrogen peroxide + light|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) associated with LED/laser light activation
9963688|NCT01231256|Experimental|preventive health consultation|Half participants randomized to a one hour preventive health consultation with their own general practitioner and a follow up consultation 3 months later
9963689|NCT01231256|No Intervention|Control|Controls are not offered preventive health consultations, but had questionnaires as the intervention arm
9963690|NCT01231269|Experimental|MRI|diffusion-weighted MRI
9963691|NCT01231282|Experimental|diffusion-weighted MRI|MRI
9963692|NCT01231295||Memory problems|Group with clinically validated memory problems
10007384|NCT01603472||Subjects not on Parenteral Nutrion|Controls are those who have never been on PN but can be fed via a feeding tube
10007385|NCT01603485|Experimental|Lersivirine|
10007386|NCT01603498|Experimental|Dexamethasone 8mg|
10007387|NCT01603498|Experimental|Methylprednisolone|Methylprednisolone 40mg
10007388|NCT01603524|Active Comparator|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
10007389|NCT01603524|Experimental|OMSC + Performance Feedback Group|The OMSC + Provider Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic.
10007390|NCT01603537||PHTLS|The exposure is defined from the dichotomization of the probability in each event/accident that at least one of the caring ambulance crew members was PHTLS certified.
10007391|NCT01603537||No PHTLS|Not exposed to PHTLS
10007392|NCT01603550|Experimental|Energy Restriction|
10007393|NCT01603550|Experimental|Sleep Deprivation|
10007394|NCT01603563|Experimental|Stepped Care TF-CBT|Patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
10007395|NCT01603563|Active Comparator|Standard TF-CBT|Patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
10007396|NCT01603576|Experimental|Suprachoroidal retinal prosthesis|
10007397|NCT01603589|Active Comparator|MiECC group|Patients operated for elective coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation (MiECC).
10007398|NCT01603589|Active Comparator|CECC group|Patients operated for elective coronary artery bypass grafting under conventional extracorporeal circulation (CECC).
10007399|NCT01603654|Experimental|sodium picosulphate/magnesium citrate|
10007400|NCT01603654|Active Comparator|low-volume PEG -ascorbic acid|
10007401|NCT01603667|Experimental|PG2 Injection 500 mg|PG2 Injection 500 mg
10007402|NCT01603667|Placebo Comparator|Placebo|Placebo
10007403|NCT01603680|Other|Circumferential (C)|"Circumferential(C) spread group will be defined as mepivacaine injectate visualized by ultrasonography all around the median and ulnar nerves imaged in short axis."
10007404|NCT01603680|Other|Non circumferential (NC)|Local anesthetic spread will be asymmetrical around the median and ulnar nerves, the mepivacaine will be partially in contact with the nerve
10007405|NCT01603693|Experimental|Bio-Oss|In this arm,GBR will be performed with DBBM (Bio-Oss, Geistlich) in 25 patients.
10007406|NCT01603693|Experimental|Bio-Oss and BondBone|In this arm, GBR will be performed using a combination of DBBM (Bio-Oss, Geistlich) and bi-phasic calcium sulphate (BondBone, Augma) in 25 patients.
10007407|NCT01603706|Active Comparator|Echo guided implantation group|Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.
10007408|NCT01603706|No Intervention|Conventional implantation group|Patients undergoing conventional LV lead implantation
10007409|NCT01603719|No Intervention|Standard Formula|Standard formula with no supplementation
10007410|NCT01603719|Experimental|experimental formula|infant formula with higher beta-palmitate and supplemented GOS
10007411|NCT01603732||Moms w HLHS or variant|Mom's fetal diagnosis Hypoplastic Left Heart Syndrome/variant
10007412|NCT01603732||Moms w/ Other congential heart defect)|Moms fetal diagnosis -other congenital heart defects
10007413|NCT01603732||Moms-fetal - echo normal|Moms echo fetal diagnosis is normal.
10007414|NCT01603732||Random Healthy Moms|Mom with healthy pregnancy.
10007415|NCT01603745|Active Comparator|NOMAC-valerate estradiol|E/P therapy
10007416|NCT01603745|Active Comparator|Drospirenone/ethinylestradiol|E/P therapy
9963693|NCT01231295||Reference group|Group without memory problems
9963694|NCT01231308|Active Comparator|Lifestyle modification|Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
9963695|NCT01231308|Experimental|Roux-en-Y-Gastric Bypass|A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
9963696|NCT01231360|Active Comparator|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
10007417|NCT01603758|No Intervention|Observational Arm|Cholesterol metabolic parameters will be measured in 100 subjects in an observational study. Results will be related to circulating biomarkers and carotid intima-media thickness.
10007418|NCT01603758|Placebo Comparator|Ezetimibe Interventional Arm|Cholesterol metabolic parameters will be measured before and after ezetimibe or placebo intervention. Changes due to ezetimibe will be determined
10007419|NCT01603771||Combined|Participants assigned to this group have been randomized to the Combined group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month standardized aerobic training program at a local recreational center, 3 times per week for 1 hour. Participants in this group also perform an 8-week cognitive training program 3 days per week for 1 hour, during months 5 and 6. The cognitive training program is computer-based, and focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. The cognitive training is conducted on concurrent days with aerobic exercise training sessions, also on site at the recreational center.
10007420|NCT01603771||Control|Participants assigned to this group have been randomized to the Control group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month home exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes and record their activity on a calendar. Participants also attend weekly 1-hour Health Education sessions for 8 weeks, during months 5 and 6. These sessions cover topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and home energy conservation.
10007421|NCT01603784|Experimental|Combined|Aerobic Exercise + Cognitive Training
10007422|NCT01603784|Experimental|Exercise|Aerobic Exercise + Health Education
10007423|NCT01603784|Experimental|Cognitive|Home Exercise + Cognitive Training
10007424|NCT01603784|Experimental|Control|Home Exercise + Health Education
10007425|NCT01603797|Experimental|Internet delivered ACT|Internet delivered acceptance and commitment therapy (ACT), 7 weeks treatment
10007426|NCT01603797|Active Comparator|Online discussion forum|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
10007427|NCT01603810||BCC|Adult of any age or gender with capacity to give informed consent who has a basal cell carinoma requiring surgical excision and involving the periocular skin
10007428|NCT01603823||Healthy volunteers|
10007429|NCT01603823||St.p. Pars plana vitrectomy|
10007430|NCT01603836|Experimental|bone marrow concentrate|In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
10007431|NCT01603849|Experimental|A Prophylactic Cranial Irradiation|Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.
10007432|NCT01603849|No Intervention|B Observation Group|Patients in this arm will be observed (not receiving WBRT)
10007433|NCT01603862|Experimental|ThinkingFit|
10007434|NCT01603888||healthy newborns, BNP, NT-proBNP|healthy newborns
10007435|NCT01603888||infants, BNP, NT-proBNP|infants
10007436|NCT01603888||children with heart disease, BNP, NT-proBNP|children with heart disease
10007437|NCT01603901|Experimental|Investigated Wounds|
10007438|NCT01603914|Experimental|scheduled wire-guided every six days|scheduled wire-guided every six days and a replacement of the catheter in a different place after 12 days from randomization.
10007439|NCT01603914|Experimental|Scheduled replacement every six days|Scheduled replacement every six days in a different location
10007440|NCT01603914|Experimental|replacement guided by clinical criteria|re change of catheter strategy guided by clinical suspicious of catheter-related bacteremia and replacement of the catheter in a different location.
10007441|NCT01603927||Colonoscopy with Narrow band imaging (NBI)|All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
10007442|NCT01603979|Experimental|Dose-escalation AV-203 Monotherapy|dose-escalation of monotherapy AV-203 (an ERBB3 inhibitory antibody) by IV every two weeks
10007443|NCT01604005|Experimental|PIT Arm|
10007444|NCT01604005|No Intervention|No PIT Arm|
10007445|NCT01604018||Placebo|Subjects previously randomized to receive placebo in study CP005 and completed CP005A.
10007446|NCT01604018||Cat-PAD Group 1|Subjects previously randomized to receive Cat-PAD dose 1 in study CP005 and completed CP005A.
10007447|NCT01604018||Cat-Pad Group 2|Subjects previously randomized to receive Cat-PAD dose 2 in study CP005 and completed CP005A.
10007448|NCT01604031|Experimental|B-CLL vaccine|Patients will receive doses of vaccine at 2 week intervals for 5 doses and at 4 week intervals for doses 6-16. The injection will be performed subcutaneously in the deltoid region of the upper arm.
10007449|NCT01604044|Active Comparator|HP-hMG|
10007450|NCT01604044|Active Comparator|rFSH plus rLH|
10007451|NCT01604057|Experimental|Low Dose Nasal Spray|
10007452|NCT01604057|Experimental|Mid Dose Nasal Spray|
10007453|NCT01604057|Experimental|High Dose Nasal Spray|
10007454|NCT01604057|Active Comparator|Forteo|20ug subcutaneous injection daily
10007455|NCT01604057|Placebo Comparator|Placebo Nasal Spray|
10007456|NCT01604070||Nextra fusion|group that has the nextra device
10007457|NCT01604070||k wire fixation|control group fixated with k wire
10007458|NCT01604096|Experimental|Intervention areas|Provinces of Modena and Parma (about 1.100.000 inhabitants - campaign targeted to the general population), in Northern Italy (Emilia-Romagna Region)
10007459|NCT01604096|No Intervention|Control|All the other provinces in the Emilia-Romagna Region (where the information campaign has not been implemented)
10007460|NCT01604135|Active Comparator|Corneal Collagen Crosslinking|The keratokonic eye which progresses most is included and randomized. Significant progression is defined in the eligibility criteria section. If randomized to the treatment arm the cornea is treated with collagen crosslinking as described below.
10007461|NCT01604135|No Intervention|Control group|The keratokonic eye which progresses most is included and randomized to either the treatment group (CXL) or the control group.
10007462|NCT01604148||HoLEP group|Holmium Laser Enucleation of Prostate Group
10007463|NCT01604161||Somatropin|
10007464|NCT01604174|Experimental|Interactive Virtual Telerehabilitation|Rehabilitation by IVT
10007465|NCT01604174|Active Comparator|Standard rehabilitation care|Standard care rehabilitation after total knee arthroplasty
10007466|NCT01604187|Active Comparator|Fentanyl|Ten minutes before the procedure fentanyl 100 mikrograms sublingual tablet will be given to the patient.
10007467|NCT01604187|Placebo Comparator|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
10007468|NCT01604200||Dentists|Dentists in practice
10007469|NCT01604213|Experimental|Vildagliptin+metformin|Oral Vildagliptin+metformin combination
10007470|NCT01604213|Active Comparator|Metformin only|Oral metformin only
10007471|NCT01604226||Gynecologic surgery group|Those undergoing gynecologic laparoscopic surgery with TIVA
10007472|NCT01604226||Urologic surgery group|Those undergoing urologic surgery with TIVA
10007473|NCT01604239|Experimental|Shinbaro|
10007474|NCT01604252||Cohort|
10007475|NCT01604304|Active Comparator|Extracorporeal shockwave lithotripsy|stone treatment using electroconductive technology
10007476|NCT01604304|Active Comparator|Flexible ureteroscopy|intra renal retrograde surgery with or without laser and stone extraction
10007477|NCT01604317|Active Comparator|Resuscitation-torso plastic bag|Resuscitation with plastic bag covering torso and lower extremities for first hour to assist with temperature regulation.
10007478|NCT01604317|Active Comparator|Resuscitation-partial-head plastic bag|Resuscitation with plastic bag covering torso, upper and lower extremities, and a portion of the head for first hour after birth to assist with temperature regulation.
10007479|NCT01604330|Experimental|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
10007480|NCT01604330|Placebo Comparator|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
10007481|NCT01604356|Experimental|Electro-acupuncture|
9476677|NCT03569410|Active Comparator|Supplement Group|The protein supplement group was instructed by their dietician in how many protein supplements to consume in addition to their natural food intake in order to reach their goal protein intake.
10007482|NCT01604369|Experimental|Cryoablation|
10007483|NCT01604382|Experimental|treatment|Receives General Anesthesia as described above
10007484|NCT01604382|Placebo Comparator|Placebo|Patients receives neuraxial anesthesia as described above
10035367|NCT01805505|Active Comparator|Transabdominal ultrasound-guided embryo transfer|Transabdominal ultrasound-guided transfer of two day-3 embryos
10035368|NCT01805518|Active Comparator|Scelectium Tortuosum|S Tortuosum
10035369|NCT01805518|Placebo Comparator|Sugar pill/placebo|Sugar pill/placebo
10035370|NCT01805531||Rivaroxaban|
10035371|NCT01805544||Rivaroxaban|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
10035372|NCT01805570|Active Comparator|Prasugrel loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI.
10035373|NCT01805570|Active Comparator|Ticagrelor loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI.
10035374|NCT01805583|Experimental|ACT|The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
10035375|NCT01805583|Experimental|WPI|"This interventions aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
10035376|NCT01805583|Experimental|ACT and WPI|"The study participants receive both ACT and WPI. The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action. WPI aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
10035377|NCT01805583|No Intervention|Control group|Treatment as usual (TAU) which means that the participant continues in ordinary health care and does not receive interventions other than the initial assessment.
10035378|NCT01805596|Experimental|clopidogrel-ticagrelor|21 days clopidogrel followed by 21 days ticagrelor
10035379|NCT01805596|Experimental|ticagrelor-clopidogrel|ticagrelor for 21 days followed by clopidogrel for 21 days
10035380|NCT01805622|Experimental|Passive Arm #1|Active Arm #1, 2; Passive Arm #1, 2 Community coalitions randomized to the Passive Arm #1-Web Access Without Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will not participate in monthly technical assistance teleconferences.
10035381|NCT01805622|Experimental|Passive Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to the Passive Arm #2-Web Access With Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will participate in monthly technical assistance teleconferences.
10035382|NCT01805622|Active Comparator|Active Arm #1|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #1-In-Person Access Without Technical Assistance will receive training from intervention developers with access to facilitator training materials but will not participate in monthly technical assistance teleconferences.
10035383|NCT01805622|Active Comparator|Active Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #2-In-Person Access with Technical Assistance will receive training from intervention developers with access to facilitator training materials and will participate in monthly technical assistance teleconferences.
10035384|NCT01805635||Children suspected of allergic diseases|Children suspected of allergic diseases No intervention
10035385|NCT01805648|Experimental|rhTPO|Active investigational product
10035386|NCT01805661|Active Comparator|Femoral With Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa
10035387|NCT01805661|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
10035388|NCT01805674||isoflavones combined with magnolia|A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.
10035389|NCT01805700|Experimental|Regular caffeine enhanced energy drink|Regular caffeine enhanced energy drink (containing 240mg caffeine & 84g glucose) e.g. regular red bull cans (x3)
10035390|NCT01805700|Experimental|Diet Caffeine enhanced energy drink|Diet Caffeine enhanced energy drink ( containing 240mg of caffeine alone) e.g. Red Bull light)
10035391|NCT01805700|Active Comparator|Glucose drink|Glucose drink (containing 84g glucose alone)
10035392|NCT01805713||CF Infant Cohort|Infants with CF followed for the first two years of life.
10035393|NCT01805713||CF Child/Adult Cohort|CF patients > 8 years of age followed during hospitalization for pulmonary exacerbation and when well for two years.
10035394|NCT01805726|Placebo Comparator|Xylocain (C)|(C): Local anesthesia
10007485|NCT01604395||growth hormone|
10007486|NCT01604421|Sham Comparator|Thermoregulation-standard care|Standard thermoregulation without a plastic bag from one hour after birth until discharge or 24 hours after birth, whichever comes first.
10007487|NCT01604421|Active Comparator|Thermoregulation-with plastic bag|Thermoregulation with plastic bag covering torso and lower extremities from one hour after birth until discharge or 24 hours after birth to assist with thermoregulation. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
10007488|NCT01604434|Sham Comparator|Incubator-no plastic bag|Placement into an incubator without a plastic bag
10007489|NCT01604434|Active Comparator|Incubator-torso bag|Placement into a plastic bag inside incubator
10007490|NCT01604447|Active Comparator|Incubator removal-torso bag|Use plastic bag covering the torso and lower extremities for temperature regulation with standard bundling practices when removing infant from incubator
9476678|NCT03569410|Experimental|Natural Food Group|The Natural food group was instructed by their dietician in how much additional protein rich foods to eat in order to reach their goal protein intake.
10007491|NCT01604447|Placebo Comparator|Incubator removal-no plastic bag|Standard bundling practices when removing the infant from the incubator. No plastic bag used.
10007492|NCT01604460|Sham Comparator|Resuscitation-no plastic bag|Resuscitation per standard of care without a plastic bag
10007493|NCT01604460|Active Comparator|Resuscitation-torso bag|Use of plastic bag covering the torso and lower extremities for temperature regulation during and after resuscitation for the first hour after birth
10007494|NCT01604473||Chronic Kidney Disease|Individuals with Chronic Kidney Disease stages IV or V anticipating the need for hemodialysis access through an arterio-venous fistula.
10007495|NCT01604486||MI without ischaemic preconditioning|Myocardial infarction unheralded by any previous cardiovascular disease diagnosis and without symptoms of chest pain in the previous 90 days.
10007496|NCT01604486||MI with longstanding disease|Patients with myocardial infarction who have had diagnosed atherosclerotic disease for longer than 90 days preceding infarct.
10007497|NCT01604486||MI with only chest pain|Patients with chest pain in the 90 days preceding MI, but with no prior atherosclerotic disease diagnoses.
10007498|NCT01604486||MI with disease and chest pain|Myocardial infarction occurring with previously diagnosed atherosclerotic disease of longer than 90 days' duration, but with chest pain in 90 days preceding infarct.
10007499|NCT01604499|Experimental|Feedback only|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
10007500|NCT01604499|Experimental|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
10007501|NCT01604499|No Intervention|Control group|
10007502|NCT01604512|Experimental|Pts with a brain tumor|The study will prospectively enroll patients who have increasing size and/or enhancement of brain lesion(s) after brain radiation therapy for a neoplasm (either primary or metastatic), where. it is unclear if a lesion represents radiation injury or progressive tumor. At the discretion of PI the RSI sequence may be repeated at SOC FDG or other radiotracer imaging carried out while the patient is still on study, if deemed clinically necessary.
10007503|NCT01604525|Sham Comparator|Control|Participants randomized to this group received access to an untailored general interest/lifestyle website.
10007504|NCT01604525|Experimental|Tailored Health and Lifestyle Web|Participants randomized to this arm received tailored web content about health and wellness, with weekly goal-setting and feedback.
10007505|NCT01604525|Experimental|Tailored Web plus Peer Coaching|Participants randomized to this arm received access to weekly tailored health and wellness web content, plus weekly feedback from a peer health coach (videos uploaded to the web and phone calls).
10007506|NCT01604538||patients with acute pulmonary embolism|
10007507|NCT01604564||Colitis Ulcerosa|Colitis Ulcerosa With creation of IPAA
10007508|NCT01604564||Familial Adenomatous Polyposis|Familial Adenomatous Polyposis with creation of IPAA
10007509|NCT01604577|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
10007510|NCT01604577|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
10007511|NCT01604590||glioblastoma patients on bevacizumab|
10007512|NCT01604603||Control|
10007513|NCT01604603||Oligomenorrhea|
10007514|NCT01604603||Amenorrhea|
9667625|NCT03322215|Active Comparator|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
10007515|NCT01604603||premature ovarian failure|
10007516|NCT01604616||PCFL GROUP|patients in this group had the PFCL for a period of 7-10 days before it was replaced by SF6 gas or silicone oil
10007517|NCT01604616||control group|in thos group no PFCL was left in the eye and either SF6 or silicone oil was the definitive treatment at the time of the retinal detachment surgery repair.
10007518|NCT01604629|Experimental|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
10007519|NCT01604629|Active Comparator|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
10007520|NCT01604642|Other|cachectic versus no cachectic patients|blood tests, muscular biopsies
10007521|NCT01604655|Active Comparator|Coronary CT Angiography|Patient admitted with chest pain is randomized to CCTA for assessment.
10007522|NCT01604655|Active Comparator|Stress Test|Patients admitted with chest pain are randomized to a stress test (stress SPECT or Echocardiography) for assessment.
10007523|NCT01604668||RevF vs RevG vs Pronto-7|Comparison of hemoglobin levels derived by continuous hemoglobin sensor RevF versus continuous hemoglobin sensor RevG versus an intermittent hemoglobin level derived from the Pronto-7 hand-held device versus a hemoglobin derived from a blood sample.
10007524|NCT01604681|Placebo Comparator|placebo group|3 g of powdered gelatin encapsulated in opaque capsules.
10007525|NCT01604681|Experimental|Flaxseed oil group|Oil extracted from linseed by pressing the cold and encapsulated, providing 3g per day containing 1.75 g of alpha linolenic acid.
10007526|NCT01604694|Experimental|TAP Block with levobupivacaïne|
10007527|NCT01604694|Placebo Comparator|TAP Block with Placebo|
10007528|NCT01604707|No Intervention|Control group|Standard care
10007529|NCT01604707|Experimental|Medical Yoga|Group training with medical yoga in primary health care.
10007530|NCT01604733||HYPERCHOLESTEROLEMIC PATIENTS|
10007531|NCT01604746|No Intervention|Safety assessment|Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.
10007532|NCT01604759|Other|Polarized probe measurement.|All patients belong under this arm as all will be measured by the polarized probe and the data will be compared to the biopsy site's pathology results.
10007533|NCT01604798||Colorectal Cancer Patients|Patients with histologically confirmed colorectal cancer
10007534|NCT01604798||Healthy Controls|Healthy volunteers
10007535|NCT01604811|Experimental|Tested product|
10007536|NCT01604811|Active Comparator|Comparator|
10007537|NCT01604837||Pelvic malignancy group|those with diagnosis of gynecologic or urologic malignancy
10007538|NCT01604837||Pelvic chronic disease group|those with chronic pelvic pain with constitutional cause e.g. endometriosis
10007539|NCT01604863|Experimental|Arm A|HGS1036 + Paclitaxel + Carboplatin
10007540|NCT01604863|Experimental|Arm B|HGS1036 + Cisplatin + Etoposide
10007541|NCT01604863|Experimental|Arm C|HGS1036 + Docetaxel
10007542|NCT01604902||Psoriasis vulgaris|Patients with psoriasis vulgaris who are going to be treated with biological drugs independent of this project(according to national guidelines).
10007543|NCT01604915|Placebo Comparator|Group R|Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered.
10007544|NCT01604915|Experimental|Group DR|Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
10007545|NCT01604928|Experimental|YM178 Dose 1|low dose
10007546|NCT01604928|Experimental|YM178 Dose 2|high dose
10007547|NCT01604928|Active Comparator|Tolterodine|Oral
10007548|NCT01604928|Placebo Comparator|Placebo|Oral
10007549|NCT01604954|Other|Non-obese|Non-obese women (BMI between 18.5 and 25 kg/m2)
10007550|NCT01604954|Other|Obese|Obese women (BMI between 30 and 40 kg/m2)
10007551|NCT01604980|Experimental|Protein Intakes|subjects will recieve differnt levels of protein intakes varying from 0.2 to2.0g/kg/day.
10007552|NCT01604993|Experimental|High nitrate dietary source|556 grams of high nitrate spinach soup that is orally consumed as a single dose for 7 days.
10007553|NCT01604993|Placebo Comparator|No Nitrate dietary source|556g low nitrate asparagus soup; orally consumed as a single does for 7 days.
10007554|NCT01605006|Other|NeuRx Diaphragm Pacing System (DPS)|Surgical implantation of the NeuRx DPS (on label use).
10007555|NCT01605045|Experimental|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique)versus
10007556|NCT01605045|Active Comparator|Standard technique|Coronary anatomy visualized and documented using cinematography alone (standard technique)
10007557|NCT01605084|Experimental|Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone|
10007558|NCT01605084|Experimental|Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone|
9802406|NCT05282550|Placebo Comparator|Placebo First|Placebo and then Trazodone (50 mg at bedtime) after a 4-week washout period.
10007559|NCT01605110|Experimental|Hyperbaric oxygen therapy|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
10007560|NCT01605110|Sham Comparator|Air sham|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
10007561|NCT01605123||Lean children|n=100 (anticipated), n=70 currently Age: 6-25 years BMI-SDS: -1.88 to +1.23 , currently -0.25±0.77; Height-SDS: > - 2 SDS, currently 0.03±1.07;
10007562|NCT01605123||Obese children|n=106 Age: 6-25 years BMI-SDS: >1.23 , currently 2.41±0.52; Height-SDS: > - 2 SDS, currently 0.80±1.18;
10007563|NCT01605123||Obese Exercise Group|Obese children will engage in increased physical activity (one to two lessons per week) at 40-60 and 60-80% of maximal exercise capacity (n=50 each anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
10007564|NCT01605123||Classical Lifestyle Intervention|Obese children will receive a classical lifestyle intervention, including dietary, activity and psychosocial counselling (n=50 anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
10007565|NCT01605149||Case|Patients with Type 1 Diabetes Mellitus
10007566|NCT01605201|Experimental|Implantation of cartilage graft|
10007567|NCT01605214||Bilateral Lung Transplant|All patients undergoing bilateral lung transplant for any indication will be considered for enrollment in the study. The characteristics of measurements of extravascular lung water will be compared following surgery in those who develop primary graft dysfunction compared to those who do not.
10007568|NCT01605240|Active Comparator|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
10007569|NCT01605240|Active Comparator|Acetaminophen and Ibuprofen|Following reduction of their fracture, these patients will receive acetaminophen (15mg/ml) and ibuprofen (10mg/ml) at regular dosing intervals.
10007570|NCT01605253|Active Comparator|Eszopiclone|The total study duration is 16 weeks, with subjects taking 3mg eszopiclone at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
10007571|NCT01605253|Placebo Comparator|Placebo|The total study duration is 16 weeks, with subjects taking placebo at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
9963697|NCT01231360|Active Comparator|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
9963698|NCT01231425||With usual concomitant treatment|Two observational cohorts of patients will be evaluated: with and without concomitant analgesic/ antiinflammatory drugs. The objective is evaluate that both therapies (drugs and acupuncture) could be used as adjunctive therapy in order to maximize the analgesia that could be reached
9963699|NCT01231425||Without usual concomitant treatment|This group include patients that are not been treated with analgesic drugs at the beginning of the study. As an observational and naturalistic study any indicated treatment is allowed in any time
9963700|NCT01231438|Experimental|Renvela|Treatment for 2 weeks
9963701|NCT01231438|Experimental|Etalpha|Vit D Treatment for 2 weeks
9963702|NCT01231451|Experimental|All Subjects|All Subjects will receive the same intervention
9963703|NCT01231477||Volunteers|Healthy volunteers not submitted to anesthesia nor surgery.
9963704|NCT01231477||Sevoflurane Group|This group was submitted to inhalational anesthesia with sevoflurane and otorhinolaryngological surgery.
9963705|NCT01231490|Experimental|Active|
9963706|NCT01231490|Placebo Comparator|Placebo|
9963707|NCT01231529|Experimental|Part 1 Cohort 1|8 subjects with moderate hepatic impairment defined by a Child-Pugh score of 7 to 9 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
9963708|NCT01231529|Experimental|Part 1 Cohort 2|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 1 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
9963709|NCT01231529|Experimental|Part 2 Cohort 3|8 subjects with mild hepatic impairment defined by a Child-Pugh score of 5 to 6 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
9963710|NCT01231529|Experimental|Part 2 Cohort 4|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 3 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
9963711|NCT01231542|Experimental|Arm 1|Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.
9963712|NCT01231542|Experimental|Arm 2|Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects in Arm 2 will receive GSK1349572 50 mg once daily for 7 days and GSK1349572 50 mg once daily in combination with rifabutin 300 mg once daily for 14 days.
9963713|NCT01231568|Experimental|Cohort 1 Treatment Sequence 1|Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
10007572|NCT01605266||Nephrotic Syndrome|The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.
10007573|NCT01605279|Experimental|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
10007574|NCT01605279|Placebo Comparator|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.
10007575|NCT01605305|Experimental|FOLFOX6|
10007576|NCT01605318|Experimental|IMMU-130|All patients receive IMMU-130 administered in 21-day treatment cycles consisting of once or twice weekly for 2 consecutive weeks followed by a 1-week rest period. Treatment can be continued in the absence of unacceptable toxicity for a period of up to 8 cycles until the first documentation of Progressive Disease by CT (physician discretion), but must terminate study treatment upon the second documentation of Progressive Disease.
10007577|NCT01605331|Experimental|sustained-release recombinant human GH (SR-rhGH)|12-week subcutaneous administration, 2mg/week
10007578|NCT01605344|Experimental|Arm A|ARM A subjects will receive atorvastatin 20 mg orally once daily given for two weeks prior to FOLFIRI. The last dose of atorvastatin will be taken day 1 of FOLFIRI. ARM A will then receive no statin for the next 2 weeks. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
10007579|NCT01605344|Experimental|Arm B|ARM B subjects will receive no atorvastatin prior to day 1 of FOLFIRI. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks prior to day 15 of FOLFIRI. The last dose of atorvastatin will be taken day 15 of FOLFIRI. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
10007580|NCT01605357|Active Comparator|Standard Care|Patients will be managed to maintain a goal serum sodium of > 135 mmol/L , a well recognized value in the management of severe traumatic brain injury.
10007581|NCT01605357|Experimental|Induced Hypernatremia|Patients will be treated with induced, sustained hypernatremia for 5 days following injury by using hypertonic saline to target a goal serum sodium of 150-160 mmol/L
10007582|NCT01605383|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head"
10007583|NCT01605383|Sham Comparator|Standard Treatment|Isolated core decompression
10007584|NCT01605409|Active Comparator|Standard ACLS|Patients in the standard ACLS group will be resuscitated until ROSC or termination of efforts. If ROSC is achieved they will be transported to the emergency department and treated according to ERC guidelines and GCP.
10007585|NCT01605409|Experimental|ECPB|"ACLS provided for 15 minutes by EMS personnel according to current guidelines of the ERC.~CPR during transportation will be performed by EMS personnel according to ERC guidelines.~At the ED cannulation will be performed percutaneously if feasible. The femoral artery will be cannulated with a 17-19 - Fr and the femoral vein will be cannulated simultaneously with heparin coated 19-25 - Fr catheter or a smart cannula. An antegrade 8 - Fr cannula will be placed to supply perfusion for the cannulated leg if feasible. The procedures will be performed ultrasound-guided and the size of the cannulae will be adapted according to vessel size. Correct placement of the venous cannulae will be verified via ultrasound. Cardiopulmonary bypass will be performed by using the Lifebridge(Sorin®) or the Cardiohelp(Maquet®) ECMO device, according to protocol."
10007586|NCT01605448|Experimental|MBSR|Mindfulness Based Stress Reduction
10007587|NCT01605448|No Intervention|Control Group|Continue in Usual care; offered the intervention at the end of the study
10007588|NCT01605474|Active Comparator|Outpatient Cervical Ripening|Patients who are randomized to this arm will be allowed discharged home for 12 hours after fetal status is assessed and noted to be reassuring with the foley bulb in place. They will return sooner if they experience rupture of membranes or enter active labor or if the foley bulb falls out.
10007589|NCT01605474|No Intervention|Inpatient Cervical Ripening|In this arm, the fetus will be assessed and a foley bulb placed but these patients will be kept in the hospital.
10007590|NCT01605487|Other|Rupatadine 20mg - Placebo - Rupatadine 40mg|
10007591|NCT01605487|Other|Rupatadine 20mg - Rupatadine 40mg - Placebo|
10007592|NCT01605487|Other|Placebo - Rupatadine 20mg - Rupatadine 40mg|
10007593|NCT01605487|Other|Rupatadine 40mg - Placebo - Rupatadine 20mg|
10007594|NCT01605487|Other|Placebo - Rupatadine 40mg - Rupatadine 20mg|
10007595|NCT01605487|Other|Rupatadine 40mg - Rupatadine 20mg - Placebo|
10007596|NCT01605500||Medtronic ICDs|Patients with Generation 2 Medtronic ICDs
10007597|NCT01605513|Experimental|recombinant interferon|PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
10007598|NCT01605526|Experimental|Single Arm|
10007599|NCT01605591|Active Comparator|the DLT bending to the right|
10007600|NCT01605591|Active Comparator|the DLT bending to the left|
10007601|NCT01605604|Experimental|recieves Buddhist mindfullness|
10007602|NCT01605630|Experimental|Family-based cancer literacy intervention|
10007603|NCT01605630|Active Comparator|Control|Standard of care
10007604|NCT01605656||Focus Groups + Interviews + Questionnaires|HIV-positive women recruited from the population of individuals seeking care at Thomas Street Health Center (TSHC) of the Harris County Hospital District (HCHD).
10007605|NCT01605682|Experimental|Berry extract 125|Fresh berry extract containing 125mg of polyphenols
10007606|NCT01605682|Experimental|Berry extract 250|Fresh berry extract containing 250mg of polyphenols
10007607|NCT01605682|Experimental|Berry extract 500|Fresh berry extract containing 500mg of polyphenols
10007608|NCT01605682|Placebo Comparator|Placebo|Berry flavoured juice containing no polyphenols
10007609|NCT01605695||Normal healthy adults|The concentration of iNOS will be measured in plasma samples obtained at the time of blood donation from normal healthy adult humans
10007610|NCT01605721|Experimental|XIENCE PRIMETM everolimus-eluting coronary stent|
10007611|NCT01605734|Active Comparator|Group TACE|TACE will be carried out with chemotherapeutic agents and lipiodol; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated if clinically indicated
10007612|NCT01605734|Experimental|Group Combination|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
10007613|NCT01605747|Experimental|Culturelle|
10007614|NCT01605747|Placebo Comparator|Placebo|
10007615|NCT01605760|No Intervention|non immunotherapy treatment|
10007616|NCT01605760|Active Comparator|sublingual immunotherapy course|
10007617|NCT01605773|Experimental|repaglinide|
10007618|NCT01605773|Active Comparator|glyburide|
10007619|NCT01605786|Experimental|PEBS Low dose|
10007620|NCT01605786|Experimental|PEBS High dose|
10007621|NCT01605786|Active Comparator|Control|
10007622|NCT01605812||high myopia|high myopia (axial length>26mm)
10007623|NCT01605812||emmetropia|emmetropia (22<axial length<25mm) as control group.
10007624|NCT01605851|Other|Closure, Foramen Ovale|Patients undergoing device closure of PFO
10007625|NCT01605929|Experimental|Retroclavicular Brachial Plexus Block|
10007626|NCT01605955||Fingertip Pulse Oximeter|SPO2 measurement range: 70%-99%
10007627|NCT01605955||CO-oximeter|SaO2 measurement range: 70%-99%
10007628|NCT01605968|Experimental|BCT Silver Bandage|
10007629|NCT01605968|Active Comparator|Aquacel® Ag. Dressing|
10007630|NCT01605981|Experimental|Nilotinib oral|Nilotinib oral dose of 400 mg BID (800 mg/day) continuous dosing for up to 24 months. Nilotinib oral dose of 300 mg BID (600 mg/day) continuous dosing in case of intolerance. Nilotinib oral dose of 400 mg QD (400 mg/day) continuous dosing in case of intolerance
10007631|NCT01605994|Experimental|Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution|"BMS-933043 2 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007632|NCT01605994|Experimental|Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution|"BMS-933043 5 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007633|NCT01605994|Experimental|Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution|"BMS-933043 10 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007634|NCT01605994|Experimental|Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution|"BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007635|NCT01605994|Experimental|Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution|"BMS-933043 50 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days~CSF sampling required"
10007636|NCT01605994|Experimental|Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution|"BMS-933043 100 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10035395|NCT01805726|Active Comparator|Alfentanil Group + Xylocain (A)|Local anesthesia and Alfentanil
10007637|NCT01605994|Experimental|Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution|"BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007638|NCT01605994|Experimental|Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose|"MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required~BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
9802407|NCT05282147|Other|Babies undergoing newborn eye screening|Babies having newborn eye screening with the intervention (Digital Imaging) technique in addition to the standard ophthalmoscopic technique.
10007639|NCT01605994|Experimental|Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose|"Japanese Subjects. CSF sampling not required.~BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007640|NCT01605994|Experimental|Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose|"BMS-933043 350 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007641|NCT01605994|Experimental|CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose|"If Panel 5 does not run. CSF Sampling at steady state~BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
10007642|NCT01606020|Active Comparator|Sleep deprivation First|"First night D7 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.~Second night D28 :~Overnight, the subjects stay in their homes. No intervention during this night."
10007643|NCT01606020|Active Comparator|sleep deprivation second|"First night D7 :~Overnight, the subjects stay in their homes. No intervention during this night.~Second night D28 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep."
10007644|NCT01606033|Other|phase II non randomized study|"phase II non randomized study, Case : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
10007645|NCT01606033|Other|blind randomized phase II or III study|"blind randomized phase II or III study: control : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
10007646|NCT01606033|Other|open randomized phase II or III study|"open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~-understanding of the implications of participating in a clinical trial"
10007647|NCT01606033|Other|receiving standard treatment|"receiving standard treatment : 120 patients description of patients feeling by questionnaires :~-understanding of the implications of participating in a clinical trial"
10007648|NCT01606046|Active Comparator|vapocoolant spray|
10007649|NCT01606046|Active Comparator|topical anesthetic agent|
10007650|NCT01606046|No Intervention|Control|no interventions
10007651|NCT01606059|Active Comparator|DW-0919|
10007652|NCT01606059|Experimental|DW-0920|
10007653|NCT01606072|Experimental|Desmopressin|
10007654|NCT01606085|Experimental|HF-DM Self Care|educational counseling intervention about integrated HF-DM self care outcomes
10007655|NCT01606085|No Intervention|Usual Care|Usual Care provided by providers
10007656|NCT01606111|Placebo Comparator|0.9% NaCl, saline|
10007657|NCT01606111|Experimental|Cerebrolysin|
10007658|NCT01606163|Experimental|group 1|"Drug:GC1102~Amount:3ml (30,000IU)"
10007659|NCT01606163|Experimental|group 2|"Drug: GC1102~Amount: 5ml(50,000IU)"
10007660|NCT01606163|Experimental|group 3|"Drug: GC1102~Amount: 8ml (80,000IU)"
10007661|NCT01606163|Placebo Comparator|group 4|drug: JW normal saline
10035396|NCT01805726|Active Comparator|Dexmedetomidine Group + Xylocain (D)|Local anesthesia and dexmedetomidine
10035397|NCT01805752|Experimental|Integrated family-focused PMTCT arm|"Intervention package includes: 1) task-shifting to lower-cadre providers at PMTCT sites; 2) POC CD4+ cell count testing; (3) integrated mother-infant care; and (4) a prominent role for influential family members (male partners), working in close partnership with community-based health workers/volunteers.~Patients attending sites randomized to this arm will also receive group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired."
10007662|NCT01606215|Experimental|mesenchymal stem cells|1-2 x106 MSCs/kg administered at Week 0
10007663|NCT01606215|Sham Comparator|Placebo|Suspension media administered at Week 0
10007664|NCT01606241|Experimental|Treatment (cyclophosphamide and vaccine therapy)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1. Within 3-5 days, patients receive multi-epitope folate receptor alpha peptide vaccine ID on day 1. Vaccine treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10007665|NCT01606267|No Intervention|Routine HEP|This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities.
10007666|NCT01606267|Experimental|HEP+ICCM|This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities.
10007667|NCT01606293||Carcinomas of the Cervix Survey|Women with small and large cell carcinomas of the cervix, who are members of the Facebook group found at the uniform resource locator https://www.facebook.com/SmallCellCC through an online link.
10007668|NCT01606332|No Intervention|Single in interscalene block|Single indwelling interscalene block with ropivacaine 0.5% 10ml
10007669|NCT01606332|Experimental|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
10007670|NCT01606345|Experimental|Phase I Dose Escalation|Dose escalation: 200 mg/75 ml effluent, 400 mg/75 ml effluent, 800 mg/75 ml effluent
10007671|NCT01606358||Ovarian Cancer|
10007672|NCT01606371|Placebo Comparator|Healthy-Placebo|Placebo (capsule) administered once, orally
10007673|NCT01606371|Experimental|Healthy-2.5 mg LY2409021|2.5 mg LY2409021 administered once, orally
10007674|NCT01606371|Experimental|Healthy-10 mg LY2409021|10 mg LY2409021 administered once, orally
10007675|NCT01606371|Experimental|Healthy-30 mg LY2409021|30 mg LY2409021 administered once, orally
10007676|NCT01606371|Experimental|Healthy-100 mg LY2409021|100 mg LY2409021 administered once, orally
10007677|NCT01606371|Experimental|Healthy-250 mg LY2409021|250 mg LY2409021 administered once, orally
10007678|NCT01606371|Experimental|Healthy-500 mg LY2409021|500 mg LY2409021 administered once, orally
10007679|NCT01606371|Placebo Comparator|Diabetic-Placebo|Placebo (capsule) administered once, orally
10007680|NCT01606371|Experimental|Diabetic-75 mg LY2409021|75 mg LY2409021 administered once, orally
10007681|NCT01606371|Experimental|Diabetic-200 mg LY2409021|200 mg LY2409021 administered once, orally
10007682|NCT01606371|Experimental|Diabetic-500 mg LY2409021|500 mg LY2409021 administered once, orally
10007683|NCT01606384|Placebo Comparator|Placebo|Twice daily
10007684|NCT01606384|Experimental|SSR149415 - 100mg|Twice daily
10007685|NCT01606384|Experimental|SSR149415 - 250mg|Twice daily
10007686|NCT01606397|Placebo Comparator|Placebo|Placebo administered orally once daily for 4 weeks
10007687|NCT01606397|Experimental|5 mg LY2409021|5 mg LY2409021 administered orally once daily for 4 weeks
10007688|NCT01606397|Experimental|30 mg LY2409021|30 mg LY2409021 administered orally once daily for 4 weeks
10007689|NCT01606397|Experimental|60 mg LY2409021|60 mg LY2409021 administered orally once daily for 4 weeks
10007690|NCT01606397|Experimental|90 mg LY2409021|90 mg LY2409021 administered orally once daily for 4 weeks
10007691|NCT01606410||young, sedentary|
10007692|NCT01606410||young, active|
10007693|NCT01606410||old, sedentary|
10007694|NCT01606410||old, active|
10007695|NCT01606423|Placebo Comparator|Placebo|Administered once, orally
10007696|NCT01606423|Experimental|10 mg LY2409021|10 mg LY2409021 administered once, orally
10007697|NCT01606423|Experimental|22.5 mg LY2409021|22.5 mg LY2409021 administered once, orally
10007698|NCT01606423|Experimental|60 mg LY2409021|60 mg LY2409021 administered once, orally
10007699|NCT01606423|Experimental|200 mg LY2409021|200 mg LY2409021 administered once, orally
10007700|NCT01606423|Experimental|500 mg LY2409021|500 mg LY2409021 administered once, orally
10007701|NCT01606436|Placebo Comparator|Sugar pill|Placebo matching pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
10007702|NCT01606436|Experimental|400 mg pomaglumetad methionil|400 mg pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
10007703|NCT01606436|Other|400 mg Moxifloxacin|Positive control, unblinded moxifloxacin administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
10007704|NCT01606449||Group 1|Group 1 = Patients with type II Hiatal Hernia submitted to surgical therapy
10007705|NCT01606449||Group 2|Group 2 = Patients with type III Hiatal Hernia submitted to surgical therapy
10007706|NCT01606449||Group 3|Group 3 = Patients with type IV Hiatal Hernia submitted to surgical therapy
10007707|NCT01606462|Experimental|Oxytocin|one application of 24 IU oxytocin per volunteer
10007708|NCT01606462|Placebo Comparator|Placebo|sodium chloride solution, intranasal application, 3 puffs per nostril one application per volunteer
10035398|NCT01805752|No Intervention|Standard of care|Arm will receive standard of care activities, namely: group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, linkage to family spacing services, if desired.
10007709|NCT01606488|Other|Surgical Group|"Subjects scheduled to undergo total knee or total hip replacement at the SFVAMC.~Subjects in this arm of the study will undergo the florbetapir PET scan once prior to their surgery.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
10007710|NCT01606488|Other|Non-surgical group|"Subjects being seen in at the SFVAMC orthopedic clinic for knee or hip pain but are not anticipating surgical intervention.~Subjects in this arm will not undergo the florbetapir PET scan.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
10007711|NCT01606501||Limb Salvage patients|Patients undergoing limb salvage following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
10007712|NCT01606501||Transtibial Amputation patients|Patients undergoing transtibial amputation following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
10007713|NCT01606514|Experimental|Child, Parenting, & Parent Web-Intervention|Bounce Back Now Child, Parenting, & Parent Psychoeducation & Self-Help Web-Intervention.
10007714|NCT01606514|Experimental|Child & Parenting Web-Intervention|Bounce Back Now Child & Parenting Psychoeducation and Self-Help Web-Intervention.
10007715|NCT01606514|No Intervention|Child & Parent Web-based Assessment|Bounce Back Now Web-Based Symptom Assessment
10007716|NCT01606527|Experimental|Ibuprofen|Ibuprofen 600mg taken three times daily for four days.
10007717|NCT01606527|Placebo Comparator|placebo|Avicel placebo capsules three times daily for four days
10007718|NCT01606540|Experimental|Reposition and immobilism|"The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain.~After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition."
10007719|NCT01606540|Active Comparator|Surgery|"The method of surgery is type bridging.~After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation."
10007720|NCT01606553|Experimental|High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a dual-vave prototype
10007721|NCT01606553|Active Comparator|Sham High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a sham dual-vave prototype
10007722|NCT01606579|Experimental|Part I|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
10007723|NCT01606579|Experimental|Part II|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
10007724|NCT01606579|Experimental|Part III Arm A|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age."
10007725|NCT01606579|Experimental|Part III Arm B|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC."
10007726|NCT01606579|Experimental|Part III Arm C|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP."
9802408|NCT05282004|Experimental|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
10007727|NCT01606592|Experimental|Randomized Panic Control Treatment|Patients who have been randomized to the randomization condition are assigned to PCT
10035399|NCT01805765|Active Comparator|Qing'E pills|9 g pills,twice a day for 12 weeks
10007728|NCT01606592|Experimental|Randomized Panic-Focused Psychodynamic Psychotherapy|Patients who have been randomized to the randomization condition are assigned to PFPP
10007729|NCT01606592|Experimental|Self-selected Panic Control Treatment|Patients who have been randomized to the self-selection condition choose PCT
10007730|NCT01606592|Experimental|Self-selected Panic-Focussed Psychodynamic Psychotherapy|Patients who have been randomized to the self-selection condition choose PFPP
10007731|NCT01606592|Experimental|Waiting-list|Patients who have been randomized to the waiting-list are offered sparse contact over telephone for 12 weeks and are then re-randomized to one of the other four arms
10007732|NCT01606605||Diffuse large B-cell lymphoma|Patients diagnosed and treated at the Samsung Medical Center
10007733|NCT01606618||Spina bifida aperta|
10007734|NCT01606618||Acquired traumatic spinal cord injury|
10007735|NCT01606631||Arm 1 : experimental (case)|Patients included in the study and admitted to the ICU either directly from UAA or after a hospitalization in a specialty, for a severe sepsis or septic shock on their infectious disease community.
10007736|NCT01606631||Arm 2 : control|Patients included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before hospital discharge.
10007737|NCT01606644|Experimental|HBO|30 90-minute hyperbaric oxygen sessions at 2.4 atm.
10007738|NCT01606644|No Intervention|No HBO|No intervention. No hyperbaric oxygen is administered. Otherwise, the patient will follow the examination program.
10007739|NCT01606657|Active Comparator|Irrigation|THE PATIENT IS TO HAVE IRRIGATION OF THE ABSCESS WITH NORMAL SALINE AS PART OF THE I&D PROCEDURE
10007740|NCT01606657|Placebo Comparator|No Irrigation|THE PATIENT IS NOT TO HAVE IRRIGATION OF THE ABSCESS AS PART OF THE I&D PROCEDURE
10007741|NCT01606683|Experimental|GROUP 1|Infant formula supplemented with with functional ingredients (galacto-oligosaccharides, beta-palmitate, fermented milk). Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.
10007742|NCT01606683|Other|GROUP 2|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
10007743|NCT01606683|Other|CONTROL GROUP|Breast milk
10007744|NCT01606696|Experimental|HIIT|Higher intensity interval training.
10007745|NCT01606696|Active Comparator|Standard intensity non-interval training|Standard intensity non-interval training
10007746|NCT01606722||Darunavir-ritonavir monotherapy|HIV-infected patients with undetectable viral load for at least for 6 months on stable therapy and no darunavir related mutations in the HIV-protease gene
10007747|NCT01606774|Experimental|Low risk patients|Patients who agreed to 4 telemedicine obstetrical visits
10007748|NCT01606813|Active Comparator|Brief physician counseling (BPC) + Usual care (UC)|The participant will receive standard care. They will receive BPC from their PCP on weight loss by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss.
10007749|NCT01606813|Experimental|BPC + Internet Weight Control Program (IWCP)|The participant will receive BPC from their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program.
10007750|NCT01606813|Experimental|BPC + IWCP + Follow up email notes from PCP|The participant will receive BPC form their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program. And they will receive brief follow up email notes from PCPs on how their weight loss is going (from data collected from the weight loss website).
10007751|NCT01606865||elective and acute non-cardiac surgery|
10007752|NCT01606878|Experimental|Part A (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (oral solution) PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
10035400|NCT01805765|Placebo Comparator|Placebo|9 g pills,twice a day for 12 weeks
10007753|NCT01606878|Experimental|Part B (crizotinib, vincristine, dexrazoxane, doxorubicin)|Patients receive crizotinib (oral solution) PO BID as in Part A. Patients also receive vincristine sulfate IV on day 1, dexrazoxane hydrochloride IV on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
10007754|NCT01606878|Experimental|Part C (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (capsule formulation) PO BID, cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
10007755|NCT01606891|Experimental|parent-targeted intervention|experimental
10007756|NCT01606891|No Intervention|Primary Care|Standard primary care
10007757|NCT01606904|Experimental|Weight loss counseling|Cognitive behavioral therapy - based weight loss program
10007758|NCT01606904|Other|Control|Short term weight loss counseling, control group
10007759|NCT01606917|Experimental|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity.
10007760|NCT01606917|No Intervention|Usual care|Usual care
10007761|NCT01606930|No Intervention|Usual Care Group|"Group will see their physician without receiving the activation instrument."
10007762|NCT01606930|Active Comparator|"Activated Group"|"Group will be given an activation instrument to complete before their appointment and instructed to refer to and use the instrument during their clinical encounter."
10007763|NCT01606956|Experimental|resting volume group|
10007764|NCT01606956|Active Comparator|half the maximum volume group|
10007765|NCT01606969|Experimental|Dex group|dexmedetomidine-lidocaine solution,
10007766|NCT01606969|Active Comparator|Control group|epinephrine-lidocaine solution
10007767|NCT01606995||Group 1|
10007768|NCT01607008|Other|MRI imaging|Use of MRI imaging in conjunction with standard radiation treatment
10007769|NCT01607021||Chinese children with HCV RNA positive|"A sample of 200 children with a recent confirmation of anti-HCV-antibody positive and HCV RNA positive. All the children were treated with antiviral therapy, and the course of treatment depend on HCV Viral genotyping(ie, genotype 1,2,3,4 subtypes).~Primary Outcome Measures:~Virologic response [ Time Frame: Weeks 2, 4, 6, 8, 10, and 12 ] Sustained virologic response (SVR, defined as plasma HCV RNA < lower limit of quantification [LLoQ] at 24 weeks after treatment cessation) following antiviral treatment.~Secondary Outcome Measures: Safety and tolerability of therapy. [ Time Frame: Up to 48 weeks ] measured by frequency of laboratory abnormalities , reported adverse events and discontinuations due to adverse events"
10007770|NCT01607034|Experimental|Sequence 1 - tablet-fast|150 mg Dexpramipexole (intact tablet) single dose under fasted condition
10007771|NCT01607034|Experimental|Sequence 2 - tablet-fed|150 mg Dexpramipexole (intact tablet) single dose under fed condition
10007772|NCT01607034|Experimental|Sequence 3 - water-fast|150 mg Dexpramipexole single dose dispersed in water under fasted condition
10007773|NCT01607034|Experimental|Sequence 4 - apple-fast|150 mg Dexpramipexole single dose crushed and mixed in applesauce under fasted condition
10007774|NCT01607060|Experimental|Lactulone|Patients receiving lactulone
10007775|NCT01607060|Active Comparator|Control|Observational group. Compare to lactulone group.
10007776|NCT01607086|Experimental|Group 1|To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.
9480695|NCT05261945|Experimental|Stretching Exercises And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 minutes, TENS and hot pack is applied for 15 minutes at the same time, then ultrasound will applied for 5 minutes.~Stretching exercises will be done in the following order;~For trapezius: Stretching into lateral flexion for the upper part, For scalene: rotation and ipsilateral flexion For the extensor muscles: flexion will be performed.~Performing each action for 30 seconds with 5 repetitions for 10 minutes Finally, by retruding the jaw, a neck straightening exercise can be performed."
10007777|NCT01607086|Experimental|Group 2|To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.
10007778|NCT01607099|Experimental|Pico Prep|Arm in which sodium- picosulfate/magnesium citrate is used for bowel cleansing
10007779|NCT01607099|No Intervention|Standard|The standard drug macrogol is used for bowel cleansing
9480696|NCT05261932||The accuracy of expert with or with-out AI|
9480697|NCT05261932||The accuracy non-expert with or with-out AI|
10007780|NCT01607125|Experimental|Vortioxetine|
10007781|NCT01607125|Placebo Comparator|Placebo|
10007782|NCT01607138||Total laryngectomy|A group of patients who underwent total laryngectomy with trechea esophageal puncture (TEP)
10007783|NCT01607151|Active Comparator|Normothermia|Core temperature 36-37 C
10007784|NCT01607151|Experimental|Hypothermia|Core temperature 32-34 C
10007785|NCT01607164|Experimental|Online self-help mood management|"Healthy Mood Project Website~Online self-help automated mood management course available in Spanish and English via a website.~Intervention consisted of 8 cognitive-behavioral mood management lessons."
10007786|NCT01607177|Experimental|Text message group|Patients randomised to this group will receive daily text message reminders used to motivate them to exercise in the preoperative period. They will also receive an exercise information sheet to complement the text messages.
10007787|NCT01607177|No Intervention|No text message group|Patients randomised to this group will receive standardised exercise advice but will not receive the text message reminders or the exercise information sheet.
10007788|NCT01607190||Patients with diabetic retinopathy.|
10007789|NCT01607216||Premature Infant|Infants born 23 0/7 weeks gestation to 35 6/7 weeks gestation.
10007790|NCT01607216||Healthy Full Term Infants|Infants born between 37 0/7 weeks gestation to 41 6/7 weeks gestation.
10007791|NCT01607229||otherwise healthy with various BMI|
10007792|NCT01607242||patients|patients undergoing total thyroidectomy
10007793|NCT01607268||Pure Autonomic Failure|Pure autonomic failure is a type of primary autonomic failure characterized by peripheral autonomic nervous system impairment.
10007794|NCT01607268||Multiple System Atrophy|Multiple system atrophy is a type of primary autonomic failure characterized by central autonomic nervous system impairment.
10007795|NCT01607281||anesthesiologists, experience|There is one arm. All participating anesthesiologists wıll fulfill the questionary survey and show the imaginary puncture site by USG bilaterally.
10007796|NCT01607307|Active Comparator|Oral/enteral TJ-100 solution|Oral/enteral TJ-100 solution
10007797|NCT01607307|Placebo Comparator|Oral/enteral placebo solution|Oral/enteral placebo solution
10007798|NCT01607333||Completed suicide|Patients who completed suicide
10007799|NCT01607333||Suicide attempt|Patients who have attempted suicide, or performed preparatory acts toward imminent suicidal behavior, suicidal ideation plus indeterminate or potentially suicidal events
10007800|NCT01607333||Not completed suicide|Patients who have not completed suicide
10007801|NCT01607359||dabigatran group|All patients receiving dabigatran as periprocedural anticoagulation during the study time period
10007802|NCT01607359||warfarin group|A randomly selected group of patients treated with warfarin during the study time period matching the number of dabigatran treated patients in the same time period.
10007803|NCT01607372|Experimental|GSK2245035 - 40 ng or placebo|Subjects will receive GSK2245035 - 40 nanogram (ng) or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
10007804|NCT01607372|Experimental|GSK2245035 - 80 ng or placebo|Subjects will receive GSK2245035 - 80 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
10007805|NCT01607372|Experimental|GSK2245035 - 120 ng or placebo|Subjects will receive GSK2245035 - 120 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
10007806|NCT01607372|Experimental|GSK2245035 - 160 ng or placebo|Subjects will receive GSK2245035 - 160 ng or placebo once per week, for four treatment weeks. There will be washout period of 7 days between treatment periods.
10007807|NCT01607385|Active Comparator|GSK2330672|
10007808|NCT01607385|Placebo Comparator|Placebo|
10007809|NCT01607424|Experimental|RECOS: 42 hours CR, 14 week-treatment.|RECOS(Cognitive Remediation for Schizophrenia) exercises were designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 5 main cognitive functions. RECOS modules focus on the relevant cognitive domains, which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS was determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participated in the module corresponding to his/her most altered cognitive area.
10007810|NCT01607424|Active Comparator|CRT: 42 hours CR, 14 week-treatment|CRT (Cognitive Remediation Therapy) exercises are the ones used by Wykes et al (1999). The CRT method consists of 3 modules: flexibility, memory (A and B) and planning (A and B). Each module involves a series of paper and pencil exercises with parallel forms providing with gradual difficulty.
10007811|NCT01607463|Experimental|active TENS group|Two electrodes were attached to the radial side of dominant forearm. In the active TENS group, TENS was delivered via two electrodes on the venous cannulation site
10007812|NCT01607463|Placebo Comparator|Placebo group|"Two electrodes were attached to the radial side of dominant forearm. In the placebo group the TENS device had no current output although the power on indicator light remained active."
10007813|NCT01607489|Other|pulmonary vascular disease|Dual-energy computed tomography investigation
10007814|NCT01607515|Other|suspected PH|Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
10035401|NCT01805778||Acute Cohort|Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
10007815|NCT01607528|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day
10007816|NCT01607528|Placebo Comparator|Placebo|A similar looking and tasting powder
10007817|NCT01607541|Experimental|Peer-driven intervention|"The PDI entails structured intervention sessions including a computerized CARE for Prevention tool and HIV pre-test and post-test counseling, the opportunity to educate three peers on core education messages, and navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and six months of navigation)"
10007818|NCT01607541|Active Comparator|Control|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
10007819|NCT01607580|Experimental|low-dose glucocorticoid|drug
10007820|NCT01607580|Other|no intervention after transplant|
10007821|NCT01607632|Experimental|loving-kindness meditation|
10007822|NCT01607671|Experimental|Timolol|This group will receive ophthalmic Timolol maleate 0.5%, 1 drop to the effected eye twice daily for 4 weeks.
10007823|NCT01607671|No Intervention|Standard Care|This group will be treated with current standard care. This does not include Timolol or other medications to reduce intraocular pressure.
10007824|NCT01607684|Other|Diabetes mellitus group|Subjects with Diabetes mellitus and symptoms of diabetic gastroparesis
10007825|NCT01607684|Other|Control group|Healthy volunteers as matched pairs according to gender and age
10007826|NCT01607697|Experimental|Mindfulness Training|Group received Mindfulness Training
10007827|NCT01607697|No Intervention|Waitlist Control|Group received Usual Care
10007828|NCT01607710||Generalized Anxiety Disorder|The group of participants diagnosed with generalized anxiety disorder.
10007829|NCT01607710||Nonclinical Control Group|The comparison group of participants with no psychiatric diagnoses.
10007830|NCT01607723|Other|NAVA ventilatory mode|
10007831|NCT01607723|Other|PAV+ ventilatory mode|
10007832|NCT01607736|No Intervention|Inactive Comparator|
10007833|NCT01607736|Experimental|Virtual Gait Training|
10007834|NCT01607749|Experimental|Educational Program|"Students in the intervention schools learn the educational program Asthma, Sport and Health in three sessions during a period of 6 weeks. The content of the educational program has been published elsewhere."
10007835|NCT01607749|No Intervention|Asthma information for teachers|Information about asthma the Ministry of Education to all schools in the community.
10007836|NCT01607762|Experimental|Cohort A: Aripiprazole|
10007837|NCT01607762|Experimental|Cohort B: Quetiapine|
10007838|NCT01607762|Experimental|Cohort C: Olanzapine|
10007839|NCT01607762|Experimental|Cohort D: Risperidone|
10007840|NCT01607762|Experimental|Cohort E: Paliperidone|
10007841|NCT01607775|Active Comparator|PEEK-cage|Patients will receive a PEEK-cage
10007842|NCT01607775|Experimental|PMMA-cage|
10007843|NCT01607801||non-absorbable suture NAS|having their umbilical hernia repaired with NAS
10007844|NCT01607801||Long-term-absorbable suture (LAS)|patients having their umbilical hernia repair with LAS
10007845|NCT01607801||Absorbable sutures (AS)|patients having their umbilical hernia repair with AS
10007846|NCT01607801||Mesh repair|Patients having umbilical hernia mesh repair
10007847|NCT01607814||Cirrhotic Patients|Patients affected by cirrhosis of any etiology and severity
10007848|NCT01607814||Control Group|Subjects age, sex and comorbidities matched
10007849|NCT01607827|Active Comparator|Polyp removal upon insertion and withdrawal|
10007850|NCT01607827|No Intervention|Polyp removal upon withdrawal only|
10007851|NCT01607840|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
10007852|NCT01607840|Experimental|Cathodal|transcranial direct current stimulation using cathodal stimulation over the brain area of interest
10035402|NCT01805778||Survivor Cohort|Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
10007853|NCT01607840|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without actually delivering tDCS
10007854|NCT01607866|Experimental|Quadrant parotidectomy|Patients in this arm will receive excision of the parotid gland quadrant harboring the tumor
10007855|NCT01607866|Active Comparator|Superficial parotidectomy|Patients in this group will receive superficial parotidectomy
10007856|NCT01607879|Experimental|Standard of care ADT + (HMB + AG)|Standard of care androgen deprivation therapy plus the nutritional supplement HMB + arginine + glutamine (AG)
10007857|NCT01607879|Active Comparator|Standard of care ADT|Standard of care androgen deprivation therapy
10007858|NCT01607918|Experimental|Sequential therapy 10 days|Sequential therapy
10007859|NCT01607918|Active Comparator|Triple therapy 14 days|Triple therapy
10007860|NCT01607931|No Intervention|Resting Trial|a 1 hour period of rest immediately prior to OGTT or isoglycemic clamp
10007861|NCT01607931|Experimental|Exercise Trial|a 1 hour cycling exercise bout immediately prior to the OGTT or isoglycemic clamp
10007862|NCT01607944||Normal Glucose Tolerance|
10007863|NCT01607944||Type 2 Diabetes|
10035403|NCT01805804|Placebo Comparator|Placebo|Placebo pills to match valsartan tablets administered once daily
10035404|NCT01805804|Experimental|valsartan 80mg daily|Valsartan 80mg tablet once daily
10035405|NCT01805804|Experimental|valsartan 160mg daily|Valsartan 160mg tablet once daily
10035406|NCT01805817|Experimental|Levonorgestrel releasing intrauterine device, contraception|LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year
10035407|NCT01805817|Experimental|YASMIN® (Drospirenone/Ethinyl Estradiol), contraception|oral, once a day, 1 year
10035408|NCT01805817|Experimental|Copper T 380 A , contraception|intrauterine device, once per 10 year, 1 year period
10035409|NCT01805830|Experimental|MP513 group|
10035410|NCT01805830|Placebo Comparator|Placebo group|
10035411|NCT01805843||chronic meloid leukemia|echo, exercise echo, and if indicated, right heart catheter
10035412|NCT01805856|Experimental|Group A (intervention PIPC)|Patients in group A (intervention PIPC) were given AMP of 2g PIPC intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose PIPC was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
10035413|NCT01805856|Experimental|Group B (intervention CEZ)|Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
10035414|NCT01805856|No Intervention|Group C (without AMP)|Patients in Group C underwent surgery without any AMP.
10035415|NCT01805908|Experimental|111In-Pertuzumab + SPECT-CT|Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
10035416|NCT01805921|Experimental|Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|"Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
10035417|NCT01805921|Experimental|Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|"Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.~Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks."
10035418|NCT01805921|Experimental|Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|"Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
10035419|NCT01805921|Experimental|Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)|"Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
10035420|NCT01805921|No Intervention|Arm 5. No vaccine|Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.
10007864|NCT01607970|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
9667643|NCT03292458|Experimental|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
10007865|NCT01607970|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
10007866|NCT01607983|Experimental|inhaled nitric oxide|
10007867|NCT01607996|Active Comparator|Patient controlled intravenous analgesia|Fentanyl (10 microg/ml) continuous intravenous infusion at a rate of 10 to 20 microg/h
10007868|NCT01607996|Experimental|Epidural anesthesia|Carbostesin (0.1%) and Fentanyl (2 microg/ml) at a continuous flow of 6 to 15 ml/hour
10007869|NCT01608009|Experimental|Pazopanib and paclitaxel|
10007870|NCT01608022|Experimental|PF804|
10007871|NCT01608035|Experimental|sciatic catheter|
10007872|NCT01608035|Active Comparator|Stump catheter|
10007873|NCT01608048|No Intervention|control|
10007874|NCT01608048|Experimental|TEAS|
10007875|NCT01608048|Experimental|EA:electro-acupuncture|
10007876|NCT01608074|Experimental|BRCA mutation carriers|"Women with BRCA1 or BRCA 2 mutation or a family history of breast/ovarian cancer.~Radical fimbriectomy. Histopathology SEE-FIM"
10007877|NCT01608126|Active Comparator|Combined Cervical Block|
10007878|NCT01608126|Active Comparator|Median Cervical Block US guided|
10007879|NCT01608139|Experimental|Curcumin + Sorafenib + Vorinostat|"Participant assigned to a dose level of the study drug combination based on when joined this study. Up to 9 dose levels of the study drug combination will be tested. Three (3) to 6 participants will be enrolled at each dose level of the study drug combination. During first cycle only, Curcumin initiated on Day 1, Vorinostat on Day 3 and Sorafenib on Day 5. Beginning with Cycle 1 Day 5, all agents administered continuously. Cycle of therapy is 28 days.~Starting dose of Curcumin: 4 grams by mouth per day on Day 1. Starting dose of Sorafenib: 200 mg by mouth daily beginning on Day 5. Starting dose of Vorinostat: 100 mg by mouth daily beginning on Day 3."
10007880|NCT01608152||Group I (focus group)|Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.
10007881|NCT01608152||Group II (access to the game)|Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.
10007882|NCT01608165|Other|Partial nephrectomy|Patients randomised to this arm will undergo a partial nephrectomy
10007883|NCT01608165|Other|Radiofrequency ablation|Patients randomised to this arm will undergo radiofrequency ablation
10007884|NCT01608165|Other|cryoablation|Patients randomised to this arm will undergo cryoablation
10007885|NCT01608191|No Intervention|Ordinary primary care follow up|Ordinary follow up after 24 weeks of LCD diet + reintroduction of food.
10007886|NCT01608191|Active Comparator|CBT follow up|11 weeks intervention programme with CBT conducted via internet.
10007887|NCT01608217|Active Comparator|Namisol|Namisol is a tablet containing delta-9-tetrahydrocannabinol, the main cannabinoid from Cannabis sativa L. Namisol is added to a standardized treatment with acetaminophen.
10007888|NCT01608217|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product. Placebo is added to a standardized treatment with acetaminophen.
10007889|NCT01608243|Experimental|SLIT tablets of HDM allergen extracts|
10007890|NCT01608243|Placebo Comparator|Placebo|
10007891|NCT01608256||mild cognitive impairment|men and women, aged 50 to 70. The inclusion criteria are:diagnosis of MCI (given by a neurologist), valid driver's license and driving experience of at least a year. the exclusion criteria are: people diagnosed with other neurological damage such as: dementia, CVA and head injury, people with sensory or motor impairment.
10007892|NCT01608256||Healthy people|Men and women, ages 50-70. the inclusion criteria are: healthy people with out neurological disease or psychiatric illness, have valid driver's license and driving experience of at least a year.
10007893|NCT01608269|Other|ABC/3TC (Epzicom), NRTI|
10007894|NCT01608282|Experimental|OPEN Intervention Group|Intervention group participants will receive an email prompt to access the OPEN website every two weeks for the first three months, with a short message about the ongoing projects at the Arthritis Research Centre of Canada. The OPEN website will remain accessible throughout the study, but no further prompting emails will be sent after Month 3. In addition, they will receive an education pamphlet produced by The Arthritis Society containing information about osteoarthritis, physical activity and other treatments.
10007895|NCT01608282|No Intervention|Control Group|Control group participants will receive, by email, the same Arthritis Society pamphlet as the Intervention group. Participants will also receive, by email, the same short message about the ongoing projects at the Arthritis Research Centre of Canada, every two weeks for the first three months (i.e. the same schedule as the intervention group receiving the prompting email so that the number of contacts is equal in both groups), but without the prompting to use the OPEN website.
10007896|NCT01608334|Experimental|group A|Fentanyl
10007897|NCT01608334|Active Comparator|Group B|Sufentanil
10007898|NCT01608347|Experimental|LMWH + Folic acid group|Daily 40 mg of enoxaparin (LMWH) (Clexane, Sanofi Aventis, Paris, France)subconsciously started once positive pregnancy test. Treatment will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tab once/daily until 13 weeks' of gestation.
10007899|NCT01608347|Active Comparator|Folic acid|500 microgram folic acid tab/day started once positive pregnancy test and will be continued until 13 weeks' of gestation.
10007900|NCT01608360|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
10007901|NCT01608360|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
10007902|NCT01608373|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
9517910|NCT03301792|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
10007903|NCT01608373|Active Comparator|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc.
10007904|NCT01608373|Placebo Comparator|Intravenous normal saline group|The patients in Group C (placebo control group) received normal saline intravenous injection
10007905|NCT01608386|Experimental|anterior approach+IVC clamping|Use anterior approach combined with infrahepatic Inferior Vena Cava clamping in right hepatectomy for HCC patients.
10007906|NCT01608386|No Intervention|anterior approach|Only use anterior approach in right hepatectomy for HCC patients.
10007907|NCT01608399|Experimental|Metacognitive therapy|
10007908|NCT01608399|No Intervention|Waiting list control|
10007909|NCT01608412|Active Comparator|Tacrolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Tacrolimus"
10007910|NCT01608412|Active Comparator|Everolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Everolimus"
10007911|NCT01608425|No Intervention|Control|Control group. Regular treatment.
10007912|NCT01608425|Experimental|Diabetes ulcer monitoring|Receives a telemedicine intervention: Diabetes ulcer monitoring.
10007913|NCT01608438|Experimental|SCI Static|SCI group that practices with a static body-machine map
10007914|NCT01608438|Experimental|SCI Machine Learning|Spinal Cord Injury patients who practice with a body-machine map that is adapted using machine learning
10007915|NCT01608451|No Intervention|No additional treatment|No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
10007916|NCT01608451|Active Comparator|Inj. Proluton|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
10007917|NCT01608451|Active Comparator|Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
10007918|NCT01608451|Active Comparator|Inj. Proluton and Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
10007919|NCT01608464|Active Comparator|Arm A|Arm A: will receive combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
10007920|NCT01608464|Experimental|Arm B|"Arm B will receive combination of cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.~PET scan will be repeated 3-4 weeks after end of concurrent chemo-radiation therapy Patients in Arm A and B will go for esophagectomy 4-6 weeks after end of concurrent chemo-radiation therapy or chemotherapy"
10007921|NCT01608503|Experimental|respiration cycle|lung inflation and deflation
10007922|NCT01608516|Experimental|68Ga-NODAGA-RGD radiotracer|All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.
10007923|NCT01608529|Experimental|Cyclist group|
10007924|NCT01608542|Experimental|Fostamatinib 100mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 100mg single and multiple twice daily doses
10007925|NCT01608542|Experimental|Fostamatinib 200mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 200mg single and multiple twice daily doses
10007926|NCT01608555|Experimental|inhaled tobramycin once-a-day|Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.
10007927|NCT01608568|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
10007928|NCT01608568|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
10007929|NCT01608581|Experimental|exposure to multi-media campaign|A multimedia campaign highlighting dangers of gasoline and fire was delivered to an intervention region in the state of Queensland
10007930|NCT01608594|Experimental|Ipilimumab 10 mg/kg + HDI|Ipilimumab 10 mg/kg + standard dose IFN alpha
10007931|NCT01608594|Experimental|Ipilimumab 3mg/kg + HDI|Ipilimumab 3mg/kg + standard dose IFN alpha
10007932|NCT01608633|Experimental|Spray and stretch|
10007933|NCT01608633|No Intervention|Control|
10007934|NCT01608646|No Intervention|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
10007935|NCT01608685||Renal transplant recipients|Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent
10007936|NCT01608698|Experimental|Belara|The participants who receive OCP in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®).
10007937|NCT01608698|Experimental|Yasmin|The participants who receive OCP in combination of 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®).
10007938|NCT01608711|Experimental|AGS-1C4D4 plus gemcitabine|Subjects will receive a maintenance dose of AGS-1C4D4 every 3 weeks (Q3W) in addition to the gemcitabine administration.
10007939|NCT01608737|Experimental|2. BI 201335 for 24 weeks|BI 201335 once daily low dose for 24 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
10007940|NCT01608737|Experimental|3. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
10007941|NCT01608737|Active Comparator|1. PegIFN/RBV|PegIFN/RBV for 48 weeks in treatment-naive patients
10007942|NCT01608737|Active Comparator|4. PegIFN/RBV|PegIFN/RBV for 48 weeks in prior relapser patients
10007943|NCT01608737|Experimental|5. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in prior relapser patients
10007944|NCT01608750|Experimental|pantoprazole|
10007945|NCT01608750|Placebo Comparator|folic acid|
10007946|NCT01608763|Experimental|Full personalized feedback|Participant provided with the full CYD personalized feedback summary.
10007947|NCT01608763|Experimental|Only normative feedback|Participant provided with just the normative feedback component of the CYD personalized feedback summary.
10007948|NCT01608763|Experimental|Just other personalized feedback|Participant provided with all the other personalized feedback components of the CYD intervention (i.e., no normative feedback).
10007949|NCT01608763|No Intervention|No intervention control|Participant provided with a list describing the components of the CYD intervention but not provided any personalized feedback.
10007950|NCT01608776|Active Comparator|SOC - Standard of Care|Wound cleansing and debridement as needed, moist wound healing dressing, and off-loading
10007951|NCT01608776|Active Comparator|SOC + MIST Therapy|Wound cleansing and debridement as needed, moist wound healing dressing, off-loading, and MIST treatment
10007952|NCT01608789|Experimental|Virtue® Male Sling|Patient implanted Virtue® Male Sling
10007953|NCT01608802|Active Comparator|Standard care|Standard care will be provided to the control group, i.e. existing HIV outpatient multiprofessional care, ART monitoring and adherence support.
10007954|NCT01608802|Experimental|Palliative care|Palliative care delivered by an existing nurse who has been provided with palliative care training, palliative care patient management planning records, and clinical supervision
10007955|NCT01608841|No Intervention|Gemcitabine|
10007956|NCT01608841|Experimental|Gemcitabine plus erlotinib|
10007957|NCT01608854||24 Hour Antibiotics|Patients were randomized to receive 24 hours of postoperative antibiotics following spine surgery
10007958|NCT01608854||Duration Antibiotics|Patients were randomized to receive antibiotics for the duration of time a spinal drain was in place following spinal surgery
10007959|NCT01608880|Placebo Comparator|Polysporin Control|Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
10007960|NCT01608880|Active Comparator|Nitroglycerin|Patients in treatment group will receive nitroglycerin ointment application
10007961|NCT01608893|Active Comparator|Metoprolol|The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.
10007962|NCT01608893|Active Comparator|Carvedilol|The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.
10007963|NCT01608919|No Intervention|diagnostic blood tests|We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
10007964|NCT01608932|No Intervention|Control Group|Treatment as usual
10007965|NCT01608932|Experimental|Telemonitoring for frail patients with chronic diseases|Telemonitoring for frail patients with chronic diseases
10007966|NCT01608945||steroid,liver function I/R|
10007967|NCT01608958|Active Comparator|IV infusion|Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.
10007968|NCT01608958|Active Comparator|IM Injection|Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.
10007969|NCT01608984|Active Comparator|RIPC-CABG|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.
10007970|NCT01608984|Placebo Comparator|Control-CABG|Control group: Coronary artery bypass grafting without RIPC protocol
10007971|NCT01608984|Active Comparator|RIPC-OPCAB|Remote ischemic preconditioning (RIPC) protocol before Off-pump coronary artery bypass surgery (OPCAB) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before first coronary artery incision and 5 to 10 Minutes after completion of the coronary anastomoses. Blood samples are taken up to 72 hours postoperatively.
10007972|NCT01608984|Placebo Comparator|Control-OPCAB|Control group: Off-pump Coronary artery bypass surgery without RIPC protocol
10007973|NCT01609036||Cohort|
10007974|NCT01609049||Participants with Chronic Hepatitis C|Naive and previously treated participants who received peginterferon alfa-2a in combination with ribavirin as per local labeling requirements.
10007975|NCT01609075||Cohort|
10007976|NCT01609088|Experimental|Erythritol-containing beverage|
10007977|NCT01609101|Other|Coopdech® videolaryngoscope|
10007978|NCT01609101|Other|C-MAC® videolaryngoscope|
10007979|NCT01609101|Other|McGrath® Series 5 videolaryngoscope|
10007980|NCT01609101|Other|Glidescope® Cobalt videolaryngoscope|
10007981|NCT01609101|Other|King Vision® videolaryngoscope|
10007982|NCT01609101|Other|Venner® videolaryngoscope|
10007983|NCT01609101|Other|McGrath MAC® videolaryngoscope|
10007984|NCT01609114||control groups|chemotherapy (C/T) is applied in the morning. After 4-6 hrs, RT is delivered (according to the clinical practice).
10007985|NCT01609114||experimental groups|RT is delivered in the morning. After 4-6 hrs, C/T is applied.
10007986|NCT01609127|Experimental|Tesetaxel every 3 weeks|Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle
10007987|NCT01609127|Experimental|Tesetaxel weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle
10007988|NCT01609127|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle
10007989|NCT01609140|Experimental|A|
10007990|NCT01609140|Experimental|B|
10007991|NCT01609140|Experimental|C|
10007992|NCT01609140|Experimental|D|
10007993|NCT01609140|Experimental|E|
10007994|NCT01609140|Placebo Comparator|F|
10007995|NCT01609153|Active Comparator|Olanzapine or Placebo|
10007996|NCT01609153|Active Comparator|Amisulpride or Placebo|
10007997|NCT01609153|Active Comparator|Olanzapine and Amisulpride|
10007998|NCT01609166|Experimental|Allopurinol 3% cream|Allopurinol 3% cream in one side of the body
10007999|NCT01609166|Placebo Comparator|Placebo cream|Placebo cream in the other side of the body
10008000|NCT01609179|Experimental|IPI-926|
10008001|NCT01609192|Experimental|hydroxyurea|
10008002|NCT01609205|Experimental|Arm 1|Adalimumab
10008003|NCT01609244|Active Comparator|Bilevel|Bilevel therapy
10008004|NCT01609244|Active Comparator|Servoventilation|servoventilation therapy
10008005|NCT01609270||CardioRoot|All subjects receive the CardioRoot graft at baseline implant procedure.
10008006|NCT01609283|Experimental|Autologous Mesenchymal Stem Cells|
10008007|NCT01609309|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
10008008|NCT01609309|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
10008009|NCT01609322|Active Comparator|Education about falls|In-person education about falls with a health educator.
10008010|NCT01609322|Experimental|Activity, Balance, Learning, and Exposure|Intervention combining medication review, exercise, home safety evaluation, and exposure therapy.
10008011|NCT01609335|Other|Cognitively Normal Subjects|Study participation will consist of tests of memory and thinking, a MRI, and two PET scans. F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.
10008012|NCT01609361|No Intervention|1: Standard surgery + Standard care|standard surgery and Standard care after surgery
10008013|NCT01609361|Other|2: Laparoscopy + Rehabilitation program|Laparoscopic colorectal surgery with rehabilitation program
10008014|NCT01609374|Experimental|M6-C Artificial Cervical Disc|
10008015|NCT01609374|Active Comparator|Anterior Cervical Discectomy and Fusion|
10008016|NCT01609387|Experimental|Gastric Banding new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
10008017|NCT01609387|Active Comparator|Gastric Banding current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
10008018|NCT01609387|Experimental|RYGB new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients
10008019|NCT01609387|Active Comparator|RYGB current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients)
10008020|NCT01609387|Experimental|Gastric sleeve new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
10008021|NCT01609387|Active Comparator|Gastric sleeve current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
10008022|NCT01609400||Breast enhancement|
10008023|NCT01609413|Experimental|AlgaeCal|Calcium supplements derived from ocean algae. One dose equals 3 capsules containing 180 mg calcium each.
10008024|NCT01609413|Active Comparator|Caltrate 600|Proprietary calcium supplement. One dose contains 600 mg of calcium.
10008025|NCT01609426||children with idiopathic nephrotic syndrome|children below 16 years of age with a steroid dependent nephrotic syndrome
10008026|NCT01609439|Placebo Comparator|Placebo|
10008027|NCT01609439|Experimental|Treatment|Pre-operative Vitamin D 800 units x 4 weeks
10008028|NCT01609452|Experimental|Blisibimod|
10008029|NCT01609452|Placebo Comparator|Placebo|
10008030|NCT01609465||Stable angina|
10008031|NCT01609491|Active Comparator|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) will be used in the syringes
10008032|NCT01609491|Active Comparator|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
10008033|NCT01609504|Experimental|Transanal Endoscopic Microsurgery|Patients were treated by TEM as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT (ELRR- Endo Luminal Loco Regional Resection)
10008034|NCT01609504|Active Comparator|Total Mesorectal Excision|
10008035|NCT01609517||Obese group|patients with BMI >= 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
10008036|NCT01609517||Non-obese group|patients with BMI < 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
10008037|NCT01609530|Active Comparator|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
10008038|NCT01609530|Experimental|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
10008039|NCT01609569||coronary complication|"patients with coronary complication and patients without coronary complications.~pro-calcitonin will be measured in both groups to see if any correlation."
10035421|NCT01805921|Experimental|Arm 6. MVA-RSV (IM)|Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.
10035422|NCT01805921|Experimental|Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.
10035423|NCT01805921|Experimental|Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
10035424|NCT01805921|Experimental|Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
10035425|NCT01805934|Active Comparator|Group RBLF|receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
10008040|NCT01609595|Experimental|Treatment|Study drug treatment
10008041|NCT01609608|Experimental|vibration|
10008042|NCT01609608|Placebo Comparator|placebo|
10008043|NCT01609621||Retrograde access|
10008044|NCT01609634|Active Comparator|Key Group of interest|Subjects who started test product / control product 1 / control product 2 by 1-month of age
10008045|NCT01609634|Active Comparator|Other-fed Group|Subjects who started test product / control product 1 / control product 2 and continued on breast-feeding
10008046|NCT01609634|Active Comparator|Breast Fed Reference Group|Subjects who are exclusively breast-fed up to 4 months of age and not started on test product / control product 1 / control product 2.
10008047|NCT01609647|Experimental|Prasugrel|Reloading with prasugrel 20mg & followed by administration of 5mg/day for 30 days
10008048|NCT01609647|Active Comparator|Clopidogrel|Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
10008049|NCT01609660|No Intervention|Control group|No intervention at all
10008050|NCT01609660|Experimental|Study group|Use of Saccharomyces boulardii, 100mg for at least seven days before surgery
10008051|NCT01609673|No Intervention|Control|"35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.~Medications will be administered orally, twice a day"
10008052|NCT01609673|Active Comparator|Intervention|"35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
10008053|NCT01609699|Experimental|Group A - will undergo 3 successive treatments, 1 week apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
10008054|NCT01609699|Experimental|Group B - will undergo 3 successive treatments, 2 weeks apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
10008055|NCT01609712||Patient with vertebral compression fracture|RF kyphoplasty is standard of care in our hospital for patients with osteoporortic compression fractures. We are intersetd, if it also can improve the lung function.
10008056|NCT01609725|Experimental|Comprehensive treatment|Test treatment group
10008057|NCT01609725|Other|Community treatment|Control treatment group
10008058|NCT01609738||Sinus node dysfunction|Patients with sinus node dysfunction and structurally normal hearts
10008059|NCT01609738||CRT indication|Patients with an indication for CRT (heart failure with an LVEF <35% and LBBB)
10008060|NCT01609751|Experimental|Yakult 62 ml daily|
10008061|NCT01609764|Experimental|Exercise|Follows the fitness program as described in the intervention
10008062|NCT01609764|No Intervention|Control|Will not follow any regular fitness activity during one year
10008063|NCT01609777|Other|Handover with SBAR|Handover with handover tool.
10008064|NCT01609803||Correlative studies|Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and protein overexpression by FISH and IHC.
10008065|NCT01609816|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months
10008066|NCT01609855|Experimental|HBB- Hioscine Butyl Bromide|
10008067|NCT01609855|Placebo Comparator|Placebo arm|
10008068|NCT01609868|Active Comparator|control|infants in this arm will receive the current treatment that is standard of care for these infants, powder protein modular to achieve 4 gm/kg/day
10008069|NCT01609868|Experimental|experimental|this group will receive a liquid protein modular that recently became commercially avaliable, to achieve the same protein of 4 grm/kg/day as the powder comparision group
10008070|NCT01609881|Other|Acuvail|Acuvail as preventive for inflammation and possible decrease or prevent diabetic retinopathy. The study has four arms - diabetic ketorolac, diabetic control, normal eyes ketorolac, normal eyes control. patients are randomized to ketorolac or control.
10008071|NCT01609881|Placebo Comparator|Placebo|Placebo using artificial tear drops
10008072|NCT01609894|Experimental|Individualized fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
10035426|NCT01805934|Active Comparator|Group RA|receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
10008073|NCT01609894|Active Comparator|Routine fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches."
10008074|NCT01609907|Experimental|Sequence 1|
10008075|NCT01609907|Experimental|Sequence 2|
10008076|NCT01609907|Experimental|Sequence 3|
10008077|NCT01609907|Experimental|Sequence 4|
10008078|NCT01609907|Experimental|Sequence 5|
10008079|NCT01609907|Experimental|Sequence 6|
10008080|NCT01609920|Experimental|Gadofosveset MRL|
10008081|NCT01609959|Active Comparator|Azilsartan group|
10008082|NCT01609959|Active Comparator|Valsartan group|
10008083|NCT01609972|Experimental|Test|Subjects randomized to this arm will be trialed and implanted with the Nevro Senza System
10008084|NCT01609972|Active Comparator|Control|Subjects randomized to this arm will be trialed and implanted with a commercially available SCS system.
10008085|NCT01609998|Experimental|Group 1A (12-17yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
10008086|NCT01609998|Experimental|Group 1B (6-11yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
10008087|NCT01609998|Experimental|Group 2A (12-17yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
10008088|NCT01609998|Experimental|Group 2B (6-11yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
10008089|NCT01609998|Active Comparator|Group 3A: (12-17yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
10008090|NCT01609998|Active Comparator|Group 3B: (6-11yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
10008091|NCT01610024|Active Comparator|Beetroot|
10008092|NCT01610050|Experimental|LFA102|
10008093|NCT01610089|Experimental|stable isotope infusion|Infusion of isotopes [15N2-ureido] arginine, [5-13C,4, 4, 5, 5-D4] citrulline, [15N]citrulline, 15N sodium nitrate and [15N][18O3] potassium nitrate,[18O][13C]urea.
10008094|NCT01610128||chronic urticaria patients|all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
10008095|NCT01610141|Experimental|Genotype-guided warfarin dosing|A pharmacogenetic dosing algorithm including clinical factors and genotype information (VKORC1, CYP2C9 and CYP4F2) will be used to determine warfarin doses.
10008096|NCT01610141|Active Comparator|Non-genotype guided warfarin dosing|A fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
10008097|NCT01610180|Other|Eltrombopag Olamine|Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count
10008098|NCT01610193||Right sided abdominal pain|Patients that present at the Emergency Department with abdominal pain and a clinical suspicion of appendicitis.
10008099|NCT01610219|Active Comparator|Lifestyle Modification for Diabetes Prevention|Family based intervention utilizing Traffic Light Diet, self monitoring, parent behavioral skill training and tool kit of items promoting physical activity.
10008100|NCT01610219|Other|Nutrition and Physical Activity|Family based intervention providing education on healthy eating and physical activity but no behavioral skills training, goal setting, self monitoring or physical activity toolkit.
10008101|NCT01610232|Experimental|LED Group|Phototherapy associated with treadmill training
10008102|NCT01610232|Active Comparator|Exercise Group|Treadmill training
10008103|NCT01610232|No Intervention|Sedentary Group|Neither physical training nor phototherapy
10008104|NCT01610310|Experimental|peginterferon beta-1a PFS/autoinjector|A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.
10008105|NCT01610310|Experimental|peginterferon beta-1a autoinjector / PFS|A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.
10008106|NCT01610323|Experimental|Exercise group|Exercise intervention
10008107|NCT01610323|Other|Control group|Standard care
10008108|NCT01610362|Active Comparator|5-dose IM rabies vaccines, HRIG 20 IU/kg|Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg
10008109|NCT01610362|Experimental|5-dose IM rabies vaccines, HRIG 40 IU/kg|Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg
10008110|NCT01610375|Other|Telephone Follow-up|Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up. However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up. Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
10008111|NCT01610388|Experimental|Cohort A1|Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
10008112|NCT01610388|Experimental|Cohort A2|Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
10008113|NCT01610388|Experimental|Cohort B|Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days
10008114|NCT01610388|Experimental|Cohort C|Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days
10008115|NCT01610388|Experimental|Cohort D|Single dose 2000mg IV GSK1322322J/placebo
10008116|NCT01610388|Experimental|Cohort E|Single dose 3000mg IV GSK1322322J/placebo
10008117|NCT01610388|Experimental|Cohort F|1000mg IV GSK1322322J/placebo followed by BID for 4 days
10008118|NCT01610401|Active Comparator|Pretreatment with metformin|Pretreatment with metformin 500 mg three times a day for 3 days.
10008119|NCT01610401|No Intervention|No pretreatment.|no intervention
10008120|NCT01610401|Active Comparator|Pretreatment with Metformin/caffeine|to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion
10008121|NCT01610401|Other|No metformin, only pretreatment with caffeine|No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).
10008122|NCT01610440|Experimental|Intervention Group|Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
10008123|NCT01610466|Experimental|Curriculum training group|Surgical residents in the curriculum training group will complete the entire curriculum. They will participate in a cognitive component, which will consist of self-directed readings and a faculty-led seminar. Participants will also train to proficiency in laparoscopic jejunojejunostomy and gastrojejunostomy using a laparoscopic box trainer with cadaveric porcine bowels. Finally, for the non-technical skills component participants will participate in an introductory lecture on non-technical skills in surgery, as well as a practice crisis scenario with a debriefing session.
10008124|NCT01610466|No Intervention|Conventional training group|Participants in the conventional training group will proceed through surgical residency training in the usual fashion.
10008125|NCT01610479|Experimental|TAS-114/S-1|TAS-114 plus S-1
10008126|NCT01610518|Experimental|250 mL medium viscosity|250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
10008127|NCT01610518|Experimental|600 mL low viscosity|600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
10008128|NCT01610518|Experimental|250 mL high viscosity|250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
10008129|NCT01610518|Experimental|600 mL medium viscosity|600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
10008130|NCT01610518|Placebo Comparator|250mL control|250 mL beverage containing 50g glucose
10008131|NCT01610518|Placebo Comparator|600mL control|600mL beverage containing 50g glucose
10008132|NCT01610609|Experimental|Population Health Management Intervention|Participants randomized to this arm will receive the population health management intervention.
10008133|NCT01610609|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
10008134|NCT01610635|Experimental|Male - 8 weeks|Male donors assigned to an 8 week donation interval frequency
10008135|NCT01610635|Experimental|Male - 10 weeks|Male donors assigned to 10 week donation interval frequency
10008136|NCT01610635|No Intervention|Male - 12 weeks|Male donors assigned to 12 week donation interval frequency
10008137|NCT01610635|Experimental|Female - 12 weeks|Female donors assigned to 12 week donation interval frequency
10008138|NCT01610635|Experimental|Female - 14 weeks|Female donors assigned to 14 week donation interval frequency
10008139|NCT01610635|No Intervention|Female - 16 weeks|Female donors assigned to 16 week donation interval frequency
10008140|NCT01610648||Patients presenting for a diagnostic sleep study|Patients presenting to the TMC sleep center for sleep study
10008141|NCT01610661|Other|Unrefined-carbohydrate|unrefined carbohydrate diet
10008142|NCT01610661|Other|Refined-carbohydrate|refined carbohydrate diet
10008143|NCT01610661|Other|Simple-carbohydrate|simple carbohydrate diet
10008144|NCT01610674|Experimental|Tailored improvement strategy|In 3 hospitals a tailored strategy to improve perioperative diabetes care is performed
10008145|NCT01610674|No Intervention|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals
10008146|NCT01610726|Active Comparator|enhanced recovery|
10008147|NCT01610726|No Intervention|conventional recovery|
10008148|NCT01610739|Other|Median nerve perfusion|Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
10008149|NCT01610765|Active Comparator|Novel Antiviral Drug|Subjects will be randomized to receive one of 3 oral doses of a Novel Antiviral Drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
10008150|NCT01610765|Placebo Comparator|Placebo|Subjects will be randomized to receive one of 3 oral doses of placebo matched in volume to active drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
10008151|NCT01610778|Placebo Comparator|Placebo|
10008152|NCT01610778|Experimental|Supplement|
10008153|NCT01610804||CSCR-Patients|Patients suffering from Central Serous Chorioretinopathy
10008154|NCT01610804||Healthy Subjects|Healthy subjects with (assumed) normal choroidal thickness
10008155|NCT01610817||Patients with the InPAct intervention|The InPAct intervention will be presented to the last patients recruited by each general practitioner
10008156|NCT01610817||Patients without the InPAct intervention|The InPAct intervention will not be presented to the first patients recruited by each general practitioner
10008157|NCT01610830||Group A|have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (<5 RBCs per mm3), the absence of proteinuria (proteinuria <0.1 g/24h) and the absence of renal dysfunction (MDRD> 80 ml / min).
10008158|NCT01610830||group B|"HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:~Group B1 patients with moderate renal disease if renal biopsy was not indicated or no evidence of histologic severity in renal biopsy (histological classification class 1 or 25)~Group B2 patients with severe renal impairment, with signs of histological severity in renal biopsy (class 3, 4 or 5)."
10008159|NCT01610856|Experimental|PEG - 4 L|4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
10008160|NCT01610856|Active Comparator|Split Dose PEG|4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy
10008161|NCT01610869|Experimental|Cyclophosphamide and BIBF-1120|Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
10008162|NCT01610869|Placebo Comparator|Cyclophosphamide and placebo|Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
10008163|NCT01610882|Other|Panda first|Panda evaluation of post-operative pain first, followed by manual method of pain assessment.
10008164|NCT01610882|Other|Manual first|Manual evaluation of post-operative pain first followed by Panda pain assessment.
10008165|NCT01610895|Active Comparator|Split-dose PEG Based Lavage (2L + 2L) + Low-fiber Diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast, a low-fibre lunch by 2PM and then drink only clear fluids until after the procedure is completed.
10008166|NCT01610895|Placebo Comparator|Split-dose PEG Based Lavage (2L + 2L) + Clear fluid diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast and then drink only clear fluids until after the procedure is completed.
10008167|NCT01610908|Experimental|Schroth exercises|The experimental group receives the Schroth exercises treatment.Patients in this arm receive 5 individual sessions with a Schroth therapist for introduction to the approach. They they receive a home program consisting of 3-4 exercises to do at home everyday for 30-45 minutes. They come to weekly group therapy sessions to where exercise prescription is adjusted.
9963714|NCT01231568|Experimental|Cohort 1 Treatment Sequence 2|Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
9963715|NCT01231568|Experimental|Cohort 2 Treatment Sequence 1|Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
9963716|NCT01231568|Experimental|Cohort 2 Treatment Sequence 2|Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
9963717|NCT01231594|Experimental|Cohort A|Subjects who have received </= 8 weeks of GSK2118436 monotherapy in the parent study
9963718|NCT01231594|Experimental|Cohort B|Subjects who have received >8 weeks of continuous treatment with GSK2118436 either as monotherapy or combination therapy with another approved anti-cancer agent
9963719|NCT01231594|Experimental|Cohort C|Subjects who have received >8 weeks of continuous treatment with GSK2118436 in combination with a MEK inhibitor, GSK1120212
9963720|NCT01231672||Septic shock patients|
9963721|NCT01231685|Active Comparator|ritonavir-boosted protease inhibitor|
9963722|NCT01231685|Experimental|Raltegravir|
9963723|NCT01231698|Experimental|esmolol|
9963724|NCT01231698|Other|control|
9963725|NCT01231711|Experimental|Vets Prevail|N=50. Participants were recent veterans (deployed after September 11, 2001) of operations in Iraq and Afghanistan who were experiencing depression/distress symptoms at the time of screening (CES-D > 8) but who were not considered to be inappropriate for a health promotion intervention (CES-D > 35 indicating severe depressed mood or exhibiting self-harm risk).
9963726|NCT01231724|Active Comparator|Allstate Nasal Spray|
9963727|NCT01231724|Placebo Comparator|Placebo Nasal Spray|
9963728|NCT01231737|Active Comparator|Prulifloxacin|
9963729|NCT01231763||Healthy volunteers|
9963730|NCT01231776|No Intervention|control group|
9963731|NCT01231776|Active Comparator|acupuncture preoperative|acupuncture before operation for one week
9963732|NCT01231776|Active Comparator|acupuncture in hospital|acupuncture all the time in hospital
9963733|NCT01231789|Sham Comparator|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
9963734|NCT01231789|Experimental|RIPC treatment|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
9963735|NCT01231802|Experimental|Arm 1: Eniluracil/5-FU/Leucovorin|Arm 1: (weekly, 28-day cycle): Approximately eighty subjects will orally self-administer eniluracil approximately 13 hr (range of 11-16 hr) before receiving 5 FU and leucovorin. The next day they will orally self-administer 5-FU and leucovorin. On the third day, they will orally self-administer leucovorin. The regimen is taken once per week for three consecutive weeks followed by one-week off-treatment.
9963736|NCT01231802|Active Comparator|Arm 2: Capecitabine|Arm 2: (bid daily, 21-day cycle): Approximately sixty subjects will self-administer oral capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
9963737|NCT01231815|Experimental|PET|15O-H2O PET
9963738|NCT01231815|Experimental|MRI|MRI
9963739|NCT01231828|Experimental|Carnitine|Versus placebo.
9963740|NCT01231828|Experimental|Lactulose|Versus placebo
9963741|NCT01231854|Active Comparator|Ciclosporingroup|
9963742|NCT01231854|Active Comparator|Alitretinoingroup|
9963743|NCT01231880|Experimental|Four monthly IPT|IPT give once a school term (every four months)
9963744|NCT01231880|Experimental|Monthly IPT|IPT given every month
9963745|NCT01231880|Placebo Comparator|Placebo|No active drug in the placebo
9963746|NCT01231893|Experimental|olfactory ensheathing cell recipient|
9963747|NCT01231893|Active Comparator|control|
9963748|NCT01231919|Experimental|Treatment (Akt inhibitor)|Patients receive oral Akt inhibitor MK2206 every other day (schedule 1) OR once weekly (schedule 2) on days 1-28. Treatment repeats every 28 days for up 12 courses (1 year) in the absence of disease progression or unacceptable toxicity.
9963749|NCT01231997|Experimental|Healthy Volunteers|
9963750|NCT01231997|Experimental|Patients with mild renal impairment|
9963751|NCT01231997|Experimental|Patients with moderate renal impairment|
9963752|NCT01231997|Experimental|Patients with severe renal impairment|
9963753|NCT01232010|Experimental|Healthy Volunteers|
9963754|NCT01232010|Experimental|Patients with severe renal impairment|
9963755|NCT01232023|Experimental|100mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
9963756|NCT01232023|Experimental|200mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
9963757|NCT01232023|Experimental|400mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
9963758|NCT01232023|Experimental|800mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
9963759|NCT01232036|Active Comparator|A|Reference
9963760|NCT01232036|Experimental|B|Test
9963761|NCT01232036|Placebo Comparator|C|Placebo
9963762|NCT01232049|Experimental|A|Pitavastatin 4mg
9963763|NCT01232049|Experimental|B|Valsartan 320mg
9963764|NCT01232049|Experimental|C|Pitavastatin 4mg + Valsartan 320mg
9963765|NCT01232075|Experimental|Extended letrozole regimen|
9963766|NCT01232075|Active Comparator|Clomiphene citrate regimen|
9963767|NCT01232088||Data collection group: ICU physicians|Online survey for ICU physicians (members of the European Society of Intensive Care Medicine (ESICM)).
9963768|NCT01232101|Active Comparator|covered self expandable metallic stents|Patients with bile malignant bile duct strictures are randomized to covered or uncovered stent
9963769|NCT01232101|Active Comparator|Uncovered self expandable metallic stent|
9963770|NCT01232140|Experimental|CRP-guided antibiotic treatment|If CRP> 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment is withheld.
9963771|NCT01232140|Other|GOLD strategy-antibiotic treatment|According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.
9963772|NCT01232153|Active Comparator|NIV preoxygenation|
9963773|NCT01232153|No Intervention|Classical preoxygenation|
9963774|NCT01232166|Experimental|Endobronchial Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
9963775|NCT01232166|Active Comparator|Endobronchial Intubation, Observation|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
9963776|NCT01232166|Active Comparator|Endobronchial intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
9963777|NCT01232166|Active Comparator|Endobronchial intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
9963778|NCT01232166|Experimental|Endotracheal Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the trachea, 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
9963779|NCT01232166|Active Comparator|Endotracheal Intubation, observation|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5-3cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
9963780|NCT01232166|Active Comparator|Endotracheal intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5 - 4 cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
9963781|NCT01232166|Active Comparator|Endotracheal intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
9963782|NCT01232179|Active Comparator|conventional prp|
9963783|NCT01232179|Active Comparator|targeted PRP|
9963784|NCT01232192|No Intervention|Antenatal model|
9963785|NCT01232192|Experimental|Antenatal Model|
9963786|NCT01232218|Active Comparator|Current Standard Treatment|Current standard treatment for hemiplegic shoulder pain will be provided to this group.
10008168|NCT01610908|No Intervention|Standard of care|"The Standard of care is a control group that will continue receiving the standard North American treatment prescribed by a surgeon (observation or brace [if meeting SRS criteria]) for of 6 months. After 6 months, the participants will receive the Schroth exercises intervention for 6 months."
10008169|NCT01610908|Active Comparator|Global Postural Re-education (Montréal)|"The active group (in Montréal only) receives the Global Postural Re-Education exercises treatment.Patients in this arm come to weekly individual 1 hour long therapy sessions where exercise prescription is adjusted. Selection of posture exercises is based on scoliosis type, on muscular chain stiffness associated with posture alterations and on position increasing scoliosis or pain (lying, sitting, standing).~They they receive a 15-min home program consisting of 1 to 2 exercises to do at home everyday."
10008170|NCT01610921|Experimental|bronchial provocationtest|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
10008171|NCT01610934|Experimental|liraglutide|
10008172|NCT01610934|Active Comparator|glimepiride|
10008173|NCT01610947|Active Comparator|Maintain|Continuation of usual treatment with fixed intervals according to standard recommendations
10008174|NCT01610947|Active Comparator|Spacing|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.
10008175|NCT01610960|Active Comparator|HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
10008176|NCT01610960|Sham Comparator|Facemask|The facemask will be used by each patient.
10008177|NCT01610973|Experimental|Manual preparation|Manual preparation of the graft
10008178|NCT01610973|Active Comparator|Automatized preparation|Automatized preparation of the graft with microkeratoma
10008179|NCT01610986|Experimental|Glucose-fructose|Participants will take glucose-fructose drinks during training sessions
10008180|NCT01610986|Experimental|Water|Participants will take only water during training sessions
10008181|NCT01610999|Experimental|Cohort A|0.24 mg/kg plerixafor on day 1
10008182|NCT01610999|Experimental|Cohort B|0.24 mg/kg plerixafor daily on days 1 & 2
10008183|NCT01610999|No Intervention|Cohort C|"Six control subjects will have research bloods drawn but receive no plerixafor."
10008184|NCT01611038|Placebo Comparator|Placebo|Placebo given daily
10008185|NCT01611038|Experimental|Methylselenocysteine|Methylselenocysteine given daily
10008186|NCT01611051|Experimental|Pegylated rhG-CSF: 100µg/kg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
10008187|NCT01611051|Experimental|Pegylated rhG-CSF: 6mg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 6mg
10008188|NCT01611051|Active Comparator|rhG-CSF 5ug/kg/day|Chemtherapy naive patients receiving chemotherapy and rhG-CSF 5ug/kg/day
10008189|NCT01611064|Active Comparator|Oxygen|Volunteer receives oxygen at a rate of 10litres/minute by mask
10008190|NCT01611064|Placebo Comparator|Air|Volunteer receives normal air at a rate of 10litres/minute by mask
10008191|NCT01611077|Other|Single Arm|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
10008192|NCT01611103|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS
9963787|NCT01232218|Experimental|Standard treatment + study technique|Participants will receive current standard treatment for hemiplegic shoulder pain PLUS an additional stretching/strengthening technique. Both groups will be allotted the same treatment time.
9963788|NCT01232231|Active Comparator|decolonization treatment|topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
9963789|NCT01232231|Other|education|No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning
9963790|NCT01232244||Healthy young males|
9963791|NCT01232257|Experimental|Healthy volunteers|
9963792|NCT01232257|Experimental|CKD patients|Patients with CKD stage 3-4 (GFR 15-60 ml/min)
9963793|NCT01232257|Experimental|Hemodialysis patients|
9963794|NCT01232257|Experimental|Peritoneal dialysis patients|
9963795|NCT01232270|Active Comparator|fentanyl|
9963796|NCT01232270|Placebo Comparator|saline|
9963797|NCT01232309|Active Comparator|High Dose Chitin-Glucan|Daily oral dose of 4.5 g of chitin-glucan
9963798|NCT01232309|Active Comparator|Low Dose Chitin-Glucan|Daily oral dose of 1.5 g chitin-glucan
9963799|NCT01232309|Experimental|Low Dose Chitin-Glucan + Olive Extract|Daily oral dose of 1.5 g chitin-glucan + 135 mg olive extract
9963800|NCT01232309|Placebo Comparator|Placebo|Placebo (Rice Flour)
9963801|NCT01232322||Pulmicort Respules|Those with an exposure
9963802|NCT01232348||Symbicort|Those with an exposure
9963803|NCT01232361||Methylphenidate|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
9963804|NCT01232361||Amphetamine / dextroamphetamine|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
9963805|NCT01232374|Experimental|Nimotuzumab plus chemo-irradiation|Nimotuzumab，chemotherapy(cisplatin )，radiotherapy
9963806|NCT01232374|Placebo Comparator|Placebo plus chemo-irradiation|Placebo，chemotherapy(cisplatin)，radiotherapy
9963807|NCT01232387||Fetomaternal hemorrhage - Mothers|Mothers in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
9963808|NCT01232387||Fetomaternal hemorrhage - Babies|Babies in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
9963809|NCT01232400|Experimental|esmolol|Esmolol will be used preferentially to control hypertension.
9963810|NCT01232400|No Intervention|Standard care|Standard care for SAH includes other hypertensives such as nicardipine.
9963811|NCT01232413|Placebo Comparator|Treatment A|Placebo
9963812|NCT01232413|Experimental|Treatment B|ASP1941 low dose
9963813|NCT01232413|Experimental|Treatment C|ASP1941 high dose
9963814|NCT01232413|Active Comparator|Treatment D|Moxifloxacin
10008193|NCT01611103|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
10008194|NCT01611129|Active Comparator|reading about hearing loss and its management|General self-reading reading about hearing loss and its management This would run for 30 days and the participants have to manage their own time.
10008195|NCT01611129|Experimental|Internet-based counseling|This would involve 4 stages of designated internet sessions and additional tasks which the patients can complete in their own time. This programme should be completed within 30 days.
10008196|NCT01611142|Experimental|KW-0761|
10008197|NCT01611168|No Intervention|Usual Care|
10008198|NCT01611168|Experimental|Intervention Group, treatment algorithms|
10008199|NCT01611181|Active Comparator|Hemoboost (iron supplementation)|A registered natural product containing specially haemolysed haemoglobin and iron dextran.
10008200|NCT01611181|Active Comparator|Kräuterblut (iron supplementation)|A registered natural product made from a number of herbs with ferrous gluconate as the active substance.
10008201|NCT01611181|Active Comparator|Ferrofumerat (iron supplementation)|Ferrous sulphate
10008202|NCT01611207|Experimental|Negative Pressure Wound Therapy|Used therapy systems
10008203|NCT01611207|Active Comparator|Standard Conventional Wound Therapy|Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
10008204|NCT01611220|No Intervention|Control|Standard cognitive behavior inpatient treatment
10008205|NCT01611220|Experimental|RePAN|Standard cognitive behavior inpatient treatment plus 8 dissonance relapse prevention groups
10008206|NCT01611233||DePuy ASR THA|Adults having received a Depuy ASR metal on metal hip system which is subject to a voluntary recall.
10008207|NCT01611246||Anesthetization|Anesthetization
9963815|NCT01232426|Experimental|Operative|operative treatment of a Mallet fracture with a biodegradable Meniscus Arrow®
9963816|NCT01232426|Active Comparator|Conservative|Conservative treatment of a Mallet fracture with a Mallet splint
9963817|NCT01232439|Experimental|opioid receptor kappa antagonist|
9963818|NCT01232478|Experimental|Comprehensive Adherence Program (CAP)|The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
9963819|NCT01232478|Experimental|Standard Care (SC)|Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
9963820|NCT01232530||Safety Active Surveillance Group|For the active surveillance, all age groups, including children less than 5 years of age, will be identified from the census database and encouraged to attend the health facility whenever sick. Those with a diagnosis of malaria and treated with an antimalarial drug will be actively monitored for AEs.
9963821|NCT01232530||Safety Passive Surveillance Group|For the people under passive surveillance, sick subjects attending the health facilities, diagnosed with malaria and treated with an antimalarial drug will be identified from the census database. The treatment administered will be recorded in a drug exposure log book and the patients will be encouraged to report passively any AE/ADR.
9963822|NCT01232530||Early Pregnancy Exposure to ACTs Group|All the pregnant women identified during the repeat surveys will be included in a pregnancy cohort. At the time the pregnant woman is identified, her possible exposure to ACTs will be extracted from the drug exposure log book or elicited by history. Births identified through the repeat surveys or any other outcome of pregnancy will be retrospectively matched with antimalarial treatment exposure, particularly during the first trimester of the pregnancy.
10008208|NCT01611272||1|Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
10008209|NCT01611285||Robotic Sacrocolpopexy patients|Patients who underwent Robotic Sacrocolpopexy to treat pelvic organ prolapse between 2009 and 2010
10008210|NCT01611285||UPHOLD patients|Patients who underwent the UPHOLD procedure to treat pelvic organ prolapse from 2009-2010.
10008211|NCT01611311|Experimental|BI 409306 BS medium dose|Film-coated tablet
10008212|NCT01611311|Experimental|BI 409306 BS high dose|Film-coated tablet
10008213|NCT01611311|Placebo Comparator|Placebo|Film-coated tablet
10035427|NCT01805947||Lifestyle Modification|"All patients with chronic pain conditions participate in a 8-weeks structured group program. Detailed information on the mindfulness based program can be found in the publication by Paul, A. et al. An Integrative Day Care Clinic for chronically ill patients: Concept and case presentation in the European Journal of Integrative Medicine, 2012, 4(4):e455-e459."
10035428|NCT01805960|Experimental|Canakinumab|1 s.c. injection of canakinumab 150mg directly after cardioversion
10035429|NCT01805960|Placebo Comparator|Placebo|1 s.c. injection directly after cardioversion
10035430|NCT01805973|No Intervention|Control|Standard pre-operative care, no active intervention
10035431|NCT01805973|Experimental|Exercise Training|"Supervised Exercise Training Programme Patients will be required to attend three 50 minute exercise sessions per week for 18 weeks. They will exercise in groups of 8-12 and will be supervised by an experienced exercise physiologist. Each session will comprise a 15 minute warm up, 30 minutes of moderate intensity aerobic exercise followed by a 10 minute cool down period.~The patients will have the option to choose from three different exercise programmes tailored to individuals of mixed abilities (and co-morbidities)."
10035432|NCT01805986||MS patient|
9476679|NCT03569384|Experimental|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
9476680|NCT03569384|Active Comparator|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
10035433|NCT01805999|Experimental|7 g Ispaghula|Volunteer will take 7 g of ispaghula 3 times daily for one week
10035434|NCT01805999|Placebo Comparator|7 g placebo|Volunteer will take 7 g of a placebo 3 times a day for one week
10035435|NCT01805999|Active Comparator|3.5g ispaghula + 3.5 g placebo|Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
10035436|NCT01806012|Experimental|Enseal|Tissue sealing with Enseal device
10035437|NCT01806012|Active Comparator|Supracervical hysterectomy using conventional instruments|Supracervical hysterectomy using conventional instruments
10035438|NCT01806025||Cystic Fibrosis Patients|Patients with Cystic Fibrosis with two known severe (class I and class II) mutations
10035439|NCT01806038|Experimental|RPh Counseling + Outpatient Dispensing|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist.
10035440|NCT01806038|Active Comparator|Routine Med Dispensing + Counseling|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
10035441|NCT01806077|Experimental|PZ-128|
10035442|NCT01806090|Active Comparator|Clopidogrel|Continue clopidogrel for 7 days prior to the endoscopic procedure
10035443|NCT01806090|Placebo Comparator|Placebo|Placebo daily for 7 days prior to the endoscopic procedure
10035444|NCT01806103|Experimental|Antimicrobial Stewardship Bundle|"An intervention bundle to reduce outpatient antibiotic use in children will include education, creation of and access to guidelines, and audit of and feedback on individual prescribing within the context of achievable benchmarks."
10035445|NCT01806103|No Intervention|Control|Control sites will be within strata to maintain balance of treatment arm within strata
10035446|NCT01806116|Experimental|decitabine + transplantation|
10035447|NCT01806129|No Intervention|Arm A (no intervention)|Patients undergo usual standard practice related to reproductive health.
10035448|NCT01806129|Experimental|Arm B (reproductive health program)|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
10035449|NCT01806142|Experimental|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
10008214|NCT01611324|Experimental|Alkalinised anesthetic solution|
10008215|NCT01611324|Active Comparator|Non alkalinised anesthetic solution|
10008216|NCT01611337|Other|insight evaluation|insight evaluation using the Q8 scale
10008217|NCT01611350|Experimental|Health Marketing Message|Marketing message focused on health effects of cooking with wood on a three stone fire.
10008218|NCT01611350|Experimental|Savings Marketing Message|Marketing message focused on savings (both time and money) related to using an energy efficient cookstove.
10008219|NCT01611350|Experimental|Savings and Health Marketing Messages Combined|One group will receive both the savings and health marketing messages.
10008220|NCT01611350|Experimental|Novel Sales Offer|This group will receive a free trial and time payments when purchasing an energy efficient cookstove.
10008221|NCT01611350|Experimental|Early vs. Late Buyers|Of those who accept the Novel Sales Offer, half the buyers will randomly be selected to start their free trial within a few weeks of the sales meeting, while the other half- the late buyers- will start their free trial a within 2 months of the sales meeting.
10008222|NCT01611363|Experimental|Part A|Ipragliflozin (low dose) & Placebo
10008223|NCT01611363|Experimental|Part B|Ipragliflozin (high dose)
10008224|NCT01611389|Experimental|Long AV delay.|
10008225|NCT01611389|Active Comparator|Short AV delay.|
10008226|NCT01611415|Experimental|ipragliflozin|
10008227|NCT01611415|Experimental|furosemide|
10008228|NCT01611415|Experimental|ipragliflozin & furosemide|
10008229|NCT01611428|Experimental|Ipragliflozin - oral|open label
10008230|NCT01611428|Experimental|Ipragliflozin - i.v.|open label
10008231|NCT01611441||Patients with osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery.
10008232|NCT01611467|Experimental|20 mg oral CC-223 with microtracer|A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution
10008233|NCT01611467|Experimental|20 mg oral CC-223 fasting|A single 20-mg oral dose of CC-223 tablet under fasting conditions
10008234|NCT01611467|Experimental|20 mg oral CC-223 fed|A single 20-mg oral dose of CC-223 tablet under fed conditions
10008235|NCT01611493|Experimental|Osseotite Prevail Implant|The Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure.
10008236|NCT01611493|Active Comparator|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
10008237|NCT01611506|Experimental|Cetuximab, capecitabine, cisplatin based chemoradiation|"Induction chemotherapy:~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.~Followed by:~Radio-chemo-immunotherapy:~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week~Surgery:~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy~Postoperative treatment:~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator."
10008238|NCT01611519||Early (within 48 hours of surgery)|Patients will have their urinary catheter removed within 48 hours of surgery
10008239|NCT01611519||Late (6 hours after epidural removal)|Patients will have their urinary catheter removed 6 hours after their epidural is removed
10008240|NCT01611532||Acute pancreatitis|All adult patients (>18y.o.) requiring admission for acute pancreatitis (amylase >3 times the upper limit of normal and typical symptoms of abdominal pain and vomiting)
10008241|NCT01611545||Clopidogrel|Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
10008242|NCT01611584|Experimental|ALA|No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.
10008243|NCT01611610|Other|Ambulant SMA|
10008244|NCT01611610|Other|Non-ambulant SMA|
10008245|NCT01611623|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation based on safety outcomes
10008246|NCT01611649|Experimental|Dairy lipids and plant oils|
10008247|NCT01611649|Experimental|Plant oils|
10008248|NCT01611649|Experimental|Dairy lipids and plant oils, DHA+ARA|DHA: docosahexaenoic acid, ARA: arachidonic acid
10008249|NCT01611649|No Intervention|Human milk|
10008250|NCT01611675|Experimental|Treatment Arm|Leflunomide + Vemurafenib
10008251|NCT01611688|Experimental|Active|
10008252|NCT01611688|Placebo Comparator|Placebo|
10008253|NCT01611701|Active Comparator|Cryoballoon group|
10008254|NCT01611701|Active Comparator|RF group|
10008255|NCT01611714|Experimental|Audit-feedback|Arm 1: Audit-feedback only
10008256|NCT01611714|Experimental|CDS message|Arm 2: CDS message only
10008257|NCT01611714|Experimental|Both Interventions|Arm 3: Audit-feedback and CDS message
10008258|NCT01611714|No Intervention|Control|Arm 4: Control
10008259|NCT01611727|Experimental|Cisplatin|
10008260|NCT01611740||Preterm infants|Telemonitoring system prototype developed by INSERM U-642
10008261|NCT01611753|Active Comparator|liberal group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL.
10008262|NCT01611753|Active Comparator|restrictive group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 7.0 g/dL.
10008263|NCT01611766|Experimental|secondary cytoreductive surgery|SCR followed by chemotherapy
10008264|NCT01611766|Active Comparator|Salvage Chemotherapy|platinum-based chemotherapy
10008265|NCT01611805|Experimental|GSK1605786 250mg|Opaque Swedish orange body and cap.
10008266|NCT01611805|Placebo Comparator|Placebo|Opaque Swedish orange body and cap.
10008267|NCT01611805|Experimental|GSK1605786 500mg|Opaque Swedish orange body and cap.
10008268|NCT01611805|Experimental|GSK1605786 1000mg|Opaque Swedish orange body and cap.
10008269|NCT01611805|Experimental|GSK1605786 500mg in fed|Opaque Swedish orange body and cap.
10008270|NCT01611818|Other|Low intensity Internet-delivered psychotherapy|Low intensity Internet-delivered psychotherapy + improved treatment as usual by GP.
10008271|NCT01611818|Other|Self-guided Internet-delivered psychotherapy|Self-guided Internet-delivered psychotherapy + improved treatment as usual
10008272|NCT01611818|Other|Improved treatment as usual by GP|
10008273|NCT01611831|Experimental|ACT in group|Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
10008274|NCT01611831|Active Comparator|Improved Treatment as usual by General practitioner|Patients assigned to this arm will receive treatment as usual by their General Practitioner in the Primary Care center. To enhance treatment, investigators participating in the trial will receive the Guidelines for fibromyalgia treatment in Primary Care handed by Health Service in Aragón.
10008275|NCT01611844|Experimental|Medical device : micro-needle BD 1.5 mm 30G|
10008276|NCT01611844|Active Comparator|Manthoux method: lance 26G X 16mm|
10008277|NCT01611896|Active Comparator|Selenium|
10008278|NCT01611896|Placebo Comparator|Placebo|
10008279|NCT01611909|Experimental|2% PMDO|
10008280|NCT01611909|Experimental|5% PMDO|
10008281|NCT01611909|Active Comparator|Mupirocin|
10008282|NCT01611922||Symptomatic Lens Wearers|Contact lens wearers reporting a habitual wear time of less than eight hours and a noticeable reduction in comfort over a wearing day
10008283|NCT01611922||Non-Symptomatic Contact Lens Wearers|Contact lens wearers reporting a comfortable wear time of more than 10 hours and minimal reduction in comfort over a wearing day
10008284|NCT01611922||Asymptomatic Non-Contact Lens Wearers|Non-contact lens wearers reporting a minimal reduction in ocular comfort over the course of a day
10008285|NCT01611961|Experimental|DT-LM|Docetaxel Lipid Microsphere (DT-LM)
10008286|NCT01611961|Active Comparator|Taxotere|Commerical Product
10008287|NCT01611987|Experimental|MSTEP|The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
10008288|NCT01611987|Active Comparator|General guideline approach|The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
10008289|NCT01612013|Active Comparator|Intravenous NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
10035450|NCT01806142|Active Comparator|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
10035451|NCT01806155||Craniotomy|Patient undergoing major craniotomy
10008290|NCT01612013|Active Comparator|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
10008291|NCT01612013|Active Comparator|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
10008292|NCT01612013|Placebo Comparator|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
10008293|NCT01612026||Ultrasound|
10008294|NCT01612026||Fluoroscopy|
10008295|NCT01612052|Active Comparator|Cefazolin plus Daptomycin|
10008296|NCT01612052|Active Comparator|Cefazolin plus Vancomycin|
10008297|NCT01612065|Active Comparator|Misoprostol vaginally, 200 ug|200 ug misoprostol in the posterior vaginal fornix
10008298|NCT01612065|Active Comparator|Misoprostol vaginally, 400ug|Misoprostol in the posterior vaginal fornix
10008299|NCT01612078|Experimental|Droxidopa, antihypotensive drug, tablet|
10008300|NCT01612078|Placebo Comparator|placebo, tablet|
10008301|NCT01612091|Experimental|Monitoring Messenger|
10008302|NCT01612091|Active Comparator|Control|Traditional tools (monitors, paper records)
10008303|NCT01612104|Experimental|Psychological First Aid|Psychological material developed for children and adolescents, based on cognitive behavioral theory, used to structure therapeutic conversations and/or for self-help.
10008304|NCT01612117||consecutive, PCP patients|All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
10008305|NCT01612130|Experimental|Valeriana officinalis L (100mg)|100 mg of Valeriana officinalis L. (Valerian)
10008306|NCT01612130|Placebo Comparator|Placebo (100 mg)|Placebo 100mg
10008307|NCT01612143|Active Comparator|A: STV capsule (after high fat meal)|
9802409|NCT05280782|Experimental|Dosimetry Group|Normal Volunteers will receive a single intravenous injection of 8 mCi ± 20% (6.4-9.6 mCi) of the PET radiotracer 68Ga-Galmydar. They will undergo whole-body PET/CT imaging at three-time points, immediately post [68Ga]Galmydar injection, and at 2 hours and 4 hours after injection. Serum chemistries, complete blood count, EKG, vital signs, and physical examination will performed before injection and at the completion of the examinations.
10008308|NCT01612143|Active Comparator|B: STV capsule (fasted state)|
10008309|NCT01612143|Experimental|C: STV tablet (after high fat meal)|
10008310|NCT01612143|Experimental|D: STV tablet (fasted state)|
10008311|NCT01612169|No Intervention|Treatment as Usual (TAU) Group|"Participants assigned to the TAU group will receive the standard treatment provided at each hospital for linking patients to HIV and substance use care.~During the formal site selection process, a thorough assessment will be conducted of each site's standard practice for linkage to HIV care and substance use treatment. Throughout the course of the trial, hospital sites will be monitored for any potential changes that might occur in standard practice around linkage to HIV care and substance use treatment."
10008312|NCT01612169|Experimental|Patient Navigation (PN) Group|"The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.~After the initial four meetings, patient navigators will meet with PN group participants ideally twice monthly during months 2 and 3 and once monthly during months 4 - 6."
9802415|NCT05275556|No Intervention|Colonoscopy (Standard of Care)|The control arm is colonoscopy with High Definition White Light Endoscopy (HD-WLE) per standard of care.
9802416|NCT05275556|Experimental|CADe Device|The intervention arm is colonoscopy with HD-WLE per standard of care plus the CADe Device.
10008313|NCT01612169|Experimental|Patient Navigator Plus Contingency Management (PN+CM) Group|"Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM). Using the principles of contingency management, this combined intervention will incorporate viral load suppression as a target of reinforcement as well as several other behaviors (HIV clinical care, medication adherence, cessation or reduction of substance use) that are hypothesized to be moderators or mediators of the primary outcome.~For participants randomly assigned to the PN+CM study group, patient navigators will: 1) effectively communicate the incentive plan to the participant, 2) track each of the seven target behaviors that may earn participant incentives, 3) verify occurrence of the target behaviors, 4) deliver incentives according to the protocol, and 5) maintain a record of incentives delivered. PNs will use a computer-based tracking program to facilitate this work."
10008314|NCT01612182||ESBL(+) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
10035452|NCT01806181|Other|Cancer Treatment|
9963823|NCT01232530||ACT Effectiveness Monitoring Group|"Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in real life conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised."
9963824|NCT01232608|Experimental|Exercise|12 months of exercise training
9963825|NCT01232608|No Intervention|Control|Normal follow-up by primary physician
9963826|NCT01232621|Experimental|Physician introduction|Physicians will introduce Research Coordinators (RCs) by name to SDMs and acknowledge patient eligibility to participate in a study using a standardized script.
9963827|NCT01232621|Active Comparator|Non-physician introduction (usual approach)|RCs will either introduce themselves or be introduced by a non-physician member of the health care team.
9963828|NCT01232634||All Subjects|
9963829|NCT01232647|Active Comparator|Vitamin k1|1.0 mg of vitamin K1 (phylloquinone) and placebo MK4 will be given to one of the treatment arm for 18 months
9963830|NCT01232647|Placebo Comparator|placebo vitamin K1 and MK4|placebo pill of both vitamin K1 and MK4 given for 18 months to the control arm
9963831|NCT01232647|Active Comparator|Menatetrenone MK4|45 mg MK4 given daily and placebo vitamin K1 will be given to one of treatment arm for 18 months
9963832|NCT01232660|Active Comparator|Delayed|Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
9963833|NCT01232660|Experimental|Immediate|Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
9963834|NCT01232673|Experimental|BMAC treatment active group|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC. This ammount is applied by one ml per injection into the critical limb ischemia along the calf vessels.
9963835|NCT01232673|No Intervention|Control Study Group|Standard treatment group of patients with CLI after surgical or interventional revascularisation will serve as control.
9963836|NCT01232686|No Intervention|Control area|In the control areas we will monitor the prevalence and treatment of communicable diseases without giving the participants online access to disease surveillance information
9963837|NCT01232686|Experimental|Intervention area|In these areas we will give study participants online access to epidemiological data for communicable diseases
9963838|NCT01232699|Active Comparator|Internet Obesity Treatment|Participants will attend weekly class sessions on line and track food and exercise in an on-line journal.
9963839|NCT01232699|Experimental|Internet Obesity Treatment with MI|Participants will attend weekly classes on line, record food and exercise in an on-line journal, and will have no more than 6 individual motivational interviewing sessions.
9963840|NCT01232699|Experimental|Contingent MI|Intervention is the same as for the MI arm, however participants will only receive MI if meeting certain treatment participation conditions.
9963841|NCT01232712|Experimental|ImMucin|Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
9963842|NCT01232725|Experimental|Donor Human Milk|VLBW infants randomized to be fed donor human milk, fortified as appropriate, for all feedings for which maternal milk is not available, including infants who receive no maternal milk
9963843|NCT01232725|Experimental|Preterm Formula|VLBW infants randomized to receive preterm infant formula for any feedings for which maternal milk is unavailable, including infants receiving no maternal milk
9963844|NCT01232764|Experimental|Multi-disciplinary wound care team|Stepped wedge study design i.e. start date of exposure is randomized.
9963845|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.75mg/0.03cc|1/3 of study participants will be randomized to this treatment in one eye (study eye) and the other eye will receive laser (fellow eye)
10008315|NCT01612182||ESBL(-) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
10008316|NCT01612195|Experimental|Anal fistula plug|
10008317|NCT01612208||Distal femur fractures|(AO/OTA types 33-A and 33-C)
10008318|NCT01612234|Experimental|High palmitate or high oleate diet.|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
10008319|NCT01612234|Experimental|high palmitate or high oleate diet|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
10008320|NCT01612260|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks
10008321|NCT01612260|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. po for 12weeks
10008322|NCT01612273|Experimental|Disgren|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
10008323|NCT01612273|Experimental|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
10008324|NCT01612286|Experimental|endostatin|chemotherapy concurrently with endostatin
10008325|NCT01612299|Active Comparator|Standard Immunosuppression|Tacrolimus + Myfortic®/Cellcept + Corticosteroids
10008326|NCT01612299|Experimental|Zortress®|Tacrolimus + Zortress® + Corticosteroids
10008327|NCT01612312|Active Comparator|Thrombectomy|
10008328|NCT01612312|Other|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
10008329|NCT01612325|Experimental|Holmium-166 MS radioembolization|Single radioembolization met Holmium-166 polylactic microspheres administered
10008330|NCT01612338|Experimental|Targeted|Targeted letter and booklet
10008331|NCT01612338|Experimental|Tailored|Tailored letter and booklet, enhanced family communication and support brochure
10008332|NCT01612364|Experimental|thoracic sympathetic block|Sympathetic block of upper limb via thoracic vertebra T3
10008333|NCT01612364|Active Comparator|control block|Same medication used in experimental group, but in dorsal subcutaneous
10008334|NCT01612377|Experimental|prednisolone-dipyridamole|
9803667|NCT03594955|Experimental|SAR440234|SAR440234 was administered as intravenous infusion once weekly for 6 weeks per Cycle. Per plan, participants were to receive first 2 to 3 doses as Lead-in doses followed by a fixed dose until the end of treatment or unless the dose needs to be decreased for safety reasons. Due to early study termination, all participants received only 1 treatment cycle at a dose of 1 nanogram per kilogram (ng/kg) once weekly.
9803668|NCT03592329|Experimental|active tVNS + SRT A|active tVNS and Stress Reduction Training A
9803669|NCT03592329|Experimental|active tVNS + SRT B|active tVNS and Stress Reduction Training B
10008335|NCT01612377|Active Comparator|prednisone 5mg|
10008336|NCT01612377|Active Comparator|prednisone 7.5mg|
10008337|NCT01612390||group 1|receive 400 Mg sublingual misoprostol.
10008338|NCT01612390||group 2|receive 600 Mg sublingual misoprostol.
10008339|NCT01612390||group 3|receive 5IU of intravenous oxytocin.
10008340|NCT01612403||Single group|Single group: all participants receive same intervention throughout study (Non-randomised)
10008341|NCT01612416|Sham Comparator|Normal subjects|
10008342|NCT01612416|Active Comparator|Primary open angle glaucoma|
10008343|NCT01612416|Active Comparator|Normal tension glaucoma|
10008344|NCT01612429|Experimental|Amino acid supplementation|Up to 500 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 6 weeks.
10008345|NCT01612442|Experimental|Integrated education|
10008346|NCT01612442|No Intervention|Control|
10008347|NCT01612442|Experimental|Nutrition education|
10008348|NCT01612455|No Intervention|Standard of Care|Control participants will receive the narcology hospital's standard of care. With regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care - the outpatient clinic that is involved in the intervention. Control patients will be referred to outpatient narcology care as part of standard of care. If control participants are newly diagnosed with HIV infection at the addiction hospital, they will receive HIV post test counseling consistent with CDC recommendations (this represents an enhancement of the current standard of care in Russia).
10008349|NCT01612455|Experimental|LINC Case Management (Intervention)|LINC Case Management (study Intervention) - see Intervention description
10008350|NCT01612468|Experimental|Liraglutide|
10008351|NCT01612468|Placebo Comparator|Placebo|
10008352|NCT01612481|Active Comparator|chest radiography|clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
10008353|NCT01612481|Active Comparator|chest CT|clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year
10008354|NCT01612507|Experimental|A|600 mg Ceftaroline fosamil 1 h infusion
10008355|NCT01612507|Experimental|B|Placebo 1 h infusion
10008356|NCT01612507|Experimental|C|600 mg Ceftaroline fosamil 2 h infusion
10008357|NCT01612507|Experimental|D|Placebo 2 h infusion
10008358|NCT01612520|Active Comparator|telecoaching|
9803670|NCT03592329|Other|sham tVNS + SRT A|sham stimulation and Stress Reduction Training A
9803671|NCT03592329|Other|sham tVNS + SRT B|sham tVNS and Stress Reduction Training B
9963846|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.625mg/0.025cc|1/3 of patients will be randomized to this treatment in 1 eye (study eye) and the other eye will receive laser (fellow eye).
9963847|NCT01232777|Active Comparator|Laser ablation|1/3 of study participants will be randomized to this treatment in both eyes (study eye and fellow eye)
9963848|NCT01232803|Active Comparator|2% N-9 gel|Rectal application of 2% N-9 gel
9963849|NCT01232803|Placebo Comparator|HEC placebo gel|Rectal application of HEC placebo gel
9963850|NCT01232803|No Intervention|no-treatment arm|no intervention
9963851|NCT01232803|Experimental|Tenofovir 1% gel|rectal application of Tenofovir 1% gel
9963852|NCT01232816||Delayed graft function|These are patients in whom dialysis is required following transplantation.
9963853|NCT01232816||Immediate function|These are patients in whom no dialysis is required and creatinine declines by >20% in the first 24 hours following transplantation.
9963854|NCT01232881||Tumor and Serum Collection|"Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.~Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib."
10008359|NCT01612520|No Intervention|control|
10008360|NCT01612598|Experimental|Supportive Care (PCI)|"PCI PART I: Patients undergo comprehensive PC assessment based on baseline data and complete goals of care discussion.~PCI PART II: Following the first dose of phase I investigational treatment, patients meet with the IDT, where PC recommendations are made. This is followed by two patient educational sessions that will cover QOL-related domains, including physical, social, emotional, and spiritual well-being. Supportive care referrals are made based on IDT recommendations."
9803672|NCT03573921|Experimental|Gastrografin Arm|Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
10008361|NCT01612611||a cohort using Shenmai injection|
10008362|NCT01612637|Experimental|Group 1|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
10008363|NCT01612637|Active Comparator|Group 2|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
10008364|NCT01612650|Active Comparator|breast cancer histologically proven|Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment
10008365|NCT01612650|Active Comparator|surveillance of a treated breast cancer|surveillance of patient already treated for breast cancer must have annual mammography
10008366|NCT01612650|Active Comparator|diagnosis of a detected anomaly|patient addressed for diagnosis of a detected anomaly
10008367|NCT01612689|Experimental|Physiologic Data Collection|
10008368|NCT01612715||Study Population|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the study.
10008369|NCT01612728|Experimental|Women with Arthralgia|Women who develop joint pain on Aromatase Inhibitor therapy will be placed on the clinical algorithm, as specified in the protocol.
10008370|NCT01612728|Other|Women without Arthralgia|Women who do not develop arthralgia will continue to have their joint pain and strength measured, as well as their medication compliance. However, they will not be placed on the clinical algorithm which is meant for alleviation of joint pains.
10008371|NCT01612741||Group 1|
9803673|NCT03573921|Experimental|Control Arm|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
10008372|NCT01612754|No Intervention|Reference group - cloaked noise meters|"Reference group or phase 1~Theatre equipped with multiple sound meters disguised as CO2 meter for sound probing in the absence of a research clerk with personnel completely unaware of sound measurements."
9476681|NCT03569358|Experimental|Virtual Reality and EEG Interventions|In the interventional arm, 20 subjects will receive twice daily sessions of immersive virtual reality for a maximum of 15 minutes, with EEG headband recording starting 5 minutes prior to and 5 minutes after the intervention, for a maximum of 4 consecutive days.
9476682|NCT03569358|Active Comparator|EEG Intervention group|In the control arm, 10 subjects would have EEG recorded for 25 mins twice daily, with a minimum of 4 hours intervening, for 3 consecutive days, with the EEG headband. There would be no immersive virtual reality sessions.
9476683|NCT03569358|Active Comparator|Healthy Volunteers|At the completion of the above intensive care study recruitment, demographic data of the interventional immersive virtual reality arm would analysed to recuit 10 age-matched healthy volunteers with no known cognitive disorders or visual impairment. This is to compare study data with healthy controls. A 25 minute session consisting of 15 minutes of immersive virtual reality and 5 minutes of EEG recording with the EEG headband before and after the intervention would be performed. Eye-tracking and EEG data from these groups of patients would be compared against subjects in both arms of the study performed in the intensive care unit to investigate for exploratory differences.
10008373|NCT01612754|Sham Comparator|Control Noise AND Stress measurements|"Control Group - Phase 2~No intervention but research clerk is present in theatre to protocoll the operation and test for stress by collecting saliva cortisol and probing electrodermal activity"
10008374|NCT01612754|Experimental|Noise Reduction Intervention Group|"Intervention Group - Phase 3~A panel of noise reduction measures (staff workplace rules, technical devices as optical noise warners, optical telephones) is put into effect. Surgeons are monitored by biometry, psychometry and the outcome."
10008375|NCT01612806|Experimental|PriMatrix|PriMatrix Dermal Repair Scaffold
10008376|NCT01612806|Experimental|PriMatrix Ag|PriMatrix Ag Antimicrobial Dermal Repair Scaffold
10008377|NCT01612806|Active Comparator|Standard of Care|Standard of Care Moist Wound Therapy
10008378|NCT01612832|Experimental|Lyrica|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
10008379|NCT01612832|Active Comparator|Control|no liryca treatment
10008380|NCT01612845|Experimental|PRF|the group in which the PRF was administered
10008381|NCT01612845|Active Comparator|Control|repair without PRF
9803674|NCT03560609|Active Comparator|Subjects With Keratoconus|
9803675|NCT03560609|Active Comparator|Subjects with Glaucoma|
10008382|NCT01612871|Experimental|hormone therapy treatment|Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
10008383|NCT01612897|Experimental|Computer based reminders to MD|Children in this arm attend a clinic that is randomly assigned to receive physician alerts to screen appropriate children for autism.
10008384|NCT01612897|No Intervention|Usual care arm|Children in this are receive usual care from a clinic randomly chosen to serve as a control.
10008385|NCT01612910|Experimental|microencapsulated diindolylmethane, lab. biomarker analysis|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
10008386|NCT01612923|Experimental|midwife|Gynecological exam and ultrasound performed by midwife, medical abortion service provided by midwife,contraceptive advice provided by midwife. Follow-up visit provided by midwife
10008387|NCT01612923|No Intervention|Physician|Gynecological exam and ultrasound and contraceptive advice provided by physician. Medical abortion service and follow-up visit provided by midwife
10008388|NCT01612936|Experimental|Allergic asthmatic, allergic nonasthmatic|Adults who are allergic asthmatics or allergic non-asthmatics will receive segmental allergen challenge to the lung
10035453|NCT01806194|Active Comparator|Educational control arm|Control group receives 16 mailings of diabetes educational materials but no regular contact with community health workers
10008389|NCT01612962||bony debridement or amputation|In this study, the investigators will perform a retrospective chart analysis of patients that underwent a bony debridement or amputation in the operating room at Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger
10008390|NCT01612975|Placebo Comparator|Placebo|This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
10008391|NCT01612975|Experimental|Naproxen|Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
10035454|NCT01806194|Experimental|Lifestyle counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers.
10035455|NCT01806207|Active Comparator|Durolane injection|Intraarticular injection of 3 ml Durolane.
10035456|NCT01806207|Placebo Comparator|Saline injection|Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.
10035457|NCT01806220|Active Comparator|biopsy of retrocrycoid laryngeal mucosa|"During upper digestive endoscopy a biopsy specimen of the retrocrycoid laryngeal mucosa was obtained with a forceps introduced by the working channel of the scope.~Intervention: biopsy of retrocrycoid laryngeal mucosa"
10035458|NCT01806220|Active Comparator|biopsy of distal esophagus mucosa|"during upper digestive endoscopy a biopsy specimen of the distal esophageal mucosa was obtained~Intervention:biopsy of distal esophagus mucosa"
9476684|NCT03569345|Experimental|Arm|Basal cell carcinoma (BCC) patients Patients (>18 pr) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on face/scalp, <50 mm on trunk/extremities)
10035459|NCT01806233|Experimental|Acupuncture|acupuncture
10035460|NCT01806233|Experimental|Rehabilitation|rehabilitation exercise
10035461|NCT01806246|Experimental|integrative rehabilitation program|28 sessions during 12 months with focus on psychoeducation, activity planning, and thoughts and feelings connected to having a serious chronic disease. From week 13 to week 32 a training programme aiming at balancing heart rate variability.
10035462|NCT01806272|Experimental|Arm A|"Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.~Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
10035463|NCT01806272|Active Comparator|Arm B|"Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
10035464|NCT01806285||Patients with Respiratory Symptoms|
10035465|NCT01806311|Active Comparator|PartA: Candesartan, Candesartan + Amolodipine|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
10035466|NCT01806311|Active Comparator|PartB: Amlodipine, Amlodipine+Candesartan|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
10035467|NCT01806324|Experimental|HL040XC(Atorvastatin+Losartan)|HL040XC lag time released combination drug
10035468|NCT01806324|Active Comparator|Losartan + Atorvastatin|Coadministration group
10008392|NCT01612988|Experimental|Chemotherapy BOMP|Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
10008393|NCT01613001||DoD Beneficiaries|"Exclusion: Active Duty Air Force members with the following conditions will be excluded from the study:~Documented preexisting musculoskeletal injury/disease before onset of obesity~Hypothyroidism/Hyperthyroidism~Hyperparathyroidism~Osteopenia/Osteoporosis~Nicotine dependence~Alcohol dependence~Eating disorders (anorexia nervosa, bulimia nervosa)~Cancer requiring chemotherapy or radiation therapy~Status-post gastrectomy~Status-post bilateral oophorectomy~Crohn's Disease~Ulcerative Colitis~Celiac Disease~Cushing's Disease~Prior to or during the study period, more than 6 months of taking proton pump inhibitors, medroxyprogesterone acetate, bisphosphonates, methotrexate, selective serotonin reuptake inhibitors, or inhaled/intranasal corticosteroids~Prior to or during the study period, more than 1 month of taking fluoroquinolones, oral or intramuscular corticosteroids, oral or intramuscular testosterone, or leuprolide"
10008394|NCT01613040|Experimental|Treatment A|
10008395|NCT01613040|Experimental|Treatment B|
10008396|NCT01613040|Placebo Comparator|Treatment C|
10008397|NCT01613040|Placebo Comparator|Treatment D|
10008398|NCT01613066|Experimental|Treatment|Patients with high risk haematological malignancies
10008399|NCT01613079|Placebo Comparator|Methotrexate|Patients were treated with methotrexate alone.
10008400|NCT01613079|Experimental|T2|Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
10008401|NCT01613079|Experimental|MTX+T2|The patients were treated with methotrexate and T2.
10008402|NCT01613092|Experimental|Conventional|Preoperative Antibiotics
10008403|NCT01613092|Active Comparator|Aggressive (Incremental)|Preoperative antibiotics, antibiotic wash and post operative antibiotics
10008404|NCT01613105||Group 1|
10008405|NCT01613170|Experimental|Toviaz and Premarin Vaginal Cream|Toviaz 4 mg PO q day and premarin cream 1 g per vagina 2 times a week.
10008406|NCT01613170|Placebo Comparator|Toviaz , Placebo Premarin Vaginal Cream|Toviaz 4 mg PO q day and placebo cream 1 g per vagina 2 times a week.
10008407|NCT01613183|Experimental|Chinese Medicine group|Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
10008408|NCT01613183|Placebo Comparator|placebo group|
10008409|NCT01613196|Experimental|Positron Emission Tomography|Positron Emission Tomography
10008410|NCT01613209|Experimental|Olmesartan/Amlodipin fixed combination|
10008411|NCT01613235|No Intervention|No intervention|No induced hypertension (reference group)
10008412|NCT01613235|Active Comparator|Induced hypertension|Patients who are randomised to this arm will have their blood pressure raised with vasopressors and fluids. Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
10008413|NCT01613261|Experimental|TAK-733 and alisertib|
10008414|NCT01613274|Experimental|Gum chewing|Chewing mint flavored sugarless gum for 10-20 minutes three times a day following colon resection.
10008415|NCT01613274|Placebo Comparator|no gum chewing|no gum chewing
10008416|NCT01613287|Experimental|Immunoadsorption|Patients are treated with the TheraSorb® Ig flex adsorber used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy (5 treatments) performed over 5 to 8 consecutive days
10008417|NCT01613300|Experimental|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
10008418|NCT01613352|Experimental|Day surgery group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to ambulatory surgery group.
10008419|NCT01613352|Active Comparator|In-Patient group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to in-patient group.
10008420|NCT01613365|Experimental|chlorhexidine gluconate|
10008421|NCT01613365|Experimental|placebo|
10008422|NCT01613391||RYGBP|Patients underwent Roux-en-Y Gastric Bypass for morbid obesity.
10008423|NCT01613391||LAGB|Patients underwent Laparoscopic Adjustable Gastric Banding for morbid obesity.
9476685|NCT03569332|Experimental|Test Group|Participants will receive the mobile self-input tool providing alarm on tablet, and their practicing rate will be sent to Nurse's Dashboard.
9963855|NCT01232907|Experimental|L-Carnitine|This study has a single subject design. Each subject acts as its own control. All subjects will go through intervention phase (treatment with L-Carnitine).
9963856|NCT01232933|Experimental|VPS System|Use of navigational VPS system to place catheter
9963857|NCT01232959|Experimental|Transvaginal Surgery|Gallbladder will be removed through the vagina
9963858|NCT01232972|Experimental|oocyte freezing|includes any women who elects to preserve her fertility by vitrifying her unfertilized eggs.
9963859|NCT01232985|Experimental|RD047-26|Study Device
9963860|NCT01232998||Patient Satisfaction with nursing care|
9963861|NCT01232998||satisfaction of waiting time for first time visit|
9963862|NCT01232998||patient satisfaction|
9963863|NCT01233024|Placebo Comparator|Low fiber control|no treatment dinner bar, no treatment breakfast bar
9963864|NCT01233024|Experimental|Promitor soluble corn fiber|12g in dinner bar, 11g in breakfast bar
9963865|NCT01233024|Experimental|FiberSym resistant starch|12g in dinner bar, 11g breakfast bar
9963866|NCT01233024|Experimental|Orafti P95 fructooligosaccharide|12g in dinner bar, 11g in breakfast bar
9963867|NCT01233024|Experimental|Orafti HPX inulin|12g in dinner bar, 11g in breakfast bar
9963868|NCT01233063|Experimental|Alive2|Lifestyle Intervention delivered via email and web
9963869|NCT01233063|Experimental|Alive2 plus automated phone/print|All of Arm 1 components, plus biweekly tailored automated phone coaching plus monthly tailored automated print materials.
9963870|NCT01233063|Placebo Comparator|Control|Monthly emailed newsletter on other aspects of wellness, excluding diet and physical activity
9963871|NCT01233089|Experimental|CARE|Investigational single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
9963872|NCT01233089|Active Comparator|AIR OPTIX AQUA|Commercially available single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
9963873|NCT01233089|Active Comparator|AIR OPTIX AQUA MULTIFOCAL|Commercially available multifocal contact lenses worn bilaterally on a daily wear basis and replaced monthly
9963874|NCT01233102|Active Comparator|Conserved Therapy|Conserved Therapy
9963875|NCT01233102|Experimental|Interventional Therapy|"Patients with liver cirrhosis will be randomly divided into three groups.~1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
9963876|NCT01233115||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections
9963877|NCT01233128||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
9963878|NCT01233141||one group only|all participants
9963879|NCT01233154|Experimental|L. paracasei|L. paracasei
9963880|NCT01233154|Experimental|L. acidophilus + B. lactis|L. acidophilus + B. lactis
9963881|NCT01233167|Experimental|clopidogrel|
9963882|NCT01233167|Placebo Comparator|placebo|
9963883|NCT01233167|Experimental|steply discontinued clopidogrel|
9963884|NCT01233180|Active Comparator|Gua Sha|Single Gua Sha treatment of the neck and shoulder region.
9963885|NCT01233180|Active Comparator|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region.
9963886|NCT01233193|Experimental|Intervention|The intervention group receive an pharmacist intervention (health education, Home Blood Pressure Monitoring and Referral to physician as needed) This group will be followed for 6 months
9963887|NCT01233193|No Intervention|Control|The control group receive usual care in the community pharmacy
9963888|NCT01233206|Experimental|Experimental group|Patients receiving metformin pretreatment and co-administration
9963889|NCT01233206|Placebo Comparator|Control group|Placebo
9963890|NCT01233219||Group A|Homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene
9963891|NCT01233219||Group B|Both homozygous and heterozygous patients for the less frequent allele of the polymorphism A118G of OPRM1 gene
9963892|NCT01233245||Group 1|
9963893|NCT01233271|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
9963894|NCT01233323||All study patients (single arm study)|All eligible patients will be included in the only study arm and will undergo study testing.
9963895|NCT01233349|Experimental|Litramine|
9963896|NCT01233349|Placebo Comparator|Placebo|
9963897|NCT01233362|Active Comparator|Arm 1: Adults; 14 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
9963898|NCT01233362|Active Comparator|Arm 2: Adults; 28 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
9963899|NCT01233362|Active Comparator|Arm 3: children; 14 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
9963900|NCT01233362|Active Comparator|Arm 4: children; 28 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
9963901|NCT01233362|Active Comparator|Arm 5: Adults; 14 days Interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
9963902|NCT01233362|Active Comparator|Arm 6: Adults; 28 days interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
9963903|NCT01233388||Text message surveillance|enroll for text message surveillance
9963904|NCT01233401||Mothers|
9963905|NCT01233401||Other Infant Caregivers|Includes fathers, grandparents, and other adults who are infant caregivers
9963906|NCT01233414|Experimental|Parent Training|
9963907|NCT01233414|Active Comparator|Psychoeducation|
9963908|NCT01233440|Experimental|Cohort 1|25 IU/kg dose
9963909|NCT01233440|Experimental|Cohort 2|50 IU/kg dose
9963910|NCT01233440|Experimental|Cohort 3|75 IU/kg dose
9963911|NCT01233453|Active Comparator|the everolimus eluting ® stent|the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent
9963912|NCT01233453|Active Comparator|Biolimus A9 stent|the Biolimus A9 eluting NOBORI® stent
9963913|NCT01233505|Experimental|Treatment (veliparib, capecitabine, oxaliplatin)|Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9963914|NCT01233531|Other|A--Monthly cash transfers|Monthly cash transfer payments
9963915|NCT01233531|Other|B--No cash transfers|No cash transfers.
9963916|NCT01233544|Experimental|Stereotactic body radiation therapy|Colorectal liver metastases treated by SBRT
9963917|NCT01233544|Active Comparator|Radiofrequency ablation|Colorectal liver metastases treated by RFA
9963918|NCT01233557||Bone Metastases|
9963919|NCT01233570|Experimental|Topical tacrolimus|Once daily topical application
9963920|NCT01233583||Betamethasone/Calcipotriol (Dovobet)|patients in whom decision to treat with Dovobet by their dermatologist
9963921|NCT01233583||Acitretin (neotigason)|patients in whom decision to treat with neotigason by their dermatologist
9963922|NCT01233583||narrow-band UVB|patients in whom decision to treat with narrow band UVB by their dermatologist
9963923|NCT01233583||Anti TNF-alpha|patients in whom decision to treat with anti TNF-alpha(adalimumab-etanercept-infliximab) by their dermatologist
9963924|NCT01233596|Active Comparator|Monocanalicular intubation|Monocanalicular intubations (MCI; n=35 eyes) through the inferior canaliculus intubations performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
9963925|NCT01233596|Active Comparator|Bicanalicular intubation|Bicanalicular intubation (BCI; n=35 eyes) performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
9963926|NCT01233622|Experimental|Vildagliptin (metformin + glimepiride)|
9963927|NCT01233622|Placebo Comparator|Placebo (metformin + glimepiride)|
9963928|NCT01233635|Experimental|A Group 1 no drug|Patients who have not taken ACE/ARB, randomized to no drug.
9963929|NCT01233635|Experimental|A Group 2|Patients who have not taken ACE/ARB, randomized to take cozaar.
9963930|NCT01233635|Experimental|B|Patients currently taking ACE/ARB will have their prescription changed to cozaar.
9963931|NCT01233648|Active Comparator|AF|
9963932|NCT01233648|Active Comparator|SR|
9963933|NCT01233661|Experimental|short AVD pacing|short AVD pacing
10008424|NCT01613404||Patients with nurse case manager|Patients will receive a dedicated nurse case manager (intervention group) in this group.
10008425|NCT01613404||Patients with no nurse case manager|Patients will not receive nurse case manager (control group) in this group.
10008426|NCT01613430|Active Comparator|Printed Educational Material (PEM) only|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
10008427|NCT01613430|Experimental|Coach Training (COACH)|The COACH intervention consists of the Printed Educational Materials (PEM) plus the addition of cancer-related training for participant-designated coaches.
10008428|NCT01613443||Control|Healthy volunteers without medication
10008429|NCT01613443||Phenprocoumon|Patients receiving Marcumar having target INR 2-3
10008430|NCT01613443||Dabigatran|Patients receiving therapeutic dosis of Pradaxa
10008431|NCT01613443||Rivaroxaban|Patients receiving therapeutic dosis of Xarelto
10008432|NCT01613456|Placebo Comparator|Placebo|Dicalcium phosphate, Maltodextrin and Magnesium stearate.
10008433|NCT01613456|Experimental|Saccharomyces cerevisiae CNCM I-3856|
10008434|NCT01613469|Other|5FU/Leucovorin- post distal rectal srgy|Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer
10008435|NCT01613482|Active Comparator|Arm A|Without cerebral prophylactic radiation
10008436|NCT01613482|Experimental|Arm B|With cerebral prophylactic radiation
10008437|NCT01613495|Placebo Comparator|Placebo|Normal Saline
10008438|NCT01613495|Active Comparator|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
10008439|NCT01613508|Active Comparator|Direct Anterior Approach|An oblique incision is made over the anterior margin of the tensor muscle. The fascia of the tensor muscle is identified and incised. The muscle is swept digitally laterally and a retractor is placed over the superior aspect of the femoral neck. The hip capsule is then incised and retracted.
10008440|NCT01613508|Active Comparator|Mini-Posterior Approach|The surgical approach involved a 7 to 9.5 cm incision along the posterior aspect of the femur starting at the tip of the greater trochanter and proceeding distally. The fascia of the gluteus maximus was split, and blunt dissection revealed the underlying abductor and external rotator musculature. The external rotators an the hip capsule were incised and preserved as one layer, with an attempt being made to preserve the insertion of the quadratus femoris on the femur. The hip was dislocated posteriorly and the femoral neck was cut in accordance with the preoperative plan.
10008441|NCT01613521|Experimental|DCE-MRI and 18F-FMISO PET|Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.
10008442|NCT01613534|Experimental|APC plus oral sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) administration for four weeks.
10008443|NCT01613534|Placebo Comparator|APC plus placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks.
10008444|NCT01613547|Active Comparator|Routine antibiotic prescription|Routine antibiotic prescription with amoxicillin (80 mg/kg/day for 7 days)
10008445|NCT01613547|Placebo Comparator|No routine antibiotic prescription|
10008446|NCT01613586|Experimental|Low dose ASP3652 twice daily|50 mg twice daily for 12 weeks
10008447|NCT01613586|Experimental|Medium dose ASP3652 twice daily|150 mg twice daily for 12 weeks
10008448|NCT01613586|Experimental|High dose ASP3652 twice daily|300 mg twice daily for 12 weeks
10008449|NCT01613586|Placebo Comparator|Placebo|Matching placebo twice daily for 12 weeks
10008450|NCT01613612|Sham Comparator|control group:core decompression|single core decompression
10008451|NCT01613612|Active Comparator|Treatment group: BMCs+core decompression|Enriched bone marrow cells combined with core decompression
10008452|NCT01613625|Experimental|Elastography|
10035469|NCT01806337|Experimental|Alemtuzumab, antibody|alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg
10008453|NCT01613638|Other|Congenital malformations|"All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.~born from mothers living in Brittany at delivery~with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth~or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)"
10008454|NCT01613638|Other|control|2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.
10008455|NCT01613651|Experimental|Arm I (RALP)|Patients undergo RALP.
10008456|NCT01613651|Experimental|Arm II (RALP and placement of pelvic drain)|Patients undergo RALP and placement of pelvic drain.
10008457|NCT01613664|Experimental|tisseel|tisseel will be applied during the surgery
10008458|NCT01613664|Placebo Comparator|no tisseel|no tisseel will be applied during the surgery
10008459|NCT01613677|Experimental|BKM120|
10008460|NCT01613690|Experimental|Healthy volunteers|control group receiving 100 μg NVA237
9476686|NCT03569332|No Intervention|Control Group|Participants will receive the mobile self-input tool on tablet (to compare the rate with Test group). But it won't contain alarm function and their practicing rate won't be sent to Nurse's Dashboard, either.
9803676|NCT03555149|Active Comparator|Regorafenib (Control)|Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
10008461|NCT01613690|Experimental|Mild renal impairment|(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
10008462|NCT01613690|Experimental|Moderate renal impairment|(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
10008463|NCT01613690|Experimental|Severe renal impairment|(eGFR <30 mL/min1.73m2) receiving 100 μg NVA237
10008464|NCT01613690|Experimental|End-stage subjects requiring dialysis (ESRD)|receiving 100 μg NVA237
10008465|NCT01613703|Experimental|Experimental|
10008466|NCT01613729|Active Comparator|Rosuvastation 5 Initiator Arm|These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
10008467|NCT01613729|Active Comparator|Rosuvastatin 10 initiator arm|These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
10008468|NCT01613755|Active Comparator|Metformin therapy with concomitant use of dipyridamole|Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days
10008469|NCT01613755|Active Comparator|Metformin therapy|Metformin 500 mg twice daily for four days
10008470|NCT01613781|Active Comparator|T1/Tc amplitude-guided group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
10008471|NCT01613781|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
10008472|NCT01613794|No Intervention|No intervention|
10008473|NCT01613794|Experimental|Rosuvastatin|
10008474|NCT01613807|Experimental|Mix 50/50|3 doses of Mix 50/50 at mealtime
10008475|NCT01613807|Active Comparator|Usual insulin regimen|3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
10008476|NCT01613820|Experimental|Ketamine plus placebo|Subjects assigned to this paradigm will receive a 15 minute infusion of normal saline (placebo) followed by IV ketamine at 0.25mg/kg over 45 minutes twice a week for 3 weeks.
10008477|NCT01613820|Experimental|Scopolamine plus placebo|Subjects will receive a 15 minute infusion of IV scopolamine 2ug/kg followed by a 45 minute infusion of normal saline (placebo).
10008478|NCT01613820|Experimental|Ketamine plus scopolamine|Subject will receive an IV scopolamine infusion at a dose of 2ug/kg over 15 minutes, followed by an IV infusion of ketamine at a dose of 0.25mg/kg over 45 minutes.
10008479|NCT01613833||Primary OA Group|Subjects who are to undergo primary total knee arthroplasty due to primary OA which may include but is not limited to bilateral or peripheral involvement with no significant history of overuse or trauma to the joint.
10008480|NCT01613833||Secondary/Post-traumatic OA Group|Subjects who are to undergo primary total knee arthroplasty due to osteoarthritis of the knee that is secondary to injury or overuse of the joint.
10008481|NCT01613846|Experimental|Sorafenib followed by pazopanib|"Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.~During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
10008482|NCT01613846|Experimental|Pazopanib followed by Sorafenib|"Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:~During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
10008483|NCT01613872|No Intervention|Control|Wait List Control
10008484|NCT01613872|Experimental|Mindfulness Based Stress Reduction|An 8 week standardized protocol of stress reduction using gentle yoga and meditation
10008485|NCT01613885||Twins|Twins that are ages 0 to 80 years, with or without allergy disease.
10008486|NCT01613898||CTX Group|
10008487|NCT01613911||Epileptics having invasive monitoring|People between 10 and 65 years of age with epilepsy and who are coming in to have invasive electrophysiological monitoring.
10008488|NCT01613924|Placebo Comparator|Heat based treatment/no treatment|Split face treatment with handheld acne heat based device and no treatment
10008489|NCT01613924|Active Comparator|Heat based treatment/benzoyl peroxide|Split face treatment with handheld acne heat based device and benzoyl peroxide 4%
10008490|NCT01613937|Experimental|Lifestyle|12 once weekly Lifestyle training program
9963934|NCT01233661|No Intervention|prior (stable) programming|prior (stable) programming
9963935|NCT01233674||patients referred for standard of care MRI|
9963936|NCT01233713|Active Comparator|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering ileostomy, followed by a stoma reversal operation.
9963937|NCT01233713|Active Comparator|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
9963938|NCT01233739|Placebo Comparator|Placebo|
9963939|NCT01233739|Experimental|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
9963940|NCT01233752||Group A|Homozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the more frequent allele of the polymorphism A118G of OPRM1 gene
9963941|NCT01233752||Group B|Both homozygous and heterozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the less frequent allele of the polymorphism A118G of OPRM1 gene
9963942|NCT01233765||Control volunteers with periodontal health|Control volunteers with periodontal health
9963943|NCT01233765||Patient volunteers with chronic periodontitis|Patient volunteers with chronic periodontitis
9963944|NCT01233778|Experimental|Canola Oil|
9963945|NCT01233778|Experimental|High Oleic Acid Canola + DHA|
9963946|NCT01233778|Experimental|High Oleic Canola Oil|
9963947|NCT01233778|Experimental|Flax & Safflower Oil (60:40)|
9963948|NCT01233778|Experimental|Safflower & Corn Oil (75:25)|
9963949|NCT01233791|Experimental|Vaginal Diazepam Suppository|Patients in this arm will be asked to use one vaginal suppository every night for 28 days
9963950|NCT01233791|Placebo Comparator|Vaginal Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
9963951|NCT01233804|No Intervention|Opting in|Currently, pregnant women have to sign a consent stating that they want the influenza vaccine (at the clinics where the study is being conducted). Therefore, this group is the same as usual care. However, women will then be asked if they would like to take part in parts 2 and 3 of the study.
9963952|NCT01233804|Experimental|Opting Out|Women will sign a consent form only if they do not want to receive the flu vaccine.
9963953|NCT01233830|Experimental|1|
9963954|NCT01233830|Placebo Comparator|2|
9963955|NCT01233843|Other|Drug and radiation|Radiotherapy : 70 grays , fractionization : 2Gy/day, 5 days / week, for 7 weeks . Concurrent administration of Carboplatin: 70 mg/m2/day (day 1 until day 4)and 5FU 600 mg/m2/day (day 1 until day 4). Weeks 1; 4; 7.
9963956|NCT01233843|Experimental|drug and radiation|"Induction chemotherapy by Docetaxel 100mg/m2, day 1; cisplatin 100mg/m2, day 1; 5-Fluorouracil 1000mg/m2 (from day 1 to day 5), for a total of three cycles .Those cycles are administrated at day 1; day 22, day43.~This induction chemotherapy is followed ( for responders or stable disease patients)by radiotherapy (70 grays for 7 weeks) and concurrent Erbitux( weekly administration)."
9963957|NCT01233882|Experimental|Healthy Volunteers|
9963958|NCT01233882|Experimental|Mild Renal Impairment|
9963959|NCT01233882|Experimental|Moderate Renal Impairment|
9963960|NCT01233882|Experimental|Severe Renal Impairment|
9963961|NCT01233895|Experimental|AVE1642/ AVE1642 with Velcade|
9963962|NCT01233908||PTSD|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and developed an associated posttraumatic stress disorder
9963963|NCT01233908||PTSD - negative|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and did not develope an associated posttraumatic stress disorder
9963964|NCT01233934|Active Comparator|Dexchlorpheniramine 1% Cream|
9963965|NCT01233934|Experimental|Dexchlorpheniramine 1% Gel|
9963966|NCT01233947|Experimental|AFP464|74 mg/m2 AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycle.
9963967|NCT01233947|Experimental|AFP464 + Faslodex|AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycles and Faslodex administered per package label.
9963968|NCT01233973|No Intervention|control subjects|verbal narrative of advance care planning
9963969|NCT01233973|Experimental|intervention group|video decision aid viewed by subjects
9963970|NCT01233986||Case group - Large artery atherosclerosis|
9963971|NCT01233986||Control group-Small vessel occlusion|
9963972|NCT01234012|Experimental|Treatment: IMF-001|100 or 200 mcg will be administered to patients subcutaneously every 2 weeks for 6 injections.
10008491|NCT01613950|Experimental|BYL719 + AUY922|Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
10008492|NCT01613963||Patients with ocular inflammation|Patients with ocular inflammation
10008493|NCT01613976|Experimental|Panobinostat and Azacitidine|combination regimen
10008494|NCT01613989|Active Comparator|Treatment 1|Reference group, installation of hip prothesis following standard procedure
10008495|NCT01613989|Active Comparator|Treatment 2|:treatment group,installation of hip prosthesis with assistance by computer based on imaging EOS
10008496|NCT01614002||carcinoma, Doce onkovis (Docetaxel)|treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region.
10008497|NCT01614015|Experimental|Supervision as Usual|Supervision as Usual
10008498|NCT01614015|Experimental|Observation Based Supervision|Behavioral
10008499|NCT01614028|Active Comparator|Total Hip Arthroplasty using Fitmore femoral stem|
10008500|NCT01614028|Active Comparator|Total Hip Arthroplasty using M/L Taper Femoral stem|
10008501|NCT01614041|Active Comparator|Control Group|Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
10008502|NCT01614041|Experimental|Study Group|Comparative high dose of tandospirone treatment, 60 mg/day
10008503|NCT01614054|Experimental|Survey Group|Patients will receive a survey along with their meal tray, provided by Food and Nutrition Services. The survey will consist of questions related to smoking habits, desire for NRT and desire for assistance with smoking cessation. The results of these surveys will be collected by allied health professionals and forwarded to the CTU team. The CTU team will then be encouraged to use that information to engage in a discussion with the patient regarding prescription of NRT. It will then be left to the discretion of the HCP whether or not to prescribe NRT taking into account patient preference, absence of contraindications and clinical benefit. All those participating in the survey will be offered referral to a smoking cessation clinic upon discharge.
10008504|NCT01614054|No Intervention|Standard of Care|In the control arm, surveys will also be given out to all patients along with their meal trays. However, these surveys will include only questions related to smoking habits in order to get a baseline number of smokers. The surveys will then be collected by the allied health and nursing staff and forwarded only to the research team. The HCP taking care of the patients will still provide standard of care treatment with NRT and smoking cessation referral as clinically indicated.
10008505|NCT01614080||High sc-tPA/tc-tPA ratio group|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The High sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio higher than the median
10008506|NCT01614080||Low sc-tPA/tc-tPA ratio|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The Low sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio lower than the median
9476687|NCT03569319|Experimental|"Group 1: THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=10)"
9963973|NCT01234051|Experimental|Docetaxel, oxaliplatin, palliative chemotherapy|
9963974|NCT01234064|Active Comparator|Graduated Compression Stockings|
9963975|NCT01234064|Other|No Graduated Compression Stockings|
9963976|NCT01234077|No Intervention|ECG recording|In-laboratory vs. in-home recordings
9963977|NCT01234090||Persons with Aphasia|
9963978|NCT01234116|Active Comparator|Kaletra|Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
9963979|NCT01234116|Active Comparator|Raltegravir|Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
9963980|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.
9963981|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
9963982|NCT01234129||zoledronic acid|Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid
9963983|NCT01234142|Experimental|Cohort 1|
9963984|NCT01234142|Experimental|Cohort 2|
9963985|NCT01234142|Experimental|Cohort 3|
9963986|NCT01234142|Experimental|Cohort 4|
9963987|NCT01234155|No Intervention|Control|
9963988|NCT01234155|Experimental|Exercise - Continuous Walking|
9963989|NCT01234155|Experimental|Exercise - Interval Walking|
9963990|NCT01234181|Experimental|BMSCs transplantation|
9963991|NCT01234181|Sham Comparator|No BMSCs transplantation|
9963992|NCT01234194|Active Comparator|Group 1|
9963993|NCT01234194|Active Comparator|Group 2|
9963994|NCT01234220||Adrenal Venous Sampling (AVS)|Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
9963995|NCT01234233|No Intervention|Group 1|Control group - no intervention: no preoperative warming
9963996|NCT01234233|Active Comparator|Group 2 - 10 min prewarming|10 min prewarming preoperatively
9963997|NCT01234233|Active Comparator|Group 3 - 20 min prewarming|20 min prewarming preoperatively
9963998|NCT01234233|Active Comparator|Group 4 - 30 min prewarming|30 min prewarming preoperatively
9963999|NCT01234246||Patients with colorectal cancer|Patients with colorectal cancer are included
9964000|NCT01234246||Partners|Partners of patients with colorectal cancer are included
9964001|NCT01234259|Experimental|Study group|Device: Venus Freeze (MP)2 V2 system
9964002|NCT01234259|Sham Comparator|control group:|Sham comparator
9964003|NCT01234272|Experimental|ITM-IVPCA|ITM-IVPCA:intrathecal morphine and IV-fentanyl patient controlled analgesia
9964004|NCT01234272|Active Comparator|PCEA|PCEA:epidural PCA(patient controlled analgesia)
9964005|NCT01234285|Experimental|intravenous heparin aPTT 40-50 seconds|Patients 11-15: IV heparin, target aPTT range 40-50 seconds
9964006|NCT01234285|Experimental|intravenous heparin|Patients 26-40: IV heparin, target range aPTT 50-60 seconds
9964007|NCT01234285|Experimental|Intravenous heparin|Patients 41-55 IV heparin, target aPTT range 60-70 seconds
9964008|NCT01234285|Active Comparator|sq heparin three times a day|Patients 1-10 will receive subcutaneous heparin three times a day
9964009|NCT01234298|Experimental|SPD489 Low-Dose|
9964010|NCT01234298|Experimental|SPD489 High-Dose|
9964011|NCT01234298|Placebo Comparator|Placebo|
9964012|NCT01234324|Experimental|Arm 1: ECX + Panitumumab|
9964013|NCT01234324|Active Comparator|Arm 2: EXC alone|
9964014|NCT01234363|Experimental|Magnetic Resonance Elastography, Supersonic Shear Imaging|Magnetic Resonance Elastography and Supersonic Shear Imaging
9964015|NCT01234376||Control patients|
9964016|NCT01234376||Patients with eosinophilic esophagitis|
9964017|NCT01234389|Other|H. pylori positive patients|
9964018|NCT01234389|Other|H. pylori negative patients|
9964019|NCT01234415|Experimental|Patient|
9964020|NCT01234428|Other|surgery|
9964021|NCT01234441|Sham Comparator|Control|This group of patients will receive a non-nutritive beverage, and no exercise.
9964022|NCT01234441|Active Comparator|Protein|This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session
9964023|NCT01234441|Active Comparator|Protein + Exercise|This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment
9964024|NCT01234454|Experimental|Risperidone Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
9964025|NCT01234454|Experimental|Olanzapine Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
9964026|NCT01234454|No Intervention|Thiothixene|Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
9964027|NCT01234493|Active Comparator|fixation|Syndesmosis fixation with one 3.5mm fully threaded screw
9964028|NCT01234493|Active Comparator|no fixation|No syndesmosis fixation
9964029|NCT01234506|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
9964030|NCT01234506|Placebo Comparator|Placebo|An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
9964031|NCT01234532|Experimental|entinostat & anastrozole neoadjuvant|"Neoadjuvant entinostat daily on days 1, 8, 15, 22, and 29 + anastrozole daily on days 4-29 followed by surgery ie either lumpectomy or mastectomy.~Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
9964032|NCT01234545||A|
9964033|NCT01234558|Placebo Comparator|Normal Saline|IV placebo
9964034|NCT01234558|Experimental|GLYX-13, 1 mg/kg|
9964035|NCT01234558|Experimental|GLYX-13, 5 mg/kg|
9964036|NCT01234558|Experimental|GLYX-13, 10 mg/kg|
9964037|NCT01234584|Experimental|Group A|23 implants using SPK Abutments
9964038|NCT01234584|Active Comparator|Group B|implants using CPK Abutments
9964039|NCT01234597|Active Comparator|Arm A: Without Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the treating physician"
9964040|NCT01234597|Experimental|Arm B: Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: the patients are connected to a CGM sensor. Insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the national coordinator based on the data collected in the past previous days of CGM sensor monitoring."
9964041|NCT01234610|Experimental|Exercise|Exercise
9964042|NCT01234610|No Intervention|Control|No exercise
9964043|NCT01234623||UCB eyedrops, single arm|One-centre pilot study, open, non randomized.
9964044|NCT01234636|Active Comparator|cis9,trans 11 CLA oil|50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA
9964045|NCT01234636|Placebo Comparator|Placebo oil|50 volunteers cross over design, placebo oil 4g/day
9964046|NCT01234662|Active Comparator|Group 1|Spinal anesthesia + intrathecal opioid bolus (SPA)
9964047|NCT01234662|Active Comparator|Group 2|CSE + epidural opioid bolus (CSE)
9964048|NCT01234662|Experimental|Group 3|CSE + continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs (CSEPCEA)
9964049|NCT01234688|Experimental|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
9964050|NCT01234688|No Intervention|Control|Patients allocated to the control group remained in regular dialysis treatment during the same timeframe.
9964051|NCT01234701||Primary liver tumors, non-cirrhotic|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonance Imaging (MRI) and underwent resection for primary liver tumors.
9964052|NCT01234727||Diabetes|Patients with Type 1 or Type 2 diabetes requiring insulin.
9964053|NCT01234740|Experimental|Arm I|Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.
9964054|NCT01234753|No Intervention|Usulal care|Usual care by a visit to physician at the hospital out-patient clinic
9964055|NCT01234792|Experimental|NIC-6|6 mg Experimental nicotine gum
9964056|NCT01234792|Active Comparator|NIC-4|4 mg Nicotine Gum
9964057|NCT01234792|Active Comparator|NIC-2|2 mg Nicotine Gum
9964058|NCT01234805|Experimental|Supportive care (yoga therapy)|Patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. Patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12.
9964059|NCT01234818|Experimental|LNG-IUS, endometrial hyperplasia|
9964060|NCT01234844|Other|care of guinea pigs|"Each patient serves as own control receiving pet therapy and usual occupational therapy on alternate days."
9964061|NCT01234857|Experimental|Part A: ridaforolimus + dalotuzumab|Approximately 15 patients will be enrolled to the ridaforolimus-dalotuzumab combination treatment arm. Subsequent Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to exemestane single-therapy treatment.
9964062|NCT01234857|Active Comparator|Part A: exemestane|Exemestane 25 mg daily; single-agent therapy.
9964063|NCT01234857|Experimental|Part B: ridaforolimus + dalotuzumab|Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to one of two single-therapy treatments (ridaforolimus alone or dalotuzumab alone). With the implementation of Amendment 3, this study arm will not be opened.
9964064|NCT01234857|Experimental|Part B: ridaforolimus|Ridaforolimus; 40 mg daily five days a week, single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
9964065|NCT01234857|Experimental|Part B: dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg weekly; single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
9964066|NCT01234896|Experimental|Nicotine Gum 6|6 mg Nicotine medicated gum
9964067|NCT01234896|Active Comparator|Nicotine Gum 4|4 mg Nicotine Gum
9964068|NCT01234896|Active Comparator|Nicotine Gum 2|2 mg Nicotine Gum
9964069|NCT01234896|Active Comparator|Nicotine Lozenge|4 mg Nicotine Lozenge
10008507|NCT01614106|Experimental|Intervention|The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
10008508|NCT01614106|No Intervention|Treatment as Usual (TAU)|The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals.
10008509|NCT01614119|Experimental|Sportsmen|One single group of active healthy subjects was investigated
10008510|NCT01614132|Experimental|Vincristin, CCNU, cis-platin|"radiotherapy and concomitant chemotherapy (7 cycles of 7 days):~2 mg/m2 vincristin i.v.~55,0 Gy Posterior cranial fossa (M0)~55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)~maintenance chemotherapy (8 cycles of 42 days):~once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.~once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v."
10008511|NCT01614145||Proven/probable CNS IA|Immunocompromised patients with proven/probable invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
10008512|NCT01614145||Possible/No CNS IA|Immunocompromised patients with possible/NoIA invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
10008513|NCT01614158||acute N-AION (< 7 d)|"physical, intellectual and linguistic abilities, in order to understand the test requirements~willingness to comply with the protocol (4 visits)~45 - 80 years, informed consent~acute N-AION (< 7 d)~D-BCVA > 0.1 (2/20)~RAPD ≥ 0.3 logE steps (neutral density filters)"
10008514|NCT01614184|Experimental|All patients|All patients enrolled in study.
9476688|NCT03569319|Experimental|"Group 2: THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=10)"
9476689|NCT03569319|Placebo Comparator|Group 3: Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention) (n=10)"
10008515|NCT01614197|Experimental|Dose Level 1|This is the starting dose of temsirolimus at 7.5 mg/m^2 given IV. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
10008516|NCT01614197|Experimental|Dose Level 2|If Dose Level 1 is tolerated, the study will escalate to Dose Level 2 following the dose escalation schedule. Dose Level 2 will be administered via IV at 10 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
10008517|NCT01614197|Experimental|Dose Level 3|If Dose Level 2 is tolerated, the study will escalate to Dose Level 3 following the dose escalation schedule. Dose Level 3 will be administered via IV at 15 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
10008518|NCT01614197|Experimental|Dose Level 4|If Dose Level 3 is tolerated, the study will escalate to Dose Level 4 following the dose escalation schedule. Dose Level 4 will be administered via IV at 25 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8. Temsirolimus will not be escalated beyond Dose Level 4.
10008519|NCT01614223|Active Comparator|ACP treatment|
10008520|NCT01614223|Active Comparator|Corticosteroid treatment|
10008521|NCT01614236|Active Comparator|control|patients will be randomized similarly but will undergo surgery under epidural analgesia
10008522|NCT01614236|Active Comparator|Lyrica|Patients will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
10008523|NCT01614262|Experimental|Continuous Glucose Monitoring|The Continuous Glucose Monitoring (CGM) arm will receive care based upon results from there CGM data; treatment decisions are based on algorithm and CGM data
10008524|NCT01614262|Active Comparator|Self Monitoring Blood Glucose|Subjects in the Self Monitoring Blood Glucose group will have treatment decisions based on self monitored blood glucose values and not CGM values, per current standard of care.
10008525|NCT01614275|Experimental|Technology-enhanced Parent Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training military parents of children with autism, regardless of their geographic location, to implement effective behavior management and teaching strategies with high procedural integrity (90% accuracy).
10008526|NCT01614275|Experimental|Technology-enhanced Tutor Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training tutors to implement early intervention services that are commonly used with children diagnosed with autism with high procedural integrity (above 80%).
10008527|NCT01614275|Experimental|Technology-enhanced Early Intensive Behavioral Intervention|The investigators will demonstrate that technology-enhanced service delivery will provide remote access to efficient and effective EIBI services to military families affected by autism.
10008528|NCT01614275|Placebo Comparator|Wait-list No-intervention Control Group|Tutors and families will be assigned to treatment and control groups using the process of minimization, which has been recommended for small clinical trials because it minimizes differences between the groups on relevant covariables while guarding against bias in ways comparable to simple randomization. The control group will not receive intervention services.
10008529|NCT01614288|Active Comparator|Knee Arthroscopy + HTO|
10008530|NCT01614288|Active Comparator|HTO Alone|
10008531|NCT01614301|Experimental|Experimental Arm|Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity
10008532|NCT01614301|Other|Controll Arm|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
10008533|NCT01614314|Active Comparator|Auto-instructional guide|The subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
10008534|NCT01614314|Experimental|Preceptorship|The subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
10008535|NCT01614327||Retinal Screening; Diabetes 1 and 2|Patients diagnosed as either having Pre-Diabetes, Diabetes 1 or Diabetes 2
10008536|NCT01614340|Other|Usual Care|Usual Physical Therapy Plan of Care
10008537|NCT01614340|Other|Usual Care Plus Pain Management Program|Behavioral: Cognitive-Behavioral Pain Self-management Program.
10008538|NCT01614353||Study Cohort|All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
10008539|NCT01614366|Active Comparator|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
10008540|NCT01614366|Experimental|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
9476690|NCT03569306|Experimental|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
10008541|NCT01614366|Experimental|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
10008542|NCT01614366|Experimental|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
10008543|NCT01614379||Healthy control subject|10 healthy control subjects for statistical comparison
10008544|NCT01614379||Type 1 diabetic patient|40 type 1 diabetic patients with diabetic foot ulcers.
10008545|NCT01614405|Placebo Comparator|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada. Then there is an option for an 18 month follow-up study.
10008546|NCT01614405|Active Comparator|Truvada and Kaletra|Patients will be take Truvada and Kaletra for 6 months with the option of open label for additional 18 months.
10008547|NCT01614418|Experimental|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation using BARRX HALO90 catheter
10008548|NCT01614431|Experimental|N acetyl cysteine|NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)
10008549|NCT01614444|Active Comparator|Acupressure Treatment|
10008550|NCT01614444|Placebo Comparator|Placebo Acupressure Treatment|
10008551|NCT01614483|Experimental|Yellow cassava + placebo capsule|
10008552|NCT01614483|Placebo Comparator|White cassava + placebo capsule|
10008553|NCT01614483|Active Comparator|White cassava + B-carotene capsule|
10008554|NCT01614522|Experimental|HER-2 Amplified|
9667644|NCT03292458|Experimental|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
9964070|NCT01234909||Atopic dermatitis|Pediatric patients ages 1-18 years old with atopic dermatitis
9964071|NCT01234935|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
9964072|NCT01234935|Experimental|Arm II|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity. NOTE: *Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
9964073|NCT01234948||Chronic periodontitis patients|Chronic periodontitis patients had at least one site per quadrant with clinical probing depth (CPD) > 5mm and radiographic evidence of bone loss
9964074|NCT01234948||Generalised chronic gingivitis patients|Generalised chronic gingivitis patients presented with bleeding on probing (BOP) at > 30% of sites, CPDs < 4mm and no evidence of bone loss
9964075|NCT01234948||Periodontally healthy subjects|Healthy subjects had < 10% sites with BOP and no sites with CPD > 3mm
9964076|NCT01234961|Experimental|Redesigning Daily Occupations|The ReDO intervention focuses on how people compose their everyday lives. Supporting people in how to change and modify their patterns of daily occupations is a new intervention method for people with stress-related disorders, but it has been shown to be effective in improving quality of life and self-rated health in other target groups. The basic idea is that re-structuring of an individual's lifestyle and pattern of daily occupations will lead to a healthier balance between the occupations of everyday life, and that this balance will promote wellness and improved work capacity. The program is group based and comprises 16 weeks, with sessions 2 x 2 hours per week, followed by 3-4 booster sessions.
9964077|NCT01234961|Active Comparator|Care as usual|Standard rehabilitation provided by the Social Insurance Office, such as stress management, physical therapy, mindfulness training.
9964078|NCT01234974|Experimental|Pasireotide|Pasireotide 60 mg day 1 every 28 days
9964079|NCT01234987||Breast cancer|
9964080|NCT01234987||Colon cancer|
9964081|NCT01234987||Lung Cancer|
9964082|NCT01235000||2010-11 influenza vaccine recipients|Participants of an earlier clinical trial (TITRE II) to evaluate prime-boost response across B lineages in 2009-10
9964083|NCT01235013|Experimental|Maraviroc|
9964084|NCT01235013|No Intervention|Control|Patients continue with their usual treatment
9964085|NCT01235026|Experimental|Synbiotic|"Dietary Supplement: Synbiotic: combination of the prebiotic Oligofructose with the probiotic Bifidobacterium animalis subsp. lactis Bb12"
9964086|NCT01235026|Placebo Comparator|Placebo|Dietary supplement: placebo: maltodextrin
9964087|NCT01235052|Experimental|TEP with 18F-FMISO|TEP with 18F-FMISO
9964088|NCT01235065|Active Comparator|direct laryngoscope|emergency intubation with direct laryngoscopy technique
9964089|NCT01235065|Active Comparator|video laryngoscope|emergency intubation with video laryngoscopy technique
9964090|NCT01235078||Intraosseous vascular access|subjects with urgent vascular access needs in whom intraosseous vascular access has been attempted and/or established.
9964091|NCT01235091|Other|Standard|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
9964092|NCT01235091|Experimental|SI/WWE|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam
9964093|NCT01235091|Experimental|SI/WWE/PD|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam and Peer-delivered Enhanced Intervention
9964094|NCT01235104||Total nephrectomy|
9964095|NCT01235143|Experimental|desflurane anesthesia|maintenance anesthesia with desflurane
9964096|NCT01235143|Active Comparator|sevoflurane|maintenance anesthesia with sevoflurane
10008555|NCT01614522|Experimental|HER-1 & HER-2 Co-expression|
10008556|NCT01614535|Experimental|Female group|Female gender patients undergoing thyroidectomy
10008557|NCT01614535|Active Comparator|Male group|Male gender patients undergoing thyroidectomy
10008558|NCT01614548||all patients|We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.
10008559|NCT01614587||Cases|"Early, unexplained recurrence (within six months of procedure) after Sacrocolpopexy~The recurrence required treatment (surgery or pessary)"
10008560|NCT01614587||Controls|"Sacrocolpopexy during the same period~No recurrence, no reoperation, no retreatment to date (minimum of 12 months from surgery)"
10008561|NCT01614639|Experimental|Traditional Acupuncture|Traditional Acupuncture given at 2 visits.
10008562|NCT01614639|Experimental|Electroacupuncture|Electro-acupuncture given at 2 visits.
10035470|NCT01806350|Experimental|Arm I (PFMT)|Patients receive a handout describing behavioral management tips for urinary incontinence, including information and suggestions about optimal volume fluid intake, constipation management, measures to reduce urgency by spreading fluid intake, and avoiding caffeine and other bladder irritants that have proved effective in other intervention trials. Patients undergo PFMT over 20-30 minutes teaching them to contract the pelvic floor muscles correctly and receive feedback to avoid the contraction of abdominal, gluteal or adductor muscles. Patients are asked to perform 3 sets of 10 pelvic muscle contractions with a goal of holding the contraction for 5 seconds daily for 12 weeks and also receive a reminder phone call to address concerns and review the instructions at 4 weeks.
10035471|NCT01806350|Active Comparator|Arm II (usual care)|Patients receive usual care for urinary incontinence, with an option to join the training program after completion of study.
10035472|NCT01806363|Active Comparator|Part A: Telmisartan, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
10035473|NCT01806363|Active Comparator|Part B: Chlorthalidone, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
10035474|NCT01806376|Experimental|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
10035475|NCT01806402||Retina|Having clinical diagnosis of retina pathology
10035476|NCT01806402||Glaucoma|Having clinical diagnosis of glaucoma
10035477|NCT01806415|Experimental|Fenobam 50 mg|Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule.
10035478|NCT01806415|Experimental|Fenobam 100 mg|Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.
10035479|NCT01806415|Experimental|Fenobam 150 mg|Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.
10035480|NCT01806415|Placebo Comparator|Placebo arm|Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
10035481|NCT01806428||aPC treatment group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis treated with activated protein C at 24 mcg/Kg/h for 96 hours
10035482|NCT01806428||Control group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis not treated with activated protein C because of contraindications
10035483|NCT01806441|Experimental|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
10035484|NCT01806441|Active Comparator|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
10035485|NCT01806454|Active Comparator|calcium A|tablets, 600mg per day,till birth
10035486|NCT01806454|Active Comparator|calcium B|tablets,1200mg per day,till birth
10035487|NCT01806467||critically ill patients|patients admitted to the medical-surgical ICU
10035488|NCT01806467||post-cardiac surgical patients|patients admitted to the post-cardiac surgical ICU
10008563|NCT01614652|Experimental|Parachute Implant and All Appropriate Medical Therapy (AAMT)|
10008564|NCT01614652|No Intervention|All Appropriate Medical Therapy (AAMT)|
10008565|NCT01614665|Active Comparator|Tacrolimus|Participants receive tacrolimus twice daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus twice daily up to end of Part B and C of the study.
10008566|NCT01614665|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B and of the study.
10008567|NCT01614678|Other|AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto|Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
10008568|NCT01614678|Other|AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto|Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
10008569|NCT01614691|Experimental|SPARC1203 low dose|
10008570|NCT01614691|Experimental|SPARC1203 mid dose|
10008571|NCT01614691|Experimental|SPARC1203 high dose|
10008572|NCT01614691|Placebo Comparator|Placebo|
10008573|NCT01614704||Adjuvant treatment|Patients in this group will be offered the option of ovarien cryopreservation as well as the follow up of the follicule stock during chemotherapy.
10008574|NCT01614704||Neo adjuvant treatment|patients in this group will only have the follow up of the follicule stock.
10008575|NCT01614717|Active Comparator|Treatment Group|CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing
10008576|NCT01614717|Placebo Comparator|Control Group|CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI
10008577|NCT01614730|Sham Comparator|Modified Neurotech Vital Device|Checking to see no contraction is stimulated during treatment with the Modified Neurotech Device
10008578|NCT01614730|Active Comparator|Neurotech Vital Device|Checking to see a contraction is stimulated during treatment of the Neurotech Vital Device
10008579|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
10008580|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.01 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
10008581|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.03 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
10008582|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.06 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
10008583|NCT01614756|Experimental|Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
10008584|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.3 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
10008585|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
10008586|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
10008587|NCT01614756|Experimental|Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 3 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
10008588|NCT01614756|Experimental|Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 10.0 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
10008589|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 1)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose"
10008590|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 2)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
10008591|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 3)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
10008592|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 4)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and >1.0mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
10008593|NCT01614782|Experimental|0.35 mg MK-5823 - Healthy Participants|
10008594|NCT01614782|Experimental|0.7 mg MK-5823 - Healthy Participants|
10008595|NCT01614782|Experimental|1.4 mg MK-5823 - Healthy Participants|
10008596|NCT01614782|Experimental|2.8 mg MK-5823 - Healthy Participants|
10008597|NCT01614782|Experimental|1.4 mg MK-5823 - Participants with T2DM|
10008598|NCT01614782|Experimental|2.8 mg MK-5823 - Participants with T2DM|
10008599|NCT01614808||Observational|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
10008600|NCT01614834||chronic urticaria patients|all patients suffering from chronic forms of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
10008601|NCT01614873|Active Comparator|Pressure Support Ventilator|"Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden).~During pressure support the inspiratory muscles are assisted by a constant inspiratory pressure adjusted by the prescriptor and applied to the airway by either an invasive or a non invasive interface. Then the subject initiate the inspiratory effort and a constant pressure is delivered to the airway in order to assist inspiration. Three levels of pressure will be tested (5 cmH2O, 8 cmH2O and 12 cmH2O)"
10008602|NCT01614873|Experimental|NAVA|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram. Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). During NAVA the inspiratory muscles are assisted by a pressure which is proportional to this electrical activity. Then the subject initiate the inspiratory effort and a pressure proportional to the integrated EMG activity is delivered to the airway in order to assist inspiration. The adjustment of the level of NAVA (expressed in cmH2O/microvolt) will be adjusted in order to obtain a peak pressure similar to pressure support (5 cmH2O, 8 cmH2O and 12 cmH2O)
10008603|NCT01614938|Active Comparator|cisplatin-radiotherapy (CRT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent weekly cisplatin and radiotherapy
10008604|NCT01614938|Experimental|cetuximab-radiotherapy (ERT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent cetuximab and radiotherapy
10008605|NCT01614951|Experimental|Pulmonary perfusion|
10008606|NCT01614951|Experimental|Pulmoplegia|
10008607|NCT01614951|Other|Control group|
10008608|NCT01614964|Experimental|AQ-13|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
10008609|NCT01614964|Active Comparator|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention: Active Comparator: Coartem. Participants randomized to the Coartem arm will be treated with 80 mg artemether and 480 mg lumefantrine at the time of diagnosis and 8 hours later on day 1, the same doses (80 mg artemether and 480 mg lumefantrine) twice on day 2 (24 and 36 hours after diagnosis) and twice more on day 3 (48 and 60 hours after diagnosis) for total oral doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
10008610|NCT01614977|Experimental|Methylprednisolone|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days."
10008611|NCT01614977|No Intervention|Placebo|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~placebo pills with an identical outward appearance and volume prescribed according to the same schedule."
10008612|NCT01614990|Active Comparator|Macimorelin|
10008613|NCT01614990|Placebo Comparator|Placebo|
10008614|NCT01615003|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
10008615|NCT01615003|Placebo Comparator|control group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
10008616|NCT01615016|Experimental|MISurf|Minimally Surfactant application via small tube inserted into the trachea under CPAP therapy without formal intubation and without mechanical ventilation
10008617|NCT01615016|Active Comparator|InSurE|Surfactant application via Intubation - Surfactant Application - Extubation sequence
10008618|NCT01615042|Experimental|Dose Escalation/High Dose Lenalidomide|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
10008619|NCT01615055|Experimental|Fluoxetine tablets|
10008620|NCT01615055|Placebo Comparator|Placebo tablets|
10008621|NCT01615068||Cohort|
10008622|NCT01615081|Active Comparator|Sucrose solution|75 g sucrose (75 g carbohydrate) desolved in 750 ml water
10008623|NCT01615081|Experimental|Malt extract solution|183 g malt extract (corresponding to 75 g carbohydrate and 103 ml water) desolved in 647 ml water
10008624|NCT01615094||High-risk Stage B Heart Failure Patients|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
10008625|NCT01615107|Experimental|GROUP 1: Oxytocin infusion alone|GROUP 1: Oxytocin infusion alone
10008626|NCT01615107|Experimental|double balloonand oxytocin|insertion of the double balloon and oxytocin
10008627|NCT01615146|Experimental|Therapeutic Platelet Transfusion Arm|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
10008628|NCT01615146|Active Comparator|Prophylactic Platelet Transfusion Group|Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is < 10 x 109/L.
10008629|NCT01615159|No Intervention|Self directed control|
10008630|NCT01615159|Active Comparator|Behavior and lifestyle counseling|
10008631|NCT01615172|Active Comparator|Aortic cannulation|routine placement of aortic cannula
10008632|NCT01615172|Active Comparator|axilaris cannulation|new type of cannulation
10008633|NCT01615185|Experimental|sulpiride plus amisulpride|sulpiride 800mg/d + amisulpride 400mg/d
10008634|NCT01615185|Active Comparator|full-dose amisulpride|amisulpride 800mg/d
10008635|NCT01615211|No Intervention|Standard treatment|patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
10008636|NCT01615211|Active Comparator|trilostane|patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
10008637|NCT01615211|Active Comparator|Letrozole|Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
10008638|NCT01615224|No Intervention|single dose|Patients receive the standard treatment with 800mcg of vaginal misoprostol
10008639|NCT01615224|Experimental|repeated doses|patients receive 800mcg of vaginal misoprostol. In addition to this they receive repeated doses of 400mcg oral misoprostol after 3 and 5 hours. Women of more than 9 weeks pregnancy according to last menstrual period will be given a choice of vacuum aspiration or further medical treatment with 2 additional doses of misoprostol given after 7 and 9 hours after the initial vaginal treatment.
10008640|NCT01615237|Active Comparator|CBP + PF|Field sites randomly assigned to Arm 2 will receive as an intervention current best practices and quarterly audits and performance feedback reports (PF) on provider delivery of cessation services using chart audit procedures that we have used successfully in prior work. Depending on what is used at the site, paper or Electronic Dental Record, we will work with the site to create a registry of patients who are tobacco users.
10008641|NCT01615237|Active Comparator|CBP + PF + P4P|Field sites randomly assigned to this implementation condition (Arm 3) will receive current best practices (CBP), quarterly audit and performance feedback reports (PF), and financial incentives (pay for performance, P4P) for every documented (documentation in patient chart of counseling, prescription, or referral to the quit-line) delivery of adherence to clinical practice guidelines.
10008642|NCT01615237|Active Comparator|Current Best Practices (CBP)|All dental field sites will receive current best practices (CBP) for training and technical assistance in promoting adoption of clinical practice guidelines for treating tobacco dependence.
10008643|NCT01615250|No Intervention|Standard therapy|Treatment with standard therapy. Cardiospec shock-wave therapy
10008644|NCT01615250|Active Comparator|Stem cells|Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
10008645|NCT01615276|Placebo Comparator|Protein ingestion|Protein ingestion directly after the contralateral leg received NMES
10008646|NCT01615276|Experimental|Protein ingestion after NMES|Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
10008647|NCT01615289|Active Comparator|Green tea extract, 250 ml|Single intragastric instillation of 250 ml green tea extract
10008648|NCT01615289|Active Comparator|Green tea extract, 500 ml|Intragastric instillation of 500 ml green tea extract solution
10008649|NCT01615289|Placebo Comparator|Control solution, 250 ml|Intragastric instillation of 250 ml control solution
10008650|NCT01615289|Placebo Comparator|Control solution, 500 ml|Single intragastric instillation of 500 ml control solution
10008651|NCT01615302|Active Comparator|Mucosa advancement flap|
10008652|NCT01615302|Experimental|Mucosa advancement flap + PRP|Platelet rich plasma added to the mucosa advancement flap
10008653|NCT01615354|Placebo Comparator|Placebo|
10008654|NCT01615354|Experimental|Treatment|
10008655|NCT01615380|Active Comparator|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
10008656|NCT01615380|Experimental|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
10008657|NCT01615393|Active Comparator|Ribavirin capsule arm|
10008658|NCT01615393|Experimental|Ribavirin tablet arm|
10008659|NCT01615406|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
10008660|NCT01615419||Cohort|
10008661|NCT01615445|Active Comparator|Resveratrol|Group A Participants will received resveratrol 500 mg twice daily for 1 week then 1000 mg twice daily for 3 weeks, according to tolerance. They will discontinue medication for 2 weeks. The will receive placebo for 4 weeks.
10008662|NCT01615445|Placebo Comparator|Placebo|Group B (n=6) Will receive placebo for 4 weeks, they will discontinue medication for two weeks. Then receive resveratrol for 4 weeks
10008663|NCT01615458|Active Comparator|Usual Care|Patients will receive their usual care from providers at the clinic.
10008664|NCT01615471|Active Comparator|Large Group|In person group sessions in large group format (up to 125 others)
10008665|NCT01615471|Active Comparator|Small group|Small group in person sessions (up to 25 other participants)
10008666|NCT01615497|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on alcohol and substance abuse.
10008667|NCT01615497|Experimental|Web-based CBT4CBT for alcohol plus TAU|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
10008668|NCT01615497|Active Comparator|Web-based CBT with minimal clinical contact|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
10008669|NCT01615510|Experimental|Capsaicin (topical)|300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
10008670|NCT01615510|Experimental|Menthol (topical)|1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
10008671|NCT01615523||Children/adolescents born preterm|
10008672|NCT01615523||Control children and adolescents|
10008673|NCT01615536|Experimental|Canine fossa trephine group (CFT)|
10008674|NCT01615536|Active Comparator|Non Canine fossa trephine group (NonCFT)|
10008675|NCT01615549|Active Comparator|Free training|
10008676|NCT01615549|Experimental|Proficiency-based training|
10008677|NCT01615562||PCOS adolescents|Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
10008678|NCT01615562||PCOS women|Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).
10008679|NCT01615575|Active Comparator|Haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and addiction of rectal mucopexy.
10008680|NCT01615575|Active Comparator|Stapler haemorrhoidopexy|Haemorrhoidopexy was performed with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA.)
10008681|NCT01615588|Experimental|honey|Manuka honey
10008682|NCT01615601||darunavir (PREZISTA)|PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
10008683|NCT01615601||etravirine (INTELENCE)|INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
10008684|NCT01615614|Experimental|Treatment A|Rilpivirine 25 mg once daily will be administered for 11 days
10008685|NCT01615614|Experimental|Treatment B|Rilpivirine 50 mg once daily will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days
10008686|NCT01615614|Experimental|Treatment C|Rilpivirine (in a regimen to be determined based on an interim pharmacokinetic analysis of treatment A and B) will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days.
10008687|NCT01615627|Experimental|Hypotonic Treprostinil Solution|Hypotonic Treprostinil Solution
10008688|NCT01615627|Active Comparator|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
10008689|NCT01615640||Osteosarcoma patients|Patients with an histologically proven osteosarcoma will be entered into the study.
10008690|NCT01615653|Active Comparator|EUS 1|
10008691|NCT01615653|Active Comparator|EUS 2|
10008692|NCT01615666||Healthy volunteers|Healthy volunteers who will undergo functional MRI (fMRI) to obtain fMRI index
10008693|NCT01615666||Alzheimer's disease|Individuals with Alzheimer's disease who will undergo functional MRI (fMRI) to obtain fMRI index
10008694|NCT01615666||Non-Alzheimer's dementia|Individuals with Non-Alzheimer's dementia who will undergo functional MRI (fMRI) to obtain fMRI index
10008695|NCT01615666||Amnestic mild cognitive impairment|Individuals with Amnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
10008696|NCT01615666||Nonamnestic mild cognitive impairment|Individuals with Nonamnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
10008697|NCT01615692||36-mth follow up visit|The cohort will consist of original subjects of the SOX Trial who consent to participate in the extension to follow up sub study.
10008698|NCT01615705||Blood Draw|"SOX Subjects:~The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study."
10008699|NCT01615718|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
10008700|NCT01615718|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
10008701|NCT01615718|Active Comparator|Active Electrical Stim/Sham Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.
10008702|NCT01615718|Active Comparator|Sham Electrical Stim/Active Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
10008703|NCT01615744||Surgical ORIF calcaneal fx|
10008704|NCT01615744||Conservative treatment calcaneal fx|
10008705|NCT01615757|Experimental|Arm B, Ara-c - 12 gm/m2|Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
10008706|NCT01615757|Active Comparator|Arm A. Ara-c 18 gm/m2|Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5
10008707|NCT01615770|No Intervention|Open Label CBT and Pharmacotherapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label, this group received general supportive therapy delivered via four telephone calls made to participants over a 12-week period.
10008708|NCT01615770|Experimental|Behavioral: cognitive behavior therapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label treatment, half the participants received an additional 12 weeks of CBT that combined clinic-based skills training sessions, voicemail monitoring and telephone counseling
10008709|NCT01615783||Medicaid beneficiaries|Medicaid beneficiaries with at least one medical or pharmacy claim during each year in the identification period (2004-2006)
10008710|NCT01615796|Experimental|Cohort A1|GSK2140944 200mg single dose
10008711|NCT01615796|Experimental|Cohort A2|GSK2140944 600mg single dose
10008712|NCT01615796|Experimental|Cohort A3|GSK2140944 1200mg single dose
10008713|NCT01615796|Experimental|Cohort A4|GSK2140944 1800mg single dose
10008714|NCT01615796|Experimental|Cohort A5|GSK2140944 1800mg single dose
10008715|NCT01615796|Experimental|Cohort A6|GSK2140944 dose to be determined, single dose
9964097|NCT01235169|Experimental|Proximal Femoral Nail Antirotation|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation
9964098|NCT01235182||acute dyspnea, field, diagnostic|All patients with shortness of breath as the primary complaint (defined as eitherthe sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea and were age >18 years.
9964099|NCT01235208|Experimental|Eurodiet treatment|
9964100|NCT01235221|Experimental|BIIB041 (Fampridine-SR)|Participants take 10 mg sustained-release tablets of fampridine twice daily for up to 27 months or until the product is commercially available.
9964101|NCT01235247|Experimental|reminders, no reminder|
9964102|NCT01235260||001|Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)
9964103|NCT01235260||002|Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
9964104|NCT01235273|Experimental|GH replacement therapy|
9964105|NCT01235273|Placebo Comparator|Placebo|
9964106|NCT01235286|Experimental|remote ischemic preconditioning|
9964107|NCT01235299||Healthy subjects|
9964108|NCT01235299||Subjects suffering from Diabetes mellitus|
9964109|NCT01235299||Subjects suffering from peripheral arterial occlusive disease|
9964110|NCT01235312||Healthy subjects|
9964111|NCT01235312||Patients suffering from Diabetes mellitus|
9964112|NCT01235312||Patients suffering from peripheral arterial occlusive disease|
9964113|NCT01235325|Placebo Comparator|Placebo oil capsule|Banner Pharmacaps Europe
9964114|NCT01235325|Experimental|phylloquinone (1000 mcg)|Banner Pharmacaps Europe
9964115|NCT01235364|Experimental|Digital|The patient was randomized to digital insertion of the Foley catheter
9964116|NCT01235364|Experimental|Speculum|
9964117|NCT01235390|Experimental|5 g of walnuts|
9964118|NCT01235390|Experimental|40 g of walnuts|
9964119|NCT01235416|Active Comparator|AMG 706 50mg|50 mg, once daily. (Cohort 1)
9964120|NCT01235416|Active Comparator|AMG 706 75mg|75 mg, twice daily. (Cohort 2)
9964121|NCT01235416|Active Comparator|AMG 706 125mg|125 mg, once daily. (Cohort 3)
9964122|NCT01235429|Experimental|Educational|Participants will receive 12 diabetes self-management educational lessons in a small group setting located within the participating communities and delivered by trained community health workers.
9964123|NCT01235429|Active Comparator|Delayed education|The delayed education group will receive the same intervention after the intervention group has completed the educational lessons and all participants have completed the follow-up assessments.
9964124|NCT01235455||Group 1|
9964125|NCT01235468|Experimental|CB expnasion|ex-vivo expansion of cord blood for transplantation
9964126|NCT01235481|Experimental|Exercise DVD|Exercise DVD to be used by participants 30-60 minutes, once daily to facilitate maintenance exercise training
9964127|NCT01235481|Other|Usual Care|Participants advised to perform maintenance exercise training 30-60 minutes, once daily without benefit of exercise DVD
9964128|NCT01235520|Experimental|1|
9964129|NCT01235520|Experimental|2|
9964130|NCT01235520|Placebo Comparator|3|
9964131|NCT01235533|Experimental|N-3 fatty acids|Participants in this arm were received three capsules of n-3 fatty acids. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g。
9964132|NCT01235533|Placebo Comparator|Placebo|Participants in this arm were received three identical capsules per day. All capsules included olive oil.
9964133|NCT01235572|Experimental|Health services research (early discharge, outpatient care)|Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
9964134|NCT01235624|Other|patient|Patient suffering of adRP that accept to participate at this study have a blood prelevement for genetic analysis (intervention)
9964135|NCT01235637|Active Comparator|Alfentanil|
9964136|NCT01235637|Sham Comparator|Sufentanil|
9964137|NCT01235650||Spinal fusion|Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis
9964138|NCT01235663|Experimental|advisory support|advisory support for six months to prolong the breast-feeding period
9964139|NCT01235676|Experimental|Diet|Calorie restriction to reduce weight gain
9964140|NCT01235676|Experimental|Exercise|Exercise to reduce weight gain
9964141|NCT01235767|Experimental|ASF supplement pre-pregnancy to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
9964142|NCT01235767|Experimental|ASF Supplement mid-gestation to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
9964143|NCT01235767|No Intervention|Routine prenatal care|Nutrition education and iron-folate supplements during pregnancy
9964144|NCT01235806|Other|MRI|MRI of the scaphoid bone fracture suspicion
9964145|NCT01235819|Active Comparator|Insulin alone|Type 1 DM only on Insulin
9964146|NCT01235819|Active Comparator|Insulin and Exenatide|Newly detected Type 1 DM on Insulin and exenatide
9964147|NCT01235819|Active Comparator|Insulin and Sitagliptin|Newly detected Type 1 DM using Insulin and Sitagliptin
9964148|NCT01235832|Active Comparator|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
9964149|NCT01235832|Active Comparator|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
9964150|NCT01235832|Experimental|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
9964151|NCT01235845|Experimental|DC-DCIK|
9802417|NCT05274919||Patients scheduled for brain MRI with contrast injection|Inclusion at Erasmus MC and LUMC: The first cohort consists of 60 patients scheduled for brain MRI as part of their standard clinical diagnostic procedure and in whom contrast agent administration is part of their standard radiological assessment. These patients do not necessarily have a brain tumor as the purpose here is to develop and evaluate the vascular signature mapping sequence in general. Usually, such testing would be done in healthy volunteers, but contrast agent is required for the vascular signature mapping sequence. To avoid unnecessary contrast agent administration, the sequence will be tested in this patient cohort instead. In this study part, the outcome is the optimized protocol itself, with which the investigators could obtain additional information about the vascular structure throughout the brain. Therefore this group of subjects is expected to be sufficiently homogeneous for the research aim of this part of the study.
9667645|NCT03290560|Experimental|Recombinant human tissue kallikrein|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
9964152|NCT01235858|Other|Gown group|Anesthesiologists wearing sterile gown for epidural insertion
9964153|NCT01235858|Other|No Gown group|Anesthesiologists not wearing gown for epidural insertion
9964154|NCT01235871|Experimental|SB1578|
9964155|NCT01235871|Placebo Comparator|Placebo|
9964156|NCT01235884|Active Comparator|Lactobacillus reuteri|Dietary Supplement
9964157|NCT01235884|Placebo Comparator|Placebo|Dietary Supplement
9964158|NCT01235962|Experimental|pazopanib|Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
10008716|NCT01615796|Experimental|Cohort B1|GSK2140944 400 mg repeat dose BID up to 7 days
9476691|NCT03569306|Active Comparator|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
10008717|NCT01615796|Experimental|Cohort B2|GSK2140944 750 mg repeat dose BID up to 7 days
10008718|NCT01615796|Experimental|Cohort B3|GSK2140944 1000 mg repeat dose BID up to 7 days
10008719|NCT01615796|Experimental|Cohort B4|GSK2140944 to be determined repeat dose BID up to 7 days
10008720|NCT01615796|Experimental|Cohort B5|GSK2140944 to be determined repeat dose TID up to 14 days
10008721|NCT01615796|Experimental|Cohort B6|GSK2140944 to be determined repeat dose TID up to 14 days
10008722|NCT01615848|Experimental|mediterranean diet restricted calorie|1500 k/calories 47-51% carbohydrate 14-17% protein 33-36% fat: 7-7.6% saturated fat 22-30% monounsaturated & polyunsaturated fat
10008723|NCT01615848|Experimental|high protein diet, restricted calorie|1500 k/calories 40 % carbohydrate 30% protein 30% fat
10008724|NCT01615861|Experimental|IOL implantation|Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
10008725|NCT01615887|Experimental|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
10008726|NCT01615887|Placebo Comparator|Sugar pill|Placebo will be administered in the same fashion as the treatment arm
10008727|NCT01615900|Other|Teleconsultation|
9476692|NCT03569267|Experimental|OLX10010|OLX10010, an siRNA therapeutic, with four different doses by Groups (dose ascending manner with 1, 4, 10, 20 mg)
9476693|NCT03569267|Placebo Comparator|Placebo|placebo
9476694|NCT03569254|Experimental|Neomedlight Phototherapy Blanket|Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
9476695|NCT03569254|Active Comparator|Ohmeda-Fiber Optic Phototherapy Blanket|Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
9476696|NCT03569241|Other|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
9476697|NCT03569241|Experimental|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
9476698|NCT03569189|Experimental|High Fat Diet|Participants will consume a high-fat, high-calorie diet for 7 days (i.e. westernised diet) following a 3-day weight maintenance diet. Measurements will be made pre- and post-high fat diet intervention.
9476699|NCT03569176|Experimental|Autism Glass Intervention|Participants in the experimental group will receive the autism glass for 6 weeks once they are assigned to the experimental condition. Participants will be asked to use the glasses at least 3 times a week for 20 minutes sessions in addition to continuing Applied Behavior Analysis (ABA) therapy.
9667646|NCT03290560|Placebo Comparator|Placebo|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
10008728|NCT01615900|Other|Standard consultation|
10008729|NCT01615913|Experimental|3% terbinafine patch|A 10-cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
10008730|NCT01615913|Experimental|6% terbinafine patch|A 10-cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
10008731|NCT01615913|Experimental|8% terbinafine patch|A 10-cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
10008732|NCT01615952||Sitting Position (head of bed 90 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
10008733|NCT01615952||Semi-sitting position (45 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
10008734|NCT01615952||Supine position|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
10008735|NCT01615965|Experimental|micrometastases|Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
10008736|NCT01615978|Experimental|Fixed dose: 5 mcg/kg|
10008737|NCT01615978|Experimental|Escalated dose: 10 mcg/kg|
10008738|NCT01615991|Other|radiosynoviorthesis with yttrium-90 or rhenium -186|Patients suffering from arthritis or chronic inflammatory joint disease.
10008739|NCT01616004|Experimental|N2O|N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes
10008740|NCT01616004|Sham Comparator|Air|
10008741|NCT01616030|Experimental|Strength training, fractured limb|"Knee-extension strength training of the fractured limb:~Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery."
10008742|NCT01616043|Experimental|Glyaderm + STSG|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds of the patients are covered with Glyaderm®. After 6-8 days the wounds are finally covered with a thin STSG.
10008743|NCT01616043|Other|STSG alone|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds are immediately covered with a thin STSG.
10008744|NCT01616069|Active Comparator|epinephrine|Assessment of systolic and diastolic heart function during CABAG with CPB with levosimendan using TEE.
10008745|NCT01616069|Active Comparator|levosimendan|Assessment of systolic and diastolic heart function during CABAG with CPB with epinephrine using TEE.
10008746|NCT01616095||Adults with Growth Hormone Deficiency|if multiple hormonal deficiences exist, long term adequate supplementation is provided and tightly monitored.
10008747|NCT01616095||Healthy Controls|matched for BMI, age, and gender
10008748|NCT01616108|Experimental|Bupivacaine Injection|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
10008749|NCT01616121|Active Comparator|Conventional Treatment Heart Failure|Conventional Treatment
10008750|NCT01616121|Experimental|Lung Impedance-Guided Therapy|Lung Impedance-Guided Therapy
10008751|NCT01616134|Active Comparator|Korea Red Ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.
10008752|NCT01616134|Placebo Comparator|placebo contating constarch|
10008753|NCT01616147|Experimental|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
10008754|NCT01616147|Active Comparator|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
10008755|NCT01616186|Experimental|Everolimus/Sorafenib|Patients will be stratified by current smoking status (smoker: yes or no0, for each smoking stratum patients will be randomized in a 2:1 ratio
10008756|NCT01616186|Active Comparator|Sunitinib|"Sunitinib is the concurrent control group~Patients will be stratified by current smoking status (smoker: yes or no), for each smoking stratum patients will be randomized in a 2:1 ratio"
10008757|NCT01616212|Experimental|TX1|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
10008758|NCT01616212|Experimental|TX 2|Motivational Enhancement Therapy for adolescents
10008759|NCT01616212|Experimental|TX3|Drug Education for adolescents, Parenting Wisely for parents
10008760|NCT01616212|Experimental|TX4|Drug Education for adolescents
10008761|NCT01616225|Active Comparator|No Growth Hormone Supplementation|
10008762|NCT01616225|Experimental|Luteal Growth Hormone Start|Growth hormone starting in the luteal phase of the previous menstrual cycle.
10008763|NCT01616225|Experimental|Follicular Growth Hormone Start|Starting growth hormone during the follicular phase of the prior menstrual cycle.
10008764|NCT01616238|Experimental|Philadelphia Positive Patients|All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
10008765|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive|Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
10008766|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive +|Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
10008767|NCT01616238|Experimental|Philadelphia -ve Patients- Non Intensive|Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
10008768|NCT01616238|No Intervention|Registration only|Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.
10008769|NCT01616251|Experimental|Vegetable protein meal|Vegetable protein meal based on legumes (3.6 MJ, 19E% protein, 28 g dietary fibers)
10008770|NCT01616251|Experimental|Egg protein meal + fibers|Protein meal based on eggs and added pea dietary fibers (3.6 MJ, 19E% protein, 28 g dietary fibers)
10008771|NCT01616251|Experimental|Egg protein meal|Protein meal based on egg without added dietary fibers (3.6 MJ, 19E% protein, 6 g dietary fibers)
10008772|NCT01616251|Experimental|Meat protein meal + fibers|Protein meal based on meat and added pea dietary fibers (3.6 MJ, 19E% protein, 29 g dietary fibers)
10008773|NCT01616277|Placebo Comparator|1|
10008774|NCT01616277|Placebo Comparator|2|
10008775|NCT01616277|Placebo Comparator|3|
10008776|NCT01616277|Placebo Comparator|4|
10008777|NCT01616277|Placebo Comparator|5|Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
10008778|NCT01616277|Placebo Comparator|6|
10008779|NCT01616277|Placebo Comparator|7|
10035489|NCT01806480|Experimental|Person-centred proactive breastfeeding telephone support|Proactive breastfeeding telephone support initiated by the Breastfeeding Support Team (BST) at the NICU from which the infant is discharged. Daily phone calls from one member in the BST to the mother will be performed from day 1 until day 14 after discharge. In addition to this, the mother has the option to call someone in the BST during the same period (reactive). The telephone support will be conducted with a person-centered approach. Thus, the mother is enabled to talk about whatever feels important to her including the situation with the new infant at home and her breastfeeding. The feeding support team member should during the telephone support session: have an authentic presence, characterized by being there for the mother, having an empathic approach, taking time touching base, providing affirmation, being responsive, sharing the mother's experience and enabling a relationship.
10035490|NCT01806480|No Intervention|Person-centred reactive breastfeeding telephone support|The control group (and the intervention group) will be offered the possibility to person-centred reactive telephone support initiated by the mother who can phone the feeding support team from day 1 after discharge until day 14 after discharge, between 08.00-16.00 every day. Each NICU will set up a specific telephone number for their telephone support, and schedule the members in the BST for availability. The same level of person-centeredness will be provided in both reactive and proactive telephone support.
10035491|NCT01806493||obese subjects|One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);
10035492|NCT01806532||18F-FDG PET-CT|A total of 10 patients with acute respiratory distress syndrome (ARDS) will be imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan.
10035493|NCT01806558|Experimental|Women with lesion on MBI|Women with lesion on MBI
10035494|NCT01806610|Experimental|BPS804|Single dose BPS804 administration.
10035495|NCT01806610|Placebo Comparator|Placebo|Single dose placebo administration.
10035496|NCT01806636||Treatment|Patients treated with PneumRx Coil System
10035497|NCT01806649|Experimental|BKM120|BKM120, starting at 100 mg oral once daily
10035498|NCT01806701|Experimental|Psychotherapy|Trauma-focused Cognitive Behavioral Therapy
10035499|NCT01806727|Active Comparator|Diabetes Self Management (DSM)|Diabetes Self Management education, delivered in the clinics, using group-based visits and targeting improved control of hemoglobin A1c and related risk factors.
10035500|NCT01806727|Experimental|Community Lifestyle Weight Loss (LWL)|Participants with type 2 diabetes will be enrolled in a 12 month lifestyle intervention designed to achieve a mean >7% weight loss induced through caloric restriction and increased physical activity. The intervention will be delivered via supervised Community Health Workers (CHWs). Most meetings will be at a community location.
10035501|NCT01806753|Experimental|midazolam/propofol injection|Intermittent midazolam/propofol injection controlled by endoscopist
10035502|NCT01806753|Active Comparator|propofol infusion|Continuous propofol infusion with opioid administration
10035503|NCT01806766|Active Comparator|Ceramic on Ceramic|Ceramic on Ceramic bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
10035504|NCT01806766|Active Comparator|Ceramic on HXPE|Ceramic on HIghly crosslinked polyethylene bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
10035505|NCT01806792|Experimental|Risendronate and Cholecalciferol combination|risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.
10035506|NCT01806792|Active Comparator|Risedronate|risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.
10035507|NCT01806805|Experimental|Zonegran|Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
10008780|NCT01616316|Experimental|subfascial flap|
10008781|NCT01616316|Experimental|Subplatysmal flap|
10008782|NCT01616329||Cases and Controls|Cases: alloantibody formers Controls: non-alloantibody formers
10008783|NCT01616342|Active Comparator|Comprehensive Medical Management|Comprehensive Medical Management will include analgesic management in accordance with guidelines and practices at the site.
10008784|NCT01616342|Active Comparator|Spinal Cord Stimulation (SCS)|Subjects assigned to Arm A, CMM + SCS, will be treated with electrical pulses from a surgically implanted Precision Plus® SCS System (Boston Scientific Corporation).
10008785|NCT01616368|Experimental|MEAL|Participation in an 8-week mindful eating course
10008786|NCT01616381|Active Comparator|Sildenafil|Sildenafil tablets 40 mg x 3 daily
10008787|NCT01616381|Placebo Comparator|Placebo|Placebo tablet x 3 daily
10008788|NCT01616394||children with congenital heart disease|
10008789|NCT01616407|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject.
9802418|NCT05274919||Patients diagnosed with suspected glioma scheduled for brain MRI|Inclusion at Erasmus MC and LUMC: The second cohort consists of 20 glioma patients in whom the vascular signature mapping sequence is tested specifically for glioma and for a direct comparison between 3T and 7T, where the 3T scan is an extension of the diagnostic care and the additional 7T scan is optional. This number of patients is sufficient to provide information on differences in the ability to measure tumor vascularity between 3T and 7T, while minimizing the extra patient burden.
10008790|NCT01616420|No Intervention|Delayed aPS|
10008791|NCT01616420|Experimental|Immediate aPS|
10008792|NCT01616433|Active Comparator|Arthritis Foundation Exercise Program|
10008793|NCT01616433|Experimental|AFEP + 10 Keys to Healthy Aging|"Arthritis Foundation Exercise Program integrated with the 10 Keys to Healthy Aging"
10008794|NCT01616446||remission|Nephrotic patients in remission
10008795|NCT01616446||relapse|Nephrotic patients in recidive
10008796|NCT01616472||Incident diabetes cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with diabetes during follow-up, subsequent to SLE diagnosis.
10008797|NCT01616472||Incident diabetes controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of diabetes during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
10008798|NCT01616472||Incident hypertension cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with hypertension during follow-up, subsequent to SLE diagnosis.
10008799|NCT01616472||Incident hypertension controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of hypertension during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
10008800|NCT01616472||Incident cataract cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with cataract during follow-up, subsequent to SLE diagnosis.
10008801|NCT01616472||Incident cataract controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of cataract during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
10008802|NCT01616472||Incident osteoporosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with osteoporosis during follow-up, subsequent to SLE diagnosis.
10008803|NCT01616472||Incident osteoporosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of osteoporosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
10008804|NCT01616472||Incident avascular necrosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with avascular necrosis during follow-up, subsequent to SLE diagnosis
10008805|NCT01616472||Incident avascular necrosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of avascular necrosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
10008806|NCT01616485|Experimental|Treatment A|TA-1790 + glyceryl trinitrate
10008807|NCT01616485|Active Comparator|Treatment B|sildenafil citrate + glyceryl trinitrate
10008808|NCT01616485|Placebo Comparator|Treatment C|placebo + glyceryl trinitrate
10008809|NCT01616498||Lean|Comparison data from this lean cohort will be compared to the obese older adults are already being collected in an R01-funded study (Improving Muscle for Functional Independence Trial; IRB00009098; NCT01049698)
10008810|NCT01616511||Pathway CH-1 Subjects|
10008811|NCT01616550||Patients undergoing thoracic surgery|Assessment of postoperative pain management in patients undergoing elective thoracoscopy or thoracotomy in a teaching hospital
10008812|NCT01616589||Fragile X full mutation (affected)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed >200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome
10008813|NCT01616589||Fragile X premutation (carriers)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome
10008814|NCT01616589||Fragile X intermediate|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation
10008815|NCT01616602|Placebo Comparator|Left-sided Position|
10008816|NCT01616602|Experimental|Prone Position|
10008817|NCT01616615|Experimental|ASPIRIN|150 mg milligram(s)/ day oral use
10008818|NCT01616615|Placebo Comparator|PLACEBO|
10008819|NCT01616628|No Intervention|Wait listed control|Participants grocery shop without the intervention for extended baseline and have delayed entrance into the intervention period.
10008820|NCT01616628|Experimental|Rewards for purchases & topic education|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables.
10008821|NCT01616641||rheumatoid arthritis group|75 patients with rheumatoid arthritis
10008822|NCT01616641||control group|75 healthy women
10008823|NCT01616667|Active Comparator|Modified direct lateral approach|The patients included is operated with a total hip arthroplasty using a modified direct lateral approach
10008824|NCT01616667|Active Comparator|Posterior approach|The patients included is operated with a total hip arthroplasty using posterior approach
10008825|NCT01616680|Experimental|Supportive care (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15.
10008826|NCT01616719|Other|DTRAX graft|
10008827|NCT01616732|Active Comparator|testosterone|against placebo
10008828|NCT01616732|Placebo Comparator|placebo|
10008829|NCT01616758|Experimental|GTx-024 9mg|GTx-024 dosage of three soft gels once daily to equal 9mg
10008830|NCT01616784|Active Comparator|Multiple daily injections plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
10008831|NCT01616784|Experimental|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
10008832|NCT01616797|Experimental|Computerized intervention|Participants will be asked to visit a customized website and engage in computerized exercises. Cognitive and emotion training games.
10008833|NCT01616797|Sham Comparator|Control|Participants will be asked to visit a customized website and engage in computerized games.
10008834|NCT01616810||observation|Healthy participants
10008835|NCT01616823||HIV Positive Women|HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
10008836|NCT01616836|Active Comparator|continuous FNB|Bolus femoral nerve block (ropivacaine 0.5% 20 mL), continuous infusion 48 hours (ropivacaine 0.2%, 5 mL/h), placebo local infiltration
10008837|NCT01616836|Active Comparator|single FNB|femoral nerve block (ropivacaine 0.5% 20 mL), placebo femoral nerve block infusion, placebo local infiltration
10008838|NCT01616836|Active Comparator|LIA|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia
10008839|NCT01616849|Experimental|PF+ Nimotuzumab|Patients treated with cisplatin and 5-Fu combined with nimotuzumab
10008840|NCT01616862||Parents of PA positive CF children|parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa
10008841|NCT01616862||parents of Pa negative CF children|parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa
10008842|NCT01616875|Experimental|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles
10008843|NCT01616888|Active Comparator|Treatment arm|SFA angioplasty with In.Pact Admiral drug eluting balloon
10008844|NCT01616901|Experimental|Spontaneous breathing trial|
10008845|NCT01616914||delirium group|patients with delirium during ICU stay
10008846|NCT01616914||non-delirium group|patients without delirium during ICU stay
10008847|NCT01616927|No Intervention|standard care|Subjects in this arm will receive standard care
10008848|NCT01616927|Experimental|Lanreotide|
10008849|NCT01616940|No Intervention|Standard-of-care|Standard-of-care at 3 demonstration sites includes: HIV medical care, medical case management, and referral to substance abuse, mental health, and housing services.
10008850|NCT01616940|Experimental|Enhanced Peer Intervention|Provides emotional, informational, and instrumental peer support, in addition to Standard-of-Care.
10008851|NCT01616966|Active Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane during surgery.
10008852|NCT01616966|Active Comparator|Anesthesia with propofol|Anesthesia was maintained with propofol during surgery.
10008853|NCT01616979||OPCAB surgery|Fifteen elective OPCAB surgery patients who undergo grafting in the left circumflex artery territory due to three-vessel disease
10008854|NCT01616992||Interstitial Cystitis|
10008855|NCT01616992||Myofascial Pelvic Pain|
10008856|NCT01616992||Healthy|
10008857|NCT01616992||First Degree Relative|
10008858|NCT01617018||Exposed group|Biotherapy
10008859|NCT01617018||Non-exposed group|Major conventional systemic therapy (methotrexate or cyclosporine)
10008860|NCT01617031||Diabetic patients with coronary artery disease|Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis >50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
10008861|NCT01617044|Experimental|Treatment|"iron 3 mg/kg/day elemental iron FeSO4 up to 45 mg (dose to be determined by PI)~+ vitamin C-250 mg chewable tab~+ probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)"
10008862|NCT01617044|Placebo Comparator|Control|"iron 3 mg/kg/day elemental iron FeSO4 to 45 mg~+ vitamin C-250 mg chewable tab~+ placebo (identical capsule)"
10008863|NCT01617057|Experimental|Skelid|tiludronic acid
10008864|NCT01617057|Placebo Comparator|Control|Placebo
9802419|NCT05274919||Patients with (suspected) glioma|"Inclusion at Erasmus MC and LUMC: The third cohort consists of 100 adult patients referred for biopsy or surgery of suspected glioma. The diagnosis of glioma is based on a multitude of factors, such as initial presentation (headaches, vomiting, potential changes in character). Based on the initial presentation a patient may be suspected of having a glioma, which is often confirmed using imaging. Although a true conclusion requires analysis of tissue, in an overwhelming majority of the cases (99%), analysis of the imaging is sufficient to confirm the presence of glioma. Thus, the investigators can be relatively certain about the inclusion of glioma patients based on the initial presentation and imaging alone.~Since there is a close collaboration with the Neurology departments of both the LUMC and Haaglanden Medical Center (HMC) in The Hague, the investigators broaden their inclusion capacity also to this hospital."
10008865|NCT01617109|Placebo Comparator|Placebo|
10008866|NCT01617109|Experimental|Ca/Vit D|
10008867|NCT01617122|Experimental|Bacteriophage|Subjects receive bacteriophage vaccinations and blood draws
10008868|NCT01617135|Experimental|CVT-301 Low Dose|CVT-Low; levodopa inhalation powder (LIP)
10008869|NCT01617135|Experimental|CVT-301 High Dose|CVT-High; levodopa inhalation powder (LIP)
10008870|NCT01617135|Placebo Comparator|Inhaled Placebo|Inhaled placebo powder
10008871|NCT01617135|Active Comparator|Oral Sinemet (carbidopa/levodopa)|Open-label oral carbidopa/levodopa (CD/LD)
10008872|NCT01617161|Active Comparator|PBT|Proton Beam Therapy
10008873|NCT01617161|Active Comparator|IMRT|Intensity Modulated Radiation Therapy
10008874|NCT01617174||assessments completed by patients|"A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health & Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing moderate or worse pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff."
10008875|NCT01617200|Experimental|Asenapine 2.5 mg BID|
10008876|NCT01617200|Experimental|Asenapine 5 mg BID|
10008877|NCT01617200|Active Comparator|Olanzapine 15 mg QD|
10008878|NCT01617200|Experimental|Placebo switched to Asenapine 2.5 mg BID|
10008879|NCT01617213|Experimental|Maintenance Lenalidomide After Melphalan|
10008880|NCT01617226|Active Comparator|azacitidine|azacitidine (75mg/m2) by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. This should be delivered in a 5-2-2 schedule
10008881|NCT01617226|Active Comparator|azacitidine and vorinostat|Patients will receive (75mg/m2) azacitidine by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. Azacitidine should be delivered in a 5-2-2 schedule. Vorinostat (300mg bid) will be taken orally for 7 consecutive days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles. (Day 3 is defined as the 3rd day of azacitidine administration).
10008882|NCT01617239|Experimental|Group 1|1 x standard dose (0.5 mL) on Day 1, Day 29, and Day 57
10008883|NCT01617239|Experimental|Group 2|1 x double standard dose (1.0 mL) on Day 1 and 1 x standard dose (0.5 mL) on Day 57.
10008884|NCT01617239|Experimental|Group 3|1 x triple standard dose (1.5 mL) on Day 1
10008885|NCT01617252|Experimental|Optiflow|
10008886|NCT01617252|Experimental|Facial mask|
10008887|NCT01617265|Experimental|Prevention of oversedation group|In this arm sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated intravenous (IV) hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
10008888|NCT01617265|Active Comparator|Conventional sedation group|In this arm, sedation will be administered according to the usual practices in each participating center.
10008889|NCT01617278|Experimental|I-Scan 1|I-Scan 1 modality will be used by the endoscopist for the entire procedure
10008890|NCT01617278|Experimental|HD Colon|High definition white light modality will be used by the endoscopist for the entire procedure
10008891|NCT01617278|Experimental|I-scan 2|I-Scan 2 modality will be used by th endoscopist through out the procedure
10008892|NCT01617291|Experimental|Induced Hypothermia|Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
10008893|NCT01617291|No Intervention|Regular Care|Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia
10008894|NCT01617304|Experimental|low AGE, glucose|Food prepared by boiling/steaming and 20 g of glucose 3 times a day in a water solution
10008895|NCT01617304|Experimental|low AGE, fructose|Food prepared by boiling/steaming and 20 g of fructose 3 times a day in a water solution
10008896|NCT01617304|Experimental|high AGE, fructose|Food prepared by frying/baking and 20 g of fructose 3 times a day in a water solution
10008897|NCT01617304|Experimental|high AGE, glucose|Food prepared by frying/baking and 20 g of glucose 3 times a day in a water solution
10008898|NCT01617317|Active Comparator|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
10008899|NCT01617317|Experimental|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)
10008900|NCT01617330|Experimental|Diesel exhaust|2 hour exposure to diesel exhaust at 100 microgram per cubic meter during intermittent exercise
10008901|NCT01617330|Experimental|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise
10008902|NCT01617343|No Intervention|Usual care|Patients in this control group will receive usual care following stroke including standard physiotherapy and occupational therapy.
10008903|NCT01617343|Experimental|HEP-OKS|
10008904|NCT01617356|Active Comparator|Dextrose Injection|
10008905|NCT01617356|Active Comparator|Sterile Water Injection|
10008906|NCT01617382||Registry|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
10008907|NCT01617473|Experimental|procedure/surgery|transplant with G-CSF mobilized PBSCs
10008908|NCT01617473|No Intervention|other|no intervention after transplant with mobilized BMPB
10008909|NCT01617486|Experimental|BALANCE|
10008910|NCT01617499||University employees|Participants will include employees of Washington University in St. Louis. Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
10008911|NCT01617525|Experimental|Korean Recommended Diet|A dietary pattern that follows the recommendations by the Korean Rural Development Administration.
10008912|NCT01617525|Active Comparator|US Recommended Diet|Diet based on recipes and menus developed by the USDA Dietary Guidelines for Americans intramural team.
10008913|NCT01617525|Active Comparator|Typical American Diet|Diet based on data from the NHANES surveys, as summarized in the USDA report What We Eat in America.
10008914|NCT01617538|Experimental|Atorvastatin|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.
10008915|NCT01617538|No Intervention|compare|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.
10008916|NCT01617551|Experimental|Renal denervation|Patient group randomized to renal denervation
10008917|NCT01617551|Sham Comparator|Sham|Patients randomized to sham procedure
10008918|NCT01617564|Active Comparator|Bupivacain|
10008919|NCT01617564|Sham Comparator|Sodium Chloride|
10008920|NCT01617590|Experimental|leflunomide|Leflunomide 10-20 mg/d
10008921|NCT01617590|Active Comparator|methotrexate|MTX 7.5-15 mg/week
10008922|NCT01617616||Normal tilt test|Patients with normal tilt table testing (they may have symptoms which precipitated the tilt, but in the end did not qualify as POTS, NMH, ETC.)
10008923|NCT01617616||confirmed POTS diagnosis|after review of tilt table results, this group will be the confirmed postural orthostatic tachycardic syndrome group patient
10008924|NCT01617616||Neurocardiogenic syncope on tilt|This group is comprised of patients with confirmed diagnosis of neurocardiogenic syncope on tilt
10008925|NCT01617616||Neurally-mediated hypotension|Patients with confirmed diagnosis neurally mediated hypotension
10008926|NCT01617642||Control group|Healthy control group, matched for age and gender
10008927|NCT01617642||Acute intermittent porphyria|Patients with acute intermittent porphyria.
10008928|NCT01617694|Experimental|group R|continuation of remifentanil target controlled infusion (TCI) at effect-site concentration of 2 ng/ml during anesthetic recovery until extubation.
10008929|NCT01617694|Active Comparator|group D|remifentanil TCI discontinuation and dexmedetomidine 0.5 mg/kg intravenous injection before 10 min of the end of surgery
10008930|NCT01617707|Active Comparator|conventional sedation group|midazolam
10008931|NCT01617707|Experimental|BPS group|midazolam plus propofol
10008932|NCT01617733|Experimental|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
10008933|NCT01617746|Experimental|Ambrisentan|5mg od ambrisentan
10008934|NCT01617746|Experimental|Bosentan|62.5mg bosentan
10008935|NCT01617746|Placebo Comparator|Placebo|
10008936|NCT01617772|Experimental|Atorvastatin|20mg atorvastatin daily
10008937|NCT01617772|Experimental|Carnitine|1000mg L-carnitine daily
10008938|NCT01617772|Experimental|Atoral|1000mg L-carnitine and 20mg atorvastatin
10008939|NCT01617772|Placebo Comparator|Placebo|Identically looking placebo
10008940|NCT01617785||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
10008941|NCT01617785||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization
10008942|NCT01617785||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
10008943|NCT01617798|Placebo Comparator|Control-- furosemide (lasix) only|"Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).~No actual placebo is administered."
10008944|NCT01617798|Active Comparator|Study Arm|Study arm receives evolving standard of care diuresis with furosemide and metolazone.
10008945|NCT01617824|Experimental|Linagliptin|Linagliptin 5 mg tablets daily for 4 days
10008946|NCT01617824|Placebo Comparator|Placebo|Placebo tablets 1 daily for 4 days
10008947|NCT01617837|Active Comparator|P6 acupressure group|"In the end of the operation Sea-Band®, a single-sized elastic acupressure band with a plastic button, was placed unilaterally at the place of P6 (the P6 Neiguan acupoint, located about 3 cm proximal to the distal wrist, between the tendons of the flexor carpi radialis and the palmaris longus)to apply acupressure."
10008948|NCT01617837|Placebo Comparator|Placebo group|In the end of the operation an identical Sea-Band® with no button and thereby no acupressure was placed unilaterally at the place of P6.
10008949|NCT01617850|Experimental|optimized physical exercise training|Intervention: Supervised physical exercise training x3 weekly for 12 weeks
10008950|NCT01617850|Active Comparator|conventional group|Intervention: Supervised physical exercise training x2 weekly for 8 weeks
10008951|NCT01617889|Active Comparator|Powdered milk-based formula, standard fat blend|
10008952|NCT01617889|Experimental|Powder milk-based formula, alternate fat blend|
10008953|NCT01617928|Experimental|veliparib (ABT-888)|
10008954|NCT01617941|Experimental|BGG492|At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).
10008955|NCT01617941|Placebo Comparator|Placebo|At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).
10008956|NCT01617954||Subjects with MammaPrint Result|
9964159|NCT01235962|Placebo Comparator|placebo|placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
9964160|NCT01235988||Eltrombopag & standard of care|
9964161|NCT01235988||Standard of care|
9964162|NCT01236014||Eltrombopag & standard of care|
9964163|NCT01236014||Romiplostim & standard of care|
9964164|NCT01236014||Standard of care|
9964165|NCT01236027||HIV-negative women|HIV-negative women who agree to have specimens collected for validation of laboratory procedures
9964166|NCT01236040|Experimental|Group A|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
9964167|NCT01236040|Experimental|Group B|Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.
9964168|NCT01236040|Placebo Comparator|Group C|Subjects will receive 2 doses of a placebo at a 21-day interval.
9964169|NCT01236040|Experimental|Group D|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
9964170|NCT01236040|Experimental|Group E|Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.
9964171|NCT01236040|Experimental|Group F|Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.
9964172|NCT01236066||Study Group|Australian children aged < 5 years who have been vaccinated with RotaTeq or Rotarix from 2007 to 2009 as well as all children aged < 5 years hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis.
9964173|NCT01236079|Experimental|Assisted Referral & IVR|
9964174|NCT01236079|No Intervention|Usual Care|
9964175|NCT01236131||Endometrial biospy samples|The Endometrial Biopsy samples will be provided by women enrolled in the University of Pittsburgh IRB PRO10010112 and PRO10010159
10008957|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
9802420|NCT05269433|Active Comparator|PSE + OCAT-sham|Psycho-education video + an active placebo training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is an undirected scrambled sentences task with online contingent feedback (only) on the speed with which the sentences were made. In this condition, participants will not receive feedback on emotional attention.
9802421|NCT05269433|Experimental|PSE + OCAT|Psycho-education video + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
9964176|NCT01236144|Experimental|AC220 Intervention|
9964177|NCT01236144|Experimental|Plerixafor Intervention|
9964178|NCT01236144|Experimental|Ganetespib|
9964179|NCT01236157||Chest Pain|All patients that call to the SAMU-ACS because of chest pain are included
9964180|NCT01236209|Active Comparator|web page|"Control group:~Information web page with some mindfulness exercises"
10008958|NCT01617993||Women undergoing IVF treatment|Women undergoing IVF treatment
10008959|NCT01618006|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period.
10008960|NCT01618006|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
10008961|NCT01618006|Experimental|Aspirin 81mg four times daily|Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
10008962|NCT01618032|Experimental|HVLA|High velocity and low amplitude traction manipulation on the ankle joint
10008963|NCT01618032|Experimental|MWM|Mobilization with movement on ankle joint as Mulligan
10008964|NCT01618032|Sham Comparator|placebo|Contact without therapeutic effect
10008965|NCT01618045||Fermented Papaya Preparation (FPP)|This a is single arm study - all participants will receive and take fermented papaya preparation (FPP) for a total of 6 weeks. Participants will take 3 grams of FPP three times per day (a total of 9 grams per day).
10008966|NCT01618058||ARV-Treated Participants|Those participants who received dapivirine during HIV seroconversion
10008967|NCT01618058||ARV-Naive Participants|Those participants who received placebo during HIV seroconversion
10008968|NCT01618071|Active Comparator|Oleic acid|75 g high oleic acid sunflower oil.
10008969|NCT01618071|Active Comparator|Linoleic acid|75 g high linoleic acid sunflower oil.
10008970|NCT01618071|Experimental|Eicosapentaenoic acid and docosahexaenoic acid|5 g EPA and DHA derived from fish oil, made up to a total of 75 g with high oleic sunflower oil.
10008971|NCT01618071|Experimental|Docosahexaenoic acid|5 g DHA derived from algal oil, made up to a total of 75 g with high oleic sunflower oil.
10008972|NCT01618084|Experimental|Tritanium cup|
10008973|NCT01618084|Active Comparator|Trident HA cup|
10008974|NCT01618097|Experimental|DVD Decision Aid|Patient assigned to watch DVD decision aid.
10008975|NCT01618097|Experimental|Internet Based Decision Aid|Patient assigned to watch OA specific internet based decision aid.
10008976|NCT01618110|Active Comparator|Treatment Group|
10008977|NCT01618110|Sham Comparator|Sham group|Sham TMS coil (same noise, minimal magnetic field)
10008978|NCT01618123||All CPU subjects|All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
10008979|NCT01618136|Experimental|E7449|
10008980|NCT01618136|Active Comparator|E7449 plus TMZ|
10008981|NCT01618136|Active Comparator|E7449 plus carboplatin and paclitaxel|
10008982|NCT01618149||severe knee OA who are indicated for total knee arthroplasty|the woman who are indicated for TKR and are post menopausal will be recruited in this study. We will excluded the patients who had immune disease ,previous fracture of femur and end stage of renal disease
10008983|NCT01618175|Experimental|Home oxygen therapy|Infants with acute bronchiolitis of low to moderate severity will be discharged home with supplemental oxygen and monitored by phone calls and home visits.
10008984|NCT01618188|Experimental|Formulation A|
10008985|NCT01618188|Experimental|Formulation B|
10008986|NCT01618188|Active Comparator|Insulin Aspart|
10008987|NCT01618201||50 subjects with migraine without aura|Inflammation Migraine Headache
10008988|NCT01618201||50 subjects with migraine with aura|Inflammation Migraine Headache
10008989|NCT01618201||50 subjects with tension headache and cluster headache|Inflammation Migraine Headache
10008990|NCT01618201||50 healthy subjects|Inflammation Migraine Headache
10008991|NCT01618253|Experimental|Radiation therapy with concurrent sorafenib|
10008992|NCT01618292||Robotic-assisted sacrocolpopexy patients|Patients who underwent robotic-assisted laparoscopic sacrocolpopexy between January 2007 and August 2011.
10008993|NCT01618318||General asthma population|People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
10008994|NCT01618331|Active Comparator|Protein supplementation|Patients consume a drink after each exercise session. The drink consist of whey protein, maltodextrin, and flavors mixed in water.
10008995|NCT01618331|Placebo Comparator|Placebo supplement|Patients consume a drink after each exercise session. The drink consist of flavors mixed in water.
10008996|NCT01618331|No Intervention|Control|Patients will be tested before and after a none-intervention period of 12 weeks.
10008997|NCT01618357|Experimental|Intervention|All subjects will receive pre-operative Neo-Adjuvant Chemotherapy (NAC) but only those with an incomplete response to NAC will be treated with the PARPi experimental portion of the trial explained below. Those with a complete response will be treated per standard of care.
10008998|NCT01618370|Experimental|Radium-223 dichloride|
10008999|NCT01618383|Other|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
10009000|NCT01618409|Experimental|PictureRx cards|Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
9802422|NCT05269433|Experimental|PSE + OCAT+|Psycho-education video + short motivational video before each training session + an attention training consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks) will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback on how much attention was paid to positive vs. negative words (emotional attention), along with feedback on the speed with which the sentences were made.
9802423|NCT05263635|Experimental|Music therapy + Standard of Care Enhanced Recovery After Surgery (ERAS)|All participants will have complete Enhanced Recovery After Surgery (ERAS) standard of care. A preoperative music intervention will be played first in the preoperative holding area, a second music intervention played immediately following the induction of anesthesia in the operating room, and a third music intervention played in the recovery room when the patient is awake and responsive.
10009001|NCT01618409|No Intervention|Control|Usual care
10009002|NCT01618435|Active Comparator|Fusion, allograft|Allograft used for fusion in the operation site
10009003|NCT01618435|Experimental|Fusion, i-FACTOR|i-FACTOR used for fusion in the operation site
10009004|NCT01618448|Experimental|Placebo|Placebo once daily
10009005|NCT01618448|Experimental|Tolvaptan|Tolvaptan 15mg once daily
10009006|NCT01618461|No Intervention|Text instructions|Medication instructions displayed in text format
10009007|NCT01618461|Experimental|Drug indication icons|Icons illustrate the purpose of each medication
10009008|NCT01618461|Experimental|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
10009009|NCT01618461|Experimental|Icons + Structured instructions|Icons illustrate the purpose of each medication, and a graphical format shows what time(s) of day each medication should be taken
10009010|NCT01618474|Experimental|DX|DX: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
10009011|NCT01618474|Active Comparator|XELOX|XELOX: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
10009012|NCT01618487|Active Comparator|Arthroscopic tenotomy|Patients who are in this group will have arthroscopic tenotomy. A scope is used to see the tendon and release it.
10009013|NCT01618487|Active Comparator|Open tenotomy|Patients in this group will undergo open tenotomy. This involves opening the skin to expose the muscle and tendon, and then the tendon is released.
10009014|NCT01618487|Active Comparator|Debridement and repair|The patients in this group will undergo an arthroscopic technique (scope and small incision) to go in and remove any tissue that is diseased/does not belong and repair the tear(s) in the tendon.
10009015|NCT01618500||INPH-patients|"Inclusion criteria~Older than 60 years of age Probable INPH according to the NIH guidelines Planned shunt surgery based on a diagnosis of INPH.~Exclusion criteria~Known cause for hydrocephalus (i.e., secondary NPH). Medical condition preventing cognitive testing (e.g. deafness, blindness).~Patients not considered for shunt operation."
10009016|NCT01618513|Experimental|SA monitored by GH|
10009017|NCT01618513|Experimental|SA monitored by IGF-I|
10009018|NCT01618513|No Intervention|Control|Control, patients who have achieved sufficient disease control by surgery alone.
10009019|NCT01618526|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch
10009020|NCT01618526|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.
10009021|NCT01618552|Experimental|SEE IT training (interviewing skills)|Intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) with patients who have coexisting depression and diabetes
10009022|NCT01618552|Active Comparator|Control (knowledge enhancement)|Brief video clip designed to increase primary care physician awareness of new medication treatments for patients with diabetes
10009023|NCT01618565|Experimental|Hands-On Training|30 minutes hands-on training of maneuvers to manage shoulder dystocia
10009024|NCT01618565|Active Comparator|Demonstration|30 minutes passive training by watching an expert instructor explain and perform maneuvers to manage shoulder dystocia
10009025|NCT01618578||Patients with CRPS|24 patients with CRPS of the upper limb type 1 were included into the study.
10009026|NCT01618578||Patients with unilateral upper limb pain|21 patients with unilateral upper limb pain served as controls.
10009027|NCT01618578||healthy subjects|24 healthy subjects were age- and sex matched to patients with CRPS.
10009028|NCT01618591|Experimental|Acute Watery Diarrhea|
10009029|NCT01618591|Experimental|Acute Dysentery/Febrile|
10009030|NCT01618604||Healthy|26 healthy voluntary probands
10009031|NCT01618617|Experimental|Probiotic, high dose|High dose Multistrain probiotic, 100 billion cfu/day
10009032|NCT01618617|Experimental|Probiotic, low dose|Low dose Multistrain probiotic, 15 billion cfu/day
10009033|NCT01618617|Placebo Comparator|Placebo|Placebo
10009034|NCT01618630|Experimental|EAA Supplementation + Exercise Training|Drink an amino acid supplementation during exercise training.
10009035|NCT01618630|Placebo Comparator|Placebo + Exercise Training|Drink a placebo supplementation during exercise training.
10009036|NCT01618643||Acetic acid chromoendoscopy|"Patients with known Barrett's metaplasia under surveillance~Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia~Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion"
10009037|NCT01618682||Hand Transplant Patients|These will be subjects who have undergone a hand transplant.
10009038|NCT01618682||Hand Replant Patients|These will be patients who have undergone a hand replant procedure.
10009039|NCT01618734||Romiplostim and eltrombopag in ITP|ITP patients who received alternatively romiplostim or eltrombopag with at least two months of follow-up for each period.
10009040|NCT01618747||Cohort|
10009041|NCT01618760|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
10009042|NCT01618760|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
10009043|NCT01618786|Experimental|Compliant Flooring (CF)|Compliant flooring
10009044|NCT01618786|Placebo Comparator|Control (CON)|Non-compliant flooring
10009045|NCT01618799|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
10009046|NCT01618799|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
10009047|NCT01618812||Pes plano valgus|Children with painful flatfeet
10009048|NCT01618825|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
10009049|NCT01618825|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
10009050|NCT01618851|Experimental|IMRT with SBRT Boost|Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to PTV) followed by IMRT (45 Gy in 25 fractions) over 6-7 weeks.
10009051|NCT01618877|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) infusion.
9802424|NCT05263635|Active Comparator|Standard of Care Enhanced Recovery After Surgery (ERAS)|Participants randomized into the control group will receive complete Enhanced Recovery After Surgery (ERAS) standard of care and no music therapy sessions.
9802426|NCT05260957|Experimental|Combination CAR-T Cell Therapy, Mosunetuzumab + Polatuzumab|"Participants will receive study treatment in three phases: Induction Phase, CAR-T Treatment Phase and Consolidation Phase.~During the Induction Phase (Days -42, through -6), participants will receive Mosunetuzumab on Days -42, -35, -28, and -7; and Polatuzumab on Day -28. On Day -6, participants will be evaluated in clinic.~During the CAR-T Treatment Phase (Days -5, through Day 0), participants will receive lymphodepleting chemotherapy for three consecutive days beginning on Day -5, followed by CAR-T Cell therapy via infusion on Day 0.~During the Consolidation Phase (Days +1 through +90), participants will receive Mosunetuzumab on Day +14; and combination Mosunetuzumab and Polatuzumab on Days +35, +56 and +77."
10009052|NCT01618877|Placebo Comparator|Placebo infusion|
10009053|NCT01618890|Experimental|HVPG-propranolol arm|"A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.~A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices."
10009054|NCT01618890|No Intervention|Propranolol arm|Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
10009055|NCT01618903|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
10009056|NCT01618903|Experimental|Levetiracetam oral tablet|Levetiracetam oral tablet administered as one single dose.
10009057|NCT01618929|Active Comparator|asthma with food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design).
10009058|NCT01618929|Active Comparator|asthma without food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design)
10009059|NCT01618981|Experimental|first active|
9802427|NCT05257356|Experimental|Chronic Pain Patients|"All participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The performance of chronic pain patients will be compared to healthy volunteers to characterize possible alterations in patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of pain, which is assumed to be already increased in patients.~Primary objectives: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain, and that enhanced emotional-motivational pain responses in chronic pain can be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals.~Secondary objective: Assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses."
9802428|NCT05257356|Experimental|Healthy Controls|"Substudy 1: Participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. Associative learning by monetary reinforcement is implemented to diminish the pain aversiveness. Substudy2: Participants perform the same task combined with MRI assessing the counterconditioning effects on frontostriatal circuits.~Primary objective: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain (Substudy 1). Assess the neural correlates of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity in frontostriatal networks compared to the unchanged natural state (Substudy 2).~Secondary objective: To assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses (Substudy1+2)."
9802429|NCT05255250|Experimental|PLAYshop Intervention|Participants will receive a 60 minute virtual physical literacy workshop, an equipment goody-bag with basic play equipment and printed resources, and access to a digital app with an online toolkit and four bi-weekly boosters lessons.
10009060|NCT01618981|Experimental|first inactive|
10009061|NCT01618994||Expert Surgeons|Gynecologic robotic surgeons, each averaging >75 robotic cases per year
10009062|NCT01618994||Study Surgeons|Gynecologic surgeons who are completely naive to robotics
10009063|NCT01618994||Control Surgeons|Gynecologic surgeons with full robotic privileges but were not averaging more than 2 cases a month and had never used the simulator
10009064|NCT01619007||Group 1|
10009065|NCT01619007||Group 2|
10009066|NCT01619020|Active Comparator|Flaxseed Lignans|Capsules
10009067|NCT01619020|Placebo Comparator|Placebo|Capsules
10009068|NCT01619033|Experimental|impaired renal function subjects|impaired renal function subjects
10009069|NCT01619033|Other|Healthy volunteers|matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
10009070|NCT01619046|Active Comparator|PK substudy|A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).
10009071|NCT01619046|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.
10009072|NCT01619046|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.
10009073|NCT01619046|Experimental|Surgical substudy|Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects
10009074|NCT01619072|Active Comparator|Misoprostol|800 mcg sublingual misoprostol + referral to higher level care
10009075|NCT01619072|Placebo Comparator|Placebo|Placebo + referral to higher level care
10009076|NCT01619098|Experimental|Patient Navigator|Hospital-based Patient Navigator (a bilingual community health worker) engaged in discharge planning and made outreach phone calls to patients for 30 days after discharge and assisted patints with follow-up appointments, obtaining and taking medications, transportation, financial barriers, and linkages to community resources
10009077|NCT01619098|No Intervention|Usual Care|Home care plan at discharge, outreach phone call from RN at patient's primary care clinic
10009078|NCT01619111|Active Comparator|standard therapy|standard chemo- or endocrine therapy
10009079|NCT01619111|Experimental|standard therapy + lapatinib|standard chemo- or endocrine therapy + lapatinib
10009080|NCT01619137|Active Comparator|Povidone-iodine And normal salin|40 patients with complaint of ununion wound of laparatomy or episiotomy coming to Gynecologist's office or hospital enrolled to this study randomly recieve Povidone-iodine And normal salin treatment.
10009081|NCT01619137|Active Comparator|water and soap|40 patients coming to Gynecologist's offices or hospital with complaint of ununion wound of laparatomy or episiotomy in Bandarabbas enrolled to this study and randomly recieve water and soap to irrigation of the wound (it's not require to be at hospital), washing is for each 6-8 hours per day. and if not difference seen after 4 day, treatment change to Povidone-iodine And normal salin.
10009082|NCT01619150|Other|Etoricoxib, followed by placebo|4 weeks of treatment with etoricoxib, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with placebo.
10009083|NCT01619150|Other|Placebo, followed by etoricoxib|4 weeks of treatment with placebo, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with etoricoxib.
10009084|NCT01619163|Experimental|prednisolone|
10009085|NCT01619163|Placebo Comparator|Placebo|
10009086|NCT01619176|Experimental|Acupuncture|Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
10009087|NCT01619176|Active Comparator|Control|Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
10009088|NCT01619189|Experimental|Tranplantation of cultured LSC in stage 3 limbal deficiency|Transplantation of Allogeneic or Autologous Limbal Epithelial Stem Cells Cultured on Human Amniotic Membrane with no Feeders in stage 3 unilateral or bilateral limbal stem cell deficiency.
10009089|NCT01619202|Experimental|Risk Anticipation-Perception Training|Complete the Risk Anticipation-Perception Training (RAPT) program
10009090|NCT01619202|No Intervention|No training program|Does not complete the Risk Anticipation-Perception Training (RAPT) program
10009091|NCT01619215||Bariatric Surgery|As the number of patients dropping out during follow-up, we had difficulty achieving our secondary outcomes, and so the team decided to continue the recruitment until all our outcomes are reached. Main part of the primary outcomes is finalised and published The effects of bariatric surgeries on nonalcoholic fatty liver disease. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. Surg Endosc. 2016 Jul 12
10009092|NCT01619228||Premature Infants|Infants born at < 37 weeks gestational age
10009093|NCT01619228||Full Term Infants|Infants born at equal to or greater than 37 weeks gestational age
10009094|NCT01619228||Adults|Adults are parents of infants enrolled in the study
10009095|NCT01619241||advanced non-small cell lung cancer|
10009096|NCT01619254|Experimental|Hand hygiene|Hand washing with soap measures will be carried out as an intervention activity
10009097|NCT01619254|Experimental|Hand finger nail hygiene|Hand finger nail clipping activities
10009098|NCT01619254|Experimental|Hand and finger nails hygiene|Both hand washing with soap and hand finger nail clipping activities will be implemented
10009099|NCT01619254|Placebo Comparator|Customary practice|No hand washing with soap and nail clipping activities. House holds and children assigned to the control group will not have the interventions (hand washing with soap and nail clipping activities)
10009100|NCT01619267||device associated infection|patients with proven device associated infection
10009101|NCT01619267||control group|patients without device associated infection
10009102|NCT01619280|Experimental|Nebulized sodium nitroprusside|
10009103|NCT01619293||Epidural H.|patients with hematoma epidurale
10009104|NCT01619293||Subdural H.|patients with hematoma subdurale
10009105|NCT01619293||Subarachnoidal H.|patients with hematoma subarachnoidale
10009106|NCT01619293||Intracerebral H.|patients with hematoma intracerebrale
10009107|NCT01619293||E. cerebri|patients with edema cerebri
10009108|NCT01619293||Concussion|patients with concussion
10009109|NCT01619319|Experimental|Cognitive Remediation Therapy|A computerised cognitive remediation intervention called the Brain Fitness program is compared against a placebo intervention consisting of computer games
10009110|NCT01619319|Active Comparator|computer games|computer games
10009111|NCT01619345|Experimental|Period 1: NN9924 with 50 mL water|
10009112|NCT01619345|Experimental|Period 2: NN9924 with 240 mL water|
10009113|NCT01619371||Lactating women|Lactating women willing to use a breast pump.
10009114|NCT01619384|No Intervention|Treatment as Usual|Usual VA care
10009115|NCT01619384|Experimental|MBSR|participation in an 8-week stress reduction course (mindfulness-based stress reduction)
10009116|NCT01619397|Other|Condom|Test condom with new Xanthan gum condom coating
10009117|NCT01619436|Active Comparator|clonidine|clonidine 2 mg/kg IV
10009118|NCT01619436|Placebo Comparator|ringer lactato 1 ml|Ringer lactato 1 ml IV as Placebo
10009119|NCT01619449|Experimental|Renal replacement therapy|Liver transplant recipients who receive continuous renal replacement therapy intra-operatively.
10009120|NCT01619449|Active Comparator|No CRRT|This arm consists of standard of care without CRRT in the OR for OLT
10009121|NCT01619462|Other|Synflorix or PCV10|130 children will receive Synflorix at 1-2-3 months
10009122|NCT01619462|Other|Prevenar 13|130 children will receive Prevenar 13 at 1-2-3 months
10009123|NCT01619475||Prospective|Individuals approved as liver donors and recipients shortly Pre-donation/Pre-transplant at the study sites.
10009124|NCT01619475||Long-Term Follow-up|"Donors and recipients enrolled in the original A2ALL Cohort study.~Donors and LDLT recipients whose donation/transplant occurred during the period of time that began with the end of enrollment into the original Cohort study (Aug. 31, 2009) and ended with the opening of the enrollment in the current core protocol; this is referred to as the Gap Era.~LDLT recipients and donors who were not in the original Cohort study or from the Gap Era will enter the study at time proximate to time of living donation."
10009125|NCT01619475||HCV-Infected Liver Transplant Recipients|Male and female HCV-infected adult liver transplant recipients from those enrolled in the A2ALL-1 Cohort study and from those concurrently transplanted at the new A2ALL-2 centers (University of Toronto, University of Pittsburgh, Lahey Clinic).
10009126|NCT01619488|Experimental|Gastric Banding|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
10009127|NCT01619527|Experimental|Treatment A|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
10009128|NCT01619527|Experimental|Treatment B|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
10009129|NCT01619527|Experimental|Treatment C|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
10009130|NCT01619527|Experimental|Treatment D|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
10009131|NCT01619527|Experimental|Treatment E|Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
10009132|NCT01619527|Experimental|Treatment F|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).
10009133|NCT01619540|Other|acute heart failure|control arm
10009134|NCT01619540|Experimental|COPD exacerbation|COPD exacerbation
10009135|NCT01619566|No Intervention|Control|Control subjects undergo a skin biopsy.
10009136|NCT01619566|Experimental|Treatment|Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
10009137|NCT01619592|Active Comparator|Intervention group|webbased education (telemonitoring)
10009138|NCT01619592|No Intervention|control group|standard care
10009139|NCT01619605|Experimental|Shrim|
10009140|NCT01619631|Experimental|12-week Tai Chi intervention|
10009141|NCT01619631|Active Comparator|Education control group|After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
10009142|NCT01619631|No Intervention|Waitlist control group|The waitlist control will not receive any intervention during the duration of the study. After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
10035508|NCT01806805|Placebo Comparator|placebo|Placebo /Experimental Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
10035509|NCT01806818|Experimental|Eperisone 50mg BID|Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days
10035510|NCT01806818|Experimental|Epirisone 50mg TID|
10035511|NCT01806818|Placebo Comparator|Placebo comparator|
10035512|NCT01806870|Experimental|Nutritional Supplements Zinc and SAMe|Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
10035513|NCT01806883|Experimental|Rehabilitation using Nintendo-Wii|30 patients will receive rehabilitation using Nintendo-Wii.
10035514|NCT01806883|Active Comparator|Traditional physiotherapy|30 patients will receive traditional physiotherapy.
10035515|NCT01806909|Other|Intranasal|Ad4-H5-VTN intranasal vaccine administered in cohorts of 3 at increasing dosages
10035516|NCT01806922|Experimental|Yoga training, Tradiational physiotherapy|Experimental Group(20 people) receive tradiational physiotherapy(4 times in a week, every time 1 hour), and 8-weeks yoga training(2 time in a week, every time 1 hour)
10035517|NCT01806922|No Intervention|Tradiational physiotherapy|Control Group(20 people)only receive tradiational rehabiliation( 4 times in a week, every time 1 hour ) for 8 weeks.
10035518|NCT01806935|Experimental|DC086|cream
10035519|NCT01806935|Placebo Comparator|placebo|
10035520|NCT01806948|Placebo Comparator|Control|Single dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, placebo will be intravenously injected at 4 hours after surgery.
9802430|NCT05255250|No Intervention|Control|Participants will receive the 60 minute virtual physical literacy workshop, equipment goody-bag, and access to the digital app after completing 2-month follow-up measures.
9802431|NCT05255055|Experimental|Manual Therapy Group|Manipulation of the high dorsal region in extension. Cervical mobilizations. Massage therapy. Suboccipital inhibition. Once a week.
9802432|NCT05255055|Experimental|Therapeutic Exercise Group|Recruitment and strengthening of the cervical flexors. Isometric cervical exercises with self-resistance. Shoulder girdle strengthening exercise. Alternating days.
9802433|NCT05254678|Active Comparator|Standard exercise program|Participants in this group will take part the general exercise program delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent exercise workouts within the application, and (3) exercise specific education within the Education Module of the HEAL-ME application.
10009143|NCT01619644|Experimental|Sodium Valproate|Group of 40 patients receiving one year of sodium valproate
10009144|NCT01619644|Placebo Comparator|Placebo|Group of 20 patients receiving one year of placebo
10009145|NCT01619657|Experimental|Hypertonic Saline|Inhalation with 6% Hypertonic Saline twice daily over 1 year
10009146|NCT01619657|Active Comparator|Isotonic Saline|Inhalation with 0.9% Isotonic Saline twice daily over 1 year
10009147|NCT01619670|No Intervention|no intervention|standard wound care
10009148|NCT01619670|Active Comparator|Apligraf|non adhesive layer with apligraf
10009149|NCT01619683|Experimental|Androxal|
10009150|NCT01619683|Placebo Comparator|Placebo|
10009151|NCT01619696|Experimental|Intervention|
10009152|NCT01619709|Other|lobar hemorrhage group|PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
10009153|NCT01619709|Other|deep hemorrhage group|PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
10009154|NCT01619735||Fragments basketed|"Active extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments."
10009155|NCT01619735||Fragments dusted|"Dusting is whereby the stones are broken into tiny fragments or dust with the intention that achieving such a small stone size will allow the stones to pass spontaneously."
10009156|NCT01619748||Untreated OSA patients|Patients with obstructive sleep apnoea who are untreated
10009157|NCT01619748||OSA patients highly compliant with CPAP|OSA patients established on CPAP therapy (high compliance, > 80% nightly use for ≥ 4 h per night)
10009158|NCT01619748||OSA patients poorly compliant with CPAP|OSA patients established on CPAP therapy (poor compliance, 10% < nightly use < 50% or < 4 h per night)
10009159|NCT01619748||Age and BMI-matched controls|Age and BMI-matched controls without OSA
10009160|NCT01619761|Experimental|Treatment Plan 1 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -8 to -2, fludarabine phosphate IV over 1 hour on days -7 to -4, and melphalan IV over 30 minutes on day -4. CD20 positive patients also receive rituximab IV over 6 hours on days -8 to -4.
10009161|NCT01619761|Experimental|Treatment Plan 2 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -7 to -2, cyclophosphamide IV over 3 hours on day -7, and undergo TBI on day -3. Patients also receive rituximab and fludarabine phosphate as in Treatment Plan 1.
10009162|NCT01619813|Active Comparator|Docetaxel, Reolysin and Prednisone|
10009163|NCT01619813|Active Comparator|Docetaxel and Prednisone|
10009164|NCT01619826|Experimental|Treatment Group|Participants randomized to the physical activity-based afterschool intervention
10009165|NCT01619826|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
10009166|NCT01619891|Active Comparator|Vitamin D|Vitamin D 100mcg per day
10009167|NCT01619891|Placebo Comparator|Placebo|Standard optimal therapy
10009168|NCT01619904|Experimental|Goal-Directed Therapy|
10009169|NCT01619904|Active Comparator|Standard Therapy|
10009170|NCT01619917|Active Comparator|Proximal|location of the scar proximal to heart
10009171|NCT01619917|Experimental|Distal|location of scar distal to heart
10009172|NCT01619930|Experimental|1a|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
10009173|NCT01619930|Experimental|1b|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
10009174|NCT01619930|Experimental|2a|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
10009175|NCT01619930|Experimental|2b|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
10009176|NCT01619930|Experimental|3a|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
10009177|NCT01619930|Experimental|3b|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
10009178|NCT01619930|Experimental|4a|"In phase 1, group 4 undergoes behavioral activation without added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
10009179|NCT01619930|Experimental|4b|"In phase 1, group 4 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
10009180|NCT01619930|No Intervention|Phase 1 Waiting list control group|Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
10009181|NCT01619943||Patients with minor head injury|MHI is defined as a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.
10009182|NCT01619956|Experimental|OSFE with grafting|OSFE with grafting (autogenous bone chips+xenograft material with a ratio of 1:4)
10009183|NCT01619956|Active Comparator|OSFE without grafting|OSFE without grafting. No grafting materials or autogenous bone chips were used.
10009184|NCT01619969|Experimental|Celgosivir|
10009185|NCT01619969|Placebo Comparator|Placebo|
10009186|NCT01620008|No Intervention|Immediate Cord Clamping (ICC)|The infant will be placed on the maternal abdomen and the umbilical cord will be clamped immediately after birth (routine care).
10009187|NCT01620008|Experimental|Delayed Cord Clamping (DCC)|At birth, infants will be placed on the maternal abdomen and the cord clamping will be delayed for 5 minutes. If the provider is unable to delay the cord clamping, the cord will be milked 5 times.
10009188|NCT01620021||Healthy|Ten healthy volunteers with no history of gait and balance issues will be recruited to participate in the study.The participants must be between 18 and 65 years of age.
10009189|NCT01620034|Active Comparator|11 Day Arm|
10009190|NCT01620034|Experimental|4 Day Arm|
10009191|NCT01620073|Other|Partner friendly arm|Proportion of males counseled and tested using routine standards of prenatal care
10009192|NCT01620073|Experimental|Home based arm|Proportion of male partners accepting HIV counseling and testing following home visits for couple HIV counseling and testing during pregnancy
10009193|NCT01620099|Experimental|Asthmatic nonsmokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who never smoked. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
10035521|NCT01806948|Experimental|Experimental|Double dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, Ramosetron 0.3 mg will be intravenously injected at 4 hours after surgery.
10035522|NCT01806974|Other|patient with parodontitis|Patient with rheumatoid arthritis and pparodontitis.
10035523|NCT01806974|Other|Patient without parodontitis|Patient with rheumatoid arthritis but periodontally healthy
10009194|NCT01620099|Active Comparator|Asthmatic smokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who smoked with a smoking habit ranging from 10 to 20 pack/years. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
10009195|NCT01620112|Active Comparator|low clonidine concentration|clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus
10009196|NCT01620112|Active Comparator|lidocaine 20 ml 1,5%|lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery
10009197|NCT01620112|Active Comparator|high clonidine concentration|clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus
10009198|NCT01620112|Active Comparator|40 ml lidocaine 1,5%|40 ml of lidocaine 1,5% without clonidine for upper brachial plexus
10009199|NCT01620125|Other|Lactobacillus reuteri|Dietary supplementation with Lactobacillus reuteri DSM 17938
10009200|NCT01620151|No Intervention|No extended neck|Patient will not undergo thyroid surgery with extended neck
10009201|NCT01620151|Experimental|Extended neck|Patients who undergoing thyroid surgeries are positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier.
10009202|NCT01620164|Other|Parkinsonian patients OFF/ON|9 patients will be evaluated with psychophysical measurements of 3D perception, in OFF then ON conditions
10009203|NCT01620164|Other|healthy subjects|Healthy subjects will be evaluated with psychophysical measurements of 3D perception, without treatment
10009204|NCT01620164|Other|Parkinsonian patients ON/OFF|9 patients will be evaluated with psychophysical measurements of 3D perception, in ON and then OFF conditions
10009205|NCT01620229|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
10009206|NCT01620242|Experimental|Cabazitaxel|All patients are treated with Cabazitaxel.
10009207|NCT01620268|No Intervention|Control Group|Patients receive standard of care.
10009208|NCT01620268|Experimental|Treatment Group|Dose adjusted leflunomide plus 600 mg orotic acid.
10009209|NCT01620281|Experimental|Immediate treatment (IT)|Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
10009210|NCT01620281|Other|Waiting List Control (WLC)|The WLC group will go through the same evaluations at the same time intervals but will begin treatments 3 weeks later during which they will fill the diary daily but not use the device.
10009211|NCT01620294|Experimental|triclosan|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
10009212|NCT01620294|Experimental|uncoated|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
10009213|NCT01620307|Active Comparator|with Rapamune treatment|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were received Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
10009214|NCT01620307|Placebo Comparator|Without Rapamune treatment.|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were not to receive Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
10009215|NCT01620320||Stress echography|Nine to twelve months after their left main angioplasty, patients will go through a stress echo and then the usual control angiography (done routinely in most patient in our center). Patients will act as their own control.
10009216|NCT01620333|Experimental|Treatment period 1|
10009217|NCT01620333|Experimental|Treatment period 2|
10009218|NCT01620346|Active Comparator|ICSI group|This group was provided with conventional intracytoplasmic sperm injection (ICSI). This treatment is routinely used to treat infertility. Sperm selection in the ICSI group is analysed under a magnification of 400x using an inverted microscope.
10035524|NCT01806987|Experimental|KITS Program|The KITS Program consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
9517911|NCT03301766|Experimental|Lidocaine 5% patch|"Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
10009219|NCT01620346|Experimental|Intracytoplasmic morphologically selected sperm injection|Intracytoplasmic morphologically selected sperm injection (IMSI) is an established modified ICSI procedure. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
10009220|NCT01620359|Experimental|ExAblate|
10009221|NCT01620372||Treatment cohort (chemo/radiotherapy)|- those who have survived at least 5 years from the date of diagnosis
10009222|NCT01620372||Self-questionnaire cohort|- those with a complete address, who come of age, are still alive and sent back a signed consent agreement
10009223|NCT01620372||Medical Insurance cohort|- those who come of age and authorize the access to the medical facilities of the French Health Insurance Information System
10009224|NCT01620385|Experimental|ciPDA|
10009225|NCT01620398|Experimental|BALANCE group|BALANCE Program is composed by 3 concepts: a) a diet composed of 50-60% of energy from carbohydrate, 10-15% of energy from protein; 25-35% of energy from fat (<7% saturated fatty acid; <10% polyunsaturated fatty acid; <20% monounsaturated fatty acid, <1% trans fatty acid), <200 mg/day of cholesterol, 20-30 g/day of fiber and <2400 mg/day of sodium; b) Nutrition education program based on ludic strategies and indication of affordable foods; c) An intense follow up by individual and group visits and phone calls.
10009226|NCT01620398|Active Comparator|Control Diet group|generalized advices to follow a low fat, low energy, low sodium and low cholesterol diet are given.
10009227|NCT01620411|Experimental|Comprehensive Medical Management (CMM)|This arm will receive standard of care treatment for injuries sustained while on active duty. Non-Invasive.
10009228|NCT01620411|Experimental|CMM + Spinal Cord Stimulator (SCS)|This arm will combine comprehensive medical management with placement of a spinal cord stimulator.
10009229|NCT01620424|Experimental|Dosing visit 1|
10009230|NCT01620424|Experimental|Dosing visit 2|
10009231|NCT01620437|Experimental|Formulation A|
10009232|NCT01620437|Experimental|Formulation B|
10009233|NCT01620450|Experimental|NN2000|
10009234|NCT01620450|Active Comparator|NN-X14|
10009235|NCT01620463|Experimental|NNC 90-1170|
10009236|NCT01620463|Placebo Comparator|Placebo|
10009237|NCT01620476|Experimental|5 mcg/kg|
10009238|NCT01620476|Experimental|10 mcg/kg|
10009239|NCT01620476|Experimental|15 mcg/kg|
10009240|NCT01620502|Active Comparator|EPA 3.5 g/day|
10009241|NCT01620502|Placebo Comparator|Placebo capsules|oleic oil
10009242|NCT01620502|Experimental|DHA 1.75 g/day|DHA 1.75 g/day
10009243|NCT01620541||Preference, Ankle Arthrodesis|
10009244|NCT01620541||Preference, Ankle Arthroplasty|
10009245|NCT01620554|Experimental|BF2.649 5mg|
10009246|NCT01620554|Experimental|BF2.649 10mg|
10009247|NCT01620554|Experimental|BF2.649 20mg|
10009248|NCT01620554|Experimental|BF2.649 40mg|
10009249|NCT01620554|Placebo Comparator|Placebo|
10009250|NCT01620580|Active Comparator|Self Management Strategies|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3."
10009251|NCT01620580|Active Comparator|Dietary Information|Control arm
9517912|NCT03301766|Active Comparator|Non-medicated patch|"Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
9964181|NCT01236209|Experimental|Webpage and situational feedback|"Intervention group:~have access to the same web-page with information about coping with pain and relaxation and are completing 3 diaries and receiving personalized feedback for 4 weeks at home through a smartphone."
9964182|NCT01236222|No Intervention|Control group|
9964183|NCT01236222|Experimental|Cycling to school|
9964184|NCT01236235||ARV-naïve HIV patients initiated on ATV/RTV-based therapy|"Anti-retroviral (ARV)-naïve HIV patients initiated on ATV/RTV-based therapy between 2008-2010~One cohort being observed for 3 different countries"
9964185|NCT01236248|Experimental|Prevention Program|Girls and their mothers who are assigned to participate in a tobacco, alcohol, and other drug use prevention program aimed at young girls.
9964186|NCT01236248|No Intervention|No Prevention Program|Girls and their mothers who are assigned to participate in questionnaires only.
9964187|NCT01236261||Fungemia|Patients with a fungal isolate from a blood culture
9964188|NCT01236274||Antipsychotic agents AND MI|In the self-controlled case series study, patients who experienced a myocardial infarction and received an antipsychotic agent during up to standard (UTS) follow-up in the GPRD will be included and will act as their own control.
9964189|NCT01236274||Myocardial Infarction|In the case-control study, all cases with a first recorded occurrence of MI during up to standard (UTS) follow-up in the GPRD will be identified
9964190|NCT01236274||No Myocardial Infarction|In the case-control study, a control group with subjects who never experienced a myocardial infarction will be matched to cases (5:1) by age, gender, General Practitioner and registration in the GPRD on the date of MI of the case
9964191|NCT01236313||TEE report|Cardiac surgery patients requiring TEE
9964192|NCT01236417|Experimental|Exercise|Subjects will be participating in a home-based flexibility and exercise program
9964193|NCT01236443|Experimental|HPPH|3 mg/m2
9964194|NCT01236469||Retrospective Patients|Pediatric (21 years of age or younger) patients who received a CryoValve SG Aortic Valve distributed during the 2000 to 2003 period as an aortic valve replacement.
10009252|NCT01620606|Experimental|SLCBT|Social Learning and Cognitive Behavioral Therapy
9964195|NCT01236482|Active Comparator|Oxytocin|
9964196|NCT01236482|Experimental|Oxytocin - ergometrine|
9964197|NCT01236495|Experimental|spinal morphine 0.2 mg|spinal morphine 0.2 mg
9964198|NCT01236495|Active Comparator|spinal morphine 0.3 mg|spinal morphine 0.3 mg
9964199|NCT01236508|Experimental|Nuclear imaging|PET/CT imaging with F-18 fluorodeoxyglucose
9964200|NCT01236599|No Intervention|traditional care|Preterm Infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off and wrapped up in a sterile preheated field
9964201|NCT01236599|Experimental|Polyethylene bag with previous drying|infants were placed under the radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off, and wrapped up in a polyethylene bag, leaving their faces discovered as well as the access at umbilical catheters or veined access.
10009253|NCT01620606|Experimental|SLCBT-R|Phone-based Social Learning and Cognitive Behavioral Therapy
10009254|NCT01620606|Active Comparator|ES|Education and Support
10009255|NCT01620619|Active Comparator|Arthroscopic Bankart Repair & Rotator Interval Closure|
10009256|NCT01620619|Active Comparator|Arthoscopic Bankart Repair alone|
10009257|NCT01620632||Altered gastric anatomy|Patients who have an altered gastric who need an ERCP
10009258|NCT01620645||COPD, GOLD II severity or above|
10009259|NCT01620671|Active Comparator|Conventional surgery|The patients who will have a conventional surgical treatment will be included.
10009260|NCT01620671|Active Comparator|Fast-track surgery|The patients who will have fast-track surgery will be included.
10009261|NCT01620684|Active Comparator|metyrapone|Overnight metyrapone treatment (total dose of 30 mg/kg)
10009262|NCT01620684|Placebo Comparator|sugar pill|Overnight treatment with placebo capsules
10009263|NCT01620697||Perirenal fat|
10009264|NCT01620710|Other|prostate bed|"irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)~This arm has already finished recruitment"
10009265|NCT01620710|Other|prostate bed & lymph nodes|irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
10009266|NCT01620723|Experimental|New breastfeeding programme|"The breastfeeding programme consists of four core elements:~breastfeeding is a parental task~skin to skin contact during the first three days~frequent breastfeeding at least 8 times a day~good positioning, preferable in a laid back position~Moreover communication was supposed to enhance breastfeeding self-efficacy, using Banduras theory of self-efficacy"
10009267|NCT01620723|Active Comparator|Treatment as usual|Breastfeeding counselling uses the national handbook of breastfeeding as reference
10009268|NCT01620736|Experimental|Raltegravir|Treatment with raltegravir for 8 wks
10009269|NCT01620749|Experimental|MEL050|
10009270|NCT01620775|Experimental|Knee osteoarthritis (MRI, surveys, pain testing)|Subjects previously diagnosed with knee osteoarthritis will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
10009271|NCT01620775|Active Comparator|Healthy controls (MRI, surveys,pain testing)|Healthy volunteers will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
10009272|NCT01620775|Experimental|diabetic peripheral neuropathy|Subjects previously diagnosed with diabetic peripheral neuropathy will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
10009273|NCT01620775|Experimental|chronic low back pain|Subjects previously diagnosed with chronic low back pain will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
10009274|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 50mg|
10009275|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 100mg|
10009276|NCT01620788|Active Comparator|Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)|
10009277|NCT01620788|Active Comparator|Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)|
10009278|NCT01620801|Experimental|Low dose|AAV8-hFIX19
10009279|NCT01620801|Experimental|Middle dose|AAV8-hFIX19
10009280|NCT01620801|Experimental|High dose|AAV8-hFIX19
10009281|NCT01620814|Experimental|Dinoprostone and misoprostol|"For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.~After drugs administration, cervical canal will be again evaluated with above mentioned way by bougie before hysteroscopy"
10009282|NCT01620814|Experimental|Misoprostol and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
10009283|NCT01620814|Experimental|dinoprostone and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
10009284|NCT01620827|Active Comparator|Hospital Landline|Subjects in this arm have all of their follow-up phone calls placed from a hospital landline number.
10009285|NCT01620827|Active Comparator|Private Cell Phone|Subjects in this arm have all of their follow-up phone calls placed from a private cell phone number.
10009286|NCT01620840||Lacosamid-i.v. treatment|
9802434|NCT05254678|Experimental|Integrated physiotherapy and exercise|Participants in this group will take part in an integrated physiotherapy and exercise intervention delivered through the Active Living module of the HEAL-ME application. The program comprises (1) supervised group physiotherapeutic exercise sessions (connection via zoom platform embedded in HEAL-ME), (2) independent physiotherapeutic exercise workouts, and (3) breast cancer specific physiotherapy education delivered through weekly modules.
10009287|NCT01620866|Experimental|EMDR|
10009288|NCT01620866|No Intervention|TAU|Treatment as usual (TAU)
10009289|NCT01620892||Unicondylar knee replacement|This is a non-intervational, retrospective, observational study of a case series cohort of patients who received a particular surgical operation during a specified time period.
10009290|NCT01620905|Experimental|Cervical spine manipulation|Subjects received cervical spine manipulation
10009291|NCT01620931|Experimental|RO5469754|
10009292|NCT01620931|Placebo Comparator|Placebo|
10009293|NCT01620944|Experimental|Arm1: ATV/RTVHS+3TC|
10009294|NCT01620944|Active Comparator|Arm2: ATV/RTVHS+TDF/FTC|
10009295|NCT01620957||Coma patients|
10009296|NCT01620970|Experimental|PF03446962|Investigational study drug, administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
10009297|NCT01620996|Active Comparator|1|Duffus Street Medical Centre
10009298|NCT01620996|Active Comparator|2|Sydney Family Practice
10009299|NCT01620996|No Intervention|no counseling|HRA assessment pre and post but no counselling
10009300|NCT01621022|Active Comparator|Active bupropion-Active gum|150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
10009301|NCT01621022|Active Comparator|Active bupropion-Placebo gum|150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
10009302|NCT01621022|Active Comparator|Placebo medication-Placebo gum|Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)
10009303|NCT01621035||elderly (> 70 y)|
10009304|NCT01621061||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension
10009305|NCT01621061||High altitude control|Healthy highlanders
10009306|NCT01621061||Low altitude control|Healthy lowlanders
10009307|NCT01621074|Active Comparator|Sodium bicarbonate|
10009308|NCT01621074|Placebo Comparator|Placebo|
10009309|NCT01621087|Experimental|Safflower oil|
10009310|NCT01621087|No Intervention|Control group (no diet instruction)|
10009311|NCT01621100|Experimental|OROS hydromorphone|Once-Daily OROS (Osmotic release oral system [a controlled release oral drug delivery system in the form of a tablet]) hydromorphone
10009312|NCT01621113|Experimental|Locomotor Training + Dalfampridine|Subjects randomized to this group will undergo 10 weeks of double-blind treatment with extended release dalfampridine tablets (10 mg twice daily) while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
10009313|NCT01621113|Placebo Comparator|Locomotor Training + Placebo|Subjects randomized to this group will undergo identical treatment, but will take placebo tablets while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
10009314|NCT01621139|Experimental|Real acupuncture|Real acupuncture group
10009315|NCT01621139|Sham Comparator|Sham acupuncture|Sham acupuncture group
10009316|NCT01621165|Active Comparator|prazosin|Add prazosin to usual medications and monitor manic symptoms and for adverse effects
10009317|NCT01621165|Placebo Comparator|Placebo|
10009318|NCT01621204|Experimental|Eltrombopag|Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
10009319|NCT01621204|Active Comparator|IVIG infusion|Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.
9517913|NCT03301727|Active Comparator|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
9964202|NCT01236599|Experimental|Polyethylene bag without previous drying|Preterm infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel) and without previous body drying (only the head was dried), were wrapped up with the polyethylene bag, leaving their faces discovered as well as the access to umbilical catheters or veined access
9964203|NCT01236612|Experimental|Immunization + bloodstage challenge|
9964204|NCT01236612|Active Comparator|Immunization + mosquito challenge|
9964205|NCT01236612|Placebo Comparator|Control - Bloodstage challenge|
9964206|NCT01236612|Placebo Comparator|Control - Mosquito challenge|
9964207|NCT01236625||No adhesiolysis|All patient undergoing elective laparotomy or laparoscopy with no need for adhesiolysis during the procedure.
9964208|NCT01236625||Adhesiolysis|All patient undergoing elective laparotomy or laparoscopy requiring adhesiolysis during the procedure.
9964209|NCT01236651|Experimental|meperidine and duration of 1st stage of labor|meperidine 100mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
10009320|NCT01621217|Experimental|Cetuximab, Mitomycin C, Fluoruracil|
9964210|NCT01236651|Experimental|drotaverine and duration of 1st stage of labor|drotaverine 40mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
9964211|NCT01236664|Experimental|Memory Training|
9964212|NCT01236664|Active Comparator|Control workshop|
10009321|NCT01621256|Experimental|Ancrod|Ancrod
10009322|NCT01621256|Placebo Comparator|Saline solution|Saline solution
10009323|NCT01621269|Experimental|Fingolimod|
9476700|NCT03569176|Other|Crossover Control for Autism Glass|Participants randomized to the control arm, will continue treatment as usual (receiving ABA twice a week) while the intervention participants will receive the Autism Glass intervention (while continuing to receive ABA therapy). After 6 weeks, control participants will receive the Autism Glass intervention after which, they will be asked to come in for a second round of follow-up testing following 6 weeks of use (at week 18).
9802435|NCT05253274|Experimental|Virtual Reality application group|VR application will be applied to the experimental group during the emergency surgical intervention under local anesthesia.
10009324|NCT01621282|Experimental|Education|Departments passed 6-month interactive educational course
9802436|NCT05253274|No Intervention|Control|The patients in the control group routinely receives standard care in the emergency service. No application will be made to the control group.
9802437|NCT05252936|Experimental|Spanish language content|Social media campaign content with Spanish language voiceover
10009325|NCT01621282|No Intervention|No Education|Departments not passed 6-month interactive educational course
10009326|NCT01621308||IP insulin|Patients treated with continuous intraperitoneal insulin infusion using a implantable pump
10009327|NCT01621308||SC insulin|Patients treated with subcutaneous insulin, both multiple daily injections and continuous subcutaneous insulin infusion
10009328|NCT01621321|Experimental|Steroid group|
10009329|NCT01621321|Experimental|Voriconazole group|
10009330|NCT01621334|Experimental|Motivational Enhancement Therapy|Motivational Enhancement Therapy
10009331|NCT01621334|Other|Educational brochure|Intimate Partner Violence, Substance Abuse, and HIV risky behaviors Education
10009332|NCT01621360|Active Comparator|Arthroscopic surgery|Arthroscopic surgery of the hip plus optimized medical management
10009333|NCT01621360|Active Comparator|Conservative management|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
10009334|NCT01621373|Other|propofol|All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.
10035525|NCT01806987|No Intervention|Services as usual|These include any services that the child and family might already be receiving in the community.
10035526|NCT01807039||patients after surgery with isolated proximal femur fracture|Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
10035527|NCT01807052||Observational|Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
10035528|NCT01807078|Active Comparator|Ezetimibe|Patients will receive for 6 months ezetimibe (10 mg/day)
10035529|NCT01807078|Active Comparator|Nutraceuticals|Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
10035530|NCT01807117|Experimental|Diagnostic (PET-CT and PET-MRI)|Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
10035531|NCT01807130|Placebo Comparator|Registry|Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
9802438|NCT05252936|Experimental|K'iche' language content|Social media campaign content with K'iche' language voiceover
9802439|NCT05252936|Experimental|Kaqchikel language content|Social media campaign content with Kaqchikel language voiceover
9802440|NCT05252936|Active Comparator|Control|A control group that is not exposed to any of the social media campaign content will serve as control to allow for comparison of outcomes with treatment arms.
10035532|NCT01807130|Experimental|Intervention|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.
10035533|NCT01807143||Correlative studies|Tissue samples are analyzed for translocations and deletions and analyzed using PCR or FISH.
10035534|NCT01807169|Experimental|Colonic polypectomy or endoscopic mucosal resection|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
10035535|NCT01807195||the medical records of those in whom a contrast medium|
10035536|NCT01807208|Experimental|Educational tool|Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
10035537|NCT01807208|No Intervention|Usual care|Patients in this arm of the study will receive usual care.
10035538|NCT01807247||Hemiparetic|Intensive lower limbs muscles strengthening
10035539|NCT01807247||Spinal cord injury|Intensive lower limbs muscles strengthening
10035540|NCT01807247||Multiple sclerosis|Intensive lower limbs muscles strengthening
10037262|NCT01823458|Experimental|Lottery Insurance|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
10037263|NCT01823458|Experimental|Standard Lottery|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Subjects in the 'Standard Lottery' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They also receive the expected value of the insurance ($2) for attending a second exercise class during the week on either Wednesday or Thursday. They have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
10037264|NCT01823471|Experimental|I-scan first group|After the caecum is reached patients will be first examined with high definition i-scan endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass white light will be used.
9802441|NCT05252442||Pre-COVID-19|
9802442|NCT05252442||COVID-19|
9802443|NCT05252442||COVID-19 vaccination roll-out|
10009335|NCT01621386|Experimental|All Participants|Participants (male or female) that are between 18-65 years of age with a clinical diagnosis of asthma will take montelukast for 2 weeks (treatment period 1) and then take prednisone for 2 weeks (treatment period 2)
10009336|NCT01621399|Placebo Comparator|Vehicle|Treatment with the vehicle (placebo)
10009337|NCT01621399|Experimental|Product 55394|Treatment with product 55394
10009338|NCT01621425||TAC regimen|Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol
10009339|NCT01621425||PRODOC regimen|male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol
10009340|NCT01621451|Active Comparator|immediate|Patients who receive pantoprazole plus aspirin and/or clopidogrel within 3~4 days after EMR/ESD
10009341|NCT01621451|Active Comparator|2 weeks|Patients who receive pantoprazole plus aspirin and/or clopidogrel at 2 weeks after EMR/ESD
10009342|NCT01621464|Placebo Comparator|Control|Pacemaker implanted but NO pacing (mode DDI, 30 bpm and sub-threshold)
10009343|NCT01621464|Experimental|CLS group|pacemaker implanted programmed with the contractility sensor activated (mode DDD-CLS)
10009344|NCT01621516||Healthy controls|10 healthy volunteers
10009345|NCT01621516||Solitary small bowel transplant patients|3
10009346|NCT01621516||Liver/small bowel transplant patients|3
10009347|NCT01621555||PSOASS Patients|Patients undergoing elective arthroscopic shoulder surgery
10009348|NCT01621568|Experimental|Arm 1|Single Group Assignment for Thymoma and Thymic Carcimoma
10009349|NCT01621620|Experimental|yohimbin|
10009350|NCT01621646|Placebo Comparator|egg white (control)|egg whites, 4 ounces per day for six months
10009351|NCT01621646|Experimental|eggs|eggs, 2 large per day for 6 months
10009352|NCT01621659|Experimental|multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
10009353|NCT01621659|No Intervention|Observational arm|Participants randomized to observational arm will receive usual care.
10009354|NCT01621685|Experimental|Spirometry, auscultation, questionnaire|>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score >4
10009355|NCT01621698|Active Comparator|Early paravertebral block|The early group will have Local anaesthetic placed at the start of surgery and have normal saline placed at the close.
10009356|NCT01621698|Active Comparator|Late paravertebral block|The late group will have normal saline placed at the start of surgery and local anaesthetic placed at the close.
10009357|NCT01621711|No Intervention|Usual Care|Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
10009358|NCT01621711|Experimental|Linkage patient activation intervention|Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
10009359|NCT01621724|Experimental|Single arm cohort study|WT1 TCR-transduced T cells
10009360|NCT01621750|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
9802444|NCT05252390|Experimental|Phase 1 Monotherapy Dose Escalation|NUV-868 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.
10009361|NCT01621750|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
10009362|NCT01621763|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
10009363|NCT01621763|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
10009364|NCT01621789|Experimental|dye of lutein, zeaxanthin, trypan blue|during the surgery will be evaluated if the dye is suitable for dyeing anterior lens capsule
10009365|NCT01621815|Active Comparator|Anxiety and Depression|Adolescents diagnosed with anxiety and/or depression
10009366|NCT01621815|Active Comparator|ADD|Adolescents diagnosed with ADD (without hyperactive element)
10009367|NCT01621815|Active Comparator|ADHD, Behavioral|Adolescents diagnosed with ADHD (with hyperactivity), with or without behavioral problems
10009368|NCT01621815|Active Comparator|PDD|Adolescents diagnosed with PDD Spectrum Disorders
10009369|NCT01621815|Active Comparator|Control|Adolescents without a psychiatric diagnosis
10009370|NCT01621828|Other|video|video showing a patient's pathway into the operating room.
9476701|NCT03569150|Other|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
9476702|NCT03569150|No Intervention|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
9476703|NCT03569124||Training group|
10009371|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
10009372|NCT01621841||Glaucoma subjects|
10009373|NCT01621841||heathly subjects|
10009374|NCT01621854|Experimental|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
10009375|NCT01621867|Active Comparator|pGM169/GL67A (CFTR Gene/Lipid Vector)|
10009376|NCT01621867|Placebo Comparator|Placebo|
10009377|NCT01621893||BML of the Knee|Subject has single bone marrow lesion of tibia, single BML of femur, or adjoining BML's of tibia & femur on which a Subchondroplasty procedure is performed
10009378|NCT01621906|Experimental|Cohort 1|Cohort 1 will include the first ten patients treated with WBRT concomitantly with sorafenib (on a separate phase I trial). We will perform a pilot study of serial FLT-PET imaging of the brain at baseline (< 4 weeks prior to initiation of WBRT), up to 7-10 days post-WBRT and 10-12 weeks after WBRT in patients with metastatic breast cancer to the brain (N=20) treated with WBRT with or without sorafenib.
10009379|NCT01621906|Experimental|Cohort 2|Cohort 2 will include patients treated with standard WBRT alone. Patients in both these cohorts will also be assessed with standard non-invasive MRI in addition to [18F] FLT PET at baseline (< 4 weeks of WBRT) and 10-12 weeks after completion of WBRT.
10009380|NCT01621932|Active Comparator|Surgical approach 1|Direct anterior surgical approach with capsulectomy
10009381|NCT01621932|Active Comparator|Surgical approach 2|Direct anterior approach without capsulectomy
10009382|NCT01621945||Bras A|children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
10009383|NCT01621958|Experimental|Motor training|
10009384|NCT01621958|Placebo Comparator|Intensity control|
10009385|NCT01621971|Experimental|milrinone inhalation|inhaled milirinone and IV placebo (0.9% normal saline 0.05 ml/kg) are administered in Group IH.
10009386|NCT01621971|Active Comparator|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an IV bolus of milrinone (50 μg/kg) are administered in Group IV
10009387|NCT01621984|Experimental|Therapeutic Riding/ Hippotherapy|12 week Therapeutic Riding program that focused on gross motor function, gross motor performance, balance, spasticity, posture and quality of life
10009388|NCT01621984|No Intervention|without Therapeutic Riding/ Hippotherapy|
10009389|NCT01621997|Experimental|operation inspection|During retraining the patients performed bag exchange under the supervision of a nurse. The nurse ensured that each error listed in the NAC form should be avoided, thus immediately corrected any wrong steps if only.
10009390|NCT01621997|Experimental|verbal education|"Patients in the oral education group also underwent retraining every 2 months. A nurse would address all items in the NAC form one by one, to remind the patient of the key points of bag exchange. Scores calculated by the sum of error items during the bag exchange for patients in technique inspection group, or by the sum of yes in the interactive quiz for patients in verbal education group."
10009391|NCT01621997|Experimental|usual care|Patients in the usual care group did not receive any retraining
10009392|NCT01622023|Experimental|Study group|intrauterine insemination after 24 hours
10009393|NCT01622023|Active Comparator|Control group|intrauterine insemination after 48 hours
10009394|NCT01622036||Cancer patients undergoing first medical oncology visit.|
10009395|NCT01622049||TTTS treatment method|This is an observational trial. Patients who meet eligibility criteria and give written informed consent will have SLPCV. All subjects will receive ongoing standard-of-care prenatal care for the duration of their pregnancy from their referring perinatologist or obstetrician.
10009396|NCT01622075|Experimental|SeQuent® Please|Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
10009397|NCT01622075|Active Comparator|Taxus Liberte|Paclitaxel Drug-eluting Coronary Stent and Conveying System
10009398|NCT01622101|Experimental|zantrex|The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
10009399|NCT01622101|Placebo Comparator|Control|The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or appearance.
10009400|NCT01622114|Experimental|Menstralean group|"Represents a program which is designed to induce weight loss by taking into account the physiology of each menstrual phase in terms of adjusting diet and physical activity to the body's cyclic changes in energy demands.~The diet will be adjusted to match one menstrual cycle in duration (approx. 1 month) and will be separated into three phases corresponding to three menstrual phases: menstruation (days 1-5), the follicular phase (days 6-14), and the luteal phase (days 15-28). All women in this group will start the program at day 1 in their cycle. The diet will be repeated six times for each woman, which equals six months."
10009401|NCT01622114|Active Comparator|Control Group:|"Represents a program where subjects engage in a similar diet and exercise program as the Menstralean Group, specifically based on the educational diet system Eat for Life. Importantly, the subjects in Control group will start the program at a random time in their menstrual cycles.~Eat for Life is a simple tool for controlling the energy content and nutritional composition of your diet. The method is based on a system of counters that ensure strict control of the diet whilst still allowing a great deal of freedom of choice. The subjects in the Control Group will also receive exactly the same attention and undergo the same visits and measurements as the Menstralean Group."
10009402|NCT01622127||incisional hernias|
10009403|NCT01622153|Placebo Comparator|Formocresol (control)|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
10009404|NCT01622153|Active Comparator|Laser|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
10009405|NCT01622166|Experimental|art therapy|12 sessions of art therapy / 6 weeks
10009406|NCT01622166|No Intervention|TAU|treatment as usual / 6 weeks
9476704|NCT03569124||Non-Training group|
9476705|NCT03569085|Experimental|Sevoflurane then isoflurane|
9802445|NCT05252390|Experimental|Phase 1b Dose Escalation: NUV-868 + Olaparib|"NUV-868 will be administered at escalating dose levels in combination with olaparib until the recommended Phase 2 combination dose (RP2cD) is determined.~300 mg olaparib will be administered orally twice daily throughout the 28-day cycles of NUV-868."
9802446|NCT05252390|Experimental|Phase 1b Dose Escalation: NUV-868 + Enzalutamide|"NUV-868 will be administered daily at escalating dose levels in combination with enzalutamide until the RP2cD is determined.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-868."
9802447|NCT05252390|Experimental|Phase 2 Monotherapy Expansion|NUV-868 will be administered at the RP2D.
10009407|NCT01622179|Experimental|Indirectly|The epitenon was repaired and sewed indirectly.
10009408|NCT01622179|Placebo Comparator|Directly|The epitenon was unrepaired and sewed directly.
10009409|NCT01622192|Experimental|Automated probe|
10009410|NCT01622205|Experimental|Active|Early supported discharge
10009411|NCT01622205|Other|Control|Ordinary rehabilitation
10009412|NCT01622218|Experimental|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers.
10009413|NCT01622218|No Intervention|Control|Assessment of child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect on the total consumption of analgesics and on the post- surgery inflammatory markers.
10009414|NCT01622244|Experimental|Intervention arm|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
10009415|NCT01622244|Active Comparator|Counseling and Resource Education (CARE)|Participants will receive care as usual in the community. In addition, participants in this arm will receive an educational session and resource guide outlining available community-based services
10009416|NCT01622283|Experimental|Levocetirizine oral solution 5 mg|Levocetirizine oral solution 5 mg
10009417|NCT01622283|Active Comparator|Cetirizine dry syrup 10 mg|Cetirizine dry syrup 10 mg
10009418|NCT01622309|Active Comparator|eggplant meal|13 g meal of eggplant/day
10009419|NCT01622309|Placebo Comparator|cassava meal|13 g of placebo/day
10009420|NCT01622322|Experimental|Nitrous oxide|Subjects will receive General anesthesia with Nitrous Oxide.
9802448|NCT05252390|Experimental|Phase 2b Combination Expansion: NUV-868 + Olaparib|"NUV-868 will be administered at the RP2cD.~300 mg olaparib will be administered orally twice daily throughout the 28-day cycles of NUV-868."
9802449|NCT05252390|Experimental|Phase 2b Combination Expansion: NUV-868 + Enzalutamide|"NUV-868 will be administered at the RP2cD.~160 mg enzalutamide will be administered orally daily throughout the 28-day cycles of NUV-868."
9802450|NCT05251753|Experimental|A K-Lock left|A) left side K-Lock with right side suture-based technique
9802451|NCT05251753|Experimental|B K-Lock right|B) right side K-Lock with left side suture-based technique.
10009421|NCT01622322|Placebo Comparator|Oxygen|Subjects will receive General anesthesia with oxygen.
10009422|NCT01622361|Active Comparator|Chemotherapy Group|Chemotherapy Adriamycin+Cyclophosphamide>Docetaxel
10009423|NCT01622361|Experimental|Endocrine therapy group|Endocrine therapy(GnRHa with Tamoxifen) group
10009424|NCT01622374|Active Comparator|Silence|the subjects received 10 minutes of silence through headphone
10009425|NCT01622374|Experimental|Music for the mind|
10009426|NCT01622374|Experimental|Mozart music|
10009427|NCT01622374|Experimental|Iranian traditional music|
10009428|NCT01622387|Experimental|Radial artery|Use of the radial artery as a conduit in CABG surgery
9802452|NCT05251259|Experimental|Lead-in PK Cohort (AZD5718 Dose A)|Randomized participants will receive AZD5718 dose A
9802453|NCT05251259|Experimental|Part 1: AZD5718 Dose A|Randomised participants will receive AZD5718 Dose A
10009429|NCT01622387|Active Comparator|Long saphenous vein|Use of long saphenous vein as a conduit in CABG surgery
10009430|NCT01622400|Experimental|Therapeutic education HTA Vasc|125 subjects who participate in the therapeutic education program
10009431|NCT01622400|No Intervention|Control group|125 subjects who don't participate in the therapeutic education program
10009432|NCT01622413|Experimental|Endscopy|
10009433|NCT01622413|Active Comparator|Microsurgery|
10009434|NCT01622426|Active Comparator|New formula IgE mediated testing|Children with IgE-mediated CMA performed oral food challenge with the new formula
10009435|NCT01622426|Active Comparator|New formula non-IgE-mediated testing|Children with non-IgE-mediated CMA performed oral food challenge with the new formula
9802454|NCT05251259|Experimental|Part 2: AZD5718 Dose A|Randomised participants will receive AZD5718 Dose A
9802455|NCT05251259|Experimental|Part 2: AZD5718 Dose B|Randomised participants will receive AZD5718 Dose B
9802456|NCT05251259|Experimental|Part 2: AZD5718 Dose C|Randomised participants will receive AZD5718 Dose C
9802457|NCT05251259|Active Comparator|Part 2: Montelukast Dose X|Participants will receive montelukast dose X
9802458|NCT05251259|Placebo Comparator|Lead-in PK, Part 1 and Part 2 Placebo|Randomized participants will receive placebo
9802459|NCT05250713|Experimental|tDCS|Patients receiving tDCS during SEEG investigation
9802460|NCT05250713|Experimental|tACS|Patients receiving tACS during SEEG intervention
9802461|NCT05250258||telephone peer support|Telephone peer support from experinenced father to father
9802462|NCT05250258||Routine care|Standard care as usual in child health care, one visit for fathers and nothing added
9802463|NCT05247255|Active Comparator|Intervention Group|Quadratus lumborum nerve block with 0.25% ropivacaine
9802464|NCT05247255|Placebo Comparator|Control Group|Quadratus lumborum nerve block with saline
9802465|NCT05245500|Experimental|Phase 1/1B|Dose Escalation/Evaluation
9802466|NCT05245500|Experimental|Phase 2|MRTX1719 RP2D administered to separate cohorts of patients with selected solid tumor malignancies with MTAP homozygous deletion to include the following: Mesothelioma, Pancreatic Adenocarcinoma, NSCLC, Malignant Peripheral Nerve Sheath Tumor, Other Solid Tumors
9802467|NCT05241873|Experimental|Phase I - Dose Escalation|Multiple doses of BLU-451 for oral administration
10009436|NCT01622439|Experimental|Single, open labeld.|
10009437|NCT01622465|Experimental|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises.
10009438|NCT01622465|Active Comparator|Conventional exercises|Patients will participate only of the conventional exercises program.
10009439|NCT01622478||Clinically node-positive patients before NAC|"Patients with clinically positive lymph node receiving neoadjuvant chemotherapy~Clinically negative-node after NAC~Clinically positive-node after NAC"
10009440|NCT01622491||Case control|A case-control study with cases (individuals hospitalized with influenza or pneumonia during the second wave of the pandemic) and controls (non-hospitalized individuals) identified using the MH Hospital Separation Abstract Database and the MH Population Registry, respectively. Information on receipt of vaccines will be obtained by record linkage to the MIMS.
10009441|NCT01622504|Experimental|Test Product Dose 1|
10009442|NCT01622504|Experimental|Test Product Dose 2|
10009443|NCT01622504|Active Comparator|Comparator Product|
10009444|NCT01622530||Amputees|upper limb amputees
10009445|NCT01622530||Non-amputees|No longer recruiting non-amputees
10009446|NCT01622556|Experimental|Reduced Intensity Conditioning with UCB Transplant|
10009447|NCT01622608|Experimental|Kiosk Users|
10009448|NCT01622608|No Intervention|Non-Kiosk Users|
10009449|NCT01622621|Active Comparator|Randomized Sublobar Resection|Randomized by computer to receive a sublobar resection.
10009450|NCT01622621|Active Comparator|Randomized SBRT|Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
10009451|NCT01622621|Active Comparator|Observation Sublobar Resection|Patient decides with doctor to undergo a sublobar resection.
10009452|NCT01622621|Active Comparator|Observation SBRT|Patient decides with doctor to undergo SBRT.
10009453|NCT01622634|Active Comparator|Higher Protein Diet (PRO)|
10009454|NCT01622634|Active Comparator|Higher Carbohydrate Diet (CARB)|
10009455|NCT01622634|Active Comparator|PRO & Interval Exercise (PRO+EX)|
10009456|NCT01622634|Active Comparator|CARB & Interval Exercise (CARB+EX)|
10009457|NCT01622647|Active Comparator|NCPAP Group|Group of patients that do receive NCPAP treatment
10009458|NCT01622647|No Intervention|No NCPAP|subjects will not receive NCPAP
10009459|NCT01622686|No Intervention|Traditional prescription drug labels|Routine drug labels provided by the participating pharmacies
9476706|NCT03569072|Experimental|Dose escalated functionally adapted radiation therapy|This is a single arm study
10009460|NCT01622686|Experimental|Reformatted medication labels|Prescription drug container labels that follow a new format and also include illustrations
10009461|NCT01622712|Experimental|Unilateral inguinal hernia|A Nitinol containing large pore polypropylene mesh will be placed in patients with unilateral inguinal hernia.
10009462|NCT01622725|Experimental|Resorbable mesh|Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.
10009463|NCT01622725|Active Comparator|Non-resorbable mesh|Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.
10009464|NCT01622764|Experimental|Molecular imaging with 89Zr-RO5323441|
10009465|NCT01622777|Experimental|Rosuvastatin|20 mg daily of oral rosuvastatin
10009466|NCT01622777|Placebo Comparator|Placebo|
10009467|NCT01622790|Experimental|Arm 1|33 subjects will receive a single dose of each of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 1followed by dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
10009468|NCT01622790|Experimental|Arm 2|33 subjects will receive dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 1 followed by a single dose of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
10009469|NCT01622803|Active Comparator|parallel stent|parallel stent insertion group
10009470|NCT01622803|Active Comparator|Y-stent|Y-stent insertion group
10009471|NCT01622829|Experimental|group1|"Usual Physiotherapy, additional: Prescription for Activity with a structured fitness program and individual instructions to become more active in the daily living situation"
10009472|NCT01622829|Experimental|group 2|"usual Physiotherapy , additional: Prescription for Activity without instructions"
10009473|NCT01622829|No Intervention|group 3|control, usual physiotherapy
10009474|NCT01622842||Bioimpedance|8 females and 8 males BMI from 19 to 46 SBP from 119 to 182
10009475|NCT01622855|Experimental|PPRS video|Prevention of post sexual assault stress
10009476|NCT01622855|No Intervention|Standard care|Receipt of standard services
10009477|NCT01622881|Active Comparator|Nefopam|
10009478|NCT01622881|Placebo Comparator|Control|
10009479|NCT01622907||Pts Symptomatic Recurrent Persistent AF|Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for > 1-year < 5 years duration
10009480|NCT01622920|Other|ultrasound enamel thickness measurements|Enamel thickness will be measured with ultrasound
10009481|NCT01622933|Experimental|Vaccine + IFN|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines. Approximately 30 days after the last vaccine subjects will receive IFN intravenously 5 days a week for 4 weeks.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and after the IFN treatment."
10037265|NCT01823471|Active Comparator|White light first group|After the caecum is reached patients will be first examined with high definition white light endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass i-scan will be used.
10009482|NCT01622933|Experimental|Vaccine only|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and again approximately 2 months after the last vaccine."
9802468|NCT05241873|Experimental|Phase II - Dose Expansion|Oral dose of BLU-451 at the dose determined during Dose Escalation
10009483|NCT01622946|Active Comparator|Placebo|The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
10009484|NCT01622946|Placebo Comparator|Tranexamic acid|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
10009485|NCT01622959|Active Comparator|acupuncture|"Inclusion criteria:~Traumatic and non traumatic acute pain with visual analog pain scale ( VAPS) > 40 (on a scale 0-100) Age ≥18 years Presigned consentement to participate in the study.~Exclusion criteria:~Temperature > 37.7° C, Anticoagulation medication use or the presence of a mechanical heart valve, Skin infections that would preclude certain acupuncture points being used, Refusal, inability to consent or communication difficulties, Acute major trauma, Any form of analgesia up to 60 minutes prior to study start, An initial pain score ≤ 40 on the pain scale (score range 0-100), Opiate contraindication, Pregnancy, Presentation to the ED > 4 times in the previous 3 months with the same condition."
10009486|NCT01622959|Sham Comparator|morphine|drug:5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%.
10009487|NCT01622972|Experimental|Group 1|Healthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
10009488|NCT01622972|Experimental|Group 2|Healthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
10009489|NCT01622972|Experimental|Group 3|Patients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
10009490|NCT01623011|Experimental|Arthroscopic Sub-acromial Decompression|Arthroscopic sub-acromial decompression surgery.
10009491|NCT01623011|Active Comparator|Shoulder Arthroscopy|Shoulder arthroscopy only.
10009492|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Active monitoring with specialist reassessment - non-operative control.
10009493|NCT01623024|Experimental|Vitamin D and Lifestyle counseling|
10009494|NCT01623024|Active Comparator|Lifestyle counseling|
10009495|NCT01623063|Experimental|Infertile|patients from our human reproduction center
10009496|NCT01623063|Active Comparator|Fertile|patients with comproved fertility
10037266|NCT01823484|Experimental|AN 69 ST hemofilter|Use AN 69 ST hemofilter during CRRT
10037267|NCT01823484|Active Comparator|AN 69 hemofilter|Use AN 69 hemofilter during CRRT
10009497|NCT01623076||Neuromyelitis Optica Spectrum Disorder|Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included
10009498|NCT01623076||Transverse Myelitis and Optic Neuritis|Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.
10009499|NCT01623076||Healthy Controls|patients without a history of CNS inflammation
10009500|NCT01623076||Neuromyelitis Optica|patients diagnosed with NMO
10009501|NCT01623089||severe asthma|
10009502|NCT01623102|Experimental|Arm I: bevacizumab plus chemotherapy|Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).
10009503|NCT01623102|Active Comparator|Arm II: chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10009504|NCT01623128|Experimental|Breastfeeding video|Participants randomized to this arm view the intervention video - Injoy Videos Better Breastfeeding video.
10009505|NCT01623128|Placebo Comparator|Sham video|Participants randomized to this arm view the sham video Injoy Videos Your Healthy Pregnancy: Prenatal Nutrition and Exercise video.
10009506|NCT01623141||Patients with CRPS|18 patients with unilateral CPRS of the upper limb were included to the study
10009507|NCT01623141||Patients with limb pain of other origin|17 patients with unilateral upper limb pain of other origin served as control group
9476707|NCT03569059|Experimental|Early Robotic/VR Therapy (EVR)|Subjects in this group will receive state-of-art inpatient usual care therapy plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated 5-30 days post stroke.
10009508|NCT01623141||Healthy subjects|18 healthy subjects were included to establish reference data for the pressure pain thresholds
10009509|NCT01623180|Experimental|BioFreedom™ Drug Coated Stent (DCS)|BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.
10009510|NCT01623180|Active Comparator|Gazelle™ Bare Metal Coronary Stent (BMS)|GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.
10009511|NCT01623193|Active Comparator|Control|Patients receive standard 4:1 cardioplegia for myocardial protection during cardiac surgery
10009512|NCT01623193|Experimental|Treatment|Patients receive all-blood cardiolpegia for myocardial protection during surgery
10009513|NCT01623206|Experimental|Desmopressin|Four dose levels and two dosing schedules with 3 patients in each group.
10037268|NCT01823523|Active Comparator|Cefazolin, Cephalexin, Clindamycin|"Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin~Clindamycin will be used in patients with allergy"
9802469|NCT05238883|Experimental|HFB200301 - Dose Escalation|Participants will be administered HFB200301 at dose levels 1-5 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).
9802470|NCT05238883|Experimental|HFB200301 - Dose Expansion|Participants will be administered HFB200301 at RDE as an intravenous infusion.
9964213|NCT01236677||Community acquired pneumonia,age≥14 ys|Patients with community acquired pneumonia,age≥14 ys and less than one week after the onset of symptoms, without pregnancy,breast-feeding,HIV infection,recent 90-day hospitalized history and in nursing homes or rehabilitation hospitals
9964214|NCT01236703||ICU patients|ICU patients (post-operative and none operative patients) will be enrolled in the study. They are followed up until the end of ICU stay or, for a maximum of 60 days.
9964215|NCT01236716|Experimental|Albumin paclitaxel plus carboplatin|Treatment of Albumin paclitaxel plus carboplatin
9964216|NCT01236716|Active Comparator|Gemcitabine plus carboplatin|Treatment of Gemcitabine plus carboplatin
9964217|NCT01236729||Knee replacement recipients|Patients (aged 75 years or over) with late-stage arthritis who have undergone or are undergoing primary knee replacement
9964218|NCT01236781|Experimental|Group A: Screening|Group A comprises 500 asymptomatic women with no history of breast cancer who are scheduled for routine screening of the breasts with FFDM.
10009514|NCT01623219|Experimental|TeleMedicine Prolonged Exposure|Veterans will receive prolonged exposure therapy (PE)delivered via telemedicine instead of in person. For this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. The first 2 sessions of each treatment will involve education, rational and treatment preparation. Sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. The purpose of this study is to determine if this treatment is effective when given through telehealth.
10009515|NCT01623232|Experimental|adjuvant plus 1 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 1 �g of HA antigen
10009516|NCT01623232|Experimental|adjuvant plus 3 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 3 �g of HA antigen
10009517|NCT01623232|Experimental|adjuvant plus 5 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 5 �g of HA antigen
10009518|NCT01623232|Active Comparator|licensed influenza vaccine|licensed, inactivated, standard dose influenza vaccine without adjuvant
10009519|NCT01623245||Hypertrophic Cardiomyopathy|In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis
10009520|NCT01623258||Standard of Care|Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging
10009521|NCT01623258||Research|SOC with sentinel lymph node analysis
10009522|NCT01623284|Experimental|PiB and FDG positron emission tomography (PET)|All subjects will receive PiB and FDG PET diagnosis on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
10009523|NCT01623297||Laparoscopic colon surgery|Patients over age 65 having laparoscopic colon resection for colonic adenocarcinoma
10009524|NCT01623297||Open colon surgery|Patients over age 65 having open colon resection for colonic adenocarcinoma
10009525|NCT01623336|Active Comparator|Pegasys ®|Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
10009526|NCT01623336|Experimental|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
10009527|NCT01623349|Experimental|Arm BKM|BKM120 and Olaparib
10009528|NCT01623349|Experimental|Arm BYL|BYL719 and Olaparib
10009529|NCT01623362|Experimental|Low-fluoride acidic dentifrice|
10009530|NCT01623362|No Intervention|Conventional dentifrice|1100µgF/g-pH7.0
10009531|NCT01623362|Experimental|neutral pH and low-fluoride dentifrice|550 ppm pH 7
10009532|NCT01623375|Experimental|s.c.|
10009533|NCT01623375|Experimental|i.v.|
10009534|NCT01623388||Phase I|
10009535|NCT01623401|Experimental|TR-701 FA|TR-701 FA 200 mg oral once daily
10009536|NCT01623414||Healthy schoolchildren|
10009537|NCT01623427|Experimental|Vacuum|the group of patients assigned to application of vacuum to the wound dressing
10009538|NCT01623427|Active Comparator|Control|The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.
10009539|NCT01623440||Placebo/Naltrexone and fMRI|A placebo or Naltrexone will be given before fMRI. All participants will undergo both procedures. Naltrexone/placebo are not used as an intervention.
10009540|NCT01623453||Low dose group|Group1. Low dose group
10009541|NCT01623453||High dose group|Group2. High dose group
10009542|NCT01623492||diagnosis of Eisenmenger Syndrome|subjects with diagnosis of Eisenmenger Syndrome
10009543|NCT01623505|Experimental|Champix|
10009544|NCT01623505|Experimental|Long & Combination patch treatment|
10009545|NCT01623505|Experimental|Standard patch treatment|
10009546|NCT01623518|Experimental|ChAdOx1-NP+M1|
10009547|NCT01623544||Symbicort|BFC patients new to ICS/LABA combination therapy
10009548|NCT01623544||Advair|FSC patients new to ICS/LABA combination therapy
10009549|NCT01623557|Active Comparator|Group 1: ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
10009550|NCT01623557|Active Comparator|Group 2: ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
10009551|NCT01623557|Active Comparator|Group 3: Unvaccinated Infectivity Controls|
10009552|NCT01623570|Experimental|Pergoveris: 150IU r-hFSH+ 75IU r-hLH|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
9802471|NCT05237401|Active Comparator|Non-Surgical Periodontal treatment (NSPT)|Half of the study participants (controls) will be randomised to receive continued non-surgical periodontal treatment (NSPT). All treatment will be carried out by the same therapist in each centre, including oral hygiene.
9803677|NCT03555149|Experimental|Atezolizumab + Imprime PGG + Bevacizumab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
10009553|NCT01623570|Experimental|Menopur: hMG-HP (150IU)|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
10009554|NCT01623583|Experimental|Enhanced Needle Phobia Intervention|Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
10009555|NCT01623583|Active Comparator|Standard Needle Phobia Intervention|Patients will receive the standard intervention for needle phobia
10009556|NCT01623609|Experimental|A|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fasted conditions
10009557|NCT01623609|Experimental|B|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fed conditions
10009558|NCT01623609|Experimental|C|Naloxegol film-coated IR tablet 25 mg Phase III formulation under fasted conditions
9517914|NCT03301727|Active Comparator|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
9803678|NCT03555149|Experimental|Atezolizumab + Isatuximab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
10009559|NCT01623622|Experimental|HC-58 low dose|Low dose
10009560|NCT01623622|Experimental|HC-58 high dose|High dose
10009561|NCT01623622|Placebo Comparator|Placebo|
10009562|NCT01623635|Experimental|Case - adnexal|
10009563|NCT01623635|Placebo Comparator|placebo - adnexal|
10009564|NCT01623635|Experimental|case - uterine|
10009565|NCT01623635|Placebo Comparator|placebo - uterine|
10009566|NCT01623648|Experimental|Arm 1 Whey Breakfast|The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
10009567|NCT01623648|Active Comparator|Arm 2: No Whey Breakfast|The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
10009568|NCT01623648|Placebo Comparator|Arm 3: Low Protein Breakfast|The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
10009569|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0% (7 ml/kg)
10009570|NCT01623687|Active Comparator|Regenerex|
10009571|NCT01623687|Active Comparator|Lub cup|
10009572|NCT01623687|Active Comparator|SP II|
9964219|NCT01236781|Experimental|Group B: Diagnostic Enriched Population|Approximately 50 asymptomatic women with no history of breast cancer who have been informed of positive (abnormal) findings from a recent (within 30 days) FFDM screening will be recruited to Group B prior to their diagnostic imaging (e.g., diagnostic FFDM and/or ultrasound and/or other).
9964220|NCT01236794|Experimental|Lifestyle and Exercise Intervention|
9964221|NCT01236807|Active Comparator|MR Inform|Management guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
9964222|NCT01236807|Active Comparator|FFR Inform|Management guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
9964223|NCT01236820||Normal|Healthy population
9964224|NCT01236820||CKD Patients|Chronic Kidney Disease, in Stage III-V
9964225|NCT01236820||HD patients|End-stage renal disease patients undergoing hemodialysis
9964226|NCT01236833|No Intervention|Fasting|
9964227|NCT01236833|Active Comparator|Lactated Ringer's Solution|
9964228|NCT01236846|Placebo Comparator|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
9964229|NCT01236846|Experimental|VDR Genotype (aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
9964230|NCT01236846|Experimental|VDR Genotype (AA)|Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
9964231|NCT01236846|Experimental|VDR genotype (Aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
9964232|NCT01236859|Placebo Comparator|placebo|The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation
9964233|NCT01236859|Active Comparator|gabapentin|Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.
9964234|NCT01236872|Experimental|Beetroot juice|250ml beetroot juice ingestion
9964235|NCT01236872|Placebo Comparator|Water|250ml low-nitrate water placebo
9964236|NCT01236885|Experimental|Supportive care (Glucommander)|Patients receive blood glucose management with IV insulin using Glucommander.
9964237|NCT01236898|Experimental|NPC-09|Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days
9964238|NCT01236911||Calcium after moderate-severe TBI|Patients with moderate -severe TBI with less as 24 hrs , admitted in emergency. We will measure seric calcium to compare the differences between both groups
9964239|NCT01236924|Experimental|Lifestyle counseling|
9964240|NCT01236937|Active Comparator|Bellows-based breath hold biopsy|CT guided biopsy is preformed with the use a bellows-based breath
9964241|NCT01236937|No Intervention|No Bellows-based breath hold.|CT guided biopsy is preformed without the use a bellows-based breath
9964242|NCT01236950|Experimental|Delmopinol mouthrinse|Subjects use the delmopinol mouthrinse
9964243|NCT01236950|No Intervention|Control|Subjects with no use of mouthrinse
9964244|NCT01236950|Experimental|Essential oils mouthrinse|Subjects using the essential oils mouthrinse
9964245|NCT01236963|Experimental|Essential oils mouthrinse|Subjects use the essential oils mouthrinse
10009573|NCT01623687|Active Comparator|Corail|
10009574|NCT01623700||dual antiplatelet treatment 12 months after ACS event|
10009575|NCT01623700||dual antiplatelet treatment 6 months after ACS event|
10009576|NCT01623700||dual antiplatelet treatment 3 months after ACS event|
10009577|NCT01623713|Active Comparator|Risperidone|
10009578|NCT01623713|Experimental|iloperidone|
10009579|NCT01623726|Experimental|tDCS active|Active tDCS as foreseen in research protocol: daily sessions for 10 days with 2mA intensity stimulation during 20 minutes.
10009580|NCT01623726|Placebo Comparator|tDCS sham|Sham tDCS : as foreseen in research protocol: sham stimulation with initial stimulation followed by turning off the device during the same time of intervention as to guarantee blinding
10009581|NCT01623778||Add on ADV|Patients with inadequate response to interferon at 24 weeks received interferon add on ADV optimized therapy
10009582|NCT01623778||Switch to LDT|Patients with inadequate response to interferon at 24 weeks received switching to LDT therapy
10009583|NCT01623791||Group 1|Group 1: mild pre-eclamptic group Mild and severe pre-eclampsia were defined American College of Obstetrics and Gynecology criteria (ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia. January 2002.)
10009584|NCT01623791||Group 2|Group 2: severe pre-eclamptic group
10009585|NCT01623804|Active Comparator|Low intensity, pulsed ultrasound|
10009586|NCT01623804|Sham Comparator|Sham ultrasound|
10009587|NCT01623817|No Intervention|Vancomcyin, maintain dose|This arm is received only maintain dose of vancomycin (15mg/kg twice a day or 1g twice a day).
10009588|NCT01623817|Experimental|Vancomycin loading|This group is received loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
10009589|NCT01623843|Active Comparator|Arthroscopic Lavage|Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
10009590|NCT01623843|Experimental|Arthroscopic Osteochondroplasty|After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
10009591|NCT01623856||Observational|DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.
10009592|NCT01623908|Experimental|Zoledronate|
10009593|NCT01623921|Other|control|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
10009594|NCT01623921|Active Comparator|Celecoxib|Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
10009595|NCT01623921|Active Comparator|rosuvastatin|Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
10009596|NCT01623921|Active Comparator|Combined therapy|Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
10009597|NCT01623934||Phase 1: Pregnant women|
10009598|NCT01623934||Phase 2: Mother-offspring dyad|
10009599|NCT01623947|Placebo Comparator|Placebo|
10009600|NCT01623947|Active Comparator|2.8 g Sustamine|
10009601|NCT01623947|Active Comparator|19.6 g Sustamine|
10009602|NCT01623973|Experimental|With restraint|The group with restraint underwent specific training of paretic upper limb and use of restraint.
10009603|NCT01623973|Active Comparator|no restraint|"The group control without restraint submitted only to the specific training of paretic upper limb"
10009604|NCT01623986||St. Michael's Hospital Patients|Patients who are referred to the St. Michael's Hospital echocardiography (ECHO) lab.
9803679|NCT03555149|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
9964246|NCT01236963|Active Comparator|Dental floss|Subjects use dental floss
9964247|NCT01236976|Experimental|Intervention Group|Participants in Group A will receive a triad of interventions comprising body weight supported treadmill training (BWSTT) using the Therastride Treadmill System, functional electrical stimulation (FES)-assisted cycling, and trunk and upper and lower limb exercise. These interventions will be provided at the spinal unit.
9964248|NCT01236976|Other|Control Group|Participants in Group B will receive an upper body strength and fitness program. This program may be provided at the spinal unit, or an appropriately equipped gymnasium as approved by the SCIPA Full-On Project Committee. It will be based on the Burn Rubber Burn (BRB) exercise program already established in Sydney. BRB is a circuit-based exercise program incorporating resistance and cardiovascular training. For this protocol, the circuit will comprise several stations using different pieces of equipment.
9964249|NCT01236989|Experimental|Anatomical resection|
9964250|NCT01236989|Active Comparator|Non-anatomical resection|
9964251|NCT01237002||Group 1|117 patients with cumulative clamping time between 60 and 120 minutes
9964252|NCT01237002||Group 2|72 patients with cumulative clamping time longer than 120 minutes
9964253|NCT01237028|Experimental|oral calcitriol|Calcio®
9964254|NCT01237028|No Intervention|placebo|
9964255|NCT01237067|Experimental|Group 1|Dose esc: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis
9964256|NCT01237067|Experimental|Group 2A|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
10009605|NCT01624012|Active Comparator|NIV NAVA|Noninvasive ventilation in this group is practiced with NIV NAVA
10009606|NCT01624012|Active Comparator|ncpap|Patients randomized to this arm will receive noninvasive ventilation with continuous nasal CPAP as routinely in neonatal intensive care unit.
10009607|NCT01624025|Experimental|HER2 positive|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)
10009608|NCT01624025|Active Comparator|HER2 negative|"Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.~(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)"
10009609|NCT01624038|Active Comparator|Hydroxyurea,blood transfusion|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
10009610|NCT01624038|Experimental|Hydroxyurea, Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued. White cell count and platelet count were determined on a monthly basis. Side effects such as nausea, vomiting, diarrhea, rashes, and malaise, experienced during the first 6 h after taking the HU will be considered as clinical toxicity.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
10009611|NCT01624051|Active Comparator|Body Surface Area Dosing|Standard dosing arm based on body surface area
10009612|NCT01624051|Experimental|Lean Body Mass Dosing|Experimental dosing arm based on individual lean body mass
10009613|NCT01624064|Active Comparator|Enalapril, Proteinuria < 1g/day|
10009614|NCT01624064|Placebo Comparator|Calcium, Proteinuria < 1g/day|
10009615|NCT01624064|Active Comparator|Enalapril, Proteinuria > 1g/day|
10009616|NCT01624064|Placebo Comparator|Calcium, Proteinuria > 1g/day|
10009617|NCT01624077|Experimental|Regulatory T cells|Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
10009618|NCT01624103|Experimental|Elderly (32 mL LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 32 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
10009619|NCT01624103|Experimental|Elderly (20 ml LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 20 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
10009620|NCT01624116|Active Comparator|Diet and lifestyle measures alone.|Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period
10009621|NCT01624116|Active Comparator|Metformin monotherapy|Type 2 diabetics on biguanide treatment.
10009622|NCT01624116|Active Comparator|Metformin + Sulphonylurea.|Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.
10009623|NCT01624116|Active Comparator|Metformin + Sitagliptin|Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.
10009624|NCT01624129||eosinophilic esophagitis|patients with histopathological defined eosinophilic esophagitis
10009625|NCT01624155|Experimental|Women taking teratogens|Women taking teratogens
10009626|NCT01624207|Experimental|Atorva|generic formulation (Atorva®) of atorvastatin 20mg once daily
10009627|NCT01624207|Active Comparator|Lipitor|branded formulation (Lipitor®) of atorvastatin 20mg once daily
10009628|NCT01624246|Experimental|Ceftaroline fosamil/Avibactam|
10009629|NCT01624272|No Intervention|Control|Usual care
10009630|NCT01624272|Experimental|Threshold Inspiratory Muscle Training|Inspiratory muscle training regime
10009631|NCT01624272|Experimental|Controlled breathing exercises|Yoga Pranayama breathing exercises
10009632|NCT01624285|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID.
10009633|NCT01624285|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID.
10009634|NCT01624298|No Intervention|Wait List Control Group|The wait list control group will be asked to wait for approximately 4 1/2 months before being reassessed and then, unless found to be ineffective or harmful, receive the intervention being provided by the counselor.
10009635|NCT01624298|Experimental|Intervention Group|Children randomized into the intervention group will immediately receive the Trauma Focused Cognitive Behavioral Therapy with a trained counselor for 12 weeks.
10009636|NCT01624311|Experimental|Adjunct Hypothermia Arm|Patients that receive adjunct therapeutic hypothermia in addition to standard of care therapy
10009637|NCT01624311|Other|Historic Controls|Patients that were treated with standard of care therapy for the same conditions at the sponsoring institution over the past 10 years.
10009638|NCT01624337|Experimental|DHA-piperaquine|DHA-piperaquine monthly 2 day treatment course
10009639|NCT01624337|Placebo Comparator|Placebo|Matching placebo control
10009640|NCT01624376|Active Comparator|DLX105|DLX105 local injection into the identified fistula(s)
10009641|NCT01624376|Placebo Comparator|Placebo Injection|
10009642|NCT01624389|Experimental|F18-AV45|
10009643|NCT01624402|Experimental|Ecosystem Focused Therapy (EFT)|Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.
10009644|NCT01624402|Active Comparator|Education on Stroke and Depression (ESD)|Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.
10009645|NCT01624428|Active Comparator|varenicline|
10009646|NCT01624428|Placebo Comparator|Placebo|
10009647|NCT01624441|Experimental|Treatment (dinaciclib and epirubicin hydrochloride)|Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
10009648|NCT01624454|Active Comparator|large volume|bowel cleansing with PEG
10009649|NCT01624454|Active Comparator|Osmotic|
10009650|NCT01624493|Experimental|Phase II Arm A|Phase II Arm A will randomize patients to treatment regimen of carboplatin and gemcitabine without BNC105P
10009651|NCT01624493|Experimental|Phase II Arm B|Phase II Arm B will randomize patients to treatment regimen of carboplatin and gemcitabine and will include BNC105P
10009652|NCT01624519|Other|1|
10009653|NCT01624532|Experimental|GC1109|"Step1: GC1109 0.3 mL or 0.5 mL or 0.1mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
10009654|NCT01624532|Placebo Comparator|Placebo of GC1109|"Step1: Placebo of GC1109 0.5mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: Placebo of GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
10009655|NCT01624545|Active Comparator|1|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
10009656|NCT01624545|No Intervention|2|Patients in this study arm will undergo neurological evaluation on day 2 and day 30 without follow-up CT scan.
10009657|NCT01624558|Experimental|Treatment (filter in circuit)|After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
10009658|NCT01624558|No Intervention|No Intervention Control|After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
10009659|NCT01624571|Experimental|Group 1|300mg/day
10009660|NCT01624571|Experimental|Group 2|600mg/day
10009661|NCT01624571|Experimental|Group 3|900mg/day
10009662|NCT01624571|Placebo Comparator|Placebo|Control Group
10009663|NCT01624584|Experimental|Experimental treatment|6 sessions of anxiety treatment
10009664|NCT01624584|Active Comparator|Traditional Treatment|Six sessions of anxiety treatment
10009665|NCT01624597|No Intervention|Usual Care|Participants will have a passive in-vehicle video device installed in their car to measure driving errors and safety behaviors.
10009666|NCT01624597|Experimental|In-vehicle video feedback|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors.
10009667|NCT01624597|Experimental|In-vehicle video feedback, parent communication|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors. Parents will participate in an intervention that provides input on teaching and communicating about driving skills and safety behaviors.
10009668|NCT01624610|Active Comparator|Diet 1|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 1 can be used to control their IBS symptoms.
10009669|NCT01624610|Active Comparator|Diet 2|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 2 can be used to control their IBS symptoms.
10009670|NCT01624649||Patients with ADHD|Patients will receive methylphenidate hydrochloride or atomoxetine. The methylphenidate hydrochloride is available in three forms. 1) Immediate release 2) Extended release 3) Osmotic release oral system
10009671|NCT01624675|Experimental|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
10009672|NCT01624675|Placebo Comparator|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
10009673|NCT01624701|Experimental|Expanded|'Ex vivo expanded cord blood cells
10009674|NCT01624714|Experimental|Alemtuzumab Naive|Alemtuzumab Subjects (30) with prior treatment refractoriness and treatment experience EDSS 3.0-7.0 inclusive, without contraindications to alemtuzumab
10009675|NCT01624714|Experimental|Alemtuzumab Experienced|Subjects with treatment refractory MS and prior alemtuzumab therapy (30)
10009676|NCT01624727|No Intervention|Usual care|Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
10009677|NCT01624727|Active Comparator|Lovaza (Omega 3 ethyl esters)|
10037269|NCT01823523|Placebo Comparator|cefazolin, clindamycin, placebo|"Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo~clindamycin will be used if patient has allergy"
10009678|NCT01624753|Experimental|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
10035541|NCT01807260|Active Comparator|conventional Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
10035542|NCT01807260|Active Comparator|stepwise Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the stepwise group, the voltage was started at 10 kV and increased stepwise (every 250 shock waves) to 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
10035543|NCT01807273||Hemiplegic subjects|60 hemiplegic outpatients walking test
10035544|NCT01807286|Experimental|Pomalidomide + Melphalan + Dexamethasone|Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
10035545|NCT01807312|Experimental|CO2 insufflation|CO2 insufflations was applicated in routine colonoscopy examination with Endoscopic CO2 regulation unit and accessories
10035546|NCT01807312|Placebo Comparator|Air insufflation|Air insufflations is applicated in Routine Colonoscopy Examination
10035547|NCT01807325||pancreas cysts and solid masses|patents referred for solid and cystic lesions of the pancreas who will have a biopsy for usual medical care.
10035548|NCT01807338||saline|Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031
10035549|NCT01807364||Congenital adrenal hyperplasia|Patients > 18 yrs with classical or non classical CAH diagnosed during childhood
10035550|NCT01807364||controls|control patients
10035551|NCT01807377|Experimental|PF-05175157, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
10035552|NCT01807377|Experimental|Placebo, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
10035553|NCT01807403|Experimental|Deep brain stimulation of subthalamic nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Stimulation of subthalamic nucleus
10035554|NCT01807403|Experimental|Deep brain stimulation of caudate nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker. Caudate nucleus stimulation
10035555|NCT01807403|Experimental|Deep brain stimulation of nucleus accumbens|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Nucleus accumbens stimulation.
10035556|NCT01807416|Active Comparator|standard platform , standard abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to standard designed prosthetic abutments
10035557|NCT01807416|Active Comparator|standard platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to flat designed prosthetic abutments
10035558|NCT01807416|Active Comparator|switching platform, standard abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to standard designed prosthetic abutments
10035559|NCT01807416|Active Comparator|switching platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to flat designed prosthetic abutments
10035560|NCT01807429|Experimental|Ketamine-midazolam|300 to 500 mcg/kg ketamine plus 0.03 mg/kg midazolam
10035561|NCT01807429|Active Comparator|Morphine|0.05 to 0.1 mg/kg morphine
10035562|NCT01807442|Other|Optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of greater than or equal to 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of greater than or equal to 15 suggests optimal adherence to health behaviors."
10035563|NCT01807442|Other|Sub-optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of less than 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of less than 15 suggests sub-optimal adherence to health behaviors."
10035564|NCT01807468|Experimental|HaploSC+NK|
10035565|NCT01807481|Experimental|Mircera Arm|Once Monthly Mircera
10009679|NCT01624766|Experimental|Arm I (everolimus, anakinra)|Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
10009680|NCT01624766|Experimental|Arm II (everolimus, denosumab)|Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
10009681|NCT01624792|Experimental|Healthy older adults|Healthy controls will receive each intervention (olive oil or fish oil with 3.5 g EPA+DHA) one time and for only one day per intervention .
10009682|NCT01624792|Experimental|COPD patients|COPD patients will receive one out of three possible interventions (olive oil or fish oil with 3.5 g EPA+DHA or fish oil and placebo with 2 g EPA+DHA) for 4 (+/- 7 days) weeks.
10009683|NCT01624805|Experimental|Treatment (methylprednisolone, hATG, cyclosporine, G-CSF)|Patients receive methylprednisolone IV over 10 minutes on days 1-4 and IV or PO with taper over days 5-30. Patients also receive horse anti-thymocyte globulin IV over 8 hours daily on days 1-4, cyclosporine PO BID on days 1-180, and pegfilgrastim or pegfilgrastim biosimilar SC on day 5 and/or filgrastim SC beginning on day 5 and continuing until absolute neutrophil count recovers. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
10009684|NCT01624818|Experimental|Group 2, 6-7 years|18 children (6-7 years) with heart disease participating in a rehabilitation programme in Geilomo childrens hospital
10009685|NCT01624818|Experimental|Group 1, 11-12 years|18 children(11-12 years) with heart disease participating in a rehabilitation programme at Geilomo childrens hospital.
10009686|NCT01624831||Individuals with Longstanding Psychosis|Individuals with symptoms of psychosis that have been present for 5 or more years
10009687|NCT01624844|Experimental|Calculation of dural sac volume|
10009688|NCT01624857|Placebo Comparator|control group|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
10009689|NCT01624857|Active Comparator|statin group|Rosuvastatin 20mg/d for at least 5 days before the CABG surgery, then continue to take for a month
10009690|NCT01624935|Experimental|psychotherapy|psychotherapy
10009691|NCT01624935|Other|treatment as usual|TAU control
10009692|NCT01624961|Experimental|50 PfSPZ IV|PfSPZ Challenge
10009693|NCT01624961|Experimental|200 PfSPZ IV|PfSPZ Challenge
10009694|NCT01624961|Experimental|800 PfSPZ IV|PfSPZ Challenge
10009695|NCT01624961|Experimental|3200 PfSPZ IV|PfSPZ Challenge
10009696|NCT01624961|Experimental|2500 PfSPZ ID|PfSPZ Challenge
10009697|NCT01624987|Experimental|NET for Forensic Offender Rehabilitation|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
10009698|NCT01625026|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
10009699|NCT01625026|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
10009700|NCT01625026|Active Comparator|Gallstones OCA|Obeticholic acid 25 mg/day in three weeks
10009701|NCT01625026|Placebo Comparator|Gallstones Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
10009702|NCT01625039|Experimental|Intervention|Participated in weekly educational workshops
10009703|NCT01625039|Active Comparator|Control group|Received once off educational session and materials
10009704|NCT01625052|Experimental|Baska|
10009705|NCT01625065||pain patients|patients from a specific pain management department, patients with long duration of pain, mostly insufficiently treated pain
10009706|NCT01625065||pre-surgical patients|patients from a surgical outpatient department with current pain
10009707|NCT01625078|Experimental|Baska mask|
10009708|NCT01625117|No Intervention|Control Group|
10009709|NCT01625117|Experimental|A variant of Narrative exposure therapy|
10009710|NCT01625130|Active Comparator|broccoli sprout homogenate (BSH)|Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
10009711|NCT01625130|Placebo Comparator|alfalfa sprout homogenate|Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
10009712|NCT01625143||Observational|Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
10009713|NCT01625156|Experimental|Treatment (tivantinib, temsirolimus)|Patients receive tivantinib PO BID and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 (days 8, 15, 22, and 29 of course 1). Courses repeat every 28 days (35 days in course 1) in the absence of disease progression or unacceptable toxicity.
10009714|NCT01625195|Placebo Comparator|Omega-3 fatty acid supplement|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with eachthe breackfast and two capsules with dinner. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
10009715|NCT01625195|Active Comparator|Placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 50:50% corn/soybean oil as used in other randomized placebo-controlled trials.
10009716|NCT01625208|Experimental|Combined nerve block|Participants in this group will receive a supraclavicular brachial plexus block plus a median or ulnar nerve block.
10009717|NCT01625208|Active Comparator|Single nerve block|Participants in this group will receive a supraclavicular brachial plexus block only.
10009718|NCT01625247|Experimental|1 arm|Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc.
10009719|NCT01625247|Active Comparator|2 arm|Patients under LC. Allocation to sham drain,
10009720|NCT01625260|Experimental|Gemcitabine in combination with ALT-801|
10009721|NCT01625273|No Intervention|IF (Infant formula)|
10009722|NCT01625273|Experimental|IF with L. paracasei strain F19|
10009723|NCT01625299|Experimental|Gluten and Milk group|Subject on a gluten and dairy free diet will receive supplement of gluten and dry milk daily
10009724|NCT01625299|Placebo Comparator|Rice flour|Subjects will be on a gluten and dairy free diet and receive daily supplement of rice flour (placebo)
10009725|NCT01625312||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
10009726|NCT01625312||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization.
10009727|NCT01625312||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
10009728|NCT01625325||extremely obese|BMI ≥35kg/m2
10009729|NCT01625325||obese|BMI 30-34.9kg/m2
10009730|NCT01625351|Experimental|Treatment|"Participants to undergo transplantation. They receive alemtuzumab, fludarabine, sirolimus, busulfan, melphalan, and stem cells.~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.~Cells for infusion are prepared using the CliniMACS System."
10009731|NCT01625364|Experimental|Open Airways for Schools|OAS is a school-based non-academic asthma health education program for elementary students with asthma and their parents.
10035566|NCT01807494|Active Comparator|Posterior approach|Subjects in this group will total hip replacement performed with a posterior surgical approach and total hip replacement components.
10009732|NCT01625364|Experimental|SHARP program|The Staying Health-Asthma Responsible & Prepared (SHARP) program is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregiver.
10009733|NCT01625403|Experimental|rhBNP treated|standard of care with rhBNP
10009734|NCT01625403|Active Comparator|standard of care|standard of care
10009735|NCT01625429|Experimental|neoadjuvant|
10009736|NCT01625442|Active Comparator|Saffron|Saffron treatment group received saffron tablets daily for 45 days
10009737|NCT01625442|Active Comparator|Barberry|Barberry group received barberry tablets daily for 45 days
10009738|NCT01625442|Placebo Comparator|Placebo|Placebo group received placebo tablets daily for 45 days
10009739|NCT01625468|No Intervention|Control|Participant receives usual care
10009740|NCT01625468|Experimental|Intervention|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
10009741|NCT01625481|Experimental|Seal-V|A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.
10009742|NCT01625494|Experimental|Irbesartan/Amlodipine 150/5 mg fixed combination|"1 tablet once daily in the morning for 4 weeks Patient will be first treated with irbesartan 150mg or amlodipine 5mg, 1 tablet /day for 4 weeks.~If OBPM is controlled on monotherapy at week 4 (SBP <140 mmHg and DBP<90 mmHg), patient will be withdrawn from the study"
10009743|NCT01625494|Experimental|Irbesartan/Amlodipine 150/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks
10009744|NCT01625494|Experimental|Irbesartan/Amlodipine 300/5 mg fixed combination|1 tablet once daily in the morning for 4 weeks
10009745|NCT01625494|Experimental|Irbesartan/Amlodipine 300/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks. If OBPM is controlled at week 12, patients will continue on the same therapy until the end of the study
10009746|NCT01625520|Experimental|SOM230 alone or in combination with RAD001|Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
10009747|NCT01625533||SA group|Patients using SA for the diagnosis of coronary artery disease are assigned to the SA group.
10009748|NCT01625533||DARCA group|Patients using DARCA for the diagnosis of coronary artery disease are assigned to the DARCA group.
10009749|NCT01625546|Experimental|High intensity whole-body infrared heating|Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
10009750|NCT01625546|Sham Comparator|Low intensity whole-body infrared heating|Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
10009751|NCT01625559|Experimental|50,000 cells|Biological: MA09-hRPE Cellular therapy
10009752|NCT01625572|No Intervention|general anesthesia and epidural catheter (control)|"General anaesthesia~total intravenous anaesthesia with propofol 5-10 mg / kg / h,~remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~use of a bispectral index~monitoring with a target range of 40-60~at the end of the anaesthesia all patients get 0.1 mg / kg morphine intravenously epidural catheter~plant of the epidural catheter under sterile conditions at the intervertebral space of the vertebral body 8-10 of the thoracic spine• local anaesthesia with lidocaine 1%~puncture with a Tuohy 18 G- needle, Lost of resistance technique~after a negative test dose with bupivacaine 0,5% isobar we inject fractional ropivacaine 10 ml 0,2%, after that continuous administration of ropivacaine 0,2% via patient-controlled-analgesia-device with a sweep rate of 6 ml/h, all Patients also receive an intravenous morphine-patient-controlled-analgesia-device"
10009753|NCT01625572|Experimental|general anesthesia and regional anesthesia|"General anesthesia~anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~Bispektralindex monitoring with a target range of 40-60~at the end of the anesthesia all patients get 0.1 mg / kg morphine intravenously Transversus abdominis plane blockade~ultrasound visible needles, a special pin detection software~under visual control the needle moves into the space between Musculus obliquus internus and M. transversus abdominis~Under sonographic control we inject a local anesthetic depot (30 ml of ropivacaine 0.375%)~puncture is performed under constant protective nerve stimulation with a current of 1 mA, pulse duration 0.1 ms, frequency 2 Hz All Patients receive an i.v. Morphine-patient-controlled-analgesia-device"
10009754|NCT01625572|Experimental|general anaesthesia and intravenous pain therapy|"General anaesthesia~total intravenous anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~we use a of BIS monitoring with a target range of 40-60~at the end of the aneasthesia all patients get 0.1 mg / kg morphine intravenously intravenous pain therapy with~Morphine-patient-controlled-analgesia-device"
10009755|NCT01625585||Consecutive patients undergoing SBE for OGIB|
10009756|NCT01625598||People with diabetes|People with diabetes who are referred to an ophthalmologist for a dilated eye examination
10009757|NCT01625624|Placebo Comparator|Control Food Product|
10009758|NCT01625624|Experimental|Experimental Food Product|
10009759|NCT01625637|Experimental|AAT-avoid cigarette condition|Adolescent smokers are trained to avoid tobacco in a training AAT
10009760|NCT01625637|Placebo Comparator|AAT-no contingency continued assessment|
10009761|NCT01625650||Rheumatology|Patients who present at enrolling sites across the US are invited to enroll if eligible.
10009762|NCT01625663||Barth syndrome|Children (8-17 yrs) and adults (18-35 yrs)
10009763|NCT01625663||Controls|Children (8-15 yrs) and adults (18-35 yrs)
10009764|NCT01625676|Experimental|CIAT-Group|Patients received a modified constraint-induced therapy schedule
10009765|NCT01625676|Active Comparator|standard treatment group|patients received a standard aphasia therapy
10009766|NCT01625702|Experimental|cisplatin plus capecitabine|gastric cancer patients treated with capecitabine/cisplatin
10009767|NCT01625702|Experimental|capecitabine plus paclitaxel|gastric cancer patients treated with capecitabine/paclitaxel
10009768|NCT01625715|No Intervention|Case control|Routine therapy during peanut desensitization
10009769|NCT01625715|Experimental|ketotifen|rising doses of ketotifen
10009770|NCT01625728||Experimental group.|Participants are either student teachers or practicing teachers.
10009771|NCT01625728||Control Group.|Participants are no students teachers or practicing teachers.
10009772|NCT01625741|Experimental|rituximab|4 monthly administrations of rituximab
10009773|NCT01625754||Cardiac rehabilitation|This study recruits individuals that are currently participating in a cardiac rehabilitation exercise program.
10009774|NCT01625767|Experimental|Approach Avoidance Task experiment|Approach Avoidance Task experiment
10009775|NCT01625780|Experimental|Study group: 3-layer block|Patients in this group will receive the 3-layer ilioinguinal nerve block.
10009776|NCT01625780|Active Comparator|Control: single-shot block|Patients in this group will receive a standard, single-shot ilioinguinal nerve block.
10009777|NCT01625793|Active Comparator|HCV Interferon-alpha group|Subjects receiving treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection.
10009778|NCT01625793|Placebo Comparator|HCV Control Group|Subjects delaying the start of treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection by 7 weeks.
10009779|NCT01625806|Active Comparator|RO4602522|
10009780|NCT01625806|Experimental|RO4602522 + ketoconazole|
10009781|NCT01625819|Experimental|Tai Chi|32 1-hour group sessions of Tai Chi instruction
9803680|NCT03555149|Experimental|Atezolizumab + Idasanutlin|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
10009782|NCT01625819|Active Comparator|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
10009783|NCT01625819|Placebo Comparator|Health Education|32 1-hour bi-weekly group sessions of health education
10009784|NCT01625819|No Intervention|Care as Usual|Receive usual cardiology care for 4 months between pre- and post-treatment testing
10009785|NCT01625832|Experimental|1|CSO first
10009786|NCT01625832|Experimental|2|CSO second
10009787|NCT01625858||Supreme / other pediatric SGA|pediatric patients undergoing general anesthesia being treated with LMA Supreme or another pediatric supraglottic airway device
10009788|NCT01625871|Experimental|artemether-lumefantrine|tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
10009789|NCT01625949|Active Comparator|Control Arm (Standard Therapy)|Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting
10009790|NCT01625949|Experimental|Intracoronary stem cells|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting
10009791|NCT01625962||mTBI|"Service members who have sustained impact-induced mTBI or blast-induced mTBI (n = 74 completers)"
10009792|NCT01625962||ECI|Service members who have sustained an extracranial injury (ECI) with no evidence of TBI (n = 32 completers)
10009793|NCT01625975||Growth modulation with Eight plate|Pediatric patients undergoing growth modulation with the Eight plate system
10009794|NCT01626001|Experimental|Cohort 1|Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject < 60 minutes.
10009795|NCT01626001|Experimental|Cohort 2|Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
10009796|NCT01626014|Experimental|Intervention Group|Using the Prototype System website: An interactive educational system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
10009797|NCT01626014|Active Comparator|Control Group|Using the Usual Care Educational Website : a website which will contain information regarding ovarian cancer however it will not be interactive. It will contain pdf documents of the material handed out in clinic (usual care).
10009798|NCT01626040||PEG-P prep|Children taking the one day polyethylene glycol powder preparation for outpatient colonoscopy
10009799|NCT01626053|No Intervention|control group|
10009800|NCT01626053|Experimental|lifestyle counseling|These participant received the ASMART interventions.
10009801|NCT01626066|Experimental|LUM015|Receive single dose of LUM015 through a vein in the arm the day prior to surgery
10009802|NCT01626131|Experimental|Exercise treatment|Aerobic and resistance training
10009803|NCT01626131|Experimental|Stretching treatment|
10009804|NCT01626144||Breast cancer, exemestane treatment|Breast cancer patients receiving standard of care exemestane
10009805|NCT01626170||Correlative (laboratory biomarker analysis)|Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).
10009806|NCT01626196||Colonoscopy patients|Patients undergoing with bowel cleansing procedures according to the clinics' usual routine
10009807|NCT01626209|Experimental|BKM120 at: 80 and 100mg/day dose levels|
10035567|NCT01807494|Active Comparator|Anterior Approach|Subjects in this group will have total hip replacement performed with a direct anterior surgical approach and total hip replacement components.
10035568|NCT01807507||Healthy Volunteers|
9802472|NCT05237401|Experimental|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|"The other half of the study participants (test) will be randomised to receive surgical periodontal treatment in the form of open flap debridement (OFD). The aim of the surgery will be to achieve thorough debridement of the furcation area and (if possible) improve accessibility for patient-performed hygiene in the furcation area.~Some of the included maxillary molars may have additional FI on the same tooth (for example, grade III FI buccal to mesial and grade I, II or III distal). In this occurrence, the other furcation will be treated according to judgment by the treating clinician. We anticipate that, based on inclusion criteria, the majority of cases will have multiple grade III FI."
9802473|NCT05237232||Patients|Newborns, infants and children hospitalized in pediatric intensive care unit (PICU) at Trousseau Hospital, having been treated with jugulocarotid ECMO and weaned alive off ECMO.
10037270|NCT01823562|Active Comparator|Arm I (regular diet)|Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
9802474|NCT05237232||Controls|Newborns treated for hypoxic-ischemic encephalopathy in the PICU of Trousseau Hospital.
10009808|NCT01626222|Experimental|Everolimus & Exemestane|This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
10009809|NCT01626235||NSAID only|Subjects have their pain treated post-ED care with NSAID medication alone
10009810|NCT01626235||Opioid only|Subjects have their pain treated post-ED care with opioid medication alone
10009811|NCT01626235||NSAID + Opioid|Subjects have their pain treated post-ED care with NSAID medication and opioid as PRN rescue analgesia
10009812|NCT01626248||Group A TX Naive|Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
10009813|NCT01626248||Group B TY 4-12 doses|Patient is currently prescribed and is taking natalizumab, has 4 to 12 doses. If interested patient could be consented and assigned to Group B. Patients will have their blood drawn Day 0; and around the time of the patient's 18th dose.
10009814|NCT01626248||Group C 18 plus TY|Patient currently or close to being at 18 doses or 18 plus doses of natalizumab. If interested patient consented and assigned to Group C. Patient will have their blood drawn once: Day 0.
10009815|NCT01626248||Group D Other DMT 18 plus|Patient is close to or currently at 18 doses or more of interferon beta-1a or glatiramer acetate. If interested patient consented and assigned to Group D. Patient will have their blood drawn once: Day 0.
9476708|NCT03569059|Experimental|Delayed Robotic/VR Therapy (DVR)|Subjects in this group will receive state-of-art usual care therapy (inpatient and outpatient) plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated within 31-60 days post stroke.
9476709|NCT03569059|No Intervention|Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care.
9476710|NCT03569059|Experimental|Dose-Matched Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care plus an extra hour of state-of-art usual care.
9517915|NCT03301727|Other|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
9517916|NCT03301701|Experimental|Arm 1|Radical prostatectomy
10009816|NCT01626248||Group E - Non-MS|10 participants without Multiple Sclerosis or other immunological illness. If interested participants consented and assigned to Group E. Participants will have their blood drawn once: Day 0.
10009817|NCT01626261||cardiac pacemaker|
10009818|NCT01626274|Experimental|Device: in-ear sensor|Patients who routinely undergo a polysomnography night (1 night) are monitored via in-ear sensor which will be embedded in the auditory canal. During this night vital signs parameters are monitored, processed and subsequently compared to the polysomnography data.
10009819|NCT01626287|Experimental|Black tea bag|
10009820|NCT01626287|Active Comparator|ice packs|20 randomly chosen participants will be given frozen ice packs for perineal pain relief
10009821|NCT01626313|Active Comparator|Immediate intervention|Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT
10009822|NCT01626313|Active Comparator|Waitlisted|Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT
10009823|NCT01626326||Stop smoking app|Stop smoking iPhone research app provided at no charge via the iTunes store
10009824|NCT01626365|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
9964257|NCT01237067|Experimental|Group 2B|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
9964258|NCT01237106|Experimental|In Vitro Maturation (IVM)|
9964259|NCT01237119|Experimental|Liraglutide|A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
9964260|NCT01237119|Placebo Comparator|Placebo|Liraglutide-Placebo manufactured by Novo Nordisk.
9964261|NCT01237145||non-EAA, pigeon|subject with BAL because of diseases not suspected to be EAA
10009825|NCT01626365|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
10009826|NCT01626404||Patients enrolled|All patients enrolled in the study
9802475|NCT05235009||Cohort 1|"Adults >= 18 years old with cancer or imminent cancer diagnosis (cases) versus cancer-free and no imminent cancer diagnosis (controls).~Cohort 1 is intended for the development of 3 free GAGome MCED tests."
9802476|NCT05235009||Cohort 2|"Adults between 35 - 80 years old asymptomatic for cancer and with no recent history of cancer (> 5 years since curative-intent treatment for cancer).~Cohort 2 is intended for the validation of the combined free GAGome MCED test (primary endpoint) and the plasma and urine free GAGome MCED tests (secondary endpoints)."
9802477|NCT05233098||Clinical Cohort|Patients enrolled in the study will have 3 imaging scans taken after Tc-99m MAA injection. The final scan will occur between 18 and 24 hours after Tc-99m MAA injection.
10009827|NCT01626417|No Intervention|Patient Population|Chronic post-stroke subjects with varied impairment level, who have completed routine rehabilitative physical therapy.
10009828|NCT01626430|Experimental|200 mg gd-TRF|
10009829|NCT01626430|Experimental|400 mg gd-TRF|
10009830|NCT01626430|Experimental|Placebo|
10009831|NCT01626443|Active Comparator|Folic acid|
10009832|NCT01626443|Experimental|Inofolic Combi|
10009833|NCT01626469|Active Comparator|Arm A|Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)
10009834|NCT01626469|Placebo Comparator|Captopril|Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)
10035569|NCT01807533|Experimental|Family-centered intervention program|FCIP: family members were encouraged to present in all intervention sessions included 5 in-hospital intervention, 7 after-discharge interventions (0, 1, 2, 4, 6, 9, and 12 months of corrected age), and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
10035570|NCT01807533|Other|Usual care intervention program|UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
10035571|NCT01807572||obesity risk status|Lean adolescents at high-risk for obesity, by virtue of parental obesity, and lean adolescents at low-risk for obesity, by virtue of lean parents.
10035572|NCT01807611|Experimental|Transplant Recipients|"Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System."
10035573|NCT01807663|Experimental|healthy volunteers|Free breath monitoring. Correlation between two device for recording parameters of ventilation.
10035574|NCT01807663|Experimental|Chronic patient|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
10035575|NCT01807663|Experimental|ACUTE PATIENT|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
10035576|NCT01807676|Active Comparator|ET View Double Lumen Tube|Patients assigned to the thisgroup will be intubated using the VivaSight-DL.
10035577|NCT01807676|Active Comparator|conventional Double Lumen Tube|Patients assigned to the first group will be intubated using conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany).
10037271|NCT01823562|Active Comparator|Arm II (low polyphenol diet)|Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
10009835|NCT01626482|Placebo Comparator|Sham tape|
10009836|NCT01626482|Experimental|Kinesio Tape|
10009837|NCT01626508||breast-milk bank|breast milk collected and processed by the breast-milk bank before being used
10009838|NCT01626508||breast milk|breast milk used without any treatment, directly by children
10009839|NCT01626521||COPD Exacerbation|Patients admitted to hospital with COPD exacerbation
10009840|NCT01626534|Active Comparator|clopidogrel group|
10009841|NCT01626534|Experimental|tricagrelor group|
10009842|NCT01626560|Other|Daptomicina|
10009843|NCT01626560|Other|Vancomycin|
10009844|NCT01626586|Experimental|Group Therapy|"This study includes having an initial assessment completed; participating in a 6 session group therapy intervention over a 7 week time period; and returning at 2 and 4 months after group therapy intervention for booster follow-up sessions. During the group intervention sessions, the parent group and the youth group will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
10009845|NCT01626586|Active Comparator|Individual Arm|"This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the booster follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
9802478|NCT05231343|Experimental|Dual mini-fragment plating|
10009846|NCT01626586|Active Comparator|Recently Diagnosed Arm|"This study includes enrolling patients with Type 1 Diabetes, who are recently diagnosed (<1 year) to participate in a 4 session group therapy intervention over a 4 week time period; and returning at 2 months after the last group session for the booster follow-up session. During the group sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15-20 minutes."
10009847|NCT01626612|Experimental|a strategy based on de-escalation|
10009848|NCT01626612|Active Comparator|a conservative strategy|
10009849|NCT01626625|Experimental|stem cells|stem cells + hydroxy apatite
10009850|NCT01626625|Active Comparator|autograft|
10009851|NCT01626638|Experimental|Experimental|
10009852|NCT01626651|Experimental|Ibrutinib and Ketoconazole|
10009853|NCT01626677|Experimental|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
10009854|NCT01626677|Active Comparator|Microfracture|conventional treatment method
10009855|NCT01626703|Experimental|intervention|remiding call
10009856|NCT01626703|No Intervention|Control|No intervention
10009857|NCT01626716|Experimental|case management|patients who assigned to the intervention group will take 7 times phone calls from case manager
10009858|NCT01626716|No Intervention|control|usual care
10009859|NCT01626729|Experimental|Traffic Light|
10009860|NCT01626729|Experimental|Traffic Light+|
9517917|NCT03301701|Active Comparator|Arm 2|Radiotherapy
10009861|NCT01626729|Experimental|Facts Up Front|
9802479|NCT05231343|Active Comparator|Single precontoured plating|
10009862|NCT01626729|Experimental|Facts Up Front+|
10009863|NCT01626729|Placebo Comparator|No front of package label|
10009864|NCT01626742|Placebo Comparator|Ready to drink flavored beverage|
10009865|NCT01626742|Experimental|Ready to drink flavored beverage w/ AN 777|
10009866|NCT01626755|Experimental|Nerve block|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: infusion of local anesthetic."
10009867|NCT01626755|Active Comparator|Control|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: saline infusion."
10009868|NCT01626768||Enrolled patients|
10009869|NCT01626794|Experimental|VARIVAX™ VEP|
10009870|NCT01626794|Active Comparator|VARIVAX™ 2007 Process|
10009871|NCT01626807|Experimental|Walking school bus|
10009872|NCT01626807|No Intervention|Usual care|
10009873|NCT01626833|Active Comparator|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx®
10009874|NCT01626833|Placebo Comparator|Placebo|Placebo
10009875|NCT01626846||NF1 teenagers|
10009876|NCT01626898|Experimental|HOLA en Grupos|The Spanish language HOLA en Grupos intervention consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants.
10009877|NCT01626898|Active Comparator|General health intervention|The Spanish language comparison condition consists of four 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
10009878|NCT01626911|Experimental|CRAI|CRAI of LMWH in the celiac trunk
10009879|NCT01626911|Other|Conservative treatment|Conservative treatment without CRAI, control group
10009880|NCT01626924|Experimental|2-Iminobiotin|
10009881|NCT01626937|Experimental|Non invasive ventilation with conventional treatment|
10009882|NCT01626937|Active Comparator|conventional medical treatment|
10009883|NCT01626950||Cases - Stage III-IV breast cancer|The women in this group have been diagnosed with stage III-IV incident cancer.
10009884|NCT01626950||Controls: Stage I-II breast cancer|The women in this group have been diagnosed with stage I-II incident cancer.
10009885|NCT01626963|Experimental|SPA|Single-port access surgery
10009886|NCT01626963|Active Comparator|CL|Conventional Laparoscopic access
10009887|NCT01626976|Experimental|Cohort 1|
10009888|NCT01626976|Experimental|Cohort 2|
10009889|NCT01626976|Experimental|Cohort 3|
10009890|NCT01626976|Experimental|Cohort 4|
10009891|NCT01626976|Experimental|Cohort 5|
10009892|NCT01627015|Experimental|Modified infant follow-on formula|Infants are fed a modified infant follow-on formula (modified carbohydrate composition) for 4 weeks, according to protocol
10009893|NCT01627015|Active Comparator|Standard infant follow-on formula|Infants are fed a commercial follow-on formula for 4 weeks, according to protocol
9802482|NCT05229068|Experimental|Prior_RSV MAT Group|Maternal participants who received a single 120 µg dose of RSV MAT vaccine at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery).
9802483|NCT05229068|Experimental|Prior_Placebo Group|Maternal participants who received a single dose of placebo at Day 1 in RSV MAT-004 (NCT04126213), RSV MAT-009 (NCT04605159) or RSV MAT-012 (NCT04980391) parent studies or who did not participate in the parent studies and did not receive any RSV vaccine in the past*, will receive a single dose of RSV MAT vaccine at Day 1 in the current study and are followed-up until the study end (Day 181 post-delivery). *The unvaccinated participants are enrolled if the study cannot enroll sufficient numbers of the maternal participants who received placebo in the parent studies.
10009894|NCT01627041|Experimental|Arm I (daunorubicin hydrochloride, cytarabine)|Patients receive induction chemotherapy comprising daunorubicin hydrochloride IV daily on days 1-3 and cytarabine IV continuously on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
10009895|NCT01627041|Experimental|Arm II (decitabine, daunorubicin hydrochloride, cytarabine)|Patients receive decitabine IV over 1 hour on days -5 to -1. Patients then receive induction chemotherapy as in arm I in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
10009896|NCT01627054|Experimental|AT7519M|
10009897|NCT01627080||Cardiac Biomarkers|Patients with histologically proven esophageal cancer to be treated with radiation therapy with concurrent chemotherapy to a final dose of >/=40 Gy included in this study at UT MD Anderson Cancer Center in Houston, Texas.
10009898|NCT01627106|Experimental|Vernakalant|
10009899|NCT01627106|Active Comparator|Amiodarone|
10009900|NCT01627119||Gastric cancer patients|Gastric cancer patients who receive curative surgery at National Taiwan University Hospital
10009901|NCT01627132|Experimental|dasatinib|
10009902|NCT01627145|Experimental|antimuscariniz drug|
10009903|NCT01627158|Experimental|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
10009904|NCT01627158|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler
10009905|NCT01627158|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
10009906|NCT01627158|Active Comparator|Charcoal and Symbicort Turbuhaler|
10009907|NCT01627171|Active Comparator|PEG Lyte|PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.
10009908|NCT01627171|Experimental|Pico Salax Split|Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.
10009909|NCT01627171|Experimental|Pico Salax Night Before|2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy
10009910|NCT01627184||Athletes with diabetes mellitus|Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time
10009911|NCT01627197|Active Comparator|Intraaterial chemotherapy|"This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms~Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended)."
10009912|NCT01627197|No Intervention|Watchful waiting|Arm 2 (control): No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
10009913|NCT01627223|Experimental|Lamivudine 100 mg p.o. q.d.|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
10009914|NCT01627223|Experimental|Entecavir 0.5 mg p.o. q.d|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
10009915|NCT01627236|Experimental|glucocorticoid treatment group|
10009916|NCT01627236|No Intervention|conventional treatment|
10009917|NCT01627262|Placebo Comparator|Placebo|
10009918|NCT01627262|Experimental|Mesalamine|
10009919|NCT01627275|Experimental|DLI from HLA-identical donor|Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.
10009920|NCT01627301|Experimental|Device-guided Breathing (DGB)|Participants randomized to the DGB group use a device to guide their breathing to a slow breathing rate.
10009921|NCT01627301|Sham Comparator|Sham DGB|Participants randomized to the sham DGB group use a device identical to the DGB device but respiratory rates are not guided lower than the physiological rate.
10009922|NCT01627301|Experimental|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants randomized to use a tVNS device to deliver mild electrical stimulation to the vagal nerve.
10009923|NCT01627301|Sham Comparator|Sham tVNS|Participants randomized to use the sham tVNS device which vibrates but does not stimulate the vagal nerve.
10009924|NCT01627353|Active Comparator|Standard of Care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
10009925|NCT01627353|Experimental|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.25% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
10037272|NCT01823562|Active Comparator|Arm III (low ellagitannin diet)|Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
9802484|NCT05228197||Calibration Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen [PSA], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion criteria but in addition, purposive identification of cases with a variety and representative sample of different pathology features are needed for this stage (e.g. normal glands, cancer glands, high-grade PIN, inflammation)."
9802485|NCT05228197||Validation Stage|"Patients referred to hospital urology departments by their GP due to a clinical suspicion of prostate cancer (elevated serum prostate specific antigen [PSA], abnormal feeling prostate on rectal examination). These patients are normally recommended to undergo a prostate MRI as part of standard care.~Patients will need to meet the Inclusion/Exclusion."
9802486|NCT05223439||Individuals diagnosed with neuropathic pain due to lumbar disc degeneration|Individuals with neuropathic pain due to lumbar disc degeneration were included in this group.
9802487|NCT05223439||Individuals with lumbar disc degeneration but no neuropathic pain|Individuals without neuropathic pain due to lumbar disc degeneration were included in this group.
9802488|NCT05223439||Healthy Controls|Healthy individuals who did not have any problems that would affect gait were included.
9802489|NCT05220748|Experimental|RM-1995 Photoimmunotherapy (Phase 1a Monotherapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
9802490|NCT05220748|Active Comparator|RM-1995 Photoimmunotherapy + Pembrolizumab (Phased 1b Combination Therapy)|Patients with locally advanced cuSCC or HNSCC or metastatic disease that has recurred or progressed, despite all available standard therapies.
9802491|NCT05218343|No Intervention|Control|No change in default dose or frequency selected for the eight targeted drugs
9802492|NCT05218343|Experimental|Intervention|The first option a prescriber sees when prescribing any of eight high-risk drugs for elderly hospitalized patients will be modified; the first frequency option a prescriber sees will be modified as well. Providers retain the ability to prescribe any dose or frequency.
9802493|NCT05215574|Experimental|NGM831 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
9802494|NCT05215574|Experimental|NGM831 Combination Dose Finding with Pembrolizumab|Part 1b NGM831 plus pembrolizumab
9517918|NCT03301688|Experimental|A group (JS001 20161002)|The subjects of A group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161002.
9964262|NCT01237145||EAA, pigeon|Bird fanciers with a typical clinical presentation suspected for pigeon induced EAA
9964263|NCT01237158||healthy controls|
9476711|NCT03569046|Active Comparator|group l|ear block by local anaesthetic injection 0.25% bupivacaine. general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
9964264|NCT01237158||bipolar disorder type I|
9964265|NCT01237171||Sub-lobar resection with Cesium-131|All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
9964266|NCT01237184||biocortical fixation|Bi-cortically fixed implants intentionally engaging sinus floor beyond up to 1-2mm without graft but using stopper drill and self-threading concept
9802495|NCT05215574|Experimental|NGM831 Monotherapy Dose Expansion|Part 2a Single Agent Dose Expansion
9802496|NCT05213169|Experimental|Apomorphine|"Apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: titration phase from 0 to 4 mg/h (5 days), maintenance phase at 4 mg/h, titration-maintenance phase with possible increase up to 6 mg/h depending on tolerance (18 days).~Domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects 2 days before the initiation of apomorphine and maintained at least 7 days before an optional tapering off in the absence side effects."
9802497|NCT05213169|Placebo Comparator|Isotonic saline|Sodium chloride infusion following the administration procedure described for apomorphine
9802498|NCT05212623|Experimental|Group A|"Subjects received 2 doses of 0.25 mL of quadrivalent influenza vaccine, 4 weeks apart.~Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata)."
9802499|NCT05212623|Experimental|Group B|Subjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.(Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata).
9802500|NCT05212623|Active Comparator|Group C|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 type of virus strains, including BY).
9802501|NCT05212623|Active Comparator|Group D|Subjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 types of virus strains, including BV).
10009926|NCT01627366|Experimental|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
10009927|NCT01627366|No Intervention|Usual care|Receipt of usual medical care.
10009928|NCT01627379|Active Comparator|Arm A: Cisplatin, 5-Fluorouracil|Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
10009929|NCT01627379|Experimental|Arm B: Cisplatin, 5-Fluorouracil and Panitumumab|Chemotherapy plus Panitumumab will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
9802502|NCT05211973||Fried Frailty Phenotype 0|Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
10009930|NCT01627392|Experimental|Smoking abstinence|
9802503|NCT05211973||Fried Frailty Phenotype 1-2|Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
9802504|NCT05211973||Fried Frailty Phenotype 3+|Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.
9802505|NCT05210998|Experimental|grup 1:|"Education Group:~Gradual aerobic exercise training: Gradual aerobic exercise training as supervised training with a bicycle ergometer in the hospital environment two days a week and brisk walking at home once a week (20-40 minutes a day, 3 days a week)~Respiratory muscle training: Respiratory muscle training as Inspiratory muscle training (IMT)+ Expiratory muscle training (EMT) (5 days a week, 15 min IMT and 15 min EMT per day) at 50% of MIP and 30% of MEP"
9802506|NCT05210998|Other|grup 2:|"Control Group:~Gradual Aerobic exercise training: Gradual aerobic exercise training as supervised training with a bicycle ergometer in the hospital environment twice a week and brisk walking at home once a week (20-40 minutes per day, 3 days a week)"
9802507|NCT05210283||Stage ll or lll|Patients with stage ll or lll colorectal cancer
9802508|NCT05210114|Experimental|Skin Hydration Sensor|
9802509|NCT05202366||Treatment group|Only one treatment group (CGB-400 Topical Gel) will be used for analysis
10009931|NCT01627418|Experimental|Voucher|"Receive the intervention (Energy Voucher) the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
10009932|NCT01627418|Other|Control|"Receive the intervention the second winter enrolled in the study (thus No intervention : control arm). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
10009933|NCT01627431|Other|Antiplatelet therapy|Patients underwent peripheral revascularization procedures undergoing a double antiplatelet therapy
10009934|NCT01627444|Experimental|ear acupuncture|
10009935|NCT01627444|Placebo Comparator|Placebo acupuncture|No needle insertion, only stickers on acupuncture points.
10009936|NCT01627457|Experimental|GEx Training|CAD Patients in cardiac rehabilitation phase II (inpatient) and phase III (at home)in order to analyze data for quality of heart rate measurement and data acquisition by device as well as for practicability and technical problems at home.
10009937|NCT01627470||Cohort|Emergency Patients with applied arterial blood pressure measurement
10009938|NCT01627483|Experimental|Medication review|Assessment of risks of falls and fractures, medication review
10009939|NCT01627483|No Intervention|Controll|
10009940|NCT01627522|Active Comparator|Finastide low dose|2 weeks of daily 5mg finastride before operation
10009941|NCT01627522|Active Comparator|Finastide high dose|4 weeks of daily 5mg finastride before operation
10009942|NCT01627522|No Intervention|Control|Control
10009943|NCT01627535|Experimental|Optical Imaging|Patients undergo i2DOS
10009944|NCT01627548|Active Comparator|Waitlisted Intervention|Couple will be consented, assessed and randomized to a waitlist of 4 months. The couple will be reassessed at 8 weeks and prior to initiating intervention.
10009945|NCT01627548|Active Comparator|Immediate Intervention|Eligible couples who are randomized to immediate intervention will begin sessions with a trained interventionist within weeks of consent and initial assessments
10009946|NCT01627561|Experimental|Cervarix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received two doses of Cervarix vaccine at Day 0 and Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
10009947|NCT01627561|Active Comparator|Priorix + Infanrix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received one dose of Priorix vaccine at Day 0 and one dose of Infanrix vaccine at Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
10009948|NCT01627587|Experimental|Ketoconazole-Part A|Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
10009949|NCT01627587|Experimental|Food-Part B|Healthy Female Volunteers of child bearing potential will receive Treament D and E
10009950|NCT01627600||Atahualpa residents aged ≥ 40 years|All Atahualpa residentes aged 40 ≥ years will be screened by field questionnaires. Then, those with suspected stroke or ischemic heart disease will be evaluated by neurologists and cardiologists. Cardiovascular health metrics will be evaluated in those negative for stroke or ischemic heart disease.
10009951|NCT01627613|Experimental|AP301|Treatment group
10009952|NCT01627613|Placebo Comparator|saline solution|Placebo group
10009953|NCT01627626|Experimental|0.1% pilocarpine mouthwash|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline
10009954|NCT01627626|Placebo Comparator|0.9% saline mouthwash|0.9% saline as a mouthwash
9517919|NCT03301688|Experimental|B group (JS001 20161108)|The subjects of B group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161108.
10009955|NCT01627639|Active Comparator|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
10009956|NCT01627639|Placebo Comparator|Placebo|Placebo
10009957|NCT01627652|Experimental|altitude|subjects will be studies at sea level and at high altitude
10009958|NCT01627665|Active Comparator|D->R->C+R|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban
10009959|NCT01627665|Active Comparator|D->R->C+D|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran
10009960|NCT01627665|Active Comparator|R->D->C+D|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran
10009961|NCT01627665|Active Comparator|R->D->C+R|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban
10009962|NCT01627678|Experimental|Arm 1= Arm A: Vacc-C5 /GM-CSF.|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
10009963|NCT01627678|Experimental|Arm 2=Arm B: Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
10009964|NCT01627704|Other|Fluoroestradiol (18F)|
10009965|NCT01627717|Experimental|Maraviroc Boceprevir|
10009966|NCT01627730|Experimental|3th year medical students|
10009967|NCT01627730|Experimental|nurses in critical care units|
10009968|NCT01627743||COPD patients grade C and D|
10009969|NCT01627756|Experimental|Ventilation Group|Volume controlled ventilation was done during the whole surgery.
10009970|NCT01627756|Active Comparator|Non-ventilation Group|In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
10009971|NCT01627769||second degree blisters patients|blister fluids of second degree burns
10009972|NCT01627769||cryotherapy blisters|blister fluids of cryosurgery wounds
10009973|NCT01627795|Experimental|Oshadi D and Oshadi R|anti cancer agents
10009974|NCT01627834|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
10009975|NCT01627834|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
10009976|NCT01627847|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
9964267|NCT01237184||unicortical fixation|Short implants placed in proximity of the sinus without sinus floor involvement
9964268|NCT01237184||indirect sinus lift|implants engaging both crest and sinus floor but with green stick fracture
9964269|NCT01237236|Experimental|LEE011|
9964270|NCT01237249|Active Comparator|MPV followed by Revlimid/Low Dose Dexamethasone (Rd)|Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
9964271|NCT01237249|Experimental|Alternating MPV with Revlimid/Low Dose Dexamethasone|Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)
9964272|NCT01237262|Active Comparator|TNF alfa inhibitors|Male and female adult patients with a diagnosis of moderate to severe psoriasis (when PASI score is > 10 and BSA is > 10%). The overall study enrolment plan is 20 patients. Patients will be screened before the beginning of clinical trial by blood sample in order to exclude major contraindications to use of anti TNF α drugs.
9964273|NCT01237275|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline
9964274|NCT01237288|Experimental|Z-521|
9964275|NCT01237314||Glargine Group|After baseline titration of metformin, this group will take glargine along with metformin.
9964276|NCT01237314||Exenatide Group|After baseline titration of metformin, this group will take exenatide along with metformin.
9964277|NCT01237314||Glargine and Exenatide Group|After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
9964278|NCT01237366|Experimental|Reslient Affective Processing Therapy (RAPT)|
9964279|NCT01237366|No Intervention|Attention-Control|Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
9964280|NCT01237379||Health Controls|
9964281|NCT01237379||Bipolar Patients with High-Risk of Mania|
9964282|NCT01237379||Bipolar Patients with Ultra-High Risk|
9964283|NCT01237379||First Manic Episode Bipolar Youth|
9964284|NCT01237392|Active Comparator|Contact Ultrasonic Debridement Device|
9964285|NCT01237392|Active Comparator|Standard Sharp Debridement|
9964286|NCT01237405||Knee Osteoarthritis|"Unilateral or bilateral knee osteoarthritis on radiograph associated with knee pain on most days of any one-month in the last year in at least one knee.~Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi)."
9964287|NCT01237418||Myocardial Infarction|Any patient over 18 years admitted for myocardial infarction (MI) of less than 48 hours, characterized by the typical rise and fall of troponin or CPKMb
9964288|NCT01237431|Experimental|liver transplanted patients|Target group to confirm the hypothesis. Transplantation has to be between 6 an 24 Month before participation.
9964289|NCT01237431|Active Comparator|kidney transplanted patients|Control group, age, gender and medication matched. Transplantation has to be between 6 an 24 Month before participation.
9964290|NCT01237444|Experimental|lopinavir/ritonavir plus lamivudine|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
9964291|NCT01237444|Active Comparator|lopinavir/ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype"
9964292|NCT01237457|Experimental|Treatment|
9964293|NCT01237470|Experimental|Desarda group|Patients with primary inguinal hernia operated using the Desarda technique
9964294|NCT01237470|Experimental|Lichtenstein group|Patients with primary inguinal hernia operated using the Lichtenstein technique.
9964295|NCT01237483|Other|Erbitux Radiotherapy|Radiotherapy during 5 weeks and concurrent Erbitux once a week.
9964296|NCT01237496|Experimental|1|
9964297|NCT01237509||group1|Patients with T1D
9964298|NCT01237522|Active Comparator|Homozygote for the A270S wildetype|
9964299|NCT01237522|Active Comparator|Homo- or heterozygote for A270S minor alleles|
9964300|NCT01237535|Experimental|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel)Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.
10009977|NCT01627847|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
10009978|NCT01627873|Experimental|Remifentanyl|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
10009979|NCT01627873|Active Comparator|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
10009980|NCT01627886|Experimental|Ibandronate sodium tablets 150 mg|Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
10009981|NCT01627886|Active Comparator|Boniva|Boniva Tablets 150 mg of Roche Laboratories Inc, USA
10009982|NCT01627925|Experimental|Face mask and nasal mask without PEEP|Face mask ventilation and nasal mask ventilation without PEEP
10009983|NCT01627925|Experimental|Nasal mask and face mask with PEEP|Nasal mask ventilation and face mask ventilation with PEEP
10009984|NCT01627938|Experimental|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1
10009985|NCT01627938|Placebo Comparator|Placebo plus Mitoxantrone (MX)|Placebo + MX (12 mg/m2)
10009986|NCT01627951|Active Comparator|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
10009987|NCT01627951|Experimental|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
10009988|NCT01627951|Experimental|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
10009989|NCT01627964||normal heart function|normal heart function
10009990|NCT01627964||abnormal heart function|abnormal heart function
10009991|NCT01627977|Experimental|Dye of Lutein/Zeaxanthin/Brilliant Blue|during the surgery will be evaluated if the dye is suitable for dyeing the internal limiting membrane as well as the epiretinal membrane
10009992|NCT01628003|Active Comparator|healthy persons|
10009993|NCT01628003|Experimental|patients after moderate-severe TBI|
10009994|NCT01628029|Experimental|Arm I (methylphenidate, melatonin, light therapy, CBT)|Patients undergo CBT comprising 3 30-minute counseling sessions between baseline and day 14. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
10009995|NCT01628029|Experimental|Arm II (placebo, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
10009996|NCT01628029|Experimental|Arm III (methylphenidate, melatonin, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
10009997|NCT01628029|Experimental|Arm IV (methylphenidate, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
10009998|NCT01628029|Experimental|Arm V (placebo, melatonin, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
10009999|NCT01628029|Experimental|Arm VI (placebo, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
10010000|NCT01628029|Experimental|Arm VII (methylphenidate, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
10010001|NCT01628029|Experimental|Arm VIII (placebo, melatonin, sham light intervention, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
10037273|NCT01823562|Experimental|Arm IV (lower-dose lyophilized black raspberry gummy)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
10010002|NCT01628055|Experimental|Privigen|The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
10010003|NCT01628055|Placebo Comparator|Normal Saline|The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
10010004|NCT01628068|Active Comparator|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
10010005|NCT01628068|No Intervention|Oral anticoagulation|Oral anticoagulation
10010006|NCT01628081|Experimental|Alga Dunaliella bardawil|After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
10010007|NCT01628081|Placebo Comparator|Placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
10010008|NCT01628133||blood transfusion group|
10010009|NCT01628146|Experimental|SUPRACOR LASIK treatment|SUPRACOR LASIK treatment
10035578|NCT01807702|Experimental|13C-pyruvate,13C-Lactate and dichloroacetate|During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
10035579|NCT01807715||Study group|Women seeking first trimester surgical abortion
10035580|NCT01807728|Experimental|Group 1 Training Program|
10035581|NCT01807728|Experimental|Group 2 Training Program|
10035582|NCT01807741|Experimental|Asenapine Group|Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.
10035583|NCT01807741|Active Comparator|Placebo Group|Sublingual tablets similar to the asenapine tablets.
9802510|NCT05202301||Darolutamide cohort (Daro)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Darolutamide as initial treatment
9802511|NCT05202301||Enzalutamide cohort (Enza)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Enzalutamide as initial treatment
9802512|NCT05202301||Apalutamide cohort (Apa)|Participants received Second Generation Androgen Receptor Inhibitor (SGARI) Apalutamide as initial treatment
9517920|NCT03301675|Experimental|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
10035584|NCT01807754||Imaging scans for breast cancer screening|"To simulate the performance of the combination of three new breast imaging systems to digital mammography and hand-held ultrasound that are currently used to find and evaluate breast masses.~These three different systems make images of the breast in several ways to find breast masses and to distinguish normal and abnormal masses. This may result in less unnecessary call-backs from mammography."
9802513|NCT05201638|Experimental|IMU-838|"IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.~Formulation:~Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning."
9802514|NCT05201638|Placebo Comparator|Placebo|Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.
10035585|NCT01807767|Experimental|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
10035586|NCT01807767|Other|Myfortic and Tacrolimus|Normal Care: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
10035587|NCT01807780|Other|single arm :vaccinated|military personnel vaccinated with multiple vaccines and monitored about safety, immunogenicity and efficacy
10035588|NCT01807793|Active Comparator|Psychoeducation|Psychoeducation will include attending individual and group sessions.
10035589|NCT01807793|No Intervention|Care as usual|Receive care as usual
10010010|NCT01628172|Experimental|Biosense Webster Celcius Thermacool catheter|These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
10010011|NCT01628172|No Intervention|renal angiogram only|Control Group: Control arm will not receive intervention but will be followed for 1 year.
10010012|NCT01628185||Pain Observations|Adult ICU patients who are not comatose with Richmond Agitation-Sedation Scale (RASS) score of -3 to 4 and unable to self-report pain. Patients will be excluded for neurological deficits (acute or chronic) that prevent observation of the muscle tonus or movement
10010013|NCT01628211|Experimental|Second look laparoscopy|Second look laparoscopy to evaluate for and treat peritoneal carcinosis
10010014|NCT01628211|No Intervention|standard follow up|
10010015|NCT01628224||CCATT Team|Measurements will be taken on groups of 3 people each. There will be a total of 16 such teams, with total membership of 48 individuals
10010016|NCT01628237|Active Comparator|Monocolumn spinal cord stimulation|Specify 5-6-5 Lead (only one column)
10010017|NCT01628237|Experimental|Multicolumn spinal cord stimulation|Specify 5-6-5 Lead
10010018|NCT01628263|Experimental|Follow up Clinic|Participants will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse.
10010019|NCT01628263|No Intervention|Control|Participants will not receive an offer of a follow up clinic
10010020|NCT01628276|Experimental|Rehab first|
10010021|NCT01628276|Experimental|Rehab Second|
10010022|NCT01628276|No Intervention|Non Rehab|
10010023|NCT01628289|Other|free screening group|Subjects in this group receive free diabetic retinopathy screening.
10010024|NCT01628289|Other|Pay screening group|Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
10010025|NCT01628302|No Intervention|Normal salt diet|The group had normal salt diet (250mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had low salt diet (50mmol) at the last 3 weeks of the study.
10010026|NCT01628302|Experimental|Low salt diet|The group had low salt diet (50mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had normal salt diet at the last 3 weeks of the study.
10010027|NCT01628315||Mulitple Sclerosis|Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
10010028|NCT01628328||Stenting|patient who received colonic stenting for obstructive colorectal cancer
10010029|NCT01628328||Control|patients who had only colonoscopy without obstruction and without stenting
10010030|NCT01628341||Patients with diabetes (type 1 and 2)|
10010031|NCT01628380|Active Comparator|CRS + HIPEC|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel
10010032|NCT01628380|Active Comparator|CRS alone|Cytoreductive Surgery alone
10035590|NCT01807806|Experimental|Role-playing game|All eligible participants were invited to play the role playing game
10035591|NCT01807832|Other|chronic cough|Capsaicine challenge in chronic cough patients
10010033|NCT01628419|Experimental|Health intervention program|Health promotion intervention program will be implemented at each workplace and will include: exercise program, nutritional counseling for the kitchen service, lectures on different topics (physical activity, nutrition, sleeping behaviour etc.).
10010034|NCT01628432|Experimental|conservative hysterectomy I|bilateral salpingectomy during hysterectomy with conservation of the ovaries
10010035|NCT01628432|Active Comparator|conservative hysterectomy II|standard conservative hysterectomy with conservation of both ovaries and tubes
10010036|NCT01628445|Active Comparator|liraglutide|liraglutide 1.8 mg injected once daily
10010037|NCT01628445|Placebo Comparator|Placebo injection|
10010038|NCT01628458|Experimental|radiofrequency ablation|
10010039|NCT01628471|Experimental|Decitabine + genistein single arm|decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day
10010040|NCT01628484|Other|Skin Preparation Testing|The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
10010041|NCT01628497||Positive filariasis test|Those testing positive for filariasis
10010042|NCT01628497||Filariasis negative|
10010043|NCT01628536|Experimental|Black cohosh|
10010044|NCT01628562|Active Comparator|GroupE/Esmolol infusion|Heart rate control, Beta blocker
10010045|NCT01628562|Experimental|GroupR/Remifentanil infusion|Heart rate control, opioid
10010046|NCT01628575||PAO|patients undergoing orthodontic treatment with the addition of pretreatment periodontal surgery for bone decortication.
10010047|NCT01628627|Experimental|FREMS|Frequency Modulated Neural Stimulation (FREMS)
10010048|NCT01628627|Sham Comparator|Control|
10010049|NCT01628640|Experimental|Arm A (viral therapy in single tumor location)|Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
10010050|NCT01628640|Experimental|Arm B (viral therapy in multiple locations)|Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
10010051|NCT01628653|Experimental|U-SMART|U-SMART (Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training)
10010052|NCT01628666|Experimental|Conventional|Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients.
10010053|NCT01628666|Experimental|Incremental|Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative.
10010054|NCT01628679|Experimental|physical therapy treatment|
10010055|NCT01628705|Sham Comparator|Nutritional intervention|The subjects were undergoing nutritional intervention.
10010056|NCT01628705|Experimental|Nutritional intervention with green tea|The subjects were undergoing nutritional intervention complemented with green tea.
10010057|NCT01628731|Active Comparator|furosemide|furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
10010058|NCT01628731|Active Comparator|ethacryinic acid|ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
10010059|NCT01628744||Patients with mycobacterial infection|
10010060|NCT01628757||neoadjuvant chemotherapy|
10010061|NCT01628770|Experimental|parenteral iron|dose will be calculated according to Ganzoni's formula, and will be administered by intravenous infusion
10010062|NCT01628770|Active Comparator|oral iron|oral iron in form of ferrous sulphate 200 mg twice daily
10010063|NCT01628783|Placebo Comparator|Placebo|Microgranular cellulose in gelatine capsules.
10010064|NCT01628783|Experimental|Escitalopram 10 mg|Escitalopram in gelatine capsule
10010065|NCT01628809|Active Comparator|Rest and Relaxation|three-day relaxation retreat without mindfulness components
10010066|NCT01628809|Experimental|Mindfulness-Based Meditation|three-day mindfulness-based meditation retreat
10010067|NCT01628822|Experimental|Active relaxation|
10010068|NCT01628822|Placebo Comparator|Placebo relaxation|
10010069|NCT01628835|Experimental|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided.
10010070|NCT01628835|Active Comparator|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
10010071|NCT01628861|Active Comparator|education only|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided.
10010072|NCT01628861|Experimental|prompt + education|"A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided. Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
10010073|NCT01628887|Experimental|Supportive Care (BBCEI)|Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
10010074|NCT01628900|Active Comparator|ambulatory|Patient will be treated for 7 days at home, then 3 follow-up visit at hospital.
10010075|NCT01628900|Active Comparator|hospitalisation|7 days for mono-antibiotherapy at hospital.
10010076|NCT01628939||current low back pain|subjects with current low back pain (i.e. more than 30 days of low back pain in the last three months)
10010077|NCT01628939||controls|subjects with less than 30 days of low back pain in the last three months
10010078|NCT01628952|Experimental|TAP|
10010079|NCT01628952|Active Comparator|curare|Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
10010080|NCT01628978||Auscultation group|The depth of endotracheal tube placement is determined by auscultation.
10010081|NCT01628978||Ultrasonography group|The depth of placement of endotracheal tube placement is determined by ultrasonographic finding of pleural sliding sign.
10010082|NCT01628991|Experimental|behavioural intervention|Recieving interventional behavioural program
10010083|NCT01628991|Experimental|vaginal cone|intravaginal device insertion(vaginal cone)
10010084|NCT01629004|Other|Non-responders|"Non-responders to an initial mailed CRC screening invitation from their family physician.~FOBT kit. Mailed invitation."
10010085|NCT01629004|Other|Recall patients|"Those who responded to the initial mailed CRC screening invitation and are now due for repeat screening (i.e., recall patients).~FOBT kit. Mailed invitation."
10010086|NCT01629030||Coronary Artery Bypass Graft Group|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung Medical Center during the period of January 2008 and December 2011.
10010087|NCT01629056|Active Comparator|Contact ECI active|Contact ECI active
10010088|NCT01629056|Placebo Comparator|Contact information deactivated|RF ablation without contact data
10010089|NCT01629069|Active Comparator|Participant in MBRT|6 sessions of Mindfulness Based Resilience Training
10010090|NCT01629095||NAFLD|Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.
10010091|NCT01629095||NASH|Patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes havebeen ruled out are eligible to participate.
10010092|NCT01629121|Experimental|education intervention|The intervention delivered education about the benefits of bicycle helmet use and safety and was designed to be sensitive to the age and educational level of the study participant.
9517921|NCT03301675|No Intervention|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
10010093|NCT01629121|No Intervention|control|Printed materials were given to the control group, along with a helmet for each participant.
10010094|NCT01629147|Experimental|Biogaia|5 drops containing Lactobacillus reuteri Protectis
10010095|NCT01629147|Placebo Comparator|Placebo|- 5 drops identical in appearance and taste
10010096|NCT01629173|Experimental|Dynamic impression insole|We sequentially padded P-cell, Ethylene Vinyl Acetate, and Multiform on the 9-mm thick plastazote under daily walking compression to make dynamic impression insole.
10010097|NCT01629173|Experimental|Custom molded insole|The custom molded insole was made by sequentially padded Multiform, P-cell, EVA, and cork on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
10010098|NCT01629173|Experimental|9-mm uncompressed Plastazote insole|We used 9-mm flat Plastazote as an insole
10010099|NCT01629173|Experimental|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) as an insole
10010100|NCT01629186|Experimental|outcome|"Cardiopulmonary parameters were measured and recorded at baseline, just before and at every minute during NC-AC, and at the end of the FB session. In infants who already had an arterial line, arterial blood gas (ABG) analyses were taken for study. Data was represented as mean ± SD. The results obtained from the baseline and different stages. The values were considered statistically significant only when p < 0.05.~Technique failure was defined as: any vital signs of hypoxia did not return to accepted levels(HR>100 beat/min, SpO2>90%, mean BP>50 mmHg)within 2 minutes of the experimental CPR technique. Then traditional CPR procedures involving bag-mask ventilation, endotracheal intubation, Ambu bag ventilation or even chest compressions were substituted."
10010101|NCT01629199|Experimental|rhEGF(recombinant human Epidermal Growth Factor)|BID
10010102|NCT01629199|Placebo Comparator|placebo|BID
10010103|NCT01629212|Experimental|Tiropramide HCl|
10010104|NCT01629212|Active Comparator|Octylonium bromide|
9517922|NCT03301636|Experimental|Pembrolizumab + Indoximiod|
9517923|NCT03301636|Experimental|Nivolumab + Indoximiod|
10010105|NCT01629225|No Intervention|candesartan|All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
10010106|NCT01629238||group 1|group 1 = consumers of marketed drinkable low fat fermented milk enriched with plant sterol
10010107|NCT01629238||group 2|group 2 = non-consumers of marketed drinkable low fat fermented milk enriched with plant sterol
10010108|NCT01629251|Active Comparator|Closed-loop with standard meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard meal insulin dosing will be performed at each meal, following individual standard clinical practice.
10010109|NCT01629251|Experimental|Closed-loop with reduced meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. The standard meal insulin dose will be reduced by 20 to 50%.
10010110|NCT01629277|Active Comparator|Control|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
10010111|NCT01629277|Experimental|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
10010112|NCT01629303|Experimental|Arm on-off|"After the definitive implantation, stimulators are placed in position OFF during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks"
10010113|NCT01629303|Experimental|Arm off-on|"After the definitive implantation, stimulators are placed in position ON during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks"
10010114|NCT01629316|Experimental|Text reminders, counseling, link coordinator|Text reminders, counseling, link coordination
10010115|NCT01629316|Active Comparator|Standard of care - control arm|
10010116|NCT01629342||Transient Ischemic Attack Patients|Patients discharged after a Transient Ischemic Attack
10010117|NCT01629355||Schizophrenia|Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.
10010118|NCT01629355||ADHD|Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.
10010119|NCT01629355||Bipolar disorder|Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.
10010120|NCT01629355||Healthy controls|Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.
10010121|NCT01629368|Experimental|Dosing Period 1|
10010122|NCT01629368|Experimental|Dosing Period 2|
10010123|NCT01629394|Active Comparator|Group A: Sugammadex CBW-open|Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
10010124|NCT01629394|Active Comparator|Group B: Sugammadex IBW-open|Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
9802515|NCT05199987|Active Comparator|Standard Occupational Therapy|This group will receive standard occupational therapy sessions
9802516|NCT05199987|Experimental|Occupational Therapy with Breathing Control Exercises|This group will receive the same component of the control group + breathing control exercises
9802517|NCT05199090|Active Comparator|MBL949 Arm 1|One dose C followed by two doses E followed by five doses D of MBL949
10010125|NCT01629394|Active Comparator|Group C: Neostigmine CBW-open|Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
10010126|NCT01629394|Active Comparator|Group D: Neostigmine-IBW|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
10010127|NCT01629394|Active Comparator|Group E: Sugammadex CBW-Lap|Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
10010128|NCT01629394|Active Comparator|Group F: Sugammadex IBW-Lap|Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
10010129|NCT01629394|Active Comparator|Group G: Neostigmine CBW-Lap|Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
10010130|NCT01629394|Active Comparator|Group H: Neostigmine IBW-Lap|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
10010131|NCT01629407||Glaucoma|Patients with glaucoma
10010132|NCT01629420|Experimental|Drug:KLH-2109 lower dose|
10010133|NCT01629420|Experimental|Drug:KLH-2109 higher dose|
10010134|NCT01629433||botulinum A toxin|18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics.
10010135|NCT01629446|Experimental|Lofexidine HCl with 14C tracer|
10010136|NCT01629459|Experimental|Resistance exercise training|Participants will undergo resistance exercise training 3x/wk for 12 weeks at a physical therapy or cardiac rehabilitation facility near the participant's home.
10010137|NCT01629472|Experimental|VSLA + gender dialogue groups: treatment|
10010138|NCT01629472|Active Comparator|VSLA only: control|
10010139|NCT01629485|Experimental|Whole Task|Trainees will undergo whole task mastery training in the TEP simulator after completing the video curriculum portion.
10010140|NCT01629485|Experimental|Part Task|Trainees will undergo a random part task mastery training in the TEP simulator after completing the video portion of the curriculum.
10010141|NCT01629498|Experimental|Arm I (image-guided IMRT)|Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
10010142|NCT01629498|Experimental|Arm II (image-guided IMPT)|Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
10010143|NCT01629511|Experimental|Treatment (combination chemotherapy, stem cell transplant)|Participants receive gemcitabine IV over 10-25 minutes on days -6 and -4, clofarabine IV over 1 hour and busulfan IV over 3 hours on days -6 to -3. Participants with matched unrelated donors also receive anti-thymocyte globulin IV over 4 hours on days -3 to -1. Starting day -2, participants receive tacrolimus PO daily for up to 6 months. Participants undergo hematopoietic allogeneic stem cell transplant on day 0, then receive methotrexate IV over 15 minutes on days 1, 3, 6 and 11, and filgrastim SC QD beginning 1 week after transplant until blood cell levels return to normal.
10010144|NCT01629524||Colorectal cancer patients|Colorectal cancer patients undergoing elective colorectal resection
10010145|NCT01629537|Other|Placebo|Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.
10010146|NCT01629537|Experimental|Stellate Ganglion Block (SGB)|Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.
10010147|NCT01629550|Active Comparator|PVI paint|5% alcoholic povidone iodine paint
10010148|NCT01629550|Active Comparator|PVI scrub and paint|detersion with 4% povidone iodine scrub followed by 5% alcoholic povidone iodine paint
10010149|NCT01629550|Active Comparator|Chlorhexidine paint|2% alcoholic chlorhexidine paint
10010150|NCT01629550|Active Comparator|chlorhexidine scrub and paint|Detersion with 4% chlorhexidine scrub followed 2% alcoholic chlorhexidine paint
10010151|NCT01629576|No Intervention|control group|
10010152|NCT01629576|Experimental|low reward|economic incentive
10010153|NCT01629576|Experimental|high reward|economic incentive
10010154|NCT01629602|Experimental|vascularized nerve graft|The investigators combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
10010155|NCT01629628|Experimental|Adalimumab|
10010156|NCT01629628|Active Comparator|6-mercaptopurine|
10010157|NCT01629641||Normals|Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
10010158|NCT01629654|Experimental|Lifestyle counseling|Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
10010159|NCT01629680|Experimental|Healthy subjects I|
10010160|NCT01629680|Placebo Comparator|Healthy subjects II|
10010161|NCT01629732|Experimental|Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)"
10010162|NCT01629732|Experimental|Arm 2: Daclasasvir + BMS-986094 (200 mg)|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)"
10010163|NCT01629732|Experimental|Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)"
10010164|NCT01629732|Experimental|Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)"
10010165|NCT01629732|Experimental|Arm 5: Daclasasvir + BMS-986094 (200 mg)|Genotype 1 PI-failure subjects
10010166|NCT01629732|Experimental|Arm 6: Daclasasvir + BMS-986094 (200 mg)|Genotype 4 naive subjects
10010167|NCT01629732|Experimental|Arm 7: Daclasasvir + BMS-986094 (200 mg)|Genotype 2/3 NR/relapse Subjects
10010168|NCT01629758|Experimental|Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
10010169|NCT01629758|Experimental|Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
10010170|NCT01629758|Experimental|Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
10010171|NCT01629849|Experimental|BI 1021958 qd|Multiple rising dose
10010172|NCT01629849|Placebo Comparator|Placebo to BI 1021958 qd|Matching placebo as tablets
10010173|NCT01629849|Experimental|BI 1021958 bid|Multiple rising dose
10010174|NCT01629849|Placebo Comparator|Placebo to BI 1021958 bid|Matching palcebo as tablet
10010175|NCT01629875|Experimental|DWP450|
10010176|NCT01629875|Active Comparator|Botox|
10010177|NCT01629888|Experimental|1 = Tested product|
10010178|NCT01629888|Placebo Comparator|2 = Control product|
10035592|NCT01807845|Active Comparator|Skimmilk VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80;
10035593|NCT01807845|Placebo Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
10035594|NCT01807845|Active Comparator|enriched skimmilk with VD|enriched skimmilk with VD
10035595|NCT01807858|Active Comparator|Bifidobacterium lactis|5 billion Bifidobacterium lactis
10035596|NCT01807858|Active Comparator|İnulin|900 mg İnulin per day will be given
10035597|NCT01807858|Placebo Comparator|Maltodextrin|Maltodextrin
10035598|NCT01807858|Active Comparator|Bifidobacterium lactis plus İnülin|5 billion active Bifidobacterium lactis plus 900 mg İnülin per day
10035599|NCT01807884|Experimental|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
10035600|NCT01807884|Placebo Comparator|Routine oral care|Oral suction followed by mouth care and tracheal suction
10035601|NCT01807910|Experimental|Fructose|Participants will receive fructose (3g/kg/day) for 2 weeks.
10035602|NCT01807910|Active Comparator|Glucose|Participants will receive glucose (3g/kg/day) for 2 weeks.
10035603|NCT01807936|Experimental|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field lymphadenectomy
10035604|NCT01807936|No Intervention|Two -field lymphadenectomy|Thoracic-upper abdominal two -field lymphadenectomy
10035605|NCT01807962|Active Comparator|rapidocain and bethametsaone|"Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)"
10035606|NCT01807962|Placebo Comparator|sterile saline|Placebo arm with 5ml of sterile saline (NaCl) solution
10035607|NCT01807975|Experimental|post allogreffe patients|Functional evaluation of distal airway by forced oscillation technique : relevance earlier diagnostic of pulmonary syndrom of oblitérant bronchiolit in post allogreffe patients
10035608|NCT01807988|Experimental|iCBT|Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
10035609|NCT01807988|No Intervention|Control group|The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses. They will also receive feedback on there self-reported symptoms.
10035610|NCT01808014|Experimental|The addition of Nefopam|The addition of Nefopam for intravenous patient-controlled analgesia in patients with lumbar spinal surgery would reduce the side effects seen in monotherapy with opioid analgesia and result in effective pain management.
10035611|NCT01808027||Acute myocardial infarction|patient with suspected acute coronary syndrome (ACS).
10035612|NCT01808040|Experimental|1|"Tak700 (orteronel) dose escalation schedule:~1a 200 mg PO BID TAK700~1b 200mg PO BID TAK + glucocorticoid~1a 300mg PO BID TAK700 starting dose~1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid"
10035613|NCT01808053||Healthy older and independently living adults|The BodyGuardian remote health monitoring system will used by healthy older and independently living adults
10035614|NCT01808079||Ancillary-correlative (genetic markers of Wilms tumor)|Samples are analyzed for SNP profiling using real-time PCR and MLPA.
9964301|NCT01237535|Experimental|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].
9964302|NCT01237535|No Intervention|No luteal support|
9964303|NCT01237548||All participants|Normal People who have smoked Water-pipe, at least once before.
10010179|NCT01629927||HED-affected males|Male subjects affected by HED
10010180|NCT01629927||Male controls|Male subjects not affected by HED
10010181|NCT01629940||Male HED-Affected Individuals|Male subjects affected by HED
10010182|NCT01629940||Male controls|Male subjects not affected by HED
10010183|NCT01629979|Experimental|A: Grafting of autologous epidermal harvested cells and UVB|"Grafting with epidermal cells: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
10010184|NCT01629979|Active Comparator|UVB treatment|UVB treatment twice a week during 3months
10010185|NCT01629992|Experimental|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
10010186|NCT01629992|No Intervention|Control|The control group received no preoperative counseling either oral or written.
10010187|NCT01630005|Experimental|Talk therapy|A cohort of 25 patients
10010188|NCT01630018|Active Comparator|Topotecan|Topotecan
10010189|NCT01630018|Active Comparator|Camtobell|Belotecan
10010190|NCT01630031||Control group|Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.
10010191|NCT01630031||CF group|Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.
10010192|NCT01630044|Experimental|TNM device, active treatment|This is an active-only assessment of the experimental neuromodulation device
10010193|NCT01630057|Experimental|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
10010194|NCT01630057|Active Comparator|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
10010195|NCT01630070|Experimental|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
10010196|NCT01630083|Active Comparator|EOX Treatment|Participants will receive up to 8 cycles of epirubicin, oxaliplatin and capecitabine (EOX) chemotherapy treatment alone (50 mg/m^2 epirubicin intravenously on day 1 of each cycle, 130 mg/m^2 oxaliplatin intravenously on day 1 of each cycle, 625 mg/m^2 capecitabine orally twice daily on days 1 to 21 of each cycle). The first dose of capecitabine to be taken in the evening of day 1.
10010197|NCT01630083|Experimental|EOX+zolbetuximab 800/600 mg/m^2|Participants will received up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab administered as loading dose of 800 mg/m^2 intravenously on day 1 of cycle 1 followed by 600 mg/m^2 intravenously on day 1 of each subsequent cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (600 mg/m^2 every 3 weeks to be administered intravenously as a 2-hour infusion) until progressive disease (PD), withdrawal of consent or unacceptable toxicity. PD per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study, an absolute increase of at least 5mm must also be demonstrated, unequivocal progression of existing non-target lesions and appearance of one or more new lesions is considered progression.
10010198|NCT01630083|Experimental|EOX+zolbetuximab 1000 mg/m^2|Participants will receive up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab 1000 mg/m^2 intravenously on day 1 of each cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (1000 mg/m^2 every 3 weeks administered intravenously as a 2-hour infusion ) until PD, withdrawal of consent or unacceptable toxicity.
10010199|NCT01630096|Active Comparator|Nu-Lytely|Bowel prep solution.
10010200|NCT01630096|No Intervention|Control|Standard of care.
10010201|NCT01630122||patients newly diagnosed non small cell lung cancer|patients with presumed newly diagnosed non small cell lung cancer, where radiographic studies and clinical description favor a probable diagnosis of non small cell lung cancer
10010202|NCT01630148|Active Comparator|Bemiparin|group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
10010203|NCT01630148|No Intervention|control group|women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention. The patients will be followed up to 30 days after surgery.
10010204|NCT01630161|Active Comparator|Usual Care|Participants randomized to the Usual Care condition will receive standard care following recruitment.
10010205|NCT01630161|Active Comparator|Relapse-Prevention Intervention|Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
9802518|NCT05199090|Active Comparator|MBL949 Arm 2|Two doses C followed by six doses D of MBL949
10010206|NCT01630187|Active Comparator|Carbetocin 100 mcg|
10010207|NCT01630187|Experimental|Carbetocin 50 mcg|
10010208|NCT01630226|Experimental|Neoadjuvant Cisplatin Chemotherapy|
10010209|NCT01630239|Experimental|Visualise Thermal Therapy System|
10010210|NCT01630252|Active Comparator|Part A2 - Active Treatment arm|PGL5001 for 8 weeks + one DMPA injection
10010211|NCT01630252|Placebo Comparator|Part A2 - Placebo Treatment arm|PGL5001 matching placebo for 8 weeks + one DMPA injection
10010212|NCT01630252|Active Comparator|Part B - Active treatment arm|PGL5001 for 20 weeks + two DMPA injections
10010213|NCT01630252|Placebo Comparator|Part B - Placebo Treatment arm|PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
10010214|NCT01630252|Experimental|Part A1 - Active Treatment arm|PGL5001 for 8 weeks + one unique DMPA 150 mg injection
10010215|NCT01630265|Active Comparator|Written Discharge Instructions|Group of caregivers who read written discharge instructions that are the standard discharge instructions given in our pediatric ED
10010216|NCT01630265|Experimental|Video Discharge Instructions|Group of caregivers who watched the 3-minute video covering the information in the standard written discharge instructions
10010217|NCT01630278|No Intervention|Small ductus|
10010218|NCT01630278|Experimental|Large ductus ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
10010219|NCT01630278|Placebo Comparator|Large ductus placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
10010220|NCT01630291|Experimental|Electrical stimulation|
10010221|NCT01630304|Experimental|WelTel SMS service|"In addition to standard care, weekly text messages will be delivered to participants randomized to this arm for a one year period. Participants will be requested to respond to the outgoing message Mambo? within 48 hours; they may respond that they are doing well (sawa) or that they have a problem (shida). A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
10010222|NCT01630304|No Intervention|Standard care|This arm will receive standard clinical care.
10010223|NCT01630317|Experimental|Peripheral acces|
10010224|NCT01630317|Placebo Comparator|Central access|
10010225|NCT01630330|Active Comparator|Contact Force Known|Ablation with contact force data known
10010226|NCT01630330|Experimental|Contact Force Not Known|Contact Force data unavailable during ablation
10010227|NCT01630343|Experimental|Regular oral Panadol and Tramadol|Geriatric (age >65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
10010228|NCT01630343|Experimental|Panadol and tramadol oral in prn basis|Control group is that patient having geriatric hip fracture will have oral analgesics ( Panadol 500mg Q4H and tramadol 50mg Q4H ) in prn basis.
10010229|NCT01630356|Experimental|Intervention group|
10010230|NCT01630356|Active Comparator|Control group|
10010231|NCT01630369|Experimental|Human Insulin|Dosage of human insulin (Insuman Basal/Comb/Rapid) will be individually adjusted in accordance with the Summary of Product Characteristics (SmPC). Patients will follow the titration algorithm recommended by the physician.
10010232|NCT01630395|No Intervention|conventional|Two-lung ventilation: tidal volume = 10 ml/kg, no PEEP. One-lung ventilation: tidal volume = 10 ml/kg, no PEEP
10010233|NCT01630395|Active Comparator|Protective|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O.
10010234|NCT01630395|Active Comparator|Recruitment|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
10010235|NCT01630408|Experimental|Paricalcitol|Paricalcitol oral capsules (1 mcg per day for 48 weeks)
10010236|NCT01630473|Experimental|Corticotomy-assisted orthodontics|This group of patients will receive corticotomy surgical procedure at day 0. Orthodontic activation will start immediately after surgery.
10010237|NCT01630473|Active Comparator|Conventional orthodontics|This group of patients will receive conventional orthodontics starting at day 0.
10010238|NCT01630486||glomerulonephritis|adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
10010239|NCT01630486||hypertensive nephropathy|adult CKD patients, whose underlying etiology is hypertensive nephropathy
10010240|NCT01630486||polycystic kidney disease|adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
10010241|NCT01630486||diabetic nephropathy|adult CKD patients, whose underlying etiology is diabetic nephropathy
10010242|NCT01630499|Experimental|Tailored Lifestyle Intervention (TLI)|Participants randomized to the TLI condition will receive a 3-month weight management program tailored to the specific needs of women in remission from breast cancer.
10010243|NCT01630499|Active Comparator|Commercial Weight Loss Program (CLWP)|Participants randomized to the CWLP condition will receive a 3-month commercial weight loss program (i.e., Weight Watchers) at no cost.
10010244|NCT01630512|Experimental|MBCT|
10010245|NCT01630512|Experimental|CBT|
10010246|NCT01630512|No Intervention|Waitlist|
10010247|NCT01630525||Prodromal AD participants|
10010248|NCT01630525||Typical AD participants|
10010249|NCT01630525||Control participants|
10010250|NCT01630538|Experimental|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.
10010251|NCT01630551|Active Comparator|Fishoil nutritional supplement|90 day supply of daily oral administration of a fish oil nutritional supplement (TheraTears Nutrition; Advanced Vision Research, Woburn, MA)
10010252|NCT01630551|Placebo Comparator|Olive oil capsules|90 day supply of a daily dose of placebo olive oil capsules
10010253|NCT01630564|Experimental|Treatment (T-cell infusion)|Patients undergo ex vivo-expanded umbilical cord blood progenitor cell donor T cell infusion with aldesleukin 11-14 days after T-cell co-stimulation begins.
10010254|NCT01630577|Experimental|responder to fluid challenge|fluid challenge
10010255|NCT01630603||mother infants pairs|
10010256|NCT01630629||African-American Lactating Women|Healthy African-American women who are exclusively breast-feeding.
10010257|NCT01630629||Caucasian Lactating Women|Healthy Caucasian women who are exclusively breast-feeding.
10010258|NCT01630668|Experimental|One-a-Day L. reuteri NCIMB 30242 supplement capsule|
10010259|NCT01630668|Placebo Comparator|One-a-Day placebo capsule|
10010260|NCT01630681|Experimental|Internet-based stepped care|Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
10010261|NCT01630681|No Intervention|Standard care|
10010262|NCT01630720|Active Comparator|vitamin C|vitamin C 500 mg twice daily
10010263|NCT01630720|Active Comparator|vitamin D|vitamin D 5000 IU daily
10010264|NCT01630733|Experimental|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
10010265|NCT01630733|Active Comparator|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
10010266|NCT01630746|Experimental|TAK-438 20 mg/day|
10010267|NCT01630746|Experimental|TAK-438 40 mg/day|
10010268|NCT01630759|Experimental|Telemonitoring|The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
9802519|NCT05199090|Active Comparator|MBL949 Arm 3|One dose G followed by seven doses D of MBL949
9802520|NCT05199090|Active Comparator|MBL949 Arm 4|One dose A followed by seven doses B of MBL949
10010269|NCT01630759|Active Comparator|Control group|Control group will consist of usual care and review at clinic.
10010270|NCT01630798|Experimental|Application of peptide|
10010271|NCT01630824|Other|Education|Kidney transplant recipients, who undergo the structured education program
10010272|NCT01630824|No Intervention|Control|Kidney transplant recipients without structured education programm
10010273|NCT01630837|Other|12h|Frequency of oral hygiene was 12 to 12 hours.
10010274|NCT01630837|Other|24h|Frequency of oral hygiene was 24 to 24 hours.
10010275|NCT01630837|Other|48h|Frequency of oral hygiene was 48 to 48 hours.
10010276|NCT01630837|Other|72h|Frequency of oral hygiene was 72 to 72 hours.
10010277|NCT01630850|Experimental|Allogenic islet cells (human, U. Chicago)|
10010278|NCT01630863|Experimental|50% group|power of PDT is applied to the patients at 50% of the full energy based on TAP study.
10010279|NCT01630863|Experimental|40% group|Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
10010280|NCT01630863|Experimental|30% group|Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
10010281|NCT01630876|Sham Comparator|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
10010282|NCT01630876|Experimental|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.
10010283|NCT01630928|Experimental|Renal sympathetic denervation|Patients with treatment resistant hypertension
10010284|NCT01630941|Active Comparator|Denosumab|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
10010285|NCT01630941|Placebo Comparator|saline|1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
10010286|NCT01630954|Active Comparator|Single evacuation of mole,|
10010287|NCT01630954|Active Comparator|Double evacuation of mole|
10010288|NCT01630967|Experimental|Degarelix|Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
10010289|NCT01630993|Experimental|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
10010290|NCT01630993|No Intervention|Immediate Cord Clamping|At birth, the infant will be held at the level of the placenta and umbilical cord will be clamped within 10 seconds (routine practice).
10010291|NCT01631006|Sham Comparator|Low CPAP pressure|Patients are submmited to a CPAP with low pressure for 20 minutes
10010292|NCT01631006|Active Comparator|High CPAP pressure|Patients are submmited to a high pressure of CPAP for 20 minutes
10010293|NCT01631019|Active Comparator|with mobile phone assistance|In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
10010294|NCT01631019|Placebo Comparator|with free walk|Patients in the control group were educated the same exercise protocol, but were only verbally asked to freely take the walking exercise training at home. The adherence to the walking exercise at home was reported by the patients themselves at every return visits. All the patients received ISWT, spirometry and blood sample for inflammatory biomarkers at baseline, 1, 2, 3 and 6 months.
9802521|NCT05199090|Active Comparator|MBL949 Arm 5|One dose C followed by two doses E followed by five doses F of MBL949
9964304|NCT01237561|Experimental|spirometry, patient activation tool|"Receive Portable Spirometer~Spirometry training of staff~Provide clinician with web-based COPD interactive guideline tool~Provide clinician with patient activation tool~Train clinicians (tools, integration into workflow)~Academic Detailing"
9964305|NCT01237561|No Intervention|Usual Care|Spirometer and spirometry training of staff
9964306|NCT01237574||Patients|Patients with chronic alcoholic and/or metabolic liver disease
9964307|NCT01237600|Experimental|Cultivated limbal transplantation|
9964308|NCT01237639|Experimental|Restrictive Red blood cell Transfusion|Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L
9964309|NCT01237639|Active Comparator|Liberal Red blood Cell Transfusion|Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L
9964310|NCT01237652||ISH and normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
9964311|NCT01237652||ISH, Normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
9964312|NCT01237665|Experimental|IXO regimen|single-group
9964313|NCT01237691|Experimental|HOPE supervision|Parolee supervised under California's new HOPE parole model.
10010295|NCT01631032|Placebo Comparator|Control|control group receive placebo capsule with same look, smell and flavor compared with experiment group. The scheme for medication is 3 times a day, 3gm each time, total 9gm per day.
10035615|NCT01808105|Other|Human Milk|Reference group, breast feeding ad libitum
9964314|NCT01237691|Active Comparator|Parole-as-usual|Parolees supervised under California parole-as-usual.
9964315|NCT01237704|Active Comparator|Traditional rehabilitation (TR)|
9964316|NCT01237704|Active Comparator|Transcutaneous electrical stimulation (ES)|
9964317|NCT01237717||normotensive subjects|subjects without hypertension, and without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,
9964318|NCT01237717||Hypertensive subjects|"subjects with hypertension,~currently not treated at least within 6 months~without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,"
9964319|NCT01237730|Active Comparator|Cefuroxime group|Use the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
9964320|NCT01237730|Experimental|Tailored antibiotics group|Tailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
9964321|NCT01237756|Experimental|pediatric|
9964322|NCT01237769|Active Comparator|Vitamin D|All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.
9964323|NCT01237769|Active Comparator|Lifestyle measures|
9964324|NCT01237782|Experimental|Propolis solution|A proprietary denture cleanser with propolis as the active agent.
9964325|NCT01237782|Placebo Comparator|Saline solultion|Physiologic saline solution.
9964326|NCT01237795|Experimental|0.01% fluorosurfactant|An experimental formula for denture hygiene containing 0.01% fluorosurfactant.
9964327|NCT01237795|Experimental|1.0% chloramine T|An experimental formula for denture hygiene containing 1.0% chloramine T.
9964328|NCT01237795|Experimental|0.2% chloramine T|An experimental formula for denture hygiene containing 0.2% chloramine T.
9964329|NCT01237795|Active Comparator|Proprietary dentifrice.|A proprietary denture-specific dentifrice.
9964330|NCT01237808|Active Comparator|Standard arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA
9964331|NCT01237808|Experimental|Investigational arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)
9964332|NCT01237834||Heavy smokers, 15 or more cigarettes/day|Nicotine dependent.
9964333|NCT01237834||Light smokers (chippers)|Less than 2 cigarettes/day, at least 2 days/week. Non nicotine-dependent.
9964334|NCT01237834||Non smokers|
9964335|NCT01237847|Other|Wait List|
9964336|NCT01237847|Experimental|2 phone sessions|
9964337|NCT01237847|Experimental|4 phone sessions|
9964338|NCT01237873|Experimental|Ali/Amlo|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
9802522|NCT05199090|Placebo Comparator|Placebo|"MBL949 Arm 1, MBL949 Arm 2 and placebo to be enrolled in a 1:1:1 ratio~MBL949 Arm 3, MBL949 Arm 4 and placebo to be enrolled in a 1:1:1 ratio~If MBL949 Arm 1 is tolerated, MBL949 Arm 5 to be enrolled with a 2:1 ratio (MBL:placebo) within each stratum. MBL949 arm 5 will have 12 participants and 6 participants added to placebo arm"
9802523|NCT05197257|Experimental|Men with pathologically proven prostate adenocarcinoma|The intervention is a PET scan with the radiolabelled PSMA ligand, 68Ga-PSMA-11. The PET may be combined with a CT scan as a PET/CT or an MRI scan as PET/MRI. 68Ga-PSMA-11 PET/CT will be acquired using a modern digital GE PET/CT scanner or a modern digital PET / MRI scanner.
9964339|NCT01237925|Experimental|Dexchlorpheniramine 1% gel|
9964340|NCT01237925|Active Comparator|Dexchlorpheniramine 1% cream|
9964341|NCT01237938|Experimental|Low Glycemic Diet|
9964342|NCT01237964|Experimental|Xiaflex ( Collagenase use)|all 10 patients will be selected from out burn's clinic pool and will be injected using collagenase
9964343|NCT01237977|Experimental|Botulinum toxin type A(Meditoxin®)|
9964344|NCT01237977|Active Comparator|Botulinum toxin type A(Botox®)|
9964345|NCT01238003||Hospitalized patients|
9964346|NCT01238016|Other|device|Device implant and EEG recording
9964347|NCT01238029|Experimental|Capecitabine, Lapatinib, Vinorelbine|
9964348|NCT01238042|Experimental|Light Dose Escalation|Light Dose escalated from 150 joules/cm to 200 joules/cm
9964349|NCT01238055|Experimental|Docetaxel + Sunitinib|Docetaxel and Sunitinib
9964350|NCT01238055|Active Comparator|Docetaxel|Docetaxel only
9964351|NCT01238068|Active Comparator|Gamma nail, fracture stabilization, better walking|
9964352|NCT01238094|Experimental|FOLFIRI or XELIRI/simvastatin|FOLFIRI or XELIRI/simvastatin
9964353|NCT01238107|Experimental|High dose|
9964354|NCT01238107|Experimental|Low dose|
9964355|NCT01238107|Placebo Comparator|Placebo|
9964356|NCT01238133|Experimental|Treatment (RO4929097, paclitaxel, carboplatin, surgery)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17, paclitaxel IV over 60 minutes on days 1, 8, and 15 (day -1 of course one), and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after completion of neoadjuvant therapy, patients undergo definitive breast surgery.
9964357|NCT01238146|Experimental|Arm I|Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.
9964358|NCT01238146|Experimental|Arm II|Patients receive rituximab and bendamustine hydrochloride as in arm I.
9964359|NCT01238159|Experimental|CCRT+MIDLE|Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.
9964360|NCT01238224|Placebo Comparator|Placebo|A single dose of placebo is administered 30 min before a mixed meal.
9964361|NCT01238224|Active Comparator|Tadalafil|A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
9964362|NCT01238237|Experimental|Cetuximab|
9964363|NCT01238250||Copy Number Variants|Individuals with documented pathogenic or likely pathogenic copy number variants related to autism and other neurodevelopmental disorders.
9964364|NCT01238250||Gene Variants|Individuals with documented pathogenic or likely pathogenic variants in a gene related to autism and other neurodevelopmental disorders.
9964365|NCT01238289|Placebo Comparator|Control group|This arm continues with standard care at community clinic
9964366|NCT01238289|Experimental|Peer Education|This group receives 8 weeks of peer led self management education classes and subsequent monthly support groups for a total of 10 months
9964367|NCT01238302|Placebo Comparator|Conventional group|
9964368|NCT01238302|Experimental|PRP group|
9964369|NCT01238315|Other|HuCNS-SC|
9964370|NCT01238328|Experimental|Transplantation|
9964371|NCT01238354|Active Comparator|Without friend|Being in the weight loss programme without friend or family member
9964372|NCT01238354|Experimental|With friend|Having the friend or family member stay together with the patient for 2-3 days for every 3 week stay at the clinic in the weight loss programme
9964373|NCT01238367|Experimental|recombinant factor VIII (N8)|
9964374|NCT01238380||Diabetes diagnosed under 30 years|Patients currently under 50 years of age diagnosed with diabetes under 30 years.
9964375|NCT01238393|Experimental|Ranibizumab|('intravitreal ranibizumab' )
9964376|NCT01238406|Experimental|MD-logic Artificial Pancreas (MDLAP) system|Use of the closed loop MD-logic Artificial Pancreas(MDLAP)System
9964377|NCT01238406|Active Comparator|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
9964378|NCT01238419|Experimental|Physiotulle|
9964379|NCT01238419|Placebo Comparator|Urgotul|
9964380|NCT01238432||Inpatient population|Children with asthma who are admitted to the hospital with an exacerbation.
9964381|NCT01238432||Outpatient population|Children with asthma who have not been admitted to the hospital with an exacerbation.
9964382|NCT01238432||Healthy controls|Children without asthma or any other chronic condition.
9964383|NCT01238458|Experimental|[18F]AV-45 PET amyloid binding imaging|
10010296|NCT01631032|Experimental|Chinese herbal products (CHP)|CHP group receive Qi-tonifying Chinese herbal products capsule, 3 times a day, 3gm each time, total 9gm per day
10010297|NCT01631045||15 min|Subjects post-meal brain MRI will be 15 minutes after breakfast.
10010298|NCT01631045||30 min|Subjects post-meal brain MRI will be 30 minutes after breakfast.
10010299|NCT01631045||60|Subjects post-meal brain MRI will be 60 minutes after breakfast.
10010300|NCT01631045||120|Subjects post-meal brain MRI will be 120 minutes after breakfast.
10010301|NCT01631045||180|Subjects post-meal brain MRI will be 180 minutes after breakfast.
10010302|NCT01631045||240|Subjects post-meal brain MRI will be 240 minutes after breakfast.
10010303|NCT01631045||300|Subjects post-meal brain MRI will be 300 minutes after breakfast.
10010304|NCT01631058|Experimental|Everolimus|"Number of patients: 45 Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
10010305|NCT01631123|Experimental|Diet interventions|Sequential dietary intervention
10010306|NCT01631136|Active Comparator|Continuous maintenance Therapy|Induction chemotherapy by cisplatin + pemetrexed and maintenance therapy by pemetrexed
10010307|NCT01631136|Experimental|Maintenance according to the response of induction|"Induction chemotherapy by cisplatin + gemcitabine followed by :~continuous maintenance therapy by gemcitabine if response disease~switch maintenance therapy by pemetrexed if stable disease"
10010308|NCT01631162|No Intervention|lung disease|
10010309|NCT01631175|Experimental|(PO-Bado, FBK-R10, PHQ) Active Comparator|
10010310|NCT01631201|Experimental|Rifalazil 25 milligram|
10010311|NCT01631201|Active Comparator|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
10010312|NCT01631240||Adults 18-39 years|Healthy adults aged 18-39 years
10010313|NCT01631253|Active Comparator|single-port access laparoscopic ovarian cyst enucleation|Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)
10010314|NCT01631253|Active Comparator|two-port laparoscopic access ovarian cyst enucleation|Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.
10010315|NCT01631253|Active Comparator|four-port access laparoscopic ovarian cyst enucleation|Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.
10010316|NCT01631266|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
10010317|NCT01631266|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
10010318|NCT01631279|Experimental|PR610|
10010319|NCT01631305|Experimental|Levothyroxine|3 mcg/kg/day
10010320|NCT01631305|Placebo Comparator|Control|Calcium magnesia.
10010321|NCT01631318|Experimental|Diagnostic (3D contrast-enhanced ultrasound imaging)|Patients undergo 3D dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy and at 2 weeks.
10010322|NCT01631344|No Intervention|Physical Therapy|Conventional Physical Therapy
10010323|NCT01631344|Experimental|Daily physical activity consultation, Using Stage of change|
10010324|NCT01631357|Experimental|Arm 1: CIK+CT|Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.
10010325|NCT01631357|Active Comparator|Arm 2: CT|Arm 2: We design chemotherapy alone as a control arm
10010326|NCT01631370|Experimental|Renal denervation|The patients will be examined prior to renal denervation and 6 months after. Thus the patients are their own controls.
10010327|NCT01631383|Placebo Comparator|Placebo|
10010328|NCT01631383|Active Comparator|l-THP|
10010329|NCT01631396||Patients recieving Sugammadex|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
10010330|NCT01631396||Patients recieving Neostigmine|Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
10010331|NCT01631409||Cohort 0|"Cohort 0 is allocated for the following two patient groups:~The patients with suspicion of angina although in whom the thorough investigation has not revealed CHD and the pain syndrome has been received the extracardiac interpretation (e.g. vertebral osteochondrosis, left side humeroscapular periarthritis, herpes zoster, intercostal neuralgia Tietze syndrome etc.)~The patients with subclinical manifestation of coronary atherosclerosis without angina (Class 0 angina, here and further is according to the Canadian Cardiovascular Society Angina Classification). This subgroup of the patients is recommended the proper diet, life style modification, lipid targeting medications in some cases, and no antianginal treatment."
10010332|NCT01631409||Cohort I|Represents patients with Class 1 angina, who receive OMT.
10010333|NCT01631409||Cohort II|"Comprises the patients with Class 2-4 angina, they are on MAAMT. The cohort is further divided in two groups:~The patients for whom MAAMT is effective.~The patients for whom MAAMT is not effective or not sufficiently effective, although those patients have not received any invasive, surgical or CSWT interventions yet.~They are those patients who then form cohorts III-VI."
10010334|NCT01631409||Cohort III|Consists of patients already received PCA. They also continue various MAAMT.
10010335|NCT01631409||Cohort IV|Includes the patients after CABG. They also are on various MAAMT.
10010336|NCT01631409||Cohort V|Incorporates the patients who have already underwent CSWT. They also receive individualized MAAMT.
10010337|NCT01631409||Cohort VI|"The cohort is composed of the patients who for various reasons have not been exposed to any intervention except MAAMT and continue to be on it.~The algorithm of the cohort formation is graphically demonstrated in the Diagram The logic tree of the cohort formation (see the link at the bottom of the protocol)."
10010338|NCT01631422|Experimental|Single Arm|
10010339|NCT01631448|No Intervention|Control|Patients fron this group do not receive the fibrin sealant
10010340|NCT01631448|Active Comparator|Fibrin group|Patients from this group will receive the fibrin sealant
10010341|NCT01631461||1. Deep pain group|1. Deep pain group; Pain in the breast
10010342|NCT01631461||2. Superficial pain group|Pain on the nipple and/or aereola
10010343|NCT01631461||3. Control group|No pain or other breastfeeding problems
10010344|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 1)|
10010345|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 1)|
10010346|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 1)|
10010347|NCT01631487|Experimental|Caucasian Group 1: JNJ-39439335/placebo (Part 1)|
10010348|NCT01631487|Experimental|Caucasian Group 2: JNJ-39439335/placebo (Part 1)|
10010349|NCT01631487|Experimental|Caucasian Group 3: JNJ-39439335/placebo (Part 1)|
10010350|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 2)|
10010351|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 2)|
10010352|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 2)|
10010353|NCT01631500|Other|Conventional treatment|Patients receive usual treatments provided at primary care settings, e.g. antidepressants, sessions with a curator or psychotherapist and physiotherapy.
10010354|NCT01631500|Experimental|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
10010355|NCT01631500|Active Comparator|Terapeutic acupuncture|Therapeutic acupuncture alone, eight individual sessions, once a week. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
10010356|NCT01631513|Experimental|Nucynta ER|Nucynta ER will be 100 to 250 mg every 12 hours
10010357|NCT01631526|Experimental|Vitamin D|vitamin D 20,000 IU per day for 2 weeks followed by 10,000 IU per day for a further 7 days
10010358|NCT01631539|Other|Chemoembolization|chemoembolization with DC Bead™ loaded with Irinotecan
10010359|NCT01631565|No Intervention|Standard care|Usual care given to the patients. Treatment, follow-up.
10010360|NCT01631565|Experimental|Early Palliative Care|"Intervention: Early allocation to palliative care. Intervention: Nutritional counseling. Intervention: patient and care-taker psychoeducation, depression and anxiety evaluation.~Standard of care: Oncological treatment according to stage of disease (IIIb/IV).~Treatment: Chemotherapy (platins, taxans, TKIs) Baseline: BMI, and anthropometric characteristics (weight, height). Follow-up: During 6 chemotherapy circles with: Quality of Life (EORTC qlq-c30), HADS, ESAS and ZARIT."
10035616|NCT01808105|Active Comparator|Control Formula|Ready to feed infant formula, feed ad libitum
10035617|NCT01808105|Experimental|Experimental Formula 1|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
10035618|NCT01808105|Experimental|Experimental Formula 2|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
10035619|NCT01808131|Experimental|lesinurad 200 mg + allopurinol|
10035620|NCT01808131|Experimental|lesinurad 400 mg + allopurinol|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 4, dated 07 October 2015.
10035621|NCT01808157|Experimental|0.05% w/w CT327 ointment|Active
10035622|NCT01808157|Experimental|0.5% w/w CT327 ointment|Active
10035623|NCT01808157|Placebo Comparator|vehicle|Placebo
10035624|NCT01808170|Active Comparator|laparoscopic ovarian cystectomy|laparoscopic ovarian cystectomy will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
10035625|NCT01808170|Active Comparator|laparoscopic cyst deroofing|laparoscopic cyst deroofing will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
10035626|NCT01808235|Experimental|Oral health intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
10035627|NCT01808261|Placebo Comparator|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
10035628|NCT01808261|Active Comparator|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
10035629|NCT01808274|Experimental|TAVR|with CENTERA self-expanding valve
10035630|NCT01808287|Experimental|High risk population|SAPIEN 3 transcatheter heart valve was implanted in high risk patients
10035631|NCT01808287|Experimental|Intermediate risk population|SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients
10035632|NCT01808300|Experimental|A-B-C|Drug will be administered to according to A-B-C sequence for 3 period.
10035633|NCT01808300|Experimental|A-C-B|Drug will be administered to according to A-C-B sequence for 3 period.
10035634|NCT01808300|Experimental|B-C-A|Drug will be administered to according to B-C-A sequence for 3 period.
10035635|NCT01808300|Experimental|B-A-C|Drug will be administered to according to B-A-C sequence for 3 period.
10035636|NCT01808300|Experimental|C-A-B|Drug will be administered to according to C-A-B sequence for 3 period.
10035637|NCT01808300|Experimental|C-B-A|Drug will be administered to according to C-B-A sequence for 3 period.
10035638|NCT01808352|Other|Daily PrEP + coordination of client centered svs|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
10035639|NCT01808365||Study cohort|
9964384|NCT01238484|Active Comparator|Control|Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
9964385|NCT01238484|Experimental|Experimental|Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.
9964386|NCT01238497||Registry 1 - SOURCE XT|Registry 1: All patients implanted with a SAPIEN XT valve, via Transfemoral access using NovaFlex (for 23mm and 26mm valve), or via Transapical access using Ascendra2 (23mm, 26mm and 29mm valve)
9964387|NCT01238497||Registry 2 - Ascendra+|Registry 2: All patients implanted with a SAPIEN XT Valve, via Transapical or Transaortic access using Ascendra+ delivery system (23mm, 26mm and 29mm valve)
9964388|NCT01238497||Registry 3 - NovaFlex+ 29 mm|Registry 3: All patients implanted with a SAPIEN XT valve, 29mm only, via Transfemoral access using NovaFlex+
9964389|NCT01238510|Active Comparator|Provisional fKBT|Stent technique that final kissing balloon technique(fKBT) is performed if side branch flow was aggravated to TIMI0-2 after stent deployment
9964390|NCT01238510|Active Comparator|Routine fKBT|Stent technique that fKBT was mandatory irrespective of side branch flow after stenting.
9964391|NCT01238523|Experimental|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
9964392|NCT01238523|Experimental|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
9964393|NCT01238562|Experimental|YPEG-Filgrastim, 10mcg/kg|
9964394|NCT01238562|Experimental|YPEG-Filgrastim, 20mcg/kg|
9964395|NCT01238562|Experimental|YPEG-Filgrastim, 30mcg/kg|
9964396|NCT01238562|Experimental|YPEG-Filgrastim, 45mcg/kg|
9964397|NCT01238562|Experimental|YPEG-Filgrastim, 60mcg/kg|
9964398|NCT01238614|Experimental|PSF-JIT|Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.
9964399|NCT01238614|Experimental|PSF|Mothers in this arm receive screening questions on the prescreener form
9964400|NCT01238614|Placebo Comparator|Control|Mothers in this arm receive no maternal depression CHICA additional care
9964401|NCT01238627|Experimental|Nicotine Sublingual Tablet Mint (NSTM)-2|Experimental 2 mg NSTM
9964402|NCT01238627|Active Comparator|Microtab-2|2 mg Nicotine tablet
9964403|NCT01238627|Experimental|NSTM-4|Experimental 4 mg Nicotine Sublingual Tablet Mint
9964404|NCT01238627|Active Comparator|Microtab-4|2 x 2 mg Nicotine tablet
9964405|NCT01238679|Experimental|Cohort 1|Participants received an oral solution of 0.03 milligrams (mg) of PF-04958242, every 12 hours for 14 days.
9964406|NCT01238679|Experimental|Cohort 2|Participants received an oral solution of 0.05 mg of PF-04958242, every 24 hours for 14 days.
9964407|NCT01238679|Experimental|Cohort 3|Participants received an oral solution of 0.10 mg of PF-04958242, every 24 hours for 14 days.
9964408|NCT01238679|Experimental|Cohort 4|Participants received an oral solution of 0.15 mg of PF-04958242, every 24 hours for 14 days.
9964409|NCT01238679|Experimental|Cohort 5|Participants received an oral solution of 0.20 mg of PF-04958242, every 24 hours for 14 days.
9964410|NCT01238679|Experimental|Cohort 6|Participants received an oral solution of 0.25 mg of PF-04958242, every 24 hours for 14 days.
9964411|NCT01238679|Placebo Comparator|Matching Placebo|Participants received an oral solution of matching placebo, every 12 or 24 hours for 14 days.
9964412|NCT01238692|Experimental|LBH589|
9964413|NCT01238692|Experimental|LBH589 plus Rituximab|
9964414|NCT01238705|Active Comparator|Felodipine,Irbesartan,Sexual Dysfunction|
9964415|NCT01238705|Active Comparator|Felodipine,Metoprolol,Sexual Dysfunction|
9964416|NCT01238718|Active Comparator|lidocaine|
9964417|NCT01238718|Placebo Comparator|normal saline|
9964418|NCT01238731||Valve replacement|Patients undergoing valve replacement for severe valve disease will be screened for study entry
9964419|NCT01238744|Placebo Comparator|Study I: control drink|
9964420|NCT01238744|Experimental|Study I: flaxseed drink|
9964421|NCT01238744|Active Comparator|Study II: flaxseed drink|
9964422|NCT01238744|Experimental|Study II: flaxseed tablets|
9964423|NCT01238757|Active Comparator|Non-Invasive Pressure support|"in this arm, non-invasive pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS) with ETS +15% with ETS -15%"
9964424|NCT01238757|Active Comparator|NAVA|"Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm. Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.~The proportion named gain is chosen to obtain under NAVA the same peak pressure than during Presure Support"
9964425|NCT01238770|Experimental|Cyclophosphamid + Pazopanib|Cyclophosphamid + Pazopanib
9964426|NCT01238783|Experimental|AL-15469A 0.5% and AL-65150.3% Ophthalmic Suspension|
9964427|NCT01238783|Experimental|AL-15469A 0.5%|
9964428|NCT01238783|Experimental|AL-6515 0.3%|
9964429|NCT01238783|Placebo Comparator|Vehicle|
9964430|NCT01238796|Experimental|Normal renal function|Subjects with normal renal function
9964431|NCT01238796|Experimental|Severe renal impairment|Subjects with severe renal impairment
9964432|NCT01238796|Experimental|End stage renal disease|Subjects with end stage renal disease
9964433|NCT01238809||1|
9964434|NCT01238874|No Intervention|No intervention|Mostly observational study with 1 patient global assessment.
9964435|NCT01238887|Placebo Comparator|microcrystalline cellulose|
9964436|NCT01238887|Active Comparator|Hydroxycitric acid|2800 mg divided in three doses per day
9964437|NCT01238887|Active Comparator|Hydroxycitric Acid|5400 mg divided into three doses per day
9964438|NCT01238913||benign esophageal lesions|All patients who have a benign esophageal lesion where it is medically indicated that they receive a stent.
9964439|NCT01238926|Experimental|PD vitamin supplementation|
10035640|NCT01808378|Experimental|Autologous Stem Cells|Autologous expanded adipose-derived stem cells
9802524|NCT05192265|Experimental|Pyramax™|Artesunate-pyronaridine is indicated for the blood-stage treatment of the two dominant strains of malaria: P. falciparum and P. vivax. The medicine is also available in a child-friendly granule formulation to enhance palatability in this vulnerable population. Dosing was administered according to body weight: 5 - <8kg - one sachet daily for 3 days; 8 - <15Kg - two sachets daily for 3 days; 15 - <20 Kg - three sachets daily for 3 days; 20 - <24 Kg - one tablet daily for 3 days; and 24 - <45 Kg - two tablets daily for 3 days.
9803681|NCT03555149|Experimental|Atezolizumab + Regorafenib|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
9964440|NCT01238926|Experimental|PD exercise intervention|
9964441|NCT01238926|Experimental|PD vitamin + exercise|
9964442|NCT01238926|No Intervention|PD control|
9964443|NCT01238939|Experimental|Treatment|
9964444|NCT01238965|Experimental|Arm I|Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46 hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9964445|NCT01238978|Experimental|Vildagliptin|
9964446|NCT01238978|Active Comparator|other Oral Antidiabetic Drug in a different therapeutic class|
9964447|NCT01239004|Placebo Comparator|Placebo|
9964448|NCT01239004|Experimental|Colesevelam|
9964449|NCT01239017|Experimental|Dose 1|SC REGN475 Dose 1 and IV Placebo
9964450|NCT01239017|Experimental|Dose 2|SC REGN475 Dose 2 and IV Placebo
9964451|NCT01239017|Experimental|Dose 3|SC REGN475 Dose 3 and IV Placebo
9964452|NCT01239017|Experimental|Dose 4|SC Placebo and IV REGN475 Dose 4
9964453|NCT01239017|Placebo Comparator|Dose 5|SC Placebo and IV Placebo
9964454|NCT01239030|Active Comparator|10 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
9964455|NCT01239030|Active Comparator|15 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
9964456|NCT01239030|Active Comparator|20 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
9964457|NCT01239030|Active Comparator|40 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
9964458|NCT01239030|Placebo Comparator|Placebo|Placebo Capsules
9964459|NCT01239069|Experimental|DE-110 ophthalmic suspension high dose|
9964460|NCT01239069|Experimental|DE-110 ophthalmic suspension low dose|
9964461|NCT01239069|Placebo Comparator|Placebo|
9964462|NCT01239095|Experimental|Green Tea and Milk Thistle Supplements|Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.
9964463|NCT01239134|Experimental|TRX518|
9964464|NCT01239147|Other|Whole grain diet|
9964465|NCT01239147|Other|Refined grain diet|
10010361|NCT01631578|Experimental|Injection of mitochondrial concentrate|A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
10010362|NCT01631578|Active Comparator|Control|ICSI will be performed conventionally.
10010363|NCT01631591||eosinophilic esophagitis|PATIENTS WITH A CURRENT DIAGNOSIS OF eosinophilic esophagitis.
10010364|NCT01631591||GERD|PATIENTS WITH A DIAGNOSIS WITH GERD.
10010365|NCT01631669|Experimental|Celebrex|Receive Celebrex
10010366|NCT01631669|No Intervention|Control|no placebo administered
10010367|NCT01631708|Active Comparator|Erythrocytapheresis|"Erythrocytapheresis is a procedure whereby whole blood is drawn from an individual and all elements except erythrocytes are returned to the donor. An automated filtration process removes the erythrocytes.~Those in arm 1 will have third weekly erythrocytapheresis until their SF is returned to the normal range."
10010368|NCT01631708|Sham Comparator|Plasmapheresis|"In plasmapheresis, the plasma is removed by the automated filtration process whilst other blood elements including erythrocytes are returned to the subject.~Those in arm 2 will have plasmapheresis with the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm."
10010369|NCT01631721||Cohort 1|Cohort of adolescents recruited in 2012-2013 of study
10010370|NCT01631721||Cohort 2|Cohort of adolescents recruited in year 2013-2014 of study
10010371|NCT01631721||Cohort 3|Cohort of adolescents recruited in year 2014-15 of study
10010372|NCT01631760||MicroRNA ages 5-12 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
10010373|NCT01631760||MicroRNA ages 13-55 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
10010374|NCT01631760||MicroRNA ages 56-85 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
10010375|NCT01631773||subjects w/ Nasal polyps & AERD disease|subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
10010376|NCT01631773||subjects w/ nasal polyps without AERD|subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
10010377|NCT01631786||Preserved ovaries|Ovaries or ovarian segments that have been fixed in 10% Formalin
10010378|NCT01631786||Fresh/non-preserved ovaries|Ovaries that have been surgically removed and placed in sterile saline
10010379|NCT01631799|Active Comparator|Femoral Block|One group received a femoral block for analgesia after surgery. Ropivacain was administered continuously for three days.
10010380|NCT01631799|Active Comparator|Epidural Analgesia|One group received an epidural analgesia after surgery for three days.
10010381|NCT01631838|Experimental|Tocotrienol-rich fraction 400mg|
10010382|NCT01631838|Experimental|Placebo|
10010383|NCT01631877|Experimental|enoxaparin with acenocoumarol|Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly. The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
10010384|NCT01631877|Placebo Comparator|Placebo|Injection placebo will be given for 5 days along with placebo tablets.
10010385|NCT01631890|Active Comparator|standard endotherapy|
10010386|NCT01631890|Experimental|Endoscopic Ultrasound assisted endoscopic glue injection|
10010387|NCT01631903|Experimental|Arm 2 (3mg)|
10010388|NCT01631903|Experimental|Arm 3 (6 mg)|
10010389|NCT01631903|Experimental|Arm 4 (12 mg)|
10010390|NCT01631903|Experimental|Arm 5 (24 mg)|
10010391|NCT01631903|Experimental|PK arm (12 mg)|PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
10010392|NCT01631916|Experimental|Corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
10010393|NCT01631916|No Intervention|Control|No intervention
10010394|NCT01631942|Experimental|Low dose (healthy subjects)|
10010395|NCT01631942|Experimental|Medium dose (subjects with haemophilia)|
10010396|NCT01631942|Experimental|High dose (subjects with haemophilia)|
10010397|NCT01631955||Cystitis|female with cystitis symptoms
10010398|NCT01631968|Experimental|Cement with erytromycin and colistin|In this group the knee arthroplasty was fixed with cement with erythromycin and colistin.
10010399|NCT01631968|Placebo Comparator|Cement without antibiotic|In this group the knee arthroplasty was fixed with standard cement, without any antibiotics.
10010400|NCT01631981|Experimental|PGL2001|PGL2001 + NETA followed by NETA-only follow-up period
10010401|NCT01631981|Placebo Comparator|Placebo|Placebo + NETA followed by NETA-only follow-up period
10010402|NCT01631994|Experimental|Oral Dissolving metoclopramide|Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
10010403|NCT01631994|No Intervention|control group|This is the control group that will only ingest the capsule during video capsule endoscopy.
10010404|NCT01632007|Experimental|SYR-472 100 mg|
10010405|NCT01632007|Active Comparator|Alogliptin 25 mg|
10010406|NCT01632007|Placebo Comparator|Placebo|
10010407|NCT01632033||Investigation for lower limb arteries|Patients referred for investigation of assumed peripheral artery disease (PAD)
10010408|NCT01632046|Active Comparator|BicaVera, dialysis|Two Parallel arms. If patient randomised to the BicaVera arm he will be dialysed with bicarbonate based PD fluid (BicaVera) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
10010409|NCT01632046|Active Comparator|Balance, dialysis|If patient is randomised to the Balance arm, he will be dialysed with lactate based PD fluid (Balance) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
10010410|NCT01632059||septical patients|inclusion criteria are severe sepsis and septical shock and must be > 18 y/o
10010411|NCT01632072|Experimental|Nutritional counseling|Dietary supplement
10010412|NCT01632072|No Intervention|No nutritional counceling|
10010413|NCT01632085|Other|Group SU (Single use or Laryngobloc ®) ®)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Laryngobloc ®.
10010414|NCT01632085|Other|Group R (Reusable handle)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Disposable Metal Blade.
10010415|NCT01632098||extremely obese|BMI ≥35kg/m2
9802525|NCT05192265|Active Comparator|Coartem™|"We used the standard six-dose regimen of artemether-lumefantrine dispersible tablets twice daily according to body weights. Each dispersible tablet contains 20mg of artemether/120mg of lumefantrine) and the patients were dosed as follows: 5 -<15Kg one tablet, 15 - <25 Kg two tablets, 25 - <35 Kg three tablets, and ≥35 Kg four tablets at the following dosing intervals:~0 hour - 1st dose;~8 hours - 2nd dose;~24 hours - 3rd dose;~36 hours - 4th dose;~48 hours - 5th dose~60 hours - 6th dose."
10010416|NCT01632098||obese|BMI 30-34.9kg/m2
10010417|NCT01632163|Experimental|Lixisenatide|24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
10010418|NCT01632163|Placebo Comparator|Placebo|24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
10010419|NCT01632176|No Intervention|Standard of care|Patients in the control group will not receive any intervention, but will receive standard care for dating abuse issues.
10010420|NCT01632176|Experimental|Intervention|Patients in the intervention group will participate in brief, motivational interview and one booster session to prevent adolescent dating abuse.
10010421|NCT01632189|Experimental|Varenicline|Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.
10010422|NCT01632254||Patients with ≥70% carotid artery stenosis|
10010423|NCT01632293|Experimental|exercise|Individuals with multiple sclerosis and age and gender matched healthy controls will participate in a supervised exercise program for 12 weeks.
10010424|NCT01632319|Experimental|MI + CBT|Motivational Interviewing (MI) and cognitive behavioral therapy (CBT). In this course of therapy students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms.
10010425|NCT01632319|Active Comparator|CBT|Cognitive behavior therapy (CBT)
10010426|NCT01632332|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
10010427|NCT01632358|Experimental|TAP311 capsules|Patients will receive TAP311 capsule orally once daily for 14 days.
10010428|NCT01632358|Placebo Comparator|Placebo of TAP311 capsules|Matching placebo to TAP311 capsule, once daily for 14 days
10010429|NCT01632371|Experimental|Paclitaxel Eluting Balloon + Scoring Balloon|Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon
10010430|NCT01632371|Active Comparator|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon
10010431|NCT01632397|Experimental|CBT-based counseling|Cognitive behavioral based intervention to promote PrEP adherence.
10010432|NCT01632397|Active Comparator|Health education and supportive counseling|Time matched supportive counseling
10010433|NCT01632410||Study group 1|"Post hemispheral ischemic stroke cognitively intact. Exclusion: Subjects with severe visual or hearing impairments, stroke location brain steam.~The group will be divided in to 4 goups acording to stroke specific location as demonstrated in MRI."
10010434|NCT01632410||Control|Control: Healthy subjects resemble in age and sex
10010435|NCT01632410||Study -3|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
10010436|NCT01632410||Stydy -2|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
10010437|NCT01632410||Stydy- 4|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
10010438|NCT01632436|Experimental|Stage 1 -Moderate Hepatic Impairment|Pixantrone
10010439|NCT01632436|Experimental|Stage 2 - Severe Hepatic Impairment|Pixantrone
10010440|NCT01632449|Experimental|1|Test product
10010441|NCT01632449|Experimental|2|Reference product
10010442|NCT01632462|Active Comparator|VSL#3 arm|15 patients with a diagnosis of Crohn's disease will be exposed to VSL#3 for 8 weeks
10010443|NCT01632462|Placebo Comparator|placebo group|15 patients affected by Crohn's disease will be exposed to a placebo for 8 weeks
10010444|NCT01632475||Pneumostem®|Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
10010445|NCT01632488||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting Rome III criteria of irritable bowel syndrome.
10010446|NCT01632488||Inflammation|Patients with long standing history or short onset of inflammatory bowel disease.
10010447|NCT01632488||Normal controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
10010448|NCT01632514|Active Comparator|Vitamin D deficiency treatment|subjects with 25OHD < 20 ng/mL that will receive 100,000U of cholecalciferol weekly for 4 weeks before surgery
10010449|NCT01632514|No Intervention|Vitamin D deficiency observation|subjects with 25OHD < 20 ng/mL that will not receive cholecalciferol before surgery
10010450|NCT01632514|No Intervention|Vitamin D sufficiency|controls with 25OHD >= 20 ng/mL that will not receive cholecalciferol before surgery
10010451|NCT01632527|Experimental|HuCNS-SC|HuCNS-SC cells
10010452|NCT01632540||Perennial Allergic Rhinitis patients|
10010453|NCT01632553||Cases|women who have experienced DVA
10010454|NCT01632553||Controls|women who have not experienced DVA
10010455|NCT01632592|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
10010456|NCT01632592|Placebo Comparator|Placebo|
10010457|NCT01632605|Experimental|Sirolimus|Daily single oral dose of 1-3mg sirolimus with an initial loading dose of 6mg.
10010458|NCT01632618|Experimental|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
10010459|NCT01632618|Active Comparator|Passive control intervention|Passive physical therapy interventions, including moist heat, ultrasound, massage and flexibility exercises
10010460|NCT01632631||PROcedure rehearsal|PROcedure rehearsal performed before real EVAR procedure No intervention
10010461|NCT01632631||No PROcedure rehearsal|no PROcedure rehearsal performed before real EVAR procedure No intervention
10010462|NCT01632657|Experimental|Sumatriptan|Subcutaneous injection of sumatriptan (6 mg)
10010463|NCT01632657|Placebo Comparator|Placebo|Matching placebo (0.9% saline)
10010464|NCT01632670|Experimental|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
10010465|NCT01632670|No Intervention|No music therapy|
10010466|NCT01632696|Experimental|I-124 PGN650 for PET/CT|
10010467|NCT01632722|Active Comparator|ArmA|
10010468|NCT01632722|Active Comparator|ArmB|
10010469|NCT01632748|Experimental|Modified Neurotech Vital Device|Checking to observe stimulation delivered using this device
10010470|NCT01632748|Active Comparator|Neurotech Vital Device|Checking to see if stimulation observed using this device
10010471|NCT01632761|Active Comparator|Vitamin D + fish oil|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
10010472|NCT01632761|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Dietary Supplement: Fish oil placebo Fish oil placebo
10010473|NCT01632761|Active Comparator|Vitamin D placebo + fish oil|"Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D3 placebo Vitamin D placebo"
10010474|NCT01632761|Active Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement:Vitamin D3 placebo Vitamin D placebo Dietary Supplement: Fish oil placebo Fish oil placebo
10010475|NCT01632813||CHD group|Seven-year-old children with CHD who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). The children of the CHD-group underwent cardiac surgery as infants (=<1year).
10010476|NCT01632813||Control group|Seven-year-old healthy control children who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). These children have never undergone cardiac surgery.
10010477|NCT01632839||Vaginal surgery +prothesis +sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are sexually active.
10010478|NCT01632839||Vaginal surgery +prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are NOT sexually active.
10010479|NCT01632839||Vaginal surgery -prothesis + sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are sexually active.
10010480|NCT01632839||Vaginal surgery -prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are NOT sexually active.
10010481|NCT01632839||Abdominal surgery +sexuality|The 50 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are sexually active.
10010482|NCT01632839||Abdominal surgery -sexuality|The 25 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are NOT sexually active.
10010483|NCT01632839||Urinary incontinence surgery + sexuality|The 50 patients included in this group will have surgery for urinary incontinence; these patients are sexually active.
10010484|NCT01632839||Urinary incontinence surgery - sexuality|The 25 patients included in this group will have surgery for urinary incontinence; these patients are NOT sexually active.
10010485|NCT01632852|Experimental|CSL362|See Intervention Description
10010486|NCT01632865|Experimental|recanalization and stenting|
10010487|NCT01632917|Experimental|ATX-101 - EU|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
10010488|NCT01632917|Experimental|ATX-101 - US|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
10010489|NCT01632943|Experimental|Symplicity renal denervation system|
10010490|NCT01632956||in-person support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
10010491|NCT01632956||virtual support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
10010492|NCT01632969||families or next-of-kin of deceased patients|The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
10010493|NCT01632982|Other|standard treatment|the standard drug counseling offered to patients in methadone maintenance treatment at the study site
10010494|NCT01632982|Experimental|Mobile Therapeutic System (MTS)|The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
10010495|NCT01632982|Active Comparator|mobile control|a mobile phone-based application that directs participants to the NIDA website's home page
10010496|NCT01633008|Experimental|1|Attend three 2-hour sessions held over two consecutive days
10010497|NCT01633047|Experimental|Electrical stimulation|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training) associated with electrostimulation.
9667647|NCT03289910|Experimental|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10010498|NCT01633047|Active Comparator|Physical therapy exercises|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training).
10010499|NCT01633073|Active Comparator|LMA Supreme|
10010500|NCT01633073|Active Comparator|i-gel|
10010501|NCT01633086|Active Comparator|nitric oxide gel|"st gel: sodium nitrites~nd gel: maleic/ascorbic acids"
10010502|NCT01633086|Placebo Comparator|Placebo gel|"st gel: phosphate-buffered saline~nd gel: maleic/ascorbic acids"
10010503|NCT01633099|Other|Decitabine, CR rate,OS,EFS,RFS|Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
10010504|NCT01633125|Experimental|Group music therapy|Participants in the experimental group will take part in biweekly group music therapy for 10 weeks (20 sessions). Each group will be formed by 6 to 8 people, and each session will last for 90 minutes.The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The active techniques will include musical improvisation as a medium to work with participants according to therapeutic goals and participants' needs.
10010505|NCT01633125|No Intervention|No music therapy|Participants assigned to the control group will not receive any specific treatment in this study. The usual care that is normally available at the prison will continue to be available for all participants during the study.Due to ethical considerations, the control group will receive group music therapy or psychotherapy by academically qualified therapists for 5 weeks after the study is finished.
10010506|NCT01633138|Active Comparator|CRT-S|Cognitive Remediation Therapy - Standard
10010507|NCT01633138|Experimental|CRT-CM|Cognitive Remediation Therapy plus Contingency Management
10010508|NCT01633151||20 volunteers|
10010509|NCT01633164|Experimental|SCI Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
10010510|NCT01633164|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 30 weeks during which the interventional group will receive the active treatment and have their progress tracked.
10010511|NCT01633177|Active Comparator|Vitamin D and Omega-3|
10010512|NCT01633177|Active Comparator|Vitamin D and Omega-3 placebo|
10010513|NCT01633177|Active Comparator|Vitamin D placebo and Omega-3|
10010514|NCT01633177|Placebo Comparator|Vitamin D placebo and Omega-3 placebo|
10010515|NCT01633190||Rotavirus|- Children (0-16 years of age)admitted to hospital (through to December 31, 2020)
10010516|NCT01633203||locally advanced gastric cancer|Patients with resectable, locally advanced cT3-4 and/or N+ gastric carcinoma treated with 3 perioperative epirubicin cisplatin capecitabine polychemotherapy
10010517|NCT01633216|Active Comparator|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
10010518|NCT01633216|Active Comparator|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
10010519|NCT01633216|Active Comparator|Monovalent OPV 2week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
10010520|NCT01633216|Active Comparator|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
10010521|NCT01633216|Active Comparator|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
10010522|NCT01633281|Experimental|acupuncture treatment|
10010523|NCT01633294|Active Comparator|Antibiotic group|women submitted to antibiotic prophylaxis
10010524|NCT01633294|No Intervention|Control group|
10010525|NCT01633307|Experimental|Experimental|Intervention (Teaching program)
10010526|NCT01633307|No Intervention|Control group|No teaching program
10010527|NCT01633333|Experimental|Water exchange|Colonoscopy with water exchange as the sole modality to reach the cecum. Carbon dioxide can be used in case of intubation failure with the test method.
10010528|NCT01633333|Active Comparator|Carbon dioxide insufflation|Carbon dioxide insufflation will be used in standard fashion to reach the cecum.
10010529|NCT01633346||Tocilizumab treated patients|Rheumatoid arthritis patients
10010530|NCT01633359|Experimental|Intensive statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Intensive Atorvastatin protocol indicates that 80mg Atorvastatin will be administrated before CAG, and then are followed with 20mg Atorvastatin during the entire study period."
10037274|NCT01823562|Experimental|Arm V (higher-dose black raspberry gummy)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
10010531|NCT01633359|Experimental|Routine statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period."
10010532|NCT01633385||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
10010533|NCT01633385||Control Group|age- and sex matched to subject-group
10035641|NCT01808391||Clinical Follow-up Cohort|The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
10035642|NCT01808391||Routine Angiographic Follow-up Cohort|The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
10035643|NCT01808404|Experimental|Web-Based Guided Self-Help|The study is an open trial and all participants will be assigned to the same intervention arm.
10035644|NCT01808417|Experimental|Near Infrared Imaging|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
10035645|NCT01808430||VATS for NSCLC patients|VATS for confirmed non-small cell lung cancer (NSCLC)
10035646|NCT01808443|Active Comparator|Cryotherapy|Cryotherapy, at most 4 times
10035647|NCT01808443|Experimental|laser|laser, at most 4 times
10035648|NCT01808456|Experimental|High Dose Flu Vaccine|influenza trivalent inactive vaccine high dose. IM (intramuscular) injection one time administration
10035649|NCT01808456|Active Comparator|Flu Vaccine|influenza trivalent inactive vaccine IM injection one time administration
10035650|NCT01808469|Experimental|NI-0101|NI-0101 is an anti-Toll-like receptor monoclonal antibody.
10035651|NCT01808469|Placebo Comparator|Placebo|The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance.
9667648|NCT03289910|Active Comparator|Arm B (topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9667649|NCT03287843|Experimental|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
10035652|NCT01808482|Experimental|Part A: GSK2618960|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session.
10035653|NCT01808482|Placebo Comparator|Part A: Placebo|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session
10035654|NCT01808482|Experimental|Part B: GSK2618960|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
10035655|NCT01808482|Placebo Comparator|Part B: Placebo|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
10035656|NCT01808482|Experimental|Part C: GSK2618960|Subjects will receive active treatments for 2 to 4 repeated doses (dose decided from Part A& B)
10035657|NCT01808521|Experimental|N-acetylcysteine|IV administration of N-acetylcysteine (Acetadote) at 150mg/Kg loading bolus over 60 minutes followed by 150mg/Kg over 17 hours if loading dose was well tolerated.
10035658|NCT01808586|Experimental|Dexamethasone|Intra-articular corticosteroid number 2.
10035659|NCT01808586|Experimental|Betamethasone|Subjects will receive either betamethasone or dexamethasone injected into the cervical facet joints (levels determined by experienced physician).
10010534|NCT01633437|Placebo Comparator|Sugar pill|
10010535|NCT01633437|Experimental|CX157|CX157 is a reversible monoamine oxidase inhibitor (RIMA) in Phase II development for the treatment of depression.
10010536|NCT01633450|Experimental|Zinc biofortified rice|
10010537|NCT01633450|Active Comparator|Rice extrinsically fortified with zinc|
10010538|NCT01633476|Active Comparator|Valaciclovir|Active treatment with valaciclovir
10010539|NCT01633476|No Intervention|No additional treatment|No additional treatment
10010540|NCT01633489||LAL Deficiency patients|Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.
10010541|NCT01633502|Placebo Comparator|Conventional circulatory support|Patients randomized to conventional circulatory support.
10010542|NCT01633502|Active Comparator|Impella|Patients randomized to Impella CP
10010543|NCT01633515|Other|Intralesional cryotherapy|10 BCC (skin lesions) in the lower extremity of elderlies with risk factors for surgical complications.
10010544|NCT01633528|Experimental|Asprin|With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin.
10010545|NCT01633528|Placebo Comparator|placebo|With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo
10010546|NCT01633554||Chronic Hepatitis B Group|Patients with chronic hepatitis B
10010547|NCT01633554||Cirrhosis|Patients with liver cirrhosis
9476712|NCT03569046|Placebo Comparator|Group II|ear block by Normal Saline Flush, 0.9% Injectable Solution . general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
9476713|NCT03569007|Active Comparator|Larazotide 0.25 mg|Larazotide 0.25 mg capsules TID
9476714|NCT03569007|Active Comparator|Larazotide 0.50 mg|Larazotide 0.50 mg capsules TID
9476715|NCT03569007|Placebo Comparator|Placebo|Matching placebo capsules TID
10010548|NCT01633554||Control Group|Control Group: Healthy Volunteers
10010549|NCT01633567|Experimental|Culturally Targeted Cessation Program|The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
10010550|NCT01633567|Active Comparator|Non-Targeted Cessation Program|Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.
10010551|NCT01633580|Placebo Comparator|Day 2 group|Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
10010552|NCT01633580|Active Comparator|Day 4 group|Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
10010553|NCT01633593|Experimental|donepezil|Donepezil 5mg/day during 2 weeks
10010554|NCT01633593|Placebo Comparator|placebo|placebo comparator to donepezil (double blind)
10010555|NCT01633606||Acute patients|Patients admitted to the surgical and general ICU (including burn unit), to the coronary care unit, to the emergency department high care zone, to the medical ICU, to the medical medium care unit
10010556|NCT01633632|Active Comparator|Cognitive behavioral therapy|This group will receive a standardized, 8-session cognitive behavioral therapy course that is offered to the public at our practice.
10010557|NCT01633632|Experimental|Cognitive behavioral therapy + yoga|This group will receive the standardized, 8-session cognitive behavioral therapy course + 8 sessions of Hatha yoga.
10010558|NCT01633632|Experimental|Hatha yoga|This group will receive 8 sessions of Hatha yoga and printed materials to assist with their quit attempt
10010559|NCT01633645|Experimental|Velcade/GEM/CDDP|Bortezomib / Gemcitabine / Cisplatin
10010560|NCT01633658|Active Comparator|Vitamin D Cholecalciferol|A single dose of 2500 micrograms cholecalciferol
10010561|NCT01633658|Experimental|25(OH)D|A single dose of 625 micrograms 25(OH)D
10010562|NCT01633671||Suspected APE|Post-surgical patients with clinically suspected acute pulmonary embolism
10010563|NCT01633684||Diabetes|patients with Type 1 Diabetes Mellitus
10010564|NCT01633684||Control|Age and sex matched control subjects
10010565|NCT01633697|Experimental|Education-Pranayama|Subjects will receive education about COPD with special attention to breathing techniques
10010566|NCT01633697|Sham Comparator|Education-Control|Subjects will receive education alone about COPD.
10010567|NCT01633723|Experimental|DA-6886|
10010568|NCT01633723|Placebo Comparator|DA-6886 placebo|
10010569|NCT01633736|Experimental|home progressive resistance exercise|
10010570|NCT01633749|Experimental|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
10010571|NCT01633762|Experimental|meropenem, gentamicin, vancomycin|
10010572|NCT01633775||Ahmed glaucoma implant|
10010573|NCT01633775||Trabeculectomy with mitomycin C (MMC)|
10010574|NCT01633801|Other|High flows|
10010575|NCT01633801|Other|oxygen therapy|
10010576|NCT01633840|Active Comparator|Elemental E028 with added food allergens|
10010577|NCT01633840|Placebo Comparator|Elemental E028|
10010578|NCT01633866||Advances in Radio Frequency for MRI|advances in radio frequency (RF) coil magnetic resonance imaging (MRI)
10010579|NCT01633879|Experimental|parent education|audio-CD parent EDC supporting positive parenting practices
10010580|NCT01633879|Experimental|parent and school intervention|health and success parent and school intervention
10010581|NCT01633879|No Intervention|print materials|brochures to parents
10010582|NCT01633905||alcohol-dependent patients|22 recently detoxified participants diagnosed as alcohol-dependant on the basis of DSM-IV criteria who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
10010583|NCT01633905||control group|22 healthy controls without any psychiatric or neurological diagnosis who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
10010584|NCT01633918|Experimental|Internet-supported FeetEnergy approach|Schools which integrate Internet-supported approach with two home works in three health education lessons on physical activity
10010585|NCT01633918|Active Comparator|Usual health education|Schools which follow their usual practices in carrying out health education classes on physical activity
10010586|NCT01633957|Experimental|Genotype-based Warfarin Initiation|
10010587|NCT01633957|Active Comparator|clinical factor-based warfarin initiation|
10010588|NCT01633970|Experimental|A: Atezolizumab + Bevacizumab|Participants will receive atezolizumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion (or a selected dose level not to exceed the single agent MTD or MAD determined in Study PCD4989g) with bevacizumab 15 mg/kg every 3 weeks (q3w). After establishment of MTD or MAD, participants will receive bevacizumab 15 mg/kg IV infusion on Day 1 of Cycle 1 followed by atezolizumab 1200 mg IV infusion q3w after Days 5-7 and then atezolizumab 1200 mg q3w and bevacizumab 15 mg/kg q3w on Day 1 of all subsequent cycles until disease progression or unacceptable toxicity.
10010589|NCT01633970|Experimental|B: Atezolizumab + Bevacizumab + FOLFOX|Participants will receive FOLFOX IV infusion (oxaliplatin [85 milligrams per square meter {mg/m^2}], leucovorin [400 mg/m^2], 5-FU [400 mg/m^2]) on Day 1 of Cycle 1 and then atezolizumab 800 mg IV infusion every 2 weeks (q2w), bevacizumab 10 mg/kg IV infusion q3w and FOLFOX q2w on Day 1 of all subsequent cycles as per institutional guidelines until disease progression or unacceptable toxicity.
10010590|NCT01633970|Experimental|C: Atezolizumab + Carboplatin + Paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with paclitaxel 200 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) until disease progression or unacceptable toxicity.
10010591|NCT01633970|Experimental|D: Atezolizumab + Carboplatin + Pemetrexed|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with premetrexed 500 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
10010592|NCT01633970|Experimental|E: Atezolizumab + Carboplatin + Nab-paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w (on Day 1 of every 3-week cycle) in combination with nab-paclitaxel 100 mg/m^2 IV infusion once weekly (qw) (on Days 1, 8 and 15 of every 3-week cycle) and then carboplatin IV infusion q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
10010593|NCT01633970|Experimental|F: Atezolizumab + Nab-paclitaxel|Participants will receive atezolizumab 800 mg IV infusion q2w (Days 1 and 15) in combination with nab-paclitaxel 125 mg/m^2 IV infusion qw (on Days 1, 8 and 15 of every 3-week cycle) until disease progression or unacceptable toxicity.
10010594|NCT01633983|Experimental|Methotrexate|Chronic CSC will be given an immediate MTX treatment
10010595|NCT01633983|Experimental|Delayed treatment|Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered
10010596|NCT01633996|Experimental|Acupuncture|All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).
10010597|NCT01634009|Active Comparator|Standard RUTF (control)|Children will receive standard RUTF in this arm and will be considered as control arm
10010598|NCT01634009|No Intervention|Standard RUTF|Will act as control
10010599|NCT01634022|Experimental|Acupuncture|Adults with depression who are not currently taking an antidepressant medication.
10010600|NCT01634035||diabetic hemodialysis|all patient diabetic and on hemodialysis were involved if they are on hemodialysis for more than 3 months
10010601|NCT01634061|Experimental|Dose escalation: BEZ235 + Zytiga®|BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
9476716|NCT03568981||Partial Breast Irradiation (PBI)|Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer
10035660|NCT01808586|Active Comparator|Intramuscular injection|Subjects in this group will receive lidocaine injection directly into tender myofascial trigger points.
9964466|NCT01239173|Active Comparator|1|Post-traumatic stress disorder patient receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
9964467|NCT01239173|Placebo Comparator|2|Post-traumatic stress disorder receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
10010602|NCT01634061|Experimental|Dose escalation: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
10010603|NCT01634061|Experimental|Dose expansion: BEZ235 + Zytiga®|"BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate~Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label"
10010604|NCT01634061|Experimental|Dose Expansion: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
10010605|NCT01634074||OSA patients|Patients with Obstructive Sleep Apnea (OSA), or suspected OSA
10010606|NCT01634126|Active Comparator|1 FIT kit|
10010607|NCT01634126|Active Comparator|2 FIT kit|
10010608|NCT01634204|Experimental|KiloCoach|Study subjects use the KiloCoach program on at least 4 days per week within the first half of the 6 months intervention period. In the second half, program usage is ad libitum.
10010609|NCT01634204|No Intervention|Control|Study subjects try to reduce body weight on their own, without participating in an organized weight loss program, over a period of 6 months.
10010610|NCT01634217|Experimental|Cohort 1|Administered 3 x 10^6 iTregs/kg infusion
10010611|NCT01634217|Experimental|Cohort 2|Administered 3 x 10^7 iTregs/kg infusion
10010612|NCT01634217|Experimental|Cohort 3|Administered 3 x 10^8 iTregs/kg infusion
10010613|NCT01634217|Experimental|Cohort 4|Administered 10 x 10^8 iTregs/kg infusion
10010614|NCT01634217|Experimental|Cohort 5 Extension|Administered 10 x 10^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
10010615|NCT01634282|Experimental|OPC-262|
10010616|NCT01634295|Experimental|CKD-828 2.5/40, 2.5/80, 5/80mg|
10010617|NCT01634295|Active Comparator|S-Amlodipine 2.5, 5mg|
10010618|NCT01634308|Experimental|Novosis(bongros/BMP-2)|
10010619|NCT01634308|Active Comparator|Bio-oss|
10010620|NCT01634321|Experimental|Luphere|
10010621|NCT01634334|Experimental|Real-time Intervention|
10010622|NCT01634334|Active Comparator|Usual Education|Participants will receive usual education about secondhand and thirdhand smoke.
10010623|NCT01634347|Experimental|Propranolol and memory reactivation|
10010624|NCT01634347|Placebo Comparator|Placebo and memory reactivation|
10010625|NCT01634412|Experimental|SL TNX-102 at pH 3.5|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5
10010626|NCT01634412|Experimental|SL TNX-102 at pH 7.1|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1
10010627|NCT01634412|Active Comparator|Cyclobenzaprine tablets|5 mg cyclobenzaprine tablet once
10010628|NCT01634412|Active Comparator|Cyclobenzaprine IV|2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4
9964468|NCT01239173|Active Comparator|3|Controls receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
9476717|NCT03568981||Whole Breast Irradiation (WBI)|Patients receiving whole breast irradiation for breast cancer
9476718|NCT03568968|Experimental|Nicotinamide Riboside|nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is tablets.
9964469|NCT01239173|Placebo Comparator|4|Controls receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
9964470|NCT01239186||Oligozoospermia|infertile patients presenting a reduced sperm count (less than 20 Millions of spermatozoa/ml)
9964471|NCT01239199|Experimental|Exhaled NO|
9964472|NCT01239225|Experimental|Abdominal ultrasound|Abdominal ultrasound
9964473|NCT01239238||Care as usual|Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
9964474|NCT01239251||breast cancer patients taking endocrine therapy|Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
9964475|NCT01239277|Experimental|protein (elderly)|
9964476|NCT01239277|Experimental|protein and carbohydrate (elderly)|
9964477|NCT01239277|Experimental|protein and carbohydrate (young)|
9964478|NCT01239277|Experimental|protein and leucine (elderly)|
9964479|NCT01239303|Active Comparator|citrulline|
9964480|NCT01239303|Placebo Comparator|alanine|
9964481|NCT01239329||Complex multiple disabilities|People with complex multiple disabilities, living in a care institution participating in the Governor Kremers Centre (GKC.)
9964482|NCT01239368|Experimental|Cohort B - Relapsed Multiple Myeloma|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma
9964483|NCT01239368|Experimental|Cohort A - Prevention of Relapse|Th1/Tc1.Rapa Prevention of Relapse
9964484|NCT01239407|No Intervention|Treatment as usual|"The treatment as usual arm consists of two phone or in-person interviews:~Patients are asked questions about their mental health, their views of mental health, and how they cope with their mental health (including any treatment they might be receiving).~Patients are asked the same questions 6 months after the initial interview."
9964485|NCT01239407|Experimental|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
9964486|NCT01239433||mechanically ventilated patients|ICU patients on mechanical ventilation. Daily endotracheal suctioning performed to reduce secretions. Data recorded during these therapeutic interventions.
9964487|NCT01239459|Experimental|Severe impaired renal function|Subjects with severe renal impairment as defined by Cockroft-Gault formula
9964488|NCT01239459|Experimental|Normal renal function|Subjects with normal renal function as defined by Cockroft-Gault formula
9964489|NCT01239485|Experimental|Irinotecan|
9964490|NCT01239498|Experimental|Saline + Lidocaine/Adrenaline|
9964491|NCT01239498|Placebo Comparator|Lidocaine/Adrenaline only|
9964492|NCT01239524|Other|DE-group|surgical denervation by excising 1 cm of proximal thoracodorsal nerve
9964493|NCT01239524|Other|IN group|thoracodorsal nerve is saved intact
9964494|NCT01239537||Baxter H1N1 vaccine|Previously received 2 dose schedule of Baxter H1N1 vaccine
9964495|NCT01239537||GSK H1N1 vaccine|Previously received 2 dose schedule of GSK H1N1 vaccine
9964496|NCT01239550|Experimental|Insulin Detemir Treatment|"Insulin detemir treatment: Insulin detemir will be administered subcutaneously, once daily. Dose ranges from approximately 0.1 U/kg up to 0.6 u/kg or higher. The dosing regimen will employ a strategy similar to the 303algorithm, where, with close interaction with study personnel (rather than self-titration), bedtime insulin dosing will be titrated up by 3 units until AM fasting sugars within the prescribed protocol range are achieved (90-110 mg/dl). Subjects will have contact with study personnel on weekly basis for glycemia monitoring and adjustments. Similarly, documented hypoglycemia (blood sugars less than 70) will trigger a dose reduction, and it is expected that with weight loss, tolerable insulin dosages will drift downward. The treatment period is 24 weeks."
9665140|NCT05169658|Experimental|Treatment (mosunetuzumab, obinutuzumab, polatuzumab vedotin)|"PART A: Patients receive mosunetuzumab SC over 30 seconds-2 minutes on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.~PART B: Beginning cycle 9, patients who do not achieve a CR receive obinutuzumab IV on day 1 of cycle 9 and day 1 of subsequent cycles and polatuzumab vedotin IV on day 1. Treatment repeats every 21 day for 6 cycles in the absence of disease progression or unacceptable toxicity."
10010629|NCT01634425|No Intervention|Group 1 - no pre-hospital biomarkers|Standard of Care
10010630|NCT01634425|Experimental|Group 2 - pre-hospital biomarkers|Troponin and BNP measured on a POC meter in the ambulance on the way to the hospital.
10010631|NCT01634438|Experimental|low dose heparin|30 units per kilogram of unfractionated heparin
10010632|NCT01634438|Active Comparator|High dose heparin|70 units per kilogram of unfractionated heparin (UFH) intravenously
10010633|NCT01634451|Active Comparator|Education Package|2 ICUs; one large and one small. Randomised to receive bespoke education package for the 9 month intervention period
10010634|NCT01634451|Active Comparator|Education and Feedback|2 ICUs; one large and one small. Randomised to receive a bespoke education package and real-time,site specific, outcome process feedback they will disseminate to their staff for the 9 month intervention period.
10010635|NCT01634451|Active Comparator|Education and Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
10010636|NCT01634451|Active Comparator|Education, Feedback, Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package, real-time,site specific, outcome process feedback they will disseminate to their staff and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
10010637|NCT01634464||Control group|women with 18.5 > BMI < 25
10010638|NCT01634464||Pregnant women with overweight|BMI≥25 before the pregnancy
10010639|NCT01634464||Pregnant women with obesity|BMI≥30 before the pregnancy
10010640|NCT01634464||Pregnant women with gestational diabetes|Gestational diabetes
10010641|NCT01634477||HIV-infected patients group|HIV positive
10010642|NCT01634477||HIV-uninfected patients group|HIV negative
10010643|NCT01634490||infants receiving extensively hydrolysed casein formula|infants receiving extensively hydrolysed casein formula as substitutive formula
10010644|NCT01634490||extensively hydrolysed casein formula with Lactobacillus GG|infants receiving extensively hydrolysed casein with LGG as substitutive formula
10010645|NCT01634490||infants receiving rice hydrolyzed formula|infants receiving rice hydrolyzed formula as substitutive formula
10010646|NCT01634490||infants receiving soy-based formula|infants receiving soy-based formula as substitutive formula
10010647|NCT01634490||infants receiving amino-acid based formula|infants receiving amino-acid based formula as substitutive formula
10010648|NCT01634503|Experimental|1mg of GX-188E by electroporation|
10010649|NCT01634503|Experimental|2mg of GX-188E by electroporation|
10010650|NCT01634503|Experimental|4mg of GX-188E by electroporation|
10010651|NCT01634516|Experimental|Dietary support|Face to face intervention plus subsequent telephone support
10010652|NCT01634516|Placebo Comparator|No dietary support|No face to face intervention plus subsequent telephone support
10010653|NCT01634529|Experimental|Single Ascending Dose|Single ascending doses of V158866 compared to Placebo
10010654|NCT01634529|Experimental|Multiple ascending doses|Multiple ascending doses of V158866 compared to Placebo
10010655|NCT01634542||Cohort|
10010656|NCT01634568|Experimental|Single Ascending Dose|Single Ascending Doses of V81444 compared to placebo
10010657|NCT01634568|Experimental|Multiple Ascending Doses|Multiple ascending doses of V81444 compared to placebo
10010658|NCT01634594|Experimental|sevoflurane-remifentanil (group R)|Continuous infusion of remifentanil at 0.05 ~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC
10010659|NCT01634594|Active Comparator|sevoflurane-nicardipine (group N)|Continuous infusion of nicardipine at 1 ~ 7 mcg/kg/min with sevoflurane concentration of 1 MAC
10010660|NCT01634594|Active Comparator|sevoflurane-dexmedetomidine (group D)|Continuous infusion of dexmedetomidine at 0.2 ~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC
10010661|NCT01634607||HIV uninfected|HIV negative patients
10010662|NCT01634607||HIV-infected, HAART naïve, high CD4 count|HIV positive patients with high CD4 and not on HIV treatment
10010663|NCT01634607||HIV-infected with planned to start HAART group|HIV positive patients who will start HIV treatment
10010664|NCT01634646|Placebo Comparator|Overweight, elevated total cholesterol|All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
10010665|NCT01634672||hemodialysis patients|
10010666|NCT01634672||Peritoneal dialysis patients|
10010667|NCT01634685|Experimental|Bavituximab, Capecitabine, Radiation|one arm
10010668|NCT01634698|Experimental|RDR test (1500 UI vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
10010669|NCT01634698|Experimental|RDR test (2500 IU vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
10010670|NCT01634724|Experimental|GnRH agonist withdrawal|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group.
10010671|NCT01634724|No Intervention|control group|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. In the control group, GnRHa (triptorelin, 0.05mg/d,)was used to the day of ovulation trigger.
10010672|NCT01634737||Patients with shellfish allergy|Patients with symptoms of allergy to shellfish (OAS-Oral allergy syndrome and/or systemic symptoms) and circulating IgE positive for the extract of shrimp (> 0.10 kU/L)
10010673|NCT01634737||Patients with respiratory allergy|Patients with respiratory allergy and IgE positive to dust mites, asymptomatic for shrimp or other shellfish and circulating IgE positive for shrimp
10010674|NCT01634750|Experimental|ManNac|
10010675|NCT01634750|Placebo Comparator|Placebo|
10010676|NCT01634763|Experimental|Dose-escalation|Open-label dose escalation study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)
10010677|NCT01634763|Experimental|Dose-expansion|Open-label study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in ALK to see further safety, anti-tumor activity, and PK data in patients who has progressed since prior therapy with alectinib
10010678|NCT01634776|Placebo Comparator|Corn oil|1288 mg/day corn oil
10010679|NCT01634776|Experimental|Flaxseed oil|1200 mg/day flaxseed oil
10010680|NCT01634789|Experimental|Test Treatment 1: bazedoxifene|Test Treatment 1
10010681|NCT01634789|Experimental|Test Treatment 2: bazedoxifene|Test Treatment 2
10010682|NCT01634789|Experimental|Test Treatment 3: bazedoxifene|Test Treatment 3
10010683|NCT01634789|Experimental|Reference Treatment: bazedoxifene/conjugated estrogens|Reference Treatment
10010684|NCT01634802|No Intervention|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
10010685|NCT01634802|Experimental|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
10010686|NCT01634815|Experimental|lactate group|
10010687|NCT01634828||Minimal blood loss patients|
10010688|NCT01634828||Moderate to heavy blood loss patients|
10010689|NCT01634841|Active Comparator|Walnut group|This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
10010690|NCT01634841|Active Comparator|Control group|This group will eat their habitual diet and refrain from eating walnuts.
10010691|NCT01634867||Intraosseous (IO) drug delivery|patients in whom intraosseous (IO) vascular access has been established for rapid sequence intubation drug delivery.
10010692|NCT01634867||Peripheral intravenous (IV) drug delivery|patients in whom peripheral intravenous (IV) vascular access has been established for rapid sequence intubation drug delivery.
10010693|NCT01634880|Experimental|Postoperative Radiotherapy and Panitumumab|
10010694|NCT01634893|Experimental|Sorafenib plus Hydroxychloroquine|"Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
10010695|NCT01634906|Experimental|Discontinuation of statin therapy|
10010696|NCT01634919||Chronic hepatitis C|Chronic hepatitis C
10010697|NCT01634932|Experimental|regular-iron millet|
10010698|NCT01634932|Experimental|iron-biofortified millet|
10010699|NCT01634932|Experimental|Post-harvest iron-fortified millet|
10010700|NCT01634945|Placebo Comparator|Placebo|Placebo
10010701|NCT01634945|Experimental|FeFum porridge + IPT of malaria|
10010702|NCT01634945|Experimental|IPT of malaria|
10010703|NCT01634945|Experimental|FeFum porridge|
10010704|NCT01634945|Experimental|FePP porridge|
10010705|NCT01634958|Experimental|10.000 DPP/ml suspension for s.c. inj.|
10010706|NCT01634958|Experimental|5.000 DPP/ml suspension for s.c. inj.|
10010707|NCT01634958|Experimental|1.000 DPP/ml suspension for s.c. inj.|
10010708|NCT01634958|Experimental|100 DPP/ml suspension for s.c. inj.|
10010709|NCT01634971|No Intervention|External Drainage of pancreatic duct|External Drainage of pancreatic duct was used in PD.
10010710|NCT01634971|Experimental|Internal Drainage of Pancreatic Duct|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
10010711|NCT01635010|No Intervention|Control|
10010712|NCT01635010|Experimental|Obstructive sleep apnea|
10010713|NCT01635023|Experimental|AZD6244 white capsule|75mg AZD6244 white (current Phase II) capsule
10010714|NCT01635023|Experimental|AZD6244 blue capsule|75mg AZD6244 blue (planned Phase III) capsule
10010715|NCT01635023|Experimental|AZD6244 solution|35mg AZD6244 oral solution
10010716|NCT01635036||Women undergoing IVF treatment|Women undergoing IVF treatment
10010717|NCT01635049||Women undergoing IVF treatment and CCS|•Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical need by the clinical site reproductive endocrinologist.
10010718|NCT01635075|Experimental|Exercise|1-mile treadmill walk
10010719|NCT01635075|Placebo Comparator|Passive|20 min inactivity
10035661|NCT01808586|Active Comparator|Home exercise|Subjects in this group will receive education and a pamphlet on a set of standardized home exercises for neck pain
10035662|NCT01808599|Experimental|Chlorambucil, Rituximab i.v., Rituximab s.c.|"Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).~Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
10035663|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 atmospheres absolute(ATA).
10035664|NCT01808638|Other|Lead in safety period|Cohort of three subjects with non-pancreatic cancer for whom conventional treatment options have failed, will be treated. If one of the subjects in the safety cohort experiences an unacceptable toxicity, the safety cohort is expanded to six subjects.
10035665|NCT01808638|Experimental|Treatment arm 1|Subjects with advanced pancreatic cancer will be treated.
10035666|NCT01808638|Experimental|Treatment arm 2|Subjects with advanced pancreatic cancer will be treated.
10035667|NCT01808664|Experimental|Standardized Patient Instructor Intervention|"Primary care physicians (PCPs) randomized to intervention will receive over a three month run-in period two visits by standardized patient instructors portraying: 1) a 48 year-old patient with low back pain for less than six-weeks and no red flags for immediate spinal imaging; and 2) a 50 year-old recently menopausal woman establishing care with concerns about osteoporosis risk."
10010720|NCT01635088|Other|Mometasone furoate 220 vs. Mometasone furoate 440|
10010721|NCT01635088|Active Comparator|Mometasone 220 mcg vs. 440 mcg|Inhaled steroid
10010722|NCT01635114|Active Comparator|resVida (resveratrol)|
10010723|NCT01635114|Placebo Comparator|Placebo|
10010724|NCT01635127|Experimental|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
10010725|NCT01635127|Placebo Comparator|Placebo|Constituent, inactive
10010726|NCT01635140|Experimental|Hypofractionated arm|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
10010727|NCT01635140|Other|Conventional arm|The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.
10010728|NCT01635166|Other|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement
10010729|NCT01635179|Experimental|Cricoid pressure|A cricoid pressure of 30 N is done to occlude esophagus under a rapid sequence induction.
10010730|NCT01635192|Active Comparator|VSL#3|
10010731|NCT01635192|Placebo Comparator|Inactive treatment|
10010732|NCT01635205|Experimental|paraspinous block|Paraspinous anesthetic block in the thoracolumbar region, in sensitized segments
10010733|NCT01635205|Sham Comparator|control|Subcutaneous puncture with no anesthetic effect
9476719|NCT03568968|Placebo Comparator|Placebo Comparator|Placebo tablets, no active ingredients.
10010734|NCT01635231|Active Comparator|thiazide, diuretic|1.25 mg thiazide twice daily for 5 days
10010735|NCT01635231|Active Comparator|amiloride, diuretic|5 mg of amiloride twice daily
10010736|NCT01635231|Placebo Comparator|calcium|placebo twice daily for 5 days
10010737|NCT01635257||suspected pulmonary embolism patients|patients with clinical suspicion of PE and with a simplified Well's score>4 (PE likely) or with a D-dimer value ≥500ng/ml presenting to the emergency departments of Careggi University Hospital (Firenze), of San Luigi Gonzaga University Hospital (Torino) of Ospedale Pierantoni-Morgagni (Forlì)
10010738|NCT01635270|Experimental|midP arm|Patients treated with midP radiotherapy strategy.
10010739|NCT01635270|Active Comparator|ITV arm|Patient treated with radiotherapy ITV strategy
10010740|NCT01635296|Experimental|A: Previously untreated|
10010741|NCT01635296|Experimental|B: Relapse/Refractory|
10010742|NCT01635309||Non-cardiac surgical patients|>= 45 years old, undergoing non-cardiac surgery requiring regional or general anaesthetic and an overnight stay with cardiac risk factors
10010743|NCT01635322||Lumbar or thoraco-lumbar Adult Deformity|Lumbar or thoraco-lumbar Adult Deformity
10010744|NCT01635335|Experimental|HIV-specific|7-hour multiple family workshop focused on providing information and skills related to HIV prevention. Specific focus on parent-adolescent communication and parental monitoring.
10010745|NCT01635335|Active Comparator|General Health Promotion|7-hour multiple family workshop focused on providing information related to various adolescent health risk behaviors, including smoking, alcohol, violence, nutrition, and exercise.
10010746|NCT01635348|Experimental|motor skill gait exercise arm|motor skill gait exercise intervention: stepping and walking patterns, and speed interval treadmill-assisted walking to enhance timing and coordination in walking
10010747|NCT01635348|Active Comparator|aerobic gait exercise arm|aerobic gait exercise intervention: treadmill-assisted and overground walking exercise to enhance walking practice and improve endurance in walking
10010748|NCT01635361|Experimental|NMS|Patients in this arm will receive the full NMS service
10010749|NCT01635361|No Intervention|Current Practice|Patients in this arm will receive the normal advice with their new medicine as dictated by current professional practice
10035668|NCT01808664|Active Comparator|Control|"In the latter half of visits with control PCPs, standardized patient instructors (SPIs) will share information regarding low back pain or bone health that are unrelated to diagnostic testing, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
10035669|NCT01808677||Thoracic Reirradiation Registry|Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
10037275|NCT01823562|Experimental|Arm VI (lower-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
9476720|NCT03568955||Swiss Bereaved|Adults from the Swiss population who have lost a loved one at least 6 months to 10 years prior to testing
10037276|NCT01823562|Experimental|Arm VII (higher-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
9476721|NCT03568955||Japanese Bereaved|Adults from the Japanese population who have lost a loved one at least 6 months to 10 years prior to testing
10010750|NCT01635374|Experimental|Per-Oral Endoscopic Esophagomyotomy|Patients will have a standard pre-operative work-up that may include upper endoscopy (EGD), endoscopic ultrasound (EUS), upper GI X-rays, high-resolution manometry, pH, FLIP and impedance measurement studies. Once a diagnosis of esophageal motility disorder is confirmed, patients will be offered POEM or standard treatment. Patients undergoing POEM will review and sign the study consent prior to their procedure. Patients will return and be evaluated two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Also, at this visit and at the preoperative visit, patients will complete a standardized Quality of Life assessment. Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record. Patients will then return at 6 weeks post-op to complete a second set of questionnaires and have a high resolution manometry performed to assess residual LES pressure.
10010751|NCT01635387|Experimental|Aliskiren|
10010752|NCT01635387|Placebo Comparator|Placebo|
9476722|NCT03568955||Chinese Bereaved|Adults from the Chinese population who have lost a loved one at least 6 months to 10 years prior to testing
10010753|NCT01635400|Other|UGT1A1 wild type (6/6)|
10010754|NCT01635400|Other|UGT1A1 heterozygous genotype (6/7)|
10010755|NCT01635400|Other|UGT1A1 homozygous genotype(7/7)|
10010756|NCT01635413|Experimental|Arm I (strength training)|Patients attend strength training classes for 1 hour 2 days per week.
10010757|NCT01635413|Experimental|Arm II (tai chi)|Patients attend tai chi classes for 1 hour 2 days per week.
10010758|NCT01635413|Active Comparator|Arm III (control)|Patients attend supervised stretching and relaxation classes for 1 hour 2 days per week.
10010759|NCT01635426|Active Comparator|Aspirin|
10010760|NCT01635426|Active Comparator|Clopidogrel|
10010761|NCT01635452||Patients treated with Esmya|
10010762|NCT01635465||Observation group:vinorelbine plus capecitabine|
10010763|NCT01635465||Control group:docetaxel plus capecitabine|
10010764|NCT01635517||Tolvaptan|Tolvaptan administration
10010765|NCT01635530|Active Comparator|Ceftriaxone|Treatment of intravenous ceftriaxone (2 g/day), three weeks
10010766|NCT01635530|Experimental|Doxycycline|Treatment with oral doxycycline (200mg / day), four weeks
10010767|NCT01635543||Crohn's Disease with peri-anal fistulas|Identifying Crohn's Disease patients with peri-anal fistulas and suffering from sexual dysfunction.
10010768|NCT01635569|Active Comparator|OCD-affected subjects (Group 1)|OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
10010769|NCT01635569|Active Comparator|OCD-affected subjects (Group 2)|Waitlist affected-controls awaiting a treatment spot.
10010770|NCT01635582|Active Comparator|Control group|Conventional hand exercise program
10010771|NCT01635582|Experimental|Experimental group|Computer gaming hand exercise regimen'
10010772|NCT01635595||Patients with BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia with preoperative diagnosis of BIM underwent subtotal esophagectomy and gastric pull up.
10010773|NCT01635595||Patients without BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia without preoperative diagnosis of BIM underwent subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy.
10010774|NCT01635608|Active Comparator|non-caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml non-caloric water immediately before administration after overnight fasting
10010775|NCT01635608|Active Comparator|caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml caloric water immediately before oral administration after overnight fasting
10010776|NCT01635621|Experimental|OKZ 120 mg|
10010777|NCT01635621|Experimental|OKZ 240 mg|
10010778|NCT01635621|Experimental|OKZ 120 mg with 480 mg loading dose at Week 0|
10010779|NCT01635621|Placebo Comparator|Placebo|
10010780|NCT01635634|Sham Comparator|Sham Cupping|Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
10010781|NCT01635634|Experimental|Cupping Therapy|Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
10010782|NCT01635634|No Intervention|Wait list|Wait list control no specific intervention for 3 weeks study period
10010783|NCT01635647|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
10010784|NCT01635647|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
10010785|NCT01635660|Active Comparator|C-MAC System|
10010786|NCT01635660|Active Comparator|AP Advance|
10010787|NCT01635660|Active Comparator|King Vision|
10010788|NCT01635673|No Intervention|Control Group|A group that continues with their normal daily activities for the duration of the study
10010789|NCT01635673|Experimental|Exercise Group|This group exercises 3 times each week
10010790|NCT01635686|Experimental|DWP422|
10010791|NCT01635686|Active Comparator|ENBREL|
10010792|NCT01635712|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days on a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level
10010793|NCT01635738|Experimental|LP GMNL-133 group|Arm: LP GMNL-133 group One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
10010794|NCT01635738|Experimental|LF GM-090 group|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
10010795|NCT01635738|Experimental|LP GMNL-133+LF GM-090 group|One capsule with 2x10^9 (cfu) LP GMNL-133+ 2x10^9 (cfu)LF GM-090, once daily, PO
10010796|NCT01635738|Placebo Comparator|Placebo|
10010797|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(fasted)|
10010798|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(after high fat meal)|
10010799|NCT01635751|Active Comparator|Lyrica Capsule 75mg(fasted)|
10010800|NCT01635777|Experimental|12 weeks|miltefosine 12 weeks
10010801|NCT01635777|Experimental|8 weeks|miltefosine 8 weeks
10010802|NCT01635790|Active Comparator|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
10010803|NCT01635790|Active Comparator|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
10010804|NCT01635803|Active Comparator|Ranibizumab|Monthly injections with ranibizumab during 6 months
10010805|NCT01635803|Active Comparator|Bevacizumab|Monthly injections with bevacizumab during 6 months
10010806|NCT01635816|Active Comparator|JE Vaccine existing facilities|will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
10010807|NCT01635816|Active Comparator|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
10010808|NCT01635816|Active Comparator|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
10010809|NCT01635816|Active Comparator|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
10010810|NCT01635829|Experimental|Panel 1|Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
10010811|NCT01635829|Experimental|Panel 2|"Part 1 of Panel 2: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 2: Participants will receive carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
10010812|NCT01635868||umbilical hernia repair|patients having umbilical or epigastric hernia repair from 2008-2010 in Zealand
10010813|NCT01635894|Experimental|nurse specialist|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
10010814|NCT01635894|Experimental|practice nurse|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
10010815|NCT01635894|No Intervention|Control|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment (but no training given) and were followed-up for their final assessment at 3 months."
10010816|NCT01635946|Experimental|Isavuconazole and atorvastatin|Atorvastatin on Days 1 and 12, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 15
10010817|NCT01635959||Patients with Gastrointestinal Trackt Symptoms|
10010818|NCT01635972|Experimental|Isavuconazole and bupropion|Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.
10010819|NCT01635985|Experimental|1|AZD5423 iv
10010820|NCT01635985|Experimental|2|AZD5423 inhalation, Spira
10010821|NCT01635985|Experimental|3|AZD5423 inhalation I-neb
10010822|NCT01635985|Experimental|4|AZD5423 oral
10010823|NCT01635985|Experimental|5|AZD5423 inhalation Turbuhaler
10010824|NCT01635985|Experimental|6|AZD5423, New Dry Powder Inhaler
10010825|NCT01636011|Experimental|OMM Treatment|In this group the subjects are given 5 different OMM treatments addressing the thoracic cage.
10010826|NCT01636011|Sham Comparator|Light Touch sham|In this group the physician uses the dorsum of his hand to the same areas and for the same time that the OMM treatment arm receives.
10010827|NCT01636024|Experimental|1|Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
10010828|NCT01636024|Placebo Comparator|2|Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
10010829|NCT01636037|Experimental|L-Dopa (Sinemet)|Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
10010830|NCT01636050|Experimental|Training group|
10010831|NCT01636050|Experimental|Control group|
10010832|NCT01636089|Experimental|bicarbonates|sodium bicarbonates 1,4%
10010833|NCT01636089|Active Comparator|saline|sodium chloride 0,9%
10010834|NCT01636128|Experimental|Sulindac first (Treatment Sequence B)|Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO
10010835|NCT01636128|Experimental|DFMO first (Treatment Sequence A)|DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac
10010836|NCT01636141|Placebo Comparator|Placebo gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
10010837|NCT01636141|Active Comparator|OLT1177 Gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
10010838|NCT01636154|No Intervention|The basic treatment|Comply to the Chinese guidelines of acute ischemic stroke in 2010
10010839|NCT01636154|Other|Clearing heat|Treat with KDZ injection on the basis of the basic treatment
10010840|NCT01636154|Other|Promoting blood circulation|Treat with Xueshuantong injection on the basis of the basic treatment
10010841|NCT01636154|Experimental|Clearing heat & Promoting blood circulation|Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
10010842|NCT01636180|Experimental|Clopidogrel - Repeated Loading Dose|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
10010843|NCT01636180|Active Comparator|Clopidogrel - standard of care|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
10010844|NCT01636193||Rota Group|Subjects will receive Rotarix® as per routine practice.
10010845|NCT01636232||ICU sepsis group|The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
10010846|NCT01636232||ICU control group|the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
10010847|NCT01636232||healthy control group|the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
10010848|NCT01636245|Experimental|Lot 1|inactivated vaccine (Lot 1) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
10010849|NCT01636245|Experimental|Lot 2|inactivated vaccine (Lot 2) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
10010850|NCT01636245|Experimental|Lot 3|inactivated vaccine (Lot 3) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
10010851|NCT01636245|Placebo Comparator|Placebo|Placebo in 350 infants aged 6 months to 5 years old on day 0,28
10010852|NCT01636271||Group 1: subjects from LPL100601|randomized subjects in study LPL100601
10010853|NCT01636271||Group 2: subjects from SB480848/033|randomized subjects in study SB480848/033
10010854|NCT01636310|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
10010855|NCT01636310|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
10010856|NCT01636323|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
10010857|NCT01636323|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
10010858|NCT01636336|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
10010859|NCT01636336|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
10010860|NCT01636349|Experimental|Recreational soccer training|12 men participate in recreational soccer training for 6 months
10010861|NCT01636349|No Intervention|Control group|10 subjects serve as a control group with no change in lifestyle in the study period
10010862|NCT01636388|Experimental|Allogeneic Stem Cell Transplantation|Reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma.
10010863|NCT01636401|Active Comparator|aclidinium bromide|
10010864|NCT01636401|Placebo Comparator|Placebo|
10010865|NCT01636440|Other|Reliability|The same testing procedure is repeated after a delay of 7 days to test the reliability of the measure
10010866|NCT01636479|Experimental|SAR405838|SAR405838 in escalating doses
10010867|NCT01636492|Experimental|Bitopertin|
10010868|NCT01636492|Placebo Comparator|Placebo|
10010869|NCT01636505|Active Comparator|short protocol|gnrh agonist versus gnrh antagonist
10010870|NCT01636505|Active Comparator|long protocol|
10010871|NCT01636518||Atrial Fibrillation|Patients with Atrial Fibrillation that undergo standard of care procedure at the University of Kansas Hospital
10010872|NCT01636531|Experimental|HCLF|
10010873|NCT01636531|Active Comparator|LyoF|
10010874|NCT01636557|Experimental|Sirukumab and 5-probe cocktail|The 5-probe cocktail will consist of oral doses of midazolam, warfarin/vitamin K, omeprazole, and caffeine.
10010875|NCT01636570|Active Comparator|Vitamin D3 (cholecalciferol)|10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
10010876|NCT01636570|Placebo Comparator|Sugar Pill|Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
10010877|NCT01636583|Experimental|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
10010878|NCT01636583|Active Comparator|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
10010879|NCT01636583|Active Comparator|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
10010880|NCT01636609|Experimental|Arm I (tosedostat, cytarabine)|Participants receive tosedostat PO QD on days 1-28 and cytarabine SC BID on days 1-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10010881|NCT01636609|Experimental|Arm II (tosedostat, azacitidine)|Participants receive tosedostat PO QD on days 1-28 and azacitidine IV over 10-40 minutes or SC on days 1-7. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
10010882|NCT01636622|Experimental|Vemurafenib + Carboplatin + Paclitaxel|"All 3 study drugs will start on day 1 of cycle 1. Cycle defined as 3 weeks. On day 1, paclitaxel and carboplatin will be administered first, and the vemurafenib administration will start in the evening that day.~Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.~Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.~Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle."
10010883|NCT01636635|Active Comparator|Young (18-45 years)|Obese young women (18-45y) undergoing calorie restriction.
10010884|NCT01636635|Experimental|Older (>60 years)|Obese older women (>60y) undergoing calorie restriction.
10010885|NCT01636700|Active Comparator|tramadol infiltration|infiltration of tramadol 2mg/kg
10010886|NCT01636700|Placebo Comparator|Saline solution|Infiltration of saline
10010887|NCT01636726||Patients with AMI|All patients of the study population with a record/diagnosis of AMI during the study period
10010888|NCT01636726||Patients without AMI|All patients of the study population without a record/diagnosis of AMI during the study period
10010889|NCT01636739||Rota Group|Subjects will receive Rotarix® as per routine practice
10010890|NCT01636752|Experimental|Deprexis|Online self-help with and without e-mail-support
10010891|NCT01636752|No Intervention|Control|
10010892|NCT01636791|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
10010893|NCT01636791|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
10010894|NCT01636791|Experimental|CBT and Return to work|Participants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
10035670|NCT01808703|Experimental|Scaling and root planing plus PerioPatch|"All subjects in this group will receive scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam). Thereafter, PeriZone PerioPatch will be dispensed to subjects per randomization for administration over the trial period. Subjects will apply study patches (i.e., BID on Days 1, 28 and 42; QD on Days 2-6; Days 14-20, 29-30 and 43-44) to designated treatment sites (i.e., measuring 6 mm or more in pocket depth at Baseline)."
10035671|NCT01808703|Active Comparator|Scaling and root planing alone|Subjects in this group will receive only scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam).
10035672|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) on muscle damage|Effects of low-level laser therapy (LLLT)on muscle damage
10035673|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) placebo on muscle damage|Effects of low-level laser therapy (LLLT) placebo on muscle damage
10035674|NCT01808729||FMD or CAD (as appropriate)|The study group will either have FMD, early onset CAD, or other rare/unusual vascular disorder. These differing disorders will be sub-groups within the overall study
10035675|NCT01808729||Healthy control subjects without vascular disease|Healthy controls will not exhibit signs, symptoms or other evidence of vascular disease.
10035676|NCT01808742||Treatment|Treatment with CryoTouch III device
10035677|NCT01808768|Experimental|Alcaftadine|subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
10035678|NCT01808781|Experimental|Intervention group|Home exercise program plus walking program during 8-week period
10035679|NCT01808781|Active Comparator|Comparison group|Walking only program throughout the 8-week period.
10035680|NCT01808807||cesarean section rate after audit|cesarean section rate after audit
10035681|NCT01808833||Frail patients|
10035682|NCT01808833||Non-frail patients|
10035683|NCT01808846||Lean Adolescents|Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results
10035684|NCT01808846||Obese Insulin Sensitive|Obese Insulin Sensitive Adolescents aged 12-17 with BMI>95th% and whole body insulin sensitivity index > 3.
10035685|NCT01808846||Obese Insulin Resistant Adolscent|Obese Insulin Resistant Adolescents 12-17 with BMI> 95th% and WBISI<1.2.
10035686|NCT01808859|Experimental|Tourniquet|The Torniquet will be inflated to 100 mmHg over systolic pressure just before skin incision. The tourniquet will be deflated when the last stich/agraf is fixed
10010895|NCT01636804||Quicksite and Quickflex|Patients who have received the leads affected by the medical product advisory
10010896|NCT01636830|Active Comparator|Toothbrush type - medium|This is a crossover study, where the person used either a soft brush (control) and the medium brush (test).
10010897|NCT01636830|Active Comparator|Toothbrush type - soft|This is a crossover study, where the person used either a soft brush (control)and the medium brush(test).
10010898|NCT01636856|Active Comparator|1|Oropharyngeal exercises and oropharyngeal functions
10010899|NCT01636856|Sham Comparator|2|Nasal dilator, respiratory exercise, nasal lavage
10010900|NCT01636869|Experimental|bupicavaine|
10010901|NCT01636895|Experimental|SP-IPTp efficacy|Efficacy of suphladoxine/pyrimethamine as IPTp
10010902|NCT01636908|Experimental|Kinase inhibitor|Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
10010903|NCT01636973|Experimental|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
10010904|NCT01636999|Experimental|Butorphanol|The main study arm will be examining how well a 50% Nitrous Oxide/50% Oxygen gas mixture is in reducing labor pains in term labor patients with less than 5 cm cervical dilation, compared to 2mg of Butorphanol (a common synthetic opiod used for labor pains in this setting).
10010905|NCT01637012|Experimental|ALEX stent arm|implantation of ALEX stent during index procedure
10010906|NCT01637025|Experimental|Traumastem - oxidized cellulose strip|
10010907|NCT01637025|Active Comparator|Surgicel® Original - oxidized regenerated cellulose strip|
10010908|NCT01637038|No Intervention|Control Group|no intervention
10010909|NCT01637038|Experimental|RIPC group|Those undergoing remote ischemic postconditioning
10010910|NCT01637103|Experimental|Cognitive therapy of depression|
10010911|NCT01637103|Experimental|Bright light therapy|
10010912|NCT01637103|No Intervention|Waiting list|
10010913|NCT01637116||autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
10010914|NCT01637116||autoreactive, non-autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
10010915|NCT01637116||non-autoreactive chronic spontaneous urticaria|Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
10010916|NCT01637129|Active Comparator|Magnetic Stimulation|Active Magnetic Stimulation with repetitive transcranial magnetic stimulation
10010917|NCT01637129|Placebo Comparator|No Intervention|Sham Magnetic Stimulation
10010918|NCT01637155|Experimental|Cholecalciferol|
10010919|NCT01637168|Experimental|Test Group|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
10010920|NCT01637168|Active Comparator|Comparator Group|Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
10010921|NCT01637181|Active Comparator|EVLA 940 nm|
10010922|NCT01637181|Active Comparator|EVLA 1470 nm|
10010923|NCT01637194|Experimental|Treatment (enzyme inhibitor, monoclonal antibody therapy)|Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10010924|NCT01637207|Experimental|palpation|
10010925|NCT01637207|Experimental|ultrasound|
10010926|NCT01637220||case, control|Blood volume collected specifically for this study
10010927|NCT01637233||NRTI + PI|This is the randomisation of the main study, Arm 1
10010928|NCT01637233||maraviroc + PI|this is the randomisation of the main study, Arm 2
10010929|NCT01637233||maraviroc + NRTI|this is the randomisation of the main study, Arm 3
10010930|NCT01637259|Active Comparator|NRTI + PI|arm 1
10010931|NCT01637259|Active Comparator|PI + maraviroc|arm 2
10010932|NCT01637259|Active Comparator|NRTI + maraviroc|arm 3
10010933|NCT01637285|Experimental|PF-04856883 Treatment Arm 1|
10010934|NCT01637285|Experimental|PF-04856883 Treatment Arm 2|
10010935|NCT01637285|Experimental|PF-04856883 Treatment Arm 3|
10010936|NCT01637285|Experimental|PF-04856883 Treatment Arm 4|
10010937|NCT01637311|Experimental|Failed HM|Patients were eligible for enrollment in the study if they were age greater than 18 years and had recurrence/persistence of symptoms after primary HM with an Eckardt symptom score ≥ 4.
10010938|NCT01637337|Active Comparator|laparoscopic pyelolithotomy|
10010939|NCT01637337|Sham Comparator|percutaneous nephrolithotomy|
10010940|NCT01637350||Subtotal gastrectomy , BillrothⅠ|
10010941|NCT01637350||Subtotal gastrectomy , BillrothⅡ|
9476723|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
9667650|NCT03287843|Experimental|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
10010942|NCT01637350||total gastrectomy, jejunal interposition|
10010943|NCT01637350||total gastrectomy , Roux-en-Y|
10010944|NCT01637363|No Intervention|Regular treatment|This group is offered regular treatment from the job center i.e. exercise, mindfulness
10010945|NCT01637363|Experimental|Psychoeducation|6 x 2 hours of psychoeducation
10010946|NCT01637389|No Intervention|Control Arm|All communities (independent units/clusters) start in the control and have no intervention. All control communities cross-over to the intervention in a randomized sequence over the course of 12-15 month study.
10010947|NCT01637389|Experimental|Basic Safe Water Program|The Basic program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Basic program.
10010948|NCT01637389|Experimental|Enhanced Safe Water Program|The Enhanced program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Enhanced program.
10010949|NCT01637441|Experimental|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
10010950|NCT01637441|Experimental|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
10010951|NCT01637454|Active Comparator|Terlipressin and Type-2 HRS|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
10010952|NCT01637454|Active Comparator|Noradrenaline and Type-2 HRS|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
10010953|NCT01637467|Experimental|EMS intervention|The experimental group will received EMS at a therapeutic level.
10010954|NCT01637467|Sham Comparator|Sham|The sham group will receive EMS at a sub-therapeutic level.
10010955|NCT01637480|Experimental|Patellofemoral Pain Syndrome|Participants with Patellofemoral Pain Syndrome
10010956|NCT01637480|Active Comparator|Healthy control|Age- and gender-matched participants without Patellofemoral Pain Syndrome
10010957|NCT01637493|Experimental|Pegfilgrastim, 30mcg/kg|
10010958|NCT01637493|Experimental|Pegfilgrastim, 60mcg/kg|
10010959|NCT01637493|Experimental|Pegfilgrastim, 100mcg/kg|
10010960|NCT01637493|Experimental|Pegfilgrastim, 200mcg/kg|
10010961|NCT01637506||Study group|"Age > 19~Radiological evidence indicating presence of a current renal or ureteric stone"
10010962|NCT01637506||Control group|"Age > 19.~No history of kidney stone disease"
10010963|NCT01637519||Ureteral stone|Ten (10) patients with a unilateral, mid- or distal, ureteral (tube connecting kidney and bladder in the urinary system) stone will be enrolled and brought to completion in this study.
10010964|NCT01637532|Other|Group 1|Carboplatin/Caelyx
10010965|NCT01637532|Experimental|Group 2|Carboplatin/Caelyx or doxorubicin plus Tocilizumab
10010966|NCT01637532|Experimental|Group 3|Carboplatin/Caelyx or doxorubicin plus Tocilizumab plus Peg-Intron
10010967|NCT01637545|Active Comparator|Preop. ramosetron 0.3mg i.v.|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery
10010968|NCT01637545|Active Comparator|Postop. ramosetron 0.3mg i.v.|G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
10010969|NCT01637545|Active Comparator|No Ramosetron|G3 - No medication but regular antiemetics injection if the patient wants
10010970|NCT01637558|No Intervention|Main TB cohort|Children with tuberculosis 0-12 years of age
10010971|NCT01637558|Experimental|Lopinavir/Ritonavir - Cases|children 3-20 kg with tuberculosis and indication for LPV/r-based ART
10010972|NCT01637558|Experimental|Lopinavir/Ritonavir - Controls|Children 3-20 kg on LPV/r-based ART; no TB
10010973|NCT01637558|Experimental|Nevirapine arm|children with TB and indication for nevi rapine-based ART
10010974|NCT01637571|Active Comparator|Dexilant|60mg of Dexilant QD for 12 weeks
10010975|NCT01637571|Placebo Comparator|Placebo|60mg of Dexilant placebo QD for 12 weeks
10010976|NCT01637610||PPROM|All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.
10010977|NCT01637636|Experimental|Rifampin|
10010978|NCT01637636|Experimental|Ketoconazole|
9476724|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
10010979|NCT01637649||Stroke patients with dysphagia|Stroke patients with confirmed evidence of aspiration and severe dysphagia tha would require modified diet or nasogastric tube feeding
10010980|NCT01637649||Stroke patients without dysphagia|Stroke patients but with no gross evidence of dysphagia or with mild dysphagia with a Penetration aspiration scale of less than 4
10010981|NCT01637649||healthy volunteer group|healthy volunteers with no prior history of dysphagia or stroke and who are not included in the exclusion criteria
10010982|NCT01637662|Experimental|Healthy subjects|
10010983|NCT01637675|Active Comparator|20 mg sildenafil citrate tablets by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
10010984|NCT01637675|Experimental|sodium tanshinone IIA sulfonate, sildenafil citrate tablets|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration
10010985|NCT01637701|Active Comparator|PkEP|Patients in this group undergo PkEP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
10010986|NCT01637701|Active Comparator|B-TURP|Patients in this group undergo B-TURP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
10010987|NCT01637714|Experimental|Multi-strain probiotics|
10010988|NCT01637714|Placebo Comparator|Placebo powder|
10010989|NCT01637727||GDM1|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
10010990|NCT01637727||GDM|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
10010991|NCT01637740||eyes with pseudoexfoliation syndrome|cataract myopic eyes with pseudoexfoliation syndrome
10010992|NCT01637740||eyes without pseudoexfoliation syndrome|cataract myopic eyes without pseudoexfoliation syndrome
10010993|NCT01637753|Experimental|Carmustine Sustained Release Implant|
10010994|NCT01637753|Sham Comparator|Surgical control group|
10010995|NCT01637766|Experimental|Selective intra-arterial chemotherapy|Subjects recruited to this study will receive intra-arterial injections of chemotherapy (melphalan) in the branches of the arteries feeding the metastatic spinal tumor. Subjects will receive general anesthesia or conscious sedation. A catheter will be guided using X-ray from the femoral artery at the top of the leg to the arteries of the spine. A dye will be injected through the catheter to show the arteries in greater detail. The chemotherapy is then injected into the tumor. We will inject the maximum systemic dose adjusted to white blood count and platelet count. Subjects will undergo three cycles of chemotherapy three to six weeks apart.
10010996|NCT01637779|Experimental|fact sheet review|mothers will review a fact sheet containing information about pain management during immunization then complete a knowledge test afterward
10010997|NCT01637779|Placebo Comparator|control unrelated material|mothers will review material unrelated to pain management during immunization then complete a knowledge test
10010998|NCT01637779|Experimental|pre-test, review of fact sheet|mothers do a pre-test, then read a fact sheet about how to manage immunization pain, then repeat the test
10010999|NCT01637779|Placebo Comparator|pre-test, control unrelated information|mothers do a pre-test, then read unrelated material, then repeat the test
10011000|NCT01637792|Experimental|Three 2-liter exchanges group|A group of randomly assigned patients undergoing three 2-liter exchanges daily CAPD.
10011001|NCT01637792|Active Comparator|Four 2-liter exchanges group|A group of randomly assigned patients undergoing four 2-liter exchanges daily CAPD.
10011002|NCT01637805|Experimental|AAV-DC-CTL|
10011003|NCT01637818|Other|Lichtenstein's Operation|
10011004|NCT01637818|Other|Mesh Plug Repair|
10011005|NCT01637831|Experimental|Patients with OSA and IPF|Participants with Obstructive Sleep Apnea (OSA)and Idiopathic Pulmonary Fibrosis (IPF).This arm will complete pre-treatment questionnaires assessing sleep and quality of life, undergo six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and complete post-treatment the same questionnaires 1, 3 and 6 months later.
10011006|NCT01637844|Experimental|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
10011007|NCT01637844|No Intervention|Control|Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
10011008|NCT01637857|Sham Comparator|lifestyle counseling|Group of patients treated with sham oligoantigenic diet
10011009|NCT01637857|Experimental|oligoantigenic diet|Treatment with oligoantigenic diat
10011010|NCT01637883|No Intervention|nothing|nothing will be dripped on the cuff of the endotracheal tube in the control group
10011011|NCT01637883|Experimental|benzydamine HCl|benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia
10011012|NCT01637896|Experimental|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
9476725|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
10011013|NCT01637896|Active Comparator|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
10011014|NCT01637909|Active Comparator|general management|
10011015|NCT01637909|Experimental|The treatment group1|Korean DASH diet with sodium reduction intervention
10011016|NCT01637909|Experimental|The treatment group2|Korean DASH diet with sodium reduction intervention and excersize intervention
10011017|NCT01637948|Active Comparator|Listerine|essential oil mouthrinse
10011018|NCT01637948|No Intervention|Negative control|without intervention
10011019|NCT01637948|Experimental|Chinese medicine mouthrinse|5% Fructus Mume extract and 2% sodium bicarbonate
10011020|NCT01637974|Experimental|with INTERCOAT|injection of intercoat into the euterine cavity at the end of hysteroscopy
10011021|NCT01637974|No Intervention|without INTERCOAT|without INTERCOAT
10011022|NCT01637987|Active Comparator|Unassisted vein visualization|
10011023|NCT01637987|Active Comparator|Wee Sight Transilluminator|
10011024|NCT01637987|Active Comparator|Near Infra-red light (VeinViewer)|
10011025|NCT01638026|Experimental|Gnrh agonist , hcg|Gnrh agonist for final oocyte maturation, hcg for luteal support
10011026|NCT01638039|Active Comparator|Diarrheal disease|
10011027|NCT01638039|Active Comparator|Control|Samples of stool, blood, urine saliva
10011028|NCT01638065||Standard|Standard IV Access without device
10011029|NCT01638065||VeinViewer|IV access with VeinViewer device
10011030|NCT01638078|Active Comparator|Thalidomide|Thalidomide
10011031|NCT01638078|Placebo Comparator|Placebo|Placebo
10011032|NCT01638091|Experimental|All participating endoscopists|All endoscopists will undergo ex vivo training and will participate in in vivo practice-based learning.
10011033|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min (with low sodium diet)|0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake
10011034|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min|0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
10011035|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min (low sodium diet)|0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
10011036|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min|0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
10011037|NCT01638104|Experimental|ANX-042: 0.0065 mcg/kg/min (low sodium diet)|0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
10011038|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min (low sodium diet)|0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
10011039|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min|0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
10011040|NCT01638104|Experimental|ANX-042: 0.03 mcg/kg/min|0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
10011041|NCT01638104|Experimental|ANX-042: 0.1 mcg/kg/min|0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
10011042|NCT01638104|Experimental|ANX-042: 0.3 mcg/kg/min|0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
10011043|NCT01638104|Placebo Comparator|Placebo (low sodium diet)|Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
10011044|NCT01638104|Placebo Comparator|Placebo|Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
10011045|NCT01638117|Placebo Comparator|PAC14028-Vehicle|PAC-14028 Cream Vehicle
10011046|NCT01638117|Experimental|PAC14028-0.1|PAC-14028 Cream 0.1%
10011047|NCT01638117|Experimental|PAC14028-0.3|PAC-14028 Cream 0.3%
10011048|NCT01638117|Experimental|PAC14028-1.0|PAC-14028 Cream 1%
10011049|NCT01638117|Placebo Comparator|Placebo|Saline
10011050|NCT01638117|Active Comparator|Positive control|Sodium Lauryl Sulfate, 0.5%
10011051|NCT01638143|Active Comparator|Gnosis P-1000 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
9476726|NCT03568903|Experimental|Intervention group|Comprehensive physical therapy intervention in small groups (3 members), altogether 16 sessions were performed during a period of 8 weeks (twice a week). Each session lasted 1 hour.
9476727|NCT03568903|No Intervention|Control group|Control group members did not receive any specific intervention during study period, but if needed, medical treatment (medication, it's dosage etc) of Parkinson Disease was changed during study period. They were assigned to individual therapy after the study period.
10011052|NCT01638143|Active Comparator|Gnosis M1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
10011053|NCT01638143|Active Comparator|MenaQ7 M-1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
10011054|NCT01638169||20 children with DMD|
10011055|NCT01638182|Active Comparator|vitamin K1 capsules|27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1
10011056|NCT01638182|Active Comparator|Vitamin K2-capsules|27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
10011057|NCT01638182|Placebo Comparator|Placebo capsules|27 participants received for 3 months 1 placebo capsule per day
10011058|NCT01638195|Experimental|Externally Focused Ultrasound|
10011059|NCT01638208|Experimental|VSL#3|Patients with IBS-D as per ROME III
10011060|NCT01638208|No Intervention|Healthy Controls|Healthy controls
10011061|NCT01638221||heavy weight mesh|Surgipro mesh is a heavier weighted mesh with less flexibility after surgery
10011062|NCT01638221||light weight mesh|UltraPro mesh is a lighter weighted mesh with theoretically less stiffness and more flexibility compared to heavier weighted meshes
10011063|NCT01638234|Placebo Comparator|Starch pill|
10011064|NCT01638234|Experimental|Melatonin|
10011065|NCT01638247|Active Comparator|Tamoxifen|Tamoxifen alone (daily).
10011066|NCT01638247|Experimental|Tamoxifen and GnRH analogue|Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
10011067|NCT01638247|Experimental|Exemestane and GnRH analogue|Exemestane (daily) + GnRH analogue (at randomisation and after three months).
10011068|NCT01638260|Placebo Comparator|Liraglutide|Subjects will inject liraglutide once daily for 26 weeks
10011069|NCT01638260|Active Comparator|Liraglutide and NEAT|Subjects will inject liraglutide once daily and combine this treatment with activating lifestyle, by increasing NEAT.
10011070|NCT01638273|Experimental|GLA5PR GLARS tablet 150mg(mealed)|Pregabalin 150mg
10011071|NCT01638273|Active Comparator|Lyrica Capsule 75mg(mealed)|Pregabalin 75mg
10011072|NCT01638286||Eperisone|
10011073|NCT01638286||Aceclofenac|
10011074|NCT01638286||Eperisone hydrochloride, Aceclofenac|
10011075|NCT01638299|Experimental|Hypo-Hyper Minimizer (HHM) System|
10011076|NCT01638325|Active Comparator|Insulin Lispro|15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
10011077|NCT01638325|Experimental|BC106 Insulin Lispro|15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
10011078|NCT01638338|Experimental|Web site|"A specific web site for randomization and risky alcohol consumption counseling will be beta tested and created. Risky drinkers allocated to this arm will receive web assisted brief motivational interview.~They will first be assessed towards risky alcohol consumption and Quality of life (AUDIT and EQ5D). Personal health status will also be assessed with a Likert scale. Brief Intervention will be administered following a consistent number of web pages reporting brief motivational interview Web assisted brief motivational interview on risky drinking"
10011079|NCT01638338|Experimental|Face to Face|Risky drinking brief motivational interview provided by the GP.
10011080|NCT01638351|Active Comparator|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
10011081|NCT01638351|Experimental|Resistance exercise|Progressive resistance training, 3 times a week for 12 weeks
10011082|NCT01638364|Active Comparator|alcoholic beverage|95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
10011083|NCT01638364|Placebo Comparator|non-alcoholic beverage|Orange juice and tonic water.
10011084|NCT01638377|Experimental|Naltrexone|Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
10011085|NCT01638377|Placebo Comparator|Control|Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
10011086|NCT01638403|Experimental|BF2.649|BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
10011087|NCT01638403|Active Comparator|Vigil|"Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.~Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement."
10011088|NCT01638403|Placebo Comparator|Placebo|
10011089|NCT01638442|Experimental|Treatment A|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
10011090|NCT01638442|Experimental|Treatment B|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
10011091|NCT01638455|Experimental|Test Group|All subjects will be enrolled in the test group and will receive the noninvasive device
10011092|NCT01638494|Experimental|Colecalcium testing|administration of Colecalcium
10035687|NCT01808859|No Intervention|No tourniquet|"The patients operated on in the non-tourniquet group will have the same surgery and surgical technique but without tourniquet~hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks."
10035688|NCT01808872||Heart Failure|
10011093|NCT01638520|Experimental|Pascolizumab|The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.
10011094|NCT01638520|Placebo Comparator|Placebo|For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.
10011095|NCT01638572||neuroblastoma patients|
10011096|NCT01638585|No Intervention|standard therapy|patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
10011097|NCT01638585|Active Comparator|urokinase|patients receiving urokinase short infusions in addition to standard therapy
10011098|NCT01638598|Experimental|BI 1021958 dose group 1|subject to receive a tablet containing dose group 1 BI 1021958 single dose
10011099|NCT01638598|Experimental|BI 1021958 dose group 2|subject to receive a tablet containing dose group 2 BI 1021958 single dose
10011100|NCT01638598|Experimental|BI 1021958 dose group 3|subject to receive a tablet containing dose group 3 BI 1021958 single dose
10011101|NCT01638598|Experimental|BI 1021958 dose group 4|subject to receive a tablet containing dose group 4 BI 1021958 single dose
10011102|NCT01638598|Experimental|BI 1021958 dose group 5|subject to receive a tablet containing dose group 5 BI 1021958 single dose
10011103|NCT01638611|Active Comparator|HIP2B|Six subjects per dosing cohort will receive HIP2B
10011104|NCT01638611|Placebo Comparator|Placebo|Two subjects per dosing cohort will receive placebo.
10011105|NCT01638624|Active Comparator|Propofol|Propofol infusion group: Under spinal anesthesia, a continuous intravenous infusion (2mg/kg/h) of propofol will be use during the operation
10011106|NCT01638624|Placebo Comparator|Control group|Placebo group: Under spinal anesthesia, a continuous intravenous infusion of volume-equivalent placebo will use during the operation
10011107|NCT01638637||Specimen Collection|
9665141|NCT05169346|Active Comparator|Active Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of active neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
10011108|NCT01638650|Experimental|Single Arm|
10011109|NCT01638663|Active Comparator|Tolvaptan|Oral administration of 15 mg Tolvaptan on each examination day.
10011110|NCT01638663|Placebo Comparator|Placebo|Oral administration of 15 mg Unikalk tablet on each examination day.
10011111|NCT01638676|Experimental|Vemurafenib and Metformin|
10011112|NCT01638702|Active Comparator|Right sided PICC placement|Insertion of PICC on the right arm
10011113|NCT01638702|Placebo Comparator|Left sided arm placement|Insertion of PICC on the left arm
10011114|NCT01638715|Experimental|Infliximab|Infliximab (Remicade®) will be administered i.v.at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
10011115|NCT01638715|Experimental|Abatacept|Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c.application at a dose of 125mg weekly.
10011116|NCT01638715|Experimental|Tocilizumab|Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
10011117|NCT01638715|Experimental|Rituximab|Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26. Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
10011118|NCT01638728||Endotracheal tube|
10011119|NCT01638767|Experimental|NuvaRing|Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
10011120|NCT01638767|Active Comparator|Marvelon|Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.
10011121|NCT01638780|Placebo Comparator|placebo|A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
10011122|NCT01638780|Active Comparator|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
10011123|NCT01638793|Experimental|Capnography|Capnographic respiration monitoring
10011124|NCT01638793|Active Comparator|Pulse-Oxymetry|pulse-oxymetric respiration monitoring
10011125|NCT01638806|Experimental|Group I: PPCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
10011126|NCT01638806|No Intervention|Conventional: Group II|Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score > 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.
9476728|NCT03568890|Active Comparator|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 8 weeks.
10011127|NCT01638845|Active Comparator|continuous perineural catheter|
10011128|NCT01638845|No Intervention|Control|
10011129|NCT01638858|Experimental|Lucentis (Ranibizumab)|
10011130|NCT01638871|Experimental|Intervention Group|Study arm will complete the 8-week Internet-based pain coping skills program.
10011131|NCT01638871|No Intervention|Control Group|This study arm will only provide demographic and pain-related information.
10011132|NCT01638884|Experimental|Young Healthy Subjects|
10011133|NCT01638884|Experimental|Middle age Healthy Subjects|
10011134|NCT01638884|Experimental|Elderly Healthy Subjects|
10011135|NCT01638884|Experimental|Mild Cognitive Impairment patients|
10011136|NCT01638884|Experimental|Alzheimer Disease patients|
10011137|NCT01638910|Experimental|EV/DNG (Qlaira, BAY86-5027)|
10011138|NCT01638923|Experimental|Arm 1|
10011139|NCT01638923|Placebo Comparator|Arm 2|
10011140|NCT01638936|Experimental|BT062|BT062 administered intravenously on days 1, 8 and 15 of each 28-day cycle, and lenalidomide or pomalidomide and dexamethasone administered orally to subjects with relapsed or relapsed/refractory MM
10011141|NCT01638949|Experimental|Young controls|
10011142|NCT01638949|Experimental|Middle age controls|
10011143|NCT01638949|Experimental|Elderly controls|
10011144|NCT01638949|Experimental|Asymptomatic subjects|Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
10011145|NCT01638949|Experimental|Subjectif Cognitive Impariment patients|
10011146|NCT01638949|Experimental|Mild Cognitive Impairment patients|
10011147|NCT01638949|Experimental|Alzheimer Disease patients|
10011148|NCT01638949|Experimental|Non degenerative amnsesic syndrome|
10011149|NCT01638962|Experimental|NEMEX|NEuroMuscular EXercise
10011150|NCT01638962|Active Comparator|PHARMA|PHARMAcological pain relief
10011151|NCT01638975|Experimental|Computerized response inhibition training|Participants in this condition receive 8 computerized training sessions over a 4 week period.
9964497|NCT01239550|No Intervention|Comparator: No insulin|"The main hypothesis is that diabetes can be changed  with early and careful insulinization capturing effects on brain function ultimately leading to weight loss. . Seek to determine in a quantitative manner whether insulin detemir restores brain dopamine neurotransmission, a control group not treated with insulin is required. The strength of this study is our ability to test the specific molecular (D2R, DAT, functional MRI responses) and integrated output (functional brain responses, mood, cognitive function, reward responses etc.) of CNS dopaminergic pathways in order to shed unprecedented light upon mechanisms of detemir action in obesity and diabetes."
9964498|NCT01239563|Experimental|Thymoglobulin|Thymoglobulin induction group
9964499|NCT01239563|Active Comparator|Basiliximab|Basiliximab induction - 20 mg, day 0 and day 4
9964500|NCT01239589||1|patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
9964501|NCT01239589||2|patients admitted as for an acute bipolar manic episode and treated with quetiapine XR
9964502|NCT01239602||Normal control|
9964503|NCT01239602||with Stem cell therapy plus G-CSF|
9964504|NCT01239602||G-CSF along|
9964505|NCT01239615||healthy volunteers|
10011152|NCT01638975|No Intervention|Waitlist Control|Participants assigned to this condition wait without an intervention until the second assessment (4 weeks after the baseline assessment).
10011153|NCT01638988|Experimental|Metformin|
10011154|NCT01638988|Active Comparator|Clomiphene Citrate|
10011155|NCT01639014|Experimental|F2695|
10011156|NCT01639014|Placebo Comparator|placebo|
10011157|NCT01639027|Active Comparator|Drotaverine|Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
10011158|NCT01639027|Placebo Comparator|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.
10011159|NCT01639053||Gel Participants|
10011160|NCT01639053||Control Participants|
10011161|NCT01639066|Experimental|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
10011162|NCT01639066|Active Comparator|Tenofovir monotherapy|Tenofovir 300 mg/day orally
10011163|NCT01639079|No Intervention|Usual Care for Smoking|Usual care for smoking cessation with access to the web site after 6 months
10011164|NCT01639079|Experimental|Internet Smoking Cessation Web Site|"Internet Stop Smoking site (TC5) offers a menu of several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx"
10011165|NCT01639092|Experimental|Tenofovir monotherapy|Tenofovir 300 mg/day orally
10011166|NCT01639092|Active Comparator|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
10011167|NCT01639105|Experimental|treated half of the scar|
10011168|NCT01639105|No Intervention|untreated half of the scar|
9476729|NCT03568890|Active Comparator|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 8 weeks.
9476730|NCT03568877|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks
9476731|NCT03568877|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks
9476732|NCT03568864|Placebo Comparator|Low nucleotide meal|Mixed meal containing mycoprotein with a reduced nucleotide content (~ 2% nucleotides)
9476733|NCT03568864|Experimental|High nucleotide meal|Mixed meal containing mycoprotein with a high nucleotide content (~ 10% nucleotides)
9476734|NCT03568838|Experimental|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
9476735|NCT03568838|No Intervention|Standard Therapy|Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
9476736|NCT03568825|Experimental|Number of Osteopatic Manual Therapy|Intervention: OMT. Osteopatic Manual treatment consisting of Thoracic spine, Diaphragm mobilisation, Traction of the cardia and posture correction.
9476737|NCT03568825|Experimental|Interval in days between each OMT|Intervention: OMT. The time between each OMT's is calculated by the study design. Each OMT intervantion consists of Thoracic spine and Diaphragm mobilisation, Traction of the cardia and Posture correction.
9476738|NCT03568812|Experimental|Probiotics Rillus®|Rillus®, Chewing tablet containing viable cell 1.0 x 10^9 colony forming unit (Lactobacillus plantarum 8.55 mg, Streptococcus thermophilus 8.55 mg, Bifidobacterium bifidum 2.55 mg, fructooligosaccharide 480 mg), isomalt, xylitol, milk flavour, vanilla flavour Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
9476739|NCT03568812|Placebo Comparator|Placebo|Placebo: Chewing tablet with identical flavour, colour, smell, and size as investigational drug Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
9476740|NCT03568799|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
9964506|NCT01239654|Active Comparator|everolimus|everolimus-eluting stent
9964507|NCT01239654|Active Comparator|zotarolimus|zotarolimus-eluting stent
9964508|NCT01239667|Experimental|Life style counseling|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
9964509|NCT01239693|Active Comparator|IFA group|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
9964510|NCT01239693|Active Comparator|MMN group|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients' Children from 6 to 18 months of age: None
9964511|NCT01239693|Experimental|LNS group|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
9964512|NCT01239706|Experimental|NTx 265|
9964513|NCT01239719|Experimental|Dexamethasone + Clemastine|Dexamethasone + clemastine fumarate cream
9964514|NCT01239719|Active Comparator|Dexamethasone|Dexamethasone 0.5 mg
9964515|NCT01239771|Experimental|1|TC-5214
9964516|NCT01239771|Placebo Comparator|2|Placebo matched to TC-5214
9964517|NCT01239784|Experimental|All Subjects|A total of 20 children and their parents will be recruited for this study. Ten children will have had the Glenn procedure and 10 infants will have had the arterial switch operation.
9964518|NCT01239810||Control group|Receiving no treatment
9964519|NCT01239810||hyaluronic acid|treatment group receiving intraarticular hyaluronic acid
9964520|NCT01239823|Experimental|Whole Body Vibration Training|The subjects will participate in a 12-week whole body vibration exercise program with 2 sessions (1/2 hour) per week.
9964521|NCT01239823|Experimental|Exercise without vibration|The subjects will participate in a 12-week exercise program with 2 sessions (1/2 hour) per week.
9964522|NCT01239836|Experimental|Self-management|
9964523|NCT01239836|Sham Comparator|General Health Lecture|
9964524|NCT01239836|Experimental|Combined workshop and self-management|
9964525|NCT01239836|Experimental|Workshop|
9964526|NCT01239862|Experimental|Autologous cell transplantation|We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion criteria were age 18-50 years, chronic and accelerated silicosis, forced expiratory volume in 1s <60% and >40%, forced vital capacity ≥60% and arterial oxygen saturation >90%. BMDMCs were administered through bronchoscopy (2×107 cells) into both lungs. Physical examination, laboratory evaluations, quality of life questionnaires, thoracic computed tomography scans, lung function tests, and perfusion scintigraphy were performed before the beginning of treatment and up to 360 days after BMDMC (Bone Marrow Derived Mononuclear Cells) therapy. Additionally, whole-body and planar scans were evaluated 2 and 24 h after instillation.
9964527|NCT01239875|Experimental|Arm A|Patients receive pneumococcal polyvalent vaccine intramuscularly in weeks -4, 2, and 10. Patients undergo cryoablation followed by dendritic cell vaccine (CA-DC) intratumorally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
9964528|NCT01239875|Experimental|Arm B|Patients receive pneumococcal polyvalent vaccine as in arm A. Patients also receive autologous dendritic cell-tumor fusion vaccine (TL-DC) intradermally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
9964529|NCT01239888|Active Comparator|Oxytocin|
9964530|NCT01239888|Active Comparator|Oxytocin and Tibolone|
9964531|NCT01239888|Placebo Comparator|Placebo|
9964532|NCT01239940|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
9964533|NCT01239940|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
10011169|NCT01639131|Experimental|ARM I|Patients will receive intravenous gemcitabine 800mg/m2 on days 1 and 8 and docetaxel 70mg/m2 on day 8 of each 21 day cycle. Patients will receive filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle.
10011170|NCT01639170|Experimental|subjects undergoing abdominal surgery|"Subjects who undergone abdominal intervention and reported major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.~Exclusion criteria: inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes."
10011171|NCT01639183|Experimental|Rotating-oscillating Power Toothbrush|Nursing home residents will be randomly assigned to receive power toothbrushing twice daily by their caregivers using a rotating-oscillating power toothbrush.
10011172|NCT01639183|Active Comparator|Standard Care|This arm comprises the control group where nursing home residents will receive standard daily oral care as usual.
10011173|NCT01639196|Experimental|Self-compassion writing|
10011174|NCT01639196|Active Comparator|Self-efficacy writing|
10011175|NCT01639209|Experimental|Vitrectomy|
10011176|NCT01639209|Experimental|Pneumatic retinopexy|
10011177|NCT01639248|Experimental|ENMD-2076 Treatment|ENMD-2076
10011178|NCT01639274|Other|COPD|
10011179|NCT01639287||Painless|"Painless synovitis group(called cold synovitis)"
10011180|NCT01639287||Painful|Painful synovitis group
10011181|NCT01639300|Experimental|GNbAC1|
10011182|NCT01639300|Placebo Comparator|GNbAC1 placebo|
10011183|NCT01639326|Experimental|Irinotecan high doses|Patients will receive irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
10011184|NCT01639326|Active Comparator|Irinotecan standard doses|Patients will receive irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours
10011185|NCT01639378|Experimental|Renal Denervation|Subjects are treated with renal denervation after randomisation and maintained on heart failure medications
10011186|NCT01639378|No Intervention|Control group|Subject will have a sham procedure and not receive renal denervation. They will continue with the heart failure medications
10011187|NCT01639391|Experimental|patients|
10011188|NCT01639404|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation
10011189|NCT01639430||Geriatric patients ED|Consecutive patients >= 75 years in the emergency department.
10011190|NCT01639456|Experimental|Patients Using CD3-/CD19- NK cell product|Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
9964534|NCT01239953|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
9964535|NCT01239953|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
9964536|NCT01239979||Stable, Unstable , control|
9964537|NCT01240005|Experimental|DCIK|
9964538|NCT01240018|Placebo Comparator|Placebo|
9964539|NCT01240018|Active Comparator|High dose Lb. casei|
9964540|NCT01240044|No Intervention|Control Group|In this group the newborns remained at rest 20 minutes and receive no intervention of respiratory therapy.
9964541|NCT01240044|Experimental|Physical Therapy|In this group the newborns are submitted to the mechanical vibrator.
9964542|NCT01240044|Experimental|Thoracoabdominal rebalancing|In this group the newborns receive the thoracoabdominal rebalancing.
9964543|NCT01240057|Placebo Comparator|expectant management during pregnancy|watchful waiting during pregnancy
9964544|NCT01240057|Experimental|fetal endoluminal tracheal occlusion|fetoscopic balloon occlusion at 27 to 29+6 weeks of gestation
9964545|NCT01240070|Active Comparator|Usual Care|Clinical practice in type 2 diabetes treatment
9964546|NCT01240070|Active Comparator|Intensive Care|Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.
9964547|NCT01240083|Experimental|Thetaburst Stimulation|1: Thetaburst stimulation: right DLPFC continuous TBS followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 stimuli, 80% motorthreshold
9964548|NCT01240083|Experimental|High frequency rTMS|2: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC, 110% motor threshold, followed by 1000 stimuli of 10 Hz over the left DLPFC , 110% motorthreshold
9964549|NCT01240083|Experimental|Placebo Stimulation|3: Sham Stimulation (Sham coil): right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
9964550|NCT01240096|Active Comparator|Mirtazapine|mirtazapine 15 mg daily
9964551|NCT01240096|Placebo Comparator|Placebo|Placebo once daily
9964552|NCT01240109|Active Comparator|propofol|
9964553|NCT01240109|Active Comparator|sevoflurane|
9964554|NCT01240148|Experimental|1|150 μL intradermal injection of 1 μmol/L AZD3161
9964555|NCT01240148|Experimental|2|150 μL intradermal injection of 6 μmol/L AZD3161
9964556|NCT01240148|Experimental|3|150 μL intradermal injection of 30 μmol/L AZD3161
9964557|NCT01240148|Active Comparator|4|150 μL intradermal injection of 10 mg/mL Lidocaine
9964558|NCT01240148|Placebo Comparator|5|150 μL intradermal injection of AZD3161 placebo
9964559|NCT01240161||Patients with high grade gliomas|All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
9964560|NCT01240174|Other|Intervention Arm|Single arm in the study of doctors receiving feedback about their antibiotic prescribing rate for acute bronchitis.
10011191|NCT01639456|Experimental|Patients Using CD3-/CD56+ purified NK cell product|Patients receive the apheresis product (collected day -1): purified for NK cells using the CliniMACS® CD3 Reagent System (Miltenyi Biotec) in combination with the large-scale tubing set to deplete CD3+ cells and then use the CliniMACS® CD56 Reagent System to enrich CD56+ NK cells (CD3-CD56+ natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
10011192|NCT01639482||Citalopram|Patients with bipolar disorder
10011193|NCT01639482||Placebo|Patients with bipolar disorder
10011194|NCT01639508|Experimental|Cabozantinib|This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion. Patients in GROUP D will have tumors with a RET fusion and have progressed on a selective RET TKI.
10011195|NCT01639521|Experimental|Arm A (gemcitabine hydrochloride, cisplatin)|Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
10011196|NCT01639521|Experimental|Arm B (MVAC)|Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
10011197|NCT01639534||Biomarkers, Carotid Stenting, Blood sample|Subjects requiring Carotid Stenting Procedure at Virginia Commonwealth University/Medical College of Virginia Health Systems
10011198|NCT01639547|Experimental|PEGASYS® plus ROBATROL® for 36 weeks|
10011199|NCT01639547|Active Comparator|PEGASYS® plus ROBATROL® for 48 weeks|
10011200|NCT01639586|Active Comparator|D|Impact of the day care on health profit of patient
10011201|NCT01639586|Active Comparator|C|No access to a respite structure
10011202|NCT01639586|Active Comparator|B|Respite platform
10011203|NCT01639612|Experimental|ALD-451|Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide
10011204|NCT01639625|Experimental|CIGB300|
10011205|NCT01639638|Placebo Comparator|Placebo|
10011206|NCT01639638|Experimental|CIGB-300 - 5 mg|
10011207|NCT01639638|Experimental|CIGB-300 - 15 mg|
10011208|NCT01639651|Active Comparator|Control Group|
10011209|NCT01639651|Experimental|Mobilization Group|
10011210|NCT01639677|Experimental|Laparoscopic gastric bypass|
10011211|NCT01639677|Active Comparator|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
10011212|NCT01639716||Lymphoma group|
10011213|NCT01639716||healthy group|
10011214|NCT01639716||IL-10 high|
10011215|NCT01639716||IL-10 low|
10011216|NCT01639716||IL-4 high|
10011217|NCT01639716||IL-4 low|
10011218|NCT01639716||lymphopenia|
9476741|NCT03568786|Experimental|End-inspiratory pause (EIP) 10%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a of 10% of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 10% of total inspiratory time.
10011219|NCT01639768|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
10011220|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 3,333 AUN/ml|
10011221|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 10,000 AUN/ml|
10011222|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
10011223|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 40,000 AUN/ml|Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee
10011224|NCT01639781|Active Comparator|flavanol rich intervention|flavanol rich drink
10011225|NCT01639781|Placebo Comparator|flavanol free intervention|flavanol free drink
10011226|NCT01639794||Male patients with non-neurogenic LUTS taking VESITRIM|Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
10011227|NCT01639807|Active Comparator|latanoprost 2-8˚ C|latanoprost(0.005%)stored at 2-8˚ C
10011228|NCT01639807|Experimental|SLT|Selective laser Trabeculoplasty
10011229|NCT01639820|Experimental|Strategy A|Only identification of sentinel nodes (without pelvic lymph-node dissection)
10011230|NCT01639820|Other|Strategy B|Identification of sentinel nodes + full pelvic lymph-node dissection
10011231|NCT01639846|Experimental|RX-10045 active arm|RX-10045 Ophthalmic Solution, 0.09%
10011232|NCT01639846|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
10011233|NCT01639859|Experimental|Elastography|
10011234|NCT01639885|No Intervention|Group 1|Patients will receive standard care (gemcitabine)
10011235|NCT01639885|Experimental|Group 2|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron)
10011236|NCT01639885|Experimental|Group 3|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron) and p53 SLP vaccin
10011237|NCT01639898|Experimental|"Group 1 (2-cycles trial)"|"The 2-cycles trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1)."
10011238|NCT01639898|Experimental|"Group 2 ( 9 cylces Trial)"|"The 9-cycles trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2)."
10011239|NCT01639911|Experimental|Treated Patients with Solid Tumor|Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.
10011240|NCT01640002|Active Comparator|Propantheline|
10011241|NCT01640002|Placebo Comparator|Placebo|
10011242|NCT01640015|Experimental|low frequency diet|Participants will be assigned to a low frequency diet (fixed energy intake)
10011243|NCT01640015|Experimental|High frequency diet|
10011244|NCT01640041|Experimental|Implanted|All participants.
10011245|NCT01640067|Experimental|Human Neural Stem Cells Suspension|50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.
10011246|NCT01640093|Experimental|Treatment B|Abiraterone acetate (500 mg), 2 coated, reformulated tablets.
10011247|NCT01640093|Experimental|Treatment C|Abiraterone acetate (250 mg), 4 coated, reformulated tablets.
10011248|NCT01640093|Experimental|Treatment D|Abiraterone acetate (500 mg), 2 coated, reformulated tablets, showing slower in vitro dissolution.
10011249|NCT01640093|Active Comparator|Treatment A|Abiraterone acetate (250 mg), 4 uncoated, current commercial tablets.
10011250|NCT01640106|Experimental|Omega-3|Treatment arm, using the omega-3 product (fish oil/paste)
10011251|NCT01640106|Placebo Comparator|Control|Placebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste
10011252|NCT01640119|Placebo Comparator|no intervention|
10011253|NCT01640119|Experimental|Bicarbonate|
9964561|NCT01240187|Experimental|Experimental 1|
9964562|NCT01240187|Experimental|Experimental 2|
10011254|NCT01640145|Placebo Comparator|Carbohydrate|
10011255|NCT01640145|Active Comparator|Protein continous boluses|
10011256|NCT01640145|Active Comparator|Protein 2 boluses|
10011257|NCT01640158|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training, up to 65 hours
10011258|NCT01640158|Active Comparator|Active Comparator|Commercially available computerized training, up to 65 hours
10011259|NCT01640223|Experimental|D-3 sensor|patients will be equiped with 2 Dexcom sensors 3 days before hospitalization
10011260|NCT01640223|Experimental|D-1 sensor|patients will be equiped with 2 Dexcom sensors one day before hospitalization
10011261|NCT01640262||localized prostate cancer|Danish men with localized prostate cancer
10035689|NCT01808885|Experimental|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
10035690|NCT01808885|Placebo Comparator|placebo|placebo (3 soft capsules, od) will be administered orally for 6 months
10035691|NCT01808898|Experimental|Local anaesthetic|2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
10035692|NCT01808898|Placebo Comparator|Saline|2mls of Normal Saline solution in a 5ml syringe
9964563|NCT01240213|Active Comparator|Vitamin D|2000 IU per day of Vitamin D
9964564|NCT01240213|Placebo Comparator|Placebo|
9964565|NCT01240226|Experimental|A|
9964566|NCT01240226|Experimental|B|
9964567|NCT01240239||telephone group|The telephone group must be healthy adults scheduled for an ENT surgery.
9964568|NCT01240239||telemedicine group|This group if qualified will randomly be chosen to be in the telemedicine group.
9964569|NCT01240239||pre-anesthesia consultation|This will be the group that will be randomized to the pre-anesthesia clinic.
10035693|NCT01808911|Active Comparator|Bras A|Steroid 1mg/kg/d and Cyclophosphamide 2mg/kg/d
10035694|NCT01808911|Experimental|Bras B|Steroid 1mg/kg/d and Rituximab 375 mg/m2 every week during four weeks
10035695|NCT01808976|Active Comparator|Evolution|This app is designed to be a cognitive training game that conditions the CCN. This is done by having participants play a multitasking game that targets their perceptual discrimination abilities, selective attention, and visuomotor tracking skills. At the first session, participants will be directed to an initial assessment of each of these cognitive control skills in a single task and dual-task setting (a total of 3 different diagnostics, described below). Each week, this diagnostic phase will reflect the training paradigm they will encounter for that week, as each week the perceptual and tracking challenges will increase.
10035696|NCT01808976|Experimental|Problem Solving Therapy|This app is based on the social problem solving protocol developed by Nezu and D'Zurilla . The app begins with explaining the PST steps. Participants are informed that they can learn each step one session at a time, or they can chose to learn all the steps at once. After each step completed, participants are asked if they want to continue onto the next step or save it for the next session, thus the app tailors itself to the users ability to absorb new information.
10035697|NCT01808976|Active Comparator|Basic health push app|This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
9964570|NCT01240252|Experimental|Type 2 Diabetes Mellitus Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
10035698|NCT01809002|Experimental|Processed Nerve Allograft|Processed Nerve Allograft
10035699|NCT01809002|Active Comparator|Collagen Nerve Cuff|
10035700|NCT01809015||Cohort A: Regular medical care|Patients treated with vitamin K antagonists in regular medical care system
10035701|NCT01809015||Cohort B: Coagulation service|Patients with oral anticoagulation therapy in a telemedicine-based coagulation service
10035702|NCT01809028|Active Comparator|EUS FNA with 2 passes|biopsy with 2 passes of the needle
10011262|NCT01640275|Active Comparator|Propofol based intravenous anesthesia|patients will receive propofol based intravenous anesthesia
10011263|NCT01640275|Experimental|Isoflurane Based Inhaled Anesthesia|patients will receive isoflurane based inhaled anesthesia
10011264|NCT01640301|Experimental|Arm I (high-risk for relapse after HCT)|Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
10011265|NCT01640301|Experimental|Arm II (relapsed after HCT)|Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
10011266|NCT01640392|Experimental|HIV prevention groups|Participants randomly assigned to the MyLife Intervention arm receive three 1.5-hour HIV behavioral risk-reduction group sessions over a 1-3 week period.
10011267|NCT01640392|No Intervention|Wait-list control|Participants randomly assigned to the Wait-list Control arm receive the MyLife MyStyle group sessions once they have completed a 6-month follow-up assessment.
10011268|NCT01640405|Active Comparator|Control|modified FOLFOX6 + bevacizumab
10011269|NCT01640405|Experimental|Experimental|FOLFOXIRI+bevacizumab
10011270|NCT01640418|Experimental|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
9802526|NCT05191004|Experimental|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with fulvestrant until the recommended Phase 2 combination dose (RP2cD) is determined.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
10011271|NCT01640418|No Intervention|Standard Care|Standard Care
10011272|NCT01640431|Experimental|Lumbar stabilization exercises|In the Segmental Stabilization group exercises the focus is on the transversus abdominis and lumbar multifidus muscles.
10011273|NCT01640431|Experimental|TENS group|In this group, patients are treated with TENS in the lumbar region for an hour.
10011274|NCT01640444|Experimental|A|FOLFIRI+bevacizumab
10011275|NCT01640444|Experimental|B|FOLFIRI + cetuximab
10011276|NCT01640457|Experimental|NDplus|NOVOCART® Disc plus (Autologous Disc Chondrocyte Transplantation System)
10011277|NCT01640457|Placebo Comparator|NDbasic|NOVOCART® Disc basic (media with no active cell component)
10011278|NCT01640457|No Intervention|Sequestrectomy only (SC)|Sequestrectomy (standard of care)
10011279|NCT01640470|Experimental|Assistive technology|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will include recommendations for assistive technology, possibly entailing financial assistance to repair or to acquire new AT, and training. New equipment will likely include devices such as bathroom grab bars, raised toilet seats, walkers, and bath chairs.
10011280|NCT01640470|Active Comparator|Customary care|Participants in this arm will receive customary care.
10011281|NCT01640496|Active Comparator|Vitamin D|Subjects will take 1 pill per day for 8 weeks.
10011282|NCT01640496|Placebo Comparator|Placebo|Subjects will be asked to take 1 pill per day for 8 weeks.
10011283|NCT01640509|Experimental|synchrotron radiation|treated by synchrotron radiation
10011284|NCT01640522|Experimental|Collaborative Care Intervention|Care coordinator facilitates the assessment and treatment of cancer-related symptoms
9802527|NCT05191004|Experimental|Phase 2 NUV-422 + fulvestrant|"NUV-422 will be administered orally at the RP2cD in combination with fulvestrant.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
10011285|NCT01640522|Active Comparator|Enhanced Usual Care|Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
10011286|NCT01640535|Experimental|Test arm|Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg
10011287|NCT01640535|Active Comparator|Comparator arm I|Matching placebo of Montelukast sodium 10mg + Levocetirizine dihydrochloride 5 mg
10011288|NCT01640535|Active Comparator|Comparator arm II|Montelukast sodium 10mg + matching placebo of Levocetirizine dihydrochloride 5mg
10011289|NCT01640561|Experimental|MISC|The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein (consultant) has been used to enhance the development of children throughout the developing world, with the support of such international aid agencies as the World Health Organization (WHO), UNICEF, Norwegian Agency for Development Cooperation (NORAD), and Redd Barna (Norway).
10011290|NCT01640561|Active Comparator|Enhanced Treatment as Usual|
10011291|NCT01640574|Experimental|DHA-P 7 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
10011292|NCT01640574|Experimental|DHA-P 14 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
10011293|NCT01640574|Active Comparator|Chloroquine 7 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
10011294|NCT01640574|Active Comparator|Chloroquine 14 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
10011295|NCT01640587|Experimental|DP|2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
10011296|NCT01640587|Active Comparator|MAS3|4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2
10011297|NCT01640600||Children exposed to SSRIs in utero|This group are comprised of children whose mothers used antidepressants during pregnancy and who were therefore exposed to antidepressants in utero.
10011298|NCT01640600||Children exposed to nicotine in utero|This group is comprised of children whose mothers smoked cigarettes during pregnancy and who were therefore exposed to nicotine in utero.
10011299|NCT01640600||Children exposed to neither nicotine nor SSRIs|This group is comprised of children who were exposed to neither nicotine nor SSRIs in utero.
10011300|NCT01640626|Active Comparator|Health Education|Deworming will be conducted in both schools. A health education package will be introduced to schoolchildren in the intervention school (School A) only. Both schools will be followed up for 6 months.
10011301|NCT01640626|No Intervention|Control|Schoolchildren in school B will serve as a control group. No intervention (Health education package) will be given after complete deworming at baseline.
10011302|NCT01640639|Active Comparator|Thalidomide|Thalidomide
10011303|NCT01640639|Placebo Comparator|Placebo|Placebo
10011304|NCT01640652|Experimental|Low dose vaccine arm|To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
10011305|NCT01640652|Experimental|High dose vaccine arm|To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
10011306|NCT01640665|Experimental|Sorafenib and Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days
10011307|NCT01640678|Experimental|ReCell epidermal cell suspension grafting|CO2 laser abrasion + ReCell epidermal cell suspension + UV-therapy
10011308|NCT01640678|Active Comparator|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
10011309|NCT01640678|No Intervention|No treatment + UV-therapy|
10011310|NCT01640691|Experimental|Study vaccine (AdimFlu-W)|0.5 mL/dose, a total of 2 doses, 21 days apart
10011311|NCT01640730|Experimental|Kanglaite injection|
10011312|NCT01640743|Experimental|Evertwist 1|Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).
10011313|NCT01640743|Experimental|Evertwist 2|Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).
10011314|NCT01640769|Active Comparator|Image guided delivery of pacing leads|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm) versus standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
10011315|NCT01640769|Placebo Comparator|Standard delivery of pacing leads|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
9964571|NCT01240252|Experimental|Overweight or Obese Subjects with Normal Glucose Tolerance|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
9964572|NCT01240252|Placebo Comparator|Non-Obese Control Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
9964573|NCT01240265|Experimental|Vitamin D 150,000 units once|Single dose of vitamin D3 150,000 IU given orally once
9964574|NCT01240265|Experimental|Vitamin D 5000 units daily|Vitamin D3 5000 IU daily given orally for 28 days
9964575|NCT01240291|Experimental|alanyl-glutamine|Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
9964576|NCT01240291|Placebo Comparator|normal saline|Intravenous placebo (normal saline; 0.9 %)
9964577|NCT01240369||VEGF-C low|
9964578|NCT01240369||VEGF-C high|
9964579|NCT01240369||miR-326 low|
9964580|NCT01240369||miR-326 high|
9964581|NCT01240395|Experimental|MBCT intervention|
9964582|NCT01240395|No Intervention|Control group|
9964583|NCT01240408|Experimental|Treatment group 1|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
9964584|NCT01240408|Experimental|Treatment group 2|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
9964585|NCT01240434|Active Comparator|Fascia closure of the surgical trocars|Arm in which all the surgical trocar orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone)
9964586|NCT01240434|No Intervention|Trocar site without closure|All the orifices of the trocar site are left open, closing only the skin.
9964587|NCT01240447|Other|Best support treatment|
9964588|NCT01240447|Experimental|Racotumomab vaccine|
9964589|NCT01240460|Experimental|1|Twice-daily dosing (every 12 hours) XL765
9964590|NCT01240460|Experimental|2|Once-daily dosing XL147
9964591|NCT01240460|Experimental|3|Once-daily dosing XL765
9964592|NCT01240499|Experimental|Health-At-Every-Size (HAES)|
9964593|NCT01240499|Active Comparator|Social Support (SS)|
9964594|NCT01240499|No Intervention|Control|
9964595|NCT01240525|Other|CD4 DLI|Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.
9964596|NCT01240525|Other|No DLI|Patients will receive no DLI post transplant as trial treatment.
9964597|NCT01240538|Experimental|Treatment (virus and chemotherapy)|Patients receive wild-type reovirus IV over 60 minutes QD on days 1-5. Some patients also receive cyclophosphamide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9964598|NCT01240629|Experimental|Arm I|Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9964599|NCT01240642|Experimental|ASA404|
9964600|NCT01240655|Experimental|LCL161 + Paclitaxel|
9964601|NCT01240668||Hyponatremia Patients|Euvolemic or hypervolemic hyponatremia with serum sodium ≤130 mmol/L
9964602|NCT01240681|Other|FLT PET and BOLD MRI scan|All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy
9964603|NCT01240707|Other|LF tests, Fiberoptic bronchoscopy|Spirometry, Peak Expiratory Flow (PEF). Bronchoscopic assessment of soot in central airways.
9964604|NCT01240720|Experimental|I131-F16SIP|"Phase I: Multicentre, open-label, two-step singlearm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-F16SIP, given at the RD of 55.5 mCi/m2, as determined in phase I."
9964605|NCT01240772|Experimental|DGALM|doppler-guided arterial ligation with mucopexy
9964606|NCT01240772|Active Comparator|SH|stapled haemorrhoidopexy according to Longo
9964607|NCT01240798||Depression, anxiety|
9964608|NCT01240824|Experimental|BCG + aminophylline|Bacillus Calmette-Guerin (BCG) plus one of three escalating doses of aminophylline administered intravesically.
9964609|NCT01240837|Active Comparator|glucose|
9964610|NCT01240837|Active Comparator|sucrose|
9964611|NCT01240837|Experimental|palm sugar|
9964612|NCT01240850|Active Comparator|Prednisone|
9964613|NCT01240850|Experimental|Methotrexate+Prednisone|
9964614|NCT01240889|Active Comparator|montelukast|luekotriene inhibitor
9964615|NCT01240889|Active Comparator|Fluticasone|Nasal steroid
9964616|NCT01240928|Experimental|MK-2206 + exemestane +/- goserelin|Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
9964617|NCT01240941|Experimental|MK-2206|MK-2206 maximum tolerated dose found from Phase Ib trial (under a separate NCT number) taken orally on a weekly basis
10011316|NCT01640782|Experimental|Sequential regimen|Sequential treatment with CPT-11 plus Fluorouracil (FU), folinic acid (LV) and Docetaxel (TXT) plus Cisplatin (CDDP)
10011317|NCT01640782|Active Comparator|De Gramont regimen|Fluorouracil (5-FU), folinic acid (LV)
9964618|NCT01240954|Active Comparator|OSIRIS|
9964619|NCT01240954|Experimental|OSIRIS other concentration 1|
9964620|NCT01240954|Experimental|OSIRIS other concentration 2|
9964621|NCT01240980|Experimental|BMS-903452 (0.1 mg) or Placebo - A1|(Healthy Subjects)
9964622|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - A2|(Healthy Subjects)
9964623|NCT01240980|Experimental|BMS-903452 (3.0 mg) or Placebo - A3|(Healthy Subjects)
9964624|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A4|(Healthy Subjects)
9964625|NCT01240980|Experimental|BMS-903452 (30 mg) or Placebo - A5|(Healthy Subjects)
9964626|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A6|(Healthy Subjects)
9964627|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - A7|(Healthy Subjects)
9964628|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - B1|(Subjects with type 2 Diabetes Mellitus)
9964629|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - B2|(Subjects with type 2 Diabetes Mellitus)
9964630|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - B3|(Subjects with type 2 Diabetes Mellitus)
9964631|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A11|(Healthy Subjects)
9964632|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A12|(Healthy Subjects)
9964633|NCT01240993|Active Comparator|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study.
9964634|NCT01240993|Experimental|Mothers and Toddlers Program|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
9964635|NCT01241006|Active Comparator|Dexamethasone|Single dose of Dexamethasone 12 mg PO and 4 days of placebo capsules
9964636|NCT01241006|Active Comparator|Prednisone|Prednisone 60mg PO capsules for 5 days
9964637|NCT01241019|Experimental|Topiramate|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate
9964638|NCT01241019|No Intervention|Control|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia
9964639|NCT01241032|Experimental|Udenafil|Udenafil 200mg
9964640|NCT01241032|Active Comparator|Udenafil + Alcohol|Udenafil 200mg + Alcohol
10011318|NCT01640821|Experimental|Intervention group (CdM?)|This group will be composed of women that are seeking help for weight-related problems that have been referred to the CdM? program.
10035703|NCT01809028|Active Comparator|EUS FNA with 4 passes|biopsy with 4 passes of the needle
10011319|NCT01640821|No Intervention|Control group|This group will be composed of women that are seeking help for weight-related problems but that are actually on the waiting list for participating to the CdM? program.
10011320|NCT01640847|Experimental|Arm RT: HIFU plus ThermoDox|Index lesion has been treated with EBRT and is currently painful, but these subjects have already received their maximum cumulative EBRT dose.
10011321|NCT01640847|Experimental|Arm NRT: HIFU plus ThermoDox|Subjects have no yet received any radiation to the index lesion.
10011322|NCT01640886||Standard of Care|"Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)~Comparison to the reference method (30 ug cefoxitin disc diffusion)."
10011323|NCT01640886||KeyPath Test Group|All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.
10011324|NCT01640899|Other|Single-arm study|This is a single-arm study. Just one group (i.e. the patients)
10011325|NCT01640912|Experimental|RXI-109|
10011326|NCT01640912|Placebo Comparator|Placebo|
9802528|NCT05191004|Experimental|Phase 2 NUV-422 monotherapy|NUV-422 will be administered orally at the RP2cD.
10011327|NCT01640977||Open PLIF|The PLIF procedure achieves access to the degenerated disc from the back of the spine, and is performed through a single midline posterior incision that is typically expanded bilaterally past the facet joints to expose bony landmarks for pedicle screw fixation, which are traditionally placed in a trajectory from lateral to medial, requiring a more lateral starting point.
10011328|NCT01640977||MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach, avoiding the far lateral exposure typical of the traditional PLIF.
10011329|NCT01640990|Experimental|Cohort 1|slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg), and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg)
10011330|NCT01640990|Experimental|Cohort 2|Dose to be determined after analysis of Cohort 1
10011331|NCT01641003||Fresh tumor specimen|Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab.
10011332|NCT01641016|Active Comparator|Continuous Therapy|Continue with current antiretroviral therapy regime as per standard care
10011333|NCT01641016|Experimental|Short Cycle Therapy|Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
10011334|NCT01641029||pyelonephritis|Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.
10011335|NCT01641068|Experimental|Arm I (memory and thinking skills workshop)|Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).
10035704|NCT01809041|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
10035705|NCT01809041|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) and remifentanil (0.1 - 0.5 µg/kg/min)
10011336|NCT01641068|Active Comparator|Arm II (Education Workshop)|Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
10011337|NCT01641146|Experimental|Enhanced Sexual Health Intervention for Men|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
10011338|NCT01641146|Active Comparator|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
10011339|NCT01641172|Active Comparator|Patients|Patients with disseminated testicular cancer
10011340|NCT01641172|Placebo Comparator|Healthy volunteers|Healthy men, age 18-50 years old
10011341|NCT01641185|Experimental|protons|irradiation 20 x 3,3 GyE protons
10011342|NCT01641185|Experimental|carbon ions|irradiation 20 x 3,3 GyE carbon ions
10011343|NCT01641211|Experimental|Video intervention|Group that will watch the Meducation inhaler device technique videos.
10011344|NCT01641211|Other|Control|This group will watch a nutrition video.
10011345|NCT01641224|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
10011346|NCT01641224|Active Comparator|Pinaverium|
10011347|NCT01641224|Placebo Comparator|Placebo|Placebo is blindly given to patients
10011348|NCT01641250|Experimental|Part A: RO5429083|
10011349|NCT01641250|Experimental|Part B: RO5429083 + cytarabine|
10011350|NCT01641263|Experimental|Cognitive Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
10011351|NCT01641263|Active Comparator|Sleep Seminar|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
10011352|NCT01641276|Experimental|hepatitis|hepatitis B carriers patients
10011353|NCT01641276|Experimental|hepatocellular carcinoma patients|hepatites B carriers patients with associated hepatocellular carcinoma
10011354|NCT01641289|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate"
10011355|NCT01641289|Active Comparator|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
10035706|NCT01809067|Active Comparator|Lavender Aromatherapy Inhalers|Lavender Aromatherapy Inhalers
10011356|NCT01641302||Patients undergoing robot-assisted laparoscopic prostatectomy|Patients undergoing robot-assisted laparoscopic prostatectomy under general anesthesia
10011357|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,28 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 28 with equine rabies immunoglobulin 40 IU/Kg on day 0.
10011358|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,14 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 14 with equine rabies immunoglobulin 40 IU/Kg on day 0.
10011359|NCT01641315|Active Comparator|Rabies vaccine, IM Day 0,3,7,14,28 with RIG|Rabies exposed victims receive rabies vaccination intramuscularly on Day 0,3,7,14,28 with equine rabies immunoglobulin 40 IU/Kg on day 0
10011360|NCT01641328|Active Comparator|Waitlist Control / Home-based training|This group will serve as a waitlist control group while the active group is performing training. Following assessment at the end of the active group period, this group will begin home-based training and will be assessed at the end of that 10 week period.
10011361|NCT01641328|Experimental|Cognitive Activation Group|This group will attend the 3/week group intervention meetings over 10 weeks.
10011362|NCT01641341|Placebo Comparator|Placebo capsule|Placebo capsule (sugar pill with no active medication)
10011363|NCT01641341|Active Comparator|Active treatment|"Active treatment will consist of the following interventions:~Bowel Dysbiosis - probiotics Bifidobacterium infantis,~Maldigestion/Malabsorption - Pancrelipase~Parasitic infection/presence - Nitazoxanide"
10011364|NCT01641393|Experimental|EUR-1008 then Kreon|"EUR-1008 during Treatment Period 1 (29 days ±2 days) and~Kreon during Treatment Period 2 (29 days ±2 days)."
10011365|NCT01641393|Experimental|Kreon then EUR-1008|"Kreon during Treatment Period 1 (29 days ±2 days) and~EUR-1008 during Treatment Period 2 (29 days ±2 days)."
10011366|NCT01641406|Experimental|ER- (Triple Neg. and ER- PR+ Her 2 -)|Experimental chemotherapy using neoadjuvant approach
10011367|NCT01641406|Experimental|Her 2 +|Experimental chemotherapy using neoadjuvant approach
10011368|NCT01641406|Experimental|ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)|Experimental chemotherapy using neoadjuvant approach
10011369|NCT01641419|Placebo Comparator|Placebo|Ropivacaine 0.5% plus 2ml of normal saline used for nerve block
10011370|NCT01641419|Active Comparator|Dexamethasone 4 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 4 mg used for nerve block
10011371|NCT01641419|Active Comparator|Dexamethasone 8 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 8 mg used for nerve block
10011372|NCT01641432|Experimental|TAPAT|Computerized Tonic and Phasic Attention training consisting of visual, auditory, and spatial stimuli that requires sustained attention (24 minutes). Training is followed by a computerized cognitive exercise (12 minutes).
10011373|NCT01641432|Active Comparator|Active Comparator|Computerized conventional board-games that lack the therapeutic effect of the TAPAT exercises. Active control has stimulus parameters similar to the TAPAT exercises (eg. stimuli is presented on the computer, participant responses are collected, session time and improvement is measured).
10011374|NCT01641458|Experimental|fluoropyrimidine-based chemotherapy|DPYD-genotype and TDM-driven dosing of 5FU/Capecitabine
10011375|NCT01641484|Experimental|local control 19.8Gy|local control at 19.8 Gy, at Day 14
10011376|NCT01641497|Active Comparator|3D conformational radiotherapy|25 * 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
10011377|NCT01641497|Experimental|Intensity-Modulated Radiation Therapy|25 * 1.8 Gy in 5 weeks (=45 Gy). IMRT
10011378|NCT01641510|Experimental|Prasugrel|Loading and maintenance dose of prasugrel
10011379|NCT01641510|Active Comparator|Clopidogrel|Loading and maintenance dose of clopidogrel
10011380|NCT01641523||Hydroxyapatite Cranioplasty|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
10011381|NCT01641523||polymethylmethacrylate|patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis
10011382|NCT01641523||autologous bone|patients underwent to cranioplasty reconstruction by autologous bone repositioning
10011383|NCT01641536|Experimental|1mg of HB-110|The subjects in this group will be administered 1 mg of HB-110 according to the protocol.
10011384|NCT01641536|Experimental|2mg of HB-110|The subjects in this group will be administered 2 mg of HB-110 according to the protocol.
10011385|NCT01641536|Experimental|4mg of HB-110|The subjects in this group will be administered 4 mg of HB-110 according to the protocol.
10011386|NCT01641549|Experimental|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
10011387|NCT01641549|Active Comparator|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent
10011388|NCT01641562||TAXANES|patients with early breast cancer, scheduled to receive taxanes, with doses according to the stage of the disease
10011389|NCT01641575|Experimental|CO-1.01 and Cisplatin|
10011390|NCT01641614|Experimental|Beating heart surgery|Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
10011391|NCT01641614|Active Comparator|heart surgery Group B|Group B (arrested heart) surgery was performed under moderate hypothermia (32⁰C) as technique requirement (3). After cardiac arrest, during the period of cross clamping, the aortic root was perfused through the cardioplegias's cannula with oxygenated blood at a rate between 200 mL/min to 300 mL/min for 2 minutes with 15 minutes intervals.Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
10011392|NCT01641627|Experimental|vibration|proprioceptive stimulation of the lower limb using vibration and plantar pressure boots
10011393|NCT01641666|Experimental|Peg2b + Ribavirin + Boceprevir|Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
10011394|NCT01641679||Suspected recurrent DTC|100 patients with biochemically suspected recurrent DTC
10011395|NCT01641705||Control Group|Group of nonsmokers individuals without respiratory disease.
10011396|NCT01641705||RA patients 1|RA patients nonsmokers with up to five years of disease.
10011397|NCT01641705||RA group 2|RA patients nonsmokers with six to ten years of disease.
10011398|NCT01641705||RA group 3|RA patients nonsmokers with eleven to fifteen years of disease.
10011399|NCT01641705||RA group 4|RA patients nonsmokers with sixteen or more years of disease
10011400|NCT01641718|Experimental|Single sided glue|Mesh is fixed with Tisseel for single sided inguinal hernias.
10011401|NCT01641718|Active Comparator|Single sided stapled|Mesh is fixed with staples for single sided inguinal hernias.
10011402|NCT01641718|Other|Bilateral glue right|"For bilateral inguinal hernias mesh on the right side is fixed with Tisseel, on the left with staples.~Experimental treatment and active comparator in the same patient."
10011403|NCT01641718|Other|Bilateral glue left|"For bilateral inguinal hernias mesh on the left side is fixed with Tisseel, on the right with staples.~Experimental treatment and active comparator in the same patient."
10011404|NCT01641731|Active Comparator|Cow's milk|
10011405|NCT01641731|No Intervention|Control group|
10011406|NCT01641744|Experimental|Group Attachment Based Intervention (GABI)|
10011407|NCT01641744|Active Comparator|Systematic Training for Effective Parenting (STEP)|
10011408|NCT01641757|Experimental|periodontal treatment group|non surgical periodontal therapy will be given to study subjects which will be selected by randomization from total study sample. at the end of study, serum albumin levels of both study and control groups will be compared.
10011409|NCT01641770|Experimental|Dietary Counseling + ONS|
10011410|NCT01641770|Active Comparator|Dietary Counseling|
10011411|NCT01641783|Experimental|nanoparticle Albumin-bound paclitaxel|evaluate one dose level of nab-paclitaxel:125mg/m2
10011412|NCT01641874|Experimental|Specific directional exercise|During the assessment a specific exercise will be identified for this group. The exercise will consist of a repeated specific end range movement of the knee
10011413|NCT01641874|Active Comparator|Evidence based exercise|Quadriceps strengthening and advice on aerobic exercises will be given
10011414|NCT01641874|No Intervention|No intervention|Patient waits on the surgeons waiting list for next appointment or for planned knee surgery
10011415|NCT01641887||GERD patients|Patients who have GERD will be recruited for this study.
10011416|NCT01641913|Experimental|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
10011417|NCT01641965|Active Comparator|early non invasive ventilation|Patients assigned to this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB)immediately after randomization (when their FVC reaches the threshold of the 75% of the predicted value)
10011418|NCT01641965|Active Comparator|standard|patients in this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB) when they fulfil at least one of the following criteria: (i) FVC < 50% predicted, (ii) orthopnea, and/or (iii) PaCO2 > 45 mmHg.
10011419|NCT01642017|Experimental|Pazopanib|Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.
10011420|NCT01642030|Other|Methadone Maintenance|
10011421|NCT01642030|Other|Buprenorphine Maintenance|
10011422|NCT01642069||Observational|Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or MLL-rearrangements, and other gene expression profiling by RT-PCR and karyotyping or FISH. Results are then compared with each patient's outcome data.
10011423|NCT01642095||Basic science (FAK expression)|Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
10011424|NCT01642108|Other|Sitagliptin|
10011425|NCT01642121||Observational|Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by single-cell PCR analysis, flow cytometry, and reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice. Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed for human lymphoid- and myeloid-lineage cells by FACS.
10011426|NCT01642134|Active Comparator|Duoplavin|Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.
10011427|NCT01642134|Sham Comparator|acenocumarol|
10011428|NCT01642160|Active Comparator|Standard of care|Participants randomized to this arm will have the usual follow up care without any additional information.
9518049|NCT03300375|Experimental|Wait-List Control Condition Group|Participants who are assigned to the CON group will wait to participate in the resistance training after a three month wait period. Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time. The participants will be contacted by phone on a monthly basis during the study period to determine if any changes in LBP symptoms have occurred. At month three, these participants will also receive the elastic resistive bands and a stability pad.
10011429|NCT01642160|Active Comparator|Additional Education|This arm will receive a weekly text message or e-mail asking participants to sign on to the web page that we will provide. Once they sign on, they will see additional educational materials and questions regarding their CPAP use. Based on their response, they will be directed to suggestion or sites to help improve their compliance with their CPAP.
10011430|NCT01642173|Other|OCT at baseline|"Subjects enrolled in the NIH funded and IRB approved (08-008161) protocol Lp-PLA2 and Coronary Atherosclerosis in Humans with a positive diagnosis of coronary artery endothelial dysfunction will be studied using Optical Coherence Tomography during the angiogram at baseline."
10011431|NCT01642173|Other|OCT following 6 month Lp-PLa2 inhibition|"Subjects who are enrolled in IRB 10-000044 Lp-PLA2 and Coronary Atherosclerosis in Humans Aim III a study in which the investigators are examining the impact of long-term inhibition of Lp-PLA2, with a specific novel inhibitor or placebo, on Lp-PLA2 activity and improvement in coronary endothelial function will be studied using Optical Coherence Tomography during the 6 month return angiogram."
10011432|NCT01642186|Experimental|Arm A everolimus|"Everolimus will be administered at the following doses:~Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
10035707|NCT01809067|No Intervention|No aromatherapy|No aromatherapy
10011433|NCT01642186|Experimental|Arm B letrozole plus leuprolide|"Day 1 of Cycle 1: Leuprolide 7.5 mg IM will be administered by a nurse in clinic.~Letrozole will be dispensed and will be taken at home. Patients will be instructed to take letrozole at the same time each day, consistently with food or without food, and swallowed whole with a glass of water. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
10011434|NCT01642186|Experimental|Arm C combination everolimus, letrozole and leuprolide|"Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. Leuprolide 7.5 mg IM will be given every 4 weeks (+/- 7 days). Everolimus and letrozole will be administered continuously using the same dose, schedule and administration. Everolimus, letrozole and leuprolide should be administered concurrently at all times."
10011435|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|
10011436|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|
10011437|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss|
10035708|NCT01809080||2020|
10035709|NCT01809080||2019|
10035710|NCT01809080||2018|
10035711|NCT01809080||2017|
10035712|NCT01809080||2016|
10035713|NCT01809080||2015|
10035714|NCT01809080||2014|
10035715|NCT01809080||2013|
10035716|NCT01809080||2012|
10035717|NCT01809080||2011|
10035718|NCT01809080||2010|
10035719|NCT01809080||2009|
10035720|NCT01809080||2008|
10035721|NCT01809080||2007|
9518050|NCT03300362|Experimental|Seasonal influenza & MVA-NP+M1|Two vaccinations will be administered: Seasonal influenza vaccine & MVA-NP+M1
10035722|NCT01809080||2021|
10035723|NCT01809093||Blood draw|Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
10037277|NCT01823575|Experimental|Silicone-covered metallic ureteral stent|Deployment of a silicone-covered metallic ureteral stent for malignant ureteral obstruction and compare the results with placement of a double-J stent in terms of primary patency rate at 3 month follow-up (primary end point)
10037278|NCT01823575|Active Comparator|Double-J stent|Placement of a double-J stent for malignant ureteral obstruction and compare these results to deployment of a silicone-covered metallic stent in terms of primary patency rate at 3 month follow-up.
10037279|NCT01823588|No Intervention|Usual care|Educational program and usual cardiovascular prevention.
10037280|NCT01823588|Experimental|Nurse-led reminder through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse-care manager (NCM)
10037281|NCT01823601|Active Comparator|Seminars in Health|This group of volunteers will attend to seminars in health. Each seminar will last about 120 minutes, a similar period of time used for training experimental group.
10037282|NCT01823601|Experimental|Behavioral Management Program|"Behavioral Management Program consists in to teach to the volunteers procedures which involve autogenic muscle relaxation, progressive self-focus meditation and cognitive-behavioral training to change thoughts, beliefs and behavior in order to control emotions. This program will consist in 10 weekly sessions of about 120 minutes each."
10037283|NCT01823627|Other|Spirometry with reversibility test|Spirometry with reversibility test
10037284|NCT01823640|Experimental|Placebo-HRV|inoculation with placebo followed by inoculation with HRV
10037285|NCT01823640|Experimental|HRV-HRV|inoculation with HRV followed by a second inoculation with HRV
10037286|NCT01823666||Mild cognitive impairment|People with cognitive complaint will be recruited. Who can be diagnosed as mild cognitive impairment will be enrolled according to the MCI criteria.
10037287|NCT01823666||Control|Normal cognition.
10037288|NCT01823692|Other|Distal Radius Fracture|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
10037289|NCT01823705|Experimental|Gastric Electrical Stimulation (GES)|Gastric Electrical Stimulation (GES) therapy for the treatment of obesity.
10011438|NCT01642264|No Intervention|Control (Delayed Training) Condition|Participants in this condition were assessed at 1 week, 1 month and 3 months post-enrollment, and were provided access to the WeBREATHe training website upon completion of their 3-month assessment.
10011439|NCT01642264|Experimental|Intervention (Training) Condition|In this condition, participants used the WeBREATHe training program website for 1 week, and completed assessments at 1 week, 1 month, and 3 months post-training.
9476742|NCT03568786|Experimental|End-inspiratory pause (EIP) 30%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a 30 % of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 30 % of total inspiratory time.
10011440|NCT01642303|Experimental|vodcasting|students who listen to downloaded vodcasting
9518051|NCT03300362|Placebo Comparator|Seasonal influenza & saline placebo|Two vaccinations will be administered: Seasonal influenza vaccine & sodium chloride
9518052|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
10011441|NCT01642303|No Intervention|control|listen to the student book listening file
10011442|NCT01642316|Experimental|washback|students received 8 specific related formative test for that lesson plus a pre-test and post-test, Michigan English language proficiency test
10011443|NCT01642316|Other|control|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
10011444|NCT01642342|Experimental|Weekly Treatment (sEphB4-HSA)|Patients receive recombinant albumin fusion protein sEphB4-HSA IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10011445|NCT01642342|Experimental|Every 2 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10011446|NCT01642342|Experimental|Every 3 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10011447|NCT01642355|No Intervention|Usual Care|Usual care includes physician assistant and/or nurse based medical and lifestyle recommendations in consultation with cardiac catheterization attending or patient's clinical cardiologist to potentially improve the patient's medical and lifestyle regimen. Relevant educational material is routinely distributed to patients.
10011448|NCT01642355|Active Comparator|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
10011449|NCT01642355|Active Comparator|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
10011450|NCT01642368|Placebo Comparator|Regular Diet|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
10011451|NCT01642368|Active Comparator|Medium Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
10011452|NCT01642368|Active Comparator|High Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
10011453|NCT01642381|Active Comparator|Psychotherapy|
10011454|NCT01642381|No Intervention|"Self-Change Control (SCC)"|SCC participants will be told that they should attempt to reduce their drinking over the course of 8 weeks. (If unsuccessful, they will be offered Full Motivational Interviewing therapy sessions.)
10011455|NCT01642394|No Intervention|Standardized care|The control group will receive usual care for secondary prevention of type 2 diabetes according to usual care in Osakidetza's primary care.
10011456|NCT01642394|Experimental|Self-management education programme|Attendees will receive the Diabetes Self-Management Programme in spanish version (Manejo personal de la diabetes).
10011457|NCT01642420||Mild cognitive impairment|Patients diagnosed with mild cognitive impairment
10011458|NCT01642420||Alzheimers disease|Patients diagnosed with mild Alzheimers disease
10011459|NCT01642420||Healthy control persons|Age matched healthy persons
10011460|NCT01642433|Placebo Comparator|Sugar pills|
10011461|NCT01642433|Active Comparator|Prazosin pills|
10011462|NCT01642446|Experimental|surgery|Precise hepatectomy
10011463|NCT01642446|Active Comparator|combined intervention|transcatheter hepatic arterial chemoembolization and/or ablation
10011464|NCT01642459|Experimental|Same direction cannulation|The inserted direction of arterial needle is same as the direction of blood flow.
10011465|NCT01642459|Active Comparator|Opposite direction cannulation|The inserted direction of arterial needle is opposite to the direction of blood flow.
10011466|NCT01642472|Experimental|Ulipristal Acetate (PGL4001) 10mg|Ulipristal Acetate (PGL4001)10mg daily administration
10011467|NCT01642498|Experimental|Group A|ROX Coupler + continuing standard antihypertensive medications
10011468|NCT01642498|No Intervention|Group B|Continuing standard antihypertensive medications
10011469|NCT01642511|Active Comparator|Control Group|conventional technique: 99mTc-labeled Sulfur Colloid was injected into the tumor quadrant 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
10011470|NCT01642511|Experimental|Study Group|modified technique: 99mTc-labeled Sulfur Colloid was injected into 2 quadrants of the breast 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
10011471|NCT01642524|Experimental|hypertonic saline mixed Dextran|hypertonic saline mixed Dextran
10011472|NCT01642524|Placebo Comparator|Placebo controlled|Saline solution
10011473|NCT01642537|Other|Rhythmia Mapping System & Catheter|This is a single arm diagnostic feasibility study with the Rhythmia Mapping System and the Rhythmia Mapping Catheter
10011474|NCT01642563|Experimental|Pathogen reduced platelets|Transfusion
10011475|NCT01642563|Active Comparator|Standard platelets|Transfusion
10011476|NCT01642576|Experimental|diet modification|counselling on caloric restriction and healthy eating
10011477|NCT01642576|Experimental|weight management program|dietician and sports trainer, physician counselling on weight loss
10011478|NCT01642628|Experimental|Body Image/Mirror Education|Participants in the mirror arm will receive a mirror and mirror viewing education from oncology nurse navigators.
10011479|NCT01642628|No Intervention|Standard Care|Patients allocated to the control group will receive the usual pre and post-op standard care that does not include the use or discussion of mirrors.
10011480|NCT01642641|Active Comparator|Non-surgical subgingival debridement|
10011481|NCT01642641|Active Comparator|Simplified Papilla Preservation Flap|
10011482|NCT01642641|Active Comparator|Resective Flap with Osseous Recontouring|
10011483|NCT01642654|Active Comparator|Control|
10011484|NCT01642654|Experimental|Treatment|
10011485|NCT01642667|Placebo Comparator|primary PCI|
10011486|NCT01642667|Active Comparator|prouk-PCI|
10011487|NCT01642680|Experimental|Physical activity during chemotherapy|This group will start with a physical activity program 3 months before the end of their chemotherapeutic regimen. After chemotherapy they will continue the PA program for another 3 months.
10011488|NCT01642680|Active Comparator|Physical activity after chemotherapy|This group will start with a physical activity program after the end of their chemotherapeutic regimen. The physical activity program wil take 6 months to complete.
10011489|NCT01642693|Experimental|Teeth with intrusive movement and low power laser|Histological changes and root resorption were assesed in Teeth with intrusive movement after a low power laser application
10011490|NCT01642693|Experimental|Teeth with intrusive movements with no laser|Histological changes and root resorption in Teeth with intrusive movements with no laser
10011491|NCT01642706||RA patients|Patients affected by Rheumatoid arthritis.
10011492|NCT01642706||Control|"Subjects affected by either :~mechanical pathology~systemic auto-immune pathology~other inflammatory rheumatism"
10011493|NCT01642719|Placebo Comparator|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline
9964641|NCT01241045||misoprostol|"2 groups:-~Group 1:-those with Ph<5. (n=50).~Group 2:-those with Ph > or=5. (n=50). -Each group is subdivided into another two groups:-~Group 1A (n=25). - Group 1B (n=25).~Group 2A (n=25). - Group 2B (n=25).~All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours"
9964642|NCT01241071|Experimental|Myofascial treatment|Myofascial release techniques of different muscles implicated in low back pain
9964643|NCT01241071|Placebo Comparator|Placebo|
9964644|NCT01241084|Placebo Comparator|Placebo|Antileukotrienes+Placebo
9964645|NCT01241084|Active Comparator|Lactobacillus reuteri|Antileukotrienes+Lactobacillus reuteri
9964646|NCT01241097|Experimental|high-dose simvastatin, combined, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
9964647|NCT01241110|Active Comparator|azitromicin,PID treatment,ofluxacin|
9964648|NCT01241123|Placebo Comparator|Traditional Ambulation regimen|All patients will receive pedometers to record the total amount of ambulation. These patients will ambulate without limitations or goals. Most surgeons request that post-operative patients ambulate at least 2 to 3 times a day.
9964649|NCT01241123|Active Comparator|Walkers|All patients will receive pedometers to record the total amount of ambulation. Patients in the experimental group will have assigned nursing staff assisting in ambulation in these patients at least three times a day.
9964650|NCT01241136|Placebo Comparator|Open traditional pilonidal cystectomy|traditional complete wide-excision pilonidal cystectomy
9964651|NCT01241136|Experimental|Minimal invasive pilonidal cystotomy|Using only Keyes Trephines to unroof and curette the pilonidal cyst cavity
9964652|NCT01241149|Active Comparator|Normal pH, abnormal Impedance|After 24hr pH-metry and impedance, those patients with normal pH (i.e. DeMeester score <14.7) but with abnormal impedance scores will be offered anti-reflux surgery
9964653|NCT01241149|Placebo Comparator|Abnormal pH|After 24hr pH-metry and impedance, those with abnormal pH scores (i.e. DeMeester score >14.7)will be offered anti-reflux surgery
9964654|NCT01241162|Experimental|Single arm study|Biological/Vaccine: Autologous dendritic cell vaccine with adjuvant
9964655|NCT01241175|Experimental|magnesium sulfate|
9964656|NCT01241175|Placebo Comparator|normal saline|
9964657|NCT01241188|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
9964658|NCT01241188|Active Comparator|2 TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
9964659|NCT01241201|Placebo Comparator|Placebo|placebo for probiotic treatment
9964660|NCT01241227||Chronic liver disease|All patients with chronic liver disease followed using FibroScan and non-invasive markers
9964661|NCT01241253|No Intervention|Cross-over study|beans and rice in a 50 gram carbohydrate dose
9964662|NCT01241266||1|Target subject population are the consecutive patients hospitalized due to peptic ulcer bleeding. Subjects should be: ≥18 years; admitted to the hospital with an overt upper GI bleed (hematemesis/coffee ground vomiting, melena, hematochezia and other clin
9964663|NCT01241357||Observation only|This study has a single arm and no intervention.
9964664|NCT01241370||Lean healthy subjects|Homeostasis Model Assessment score (HOMAs) ≤ 2, Body Mass Index (BMI) ≤ 28 kg/m2
9964665|NCT01241370||Insulin-resistnat subjects|HOMAs > 2, BMI > 28 kg/m2
9964666|NCT01241370||Type 2 diabetic patients|
10011494|NCT01642719|Experimental|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks. For example, if they spend 9 hr TIB during baseline, they will reduce their TIB to 8 hr.
10011495|NCT01642745|Experimental|Methacholine (Provocholine) with deep inhalation|
10011496|NCT01642745|Experimental|Mannitol (Aridol)|
10011497|NCT01642745|Active Comparator|Methacholine (Provocholine) tidal breathing|
10011498|NCT01642758|Experimental|Sodium 2,2 dimethylbutyrate|A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
10011499|NCT01642771|Active Comparator|5-Fu/epirubicin/CTX following Docetaxel|Docetaxel for the first 3 cycles of chemotherapy followed by 3 cycles of FEC (Fluorouracil, epirubicin and cyclophosphamide) chemotherapy
10011500|NCT01642771|Experimental|Docetaxel/capecitabine followed by XEC|Docetaxel/ capecitabine (TX) for the first 3 cycles of chemotherapy followed by 3 cycles of capecitabine/epirubicin/cyclophosphamide (XEC) chemotherapy
10011501|NCT01642784||Culprit lesion IRA revascularization|Culprit lesion IRA revascularization
10011502|NCT01642784||Complete IRA revascularization|Complete IRA revascularization
10011503|NCT01642797|Experimental|CLE-TB|Confocal laser endomicroscopy with Targeted Biopsy
10011504|NCT01642797|Experimental|WLE-SB|Standard White-light endoscopy with Standard Biopsy
10011505|NCT01642810|Active Comparator|Treatment-as-usual|Participants continue their pre-study treatment plan, based on their physician/other professional recommendations
10011506|NCT01642810|Experimental|Online ABBT treatment + TAU|Participants to complete a 6-unit online Acceptance-based behavioural treatment including training in pacing, mindfulness, acceptance, cognitive defusion, willingness, and exercise while also maintaining their pre-study treatment.
10011507|NCT01642823||retinablastoma tumor tissue|
10035724|NCT01809119|Experimental|Laparoscopic Partial Nephrectomy|Patients with kidney neoplasms submitted to laparoscopic partial nephrectomy
10035725|NCT01809119|Active Comparator|Open Partial Nephrectomy|Patients with kidney neoplasms submitted to open partial nephrectomy
10011508|NCT01642836|Experimental|multi-component, multi-level, multi-setting (MMM)|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
10011509|NCT01642836|Active Comparator|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
10011510|NCT01642849|Experimental|high protein diet|12 subjects will be place on a high protein diet
10011511|NCT01642849|Experimental|high carbohydrate diet|12 subjects will be put on a high carbohydrate diet for 6 months
10011512|NCT01642862|Experimental|Liquid formulation of Simvastatin|
10011513|NCT01642862|Active Comparator|Tablet formulation of Simvastatin|
10011514|NCT01642875|Experimental|EN|early enteral nutrition with standard enteral formulas administered through a nasojejunal tube
10011515|NCT01642875|Active Comparator|PerOs|early oral nutrition with hospital diets and oral formulas
10011516|NCT01642888|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
10011517|NCT01642888|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
10011518|NCT01642927||Intra-Aortic Balloon Pump (IABP) Group|Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
10011519|NCT01642927||IABP/LVAD Group|Post-LVAD surgical patients with IABP
10011520|NCT01642927||Post-LVAD Group|LVAD patients 3 months or greater post-implantation undergoing echocardiography
10011521|NCT01642927||LVAD Event Group|LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
9665142|NCT05169346|Sham Comparator|Sham Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of sham (placebo) neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
10011522|NCT01642927||Arrhythmia group|LVAD patient with an irregular heartbeat.
10011523|NCT01642927||Valvular disease group|LVAD patient with valvular heart disease
9667651|NCT03285763|Experimental|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
9667652|NCT03284268|Experimental|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
10011524|NCT01642927||Normal control group|Healthy participant without any known heart disease (Control group).
10011525|NCT01642940|Active Comparator|Prasugrel|
10011526|NCT01642940|Experimental|Ticagrelor|
10011527|NCT01642953|Experimental|Early recovery|"Patients who enroll in this arm are supplied a liquid diet one day before surgery without bowel preparation.~After gastric cancer surgery, they start sips of water on postoperative first day, and they are discharged once they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination."
10011528|NCT01642966|Active Comparator|Prasugrel|Prasugrel 10mg/day for 15 days
10011529|NCT01642966|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
10011530|NCT01642979|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
10011531|NCT01642979|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
10011532|NCT01642979|Active Comparator|Glucocorticoids|Glucocorticoids
10011533|NCT01642992||Coronary bifurcation lesion|
10035726|NCT01809145|Other|metal hypersensitivity|peripheral blood test for metal hypersensitivity (MELISA test)
9802529|NCT05191004|Experimental|Phase 2 fulvestrant monotherapy|500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter.
9802530|NCT05190874||Device: Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler Interference Screw System
9964667|NCT01241383|Experimental|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
9964668|NCT01241396||001|Any MMY treatment Any line of treatment for MMY
9964669|NCT01241409|Experimental|Treatment sequence ABC|
9964670|NCT01241409|Experimental|Treatment sequence ACB|
9964671|NCT01241409|Experimental|Treatment sequence BAC|
9964672|NCT01241409|Experimental|Treatment sequence BCA|
9964673|NCT01241409|Experimental|Treatment sequence CAB|
9964674|NCT01241409|Experimental|Treatment sequence CBA|
9964675|NCT01241422|Experimental|Treatment A: JNJ 40929837|
9964676|NCT01241422|Placebo Comparator|Treatment B: Placebo|
9964677|NCT01241422|Other|Treatment C: Montelukast|
9964678|NCT01241474|Experimental|Fish oil|
9964679|NCT01241474|Placebo Comparator|Maize (corn) oil|
9964680|NCT01241487|Experimental|1|valsartan/amlodipine
9964681|NCT01241500|Experimental|ON 01910.Na + best supportive care (BSC)|Patients will receive ON 01910.Na 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards and best supportive care (BSC).
9964682|NCT01241500|No Intervention|Best supportive care (BSC)|Patients will receive best supportive care (BSC).
9964683|NCT01241526|Experimental|Disease management program|
9964684|NCT01241526|Active Comparator|Usual site management|
9964685|NCT01241578|Experimental|Mobile Phone Intervention|Participants receive a behavioral intervention via mobile phone and brief in-person counseling sessions.
9964686|NCT01241617|Active Comparator|Duet TRS|Endo GIA with integrated Duet TRS
9964687|NCT01241617|Active Comparator|Endo GIA|Endo GIA stapler with Single Use Loading units
9964688|NCT01241643|Experimental|CYT107|repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
9964689|NCT01241643|No Intervention|Control|Control arm with possible CYT107 injection after 12 months of study participation
9964690|NCT01241656|Experimental|Mail DVD|
9964691|NCT01241656|Experimental|Invite to SMA to view and discuss DESI|
9964692|NCT01241656|Experimental|SMA and DVD|
9964693|NCT01241656|No Intervention|Encouraged to talk to physician|
9964694|NCT01241669|Experimental|Arm 1|
9964695|NCT01241669|Experimental|Arm 2|
9964696|NCT01241682|Experimental|DC immunotherapy + CTX|Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.
9964697|NCT01241695|Experimental|Test|Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement
9964698|NCT01241695|Placebo Comparator|Control|Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement
9964699|NCT01241708|Experimental|Tandem Transplantation with Melphalan and Bortezomib|Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma
9964700|NCT01241721|Experimental|Positron Emission Mammography (PEM)|Positron Emission Mammography (PEM)
9964701|NCT01241734|Experimental|Revlimid (Lenalidomide) in Combination|Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
9964702|NCT01241747|Experimental|Supervised Exercise|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes at an exercise intensity of 40% of exercise capacity.
9964703|NCT01241747|Active Comparator|Control|Light resistance training without any walking
9964704|NCT01241773|Experimental|001|TMC435 Two 75 mg capsules once daily for 14 days
9964705|NCT01241773|Experimental|002|efavirenz One 600 mg tablet once daily for 14 days
9964706|NCT01241773|Experimental|003|TMC435 + efavirenz Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet once daily for 14 days
9964707|NCT01241773|Experimental|004|TMC435 Two 75 mg capsules once daily for 7 days
9964708|NCT01241773|Experimental|005|raltegravir One 400 mg tablet twice daily for 7 days
9964709|NCT01241773|Experimental|006|TMC435 + raltegravir Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
9964710|NCT01241799|Experimental|1|Pancreatic biopsy with stylet in then stylet out
9964711|NCT01241799|Experimental|2|Pancreatic biopsy with stylet out then stylet in
9964712|NCT01241812|Experimental|A.|10 weeks of partially supervised lower limb muscle strengthening targeting the following muscles groups: quadriceps, hamstrings, hip abductors.
9964713|NCT01241812|No Intervention|B|
9964714|NCT01241825|Active Comparator|1.|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy.
9964715|NCT01241825|Placebo Comparator|2.|The control group will not chew chewing gum while undergoing capsule endoscopy.
9964716|NCT01241838|Placebo Comparator|Normal left ventricular size|Postoperative patient with normal left ventricular size
9964717|NCT01241838|Active Comparator|Left ventricular hypertrophy|Postoperative patient with left ventricular hypertrophy
9964718|NCT01241851|Active Comparator|Aerobic exercise|
9964719|NCT01241851|Active Comparator|Resistance exercise|
9964720|NCT01241851|No Intervention|Control|
9964721|NCT01241864|Experimental|Allogenic islet cells (human, U. Chicago)|
9964722|NCT01241877|Experimental|astaxanthin|
9964723|NCT01241877|Placebo Comparator|placebo|
9964724|NCT01241890||Children with Cystic Fibrosis, care as usual|Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
9964725|NCT01241929|Experimental|video decision aid|Video decision aid arm
9964726|NCT01241929|No Intervention|Usual Care -- Verbal Description Arm|Verbal description of CPR (i.e., without the video).
9964727|NCT01241942|Experimental|EVLP with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.
9964728|NCT01241942|Active Comparator|Conventional Lung transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
9964729|NCT01241955|No Intervention|verbal description of CPR|verbal description of CPR
9964730|NCT01241955|Experimental|Video decision aid|Video decision aid of CPR
9964731|NCT01241968|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
9964732|NCT01241968|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
9964733|NCT01241981||Digital Breast Tomosynthesis|Digital Breast Tomosynthesis
9964734|NCT01241994|No Intervention|basal hemodialysis|
9964735|NCT01241994|Active Comparator|AASD|
9964736|NCT01242033|Experimental|one cup red raspberries|treatment meal consists of one cup red raspberries
9964737|NCT01242033|Experimental|two cups red raspberries|treatment meal consists of two cups red raspberries
9964738|NCT01242033|Experimental|four cups red raspberries|treatment meal consists of four cups red raspberries
9964739|NCT01242033|Placebo Comparator|bread|treatment meal consists of two slices white bread
9964740|NCT01242033|Active Comparator|vitamin C|treatment meal consists of two slices white bread and 200 mg vitamin C in the form of supplemental ascorbic acid
9964741|NCT01242046|Experimental|Caffeine|Participants will ingest a tablet with 400 mg caffeine
9964742|NCT01242046|Placebo Comparator|Placebo|Participants will ingest an inert placebo tablet
9964743|NCT01242059|Experimental|Control Tomato Soup|
9964744|NCT01242059|Experimental|10 g of yellow pea fiber|
9964745|NCT01242059|Experimental|20 g of yellow pea fiber|
9964746|NCT01242059|Experimental|10 g of yellow pea protein|
9964747|NCT01242059|Experimental|20 g of yellow pea protein|
9964748|NCT01242072|Experimental|PaCE|Palifosfamide, Carboplatin and Etoposide
9964749|NCT01242098||Fostair switch cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair
9964750|NCT01242098||Seretide continuation cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide
9964751|NCT01242124|Experimental|side-to-side stapled esophagogastric anastomosis arm|
9964752|NCT01242124|Active Comparator|circular-stapled esophagogastric anastomosis arm|
9964753|NCT01242137||Extensive metabolizers|
9964754|NCT01242137||Intermediate mtabolizers|
9964755|NCT01242137||Poor metabolizers|
9964756|NCT01242150|Experimental|NCPAP Helmet|Infants with mild Acute Respiratory Failure who need NCPAP
9964757|NCT01242150|Active Comparator|NCPAP facial mask|Infants with mild Acute Respiratory failure who need NCPAP
9964758|NCT01242202|Experimental|ASP group|Concomitant administration of ASP1941 and α- glucosidase inhibitor
9964759|NCT01242215|Experimental|ASP group|ASP1941 and sulfonylurea
9964760|NCT01242215|Placebo Comparator|Placebo group|placebo and sulfonylurea
9964761|NCT01242228|Experimental|ASP group|Concomitant administration of ASP1941 and DPP-4 inhibitor
9964762|NCT01242254|Experimental|Group A|Patients will receive an intravitreal injection of KH902 0.5mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
9964763|NCT01242254|Experimental|Group B|Patients will receive an intravitreal injection of KH902 2.0mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
9964764|NCT01242267|Other|Thalidomide with melphalan|Safety/Efficacy -
9964765|NCT01242280|Active Comparator|Self-expandable esophageal stent|"The patient will receive a self-expandable esophageal stent (SX-Ella-Danis) without endoscopical guidance but under slight sedation. An immediate X-ray will be done to assess the correct placement of the stent.~After a maximum of 7 days, the stent will be removed by using the specifically designed devices."
9964766|NCT01242280|Active Comparator|Sengstaken-Blakemore tube|The esophageal tamponade will be done as described elsewhere. The gastric content will be checked hourly and the correct placement of the tube will be checked by an immediate X-ray. The esophageal balloon will be inflated a maximum of 24 hours.
9964767|NCT01242293|Active Comparator|0.9% Saline with glucose 5%|rate of infusion is 125cc/h
9964768|NCT01242293|Active Comparator|Ringer lactate|rate of infusion is 250cc/h
9964769|NCT01242293|Active Comparator|Ringer lactate - Controls|rate of infusion is 125cc/h
9964770|NCT01242306|Placebo Comparator|BMS arm|bare metal stent arm
9964771|NCT01242306|Active Comparator|SES arm|sirolimus eluting stent arm
9964772|NCT01242319||Multi-modal practice intervention|15 intervention practices receive academic detailing, patient activation computer kiosk, decision supported PDA, and coronary risk factor management toolbox
9964773|NCT01242319||Usual care|15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines
9964774|NCT01242332|No Intervention|placebo|po 2 hrs before surgery
9964775|NCT01242332|Experimental|Pregabalin|75 mg po 2 hrs before surgery
9964776|NCT01242345|No Intervention|No Intervention|Standard monitoring.
9964777|NCT01242345|Experimental|Capnography|Arm with capnographic monitoring
9964778|NCT01242358|Experimental|Capnography|Arm with capnographic monitoring
9964779|NCT01242358|Placebo Comparator|Standard monitoring|Standard monitoring
9964780|NCT01242384|No Intervention|Expectant Management|
9964781|NCT01242384|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
9964782|NCT01242397|Other|CRT ON|After implant, patients will be randomized to CRT pacing ON vs OFF in crossover fashion with 3 months in each period
10011534|NCT01643005|Active Comparator|Active Control Group|For the active control group we will use Nurturing Parenting Groups currently being run by the community collaborator.
10011535|NCT01643005|Experimental|Relationship Strengthening HIV Prevent.|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
10011536|NCT01643018|Experimental|laparoscopic surgery|-Laparoscopic surgery group describes the patients treated with laparoscopic surgery
10011537|NCT01643018|Active Comparator|Open Surgery|-open surgery group describes the patients treated with traditional open surgery
10011538|NCT01643031|Experimental|Ticagrelor|Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).
10011539|NCT01643031|Active Comparator|Continued Clopidogrel|Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
10011540|NCT01643057||Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
10011541|NCT01643070|Active Comparator|XELOX RT|Concurrent XELOX-RT
10011542|NCT01643070|Active Comparator|Induction XELOX|Induction XELOX followed by XELOX-RT
10011543|NCT01643083|Active Comparator|Rifaximin|
10011544|NCT01643083|Placebo Comparator|Placebo|
10011545|NCT01643096|Other|sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
10011546|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
10011547|NCT01643109|Experimental|CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
10011548|NCT01643109|No Intervention|Comparison|Standard therapy.
10011549|NCT01643122||Group 1|
10011550|NCT01643122||Group 2|
10011551|NCT01643135|Active Comparator|tranexamic acid|Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.
10011552|NCT01643135|Placebo Comparator|0.9% NaCl|0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose
10011553|NCT01643148||breast cancer patients (cases)|36 subjects
10011554|NCT01643148||controls|36 subjects
10011555|NCT01643161|Experimental|TAU+GSH|Treatment As Usual plus Guided Self Help.
10011556|NCT01643161|Active Comparator|TAU|Treatment AS Usual.
10011557|NCT01643174||Surgical treatment|
10011558|NCT01643187|Experimental|Fortified beverage|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
10011559|NCT01643187|Active Comparator|Group receiving lactose-free milk|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
10011560|NCT01643239|Experimental|Hospital-based mCIT with individualized intervention|Hospital-based modified constraint-induced therapy(mCIT)
10011561|NCT01643239|Experimental|Hospital-based mCIT with group therapy|Hospital-based modified constraint-induced therapy(mCIT)
10011562|NCT01643239|Other|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
10011563|NCT01643252|Placebo Comparator|Placebo and UVA light exposure|
10011564|NCT01643252|Active Comparator|Riboflavin drops and UVA light exposure|
10011565|NCT01643265|Active Comparator|Whey Milk Protein|
10011566|NCT01643265|Experimental|Bovine Albumin Concentrate|
10011567|NCT01643278|Experimental|Treatment (dasatinib and ipilimumab)|Patients receive dasatinib PO QD for 7 days. Patients then receive dasatinib PO QD and ipilimumab IV once on weeks 1, 4, 7 and 10. Beginning on week 24, patients then receive dasatinib PO QD and ipilimumab IV once every 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
10011568|NCT01643291|Experimental|Ultrasound|
10011569|NCT01643304||Group 1|
9802531|NCT05188703|Experimental|Intervention arm|Intervention consists of standard of care eye exam and enrollment in a patient navigation program.
9964783|NCT01242397|Other|CRT- OFF|After implant, patients will be randomized to CRT pacing OFF vs ON in crossover fashion with 3 months in each period
9964784|NCT01242410|No Intervention|Expectant Management|
9964785|NCT01242410|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
9964786|NCT01242423|Experimental|superficial 2nd degree burn|Group A (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a superficial 2nd degree burn on ≥1% and ≤30% of the surface of the body.
9964787|NCT01242423|Experimental|deep 2nd degree burn|Group B (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a deep 2nd degree burn on ≥1% and ≤30% of the surface of the body.
9964788|NCT01242423|Experimental|skin excision for the purpose of a skin graft|Group C (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of BBS.
9964789|NCT01242462|Active Comparator|AB|2 hours of treatment with conventional ventilation strategy, then crossover to 2 hours of treatment with mid-frequency ventilation strategy
9964790|NCT01242462|Active Comparator|BA|2 hours of treatment with mid-frequency ventilation strategy, then crossover to 2 hours of treatment with conventional ventilation strategy
9964791|NCT01242475|Experimental|0.1µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
9964792|NCT01242475|Active Comparator|2TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
9964793|NCT01242501|Experimental|60 Min. Risk Reduction Counseling|Single 60 min Social Cognitive Theory-based counseling session delivered in STI clinic setting in Cape Town South Africa. Includes educational, motivational, and sexual risk reduction skills components delivered in a single face-to-face counseling session.
9964794|NCT01242501|Active Comparator|20-min single session education|Single brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
9964795|NCT01242553||Normal|Normal results from clinical exam and free of ocular pathology.
9964796|NCT01242553||Retina|Clinical exam results consistent with retina pathology
9964797|NCT01242553||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
9964798|NCT01242553||Cornea|Clinical exam results consistent with cornea pathology.
9964799|NCT01242566|Experimental|temozolomide|Administration of temozolomide 150-200 mg/m2/day for 5 consecutive days every 4 weeks for a maximum of 12 cycles or until disease progression or prohibited toxicity
9964800|NCT01242579|Active Comparator|Maraviroc Vaginal Gel|Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
9964801|NCT01242579|Active Comparator|Dapivirine Vaginal Gel|Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
9964802|NCT01242579|Placebo Comparator|Matching Placebo Gel|Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
9964803|NCT01242579|Experimental|Maraviroc/Dapivirine Gel|Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
9964804|NCT01242592|Experimental|Homeopathy|
9964805|NCT01242592|Placebo Comparator|Placebo|
9964806|NCT01242605|Experimental|single armed|This is not a randomised trial, there is only one study group. All patients will receive cisplatin/gemcitabine chemotherapy in addition to oral daily dosing of selumetinib
9964807|NCT01242618|Experimental|engineered nasal cartilage graft|Biological intervention: autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold
9964808|NCT01242631|Experimental|Everolimus 10 mg daily|
9964809|NCT01242657|No Intervention|Brief Advice|Standard of care arm with no intervention; includes standard communication regarding youth tobacco cessation such as a brief discussion and printed materials
9964810|NCT01242657|Active Comparator|Not On Tobacco (N-O-T) Program|Teens randomized to this arm participated in the N-O-T program, a proven teen cessation program.
9964811|NCT01242657|Experimental|Quit & Fit|Teens randomized to this arm participated in the Not On Tobacco (N-O-T) program with an added physical activity module.
9964812|NCT01242670|Experimental|Ross River Virus Vaccine|Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
9964813|NCT01242683|Experimental|Case-Management for Behavior Change|Individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
9964814|NCT01242683|Experimental|Case-Management plus Home Visits|Community health worker lifestyle support for weight loss strategies conducted in participants' homes and neighborhood. Also, receive individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
10011570|NCT01643343||Typically Developing|Typically developing toddler volunteers between the ages of 8 months and 3 years
10011571|NCT01643343||Autism|Children between the ages of 8 months and 6 years with a diagnosis of an autism spectrum disorder
10011572|NCT01643356|Active Comparator|Fiber Cereal|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided high fiber cereal to manage hunger.
10011573|NCT01643356|No Intervention|Control Group|Women assigned to this arm of the study will receive routine clinical care and no additional interventions.
9665216|NCT05131022|Experimental|Phase 1b Cohort Expansion in PCNSL or secondary CNS involvement|PCNSL with disease progression on 1 prior therapy, or any of the indications listed above with CNS involvement, with disease progression on 1 prior therapy
10011574|NCT01643356|Active Comparator|Resistant Starch|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided resistant starch to control hunger
10011575|NCT01643369|Experimental|Compassion Meditation Group|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
10011576|NCT01643369|Active Comparator|Health Education and Wellness Group|Eight week training in health and wellness, using a curriculum developed specifically for this study.
10011577|NCT01643369|Experimental|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
10011578|NCT01643395|Experimental|vertebroplasty|
10011579|NCT01643395|Other|conservative therapy (brace)|
10011580|NCT01643421|Experimental|Deep inspiration and expiratory positive airway pressure|The protocol of deep inspiration combined to expiratory positive airway pressure will be applied in asthmatic subjects.
10011581|NCT01643421|No Intervention|Control|
10011582|NCT01643434|Active Comparator|Spironolactone|
10011583|NCT01643434|Active Comparator|Clonidine|
10011584|NCT01643447|Active Comparator|Diammonium glycyrrhizinate|Conventional drugs protect liver
10011585|NCT01643447|Experimental|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
10011586|NCT01643486|Experimental|iTouch phosphate counting program|All patients will have an iTouch that will help them to calculate the required number of phosphate binders to be taken with each meal
10011587|NCT01643486|Active Comparator|Usual Care|Participants in the active comparator group will document their meals in the iTouch but continue to take their phosphate binders as prescribed by their MD/dietician
10011588|NCT01643499|Experimental|Treatment (mFOLFIRINOX)|Patients receive oxaliplatin IV over 2 hours on, irinotecan hydrochloride IV over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10011589|NCT01643538|Active Comparator|Control Arm|"Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or charity donations in this group."
10011590|NCT01643538|Experimental|Personal Financial Incentives Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will receive $20. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
10011591|NCT01643538|Experimental|Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week participants will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity. Charity donation is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
10035727|NCT01809158|Active Comparator|minocycline|Subjects randomized to the minocycline group will take 2 tablets per day, each 100mg of minocycline, for a total daily dose of 200mg of minocycline.
10035728|NCT01809158|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 2 tablets of placebo (matched for minocycline) per day.
10011592|NCT01643538|Experimental|Combined Financial Incentives & Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will receive money and/or be notified that a donation of the selected amount has been sent to the charity, depending on their selected preference. Incentives are terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
10011593|NCT01643551||LVAD Group|18 years and older Planning to undergo VAD implantation
10011594|NCT01643551||Cardiac Surgery Group|18 years or older Planning to undergo valve or coronary bypass surgery
10011595|NCT01643564||Group 1|Heart Transplant Recipients with Unexplained Graft Dysfunction
9518053|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
10011596|NCT01643564||Group 2|Normal Control
10011597|NCT01643564||Group 3|Class III-IV Heart Failure
10011598|NCT01643564||Group 4|Heart Transplant Recipients with Normal Graft Function
10011599|NCT01643577|Active Comparator|Acupuncture protocol for gastroparesis|Patients randomized to this arm will receive an acupuncture protocol that with points designed to treat gastroparesis
10011600|NCT01643577|Placebo Comparator|Acupuncture for musculoskeletal pain|Patients randomized to this arm will receive acupuncture therapy consisting of points designed to treat musculoskeletal pain.
10011601|NCT01643590|Placebo Comparator|Placebo|
10011602|NCT01643590|Experimental|15 mg dose of JVS-100|15 mg dose of JVS-100
10011603|NCT01643590|Experimental|30 mg dose of JVS-100|30 mg dose of JVS-100
10011604|NCT01643603|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. Patients who are day 100-180 post transplant will be eligible. The treatment will be started as close to day 100 as possible. The range of days is provided to ensure that patients have recovered from toxicities associated with ASCT and are not deemed ineligible if they were recovering from any toxicity associated with ASCT at day 100.The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months.
10011605|NCT01643629|Other|Study arm A|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
10011606|NCT01643629|Other|Control Arm B|Control arm B will include subjects receiving Standard therapy
10011607|NCT01643642|Experimental|Cognitive behavioral treatment/farmacotherapy intervention|Brief intervention; intake, cognitive behavioral treatment/farmacotherapy (SSRI) and ROM
10011608|NCT01643642|Other|Treatment As Usual|Control group, TAU
10011609|NCT01643655|Experimental|Autologous Adipose Tissue Derived MSCs|
10011610|NCT01643681|Experimental|AdMSC|Autologous Adipose Tissue derived Mesenchymal Stem Cells
9518054|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
10011611|NCT01643694|Experimental|Electronic intervention|Completion of 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks
10011612|NCT01643694|No Intervention|control group|Completion of baseline and 3 mo survey
10011613|NCT01643720||Autism Spectrum Disorders|Children with Autism Disorders and their parents
10011614|NCT01643720||Typically Developing|Typically Developing children and their parents
10011615|NCT01643733|Experimental|Transonics Arm|Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
10011616|NCT01643733|No Intervention|Control arm|Patient will undergo normal fistula intervention guided only by angiographic assessment
10011617|NCT01643746|Active Comparator|Supera stent|The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
10011618|NCT01643746|Active Comparator|LifeStent|LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.
10011619|NCT01643759|Experimental|buprenorphine transdermal system|buprenorphine transdermal system
10011620|NCT01643785|Experimental|with Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] plus 20,000 units of pronase (endonase), BID for 7 days
10011621|NCT01643785|No Intervention|without Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] for 7 days
10011622|NCT01643811||Gastrectomy|Patients who underwent gastrectomy for early gastric cancer
10011623|NCT01643811||Endoscopic submucosal dissection|Patients who underwent endoscopic submucosal dissection for early gastric cancer
9518055|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
9518056|NCT03300323|Active Comparator|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
9964815|NCT01242683|Placebo Comparator|Usual Primary Care|Continuation of usual primary care managed by the participants' usual physician or nurse practitioner source of care.
9964816|NCT01242696||Coronary artery stenting|All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
9964817|NCT01242722||1|Two experimental and/or intervention groups under 1 arm.
9964818|NCT01242735|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
9964819|NCT01242735|Active Comparator|Health and Wellness|12-week health and wellness education control (HEC)
9964820|NCT01242761||Symptomatic rotator cuff tear|Patients with symptomatic rotator cuff tears presenting to hospital clinic after having ultrasound exam in community with indications for surgery
9964821|NCT01242774|Experimental|Panobinostat|
9964822|NCT01242787|Active Comparator|Entecavir 0.5 mg|Entecavir 0.5 mg
9964823|NCT01242787|Experimental|LB80380|Optimal dose of LB80380 (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
9964824|NCT01242826|Experimental|A|
9964825|NCT01242839|Experimental|CACICOL20|Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer
9964826|NCT01242839|Placebo Comparator|Placebo|The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.
9964827|NCT01242839|Experimental|CACICOL20 and Placebo|Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.
9964828|NCT01242852|Experimental|Additional diagnostic tests|Participants in the experimental arm will undergo standard hysteroscopy with treatment-on-the spot of predefined intrauterine abnormalities. In two of the participating clinics, also a 'Saline Infusion Sonography' (SIS) will be performed, 1 week before the hysteroscopy. After the additional diagnostic test(s), standard IVF/ICSI treatment will be initiated.
9964829|NCT01242852|No Intervention|Routine fertility workup|Patients allocated to the conventional strategy will be scheduled for IVF and undergo standard treatment, without SIS or hysteroscopy.
9964830|NCT01242865|Other|Attention and Interpretation Therapy|
9964831|NCT01242878||healthy volunteers|ethnically matched people who do not have sickle cell disease
9964832|NCT01242878||patients|sickle cell disease patients
9964833|NCT01242904|Experimental|bimodal solution|200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
9964834|NCT01242904|Active Comparator|icodextrin|200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
9964835|NCT01242917|Placebo Comparator|Placebo|
9964836|NCT01242917|Experimental|CCX354-C 100mg twice daily|
10035729|NCT01809171|Experimental|vitamin D3|1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
9964837|NCT01242917|Experimental|CCX354-C 200mg once daily|
9964838|NCT01242943|Experimental|L19SIP I131|"Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I."
9964839|NCT01242956|Experimental|Verum group|video-based training after stroke
9964840|NCT01242956|Placebo Comparator|Placebo group|non-video group
9964841|NCT01242982|Experimental|Operation|Closed reduction and operated for fixation with 2 antegrade intramedullary Kirschner wires.
9964842|NCT01242982|Active Comparator|Conservative treatment|Treated conservatively with reduction and then Plaster of Paris.
9964843|NCT01242995||pancreatobiliary disorders/thin scope|All patients will be evaluated with cholangioscopy and/or pancreatoscopy using the thin scope.
9964844|NCT01243047|Active Comparator|Arm A|Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily
9964845|NCT01243047|Active Comparator|Arm B|Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
10011624|NCT01643824|Experimental|Proton Beam Therapy|"Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
10011625|NCT01643863||Cohort|
10011626|NCT01643889|Experimental|Sequence group ADBC|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
10011627|NCT01643889|Experimental|Sequence group BACD|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
10011628|NCT01643889|Experimental|Sequence group CBDA|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
10011629|NCT01643889|Experimental|Sequence group DCAB|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
10011630|NCT01643915|Active Comparator|Control group|Patients with conventional treatment. No distraction method during the treatment visits.
10011631|NCT01643915|Experimental|Experimental group 1|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
10011632|NCT01643915|Experimental|Experimental group 2|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
10035730|NCT01809171|Placebo Comparator|Placebo|1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months
10035731|NCT01809184|Experimental|Dose level 1|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
10035732|NCT01809184|Experimental|Dose level 2|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
10035733|NCT01809184|Experimental|Dose level 3|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
10035734|NCT01809184|Experimental|Dose level 4|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
10011633|NCT01643941|Experimental|1|SA4Ag vaccine low dose
10011634|NCT01643941|Experimental|2|SA4Ag vaccine mid dose
10011635|NCT01643941|Experimental|3|SA4Ag vaccine high dose
10011636|NCT01643941|Experimental|4|SA3Ag vaccine
10011637|NCT01643941|Placebo Comparator|5|Placebo
10011638|NCT01643954|No Intervention|Arm A|Patients with prostate cancer who have undergone robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center.
10011639|NCT01643954|Other|Arm B|Patients with prostate cancer that will undergo robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center .
10011640|NCT01643967|Experimental|Ozone therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
10011641|NCT01643967|Active Comparator|sunflower oil|"The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.~Other Names:~Sunflower oil"
10011642|NCT01643980|Experimental|Vaginal micronized progesterone|200 mg vaginal route per day
10011643|NCT01643980|Active Comparator|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
10011644|NCT01643993|Experimental|hCG at Time of Embryo Transfer|Patients will have hCG and media (for a total of 20 microliters) inserted during a mock embryo transfer immediately prior to actual embryo transfer.
10011645|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
10011646|NCT01644006|Experimental|Device: Teleconsultation|"In cases of suspected acute coronary syndrome (including STEMI), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
10011647|NCT01644006|No Intervention|Historical Matched Pairs|Historical matched pairs were searched from local protocols. During this phase no teleconsultation system was existent.
10011648|NCT01644019|Experimental|Device: Teleconsultation|"In cases of suspected acute stroke (including intracranial hemorrhage), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, neurological diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
10011649|NCT01644032|Experimental|Device_ Teleconsultation|"Six ambulances from five different Emergency Medical Service (EMS) districts are equipped with a portable telemedicine system. In cases of emergencies, where intravenous analgesia is necessary, if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team and can delegate the application of morphine and other analgesics. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The safety, efficacy and the quality of analgesia should be compared with regular EMS."
10011650|NCT01644032|No Intervention|Historical Control Period|After completion of the study arm, matched pairs from a historical phase (without the ability of teleconsultation) were searched. Local cases were always matched with comparable controls from the same location.
10035735|NCT01809184|Experimental|Dose level 5|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
10035736|NCT01809184|Experimental|Dose level 6|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
10011651|NCT01644045|Experimental|Device: Teleconsultation|"In cases of acute obstructive, respiratory emergencies if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
10011652|NCT01644071|Experimental|arm 1|application of three treatments and three masurements within 3 weeks
10011653|NCT01644084|Experimental|HA (priming)-HES (up to 15 ml/kg after CPB)|
10011654|NCT01644084|Active Comparator|HES (priming)-HES (up to 15 ml/kg after CPB)|
10011655|NCT01644084|Active Comparator|HA (priming)-nonHES (only crystalloids after CPB)|
10011656|NCT01644097|Experimental|Arm I (probiotic mix)|Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
10011657|NCT01644097|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity.
10011658|NCT01644110|Experimental|ruxolitinib/pomalidomide|"Cohort 1 (Patient 1 - Patient 41): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.~Cohort 2 (Patient 42 - Patient 90): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be started at 0.5 mg once daily up to 2 mg once daily."
10011659|NCT01644123||Nursing home residents|
10011660|NCT01644136|Experimental|Supportive care (microsphere-mediated lymphocele prevention)|Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis.
10011661|NCT01644162|Other|iVAPS ventilation|3 months of ventilator use in iVAPS mode with data monitoring
10011662|NCT01644201|Active Comparator|High viscosity non-starch polysaccharide, PolyGlycopleX®-PGX®|
10011663|NCT01644201|Placebo Comparator|Placebo (Rice Flour)|
10011664|NCT01644214|No Intervention|Pessary Check at 3 months|Patients seen at 3 month intervals for pessary check-ups is the most common interval check in our clinic so this arm is considered the control group.
10011665|NCT01644214|Experimental|6 month Pessary Check|Those that will be seen at 6 month follow-up visits for pessary maintenance will be considered the experimental group of the study.
10011666|NCT01644253|Experimental|Cohort 1 - Previously Untreated CLL|20 mg/kg TRU-016 + Rituximab
10011667|NCT01644253|Experimental|Cohort 2 - Relapsed CLL|20 mg/kg TRU-016 + Rituximab
10011668|NCT01644253|Experimental|Cohort 3 - Previously Untreated CLL|10 mg/kg TRU-016 + Rituximab
10011669|NCT01644253|Experimental|Cohort 4 - Previously Untreated CLL|20 mg/kg TRU-016 20 + Obinutuzumab
10011670|NCT01644253|Experimental|Cohort 5 - Relapse CLL|20 mg/kg TRU-016 + idelalisib + rituximab
10011671|NCT01644253|Experimental|Cohort 6 - With CLL on ibrutinib with no complete response|20 mg/kg TRU-016 + ibrutinib
10011672|NCT01644253|Experimental|Cohort 7 - With CLL on ibrutinib with stable disease|20 mg/kg TRU-016 + ibrutinib
10011673|NCT01644253|Experimental|Cohort 8 - With relapsed or refractory PTCL|20 mg/kg TRU-016 + 90 mg/m2 bendamustine
10011674|NCT01644279||Young|Young (age 20-35 years old)
10011675|NCT01644279||Old high-functioning|Old high-functioning (age 70-99 years old)
10011676|NCT01644279||Old low-functioning|Old low-functioning (age 70-99 years old)
10011677|NCT01644305||Polycystic Ovary Syndrome|
9518057|NCT03300323|Active Comparator|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
10011678|NCT01644305||Idiopathic hirsutism|
10011679|NCT01644305||Control|
10011680|NCT01644318||authoimmıne thyroiditis and habitual abortus|
10011681|NCT01644318||authoimmune thyroiditis|
10011682|NCT01644318||healthy controls|
10011683|NCT01644344|Active Comparator|X-ray|Control group: patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks. Each time radiographs are completed, the surgeon or resident will document if a change in fixation position is noted and if a change in patient management will be entertained (addition, modification or maintenance of cast or splint use, modification of or decision not to advance activity level, need for further surgery to adjust fixation or fracture reduction). The patients' time spent in clinic will be recorded upon arrival and upon completion of the patient-physician interaction.
10011684|NCT01644344|Active Comparator|No X-ray|
10011685|NCT01644357|No Intervention|Dispensing only|Non clinical pharmacists will dispense drugs to patients and usual care will be offered.
10011686|NCT01644357|Experimental|Pharmaceutical care|Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.
10011687|NCT01644370|Other|HIV positive with aeroallergen|positive for aeroallergen at baseline
10011688|NCT01644370|Other|HIV positive without aeroallergen|negative for aeroallergen at baseline
10011689|NCT01644370|No Intervention|control|HIV negative children (n=10)
10011690|NCT01644383|Experimental|Treatment arm (logotherapy)|Participants in Arm I will attend the logotherapy group sessions by the trained psychologist for 4 visits (see Table II, III). The number of participants in group sessions will be 20 participants per group.
10011691|NCT01644383|No Intervention|Control arm (general health education)|Participants in Arm II will attend the routine health education by the nurse. The number of participants in group session will be 20 participants per group.
10011692|NCT01644422|Other|Study arm A|Subjects will receive hair follicles transplants that are dipped in HPL before transplant
10011693|NCT01644422|Other|Study arm B|Subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection one week after transplant
10011694|NCT01644422|Other|Control arm C|Subject will receive Standard hair follicle transplant
10011695|NCT01644435|Other|Study arm A|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
10011696|NCT01644435|Other|Study arm B|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring.
10011697|NCT01644448|Other|Study arm A|Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
10011698|NCT01644448|Other|Control Arm B|Topical Applications of the standard therapy as directed by the investigator
10011699|NCT01644461|Other|Study Group|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
10011700|NCT01644487|Experimental|Primary stenting|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
10011701|NCT01644487|Active Comparator|Balloon only|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
9802532|NCT05184504||Patients with pathological diagnosis of renal cell carcinoma|
10011702|NCT01644513||Positive Responders|Have received at least one injection with no evidence of residual subretinal or intra-retinal fluid present on Spectral Domain Optical Coherence Tomography (SDOCT) one month (+/- 1 week) following most recent injection.
10011703|NCT01644513||Suboptimal Responders|Have received three or more injections in last six months with residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection; Have not demonstrated complete resolution of fluid following any of the injections in the last 6 months Show leakage on Fluorescein Angiography (FA) or Indocyanine Green (ICG) imaging at some time during last 12 months
10011704|NCT01644526|Experimental|Hemoaccess Valve System|Valve system for use with AV graft
10011705|NCT01644539|Other|Control|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion of 500 ml non caloric load consisting of water and thickening agent (guar gum), over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml non caloric load consisting of water and thickening agent (guar gum) in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
10035737|NCT01809184|Experimental|Dose level 7|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
9803682|NCT03555149|Experimental|Atezolizumab + Regorafenib + AB928|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
9518058|NCT03300310|Experimental|with nursing visit|a nurse visit is scheduled twice a week during 3 months at patient home.
9518059|NCT03300310|Experimental|without nursing visit|no nursing visit
9964846|NCT01243060|Experimental|Almorexant 100mg|Subjects will receive a one-time dose of Almorexant 100mg.
9964847|NCT01243060|Experimental|Almorexant 200mg|Subjects will receive a one-time dose of Almorexant 200mg.
9964848|NCT01243060|Active Comparator|Zolpidem|Subjects will receive a one-time dose of Zolpidem 10mg.
9964849|NCT01243060|Placebo Comparator|Placebo|Subjects will receive a one-time dose of Placebo.
9964850|NCT01243086|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
9964851|NCT01243086|Active Comparator|Ranibizumab and OZURDEX|Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
9964852|NCT01243099||In-stent (BMS) restenosis|
9964853|NCT01243099||De-novo coronary lesion|
9964854|NCT01243164|Experimental|Wheelchair Skills Training Program|A standardized wheelchair skills training program to teach 32 specific wheelchair skills.
9964855|NCT01243203|Placebo Comparator|Placebo|patient will receive placebo pills
9964856|NCT01243216|Experimental|Ultrasound Group|Patients in the Ultrasound Group will have a pre-procedure ultrasound of the spine prior to needle placement
9964857|NCT01243216|No Intervention|No Ultrasound Group|Patients in the No Ultrasound Group will not have a pre-procedure ultrasound of the spine performed prior to needle placement.
9964858|NCT01243255||1|Patients with hypercholesterolemia on lipid lowering pharmacological treatment
9964859|NCT01243281|Active Comparator|drug combination|
9964860|NCT01243307|Experimental|CT327 treatment period 1|Subjects in Group 1 will receive CT327 during treatment/testing period 1 and placebo during treatment/testing period 2
9964861|NCT01243307|Experimental|CT327 treatment period 2|Subjects in Group 2 will receive placebo during treatment/testing period 1 and CT327 during treatment/testing period 2
9964862|NCT01243359|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive sunitinib malate PO on days 1-28 and bevacizumab IV over 30-90 minutes on day 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9964863|NCT01243372||Correlative (BRAF V600E mutation analysis)|Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and outcome data from patients enrolled on CALGB-C80405.
9964864|NCT01243385|Other|Metformin|Metformin at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
9964865|NCT01243398|Experimental|Gefitinib 500mg once daily|Gefitinib 500mg once daily
9964866|NCT01243398|Placebo Comparator|Placebo|Gefitinib 500mg once daily
9964867|NCT01243437|Experimental|ciprofloxacin|
9964868|NCT01243437|Active Comparator|doxycycline|
9964869|NCT01243476|Experimental|lenalidomide|Experimental treatment branch with Lenalidomide 5 mg/day (oral use)
9964870|NCT01243476|Placebo Comparator|placebo|Placebo branch (oral use)
9964871|NCT01243489|Other|patient diary|compliance supporting measure: patients uses patient diary from month 6 to 12
9964872|NCT01243489|Other|"Information service Leben mit CML"|"compliance supporting measure: patient uses the Information service Leben mit CML"
9964873|NCT01243502|Experimental|0.01% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.01% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
9964874|NCT01243502|Experimental|0.001% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.001% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
9964875|NCT01243515||Chronic Kidney Disease|minimum 7 subjects (male and female)
9964876|NCT01243515||Healthy subjects|minimum 3 subjects (male and female)
9964877|NCT01243528||Patients in neurological rehabilitation|Patients suffering from a neurological disease
9964878|NCT01243541|Experimental|Arm I|Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
9964879|NCT01243541|Experimental|Arm II|Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
9964880|NCT01243554|Experimental|Exercise training|Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
9964881|NCT01243554|No Intervention|Control|Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive
9964882|NCT01243606|Experimental|Single Diagnosis Treatment Protocols|Four disorder-specific cognitive-behavioral treatments will be conducted in accordance with treatment manuals of demonstrated efficacy. SDPs will be matched to the principal anxiety disorder diagnosis.
9964883|NCT01243606|Experimental|Unified Protocol|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders will be individually administered in accordance with a treatment protocol.
9964884|NCT01243606|No Intervention|Waitlist Control|Waitlist participants will not receive treatment during a 16-week waitlist period, but will receive the treatment of their choice immediately following the 16 week waiting period.
9964885|NCT01243658|Experimental|Oxytocin|Oxytocin
9964886|NCT01243658|Placebo Comparator|Placebo|Placebo
9964887|NCT01243684|Active Comparator|Healty volunteers|
9964888|NCT01243684|Experimental|Patients|
9964889|NCT01243697|Experimental|desogestrel|Tablets of 75 µg, once daily during 112 days
9964890|NCT01243710|Experimental|Taurolidine with heparin|
9964891|NCT01243710|Active Comparator|Heparin|
9964892|NCT01243723|Experimental|Eductyl suppository|
9964893|NCT01243723|Placebo Comparator|Placebo suppository|
9964894|NCT01243736|No Intervention|Standard prep|One group will receive the standard bowel preparation, which consists of eating no solid foods after 7 p.m. the evening prior to the capsule endoscopy test and being able to consume clear liquids up to 4 hours prior to the capsule endoscopy test
9964895|NCT01243736|Active Comparator|Combination Prep|"The other group will receive the combination bowel preparation, which consists of taking the standard bowel preparation plus:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
9964896|NCT01243788|Active Comparator|Ipratropium/Albuterol|Ipratropium/Albuterol 36/206ug QID
9964897|NCT01243801|Active Comparator|Epidural ketamine|"Bolus of epidural ketamine during the induction of anesthesia~Epidural infusion of ketamine during the first 48 h after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
9964898|NCT01243801|Active Comparator|Intravenous ketamine|"Bolus of intravenous ketamine administered during the induction of anesthesia~Intravenous infusion during the first 48 hours after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine plus fentanyl"
9964899|NCT01243801|Placebo Comparator|Placebo|"Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
9964900|NCT01243814|Active Comparator|supartz|active intervention arm
9964901|NCT01243814|Placebo Comparator|saline injection|placebo intervention arm
10011706|NCT01644539|Other|Oral ingestion|"Subjects participated in a 35 min fmri scan. Intervention: Oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk, over 5 min.~Time frame while scanning:~-5 - 0 min : baseline fmri scan 0 - 5 min: oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
10011707|NCT01644539|Other|Intra Gastric|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk, over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
10011708|NCT01644552||eye examinations|
10011709|NCT01644578|Other|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
10011710|NCT01644604|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
10011711|NCT01644604|No Intervention|Control Group|Subjects are maintained on baseline anti-hypertensive medications
10011712|NCT01644630|Active Comparator|Cemented single crowns|Cemented single crown: zirconia abutment (Straumann Cares abutment) with an all-ceramic lithium disilicate crown
10011713|NCT01644630|Active Comparator|Screw-retained single crown|Screw-retained single crown: zirconia abutment (Straumann Cares abutment), directly veneered with veneering ceramic
10011714|NCT01644656|Experimental|acoustic radiation force impulse (ARFI)|Imaging of liver and spleen using modified ultrasound
10011715|NCT01644682|Experimental|Arm-1|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IWFPL intervention.
10011716|NCT01644682|Experimental|Arm-2|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IDWL intervention.
10011717|NCT01644682|Experimental|Arm-3|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive ITN intervention.
10011718|NCT01644682|No Intervention|Control|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will not receive any intervention, Control group
10011719|NCT01644708||Overweight, obese adult patients|Patients following a self empowerment group will be included in the study
10011720|NCT01644721|Experimental|Early measles vaccine|An additional measles vaccine at 4 months of age, at least 28 days after the third dose of pentavalent vaccine
10011721|NCT01644721|No Intervention|Control|Follows the normal vaccination schedule
10011722|NCT01644747|Active Comparator|active tDCS|a group named G1 and treated by medication with SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and 10 sessions of active anodal tDCS at 2 sessions per day (1 morning and 1 afternoon with a gap of 3h) for 5 days with an electric current 2 mA.
10011723|NCT01644747|Sham Comparator|sham tDCS|a group named G2 and treated by medication with SSRIs or SNRIs for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and sham tDCS.
10011724|NCT01644760|Experimental|Study population|Healthy subjects with spontaneous ventilation, 18 to 50 years of age.
10011725|NCT01644773|Experimental|Chemotherapy|Research participants with high grade glioma or diffuse intrinsic pontine glioma will receive crizotinib and dasatinib.
10011726|NCT01644799|Experimental|lenalidomide and idelalisib|"Lenalidomide:~Lenalidomide will be administered orally on days 1-21 followed by 7 days of rest, every 28 days. A treatment cycle will be considered 28 days in length. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of 12 cycles.~Idelalisib:~Dosing is fixed in all cohorts receiving idelalisib at 150 mg orally (twice daily) for 12 cycles, with the exception of dose modifications for toxicity."
10035738|NCT01809223|Experimental|conbercept treatment group|Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
10011727|NCT01644812|Active Comparator|Aerobic exercise|The exercise intervention is a 12-week program involving 150 minutes of moderate intensity exercise (65-69% of participant's age-predicted [220-age] maximum heart rate) each week. Participants will complete one 50-minute supervised treadmill exercise session in the laboratory and 100 minutes of exercise on their own. These exercises may include walking, jogging, biking, or other forms of aerobic exercise. The at-home exercise regimen will be individualized for each participant.
10011728|NCT01644812|Sham Comparator|stretching|The exercise intervention is a 12-week program involving 150 minutes of stretching each week (one 50-minute stretching session in the laboratory and 100 minutes of stretching at home). Participants in the stretching condition will work with a facilitator to create a stretching regimen for 100 minutes of home stretching throughout the week. The facilitator will provide a list of potential stretches with descriptions on how to perform them.
10011729|NCT01644825|Experimental|paclitaxel and pazopanib|
10011730|NCT01644825|Active Comparator|paclitaxel|
10011731|NCT01644838|Experimental|Promethazine|25 mg of promethazine
10011732|NCT01644838|Experimental|Hyoscine|20 mg of hyoscine
10011733|NCT01644851|Experimental|Executive function training|Executive function training
10011734|NCT01644851|Placebo Comparator|Word game training|Computer-based training in tasks related to verbal processing.
10011735|NCT01644864|Placebo Comparator|Placebo|saline injection
10011736|NCT01644864|Experimental|Experimental|0.375% ROPIVACAINE
10011737|NCT01644877|Experimental|DAS181|DAS181-F02, 4.5 mg qd x 10 days
10011738|NCT01644877|Placebo Comparator|Lactose Placebo|placebo, 4.5 mg qd x 10 days
10011739|NCT01644916|Other|Usual control|Usual control will be provided with usual standard management of COPD and psychiatric comorbidities.
10011740|NCT01644916|Other|Integrated care|Integrated care will be provided with integrated care management.
10011741|NCT01644929|Experimental|1 tDCS-Sham|tDC stimulation for 3 weeks, then cross-over to sham stimulation
10011742|NCT01644929|Experimental|2 Sham-tDCS|Sham stimulation for 3 weeks, then cross over to tDCS stimulation
10011743|NCT01644929|Sham Comparator|3 Sham-Sham|Treatment for 6 weeks daily with sham stimulation
10011744|NCT01644942|Other|Insulin sensitive patients|
10011745|NCT01644942|Other|Insulin resistant patients|
10011746|NCT01644955|Experimental|Treatment (carboplatin)|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room and then receive carboplatin administered intracerebrally by convection enhanced delivery.
10011747|NCT01644968|Experimental|KLH + anti-OX40|Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
9518060|NCT03300297|Active Comparator|Cervical Spine Thrust Joint Manipulation|Thrust Manipulation delivered to C0/1 and C2/3 on both the right and left side
9518061|NCT03300297|Sham Comparator|Cervical Spine Sham Manipulation|Sham Manipulation delivered to C0/1 and C2/3 on both the right and left side
9518062|NCT03300284||Thyroid cancer|This study does not involve any intervention, but rather data collection on patient and physician preferences and beliefs, communication, and patient psychological outcomes.
10011748|NCT01644968|Experimental|Tetanus vaccine + anti-OX40|Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH
10011749|NCT01644981||VLBW infants|
10011750|NCT01644994|Experimental|intracavitary cisplatin-fibrin|single dose local intracavitary cisplatin-fibrin application after pleurectomy/decortication
10011751|NCT01645033|Experimental|TAU plus computerized CBT|Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
10011752|NCT01645033|Active Comparator|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
10011753|NCT01645046|Active Comparator|Coenzyme A 200mg|Coenzyme A 200mg per day.
10011754|NCT01645046|Placebo Comparator|Placebo|Capsule without coenzyme A.
10011755|NCT01645046|Active Comparator|Coenzyme A 400mg|Coenzyme A 400mg per day.
10011756|NCT01645072|Experimental|Low glycemic index diet|The patients will be started on low glycemic index diet.
10011757|NCT01645072|Other|Control group|Standard care. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented.
10011758|NCT01645085|Experimental|Treatment A|100mg MCC-based 13% drug-loaded tablets
10011759|NCT01645085|Experimental|Treatment B|100mg mannitol-based 38% drug-loaded tablets
9518063|NCT03300271|Other|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
9518064|NCT03300271|Experimental|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
9964902|NCT01243827|Experimental|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
9964903|NCT01243827|Experimental|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
9964904|NCT01243853|Active Comparator|Alpha-galactosidase|
9964905|NCT01243853|Placebo Comparator|Placebo|
9964906|NCT01243866|Experimental|Early treatment|comprehensive dental treatment
9964907|NCT01243866|No Intervention|Regualr treatment|Regular treatment consisted of children who would be on a waiting list for regular dental treatment at KFAFH for at least 8 months
9964908|NCT01243879|Active Comparator|Fasting with stimuli|Fasting in the presence of food-related stimuli
9964909|NCT01243879|Sham Comparator|Fasting without stimuli|Fasting in the absence of food-related stimuli
9964910|NCT01243905|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the child (TAU)
9964911|NCT01243905|Placebo Comparator|Treatment as usual|Treatment as usual for the child (TAU)
9964912|NCT01243918|Experimental|VNI/Optiflow, Immunodeficient patients|VNI = non invasive ventilation
9964913|NCT01243918|Experimental|Optiflow/VNI, Immunodeficient patients|VNI = non invasive ventilation
9964914|NCT01243918|Experimental|Ospal/Optiflow, Immunocompetent patients|
9964915|NCT01243918|Experimental|Optiflow/Ospal, Immunocompetent patients|
9964916|NCT01243931|Experimental|Surgery|OCT is assisting in surgery guidance.
9964917|NCT01243970|Active Comparator|phenylephrine infusion|
9964918|NCT01243970|Active Comparator|Ephedrine infusion|
9964919|NCT01243983|Experimental|LX211|
9964920|NCT01243983|Placebo Comparator|Placebo|
9964921|NCT01243996|Experimental|Infant treated with high dose ibuprofen|
9964922|NCT01244009|Experimental|MK-4827|All Participants
9964923|NCT01244022||Colorectal cancer patients|Patients with pathohistologically verified colorectal cancer or adenoma with epithelial dysplasia
9964924|NCT01244074|Experimental|biofeedback|
9964925|NCT01244100|Experimental|PL2200|
9964926|NCT01244139|Experimental|Active study drug|Treatment
9964927|NCT01244139|Experimental|Comparator|Dummy drug
9964928|NCT01244152|Experimental|Intervention|
9964929|NCT01244152|Active Comparator|Control Group|
9964930|NCT01244165|Other|Cytrix|Observational Study
9964931|NCT01244165|Other|Control Group|Patients with similar indications who were treated at the same centers using other products
9964932|NCT01244178|Experimental|Tight Glucose Control Hyperinsulinemic Group|
9964933|NCT01244178|Experimental|Non-Tight Glucose Control Hyperinsulinemic Group|
9964934|NCT01244178|Active Comparator|Standard Insulin Protocol Group|
9964935|NCT01244204|Experimental|Vitamin D|
9964936|NCT01244204|Placebo Comparator|Placebo|
9964937|NCT01244217|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old
9964938|NCT01244217|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
9964939|NCT01244217|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
9964940|NCT01244230|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old - Type: Experimental
9964941|NCT01244230|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
9964942|NCT01244230|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
9964943|NCT01244256|Experimental|Treatment with Clotrimazole + Gentamicin + Beclomethasone|
9964944|NCT01244256|Active Comparator|Treatment with Clotrimazole + Gentamicin|
9964945|NCT01244269|Experimental|Methylphenidate 10|Methylphenidate 10mg three times daily for a total of 7 doses.
9964946|NCT01244269|Placebo Comparator|Placebo 10|Placebo capsule three times daily for a total of 7 doses.
9964947|NCT01244269|Experimental|Methylpheindate 20|Methylphenidate 20mg three times daily for a total of 7 doses.
9964948|NCT01244269|Placebo Comparator|Placebo 20|Placebo capsule three times daily for a total of 7 doses.
9964949|NCT01244282|Experimental|All Participants|fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol
9964950|NCT01244295|Experimental|Complicated Grief Treatment|Targeted psychotherapy for complicated grief
9964951|NCT01244295|Active Comparator|Interpersonal Therapy|Standard IPT is a comparator treatment
9964952|NCT01244321||CoSeal Group|Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
9964953|NCT01244321||CoSeal Control Group|Subjects who had a LVAD for more than 6 weeks.
9964954|NCT01244334|Active Comparator|Difluprednate Ophthalmic Emulsion 0.05%|
9964955|NCT01244334|Active Comparator|Prednisolone acetate suspension 0.1%|
9964956|NCT01244347|Experimental|folic acid 4 mg|
9964957|NCT01244347|Active Comparator|folic acid 0.4 mg|
9964958|NCT01244360|Placebo Comparator|Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
9964959|NCT01244360|Active Comparator|Dietary Supplement: resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
9964960|NCT01244373||Patients with senile cataract|Patients with senile cataract
9964961|NCT01244386||Inflammatory bowel disease|Patients with inflammatory bowel disease requiring CT for clinical purposes will be studied.
9964962|NCT01244464|Experimental|Study Group|
10011760|NCT01645085|Experimental|Treatment C|150mg MCC-based 13% drug-loaded tablets
10011761|NCT01645085|Experimental|Treatment D|150mg mannitol-based 38% drug-loaded tablets
10011762|NCT01645124|Active Comparator|Cytoreduction for HCT < 45%|Patients will be treated with phlebotomy and/or HU more intensively, with the goal to reach and maintain the target of hematocrit(HCT)below 45%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
10011763|NCT01645124|Experimental|Cytoreduction for HCT between 45 and 50%|Patients will be treated with phlebotomy and/or HU less intensively, with the goal to reach and maintain the target of hematocrit(HCT)between 45% and 50%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
10011764|NCT01645137|Experimental|OMT|patients under usual medical care plus osteopathic treatment
10011765|NCT01645137|Other|control|patients under usual medical care
10011766|NCT01645150|Experimental|Strength training group|12 weeks of progressive strength training
10011767|NCT01645150|No Intervention|Control group|No intervention
10011768|NCT01645163|Experimental|Mobile phone counselling|
10011769|NCT01645189|Experimental|Test drug|Idursulfase-beta
10011770|NCT01645202|Active Comparator|TAVI with Edwards Sapien XT valve|
10011771|NCT01645202|Active Comparator|TAVI with Medtronic CoreValve|
10011772|NCT01645215|Experimental|Fruquintinib capsule|cohort 1: fruquintinb continuous oral dosing (1mg once a day) cohort 2: fruquintinb continuous oral dosing (2mg once a day) cohort 3: fruquintinb continuous oral dosing (4mg once a day) cohort 4: fruquintinb continuous oral dosing (6mg once a day) cohort 5: fruquintinb continuous oral dosing (5mg once a day) cohort 6: fruquintinb oral dosing, 3 weeks on/1 week off (5mg once a day) cohort 7: fruquintinb oral dosing, 3 weeks on/1 week off (6mg once a day)
10011773|NCT01645228||significant coronary artery stenosis|anyone coronary segment > 50% diameter stenosis
10011774|NCT01645241|Experimental|Lutheal phase ovarian stimulation|Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
10011775|NCT01645254|Experimental|Argemone mexicana|"Argemone mexicana is traditional medicinal plant known as having an antimalarial activity.~The aerial part of this plant is used. The decoction of the powder of the plant will be used."
10011776|NCT01645267|Experimental|Osteotomy|Using hydroxyapatite bone graft material
10011777|NCT01645293|Experimental|Genetically modified T cells #1138|
10011778|NCT01645319||White, non-hispanic - Medication Treatment Pathway|
9964963|NCT01244542|Experimental|Patients with schizophrenia|
9964964|NCT01244542|Active Comparator|Healthy controls|controls matched with patients on age, sex and education level
9964965|NCT01244555|Experimental|Massage treatment|
9964966|NCT01244555|Experimental|Ultrasound|
9964967|NCT01244555|No Intervention|Wait-list|
9964968|NCT01244568|No Intervention|Usual care|
9964969|NCT01244568|Experimental|Prostate cancer treatment DESI|
9964970|NCT01244581|Experimental|Amoxicillin-clavulanate|Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
9964971|NCT01244581|Placebo Comparator|Placebo|
9964972|NCT01244594|Experimental|High cadence, low resistance|Subjects in this arm will cycle with functional electrical stimulation at a higher cadence (speed) and a lower resistance.
9964973|NCT01244594|Experimental|Low cadence, high resistance|Subjects in this arm will cycle with functional electrical stimulation at a lower cadence (speed) and a higher resistance.
9964974|NCT01244607|Placebo Comparator|Placebo|
9964975|NCT01244607|Experimental|NI-0801|
9964976|NCT01244646||1|Patients with Diabetes Mellitus Type 2
9964977|NCT01244659|Experimental|Tacrolimus from EMS|Group 1: Tacrolimus from EMS + Myfortic® + Steroids
9964978|NCT01244659|Active Comparator|Prograf|Group 2: Prograf® + Myfortic® + Steroids
9964979|NCT01244672|Active Comparator|Trans-anal dearterialization|24 patients were assigned to the Transanal hemorrhoidal dearterialization with mucopexy arm, which is a Doppler guided procedure for suture ligation of hemorrhidal arteries rather than excisional
9964980|NCT01244672|Active Comparator|Ferguson|17 patients were randomized to Ferguson method, which is the operative gold standard for hemorrhoids. This is an excisional surgery.
9964981|NCT01244685|Active Comparator|probe|Patients in the 'goal-directed fluid' Lactated Ringers solution according to ideal body weight for the first 24 hours. The fluids will be changed after the first 24 hours and continued until the patient is tolerating a regular diet. The Deltex CardioQ esophageal probe will be evaluated every 15 minutes in the Post Anesthesia Care Unit (PACU) by the Anesthesia service. Stroke Volume (SV), Flow Time Corrected (FTc), and Peak Velocity (PV) will be measured. A short FTc (<330 ms) indicative of hypovolemia will receive a 3cc/kg fluid challenge with Lactated Ringers crystalloid solution over 5 minutes. A SV increase of >10% will receive a further 3cc/kg fluid challenge. A SV increase of <10% will not receive further fluid challenge.
9964982|NCT01244685|No Intervention|Standard Fluid|Patients in the 'standard fluid' group will receive Lactated Ringers solution for 24 hours post-operatively at 1 times maintenance rate according to ideal body weight. Then the fluids will be changed to physiologic maintenance with D5½NS at the same rate. Fluids will be decreased by ½ once the patient is tolerating a clear liquid diet, and then discontinued once the patient is tolerating a regular diet.
9964983|NCT01244698|Other|Antibiotics until Drain Removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
9964984|NCT01244698|Experimental|Early discontinuation of antibiotics|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
9964985|NCT01244737|Experimental|New diagnosis of brain tumor|In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using [18F] FLT.
9964986|NCT01244737|Experimental|Possible recurrent brain tumor|In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using [18F] PET.
10011779|NCT01645319||White, non-Hispanic - Laser Surgery Treatment Pathway|
10011780|NCT01645319||White, non-Hispanic - Incisional/Other Treatment Pathway|
10011781|NCT01645319||Hispanic - Medication Treatment Pathway|
10011782|NCT01645319||Hispanic - Laser Surgery Treatment Pathway|
10011783|NCT01645319||Hispanic - Incisional/Other Surgery Treatment Pathway|
10011784|NCT01645319||Asian - Medication Treatment Pathway|
10011785|NCT01645319||Asian - Laser Surgery Treatment Pathway|
10011786|NCT01645319||Asian - Incisional/Other Surgery Treatment Pathway|
10011787|NCT01645319||Black - Medication Treatment Pathway|
10011788|NCT01645319||Black - Laser Surgery Treatment Pathway|
10011789|NCT01645319||Black - Incisional/Other Surgery Treatment Pathway|
10011790|NCT01645332|Placebo Comparator|Treatment I (control)|Placebo of DLBS3233 once daily for 12 weeks + lifestyle modification
10011791|NCT01645332|Experimental|Treatment II|100 mg DLBS3233 once daily for 12 weeks + lifestyle modification
10011792|NCT01645345|Other|RF Pixel handpiece treatment|There is only one arm, and that is a treatment arm. For patients with wrinkles and acne scars, they are being treated with the RF Pixel handpiece to decrease the appearance of these cosmetic deficiencies. The improvement is documented in before and after photographs.
10011793|NCT01645358|Experimental|Helmet to deliver NIV|
10011794|NCT01645358|Active Comparator|Total Face to deliver NIV|
10011795|NCT01645371||Subjects with opioid induced constipation|
10011796|NCT01645384|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
10011797|NCT01645384|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
10011798|NCT01645397||Asthma, elevated exhaled NO|Children with asthma with elevated exhaled NO at initial evaluation (>25ppb)
10011799|NCT01645410|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
10011800|NCT01645410|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
10011801|NCT01645423|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
10011802|NCT01645423|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
10011803|NCT01645436|Experimental|treatment (exercise)|combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
10011804|NCT01645436|No Intervention|control (usual care)|Usual hospital care with no exercise
10011805|NCT01645449|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
10011806|NCT01645449|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
10011807|NCT01645475|Experimental|Desmopressin lyophilisate (Melt)|Patients receiving Desmopressin lyophilisate (Melt).
10011808|NCT01645566|Experimental|intervention|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
10011809|NCT01645566|No Intervention|Control|No instructions
10011810|NCT01645722|Other|Procedure/Surgery: Enriched Fat grafting|Enriched Fat grafting
10011811|NCT01645748|Experimental|S-1, induction chemotherapy|Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy
10011812|NCT01645761|Experimental|PPI-based triple therapy with endonase|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.
10011813|NCT01645761|No Intervention|PPI-based triple therapy|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week)
10011814|NCT01645774|Experimental|10s injections duration|10s injections duration
10011815|NCT01645774|Experimental|10s injection duration , waiting 10s|10s injection duration and waiting 10s before withdrawing the needle
10011816|NCT01645774|Experimental|15s injection duration,waiting 5s|15s injection duration and waiting 5s before withdrawing the needle
10011817|NCT01645774|Experimental|5s injection duration , waiting 15s|5s injection duration and waiting 15s before withdrawing the needle
10011818|NCT01645787|Active Comparator|4-aminopyridine (Ampyra)|10 mg tab/ 1 tab twice daily
10011819|NCT01645787|Placebo Comparator|Sugar pill|Placebo 1 tab /twice daily
10011820|NCT01645800|Experimental|Lysozyme hydrochloride|
10011821|NCT01645800|Placebo Comparator|Placebo|
10035739|NCT01809223|Sham Comparator|sham injection group|Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
10011822|NCT01645826|Experimental|Diltiazem|The study agent will be Diltiazem and will start at 60 mg po BID then titrated up every two weeks until at a maximum dose of 180mg po BID.
10011823|NCT01645826|Placebo Comparator|Sugar Pill|The placebo group of patients will be treated with Drug A (sugar pill) PO bid and titrated up every two weeks for next titration dose (actually will be an unchanged concentration).
10011824|NCT01645839|Experimental|Systemic treatment with Depocyte|Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.
10011825|NCT01645839|No Intervention|Systemic treatment without Depocyte|No intrathecal injection.
10011826|NCT01645852|No Intervention|Control|No specified diet for one week prior to hepatic resection.
10011827|NCT01645852|Active Comparator|Low calorie diet|Low calorie diet (five units of Optifast 800 {Nestle Nutrition, Vevey, Switzerland} plus an unlimited volume of calorie free fluids per day) for one week prior to hepatic resection.
10011828|NCT01645865||Control|
10011829|NCT01645865||Intervention|
10011830|NCT01645878|Experimental|Hands on|breast feeding instructed by direct help of instructor
10011831|NCT01645878|Experimental|hands off|
10011832|NCT01645878|Other|Control|Routin breast feeding education
10011833|NCT01645891|Active Comparator|CDO with standard MWT|CDO (continuously supply pure oxygen) with standard Moist Wound Therapy
10011834|NCT01645891|Sham Comparator|Moist Wound Therapy|Moist Wound Therapy. De-activated Sham device placed to wound in order to blind patient and study staff.
10011835|NCT01645904||Group 1|Patients participate in audiotaped focus group regarding web-based program, and fill out demographics questionnaire.
10011836|NCT01645904||Group 2|Patients come to Behavioral Research and Treatment Center (BRTC) at MD Anderson to use initial version of My Family Garden website. Completion of Website Analysis and MeasureMent Inventory (WAMMI), and demographics questionnaires.
10011837|NCT01645904||Group 3|Patients use final version of My Family Garden website, and are interviewed which will be audiotaped. Completion of Website Analysis and MeasureMent Inventory (WAMMI), questionnaire and demographics questionnaire.
10011838|NCT01645917|Experimental|Ablation|Ablation with Arctic Front Advance Cardiac CryoAblation system
10011839|NCT01645943|No Intervention|Conservative|Coronary angiogram only if recurrent ischemia or peristent heart failure or inducible ischemia in predischarge stress test if perfomed
10011840|NCT01645943|Active Comparator|Invasive|Routine coronary angiogram
10011841|NCT01645956||Single group|
10011842|NCT01645969||Cohort|
10011843|NCT01645995|Experimental|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
10011844|NCT01645995|Experimental|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
10011845|NCT01646008||respiratory|
10011846|NCT01646047|Experimental|supplement - no retinopathy|subjects receiving active supplement and with no retinopathy based on clinical examination
10011847|NCT01646047|Placebo Comparator|placebo - no retinopathy|patients receiving placebo and who have no diabetic retinopathy based on clinical examination
10011848|NCT01646047|Experimental|supplement - retinopathy|patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
10011849|NCT01646047|Placebo Comparator|placebo - retinopathy|patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
10011850|NCT01646060|Experimental|Blood Draw|
10011851|NCT01646086|Experimental|weekly weight tracking|12 month behavioral weight loss intervention
10011852|NCT01646086|Active Comparator|daily weight tracking|12 month behavioral weight loss intervention
10011853|NCT01646086|Active Comparator|no weight tracking|12 month behavioral weight loss intervention
10011854|NCT01646099|Experimental|Sun Protection Education|Distribution of the internet-based sun protection educational program.
10011855|NCT01646099|No Intervention|Control|Distribution of general skin care information.
10011856|NCT01646164||Dill seed|used dill seed infusion (1 tablespoon whole dill seed seeped in a half or whole cup boiling water for 3-4 min)
10011857|NCT01646164||No used Dill seed|those who had not used any herbal drugs were placed at the control group
10011858|NCT01646190|Active Comparator|Standard care|Preoperative: Fasting state after midnight, no intake of oral carbohydrate load Preanesthetic medication No preoperative utilization of inspirex Intraoperative: Effective perioperative analgesia Routine nasogastric tube and abdominal drainage at surgeon discretion Postoperative: Removal of the nasogastric tube after return of bowel function removal of abdominal drainage at surgeon discretion or if volume <50cc Oral liquids and stepwise oral nutrition (water to others liquids to progressive normal or low-fiber nutrition Switch to oral medication after oral nutrition tolerance Urinary catheter removal when the mobilization is satisfactory Mobilization: non standardized and encouraged stepwise mobilization Discharge criteria discussed at surgeon discretion
10011859|NCT01646190|Experimental|FT perioperative care|Preoperative carbohydrate load No preanesthetic medication General anesthesia and intravenous analgesia Transoesophageal US-Doppler for individualized i.v fluids therapy POD 0: No Nasogastric tube postoperatively Oral liquids 0.3-0.5L 6h after extubation First mobilization 6h after surgery (2h) Stimulation of inspirex utilization (6-8t/d) POD 1: Free oral liquids; progressive normal or low-fiber diet Switch to oral medication Urinary catheter removal Mobilization: >4 h out of bed (walking, chair) inspirex utilization POD 2: Free oral liquids; normal or low-fiber diet Mobilization: >6 h out of bed (walking, chair), inspirex utilization POD 3: Complete mobilization as preoperatively First evaluation of discharge criteria in the afternoon
10035740|NCT01809236|Experimental|0.5 mg Conbercept|patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
10011860|NCT01646229|Active Comparator|Polymyxin-B hemoperfusion|In the HEMOPERFUSION group, a veno-venous dialysis catheter type GamCath 12 F, 3 lumen will be inserted instead of a regular double or triple-lumen central venous catheter, and connected to the Toraymyxin® (PMX-20-R) device for endotoxin adsorption by hemoperfusion with the DECAPSMART pump. The length of the hemoperfusion will be a minimum of 120 min and started just before the beginning of the surgical intervention in the OR and stopped at the end of surgery.
10011861|NCT01646229|Active Comparator|Control|"In the CONTROL group, the administration of fluids (250 to 500ml crystalloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP between > 8 and 12 < mmHg, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mMol/L, normalisation of the BE.~At the discretion of the attending anaesthesiologist with the FMH level, a PiCCO monitoring, a transoesophageal echography, or a pulmonary artery catheter, will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
10011862|NCT01646242|Experimental|Cold snare polypectomy|
10011863|NCT01646242|Experimental|Double biopsy polypectomy|
10011864|NCT01646281|Active Comparator|Flecainide|Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
10011865|NCT01646281|Active Comparator|Vernakalant|Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
10011866|NCT01646294|Experimental|OCAS-F|YM178 OCAS tablet (OCAS-Fast) taken orally under fasted and fed condition
10011867|NCT01646294|Experimental|OCAS-S|YM178 OCAS tablet (OCAS-Slow) taken orally under fasted and fed condition
10011868|NCT01646294|Experimental|OCAS-M|YM178 OCAS tablet (OCAS-Medium) taken orally under fasted and fed condition
10011869|NCT01646307|Placebo Comparator|standard care group|patients receive atorvastatin 20 mg/d
10011870|NCT01646307|Active Comparator|intensive rosuvastatin|administrated with rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI
10011871|NCT01646307|Active Comparator|intensive atorvastatin|patients will be administrated with atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI;
10011872|NCT01646333|Active Comparator|Supportive Therapy|The supportive therapy offers patients and support persons the opportunity to discuss and reflect upon both Parkinson's Disease and non-Parkinson's Disease related problems.
10011873|NCT01646333|Experimental|Memory and Problem-Solving Intervention|The memory and problem solving training consists of a day calendar manual and note taking system and problem solving techniques. The neurocognitive memory intervention was adapted from a 6-week manualized day calendar and note taking system previously evaluated in an amnestic MCI sample and a brain tumor sample. The problem solving intervention was adapted from an originally 12-week intervention, which was later adapted into a 6-week brain tumor sample.
10011874|NCT01646359|Experimental|corrected flow time|
10011875|NCT01646372|Active Comparator|Control Group|This group gets a simulation based ACLS refresher as treatment, but no access to cognitive aids for any of the tests.
10011876|NCT01646372|Active Comparator|2nd Control Group|This group receives a standard Simulation based ACLS refresher as the intervention, like the control group. No mention is made of Cognitive Aids in the teaching, but they are available during the post-test and retention post-test.
10011877|NCT01646372|Experimental|Cognitive Aid Group|This group receives Cognitive Aid based teaching as the intervention. They also have access to cognitive aids for post-test and retention post-test
10011878|NCT01646411||assorted acute infection|300 patients diagnosed with assorted acute infection.
10011879|NCT01646437|Experimental|Polycap vs. matching placebo|Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo
10011880|NCT01646437|Experimental|Aspirin vs. matching placebo|Once daily 75mg tablet of Aspirin vs. matching placebo
10011881|NCT01646437|Experimental|Vitamin D vs. matching placebo|Monthly oral dosage of 60,000IU vs. matching placebo
10011882|NCT01646450|Experimental|Icotinib|Icotinib: 125mg, oral administration, three times per day.
10011883|NCT01646463|Experimental|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills is the standard CenteringPregnancy prenatal healthcare intervention combined with mindfulness meditation and mindful movement/yoga applied to pregnancy, childbirth, and parenting.
10011884|NCT01646463|Active Comparator|CenteringPregnancy|CenteringPregnancy is group-based prenatal healthcare delivered according to the guidelines of the American College of Obstetrics and Gynecology. It includes assessment, support, and health education delivered in a healthcare empowerment framework.
10011885|NCT01646476|Active Comparator|Covered stent (Bona stent, pyloric/duodenal covered)|WAVE covered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
10011886|NCT01646476|Active Comparator|Uncovered stent (Bona stent, pyloric/duodenal)|uncovered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
10011887|NCT01646489|Experimental|Miravirsen sodium|
10011888|NCT01646489|Active Comparator|Telaprevir|
9667653|NCT03282097|Experimental|Mammogram decision aid|Will be mailed the DECAD decision aid before their next PCP visit in order to better inform their decision to continue or stop mammography.
10011889|NCT01646502|Experimental|Esp-supplemented standard wound care|500 pmol Esp protein will be added to the standard wound care protocol.
10011890|NCT01646502|Active Comparator|Standard wound care|"The standard treatment protocol established at the Vancouver Wound Healing Clinic is based on the Best Clinical Practice Guidelines for Venous Leg Ulcers from the Canadian Association of Wound Care."
10011891|NCT01646515|Placebo Comparator|placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
10011892|NCT01646515|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
10011893|NCT01646528||Consecutive patients for CLE examination|
10011894|NCT01646541||Asymptomatic|No dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class I]
10011895|NCT01646541||Symptomatic|Dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class II, III, or IV]
10011896|NCT01646554|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
10011897|NCT01646554|Experimental|Arm B: modified FOLFOX6 + Aflibercept and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Aflibercept 4 mg/kg intravenous infusion 1-h~Hour 1: Oxaliplatin 85 mg/m2 2-h infusion~Hour 1: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 3: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~Day 1 of a 14 day cycle~Aflibercept should be given in all cycles, except cycle 6 of pre-operative treatment."
10011898|NCT01646567|Experimental|SHP-141C & Placebo & Calcipotriol & Betamethasone Valerate|A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.
10011899|NCT01646580|Experimental|ciclopirox|
10011900|NCT01646606|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be measured at a frequency determined by the responsible physician (as is current practice). The reading will be displayed on the bedside monitor in the participants' room.
10011901|NCT01646606|Experimental|Intermittent oxygen monitoring|
10011902|NCT01646619|Active Comparator|Hypothermia + Magnesium Sulphate|
10011903|NCT01646619|Placebo Comparator|Hypothermia+ Placebo|
10011904|NCT01646632|Experimental|Physical exercise intervention|Progressive resistance training, balance training, functional training
10011905|NCT01646632|Placebo Comparator|Lifestyle counseling|Recreational sessions
10011906|NCT01646684|Experimental|SOM230|
10011907|NCT01646697|Experimental|Diagnostic (cytopathologic evaluation)|Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
10011908|NCT01646710|Experimental|Food Based Recommendations|Developing and pretesting tool for FBRs for infants 9 to 11 months old
10011909|NCT01646723|Experimental|VALID Intervention|Volunteers Adding Life in Dementia (VALID) Program
10011910|NCT01646736|Placebo Comparator|GC+CYC|Patients were treated with Glucocorticosteroid and Cyclophosphamide.
10011911|NCT01646736|Experimental|GC+T2|Patients were treated with Glucocorticosteroid and oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
10011912|NCT01646749|Experimental|Protein intake of 5 energy percent (En%)|
10011913|NCT01646749|Experimental|Protein intake of 15 En%|
10011914|NCT01646749|Experimental|Protein intake of 30 En%|
10011915|NCT01646775|Experimental|Epidural bupivacaine|
10011916|NCT01646775|Active Comparator|Epidural bupivacaine and fentanyl|
10011917|NCT01646788|Experimental|Experimental|NMB's PTA Balloon catheter with Paclitaxel drug
10011918|NCT01646801|Experimental|Experimental|NMB's Paclitaxel Drug ejecting balloon catheter
10011919|NCT01646840|Experimental|PF-04958242 capsule|
10011920|NCT01646840|Active Comparator|PF-04958242 oral solution|
10011921|NCT01646853|Experimental|Concurrent radiochemotherapy|
10011922|NCT01646866||Siblings of Children with Autism Spectrum Disorders|This group is comprised of 6-12 month old siblings of a child with an expert clinical diagnosis of autism spectrum disorders.
10011923|NCT01647178|Active Comparator|Manual closure|Patients are closed with a manual, straight wire, conventional closure technique
10011924|NCT01647178|Active Comparator|TORQ closure|Patients are undergo a TORQ assisted sternal closure
10011925|NCT01647191|Experimental|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
10011926|NCT01647191|Active Comparator|control group|The investigators will adopt previous treatment in the clinics to intervent the patients without any type of target intervention for this group.
10011927|NCT01647204|No Intervention|usual mealtime care|patients admitted to the control ward receiving no intervention but usual mealtime help from ward staff
10011928|NCT01647204|Experimental|mealtime assistance|Additional lunchtime help from trained volunteer mealtime assistants to supplement help from the ward staff
10011929|NCT01647243|Experimental|Preoperative strength training|Progressive strength training on group basis four weeks before the operation and progressive strength training on group basis four weeks after the operation
10011930|NCT01647243|No Intervention|Living as usual|The patients are living as usual the last 4 weeks before operation
10011931|NCT01647256|Experimental|Nikkomycin Z fed - fasting|"Period 1:~Day 1: Nikkomycin Z 500 mg with high fat breakfast~Period 2:~Day 1: Nikkomycin Z 500 mg under fasted conditions"
10011932|NCT01647256|Experimental|Nikkomycin Z fasting - fed|"Period 1:~Day 1: Nikkomycin Z 500 mg under fasted conditions~Period 2:~Day 1: Nikkomycin Z 500 mg with high fat breakfast"
10011933|NCT01647269|Experimental|DBS Off first|
10011934|NCT01647269|Experimental|DBS On First|
10011935|NCT01647321|Active Comparator|Active cycling|Individuals will receive functional electrical stimulation while on the stationary bike and instructed to actively pedal.
10011936|NCT01647321|Sham Comparator|Passive cycling|Individuals will receive active functional electrical stimulation (FES) while on the stationary bike and instructed to relax their legs, allowing the FES to move their legs on the stationary bike.
10011937|NCT01647334|Experimental|Shrinking Target Adaptive Radiotherapy|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
10011938|NCT01647347|Experimental|test treatment|"Test treatment:~1 min mouthwash with 10% PVP-iodine~1 min subgingival rinsing with 10% PVP-iodine~1 min ultrasonic debridement with 10% PVP-iodine as cooling liquid~blood sampling from the V.mediana cupidi"
10011939|NCT01647347|Placebo Comparator|Control group|"Control:~1 min mouthwash with water~1 min subgingival rinsing with water~1 min ultrasonic debridement with water as cooling liquid~blood sampling from the V.mediana cupidi"
10011940|NCT01647360||Women with Heavy Menstrual Bleeding (HMB)|
10011941|NCT01647386||MBT Revision Component|
10011942|NCT01647399||Phenotypic Clusters|500 urban youth
10011943|NCT01647412|Active Comparator|Growth Hormone, Exclusion Diet, and Nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
10011944|NCT01647412|Placebo Comparator|rhGH placebo, Exclusion diet, and nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
10011945|NCT01647425||head and neck or lung cancer|patient with a first head and neck cancer or first lung cancer
10011946|NCT01647477|Active Comparator|questionnaires|4 questionnaires to answer at baseline 45 minutes approx.
10011947|NCT01647477|Experimental|interview|semi directive interview 105 patients
10011948|NCT01647490|Active Comparator|Right Ventricular Apex (RVA)|In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
10011949|NCT01647490|Experimental|Right Ventricular Septum (RVS)|In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
10011950|NCT01647503||Tumor group|Parathyroid adenoma, hyperplasia and carcinoma
10011951|NCT01647503||Normal|Normal parathyroid samples
10011952|NCT01647529|Experimental|Ganciclovir|Treatment with topical ganciclovir ointment
10011953|NCT01647555||patient with epidermoid cancer|receiving Cetuximab and radiotherapy
10011954|NCT01647568||Control|Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
10011955|NCT01647568||Thienopyridine Users|Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
10011956|NCT01647594|Active Comparator|Young Women's Intervention (YWI)|
10011957|NCT01647594|Active Comparator|Physical Activity Intervention (PAI)|
10011958|NCT01647607|Experimental|Young Women's Intervention (YWI)|This arm involves administration of an educational intervention that focuses on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
10011959|NCT01647607|Active Comparator|Physical Activity Intervention (PAI)|This arm involves administration of an educational intervention that focuses on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
10011960|NCT01647620|Active Comparator|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily
10011961|NCT01647620|Placebo Comparator|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
10011962|NCT01647633|Experimental|Calcium Glycerophosphate Nasal Wash|Nasal spray wash twice daily and up to four additional times per day as needed for nasal allergy symptoms
10011963|NCT01647646|Active Comparator|Symbicort|"We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period.~Intervention drug: Seretide fixed doses therapy"
10011964|NCT01647646|Experimental|Seretide|In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year
10011965|NCT01647659|Experimental|GSK1120212 tablet|GSK1120212 tablet
10011966|NCT01647659|Experimental|GSK1120212 powder for oral solution|GSK1120212 powder for oral solution
10011967|NCT01647672|Experimental|Abraxane|Abraxane for neoadjuvant chemotherapy
10011968|NCT01647685|Active Comparator|Nanocort|Two weekly IV infusions of 144 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
10011969|NCT01647685|Active Comparator|Methylprednisolone|Methylprednisolone sodium succinate 125 mg infusion.
10011970|NCT01647685|Placebo Comparator|Saline|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
10011971|NCT01647698|Experimental|Early training group|The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).
10011972|NCT01647698|Experimental|Late training group|The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.
10011973|NCT01647698|Placebo Comparator|No training group|The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
9476743|NCT03568773|Experimental|High-intensity interval training|"The HIIT protocol is being performed with the cycling mode. The program consists of repeated intense explosions alternating with recovery intervals.~The adaptation period consists of 4 shots of 20 seconds interspersed by 180 seconds interval (active recovery). From the first to the fourth week the volunteers performed from four to six race shots from 30 to 45s with intervals from 180s to 120s. From the fifth week until the end of the intervention, training takes place with six shots of 60s with a 120s interval between running shots. The work intensity for all sessions is above 95% of VO2max, with 30W of recovery. In addition, participants refer to number 19 on the Borg Scale. Sessions range from 12 to 36 minutes without heating and recovery. In total there are 12 weeks of training."
10011974|NCT01647724||control 1|standard recall letter to perform HPV test at the clinic
10011975|NCT01647724||Intervention 1|direct mailing of the self sampling device at home
10011976|NCT01647724||intervention 2|invitation to retire the self sampling device in local pharmacy
10011977|NCT01647750|Other|Lower dose of levothyroxine|Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
10011978|NCT01647750|Other|Standard dose of levothyroxine|Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
10011979|NCT01647776||Individuals without colon polyps|
10011980|NCT01647776||Individuals with colon polyps|
10011981|NCT01647789|Experimental|CFG920|
10011982|NCT01647802|Experimental|Turner-Vertic'Easy-Tina|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Vertic'Easy; (3) Tina.
10011983|NCT01647802|Experimental|Turner-Tina-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Tina; (3) Vertic'Easy.
10011984|NCT01647802|Experimental|Vertic'Easy-Turner-Tina|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Turner; (3) Tina.
10011985|NCT01647802|Experimental|Vertic'Easy-Tina-Turner|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Tina; (3) Turner.
10011986|NCT01647802|Experimental|Tina-Turner-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Turner; (3) Vertic'Easy.
10011987|NCT01647802|Experimental|Tina-Vertic'Easy-Turner|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Vertic'Easy; (3) Turner.
10011988|NCT01647815|Experimental|50 healthy volunteers|The study population consists of healthy volunteers aged 18 to 50 years and without previous surgery, trauma, or thrombosis of the axilla or the shoulder girdle.
10011989|NCT01647828|Experimental|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel
10011990|NCT01647828|Experimental|Gemcitabine and Nab-Paclitaxel plus Placebo|Gemcitabine and Nab-Paclitaxel plus Placebo
10035741|NCT01809275|Experimental|QBECO|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
10035742|NCT01809275|Placebo Comparator|Placebo|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
10035743|NCT01809301|Active Comparator|Niaspan|Single dose of one NIASPAN® 1000 mg Extended-Release Tablet following dinner
10035744|NCT01809301|Experimental|TRIA-662|Single dose of two TRIA-662, 500 mg Immediate-Release Tablets following dinner
10035745|NCT01809340|Experimental|Minocycline|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
10035746|NCT01809340|Placebo Comparator|Placebo|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive placebo twice daily for up to 6 weeks in a blinded manner
10035747|NCT01809340|Experimental|Ketamine and Minocycline|All patients will receive 6 IV infusions of ketamine and oral minocycline twice daily during a 12-day open-label treatment phase
10035748|NCT01809353|Experimental|Group A: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
10035749|NCT01809353|Experimental|Group A: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
10035750|NCT01809353|Experimental|Group A: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
10035751|NCT01809353|Placebo Comparator|Group A: Placebo|Each participant will receive matching placebo as a single intravenous dose.
10035752|NCT01809353|Experimental|Group B: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
10035753|NCT01809353|Experimental|Group B: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
10035754|NCT01809353|Experimental|Group B: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
10035755|NCT01809353|Placebo Comparator|Group B: Placebo|Each participant will receive matching placebo as a single intravenous dose.
10035756|NCT01809366|Experimental|seminal plasma insemination|seminal plasma insemination
10035757|NCT01809366|Placebo Comparator|culture medium insemination|culture medium insemination
10035758|NCT01809379|Experimental|intraperitoneal chemotherapy|Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
10035759|NCT01809392|Experimental|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
10035760|NCT01809392|No Intervention|no decitabine|
10035761|NCT01809418|Experimental|keePAP|
10035762|NCT01809431|Experimental|intervention|Breastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
10035763|NCT01809431|No Intervention|Wait-listed control group|Wait-listed control group receive usual care delivered by their health care provider and after completion of their time in the study they are offered the intervention
10035764|NCT01809444|Active Comparator|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.
10035765|NCT01809444|Experimental|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
10035766|NCT01809457|Experimental|educational poster|poster display for 2 weeks in classrooms,
10035767|NCT01809457|No Intervention|control|no intervention, waiting for two weeks
10035768|NCT01809470|Experimental|Watching TV|Watching TV (comedy, 'Friends') for 1 hour
10035769|NCT01809470|Experimental|FIFA2013|Playing the video game 'FIFA2013' for 1 hour
10035770|NCT01809470|Experimental|Call of Duty|Playing the video game 'Call of duty' for 1 hour
10011991|NCT01647841||Pregnant women and infants|HIV+ and HIV- pregnant women, HIV-exposed and HIV-unexposed infants, ARV-exposed and ARV-unexposed infants
10011992|NCT01647854|Experimental|Device: Teleconsultation|"If patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The safety and efficacy of the introduction and operation of this system should be evaluated."
10011993|NCT01647867|Experimental|Met analysis|Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
10011994|NCT01647880|Experimental|Fingolimod (Gilenya®)|0,5 mg once a day in the morning, oral
10011995|NCT01647880|Active Comparator|Interferon beta-1b (Extavia®)|every second day, s.c.
10011996|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose|
10011997|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose|
10011998|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose|
10011999|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation|
10012000|NCT01647919|Experimental|cogniVida™ 100 mg/day|
10012001|NCT01647919|Placebo Comparator|Placebo|
10012002|NCT01647932|Active Comparator|Loop plus thiazide-type diuretic|Loop diuretic plus hydrochlorothiazide
10012003|NCT01647932|Placebo Comparator|Loop diuretic plus placebo|Loop diuretic plus placebo
10012004|NCT01647971|Experimental|ublituximab|"Phase I:~4 cohorts with IV ublituximab starting with 450 mg followed by 600 mg, 900 mg or 1200 mg in each cohort (3 - 6 patients per cohort). Infusions will be on days 1, 8, 15 and 22 of cycle 1 followed by a planned maintenance with a single infusion monthly starting cycle 3. Patients with CLL or SLL will have infusions on Days 1, 8 and 15 of cycle 1 & 2 followed by a planned maintenance with a single infusion monthly starting cycle 3. Expansion of patient enrollment in select cohorts will apply."
10012005|NCT01647984|Placebo Comparator|Placebo|Inert Placebo - Vitamin B complex + diet
10012006|NCT01647984|Active Comparator|Ritmonutra|Omega-3 polyunsaturated fatty acids, Hawthorn, Astaxanthin, Vitamin E, Vitamin B complex + diet
10012007|NCT01647997|Experimental|study 1a|whole body lactate production after bacterial endotoxin challenge
10012008|NCT01647997|No Intervention|study 1b|basal whole body lactate production
10012009|NCT01647997|Experimental|study 2a|muscle lactate concentration after bacterial endotoxin challenge
10012010|NCT01647997|No Intervention|study 2b|basal muscle lactate concentrations
10012011|NCT01648010|Experimental|TC-3 gel|TC-3 gel group undergo intravesical instillation of the investigatory device
10012012|NCT01648010|Experimental|MMC- gel|MMC gel group undergo intravesical instillation of the reverse thermal gelation device mixed with MMC
10012013|NCT01648036|Experimental|Unfractionated Heparin|
10012014|NCT01648036|Active Comparator|Dalteparin|Standard of care
10012015|NCT01648049|Experimental|CBT|Cognitive behavior therapy for both insomnia and depression featuring stimulus control and cognitive therapy.
10012016|NCT01648049|Active Comparator|Treatment as Usual|No additional treatment besides regular care.
10012017|NCT01648062|Active Comparator|Arousal reduction using guided imagery|Sleep Self-Regulation Using Mental Imagery: Participants in the arousal reduction condition were instructed to imagine wearing a backpack loaded with their worries, then putting the heavy backpack down, and then experiencing the relief and freedom from tension.
9518065|NCT03300271|Experimental|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
10012018|NCT01648062|Active Comparator|Mental simulation of sleep behavior|Sleep Self-Regulation Using Mental Imagery: Participants in this condition received instructions to visualize a specific behavioral plan designed to meet the goal of obtaining quality sleep each night through the practice of certain behaviors. To form the behavioral plan, participants visualised changing into comfortable clothes and taking time to relax prior to going to bed, the time they planned to go to sleep, where they planned to sleep, and the bedtime routine they follow to help them to get to sleep. At bedtime, they were instructed to mentally run through a checklist of these behaviors and then do any behaviors that they had not yet completed.
10012019|NCT01648062|Active Comparator|Combination|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to practice a combination of the guided imagery (for relaxation) and mental simulation imagery for sleep-related behaviour
10012020|NCT01648062|Sham Comparator|Control|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to imagine a typical post work activity
10012021|NCT01648075|Experimental|Experimental: Probiotic enriched milk|150 ml of skimmed milk enriched with probiotic (Lactobacillus rhamnosus LRH08) once a day
10012022|NCT01648075|Placebo Comparator|Skimmed Milk|150 ml of skimmed milk once a day
10012023|NCT01648088||Pre-op THA and TKA patients|Patients who are scheduled for total joint arthroplasty
10012024|NCT01648114|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
10012025|NCT01648114|Experimental|Antenatal Breastfeeding Intervention|Antenatal intervention group will receive usual care plus a 20 to 30-minute one-to-one educational intervention about breastfeeding.
10012026|NCT01648127|Experimental|Ceftaroline|Ceftaroline intravenous 600 mg single dose
10012027|NCT01648153|Active Comparator|GSK1070806 0.25mg/kg|TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
10012028|NCT01648153|Active Comparator|GSK1070806 5mg/kg|Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
10012029|NCT01648153|Placebo Comparator|Placebo (Saline)|Two IV administrations of saline 4 weeks apart
10012030|NCT01648179|Experimental|GSK1322322 IV formulation|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via IV formulation
10012031|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fasted)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fasted)
10012032|NCT01648179|Experimental|GSK1322322 Oral mesylate salt solution|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Oral mesylate salt solution
10012033|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fed)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fed)
10012034|NCT01648192|Experimental|2.5 mg|Losmapimod for single dose
10012035|NCT01648192|Experimental|7.5 mg|Losmapimod for single dose
10012036|NCT01648192|Experimental|20 mg|Losmapimod for single dose
10012037|NCT01648192|Placebo Comparator|Placebo|Placebo
10012038|NCT01648192|Experimental|7.5 mg BID|Losmapimod for repeat dose (14 days)
10012039|NCT01648192|Placebo Comparator|Placebo BID|Placebo
10012040|NCT01648218|Active Comparator|Neutral protamine hagedorn (NPH) insulin|"Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
10012041|NCT01648218|Experimental|Regular or Aspart insulin|"Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid."
10012042|NCT01648218|Experimental|Insulin glargine|"Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
10012043|NCT01648231|Other|Treatment Period 1|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
10012044|NCT01648231|Other|Treatment Period 2|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
10012045|NCT01648231|Other|Treatment Period 3|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
10012046|NCT01648244|Experimental|Computer-Assisted Decision Support|These providers will use the CADS program to treat their enrolled patients.
10012047|NCT01648257|Experimental|GSK1265744 Na Salt Tablets|Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.
10012048|NCT01648257|Experimental|GSK1265744 Free Acid Nanomilled Capsules|Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
10012049|NCT01648257|Experimental|GSK1265744 Free Acid Micronized Capsules|Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
10012050|NCT01648309||TAVI|patients with significant aortic stenosis that are candidates for transvascular aortic valve implantation
10012051|NCT01648335|Active Comparator|immobilization of the shoulder in internal rotation|
10012052|NCT01648335|Experimental|Immobilization of the shoulder in external rotation|
10012053|NCT01648465|Experimental|Everolimus|
10012054|NCT01648478|Experimental|Single Arm|
9964987|NCT01244737|Experimental|Brain tumor response to chemotherapy|"In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using [18F] FLT before the start and after two cycles of chemotherapy.~Despite much effort and working with referring physicians at multiple hospitals, enrollment in this arm remained low, and it seemed unlikely that meaningful enrollment would be accomplished. A revised study plan was submitted to the granting agency and FDA, and this arm was closed to further enrollment."
9964988|NCT01244750||First line TKI treatment: Imatinib|Diagnosed CML patients who receive first line TKI treatment: Imatinib
10012055|NCT01648504|Experimental|Intervention with eGuide to colonoscopy|The investigators will prospectively enroll and follow patients who receive the eGuide to Colonoscopy and determine benefit and satisfaction with the intervention as part of a pilot study.
10012056|NCT01648517|Experimental|Arm A|Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)
10012057|NCT01648517|Active Comparator|Arm B|standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin
10012058|NCT01648543|Active Comparator|block method: angle|The entry angle of angular method which is one method of lumbar sympathetic ganglion block is 30 degree of anterior-posterior view of C-arm.
10012059|NCT01648543|Active Comparator|block method: distance|The entry point of modified Reid method which is popular method of lumbar sympathetic ganglion block is 7~7.5cm from midline of spinous process of lumbar spine.
10012060|NCT01648556|Other|patients with a thrombopenia isolated|Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet < 100 G/l Blood tests and bone marrow biopsy repeated
10012061|NCT01648595|Experimental|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour. In control group was not intervention.
10012062|NCT01648595|No Intervention|Without Fentanyl|The control group did not receive Fentanyl.
10012063|NCT01648608|Experimental|Exemestane|Exemestane for neoadjuvant chemotherapy
10012064|NCT01648621|Experimental|Case Management|In addition to usual care, the intervention group will receive case management that includes: 40 minute standardized education session, an individualized action plan, an individualized care plan for management of COPD and comorbidities, standardized reinforcement/motivational interviewing and action plan teach-back sessions and assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions), tele-home monitoring, coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and CCAC facilitated by the case manager, priority access to ambulatory clinics.
10012065|NCT01648621|Active Comparator|Usual care|Usual care for these patients comprises: Dictated patient summary, referral to an 8 week in-hospital rehabilitation and self-management education program, referral to a smoking cessation program (as applicable), individualized action plan developed with treating respirologist at the discretion of the attending respirologist, Referral to web based educational materials and resources.
10012066|NCT01648634|Experimental|Nebivolol|
10012067|NCT01648634|Placebo Comparator|Placebo|
10012068|NCT01648660|Active Comparator|D2x - D1x|"Cross Over from double dosage to single dosage:~daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA"
10012069|NCT01648660|Active Comparator|D1x - D2x|"Cross Over from double dosage to single dosage:~daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA"
10012070|NCT01648660|Active Comparator|D1x - D1x|single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)
10012071|NCT01648686|Active Comparator|Women treated by bisphosphonate|Postmenopausal osteoporotic women treated by alendronate 70 mg weekly per os
10012072|NCT01648686|Sham Comparator|Women didn't treat by bisphosphonate|Postmenopausal osteoporotic women untreated by bisphosphonates
10012073|NCT01648712|Other|Balance Circuit|24 patients will be assigned to the Balance group , using a non -heparin extracorporeal pediatric device for operation . The intervention is to use the Balance circuit for this arm
10012074|NCT01648712|Other|Carmeda Circuit|"24 patients will be assigned to the Carmeda group, using a coated heparin extracorporeal pediatric device for operation.~The intervention is to use the Carmeda circuit for this arm. The intervention is the Carmeda circuit."
10012075|NCT01648725|Experimental|Hypnosis|standard care plus hypnosis followed by closed-loop administration of propofol for anesthesia induction
10012076|NCT01648725|Active Comparator|Control|standard care without hypnosis followed by closed-loop administration of propofol for anesthesia induction
10012077|NCT01648738|Experimental|Spa therapy, exercise and educational therapy|Spa therapy, exercise and educational therapy
10012078|NCT01648738|Active Comparator|Usual care and counselling (Back book)|Usual care and counselling (Back book)
10012079|NCT01648777|Experimental|L bupivacaine|Drug (L bupivacaine) and device (catheter) 750 patients undergoing cardiac surgery with sternotomy are treated with L-bupivacain in the multiperforated catheter of analgesia
10012080|NCT01648777|Placebo Comparator|placebo|Isotonic Nacl 9°/00 solution 750 patients undergoing cardiac surgery with sternotomy are treated with isotonic NaCl solution (placebo) in the multiperforated catheter of analgesia
10012081|NCT01648816||postpartum depression|caucasian mothers with postpartum depression
10012082|NCT01648816||control|caucasian mothers without depression
10012083|NCT01648829|Active Comparator|Atorvastatin|os, 20 mg, once per day, for 30 days
10012084|NCT01648829|Active Comparator|Pitavastatin|os, 4 mg, once per day, for 30 days
10012085|NCT01648842||Pregnant women|
10012086|NCT01648855||Preterm babies|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age from mother with preeclampsia
10012087|NCT01648868|Experimental|Excitatory effects of rTMS|Study excitatory effects of rTMS applied to the STS in patients with autism
10012088|NCT01648868|Active Comparator|Inhibitory effects of rTMS|Study inhibitory effects of rTMS applied to the STS in healthy controls
10012089|NCT01648894|Experimental|11 weeks|The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
9964989|NCT01244750||First line TKI treatment: Nilotinib|Diagnosed CML patients who receive first line TKI treatment: Nilotinib
9964990|NCT01244750||First line TKI treatment: Dasatinib|Diagnosed CML patients who receive first line TKI treatment: Dasatinib
9964991|NCT01244750||Imatinib treated patients|Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
9964992|NCT01244776|Experimental|Acellular corneal matrix|
9964993|NCT01244789|Active Comparator|Observation|postoperative observation only
9964994|NCT01244789|Experimental|Combination chemotherapy|postoperative 6 courses of 3 weekly iv carboplatin-paclitaxel combination chemotherapy
9964995|NCT01244802||Group 1: 18 to 45 years of age|Between the ages of 18 and 45 at the time of yellow fever vaccination
9964996|NCT01244802||Group 2: 55 years of age and above|Aged 55 or greater at the time of yellow fever vaccination
9964997|NCT01244841|No Intervention|Standard care|Randomised to standard post MI care and length of hospital stay decided by treating physician.
9964998|NCT01244841|Active Comparator|Early discharge|Randomised patient where all post MI investigations, treatment, follow-up plans and information will be performed within 3 days, and the patients are thereafter discharged.
9964999|NCT01244854|Other|Arm 1|Enhanced Usual Care; patients receive care as usual, with additional mailings on wellness newsletter topics
9965000|NCT01244867|Experimental|20 microgram H5 VLP vaccine + Alhydrogel|
9965001|NCT01244867|Experimental|30 micrograms H5 VLP vaccine + Alhydrogel|
9965002|NCT01244867|Experimental|45 micrograms H5 VLP vaccine + Alhydrogel|
9965003|NCT01244867|Experimental|45 micrograms H5 VLP vaccine|
9965004|NCT01244867|Placebo Comparator|Placebo|
9965005|NCT01244880|Experimental|Saline/PF-02545920|Treatments are co-administered
9965006|NCT01244880|Experimental|Ketamine/PF-02545920|Treatments are co-administered
9965007|NCT01244880|Placebo Comparator|Saline/Placebo|Treatments are co-administered
9965008|NCT01244880|Experimental|Ketamine/Placebo|Treatments are co-administered
9965009|NCT01244945|Experimental|L. reuteri DSM 17938|
9965010|NCT01244945|Placebo Comparator|Placebo|
9965011|NCT01244958|Active Comparator|Rituximab 1000 mg|Administration of 1000 mg Rituximab in Part I, followed by either re-treatment with 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
10012090|NCT01648894|Other|7 weeks|The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
10012091|NCT01648907||SPONDYLARTHRITIS COHORT|
9803683|NCT03555149|Experimental|Atezolizumab + LOAd703|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
9803684|NCT03552562|Other|30 patients with no signs of diabetic retinopathy|
10012092|NCT01648933|Experimental|Sarcoidosis|"Rubidium PET:~Myocardial Perfusion Imaging"
10012093|NCT01648946|Active Comparator|Liberal Transfusion Strategy|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
10012094|NCT01648946|Active Comparator|Restrictive Transfusion Strategy|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
10012095|NCT01648972|Experimental|Gastrografin|
10012096|NCT01648972|Placebo Comparator|Placebo|
10012097|NCT01648985||Acute stroke and TIA patients|Cohort of acute stroke patients, admitted to the Stroke Unit Danderyd hospital 2010 - 2012
10012098|NCT01648998|Experimental|Fludrocortisone|Fludrocortisone 500 mg in capsule
10012099|NCT01648998|Placebo Comparator|Placebo|Placebo capsule, single dose, main ingredient lactose
10012100|NCT01649011||Scores of the ODI and RMQ for low back pain|
10012101|NCT01649024|Experimental|single arm of Tremelimumab|Tremelimumab is administered at 15 mg/kg on day 1 every 12 weeks for 4 doses
10012102|NCT01649037|Experimental|nor adrenaline and terlipressin|
10012103|NCT01649037|Active Comparator|step up terlipressin|
10012104|NCT01649050|Experimental|BGG492|BGG492 tablets administered orally
9802533|NCT05183932||Surgery|"Participants will have standard of care lobectomy/segmentectomy/wedge resection. Decision for treatment will be made at the discretion of the treating physician.~PROMIS instruments include 8 domains and will be completed prior to treatment, 1 month post-treatment, 6 months post-treatment, 12 months post-treatment, 24 months post-treatment, and 36 months post-treatment~Bank 2.0 - Physical Function~Bank v1.1 - Pain Interference~Bank v1.0 - Fatigue~Bank v1.0 - Depression~Bank v1.0 - Anxiety~Bank v1.0 - Dyspnea Severity~Bank v2.0 - Ability to Participate in Social Roles and Activities~Bank v2.0 - Cognitive Function"
10012105|NCT01649050|Placebo Comparator|Placebo|Matching placebo administered orally
10012106|NCT01649063||the shape and frequency of uterine contractions in delivery|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
10012107|NCT01649063||the shape and frequency of uterine contractions in cesarean|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
10012108|NCT01649089|Experimental|Treatment (cone biopsy/lymphadenectomy or hysterectomy)|Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
10012109|NCT01649102|Experimental|Palindroom catheter|Insertion of Palindroom catheter
10012110|NCT01649102|Experimental|Hemoglide Bard Catheter|Insertion of Hemoglide Bard Catheter
10012111|NCT01649115|No Intervention|Usual Care|The Usual Care arm, will not be receiving the interactive nutrition education. They will be meeting with the Registered Dietitian twice in person after the participants are randomized in each arm, and once on the phone. The first meeting, they will be receiving pamphlets and handouts, which are typically given as part of usual care. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool. The second meeting and the follow-up phone call are both the same for usual care and the Healthy Lifestyles Passport arm.
10012112|NCT01649115|Experimental|Healthy Lifestyles Passport|The Healthy Lifestyles Passport arm will be receiving the intervention. They will be meeting with the Registered Dietitian twice in person after the participants are randomized into each arm, and once on the phone. The first meeting, they will be receiving the Healthy Lifestyles Passport, including the interactive nutrition education. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool.
10012113|NCT01649141|Experimental|Treatment Group|Trauma-Focused Cognitive Behavioral Therapy
10012114|NCT01649154|Active Comparator|Ligasure Small-JAW|
10012115|NCT01649154|Active Comparator|Harmonic Focus|
10012116|NCT01649154|Active Comparator|Clamp-and-Tie technique|
10012117|NCT01649167||Overweight/obesity|Pregnant women with overweight/obesity
10012118|NCT01649167||gestational diabetes|Pregnant women with gestational diabetes
9803685|NCT03552562|Other|30 patients with mild diabetic retinopathy|
10012119|NCT01649167||normal weight|Pregnant women with normal weight
10012120|NCT01649193||Chronic Respiratory Disease|Any patient with a chronic respiratory disease referred for pulmonary rehabilitation
10012121|NCT01649206|Experimental|Group A: RTA|Percutaneous Radiofrequency Thermal Ablation (RTA).
10012122|NCT01649206|No Intervention|Group B: untreated|No treatment, only follow-up
10012123|NCT01649219|Experimental|Exercise intervention|3-month supervised exercise intervention 3 times per week; 60min per time.
10012124|NCT01649219|No Intervention|No intervention|Standard couselling at baseline
10012125|NCT01649245|Experimental|Reiferon retard plus ribavirin|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses
10012126|NCT01649258|Experimental|Supportive care (antiemetics)|Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.
10012127|NCT01649310|Experimental|WVB Training|
10012128|NCT01649336|Experimental|MEK162 + paclitaxel|
9803686|NCT03552562|Other|30 patients with moderate to severe diabetic retinopathy|
10012129|NCT01649401|Active Comparator|Standard nubulizer|"Nebulizer sessions for the patients in this arm will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
10012130|NCT01649401|Experimental|Experimental nebulizer|"Nebulizer sessions for the patients in this arm will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
10012131|NCT01649440||Normal control|Healthy volunteers
10012132|NCT01649440||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
10012133|NCT01649440||sepsis|sepsis is defined as SIRS plus confirmed infection.
9965012|NCT01244958|Placebo Comparator|Placebo|Administration of Placebo in Part I followed by re-treatment with either 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
9965013|NCT01244971|Active Comparator|Acarbose|
9965014|NCT01244971|Active Comparator|Exercise|
9965015|NCT01244971|Experimental|Exercise + Acarbose|
9965016|NCT01244997|Experimental|Immediate implant placement|This arm is an immediate placement of a dental implant following tooth extraction.
9965017|NCT01244997|Active Comparator|Delayed Implant|This is the traditional method for implants. This arm will be done following a healing of the area.
10012134|NCT01649440||severe sepsis|"sepsis associated with organ dysfunction, hypoperfusion, or hypotension.~sepsis with arterial hypotension, despite adequate fluid resuscitation."
10012135|NCT01649440||death|sepsis patients within 48 hours before death.
10012136|NCT01649453||Cancer of uncertain primary|
10012137|NCT01649466|Experimental|Vildagliptin|Patients randomized to the vildagliptin group will receive 50mg vildagliptin once daily add-on to their current glimepiride monotherapy for 24 weeks. No dose titrations are permitted during the study.
10012138|NCT01649466|Active Comparator|Protaphane|Patients randomized to the Protaphane group will receive a individualized dose of Protaphane once daily as bedtime dose. The Protaphane dose will be titrated within the first 4 weeks to reach fasting plasma glucose values below 100 mg/dl.
10012139|NCT01649479|Other|Suspected Obstetrical APS; confirmed APS|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients have APS.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
10012140|NCT01649479|Other|Sus. Obst. APS, confirmed thrombophilia|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients are thrombophilic.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
10012141|NCT01649479|Other|Suspected Obstectrical APS; unconfirmed|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork cannot confirm APS, nor thrombophilia.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
10012142|NCT01649492|No Intervention|diclofenac without pineapple juice|single dose of diclofenac 25 mg without pre-exposure to pineapple juice
10012143|NCT01649492|Active Comparator|diclofenac with pineapple juice|single dose of diclofenac 25 mg with pre-exposure to pineapple juice
10012144|NCT01649531|Active Comparator|Test group|1 Implant, to be placed in the position with greater vertical bone height with a mesial or distal cantilever.
10012145|NCT01649531|Active Comparator|Control group|2 Implants
10012146|NCT01649544|Experimental|EPICOR|"Cardiac ablation system EPICOR (CE n°0344).~ablation device EpicorTM UltraCinchTM LP (Class III device)~Positioning system and calibration EpicorTM LP (LP PASTM; device Class IIa)~Cable connection EpicorTM LP (unsterile)~Ablation Control System EpicorTM LP (Class IIb)"
10012147|NCT01649544|Active Comparator|Amiodarone|"Cordarone :~400 mg/d during the 2 first months 200 mg/d from 3th to 18th month"
10012148|NCT01649570|Experimental|Insulin aspart|
10012149|NCT01649583|Experimental|Jaw Dynasplint System|
10012150|NCT01649583|No Intervention|Control Arm|
9803687|NCT03552562|Other|30 healthy age-and sex- matched control subjects|
9965018|NCT01245010|Experimental|Water|Water and education provision
9965019|NCT01245010|Active Comparator|Control|Education only
9965020|NCT01245023|Active Comparator|laparoscopy|laparoscopic adhesiolysis and application of Sprayshield spray to prevent further adhesions
9965021|NCT01245023|Placebo Comparator|placebo-control|anaethesia and skin incisions without laparoscopy or related procedures
9965022|NCT01245036|Active Comparator|Glucocorticoid arm|Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
9965023|NCT01245075|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
9965024|NCT01245075|Sham Comparator|Placebo|Stimulator setting is OFF
9965025|NCT01245088|Experimental|chondroitin sulfate|400 mg (one table) TID
9965026|NCT01245127|Experimental|Canakinumab|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.~Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
9965027|NCT01245153|Experimental|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught Foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water. Subjects will contract pelvic floor muscle in standing position by contracting the pelvic floor muscle, hold and count 1 to 5, then relax and count 1 to 5. Subjects are instructed to do the exercise 15 times/set, 3 sets/day, every day for 6 weeks.
9965028|NCT01245153|Active Comparator|Control group|Patients receive Pelvic floor muscle training without inserting any kinds of equipment.
9965029|NCT01245166|Active Comparator|Acarbose|
9965030|NCT01245166|Experimental|Metformin/Acarbose|
9965031|NCT01245179|Experimental|Panobinostat|All patients will receive Panobinostat at specified dose levels and dosing schedules.
9965032|NCT01245205|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive Akt inhibitor MK2206 PO QOD for 28 days (35 days for course 1) and lapatinib ditosylate PO QD or BID on days 1-28 (days 9-35 for course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9965033|NCT01245244|Experimental|Morphine|
9965034|NCT01245244|Placebo Comparator|Placebo|
9965035|NCT01245257||Alcoholic Hepatitis|Patients with alcoholic hepatitis
9965036|NCT01245296|Other|Early cord clamping (ECC)|Early cord clamping consisted of early (< 10 s) clamping of the umbilical cord and obtaining blood gas samples after clamping.
9965037|NCT01245296|Other|Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (> 180 s) clamping of the umbilical cord and obtaining blood gas samples before clamping (within 30 seconds).
9965038|NCT01245309|Experimental|scratching|endometrial scratching prior ivf cycle
9965039|NCT01245309|Placebo Comparator|PLACEBO|PLACEBO PROCEDURE
9965040|NCT01245322|Active Comparator|Lactobacilli|different lactobacilli.
9965041|NCT01245335|Active Comparator|BMAC Treatment|Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
9965042|NCT01245335|Placebo Comparator|Placebo Injection|Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
9965043|NCT01245348||Schizophrenia|Patient with schizophrenia
9965044|NCT01245348||Bipolar|Patient with bipolar disorder
9965045|NCT01245361|Experimental|Infliximab|Group I: Infliximab 3 mg/kg wk 0,2,6
9965046|NCT01245361|Placebo Comparator|sodium chloride|RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride
9965047|NCT01245400|Experimental|Z-Lig|Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) graft implantation performed under anesthesia during an arthroscopic procedure.
9965048|NCT01245400|Active Comparator|Allograft|Allograft bone/tendon graft implantation performed under anesthesia during an arthroscopic procedure.
9965049|NCT01245426|Experimental|GW870086 2mg|GW870086 2mg once daily in the morning for 27 ± 2 days
9965050|NCT01245426|Experimental|GW870086 4mg|GW870086 4mg once daily in the morning for 27 ± 2 days
9965051|NCT01245426|Placebo Comparator|Placebo|Placebo once daily in the morning for 27 ± 2 days
9965052|NCT01245426|Experimental|GW870086 1mg|GW870086 1mg once daily in the morning for 27 ± 2 days
9965053|NCT01245426|Experimental|GW870086 3mg|GW870086 3mg once daily in the morning for 27 ± 2 days
9965054|NCT01245452|Experimental|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
9965055|NCT01245452|Active Comparator|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
9965056|NCT01245465|Experimental|Profermin|Daily oral intake of a food for special medical purposes (Profermin)
9965057|NCT01245504||Lower-limb amputee|Subjects with at least one lower limb amputated at teh trans-tibial level
9965058|NCT01245517|Experimental|Dietary Phosphorus Education Program|
9965059|NCT01245530|Active Comparator|Aricept|Intervention: Drug: Aricept
9965060|NCT01245530|Experimental|INM-176|Intervention: Drug: INM-176
9965061|NCT01245543|Experimental|AC480IV|Dose range finding study
9803688|NCT03552471|Experimental|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9965062|NCT01245543|Experimental|Docetaxel|Dose range finding study in subjects with solid tumors
9518066|NCT03300258|Other|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
9965063|NCT01245556|Experimental|BMS-908662 or Ipilimumab (A)|
9965064|NCT01245556|Experimental|BMS-908662 or Ipilimumab (B)|
9965065|NCT01245569|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
9965066|NCT01245569|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
9965067|NCT01245582|Experimental|SECOX regimen|Oxaliplatin (Eloxatin) 85mg/m2 , 2 hour infusion, day 1 Capecitabine (Xeloda) 850 mg/m2 BID orally daily, from day 1 to 7 Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
9965068|NCT01245582|Active Comparator|Sorafenib alone|Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
9965069|NCT01245608|Experimental|Polypill|Single daily dose of PolyPill and 6-monthly visits
9965070|NCT01245608|No Intervention|Control|Only 6-monthly visits
9965071|NCT01245621|Active Comparator|Early entry group|Early entry group will begin the intervention at time of diagnosis of advanced cancer
9965072|NCT01245621|Active Comparator|Later entry group|Later entry group will begin the intervention 12 weeks after enrollment in the study.
9965073|NCT01245660|Experimental|Patient|
9965074|NCT01245686|Active Comparator|One-on-one counseling|Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
9965075|NCT01245686|Active Comparator|Web counseling|Participants in this arm will receive 4 intensive counseling sessions over the web. They will also receive 3 maintenance sessions over the web.
9965076|NCT01245725|Experimental|Tirofiban (Aggrastat)|
9965077|NCT01245725|Placebo Comparator|Placebo|
9965078|NCT01245777|Experimental|ferric carboxymaltose|Hb> 11 g/dl and Ferritin < 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and < 11g/dl; Ferritin < 35 (controlled by CRP): 700 mg Hb ≥9 and < 10 g/dl; Ferritin < 35 (controlled by CRP): 800 mg Hb < 9g/dl; Ferritin < 35 (controlled by CRP): 900 mg
9965079|NCT01245790|Experimental|1|Healthy subjects (Stage 1)
9965080|NCT01245790|Experimental|2|Mild renal impairment (Stage 2)
9965081|NCT01245790|Experimental|3|Moderate renal impairment (Stage 2)
9965082|NCT01245790|Experimental|4|Severe renal impairment (Stage 2)
9965083|NCT01245790|Experimental|5|End stage renal disease (Stage 1)
9965084|NCT01245803|Experimental|rosuvastatin,one month,lipid lowering|additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
9965085|NCT01245803|Placebo Comparator|sugar pill, one month|sugar pill is given 18-24hr and 4-6hr before PCI as control
9965086|NCT01245816|Experimental|Eflornithine plus Sulindac|Eflornithine 500 mg and Sulindac 150 mg
9965087|NCT01245816|Active Comparator|Elfornithine plus Placebo|Eflornithine 500 mg and Placebo
9965088|NCT01245816|Active Comparator|Sulindac plus Placebo|Sulindac 150 mg and Placebo
9965089|NCT01245829|Placebo Comparator|Matt|A standard non antimicrobial laminated chart which will form the control group (group 1).
9965090|NCT01245829|Experimental|Cellomed|Observation charts coated in a laminate with antimicrobial properties (Cellomed) will form group 2.
9965091|NCT01245842|No Intervention|Usual care|
9965092|NCT01245842|Experimental|Exercise group|
9965093|NCT01245855|No Intervention|PGE1 group and control group|the control group: received only the conventional medications, the PGE1 group: received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
9965094|NCT01245868|Experimental|Bupivacaine|Bupivacaine as used routinely
9965095|NCT01245868|Placebo Comparator|Lidocaine added to bupivacaine|lidocaine is added to bupivacaine
9965096|NCT01245881|Experimental|Treatment group|Broad-spectrum UV block plus non-ablative 1,550-nm fractional treatment
9965097|NCT01245881|Active Comparator|Control group|
9965098|NCT01245894|Active Comparator|Low-dose Rosuvastatin|5mg Rosuvastatin/day
9965099|NCT01245894|Active Comparator|High-dose Rosuvastatin|Rosuvastatin 40mg/day
9965100|NCT01245907|Experimental|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
9965101|NCT01245907|No Intervention|Waiting-list/control|No intervention for 10 weeks but the same registrations and diaries and forms as the interventional group
9965102|NCT01245920|Experimental|FDBA + Membrane Group|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
9965103|NCT01245920|Active Comparator|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
9965104|NCT01245946|Experimental|Photodynamic therapy|
9965105|NCT01245946|Experimental|Conventional therapy|
9802534|NCT05183932||Stereotactic body radiotherapy (SBRT)|"Participants will have standard of care 1-5 fractions of radiation therapy. Decision for treatment will be made at the discretion of the treating physician.~PROMIS instruments include 8 domains and will be completed prior to treatment, 1 month post-treatment, 6 months post-treatment, 12 months post-treatment, 24 months post-treatment, and 36 months post-treatment~Bank v2.0 - Physical Function~Bank v1.1 - Pain Interference~Bank v1.0 - Fatigue~Bank v1.0 - Depression~Bank v1.0 - Anxiety~Bank v1.0 - Dyspnea Severity~Bank v2.0 - Ability to Participate in Social Roles and Activities~Bank v2.0 - Cognitive Function"
9802535|NCT05183360|Experimental|BI 706321 single dose|
9802536|NCT05183360|Experimental|BI 706321 multiple dose|
9802537|NCT05183360|Placebo Comparator|Placebo|
9802538|NCT05182606|Experimental|Implementation bundle|"Participating clinics will experience integration of the Implementation Bundle into their practices."
9965106|NCT01245959|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
9965107|NCT01245959|Active Comparator|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
9965108|NCT01245985|Experimental|treatment arm|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
9965109|NCT01245998|Active Comparator|dalteparin 5000 I.U./24 h s.c.|
9965110|NCT01245998|Active Comparator|dalteparin 15000 I.U./24 h s.c.|
9965111|NCT01246024|Experimental|Hypoxia|
9965112|NCT01246037|Experimental|First placebo|First half year placebo, second half year bisoprolol
9965113|NCT01246037|Experimental|First Bisoprolol|First half year bisoprolol, second half year placebo
9965114|NCT01246089|Experimental|Ranabizumab|Myopic eyes with retinal neovascularization
9965115|NCT01246102|Experimental|1|starting at 20 mg/m2
9965116|NCT01246141||Repair group|patients in repair group underwent tricuspid repair for functional tricuspid regurgitation.
9965117|NCT01246141||replacement group|In this group, patients underwent tricuspid valve replacement for functional tricuspid regurgitation.
9965118|NCT01246154||EXERCISE TOLERANCE|
9965119|NCT01246167|Active Comparator|Conservative|Active physiotherapy and self-training
9965120|NCT01246167|Active Comparator|Philos locking plate|After operative treatment active physiotherapy and self-training
9965121|NCT01246167|Active Comparator|Epoca prosthesis|After operative treatment active physiotherapy and self-training
9965122|NCT01246193|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
9965123|NCT01246193|Active Comparator|Combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
9965124|NCT01246219|Experimental|GH treatment|4 years of GH treatment
9965125|NCT01246219|Placebo Comparator|Placebo|1 year treatment with placebo followed by optional 3 years of GH treatment
9965126|NCT01246219|No Intervention|Non treatment group|
9965127|NCT01246232|Experimental|Amisulpride|400mg, 2 x 200mg amisulpride capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules for the remaining 8 weeks.
9965128|NCT01246232|Placebo Comparator|Placebo|400mg, 2 x 200mg amisulpride capsules, or 2 matching placebo capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules, or 4 matching placebo capsules for the remaining 8 weeks.
9965129|NCT01246271||Sub urethral sling|
9965130|NCT01246271||sus with anterior vainal wall repair|
9965131|NCT01246284|Active Comparator|A|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
9965132|NCT01246284|Active Comparator|B|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
9965133|NCT01246284|Active Comparator|C|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
9965134|NCT01246284|Placebo Comparator|D|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment.
9965135|NCT01246323|Active Comparator|combined anesthesia|Patients will receive spinal and general anesthesia for benign laparoscopy gynecological surgery
9965136|NCT01246323|No Intervention|Control|
9965137|NCT01246336||Patients with parkinsonism|Patients suffering from Parkinson's disease or parkinsonism
9965138|NCT01246336||Healthy controls|Patients not suffering from Parkinson's disease or any other neurological disorder
9965139|NCT01246362|Placebo Comparator|Control|Given placebo tablets preoperatively
9965140|NCT01246362|Active Comparator|Etoricoxib|Given etoricoxib preoperatively
9965141|NCT01246388||Chronic Liver Disease|
9965142|NCT01246414||Allergic asthma|Patients with allergic asthma
9965143|NCT01246414||Non-allergic asthma|Patients with non-allergic asthma
10012151|NCT01649622|Experimental|Bendamustine|"Patients receive Bendamustine at dose of 75 mg/m2 by vein over 30 minutes twice daily for four days (Days 1-4). Bendamustine dose based on actual body weight.~Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses."
10012152|NCT01649635|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3
10012153|NCT01649648|Experimental|Intervention|Autologous cord blood cells arm
10012154|NCT01649674|Active Comparator|PEG|polyethylene glycol solution 2 liters
10012155|NCT01649674|Active Comparator|NapP|Sodium picosulphate and magnesium citrate solution 300 ml
10012156|NCT01649687|Experimental|Mesenchymal stem cells(MSC) treatment|All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells
10012157|NCT01649700|Experimental|Mesenchymal stem cells treatment|All subjects will receive autologous adipose-derived mesenchymal stem cells
10012158|NCT01649713|Experimental|Fluval AB vaccination|In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
10035771|NCT01809483|Experimental|Bandage contact lens group|subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and bandage contact lens. Bandage contact lenses maintained for 24 hours. Antibiotic eye drops were instilled without removing the contact lenses
10035772|NCT01809483|Active Comparator|Pressure patching group|Subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and pressure patching. Pressure patching maintained for 24 hours and only opened for drug application. Subject and their families were educated on how to perform a good pressure patching
10035773|NCT01809496|Active Comparator|Informational counseling, patient only|The purpose of this experimental group is to evaluate the effectiveness of informational counseling alone. This type of counseling is considered the standard of care in audiologic practice. Patients in this will review this material in detail with a member of the study team for approximately 30 minutes at the second visit. Spouses in this experimental group will be will review material regarding VA services with a member of the study team for about 30 minutes.
10035774|NCT01809496|Experimental|Informational Counseling, couples|The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
10035775|NCT01809496|Experimental|Patient Centered Counseling,patient only|In order to assess the effects of enhanced patient-centered counseling (PCC), the patients assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. In addition to the PCC techniques used in audiology, this counseling also will involve the core components of motivational interviewing. These principles and methods will be used to allow the patient to clearly express his/her expectations of, concerns about, and motivations for hearing-aid use. The spouses in this experimental group will be given information regarding VA services. This material will be reviewed with a member of the research team for about 30 minutes at the second visit.
10035776|NCT01809496|Experimental|Patient Centered Counseling, couples|In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
10037290|NCT01823744|Experimental|micronutrient supplementation|"All the enrolled subjects will recieve orally, onca a day, during school days a chocolate bar including vitamins and minerals.~The micronitrient supplementation will be consumed over 6 weeks, 5 days/week."
10037291|NCT01823757||Non-pharmaceutical care|Veterans do not receiving pharmaceutical care
10037292|NCT01823757||Pharmaceutical care|Veterans receiving pharmaceutical care
10012159|NCT01649726|Other|Standard strategy|Apnea test according to recommendations
10012160|NCT01649726|Experimental|CPAP strategy|Apnea test with CPAP connection
10012161|NCT01649739|Experimental|Levitra|
10012162|NCT01649752|Experimental|Differentiated stem cell therapy group|After ovum pick-up, MSC differentiated to endometrium is deposited in the uterine cavity.Embryo transfer will be done at day 5 at the blastocyst stage.
10012163|NCT01649752|Experimental|undifferentiated stem cell therapy group|Immediately postmenstrual undifferentiated MSC is deposited in the uterine cavity. Ovum pick-up will be done as usual.Embryo transfer will be done at day 5 at the blastocyst stage.
10012164|NCT01649752|No Intervention|Control group|ovum pick-up as usual and embryo transfer at day 5 at the blastocyst stage.
10012165|NCT01649778||Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
10012166|NCT01649817||Cohort|
10012167|NCT01649830|Experimental|Radiotherapy plus adjuvant temozolomide|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
10012168|NCT01649830|Active Comparator|Radiotherapy|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
10012169|NCT01649843|Experimental|EA|Patients were eligible for enrollment in the study if they had an Eckardt symptom score ≥ 4. The diagnosis of achalasia was made on the basis of the absence of peristalsis and on impaired relaxation of the LES on established methods (barium swallow, manometry, esophagogastroduodenoscopy (EGD)).
10012170|NCT01649882|Experimental|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
10012171|NCT01649895|Experimental|D-Cycloserine|D-Cycloserine, 5 pills (50mg), once per week in 5 weeks.
10012172|NCT01649895|Placebo Comparator|Placebo|Placebo: 5 pills for 5 weeks, once per week.
10012173|NCT01649908||sectional cross clamping|
10012174|NCT01649908||simultaniously cross clamping|
10012175|NCT01649908||EVAR|
10012176|NCT01649921|Active Comparator|Interferon-gamma|
10012177|NCT01649921|Placebo Comparator|Saline 0.9%|
10012178|NCT01649934|No Intervention|Scheduling as Usual|Participants will be subject to the current appointment scheduling procedures.
10012179|NCT01649934|Experimental|Contact Clinic|This group will be required to contact the clinic themselves to make appointments.
10012180|NCT01649934|Experimental|Implementation Intentions|This group will create Implementation Intentions to contact the clinic to make their appointments and to attend those appointments.
10012181|NCT01649960|Other|Rapamycin|Oral rapamycin was given during the nonrandomized phase of the study. The doses that were used of rapamycin were 0.5mg, 1mg, or 2mg.
9965144|NCT01246414||Non-asthmatic controls|Non-asthmatic controls
9965145|NCT01246427|Experimental|BRN01|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
10012182|NCT01649986|Active Comparator|Non-pharmacologic intervention|Patients assigned by their own general practitioner to have non-pharmacologic intervention and prevention strategies will be given details on lifestyle approaches and dietary strategies
10012183|NCT01649986|Active Comparator|Nutraceuticals|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
10012184|NCT01650012|Experimental|Eplerenone|Target of 50 mg/day
10012185|NCT01650012|Placebo Comparator|Placebo|Matching placebo
10012186|NCT01650025|Placebo Comparator|VSL#3 placebo|The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
10012187|NCT01650025|Active Comparator|VSL#3 active probiotic|VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
10012188|NCT01650038|Active Comparator|faecal transplantation; donor faeces|2 times treatment with faecal transplantation: faeces from a healthy donor processed for duodenal tube infusion. after bowel lavage with macrogol.
10012189|NCT01650038|Placebo Comparator|faecal transplantation; placebo|2 times treatment with (own) faecal transplantation: faeces from the patient processed for duodenal tube infusion. after bowel lavage with macrogol.
10012190|NCT01650090|Experimental|ILC|Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
10012191|NCT01650129|Experimental|BIAsp|
10012192|NCT01650129|Experimental|BHI|
10012193|NCT01650142||NF1GeneModif Cohort|Adult patients with neurofibromatosis 1
10012194|NCT01650155|Experimental|BI 1005273 i.v.|single dose i.v. infusion
10012195|NCT01650155|Placebo Comparator|BI 1005273 i.v. Placebo|single dose i.v. infusion (Placebo)
10012196|NCT01650155|Experimental|BI 1005273 s.c.|single dose s.c. injection
10012197|NCT01650155|Placebo Comparator|BI 1005273 s.c. Placebo|single dose s.c. injection (Placebo)
10012198|NCT01650168||NOMAC-E2|New users of NOMAC-E2
10012199|NCT01650168||LNG-COCs|New users of levonorgestrel-containing COCs
10012200|NCT01650181|Active Comparator|Metformin|Patients treated with diet, exercise and metformin
10012201|NCT01650181|Active Comparator|Suplement|Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).
10012202|NCT01650207|Experimental|EA group|To acupuncture the Juanyu (Li15) & Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes.
10012203|NCT01650207|Experimental|TENS group|The electrical patches were placed on the Juanyu (Li15) & Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) & Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes.
10012204|NCT01650207|Sham Comparator|sham-acupuncutre|The Park's Sham Device were placed on the Juanyu (Li15) & Jugu (Li16).
10012205|NCT01650220||Veterans with a history of PTSD|
10012206|NCT01650220||Veterans without a history of PTSD|
9802539|NCT05176808|Active Comparator|Telehealth Parent Coaching (TC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting the child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is 12 weeks with 2 sessions per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Trained study coaches will join families in their homes remotely via Kennedy Krieger Institute's secure Zoom password-protected account to provide coaching."
10012207|NCT01650233|Experimental|Mindfulness-based stress reduction|The mindfulness-based stress reduction (MBSR) program was previously adapted for urban youth and here further adapted to 12 weekly 50-minute classes for use in school.
10012208|NCT01650233|Placebo Comparator|Healthy Topics|An age-appropriate health education curriculum was used as a non-specific group comparison for the MBSR program to control for the effects of: positive adult instruction, interactive peer group instruction, learning new material, group size and location, time, and attention.
10012209|NCT01650272|Experimental|5%Minoxidil solution|"This arm AGA patient receive 5%Minoxidil solution ( Propylene glycol solvent ) to use for 6 month.~Record efficacy and safety as described."
10012210|NCT01650272|Experimental|5%Minoxidil milky lotion|This arm AGA patient receive 5%Minoxidil milky lotion to use for 6 month. Record efficacy and safety as described.
10012211|NCT01650311||Healthy controls|Healthy control group will include participants consenting prior to colorectal cancer screening.
10012212|NCT01650311||CD patient groups|The patient groups will include patients with clinical diagnosis of CD.
10012213|NCT01650311||UC patient group|The patient groups will include patients with clinical diagnosis of UC.
10012214|NCT01650337|Experimental|Smartphone Application|Patients will be given access to a smartphone application for weight loss and instructed on how to use it.
10012215|NCT01650337|No Intervention|Usual primary care|
10012216|NCT01650363|Active Comparator|Acupuncture, homeopathy, osteopathy and reflexology|patients will receive combinations of acupuncture, homeopathy, osteopathy and reflexology
10012217|NCT01650363|Placebo Comparator|homeopathic placebo medication|
10012218|NCT01650376|Experimental|Olaparib plus carboplatin and paclitaxel|
10012219|NCT01650389|Experimental|MVA85A|1 x 10(superscript'8') pfu MVA85A vaccine intradermal within 96 hours of birth
10012220|NCT01650389|Active Comparator|Candin|Equal volume intradermal administration within 96 hours of birth
10012221|NCT01650415|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
10012222|NCT01650415|Placebo Comparator|Placebo and Rehabilitation|Placebo erythropoietin and rehabilitation
10012223|NCT01650428|Experimental|FOLFOX & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
10037293|NCT01823770|Active Comparator|Rotigotine|Patients randomized to rotigotine who will be treated with rotigotine patchs
10012224|NCT01650428|Experimental|FOLFOXIRI & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Irinotecan - 165 mg/m2 IV over 1 hour, Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
10012225|NCT01650441|Experimental|beclomethasone dipropionate + formoterol fumarate|All patients will be treated with the active product. No placebo arm will be used. The active product is a fixed combination containing extra-fine beclometasone dipropionate and formoterol fumarate in a new dry powder inhaler device, NEXThaler® (Chiesi Farmaceutici, Parma, Italy).
10012226|NCT01650454|Experimental|Patients from Memento cohort.|"Patients with mild cognitive impairment included in MEMENTO cohort.~These patients will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12."
10012227|NCT01650454|Experimental|Patients with memory disorders|Patients with mild cognitive impairment not included in MEMENTO cohort. For these patients a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
10012228|NCT01650454|Active Comparator|Healthy volunteers|Healthy volunteers matched in age, sex and educational level with patients. For these volunteers a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
10012229|NCT01650454|Active Comparator|control group|this group is composed with Healthy volunteers these volunteers will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12.
10012230|NCT01650467||Healthy controls|60 healthy controls with no hematological pathologies
10012231|NCT01650467||Imatinib optimal response|30 CML patients who are optimal responders to imatinib treatment
10012232|NCT01650467||Imatinib primary resistance|30 CML patients who have primary resistance to imatinib treatment
10012233|NCT01650480|Experimental|Intervention group|
10012234|NCT01650480|No Intervention|Control group|
10012235|NCT01650493||Group A|Clinpro 5000
10012236|NCT01650493||Group B|MI Paste Plus
10012237|NCT01650493||Group C|Toms of Maine
10012238|NCT01650506|Experimental|Erlotinib + Metformin|This is a single arm phase 1 study. All patients will receive erlotinib and metformin.
10012239|NCT01650532|Experimental|Yoga Condition|Participants will be instructed to learn yoga postures as well as yoga based breathing and meditative practices by certified yoga instructors. Primary Hatha yoga postures will be performed using props like yoga mats, blocks, belts and blankets. Classes will be held 3 times a week for 8 weeks.
10012240|NCT01650532|Active Comparator|Stretching Condition|Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
10012241|NCT01650597|Experimental|Part 1 - Panel 1|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
10012242|NCT01650597|Experimental|Part 1 - Panel 2|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
10012243|NCT01650597|Experimental|Part 2 (parallel)- additional cohort|The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.
10012244|NCT01650610|Experimental|Gait training executive functions tasks|This group will perform a gait training associated with the tasks that require the main executive functions.
10012245|NCT01650623|Experimental|Gait training executive functions tasks|The experimental group will perform a gait training associated with the tasks that require the main executive functions (dual-task condition).
10012246|NCT01650623|Active Comparator|Gait training alone|The control group will perform a gait training alone, without associated tasks (single-task condition).
10012247|NCT01650649|Active Comparator|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
10012248|NCT01650649|Placebo Comparator|Placebo titration in methadone maintained subjects|Methadone maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc) to mimic titration for subjects randomized to lofexidine.
10012249|NCT01650662|Experimental|Cyclosporine A|"The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.~The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, Cremophor® EL and 94% ethyl alcohol in a 5 ml vial.~Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction."
10012250|NCT01650662|Experimental|Control group|The control group received on the top of recommended standard care for acute myocardial infarction.
10012251|NCT01650675|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
10012252|NCT01650675|Experimental|Indirect intervention|Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
10012253|NCT01650688||Epiblepharon|subjects demonstrating prominent corneal touch by cilia and/or related subjective symptoms
10012254|NCT01650701|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
10012255|NCT01650701|Active Comparator|Control|• ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
10012256|NCT01650714|Experimental|Full thickness gastric biopsy|Full thickness gastric biopsy
10012257|NCT01650727|Experimental|Dinaciclib + Rituximab|"Rituximab will be administered in Cycles 1 and 3-13.~Dinaciclib will be administered in Cycles 2-13."
10012258|NCT01650740|Experimental|Open-label duloxetine|12 week treatment with duloxetine
10012259|NCT01650740|Experimental|Open-label Placebo|4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
10012260|NCT01650740|Experimental|Supportive clinical management|4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
10012261|NCT01650753|Experimental|Probiotic Powder|Probiotic: Bifidobacterium longum subsp longum AH1206
9965146|NCT01246427|Placebo Comparator|Placebo|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
10012262|NCT01650753|Placebo Comparator|Placebo Powder|Equivalent amount (same volume) of maltodextrin
10012263|NCT01650792|Active Comparator|Aspirin|Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
10012264|NCT01650792|No Intervention|Best medical treatment|Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
10012265|NCT01650818|Experimental|Aerobic exercise training|
10012266|NCT01650818|Active Comparator|Standard physical therapy|
9965147|NCT01246440|Experimental|Catumaxomab|
9965148|NCT01246453|Active Comparator|urokinase|
9965149|NCT01246453|Active Comparator|Alteplase|
9965150|NCT01246492|Placebo Comparator|45g glucose|glucose water
9965151|NCT01246492|Active Comparator|45g glucose + 150mg aspartame|glucose water aspartame
9965152|NCT01246492|Active Comparator|45g glucose + 20 mg saccharin|glucose water saccharin
9965153|NCT01246492|Active Comparator|45g glucose + 85mg asculfame - K|glucose water aseulfame- k
9965154|NCT01246518|Active Comparator|MOB015 for 3 months|
9965155|NCT01246518|Active Comparator|MOB015 for 9 months|
9965156|NCT01246531||Urolithiasis|Case arm: men above fifty years-old with urolithiasis
9965157|NCT01246531||Control|Control arm: men above fifty years-old without urolithiasis
9965158|NCT01246544||Data collection group: physicians|Online survey for physicians/members of the innovation alliance Berlin-Brandenburg (INABBRA)
9965159|NCT01246570|Experimental|Maintenance program|"Patients will attend a motivational exercise session once monthly. They will also be tested (exercise test with measurement of peak oxygen uptake) every third months."
9965160|NCT01246570|Active Comparator|Control|Usual care. The patients will receive the usual care provided by the hospital and community health services
9965161|NCT01246596|Active Comparator|chronic periodontitis|
9965162|NCT01246596|Active Comparator|aggressive periodontitis|
9965163|NCT01246596|Active Comparator|healthy patient (orthodontics extraction)|
9965164|NCT01246622|Experimental|Treatment (biological therapy)|Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9965165|NCT01246635|Experimental|TRUFIT CB with accelerated rehab.|
9965166|NCT01246635|Experimental|TRUFIT CB with standard rehab.|
9965167|NCT01246635|Active Comparator|• Microfracture with rehabilitation|
9965168|NCT01246648|Active Comparator|chronic periodontitis|
9965169|NCT01246648|Active Comparator|agressive periodontitis|
9965170|NCT01246648|Active Comparator|healthy patients|
9965171|NCT01246674||Hypothesis generating study|Consecutive total hip arthroplasty patients
9965172|NCT01246687|Experimental|e-Intervention group|Receive stage-specific dietary intervention via the website & standard care at the outpatient clinic.
9965173|NCT01246687|No Intervention|Control group|Continue with the standard diabetes care at the outpatient clinic without getting access to the web-based intervention.
9965174|NCT01246700|Experimental|Group A|Participants received 12 weeks of Sensory Attention Focused Exercise, then received 12 weeks of no exercise.
9965175|NCT01246700|Experimental|Group B|Participants received no treatment for 12 weeks, then received Sensory Attention Focused Exercise for 12 weeks.
9965176|NCT01246752|Experimental|Human Stem Cell Transplantation|Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
9965177|NCT01246752|Active Comparator|Consolidating Chemotherapy|Patients receive a standard chemotherapy as consolidation therapy
9965178|NCT01246765||Pregnant women using atypical antipsychotic(s)|Pregnant women who have taken at least one type of atypical antipsychotic at some point during this pregnancy.
9965179|NCT01246765||Pregnant women not using atypical antipsychotics|Pregnant women who have not taken an atypical antipsychotic during pregnancy.
9965180|NCT01246778||With/without sunitinib|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
9965181|NCT01246778||With/without sunitinib IP|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
10012267|NCT01650870|Active Comparator|Evening Only (full-dose)|The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
10037294|NCT01823770|Placebo Comparator|Placebo|Patients randomized on the placebo group who will be treated with placebo patchs
9965182|NCT01246804|Experimental|ginkgo biloba + raltegravir|15 days ginkgo biloba 120mg BID + raltegravir 400mg SD
9965183|NCT01246804|Active Comparator|raltegravir|single dose raltegravir 400mg
9965184|NCT01246830||3D cephalometric analysis|
9965185|NCT01246830||2D cephalometric analysis|
9965186|NCT01246843||metastatic Renal Cell Carcinoma without treatment|patients with metastasized RCC who did not receive treatment
9965187|NCT01246843||mRCC with treatment|"patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for~≥ 8 weeks"
9965188|NCT01246882|Experimental|Augmented activity feedback|Feedback three times per week about 10-m walking speed, plus amount and types of physical activity measured using wireless bilateral ankle sensors that detect bouts of walking and cycling speed, duration, and distance.
9965189|NCT01246882|Active Comparator|speed-only feedback|Feedback three times per week about overground walking speed over 10 meters.
9965190|NCT01246908|Experimental|CX157 (TriRima)|CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)
9965191|NCT01246908|Placebo Comparator|Placebo|
9965192|NCT01246921|Active Comparator|fluticasone proprionate 0.05 %|Group reveiving 12 months NB-UVB phototherapy twice a week in combination with fluticasone proprionate 0.05 % cream in an intermittent scheme
9965193|NCT01246921|No Intervention|no intervention|Group receiving 12 months NB-UVB phototherapy twice weekly, without any topical treatment
9965194|NCT01246934|No Intervention|COMPLICATION|
9965195|NCT01246947|Active Comparator|Mitral surgery alone|Mitral valve surgery randomization for no repair of the moderate tricuspid regurgitation
9965196|NCT01246947|Active Comparator|Mitral surgery w/Tricuspid valve repair|Mitral valve surgery with randomization to repair the moderate tricuspid regurgitation
9965197|NCT01247012|Active Comparator|Lipid minimization|
9965198|NCT01247012|Experimental|Omegaven|
9965199|NCT01247025||Veterans|Veterans receiving mental health services at the Eastern Colorado Healthcare System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC)
9965200|NCT01247038|Experimental|Metal on ceramic articulation|The arm consists of patients with Ceramic femoral heads articulating with metal acetabular cups
9965201|NCT01247038|Active Comparator|Metal-on-metal|The arm consists of patients with Metal femoral heads articulating with metal acetabular cups
9965202|NCT01247051|Experimental|Precoating|
9965203|NCT01247051|Active Comparator|Standard priming|
9965204|NCT01247077|Active Comparator|placebo|Placebo and thyroxin + methimazole
9965205|NCT01247077|Placebo Comparator|selenium|selenium + methimazole + thyroxin
9965206|NCT01247103|Placebo Comparator|Part A: single ascending dose|AZD4316: single oral dose, with 1 group with/without food
9965207|NCT01247103|Placebo Comparator|Part B: multiple ascending dose|AZD4316: multiple oral doses
9965208|NCT01247129|Experimental|SIEA,delay procedure,widening of diameter|
9965209|NCT01247142||Invasive pulmonary aspergillosis (IPA)|Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
9965210|NCT01247142||Controls|Patients without signs of infection.
9965211|NCT01247155||first day review|
9965212|NCT01247155||non-first day review|
9965213|NCT01247168|Experimental|1|
9965214|NCT01247181|Experimental|Mobile phone text message|
9965215|NCT01247181|Active Comparator|No Mobile phone text message|Usual care provided at clinic
9965216|NCT01247194|Active Comparator|Cohort A|"PPI-461 50 mg~or placebo"
9965217|NCT01247194|Active Comparator|Cohort B|"PPI-461 100 mg~or placebo"
9965218|NCT01247194|Active Comparator|Cohort C|"PPI-461 200 mg~or placebo"
9965219|NCT01247246|Placebo Comparator|Placebo|
9965220|NCT01247246|Active Comparator|SCV-07 0.1mg/kg|
9965221|NCT01247246|Active Comparator|SCV-07 0.3mg/kg|
9965222|NCT01247246|Active Comparator|SCV-07 1.0mg/kg|
9965223|NCT01247259|Active Comparator|SLIT-mono|
9965224|NCT01247259|Active Comparator|SLIT-poly|
9965225|NCT01247311|Active Comparator|1.|"1,25 Vitamin D (0.50ug *3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
9965226|NCT01247311|Active Comparator|2.|"25 Vitamin D (5000IU * 3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
9965227|NCT01247311|Placebo Comparator|3.|Placebo given orally 3xweek for six months
9965228|NCT01247337|Experimental|Single arm chemotherapy treatment|
9965229|NCT01247376|No Intervention|No Cooling and compression|
9965230|NCT01247376|Experimental|Intervention with cooling and compression|
9965231|NCT01247389|Active Comparator|midline incision|
9965232|NCT01247389|Active Comparator|transverse incision|
9965233|NCT01247402|Active Comparator|Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2)
9965234|NCT01247402|Active Comparator|Standard balloon angioplasty|standard balloon angioplasty
9965235|NCT01247415||Anaphylaxis|Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis
9965236|NCT01247415||Allergic-like reactions|Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group
10012268|NCT01650870|Experimental|Split-dose|The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.
10012269|NCT01650883|Experimental|Cholecaliferol 50,000 IU PO Q10 days x 40 days|Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3. They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
10012270|NCT01650883|Experimental|Cholecalciferol 5,000 IU PO daily x 40 days|Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU. These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
10012271|NCT01650896|No Intervention|General Medicine|
10012272|NCT01650896|Active Comparator|Geriatric Medicine|Daily medical review, adjust medications, treat infection, occupational therapy
10012273|NCT01650935|Active Comparator|Oxalate restricted|After a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
10012274|NCT01650935|Active Comparator|DASH diet|The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
10012275|NCT01650948||AMD subjects with GA and/or RPED|All subjects will have AMD and GA and/or RPED.
10012276|NCT01650948||AMD subjects with CNV alone|All subjects will have the CNV form of AMD only.
10012277|NCT01650961|Experimental|Palonosetron|Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
10012278|NCT01650961|Placebo Comparator|Control|Intravenous administration of normal saline before the induction of general anesthesia
10012279|NCT01650974|No Intervention|conventional oxygen therapy|conventional nasal prong with FiO2 ~0.4
10012280|NCT01650974|Experimental|HFNOT|high flow nasal oxygen therapy with starting FiO2 0.4 and Flow 40 L/min
10012281|NCT01650974|Sham Comparator|sham-HFNOT|same device with FiO2 ~0.4, NO high flow
10012282|NCT01650987||Col 1|Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
10012283|NCT01650987||Col 2|Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
10012284|NCT01650987||Col 3|patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
10012285|NCT01650987||Endometrial 4|patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
10012286|NCT01650987||endometrial 5|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
10012287|NCT01650987||endometrial 6|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
10012288|NCT01651013||metastatic colorectal cancer|
10012289|NCT01651026||rectal cancer|
10012290|NCT01651065|Experimental|Microclinics Group A|Subjects will be receiving a 10/9-month Microclinic Diabetes Education Program (Team Up 4 Health) and 6 months of follow up. In the intervention these subjects will engage in the Microclinic Program support groups. The intervention program consists of 25 event sessions. Sessions are offered weekly the first month, and biweekly thereafter.
10012291|NCT01651065|Placebo Comparator|Group C Controls|Individuals will receive screening by clinical staff. Control group subjects will receive clinic screenings only; they will not participate in program activities.
10012292|NCT01651091|Experimental|Meditation Awareness Training|
10012293|NCT01651091|Active Comparator|Treatment as Usual|
10012294|NCT01651130|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, once following delivery of the fetal head.
10012295|NCT01651130|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, once following delivery of the fetal head.
10012296|NCT01651130|Active Comparator|Carbetocin 15mcg|Carbetocin 15mcg, once following delivery of the fetal head.
10012297|NCT01651130|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg, following delivery of the fetal head.
10012298|NCT01651130|Active Comparator|Carbetocin 5mcg|Carbetocin 5mcg, following delivery of the fetal head.
10012299|NCT01651130|Active Comparator|Carbetocin 2mcg|Carbetocin 2mcg, following delivery of the fetal head.
10012300|NCT01651156|Placebo Comparator|placebo|Frequency: once per day Duration: 7days
10012301|NCT01651156|Experimental|Tolvaptan|Tolvaptan tablet Frequency: once per day Duration: 7days
10012302|NCT01651169|Experimental|methylphenidate tablets (10mg), ADHD|Fifteen patients of ADHD
10012303|NCT01651169|Experimental|methylphenidate tablets, Methamphetamine abusers and ADHD|Fifteen patients of ADHD with Methamphetamine abuse for at least 2 years plus
10012304|NCT01651182|Placebo Comparator|Standard Care|No tranexamic acid
10012305|NCT01651182|Experimental|Dose 1|1 g bolus + 1 g infusion from induction over 8 hours
10012306|NCT01651182|Experimental|Dose 2|1 g bolus + 10 mg/kg/hr from induction until end of surgery
10012307|NCT01651221|Experimental|Olfactory|Habituation of olfactory response
10012308|NCT01651221|Experimental|gustatory|Habituation of gustatory response.
10012309|NCT01651221|Experimental|olfactory and gustatory|Habituation of olfactory and gustatory response
10012310|NCT01651234|Experimental|Active|
10012311|NCT01651234|Placebo Comparator|Placebo|
10012312|NCT01651247||Group A|Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
10012313|NCT01651247||Group B|Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
10012314|NCT01651273|Experimental|Arm 1: BMS-852927 (0.25 mg)|
10012315|NCT01651273|Experimental|Arm 2: BMS-852927 (1.0 mg)|
10012316|NCT01651273|Experimental|Arm 3: BMS-852927 (2.5 mg)|
10012317|NCT01651273|Placebo Comparator|Arm 4: Placebo|
10012318|NCT01651286|Experimental|nasal mask|when the patient is apneic after the injection of anesthetics in the operating room, a nasal mask will be applied with positive pressure ventilation for 1 min. Then the nasal mask will be replaced with a full face mask for 1 min. Subsequently, the face mask will be replaced with the nasal mask.
10012319|NCT01651286|Active Comparator|full face mask|when the patient is apneic after the injection of anesthetics in the operating room, a full face mask will be applied with positive pressure ventilation for 1 min. Then the full face mask will be replaced with a nasal mask for 1 min. Subsequently, the nasal mask will be replaced with the full face mask.
10012320|NCT01651312|Experimental|14C-labeled YM178|Single oral administration of 14C-labeled YM178
10012321|NCT01651325|Experimental|Isavuconazole and dextromethorphan|Dextromethorphan on Day 1and Day 10, Isavuconazole three times per day (TID) on Days 6 and 7, and once daily (QD) on Days 8 thru 12.
10012322|NCT01651338|Experimental|accupuncture,|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
10012323|NCT01651364|Placebo Comparator|Placebo|
10012324|NCT01651364|Active Comparator|Cabergoline|
10012325|NCT01651377|Placebo Comparator|Placebo|
10012326|NCT01651377|Active Comparator|Pramipexole|
10012327|NCT01651390|Experimental|Drug coated balloon|Percutaneous coronary intervention with the Pantera Lux drug coated balloon.
10012328|NCT01651390|Active Comparator|Drug eluting stent|Percutaneous coronary intervention with the Orsiro drug eluting stent.
10012329|NCT01651416|Active Comparator|HMM using short-acting ACT|Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
10012330|NCT01651416|Experimental|HMM using short-acting ACT plus SMC|Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
10012331|NCT01651416|Experimental|HMM using a long-acting ACT|Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
10012332|NCT01651429|Experimental|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
10012333|NCT01651455||Cohort first decade|Patients born between 01/01/1979 and 12/31/1984
10012334|NCT01651455||Cohort second decade|Patients born between 01/01/1991 and 12/31/1996
10012335|NCT01651468|Experimental|HEMOFIX|3 grams a day
10012336|NCT01651481|Experimental|TR|HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal
10012337|NCT01651481|Experimental|RT|coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet)
10012338|NCT01651494|Active Comparator|DAS181-F04|DAS181-F04: 20 mg single-dose each day via inhalation for 3 days; 6 subjects
10012339|NCT01651494|Placebo Comparator|Placebo|Placebo: 20 mg single-dose each day via inhalation for 3 days; 3 subjects
10012340|NCT01651507||HLP|Patients with pulmonary LCH from eight teaching hospitals evaluated between June 1989 and February 2005 were considered for this study, if they were followed for at least 6 months and evaluated by ≥ 2 lung HRCT and lung function tests at the same time or within a 2 months period
10035777|NCT01809522|Experimental|Posterior reconstruction of the musculofascial plate|These patients will receive reconstruction of the muscolofascial plate after radical prostatectomy. The reconstruction will be performed using two 3-0 Poliglecaprone sutures (on RB-1 needles) tied together, with each individual length being 12-15 cm. seven - Ten knots will be placed when tying the sutures to provide a bolster. The free edge of the remaining Denonvillier's fascia will be identified after the prostatectomy and approximated to the posterior aspect of the rhabdosphincter and the posterior median raphe using one arm of the continuous suture. As a rule, four passes will be taken from the right to the left and the suture is locked. The second layer of the reconstruction will be then performed with the other arm of the suture approximating the posterior lip of the bladder neck (full thickness) and the vesicoprostatic muscle to the posterior urethral edge and to the already reconstructed median raphe .This suture will be then tied to the end of the first suture arm.
10012341|NCT01651520|Experimental|Relapsing patients < 5 years|Relapsing patients < 5 years
10012342|NCT01651520|Experimental|relapsing patients < 10 years|relapsing patients < 10 years
10012343|NCT01651520|Experimental|primary progressive patients < 10 years|primary progressive patients < 10 years
10012344|NCT01651520|Other|healthy volunteers|healthy volunteers
10012345|NCT01651546|Other|Cohort|Patients with dysvoiding function and chronic urinary retention, with an indication to CISC.
10012346|NCT01651572|Experimental|Cisatracurium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.~Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
10012347|NCT01651572|Experimental|Rocuronium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl~Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
10012348|NCT01651585|Experimental|Valacyclovir arrow|Experimental : Valacyclovir arrow 500mg give Valacyclovir arrow to all participants (open phase)
10012349|NCT01651598|Experimental|BI 144807|Subjects receive multiple BID doses of BI 144807 solution
9518067|NCT03300258|Other|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
10012350|NCT01651598|Placebo Comparator|Placebo|Subjects receive multiple BID doses of Placebo solution
10012351|NCT01651611|Experimental|Extensive TTA interaction|Persons interested in quitting smoking will receive multiple in-person visits from a peer Tobacco Treatment Advocate (TTA) who will provide motivational interviewing, basic smoking cessation counseling assistance, navigation to smoking cessation resources, and social support.
10012352|NCT01651611|Active Comparator|Minimal TTA interaction|Persons interested in quitting smoking will receive a single in-person visit from a peer Tobacco Treatment Advocate (TTA) who will provide basic smoking cessation counseling assistance.
10012353|NCT01651624|Experimental|Computed tomographic colonography (CTC), reduced prep|Subjects invited to undergo CTC with reduced cathartic preparation
10012354|NCT01651624|Experimental|Computed tomographic colonography (CTC), standard prep|Subjects invited to undergo CTC with standard bowel preparation
10012355|NCT01651624|Active Comparator|Faecal occult blood test (FOBT)|Subjects invited to undergo FOBT
10012356|NCT01651624|Experimental|Colonoscopy|Subjects invited to undergo colonoscopy
10012357|NCT01651637|Experimental|Synthetic Surfactant|Cohort Design
10035778|NCT01809522|No Intervention|Standard radical prostectomy|
9965237|NCT01247415||ORS cases|ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus ≥1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration) (ref: Public Health Agency of Canada: User Guide: Report of Adverse Events Following Immunization (AEFI) Appendix III National Case Definitions of AEFIs of Special Interest: oculo-respiratory Syndrome. http://www.phac-pc.gc.ca/im/aefi_guide/ann3-eng.php
9965238|NCT01247415||Controls|Controls will be individuals who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine.
9965239|NCT01247454|Other|academic detailing|All arms will receive this intervention
9965240|NCT01247454|Experimental|Electronic Health Record (EHR) prompt|One intervention arm will receive the EHR prompt along with the academic detailing
9965241|NCT01247454|Experimental|EHR prompt and patient prompt|The final arm will receive this combined intervention plus the academic detailing
9965242|NCT01247467||Breast Tumor|Breast Tumor Blocks
9965243|NCT01247480||Breast cancer patients|
9965244|NCT01247506||1|tumor tissues of HCC patients
9965245|NCT01247506||2|paired nontumor tissues of HCC patients
9965246|NCT01247519|No Intervention|observation|
9965247|NCT01247519|Experimental|Intervention|
9965248|NCT01247532|Experimental|Waitlist|
9965249|NCT01247545|Placebo Comparator|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
9965250|NCT01247545|Active Comparator|Remote ischaemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
9965251|NCT01247558||Test Cohort|100 randomized subjects administered Metanx®
9965252|NCT01247558||Control Cohort|400 subjects with diabetes mellitus meeting the same inclusion and exclusion criteria as the test cohort who have not been treated with Metanx®.
9965253|NCT01247610||ADHD group|
9965254|NCT01247610||Control group|
9965255|NCT01247636|Experimental|Home-exercise|
9965256|NCT01247649|Experimental|Study group|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
9965257|NCT01247662||ASD group|
9965258|NCT01247662||ADHD group|
9965259|NCT01247662||Normally developing control group|
9965260|NCT01247688|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Cytoxan, Fludarabine, Total Body Irradiation (TBI), Cord Blood Stem Cell Infusion
9965261|NCT01247701|Experimental|Umbilical Cord Blood Transplant|Busulfan,Cyclophosphamide, Fludarabine, Cord Blood Stem Cell Infusion
9965262|NCT01247714|Active Comparator|Group 1|The group 1 will receive the experimental product T-Diet plus Diabet NP for the first month followed by a reference diet corresponding to a current marketed product (Glucerna SR, Abbott) for the second month, then the patients will receive a control product non specific for diabetic patients (T-Diet plus Standard)for the third month, and finally a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the fourth month.
9965263|NCT01247714|Active Comparator|Group 2|The group 2 will receive a reference diet corresponding to a current marketed product (Glucerna SR, Abbott)for the first month, followed by the experimental product T-Diet plus Diabet NP for the second month, then the patients will receive a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the third month, and finally a control product non specific for diabetic patients (T-Diet plus Standard)for the fourth month
9965264|NCT01247740|Experimental|1|three chamber bag for parenteral nutrition containing lipids, glucose, amino acids and electrolytes
9965265|NCT01247740|Active Comparator|2|compounded monobag including lipids, glucose, amino acids and electrolytes
9965266|NCT01247753|Experimental|Intervention|
9965267|NCT01247753|No Intervention|Control|
9965268|NCT01247766||Patients with rheumatoid arthritis (RA) who receive abatacept|
9965269|NCT01247766||Patients with RA who receive BDM drugs|biologic disease-modifying (BDM)
9965270|NCT01247766||Patients with RA who receive non-biologic DMARDs|disease-modifying anti-rheumatic drugs (DMARDs)
9965271|NCT01247779|Active Comparator|Standard Coelioscopy|gynecologic surgery - standard coelioscopy
9965272|NCT01247779|Experimental|Robot-assisted coelioscopy|gynecologic surgery - robot assisted coelioscopy
9965273|NCT01247792|No Intervention|"Before"|No Intervention Observation of current practice
9965274|NCT01247792|Other|"After"|SOPs for decision-making and communication Assessment of practice after implementation of SOPs
9965275|NCT01247805|Experimental|Treatment A|Revatio: 1 x 20 mg IR oral tablet.
9965276|NCT01247805|Experimental|Treatment B|2 x 10 mg sildenafil citrate IR oral tablet.
9965277|NCT01247805|Experimental|Treatment C|2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
9965278|NCT01247818|Experimental|PH-10 Treatment (High Dose Cohort)|
9965279|NCT01247818|Experimental|PH-10 Treatment (Mid Dose Cohort)|
9965280|NCT01247818|Experimental|PH-10 Treatment (Low Dose Cohort)|
9965281|NCT01247818|Placebo Comparator|Vehicle Control|
9965282|NCT01247831|Other|glaucoma patients|All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
9965283|NCT01247844|Other|Day 7|removal of Shang Ring at 7 days
9965284|NCT01247844|Other|Day 14|removal of Shang Ring at 14 days
9965285|NCT01247844|Other|Day 21|removal of Shang Ring at 21 days
9965286|NCT01247857|Active Comparator|Preoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity before surgery
9965287|NCT01247857|Active Comparator|Postoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity after surgery
9965288|NCT01247857|Placebo Comparator|Control|Nebulization of normal saline 3 ml before and after surgery
9965289|NCT01247870|Experimental|Metformin|Metformin 1 g twice daily for 28-35 days
9965290|NCT01247870|Placebo Comparator|Placebo|Matched placebo capsules
9965291|NCT01247883|Active Comparator|single dose PF-04634817 tablet|subjects receive a single dose of PF-04634817 as a tablet
9965292|NCT01247883|Active Comparator|single dose PF-04634817 solution|subjects receive a single dose of PF-04634817 as a solution
9965293|NCT01247896|Experimental|Active|
9965294|NCT01247896|Placebo Comparator|Placebo|
9965295|NCT01247909|Experimental|Ceftriaxone|Ceftriaxone in infants with sepsis and bacterial meningitis
9965296|NCT01247909|Active Comparator|Penicillin and gentamicin|Penicillin and Gentamicin in infants with sepsis and bacterial meningitis
9965297|NCT01247935|Experimental|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
9965298|NCT01247935|Experimental|transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
9965299|NCT01247935|No Intervention|Control|patient are monitored for pain and discomfort
9965300|NCT01247948|Experimental|navigation assisted spine surgery|
9965301|NCT01247961|Experimental|10 mg intravenous dexamethasone|Subjects randomized to intervention arm will receive single dose of 10 mg intravenous dexamethasone.
9965302|NCT01247961|Placebo Comparator|Placebo|Equal volume of normal saline administered as a single intravenous dose at enrollment.
9965303|NCT01247987|Active Comparator|Blastocyst cryopreservation|Subjects randomly assigned to this arm of the study will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent menstrual cycle.
9965304|NCT01247987|Experimental|Bipronuclear oocyte cryopreservation|Subjects randomly assigned to this arm of the study will have all of their bipronuclear oocytes cryopreserved, followed by thaw, extended culture, and transfer in a subsequent menstrual cycle.
9965305|NCT01248000||classical Hodgkin lymphoma|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
9965306|NCT01248026|Experimental|Buttermilk|
9965307|NCT01248026|Placebo Comparator|Placebo|
9965308|NCT01248039||Total arthroplasty|Patients with osteoarthrosis going for hip or knee arthroplasty
9965309|NCT01248052|Experimental|LY2979165 (Part A)|single oral doses at dose levels ranging from 20 to 1000 mg
9965310|NCT01248052|Placebo Comparator|Placebo (Part A)|single oral dose
9965311|NCT01248052|Experimental|LY2979165 - low dose (Part B)|single oral low dose of LY297165 (dose to be determined by Part A)
9965312|NCT01248052|Experimental|LY2979165 - high dose (Part B)|single oral high dose of LY2979165 (dose determined from Part A)
9965313|NCT01248052|Placebo Comparator|Placebo - Part B|single oral dose
9965314|NCT01248078|Active Comparator|Cefazolin A|administered before skin incision
9965315|NCT01248078|Active Comparator|Cefazolin B|after umbilical cord clamping
9965316|NCT01248078|Placebo Comparator|saline solution|administered before skin incision
9965317|NCT01248091|Placebo Comparator|Placebo gel|
9965318|NCT01248091|Experimental|Nitroprusside Gel|
9965319|NCT01248117|Experimental|Previously Treated|With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial
9965320|NCT01248117|Experimental|Treatment-Naive|Treatment-Naive: no previous treatment for PCV
9965321|NCT01248143|Experimental|Green tea|
9965322|NCT01248143|Experimental|FPP|
9965323|NCT01248156||Intervention|Patients with persistent, long standing persistent and paroxysmal AF, who will receive ablation at sites that potentially maintain human AF.
9965324|NCT01248156||Control|Patients with persistent, long standing persistent and paroxysmal AF, who receive conventional ablation as determined by the operator at each site, and based upon Heart Rhythm Society guidelines.
9965325|NCT01248169||Hydralazine|This group will receive administration of the antihypertensive Hydralazine for the attempted control of their blood pressure and stabilization of their hemodynamic state.
9965326|NCT01248169||Labetalol|This group will receive administration of the antihypertensive Labetalol for the attempted control of their blood pressure and stabilization of their hemodynamic state.
9965327|NCT01248195|Other|Phase I: 1 arm 'amisulpride open label'|For 4 weeks, all patients will be treated with amisulpride open label.
9965328|NCT01248195|Active Comparator|Phase II: 'amisulpride double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'
9965329|NCT01248195|Active Comparator|Phase II 'olanzapine double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'
9965330|NCT01248195|Other|Phase III: 1 arm 'clozapine open label'|Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'
9965331|NCT01248195|Experimental|Psychosocial intervention|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.
10012358|NCT01651650|Other|Inhalation of Placebo Dry Powder|Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
10012359|NCT01651663|Experimental|Arbidol (Umifenovir)|
9965332|NCT01248195|No Intervention|Psychosocial Intervention phase: 'TAU'|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.
9965333|NCT01248208|Experimental|FluMist (LAIV) group|FluMist influenza vaccine 0.2 mL intranasal vaccine once
9965334|NCT01248208|Active Comparator|Flu shot (TIV) group|"Patients 6 months to 2 yrs or > 49 years or WITH a history of asthma symptoms / treatment within the past 12 months will receive intramuscular influenza vaccination. History/Treatment of asthma in the past 12 months is defined as follows:~wheezing in the past 12 months~use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months~emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months."
9965335|NCT01248234|Active Comparator|Propofol|Propofol alone will be used to put an elderly hypertensive patient to sleep for surgery.
9965336|NCT01248234|Active Comparator|Etomidate|Etomidate alone will be used to put an elderly hypertensive patient to sleep.
9965337|NCT01248234|Active Comparator|Propofol and Etomidate|A combination of Etomidate and Propofol will be used to put an elderly hypertensive patient to sleep for surgery.
9965338|NCT01248260|Experimental|Higher-strength folic acid|Higher-strength folic acid (4mg).
9965339|NCT01248260|No Intervention|Low-strength folic acid|Low-strength (0.8mg) folic acid (standard of care)
9965340|NCT01248273|Experimental|immunization|This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21. This is a phase I study to assess toxicity and immunogenicity.
9965341|NCT01248286|Experimental|Whole grain rice|
9965342|NCT01248286|Active Comparator|Refined grain rice|
9965343|NCT01248299|Experimental|Chemotherapy plus best supportive care|Chemotherapy plus best supportive care with follow up at each cycle of the treatment with FU-CDDP; LV5FU2-CDDP; FOLFOX; TPF
9965344|NCT01248299|Active Comparator|Best supportive care|Best supportive care with follow up every 6 weeks
9965345|NCT01248312||morbidly obese|BMI >45
9965346|NCT01248312||thin patients|BMI <45
9965347|NCT01248325|Experimental|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
9965348|NCT01248325|Active Comparator|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
9965349|NCT01248338|Active Comparator|metoprolol, tablets|metoprolol succinate 50-100 mg orally daily for one year
9965350|NCT01248338|Experimental|nebivolol|nebivolol 5 mg capsule once daily for one year
9965351|NCT01248351|Experimental|autologous stored platelets|
9965352|NCT01248377||Cephalosporins allergic patients|
9965353|NCT01248390|Experimental|Interactive Metronome therapy|Fifteen one-hour training sessions using Interactive Metronome system, in addition to treatment as usual.
9965354|NCT01248390|No Intervention|Treatment as Usual|Standard of care symptom management.
9965355|NCT01248403|Active Comparator|paclitaxel + placebo|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ Placebo (2 tablets / day) d1-d28"
9965356|NCT01248403|Experimental|paclitaxel + RAD001|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ RAD001 10mg (2 x5 mg tablets / day) d1-d28"
9965357|NCT01248429||Patient treated by TKI|Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
10012360|NCT01651663|Placebo Comparator|placebo|
10012361|NCT01651663|Experimental|Arbidol (Umifenovir) prophylaxis|
10012362|NCT01651663|Placebo Comparator|placebo prophylaxis|
10012363|NCT01651676|Experimental|COPD arm|"VQ11 validation:~Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire"
10012364|NCT01651689||Scalp biopsy|Subjects are on scadule list for hair transplantation in Siriraj hospital. Scalp biopsy with punch biopsy No.4 Scalp biopsy by punch biopsy No.4 at occipital area was done in subjects who have hair transplantaion.
10012365|NCT01651702|Active Comparator|Carto|Patients in whom Carto system will be used
10012366|NCT01651702|Active Comparator|Ensite|Patients in whom Ensite system will be used
10012367|NCT01651715|Experimental|TAO1, oral homeopathic antibodies|TAO1 is an investigational medicinal product containing homeopathic dilutions (<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.
10012368|NCT01651715|Placebo Comparator|Placebo|Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide
10012369|NCT01651728|Experimental|Simvastatin|Tablet 20 mg once daily for 30 days
10012370|NCT01651728|Placebo Comparator|Placebo|Placebo tablet once daily for 30 days
10012371|NCT01651741|Experimental|Seaweed and Duolac7S|Seaweed: Real Seaweed granule, Duolac7S: Real probiotics
10012372|NCT01651741|Placebo Comparator|Seaweed and Duolac7S-P|Seaweed: Real Seaweed granule, Duolac7S-P: Placebo probiotics
10012373|NCT01651754|Other|Seasonal influenza vaccination|
10012374|NCT01651767|Experimental|Panel I|Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
10012375|NCT01651767|Experimental|Panel II|Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
10012376|NCT01651767|Experimental|Panel III|Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
10012377|NCT01651767|Experimental|Panel IV|Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.
10012378|NCT01651819|Experimental|Urological physical therapy|Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.
10012379|NCT01651832|No Intervention|usual care|routine care and case management
10012380|NCT01651832|Experimental|SCAN-Intervention|
10012381|NCT01651845||Image Guided Intervention|Standard of care white light visual wound assessment followed by fluorescence image-guided wound assessment
10012382|NCT01651858|Experimental|Nurigra Chewable tablet|
10012383|NCT01651858|Active Comparator|Viagra|
10012384|NCT01651884|Experimental|High-Definition tDCS|
10012385|NCT01651884|Experimental|Sponge tDCS|
10012386|NCT01651897||Delirious in the ED|Patients who were delirious in the ED at either the 0-hour or 3-hour delirium assessment.
10012387|NCT01651897||Non-Delirious in the ED|Patients who were non-delirious in the ED at both the 0-hour or 3-hour delirium assessment.
10012388|NCT01651910||Controlled Pain|Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
10012389|NCT01651910||Uncontrolled Pain|Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
10035779|NCT01809535|Experimental|The Monthly EVL|Patients in the Monthly group were received EVL at 28-day treatment intervals.
10012390|NCT01651910||Breakthrough pain|Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.
10012391|NCT01651923|Other|Group A|"First periody: Heparin Test Drug (Blau Farmacêutica S/A)~Secundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
10012392|NCT01651923|Other|Group B|"First periody: Heparin Comparator Drug (APP Pharmaceuticals)~Secundy periody: Heperin Test Drug (Blau Farmacêutica S/A)"
10012393|NCT01651962|Experimental|Terbutaline|Terbutaline 0.125mg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
10012394|NCT01651962|Active Comparator|Fentanyl|Fentanyl 100mcg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
10012395|NCT01651962|Placebo Comparator|Placebo|0.9% NaCl i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
10012396|NCT01651975|Other|Thickenup|
10012397|NCT01651988|Active Comparator|Ketofol 1:1|1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.
10012398|NCT01651988|Experimental|Ketofol 1:2|2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.
10012399|NCT01652014|Experimental|Arm I|"Double UCB transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0."
10012400|NCT01652014|Experimental|Arm II|"Sub-threshold single UCB + irradiated PBMCs transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion."
10012401|NCT01652027||Previously Untreated Patients with Hemophilia A|
10012402|NCT01652053||Disc Nucleus Replacement|Disc Nucleus Replacement (InterCushion DNP)
10012403|NCT01652066|Placebo Comparator|Placebo|oral consumption, once per day in the morning, fasting, with a glass of water
10012404|NCT01652066|Experimental|Mixture of probiotics|"at least 10x7 cfu/tablet of a mixture of probiotics~oral consumption, once per day in the morning, fasting, with a glass of water"
10012405|NCT01652079|Experimental|Treatment Arm|CRLX101
10012406|NCT01652105|Experimental|Diet|New developed diet
10012407|NCT01652105|Active Comparator|Prodimed|Standard VLCD
10012408|NCT01652118|Active Comparator|Clarithromycin|Fist group treated with clarithromycin which is include 10 days application.
10012409|NCT01652118|Placebo Comparator|placebo|Second group treated with salin as same as amount of clarithromycine volume
10012410|NCT01652131|Other|Tetrastarch (130/0.4)|In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.
10012411|NCT01652144|Experimental|AT7519M|AT7519M: 27 mg/m2 IV injection, 1 hour infusion, 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
10012412|NCT01652157||Cystic fibrosis (CF) patients in the CF Patient Registry|Patients diagnosed with cystic fibrosis at participating sites who are providing data to the Cystic Fibrosis Patient Registry
10012413|NCT01652183|Placebo Comparator|Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl|
10012414|NCT01652183|Active Comparator|Group Paracetamol(n=32):iv 15mg/kg paracetamol|The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was >3.
10012415|NCT01652196|Experimental|Aflibercept (combination chemotherapy)|Patients receive aflibercept and fluorouracil and then continuously over 46 hours on days 1 and 15.If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted. Correlative Studies are required to be available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.DCE MRI (dynamic contrast-enhanced magnetic resonance imaging)images at weeks 0, and after 8 weeks +/- 1 week of treatment(after Cycle 2). 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG).FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers,including colorectal cancer (99-102).
10012416|NCT01652209|No Intervention|Control|"After implementing PCI, contemporary drug treatment is conducted.~*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, β-blocker, CCB, Diuretics, Statin, etc.)"
9965358|NCT01248442|Experimental|Cholecalciferol|
9965359|NCT01248442|Placebo Comparator|Placebo|
9965360|NCT01248481||Group 1|
9965361|NCT01248494|Experimental|BEZ235 + Letrozole|
9965362|NCT01248494|Experimental|BKM120 + Letrozole|
9965363|NCT01248494|Experimental|Intermittent BKM120 + Letrozole|
9965364|NCT01248520|Placebo Comparator|General health information|Pregnant women receiving text messages containing general health messages without including information regarding the importance of the influenza vaccination
9965365|NCT01248520|Active Comparator|Influenza and general health information|Pregnant women receiving text messages with influenza facts and the importance of the influenza vaccination, as well as general health messages Intervention: Text messages with influenza facts
10012417|NCT01652209|Experimental|Single dose of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted.
10012418|NCT01652222|Experimental|CONEM-BETA + socio-educational training|"Caregivers will receive 4 socioeducational training sessions during an 8 week period. These sessions will focus on the description and process of the Alzheimer's disease (AD), and will also provide to the caregivers resources and strategies to cope with AD. During the last 4 weeks, they will also systematically play with the patient at home with the CONEM-BETA game.~After that period, caregivers will use the game based on their preference and frequence during a period of 6 more weeks."
10012419|NCT01652222|Active Comparator|Socio-educational training only|Caregivers will receive the same 4 socioeducational training sessions as the experimental group, during an 8 week period.
10012420|NCT01652222|No Intervention|Control|Caregivers of this group will behave with his/her patient during the trial as they have been doing so far, but will receive no intervention
10012421|NCT01652248|Placebo Comparator|Standard generator replacement|Standard generator replacement
10012422|NCT01652248|Active Comparator|Upgrade to cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
10012423|NCT01652261|Experimental|experimental arm|"An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
10012424|NCT01652261|Active Comparator|standard arm|"A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
10012425|NCT01652274||Mother|study objectives to Mother only
10012426|NCT01652274||Father|study objectives to Father only
10012427|NCT01652300|Experimental|test group|For test group intervention was two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
10012428|NCT01652300|Other|control|received no education
10012429|NCT01652313|Experimental|Rasagiline|
10012430|NCT01652326||Benzodiazepine-resistant|those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
10012431|NCT01652339|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
10012432|NCT01652339|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
10012433|NCT01652352||Individuals with Disability|Power wheelchair-bound individuals with conditions which affect upper and lower body mobility, strength, or dexterity. Such conditions may include but are not limited to spinal cord injury, Multiple Sclerosis, Cerebral Palsy, or other conditions which affect overall mobility.
10012434|NCT01652352||Able-Bodied Individuals|Those who possess no condition or injury resulting in loss of mobility.
10012435|NCT01652365|Experimental|RDT Training and Subsidy Offered|Licensed drug shops within villages selected randomly to be in this arm will be invited to training on RDTs and offered access to subsidized RDTs available for purchase at a local wholesale pharmacy in Mbale, Uganda.
10035780|NCT01809535|Active Comparator|The Biweekly EVL|Patients in the Biweekly group received repeating EVL every 2 weeks.
10012436|NCT01652365|Experimental|Information/Education Campaign|Community meetings describing RDTs and encouraging community members to be diagnosed prior to taking malaria treatment will be held in villages randomly assigned to this treatment arm.
10012437|NCT01652365|Experimental|RDT Training/Subsidy + Information/Education Campaign|Includes both the training and subsidy component and the information/education campaign component.
10012438|NCT01652365|No Intervention|Control|
10012439|NCT01652378||Cocaine-Addicted Participants|Group of participants diagnosed with cocaine dependence
10012440|NCT01652378||Control Participants|healthy control volunteers
10012441|NCT01652391|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
10012442|NCT01652391|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
10012443|NCT01652404|Experimental|Procalcitonin-guided treatment|The duration of antibiotics will be determined by the procalcitonin levels.
10012444|NCT01652404|Active Comparator|Conventional treatment|The duration of antibiotics will be determined by the treating physician.
10012445|NCT01652417|No Intervention|oral prednisone|Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
10012446|NCT01652417|Experimental|methylprednisolone bolus|methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
10012447|NCT01652430||PTSD cohort|
10012448|NCT01652430||No PTSD cohort|
10012449|NCT01652456|Experimental|Group A|
10012450|NCT01652456|No Intervention|Group B|
10012451|NCT01652508|Placebo Comparator|Control|Participants are given printed self-help leaflet on smoking cessation developed by the Department of Health, Hong Kong.
10012452|NCT01652508|Experimental|Acceptance and Commitment Therapy|All participants are given a self-help leaflet on smoking cessation. Participants are also given an initial session of face-to-face ACT at a primary health service clinic. In addition, two more subsequent ACT sessions are provided by telephone at one week and one month after the initial intervention.
10012453|NCT01652521||candidates for pleural fluid drainage|patients who are candidates for pleural fluid drainage.
10012454|NCT01652534|Active Comparator|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day
10012455|NCT01652534|Placebo Comparator|placebo|Sugar Pill
10012456|NCT01652547|Experimental|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs), switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
10012457|NCT01652547|Experimental|Pasireotide long acting release|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
10012458|NCT01652560||bevacizumab combined neoadjuvant chemotherapy|
10012459|NCT01652586|Experimental|dexmedetomidine-remifentanil|intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min
10012460|NCT01652586|Active Comparator|midazolam-remifentanil|remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg
10012461|NCT01652599|Experimental|Eltrombopag and dexamethasone|
10012462|NCT01652612|No Intervention|Control|zero PEEP
10012463|NCT01652612|Experimental|OLV strategy: PEEP|1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery
10012464|NCT01652612|Experimental|OLV strategy: PEEP followed by AR|"alveolar recruitment strategy before one lung ventilation~8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery"
10012465|NCT01652625|Experimental|Yunnan Baiyao toothpaste|The toothpaste containing 6.5 milligrams of Yunnan Baiyao was used twice daily as part of the patient's routine oral hygiene for 5 days.
10012466|NCT01652625|Active Comparator|placebo toothpaste|One gram of placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
10012467|NCT01652638|Experimental|Group A|"First periody: Test Drug (Heparin Blau Farmacêutica S/A)~Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals)"
9965366|NCT01248546||Digital mammography|
9965367|NCT01248572|Experimental|Softec HD IOL|
9965368|NCT01248611|Experimental|fentanyl|cancer patients with pain
9965369|NCT01248624|Active Comparator|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
9965370|NCT01248624|Placebo Comparator|Conventional Cancer Care|This control arm receives standard cancer care.
9965371|NCT01248637||Pimonidazole hydrochloride|Oral pimonidazole is administered at a dose of 0.5gm/m2 once approximately 24 hrs prior to surgery
9965372|NCT01248650|Active Comparator|TRK-820 5 μg|Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route
9965373|NCT01248650|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route
9965374|NCT01248663|Active Comparator|antecolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing an antecolic duodeno-jejunostomy
9965375|NCT01248663|Experimental|retrocolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing a retrocolic duodeno-jejunostomy
9965376|NCT01248689|Active Comparator|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
9965377|NCT01248689|Active Comparator|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
9965378|NCT01248689|Active Comparator|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
9965379|NCT01248702|Experimental|Critical Pathway|
9965380|NCT01248702|No Intervention|Standard Practice|
9965381|NCT01248754|Experimental|18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
9965382|NCT01248806||Smokers or former smokers, Aged ≥ 50|Men and women current daily smokers or former smokers, Aged ≥ 50
9965383|NCT01248819|Active Comparator|Instillation|Instillation of Ropivacaine 100 mg in the abdominal cavity
9965384|NCT01248819|Experimental|Nebulization|Nebulization of Ropivacaine 60 mg in the abdominal cavity
9965385|NCT01248832|Experimental|Telephone Counseling|Telephone Counseling
9965386|NCT01248832|Active Comparator|Self-help Materials|Self-help Materials
9965387|NCT01248858|Experimental|GSK2126458 and GSK1120212|The first combination schedule that will be tested involves giving both GSK2126458 and GSK1120212 continuously once a day in the morning until the subjects withdraw from the study. Other dosing schedules with both drugs will also be tested and these schedules are described below GSK2126458 will be dosed twice per day (morning and evening) continuously and GSK1120212 will be dosed once a day in the morning on a continuous schedule. Subjects will be treated with both drugs and remain in the study as long as they are benefiting from therapy. Another schedule that will be tested involves giving GSK2126458 twice each day (morning and evening) on an intermittent schedule (4 days of treatment, 10 days rest, then 4 days treatment, 10 days rest). GSK1120212 will be dosed once each day in the morning on a continuous schedule. Subjects will be treated with both drugs as long as they are benefiting from therapy.
9965388|NCT01248871|Active Comparator|SEVO|sevoflurane-remifentanil/sufentanil combination
9965389|NCT01248871|Active Comparator|SERE|volatile agent only during reperfusion
9965390|NCT01248871|Active Comparator|propofol|propofol-remifentanil/sufentanil
9965391|NCT01248897||erbB2+/Her2 Breast Cancer Patients|erbB2+/Her2 Breast Cancer Patients Treated with Lapatinib and Other Anti-erbB2/Her2 Therapy
9965392|NCT01248910|Experimental|Alpine Skiing|
9965393|NCT01248910|No Intervention|Control group|
9965394|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + G-CSF|
9965395|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF|
9965396|NCT01248923|Experimental|ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF|
9965397|NCT01248988||Synflorix Group|Infants and children who received at least one dose of Synflorix™ as a part of routine practice at a private clinic or hospital
9965398|NCT01249001|Experimental|Group 1|This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
9965399|NCT01249001|Experimental|Group 2|This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.
9965400|NCT01249014|No Intervention|Control|No peri-operative warming.
9965401|NCT01249014|Experimental|Warmed fluids|Patients will receive warmed i.v. fluids administered pre- and intra-operatively.
9965402|NCT01249014|Experimental|Warmed fluids and warm air|Patients will receive warmed i.v. fluids administered pre- and intra-operatively, and warmed air blown into a blanket covering the body intra-operatively.
9965403|NCT01249079||Schizophrenia Family|
9965404|NCT01249105|Experimental|Part 1|Patients with recurrent glioblastoma multiforme (GBM) who require reoperation.
10012468|NCT01652638|Experimental|Group B|"First periody: Comparator Drug (Heparin APP Pharmaceuticals)~Secundy periody: Test Drug (heparin Blau Farmacêutica S/A)"
10012469|NCT01652651|Experimental|Psychological Intervention|
10012470|NCT01652677|Experimental|Low-frequency stimulation|Stimulation mode: 1 Hz, 100% MT, 20 minutes, unaffected hemisphere
10012471|NCT01652677|Experimental|High frequency stimulation|Stimulation mode: 10 Hz, 80% MT, 2 seconds - stimulation, 58 seconds - rest. - 8 session; affected hemisphere
10012472|NCT01652677|Sham Comparator|Sham stimulation|Patients will receive standard treatment (kinesotherapy, physiotherapy) and simulate of transcranial magnetic stimulation. Also patients will not know about simulation (blind group)
10012473|NCT01652677|Experimental|Both hemispheric stimulation|Stimulation mode: low-frequency to unaffected hemisphere than high-frequency to affected.
10012474|NCT01652742|Experimental|BI 135585 XX|one single dose
10012475|NCT01652755||AKI group|patients with AKI after cardiopulmonary bypass surgery
10012476|NCT01652755||non-AKI group|patients without AKI during study period
10012477|NCT01652768|Active Comparator|Arm A: Usual Care Group|Usual care is defined as standard post-operative care on a surgical unit in University Hospitals Case Medical Center. Discharge planning will be provided by the assigned in-patient social worker. Referrals to the assigned outpatient social worker will be made as appropriate. Patients and caregivers will be seen in the ambulatory medical oncology setting about three to six weeks after surgery, depending on post-operative recovery time. The research assistant will administer the research questionnaires at week one post-surgery and 8-10 weeks post surgery.
10012478|NCT01652768|Experimental|Arm B: PRESENCE Intervention|The unique features of the PRESENCE Project (PP) Intervention are 1) the early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse); 2) an educational information session for patients and caregivers; and 3) frequent (every two week and as needed) telephone or clinic visits during the first ten weeks post operatively (Figure 1). In usual care, the patient and caregiver receive little supportive care until they begin cancer treatment. The intervention provides aggressive supportive care from the time of diagnosis.
10012479|NCT01652781|Experimental|5-day arm|azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care
10012480|NCT01652781|Active Comparator|7-day arm|azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
10012481|NCT01652794|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, and SBRT)|Patients also receive carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on day 1 and undergo SBRT on days 2-4.
10012482|NCT01652807|Experimental|Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching.
10012483|NCT01652807|No Intervention|Waitlist (Delayed Yoga)|Participants assigned randomly to the control condition will provided an identical free two-month membership to Bikram Yoga Dallas after the week following their post-intervention session.
10012484|NCT01652820|Experimental|Docetaxel +Carboplatin +concomitant chemoradiation|Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
10012485|NCT01652820|Experimental|C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom|Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
10012486|NCT01652833||Round 1|survey of 150 oncologists
10012487|NCT01652833||Round 2|survey of 150 oncologists approximately 12 months after round 1
10012488|NCT01652833||Round 3|survey of 150 oncologists approximately 24 months after round 1
10012489|NCT01652859|Experimental|Liposomal Amphotericin B|Generic drug
10012490|NCT01652859|Active Comparator|AmBisome|RLD
10012491|NCT01652898|Active Comparator|Esmolol hydrochloride|Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
10012492|NCT01652898|Active Comparator|ONO LDL50|ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
10012493|NCT01652898|Experimental|AOP LDLA202|AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
10012494|NCT01652911|Experimental|Cell Pouch|Participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
10012495|NCT01652924|Experimental|Mechanical ventilation|1: Active Comparator Children 1 month-14 years of age Intervention:Mechanical ventilation with facial mask during anesthetic induction
10012496|NCT01652924|Active Comparator|Manual ventilation|2: Active Comparator Children 1 month-14 years of age Intervention: Manual ventilation with facial mask during anesthetic induction
10012497|NCT01652937|Placebo Comparator|Placebo + Background Therapy|Background therapy including DMARD(s) approved by protocol
10012498|NCT01652937|Experimental|BIIB057 Dose 1 + Background Therapy|Background therapy including DMARD(s) approved by protocol
10012499|NCT01652937|Experimental|BIIB057 Dose 2 + Background Therapy|Background therapy including DMARD(s) approved by protocol
10012500|NCT01652937|Experimental|BIIB057 Dose 3 + Background Therapy|Background therapy including DMARD(s) approved by protocol
10035781|NCT01809561||endometriosis|The study group will consist of women with suspected endometriosis facing surgical treatment
10035782|NCT01809561||no endometriosis|The control group will consist of healthy women facing gynecologic surgery for different indication
10035783|NCT01809587|Experimental|IQP-PO-101|Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)
9965405|NCT01249105|Experimental|Part 2|Participants with GBM and with anaplastic glioma
9965406|NCT01249144|Active Comparator|Tecnis Z9002 Intraocular Lens (IOL)|
10035784|NCT01809600||Patients with Burkitt's Lymphoma|should be diagnosed pathologically by WHO 2008 criteria
9965407|NCT01249144|Active Comparator|Softec HD Intraocular Lens (IOL)|
9965408|NCT01249170|Other|First year fellow|
9965409|NCT01249170|Other|Second Year Fellow|
9965410|NCT01249183|Experimental|1- VAXIGRIP and REPEVAX concomitantly|
9965411|NCT01249183|Active Comparator|2-REPEVAX 28 days after VAXIGRIP|
9965412|NCT01249196|Placebo Comparator|Placebo|
9965413|NCT01249196|Experimental|SK-PC-B70M 200mg bid|
9965414|NCT01249196|Experimental|SK-PC-B70M 300mg bid|
10035785|NCT01809613||Deep Brain Stimulation|Functional Magnetic Resonance Imaging (fMRI) will be performed to determine the areas of BOLD signal modulation with DBS.
9965415|NCT01249196|Other|Donepezil|
9965416|NCT01249209|Other|lifestyle advice|
9965417|NCT01249222|No Intervention|conventional treatment|
9965418|NCT01249222|Experimental|Plasmapheresis|
9965419|NCT01249235|Active Comparator|Patch|The operative eye will be patched.
9965420|NCT01249235|Experimental|Bandage Contact Lens|The operative eye will have a bandage contact lens
9965421|NCT01249248||Male basketball players|
9965422|NCT01249248||Female basketball players|
9965423|NCT01249248||Baseball players|
9965424|NCT01249248||Softball players|
9965425|NCT01249248||Football players|
9965426|NCT01249248||Female vollyball players|
9965427|NCT01249248||Male soccer players|
9965428|NCT01249248||Female soccer players|
9965429|NCT01249300||Dysphagia|Patients with CVA which causes dysphagia
9965430|NCT01249339|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes.
9965431|NCT01249339|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
9965432|NCT01249339|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes.
9965433|NCT01249339|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
9965434|NCT01249352|Active Comparator|STANDARD CHEMORADIATION|"Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
9965435|NCT01249352|Experimental|CHEMORADIATION + NIMOTUZUMAB|"Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
9965436|NCT01249378|Active Comparator|10 g non emulsified of milk fat|They are compared using the repeated measurements taken within subjects
9965437|NCT01249378|Active Comparator|40 g non emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
9965438|NCT01249378|Active Comparator|40 g finely emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
9965439|NCT01249391|Active Comparator|Intervention (splinting)|Splinting of nominated joint in this group
9965440|NCT01249391|No Intervention|Control|Observation and usual treatment only.
9965441|NCT01249430|Experimental|Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)|Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
10012501|NCT01652950|Experimental|Vitality Wellness program Direct Payment|In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
10012502|NCT01652950|Experimental|Vitality Wellness Program Lottery Incentive|Members of the Lottery Incentive group were entered into a cash-prize draw at the end of each month following registration, if they achieved physical activity targets. The chance of winning was set at one in fifty with an expected value identical to the direct payment group. Four lottery payouts corresponding to the member's levels of engagement were made at the end of each month following registration. Enrollment took place over a period of 5 months, and the intervention took place over a period of 12 months following registration.
10012503|NCT01652950|Experimental|Vitality Wellness Program Charity Incentive|Members of the Charity Incentive Group were offered a selection of charities to which earned rewards could be donated. Nominated charities received the payouts at the end of each month of registration, for 5 different levels of engagement of the individual members. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
10012504|NCT01652950|Experimental|Vitality Wellness Program Choice Incentive|Members of the Choice Incentive Group were asked to choose one of the three aforementioned incentive options on enrollment to the study. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
10012505|NCT01652950|Other|Vitality Wellness Program Standard of Care|The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
10012506|NCT01652950|Active Comparator|Vitality Wellness Program Enhanced Communication|"In this group, members were offered the base program and, in addition, were sent bi-weekly communications by alternating email and text messaging which included information on the importance of physical activity, tips on accumulating fitness points on the base program, a status update of points earned and information on benefits and rewards offered on the program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration."
10035786|NCT01809626|Experimental|Zolpidem (10 mg)|Oral administration of the drug zolpidem (Ambien)
10035787|NCT01809626|Placebo Comparator|Gelatin capsule|Oral administration of a placebo pill that is packaged identically to the active condition.
10035788|NCT01809652|Experimental|Remote Implant Support|Implant supported through remote implant support capability
10035789|NCT01809665||ICD/CRT-P therapy|Standard indication for ICD or triple-chamber pacemaker therapy
9476744|NCT03568773|Experimental|Aerobic exercise moderate intensity|The training protocol was started, with the sessions held in the open air. From the first to the fourth week, the volunteers gave sessions of 40 to 60 minutes, intensity in L1, three sessions / week. In the fifth week, the intensity was increased to the midpoint between L1 and half of L2, maintaining 60 minutes per session and frequency three times per week. From the sixth week, the weekly frequency increased to five days, with three supervised sessions and two unsupervised sessions, but with a smartphone application that recorded distance traveled and intensity. From the ninth week on, the weekly frequency was maintained and the intensity increased for L2. In supervised sessions, training intensity is also monitored by heart rate using a Polar heart rate monitor.
9476745|NCT03568773|Experimental|Control Group|The control group attends stretching classes once a week and sessions lasting 60 minutes. At the end of the fifteen weeks (three weeks of adaptation and twelve weeks of training) of the study, these volunteers will be invited to engage in the aerobic training program regardless of their participation in the research.
9476746|NCT03568747|Experimental|NIV plus oxygen therapy|noninvasive ventilation (dual-limb NIV) is given at peak exercise until the borg scale reaches it's baseline point
9476747|NCT03568747|Experimental|oxygen therapy|oxygen therapy is given at peak exercise until the borg scale reaches it's baseline point
9476748|NCT03568734|Experimental|Transplant arm|Fecal transplant sample given to child at delivery
9476749|NCT03568721|Experimental|ibuprofen|ibuprofen (400 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
9476750|NCT03568721|Experimental|acetaminophen|acetaminophen (500 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
9476751|NCT03568721|Experimental|chewing gum|chewing gum (01 tablet) immediately after insertion of the initial archwire and 6/6 hs of chewing gum for a week if there is any orthodontic pain.
9476752|NCT03568721|No Intervention|control|control (no reliever for orthodontic pain)
9476753|NCT03568708|No Intervention|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
9965442|NCT01249443|Experimental|Treatment (carboplatin, paclitaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Before February 1, 2013, patients also received vorinostat PO once daily on days 1-5 with paclitaxel and carboplatin."
9965443|NCT01249456||Femara(Letrozole)|
9965444|NCT01249469|Placebo Comparator|Vehicle|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
9965445|NCT01249469|Experimental|Skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
9965446|NCT01249482||Late eradication|Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
9965447|NCT01249482||Negative HP|For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
9965448|NCT01249482||Early eradication|Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
9965449|NCT01249508|Experimental|implemented nutrition label|A one-group pre-/post-design is used for the evaluation of the university canteen-based nutrition labeling program. This means that all participants of the program are exposed to the nutrition label implemented in the university canteen. The subject essentially serves as its own control based on pre-test behaviour. The nutrition label implemented is a star rating label calculated and assigned to each meal offered at the university canteens and based on the content of energy, saturated fat, sodium and fibre (expressed as vegetable portion).
9965450|NCT01249534||Patients after gastroesophageal cancer surgery|
9965451|NCT01249547|Experimental|axitinib arm|
9965452|NCT01249560||raltegravir|"To illustrate the cause and effect relationship between the abnormalities of the distribution(casting) of the molecules of co-activation and the rate of apoptose, we compare also 2 groups: a first group of patients with a rate of apoptose normal ( n=10 ), and another group of patients having a rate of apoptose aggravated ( n=10 ).~20 eligible patients will receive their treatment to J1 and will be estimated for the residual concentration of the raltegravir ®, the antiretroviral activity, the tolerance and the observance at the treatments of the study in the visits of evaluation of M1, M2, M3, M6, M12, and / or in case of premature stop(ruling) of the try(essay). Every visit will give rise to a clinical evaluation of the patient. The arisen of unwanted events"
9965453|NCT01249573|Experimental|fascia therapy|arm where fascia therapy is used as a treatment for an acute ankle distortion
9965454|NCT01249573|Experimental|transcutaneous fibrolysis|arm where transcutaneous fibrolysis is used as a treatment for an acute ankle distortion
9965455|NCT01249573|Placebo Comparator|placebo|arm where placebo therapy is used as a treatment for an acute ankle distortion
9965456|NCT01249586|Placebo Comparator|Traditional teaching|A traditional class of blindness prevention.
9965457|NCT01249612|Placebo Comparator|Control treatment|Elbow joint icing using two plastic bags with crushed ice
9965458|NCT01249612|Active Comparator|Active treatment|Knee joint icing using two plastic bags with crushed ice
9965459|NCT01249638|Experimental|Cap+Bev until PD followed by CAPIRI +Bev|"Capecitabine + Bevacizumab~In case of Progression Escalation to:~Capecitabine + Irinotecan + Bevacizumab"
9965460|NCT01249638|Active Comparator|Capiri + Bev|Capecitabine + Irinotecan + Bevacizumab
9965461|NCT01249677|Experimental|insulin glargine|patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
9965462|NCT01249690|Experimental|PAD|
9965463|NCT01249690|Experimental|TAD|
9965464|NCT01249755||delirious patients|The cohort is divided in delirious and non-delirious patients
9965465|NCT01249768||Cohort|The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months
9965466|NCT01249781||resilience in caregivers whose child with ALL|
9965467|NCT01249794|No Intervention|Best available treatment|
9965468|NCT01249794|Experimental|non invasive ventilation|
9965469|NCT01249807||1|Patients, Family, Community member
9965470|NCT01249820|Experimental|group A|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
9965471|NCT01249820|Experimental|group B|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
9965472|NCT01249846|Experimental|Arm 1|Each one of the two selected periodontal pockets (target pockets) will be randomized to the Frequent PerioChip® treatment or to the Routine PerioChip®.
9965473|NCT01249846|Placebo Comparator|Arm 2|Each one of the two selected target pockets will be randomized to the Frequent PerioChip® treatment or to the Frequent Placebo Chip treatment.
9965474|NCT01249859||Signet ring cell carcinoma|
9965475|NCT01249859||non signet ring cell adenocarcinoma|
9965476|NCT01249911|Experimental|Lreuteri|Group of 130 infants allocated to receive L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
9965477|NCT01249911|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
9965478|NCT01249924|Other|CPAP Group|CPAP Treatment
9965479|NCT01249924|Other|Control Group|Routine care
9965480|NCT01249937|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
9965481|NCT01249937|Active Comparator|Ranibizumab and Triamcinolone acetonide|"Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections.~Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and Triamcinolone Acetonide will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration."
9965482|NCT01249950||adolescents|adolescents with morbid obesity
9965483|NCT01249963|Experimental|Experimental Group|Patients of this group will receive 400 ml per day of T-Diet plus Atémpero product during 28 days.
9965484|NCT01249963|Active Comparator|Control Diet|Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days.
9965485|NCT01249976|Experimental|catheter-spearing diagnostic methods|experimental
9965486|NCT01249989|Experimental|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
9965487|NCT01249989|Experimental|Simultaneous MBC Condition|Participants in the simultaneous condition will target FV+, Sed- and PA+ simultaneously. Participants will wear accelerometers and enter diet and sedentary activity 5 days/week on their Smartphone. All 3 goal thermometers will be activated from the outset of prescription (FV, Sed, PA). In week 1-2, participants will close 1/3 of the gap between their baseline FV, Sed, and PA behavior and their goals. In week 3-4 participants will close 2/3 of the gap, and 100% of their goals in weeks 5-6. Participants will maintain their target behaviors for FV, Sed and PA through week 12.
9965488|NCT01249989|Active Comparator|Stress Management Control|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
9965489|NCT01250015||control|given standard nhs advice leaflet
9965490|NCT01250015||interventional|given standard nhs advice leaflet with numerical information and pictograms
9965491|NCT01250041|Active Comparator|femoral block|
9965492|NCT01250041|Experimental|saphenous block|
9965493|NCT01250080|Experimental|Glutamine|
9965494|NCT01250080|Sham Comparator|Control|
9965495|NCT01250106|Experimental|Probiotic capsule|
9965496|NCT01250106|Placebo Comparator|placebo capsule|
9965497|NCT01250132|Other|Moderate to severe Traumatic Brain Injury|"Assessment of hypopituitarism. Blood tests at different moments:~day 0~when leaving intensive care unit~month 3~month 12"
9965498|NCT01250158|Experimental|Liver-PILP kit|Liver-PILP kit
9965499|NCT01250197|Experimental|Formulation A|AR-12286 Ophthalmic Solution Formulation A
9965500|NCT01250197|Experimental|Formulation B|AR-12286 Ophthalmic Solution Formulation B
9965501|NCT01250236||verum|brimonidine 0.1% eye drops twice daily
9965502|NCT01250236||placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
9965503|NCT01250249|Active Comparator|BCG Vaccine - Intradermal injection|"Subjects must be in the age group of 0 - 14 years of age.~2. Subject's parent should be able to understand and have to sign the informed consent form after being explained by the investigator. They must be aware of the experimental nature of the therapy, its potential benefits, side effects and risks.~3. Ability to comply with the schedule of treatment and follow-up.~4. Absence of BCG scar~5. Tuberculin negative~6. No evidence of any other infection~7. No evidence of skin disease~Skin testing with tuberculin is not generally carried out before giving BCG but when performed, those who are found to be positive reactors need not to be immunized"
9965504|NCT01250262|Active Comparator|Standard care|Subjects will receive normal medical care and follow up during the four month study period if assigned to this group.
9965505|NCT01250262|Active Comparator|Isolated Lumbar Resistance Exercise Program|Lumbar extension exercise protocol to increase strength and reduce pain.
9965506|NCT01250262|Active Comparator|Total Body Resistance Exercise Program|Training protocol for 1 set for each exercise: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl
9965507|NCT01250275|Experimental|Acute Phase: traditional canola oil|Participants will receive banana bread containing traditional canola oil once weekly during the 5-week schedule
9965508|NCT01250275|Active Comparator|Acute Phase: high oleic canola oil|Participants will receive banana bread containing high oleic canola oil once weekly during the 5-week schedule
9965509|NCT01250275|Active Comparator|Acute Phase: soybean oil|Participants will receive banana bread containing soybean oil once weekly during the 5-week schedule
9965510|NCT01250275|Active Comparator|Acute Phase: high linoleic safflower oil|Participants will receive banana bread containing high linoleic safflower oil once weekly during the 5-week schedule
9965511|NCT01250275|Active Comparator|Acute Phase: coconut oil|Participants will receive banana bread containing coconut oil once weekly during the 5-week schedule
9965512|NCT01250275|Experimental|Chronic Phase: traditional canola oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing traditional canola oil for a total of 8 weeks
9965513|NCT01250275|Active Comparator|Chronic Phase: safflower oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing an oil mixture representing the typical western diet for a total of 8 weeks
10012507|NCT01652963|No Intervention|Control task|The no-intervention control task consists of a presentation of the stimuli used in the training task. Participants will see situations and listen to the simultaneous voice recordings. Unlike in the training task participants will not receive instructions to link situations and emotions. There is no task requirement, just a presentation of the situation stimuli to assure that potential training effects are due to the training programme and not merely to the presentation of scenarios. The duration of the presentation of stimulus materials in the control group will range between fifteen and thirty minutes. The variable duration is necessary so the primary investigator cannot assume a participant's intervention group based on the duration of the intervention task.
10012508|NCT01652963|Experimental|Reed and Clements Training Task|The training task consists of 2 blocks of 6 items with items presented randomly within each block and blocks being counterbalanced between participants. Block 1 presents a situation and prompts participants to identify whether they would feel happy or sad in the given situation. Block 2 presents an emotion (happy or sad) and prompts the participant to identify which of two situations (positive or negative) most likely preceded this emotion. Within each block there will be at least one and maximum three training rounds. The second and third training rounds will only consist of the items to which the participant responded incorrect in the previous round. Each item in rounds 2 and 3 will be followed by feedback.
10012509|NCT01652989|Experimental|Weight loss maintenance intervention delivered via DVD|Weight loss maintenance intervention delivered via DVD (without a peer facilitator) to employee participants within the respective worksites randomized to this arm. Using DVD technology, a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period will be delivered to the participants of this arm using DVD-produced lessons of PILI Maintenance
10012510|NCT01652989|Experimental|Weight loss maintenance intervention Face-to-Face|The PILI Maintenance delivered face-to-face in a group setting by trained peer facilitators to employee participants within the respective worksites randomized to this arm. The trained peer facilitator will deliver a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period, meeting bi-weekly for the first 2 months and then monthly for the remaining 7 months with a group of 8 to 15 participants.
10012511|NCT01653002||Lung cancer with lymph node involvement|
10012512|NCT01653015|Experimental|Influenza vaccine LAIV|Live attenuated influenza vaccine (LAIV).
10012513|NCT01653015|Active Comparator|Influenza vaccine TIV|Trivalent inactivated vaccine (TIV).
10012514|NCT01653041|Experimental|Everolimus|Single arm
10012515|NCT01653054|Experimental|IBD patients ON Immunosuppression|
10012516|NCT01653054|Experimental|IBD Patients OFF Immunosuppression|
10012517|NCT01653067|Experimental|Rituximab, Temsirolimus, DHAP, intravenous|"This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.~Treatment regimen part I:~Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4~...repeat day 22, up to a maximum of 4 cycles~In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
9965514|NCT01250288||Consumers|Consumers (patients or their designated proxies) who have registered to use the personal health management technology platform offered by the Brooklyn Health Information Xchange (BHIX) or Long Island Patient Information Xchange (LIPIX).
9965515|NCT01250288||Providers|Providers who are authorized to view the data entered by consumers in either (1) BHIX's personal health management system, along with BHIX health information exchange data; OR LIPIX's secure messaging system (SMS), along with LIPIX health information exchange data.
9965516|NCT01250301|Experimental|De-nicotinised cigarettes + standard treatment|
9965517|NCT01250301|Active Comparator|Standard treatment|
9965518|NCT01250314|Other|With fracture|Patients with fracture
9965519|NCT01250314|Other|Without fracture|Patients without fracture
9965520|NCT01250327|Experimental|Melody|insertion of a pulmonic valved stent
9965521|NCT01250327|Active Comparator|Bare stent|insertion of a bare metal stent
9965522|NCT01250327|Active Comparator|Surgery|conventional surgery methode.
9965523|NCT01250340|Experimental|Aspirin|100 mg/day for 30 days
9965524|NCT01250340|Placebo Comparator|Placebo|1 cp /day for 30 days
9965525|NCT01250353|Experimental|conjunctival autograft|The conjunctival autograft was performed after the pterygium surgery like usual technique.
9965526|NCT01250353|Experimental|latex biomembrane application|The latex biomembrane was applied after pterygium surgery to recover the bare sclera area. This device was closed to conjunctiva with running suture anchored at some places to episclera. The sutures was removed at fourteenth day after surgery.
9965527|NCT01250366|Experimental|Arm 1: INX-08189 (9 mg) or Placebo|
9965528|NCT01250366|Experimental|Arm 2: INX-08189 (25 mg) or Placebo|
9965529|NCT01250366|Experimental|Arm 3: INX-08189 (50 mg + 9 mg) or Placebo|
9965530|NCT01250366|Experimental|Arm 4: INX-08189 (50 mg) or Placebo|
9965531|NCT01250366|Experimental|Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin|
9965532|NCT01250366|Experimental|Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin|
9965533|NCT01250366|Experimental|Arm 7: INX-08189 (100 mg) or Placebo|
9965534|NCT01250392|Other|Control Arm|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment.
9965535|NCT01250392|Experimental|Active Choice Only Arm|The active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
9965536|NCT01250405|Active Comparator|Cinacalcet|
9965537|NCT01250405|Placebo Comparator|Placebo|
9965538|NCT01250431|Experimental|EFT (Emotional Freedom Techniques)|10 sessions of EFT.
9965539|NCT01250431|No Intervention|Wait List|10 week wait period.
9965540|NCT01250444|Experimental|Inspiratory Muscle Training|It will me performed a loaded training of ventilatory muscles in patients with Hypertension. Its is done with the practice of breathing exercises associated to an training device, specific for this kind of intervention.
9965541|NCT01250457|Experimental|Topical timolol|topical Timolol 0.5% solution applied twice daily
9965542|NCT01250470|Experimental|Treatment (vaccine therapy)|"Patients receive Montanide ISA-51/survivin peptide vaccine SC followed by sargramostim SC on day 0. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~TREATMENT EXTENSION: After completion of study treatment, select patients may receive additional doses of Montanide ISA-51/survivin peptide vaccine SC and sargramostim SC. Treatment repeats every 3 months in the absence of disease progression or unacceptable toxicity."
9965543|NCT01250483||BPH|men aged more than 40 years who presented with BPH/LUTS and showed negative results of transrectal prostate biopsy before the period of AB medication
9965544|NCT01250483||prostate cancer|men aged more than 40 years who presented with BPH/LUTS and showed positive results of transrectal prostate biopsy before the period of AB medication
9965545|NCT01250496|Experimental|Aminophylline|75 mg of intravenous aminophylline.
9965546|NCT01250496|Placebo Comparator|Placebo|Matching normal saline placebo (sterile salt water).
9965547|NCT01250535|Experimental|Warfarin plus lovastatin|Warfarin plus lovastatin
9965548|NCT01250535|Placebo Comparator|Warfarin plus placebo|Warfarin plus placebo
9965549|NCT01250548|Active Comparator|2|
9965550|NCT01250548|Placebo Comparator|Apremilast|Placebo Compared to apremilast arm
9965551|NCT01250574||Postoperative infections|
9965552|NCT01250574||Bacterial infections in the GI tract|
9965553|NCT01250587|Experimental|PDC31|
9965554|NCT01250600|Experimental|Remote-care|Home exercise monitored by the remote care system
9965555|NCT01250600|Active Comparator|Control|Home exercise under expert's instruction
9965556|NCT01106794||Patient samples|Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
9965557|NCT01250626||a single-group study|Pediatric OPD, age < 18 y/o.
9965558|NCT01250652|Active Comparator|Levocetirizine|24 patients will received 20 mg Levocetirizine daily
9965559|NCT01250652|Experimental|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
9965560|NCT01250665||clinically isolated syndrome|In this study the term clinically isolated syndrome (CIS) is defined according to the Task Force on Differential Diagnosis in MS, as a monophasic presentation of neurological symptoms with suspected underlying inflammatory demyelinating disease (Miller 2008).
9965561|NCT01250665||remitting, relapsing MS|remitting relapsing MS according to the criteria by Poser (Poser 1983) or McDonald (McDonald 2001)
9965562|NCT01250678||neurocognitive impaired|MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
9965563|NCT01250678||neurocognitive non-impaired|MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
9965564|NCT01250691||hospital acquired pneumonia|
9965565|NCT01250691||isolated rooms|
9965566|NCT01250691||ward-type ICU|
9965567|NCT01250743|Experimental|Ascorbic Acid (Vitamin C)|
9965568|NCT01250782|Placebo Comparator|Physiological Serum|
10012518|NCT01653106|Experimental|Arm I (cryotherapy 120 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes.
10012519|NCT01653106|Active Comparator|Arm II (cryotherapy 360 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.
10012520|NCT01653119|Active Comparator|High loading dose of rosuvastatin|rosuvastatin 20mg/d×1w
10012521|NCT01653119|Active Comparator|Routine rosuvastatin therapy|rosuvastatin 10mg/d×1w
10012522|NCT01653145|Active Comparator|Diet A|Low Fat High Energy Density (1.6 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
10012523|NCT01653145|Active Comparator|Diet B|High Fat Low Energy Density (1.05 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
10012524|NCT01653145|Active Comparator|Diet C|High Carbohydrate Low Energy Density (1.05 kcal/g)-20% Fat, 65% Carbohydrate, 15% Protein
10012525|NCT01653171|No Intervention|Control|Standard upper endoscopy withouth premedication
10012526|NCT01653171|Placebo Comparator|Water|100 mL of water, 20 minutes before upper endoscopy
10012527|NCT01653171|Experimental|Simethicone|Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination
10012528|NCT01653171|Experimental|N-acetylcysteine 500 mg + Simethicone|N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
10012529|NCT01653171|Experimental|N-acetylcysteine 1000 mg + Simethicone|N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
10012530|NCT01653184|Experimental|Experimental: AREDS 2 Vitamin formula 1g|"Patients will receive oral supplementation with the commercially available AREDS2 vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
10012531|NCT01653184|Experimental|Eye Omega Advantage 2g|Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage® and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)
10035790|NCT01809678|Experimental|Smoking Cessation plus Yoga|Twice weekly, 1-hour yoga classes delivered for 8 weeks combined with once-weekly, 1-hour cognitive-behavioral smoking cessation classes.
10035791|NCT01809678|Active Comparator|Smoking Cessation plus Wellness|Twice-weekly, 1-hour Wellness classes given on a variety of health topics twice weekly to match schedule of the yoga classes, plus 1-hour per week of cognitive-behavioral smoking cessation
10035792|NCT01809691|Experimental|ADT + TAK-700|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~TAK-700, 300 mg, PO, twice daily"
10035793|NCT01809691|Active Comparator|ADT + Bicalutamide|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~Bicalutamide, 50 mg, PO, q daily"
10035794|NCT01809717|Experimental|Weight Lifting Exercises|
10035795|NCT01809730||Cardiovascular risk|patients with CV disease
10035796|NCT01809743|Active Comparator|Regadenoson central - peripheral|First bolus regadenoson administered central, second bolus administered peripheral
10035797|NCT01809743|Active Comparator|Regadenoson peripheral - central|First bolus regadenoson administered peripheral, second bolus administered central
10035798|NCT01809743|Active Comparator|Regadenoson central - central|First bolus regadenoson administered central, second bolus administered central
10035799|NCT01809743|Active Comparator|Regadenoson peripheral - peripheral|First bolus regadenoson administered peripheral, second bolus administered peripheral
10035800|NCT01809756|Active Comparator|Caphosol|
10035801|NCT01809756|No Intervention|No intervention|
10035802|NCT01809769|Experimental|Mesenchymal stem cells low-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
10035803|NCT01809769|Experimental|Mesenchymal stem cells mid-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
10035804|NCT01809769|Experimental|Mesenchymal stem cells high-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
10035805|NCT01809782||Study group:20 patients undergoing two stage liver-operation|Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
10035806|NCT01809782||Control group: 20 patients (ASA class II/III)|Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
10035807|NCT01809795|Experimental|Blueberry Smoothie|Participants in this group will receive a smoothie containing 1 1/2 cups of freeze-dried whole blueberries crushed into a powder.
9518068|NCT03300258|Experimental|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
10035808|NCT01809795|Sham Comparator|Sham Smoothie|Participants in this group will receive a smoothie that contains no blueberries.
10035809|NCT01809808||Acromegaly Subjects|People who have a biochemical diagnosis of acromegaly, and will or have already undergone surgery for acromegaly and will be taking medications for acromegaly . Subjects will undergo blood sampling, metabolic rate measurement, adipose tissue biopsy and total body magnetic resonance imaging before and over time after either surgery or medical therapy for acromegaly.
10035810|NCT01809808||Healthy Subjects|People who are not diagnosed with acromegaly, responding to flyer or by word of mouth for participation, without medical problems, not taking medications, and with a stable weight for 3 months prior to study. Subjects will undergo blood sampling, total body MRI and adipose tissue biopsy once.
10035811|NCT01809821|Experimental|Online Sleep Education|The sleep intervention is a multi-component online intervention consisting of sleep information and sleep hygiene education, along with behavioural and cognitive components.
10012532|NCT01653197|Experimental|Control|"On top of reminder, state: Here's a fun fact to cheer you on your way: and include a curiosity-inducing question and answer (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space? // A: Texas)"
10012533|NCT01653197|Experimental|Curiosity|"On top of reminder, state: Here's a fun fact to cheer you on your way. and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)."
10012534|NCT01653197|Experimental|Curiosity linked to Action|"On top of reminder, state: Here's a fun fact to cheer you on your way. Reward yourself by scratching off the answer only after you've made your [colonoscopy/mammogram/etc.] appointment! and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)"
10012535|NCT01653236|Experimental|Experimental Arm B|48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg
10012536|NCT01653236|Active Comparator|Control Arm|48 weeks of peginterferon alfa-2b and ribavirin
10012537|NCT01653249|Experimental|vaccination|an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
10037295|NCT01823770|No Intervention|Control group|Volunteers matched on sex, age and BMI with RLS patients who will not receive treatment(no treatment)
9476754|NCT03568708|Experimental|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
9518069|NCT03300258|Active Comparator|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
10012538|NCT01653275|Experimental|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
10012539|NCT01653301|Experimental|XELOX-RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
10012540|NCT01653301|Active Comparator|XELAC-RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
10012541|NCT01653314|Experimental|Megavec|
10012542|NCT01653314|Active Comparator|Glivec|
10012543|NCT01653340|Experimental|High Frequency Spinal Cord Stimulation through Senza™|"During the trial implant of Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine, the 2 leads will be positioned to cover the C2-C3 cervical levels.~Over the following 2 weeks, the investigator will optimize therapy delivery by identifying the stimulation settings providing maximal headache pain relief.~The subject will be asked to attend the clinic at the end of the trial period. Together with his/her physician, the subject will discuss his/her experience over the past 2 weeks (satisfaction with the therapy), and decide whether or not move forward with a Nevro Senza IPG.~The Nevro Senza IPG will be implanted in the buttock or abdomen area as outlined in the Physician's Manual. Fluoroscopy and impedance measurements may be used during the procedure to confirm lead placement and location.~Before hospital discharge, the IPG will be programmed with the optimal settings identified during the trial phase."
10012544|NCT01653353|Experimental|Entire group|A peer-applied guideline will be applied to the physicians.
10012545|NCT01653366|Experimental|Arm A-Pedometer and Goal setting|"Physical Activity Goal Setting~Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log."
10012546|NCT01653366|No Intervention|ARM B|Patients receive standard physical activity recommendations and follow up.
10012547|NCT01653392||Anthrax Vaccine Adsorbed|Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry.
10012548|NCT01653431|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation combined with cognitive training
10012549|NCT01653431|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation combined with cognitive training
10012550|NCT01653444|Experimental|GC1119 0.5 mg/kg|0.5 mg/kg biweekly
10012551|NCT01653444|Experimental|GC1119 1.0 mg/kg|1.0 mg/kg biweekly
10012552|NCT01653457|Placebo Comparator|Placebo|
10012553|NCT01653457|Active Comparator|Memantine|
10012554|NCT01653470|Experimental|Arm A: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
10012555|NCT01653470|Experimental|Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024|5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
10012556|NCT01653470|Experimental|Arm C: Carboplatin/Paclitaxel + BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity
10012557|NCT01653470|Experimental|Arm D: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity
10012558|NCT01653470|Experimental|Arm F: Carboplatin/Paclitaxcel and BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity
10012559|NCT01653483|Experimental|GSK573719|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
10012560|NCT01653483|Placebo Comparator|GSK573719 matched-placebo|Placebo
10012561|NCT01653496|Experimental|Enhanced recovery after surgery|Patients who receive ERAS program after gastric cancer surgery
10012562|NCT01653522|Experimental|Triptan|
10012563|NCT01653522|Experimental|Doxycycline|
10012564|NCT01653522|Experimental|Triptan + Doxycycline|
10012565|NCT01653522|No Intervention|Control|
10012566|NCT01653548|Experimental|HR training + Portable HR|100 subjects who receive Habituation Reminder training and who have access to the HR via a cellular phone.
10012567|NCT01653548|Experimental|HR Training + no portable HR|50 subjects who receive Habituation Reminder training and who do not have access to the HR via a cellular phone.
9518070|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
9965569|NCT01250782|Active Comparator|Glutamine|
9965570|NCT01250795|Experimental|15 ug HAI-05 plus Alhydrogel|vaccine
9965571|NCT01250795|Experimental|45 ug HAI-05 plus Alhydrogel|vaccine
9965572|NCT01250795|Experimental|90 ug HAI-05 plus Alhydrogel|vaccine
9965573|NCT01250795|Experimental|90 ug HAI-05 in saline|vaccine
9965574|NCT01250795|Placebo Comparator|Saline|placebo
9965575|NCT01250821|Experimental|Ovulation induction|
9965576|NCT01250847|Experimental|Seroquel-XR|The subjects At-Risk Mental States will be treated with Quetiapine(Seroquel-XR) from baseline to end of trial.
9965577|NCT01250847|Experimental|Schizophrenia Comparator|The subject with schizophrenia will be treated with standard treatment
9965578|NCT01250847|No Intervention|Healthy Control Comparator|The subjects will not be required to treat
9965579|NCT01250860|Sham Comparator|Control Group|Control DoboMed group - only specific active exercises: symmetrical positions for exercising; asymmetrical active movements; thoracic spine kyphotization; transverse plane derotation; apical area involvement; concave ribs mobilization; exteroceptive facilitation; respiration-directed movements of the thorax and spine; three-dimensional displacement of vertebra; active autocorrection.
9965580|NCT01250860|Experimental|Experimental group|"Experimental DoboMed and Kaltenborn manual therapy. Suitable techniques were chosen according to manual examination: cervical spine; thoracic spine; lumbar spine; costovertebral articles; pelvis position. During the 15 sessions in group DK we used:derotational manual terapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method; the manual techniques used in continuation study were different from techniques in pilot study."
9965581|NCT01250886|Placebo Comparator|Normal saline solution|Blood sample is obtained from patient in either forearm immediately before a Normal saline solution administered on the same site. The volume of fluid administration is calculated by means of Holliday and Segar formula.
9965582|NCT01250886|Active Comparator|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
9965583|NCT01250886|Active Comparator|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
9965584|NCT01250938|Experimental|ESI - Community Outreach|All families receive the same Early Social Intervention - Community Outreach (ESI-CO) treatment for 3 months in addition to 6 months of community resource support.
9965585|NCT01250951|Experimental|Deferasirox|
9965586|NCT01250964|Active Comparator|Wound-assisted lens injection|Wound-assisted lens injection is considered neither superior or inferior to wound-directed lens injection.
9965587|NCT01250964|Active Comparator|Wound-directed lens injection|Wound-directed lens injection is neither considered superior nor inferior to wound-assisted lens injection.
9965588|NCT01251029|Experimental|sugar pil and saline|
9965589|NCT01251055|Placebo Comparator|Placebo|
9965590|NCT01251055|Experimental|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1 4000 mg/day
9965591|NCT01251068|Experimental|gest age, cerebral ,somatic oxygenation measurement|
9965592|NCT01251081|Experimental|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
9965593|NCT01251081|Sham Comparator|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
9965594|NCT01251107|Experimental|Arm B|BEACOPP (Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for 4 escalated cycles followed by 4 standard cycles
9965595|NCT01251107|Active Comparator|Arm A|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 6 to 8 cycles
9965596|NCT01251133|Experimental|LBVH0101|
9965597|NCT01251133|Active Comparator|Hiberix|
9965598|NCT01251172|Experimental|Treatment (RO4929097 after autologous stem cell transplant)|"STEM CELL TRANSPLANTATION AND CHEMOTHERAPY: Patients undergo standard mobilization and collection of autologous peripheral stem cells (>= 4.0 x 10^6 CD34+ cells/kg). Patients then receive high-dose melphalan IV on days -3 and -2 and undergo autologous stem cell transfusion on day 0. Patients with progressive disease, stable disease, partial response, stringent complete response, or complete response are taken off study; patients with residual/persistent disease (VGPR) continue to therapeutic treatment.~THERAPEUTIC TREATMENT: Beginning 100-110 days after transplantation, patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
9965599|NCT01251185|Experimental|CHF|Single-arm, open label, subjects with Congestive Heart Failure, with ischemic etiology.
9965600|NCT01251198||Acute coronary Syndrome|Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab).
9965601|NCT01251211|Active Comparator|botulinum toxin type A|botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)
9965602|NCT01251211|Placebo Comparator|sodium chloride 9 %|sodium chloride 9 % will be used as a neutral placebo
9965603|NCT01251224|Active Comparator|Education Group|This group will receive IPM education at baseline, and then the full IPM intervention after completing the study.
9965604|NCT01251224|Experimental|IPM Group|This group will receive the full IPM intervention at baseline.
9965605|NCT01251237|Experimental|Moviprep Orange|All patients receive 2 litres of NRL0706 solution.
9965606|NCT01251250|Experimental|Arm I|Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9965607|NCT01251263|Other|Group 1|Cyclic OC users prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
9965608|NCT01251263|Other|Group 2|Spontaneous ovulation group prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
9965609|NCT01251302||Prospective Cohort|Patient presenting with chest pain or anginal equivalent and receiving a resulted age, sex and gene expression score (ASGES) to assist in diagnosis.
10012568|NCT01653548|Experimental|No HR training|50 subjects who do not receive HR training.
10012569|NCT01653561|Experimental|Apatinib|Apatinib 500mg/d
9518071|NCT03300219|Experimental|telerehabilitation|Telerehabilitation refers to the use of technologies to provide rehabilitation services to people in their homes. The intervention will be performed by real-time video-conferencing using an iPad® and Skype™, a software program that allows video calls over the Internet
10012570|NCT01653574|Experimental|Famitinib Malate|Famitinib 25mg/d
10012571|NCT01653600|Experimental|LifeStent|same to SMART CONTROL Stent
10012572|NCT01653600|Active Comparator|SMART CONTROL Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus LifeStent) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, clopidogrel will be stopped and changed into cilostazol. Patients were randomized to receive cilostazol 100mg bid either 11 month duration or 5 month duration in separate groups of SMART stent group and LifeStent group. Randomization procedure will be performed using a web-based program
10012573|NCT01653626|Experimental|package|
10012574|NCT01653639|Experimental|Arm 1|
10012575|NCT01653639|Experimental|Arm 2|
10012576|NCT01653652|Placebo Comparator|Placebo|maltodextrin powder to be taken daily
10012577|NCT01653652|Active Comparator|Probiotic|Probiotic blended in maltodextrin powder to be taken daily
10012578|NCT01653665|Active Comparator|Leukine (Sargramostim, GM-CSF)|Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
10012579|NCT01653665|Placebo Comparator|Placebo (normal saline)|Participants in the randomised controlled trial may be randomised to receive a daily subcutaneous injection of normal saline (placebo) for 4 or 7 days as decided following the results of the dose finding study
10012580|NCT01653678|Active Comparator|Vitamin D + fish oil|
10012581|NCT01653678|Active Comparator|Vitamin D + fish oil placebo|
10012582|NCT01653678|Active Comparator|Vitamin D placebo + fish oil|
10012583|NCT01653678|Placebo Comparator|Vitamin D placebo + fish oil placebo|
10012584|NCT01653691|Active Comparator|Pulse Dye Laser, burn scars|A scar will be located on the study subject's torso or thigh and divided in half. Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side. Each side will be evaluated during outpatient visits. 12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
10012585|NCT01653691|Sham Comparator|No treatment to half of scar|A scar on the child's torso or thigh will be divided in half. One side will receive laser treatment and the other half will receive laser or sham treatment.
10012586|NCT01653717|Experimental|T-Cell Infusion + Chemotherapy|Peripheral blood mononuclear cells (PBMC) collected via venipuncture or steady state leukapheresis after enrollment. Clinically successful T-cell production defined as amount of T-cells required for dose level for which the patient is enrolled. Fludarabine 25 mg/m2 by vein on Days -5 to Day -3. Cyclophosphamide 250 mg/kg by vein on Days -5 to -3. Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
10012587|NCT01653730|Experimental|Eclipse 3 portable oxygen concentrator|Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
10012588|NCT01653730|Experimental|iGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
10012589|NCT01653730|Experimental|EverGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
10012590|NCT01653730|No Intervention|Control portable oxygen concentrator|6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
10012591|NCT01653756|Active Comparator|IPI-145|Capsules
10012592|NCT01653756|Placebo Comparator|Placebo|Capsules
10012593|NCT01653795|Active Comparator|LMA Unique|
10012594|NCT01653795|Active Comparator|LMA Supreme|
10012595|NCT01653808|Experimental|Elisio-210H with HD|hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer
10012596|NCT01653808|Active Comparator|Elisio-210H with on line HDF|hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer
10012597|NCT01653821|Experimental|Carotid body excision|Patients undergoing unilateral or bilateral removal of carotid body.
10012598|NCT01653834|Experimental|Lymphocyte harvesting & reinfusion|Patients with a newly diagnosed high grade glioma (Grade III or IV), have a post-operative treatment plan that includes standard radiation and temozolomide, and have normal bone marrow function with Hematocrit ≥ 30%, platelet ≥ 100K, ANC ≥ 1000, and absolute lymphocyte count ≥ 1000 prior entry to this study are eligible for enrollment.
10012599|NCT01653860|Experimental|The Brøset anger management model|Group treatment
10012600|NCT01653860|Active Comparator|ordinary group treatment|Group treatment
10012601|NCT01653886|Experimental|Pilot Group 1|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
10037296|NCT01823783|Other|DMD infant|Muscle biopsy
10012602|NCT01653886|Experimental|Pilot Group 2|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
10012603|NCT01653886|Experimental|Pilot Group 3|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
10012604|NCT01653886|Experimental|Pilot Group 4|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
10012605|NCT01653938|No Intervention|control group|
10012606|NCT01653938|Experimental|Video Arm|Use of video decision aid in the experimental arm.
10012607|NCT01653951|Experimental|Nurse-led care management|Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
10012608|NCT01653951|Experimental|peer-led self managment|Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups
10012609|NCT01653977|Active Comparator|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
10012610|NCT01653977|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
10012611|NCT01653990|Experimental|moxifloxacin, pill|Oral dose of 400mg moxifloxacin
10012612|NCT01653990|Placebo Comparator|moxifloxacin-placebo,pill|A pill of moxifloxacin-placebo
10012613|NCT01654003|Active Comparator|CONTROL|"In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
10012614|NCT01654003|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
10012615|NCT01654016|Active Comparator|Detralex|Detralex 500 mg twice daily for three month prior to surgery
10012616|NCT01654016|No Intervention|Not taking Detralex|Not taking Detralex for three months prior to surgery
10012617|NCT01654029|No Intervention|Control group receiving usual care|Usual care consists of speech language therapy for some patients. Most care is focused on swallowing assessments.
10012618|NCT01654029|Experimental|PCCI Intervention|The Patient-Centred Communication Intervention consists of 1) development of a communication care plan; 2)a workshop for staff focused on communication and behavioural management strategies,: and 3) implementing a staff support system.
10012619|NCT01654042|No Intervention|Standard interval between PT testing|Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
10012620|NCT01654042|Experimental|Prolonged interval between PT testing|Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
10012621|NCT01654081|Experimental|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
10037297|NCT01823783|Other|Control infant|Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)
10012622|NCT01654094|Experimental|P6 Low Adherent Dressing|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
10012623|NCT01654094|Active Comparator|Standard of Care (SOC)|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
10012624|NCT01654120|Experimental|liraglutide plus insulin|Patients were randomized to receive liraglutide plus insulin (LIRA) for 12 months.
10012625|NCT01654120|Active Comparator|Insulin titration only|Patients were randomized to receive insulin only (control) for 6 months. The controls were then crossed over to receive liraglutide plus insulin for 6 months after the initial control period.
10012626|NCT01654146|Active Comparator|Arm 1 (Control Arm)|Carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles
10012627|NCT01654146|Experimental|Arm 2 (Research arm)|Carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles
10012628|NCT01654146|Experimental|Arm 3 (Research arm)|Dose-fractionated weekly carboplatin and weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.
10012629|NCT01654172|Experimental|High Flavanol Cocoa|"Cocoa drink containing ~450mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
10012630|NCT01654172|Placebo Comparator|Low Flavanol Cocoa|"Cocoa drink containing ~25mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
10012631|NCT01654185|Experimental|AI plus Dimethyldiguanide|AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
10012632|NCT01654185|Active Comparator|Aromatase Inhibitor|AI monotherapy
10012633|NCT01654198||Psoriatic arthritis|
10012634|NCT01654211|Experimental|Part 1: iv danoprevir|
10012635|NCT01654211|Placebo Comparator|Part 1: placebo|
10012636|NCT01654211|Experimental|Part 2 A: iv danoprevir|
10012637|NCT01654211|Active Comparator|Part 2 B: oral danoprevir|
10012638|NCT01654211|Active Comparator|Part 2 C: ritonavir|
10012639|NCT01654211|Experimental|Part 3 D: iv danoprevir|
10012640|NCT01654211|Experimental|Part 3 E: iv danoprevir + cyclosporine|
10012641|NCT01654237|No Intervention|Muskind|three questionnaires to be completed by the subjects
10012642|NCT01654328|Experimental|Arm A: sodium chloride tablets|Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
10012643|NCT01654328|Active Comparator|B: isotonic saline intravenously|Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
10012644|NCT01654341|No Intervention|Usual Care Group|Subjects undergo usual standard of care
10012645|NCT01654341|Experimental|Intervention Group|Intervention with exercise, dietary and educational programs
10012646|NCT01654367|Experimental|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
10012647|NCT01654393|Experimental|OAR group|Patients with ankle injuries who are assessed by OAR trained triage nurses applying the OAR.
10012648|NCT01654393|No Intervention|Control for OAR Triage Nurses|Patients with ankle injuries that are seen by OAR triage nurses but not assessed in accordance with the OAR.
10012649|NCT01654406|Active Comparator|Control|Pulsed dye laser (V-beam)
10012650|NCT01654406|Experimental|Experimental group|Fractional CO2 laser(eCO2)and pulsed dye laser (V-beam)
10012651|NCT01654419|Active Comparator|Class II elastics alone|Use of class II elastics alone to correct class II dental malocclusions
10012652|NCT01654419|Experimental|Class II elastics with Sliding Jig|Class II elastics with Sliding Jig for correction of dental class II malocclusion
10012653|NCT01654432|Placebo Comparator|General anaesthesia and sham nerve block|Breast cancer surgery under general anaesthesia
10012654|NCT01654432|Active Comparator|Paravertebral Blocks (PVB)|Breast cancer surgery under ultrasound-guided paravertebral blocks plus general anesthesia
10012655|NCT01654458|Experimental|Immediate Treatment Condition|Receives the 12-week GyneGals Support Group within a month of completing the baseline assessment.
10012656|NCT01654458|No Intervention|Waitlist Control Condition|Waitlist control group receives the 12-week GyneGals Support Group only after its involvement in the study has ended, as a courtesy.
10012657|NCT01654471||Medical treatment|only medical treatment (regardless of the kinds of medicine)
10012658|NCT01654471||Surgical or endovascular treatemnt group|patients underwent surgery or endovascular therapy
10012659|NCT01654484|Experimental|Low Dose DE-117|Monotherapy
10012660|NCT01654484|Experimental|Medium Dose DE-117|Monotherapy
10012661|NCT01654484|Experimental|High Dose DE-117|Monotherapy
10012662|NCT01654484|Experimental|Low Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
10012663|NCT01654484|Experimental|Med. Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
10012664|NCT01654484|Experimental|High Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
10012665|NCT01654484|Active Comparator|0.0015% tafluprost|Monotherapy
10012666|NCT01654484|Placebo Comparator|Placebo|Monotherapy
10012667|NCT01654497|Experimental|Dexanabinol|
10012668|NCT01654510|Experimental|Cognitive Behavioral Therapy Group|
10012669|NCT01654510|Active Comparator|Vocational Services as Usual Control|Vocational services typically present in a comprehensive vocational service center.
10012670|NCT01654562|Experimental|CHM|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
10012671|NCT01654562|Active Comparator|Age-matched controls|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
10012672|NCT01654575|Experimental|Methotrexate|25mg/week orally
10012673|NCT01654575|Active Comparator|Placebo|"Placebo-sugar tablets identical in colour and shape to methotrexate given once a week for 16 weeks."
10012674|NCT01654614||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
10012675|NCT01654614||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
10012676|NCT01654627|Experimental|Regenecure AMCA GBR Dental membrane|16 patients will undergo the guided bone regeneration procedure using the Regenecure AMCA Membrane
10012677|NCT01654627|Active Comparator|Collagen membrane|16 patients will undergo the guided bone regeneration procedure using a commercially available collagen membrane
10012678|NCT01654640|Experimental|Metformin group|Metformin 500mg 1 tablet p.o. bid
10012679|NCT01654640|Placebo Comparator|Placebo group|1 tablet p.o. bid
10012680|NCT01654653|Experimental|HSL(Totilac)|Hypertonic Sodium Lactate
10012681|NCT01654653|Active Comparator|6% HES (Voluven)|6% Hydroxyethyl Starch
10012682|NCT01654679|Active Comparator|wIRA irradiation|Patients in Group A received local water-filtered infrared A (wIRA) irradiation once for 20 min preoperatively.
10012683|NCT01654679|Sham Comparator|visible light only|Patients assigned to Group B only received normal visible light application for 20 min prior to surgery.
10012684|NCT01654692|Experimental|Single arm of ipilimumab and fotemustine|Ipilimumab in combination with Fotemustine
10012685|NCT01654705|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
10012686|NCT01654705|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
10012687|NCT01654718|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
10012688|NCT01654718|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
10012689|NCT01654731|Experimental|Bezafibrate|400 mg/Day
10012690|NCT01654731|Placebo Comparator|Placebo|1 tablet/ day
10012691|NCT01654770|Active Comparator|video capsule endoscopy|Video capsule endoscopy is performed every recruited patient.
10012692|NCT01654770|Active Comparator|double balloon enteroscopy|Double balloon enteroscopy is performed after video capsule endoscopy in every recruited patient. (Tandem study)
10012693|NCT01654783||5-ASA|Patient's treated with oral 5-ASA
9965610|NCT01251302||Retrospective Cohort|Patients presenting with chest pain or anginal equivalent who did not receive an age, sex and gene expression score (ASGES) to assist in diagnosis. Note: this cohort was historical.
9965611|NCT01251328|Active Comparator|General anaesthesia|General anaesthesia is performed under standardized conditions
9965612|NCT01251328|Active Comparator|Sedation|Sedation is performed under standardized conditions
9965613|NCT01251341|Experimental|Compassion Meditation Group|
9965614|NCT01251341|Active Comparator|Health Education and Wellness Group|
9965615|NCT01251341|Experimental|Mindful Attention Training|
9965616|NCT01251406|Placebo Comparator|Placebo|Subcutaneous administration for daily for 8 hours a day for 10 days
9965617|NCT01251406|Experimental|rhNRG-1 Dose 1|Subcutaneous administration for daily for 8 hours a day for 10 days
9965618|NCT01251406|Experimental|rhNRG-1 Dose 2|Subcutaneous administration for 8 hours a day for 10 days
9965619|NCT01251419|Experimental|Testimonial and Union Arm|The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
9965620|NCT01251419|Experimental|Control|The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
9965621|NCT01251419|Experimental|Testimonial Treatment Arm|The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
9965622|NCT01251432||chronic otitis media|adults who have had tympanostomy tube(s) inserted for chronic otitis media
9965623|NCT01251432||Eustachian tube dysfunction|adults who have had tympanostomy tube(s) inserted for the clinical diagnosis of Eustachian tube dysfunction
9965624|NCT01251458|Experimental|Torisel|
9965625|NCT01251471|Experimental|Escitalopram|Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks
9965626|NCT01251510||Healthy adults|
9965627|NCT01251510||Type 2 diabetes|
9965628|NCT01251523|Active Comparator|PACE Plus|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
9965629|NCT01251523|Active Comparator|PACE|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
9965630|NCT01251523|No Intervention|Control|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
9965631|NCT01251549|Experimental|Experimental: A|A group of paraplegics.
9965632|NCT01251562|Experimental|Cohort 1|"5.62 mg/kg~Sterile Compound C31510 for Injection"
9965633|NCT01251562|Experimental|Cohort 2|"11.25 mg/kg~Sterile Compound C31510 for Injection"
9965634|NCT01251562|Experimental|Cohort 3|"22.5 mg/kg~Sterile Compound C31510 for Injection"
9965635|NCT01251562|Experimental|Cohort 4|33.0 mg/kg
9965636|NCT01251562|Experimental|Cohort 5|"44.0 mg/kg~Sterile Compound C31510 for Injection"
9965637|NCT01251562|Experimental|Cohort 6|"58.7 mg/kg~Sterile Compound C31510 for Injection"
9965638|NCT01251562|Experimental|Cohort 7|"78.2 mg/kg~Sterile Compound C31510 for Injection"
9965639|NCT01251562|Experimental|Cohort 8|"104.3 mg/kg~Sterile Compound C31510 for Injection"
9965640|NCT01251562|Experimental|Cohort 9|"139.0 mg/kg~Sterile Compound C31510 for Injection"
9965641|NCT01251601||Raltegravir in Pregnancy|HIV positive pregnant women currently on raltegravir as part of combination antiretroviral therapy
9965642|NCT01251627|Experimental|Decitabine|Eligible patients will recieve Dacogen 20mg/m2 in 1 hour iv infusion for 5 days every 28 days (1 cycle)plus Best Supportive Care.A total of 6 courses is planned.
9965643|NCT01251640|Experimental|Arm 1|
9965644|NCT01251666|Other|Magstream + Oc Sensor + Hemoccult II|"Each patient will perform all three tests:~Magstream: 2 samples (each on a different stool)~OC Sensor: 2 samples (each on a different stool)~Hemoccult II: 6 samples (2 samples per stool, on 3 different stools)~Each test will be considered as positive if at least one sample is positive (cutoff for Magstream 55 ng/ml and for OC Sensor 150 ng/ml).~Screening will be considered as positive if at least one of the three tests is positive, leading to a colonoscopy"
9965645|NCT01251679|No Intervention|Control|Control: nutrition, physical activity and smoking cessation education
9965646|NCT01251679|Experimental|Hand washing|Intervention 1: hand washing education and material
9965647|NCT01251679|Experimental|Hand washing and surgical mask|Intervention 2: hand washing education and material AND paper surgical face masks
10012694|NCT01654809|Experimental|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
10012695|NCT01654809|Active Comparator|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
10012696|NCT01654809|Active Comparator|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
9965648|NCT01251692|Experimental|1|A retrospective chart review of 26 eyes of 23 patients with recurrent corneal erosions treated by PTK from 1996 to 2000 was performed. All eyes had failed to respond to conventional therapy. Data regarding the preoperative and postoperative best-corrected visual acuity (BCVA), spherical equivalent (SE), symptomatic relief, incidence of recurrence, and complications arising from the laser treatment were analyzed. The mean duration of symptoms prior to PTK was 18 months (range, 8 to 36 months). The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser. Mean postoperative follow-up was 12 years (range, 10 to 14 years).
9965649|NCT01251718||Donepezil Hydrochloride|
9965650|NCT01251731|Experimental|Treatment Group 1|
9965651|NCT01251731|Experimental|Treatment Group 2|
9965652|NCT01251731|Experimental|Treatment Group 3|
9965653|NCT01251731|Experimental|Treatment Group 4|
9965654|NCT01251783|Active Comparator|Infant Formula|Infant Formula without lactobaillus or Metlin or Metlos
9965655|NCT01251783|Active Comparator|Fully breast milk|Group non randomized with fully breast milk
9965656|NCT01251783|Experimental|Metlin+Metlos+Lactobacillus GG|Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC
9965657|NCT01251783|Active Comparator|Metlin+Lactobacillus GG|Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC
9965658|NCT01251783|Active Comparator|Metlos+Lactobacillus GG|Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC
9965659|NCT01251783|Active Comparator|Lactobacillus GG|Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos
9965660|NCT01251796|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
9965661|NCT01251809|Experimental|PEG-rASNase 500|500 U/m2 BSA at day 0
9965662|NCT01251809|Experimental|PEG-rASNase 1000|1000 U/m2 BSA at day 0
9965663|NCT01251809|Experimental|PEG-rASNase 1500|1500 U/m2 at day 0
9965664|NCT01251809|Active Comparator|Oncaspar|2000 U/m2 at day 0
9965665|NCT01251822|Experimental|PEG 3350|PEG 3350 plus electrolytes in solution plus placebo tablets
9965666|NCT01251822|Active Comparator|Prucalopride|Prucalopride tablets plus placebo solution
9965667|NCT01251835|Active Comparator|Sitaxsentan|
9965668|NCT01251835|Experimental|Sitaxsentan plus Rifampin|
9965669|NCT01251848|Active Comparator|Treatment A|
9965670|NCT01251848|Active Comparator|Treatment B|
9965671|NCT01251848|Experimental|Treatment C|
10012697|NCT01654822|Placebo Comparator|olive oil with 10% d-limonene|Topical spray one-time administration 2 puffs of 100µl
10012698|NCT01654822|Experimental|AV2-DM antiviral spray|Topical spray one-time application 2 puffs of 100µl
10012699|NCT01654835|Active Comparator|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
10012700|NCT01654835|Placebo Comparator|no low blood pressure alert|The Low Blood Pressure condition will be monitored by treatment team, but additional alert will not be sent to treatment team.
10012701|NCT01654848||orthotopic Liver Transplantation|consecutive inclusion of all recipients
10012702|NCT01654874|Experimental|Preparation A|20 (±3) mCi 99mTc-MIP-1404 (preparation A)
10012703|NCT01654874|Experimental|Preparation B|20 (±3) mCi 99mTc-MIP-1404 (preparation B)
10012704|NCT01654900||Patients age >75 y who underwent open hear surgeary|The cohort study consist of all patients > 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center.
10012705|NCT01654913|Experimental|surgical patients|patients studied just before induction of anesthesia
10012706|NCT01654926||Heart Failure patients|
10012707|NCT01654939|Experimental|rifaximin|All patients will be taking rifaximin 550 mg twice daily
10012708|NCT01654965|Experimental|Treatment (tivantinib, topotecan hydrochloride, pegfilgrastim)|Patients receive tivantinib PO BID on days 1-21, topotecan hydrochloride IV over 30 minutes on days 1-5, and pegfilgrastim SC on day 6. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10012709|NCT01654991|Active Comparator|Clinic-Based Testing|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
10012710|NCT01654991|Experimental|Home-Based Testing|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
10012711|NCT01655004|Experimental|exemestane standard treatment|Patients will receive exemestane 25mg daily orally after a meal until progression of disease, intolerable toxicities, voluntary withdrawal or termination of the study.
10012712|NCT01655017|Experimental|biopsy|Obesity with BMI> 40 kg/m² or obesity with BMI between >35 kg/m² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
10012713|NCT01655017|No Intervention|healthy volunteers|biopsy during a surgery
10012714|NCT01655030|Experimental|creatine monohydrate|6g qd for 6 weeks
10012715|NCT01655030|Placebo Comparator|placebo|6g qd for 6 weeks
10012716|NCT01655056|Experimental|low male dose|Japanese and Caucasian males
10012717|NCT01655056|Experimental|medium male dose|Japanese and Caucasian males
10012718|NCT01655056|Experimental|high male dose|Japanese and Caucasian males
10012719|NCT01655056|Experimental|high female dose|Japanese and Caucasian females
10012720|NCT01655056|Experimental|highest male dose|Japanese and Caucasian males
10012721|NCT01655082|Experimental|V0116|One patch per day (during 24 hours) for 21 days
10012722|NCT01655082|Active Comparator|Reference|One patch per day (during 24 hours) for 21 days
10035812|NCT01809821|No Intervention|Usual CV care|Specialist nurses will administer the CV risk factor education intervention to participants in small groups over one hour.
10035813|NCT01809847|Experimental|Ofatumumab|First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
10035814|NCT01809860|Experimental|isavuconazole and sirolimus|Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days
10035815|NCT01809873|Experimental|Performance based incentives|Performance based incentives: The Incentive arm will receive monthly visits and external quality assurance of malaria diagnostic accuracy, identical to the comparison. Incentive arm will also receive quarterly incentives linked to performance of the facility around six indicators of appropriate malaria case management
10035816|NCT01809873|No Intervention|Comparison|The comparison arm will receive monthly visits and monthly external quality assurance of malaria diagnostic accuracy.
10035817|NCT01809886|Experimental|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
10035818|NCT01809886|Active Comparator|Neostigmina|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
10035819|NCT01809912|Experimental|Greenstatin|"Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.~Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V~) on a compassionate use basis at the same dose and regimen ."
10035820|NCT01809925|Experimental|psyllium fiber 6.8g|Two (2) packets Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g) thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
10035821|NCT01809925|Placebo Comparator|placebo|One (1) level teaspoon of placebo product thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
10035822|NCT01809951||Isomil Advance with LCP|4 spoonful of Isomil Advance with LCP in 240 mL of water, 4 times a day
10037298|NCT01823796||Healthy women.|35 healthy women. Control group.
10012723|NCT01655095|Experimental|PEG and Prucalopride|
10012724|NCT01655095|Experimental|Picosalax and Prucalopride|
10012725|NCT01655108|Placebo Comparator|Saline|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
10012726|NCT01655108|Active Comparator|Minoxidil 0.5% /2ml|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
10012727|NCT01655121|Experimental|Autoimmune hepatitis (Non-cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
10012728|NCT01655121|Experimental|Autoimmune hepatitis (Cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
10012729|NCT01655147|Experimental|Abiraterone acetate + Rifampicin|Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2.
10012730|NCT01655160|Experimental|mirror therapy treatment|Three groups will be involved in this part of the whole project:MT with low-intensity group (MT-LI), MT with moderate-intensity group (MT-MI), MT with high-intensity group (MT-HI)
10012731|NCT01655160|Active Comparator|control intervention group|The part of this project will involve 1 treatment groups:control intervention group (CI)
10012732|NCT01655173|Experimental|Cognitive behaviour therapy|36 weekly sessions (1 calendar year) of Cognitive behaviour therapy in a group setting.
10012733|NCT01655173|Active Comparator|Recreational activity intervention|36 sessions (1 calendar year) of a group intervention to enable social interaction and to break social isolation.
10012734|NCT01655186|Placebo Comparator|Placebo|Oral, once daily
10012735|NCT01655186|Experimental|Bardoxolone Methyl|Oral, once daily
10012736|NCT01655199|Experimental|COPD group|Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
10012737|NCT01655212|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
10012738|NCT01655212|No Intervention|Control|Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.
10012739|NCT01655238||95-99% BMI ASC|Patients having a BMI between 95-99% who are seen in the ambulatory surgery centers.
10012740|NCT01655238||95-99% BMI NCH main OR|Patients having a BMI between 95-99% who are seen in the main operating rooms.
10012741|NCT01655238||>99% BMI NCH main OR|Patients having a BMI >99% who are seen in the main operating rooms.
10012742|NCT01655251|Experimental|Intervention|Video (DVD) discharge instructions
10012743|NCT01655251|No Intervention|Control|
10012744|NCT01655264|Active Comparator|Home-based self training exercises|The control group will receive home-based self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
10012745|NCT01655264|Experimental|Tele-rehabilitation exercises|The experimental group will receive tele-rehabilitation treatment of comparable duration and intensity to those in the home-based self training exercise group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
10012746|NCT01655277|Experimental|Adductor Canal block first|This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
10012747|NCT01655277|Experimental|Femoral nerve block first|This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
10012748|NCT01655290|Experimental|Gadobutrol|first session gadobutrol second session gadobenate dimeglumin
10012749|NCT01655290|Experimental|Demeglumin|first session gadobenate dimeglumin second session gadobutrol
10012750|NCT01655303|Experimental|Metoprolol Per Oral|50 mg Metoprolol
10012751|NCT01655303|Experimental|Verapamil|40 mg Verapamil Per Oral
10012752|NCT01655303|Experimental|Propranolol|40 mg Propranolol Per Oral
10012753|NCT01655303|Experimental|Diltiazem|60 mg Diltiazem Per Oral
10012754|NCT01655316|Experimental|Verapamil|40 mg Verapamil Per Oral
10012755|NCT01655342||formocresol|
10012756|NCT01655355||Revison of the hip joint|
10012757|NCT01655368|Experimental|Interventional: STEM modules|8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module (for schizophrenia or depression)
10012758|NCT01655368|Other|Interventional Control|11 sessions + 1 booster session of psychoeducation for schizophrenia or depression)
10012759|NCT01655407|Experimental|Treatment|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
10012760|NCT01655407|Active Comparator|Control|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
10012761|NCT01655420||LASIK|Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
10012762|NCT01655433|Experimental|Therapeutic Hypothermia Treatment|
10012763|NCT01655433|Active Comparator|No Hypothermia Treatment|control group is no hypothermia treatment
10012764|NCT01655446|Experimental|Robotic Rehabilitation with FES|Robotic rehabilitation combined Functional Electrical Stimulation (FES)
10012765|NCT01655446|Experimental|Mirror Therapy|Mirror Therapy (MT)
10012766|NCT01655446|Active Comparator|Conventional Rehabilitation|Conventional Rehabilitation (CR) mainly focuses on occupational therapy training
10012767|NCT01655446|Experimental|Robotic Rehabilitation|Robotic Rehabilitation (RR)
10012768|NCT01655446|Placebo Comparator|Robotic Rehabilitation with PI|Robotic rehabilitation with Placebo Intervention (RR-PI)
10012769|NCT01655459||Ultrasound exam of upper airway|Following Internal Review Board approval(4-2011-0800) and written informed consent, total 100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular urologic surgeries were included in the study. Children with upper respiratory tract infection, restricted mouth opening, congenital heart disease and those at risk for aspiration were excluded.
10012770|NCT01655472|Active Comparator|healthy parents|
10012771|NCT01655472|Active Comparator|schizophrenic parents|
10012772|NCT01655485|Experimental|Patient teaching|ipad application for social script book
10012773|NCT01655511|Experimental|Period 1|240 mg tafamidis arm
10012774|NCT01655511|Experimental|Period 2|480 mg arm
10012775|NCT01655511|Experimental|Period 3|TBD dose
10012776|NCT01655524|Experimental|ASSUAGE Protocol|There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared.
10012777|NCT01655550|Other|Standard of Care|Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice
10012778|NCT01655550|Experimental|Withold Oral Contrast|Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine
10012779|NCT01655576|No Intervention|Routine clamping|After delivery of the newborn, umbilical cord at mothers end, will be left clamped until delivery of the placenta.
10012780|NCT01655576|Experimental|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
10012781|NCT01655602|Experimental|upper edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of upper edge of linear incision before wound closure
10012782|NCT01655602|Experimental|lower edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of lower edge of linear incision before wound closure
10012783|NCT01655602|Experimental|Both edge trimming|Surgery: trichophytic closure The 0.5-millimetre trimming of both edge of linear incision before wound closure
10012784|NCT01655615|Experimental|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
10012785|NCT01655628|Experimental|GC chemotherapy plus CIK cells|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks); however,the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus 8 cycles CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
10037299|NCT01823796||Fibromyalgia women group|35 women with fibromyalgia were measured at baseline of the observational study.
10012786|NCT01655628|Active Comparator|GC chemotherapy|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
10012787|NCT01655641|Experimental|Tranexamic acid arm|"Along with the standard of care (routine surgical care involved in preventing blood loss during surgery) this arm will receive drug Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV for non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
10012788|NCT01655641|Active Comparator|Standard of care arm|Includes routine surgical care involved in preventing blood loss during and after surgery.
10012789|NCT01655654|No Intervention|Cohort 1|All employees within the acute care hospital that signed the informed consent form and provided their individual data.
10012790|NCT01655654|Active Comparator|Cohort 2|All subjects of cohort 1 who also are considered hypertensive and participated in one or more study interventions, which include behavioral interventions (an increase in physical activity, or dietary changes) or who have a primary care provider visit to discuss hypertension.
10012791|NCT01655667||Chronic Obstructive Pulmonary Disease|All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.
10012792|NCT01655706|Active Comparator|escitalopram (10-20mg)|Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
10012793|NCT01655706|Active Comparator|aripiprazole (2-10mg)|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
10012794|NCT01655732|Experimental|Atraumatic Restorative Treatment|ART is Atraumatic Restorative Treatment involving removal of soft carious enamel and dentine by hand instruments only and then restore the resulting cavity and adjacent pits and fissures with an adhesive restorative material.
10012795|NCT01655745|Experimental|FDG PET/MR, No Chemotherapy Arm|Patients that are NOT receiving chemotherapy but are only completing surgical intervention.
10012796|NCT01655745|Experimental|FDG PET/MR, Chemotherapy Arm|Patients that are receiving chemotherapy prior to completing surgical intervention. These patients will receive a FDG PET/MR prior to chemotherapy and after completion of chemotherapy (at the time of pre-op, before surgical intervention).
10012797|NCT01655758|Active Comparator|timolol|60-day treatment phase with 0.5% timolol eyedrops, b.i.d.
10012798|NCT01655758|Active Comparator|'timolol-dorzolamide fixed combination'|60-day treatment phase with the fixed combination of 0.5% timolol-2% dorzolamide, eyedrops, b.i.d.
10012799|NCT01655758|Active Comparator|xalatan|60-day treatment phase with 0.005% latanoprost, eyedrops, QD
10012800|NCT01655758|Active Comparator|travatan|60-day treatment phase with 0.004% travoprost, eyedrops, QD
10012801|NCT01655758|Active Comparator|lumigan|60-day treatment phase with 0.03% bimatoprost, eyedrops, QD
10012802|NCT01655771|Experimental|Elderly|TD-1211 Dose 1
10012803|NCT01655771|Experimental|Younger|TD-1211 Dose 2
10012804|NCT01655797|Experimental|CBT|The treatment group received manualized CBT-I using a adapted version of a manual designed for use by primary care personnel. Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
10012805|NCT01655797|No Intervention|Wait-list|A deferred treatment wait-list condition, with no restrictions placed on the usual care.
10012806|NCT01655810|Active Comparator|Vitamin D 4000 IU|PO daily
10012807|NCT01655810|Active Comparator|Vitamin D 600 IU|PO daily
10012808|NCT01655849|Experimental|Z160|375mg BID
10012809|NCT01655849|Placebo Comparator|placebo|matching placebo control
10012810|NCT01655862||OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
10012811|NCT01655875|Experimental|bone marrow transplant|
10012812|NCT01655888|Experimental|single arm with Tremelimumab|Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity
10012813|NCT01655914|Active Comparator|Arm A|"Sequence of Exposure:~Sequence A (N=5) Week 1: S/L 1.1 mg Week 2: S/L 2.2 mg Week 3: IV 0.2 mg Week 4: S/L 2.2 mg with 240 ml water"
10012814|NCT01655914|Active Comparator|Arm B|Sequence B (N=5) Week 1: IV 0.2 mg Week 2: S/L 2.2 mg Week 3: S/L 1.1 mg Week 4: S/L 2.2 mg with high fat diet
10012815|NCT01655927|Experimental|Tranexamic Acid|15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
10012816|NCT01655927|Placebo Comparator|Saline (Placebo)|15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
10012817|NCT01655940||Cardiac bypass patients|
10012818|NCT01655953|Experimental|Campaign 1|
10012819|NCT01655953|Experimental|Campaign 2|
10012820|NCT01655966|Active Comparator|Standard of care|Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
10037300|NCT01823809|Other|Imaging arm|There is one study arm only. The imaging modalities will be performed in all patients.
10012821|NCT01655966|Experimental|Triple therapy|Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
10012822|NCT01655979|Experimental|MEP-1|
10012823|NCT01655979|Experimental|MEP-2|
10012824|NCT01655992|Experimental|S1 generic|40mg／m2 bid four weeks on two weeks off
10012825|NCT01655992|Active Comparator|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
10012826|NCT01656005|Experimental|Carvedilol|Beclometasone/Formoterol Beclometasone Tiotropium
10012827|NCT01656005|Active Comparator|Bisoprolol|Beclometasone/Formoterol Beclometasone Tiotropium
10012828|NCT01656018|Experimental|Arm 1A|Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
10012829|NCT01656018|Experimental|Arm 1B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
10012830|NCT01656018|Experimental|Arm 2A|Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
10012831|NCT01656018|Experimental|Arm 2B|Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
10012832|NCT01656018|Experimental|Arm 3A|Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
10012833|NCT01656018|Experimental|Arm 3B|Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
10012834|NCT01656018|Experimental|Arm 4A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
10012835|NCT01656018|Experimental|Arm 4B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
10012836|NCT01656018|Experimental|Arm 5A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
10012837|NCT01656018|Experimental|Arm 5B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.
10012838|NCT01656044|Active Comparator|Arm I (SSD)|Patients receive SSD over their closed laparotomy incision at the conclusion of their surgery.
10012839|NCT01656044|Experimental|Arm II (NPT)|Patients receive NPT dressing over their closed laparotomy incision at the conclusion of their surgery.
10012840|NCT01656057|Experimental|Acetaminophen+saline|Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
10012841|NCT01656057|Experimental|Acetaminophen+CCK|Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
10012842|NCT01656057|Experimental|Metformin+saline|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
10012843|NCT01656057|Experimental|Metformin+CCK|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
10012844|NCT01656057|Experimental|Colesevelam+saline|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline
10012845|NCT01656057|Experimental|Colesevelam+CCK|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
10012846|NCT01656070|Experimental|Vitamin D|"oral cholecalciferol 1000000 UI (vitamin D3).~At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers."
10012847|NCT01656070|Placebo Comparator|placebo|"placebo~At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers."
10012848|NCT01656083||SM intervention + varenicline|In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.
10012849|NCT01656083||Non-SM intervention group: varenicline|varenicline only
10012850|NCT01656096|Experimental|Renal sympathetic denervation|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
10012851|NCT01656096|Sham Comparator|Sham procedure|Sham procedure mimicking the renal sympathetic denervation procedure in the experimental arm
10012852|NCT01656109|Experimental|PI-experience group|Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load < 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART
10012853|NCT01656109|Experimental|PI-naïve group|Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit
10012854|NCT01656122|Experimental|PK|PK of abacavir and lamivudine
10012855|NCT01656135|Other|Reference Group|"Basiliximab (Simulect®):~Day 0: 20mg IV ≤2h prior to surgery~Day 4: 20mg IV~Prednisolone:~Day 0: 500mg IV (250mg pre-op, 250mg intra-op)~Day 1: 125mg IV~Day 2 - 14: 20mg/day oral~Week 3 - 4: 15mg/day oral~Week 5 - 8: 10mg/day oral~Week 9 - 12: 5mg/day oral~Week 13 - 14: 2.5mg/day oral~Week 15 - Study End: Cessation~Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.~Mycophenolate Mofetil (MMF, or biologic equivalent):~Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:~Day -1 - 14: 2g/day oral~Day 15 - Study End 1.5g/day oral (750mg twice daily)~Tacrolimus (or biologic equivalent):~Day -4 - 14: 3-12ng/ml~Week 3 - 12: 3-10ng/ml~Week 13 - 36: 3-8ng/ml~Week 37 - Study End: 3-6ng/ml"
10012856|NCT01656148|Experimental|Fampridine-SR|Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
10012857|NCT01656148|Placebo Comparator|Placebo|In the intervention phase 50% will receive placebo BID
10012858|NCT01656174||No Treatment|
10012859|NCT01656213|Experimental|visual-feedback handgrip exercise|Subjects allocated to treatment will be trained in the laptop-based exercise that takes 20 minutes/session. Subjects will be encouraged to perform the exercise 2-3 times per dialysis session
10012860|NCT01656213|No Intervention|Control Arm|"60 similar ESRD stroke patients will be randomly assigned to the non-intervention arm. These patients will receive standard advice during dialysis (rest or gentle activity, e.g. reading).~Note that both groups of patients will also receive standard multidisciplinary rehabilitation care following a stroke, including therapy sessions at times other than receiving dialysis"
10012861|NCT01656226|Experimental|Eryfotona AK-NMSC® cream|
10012862|NCT01656226|Other|Sunscreen SPF 50+|
10012863|NCT01656265|Experimental|ARQ 197|
10012864|NCT01656278|Active Comparator|Conventional biochemical and clinical examinations|Biochemical and clinical examinations
10012865|NCT01656278|Experimental|Conventional biochemical and clinical examinations and MRI.|Biochemical and clinical examinations and MRI.
10012866|NCT01656317|Active Comparator|Mobilisation of patients after SAH|"Patients which were treated after SAH in 2012 will receive early multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~Mobilisation will be initiated and completed according to mobilisations guidelines which are developed and adjusted to the patients in early stage after aneurysmal SAH."
10012867|NCT01656317|No Intervention|Patients after SAH from 2011|Patients after SAH from 2011 which did not receive early rehabilitation and mobilisation will be followed up 3-6 annd 12 months after SAH and outcome measures compared with patients from 2011.
10012868|NCT01656330|Experimental|Rivaroxaban + Profilnine SD|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Profilnine SD 50 IU/kg.
10012869|NCT01656330|Experimental|Rivaroxaban + Beriplex P/N|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Beriplex 50 IU/kg.
9476755|NCT03568695|Other|Detected patients|If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
10012870|NCT01656330|Experimental|Rivaroxaban + Saline|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single 100cc bolus of saline.
10012871|NCT01656343||Belatacept treated kidney-only transplant recipients|
10012872|NCT01656343||CNI treated kidney-only transplant recipients|
10012873|NCT01656356|Active Comparator|A/17/turkey/Turkey/05/133 (H5N2)|
10012874|NCT01656356|Placebo Comparator|Placebo|
10012875|NCT01656369|Active Comparator|Group I delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed. Postoperatively, minimal pain medication was required. Early ambulation was encouraged, and patients' diets were advanced as tolerated.
10012876|NCT01656369|Active Comparator|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
10012877|NCT01656382|Active Comparator|5 mg/kg/d ABLC x 14 days|5 mg/kg/d of Amphotericin B Lipid Complex for 14 days
10012878|NCT01656382|Experimental|10/kg/kg/d x 7 days|10 mg/kg/d of Amphotericin B Lipid Complex for 7 days
10012879|NCT01656421||COPD|Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
10012880|NCT01656421||Comparators|Current or ex-smokers free from from Respiratory Disease
10012881|NCT01656447||Patients with Scleroderma|Patients who have been diagnosed at any point in their life with Scleroderma will compose the cohort.
10012882|NCT01656473|Experimental|MI and DBT|Individual Motivational Interview session followed by 12-week Dialectical Behaviour Therapy skills group
10012883|NCT01656499|Active Comparator|Arabinoxylanoligosaccharides (AXOS)|AXOS (2 x 5g WBE/day)
10012884|NCT01656499|Placebo Comparator|Maltodextrine (placebo)|Maltodextrine (2 x 5g/day)
10012885|NCT01656512|Active Comparator|Arm ( A)|Arm ( A) : patients will receive calcium & vitamin D
10012886|NCT01656512|Experimental|Arm (B)|we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
10012887|NCT01656525|Experimental|1|
10012888|NCT01656525|Experimental|2|
10012889|NCT01656525|Experimental|3|
10012890|NCT01656525|Experimental|4|
10012891|NCT01656538|Experimental|Paclitaxel plus Reolysin|Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16.
10012892|NCT01656538|Active Comparator|Paclitaxel|Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks.
10012893|NCT01656551|Active Comparator|A: Gemcitabine|Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks
10012894|NCT01656551|Experimental|B: Gemcitabine + Cisplatin|Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks
10012895|NCT01656551|Active Comparator|C: Pemetrexed|
10012896|NCT01656551|Experimental|D: Pemetrexed + Cisplatin|
10012897|NCT01656590|Other|High Protein and Exercise therapy along-with Nocturnal Enteral|
10012898|NCT01656616||EMS cyanide exposure patients|
10012899|NCT01656642|Experimental|Cohort 1 (C1): Ate+Vem - No Run-in|Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.
10012900|NCT01656642|Experimental|Cohort 2 (C2): Ate+Vem (56 Day Run-in)|Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
10012901|NCT01656642|Experimental|Cohort 3 (C3): Ate+Vem (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
10012902|NCT01656642|Experimental|Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.
10012903|NCT01656642|Experimental|ECA: Ate+Vem+Cob (Mandatory Biopsy PD)|Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
10012904|NCT01656642|Experimental|ECB: Ate+Vem+Cob (Mandatory Biopsy)|Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
10037301|NCT01823822|Experimental|Oral protein supplement (Tested product)|
10012905|NCT01656642|Experimental|ECC: Ate+Vem+Cob (No Mandatory Biopsy)|Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
10012906|NCT01656655||PTSD group|Patients with PTSD
10012907|NCT01656655||Control Group|non PTSD group
10012908|NCT01656668|Experimental|BC1036|BC1036 300 mg capsule capsule by mouth, twice daily, for 14 days.
10012909|NCT01656668|Placebo Comparator|Sugar Pill|Sugar placebo capsule by mouth, twice daily, for 14 days.
10012910|NCT01656681|Experimental|THIAA|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
10012911|NCT01656681|Active Comparator|Placebo|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
10012912|NCT01656707|Experimental|ACRA|Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
10012913|NCT01656707|Experimental|Cognitive Behavioral Therapy (CBT)|Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
10012914|NCT01656720|Placebo Comparator|Placebo|Placebo 2g Suppository
10012915|NCT01656720|Active Comparator|NRL001 5mg|5mg NRL001 in a 2g suppository
10012916|NCT01656720|Active Comparator|NRL001 7.5mg|7.5mg NRL001 in a 2g suppository
10012917|NCT01656720|Active Comparator|NRL001 10mg|10mg NRL001 in a 2g suppository
10012918|NCT01656746|Experimental|Treatment (single incision laparoscopic surgery)|Patients undergo single incision laparoscopic surgery with GelPort® attachment.
10012919|NCT01656785|Experimental|Brain 68Ga-BNOTA-PRGD2|We will perform brain 68Ga-BNOTA-PRGD2 PET/CT on stroke patients to determine its value.
10035823|NCT01809977|Other|total removal|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
10035824|NCT01809977|Other|partial removal|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
10035825|NCT01809990|Experimental|internet-delivered cognitive behavior therapy|Participants will be assigned to a 12 weeks internet-delivered cognitive behavior therapy program including therapist contact via an internet platform and telephone.
10035826|NCT01810003|Experimental|High DHA|High DHA supplementation (3g/day)
9476756|NCT03568643|Experimental|Azithromycin|children in this arm will receive one dose of azithromycin
10035827|NCT01810003|Experimental|High EPA|EPA supplementation (3g/day)
10035828|NCT01810003|Placebo Comparator|Placebo|Placebo (3g corn oil/day)
10035829|NCT01810029|Experimental|Cardiac Rehabilitation plus Transcendental Meditation|a standard validated cardiac rehabilitation program plus a standard validated stress reduction component, the Transcendental Meditation program
10035830|NCT01810029|Active Comparator|Cardiac Rehabilitation|This control is a standard Cardiac Rehabilitation without a stress reduction technique
10035831|NCT01810068|Sham Comparator|Placebo|patients who are undergoing diagnostic cystoscopy
10035832|NCT01810068|Active Comparator|HOLEP|Holmium laser enucleation of the prostate
10035833|NCT01810068|Active Comparator|monopolar TURP|Monopolar transurethral resection of the prostate
10035834|NCT01810068|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate
10035835|NCT01810081||cholecystectomy|cholecystectomy group: H.Pylori infection in gall bladder
10035836|NCT01810094||Minimally invasive Approach|Patients with a thoracolumbar Fracture A3.1 to A 3.3 treated by fracture fixation by a minimally invasive approach
10035837|NCT01810107||Children Examined with the OCT Probe|Children undergoing surgery will also have the Optical Coherence Tomography probe.
10035838|NCT01810107||Adults|Adults undergoing surgery will also have the Optical Coherence Tomography probe.
10035839|NCT01810120|Experimental|TCR alfa beta depleted graft, infusion|The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.
10035840|NCT01810133||Anesthesia patients|All patients undergoing general anesthesia between January 2006 and December 2011 in Charité - University Berlin
10035841|NCT01810146|No Intervention|Digestive functions investigations|Results from digestive functions investigations will be compared between patients eligible for bariatric surgery (BMI>40kg/m2) and volunteers (BMI between 20 and 25kg/m2).
10035842|NCT01810159|Experimental|ICC|Integrated collaborative care
10035843|NCT01810159|Active Comparator|E&R|Education and Resources--enhanced usual care
10035844|NCT01810172|Active Comparator|Dry suction pleural drainage system|The control group will have their chest tube connected to a dry suction pleural drainage system The intervention will be the dry suction pleural drainage system
10035845|NCT01810172|Experimental|Digital pleural drainage system|The experimental group will have their chest tube connected to a digital pleural drainage. The intervention will be the digital pleural drainage system.
10035846|NCT01810185|Experimental|Low dose naltrexone|Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks.
10035847|NCT01810185|Placebo Comparator|Placebo|Subjects in this arm will recieve a placebo daily for 12 weeks.
10035848|NCT01810198|Active Comparator|Cardiac CT|Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)
10012920|NCT01656798|Experimental|fasted condition|
10012921|NCT01656798|Experimental|fec condition|
9476757|NCT03568643|Active Comparator|Amoxicillin|Children in this arm will receive a 7 day course of amoxicillin (standard of care)
10012922|NCT01656811|Experimental|levalbuterol 90 mcg|levalbuterol 90 mcg delivered via metered dose inhaler (MDI)
10012923|NCT01656811|Experimental|levalbuterol 180 mcg|levalbuterol 180 mcg delivered via MDI
10012924|NCT01656811|Active Comparator|racemic albuterol 180 mcg|racemic albuterol 180 mcg delivered via MDI
10012925|NCT01656811|Placebo Comparator|Placebo|Placebo delivered via MDI
10012926|NCT01656837|Experimental|MST-BSF|MST-BSF integrates two models with empirical support for their effectiveness, MST-CAN for child maltreatment (Swenson, Schaeffer, Henggeler, Faldowski, & Mayhew, 2012) and RBT for adult substance abuse (Tuten, Jones, Schaeffer, Wong, & Stitzer, 2012) into one comprehensive treatment package. MST-BSF is intended to be comprehensive. The major interventions within the MST-BSF arm include safety planning and implementation, functional analysis of the abuse incident, cognitive behavioral interventions for PTSD symptomatology and low anger management, family communication and problem solving, abuse clarification, and Reinforcement Based Treatment for adult substance abuse. RBT is an incentive-based drug treatment program for adults who abuse opiates, cocaine, or other illicit drugs.
10012927|NCT01656837|Experimental|Comprehensive Community Treatment|Families randomized to the CCT condition receive an array of services consistent with existing DCF practices. Project Safe community providers offer individual, couples, and family therapy for substance abuse/dependence, early intervention groups, treatment for co-occurring disorders, gender-specific trauma/substance abuse groups, and relapse prevention groups. The DCF caseworker also is responsible for coordinating care for the behavioral and mental health needs of the children. Services include individual outpatient treatment, family therapy, intensive in-home treatment, extended day programs, intensive outpatient, partial and inpatient hospitalization, residential programs/temporary housing (safe homes, shelters), emergency mobile psychiatric services, and crisis stabilization.
10012928|NCT01656863||Parents|Parents reporting to the emergency room with dehydrated children
10012929|NCT01656876|Experimental|Mirror therapy|mirror box training with or without sham mesh glove stimulation
10012930|NCT01656876|Experimental|Mirror therapy + Mesh glove stimulation|Mirror therapy combined with mesh glove stimulation
10012931|NCT01656876|Active Comparator|Controlled intervention|conventional interventions
10012932|NCT01656902|Experimental|N3D plus|NOVOCART® 3D plus (Autologous Chondrocyte Transplantation System)
10012933|NCT01656902|Active Comparator|Microfracture|Microfracture is the standard care surgery.
10012934|NCT01656915||Healthy men|Healthy male subjects with normal weight
10012935|NCT01656915||Compromised men|pre-diabetic overweight, male subjects
10012936|NCT01656928|Other|Waiting-list control|Allocation to waiting-list Control. Receives intervention 6 months later.
10012937|NCT01656928|Active Comparator|Intervention|Allocation to intervention. Directly starts with nutritional intervention.
10012938|NCT01656941||d-Transposition of the Great Arteries|Neonates with d-transposition of the great arteries (dTGA) undergoing the arterial switch operation with cardiopulmonary bypass
10012939|NCT01656941||Single ventricle cardiac disease|Neonates with single ventricle cardiac disease (SVCD) undergoing stage I surgical palliation (Norwood) with cardiopulmonary bypass
10012940|NCT01656954||Anticipated volume/blood administration|Patients who may receive IV fluid boluses or blood products for restoration of vascular volume. Prior to receiving IV fluid boluses or blood products, the patient will undergo a passive leg raise. (PLR)
10012941|NCT01656980|Experimental|Carmustine Sustained Release Implant|For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
10012942|NCT01656980|Sham Comparator|Tumor Resection Surgery|For subjects in this control group, they accept no implants while gliomas maximally be resected.
10012943|NCT01656993||ASA activity|Participants (age 2.0 days to 12 months) undergoing cardiac surgery for a shunt and planned treatment with aspirin
10012944|NCT01657045|Experimental|Cohort 1|Subjects will be randomized to receive injections JVS-100 or placebo.
10012945|NCT01657045|Experimental|Cohort 2|Subjects will be randomized to receive injections JVS-100 or placebo.
10012946|NCT01657045|Experimental|Cohort 3|Subjects will be randomized to receive injections of JVS-100 or placebo.
10012947|NCT01657058|Experimental|Treatment # 1|Soluble viscous fibre blend powder in hydrophobic matrix
10012948|NCT01657058|Experimental|Treatment # 2|Soluble viscous fibre blend in pre hydrated form
10012949|NCT01657058|Placebo Comparator|Control # 1|No soluble viscous fibre blend
10012950|NCT01657058|Experimental|Treatment # 3|Soluble viscous fibre blend premixed with ½ carbohydrate gel
10012951|NCT01657058|Placebo Comparator|Control # 2|No soluble viscous fibre blend, ½ carbohydrate jello
10012952|NCT01657071|Experimental|Group A|
10012953|NCT01657071|Active Comparator|Group B|
10012954|NCT01657084|Experimental|Tonic-clonic seizures|Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
10012955|NCT01657084|Experimental|Generalized Paroxysms|Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
10012956|NCT01657084|Experimental|Group 3|Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
10012957|NCT01657097|Experimental|INCS|Fluticasone propionate 400 microgram daily
10012958|NCT01657097|Placebo Comparator|Placebo|Placebo
10012959|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
10012960|NCT01657123|Placebo Comparator|placebo|
10012961|NCT01657123|Experimental|hydrocortisone stress dosage|
10012962|NCT01657136|Active Comparator|Ivabradine|Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).
10012963|NCT01657136|Active Comparator|Beta blocker (Bisoprololo)|Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
10012964|NCT01657149|Experimental|Research Group|receive lymphatic massage and individual physiotherapy
10012965|NCT01657149|Active Comparator|Control group|receive individual physiotherapy only
10012966|NCT01657175|Experimental|Supportive care|The patients randomized to the supportive care arm get an extended supportive care during the first year after surgery.
10012967|NCT01657175|No Intervention|Control|"The patients randomized to the control group get care as usual"
10012968|NCT01657188||Heart failure, sleep-disordered breathing|Patients with stable heart failure NYHA ≥ II, EF ≤ 45% with or without central sleep apnea (apnea-hypopnea index ≥ 15/h) with or without adaptive servoventilation
10012969|NCT01657201|Experimental|Sequence 1|SYP-1018 200mg → Voriconazole 200mg
10012970|NCT01657201|Experimental|Sequence 2|Voriconazole 200mg → SYP-1018 200mg
10012971|NCT01657214|Experimental|Dose escalation|SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is >340 mg/m^2.
10012972|NCT01657227|Experimental|Intervention to Patients|Only patients receive intervention
10012973|NCT01657227|Experimental|Intervention to healthcare Professionals|Primary care physicians and nurses practitioners receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
10012974|NCT01657227|Experimental|Mixed Intervention|Patients and healthcare professionals (primary care physicians and nurses practitioners) associated with these patients receive intervention
10012975|NCT01657227|Other|Control|Patients receive usual care
10012976|NCT01657240|Experimental|PRO-118|pro-118 ophthalmic solution, instill one drop in each eye once a day for 21 days
10012977|NCT01657240|Active Comparator|Olopatadine Hydrochloride|Olopatadine Hydrochloride ophthalmic solution 2%, instill one drop in each eye once a day for 21 days
10012978|NCT01657279|Experimental|Randomized clinical scenarios|Clinicians are randomized to a sequence of 5 clinical scenarios
9476758|NCT03568617|Experimental|rTMS group|
10012979|NCT01657318||Chronic Wound Group|Treatment with Olivamine containing wound care products
10012980|NCT01657331|Experimental|Brentuximab Vedotin / Bendamustine|Subjects with relapsed or refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma will receive Brentuximab Vedotin in combination with Bendamustine, and prophylactic Neulasta
10012981|NCT01657357||PAO, osteoarhritis, THA|
10012982|NCT01657396|Active Comparator|Standard Oral Hygiene|Oral hygiene provided by current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
10012983|NCT01657396|Active Comparator|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
10012984|NCT01657396|Active Comparator|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
10012985|NCT01657409|Experimental|BoNT-A (10 injection)|100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body
10012986|NCT01657409|Experimental|BoNT-A (20 injections)|100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body
10012987|NCT01657409|Experimental|BoNT-A (40 injections)|100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body
10012988|NCT01657422|Experimental|PACE+ Intervention|Intervention Group
10037302|NCT01823822|Active Comparator|Iso-caloric supplement (Control product)|
9802540|NCT05176808|Active Comparator|In-person Coaching(IPC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is12 weeks with sessions 2 times per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Coaching will be delivered in families' homes by trained study coaches to support parent implementation of NDBI strategies during daily life activities with their toddler with ASD."
10012989|NCT01657422|No Intervention|Sun Protection|Control / Comparison group. Patients assigned to the comparison group will receive intervention strategies over a the course of 2 years including: (1) completion of a 30-minute office-based computer program resulting in on-screen feedback to address excess sun exposure prevention, and (2) 4 phone calls and 4 mailings over a 24-month period conducted by PACE+ staff members.
10012990|NCT01657435||Ceramax COC 28mm Acetabular Cup|The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.
10012991|NCT01657448|Experimental|Methenamine, Methylthioninium|
10012992|NCT01657448|Active Comparator|Phenazopyridine|
10012993|NCT01657474|Experimental|Weekly Application of EpiFix|Weekly application of EpiFix plus standard of care
10012994|NCT01657474|Experimental|Biweekly application of EpiFix|Biweekly application of EpiFix plus standard of care
10012995|NCT01657487|Experimental|Fluticasone/salmeterol high dose|COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)
10012996|NCT01657487|Active Comparator|Fluticasone/Salmeterol medium dose|COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)
10012997|NCT01657526|Experimental|Group A|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
10012998|NCT01657526|Placebo Comparator|Group B|Subjects in this group will receive placebo in Step 1 of the study
10012999|NCT01657526|Experimental|Group C|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
10013000|NCT01657526|Placebo Comparator|Group D|Subjects in this group will receive placebo in Step 2 of the study
10013001|NCT01657539|Experimental|Probiotics|Group of patients using yogurt containing probiotics during the experimental phase of the study.
10013002|NCT01657539|Placebo Comparator|Control Yogurt|Group of patients that will use a placebo yogurt for providing comparison with the experimental group.
10013003|NCT01657552|Experimental|Eltrombopag|Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.
10013004|NCT01657552|Experimental|Boceprevir|Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.
10013005|NCT01657552|Experimental|Telaprevir|Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.
10013006|NCT01657552|Experimental|Eltrombopag and Broceprevir|Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
10013007|NCT01657552|Experimental|Eltrombopag and Telaprevir|Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
10013008|NCT01657565||open appendectomy|
10013009|NCT01657565||laparscopic appendectomy|
10013010|NCT01657578|Experimental|neonates of less than 32 weeks gestational age|omeprazole
10013011|NCT01657578|Experimental|neonates born between 32 and 35 weeks of GA|omeprazole
10013012|NCT01657578|Experimental|neonates of more than 36 weeks of GA|omeprazole
10013013|NCT01657604|Experimental|Nilotinib+IFN|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with Peginterferon α2b at a starting target dose of 30μg/week.
10013014|NCT01657604|Active Comparator|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily.
10013015|NCT01657630||Accu-Chek Combo|15 type 1 young patients under 6 years old who begin to use the Accu-Chek Combo System
10013016|NCT01657643|Placebo Comparator|Placebo|Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
10013017|NCT01657643|Experimental|Probiotics|Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics [daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)]
10013018|NCT01657656|Experimental|Vitamin D group|Vitamin D supplement by Tishcon
10013019|NCT01657656|Placebo Comparator|Control group|Identically appearing capsules
10013020|NCT01657669|Other|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).
10013021|NCT01657682|Experimental|Cohort A - No prior FLT3 TKI exposure|Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
10013022|NCT01657682|Experimental|Cohort B - Prior therapy with FLT3 TKI|Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
10013023|NCT01657708|Other|Shared Desicion Making Model|
10013024|NCT01657721|No Intervention|Wait-list Control|"Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies.~After a 5-week period, participants in this arm will have access to the working memory training."
10013025|NCT01657721|Experimental|15 Minute Training|Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
10013026|NCT01657721|Experimental|30 Minute Training|Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
10013027|NCT01657734||HGG2003|"**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial~Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy)."
10013028|NCT01657734||HGG2010|"**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial~prospective double blind placebo controlled randomised clinical trial HGG-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy)."
10013029|NCT01657747|No Intervention|Not applicable (imaging study)|
10013030|NCT01657773||colorectal cancer, without nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
10013031|NCT01657773||colorectal cancer, with nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
10013032|NCT01657786|Experimental|Ondansetron administration group|
10013033|NCT01657812|Experimental|dexmedetomidine|Drug:dexmedetomidine,dexmedetomidine 1.0μg/kg intravenous injection within 15 minutes before the induction of general anesthesia and followed by Dex 0.4μg/kg/h until 40min before the end of surgery
10013034|NCT01657812|Active Comparator|epidural|Epidural:continuous epidural block (T8-9) 4 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery
10013035|NCT01657812|Placebo Comparator|control|Drug: normalsaline
10013036|NCT01657825|Experimental|Isavuconazole and warfarin|Isavuconazole three times daily (TID) for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20
10013037|NCT01657838|Experimental|Arm 1: isavuconazole only|Single dose of isavuconazole on Day 1
10013038|NCT01657838|Experimental|Arm 2: isavuconazole + ketoconazole|Single dose of isavuconazole on Day 4 and ketoconazole twice daily (BID) for 24 days
10013039|NCT01657851|Experimental|dutasteride/tamsulosin|The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.
10013040|NCT01657851|Active Comparator|dutasteride|Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
10013041|NCT01657851|Active Comparator|tamsulosin|Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia
10013042|NCT01657864||Patients with aseptic meningitis|All patients of the study population with a record/diagnosis of aseptic meningitis during the study period
10013043|NCT01657864||Patients without aseptic meningitis|All patients of the study population without a record/diagnosis of aseptic meningitis during the study period
10013044|NCT01657890|Experimental|Arm 1: Isavuconazole in healthy non-elderly male subjects|age 18 to 45 years
10013045|NCT01657890|Experimental|Arm 2: Isavuconazole in healthy non-elderly female subjects|age 18 to 45 years
10013046|NCT01657890|Experimental|Arm 3: Isavuconazole in healthy elderly male subjects|age 65 years and older
10013047|NCT01657890|Experimental|Arm 4: Isavuconazole in healthy elderly female subjects|age 65 years and older
10013048|NCT01657916||5 year sling implants|Patients who underwent implant of the Align Urethral Support System between June 2007 and December 2008
10013049|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given ID|
10013050|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given IM|
10013051|NCT01657929|Active Comparator|20 µg H5-VLP alone given ID|
9476759|NCT03568604|Experimental|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
9802541|NCT05176509|Experimental|Intervention/treatment|
9802542|NCT05175599|No Intervention|Land Birth|Women in the land birth group will labor and give birth according to standard of care procedures.
9802543|NCT05175599|Experimental|Water Birth|Women in the water birth group will give birth in the water. During the first stage of labor, women may enter or leave the water at any point.
10013052|NCT01657929|Active Comparator|20 µg H5-VLP + 1 mg Alhydrogel(R) given IM|
10013053|NCT01657929|Active Comparator|90 µg licensed H5N1 vaccine|
10013054|NCT01657942|Experimental|ExABlate MR Guided Focus Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
10013055|NCT01657955|Experimental|Bendamustine Hydrochloride Injection|d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.
10013056|NCT01657955|Active Comparator|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC<4×109 /L at d12-d14 );
10013057|NCT01657968||Acute tonsillitis|Patients with acute tonsillitis aged 15 to 40 years meeting at least two of Centors criteria.
10013058|NCT01657968||Healthy control patients|Control patients aged 15 to 40 years.
10013059|NCT01657513|Experimental|tnf-alfa treatment (infliximab, adalimumab, or etanercept)|This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
10013060|NCT01657981|Experimental|Treatment arm 1|
10013061|NCT01657994|Experimental|therapy plus fes|robotic gait training plus functional electrical stimulation
10013062|NCT01658007|Experimental|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leuk
10013063|NCT01658033|Experimental|Avastin + mFOLFOX6|Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
10013064|NCT01658046|Experimental|NMES group|10 weeks neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
10013065|NCT01658046|Sham Comparator|Control group|10 weeks sham neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
10013066|NCT01658085||Study group: HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
10013067|NCT01658085||Control group: ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
10013068|NCT01658098||4-6 weeks after delivery|all patients on their 4th-6th weeks after delivery
10013069|NCT01658111|Active Comparator|Traditional physiotherapy|Each subject will receive 4 weeks of traditional upper limb rehabilitation treatment (20 sessions, 5 days a week for 4 weeks).
10013070|NCT01658111|Experimental|Robot Group|Each subject will be asked to perform five sessions per week goal-directed, planar reaching tasks, which emphasizes shoulder and elbow movements, moving from the centre target to each of 8 peripheral targets equally spaced on a 0.14 m radius circumference around a centre target using the InMotion2 (IM2) system (20 sessions- 5 days a week for 4 weeks).
10013071|NCT01658124|Experimental|Tranexamic acid|(total dose 8 grams)
10013072|NCT01658124|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
10013073|NCT01658137|Active Comparator|Typical Western Diet|"The comparator dietary pattern (Typical Western Diet) approximates the inflammatory dietary pattern typically consumed by North Americans. It contains refined grains, processed foods, dairy fat, meats, sugar and high glycemic index foods, and few fruits, nuts, legumes, and vegetables. The fruits and vegetables are highly processed (e.g. juices) and lower in micronutrients than those in the intervention diet. The saturated fat content of this diet does not meet national guidelines for health. The polyunsaturated fat:saturated fat ratio is ~0.5 (low)."
10013074|NCT01658137|Experimental|Prudent Diet|"The experimental dietary pattern (Prudent Diet) is based on intakes of foods hypothesized to have beneficial effects on inflammation and long-term health. This dietary pattern includes micronutrient and macronutrient levels consistent with healthy eating in epidemiological studies and randomized controlled trials. The diet is constructed with low-fat dairy products, fish, chicken, and lean meats to minimize saturated fat and increase protein and calcium. The diet is rich in fruits, vegetables, whole grains, nuts, legumes, and seeds that are good sources of potassium, magnesium, and dietary fiber. This diet provides a 'favorable' macronutrient profile that is low in saturated fat, has a polyunsaturated/saturated fat ratio of ~1.0 (high), and low in high glycemic index carbohydrates."
10013075|NCT01658176|Experimental|PF-04691502 + Exemestane|PF-04691502 in combination with Exemestane
10013076|NCT01658176|Active Comparator|Exemestane|Exemestane alone
10013077|NCT01658202|Other|Sequence 1|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
10013078|NCT01658202|Other|Sequence 2|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
10013079|NCT01658215|Other|Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
10013080|NCT01658215|Other|Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
10013081|NCT01658241|Experimental|Single Arm Main population|
10013082|NCT01658254|Experimental|Survey by email|One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
10013083|NCT01658254|No Intervention|Non interventional arm|This arm will receive no intervention (no email with the survey)
10013084|NCT01658267|Experimental|Nutritional Supplement|Instructions and techniques to improve the quality of the diet to meet the child's daily nutritional requirements will be provided.
10013085|NCT01658280|Active Comparator|Conventional TBNA + ROSE|"Patients allocated in this group will undergo conventional TBNA, performed in a bronchoscopy suite by the same operator under conscious sedation, using 19-G needle size. Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.~In case of samples obtained from conventional TBNA defined as non diagnostic, the operator will shift to the EBUS procedure.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs"
10013086|NCT01658280|Experimental|EBUS-TBNA + ROSE|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
10013087|NCT01658306|Experimental|remote ischemic preconditioning|Receiving remote ischemic preconditioning (RIPC) treatment with pressure set at 200 mmHg.
10013088|NCT01658306|Sham Comparator|placebo remote ischemic preconditioning|Receiving sham RIPC treatment with pressure set at 50 mmHg
10013089|NCT01658319|Experimental|Treatment (chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days 1-5 and methoxyamine IV over 1 hour on day 1 (day 2 of course 1). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10013090|NCT01658332|Experimental|specific procedure|Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
10013091|NCT01658358|Experimental|Phase I part :Systemic Therapy|"Drug: Lapatinib~Drug: Lipo-Dox"
10013092|NCT01658358|Experimental|Phase II part|"Drug: Lapatinib~Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
10013093|NCT01658371||efavirenz|HIV patients on efavirenz
10013094|NCT01658384||cognitive evolution, observational,MS|multiple sclerosis tysabri treated patients
10013095|NCT01658397|Experimental|Fasting|Ten day fast
10013096|NCT01658410|Active Comparator|BQ-123|
10013097|NCT01658410|Placebo Comparator|NaCl|
10013098|NCT01658423||Junior high school student|All subjects participated in measurements of body composition, muscle strength and motor fitness
10013099|NCT01658449|Experimental|group A|
10013100|NCT01658449|Experimental|group B|
10035849|NCT01810198|Active Comparator|Invasive Coronary Angiography|Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography
10035850|NCT01810211|Experimental|Horizontal Adduction Stretch and Pendulums|"Horizontal Adduction Stretch- Individual standing with their operative scapula against a wall and rotating toward the side to be stretched to stabilize scapula and the operative arm is relaxed. The opposite hand is placed under the elbow of the involved extremity and assists the operative shoulder into horizontal adduction attempting to bring the hand to the opposite shoulder.~Pendulum -Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
10035851|NCT01810211|Experimental|Modified Sleeper Stretch and Pendulum|"Modified Sleeper Stretch: Individual in supine with operative shoulder abducted to approximately 45 degrees and elbow at 90 degrees of flexion with neutral rotation of the glenohumeral joint. The individual then places other hand on the wrist of the involved extremity and passively moves the glenohumeral joint into internal rotation.~Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
10035852|NCT01810211|No Intervention|Pendulum Exercise|Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction.
10035853|NCT01810224|Active Comparator|Angio-guided arm|In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.
10035854|NCT01810224|Experimental|FFR-guided arm|In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.
10035855|NCT01810237|Experimental|Dabigtran instead of LMWH for perioperative bridging.|
10035856|NCT01810250||Abdominal Aortic Aneurysm (Challenging anatomy)|Endovascular aneurysm repair
10035857|NCT01810276|Placebo Comparator|Saline|400 mL of Saline will be given intravenously over 2 hours once.
10035858|NCT01810276|Active Comparator|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
10035859|NCT01810315|No Intervention|Baseline|Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time.
10035860|NCT01810315|Experimental|TFV 1% Gel|"Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.~Premenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase. Postmenopausal women will undergo sampling after TFV gel use one time."
10013101|NCT01658462|Experimental|Arm A|Docetaxel + Nintedanib
10013102|NCT01658462|Active Comparator|Arm B|Docetaxel + increase of the dose
10013103|NCT01658475||periodontitis|those with periodontitis and those without periodontitis
10013104|NCT01658488|Other|Regular Rice|2 servings per day of non-fortified rice
10013105|NCT01658488|Other|Iron-fortified Rice|2 servings per day of Rice enriched in iron for women with iron-deficient anemia to restore their blood counts more efficiently than the standard rice not enriched with iron.
10013106|NCT01658527|Experimental|Orteronel, 300 mg twice daily|
10013107|NCT01658527|Active Comparator|Bicalutamide 50 mg per day|
10013108|NCT01658553|Experimental|GSK1120212 Qtc study|Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
10013109|NCT01658592|Experimental|NAC-VC Deep Brain Stimulation|The contractors located in NAc and VC are ON at the same time
10013110|NCT01658592|Sham Comparator|Placebo A|Stimulator setting is OFF
10013111|NCT01658592|Experimental|Placebo B|The contractor located in NAc is on
10013112|NCT01658592|Experimental|Placebo C|The contactor located in VC is on
10013113|NCT01658605|Experimental|GSK1605786|Administered orally for 16 weeks in a 2:1 ratio
10013114|NCT01658605|Placebo Comparator|Placebo|Administered orally for 16 weeks in a 2:1 ratio
10013115|NCT01658631||Anesthesia|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during the induction of anesthesia
10013116|NCT01658631||Intensive Care Unit patients|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during a passive legs raising test
10013117|NCT01658644|No Intervention|Group A|Patients participating in group A, will not be exposed to any interventions, they will partake in the typical hospital and communication experience.
10013118|NCT01658644|Experimental|Group B (text handout)|Patients assigned to group B will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will NOT be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
10013119|NCT01658644|Experimental|Group C (text & image handout)|Patients assigned to group C will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will also be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
10013120|NCT01658670|Active Comparator|Enhanced Usual Care (EUC) exercise group|The EUC group is provided paid access to the exercise facility and has access to regular facility staff for the 18 month study period.
10013121|NCT01658670|Experimental|HEART Camp (HC) Intervention group|The HC intervention group will be provided paid access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
10013122|NCT01658696|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
10013123|NCT01658696|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
10013124|NCT01658709||Ankle Injured|Volunteers with an ankle injury
10013125|NCT01658709||Healthy|Healthy Volunteers
10013126|NCT01658722||Observational|Long term follow-up
10013127|NCT01658748|Active Comparator|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will have stimulators turned on approximately 1 week after the 3-4 week post-surgery EEG telemetry session that determines safety parameters for stimulator settings. Subjects will be followed weekly for the next 12 weeks, with adjustments in stimulator settings according to prescribed protocol based on changes in rating scale scores (CAPS, CGI-I, ADIPS, LFIPS, HAMA, MADRS, YMRS).
10013128|NCT01658748|Sham Comparator|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
10013129|NCT01658761|Experimental|Myopic traction maculopathy|The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed.
10013130|NCT01658774|Active Comparator|Albendazole & Vitamin C|Anthelmintics. A single dose of Albendazole (400mg) at month 0 and single dose of Vitamin C (500 mg) at 3, 6, 9 and 12 months.
10013131|NCT01658774|Experimental|Albendazole|Anthelmintics. A single does of Albendazole (400mg) every three months for 12 months
10013132|NCT01658787||Endovascular aortic repair|Patients treated with Gore Endovascular Aortic Products.
10013133|NCT01658800|Experimental|VAX161C vaccine|Subjects will be injected into the arm on 2 occasions during the study, once on Day 0 and then again on Day 21 with the vaccine VAX161C
10013134|NCT01658852|Active Comparator|Metronidazole|active drug: metronidazole 500mg three time per day for 10 days
10013135|NCT01658852|Placebo Comparator|Placebo|Placebo three times per day for 10days
10013136|NCT01658865||Transnasal endoscopy|Healthy volunteers and patients with esophageal motor symptom will be enrolled and esophageal motility assessed by transnasal endoscopy according to clinical and manometric diagnosis
10013137|NCT01658878|Experimental|Non-infected: Nivolumab|Nivolumab intravenous solution on specific days
10013138|NCT01658878|Experimental|HCV-infected: Nivolumab|Nivolumab intravenous solution on specific days
10013139|NCT01658878|Experimental|HBV-infected: Nivolumab|Nivolumab intravenous solution on specific days
10013140|NCT01658878|Experimental|Nivolumab|Nivolumab intravenous solution on specific days
10013141|NCT01658878|Active Comparator|Sorafenib|Sorafenib tablets on specific days
10013142|NCT01658878|Experimental|Nivolumab plus Ipilimumab Combination|Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
10013143|NCT01658878|Experimental|Child-Pugh B|Nivolumab intravenous solution on specific days
10013144|NCT01658878|Experimental|Nivolumab plus Cabozantinib Combination|Nivolumab intravenous solution + cabozantinib oral tablets on specific days
10013145|NCT01658878|Experimental|Nivolumab plus Ipilimumab plus Cabozantinib|Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
10013146|NCT01658891|Experimental|CHF 1535 50/6 µg|
10013147|NCT01658891|Active Comparator|beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|
10013148|NCT01658956|Experimental|Subcutaneous GCSF 5 µg/kg days 8 and 12|Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
10013149|NCT01658956|No Intervention|No intervention|
10013150|NCT01658982||cirrhotic patients|cardiopulmonary exercise testing
10013151|NCT01659008|Experimental|estradiol|estradiol PO 0.5mg 2 tabs three times a day for 2 days
10013152|NCT01659008|Experimental|Lysteda|Lysteda 650mg PO 2 tabs three times a day for 2 days
10013153|NCT01659034|Experimental|Thienopyridine|Thienopyridine treatment for 3 months after implantation of everolimus-eluting Stents
10013154|NCT01659047|Experimental|GS-1101|GS-1101 (oral; 150 mg BID)
10013155|NCT01659060|Experimental|Dark chocolate|
10013156|NCT01659060|Placebo Comparator|Placebo chocolate|
10013157|NCT01659073|Experimental|Caloric Vestibular Stimulation|Caloric vestibular stimulation performed by a modified stethescope ear attachment attached to an MRI compatible infusion pump.
10013158|NCT01659086|Experimental|Group A|Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo
10013159|NCT01659086|Experimental|Group B|Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo
10013160|NCT01659086|Experimental|Group C|Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo
10013161|NCT01659086|Experimental|Group D|Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo
10013162|NCT01659086|Experimental|Group E|Subjects will receive the investigational vaccine GSK2654909A and placebo
10013163|NCT01659086|Experimental|Group F|Subjects will receive the investigational vaccine GSK2654911A formulation 5
10013164|NCT01659086|Experimental|Group G|Subjects will receive the investigational vaccine GSK2654911A formulation 6
10013165|NCT01659086|Experimental|Group H|Subjects will receive the investigational vaccine GSK2654911A formulation 7
10013166|NCT01659086|Experimental|Group I|Subjects will receive the investigational vaccine GSK2654911A formulation 8
10013167|NCT01659086|Experimental|Group J|Subjects will receive the investigational vaccine GSK2654909A
10013168|NCT01659086|Placebo Comparator|Placebo Group|Subjects will receive Placebo
10013169|NCT01659099|Experimental|GA101|GA101 - Chemotherapy (ACVBP or CHOP)
10013170|NCT01659099|Active Comparator|Rituximab|Rituximab - Chemotherapy (ACVBP or CHOP)
10013171|NCT01659112|Experimental|Stabilization Group|A core stabilization plus traditional upper extremity rehabilitation approach was performed.
10013172|NCT01659112|Active Comparator|Control Group|A traditional upper extremity rehabilitation-only approach was performed.
10013173|NCT01659164|Experimental|Group treatment (uncontrolled)|Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
10013174|NCT01659177|Experimental|LY2140023 fasting|Single oral dose of 80 mg LY2140023 given in fasted state
10013175|NCT01659177|Experimental|LY2140023 + food|Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
10013176|NCT01659190|Experimental|Oiled-limestone liniment|the removal of the collecting bag is made with the Oiled-limestone liniment.
10013177|NCT01659190|No Intervention|without Oiled-limestone liniment|the removal of the collecting bag is made without any special precautions
10013178|NCT01659203|Experimental|Treatment Arm IMPT|IG-IMPT with SIB to the high risk margin
10013179|NCT01659203|Experimental|Treatment Arm IMRT|IG IMRT with SIB to the high risk margin
10013180|NCT01659216||patients improved by EPNS; follow-up|Ninety female UFS patients with ≥50% symptom improvement at the end of EPNS treatment (Jul. 2001 to Jun. 2005) were followed up by a telephone questionnaire for at least 5 years.
9802544|NCT05174650|Experimental|Combined treatment with Atezolizumab and Derazantinib|Treatment with Atezolizumab 1200 mg i.v. every 3 weeks and Derazantinib 300 mp p.o. once daily for a maximum of 96 weeks or until disease progression or unacceptable toxicity or study termination
9802545|NCT05173389|Other|Group 1|TechnoBody
10013181|NCT01659229||PFC CR 150 total knee implant|Study group implant: PFC CR 150 Control group implant: PFC CR standard
10013182|NCT01659229||PFC CR Standard|study group implant: PFC CR 150 control group implant: PFC CR Standard
10013183|NCT01659242|Active Comparator|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
10013184|NCT01659242|Active Comparator|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
10013185|NCT01659281|Active Comparator|1|2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours
10013186|NCT01659281|Active Comparator|2|3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours
10013187|NCT01659294|Experimental|nurse case management|nurse case management of diabetic variables
10013188|NCT01659294|Active Comparator|standard diabetologist care|standard diabetologist care
10013189|NCT01659307|Active Comparator|Aspirin 75mg|Aspirin 75mg once daily for 7 days. Administered by mouth.
10013190|NCT01659307|Active Comparator|Aspirin 1200mg|Asprin 600mg twice daily for 7 days. Administered by mouth.
10013191|NCT01659307|Placebo Comparator|Lactose powder|Placebo for 7 days. Administered by mouth.
10013192|NCT01659333||Peritoneal dialysis, hypervolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
10013193|NCT01659333||Peritoneal dialysis, normovolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
9476760|NCT03568591|Experimental|Intervention Group (Treatment)|A treatment group cohort who have self-referred for the psychosensory therapy intervention (Havening Techniques).
9802546|NCT05173389|Other|Group 2|Thera Trainer
9802547|NCT05172024||Participants with SARS-CoV-2 Infection|
9802548|NCT05172024||Participants without SARS-CoV-2 Infection|
10013194|NCT01659346|Experimental|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication
10013195|NCT01659346|Active Comparator|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
10013196|NCT01659359|Experimental|virtual reality glasses and Lidocaine|virtual reality glasses and 5 ml Lidocaine 2%
10013197|NCT01659359|Experimental|Lidocaine|5 cc Lidocaine2%
10013198|NCT01659372|Experimental|Low level laser therapy|this arm recieves low level laser therapy treatment for 12 sessions.
10013199|NCT01659372|Experimental|naproxen|this arm takes naproxen 500 mg twice daily for 3weeks
10013200|NCT01659398|Experimental|Enhanced external counterpulsation (EECP)|
10013201|NCT01659398|No Intervention|Subjects not receiving EECP|Control group to measure data from experimental group against.
10013202|NCT01659411||Adult CHD Patients|observational
10013203|NCT01659424|Other|Single Arm|This is a single arm study.
10013204|NCT01659437|Active Comparator|SR8|Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
10013205|NCT01659437|Experimental|CR8|Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks
10013206|NCT01659450|Experimental|Low energy dense|Diet of the LED group contained 30%fat, 15% protein and 55% carbohydrate. Most of the consumed carbohydrates in the LED diet group were fruits, vegetables and whole grains. In addition, this group received more servings of vegetables groups daily in the form of liquid diets or some menus contain more vegetables
10013207|NCT01659450|Experimental|control|In the group with a control diet, 35% of the energy was provided by fat, 15% by protein and 50% by carbohydrate
10013208|NCT01659463|Experimental|ICON - low viscosity resin|APPLICATION OF A LOW VISCOSITY RESIN IN EARLY PROXIMAL CARIES LESIONS
10013209|NCT01659463|Active Comparator|INSTRUCTIONS ORAL HYGIENE|INSTRUCTION ORAL HYGIENE AND DIET AND TOOPICAL FLUORIDE APPLICATIONS
10013210|NCT01659476|Experimental|Asthma|Individuals diagnosed with asthma.
10013211|NCT01659476|Experimental|Cough Variant Asthma|Individuals diagnosed with cough variant asthma.
10013212|NCT01659476|Experimental|Mch-induced cough w/normal airway sensitivity|Individuals with chronic cough normal PC20 MCh(>16 mg/mL) & who cough during Mch challenge testing.
10013213|NCT01659476|Experimental|Normal|Individuals with no history of asthma or chronic cough
10013214|NCT01659489||women undergoing laproscopy fo rsuspected adnexal torsion|
10013215|NCT01659502|Experimental|TL-118 alone or with pancreas cancer chemotherapy|
10013216|NCT01659541|Experimental|Procedure & Device|Procedure/Surgery: Implantation of device; Device: Expiratory Muscle Stimulator
10013217|NCT01659580|Experimental|T89 high dose|T89 225mg bid
10013218|NCT01659580|Experimental|T89 low dose|T89 150mg bid
10013219|NCT01659580|Experimental|Sanqi+Bingpian|225mg bid
10013220|NCT01659580|Placebo Comparator|Placebo|225mg bid
10013221|NCT01659593|Experimental|procog|cognitive remedial program 13 sessions over a 6-month period
10013222|NCT01659593|Placebo Comparator|DISINT|Interactive discussion program of 13 group sessions in a 6-month period
10013223|NCT01659619|Experimental|erythromycin|
10013224|NCT01659619|No Intervention|saline|
10013225|NCT01659645|Experimental|FACBC|
10013226|NCT01659671|Active Comparator|Uvulopalatopharyngoplasty|One arm is Uvulopalatopharyngoplasty(intervention group of 32 patients), one arm is expectancy (control group of 33 patients). After six months the controls have delayed surgery and then both groups are followed for two years
10013227|NCT01659671|Active Comparator|Control|After six months the controls have delayed surgery then are followed for 2 year
10013228|NCT01659684|Experimental|standard intravenous immunoglobulin|Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.
10013229|NCT01659697||Intensive Lifestyle counseling|
10013230|NCT01659697||usual lifestyle counseling|
10013231|NCT01659710||Study Babies|Study video at 50-55 weeks gestational age, motor assessments at 24m (+/- 6 months) and again at 4 years (+/- 1 year).
10013232|NCT01659710||Control Babies|Video at 50-55 weeks gestational age, motor assessment at 24 months (+/- 6 months).
10013233|NCT01659723|Active Comparator|A - Immediate start|Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
10013234|NCT01659723|No Intervention|B - delayed start|Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
10013235|NCT01659762|Experimental|autologous mesenchymal stromal cells|
10013236|NCT01659775|Experimental|Sancuso patch|
10013237|NCT01659775|Active Comparator|Zofran|
10013238|NCT01659788|Experimental|Coenzyme Q10 concomitant treatment|"Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment~Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.~Other name: Ubiquinone"
10013239|NCT01659788|Placebo Comparator|Placebo|1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
10013240|NCT01659814||Individuals with Major Depressive Disorder|
10013241|NCT01659814||Healthy Control Individuals|
10013242|NCT01659827|Sham Comparator|Control|Initial injections of Marcaine and Saline (one each)
10013243|NCT01659827|Experimental|0.5cc AmnioFix Injectable|Initial injections of Marcaine and 0.5cc AmnioFix (one each)
10013244|NCT01659827|Experimental|1.25cc AmnioFix Injectable|Initial injections of Marcaine and 1.25cc AmnioFix (one each)
10013245|NCT01659840|Other|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
10013246|NCT01659840|Other|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
10013247|NCT01659879|Experimental|multimedia information|Health information concerning the child's diagnosis, treatment and recovery time after evaluation by the pediatrician, using a 15 minutes long standardized health information package with multimedia elements from the Norwegian website www.syktbarn.no (English version: www.childhealthguide.com)
10013248|NCT01659879|Active Comparator|verbal information|Verbal health information by a nurse in the acute ward concerning the child's diagnosis, treatment and recovery time, after the evaluation by the pediatrician
10013249|NCT01659892|Active Comparator|Montelukast|5 mg Chewable Tablet
10013250|NCT01659892|Active Comparator|Singulair|5 mg Chewable Tablet
10013251|NCT01659905|Active Comparator|Montelukast|5 mg Chewable Tablet
10013252|NCT01659905|Active Comparator|Singulair|5 mg Chewable Tablet
10013253|NCT01659918|Active Comparator|Montelukast|10 mg Tablet
10013254|NCT01659918|Active Comparator|Singulair|10 mg Tablet
10013255|NCT01659931|Active Comparator|Montelukast|10 mg Tablet
10013256|NCT01659931|Active Comparator|Singulair|10 mg Tablet
10013257|NCT01659944|Experimental|Metoprolol alone then eliglustat + metoprolol|In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
10013258|NCT01659957|Experimental|Group Couples Couseling|Patients randomized to this arm will receive group couples counseling plus 12-step oriented alcoholism counseling.
10013259|NCT01659957|Experimental|One-on-One Couples Couseling|Patients randomized to this arm will receive one-on-one couples counseling plus 12-step oriented alcoholism counseling.
10013260|NCT01659970||Cohort|
10013261|NCT01659983|Experimental|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
10013262|NCT01659983|Active Comparator|Delayed primary wound closure|A wound will be left open with saline-soaked gauze packing after the operative procedure and will be sutured around day 3 to 7 after operation
10013263|NCT01660009|Experimental|Hypoglycemia First|Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
10013264|NCT01660009|Experimental|Euglycemia First|Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
10013265|NCT01660048|Experimental|SILS TEP repair|Half of the patients will undergo laparoscopic total extraperitoneal inguinal hernia repair using a single port (Triport)
10013266|NCT01660048|Active Comparator|Multiports TEP repair|Half of the patients will undergo the conventional multiports total extraperitoneal inguinal hernia repair
10013267|NCT01660061||APS patients|Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
10013268|NCT01660061||Controls|Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
10013269|NCT01660074|Experimental|Test food, reference food|Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
10013270|NCT01660100|Active Comparator|Pulmonary vein antrum isolation (PVAI)|Pulmonary vein antrum isolation (PVAI)
9802549|NCT05171907|No Intervention|Control Group|Patients into the control group will receive the same assessments as patients in the intervention group, for the same time (in 1th, 8th, 24, and 48 weeks), but they will not receive nutritional teleconsultation.
10013271|NCT01660100|Active Comparator|PVAI plus left atrial posterior wall (LAPW) isolation|PVAI plus left atrial posterior wall (LAPW) isolation
10013272|NCT01660126|Active Comparator|Levothyroxine|Oral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
10013273|NCT01660126|Placebo Comparator|Placebo|Matched placebo
10013274|NCT01660139||Dermatology Clinic Patients|Patient attending dermatology clinics
10013275|NCT01660139||Primary Clinic Patients|Patient attending primary care clinics
10013276|NCT01660152|Experimental|Group A (vacuum therapy, holding erection for 2 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
10013277|NCT01660152|Experimental|Group B (vacuum therapy, holding erection for 5 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
10013278|NCT01660165||Observational|Pregnant women
10013279|NCT01660204|Active Comparator|Betalactam monotherapy|Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone
10013280|NCT01660204|Active Comparator|Betalactam combination with macrolide|Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin
10013281|NCT01660204|Active Comparator|Quinolone monotherapy|Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin
10035861|NCT01810315|Experimental|Estradiol Vaginal Cream|Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night
10035862|NCT01810315|Experimental|TFV 1% gel and estradiol cream|Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel. In addition, participants will one gram of estradiol cream into the vagina every other night.
10035863|NCT01810328|Active Comparator|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
10035864|NCT01810328|Active Comparator|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
10035865|NCT01810341||Development Group|In the Development Phase, analyses will be performed until the classification algorithm is finalized.
10035866|NCT01810341||Validation Group|The Validation Phase will assess the performance of the finalized classification algorithm in 300 subjects.
10035867|NCT01810354|Experimental|Two grams cefazolin|Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
10035868|NCT01810354|Active Comparator|Three grams cefazolin|Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
10035869|NCT01810367|Experimental|ABX Combined With Cisplatin|ABX，100mg/m2，d1、8、15，ivgtt,in 30 min，28day one cycle； cisplin 75mg/m2 d1 ivgtt
10035870|NCT01810367|Active Comparator|Gemcitabine Combined With Cisplatin|gemcitabine 1000mg/m2，d1、8；cisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle.
10035871|NCT01810393|Experimental|Trastuzumab IV Then Trastuzumab SC|Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
10035872|NCT01810393|Experimental|Trastuzumab SC Then Trastuzumab IV|Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
10035873|NCT01810406|Experimental|Epidural Volume Extension|CSE with 10 ml EVE
10035874|NCT01810406|Active Comparator|No Epidural Volume Extension|CSE without EVE
10035875|NCT01810419|Experimental|normal and various degrees splenomegaly|"Vscan Ultrasound (GE Healthcare, USA) Conventional Ultrasound (Ultrasonix) used to determine spleen size Crossover design, all subjects will be measured with both devices. half will have the handheld done first, then conventional half the Conventional done first, then handheld~Will complete questionaire for both:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
10035876|NCT01810445||1|Patients undergoing a surgical bladder procedure in the main O.R.
10035877|NCT01810458||AATD ZZ and Rare Alleles Group|Participants will get a history and physical (H&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.
10035878|NCT01810471|Experimental|ankle supports|
10013282|NCT01660217|Experimental|Initial Verbal Instruction Group|"The group who initially received only verbal instruction, and then later (in the crossover portion) received a written Eczema Action Plan (EAP)"
10013283|NCT01660217|Experimental|Written Eczema Action Plan (EAP)|The group given a written EAP after verbal instruction
10013284|NCT01660295|Experimental|Certoparin control|Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.
10013285|NCT01660295|Experimental|Certoparin Renal|"Participants receive dose escalation upon medical criteria qualification at each period:~Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4."
10013286|NCT01660308||Tumor induced osteomalcia|
10013287|NCT01660347|Experimental|Supportive care (allogeneic PBSCT boost)|Patients undergo allogeneic PBSCT boost from cells selected for CD34+ using the CliniMACS CD34 Reagent System.
10013288|NCT01660360|Experimental|Tanibirumab|The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
10013289|NCT01660373|Experimental|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
10013290|NCT01660373|Active Comparator|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
10013291|NCT01660386|Experimental|Sitagliptin|the subjects are asked to take one pill of sitagliptin(100mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
10013292|NCT01660386|Experimental|Saxagliptin|the subjects are asked to take one pill of saxagliptin(5mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
10013293|NCT01660386|Experimental|Glimepiride|the subjects are asked to take one pill of glimepiride(2mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
10013294|NCT01660386|Other|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
10013295|NCT01660399|Experimental|Docetaxel/Boanmycin|Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
10013296|NCT01660399|Placebo Comparator|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1, 21days a cycle.
10013297|NCT01660425|No Intervention|treatment as usual with MPH|In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
10013298|NCT01660425|Active Comparator|Psychosocial intervention|Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
10013299|NCT01660438||Stress urinary incontinence|Stress urinary incontinence
10013300|NCT01660464|Experimental|ADHD-Team|Intervention
10013301|NCT01660477|Experimental|Arm 1: isavuconazole only|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13
10013302|NCT01660477|Experimental|Arm 2 : LPV/RTV only|Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13
10013303|NCT01660477|Experimental|Arm 3: isavuconazole and LPV/RTV|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir twice daily (BID) on Days 1-13
10013304|NCT01660490||Proximal femur fractures with ORIF|Proximal femur fractures treated with ORIF
10013305|NCT01660503|Placebo Comparator|No SCF|Twice daily consumption of snack foods containing no SCF.
10013306|NCT01660503|Experimental|10 grams SCF|Twice daily consumption of snack foods, each containing 5 grams SCF
10013307|NCT01660503|Experimental|20 grams SCF|Twice daily consumption of snack foods, each containing 10 grams SCF
10013308|NCT01660516||Tea|Black tea ingestion
9476761|NCT03568591|No Intervention|Control Group (Waiting List)|Self-referral waiting list cohort (usual care).
10013309|NCT01660529|Experimental|hTERT/Survivin Multi-Peptide Vaccination|single-arm Phase I study for patients with metastatic breast cancer who have failed at least one regimen for metastatic disease
10013310|NCT01660542|Experimental|doxorubicin/cyclophosphamide|Neoadjuvant Chemotherapy with Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide
10013311|NCT01660555||Patiënts scheduled for colonoscopy|Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale <3
10013312|NCT01660568||relapsed or refractory NK/T cell lymphoma with gemcitabine|
10013313|NCT01660581|Experimental|CD133+|intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow
10013314|NCT01660581|Placebo Comparator|Placebo|intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum
10013315|NCT01660594||Stable chest pain|All patients presenting with stable chest pain and referred by their general practitioners to the chest pain clinic in the hospital who had CT calcium scoring performed besides standard assessment.
10013316|NCT01660607|Experimental|Dose escalation|For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
10013317|NCT01660620|Experimental|betaxolol|betaxolol 0.25% 2 per day for 3 weeks
10013318|NCT01660620|Placebo Comparator|placebo|masked labeling also 2 per day administration
10013319|NCT01660646|Other|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
10013320|NCT01660646|No Intervention|control|
10013321|NCT01660659|Experimental|cooking with Biomass Briquettes and Rocket Stove|cooking with Biomass Briquettes and Rocket Stove
10013322|NCT01660659|No Intervention|standard cooking|standard way of cooking
10013323|NCT01660685|Experimental|Tracking + Journaling + Website|In addition to standard care, participants will complete daily tracking and journaling and receive weekly feedback based on their individual entries.
10013324|NCT01660685|Active Comparator|Enhanced Usual Care|Participants receive standard care
10013325|NCT01660724|Experimental|Ultrasound guided arterial puncture|Patients randomised to the this arm has arterial puncture performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
10013326|NCT01660724|Active Comparator|Conventional arterial puncture technique|Patients randomised to the active comparator arm has arterial puncture performed using the conventional technique
10013327|NCT01660750|Experimental|Carfilzomib, Cyclophosphamide, Dexamethasone|All eligible subjects will receive Carfilzomib, Cyclophosphamide, and Dexamethasone.
10013328|NCT01660776||DLBCL (diffuse large B-cell lymphoma)|DLBCL (diffuse large B-cell lymphoma)
10013329|NCT01660776||Hodgkin's lymphoma|Hodgkin's lymphoma
10013330|NCT01660776||metastatic breast cancer|metastatic breast cancer or with lymph node involvement
10013331|NCT01660776||immune thrombocytopenia (ITP)|immune thrombocytopenia (ITP)
10013332|NCT01660776||healthy volunteers|healthy volunteers
10013333|NCT01660776||non-small cell lung cancer|non-small cell lung cancer
10013334|NCT01660789|Other|Lifestyle intervention|Lifestyle intervention.
10013335|NCT01660828|Active Comparator|Intensive cycling test preceded by RIPC|Intensive cycling test preceded by a RIPC protocol.
10013336|NCT01660828|No Intervention|No intervention/ RIPC|Intensive cycling test not preceded by a RIPC protocol.
10013337|NCT01660841|Experimental|Arm 1|
10013338|NCT01660854|Experimental|Heterologous challenge|"Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge.~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
10013339|NCT01660854|Active Comparator|Challenge control|"Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135).~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
10013340|NCT01660867|Placebo Comparator|0.9% saline + oral placebo|nebulized epinephrine + 0.9% saline + placebo => epinephrine + 0.9% saline
10013341|NCT01660867|Experimental|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
10013342|NCT01660867|Active Comparator|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
10013343|NCT01660880||aripiprazole|Patient group who is treated with aripiprazole
10013344|NCT01660919|Placebo Comparator|placebo|placebo
10013345|NCT01660919|Active Comparator|rosuvastatin 5|rosuvastatin 5 mg
10013346|NCT01660919|Active Comparator|rosuvastatin 10|rosuvastatin 10 mg
10013347|NCT01660919|Active Comparator|rosuvastatin 20|rosuvastatin 20 mg
10013348|NCT01660932|Placebo Comparator|placebo|placebo
10013349|NCT01660932|Active Comparator|omega 1|omega 1 gm
10013350|NCT01660932|Active Comparator|omega 2|omega 2 gm
10013351|NCT01660932|Active Comparator|omega 4|omega 4 gm
10013352|NCT01660945|Placebo Comparator|placebo|placebo
10013353|NCT01660945|Active Comparator|vytorin 10|vytorin 10 mg
10013354|NCT01660945|Active Comparator|vytorin 20|vytorin 20 mg
10013355|NCT01660958|Experimental|Infants: MNP|• Infants will receive sachets of multiple micronutrient powder (MNP) vs. placebo.
10013356|NCT01660958|Experimental|Infants: Early Learning|• Infant will receive early learning messages delivered in the home by village level workers vs. routine care.
10035879|NCT01810497|Active Comparator|Seven-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for seven days after otoplasty
10013357|NCT01660958|No Intervention|Infants: No intervention|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Infant phase. Routine care - no early learning intervention"
10013358|NCT01660958|Experimental|Infants: MNP/Early Learning|"Infants receive the MNP plus early learning intervention by receiving MNP sachets~Caregivers receive early learning messaged delivered at home biweekly for one year"
10013359|NCT01660958|Experimental|Preschoolers:MNP/High qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
10013360|NCT01660958|No Intervention|Preschoolers:Placebo/High qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
10013361|NCT01660958|Experimental|Preschoolers:MNP/Low qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
10013362|NCT01660958|No Intervention|Preschoolers:Placebo/Low qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
10013363|NCT01661075||mTBI|These individuals will have had an mTBI during their respective collegiate athletic season.
10013364|NCT01661075||healthy controls|Recruitment of healthy controls who have not suffered an mTBI for balancing testing.
10013365|NCT01661101|Experimental|Dabigatran|Dabigatran 110 mg capsule taken twice daily
10013366|NCT01661101|Experimental|Omeprazole|Omeprazole 20 mg capsule taken once daily
10013367|NCT01661101|Placebo Comparator|Placebo (dabigatran)|Dabigatran placebo taken twice daily
10013368|NCT01661101|Placebo Comparator|Placebo (omeprazole)|Omeprazole placebo taken once daily
10013369|NCT01661153||Cohort|
10013370|NCT01661192|Experimental|AAT( Alpha 1 Antitrypsin)|Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.
10013371|NCT01661192|No Intervention|Follow up group|Subjects who have not maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L or subjects with peak stimulated C -peptide secretion ≥ 0.2nmol/L who are reluctant to receive additional study drug, will be followed up only with no administration of investigational product
9476762|NCT03568578|Active Comparator|Entecavir Group|Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.
10013372|NCT01661218||complications|catheter-related venous thrombosis catheter-related infections
10013373|NCT01661231|Experimental|Investigational Stents|Device: Astron/Pulsar-18 Stents Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
10013374|NCT01661244|Experimental|Part A - Single dose escalation|
10013375|NCT01661244|Experimental|Part B - 14 day repeat dose escalation|
10013376|NCT01661257|Experimental|TIM-3|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
10013377|NCT01661296|Active Comparator|Sodium stibogluconate|Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
10013378|NCT01661296|Active Comparator|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
10013379|NCT01661309|Placebo Comparator|Inactive lozenge|Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
10013380|NCT01661309|Experimental|Methylcobalamin|Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
10013381|NCT01661322|Active Comparator|Intensive antiplatelet therapy|Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
10013382|NCT01661322|No Intervention|Guideline antiplatelet therapy|This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.
10035880|NCT01810497|Active Comparator|Thirty-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for thirty days after otoplasty
10037303|NCT01823848|Active Comparator|Sodium phosphate enema|Administration of sodium phosphate (fleets) enema for functional constipation in children ages 4-12 years Age 4-5: 33ml per rectum Age 5-12: 66ml per rectum
10013383|NCT01661335|Experimental|Ondansetron, dexamethasone, aprepitant|Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
10013384|NCT01661335|Placebo Comparator|Ondansetron, Dexamethasone, placebo|Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
10013385|NCT01661348||Prevena System placement|Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).
10013386|NCT01661348||Standard of care postoperative care|Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).
10013387|NCT01661361||vancomycin cohort|
10013388|NCT01661374||Mechanically Ventilated|
10013389|NCT01661374||Chronic obstructive pulmonary disease (COPD).|
10013390|NCT01661387||Plenadren|Modified release hydrocortisone
10013391|NCT01661387||Other Glucocorticoid Replacement Therapy|
10013392|NCT01661413||Acute Leukemia|Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
10013393|NCT01661426|Active Comparator|Low-Carbohydrate Diet first, then Low-Fat Diet (IR)|Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
10013394|NCT01661426|Active Comparator|Low-Fat Diet first, then Low-Carbohydrate Diet (IS)|Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
10013395|NCT01661439||Low molecular weight heparin|SC LMWH IN patients with recurrent pregnancy loss
10013396|NCT01661452||patients in UAB ER,|
10013397|NCT01661478||Emergency Department personnel|survey
10013398|NCT01661478||Department of Psychiatry personnel|survey
10013399|NCT01661504|No Intervention|Referral Card Only|Women participants at control clinics will be given a referral card containing general information on IPV and a list of resources specific to their community
10013400|NCT01661504|Experimental|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions at 3 months post-baseline / initial counseling
10013401|NCT01661517|Experimental|Lifestyle Counseling|motivational interviewer
10013402|NCT01661530|Experimental|Vitamin E enhanced diet|Range of three vitamin E enhanced soups (400g/tin) containing 18-20mg vitamin in natural food form. Three portions per week
10013403|NCT01661530|Placebo Comparator|Non-enhanced dietary intervention|Range of three similar looking and tasting soups (400g/tin) with naturally low (<3mg) vitamin E content. Three portions per week
10013404|NCT01661543|Experimental|Bean consumption to lower cholesterol|This arm will consume 90 grams of beans per day for 5 out of 7 days for 6 weeks.
10013405|NCT01661543|Placebo Comparator|Control (rice) consumed to show results|The control group will consume 90 grams of rice per day for 5 out of 7 days for 6 weeks.
9476763|NCT03568578|Experimental|Entecavir and Anluohuaxian Group|Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.
9665217|NCT05130983|Experimental|15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46|Arm 1: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).
10013406|NCT01661543|Experimental|Peas consumed to lower cholesterol|This arm will consume 90g of peas per day for 5 days out of each week for 6 weeks.
10013407|NCT01661556|Experimental|Miconazole|OTC topical prescription used for fungal treatment that can be useful to the treatment of melasma due to its depigmenting properties.
10013408|NCT01661556|Active Comparator|Hydroquinone|Hydroquinone 4% cream (Topical use) a depigmenting agent used as reference will be used as control. It will be applied twice a day for 9 weeks.
10013409|NCT01661556|Placebo Comparator|Placebo|Moisturizer cream without pharmacological effects will be used as a control.
10013410|NCT01661569|Experimental|Headspace On-the-go app|Participants were given access to a 45-day mindfulness meditation programme via the Headspace smartphone app
10013411|NCT01661569|No Intervention|Waitlist control|Participants will be asked to wait for 8 weeks before starting the intervention
10013412|NCT01661582|Placebo Comparator|Filtered Air Exposure|Subjects will be exposed to filtered air for 1 hour during intermittent exercise in a purpose-built exposure facility
10013413|NCT01661582|Experimental|Dilute Diesel Exhaust Exposure|Subjects will be exposed to dilute diesel exhaust (~300 mcg/m3) for 1 hour during intermittent exercise in a purpose-built exposure facility
10013414|NCT01661608|Experimental|EOS|Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures
10013415|NCT01661647|Experimental|3D knee kinematic assessment|3D knee kinematic assessment under local anesthesia
10013416|NCT01661660|Active Comparator|Control subjects|Control subjects were people with memory complaints coming for a consultation and prevention.
10013417|NCT01661660|Experimental|Predementia / MCI patients|Subjects at predementia stage or MCI stage
10013418|NCT01661660|Experimental|Dementia patient|Subjects at demential stage
10013419|NCT01661673|Experimental|Arm 1|10 mg EVP-0962 Orally administered once daily for 14 days
10013420|NCT01661673|Experimental|Arm 2|50 mg EVP-0962 Orally administered once daily for 14 days
10013421|NCT01661673|Experimental|Arm 3|100 mg EVP-0962 Orally administered once daily for 14 days
10013422|NCT01661673|Experimental|Arm 4|200 mg EVP-0962 Orally administered once daily for 14 days
10013423|NCT01661673|Placebo Comparator|Arm 5|Placebo orally administered for 14 days
10013424|NCT01661699||Sleep apnea|Those suspected of sleep apnea and scheduled for polysomnography and treated with CPAP therapy.
10013425|NCT01661725|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5ml/ vial
10013426|NCT01661738|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5 ml/ vial
10013427|NCT01661751|Experimental|ACYW135 Meningococcal Vaccine|0.5 ml/ dose, containing 50 μg of each antigen; lot No.: 20040601, manufacturing date: June 9, 2004 and the expiration date: till June 2006
10013428|NCT01661751|Active Comparator|A+C Meningococcal Vaccine|0.5 ml/ dose; each ampoule or dose contains 100 μg (one single human dose) and 50 μg of each antigen; lot No.: 20050805 and the expiration date: Aug. 24, 2007
10013429|NCT01661777|Other|Nasal steroid and Antihistamine|Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
10013430|NCT01661777|Active Comparator|Myringotomy tubes|Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
10013431|NCT01661777|Active Comparator|Low salt diet and diuretic|Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
10013432|NCT01661803||group-A and group-B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
10013433|NCT01661803||group-A and group--B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
10013434|NCT01661816||Within chemotherapy|30 couples, interviewed within chemotherapy (6 to 8 months after diagnosis)
10013435|NCT01661816||within Herceptin|30 couples, within herceptin treatment (the first year after diagnosis)
10013436|NCT01661816||within hormonotherapy|30 couples, within hormonotherapy (between 2 and 7 years after diagnosis)
10013437|NCT01661816||without hormonotherapy|30 couples, did not received hormonotherapy (1 year after diagnosis)
10013438|NCT01661816||end of treatment|30 couples, after end of treatments for patients who did received hormonotherapy (7 years after diagnosis)
10013439|NCT01661829||Biofeedback|Patients will undergo biofeedback therapy between 1st adjuvant chemotherapy and stoma closure(= after 3rd ajduvant chemotherapy)
10013440|NCT01661829||Kegel|Patients will be trained to take excersise for their anal sphincter by Kegel.
10013441|NCT01661842|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 96 study visit."
10013442|NCT01661842|Experimental|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
10013443|NCT01661855|Active Comparator|Riluzole|
10013444|NCT01661855|Placebo Comparator|Placebo|
10013445|NCT01661868|Active Comparator|PARP Inhibitor Naive|Patients with no prior PARP inhibitor treatment
10013446|NCT01661868|Active Comparator|Prior PARP Inhibitor|Patients previously treated with a PARP inhibitor other than olaparib
10013447|NCT01661894|Active Comparator|Intervention|Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
10013448|NCT01661894|No Intervention|Wait-List Control|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
10037304|NCT01823848|Active Comparator|Normal saline enema|Administration of normal saline enema for functional constipation in children ages 4-12 years Admininstered as 10ml/kg with maximum of 700ml
10013449|NCT01661907|Experimental|Combined Epi-GA/PCEA|"Patients assigned to this group (experimental group) will receive combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA).~An epidural catheter will be placed before anesthesia induction. General anesthesia will be induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.375%-0.5% ropivacaine given through the epidural catheter for analgesia maintenance. Patient-controlled epidural analgesia will be provided for postoperative analgesia (established with 0.12% ropivacaine and 0.5 μg/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr)."
10013450|NCT01661907|Active Comparator|GA/PCIA|"Patients assigned to this group (control group) will receive general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA).~General anesthesia will be induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia will then be maintained by inhalation of sevoflurane with or without nitrous oxide, and/or continuous intravenous infusion of propofol. Sufentanil and rocuronium will be given when needed. Patient-controlled intravenous analgesia will be provided for postoperative analgesia (established with 50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion)."
10013451|NCT01661920|Experimental|INTERVENTION GROUP|Patients with diagnosis of CAP with shorten treatment, defined as 5 days antibiotic treatment.
10013452|NCT01661920|Active Comparator|CONTROL GROUP|Patients with diagnosis of CAP which antibiotic treatment duration will be not modified by their doctors.
10013453|NCT01661985|Active Comparator|Drug: Azithromycin 1g|Azithromycin 1 g,single dose (per os)
10013454|NCT01661985|Active Comparator|Drug: Doxycycline/lymecycline 9/10days|Tetracycline either as Doxycycline or during June and July lymecycline (due to lower risk of photo-sensitivity) given for treatment in 9(10)days (per os).
10013455|NCT01661985|Active Comparator|Azithromycin 1.5 g|Patients not randomized but receiving the first line treatment when a confirmed Mg infection
10013456|NCT01661998||Harms Study Group|
10013457|NCT01662011|Experimental|NAVA group|Patients ventilated with the mode of neurally adjusted ventilatory assist
10013458|NCT01662011|Active Comparator|PSV group|Patients ventilated with the mode of pressure support ventilation.
10013459|NCT01662037|Experimental|Bosentan group|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
10013460|NCT01662037|No Intervention|Routinely group|Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
10013461|NCT01662050|Experimental|One arm for all patients.|Rituximab, Bendamustine, Cytarabine
10013462|NCT01662076|Experimental|Sublingual or Oral Liquid Homeopathy|The homeopathic remedy will be administered as 1 lactose/sucrose globule 2.5 mm in diameter to be administered sublingually up to 3 times per day or as 0.2 ml of a 30% ethanol based liquid homeopathic remedy administered orally up to 3 times per day. The homeopathic remedy and/or the homeopathic remedy potency can be changed on a daily basis during the course of treatment. However, only one homeopathic remedy and potency will be administered at a given time.
10013463|NCT01662089|Experimental|Chelate zinc suppliment|15mg Chelate zinc suppliment : additional to standard 5% minoxidil
10013464|NCT01662089|Placebo Comparator|Placebo drug|Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil
10013465|NCT01662128|Experimental|Xeloda|Xeloda
10035881|NCT01810510|Experimental|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
10035882|NCT01810510|Experimental|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
10035883|NCT01810523|Experimental|Narrative|This arm will receive information regarding leg injuries and X-ray usage in narrative form in addition to standard of care discharge information.
10013466|NCT01662154|Experimental|Nerve stimulator|Patients in this group will have their nerve blocks assessed with a common nerve stimulator (Stimuplex HNS 12, B.Braun, Germany).
10013467|NCT01662154|Active Comparator|Neurometer|Patients in this group will have their nerve block assessed using the Neurometer.
10013468|NCT01662167|Experimental|Multiple dose mtx|mtx
10013469|NCT01662167|Experimental|Single Dose|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
10013470|NCT01662180||Subfertile couples|"Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles~All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle."
10013471|NCT01662193|Experimental|vitamin D3|vitamin D3 supplement 50000 IU vitamin D3 per week
10013472|NCT01662193|Experimental|calcium supplement|calcium supplement 1000 mg calcium carbonate daily
10013473|NCT01662193|Experimental|vitamin D and calcium supplement|vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
10013474|NCT01662193|Placebo Comparator|placebo|placebo
10013475|NCT01662206|Experimental|Probiotic|Capsules containing Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum
10013476|NCT01662206|Placebo Comparator|Placebo|Capsules containing placebo
10013477|NCT01662219|Experimental|superficial cervical plexus block|superficial cervical plexus block for experimental group
10013478|NCT01662219|No Intervention|No Block|no superficial cervical plexus block for the no intervention group
10013479|NCT01662232|Active Comparator|Green tea beverage|200 mg EGCG as green tea beverage.
10013480|NCT01662232|Active Comparator|Green tea extract|200 mg EGCG as green tea extract and same volume water as for tea beverage.
10013481|NCT01662232|Active Comparator|Epigallocatechin-3-gallate (EGCG)|200 mg EGCG and same volume water as for tea beverage.
10013482|NCT01662232|Placebo Comparator|Placebo (Water)|Same volume water as for all intervention arms.
10013483|NCT01662258|Experimental|Point-of-Care diagnostic laboratory test|Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests.
10013484|NCT01662258|No Intervention|Empiric therapy|Option of no application of POC laboratory tests
10013485|NCT01662271||adolescents with extreme obesity|BMI ≥35kg/m2
10013486|NCT01662271||adolescents with obesity|BMI 30-34.9kg/m2
10013487|NCT01662284||Triple Negative Breast|124I-NM404 in triple negative breast cancer
10013488|NCT01662284||Prostate|124I-NM404 in prostate cancer
10013489|NCT01662284||Colorectal|124I-NM404 in colorectal cancer
10013490|NCT01662284||Gastric|124I-NM404 in gastric cancer
10013491|NCT01662284||Ovarian|124I-NM404 in ovarian cancer
10013492|NCT01662284||Pancreatic|124I-NM404 in pancreatic cancer
10013493|NCT01662284||Esophageal|124I-NM404 in esophageal cancer
10013494|NCT01662284||Sarcoma|124I-NM404 in soft tissue sarcoma
10013495|NCT01662284||Head & Neck|124I-NM404 in head and neck cancer
10013496|NCT01662323|Active Comparator|Training of the GP's, intervention|General practitioners are trained to diagnose and treat heart failure according the recommendations of the NHG-standard.
10013497|NCT01662323|Active Comparator|Controle|General practitioners giving care as usual to their heart failure patients.
10013498|NCT01662349|Experimental|Plasma|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
10013499|NCT01662375||MIII|
10013500|NCT01662388|Experimental|automatrix band, Separation ring|The prepared teeth received Automatrix band (similar to the control group, product code# 62422513). The Automatrix was burnished against the adjacent tooth gently. Anatomical wedges were applied in the proximal area and then the separation ring (BiTine® round ring by Palodent systems, Dentsply International, DE, USA product # 659040) placed with the help of retainer forceps.
10013501|NCT01662388|Active Comparator|automatrix band|Teeth received Automatrix band alone (Wide-Regular type, dimensions 7.9 mm height and 0.05mm thickness, product code # 62422513). It was secured on the prepared tooth and burnished against the adjacent tooth gently. Anatomical wedges were placed in the inter-proximal area gingival to the cavity preparation.
10013502|NCT01662401|Experimental|Peripheral Nerve Block|bilateral rectus sheath and ilioinguinal nerve blocks under ultrasound guidance after induction of general anesthesia administered to subject
10013503|NCT01662401|Experimental|local anesthetic infiltration|local anesthetic infiltration will be administered after induction of general anesthesia
10013504|NCT01662414|Active Comparator|HMS 90®|
10013505|NCT01662414|Placebo Comparator|Placebo (Soy protein)|
10013506|NCT01662427||Questionniare|
10013507|NCT01662466|Active Comparator|DHEA+Testosterone|These patients will be administered the testosterone cream along with standard DHEA supplements
10013508|NCT01662466|Placebo Comparator|DHEA+Placebo|These patients will receive the placebo cream along with her DHEA supplements. In other words, no testosterone will be administered.
10013509|NCT01662518|Experimental|DDS-25|Intravitreal injection of DDS-25(Dexamethasone drug delivery system )
10013510|NCT01662544|Experimental|HHFNC|Heated High Flow arm
10013511|NCT01662544|Active Comparator|Standard Nasal Cannula|Standard treatment
10013512|NCT01662557|Active Comparator|Family Behavior Modification|Family-based behavior modification with parent and child using goal setting, self monitoring, reinforcement, behavioral skills training, and tasting opportunities.
10013513|NCT01662557|Other|Minimal Nutrition Information|Weekly mailings emphasizing healthy eating guidelines for families.
10013514|NCT01662570|Active Comparator|Beverage Choice Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake.
10013515|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included.
10013516|NCT01662622|Experimental|Sevoflurane|Anaesthesia was induced by 8% sevoflurane. Cisatracurium 0.15mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow 2L min-1. Gas concentrations were analysed using a gas analyser.The end-tidal concentration of carbon dioxide was maintained at 4.7kPa; an esophageal temperature probe was inserted and a warming unit was used if necessary to maintain normothermia (35.5°-38.5°). The surgical incision was performed at least 30min after tracheal intubation. When arterial blood pressure (MAP) decrease exceeding 20% of baseline values. Phenylephrine 0.1mg was administered intravenously if necessary to maintained MAP and recorded.
10013517|NCT01662661|Experimental|Arm AB|Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension followed by Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet, administered on Day 1.
10013518|NCT01662661|Experimental|Arm BA|Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet followed by Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension, administered on Day 1.
10013519|NCT01662674|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
10013520|NCT01662674|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 1000mg
10013521|NCT01662687|Experimental|Sancuso patch|
10013522|NCT01662687|Active Comparator|Kytril|
10013523|NCT01662700|Experimental|AS2|"Artesunate 2 mg/kg/day for 5 days Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
10013524|NCT01662700|Active Comparator|Chloroquine|"CH25: Chloroquine 25 mg/kg: 15 mg base/kg on the first days (D0), followed by 5 mg base/kg daily on the second and third day (day1-2) (total 25 mg base/ kg).~Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
10013525|NCT01662713|Experimental|NMSC Imaging|Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
10013526|NCT01662726|Experimental|Irosustat|Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.
10013527|NCT01662804|Experimental|hu3F8 and rIL-2|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8 (day 1 and day 8) in the presence of 6 × 10^6 U rIL-2/m^2/d x 5 days sc (day 8 through day 12). These 2 doses of hu3F8 and 5 doses of rIL-2 constitute a treatment cycle.
10013528|NCT01662817||Intervention|Intervention group primary care physician (PCP) receives one day training in depression screening guidelines and uses guidelines for six months
10013529|NCT01662817||Control|Control group PCP manages depression in the usual way for six months
10013530|NCT01662830||MWCC clients|This study will be a systematic retrospective chart review of clients participating in the Jump Start (5 & 1) Plan at three different MWCC locations in Texas during the years 2007 - 2010.
10013531|NCT01662843||BRIPPED scan|Patients presenting with undifferentiated shortness of breath who receive the ultrasound scan in addition to standard of care
10013532|NCT01662843||Control|Patients who only receive the standard of care for undifferentiated shortness of breath
10035884|NCT01810523|Placebo Comparator|Control|This arm will receive a blank piece of paper in addition to the standard of care discharge information.
10013533|NCT01662869|Experimental|Onartuzumab+mFOLFOX6|Participants will receive onartuzumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion + mFOLFOX6 (oxaliplatin, folinic acid, and 5-fluoruracil) regimen. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with onartuzumab. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with onartuzumab will continue treatment with onartuzumab until disease progression, unacceptable toxicity, or death.
10013534|NCT01662869|Placebo Comparator|Placebo+mFOLFOX6|Participants will receive onartuzumab matching placebo + mFOLFOX6. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with placebo. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with placebo will continue treatment with placebo until disease progression, unacceptable toxicity, or death.
10013535|NCT01662921|Active Comparator|NPH and insulin lispro|Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
10013536|NCT01662921|Active Comparator|NPH and insulin glulisine|Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
10013537|NCT01662934|Sham Comparator|Sham|Using not functioning device
10013538|NCT01662934|Experimental|Experimental|Using functioning device
10013539|NCT01662947|Experimental|DUT Arm|"DUT: Transtek Wrist Blood Pressure Monitor TMB-1117~Measurement: Blood Pressure~Groups/Cohorts: DUT"
10013540|NCT01662947|Experimental|Reference Arm|"Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Measurement: Blood Pressure~Groups/Cohorts: Reference"
10013541|NCT01662973|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 48 study visit."
10013542|NCT01662973|Placebo Comparator|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
10013543|NCT01663025|Experimental|Hand Reflexology|Participants in this condition will receive hand reflexology, performed by a trained reflexologist during their treatment. This will be in addition to usual standard care therefore the surgeon will speak to the participant occasionally to ensure they are comfortable.
10013544|NCT01663025|No Intervention|Control|Participants in condition will form the control group for the study. They will receive usual standard care during treatment which will involve the surgeon speaking to them occasionally to ensure that they are comfortable.
10013545|NCT01663038|Active Comparator|Clopidogrel and Aspirin|
10013546|NCT01663038|Experimental|Copidogrel|
10013547|NCT01663051||Stent|Stent
10013548|NCT01663064|Experimental|Endovascular|Endovascular treatment
10013549|NCT01663077|Experimental|Clozapine|Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month
10013550|NCT01663090|Experimental|Nanoparticle enhanced MRI|
10013551|NCT01663116|Experimental|Treatment|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
10013552|NCT01663116|Placebo Comparator|Placebo|Lactate Ringer´s solution
10013553|NCT01663129||Leukemia Patient Group|Acute Lymphoblastic Leukemia (ALL)
10013554|NCT01663129||Rheumatic Disease Patient Group|"Juvenile Idiopathic Arthritis (JIA)~Systemic Lupus Erythematosis~Juvenile Dermatomyositis~Scleroderma~Overlap Syndromes~Sjogren's syndrome~Sarcoidosis~Systemic Vasculitis (excluding Kawasaki's disease and Henoch-Schonlein Purpura)~Systemic vasculitis as defined by the Chapel Hill Concensus Conference on Nomenclature. Other forms of systemic vasculitis, including Giant cell (temporal) arteritis, Takayasu's arteritis, Polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome, Microscopic polyangiitis, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Behcet's disease, Other vasculitis~Other rheumatic disease"
10013555|NCT01663129||Nephrotic Syndrome Patient Group|"Nephrotic syndrome will be classified according to the following categories:~Idiopathic nephrotic syndrome, without renal biopsy histology, presumed minimal change disease (MCD), Focal segmental glomerulosclerosis (FSGS), confirmed on biopsy, Minimal change disease, confirmed on biopsy Nephrotic syndrome with Henoch-Schonlein Purpura (HSP)."
10013556|NCT01663142||Patients who receive surgical resection for intestinal in CD|
10013557|NCT01663155||all enrolled subjects|Intervention is chest x-ray and CT scan. The chest x-ray image is read first without computer aided detection (CAD) and then a second time with computer aided detection (CAD) the CT scan is read by one reader. Subjects are asked to contribute breath and blood samples.
10013558|NCT01663168|Active Comparator|Rifabutin three times a week|Rifabutin 150mg tablet three times a week (Mon-Wed-Fri) in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
10013559|NCT01663168|Experimental|Rifabutin daily|Rifabutin 150mg tablet daily in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
10013560|NCT01663194||N/L ratio tertile 2|patients were divided in to the tertiles
10013561|NCT01663194||N/L ratio tertile 3|patients were divided in to the tertiles
10013562|NCT01663194||N/L ratio tertile 1|patients were divided in to the tertiles
10013563|NCT01663207||obese individuals with prediabetes|
10013564|NCT01663220||obese individuals with type 2 diabetes mellitus|
10013565|NCT01663246|Active Comparator|Healthy Adults|Healthy adults over the age of 18, with no history of surgery to the salivary glands, or cancer therapy.
10013566|NCT01663246|Active Comparator|Radiation for Head and Neck Cancer|History of radiation therapy for head and neck cancer.
10013567|NCT01663298||Control group|Subjects must have never smoked and must be non-diabetic.
10013568|NCT01663298||Smoking group|Subjects must have had at least 5 pack-years of self-reported smoking history, must be currently smoking and must be non-diabetic.
10013569|NCT01663298||Diabetic group|Subjects must have type 2 diabetes. The condition must be diagnosed subjects must be treated by medications and/or insulin. A HbA1C test result either within past 3 months or performed in the first visit must be available. They must have never smoked.
10013570|NCT01663311|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
10013571|NCT01663311|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
10013572|NCT01663324|Experimental|single site rTMS|"Low frequency temporoparietal transcranial magnetic stimulation~Intervention: Device: rTMS intervention 1"
10013573|NCT01663324|Experimental|multisite rTMS|"Combined high frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation~Intervention: Device: rTMS Intervention 2"
10013574|NCT01663337|Active Comparator|Cognitive Processing Therapy (CPT)|
10013575|NCT01663337|Active Comparator|Relapse Prevention Therapy (RP)|
10013576|NCT01663337|No Intervention|Assessment Only (AO)|AO functions as a benchmark comparison condition. Consists of baseline assessment, daily interactive voice response (IVR) monitoring, and immediate post-test assessment. Not an active treatment
10013577|NCT01663350||All-risk pregnant women|All-risk pregnancies undergoing conventional forms of prenatal screening
10013578|NCT01663389|Experimental|GSK1322322 1000 mg IV|On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie [μCi] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.
10013579|NCT01663389|Experimental|GSK1322322 1200 mg Oral Solution|On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).
10013580|NCT01663415|Experimental|Enzalutamide|
10013581|NCT01663428|Experimental|Sup-ER Splint|Experimental group that will receive Sup-ER splint.
10013582|NCT01663428|Active Comparator|Control (Currently accepted treatment)|Control group that will receive the currently accepted treatment.
9518072|NCT03300206||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging.
10013583|NCT01663441|Experimental|A1|"Patients in this treatment group will receive NL201(5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(7.5μg/kg).~Only for Dose-finding in Phase Ⅲa."
10013584|NCT01663441|Experimental|A2|"Patients in this treatment group will receive NL201(7.5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(5μg/kg).~Only for Dose-finding in Phase Ⅲa."
10013585|NCT01663441|Active Comparator|A|"Patients in this treatment group will receive NL201（optimal dosing dose）in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive rhIL-11(25μg/kg).~Only in Phase Ⅲb."
10013586|NCT01663441|Active Comparator|B|"Patients in this treatment group will receive rhIL-11(25μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201（optimal dosing dose）.~Only in Phase Ⅲb."
10013587|NCT01663454|Experimental|Cogmed Robomemo working memory training|Participants will complete 25 sessions (5 weeks) of Cogmed Robomemo (Pearson assessment) working memory training
10013588|NCT01663467|Active Comparator|Ginkgo biloba only|control group Ginexin-F 80mg tablet will be given twice a day for 6 months.
10013589|NCT01663467|Experimental|Ginkgo biloba + modified TRT|"experimental group modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
10013590|NCT01663493|Other|Fine needle aspiration needle|standard Beacon FNA needle
10013591|NCT01663493|Other|fine needle biopsy needle|SharkCore fine needle biopsy needle
10013592|NCT01663519|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
10013593|NCT01663519|Experimental|Custom made insoles 35 shore|Custom made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate
10013594|NCT01663519|Experimental|55 shore Custom made insoles|Custom made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate
10035885|NCT01810536|Experimental|Hi-flow nasal cannula|This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
10035886|NCT01810536|Active Comparator|Venturi mask|This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks
10013595|NCT01663558|Active Comparator|imiquimod|"i. Each subject will use an imiquimod anal suppository three times weekly (overnight on Monday, Wednesday, Friday) for 12 weeks.~ii. Each subject will be asked to abstain from receptive anal sex during therapy period (12 weeks).~iii. If local imiquimod adverse effects are severe, a 7-day period off of treatment will be permitted.~iv. During 12 week therapy period, each subject will be evaluated 2, 4, 8, and 12 weeks after starting therapy. At each visit, subject will complete a therapy questionnaire and undergo anal Pap, HRA with biopsies as indicated, and anal HPV testing.~v. After therapy completed (12 weeks), subject will enter 12 month observation period."
10013596|NCT01663558|Active Comparator|ablative|"i. Subject will be referred to colorectal surgeon, will complete a therapy questionnaire, and will be treated in accordance with treatment algorithm which is already in use.~ii. Subject will be asked to abstain from receptive anal sex for 12 weeks after ablative therapy.~iii. After therapy, subject will enter 12 month observation period."
10013597|NCT01663558|No Intervention|Observation|"i. Given lack of accepted guidelines and outcome data on dysplasia management, the study PI will thoroughly discuss risks and benefits of observation/monitoring and treatment of dysplasia.~ii. If treatment is chosen, subject will be randomized to 1) ablative group, or 2) imiquimod group and begin therapy. Observation subjects will continue observation visits (observation questionnaire, anal Pap, HRA with biopsies as indicated, and anal HPV testing) every 3 months for 12 months (4 additional study visits)."
10013598|NCT01663597||Cohort 1|40 subjects with high grarde myopia ranging from -10 diopters to -4.01 diopters
10013599|NCT01663597||Cohort 2|40 subjects with moderate myopia ranging from -4 diopters to -1.01 diopter
10013600|NCT01663597||Cohort 3|40 subjects with emmetropia, -1 diopter to +1 diopter
10013601|NCT01663597||Cohort 4|40 subjects with hyperopia, +1.01 diopter and more
10013602|NCT01663610|Experimental|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
10013603|NCT01663610|No Intervention|Wait List Control (CONT)|Weekly registrations only. After 6 weeks the Internet-based course without therapist support well be offered (SelfSMART)
10013604|NCT01663649|Experimental|Deprexis|Deprexis (Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.)
10013605|NCT01663649|Active Comparator|Wait-list|Wait-list group (Subjects receive access to deprexis after six months)
10013606|NCT01663662|Active Comparator|Tolvaptan Arm|"Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing:~Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr"
10013607|NCT01663662|Placebo Comparator|Placebo|Placebo x 3 days and standard of care continuous infusion diuretic
10013608|NCT01663675||Trisomy 21 (Down syndrome)|Trisomy 21 (Down syndrome)
10013609|NCT01663688||Normative Data Collection|
10013610|NCT01663701|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders. Blood cultures are drawn in all patients. Antibiotics are specified by the admitting doctors.
10013611|NCT01663701|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings. Antibiotics are specified by the admitting doctors.
10013612|NCT01663753|Experimental|18F-FDG-PET|The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)
10013613|NCT01663766|Experimental|Milatuzumab|Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
10013614|NCT01663792|Placebo Comparator|Placebo|5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
10013615|NCT01663792|Experimental|Seaweed|Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
10013616|NCT01663792|Placebo Comparator|Placebo2|5 g/d placebo in 10 500-mg capsules for one month
10013617|NCT01663805|Active Comparator|Everolimus|SCD/ECD: BXB (2x20mg, D1 and D4) + EVL (3.0 -8.0ng/ml) + MYF (1440mg/d)+ Prednisone
10013618|NCT01663805|No Intervention|mycophenolate sodium|SCD/ECD: BXB (2x20mg, D1 and D4) + TAC + MYF (1440mg/d)+ Prednisone
10013619|NCT01663818|Experimental|Treatment group|Treatment with Tack-IT Endovascular Staple
10013620|NCT01663831|Experimental|Topical Repellent & LLIN|
10013621|NCT01663831|No Intervention|Long Lasting Insecticidal Nets|"Brand Name LLIN: Olyset Net~Active ingredient: permethrin"
10013622|NCT01663844|Experimental|(Study 1) ICBT for insomnia and depression|
10013623|NCT01663844|Active Comparator|(Study 1) ICBT for depr. plus placebo insomnia intervention|
10013624|NCT01663844|Experimental|(Study 2) ICBT for insomnia with added support|
10013625|NCT01663844|Active Comparator|(Study 2) ICBT for insomnia with regular level of support|
10013626|NCT01663870||Breast Cancer Survivors|Patients in the LBJ General Hospital Cancer Survivorship Clinic.
10013627|NCT01663870||Clinic Stakeholders|Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
10013628|NCT01663883|Experimental|Healthy subjects|
10013629|NCT01663909|No Intervention|Standard care|
10013630|NCT01663909|Experimental|Guided imagery|
10013631|NCT01663948||Patients with Plastic bronchitis|
10013632|NCT01663961|Experimental|YM178 OCAS + digoxin|
10013633|NCT01663974||Bipolar disorder patients|
10013634|NCT01664000|Experimental|Kevetrin|thioureidobutyronitrile intravenous once/week for 3 weeks/ cycle
10013635|NCT01664013|Experimental|Neuronox|Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.
10013636|NCT01664026|No Intervention|Control|Subjects assigned to the usual care group will receive general lifestyle recommendations as per their country standards of care.
10013637|NCT01664026|Experimental|Web|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
10013638|NCT01664026|Experimental|Web+|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
10013639|NCT01664065|Experimental|AZ drug: A|200 mg Ceftaroline fosamil 1h infusion
10013640|NCT01664065|Experimental|AZ drug: B|600 mg Ceftaroline fosamil 1h infusion
10013641|NCT01664143|Placebo Comparator|Placebo|
10013642|NCT01664143|Experimental|RO5508887|
10035887|NCT01810549|Active Comparator|Anakinra|Anakinra 100mg. Every subject will receive one subcutaneous injection of study drug once during the study, a total of one injection.
10035888|NCT01810549|Placebo Comparator|Placebo|Every study participant will receive a single subcutaneous injection of Placebo once during the study, a total of one injection.
10035889|NCT01810562|Experimental|Specific treatment + std stroke care|Specific treatment in addition to standard stroke care
10035890|NCT01810562|No Intervention|Std stroke care|Patients receive only standard stroke treatment and no specific treatment.
10035891|NCT01810588|Experimental|All Patients|"Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
10035892|NCT01810601|Experimental|Ultrasound guided embryo transfer|GnRh, HMG, HCG, Progesterone 45 patients had ultrasound guided embryo transfer during ICSI
10035893|NCT01810601|Placebo Comparator|clinical touch technique|GnRh, HMG, HCG, Progesterone 45 patients had embryo transfer using clinical touch technique during ICSI
10035894|NCT01810614|Experimental|ADPKD Diet|All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
10035895|NCT01810627||MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
10035896|NCT01810640|No Intervention|Control|In this group a liver biopsy will not be performed. All management would be as per standard of practice
10035897|NCT01810640|Active Comparator|Percutaneous liver biopsy|In this group a percutaneous biopsy of the liver will be performed prior to organ recovery
10035898|NCT01810653|Experimental|Macrogol (Transipeg)|
10035899|NCT01810653|Active Comparator|Macrogol (Forlax)|
10035900|NCT01810679|Experimental|Perceval S Aortic Heart Valve|Treatment with the Perceval S Aortic Heart Valve
10035901|NCT01810718|Experimental|Nilotinib|"3 patients (pts) will receive Nilotinib 200 mg daily dose. If no dose-limiting toxicity, the next 3 pts will be treated with next dose of Nilotinib 300 mg daily dose.~Doses will not be escalated beyond 600 or below 200 mg/die. The dose estimated as the MTD in phase I will be used for phase II."
10013643|NCT01664156|Experimental|Korean red ginseng|The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
10013644|NCT01664156|Placebo Comparator|placebo|Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
10013645|NCT01664169||Single group|"The samples required for this study are stored in the CALGB Pathology Coordinating Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No additional samples are required from patients.~The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3, IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
10013646|NCT01664182|Experimental|Arm I (trebananib monotherapy)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
10013647|NCT01664182|Experimental|Arm II (trebananib and anti-VEGF therapy)|Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29, pazopanib hydrochloride PO QD on days 1-42, sorafenib tosylate PO BID on days 1-42, or sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
10013648|NCT01664195|Other|Group A|Epoetin alfa Test drug in the first period and comparator drug in the second period.
10013649|NCT01664195|Other|Group B|Epoetin alfa Comparator Drug in the first period and test drug in the second period
10013650|NCT01664221|Experimental|Eritromax|Eritromax (Epoetin alfa) intravenous administration, dose: 100 IU/kg
10013651|NCT01664221|Active Comparator|Eprex|Eprex (Epoetin alfa) intravenous administration: 100 IU/kg
10013652|NCT01664234|Experimental|laryngoscopy with simultaneous insufflation of oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
10013653|NCT01664234|Placebo Comparator|laryngoscopy without simultaneous oxygen insufflation|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
10013654|NCT01664260|Experimental|N-acetylcysteine + Escitalopram|The subjects with posttraumatic stress disorder, treated with N-acetylcysteine in addition to escitalopram
10013655|NCT01664260|Placebo Comparator|Placebo + Escitalopram|The subjects with posttraumatic stress disorder, treated with placebo in addition to escitalopram
10013656|NCT01664507|Active Comparator|conventional dose epinephrine|L-epinephrine (1:1000) 0.5 mL/kg (maximum 5mL) + normal saline : total 5mL
10013657|NCT01664507|Experimental|low dose epinephrine|L-epinephrine (1:1000) 0.1 mL/kg (maximum 1mL) + normal saline : total 5mL
10013658|NCT01664520|Experimental|Dexmedetomine infusion|
10013659|NCT01664546||Molecular blastocyst karyotype|Trophectoderm biopsy for genetic study by aCGH
10013660|NCT01664572||Healthy subjects|
10013661|NCT01664585|Experimental|Training group|"The rationale and means for the exercise program are to~Motivate and teach participants for postural and motor control and strengthening exercises~Monitor and motivate to continue exercise training, and to increase their physical activity~Training is organised six times as a 60-min session during six months: two individually supervised sessions, and four following training sessions will be accomplished in groups of 10 participants guided by an experienced physical therapist. Three weekly similar home training sessions are recommended for participants. Information on amount of exercise sessions per week and repetitions of each exercise will be collected via exercise diary. To perform home training, a DVD and/or booklet will be provided to participants in the training group."
10013662|NCT01664585|Sham Comparator|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0), and the participants in this group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
10013663|NCT01664598|Experimental|RoActemra/Actemra|
10013664|NCT01664611|Experimental|Treatment arm|Participants in this arm will receive remote ischaemic conditioning on a daily basis for 4 weeks post MI
10013665|NCT01664611|Sham Comparator|Sham arm|Participants in this arm will receive sham ischaemic conditioning on a daily basis for 4 weeks post MI
10013666|NCT01664637|Experimental|TZP-102 three times a day|10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
10013667|NCT01664637|Placebo Comparator|Placebo three times a day|Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.
10013668|NCT01664650|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
10013669|NCT01664650|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
10013670|NCT01664663|Active Comparator|Arm A:Standard radiochemotherapy|Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
10013671|NCT01664663|Experimental|Arm B Escalated radiochemotherapy|Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.
10013672|NCT01664676|Experimental|Liraglutide|1.2 mg liraglutide sc. (single-dose)
10013673|NCT01664676|Placebo Comparator|Placebo-liraglutide|Placebo liraglutide sc. (single-dose)
10013674|NCT01664689|Active Comparator|DiscoVisc|microcoaxial phacoemulsification performed with discovisc
10013675|NCT01664689|Active Comparator|Healon 5|microcoaxial phacoemulsification using healon 5
10013676|NCT01664689|Active Comparator|Celoftal|microcoaxial phacoemulsification using celoftal
10013677|NCT01664702|Experimental|Recommended dairy diet|Recommended servings of dairy products per day
10013678|NCT01664702|Experimental|Low dairy diet|One or fewer dairy servings per day
10013679|NCT01664715|Active Comparator|150 Minutes per Week|Performs 150 minutes of physical activity per week.
10013680|NCT01664715|Active Comparator|225 Minutes per Week|Performs 225 minutes of physical activity per week.
10013681|NCT01664715|Active Comparator|300 Minutes per Week|Performs 300 minutes of physical activity per week.
10013682|NCT01664728|Experimental|Abiraterone acetate|
10013683|NCT01664754|Experimental|Treatment (exemestane, pemetrexed disodium, and carboplatin)|Patients receive exemestane PO QD on days 1-28 and pemetrexed disodium IV over 15 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10013684|NCT01664767|Experimental|Thermal water inhalation|Patients will perform 12 days of sulfur thermal water inhalation
10013685|NCT01664767|Placebo Comparator|Isotonic saline inhalation|Patients will perform 12 days of isotonic saline inhalation
10013686|NCT01664780||Patients after liver transplantation|
9518073|NCT03300206||Standard of Care|Each of the participating sites will currently be using a vacuum assisted breast biopsy system along with a specimen radiography system (or other specimen imaging system).
10013687|NCT01664819|Active Comparator|Antioxidant supplementation|Randomized to receive antioxidant supplementation (vitamin C, 500 mg; beta carotene, 15 mg; and alpha-tocopherol, 400 IU) three times per week for five years.
10013688|NCT01664819|Placebo Comparator|Placebo|Randomized to receive placebo three times per week for five years
10013689|NCT01664832|Experimental|S-nIMV|nIMV synchronized using abdominal pressure capsule sensor device
10013690|NCT01664832|Placebo Comparator|nIMV|non-synchronized nasal intermittent mandatory ventilation group
10013691|NCT01664845|Active Comparator|metformin, pegylated-IFN, ribavirin|metformin,pegylated-IFN and ribavirin
10013692|NCT01664845|Placebo Comparator|Pegylated-IFN and ribavirin|pegylated -IFN and ribavirin
10013693|NCT01664871|Experimental|Levels of SIlver and Fluoride in Plasma|
10013694|NCT01664884||Bipolar Disorder Patients|Bipolar Disorder Patients, with age between 18 to 40 years old, at euthymic phase.
10013695|NCT01664884||Schizophrenia Patients|Schizophrenia Patients, with age between 18 to 40 years old, with minimum or none positive symptoms.
10035902|NCT01810731|Experimental|Quadrivalent Influenza Vaccine (QIV)|"15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
10037305|NCT01823848|Experimental|Mineral oil enema|Administration of mineral oil enema for functional constipation in children ages 4-12 years Administered as 66ml per rectum
10013696|NCT01664910|Experimental|Treatment (transplant)|Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.
10013697|NCT01664936||pts receiving a PET/CT scan with Metastatic LNs|This study seeks to optically image the Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I in a cohort of patients with primary tumor sites and from pathologic lymph nodes after routine 18F-FDG PET 31I radiotherapy and/or investigational study scans. We will include a subset of patients with normal lymph nodes during screening. This subset of patients will be imaged as a negative control for this study.
10013698|NCT01664962||Patients|Women with severe Vulvodynia
10013699|NCT01664962||Healthy controls|Women without vulvodynia
10013700|NCT01664988|Experimental|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
10013701|NCT01664988|Experimental|breath control|include deep diaphragmatic breathing and decrease breath rate to 6-10/min
10013702|NCT01664988|Other|control|received routine care of clinic or health center and control their blood pressure weekly and use drugs if necessary
10013703|NCT01665001|Experimental|Multiagent induction-consolidation|Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
10013704|NCT01665014|Experimental|Total marrow irradiation|Double autologous hematopoietic stem cell transplantation using TMI and HD-Mel
10013705|NCT01665027|Experimental|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head. He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers).
10013706|NCT01665027|Experimental|routine manual maneuvers for fetal head extraction|"Procedure/Surgery:~fetal head techniques like fundal pushing, pulling technique or reverse breech extraction"
10013707|NCT01665066|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
10013708|NCT01665066|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
10013709|NCT01665066|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
10013710|NCT01665066|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
10013711|NCT01665066|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
10013712|NCT01665079|Experimental|Propofol|14 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery
10037306|NCT01823874|Experimental|ID virtual reality distraction|virtual reality distraction
10013713|NCT01665105|Experimental|Zusanli Group|electroacupuncture at both Zusanli on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
10013714|NCT01665105|Active Comparator|Yanlingquan Group|electroacupuncture at both Yanglingquan on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
10013715|NCT01665105|Sham Comparator|Sham Group|acupuncture without electrical stimulation at non-acupoint on the leg, and record simultaneously pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
10013716|NCT01665118|Experimental|Treated Thigh|Trusculpt (Radio Frequency) Device
10013717|NCT01665118|No Intervention|Untreated Contra-lateral Thigh|To be used as the self control in this split body study.
10013718|NCT01665131|Experimental|Subcutaneous ICD group|
10013719|NCT01665183|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
10013720|NCT01665196|Experimental|18F-FDG PET/CT scanning|18F-FDG PET/CT scanning will be performed in patients with IgG4RD to determine the pictorial characteristics and measure the standardized uptake values (SUVs) of the lesions and their response to treatment.
10013721|NCT01665209|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
10013722|NCT01665209|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
10013723|NCT01665222|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
10013724|NCT01665222|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
10013725|NCT01665235|Active Comparator|amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
10013726|NCT01665235|Experimental|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
10013727|NCT01665248|Other|stable angina pectoris or acute coronary syndrome|
9518074|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
9518075|NCT03300167|Experimental|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
9518076|NCT03300154|Experimental|Financial incentives|
10013728|NCT01665274|Active Comparator|XELOX adjuvant group|"D2 resection~XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 6 cycles"
10013729|NCT01665274|Experimental|XELOX neoadjuvant|"XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy before operation.~D2 resection~After operation:~CR/PR: XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1，40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation."
10013730|NCT01665313||participants|Full-time faculty with morning and afternoon outpatient clinics on the same day in SNUH
10013731|NCT01665326||Infantile Pompe disease|Individuals with a confirmed diagnosis of Infantile Pompe disease
10013732|NCT01665339|Experimental|preload|subjects in preload group consumed salad, yogurt and water 15 minutes before the main meal.
10013733|NCT01665339|Experimental|control|subjects in control group consumed salad and yogurt with meal.
10013734|NCT01665365|Experimental|1. Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention (intervention group).
10013735|NCT01665365|No Intervention|2.|Primary percutaneous coronary intervention (control group).
10013736|NCT01665378|Experimental|Multiple micronutrient - 1|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
10013737|NCT01665378|Active Comparator|Iron and folic acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
10013738|NCT01665378|Placebo Comparator|Folic Acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
9518077|NCT03300154|Experimental|Framing (SMS)|
9518078|NCT03300154|No Intervention|Usual care|
10013739|NCT01665378|Experimental|Multiple Micronutrient - 2|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
10013740|NCT01665378|Active Comparator|Iron and Folic Acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
10013741|NCT01665378|Placebo Comparator|Folic acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
10013742|NCT01665404|Experimental|Dosing Period 1|
10013743|NCT01665404|Experimental|Dosing Period 2|
10013744|NCT01665417|Experimental|Experimental Icotinib|Icotinib: 125mg, oral administration, three times per day.
10013745|NCT01665417|Active Comparator|Chemotherapy Regimen 1|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
10013746|NCT01665417|Active Comparator|Chemotherapy Regimen 2|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
10013747|NCT01665456||Cases (women with complications)|Cases are women aged 15-49 years who delivered within 12 months prior to data collection and had experienced obstetric complication(s) that either necessitated treatment or hospitalization in order to prevent the likelihood of death of the mother.
10013748|NCT01665456||Control (women who did not experience any complications)|Controls are women aged 15-49 years who delivered within 12 months prior to data collection. They did not have or develop any of the complications which cases experienced or suffered from.Although controls did not have complications, they were individually matched on the basis of age and location. The idea was to compare how many cases were exposed versus how many controls were exposed.
9802550|NCT05171907|Other|Intervention Group|Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
9802551|NCT05171686|Experimental|Diuretic augmentation|The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed.
10013749|NCT01665469|Placebo Comparator|Placebo|Soft gel capsule without test material
10013750|NCT01665469|Experimental|Tomato extracted lycopene|Soft gel cups for oral use
10013751|NCT01665482|Active Comparator|Saturated fat rich diet|
10013752|NCT01665482|Active Comparator|Monounsaturated fat rich diet|
9802552|NCT05169372||Subjects with locally or biochemical recurrence prostate cancer|
9802553|NCT05168826||Transcatheter Aortic Valve Implantation (TAVI)|
10013753|NCT01665482|Active Comparator|Carbohydrate/ Low fat diet|
9802554|NCT05168631||Patients aged 18 years or older with histologically confirmed neuroendocrine tumor|Metastatic or inoperable disease; Patients with clinical information about the therapies received, including exclusive palliative care;
10013754|NCT01665495|No Intervention|Pericardiocentesis|Pericardial fluid drained by simple echo-guided pericardiocentesis
10013755|NCT01665495|Active Comparator|Extended pericardial drainage|Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return<30ml
10037307|NCT01823874|Experimental|HMD virtual reality distraction|virtual reality distraction
10013756|NCT01665534|Experimental|Effect of salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks. During the low salt intake period, patients received a 10-20 mmol sodium diet + placebo tablets for two weeks.
10013757|NCT01665547|Active Comparator|l-carnitine|adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene
10013758|NCT01665560||Smokers--Currently Smoking|Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO >10 ppm.
10013759|NCT01665560||Non-Smoker|Healthy individuals meeting the inclusion criteria who claim to not smoke. This is confirmed w/ CO testing.
10013760|NCT01665586|Placebo Comparator|Group C|: Spinal anesthesia with 6mg bupivacaine and intrathecal placebo(normal saline) added
10013761|NCT01665586|Active Comparator|Group F|: Spinal anesthesia with 6mg bupivacaine and intrathecal small dose of fentanyl(20micro gram)
10013762|NCT01665612|Experimental|MPDS1|Contact lens care solution
10013763|NCT01665612|Active Comparator|MPDS2|Contact lens care solution
10013764|NCT01665612|Active Comparator|MPDS3|Contact lens care solution
10013765|NCT01665625|Experimental|regional interventional chemotherapy group|
10013766|NCT01665625|No Intervention|systemic chemotherapy|
10013767|NCT01665638|Experimental|Treatment Sequence Group AB|
10013768|NCT01665638|Experimental|Treatment Sequence Group BA|
10013769|NCT01665651|Placebo Comparator|kidney Yin deficiency with placebo|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules placebo treatment besides basic treatment.
10013770|NCT01665651|Placebo Comparator|kidney Yang deficiency with placebo|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules placebo treatment besides basic treatment.
10013771|NCT01665651|Experimental|kidney Yin deficiency with Zuogui|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules treatment besides basic treatment.
10013772|NCT01665651|Experimental|kidney Yang deficiency with Yougui|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules treatment besides basic treatment.
10013773|NCT01665664|Other|Hypocaloric feeding group|intervention - Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
10013774|NCT01665664|No Intervention|Full energy feeding group|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 100% of REE will be provided.
10013775|NCT01665677|Experimental|Atorvastatin calcium (Lipitor)|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
10013776|NCT01665677|Experimental|Unrelated Donor|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
10013777|NCT01665690|Experimental|Intervention period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
10013778|NCT01665690|No Intervention|Control Period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
10013779|NCT01665703|Experimental|FDG PET/MR|Participents will undergo a gadolinium enhanced FDG PET/MR study.
10013780|NCT01665729||artery-artery embolus|There is no hypoperfusion ( contralateral compensatory is good )
10013781|NCT01665729||Hypoperfusion|Contralateral compensatory not sufficient
10013782|NCT01665729||Hypoperfusion and embolus amotic|Hypoperfusion and embolus amotic
10013783|NCT01665742|Active Comparator|Anti-inflammatory supplement|"8-weeks of daily supplementation with:~1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene~in conjunction with a weight management programme"
10013784|NCT01665742|Placebo Comparator|Placebo supplement|"8 weeks of daily supplementation with:~1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets~in conjunction with a weight management programme"
10013785|NCT01665755|Experimental|Precompression|Control arm
10013786|NCT01665755|Active Comparator|Upstroke Compression|Intervention arm
10013787|NCT01665781|Experimental|Erythropoietin|Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
10013788|NCT01665781|No Intervention|Control|No erythropoietin
10013789|NCT01665820||Auscultate with mechanical stethoscope|Cardiologist & Medical Resident auscultate using mechanical stethoscope
10013790|NCT01665820||Auscultate with electronic stethoscope|Cardiologist & Medical Resident auscultate using electronic stethoscope
10013791|NCT01665846|Experimental|Ferumoxotyol|Brain MRI will be performed before and 48 +/- 8 hours after ferumoxytol administration.
10013792|NCT01665859||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
10013793|NCT01665885|Active Comparator|Endovascular cooling|Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter
10013794|NCT01665885|Active Comparator|Surface cooling|Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads
10013795|NCT01665885|No Intervention|Control group|Best medical treatment following international stroke guidelines
10013796|NCT01665898|Active Comparator|Cold biopsy forceps|Cold biopsy forceps for removal of colon polyps
10013797|NCT01665898|Active Comparator|Cold Snare Biopsy|Cold snare biopsy for removal of colon polyps
10013798|NCT01665924|Experimental|40-50 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
10013799|NCT01665924|Experimental|65-74 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
10013800|NCT01665924|Experimental|75 years and older|GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
10013801|NCT01665937|Experimental|STA-9090|Patients receiving STA-9090
10013802|NCT01665963|Active Comparator|TopClosure(c) Treated Wound|Pressure Bandage using the TopClosure(C) System
10013803|NCT01665963|Active Comparator|Traditional Wound Closure Treatment|Pressure Bandage
10013804|NCT01665976|Experimental|A: film coated tablets, fasted condition|
10013805|NCT01665976|Experimental|B: film coated tablets, fed condition|
10013806|NCT01665976|Experimental|C: hard gelatin capsules|
10013807|NCT01665976|Experimental|D: oral suspension|
10013808|NCT01665989|Experimental|Group Lifestyle program|The group lifestyle program used in the IDOLc study is adapted from the first 6 months of the Look AHEAD program and will include 19 group sessions offered over a six month period. Each of 2 groups will contain up to 15 patients with type 2 diabetes and will last 1-1.5 hours. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. The program fosters the development of knowledge and lifestyle skills to change diet and exercise habits through use of goal setting, problem solving, stimulus control and other behavioral techniques that have resulted in weight loss, weight maintenance and improved glycemic control.
10013809|NCT01665989|Active Comparator|Usual Care|A research assistant will provide the usual care group participants with brief (~15-20 minutes) counseling which reviews an educational handout emphasizing that modest weight loss (5 - 10%) via caloric restriction and gradual adoption of moderate increases in daily physical activity (equivalent to brisk walking for 30 minutes daily) is safe and effective in managing diabetes; and refer them to Nutrition Services for follow up.
10013810|NCT01666015|Experimental|Exercise (EX)|This group will perform two phases of an EX program.
10013811|NCT01666015|Active Comparator|Standard Care|This group will follow the standard care without any EX prescription.
10013812|NCT01666028|Experimental|Closed Loop Glucose control|Subject's glucose level is controlled by the automated closed loop glucose control system
10013813|NCT01666028|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
10013814|NCT01666041|Placebo Comparator|placebo|placebo
10013815|NCT01666041|Active Comparator|fenofibrate/omega|fenofibrate/omega
10013816|NCT01666041|Active Comparator|fenofibrate|fenofibrate
10013817|NCT01666054|Active Comparator|Proportional Assist Ventilation (PAV)|Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
10013818|NCT01666054|Active Comparator|Pressure Support Ventilation (PSV)|Pressure Support Ventilation on the PV840 ventilator will be used according to a weaning algorithm. If patients develop distress despite maximal level of support on PSV, they will be temporarily switched to assist-control mode.
10013819|NCT01666067|Active Comparator|placebo|placebo
10013820|NCT01666067|Active Comparator|vytorin|vytorin
10013821|NCT01666067|Active Comparator|simvastatin|simvastatin
10013822|NCT01666080|Other|Reduced Intensity Conditioning|Includes patients receiving a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using reduced intensity conditioning (RIC). Patients will receive busulfan, fludarabine, total body irradiation and stem cell transplant. Keppra will be given for seizure prophylaxis.
10037308|NCT01823887|Experimental|Left Sided Stimulation|Left cervical Vagus Nerve Stimulation (VNS)
10013823|NCT01666093|Other|revascularization group|patients will revascularized after a conservative treatment failure of at least 4 weeks
10013824|NCT01666106||Subjects with cancer and ONJ|Subjects with cancer and positively adjudicated ONJ
10035903|NCT01810731|Active Comparator|Inactivated Polio Vaccine|A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
10035904|NCT01810731|Experimental|Double Dose QIV|"30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
10035905|NCT01810744|Other|metastatic colorectal cancer|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
10035906|NCT01810744|Other|glioblastoma|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
10035907|NCT01810757|Active Comparator|Standard planning|Standard planning radiotherapy
10035908|NCT01810757|Experimental|Adaptive planning|Adaptive planning radiotherapy
10037309|NCT01823887|Experimental|Right Sided Stimulation|Right Cervical Vagus Nerve Stimulation (VNS)
10037310|NCT01823900|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 7 days apart in a fasted state
10037311|NCT01823913|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 14 days apart in a fasted state
10037312|NCT01823926|Active Comparator|Control Group|Noninvasive ventilation + jet nebulizer
10037313|NCT01823926|Experimental|Experimental Group|Noninvasive ventilation + vibrating mesh nebulizer
10037314|NCT01823939|Other|Males / Females (Healthy)|Part A: This initial part of the study will be conducted in adult Bangladeshi healthy volunteers (4 males, 4 females) to assess the pharmacokinetics, safety, and tolerability of single doses of iOWH032. Participants will be admitted to the Clinical Trial Unit (CTU) of icddr,b (located at a 10 minute drive from the icddr,b main campus) the day prior to dosing and remain for 48 hours after dosing, unless treatment and/or follow-up of an adverse event (AE) require longer in-unit observation or treatment.
10037315|NCT01823939|Other|Males (Patient)|Part B: Patients will be eligible for the study if they have clinically severe dehydration and meet all other inclusion and exclusion criteria. Upon signing consent, they will be admitted to the Research Ward of the Dhaka Hospital of icddr,b.
10037316|NCT01823952||Males|Adult 18-65
10037317|NCT01823965|Experimental|ranibizumab|
10037318|NCT01823978|Experimental|BPX-201|BPX-201 vaccine plus AP1903
10037319|NCT01824004|Experimental|S-1,chemoradiotherapy, adjuvant treatment|Pts with radically D2 resected adenocarcinoma of the stomach or GEJ in AJCC stage Ib-IV (M0) were eligible for this study. Pts were treated with S-1 (40-60 mg depending on BSA) b.i.d. for 3 wks, and cisplatin (60 mg/m²) iv on day 1, followed by a 2-wk rest period, within a 5-wk cycle. Subsequently, radiotherapy (RT) started which consisted of 25 fractions of 1.8 Gy to a total dose of 45 Gy in 5 wks (5 fractions/wk). On RT days, S-1 (40-60 mg depending on BSA ) b.i.d., 5 days/wk was given. One month after the completion of RT, two 5-wk cycles of S-1/ciplatin chemotherapy were given.
10037320|NCT01824017|Other|Blood Draw|Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting
10037321|NCT01824030|Active Comparator|FFR guided PCI arm|Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80
10037322|NCT01824030|Active Comparator|OCT guided PCI arm|"Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:~percentage area stenosis ≥75 %~percentage area stenosis between 50 and 75% and minimal lumen area <2.5 mm2~percentage area stenosis between 50 and 75% and major plaque ulceration"
10037323|NCT01824043|Experimental|vitreous hemorrhage group|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
10037324|NCT01824056|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP . Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
10037325|NCT01824069|Experimental|Autologous mesenchymal stem cells|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis
10037326|NCT01824095|Placebo Comparator|placebo|Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
10037327|NCT01824095|Experimental|dietary supplement|"Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day."
10037328|NCT01824108|Active Comparator|control group: Lumbar discectomy|Lumbar discectomy alone
10037329|NCT01824108|Experimental|Treatment group: lumbar discectomy + Wallis implant|lumbar discectomy combined with Wallis interspinous dynamic stability system
10013825|NCT01666132|Experimental|Intramyocardial injection of BM cells|
10013826|NCT01666132|Experimental|Intramyocardial / intracoronary injection of BM cells|
10013827|NCT01666132|Other|control|
10013828|NCT01666158|Active Comparator|Exercise|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. Additionally, these patients will be given a specific physical exercise program before and after surgery by kinesiologist.
10013829|NCT01666158|No Intervention|Standard nutrition counselling|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. This group will receive general instructions on exercises (breathing, ankle rotation) to be done during hospital stay by kinesiologist.
10013830|NCT01666223|Experimental|Colesevelam|
10013831|NCT01666223|Experimental|Chenodeoxycholic acid|
10013832|NCT01666223|Experimental|Colesevelam + chenodeoxycholic acid|
10013833|NCT01666223|Experimental|Placebo|
10013834|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
10013835|NCT01666249|Experimental|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
10013836|NCT01666262|Experimental|A/17/CA/2009/38 (H1N1)|
10013837|NCT01666262|Placebo Comparator|Stabilizer|
10013838|NCT01666275||Aspirin desensitization|This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.
10013839|NCT01666288||IT Anaphylaxis|Blood samples will be taken from patient that develop anaphylaxis to routine outpatient allergen or venom immunotherapy.
10013840|NCT01666301|Active Comparator|C.E.R.A.|C.E.R.A. every 4 and then every 2 weeks
10013841|NCT01666301|Active Comparator|Darbepoetin|Darbepoetin alfa every 4 and then every 2 weeks
10013842|NCT01666327|Experimental|MT-1303|
10013843|NCT01666353|Experimental|Therapeutic response for solid tumors|Adult patients, with documented metastatic melanoma, RCC or NSCLC, about to initiate any line of immune checkpoint blockade therapy will receive a FDG PET scan during mid treatment to check for change in disease.
10013844|NCT01666366|Active Comparator|In Situ Bilateral mammary grafting|Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
10013845|NCT01666366|Active Comparator|Y composite Bilateral mammary grafting|Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
10013846|NCT01666379|Experimental|Fentanyl|
10013847|NCT01666379|Placebo Comparator|placebo|
10013848|NCT01666392|Experimental|Fish oil (Omega-3 fatty acid)|2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA
10013849|NCT01666392|Placebo Comparator|Soybean oil|2 capsules/day
10013850|NCT01666405|Experimental|Urgent(R) PC Neuromodulation System|Urgent(R) PC Neuromodulation System
10013851|NCT01666418|Other|Pazopanib/Paclitaxel|
10013852|NCT01666431|Other|Lapatinib|
10013853|NCT01666457||Pre-SOFFI infants|Infants discharged from the NICU prior to the implementation of the SOFFI infant driven feeding program with NICU staff.
10013854|NCT01666457||Post SOFFI infants|Subject infants discharged from the NICU at least 6 months after the implementation of the SOFFI infant driven feeding program and
10013855|NCT01666470||Drug allergy patients|Patients with a history of drug allergy in Thailand
10013856|NCT01666483|Active Comparator|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
10035909|NCT01810770|Experimental|Radium-223 dichloride|
10035910|NCT01810796|Experimental|Ranolazine treatment|Ranolazine 500-1000mg bid
10035911|NCT01810796|Placebo Comparator|Placebo|Placebo
10035912|NCT01810809|Active Comparator|Articular Lavage|Patients from Group Zero will receive articular lavage with saline injection
10013857|NCT01666483|Active Comparator|laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip.Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
10013858|NCT01666496|Experimental|Experimental Video Game|Participants will play the experimental videogame for 6 weeks. The intervention will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
10013859|NCT01666496|Other|Off the Shelf Video Game|Participants will play the off the shelf videogame for 6 weeks. The intervention be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
10013860|NCT01666509|Experimental|Rossoseq™|Gel, topically applied twice daily
10013861|NCT01666509|Placebo Comparator|Vehicle|Gel, topically applied twice
10013862|NCT01666522|Experimental|Vitamin D|vitamin D-oral cholecalciferol 2000 IU/day for 4 months
10013863|NCT01666522|Active Comparator|Physical activity|A 3-day/week exercise programme lasting 60 minutes each day for 4 months was instigated.
10013864|NCT01666522|Experimental|Vitamin D and Physical activity|Vitamin D -oral cholecalciferol 2000 IU/day and Physical activity-60-minute 3-day/week exercise programme
10013865|NCT01666522|Placebo Comparator|Control|The control group was provided with health education using videotaped presentations, physician talks on topics concerning bone and muscle health.
10013866|NCT01666535|Other|Influenza vaccination Timing #1|Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).
10013867|NCT01666535|Other|Influenza vaccination Timing #2|Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)
10013868|NCT01666561|Experimental|Breakfast Test Cereal 1, Oat based|"Test cereal 1, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
10013869|NCT01666561|Experimental|Breakfast Test Cereal 2, Oat-based|"Test Cereal 2, Oat-based breakfast cereal. You will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat oat brand cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
10013870|NCT01666561|Experimental|Ready-to-eat cereal|"Ready-to-eat cereal, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~one Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
10013871|NCT01666574|Experimental|Test cereal 1, Oat-based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based cereal will cause people to eat less at lunch.
10013872|NCT01666574|Experimental|Test Cereal 2, Oat based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based ready-to-eat cereal will cause people to eat less at lunch.
10013873|NCT01666587|No Intervention|control|Control trial to determine the impact of the ischemic injury on vascular function without intervention
10013874|NCT01666587|Experimental|Antioxidant load|Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery
10013875|NCT01666587|Experimental|Prostaglandin inhibition|Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery
10013876|NCT01666587|Experimental|Combined|Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery
10013877|NCT01666600|Experimental|BIBF 1120 + reirradiation|2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
10013878|NCT01666600|Active Comparator|reirradiation alone|radiotherapy (2 Gy / fraction; 36 Gy in total)
10013879|NCT01666613|Experimental|1|AZD8683 iv
10013880|NCT01666613|Experimental|2|AZD8683 oral
10013881|NCT01666613|Experimental|3|AZD8683 inhalation New Dry Powder Inhaler
10013882|NCT01666613|Experimental|4|AZD8683 inhalation Turbuhaler™
10013883|NCT01666626||Crohn's Inpatients|Crohn's Inpatients, with clinical small bowel obstruction All undergo ultrasound stiffness imaging (USI) of distal affected ileum.
10013884|NCT01666626||Crohn's Outpatients|Crohn's Outpatients, starting anti-TNF therapy All undergo ultrasound stiffness imaging (USI) at week 0, 6, 14
10013885|NCT01666639|Active Comparator|Control Group|
10013886|NCT01666639|Experimental|Intervention Group|
10013887|NCT01666665|Active Comparator|metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
10013888|NCT01666665|Placebo Comparator|Sugar pill|sugar pill up to 3 times per day for 12 months
10013889|NCT01666678|Experimental|Arm 1|
10013890|NCT01666678|Active Comparator|Arm 2|
10013891|NCT01666678|Active Comparator|Arm 3|
10013892|NCT01666678|Experimental|Arm 4|
10013893|NCT01666691|Placebo Comparator|Placebo|ZGN-440 sterile diluent
10013894|NCT01666691|Experimental|0.3 mg Beloranib|0.3 mg ZGN-440 for injectable suspension
10013895|NCT01666691|Experimental|0.6 mg Beloranib|0.6 mg ZGN-440 for injectable suspension
10013896|NCT01666691|Experimental|1.2 mg Beloranib|1.2 mg ZGN-440 for injectable suspension
10013897|NCT01666691|Experimental|2.4 mg Beloranib|2.4 mg ZGN-440 for injectable suspension
10013898|NCT01666691|Experimental|3.2 mg Beloranib|3.2 mg ZGN-440 for injectable suspension
10013899|NCT01666704|Experimental|Treatment A: BMS-823778 (2mg)|
10013900|NCT01666704|Experimental|Treatment B: BMS-823778 (15mg)|
10013901|NCT01666704|Placebo Comparator|Treatment C: Placebo|
10013902|NCT01666717||Healthy controls (HC)|HC
10013903|NCT01666717||Inflammatory Bowel Disease (IBD) patients|Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
10013904|NCT01666743|Experimental|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
10013905|NCT01666756|Experimental|Treatment (Chinese herbal formulation PHY906 and sorafenib)|Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10013906|NCT01666769|Other|Treatment Dosing|Age group: 0 - <2y, Micafungin 8 mg/kg/day IV
10013907|NCT01666769|Other|Prophylaxis dosing|Age group: 0-<2y, Micafungin 4 mg/kg/day IV
10013908|NCT01666769|Other|Standard of care Dosing|Age group: 2-17.85 y, Micafungin standard of care dosing (decided by treating physician)
10013909|NCT01666795||IVIG therapy in ITP|IVIG therapy in untreated adults with severe ITP
10013910|NCT01666821||early and intermediate-stage AMD|Follow-up observation was implemented in whose fundus examination show lesions in the early and intermediate-stage AMD
10013911|NCT01666847|Experimental|Cord Milking|Infant receiving cord milking intervention before umbilical cord clamped.
10013912|NCT01666847|No Intervention|Immediate Cord Clamping|Infant whose umbilical cord is immediately clamped after delivery.
10013913|NCT01666860||Anterior Lumbar Interbody Fusion procedure|
10013914|NCT01666873||total knee prosthesis|Patients that undergo a total knee prosthesis.
10013915|NCT01666886|Experimental|Mandibular Advancement Device (MAD)|Mandibular advancement during therapy with a mandibular advancement device (MAD) in 90% of maximal protrusion
10013916|NCT01666899|Experimental|Skin and blood vessel procedures|All patients will be placed into Arm 1. They will undergo punch biopsies of the breast skin at the time of mastectomy and at 2, 4, 6, 8 and 12 months after completion of radiation therapy. Three more biopsies will be taken at 3, 6, and 12 months after completion of reconstruction. Patients will also undergo skin blood flow studies with a laser imaging device prior to each biopsy procedure. Ultrasound studies of the chest vessels will be performed 4 times over the course of the study- once prior to radiation and at 2, 6 and 12 months after radiation.
10013917|NCT01666925|Experimental|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
10013918|NCT01666925|Active Comparator|Rabies vaccine|2 x 2.5IU Verorab
10013919|NCT01666938|Experimental|Diabetes Education Group & Telephone counseling|This step was done for four months.
10013920|NCT01666938|Active Comparator|Telephone counseling about physical activity|This step was done for four months.
10013921|NCT01666964||3 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe
10013922|NCT01666964||6 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe
10013923|NCT01666990|Experimental|TwHF, lifestyle counseling|Participants will receive TwHF (20mg each time, 3 times per day, for 48 weeks) from Day 0 through the Week 48 study visit.
10013924|NCT01666990|Placebo Comparator|placebo, Lifestyle|Participants will receive placebo treatment (20mg each time, three times per day for 48 weeks) from Day 0 through the Week 48 study visit.
10013925|NCT01667003||Orsiro DES|
10013926|NCT01667016||Orsiro DES|
10013927|NCT01667042||Without Interstitial lung disease (ILD)|
10013928|NCT01667042||With Interstitial lung disease (ILD)|
10013929|NCT01667055||Patients with suspected drug allergy|Patients with a history of hypersensitivity reaction to beta-lactam antibiotics
10013930|NCT01667068||Regional Ruhrgebiets Cohort|HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
10013931|NCT01667081||Grazoprevir|Participants who previously received grazoprevir as study treatment on a prior study.
10013932|NCT01667094|Active Comparator|Intermittent, short infusion|"Infusion over 30 minutes of either:~Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24~Antibiotic chosen by treating physician"
10013933|NCT01667094|Experimental|Continuous infusion|"Continuous infusion of either:~Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g~Antibiotic chosen by treating physician"
10013934|NCT01667120|Placebo Comparator|Placebo|Postoperative surgical neonates will receive an equivalent volume of 0.9% normal saline as placebo.
10013935|NCT01667120|Experimental|Ketorolac|Postoperative ketorolac 0.5mg/kg intravenously every 8 hrs for 72hrs will be administered.
10013936|NCT01667133|Experimental|Phase 1 dose escalation|Phase 1
10013937|NCT01667133|Experimental|Phase 2 expansion|Phase 2
10013938|NCT01667146|Experimental|PHARLAP ventilation group|PHARLAP mechanical ventilation strategy
10013939|NCT01667146|Active Comparator|Control group ventilation|Control group mechanical ventilation strategy
10013940|NCT01667159|Experimental|Integrated Cognitive Behavioral Therapy|Adolescents and their parent(s) will receive integrated cognitive behavioral therapy.
10013941|NCT01667159|Active Comparator|Standard Care|Adolescents and their parent(s) will receive treatment as usual through a community intensive outpatient program.
10013942|NCT01667172|Other|point-of-care test for CRP|
10013943|NCT01667185||Pediatric subjects with diabetes mellitus|
10013944|NCT01667198|Experimental|Train the leaders course|
10013945|NCT01667198|Active Comparator|Audit and feedback|
10013946|NCT01667211|Experimental|albumin-bound paclitaxel plus nedaplatin|albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
10013947|NCT01667237|Experimental|Pulmonary rehabilitation|
10013948|NCT01667263|Experimental|All-trans retinoic acid ＆Danazol|Danazol 400mg po and ATRA 10mg bid po
10013949|NCT01667263|Active Comparator|Danazol|Danazol 400mg po
10013950|NCT01667289|Active Comparator|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
10013951|NCT01667289|Experimental|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
10013952|NCT01667302|Experimental|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
10013953|NCT01667315|Experimental|Bupivacaine|Bupivacaine 0,375%
10013954|NCT01667328|Experimental|Massage therapy|This group will received presurgical massage
10013955|NCT01667328|Placebo Comparator|Control|Standard of care with no massage
10013956|NCT01667354|Experimental|Intervention Clinics|Providers in intervention clinics will receive a training followed by telephone coaching and follow-up visits for six months.
10013957|NCT01667354|No Intervention|Control Clinics|Control clinics will receive all intervention materials at the completion of the study.
10013958|NCT01667367|Placebo Comparator|Placebo|
10013959|NCT01667367|Experimental|RG1662|
10013960|NCT01667380||Cohort|
10013961|NCT01667393|Experimental|IDEV SUPERA Stent|Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.
10013962|NCT01667393|Active Comparator|Percutaneous Transluminal Angioplasty|The target lesion will be treated by PTA alone.
10013963|NCT01667445|Experimental|epimorph|single dose administration of 150mcg epimorph
10013964|NCT01667445|Active Comparator|spinal analgesia|spinal alone
10013965|NCT01667458||Cohort|
10013966|NCT01667484|Placebo Comparator|Placebo|treatment group #1
10013967|NCT01667484|Active Comparator|Adderall XR 5mg|treatment group #2
10013968|NCT01667484|Active Comparator|Adderal XR 10mg|treatment group #3
10013969|NCT01667497|Experimental|Fampridine SR|Fampridine SR 10mg BID
10013970|NCT01667497|Placebo Comparator|Placebo|non-drug
10013971|NCT01667510|Experimental|Cardio Mato|Soft gel capsule for oral use (Grade A Lyc-O-Mato, a tomato extracted lycopene)
10013972|NCT01667510|Placebo Comparator|Placebo|Soft gel capsule without test material, for oral use
10013973|NCT01667523|Experimental|Capsaicin|
10013974|NCT01667523|Experimental|Cinnamaldehyde|
10013975|NCT01667523|Placebo Comparator|Placebo|Physiological saline
10013976|NCT01667575|Experimental|10 day Quadruple Therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
10013977|NCT01667575|Active Comparator|10 day Triple therapy|Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
10013978|NCT01667575|Active Comparator|14 day quadruple therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
10013979|NCT01667588||Pre-Dialysis|
10013980|NCT01667588||Dialysis|
10013981|NCT01667601|Experimental|Mindfulness-based program|A structured, researcher-designed mindfulness-based psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education programs by Chien et al. (2010) and Lehman et al. (2004), as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn (1990).
10013982|NCT01667601|Other|Routine Care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
10013983|NCT01667601|Active Comparator|Psychoeducation group|"A psychoeducation group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.~References:~Chien WT, Bressington D. A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Res 2015;229:277-86.~Macpherson R, Jerrom B, Hughes AA. controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-17."
10013984|NCT01667614|No Intervention|ACE/ARB|In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
10013985|NCT01667614|Active Comparator|Spironolactone/ARB|spironolacone 25 mg tablets added to losartan
10013986|NCT01667627|Active Comparator|BIO-25, Probiotic-mixture|Two capsules a day.
10013987|NCT01667627|Placebo Comparator|Placebo|Identical to the Bio-25 capsule: same taste, same colour, same appearance
10013988|NCT01667640|Active Comparator|whole brain irradiation|whole brain irradiation with 40 Gy, with fixation mask, radiation of the entire brain, skull base and meninges
10013989|NCT01667640|Experimental|sector irradiation|irradiation of the resection margin plus 5 mm safety margin with 30 Gy in 5 fractions
10013990|NCT01667653|Experimental|Augmentin/Probiotic|Participants are provided in double blinded fashion probiotic to take with antibiotics
10013991|NCT01667653|Experimental|Augmentin/placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
10013992|NCT01667666|Experimental|Nebulized HTS|The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
10013993|NCT01667692|Experimental|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
10013994|NCT01667692|Experimental|clarithromycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
10013995|NCT01667705||SkyCeiling during CT-Suite visit|Patients in the trial group are exposed to the SkyCeiling during their procedure.
10013996|NCT01667705||No SkyCeiling during CT-Suite visit|Patients in the trial group are not exposed to the SkyCeiling during their procedure.
10013997|NCT01667718|Active Comparator|Levofloxacin-triple therapy|Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
10013998|NCT01667718|Experimental|Levofloxacin-quadruple therapy|Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
10013999|NCT01667744|Placebo Comparator|Placebo|Placebo pill
10014000|NCT01667757||low post DES FFR group (<0.9)|the patient with FFR values less than 0.9 after DES procedure
10014001|NCT01667757||high post DES FFR group (≥0.9)|the patient with FFR values greater than 0.9 after DES procedure
10014002|NCT01667770|Active Comparator|surgery - autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using autologous graft
10014003|NCT01667770|Active Comparator|surgery - non-autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using using non-autologous graft
10035913|NCT01810809|Experimental|Group 1|Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
10035914|NCT01810809|Experimental|Group 2|Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
10035915|NCT01810809|Experimental|Group 3|Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
10035916|NCT01810822||Genesis French-Belgium Study|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 501 patients, including 279 individuals (55.7%) with diagnosis of diabetic nephropathy.
10035917|NCT01810822||GENEDIAB|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
10035918|NCT01810822||Brazilian cohort|The cohort comprised 451 patients with type 1 diabetes for more than 10 years (56% women; aged 36 ± 11 years, mean ± SD) recruited in diabetes/endocrinology departments of three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre (RS), Brazil.
10035919|NCT01810848|Active Comparator|Hylan G-F 20|Patients will receive a single injection of hylan G-F 20 6ml into affected knee. Injections will be performed under fluoroscopic guidance.
10014004|NCT01667783|Active Comparator|Gastric Banding|Laparoscopic Adjustable Gastric Banding
10014005|NCT01667783|Active Comparator|Medical Weight Loss|Medical Weight Loss using a comprehensive lifestyle intervention consisting of diet (meal replacements), physical activity and behavioral techniques
10014006|NCT01667783|Active Comparator|Gastric Bypass|Roux-en-Y Gastric Bypass
10014007|NCT01667809|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common subclinical mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
10014008|NCT01667809|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
10014009|NCT01667822|Active Comparator|Continued guided self help CBT|Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).
10014010|NCT01667822|Experimental|CBT individual therapy|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
10014011|NCT01667835|Experimental|Yoga Intervention|
10014012|NCT01667835|No Intervention|Control|
10014013|NCT01667861||(Wind) musicians|Members of (professional) orchestras, especially wind instrument players.
10014014|NCT01667874|No Intervention|No Collatamp sponge|Joint infection treated without the use of the Collatamp G sponge.
10014015|NCT01667874|Experimental|Collatamp G sponge|Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
10014016|NCT01667887||Femur Fractures|Patients with Distal Femur Fractures
10014017|NCT01667913|No Intervention|6 minutes walking test|
10014018|NCT01667939|Experimental|pregnancy diet|Healthy Eating Index (HEI) in supervised pregnancies
10014019|NCT01667939|No Intervention|unsupervised pregnancy|women attending the obstetrics unit who did not follow a supervised diet
10014020|NCT01667952||Cancer Survivors|The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
10014021|NCT01667965||pts receiving palliative radiation therapy|The design of the study will be a prospective non-randomized cohort study with structured questionnaires administered to all enrolled patients at two or three time-points.
10014022|NCT01668043|Experimental|Antibody UB-421 Cohort 1|10 mg/kg BW, 8 weekly doses for 8-week treatment period
10014023|NCT01668043|Experimental|Antibody UB-421 Cohort 2|25 mg/kg BW, 4 biweekly doses for 8-week treatment period
10035920|NCT01810848|Sham Comparator|Control|Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
10014024|NCT01668056|Active Comparator|Control|Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
10014025|NCT01668056|Experimental|Ovulation induction|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will receive 250 micrograms of choriogonadotropin alfa subcutaneously. Daily transvaginal ultrasound scans will be done starting two days after the administration of the medication until a cohort of ovarian follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
10014026|NCT01668056|Experimental|Dominant follicle aspiration|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
10014027|NCT01668069|Experimental|Ondansetron|study drug
10014028|NCT01668069|No Intervention|Doxylamine and Pyridoxine (vitamin B6)|other nausea treatment in use
10014029|NCT01668095||Ancillary-Correlative (biomarker analysis)|Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
10014030|NCT01668108||carcinoma, Paclitaxel onkovis (Paclitaxel)|treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.
10014031|NCT01668121|Experimental|Symbicort Turbohaler|Symbicort Turbohaler
10014032|NCT01668121|Active Comparator|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
10014033|NCT01668134|Experimental|Stereotactic radiation|
10014034|NCT01668160|Experimental|Revision Total Hip|patients recieving a revision total hip replacement will be assessed for implant stability and wear using RSA. Tantalum beads will be placed in the polyethylene and surrounding pelvic and femoral bone.
10014035|NCT01668199|Experimental|14C TZP-101|
10014036|NCT01668212||natural In Vitro Fertilization cycle|Patient doing following natural In Vitro fertilization cycle
10014037|NCT01668238||malignant tumor|Inpatients with malignant tumors of thyroid and breast
10014038|NCT01668238||benign tumor|Inpatients with benign tumors of thyroid and breast
10014039|NCT01668238||Healthy volunteers|Volunteers without thyroid or breast tumors
10014040|NCT01668251||Fetal ascertainment|Girls who are diagnosed with Turner syndrome because of concerns raised by an abnormal fetal ultrasound.
10014041|NCT01668251||Maternal ascertainment|Girls who are diagnosed with Turner syndrome because their mothers had an amniocentesis for a reason other than an abnormal fetal ultrasound concerning for Turner syndrome. For example an amniocentesis was done because of advanced maternal age or because of an abnormal triple screen or because another condition was being screened for such as trisomy 21.
10014042|NCT01668264|Experimental|Magnetic Resonance Imaging (MRI)|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
9665218|NCT05130983|Experimental|15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46|Arm 2: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15).
10014043|NCT01668264|Experimental|Echocardiograph|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
10014044|NCT01668277|Experimental|3 ml/kg 7.2% NaCl|The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
10014045|NCT01668277|Active Comparator|3 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
10014046|NCT01668277|Active Comparator|20 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
10014047|NCT01668290||Stress Echocardiography|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Stress Echocardiography.
10014048|NCT01668290||SPECT|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Single Photon Emission Computed Tomography (SPECT)
10014049|NCT01668290||CCTA|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Cardiac Computed Tomographic Angiography (CCTA)
10014050|NCT01668303|Experimental|Miami Juvenile Drug Court-MDFT|Multidimensional family therapy (MDFT) is primarily a family-based approach (Liddle, 2002)which conducts individual sessions with the teen and parent[s] but not peer-group sessions.
10014051|NCT01668303|Other|Miami Juvenile Drug Court -TAU|The Treatment as Usual (TAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions.
10014052|NCT01668316|Experimental|Weight loss|12 week weight loss program with biweekly meetings with a Registered Dietitian. Participants will be given a nutrition prescription and asked to record dietary intake online. Participants will be given a pedometer and record daily physical activity.
10014053|NCT01668316|No Intervention|Control|Participants asked to not change dietary and physical activity habits.
10014054|NCT01668342|Experimental|SMS assessments & feedback|Daily symptom assessments of headaches, trouble ocncentrating and irritability/anxiety with self-care feedback based on response severity.
10014055|NCT01668342|No Intervention|Control|Standard of care
10014056|NCT01668368|Other|Esophageal balloon group|"Esophageal balloon will be inserted, and esophageal pressure will be measured in patients with acute respiratory failure.~Intervention - PEEP and Inspiratory pressure will be adjusted according to the measured esophageal pressure."
10014057|NCT01668381||HCC patients|Hepatocellular carcinoma patients treated by radiofrequency ablation
10014058|NCT01668394|Active Comparator|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
10014059|NCT01668394|Placebo Comparator|Control arm|Usual care. Teaching style: deductive.
10014060|NCT01668407|Experimental|Robot-Assisted Gait Training (RAGT)|Robot-Assisted Gait Training (RAGT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
10014061|NCT01668407|Active Comparator|Treadmill Gait Training (TT)|Treadmill Gait Training (TT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
10014062|NCT01668420|Experimental|noxious thermal stimulation|Heat-pain:46-47°C and Cold-pain:2-3°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
10014063|NCT01668420|Active Comparator|thermal stimulation (innocuous)|Heat:40-41°C and Cold:23-24°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
10014064|NCT01668433|Active Comparator|G6PD Normal|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
10014065|NCT01668433|Experimental|G6PD deficiency|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
10014066|NCT01668446|Experimental|sildenafil|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
10014067|NCT01668446|Experimental|Sildenafil and estradiol valerat|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
10014068|NCT01668459|Experimental|Cabazitaxel|6 cycles (3 weekly) of 25 mg/m^2 IV infusion
10014069|NCT01668459|Other|Best Supportive Care|Best supportive care including single agent chemotherapy as determined by the patient's study doctor
10014070|NCT01668485|Experimental|Islet transplant recipients|Hypoglycemic and euglycemic glucose clamp
10014071|NCT01668485|Placebo Comparator|Type 1 diabetic subjects|Hypoglycemic and euglycemic glucose clamp.
10014072|NCT01668485|Active Comparator|Non-diabetic subjects|Hypoglycemic and euglycemic glucose clamp
10014073|NCT01668498|Experimental|Erythromycin|Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
10014074|NCT01668498|Active Comparator|Doxycyline|Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
10014075|NCT01668511|Experimental|Group 1|Randomized 7 drug/2 placebo by group
10014076|NCT01668511|Experimental|Group 2|Randomized 7 drug/2 placebo by group
10014077|NCT01668511|Experimental|Group 3|Randomized 7 drug/2 placebo by group
10014078|NCT01668511|Experimental|Group 4|Randomized 7 drug/2 placebo by group
10014079|NCT01668524|Experimental|Single Arm: ATS907|Single-cohort, dose-escalation
10014080|NCT01668563|Active Comparator|Endovascular management|Endovascular treatment will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
10014081|NCT01668563|Active Comparator|Surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
10014082|NCT01668641|Experimental|capsule, 30mg GLPG0634 once a day|3 capsules of 10 mg once a day
10014083|NCT01668641|Experimental|capsules, 75mg GLPG0634 once a day|3 capsules of 25mg once a day
10014084|NCT01668641|Experimental|capsules, 150mg GLPG0634 once a day|3 capsules of 50mg once a day
10014085|NCT01668641|Experimental|capsules, 300mg GLPG0634 once a day|3 capsules of 100mg once a day
10014086|NCT01668641|Placebo Comparator|capsules, placebo once a day|3 capsules placebo once a day
10014087|NCT01668680|Experimental|LDM anti-angiogenic chemotherapy|LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
10014088|NCT01668680|No Intervention|observation|observation only
10014089|NCT01668693|Active Comparator|RIF ERA Receptive 1|"With the receptive results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis."
10014090|NCT01668693|Experimental|RIF ERA Non Receptive|"The Non Receptive results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the Receptive daignosis. A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool."
10014091|NCT01668706||Methadone maintenance treatment (MMT)|
10014092|NCT01668706||Buprenorphine-Naloxone treatment (BNT)|
10014093|NCT01668706||Medication-free ex-addicts(MF)|
10014094|NCT01668706||Normal control (NC)|
10014095|NCT01668732||community heroin addicts|
10014096|NCT01668745|Experimental|Early measles vaccine|The intervention is about to administer an early standard dose of Edmonston-Zagreb (EZ) measles vaccine in addition to the conventional dose. As such children will be randomised to receive either an early measles vaccine at 4 months after DTP3 or not. Thereafter both groups of children will receive the recommended EZ measles vaccine at 9 months of age according to WHO policy.
10014097|NCT01668745|No Intervention|Control|
10014098|NCT01668810||Beijing region|include six hospitals
10014099|NCT01668810||Guangdong Province|include 3 hospitals
10014100|NCT01668810||Jiangsu province|include 3 hospitals
10014101|NCT01668810||Hebei province|include 6 hospitals
10014102|NCT01668810||Hubei Province|include 7 hospitals
10014103|NCT01668810||Shanxi province|include 3 hospitals
10014104|NCT01668810||Jiangxi province|include 3 hospitals
10014105|NCT01668810||Jilin province|include 6 hospitals
10014106|NCT01668810||Sichuan province|include 3 hospitals
10014107|NCT01668810||Shaanxi province|include 3 hospitals
10014108|NCT01668823|Experimental|Treatment (PDT using HPPH)|Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
10014109|NCT01668849|Experimental|1 - Grape extract|Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.
10014110|NCT01668849|Active Comparator|2 - Lortab, Fentanyl patch, mouthwash|Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.
10014111|NCT01668862|Other|Study arm A|Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
10014112|NCT01668862|Other|Control Arm B|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
10014113|NCT01668875|Experimental|Treatment condition|In intervention period patients were received head-down 30 degree postural drainage position for 10 min.
10014114|NCT01668875|Experimental|Sham condition|In intervention period patients were received horizontal supine lying for 10 min.
9665219|NCT05130450|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
10014115|NCT01668888||Apparently Helathy Subjects|
10014116|NCT01668901|Experimental|warfarin|medication
10014117|NCT01668901|Active Comparator|aspirin|medication
10014118|NCT01668914|Experimental|clinically positive axillary nodes|3~18 hours before surgery, under ultrasonographic guidance, 0.5~1.0 mCi 99mTc-SC in sterile saline (total volume 0.2~2.0 mL) is injected intraparenchymally into 2 quadrants of breast. Subsequently, LSG is performed 0.5~1.0 hour before surgery. Methylthioninium was injected intraparenchymally. IM-SLNB is performed during the surgery and the IMSLNs were sent to histologic examination
10014119|NCT01668927|Experimental|tetracycline/furazolidone|one of the four empirical rescue therapies
10014120|NCT01668927|Experimental|amoxicillin/tetracycline|one of the four empirical rescue therapies
10014121|NCT01668927|Experimental|amoxicillin/furazolidone|one of the four empirical rescue therapies
10014122|NCT01668927|Active Comparator|tetracycline /metronidazole|Classical rescue therapy
10014123|NCT01668979||new system to detect Near Falls|the new system comprises of a treadmill and a virtual reality simulation that will be used to induce Near Falls in healthy older adults with a history of falls.
10014124|NCT01668992|Experimental|Family intervention|Families receive 12-week program on parenting skills, discipline methods and family communication.
10014125|NCT01668992|No Intervention|Waitlist control|Families are on a waitlist and receive the intervention only after the trial is complete.
10014126|NCT01669005||Bone marrow transplant unit patients|hospitalized patients in the bone marrow transplant unit for an autologous or allogeneic hematopoietic stem cells transplantation or induction/consolidation chemotherapy
10014127|NCT01669018|Active Comparator|Lumbar ultrasound trident (LUT)|Lumbar plexus block using LUT technique
10014128|NCT01669018|Experimental|Supra Sacral Parallel Shift (SSPS)|Lumbar plexus block using SSPS technique
10014129|NCT01669031|No Intervention|Control Group|No practice tests are performed in this arm
10014130|NCT01669031|Experimental|Practice Program|"At the 3 study visits exposed to a training session (simulated visual field test on a computer).~Visit 1 they get 2 simulated tests tests per eye. At visits 2 and 3 they get 1 simulated test per eye. Each simulated test takes 3-15 minutes"
10014131|NCT01669044||dexmedetomidine,hemodynamics,injection|Group 1:when the patient can be roused after major abdominal surgery ，we will inject dexmedetomidine at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
10035921|NCT01810861||Serotype distribution (this is a non-interventional study)|Serotype distribution both in pediatrics and adults (this is a non interventional study)
10014132|NCT01669044||propofol,hemodynamics,injection|Group 2 :when the patient can be roused after major abdominal surgery ，we will inject propofol at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg.h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores
10014133|NCT01669057||Congenital heart defect（CHD） group|
10014134|NCT01669057||Normal control group|
10014135|NCT01669070|Experimental|FF 50 mcg powder inhalation|Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
10014136|NCT01669070|Experimental|FF 100 mcg powder inhalation|Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
10014137|NCT01669070|Experimental|FF 200 mcg powder inhalation|Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
10014138|NCT01669070|Experimental|FF 250 mcg IV|Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.
10014139|NCT01669083|Experimental|Cohort 1: GSK557296 10 mg|GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6
10014140|NCT01669083|Experimental|Cohort 2: GSK557296 150 mg|GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13
10014141|NCT01669083|Experimental|Cohort 3|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6
10014142|NCT01669083|Experimental|Cohort 4|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6
10014143|NCT01669109|Experimental|Hatha yoga|"10 weeks of Hatha yoga, designed for patients with colorectal cancer, as a group intervention~1 weekly class (90 minutes)"
10014144|NCT01669109|No Intervention|Usual care|Patients continue their self-directed usual care
10014145|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|The cerebral oxygen saturation of the right and left frontal lobe as well as the thigh oxygen saturation are monitored during spinal anesthesia by means of the near-infrared spectroscopy. Hemodynamic variables were recorded at the same time points.
10014146|NCT01669161|Experimental|VNS|VNS (vagus nerve stimulation) paired with rehabilitation as provided by the Vivistim System.
10014147|NCT01669161|Active Comparator|Rehab Only|Rehabilitation only (no implant, no VNS)
10014148|NCT01669187|Active Comparator|Education brochure|The control group will receive a standard education brochure which will be provided pre-operatively to the participants.
10014149|NCT01669187|Experimental|Live education and exercise instruction|The intervention group will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
10014150|NCT01669200|Placebo Comparator|Placebo Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
10014151|NCT01669200|Experimental|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
10014152|NCT01669213|Active Comparator|ramosetron 0.3 mg|preparation of ramosetron 0.3 mg
10014153|NCT01669213|Active Comparator|ondansetron 8 mg|preparation of ondansetron 8mg
10014154|NCT01669213|Active Comparator|ondansetron 4 mg|preparation of ondansetron 4mg
10014155|NCT01669213|Placebo Comparator|non 5-HT3 receptor antagonist|preparation of normal saline 5 ml
10014156|NCT01669226|Experimental|Regimen B, PEip and TCiv therapy|Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
10014157|NCT01669226|Active Comparator|Regimen A: Standard TCiv therapy|IV paclitaxel plus carboplatin or docetaxel plus carboplatin
10035922|NCT01810874|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
10014158|NCT01669239|Experimental|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
10014159|NCT01669252|Experimental|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
10014160|NCT01669265||OSNA|Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
10014161|NCT01669278|No Intervention|Traditional flexible nasopharyngolaryngoscopy|No sheath procedure
10014162|NCT01669278|Active Comparator|Sheath flexible nasopharyngolaryngoscopy|Flexible nasopharyngolaryngoscopy using endosheath
10014163|NCT01669291|Active Comparator|Bravelle & Menopur Agonist Long Protocol|Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation.
10014164|NCT01669291|Active Comparator|Bravelle & Menopur Antagonist Protocol|Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation.
10014165|NCT01669304|Experimental|Verapamil|Verapamil extended release oral tablets administered in a flexible dose format ranging from 120 mg to 360 mg daily, as determined by severity of headache and dizziness.
10014166|NCT01669304|Experimental|Sertraline|Sertraline oral tablets administered in a flexible dose format ranging from 25 mg to 150 mg daily depending on severity of headache and dizziness.
10014167|NCT01669317|Experimental|Cherry Juice Standardized|You will be given an 8-ounce glass of cherry juice to drink when you arrive at the Sleep Laboratory.
10014168|NCT01669317|Placebo Comparator|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice to drink when you arrive at the Sleep Laboratory.
9476764|NCT03568565|Experimental|ePREP Program|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
9476765|NCT03568565|Experimental|ePREP Program plus Coach|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Couples also have four, brief video or phone calls with a coach throughout the program.
9476766|NCT03568565|Experimental|OurRelationship Program|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner.Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
9476767|NCT03568565|Experimental|OurRelationship Program plus Coach|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s). Couples also have four, brief video or phone calls with a coach throughout the program.
9476768|NCT03568565|No Intervention|Waitlist|Participants are assessed at 1, 2, 4, and 6 months after randomization; however, no active intervention is given during the waitlist period.
9476769|NCT03568526|Experimental|Supportive Care (sensorimotor rehabilitation program)|Patients attend 1 therapy session to receive education and training in the use of the home program. Patients then complete exercises over 90 minutes per week for 6 weeks.
9476770|NCT03568513|Experimental|Treatment|Patients in the treatment arm with weight between 35 kg to 50 kg will receive 50 mg capsule of curcumin twice a day (maximum dose 2.8 mg/kg/day, which is within the GRAS approved dose) and those over 50 kg in weight will receive three curcumin capsules a day (maximum dose 3 mg/kg/day, within GRAS recommended dose). Study duration will be 8 weeks.
9476771|NCT03568513|Placebo Comparator|Placebo|Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
9476772|NCT03568487|Experimental|Intensive scapula-focused approach|
9476773|NCT03568487|Active Comparator|Control therapy|
9476774|NCT03568474|Experimental|Silver Diamine Fluoride|Silver Diamine fluoride will be applied after after minimal caries removal then glass ionomer over it followed by composite resin restoration.
9476775|NCT03568474|Active Comparator|Glass Ionomer|Glass ionomer will be applied after minimal caries removal followed by composite resin restoration.
9476776|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
9476777|NCT03568409|Experimental|Group A: ABO-GLYC|Libramed
9476778|NCT03568409|Placebo Comparator|Group B: Placebo|
9476779|NCT03568396||Pupillometry|The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.
9476780|NCT03568370|Experimental|olive oil|use one drop olive oil on each nipple after each feeding
9476781|NCT03568370|No Intervention|breast milk|use breast milk on each nipple after each feeding
9476782|NCT03568357||Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
9476783|NCT03568331|Experimental|Tradipitant|
10014169|NCT01669330|Active Comparator|Total fundoplication|Procedure: Laparoscopic Nissen fundoplication
10014170|NCT01669330|Active Comparator|Anterior partial fundoplication|Procedure: Laparoscopic anterior partial fundoplication
10014171|NCT01669356|Experimental|PN supplement|Parenteral supplement with enteral nutrition for patients after esophagectomy
10014172|NCT01669356|Active Comparator|EN alone|Enteral nutrition alone for patients after esophagectomy
10014173|NCT01669369|Placebo Comparator|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
9476784|NCT03568331|Placebo Comparator|Placebo|
10014174|NCT01669369|Experimental|Lithium Carbonate|Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
10014175|NCT01669382|Active Comparator|Exo Seal system|Percutaneous coronary intervention
10014176|NCT01669382|Active Comparator|AngioSeal system|percutaneous coronary intervention
10014177|NCT01669395|Experimental|Early homebased rehabilitation|After discharge from the hospital patients are offered a homebased rehabilitation program lasting 6 weeks.
10014178|NCT01669395|Experimental|control group: Ususal care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
9476785|NCT03568279|Active Comparator|Control|The attending anesthesiologist provided intubation without two-handed jaw thrust.
9476786|NCT03568279|Experimental|Two-hand|The attending anesthesiologist provided intubation with two-handed jaw thrust.
9476787|NCT03568253|Active Comparator|Bulk fil composite|
9476788|NCT03568253|Active Comparator|High viscosity glass ionomer|
9476789|NCT03568240||30 men suffering from apnea|
9476790|NCT03568240||15 men defined as snorers|
10014179|NCT01669408|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
10014180|NCT01669408|No Intervention|Control group|Best medical treatment following international stroke guidelines
10014181|NCT01669447|Experimental|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
10014182|NCT01669460|Experimental|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days
10014183|NCT01669473|Experimental|Intervention Arm|"EHR Based Strategy to promote Safe and Appropriate Drug Use~Patients randomized to the intervention arm will be given (3) print tools to assist in safe and appropriate medication use. These include a Medreview, Medsheet,and Medlist."
10014184|NCT01669473|No Intervention|Standard Care Arm|The control group will receive regular standard care at the Clinic. They will not receive any print tools.
10014185|NCT01669486||ICU patients|All patients admitted to ICU for a minimal hospitalization of 24 hours, invasive mechanically ventilated, will be evaluated with CPOT and BPS scores, during nurses work, in particular before and after nurses manoeuvers.
10014186|NCT01669499|Placebo Comparator|Placebo|Placebo on day 0-3
10014187|NCT01669499|Active Comparator|Dexamethasone acetate day 0|8 mg dexamethasone on day 0
10014188|NCT01669499|Active Comparator|Dexamethasone acetate day 0-3|8 mg dexamethasone on day 0-3
10014189|NCT01669512|Active Comparator|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56 6 Volunteers
10014190|NCT01669512|Experimental|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56 8 Volunteers
10014191|NCT01669512|Experimental|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56 8 Volunteers
10035923|NCT01810874|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
10035924|NCT01810887|Experimental|Ritonavir and darunavir|Ritonavir will be administered orally twice daily at a dose of 100 milligram (mg) from Day 1-5. Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 mg on Day 3.
10035925|NCT01810900|Experimental|Protescal|Protescal is applied to this arm.
10035926|NCT01810900|No Intervention|non-treatment|
10035927|NCT01810926|Experimental|MRD-Regimen&Polyclonal antibody|Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 & ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
10037330|NCT01824121|Active Comparator|immediate stem cell therapy|patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.
10014192|NCT01669525||No treatment|Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
9476791|NCT03568240||15 men without complaints|
9476792|NCT03568227|Experimental|Healthy Subjects|"The study has a 2 (Intervention: Hypnosis, Control) x 2 (State: 1 & 2) factorial within-subjects design, resulting in a total of 4 conditions. All volunteers participate at the 4 conditions in the same session.The order of the interventions is counterbalanced resulting in two possible sequences:~Sequence 1: Hypnosis State 1, Hypnosis State 2, Control State 1, Control State 2~Sequence 2: Control State 1, Control State2, Hypnosis State 1, Hypnosis State 2~Volunteers will be randomly allocated to the two sequence types."
9476793|NCT03568214|Experimental|Individualized moderate + high-intensity|"12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)~4 days per week of MICT for 50 minutes per session~1 day per week of HIIT for 35 minutes per session~Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)~The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
9476794|NCT03568214|Experimental|Standardized moderate-intensity|"12 weeks of MICT~5 days per week of MICT for 50 minutes per session~Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
9476795|NCT03568214|No Intervention|Control|non-exercise control group testing at baseline and post-program (12 weeks)
9476796|NCT03568201|Experimental|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
9476797|NCT03568201|Sham Comparator|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
9476798|NCT03568175|Experimental|JR-141 2.0 mg/kg/week|
9480698|NCT05261919|Experimental|acupuncture with manipulation group|"30 participant were recruited in this study. All the participants received acupuncture at the acupoints (HT7、HT3、SI5、SI8、BL57、BL40、KI3、KI10) and were measured by an Agilent B1500A semiconductor analyzer.~The investigator perform acupuncture with supplementation manipulation first, followed by a measurement of the electrical characteristics using Agilent B1500A. The investigator remove the acupuncture and then perform acupuncture with draining manipulation, followed by measurements. After one meridian measurements were completed, the investigator removed the needle and proceeded to the next meridian to repeat the same procedure."
9480699|NCT05261906|Experimental|LIBERATE Intervention|
9518079|NCT03300128|Experimental|Incredible Years - ASD|The intervention, The Incredible Years Parent Program for Autism Spectrum and Language Delays (IY-ASD; more information is here: http://www.incredibleyears.com/programs/parent/autism-spectrum-language-delays/) is a 14-week course that meets for 2 hours every week. Ideally, an IY-ASD group will be composed of approximately 10 parents and other primary caregivers of children who have autism.
10014193|NCT01669551||Structural or Valvular Heart Disease|
10014194|NCT01669564|Active Comparator|Activated Patients|Will use HIT patient feedback to activate patients.
10014195|NCT01669564|Other|Control patients|Patients will not receive HIT patient feedback.
10014196|NCT01669564|Other|Intervention Physicians|Will use HIT patient feedback to activate patients.
10014197|NCT01669564|Other|Control Physicians|Patients will not receive HIT patient feedback.
10014198|NCT01669590||old (60-75yr)|
10014199|NCT01669590||young (18-35y)|
10014200|NCT01669668|Experimental|RFA|Patients undergo laparoscopic ultrasound followed by RFA.
10014201|NCT01669681||Included in the cohort COBRA|
10014202|NCT01669694||Women with Pelvic Pain|Women with Pelvic Pain undergoing pelvic floor PT in the Beaumont Women's Urology Center
10014203|NCT01669707|Experimental|Endostar -Continued Pumping into+GP|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin
10014204|NCT01669707|Active Comparator|Endostar -injecting into +GP|Endostar that is injecting into vein with Gemcitabine -Cisplatin
10014205|NCT01669733|Experimental|Live/Recorded Music Group|The music therapist will prepare a preferred song to be performed live in the preoperative room. Subjects in the live music group will listen to recorded music intraoperatively.
10014206|NCT01669733|Experimental|Recorded Music Group|Recorded music group will be given an iPod and headphones and will listen to a recorded version of a preferred song.
10014207|NCT01669733|Active Comparator|No Music (Standard of care)|The control group will receive standard of care and no music.
10014208|NCT01669746|Experimental|Treatment|
10014209|NCT01669759||fatigue|
10014210|NCT01669772|Other|DA-9701 and placebo|Administer DA-9701 for 1week and assess the study outcomes. After 1 week of washout period, administer placebo for 1week and assess the outcomes again.
10014211|NCT01669772|Other|Placebo and DA-9701|Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
10014212|NCT01669824||Group 1|
10014213|NCT01669837||Patient group|Administration of surgical tissue glue.
10014214|NCT01669850|Experimental|Clipped anastomosis|A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
10014215|NCT01669850|Active Comparator|Handsewn anastomosis|A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.
10014216|NCT01669876|Active Comparator|Dietary Supplement: Anatabloc(R)|Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day
10014217|NCT01669876|Placebo Comparator|Placebo|Placebo, as mint-flavored lozenge, to be taken 2-3 times each day
10014218|NCT01669889||Cohort|
10014219|NCT01669941|Experimental|IPTp-DP|At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
10014220|NCT01669941|Experimental|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
10014221|NCT01669941|Active Comparator|IPTp-SP|Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.
10014222|NCT01669954||Controls, females|Controls who are presumed HIV uninfected, females, aged 18 or above
10014223|NCT01669954||Controls, males|Controls presumed HIV uninfected, males, aged 18 or above
10014224|NCT01669954||HIV infected patients, males|HIV patients, males, aged 18 or above
10014225|NCT01669954||HIV patients,|HIV patients, females, aged 18 or above
10014226|NCT01669967|Placebo Comparator|Diphenhydramine(Benadryl)|
10014227|NCT01669967|Active Comparator|Lidocaine|
10014228|NCT01670006|Experimental|Cochlear Implantation|Cochlear Nucleus Cochlear Implant System
10014229|NCT01670058||Belatacept treated adult kidney-only transplant recipients|All adult kidney-only transplant recipients treated with Nulojix (Belatacept)
10014230|NCT01670058||CNIs at transplantation|
10014231|NCT01670071|Experimental|Paliperidone extended-release|
10014232|NCT01670071|Active Comparator|Risperidone immediate-release|
10014233|NCT01670084|Experimental|Treatment (nilotinib, combination chemotherapy)|See Detailed Description
10014234|NCT01670123|Experimental|Mobile Phone Condition|This arm will involve daily self-monitoring with an electronic mobile device with responses to survey questions about mood status. Mood status reports are linked with personalized coping strategies.
10014235|NCT01670123|Placebo Comparator|Paper-and-pencil condition|This arm will complete a paper-and-pencil mood chart on a daily basis
10014236|NCT01670136|No Intervention|sildenafil, standard of care|Infants receiving sildenafil as standard of care
10014237|NCT01670136|Other|sildenafil administered for study|1 dose of sildenafil administered for study
10014238|NCT01670149|Placebo Comparator|Placebo|Identical looking tablet
10014239|NCT01670149|Active Comparator|Rifaximin , Xifaxanta™|2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),
10014240|NCT01670162|Experimental|3 loading doses, then every 2 months|All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.
10014241|NCT01670175|Experimental|Sirolimus, Cyclophosphamide, Topotecan|Sirolimus, Cyclophosphamide, Topotecan Patients accrued to dose levels in cohorts of 3 (3+3 design). Patients will receive daily oral sirolimus and cyclophosphamide days 1-21 in 28-day cycle, combined with oral topotecan given on days 1-14. Sirolimus will be dosed based on steady-state plasma trough concentrations.
10014242|NCT01670214|Active Comparator|Pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions phase 1 treatment and added 6 sessions for phase 2 treatment (3 sessions per week)
10014243|NCT01670214|Placebo Comparator|pulsed electromagnetic field|patients are placed under off instrument while who is kept blind to know it for 6 sessions (3 sessions per week).
10014244|NCT01670227|Experimental|PARENTCORPS|ParentCorps is a school-based, family-focused universal intervention designed to attenuate the multiple risks associated with urban poverty, on children's health and development
10014245|NCT01670227|Other|Control Condition|No intervention
10014246|NCT01670240|Active Comparator|Adalimumab|Every second week, mg: 160-80-40-40-40-40 12 weeks in all
10014247|NCT01670240|Placebo Comparator|Placebo|Given as the active comparator, every second week
10014248|NCT01670253|No Intervention|Group 2|6 hours of total fast for all solid and liquid food / drinks
10014249|NCT01670253|Experimental|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
10014250|NCT01670266|Experimental|Experimental Arm 1|Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
10014251|NCT01670266|Experimental|Experimental Arm 2|Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
10014252|NCT01670266|Experimental|Experimental Arm 3|Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
10014253|NCT01670266|Experimental|Experimental Arm 4|Experimental Eye drop, 2 sequence crossover Cohort [1 dose; 1-30 µg/mL]to be determined and placebo
10014254|NCT01670266|Placebo Comparator|Placebo Arm|Matched placebo eye drops dosed in same manner as ONO-9054
10014255|NCT01670305|Experimental|Residual pocket - PDT|Photosensitizer plus diiodo laser
10014256|NCT01670305|Placebo Comparator|Residual pocket - Photosensitizer|Photosensitizer alone
10014257|NCT01670305|Active Comparator|Residual pocket - SRP|scaling and root planing alone
10014258|NCT01670305|Experimental|Furcation - PDT+SRP|Photosensitizer plus diiodo laser associated with scaling and root planing
10014259|NCT01670305|Active Comparator|Furcation - SRP|Photosensitizer associated with scaling and root planing
10014260|NCT01670318|Experimental|platinum chromium everolimus-eluting stent|
10014261|NCT01670331|Active Comparator|Psychological preparation|Patients undergo 3 seminar sessions with the bariatric psychologist prior to their surgery. These will aim to prepare them for the lifestyle changes that will occur / they will have to make after surgery
10014262|NCT01670331|No Intervention|Surgery as usual|Patients will proceed to surgery as usual. They will complete psychological assessment forms at their follow up clinic sessions.
9476799|NCT03568162|Experimental|ISB 830 - Part 1 Group 1|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
10014263|NCT01670344|Other|A|Treatment with investigational method (virtual implant positioning system)
10014264|NCT01670344|Other|B|Treatment with surgical standard of care
10014265|NCT01670357|Experimental|DA-6034 Low dose|DA-6034 3%
10014266|NCT01670357|Experimental|DA-6034 High dose|DA-6034 5%
10014267|NCT01670357|Placebo Comparator|Placebo|DA-6034 Placebo
10014268|NCT01670370|Experimental|Rituximab+Gemcitabine+oxaliplatin (R-GemOx)|Rituximab: 375 mg/m2 IV day1, Gemcitabine 1g/m2 IV day 2, oxaliplatin 100mg/m2 IV day2(every 14 days)
10014269|NCT01670383||Postresuscitation group|Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
10014270|NCT01670383||Sepsis group|Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS>=2 and infection is suspected for a cause) and admitted to the ICU.
10014271|NCT01670396||in-stent restenosis|
10014272|NCT01670396||non-in-stent restenosis|
10014273|NCT01670435||Group 1|
10014274|NCT01670448|Active Comparator|PECBLOCK performed with bupivacaine|Active drug given through PECBLOCK in these patients.
9476800|NCT03568162|Experimental|ISB 830 - Part 1 Group 2|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
9476801|NCT03568162|Experimental|ISB 830 - Part 1 Group 3|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
9476802|NCT03568162|Placebo Comparator|Placebo - Part 1 Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
10014275|NCT01670448|Placebo Comparator|PECBLOCK performed with NaCl 0.9%|Placebo drug given through PECBLOCK in these patients
10014276|NCT01670461|Experimental|FACE Advance Care Planning|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
10014277|NCT01670461|Other|Standard of Care (SOC) Control|Standard of Care Control: Advance Directive Information Booklet plus Advance Directive Checklist.
10014278|NCT01670474|Experimental|fmDLC and rt-PA (2mg/2mL actilysis)|"Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
10014279|NCT01670474|Active Comparator|polyDLC and rt-PA (2mg/2mL actilysis)|"The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
10014280|NCT01670474|Active Comparator|siDLC and rt-PA (2mg/2mL actilysis)|"Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
10014281|NCT01670513|Experimental|IDP-118 Low Strength|IDP-118 Low Strength
10014282|NCT01670513|Experimental|IDP-118 High Strength|IDP-118 High Strength
10014283|NCT01670552|Experimental|Nimesulide + Pantoprazole|Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
10014284|NCT01670552|Active Comparator|Naproxen + Esomeprazole|Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
10014285|NCT01670565|Experimental|Mycophenolate mofetil + Belimumab|All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study.
10014286|NCT01670565|Placebo Comparator|Mycophenolate Mofetil + Saline (placebo)|In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion.
10014287|NCT01670578|Experimental|PRP Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
10014288|NCT01670578|Active Comparator|Hyaluronan Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
10014289|NCT01670591|Experimental|PS - Prevention in School|Teachers learn to use the core program components (defining and teaching school rules and the handling of rule breakings, principles of positive behavior support)with help from external consultants during approximately 1.5 years.
10014290|NCT01670591|No Intervention|Business as usual|
10014291|NCT01670604|Experimental|VOL group|patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
10014292|NCT01670604|Experimental|TET group|patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L
10014293|NCT01670617|Other|DeNovo NT Graft|DeNovo NT Graft stratified by lesion location - femur or patella
10014294|NCT01670630|Active Comparator|Sheathed speculum|"Investigators will perform a vaginal speculum examination with either a sheathed or a standard (non sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception."
10014295|NCT01670630|Active Comparator|Standard speculum examination|Investigators will perform a vaginal speculum examination with either a standard or a sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception.
10014296|NCT01670643||Video camera magnifier|
10014297|NCT01670669|Active Comparator|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
10014298|NCT01670682|Active Comparator|fascia fixation group|procedure: ischia spinous fascia fixation
10014299|NCT01670682|Active Comparator|mesh group|Procedure: Modified Pelvic Floor Reconstruction Surgery with mesh
10014300|NCT01670695||IgG4-RD|Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
10014301|NCT01670708|Experimental|HOPE|Participation in HOPE program
10014302|NCT01670708|Active Comparator|Probation as Usual|Participation in probation as usual
10014303|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - mild hepatic function|Injection through subcutaneous (SC) administration in patients with mild hepatic function
10014304|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - moderate hepatic function|Injection through subcutaneous (SC) administration in patients with moderate hepatic function
10014305|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - normal hepatic function|Injection through subcutaneous (SC) administration in patients with normal hepatic function
10014306|NCT01670747||ARDS|Sedated and mechanically ventilated patients admitted to ICU
10014307|NCT01670773|Experimental|CAT-1004 Dose #1|Single dose #1
10014308|NCT01670773|Active Comparator|Salsalate + DHA|Single dose #2
10014309|NCT01670773|Placebo Comparator|Placebo|Single Dose #3
10014310|NCT01670786|Experimental|Iodopovidone 1%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 1% administration into pleural cavity.
10014311|NCT01670786|Experimental|Iodopovidone 2%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 2% administration into pleural cavity.
10037331|NCT01824121|Sham Comparator|delayed stem cell therapy|patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months
9476803|NCT03568162|Experimental|ISB 830 - Part 2 Group 5|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
9476804|NCT03568162|Placebo Comparator|Placebo - Part 2 Group 6|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
9476805|NCT03568149||Group A: endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
9476806|NCT03568149||Group B: no endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
9476807|NCT03568136|Experimental|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
9665220|NCT05129319|Active Comparator|OLD (4 U per 0.1 mL)|The total Jeuveau dose will be 20U divided into 5 injections. Each subject will receive a total of 0.5 mL of Jeuveau during the treatment.
10037332|NCT01824134|Active Comparator|Klean & Klear|aloe vera gel
10037333|NCT01824134|Active Comparator|The Skin Gel|aloe vera gel
10037334|NCT01824147||CABG Patients|Patients undergoing surgery for coronary revascularization.
10037335|NCT01824173|Experimental|Amino Acid Infusion in Lean|Amino Acid Infusion in Lean
10014312|NCT01670799|Experimental|Ketorolac|"All patients will receive a single dose of IV ketorolac for pain management for the indication of post-operative pain control. Patients less than 65 years of age and in otherwise good health will receive a 30mg IV single dose. Patients 65 years of age or greater, or who have mild renal insufficiency or are of low weight (as per section 3.2) will receive a single 15 mg dose IV ketorolac.~In patients who have a clinical pain response and have no contraindications to multi-dose (every 6 hours over 24 hours), additional doses will be given per physician discretion based on clinical indication. Patients receiving 24 hour dosing will be eligible for sample time points after 24 hour dosing."
10014313|NCT01670812|Experimental|FFP+HDMP+Rituximab|Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
9665221|NCT05129319|Active Comparator|COLD (4 U per 0.02 mL group)|The total Jeuveau dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL of Jeuveau during the treatment.
10014314|NCT01670838||subarachnoid haemorrhage|nontraumatic subarachnoid haemorrhage
10014315|NCT01670851||Strattice|eLAPE
10014316|NCT01670864|Experimental|Counseling group|Study participants in the counseling group will receive a brief on-site face-to-face smoking cessation counseling from our trained smoking cessation counselor on the study site after signing the consent form. They will receive advice on quitting smoking and specific warning about the hazardous effects of smoking on health. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
10014317|NCT01670864|Experimental|SMS intervention group|Study participants in the SMS group will receive SMS text messages on smoking cessation advice and warning on the hazardous effects of smoking on health. The participants will receive a total of 16 tailored SMS messages after recruitment.
10014318|NCT01670864|No Intervention|Control group|Study participants in the control group will not receive any quitting assistance other than the self-help materials from the recruitment sites.
10014319|NCT01670890|Active Comparator|TMZ group|patients were treated with TMZ alone
10014320|NCT01670890|Experimental|TMZ plus CDDP group|patients were treated with TMZ plus CDDP
10014321|NCT01670903||ARBs|Hypertensive patients treated with ARBs
10014322|NCT01670903||ACE inhibitors|Hypertensive patients treated with ACE inhibitors
10014323|NCT01670903||non ARB/ACE|Hypertensive patients treated with non ARBs or ACE inhibitors meds
10037336|NCT01824173|Experimental|Amino acid Infusion in Obese|Amino acid Infusion in Obese
10014324|NCT01670916||Probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
10014325|NCT01670916||Control|Probiotics never given
10014326|NCT01670929|Active Comparator|Progesterone group|progesterone (400 mg pessary, once daily)
10014327|NCT01670929|Placebo Comparator|Placebo group|Placebo (pessary, once daily)
10014328|NCT01670942||Traumatic Pneumothorax1|hypobaric chamber
10014329|NCT01670955|Active Comparator|Jobelyn + Ferrous Sulphate + Folic Acid|Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
10014330|NCT01670955|Active Comparator|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
10014331|NCT01670994|Experimental|ALT-801|
10014332|NCT01671020|Active Comparator|(R)(T)|Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg
10014333|NCT01671020|Active Comparator|(T)(R)|Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg
10014334|NCT01671033|Experimental|Muscle Relaxation|The patients of this arm practice on-line muscle relaxation every day.They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
10014335|NCT01671033|Experimental|Muscle Relaxation with Biofeedback|The patients of this arm practice on-line muscle relaxation with finger temperature biofeedback every day. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
10014336|NCT01671033|No Intervention|Waiting-List|The patients of this arm waited for four weeks. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR (APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Impressions-Improvement(CGI) were performed by well-trained clinicians.
10014337|NCT01671046||Cohort|
10014338|NCT01671072|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10^7 cells
10014339|NCT01671072|Placebo Comparator|Normal Saline|Single intra-articular injection to the damaged knee joint at the same volume
10014340|NCT01671098||Control|Healthy adults
10014341|NCT01671098||Balloon Sinuplasty|Patients who had balloon sinuplasty
10014342|NCT01671098||FESS-Uncinectomy|Patients who had FESS-Uncinectomy
10014343|NCT01671124||Soline capsule|Salvia divinorum, Lycium, Chenpi and Dihuang
10014344|NCT01671137|Active Comparator|Lactobacillus Rhamnosus Strain GG|LGG (6 × 109 colony forming units)
10014345|NCT01671137|Placebo Comparator|Placebo|Placebo
10014346|NCT01671150|Placebo Comparator|Placebo control|half of the participants will receive a placebo control
10014347|NCT01671150|Active Comparator|Endotoxin (Inflammatory challenge)|
10014348|NCT01671163||Subjects requiring fiducial placement|Endoscopic Ultrasound (EUS) for fiducial placement
10014349|NCT01671189|Experimental|SMS Appointment Reminders|150 patients will be randomly assigned to the intervention arm of the study and receive text reminders about their upcoming appointments.
10014350|NCT01671189|No Intervention|Existing Reminder Protocol|150 patients will be randomly assigned to the control arm of the study and will not receive SMS reminders about their upcoming appointments. They will, however, be subject to the clinics' existing reminder protocol (phone call reminders by either clinic personnel or computer machine).
10014351|NCT01671228|Experimental|decision aid|The Yorkshire Dialysis Decision Aid (YoDDA). Delivered as a leaflet in clinic and a web resource outside the NHS.
10014352|NCT01671228|Experimental|Decision Aid + values task|The Yorkshire Dialysis Decision Aid (YoDDA) + values clarification questions. delivered as a leaflet in clinic and a web-based resource outside the NHS.
10014353|NCT01671228|Experimental|Decision Aid + patient stories|The Yorkshire Dialysis Decision Aid (YoDDA) + patient stories. Delivered as an web-based resource outside the NHS.
10014354|NCT01671228|No Intervention|usual predialysis education|The consultations and information usually provided by the predialysis health professionals
10014355|NCT01671241|Experimental|Total body polyethylene wrap (body plus head)|The entire body surface (body plus head) is covered by a polyethylene wrap
10014356|NCT01671241|Active Comparator|Polyethylene wrap (body)|A polyethylene wrap covers the patient's body up to the neck
10014357|NCT01671254|Active Comparator|FishOil + placebo|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule
10014358|NCT01671254|Experimental|FishOil + CBE75|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)
10014359|NCT01671254|Experimental|FishOil + CBE150|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)
10014360|NCT01671267|Experimental|Strength training|Strength training of the shoulder, arm and hand muscles for 3 x 10 minutes a week.
10014361|NCT01671267|Active Comparator|Ergonomic|Receives counseling on workstation adjustment and optimal use of the work tools.
10014362|NCT01671306||Collateral, coronary disease|Patients are grouped into 2: Good and poor collateral development
10014363|NCT01671306||collateral|Patients are grouped into 2: Good and poor collateral development
10014364|NCT01671358||Isolation Rooms for MRSA|Rooms that currently have a patient in them that are in isolation status due to MRSA
10014365|NCT01671358||Non-isolation rooms|Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
10014366|NCT01671371|Other|Immediate Ultrasound|A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
10014367|NCT01671371|Other|Delayed Ultrasound|A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization
10014368|NCT01671384|Active Comparator|Valproate, levocarnitine|"The patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
10014369|NCT01671384|Placebo Comparator|Placebo|"All patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
10014370|NCT01671397|Experimental|Diet, exercise, sleep hygiene counseling|Subjects will meet with a dietitian and a physician and receive counseling on diet restriction, exercise goals, and good sleep hygiene. Subjects will identify goals in each domain and keep a calendar of the success with achieving these goals.
10014371|NCT01671397|Active Comparator|Diet and exercise counseling|Subjects will meet with a dietitian and a physician and receive counseling on calorie restriction and exercise. They will identify goals in each domain and keep a calendar to determine their success with achieving these goals.
10037337|NCT01824173|Experimental|Exercise in lean|Exercise in lean
10037338|NCT01824173|Experimental|Exercise in Obese|Exercise in Obese
10014372|NCT01671410|Experimental|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
10014373|NCT01671410|Active Comparator|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
10014374|NCT01671436|Experimental|Central Meditation and Imagery Therapy|Intervention involved Central Meditation, may be characterized by a voluntary, regulated attentional set towards a specific stimulus or set of stimuli and visualization exercises utilized within CMIT, which primarily involves two types of thought experiments: 1) creating mental models of how a person fits into the larger world and universe according to evolutionary biology and modern cosmology, in order to gain a larger perspective on emotions and thought patterns, and 2) backcasting, the generation of a desirable future coupled with mental time travel back to the present to determine how to create that future with present-day actions.
10014375|NCT01671449|Active Comparator|S-1 plus Cisplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Cisplatin: 60 mg/ m2/day, i.v., day 1~Every 3 weeks"
10014376|NCT01671449|Experimental|S-1 plus Oxaliplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Oxaliplatin: 130 mg/ m2/day, i.v., day 1~Every 3 weeks"
10014377|NCT01671475|Experimental|Routine care plus microEEG|Subjects allocated to this group will undergo an EEG using microEEG device in addition to their routine care. The microEEG device will be used with commercially available electrodes in a headpiece configuration.
10014378|NCT01671475|No Intervention|Routine care only (control group)|Subjects allocated to the control group will receive routine care without microEEG. The treating physician may request a standard EEG, which will be performed by the hospital EEG laboratory, if available.
10014379|NCT01671501|Experimental|Motivational Interviewing|The intervention consists of one 45-minute in-person session followed by two 20-minute telephone sessions.The first telephone MI session will occur approximately 10 days after the in-person session. The second call will occur 30 days after the first call. The same research clinician will conduct both the in-person session and phone sessions. The calls will include a review of material covered in the initial session, questions on alcohol use, open-ended questions regarding patients' current motivational level, and a review of the patient's initial goals regarding alcohol consumption and will last about 20 minutes. If after six months hazardous drinking is noted, three more motivational interviewing phone sessions will be delivered by the research clinician.
10014380|NCT01671501|Experimental|Email Feedback|Each participant will receive up to three detailed emails, (if participants respond to a first, initial email with information on alcohol use risks). The initial and subsequent emails will be brief in length, and will include specific information on hazardous drinking levels, standard drink size; as well as advice to reduce drinking to non-hazardous levels. Each email will conclude with contact numbers for patients to receive further information and assistance if needed, including information on how to easily access SU treatment; and will encourage participants to respond to the research clinician with questions. If after six months hazardous drinking is detected, up to 3 more detailed emails will be delivered to the participant.
10014381|NCT01671501|Other|Usual Care|Participants in this arm will receive routine primary care services only. Usual care in this health care setting may include alcohol screening, brief intervention and referral to treatment (SBIRT) delivered by usual care clinic staff
10014382|NCT01671514|Experimental|Sedentary|The sedentary arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
10014383|NCT01671514|Experimental|Heart failure/diabetes|The heart failure/diabetes arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
10014384|NCT01671527||Cervical Dystonia: DBS Subjects|Subjects who have undergone or plan to undergo DBS surgery for cervical dystonia
10014385|NCT01671527||Cervical Dystonia: Control Subjects|Subjects who DO NOT plan to undergo DBS surgery for cervical dystonia
10014386|NCT01671527||Healthy Controls|Healthy control subjects who do not have dystonia.
10014387|NCT01671540|Experimental|Intrapulmonary percussive ventilation|IPV is applied for 1 week (once a day) during the physical therapy treatment of the patient
10014388|NCT01671540|Active Comparator|standard airwy claerance regime|The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises
10014389|NCT01671553|Experimental|Counseling group|Study participants in the intervention group were received an intensive smoking cessation telephone counselling with 2-weeks free and 6-weeks discount nicotine replacement therapy (NRT).
10014390|NCT01671553|No Intervention|Control group|Study participants in the control group were not received any quitting assistance other than the self-help materials provided by Hong Kong Council on Smoking and Health (COSH).
10014391|NCT01671566|Experimental|Home based interval training|12 weeks home based interval training
10014392|NCT01671566|No Intervention|Control group|No structured exercise training.
10014393|NCT01671579|Other|Pediatric small bowel Crohn disease|Subjects with previously diagnosed PSBCD (pediatric small bowel Crohn disease)who are scheduled for a clinically MRE (magnetic resonance enterography)imaging exam.
10014394|NCT01671592|Experimental|Day 1 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
10014395|NCT01671592|Experimental|Day 3 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
10014396|NCT01671592|Experimental|Day 1 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
10014397|NCT01671592|Experimental|Day 3 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
10014398|NCT01671631||Acute Coronary Syndrome|Patients with Acute Coronary Syndrome and multivessel coronary artery disease undergoing functional evaluation of non-culprit lesions.
10014399|NCT01671644||Eeva Test Group|Day 3 embryo transfers that used Eeva predictions with morphology grading.
10014400|NCT01671644||Matched case control group|Day 3 embryo transfers using morphology grading only (from a matched concurrent control group).
10014401|NCT01671657||Eeva Test Group|Day 3 embryo transfers that used Eeva with morphology grading (Test Group).
10014402|NCT01671657||Matched case control group|Day 3 embryo transfers using morphology grading only (from concurrent Control Group).
10014403|NCT01671670|Experimental|acupuncture group|use traditional acupuncture to treat functional dyspepsia
10014404|NCT01671670|Sham Comparator|sham acupuncture group|use penetrating sham acupuncture to manage functional dyspepsia
10014405|NCT01671709|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
10014406|NCT01671709|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
10014407|NCT01671722|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
10014408|NCT01671722|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
10014409|NCT01671735|Experimental|VA DPP|Pre-Diabetic Participants eligible for VA DPP receive a curriculum based life-style intervention program tailored off of the original DPP but in a group format
10014410|NCT01671735|No Intervention|VA DPP-eligible MOVE!|Pre-Diabetic participants who screen and are eligible for VA DPP but bc of class being filled - have been assigned to MOVE!
9665222|NCT05129124|Experimental|T01: +6.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
10014411|NCT01671761||young adults|19-24 years old
10014412|NCT01671761||adolescents|15-18 years old
10014413|NCT01671774|Experimental|IMAB362 + ZA|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1.
10014414|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (1 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
10014415|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (3 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
10014416|NCT01671774|Active Comparator|IMAB362|Participants received IMAB362 only on Day 1 of each cycle every 3 weeks.
10014417|NCT01671787|Experimental|GS-7340 8mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
10014418|NCT01671787|Experimental|GS-7340 25mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
10014419|NCT01671787|Experimental|GS-7340 40mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
10014420|NCT01671787|Experimental|GS-7340 120mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
10037339|NCT01824186|Experimental|SILC|Subjects in this arm were randomized to undergo single-incision laparoscopic cholecystectomy, through a transumbilical incision
10014421|NCT01671787|Experimental|Tenofovir disoproxil fumarate 300mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
10014422|NCT01671800|Experimental|Botulinum Type B (Myobloc)|Each vial of active drug will contain 5000 unit/ml of Myobloc, with a total volume of 1 mL. The injections will be spaces 6 cm apart and will cover the entire area to be injected. Each site will receive a volume of 0.08 ml (400 units).
10014423|NCT01671800|Placebo Comparator|Saline solution|The volume to be injected will be calculated assuming the injectate is an active drug, and will therefore be an equivalent volume as an active drug (i.e. 0.08 mL per injection site with a 6 cm spacing interval)
10014424|NCT01671813|Experimental|Brentuximab vedotin Treatment|Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
10014425|NCT01671826||above 65 years old|
10014426|NCT01671852|Active Comparator|Nasonex|The intervention group will receive mometasone nasal sprays at the dosage outlined below for 8 weeks. For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
10014427|NCT01671852|Placebo Comparator|Saline|The placebo group will receive saline nasal sprays for 8 weeks.
10014428|NCT01671878|Other|Reference Glucose|Glucose standard
10014429|NCT01671878|Experimental|Test Food 1|Cereal
10014430|NCT01671878|Experimental|Test Food 2|Biscuit
10014431|NCT01671891||rectal cancer with stage II-IV|rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
10014432|NCT01671904|Experimental|1L CLL BR+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
10014433|NCT01671904|Experimental|1L CLL BG+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and obinutuzumab (BG). Participants received six 28-day cycles of BG+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
10014434|NCT01671904|Experimental|R/R CLL BR+V|Participants with relapsed/refractory (R/R) CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with R/R CLL continued single-agent venetoclax until disease progression, death, or unacceptable toxicity.
10014435|NCT01671917|Experimental|Educational and exercise program|
10014436|NCT01671917|Active Comparator|Usual care|
10014437|NCT01671930||cardiac computed tomographic angiography|Patients refered for cardiac computed tomographic angiography by a cardiologist.
10014438|NCT01671943|Experimental|Breast carcinoma up to 2.0 cm|
10014439|NCT01671956|Experimental|Bertilimumab|Bertilimumab 10 mg/kg will be administered by IV infusion over 30 minutes
10014440|NCT01671956|Placebo Comparator|Placebo|Phosphate buffered saline (PBS) placebo will be administered by IV infusion over 30 minutes.
10014441|NCT01671969|Experimental|very low calorie diet|
10014442|NCT01671982|Experimental|Tenofovir-containing HAART|
10014443|NCT01671995|Experimental|Nurse monitored heart failure program|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
10014444|NCT01671995|Active Comparator|Standard primary health care|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
10014445|NCT01672008|Experimental|NOX-100/Placebo|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
10014446|NCT01672008|Experimental|Placebo/NOX-100|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
10014447|NCT01672021|Other|PET/MRI|PET/MRI
10014448|NCT01672034||Obese, BMI > 35|
10014449|NCT01672047|Experimental|Treament|Intervention Vitamin D2
10014450|NCT01672047|No Intervention|Control|Not take Vitamin D2
10014451|NCT01672086||Stelkast Surpass Patients|
10014452|NCT01672099|Active Comparator|nutrient enriched dairy|Yoghurt product which contains vitamin K2 and extra dairy nutrients; all in a concentration of 15% of the recommended allowed daily intake (RDI)
10014453|NCT01672099|Placebo Comparator|Basic dairy|2 basic yoghurt products
10014454|NCT01672112|Other|Codeine|Oral Codeine 60mg 6hrly/prn
10014455|NCT01672112|Active Comparator|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
10014456|NCT01672125||women who have completed treatments|women who have completed breast cancer treatments, with a diagnosis of unilateral arm lymphedema, in the intensive phase of lymphedema treatment
10014457|NCT01672125||women who have completed treatment in maintenance phase|women who have completed breast cancer treatment and are in the maintenance phase of lymph edema treatment
10014458|NCT01672125||healthy women|healthy women adjusted in age and BMI
10014459|NCT01672138|Active Comparator|Control|Pulmonary Vein Antrum Isolation (PVAI) + isolation of left atrial posterior wall
10014460|NCT01672138|Active Comparator|Study I|PVAI+ scar homogenization
10014461|NCT01672138|Active Comparator|Study II|PVAI + isolation of left atrial posterior wall + non-PV triggers ablation
10014462|NCT01672164||Liver Transplant Recipients|
10014463|NCT01672177|No Intervention|Control|Individuals in the control group will not receive any training.
10014464|NCT01672177|Experimental|Intervention|Individuals in the intervention group will receive two hour long weekly training sessions for seven to eight months. The content of the training focuses on health promotion, health seeking behaviours and chronic disease management.
10014465|NCT01672190|Experimental|Yoga Therapy|Women in the Yoga Therapy Group will receive twice weekly yoga classes for 6 weeks.
10014466|NCT01672190|No Intervention|Control|Women in the Control Group will wait 6 weeks before receiving a gift certificate for yoga classes at an external yoga studio in the San Francisco Bay Area
10014467|NCT01672203||PE peripheral with fibrinolysis|Patients with peripheral PE who received fibrinolysis therapy
10014468|NCT01672203||PE peripheral, no fibrinolysis|Patients with peripheral PE who did not receive fibrinolysis
10014469|NCT01672203||PE central with fibrinolysis|Patients with central PE who received fibrinolysis therapy
10014470|NCT01672203||PE central, no fibrinolysis|Patients with central PE who did not receive fibrinolysis
10014471|NCT01672216|Experimental|Triple Target Treatment|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
10014472|NCT01672216|Active Comparator|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
10014473|NCT01672229|Experimental|Dose-escalation|Bortezomib starting dose is 0.2 mg/m2 subcutaneously which will be given weekly with incremental increase of 0.2 mg/m2 every other week, if no improvement is seen, and no dose limiting toxicities are observed to the maximum dose of 1.6 mg/m2. Bortezomib will be administered in the outpatient clinic.
10014474|NCT01672268|Active Comparator|Standard TAVI procedure|Patients without Cardiac CT measures before TAVI
10014475|NCT01672268|Experimental|Cardiac CT scan before TAVI procedure|patients with cardiac CT measures before TAVI
10014476|NCT01672281|Experimental|vibrox training|
10014477|NCT01672281|Experimental|resistance training|
10014478|NCT01672307|Experimental|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
10014479|NCT01672307|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
10014480|NCT01672320||Phase II|An evaluation of long-term outcomes, patient reported outcomes, and radiographic analysis will be conducted prospectively on 500 patients
10014481|NCT01672320||Phase I|An analysis of post-operative component positioning will be evaluated for 500 patients, retrospectively.
10014482|NCT01672333|Experimental|Pathological Response|
10014483|NCT01672346|Active Comparator|Arm I|PVAI with ablation of posterior wall contained within pulmonary veins using energy up to 30 watts and post-ablation adenosine challenge
10014484|NCT01672346|Active Comparator|Arm II|AF ablationPVAI with ablation of posterior wall contained within pulmonary veins using energy up to 40 watts and post-ablation adenosine challenge
10014485|NCT01672359|Experimental|Ginkgo Synergy® and Choline|Ginkgo Synergy® (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)
10014486|NCT01672359|Experimental|OPC Synergy® and Catalyn|OPC Synergy® (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn® (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)
10014487|NCT01672359|Placebo Comparator|Placebo|cellulose pills to simulate actual products
10014488|NCT01672372|Placebo Comparator|Placebo Max Stress B|oil/water emulsion with food coloring to simulate actual product
10014489|NCT01672372|Experimental|Max Stress B|whole-nutrient natural source extract from probiotic colonies that contains vitamins B1, B2, B5, B6, B12, and folate, PABA, biotin, inositol, purified water and certified organic alcohol.
10014490|NCT01672385|Experimental|Intervention Group|Telemonitoring plus self-management support
10014491|NCT01672385|No Intervention|Usual Care Group|Usual Care
10014492|NCT01672398|Experimental|Intervention Group|Telemonitoring plus self-management support
10014493|NCT01672398|No Intervention|Usual Care Group|Usual Care
10014494|NCT01672424||Group P: High Protein Drink|Patients receiving the high protein drink with 30 grams of protein in 11 fluid ounces.
10014495|NCT01672424||Group C: Ice Chips|The control group consisting patient receiving 11 ounces of ice chips
10014496|NCT01672437|Experimental|Birth and parent preparation|"The following subjects will be covered in the sessions:~Session 1 (25 weeks gestation):~Common challenges in the transition to parenthood and in the relationship~Couple communication~Session 2 (33 weeks gestation):~Expectations in relation to birth~The normal course of labour~Obstetric intervention~Pain relief,coping strategies~Partner support~Session 3 (35 weeks gestation):~Feeding a newborn~Interpreting the newborn's signs, symptoms and behaviour~Taking care of a newborn~Mood swings, postnatal depressive symptomatology~Session 4 (5 weeks post-partum):~Birth experiences~Mood swings, postnatal depressive symptomatology~The first time at home with a newborn~Couplehood - partner support, communication, division of household tasks"
10014497|NCT01672437|No Intervention|control group|The control group are offered two lectures in an auditorium during pregnancy - one on breastfeeding and one on labour. This is standard care.
10014498|NCT01672450|Experimental|All patients|All participants in this study will receive the same treatment.
10014499|NCT01672463|Experimental|All patients|All participants enrolled in this study
10014500|NCT01672476|Placebo Comparator|Placebo|1 capsule/day of placebo will be orally administered for the study period (8 weeks)
10014501|NCT01672476|Active Comparator|Valsartan 80mg|(As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
10014502|NCT01672476|Experimental|Fimasartan 30mg|30mg/day of Fimasartan will be orally administered for the study period (8 weeks)
10014503|NCT01672502|Experimental|Intervention|Firefighters in this group will receive at the beginning of the study an introduction to the study, sleep education, sleep disorder screening survey, health survey, increased sleep opportunities at their fire department, followed later by physiological monitoring of a portion of the firefighters, and then finally an 'end of year' survey at the end of the study.
10014504|NCT01672502|Active Comparator|Control|Firefighters in this group will only receive an introduction to the study and a health survey, followed later by physiological monitoring of a portion of the firefighters, and then at the end of the study will receive the sleep disorders screening survey, sleep education (Intervention group received screening survey and education much earlier at the beginning of the study), and an 'end of year' survey. None of these firefighters will receive the increased sleep opportunities as the Intervention group will.
10014505|NCT01672515|Experimental|RIPC group|RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
10014506|NCT01672515|Sham Comparator|Control group|RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
10014507|NCT01672528||Cardiac arrhythmia patients|Patients with cardiac arrhythmias consented to and awaiting a cardiac ablation procedure or post ablation.
10014508|NCT01672541|Experimental|Dating Matters Comprehensive Approach|Schools randomly assigned to the comprehensive approach will: implement 6th, 7th, and 8th grade student curricula in English to all the students in these grades; offer parent programs for parents of 6th, 7th, and 8th graders;implement a communications campaign involving brand ambassadors, a text message campaign, and social media campaign;encourage all educators to take an online training about teen dating violence for educators;be supported in assessing and informing local school or community policies relevant to teen dating violence.
10014509|NCT01672541|Active Comparator|Standard of Care Safe Dates Approach|Schools randomly assigned to the standard of care approach will implement Safe Dates as it is published in their schools 8th grade classes.
10014510|NCT01672554|Other|Seroquel XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
10014511|NCT01672567|Experimental|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
10014512|NCT01672567|Experimental|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
10014513|NCT01672567|Experimental|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
10014514|NCT01672580|Active Comparator|Random-Cloro|exposure to water chlorination
10014515|NCT01672580|Active Comparator|Random-Vitamin|exposure to vitamin use
10014516|NCT01672580|Experimental|Indegree-Cloro|high in-degree, exposure to water chlorination
10014517|NCT01672580|Experimental|Indegree-Vitamin|high in-degree, exposure to vitamin use
10014518|NCT01672580|Experimental|Nominated-Cloro|nominated by random, exposure to water chlorination
10014519|NCT01672580|Experimental|Nominated-Vitamin|nominated by random, exposure to vitamin use
10014520|NCT01672593|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the autologous PRFG(platelet-rich fibrin glue) group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
9665223|NCT05129124|Experimental|T02: +6.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
10014521|NCT01672593|Active Comparator|Bioseal treatment|The commercial fibrin sealants used in the study were purchased from Guangzhou Bioseal Biotech Co. Ltd, Guangzhou, China. Upon application, two components, fibrinogen and thrombin, were placed separately in two syringes which were joined by a Y-shaped connector. The trunk of the Y-shaped connecter was connected to a single lumen catheter.
10014522|NCT01672606|Experimental|Rocuronium|Intravenous infusion of rocuronium with the goal of TOF 0.70 and >0.90
10014523|NCT01672619||children with craniosynostosis|children with craniosynostosis aged 6 months to 13
10014524|NCT01672632|Experimental|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
10014525|NCT01672645|Experimental|PF-05402536|
10014526|NCT01672645|Experimental|PF-06413367|Intramuscular, multiple dose
10014527|NCT01672645|Placebo Comparator|Placebo|Intramuscular
10014528|NCT01672671|Experimental|Neoadjuvant platinum-based chemotherapy|Doxorubicin, Paclitaxel, Cisplatin
10014529|NCT01672684|Experimental|Arm I (experimental arm)|Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
10014530|NCT01672684|Active Comparator|Arm II (control arm)|Participants receive an educational workbook journal.
10014531|NCT01672697|Experimental|Physical & Behavioral Therapy Group|"Intervention Group: Randomized to Physical Therapy (PT)~2-week visit which includes: Demographic Data, Physical Exam, ehavioral Therapy (BT) handouts Functional questionnaires administered Physiologic measurements obtained~Follow-up Evaluation-6-week visit PT session #1 Functional questionnaires administered~Follow-up Evaluation-8-week visit PT session #2~Follow-up Evaluation-10-week visit PT session #3~Study Completion Visit-12-week visit Functional questionnaires administered PT session #4 Physiologic measurements Physical Exam~Long-term Follow-up-24-weeks Functional questionnaires administered by mail"
10014532|NCT01672697|No Intervention|Control Group|"Control Group:~Baseline Data obtained at 2-week visit Demographic Data General Physical Exam findings Functional questionnaires administered in person (FIQOL, FISI, SF-12, FSFI, UDI-6, IIQ-7) Physiologic measurements obtained (Vaginal EMG, Anal-rectal manometry)~Follow-up Evaluation at 6-week visit Functional questionnaires administered in person at patient's previously scheduled postpartum office visit with primary Ob/Gyn or by mail~Study Completion Visit at 12-week visit Functional questionnaires administered Physiologic measurements obtained Physical Exam findings~Long-term Follow-up at 24-weeks - Functional questionnaires administered by mail"
10014533|NCT01672749||Spine based dual growing rod or VEPTR|Patients treated with the TROLLEY system will be compared with patients from the Chest Wall and Spine Deformity Study Group (CWSDSG) and the Growing Spine Study Group (GSSG) treated with a spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America). For each patient in the TROLLEY group a patient from each of the databases will be selected to be matched based on diagnosis, age, gender, and spine deformity classification.
10014534|NCT01672749||TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs). The TROLLEY system is CE marked at the time of the study conduct.
10014535|NCT01672762|Experimental|ASP1941 group|oral
10014536|NCT01672775|Experimental|Cohort 1 AGS-16C3F highest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
10014537|NCT01672775|Experimental|Cohort 0 AGS-16C3F higher dose|Renal Cell Carcinoma subjects with clear and non-clear histology
10014538|NCT01672775|Experimental|Cohort (-1) AGS-16C3F high dose|Renal Cell Carcinoma subjects with clear and non-clear histology
10014539|NCT01672775|Experimental|Cohort (-2) AGS-16C3F middle dose|Renal Cell Carcinoma subjects with clear and non-clear histology
10014540|NCT01672775|Experimental|Cohort (-3) AGS-16C3F low dose|Renal Cell Carcinoma subjects with clear and non-clear histology
10014541|NCT01672775|Experimental|Cohort (-4) AGS-16C3F lowest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
10014542|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Clear Cell Histology|Expansion Cohort
10014543|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Papillary Histology|Expansion Cohort
10014544|NCT01672814|Active Comparator|Keraflex combined with Crosslinking|Vedera KXS microwave system used in conjunction with corneal collagen crosslinking performed with VibeX (Riboflavin ophthalmic solution)and the KXL UV System
10014545|NCT01672814|Active Comparator|Corneal collagen crosslinking alone|Corneal collagen crosslinking alone performed with VibeX (Riboflavin Ophthalmic Solution)and the KXL UV system
10014546|NCT01672840|Experimental|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
10014547|NCT01672840|Experimental|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
10014548|NCT01672931||BMI over 30|Women undergoing IVF with BMI over 30
10014549|NCT01672931||BMI 20-25|Women undergoing IVF treatments with BMI between 20-25
10014550|NCT01672944|Experimental|TBCCN-developed educational materials|"Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled Biobanking Hope for a Cancer Cure, and Spanish kit is entitled Biobanco: Una esperanza de cura para el cancer."
10037340|NCT01824186|Active Comparator|LC|Subjects in this arm were randomized to undergo conventional 4-port laparoscopic cholecystectomy. Wound sites at umbilicus, right hypocondrium, epigastrium and right flank
10014551|NCT01672944|Other|Control Group|"Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled Providing your Tissue for Research: What you need to Know, Spanish brochure is entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
10014552|NCT01673035|Experimental|internet-based CBT|Cognitive behavior therapy delivered via the internet: 12 weeks, therapist-guided
10014553|NCT01673035|Active Comparator|internet-based BSM|behavioral stress management delivered via the internet: 12 weeks, therapist-guided
10014554|NCT01673048|Active Comparator|Femoral fracture, ESIN|"Prospectively all patients treated with the 3-nail-configuration for dislocated femoral shaft fractures were enrolled; 25 patients are planned, 18 could be enrolled Comparison will be with own previous data of patients treated with the classical 2-C-shaped ESIN-osteosynthesis"
10035928|NCT01810926|Sham Comparator|MRD-Regimen|Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
10035929|NCT01810926|Experimental|MUD-Regimen & Rituximab|Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 & Rituximab in a single infusion of 200 mg/m2 on day -1
10035930|NCT01810926|Sham Comparator|MUD-Regimen|Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
10035931|NCT01810965|Experimental|Cohort|
10035932|NCT01810978|Active Comparator|Bifidobacterium lactis plus inulin|Bifidobacterium lactis plus inulin
10035933|NCT01810978|Placebo Comparator|maltodextrin|maltodextrin
10035934|NCT01811017|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
10035935|NCT01811017|Experimental|Nanosecond 755nm Alexandrite Laser|Nanosecond 755nm Alexandrite Laser
10035936|NCT01811043|Experimental|Guided Meditation|Guided meditation is played via headphones during biopsy
10035937|NCT01811043|Active Comparator|Music|Music is played via headphones during biopsy
10035938|NCT01811043|Placebo Comparator|Supportive Dialogue|Supportive dialogue is provided during biopsy by the radiologist performing the procedure
10035939|NCT01811056|No Intervention|In-Center Use of Mifepristone|Participants who choose to take mifepristone in the center
10035940|NCT01811056|Experimental|Out-of-Center Use of Mifepristone|Participants who choose to take the mifepristone outside of the center
10035941|NCT01811082|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
10035942|NCT01811082|Active Comparator|Pantethine 600mg|Pantethine 600mg per day.
10035943|NCT01811095|Experimental|Training arm|"The training arm participates in the robotic suturing simulation curriculum, a proficiency curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average."
10035944|NCT01811095|Placebo Comparator|Control|Participants in this group carry on with regular training (residents) or regular clinical work (attending surgeons) without robotic simulator training during the five week period when they are in the control group.
10035945|NCT01811108||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
10014555|NCT01673087|Experimental|laboratory HPA probes|"All subjects will be studied with multiple probes of HPA axis function over the course of one to two months:~Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus."
10014556|NCT01673100|Experimental|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. These messages will be tips to help them engage in physical activity and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
10014557|NCT01673100|No Intervention|Atttention Control|Subjects in the attention control group will receive only general health messages on their study cell phone (not physical activity promoting messages). They also will receive any usual post-PCI procedure care that all get.
10014558|NCT01673139|Experimental|Moderate exercise|Moderate exercise
10014559|NCT01673139|Experimental|Control|Control group
10014560|NCT01673139|Experimental|Interval exercise|interval exercise
10014561|NCT01673152|Placebo Comparator|Maltodextrin|
10014562|NCT01673152|Experimental|Oligofructose|Orafti P95, Beneo-Orafti, Belgium,
10014563|NCT01673165|Active Comparator|Specialized Formula|25 infants of mothers who do not have breast milk or do not want to use the skimming technique. These infants will receive our standard of care - specialized formula for the treatment of chylothorax
10014564|NCT01673165|Experimental|Skimmed mother's milk|25 infants of mothers who have breast milk and who also want to learn the skimming technique will be taught the technique. The infants will then receive the skimmed breast milk for the treatment of chylothorax
10014565|NCT01673204|Experimental|Calcitriol|Calcitriol
10014566|NCT01673204|Placebo Comparator|Placebo|Placebo
10014567|NCT01673217|Experimental|Treatment (chemotherapy and vaccine therapy)|Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
10014568|NCT01673230|Other|Ventricular dysfunction|cardiac surgery for ventricular dysfunction
10014569|NCT01673243||Cancer|Parents of children with cancer will complete a questionnaire.
10014570|NCT01673243||Sickle cell disease|Parents of children with sickle cell disease will complete a questionnaire.
10014571|NCT01673243||Survivors|Parents of survivors of childhood cancer will complete a questionnaire.
10014572|NCT01673269|Experimental|ERCP with direct examination of the CBD|
10014573|NCT01673295|Experimental|RTX group|Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.
10014574|NCT01673295|Active Comparator|Control group|Subjects will not receive RTX infusions and will be followed in standard of care
10014575|NCT01673308|Experimental|Treatment arm|Lenalidomide treatment arm
9665224|NCT05129124|Experimental|T03: -3.00-2.75 x180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
10014576|NCT01673321|Experimental|Non-fat Yogurt-Plain flavored|Protein to carbohydrate ratio: 2.30
10014577|NCT01673321|Experimental|Skim milk|Protein to carbohydrate ratio: 0.69
10014578|NCT01673321|Experimental|Non-fat Yogurt with honey-Plain flavored|Protein to carbohydrate ratio: 1.24
10014579|NCT01673321|Experimental|Orange juice|Protein to carbohydrate ratio: 0.07
10014580|NCT01673321|Experimental|Non-fat Yogurt-Strawberry flavored|Protein to carbohydrate ratio: 0.79
10014581|NCT01673334|Experimental|Fine Needle Aspiration and Core Biospsy|Patients will undergo both FNA and core biopsy during EUS evaluation of a solid pancreatic tumor.
10014582|NCT01673360||Elevate PC|Subjects implanted with Elevate PC
10014583|NCT01673360||Mini Arc Pro|Subjects implanted with Mini Arc Pro
10014584|NCT01673360||RetroArc|Subjects implanted with RetroArc
10014585|NCT01673399|Active Comparator|Atosiban|Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.
10014586|NCT01673399|Placebo Comparator|placebo|Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours
10014587|NCT01673412|Experimental|interventional arm|Psychological tests
10014588|NCT01673451|Placebo Comparator|Placebo comparator|
10014589|NCT01673451|Experimental|E2006|
10014590|NCT01673464||High School Athletes|
10014591|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx flex|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
10014592|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx smile|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
10014593|NCT01673516|Active Comparator|group Co|"group Co receives intensive medical therapy utilizing integrated hemodynamic management calculated by impedance cardiography of The HOTMAN® System"
10014594|NCT01673516|Active Comparator|group RDN|"For patients who will be randomly assigned to undergo renal denervation by The SymplicityTM Renal Denervation System, the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Symplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm."
10014595|NCT01673529|Experimental|study population|All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator
10014596|NCT01673542|Experimental|Lidocaine-Prilocaine 5%|
10014597|NCT01673542|Placebo Comparator|Dexeryl|
10014598|NCT01673555|Experimental|GSK1278863 5mg|GSK1278863 5mg
10014599|NCT01673555|Experimental|GSK1278863 100mg|GSK1278863 100mg
10014600|NCT01673555|Placebo Comparator|Placebo|Placebo
10014601|NCT01673581||Low risk prostate cancer|
10014602|NCT01673633||SSc|Sacroiliitis
10014603|NCT01673633||Rheumatoid arthritis|Sacroiliitis
10014604|NCT01673633||Healthy controls|Sacroiliitis
10014605|NCT01673672|Placebo Comparator|Placebo|7 weekly/biweekly injections of a placebo buffer
10014606|NCT01673672|Experimental|CYT003 low dose|7 weekly/biweekly injections of CYT003 low dose
10014607|NCT01673672|Experimental|CYT003 medium dose|7 weekly/biweekly injections of CYT003 medium dose
10014608|NCT01673672|Experimental|CYT003 high dose|7 weekly/biweekly injections of CYT003 high dose
10014609|NCT01673685|Placebo Comparator|Portable Oxygen Cylinder|Portable Oxygen Cylinder
10014610|NCT01673685|Active Comparator|Portable Oxygen Concentrator|Portable Oxygen Concentrator
10014611|NCT01673711||Basic Science (deuterated phenanthrene tetraol)|Patients receive deuterated phenanthrene tetraol PO and collect urine for 6 hours after dosing.
10014612|NCT01673724|Experimental|pramipexole|dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks
10014613|NCT01673724|Active Comparator|Bromocriptine|bromocriptine dosage form: white round tablet
10014614|NCT01673737|Experimental|Part A Monotherapy|Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose
10014615|NCT01673737|Experimental|Part B Combination|Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination
10014616|NCT01673750||Participants|Participants will have documented HIV infection and are aware of their diagnosis. They will complete a one-time questionnaire.
10014617|NCT01673763|Active Comparator|Stent|Stent insertion into the main pancreatic duct
10014618|NCT01673763|No Intervention|No stent|No stent insertion into the main pancreatic duct
10014619|NCT01673776|No Intervention|K group|commonly used therapy
10014620|NCT01673776|Experimental|M group|multimodal intervention
10014621|NCT01673789|Experimental|Stem Cell Educator|The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
10014622|NCT01673815|Experimental|1st: R eye video. 2nd: L eye no video|The right eye will be examined first with video, followed by the left eye without video.
10014623|NCT01673815|Experimental|1st: R eye no video. 2nd: L eye video|The right eye will be examined without video, followed by the left eye with video.
10014624|NCT01673815|Experimental|1st: L eye video. 2nd: R eye no video|The left eye will be examined first with video, followed by the right eye without video.
10014625|NCT01673815|Experimental|1st: L eye no video. 2nd: R eye video|The left eye will be examined first without video, followed by the right eye with video.
10014626|NCT01673841||Relative + absolute cerebral oxygen saturation.|
10014627|NCT01673880|Other|E2006 2.5 mg|
9476808|NCT03568136|Placebo Comparator|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
10014628|NCT01673880|Other|E2006 10mg|
10014629|NCT01673880|Other|E2006 25 mg|
10014630|NCT01673906|Experimental|Diagnostic work up|The patients enrolled in the study (see below), with a consistent clinical suspicion of a primary duodenal-pancreatic NET.
10014631|NCT01673932|Experimental|Group A - UCBMC Early Treatment Group|Group A subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0.
10014632|NCT01673932|Experimental|Group B - UCBMC Delayed Treatment Group|Group B subject will partipate in 6 months observation and then receive the UCBMC transplant at month 6.
10014633|NCT01673945|Active Comparator|EUS-FNA with the CLA-EUS|patients examined with the CLA-EUS
10014634|NCT01673945|Experimental|EUS-FNA With the FV-EUS|patients examined with the FV-EUS
10014635|NCT01673958|Experimental|Stair descending group|Stair descending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
10014636|NCT01673958|Experimental|Stair ascending group|Stair ascending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
10014637|NCT01673971||Natural History|
10014638|NCT01673971||Treatment|
10014639|NCT01673997|Experimental|Metoprolol Succinate ER Tablets, 200 mg|Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd
10014640|NCT01673997|Active Comparator|TOPROL-XL ER Tablets 200 mg|TOPROL-XL ER Tablets 200 mg of AstraZeneca
10014641|NCT01674023||human vitreous, human blood serum, PCR|"human vitreous and blood serum sampling, PCR~1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases"
10014642|NCT01674036|Experimental|Part 1 (GZFD00111/TDU12766): Genz-682452|Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used.
10014643|NCT01674036|Placebo Comparator|Part 1 (GZFD00111/TDU12766): Placebo|Participants will receive a single oral dose of placebo.
10014644|NCT01674036|Experimental|Part 2 (GZFD00211/FED12767): Genz-682452|Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1.
10014645|NCT01674049|Experimental|Exercise and Immediate Nutrition|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk immediately after the exercise bout
10014646|NCT01674049|Active Comparator|Exercise and Nutrition 3 hours Post-Bout|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk three hours after the exercise bout
10014647|NCT01674075||Healthy adult volunteers|Healthy adult volunteers will be administered a J-Tip to the dorsum of his/her hand.
10014648|NCT01674088||Irritable Bowel Syndrome|Subjects meeting Rome III criteria will be included as the group Irritable Bowel Syndrome
10014649|NCT01674088||Healthy Controls|Subjects not meeting Rome III criteria and meeting clinical definitions of general good health will be considered as Healthy Controls
10014650|NCT01674101|Experimental|Physical Therapy|"The intervention group will receive PT 3 times per week for 60 minutes each session. The therapy sessions will include endurance, strengthening, and stretching exercises.~Exercise time and resistance will be progressed per individual's medical status and per participant's tolerance. All participants will be given a tailored home exercise program (HEP).~Participants will participate in PT 10 weeks prior to surgery and 10-12 weeks after surgery. Subjects will be seen by the physical therapist both when inpatient and outpatient. Patients will not be seen for PT if platelet count is less than 20,000mm3 and/or hemoglobin is less than 8g/dL."
10014651|NCT01674114|Experimental|TAP block|transversus abdominis plane block (TAP block). Ultrasound guided TAP-block at the end of surgery using 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml bilaterally by the anaesthesiologist, and 20 ml NaCl intracutaneously in the operating wound performed by the obstetrician
10014652|NCT01674114|Active Comparator|control|Ultrasound guided TAP block at the end of surgery with 20 ml NaCl bilaterally and 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml intracutaneously in the surgical wound(standard practice)
10014653|NCT01674127|Experimental|Methyldopa|In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
10014654|NCT01674127|Placebo Comparator|placebo|
10014655|NCT01674140|Placebo Comparator|Arm I|Patients receive an approved endocrine therapy comprising tamoxifen citrate*, goserelin acetate** or leuprolide acetate**, or an aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
10014656|NCT01674140|Experimental|Arm II|Patients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
9665225|NCT05129124|Experimental|T04: -3.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
10014657|NCT01674153|Experimental|HD-Exercise-HDF|Prescribe intra-dialytic exercise of three bouts in 4 hours dialysis session.
10014658|NCT01674166|Experimental|prucalopride|single dose 0.03 mg/kg prucalopride open label
10014659|NCT01674179||ACR diagnosis of Fibromyalgia|
10014660|NCT01674179||Patients without Fibromyalgia|
10014661|NCT01674192|Experimental|prucalopride|single dose of 2 mg prucalopride
10014662|NCT01674205|Experimental|Group 1 (Inpatient, H2N3 MO 2006/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
10014663|NCT01674205|Experimental|Group 2 (Inpatient, H9N2 G9/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
10014664|NCT01674205|Experimental|Group 3 (Outpatient, seasonal LAIV [FluMist®])|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
10014665|NCT01674205|Placebo Comparator|Group 4 (Both inpatient and outpatient, placebo)|Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
10014666|NCT01674218|Experimental|Treatment E|PA-824 400 mg plus moxifloxacin 400 mg
10014667|NCT01674218|Active Comparator|Treatment D|PA-824 placebo plus moxifloxacin 400 mg
10014668|NCT01674218|Experimental|Treatment C|PA-824 1000 mg plus moxifloxacin placebo
10014669|NCT01674218|Experimental|Treatment B|PA-824 400 mg plus moxifloxacin placebo
10014670|NCT01674218|Placebo Comparator|Treatment A|PA-824 placebo and moxifloxacin placebo
10014671|NCT01674231|Active Comparator|Grape|Grapes in the form of a Freeze-dried Whole Grape Powder. 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
10014672|NCT01674231|Placebo Comparator|Sugar|Grape Powder Placebo. 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
10014673|NCT01674244|Experimental|Integrative Exercise|Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
10014674|NCT01674244|Active Comparator|Monitor Only Waitlist|Monitor Only Waitlist
10014675|NCT01674257||Carotid Endarterectomy|Patients due to undergo carotid endarterectomy for symptomatic carotid artery stenosis will undergo an 18F-Fluoride PET/CT, an 18F-Flurodeoxyglucose PET/CT and a USPIO (ferumoxytol)-enhanced MRI scan (2 MRI scans).
10014676|NCT01674270|Experimental|Degarelix|Degarelix Alone
10014677|NCT01674270|Experimental|Degarelix + Casodex|Degarelix and Casodex
10014678|NCT01674270|Active Comparator|LHRH Agonist + Casodex|LHRH Agonist and Casodex
10014679|NCT01674283|Experimental|Glucagon|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.~The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer."
10014680|NCT01674283|Placebo Comparator|Sodium chloride 0.9%|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.~The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer."
10014681|NCT01674296||Group 1 (2012-2013)|Monitoring of Dietary Intake, Physical Activity and Stress
10014682|NCT01674296||Group 2 (2013-2014)|Monitoring of Dietary Intake, Physical Activity and Stress
10014683|NCT01674309|Other|single arm study/ non randomized trial|FOLFORINOX
10014684|NCT01674322|Experimental|Ibrutinib|All participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
10014685|NCT01674335|No Intervention|Delayed-Intervention|A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
10014686|NCT01674335|Active Comparator|Operant Learning|
10014687|NCT01674335|Active Comparator|Energy Conservation|
10014688|NCT01674348|Active Comparator|P2202|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
10014689|NCT01674348|Placebo Comparator|Placebo|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
10014690|NCT01674374|Experimental|Arm I (SAMITAL)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules PO QID. Patients may continue to receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
10014691|NCT01674374|Placebo Comparator|Arm II (placebo)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive placebo PO QID. Patients may continue to receive placebo for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
10035946|NCT01811121|Experimental|5-aminolévulinique acid (5-ALA)|5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
10014692|NCT01674387|Experimental|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral cervical Jiaji (EX-B2),and two trigger points.Bilateral Jianzhongshu (SI15) and Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
10014693|NCT01674387|Other|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS(Transcutaneous Electrical Nerve Stimulation) therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
10014694|NCT01674413|Placebo Comparator|Placebo/Step-Down|1 syringe of placebo SC q 2 weeks.
10014695|NCT01674413|Active Comparator|PRNLOAD Arm|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38)
10014696|NCT01674413|Active Comparator|Maintenance Arm|Adalimumab 40 mg q 2 weeks.
10014697|NCT01674426|Experimental|Cognitive behavior therapy|Cognitive behavior therapy consisting of 16 sessions over 20 weeks
10014698|NCT01674426|Placebo Comparator|observation|Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed
10014699|NCT01674439|Experimental|With supplementation of ADRC|Fat graft with supplementation of ADRC
10014700|NCT01674439|Active Comparator|Without supplementation of ADRC|Fat grafts without supplementation of ADRC
10014701|NCT01674452|Experimental|home-based group|
10014702|NCT01674452|Active Comparator|supervised exercise group|
10014703|NCT01674452|No Intervention|control|Control group:no intervention
10014704|NCT01674465||CNI-induced nephrotoxicity|Hypoxyprobe-1
10014705|NCT01674491|Experimental|4.5g/day black soy peptide|4.5 g/day, 8weeks
10014706|NCT01674491|Placebo Comparator|placebo|similar appearance to the black soy peptide tablet, 8 weeks
10014707|NCT01674504|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
10014708|NCT01674504|Active Comparator|SINGTJLAIR ®|SINGTJLAIR ® (containing Montelukast sodium)chewable tablets 5mg of Merck Sharp & Dohme Ltd., USA
10014709|NCT01674517|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
10014710|NCT01674517|Active Comparator|SINGULAIR®|SINGULAIR®(containing Montelukast sodium) chewable tablets 4mg and 5mg of Merck Sharp & Dohme Ltd., USA
10014711|NCT01674530|Experimental|Lubiprostone|Manufactured by Dr Reddy's Laboratories Ltd( 24 mcg administered for 7 days )
10014712|NCT01674530|Active Comparator|AMITIZA®|Manufactured by Sucampo Pharmaceuticals(24 mcg administered for 7 days)
10014713|NCT01674530|Placebo Comparator|Placebo|Manufactured by Dr Reddy's Laboratories Ltd ( 24 mcg adminstered for 7 days )
10014714|NCT01674543|Experimental|Resistance training|
10014715|NCT01674543|Experimental|Concurrent training|
10014716|NCT01674543|Sham Comparator|Control Group|
10014717|NCT01674556|Experimental|Contrast-enhanced ultrasound (CEUS)|
10014718|NCT01674582|Other|MRI, Neuropsychological testing|
10014719|NCT01674595|Experimental|Immunotherapy|AVANZ
10014720|NCT01674660||volume status|volume status:group1 over volume status,group2 normal volume status,group3 low volume status
10014721|NCT01674660||night blood pressure|night blood pressure：group1 nondipper,group2 dipper,group3 extreme dipper,group4 riser
10014722|NCT01674660||interdialysis weight gain|interdialysis weight gain:group1 >5% dry weight,group2 <5% dry weight
10014723|NCT01674686|Experimental|A|Sarpogrelate versus placebo
10014724|NCT01674686|Experimental|B|Atorvastatin 80mg versus no statin or simvastatin 20 mg if LDL > 130 mg/dl
10014725|NCT01674699||EXCOR|Pediatric candidates age 0 - 21 with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR® Pediatric.
10014726|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Stratum A
10014727|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevazizumab|Stratum B:
10014728|NCT01674751|Experimental|Immediate intervention|Group begins the 4 week Pre-Ordering Program intervention immediately following a 4-wk baseline period.
10014729|NCT01674751|Other|Wait-listed control|Group begins the 4 week Pre-Ordering Program intervention following an 8-wk baseline period.
10014730|NCT01674764||Early surgical intervention = Cohort 1|≤ 12 hours after the tSCI
10014731|NCT01674764||Late surgical intervention = Cohort 2|> 12 hours and < 14 days after the tSCI
10014732|NCT01674777|Experimental|under fasting condition group|Subjects will receive a single dose of ASP1941 under fasting condition
10014733|NCT01674777|Experimental|before meal group|Subjects will receive a single dose of ASP1941 before meal
10014734|NCT01674777|Experimental|after meal condition|Subjects will receive a single dose of ASP1941 after meal
10014735|NCT01674790|Experimental|AEROBIC group|6-week program of one 20-min session of aerobic training and one 20-min session of ROM exercise 5 days/week.
10014736|NCT01674790|Experimental|COGNITIVE group|6-week program of one 20-min session of cognitive training and one 20-min session of ROM exercise 5 days/week.
10014737|NCT01674790|Experimental|AEROBIC + COGNITIVE group|6-week program of one 20-min session of aerobic training and one 20-min session of cognitive training 5 days/week.
10014738|NCT01674790|Experimental|CONTROL group|6-week program of one 20-min session of ROM exercise and one 20-min session of unstructured mental activity 5 days/week.
10014739|NCT01674803|Active Comparator|Orsiro|
10014740|NCT01674803|Active Comparator|Synergy|
10014741|NCT01674803|Active Comparator|Resolute Integrity|
10014742|NCT01674816|Active Comparator|Repeated Measurements of Knee Alignment and Kinematics|Patients in the Repeated Measurements Arm will have the kinematic measurement protocol repeated twice before and twice after the surgical procedure; the procedure itself will be performed with the traditional technique, i.e without guidance by the system.
10035947|NCT01811121|Placebo Comparator|Placebo|Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
9476809|NCT03568071|Experimental|Cohort A - dose regimen A|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen A) will be administered on Day 1.
10035948|NCT01811134|Experimental|PIPELINE flow diverter stent|flow diverter stent
10014743|NCT01674816|Active Comparator|Computer Guidance of Surgical Actions|Patients in the Computer Guidance of Surgical Actions Arm will have the kinematic measurement protocol performed only once before and once after the surgical procedure; the procedure itself will be performed with guidance by the system.
10014744|NCT01674829|Experimental|Biological: MA09-hRPE Cellular therapy|"Biological: MA09-hRPE Cellular therapy~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
10035949|NCT01811134|Active Comparator|Coils, with or without expendable stent|Coils
10035950|NCT01811160|Experimental|Melatonin 5mg (extended release capsules)|Subjects received melatonin (extended release) 5mg nightly during the follow up period
10014745|NCT01674842|Experimental|Cisplatin + Radiation Therapy|Cisplatin concurrently with radiation therapy
10014746|NCT01674855|Experimental|DA-3031|PEG-G-CSF
10014747|NCT01674855|Active Comparator|Leucostim®|G-CSF
10014748|NCT01674868|Experimental|Fluoxetine|Subjects will take 20 mg fluoxetine daily for 90 days after stroke
10014749|NCT01674868|Placebo Comparator|placebo|Subjects will take one pill daily for 90 days after stroke.
10014750|NCT01674881|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|This group will receive MBCT for 8 consecutive weeks.
10014751|NCT01674881|Other|Waitlist control group|This group is a waitlist control group.
10014752|NCT01674894||Group 1|Women treated with Menopur
10014753|NCT01674894||Group 2|Women treated with Menopur and Bravelle
10014754|NCT01674907||Cohort|
10014755|NCT01674920|Experimental|Choices|"The 3-month twelve-session intervention, Choices, included topics on nutrition, physical activity, and resiliency. Parents, boys and girls met separately. The sessions were developed for delivery by a family physician, two family medicine residents, and a nutritionist, who received training in positive psychology and resilience skills. All children were measured on the same dates, but children were randomly assigned to two cohorts, beginning 6 months apart, to facilitate statistical analysis by having one group experience normal growth on study prior to intervention."
10014756|NCT01674933|Active Comparator|treatment as usual|any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing
10014757|NCT01674933|Experimental|Duraphat® Fluoride Varnish|treatment as usual (ie any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing) plus up to 4 six-monthly applications of Duraphat Fluoride Varnish in the nursery school setting.
10014758|NCT01674946|Placebo Comparator|ID saline|ID saline by feeding tube
10014759|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
10014760|NCT01674946|Active Comparator|ID + CDCA (15 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
10014761|NCT01674946|Active Comparator|ID saline + oleanolic acid (1 mmol/L)|
10014762|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L) + oleic acid|
10014763|NCT01674946|Placebo Comparator|ID saline + oleic acid (20 mmol/L)|
10014764|NCT01674959|Experimental|concurrent chemoradiation|"• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
10014765|NCT01674972||NAFLD|Patients with biopsy proven NAFLD
10014766|NCT01674972||Control|Matched healthy control subjects
10014767|NCT01674985|Experimental|Decitabine and cytarabine|induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days
10014768|NCT01675024|Experimental|Rotigotine, Period 1|In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
10014769|NCT01675024|Experimental|Rotigotine, Period 2|In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.
10014770|NCT01675037||obstructive|obstructive hydrocephalus in children and adults with biological evaluation
10014771|NCT01675076|Experimental|Continued NOAC|- Patients continue on their chronic dose of Dabigatran or Rivaroxaban or Apixaban throughout
10014772|NCT01675076|Active Comparator|Interrupted NOAC|"Interrupted Dabigatran:~Discontinue Dabigatran 1 day before surgery if GFR > 50 mL/min or discontinue 2 days before surgery if GFR 30-50 mL/min~Resume Dabigatran at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Rivaroxaban:~Discontinue Rivaroxaban 1 full day before surgery~Resume Rivaroxaban at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Apixaban:~Discontinue Apixaban 1 full day before surgery~Resume Apixaban at next regular dose timing >or = 24 hours after the end of surgery"
10014773|NCT01675089|Experimental|Zoledronic acid|Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
10014774|NCT01675089|No Intervention|Control|The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
10014775|NCT01675115|Active Comparator|BNG-1 plus Aspirin|BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks
10014776|NCT01675115|Sham Comparator|Aspirin|Aspirin 100mg QD for 4 weeks
10014777|NCT01675180|Other|Information|Women randomized to the intervention will recieve information and counseling on oral health care during pregnancy
10014778|NCT01675180|No Intervention|Control|
10014779|NCT01675193|No Intervention|Current screening protocol|Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
10014780|NCT01675193|Other|Disinvestment protocol|No eye screening at 6-9 and 14-24 months
10014781|NCT01675206|Active Comparator|360 µg Vit K2|Administration of 360 µg of Vitamin K2 thrice weekly
10014782|NCT01675206|Active Comparator|720 µg Vit K2|Administration of 720 µg of Vitamin K2 thrice weekly
10014783|NCT01675206|Active Comparator|1080 µg Vit K2|Administration of 1080 µg of Vitamin K2 thrice weekly
10014784|NCT01675219|Experimental|Group B|Blue light TUR-BT with no adjuvant instillations
10014785|NCT01675219|Active Comparator|Group A|White light TUR-BT with no adjuvant instillations
10014786|NCT01675219|Experimental|Group C|White light TUR-BT with six weekly optimized mitomycin-C instillations.
10014787|NCT01675219|Experimental|Group D|Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.
10014788|NCT01675232|Active Comparator|Soak and smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment immediately to wet skin once a day and dry skin once a day.
10014789|NCT01675232|Active Comparator|Dry smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment to dry skin twice a day.
10014790|NCT01675245||Velcade|Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
10014791|NCT01675258||Control|Healthy adults above the age of 18 years
10014792|NCT01675258||Study|Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
10014793|NCT01675271|Active Comparator|individual exercise|individualized exercise program
10014794|NCT01675271|Active Comparator|general exercise|general exercise program
10014795|NCT01675271|No Intervention|control|No exercise and dietary counselling
10014796|NCT01675284|Experimental|Low Dosage AT-301|7.5 µg hemagglutinin (HA)
10014797|NCT01675284|Experimental|Middle Dosage AT-301|15 µg hemagglutinin (HA)
10014798|NCT01675284|Experimental|High Dosage AT-301|30 µg hemagglutinin (HA)
10014799|NCT01675310|Experimental|medical nutrition therapy + metformin|medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)
10014800|NCT01675310|Active Comparator|medical nutrition therapy|medical nutrition therapy without trans-gestational metformin
10014801|NCT01675323||RLS Patients|Participants who have diagnosed RLS with diagnosis confirmed by study investigators.
10014802|NCT01675323||Healthy Controls|Participants without RLS who are generally healthy and matched for gender, age, educational level, and race to patients in the RLS group.
10014803|NCT01675349|Experimental|Chenopodium album allergen extract|Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
10014804|NCT01675362|Placebo Comparator|Control group|They will receive placebo
10014805|NCT01675362|Active Comparator|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
10014806|NCT01675362|Active Comparator|Calcium channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
10014807|NCT01675362|Active Comparator|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
10014808|NCT01675375|Experimental|Eye shield|Eye shield place on post Laser Vision Correction eye
10014809|NCT01675388|Experimental|Hypothermia|Hypothermia to 33.5 deg Centigrade
10014810|NCT01675401|Experimental|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
10014811|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
10014812|NCT01675440||Severe (≥3-4+) Mitral Valve Regurgitation|Mitral valve regurgitation ≥3-4+
10014813|NCT01675440||Severe (≥3-4+) Tricuspid Valve Regurgitation|Tricuspid valve regurgitation ≥3-4+
10014814|NCT01675440||End Stage Renal Disease (ESRD)|End stage renal disease requiring renal replacement therapy or a creatinine clearance (CRCL) <20 cc/min, but not on dialysis
10014815|NCT01675440||Low Gradient Low Output Aortic Stenosis|Low gradient low output aortic stenosis
10014816|NCT01675440||Failed Bioprosthetic Surgical Aortic Valve|Stenosed, insufficient or combined bioprosthetic surgical aortic valve failure
10014817|NCT01675440||2 or More Conditions|2 or more of the listed conditions
10014818|NCT01675466|Active Comparator|early laparoscopy|early laparoscopy, aiming to achieve this within 12 hours
10014819|NCT01675466|Placebo Comparator|active observation|"standard management - the wait and see approach with serial examinations and investigations as deemed necessary"
10014820|NCT01675505||Patients|"Inclusion criteria:~Patients with first-diagnosed colon cancer. Age 18-60 y.o.~Exclusion criteria:~Metastatic colon cancer. Former psychiatric history. Substance use. Previous serious medical conditions."
10014821|NCT01675518|Experimental|Part-1 dose 1|
10014822|NCT01675518|Experimental|Part-1 dose 2|
10014823|NCT01675518|Experimental|Part-1 dose 3|
10014824|NCT01675518|Experimental|Part-1 dose 4|
10014825|NCT01675518|Experimental|Part-1 dose 5|
10014826|NCT01675518|Experimental|Part-1 dose 6|
10014827|NCT01675518|Placebo Comparator|Part-1 placebo|
10014828|NCT01675518|Experimental|Part-2 fed|
10014829|NCT01675518|Experimental|Part-2 fasted|
10014830|NCT01675557|Active Comparator|Vitamin D2|a single oral dose of vitamin D2
10014831|NCT01675557|Placebo Comparator|Placebo|a single oral dose of a placebo
10014832|NCT01675557|Experimental|Vitamin D3|A single oral dose of vitamin D3
10014833|NCT01675570|Experimental|RX-10045 active arm|RX-10045 Opththalmic Solution, 0.09%
10014834|NCT01675570|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
10014835|NCT01675583||Standard Care Group|Subjects who will undergo only standard wound care management.
10014836|NCT01675583||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
10014837|NCT01675648|Experimental|Lofexidine & Diazepam Placebo|"Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm."
10014838|NCT01675648|Active Comparator|Diazepam & Lofexidine Placebo|"The initial dosage of Diazepam is 10 mg per day on Day 1&2, the dosage will be increased to 15 mg per day on Day 3&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6&7, 2mg per day on Day 8&9&10.~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm."
10014839|NCT01675674||Dried blood spot test for MPS|"For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria).~For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria)."
10014840|NCT01675687|Experimental|Internet|"Participants of this intervention group get follow up support via Internet.~They have access to new inputs biweekly consisting of~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~News and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be available each month.~Tailored feedback of their behaviour will be given by documentation on spreadsheets."
10014841|NCT01675687|Experimental|Printed Manual|"Participants of this intervention group get follow up support via a printed manual.~The manual consist of all the same inputs as are available to the Internet follow up group.~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~All inputs will be given at once at the beginning of the follow up intervention, only news and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be sent per mail each month.~There is no tailored feedback of their behaviour as the paper-pencil documentation on spreadsheets can't be monitored by the psychologists."
10014842|NCT01675700|Experimental|Myofascial trigger point|Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point.
10014843|NCT01675713|Experimental|Lifestyle intervention|10-14 weeks intensive lifestyle intervention
10014844|NCT01675713|No Intervention|Controls|No treatment, waiting list
10014845|NCT01675726|Other|quality of life|
10014846|NCT01675739|Active Comparator|No-SMS group|In No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy without SMS.
10014847|NCT01675739|Experimental|SMS group|Patients in SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled short message service(SMS)
10014848|NCT01675791|Placebo Comparator|ALK tree AIT Placebo|1 AIT administered sublingually every day
10014849|NCT01675791|Experimental|ALK tree AIT 0.5 DU|1 AIT administered sublingually every day
10014850|NCT01675791|Experimental|ALK tree AIT 1 DU|1 AIT administered sublingually every day
10014851|NCT01675791|Experimental|ALK tree AIT 2 DU|1 AIT administered sublingually every day
10014852|NCT01675791|Experimental|ALK tree AIT 4 DU|1 AIT administered sublingually every day
10014853|NCT01675791|Experimental|ALK tree AIT 7 DU|1 AIT administered sublingually every day
10014854|NCT01675791|Experimental|ALK tree AIT 12 DU|1 AIT administered sublingually every day
9802555|NCT05167643|Experimental|Trastuzumab injection+Piperacillil tablets+Letrozole tablets|Trastuzumab injection:Once in 21 days IVD；Piperacillil tablets:125mg qd (d1-21) PO；Letrozole tablets:2.5mg POqd；According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
10014855|NCT01675804|Experimental|Computerized cognitive rehabilitation|-Computer-assisted cognitive rehabilitation (CACR): 20 Ninety-minute sessions of CACR.
10014856|NCT01675804|Placebo Comparator|Placebo CACR [PCACR]|-PCACR group simultaneously received 20 Ninety-minute sessions of Placebo CACR.
10014857|NCT01675804|Experimental|Ritalin|-2 to 3 doses of 10 mg Ritalin tablets per day during two months.
10014858|NCT01675843|Experimental|Group A|controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI)
10014859|NCT01675843|No Intervention|Group B|Controlled ovarian hyperstimulation (COH)+ Timed Intercourse (TI)
10014860|NCT01675856|Active Comparator|Urgent endoscopy|Oesophagogastroduodenoscopy done within 6hours of first GI specialists consultation
10014861|NCT01675856|Placebo Comparator|Early endoscopy|Oesophagogastroduodenoscopy done within 24hours of first GI specialists consultation
10014862|NCT01675869|Experimental|ETAM group|Executive Function/Metacognitive Training Program: An 8-week program, which addresses major areas of deficit in ADHD; namely, attention (the ability to concentrate and focus), inhibition (the ability to control ones behaviors), and memory (the ability to remember information).
10014863|NCT01675869|Active Comparator|Attention Control|Attention control group: An 8-week program which provides education regarding several topics relevant for preschool children including nutrition, sleep, temperament, etc.
10014864|NCT01675895|Experimental|Group Levobupivacaine lidocaine|Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine
10014865|NCT01675895|Active Comparator|Group Control|Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline
10014866|NCT01675921|No Intervention|Control|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to this study website at the start and at the end of the study."
10014867|NCT01675921|Experimental|Facebook group|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to the study website at all times throughout the study.~Participants will have access to the secret study group on Facebook for 12 months.~Participants will take the ACT survey once a month for 12 months."
10014868|NCT01675934|Active Comparator|Adult colonoscope|Use of the adult colonoscope.
10014869|NCT01675934|Active Comparator|Pediatric colonoscope|Use of the pediatric colonoscope.
10014870|NCT01675947|Experimental|Sirolimus|Monthly 20 μL (440 μg) intravitreal injection of sirolimus
10014871|NCT01675947|Sham Comparator|Lidocaine|Monthly subconjunctival injection of 2% lidocaine
10014872|NCT01675973|Experimental|Subjects with severe renal impairment|Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
10014873|NCT01675973|Experimental|Subjects with normal renal function|Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
10014874|NCT01675986|Experimental|Pregabaline|Groups PREGABALINE : 150 mg de LYRICA®
10014875|NCT01675986|Experimental|Hydroxyzine|Groups HYDROXYZINE : 75 mg d'ATARAX®
10014876|NCT01675986|Placebo Comparator|Lactose|Groups placebo : 4 g de lactose
10014877|NCT01675999|Experimental|1|"Perioperative simplified FOLFOX-4 chemotherapy~- Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by simplified FOLFOX-4 (8 cycles)."
10014878|NCT01675999|Experimental|2|Perioperative FOLFOX4+Cetuximab chemotherapy Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h)+ Cetuximab (IV 500 mg/m2 every 2 weeks) for 4 cycles followed by colectomy (3 to 5 weeks after), followed by simplified FOLFOX-4 + Cetuximab (8 cycles).
10014879|NCT01675999|Other|3|Surgery followed by FOLFOX4 chemotherapy No preoperative chemotherapy Colectomy (maximum 4 weeks after randomization) followed by simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 12 cycles.
10014880|NCT01676025|Experimental|PRA|Persons who get PRA surgery.
10014881|NCT01676025|Experimental|LA|Persons who get LA surgery.
10014882|NCT01676038|Active Comparator|Pinless-Navigated Total Knee Arthroplasty|The patients underwent total knee arthroplasty using a Pinless-Navigated system that is designed to restore the mechanical alignment of the lower limb.
10014883|NCT01676038|Active Comparator|Conventional Total Knee Arthroplasty|The patients underwent total knee arthroplasty using conventional technique.
10014884|NCT01676051||Chloraprep|
10014885|NCT01676051||Duraprep|
10014886|NCT01676051||Betadine only|
10014887|NCT01676064|Active Comparator|liberal fluid group|during surgery 7 ml/kg/hr RL during first intraoperative hr, 5 ml/kg/hr for the subsequent hours.After surgery ( PACU) 1,5 ml/kg/hr;After operation ward on the day of surgery 1,5 ml/kg/hr; Postoperative day 1- 1,5 ml/kg/hr RL, oral fluids;Postoperative day 2-oral fluids and solid food according to surgical allowance.
10014888|NCT01676064|Active Comparator|restrictive fluid group|"during surgery-RL according to 4-2-1 4 ml/kg/hr for first 10 kg (=40ml/hr) then 2 ml/kg/hr for next 10 kg (=20ml/hr)then 1 ml/kg/hr for any kg over 20 kg of weight. This always gives 60ml/hr for first 20 kg then you add 1 ml/kg/hr for each kg over 20 kg.~After surgery (PACU):4-2-1 rule. After operation ward on the day of surgery 1,5 ml/kg/hr.Postoperative day 1:1,5 ml/kg/hr RL, oral fluids. Postoperative day 2:oral fluids and solid food according to surgical allowance."
10014889|NCT01676077||Patients with a genetically confirmed dysferlinopathy|
10014890|NCT01676103|Experimental|Tyrosine|Tyrosine supplementation (500 mg 2x daily) for 7 days
10014891|NCT01676103|Placebo Comparator|Sugar pill|Placebo sugar pills (2x daily) for 7 days
10014892|NCT01676129|Experimental|Nocipoint Therapy|"Nocipoint therapy (NT) follows rules of TENS stimulation in each session, all within the general FDA guidelines of TENS uses. The key points of Nocipoint Therapy include the following:~The stimulation pads are located at the skin surface location of the nociceptors of the muscle/tissue in pain (i.e., Nocipoint)~The intensity is set to induce C-fiber response during the stimulation~The duration of stimulation (about 1.5-4 minutes for each tissue stimulation)~Stimulations for different tissues (muscles, ligaments) are sequenced such that later stimulations will not cause re-injury of previously treated tissues.~Patient are instructed not to use the newly recovered muscle/tissue too much for an estimated rest period depending on his/her age."
10014893|NCT01676129|Active Comparator|Physical Therapy|"Patients in this group will be treated with comprehensive physical therapy program including typical electrical stimulation using a standard transcutaneous electrical nerve stimulation (TENS) device, manual myofascial release and postural correction exercise.~The application of TENS will follow general physical therapy guidelines, especially for TMD. Manual myofacial release will be applied on orofacial muscles and neck muscles.~TENS will serve both as a part of the standard of care and as placebo, as the same TENS device is used in both arms."
10014894|NCT01676142||Patients with NTM pulmonary infection|
10014895|NCT01676142||Patients with other pathogen related lung infection|
10014896|NCT01676142||Patient with NTM pulmonary colonization|
10014897|NCT01676155||Patient with active tuberculosis|
10014898|NCT01676155||Patients with diagnosis of latent tuberculosis infection|
10014899|NCT01676155||Patient without latent tuberculosis or active tuberculosis|
10014900|NCT01676168||hypertrophic scar|1x1cm2 hypertrophic scar of post-burn patients are taked by visiting staff when they accept scar-reconstructive surgery.
10014901|NCT01676168||normal skin|When the patient accept skin grafting surgery, visiting staff will take 1x1cm2 normal skin.
10014902|NCT01676181|Active Comparator|Adenotonsillectomy|Total removal of tonsils and adenoids with cold steel
10014903|NCT01676181|Active Comparator|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
10014904|NCT01676194|Experimental|Intra-arterial administration of DC BeadsR|Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
10014905|NCT01676194|No Intervention|Control|Usual care
10014906|NCT01676207||1|CAD
10014907|NCT01676207||2|no CAD
10014908|NCT01676233|Experimental|Sequence 1|Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal
10014909|NCT01676233|Experimental|Sequence 2|Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal
10014910|NCT01676246|Active Comparator|flupirtine per os single dose|100 mg flupirtine per os, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
10014911|NCT01676246|Active Comparator|flupirtine intravenous|100 mg flupirtine intravenous, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
10014912|NCT01676246|Active Comparator|flupirtine per os steady state|400 mg flupirtine per os, pharmacokinetics of flupirtine, electric pain measurement
10014913|NCT01676259|Experimental|siG12D-LODER + chemotherapy|Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
10014914|NCT01676285|Active Comparator|Metoprolol succinate|Metoprolol succinate
10014915|NCT01676285|Placebo Comparator|Placebo|Placebo
10014916|NCT01676285|No Intervention|Follow up|Group without cirrhotic cardiomyopathy, only follow up without randomization.
10014917|NCT01676324||Inflammatory Bowel Disease|Those with Inflammatory Bowel Disease (known) and those with no Inflammatory Bowel Disease (not previously diagnosed)
10014918|NCT01676337|No Intervention|Control|Patients randomized to the control arm will not receive text message reminder regarding their upcoming appointment.
10035951|NCT01811160|Placebo Comparator|Placebo|Subjects received a placebo capsule nightly during the eight week follow up period.
9476810|NCT03568071|Experimental|Cohort B - dose regimen B|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen B) will be administered on Day 1.
10014919|NCT01676337|Experimental|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
10014920|NCT01676363|Experimental|Diflunisal|
10014921|NCT01676376|Active Comparator|eSVS Mesh treated saphenous vein graft|Each subject will be randomized to an eSVS Mesh treated SVG to the right or left coronary system.
10014922|NCT01676376|Sham Comparator|Control saphenous vein graft|Each subject will be randomized to an untreated (no eSVS Mesh) SVG to the right or left coronary system.
10014923|NCT01676376|Active Comparator|Single Vessel Treatment|Each subject with receive one SVG with eSVS Mesh either to the right or left coronary system.
10014924|NCT01676389|Experimental|OMM Hands-On Treatment|The Osteopathic Manual Medicine (OMM) Hands-On Treatment group will be receiving an osteopathic structural exam along with 7 gentle, non-thrusting techniques during each treatment session that lasts 20-30 minutes. The Sham treatment group will be receiving only an osteopathic structural exam that will be slowed down in order to be a similar duration to the full treatment group session (approximately 20-30 minutes).
10014925|NCT01676389|Placebo Comparator|Sham OMM|Sham Osteopathic Manual Medicine (OMM)
10014926|NCT01676402|Experimental|Group 1: HA DNA + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV ID at Week 14±2 wks
10014927|NCT01676402|Experimental|Group 2: HA DNA + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV IM at Week 14±2 wks
10014928|NCT01676402|Experimental|Group 3: TIV ID + TIV ID|licensed 2012/13 TIV ID at Day 0 and licensed 2013/14 TIV ID at Week 44±2 weeks
10014929|NCT01676402|Experimental|Group 4: TIV IM + TIV IM|2012/13 licensed TIV IM at Day 0 and licensed 2013/14 TIV IM at Week 44±2 weeks
10014930|NCT01676402|Experimental|Group 5: (HA DNA and TIV ID) + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV ID at Day 0 followed by licensed 2013/14 TIV ID at Week 44±2 weeks
10014931|NCT01676402|Experimental|Group 6: (HA DNA and TIV IM) + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV IM at Day 0 followed by licensed 2013/14 TIV IM at Week 44±2 weeks
10014932|NCT01676428|Experimental|Radiotherapy|"The interventional treatment will be prescribed as a 2-tiered dose scheduled dependant of target size.~For lesions <5cm, a single fraction of 26 Gy will be prescribed. For lesions ≥5cm a fractionated course of 15Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
10014933|NCT01676441|Experimental|cellgram-spine|posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10^7 and 3.2 X10^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively
10014934|NCT01676454||Vasopressin levels.|"Cohort will consist of subjects with a minor injury or injuries defined as:~no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;~no blood transfusion requirement;~base deficit < 5 mEq/L;~no requirement for mechanical ventilation other than transiently during orthopedic surgery."
9476811|NCT03568071|Experimental|Cohort C - dose regimen C|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen C) will be administered on Day 1.
9665226|NCT05129124|Experimental|T05: -9.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
9665227|NCT05129124|Experimental|T06: -9.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
10014935|NCT01676467||Smoking asthma on steroids|Smokers with persistent asthma on background steroid therapy
10014936|NCT01676467||Smoking asthma steroid naïve|Smokers with persistent asthma, steroid naive
10014937|NCT01676467||asthma on steroids|Non-Smokers with persistent asthma on background steroid therapy
10014938|NCT01676467||asthma, steroid naïve|Non-smokers with persistent asthma, steroid naive
10014939|NCT01676467||Healthy smoking|Healthy smoking control subjects
10014940|NCT01676467||Healthy non-smoking|Healthy non-smoking control subjects
10014941|NCT01676480|Experimental|ADT group|
10014942|NCT01676480|Experimental|Control group|
10014943|NCT01676493|Experimental|Codeine|Codeine Sulfate Oral Solution and Tablet
10014944|NCT01676519||PCI|diabetic patients undergoing percutaneous coronary intervention
10014945|NCT01676545||Chronic Periodontitis|
10014946|NCT01676545||Control|
10014947|NCT01676558|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
10035952|NCT01811173|Experimental|Nurse-physician comprehensive care|Comprehensive self management support and care coordination by a nurse-primary care physician team
10035953|NCT01811173|No Intervention|Usual care survey control group|Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study
10035954|NCT01811173|No Intervention|Usual care blinded control group|Patients will receive usual primary care.
10035955|NCT01811251|Experimental|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
10035956|NCT01811251|Placebo Comparator|Lactose (150mg), NaC1 0.9% (50ml)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
10035957|NCT01811264|Experimental|Intervention|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. Then they will be helped through the Patient-Participation Aid (PPA) by the research assistant (RA). Then they will meet with their doctor while the visit is video-recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication. Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
9802556|NCT05166343|No Intervention|Standard of Care|All POHCA events will be handled per standard of care of epinephrine administration via intravenous or intraosseous (IV/IO) based on patient estimated weight.
10014948|NCT01676571|Experimental|Lu AA21004|
10014949|NCT01676584|Placebo Comparator|Placebo|
10014950|NCT01676584|Experimental|RO6811135|
10014951|NCT01676597|Experimental|rifaximin and pentoxifylline|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
10014952|NCT01676597|Active Comparator|pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
10014953|NCT01676610||Infants presenting to the Clinic|Infants presenting to the Bilal and Bhains Colony Health Center. Devices used to measure Pulse Oximetry (PO) include Rad-5v by Masimo, TuffSat by GE, N-65 by Nellcor, PRO2 by Conmed, and Lifebox by Acare.
10014954|NCT01676623|Active Comparator|Comparison area, only standard government services|This intervention arm will receive the standard government services offered at CHCs all over Vietnam. In addition, participants in this arm will be exposed to the nationwide mass media campaign.
10014955|NCT01676623|Experimental|A&T Franchise|In this arm, the 20 CHCs will offer Alive & Thrive branded franchise services with enhanced quality of IYCF counseling through interpersonal contact between health workers at the commune level and clients who use the commune health services. In addition, the clients could also be exposed to the mass media campaign.
10014956|NCT01676636||Pregnant Women|Women who are 13 to 30 weeks pregnant. Each participant will take all 4 different calcium vehicles and decide which one they prefer.
10014957|NCT01676649|Experimental|A|Arm A: Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 4, week 7, week 10, and week 13)
10014958|NCT01676649|Experimental|B|Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 5, week 8, week 11, and week 14)
10014959|NCT01676662|Experimental|Treatment on Day 0|Subjects who are treated with the Solace Bladder Control System upon entry into the trial.
10014960|NCT01676662|Sham Comparator|Sham Treatment on Day 0|Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.
10014961|NCT01676675|Experimental|7.5μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21
10014962|NCT01676675|Experimental|15μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
10014963|NCT01676675|Experimental|30μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
10014964|NCT01676675|Experimental|7.5μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
10014965|NCT01676675|Experimental|15μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
10014966|NCT01676675|Experimental|30μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
10014967|NCT01676675|Placebo Comparator|0/0.5ml in adolescents (12-17 years old)|0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21
10014968|NCT01676675|Placebo Comparator|0/0.5ml in adults(18-60 years old)|0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21
10014969|NCT01676740|Placebo Comparator|Mild anemia, normal hematinics|Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo
10014970|NCT01676740|Experimental|Anemia, normal hematinics|Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given
10014971|NCT01676740|Other|Deficeicnt hematinics|Iron supplement will be provided
10014972|NCT01676753|Experimental|Dinaciclib & Pembrolizumab Treatment|Dinaciclib is administered on days 1 and 8 of a 21-day cycle in combination with pembrolizumab administered on day 1 of each 21-day cycle.
10014973|NCT01676779|Experimental|Arm A dendritic cell therapy|Arm-A, patients will receive Dendritic Cell therapy during one year following randomization.
10014974|NCT01676779|Experimental|Arm B Dendritic cell therapy|Arm-B, patients will initiate Dendritic Cell therapy only after documented recurrence of the melanoma that cannot be salvaged by local therapy.
10014975|NCT01676792|Experimental|Lesion reduction|
9476812|NCT03568071|Experimental|Cohort D - dose regimen D|MOR106 will be administered as IV infusion. Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen D) will be administered on Day 1.
9665228|NCT05129124|Experimental|T07: -12.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
10014976|NCT01676844|Experimental|Oral thin film therapy|One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
10014977|NCT01676844|Active Comparator|Standard therapy|Standard oral phosphate supplementation as per NHS Greater Glasgow and Clyde Guidelines. An oral solution containing potassium acid phosphate (1 mmol/mL) will be administered at a dosage of 0.5 mM/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Standard therapy will continue until the participant has received treatment for 14 consecutive days.
10014978|NCT01676857||CP/CPPS group|The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
10014979|NCT01676857||Control group|Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
10014980|NCT01676870|Experimental|1x4 aerobic interval training|1x4min aerobic interval training (1-AIT), 3 times a week
10014981|NCT01676870|Experimental|4x4 aerobic interval training|4x4min aerobic interval training (4-AIT), vigorously exercise according to today's guidelines, 3 times a week
10014982|NCT01676870|Active Comparator|traditional moderate training|traditional moderate training (CME), moderate exercise at least 30 min, 5 days a week or more, according to today's guidelines
10014983|NCT01676883|Experimental|body composition assessment|Bioelectric impedance measurement pre- and post removal of calluses and corns (pedicure), then air-displacement plethysmography (gold standard)
10014984|NCT01676922||Cohort|
10014985|NCT01676935|Experimental|ABT-126|ABT-126 Open-label dose
10014986|NCT01676948|Experimental|Canakinumab - Cohort 1, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
10014987|NCT01676948|Experimental|Canakinumab - Cohort 1, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
10014988|NCT01676948|Experimental|Canakinumab - Cohort 2, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
10014989|NCT01676948|Experimental|Canakinumab - Cohort 2, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
10014990|NCT01676948|Experimental|Cohort 2 - canakinumab dose reduction|
10014991|NCT01676948|Experimental|Cohort 1 - canakinumab dose reduction|
10014992|NCT01676974||Travelers|Travelers and their family members
10014993|NCT01676987|Experimental|Fixed Combination of Budesonide and formoterol|Group 1 (experimental): Fixed Combination of Budesonide and formoterol
10014994|NCT01676987|Active Comparator|Budesonide|Group 2 (comparator): Budesonide
10014995|NCT01677013|No Intervention|Oral medication treatment|type 2 diabetics with only oral medications
10014996|NCT01677013|Experimental|Oral medication plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
10014997|NCT01677013|No Intervention|Oral medication plus insulin treatment|Type 2 diabetics who need insulin therapy with oral medications
10014998|NCT01677013|Experimental|Oral medication plus insulin plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
10014999|NCT01677039|Active Comparator|Treatment A|
10015000|NCT01677039|Experimental|Treatment B|
10015001|NCT01677039|Experimental|Treatment C|
10015002|NCT01677065||Treatment A|Controlled release oxycodone test formulation 40 mg
10015003|NCT01677065||Treatment B|Immediate release oxycodone reference drug 20 mg
10015004|NCT01677078|Experimental|Neuronavigation system|"10 sessions of rTMS coupled with a neuronavigation system~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~rTMS: System Mag Pro (Magventure, Denmark)~Neuronavigation system: Syneika One (Syneika, France)"
10015005|NCT01677078|Sham Comparator|Standard localisation method|"10 sessions of rTMS with manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~- rTMS: System Mag Pro (Magventure, Denmark)"
9802557|NCT05166343|Other|Intramuscular Epinephrine Dose|"POHCA events will be handled per standard of care, however, first dose epinephrine administration will be via intramuscular (IM) autoinjector. Dosing will be dependent on weight as follows:~3-5kg=0.3mg IM epinephrine 6-9kg=0.5mg IM epinephrine 10-24kg=1.0mg IM epinephrine~≥25kg=1.5mg IM epinephrine"
9802558|NCT05164562||type 1 diabetes|"type 1 diabetes group: patients with type 1 diabetes"
9802559|NCT05164432|Experimental|High risk of preterm birth|Women at high risk of preterm birth
9802560|NCT05164432|Active Comparator|Women with low risk pregnancies|Women with uncomplicated pregnancies anticipated to deliver at term
9802561|NCT05161377|Active Comparator|Surgical management|
9802562|NCT05161377|Active Comparator|Endovascular management|
9802563|NCT05161338|Experimental|FROZEN EMBRYO TRANSFER|Women who undergo an artificial cycle for frozen embryo transfer and receive luteal phase support.
9802564|NCT05156125|Experimental|VTX002 Dose A|VTX002 Dose A tablet administered orally once daily
9802565|NCT05156125|Experimental|VTX002 Dose B|VTX002 Dose B tablet administered orally once daily
9802566|NCT05156125|Placebo Comparator|Placebo|Placebo tablet administered orally once daily
9802567|NCT05155267||Chronic Kidney disease participants (CKD)|CKD submitted to hemodialysis
9802568|NCT05155267||Controls|Healthy participants
9802569|NCT05154500|Experimental|Biofortified Potato with iron or zinc ('A')|Women volunteers will consume biofortified ('A') for one day in zinc study, and 10 days in iron study Zinc study and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p>0.05). Based on this study design, every woman is her own control.
9802570|NCT05154500|Placebo Comparator|Non Biofortified potato with iron or zinc ('B')|Women volunteers will consume no biofortified ('B') for one day in zinc study, and 10 days in iron study
9802571|NCT05152199|Other|Cystoscopy with use of obturator sheath|This intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
9802572|NCT05152199|Active Comparator|Cystoscopy without use of obturator sheath|This intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
10015006|NCT01677091|Active Comparator|Control group|This group will benefit from conventional rehabilitation
10015007|NCT01677091|Experimental|Cervical vibration|This group will benefit from a daily 20 minutes session, with vibration of neck muscles during 10 minutes
9802573|NCT05149755|Experimental|Medtronic Evolut PRO+ TAVR System and guideline-directed management and therapy (GDMT)|
9802574|NCT05149755|No Intervention|Clinical site determined guideline-directed management and therapy (GDMT) alone|
9802575|NCT05147298|Experimental|Environmental group intervention (E only)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment
9802576|NCT05147298|Experimental|Individual-level eHealth phone program intervention (I only)|An automated telephone-based physical activity program.
9802577|NCT05147298|Experimental|Combined group (E and I interventions)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment and an automated telephone-based physical activity program.
9802578|NCT05147298|No Intervention|Control group (no interventions)|No interventions for residents to increase activity levels.
9802579|NCT05146167|Experimental|Bodhi AIM|Participants randomized to the intervention group will receive the Bodhi AIM app
9802580|NCT05146167|Active Comparator|HIB|Participants randomized to the health promotion control group will receive the HIB app
10015008|NCT01677091|Experimental|Prism adaptation|This group will benefit from a daily 20 minutes session, with prism adaptation during 10 minutes
10015009|NCT01677091|Experimental|Cervical vibration + Prism adaptation|This group will receive a daily 30 minutes session, with cervical vibration during 10 minutes + prism adaptation during 10 minutes
10015010|NCT01677104|Active Comparator|DPP-IV inhibitor|Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
10015011|NCT01677104|Placebo Comparator|Placebo pill|One placebo tablet before microinjection
10015012|NCT01677143|Active Comparator|bupivacaine|Injection of 5 ml bupivacaine, 5mg/ml in each port site.
10015013|NCT01677143|Placebo Comparator|Placebo|Injection of 5 ml saline in each port site.
10015014|NCT01677156||Receiving Corus CAD (ASGES)|Patients receiving Corus CAD (ASGES) to aid in the diagnosis of obstructive CAD
10015015|NCT01677169|Experimental|59 mL noni juice|Ingestion of 59 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) twice daily (118 mL daily total) for 30 days.
10015016|NCT01677169|Placebo Comparator|Placebo|Ingestion of 59 mL of placebo (mixture of grape and blueberry juices and natural cheese flavor) twice daily (118 mL daily total) for 30 days.
10015017|NCT01677169|Experimental|29.5 mL noni dose|Ingestion of 29.5 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) daily for 30 days.
10015018|NCT01677208|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
10015019|NCT01677208|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
10015020|NCT01677234||Pregnant women|Pregnant women undergoing a cesarean section
10015021|NCT01677247|Experimental|Group I (Test)|Test : glimepiride 4 mg tablet of PT Dexa Medica
10015022|NCT01677247|Active Comparator|Group II (Reference)|Reference : glimepiride (Amaryl) 4 mg tablet of PT Sanofi-Aventis, Indonesia
10015023|NCT01677260|Experimental|Group I|500 mg metformin hydrochloride extended release caplet (PT Ferron Par Pharmaceuticals)
10015024|NCT01677260|Active Comparator|Group II|500 mg metformin hydrochloride prolonged release tablet (PT Merck Pharmaceuticals)
10015025|NCT01677273|Active Comparator|Hydrolyzed casein|Hydrolyzed casein
10015026|NCT01677273|Active Comparator|Intact casein|Intact casein
10015027|NCT01677273|Active Comparator|Intact whey protein|Intact whey protein
10015028|NCT01677325|Experimental|Chinese herb|Chinese herb
10015029|NCT01677351|Active Comparator|group 2: clonidine 4mcg.kg|this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.
10015030|NCT01677351|Placebo Comparator|Group 1: sterile saline solution|this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery
10015031|NCT01677364|Active Comparator|induction of labour|drug- infusion of 30U oxytocin diluted in 500ml normal saline given at rate of 3mU/min and subsequently dose increased 3mU/min every 45 min
9665229|NCT05129124|Experimental|T08: -12.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
10015032|NCT01677364|No Intervention|Spontaneous Labour|patients were allowed to go into spontaneous labour
10015033|NCT01677390|Experimental|Arm 1|SGN-75, everolimus
10015034|NCT01677403|Active Comparator|Nebulised Tobramycin|Nebulised Tobramycin
10015035|NCT01677403|Placebo Comparator|Nebulised 0.9% Saline|Nebulised 0.9% Saline
10015036|NCT01677416||Rheumatoid Arthritis Group|RA with at least one year since diagnosis, asymptomatic feet, and age between 18 and 65 years
10015037|NCT01677416||Control group|Absence of known osteoarticular disease
10015038|NCT01677429|Experimental|VR movie + balance challenge|VR-based balance training
10015039|NCT01677429|Sham Comparator|still pictures from VR|Exposure to still pictures from the same VR scene but no balance challenge
10015040|NCT01677429|Active Comparator|Cognitive Behavioral Therapy|Standard CBT protocol for the treatment of panic disorder
10015041|NCT01677442|Experimental|no-intubated group|Experimental: no-intubated thoracic epidural anesthesia Thoracic epidural anesthesia at the T5/T6 thoracic interspace
10015042|NCT01677442|Active Comparator|intubated group|Active Comparator:double-lumen endotracheal intubated anesthesia
10015043|NCT01677455|Experimental|HER2+ breast cancer|
10015044|NCT01677455|Experimental|Triple negative breast cancer|Closed to enrollment
10015045|NCT01677455|Experimental|ER/PR+ Refractory to Prior Hormonal Treatment|
10015046|NCT01677468|Experimental|Intermediate embolization|TACE with substatsis using gelfoam
10015047|NCT01677468|Active Comparator|Complete embolization|TACE with complete embolization using gelfoam
10015048|NCT01677481||Femoral|Coronary angiography procedures performed using transfemoral access
10015049|NCT01677481||Left radial access|Coronary angiography procedures performed using left radial access site.
10015050|NCT01677481||Right radial Access|Coronary angiography procedures performed using Right radial access site.
10015051|NCT01677494||heart failure with preserved ejection fraction|- Inclusion Elevated BNP EF > 50%
10015052|NCT01677520||18-30 yrs, 31-50 yrs, 51-70 yrs|No intervention
10015053|NCT01677533|Active Comparator|PM-Data|Team will receive data only.
10015054|NCT01677533|Experimental|PM-Support|Team will receive data and panel management support
10015055|NCT01677533|Experimental|PM-Education|Team will receive data, panel management support, and educational interventions.
10015056|NCT01677546|Experimental|CSII+BC+CL|Patients using insulin pump (CSII) bolus calculator (BC) wirelessly connected with blood glucose meter Contour Link (CL)
10015057|NCT01677546|Experimental|CSII+BC|Patients using insulin pump (CSII) bolus calculator (BC) without wireless connection with blood glucose meter (CL)
10015058|NCT01677546|No Intervention|CSII (insulin pump only)|Patients using insulin pump (CSII) without BC and connection with CL
10015059|NCT01677559|Experimental|Dose Level 0|"MLN8237 20 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
10015060|NCT01677559|Experimental|Dose Level 1|"MLN8237 30 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
10015061|NCT01677559|Experimental|Dose Level 2|"MLN8237 40 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
10015062|NCT01677559|Experimental|Dose Level 3|"MLN8237 50 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
10015063|NCT01677559|Experimental|MTD Expansion Phase|"MLN8237 as determined during the dose escalation phase on Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
10015064|NCT01677572|Experimental|Low-dose #1 Aducanumab|Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
10015065|NCT01677572|Experimental|Low-dose #2 Aducanumab|Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
10015066|NCT01677572|Placebo Comparator|Placebo (low dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
10015067|NCT01677572|Experimental|Mid-dose Aducanumab|Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
10015068|NCT01677572|Placebo Comparator|Placebo (mid dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
10015069|NCT01677572|Experimental|High-dose Aducanumab|Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
10015070|NCT01677572|Placebo Comparator|Placebo (high dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
10015071|NCT01677572|Experimental|Aducanumab Titration|Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
10015072|NCT01677572|Placebo Comparator|Placebo (Titration Group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
10015073|NCT01677598||Patients with plaque psoriasis|Patients with plaque psoriasis using ustekinumab in Asia-Pacific countries.
10015074|NCT01677611|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial.Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of either resveratrol.The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia. Subjects were instructed to abstain from foods with high resveratrol content during the entire duration of the trial.
10015075|NCT01677611|Placebo Comparator|Placebo|All subjects underwent a 2-week run-in period during which placebo was administered. The placebo was manufactured so that it was not distinguishable by color, form, or taste from the active drug. Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of matching placebo and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
10015076|NCT01677637||All measurements|Total measured population
10015077|NCT01677650|Active Comparator|Methadone 0.5 mg/kg|Methadone 0.5 mg/kg
10015078|NCT01677650|Experimental|Methadone 0.4 mg/kg|Methadone 0.4 mg/kg
10015079|NCT01677650|Active Comparator|Methadone 0.3 mg/kg|Methadone 0.3 mg/kg
10015080|NCT01677650|Active Comparator|Methadone 0.2 mg/kg|Methadone 0.2 mg/kg
9802581|NCT05145400|Experimental|Single Arm|All subjects will receive the same treatment on the study, consisting of isatuximab, lenalidomide, and dexamethasone with 28 days cycles.
10015081|NCT01677650|Active Comparator|Methadone 0.15 mg/kg|Methadone 0.15 mg/kg
10015082|NCT01677676|Active Comparator|Group 2|FP-01.1 (250µg/peptide)
10015083|NCT01677676|Active Comparator|Group 3|FP-01.1-Adjuvant (150µg/peptide / 10.8mg)
10015084|NCT01677676|Active Comparator|Group 4|FP-01.1-Adjuvant (250µg/peptide / 18mg)
10015085|NCT01677676|Active Comparator|Group 1|FP-01.1 (150µg/peptide)
10015086|NCT01677689|Placebo Comparator|Control Group|Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal
10015087|NCT01677689|Experimental|Study Group|Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
10015088|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
10015089|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
10015090|NCT01677702|Placebo Comparator|Recombined low-protein milk|Total 250mL placebo milk will be taken once per day at 10am daily during the 84 days intervention.
10015091|NCT01677715|Active Comparator|"Yili Mei Yi Tian lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
10015092|NCT01677715|Placebo Comparator|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
10015093|NCT01677728||arm A|patients received chemotherapy alone
10015094|NCT01677728||arm B|patients received target therapy combined with chemotherapy
10015095|NCT01677780|Experimental|RO5045337|Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
10015096|NCT01677793||Child and adolescent population|
10015097|NCT01677806|Experimental|Percutaneous vertebroplasty|
10015098|NCT01677806|Active Comparator|Conservative therapy|
10015099|NCT01677832||ADHD/Taiwan|
10015100|NCT01677832||Control/Taiwan|
10015101|NCT01677832||ADHD/Germany|
10015102|NCT01677832||Control/Germany|
10015103|NCT01677845|Experimental|Radiation Therapy|Radiation Therapy
10015104|NCT01677871|Experimental|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
10015105|NCT01677871|Active Comparator|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
10015106|NCT01677871|Experimental|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
10015107|NCT01677871|Active Comparator|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
10015108|NCT01677884|Experimental|Patients with metastatic CRC|
10015109|NCT01677897|Experimental|Metformin|Metformin 2x1000mg orally per day
10015110|NCT01677923|No Intervention|Control without Metformin|Conventional management of obesity including basic instructions on diet and physical activity
10015111|NCT01677923|Experimental|Control with Metformin|Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
10015112|NCT01677923|Experimental|Intervention with Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
10015113|NCT01677923|No Intervention|Intervention without Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian
10015114|NCT01677949|Experimental|ALL patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute lymphoblastic leukemia (ALL) along with Clofarabine, Etoposide and Cyclophosphamide.
10015115|NCT01677949|Experimental|AML patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute myeloid leukemia (AML) along with Clofarabine, Etoposide and Cyclophosphamide.
10015116|NCT01677962|Experimental|dendritic cell and Poly-ICLC vaccination|Dendritic cell and Poly-ICLC vaccination will be administered directly into the tumor on Day 0 and Day 14 of Treatment Phase. Subjects will then have standard of care procedures along with injections of Poly-ICLC and dendritic cells for the remainder of the study.
10015117|NCT01677975|Experimental|ultrasound, dynamic lymphscintigraphy|
10015118|NCT01678001|Active Comparator|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
10015119|NCT01678001|Placebo Comparator|Placebo|Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
10015120|NCT01678014|Experimental|Anorexia|Anorexia patients
10015121|NCT01678040||Cardiac Magnetic Resonance|"The CMR examinations will be performed in the cardiac MRI scanner (Siemens Avanto, 1.5 Tesla, Erlangen, Germany) at the Hospital for Sick Children. A brief echocardiogram will be performed using a GE Vivid 7 or Vivid E9 machine (General Electric Medical Systems, Wisconsin, USA) We will image from standard parasternal long axis and apical four-chamber before and after completed hydration."
10015122|NCT01678053|Experimental|PPI and BOTOX|onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
10015123|NCT01678053|Other|Proton pump inhibitor only|omeprazole 40mg po bid for 3 months(standard of care)
9802582|NCT05144191|Other|Insignia uncemented Hip Stem|"The Insignia™ Hip Stem is a collared stem that features a plasma-sprayed Hydroxyapatite (HA) coating over plasma-sprayed titanium in the proximal region and a plasma-sprayed HA coating over grit blast in the distal region and collar underside.~Insignia™ Hip Stems are intended for 'cement less' use only and are intended for total arthroplasty procedures."
9802583|NCT05142553|Experimental|COVID-19 Vaccine HIPRA|40 ug/0.5 ml
9802584|NCT05142553|Active Comparator|Cominarty (Pfizer-BioNtech)|30 micrograms/dose concentrate for dispersion for injection
9802585|NCT05140551|Experimental|COMPASS|This is a single arm study. We are investigating COMPASS digital CBT.
9802586|NCT05137054|Experimental|Cohort 1: R5458 + Dd Combo|R5458 + Daratumumab and dexamethasone (Dd)
9802587|NCT05137054|Experimental|Cohort 2: R5458 + Kd Combo|R5458 + Carfilzomib and dexamethasone (Kd)
9802588|NCT05137054|Experimental|Cohort 3: R5458 + Rd Combo|R5458 + Lenalidomide and dexamethasone (Rd)
9802589|NCT05137054|Experimental|Cohort 4: R5458 + Vd Combo|R5458 + Bortezomib and dexamethasone (Vd)
9802590|NCT05136339|Experimental|Immediate Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions immediately after enrollment.
9802591|NCT05136339|Experimental|Delayed Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions approximately 12 months after enrollment.
9802592|NCT05134740|Experimental|Experimental Arm|Patients receiving autologous TAA-specific cytotoxic CTLs
9802593|NCT05134311|Experimental|3D-US|These subjects will have a 3D rendering of their vascular testing shown to them.
9802594|NCT05134311|No Intervention|Standard US|These subjects will be shown a hand drawn sketch of the results of the vascular testing.
9802595|NCT05129371|Active Comparator|Breathing Exercise Group|This group will be given breathing exercises in accordance with the determined protocol.
9802596|NCT05129371|Placebo Comparator|Placebo Breathing Group|Normal breathing of this group will be monitored.
9802597|NCT05129371|No Intervention|Control Group|No application will be made to this group.
9802598|NCT05129306||Patients|Patients with moderate to severe Allergic Rhinitis who have been prescribed RYALTRIS® nasal spray by their healthcare professional. Observational.
9802599|NCT05129228|Experimental|OCT-guided saphenous vein graft coronary artery bypass graft surgery|Optical Coherence Tomography (OCT) provides high quality intravascular images by using infrared light. OCT will assess the harvested saphenous vein conduit in Coronary Bypass Graft Surgery (CABG). Abnormalities found in the harvested conduits via OCT, at the discretion of the surgeon, will not be utilized for CABG.
9802600|NCT05129228|No Intervention|Visual inspection-guided saphenous vein graft coronary artery graft surgery|Harvested saphenous vein conduits will be assessed visually and will undergo a blinded OCT.
9802601|NCT05128994|Experimental|Non-invasive FES|Wearable FES sleeve with non-invasive user controls
9802602|NCT05127928|Experimental|Supplementation|Vitamin C and Vitamin E before exercise
9802603|NCT05127928|Placebo Comparator|Placebo|Placebo before exercise
9802604|NCT05127577|Experimental|Abdominal massage group|Abdominal massage will be applied to the experimental group 2 times a day, morning and evening, until defecation, starting in the evening of the first day after the surgical intervention.
9802605|NCT05127577|No Intervention|Control group|The control group will be received routine treatment and care in the unit.
9802606|NCT05127486|Experimental|Galcanezumab|"Galcanezumab administered subcutaneously (SC).~Placebo for rimegepant will be used for blinding."
9802607|NCT05127486|Active Comparator|Rimegepant|"Rimegepant administered oral disintegrating tablets (ODT).~Placebo for galcanezumab will be used for blinding."
9802608|NCT05123001|Experimental|Device physiological monitoring|Patients will receive wearable sensor devices (Biostrap arm band)
9802609|NCT05123001|No Intervention|Microsampling|Blood microsamples will be collected at start of conditioning chemotherapy, daily while in the hospital, and after leaving the hospital and outpatient appointments.
9802610|NCT05123001|No Intervention|Biostrap mobile App|Data collection from wearable sensor.
9802611|NCT05122143|Experimental|Sequence 1|Treatment sequence for the 3 treatment exposure visits is ABC.
9802612|NCT05122143|Experimental|Sequence 2|Treatment sequence for the 3 treatment exposure visits is BCA.
9802613|NCT05122143|Experimental|Sequence 3|Treatment sequence for the 3 treatment exposure visits is CAB.
9802614|NCT05122143|Experimental|Sequence 4|Treatment sequence for the 3 treatment exposure visits is ACB.
9802615|NCT05122143|Experimental|Sequence 5|Treatment sequence for the 3 treatment exposure visits is BAC.
9802616|NCT05122143|Experimental|Sequence 6|Treatment sequence for the 3 treatment exposure visits is CBA.
10015124|NCT01678066||Bilateral cardiac output|This is a prospective, non-randomized study to collect data from two noninvasive FDA-approved cardiac output monitors simultaneously in pediatric patients under general anesthesia in the operating room from age 1 month old to 8 years old with all types of medical conditions. We will enroll 50 male and female pediatric patients who are having lower abdominal and lower extremity surgery in this study so that the additional 8 EKG leads placed on the patients do not interfere with the surgical site or patient positioning.
10015125|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (500 mg/day)|Encapsulated Calcium
10015126|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)|Encapsulated Calcium
10015127|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)|Encapsulated Calcium
10015128|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (500 mg/day)|Non-capsulated Calcium
10015129|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1000 mg/day)|Non-capsulated Calcium
10015130|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1500 mg/day)|Non-capsulated Calcium
10015131|NCT01678105|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
10015132|NCT01678118||minority smokers|A single arm ABA design will be used to pilot a tobacco-focused patient navigation (TPN) intervention for low income, minority smokers.
10015133|NCT01678157||Documented symptomatic paraesophageal hernia|"Documented symptomatic paraesophageal hernia.~Greater than 5 cm hiatal hernia on upper gastrointestinal study.~Evidence that the stomach or other viscera is present in the hernia and does not spontaneously reduce from the mediastinum.~Significant symptoms or signs of a paraesophageal hernia including but not limited to heartburn,dysphagia, chest pain, shortness of breath, postprandial abdominal pain, early satiety, odynophagia, or chronic anemia.~Consenting adult 19 years of age or older~Must be able to participate in follow-up evaluation.~Free of cognitive impairment"
10015134|NCT01678183|Experimental|Monthly Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension, and hypercholesterolemia at the pharmacy on time. The intervention is the cash incentive.
10015135|NCT01678183|Experimental|Monthly and Final Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension and hypercholesterolemia at the pharmacy on time, as well as an additional financial incentive for each full percentage point of decrease in their hemoglobin A1c over the eight-month course of the study. The two cash incentives are the intervention.
10015136|NCT01678183|No Intervention|Control|These subjects will complete the enrollment process for the study but will be randomized to a group that receives usual care.
10015137|NCT01678235|Experimental|GLU_ASP|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin glulisine~Second day: insulin aspart"
10015138|NCT01678235|Experimental|ASP_GLU|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin aspart~Second day: insulin glulisine"
10015139|NCT01678261||1a Turner syndrome 45,X|Blood from 50 persons with Turner syndrome an karyotype 45,X
10015140|NCT01678261||1b Controls for TS 45,X|50 healthy aged female controls matched to the TS 45,X cohort
10015141|NCT01678261||2a Turner syndrome 45,X mosaics|Blood from 50 persons with Turner syndrome an karyotype 45,X mosaics
10015142|NCT01678261||2b Controls for TS 45,X mosaics|50 healthy aged female controls matched to the TS 45,X mosaics cohort
10015143|NCT01678261||3a Paraffin embedded aortic tissue TS|3a Paraffin embedded samples of aortic tissue from 10 persons with TS
10015144|NCT01678261||3b Paraffin embedded aortic tissue from 10 controls|3b Paraffin embedded samples of aortic tissue from 10 controls who did not die from aortic aneurism
10015145|NCT01678261||4a 70 47,XXY men|4a Blood from 70 men with Klinefelter syndrome (47,XXY)
10015146|NCT01678261||4b 70 controls matching group 4a|4b 70 male controls matching group 4a with respect to age.
10015147|NCT01678261||5a 5 persons with double Y-syndrome|5a Blood from 5 persons with double Y-syndrome (47,XYY)
10015148|NCT01678261||5b 20 controls matching 5a|5b 20 healthy controls matching group 5a with respect to age
10015149|NCT01678261||6a 5 persons with triple X-syndrome|6a Blood from 5 persons with triple X-syndrome (47,XXX)
10015150|NCT01678261||6b 20 controls matching 6a|6b 20 healthy controls matching group 6a with respect to age.
10015151|NCT01678261||7 10 biological parents of cohort 1a.|7 Blood from 10 biological parents of individuals in cohort 1a
10015152|NCT01678274||Turner syndrome|Females with Turner syndrome
10015153|NCT01678274||Control group|age matched females acting as controls
10035958|NCT01811264|No Intervention|Usual Care|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. They will have their doctor's visit video recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication.Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
10035959|NCT01811277|Experimental|SOX sequential S-1|4-6 cycles of SOX followed by S-1 monotherapy until disease progression
10035960|NCT01811290||Gilenya Subjects|Gilenya therapy group subjects must have been treated with Gilenya a minimum of 3 months uninterrupted prior to screening visit, and approved by the principal investigator to continue on this agent.
10035961|NCT01811290||Controlled Therapy Group|Control therapy group subjects must have been consistently on an FDA approved disease modifying therapy other than Gilenya or off such therapy a minimum of 6 months prior to screening visit.
10035962|NCT01811329|Active Comparator|Palm fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
10035963|NCT01811329|Experimental|Palm fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
10035964|NCT01811329|Active Comparator|Dairy fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.
10035965|NCT01811329|Experimental|Dairy fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
10035966|NCT01811342||Hemoglobin Measurement|Patients requiring intra-operative hemoglobin measurement.
10035967|NCT01811381|Experimental|Curcumin and aerobic exercise|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six to 12 months after the beginning of the study, subjects will take curcumin (4 capsules BID before meals, total 800 mg/day) and also participate in an aerobic yoga exercise program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
10035968|NCT01811381|Placebo Comparator|Placebo vs non-aerobic yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
10035969|NCT01811381|Active Comparator|Placebo vs Aerobic Yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
10035970|NCT01811381|Active Comparator|Curcumin vs non aerobic yoga|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Curcumin (4 capsules x BID, total 800 mg/day) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
10035971|NCT01811394|Experimental|protons|16x4GyE protons
10035972|NCT01811394|Experimental|Carbon ions|16x4GyE carbon ions
9665230|NCT05129124|Active Comparator|C01: +6.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
10015154|NCT01678287|Experimental|Arm 1 Non elderly receiving ASP1941|healthy subjects age 18 to 45 years receiving ASP1941
10015155|NCT01678287|Experimental|Arm 2 Non elderly receiving placebo|healthy subjects age 18 to 45 years receiving placebo
10015156|NCT01678287|Experimental|Arm 3 Elderly receiving ASP1941|healthy subjects age ≥ 65 years receiving ASP1941
10015157|NCT01678287|Experimental|Arm 4 Elderly receiving placebo|healthy subjects age ≥ 65 years receiving placebo
10015158|NCT01678326|Active Comparator|EUS-Rendezvous or direct intervention|EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
10015159|NCT01678326|Active Comparator|Advanced ERCP Biliary Access Techniques|Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
10015160|NCT01678339||1|
10015161|NCT01678352|Experimental|Cohort 1|Patients must have undergone surgery or biopsy alone (no postoperative radiation or chemotherapy) and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression (no progression from the initial surgery/biopsy).
10015162|NCT01678352|Experimental|Cohort 2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥ 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression.
10015163|NCT01678352|Experimental|Cohort 3|Patients with recurrent WHO grade 2 glioma may have received prior external beam radiotherapy and/or chemotherapy. Patients with stable WHO grade 2 glioma must have had prior chemotherapy (at least one cycle of Temozolomide or PCV-based chemotherapy). With regard to the prior therapy in Cohort 3, patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or observation of stable disease. The intent therefore is that patients may have had 3 prior therapies (initial therapy and treatment for 2 relapses). If the patient had a surgical resection for relapsed disease, and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse.
10015164|NCT01678365|Experimental|ceftriaxone and metronidazole for complicated appendicitis.|Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
10015165|NCT01678365|Active Comparator|Ampicillin, gentamicin, and metronidazole|Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
10015166|NCT01678378|Experimental|SHARP Intervention|School health centers randomized to the SHARP Intervention will be trained to address adolescent relationship abuse with school health center clients.
10015167|NCT01678378|No Intervention|Control|School health centers randomized to Control will provide standard of care.
10015168|NCT01678391|Experimental|Patients with common bile duct stones.|Common bile duct stone removal without fluoroscopy
10015169|NCT01678404|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
10015170|NCT01678417|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
10015171|NCT01678430|Active Comparator|Ofatumumab-Chlorambucil|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Chlorambucil: 10mg/m2 po days 1-7
10015172|NCT01678430|Experimental|Ofatumumab-Bendamustine|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Bendamustine: 70mg/m2 iv days 1 and 2
10015173|NCT01678469|Other|blood sample|
10015174|NCT01678482|Experimental|lession count reduction post treatment|"A total of 50 subjects were included.~The majority are female (62 %)~At baseline the average number of lesions was 20.5±7.1, ranging from 6 to 36 lesions.~All subjects demonstrated a reduction in lesion count.~The average improvement after one month was 56.7%±8.9%, and remained similar also after 3 months 57.7%±9.4%.~The percent of responders (with at least 40% of reduction) was 94% after 1 month and 96% after 3 months~The Percent of responders is similar for males & females and similar for cheeks & front."
10015175|NCT01678495|Experimental|Sonothrombolysis + microbubbles|"rtPA+ sonovue. SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml Powder and solvent for dispersion for injection 1 vial containing 25 mg lyophilized powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection~1 pre-filled syringe containing sodium chloride 9 mg/ml (0.9%) solution for injection~1 Mini-Spike Plus 6/8 (CE 0123) transfer system.~1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles."
10015176|NCT01678495|Active Comparator|Standard intravenous thrombolysis|Patients in thecontrol group will use thehelmetbut without U.S continuous U.S wave emission. Serial monitoring of the status ofrecanalizationaccording to theschedule set will be carried out according to theestablished schedule
10015177|NCT01678521||Hypercholesterolemic patients|Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment
9476813|NCT03568071|Experimental|Cohort E - dose regimen E|MOR106 will be administered as IV infusion.Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen E) will be administered on Day 1.
9476814|NCT03568071|Placebo Comparator|Placebo|Subjects will receive repeated doses of placebo over a 12-week treatment period.
9476815|NCT03568045|Active Comparator|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
9802617|NCT05118893||Ablation-based rhythm-control|Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial fibrillation, and additional ablation for persistent atrial fibrillation
9802618|NCT05118893||Rate-control|Rate-control included AV-nodal blocking agents and AV node ablation with permanent pacing
10015178|NCT01678534|Placebo Comparator|Placebo|In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.
10015179|NCT01678534|Experimental|Allogeneic stem cells from adipose tissue|The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg
10015180|NCT01678547|Experimental|Robot G-EO|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling.
10015181|NCT01678547|Active Comparator|Treadmill Training|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the treadmill system device, according to individually tailored exercise scheduling.
10015182|NCT01678547|Active Comparator|Ground treatment|Ground Control Group (cCG): Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) of traditional lower limb physiotherapy treatment.
10015183|NCT01678573|Experimental|Sequence 1: abiraterone acetate|"Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule ABC under fasted conditions."
10015184|NCT01678573|Experimental|Sequence 2: abiraterone acetate|"Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule BAC under fasted conditions."
10015185|NCT01678573|Experimental|Sequence 3: abiraterone acetate|"Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule CBA under fasted conditions."
10015186|NCT01678599|Other|Benznidazol|This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.
10015187|NCT01678612|No Intervention|Non copper standard surfaced objects|Rooms assigned to standard surfaced objects
10015188|NCT01678612|Experimental|Copper-alloy surfaced objects|Rooms furnished with copper surfaced objects, i.e. bed rails, bed rail levers, IV poles, nurse workstation, clipboards, sink handles.
10015189|NCT01678625||Acceleromyography group|Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
10015190|NCT01678625||Electromyography group|Train-of-four ratio calculation (T4-EMG)
10015191|NCT01678638|Active Comparator|Early inguinal hernia (IH) repair|IH repair before NICU discharge
10015192|NCT01678638|Active Comparator|Late inguinal hernia (IH) repair|IH repair as outpatient at approximately 55-60 weeks post-menstrual age
10015193|NCT01678651|Active Comparator|Human FSH|Human FSH
10015194|NCT01678651|Active Comparator|Recombinant FSH|Recombinant FSH
10015195|NCT01678664|Experimental|embolization or chemoembolization plus everolimus|After 2 sessions of embolization with microsphere of 100 to 500 µm or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site).
10015196|NCT01678677|Experimental|Group A|Subjects in this group will receive formulation 1 of NTHi vaccine.
10015197|NCT01678677|Experimental|Group B|Subjects in this group will receive formulation 2 of NTHi vaccine.
10015198|NCT01678677|Experimental|Group C|Subjects in this group will receive formulation 3 of NTHi vaccine.
10015199|NCT01678677|Experimental|Group D|Subjects in this group will receive formulation 4 of NTHi vaccine.
10015200|NCT01678677|Experimental|Group E|Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
10015201|NCT01678677|Experimental|Group F|Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
10015202|NCT01678677|Experimental|Group G|Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
10015203|NCT01678677|Experimental|Group H|Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
10015204|NCT01678677|Placebo Comparator|Group Placebo 1|Subjects in this group will receive placebo.
10015205|NCT01678677|Placebo Comparator|Group Placebo 2|Subjects in this group will receive placebo.
10015206|NCT01678690|Experimental|Gemcitabine HCl Oral Formulation|Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
10015207|NCT01678703|Active Comparator|Laminaria group|Patients in this group will have cervical preparation with laminaria MedGyn Products, Inc. USA overnight the day before the abortion
10015208|NCT01678703|Active Comparator|Misoprostol group|Patients in this group will have cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
10015209|NCT01678716|Active Comparator|Essential Health Care (EHC) only|This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
10015210|NCT01678716|Experimental|EHC + Micronutrient Powders|This arm will be based on the EHC platform but will also include EHC platform health workers promoting and selling the micronutrient powders.
10015211|NCT01678716|Experimental|EHC + BCC|This arm will have a behavior chance communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
10015212|NCT01678716|Experimental|EHC + BCC + Micronutrient powders|This arm will contain both the behavior change communication and the micronutrient powder sales intervention.
10015213|NCT01678742|Experimental|High-protein diet|
10015214|NCT01678742|Active Comparator|Standard diet|
10015215|NCT01678781||One patient group|Patients suffering from irritable bowel syndrome
10015216|NCT01678872|Other|Long Term Follow up|Long Term follow up of patients who received RetinoStat in a previous study.
10015217|NCT01678937||Control Group|"Ten Healthy individuals will have blood drawn (4 green top tubes(40 ml = 8 tsp.)) at one time point at Northwestern for control purposes. Blood will be drawn to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
10015218|NCT01678937||Monotherapy Group|"Monotherapy patients [cyclosporine (CyA) (10 patients), Tacrolimus (5 patients), mycophenolate mofetil (MMF) (10 patients), rapamycin (10 patients)]: Blood will be drawn at one time point (4 green top tubes (40 ml = 8 tsp.)) to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
10015219|NCT01678937||Conversion Group|Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
10015220|NCT01678963|Experimental|Squalamine|Squalamine eye drop 0.2%
10015221|NCT01678963|Placebo Comparator|Vehicle Control|Eye drop vehicle control
10015222|NCT01678989||Patient group|Children with BD, (20 children) 12-18 year-old who agreed to participate in the study will be established.
10015223|NCT01678989||Risk group|Twenty healthy children of 12-18 years old who have mothers and/or fathers who previously assessed by an adult psychiatrist and diagnosed as BD according to DSM-IV diagnostic criteria, and who agreed to participate in the study. The age and gender of the groups will be matched.
10015224|NCT01678989||Healthy control group|Twenty participants between the ages of 12-18 who agree to participate in the study and whose family members do not have BD. The age and the gender of the groups will be matched.
10015225|NCT01679015||Dry Eyes, Eye Allergies|Patients with ocular allergies and those with dry eyes.
10015226|NCT01679041|Experimental|Single Arm|Conditioning regimens with Alemtuzumab, Fludarabine, and Cyclophosphamide will be used for all patients.
10015227|NCT01679054||EOX|Epirubicin + Oxaliplatin + Capecitabine (EOX) Epirubicin 50 mg/m2 iv bolus d1 q3w x 8 cycles Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles Capecitabine (Xeloda) 625 mg/m2 po bid x 6 months
10015228|NCT01679054||FOLFOX4|FOLFOX4 Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
10015229|NCT01679067||HIV-GALT|
10015230|NCT01679080|Experimental|Zolendronic acid, 3 yr + placebo teriparatide, 2 yr|yearly intravenous infusion of 5mg active zoledronic acid in 3 yr
9665231|NCT05129124|Active Comparator|C02: +6.00-2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
9665232|NCT05129124|Active Comparator|C03: -3.00-2.75 x180|Commercially available Ultra for Astigmatism Contact Lenses
10015231|NCT01679080|Experimental|teriparatide 2 yr; active zol in 3rd yr|daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.
10015232|NCT01679080|Placebo Comparator|No active treatment|Observation in three years, no treatment
10015233|NCT01679093|Active Comparator|ONDANSETRON (OS)|patients receiving ondansetron at the beginning of the surgery to prevent postoperative nausea and vomiting (PONV); and paracetamol at the end of the surgery for postoperative analgesia.
10015234|NCT01679093|Active Comparator|DROPERIDOL (DRO)|patients receiving droperidol at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
10015235|NCT01679093|Active Comparator|DEXAMETHASONE (DEXA)|patients receiving dexamethasone at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
10015236|NCT01679106|Placebo Comparator|Fentanyl IV PCA and placebo TAP catheter|Patients will receive Fentanyl IV PCA and placebo TAP catheter.
10015237|NCT01679106|Active Comparator|TAP catheter with continuous infusion of Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.
10015238|NCT01679119|Experimental|IO-R-CVP|Inotuzumab Ozogamicin plus Rituximab and CVP (Cyclophosphamide, vincristine & prednisolone).
10015239|NCT01679119|Active Comparator|Gem-R-CVP|Gemcitabine plus Rituximab and CVP (Cyclophosphamide, Vincristine and Prednisolone).
10015240|NCT01679145||Alcohol- dependent patients|Detoxified alcohol- dependent patients in an inpatient setting
10015241|NCT01679145||Control group|Age- and gender matched healthy controls
10015242|NCT01679158|Experimental|Continuous Horizontal row|Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum
9665233|NCT05129124|Active Comparator|C04: -3.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
10015243|NCT01679158|Experimental|"Reduction in ring opening"|"Use the IOP system from USGI to install suture anchors to reduce the ring opening to the antrum"
10015244|NCT01679158|Experimental|Control Arm|Use the IOP system from USGI to install suture anchors in the Current V shape in distal body
10015245|NCT01679210|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
10015246|NCT01679210|No Intervention|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
10015247|NCT01679223||<40 years|subjects aged less than 40 years
10015248|NCT01679223||40-60 years|subjects aged 40-60years
10015249|NCT01679223||> 60 years|subjects aged greater than 60 years
10015250|NCT01679249||Hemodialysis patients|Stable prevalent patients on 3-times-per-week hemodialysis
10015251|NCT01679262|Other|Optimal size of OPAs|
10015252|NCT01679275|Other|measuring cerebral oxygenation|NIRS: Measurement of cerebral oxygenation using Near Infrared Spectroscopy (NIRS) during the pre-operative phase in neonates with congenital heart disease.
10015253|NCT01679288|Experimental|ultrasound arm|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
10015254|NCT01679327|Experimental|Bevacizumab plus chemotherapy（XELOX or FOLFOX）|Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days)
10015255|NCT01679340|Experimental|S-1+oxaliplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
10015256|NCT01679340|Active Comparator|S-1+cisplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
10015257|NCT01679353|Placebo Comparator|placebo group|normal saline 0.5ml
10015258|NCT01679353|Experimental|magnesum group|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
10015259|NCT01679366|No Intervention|Penicillin G|hospitalization of 30 patients given penicilline intraveniously for 72 hours
10015260|NCT01679366|Placebo Comparator|Placebo|30 hospitalized patients will be given placebo with a regular penicillin treatment
10015261|NCT01679366|Experimental|Probiotic|Probiotics will be given to 30 hospitalized patients with regular penicillin treatment
10015262|NCT01679379|Active Comparator|Absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture].
10015263|NCT01679379|Active Comparator|Non absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polypropylene non absorbable monofilament suture].
10015264|NCT01679392|Experimental|Ropivacaine|Unilateral transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
10015265|NCT01679418|Active Comparator|Drain placement (Group A)|Patients in group A received a wound drain after surgery.
10015266|NCT01679418|Sham Comparator|No-drain placement (group B)|Patients assigned to group B, did not receive a wound drain after surgery.
10015267|NCT01679431||Patients with aortic stenosis|"Patients have every year: 1) an assessment of cardiometabolic risk profile with measure of body mass index, waist circumference and fasting blood sample and 2) a comprehensive Doppler-echocardiography exam.~Computed tomography and magnetic resonance imaging are performed every 2 years."
10015268|NCT01679457|Experimental|ACT-Focused ERP|One Session.
10015269|NCT01679457|Active Comparator|TAU-ERP|One Session.
10015270|NCT01679483|Experimental|FloSeal group|This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
10015271|NCT01679483|No Intervention|No FloSeal group|All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.
10015272|NCT01679496|Experimental|Food items|Food items low in saturated fat and high in polyunsaturated fat
10015273|NCT01679496|Placebo Comparator|Control food items|Food items containing saturated fat and polyunsaturated fat according to a traditional Norwegian diet
10015274|NCT01679509|Experimental|Single-port surgery group|Single-port laparoscopic adnexal surgery
10015275|NCT01679509|Active Comparator|Three-port surgery group|Three-port laparoscopic adnexal surgery
10015276|NCT01679522|Experimental|Single-port surgery group|Single-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
10015277|NCT01679522|Active Comparator|Four-port surgery group|Four-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
10015278|NCT01679535|Experimental|Intervention|nutrition and hygiene education by community health workers
10015279|NCT01679548|Experimental|Single-port LAVH group|single-port laparoscopic assisted vaginal hysterectomy
10015280|NCT01679548|Active Comparator|Three-port LAVH group|three-port laparoscopic assisted vaginal hysterectomy
10015281|NCT01679561|Experimental|intralipids|Two hundreds patients (group1) with abnormal NK activity results (NKa)will receive intralipids 20% i.v. (9 mg/mL total blood volume -corresponds to 2 mL of intralipids 20% diluted in 250 mL saline; or 18 mg/mL - corresponds to 4 mL of intralipids 20% diluted in 250 mL saline) infusions and their NKa will be tested periodically. The determination of NK cell function will be performed by flow cytometry using K562 cells as targets,then follow up of the patients by the Doppler of endometrial blood follow at the time of luteal phase,and the clinical pregnancy rate.Group(2)of 180 patients will receive placebo.
10015282|NCT01679574|Experimental|letrozole|Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
10015283|NCT01679574|Active Comparator|Metformin and clomiphene|".Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months~Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation"
10015284|NCT01679587|Experimental|Molidustat, 80 mg|Subjects received a single oral dose of 80 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
10015285|NCT01679587|Experimental|Molidustat, 120 mg|Subjects received a single oral dose of 120 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
10015286|NCT01679587|Experimental|Molidustat, 40 mg|Subjects received a single oral dose of 40 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
10015287|NCT01679587|Experimental|Molidustat, 160 mg|Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
10015288|NCT01679639|Experimental|Aleglitazar|
10015289|NCT01679652|Experimental|Nebivolol|Tablet Nebivolol 5 mg (oral use) for 5 days
10015290|NCT01679652|Placebo Comparator|Placebo|Inactive placebo given as tablet for 5 days
10015291|NCT01679665|Experimental|320U /0.5ml in children (from 2 to 5 years old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28
10015292|NCT01679665|Placebo Comparator|0/0.5ml placebo in children (from 2 to 5 years old)|0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28
10015293|NCT01679678|Experimental|PolyHeal 2|Negatively charged 5-micron polystyrene microspheres in Water For Injection
10015294|NCT01679678|Active Comparator|PolyHeal|Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)
10015295|NCT01679691|No Intervention|Control group|Control group in whom no epidural anesthesia will be applied
10015296|NCT01679691|Active Comparator|Epidural Anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
10015297|NCT01679704|Other|Food products|Ten food products will be given to all subjects
10015298|NCT01679717|Active Comparator|Early mobilisation after CMC1-surgery|Mobilisation at two weeks after operation. The participants will wear a soft splint for six weeks.
10015299|NCT01679717|Other|Conservative treatment after CMC1-surgery|Current standard procedure: Mobilisation at six weeks after operation. The participants will wear a rigid splint for six weeks.
10015300|NCT01679730||irritable bowel syndrome patients|
10015301|NCT01679743|Experimental|A|Breast Cancer Cohort
10015302|NCT01679743|Experimental|B|Non-Small Cell Lung Cancer Cohort
10015303|NCT01679756|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy for cancer. .For the IA group, colon, transverse mesocolon, ileum and terminal ileum mesentery will be resected intracorporeally through a 45 mm endoscopic linear stapler with vascular cartridge. Then, the linear stapler will inserted through two small enterotomies and a mechanical ileo-transverse, side-to-side isoperistaltic intracorporeal anastomosis performed using the vascular cartridge with six rows of closely placed staples. The enterotomies will be then closed using a double layered continuous intra corporeal manual suture with 3-0 Polyglactin 910. The mesenteric defects will be left open. The specimen will be placed in a protective plastic bag and then extracted through a Pfannestiel incision.
10015304|NCT01679756|Active Comparator|Extracorporeal anastomosis|"Laparoscopic right hemicolectomy for cancer. In the EA group, the bowel will be externalized by widening the incision of one of the trocars or by performing a mini-laparotomy at another location (subcostal, suprapubic) protected with a plastic sheet. The ileum and colon will be then resected through a 45 mm endoscopic linear stapler with vascular cartridge (staple height = 3.85 mm) and a side-to-side isoperistaltic mechanical anastomosis will be then performed using the same vascular cartridge. The enterotomies will be then closed using a double layered continuous manual suture using a 3-0 Polyglactin 910.~In both groups, a drain will not routinely inserted."
10015305|NCT01679782||COPD nocturnal desaturator|COPD patients who spend 30% of the nigth with a SaO2 < 90%.
10015306|NCT01679782||COPD no nocturnal desaturator|COPD patients who spend less than 30% of the night with a SaO2 < 90%
10015307|NCT01679782||control group|healthy sedentary subjects
10015308|NCT01679795|Experimental|Tibolone|patientes will use tibolone 2,5mg/day during 30 days
10015309|NCT01679795|Placebo Comparator|Placebo use|Patients will use placebo for 30 days
10015310|NCT01679821||Dental students|Seventy dental students of State University of West of Paraná - UNIOESTE. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. A questionnaire and a clinical examination were employed.
10015311|NCT01679821||Removable partial denture|Seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous). Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary were not included in the research. A questionnaire and a clinical examination were employed.
10015312|NCT01679821||Double complete denture|Seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Patients wearing just one complete denture were not included in the research. A questionnaire and a clinical examination were employed.
10015313|NCT01679834||Cohort|
10015314|NCT01679860|Experimental|Clin A|Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years
10015315|NCT01679860|Experimental|Clin B|Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged > 60 ≤ 75 years
10015316|NCT01679873|Placebo Comparator|Control group|Assess abstract not reporting funding sources or conflicts of interest
10015317|NCT01679873|Experimental|Funding sources|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources only.
10015318|NCT01679873|Experimental|Funding sources/Conflicts of Interests|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources and conflicts of interest
10015319|NCT01679886|Experimental|Rubidium PET|Rubidium PET
10015320|NCT01679899|Experimental|Vildagliptin|Vildagliptin 50 mg bid for 12 months
10015321|NCT01679899|Active Comparator|Gliclazide MR|Gliclazide MR 60 or 120mg once a day for 12 months
10035973|NCT01811407|Other|Private/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Participants will be required to set a forward-looking commitment each week as to how many days during the following week they will meet their step count target. Commitment and results will be private.
10035974|NCT01811407|Experimental|Public/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments are made as in the Private/Private condition. In addition, one Facebook announcement will be posted at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week. An email will also be sent directly to 3 friends the participant chose with the same announcements.
10035975|NCT01811407|Experimental|Public/public|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments will be made as in the Private/Private condition. In addition, one message will be posted to Facebook at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week, and how they did on their previous weekly commitment. An email will also be sent directly to 3 friends the participant chose with the same announcements.
10035976|NCT01811420|Experimental|CHEMOMECHANICAL CARIES REMOVAL|Dental caries removal using papain based gel
10035977|NCT01811420|Active Comparator|conventional method|Dental caries removal using rotatory instrument
10035978|NCT01811446|Experimental|Obese|Subjects with BMI > 30
10035979|NCT01811446|Experimental|COPD|Non-hospitalized COPD patients
10035980|NCT01811459|Experimental|Quetiapine|Drug: Quetiapine 50-250 mg PO BID (5 levels of treatment) + IV Placebo Rescue IV haloperidol available.
10015322|NCT01679912|Experimental|1: phone to call center|recommendations to phone to the call center for all the patients who have an acute attack
10015323|NCT01679912|No Intervention|2: usual strategy|usual strategy. No intervention (patients does not change their practice)
10015324|NCT01679938|Experimental|primary obesity prevention|"The intervention will involve four main components:~Training of child care providers.~Curriculum sessions for children.~Family outreach activities.~Maintenance activities."
10015325|NCT01679938|No Intervention|Control group|For the control group, usual care will be provided
10015326|NCT01679964|Other|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
10015327|NCT01679977|Active Comparator|Legpress|"Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called swinging vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training."
10015328|NCT01679977|Active Comparator|E-Stim|ES training is performed with a custom-built battery-powered stimulator. The subject are seated over the edge of the therapeutic table with the trunk upright and lower legs freely swinging. Two conductive rubber electrodes covered by wet sponge are placed on the anterior thigh on each side of the body. The electrode pairs are connected to the independent channels of the stimulator and the left and the right thigh are stimulated in an alternative manner. Each repetition (i.e. ES evoked muscle contraction) is evoked by a 3.5 s train (60 Hz) of electrical pulses (rectangular, biphasic, width 0.6 ms). Consecutive contractions of the same thigh are separated by 4.5 s off intervals. Maximal tolerable intensity should be used and is monitored during the training sessions. In all the subjects this should induce a tetanic contraction of the stimulated muscles.
10015329|NCT01679977|No Intervention|Control|This group only perform the same measurements as the intervention groups and lives their live as usual in between.
10015330|NCT01679990|Experimental|PLX-PAD Low dose|PLX-PAD double low doses
10015331|NCT01679990|Active Comparator|PLX-PAD high doses|PLX-PAD double high dose
10015332|NCT01679990|Placebo Comparator|Placebo|Double Placebo doses
10015333|NCT01679990|Experimental|PLX-PAD high dose +Placebo|High dose+Placebo
10015334|NCT01680003|Experimental|Hepar-P|Hepar-P: Two capsules (250mg x 2), three times daily, orally
10015335|NCT01680003|Placebo Comparator|Placebo for Hepar-P|Placebo: Two capsules, three times daily, orally
10015336|NCT01680029|Experimental|PBASE-system 2.0|
10015337|NCT01680042|Active Comparator|phenytoin paste|this group receives phenytoin paste after oral biopsy
10015338|NCT01680042|Placebo Comparator|usual mucoadhesive paste|this group receives the usual mucoadhesive paste without phenytoin after oral biopsy
10015339|NCT01680055||AA-ATG|Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine
10015340|NCT01680068|Experimental|Pars plana vitrectomy and postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
10015341|NCT01680081|Experimental|CT perfusion group|
10015342|NCT01680094|Experimental|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
10015343|NCT01680107|Experimental|d-cycloserine|oral, capsule, 250 mg, once
10015344|NCT01680107|Placebo Comparator|sugar pill|oral, capsule, once
10015345|NCT01680120|Experimental|Continuous spinal anaesthesia|
10015346|NCT01680133||NGT|Normal glycaemic healthy control men, age between 45-65, BMI 25-35 kg/m2
10015347|NCT01680133||T2D|Type 2 diabetic men, age 45-65 yrs, BMI 25-35, diagnosed >5yrs and Hba1c 7-9%
10015348|NCT01680146|Active Comparator|PRO|Subjects will ingest 20 g of intrinsically labeled casein dissolved in water
10015349|NCT01680146|Experimental|PRO+FAT|Subjects will ingest 20 g of intrinsically labeled casein plus 26.7 g of anhydrous milk fat dissolved in water
10015350|NCT01680185|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
10015351|NCT01680185|Active Comparator|Basal insulin|NPH insulin titration regimen, as specified in the IPT-NODAT study
10015352|NCT01680185|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
10015353|NCT01680198|Placebo Comparator|Placebo|Placebo capsules daily for 12 weeks.
10015354|NCT01680198|Experimental|Paracalcitol|"see Intervention description for details."
10015355|NCT01680211|Experimental|Salacia bark extract (SR-B-01) and TLC|Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)
10015356|NCT01680211|Experimental|Sesame seeds extract (SI-S-01) and TLC|Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)
10015357|NCT01680211|Experimental|Salacia leaf extract (SR-L-01) and TLC|Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)
10015358|NCT01680211|Placebo Comparator|Placebo and TLC|Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)
10035981|NCT01811459|Experimental|Haloperidol|Drug: Haloperidol 1-5 mg BID (5 levels of treatment) + PO placebo Rescue IV haloperidol available.
10035982|NCT01811459|Placebo Comparator|Placebo|IV placebo + PO placebo Rescue IV haloperidol available.
10035983|NCT01811498|Experimental|SIACI of Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
10035984|NCT01811511|Experimental|Chungkookjang|Chungkookjang(35g/day)
10035985|NCT01811511|Placebo Comparator|Placebo|Placebo(35g/day)
10035986|NCT01811524||Glioma and meningioma patientsl|Glioma and meningioma patients of Tampere University Hospital during the study period
10015359|NCT01680224|Active Comparator|Healthy Weight|The main goal of the Healthy Weight intervention is to make small, sustainable changes to input and output on a weekly basis to achieve a balance between caloric intake and output. All sessions begin with a brief review of what was covered in the previous session, presentation of educational handouts, careful review of previous behavior change goals, and the development of healthy behavior change plans for the next session. Home exercises for all sessions consist of following individualized diet and exercise goals, and keeping a food and exercise log to determine areas for future healthy changes.
10015360|NCT01680224|Experimental|Project Health|Project Health adds dissonance-inducing activities, discussions, and homework activities to the Healthy Weight basic intervention. Each session begins with a verbal commitment to participate (to underscore the voluntary nature of participation), includes discussions of completed home practice assignments and in-session writing/sharing exercises (to create accountability), and concludes with home exercises (to increase level of effort). Completed home assignments are videotaped in subsequent sessions to increase accountability.
10015361|NCT01680224|Placebo Comparator|Control|"Some participants will be randomized to control condition whereby they will be given an psychoeducational video (Weight of the World)to view."
10015362|NCT01680237|Active Comparator|Cognitive behavior therapy|"Identification of bodily sensations, cognitions and safety behaviors characteristic of the individual patient~Modification of dysfunctional beliefs and assumptions using socratic questioning and behavioral experiments~Exposure in-vivo~Relapse prevention"
10015363|NCT01680237|Active Comparator|Exposure in-vivo|"Preparation of a brief behavior analysis of the individual case and construction of a hierarchy of relevant (internal and external) phobic situations~Exposure with internal stimuli~Exposure with external stimuli~Relapse prevention~Remark: In this condition there is no active work with the patient's catastrophic cognitions"
10015364|NCT01680250|Experimental|Sirolimus|Sirolimus administration group starting dose: 2mg/day target trough level: 4-10 ng/dL
10015365|NCT01680263|Experimental|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1 week interval"
10015366|NCT01680263|Active Comparator|NSAIDs/Physical therapy|treatment was done with NSAIDs and 10 sessions of daily physical therapy.
10015367|NCT01680276|Experimental|PBS based staff training|"The training, which will be supported by a treatment manual will comprise the following sections:~Functional Behavioural Assessment and formulation skills~• Brief Behavioural Assessment Tool for brief functional analyses~Primary Prevention~Secondary Prevention and Reactive Strategies~Periodic Service Review and Problem Solving~Developing individualised periodic service reviews~Trouble shooting"
10015368|NCT01680276|Other|Treatment as usual|Most community intellectual disability services provide a range of health interventions that include but are not limited to psychiatric assessment and management, nursing support, psychology, speech and language therapy, occupational therapy and counselling. There may be some variation in resources but service users with challenging behaviour are likely to receive a range of broadly defined behavioural management and pharmacological interventions. Staff is routinely supervised by their clinical managers weekly.
10015369|NCT01680289|Experimental|Three adhesive coats|Consecutive application of three one-bottle adhesive coats
10015370|NCT01680289|Active Comparator|Two adhesive coats|Consecutive application of two one-bottle adhesive coats
10015371|NCT01680302|Experimental|High intensity exercise|High intensity exercise(Borg 16) in intervals.
10015372|NCT01680302|Experimental|Moderate intensity exercise|Moderate intensity exercise 3 times a week.
10015373|NCT01680302|Experimental|Control group|Exercise on their own. Follow current guidelines.
10015374|NCT01680315|Experimental|Calorie information|"Low calorie yogurt~High calorie yogurt~with low calorie information sheet"
10015375|NCT01680315|Experimental|Calorie information (high)|"Low calorie yogurt~High calorie yogurt~High calorie information sheet"
10015376|NCT01680354|Active Comparator|ReLEx|One eye is treated with ReLEx the other with LASIK
10015377|NCT01680354|Active Comparator|LASIK|One eye is treated with ReLEx the other with LASIK
10015378|NCT01680367|Experimental|Arm I (control)|Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery.
10015379|NCT01680367|Experimental|Arm II (native collagen wound dressing)|Patients receive native collagen wound dressing after surgery.
10015380|NCT01680380||At-Home|Overnight sleep at home
10015381|NCT01680393|Experimental|Sequential compression device|During arthroscopic shoulder surgery, an SCD device will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
10015382|NCT01680393|Experimental|TED stockings|During arthroscopic shoulder surgery, TED stockings will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
10015383|NCT01680393|No Intervention|Control|no stockings will be applied to the patients legs
10015384|NCT01680406|Active Comparator|Artemether-lumefantrine|Weight-based dose to be administered as fixed-dose combination twice daily for three days.
10015385|NCT01680406|Experimental|Artemether-lumefantrine and primaquine|"Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
10015386|NCT01680406|Active Comparator|Chloroquine|Chloroquine will be given in a weight-based dose to be administered once daily for three days.
10015387|NCT01680406|Experimental|Chloroquine and primaquine|"Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
10015388|NCT01680419|Experimental|Mission Reconnect only|Autonomous use of the Mission Reconnect multimedia instructional program at home.
10015389|NCT01680419|Active Comparator|PREP only|Participation in a standard PREP for Strong Bonds weekend retreat program.
10015390|NCT01680419|Active Comparator|PREP plus Mission Reconnect|Participation in a standard PREP for Strong Bonds weekend retreat followed by autonomous use of the Mission Reconnect multimedia instructional program at home.
10015391|NCT01680419|No Intervention|Wait-list control|No intervention, followed by delivery of the Mission Reconnect multimedia program materials for home use after the end of the study period.
10015392|NCT01680432|Experimental|Probiotic cheese|The group received, for 30 days, was instructed to eat 30 g/day of probiotic fresh cheese enriched with Bifidobacterium lactis Bi-07.
10015393|NCT01680432|Placebo Comparator|Regular Cheese|The group placebo received, for 30 days, was instructed to consume 30g/day of regular fresh cheese.
10015394|NCT01680471|Experimental|Midazolam 0.03mg/kg|This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
10015395|NCT01680471|Experimental|Midazolam 0.05mg/kg|This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
10015396|NCT01680471|Placebo Comparator|Placebo|This group will be injected intravenous normal saline five minutes before the end of surgery.
10015397|NCT01680484|Active Comparator|Bitter chocolate|50 grams Ülker Golden %70 bitter chocolate, İstanbul, Turkey
10015398|NCT01680484|Active Comparator|Orange juice|Ülker İçim Orange Juice 250 cc, İstanbul, Turkey
10015399|NCT01680484|No Intervention|Control|Sit and rest
10015400|NCT01680510|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|50 patients will receive first the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder and after 24 weeks of washout period will receive capsule containing placebo (Starch).
10015401|NCT01680510|Placebo Comparator|Placebo (Starch)|The other 50 Patients will receive first the placebo (Starch) capsules and after 24 weeks of washout period will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
10015402|NCT01680523|Experimental|RH group|Radical hysterectomy followed by tailored adjuvant therapy
10015403|NCT01680523|Active Comparator|CCRT group|Primary concurrent chemoradiation therapy
10015404|NCT01680536|Experimental|Maraviroc, darunavir, ritonavir|Single-arm,assessing cerebrospinal fluid inflammatory markers after addition of maraviroc to patients stable on monotherapy darunavir/ritonavir
10015405|NCT01680562||skin cancer|Skin cancer patients with scheduled tumor excision and subsequent histopathological analysis of the tumor.
10015406|NCT01680575||Training cohort|This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.
10015407|NCT01680575||Validation cohort|"This is a retrospective cohort for validation of a risk prediction model developed using training cohort.~This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation."
10015408|NCT01680588|Experimental|[18F]NAV4694|Single intravenous injection of 8.1 millicuries of [18F]NAV4694
10015409|NCT01680601|Experimental|RIPC group|Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
10015410|NCT01680601|Placebo Comparator|Control|Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
10015411|NCT01680614||At Risk Adult Drinkers|CASI
10015412|NCT01680627||ADOLESCENT|
10015413|NCT01680679|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated trivalent influenza vaccine (TIV), split virion
10015414|NCT01680679|Placebo Comparator|Inactivated Polio Vaccine|Inactivated poliovirus vaccine (IPV), trivalent
10015415|NCT01680679|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
10015416|NCT01680692|Active Comparator|Continuous femoral and single shot sciatic nerve block|Will receive pre-operative continuous femoral catheter & post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine & 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr.
10015417|NCT01680692|Experimental|Continuous femoral and tibial peripheral nerve catheters|Patients will receive pre-operative continuous femoral catheter & post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) & 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at 10cc/hr.
10015418|NCT01680705|Active Comparator|Frequency: Once Daily|Patients will use high volume saline irrigation once daily post operatively.
10015419|NCT01680705|Active Comparator|Frequency: Twice Daily|Patients will use high volume saline irrigation twice daily post operatively.
10015420|NCT01680705|Active Comparator|Frequency: Three Times Daily|Patients will use high volume saline irrigation three times daily post operatively.
10015421|NCT01680718|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
10015422|NCT01680718|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
10015423|NCT01680718|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.
10015424|NCT01680731||Forceps assisted vaginal delivery|Forceps assisted vaginal delivery within 1-5 years without any interval delivery
10015425|NCT01680731||Vacuum assisted vaginal delivery|Vacuum assisted vaginal delivery within 1-5 years without any interval delivery
10015426|NCT01680731||Elective cesarean delivery|Elective cesarean vaginal delivery within 1-5 years without any interval delivery done prior to labor
10015427|NCT01680731||Spontaneous vaginal delivery|Spontaneous vaginal delivery within 1-5 years without any interval delivery
10015428|NCT01680744|Experimental|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
10015429|NCT01680744|No Intervention|Standard Treatment|
10015430|NCT01680757|Experimental|LAA exclusion with LARIAT & Accessories|Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories
10015431|NCT01680770||Hypotensive patients in shock|
10015432|NCT01680796|Experimental|Active Treatment|"Dovitinib will be given at up to four different dose levels beginning with dose level 1 on a 5 days on/2 days off dosing schedule of each 21-day cycle.~Bortezomib will be given at two different dose levels intravenously on Days 1 and 8 of each 21-day cycle.~Dexamethasone will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle."
10015433|NCT01680809|Experimental|Compression stocking 15-20mmHg|Compression stocking 15-20mmHg
10015434|NCT01680809|Experimental|Compression stocking 20-30mmHg|Compression stocking 20-30mmHg
10015435|NCT01680822||NTM patient|confirmed NTM patient
10015436|NCT01680874|Experimental|Probiotic|"This arm will receive a probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219).~The probiotic will be taken orally, once a week, for 4 weeks."
10015437|NCT01680874|Placebo Comparator|Placebo|A placebo will be taken orally, once a day, for 4 weeks.
10015438|NCT01680913|Experimental|Spinal with ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
10015439|NCT01680913|Active Comparator|Spinal by palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
10015440|NCT01680926|Experimental|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
10015441|NCT01680939|Experimental|Morphine|Receives morphine for post-surgical pain
10015442|NCT01680939|Experimental|Ibuprofen|Receives ibuprofen for post-surgical pain
10015443|NCT01680952|Active Comparator|A) TEST|
10015444|NCT01680952|Experimental|B) CONTROL|
10015445|NCT01680978|Experimental|Aleglitazar|
10015446|NCT01680978|Placebo Comparator|Placebo|
10015447|NCT01681017|Other|Facilities|Have appropriate staff trained in HBB and have HBB equipment provided
10015448|NCT01681017|Other|Master Trainers|Receive appropriate HBB training
10015449|NCT01681017|Other|Facilitators|Receive appropriate HBB training
10015450|NCT01681017|Other|Learners|Receive appropriate HBB training
10015451|NCT01681043|No Intervention|24 hour PSG under ordinary conditions|24 hour PSG in 46 patients under ordinary (routine) conditions
10015452|NCT01681043|Active Comparator|24 hours PSG under protocol 'Quiet in the room'|24 hour PSG in the same 46 patients with protocol 'Quiet in the room' from 10 p.m. til 6 a.m.
10015453|NCT01681056|Experimental|Autosuggestion|
10015454|NCT01681056|No Intervention|Standard medical theraphy|
10015455|NCT01681082|Experimental|Tai Chi Training|"Subjects will be recruited from the University of Wisconsin-Madison course, Introduction to Martial Arts: Tai Chi."
10015456|NCT01681082|No Intervention|Control|"Subjects will be recruited from the University of Wisconsin-Madison course Introduction to Psychology."
10015457|NCT01681108|Other|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
10015458|NCT01681134|Experimental|Advagraf followed by Prograf|
10015459|NCT01681134|Experimental|Prograf followed by Advagraf|
10015460|NCT01681147|No Intervention|Group One|Standard postpartum care after a pregnancy with gestational diabetes
10015461|NCT01681147|Experimental|Group Two|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes"
10015462|NCT01681147|Experimental|Group Three|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes~Self monitoring of blood glucose levels"
10015463|NCT01681160|Experimental|MAGGOT THERAPY & conventional therapy T|Maggot therapy,ADMINISTERED TWO TIMES AS A NEW METHODS OF DRESSING in experimental group.conventional therapy ,administered two times in control group
10015464|NCT01681173|Experimental|Drink enriched in fibers|7,5g enriched fiber drinks, BID
9476816|NCT03568045|Experimental|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
9476817|NCT03568045|Experimental|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
9476818|NCT03568032||the post-radiation group|patients diagnosed as non-metastatic nasopharyngeal carcinoma who received definitive IMRT more than 3 years ago
9476819|NCT03568032||the pre-radiation group|untreated patients diagnosed as non-metastatic nasopharyngeal carcinoma
9476820|NCT03568006|Experimental|Intervention|"Intervention will consist of passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint.~Besides, participants will receive a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene."
10015465|NCT01681173|Experimental|Placebo drink|Placebo drink, BID
10015466|NCT01681199|Experimental|Fluvastatin extended release tablet|Fluvastatin extended release tablet 80mg/day
10015467|NCT01681225|Experimental|EPVent|"The overall goals for the EPVent group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration [Ptpexp]. Fraction of inspired oxygen [FiO2] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target."
10015468|NCT01681225|Active Comparator|Control|The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure [PEEP] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements, and instead will follow an empiric high PEEP mechanical ventilation strategy. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level specified in a study table.
10015469|NCT01681238|Other|Protocol group 1|Using standard hemodynamic therapy
10015470|NCT01681238|Experimental|Protocol group 2|Using goal-directed therapy
10015471|NCT01681251|Experimental|Intervention|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
10015472|NCT01681251|Active Comparator|Control|Fluid titrated at the discretion of the attending anesthesiologist.
10015473|NCT01681290|Experimental|CBX129801 High Dose|Solution for injection, 2.4 mg, weekly for 52 weeks
10015474|NCT01681290|Experimental|CBX129801 Low Dose|Solution for injection, 0.8 mg, weekly for 52 weeks
10015475|NCT01681290|Placebo Comparator|Placebo|Solution for injection, vehicle with no active, weekly for 52 weeks
10015476|NCT01681303|Experimental|AST-120 group|Administration of AST-120
10015477|NCT01681303|No Intervention|2|
10015478|NCT01681316|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
10015479|NCT01681316|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
10015480|NCT01681329|Experimental|Cognitive-behavioral therapy with interpretation training|14 sessions of cognitive-behavioral therapy combined with computerized interpretation modification training
10015481|NCT01681329|Active Comparator|Cognitive-behavioral therapy with non-active training|14 sessions of cognitive-behavioral therapy combined with computerized non-active training
10015482|NCT01681355|Experimental|Intervention group|Healthy infants receiving standard cow's milk-based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition.
10015483|NCT01681381|Active Comparator|Firebird2® DES|Device:Firebird2® DES The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length.
10015484|NCT01681381|Experimental|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length.
10015485|NCT01681394|Active Comparator|Product 1|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
10015486|NCT01681394|Placebo Comparator|Control product|250 g of chocolate cream
10015487|NCT01681407||Depressed Patients|Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
10015488|NCT01681407||Non-Depressed Controls|Controls: Volunteers that had clinical screening with no depression diagnosis.
10015489|NCT01681407||Patients Relatives|Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
10015490|NCT01681420|Experimental|Approved Intervention Counseling|Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.
10015491|NCT01681420|Experimental|Approved Intervention Donation|Approved blood donors randomized to intervention and choosing donation with no HIV counseling.
10015492|NCT01681420|Experimental|Deferred Intervention|Deferred blood donors randomized to intervention with HIV counseling.
10015493|NCT01681446|Active Comparator|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
10015494|NCT01681446|No Intervention|control|no anti-cancer interventions were assigned
10015495|NCT01681485||NSCL cancer patients|Surgery, chemotherapy and/or radiation therapy
10015496|NCT01681498||Pregnancy|
10015497|NCT01681524|Experimental|Flurpiridaz F18|Open-label study of a single injection of flurpiridaz F18 for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary cathertization
10015498|NCT01681537|Experimental|Treatment Arm|Lenalidomide and re-induction chemotherapy
10015499|NCT01681550|Other|Incretin theapy combined with insulin|
10015500|NCT01681563|Experimental|Pentostatin/Cyclophosphamide/Ofatumumab|Subjects will receive up to 6 cycles of pentostatin, cyclophosphamide, and ofatumumab given every 21 days (+/- 4 days).
10015501|NCT01681602|Active Comparator|Intervention group|16 weeks of aerobic exercise
10015502|NCT01681602|No Intervention|Control group|Usual care.
10015503|NCT01681615|Active Comparator|Acetylsalicylate|Acetylsalicylic Acid Eyedrops
10015504|NCT01681615|Placebo Comparator|isotonic NaCl|Saline Eyedrops
10015505|NCT01681641|Experimental|Lifestyle counseling|Patients and spouses in the intervention group are offered 3 targeted meetings with the DBS nurse, focusing on goal setting for each individual, following DBS, based on patients and spouses own expectations, challenges and goals for everyday life after DBS.
10015506|NCT01681641|No Intervention|Control group|Patients and spouses enrolled in a control group
10015507|NCT01681654|Experimental|Immediate Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
10015508|NCT01681654|Experimental|Immediate Lifestyle Intervention - No Maintenance Program|Patients will begin the 12-week lifestyle intervention during treatment. Patients will not receive a maintenance support following the 12-week intervention.
10015509|NCT01681654|Experimental|Delayed Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
10015510|NCT01681654|Experimental|Delayed Lifestyle Intervention - No Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment completion (12 weeks following diagnosis). Patients will not receive maintenance support following the 12-week program.
10015511|NCT01681667|Active Comparator|ibuprofen|liquid ibuprofen 400mg compared to tablet ibuprofen 400mg
10015512|NCT01681667|Placebo Comparator|sugar pill or liquid|
10035987|NCT01811537|Experimental|Experimental: premeasured Neochordae|Transthoracic echocardiography(TTE) is done for all patients. The new device will be setup using the TTE measurements.The artificial Chordae loops will be made at the operation room before starting the surgery. These loops will be attached to the respective papillary muscle's head and the free edge of respective prolapsed scallop.
10035988|NCT01811550||SHINE study subjects|Subjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.
10035989|NCT01811589|Experimental|Thomale-Guide|Positioning of ventricular catheter with the Thomale-Guide instrument
10035990|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
10035991|NCT01811602|Other|Training|Pelvic floor muscle training delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction
10035992|NCT01811602|Other|Usual Care Control|Participants randomized to this arm will receive a 1-page educational pamphlet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
10035993|NCT01811615|Active Comparator|toothbrushing plus rinsing|0.06% CHX + 0.025% NaF plus toothbrushing and alcohol-containing mouth rinsing
10035994|NCT01811615|Experimental|alcohol-free experimental mouth rinse|0.06% CHX + 0.025% NaF plus toothbrushing
10035995|NCT01811615|Experimental|toothbrushing and rinsing|0.06% CHX + 0.03% CPC + 0.025% NaF, alcohol-free, mouth rinsing
10015513|NCT01681680|Other|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
10015514|NCT01681693|Experimental|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
10015515|NCT01681719|Experimental|WBV and resistance|used both interventions
10015516|NCT01681719|Experimental|WBV & resistance sham|used the vibrating platform and sham for resistance training
10015517|NCT01681719|Experimental|Resistance & sham WBV|used resistance exercises and sham for vibrating platform
10015518|NCT01681732|Experimental|Personalized Care Plan|A personalized plan based on baseline clinic visit data
10015519|NCT01681732|Active Comparator|Control|This arm will be standard care
10015520|NCT01681758|Active Comparator|PPV|use PPV to guide fluid therapy
10015521|NCT01681758|Placebo Comparator|standard care|fluids according to standard care
10015522|NCT01681797|Experimental|add-on fluorescence angiography|"The surgeon will prescribe the usual morphological assessment of the proposed flap:~CT angiography for an anterolateral thigh flap or an epigastric inferior flap~A Doppler ultrasonography for a fibula flap.~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days."
10015523|NCT01681823|Experimental|PectaSol-C Modified Citrus Pectin (MCP)|Treatment with 4.8 grams PectaSol-C Modified Citrus Pectin three times a day, away from meals for six months.
10015524|NCT01681862|Experimental|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
10015525|NCT01681875|Experimental|0.8 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)"
10015526|NCT01681875|Experimental|0.26 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar"
10015527|NCT01681875|Experimental|0.12 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar"
10015528|NCT01681875|Experimental|0.07 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar"
10015529|NCT01681875|Experimental|0.03 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar"
10015530|NCT01681875|Experimental|0.04 mg nicotine with 13 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar"
10015531|NCT01681875|Other|Usual brand|"very low nicotine content cigarettes~Usual brand cigarettes (control condition)"
10015532|NCT01681888|Experimental|Surface EMG Biofeedback|
10015533|NCT01681901||Diagnostic (ultrasound)|Patients undergo breast ultrasound imaging.
10015534|NCT01681914||Anemia|Ambulatory, HIV-infected adult patients with hemoglobin <10 g/dL will be evaluated and managed in accordance with Mozambique's new anemia guideline for non-physician clinicians. The basic steps recommended by the guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral blood smear) and treat if indicated; evaluate for adverse drug reactions and manage per Mozambican national guidelines; consider nutritional deficiencies and intestinal parasites; evaluate response to therapy at <=1 month.
10015535|NCT01681914||Fever or History of Fever|Ambulatory, HIV-infected adult patients with measured axillary temperature >=37.5 C or history of fever within the past 24 hours will be evaluated and managed in accordance with Mozambique's new fever guideline for non-physician clinicians. The basic steps of the fever guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral smear) and treat if indicated; treat any other cause of fever identified through history and physical examination; re-evaluate at next scheduled clinical visit (sooner if worse or if not improving within 48 hours of initiating treatment). Although blood cultures are seldom performed in Mozambican health centers, venipuncture specimens will also be cultured for bacterial pathogens at the first study visit.
10015536|NCT01681914||Anemia and Fever/History of Fever|Patients who meet eligibility criteria for both the anemia and fever arms will be evaluated and managed using both the new Mozambican anemia guideline and the new Mozambican fever guideline, as above.
10015537|NCT01681927||1.4kg wt gain 8AM -10 PM|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
10015538|NCT01681927||>1.4kg wt gain 8AM - 10PM no nocturia.|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
9665234|NCT05129124|Active Comparator|C05: -9.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
10015539|NCT01681927||> 1.4 kg wt gain 8AM -10PM with nocturia|Complete a questionnaire. Measure and record weight in AM and PM. Record the number of times and collect all urine passed overnight in separate containers for one week.Collection of blood and interstitial fluid samples, fluorescein dye angiography, and bioimpedance study.
10015540|NCT01681940|Experimental|Lamazym|1 mg/kg body weight
10015541|NCT01681953|Active Comparator|Lamazym|1 mg Lamazym/kg body weight
10015542|NCT01681953|Placebo Comparator|Placebo|Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol
10015543|NCT01681966|Experimental|Application of PRF110- oily solution|Post operative application of new extended release PRF110- oily solution (Ropivacaine)
10015544|NCT01681979||Women with asthma during pregnancy|Women with asthma during pregnancy will be identified based on one of the following: 1) an asthma related medical code recorded anytime before the pregnancy start date and at least one prescription for an asthma medicine in the 6 months before the pregnancy start date or during pregnancy; 2) no asthma related medical code but at least 6 prescriptions for an asthma medicine in their record before the pregnancy start date, including one in the 6 months before the pregnancy start date or during pregnancy.
10015545|NCT01682005||Complete RV vaccination|Subjects had received 2 doses of Rotarix or 3 doses of Rotateq/mixed within the vaccination window and the observation time is from the end of the vaccination window (8 months old) to end of observation.
10015546|NCT01682005||Incomplete RV vaccination|Subjects received at least one vaccination but less than complete vaccination has been received within the vaccination window and the observation time from 8 months old (if still observed) to end of observation.
10015547|NCT01682005||Any RV vaccination before 8 months|Subjects received any vaccination within the vaccination window and the observation time from 6 weeks old to earliest of end of observation or 8 months old.
10035996|NCT01811615|No Intervention|toothbrushing alone|negative control
10015548|NCT01682005||Historical unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and the observation time is from 6 weeks old (if still observed and on/before 12/31/06) to earliest of: 12/31/2006, end of observation, or 8 months old.
10015549|NCT01682005||Historical unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 8 months old (if still observed and on/before 12/31/2006) to earliest of: 12/31/2006 or end of observation.
10015550|NCT01682005||Contemporary unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 6 weeks old (if on/after 01/01/2007) to earliest of: end of observation, or 8 months old.
10015551|NCT01682005||Contemporary unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window observation time is from 8 months old (if on/after 01/01/2007) to end of observation.
10015552|NCT01682018|Experimental|intervention group|Patients that underwent dingle lung transplantation due to emphysema and developed native lung overinflation as demonstrated by chest CT and decline in pulmonary lung function tests (FEV1 ) shall undergo valves placement to the native lung
10015553|NCT01682057|Experimental|Group A|ROX Anastomic Coupler System (ACS) + continuing standard antihypertensive medications
10015554|NCT01682070|Placebo Comparator|SUBLIVAC FIX Phleum prat. 0 AUN/ml|
10015555|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 3,333 AUN/ml|
10015556|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 10,000 AUN/ml|
10015557|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
10015558|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 40,000 AUN/ml|Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee
10015559|NCT01682096|Active Comparator|Computed coronary angiography (CTA)|Patients will undergo a MDCT as the initial diagnostic test to rule out Acute Coronary Syndrome
10015560|NCT01682096|Active Comparator|Exercise stress echocardiography|Patients will undergo exercise stress echocardiography as the initial diagnostic test to rule out acute coronary syndrome.
10015561|NCT01682109|Experimental|new paediatric valacyclovir formulation|Newly developed formulation
10015562|NCT01682109|Active Comparator|reference valacyclovir formulation|Formulation derived from FDA label information
10015563|NCT01682122||Newborns|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age. Infants with gestational age > or = 35weeks and birth weight > 2500g, who are hemodynamically stable, have no cardiorespiratory abnormalities and have no evidence of sepsis. If a blood culture was drawn due to the presence of maternal risk factors (e.g. maternal fever, prolonged rupture of membranes), patients will be included only if the blood culture result is negative and in case of intrapartum antibiotic treatment, ancillary blood tests (CBC with differential, CRP) are also within the normal range
10015564|NCT01682161|Experimental|Group 1 (Immediate switch)|Paliperidone palmitate will be administered immediately after randomization and will be continued throughout the treatment phase.
10015565|NCT01682161|Experimental|Group 2 (Delayed switch)|Current oral antipsychotics will be continued until Week 8, and later on paliperidone palmitate will be administered.
9802619|NCT05115695|Active Comparator|PNF/Interventional|Upper extremity and scapular patern of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
9802620|NCT05115695|Experimental|NDT/Experimental|Upper extremity strengthening exercises consisting of Neurodevelopmental Therapy (NGT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
10015566|NCT01682174|Placebo Comparator|Control Test Drink|control drink
10015567|NCT01682174|Experimental|Experimental Test Drink|Experimental Drink
10015568|NCT01682187|Experimental|LY2157299 (Part A)|Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day.
10015569|NCT01682187|Experimental|LY2157299 + Lomustine (Part B)|"LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily.~Lomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter."
10015570|NCT01682200|Experimental|ProOxy, Effects and Side Effects in treating acne|Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months.
9802621|NCT05115409|Experimental|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL|Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL
10015571|NCT01682226|Experimental|A: standard risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
10015572|NCT01682226|Experimental|B: high risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
10015573|NCT01682239|Experimental|RVAP lead|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV apex. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
10015574|NCT01682239|Experimental|RVSP arm|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV septum. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
10015575|NCT01682252||musculoskeletal tumors|all patients undergoing surgery for musculoskeletal tumors
10015576|NCT01682265|Experimental|Stretta procedure|"Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
10015577|NCT01682265|Sham Comparator|Sham procedure|"Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
10015578|NCT01682291|Active Comparator|Life-style modifications|"Lifestyle modifications will include:~Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)"
10015579|NCT01682291|Active Comparator|Dietary supplements|Life-style modifications along with a novel combination of dietary supplements that includes: Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
10015580|NCT01682304||History of Preeclampsia|Chronic hypertension with history of preeclampsia Chronic hypertension without history of preeclampsia
10015581|NCT01682330||Fitness|
10015582|NCT01682330||Whole-body vibration|
10015583|NCT01682330||Control|
10015584|NCT01682343|Placebo Comparator|Placebo|Breakfast consisting of milk-based porridge with a normal calcium content.
10015585|NCT01682343|Experimental|High-Calcium|As control, but with a high-calcium content.
10015586|NCT01682356|Placebo Comparator|BRJ crossover to placebo|Beetroot Juice without nitrate.s Patients will be studied before and after ingestion of beetroot juice
10015587|NCT01682356|Active Comparator|Beetroot Juice|Beetroot Juice with nitrates. Patients will be studied before and after ingestion of beetroot juice with nitrates
10015588|NCT01682369|Other|Group 1 a - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
10015589|NCT01682369|Other|Group 1 b - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
10015590|NCT01682369|Other|Group 1 c - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Aggripal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Aggripal)~V3-(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
10015591|NCT01682369|Other|Group 2 a - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
10015592|NCT01682369|Other|Group 2 b - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
10015593|NCT01682369|Other|Group 2 c - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
10015594|NCT01682382||choroidal neovascular (CNV) AMD subjects|Subjects diagnosed with CNV (AREDS Grade 4b)
10015595|NCT01682382||dry AMD subjects|Subjects diagnosed with dry AMD (AREDS Grade 3)
10015596|NCT01682382||age-matched controls|Subjects without AMD (AREDS Grade 1)
10015597|NCT01682395|Active Comparator|G-SV Resection and colostomy|Gangrenous sigmoid volvulus patients randomized to undergo resection with colostomy and delayed anastomosis
10015598|NCT01682395|Experimental|G-SV Resection and anastomosis|Gangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
10015599|NCT01682395|Active Comparator|NG-SV resection and anastomosis|Nongangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
10015600|NCT01682395|Experimental|NG-SV mesosigmoidopexy|Nongangrenous sigmoid volvulus subjects randomized to undergo mesosigmoidopexy
10015601|NCT01682408|Active Comparator|Part A1|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
10015602|NCT01682408|Active Comparator|Part A2|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine
10015603|NCT01682408|Active Comparator|Part B1|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
10015604|NCT01682408|Active Comparator|Part B2|1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
10015605|NCT01682408|Active Comparator|Part B3|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
10015606|NCT01682421|Experimental|Weak steroid|Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.
10015607|NCT01682421|Experimental|Potent steroid|Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.
10015608|NCT01682434|Active Comparator|Wavefront-guided LASIK|One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
10015609|NCT01682434|Active Comparator|Conventional LASIK|One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
10035997|NCT01811628||Questionnaire + Interview|Latinos and Hispanics who are smokers and recent quitters.
9476821|NCT03568006|Active Comparator|Control|Control treatment will consist of a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene.
10015610|NCT01682447|Experimental|Extensive Pulmonary Rehabilitation (ERP)|Participants in this group are measured on primary and secondary outcome measures before and after a 12 week extensive pulmonary rehabilitation program.
10015611|NCT01682447|No Intervention|Waiting List Control group|Participants in the waiting list control group are measured on primary and secondary outcome measures before and after waiting time for the extensive pulmonary rehabilitation program and start with this program after the second moment of measurement.
10015612|NCT01682473|Experimental|Arm 1: 5/2 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
10015613|NCT01682473|Experimental|Arm 2: 21/7 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
10015614|NCT01682486|Experimental|BIP ETT, Bactigaurd coated endotracheal tube|
10015615|NCT01682486|Placebo Comparator|Standard ETT, un-coated endotracheal tube|
10015616|NCT01682499|Experimental|Calcium and Magnesium Infusion|
10015617|NCT01682525|Experimental|Ovarian tissue cryopreservation|The ovarian tissue is cryopreserved and stored at Boston IVF, which is an FDA compliant and American Association of Tissue Banks accredited long term storage facility for reproductive tissue.
10015618|NCT01682551|Experimental|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
10015619|NCT01682551|Placebo Comparator|Acetazolamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
10015620|NCT01682564|Experimental|Candemore tablet|"Candemore tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
10015621|NCT01682564|Active Comparator|Atacand tablet|"Atacand tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
10015622|NCT01682577|Experimental|Perindopril 4 mg tablets of PT Dexa Medica|"Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects."
10015623|NCT01682577|Active Comparator|Perindopril 4 mg tablets of Servier|"Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects."
10015624|NCT01682590|Experimental|Early initiation of RRT|Start of RRT within a maximum of 12 hours after randomisation.
10015625|NCT01682590|Active Comparator|Deferred RRT|Start of RRT between 48 and 60 hours after randomisation.
10015626|NCT01682616|Experimental|Arm 1|Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10015627|NCT01682629|No Intervention|Non-Scripted Debriefing, Low Realism Simulation|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. In this arm, novice instructors were provided the scenario learning objectives but NO SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing. The simulation scenario itself was conducted with an infant simulator. The low realism group had the simulator with the compressor turned off, thus eliminating the functionality of physical findings.
10015628|NCT01682629|Experimental|Scripted debriefing, Low Realism|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The lo realism group had the simulator with the compressor turned on, thus eliminating the functionality of physical findings.
10015629|NCT01682629|Experimental|non-Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITHOUT A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing WITHOUT USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
10015630|NCT01682629|Experimental|Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
10015631|NCT01682668|Experimental|Frequency of subthalamic stimulation|Comparison between healthy controls and PD patients
10015632|NCT01682694|Experimental|Glucosamine and Chondroitin|Glucosamine and Chondroitin
10015633|NCT01682694|Placebo Comparator|Placebo|Inactive ingredients
10015634|NCT01682707|Active Comparator|Laryngoscopy|Laryngoscopy Track Light teaqueal intubation
10015635|NCT01682707|Active Comparator|Track Light|
10015636|NCT01682733|Experimental|Botulinum toxin at injection site|All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.
10015637|NCT01682746|Experimental|Treatment|Photofrin (porfimer sodium) photodynamic therapy.
10015638|NCT01682772|Experimental|Olaparib 400mg|Oral Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle
9476822|NCT03567993|Active Comparator|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
9665235|NCT05129124|Active Comparator|C06: -9.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
10015639|NCT01682772|Experimental|Olaparib 300mg|Oral Olaparib at a dose of 300mg twice daily, continuously on a 28 day cycle
10035998|NCT01811641||maternal methyl-donors, infant epigenetics|women of reproductive age in rural Gambia, infants born to these women
9665236|NCT05128617||Epirubicin-cyclophosphamide|Woman with early breast cancer receiving a first cycle of epirubicin-cyclphosphamide
10015640|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 1) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
10015641|NCT01682798|Placebo Comparator|Placebo yoghurt|100g of placebo yoghurt (normal yoghurt) will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
10015642|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 2) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
10015643|NCT01682850|Active Comparator|Intervention|The Intervention Arm will receive 10 sessions of Mindfulness Based Pulmonary Rehabilitation prior to lung surgery
10015644|NCT01682850|Placebo Comparator|Usual Care|The Usual Care Arm will receive the normal care that a patient with severe COPD having a lung surgery would receive.
10015645|NCT01682889|Placebo Comparator|Placebo|NaCl 0.9% intravenously for 24 hours after induction of anaesthesia
10015646|NCT01682889|Active Comparator|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours after induction of anaesthesia
10015647|NCT01682902|Experimental|Formulation 1|
10015648|NCT01682902|Experimental|Formulation 2|
10015649|NCT01682902|Active Comparator|Insulin aspart (NovoLog®)|
10015650|NCT01682915||Group 1: ADHD+DAT1, Probands|30 ADHD probands with DAT1 variants
10015651|NCT01682915||Group 2: ADHD+DAT1, Unaffected sibling|30 same-sex unaffected siblings of Group 1
10015652|NCT01682915||Group 3: ADHD Drug-naïve, Probands|30 ADHD probands without DAT1 gene variants, who were age-, sex-, and IQ-matched to Group 1
10015653|NCT01682915||Group 4: ADHD Drug-naïve, unaffected sibling|30 same-sex unaffected siblings of Group 3
10015654|NCT01682915||Matched controls|30 age-, sex- and IQ-matched TD controls for each of 4 groups
10015655|NCT01682941|Active Comparator|Soy Bread Intervention|Arm I Soy Bread
10015656|NCT01682941|Experimental|Soy -Almond Bread Intervention|Arm II Soy-Almond Bread
10015657|NCT01682967||Experimental group|Patients suffering from PDPH would form this group
10015658|NCT01682967||Control group - Epidural|Patients who received an epidural during labour but did not have symptoms of PDPH would form this reference group
10015659|NCT01682967||Control Group without Epidural analgesia|Patients in labour who did not receive an EDA would form this cohort of controls
10015660|NCT01682980|Experimental|Strength training|The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
10015661|NCT01682980|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 75% of maximal heart rate (calculated with formula for maximal heart rate reserve).
10015662|NCT01682980|No Intervention|Control group|The control group will do as usual.
10015663|NCT01682993|Active Comparator|Corneal Cross Linking|Patients will receive a standard corneal cross linking treatment
10015664|NCT01682993|Experimental|Corneal Cross Linking and Topo Laser|Patients will receive a topography guided laser treatment in combination with a standard corneal cross linking treatment in the same session.
10035999|NCT01811667|Experimental|Sirolimus|Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.
9665237|NCT05128617||Paclitaxel|Woman with early breast cancer receiving a first cycle of paclitaxel
9665238|NCT05128344|Experimental|AMZ002|
9665239|NCT05128344|Active Comparator|Vigabatrin|
9665240|NCT05128136|Active Comparator|Silicone IVR 46mm external diameter|
10015665|NCT01683006|Active Comparator|Neuromuscular blocker group|"Continuous application of neuromuscular blockers during therapeutic hypothermia.~Bolus application of placebo in case of shivering."
10015666|NCT01683006|Placebo Comparator|Placebo group|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of neuromuscular blockers in case of shivering."
10015667|NCT01683032|Experimental|Experimental: Healthy adults|Participants, aged 21-40 years, will be recruited through an advertisement posted at the University of Haifa (including the website of Haifa University).
10015668|NCT01683045|Experimental|The Estech COBRA® Surgical System|
10015669|NCT01683097|No Intervention|Control|Questionnaire
10015670|NCT01683097|Experimental|Intervention|Standardized explanation followed by questionnaire
10015671|NCT01683136|Experimental|Deep TMS treatment|
10015672|NCT01683136|Sham Comparator|inactive stimulation|
10015673|NCT01683149|Experimental|Combination Chemotherapy|"Combination Chemotherapy: Topotecan and Sorafenib. Participants will receive the treatment in cycles. Every cycle is 28 days long. For the first cycle participants will get the chemotherapy drugs:~Topotecan PO (by mouth) once daily on days 1-5 and days 8-12~Sorafenib PO (by mouth) twice daily (BID), continuously on days 2-28 of cycle one and days 1-28 on each additional cycle.~Level -1: Topotecan 1.0 mg/m^2: Sorafenib 100 mg/m^2 BID~Level -2: Topotecan 0.8 mg/m^2: Sorafenib 100 mg/m^2 BID~Level 1: Topotecan 1.0 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 2: Topotecan 1.4 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 3: Topotecan 1.4 mg/m^2: Sorafenib 200 mg/m^2 BID~Level 4: Topotecan 1.8 mg/m^2: Sorafenib 200 mg/m^2 BID"
10015674|NCT01683162|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
10015675|NCT01683162|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin
10015676|NCT01683162|Experimental|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
10015677|NCT01683175|Experimental|Arm 1|Erlotinib 150mg daily oral up to 2 years
10015678|NCT01683175|Active Comparator|Arm 2|NP Chemotherapy for 4 cycles
10015679|NCT01683188|Other|Cohort 1|Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
10015680|NCT01683188|Other|Cohort 2|Patients who have receive >7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2
10015681|NCT01683201|Experimental|Functional exercise class|Functional exercise class 45 mins twice weekly from week 12 to week 18
10015682|NCT01683201|Placebo Comparator|Usual Care Group|Usual Care
10015683|NCT01683227|Experimental|Screening/motivational drug intervention|Screening and brief intervention counseling matched to patient's risk level delivered in the ER
10015684|NCT01683227|Placebo Comparator|Motivational placebo intervention|Screening and brief intervention for driving and traffic safety
10015685|NCT01683240|Experimental|Frimberger cholangioscope|Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures
10015686|NCT01683253|Experimental|Levodopa/Carbidopa(200mg/50mg)|
10015687|NCT01683253|Experimental|Control A (dopaminergic agonist )|Parkinson patients treated with anti-Parkinson drug over 6 months.
10015688|NCT01683253|No Intervention|Control B (no drug)|Parkinson diseased patients not treated.
10015689|NCT01683292|Experimental|Inhaled VR040|Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
10015690|NCT01683292|Placebo Comparator|Placebo|Inhaled dry powder. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
10015691|NCT01683305||Subjects who have no mammographically detectable tumors|This group will be evaluated for marker presence in NAF. no drugs administered
10015692|NCT01683305||Subjects who have non-cancerous growths|This group will be evaluated to study whether marker(s) detected in NAF are also expressed in non-cancerous tumors. No drugs administered
10015693|NCT01683305||subjects who have cancerous growths|In this group, any markers detected in NAF could also be detected in tumor tissues. No drugs administered.
10015694|NCT01683318|Experimental|Treatment|Patients will undergo Thermal Pulsation treatment of Meibomian Gland Dysfunction using the TearScience System (Lipiflow).
10015695|NCT01683357||Multiple Bilobar CLM|Patients selected for hepatectomy because carrier of multiple (> or = to 4), bilobar CLM
9665241|NCT05128136|Active Comparator|Silicone IVR 56mm external diameter|
9665242|NCT05128136|Active Comparator|Silicone IVR 66mm external diameter|
9665243|NCT05127850|Experimental|Consultation audio recording|
9665244|NCT05127629|Placebo Comparator|Control|
9665245|NCT05127629|Experimental|Collagen matrix|
9665246|NCT05127590|Experimental|RBN-2397 in combination with pembrolizumab|RBN-2397 orally in combination with the fixed approved dose of IV pembrolizumab
10015696|NCT01683370||Patients|Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
10015697|NCT01683396|Placebo Comparator|Placebo|
10015698|NCT01683396|Experimental|gevokizumab|
10015699|NCT01683435|Experimental|hylauronin binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
10015700|NCT01683461|Experimental|Enhanced Counseling|Women in the intervention arm receive: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focused on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.
10015701|NCT01683461|Active Comparator|Standard of Care|Women in the control arm receive the standard of care in terms of HIV counseling and testing during pregnancy. The standard of care for HIV counseling adheres to guidelines provided by the US Centers for Disease Control and the World Health Organization. Women receive one individual pre-test counseling session immediately before they are tested for HIV, and one individual post-test counseling session the same day that they are tested.
10015702|NCT01683474|Experimental|Venus A-Valve|single arm with intervention that percutaneous implantation of the Venus MedTech Aortic Valve Prosthesis
10015703|NCT01683500|Experimental|shock wave therapy|intervention: shock wave therapy with Modulith SLK (Storz)
10036000|NCT01811719|Experimental|Enhanced NFP (NFP+)|"Enhanced NFP(NFP+)provides for the usual NFP services plus a three-prong experimental preventive intervention:~Structured and regularly occuring assessments for intimate partner violence (IPV);~McFarlane and Parker Brochure Driven Intervention for women experiencing IPV, including safety planning, referrals, and advocacy; and~Markman and Stanley Within My Reach Training which is a skills-based curriculum delivered to all participants focusing on improving relationship deicsions and outcomes."
10036001|NCT01811719|Active Comparator|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
10036002|NCT01811745|Experimental|Jaques-Dalcroze eurhythmics training|Once-weekly 60-min Jaques-Dalcroze eurhythmics class, for 12 months.
10036003|NCT01811745|Active Comparator|Multicomponent exercise training|Once-weekly 60-min multicomponent exercise class supplemented by one 30-min home-based exercise session, for 12 months.
10036004|NCT01811758|Experimental|Culturally Specific CBT|Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
10036005|NCT01811758|Active Comparator|Standard CBT (control)|Standard cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes each. Up to 8-weeks of transdermal nicotine patches. Traditional CBT, with no focus on race: smoking and health, benefits of quitting, weight control, relapse prevention, coping skills.
10015704|NCT01683513|No Intervention|humaan chorion gonadotropine|ovulation induction with 5000E hCG
10015705|NCT01683513|Active Comparator|GnRH agonist + 1500E hCG|ovulation induction with GnRH agonist and 1500E hCG one hour after egg retrieval
10015706|NCT01683539|Experimental|The Thinking Skills for Work Program|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
10015707|NCT01683539|Active Comparator|The Cognitive Skills for Work Program|The Cognitive Skills for Work Program includes 4 components delivered by a Cognitive Specialist who works with the consumer's Employment Specialist: a) assessing the consumer's cognitive strengths and weaknesses their relation to job history b) teaching coping strategies for cognitive challenges associated with job search or maintenance c)job search planning, in which the consumer and the Cognitive and Employment Specialists help identify job leads based on the consumer's interests, and identify cognitive coping strategies and supports the consumer may need to succeed at the workplace; and d) job support consultation, in which the Cognitive and Employment Specialists consult with the consumer on additional cognitive coping strategies to enable the consumer to meet the demands of the job.
10015708|NCT01683552|Other|Aprepitant|Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
10015709|NCT01683552|Other|Aprepitant after anti-itch standard therapy|Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week
10015710|NCT01683578|Active Comparator|Variable Ventilation|Variable tidal volumes with mean at 8 mL/kg of predicted body weight
10015711|NCT01683578|No Intervention|Non-variable Ventilation|Conventional mechanical ventilation with tidal volume 8 mL/kg of predicted body weight
10015712|NCT01683591||High-risk aspiration group|Among the consecutive stroke patients, categorized to high-risk group in the patient (1) was not on alert mentality (from drowsy to comatose mentality), (2) was not able to sit upright or control his/her head, and (3) failed to pass indirect water swallow test.
10015713|NCT01683591||Low-risk aspiration group|Patents without oropharyngeal neurologic signs
10015714|NCT01683591||Intermediate-risk aspiration group|If any one of following was positive, categorized to intermediate-risk group; (1) dysarthria, (2) motor aphasia, (3) inability to close and open lips or (4) facial weakness, (5) tongue deviation or (6) uvula deviation, (7) loss of gag reflex, and (8) inability to cough voluntarily.
10015715|NCT01683617|Experimental|A treatment based on CBT and new technologies|Individuals will receive a treatment based on cognitive behavioral therapy and new technologies (virtual reality, virtual reality combined to biofeedback and mobile phones). Relaxation will be induced through the immersion in different virtual environments (e.g., lake) which will be customized with different pre-recorded audio narratives that describe the specific setting and that guide the execution of a series of relaxation exercises. During biofeedback exercises a wearable biosensor system will provide suggestions to the trainer based on the reactions of the participants, and the biosensor data will directly modify the virtual reality experience in real time.
10015716|NCT01683617|Active Comparator|Traditional treatment based on CBT|Participants will receive a treatment based on traditional cognitive behavioral therapy techniques for stress management, without the use of new technologies. Relaxation will be induced by guided imagery, through auditory narratives.
10015717|NCT01683643|Experimental|SBIRT Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
9518080|NCT03300128|Active Comparator|Circle of Parents|"Circle of Parents, the comparison condition, is an open parent support group led by a parent leader. (For more information, see http://circleofparents.org/). Participants are encouraged to share resources and other support both during groups, and between meetings."
9518081|NCT03300115|Experimental|AC0010|Each participant will be given AC0010 300mg bid.
9476823|NCT03567993|Experimental|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
9476824|NCT03567967|Experimental|San Francisco|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The San Francisco participants will receive and spend these vouchers in an environment which has implemented a sugar-sweetened beverage tax.
9476825|NCT03567967|Active Comparator|Los Angeles|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The Los Angeles participants will receive and spend these vouchers in an environment which has NOT implemented a sugar-sweetened beverage tax.
9476826|NCT03567941|Placebo Comparator|Placebo|Single dose
9476827|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 1|Single dose
9476828|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 2|Single dose
9476829|NCT03567941|Active Comparator|Reference|Single dose
9476830|NCT03567928|Active Comparator|Standard Treatment|Standard Treatment Sedation with propofol target controlled infusion (TCI) and no airway devices (mandatory spontaneous breathe)
9476831|NCT03567928|Experimental|Interventional Treatment|Interventional Treatment Sedation with propofol target controlled infusion (TCI) and Gastro Cuff Pilot Laryngeal Mask (possibility to use a pressure-support ventilation)
9476832|NCT03567915||Rice|Group that healthy volunteers eat rice.
9476833|NCT03567915||Noodle|Group that healthy volunteers eat noodle.
9476834|NCT03567902|Experimental|Group A|C-MAC videolaryngoscope intubation -> Direct laryngoscope intubation
9476835|NCT03567902|Experimental|Group B|Direct laryngoscope intubation -> C-MAC videolaryngoscope intubation
9476836|NCT03567863|Active Comparator|Group A|"The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)~20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®"
9665247|NCT05125848|Experimental|Hemodialysis Single Group Assignment|All enrolled subjects will be connected to the CM-1500 for monitoring during their hemodialysis session
10015718|NCT01683643|Active Comparator|Control Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
10015719|NCT01683656|Active Comparator|ER Niacin/laropipant|ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
10015720|NCT01683656|Placebo Comparator|ER Niacin/laropipant Placebo|ER niacin/laropiprant placebo p.m.
10015721|NCT01683669|Other|Noisy-PSV 1|different levels of variable pressure support
10015722|NCT01683669|Other|Noisy-PSV 2|different levels of variable pressure support
10015723|NCT01683682|Experimental|BIBF 1120, Vinorelbine, Carboplatin|"To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
10015724|NCT01683695|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
10015725|NCT01683695|Placebo Comparator|AMG 557 Matching Placebo|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
10015726|NCT01683708||Symbiotic group|Jaundiced patients who have symbiotic therapy
10015727|NCT01683708||No Symbiotic therapy|Jaundiced patients who not have symbiotic therapy
10015728|NCT01683721||Winx|
10015729|NCT01683734||Renal Function Observation|
10015730|NCT01683747|Experimental|Tranexamic acid|Study group receives enteral tranexamic acid in normal saline in addition to usual care.
10015731|NCT01683747|Placebo Comparator|Control group|Control group receives vehicle (normal saline) without study drug and usual care.
10015732|NCT01683760|Experimental|Population PK|
10015733|NCT01683773|Experimental|Group A|Two doses of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
10015734|NCT01683773|Experimental|Group B|One dose of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
10015735|NCT01683773|Experimental|Group C|Three doses of AERAS-402 (1x10^11 vp intramuscular injection)
10015736|NCT01683786|Experimental|Pegintron + Riba for 36 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 24 weeks (36 weeks in total HCV treatment)
10015737|NCT01683786|Active Comparator|Pegintron + Riba for 48 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 36 weeks (48 weeks in total HCV treatment)
10015738|NCT01683799|Experimental|Insomnia treatment|Cognitive Behavioral Therapy for Insomnia
10015739|NCT01683799|No Intervention|Control|
9476837|NCT03567863|Active Comparator|Group B|"The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)~22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®"
9665248|NCT05125562|Placebo Comparator|Placebo|100ml normal saline
10015740|NCT01683877|Experimental|FloSeal group|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
10015741|NCT01683877|Active Comparator|Electrocautery group|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
10015742|NCT01683890||Simple hysterectomy group|Patients will undergo simple hysterectomy due to benign uterine disease.
10015743|NCT01683903||Non coronary patients (NC)|Patient with myocardial infarction with non-coronary (NC) etiology
10015744|NCT01683903||Coronary patients (C)|Patients with myocardial infarction due to coronary disease
10015745|NCT01683929|Active Comparator|Oral glucose tolerance test|The participants will consume a beverage containing 75 gram glucose During the meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes. Also, they will record their macronutrient\caloric consumption during the 24 hour following the test.
10015746|NCT01683929|Placebo Comparator|Artificial sweetner|"participants will consume a beverage containing 0.42 gram artificial sweetener (Aspartame) During each meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes.~Also, they will record their macronutrient\caloric consumption during the 24 hour following the test."
10015747|NCT01683955|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
10015748|NCT01683955|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
10015749|NCT01683968||Sickle cell|Patient who are admitted with sickle cell crises
10015750|NCT01683981|Experimental|L-Citrulline, Exercise Capacity|L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks
10015751|NCT01684059||Single group|Single group: each participant receive same intervention (zinc sulfate) throughout study (non-randomized)
10015752|NCT01684072|Experimental|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
10015753|NCT01684072|Active Comparator|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
10015754|NCT01684085|Placebo Comparator|Encouragement to sleep|Encouraging explanation to sleep, rest and receiving Lorazepam 1mg in the first night post trauma
10015755|NCT01684085|Experimental|Encouragement to deprived sleep|Encouraging explanation to deprived sleep in the first night post trauma
10015756|NCT01684098|Other|Tc 99m EC20|
10015757|NCT01684111|Experimental|BIBF 1120, Vinorelbine|"To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
10015758|NCT01684124|Placebo Comparator|standard care|normal treatment
10015759|NCT01684124|Active Comparator|conservative O2 therapy|a value of 90-92% O2 saturation will be targeted
10015760|NCT01684137|Active Comparator|Joalis Bambi Bronchi & Joalis Bambi Analerg|10 days, 2 times per day 2,5/5 ml
10015761|NCT01684137|Placebo Comparator|Placebo & Placebo|10 days, 2 times per day 2,5/5 ml
10015762|NCT01684150|Experimental|EPZ-5676 Extension cohort|
10015763|NCT01684176|Experimental|Complex tailored intervention|"The intervention consists of 3 elements:~Medication review with recommendations focused on antithrombotics and adherence to guidelines and patient´s adherence to medications.~Discharge consultation with an pharmacist using motivational interviewing techniques.~Follow-up telephone calls one week, two months and six months after discharge."
10015764|NCT01684176|Placebo Comparator|Usual care|Usual care
10015765|NCT01684189||Patient registry|Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
10015766|NCT01684241|Experimental|RBL001/RBL002 intranodal administration|"All participants will be treated with RBL001/RBL002 after allocation to one of the four escalating dose cohorts:~Cohort-1 50 µg RBL001 and 50 µg RBL002~Cohort-2 100 µg RBL001 and 100 µg RBL002~Cohort-3 300 µg RBL001 and 300 µg RBL002~Cohort-4 600 µg RBL001 and 600 µg RBL002"
10015767|NCT01684254||Children with Cerebral Palsy (CP)|
10015768|NCT01684267|Experimental|Healthy|Healthy individuals
10015769|NCT01684267|Experimental|Post-stroke|Chronic stroke survivors
10015770|NCT01684280||gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
10015771|NCT01684293|Experimental|Cognitive Rehabilitation|Occupational therapy-based cognitive rehabilitation
10015772|NCT01684293|Placebo Comparator|Psychoeducation/games|Psychoeducation/games
10015773|NCT01684306|Experimental|Placebo|Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
10015774|NCT01684306|Experimental|Modafinil|"Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil."
10015775|NCT01684319|Placebo Comparator|Infant formula milk|Infant formula milk adapted to age of infant
10015776|NCT01684319|Active Comparator|Formula milk free of milk proteins|Milk-free formula milk adapted to age of infant
10015777|NCT01684332|Experimental|High Sugar (HS)|Study of the postprandial effects after consuming 60g of strawberry jam with high sugar content
10015778|NCT01684332|Experimental|Low Sugar (LS)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content
10015779|NCT01684332|Experimental|Low Sugar + Antioxidant (LSA)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content and an antioxidant extract from strawberry pulp
10015780|NCT01684345|Placebo Comparator|Placebo|
10015781|NCT01684345|Experimental|Dose 1 gevokizumab|
9476838|NCT03567824|Experimental|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
9802624|NCT05114668|Experimental|Stage 1|- Stage 1 (Dose Escalation Cohorts): Stage 1 is a multiple ascending dose escalation of EVT801 in patients with advanced solid tumours to evaluate the safety and tolerability of EVT801 and to determine MTD / RP2D for further investigation.
10015782|NCT01684345|Experimental|Dose 2 gevokizumab|
10015783|NCT01684358|Experimental|Immediate implant|Sino-implant (II) inserted at enrollment visit
10015784|NCT01684358|Active Comparator|Delayed implant|Sino-implant (II) inserted at 3-month follow-up visit
10015785|NCT01684371||Blue Dotted Elmore Oil|Patients applied the above oil 3 times daily for four weeks and on the fifth week stopped the application completely for the flush out period before switching to Orange Dotted Elmore Oil
10015786|NCT01684371||Orange Dotted Elmore Oil|Patients give this oil applied it three times daily on the affected knees for four weeks and on the fifth week, stopped the application totally for the flush out period before switching to the Blue Dotted Elmore Oil.
10015787|NCT01684384|Experimental|No treatment|CT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
10015788|NCT01684449|Experimental|Phase 2: Experimental Arm|Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
10015789|NCT01684462|Experimental|Human Serum Albumin 20|Human Serum Albumin 20% 100cc intravenously infused over 4~8h
10015790|NCT01684462|Placebo Comparator|0.9 % Normal saline|Treatment with same volume of normal saline
10015791|NCT01684475|Experimental|Treatment with CJH1|
10015792|NCT01684488|Active Comparator|Waitlist+EducAid|Immediately following enrollment, participants do not immediately receive any intervention. At 3 months, they are enrolled in EducAid educational programming for the 2012-2013 academic year.
10015793|NCT01684488|No Intervention|Waitlist|Participants do not receive any intervention throughout the trial period. Once the trial has concluded, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
10015794|NCT01684488|Experimental|YRI only|Immediately following enrollment, participants complete the YRI. They are then placed on a waitlist for the remainder of the trial. At the end of the trial, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
10015795|NCT01684488|Experimental|YRI+EducAid|Immediately following enrollment, participants complete the YRI. Participants are then immediately enrolled in EducAid educational programming for the 2012-2013 academic year.
10015796|NCT01684501||Amputees|Adults with history of traumatic unilateral transtibial amputation
10015797|NCT01684514|Experimental|colitis, ulcerative|Enrolled patients will be examined by conventional colonoscopy and confocal laser endomicroscopy before and after initiation of topical treatment, respectively.
10015798|NCT01684514|Sham Comparator|Control group|A control group will be examined by conventional colonoscopy and confocal laser endomicroscopy.
10015799|NCT01684527||Children Suffering From Bronchiolitis|Respiratory secretions obtained from children suffering from Bronchiolitis
10015800|NCT01684527||Healthy Children|Respiratory secretions obtained from children with no respiratory infection
10015801|NCT01684553|Experimental|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
10015802|NCT01684553|Active Comparator|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
10015803|NCT01684579|Experimental|Exercise and psychosocial counseling|Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
10015804|NCT01684605|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
10015805|NCT01684605|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
10015806|NCT01684618|Experimental|Cerebral NIRS oximetry + CPAP|Cerebral NIRS oximetry, using the INVOS Cerebral/Somatic Oximeter, and changes in regional cerebral oxygen saturation, rSO2, during induced changes in CPAP flow pressure
10015807|NCT01684631||Hip arthroplasty|Patients implanted with a PINNACLE® ULTAMET™ Metal-on-Metal implant for conventional total hip arthroplasty for the treatment of a severe hip disease or true femoral cervical fracture.
10015808|NCT01684644|Experimental|New Forest Parenting Programme|The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
9476839|NCT03567824|Other|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
9518082|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
9802625|NCT05114668|Experimental|Stage 2|- Stage 2 (Biomarker Expansion cohorts): A biomarker expansion cohort, in which all subjects will receive EVT801 at the MTD / RP2D, will be recruited to explore pharmacodynamic outcomes and further elucidate tolerability, activity, and pharmacokinetics.
10015809|NCT01684644|Other|Treatment as Usual|Treatment as usual for preschool ADHD consists of psychoeducation groups for parents.
10015810|NCT01684657|Placebo Comparator|Placebo|This is the comparator. Placebo will be matched to color, taste, size, and smell.
10015811|NCT01684657|Experimental|Asenapine|This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
10015812|NCT01684670|Experimental|Behavioral speech treatment|
10015813|NCT01684683|Experimental|Theophylline|Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks
10015814|NCT01684683|Placebo Comparator|placebo|Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks
10015815|NCT01684696|Experimental|mHealth TLC|"The mhealth TLC group will meet with a nurse before each of 4 clinician visits and use the mHealth TLC on an iPad with an interactive 3-dimensional intervention that allows individuals to experience virtual visits with their clinicians. Key aspects of mHealthTLC include informational videos about lung cancer and LCS. Blame and self-blame will be addressed, information about the role of addiction, social/cultural factors, and tobacco industry influence on smoking behaviors will be highlighted. Patients will experience practiced interaction in ever increasing complex situations with avatars (i.e., receptionist, medical assistant, and clinician). A virtual coach will accompany the patient through the virtual visit and will provide information and coaching (as needed)."
10015816|NCT01684696|Active Comparator|Attention Control|Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
10015817|NCT01684709|Experimental|Telemonitoring + self-management support|Automated assessment calls with follow-up by a Care Manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up.
10015818|NCT01684709|No Intervention|Usual Care|Usual Care
10015819|NCT01684735||women with breast cancer and chemotherapy|women recently diagnosed with breast cancer and selected to start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy
10015820|NCT01684761|Experimental|Tcelna|30-45 x 10E6 total cells in 2 ml. Subjects receive two annual courses of 5 subcutaneous doses each year (at 0, 4, 8, 12 and 24 weeks).
10015821|NCT01684761|Placebo Comparator|Placebo|Tcelna inactive ingredients (without cells) totaling 2 ml per dose. Administered subcutaneously with same two year treatment regimen as experimental treatment arm.
10015822|NCT01684774||I. USG|Patients receiving Ultrasound-guided Ankle Block
10015823|NCT01684774||II. ALG|Patients receiving Anatomic Landmark-guided Ankle Block
10015824|NCT01684787|Experimental|1|Peginterferon alfa-2a + ribavirin in normal ALT
10015825|NCT01684787|Active Comparator|2|peginterferon alfa-2a + ribavirin in elevated ALT
10015826|NCT01684800|Active Comparator|A. Desmopressin 10 microgram|
10015827|NCT01684800|Active Comparator|B. Desmopressin 25 microgram|
10015828|NCT01684800|Placebo Comparator|C. Placebo|
10015829|NCT01684813|Active Comparator|Clopidogrel|This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
10015830|NCT01684813|Experimental|Prasugrel|This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).
10015831|NCT01684865||Non-Hodgkin's Lymphoma Participants|Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will receive rituximab for maximum two years or until disease progression. Participants will be followed for one year after last dose of rituximab administered as maintenance.
10015832|NCT01684891|Experimental|RG1662|
10015833|NCT01684956|Experimental|Intradermal first|Intradermal injection experiment first, followed by subcutaneous injection experiment
10015834|NCT01684956|Experimental|Subcutaneous first|Subcutaneous injection experiment first, followed by intradermal injection experiment
10015835|NCT01684969|Active Comparator|intravenous haloperidol|intravenous haloperidol pharmacokinetics
10015836|NCT01684969|Placebo Comparator|Placebo|
10015837|NCT01684982|Experimental|everolimus eluting stent|second generation drug eluting stent
10015838|NCT01684982|Active Comparator|sirolimus eluting stent|first generation drug eluting stent
10015839|NCT01684995|Active Comparator|Minimal|Brief physician advice to quit smoking plus nicotine patch
10015840|NCT01684995|Experimental|Tailored|
10015841|NCT01685034|Experimental|Allergy Immunotherapy Group|There is only one active experimental group as this is a pilot study comparing clinical/histologic/endoscopic changes before and after treatment.
10015842|NCT01685086||Patients with severe chronic kidney disease|
10015843|NCT01685086||Patient with peritoneal dialysis|
10015844|NCT01685086||Patients with hemodialysis|
10015845|NCT01685099||Group with tuberculous pleurisy|
10015846|NCT01685099||Group with non-tuberculous pleurisy|
10015847|NCT01685112||Conventional Group|Patients who developed refractory shock, but didn't received ECMO as salvage treatment
10015848|NCT01685112||ECMO group|Patient who have septic shock, and progreseed to have ECMO as salvage therapy
10015849|NCT01685125|Active Comparator|Arm A (abiraterone acetate, prednisone)|Abiraterone acetate 1000 mg PO QD and Prednisone 5 mg PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
10015850|NCT01685125|Experimental|Arm B (abiraterone acetate, prednisone, dasatinib)|Abiraterone acetate 1000 mg PO QD, Prednisone 5 mg PO BID, and dasatinib 100 mg PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
10015851|NCT01685151|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
10015852|NCT01685151|Experimental|Ramelteon SL (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
10015853|NCT01685151|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
10015854|NCT01685164||LNG-IUS|Nulliparous women
10015855|NCT01685164||Cu-IUD|Nulliparous women
10015856|NCT01685177||SADI|Patients submitted to a second-step operation after a failed sleeve on which a single-anastomosis duodena-ileal bypass at 250 cm from the cecum is performed.
10015857|NCT01685190|Active Comparator|Prostate Alone IMRT|Participants will receive standard prostate Intensity Modulated Radiotherapy (IMRT) of 74Gy in 37 fractions delivered over 7.5 weeks.
9518083|NCT03300089|Active Comparator|General Anaesthesia|General Anaesthesia during surgery
9518084|NCT03300089|Experimental|Regional Anaesthesia|Regional Anaesthesia during surgery
10015858|NCT01685190|Experimental|Prostate & Pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
10015859|NCT01685281|Active Comparator|Metadoxine (MG01CI) 1400 mg|single dose of Metadoxine (MG01CI) 1400 mg
10015860|NCT01685281|Active Comparator|Metadoxine (MG01CI) 700 mg|Single dose of Metadoxine (MG01CI) 700 mg
10015861|NCT01685281|Placebo Comparator|Placebo|Single dose of Placebo
10015862|NCT01685294|No Intervention|Treatment as Usual (TAU)|Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.
10015863|NCT01685294|Experimental|Group Interpersonal Psychotherapy (IPT) for Depression + TAU|Participants will receive Group IPT for Depression + TAU.
10015864|NCT01685307|Experimental|intense cooking process|Test meal: 150g of beef cooked at intense temperature. Beef proteins are intrinsically labelled with 15 N protein
10015865|NCT01685307|Experimental|mild cooking process|Test meal: 150 g of beef cooked at moderate intensity. Beef proteins are intrinsically labeled with 15N.
10015866|NCT01685333|Other|Group A|First Period: Test Drug (Epoetin Alfa) Second Period: Comparator Drug
10015867|NCT01685333|Other|Group B|First period: Comparator drug Second Period: Test drug (Epoetin alfa)
10015868|NCT01685346|Experimental|Biofeedback|biofeedback-mediated stress management (BFSM)
10015869|NCT01685359|Experimental|Test Drug|Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration
10015870|NCT01685359|Active Comparator|Eprex|Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration
10015871|NCT01685385|Active Comparator|Diagnostic intervention group A|Patients who will receive the BNP test
10015872|NCT01685385|No Intervention|Group B|Patients who will not receive the BNP test.
10036006|NCT01811771|Active Comparator|Shanchol vaccine|Around 30,000 individuals will be vaccinated with two doses of oral cholera vaccine at least 14 days apart.All male and non-pregnant female residents above one year age will be targeted for vaccination.
10036007|NCT01811771|No Intervention|Non-intervention|No intervention will be given. Health education will be provided to the study participants.
10036008|NCT01811784|Experimental|Use skirt on raw sap consumption|"Phase one: Test the effectiveness of a single message of do not drink raw sap."
10036009|NCT01811784|Experimental|Ask people not to drink sap|Test the effectiveness of a risk reduction approach, encouraging people to avoid drinking sap, if they do, they should only drink sap from skirt protected trees.
10036010|NCT01811784|No Intervention|Phase 1: Routine raw sap consumption among household members.|"Test the effectiveness of a single message of do not drink raw sap"
10036011|NCT01811784|No Intervention|Phase 2:|Raw sap consumption from skirt protected trees
10036012|NCT01811797|Experimental|Low Intensity Shockwave treatment|4 weekly sessions of Low Intensity Shockwave treatment.
10036013|NCT01811797|Sham Comparator|Control group|
10036014|NCT01811810|Other|xrt and long term ADT|Radiation therapy (XRT) and long term androgen deprivation therapy
10036015|NCT01811810|Other|xrt, chemotherapy and short term ADT|radiation therapy (XRT), chemotherapy and short term ADT
10036016|NCT01811823|Other|TIV|"Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
10015873|NCT01685398|Placebo Comparator|normal saline|normal saline 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
10015874|NCT01685398|Experimental|0.5% timolol maleate eye drop|0.5% timolol maleate solution 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
10015875|NCT01685450|Other|Intracranial pressure|
10015876|NCT01685476|Other|Intracranial pressure|
10015877|NCT01685489|Experimental|Docetaxel, PSK®|A 21-day lead-in oral PSK alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 evey 3 weeks for three cycles. After the third dose of docetaxel, study drug will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
10015878|NCT01685489|Placebo Comparator|Docetaxel, Placebo|A 21-day lead-in oral placebo alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 every 3 weeks for three cycles. After the third dose of docetaxel, the placebo will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
10015879|NCT01685502||Group 1|Patients treated with Glucobay OD under practical manner
10015880|NCT01685515|Experimental|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Tetrahydrouridine
10015881|NCT01685515|Placebo Comparator|Placebo|Placebo
10015882|NCT01685528|Experimental|CBT|
10015883|NCT01685541|Experimental|Maximum AVS Content|AVS includes patient name, visit date, chief complaining, allergies, immunizations, vital signs, medications, problem list, lab order, physician contact information, referrals, instructions
10015884|NCT01685541|Experimental|Intermediate AVS content|AVS includes patient name, visit date, vital signs, medications, diagnosis, problem list, physician contact information, referrals, instructions
10015885|NCT01685541|Experimental|Minimum AVS content|AVS contains patient name, visit date, medications, diagnosis, physician contact information, referrals, instructions
10015886|NCT01685541|Active Comparator|Control Group (Usual AVS)|Content differed by clinic site
10015887|NCT01685554|Active Comparator|normothermic CPB|cardiopulmonary bypass with maintenance of normal body temperature
10015888|NCT01685554|Active Comparator|hypothermic CPB|cardiopulmonary bypass using mild hypothermia
10015889|NCT01685580|Experimental|Manufacturer VPAP ST|7 days minimum non-invasive ventilation at 2 levels of pressure (BPAP) to the intervention.
10015890|NCT01685580|No Intervention|No intervention|usual advice
10015891|NCT01685593|Sham Comparator|regular bandage|no abdominal binder
10015892|NCT01685593|Experimental|abdominal binder|binder
10015893|NCT01685619||AML Cohort|This cohort is comprised of participants who have acute myelogenous leukemia (AML).
10015894|NCT01685619||MDS Cohort|This cohort is comprised of participants who have myelodysplastic syndrome (MDS).
10015895|NCT01685632|Active Comparator|Surgery with IPCH|Patients having an IPCH (Intra Peritoneal Chemo Hyperthermia) during the surgery time
10015896|NCT01685632|Sham Comparator|patients without IPCH|Patients recused for the surgery due to intraoperative contraindication
10015897|NCT01685645|Experimental|Study population|"The study population consists of male and female patients admitted for programmed major knee surgery (arthroplasty) with a truncal analgesic block (femoral nerve block with a sciatic block) and operated under general anesthesia.~See inclusion and exclusion criteria.~Intervention: AlgiScan"
10015898|NCT01685658|Active Comparator|Ketaprofen|"Patients randomized to this arm will receive intravenous ketaprofen when treating renal colic.~Intervention: intravenous ketaprofen"
10015899|NCT01685658|Experimental|Paracetamol|"Patients randomized to this arm will receive intravenous paracetamol when treating renal colic.~Intervention: intravenous paracetamol"
10015900|NCT01685671|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
10015901|NCT01685671|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
10015902|NCT01685710|Experimental|GTN patch|GTN patch 5mg, in situ 24hrs
10015903|NCT01685710|Placebo Comparator|Placebo patch|Placebo patch, in situ for 24hrs
10015904|NCT01685723|Experimental|Counseling group|"Subjects in this group will receive a face-to-face individualized brief advice based on risk communication for 15-30 minutes from the nurse counselors and a booster intervention (10-15 minutes) at 1 week.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone.Ten subjects from the intervention group who have not quitted will be invited for a process evaluation in the form of face-to-face interviews by research assistants at 12-month follow-up."
10015905|NCT01685723|Sham Comparator|General supporting|"Subjects in this group will receive standard care without risk communication.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone."
10015906|NCT01685749||Enrolled participants|The targeted study population will include all people at Seal Beach who have been identified by the Seal Beach Lifeguards to have been stung by a jellyfish over the course of one year who are adults or children whose parent or guardian is present at the time of the injury. Children and pregnant women are included in the group.
10015907|NCT01685762|Experimental|Metformin|Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12).
10015908|NCT01685775|Experimental|Transvaginal/transumbilical cholecystectomy|Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style
10015909|NCT01685775|Active Comparator|Needlescopic cholecystectomy|Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder
10015910|NCT01685788||study participants|
10015911|NCT01685827|Active Comparator|NECT (Nifurtimox Eflornithine Combination Therapy)|"Nifurtimox tablets will be given orally three times a day, at the daily dose of 15 mg/kg/day, for 10 days.~Eflornithine (400 mg/kg/day) will be given twice daily for 7 days, as a 2-hour IV infusion."
10015912|NCT01685827|Experimental|Fexinidazole|"Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:~1 800 mg (3 tablets) once a day for 4 days,~Followed by 1 200 mg (2 tablets) once a day for 6 days. Total duration of treatment will be 10 days."
10015913|NCT01685853|Active Comparator|PEG 4 litres split|Polyethylene glycol with electrolytes (PEG)
10015914|NCT01685853|Experimental|Bisacodyl plus PEG-CS|Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)
10015915|NCT01685866|Other|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
10015916|NCT01685866|No Intervention|no medical device|in the second arm, we use no medical device
10015917|NCT01685879|Experimental|High Amylose Rice 1|Test rice with high dietary fiber content
10015918|NCT01685879|Experimental|High Amylose Rice 2|Test rice with high dietary fiber content
10015919|NCT01685879|Placebo Comparator|Control Rice|Rice portion that contains 50 g carbohydrate.
10015920|NCT01685879|Placebo Comparator|Glucose beverage|Glucose beverage with 50 g carbohydrate
10015921|NCT01685892|Experimental|Dose-Finding: Schedule A: Relapsed/Refractory CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
10015922|NCT01685892|Experimental|Dose-Finding: Schedule B: Relapsed/Refractory CLL|In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
10015923|NCT01685892|Experimental|Dose-Finding: Schedule A: Previously Untreated CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
10015924|NCT01685892|Experimental|Dose-Finding: Schedule B: Previously Untreated CLL|In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
10015925|NCT01685892|Experimental|Safety Expansion: Relapsed/Refractory CLL|In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
10015926|NCT01685892|Experimental|Safety Expansion: Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
10015927|NCT01685931|Experimental|Paliperidone Palmitate|
10015928|NCT01685944|Placebo Comparator|Placebo|
10015929|NCT01685944|Experimental|Live Pediococcus pentosaceus LP28|
10015930|NCT01685944|Experimental|Heat-killed Pediococcus pentosaceus LP28|
10015931|NCT01685957|Active Comparator|Standard dietary treatment (STD)|Dietary treatment - 6 individual sessions with a registered dietitian
10015932|NCT01685957|Experimental|"Ned i vaegt (NIV)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
9518085|NCT03300063|No Intervention|control|Standard Medical care
10015933|NCT01685957|Experimental|"Verdens bedste kur (VBK)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
10015934|NCT01685970|Placebo Comparator|High volume Split-dose PEG|Patients who are scheduled afternoon colonoscopy ingest high volume split-dose PEG for bowel preparation
10015935|NCT01685970|Active Comparator|2 sachets of picosulfate|Patients who are scheduled afternoon colonoscopy ingest 2 sachets of picosulfate at the day of colonoscopy.
10015936|NCT01686009|Experimental|Intra-nasal ketamine|0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary
10015937|NCT01686022||Pollen Allergy|Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
10015938|NCT01686061||Blepharospasm Survey Group|
10015939|NCT01686074||Chronic fatigue syndrome|
10015940|NCT01686074||fibromyalgia|
10015941|NCT01686074||chronic fatigue syndrome + fibromyalgia|
10015942|NCT01686074||healthy sedentary control|
10015943|NCT01686087|Active Comparator|Continuation of SRI|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to stay on SRI. They will receive 45 minute EX/RP booster sessions once per month.
10015944|NCT01686087|Placebo Comparator|Replace SRI w/placebo|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to gradual replacement with pill placebo. They will receive 45 minute EX/RP booster sessions once per month.
10015945|NCT01686100|Active Comparator|No touch vein grafts|The grafts were harvested with there surrounding tissues.
10015946|NCT01686100|Active Comparator|Conventional vein grafts.|The grafts were stripped from surrounding tissue.
10015947|NCT01686113|Experimental|NEFA|Participants swish and spit 5 mL of an oleic acid solution everyday for 10 days.
10015948|NCT01686113|Active Comparator|Control|Participants swish and spit 5 mL of sucrose solution everyday for 10 days.
10015949|NCT01686126|Experimental|Mirena + Metformin|Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
10015950|NCT01686126|Experimental|Mirena|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
10015951|NCT01686126|Experimental|Mirena + Weight Loss Intervention|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers
10015952|NCT01686139|Experimental|ABDM-MSC|"The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).~Maximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
10015953|NCT01686178|Experimental|Anti-smoking social marketing campaign|"In prior research, a high risk subpopulation of young adults was identified in San Diego, CA: the hipster subculture. We developed a yearlong pilot social branding intervention to decrease smoking among this group, using social events and social leaders to promote a strong nonsmoking lifestyle. The intervention rationale is based on utilizing industry market research tools to define the target audience and directly countering tobacco industry lifestyle marketing strategies. We now propose to extend this intervention to three other cities (tailoring the intervention to a high-risk subpopulation of young adults in each city) and evaluate it in a multicenter quasi-experimental controlled trial."
10015954|NCT01686178|No Intervention|Control|Survey research data will be collected in control cities with the same schedule as data collection in the cities where the intervention is taking place.
10015955|NCT01686191||Cardiac transplant recipients|
10015956|NCT01686204|Active Comparator|Non-obese individuals|Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.
10015957|NCT01686204|Experimental|Obese individuals|Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.
10015958|NCT01686217|Experimental|Dose Group 1 Treatment A|Lowest per tablet dose of ASP015K Extended Release (ER) tablets under fasted conditions
10015959|NCT01686217|Active Comparator|Dose Group 1 Treatment B|Medium per tablet dose ASP015K Immediate Release (IR) tablets under fasted conditions for comparison to lowest dose ER fasted conditions
10015960|NCT01686217|Experimental|Dose Group 1 Treatment C|Lowest per tablet dose of ASP015K ER tablets under fed conditions
10015961|NCT01686217|Experimental|Dose Group 2 Treatment D|Medium per tablet dose of ASP015K ER tablets under fasted conditions
10015962|NCT01686217|Active Comparator|Dose Group 2 Treatment E|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to medium dose ER fasted conditions
10015963|NCT01686217|Experimental|Dose Group 2 Treatment F|Medium per tablet dose of ASP015K ER tablets under fed conditions
10015964|NCT01686217|Experimental|Dose Group 3 Treatment G|Highest per tablet dose of ASP015K ER tablets under fasted conditions
10015965|NCT01686217|Active Comparator|Dose Group 3 Treatment H|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to highest dose ER under fasted conditions
10015966|NCT01686217|Experimental|Dose Group 3 Treatment I|Highest dose of ASP015K ER tablets under fed conditions
10015967|NCT01686230|Experimental|acupoints on specific meridian|Acupuncture plus foundation treatment。 We Select specific acpupoints on the heart and pericardium meridian.
10015968|NCT01686230|Active Comparator|acupoints on the other meridian|Acupuncture plus foundation treatment。We choose the acupoints on the other meridian。
10015969|NCT01686230|Sham Comparator|sham acupoints|Acupuncture plus foundation treatment。We use sham acupoints。
10015970|NCT01686230|Other|waiting-list|wait for the treatment，Only basic treatment, We will not treat the participants until they complete all the observations.
10015971|NCT01686243|Experimental|"echogenic 17G tuohy needles  Pajunk TuohySono"|Epidural will be placed with the aid of ultrasound and echogenic 17G Tuohy needles (Pajunk TuohySono).
10015972|NCT01686243|Placebo Comparator|standard epidural needles|Epidural will be placed in standard practice with standard needles.
10015973|NCT01686256|Experimental|Tc 99m EC20|A Phase 1, multi-center, open-label, single-treatment group, baseline-controlled (for safety) study designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation.
10015974|NCT01686282|Placebo Comparator|Placebo|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
10015975|NCT01686282|Experimental|Blueberry|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
10015976|NCT01686295|Experimental|iRestore Hair Rejuvenation System|Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
10015977|NCT01686295|Sham Comparator|Sham Device Arm|This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
10015978|NCT01686308|Active Comparator|Conventional Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
10015979|NCT01686308|Experimental|Yellow Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
10015980|NCT01686321|Experimental|Bendamustine and subcutaneous Rituximab|single-arm non randomized
10015981|NCT01686334|Experimental|DC vaccine|Vaccination with autologous WT1 mRNA-electroporated DCs plus follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment in combination with DC vaccination.
10015982|NCT01686334|No Intervention|Control arm|Follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment during the follow-up care
10015983|NCT01686347|Other|fetal cardiac rhythm abnormally|patient at term, in spontanous labor with fetal cardiac rythm abnormally which occurs 30 minutes after the epidural analgesia induction
10015984|NCT01686347|Other|control group|patient at term, spontaneous labor, without any fetal cardiac rhythm abnormalies during the 30 minutes after the epidural analgesia induction
10015985|NCT01686360|No Intervention|Control group 1: pre/post-test|Group receives pre and post test questions only.
10015986|NCT01686360|Experimental|Control group 2: tool and pre/post-test|Group receives decision tool without personalized information. (Behavioral: Decision Aid)
10015987|NCT01686360|Experimental|Gail score in a percentage format|Group receives Gail score in a percentage format. (Behavioral: Decision Aid)
10015988|NCT01686360|Experimental|Gail score in a frequency format|Group receives Gail score in a frequency format. (Behavioral: Decision Aid)
10015989|NCT01686360|Experimental|Frequency + Average 50 year old|Group receives Gail score in a frequency format as well as information about risk of breast cancer for the average 50 year old woman. (Behavioral: Decision Aid)
10015990|NCT01686360|Experimental|Frequency + Mammography Data|Group receives Gail score in a frequency format as well as information about the risks of mammography. (Behavioral: Decision Aid)
10015991|NCT01686360|Experimental|Frequency + Mortality Data|Group receives Gail score in a frequency format as well as information about mortality benefit of mammography. (Behavioral:Decision Aid)
10015992|NCT01686360|Experimental|Frequency + Avg 50 year old + Mamm Data + Mortality Data|Group receives Gail score in a frequency format as well as information about breast cancer risk for the average 50 year old woman, information about the risks of mammography, risk of breast cancer for the average 50 year old woman, and information about the mortality benefit associated with mammography. (Behavioral: Decision Aid)
10015993|NCT01686386|Experimental|Dose escalation benda lena dexa|"Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.~Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days."
10015994|NCT01686399|Experimental|The study has a single arm|The study has one arm The whole population of the campus will be exposed to the intervention. the effectiveness will be assessed using a random selection twice - before and after the intervention
10015995|NCT01686412|Active Comparator|Healthy patients|
10015996|NCT01686412|Active Comparator|Oncology patients|
10015997|NCT01686425|Active Comparator|Percutaneous Transhepatic cholangiography|
10015998|NCT01686425|Active Comparator|Endoscopic Ultrasound guided biliary drainage|
10015999|NCT01686464|Experimental|Magnetic - Oxygen|Magnetic and Oxygen Treatment for Bell's Palsy
10016000|NCT01686464|Active Comparator|prednisone - valacyclovir|prednisone and valacyclovir treatments for bell palsy
10016001|NCT01686477|Active Comparator|Unfortified Human Donor Milk|Used to make up any shortfall in mother's own milk
10016002|NCT01686477|Active Comparator|Fortified Human Donor Milk|Used to make up any shortfall in mother's own milk
10016003|NCT01686477|Active Comparator|Preterm Formula|Used to make up any shortfall in mother's own milk
10016004|NCT01686490|Other|D.|The focus is evaluation of LifeSkills Video/Workbook for patients about to receive an AICD. Patients who now have received their AICD were given a video/workbook pre-implantation as an intervention to reduce their concerns/distress. After implantation, they will be asked what was and was not helpful about the materials they received.
10016005|NCT01686529|Experimental|One subconjunctival injection|Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
10016006|NCT01686529|Experimental|Two subconjuctival injections|Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
10016007|NCT01686529|Active Comparator|Conventional treatment|Autoconjunctival grafting without subconjuntival bevacizumab injection
10016008|NCT01686542|Experimental|CPVI+RSM group|Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.
10016009|NCT01686542|Active Comparator|CPVI group|Circumferential pulmonary vein isolation is done alone for atrial fibrillation.
10016010|NCT01686555|Experimental|Single Dose|Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
10016011|NCT01686555|Experimental|Multiple Dose|Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)
10016012|NCT01686594|Active Comparator|PUVA maintenance treatment|Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
10016013|NCT01686594|No Intervention|No maintenance treatment|observation
10016014|NCT01686607||1) parenteral micafungin users|patients who had been treated with parenteral micafungin
10016015|NCT01686607||2) other parenteral antifungal users|patients who had been treated with a parenteral antifungal agent (not micafungin)
9518086|NCT03300063|Active Comparator|Low Flow Nocturnal Oxygen|This group will receive standard medical care as well as low flow oxygen during sleep.
9665249|NCT05125562|Experimental|10ml ExoFlo|10ml ExoFlo + 90ml normal saline
9665250|NCT05125562|Experimental|15ml ExoFlo|15ml ExoFlo + 85ml normal saline
9665251|NCT05124379|Other|Hemoclin Gel|
9665252|NCT05121805|Experimental|EMR plus snare tip soft coagulation|Post procedural prophylactic coagulation of the entire margin of the resection site creating a 2-3mm rim.
10016016|NCT01686659|Experimental|SpHb Arm|These are the patients whose primary anesthesiologists have been allocated to treat them while having access to data from a continuous noninvasive hemoglobin monitoring device
10016017|NCT01686659|No Intervention|Control Arm|These are the patients whose primary anesthesiologists have been allocated to treat them without having access to data from a continuous noninvasive hemoglobin monitoring device
10016018|NCT01686672|Experimental|Web Intervention|BeInCharge has two components: an electronic diet tracker and a 7 session intervention. The 7 treatment sessions are designed to be completed over a 7 to 10 week period. Each treatment module includes both a nutrition education and child behavior management component. Treatment sessions should be completed every 7 to 10 days, while the electronic diet tracker requires daily input.
10016019|NCT01686672|No Intervention|Usual Care|Participants will receive usual care and be assessed at baseline and week 10 for study outcomes.
10016020|NCT01686698|Active Comparator|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) sachets containing 450 x 109 bacteria, 1 sachet every 12 hours during 3 months (n=20).
10016021|NCT01686698|Placebo Comparator|Placebo|Placebo sachets, 1 sachet every 12 hours during 3 months (n=20).
10016022|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 15 mg|
10016023|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 30 mg|
10016024|NCT01686711|Placebo Comparator|SYR-322 25 mg , AD-4833 placebo|
10016025|NCT01686724|Other|Business as Usual (BAU)|This group receives services as usual in their schools. They will receive the intervention after follow-up measures are gathered.
10016026|NCT01686724|Experimental|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
10016027|NCT01686737|Experimental|Yoga|"Iyengar Yoga~12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
10016028|NCT01686737|Active Comparator|Aerobic exercise|"Walking~12 weeks of walking~2 weekly sessions of 60 minutes"
10016029|NCT01686737|No Intervention|Usual Care|
10016030|NCT01686763||subarachnoid hemorrhage disease|subarachnoid hemorrhage patients
10016031|NCT01686776|Active Comparator|123 I-HSA + 125 I-HSA|Healthy Volunteers, N=16
10016032|NCT01686776|Experimental|123 I- HSA + 125 I-HSA|Patients, planned for elective Major Abdominal Surgery, N=16
10016033|NCT01686776|Experimental|123-I-HSA+125 I-HSA|Patients, with a acute pancreatitis or cholecystitis, N=16
10016034|NCT01686789|Active Comparator|Pegylated interferon alpha-2a plus standard dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus standard dose ribavirin 100-1200 mg/day for 48 weeks
10016035|NCT01686789|Experimental|Pegylated interferon alpha-2a 180 mcgs adjusted dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus adjusted dose ribavirin for 48 weeks
10016036|NCT01686802|Active Comparator|ibuprofen|ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
10016037|NCT01686802|Active Comparator|oral morphine|oral morphine 0.5 mg/kg (max 20 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
10016038|NCT01686815||Olanzapine|Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
10016039|NCT01686815||Risperidone|Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
10016040|NCT01686815||Iloperidone|Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
10016041|NCT01686841|Experimental|Fat Reduction|
10016042|NCT01686854|Experimental|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
10016043|NCT01686854|Active Comparator|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
10016044|NCT01686867|Experimental|Commercially-made followed by locally-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. Four months later the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
10016045|NCT01686867|Experimental|Locally-made followed by commercially-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. Four months later the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
10016046|NCT01686880|Experimental|Preoperative aTARE|The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery
10016047|NCT01686893|Active Comparator|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
10016048|NCT01686893|Active Comparator|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
10016049|NCT01686906|Experimental|Bowman layer graft implantation|
10016050|NCT01686919|Experimental|milk-free|morbidly obese patients with irritable bowel syndrome (IBS) eligible for gastric bypass surgery
10016051|NCT01686945|Experimental|Healthy - 20 mg|
10016052|NCT01686945|Experimental|Healthy - 40 mg|
10016053|NCT01686945|Experimental|Healthy - 60 mg|
10016054|NCT01686945|Experimental|T2D - 20/40/60 mg|
10016055|NCT01686971||questionaire|patients will receive a questionaire and speak to a nurse regarding their needs and/ or demands.
9665253|NCT05121805|No Intervention|Standard EMR|No prophylactic coagulation
9665254|NCT05121649||Before|Injured patients included in the study from health trusts where video streaming not yet has been implemented in the EMCC
10016056|NCT01686984|Experimental|Altered breath|The group where the investigators alter the inspiratory and expiratory aspects of a ventilated breath.
10016057|NCT01686997|Active Comparator|Primairy long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic Limb 150 cm
10016058|NCT01686997|Active Comparator|Redo Long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic limb 150 cm
10016059|NCT01686997|Active Comparator|Primairy standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
10016060|NCT01686997|Active Comparator|Redo standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
10016061|NCT01687023||Tai Chi|Healthy Tai Chi practitioners
10016062|NCT01687049|Experimental|red yeast rice (RYR)|Two RYR capsules three times daily for a minimum of 6 months
10016063|NCT01687062|Active Comparator|FeSO4 + high phytate|injera test meal 1 labeled with a 4 mg staple iron isotope tag
10016064|NCT01687062|Experimental|FeSO4 + medium phytate|injera test meal 2 labeled with a 4 mg staple iron isotope tag
10016065|NCT01687062|Experimental|FeSO4 + low phytate|injera test meal 3 labeled with a 4 mg staple iron isotope tag
10016066|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:1) + high phytate|injera test meal 4 labeled with a 4 mg staple iron isotope tag
10016067|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:3) + high phytate|injera test meal 5 labeled with a 4 mg staple iron isotope tag
10016068|NCT01687075|Experimental|CR8|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
10036017|NCT01811836|Experimental|Resistant Starch|"Oral and intravenous zinc stable isotopes. Zinc: 67Zn (>97% enrichment),68Zn (>99% enrichment) and 70Zn (>95% enrichment) Days 1 and 38: children will be administered 40-75 μg of 67Zn through consumed food. At the end of these days, children will be given an intravenous injection of an accurately measured quantity of ~800 μg of 68Zn.~Days 3-35: resistant starch feeding -- which will be given to mothers and integrated into the food."
10036018|NCT01811849|Experimental|BIOD-238|Subcutaneous injection
10036019|NCT01811849|Experimental|BIOD-250|Subcutaneous injection
10036020|NCT01811849|Active Comparator|Humalog|Subcutaneous injection
10036021|NCT01811888||Patients with knee osteoarthritis|
10036022|NCT01811901|Active Comparator|Intervention group (SITS-WATCH centers)|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
10036023|NCT01811901|No Intervention|Control group (non SITS-WATCH centers in SITS registry)|Centres that do not use 15-item list of suggested interventions aiming to reduce DNT.
10036024|NCT01811914|Experimental|intraoperative TTE|TTE if a hemodynamic instability occurs
10036025|NCT01811927|Experimental|PRO-Kinetic Energy Stent|PRO-Kinetic Energy Stent
10036026|NCT01811966|Sham Comparator|Control|preoperative none substitution of i.v. fluids.
10036027|NCT01811966|Active Comparator|Volume|preoperative substitution of a defined amount of i.v. fluids (8 ml/kg RingerAcetate solution for 15 min prior to introduction of anesthesia).
10036028|NCT01811979|Active Comparator|oral sucrose solution|local anesthetic eye drops (Alcaine 0.5% drop) and a pacifier, plus 0.5 cc/kg of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity will be given
10036029|NCT01811979|Placebo Comparator|steril water|steril water 0,5 cc/kg plus topical anesthetics (Alcaine %0.5 damla) before eye examination will be given
10036030|NCT01811992|Experimental|Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:~A= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^9 vp~B= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^9 vp~C= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^10 vp~D= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^10 vp~E= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^11 vp~F= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^11 vp~Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation."
10036031|NCT01812018|Experimental|Endostar|Endostar, Gemcitabine, Docetaxel
10036032|NCT01812031|Experimental|Lung nodules|"Medical imaging intervention applied on patients included in the trial"
10036033|NCT01812070|Experimental|ACT|Acceptance & Commitment Therapy
10036034|NCT01812070|Active Comparator|CBT|Cognitive Behavioral Therapy
10036035|NCT01812096|Experimental|the pharmacokinetic of bortezomib|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of subcutaneous administration of bortezomib
10036036|NCT01812096|Active Comparator|Intravenous|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of intravenous administration of bortezomib
10036037|NCT01812122|Experimental|Glimepiride|Starting with Glimepiride. After 3 month, switching to vildagliptin.
10036038|NCT01812122|Experimental|Vildagliptin|Starting with vildagliptin. After 3 month, switching to Glimepiride.
10036039|NCT01812135|Experimental|Group 1: 400U EV71 vaccine without adjuvant|60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
10036040|NCT01812135|Experimental|Group 2: 400U EV71 vaccine without adjuvant|60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
10036041|NCT01812135|Experimental|Group 3: 400U EV71 vaccine with adjuvant|60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
10036042|NCT01812148||Peritoneal Mesotheliomas|Cytoreductive surgery and HIPEC
10036043|NCT01812161|Active Comparator|Acupuncture protocol 1|Acupuncture protocol 1：participants will receive treatment (acupuncture protocol 1, real acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
9518087|NCT03300011|Experimental|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
10016069|NCT01687127|Experimental|Folic acid supplementation|Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
10016070|NCT01687127|Experimental|5-MTHF supplementation|"The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name Metafolin) will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism."
10016071|NCT01687140|Placebo Comparator|Placebo|Participant takes one pill of placebo a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
10016072|NCT01687140|Active Comparator|DCS|Participant takes one pill of D-Cycloserine a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
10016073|NCT01687192|Experimental|Girls and young womens receiving immunosuppressive treatment|
10016074|NCT01687205|Active Comparator|Group 1|Single Dose/1 hour before and 1 hour after sex (BAT) Cohort
10016075|NCT01687205|Active Comparator|Group 2|Multiple Dose Cohort
10016076|NCT01687231|No Intervention|Neutropenic Diet|This arm is the control and subjects will receive the standard of care neutropenic diet.
10016077|NCT01687231|Experimental|Non-neutropenic Diet|This arm is interventional and subjects will receive a non-neutropenic diet without restriction.
10016078|NCT01687309|Other|Cohort A fed session|GSK2586184 800mg single dose with food
10016079|NCT01687309|Other|Cohort A fasted session|GSK2586184 single dose without food
10016080|NCT01687309|Active Comparator|Cohort B active study medication|GSK2586184 800mg single and twice daily dose for 13 days
10016081|NCT01687309|Placebo Comparator|Cohort B placebo|Placebo-to-match single and twice daily dose for 13 days
10016082|NCT01687322||total hip replacement, quality of life, functioning|
10016083|NCT01687335||cancerous patients|the patients benefiting from treatment by chemotherapy.
10016084|NCT01687348|Experimental|lidocaine|lidocaine traitment
10016085|NCT01687361|Experimental|branched-chain amino acids (BCAA) supplementation|
10016086|NCT01687361|Placebo Comparator|PLACEBO|
10016087|NCT01687374|Placebo Comparator|Placebo|
10016088|NCT01687374|Experimental|Parathyroid hormone|
10016089|NCT01687426|Active Comparator|Brimonidine Tartrate 0.025%|
10016090|NCT01687426|Placebo Comparator|Vehicle|
10016091|NCT01687439|Experimental|Treatment|Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment.
10016092|NCT01687452|Experimental|Groupe A|Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load > 1000 copies / ml
10016093|NCT01687452|Experimental|group B|Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load > 40 copies / ml
10016094|NCT01687452|Placebo Comparator|group C|Healthy volunteers
10016095|NCT01687465|Active Comparator|Argon laser trabeculoplasty|Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
10016096|NCT01687465|Active Comparator|selective laser trabeculoplasty|Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
10016097|NCT01687491|Active Comparator|Enoxa|ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
10016098|NCT01687491|Active Comparator|Lovenox|LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
10016099|NCT01687517|Experimental|Patient|90 patients suffering from sarcoidosis
10016100|NCT01687517|Active Comparator|Volunteer|100 volunteers
9518088|NCT03300011|No Intervention|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
9518089|NCT03300011|No Intervention|OMT|Patients with CTO lesion optimal medicine treatment without PCI
9518090|NCT03299998||BLOCK+|Patients who underwent maxillary and mandibulary block before surgery
10016101|NCT01687530|Experimental|AMCA bone membrane|AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
10016102|NCT01687543|Experimental|Probiotics|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
10016103|NCT01687543|Placebo Comparator|Control|Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
10016104|NCT01687556|Active Comparator|Topical EGCG 1%|Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
10016105|NCT01687556|Experimental|topical EGCG 5%|Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
10016106|NCT01687569|Placebo Comparator|Control Cracker|Base cracker snack
10016107|NCT01687569|Experimental|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
10016108|NCT01687569|Experimental|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
10016109|NCT01687582|Experimental|GLP-1 analog|Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
10016110|NCT01687621||Neonates, 1 to 10 days old|Neonates between day 1-10 of life presenting to hospitals and community health centers in Southern Province, Zambia, with no prior diagnosis of omphalitis, whose guardian, aged 15 and above, is willing to allow their newborn to participate in the study.
10016111|NCT01687634|Experimental|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
10016112|NCT01687634|Experimental|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
10016113|NCT01687647|Other|Screening|Paired-design: low-dose CT scan, sputum sample and blood test will be performed on all subjects.
10016114|NCT01687660|Experimental|acupoint-meridian group|Apply traditional acupuncture to prevent the migraine attack according to TCM theory
10016115|NCT01687660|Other|sham-acupoint group|sham-acupoint will be penetrated for migraine prophylaxis.
10016116|NCT01687660|No Intervention|waiting list|No acupuncture nor other methods will be conducted in this group.
10016117|NCT01687686||All cohort|Initially healthy patients in General Practise Research Database (GPRD) meeting the inclusion criteria at any point between 1st January 2001 and 25th March 2010
10016118|NCT01687699|Experimental|spironolactone|
10016119|NCT01687725||Renal denervation|Renal denervation using Symplicity Catheter system
10016120|NCT01687738|Experimental|Communication Intervention|Specially trained communicator addresses factual understanding and elicits other barriers to care
10016121|NCT01687738|Experimental|Real Time Registry and data feedback only|Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
10016122|NCT01687751|Experimental|Dexmedetomidine|Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
10016123|NCT01687751|Active Comparator|Midazolam|Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
10016124|NCT01687764|Experimental|CBGT+ABMT(active)|
10016125|NCT01687764|Experimental|CBGT+ABMT(placebo)|
10016126|NCT01687764|Experimental|PCI+ABMT(active)|
10016127|NCT01687764|Placebo Comparator|PCI+ABMT(placebo)|
10016128|NCT01687777|Active Comparator|Mesenchymal stem cells (MSCs)|Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)
10016129|NCT01687777|Placebo Comparator|OrthADAPT|Membrane of collagen type I (OrthoADAPT)
10016130|NCT01687803|Experimental|Physical Activity|Physical activity intervention will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
10016131|NCT01687803|Other|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
10016132|NCT01687816||No interventions to be administered|Only a nasal swab is collected, no therapeutic interventions
10016133|NCT01687829||ILM-on group|patients were scheduled to undergo macular hole surgery without internal limiting membrane (ILM) peeling
10016134|NCT01687829||ILM-off group|patients were scheduled to undergo macular hole surgery with internal limiting membrane (ILM) peeling
10016135|NCT01687842||Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
10016136|NCT01687855||OSAHS group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
10016137|NCT01687855||normal group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
10016138|NCT01687868|Experimental|dexmedetomidine continuous infusion|
10016139|NCT01687881|Sham Comparator|Sham Chiropractic|Sham Chiropractic manipulative therapy.
10016140|NCT01687881|No Intervention|Control group|No intervention: Control group.
10016141|NCT01687881|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active intervention: Chiropractic Spinal Manipulative Therapy
10016142|NCT01687894||Vasopressins & propofol|Administer vasopressin 0.05 or 0.07 IU/kg before sitting position during propofol anesthesia.
10016143|NCT01687894||Placebo & propofol|Administer saline 10 ml (placebo) 2 min before beach chair position during propofol anesthesia
10016144|NCT01687894||Vasopressins & sevoflurane|Administer vasopressin 0.05 or 0.07 IU/kg 2 min before beach chair position during sevoflurane anesthesia
9518091|NCT03299998||BLOCK -|Patients who did not undergo maxillary and mandibulary block before surgery.
10016145|NCT01687894||Placebo & sevoflurane|Placebo (saline 10 ml) for vasopressin is administered 2 min before beach chair position during sevoflurane anesthesia
10016146|NCT01687907|Active Comparator|Fear of childbirth, music|Patients referred to the motherhood out-patient clinic because of fear of childbirth. Advised to active music listening. Followed up by weekly and monthly diaries and three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
10016147|NCT01687907|No Intervention|Fear of childbirth, control|Patients referred to the motherhood out-patient clinic because of fear of childbirth. No intervention. Followed up by three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
10016148|NCT01687907|Active Comparator|Nulliparous, music|300 nulliparous women recruited from the ultrasound screening. Advised to active music listening. Three questionnaires like the other arms, weekly and monthly diaries like the other music group. Screening questionnaires about fear of childbirth.
10016149|NCT01687907|No Intervention|Nulliparous, control|300 nulliparous women recruited from ultrasound screening. No intervention. 3 Questionnaires as all the other groups. Screening questionnaire about fear of childbirth.
10016150|NCT01687933|Experimental|three-dimensional glasses (Virtual Reality glasses)|Women in case group used the glasses for 30 minutes
10016151|NCT01687933|Experimental|usual care|Women in control group did not use the glasses.
10016152|NCT01687946||Pulmonary fibrosis in aged individuals|"Group A and B:~Patients with UIP (histologically and/or radiologically proven) providing informed consent. According to functional and radiological assessment, the disease may be either limited (Group A) or advanced (Group B). The patients are usually older than 55 years."
10016153|NCT01687946||Pulmonary fibrosis and inflammation|"Groups C and D:~Patients with HP (histologically and radiologically proven) providing informed consent. According to functional and radiological assessment, the disease will be either acute or chronic. The patients will be significantly younger (mean > 10 years) than in groups A and B."
10016154|NCT01687946||Regular wound healing in lung|Patients receiving lung biopsy or bronchoscopy for reasons other that the study and volunteers providing informed consent. The group will consist of young (18-40 years) and old individuals (older than 55 years).
10016155|NCT01687959|Active Comparator|activity of peritoneal fibrinolysis|measurements of peritoneal fibrinolysis using tissue-type plasminogen activator and its specific activity, urokinase-type plasminogen activator, and plasminogen activator inhibitor type 1
10016156|NCT01687959|Active Comparator|surgical outcomes|surgical outcomes of laparoscopic cholecystectomy
10016157|NCT01688011||Lower-Risk Myelodysplastic Syndromes (LR MDS)|Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
10016158|NCT01688011||Higher-Risk Myelodysplastic Syndromes (HR MDS)|Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
10016159|NCT01688011||Acute Myeloid Leukemia (AML)|Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
10016160|NCT01688011||Myelofibrosis (MF)|Newly treated MF patients receiving treatment for MF or MF-related cytopenias. This cohort also includes patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, excluding juvenile myelomonocytic leukemia (JMML).
10016161|NCT01688011||Idiopathic cytopenia of undetermined significance (ICUS)|Newly diagnosed ICUS patients.
10016162|NCT01688024|Experimental|Mitomycin C|Up to 10 mg administered during each standard of care endoscopic retrograde cholangiography. No more than five mitomycin C applications per every twelve months will be given.
10016163|NCT01688024|Placebo Comparator|Normal saline|Given during each standard of care endoscopic retrograde cholangiography. No more than five normal saline applications per every twelve months will be performed.
10016164|NCT01688089|Experimental|ODM-103|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
10016165|NCT01688089|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
10016166|NCT01688089|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
10016167|NCT01688115|Experimental|Procedure|
10016168|NCT01688115|Active Comparator|Standard Care|
10016169|NCT01688128|Experimental|Intervention_Control group|Phase I: U-SMART for 4 weeks (2 session/week); Washout: for 2 weeks; Phase II: No intervention for 4 weeks
10016170|NCT01688128|Experimental|Control_Intervention group|Phase I: No intervention for 4 weeks; Washout: for 2 weeks; Phase II: U-SMART for 4 weeks (2 session/week)
9518092|NCT03299985|Experimental|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
10016171|NCT01688154|Active Comparator|Product 1|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)
10016172|NCT01688154|Placebo Comparator|Control product|2 empty capsules
10016173|NCT01688167|Experimental|Intervention|Experimental condition clinics offer the MC and sexual risk reduction intervention: four group counseling sessions focused on male circumcision and sexual risk reduction.
10016174|NCT01688167|No Intervention|Standard of Care|"Male participants in the standard of care control condition CHCs will receive counseling per the VCT protocol guidelines. Participants will attend four video-based time-equivalent attention-control group sessions on endemic disease prevention strategies (e.g., TB, malaria, cholera, waterborne diseases). Female partners will be invited to participate in a similar four session program devoted to endemic disease risk reduction."
10016175|NCT01688167|No Intervention|Observational|"3 CHC sites will be randomly assigned as observation only; only aggregated clinic VCT and circumcision data will be collected."
10016176|NCT01688193||HCP 1004|
10016177|NCT01688193||Vimovo 500/20mg|
10016178|NCT01688206|Experimental|Vanucizumab|Participants will receive escalating doses of vanucizumab and fixed dose of vanucizumab, intravenously every 2 weeks.
10016179|NCT01688206|Experimental|Vanucizumab + Atezolizumab|Participants will receive fixed dose of vanucizumab along with atezolizumab, intravenously every 2 weeks.
10016180|NCT01688245|No Intervention|Control|No SMS dialog
10016181|NCT01688245|Active Comparator|SMS Assessments|Weekly post-weekend drinking outcome assessments
10016182|NCT01688245|Experimental|SMS Assessments & Feedback|Weekly pre-weekend drinking intention & post-weekend drinking outcome assessments with personalized feedback and harm-reduction support
10016183|NCT01688271||Anesthesiologists|
10016184|NCT01688284|Active Comparator|No treatment|patients with recurrent miscarriages
10016185|NCT01688284|Active Comparator|OFFICE HYSTEROSCOPY|Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle
10016186|NCT01688297|Experimental|Low Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
9518093|NCT03299985|Sham Comparator|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
9518094|NCT03299972|Placebo Comparator|Control|
9518095|NCT03299972|Experimental|Whey Protein|
10016187|NCT01688297|Placebo Comparator|VXA Placebo Tablet|Oral tablets of the same size and number as the vaccine tablet doses. Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
10016188|NCT01688297|Experimental|Medium Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet
10016189|NCT01688297|Experimental|High Dose VXA-A1.1 Oral Vaccine|One dose of replication incompetent adenovirus given in an oral tablet dose. This dose was studied under protocol VXA02-003.
10016190|NCT01688323||Elderly Chemorads|Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
10016191|NCT01688349|Experimental|Cushing group|AT biopsy during partial nephrectomy
10016192|NCT01688349|Other|Controls1|normal weight metabolic healthy patients having partial nephrectomy with small AT Biopsy.
10016193|NCT01688349|Other|Controls2|obese individuals already included and having biopsies of VAT and SCAT stocked.
10016194|NCT01688362|Experimental|platelet-rich plasma protein (PRP)|Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
10016195|NCT01688362|Active Comparator|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.
10016196|NCT01688375|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid administration UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
10016197|NCT01688388|Experimental|IORT Arm|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
10016198|NCT01688401|Experimental|IA melphalan|IA melphalan is administered via the basilar artery.
9518096|NCT03299972|Experimental|Resistance Exercise + Control|
10016199|NCT01688414|Experimental|Diagnostic (fluorescence imaging, PAI)|Patients undergo fluorescence imaging and PAI during robot assisted laparoscopic surgery.
10016200|NCT01688427|Experimental|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper.
10016201|NCT01688427|Experimental|Standard DOVE intervention|The standard DOVE intervention has already been developed and tested (NR009093). The standard DOVE intervention is a brochure based 10 minute intervention that the home visitor reviews with the women. It consists of information about IPV, its effects on pregnancy and infant health, community resources and a plan for individual safety options. For the eMOCHA DOVE intervention, the DOVE 10 minute brochure intervention will be converted from the paper format to a visually colorful interactive presentation loaded into the home visitor device using the eMOCHA application. The format will be completely activated and implemented by the women. She uses small ear buds and a touch screen, so how she responds and interacts with the media enhanced eMOCHA DOVE intervention is private.
10016202|NCT01688440|Experimental|#1 Respiratory Care Solution|Low sodium physiologically based airway care solution.
10016203|NCT01688453|Active Comparator|Group 1:|Socially advantaged overweight or obese adolescents are allocated to the standard care management.
9518097|NCT03299972|Experimental|Resistance Exercise + Whey Protein|
10016204|NCT01688453|Experimental|Group 2|Socially less advantaged overweight or obese adolescents are allocated to the standard care management.
10016205|NCT01688453|Experimental|Group 3|Socially less advantaged overweight or obese adolescents are allocated to the strengthened care management.
10016206|NCT01688479|Experimental|Calendula Weleda® cream (Weleda)|Calendula Officinalis (marigold plant) is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
10016207|NCT01688479|Active Comparator|Essex® cream (Schering-Plough)|Essex cream is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
10016208|NCT01688492|Experimental|ipilimumab|This multi-institution open label study has a Phase 1 and Phase 2 component. The Phase 1 dose escalation stage is to establish the tolerability of ipilimumab to be used in combination with the standard clinical dose of abiraterone acetate plus prednisone in chemotherapy and immunotherapy-naïve patients with progressive metastatic CRPC. Due to the overlapping potential hepatic toxicity between abiraterone and ipilimumab, a Lead in Therapy with abiraterone plus prednisone for 2 cycles will assess for adverse events related to the abiraterone plus prednisone. Patients, who tolerate well the Lead in therapy as defined by Grade 1 or less AEs, will pursue Combination Therapy. Patients with AEs Grade ≥ 2 after Lead in Therapy will be excluded and replaced. The Phase 2 stage will assess efficacy and confirm an acceptable safety profile of the recommended dose.
10016209|NCT01688505||Visit-to-visit BP variability|The highest, intermediate, and the lowest visit-to-visit BP variability (Tertile grouping)
10016210|NCT01688518|Active Comparator|Synera® for 30min & Lidoderm® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
10016211|NCT01688518|Active Comparator|Lidoderm® for 30min & Synera® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
10016212|NCT01688531|Experimental|CD0271 0.1%/CD1579 2.5% gel|Split-face design, one application a day for 6 months
9518098|NCT03299946|Experimental|Arm 1|
9518099|NCT03299920|Active Comparator|Intervention|Patients will receive standardized instruction from a study nurse, tailored to understanding pain management after nerve blocks and maximizing utilization of non-opioid analgesics.
10016213|NCT01688531|Placebo Comparator|CD0271 0.1%/CD1579 2.5% gel vehicle|Split-face design, one application a day for 6 months
10016214|NCT01688544|Experimental|Ilaprazole|"Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.~After 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed"
10016215|NCT01688557|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus).
10016216|NCT01688557|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
10016217|NCT01688570|Active Comparator|Duloxetine|Neuromuscular fatigue testing with duloxetine dose
10016218|NCT01688570|Active Comparator|Cyproheptadine|Neuromuscular fatigue testing with cyproheptadine dose
10016219|NCT01688570|Placebo Comparator|Placebo|Neuromuscular fatigue testing with placebo dose
10016220|NCT01688583||Fentanyl matrix|
10016221|NCT01688622|Other|Exercise|obese women who are volunteers for the 3 months exercise programs
10016222|NCT01688648|Experimental|Lidocaine group|a bolus dose of lidocaine 1.5 mg/kg after anesthetic induction with following lidocaine infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
10016223|NCT01688648|Experimental|Dexmedetomidine group|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
10016224|NCT01688648|Experimental|Combined infusion group|Combined lidocaine and dexmedetomidine infusion with the dose specified in single infusion group
10016225|NCT01688648|No Intervention|Control group|The group without infusion of lidocaine or dexmedetomidine
10016226|NCT01688674|Placebo Comparator|Bolus arm|two hourly dextrose boluses administered via an intravenous cannula
10016227|NCT01688674|Experimental|infusion|10% dextrose infusion by burettes
10016228|NCT01688687||Superficial gastric neoplasia|Patients with superficial gastric neoplasia on diagnostic endoscopy, recieved both conventional endoscopic forcpes biopsies and pCLE. All patients were subject to endoscopic resection of the lesion.
10016229|NCT01688700|Experimental|Nimotuzumab plus chemotherapy|
10016230|NCT01688713|Experimental|Icotinib,Brain metastases|
10016231|NCT01688752||Sibling Controls|Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.
10016232|NCT01688752||Acute Lymphoblastic Leukemia Survivors|Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.
10016233|NCT01688765||First Episode Psychosis Patients|
10016234|NCT01688765||Healthy Controls|
10016235|NCT01688778|Experimental|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment.
9518100|NCT03299920|Other|Control|Patient will receive conventional instructions on postoperative pain management.
9518101|NCT03299907||COPD|Subject with FEV1/FVC post BD < 0.7 or LLN
9518102|NCT03299907||Non COPD|Subject with FEV1/FVC post BD >= 0.7 or LLN
10016236|NCT01688778|No Intervention|Standard treatment|Standard diabetes control at a Diabetes Clinic or GP
10016237|NCT01688791|Experimental|Part A: Vintafolide BIW|Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
10016238|NCT01688791|Experimental|Part A: Vintafolide TIW|Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
10016239|NCT01688791|Experimental|Parts B & C: Vintafolide Single Dose & Weekly (QW)|Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
10016240|NCT01688804|Experimental|Behavioral intervention|Behavioral intervention to reduce sedentary time delivered via mobile smartphone
10016241|NCT01688817|Other|Physician's counseling|
10016242|NCT01688817|Active Comparator|Information leaflet|
10016243|NCT01688908|No Intervention|Control Arm|Participants in this arm will not accept the endoscopic screening and only baseline and follow-up interview will be conducted in this arm.
10016244|NCT01688908|Experimental|Screening Arm|Participants in this arm will accept a baseline endoscopic screening, questionnaire investigation and follow-up interview. Subsequent re-examination and further medical services would be arranged among individuals who already have high-grade lesions found at baseline screening.
10016245|NCT01688934|Experimental|V116517 - 50 mg|V116517 50-mg tablets
10016246|NCT01688934|Experimental|V116517 - 30 mg|V116517 30-mg tablets
10016247|NCT01688934|Active Comparator|Naproxen 500 mg|Naproxen 500-mg capsules
10016248|NCT01688934|Placebo Comparator|Placebo|Placebo
10016249|NCT01688947|Experimental|V116517 - 50 mg|V116517 50-mg tablets
10016250|NCT01688947|Experimental|V116517 - 30 mg|V116517 30-mg tablets
10016251|NCT01688947|Active Comparator|Pregabalin|Pregabalin capsules
10016252|NCT01688947|Placebo Comparator|Placebo|Placebo
10016253|NCT01688960|Experimental|Cohort 1|
10016254|NCT01688960|Experimental|Cohort 2|
10016255|NCT01688960|Experimental|Cohort 3a|
10016256|NCT01688960|Experimental|Cohort 3b|
10016257|NCT01688960|Experimental|Cohort 4|
10016258|NCT01689025|Experimental|NNC0114-0006|
10016259|NCT01689025|Placebo Comparator|Placebo|
10016260|NCT01689038|Experimental|Tested product|
10016261|NCT01689051|Active Comparator|Healthy subjects|
10016262|NCT01689051|Active Comparator|Patients with type 2 diabetes|
10016263|NCT01689064|Active Comparator|Posterior Septectomy|Patient will be randomized to a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
10016264|NCT01689064|Experimental|Stamm Approach|Patient will be randomized a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
10016265|NCT01689077|Active Comparator|24 hours hypothermia|24 hours hypothermia
10016266|NCT01689077|Experimental|48 hours hypothermoa|48 hours hypothermia
10016267|NCT01689090|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions at two examination days.
10016268|NCT01689090|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions at two examination days.
10016269|NCT01689116|Experimental|Bardoxolone Methyl 20mg|
10016270|NCT01689116|Experimental|Bardoxolone Methyl 80mg|
10016271|NCT01689116|Placebo Comparator|Bardoxolone Methyl Placebo|
10016272|NCT01689116|Active Comparator|Moxifloxacin|
10016273|NCT01689129|Experimental|New formulation of insulin glargine|once daily in the evening on-top of mealtime insulin
10016274|NCT01689129|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of mealtime insulin
10016275|NCT01689142|Experimental|New formulation of insulin glargine|once daily in the evening on-top of oral antihyperglycemic drug (OADs)
10016276|NCT01689142|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of OADs
10016277|NCT01689168|Experimental|Counseling plus chiropractic adjustments|
10016278|NCT01689168|Active Comparator|Counseling alone|
10016279|NCT01689181||chronic schizophrenic patients|
9665255|NCT05121649||After|Injured patients included in the study from health trusts where video streaming has been implemented in the EMCC
9665256|NCT05121376|Experimental|BMN 331|AAV Gene Therapy Infusion
10016280|NCT01689181||healthy volunteers|
10016281|NCT01689194|Experimental|genexolPM + cisplatin|
10016282|NCT01689220|Experimental|SP-02L|
10016283|NCT01689259|Experimental|SL TNX-102 at 2.4 mg|1 x TNX-102 SL Tablets at 2.4 mg
10016284|NCT01689259|Experimental|SL TNX-102 at 4.8 mg|2 x TNX-102 SL Tablets at 2.4 mg
10016285|NCT01689259|Experimental|SL TNX-102-A at 2.4 mg|1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg
10016286|NCT01689259|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
10016287|NCT01689272|Experimental|Kidney transplantation|Kidney transplantation from alive relative donor.
10016288|NCT01689285|Active Comparator|valacyclovir tablet|Administration of 500 mg once daily on day 1 (group A) or on day 8 (group B)
10016289|NCT01689285|Experimental|valacyclovir oral solution|Administration of 500 mg once daily on day 1 (group B) or on day 8 (group A)
10016290|NCT01689298|Active Comparator|No drug pre-treatment|A control sample from each patient (no uterotonic drug will be applied during pre-treatment) will be measured concurrently with samples pre-treated with oxytocin. Controls will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given oxytocin for pre-treatment.
10016291|NCT01689298|Active Comparator|Drug pre-treatment|A sample from each patient will be pre-treated with oxytocin 10-5mol/L. These samples will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given no drug for pre-treatment (controls).
10016292|NCT01689311|Experimental|Treatment|All samples will undergo dose response treatment (increasing concentrations) of one of the four uterotonic drugs: oxytocin, ergonovine, prostaglandin F2alpha, or misoprostol.
10016293|NCT01689389||Main study population|"All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.~Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months."
10016294|NCT01689389||Schizophrenia SoC sample|Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
10016295|NCT01689389||Bipolar SoC sample|Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
10016296|NCT01689402||Intracerebral Hemorrhage Patients|Patients admitted with acute intracerebral hemorrhage within 72 hours after symptom onset.Patients are included in the study for MRI studies
10016297|NCT01689428||IVF treatment EmbryoGen|Embryo culture in EmbryoGen medium
10016298|NCT01689428||IVF treatment ISM1|Embryo culture in ISM1 medium
10016299|NCT01689454||IVF treatment ISM1|Embryo culture in ISM1 medium
10016300|NCT01689454||IVF treatment EG|Embryo culture in EmbryoGen medium
10016301|NCT01689467|Experimental|Fermented Velvet Antler extract|
10016302|NCT01689467|Placebo Comparator|Placebo|
10016303|NCT01689480||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) can be included in this study.
10016304|NCT01689493|No Intervention|usual care|usual care arm, without SMS reminder
10016305|NCT01689493|Active Comparator|patient education and daily SMS|Multifaceted patient centered intervention including : collaborative care, patient education , and daily SMS.
10016306|NCT01689506|Experimental|Volulyte|Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
10016307|NCT01689506|Active Comparator|Human Serum Albumin|5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)
10016308|NCT01689545|Experimental|Individual level|
10016309|NCT01689545|Experimental|Structural level|
10016310|NCT01689545|Experimental|Combined individual & structural level|
10016311|NCT01689545|Active Comparator|Standard of Care|
10016312|NCT01689558|Experimental|Recombine Endostatin|Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
10016313|NCT01689571|Placebo Comparator|Placebo DPI|Placebo by inhalation for 9 days
10016314|NCT01689571|Experimental|CHF6001 DPI Dose 2|CHF6001 by inhalation for 9 days
10016315|NCT01689571|Experimental|CHF6001 DPI Dose1|CHF6001 by inhalation for 9 days
10016316|NCT01689584|Other|Covar|
10016317|NCT01689597|Active Comparator|Low dose epidural morphine|One dose of 1.25 mg epidural morphine
10016318|NCT01689597|Active Comparator|High dose epidural morphine|One dose of 2.5 mg epidural morphine
10016319|NCT01689597|Placebo Comparator|Saline|One dose of 10 ml saline administered through an epidural catheter
10016320|NCT01689610||Adult female patients with MBC|This is an observational study, no interventions are specified
10016321|NCT01689623|Experimental|Panel I|Each participant will be administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
10016322|NCT01689623|Experimental|Panel II|Each participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
10016323|NCT01689636|Experimental|Single-center, open-label|"The study was designed as a single-center, open-label clinical study to evaluate the safety, pharmacokinetics, dosimetry and metabolism of Tc 99m EC20 in normal volunteers and in patients with known or suspected ovarian cancer.~Eight subjects were to be enrolled at one center: four normal subjects, four patients with ovarian cancer. Each subject was to receive a single injection of Tc 99m EC20 complex composed of 0.1 mg ligand (EC20) and 15 - 20 mCi of Tc 99m. Two (2) of the 4 normal subjects and 2 of the 4 patients were to receive an injection of 0.25-2.0 mg folic acid 1-2 minutes prior to the injection of Tc 99m EC20."
10016324|NCT01689662|Experimental|Tc 99m EC20|"Subjects will receive two intravenous injections 1-3 minutes apart:~1 mg of folic acid~1-2 mL injection of 0.1 mg of EC20 labeled with 15-25 mCi of technetium-99m"
10016325|NCT01689675|Experimental|Computer based pain management|The computer-based self-management program (CBSM) intervention will be administered over 8 sessions during the average 4 week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute CBSM intervention. The primary goals of treatment include developing skills for managing acute injury and related pain including: reducing fear avoidance beliefs and catastrophizing, improving mood, increasing perceptions of control and self-efficacy, maintaining activity and reducing pain. Skills are presented and modeled by computer-based video during sessions, audio will be used to explain models and teach skills such as relaxation training.
10016326|NCT01689675|Active Comparator|Education control|The computer exposure will be administered over 8 sessions during the average 4-week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute control condition. The primary goal of this condition is to provide a control for computer exposure. Briefly, the first session will concentrate on establishing the patient's ability to interact with the computer. The materials will provide general education regarding the injury and methods for preventing re-injury. This condition will not provide teaching and practice of specific pain management and coping management skills. This control computer education activity will equalize the computer exposure of the two groups and the duration of time devoted to injury care.
10016327|NCT01689688||EES-XIENCE V|Groups who were treated with XIENCE V® everolimus eluting stent
10016328|NCT01689714|Experimental|Tc 99m EC20|Patients received 2 intravenous (IV) injections: 1 mg of folic acid (to reduce the uptake of FolateScan in normal tissues), followed 1 to 3 minutes later by 0.1 mg of EC20 labeled with 15 to 25 mCi of technetium-99m (99mTc) over 30 seconds in a total injection volume of 1 to 2 mL.2 Each injection was given as a slow IV push via a free-flowing indwelling IV catheter in an upper extremity vein (i.e., in the antecubital fossa).
10016329|NCT01689727|Other|Technetium Tc 99m EC20|
10016330|NCT01689753|Experimental|TEGO® connector|The TEGO® connector is used during 3 consecutive hemodialyse. After each dialysis session, the dead space of the catheter is flushed with NaCl 0.9%.
10016331|NCT01689753|Active Comparator|Trisodium citrate|After each dialysis, the dead space of the catheter is filled with trisodium citrate 46.7% (Citralock®).
10016332|NCT01689766|Other|Technetium Tc 99m EC20|
10016333|NCT01689792|Active Comparator|CitraFleet|Administration of CitraFleet
10016334|NCT01689792|Experimental|MOVIPREP|Administration of MOVIPREP
10016335|NCT01689805||Patients with atopic dermatitis|
10016336|NCT01689805||Non-atopic controls|
10016337|NCT01689818|Experimental|exercise training|exercise training program which included aerobic exercise for 3 times per week.
10016338|NCT01689818|No Intervention|control|lifestyle counseling
10016339|NCT01689831|Experimental|Aplisol, potency determination|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
10016340|NCT01689831|Active Comparator|Reference standard PPD-S2, reference|Reactivity of Aplisol compared to reference standard PPD-S2.
10016341|NCT01689844|Active Comparator|Behavioral, DASH Plus - Dietary advice|This group will receive DASH diet advice and guided ordering of fruits, vegetables, nuts and beans that are high in potassium from a local supermarket.
10016342|NCT01689844|Other|DASH - C|DASH C Group will receive brief DASH diet advice and will be able to make non- guided purchases of food products from the local supermarket.
10016343|NCT01689870|Experimental|Phase 1 Cohort 1|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
10016344|NCT01689870|Experimental|Phase 1 Cohort 2|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
10016345|NCT01689870|Experimental|Phase 1 Cohort 3|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
10016346|NCT01689870|Experimental|Phase 2 Cohort 4|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5.
10016347|NCT01689883|Other|Current stimulator|The investigators have developed a device to deliver very small currents to the arm. The device will be used while subjects perform upper-limb movements using a device for upper-limb rehabilitation. Subjects will perform multiple trials of movement. During half of the trials, they will receive actual stimulation. During the other half, they will receive sham stimulation.
10016348|NCT01689896|Active Comparator|Testosterone Gel|Testosterone Gel
10016349|NCT01689896|Placebo Comparator|Placebo Gel|Placebo Gel
10016350|NCT01689922||AlterG and Physical therapy|2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
10016351|NCT01689922||Control group|1) Standard postoperative rehabilitation program
10016352|NCT01689935|No Intervention|Control|No drug, no treatment
10016353|NCT01689935|Active Comparator|ALA-PDT|Drug- topical 20% Aminolevulinic acid - ALA followed by red light irradiation - conventional photodynamic therapy -PDT
10016354|NCT01689935|Experimental|i-PDT|Drug - topical 20% Aminolevulinic acid - followed by inhibitory light during incubation time, then red light for photodynamic therapy
10016355|NCT01689935|Active Comparator|Red Light only|Red light only - no drug
10016356|NCT01689935|Active Comparator|Blue light only|Blue light only - no drug
10016357|NCT01689948|Experimental|Home rehabilitation therapy|12 weekly sessions of Home rehabilitation therapy
10016358|NCT01689961|Experimental|Nutrition+Exercise Intervention|"Structured + monitored nutrition and exercise intervention:~The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence"
10016359|NCT01689961|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health services. In addition, they will be asked to attend 2 focus group sessions exploring women's experiences with exercise, nutrition, and weight gain in pregnancy. Women will receive information about healthy pregnancy from Health Canada.
10016360|NCT01689987|Experimental|Treatment (HCQ, sirolimus, cy/dex)|Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
10016361|NCT01690013||Klinefelter|Men with Klinefelter syndrome
10016362|NCT01690013||Control|Men from the general population, matched by age, education and zipcode.
10016363|NCT01690026|Other|Brief intervention|Motivational intervention based brief intervention
10016364|NCT01690026|Other|Standard intervention|Standard intervention condition
10016365|NCT01690039||All study participants|Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
10016366|NCT01690065|Experimental|Nilotinib+AD induction|"Nilotinib plus AD induction chemotherapy~AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)~Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)~Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)"
10016367|NCT01690078||Cross sectional|Cross sectional study where subjects with PRS, micrognathia, or SGS will have a single study visit that will be scheduled within 14 days of a clinically indicated upper airway endoscopy. CT scans of the neck or maxillofacial CT will be obtained in all subjects. During upper airway endoscopy, airway measurements will be conducted. Cohort may include subjects who have previously undergone medical or surgical intervention for their airway obstruction, or who are currently undergoing multidisciplinary team management. The following data will be collected: clinical parameters, Obstructive Sleep Apnea (OSA)OSA-18 (quality of life) questionnaire, and lung function tests (subjects > 4 years of age). Clinically indicated swallowing studies and voice evaluations will be collected.
10016368|NCT01690078||Longitudinal|The prospective, longitudinal cohort arm of the study is designed to describe the effects of treatment on clinical and computational model endpoints. This is performed in a subset of subjects with PRS, micrognathia, or SGS who are scheduled for clinically indicated upper airway endoscopy and who are scheduled to complete a definitive treatment course which necessitates multiple endoscopic evaluations and follow-up imaging. Subjects will have an entry visit comparable to the cross-sectional entry visit. Longitudinal subjects will have up to 3 additional study visits over a 12 to 15-month period.
10016369|NCT01690078||Normal Control Data|Normal de-identified control data is retrospectively collected from clinically indicated CT scans of the neck and maxillofacial CT scans in children less than 18 years of age.
10016370|NCT01690091|Experimental|Metformin|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months
10016371|NCT01690091|Placebo Comparator|Placebo|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months
10016372|NCT01690104|Active Comparator|Rifampicin|Rifampicin 600 mg daily
10016373|NCT01690104|Placebo Comparator|Placebo|Placebo daily
10016374|NCT01690156||Parallel Probe Position|Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
10016375|NCT01690156||Perpendicular Probe Position|Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block
10016376|NCT01690169|Experimental|NNC0113-0987|
10016377|NCT01690169|Placebo Comparator|Placebo|
10016378|NCT01690182|Experimental|Study test meal 1|High volume, high energy density test meal. Volunteers will be given 490 mL of a high energy test meal once in the morning
10016379|NCT01690182|Experimental|Study test meal 2|High volume, low energy density test meal. Volunteers will be given 490 mL of a high volume low energy density test meal once in the morning
10016380|NCT01690182|Experimental|Study test meal 3|A low volume, high energy test meal. Volunteers will be given 140 mL high energy density test meal once in the morning.
10016381|NCT01690195|Experimental|ABT-126|ABT-126 Open-label dose
10016382|NCT01690208|Experimental|EMERALD|Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
10016383|NCT01690208|Active Comparator|Usual Care|"Irrespective of the assignment group, all patients will undergo a baseline comprehensive assessment using the JADE portal disease management system. All patients will also receive a 2-hour session on how to interpret their individualised JADE report and risk profiles, whilst the importance of achieving targets and optimizing self care will be reinforced.~Patients assigned to the UC group will be followed up in their usual clinic according to the 'standard' practice."
10016384|NCT01690221|Experimental|VEN 307|diltiazem hydrochloride 2% cream
10016385|NCT01690221|Placebo Comparator|Placebo|Placebo Cream
10016386|NCT01690234|Experimental|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
10016387|NCT01690234|Active Comparator|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
10016388|NCT01690247|Experimental|Conventional plus UC-MSC|Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
10016389|NCT01690247|Placebo Comparator|Conventional plus placebo|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
10016390|NCT01690260|Experimental|Bone Morphogenetic Protein 2|Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.
10016391|NCT01690260|Experimental|Autologous bone graft|Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.
10016392|NCT01690286|Experimental|Group 1: JNJ-38518168 3 mg/ ketoconazole|
10016393|NCT01690286|Experimental|Group 2: JNJ-38518168 30 mg/ ketoconazole|
10016394|NCT01690286|Experimental|Group 3: JNJ-38518168 10 mg/ ketoconazole (optional)|
10016395|NCT01690312|Experimental|1 (Dietary Supplement - Fish Oil)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
10016396|NCT01690312|Experimental|2 (Placebo)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
10016397|NCT01690325|Experimental|Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.|Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.
10016398|NCT01690325|Experimental|Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid|Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.
10016399|NCT01690338|Active Comparator|Vecuronium Bromide|Patients who will be performed general anesthesia and tracheal intubation. Vecuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
10016400|NCT01690338|Active Comparator|cisatracurium|Patients who will be performed general anesthesia and tracheal intubation. Cisatracurium will be used during surgery and tracheal extubation is scheduled when surgery is over.
10016401|NCT01690338|Active Comparator|rocuronium|Patients who will be performed general anesthesia and tracheal intubation. Rocuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
10016402|NCT01690351|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
10016403|NCT01690351|Experimental|PF-05089771 TS formulation fasted|Capsules TS formulation- fasted
10016404|NCT01690364|Experimental|Cisatracurium Group|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
10016405|NCT01690364|Active Comparator|Vecuronium Group|MEP monitoring with continuous infusion of vecuronium during general anesthesia
10016406|NCT01690377|Experimental|1|PDC or myDC
9518103|NCT03299894|Experimental|systematic calculation of qSOFA|Usual procedure for patient triage AND systematic calculation of qSOFA at Emergency Department triage in patients admitted with a suspected or proven bacterial infection.
10016407|NCT01690390|Active Comparator|Icotinib of Routine Dose|Oral Drug icotinib 125 mg three times per day
10016408|NCT01690390|Experimental|Icotinib of High Dose|Oral Drug icotinib 250 mg three times per day
10016409|NCT01690403|Experimental|cohort 1|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
10016410|NCT01690403|Experimental|cohort 2|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
10016411|NCT01690403|Experimental|cohort 3 (optional)|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
10016412|NCT01690416|Active Comparator|Ultrasound DNTP|the catheter will be placed using ultrasound and DNTT and Lidocaine as local anesthesia, by the same fellow as the one who performs the puncture with the traditional method
10016413|NCT01690416|Active Comparator|Traditional palpation technique|arteria cannulation by traditional palpation technique, using preprocedural lidocaine for anesthetic and palpation method by a fellow
10016414|NCT01690429|Other|OSA Patients|
10016415|NCT01690442|Experimental|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
10016416|NCT01690442|Active Comparator|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
10016417|NCT01690455||Cohort|
10016418|NCT01690468|Experimental|Triciribine & Carboplatin|"Phase I/II: 25mg/m^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin."
10016419|NCT01690494|Experimental|PACT + TAU|4-session PACT delivered to both partners together + standard treatment of care services (TAU) delivered to the male participant
10016420|NCT01690494|Active Comparator|TAU|TAU control condition delivered to the male participant
10016421|NCT01690507|Other|DCAG plus HLI|
10016422|NCT01690533||Group 1|
10016423|NCT01690559||Group 1|Patient treated with Ciproxan without dilution treatment in daily clinical practice
10016424|NCT01690572|Active Comparator|Paclitaxel coated balloon catheter|"Paclitaxel coated balloon catheter IN.PACT Falcon"
10016425|NCT01690572|Active Comparator|uncoated balloon catheter|"uncoated balloon catheter sprinter legend"
10016426|NCT01690585|Experimental|Ferinject 1000 mg|Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
10016427|NCT01690585|Placebo Comparator|Placebo|Intravenous administration of 250 ml of sodium chlorure 0.9 %
10016428|NCT01690598|Experimental|Veliparib and Topotecan|
10016429|NCT01690611|Experimental|Walking & Visual Feedback|Individuals in this arm will walk on a treadmill while viewing real time visual feedback regarding their body motions and use the visual feedback to correct their body motions.
10016430|NCT01690611|Active Comparator|Walking & No Visual Feedback|Individuals in this arm will walk on a treadmill without viewing real time visual feedback regarding their body motion.
10016431|NCT01690624|Experimental|Patients with relapsed or refractoryAML|Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
10016432|NCT01690637|Active Comparator|Oseltamivir phosphate suspension|Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
10016433|NCT01690637|Placebo Comparator|Placebo|
10016434|NCT01690650|Experimental|Oxygen + Cerebral NIRS|Induced changes in oxygen supply (100% vs. room air). Continuously monitoring of cerebral oxygen saturation.
10016435|NCT01690676|Active Comparator|Epicatechin|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
10016436|NCT01690676|Placebo Comparator|Microcrystalline cellulose|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
10016437|NCT01690689|Experimental|Surgery|Implant surgery
10036044|NCT01812161|Sham Comparator|Acupuncture protocol 2|Acupuncture protocol 2：participants will receive treatment (acupuncture protocol 2, sham acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
10016438|NCT01690702|Active Comparator|dtEC-dtD|Epirubicin and Cyclophosphamide with a tailored dose 4 cycles q2w followed by one additional week followed by Docetaxel with a tailored dose 4 cycles q2w.
10016439|NCT01690702|Experimental|EnPC|Epirubicin 150mg/qm 3 cycles q2w followed by nabPaclitaxel 260-330mg/qm (to be determined in run-in-phase) 3 cycles q2w followed by Cyclophosphamide 2000mg/qm 3 cycles q2w
10016440|NCT01690715||Hepatocellular carcinoma underwent surgery|
10016441|NCT01690728|Active Comparator|Physical Activity|40 min exercise supervised by physiotherapists two times weekly in six month.
10016442|NCT01690728|No Intervention|Control Group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
10016443|NCT01690741|Experimental|Nerofe|Nerofe administered intravenously 3x/week
10016444|NCT01690754|No Intervention|Control|This arm will receive the regular standard of care given by TB clinics.
10016445|NCT01690754|Experimental|Interactive Reminders|Patients randomized to this arm will receive Interactive SMS reminders daily.
10016446|NCT01690767|Experimental|Topical and intraurethral 2% lidocaine|2% lidocaine gel will be applied for 5 minutes to the external urethral opening. This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection. Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively.
10016447|NCT01690767|Active Comparator|Standard of care|According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only. Intervention is Health Care Lubricating Jelly.
10016448|NCT01690780|Active Comparator|Ibuprofen|
10016449|NCT01690780|Experimental|Oral morphine|
10016450|NCT01690806||dexamethasone|Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp & Dohme) intravenously 90 min before skin incision
10016451|NCT01690806||placebo|Patients who receive saline placebo intravenously 90 min before skin incision
10016452|NCT01690819|Active Comparator|Conventional Ventilatory Strategy|Conventional Ventilatory Strategy
10016453|NCT01690819|Experimental|Protective Ventilatory Strategy|Protective ventilatory strategy
10016454|NCT01690832|Active Comparator|standard saline infusion|standard i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure.
10016455|NCT01690832|Active Comparator|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.
10016456|NCT01690845|No Intervention|Control|Patients with severe HH will be treated with standard medical therapy (i.e. vasopressor support with norepinephrine in refractory hypotension = RR mean < 65 mmHg, positive inotropic support with dobutamine if the central venous oxygen saturation < 70%, renal replacement therapy in case of severe metabolic acidosis and/or renal failure, antibiotic treatment in case of suspected or proven infection, mechanical ventilation in case of severe hypoxemia or hypercapnia and/or GCS <= 8.
10016457|NCT01690845|Experimental|MARS-Group|20 patients will be allocated by randomization to the MARS arm. Additionally to standard medical therapy they will receive 4 MARS sessions on three consecutive days, MARS® therapy will be applied for at least 12 hours per session. Thereafter, MARS® treatment will be continued if the patient still has increasing aminotransferase levels, requires vasopressor support or suffers from cholestasis (defined as serum bilirubin levels > 5 mg/dL) for 3 sessions again. There will be a maximum of 7 MARS ® sessions per patient.
10016458|NCT01690858||females with medical history of repeated foetal losses|The females can be pregnant
10016459|NCT01690858||females without medical history of repeated foetal losses|The females can be pregnant
10016460|NCT01690871|Experimental|BEZ235|BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
10016461|NCT01690884|Placebo Comparator|Placebo|To determine if there is an increase in adenosine interstitial levels in the forearm.
10016462|NCT01690884|Active Comparator|Dipyridamole|To determine if there is an increase in adenosine interstitial levels in the forearm.
10016463|NCT01690884|Experimental|Ticagrelor|To determine if there is an increase in adenosine interstitial levels in the forearm.
10016464|NCT01690897|Experimental|MBCT group|Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
10016465|NCT01690897|Active Comparator|Support group|Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
10016466|NCT01690936|Experimental|Breakfast|Almonds (43g/day) were consumed with breakfast for four weeks.
10016467|NCT01690936|Experimental|Morning snack|Almonds (43g/day) were consumed alone as morning snacks for four weeks.
10016468|NCT01690936|Experimental|Lunch|Almonds (43g/day) were consumed with lunch for four weeks.
10016469|NCT01690936|Experimental|Afternoon snack|Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.
10016470|NCT01690936|No Intervention|Control no nuts|Avoided all nuts and seeds
10016471|NCT01690949|Experimental|PUR118 low dose|
10016472|NCT01690949|Experimental|PUR118 mid dose|
10016473|NCT01690949|Experimental|PUR118 high dose|
10016474|NCT01690962|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
10016475|NCT01690962|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
10016476|NCT01690975|Placebo Comparator|Placebo|Placebo Control
10016477|NCT01690975|Experimental|Benzonatate|Benzonatate Active
10016478|NCT01691001|Experimental|dexmedetomidine|
10016479|NCT01691001|Placebo Comparator|placebo group|normal saline
10016480|NCT01691040|Experimental|Open-label pilot group|Twice weekly administration of NOX-H94
10016481|NCT01691053|Active Comparator|Spironolactone|
10016482|NCT01691053|Placebo Comparator|Placebo|
10036045|NCT01812187|Experimental|SHIFT Cognitive Behavioral Therapy|Service to Home for Individually-Focused Therapy (SHIFT), a Cognitive Behavioral Treatment for Substance Use Disorders
10016483|NCT01691066|Experimental|Infant Toddler Years PRT|Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
10016484|NCT01691066|No Intervention|Community Treatment|Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
10016485|NCT01691118|Active Comparator|Fimasartan|Fimasartan 60mg qd added on conventional antihypertensive treatment for 10 months.
10016486|NCT01691118|Placebo Comparator|Placebo|Conventional antihypetensive treatment
10016487|NCT01691131|Other|Exercise training on land|High intensity exercise training on land.
10016488|NCT01691131|Other|Exercise training on water|High intensity exercise training on water.
10016489|NCT01691144||recently treated patients|
10016490|NCT01691144||2-3 years after treatment|
10016491|NCT01691157|Active Comparator|Usual physiotherapy without exercise|Will receive 6 sessions of modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
10016492|NCT01691157|Experimental|Exercise|Will receive an evidence based exercise protocol but no other physiotherapeutic modalities
10016493|NCT01691170|Active Comparator|Quadriceps Strengthening|
10016494|NCT01691170|Active Comparator|Stretching Hamstring|
10016495|NCT01691183||Study Subjects|Subjects with or without orbital disease that present to clinic for scheduled appointments.
10016496|NCT01691209|Experimental|Phoenix|Application over 29 days twice daily
10016497|NCT01691209|Active Comparator|Hydrocortison|Application over 29 days twice daily
10016498|NCT01691209|No Intervention|Untreated skin|Participants will be observed over 29 days without study treatment
10016499|NCT01691222|Other|Double lumen endotracheal tube tracheostomy|Tracheostomy with a dedicated double lumen endotracheal tube
10016500|NCT01691235||Arm 1|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
10016501|NCT01691235||Arm 2|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
10016502|NCT01691261|Experimental|Treatment|PF-05206388 Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane
10016503|NCT01691274|Experimental|PF-04895162|
10016504|NCT01691274|Placebo Comparator|Placebo|
10016505|NCT01691287|Experimental|Michael Method|14 group meeting, taking place once a week during 14 consecutive weeks
10016506|NCT01691300|Experimental|ACT PET/CT|Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
10016507|NCT01691352|Active Comparator|Wick|Patients with wick placed in their wound at the time of ostomy reversal
10016508|NCT01691352|Sham Comparator|No wick|patients with non-wicked dressing placed on their wound
10016509|NCT01691365|Active Comparator|vitamins pills|"antioxidant and B vitamins vitamins vitamin~--------------------------------------------------------------------------------"
10016510|NCT01691365|Placebo Comparator|pills|MICROCRYSTALLINE CELLULOSE
10016511|NCT01691391||Advanced CRC, candidates for anti-EGFR antibody monotherapy|Patients with histopathologically confirmed advanced CRC with K-Ras and BRAF wild type, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
10016512|NCT01691404|Active Comparator|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
10016513|NCT01691404|Active Comparator|Quercetin|Subjects will be asked to consume supplements containing 160mg of quercetin-3-glucoside daily
10016514|NCT01691404|Placebo Comparator|Placebo|Subjects will be asked to consume capsules containing a placebo (cellulose) daily
10016515|NCT01691417|Experimental|Pneumatic Sleeves|
10016516|NCT01691417|Experimental|Congestive Heart Failure Patients|
10016517|NCT01691443|Experimental|Use of the glove|The subject wear the glove for the time of the trial
10016518|NCT01691456|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
10016519|NCT01691456|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
10016520|NCT01691469|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
10016521|NCT01691469|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
10016522|NCT01691495||Superficial Vein Thrombosis (SVT)|A representative of geographical regions of patients with Superficial Vein Thrombosis (SVT) who live in several EU countries.
10016523|NCT01691547|Experimental|UMEC/VI+FF|UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
10016524|NCT01691547|Experimental|UMEC+VI|UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
10016525|NCT01691547|Experimental|FF+VI|FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
10016526|NCT01691547|Experimental|FF+UMEC|FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
10016527|NCT01691586|Experimental|Remote patient management|Remote patient management system + yearly in-clinic follow-up
10016528|NCT01691586|Other|In-Clinic follow-up|In-clinic follow-up according to standard practice (every 3-6 months)
10016529|NCT01691599||Tibia fractures|Patients with open and closed tibia fracture treated with internal fixation in India
10016530|NCT01691625|Experimental|concurrent chemoradiotherapy plus DC-CIK immunotherapy|patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
10016531|NCT01691625|Active Comparator|Concurrent chemoradiation only|patients will receive concurrent chemoradiotherapy only
10016532|NCT01691638||Periodontitis|
10016533|NCT01691638||Control|
10016534|NCT01691651|Active Comparator|Botulinum toxin type A|The group that will be subjected to the injection of botulinum toxin (subcutaneous injection of botulinum toxin type A).Subcutaneous botulinum toxin A injection will be performed in this group, (2.5 units per point application), at two points in a nasal and temporal extent of the orbicularis muscle.
10016535|NCT01691651|No Intervention|Control|The group that will not be subjected to any intervention.
10016536|NCT01691664|Active Comparator|Only radiation therapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
10016537|NCT01691664|Experimental|Radiation therapy plus DC-CIK cellular therapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~DC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
10016538|NCT01691677|Experimental|beclomethasone dipropionate|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
10016539|NCT01691677|Placebo Comparator|placebo|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
10016540|NCT01691703|Experimental|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
10016541|NCT01691716|Experimental|Tendoactive|Tendoactive dosage: 3 capsules per day
10016542|NCT01691716|Active Comparator|Eccentric training|Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
10016543|NCT01691716|Active Comparator|Tendoactive and eccentric training|Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
10016544|NCT01691729|Other|Ostomy 1|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy AccessoryProduct/Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2
10016545|NCT01691729|Other|Ostomy 2|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1
10016546|NCT01691729|Other|Ostomy 3|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product
10016547|NCT01691729|Other|Ostomy 4|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product
10016548|NCT01691729|Other|Ostomy 5|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2
10016549|NCT01691729|Other|Ostomy 6|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #1
10016550|NCT01691742|Placebo Comparator|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
10016551|NCT01691742|Active Comparator|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
10016552|NCT01691807|Experimental|Arm A|bendamustine and ofatumumab treatment of NHL
10016553|NCT01691807|Experimental|Arm B|ofatumumab only treatment of NHL
10016554|NCT01691872|Experimental|Japanese|Retigabine 300mg single-dose
10016555|NCT01691872|Experimental|Caucasian|Retigabine 300mg single-dose
10016556|NCT01691911|Experimental|Remote preconditioning|Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
10016557|NCT01691911|No Intervention|Remote preconditioning control|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
10016558|NCT01691924|Placebo Comparator|Placebo|Placebo capsules: solid microcrystalline cellulose c.s.p
10016559|NCT01691924|Experimental|PBF-509|The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
10016560|NCT01691937|Experimental|PVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with sufentanil
10016561|NCT01691937|Placebo Comparator|Placebo PVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with sufentanil
10016562|NCT01691963|No Intervention|Control group|"In the control group, anaesthesia will be induced in the same way as mentioned above for the intervention group. Also in this group, intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula. The glottic view will be scored in this position using the Cormack and Lehane classification system. If correct laryngoscope positioning cannot be achieved with a size 3 blade, a size 4 blade will be used. Hereafter, the patient's trachea will be intubated once the optimal view of the larynx had been obtained. Intubation attempts will be scored in the same way as mentioned above for the intervention group."
10016563|NCT01691963|Experimental|Epiglottic downfolding|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
10016564|NCT01691976|No Intervention|Controls|Age-matched male patients with benign prostatic hyperplasia, otherwise healthy, as controls
10016565|NCT01691976|Active Comparator|LHRHa|Prostate cancer patients receiving androgen deprivation therapy by luteinising hormone releasing-hormone agonists (LHRHa)
10016566|NCT01691976|Experimental|Oestrogen|Prostate cancer patients recruited from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Trial, randomised to receive ADT via transdermal oestrogen patches.
10016567|NCT01691989|Experimental|aleglitazar|
10016568|NCT01691989|Experimental|placebo|
10016569|NCT01692002|Placebo Comparator|Sodium chloride pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
10016570|NCT01692002|Experimental|Sodium propionate pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
10016571|NCT01692015|Experimental|Diet and nosebleed questionnaire|Participants will only be required to fill in two paper questionnaires, one on dietary history, and one on nosebleed severity.
10016572|NCT01692015|Experimental|Weighed food diary arm|Participants will be required to weigh their food for one week to generate a food dairy, and have a single blood test, in addition to filling in the two paper questionnaires, one on dietary history, and one on nosebleed severity.
10016573|NCT01692041|Active Comparator|Ivy leave|active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks
10016574|NCT01692041|Placebo Comparator|Placebo|Ivy leave placebo 5 ml twice daily p.o. for four weeks
10016575|NCT01692054||Alcohol intoxicated adolescents|Adolescents who were hospitalized due to acute alcohol intoxication
10016576|NCT01692054||Control group|adolescents who were hospitalized due to other medical conditions but not alcohol intoxication
10016577|NCT01692067||D0|Not deployed
10016578|NCT01692067||D1|Deployed to combat-related regions once
10016579|NCT01692067||D2|Deployed to combat related regions more than once
10016580|NCT01692067||D3|Deployed outside of the continental US but not to combat related regions
10016581|NCT01692080||Asthma Screenings and Camps|Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
10016582|NCT01692093|Experimental|KM110329|Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
10016583|NCT01692093|Placebo Comparator|Control|Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
10016584|NCT01692106|Experimental|peroral endoscopic myotomy (POEM)|The Procedure: per oral endoscopic myotomy (POEM)will be performed on all patients in this single arm study.
10016585|NCT01692132||Prucalopride|
10016586|NCT01692145|Experimental|KCT-0809 ophtalmic solution|
10016587|NCT01692145|Placebo Comparator|Placebo|
10016588|NCT01692158|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
10016589|NCT01692158|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
10016590|NCT01692171|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
10016591|NCT01692171|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
10016592|NCT01692184|Experimental|50 mg of AVL-292 and Placebo|50 mg AVL-292 (2 x 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition
10016593|NCT01692184|Experimental|100 mg of AVL-292 and Placebo|100 mg AVL-292 (4 x 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition
10016594|NCT01692184|Experimental|200 mg AVL-292|8 x 25 mg AVL-292 capsules orally once daily for 7 days under fasted condition
10016595|NCT01692184|Experimental|350 mg of AVL-292|350 mg AVL-292 (14 x 25 mg AVL-292 capsules) once daily for 7 days administered orally under fasted condition
10016596|NCT01692184|Placebo Comparator|Placebo - 8 capsules|8 placebo capsules once daily for 7 days administered orally under fasted condition
10016597|NCT01692184|Placebo Comparator|Placebo - 14 capsules|14 placebo capsules once daily for 7 days administered orally under fasted condition
10016598|NCT01692210||Blood Draw Pre and Post Surgery|Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
10016599|NCT01692223||Unaffected Relatives|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
10016600|NCT01692223||Pts with history of cancer|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
10016601|NCT01692223||Participants whose genomes/exomes are not sequenced|We will also recruit an additional group of participants from the general public (with or without a cancer history) who have not had their genomes or exomes sequenced to participate in focus groups to inform us about their perceptions of the hypothetical utility of learning of incidental results from their genome or exomes. For our sampling purposes, this group of participants is referred to as the 'focus group participants (sample #3-hypothetical group)
10016602|NCT01692249|Experimental|immediate spa therapy|group (A) received immediate spa treatment, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
10016603|NCT01692249|No Intervention|control group|in group (B), spa therapy was delayed for 6 months (control group).
10016604|NCT01692262|Experimental|Part A Group 1 Intermittent|Recruitment suspended and will not be re-opened. See intervention description below.
10016605|NCT01692262|Experimental|Part A Group 2 Intermittent|Recruitment complete. See intervention description below.
10016606|NCT01692262|Experimental|Part B|This part of the study will not be conducted following a review of data from Part A. See intervention description below.
10016607|NCT01692288|Experimental|Offered First Born® Program services|Family and first-born child are selected to be offered First Born® Program home visiting services.
10016608|NCT01692288|No Intervention|Not offered First Born® Program services|Family and first-born child are not selected to be offered First Born® Program home visiting services.
10016609|NCT01692314|Experimental|Obese adolescents is being compared to control ones|Patients underwent to resistance training, three times a week, during three months.
10016610|NCT01692327|Other|Obese Group|Obese group with fat overload intake.
10016611|NCT01692327|Other|Control Group|Control Group + fat overload intake
10016612|NCT01692327|Other|Glucose Intolerance|glucose intolerance + fat overload intake
10016613|NCT01692353||Exclusive cigarette smokers (SMK)|Subject's usual brand (UB) of cigarettes
10016614|NCT01692353||Exclusive moist snuff consumers (MSC)|Subject's usual brand (UB) of moist snuff
10016615|NCT01692353||Non-tobacco consumers (NTC)|No use of tobacco or nicotine-containing products of any kind
10016616|NCT01692366|Experimental|SAR302503 300mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
10016617|NCT01692366|Experimental|SAR302503 400 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
10016618|NCT01692366|Experimental|SAR302503 500 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
10016619|NCT01692379|Experimental|Endovascular treatment|Mechanical embolectomy with Solitaire FR device
10016620|NCT01692379|Active Comparator|Medical treatment|Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis
10016621|NCT01692392||Pectus carinatum|Patients who have undergone surgical repair of pectus carinatum.
10016622|NCT01692405|No Intervention|Standard method|Standard method- shaking the biopsy needle into a formalin container.
10016623|NCT01692405|Active Comparator|Download onto a biopsy sponge pad|Samples will be downloaded by moving the needle notch on a biopsy sponge pad.
10016624|NCT01692405|Experimental|Dowloading the biopsy cores using NavigoBx system|Downloading the biopsy cores using NavigoBx™ system. The NaviGoBx™ device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.
10016625|NCT01692418|Experimental|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
10016626|NCT01692418|Placebo Comparator|Placebo|Normal saline will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
10016627|NCT01692431|Experimental|DHA|High fat meal containing DHA rich oil.
10016628|NCT01692431|Experimental|EPA|High fat meal containing EPA.
10016629|NCT01692431|Placebo Comparator|Control|High fat meal with no/negligable omega-3 fatty acid content.
10016630|NCT01692457||Golimumab|Patients will be taking golimumab as per the dosing regimen given on product insert approved in Philippines.
10016631|NCT01692470||rilpivirine hydrochloride|Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications.
10016632|NCT01692483||Abiraterone acetate plus prednisone|
10036046|NCT01812200|Active Comparator|Dabigatran, Ticagrelor, ASA|Dabigatran 150mg td Ticagrelor 90 mg td ASA 100 mg od for 5 days
10036047|NCT01812200|Active Comparator|Rivaroxaban, Ticagrelor, ASA|Rivaroxaban 20 mg od Ticagrelor 90 mg td ASA 100 mg od for 5 days
10036048|NCT01812200|Active Comparator|Phenprocoumon, Ticagrelor, ASA|Phenprocoumon X mg to reach an INR of 2-3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days
10036049|NCT01812213|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 (8.1 mCi) administered once every 18 months
10036050|NCT01812226||experimental group|This group will consist of men and women who received a liver transplant for alcohol-related liver disease.
10036051|NCT01812226||control group|This group will consist of men and women who had a liver transplant for reasons that are not alcohol-related.
10036052|NCT01812239|Active Comparator|Vaginal Progesterone|Daily administration of Vaginal Progesterone (200mg) Gel between 20 weeks of pregnancy and 34 weeks of pregnancy.
10036053|NCT01812239|Placebo Comparator|Placebo|Daily vaginal administration of Placebo gel (Vanicream)between 20 weeks of pregnancy and 34 weeks of pregnancy.
10036054|NCT01812265|Experimental|PF-06305591 Dose 1|
10036055|NCT01812265|Experimental|PF-06305591 Dose 2|
10036056|NCT01812265|Placebo Comparator|Placebo|
10036057|NCT01812278|Experimental|ACT|Acceptance & Commitment Therapy
10036058|NCT01812278|Active Comparator|CBT|Cognitive Behavioral Therapy
10036059|NCT01812291|Experimental|Stepped Care Approach for Depression|"Step 1: Diabetes-Specific CBT (5 group sessions)~Step 2: Depression-Specific CBT (6 single sessions)~Step 3: Referral to Psychotherapist and/or Psychiatrist"
10036060|NCT01812291|Active Comparator|Treatment-as-usual|Standard Diabetes Education
10036061|NCT01812304|Experimental|hands-on training|probands perform predefined maneuvers to manage a vaginal breech hands-on after one instruction
10016633|NCT01692509||Patients requiring NIV|Patients requiring NIV because of acute respiratory failure
10016634|NCT01692522|Experimental|Ambu Aura-i|intubation
10016635|NCT01692522|Active Comparator|AirQ|intubation
10016636|NCT01692535|Experimental|GlideScope|intubation
10016637|NCT01692535|Experimental|Airtraq|intubation
10016638|NCT01692535|Experimental|McGrath MAC|intubation
10016639|NCT01692535|Experimental|King Vision|intubation
10016640|NCT01692535|Experimental|A.P. Advance|intubation
10016641|NCT01692535|Experimental|C-MAC|intubation
10016642|NCT01692548|Experimental|Neurofeedback|Neurofeedback: two sessions per week, 30 sessions total.
10016643|NCT01692548|No Intervention|Control|
10016644|NCT01692561||normaL|Healthy subjects without symptoms of dysautonomia.
10016645|NCT01692561||Neurocardiogenic syncope|Fainting due to sudden drop in blood pressure.
10016646|NCT01692561||Orthostatic hypotension|Sudden decrease in blood pressure while standing.
10016647|NCT01692561||Postural Orthostatic Tachycardic Syndrome|Increased heart rate when standing.
10016648|NCT01692574|Experimental|Combined|Group cognitive-behavior therapy for depression combined with behavior modification for weight loss
10016649|NCT01692574|Active Comparator|GCBT-ND|Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss
10016650|NCT01692574|Active Comparator|DSE|Behavior modification for weight loss combined with depression support and education.
10016651|NCT01692587|No Intervention|Control|No changes in dietary group
10016652|NCT01692587|Experimental|Protein restrictive diet|reduced protein diet
10016653|NCT01692600||healthy volunteers|Age-matched with the patient group, with no oral pathologies and comorbidities
10016654|NCT01692600||Late oral radiation toxicity patients|Head-and-neck cancer patients who had undergone radiation therapy and developed late radiation side ffects
10016655|NCT01692652|Experimental|Lotemax with warm compress group|topical loteprednol etabonate (lotemax 0.5%) qid and warm compress & ocular massage (a minimum of four times, once or twice a daily) for 2months
10016656|NCT01692652|Active Comparator|warm compress only group|warm compress only group
10016657|NCT01692665||stage 3 or stage 4 meibomiang gland dysfunction patients|stage 3 or stage 4 meibomiang gland dysfunction patients
10016658|NCT01692678|Experimental|Trabectedin (Part 1 and Part 2)|Trabectedin will be administered at a dose of 1.5, 1.2 or 1.0 mg/m2 as a 24-hour intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
10016659|NCT01692678|Active Comparator|Dacarbazine (Part 2)|Dacarbazine will be administered at a dose of 1 g/m2 as a longer than 30-minute intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
10016660|NCT01692704|Experimental|HAI with FUDR & systemic cisplatin and gemcitabin|FUDR: 0.2mg/kg/day continuously i.a. for 14 days Cisplatin: 25mg/m2 i.v. Gemcitabin: different doses according to dose level 600, 800, or 1000 mg/m2 i.v.
10016661|NCT01692717|Active Comparator|Atorvastatin|Citalor (Atorvastatin) - Pfizer
10016662|NCT01692717|Active Comparator|Hydrochlorothiazide + Losartan|Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp & Dohme
10016663|NCT01692717|Experimental|Atorvastatin + Hydrochlorothiazide + Losartan|Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas
10016664|NCT01692769|Active Comparator|Normal Saline|Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
10016665|NCT01692769|Active Comparator|Ringer's Lactate|Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
10016666|NCT01692795||MI patients|
10016667|NCT01692808|No Intervention|Exclusive Enteral Nutrition|This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.
10016668|NCT01692808|Experimental|EEN + Vitamin D3 3000 UI daily|Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.
10016669|NCT01692808|No Intervention|Corticosteroïd|Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month
10016670|NCT01692808|Experimental|Corticosteroids + Vitamin D3 4000 UI|Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month
10016671|NCT01692808|Experimental|Vitamin D3 4000 UI|Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.
10016672|NCT01692821|Experimental|100% oxygen breathing|
10016673|NCT01692821|Experimental|15% oxygen in N2 breathing|
10016674|NCT01692821|Experimental|12% oxygen in N2 breathing|
10016675|NCT01692834|Active Comparator|Cyclosporine in Cremophor EL®|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
10016676|NCT01692834|Active Comparator|Cyclosporine in lipid emulsion|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
10016677|NCT01692847||RRT calls prior to IGS use|Patients who triggered ACT/RRT calls prior to the installation of the IGS (Intellivue Guardian System)
10016678|NCT01692847||RRT calls during IGS use|Patients who triggered ACT/RRT calls after the installation of IGS. All patients on the study ward receive the same care in both groups. The only difference is the system used to collect vital signs and to inform the staff about patient deteriorations. In Group 2, the IGS (FDA approved and CE marked) is the vital signs collection and information system.
9476840|NCT03567811|Other|Chronic Fatigue Syndrome|"Inclusion and exclusion criteria based on 1994 Center for Disease Control (Fukuda) criteria of persistent, disabling, moderate to severe fatigue that was relieved by rest, plus at least 4 of the 8 following ancillary features: cognitive dysfunction affecting short term memory or concentration, sore throat, sore lymph nodes, sore muscles, sore joints, headache, sleep disturbance, and exertional exhaustion (post-exertional malaise). Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2"
9518104|NCT03299894|No Intervention|no systematic calculation of qSOFA|Usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection. No systematic calculation of qSOFA.
10016679|NCT01692860|Experimental|High protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of 1.5g/kg/d
10016680|NCT01692860|Placebo Comparator|Normal protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of .8g/kg/d
10016681|NCT01692873|Experimental|suspected pancreatic tumor|Realization of pancreatic tumor biopsy and blood samples
10016682|NCT01692886|Active Comparator|7vPnC (3-, 4-, 5-, 12-Month)|
10016683|NCT01692886|Experimental|13vPnC (3-, 4-, 5-, 12-Month)|
10016684|NCT01692886|Experimental|13vPnC (2-, 4-, 6-, 12-Month)|
10016685|NCT01692886|Experimental|13vPnC (3-, 5-, 12-Month)|
10016686|NCT01692899||Etanercept|Etanercept: administered as first line biotherapy in RA during the period of the study
10016687|NCT01692899||Adalimumab|Adalimumab: administered as first line biotherpy in RA during the period of the study
10016688|NCT01692899||Infliximab|Infliximab: administered as first line biotherpy in RA during the period of the study
10016689|NCT01692912|Active Comparator|Intensive Care (IC)|Rheumatologists treating to target of DAS28<2.6
10016690|NCT01692912|No Intervention|Routine Care (RC)|Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28<2.6)
10016691|NCT01692925|Experimental|Lot A|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
10016692|NCT01692925|Experimental|Lot B|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
10016693|NCT01692925|Experimental|Lot C|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
10016694|NCT01692925|Experimental|Lot D|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
10016695|NCT01692977|Experimental|Alzheimer disease patients|Alzheimer disease patients
10016696|NCT01692977|Active Comparator|control|healthy control subjects.
10016697|NCT01692990|Experimental|Fish oil|5 g/d in 10 capsules, providing 3.5 g of long-chain n-3 fatty acids
10016698|NCT01692990|Placebo Comparator|Soy bean oil|5 g/d in 10 capsules
10016699|NCT01693003|Experimental|Indacaterol first|"Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
10016700|NCT01693003|Experimental|Tiotropium first|"Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
10016701|NCT01693016|Other|inhalation group|20 children Taking blood samples and SpHb-measurement was made under inhalational anesthesia
10016702|NCT01693016|Other|non-inhalational|40 children Taking blood samples and SpHb measurements in awake and spontaneous breathing children.
10016703|NCT01693042|Active Comparator|Single intracoronary cell application|Single intracoronary application of autologous bone marrow derived mononuclear cells
10016704|NCT01693042|Active Comparator|repeated (2 times) intracoronary cell application|2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells
10016705|NCT01693055|Experimental|UltheraTM|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
10016706|NCT01693081|Active Comparator|VR040/Aspirair® inhaler|VR040 was administered as an inhaled dry powder, in a dosage of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
10016707|NCT01693081|Placebo Comparator|Placebo|Placebo was administered as an inhaled dry powder, matching to active comparator at dosages of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
10016708|NCT01693094|No Intervention|No decision aid|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
10016709|NCT01693094|Active Comparator|Decision Aid|One cohort will receive a decision aid.
10016710|NCT01693107||Operator Blinded to Contact Force|Physicians performing the ablation will be blinded to the contact force data
10016711|NCT01693133|Other|Control|Standard of Care: Moist Wound Therapy and Offloading
10016712|NCT01693133|Experimental|EpiFix plus Standard of Care|Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
10016713|NCT01693146|Active Comparator|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
10016714|NCT01693146|Active Comparator|Nasal oxygen insufflation with a TNI® 20 oxy device|Device: TNI®20 oxy Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
10016715|NCT01693159|Experimental|ECA: Ethyl-2-cyanoacrate|Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades
10016716|NCT01693159|Active Comparator|Standard treatment of the institution|Standard treatment of the institution to treat painful cetuximab-induced rhagades
10016717|NCT01693172|Active Comparator|early postoperative mobilization|Early postoperative supervised aerobic exercise, resistance and flexibility training
10016718|NCT01693172|No Intervention|Standard|Standard rehabilitation care
10016719|NCT01693211|Experimental|Group A|Capsulorhexis and pre-fragmentation of the nucleus are performed by the femtosecond laser.
10016720|NCT01693211|Active Comparator|Group B|The Capulorhexis and nuclear fragmentation are performed manually.
10016721|NCT01693237|Active Comparator|Group psychotherapy|20 sessions of systemic and narrative group psychotherapy
10016722|NCT01693237|Experimental|Group psychotherapy with feedback|20 sessions of systemic and narrative group psychotherapy with session-to-session feedback to patient and therapist.
10016723|NCT01693263||brachiocephalic fistula placed|Subjects are being asked to participate in this study because they have end-stage renal disease and they are undergoing dialysis, and their doctor has recommended that they will have brachiocephalic fistula placed for their dialysis access.
10016724|NCT01693263||Sub-study participants|As part of this study there is an additional sub-study. The researchers would like to collect more information about the vascular access from 50 subjects. For the purposes of this sub-study the following will take place: Intravenous Ultrasound (IVUS) and Hand Held Doppler
10036062|NCT01812304|Active Comparator|frontal teaching|Probands perform predefined maneuvers to resolve a vaginal breech after forntal teaching
10036063|NCT01812317|Active Comparator|Real-fire training exercise|Subjects will undergo a 20 minute standardised training exercise in a fire simulation facility.
10016725|NCT01693276|Experimental|Gemzar/Abraxane and Radiation Therapy|Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
10016726|NCT01693289|Experimental|Metformin plus letrozole|metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle
10016727|NCT01693289|Experimental|ovarian drilling|bilateral diathermy ovarian drilling, four drills each ovary
10016728|NCT01693302|Experimental|-20 minute insulin|Insulin for the meal is given 20 minutes prior to starting the meal.
10016729|NCT01693302|Experimental|0 minute insulin|Insulin for the meal is given immediately before starting to eat.
10016730|NCT01693302|Experimental|+20 minute insulin|Insulin is given 20 minutes after the start of the meal.
10016731|NCT01693315|Experimental|Cohort 1 - AMA0076 Dose A (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
10016732|NCT01693315|Experimental|Cohort 2: AMA0076 Dose B (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
10016733|NCT01693315|Experimental|Cohort 3: AMA0076 Dose C (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
10016734|NCT01693315|Experimental|Cohort 4: AMA0076 Dose D (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
10016735|NCT01693328||PecFent®|
10016736|NCT01693341|Active Comparator|Care-giver mediated training|Each patient and the caregiver of the intervention group received weekly home training and exercise counseling by a physical therapist about the caregiver mediated home exercise skill for stroke patient. The training program were progress weekly based on the patient's need.
10016737|NCT01693341|No Intervention|Standard-care|Maintain the inherent standard-care
10016738|NCT01693354|Active Comparator|HF dialysis|HF (high-flux) dialysis is standard hemodialysis treatment performed by using a high permeability dialyzer instead of a low permeability one.
10016739|NCT01693354|Experimental|Mid-dilution HDF|Mid-dilution is a newly developed hemodiafiltration therapy able to allow a simultaneous pre- and post-dilution infusion.
10016740|NCT01693380|Experimental|Influenza vaccine|"Schoolchildren from 6 to 8 years received two intra-muscular doses of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009.~Schoolchildren above 8 years received one intra-muscular dose of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009."
10016741|NCT01693380|Sham Comparator|Control vaccine|"Schoolchildren received one intra-muscular dose of 0.5 ml of Meningococcal C conjugate vaccine.~Schoolchildren under nine years of age received also one intra-muscular dose of 0.5 ml of varicella vaccine one month after the Meningococcal C vaccine."
10016742|NCT01693393|Other|Cyclosporine A|All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
10016743|NCT01693406||Normal Weight|Normal weight and normoglycemic women: Pre-pregnancy BMI between 18.5 - 24.9 kg/m2.
10016744|NCT01693406||Overweight/Obese|Overweight and normoglycemic women: Pre-pregnancy BMI between > 25 kg/m2.
10016745|NCT01693406||Gestational Diabetes|Women who develop gestational diabetes and return to normal glucose control after delivery.
10016746|NCT01693406||Type 2 Diabetes|Women who are overweight and have Type 2 Diabetes that was diagnosed before pregnancy: Pre-pregnancy BMI > 25 kg/m2.
10016747|NCT01693419|Experimental|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
10016748|NCT01693432|Experimental|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
10016749|NCT01693445|Experimental|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
10016750|NCT01693458|Experimental|Lifestyle counseling|Appreciative Inquiry Change Agents (CA) Program (NAMWEZA)
10016751|NCT01693458|Placebo Comparator|Control group|Since the design is a stepped-wedge randomized trial, those in the control group will eventually receive the intervention later in the study.
10016752|NCT01693471||SEARCH Study Group|
10016753|NCT01693497|Experimental|Dialogical exposure therapy|Psychotherapy based on a manual integrating Gestalt principles with cognitive-behavioral techniques.
10016754|NCT01693497|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy, a cognitive behavioral psychotherapy for PTSD patients. Based on a German manual adapted from Resick and Schnicke, 1993.
10016755|NCT01693510|Experimental|Exercise and Nutrition Intervention|Nutrition intervention: The proposed nutrition plan is a high protein (25% energy) diet providing low fat dairy foods and individualized to energy needs. Dairy foods are accepted by women during pregnancy as a healthy choice (from pilot study) and in our recent birth cohort study, women consumed an average of 3 or more servings of dairy per day. Exercise intervention: Most previous studies and published guidance focus on aerobic exercise such as walking as it is the easiest physical activity to implement in pregnancy in terms of setting goals of steps and monitoring of adherence using accelerometer-type devices. Walking is also the most practical since women reduced moderate and vigorous physical activity during pregnancy but levels of walking were maintained.
10016756|NCT01693510|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health. In addition, women will have the opportunity to attend one focus group session exploring women's experiences with nutrition, exercise, and weight gain in pregnancy.
10016757|NCT01693536|Experimental|Lifestyle counselling|"Three dietician visits focussed on education to find food with sodium less than 120mg/100gms.~Two physiotherapist visits focussed on teaching personalised sustainable practical exercise."
10016758|NCT01693536|No Intervention|Control|Control group was offered free skin cancer check and wait listed for the same lifestyle counselling after the six months of the study.
10016759|NCT01693549|Experimental|Cabazitaxel|Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
10016760|NCT01693575|Experimental|Pupil expansion with APX 100 device|Use of APX 100 device during standard phacoemulsification cataract extraction surgery in patients with small pupil diameter (<4.5 mm) or with documented intraoperative floppy iris syndrome in previous eye.
10016761|NCT01693588|Experimental|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
10016762|NCT01693601|Experimental|Panobinostat and Ruxolitinib|Combination of Panobinostat and Ruxolitinib
10016763|NCT01693627|Active Comparator|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
10016764|NCT01693627|Active Comparator|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
10016765|NCT01693627|Active Comparator|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
10016766|NCT01693627|Active Comparator|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
10016767|NCT01693640|Experimental|abatacept|
10016768|NCT01693666|Experimental|Lifestyle intervention group|The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change. Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM. When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period. Diet requirements include at least 5 days of food logs each week. Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
10016769|NCT01693666|No Intervention|Routine care group|Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
10016770|NCT01693679|Experimental|antiviral drug|Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients.
10016771|NCT01693705||Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated and who underwent tracheostomy
10016772|NCT01693705||Non-Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated but did not undergo tracheostomy
10016773|NCT01693731||Aromatase Inhibitor|Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
10016774|NCT01693731||No Treatment|Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
10016775|NCT01693744||Dialysis patients|Patients with stage 5 chronic kidney disease undergoing haemodialysis
10016776|NCT01693744||Chronic kidney disease patients|Stage 1-4 Chronic kidney disease patients
10016777|NCT01693744||Control group|Patients with normal renal functions
10016778|NCT01693757||BPTB group|Bone-patellar tendon-bone
10016779|NCT01693757||STG group|Semitendinosus and gracilis tendon
10016780|NCT01693757||Control|Healthy
10016781|NCT01693770|Other|MRgFUS|High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
10016782|NCT01693809|Experimental|Caffeine|Caffeine 420mg, one time
10016783|NCT01693822|Experimental|Axitinib|Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
10016784|NCT01693835||Patients|Patients with metastatic colorectal cancer
10016785|NCT01693835||Healthy subjects|Age and sec-matched healthy subjects
10016786|NCT01693848||Patients|Patients with metastatic colorectal cancer scheduled for metastatic surgery
10016787|NCT01693848||Control patients|Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
10016788|NCT01693861||Patients|Patients with metastatic colorectal cancer treated with chemotherapy
10016789|NCT01693874|Experimental|Mindfulness Based Stress Reduction|All participants in this arm receive Mindfulness Based Stress Reduction (MBSR).
10016790|NCT01693874|Active Comparator|control|All participants in this arm receive an attention control
10016791|NCT01693887||empirical therapy|immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
10016792|NCT01693887||preemptive therapy|Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。
10016793|NCT01693913|Experimental|Cognitive-behavioral|Those participating in a cognitive behaviorally supported exercise and nutrition treatment will receive a cognitive behavioral exercise and nutrition over 50 weeks
10016794|NCT01693913|Active Comparator|Nurtition education|This arm will participate in nutrition and exercise education
10016795|NCT01693926|Experimental|Acute physical activity intervention|25 min of moderate physical activity
10016796|NCT01693926|Placebo Comparator|Placebo|25 min of reading (instead of physical activity)
10016797|NCT01693939|Other|FS200 Femtosecond Laser|The LASIK flap will be created using the FS200 Femtosecond Laser
10016798|NCT01693952|Experimental|blood samples|
10016799|NCT01693965|Other|sputum samples|
9518105|NCT03299868|Experimental|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
10016800|NCT01693978|Experimental|Reinforced Prolonged Exposure (RPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks. RPE participants will receive voucher-based reinforcement contingent on attendance to scheduled Prolonged Exposure therapy sessions.
10016801|NCT01693978|Active Comparator|Standard Prolonged Exposure (SPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks.
10016802|NCT01693991|Experimental|Meaning-Making intervention (MMi)|Patients in this arm will be receiving the Meaning-Making intervention (MMi) as per intervention manual (Lee, 2006).
10016803|NCT01693991|Placebo Comparator|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
10016804|NCT01693991|No Intervention|Control Group|Patients in this group will only be receiving treatment as usual.
10016805|NCT01694017|Active Comparator|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
10016806|NCT01694017|Active Comparator|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
10016807|NCT01694030|Experimental|Neutral Condition|Participants in the neutral (control) condition of the attachment security priming experiment will be asked to spend time visualising neutral events (e.g., supermarket shopping)for 3-10 minutes at a time.
10016808|NCT01694030|Experimental|Secure condition|Participants in the attachment security priming condition will be asked to complete visualisation tasks where they think about a secure attachment figure for between 3 - 10 minutes.
10016809|NCT01694043|Experimental|Non-Food Related Commercials|Participants will watch a 30-minute Saturday Night Live television show with non-food related commercials embedded.
10016810|NCT01694043|Experimental|Healthy Food Commercials|Participants will watch a 30-minute Saturday Night Live television show with healthy food commercials embedded.
10016811|NCT01694043|Experimental|Unhealthy Food Commericlas|Participants will watch a 30-minute Saturday Night Live television show with unhealthy food commercials imbedded.
10016812|NCT01694056|Experimental|Soy protein diet|High mixed protein diet (20 en%) with 25gr of soy protein per day
10016813|NCT01694056|Active Comparator|Control diet|High mixed protein diet (20 en%)
10016814|NCT01694082|Experimental|THRIVE replication|Participants in this condition receive THRIVE with a full list of direct and indirect protective behavioral strategies to reduce alcohol consumption.
10016815|NCT01694082|Experimental|THRIVE direct strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are directly related to alcohol drinking.
10016816|NCT01694082|Experimental|THRIVE indirect strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are indirectly related to alcohol drinking.
10016817|NCT01694082|Sham Comparator|Brief brochure and assessment control|Participants will answer the same survey questions as participants in the THRIVE conditions, but will receive a brief alcohol-related brochure with only didactic content rather than the intervention components received by participants randomized to THRIVE conditions.
10016818|NCT01694095||Patients with geographic atrophy|
10016819|NCT05289804|Experimental|Active NITESGON|One electrode each will be placed over the left and right C2 dermatomes. A constant current will be applied during the word association task.
10016820|NCT05289804|Sham Comparator|Sham NITESGON|For sham NITESGON (inactive control), placement of the electrodes will be identical to active NITESGON. Current intensity (ramp down) will gradually be reduced as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.
10016821|NCT05289804|Active Comparator|Active NITESGON + local anesthesia|For active NITESGON + local anesthesia (active control; local nerve anesthesia group), patients will receive NITESGON, in combination with a topical skin anesthetic (lidocaine/prilocaine cream) to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. A current similar to active NITESGON will be applied.
10016822|NCT05289804|Active Comparator|Active C5/C6|For the active C5/C6 group (active control; same sensation different nerve), the electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. A current similar to active NITESGON will be applied.
10036064|NCT01812317|Sham Comparator|Sedentary training session|Subjects will undergo a training exercise where they will remain sedentary for 20 mins in an ambient temperature.
10036065|NCT01812330|Experimental|group 1|Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial
10036066|NCT01812330|Experimental|group 2|Group 2 will be administered with Clopidogrel 150mg daily until the end of trial
10036067|NCT01812330|Experimental|group 3|Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial
10036068|NCT01812343|Other|Exercise test|Ankle pressure Index measure before and after Maximal Exercise Tests
10036069|NCT01812356|Experimental|Argon gas probe|Cryomaze procedure using Argon gas probe
10036070|NCT01812356|Active Comparator|Nitrous oxide probe|Cryomaze procedure using Nitrous oxide probe
10036071|NCT01812369|Experimental|GC|gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles
10036072|NCT01812369|Active Comparator|MVAC-HD|Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles
10036073|NCT01812382|Experimental|Microdialysis arm|Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
10036074|NCT01812395|Active Comparator|Ultrasonic Dissector Thyroidectomy|Thyroidectomy using harmonic focus (r) device
10036075|NCT01812395|Active Comparator|Classic thyroidectomy|Patients having conventional thyroidectomy
10036076|NCT01812421|Experimental|Ischemic Stroke or TIA (ISTIA) patients|
10036077|NCT01812434|Experimental|Sildenafil|Patients will be randomized to sildenafil arm taken three times a day for 28 days and then crossed over to the alternate arm.
10036078|NCT01812434|Experimental|Placebo|Subject randomized to either Sildenafil or placebo arm
10036079|NCT01812447|Experimental|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
10036080|NCT01812447|Experimental|Spiration Valve System, α-1|α-1 antitrypsin deficiency subjects will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management. There is no randomization for this group.
10036081|NCT01812447|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
10036082|NCT01812460|Experimental|Intervention-training-group|"The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times) The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every session of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoe as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.~The weight cuffs are handed over to the patients for self guided exercise during weekends"
10016823|NCT05289765|Experimental|Group 1|Ecological Extra Virgin Olive Oil
10016824|NCT05289765|Active Comparator|Group 2|Conventional
10016825|NCT05289752|Active Comparator|Group I|GroupI: The retentive caps will be picked up by the indirect method on the cast first, then by the direct method.
10016826|NCT05289752|Active Comparator|Group II|GroupII: The retentive caps will be picked up by the direct method on the cast first, then by the indirect method.
10016827|NCT05289739|Experimental|Exercise group|Usual medical care + supervised exercise training during intensive medical treatment
10016828|NCT05289739|No Intervention|Control group|Usual medical care
10016829|NCT05289726|Experimental|Traditional chinese medicine TDX105|"Experimental group Traditional chinese medicine TDX105 (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~Basic care was the same in both groups, including routine care such as topical use of urea ointment"
10016830|NCT05289726|Placebo Comparator|placebo|"The control group received placebo granules mixed with dextrin and food coloring (Dissolve in warm water and then dilute to 600ml and soak hands and feet for 30 minutes each time, once in the morning and evening every day, until the end of the first 8 weeks of treatment with regorafenib)~- Basic care was the same in both groups, including routine care such as topical use of urea ointment"
10016831|NCT05289713|Active Comparator|Surgery|In the surgery group, patients undergo laparoscopic appendectomy within 18 hours after randomization.
10016832|NCT05289713|Active Comparator|Symptomatic treatment|Symptomatically treated patients are hospitalized for at least 24 hours, and receive intravenous fluids and analgesics according to standard clinical practice.
10016833|NCT05289700|Experimental|HBOT intervention group (2 ATA, 95 min, FIO2=1)|Hyperbaric Oxygen Therapy (HBOT) is the administration of oxygen at a pressure higher than atmospheric pressure (2 ATA). By breathing pure oxygen at twice the atmospheric pressure, its concentration in the blood is multiplied by nearly ten times. This allows a greater oxygen concentration in poorly vascularised areas of the body.
10016834|NCT05289700|Placebo Comparator|placebo group (1.3 ATA, 95 min, FIO2=0.21)|Hyperbaric chamber is the same chamber used for HBOT, but with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers.
10016835|NCT05289687|Experimental|Course 1|Daratumumab-hyaluronidase
10016836|NCT05289674|Experimental|Interventional study with a pre-, post-test design|"After the subject are diagnosed with infection (tuberculosis/TB or urinary tract infection/ UTI), they will receive 400 kcal/day (96 g/day divided 4 times consumption) of high calorie formula prescribed by the researcher (A pediatrician) for 90 days consumption ( 8640 g). the subject will be monitored every 30 days for acceptance, tolerance, weight increment, length increment evaluation.~The blood are withdrawn at day 0 (before invention) and day 90 (after intervention) to measure the IL-6 and IL-10 levels"
10016837|NCT05289661|Experimental|UT-DSAEK plus topical ripasudil|This arm will receive UT-DSAEK plus topical ripasudil 0.4%
10016838|NCT05289661|Placebo Comparator|UT-DSAEK plus topical placebo|This arm will receive UT-DSAEK plus topical placebo
10016839|NCT05289661|Experimental|DMEK plus topical ripasudil|This arm will receive DMEK plus topical ripasudil 0.4%
10016840|NCT05289661|Placebo Comparator|DMEK plus topical placebo|This arm will receive DMEK plus topical placebo
10016841|NCT05289648|Experimental|Preoperative Niraparib|Single arm. Following the initial assessment and endometrial biopsy the participants will receive niraparib for 28 days. After the treatment period the patients will be surgically staged. All participants will receive the standard of care.
10016842|NCT05289635|Experimental|test group|vertical mattress suture
10016843|NCT05289635|Other|control group|horizontal mattress suture
10016844|NCT05289609||Prospective Cohort|Liver Transplant Recipients from High-volume centers (i.e., performing >= 65 LTs per year)
10016845|NCT05289609||Retrospective Cohort|Liver Transplant Recipients from Low-to-medium volume centers (i.e., performing <65 LTs per year) and High-volume centers
10016846|NCT05289596|Experimental|Evidence-based digital therapy to treat insomnia|Participants will be assigned an evidence-based digital therapy to treat insomnia (Sleep Healthy Using the Internet (SHUT-i)
10016847|NCT05289570|Experimental|Voxelotor Arm|500 mg of voxelotor will be administered three times a day (for a maximum total daily dose of 1500 mg per day) for 5 days.
10016848|NCT05289557|Active Comparator|Bonjesta|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score >3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
10016849|NCT05289557|Placebo Comparator|Placebo|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score >3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
10016850|NCT05289531||Rectal resection patients|Four Turkish centers participated in data collection in 2016. The inclusion criteria were rectal adenocarcinoma within 15 cm from the anal verge and LAR with either PME or TME. All patients had bowel continuity restored for at least 18 months when invited for the study. Exclusion criteria included failed R0 surgery, recurrence or dissemination, having intestinal stoma, previous cancer (except minor skin cancers) dementia and inability to speak Turkish (i.e., the need for a translator during treatment). A research assistant at each center identified the consecutive series of eligible patients for each participating consultant surgeon
10016851|NCT05289531||52 patients re-questioned to answer the same questionaire as control group|"The test-retest reliability of the LARS score was evaluated by asking 52 randomly selected subgroup of eligible patients to repeat the assessment of the LARS score 2 to 4 weeks after their initial response. Agreement between tests for the LARS score category and for each of the five LARS score items is presented as proportions with 95% confidence intervals. We considered it a perfect agreement if the patient ticked the exact same response category at both tests, a moderate agreement if responses differed by one category, while 'no agreement' was applied to patients whose responses differed by two or more categories.~The intraclass correlation coefficient was used to evaluate the agreement between the initial test and the retest. The limit of agreements was calculated by using the Bland-Altman method. An ICC between 0.61 and 0.80 is considered strong agreement. A p value less than 0.05 was considered significant."
10016852|NCT05289518|Experimental|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 3 months.
10016853|NCT05289518|Sham Comparator|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 3 months.
10016854|NCT05289505||Prospective phase|This prospective phase involves all patients with an initial HADS score > 7 and initiating treatment in the radiotherapy department. The treatment sessions will be performed with music, using the MUSIC-CARE device. In the event of technical problems, unavailability of equipment, or the patient's wishes, some radiotherapy sessions may be conducted without music. Nevertheless, a minimum of one weekly session with music is required for the analysis of the study.
10016855|NCT05289492|Experimental|A: Participants will receive EOS884448|EOS884448 will be administered
10016856|NCT05289492|Experimental|B: Participants will receive EOS884448 and iberdomide|EOS884448 and iberdomide will be administered
10016857|NCT05289492|Experimental|C: Participants will receive EOS884448, iberdomide and dexamethasone|EOS884448, iberdomide and dexamethasone will be administered
10016858|NCT05289479|Active Comparator|"No pre-heating control group"|resin composite is used at room temperature without preheating
10016859|NCT05289479|Active Comparator|0ne cycle pre-heating|one cycle preheating of resin composite at 68 degree Celsius before application
10016860|NCT05289479|Active Comparator|ten cycles pre-heating|ten cycles preheating of resin composite at 68 degree Celsius before application
10016861|NCT05289466|Other|Single-arm|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
10016862|NCT05289453|Experimental|study group|patients wit acute congestive glaucoma and treated bt lens extraction by phacoemulsification after IOP control
10016863|NCT05289440|Experimental|Low-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
10016864|NCT05289440|Experimental|High-dose esketamine infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
10016865|NCT05289440|Experimental|Saline infusion on the quality of recovery after radical mastectomy|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
10016866|NCT05289427|Experimental|TIPS Block|Group TIPS; patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
10016867|NCT05289427|Active Comparator|FNB|Group FNB; patients will receive femoral nerve block (FNB) before surgical incision
10016868|NCT05289414|Active Comparator|Radiofrequency|first group of patients will be sujected to radiofrequency treatment
10016869|NCT05289414|Active Comparator|Greater occipital nerve vlock|second group of patients will be sujected to Greater occipital nerve block
10016870|NCT05289401|Active Comparator|ESPB|Unilateral erector spinae block will be performed in the lateral position . 0.5 mL/Kg of bupivacaine 0.125% will be injected taking care not to exceed the maximum recommended dose (2 mg/kg of bupivacaine)
10016871|NCT05289401|Active Comparator|CB|caudal block performed in lateral position . bolus of 1.2 ml/Kg bupivacaine 0.125% .
10016872|NCT05289375|Active Comparator|Test group (T)|Group formed by those patients who will receive the drug to be tested Vacucis
10016873|NCT05289375|Placebo Comparator|Placebo control group (P)|Group formed by those patients who will receive placebo, in the same dosage and duration
10016874|NCT05289336|Experimental|Transoral Laser Microsurgery|Transoral Laser Microsurgery
10016875|NCT05289310|Experimental|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
10016876|NCT05289310|Sham Comparator|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
10016877|NCT05289297|Active Comparator|Karydakis Flap Procedure|Vertical eccentric elliptical incision down to the post-sacral fascia, complete removal of unhealthy tissue, and normal tissue around the cyst and sinus tracts. Mobilization of the medial wound edge and advancement of the skin. Flap along the midline to the post-sacral fascia and suturing its margin to the lateral wound margin.
10016878|NCT05289297|Active Comparator|Burow's Triangle Advancement Flap Procedure|The flap is incised along the base of the wedge-shaped defect, and a small Burow's triangle is excised on the opposite side. The skin is mobilized and shifted in the direction of the arrow to close the defect. Excising the small Burow's triangle eliminates a dog ear at the base of the flap.
10016879|NCT05289284||Female soccer cohort|A female soccer cohort will be followed for 10 month regarding injuries
10016880|NCT05289258|Active Comparator|Neuropsychological treatment|Combination of different neuropsychological rehabilitation programs
10016881|NCT05289258|Experimental|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED).
10016882|NCT05289258|Other|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
10016883|NCT05289219|Experimental|Intervention Group|The duration of the program is 16-weeks, 3-times a week, for up to 50 minutes per session, starting 1 month after surgery, based on the recommendations of the WHO and the ACSM, because the guidelines for morbidly obese patients undergoing bariatric surgery are not defined. Information on exercises for morbidly obese adults is limited, so the exercise programs will follow the guidelines for adults aged 18 to 65 years healthy, with chronic diseases or disabilities
10016884|NCT05289219|No Intervention|Control Group|
10016885|NCT05289206|Experimental|Intervention - single arm|Oxford/AstraZeneca (ChAdOx1-S/nCoV-19 [recombinant]) - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
10016886|NCT05289180||Participants undergoing Heart Catherization|Participants undergoing Heart Catherization and will complete a research survey focusing on the comfort and anxiety during procedure. Participants will be followed for 18 months after enrollment. For each clinically indicated Brachial RV-EMB Biopsy during the 18-month follow up period, data from biopsy and pre and post-procedure echocardiograms will be reviewed and recorded for research purposes. A post-procedure questionnaire and post-discharge phone call will also take place after each procedure.
10016887|NCT05289128|Experimental|Experimental Group/ Active HD-tDCS|Patients randomly enrolled in this group will receive 10 sessions of anodal HD-tDCS stimulation on cortical representation zone of left diaphragmatic motor cortex associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
10016888|NCT05289128|Sham Comparator|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
10016889|NCT05289115|Experimental|Experimental Group/ Active HD-tDCS|Patients who will be randomly enrolled in this group. They will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
10016890|NCT05289115|Sham Comparator|Control Group / Sham Group|Patients enrolled in this group condition will receive 10 sessions of anodal stimulation on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
10016891|NCT05289102|Experimental|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks postpartum, and one later at 7 weeks postpartum.
10016892|NCT05289102|Active Comparator|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
10016893|NCT05289076||Colorectal liver metastsis|Tumour tissue from patients operated for colorectal liver metastases. A cubic centimeter of tumour tissue will be processed and implanted in zebra fish embryos.
10016894|NCT05289063|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP who are randomized to receive atorvastatin 10 mg daily.
10016895|NCT05289063|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP who are randomized to receive placebo daily.
10016896|NCT05289024||MABT utilizers|Chronic pain patients receiving MABT in an interdisciplinary clinic as part of their standard of care.
10016897|NCT05289011||Patients with spondyloarthritis without Inflammatory bowel disease|
10016898|NCT05288998||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
10016899|NCT05288998||Healthy Volunteers|Subjects without a family or personal history of kidney disease or concomitant systemic disorder that might affect the kidney
10016900|NCT05288972|Experimental|Mattress 1|Mattress 1 group will receive Polyurethane, Bonnel spring, medium-hard mattress
10016901|NCT05288972|Active Comparator|Mattress 2|Mattress 2 group will receive Polyurethane, pocket spring, medium mattress
10016902|NCT05288959|Experimental|Healthy participants|"All participants participate in five core sessions. Session 1 consists of MRI scans (T1-weighted, T2-weighted, diffusion MRI, resting-state fMRI). Thereafter, there are four TMS-EEG sessions. Session 2 delivers uni-focal spTMS to various cortical targets while EEG is recorded to determine inter-regional conduction delays. Thereafter, Sessions 3 - 5 deliver bi-focal TMS (PAS), each session using a different asynchrony (shorter, equal to, or longer than the conduction delay). The three PAS sessions are at least one week apart. Each of the PAS sessions have three segments: (a) TMS-EEG-behavioral recordings before PAS, (b) the PAS modulation, and (c) TMS-EEG-behavioral recordings after PAS.~In addition to these core sessions, some participants may be invited for additional sessions for parameter optimization and for assessing test-retest repeatability."
10016903|NCT05288946|Experimental|local segmental control and closed kinetic chain|the patients will receive local segmental control and closed kinetic chain three times a week for four weeks
10016904|NCT05288946|Experimental|local segmental control and open kinetic chain|the patients will receive local segmental control and open kinetic chain three times a week for four weeks
10016905|NCT05288946|Active Comparator|traditional therapy|the patients will receive traditional therapy three times a week for four week
10016906|NCT05288933|Active Comparator|Group A|20 participants will receive conventional physical therapy.TENS, the frequency of the current is 100 Hz and the duty cycle is 250 microseconds, three times per week for 4 weeks. Ultrasound waves, frequency 1 MHz with intensity 0.5 W/cm2, a pulsed mode for 5 minutes, three times per week for 4 weeks, passive stretching, and isometric exercises three times per week for 4 weeks.
10016907|NCT05288933|Experimental|Group B|20 participants will receive Instrument-Assisted Soft Tissue Mobilization (IASTM) and conventional physical therapy, the M2T blade will be used to find the exact areas of restriction in the upper trapezius. Then the M2T blade will be used, at an angle of 45 and using treatment planes 1, 2, and 3, to apply slow strokes along with the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. This procedure will be repeated twice a week for four weeks
10016908|NCT05288933|Experimental|Group C|20 participants will receive High Power Pain Threshold Ultrasound (HPPT US) and conventional physical therapy. For the HPPT US, ultrasound waves will be applied to trigger points of the upper trapezius in continuous mode, and the power of ultrasound will first increase to the threshold pain level at intensity (1.5-2 W/cm) according to the patient for 4-5 seconds with the probe placed directly on the trigger point and held motionlessly and then reduced to one-half of that intensity for15 seconds with the probe placed directly on the trigger point and move in a circular motion and repeat this three times. This procedure will be repeated twice a week for four weeks
10016909|NCT05288920|Active Comparator|Radiofrequency group|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
10016910|NCT05288920|Placebo Comparator|Steroids group|Transforaminal injection of Steroids alone
10016911|NCT05288907||Pruritus ani patients|Adult patients with pruritus ani (rectal itch) treated with lidocaine ointment
10016912|NCT05288881|Experimental|ANX105|
10016913|NCT05288881|Placebo Comparator|Placebo|
10016914|NCT05288829|Experimental|ALXN1210 SC|Participants received ALXN1210 SC.
10016915|NCT05288829|Experimental|ALXN1210 IV|Participants received ALXN1210 IV.
10016916|NCT05288829|Placebo Comparator|Placebo SC|Participants received placebo SC.
10016917|NCT05288816|Experimental|Cohort 1: ALXN1210 400 mg (Single)|A single dose of ALXN1210 was administered intravenously.
10016918|NCT05288816|Experimental|Cohort 2: ALXN1210 800 mg (Single)|A single dose of ALXN1210 was administered intravenously.
10016919|NCT05288816|Experimental|Cohort 3: ALXN1210 800 mg (Multiple)|ALXN1210 (800 mg) was administered intravenously every 4 weeks for a total of 5 doses.
10016920|NCT05288803||Control cohort|The investigators will collect outcomes for 100 Veterans treated with usual care rehabilitation after total knee arthroplasty. Data will be collected at all participating clinical locations. Data collection for these Veterans will precede data collection for the intervention cohort.
10016921|NCT05288803||Intervention cohort|The investigators will implement the clinical decision support tool in all participating clinic locations. We will collect outcomes for 100 Veterans treated in rehabilitation with use of the clinical decision support tool. Data collection for these Veterans will occur after data collection is complete for the Control cohort.
10016922|NCT05288738|Active Comparator|Group D1|PCA morphine 1mg/ml
10016923|NCT05288738|Active Comparator|Group D2|PCA morphine 1mg/ml
10016924|NCT05288725|Experimental|Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.
10016925|NCT05288725|Experimental|Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.
10016926|NCT05288725|Experimental|Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs|Participants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.
10016927|NCT05288725|Active Comparator|Corticosteroid injection|Subjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day.
10016928|NCT05288699|Experimental|Aliento|Participants complete the brief (~30 minute) intervention at baseline and will have access to intervention material for up to 1-month after the baseline appointment via the mobile health application.
10016929|NCT05288686|Experimental|SPIO arm|Superparamagnetic iron oxide guided sentinel lymph node mapping
10016930|NCT05288686|Active Comparator|Control arm|Conventional radioisotope and blue dye guided sentinel lymph node mapping
10016931|NCT05288673|Experimental|ALXN1210 400 mg|Participants received ALXN1210 every 28 days.
10016932|NCT05288673|Experimental|ALXN1210: 800 mg|Participants received ALXN1210 every 28 days.
10016933|NCT05288673|Placebo Comparator|Placebo|Participants received placebo every 28 days.
10016934|NCT05288660|Experimental|ALXN1210 200 mg|ALXN1210 was administered intravenously.
10016935|NCT05288660|Experimental|ALXN1210 400 mg|ALXN1210 was administered intravenously.
10016936|NCT05288660|Placebo Comparator|Placebo|Placebo was administered intravenously.
10016937|NCT05288595|Experimental|Pediatric patients with malignant or non-malignant hematologic condition|The infusion of the final TCRαβ/CD19 depleted product will be given through the recipient's central venous catheter and will be administered fresh, without cryopreservation whenever possible. If the product must be cryopreserved and then thawed, this will be done according to institutional standards.
10016938|NCT05288582|Other|Perfluorohexyloctane eye drop|Participants will have their tear lipid layer assessed. They will then have the eye drop instilled and will have an additional assessment of the tear lipid layer within 5 minutes of instillation of the the drop, and again 15 minutes after instillation.
10016939|NCT05288556|Experimental|Stoma Site Accessory|Stoma site accessory with enteral tube replacement procedure.
10016940|NCT05288504|Experimental|AVTX-002|Approximately 40 subjects will receive AVTX-002 at a dose of 600 mg three times during the study.
10016941|NCT05288504|Placebo Comparator|Placebo|Approximately 40 subjects will receive placebo sourced as normal saline three times during the study.
10016942|NCT05288491||Participants With Malignant Lymphoma|All participants diagnosed with histopathologically confirmed malignant lymphoma will be enrolled and observed retrospectively. Complete medical information will be collected at the time of enrollment via chart review.
10016943|NCT05288465|Experimental|Hair repigmentation during Cerebrolysin treatment for neurological diseases|Patients prescribed for Cerebrolysin treatment due neurological diseases.
10016944|NCT05288452|Experimental|Arm 1|Digital coaching+ Food delivery+ RPM
10016945|NCT05288452|Active Comparator|Arm 2|Digital coaching
10016946|NCT05288452|Active Comparator|Arm 3|Digital coaching+ Food delivery
10016947|NCT05288452|Active Comparator|Arm 4|Digital coaching+ RPM
10016948|NCT05288452|Active Comparator|Arm 5|Food delivery+ RPM
10016949|NCT05288452|Active Comparator|Arm 6|The participant's will not receive any Intervention
10016950|NCT05288452|Active Comparator|Arm 7|Food delivery
10016951|NCT05288452|Active Comparator|Arm 8|RPM
10016952|NCT05288426||participant post first BNT162b2 vaccination|Patients which developed myocarditis after the first dose of BNT162b2 vaccination
10016953|NCT05288426||participant post second BNT162b2 vaccination|Patients which developed myocarditis after the second dose of BNT162b2 vaccination
10016954|NCT05288426||participant post third BNT162b2 vaccination|Patients which developed myocarditis after the third dose of BNT162b2 vaccination diagnosed with MIS
10016955|NCT05288426||participant post COVID-19|Patients which developed myocarditis after COVID-19 infection
10016956|NCT05288413||Goldstandard DVT diagnostic through specialist sonographer|Patients with DVT symptomatic of lower limb which present at the DVT Clinic the Bays at St. Mary's Hospital will receive Goldstandard Scan through specialist.
10016957|NCT05288413||DVT diagnostic with Ultrasound probe with AutoDVT Software|Above patients will receive a second Ultrasound scan by a non-specialist with AutoDVT device.
10016958|NCT05288413||Retrospective data evaluation|result of AutoDVT is equivalent to diagnosis of specialist sonographer. Results specifically highlighted in patients with adipositas or malignant disease.
10016959|NCT05288400|Experimental|Group A|single-capsule of fixed dosed combination (FDC) of amlodipine 5 mg / bisoprolol fumarate 5 mg / perindopril arginine 5 mg
9518106|NCT03299868|Active Comparator|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
10016960|NCT05288400|Active Comparator|Group B|Free triple therapy of amlodipine 5 mg + bisoprolol fumarate 5 mg + perindopril arginine 5 mg, given concomitantly
10016961|NCT05288387|Experimental|Spinal cord stimulation in heart failure patients with hypotension|"Adhesive patches are applied to subjects' back skin. Single stimuli are delivered in order to define the stimulation threshold under the guidance of neuromyography. Vascular access is performed (jugular or subclavian) according to conventional preparation to right heart catheterization. Invasive hemodynamic measures are performed as usual.~High-frequency spinal cord stimulation at T5 level is initiated, and repeated hemodynamic measures performed within 2 minutes. Stimulation lasts for 5-10 minutes, and then ceased. Following a 5-minutes waiting period, repeat hemodynamic measures are performed. The same sequence of steps applies for stimulation levels T7-8 and a combination of T5 and T7-8.~Then the procedure is completed and data are analysed."
10016962|NCT05288374|Experimental|Celecoxib|Celecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
10016963|NCT05288374|Placebo Comparator|Placebo|A placebo pill provided by a hospital pharmacy will be administered in the day of surgery at 6 in the morning and 6 in the afternoon for 3 days.
10016964|NCT05288335|Experimental|Circular cylindrical mirror modulated frame glasses (compact)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (compact) throughout the entire course of the study.
10016965|NCT05288335|Experimental|Circular cylindrical mirror modulated frame glasses (strong defocus)|Subjects that were randomized to receive the Circular cylindrical mirror modulated frame glasses (strong defocus) throughout the entire course of the study.
10016966|NCT05288335|Experimental|single vision frame glasses|Subjects that were randomized to receive the single vision frame glasses throughout the entire course of the study.
10016967|NCT05288309|Other|RAİNSTİCK|In the 1st experimental group, the sound of the rain stick was played to distract attention. The rainstick, used by traditional societies, is a rhythm instrument that makes the sound of rain by moving it up and down. The length of the rain stick made of bamboo is 40 cm. There are spiral-shaped spines inside the tool, which is closed at both ends. It makes the sound of drizzling rain by moving it up and down.
10016968|NCT05288309|Other|KALEİDOSCOPE|In the second experimental group, kaleidoscope was used to distract attention. A kaleidoscope, or kaleidoscope, is a device that sees colorful patterns when looked into. Inside, there are three mirrors adjacent to each other with an inclination of 60 degrees between them. There are pieces of colored glass between the mirrors. When viewed from one end of this binocular, shape-shifting polygons are seen, often with images that will never be the same again. These patterns are created by the reflection of light and change constantly as the binoculars are moved.
9518107|NCT03299842|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
10016969|NCT05288283|Experimental|GWP42003-P|Participants will be initiated on a dose of GWP42003-P 2.5 milligrams per kilogram (mg/kg) twice a day (BID) (5 mg/kg/day); after 1 week, the dose will be increased to 5 mg/kg BID (10 mg/kg/day). Dose escalation up to a maximum daily dosage of 20 mg/kg/day (in increments of 5 mg/kg/day [2.5 mg/kg BID] no more rapidly than every 7 days) may occur after Day 15 based on the investigator's assessment of efficacy, safety and tolerability.
10016970|NCT05288283|Placebo Comparator|Placebo|Participants will receive the matching placebo.
10016971|NCT05288270|Experimental|Aramis Group|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
10016972|NCT05288270|Active Comparator|Conventional Group therapy|Consecutive patients, admitted to Sant' Anna Institute with diagnosis of stroke after hospital discharge that need motor and cognitive treatment and rehabilitation of neurological diseases.
10016973|NCT05288244|Experimental|foot bath|"It will be applied to the patients in group A (foot bath) every evening between 21.00-21.20 for 14 days. The steps of the procedure are as follows:~To be used in the footbath, a footbath tub, water at 38-40°C, a thermometer to measure the temperature of the water, foot towels, clean socks, gloves are prepared.~With the water temperature adjustment button in the foot bath tub, wait until the temperature of the water reaches 38-40 °C~Between 21:00 and 21:20, the feet are kept in water with a constant temperature of 38-40 °C for 20 minutes. (While the process is in progress, the water temperature is checked intermittently with a laser thermometer.)"
10016974|NCT05288244|Experimental|lavender oil snuff|"The L group (lavender oil sniffing) will be applied, the lavender oil sniffing process will be applied every evening between 21.00-21.05 for 14 days, and the process steps will be as follows;~Essential lavender oil to be used for the enterprise is obtained from a company that has business registration and TS EN ISO 9001: 2008 quality certificates with the number G06-3231 from the Ministry of Food, Agriculture and Livestock.~3 drops of the obtained lavender oil are dripped onto the cotton pad.~The prepared cotton pad is fixed on the patient's clothing in the upper chest and shoulder area with a locked needle and the patient is asked to sniff for 5 minutes (Özkaraman et al., 2018)."
10016975|NCT05288244|Experimental|foot bath and lavender oil snuff|AL group (both foot bath and lavender oil sniffing),for 14 days, every evening between 21.00-21.20, foot bath and lavender oil sniffing between 21.00-21.05 will be applied together.
10016976|NCT05288192|Active Comparator|Suprachoroidal triamcinolone injection|Eyes treated with suprachoroidal injection of triamcinolone acetonide.
10016977|NCT05288192|No Intervention|Non-treated eyes|Eyes that are receiving no interventions during the study period.
10016978|NCT05288179|Experimental|Pirfenidone group|Patient takes pirfenidone 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
10016979|NCT05288179|Placebo Comparator|placebo group|Patients take a placebo 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
10016980|NCT05288153|Experimental|the metformin group|Patients in the metformin group shall receive oral metformin at 500 mg per day for 6 months.
10016981|NCT05288153|Active Comparator|the folate group|Patients in the folate group shall receive oral folate at 5 mg three times a day for 6 months.
10016982|NCT05288140|No Intervention|usual ICU practice|The patient's evolution is reported verbally to the family.
10016983|NCT05288140|Experimental|ICU diary|Made a diary
9476841|NCT03567811|Other|Sedentary Control|Subjects who lived a sedentary lifestyle, did not meet Chronic Fatigue Syndrome criteria, and did not have any exclusionary chronic medical, psychiatric or other conditions were our Sedentary Control subjects. By design, this control group included controlled Type II diabetes and thyroid disease, chronic idiopathic fatigue, hypertension (other heart disease excluded) and other stable medical conditions. This variety of subjects were included to prevent ceiling (CFS) vs. floor (control) effects if the control group had totally pristine subjects with zero health issues. Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2
10016984|NCT05288127|Experimental|Talazoparib Single Agent|"The study will have 1 treatment group. Patients will receive a single oral dose of talazoparib (Talzenna®) 1mg/day daily for 28-day cycles until progressive disease, limiting toxicities, intercurrent medical issues, patient withdrawal of consent, death, or end of trial whichever occurs first. Treatment will be administered on an outpatient basis. Talazoparib should be taken orally once daily (i.e., continuous daily dosing) at approximately the same time each day (preferably in the morning). Talazoparib will be swallowed whole and may be taken with or without food. If a subject vomits a dose, the subject should not take a second dose that calendar day. The subject should resume daily dosing the next day.~Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered if the evidence of response or clinical benefit to talazoparib is noted."
10016985|NCT05291624||Patients with preoperative suspicion of endometriosis|Consecutive patients undergoing ultrasonographic preoperative assessment and subsequent surgical approach for deep endometriosis
10016986|NCT05291585|Experimental|the dedicated venous sinus thrombectomy stent|Patients diagnosed with acute or subacute venous sinus thrombosis within 28days from the onset of symptoms to endovascular treatment, regardless of whether anticoagulation has been performed. The dedicated venous sinus thrombectomy stent can be used to remove the thrombus to restore sinus blood flow.
10016987|NCT05291585|Active Comparator|balloon catheter thrombectomy|Intracranial thrombectomy was balloon catheter in conjunction with aspiration performed with a control product
10016988|NCT05291572|Active Comparator|Group A|will be treated by speech therapy only (fluency shaping).
10016989|NCT05291572|Active Comparator|Group B|will be treated by speech therapy (fluency shaping) plus Hyperbaric oxygen therapy.
10016990|NCT05291572|Active Comparator|Group C|will be treated by speech therapy (fluency shaping) plus medical treatment (brain stimulant).
10016991|NCT05291546|Experimental|Part A|Single ascending dose (SAD) of R9035 or matching placebo given by intravenous (IV) administration.
10016992|NCT05291546|Experimental|Part B|Selected doses of REGN5381 or matching placebo given by IV administration followed by selected doses of REGN9035 via IV infusion
10016993|NCT05291520|Experimental|VH3810109 + rHuPH20|Healthy participants will receive a single SC dose of VH3810109 injection with rHuPH20.
10016994|NCT05291507|Experimental|Muse MRgFUS System|Subjects will undergo partial ablation of half (~50%) of their tumor followed by surgical resection approximately 2-3 weeks after ablation.
10036083|NCT01812460|No Intervention|Control group|The patients randomized to the control group receive lung physiotherapy from day two of admittance. Lung physiotherapy consists of help to bring up sputum from the bronchi and lungs. The patients are instructed in breath exercises, use of Positiv Ekspiratory Pressure, breathing exercises, cough and pursed lip breathing. The patients are encouraged to spend as little time in bed as possible.
10016995|NCT05291494|Experimental|WeChat group|The patients in this group will be first assessed by a researcher on admission about anxiety and sleep (base on the State-Trait Anxiety Inventory (STAI) scale and the sleep quality scale (SQS)). Once the assessment completed, the patients are required to follow the WeChat public platform to watch the education videos when they are free. The content of the videos covers all aspects of surgery, anesthesia, and perioperative care. The videos are presented in an easy-to-understand pattern to ensure participants of all ages and levels of education comfortably understand the content.
10016996|NCT05291494|Placebo Comparator|Regular group|Patients in this group were also assessed by the same researcher on admission for anxiety and sleep (base on State-Trait Anxiety Inventory (STAI) scale; sleep quality scale (SQS) scale). Upon completion of the assessment, they received oral instruction from the ward nurse covering the same contents as above instead of the education video.
10016997|NCT05291481|Experimental|CAPAS Youth Parenting Intervention|11-week CAPAS-Youth culturally adapted intervention
10016998|NCT05291481|No Intervention|Wait-list control|Participants allocated to this condition receive the intervention until all assessments are completed for both arms in each cohort
10016999|NCT05291455|Experimental|Lacosamide|Lacosamide will be given.
10017000|NCT05291455|Active Comparator|Phenobarbitone|Phenobarbital will be given
10017001|NCT05291429|Active Comparator|VR - coaching arm|30 individuals to be enrolled in the intervention arm that also includes coaching sessions to support and encourage VR use (VR+coaching arm).
10017002|NCT05291429|Active Comparator|VR only - no coaching|30 individuals to be enrolled in the intervention arm without coaching (VR arm)
9476842|NCT03567798|Experimental|A|"UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
10017003|NCT05291429|No Intervention|No intervention - control arm|30 individuals to be enrolled in the control arm with no active intervention (comparator 2; control arm)
10017004|NCT05291416||1|healthy children aged between 4-16 years
10017005|NCT05291416||2|children aged between 4-16 years, suffering from juvenile idiopathic arthritis
10017006|NCT05291377||high disbility group|Group scored more than half of the score of the neck disability index
9476843|NCT03567798|Placebo Comparator|B|"Placebo~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
9476844|NCT03567772|Experimental|Wiifit Nintendo video game|Pulmonary rehabilitation program using video games exercise from Nintendo
10017007|NCT05291377||low disability group|Group scored less than half of the score of the neck disability index
10017008|NCT05291364|Active Comparator|Group 1|injection of ethanol and lidocaine with dexmedetomidine
10017009|NCT05291364|Active Comparator|Group 2|injection of ethanol and lidocaine Without dexmedetomidine
10017010|NCT05291351|Experimental|Pea|Treatment 1: crackers made with 25% whole pea flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse pea flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine pea flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
10017011|NCT05291351|Experimental|Lentil|Treatment 1: crackers made with 25% whole lentil flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse lentil flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine lentil flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
10017012|NCT05291351|Experimental|Oats|Treatment 1: porridge made with whole oat flour; Treatment 2: porridge made with coarse oat flour; Treatment 3: porridge made with fine oat flour; Treatment 4: porridge made with whole oats (control)
10017013|NCT05291338||HCC patients|100 hepatocellular carcinoma patients underwent TACE
9476845|NCT03567772|Active Comparator|Pulmonary rehabilitation program|Pulmonary rehabilitation program with ergometer cycle
9476846|NCT03567746|Experimental|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
9518108|NCT03299803|Experimental|Men's Healing Pathways|Men with physical disabilities will receive a 15 session weekly peer implemented program
9803689|NCT03535922|Experimental|The disease-specific PROM group|Hemodialysis (HD) units randomized to this PROMs assessment group will administer a disease-specific PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The disease-specific PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed disease-specific PROM is the ESAS-r:Renal or the IPOS-Renal.
10036084|NCT01812486|Active Comparator|control arm|NID2Gy = 50 Gy Swallowing apparatus: standard dose
10036085|NCT01812486|Experimental|Experimental de escalated arm|NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge
10037341|NCT01824199|Experimental|Omeprazole|Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire 30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
10017014|NCT05291312|Other|endoscopic assisted coblation|
10017015|NCT05291312|Other|conventional curettage|
10017016|NCT05291299|Other|Standard of Care (Control Group)|Physicians will follow standard of care and instruct participants in the control group to follow a Mediterranean diet higher in vegetables and fruits[19]. Patients will be provided with a handout detailing the basics of the Mediterranean diet. At follow up visits, physicians will ask participants about how they have been eating and if they have been following the guidelines.
10017017|NCT05291299|Experimental|Anti-inflammatory Diet (Intervention Group)|"An 8-week nutrition program consisting of an individualized elimination diet and systematic food reintroduction implemented and supervised by a Registered Dietitian. Clinical trials have shown some benefit from elimination diets for individuals with autoimmune disease [18].~The specifics of the elimination diet including duration and foods included will be individual and up to the RDs discretion based on the patient's medical and diet history, willingness, current diet, preferences, goals, and ability. The initial diet instruction with a Registered Dietitian will be a one-hour, individual secure video call, with nutrition evaluation/assessment and education on elimination diet protocol. Follow up visits will be approximately 20-30 minutes for the subsequent 7 weeks."
10017018|NCT05291273|Experimental|Intervention|All subjects will perform the same tests.
10017019|NCT05291260|Experimental|Cast immobilization|Cast immobilization to immobilize the thumb for 4 weeks. After 2 weeks the thumb will be re-examined to determine if surgery is required. It is expected that at re-evaluation at 2 weeks after starting the cast treatment about 1 in 10 patients will still need surgery.
10017020|NCT05291260|Active Comparator|Surgery|The intervention is compared to surgery, which is standard treatment for complete ulnar collateral ligament ruptures.
10017021|NCT05291247||Heavily calcified femoropopliteal disease|"Subject must be between 21 and 85 years old~Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5~Willing to comply with the specified follow-up evaluation~Written informed consent prior to any study procedures"
10017022|NCT05291234|Experimental|Stage A: ABBV-916|Participants will receive ascending doses of ABBV-916 for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Open-label Extension (OLE) Period.
10017023|NCT05291234|Placebo Comparator|Stage A: Placebo|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Open-label Extension (OLE) Period.
10017024|NCT05291234|Experimental|Stage B: ABBV-916 Dose A|Participants will receive ABBV-916 Dose A for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Open-label Extension (OLE) Period.
10017025|NCT05291234|Placebo Comparator|Stage B: Placebo for ABBV-916 Dose A|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Open-label Extension (OLE) Period.
10017026|NCT05291234|Experimental|Stage B: ABBV-916 Dose B|Participants will receive ABBV-916 Dose B for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Open-label Extension (OLE) Period.
10017027|NCT05291234|Placebo Comparator|Stage B: Placebo for ABBV-916 Dose B|Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Open-label Extension (OLE) Period.
10017028|NCT05291221|Placebo Comparator|control|At the end of the operation by 15min, 5ml saline in a medical spray bottle was sprayed down the intratracheal tube of patients.
10017029|NCT05291221|Active Comparator|Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
10017030|NCT05291221|Active Comparator|Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
10017031|NCT05291208|Experimental|Treatment group|This group will receive a cognitive training intervention combined with alternating current electrical stimulation (i.e., treatment).
10017032|NCT05291208|Sham Comparator|Control group|This group will receive a traditional cognitive training intervention with sham electrical stimulation.
10017033|NCT05291195|Experimental|Laser-devices group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite. Afterwards, depending on allocations, in the laser devices group, adjuvant treatment approaches were be performed by means of laser devices either photodynamic therapy (HELBO, Photodynamic Systems GmbH), or high power diode laser (940nm, Biolase).
10017034|NCT05291195|Experimental|Sodium hypochlorite|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
10017035|NCT05291195|Experimental|Essential oil|"Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).~Depending on allocations, in the essential oil group, the canals were be treated with adjuvant essential oil of Cymbopogon martinii and Thymus vulgaris (Herba oils, Herba doo, Belgrade, Serbia)"
10017036|NCT05291182|Experimental|Dose-escalation|The study is conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of SY-4835.
10017037|NCT05291156|Experimental|Cetuximab + avelumab|"Cetuximab + avelumab (115 patients) - cetuximab at 400 mg/m2, as loading dose, and, subsequently, at 250 mg/m2 weekly, and avelumab was given intravenously at flat dose of 800 mg, once every 2 weeks.~Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol."
10017038|NCT05291156|Active Comparator|Cetuximab|Cetuximab only (58 patients) - cetuximab at 400 mg/m2 intravenously, as loading dose, and, subsequently, at 250 mg/m2 weekly. Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol.
10017039|NCT05291130||Plasmafit® Vitelene® Vitamin E ceramic femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and bioceramic femoral heads
10017040|NCT05291130||Plasmafit® Vitelene® Vitamin E metal femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and metal femoral heads
10017041|NCT05291130||Plasmafit® polyethylene metal femoral heads|Plasmafit® Acetabular Cup System with polyethylene and metal femoral heads
10017042|NCT05291104|No Intervention|Placebo|Interventions are not received any treatments.
10017043|NCT05291104|Experimental|Intervention|Interventions are received folic acid or choline
10017044|NCT05291065|Experimental|Fasted exercise|Fasted prior to exercise
10017045|NCT05291065|Experimental|High protein breakfast exercise|High protein breakfast consumption prior to exercise
10017046|NCT05291065|Experimental|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
10017047|NCT05291052|Experimental|TIS combined therapy|All patients will be treated with the combination of tisleizumab , lenvatinib and XELOX regimen (oxaliplatin combined with capecitabine) until disease progression , unacceptable toxicity, death or the patient meets any other discontinuation criteria described in the protocol, whichever occurs first. Subjects can receive up to 8 cycles of the XELOX regimen. For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
10017048|NCT05291039|Active Comparator|Infliximab.|group 1 (n=20): patients will receive IFX,
10017049|NCT05291039|Active Comparator|Adalimumab.|group 2 (n=20): patients will receive ADA
10017050|NCT05291013|Experimental|Gastric bypass with T2DM|
10017051|NCT05291013|Experimental|Gastric bypass without T2DM|
10017052|NCT05291013|No Intervention|Control group|
9518109|NCT03299803|No Intervention|Control group|Telephone contact only
10017053|NCT05291000|Experimental|RoT-ReWiH|First, pre-tests were applied to the patients in the training and reminder by watch group at first home visit.Second home visits were conducted participants 12th weeks after the first home visit.One of the researchers presented the education program to individuals with hypertensive.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes.For the patients in this group, the alarm time was set according to the time when blood pressure medication was taken, the cord was adjusted according to the arm, and then information was given about the use of the watch. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
10037342|NCT01824212||ICD-patients|Patients to whom cardiac fibrillation will be induced during the implantation of an implantable cardioverter defibrillator (ICD) or patients with an already implanted ICD, which function needs to be revised and during the revision cardiac defibrillation will be induced.
10037343|NCT01824225|Active Comparator|PRN injection of aflibercept|Intravitreal aflibercept
10037344|NCT01824225|Active Comparator|Two months injection of aflibercept|Intravitreal afilibercept
10017054|NCT05291000|Experimental|Training group|First, pre-tests were applied to the patients in the training group at first home visit.The education program included issues related to hypertension, measurament of pressure blood, lifestyle changes and adherence to treatment. The program using face-to-face communication technique and lasted about 45 minutes. In addition, other drugs used by individuals at home (such as painkillers, antibiotics) were also evaluated during the home visit, and a red label was made on the antihypertensive drug box to distinguish antihypertensive drugs from other drugs. At the end of the interview, the blood pressure of the experimental groups was measured and the measurement value was recorded on the blood pressure follow-up card.
10017055|NCT05291000|No Intervention|Control group|Pre-tests was applied to the patients in the control group.No intervention was be applied to the patients in this group and second home visit 12th weeks after the first home visit and were readministered the post-tests.
10017056|NCT05290987|Experimental|Advanced Water S-100 ionized nasal spray|2 sprays in each nostril, 6 times a day during 8 days
10017057|NCT05290987|Placebo Comparator|Nasal spray with purified water|2 sprays in each nostril, 6 times a day during 8 days
10017058|NCT05290948|Active Comparator|investigate of the effect of intravitreal injection of bevacizumab with acetazolamide tablets|
10017059|NCT05290948|Active Comparator|Investigate the effect of intravitreal injection of bevacizumab alone|
10017060|NCT05290935|Experimental|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
10017061|NCT05290909|Experimental|The protocol of blended and problem-based learning|The experimental group will accept the protocol of blended and problem-based learning in the professional ethics course, 2 hours /per week, for 18 weeks
10017062|NCT05290909|Active Comparator|The traditional problem-oriented teaching model|The control group will accept the traditional problem-oriented teaching model in the professional ethics course, 2 hours /per week, for 18 weeks
10017063|NCT05290896|Other|Lens star biometry|Biometry done prior to phacoemulsification
10017064|NCT05290870||Subjects implanted with hydrophilic acrylic IOLs|Subjects were implanted with a HydroSmart IOL (FEMTIS, LENTIS or VISIOTIS)
10017065|NCT05290870||Subjects implanted with hydrophobic acrylic IOLs|Subjects were implanted with an ACUNEX IOL
10017066|NCT05290857|Experimental|High thrombotic risk|For patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis after GI bleeding.
10017067|NCT05290857|Experimental|Moderate thrombotic risk|For patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis after GI bleeding.
10017068|NCT05290831|Experimental|Main study group|
10017069|NCT05290818|Active Comparator|Manual Total Knee Arthroplasty|"This group will receive a conventional manual Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert. The surgeon will then make bone cuts using a manual jig and a hand held saw to prepare the bone surfaces for the implant. A measured resection technique will be employed with a three degree tibial slope. The surgeon will use a conventional jig alignment technique for intramedullary referencing for the femur and extra medullary referencing for the tibia. Once the implant is in position the knee is then balanced by the feel though a range of movement and soft tissue releases will be performed as required to balance the knee in flexion and extension."
10017070|NCT05290818|Experimental|Robotic Assisted Unicompartmental Knee Arthroplasty|This group will receive the cemented Restoris MCK (Mako, Stryker) with a highly crossed linked (X3) polyethylene insert through a less invasive to the knee joint. Instead of using a manual jig and a hand held burr will be used to prepare the bone surfaces for the implant, the MAKO robotic arm will be used by the surgeon to cut the bone at the required alignment. The information from the CT scan will be used to create a 3D model of the patient's bony anatomy and will used to plan the positioning of the implant. Once the trackers are in place registration of the knee joint surface is performed. The specified bone cuts are then performed using the robotic arm, aiming to gap balance the knee through a full range of movement.
10017071|NCT05290805|Experimental|ECMO flow rate reduction|In the intervention cohort ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
10017072|NCT05290805|No Intervention|no ECMO flow rate reduction|In this cohort ECMO flow rate is not reduced for CT image acquisition.
10037345|NCT01824238|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
10037346|NCT01824238|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
10037347|NCT01824251|Experimental|NPB-01|Intravenous immunoglobulin
10037348|NCT01824264|Experimental|LIK066 2.5 mg|Patients receive 2.5 mg of LIK066 once daily for 12 weeks
10017073|NCT05290792|Other|Intra-individual changes of physiological and activity parameters|"Participants will be administered FluMist (live attenuated influenza vaccine) to induce a low grade VRTI (Day 0). Participants will be monitored in the 7 days prior and 7 days after vaccination via symptom questionnaires, blood draws, stair tests and vital sign monitoring from wearable sensors.~Each participant will serve as their own control, relying on the baseline measurements obtained over the 7-day period prior to inoculation."
10017074|NCT05290779|Active Comparator|ultrasound|selective lumbar nerve root steroid injection under ultrasound guidance.
10017075|NCT05290779|Sham Comparator|fluoroscopy|selective lumbar nerve root steroid injection under fluoroscopy guidance.
10017076|NCT05290766|Active Comparator|Control group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on 4 implants that were placed according to the All on four concept."
10017077|NCT05290766|Active Comparator|Study group|"will receive implant-supported mandibular fixed metal acrylic prosthesis on two implants placed according to All On two concept."
10017078|NCT05290740|Active Comparator|group A|
10017079|NCT05290740|Active Comparator|group B|
10017080|NCT05290727|Other|0.15% Aquoral Lipo (Esteve) and 0.15% Hyabak (Thea)|Dosage form: topical administration multidose ophthalmic eye drops Product usage order will be determined through randomization Duration: 15 days + 15 days Frequency: dosage between 3 and 6 drops per day
10017081|NCT05290727|Other|0.15% Hyabak (Thea) and 0.15% Aquoral Lipo (Esteve)|Dosage form: topical administration multidose ophthalmic eye drops Product usage order will be determined through randomization Duration: 15 days + 15 days Frequency: dosage between 3 and 6 drops per day
10017082|NCT05290714|Experimental|Mentalization Based Treatment for Children (MBT-C)|Mentalization Based Therapy for Children (MBT-C) is a transdiagnostic time-limited (12 weekly sessions) and manualized treatment for children aged between 5 to 12 years old with the main aim of increasing mentalization and restoring epistemic trust. Parallel parental work takes place to increase parental mentalization.
10017083|NCT05290714|Active Comparator|Parenting and Social Skills Group|"Parenting groups will run for 12 weeks with 10 parents per group. They will involve activities to help parents develop effective parenting skills via working on a family genogram, providing information on child development, developing acceptance and empathy, setting boundaries and anger regulation.~The social skills groups will run for 12 weeks and will be conducted with 10 children per group. They will involve activities on self-presentation, peer communication, play skills, empathy and anger management."
10017084|NCT05290688|Other|Untreated RRMS patients|Untreated RRMS patients with a 50 ml blood sample during their routine care
10017085|NCT05290662||Participants having received oNKord® as part of the WiNK clinical trial|WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable disease and not currently proceeding to hematopoietic stem cell transplantation
10017086|NCT05290636|Experimental|single arm trial|A single-arm trial was designed. (Two-hour sessions per week for 18 weeks). The value of classroom learning and practical experience for the study subjects is emphasized in this intervention course. The case analysis teaching technique will be used extensively in the classroom, and the school's digital action learning platform will support instructional activities relevant to senior nursing and elderly nursing practice. In each section of the course, combine classroom instruction with case analysis (2 hours each, 20-30 minutes for topic teaching, 70-80 minutes for case discussion and feedback)
10017087|NCT05290597|Experimental|IBI363|Single arm
10017088|NCT05290571|Experimental|Intervention Group|Intervention Group will be asked to follow the actions in the provided video. It lasts for approximately 30 minutes, with 5-minute warm-up and cool-down exercises respectively, a 4-minute song repeating for 4 times and a 1-minute rest in between each repetition. Videos, in the form of a YouTube link, will be distributed for the Intervention Group, as well as the leaflets.
10017089|NCT05290571|Active Comparator|Control Group|Control Group will receive a leaflet on 10 actions extracted from mOEP, 2 actions from conventional OEP and 1 action from Mini-BESTest. The participants will perform 8-16 repetitions for each action, with 3-5 seconds of rest between actions.
10017090|NCT05290558|Placebo Comparator|Placebo|Patients in this arm will be given a placebo pill that resembles the actual Bu Shen Yi Jing Pill.
10017091|NCT05290558|Active Comparator|Bu Shen Yi Jing Pill|Patients in this arm will be given the BSYJ Pill.
10017092|NCT05290545|Experimental|Haplo-PBSC+Cord group|The third party UCB will be infused the day after infusion of PBSCs from HID.
10017093|NCT05290545|Active Comparator|Haplo-PBSC+BM group|The BMSCs from the same HID will be infused the day after infusion of PBSCs.
10017094|NCT05290532|Other|Individualized exercise training|Exercise training. Individual program training 2 days per week during 4 week, after one week of discharge
10017095|NCT05290532|No Intervention|No Intervention: Control|Usual care including rehabilitation when necessary
10017096|NCT05290519|Experimental|Group A|plant protein for 4 weeks than animal protein for 4 weeks
10017097|NCT05290519|Experimental|Group B|animal protein for 4 weeks than plant protein for 4 weeks
10017098|NCT05290506|Active Comparator|Prediabetes Low GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
10017099|NCT05290506|Active Comparator|Prediabetes High GLP-1|prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
10017100|NCT05290506|Active Comparator|Diabetes Low GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
10017101|NCT05290506|Active Comparator|Diabetes High GLP-1|type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.
10017102|NCT05290493|Active Comparator|NB-001|Active drug product, NB-001: Two (2) 100 mg capsules will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce; total daily dose: 400 mg.
10017103|NCT05290493|Placebo Comparator|Placebo|Placebo: Two (2) capsules (matching NB-001) will be administered orally BID with liquids or, if the subject is unable to swallow a capsule whole, capsules may be opened, and the contents sprinkled on applesauce.
10017104|NCT05290480|Experimental|Expiratory muscle training|participant performed expiratory muscle training with threshold device
10017105|NCT05290480|Experimental|Insentive spirometry|participant performed deep breathing exercise with insentive spirometry device
10017106|NCT05290467|No Intervention|control group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the control group. Participants will be scheduled for 12 routine ANC visits.
10017107|NCT05290467|Experimental|experimental group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the experimental group. Participants will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Message, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
10017108|NCT05290454|Experimental|mNGS-guided treatment group|In mNGS-guided treatment group, participants undergo mNGS, using appropriate lower respiratory tract (LRT) specimen, and conventional microbiological diagnostic tests. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Conventional microbiology diagnostic techniques will be also applied using appropriate LRT specimens and other necessary specimens (such as blood, pleural fluid, urine, et al.). Clinicians alter or confirm the definitive treatment based on mNGS results, as well as results from conventional microbiology diagnostic techniques.
10037349|NCT01824264|Experimental|LIK066 5 mg|Patients receive 5 mg of LIK066 once daily for 12 weeks
10017109|NCT05290454|No Intervention|Conventional treatment group|In conventional treatment group, participants undergo conventional microbiological tests using appropriate LRT specimen, and other necessary specimens (such as blood, pleural fluid, urine, et al.). LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Based on results of conventional microbiology diagnostic techniques, clinicians alter or confirm the definitive treatment of participants.
10017110|NCT05290441|Active Comparator|None involement|In the pathological examination, the group of patients without EGFR involvement in the biopsy material.
10017111|NCT05290441|Active Comparator|Mild|In the pathological examination, the group of patients mild EGFR involvement in the biopsy material.
10017112|NCT05290441|Active Comparator|Moderate|In the pathological examination, the group of patients moderate EGFR involvement in the biopsy material.
10017113|NCT05290441|Active Comparator|Severe|In the pathological examination, the group of patients severe EGFR involvement in the biopsy material
10017114|NCT05290428||Retrospective part|This part will enroll at least 120 cases in previously preserved samples.
10017115|NCT05290428||Prospective part|This part will enroll at least 339 cases.
10017116|NCT05290402||an application-based digital navigator|"JEEVA is a new digital health navigator app. This app can be used on a mobile phone or tablet. JEEVA has all of the surgical teaching information from the traditional paper packet and also has additional resources like brief videos, checklists, and reference photos."
10017117|NCT05290389||Physicians|All Emergency Medicine physicians and Interventional Cardiologists involved in STEMI care in the Hamilton Niagara Haldimand Brant Local Health area will be eligible for participation in this study.
10017118|NCT05290376|Active Comparator|Control group|Group I (control): patients who would be delivered mandibular implant overdenture retained by two RTx locator attachments using conventional loading protocol
10017119|NCT05290376|Active Comparator|Study group|Group II (study): patients who would be delivered mandibular overdenture retained by two RTx locator attachments using early loading protocol.
10017120|NCT05290337|Experimental|ZR-CHOP|
10017121|NCT05290324|Experimental|MIdazolam Group|Following surgery Immediately after shifting in ICU, midazolam infusion were administered as 0.25 mg/kg/min.
10017122|NCT05290324|No Intervention|Propofol Group|Following surgery after Immediately shifting in ICU propofol infusion was started at 10µg/kg/min.
10017123|NCT05290311||COMB|The 'combined' or 'COMB' group received cognitive behavioural therapy next to pharmacotherapy for ADHD in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
10017124|NCT05290311||PHA|The 'pharmacotherapy' group or 'PHA' received pharmacotherapy for ADHD only in the past. Patients chose themselves whether or not they wanted to receive cognitive behavioural therapy.
10017125|NCT05290298|Experimental|NITRATE|Multi-component nutritional formula (containing 1200 mg of potassium nitrate, 200 mg of magnesium, 50 mg of zinc, and 1000 mg of citric acid)
10017126|NCT05290298|Placebo Comparator|PLACEBO|Placebo (2.5 grams of inulin)
10017127|NCT05290272|Experimental|ViFIVE Digital Care Program|AI based digital care program that is individually tailored for each user depending on need. ViFive DCP includes illustration, voice guidance, and pose correction features of AI coach. Participants will required to complete the program.
10017128|NCT05290259||Ballroom Basics for Balance Program|The Ballroom Basics for Balance program is a 12-week physical activity program which uses dance to focus on balance for community dwelling adults.
10017129|NCT05290220|Experimental|Arm A: As first-line therapy|HLX07 1500 mg + HLX10 300 mg + HLX04 15mg/kg iv q3w
10017130|NCT05290220|Experimental|Arm B: As second-line therapy|HLX07 1500 mg iv Q3w + Lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW <60 kg) po qd
10017131|NCT05290220|Experimental|Arm C:As third-line or above therapy|HLX07 1500 mg iv Q3w
10017132|NCT05290207||Newly diagnosed male obese patients with type 2 diabetes|
10017133|NCT05290207||Newly diagnosed male non-obese patients with type 2 diabetes|
10017134|NCT05290207||Newly diagnosed male patients with type 1 diabetes|
10017135|NCT05290207||Healthy, non-obese men|
10037350|NCT01824264|Experimental|LIK066 10 mg|Patients receive 10 mg of LIK066 once daily for 12 weeks
9476847|NCT03567746|Active Comparator|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
9476848|NCT03567733||Coronary Artery Disease|Drug- eluting Stent
9518110|NCT03299790|Active Comparator|training group 1: HIIT|high-intensity interval exercise training group (T2DM patients)
10017136|NCT05290181|Experimental|Pilates exercise and whatsapp text message group|A support program including pilates exercises and sending text messages will be applied to the students in the intervention group for 8 weeks. Online pilates exercises will be done 2 days a week and individual short messages will be sent to their smartphones via the Whatsapp application 3 days a week. Participants will be provided with Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises. The exercises will be done online in the presence of a research physiotherapist with The Australian Physiotherapy & Pilates InstituteMatwork Level 1 (APPI) certificate.
10017137|NCT05290181|No Intervention|Control group|No intervention will be made in the control group.
10017138|NCT05290168|Experimental|Normal children|normal children undergoing simple surgery
10017139|NCT05290155|Experimental|Anti-CD7 CAR T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
10017140|NCT05290142|Active Comparator|Self-Guided Digital Training (DT)|"Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available online on a smartphone app as well as a website that can be accessed through an internet-enabled device.~Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface."
10017141|NCT05290142|Experimental|Digital Training with Coaching (DT-C)|In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. Participants will also be able to send text messages to coaches.
10017142|NCT05290129|Experimental|Oxytocin infusion rate 4 IU/h|The maintenance infusion rate of oxytocin will be 4 IU/h.
10017143|NCT05290129|Experimental|Oxytocin infusion rate 6 IU/h|The maintenance infusion rate of oxytocin will be 6 IU/h.
10017144|NCT05290129|Experimental|Oxytocin infusion rate 8 IU/h|The maintenance infusion rate of oxytocin will be 8 IU/h.
10017145|NCT05290129|Experimental|Oxytocin infusion rate 10 IU/h|The maintenance infusion rate of oxytocin will be 10 IU/h.
10017146|NCT05290129|Experimental|Oxytocin infusion rate 12 IU/h|The maintenance infusion rate of oxytocin will be 12 IU/h.
10017147|NCT05290129|Experimental|Oxytocin infusion rate 14 IU/h|The maintenance infusion rate of oxytocin will be 14 IU/h.
10017148|NCT05290129|Experimental|Oxytocin infusion rate 16 IU/h|The maintenance infusion rate of oxytocin will be 16 IU/h.
10017149|NCT05290116|Experimental|HAIC Combined with Tislelizumab and Apatinib|
10017150|NCT05290103|Experimental|Game intervention|Participants in this arm will receive the game intervention including 15-30 minutes of digital health game playing at school and 2 weeks of free usage of the game during free time and a 30-minute debriefing session with a researcher.
10017151|NCT05290103|No Intervention|No intervention|The participants in this arm will receive no intervention.
10017152|NCT05290090|Experimental|Rituximab, lenalidomide, zanubrutinib and RCHOP|"Rituximab, lenalidomide, zanubrutinib for 2 cycles: rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~RCHOP for 4 cycles: rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
10017153|NCT05290077|Active Comparator|Cases|group of vitiligo patients
10017154|NCT05290077|Active Comparator|control group|healthy group
10017155|NCT05290051|Experimental|Patients referred for cytogenetic analysis|Analysis of patient DNA with Optical Genome Mapping (Bionano®) and long read Sequencing (Nanopore®) in search for chromosome abnormalities (aneuploidies and SV)
10037351|NCT01824264|Experimental|LIK066 25 mg|Patients receive 25 mg of LIK066 once daily for 12 weeks
10017156|NCT05290025|Experimental|Intervention|Patients will be offered brief weekly behavioural interventions for smoking cessation and prescription-free nicotine replacement products in addidition standard opioid replacement therapy.
10017157|NCT05290025|Other|Intitial screening only|Participants will receive standard opioid replacement therapy. At the start of the intervention number of cigarettes smoked during the past week will be recorded. Smokers will be adviced to make a cessation or reduction attempt. Advice that nicotine replacement products ( patches, lozenges or gum) may be bought over the counter in grocery-stores and pharmacies and information about goverment home-pages giving cessation advice.
10017158|NCT05290012|Experimental|Dark Chocolate|Participants consumed 18 grams of dark chocolate (36 g/day, 400 mg/day of flavanols) twice daily.
10017159|NCT05290012|No Intervention|Control|No intervention was made
10017160|NCT05289999|Experimental|Using the virtual reality headset for the first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset, then the second injection following the usual conditions of care without the device
10017161|NCT05289999|Experimental|Using the virtual reality headset for the second injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus following the usual conditions of care, then the second injection using the virtual reality headset
10017162|NCT05289986|Experimental|immediate switch arm|"Experimental arm (baseline visit switch group, N=30): One DOR/TDF/3TC tablet taken orally once daily for 48 weeks.~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
10017163|NCT05289986|Active Comparator|delayed switch arm|"Control arm (deferred switch group, N=30): Participants will continue their current triple cART regimen for 24 weeks, and then switched to taking one TDF/3TC/DOR tablet orally once daily (24 -48 weeks).~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
10017164|NCT05289973|Experimental|TruNatomy Files|Newly introduced endodontic file
10017165|NCT05289973|Experimental|Hyflex EDM|Endodontic file
10017166|NCT05289947|Placebo Comparator|Placebo|500-mg placebo capsule, 4 capsules twice a day for 24 weeks
10017167|NCT05289947|Active Comparator|MLC1501 Low-dose|MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
10017168|NCT05289947|Active Comparator|MLC1501 High-dose|MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks
10017169|NCT05289934|Experimental|Children with Epilepsy|Children (age: 4- 17 years old) will participate in this study, and they will listen to Mozart K.448 (1st movement) and instrumental age-appropriate song with 10 minutes wash out in between, each lasting up to 9 minutes in the daytime (between 1-5 pm). The music stimuli will be randomly played in 2 to 7 days during the EMU stay (average 4 days). Music will be delivered via single-use earbuds.
10017170|NCT05289921|Experimental|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
10017171|NCT05289921|Active Comparator|Clostridium botulinum type A|Clostridium botulinum type A Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
10017172|NCT05289895||1|Sequence I (Retrospective study: proteomic analysis of pathological specimens and information collection of previous patients with pancreatic cancer)
10017173|NCT05289895||2|Sequence 2 (Non-interventional prospective study, sample and information collection in patients with pancreatic cancer)
10017174|NCT05289895||3|Sequence 3 (Non-intervention study, healthy subjects sample and information collection)
10017175|NCT05289882|Experimental|PASS Program Condition|Participants in this condition will take part in weekly physical activity, augmented with built-in opportunities to socially connect, and be directed to veteran-specific support services and resources.
10017176|NCT05289882|No Intervention|Waitlist Control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 6-month assessment period (following randomization). They will be asked to complete the same measures (and will be remunerated in the same way as those in the PASS program condition, based on the completion of study measures). At the end of the 6-month trial, participants in this condition will have the opportunity to participate in the PASS program.
10017177|NCT05289843|Experimental|Experimental|Rosmarinus officinals will be used as root canal irrigant in treating aysymptomatic mandibular premolars.
10017178|NCT05289843|No Intervention|Control Group|Sodium Hypochlorite used as control in root canal irrigations in treating a asymptomatic mandibular premoalrs.
10017179|NCT05293028|Experimental|Drug:F527|F527 is dose-escalated sequentially by accelerated titration and i3+3 design.
10037352|NCT01824264|Experimental|LIK066 50 mg|Patients receive 50 mg of LIK066 once daily for 12 weeks
10037353|NCT01824264|Experimental|LIK066 100 mg|Patients receive 100 mg of LIK066 once daily for 12 weeks
10037354|NCT01824264|Experimental|LIK066 150 mg|Patients receive 150 mg of LIK066 once daily for 12 weeks
9518111|NCT03299790|Active Comparator|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
10017180|NCT05293015|Experimental|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
10017181|NCT05293015|No Intervention|Regular diabetes management|The patient would go to the endocrinology outpatient clinic before hospitalization to regulate blood glucose, and be managed by by orthopedic medical staff through hospitalization. If necessary, the endocrinologist is consulted. And after the hospital, patients would be followed up by orthopedic medical staff.
10017182|NCT05293002|Experimental|Restorer Iliac Stent System|RESTORER Iliac Stent system for the treatment of Aorto-iliac lesions (TASC A, B, C and D) according to IFU
10017183|NCT05292963|Experimental|Fatherhood Works Program delivered in-person|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
10017184|NCT05292963|Experimental|Fatherhood Works Program delivered virtually|Participants receive 26 hours of Nurturing Fathers curriculum, delivered virtually over Zoom. Participants also receive employment supports, case management, and financial literacy training.
10017185|NCT05292950|Experimental|ARO-MUC5AC|ARO-MUC5AC Inhalation
10017186|NCT05292950|Placebo Comparator|Placebo|(0.9% NaCl)
10017187|NCT05292924|Experimental|Early SSC|Cesarean delivery and SSC within the first 30 minutes of birth
10017188|NCT05292924|No Intervention|Control|Cesarean delivery and SSC one hour after birth
10017189|NCT05292911|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
10017190|NCT05292911|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
10017191|NCT05292911|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
10017192|NCT05292911|Placebo Comparator|Placebo|Administered once a week for 12 weeks
10036086|NCT01812512|Other|TIPS for HF Intervention HT Training-Charleston-Pre/Post|Group 1 (Charleston): In the proposed intervention, called Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF) , the observations from the previous RRP are used along with best practices from other studies of patient-centered communication in the VA , telephone coaching for chronic disease , problem-solving and counseling skills for telehealth nurse care managers , difficulties identified by patients working with the Health Buddy for telemonitoring , participation in provider-patient communication , essentials of patient education in heart failure process and content, and teach to goal theory to improve HF self-management for patients with low health literacy . Rather than an experimental trial, this implementation quasi-experimental pilot study examines pre- and post-training nurse practices and Veteran outcomes before and after communication skills training. The same intervention will then be delivered to Group 2 HT nurse care coordinators.
10037355|NCT01824264|Active Comparator|Sitagliptin 100 mg|Patients receive 100 mg sitagliptin once daily for 12 weeks
10037356|NCT01824264|Placebo Comparator|Placebo|Patients receive placebo for 12 weeks
10037357|NCT01824277|No Intervention|Group 1|Group 1 - Standard Pre-operative Diabetes Care
10037358|NCT01824277|Experimental|Group 2|Group 2 - Structured Pre-operative Diabetes Optimization
9518112|NCT03299790|No Intervention|Detraining period|Follow-up: detraining of group 1 and 2 (T2DM patients)
9518113|NCT03299790|No Intervention|Healthy controls|
10037359|NCT01824329|Active Comparator|Prostate capsule sparing cystectomy Group|Prostate capsule sparing cystectomy involves removing the entire bladder.
10037360|NCT01824329|Active Comparator|Nerve sparing cystectomy Group|Nerve sparing cystectomy involves removal of the whole bladder and the entire prostate.
10017193|NCT05292872||OCA Treatment Group|PBC patients with a history of inadequate response or intolerance to UDCA who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021)
10017194|NCT05292872||Control Group|PBC patients with a history of inadequate response or intolerance to UDCA who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021)
10017195|NCT05292820||Transwomen vaginoplasty|Transgender women who underwent vaginoplasty
10017196|NCT05292781|Experimental|CHOICES|Experimental arm: receives the web-based reproductive education for individuals with sickle cell disease or sickle cell trait
10017197|NCT05292781|Sham Comparator|eBook|Control arm with eBook education focused on sickle cell disease and sickle cell trait.
10017198|NCT05292768||Patients with AID|
10017199|NCT05292768||Control patients with mastocytosis|
10017200|NCT05292768||Control patients with normal digestive biopsy|
10017201|NCT05292768||Control patients with renal biopsy|
10017202|NCT05292768||Control patients with inflammatory disease|
10017203|NCT05292768||Healthy control from healthcare workers|
10017204|NCT05292742|Experimental|A|Pyrotinib: 400 mg/day (once daily, orally at the same time every day), every 3 weeks for one year Capecitabine: 1000 mg/m2 orally twice daily every 3 weeks for 6 cycles Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase)
10017205|NCT05292742|Active Comparator|B|Patients in the control group will continue neoadjuvant targeted therapy, trastuzumab or trastuzumab in combination with pertuzumab. In case of neoadjuvant trastuzumab monotherapy, trastuzumab combined with pertuzumab targeted therapy is allowed in the adjuvant phase.
10017206|NCT05292703|Experimental|face-to-face group|In the face-to-face group, the intervention is a participatory activity based on art and olfactory stimulation which consists of practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, adapted to health circumstances and respecting social distancing measures. Due to the health crisis, the workshops will be offered in several groups ranging from 8 to 10 participants, these groups will be equal. A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities
10017207|NCT05292703|Experimental|remote group|For the remote group, immediately after randomization, they will receive the connection link to the internet application and an individual connection code. The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop. The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks.
10017208|NCT05292677|Experimental|Intervention (Steroid/Anesthetic Mixture)|The steroid/anesthetic mixture will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
10017209|NCT05292677|Placebo Comparator|Placebo (Normal Saline)|The placebo (Normal Saline) will be injected via a 27-gauge needle once at the baseline or during the 6-week crossover timepoint.
10017210|NCT05292664|Experimental|Cohort A|"For Part 1, participants will receive:~Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 14-20 people will participate in Part 2 (Dose Expansion) of this cohort Treatment cycle is approximately 28 days for up to 4 cycles~Venetoclax-once daily on predetermined days per protocol~Azacitidine-once daily on predetermined days per protocol~Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
10017211|NCT05292664|Experimental|Cohort B|"Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) with an underlying genetic condition that increases their risk for developing treatment-related toxicities. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 6 people will participate in Part 2 (Dose Expansion) of this cohort.~Venetoclax-once daily on predetermined days per protocol~Azacitidine-once daily on predetermined days per protocol~Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
10017212|NCT05292664|Experimental|Cohort C|"Patients with relapsed/refractory acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL) or acute leuekmai of ambiguous lineage. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 12 people will participate in Part 2 (Dose Expansion) of this cohort.~Cohort C: Treatment cycle is approximately 32 days for one cycle and will be a single treatment cycle:~Dosage, duration and timings as outlined in protocol.~Venetoclax~Dexamethasone~Vincristine~Doxorubicin~Dexrazoxane~Calaspargase pegol~Cytarabine~Methotrexate~Hydrocortisone~Leucovorin- *Cytarabine, Methotrexate, Hydrocortisone and Leucovorin may be given more frequently if leukemia/lymphoma cells are detected in spinal fluid),"
10017213|NCT05292651|Experimental|PSP technique|"The definitions of the PSP technique are:~Predilatation is mandatory with a balloon diameter equal to or maximally 0.5 mm less than the distal reference vessel diameter. We hypothesize that this lesion preparation and fracture of the calcium may result in better stent apposition, less recoil and higher minimal stent area (MSA) Also see endpoints.~The DES should be deployed at 2 atm. above the nominal pressure. This relatively low stent deployment pressure may prevent stent edge dissections.~The postdilatation is mandatory with a shorter length and (at least 0.25mm) larger diameter non-compliant balloon at 16 atm. The apposition, minimal stent area (MSA) and recoil may improve with this large, high pressure postdilatation. The slightly shorter balloon can prevent edge dissections."
10017214|NCT05292651|Active Comparator|Direct Stenting|• The DES is directly placed without any lesion preparation and deployed at a pressure at the discretion of the operator. Ideally a pressure would be achieved in which angiographic expansion of the DES is complete (without significant dog-boning)
10017215|NCT05292638|Experimental|CKDB-501A|
10017216|NCT05292638|Active Comparator|Botox®|
10017217|NCT05292612|Experimental|therapist-guided iCBT|participants would receive iCBT(C&W) for SAD under the guidance of trained therapists.
10017218|NCT05292612|Experimental|coach-guided self-help|participants would receive iCBT(C&W) for SAD under the guidance of trained coaches.
10017219|NCT05292586|Experimental|CHF 1535 pMDI|CHF 1535 pMDI 800/24µg TDD
10017220|NCT05292586|Active Comparator|CHF 718 pMDI|CHF 718 pMDI 800µg TDD
10017221|NCT05292573|Experimental|metformin group|"During the intervention period, metformin is given 500 mg tablet b.i.d.~We will deliver education for exercise and weight control to all eligible participants"
10017222|NCT05292573|No Intervention|Observation group|only exercise and weight control to all eligible participants
10017223|NCT05292560|Experimental|Positive psychology app|
10017224|NCT05292560|Other|Waiting list|
10017225|NCT05292547|Active Comparator|Arm 1|Subjects receive 20 rTMS sessions in 2 weeks
10017226|NCT05292547|Active Comparator|Arm 2|Subjects receive 20 rTMS sessions in 4 weeks
10017227|NCT05292547|Active Comparator|Arm 3|Subjects receive 20 rTMS sessions in 5 weeks
10017228|NCT05292508|Experimental|CRP Tests in addition to Usual Standard of Care|For the clusters (health posts) in this arm, the health worker will prick the finger of the eligible patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained which will be added to specimen dilution buffer and the dipstick will be placed into the diluted sample. It will be removed after the liquid rises and the timer will be started and result will be interpreted in 5 minutes. Interpretation of CRP levels: Only red color line (No blue line): <10 mg/L One blue line: 10-40 mg/L Two blue lines: 40-80 mg/L Three blue lines: >80 mg/L. CRP levels of 40 mg/L or above will be considered as increased CRP levels. The decision on antimicrobial use and other treatments will be made with the help of CRP results in addition to information obtained from the history and physical examination.
10037361|NCT01824368|Experimental|People with liver transplantation|People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
10037362|NCT01824381|Experimental|Amniotic membrane in large wounds|
9476849|NCT03567707|Experimental|C-section -Vaginal seeding|"Pregnant women who undergo C-section and (neonate) vaginal seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with gauze containing their mother's vaginal microbiota just after delivery."
10017229|NCT05292508|No Intervention|Usual Standard of Care Alone|For the clusters (health posts) in this control arm, Usual Standard of Care Alone will be provided. This usual standard of care is given to patients with febrile illness at health posts. Commonly, this involves taking a brief history and conducting a simple physical examination followed by symptomatic treatment such as paracetamol, cough medication or analgesics such as NSAIDs. Often antimicrobial treatment is also prescribed based on clinical suspicion of bacterial infection.
10017230|NCT05292495|Experimental|Cohort one: mild renal insufficiency|
10017231|NCT05292495|Experimental|Cohort two: moderate renal insufficiency|
10017232|NCT05292495|Experimental|Cohort three: severe renal insufficiency|
10017233|NCT05292495|Experimental|Cohort four: end-stage renal disease|
10017234|NCT05292495|Experimental|Cohort five: normal renal function|
10017235|NCT05292482|Experimental|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions and inject it at the proper acupoints they choose.
10017236|NCT05292482|Active Comparator|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
10017237|NCT05292469|No Intervention|Control arm|Routine hypertension care
10017238|NCT05292469|Experimental|Intervention arm|Comprehensive approach to hypertension management that includes BP audit and feedback by physician (nurse and doctor), and patient support to monitor BP, and home based patient care by community health workers to encourage self-monitoring of BP followed by tailored educational counselling on behavioral and lifestyle change in addition to routine care.
10017239|NCT05292456||RA, SLE, and vasculitis patients who have just started glucocorticoid treatment|
10017240|NCT05292456||RA, SLE and vasculitis patients receiving glucocorticoid treatment for the last 2 years|
10017241|NCT05292430||Biobank|Specimens are to be collected from subjects who are having or have had a surgical or medical procedure (such as fluid or tissue removed, a biopsy or a blood or bone marrow draw). Any subject in which the primary diagnosis of disease was made within the DHR Health System and Any subject choosing to give consent for participation will be included.
10017242|NCT05292404|Experimental|Early PCSK9 inhibitor treatment group|
10017243|NCT05292404|Other|conventional treatment group|
10017244|NCT05292391|Experimental|Group A|Dose Escalation Study.0.5 mL of 100 micrograms of Sm-p80 administered intramuscularly on Days 1, 29, and 57. N=9
10017245|NCT05292391|Experimental|Group B|Dose Escalation Study.0.5 mL of 10 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9
10017246|NCT05292391|Experimental|Group C|If dose escalation halting criteria are not met in Group A and Group B, administer 0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 180. N=9.
10017247|NCT05292391|Experimental|Group D|If dose escalation halting criteria are not met in Groups A and B, administer 0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9.
10017248|NCT05292391|Experimental|Group E|If dose escalation halting criteria are not met in Groups C and D, administer 0.5mL of 100 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29 and 57. N=9.
10017249|NCT05292378|Experimental|High CO2 Exposure first, then low CO2 exposure second.|At the first study visit the subject is exposed to 2500 ppm CO2 for 2.5 hours and at the second study visit the subject is exposed to 600 ppm CO2 for 2.5 hours.
10017250|NCT05292378|Sham Comparator|Low CO2 Exposure first, then high CO2 exposure second.|At the first study visit the subject is exposed to 600 ppm CO2 for 2.5 hours and at the second study visit the subject is exposed to 2500 ppm CO2 for 2.5 hours.
10017251|NCT05292365|Experimental|RE-PACT Intervention|Intervention participants receive respiratory illness action plans and weekly mobile health (mHealth) confidence surveillance. At times of low confidence or hospitalization, just-in-time action planning and coaching activities are conducted.
10017252|NCT05292365|No Intervention|Active Control (AC)|AC subjects will receive usual comprehensive medical care and coordination.
10017253|NCT05292339|Active Comparator|Triamcinolone injection to the hand or wrist|Participants will receive the triamcinolone injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
10017254|NCT05292339|Experimental|Ketorolac injection to the hand or wrist|Participants will receive the Ketoralac injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
10017255|NCT05292313|Other|Single distal femur implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
10017256|NCT05292313|Other|Dual distal femur implants|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
10017257|NCT05292300|No Intervention|Control Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group.
10037363|NCT01824407|Active Comparator|Active device plus standard of care|Active device plus standard of care
10017258|NCT05292300|Experimental|Cornelian Cherry Group|Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 20 g/day Cornelian Cherry powder.
9518114|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
10017259|NCT05292300|Experimental|Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
10017260|NCT05292300|Experimental|Cornelian Cherry and Diet Group|Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 20 g/day Cornelian Cherry powder for their one portion fruit a day.
10017261|NCT05292287|Experimental|Home-based Watch Intervention|The home-based watch group will receive an exercise consultation with an exercise physiologist followed by check-in sessions at 1-month, 3-months, 6-months, and 12-months post-randomisation to set and review exercise and physical activity goals. They will wear a Polar Ignite wearable activity monitor which will help to monitor and guide their exercise sessions. Text-message feedback will be provided by an exercise physiologist based on information gathered from exercise sessions recorded on the watch by the participant.
10017262|NCT05292287|No Intervention|Best Practice Usual Care Control|No intervention will be administered. Best practice usual care and activity.
10017263|NCT05292209|Experimental|Active|Riluzole 50mg BID
10017264|NCT05292209|Placebo Comparator|Control|Placebo Matching Double-Dummy Pills
10017265|NCT05292196|Experimental|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation, four weeks as a treatment cycle.
10017266|NCT05292196|Placebo Comparator|TQC3721 suspension placebo for inhalation|TQC3721 suspension placebo for inhalation, four weeks as a treatment cycle.
10017267|NCT05292170|Experimental|Males|10 consecutive day heat acclimation in males
10017268|NCT05292170|Experimental|Females + high hormones|10 consecutive day heat acclimation in females with high hormonal dose
10017269|NCT05292170|Experimental|Females + low hormones|10 consecutive day heat acclimation in females with low hormonal dose
10017270|NCT05292157||Reverse total shoulder arthroplasty|Patients who have received a reverse total shoulder arthroplasty with more than 2 years of follow-up in a temporal frame going from 2016 to 2022.
10017271|NCT05292144||Coronary Artery Disease (CAD)|
10017272|NCT05292118||Coronary Artery Disease (CAD)|
10017273|NCT05292105||Coronary Artery Disease (CAD)|
10017274|NCT05292092||Coronary Artery Disease (CAD)|
10017275|NCT05292079||Coronary Artery Disease (CAD)|
10017276|NCT05292066|Other|Duloxetine Group|Oral intake Duloxetine tablets, 30mg/day for 12 weeks.
10017277|NCT05292066|Other|Pregabalin Group|Oral intake of Pregabalin tablets, 75 mg/day for 12 weeks.
10017278|NCT05292027|Experimental|low-dose radiotherapy group|Neoadjuvant chemotherapy combined with low-dose radiotherapy sequential concurrent chemoradiotherapy
10017279|NCT05292027|No Intervention|control group|Neoadjuvant chemotherapy sequential concurrent chemoradiotherapy
10017280|NCT05292014||Coronary Artery Disease (CAD)|
10017281|NCT05292001|Experimental|Treatment|Single infusion of low molecular weight Iron Dextran
10017282|NCT05292001|Placebo Comparator|Placebo|Single infusion of normal saline
10017283|NCT05291988|Experimental|Screening (S2S education, FIT kit)|Participants receive S2S online screening education and FIT kit for sample collection.
10017284|NCT05291975|Active Comparator|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device.
10017285|NCT05291975|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light.
10017286|NCT05291910|Experimental|Inetetamab+ Toripalimab+ Albumin-Bound Paclitaxel|Drug: Inetetamab Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks Drug: Toripalimab 240mg intravenously every 3 weeks Drug: Albumin-Bound Paclitaxel 130mg/m2, IV , D1, D8, q3w
10017287|NCT05291884|Experimental|Subjects receiving the Impella BTR|
10017288|NCT05291871|Experimental|IM Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered intramuscularly
10017289|NCT05291871|Experimental|ID Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
10017290|NCT05291871|Experimental|IM Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered intramuscularly
10017291|NCT05291871|Experimental|ID Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
10017292|NCT05291845|Experimental|Candida antigen group|25 patients will be treated with Candida antigen. All patients will be directly injected with Candida antigen into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
10017293|NCT05291845|Experimental|Bivalent HPV vaccine|25 patients will be treated with the Bivalent HPV vaccine. All patients will be directly injected with the vaccine into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
10017294|NCT05291845|Experimental|both agents group|25 patients will be treated with Both agents at the same session. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
10017295|NCT05291832|Experimental|Brain.fm Music|Music with rhythmic amplitude modulation designed to drive neural oscillations.
10017296|NCT05291832|Active Comparator|Spectrally-matched Noise|Noise shaped to have the same frequency spectrum (i.e., input level across the cochlea) as the Music condition.
10017297|NCT05291819|Other|Conventional treat-to-target|Conventional treat-to-target follow-up strategy with structured clinical assessment of disease activity
10017298|NCT05291819|Experimental|Imaging informed treat-to-target|Imaging informed treat-to-target follow-up strategy with both structured clinical assessment of disease activity and structured imaging assessment of disease activity.
10017299|NCT05291806|Placebo Comparator|Reference|
10017300|NCT05291806|Active Comparator|Whole cereal kernels Dose A|
10017301|NCT05291806|Active Comparator|Whole cereal kernels Dose B|
10017302|NCT05291806|Active Comparator|Cut cereal kernels Dose A|
10017303|NCT05291793|No Intervention|NSAID group|Group 1, patients only received non-steroid anti-inflammatory oral and topical treatment for 3 weeks. (ibuprofen 2x800 mg (1600 mg daily), 1% nimesulide + 5%Lidocain (3 times a day))
10017304|NCT05291793|Active Comparator|Tenoxicam|Group 2, patients received intraarticular tenoxicam ( 20 mg) once.
10017305|NCT05291793|Active Comparator|Methylprednisolone|Group 3, patients received intraarticular methylprednisolone once(40mg).
10017306|NCT05291793|Sham Comparator|Saline|Group 4, patients received an intraarticular sterile saline injection(4ml).
10017307|NCT05291780|Experimental|SABR in unresectable LA-NSCLC|Patients fit for chemotherapy will be enrolled to sequential chemotherapy-stereotactic ablative radiotherapy (SABR), while patients unfit for chemotherapy will be enrolled to exclusive stereotactic ablative radiotherapy (SABR).
10017308|NCT05291754|Other|Cranioplasty PEEK|
10017309|NCT05291741|Active Comparator|Very Low Calorie Diet (VLCD)|VLCD
10017310|NCT05291741|Placebo Comparator|Standard care|Standard care
10017311|NCT05291715|Experimental|group 1, test group|This group will receive ozone therapy after harvesting of the free gingival graft from the palatal donor site.
10017312|NCT05291715|No Intervention|group 2, control group|Following harvesting of the free gingival graft, the palatal donor site ozone application will be simulated without starting of the ozone generator and the covered ( protected) by a periodontal pack.
10017313|NCT05291702|Other|Multitract PCNL patients|Assessment of the multitract PCNL procedure in removal of large renal stones using pneumatic or laser lithotripsy.
10017314|NCT05291676|Active Comparator|21-30 standard dose Fluad|Participants age 21-30 years will receive the standard dose Fluad
10017315|NCT05291676|Active Comparator|21-30 high dose Fluzone|Participants age 21-30 years will receive the high dose Fluzone
10017316|NCT05291676|Experimental|≥65 years standard dose Fluad|Participants age ≥65 years will receive standard dose Fluad
10017317|NCT05291676|Experimental|≥65 years high dose Fluzone|Participants age ≥65 years will receive high dose Fluzone
10017318|NCT05295160|Other|type 2 diabetes - less than 4 years duration|Patients with a duration of less than 4 years since diagnosis of type 2 diabetes, BMI > 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
10017319|NCT05295160|Other|type 2 diabetes - more than 8 years|Patients with a duration of more than 8 years since diagnosis of type 2 diabetes, BMI > 28 kg/m², non-insulin treated who agree to loose 15 kg body weight by eating a very low calorie formula diet of 800 kcal/day for men and 600 kcal/day for women. The duration of the diet is until the weight loss is achieved.
10017320|NCT05295134|Placebo Comparator|Placebo|Maltodextrin
10017321|NCT05295134|Active Comparator|Lipase: Low-Dose|Candida cylindracea lipase (75,000 FIP per serving)
10017322|NCT05295134|Active Comparator|Lipase: Medium-Dose|Candida cylindracea lipase (150,000 FIP per serving)
10017323|NCT05295134|Active Comparator|Lipase: High-Dose|Candida cylindracea lipase (225,000 FIP per serving)
10017324|NCT05295121|Experimental|XC221, fasted|Administration of XC221 in fasted state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
10017325|NCT05295121|Experimental|XC221, fed|Administration of XC221 in fed state in Dosing Periods 1 and 2 followed by administration of XC221 in fasted state in Dosing Period 3
10017326|NCT05295108|Experimental|Caring Connections intervention|The Caring Connections intervention will consist of non-demanding, messages of care and concern delivered to individuals with SCI/D who had moderate to high social isolation and/or loneliness scores on the baseline survey. The caring messages will be in the form of structured, yet personalized mailed letters from one consistent peer with SCI/D, providing long-term and steady contact. Intervention participants will receive a letter every month over a 6-month period. Following a standardized set of principles, letters will contain cheerful expressions of care and micro-moments of positivity. The PI/Co-Is will provide a brief training and work with volunteer peers with SCI/D to write the letters.
10017327|NCT05295108|Active Comparator|Attention control|We will mail informational materials to individuals with SCI/D in our control group at the same timepoints over 6 months as our intervention letter mailings. The informational materials will discuss life domains that are important to a good quality of life. Topics include community living, physical/healthy living, safety and security, social/spirituality, advocacy/engagement, and employment/volunteering. We will draw information for each topic from the Knowledge Translation Center SCI Factsheets (MSKTC 2021) and the LifeCourse Nexus library (2021).
10017328|NCT05295095|No Intervention|control group|Classical extubation technique : ETT was removed with continuous endotracheal suction
10017329|NCT05295095|Experimental|VSPEP|ETT was removed with APL valve set to 20cmH2O
10017330|NCT05295095|Experimental|VSAIPEP|ETT removed with ventilator parameters were set for PSV mode (inspiratory pressure of 10cmH2O and PEEP identical to that administered in the operating room
10017331|NCT05295069|Experimental|The intervention group|To reduce postpartum depression among the primiparous puerperal women in the intervention group, and a nursing care program was implemented under the guidance of Levine's model. This program was applied with 7 home visits between the 8th and 80th postpartum days. Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
10017332|NCT05295069|No Intervention|The control group|In the control group women received routine postpartum care. No interventions were conducted other than routine postpartum care.
10017333|NCT05295056||Permanent atrial fibrillation|Known to have permanent atrial fibrillation
10017334|NCT05295056||Paroxysmal atrial fibrillation, or high risk of atrial fibrillation|Known to have episodes of paroxysmal, non-permanent, atrial fibrillation or to have at least 2 of the following risk factors: Congestive heart failure, hypertension, diabetes, history of stroke or transient ischemic attack, history of myocardial infarction, peripheral arterial disease or aortic plaque
10017335|NCT05295056||Healthy control|Known not to have atrial fibrillation and no more than 1 of the following risk factors: Congestive heart failure, hypertension, diabetes, history of stroke or transient ischemic attack, history of myocardial infarction, peripheral arterial disease or aortic plaque
10017336|NCT05295043|Experimental|HR+/HER2- advanced breast cancer patients receiving CDK4/6 inhibitor combined with endocrine therapy|According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
10017337|NCT05295030|Active Comparator|Breast Milk-Fed Group|The infants will be breastfed during the study.
10017338|NCT05295030|Experimental|Breast Milk Simulated Formula Group|Kieember Infant formula, Ruibuen®: Infants will be fed Kieember infant formula(Phase I) from baseline (about 0-14 days) to 12 weeks old.
10017339|NCT05295030|Experimental|Traditional Formula Group|Yashili Infant formula, Ruibuen®: Infants will be fed Yashili infant formula (Phase I) from baseline (about 0-14 days) to 12 weeks old.
10017340|NCT05294991|Experimental|Calm Meditation|"Participants assigned to the Calm group will be asked to complete a minimum of 10 minutes per day of meditation, at any time of day they choose for eight weeks. During weeks 1-4 participants in the Calm group will be asked to complete the introductory 30-day program How to Meditate. Weeks 5-8, participants will be asked to complete one daily meditation that may include the Daily Calm, a different 10-minute mindfulness meditation each day, or a meditation from a various series of meditations (e.g., loving-kindness, seven days of managing stress). Participants will have complete autonomy to choose the meditation. After the participant has completed their daily meditation, participants will also be able to use the app content more broadly based on their preference."
10017341|NCT05294991|Active Comparator|Health Education Podcast|Similar to the Calm group, participants in the POD group will listen to a minimum of 10 minutes per day of a health education podcast delivered via a mobile app for eight weeks. Content was carefully chosen to exclude any recommendations for sleep, meditation, or for mindfulness-like principles or practice. A library of podcasts is available on the app. Participants are able to select the podcast based on title, time or both in an effort to mirror the delivery of the meditations in the Calm group. Similar to the Calm group, the POD group will be encouraged to use the other components of the podcast app (which we will review in detail during the intake appointments). Participation (podcasts completed, time of day, length of time, components used) will also be tracked on the app throughout the study period.
10017342|NCT05294978||Patients|-Availability of macular optical coherence tomography (OCT)
10017343|NCT05294978||Controls|-Availability of macular optical coherence tomography (OCT)
10017344|NCT05294965|Experimental|Normal weight|"A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg.~Mild cold exposure: During 120 minutes the water temperature in cooling sleeves, covering the participant's waist, is gradually decreased to 10 degrees or to the lowest tolerable temperature without shivering."
10017345|NCT05294965|Experimental|Overweight|"A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg.~Mild cold exposure: During 120 minutes the water temperature in cooling sleeves, covering the participant's waist, is gradually decreased to 10 degrees or to the lowest tolerable temperature without shivering."
10017346|NCT05294952|Experimental|preeclampsiapregnant women|"Inclusion criteria~A total of 41 women in third trimester pregnancy complicated with PE showing:~Blood pressure ≥140/90 mmHg and~Proteinuria ≥300 mg/24 hours with or without~Edema in pregnant woman after week 20 of gestation (American Congress of Obstetricians and Gynecologists (ACOG2013) (17)~B-Exclusion criteria~Patients with autoimmune, acute inflammatory, and chronic diseases, are excluded from the study."
10017347|NCT05294952|No Intervention|normal pregnant women|This will include age matched 41 normal pregnant women in their third trimester of pregnancy with normal blood pressure, absence of proteinuria, and without any other systemic or endocrine disorder.
10017348|NCT05294926|Active Comparator|deep neuromuscular blockade|
10017349|NCT05294926|Active Comparator|moderate neuromuscular blockade|
10017350|NCT05294913|Experimental|Intervention group|
10017351|NCT05294913|Placebo Comparator|Placebo control group|
10017352|NCT05294887|Experimental|bisoprolol first, diltiazem second|Crossover Design: bisoprolol first, diltiazem second, placebo third
9518115|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
10017353|NCT05294887|Experimental|bisoprolol first, placebo second|Crossover Design: bisoprolol first, placebo second, diltiazem third
10017354|NCT05294887|Experimental|diltiazem first, bisoprolol second|Crossover Design: diltiazem first, bisoprolol second, placebo third
10017355|NCT05294887|Experimental|diltiazem first, placebo second|Crossover Design: diltiazem first, placebo second, bisoprolol third
10017356|NCT05294887|Experimental|placebo first, bisoprolol second|Crossover Design: placebo first, bisoprolol second, diltiazem third
10017357|NCT05294887|Experimental|placebo first, diltiazem second|Crossover Design: placebo first, diltiazem second, bisoprolol third
10017358|NCT05294874|Active Comparator|classical gait training|physical therapy exercises including classical gait training
10017359|NCT05294874|Active Comparator|classical gait training using ankle weight|physical therapy exercises including classical gait training while using ankle weight
10017360|NCT05294874|Experimental|gait training using ankle weight after botulinum toxin injection|physical therapy exercises including classical gait training while using ankle weight and with BOTOX injection
10017361|NCT05294861|Experimental|YesMdiet|After one week baseline, the participants will be assigned to YesMdiet, consuming milk and dairy products for 14 days
10017362|NCT05294861|Active Comparator|NoMdiet|After one week baseline, the participants will be assigned to NoMdiet, consuming another source of protein and without milk or dairy products for 14 days
10017363|NCT05294848|Experimental|Gaze-Contingent Feedback Training (toward threat)|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
10017364|NCT05294848|Active Comparator|RT-Based Attention Bias Modification (toward threat)|"A dot-probe task of 160 trials. Trials begins with a fixation cross (+), on which the participant is asked to focus (500ms). Then two face stimuli (one angry one neutral) are presented above and below the fixation cross (500ms). After the stimuli disappear, a target probe (right- or left-pointing arrowhead) appears in place of one of the face stimuli. The participant is asked to indicate which target probe was presented using a predetermined key. The target probe will remain on the screen until response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the threat location (angry face). Thus, over multiple trials, learning is expected to occurs such that the threatening face predicts the location of the target probe, thereby achieving the desired change in attention pattern."
10017365|NCT05294848|Placebo Comparator|Neutral Control|This condition is also based on the dot-probe task (see Active Comparator) with a fundamental difference. In this task, only neutral faces will be displayed, and therefore, while participants are exposed to the same task parameters, there will be no attention training and there will be no exposure to threat stimuli.
10017366|NCT05294822|Experimental|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|
10017367|NCT05294809|Experimental|PsyPills|"The participants randomized in this condition will receive the mobile health application PsyPills."
10017368|NCT05294809|Experimental|OCAT|"The participants randomized in this condition will receive the mobile health application OCAT."
10017369|NCT05294809|Placebo Comparator|OCAT sham|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
10017370|NCT05294783||ACL injured patients|All the ACL injured patients recruited underwent ACL reconstruction with the same group of surgeons lead by the same chief surgeon.
10037364|NCT01824407|Sham Comparator|Sham device plus standard of care|dermaPACE device that uses a dummy applicator that does not emit shock waves
10037365|NCT01824420|Experimental|Study group|Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
9476850|NCT03567707|Experimental|C-section - Placebo Seeding|"Pregnant women who undergo C-section and (neonate) placebo seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with sterile gauze (placebo)."
10017371|NCT05294770|Experimental|Very Low Calorie Diet (VLCD)|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
10017372|NCT05294770|Active Comparator|Hypocaloric Mediterranean diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
10017373|NCT05294757|No Intervention|Control|Does not actively participate in the study
10017374|NCT05294757|Experimental|Ejercicio|Elderly people without muscle problems participating in the exercise program to see improvements in their muscle mass levels and quality
10017375|NCT05294757|Experimental|Frailty|Elderly people with frailty participating in the exercise program to see improvements in their muscle mass levels and quality
10017376|NCT05294744|Active Comparator|Corticosteroids|Corticosteroids following Standard Clinical Practice
10017377|NCT05294744|Experimental|Corticosteroids + N-acetylcysteine|Corticosteroids following Standard Clinical Practice plus N-acetylcisteine
10017378|NCT05294718|Active Comparator|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
10017379|NCT05294718|Active Comparator|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
10017380|NCT05294692|Experimental|Financial Health Incentives|"fter registration on the Caterpillar App, participants will be instructed to 'carry their phone' as much as possible during a 5-day baseline period to assess their daily step counts. In Month 1, participants will earn daily rewards (3¢ per day personalized daily step goal met; BE present bias). In Month 2, users will earn weekly rewards (25¢ per week goal met 5+ times; BE fresh start). In Month 3, users will earn team-based rewards (35¢ per week if 10+ goals are reached collaboratively with someone they know e.g., friend; BE herd mentality). Participants are expected to earn $1.25 CAD (or 0.75 British pounds) over the course of the 12-week intervention (about $5/person/yr). Rather than offer daily incentives indefinitely, Caterpillar will offer daily incentives as a temporary feature-moving to larger, less frequent, less certain (team-based) incentives as PA becomes habitual."
10017381|NCT05294679|Placebo Comparator|Propofol group|"The initial dose of propofol was 2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will commence. If subjects' MOAA/S score ≥ 1 point, additional administration of cyclopofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Additional administration of propofol: The additional dose was 0.5mg/kg/ time, and intravenous bolus was administered."
10017382|NCT05294679|Experimental|Ciprofol ground|"The initial dose of ciprofol was 0.4mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will begin; If subjects' MOAA/S score ≥ 1 point, additional administration of ciprofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Ciprofol supplemental administration: the supplemental dose was 0.1mg/kg/ time, and intravenous bolus was administered."
10017383|NCT05294666|Experimental|cyclosporine group|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
10037366|NCT01824420|Experimental|Control group|Tolterodine (Detrusitol) 4mg QD
10017384|NCT05294666|Experimental|tacrolimus group|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
10017385|NCT05294653||Type 1 Diabetes|Classified according to American Diabetes Association [ADA] 2021 guidelines
10017386|NCT05294653||Type 2 Diabetes|Classified according to American Diabetes Association [ADA] 2021 guidelines
10036087|NCT01812512|Other|TIPS for HF Intervention HT Training-Columbia-Pre/Post|Group 2 (Columbia VAMC): To test the TIPS for HF educational intervention sufficiently in a sample not previously exposed to the information, the HT program at Dorn VA Medical Center in Columbia, South Carolina has volunteered to participate as a second study site. There are six nurse care coordinators who will be recruited; the larger number supports recruitment of a comparable number with 25 Veterans with HF to be recruited in the second site for a total of 50 Veterans. Both groups will use a purposeful sampling plan, beginning with an IRB-approved flyer for recruitment. The demographic make-up of the Charleston VAMC group is comparable Columbia HT group in age, race, and NYHA HF class. Also, consistent with an implementation quasi-experimental pilot study, the second site will examine pre-training and post-training nurse care coordinator communication practices and Veteran outcomes before and after communication skills training.
10036088|NCT01812525|Active Comparator|NaCl 3% inhalations + standard therapy|"In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.~Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
10036089|NCT01812525|Placebo Comparator|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
10036090|NCT01812538|Placebo Comparator|Placebo|Placebo
10036091|NCT01812538|Experimental|Experimental 1|DIC075V 37.5 mg
10036092|NCT01812538|Experimental|Experimental 2|DIC075V 75 mg
10036093|NCT01812538|Active Comparator|Active control|Moxifloxacin hydrochloride 400 mg
10037367|NCT01824433|Active Comparator|venlafaxine|venlafaxine 75-225mg qd
10037368|NCT01824433|Active Comparator|fluoxetine|fluoxetine 20-60mg qd
10037369|NCT01824459|Active Comparator|S-1 + cisplatin(SP)|S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
10037370|NCT01824459|Experimental|S-1+Oxaliplatin（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
10037371|NCT01824485|Experimental|Group 2|Patients from Group 2 will receive an intra-articular injection of 1 ampoule (2ml) of OSTEONIL®, on a weekly basis, for 3 weeks (total of 3 injections)
10037372|NCT01824485|Experimental|Group 1|Patients from Group 1 will receive a single intra-articular injection of 3 ampoule (6ml) of OSTEONIL®
10037373|NCT01824511|Experimental|Smokers Cease Smoking|Participants are paid to quit smoking without using any medications.
10037374|NCT01824524|Experimental|OROS Hydromorphone|
10037375|NCT01824550|Experimental|home-based exercise training condition|Home based endurance exercise training
10037376|NCT01824550|No Intervention|attention control condition|Attention control condition - home based flexibility training
10037377|NCT01824563||study population|Subjects will need to be standard CI patients acording to national implant criteria and the study criteria.
10037378|NCT01824615|Experimental|Sunitinib|Use Sutent for treatment of recurrent / persisted OCCA
10037616|NCT01826669|Active Comparator|Stretching|"The respiratory muscle stretching were developed bilaterally as follows:~Upper trapezius: head lateral flexion with a hand therapist supports the the occipital region and his shoulder, promotes the stretching;~Sternocleidomastoid: was stretched with flexion lateral and rotation of the head to the side which hands on the occipital region and in the sternal region;~Scalene: with one hand on the occipital region and the other in the sternum, the two points was stretched;~Pectoralis major: the arm was abducted, flexed the forearm and hand was in the occipital region the therapist hands in the arm and in the side of the upper chest, which was stretched craniocaudal direction;~Intercostal: therapist performs with both hands to mobilize and stretch the ribs in cranial-caudal directions."
10037617|NCT01826669|No Intervention|Rest|COPD patients were not submitted to any intervention, remaining at rest in the same place, position and time period to the treatment group.
10017387|NCT05294640|Experimental|Bacteriostatic Saline as Local Anesthesia|Patients receiving bacteriostatic saline as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
10017388|NCT05294640|Active Comparator|Lidocaine with Epinephrine as Local Anesthesia|Patients receiving lidocaine with epinephrine as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
10017389|NCT05294614|Other|A B B B B B B B B C C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A B B B B B B B B C C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
10017390|NCT05294614|Other|A A B B B B B B B B C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A B B B B B B B B C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
10017391|NCT05294614|Other|A A A B B B B B B B B C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A A B B B B B B B B C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
10017392|NCT05294601|Active Comparator|HIIG Group|General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The high intensity children's games program for 12 weeks, . In this group the activities will include 3 weekly sessions. . The games last 6 minutes with a 2 minute break, four games per session; which is the one established for children of these ages according to the cited authors. The session is divided into 5 minutes of warm-up, 36 minutes of intervention and 8 minutes of cool-down. The intensity varies between 85-95% of HR max. According to the equation of Tanka et., Al. HR max = 208-0.7 x age
10017393|NCT05294601|Active Comparator|MIIG Group|: The interventions will be carried out by a graduate in physical education, recreation and / or sports and the main researcher. General nutritional recommendations will be suggested in an initial consultation with weekly telephone follow-up. The medium intensity physical activity program for 12 weeks (28). Medium intensity activities are very similar to those taught in physical education class. In this group the activities will include 3 weekly sessions, with six episodes of 10 min at 65% to 85% of maximum heart rate (HRmax) separated by 5 min of recovery.
10017394|NCT05294601|No Intervention|Control Group|In this group, measurements will be made before, during and after the study. Neither medium nor high intensity interventions will be carried out in order to generate comparisons, control biases and confounding and interaction variables. However, the interventions that have been most beneficial in the intervention groups. It could be implemented in this study once the analysis between groups has been completed, according to the recommendations and follow-up by the ethics committee.
10036094|NCT01812551|Active Comparator|Alendronate|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight >25 kg."
9476851|NCT03567707|Active Comparator|standard care|"Pregnant women who undergo spontaneous vaginal delivery (of neonate) .~Pregnant women who undergo spontaneous vaginal delivery and (neonate) receives standard care."
10017395|NCT05294588|Experimental|Experimental arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the experimental arm receive the recommended two doses of BEXSERO™ prior to bacterial challenge and control vaccines (FLULAVAL™ and TDVAX™) in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
10017396|NCT05294588|Other|Control arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the control arm receive control vaccines that have no relevance to N. gonorrhoeae infection (FLULAVAL™ and TDVAX™) prior to bacterial challenge and then receive two doses of BEXSERO™ in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
10017397|NCT05294575||OHCA in the general population|All Out-of-Hospital Cardiac Arrests
10017398|NCT05294575||Traumatic OHCA|OHCA related to Trauma
10017399|NCT05294549|Experimental|Caring Contact|
10017400|NCT05294536|Experimental|Liraglutide injection (RD12014)+ Victoza|Subjects receive liraglutide injection(RD12014) in the first cycle and Victoza in the second cycle.
10017401|NCT05294536|Experimental|Victoza + Liraglutide injection (RD12014)|Subjects receive Victoza in the first cycle and liraglutide injection(RD12014) in the second cycle.
10017402|NCT05294523|Active Comparator|Rocuronium priming dose 0.06mg/kg|Add the priming dose of rocuronium 0.06mg/kg after the first supramaximal stimulation data measured
10017403|NCT05294523|Active Comparator|Rocuronium priming dose 0.12mg/kg|Add the priming dose of rocuronium 0.12mg/kg after the first supramaximal stimulation data measured
10017404|NCT05294523|Active Comparator|Rocuronium priming dose 0.18mg/kg|Add the priming dose of rocuronium 0.18mg/kg after the first supramaximal stimulation data measured
10017405|NCT05294510|No Intervention|Control|Children who present to a village health worker during a control period are evaluated and managed using the current standard of care per Uganda National Guidelines for Integrated Community Case Management (ICCM). Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
10017406|NCT05294510|Experimental|Intervention|Children who present to a village health worker during an intervention period are evaluated and managed using a modified ICCM algorithm that includes point-of-care C-reactive protein testing. Each village will experience both Control and Intervention conditions as the study employs a stepped wedge design.
10017407|NCT05294497|Experimental|Product usage order A B N C E D|Subjects will use each of the 6 products sequentially (A B N C E D) during an evaluation period, followed by a 4 hour Test Session.
10017408|NCT05294497|Experimental|Product usage order B C A D N E|Subjects will use each of the 6 products sequentially (B C A D N E) during an evaluation period, followed by a 4 hour Test Session.
10017409|NCT05294497|Experimental|Product usage order C D B E A N|Subjects will use each of the 6 products sequentially (C D B E A N) during an evaluation period, followed by a 4 hour Test Session.
10017410|NCT05294497|Experimental|Product usage order D E C N B A|Subjects will use each of the 6 products sequentially (D E C N B A) during an evaluation period, followed by a 4 hour Test Session.
10017411|NCT05294497|Experimental|Product usage order E N D A C B|Subjects will use each of the 6 products sequentially (E N D A C B) during an evaluation period, followed by a 4 hour Test Session.
10017412|NCT05294497|Experimental|Product usage order N A E B D C|Subjects will use each of the 6 products sequentially (N A E B D C) during an evaluation period, followed by a 4 hour Test Session.
10017413|NCT05294484|Active Comparator|Fasting group|Following an overnight fast of at least 10 hours, subjects should be administered single dose of indapamide 1.5 mg SR with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.
10017414|NCT05294484|Active Comparator|Fed group|"Following an overnight fast of at least 10 hours, subjects should start the recommended meal 30 minutes prior to administration of the drug. Study subjects should eat this meal in 30 minutes or less; however, indapamide 1.5 mg SR should be administered 30 minutes after start of the meal. The drug should be administered with 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for one hour before and after drug administration. Subjects should receive standardized meals scheduled at the same time in each period of the study.~All subjects should abstain from the consumption of fruit juices during the study period. All the subjects are to be under complete medical supervision."
10017415|NCT05294445|Active Comparator|Group1: Cryo-AF-Ablation|Patients randomized in the Cryo-AF-Ablation group should receive the cryo AF ablation within 21 days from baseline.
9518116|NCT03299764|Experimental|Intervention|Non-invasive ventilation with pursed lip breathing ventilation device
9518117|NCT03299764|Active Comparator|Control|Non-invasive ventilation with standard non-invasive ventilation device
10017416|NCT05294445|No Intervention|Group 2: Usual care|Patients randomized in the usual care group should start or maintain on AAD therapy within 21 days from baseline, based on decision of the investigator according to current ESC Guidelines.
10017417|NCT05294432||Single Group|Patients of Wilderman Medical Clinic diagnosed with symptomatic Osteoarthritis of the Knee who were prescribed with at least one intra-articular corticosteroid injection.
10017418|NCT05294419|Other|cardiovascular integrated risk score (CVD-IRT)|The CVD IRT device will generate a result based on the polygenic risk score derived from participant genomic information
10017419|NCT05294406|Experimental|IPTp-DP|Pregnant women attending routine antenatal care visits in their second and third trimester are given a monthly, presumptive treatment dose of dihydroartemisinin-piperaquine of three tablets daily for three days (9 tablets). The first dose is given by directly observed therapy (DOT), and the remaining doses given to the women to take at home.
10017420|NCT05294393|Placebo Comparator|N/S 0.9%|Wound infiltration with 12 ml of N/S 0.9% at the end of surgery before wound closure
10017421|NCT05294393|Active Comparator|Ropivacaine 10%|Wound infiltration with 12 ml solution of 100mg ropivacaine at the end of surgery before wound closure
10017422|NCT05294393|Experimental|Ropivacaine 10% magnesium sulphate 10mg/kg|Wound infiltration with 12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery before wound closure
10017423|NCT05294380||oncologic|"Be between the ages of 2-18 years Being under pediatric oncology outpatient/clinical follow-up Being able to stand unaided without using a cane/walker Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
10017424|NCT05294380||control|"Be between the ages of 2-18 years Exclusion criteria; Having any of the diagnoses of hypertension, any cardiac arrhythmia-conduction disorders, coronary artery disease, heart failure, diabetes mellitus, hyperlipidemia, cardiovascular diseases, COPD, pulmonary infection, active infection.~Depression Illness that causes balance problems Peripheral vascular disease Presence of disease that prevents standing up with support Presence of diseases that may cause muscle mass loss (cerebral palsy, neuromuscular disease, congenital metabolic disorder, brain damage) mental retardation Children with a severe emotional disorder, adjustment disorder Physical disability to prevent safe and appropriate testing Having used anti-flu medicine in the last 1 week Failure to obtain consent"
10017425|NCT05294315|Active Comparator|Single level block arm - Control|Single level erector spinae block at 4th transverse process
10017426|NCT05294315|Experimental|Bi-level block arm - Intervention|Bi-level erector spinae block at 4th and 6th transverse process
10017427|NCT05294302|Active Comparator|eSCCIP/eSCCIP-SP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. A stakeholder-informed Spanish-language adaption of eSCCIP (eSCCIP-SP) has been developed and will be offered to Spanish-speaking PCCC. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
10017428|NCT05294302|Active Comparator|Coping Space|PCCC randomized to the patient education control condition will be given access to a website with information about psychosocial functioning, coping, and PTSS related to pediatric cancer. This website will be hosted on the same platform as the intervention, available in English and Spanish, and will consist of information modified from CopingSpace.org. CopingSpace.org is an evidence-informed website developed by Ryan's Case for Smiles, a national organization dedicated to supporting families impacted by pediatric cancer and other chronic diseases.
10017429|NCT05294289||PROS patients treated with alpelisib|Patients with PROS who receive treatment with alpelisb
10017430|NCT05294289||PROS patients not treated with alpelisib|Patients with PROS who don't receive treatment with apelisib
10017431|NCT05294263|Experimental|Varenicline|Varenicline will be provided at the standard recommended dose of 0.5mg daily for three days, then 0.5mg twice daily for four days, and then 1mg twice daily for the remainder of the 12-week treatment period.
10017432|NCT05294263|Placebo Comparator|Placebo|Matching placebo will be administered over the 12-week period.
10017433|NCT05294250|Experimental|XC8, fasted|Administration of XC8 20 mg in fasted state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
10017434|NCT05294250|Experimental|XC8, fed|Administration of XC8 20 mg in fed state in Dosing Periods 1 and 2 followed by administration of XC8 20 mg in fasted state in Dosing Period 3
10017435|NCT05294198|Experimental|Beet protocol|Beta vulgaris L. extract (600mg)
10017436|NCT05294198|Placebo Comparator|Placebo protocol|Starch (600mg)
10037379|NCT01824628||• HIV positive subjects receiving antiretroviral regimen|
10037380|NCT01824628||• HIV negative subjects from the pre-admission surgical clinic|
10036095|NCT01812551|Placebo Comparator|Placebo|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills)."
10037381|NCT01824641|Experimental|Eliminate|Eliminate aspiration catheter
10037382|NCT01824641|Active Comparator|Conventional primary angioplasty|Patients treated with conventional primary angioplasty
10037383|NCT01824654|Experimental|Rigid and Elastic registration softwares|
9518118|NCT03299751|Experimental|NICU newborns of at least 7 days of life with suggestive signs|
10017437|NCT05294159||Clinic-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
10017438|NCT05294159||Community-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
10017439|NCT05294146|Experimental|Loading dose Clofazimine|All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine (CFZ) once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.
10017440|NCT05294094|Experimental|intervention group|blended learning
10017441|NCT05294094|Active Comparator|control group|Teaching format as usual
10017442|NCT05294055|Experimental|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 2|
10017443|NCT05294055|Experimental|lymphoma, chemotherapy plus Mecapegfilgrastim SC on day 5|
10017444|NCT05294055|Experimental|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 2|
10017445|NCT05294055|Experimental|myltiple myeloma, chemotherapy plus Mecapegfilgrastim SC on day 5|
10017446|NCT05294042|Experimental|Paraprofessional Navigation Condition|Paraprofessional Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
10017447|NCT05294042|Active Comparator|Case Manager Navigation Condition|Case Manager Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
10017448|NCT05294042|No Intervention|Wait-List as Usual|Participants will be assigned as wait-list as usual at each agency.
10017449|NCT05293990|Other|Contrast-enhanced fluid attenuated inversion recovery|Confirmation of the difference between FLAIR contrast enhancement and T1 contrast enhancement patterns-->PACS monitor shows the maximum dimension of FLAIR and T1 contrast enhancement by two neurology radiologists on FLAIR and T1 contrast enhancement images. In addition, the maximum diameter of the T2 high-signal lesion around the tumor is obtained using FLAIR images before contrast in the same plane. (Dt2)
10017450|NCT05293977|Active Comparator|Control|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
10017451|NCT05293977|Experimental|Intervention|Patient in the intervention group was verbally provided with pharmaceutical education/counseling about his/her prescribed antibiotic.
10017452|NCT05293964|Experimental|SCR-6852|Phase Ia SCR-6852 monotherapy dose escalation and expansion
10017453|NCT05293964|Experimental|SCR-6852+palbociclib|Phase Ib SCR6852 with palbociclib dose escalation and expansion
10017454|NCT05293951|Experimental|Mirror Therapy + Cross Education|"Cross Education: Experimental participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Mirror Therapy: Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
10017455|NCT05293951|Active Comparator|Mirror Therapy Alone|"Mirror Therapy: Control participants will perform non-resisted task-specific upper limb exercises. Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~Training duration & frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
10017456|NCT05293938||OCA Treatment Group|PBC patients with a history of inadequate response or intolerance to UDCA who initiated OCA in the study window (01 Jun 2015 to 31 Dec 2021)
10017457|NCT05293938||Control Group|PBC patients with a history of inadequate response or intolerance to UDCA who were eligible but were not treated with OCA (or off-label fibrates) in the study window (01 Jun 2015 to 31 Dec 2021)
10017458|NCT05293912|Experimental|SG2501|SG2501 monotherapy intravenous (IV) infusion - Weekly doses
10017459|NCT05293886|Active Comparator|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
10017460|NCT05293886|Experimental|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
10017461|NCT05293873|Experimental|Treatment (BM-MNC trasnplatation)|Autologous bone marrow-derived mononuclear cell will transplant at baseline, and the second transplantation will be performed 6 months after the first transplantation and combination with rehabilitation therapy
10017462|NCT05293873|Other|Control group|rehabilitation therapy
10017463|NCT05293860|Experimental|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
10017464|NCT05293860|Placebo Comparator|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
10017465|NCT05293847|Experimental|Telerehabilitation exercises|Exercises about postural structures on the cervical and thoracal region. Bilateral pectoral stretching, chin tack exercises, cervical isotonic exercises, stretching of the upper trapezius and longus Colli, scapular region strengthening, shoulder capsular stretching, Wand exercises for 12 weeks and 3 times a week.
10017466|NCT05293821||Positive test subjects|documented medical history of HIV, HBV or HCV. A combination of 2 or 3 conditions is acceptable.
10017467|NCT05293821||Control|no documented medical history of HIV, HBV or HCV and are considered normal.
10017468|NCT05293808|Experimental|aspirin 100 mg bis in die|aspirin 100 mg twice daily for the first month after acute coronary syndrome
10017469|NCT05293808|Active Comparator|aspirin 200 mg|aspirin 200 mg once daily for the first month after acute coronary syndrome
10017470|NCT05293808|Active Comparator|aspririn 100 mg|aspirin 100 mg once daily
10017471|NCT05293795|Active Comparator|3d printed model|Mother r is given 3D printed model of fetus' face
10017472|NCT05293795|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
10017473|NCT05293795|No Intervention|Control|Standard of Care
10017474|NCT05293756|Experimental|Intervention: OPTIMA-BP Implementation|Participants randomized to OPTIMA-BP intervention for 6 months then observed for a 6 month follow up period
10017475|NCT05293756|No Intervention|Waitlist: OPTIMA-BP implementation|Participants randomized to waitlist for 6 months, then offered the OPTIMA-BP intervention for 6 months.
10017476|NCT05293743|Active Comparator|Straight bar|This group will continue using the straight bar as part of their brace, per their current treatment.
10017477|NCT05293743|Experimental|Dynamic bar|This group will use the novel dynamic bar for 30 days instead of their standard straight bar.
10017478|NCT05293730|Experimental|Community Health Worker (CHW)-Led Hybrid In-Person/Telehealth Program Pathway (eFRIEND)|Participants in the eFRIEND arm will receive regularly scheduled in-person and telehealth contacts with a CHW.
10017479|NCT05293730|Active Comparator|Usual Care|Usual care group will be monitored passively for outcomes under a waiver of informed consent
10017480|NCT05293717|Experimental|All Participants|
10017481|NCT05293678|Experimental|Lower IV Dose|Randomized 3:1
10017482|NCT05293678|Experimental|Mid IV Dose 1|Randomized 3:1
9518119|NCT03299738|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
9518120|NCT03299725|Experimental|Treatment arm|
10017483|NCT05293678|Experimental|Mid IV Dose 2|Randomized 3:1
10017484|NCT05293678|Experimental|Higher IV Dose|Randomized 3:1
10017485|NCT05293678|Experimental|Lower SC Dose|Randomized 3:1
10017486|NCT05293678|Experimental|Mid SC Dose|Randomized 3:1
10017487|NCT05293678|Experimental|Higher SC Dose|Randomized 3:1
10017488|NCT05293665|Experimental|double-blind UB-612 boost of ChAdOx1-S|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
10017489|NCT05293665|Active Comparator|double-blind ChAdOx1-S boost|A single injection of ChAdOx1-S on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
10017490|NCT05293665|Experimental|open-label UB-612 boost of ChAdOx1-S|A single injection of UB-612 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with ChAdOx1-S.
10017491|NCT05293665|Active Comparator|open-label ChAdOx1-S boost|A single injection of ChAdOx1-S on Day 1 in an open-label fashion in subjects who completed the primary immunization series with ChAdOx1-S.
9476852|NCT03567694|Experimental|Single Ascending Dose and Food effect|This is the SAD / Food effect arm. For SAD, a total of 80 subjects will be enrolled into 8 groups of 10 subjects each; within each group, 8 will receive HA115 at a single ascending dose 10, 25, 50, 100, 200, 400, 800, 1200 mg, and 2 subjects will be placebo control. For food effect study,10 participants will be administered HA115 at a single dose to be selected based on SAD results.
9476853|NCT03567694|Experimental|Multiple Ascending Dose|For the MAD portion, 3 dose levels will be selected based on SAD results.
10017492|NCT05293665|Experimental|double-blind UB-612 boost of BNT162b2|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2
10017493|NCT05293665|Active Comparator|double-blind BNT162b2 boost|A single injection of BNT162b2 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2.
10017494|NCT05293665|Experimental|open-label UB-612 boost of BNT162b2|A single injection of UB-612 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
10017495|NCT05293665|Active Comparator|open-label BNT162b2 boost|A single injection of BNT162b2 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
10017496|NCT05293665|Experimental|double-blind UB-612 boost of Sinopharm BIBP|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
10017497|NCT05293665|Active Comparator|double-blind Sinopharm BIBP|A single injection of Sinopharm BIBP on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
10017498|NCT05293652|Experimental|Iontophosresis group|
10017499|NCT05293652|Experimental|Phonophoresis group|
10017500|NCT05293652|Experimental|Traditional group|
10017501|NCT05293639|Experimental|Treatment Group|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
10017502|NCT05293613|Experimental|Cases|
10017503|NCT05293600|Placebo Comparator|Placebo|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
10017504|NCT05293600|Active Comparator|Interventional arm|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
10017505|NCT05293587|Experimental|Physical Activity|Physical activity sessions at public parks led by a Serenity Behavioral Health Certified Peer Specialist
10017506|NCT05293587|No Intervention|Waitlist|Participants will continue their usual care in the PEERS program. They will be offered the intervention after they have completed posttest measures.
10017507|NCT05293574|Experimental|norethisterone acetate group|". In the norethisterone acetate group, the women will receive of norethisterone acetate 5 mg twice daily and are counseled about how to take norethisterone acetate and informed of possible side effects. They also receive a diary card for recording norethisterone acetate intake to be returned to the physician on the day of the next visit. An appointment for the women in both groups was scheduled at one month of treatment for the second ultrasonography.~If there is no remission occurred another month of Norethisterone acetate will be given ."
10017508|NCT05293574|No Intervention|expectant managment group|
10017509|NCT05293561||COVID-19 cases|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
10017510|NCT05293561||control|O2 saturation readings, Mini-mental state examination (MMSE), Hamilton's anxiety (HAM-A) Hamilton's depression rating scales (HAM-D)
10017511|NCT05293535||Klotho|"Evaluate the expression of Klotho in gastric adenocarcinoma via immunohistochemistry, find the association between the expression of Klotho in gastric adenocarcinoma and demographic patient data, and clinicopathologic parameters of the patients and investigate the effect of Klotho expression on the prognosis of gastric adenocarcinoma.~Correlate between the Klotho and LRP-6 protein expression."
10017512|NCT05293535||LRP-6|"Evaluate the expression of LRP-6 protein in gastric adenocarcinoma via immunohistochemistry, find the association between the expression of LRP-6 protein in gastric adenocarcinoma and demographic patient data, and clinicopathologic parameters of the patients and investigate the effect of LRP-6 protein expression on the prognosis of gastric adenocarcinoma.~Correlate between the Klotho and LRP-6 protein expression."
10017513|NCT05293509|Experimental|Phase I: Sequential Pharmacological PTIS|
10017514|NCT05293509|Experimental|Phase II: RTC Regimen and GVHD Prophylaxis Based on Post-Cy|
10017515|NCT05293496|Experimental|Cohort 1:|MGC018 at dose level 1 and checkpoint inhibitor intravenously (IV) every 3 weeks
10017516|NCT05293496|Experimental|Cohort 2|MGC018 at dose level 2 and checkpoint inhibitor IV every 3 weeks
10017517|NCT05293496|Experimental|Cohort 3|MGC018 at dose level 3 and checkpoint inhibitor IV every 3 weeks
10017518|NCT05293496|Experimental|Cohort Expansion|Maximum tolerated dose of MGC018 and checkpoint inhibitor IV every 3 weeks
10017519|NCT05293483||COVID-19|
10017520|NCT05293483||non-COVID-19|
10017521|NCT05293431|Experimental|Active Stimulation Group|This group will receive real tACS non-invasive brain stimulation
10017522|NCT05293431|Sham Comparator|Sham Control Group|This group will receive Sham tACS non-invasive brain stimulation
10017523|NCT05293405|Experimental|Patients Group|
10017524|NCT05293405|Sham Comparator|Healthy Volunteers Group|
10017525|NCT05293379||Patients sensitized within the framework of the VACCIPREV program|The targeting of patients covered the period from July 2021 to September 2021 corresponding to the period where the booth was available at vaccination centers. Data mining will extend from July 2021 to July 2022 in order to have a follow-up of at least 3 months after the passage in the cabin and to observe the potential modifications or initiation of patient care
10017526|NCT05293353||Breast Milk Fortification with NeoKare|Prospective cohort, 50 infants
10017527|NCT05293353||No Breast Milk Fortification|Retrospective, historical cohort, approx 50 infants
10017528|NCT05293301|Experimental|Periodontal Endosccope|One randomly assigned side of the mouth received deep cleaning treatment with the operator using a periodontal endoscope or Perioscopy® for magnification
10017529|NCT05293301|Active Comparator|Traditional Loupes|One randomly assigned side of the mouth received deep cleaning treatment with the operator using traditional loupe magnification
10017530|NCT05293288|Experimental|EEG-guided general anesthesia|
10017531|NCT05293288|No Intervention|Routine care|
10017532|NCT05293275|Active Comparator|Virtual Reality Group|patients will use the virtual reality device over two days
10017533|NCT05293275|No Intervention|Standard of care|patients will receive standard of care only
10017534|NCT05293262||Patients who underwent endourological surgery for urolithiasis during COVID19|Endourological surgery (including ureteral stent insertion, ureteroscopy, retrograde intrarenal surgery)
10017535|NCT05293236|Placebo Comparator|Placebo|Nine COVID-19 patients (three from each treatment-group) treated with saline intravenous infusion
10017536|NCT05293236|Experimental|Dose 1|Seven COVID-19 patients treated with ApTOLL (0.05mg/kg) intravenous infusion
10017537|NCT05293236|Experimental|Dose 2|Seven COVID-19 patients treated with ApTOLL (0.1mg/kg) intravenous infusion
10017538|NCT05293236|Experimental|Dose 3|Seven COVID-19 patients treated with ApTOLL (0.2mg/kg) intravenous infusion
10017539|NCT05293223|Experimental|Group A|One dose Sputnik V + one dose Ad5-nCoV
10017540|NCT05293223|No Intervention|Group B|Samples stored at the immunology lab of the Buenos Aires University Medical School, corresponding to individuals vaccinated with 2 doses of Sputnik V.
10017541|NCT05293210|Experimental|Experimental arm|A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.
10017542|NCT05293210|Active Comparator|Standard treatment regimen|Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily).
10017543|NCT05293197|Experimental|SonoCloud®|SonoCloud® : dose escalation 6 cycles of sonication
10017544|NCT05293184||Individuals with Angelman Syndrome|Individuals from birth to adulthood with Angelman Syndrome
10017545|NCT05293171|Experimental|1.25 mg/kg BL-8040 + BL-8040-matching placebo administered via SC injection (Therapeutic)|1.25 mg/kg BL-8040 + BL-8040-matching placebo administered via SC injection (Therapeutic)
10017546|NCT05293171|Experimental|2 mg/kg BL-8040 administered via SC injection (Supratherapeutic)|2 mg/kg BL-8040 administered via SC injection (Supratherapeutic)
10017547|NCT05293171|Placebo Comparator|BL-8040-matching placebo administered via SC injection|BL-8040-matching placebo administered via SC injection
10017548|NCT05293171|Active Comparator|400 mg moxifloxacin (1 x 400 mg tablet) administered orally|400 mg moxifloxacin (1 x 400 mg tablet) administered orally
10017549|NCT05293145|Experimental|Building Futures Program Primary Services|Youth enrolled in the AVANCE-Houston Building Futures Program will receive primary services in either a 7 week workshop or one weekend delivery.
10017550|NCT05293132|Experimental|Montelukast group|30 patients will receive montelukast sodium 10 mg/day film coated tablets (Singulair®; Merck & Co Inc) or (Clear air®; Amoun Pharmaceutical Company S.A.E., Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
10017551|NCT05293132|Experimental|Co Enzyme Q10 group|30 patients will receive co enzyme Q10 capsule 210 mg / day (MEPACO Pharmaceutical Company (Egypt) in addition to the standard sepsis treatment starting from the onset of the diagnosis of sepsis till discharge from ICU, or death.
10017552|NCT05293132|Active Comparator|Control group|30 patients will receive the standard treatment of sepsis from the onset of the diagnosis of sepsis till discharge from ICU, or death.
10017553|NCT05293119|Experimental|Tofacitinib|In this group, study participants will be treated with per oral tofacitinib citrate (5 mg/twice daily)
10017554|NCT05293119|Active Comparator|Topical corticosteroid|In this group, patients will apply topical Mometasone furoate 0.1% once daily
10017555|NCT05293093|Experimental|Wheelchair Skills Training Program intervention study|A one-group pretest-posttest design study will be conducted, consisting of three phases (3- or 5-week baseline phase, 4-week training phase, 4-week retention phase)
10017556|NCT05293080|Experimental|Early rhythm control therapy|Patients with acute ischemic stroke and AF will receive either catheter ablation (mainly pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point. The initial therapy will be selected by the local investigator. In case of continuation or recurrence of AF, both modalities may be combined.
10017557|NCT05293080|Active Comparator|Usual care|Patients with acute ischemic stroke and AF will receive usual care following the current ESC guidelines for AF treatment.
10037384|NCT01824667|Experimental|B-GOS|2.75g daily for 4 weeks
10037385|NCT01824667|Placebo Comparator|Maltodextrin|2.75g daily for 4 weeks
10037386|NCT01824680|Experimental|obesity|
10037387|NCT01824706||craniectomy|craniectomy
10017558|NCT05293067||carotid endarterectomy|High-sensitive troponin would be measured in patients undergoing carotid endarterectomy (CEA). Patients would be followed during the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
10017559|NCT05293067||carotid artery stenting|High-sensitive troponin would be measured in patients undergoing carotid artery stenting (CAS). Patients would be followed in the immediate postoperative period (until discharge from hospital), one month after, one and two years following the surgery, when researchers will gather information regarding the study outcomes during a regular postoperative control, or through telephone interviews.
10017560|NCT05297032|Experimental|Quercetin Phytosome|All participants will receive Quercetin Phytosome
10017561|NCT05297019|Experimental|Arm 1: Mild pressure HBOT|"Mild pressure HBOT: 100% O2 @ 4.2 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
10017562|NCT05297019|Experimental|Arm 2: High pressure HBOT|"High pressure HBOT: 100% O2 @ 14 PSI for 100 minutes 3x/week for 6 weeks, 2 weeks off, and then an additional 4 weeks of therapy. Followed by 3 months of no treatment"
10017563|NCT05297019|Experimental|Arm 3: Crossover Arm|Patients will have 3 months of no treatment, and then be randomized to receive either high pressure or mild pressure HBOT
10017564|NCT05297006||Breastfeeding group|The mother can breastfeed exclusively until the infants is at least 4 months old, after which complementary foods are added scientifically according to the baby's condition.
10017565|NCT05297006||Formula group containing new compound functional ingredients|Only use formula milk powder containing oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
10017566|NCT05297006||Formula group without new compound functional ingredients|Only use formula milk powder without oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.
10017567|NCT05296993|Experimental|Extracts|The ingredients found in these serums are all naturally occurring ingredients extracted from a variety of plant species: Pinetonal, Thyvolve, Telogenic, Sentophagy, Inflasolve, Stemegenis, and CMEnhance
10017568|NCT05296980|Experimental|REMINDER program online|The REMINDER program in this arm will be delivered by videoconferencing. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
10017569|NCT05296980|Experimental|REMINDER program face-to-face|The REMINDER program in this arm will be delivered face to face. It will integrate 20 sessions (with approximate length of 45-60 min), therapist-mediated, carried out twice a week, over a period of 12 weeks. Psychoeducation sessions and part of the reminiscence and memory strategies training sessions will be facilitated in groups, as means to promote social support and modeling, and the remaining will be individual sessions. Several activities aimed to promote personal development and definition and achievement of meaningful goals will be included in the program, and the program will be manualized to facilitate its future dissemination and implementation
10017570|NCT05296980|Sham Comparator|Brain psychoeducation program|The control condition will have the same length as the experimental harms, including 20 psychoeducation sessions, with information regarding dementia modifiable risk factors, information on healthy lifestyles, and brain health promotion.
9476854|NCT03567681|Experimental|Extended release oxcarbazepine|Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
9476855|NCT03567681|Experimental|Immediate release oxcarbazepine|Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
9476856|NCT03567655|Experimental|Single group|Farlutal tab. 500mg/ Pfizer to be administered
10017571|NCT05296967|Experimental|Chewing gum|POI patients are asked to chew 20 minutes x2/ day
10017572|NCT05296967|No Intervention|No chewing|POI patients receive no intervention
10017573|NCT05296954|Experimental|Group 1|Tachycardia
10017574|NCT05296954|Active Comparator|Group 2|Without tachycardia
10017575|NCT05296941|Experimental|Brush biopsy|
10017576|NCT05296941|Active Comparator|Care as usual|
10017577|NCT05296928|Experimental|umbilical incision|Placing the laparoscopic trocar by cutting the umbilicus directly at the entrance to the abdomen
10017578|NCT05296928|Active Comparator|subumbilical incision|Placing a laparoscopic trocar by making a sub-umbilicus incision at the entrance to the abdomen
10017579|NCT05296902||SILKAM®|SILKAM® is a non-absorbable sterile suture material made from braided silk fibrils. It is available either undyed (white) or dyed black with hematein and is coated with refined paraffin wax or beeswax.
10036096|NCT01812564|Placebo Comparator|PPP|"Placebo: Platelet Poor Plasma~Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
9476857|NCT03567629|Experimental|Irinotecan-based chemotherapy|
9476858|NCT03567629|Active Comparator|Oxaliplatin-based chemotherapy|
9476859|NCT03567603||opioid exposed neonates|prenatal opioid exposure
9476860|NCT03567603||non-opioid exposed neonates|no prenatal opioid exposure
10037388|NCT01824719||Allergic group|All patients who used Reduning Injection have anaphylaxis.
10017580|NCT05296889||Ennovate® Cervical|Alll patients which were treated with the Ennovate® Cervical system in accordance with the indications given in the instructions for use
10017581|NCT05296876||carotid endarterectomy|Patients who are treated with CEA under SSPC evaluation
10017582|NCT05296863|Experimental|Non-concentrated ADSC-CM|2 ml intradermal injection of non-concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
10017583|NCT05296863|Experimental|Concentrated ADSC-CM|2 ml intradermal injection of concentrated ADSC-CM + 1 ml of 5% topical Minoxidil daily
10017584|NCT05296824||Pulmonary vein isolation (PVI) only|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) only
10017585|NCT05296824||Pulmonary vein isolation (PVI) with posterior wall isolation (PWI)|Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) with posterior wall isolation (PWI)
10017586|NCT05296772|Other|Dose escalation|A open-label single arm of JS014 alone or in combination with pembrolizumab
10017587|NCT05296720|Other|Patients|Patients with schizophrenia
10017588|NCT05296720|Other|Controls|Controls matched with patients on age, sex and education level
10017589|NCT05296707|Experimental|Inspiratory muscle training group|Thershold IMT was given this group. Applied for 7 days 6 weeks.
10017590|NCT05296707|Active Comparator|Used routine medicine group|Followed 6 weeks
10017591|NCT05296707|Active Comparator|Control Group|Health children
10017592|NCT05296655||Laryngopharegeal reflux symptoms patients|patients with symptoms of laryngopharyngeal reflux detected at an outpatient appointment with an ENT doctor
10017593|NCT05296655||Asymptomatic laryngopharegeal reflux patients|patients without symptoms of laryngopharyngeal reflux who applied for an appointment with an otorhinolaryngologist
10017594|NCT05296642|Experimental|Cycling at a Moderate Intensity Aerobic Exercise (AE) group|All participants will be asked to cycle during the first phase at a moderate intensity for 20 minutes.
10017595|NCT05296642|Experimental|Blood Flow restriction training with cycling at a moderate intensity (BFR+AE) group|All participants will be asked to wear an automated personalize tourniquet system to restrict blood flow. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Then, participants will be asked to cycle at a moderate intensity for 20 minutes during the second phase.
9802626|NCT05113316|Experimental|Messy Memories App Group|"Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days (affect rating sliders), their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.~The Messy Memories app will also collect data on how frequently and for how long each participant uses the app. Each response will trigger a prompt within the app, and will be recorded with a timestamp (date and time) to indicate when the participant provided a particular response. For all participants, self-report measures will be collected at weeks 4, 8, 12, and 16."
9802627|NCT05113316|No Intervention|Treatment as usual (TAU) Group|Subjects will not receive any study treatments or have access to the app but may seek standard treatment if they choose, in addition to completing self-report measures. For 8 weeks, TAU group will participate in the study under treatment as usual. For weeks 9-16, the TAU group will then switch and have full access to the Messy Memories App to review and use for a limited amount of time. Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days, their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.
10017596|NCT05296629|Experimental|DFD-29|DFD-29 (40 mg) extended release capsules
10017597|NCT05296629|Active Comparator|Doxycycline 40 mg|Doxycycline 40 mg modified release capsules
10017598|NCT05296629|Placebo Comparator|Placebo|Placebo capsules matching DFD-29
10017599|NCT05296564|Experimental|HBI 0201-ESO TCRT (Anti-NY-ESO-1 TCR-transduced peripheral blood lymphocytes)|"This is a two-part, non-randomized, open label, single-site Phase I/II study. The first Part A is a dose ranging maximum tolerated dose (MTD) study and Part B is an extension phase to evaluate safety at the selected safe dose. A Data Safety Monitoring Board (DSMB) will determine the safe dose for testing in the expansion phase (Part B).~Part A will be according to a 3+3 dose escalation design. A total of up to 20 patients will participate in this Part.~Part B will be an expansion phase. The objective will be to determine if the treatment regimen is associated with a clinical response rate that can rule out 5% (p0=0.05) in favor of a modest 20% Partial Response (PR) + Complete Response (CR) rate (p1=0.20).~A total of up to 43 patients may be enrolled in Part B (41 +2, allowing for up to 2 non-evaluable patients)."
10017600|NCT05296551|Experimental|Dual Task One|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is simple.
10017601|NCT05296551|Experimental|Dual Task Two|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is complex.
10017602|NCT05296551|Active Comparator|Control|Participants perform only a motor-task that is the same for all groups (no simultaneous cognitive task).
10017603|NCT05296499||Venous outflow obstruction extending to inferior vena cava, symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
10017604|NCT05296499||Venous outflow obstruction extending to inferior vena cava, not symptomatic with dyspnoea|Baseline assessments Post-operative assessments if applicable
10017605|NCT05296499||Unilateral iliac venous outflow obstruction|Baseline assessments Post-operative assessments if applicable
10017606|NCT05296499||Age and sex matched controls|Baseline assessments
10017607|NCT05296486|Experimental|phacovitrectomy surgery with silicone oil tamponade|patients who had phacovitrectomy surgery with silicone oil tamponade.The patients diagnosed cataract The patients' ages are over 50.
10017608|NCT05296486|Experimental|phacovitrectomy surgery with gas tamponade|patients who had phacovitrectomy surgery with gas tamponade.The patients diagnosed cataract The patients' ages are over 50.
10017609|NCT05296486|Experimental|phacovitrectomy surgery with balanced saline solution tamponade|patients who had phacovitrectomy surgery with balanced saline solution tamponade.The patients diagnosed cataract The patients' ages are over 50.
10017610|NCT05296486|Experimental|phacoemulsifacation surgery without vitrectomy|patients who had phacoemulsifacation surgery without vitrectomy.The patients diagnosed cataract The patients' ages are over 50.
10017611|NCT05296473|Experimental|ADHD Therapy|
10017612|NCT05296473|Active Comparator|Control Therapy|
10017613|NCT05296447||Roll Over|No intervention - all subjects that previously received RGX-314 in a parent study
10017614|NCT05296434||Control Group|Healthy volunteers undergoing MRI exam, ICG test and blood biochemical tests
10017615|NCT05296434||Child-Pugh A Group|Composed of patients with liver function of Child-Pugh A grade undergoing MRI exam, ICG test and blood biochemical tests
10017616|NCT05296434||Child-Pugh B Group|Composed of patients with liver function of Child-Pugh B grade undergoing MRI exam,ICG test and blood biochemical tests
10017617|NCT05296434||Child-Pugh C Group|Composed of patients with liver function of Child-Pugh C grade undergoing MRI exam
10017618|NCT05296395|Experimental|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (1 serving of GoodBelly fermented oat drink) once daily for 6 weeks
10017619|NCT05296395|Placebo Comparator|Heat-killed placebo control|Subjects will consume 1 serving of GoodBelly fermented oat drink that has been treated to heat kill all Lp299v once daily for 6 weeks
10017620|NCT05296382|Experimental|Crushed Tebipenem Tablet with Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through. Subjects will also receive concurrent enteral tube feeds (feeds run for 2h before dose and 4h post-dose).
10017621|NCT05296382|Experimental|Whole Tebipenem Tablet|Tebipenem tablet will be swallowed whole without crushing.
10017622|NCT05296382|Experimental|Crushed Tebipenem Tablet without Tube feeds|Crushed tebipenem tablets will be administered by syringe through the nasogastric tube and flushed with water to ensure all drug is passed through.
10017623|NCT05296369|Experimental|Experimental|Folic acid intervention
10017624|NCT05296369|No Intervention|Routine|Routine treatment intervention
10017625|NCT05296356|Experimental|OSU6162|Coated tablet, flexible dosing
10017626|NCT05296343||Adolescents and young adults|Boys and girls from 15 to 25 years old admitted to an Emergency Department (ED) following a suicidal act or considered as such by the medical team
10017627|NCT05296343||Parents|One or the two parents of the included adolescents and young adults
10017628|NCT05296343||Healthcare professionals|Professionals working in one emergency departments of the inclusion centers and who usually take care of suicidal adolescents and young adults
10017629|NCT05296317|Experimental|Arm 1 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of G-CSF|"2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
10017630|NCT05296317|Experimental|Arm 2 : Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF|"2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
10017631|NCT05296304|Experimental|Bexarotene Combined With Radiotherapy|Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.
10017632|NCT05296291|Active Comparator|High-translucent monolithic zirconia,|
10017633|NCT05296291|Active Comparator|Zirconia ceramic with porcelain|
10017634|NCT05296291|Active Comparator|Metal ceramics.|
10036097|NCT01812564|Active Comparator|PRP|"Biological: Platelet Rich Plasma~Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
10036098|NCT01812564|No Intervention|Physiotherapy|"These patients will not receive an injection.~Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
10017635|NCT05296265|Experimental|Active VR treatment|Subjects assigned to the Active VR treatment will begin by selecting an avatar, with features such as gender and skin color that can be chosen according to preference. During treatment, they will participate in a variety of games and activities developed and used by our teams including Kick, Dog Food, Quest for Fire, Chess, Checkers, Sudoku, and surfing the internet. Subjects will have substantial flexibility to select games according to their interests but will be required to spend at least 30 minutes in each session in games that require forceful, large amplitude, movements of the amputated lower limb (e.g., Quest for Fire, Kick). Time spent and level of engagement as measured by movements of the avatar or, in the case of chess, checkers, solitaire, Sudoku, and internet surfing, the number of clicks produced with each leg will be recorded for each activity using custom software
10017636|NCT05296265|Experimental|Distractor VR treatment|"Subjects assigned to the Distractor VR treatment will participate in the Cool!TM immersive VR experience (FirstHand Technology, Inc), which has been demonstrated to reduce pain in several studies but lacks the hypothesized active ingredients of our Active VR treatment (visual and auditory feedback of movement of an extrapolated amputated limb). Subjects will navigate through a pleasant VR environment while listening to relaxing music and use a joystick to shoot soap bubbles or feed seals; they do not see any rendering of their body and make no movements with their legs"
10017637|NCT05296252|Experimental|Mind Wandering Intervention|75% of participants will receive proactive and reactive mind-wandering information and redirection.
10017638|NCT05296252|Active Comparator|Mind Wandering Comparison|25% of participants will receive only mind-wandering redirection, but only at random times.
10017639|NCT05296239|Experimental|SimpleC Wellness Platform with Social Robot Interaction|
10017640|NCT05296200||Observacional group|Subjects must remain to the exposure of gravity (1G) after 4h of hyperbuoyancy floatation(spine unloading)
10017641|NCT05296174|Experimental|cognitive-oriented intervention program|"The intervention group received a 40 mins social support intervention program once a week lasting for 6 weeks.~All participants were assessed by questionnaires before and after the intervention."
10017642|NCT05296174|Active Comparator|received health education program|"The control group received health education activities with the same frequency as the intervention group.~All participants were assessed by questionnaires before and after the intervention."
10017643|NCT05296148|Experimental|Treatment|Treatment with the CroíValve DUO Coaptation Valve System
10017644|NCT05296135||Main Cohort|
10017645|NCT05296122|Experimental|Single arm|MR-Guided Laser Thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG ® Thermoguide Workstation.
10017646|NCT05296109|Experimental|Imaging group|patients with parotid tumour being imaged
10017647|NCT05296083|Experimental|G3P-01 50mg Dose Treatment Period 1|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period one dose will be 50mg of IP.
10017648|NCT05296083|Experimental|G3P-01 500mg Dose Treatment Period 2|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period two dose will be 500mg of IP.
10017649|NCT05296083|Experimental|G3P-01 1000mg Dose Treatment Period 3|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period three dose will be 1000mg of IP.
10017650|NCT05296083|Experimental|G3P-01 2000mg Dose Treatment Period 4|G3P-01 will be administered orally as a powdered mixed with water. Treatment Period four dose will be 2000mg of IP.
10017651|NCT05296070|Experimental|Loncastuximab tesirine Cycles 1-6|Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle. The total duration of treatment is approximately 18 weeks (4.5 months)
9476861|NCT03567577|Experimental|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
10017652|NCT05296057|Experimental|Participants Receiving VR-Exposure Therapy Treatment|All participants will be receiving the experimental VR-exposure therapy treatment.
10017653|NCT05296044|Experimental|JT-003|Drug: JT-003
10017654|NCT05296044|Placebo Comparator|JT-003 Placebo|Drug: JT-003 Placebo
10017655|NCT05296031|Active Comparator|Drug Eluting Stent (DES)|Drug Eluting Stent (DES). Zilver PTX.
10017656|NCT05296031|Placebo Comparator|Bare Metal Stent (BMS)|Bare Metal Stent (BMS). Zilver Flex
10036099|NCT01812577||Thoracic paravertebral block (TPVB)|Twenty patients receiving thoracic paravertebral block at level of T7, before the interventistic procedure.
10036100|NCT01812577||Deep Sedation (DS)|Twenty patients receiving local and intravenous anesthesia during the procedure.
10017657|NCT05296005|Experimental|Treatment (chemotherapy, chemoradiation, surgery)|"NEOADJUVANT CHEMOTHERAPY: Patients receive FLOT chemotherapy consisting of docetaxel intravenously (IV) , oxaliplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on day 1 or FOLFOX chemotherapy consisting of oxaliplatin IV and leucovorin IV, and fluorouracil IV continuously over 24 hours on days 1 and 2. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~NEOADJUVANT CHEMORADIATION: Within 4 weeks after completing neoadjuvant chemotherapy, patients undergo radiation therapy in 25 fractions over 5 weeks. Patients also receive either fluorouracil IV continuously for 24 hours on days 1-5 or capecitabine orally (PO) twice daily (BID) on days 1-5. Cycles repeat weekly for 5 weeks in the absence of disease progression or unacceptable toxicity.~SURGERY: Within 4-8 weeks after neoadjuvant chemoradiation, patients undergo surgical resection according to tumor location and per surgeon expertise."
9476862|NCT03567577|Experimental|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
10017658|NCT05295992|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system.
10017659|NCT05295979|Experimental|Inflammatory skin disease formula (ISDF)|Subjects will receive ISDF granules (12.5g twice daily) for 12 weeks.
10017660|NCT05295979|Placebo Comparator|Placebo|Subjects will receive placebo granules (12.5g twice daily) for 12 weeks.
10017661|NCT05295966|Experimental|Intervention Group|Subjects in the intervention group will perform 20 sessions of multisensory training
10017662|NCT05295966|Active Comparator|Control Group|Subjects in the Control Group will not perform 20 sessions of multisensory training and they will keep doing the current therapy
10017663|NCT05295953|Active Comparator|TBS (Theta burst stimulation)|Four sessions of TBS in one day
10017664|NCT05295953|Placebo Comparator|Sham TMS|Four sessions of sham TMS
10017665|NCT05295888|Experimental|Experimental Arm|130Hz TI stimulation (total 2700 sec): ramp-up (30-60 sec) => stimulation (130Hz, 2mA per electrode pair, 4mA total, 2580-2640 sec) => ramp-down (30-60sec)
10017666|NCT05295888|Sham Comparator|Sham Arm|Sham stimulation (total 2700 sec): ramp-up (30-60 sec) => ramp-down (30-60 sec) => stimulation (130Hz, 0mA, 2520-2610 sec) => ramp-down (30-60 sec)
10017667|NCT05295875|Experimental|ALT-801 Dose Level 1|
10017668|NCT05295875|Experimental|ALT-801 Dose Level 2|
10017669|NCT05295875|Experimental|ALT-801 Dose Level 3|
10017670|NCT05295875|Placebo Comparator|Placebo|
10017671|NCT05295849|Experimental|Habit App|Habit Mobile App
10017672|NCT05295836|No Intervention|CONTROL|In this phase of the study, the rectangular test will be performed in conditions of 16°C and 25-30% humidity, intaking 26 mL/kg/body weight of water one and a half hours before the test.
10017673|NCT05295836|Placebo Comparator|PLACEBO (PLA)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 26 mL/kg/body weight of water and placebo one and a half hours before the test.
10017674|NCT05295836|Experimental|GLYCEROL (GLY)|In this intervention, subjects will perform the rectangular test at 28°C and 25-30% humidity, ingesting 1.2 g + 26 mL/kg/body weight of water one and a half hours before the test.
10017675|NCT05295823|No Intervention|Healthcare provider performed standard PVR measurement using existing ultrasound technology|The Urologic healthcare provider will perform standard point-of-care PVR measurement on the participant (3 consecutive measurements during the same encounter) using existing ultrasound technology
10017676|NCT05295823|Experimental|Healthcare provider performed PVR measurement using Butterfly and bladder ultrasound images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images
10017677|NCT05295823|Experimental|Healthcare provider performed PVR measurement using Butterfly and abstract bladder images|The Urologic healthcare provider will perform PVR measurement on the participant (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images
10017678|NCT05295823|Experimental|Self PVR measurement using Butterfly and bladder ultrasound images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and bladder ultrasound images (prior to catheterization, if needed)
10017679|NCT05295823|Experimental|Self PVR measurement using Butterfly and abstract bladder images|The participant will perform self PVR measurement (3 consecutive measurements during the same encounter) using the Butterfly and abstract bladder images (prior to catheterization, if needed)
10017680|NCT05295810|No Intervention|Room Air|All participants will complete an active stand breathing room air with CO2 free to fluctuate
10017681|NCT05295810|Experimental|+0mmHg CO2 Clamped at baseline|All participants will complete an active stand with their CO2 held constant at baseline
10017682|NCT05295810|Experimental|+5mmHg CO2|All participants will complete an active stand breathing +5mmHg of CO2 relative to baseline
10017683|NCT05295810|Experimental|+10mmHg|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline
10017684|NCT05295810|Experimental|+10mmHg CO2 + 50mmHg O2|All participants will complete an active stand breathing +10mmHg of CO2 relative to baseline and 50mmHg of O2
10017685|NCT05295797|Experimental|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
10017686|NCT05295797|No Intervention|Control|Participants in the waitlist control will be assigned to a waiting list and will be invited to participate in dance classes after the intervention arm 12-week dance program has ended
10017687|NCT05295784|Active Comparator|Arm 1: Low dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 1 neonates will receive low dose intravenous caffeine citrate (5 mg/kg).
10017688|NCT05295784|Active Comparator|Arm 2: Medium dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 2 neonates will receive medium dose intravenous caffeine citrate (15 mg/kg).
10017689|NCT05295784|Active Comparator|Arm 3: High dose caffeine|Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. Arm 3 neonates will receive high dose intravenous caffeine citrate (25 mg/kg).
10017690|NCT05295771|Experimental|Test arm|Geistlich Fibro-Gide ®.
10017691|NCT05295771|Active Comparator|Control|Autogenous Connective Tissue Graft.
10017692|NCT05295745|Experimental|Cognitive remediation therapy and multidisciplinary intervention|The participants (obese adults) in the experimental group will receive treatment with cognitive remediation therapy, nutritional and physical activity instruction through 18 weekly sessions of intervention.
10017693|NCT05295745|No Intervention|Control|The control group participants will not receive the treatment until the experimental group participants complete the intervention and carry out the measurements
10017694|NCT05295719|Placebo Comparator|Placebo & Flexibility Training (Control)|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period.
10017695|NCT05295719|Active Comparator|Placebo & High-Intensity Interval Training|Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period.
10017696|NCT05295719|Active Comparator|n-3 PUFA & Flexibility Training (Control)|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in low-intensity flexibility training (control group) for 30 minutes 3 times/week for 6 weeks, a time-matched session of stretching and mobility exercises. All exercise sessions will be performed on an exercise mat and conducted under investigator supervision. Participants will cease supplementation and flexibility training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
10036101|NCT01812590|No Intervention|Resting Trial|Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
10037618|NCT01826682|Placebo Comparator|Medical treatment|29 people are being recruited in order to the inclusion criteria for the study. Placebo controlled.
9476863|NCT03567577|Experimental|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
10017697|NCT05295719|Experimental|n-3 PUFA & High-Intensity Interval Training|Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 8 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will cease supplementation and HIIT training for a 2 week follow-up period. During this time, participants will consume 8 oz per week or consuming fish twice weekly, including one serving of oily fish.
10017698|NCT05295706|Experimental|Intervention Group|Participants in this group will complete the same measures as the control group, but will additionally be involved in a counterfactual intervention conducted by an advanced graduate student.
10017699|NCT05295706|No Intervention|Control Group|Participants in this group will complete the same measures as the experimental group. Instead of being involved in a counterfactual intervention, participants will be asked about their intentions to complete future study components.
9476864|NCT03567577|Placebo Comparator|Placebo|0,9% saline solution
9476865|NCT03567564||Mechanically ventilated patients|Abdominal muscles ultrasound
10017700|NCT05295680|Experimental|Hymecromone|Participants will receive Hymecromone for six months + Standard Of Care (SOC), and will be followed for an additional nine months.
10017701|NCT05295680|No Intervention|Standard Of Care (SOC)|Participants will receive Standard Of Care (SOC), and will be followed for 15 months.
10017702|NCT05295667||Fetal Growth Retardation Group|
10017703|NCT05295654|Experimental|Kinect validation|Kinect measurements will be compared with the vicon measurements to validate the kinect system.
10017704|NCT05295576||chronic periodontitis|scaling and root planing
10017705|NCT05295576||Periodontally healthy individuals|no treatment
10017706|NCT05295563||Group 1|Children who had been injected once or twice before were included in Group 1.
10017707|NCT05295563||Group 2|Children who received 3 or more injections were included in Group 2.
10017708|NCT05295550|Experimental|Flexicurve-Smartphone İnclinometer Application|Measurement of thoracic kyphosis
10017709|NCT05295537|Active Comparator|PERCUTANEOUS LIVER BIOPSY (PLB)|Patients randomized to percutaneous liver biopsy.
10017710|NCT05295537|Experimental|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS - LB)|Patients randomized to EUS-guided liver biopsy
10017711|NCT05295524|Experimental|Patients with Cystic Fibrosis, with KAFTRIO® treatment prescription|Patients with Cystic Fibrosis, for whom treatment with KAFTRIO® is prescribed, regardless of previously prescribed CFTR modulator treatments.
10017712|NCT05295472|Experimental|Grapholearn group|Children with DLD who attend a special school for children with DLD. This group will play the computer game GL in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
10017713|NCT05295472|Active Comparator|Math game group|Children with DLD who attend a special school for children with DLD. This group will play a computer game focusing on math in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
10017714|NCT05295472|Active Comparator|Usual schooling|Children with DLD who attend a special school for children with DLD. This children will have normal schooling as usual without playing any of the above computer games.
10017715|NCT05295459|Experimental|LYR-210|Single administration of LYR-210 drug matrix (7500 μg)
10017716|NCT05295459|Sham Comparator|Sham procedure control|Single mock administration procedure
10017717|NCT05295407||Men 40-69 years old|Men with moderately-elevated PSA (2.5-10 ng/mL) undergoing prostate biopsy for detecting prostate cancer at NorthShore University HealthSystem, Northwestern University, or Johns Hopkins Hospital. The trial will not alter any clinical practice for diagnostic biopsy that includes state-of-the-art procedures (transperineal fusion biopsy, multiparametric MRI, and novel biomarkers).
10017718|NCT05295381|Experimental|abdominal weight training with cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily. Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
10017719|NCT05295381|Experimental|abdominal weight training (AWT) without cough machine (CM)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
10017720|NCT05295381|No Intervention|control|no abdominal weight training and no cough machine
10036102|NCT01812590|Experimental|Exercise Trial|Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
10017721|NCT05295368|Experimental|multicomponent intervention|1) 1. Training Nurses/service coordinators as Health Coaches and Hybrid Follow-up Approach of in-person, Telephone and Secure Video Sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
10017722|NCT05295368|No Intervention|Usual care|treated by physicians and nurses who are not trained in SKOPE treatment algorithms.
10017723|NCT05295355|Experimental|Tiotropium Bromide Combined With Odaterol|Tiotropium O Datlow inhalation spray 60 bottles per bottle, each containing 2.5 tiotropium ammonium g (equivalent to 3.124 g of thiotropium bromide) and 2.5 2.5 g (equivalent to 2.736 2.736 g of hydrochloric acid) by O Datlow. ® The inhaler was inhaled and administered twice a time, once a day, at the same time every day for 52 weeks
10017724|NCT05295355|Experimental|Tiotropium Bromide|Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）： 0.22624mg/ml (calculated by tiotropium), 60 strokes per bottle, containing 2.5 µ g of tiotropium bromide per stroke, through Neng Beile ® Inhaler inhalation administration, 2 presses per inhalation, once a day, administered at the same time every day for 52 weeks.
10017725|NCT05295342|Experimental|Girls-only intervention arm|Schools in this arm will receive only the girls intervention.
10017726|NCT05295342|Experimental|Girls and Boys intervention arm|Schools in this arm will receive both the girls and boys intervention.
10017727|NCT05295342|Active Comparator|Control|The control arm will receive the standard school-based Life Orientation curriculum.
10017728|NCT05295329|Experimental|Test group|Take compound salvia miltiorrhiza dropping pills
10017729|NCT05295329|Placebo Comparator|placebo group|Take a placebo
10017730|NCT05295316||Fibromyalgia|FM group was recruited at AMaR (rheumatic patients association of Piedmont) and the diagnosis of primary fibromyalgia was confirmed by the referring rheumatologist of the AMaR association.
10017731|NCT05295316||Control|The control group was recruited in the same geographic area as the FM participant. The general practitioner of each individual patient certified the subject's state of good health.
10017732|NCT05295303|Experimental|Interventional group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review the physiological parameters of patients randomized to the Intervention group daily and treatment can be initiated or modified accordingly through instant communication (electronic communication and/or phone).
10017733|NCT05295303|Placebo Comparator|Control group|Subjects will be provided with a home-based remote integrated post-MI management system and will be instructed to perform daily routine measurements. Site investigators will review individual patient physiological parameters and risk factors only during the clinic visits
10017734|NCT05295290|Other|myocarditis/pericarditis following COMIRNATY|myocarditis/pericarditis following COMIRNATY within 28 days of dose
10017735|NCT05295290|Other|myocarditis/pericarditis following COVID-19 or MIS-C|myocarditis/pericarditis following COVID-19 or MIS-C without exposure to COMIRNATY
10017736|NCT05295277||Standard of care genetic testing group|Individuals with genomic test results from a standard of care (SOC) test (such as CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS, etc.) will be enrolled in the study to compare the SOC result to results from optical genome mapping.
10017737|NCT05295264|Experimental|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy and published by Barakat model.~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
10017738|NCT05295264|No Intervention|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
10017739|NCT05295238|Experimental|Compass Course|Four groups of up to 12 participants (48 total) will receive the study intervention during Spring and Fall 2022. All participants will complete study questionnaires before and after the sessions.
10017740|NCT05295199|Experimental|Experimental|Routine maintenance and Progressive relaxation exercise
10017741|NCT05295199|No Intervention|Control|Routine maintenance
10017742|NCT05295173|Experimental|experimental group|Recombinant human tissue plasminogen kinase derivatives(r-PA) for injection: the first intravenous bolus injection of 18mg, after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time. Subjects were closely monitored during the treatment period and within 24 hours after administration.
10017743|NCT05295173|Active Comparator|comparative group|Recombinant human tissue plasminogen activator (rt-PA) for injection: 0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours after administration.
10017744|NCT05294900|Experimental|paclitaxel/carboplatin|paclitaxel+carboplatin
10017745|NCT05294120|Experimental|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided RadIation TherapY|"If eligible, patients will undergo pretreatment RCM/OCT imaging, followed by RT.~Six weeks after the completion of RT, patients will undergo post-treatment assessment with RCM/OCT and biopsy. If residual carcinoma is detected on the biopsy, surgical excision of the BCC will be performed. If no residual carcinoma is detected on the biopsy, the patient will be monitored for clinical evidence of recurrence for up to 3 years."
10017746|NCT05291689|Experimental|MORF-057|
10017747|NCT05291091|Experimental|Adult Cohort 1|Drug: EDG-5506 Drug: Placebo
10017748|NCT05291091|Experimental|Adult Cohort 2|Drug: EDG-5506 Drug: Placebo
10017749|NCT05291091|Experimental|Adolescent Cohort 3|Drug: EDG-5506 Drug: Placebo
10017750|NCT05291091|Experimental|Adolescent Cohort 4|Drug: EDG-5506 Drug: Placebo
10017751|NCT05290610|Other|Research IESM|Functional mapping for research application
10017752|NCT05289349|Active Comparator|group (P) for propofol|propofol 6 mg/kg/h in group P
10017753|NCT05289349|Active Comparator|group (S) for sevoflurane.|sevoflurane 1.0-1.5 minimum alveolar concentration (MAC) in group S.
10017754|NCT05288322|Experimental|Mostafa Maged maneuver to prevent and control post-partum haemorrhage|"all pregnant females ( primigravida and multi-gravida ) . this study includes forty pregnant females with normal vaginal delivery .this study includes pregnant females Inclusion criteria :-~All pregnant patients~Age is between (18) to (40) years old~The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery ."
10017755|NCT05288062|Experimental|Cohort A (lenalidomide, dexamethasone)|Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
10017756|NCT05288062|Experimental|Cohort B (lenalidomide, dexamethasone)|Patients with newly diagnosed multiple myeloma receive treatment as in Cohort A.
10017757|NCT05288062|Experimental|Cohort C (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed or refractory multiple myeloma receive lenalidomide PO QD on days 1-14 in combination with dexamethasone PO QD on days 1, 8 and 15 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
10017758|NCT05288062|Experimental|Cohort D (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed multiple myeloma after lenalidomide maintenance receive treatment as in Cohort C.
10017759|NCT05287295|Experimental|Treatment (DAY101)|Relapsed/Refractory LCH patients receive DAY101 orally on days 1,8, 15, and 22
10017760|NCT05286398|Placebo Comparator|Control group|
10017761|NCT05286398|Experimental|Bradach group|
10017762|NCT05286398|Experimental|AEP group|
10017763|NCT05282615|Experimental|Treatment Group (Emanate Tray)|Full mouth periodontal debridement + Emanate Tray (treatment group)
10017764|NCT05282615|No Intervention|Control Group|Full mouth periodontal debridement alone (control group)
10036103|NCT01812603|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide and in open-label manner
10036104|NCT01812616|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide in a double-blind manner
10036105|NCT01812616|Placebo Comparator|Placebo and Dose-Intense Temozolomide|Patients will received placebo and Dose-Intense Temozolomide and in double-blind manner
10036106|NCT01812629|Experimental|Experimental Infant Formula|Complete peptide amino acid-based infant formula
10017765|NCT05282212||Dental Implant Surgery|Subjects scheduled for a revision surgery after developing infection after implant surgery
10017766|NCT05281679|Experimental|Low-intensity resistance exercise with blood flow restriction group (L-BFR).|All the participants in the low-intensity resistance exercise with blood flow restriction group (L-BFR) will receive 3 sessions of low-intensity resistance training with blood flow restriction for a total of 5 weeks.
10017767|NCT05281679|Active Comparator|High-intensity resistance exercise without blood flow restriction group (H-BFR).|All the participants in the high-intensity resistance exercise without blood flow restriction group (H-BFR) will receive 3 sessions of high-intensity resistance training without blood flow restriction for a total of 5 weeks.
10017768|NCT05280405|Experimental|Early-Proactive Therapeutic Drug Monitoring (E-pTDM)|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6. From week 6, the infusion interval will be adjusted based on pre-infusion IFX concentrations to target a trough level grater or equal to (>=) 5 mcg/ml (> 10 μg/ml in patients with perianal disease). For IFX concentrations below target, the infusion interval will be shortened (minimum interval 2 weeks). IFX dose increase will be performed as a second step.
10017769|NCT05280405|Active Comparator|Standard dosing|Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6 followed by 5mg/kg infusions every 8 weeks.
10017770|NCT05279794|Experimental|Jones Group (Strain Counterstrain)|Jones Group consist in 90 seconds in a ralease positioning of no pain in muscle acortation
10017771|NCT05279794|Active Comparator|Myofascial Induction Group|Myofascial Induction Group consist in 15 minutes of superficial and deep lumbar fascia maneuvers
10017772|NCT05279794|Placebo Comparator|Placebo Group|Placebo Group only have to mantain no pain positioning for 3 minutes
10017773|NCT05279053||Male|
10017774|NCT05279053||Female|
10017775|NCT05277818||Patient with medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated with DIVA® implant
10017776|NCT05277818||Patient without medical device DIVA®|Adult patient, operated for at least 12 months, having had surgery for a degenerative or traumatic mono-segmental lumbar disc herniation, without any other associated pathology, operated without DIVA® implant
10017777|NCT05277558||Normal Weight-Normal Glucose Tolerant (NW-NGT)|(1) a group that is the normal weight (BMI<85th%) and has normal glucose tolerance (NW-NGT)
10017778|NCT05277558||Overweight and/or obese and has normal glucose tolerance (O-NGT)|(2) a group that is overweight and/or obese (BMI >85th%) and has normal glucose tolerance (O-NGT)
10017779|NCT05277558||Overweight and/or Obese and has dysglycemia (O-DG)|(3) group that is overweight and/or obese (BMI >85th%) and has dysglycemia (O-DG; fasting plasma glucose ≥100 mg/dl and/or 2-hour glucose ≥140 mg/dl oral glucose tolerance test (OGTT) and laboratory-based HbA1c ≥5.8 and ≤8.0%, if treatment naïve).
10017780|NCT05277025||Fibromyalgia|Participants who fulfill the 1990 and 2011 American College of Rheumatology Criteria for FM.
10017781|NCT05277025||Rheumatoid Arthritis|Participants who fulfill the 2010 ACR-EULAR classification criteria for RA.
10017782|NCT05277025||Healthy Volunteers|Participants who do not have significant pain/fatigue/anxiety/depression.
10017783|NCT05276154|Active Comparator|thermoviscous bulk fill resin composite|
10017784|NCT05276154|Active Comparator|conventional bulk fill resin composite|
10017785|NCT05276050|Experimental|Study group|Participants in this group will receive active F8-coil delivered rTMS.
10017786|NCT05276050|Active Comparator|Active control group|Participants in this group will receive active H-coil delivered rTMS.
10017787|NCT05276024||iFuse Bedrock technique|Multilevel lumbar fusion procedure with additional sacroiliac joint stabilization using the iFuse-3D system
10017788|NCT05275686|Placebo Comparator|Arm 1 (Placebo)|Arm 1 (placebo) will get placebo spray per day.
10017789|NCT05275686|Active Comparator|Arm 2 (EDS-FLU)|Arm 2 (EDS-FLU) will get 744 mcg of fluticasone propionate per day.
10017790|NCT05275647|Experimental|Treatment group : BoNT-A 100 U in Normal saline|BOTOX 100U in normal saline (BoNT-A/NS) 30ml in single intravesical instillation
10017791|NCT05275647|Placebo Comparator|Placebo group : Normal saline|Normal saline (N/S) 30ml in single intravesical instillation
10017792|NCT05275491||Mild to moderate COVID 19 patients|"According to COVID 19 treatment guidelines of National Institutes of Health (NIH):~Mild illness that show symptoms like fever, cough, nausea, vomiting, sore throat, loss of taste & smell but don't show dyspnea or abnormal chest imaging.~Moderate illness that show clinical or radiological lower respiratory disease with SpO2 > 94% on room air."
10017793|NCT05275491||Severe to critical COVID 19 patients|"According to COVID 19 treatment guidelines of National Institutes of Health (NIH):~Severe illness that show SpO2 < 94% on room air, (PaO2/FiO2) <300 mm Hg & lung infiltration > 50% with respiratory rate > 30 breath/min.~Critical illness that show respiratory failure, septic shock or multiorgan failure."
10017794|NCT05275491||Normal male subjects (Control)|
10017795|NCT05275374|Experimental|Part 1 - XP-102 Dose Escalation|XP-102
10017796|NCT05275374|Experimental|Part 2 - XP-102 + Trametinib Dose Escalation|XP-102 plus Trametinib
10017797|NCT05275374|Experimental|Part 3 - XP-102 + Trametinib Dose Expansion|XP-102 plus Trametinib
10017798|NCT05275361|Experimental|Patient: Scheduled for mammogram|"Will be asked to choose 2 social contacts (adult family member or friend identified by the participant as someone who could be engaged by the research team to encourage the participant to attend her mammogram appointment)~Will receive reminder(s) from social contact about the screening mammogram appointment~Will receive reminder from Breast Health Center about screening mammogram appointment~Will be contacted to provide experience with the study"
10017799|NCT05275361|No Intervention|Social Contact of Patient|"Facilitate enrolled patient to complete the screening mammogram.~Will receive information about screening mammograms and resources available at the Breast Imaging Center.~Will be contacted approximately 3 days prior to the patient's mammogram appointment.~Will be contacted to provide experience with the study"
10017800|NCT05274347|Experimental|Multi-faceted virtual, remote intervention|"The intervention will use the Aetonix - aTouchAwayTM software platform (AETONIX Systems Inc). Each study participant will receive a tablet with Aetonix software. Interventions Components:~Virtual physical rehabilitation: After discharge, patients will have virtual, supervised group exercise sessions twice weekly with a physiotherapist.~Cognitive behavioral therapy (CBT): After discharge, patients will receive weekly group CBT sessions delivered virtually by a psychologist. Throughout the series of CBT sessions, patients will learn strategies for problem-solving, assertive communication, relaxation, behavioural activation, time-based pacing, challenging unhelpful thinking, building motivation, and goal setting.~Remote monitoring of vital signs and symptoms: Messages will be sent to patients asking them to measure their vitals, to report symptoms, and answer questions about medications. Concerning responses will be flagged for review by the patient's healthcare team."
10017801|NCT05274334|Experimental|intervention group|Assessment of de novo lipogenesis non-invasively in exhaled breath in overnight-fasted humans by triggering feeding response by deuterium resolved mass spectrometry.
10017802|NCT05274321||Pediatric Participants|Consenting participants will undergo standard pupillary dilation in one eye and pupillary dilation in the second eye using the Nanodropper attachment.
10017803|NCT05274243|Experimental|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
10017804|NCT05274243|Placebo Comparator|Placebo|Matching placebo (provided as three capsules) three times per day for 4 weeks
10017805|NCT05274126|Experimental|Patient group (single group)|300 Patients involved in the recovery process.
10017806|NCT05274035||Perampanel|Epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (AEDs) with the optimal dose and course of treatment and needed perampanel additional treatment.
10017807|NCT05273996|Other|Depressed|Subjects receive FDA-approved antidepressants
10017808|NCT05273762|Experimental|FlowTriever|
10017809|NCT05273242|Experimental|Artesunate|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
10017810|NCT05273242|Experimental|Imatinib|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
10017811|NCT05273242|Experimental|Infliximab|Please refer to the WHO solidarity Trial Plus Protocol ISRCTN18066414
10017812|NCT05273242|No Intervention|Local Standard of Care|No other Intervention Given except the local standard of care
10017813|NCT05273086|Experimental|Sleep intervention program|The Sleep Intervention program Group will be subdivided into two groups of 10 participants to receive the sleep quality improvement program. The program consists of 2 sessions of 90 minutes during one week.
10017814|NCT05273086|No Intervention|Control Group|The control group will continue with their usual routine.
10017815|NCT05272800|Experimental|BIS Group|Dry weight is evaluated monthly by clinical examination and biannually BIS-guided.
10017816|NCT05272800|Active Comparator|CE Group|Dry weight is evaluated monthly by clinical examination alone.
10017817|NCT05272631||Retrograde Femoral Nail Advanced (RFNA) Cohort|Participants with a distal femur or femoral shaft fracture or who require revision due to a malunion or nonunion will undergo surgery with RFNA based on surgeon's decision and the site's standard of care (SOC). Participants with impending pathologic fracture are also included.
9476866|NCT03567525|Active Comparator|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
10017818|NCT05272631||Tibial Nail Advanced (TNA) Cohort|Participants with open or closed, proximal, distal or shaft fractures of the tibia, or who require revision due to a malunion or nonunion will undergo surgery with TNA based on surgeon's decision and the site's SOC.
10017819|NCT05272423||Cohort 1A|Patients who are currently progressing on a KRAS G12C inhibitor. Plasma for ctDNA analysis will be collected.
10017820|NCT05272423||Cohort 1B|Patients who have already had a sequencing assay performed to determine the resistance mechanism to a KRAS G12C inhibitor. These patients will be invited to share their data and medical history. Plasma for ctDNA analysis will be optional.
10017821|NCT05272280|Active Comparator|External oblique intercostal (EOI) block|
10017822|NCT05272280|Active Comparator|Erector spinae plane block (ESPB)|
10017823|NCT05272202|Experimental|Median nerve stimulation|
10017824|NCT05272085|Active Comparator|Ultrasound Guided Lavage Group|"The physical examination, pain scoring, functional scale, disability scale, special tests, direct radiography findings and ultrasonographic imaging findings of the patients in this group before the treatment and 1 month after the treatment will be evaluated and will be recorded. Size of calcific deposits and Gartner classification will be evaluated on direct radiography. Size, shape, acoustic shadowing, power doppler activity of calcific deposits and other bursitis, tendinitis, ruptures, effusion in the shoulder will be evaluated on ultrasonographic imaging.~Patients in this group will be treated with ultrasound-guided lavage."
10017825|NCT05272085|Active Comparator|Ultrasound Guided Subacromial Bursa Injection Group|"The physical examination, pain scoring, functional scale, disability scale, special tests, direct radiography findings and ultrasonographic imaging findings of the patients in this group before the treatment and 1 month after the treatment will be evaluated and will be recorded. Size of calcific deposits and Gartner classification will be evaluated on direct radiography. Size, shape, acoustic shadowing, power doppler activity of calcific deposits and other bursitis, tendinitis, ruptures, effusion in the shoulder will be evaluated on ultrasonographic imaging.~Patients in this group will be treated with ultrasound-guided subacromial bursa injection with corticosteroid and lidocaine."
10017826|NCT05272059|Experimental|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
10017827|NCT05272059|Placebo Comparator|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
10017828|NCT05272059|Experimental|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
10017829|NCT05272059|Experimental|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
10017830|NCT05272059|Experimental|Part B: MHS552|Participants will MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
10017831|NCT05272059|Placebo Comparator|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
10017832|NCT05271825|Experimental|Broadband amplification|broadband amplification: (125 Hz to 10 kHz)
10017833|NCT05271825|Placebo Comparator|Band-limited amplification|band-limited amplification (125 Hz to 3-4 kHz)
10017834|NCT05271773||Mayo 0|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 0 endoscopic activity.
10017835|NCT05271773||Mayo 1|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 1 endoscopic activity.
10017836|NCT05271604|Experimental|BA3021|BA3021 alone in PD-1/L1 failure patients
10017837|NCT05271383||Study group|Male and female, major or minor, who will be treated by orthognathic surgery (maxillary, mandibular, maxillomandibular or/with genioplasty). The bone maturity of the participants (assessed by investigators) need to be sufficient for the treatment.
10017838|NCT05271097|Experimental|MyLink2Care app|Participants in the MyLink2Care group will be provided with full app access and will be encouraged to use all features of the app.
10017839|NCT05271097|Active Comparator|treatment-as-usual (TAU)|Participants in the TAU group will receive the MyLink2Care app with major intervention features inactivated.
10017840|NCT05271019|No Intervention|Control group: Conventional Rehabilitation Program|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
9476867|NCT03567525|Experimental|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
10017841|NCT05271019|Experimental|Experimental group: Conventional Rehabilitation Program + Inspiratory Muscle Training (IMT)|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
10017842|NCT05270850|Active Comparator|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
10017843|NCT05270850|Experimental|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula.
10017844|NCT05270317|Active Comparator|Early-Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 6 weeks
10017845|NCT05270317|Active Comparator|Medium -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 8 weeks
10017846|NCT05270317|Active Comparator|Late -Stage Group|6 patients will be allocated randomly to participate in the clinical trial with cultivation duration of 10 weeks
10017847|NCT05269797|Experimental|Health-coaching Intervention|A nurse-lead health coaching intervention to support heart failure self-care management is employed by the nurses. This is a pre-post single group design - there is only one arm.
10017848|NCT05269602||L5 Radiculopathy|Patients who have Lumbar 5 root compression with the Magnetic Resonance İmaging
10017849|NCT05269602||S1 Radiculopathy|Patients who have Sacral 1 root compression with the Magnetic Resonance İmaging
10017850|NCT05269589|Sham Comparator|Thermoneutral|Participants will immerse their feet in a foot bath with water maintained at 36°C
10017851|NCT05269589|Experimental|Heat|Participants will immerse their feet in a foot bath with water maintained at 42°C
10017852|NCT05269576|Experimental|Single arm that receive two different interventions (clinical practice and clinical simulation).|"An analysis is carried out to the entire group prior to intervention. A second analysis is carried out to the entire group after one of the two interventions. Finally, a last analysis is carried out to the entire group after complete both types of interventions.~We apply the study in a group of medicine students of 3rth course of the degree. We examine their competencies at the beginning of the course. Re-examination is done after they do a period of clinical practice or a period of clinical simulation. At the end of the course, all the students done both interventions (clinical practice and clinical simulation), moment when we do the last examination of their competencies."
10017853|NCT05269511|Experimental|Treatment group|Chinese Herbal Medicine
10017854|NCT05269511|No Intervention|Control group|usual care
10017855|NCT05269264||patients with unilateral or bilateral, primary or secundary lower limb lymphedema (LLL)|patients with unilateral or bilateral, primary or secundary LLL who visit the center for lymphedema at UH Leuven
10017856|NCT05269264||healthy controls|age, BMI and gender matched to the patients with LLL
10017857|NCT05269264||subgroup (n=40)|a subgroup of subjects (patients & healthy controls) will be evaluated again 2 weeks later
10017858|NCT05269225|Experimental|Organic diet|Consuming organic food from the start of 2nd trimester and until gestational week 37.
10017859|NCT05269225|Placebo Comparator|Conventional diet|Consuming conventional food throughout the whole pregnancy.
10017860|NCT05269121|Experimental|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotics.
10017861|NCT05269095|Experimental|spinal anesthesia only|Patients will receive spinal anesthesia only
10017862|NCT05269095|Experimental|spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive spinal anesthesia and ultrasound-guided Genicular nerves block
10017863|NCT05269095|Experimental|Spinal anesthesia and US guided Adductor canal nerve block plus infiltration of the interspace|Patients will receive spinal anesthesia and ultrasound-guided Adductor canal nerve block plus infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (PACK) block.
10017864|NCT05269082||Cohort 1|Pediatric and adult participants who are on Gammagard S/D prescribed for any approved indication will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
9476868|NCT03567512|Experimental|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
10037619|NCT01826682|Active Comparator|Physiotherapy program+medical treatment|29 people are recruited in order to the inclusion criteria for the study. Experimental group
10017865|NCT05269082||Cohort 2|Pediatric and adult participants who were previously treated with Gammagard S/D prescribed for any approved indication and are on another human immunoglobulin treatment will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
9802628|NCT05113186|Experimental|Neoadjuvant and adjuvant therapy with lenvatinib|"Neoadjuvant therapy with lenvatinib to complete a 3-week course, stopping 1 week before the planned date of PA procedure  LENVABLA  protocol, version 1.3 du 25/05/2021 12/55~- Adjuvant therapy with lenvatinib for 3 months starting after the PA evaluation (± 14 days) The daily dose of lenvatinib will be 12 mg (≥60 kg) or 8 mg (<60 kg). Lenvatinib will be taken within 2 hours after a light meal, preferably in the morning."
10017866|NCT05269082||Cohort 3|Pediatric and adult primary immunodeficiency (PID) participants with immunoglobin A (IgA) deficiency who have a serum IgA level of less than (<) 7 milligrams per deciliter (mg/dL) (0.07 grams/liter [g/L]) or below the detectable limit and have received other therapies (prophylactic antibiotics or immunoglobulin treatment other than Gammagard S/D) will be enrolled in this cohort and evaluated during the observation period (approximately 6 months).
10017867|NCT05269069||Patients with rheumatoid arthritis|
10017868|NCT05269069||Control group|
10017869|NCT05268939|Experimental|Nasal Swab|Nasal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
10017870|NCT05268939|Experimental|Nasopharyngeal Swab|Nasopharyngeal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
10017871|NCT05268783|Experimental|NEN patients|EORTC QLQ-C30, EORTC QLQ-GI.NET21 and satisfaction survey
10017872|NCT05268679||Heart transplant recipients|Heart transplant recipients followed at Bichat Hospital and who were offered vaccination against SARS-CoV-2, regardless of whether they agreed to be vaccinated or not.
10017873|NCT05268653|Experimental|Motivational İnterviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical public health nursing doctoral student trained in Motivational Interviewing administered six motivational interviewing therapy sessions, each 30 minutes long. A 3-month follow-up will then be applied.
10017874|NCT05268653|No Intervention|Control Group|No attempt will be made
10017875|NCT05268367|Experimental|3-Week Baseline|Participants in this arm are randomized to a 3-week baseline period with repeated weekly assessment after the initial intake. Following the 3-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
10017876|NCT05268367|Experimental|5-Week Baseline|Participants in this arm are randomized to a 5-week baseline period with repeated weekly assessment after the initial intake. Following the 5-week baseline, participants receive 5 weekly sessions of Written Exposure Therapy (WET) followed by a 4-week follow-up phase with repeated weekly assessments, including a post-study evaluation one week after ending WET.
10017877|NCT05267938|Experimental|Microneedles|Microneedles is with 750μm of height in order to prepare the palatal mucosa to receive the topical anesthetic
10017878|NCT05267938|Sham Comparator|patch flat|The same device as the microneedles but without microneedles
10017879|NCT05267899|Experimental|WGI-0301|
10017880|NCT05267821|Active Comparator|Anakinra 4 mg/kg/day|IV Anakinra 4mg/kg/day x 7 days
10017881|NCT05267821|Active Comparator|Anakinra 8 mg/kg/day|IV Anakinra 8 mg/kg/day x 7 days
10017882|NCT05267821|Active Comparator|Anakinra 12 mg/kg/day|IV Anakinra 12 mg/kg/day x 7 days
10017883|NCT05267821|Active Comparator|Anakinra 16 mg/kg/day|IV Anakinra 16 mg/kg/day x 7 days
10017884|NCT05267821|Placebo Comparator|Placebo|IV placebo x 7 days
10017885|NCT05267496|Other|Conventional rehabilitation|Patients will receive conventional pulmonary rehabilitation
10017886|NCT05267496|Experimental|AEROBIKA|Patients will receive conventional pulmonary rehabilitation in addition to an oscillating positive expiratory pressure device
10017887|NCT05267431||RA patients recieved biological therapy|RA patients recieved different biological therapy
10017888|NCT05267431||RA patients recieved different DMARDS|RA patients recieved different DMARDS
10017889|NCT05266248|Experimental|Fed state|Standardized high fat breakfast before dosing
10017890|NCT05266248|Experimental|Fasted state|Remain fasted for 4 hours post-dose
10017891|NCT05266131||OSA0HT0|without OSA or hypertension (OSA0HT0)
10017892|NCT05266131||OSA1HT0|OSA without hypertension (OSA1HT0)
10017893|NCT05266131||OSA0HT1|hypertension without OSA (OSA0HT1)
10017894|NCT05266131||OSA1HT1|with OSA and hypertension (OSA1HT1)
10017895|NCT05265702|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
10017896|NCT05265624|Experimental|Early Genetic Results Disclosure|Early disclosure group receives results of genetic testing at Month 1
10017897|NCT05265624|Active Comparator|Late Genetic Results Disclosure|Late disclosure group receives results of genetic testing at Month 12
10017898|NCT05265585||Echocardiography group|
10017899|NCT05265156|Other|Plant based formula for young children|The study is designed with a single arm, so all subjects will receive the study product.
9476869|NCT03567512|Placebo Comparator|Control group|The placebo intervention will be administered in this group.
10017900|NCT05265078||Participants Diagnosed With VWD|Participants who have been diagnosed with VWD and prescribed VEYVONDI for the approved indications for the index infusion (first eligible VEYVONDI infusion) will be assessed using secondary data obtained from medical records to evaluate the safety of VEYVONDI in real-world clinical practice. All study data will be retrospectively abstracted from medical records by dedicated clinical research staff in partnership with the treating physician. The data window for this study will begin on 01 January 2019 and end 30 June 2022.
10017901|NCT05264896|Experimental|FLOT|"Patients randomized to the FLOT arm would receive perioperative FLOT~Regimen:~Docetaxel 50mg/m2, d1~5-FU 2600 mg/m², d1~Leucovorin 200 mg/m², d1~Oxaliplatin 85 mg/m², d1~Every two weeks 4 cycles pre-op and 4 cycles post-op~Granulocyte colony stimulating factor (GCSF) at 30 mu s.c. daily from Day 4 to Day 7 is recommended.~Two weeks after completion of the 4 cycles of pre-op chemotherapy, reassessment endoscopy and CT scan would be performed. Surgery would be performed 4 weeks after pre-op chemotherapy if no distant metastasis was found on CT scan.~Post-op adjuvant FLOT (x 4 cycles) will be started within 10 weeks after surgery."
9802629|NCT05112536|Experimental|Trilaciclib plus chemotherapy|"Trilaciclib lead-in, followed by trilaciclib plus anthracycline/cyclophosphamide, then trilaciclib plus taxane chemotherapy:~Lead-in trilaciclib (240mg/m2) single dose monotherapy~Trilaciclib (240mg/m2) + doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) + pembrolizumab (per Investigator discretion; 400mg)~Trilaciclib (240mg/m2) + paclitaxel (80 mg/m2) + carboplatin (per Investigator discretion; AUC 1.5)"
9802630|NCT05111808|Experimental|Methyl Blue|This group will receive intraoperative IV methyl blue
9802631|NCT05102955||1/Observational Questionnaires|All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters(physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
9802632|NCT05099133|Experimental|LEO 138559 Dose 1|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
9802633|NCT05099133|Experimental|LEO 138559 Dose 2|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
9802634|NCT05099133|Experimental|LEO 138559 Dose 3|LEO 138559 will be administered subcutaneously up to 3 injections per dosing
9802635|NCT05099133|Placebo Comparator|Placebo|LEO 138559 placebo will be administered subcutaneously up to 3 injections per dosing
9802636|NCT05097963|Experimental|Subjects undergoing EUS shear wave elastography|Subject who are eligible will undergo EUS for clinical indications. EUS shear wave measurements will be gathered and studied to determine diagnostic accuracy when compared to MR Elastography.
9802637|NCT05094531|Experimental|Intervention group|"Participants of this experimental group will have to attend the prevention program which is organised in eight 2-hour workshops, one every other week.~Groups of 10-12 participants will be established prior to the first session of the program and will remain the same throughout the program."
9802638|NCT05094531|No Intervention|No-intervention group|Participants of the no-intervention group will not have to attend the prevention program.
9802639|NCT05093829|Experimental|Vaccination at 9 months of age with NmCV-5|Infant participants randomized to receive the NmCV-5 meningococcal vaccination at 9 months of age, while receiving the current Mali EPI schedule of vaccines.
9802640|NCT05093829|Active Comparator|Vaccination at 9 months of age with MenACWY-TT|Infant participants randomized to receive the MenACWY-TT meningococcal vaccination at 9 months of age, while receiving the current Mali EPI schedule of vaccines.
9802641|NCT05093829|Experimental|Vaccination at 15 months of age with NmCV-5|Infant participants randomized to receive the NmCV-5 meningococcal vaccination at 15 months of age, while receiving the current Mali EPI schedule of vaccines.
9802642|NCT05093829|Active Comparator|Vaccination at 15 months of age with MenACWY-TT|Infant participants randomized to receive the MenACWY-TT meningococcal vaccination at 15 months of age, while receiving the current Mali EPI schedule of vaccines.
9802643|NCT05093660||Patients with acute appendicitis|Patients with acute appendicitis, after surgery and with pathohistological specimen confirmation.
9802644|NCT05093660||Patients without acute appendicitis|Patients without acute appendicitis, after laboratory, clinical and/or radiological exclusion of acute admittance.
9802645|NCT05093504|Sham Comparator|Control|Standard of care with Sham set-up
9802646|NCT05093504|Experimental|DrugSorb-ATR Intervention|Standard of care + DrugSorb-ATR system
9802647|NCT05093153||Waldenström's macroglobulinemia cohort patient|Adult patients diagnosed with Waldenström's Macroglobulinemia
9802648|NCT05093140|Experimental|camrelizumab+R-CHOP|Induction therapy: camrelizumab in combination with rituximab Immunochemotherapy: rituximab, cyclophosphamide, hydroxyldaunorubicin, vincristine, prednisone Maintenance therapy: camrelizumab in patients achieved CR after immunotherapy
9802649|NCT05091788|Experimental|Treatment Arm|All subjects will receive two coring treatments on the cheeks with the robotic coring device.
9802650|NCT05090371|Experimental|Ofatumumab|20 mg
9802651|NCT05090371|Active Comparator|DMT continued therapy|Participants randomized to the continued therapy arm will continue to take their disease modifying treatment (DMT) as prescribed commercially by their physician.
9802652|NCT05088018|Experimental|Active Cannabigerol|25 mg daily swallowable Cannabigerol tablets for 2 weeks, immediately followed by 50 mg daily swallowable Cannabigerol tablets for 2 weeks
10017902|NCT05264896|Active Comparator|XELOX|"Patients randomized to adjuvant XELOX arm would receive chemotherapy after surgery.~Capecitabine - 1,000 mg/m² twice daily.~Oxaliplatin - IV infusion, 130mg/m²"
10017903|NCT05264831|Active Comparator|Standard Of Care (SoC) procedure (PVI) with prospective registry.|If the patient presents with a SR (= successful electric cardioversion, approximately 70% of patients) the patient will be treated as per SoC in accordance with ESC recommendations. It is recommended to perform PVI procedure alone in these patients. A prospective registry for these patients will be established for this study.
10017904|NCT05264831|Experimental|PVI procedure alone|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 1: PVI procedure alone in accordance with ESC recommendations"
10017905|NCT05264831|Experimental|PVI procedure combined with substrate modulation|"If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to :~- Group 2: PVI procedure associated with substrate modulation"
9665257|NCT05121168|Experimental|Active Treatment|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
10017906|NCT05264584|Other|control arm|This arm is consisted of 60 patients.They will receive IV hydration and N-acetylcysteine (control arm).
10017907|NCT05264584|Experimental|Febuxostat arm|This arm is consisted of 60 patients.They will receive IV hydration, N-acetylcysteine and Febuxostat .
10017908|NCT05264155|Placebo Comparator|Control: one-size-fits-all|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the control group, the parameter values of the dynamic tasks were based on national guidelines."
10017909|NCT05264155|Active Comparator|Treatment: personalized|"The study was designed as a 2-arm randomized intervention trial. The experimental setup was centered around setting the complexity parameters (ie, the X values) of the 3 dynamic tasks. In particular, the parameters to determine were as follows: (1) the minimum distance of a longer walk, (2) the minimum distance of a longer bike ride, and (3) the maximum number of rewarded sports sessions (and consequently the number of rewarded points per sports session).~For the treatment group, these parameters were tailored to the users' self-reported capabilities and health goals."
10037389|NCT01824719||Control group|All patients who used Reduning Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
10017910|NCT05263830||Patient with hepatocellular carcinoma|Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting.
10017911|NCT05263739|Experimental|ESG206 dose level 1|ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle.
10017912|NCT05263739|Experimental|ESG206 dose level 2|ESG206 will be administered intravenously at dose level 2 every two weeks in a 28-day cycle.
10017913|NCT05263739|Experimental|ESG206 dose level 3|ESG206 will be administered intravenously at dose level 3 every two weeks in a 28-day cycle.
10017914|NCT05263687|Experimental|Exercise Test|maximal and anaerobic threshold cardiopulmonary parameters
10017915|NCT05263622|Experimental|Group A|Half of patients will be included in this group according to the split-mouth design.
10017916|NCT05263622|Experimental|Group B|Half of patients will be included in this group according to the split-mouth design.
10017917|NCT05263349||COPD patients|Arm with patients with respiratory disease in whom we study dreams
10017918|NCT05263349||healthy subject|Arm with healthy subjects whose dream analysis will be used as a basis to compare them to the dreams of COPD patients and see if the disease (COPD) has an influence on the patients' dreams
10017919|NCT05263167|Experimental|sodium aescinate group|Trial treatment is administered as sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
10017920|NCT05263167|Placebo Comparator|placebo group|Trial treatment is administered as 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
10017921|NCT05263037|Experimental|56-day skills-based VR program|participants in the EaseVRx-8w arm will participate in an 8-week interventional program and continue to be followed for 24 months following completion of tx
10017922|NCT05263037|Experimental|56-day skills-based VR program followed by an extended 56-day on-demand period|participants in the EaseVRx-8w plus extended on-demand arm will enroll in an 8-week interventional program and be offered an extended 8-week ondemand period, and continue to be followed for 24 months after the completion of treatment
10017923|NCT05263037|Sham Comparator|56-day control (Sham VR)|participants in the first control arm will receive 2D Sham VR virtual reality content during the 8-week interventional program and continue to be followed for 24 months after the completion of treatment. participants in the Sham VR group will receive the same Pico G2 4K headset as participants in the immersive VR groups, but rather than view 360-degree, 3D, interactive content specially selected for efficacy, they will only have access to 2D nature footage with neutral music layered on top that is selected to be neither overly relaxing nor distracting. The experience of Sham VR is similar to watching a large-screen TV, but it is not interactive. The advantage of Sham VR is that it controls for the novelty and immersion of the hardware and isolates the effect of VR skill-based training
10017924|NCT05263037|Sham Comparator|• 56-day control (Sham VR plus 8w extended on-demand)|participants in the second control arm will receive 2D Sham VR virtual reality content during the 8-week interventional program and be offered an extended 8-week on-demand period, after which they will continue to be followed for 24 months after the completion of treatment.Participants in the Sham VR group will receive the same Pico G2 4K headset as participants in the immersive VR groups, but rather than view 360-degree, 3D, interactive content specially selected for efficacy, they will only have access to 2D nature footage with neutral music layered on top that is selected to be neither overly relaxing nor distracting.
10017925|NCT05262959|Experimental|Donafenib|Donafenib: 0.1g po. BID. And it will be taken on the first day of the study. PD-1: 200mg ivgtt. Q3W. It will be used at the same time as Donafenib. TACE: The first treatment will be carried out 2-3 weeks after taking Donafenib.
10017926|NCT05262686|Experimental|belimumab plus low dose IL-2|"10mg/kg belimumab was intravenously injected to patients with systemic lupus erythematosus every month for 24 weeks.~Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL-2 was injected once a week for 12 weeks subcutaneously."
10017927|NCT05262686|Active Comparator|belimumab|10mg/kg belimumab was administrated to patients with systemic lupus erythematosus for at least 24 weeks, intravenously injected every month.
10017928|NCT05262686|Active Comparator|low dose IL-2|The first stage: interleukine-2 was added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh; The second stage: 1 million IU IL-2 was injected once a week for 12 weeks subcutaneously.
10017929|NCT05262075|Experimental|Mindfulness and Resiliency Program|This is an online mindfulness program that integrates resiliency factors to women
10017930|NCT05261386|Placebo Comparator|Placebo Comparator: CBT-008|CBT-008 vehicle ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
10017931|NCT05261386|Experimental|Experimental: 2.5% CBT-008|2.5% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
10017932|NCT05261386|Experimental|Experimental: 10% CBT-008|10% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
10017933|NCT05261334|Active Comparator|socket shield technique|immediate implant placement with socket shield technique
10017934|NCT05261334|Active Comparator|contour augmentation|early implant placement with contour bone augmentation
10017935|NCT05260164|Experimental|HIFEM+RF|"The subjects will be enrolled and assigned into one study arm and will be required to complete four (4) treatment visits.~Both flanks will be treated simultaneously with the BTL-899 device for 30 minutes per session."
10017936|NCT05260008|Experimental|ATX-101 Dose A|ATX-101 Dose A
10017937|NCT05260008|Experimental|ATX-101 Dose B|ATX-101 Dose B
10017938|NCT05260008|Placebo Comparator|saline|saline placebo via local infiltration
10017939|NCT05260008|Active Comparator|bupivacaine hydrochloride|bupivacaine hydrochloride without epinephrine via local infiltration
10017940|NCT05259566|No Intervention|no menthol ban|usual menthol cigarettes and menthol flavored e-cigarette available
10017941|NCT05259566|Experimental|menthol ban in cigarettes only|non-menthol cigarettes and menthol flavored e-cigarette available
10017942|NCT05259566|Experimental|menthol ban in both cigarettes and e-cigarettes|non-menthol cigarettes and tobacco flavored e-cigarette available,
10036107|NCT01812642|Experimental|JNJ-37822681 10 milligram|JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.
10036108|NCT01812642|Experimental|JNJ-37822681 20 milligram and placebo|JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
10036109|NCT01812720|Experimental|Treatment (carfilzomib, dexamethasone)|Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
10036110|NCT01812746|Experimental|BIND-014|
9802653|NCT05088018|Placebo Comparator|Placebo|25 mg daily swallowable placebo tablets for 2 weeks, immediately followed by 50 mg daily swallowable placebo tablets for 2 weeks
10036111|NCT01812772|Experimental|Double J-stent with a long tether|Following ureteroscopy patients will have placed a double J-stent with a long tether.
10036112|NCT01812772|Active Comparator|Double J-stent without a long tether|Following ureteroscopy patients will have a double J-stent placed without a long tether
10036113|NCT01812798|Active Comparator|Peanut|"Double Blind Placebo Controlled Food Challenge 5 gram peanut challenge~17 doses of peanut will be administered. Dose will be increased every 20-30 minutes. All doses listed are in g of peanut flour.~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000"
10036114|NCT01812798|Placebo Comparator|Placebo|Double Blind Placebo Controlled Food Challenge (No peanut - placebo only)
10036115|NCT01812824|Experimental|Intervention (Virtual Patient Advocate)|Participants assigned to the Intervention (Virtual Patient Advocate) arm will have access to the Virtual Patient Advocate system on-line for 6 months; they will be encouraged, but not required, to log on once a week.
10037390|NCT01824732||Allergic group|All patients who used Tanreqing Injection have anaphylaxis.
10017943|NCT05259540|Experimental|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days
10017944|NCT05258981|Other|Brain MRI|Obtain Brain MRI in adults with congenital heart disease and age/sex matched controls
10017945|NCT05258968|Experimental|Educational Session on the Injeti Self Esteem Model|The participant will participate in a 1 hour educational session on the Injeti Self Esteem model.
10017946|NCT05257447|Experimental|Baclofen 20mg tablet|Single oral dose of baclofen, 20 mg
10017947|NCT05257447|Experimental|Chlorzoxazone 500mg tablet|Single oral dose of chlorzoxazone, 500 mg
10017948|NCT05257447|Experimental|Baclofen 20 mg tablet and chlorzoxazone 500 mg tablet|Concurrent doses of baclofen, 20 mg, and chlorzoxazone, 500 mg
10017949|NCT05256940|Experimental|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, and is delivered in three sessions in person, virtually, or by telephone.
10017950|NCT05256940|Active Comparator|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
10017951|NCT05256888|Experimental|Time-restricted eating|Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times). Participants will also receive weekly tips to encourage a healthy lifestyle in cancer survivorship.
10017952|NCT05256888|Other|Control|Participants will receive weekly tips to encourage healthy lifestyle behaviors in cancer survivorship.
10017953|NCT05256823|Experimental|Experimental Group|Patients will be given a combination of Celecoxib and one nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
10017954|NCT05256823|Other|Control group|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
10017955|NCT05255445||Sickle cell disease (SCD)|Patients with SCD who are chronically transfused (in the U.S. and Brazil)
10017956|NCT05255445||Thalassemia|Patients with thalassemia who are chronically transfused in the U.S.
10017957|NCT05255445||Pediatric Hematology-Oncology|Patients in U.S. with pediatric oncologic diagnoses with hypo-proliferative bone marrow requiring single unit red blood cell transfusion
10017958|NCT05255445||Blood Donors|Allogenic blood donors in the US (estimated: 10,200) and allogenic blood donors in Brazil (estimated: 2,100) with extended donation genotyping using an investigational hematology array.
10017959|NCT05254535|Other|Intervention|Up to 10 rural health systems will be participating in I-SITE implementation with cluster-randomization of the order of initiation for the intervention. All sites will receive usual care teleophthalmology prior to I-SITE implementation.
10017960|NCT05254457|No Intervention|Observation Only Group|
10017961|NCT05254457|Experimental|Treated or Retreated Group|
10017962|NCT05254158|Experimental|NNC0174 0833 1.8 mg|Each participant will receive one single dose of NNC0174 0833
10017963|NCT05254158|Experimental|NNC0174 0833 0.9 mg|Each participant will receive one single dose of NNC0174 0833
10017964|NCT05254158|Experimental|NNC0174 0833 0.3 mg|Each participant will receive one single dose of NNC0174 0833
10017965|NCT05254041|Other|Mentrual Cup Removal|Menstrual Cup Removal.
10017966|NCT05254028|Active Comparator|Auricular points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.20mm x 13mm are inserted at the auricular acupuncture points shenmen (TF4), thalamus (AT4), and occiput (AT3) bilateral."
10017967|NCT05254028|Active Comparator|Body points acupuncture|"The subject of this study is healthcare workers with tension-type headache symptoms who work at Dr. Cipto Mangunkusumo Hospital. The subject of this group will be treated with filiform needles, 30-minute needle retention, 3 times a week for 2 weeks (total of 6 therapy sessions). The Huanqiu needles with a size 0.25mm x 25mm are inserted at the acupuncture points LI4 Hegu, LR3 Taichong, dan GB20 Fengchi bilateral."
10017968|NCT05253534|Experimental|Gamma Rhythm Stimulation Group|"Evaluation of the efficacy and safety of GlaucoT in patients with primary open-angle glaucoma (POAG).~In this study, it was planned to investigate the effect of reducing the progression of glaucomatous damage by applying 40 Hz flicker light therapy for 1 hour a day to POAG patients. It is planned to use visual field test, measurements of retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) layer thicknesses in optical coherence tomography to investigate the effectiveness of the treatment."
10017969|NCT05253534|No Intervention|Control Group|"This group will be monitored without using the device.The data will be used only for comparison.~Considering the sample size calculations and losses, a total of 60 patients are planned to be included in the study, with 30 patients in each group."
10017970|NCT05253482|Experimental|Intervention group|The intervention group will undergo 3 successive wet cupping therapy (WCT) sessions once in a month throughout 3 months (On 0, 30, and 60 days
10017971|NCT05253482|No Intervention|Control group|Control group will not receive any intervention
10017972|NCT05253352||Healthy volunteers|Healthy female volunteers with no history of lymphedema. Physical therapy examination, ICG lymphography, venous ultrasound and lymphoscintigraphy with SPECT/CT imaging
10017973|NCT05253352||Women with breast cancer who did not develop lymphedema|Women who have had an axillary lymph node dissection (ALND) and did not develop lymphedema. Physical therapy examination, ICG lymphography, venous ultrasound and lymphoscintigraphy with SPECT/CT imaging
10017974|NCT05253131|Experimental|Phase 1 and 2 Study of Selumentinib AZD5153 and Durvalumab|"Part A will be a phase 1 dose escalation study of the combination with selumetinib and AZD5153, and,~Part B will be phase 1 study combining the determined dose of selumetinib and AZD5153 from Part A with durvalumab.~Part C will be a phase 2 study combining selumetinib, AZD5153 with durvalumab in MPNST patients at the recommended doses from part B. A Simon's two-stage design will be used in the phase 2 trial to determine the clinical benefit in patients with unresectable or metastatic NF associated MPNST."
10017975|NCT05252832|Active Comparator|Local Infitrate|
10017976|NCT05252832|Experimental|SCPB|
10017977|NCT05252338|Experimental|Younger Adults group aged 18-55 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
10017978|NCT05252338|Experimental|Adults group aged ≥65 years|Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
10017979|NCT05251974||Compliant with beta blocker therapy|Patients observed to be compliant with beta blocker therapy by blood assay
10017980|NCT05251974||Non-compliant with beta blocker therapy|Patients observed to be non-compliant with beta blocker therapy by blood assay
10017981|NCT05250895|Experimental|Diagnostic (18F-fluoromisonidazole, PET, DCE MRI)|Patients receive 18F-fluoromisonidazole IV and undergo PET and DCE MRI within 30 days before beginning Y90 SIRT. Patients undergo Y90 SIRT per standard of care.
10017982|NCT05250505|Experimental|Treatment Arm|The Treatment Arm receives the eShunt Implant.
10017983|NCT05249920|Experimental|Edaravone Dexborneol group|Patients in this arm will be given Edaravone Dexborneol Concentrated Solution for injection twice a day for 10 to 14 days.
10017984|NCT05249920|Placebo Comparator|Edaravone Dexborneol Placebo group|Patients in this arm will be given a placebo of Edaravone Dexborneol for injection twice a day for 10 to 14 days.
10017985|NCT05249842||Respiratory function 3 months after hospital discharge in critically ill COVID-19 patients|All critically ill adult patients admitted to the ICU with confirmed diagnosis of COVID-19 were submitted at least 3 months after hospital discharge to spirometry (FVC, FEV1, FEV1 /;FVC and FEF 25-75%), the 6-minute walk test (6MWT) and evaluation of the physical component summary (PCS) of the SF-36 quality of life instrument.
10017986|NCT05249816|Experimental|NVX-CoV2373|NVX-CoV2373 (5 μg): Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg antigen and 100 μg adjuvant per mL. The vaccination regimen will comprise of 1 intramuscular (IM) injection on Day 0 of 0.5 mL injection volume at a dose of 5 μg of antigen with 50 μg Matrix-M adjuvant.
10017987|NCT05249816|Active Comparator|BBIBP CorV|Sinopharm BBIBP-CorV vaccine administered per manufacturer instructions as a single intramuscular injection.
10017988|NCT05249582|Experimental|Virtual Reality Condition|Participants will be using a virtual reality headset to engage with a mountain climbing game.
10017989|NCT05249582|Active Comparator|Control Condition|Participants will be mimicking hand movements displayed on a television screen.
10017990|NCT05247723|Experimental|SIVCA|Aspirating testicular tissue using a standard IV cannula with applied negative pressure.
10017991|NCT05247723|Active Comparator|Micro-TESE|Extracting testicular tissue surgically
10017992|NCT05246410|Experimental|Spot stent system|A system that loaded multi low radial force stents on one catheter.
10017993|NCT05246410|Active Comparator|Self-Expanding peripheral stent system|A conventional stent system that commonly used.
10017994|NCT05246267||Study group|Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
10017995|NCT05246202|Experimental|Anxiety-alcohol personalized feedback intervention (AA-PFI 2.0)|Participants complete the brief (~20-30 minute) AA-PFI 2.0 at baseline.
10017996|NCT05246202|Active Comparator|Control personalized feedback intervention (C-PFI)|Participants complete the brief (~20-30 minute) C-PFI at baseline.
10017997|NCT05245669|Experimental|ENZ215|ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
10017998|NCT05245669|Active Comparator|EU Sourced Prolia|EU sourced Prolia Injection:- 60 mg Denosumab (EU sourced Prolia) will be administered subcutaneously on day 1.
10017999|NCT05245669|Active Comparator|US Sourced Prolia|US sourced Prolia Injection:- 60 mg Denosumab (US sourced Prolia) will be administered subcutaneously on day 1.
10018000|NCT05244291|Experimental|Intervention Group 1|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times in 1 weeks.
10018001|NCT05244291|Experimental|Intervention Group 2|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
10018002|NCT05244291|No Intervention|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
10018003|NCT05243147|Experimental|nasal stents|using nasal stents after septoplasty
10018004|NCT05243147|Other|merocel|using merocel as nasal packing after septoplasty
10018005|NCT05242952|Experimental|Immediate Intervention Group|Participants will enter an online game and learn about how to prevent cardiovascular and metabolic conditions.
10018006|NCT05242952|Other|Waitlist Control Group|Participants will enter an online game at a later date after the immediate intervention group and learn about how to prevent cardiovascular and metabolic conditions.
10018007|NCT05242484|Experimental|Group 1: Guselkumab|Participants will receive guselkumab dose regimen 1 subcutaneously (SC). Participants who are eligible and willing to continue their study treatment may enter the long-term study extension and continue to receive guselkumab SC.
10018008|NCT05242484|Experimental|Group 2: Golimumab|Participants will receive golimumab dose regimen 1 SC. Participants who are eligible and willing to continue their study treatment may enter the long-term study extension and continue to receive golimumab SC.
10018009|NCT05242484|Experimental|Group 3: JNJ-78934804 (High-dose)|Participants will receive JNJ-78934804 dose regimen 1 SC. Participants who are eligible and willing to continue their study treatment may enter the long-term study extension and continue to receive JNJ-78934804 SC.
10018010|NCT05242484|Experimental|Group 4: JNJ-78934804 (Mid-dose)|Participants will receive JNJ-78934804 dose regimen 2 SC. Participants who are eligible and willing to continue their study treatment may enter the long-term study extension and continue to receive JNJ-78934804 SC.
10018011|NCT05242484|Experimental|Group 5: JNJ-78934804 (Low-dose)|Participants will receive JNJ-78934804 dose regimen 3 SC. Participants who are eligible and willing to continue their study treatment may enter the long-term study extension and continue to receive JNJ-78934804 SC.
10018012|NCT05242029|Experimental|Psilocybin|"Participants will be administered 40mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.~At 3 months, half will be randomized to receive a blinded dose of psilocybin 40mg and half a blinded dose of placebo."
10018013|NCT05242029|Placebo Comparator|Placebo|"Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.~At 3 months, participants will receive a blinded dose of psilocybin 40mg."
10018014|NCT05241457||Standard of care group|Patients will receive the standard physical therapy sessions that they would normally receive during their IRF stay, (60 to 90 min sessions, 5 to 6 days/week). This group will not receive Ekso exoskeleton gait training.
10018015|NCT05241457||Ekso exoskeleton gait training group|Patients in the Ekso group will have several (2 to 3) of their standard of care sessions replaced with Ekso gait training sessions each week.
9665258|NCT05121168|Placebo Comparator|Placebo|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
10018016|NCT05241301|Other|One to one interviews with family carers of older people from Turkish and Moroccan origin|one to one interviews
10018017|NCT05240638|Experimental|TD Drainage|Short term TD drainage
10018018|NCT05240586|Experimental|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
10018019|NCT05240586|Active Comparator|acupuncture therapy|The physicians will choose the type and number of acupuncture therapy according to participants' conditions.
10018020|NCT05240586|Active Comparator|physical therapy, medication(prn)|The physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
10018021|NCT05240365|Experimental|SDF modified Hall technique|"When Hall technique is used an accurate size of PMC is placed without local anesthesia, caries removal, or tooth preparation.~SDF is applied directly to carious lesions to arrest caries, the technique is noninvasive and relatively painless that could be a good option for treating dental caries in children"
10018022|NCT05240365|Active Comparator|Conventional pulpotomy and stainless steel crown|Amputation of the coronal pulp and treatment of the remaining vital radicular portion with a long term clinically successful medicament. Then using an accurate size of stainless steel crown.
10018023|NCT05240235|Active Comparator|Education, compression and exercise therapy|Patients will be given exercise therapy every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do home exercise at home for 10 minutes.
9802654|NCT05087095|Experimental|Proof-of-concept trial|Inform CALM adaptations for SMs, Veterans, their beneficiaries, and civilians with cancer metastasis to the brain (bMET)
10018024|NCT05240235|Active Comparator|Education, compression,exercise therapy and manual lymph drainage|Patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
10036116|NCT01812824|No Intervention|Control (Letter)|Participants in the Control (Letter) arm will take the online Preconception Risk Assessment at baseline, but not have access to the Virtual Patient Advocate system during the 6 month study period. They will be sent a list of the Preconception Risks identified through their answers to the Risk Assessment, which they can choose to share with their healthcare provider(s).
9802655|NCT05087095|Experimental|Primary Brain Tumor (PBT) CALM Intervention|CALM therapy will be provided via telehealth. Participants will complete surveys (post-session, post-intervention, and 90-day follow-up) via secure email link. Exit interviews will be conducted by phone.
9802656|NCT05087095|Active Comparator|Primary Brain Tumor (PBT) Treatment as Usual (TUC) Control|Survey Administration. Participants will be asked to complete self-report surveys of behavioral and psychological variables.
9802657|NCT05087095|Experimental|Cancer Metastasis to the Brain (bMET) CALM Intervention|CALM therapy will be provided via telehealth. Participants will complete surveys (post-session, post-intervention, and 90-day follow-up) via secure email link. Exit interviews will be conducted by phone.
9802658|NCT05087095|Active Comparator|bMET TUC Control|Survey Administration. Participants will be asked to complete self-report surveys of behavioral and psychological variables.
9802659|NCT05083533|Experimental|tele-rehabilitation|For the tele-rehabilitation online group, hamstring stretching exercises were performed with cameras and mutually via online applications.
9802660|NCT05083533|Active Comparator|home exercise|The home exercise group, the exercises were conveyed in the form of a brochure, in written form, on the necessary information. It was recorded how many days the home exercise group did the exercises on a weekly basis.
9802661|NCT05083078|Experimental|Part 1: Healthy Participants-Coadministration|Healthy participants will receive a single co-administered dose of risankizumab and guselkumab subcutaneously (SC) on Day 1.
9802662|NCT05083078|Experimental|Part 2: Psoriatic Arthritis (PsA) Participants-Coadministration|Participants with PsA will receive a single co-administered dose of risankizumab and guselkumab SC on Day 1 and Day 29.
9802663|NCT05083078|Experimental|Part 3: PsA Participants-Separate Administration|Participants with PsA will receive a single dose of either risankizumab or guselkumab SC on Day 1 and Day 29.
9802664|NCT05082025|Experimental|Part 1: Dose confirmation|Up to 6 evaluable patients to confirm a single combination dose of copanlisib and fulvestrant
9802665|NCT05082025|Experimental|Part 2: Dose expansion:|The dose expansion part will enroll in 3 indication-specific cohorts with 13 to 26 patients
9802666|NCT05080972|Experimental|in-the-kNOW mobile app.|Participants will be assigned to the in-the-kNOW mobile app for four (4) months.
9802667|NCT05080972|Active Comparator|Control condition.|Participants will be randomized to receive a one-time virtual women's health counseling session with a healthcare provider.
9802668|NCT05079984|No Intervention|Focus Groups|Utilizing the mHealth Agile Development & Evaluation Lifestyle model, Aim 1 will focus on collecting stakeholder feedback (youth with chronic pain and their parents) to inform an iterative, user-centered development process of a digital graded exposure intervention, to be trialed in Aim 2 (Arm 2).
9802669|NCT05079984|Experimental|Graded Exposure Intervention|For Aim 2, adolescents with chronic pain will be enrolled in a single-arm feasibility trial examining acceptability, feasibility, and preliminary effectiveness of a novel, digitally delivered, graded exposure treatment.
10036117|NCT01812850||Invisalign®|All subjects in the study (estimation of 40 subjects) will be treated using the Invisalign® appliance.
9802670|NCT05078320|Experimental|Internet-delivered cognitive-behaviour therapy for adolescents with body dysmorphic disorder|Cognitive-behaviour therapy, Exposure and response prevention (ERP)
10018025|NCT05239000|Experimental|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy. Consultation with geriatricians can occur in-person or remotely via telemedicine. During this visit, the geriatrician will review the results of the eRFA and create a plan to manage geriatric deficits. Geriatric co-management involves optimization of comorbid conditions, management of polypharmacy, and supportive care referrals to address geriatric deficits. Geriatricians also work in conjunction with the treating oncologists to ensure patients have appropriate pain management and bowel regimens. Additional follow up visits after the initial consultation are at the discretion of the geriatrician may vary between patients depending on the clinical need.
10036118|NCT01812863|Experimental|Supraclavicular Nerve Block|Maximum dose of 5 mL of 0.25% bupivacaine, and we base the dose on a ml/ kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. Bupivacaine is given with 1:200,000 epinephrine
9802671|NCT05077345||1/Venous blood sampling|The vessel was determined for cannulation and an anatomical tourniquet was applied. Skin antiseptic was prepared. The plastic wings of the winged angioket were held open. The skin over the vein to be accessed was stretched with the fingers of the free hand. The needle was inserted into the skin a few millimeters distal to the point to be inserted, and the blood was vascularized until the education. The cannula was advanced by retracting the stylet. The tourniquet was removed and the cannula was fixed.
9802672|NCT05077345||2/Heel puncture|The skin was prepared with an antiseptic. The baby's heel was placed at an angle between the thumb and forefinger, with the other fingers grasping the ankle from behind. Pressure was applied to the back of the ankle with the other fingers by taking support against the thumb. The first drop of blood was wiped with sterile gauze by inserting the needle, and the next drops of blood were absorbed into the paper by touching the middle of the ring on the filter paper. An adhesive bandage was applied by applying pressure to the puncture site.
9802673|NCT05077345||3:Orogastric Catheter insertion|The head of the bed was raised and the newborn was placed on his back. The midpoint distance from the tip of the nose to the ear, xiphoid and umbilicus was measured to determine the insertion length. With one hand, the infant's mouth was opened while his head was stabilized. With the other hand, the MV probe was advanced to the specified depth. The position of the OG probe was confirmed and fixed.
9802674|NCT05077345||4:Umbilical Catheter insertion|The system was filled with liquid by connecting the tap to the UK. The faucet was turned off, sterile gauze was placed around the umbilical clamp and lifted out of the sterile area. The other assistant held the cord with a clamp and lifted it vertically up and away from the sterile field. The cord and its surroundings were prepared with an antiseptic solution and covered. The umbilicus was tied with a single knot and the cord was cut horizontally with a scalpel. Bleeding on the surface of the cord was wiped with sterile gauze. The cord stump was grasped with toothed forceps close to the vessel to be catheterized. The catheter was placed in the lumen of the vessel and advanced in the vessel. When the catheter exceeded 5 cm, it was aspirated to confirm the intraluminal position. The blood that came with an average of 0.5 ml bolus solution was cleaned and the catheter was fixed.
10018026|NCT05239000|Experimental|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits. The automated report also includes suggested interventions for each deficit (e.g, referral to physical therapy. For instance, automated suggestions for a patient with a history of falls include consultation with physical therapy, neurologic evaluation, a home safety evaluation, or use of supportive devices. Automated recommendations for patient with high level of distress or depression include referral to psychiatry or social work, involvement in a cancer support group, or additional time spent addressing questions and fears. The oncology team will review the automated report from the eRFA and create an intervention plan prior to initiation of head and neck radiation and chemotherapy.
10018027|NCT05238870||Clinicians (interviewees) from Ghent University Hospital, Belgium|Semi-structured interviews with clinicians
10018028|NCT05238870||Clinicians (interviewees) from Brussels University Hospital, Belgium|Semi-structured interviews with clinicians
10018029|NCT05238870||Clinicians (interviewees) from Orebro University Hospital, Sweden|Semi-structured interviews with clinicians
10018030|NCT05238844|Experimental|ATI-2173 25mg, Vebicorvir 300mg and Tenofovir 300mg|Subjects randomized to active arm will receive active 25mg ATI-2173 + active Vebicorvir 300mg + active Tenofovir 300mg
10018031|NCT05238844|Active Comparator|Tenofovir Disoproxil Fumarate|Subjects randomized to placebo arm will receive placebo 25mg ATI-2173 + placebo Vebicorvir 300mg + active Tenofovir 300mg
10018032|NCT05238714|Experimental|[14C] venglustat|Single dose of [14C] venglustat Oral Solution under fasting conditions
10018033|NCT05238597|Experimental|A197 Ophthalmic Solution, High Dose|
10018034|NCT05238597|Experimental|A197 Ophthalmic Solution, Low Dose|
10018035|NCT05238597|Placebo Comparator|A197 Vehicle Control|
10018036|NCT05238597|Active Comparator|Active Comparator|
10018037|NCT05238532|Experimental|Single Arm|CT303
10018038|NCT05238506|Experimental|Lidocaine|1% lidocaine intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
10018039|NCT05238506|Placebo Comparator|Control|0.9% NaCl intravenous bolus of 0.15 ml/kg over 5 min before induction of anesthesia followed by 0.9% NaCl infusion at 0.15 ml/kg/h intraoperatively will be administered. The infusion will be discontinued before the patients' transfer to the postanesthesia care unit.
10018040|NCT05237661|Experimental|Dietary supplement|Dietary supplement: Moon Balance
10018041|NCT05237271|No Intervention|Control Group|Control group treats their simulated patients using standard practice and have no introduction to the new SomaLogic test.
10018042|NCT05237271|Experimental|Intervention Group 1|Intervention group 1 will receive educational materials on the single cardiovascular disease in type 2 diabetes risk score. They will then be forced to used the risk score for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
10018043|NCT05237271|Experimental|Intervention Group 2|Intervention group 2 will receive educational materials on the cardiovascular disease in type 2 diabetes (CVD-T2D) risk score as well as the panel of metabolic scores. They will then be forced to used the CVD-T2D score and the metabolic panel scores for their simulated patients, which will allow us to assess how the risk score may improve clinical practice and reduce variation.
10018044|NCT05237128|Experimental|Very low-carbohydrate diet|
10018045|NCT05237128|Experimental|Moderate-carbohydrate plate-method diet|
10018046|NCT05236608|Experimental|Nivolumab and ADG106|"Eligible patients will receive nivolumab and ADG106 by IV infusion according to the study phases below.~Phase 1b:~3 evaluable patients will be treated at the starting dose, and assessed for tolerability over the first cycle. Treatment related dose-limiting toxicities (DLT) will determine the next dose level to be studied. Dose escalation will follow the 3 + 3 study dose titration design.~Phase 2:~The dose of ADG106 given together with nivolumab will be the recommended dose in combination with nivolumab determined in phase 1b."
10018047|NCT05236465|Experimental|A 3-day course|The course consists of teaching in basic psychology, stress physiology and practice of a specific technique with self-instructions and visualization in a group setting by non-health personnel
10018048|NCT05236465|Active Comparator|Waiting list|Treatment as usual (TAU)
10018049|NCT05236205|Experimental|Control Group|This group will receive the treatment of caries removal with a lowspeed drill (conventional treatment).
10018050|NCT05236205|Experimental|Papacarie and Bixa orellana extract|In this group, partial caries removal with Papacarie and the application of Bixa orellana extract (20%) will be performed.
10018051|NCT05236205|Experimental|Total removal with aPDT|In this group, total removal of the carious tissue will be performed, with Papacarie and the application of Bixa orellana extract (20%) with blue LED (aPDT).
10018052|NCT05236205|Experimental|Partial removal with aPDT|In this group, partial removal of the carious tissue will be performed, with Papacarie and the application of Bixa orellana extract (20%) with blue LED (aPDT).
10018053|NCT05234736|Experimental|CBL-514|All 10 participants enrolled in the study will receive a single course of treatment with CBL-514 800 mg (unit dose: 2.0 mg/cm^2) on the abdomen (administered as multiple subcutaneous injections) on Day 1 only.
10018054|NCT05233566|Experimental|Ketamine Arm|On the first day following surgery and extubation, patients will receive ketamine 0.5 mg/kg over 10 minutes followed by an infusion of 0.3 mg/kg/h for 7 hours 50 minutes.
10018055|NCT05233566|Placebo Comparator|Control Arm|On the first day following surgery and extubation, patients will receive normal saline at an equal rate to that used in the ketamine arm.
10018056|NCT05232786||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
10018057|NCT05232786||Health Care Professionals (HCPs)|HCPs treating people who have obesity
10018058|NCT05231824|Active Comparator|BWL-S|1 year of remote gold standard, small group-based behavioral weight loss treatment with an MS-level clinician.
10018059|NCT05231824|Experimental|BWL-AI|1 year of remote weight loss treatment made up of a combination of (1) remote small group-based behavioral weight loss sessions, (2) 12-minute individual video calls, (2) automated text messages. An MS-level clinician will deliver the group treatment. Most video calls will be delivered by a paraprofessional coach, but some by an MS-level clinician. Each week the AI system will select one of the interventions for each participant based on which treatment the participant has responded to the best, within certain time constraints.
10018060|NCT05231187||Prospective Arm|Subjects has had a diagnostic blood culture ordered per routine standard of care.
10018061|NCT05231187||Contrived Arm|Samples of healthy whole blood spiked with bacterial strains harboring the resistance gene targets on the T2Resistance Panel.
10018062|NCT05231187||Healthy Donor Arm|Healthy donor subjects.
10018063|NCT05230550||Participants with AGHD (only severe case)|Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. The decision to treat a patient with Sogroya® has been made at the treating physician's discretion and independently from the decision to include the patient in this study.
10018064|NCT05230199|Active Comparator|Monitored standard of care|At the study site, much like other contemporary NICUs, parents are encouraged to be present 24 hours per day, with significant variability in the amount, types and timing of parent engagement. Infant holding is supported, provided the infant can maintain physiological stability during handling. Parents can hold infants on mechanical ventilation, but holding is not encouraged during times when the infant is on oscillatory ventilation and/or when chest tubes are in place. Holding time may be restricted in infants <32 weeks due to temperature instability. Nurses and therapists foster parent participation through instruction on caregiving and developmentally appropriate interactions, but these are balanced with other priorities of care. With standard of care, there is no targeted and set amount of positive sensory exposure, and practices vary based on the comfort level of nurses, the medical team, and the parents.
10018065|NCT05230199|Experimental|SENSE multisensory program|The SENSE program includes the provision of specific types and amounts of evidence-based tactile, auditory, visual, vestibular/kinesthetic, and olfactory interventions to be conducted by parents with their preterm infants, with a specific amount defined for each day of hospitalization. The program changes across PMA and an infant's tolerance of the prescribed activities. A sensory support team can fill in the gaps in intervention for infants in the SENSE group when parents are not available. The parent education materials identify specific doses of sensory inputs at each PMA. Feasibility has been established, with provision of an average of 155 hours of sensory exposures across NICU hospitalization.
10018066|NCT05227638|Active Comparator|Schroth group|The Schroth group performed Schroth exercises
10018067|NCT05227638|Active Comparator|PNF group|"PNF group (PG) performed chop and lift exercises"
10018068|NCT05227534|Experimental|Participants 40 years of age or older with cancer risk|The study will aim to enroll participants 40 years of age or older with cancer risk. Specific cancer risks will be enriched to increase the number of cancer events that are observed during the study.
10018069|NCT05227209|Experimental|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
10018070|NCT05227196|Experimental|Group 1 Sequence 1|Crossover arm
10018071|NCT05227196|Experimental|Group 1 Sequence 2|Crossover arm
10018072|NCT05227196|Experimental|Group 2 Sequence 1|Crossover arm
10018073|NCT05227196|Experimental|Group 2 Sequence 2|Crossover arm
10018074|NCT05227196|Experimental|Group 3 Sequence 1|Crossover arm
10018075|NCT05227196|Experimental|Group 3 Sequence 2|Crossover arm
10018076|NCT05227027|Experimental|Education plus game module|Participants receive an educational intervention through the Smoke Free application with the embedded game module. Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
10018077|NCT05227027|Active Comparator|Education module only|Participants receive an educational intervention through the Smoke Free application only (core app only). Participants complete questionnaires and may undergo saliva sample collection, if they report being smoke-free on follow-up.
10018078|NCT05225740|Active Comparator|Control|General stress reduction based on stress management training to help people cope with feelings of anxiety, used as an active control condition
10018079|NCT05225740|Active Comparator|Standard Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and completion of questions about the exercises and the large-group aspect
9802675|NCT05077345||5:Tracheal Intubation|The head of the infant was positioned in the midline, slightly extended, with the chin up. The head was stabilized with the right hand by turning on the light of the laryngoscope. The blade of the laryngoscope was inserted by sliding the blade over the tongue until the tip of the blade rested on the Vallecula. The blade of the laryngoscope was slid up to open the mouth even more. The other assistant gently dipped it into the suprasternal notch. The concave edge of the tube was held with the right hand, and it was advanced approximately 2 cm, passing it between the vocal cords when the vocal cords and trachea were seen.
9802676|NCT05076214|Experimental|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer.~The group training session will begin with a 3-5 minutes check-in round followed by a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied"
9802677|NCT05076214|Active Comparator|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together.
9802678|NCT05074173|Other|Patient Group|Participants will be enrolled in a bidirectional text messaging system from Tulane University Medical Group where they will receive and send text from their mobile phones to monitor their anti-hypertension medication regimen. Text messages will be sent: daily for medication and refill reminders; weekly for hypertension education messages and asking if a support person helped them with medication reminders. Study personnel will educate participants on proper blood pressure technique to conduct self-measured blood pressure (SMBP) at home. These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure. Participants will receive the Bluetooth blood pressure device to perform SMBP at enrollment.
9802679|NCT05072990||Observational group|
9802680|NCT05069142|Experimental|Intervention group|15 participants will be randomly selected to the intervention group. These individuals will receive six weeks of pre-operative exercise instruction and education, as well as six weeks of graduated post-operative exercise instruction, beginning at three weeks post-op with the surgeons clearance.
9802681|NCT05069142|No Intervention|Control group|15 participants will be randomly selected to the control group. This group will receive pre-operative education in the form of videos regarding the procedure and pain. They will not receive exercise instruction.
9802682|NCT05066204|Other|Sequence: self-study, then teaching video|Participants first do self-study, then right afterwards watch a teaching video, then become tested on a simulator and are videorecorded for evaluation
9802683|NCT05066204|Other|Sequence: teaching video, then self study|Participants first watch a teaching video, then do self-study, then become tested on a simulator and are videorecorded for evaluation
9802684|NCT05062759|Experimental|Tezepelumab|Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
9802685|NCT05062759|Placebo Comparator|Placebo to Tezepelumab|Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
10018080|NCT05225740|Experimental|Enhanced Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and post-exposure processing aimed at emphasizing harm expectancy violation
10018081|NCT05225402||Septic Shock|Adult patients with septic shock, admitted to ICUs at Hvidovre and Bispebjerg Hospital, respectively. Sedated and mechanically ventilated adult patients (>18 years).
10018082|NCT05225116|Experimental|Sintilimab+Lenvatinib+Radiotherapy|
10018083|NCT05224986|No Intervention|Variable Sleep|Participants randomized to Variable Sleep (VS) will be asked to maintain their usual sleep habits for 12 weeks, with no further information provided about sleep.
10018084|NCT05224986|Experimental|Fixed Sleep|Participants randomized to Fixed Sleep (FS) will be asked to go to bed at the same time each night for 12 weeks.
10018085|NCT05224674|Active Comparator|Large-Focused Extracorporeal Shock Wave Therapy|
10018086|NCT05224674|Active Comparator|Controlled-Unfocused Extracorporeal Shock Wave Therapy|
10018087|NCT05224674|Sham Comparator|Sham Extracorporeal Shock Wave Therapy|
10018088|NCT05224232|Experimental|Access Socket|Patients will be fitted with the access socket
10018089|NCT05224232|Active Comparator|Rigid socket|Patients will be fitted with their usual rigid socket
10018090|NCT05223894|Experimental|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
10018091|NCT05223894|Sham Comparator|Control|Coronary artery bypass grafting surgery only.
10018092|NCT05223608|Other|ImmuCCo Cohort|"Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity.~Urine collection at initiation of immunotherapy."
10018093|NCT05223517|Experimental|Acupucnture|
9476870|NCT03567499|Experimental|Part A: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 200 milligrams (mg) in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
9476871|NCT03567499|Experimental|Part A:Sequence 2|Subjects in sequence 2 will receive GSK3039294 600 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
9476872|NCT03567499|Experimental|Part A: Sequence 3|Subjects in sequence 3 will receive GSK3039294 200 mg in period 1 followed by GSK3039294 600 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session
9476873|NCT03567499|Experimental|Part A: Sequence 4|Subjects in sequence 4 will receive GSK3039294 600 mg in period 1 followed by GSK3039294 200 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
9476874|NCT03567499|Experimental|Part A: Sequence 5|Subjects in sequence 5 will receive GSK3039294 200 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
9476875|NCT03567499|Experimental|Part A: Sequence 6|Subjects in sequence 6 will receive matching placebo in period 1 followed by GSK3039294 600 mg in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
9476876|NCT03567499|Experimental|Part B: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 (dose level to be decided on results of Part 1) in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
9476877|NCT03567499|Experimental|Part B: Sequence 2|Subjects in sequence 2 will receive GSK3039294 (dose level to be decided on results of Part 1) in period 1 followed by matching placebo in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing
9476878|NCT03567473|Experimental|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine OR Oral dexamethasone and inhaled epinephrine given by MDI
9476879|NCT03567473|Placebo Comparator|Control Arm|"Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.~OR Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and inhaled placebo given by MDI."
9476880|NCT03567460|Experimental|10,000 Steps/day for Pediatric Marfan Patients|Participants will be given a Garmin VivoFit and asked to take at least 10,000 steps per day. A study coordinator will reach out at least once per week to check in on progress made and help make weekly goals.
9476881|NCT03567447|Experimental|Treatment group|This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
9476882|NCT03567447|Placebo Comparator|Non treatment group|This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
9476883|NCT03567408|Experimental|Selective PCI with bivalirudin|Before PCI, bivalirudin is intravenously injected with 0.75 mg/kg, 1.75 mg/(kg.h) through continuous intravenous drip to finish surgery (no more than 4 hours), if necessary, after the surgery, with a low dose of 0.2 mg/(kg.h) intravenous drip less than 20 hours.
10018094|NCT05223517|Sham Comparator|Sham Acupuncture|
10018095|NCT05223478|Active Comparator|Phentolamine Ophthalmic Solution 0.75%|One drop of study medication in each eye.
10018096|NCT05223478|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop of study medication in each eye.
10018097|NCT05222880|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
10018098|NCT05221320|Experimental|Stage 1 - 5 baskets included, based on primary disease|"Ulixertinib: 450mg twice daily (BID), orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
10018099|NCT05221320|Experimental|Stage 2 - basket expansion based on Stage 1|"Ulixertinib: 450mg BID, orally, days 1-28~Hydroxychloroquine: 600mg BID, orally, days 1-28~Cycles repeat every 28 days in absence of disease progression or unacceptable toxicity"
10018100|NCT05221229||Patient willing take Liraglutide|A total of 20 patients will be included in the study group after screening of inclusion and exclusion criteria. Patients will have upstream risk factors assessed at the clinic consultation and offered risk factor optimization advice. In addition, they will received daily Liraglutide injections for 9 months.
10018101|NCT05221229||Patient unwilling to take Liraglutide|Another 20 patients will be recruited as a comparator group who are unwilling to receive daily Liraglutide injections. They will have upstream risk factors assessed at the clinic consultation and offered risk factor optimization advice to compare the changes in the AF biomarkers against the study group.
10018102|NCT05221125|Experimental|Psychologically-Informed Physical Therapy (PIPT)|CBT-trained physical therapist evaluation and treatment with recommendation for Spine Health follow up after ED discharge
9476884|NCT03567408|Placebo Comparator|Unfractionated heparin|Before PCI, unfractionated heparin sodium is intravenously injected with 70-100 U/kg, and if the operation time exceeded 1h, an additional 1000 U/h would be added.
9476885|NCT03567395|Active Comparator|Melatonin|Melatonin (5 mg sublingual tablet)
10018103|NCT05221125|No Intervention|Control|Usual care only
9803690|NCT03535922|Experimental|The generic PROM group|HD units randomized to this PROMs assessment group will administer a generic PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The generic PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed generic PROM is the EQ-5D-5L.
10018104|NCT05220826|No Intervention|Surgical drainaje (the standar of care)|Surgery will consist of performing a craniotomy (burr hole or drill) and evacuation of the hematoma. Depending on the operator, the surgical procedure may incorporate the use of subdural space drainage devices (e.g. Jackson Pratt drainage) connected to a soft suction reservoir. If used, these devices should be removed within 48 hours of installation.
10018105|NCT05220826|Experimental|Surgical drainaje plus early embolization of middle meningeal artery|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
10018106|NCT05219799|Other|Hypoxia Exposure|Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
10018107|NCT05219227|Experimental|body fat mass (BFM)|body fat mass will be measured before and after interventions
10018108|NCT05219227|Experimental|Body mass index (BMI)|BMI will be calculated before and after interventions
10018109|NCT05218291|Experimental|Technology-Supported Yoga Applied Group|"The yoga initiative to be applied to the intervention group; Yoga, which is mind-breath-body work; It includes meditation, pranayama (breath work), and asanas (yoga poses).~The content of the yoga practice consists of the following poses:~-Tadasana (Mountain pose), -Urdhvahastasana, -Uttanasana, -Ardha Uttanasana, -Plank, -Ashtang Pranam, -Bhujangasana (Mini cobra), -Adho Mukha Svanasana (Downward facing dog), -Vrksasana (Tree Pose), - Utthita Trikonasana (Triangle Pose), -Virabhadrasana I (Warrior I), -Virabhadrasana II (Warrior II), -Virabhadrasana I with Anjali Mudra (Hands Reverse Namaste), -Utkatasana (Chair Pose), -Salabhasana, -Paschimottanasana , -Dandasana, -Salamba Sarvangasana (Shoulder pose), -Ardha Urdhva Dhanurasana (Half Wheel Pose), -Reverse Warrior, -Child's pose, -Ananda Balasana (Happy baby), -Wipers, -Corpse Pose"
10018110|NCT05218291|Active Comparator|Control Group|No intervention was made in caregivers.
10018111|NCT05217706|Experimental|Treatment|This group will be given ketamine 0.2mg/kg
10018112|NCT05217706|Placebo Comparator|Placebo|This group will be given normal saline in matched syringe
10018113|NCT05217251||exposed group|Parturient women will be identified with frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery with alpha asymmetry group in hospital.
10018114|NCT05217251||control group|Parturient women will be identified without frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor and will then be allocated to vaginal delivery without alpha asymmetry group in hospital.
10018115|NCT05216536||Long COVID|Adults who contracted COVID-19 and present at least one physical or cognitive long COVID-19 symptom for more than 12 weeks following the initial diagnosis.
10018116|NCT05216536||Acute COVID|Adults who contracted COVID-19 but did not experience persistent symptoms for more than 4 weeks following the initial diagnosis.
10018117|NCT05216536||Control|Adults who did not contract COVID-19.
10018118|NCT05216055|Experimental|Investigational Arm|"The study drug volume, concentration, and dose of treatment arm #1 selected is based on the Principal Investigator's prior experience recommendations by the Food Drug Administration (FDA), and evidence based on prior literature. The final concentration of ropivacaine is 0.375% and final volume of the mixture is 60mL.~Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg)~Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug)~Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg)~Normal saline 0.9%, 18.5mL"
10018119|NCT05216055|Active Comparator|Liposomal Bupivacaine (Exparel)|"The study drug for patients in the treatment arm #2 will be a mixture of liposomal bupivacaine and bupivacaine 0.25% as follows:~Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg)~Normal saline 0.9%, 40mL The total volume to be injected in each patient will be 60 mL (see below for different treatment arms)."
10018120|NCT05215808|Experimental|RBN-3143|RBN-3143 in single ascending dose followed by multiple ascending dose cohorts, randomized 3:1 ratio
10018121|NCT05215808|Active Comparator|Placebo|Placebo randomized in 1:3 ratio with ascending RBN-3143 single and multiple dosing
10018122|NCT05215808|Other|Pantoprazole|Optional Open Label PPI cohort to evaluate concurrent administration of pantoprazole on RBN-3143 pharmacokinetics
10018123|NCT05215808|Other|Midazolam|Open Label DDI Cohort (12 subjects) to evaluate the effect of RBN-3143 on the exposure of midazolam, a sensitive CYP3A4 substrate
9476886|NCT03567395|Experimental|Honey|raw honey (1.5 tablespoons)
10037391|NCT01824732||Control group|All patients who used Tanreqing Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
10018124|NCT05215548|Experimental|Group I : Surgery group|The surgery group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the surgery group would receive thoracic surgery with maximal regional control intent. Patients continue afatinib 1 to 2 weeks after surgery until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
10018125|NCT05215548|Active Comparator|Group II : Maintenance group|The control group would receive take 12 weeks of EGFR TKI before randomization. After randomization, the control group would receive afatinib until disease progression or unacceptable toxicity. The residual local and metastatic sites of disease could undergo either surveillance or maintenance radio-treatment at the discretion of the treating physician.
10018126|NCT05215327|Experimental|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of HD-QIV (0.7 mL; 60µg of each influenza antigen) 28-42 days apart
10018127|NCT05215327|Experimental|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|receive two doses of SD-QIV (0.5 mL; 15µg of each influenza antigen) 28-42 days apart
10036119|NCT01812863|Placebo Comparator|No Nerve Block|A band-aid will be placed on all patients where a supraclavicular nerve block would have been inserted, and parents will be asked to leave the band-aid on for 3 days to maintain the blindness to the treatment type by the patient.
10036120|NCT01812889|Active Comparator|Part 2|10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days
10036121|NCT01812889|Active Comparator|Part 1|20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations
10036122|NCT01812902|Experimental|Extended LND|Radical Prostatectomy with extended lymphadenectomy
10036123|NCT01812902|Active Comparator|Limited LND|Radical Prostatectomy with Limited lymphadenectomy
10036124|NCT01812915|Experimental|Cylindrical-shape cuff ETT (Group C)|Control group: Mallinckrodt HiLo(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt Hi-Lo(TM) tube.
10036125|NCT01812915|Experimental|Tapered-shape cuff ETT (Group T)|Experimental group: Mallinckrodt TaperGuard(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt TaperGuard(TM) tube.
10036126|NCT01812928|No Intervention|Gel only|This group will be given only intraurethral gel during flexible cystoscopy.
10036127|NCT01812928|Experimental|Diclofenac and Gel|This group will also receive intraurethral gel during cystoscopy but additionally diclofenac suppository will be given per rectally one hour before procedure as preemptive analgesia.
10036128|NCT01812941|Other|Burn: blood collection|Procedure: Blood draws as the intervention.
10036129|NCT01812941|Other|trauma: blood collection|blood to be collected at different time intervals. Blood draw as the intervention
10036130|NCT01812941|Other|healthy volunteers: blood collection|Blood draws as the intervention
10036131|NCT01812980|Experimental|Trivalent Inactivated Influenza Vaccine|"Single dose, intramuscular injection from a pre-filled syringe~WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
10036132|NCT01812993|No Intervention|Control|No ventilatory treatment; standard stroke care
10036133|NCT01812993|Experimental|Active|Non-invasive ventilatory treatment with auto-BPAP plus standard stroke care
10036134|NCT01813006|Active Comparator|Omega-3|Omega-3 fatty acids
10036135|NCT01813006|Placebo Comparator|Placebo|Placebo/olive oil
10036136|NCT01813032||Firefighters|20 firefighters will attend for vascular assessments following a minimum of 48 hours off-duty.
10036137|NCT01813032||Police Officers|20 police officers will attend for vascular assessments following a minimum of 48 hours off-duty.
9476887|NCT03567369|Experimental|Dexamethasone|Dexamethasone 4,0 mg / mL
9476888|NCT03567369|Experimental|Traumeel S|Traumeel 2,2 mg / mL
9476889|NCT03567356|No Intervention|Treatment as Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.
9665259|NCT05119621|Experimental|TENS application|TENS application will be applied to the experimental group before mobilization after abdominal surgery. TENS will be applied for an average of 40 minutes.
9665260|NCT05119621|No Intervention|Standard pain management|The control group will receive standard pain treatment without any intervention. The group will not receive any other intervention.
10037392|NCT01824758|Experimental|brevibloc (esmolol)|Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
10018128|NCT05215223|Experimental|whole body vibration|the patient will be received whole body vibration for three times/ week in addition to aerobic exercise for 3 times per week, 45 minutes per session for eight weeks
10018129|NCT05215223|Active Comparator|Aerboic exercise|Moderate intensity aerobic exercise in form of walking on treadmill for 3 times per week, 45 minutes per session for eight weeks
10018130|NCT05215210|Experimental|Bitter-gourd|dried bitter-gourd supplements
10018131|NCT05215210|Active Comparator|Cucumber|dried cucumber supplements
10018132|NCT05214313|Experimental|"Music therapy Intervention group (G1)"|"Patients in the Music therapy intervention group will also perform the 1st session of the program during the inclusion visit (V0). The patients will benefit from fourteen 1-hour music therapy sessions (15 min of reception, installation and debriefing at the end of the session and 45 min of program). The 14 individual sessions will be spread over three months at the rate of 2 weekly sessions the first month then a single weekly session the following month and finally 2 monthly sessions the last month. Patients will be assessed at inclusion, then the first month (V1) and at the end of the intervention (V2)."
10018133|NCT05214313|No Intervention|" Control  group (G2)"|The patients in this group will benefit from the usual care corresponding to a quarterly medical examination. The patients will be assessed on the day of inclusion (V0) and then during the routine three-month medical examination (V2). At the end of the study, these patients will be able to benefit from the same music therapy program, offered under the same operating conditions.
10018134|NCT05214027||Participants|This study follows a randomised crossover design. All participants will undergo a single 60-minute treadmill-based exercise intervention, and a resting period for equal duration in a randomised order.
10018135|NCT05213871|Experimental|IASTM group|Group (A) will receive IASTM on the right upper trapezius and levator scapulae twice a week for four weeks in addition to a postural correction program.
10018136|NCT05213871|Experimental|myofascial release group|Group (B) will receive a myofascial release on the right upper trapezius and levator scapulae twice a week for four weeks in addition to the postural correction program.
10018137|NCT05212090|Other|Pre-THA|Subjects will be receiving EOS imaging prior to Total Hip Arthoplasty
10018138|NCT05212090|Other|Post-THA|Subjects will be receiving EOS imaging after Total Hip Arthroplasty
10018139|NCT05211726|Experimental|Low Added Sugar Diet|Subjects will be provided with a diet that is low in added sugars.
10018140|NCT05211726|Experimental|High Added Sugar Diet|Subjects will be provided with a diet that is high in added sugars.
10018141|NCT05210985||premature babies|Fifty infants between 4-18 months with a history of premature birth and with the consent of their parents will be included in the study. Babies with the chromosomal anomalies, serious congenital problems, and whose parents are not willing to work will not be included in the study.
10018142|NCT05210413|Experimental|Pediatric cohort|Multicentre, open-label, non-randomized, phase I clinical study, with dose-finding and expansion phases.
10018143|NCT05210413|Experimental|Adult cohort|Multicenter phase II single-arm open-label clinical trial, with a pre-screening phase to identify patients with mature tertiary lymphoid structure (TLS).
10018144|NCT05208814|Experimental|Renal Insuffiency|Subjects with various degrees of renal insuffiency
10018145|NCT05208814|Experimental|healthy subjects|healthy subjects
10018146|NCT05208151|Active Comparator|Creative Drama Group|
10018147|NCT05208151|No Intervention|Control Group|
10018148|NCT05208073|Experimental|Intervention group|The experimental group received 6-week cosmetic therapy.
10018149|NCT05208073|No Intervention|Control group|The control group maintains the institution's original daily routine care.
10018150|NCT05208060|Experimental|MV130|Suspension of 6 inactivated whole bacteria concentrates, that contains 90% of Gram positive bacteria (V104 S. pneumoniae 60%, V102 S. aureus 15%, V101 S. epidermidis 15%) and 10% of Gram negative bacteria (V113 K. pneumoniae 4%, V105 M. catarrhalis 3%, V103 H. influenzae 3%), at a concentration of 300 FTU/mL, equivalent to ~ 10^9 bacteria/mL.
10018151|NCT05208060|Placebo Comparator|Placebo|Sodium chloride 9 mg/mL and water for injection s.q. f 1 mL.
10018152|NCT05206591|Experimental|Secukinumab|Secukinumab 300 mg s.c
10018153|NCT05206591|Placebo Comparator|Placebo|Placebo s.c.
10018154|NCT05205850|Experimental|RC118-ADC|Participants will be allocated to one of the following dose groups: 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC118-ADC followed by 14 days of dose limited toxicity (DLT) observation period.
10018155|NCT05205629||Donafenib + TACE|
9476890|NCT03567356|Experimental|MAT-Plus Intervention|"The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
10018156|NCT05204784|Experimental|Arm 1|2 Rheopheresis treatments per week x 2, followed by 8 weeks without treatment, 8 overall treatments
10018157|NCT05204784|Experimental|Arm 2|2 Rheopheresis treatments in week 1, followed by 1 treatment every 2 weeks, 8 overall treatments
10018158|NCT05204784|Active Comparator|Control Group|Standard of care treatment with intravenous iloprost
10018159|NCT05203705|Experimental|Treatment group 1|SHR2285 tablet; dose 1
10018160|NCT05203705|Experimental|Treatment group 2|SHR2285 tablet; dose 2
10018161|NCT05203705|Experimental|Treatment group 3|SHR2285 tablet; dose 3
10018162|NCT05203705|Experimental|Treatment group 4|SHR2285 tablet; dose 4
10018163|NCT05203705|Active Comparator|Treatment group 5|Enoxaparin
10018164|NCT05203315|Experimental|Treatment Group A|Subjects whose baseline Itch and/or Burning/Stinging Score is less than 2 (moderate), one tube of Duobrii along with one jar of CeraVe cream, will be dispensed to the subject at the Baseline visit. The study participant will be instructed to apply the CeraVe cream to the treatment area twice daily and advised to apply a thin layer of the Duobrii only to the affected skin once daily in the evening.
10037393|NCT01824758|Active Comparator|Aritmal (Lidocaine)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
10018165|NCT05203315|Experimental|Treatment Group B|Subjects whose baseline Itch and/or Burning/Stinging Score is greater than or equal to 2 (moderate), in addition to one tube of Duobrii along with one jar of CeraVe cream, the participant will be given a tube of hydrocortisone 1% cream and instructed to apply to the treatment area twice daily for 5 days, along with CeraVe cream. Starting at day 6 and ongoing, subjects will be instructed to discontinue the hydrocortisone cream and initiate Duobrii application every night, while continuing the CeraVe cream twice daily.
10018166|NCT05202938||Septic shock with SIMD: SIMD+|8 patients in septic shock (Sepsis-3-) with SIMD: ejection fraction (LVEF) < 45% in the first 48 hours of admission into the intensive care unit. No prior cardiac ultrasound or normal cardiac ultrasound values less than 2 years ago , or an ino-vasotropic infusion (dobutamine, norepinephrine or epinephrine) required to obtain a LVEF ≥ 45%, or a drop of ≥ 20% compared to the LVEF value record ed less than 2 years ago.
10018167|NCT05202938||Septic shock without SIMD: SIMD-|8 patients in septic shock (Sepsis-3) without SIMD. Ejection fraction (LVEF) ≥ 45% with or without ino-vasotropic infusion (dobutamine, norepinephrine or epinephrine), or similar to the LVEF recorded less than 2 years ago.
10018168|NCT05202938||Acute Heart Failure with reduced Ejection Fraction: HFrEF|8 patients with acutely reduced ejection fraction (LVEF) < 50%. with or without ino-vasotropic infusion (dobutamine, norepinephrine or epinephrine) No prior cardiac ultrasound, or normal cardiac ultrasound values less than 2 years ago, or a drop of ≥ 20% compared to the LVEF recorded less than 2 years ago. No evidence of sepsis or septic shock.
10018169|NCT05202938||Acute Heart Failure with preserved Ejection Fraction: HFpEF|8 patients with acute heart failure and a preserved ejection fraction (ejection fraction (LVEF ≥ 50% or similar to normal cardiac ultrasound values recorded less than 2 years ago). No evidence of septic shock.
10018170|NCT05202561|Experimental|Arm A|Drug: RNA tumor vaccine Administration: intramuscular injection Dose: 600 ng/ time Dosing cycle: Day 1, day 4, day 7, and day 14.
10018171|NCT05202561|Experimental|Arm B|"Drug: RNA tumor vaccine+Navuliumab Administration: intravenous injection Dose: 3 mg/kg Timing of administration: Administration was initiated 14 days after the first intramuscular injection of the RNA tumor vaccine.~Duration of administration: once every 2 weeks."
10018172|NCT05202522|No Intervention|Control Group|During the study. participants in the control group will not receive the virtual GERAS DANCE intervention. However, they will receive the virtual GERAS DANCE intervention following study completion for equal opportunity to participate in the program.
10018173|NCT05202522|Experimental|Virtual GERAS DANCE Group|Virtual GERAS DANCE will be delivered for 1-hr twice weekly for 6 weeks.
10018174|NCT05201807|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will be given the TEST Lens for the duration of the study.
10018175|NCT05200832||COVID+|Participants who have experienced COVID-19
10018176|NCT05200832||COVID-|Participants who have not experienced COVID-19
10018177|NCT05200546||"group before"|1st period of 6 months during which only the current detection technique will be used.
10018178|NCT05200546||"group after"|- 2nd period of 6 months after implementation of the PCR solution (CPO and VRE) of the BD company in parallel with the usual screening technique
10018179|NCT05200364|Experimental|Experimental :STRO-002 treatment in combination with Bevacizumab|"Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg~Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg"
10018180|NCT05200325|No Intervention|Control Group|The control group does not receive educational materials about the TissueCypher diagnostic test and will treat their simulated patients with the current standard of care tools.
10018181|NCT05200325|Experimental|Intervention Group 1|Intervention group 1 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group is then forced to use the test results in treating their simulated patients.
10018182|NCT05200325|Experimental|Intervention Group 2|Intervention group 2 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group then gets to decide whether or not they want to use the TissueCypher test results for their simulated patients.
10018183|NCT05199818|Experimental|Palonosetron HCl Buccal Film|Palonosetron HCl Buccal Film 0.5 mg 1 hr before administration of moderately emetogenic chemotherapy and normal saline injection 30 minutes before administration of moderately emetogenic chemotherapy
10018184|NCT05199818|Active Comparator|Palonosetron IV Injection|Placebo buccal film 1 har before administration of moderately emetogenic chemotherapy and Palonosetron HCl Injection 0.25 mg 30 min before administration of moderately emetogenic chemotherapy
10018185|NCT05199012|Placebo Comparator|Placebo|Placebo is maltodextrin, delivered as 2 capsules.
10018186|NCT05199012|Active Comparator|Active|The active comparator is black pepper extract, delivered as 2 capsules.
10018187|NCT05197556|Experimental|HSG4112 200 mg Multiple Dose|Multiple oral dosing of HSG4112 200 mg for 12 weeks
10018188|NCT05197556|Experimental|HSG4112 400 mg Multiple Dose|Multiple oral dosing of HSG4112 400 mg for 12 weeks
10018189|NCT05197556|Experimental|HSG4112 600 mg Multiple Dose|Multiple oral dosing of HSG4112 600 mg for 12 weeks
10018190|NCT05197556|Placebo Comparator|Placebo|Multiple oral dosing of placebo
10018191|NCT05197426|Experimental|Oral Azacitidine|
10018192|NCT05197426|Placebo Comparator|Placebo|
9665261|NCT05118945||SWITCH group: Change from Basal IQ to Control IQ|"The patients of the SWITCH group used the X:s insulin pump with the Basal IQ algorithm until the start of the study and switched to the Control IQ algorithm at study start."
10018193|NCT05197166||Nursing students|Nursing students exposed to standing environments (prolonged walking and prolonged standing) during acute clinical settings (e.g., hospitals).
10018194|NCT05196516||Cases|Individuals at age 18 to 65 with a SARS-CoV-2 infection proven by a polymerase chain reaction (PCR) test at least 12 weeks prior to inclusion and who have been referred to the clinic of post-COVID conditions at Zealand University Hospital, Region Zealand, Denmark.
10018195|NCT05196516||Controls|Healthy volunteers at age 18 to 65 with a SARS-CoV-2 infection proven by a PCR test at least 12 weeks prior to inclusion.
10018196|NCT05196152|Active Comparator|MomMoodBooster Online|
10018197|NCT05196152|Experimental|MomMoodBooster + Coach|
10018198|NCT05196009|Experimental|Mental Health and Substance Use support|Pilot Mental health and substance use peer navigation, ecological momentary assessments and virtual support group
10018199|NCT05194956|Experimental|Arm 1 - Alginate impressions followed by digital intraoral scan|The participant will have alginate impressions taken for orthodontic treatment records first. Followed by a digital intraoral scan a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
10018200|NCT05194956|Experimental|Arm 2 - Digital intraoral scan followed by alginate impressions|The participant will have a digital intraoral taken for orthodontic treatment records first. Followed by alginate impressions a minimum of 4-6 weeks washout period. After each intervention, the participant will complete a modified visual analogue scale (VAS) questionnaire about their experience.
10018201|NCT05194800|Experimental|Unilateral upper extremity amputees|Unilateral upper extremity amputees suffering from chronic phantom limb pain > 1 yr will be recruited from a hospital based outpatient Physical Medicine and Rehabilitation Amputee Clinic at UAB.
10018202|NCT05194410|Experimental|Intervention|6 months of virtual, team-based exercise
10018203|NCT05194410|Other|Control|3 months of usual exercise and then 3 months of virtual, team-based exercise
10018204|NCT05193877|Active Comparator|treatment with autologous bone marrow aspirate concentrate|autologous bone marrow aspirate is taken under local anesthesia to be centrifuged and the concentrate given intra articularly in knee joint
10018205|NCT05193877|Sham Comparator|control|control group given analgesics only
10018206|NCT05193825|Active Comparator|Group A|Patients in Group A (active comparator) will have their internal pulse generator (IPG) adjusted by conventional procedures, i.e. by regular visits at their caregivers hospital.
10018207|NCT05193825|Experimental|Group B|Patients in Group B (experimental) will have their internal pulse generator (IPG) adjusted by using a novel software (Abbot NeurosphereTM Virtual Clinics) that allows for remote IPG programming and with the aid of a visual analogue scale (VAS).
10018208|NCT05192733||Clinical Specialty|"We will compare responses across the following clinical specialties :~Neuroanesthesiologists~Neurosurgeons~Neurocritical care specialists NB: Some participants may have a double clinical specialty."
10018209|NCT05192733||Clinical Setting|"We will compare responses across the following clinical settings:~Cities~Countries~Number of cases per year"
10018210|NCT05192629|Active Comparator|Group Midazolam|"Administration of oral midazolam (0.25 mg/kg) as premedication before propofol-based sedation.~The patient receives an oral premedication containing 0.125mL/kg of midazolam (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/ml, with a maximum of 20 mg). He/she also receives an intranasal spray containing matching placebo of dexmedetomidine (NaCl 0.9%). The volume administered corresponds to 0.02 mL/kg (which corresponds to a dosage of 2 mcg/kg of pure dexmedetomidine 100 mcg/mL in group D)."
10018211|NCT05192629|Experimental|Group Dexmedetomidine|"Administration of intranasal dexmedetomidine as premedication before propofol-based sedation.~The patient receives an intranasal premedication containing 2 mcg/kg of dexmedetomidine. He/she also receives an oral solution containing matching placebo of midazolam (flavored-water prepared by the pharmacy). The volume administered corresponds to 0.125 mL/kg (which corresponds to a dosage of 0.25mg/kg of Ozalin® 2mg/mL, with a maximum of 20 mg or 10mL)."
10018212|NCT05191550|Experimental|Neurosurgeons, fellows, residents and medical students|Neurosurgeons (14), neurosurgical fellows and neurosurgical residents (24) from Montreal Neurological Institute and Hospital along with medical students (12) who are enrolled in first to fourth year of McGill medical school.
10018213|NCT05191121|Active Comparator|FTP Alone|Functional Task Practice Alone - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks followed by 10 minutes of functional training/carryover in a relevant environment without functional electrical stimulation (FES).
10018214|NCT05191121|Active Comparator|FTP+Con-FES|Functional Task Practice + Conventional Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with conventional parameter (200µs; 40Hz) functional electrical stimulation (FES). followed by 10 minutes of functional training/carryover in a relevant environment.
10018215|NCT05191121|Active Comparator|FTP+WPHF-FES|Functional Task Practice + Wide Pulse, High Frequency Functional Electrical Stimulation - Participants allocated to this group will complete 40 minutes of training focused on improving functional tasks supplemented with wide pulse, high frequency (1000µs; 100 Hz) functional electrical stimulation (FES) followed by 10 minutes of functional training/carryover in a relevant environment.
10018216|NCT05190822||Students|
10018217|NCT05189444|Experimental|Vonoprazan group|Vonoprazan + Amoxicillin + Bismuth potassium citrate Drug: Vonoprazan 20mg bid Other Names: no Drug: Amoxicillin 0.75g tid Other Names: no Drug: Bismuth potassium citrate 0.22g bid Other Names: no
10018218|NCT05189444|Active Comparator|control group: quadruple therapy|Drug: Esomeprazole 20mg bid Other Names: no Drug: Amoxicillin 1.0g bid Other Names: no Drug: Clarithromycin 0.5g bid Other Names:no Drug: Bismuth potassium citrate 0.22g bid Other Names:no
10018219|NCT05187832|Experimental|AND019 single dose escalation|Subjects will be administrated with AND019 capsule PO QD from 20 mg to 400 mg during Part 1, and 2 dose groups will be selected for dose expansion study
10018220|NCT05186662||WeChat group|
10018221|NCT05186662||Control group|
10018222|NCT05185011|Experimental|mild hepatic impairment|Subjects with mild hepatic impairment
10018223|NCT05185011|Experimental|moderate hepatic impairment|Subjects with mild moderate impairment
10018224|NCT05185011|Experimental|healthy volunteers|Subjects with normal hepatic function
10018225|NCT05183828|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD for 21-24 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of saliva samples.
10018226|NCT05183477|Experimental|fast track|patients arriving at Emergency Department with suspected wrist or scaphoid fracture, randomly allocated to the fast track pathway (xray requested at triage by nurse)
10018227|NCT05183477|Active Comparator|normal pathway|patients arriving at Emergency Department with suspected wrist or scaphoid fracture, randomly allocated to waiting room and than medical examination before asking for xrays
10018228|NCT05182905|Experimental|Arm A: Recurrent Grade IV Glioma Surgical Cohort Time Escalation|
10018229|NCT05182905|Experimental|Arm B: Recurrent Grade IV Glioma Dose Escalation|
10018230|NCT05182125|Experimental|Part A, Group 1: AdC6-HIVgp140|Participants will receive 1 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
10018231|NCT05182125|Experimental|Part A, Group 2: AdC7-HIVgp140|Participants will receive 1 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
10018232|NCT05182125|Placebo Comparator|Part A, Group 3: Placebo|Participants will receive placebo for AdC6-HIVgp140 or AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
10018233|NCT05182125|Experimental|Part B, Group 4: AdC6-HIVgp140 + AdC7-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
10018234|NCT05182125|Experimental|Part B, Group 5: AdC7-HIVgp140 + AdC6-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
10018235|NCT05182125|Placebo Comparator|Part B, Group 6: Placebo + Placebo + Placebo|Participants will receive placebo for AdC6-HIVgp140and AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0 and 3. Placebo for CH505TF/GLA-SE (labeled as Sodium Chloride for Injection, 0.9% ) to be administered as 1 mL IM injection into either thigh at month 6.
10037394|NCT01824758|Placebo Comparator|Placebo (NaCl 0.9%, 5 ml)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
10018236|NCT05182047|Experimental|Treatment Sequence AB|Participant will receive a single oral dose of butamirate citrate syrup 1.5 milligrams per milliliter (mg/mL) (Treatment A [investigational product]) on Day 1 in Treatment Period 1, followed by a single oral dose of sinecod syrup (vanilla) 1.5 mg/mL (Treatment B [Reference product]) on Day 11 in Treatment Period 2. A wash-out period of at least 10 days will be maintained between each treatment period.
10018237|NCT05182047|Experimental|Treatment Sequence BA|Participants will receive Treatment B on Day 1 in Treatment Period 1, followed by Treatment A on Day 11 in Treatment Period 2. A wash-out period of at least 10 days will be maintained between each treatment period.
10018238|NCT05180981|Experimental|Breath task|Participants will breathe in specific patterns.
10018239|NCT05180981|Experimental|Transcutaneous vagal nerve stimulation|Participants will receive transcutaneous vagal nerve stimulation in specific patterns.
10018240|NCT05180045|Experimental|LINKED-BP Program|"Patients in the LINKED-BP Program will be trained to measure their BP with an Omron 10 series device. Patients who have smartphones will download the patient facing app and receive a unique link from the study team. Patients who do not own a smartphone will be provided one with a data plan for the duration of the study. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal.~CHWs will support patients by: (1) providing education on how to manage BP through self-monitoring and practicing dietary modification and exercise; (2) reinforcing positive BP self-management through follow-up encounters; (3) assisting with linkages to existing clinical and administrative services; and (4) link participants with community resources to address health-related social needs.~The staff in each participating community health center practice will be trained in blood pressure measurement best practices."
10018241|NCT05180045|No Intervention|Enhanced Usual Care|Patients in the Enhanced Usual Care Arm, will receive care as usual from thier primary care provider and will be trained to measure their BP with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
10018242|NCT05180006|No Intervention|Arm 1A: control arm; no treatment, in TNBC patients (cohort 1)|Control arm : no treatment
10018243|NCT05180006|Experimental|Arm 1B: Atezolizumab, in TNBC patients (cohort 1)|atezolizumab alone, administered as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of neoadjuvant chemotherapy
10018244|NCT05180006|Experimental|Arm 1C: Atezolizumab + Ipatasertib, in TNBC patients (cohort 1)|atezolizumab as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of neoadjuvant chemotherapy, in combination with daily oral ipatasertib for 14 days starting at the same time as atezolizumab administration
10018245|NCT05180006|Experimental|Arm 1D: Atezolizumab + Bevacizumab, in TNBC patients (cohort 1)|atezolizumab and bevacizumab as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of neoadjuvant chemotherapy
10018246|NCT05180006|No Intervention|Arm 2A: control arm; no treatment, in HER2+ patients (cohort 2)|no treatment
10018247|NCT05180006|Experimental|Arm 2B: Atezolizumab + Trastuzumab + Pertuzumab, in HER2+ patients (cohort 2)|atezolizumab as one single IV infusion in combination with trastuzumab + pertuzumab for one IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of neoadjuvant chemotherapy
10018248|NCT05177965||Shift workers|Measurements repeated during a series of day shifts and during a series of night shifts
10036138|NCT01813045||Chronic Coronary Occlusion group|"We will also recruit 10 patients with an angiographically documented chronic (>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.~We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan."
9476891|NCT03567343|Active Comparator|Proprietary Spearmint Extract Blend|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the Proprietary Spearmint Extract Blend blend by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
9476892|NCT03567343|Placebo Comparator|Control|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the excipient, microcrystalline cellulose by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
9476893|NCT03567343|Active Comparator|Proprietary Blend And Melatonin|Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the proprietary spearmint extract blend and 1 Mg of melatonin by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
9476894|NCT03567343|Active Comparator|Melatonin|Subjects randomized into the active treatment group will be asked to consume 1 Mg of melatonin by mouth every night 30 mins before bed and complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
9476895|NCT03567330|Experimental|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
9476896|NCT03567330|Active Comparator|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
9476897|NCT03567317|No Intervention|CPAP|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP during the initial study visit, patients will resume CPAP use for one week before the second study visit.
9476898|NCT03567317|Experimental|CPAP withdrawal|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP at the second study visit, patients will withdraw CPAP one week before.
9476899|NCT03567304|No Intervention|EFV-based|"HIV-infected patients, who has been taking efavirenz (EFV)-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to continue EFV-based regimen.~EFV based regimen defines as efavirenz 600 mg per oral once daily (OD) + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."
9476900|NCT03567304|Experimental|RPV-based|"HIV-infected patients, who has been taking efavirenz-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to switch antiretroviral therapy to rilpivirine (RPV)-based regimen.~RPV based regimen defines as rilpivirine 25 mg PO OD + 2 NRTIs."
9476901|NCT03567278|Experimental|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
9476902|NCT03567239|Experimental|Using adaptive device|Participants will use a non-commercially available device, designed to meet their needs.
9476903|NCT03567226|Experimental|Intervention Group|The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
9476904|NCT03567226|Active Comparator|Control Group|Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
9476905|NCT03567200|Experimental|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
10018249|NCT05177796|Experimental|Treatment (panitumumab,pembrolizumab,neoajuvant chemotherapy)|"CYCLES 1-4: Patients receive pembrolizumab IV over 30 minutes and panitumumab IV over 30-60 minutes on day 1 of cycle 0. Cycle 0 continues for 7 days in the absence of disease progression or unacceptable toxicity. Patients then receive panitumumab IV over 30-60 minutes on days 1, 8, and 15 of cycles 1-3 and days 1 and 8 of cycle 4, pembrolizumab IV over 30 minutes on day 1 of cycles 2-4, paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1, 8 and 15 of cycles 1-4. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CYCLES 5-8: Patients receive standard of care treatment, including pembrolizumab IV over 30 minutes, doxorubicin IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
10018250|NCT05177302||Individuals with hip and/ or groin pain|The young to middle-aged physically active individuals with hip and/ or groin pain, which symptoms lasting for 2 to 6 month.
10018251|NCT05176860|Experimental|High-performance CBCT imaging|Two additional study imaging sets are acquired.
10018252|NCT05176561|Experimental|Treatment: Auditory-Cognitive Training|Behavioral: AR Group will complete sessions in their home or office via internet. Sessions will include independent work using computer software two hours per week and one hour meeting with the clinician each week. One half of the training is devoted to auditory training and one half to auditory cognitive activities. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
10018253|NCT05176561|Sham Comparator|Control: Non-auditory Cognitive Training|Behavioral: The CT Group will complete two hours of training in their home or office via internet. Sessions will include independent work using computer software two hours per week. Training exercises will be chosen from: Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Differences. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
10018254|NCT05176431|Active Comparator|Focused extracorporeal shock wave therapy|
10018255|NCT05176431|Active Comparator|Radial extracorporeal shock wave therapy|
9518121|NCT03299712|Other|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
10018256|NCT05176431|Sham Comparator|Sham extracorporeal shock wave therapy|
9518122|NCT03299660|Experimental|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
10018257|NCT05176353|Experimental|VAP diagnostic stewardship|
10018258|NCT05176210|Experimental|SAD portion - Cohort 1 (100mg)|An eligible subject will receive a single dose of 100 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 14 days.
10018259|NCT05176210|Experimental|SAD portion - Cohort 2 (200mg)|An eligible subject will receive a single dose of 200 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 14 days.
10018260|NCT05176210|Experimental|SAD portion - Cohort 3 (400mg)|An eligible subject will receive a single dose of 400 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 14 days.
9518123|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
9518124|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
10018261|NCT05176210|Experimental|FE portion - Cohort 4 (100mg)|An eligible subject will receive a single dose of 100 mg PS1 or Placebo tablets in a fasted condition on Day 1 and be followed for 14 days.
9518125|NCT03299621|Experimental|PLE (Phase Lag Entropy) monitoring|Investigators monitor the change of PLE value using the sensor of PLEM™ during propofol anesthesia.
10018262|NCT05176210|Experimental|MAD portion - Cohort 5 (50mg)|An eligible subject will receive 50 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 14 days.
10018263|NCT05176210|Experimental|MAD portion - Cohort 6 (100mg)|An eligible subject will receive 100 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 14 days.
10018264|NCT05175274|Experimental|Intervention Group|colchicine 0.5mg every 24 hours for 3 years
10018265|NCT05175274|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 3 years
9476906|NCT03567187|Experimental|Iovera|"The iovera° device consists of a reusable, portable hand-piece, along with a single-patient use sterile smart Tip (cryoprobe) and disposable nitrous oxide (N2O) cartridges (cryogen). The smart tip is composed of closed-tip stainless steel needles, thereby fully enclosing the cryogen. There are 2 types of smart tips that will be utilized during this study, depending on the depth of the nerves being treated. The shorter smart tip comes in 2 variants - three X 6.9 mm or 8.9 mm, 27-gauge needles, with an attached skin warmer to prevent damage to the underlying skin. The longer smart tip also comes in 2 variants - 55 mm 22-gauge needle or a 90 mm 20G needle.~The effect is by initiation of a cooling cycle, by fully inserting the smart tip into the procedure site and activating the cryogen flow. As the gas travels through the length of the needle, an ice ball develops around the needle freezing the surrounding tissue."
9476907|NCT03567161|Experimental|Cavitron ultrasonic surgical aspirator|"Patients.with periodontitis.~Inclusion criteria:~Having received a diagnosis of chronic periodontitis (Armitage 1999)~Being treated by full mouth debridement, and supportive periodontal treatment (SPT) in the last year (at least three sessions)~Having at least one residual pocket ≥ 5 mm with and intra bony component at least ≥ 2 mm~Exclusion criteria:~Smoking more than ten cigarettes per day~Pregnancy~Irregular compliance during SPT in the last year; and systemic conditions or therapies known to affect the healing potential of periodontal tissues (e.g., uncontrolled diabetes, oncological conditions, immunosuppressant drugs)."
9476908|NCT03567148|Active Comparator|PRF group|Four layers of PRF membranes were placed in the palatal wound and sutured with 5/0 resorbable sutures
9476909|NCT03567148|Active Comparator|Essix retainer group|An impression of palatal region was taken and the Essix retainer was prepared before the patients underwent surgery.
9476910|NCT03567148|Active Comparator|Ozone therapy group|Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
9476911|NCT03567148|Active Comparator|LLLT group|Irradiation was performed at the same points described above using a diode laser (λ=970±15 nm, 14-W source power) (SIROLaser Xtend; Sirona Dental Systems GmbH, Bensheim, Germany) that continuously emitted a wavelength with 320µm fiberoptic; the power was 2W and the tissue dose was 35 J/cm2. Total irradiation time was 30 seconds. The applications were performed immediately after surgery, and on the 1st, 3rd and 7th, days following the operation.
9476912|NCT03567148|Active Comparator|Collagen fleece group|Collagen fleece (BEGO Collagen Fleece, Bremen, Germany) was sutured with 5/0 resorbable sutures (Pegesorb, Istanbul, Turkey) on the open wound with the aid of vertical mattress sutures.
9476913|NCT03567148|No Intervention|Control group|Palatal wounds were left for spontaneous healing
9476914|NCT03567135||Experimental 1|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）
9476915|NCT03567135||control|concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）
9476916|NCT03567135||Experimental 2|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）
9476917|NCT03567122|Experimental|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
9476918|NCT03567122|Experimental|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
9802686|NCT05062369|Experimental|Participants receiving active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of active transcranial direct current stimulation (tDCS) to dorsolateral prefrontal cortex (DLPFC) while in the Lodging Plus treatment program and then 5 remote sessions of active tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
10018266|NCT05175170|Experimental|Decision-aid|Participants will spend up to one hour freely navigating the web-based decision aid. They will complete pre- and post-test measures to determine if using the decision-aid website increased knowledge and impacted decision self-efficacy regarding fertility and fertility preservation.
10018267|NCT05175092|Experimental|Intent to Treat: LDLT|Living Donor Liver Transplantation
10018268|NCT05175092|No Intervention|Control Group|Enrolled but does not receive LDLT
10018269|NCT05174624||FAMILY Cohort|This Cohort was part of a prospective population-based study in 2007, consisting of 46,001 participants in Hong Kong. It was the first large-scale programme to understand the determinants of physical, mental, and social wellbeing in Hong Kong. The Cohort has an excellent (99.8%) coverage of the neighbourhoods in Hong Kong and represents roughly 1% of all households, which enables detailed studies linking the social environment to physical and mental health.
10018270|NCT05174611|Experimental|Treatment group|Subject in treatment group will receive one capsule of 2000IU Vitamin D3 supplement per day with the duration of 16 weeks.
10018271|NCT05174611|Placebo Comparator|Placebo group|Subject in placebo group will receive one capsule of placebo per day which looks exactly same as the Vitamin D3 capsule with the duration of 16 weeks.
10018272|NCT05174585|Experimental|Arm A, JAB-BX102 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-BX102 will be administered as monotherapy to determine the MTD and RP2D.
10018273|NCT05174585|Experimental|Arm B, JAB-BX102 combination with pembrolizumab, Phase 2a, Dose Expansion|JAB-BX102 will be administered in combination with pembrolizumab in specific solid tumor patients to evaluate the preliminary antitumor activity.
10018274|NCT05171816|Experimental|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
10018275|NCT05171816|Placebo Comparator|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
10018276|NCT05170646||Participants treated with upadacitinib|
9518126|NCT03299621|Experimental|Muscle relaxant injection|Investigators monitor the change for PLE value using the sensor of PLEM™ before and after the injection of muscle relaxant.
10018277|NCT05170308|Other|Treatment (CO2 fractional laser) arm|CO2 fractional laser will be used to treat dyspigmentation in lichen planus pigmentosus in one half along sagittal midline section in each subject.
10018278|NCT05170308|No Intervention|No treatment (Control) arm|One half along sagittal midline section in each subject will not receive the CO2 fractional laser treatment.
10018279|NCT05170178|Experimental|women without experience at caring for young babies|Women with no daily contact with infants either in the family or professional circle, present or past (no siblings close in age, no presence of young children at home (spouse or child of a nanny)
10018280|NCT05170178|Experimental|Men without experience at caring for young babies|Men with no daily contact with infants either in the family or professional circle, present or past (no siblings close in age, no presence of young children at home (spouse or child of a nanny)
10018281|NCT05170178|Experimental|Women with experience at caring for young babies|Women in daily contact with infants, whether in the family or professional circle (e.g., nannies, pediatricians, midwives, maternity nurses)
10018282|NCT05170178|Experimental|Men with experience at caring for young babies|Men in daily contact with infants, whether in the family or professional circle (e.g., nannies, pediatricians, midwives, maternity nurses)
9802687|NCT05062369|Sham Comparator|Participants receiving active and sham active transcranial direct current stimulation (tDCS)|Participants in this group will receive 5 sessions of sham-tDCS sessions while in the Lodging Plus treatment program and then 5 remote sessions of active-tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
9802688|NCT05061368|Experimental|Sildenafil|Participants will be administered a 25 mg oral dose of sildenafil.
9802689|NCT05061368|Placebo Comparator|Placebo|Participants will be administered an oral placebo indistinguishable from the sildenafil pill.
10018283|NCT05169268||MainRexult Group|Subjects with schizophrenia and related disorders receiving Abilify Maintena (aripiprazole 1 monthly depot) together with Rexulti (Brexpiprazole)
9518127|NCT03299582|Experimental|Healthy subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects without cancer
9476919|NCT03567122|Active Comparator|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
9476920|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
9476921|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
10018284|NCT05169242|Experimental|Intervention group|In the intervention arm, one or more endoclips (Instinct® Clip, Cook Medical) will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
9476922|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
9476923|NCT03567109||control|healthy subjects
9476924|NCT03567083|Experimental|E-CAU with Problem Management Plus (PM+)|30 participants will be randomly assigned to E-CAU with PM+ group. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
9476925|NCT03567083|No Intervention|Enhanced care as usual (E-CAU) only|30 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a referral document), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
9476926|NCT03567070|Other|qualitative study based on an individual clinical interview|
9476927|NCT03567044|Experimental|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
9476928|NCT03567031|Experimental|Main Arm|In each patient, under ongoing standard general anesthesia in a stable state, EtCO2 is manually modified to reach predefined values, and after waiting until cerebral blood flow has reached steady state, NIRS and DTC values are noted.
9476929|NCT03566992|Active Comparator|Gastric Tube Placement|Nasoenteric tube placed in the stomach.
9476930|NCT03566992|Experimental|Small bowel|Nasoenteric tube placed in the small bowel.
9476931|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
9476932|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
9476933|NCT03566940|Experimental|Group 1: Low Dose IPV Based on Sabin Strains (sIPV)|Participants will receive intramuscular (IM) injection of the low dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of conventional Salk IPV (cIPV) at approximately 24 weeks after the third vaccination (38 weeks of age).
9476934|NCT03566940|Experimental|Group 2: Intermediate Dose sIPV|Participants will receive IM injection of the intermediate dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
9476935|NCT03566940|Experimental|Group 3: High Dose sIPV|Participants will receive IM injection of the high dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
9476936|NCT03566940|Active Comparator|Group 4: Conventional Salk IPV (cIPV)|Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
9476937|NCT03566927|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter, then a standard balloon angioplasty, followed by a Lutonix® drug-coated balloon (DCB).
9476938|NCT03566914|Experimental|Tadalafil|Tadalafil 10 mg once daily per oral for 3 months
9476939|NCT03566914|Placebo Comparator|Placebo|Tablet placebo once daily per oral for 3 months
9476940|NCT03566901|Experimental|Robot-Assisted Stair Climbing Training|Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
9476941|NCT03566901|Active Comparator|Conventional Physiotherapy|50 min of overground walking training and stair climbing up/down and lower limb mobilization and stretching exercise.
9476942|NCT03566888||Single Group|85 eligible study participants
10018285|NCT05169242|No Intervention|Control group|In the control arm, no endoclip will be applied to all post-polypectomy sites, with the exceptions of uncontrolled immediate PPB or pre-treatment in very large pedunculated polyps as specified above. The subjects with endoclips applied due to safety reasons will be included in the subsequent intention-to-treat analysis, but not the per-protocol analysis.
9476943|NCT03566875|Experimental|Total knee arthroplasty with the Stryker's MAKO™ system|The total knee arthroplasty is performed with Stryker's MAKO™ robotic system. It allows to place precisely the prosthetic implants.
10018286|NCT05168995||Asthmatic patients in treatment with BDP/FF NEXThaler® 100/6 micrograms|Not adequately controlled asthmatic patients in treatment with Beclometasone dipropionate (BDP)/formoterol fumarate (FF) 100/6 micrograms per actuation inhalation powder via NEXThaler®
10018287|NCT05168384|Experimental|Group A (ECP + SoC Group)|Extracorporeal photopheresis (ECP) plus Multiple Sclerosis (MS) standard of care
10018288|NCT05168384|Active Comparator|Group B (SoC Group)|MS standard of care alone (SoC, defined by Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN, excluding B cells therapies
10018289|NCT05168267|Experimental|Cognitive Processing Therapy (CPT) group|Arm = Cognitive Processing Therapy (CPT) Group = 4 groups of 12 (48 total; 24F/24M) receive CPT to treat PTSD
10018290|NCT05168267|Experimental|Interpersonal Process-Oriented Group Therapy (IPGT) group|Arm = Interpersonal Process-Oriented Group Therapy Group = 4 groups of 12 (48 total; 24F/24M) receive IPGT as active control group for PTSD treatment
10018291|NCT05167526|Experimental|Part 1: Single ascending dose of ASP8731|This is composed of 10 sequential cohorts (cohorts 1.1 to 1.10). Participants (6 for each cohort) will receive a single dose of ASP8731 under fasting conditions.
10018292|NCT05167526|Placebo Comparator|Part 1: Single ascending dose of placebo|Participants (2 for each cohort, cohorts 1.1 to 1.10) will receive a single dose of matching placebo under fasting conditions.
10018293|NCT05167526|Experimental|Part 1: Single dose of ASP8731 (Food effect)|Participants (8) will receive a single dose of ASP8731 with a high-fat meal.
10018294|NCT05167526|Experimental|Part 2: Multiple ascending dose of ASP8731|"This is composed of 6 sequential cohorts (cohorts 2.1 to 2.6). Participants (9 for each cohort) will receive ASP8731 for 14 consecutive days at the same dose level.~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
10018295|NCT05167526|Placebo Comparator|Part 2: Multiple Ascending Dose of Placebo|Participants (3 for each cohort) will receive matching placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.6.
10018296|NCT05167448|Experimental|Cohort 1 Phase 1|
10018297|NCT05167448|Experimental|Cohort 2 Phase 1|
10018298|NCT05167448|Experimental|RP2D Phase 2|
9476944|NCT03566875|Active Comparator|Total knee arthroplasty with mechanical ancillary|The total knee arthroplasty is performed using a mechanical ancillary. It's the conventional method.
9476945|NCT03566862||Lung cancer|Individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough.
10018299|NCT05167019|Active Comparator|Usual care|Usual care
10018300|NCT05167019|Experimental|The CODE intervention|The CODE intervention consists of 4 items, of which individual coaching sessions of 1 hour. In total each doctor taking care of hospitalized patients will be able to receive maximum 16 individual coaching sessions during the 4 months intervention period (one weekly). Every doctor will be invited to participate to at least 8 coaching sessions, to be extended on request, during the intervention period.
10018301|NCT05166915|Experimental|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2.
9476946|NCT03566862||COPD|Individuals with a confirmed diagnosis of COPD according to established criteria.
9476947|NCT03566862||Other (non-COPD) chronic lung disease|Individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma).
9476948|NCT03566862||Normal smokers|Individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment).
9476949|NCT03566849|Experimental|KC group|It mainly involve all segment in kinetic chain, not only shoulder girdle, include exercise training 3 times a week for a total 4 weeks.
9476950|NCT03566849|Experimental|CT group|It involve shoulder girdle only, include exercise training 3 times a week for a total 4 weeks.
9476951|NCT03566836||AF Detection|Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure.
9476952|NCT03566797||SC-CIP|Patients developing SC-CIP
9476953|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
9476954|NCT03566784||Electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, with the use of electrocoagulation.
9476955|NCT03566784||No electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, without the use of electrocoagulation.
9476956|NCT03566771|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 12 months
10018302|NCT05166915|Sham Comparator|Sham Control Device|Sham Control Device
9476957|NCT03566771|Active Comparator|CLOSS|Usual care plus using a web-based support system for self-monitoring weight, physical activity and communication with the clinic during 12 months
9476958|NCT03566745||Study group|Patients with mutation in AhR gene - presumed low Blood for protein activity
9476959|NCT03566745||Control|Patients without mutation in AhR gene - presumed normal Blood for protein activity
9476960|NCT03566719|Experimental|Intervention group|
9476961|NCT03566719|No Intervention|Control group|
9476962|NCT03566706|Experimental|Unhealthy Eating|
9476963|NCT03566706|Experimental|Marijuana Use|
9476964|NCT03566706|Experimental|Sedentary Behavior|
9476965|NCT03566693|Experimental|Continous Glucose Monitor|
9476966|NCT03566693|Active Comparator|Self Monitoring Blood Glucose|
10018303|NCT05166876|Experimental|Brequinar monotherapy|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
10018304|NCT05166876|Placebo Comparator|Placebo|Placebo matching brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
9476969|NCT03566654|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
9476970|NCT03566654|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50~60 mmHg
9476971|NCT03566641|Experimental|Negative pressure wound therapy|This group of patients will receive negative pressure wound therapy (prevena) as their postoperative wound care method.
9476972|NCT03566641|Active Comparator|standard care dressing|This group of patients will receive standard care dressing as their postoperative wound care method.
9476973|NCT03566628|Experimental|Warmed Saline|Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.
9476974|NCT03566628|Active Comparator|Room-Temperature Saline|Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.
10018305|NCT05166876|Experimental|Brequinar-Dipyridamole Combination|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met. All subjects assigned to this arm will also receive dipyridamole 75 mg tablets TID.
10018306|NCT05166798|Experimental|Intervention group|Cognitive control training: The adaptive Paced Auditory Serial Addition Task (aPASAT) is a Cognitive Control Training where participants need to click on the sum of the last two heard digits. Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control. Five intervention groups will each receive a different amount of sessions.
10018307|NCT05166798|No Intervention|Control group|Waitlist control group: Participants randomized to the control group will not perform the cognitive control training during the study, but will be given the opportunity to follow the training afterwards.
9476975|NCT03566602|Other|Dura Sealant Patch|Application of Dura Sealant Patch after closure of the dura mater
10018308|NCT05166018|Experimental|SuMO Patient|"92 data will be collected during the patient care episode. Among the 92 criteria, 63 are pre-operative, 29 are post-operative in order to provide an evolutionary prediction during the management of the patient.~Post-operative follow-up criteria making it possible to establish the scalability or non-scalability of the quality of life after the surgical procedure.~The results will be compared to the prediction proposed by the machine learning algorithm."
10018309|NCT05165628|Experimental|Group 1 - CYP-006TK|Participants will receive CYP-006TK dressings
10018310|NCT05165628|No Intervention|Group 2 - Standard of Care|Participants will continue to be treated as per local standard of care
10018311|NCT05165381||Contactless vital signs and stress measurement.|Contactless vital signs and stress measurement. Eligible participants will agree to have a 1.5-minute facial video recorded using an iPad. Video will be processed through a specialized algorithm to obtain BP, HR, RR, HRV and stress index. measurements.
10018312|NCT05165199|Experimental|Elobixibat|10mg Elobixibat administration for 4 weeks
10018313|NCT05164783|Experimental|Participants|Intervention: use of SCP
10036139|NCT01813045||MI (non-revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
10036140|NCT01813045||MI (revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
10036141|NCT01813084|Experimental|Part A: single dose escalation|
10036142|NCT01813084|Experimental|Part B: 14 day repeat dose escalation (healthy volunteers)|
10036143|NCT01813084|Experimental|Part C: 14 day repeat dose (asthma patients)|
10036144|NCT01813097||combination iodine 125 seed implants|30 cases should be treated with iodine 125 seed implants 0.5 mc transperineal prostate implant +Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
10036145|NCT01813097||LHRH agonists|30 cases should be treated with Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
10036146|NCT01813123|No Intervention|Control|
10036147|NCT01813123|Experimental|Intervention|RealTeen
10018314|NCT05164718|Experimental|Exercise group|
10018315|NCT05164718|Other|Control group|
10036148|NCT01813136|Active Comparator|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
10018316|NCT05163769|Experimental|Multimodal Training|The participants in the Multimodal training arm (mBCI) will undergo 48 physical and cognitive training sessions over 24 weeks on the NeeuroCycle BCI Physical and Cognitive training system. Sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session.The mBCI training program will deliver cognitive training modules in tandem with a stationary cycling regime. The cognitive training program consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. The cycling regime is divided into seven non-consecutive sections. The participant will be tasked to complete a cognitive training activity that will last about 2-3 minutes between each cycling session.
10018317|NCT05163769|Experimental|Neurocognitive-Training only|The participants in the Neurocognitive training-only arm (nBCI) will undergo 48 cognitive training sessions over 24 weeks on the NeeuroCycle BCI Cognitive training system. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. The nBCI training protocol will deliver cognitive training modules that consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. Participants will navigate the virtual space of the cognitive training program by using arrow keys on the tablet.
9476976|NCT03566589|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
10018318|NCT05163769|No Intervention|Active Control|The participants in the Active Control arm (AC) will undergo 48 sessions over 24 weeks. The sessions are scheduled three times a week for the first 12 weeks and then once a week for the subsequent 12 weeks. Sessions are spaced at least one day apart and will take about one hour per session. Participants in this arm will view informative documentaries on an electronic tablet and answer three general questions about documentary.
9476977|NCT03566576|Experimental|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
9476978|NCT03566576|Experimental|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
9476979|NCT03566563||Ex-Drug Users|These are ex drug users residing at halfway houses
9476980|NCT03566537||Cases|Patients who are going to undergo a thyroid surgery due to symptomatic non-toxic multinodular goiter, uncontrolled thyrotoxicosis or suspicious FNA
9476981|NCT03566537||Controls|Patients with benign thyroid disease, not undergoing thyroidectomy
9476982|NCT03566524|Experimental|Arginine|In this experimental arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary arginine for 21 days. Arginine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The arginine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
9518128|NCT03299582|Experimental|Healthy subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects without cancer
10018319|NCT05163639|Experimental|1. Uninjured participants - Immediate and lasting effects of non-invasive paired stimulation|Participants will take part in the following to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
10018320|NCT05163639|Experimental|2. Intraoperative participants - Immediate effects of paired stimulation|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Intraoperative pairing of cortical and spinal stimulation.
10018321|NCT05163639|Experimental|3. Intraoperative participants - Lasting effects of SCAP|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP).
10018322|NCT05163639|Experimental|4. Chronic cervical SCI participants - Lasting effects of non-invasive SCAP|Participants with chronic cervical SCI will take part in the following, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
10018323|NCT05163639|Experimental|5. Intraoperative participants - Lasting effects of SCAP at or below myelopathic region|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region.
9802690|NCT05058404|Experimental|Standard arm (A)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).~After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
10018324|NCT05163015||with oncogeriatric consultation|"with oncogeriatric consultation group: patients aged 75 and more with cancer with oncogeriatric consultation"
10018325|NCT05163015||without oncogeriatric consultation|"without oncogeriatric consultation group: patients aged 75 and more with cancer without oncogeriatric consultation"
9476983|NCT03566524|Active Comparator|Citrulline|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 21 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
10018326|NCT05161091|Experimental|Radio-induced oral mucositis / Medical Device|Patient with radio-induced oral mucositis at least grade 2 treated with experimental medical device
10018327|NCT05161091|Placebo Comparator|Radio-induced oral mucositis / Placebo comparator|Patient with radio-induced oral mucositis at least grade 2 treated with placebo
10018328|NCT05161091|Experimental|Chemo-induced oral mucositis / Medical Device|Patient with chemo-induced oral mucositis at least grade 2 treated with experimental medical device
10018329|NCT05161091|Placebo Comparator|Chemo-induced oral mucositis / placebo comparator|Patient with chemo-induced oral mucositis at least grade 2 treated with placebo
10018330|NCT05160610|Experimental|Intervention group|receiving multilevel intervention, electronic monitoring and stroke registry participation
10018331|NCT05160610|No Intervention|Control group|receiving routine care , electronic monitoring and stroke registry participation
10018332|NCT05160194|Other|GROW Intervention|Every participant received the GROW Intervention, chose not to participate in the GROW intervention, or dropped out before completing the GROW Intervention.
10018333|NCT05160012|No Intervention|Control|This group will not receive peer comparison messages and will continue with usual care.
10018334|NCT05160012|Experimental|Intervention|This group will receive peer comparison messages.
10018335|NCT05159427|Experimental|G.I Intubation|Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
10018336|NCT05159427|Experimental|SmartPill®|Single dose of Glipizide (5 mg modified-release tablet), Rifaximin (200 mg tablet) and SmartPill® administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water.
9476984|NCT03566524|Placebo Comparator|alanine|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 21 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
9476985|NCT03566498|Experimental|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
9476986|NCT03566498|Active Comparator|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
9476987|NCT03566459||Veterans with opioid use disorder (OUD)|Veterans with opioid use disorder (OUD) in VA Maine Healthcare System catchment area
9476988|NCT03566446|Experimental|36 aminoacid CALR exon 9 mutated peptide|15 vaccines, over the course of 1 year
9480700|NCT05261893|Experimental|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"In this we will use myofascial stretching Elongation Longitudinaux Avec Decoaption Osteo Articulaire for knee osteoarthritis. Each patient perform half kneeling posture with homolateral foot and knee in alignment with hip while knee flex to 90° and retrovulsion of the pelvis. Chin tucked in and head towards ceiling. Patient elbow and wrist in extension and arms in external rotation. In this homolateral arm directed anteriorly and pushing arm away from body and contralateral arm directed superiorly and tibia externally rotated.~This position maintained for 1 minute with 15 secs rest. This group will receive 40 mins of session."
9480701|NCT05261893|Experimental|Post Facilitation Stretching|"This group will receive post facilitation stretching technique. In this all the major muscles of the lower limb (quadriceps, hamstrings ,upper and lower calf muscles) are stretched .And the physiotherapist instruct the patient how to perform stretch . When we target a muscle and perform stretch patient feels sensation of stretch .~The stretch was hold on to 60 secs and repeated 3 times on each muscle group on each leg."
9480702|NCT05261880|Experimental|Neural mobilization|Neural mobilization will be given for 15 minutes with 3 repetitions. After mobilization, Kinesio taping will be applied and it will bandage till the next session.
10018337|NCT05158894||Ubrelvy-Exposed Women With Migraine|Pregnant women with migraine who took at least 1 dose of Ubrelvy, the exposure of interest, at any time during pregnancy as part of routine care.
10018338|NCT05158894||Unexposed Women With Migraine|Pregnant women with migraine (treated and untreated) who have never taken Ubrelvy (i.e., before or during the enrolled pregnancy) or who have discontinued Ubrelvy at least 3 months prior to the first day of last menstrual period (LMP).
10018339|NCT05158569|Experimental|Slow breathing exercise group|Slow breathing 5-6 breaths/minute, 3 sets of 5 minutes 2 times/day for 4 weeks.
10018340|NCT05158569|Experimental|Diaphragmatic breathing exercise group|Diaphragmatic breathing, 3 sets of 5 minutes 2 times/day for 4 weeks.
9480703|NCT05261880|Experimental|Scaphoid, hamate mobilization|Scaphoid and hamate mobilization for 20 minutes, at the end of session kinesio taping will bandage till the next session.
10018341|NCT05157620|Experimental|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
10018342|NCT05157620|Active Comparator|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
10018343|NCT05157555||"with laryngectomy group"|"with laryngectomy group: patients with laryngectomy for any type of cancer"
10018344|NCT05157529|Experimental|Aquablation|The participant will undergo aquablation procedure for Benign Prostate Hypeplasia (BPH) treatment using the AQUABEAM Robotic System and Ultrasound Accessories
10018345|NCT05157178|Experimental|4 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 4 week interval between the two doses.
10018346|NCT05157178|Experimental|8 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 8 week interval between the two doses.
10018347|NCT05157178|Active Comparator|12 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 12 week interval between the two doses.
10018348|NCT05157126|Experimental|Gentamicin|The intervention consists of 80mg of liquid gentamicin diluted in 5 mL normal saline (16mg/mL). The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
9476989|NCT03566407|Other|Single Group|This is a prospective, longitudinal descriptive study of subjects with diagnosed Crohn's disease. Blood samples for measurement of protein biomarkers (serology), fresh whole blood for detection of gene polymorphisms, and stool samples for detection and assessment of microbiome and host DNA will be collected, and colonoscopy will be performed.
9476990|NCT03566394|Experimental|Prophylactic Gabapentin|Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
9476991|NCT03566394|No Intervention|Observation|
9476992|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
9476993|NCT03566368||Study Group|Isolated Traumatic Brain Injury Patients requiring emergency surgical intervention.
9476994|NCT03566355|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
9476995|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
9476996|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
9476997|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
9476998|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
9476999|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
9477000|NCT03566329|Active Comparator|Magnesium sulphate|50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion
9477001|NCT03566329|Active Comparator|lidocaine hydrochloride|1.5mg/kg loading followed by 2mg/kg/hr infusion
9477002|NCT03566329|Placebo Comparator|NaCl 0.9% normal saline|Normal saline infusion with the same rate as the study drugs
9477003|NCT03566316|Experimental|Telmisartan/Amlodipine+Rosuvastatin|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
9477004|NCT03566316|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
9477005|NCT03566316|Active Comparator|Telmisartan +Rosuvastatin|Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.
9477006|NCT03566303|Active Comparator|Rivaroxaban|Rivaroxaban 15mg BID
9477007|NCT03566303|Placebo Comparator|Warfarin|Warfarin dose adjusted
9477008|NCT03566290|Experimental|Open-Label Extension, 3 mg GTx-024|Eligible subjects from G201002
9477009|NCT03566277|Experimental|Single-arm trial|All participants will undergo each of three conditions during the study.
9477010|NCT03566264||Participants hospitalized with ADHF|
9477011|NCT03566251|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS, Expanded Sisability Status Scale range of 0.5-4 who are able to walk independently.
9477012|NCT03566251|No Intervention|Healthy individuals|29 healthy volunteers with matching ages and genders
9477013|NCT03566225|Active Comparator|Group A|Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction
9477014|NCT03566225|Placebo Comparator|Group B|Metformin in adose 1500 mg dialy will be administered + clomiphene citrate
9477015|NCT03566212|Experimental|conventional syringe|Individuals requiring local anesthesia for dental treatment were treated in first group by using conventional syringe.
9477016|NCT03566212|Experimental|camouflaged syringe|Individuals requiring local anesthesia for dental treatment were treated in second group by using camouflage syringe.
9477017|NCT03566186|Experimental|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
9477018|NCT03566186|Placebo Comparator|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
9477019|NCT03566186|Other|non-treatment control group|(n=13) Phase 2 training + control group
10018349|NCT05157126|Placebo Comparator|Saline|The control consists of 5 mL normal saline injected immediately after wound closure at the open fracture site. The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
9477020|NCT03566160|Experimental|Cryobiopsy probe as a tool for biopsy|Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
9477021|NCT03566147|Experimental|low dose group|300,000 HuRPE cells
9477022|NCT03566147|Experimental|middle dose group|500,000 HuRPE cells
10018350|NCT05156320|Experimental|Main Efficacy Population (Apitegromab 10 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 10 mg/kg for up to 52 weeks.
10018351|NCT05156320|Experimental|Main Efficacy Population (Apitegromab 20 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
10018352|NCT05156320|Placebo Comparator|Main Efficacy Population (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
10018353|NCT05156320|Experimental|Exploratory Subpopulation (Apitegromab)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
10018354|NCT05156320|Placebo Comparator|Exploratory Subpopulation (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
10018355|NCT05156008|No Intervention|Group A|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by standard palpation of vein under strict aseptic measures. Application of tourniquet on upper arm, palpation of vein, disinfection of skin and insertion of cannula. After two unsuccessful punctures, UGVA operator will step in and perform insertion of cannula with ultrasound.~Medical staff will note:~number of attempts~time to obtain vascular access~type of cannula~DIVA score"
10018356|NCT05156008|Other|Group B|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by ultrasound guided vascular access under strict aseptic measures. With or without tourniquet applied on upper arm operator will prescan vasculature of arm to choose applicable vein. After disinfection of skin optimal vein is on plain part of arm and cannula must not end in flection (elbow, wrist) of arm.~Medical staff will note:~number of attempts, if 2 attempts fail, another operator will perform insertion~time to obtain vascular access~diameter of vein~type of cannula~DIVA score"
10018357|NCT05154240|Active Comparator|INS018_055|oral doses of INS018_055_single dose; oral doses of INS018_055_multiple ascending dose over 10days.
10018358|NCT05154240|Placebo Comparator|Placebo|No active ingredient. Frequency similar to the 2 arms above.
10018359|NCT05153915|Experimental|Tacrolimus granules (Modigraf)|"The first dose of Modigraf should be administered in the morning within 24 hours after reperfusion. Participants will be treated with a Modigraf-based immunosuppressive regimen.~The initial daily dose of Modigraf is given in two divided doses (recommended interval 12 hours) postoperatively. Subsequent oral Modigraf doses will be adjusted by the investigator based on clinical evidence of efficacy, occurrence of AEs, and tacrolimus whole blood trough level."
10018360|NCT05153278||Control group|Patients that received standard treatment (packed red blood cells) for iron deficiency anemia
10018361|NCT05153278||Experimental group|Patients that received intravenous iron instead of standard treatment (packed red blood cells) for iron deficiency anemia
10018362|NCT05153226|Experimental|Cyclophosphamide|Cyclophosphamide 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
10018363|NCT05153226|Active Comparator|ATG|ATG Grafalon 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
10018364|NCT05151601|Experimental|HMOs + Probiotics|"Dosing: A total daily dose of 2 x sachets (6g/day)~Product Comprised of:~2.5g of a proprietary blend of human milk oligosaccharides combined with~20 billion CFUs of a mixture of Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium animalis spp. lactis, and Bifidobacterium longum.~Mode of administration: oral."
10018365|NCT05151601|Placebo Comparator|Placebo|Dosing: A total daily dose of 2 x sachets (6g/day)u (8 weeks of phase 1A). Product: powdered maltodextrin. Mode of administration: oral.
10018366|NCT05150795|Active Comparator|Group Pregabalin|Patients will receive oral pregabalin capsule (150 mg) 90 min before induction of anesthesia, and will receive a bolus injection of 10 ml saline at induction of anesthesia
10018367|NCT05150795|Active Comparator|Group Fentanyl|Patients will receive oral placebo capsule identical to the trial drug in size, shape and color, 90 min before induction of anesthesia and will receive a bolus injection of 10 ml of 1µg /kg fentanyl at induction of anesthesia
10018368|NCT05150756|Active Comparator|Group Lidocaine|At induction of anesthesia, patients will receive a loading dose of intravenous (IV) 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% via infusion pump. The infusion will be continued till the end of surgery.
10018369|NCT05150756|Active Comparator|Group Morphine|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
9477023|NCT03566147|Experimental|high dose group|1,000,000 HuRPE cells
9477024|NCT03566134|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
9477025|NCT03566134|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
9477026|NCT03566134|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
9477027|NCT03566134|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
9477028|NCT03566121|Other|Continent women|Women with ICI-Q=0 Pelvic ultrasound / Urodynamic ultrasound
9477029|NCT03566121|Experimental|Incontinent women|Women with ICI-Q≥1 Pelvic ultrasound / Urodynamic ultrasound
10018370|NCT05150548||Entire Cohort|"Patients undergoing elective colectomy with data that has been collected in the NSQIP® Procedure Targeted Colectomy dataset from 2014-2019 with American Society of Anesthesiologists (ASA) Physical Status I-IV.~Patients will not be included in this cohort with urgent or emergency colectomy or indication for colectomy consisting of Acute diverticulitis, Enterocolitis (e.g. C. Difficile), and Volvulus, patients with disseminated cancer, wound infection, systemic sepsis or ventilator-dependence preoperatively."
10018371|NCT05149573|Active Comparator|4-Week Treatment with no Maintenance Period|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
9477030|NCT03566095|Active Comparator|Coaching and Voices for Food Kit|The treatment communities received community coaching from an Extension Professional or Educator in the use of the Voices for Food kit.
9477031|NCT03566095|Sham Comparator|Voices for Food Kit|The comparison community received the Voices for Food kit.
9518129|NCT03299582|Experimental|Cancer subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
10018372|NCT05149573|Sham Comparator|4-Week Sham Treatment with no Maintenance Period|Participants will be provided with a sham B. Body and B. Pad that appears identical to the active pulsed electromagnetic field (PEMF) device. The participant will lie the sham B. Body mat on any flat surface and lay on the mat with the smaller sham B. Pad placed directly over the pelvic area. The participant will be instructed to administer this sham treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the sham device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
10036149|NCT01813136|Experimental|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
9477032|NCT03566069|Experimental|Experimental Group|After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
9477033|NCT03566069|Placebo Comparator|Placebo Group|After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
9477034|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
9477035|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
9477036|NCT03566004|Other|endoscoped patients|Patients addressed for endoscopy with indication of biopsies for H. pylori detection will be enroled to provide stool specimen
9477037|NCT03565978|Experimental|BAMA solution|This group will use BAMA solution. This is an digital solution used for cardiac post-discharge management. It is an application installed on a tablet. This arm will use this application and also have usual outpatient follow up.
9477038|NCT03565978|No Intervention|Usual care|Not using the application installed on the tablet. Usual outpatient follow up.
9477039|NCT03565965|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
9477040|NCT03565965|Active Comparator|Control Group (CG)|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
9477041|NCT03565952|Experimental|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
9477042|NCT03565952|Active Comparator|Control Group|The control group does not receive treatment.
9477043|NCT03565926|Active Comparator|Manual Therapy|"Manual Therapy Protocol~Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
9477044|NCT03565926|Experimental|Hypopressive exercises|Protocol of 5 Hypopressive Exercises
9477045|NCT03565861|Placebo Comparator|Placebo|Placebo intravenous 30 minute infusion on day 1
9477046|NCT03565861|Experimental|NP10679 5 mg|NP10679 5 mg intravenous infusion on day 1
9477047|NCT03565861|Experimental|NP10679 15 mg|NP10679 15 mg intravenous infusion on day 1
9477048|NCT03565861|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion on day 1
9477049|NCT03565861|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion on day 1
9477050|NCT03565861|Experimental|NP10679 200 mg|NP10679 200 mg intravenous infusion on day 1
9477051|NCT03565861|Experimental|NP10679 300 mg|NP10679 300 mg intravenous infusion on day 1
9477052|NCT03565848||Women underwent colorectal resection for endometriosis|Women referred for colorectal resection for deep infiltrating endometriosis that underwent laparoscopic segmental colorectal resection performed with mesenteric vascular and nerve sparing surgery.
9477053|NCT03565822|Other|interview|There are two data collection phases (individual interviews +/- focus groups) with parents of children with esophageal atresia, congenital diaphragmatic hernia or short bowel syndrome.
9477054|NCT03565809||Case : ADRS group|"Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: F00-F03, G30, or G31), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine or donepezil) or memantine."
9518130|NCT03299582|Experimental|Cancer subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
10036150|NCT01813162|Active Comparator|Tenofovir 1% gel|Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
10037620|NCT01826695|Placebo Comparator|Placebo group|35 women are recruited in order to the inclusion criteria for the study. Placebo controlled. They received only standard treatment without neurodynamic intervention. They are diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and end.
10036151|NCT01813162|Active Comparator|Vaginal product alone|"Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen)."
9518131|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
10037621|NCT01826695|Active Comparator|Neurodynamic technique group|35 women are recruited, diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and at the end.
10037622|NCT01826708|No Intervention|Psychomotor retardation syndromic|Psychomotor retardation syndromic by Identification of breakpoints
10037623|NCT01826721|No Intervention|Standard of Care|Patients in the Standard of Care arm receive the usual in-hospital post-transplant medication teaching class led by a transplant pharmacist.
10037395|NCT01824797||Roux-en-Y Gastric Bypass|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
10037396|NCT01824797||Sleeve Gastrectomy|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
10037624|NCT01826721|Active Comparator|TMITT|Patients in this arm receive the standard of care plus the TMITT educational intervention.
9477055|NCT03565809||Control : non ADRS Group|Incidence analysis in non ADRS group. Each incident ADRS case was paired (1:1) to a beneficiary without any ADRS criteria, matched on age (same birth year), sex, residence area (based on of the 100 administrative 'départements') and insurance scheme.
9477056|NCT03565796|Experimental|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
9477057|NCT03565796|Experimental|Group B|AWARD advice + COSH booklet
9477058|NCT03565770|Experimental|standard care + coaching|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving individual coaching and usual standard care
9477059|NCT03565770|Sham Comparator|Standard care|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving usual standard care only.
9477060|NCT03565757|Experimental|SMART intervention|90-minute SMART small group session
9477061|NCT03565731|Experimental|ACT-PA Intervention|The primary goal of the intervention is to increase values-based autonomous motivation to increase bout-related MVPA using a single workshop. Participants will engage in basic and advanced values clarification exercise to help clarify (1) the relative importance of major values domains (e.g. social, vocational, recreational), and (2) the potential role of PA in empowering functioning in these domains. Participants will generate their own activity goals and additional values-based goals. In addition, acceptance strategies will be taught to reduce cognitive and emotional barriers to meeting values-based goals. Participants will be asked to report progress on goals each week via an automated email survey from a secure project website. Upon completing the survey, participants will receive standardized responses via email. Monthly phone calls will be brief, semi-structured, and designed to review key principles and trouble-shoot specific barriers identified by the participant.
9477062|NCT03565718|Active Comparator|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
9477063|NCT03565718|Experimental|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
10037397|NCT01824810|Experimental|Intramuscular Stimulation|Participants in this group will receive up to 12 sessions of Intramuscular Stimulation (IMS). Each session may last from 30 to 60 minutes. Primary and secondary outcome measures will be assessed prior to the first treatment, after completion of the last treatment, and 6 months after treatment is complete.
10037398|NCT01824810|Experimental|myoActivation|Participants in this group will receive up to 12 sessions of myoActivation treatment. Each treatment is approximately 15 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
9518132|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
9477064|NCT03565705||Spinal anesthesia with propofol sedation|Patients receive spinal anesthesia for analgesia to undergo open abdominal prostatectomy. Ventilation is secured via a laryngeal mask under propofol sedation and no muscular blocking is necessary.
9477065|NCT03565705||General anesthesia|General anesthesia is conducted with a combination of intravenous opioid (sufentanil) and neuromuscular blocking agent for open abdominal prostatectomy. Patients receive an induction bolus of propofol, undergo tracheal intubation and maintenance of sedation by sevoflurane.
9477066|NCT03565692||Patients treated by LUMACAFTOR-IVACAFTOR|Patients treated by LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) Patients over 6 years who are currently able to benefit from LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) according the mutation eligibility criteria and for whom conventional microbiological analysis of sputum samples and stool will be collected during their follow-up after the treatment onset.
9477067|NCT03565653|Experimental|High dietary salt|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing uniodized table salt. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
9477068|NCT03565653|Experimental|Placebo|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing a placebo (dextrose). Participants will complete both interventions in random order. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
9477069|NCT03565627|Experimental|Exercise app|7 Minute Workout Challenge by Fitness Guide Inc.
9477070|NCT03565627|Experimental|Running App|One You Couch to 5K by Public Health England
9477071|NCT03565614|Experimental|Reablement rehabilitation|Reablement rehabilitation to maintain or increase the participants' physical, psychological and social functional abilities.
9477072|NCT03565614|Active Comparator|Traditional home care|The traditional home care and required rehabilitation efforts as by the municipality's current practice.
9477073|NCT03565601||CTD patients with anti-Ro52 antibodies|Connective tissue disease patients with anti-Ro52 antibodies at diagnosis
9477074|NCT03565601||CTD patients without anti-Ro52 antibodies|Connective tissue disease patients without anti-Ro52 antibodies at diagnosis
9477075|NCT03565588|Experimental|Education session with fixed incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs to the health facility with payments conditional on being circumcised.
9477076|NCT03565588|Experimental|Education session with lottery incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs but with conditional lottery financial incentives.
9477077|NCT03565588|No Intervention|Control arm|No intervention will be administered to the control arm
9477078|NCT03565575|Experimental|Interactive tablet-based quiz|Individuals participate in an interactive tablet-based risk perception and PrEP counselling information session.
9477079|NCT03565575|No Intervention|Control arm|No intervention will be administered to the control arm
9477080|NCT03565562|No Intervention|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the 12 first months. Free access to StopBlues.
9477081|NCT03565562|Active Comparator|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops…). Free access to StopBlues.
9477082|NCT03565562|Active Comparator|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
9477083|NCT03565549|Experimental|Mnemonic|Intervention group will receive a mnemonic aid to remember the CCHR
9477084|NCT03565549|Active Comparator|CCHR rule|The control group will receive the CCHR only
10018373|NCT05149573|Active Comparator|4-Week Treatment with 1-Week-Per-Month Maintenance Period for an Additional 3 Months|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will keep the device and use it for 1 week (7 days) during the last week of the month for the following 3 months. Each participant in this group will be asked to complete a set of electronic questionnaires immediately following their week-long maintenance treatment during the last 3 months of the study.
10018374|NCT05148871|Active Comparator|3 week arm|Subjects will receive two doses of vaccine 3 weeks apart
10018375|NCT05148871|Active Comparator|4 week arm|Subjects will receive two doses of vaccine 4 weeks apart
10018376|NCT05148871|Active Comparator|5 week arm|Subjects will receive two doses of vaccine 5 weeks apart
10018377|NCT05148871|Active Comparator|6 week arm|Subjects will receive two doses of vaccine 6 weeks apart
10018378|NCT05148481|Experimental|BIIB104: Dose 1|Japanese and non-Japanese participants will receive BIIB104, Dose 1, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
10018379|NCT05148481|Experimental|BIIB104: Dose 2|Japanese and non-Japanese participants will receive BIIB104, Dose 2, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
10018380|NCT05148481|Placebo Comparator|Placebo|Japanese and non-Japanese participants will receive BIIB104-matching placebo, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
10018381|NCT05148078||General Anesthesia Decrease use : PROMISE|To decrease the total number of pediatric patients who require general anesthesia through the use of PROMISE
10018382|NCT05147584|Experimental|Interventional/Observational|The internal and external oxygen sensors will be used to record fetal oxygen during active labor and these will be be compared to the CTG retrospectively.
10018383|NCT05146778|Active Comparator|Opioid-free anesthesia group|OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.
10018384|NCT05146778|Active Comparator|Conventional anesthesia group with opioid|Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.
10037399|NCT01824810|Experimental|Neural Prolotherapy|Participants in this group will receive up to 12 sessions of neural prolotherapy. treatment. Each treatment is approximately 30 to 60 minutes minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
10037625|NCT01826734||Patients with dacryolits|The study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.
10018385|NCT05146726||BARMER insured patients|"Group I: BARMER insured patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion > 10%.~Central measures in this group are the IV contract for the creation of an organizational and financing structure for the guideline-compliant detection, diagnosis and treatment of preoperative anemia and the evaluation of the machine autotransfusion as part of the preoperative premedication visit in anesthesiology (implementation is the responsibility of the patient blood management (PBM) service)."
10018386|NCT05146726||Patients insured with another statutory health insurer than BARMER|Group II: Patients not insured with BARMER and with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion > 10% and receive early anemia detection.
9518133|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
9477085|NCT03565536|Experimental|Nexavar neoadjuvant treatment group|"After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.~operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.~then External radiation therapy after surgery."
9477086|NCT03565523|Experimental|Test Beet shot|Containing 385 mg nitrate
9477087|NCT03565523|Placebo Comparator|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
9477088|NCT03565510|No Intervention|Control|Those assigned to the Control group will receive a diet composed of 55% of carbohydrate, 15% of protein, and 30% of lipid (similar to the North American dietary pattern).
9477089|NCT03565510|Experimental|High-Protein Diet|Those assigned to the High-Protein Diet group will receive a diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based total diet replacement.
9518134|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
10037626|NCT01826747|Experimental|experimental|Luteal Phase support
10037627|NCT01826747|No Intervention|control|No luteal Phase support
10018387|NCT05145595|Experimental|Psychophysical assessments of experimental pain|"At baseline, participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed and sex hormone levels will be analyzed. In addition, demographic, social, pubertal maturation, behavioral and psychological factors will be collected via questionnaires.~In the optional follow-up portion, participants can complete short surveys every 3 months and/or return for study visits every year depending on the participant's availability. The study visits will include the same procedures as the baseline study visit. Additional surveys regarding new symptoms of pain will be completed. In some cases, participants will meet a pediatric physician who will determine if they meet the criteria for any pain syndrome (for research purposes only)."
10018388|NCT05145426|Experimental|Pain Trials|Multi visit - LIFU/Sham application, with quantitative sensory testing (using peltier device).
10018389|NCT05144828|Experimental|Intercostal Nerve Cryoablation plus Standard of Care (SOC) Pain Control|Intercostal nerve cryoablation using the CryoICE® CRYO2 cryoablation probe plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
10018390|NCT05144828|Active Comparator|Standard of Care (SOC) Pain Control|Prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
10018391|NCT05144763|Experimental|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
10018392|NCT05144763|No Intervention|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
10018393|NCT05143983|Active Comparator|depressed subjects, positive valence music listening at first|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to positive musical excepts (3 minutes)
10018394|NCT05143983|Other|depressed subjects, neutral valence music listening|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to neutral valence musical excepts (3 minutes)
10018395|NCT05143983|Other|healthy controls, positive valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to positive valence musical excepts (3 minutes)
10018396|NCT05143983|Other|healthy controls, neutral valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to neutral valence musical excepts (3 minutes)
10018397|NCT05143385|No Intervention|Control|"The variables to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: Mississippi Aphasia Screening test, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfreiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16., Will be performed on all patients who are part of the trial.~Those patients where conventional rehabilitative treatment is performed will be:~Physiotherapy sessions~Speech therapy sessions~Neuropsychology sessions~Occupational therapy sessions"
10018398|NCT05143385|Experimental|Intervention Group|The variables are to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: MAST, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfeiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16.The beginning of the intervention will be once you have completed 15 calendar days from your admission.The intervention will be carried out once a week with a duration of 20 min with one of the games chosen by the patient together with the physiotherapist.The completion of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions carried out in order to participate in the study.A registration table will be executed where the number of sessions of each patient and the type of session are quantified like a control group.
10018399|NCT05142787|Other|axillary lymph nodes requiring localisation prior to surgical excision|"The Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
10018400|NCT05142787|Other|breast lesions requiring localisation|"The Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
9518135|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
10018401|NCT05142566|Experimental|Ultrasound Closure|Open label, single arm study using ultrasound guidance during MANTA device deployment.
10018402|NCT05142449|Experimental|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day.
10018403|NCT05142449|Placebo Comparator|Placebo|Patients receive 8 capsules Placebo perioperatively and for the next 3 days 6 capsules per day.
9518136|NCT03299543||Healthy adults|Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples
9518137|NCT03299530||patients with corneal astigmatism|Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.
10018404|NCT05141513|Other|Intra Operative Radiation Therapy (IORT) Group|The IORT group is the single arm of this study. Enrolled patients who undergo standard of care treatment will also receive a study treatment of High Dose Rate (HDR) Intra Operative Radiation Therapy.
10018405|NCT05141344|Active Comparator|melatonin group|patients in this group will be premedicated One hour before the start of surgery by receiving 0.5mg/kg orally of melatonin (Melatonin 3 mg ), (the tablet will be dissolved in 5 ml of water, to be given by syringe 5ml) in the preoperative unit
10018406|NCT05141344|Placebo Comparator|placebo group|patients in group P (n =25 ) will receive a placebo( sugary tablets dissolved in 5ml of water by syringe 5 ml) one hour before the start of surgery.
10018407|NCT05140278|Experimental|1-step Artesunate parenteral arm|Argesun (Artesunate 60 mg)
10018408|NCT05140278|Experimental|2-step Artesunate parenteral arm|Artesun (Artesunate 60 mg)
10018409|NCT05140239||AbroSkib Cohort|Adult patients with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare (n=20). The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.
10018410|NCT05139316|Experimental|DTX401, Then Placebo|Participants receive single peripheral intravenous (IV) infusion of DTX401 in solution. At week 48 participants receive single peripheral IV infusion of Placebo.
10018411|NCT05139316|Placebo Comparator|Placebo, Then DTX401|Participants receive single peripheral IV infusion of Placebo. At week 48 eligible participants receive single peripheral IV infusion of DTX401 solution.
10018412|NCT05138822|Experimental|GSK3882347 + Placebo|Participants will be administered GSK3882347 plus placebo.
10018413|NCT05138822|Active Comparator|Nitrofurantoin+ Placebo|Participants will be administered nitrofurantoin plus placebo.
10018414|NCT05138549|Placebo Comparator|Control: Placebo Group|Patients will receive a 6 week daily oral supply of placebo, identical in appearance to the astaxanthin supplement.
10018415|NCT05138549|Active Comparator|Experimental: Astaxanthin Supplementation Group|Patients will receive a 6 week daily oral supply of 12 mg astaxanthin supplement.
10018416|NCT05137067|Other|Chemotherapeutic agent A (Docetaxel)|The patients with breast cancer will receive chemotherapeutic agent A
10018417|NCT05137067|Placebo Comparator|Chemotherapeutic agent A (Docetaxel) plus placebo|The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.
10018418|NCT05137067|Active Comparator|Chemotherapeutic agent A (Docetaxel) plus RaproCell|The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.
10018419|NCT05137067|Other|Chemotherapeutic agent B (Cisplatin)|The patients with lung cancer will receive Chemotherapeutic agent B
10018420|NCT05137067|Placebo Comparator|Chemotherapeutic agent B (Cisplatin) plus placebo|The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.
10018421|NCT05137067|Active Comparator|Chemotherapeutic agent B (Cisplatin) plus RaproCell|The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.
10018422|NCT05137067|Other|Chemotherapeutic agent C (Docetaxel)|The patients with prostate cancer will receive Chemotherapeutic agent C
10018423|NCT05137067|Placebo Comparator|Chemotherapeutic agent C (Docetaxel) plus placebo|The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.
10018424|NCT05137067|Active Comparator|Chemotherapeutic agent C plus (Docetaxel) RaproCell|The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.
10018425|NCT05136885|Experimental|SLS-005|SLS-005 is administered via infusion once weekly for 24 weeks.
10018426|NCT05136885|Placebo Comparator|Matching Placebo|Matching placebo is administered via infusion once weekly for 24 weeks.
10018427|NCT05136417|Experimental|left atrial appendage (LAA) occlusion with the WATCHMAN FLX device using (ICE)|100 patients undergoing LAA closure with the WATCHMAN FLX utilizing an intra-procedural ICE probe under moderate sedation.
10018428|NCT05136157|Active Comparator|Study group|Bolus-Infusion approach of rapidly acting crystalline insulin. The patient intra-operative blood glucose will be divided by 100. The resultant rapidly acting crystalline insulin units will be given intravenously over 10 minutes, and then continued as an intra-venous infusion per hour. The Capillary Blood Glucose (CBG) will be measured every 30 minutes and in the PACU with readjustment of the bolus-infusion dose as required
10018429|NCT05136157|Active Comparator|Control group|The sliding scale approach of rapidly acting crystalline insulin will be used according to the intra-operative blood glucose; 4 IU of insulin will be given when the CBG 180-250 mg/dl, 6 IU of insulin will be given when the CBG 251-300 mg/dl, 8 IU of insulin will be given when the CBG 301-350 mg/dl and 10 IU of insulin will be given when the CBG 351-400 mg/dl (5). The CBG will be measured every 30 minutes and in the PACU.
10018430|NCT05136131|Experimental|True cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. The unblinded non-MRP cardiologist will call out as per usual All clear, following which a shock is delivered as per the Ottawa Cardioversion Protocol in the 'shock' arm."
10018431|NCT05136131|Sham Comparator|Sham cardioversion|"Following anaesthesia administration, the unblinded team (non-MRP cardiologist / anesthesiologist will open the envelope indicating which arm the patient has been randomized to. Other members of the team will step out of the room. No shock is delivered in the sham shock arm."
10018432|NCT05136118|Active Comparator|Group MS|The modified surgeon assisted approach for TAPB Before the closure of the peritoneum, TAPB will be performed; at the level of the umbilicus 8 to 10cms from the midline bilaterally. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin slightly directed towards the ipsilateral anterior superior iliac spine. After feeling the 2 pops of the external and the internal oblique aponeurosis by the anesthesiologist, the surgeon will confirm proper needle placement by his hand inside the abdominal cavity. The LA will be injected after negative aspiration and a bleb will be palpated by the surgeon as the injection continues. The same procedure will be repeated on the other side.
9477090|NCT03565497|Placebo Comparator|Wellness Education Control Condition|The wellness education control condition (CC) is modeled after that used in our studies of exercise for smoking cessation, but delivered in an individual format. Content focuses on discussions of a variety of healthy lifestyle topics, such as healthy eating, time management, recommended health screenings, and cancer and cardiovascular prevention. Content is delivered using a combination of lectures, videos, handouts, and discussions while allowing participants to set their own realistic wellness goals, which they can gradually incorporate into their lives.
9477091|NCT03565497|Experimental|Mindfulness Training (MT)|Mindfulness training will be adapted for 6 individual sessions;elements include: (1) a body scan designed to teach participants to pay attention to specific parts of their bodies as a strategy to increase attentional capacities/reduce habitual mind-wandering; (2) non-judgmental awareness, and (3) 'awareness of breath' meditation, with an additional focus on helping participants become more aware of the present moment and refrain from habitually engaging in self-related pre-occupations concerning the future or the past.
9477092|NCT03565497|Experimental|Mindfulness Training Plus IE (MT+IE)|This condition will mirror the MT condition for the first 4 individual sessions, then for the final 2 individual sessions, MT will be rehearsed under conditions of sensations of anxiety/tension induced by interoceptive exposure procedures (IE).
9477093|NCT03565484|Experimental|Antimicrobial susceptibility testing guided therapy|14d bismuth quadruple therapy based on susceptibility test.
9477094|NCT03565484|Experimental|Personal medication history guided therapy|14d bismuth quadruple therapy based on previous medication history.
9477095|NCT03565484|Other|Salvage therapy for negative culture|14d bismuth quadruple therapy based on previous medication history.
9477096|NCT03565484|Other|Salvage therapy for failed eradication|14d bismuth quadruple therapy for salvage treatment.
9477097|NCT03565471||ASD patients with surgical closure|"Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
9477098|NCT03565471||ASD patients with transcatheter closure|"Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
9477099|NCT03565471||Controls|"Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
9477100|NCT03565458|Experimental|gemigliptin|gemigliptin single dose
9477101|NCT03565458|Experimental|dapagliflozin|dapagliflozin single dose
9477102|NCT03565458|Experimental|gemigliptin and dapagliflozin|co-administration of gemigliptin and dapagliflozin
9477103|NCT03565458|Experimental|empagliflozin|empagliflozin single dose
9477104|NCT03565458|Experimental|gemigliptin and empagliflozin|co-administration of gemigliptin and empagliflozin
9477105|NCT03565432||IBD in KHUH|Registered patients with Inflammatory bowel disease at Kyung Hee University Hospital
10018433|NCT05136118|Active Comparator|Group US|The ultra-sound guided approach for TAPB. After abdominal wall closure, the linear probe of the ultra- sound will be placed perpendicular to the skin at the mid-axillary line between the iliac crest and the costal margin; the TAP will be located between the internal oblique and the transversus abdominis muscle. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin and the 2 pops of the external and the internal oblique aponeurosis will be also felt. The LA will be injected after negative aspiration and its spread in the plane will be observed. The same procedure will be repeated on the other side.
10018434|NCT05135871|Experimental|Cohort 1: Mavacamten 15 mg|Cohort 1: 15 mg capsules × 1 on Day 1
10018435|NCT05135871|Experimental|Cohort 2: Mavacamten 25 mg|Cohort 2: 10 mg capsules x 1 and 15 mg capsules x 1 on Day 1
10018436|NCT05135871|Experimental|Cohort 3: Mavacamten 15 mg|Cohort 3: 15 mg capsules × 1 on Day 1
10018437|NCT05135871|Experimental|Cohort 4: Mavacamten 15 mg|Cohort 4: 15 mg capsules × 1 on Day 1
10018438|NCT05135559|Experimental|Concizumab-naïve patients|Concizumab-naïve participants below 12 years of age at the time of consent/assent
10018439|NCT05135559|Experimental|Patients comming from compassionate use|Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807
10018440|NCT05134974|Active Comparator|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
10018441|NCT05134974|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
10018442|NCT05133648||Hip Surgery without COVID-19 infection|May to December 2020
10018443|NCT05133648||Hip Surgery with COVID-19 infection|May to December 2020
10018444|NCT05133648||Hip Surgery pre-pandemic|from January 2017 to December 2019
10018445|NCT05133427|Experimental|Areas with de-novo or recurrent BCC|Areas with non-nodular de-novo or recurrent BCC area will be treated by high intensity focused ultrasound.
10018446|NCT05133271|Experimental|Scheduled cesarean section|Patient with scheduled cesarean section under spinal anesthesia.
10018447|NCT05133115|Experimental|Intervention Group|Schools with adolescents aged 12 to 15 in a context at risk. They will follow the intervention for 6 weeks (6 sessions, once a week).
10018448|NCT05133115|No Intervention|Control Group|Schools in the control group will be all waitlisted to receive the intervention during the following academic year should it prove effectiveness. They will fill in the same research questionnaires as the Intervention group and at the same time period (winter 2022, spring 2022 and autumn 2022).
10018449|NCT05132803|Experimental|Main Vaccination Arm|Participants will receive the HPV 16 TA-CIN vaccine.
10018450|NCT05132439|Experimental|Metformin ER 1000mg|daily by mouth
9477106|NCT03565419|No Intervention|Control|Participants conduct the ultrasound-guided peripheral cannulation while they confirm real-time images displayed on the viewer next to the phantom.
9477107|NCT03565419|Experimental|Intervention|Participants conduct the ultrasound-guided peripheral cannulation wearing smart glasses. They confirm real-time images displayed on the viewer of smart glasses.
9477108|NCT03565406|Experimental|Unresectable Stage III or Stage IV Melanoma|
9477109|NCT03565393|Placebo Comparator|Fibersol-2|Receive Fibersol-2 twice daily
10018451|NCT05132439|Placebo Comparator|Matching placebo|daily by mouth
10018452|NCT05132114|No Intervention|Control Group|LLETZ (without intraoperative Lugol's iodine)
10018453|NCT05132114|Experimental|Iodine group|LLETZ after the intraoperative application of Lugol's iodine
10018454|NCT05131074|Experimental|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions.
10018455|NCT05131074|Experimental|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions.
10018456|NCT05131074|No Intervention|Control Group|Patients will not receive the Collabree application.
10018457|NCT05129189|Experimental|ASC22 group|ASC22 1mg/kg hypodermic injection Q4W+Chidamide 10mg PO BIW
10018458|NCT05129137|Experimental|FDC nefopam hydrochloride 30mg / paracetamol 500mg|Single dose: 2 tablets
9477110|NCT03565393|Placebo Comparator|Placebo|Receive placebo twice daily
9477111|NCT03565367|Experimental|Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).
10018459|NCT05129137|Active Comparator|nefopam hydrochloride 30mg|Single dose: 2 tablets
10018460|NCT05129137|Active Comparator|paracetamol 500mg|Single dose: 2 tablets
10018461|NCT05129137|Active Comparator|nefopam hydrochloride 30mg and paracetamol 500mg|Single dose: 2 tablets
10018462|NCT05128968|Experimental|Simple extension|After induction of anesthesia, endotracheal intubation was performed in simple extension without a pillow using a McGrath MAC videolaryngoscope.
10018463|NCT05128968|Experimental|Head lift|After induction of anesthesia, endotracheal intubation was performed in a head lift position with a pillow using a McGrath MAC videolaryngoscope.
10018464|NCT05128968|Experimental|Sniffing position|After induction of anesthesia, endotracheal intubation was performed in a sniffing position using a McGrath MAC videolaryngoscope.
9477112|NCT03565354|Active Comparator|Treatment arm|intravenous iron isomaltose 3-10 weeks before operation date. The dose will be determined by the patient's body weight: > 50kg: 1000mg; <50kg: 20mg/kg body weight, to be infused over 30 minutes. 2 weeks after intravenous iron isomaltoside administration, blood test for hemoglobin level and iron profile would be repeated. Subjects with hemoglobin level less than 10g/dL will receive a second dose of intravenous iron isomaltoside. The second dose would be identical to the first dose
9477113|NCT03565354|No Intervention|Control arm|Patient randomized to the control arm will follow the standard perioperative care and the perioperative management they received will be identical to the treatment arm except no intravenous iron isomaltoside will be given.
9477114|NCT03565341|Experimental|Melasma|Treatment of Melasma Using PiQo4 Laser System
9477115|NCT03565302|Placebo Comparator|Control|Subjects receive placebo treatment
10037400|NCT01824810|Sham Comparator|Sham Needling Control|Participants in this group will receive up to 12 sessions of sham needle treatment. Each treatment is approximately 15 to 60 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
10037401|NCT01824836|Experimental|Supportive care (anastrozole)|Patients receive anastrozole PO QD for 12 months.
10018465|NCT05126433|Experimental|Urothelial Cancer Cohort|Participants with advanced (metastatic and/or unresectable) urothelial carcinoma who have progressed on platinum-containing regimen without any restriction on number of prior lines of therapies will receive Lurbinectedin 3.2 mg/m^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
10037402|NCT01824849|Experimental|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients.
10018466|NCT05126433|Experimental|Large Neuroendocrine Tumor of the Lung Cohort|Participants with advanced (metastatic and/or unresectable) large neuroendocrine tumor of the lung who have progressed on platinum-containing regimen without any restriction on number of prior lines of therapies will receive Lurbinectedin 3.2 mg/m^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
10037403|NCT01824849|Experimental|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients.
10037404|NCT01824862||eyes without diabetic retinopathy|eyes of patients with diabetes mellitus type 2 that does not have retinopathy
10037405|NCT01824862||CSME without centre involvement|eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
10037406|NCT01824862||CSME with centre involvement|eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
10037407|NCT01824888|Active Comparator|Control|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
10037408|NCT01824888|Experimental|JUC solution|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by pouring 1.5 ml of JUC into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
9477116|NCT03565302|Experimental|Long acting beta2-agonist|Subjects are treated with long-acting beta2-agonist formoterol
10037409|NCT01824914|Experimental|McGrath Videolaryngoscope|to compare the Cormack-Lehane grade in sedation and anesthesia by McGrath videolaryngoscope
10037410|NCT01824927|Active Comparator|First eye (FE)|Phacoemulsification cataract extraction surgery of first eye
10018467|NCT05126433|Experimental|Homologous Recombination Deficient-Positive Solid Tumor Malignancy Cohort|Participants with advanced (metastatic and/or unresectable) endometrial, biliary tract, urothelial, breast (TNBC or HR+HER2- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation who have progressed on platinum-containing regimen and received no more than 3 prior lines of chemotherapies for advanced/metastatic disease will receive Lurbinectedin 3.2 mg/m^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
10037411|NCT01824927|Active Comparator|Second eye (SE)|Phacoemulsification cataract extraction surgery of second eye
9477117|NCT03565302|Experimental|Short acting beta2-agonist|Subjects are treated with short-acting beta2-agonist terbutaline
9477118|NCT03565289||All patients|All
9477119|NCT03565276|Experimental|Experimental: TXA|Intravenous Tranexamic Acid beginning at 5mg/kg administered as part of a dose-escalation design.
10018468|NCT05126251|Experimental|Tangningtongluo group|"Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (1.6g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~Lifestyle intervention"
9477120|NCT03565263||FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~with at least one Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
9477121|NCT03565263||No FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~not a single Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
9477122|NCT03565250|Experimental|ADHD patients|children aged 8-12 ans with ADHD
9477123|NCT03565250|Active Comparator|control|children aged 8-12 ans without ADHD
9477124|NCT03565224||Cespace|The patients have been operated with Cespace Titanium Coated PEEK Cage for Degenerative Disc Disease between 2014 and 2017. All patients are invited to the Hospital for Follow-Up. Depending on the date of Initial Intervention the timeframe of follow-up for the individual Patient is 1 to 4 years.
9477125|NCT03565185|Active Comparator|End-effector|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training(end-effector type-Lokohelp) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
9477126|NCT03565185|Active Comparator|Exoskeleton|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training (exoskeleton type-Robogait) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
9477127|NCT03565185|Placebo Comparator|conventional treatment|conventional treatment methods for stroke rehabilitation 5 days a week Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level.
10037412|NCT01824927|Experimental|Steroids eye drops|Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery
10018469|NCT05126251|Placebo Comparator|Placebo group|"Placebo of Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (2.0g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks.~2） Lifestyle intervention"
10037413|NCT01824940|Placebo Comparator|Standard of Care|The Standard of Care interventions are the blanket interventions.
10037414|NCT01824940|Active Comparator|WASH|"One of two active interventions to be studied in this 2X2 (two by two) Factorial trial:~Intervention 1: a package of interventions to improve household sanitation and hygiene (WASH)"
10018470|NCT05124132|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) as delivered in the parent study (Protocol ID #201410093) consisted of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content included instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life. For the current study, participants will continue monthly approximately 2.5 hour booster sessions covering similar content for the duration of the study. Participants will be encouraged to maintain daily formal meditative activities at home.
10037415|NCT01824940|Active Comparator|Nutrition|"One of two active interventions to be studied in this 2X2 Factorial trial:~Intervention 2: a package of interventions to improve infant and young child feeding (IYCF)"
10037416|NCT01824940|Active Comparator|WASH and Nutrition|This arm receives a combination of all standard care interventions, all WASH and all IYCF interventions.
10037417|NCT01824953||atrophy-/Hp- group|Subjects without Helicobacter pylori infection and without atrophy
9518138|NCT03299517|Experimental|lidocaine|"Initial dose: antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).~Adittional dose: Lidocaine (0.75 mg / kg EV in 30 minutes)."
10037418|NCT01824953||atrophy-/Hp+|Subjects with Helicobacter pylori infection and without atrophy
10037419|NCT01824953||atrophy+/Hp+|Subjects with Helicobacter pylori infection and with atrophy
9477128|NCT03565172|Experimental|Children with spastic cerebral palsy|"Children with spastic cerebral palsy will be included. They will have 3 phases:~Baseline: 4, 5 or 6 evaluations~Intervention: 9 evaluations before and after every stretching session~Follow-up: 4, 5 or 6 evaluations~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology."
9477129|NCT03565159|Active Comparator|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
9477130|NCT03565159|Placebo Comparator|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
9477131|NCT03565146|Experimental|Pigmentation|Treatment of Pigmented Lesions Using PiQo4 Laser System
9477132|NCT03565133|Experimental|Oral quinine, gastric placebo|Oral sham feeding of quinine and a gastric capsule containing placebo (cellulose)
9477133|NCT03565133|Experimental|Oral placebo, gastric quinine|Oral sham feeding of placebo (tap water) and a gastric capsule containing quinine
9477134|NCT03565133|Experimental|Oral quinine, gastric quinine|Oral sham feeding of quinine and a gastric capsule containing quinine
10037420|NCT01824953||atrophy+/Hp-|Subjects without Helicobacter pylori infection and with atrophy
10018471|NCT05124132|Experimental|Exercise|The exercise protocol in the parent study (Protocol ID #201410093) was optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty. It consisted of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months. For the current study, participants will continue monthly approximately 1.5 hour classes focused on functional training for the duration of the study. Participants will be encouraged to continue between-session engagement in aerobic and resistance training activities at home.
10018472|NCT05124132|Experimental|Mindfulness-Based Stress Reduction + Exercise|This condition will receive both MBSR and exercise as described. Participants in this condition will attend monthly sessions with encouragement to complete at-home mindfulness practice as well as at-home exercise for the duration of the study.
10018473|NCT05124132|Active Comparator|Health Education|The health education control condition is based on a chronic disease self-management program developed at Stanford University and was used as an attentional control in the parent study (Protocol ID #201410093). This control intervention was designed to be time-equivalent to MBSR, with 8 weeks of 2.5 hour weekly group classes followed by monthly booster sessions for approximately 15 months. For the current study, participants will continue monthly approximately 1.5 hour sessions covering similar content for the duration of the study.
10018474|NCT05123885||Experimental:|Adult patients who benefited, between the start of 2015 and January 1, 2021, from a LifeVest after a myocardial infarction, followed by the implantation of an ICD before March 1, 2021.
10037421|NCT01824966||SRC<50%|Adenocarcinoma containing < 50% of signet ring cells
10037422|NCT01824966||SRC>50%|Adenocarcinoma containing > 50% of signet ring cells
10037423|NCT01824992|No Intervention|Observation|subject only got observation
10037424|NCT01824992|Experimental|Drug|subject were treated with Yallaferon®， the recombinant human interferon α-2b gel
10037425|NCT01825005||group 1:surgery|treatment = surgery only
10037426|NCT01825005||group 2: radiotherapy|treatment = radiotherapy only
10037427|NCT01825005||group 3: RT and CT, and/or hyperthermia|treatment= radiotherapy combined with chemotherapy and/or hyperthermia
9477135|NCT03565133|Placebo Comparator|Oral placebo, gastric placebo|Oral sham feeding of placebo (tap water) and a gastric capsule containing placebo (cellulose)
9477136|NCT03565120|Experimental|Arm-R|patients in this arm will receive aggressive thoracic radiotherapy.
10018475|NCT05123755|Active Comparator|AV-001 Injection with standard of care (SOC).|A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3 and to be determined (TBD) in cohort 4. The dose for cohort 4 will be determined by the Data Safety Monitoring Board (DSMB) based on emerging data from cohorts 1, 2 and 3.
10018476|NCT05123755|Placebo Comparator|AV-001 Placebo Injection with standard of care (SOC).|A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).
9477137|NCT03565094|Experimental|Lu AF28996|"Lu AF28996 solution, cohort depending dose~Part A:~Cohort 1: single oral dose of Lu AF28996~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects~Part B: 8 subjects (randomised to one of four treatment sequences)"
9477138|NCT03565081|Experimental|PWS elastic band training group|Genetically confirmed diagnosis of PWS participants were recruited. The PWS participants needed to have sufficient command of the Mandarin language to understand the study information and motivated to conduct the training program.
9477139|NCT03565055|Experimental|IPCST|Intervention = Patients that participate in IPCST programme
9477140|NCT03565055|Active Comparator|E.A.S.Y|Treatment as usual = Patients of E.A.S.Y Programme in HK Kwai Chung Hospital
9477141|NCT03565042||MoA ustekinumab|Patients with a diagnosis of psoriatic arthritis according to the CASPAR criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. An arthroscopy will be done in the swollen knee/ankle at week 0, 12 and 24.
9477142|NCT03565029|Experimental|Medium/low locally advanced rectal cancer|Patients with Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
9477143|NCT03564990|Experimental|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
9477144|NCT03564990|Sham Comparator|conventional approach|conventional follow-up with oral healthy education
9477145|NCT03564977|Experimental|CD19-targeted CAR-T cells|
9477146|NCT03564951|Active Comparator|Control|ablation of Atrial fibrillation using spatio-temporal dispersion
9477147|NCT03564951|Experimental|Isochrone|ablation of concordance zones using isochrone and voltage maps
9477148|NCT03564925|Active Comparator|Wide area circumferential ablation|Device:Smart Touch® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
9477149|NCT03564925|Experimental|Cryoballoon ablation|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
9477150|NCT03564912|Experimental|2 week group|
9477151|NCT03564912|Active Comparator|3 week group|
9477152|NCT03564899|No Intervention|control|Receive no physical activity intervention (maintain baseline physical activity participation)
9477153|NCT03564899|Experimental|Lighter intensity physical activity|Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
9477154|NCT03564899|Active Comparator|Higher intensity physical activity|Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
10018477|NCT05121740|Experimental|Arm A: Experimental 1|In the APLICOV-PC study, patients of arm A received 1.5 mg of plitidepsin / day for 3 consecutive days (total dose 4.5 mg).
10018478|NCT05121740|Experimental|Arm B: Experimental 2|In the APLICOV-PC study, patients of arm B received 2.0 mg of plitidepsin / day for 3 consecutive days (total dose 6.0 mg).
10018479|NCT05121740|Experimental|Arm C: Experimental 3|In the APLICOV-PC study, patients of arm C received 2.5 mg of plitidepsin / day for 3 consecutive days (total dose 7.5 mg).
10018480|NCT05118386|Experimental|RSM01|Participants will be randomized to receive different dose levels of RSM01. Participants will be randomized in a ratio of 6:1 where for every 6 participants receiving active drug (RSM01) 1 participant will receive Placebo.
9477155|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
10018481|NCT05118386|Placebo Comparator|Placebo|Participants will receive placebos matched to RSM01.
9477156|NCT03564847|Experimental|LTP Plus|LTP Plus Participants will receive the intervention over 4 months Weekly sessions for 2 months and fortnightly for next two months by trained non-specialists/community health workers.
10018482|NCT05116852||Both grieving a loved one to opioid-related death and have an actively using loved one|These individuals will complete the study survey for their designated experience both supporting a loved one in treatment for Opioid Use Disorder, and having lost a loved one to opioid-related death.
10018483|NCT05116852||Individuals supporting a loved one in treatment for Opioid Use Disorder|These individuals will complete the study survey for their designated experience supporting a loved one in treatment for Opioid Use Disorder.
10018484|NCT05116852||Individuals grieving a loved one to opioid-related death|These individuals will complete the study survey for their designated experience losing a loved one to opioid-related death.
10018485|NCT05115760|Experimental|Supportive care (pea protein oral nutrition supplement)|Patients receive Kate Farms pea protein oral nutrition supplement PO during their mealtimes as directed by their clinical dietitian during and up to 1 month following chemoradiation in the absence of unacceptable toxicity.
9477157|NCT03564847|No Intervention|Treatment As Usual (TAU)|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4th and 6th month post randomization.
9477158|NCT03564834|Experimental|Laparoscopic gastrectomy|A standard laparoscopic gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
9477159|NCT03564834|Active Comparator|Open gastrectomy|A standard open gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
9477160|NCT03564808|Experimental|Fat graft enriched with MSCs|Adipose tisse derrived MSCs
9477161|NCT03564808|Experimental|Fat graft only|Fat graft withiut enrichment with MSCs
9477162|NCT03564795|Experimental|KeraStat Gel|Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).
9803691|NCT03535922|Experimental|Disease-specific and generic PROMs group|HD units randomized to this PROMs assessment group will administer a disease-specific and generic PROM every 2 months to all patients able to complete the instrument for a period of 12 months. Patients will receive a copy of both their PROMs results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the two PROMs. The disease-specific and generic PROMs reports will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROMs reports will be accompanied by treatment aids for all symptoms.
10018486|NCT05114473|Experimental|Workshops|This group will attend face-to-face workshops were the educational program will be developed. These workshops will be available in several sites, and specific care providers will be assigned for each of these sites.
9518139|NCT03299517|Experimental|amiodarone|"Initial dose: antiarrythmic drugs Amiodarone (5 mg / kg EV in 30 minutes)~Adittional dose: Amiodarone (3 mg / kg EV in 30 minutes)"
9518140|NCT03299491|Experimental|MWA+IEC intervention|
9518141|NCT03299491|Experimental|IEC intervention|
9518142|NCT03299491|No Intervention|Control|
9518143|NCT03299465|Experimental|Yoga arm|A six-week restorative yoga intervention consisting of a weekly, 60-minute yoga group class led by a certified yoga instructor along with twice-weekly home practice using yoga DVD.
10037428|NCT01825005||group 4: stage IVb , any treatment|cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care
9477163|NCT03564795|Active Comparator|Silver Sulfadiazine|Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.
9803692|NCT03535922|No Intervention|The control or 'usual care' group|HD units randomized to this group will follow usual care and patients will not have any PROMs assessment; however, all the treatment aids will be made available for clinicians in this study group during the 12 months trial period.
10018487|NCT05114473|Experimental|Online-accessed material|This group will be granted online access to a platform were the educational program will be uploaded. They will be given autonomy regarding when to enter the platform and view the content.
10018488|NCT05114473|No Intervention|Control group|This group will initially no recieve an intervention and will serve as a control group.
10018489|NCT05113862|Sham Comparator|LD Vehicle GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (12.8ug) without peptides
10018490|NCT05113862|Experimental|LD PepGNP-SARSCoV2|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (12.8ug) plus peptides
10018491|NCT05113862|Sham Comparator|HD Vehicle GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (38.3ug) without peptides
10018492|NCT05113862|Experimental|HD PepGNP-SARSCoV2|High Dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (38.3ug) plus peptides
10018493|NCT05113641|Experimental|Alkalizing Fruit and Vegetables|Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session in the first week from a registered dietitian (RD), either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.
10018494|NCT05113641|Active Comparator|Sodium Bicarbonate|Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice. Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level >22 mEq/L. Participants will receive counselling from a registered dietician (RD) as part of the standard care. Intervention will last 12 months.
10018495|NCT05111561|Experimental|Treatment (ZEN-3694, binimetinib)|Patients receive ZEN-3694 orally (PO) once daily (QD) and binimetinib PO twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. During the dose expansion phase, patients will have two mandatory biopsies - one before beginning the study and the second at day 15 of cycle 1. The study biopsy takes small pieces of cancer tissue from patient's body to look for markers (substances made by, on, or in tumor cells) related to how the study treatment works.
10018496|NCT05111314|Experimental|Diagnostic (embolization, 68Ga-PSMA, PET/CT)|Patients undergoing clinically indicated hepatic artery embolization will receive 68Ga-PSMA intraarterially (IA) over 5 minutes. After 60-90 minutes, patients undergo PET/CT scan over 1 hour.
10018497|NCT05111301|Experimental|Basal Insulin Only (Group A)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
10018498|NCT05111301|Experimental|Multiple Daily Injections (Group B)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
10018499|NCT05110898|Experimental|Fixed-dose Olmesartan 20mg/40 mg + Indapamide 1,5 mg|
10018500|NCT05110898|Active Comparator|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|
10018501|NCT05110638|Experimental|SKX-16 (Luliconazole 10% Solution)|
10018502|NCT05110261|Experimental|Nirsevimab|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
10018503|NCT05110261|Placebo Comparator|Placebo|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
10018504|NCT05110001|Placebo Comparator|Standard Therapy|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
10018505|NCT05110001|Experimental|Cross-Linking with rose Bengal (RB-PDT)|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT
10018506|NCT05109442|Experimental|Escalation Phase|The Escalation phase will determine the MTD/RP2D of AFM24 in combination with atezolizumab. A traditional 3+3 design will be used to determine the RP2D.
10018507|NCT05109442|Experimental|Expansion Phase|The expansion phase will collect preliminary evidence of efficacy and further confirm the safety of AFM24 in combination with atezolizumab.
10018508|NCT05108428|Experimental|MRI-guided adaptive radiation|Patients will receive capecitabine-based chemoradiotherapy (chemotherapy with capecitabine + radiation). Dosing will be modified based on tumor changes measured daily and weekly by MR-guided radiotherapy (MRgRT) utilizing MR-linac (MRL) systems. Chemoradiotherapy will be followed by standard of care consolidated chemotherapy. (FOLFOX)
10018509|NCT05107674|Experimental|Phase 1a Dose Escalation|Multiple dose levels of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose
10018510|NCT05107674|Experimental|Phase 1b Dose Expansion in platinum-resistant EOC|Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma
10018511|NCT05107674|Experimental|Phase 1b Dose Expansion in advanced gastric/GEJ cancer|Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma
10018512|NCT05107674|Experimental|Phase 1b Dose Expansion in HNSCC|Patients with recurrent, locally advanced, or metastatic HNSCC
10018513|NCT05107674|Experimental|Phase 1b Dose Expansion in unresectable or metastatic melanoma|Patients with Stage IVa, IVb, or IVc Melanoma
10018514|NCT05107674|Experimental|Phase 1b Dose Expansion in advanced NSCLC|Patients with Stage IV adenocarcinoma NSCLC
10018515|NCT05107674|Experimental|Phase 1b Dose Expansion in mCRPC|Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA progression
9803693|NCT03535506|Experimental|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
10018516|NCT05107674|Experimental|Phase 1b Dose Expansion in mixed solid tumor cohort|Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or MSS CRC
9803694|NCT03535506|No Intervention|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
10018517|NCT05107674|Experimental|Phase 1b Dose Expansion in DLBCL-RT|Patients with DLBCL-RT previously treated with at least 1 line of standard, systemic chemotherapy, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options
10018518|NCT05107518||children with physical disabilities|his study was designed to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire-(CSA) scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
10018519|NCT05107427|Experimental|MRx0518 + Avelumab|Subjects will receive 1 capsule of MRx0518 BID throughout the treatment period and IV infusion of Avelumab every 2 weeks in 4-week cycles
10018520|NCT05107362||Symptomatic Adult and Pediatric Subjects|Untrained lay user to collect throat swab specimen and perform investigational test.
10018521|NCT05106595||Traditional Occupational Therapy|participants receiving traditional occupational therapy treatments and interventions provided in the inpatient rehabilitation setting. This includes, but is not limited to , therapeutic activity, therapeutic exercise, neuromuscular re-education. This group is retrospectively collected, and will not include participants who had access to the BAT.
10018522|NCT05106595||Bimanual Arm Trainer|Participants who are prospectively enrolled, who are appropriate for BAT use. Participants will receive additional traditional occupational therapy interventions, as deemed appropriate by treating therapists.
9803695|NCT03535337|Active Comparator|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
9803696|NCT03535337|Active Comparator|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
10037429|NCT01825018|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be taught to endorse compliance with medical guidelines, safer behaviors, and effective ways to communicate these concepts to social network members.
9803697|NCT03535337|Active Comparator|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
10037430|NCT01825018|Active Comparator|Comparison Group|Members of social networks assigned to this group will receive only HIV counseling at the baseline session.
10037431|NCT01825031|Experimental|Antiretroviral Therapy|Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs
9477164|NCT03564782|Experimental|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
9477165|NCT03564769|Experimental|Intervention Arm 1|Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
9477166|NCT03564769|Experimental|Intervention Arm 2|Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
9477167|NCT03564756|Experimental|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
9477168|NCT03564756|No Intervention|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
9477169|NCT03564730|Active Comparator|Total Knee Arthroplasty (TKA)|Patient will have complete replacement - Simultaneous vs Staged
9477170|NCT03564730|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patient will have half-knee replacement (partial) - Simultaneous vs Staged
9477171|NCT03564717|Experimental|Segmented Three dimensionally printed transfer tray|
9477172|NCT03564717|No Intervention|Full arch three dimensionally printed transfer tray|
9480704|NCT05261854|Experimental|Deep cervical muscle training using pressure biofeedback and conventional Exercises|"The duration of preesure biofeedback includes 3 sets in a session with 10 repetitions each with 2 minutes of rest between sets and 5 days a week for 6 weeks.~Conventional exercises like Stretching and strengthening of neck flexor muscles will include 10 repetitions, each held for 10s with rest of 2 minutes between sets. The session will be conducted for 6 weeks, 5 days a week."
9480705|NCT05261854|Experimental|conventional exercises for Neck pain|Only conventional exercises like stretching and strengthening of neck flexor muscles will be given.
9480706|NCT05261841||TYPE 2 DIABETES|Patients affected by type 2 diabetes
9480707|NCT05261828|Experimental|A|Short multidisciplinary program including education and rehabilitation and a personalized follow-up program
9480708|NCT05261828|Active Comparator|B|Reassuring messages and advices in agreement with the current recommendations.
9480709|NCT05261815|Experimental|Ultrasound therapy|"Continuous ultrasound therapy for 15 minutes~Traction for 30 minutes~Spinal decompression exercises for 20 min"
9480710|NCT05261815|Experimental|High Intensity Laser Therapy|"High intensity laser for 10 minutes~Traction for 30 minutes~Spinal decompression exercises for 20 min"
9480711|NCT05261802|Experimental|AVANCE-Houston FRAMEWorks Program Weekly Workshop Format|Participants in this arm receive 14 hours of Survival Skills for Healthy Families curricula over 7 weeks. Participants also receive employment supports and case management services.
9480712|NCT05261802|Experimental|AVANCE-Houston FRAMEWorks Program Weekend Retreat Format|Participants in this arm receive 14 hours of Survival Skills for Healthy Families in a compressed format during a 16-hour weekend retreat, followed by a 2-hour reflections workshop two weeks later. Participants also receive employment supports and case management services.
9480713|NCT05261789|Experimental|Turkish Get Up exercise group|Turkish Get Up exercise was given this group
9480714|NCT05261789|Experimental|Core stability exercise group|Core stability exercise was given this group
9480715|NCT05261789|Active Comparator|Control group|No intervention
9803698|NCT03535337|Active Comparator|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
10018523|NCT05104658|Experimental|Intervention arm|"Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).~In addition:~Information book on rehabilitation and physical activities in local community~1:1 conversation with patient supporters from the Heart Association~Employer material on post-treatment and potential work adjustments~Support café for relatives~Supported transition to local sports associations~Motivating phone calls from physiotherapists supporting physical activities.~In addition for patients with vulnerabilities:~patient education in small groups~pro-active counselling with a cardiac nurse, a psychologist, or a social worker from the Heart Association~paid transportation to the municipal rehabilitation Center"
9803699|NCT03535337|Active Comparator|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
9803700|NCT03535337|Active Comparator|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
9803701|NCT03535337|Active Comparator|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
9480716|NCT05261776|Experimental|Group-A|Group-A will receive pilates exercise and standard care
9480717|NCT05261776|Active Comparator|Group-B|Group-B will receive brisk walk and standard care
9480718|NCT05261724||Patients with primary brain tumors|
9480719|NCT05261724||Patients with secondary brain tumors|
9480720|NCT05261711|Experimental|AB1|AB1 is the investigational product in this study taken orally, once daily, for 8 weeks. This will be an open-label, dose escalating study with a starting dose of 2mg with additional cohorts enrolled at subsequently higher doses of 4mg, 8mg, 16mg, and 32mg.
10018524|NCT05104658|No Intervention|Control arm|Usual rehabilitation: training (1 hour 2 times a week for 6 weeks), dietary training (2x3 hours), cardiac education (2x3 hours), referred to municipal rehabilitation: training (1 hour 2 times a week for 6-12 weeks), patient education (3x2 hours by a cardiac nurse and 1x2 hours by a dietician).
10018525|NCT05103696|Experimental|Remimazolam group|Patients received remimazolam to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.3ug/kg of remifentanil during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation.
9477173|NCT03564704|Experimental|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
9477174|NCT03564665|Experimental|400mg Magnesium Glycinate BID Arm|Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
9477175|NCT03564665|Placebo Comparator|Control Arm|Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
9477176|NCT03564652|No Intervention|Arm A|Control arm: Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
9477177|NCT03564652|Experimental|Arm B|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
9477178|NCT03564652|Experimental|Arm C|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
9477179|NCT03564639||Injection drug users with HCV|People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.
9803702|NCT03535337|Active Comparator|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
10018526|NCT05103696|Active Comparator|EP group|Patients received Etomidate combined with propofol to maintain sufficient sedation (sufficient sedation as judged by MOAA/ S ≤ 4 for 3 consecutive measurements) during endoscopy procedure. And patients were slowly injected of 0.3 ug/kg of remifentanil during the examination.When the analgesia was insufficient, Remifentanil can be added 5-10 ug each time according to the situation
10037432|NCT01825031|Experimental|Opportunistic Infection (OI) Prophylaxis|Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.
9477180|NCT03564626|No Intervention|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
9477181|NCT03564626|Experimental|Health IT only|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline and at 30 days.Follow-up will be for 30 days
9803703|NCT03527108|Experimental|Patients with prior IO therapy|
9803704|NCT03519178|Experimental|Dose Escalation|Single Agent Dose Escalation
10018527|NCT05103176|Experimental|To PPC, with concurrent task|This arm will receive intermittent theta bust stimulation to the PPC site while subjects perform a grasp task
10018528|NCT05103176|Experimental|To PPC, without a concurrent task|This arm will receive intermittent theta bust stimulation to the PPC site without a concurrent task
10018529|NCT05103176|Experimental|To vertex, with concurrent task|This arm will receive intermittent theta bust stimulation to the vertex site (control condition) while subjects perform a grasp task
9477182|NCT03564626|Experimental|Health IT + Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
9477183|NCT03564600||ABC Group|Veterans with back pain for at least the past 6 months.
9803705|NCT03519178|Experimental|Dose Finding Endocrine Therapy 1 Combination|Part 1B PF-06873600 plus Endocrine Therapy 1
10018530|NCT05103033|Experimental|Systems Analysis and Improvement Approach (SAIA) for mental health|Those receiving SAIA-MH will attend a 1-week in-person training for facility learning collaboratives. Following the 1-week in-person training, SAIA-MH standard operating procedures will be implemented, including: (1) structured internal/external facilitation following tablet-based guides used in pilot study (1x per week first month; 2x per week for next two months; 1x per month for remainder); (2) facilitation in the 5-step SAIA-MH improvement process.
10018531|NCT05103033|Other|Attentional Placebo Control|"Control facilities will mimic activities of the intervention group in time and contacts, but without the active ingredient of the SAIA-MH implementation strategy"
9477184|NCT03564600||UC Group|Veterans with back pain for at least the past 6 months.
10018532|NCT05102864|Active Comparator|Active intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of active iTBS to the left dorsolateral prefrontal cortex
9803706|NCT03519178|Experimental|Dose Finding Endocrine Therapy 2 Combination|Part 1B PF-06873600 plus Endocrine Therapy 2
10018533|NCT05102864|Sham Comparator|Sham intermittent Theta Burst Stimulation|Participants will complete 10 daily sessions of sham iTBS to the left dorsolateral prefrontal cortex
10018534|NCT05101993|Experimental|AtriClip group|
10018535|NCT05101590|Experimental|Monitored with HDA|Participants undergoing elective major surgery and have an arterial line as part of their standard care with HDA included as part of their care
10018536|NCT05100771||Experimental group|The experimental group will be made up of patients with focal epilepsy
10018537|NCT05099874|Experimental|EndeavorRx|Children will be asked to begin attentional control training at home within two weeks of baseline testing and to complete 5 sessions (25 minutes each) per week for 4 weeks (total = 20 sessions).
10018538|NCT05099172|Experimental|Dose escalation|
10018539|NCT05099172|Experimental|Backfill|Dose Escalation and Backfill run concurrently
10018540|NCT05099172|Experimental|Dose expansion|Dose Expansion is initiated after Dose Escalation and Backfill.
10018541|NCT05099042|Experimental|Group intervention - questionnaire and recommendations|The intervention group will take the ESOGER questionnaire at month 0 and month 3 ( beginning and end) and receive recommendations following their needs.
10018542|NCT05099042|No Intervention|Group control - questionnaire without recommendations|The participants will only take the ESOGER questionnaire at month 0 and month 3 without recommendations.
10018543|NCT05098730|Experimental|Stroke survivors with pets|Stroke survivors with pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
10018544|NCT05098730|Active Comparator|Stroke survivors without pets|Stroke survivors without pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
10018545|NCT05098717||UIP patients|Patients with pulmonary fibrosis and UIP pattern undergoing mechanical ventilation for acute respiratory failure
10018546|NCT05098717||ARDS patients|Patients with ARDS undergoing mechanical ventilation for acute respiratory failure
10018547|NCT05098041|Experimental|Soticlestat 300 mg + Rifampin 600 mg|Soticlestat 3*100 mg tablets, orally, administered once on Day 1 in fasted state in Period 1, followed by a washout period of 4 days, further followed by Rifampin 600 mg, administered as 2*300mg capsules, orally, once daily for 13 consecutive days, from Day 1 to Day 13 in fasted state in Period 2. Soticlestat 3*100 mg tablets, will be administered orally along with rifampin 600 mg (2*300mg) capsules, orally in the morning of Day 11 in Period 2.
10018548|NCT05096949|No Intervention|Clinic visit arm|Patient will receive Cabenuva injection at the clinic
10018549|NCT05096949|Experimental|Home visit arm|Patient will receive Cabenuva injection at home
10018550|NCT05096780|Active Comparator|Beverage 1|Free caffeine 160 mg
10018551|NCT05096780|Experimental|Beverage 2|Encapsulated caffeine 160 mg
10018552|NCT05096780|Active Comparator|Beverage 3|Free caffeine 250 mg
10018553|NCT05096780|Experimental|Beverage 4|Encapsulated caffeine 250 mg
10018554|NCT05096624|Experimental|DD-TENS (Digital Denture-Transcutaneous Electrical Nerve Stimulation)|Patient with Complete Removable Prostheses according to DD-TENS system
10018555|NCT05096624|Active Comparator|Gold standard|Patient with Complete Removable Prostheses according to usual care
9803707|NCT03519178|Experimental|Dose Expansion Arm A|PF-06873600 as a Single Agent
9803708|NCT03519178|Experimental|Dose Expansion Arm B|PF-06873600 as a Single Agent in Various Tumor Types
10018556|NCT05096624|Active Comparator|Digital denture System|Patient with Complete Removable Prostheses according to Digital Denture system
10018557|NCT05096611|Active Comparator|ABC|Attachment and Biobehavioral Catch-up, 10 weekly sessions that provide parenting support
10018558|NCT05096611|Experimental|ABC+D|Attachment and Biobehavioral Catch-up plus weekly 5-10 minute videos that additional provide support for mothers' mood, stress, and coping
10018559|NCT05096403|Active Comparator|Pegcetacoplan|1080 mg, subcutaneus injection, twice weekly
10018560|NCT05096403|Placebo Comparator|Placebo|Sodium acetate, subcutaneus injection, twice weekly
10018561|NCT05096325||Study pump|Subjects receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data.
10018562|NCT05096065|Experimental|Treatment A: Leuprolide Oral Tablet, 120 mg QD|Leuprolide Oral Tablet (Ovarest), 120 mg (2 x 60 mg tablets), administered once daily (QD), for up to 35 consecutive days with food-intake restrictions.
10018563|NCT05096065|Experimental|Treatment B: Leuprolide Oral Tablet, 80 mg QD|Leuprolide Oral Tablet (Ovarest), 80 mg (2 x 40 mg tablets), administered once daily (QD) for up to 35 consecutive days with food-intake restrictions.
10018564|NCT05096065|Experimental|Treatment C: Leuprolide Oral Tablet, 60 mg QD|Leuprolide Oral Tablet (Ovarest), 60 mg, administered once daily (QD) for up to 29 consecutive days with food-intake restrictions.
10018565|NCT05096065|Experimental|Treatment D: Leuprolide Oral Tablet, 60 mg BID|Leuprolide Oral Tablet (Ovarest), 60 mg, administered twice daily (BID), 12 hours apart for up to 35 consecutive days with food-intake restrictions.
10018566|NCT05096065|Experimental|Treatment E:Leuprolide Oral Tablet (Ovarest), 40 mg BID|Leuprolide Oral Tablet (Ovarest), 40 mg, administered twice daily (BID), 12 hours apart for up to 29 consecutive days with food-intake restrictions.
9477185|NCT03564574|Experimental|Study group|"Inclusion criteria~History of consumption of OP compound.~Symptom complex consistent with OP poisoning~Age > 18 years~Informed consent from the patient or next kin.~Exclusion criteria~History of combined poisoning with a non OP compound.~All other patients not fitting in the organophosphate symptom complex.~Patients with underlying liver and kidney disease.~History suggestive of acute pancreatitis in the past.~All patients with history and clinical features of OP compound poisoning admitted to the emergency department in PGIMER during the study period, meeting the inclusion, exclusion criteria and who gave consent were enrolled in the study.~Intervention : Administration of 100mL of 20% Lipid emulsion to all patients in the study group"
9477186|NCT03564574|No Intervention|Historic controls|The control arm The study group was compared with data of patients admitted for OP poisoning between the years 2013 and 2014 ( 2 calendar years), fulfilling the inclusion and exclusion criteria as stated above.
9477187|NCT03564548|Experimental|PPP001|Inhaled cannabinoids (PPP001)
9477188|NCT03564548|Active Comparator|Morphine sulfate or Hydromorphone or Oxycodone|Oral morphine sulfate or hydromorphone or oxycodone at the previous stabilized dosage
9477189|NCT03564535|Experimental|SELF FIXATING GROUP|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
9477190|NCT03564535|Active Comparator|TACKER FIXATION GROUP|Patients will be undergoing mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
9477191|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
9477192|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
9477193|NCT03564509|Experimental|FE 999302 (dose 1) and follitropin delta|
10018567|NCT05095532|Experimental|BM-MSCs at 20x10^6|One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14
10018568|NCT05095532|Experimental|BM-MSCs at 50x10^6|One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14
10018569|NCT05095532|Placebo Comparator|Placebo|One time infusion of islets only.
9803709|NCT03519178|Experimental|Dose Expansion Arm C|PF-06873600 in Combination with Endocrine Therapy 1
9803710|NCT03519178|Experimental|Dose Expansion Arm D|PF-06873600 in Combination with Endocrine Therapy 1
9803711|NCT03519178|Experimental|Dose Expansion Arm E|PF-06873600 in Combination with Endocrine Therapy 2
10037433|NCT01825031|Experimental|Nutritional Support|Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.
10018570|NCT05095454|Experimental|Percutaneous Epidural Stimulation|Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
10018571|NCT05095454|Experimental|Transcutaneous Epidural Stimulation|Transcutaneous spinal stimulation will be delivered via skin surface-level electrodes during rehabilitation. The effects of transcutaneous stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
9477194|NCT03564509|Experimental|FE 999302 (dose 2) and follitropin delta|
9477195|NCT03564509|Experimental|FE 999302 (dose 3) and follitropin delta|
9477196|NCT03564509|Experimental|FE 999302 (dose 4) and follitropin delta|
10018572|NCT05094817||Access to Computer|Participants completing the BHA should be at least somewhat comfortable or very comfortable with using a computer and mouse and should use a computer at least once a week.
10037434|NCT01825044|Active Comparator|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
10018573|NCT05094817||No Access to Computer|Since participants in previous studies on cognitive screening are usually more educated individuals with higher income, participants who do not have proficiency/or access to a computer will be asked to complete some questionnaires to determine any sociodemographic or baseline differences between patients who are able to complete BHA vs. those who are not able to complete BHA.
10018574|NCT05094544|Experimental|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
10018575|NCT05094427||Lumbar spine surgery with preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery with a fluoroscopically-guided DR block placed by the operative neurosurgeon prior to surgery. These patients subsequently received standard of care general anesthesia and standard multimodality postoperative pain control.
10018576|NCT05094427||Lumbar spine surgery without preoperative fluoroscopically-guided DR block|Patients who have undergone lumbar spine surgery without placement of a fluoroscopically-guided DR block. These patients received standard of care general anesthesia and standard multimodality postoperative pain control.
10018577|NCT05093608|Experimental|Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab|60 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
10018578|NCT05093608|Experimental|Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab|80 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
10018579|NCT05092789|Experimental|Kinesio taping group|"Participants in this group will receive treatment through standardized therapeutic Kinesio taping along with conventional therapy.~Tape will be water proof, porous, adhesive,with width of 5cm and thickness of 0.5 mm."
10018580|NCT05092789|Experimental|Cervical thrust manipulation group|"Participants in this group will receive treatment via cervical thrust manipulation along with conventional therapy.~Manipulation will be directed on mid cervical spine."
9477197|NCT03564509|Experimental|FE 999302 (dose 5) and follitropin delta|
10018581|NCT05092789|Active Comparator|Conventional therapy group|.Participants of this group will receive only conventional therapy which will include: Hot pack for 10 minutes Stretching Exercises
9477198|NCT03564509|Placebo Comparator|Placebo and follitropin delta|
9477199|NCT03564483||Registry Observational Study|All women presenting for evaluation of Extramammary Paget's Disease (EMPD) at Mayo Clinic in Rochester MN.
10018582|NCT05092373|Experimental|Cohort 1 (TTF, cabozantinib)|Patients receive TTF continuously for at least 18 hours per day on days 1-21 of each cycle. Patients also receive cabozantinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10018583|NCT05092373|Experimental|Cohort 2 (TFF, atezolizumab, nab-paclitaxel)|Patients receive TTF continuously for at least 18 hours per day on days 1-28 of each cycle. Patients also receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each cycle and atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10018584|NCT05091710|Experimental|Follow up care program for HF patients|Discharged HF patients in rural Haiti will be receive a follow-up care program delivered by trained community health workers (CHWs).
10018585|NCT05091710|Other|Standard of care|Historical reference group who received standard of care for HF identified prior to CHW training.
10018586|NCT05090865|Other|Liberalized dietary potassium and then restricted potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2-week run-in and liberalized potassium treatment period, then cross-over to the restricted potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional Coronavirus disease (COVID)-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet.
10018587|NCT05090865|Other|Restricted dietary potassium and then liberalized potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2 week run-in and then start receiving a restricted potassium treatment period, then cross-over to the liberalized potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional COVID-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet
10018588|NCT05090423|Experimental|Experimental: balance training alone|The subjects will receive the balance training twice a week for 6 weeks.
10018589|NCT05090423|Experimental|Experimental: balance training and neurodynamic intervention for the common peroneal nerve|The subjects will receive the balance training and neurodynamic intervention for the common peroneal nerve twice a week for 6 weeks.
10018590|NCT05090384|Experimental|Steroid Taper|All enrolled patients start on the same dose of steroids for treatment of GVHD, blood samples are taken at week 1 and 2 post study start and biomarkers plus clinical response determines how steroid treatment is continued
10018591|NCT05090098||Breast cancer|Sixty patients with grade I-II-III breast cancer, whose primary treatment (surgery, radiotherapy and/or chemotherapy) is continuing, who applied to the Hospital Breast Unit clinic, will be included in the study. Patients with problems in reading and writing in Turkish, poor cognitive functions and a serious chronic disease, musculoskeletal pain or disease, severe psychiatric illness, current cancer attack or metastasis will be excluded from the study
9477200|NCT03564470|Experimental|Chidamide|Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).
9477201|NCT03564470|Experimental|Dasatinib|Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).
9477202|NCT03564457||One group of 20.000 patients|No interventions will take place as this is an observational study
9477203|NCT03564431||controls|
9477204|NCT03564431||T2DM patients|
9477205|NCT03564431||depression patients|
9477206|NCT03564431||T2DM with depression patients|
9477207|NCT03564418|Active Comparator|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
9477208|NCT03564418|Active Comparator|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.
9477209|NCT03564405|Experimental|UNI-DEB|
9477210|NCT03564392|Experimental|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
9477211|NCT03564392|No Intervention|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
9477212|NCT03564379|Experimental|Part 1: Single Dose Part|Participants will receive a single oral dose of 25 mg JNJ-42165279 or placebo tablet under fasted condition in the morning on Day 1.
9477213|NCT03564379|Experimental|Part 2: Multiple Dose Part|After a washout period of at least 10 days, same participants from Part 1 will receive multiple daily dosing of 25 mg JNJ-42165279 or placebo tablet for 10 days.
9477214|NCT03564327||Patients with sinus rhythm|
9477215|NCT03564327||patients with atrial fibrillation|
9477216|NCT03564314|Experimental|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
9477217|NCT03564314|No Intervention|Control|Usual care provided to patients with AKI on surgical units.
10018592|NCT05090098||Breast cancer survivors|Sixty patients with grade I-II-III breast cancer, whose primary treatment (surgery, radiotherapy and/or chemotherapy) was completed at least three months ago, who applied to the Hospital Breast Unit clinic, will be included in the study. Patients with problems in reading and writing in Turkish, poor cognitive functions and a serious chronic disease, musculoskeletal pain or disease, severe psychiatric illness, current cancer attack or metastasis will be excluded from the study
9477218|NCT03564301|Active Comparator|Metronidazole 250mg|Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
9477219|NCT03564301|Placebo Comparator|Placebo|Placebo: same shape, size and dosis as test
9477220|NCT03564288|Experimental|Dose Escalation Cohort|To identify the recommended phase 2 dose (RP2D) of SKI-G-801 in patients with relapsed or refractory AML (Acute Myeloid Leukemia)
9477221|NCT03564275|Experimental|Prospective Treatment Group|Proton Boost
9477222|NCT03564275|No Intervention|Retrospective Comparison Group|Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.
9477223|NCT03564262|Experimental|Cerebrovascular Reactivity|"Cerebrovascular reactivity (CVR) will be assessed using transcranial Doppler ultrasound with carbon dioxide as the vasoactive stimuli.~The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. The CVR test will be performed prior to soup consumption as well as after soup consumption."
9477224|NCT03564262|Experimental|Blood Pressure Reactivity|Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
10018593|NCT05090098||Healthy people|healthy individuals matched for age and gender will also be included in the study.
10018594|NCT05088460|Experimental|Study Arm 1|Randomized to placebo for 12 weeks and then crossover to REGN4461 for 12 weeks
10018595|NCT05088460|Experimental|Study Arm 2|Randomized to receive REGN4461 for 24 weeks
10037435|NCT01825044|Active Comparator|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
10037436|NCT01825070|Experimental|low dose|Montmorency cherry concentrate, 30 mls
10037437|NCT01825070|Experimental|higher dose|Montmorency cherry concentrate, 60 mls
10018596|NCT05088109||SI|adult patients with septic shock will be enrolled,At the time of admission (before the start of vasopressors), age of patients, source of sepsis, baseline systolic (SBP), diastolic (DBP), mean blood pressure (MAP), heart rate (HR), shock index (SI), adjusted shock index (ASI), modified shock index (MSI), diastolic shock index (DSI), baseline lactate, ABG, capillary refill time and body temperature will be recorded. Subsequent recordings will be at 0 (before starting vasopressors), 1, 2, 4, 8, and 12, 24, 48, 72 hours for all parameters except for lactate and ABG will be every 12 hours. SOFA scores, APACHE II, GCS, Charlson Comorbidity Index, will be recorded at admission; and mean total vasopressor dose, urine output will be recorded daily. Cause of death will be documented. All readings will continue for 72 after admission.
10018597|NCT05087836||Patient undergoing cardiac surgery|Each patient will has 2 sets of sensors attached at forehead and temporal area.
10018598|NCT05086471|Experimental|NaviCam SB|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
10018599|NCT05086471|Other|PillCam SB3|After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
10018600|NCT05086172|Experimental|UBA Arm|All subjects in this arm will receive ultrabrief behavioral activation therapy via a single, 90-minute session.
10018601|NCT05086172|No Intervention|Control Arm|All subjects in this arm will complete all study assessment instruments collected in the interventional arm but will not receive an intervention.
10018602|NCT05085574|Experimental|Group 1 (Study Product)|Subjects will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.
10018603|NCT05085574|Placebo Comparator|Group 2 (Reference Therapy)|Subjects will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
10018604|NCT05085002|Other|Lerociclib + letrozole or fulvestrant|
10018605|NCT05084248|Active Comparator|Low-dose|400 IU Per Orem
10018606|NCT05084248|Experimental|High-dose|4000 IU Per Orem
10018607|NCT05083572|Experimental|Group A (Lavage and Vivomixx)|Colonic lavage, followed by Vivomixx treatment
10018608|NCT05083572|Experimental|Group B (Lavage and Placebo)|Colonic lavage, followed by Placebo treatment
10018609|NCT05083572|Experimental|Group C (Vivomixx)|No colonic lavage, only Vivomixx treatment
10018610|NCT05083572|Experimental|Group D (Rifaximin and Vivomixx)|Rifaximin, followed by Vivomixx treatment
10018611|NCT05083559|Experimental|MPC AP system|Participants will use the MPC AP system for automated insulin delivery for a 9 hour study visit.
10018612|NCT05083559|Experimental|Robust R-AP system|Participants will use the Robust R-AP system for automated insulin delivery for a 9 hour study visit.
10018613|NCT05083416|Experimental|A: Prolonged Nightly Fasting|"Participants will be educated on Prolonged Nightly Fasting (PNF) and the mycircadianapp. Participants be allowed to choose any 10-hr period that falls between 6 AM- 6 PM, as feeding period. Participants will be recommended to follow study diet guidelines, eat to satiety and not count calories. Participants will be allowed to have water, beverages (<4 kcal) during the fasting period."
10018614|NCT05083416|Active Comparator|B: Regular Eating pattern|Participants will follow a traditional eating pattern with no time restrictions.
10018615|NCT05083091|Active Comparator|Monitor & Accept (MA-MBI)|14-day smartphone based mindfulness meditation attention monitoring and acceptance skills training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
10018616|NCT05083091|Active Comparator|Monitor Only (MO-MBI)|14-day smartphone based mindfulness meditation training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
10018617|NCT05083091|Active Comparator|Coping Condition (CC)|14-day smartphone based training intervention focused on coping strategies consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
10018618|NCT05081453|Experimental|Pavlik harness treatment group|Application of a pavlik harness for 2 months in position seeking 90º of flexion of both knees and 45º of hip flexion with some abduction. An ultrasound control is performed at 2 and 6 months
10018619|NCT05081453|No Intervention|Control group without intervention|Control group without intervention. An ultrasound control is performed at 2 and 6 months
10018620|NCT05081180|Experimental|Avelumab + Lenvatinib|
10037438|NCT01825083|Active Comparator|Ketamine|Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
10018621|NCT05079386|Experimental|New Voice Prosthesis|Patients will use the New Voice Prosthesis for two weeks to investigate short term feasibility and explore limitations and advantages. If the patient wishes to leave the New Voice Prosthesis in situ, this will be allowed under the condition that the subject agrees to remain in the study and report (adverse) events on an ongoing basis, until the device is removed after a maximum of 12 months.
10018622|NCT05079334|Other|High Risk / MeTree|High risk for hereditary cancer and completes the MeTree questionnaire
10018623|NCT05077657||Single-Arm|This is a multi-center, single arm, open-label study to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS).
10018624|NCT05076903|Experimental|OFA group|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
10018625|NCT05076903|Active Comparator|Control group|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
10037439|NCT01825083|Placebo Comparator|Placebo|Saline group will received the same volume in saline as the ketamine dose
10037440|NCT01825096||baseline|No intervention. Participants are scanned at baseline.
9480721|NCT05261698|Active Comparator|Arms|Control group: in control group moist heating pads along with TENS shall be applied on neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed.
10037441|NCT01825109|Experimental|6 weeks RV & normal breast feeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
10037442|NCT01825109|Experimental|6 weeks RV & delayed breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
10037443|NCT01825109|Experimental|14 weeks RV & Normal breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
10037444|NCT01825109|Experimental|14 weeks RV & delayed breastfeedin|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
10037445|NCT01825135|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes
10037446|NCT01825135|Sham Comparator|Sham stimulation|Sham stimulation will be applied to the quadriceps for 30 minutes
9477225|NCT03564249|Experimental|Group 1 Young patients with constipation|25 young patients that present at secondary or tertiary care with intractable constipation. They will undergo the new MRI gastrointestinal transit test (MiniCap) once before standard treatment for constipation and once after the treatment.
9477226|NCT03564249|Experimental|Group 2 Healthy participants|25 young healthy controls matched for gender. They will undergo the new MRI gastrointestinal transit test (MiniCap) once.
9477227|NCT03564236|Active Comparator|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:~oral prednisolone 40 mg/day for 5 days;~antibiotics prescribed according to the following criteria: fever (body temperature > 38.5 degrees Celsius), elevated C-reactive protein (CRP) >50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 <30% of predicted;~high dose inhaled corticosteroids, beta-agonists and or anticholinergics.~Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
9477228|NCT03564236|Experimental|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:~nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.~During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.~After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
9477229|NCT03564223||Parents/Guardians|"Parents/Guardians aged over 18, attending Great Ormond Street Hospital Outpatients.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
9477230|NCT03564223||Paediatricians|"Paediatricians working at Great Ormond Street Hospital NHS Foundation Trust.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
10037447|NCT01825148||Type 1 Diabetes|patients with long standing T1D
9477231|NCT03564210|Active Comparator|Screen time permitted|Concussion sufferers permitted screen time for first 48 hours of recovery
9803712|NCT03517371|Experimental|mHealth delivered exercise program|"Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application (app). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature."
10037448|NCT01825148||Healthy volunteer|healthy volunteers with normal glucose tolerance
10037449|NCT01825174|Active Comparator|Non-overweight children in ball games program|twice a week different ball games 90min
10037450|NCT01825174|Experimental|Overweight children in nutrition counseling program|9 units of 90min each of nutrition counseling
10037451|NCT01825174|Placebo Comparator|Control group overweight children|No intervention during six months
9477232|NCT03564210|Active Comparator|Screen time abstain|Concussion sufferers asked to abstain from screen time for first 48 hours of recovery
9477233|NCT03564197|Other|Nivolumab|nivolumab containing treatment according to label
9477234|NCT03564184|Experimental|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
9477235|NCT03564184|Experimental|MT during NICU|Consists of music therapy during NICU hospitalization, along with standard care.
9477236|NCT03564184|Experimental|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
9477237|NCT03564184|Experimental|No MT|Consists of standard care.
9477238|NCT03564171|No Intervention|Standard of Care|Patients will receive standard treatment without added intervention.
9477239|NCT03564171|Experimental|Intervention|"These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :~exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy."
9477240|NCT03564158|Experimental|meropenem 2 g- vaborbactam 2 g|Approved Dose
9477241|NCT03564158|Experimental|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
9477242|NCT03564158|Active Comparator|Moxifloxacin 400 mg|Active Control
9477243|NCT03564158|Placebo Comparator|Normal Saline (placebo)|Placebo
9477244|NCT03564106|Experimental|group A|receive intraarticular radiofrequency + methylprednisolone (30 mg)
9477245|NCT03564106|Experimental|group C|receive intraarticular methylprednisolone (30 mg)
9803713|NCT03517371|Active Comparator|Exercise only|Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
9803714|NCT03516305|Experimental|Staccato Alprazolam 1 mg|a single inhaled dose
10037452|NCT01825174|Experimental|Overweight children in ball games program|twice a week different ball games 90min
10037453|NCT01825174|Experimental|Overweight children in ball games and nutrition counseling|twice a week different ball games 90min and 9 units of 90min each of nutrition counseling
10037454|NCT01825174|Placebo Comparator|Non-overweight control (no intervention)|
10037455|NCT01825187|Active Comparator|Treatment Group 1|Patients in this group will be randomized to receive the ULTRAPRO mesh
10037456|NCT01825187|Active Comparator|Treatment Group 2|Patients in this group will be randomized to receive the 3DMAX Mesh
10018626|NCT05076435|Experimental|Restrictive fluid administration|"No IV fluids unless one of the extenuating circumstances occur;~In case of severe hypoperfusion or severe circulatory impairment defined by either: 1) Lactate≥4 mmol/L, 2) Hypotension (systolic BP < 90 mmHg), 3) Mottling beyond the kneecap (mottling score >2) OR 4) Urinary output<0.1 mL/kg bodyweight/h (only in the first 4hrs after randomization) then a bolus of 250 ml of IV crystalloid solution may be given followed by re-evaluation~In case of overt fluid losses (e.g. vomiting, large aspirates,) IV fluid may be given to correct for the loss, but not above the volume lost.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~Correct dehydration or electrolyte deficiencies Ensure a total fluid input of 1 L in 24hrs~IV fluids may be given as carrier for medication, but with lowest possible volume"
10018627|NCT05076435|Active Comparator|Usual care (standard care)|"There will be no upper limit for the use of either IV or oral/enteral fluids~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
10018628|NCT05075772|Experimental|BI 765080 - Administration mode 1 (T)|Subcutaneous (SC) injection (Test, T)
10018629|NCT05075772|Experimental|BI 765080 - Administration mode 2 (R)|Intravenous (IV) infusion (Reference, R)
9477246|NCT03564093|Experimental|Dexmedetomidine|1µg/kg intranasal dexmedetomidine
9477247|NCT03564093|Placebo Comparator|Placebo|0,01ml/kg intranasal 4,5% saline
9477248|NCT03564080|No Intervention|Control - PAD|This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
9477249|NCT03564080|Experimental|Combined - PAD and CAD|This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
10018630|NCT05074810|Experimental|VS-6766+sotorasib|To determine the recommended phase 2 dose (RP2D) for VS 6766 in combination with sotorasib in G12C inhibitor naïve and exposed patients
10018631|NCT05074810|Experimental|VS-6766+sotorasib - G12C inhibitor naïve|To determine the efficacy of the RP2D identified from Part A in G12C inhibitor naïve patients
10018632|NCT05074810|Experimental|VS-6766+sotorasib - G12C inhibitor exposed|To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients
10018633|NCT05074615|Experimental|Cranio-Cervical Flexion Training Group|"Participants of this group will receive conventional training along with cranio-cervical flexion training and home plan.~Cranio-cervical flexion training will be given with the help of pressure biofeedback unit. the cuff will be inflated at a specific pressure level and patient will be asked to maintain that pressure and gradually increase it."
10018634|NCT05074615|Active Comparator|Conventional Therapy Group|Participants of this group will receive only conventional therapy and home plan will be given which includes; hot pack, TENS, neck isometrics and passive stretching of neck musculature. Home plan will include self-stretches and neck isometrics.
10018635|NCT05073120||Piqray Prescriber's/HCP receiving the guide for hyperglycemia|HCPs prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material).
10018636|NCT05071612|Experimental|AD109 Dose 1|
10018637|NCT05071612|Experimental|AD109 Dose 2|
10018638|NCT05071612|Experimental|AD504 Dose 1|
10018639|NCT05071612|Experimental|AD504 Dose 2|
10018640|NCT05071612|Active Comparator|Atomoxetine 1|
10018641|NCT05071612|Active Comparator|Atomoxetine 2|
10018642|NCT05071612|Placebo Comparator|Placebo 1|
10018643|NCT05071612|Placebo Comparator|Placebo 2|
10018644|NCT05070364|Experimental|Peginterferon Lambda for 48 weeks|Peginterferon Lambda 180 mcg once weekly for 48 weeks with 24 weeks follow-up
10018645|NCT05070364|No Intervention|No treatment for 12 weeks|No treatment for 12 weeks followed by Peginterferon Lambda 180 mcg once weekly for 48 weeks and 24 weeks follow-up
10018646|NCT05070312|Experimental|MEDI3506 dose 1|MEDI3506 dose1
10018647|NCT05070312|Experimental|MEDI3506 dose 2|MEDI3506 dose 2
10018648|NCT05070312|Placebo Comparator|Placebo|Placebo 2 mL and 4 mL
10018649|NCT05067972|Experimental|Monotherapy dose escalation (Part 1)|Participants will receive PF-07260437
10018650|NCT05067972|Experimental|Dose Expansion (Part 2A) - Tumor specific Arm A|Participants will receive PF-07260437
10018651|NCT05067972|Experimental|Dose Expansion (Part 2B) - Tumor specific Arm B|Participants will receive PF-07260437
10018652|NCT05067972|Experimental|Dose Expansion (Part 2C) - Tumor specific Arm C|Participants will receive PF07260437
10018653|NCT05067842||Locally advanced esophageal or gastroesophageal adenocarcinoma|Subjects with diagnosed locally advanced esophageal or gastroesophageal adenocarcinoma.
10018654|NCT05067764|Experimental|Aponeurectomy with grafting|The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.
10018655|NCT05067764|Active Comparator|Aponeurectomy alone|The control group evaluates the aponeurectomy alone.
10018656|NCT05066815|Experimental|Hybrid superstructure|Vita Enamic is a Hybrid ceramic consists of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
10018657|NCT05066815|Active Comparator|Ceramic superstructure|IPS Emax is the mostly used ceramic superstructures in implant supported restorations.
10018658|NCT05066672|Experimental|NV-5138 400 mg oral capsules|Either 2 or 4 400 mg oral capsules administered once daily
10018659|NCT05066672|Placebo Comparator|matched placebo|2 or 4 oral capsules administered once daily
10018660|NCT05065333|Experimental|Septic Shock Clinical Decision Support|Emergency Department sites in this arm will have Clinical Decision Support (CDS) alerts active in the Electronic Health Record during clinical ED care of patients with suspected sepsis, in addition to following usual institutional standard of care for sepsis. The CDS will alert providers to patients at high risk for developing septic shock.
10037457|NCT01825187|Other|Evaluation of Surgical Residents|Surgical residents will be evaluated on the ease of use and the amount of time it takes for them to perform the surgery using these two different meshes.
10018661|NCT05065333|Active Comparator|Clinical Diagnosis Only|Emergency Department sites in this arm will follow the institutional standard for sepsis care without Clinical Decision Support. Standard care includes clinical diagnosis of sepsis supported by institutional sepsis education, a sepsis pathway and orderset.
10018662|NCT05065151|Experimental|Stimulation|Patients will be getting standard clinically acceptable stimulation within already safety validated stimulation ranges through their Medtronic Percept PC device.
10018663|NCT05065151|Experimental|No Stimulation|Patients will have stimulation turned off through their Medtronic Percept PC device.
10018664|NCT05064813|Experimental|Mindfulness Based Stress Reduction Group|8 weeks of Mindfulness Based Stress Reduction Group (MBSR).
10018665|NCT05064813|Active Comparator|Stress Education Group|8 weeks of Stress Education Group (SE).
10018666|NCT05064046|Experimental|LuCa + Health Disparity module|"Participants will be asked to complete the Health Disparities module that is an interactive CME/CE online course which offers 0.5 continuing education credit hours.~The will also be asked to complete the LuCa course."
10018667|NCT05064046|Active Comparator|LuCa only module|"LuCa is a free interactive CME/CE online course entitled, Lung Cancer and the Primary Care Provider. For the purpose of this study, participants will be asked to complete session 1 which offers 1.0 continuing education credit hours, including AMA PRA Category 1 credits, AANP, and AAFP Prescribed credits."
10018668|NCT05058859|Experimental|Study Drug|The study drug is Dapagliflozin
10018669|NCT05058794|Experimental|Resistance exercise group|"During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and LOP was calculated in the body position that the blood flow restriction (BFR) stimulus would be applied. BFR pressure was set at 50% occlusion.Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.~Secondly, Rest between sets (1 min) Therapist will help these positions to maintain Knee extension and Wall Squatting.~The study includes interventional protocol of 6 weeks. Total sessions will be 12 and in each week there will 2 sessions with alternative days and follow up."
10018670|NCT05058794|Active Comparator|Conventional Therapy Group|Patients in this group will receive treatment via Knee extension,Wall squatting Each training session includes 3 minutes warm-up.First, participants will perform 2 sets with 15 repetitions in (0 to 90 degree.) Secondly, Rest between sets (1 min) Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. The study includes interventional protocol of 6 weeks. The sessions will be given on 2 alternate days making it a total of 12 sessions and then follow up.
10018671|NCT05058547|Experimental|SWEPPE|Participants will receive the smartphone application SWEPPE.
10018672|NCT05058547|No Intervention|Control|Participants randomized to the control group will not receive any active intervention for return to work after completing an Interdisciplinary Pain Rehabilitation Program .
10018673|NCT05057819|Experimental|Empagliflozin first, Placebo second|Oral empagliflozin 25 mg daily in the morning for 20 days, followed by oral placebo (daily in the morning) for 20 days after a wash-out period of 2-6 weeks
10018674|NCT05057819|Placebo Comparator|Placebo first, Empagliflozin second|Oral placebo (daily in the morning) for 20 days, followed by oral empagliflozin 25 mg daily in the morning for 20 days after a wash-out period of 2-6 weeks
10018675|NCT05057273|Experimental|omilancor (BT-11) 1,000mg|Participants will be randomized to receive BT-11 1000 mg tablets/Saline SC or Adalimumab SC/Placebo to BT-11 1000 mg tablets. Randomization to oral BT-11 or SC Adalimumab will be in a 3:1 ratio. The first dose of BT-11 1000 mg/ Saline SC, Adalimumab/ BT-11 matching placebo will be administered on site. All participants will take one tablet by the mouth of BT-11 1000 mg or matching placebo daily for 12 weeks, preferably at the same time in the morning.
10018676|NCT05057273|Active Comparator|adalimumab|Each participant will receive Adalimumab/Saline SC injections administered by an unblinded study nurse according to the following schedule: Week 0 (First dose): Adalimumab 160 mg/Saline SC (4 kits). Week 2: Adalimumab 80 mg/Saline SC (2 kits). Weeks 4, 6, 8, 10, and 12 (Last dose): 40 mg/Saline SC(1 kit).
10018677|NCT05056870|Experimental|Test/Control|Eligible subjects will be randomized to the sequence, Test/Control
10018678|NCT05056870|Experimental|Control/Test|Eligible subjects will be randomized to the sequence, Control/Test
10018679|NCT05056441||Cohort 1: Vedolizumab|Biologic-naïve participants diagnosed with CD, who have initiated vedolizumab treatment will be observed from the data of diagnosis of CD until the date of index when vedolizumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when vedolizumab treatment was initiated.
10018680|NCT05056441||Cohort 2: Ustekinumab|Biologic-naïve participants diagnosed with CD, who have initiated ustekinumab treatment will be observed from the data of diagnosis of CD until the date of index when ustekinumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when ustekinumab treatment was initiated.
10018681|NCT05055661|No Intervention|The control group|Patients randomized to the control group will receive conventional service at the reference Basic Health Unit and be contacted throughout the six months to collect the study variables, by telephone contact.
10018682|NCT05055661|Experimental|The intervention group|Patients randomized to the intervention grop will receive the same conventional service as the control group at the reference Basic Health Unit and also will be carried, once a month, the pharmaceutical teleconsultation during six months, by video call. The study variables will be collected in the same periods as the control group patients, by telephone contact.
10018683|NCT05053997|Experimental|NAVIGATE intervention arm|Nurse navigation
10018684|NCT05053997|No Intervention|Navigate control arm|Standard treatment and care
10018685|NCT05053646|Experimental|Marrow venting arm|Meniscal suture associated with marrow venting procedure
10018686|NCT05053646|Active Comparator|Control arm|Meniscal suture alone, without marrow venting procedure
10037458|NCT01825213||Multispectral CT of the liver|Images of lesions and liver will be compared to histology.
10037459|NCT01825226|Experimental|Program participation|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
10037460|NCT01825226|No Intervention|Control|
10018687|NCT05053139|Experimental|no PPX- no PPX - Mim8 PPXQW|Participants not receiving prophylaxis will not enter the run-in period. In arm 1, participants will be randomised to continue no prophylaxis (on-demand treatment with their Standard of Care FVIII concentrates) in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen
10018688|NCT05053139|Experimental|no PPX - Mim8 PPXQW - Mim8 PPXQW|Participants not receiving prophylaxis will not enter the run-in period. In arm 2, participants will be randomised to Mim8 once-weekly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen
9477250|NCT03564054|Experimental|Photodynamic Therapy|Photodynamic therapy (PDT) uses activation of a photosensitizer by light of a specific wavelength to generate reactive oxygen species and singlet oxygen that causes direct cell damage and death, apoptosis, tumor vasculature damage and thrombosis, and inflammation leading to an immunological response.Following randomization, subjects will undergo treatment with either PDT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment
10018689|NCT05053139|Experimental|PPX - Mim8 PPXQW|Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 3, participants will be randomised to once-weekly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.
10037461|NCT01825239|Other|Electrophysiology Study|This is a single arm study, all study participants will be referred for an Electrophysiology Study
10037462|NCT01825252|Experimental|Social Network Intervention|Approximately 20% of people in this condition will be trained to have discussions endorsing less risky behaviors with their social network members.
9477251|NCT03564054|Experimental|Argon Plasma Coagulation|Argon plasma coagulation (APC) is a noncontact form of electrocautery. Following randomization, subjects will undergo treatment with either DPT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment.
9477252|NCT03564028|Experimental|energy conservation technique|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
9477253|NCT03564028|Other|Control session|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
9477254|NCT03564015|Experimental|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
9477255|NCT03564015|Active Comparator|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.
9477256|NCT03564002||obese subjects|
9477257|NCT03564002||lean subjects|
9477258|NCT03563989|Experimental|Stentys Xposition S Self-Apposing stent|STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System
9477259|NCT03563989|Active Comparator|Conventional Balloon-expandable stent|Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.
9477260|NCT03563963|Active Comparator|Lidocaine 2% in Endotracheal Tube cuff|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
9477261|NCT03563963|Experimental|Ropivacaine 0.5% Endotracheal Tube cuff|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
9477262|NCT03563963|Active Comparator|Air in the Endotracheal Tube cuff|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
9477263|NCT03563950|Experimental|Rifampin + BMS-986224|Oral administration
9477264|NCT03563937||Phenprocoumon|Patients with NVAF who initiated the treatment of Phenprocoumon.
9477265|NCT03563937||Apixaban|Patients with NVAF who initiated the treatment of Apixaban.
9477266|NCT03563937||Rivaroxaban (Xarelto, BAY59-7939)|Patients with NVAF who initiated the treatment of Rivaroxaban.
9477267|NCT03563937||Edoxaban|Patients with NVAF who initiated the treatment of Edoxaban.
9477268|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
9477269|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
9477270|NCT03563911|Experimental|Brief Mindfulness-Based Intervention|Those assigned to the Brief Mindfulness-Based Intervention (BMBI) Arm will receive BMBI.
9477271|NCT03563911|Active Comparator|Control/Nutrition Education|Those assigned to the Control/Nutrition Education Arm will receive the nutrition education intervention.
9477272|NCT03563885|Experimental|RYGB or SG|Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
9477273|NCT03563885|No Intervention|Lean|Lean control subjects doing baseline testing only.
10018690|NCT05053139|Experimental|PPX- Mim8 PPXQM|Participants on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 4, participants will be randomised to once-monthly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthly Mim8 prophylaxis regimen.
10018691|NCT05052801|Experimental|Bemarituzumab with mFOLFOX6|
10018692|NCT05052801|Active Comparator|Placebo with mFOLFOX6|
10018693|NCT05052736|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
10018694|NCT05052736|Placebo Comparator|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
10018695|NCT05052268|Experimental|Phase 1 XTX202 Dose Escalation|Phase 1 Dose Escalation of XTX202 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
10018696|NCT05052268|Experimental|Phase 2 XTX202 Dose Expansion|"Part 2A will enroll patients with metastatic renal cell carcinoma who have progressed following standard-of-care treatment.~Part 2B will enroll patients with melanoma who have progressed following standard-of-care treatment."
10018697|NCT05051852||Women with low-grade squamous intraepithelial lesion (LSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as low-grade squamous intraepithelial lesion (LSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
10018698|NCT05051631|Experimental|Intervention plus 12 months maintenance|Clinics in this group will be in the control phase for 2 months, receive the 4 month intervention, and be in the maintenance phase for 12 months.
10018699|NCT05051631|Experimental|Intervention plus 10 months maintenance|Clinics in this group will be in the control phase for 4 months, receive the 4 month intervention, and be in the maintenance phase for 10 months.
10018700|NCT05051631|Experimental|Intervention plus 8 months maintenance|Clinics in this group will be in the control phase for 6 months, receive the 4 month intervention, and be in the maintenance phase for 8 months.
9803715|NCT03514394|Active Comparator|Problem Solving Therapy (PST)|6 weekly sessions to teach patients seven steps of problem solving (problem orientation, problem definition, goal setting, brain storming, decision making, action planning, solution evaluation).
9803716|NCT03514394|Experimental|Modified PST|This intervention will be a modification of PST, based on clinician feedback. It will be developed in phase 1 and 2 of this study. It will include elements of cognitive processing therapy, behavioral activation and distress tolerance. Anticipated number of sessions is 6.
10018701|NCT05051631|Experimental|Intervention plus 6 months maintenance|Clinics in this group will be in the control phase for 8 months, receive the 4 month intervention, and be in the maintenance phase for 6 months.
9477274|NCT03563872|Active Comparator|Active Comparator|Team-based care
9477275|NCT03563872|Experimental|Intervention|Enhanced team-based care
10018702|NCT05051631|Experimental|Intervention plus 4 months maintenance|Clinics in this group will be in the control phase for 10 months, receive the 4 month intervention, and be in the maintenance phase for 4 months.
10018703|NCT05050136|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
10018704|NCT05050136|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
10018705|NCT05050136|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
10018706|NCT05049733|Experimental|Arm 1|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 1 mg/kg and then switch to other doses after washout periods.
10018707|NCT05049733|Experimental|Arm 2|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 2 mg/kg and then switch to other doses after washout periods.
10018708|NCT05049733|Experimental|Arm 3|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 4 mg/kg and then switch to other doses after washout periods.
10018709|NCT05049733|Placebo Comparator|Arm 4|Participants will begin with ingestion of placebo soft gel tablets that do not contain cannabinoids and then switch to other doses after washout periods.
10018710|NCT05049135||Sleep apnea group|Patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
9477276|NCT03563846|Experimental|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
10018711|NCT05049135||Control group|partners of patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
9477277|NCT03563846|Experimental|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
9477278|NCT03563833|Other|Minimal Flow Anesthesia|"Minimal Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5). In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
9477279|NCT03563833|Other|High Flow Anesthesia|"High Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5) In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
9477280|NCT03563807|Experimental|Golf|Group golf lessons will be led by professional golf instructors.
9477281|NCT03563807|Active Comparator|Tai Chi|Group Tai Chi classes led by a certified Tai Chi instructor.
9477282|NCT03563794|Experimental|CSII(insulin Lispro)+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
9477283|NCT03563794|Active Comparator|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
9477284|NCT03563781|Other|SENTINEL NODE|Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)
9477285|NCT03563768|Experimental|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
9477286|NCT03563768|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
9477287|NCT03563755|Experimental|Cognitive Bias Modification (CBM) + Treatment as usual|Participants will receive access to a 3-week online training programme alongside their usual treatment.
9477288|NCT03563755|No Intervention|Treatment as usual|Participants will continue to receive their usual treatment.
10018712|NCT05049122|Experimental|Dupilumab|Dupilumab every 2 weeks (q2w). Dosing interval may be changed from q2w to q4w at week 24
10018713|NCT05049005|Active Comparator|RED FOOD Intervention Group|Participants in the RED FOOD group will be taught a simplified way of identifying high-calorie foods (red foods) and reducing them using the Traffic Light Diet. Limiting the number of red foods consumed is a simple way to reduce calories without having to track calories. Participants in this group will use the study website to track their red foods and will be given a daily red food limit base on their baseline weight and will track their red foods on the study website daily. Participants will be recommended to enter their red foods at least once per day (at which time they would enter all red foods for the day), but ideally multiple times per day to reduce errors associated with recall.
10018714|NCT05049005|Experimental|GREEN FOOD Intervention Group|Participants in the GREEN FOOD group will be taught a simplified way of identifying low-calorie foods (green foods) and maximizing them using the Traffic Light Diet. Maximizing the number of green foods consumed is a simple way to reduce dietary energy density while allowing for consumption of a satisfying amount (i.e. weight and volume) of food. Maximizing green food consumption may simultaneously reduce red food consumption, thereby reducing calorie intake and promoting greater diet quality than red food reduction alone. Participants in this group will also use the study website to track their green foods and will be given a daily green food goal based on their baseline weight and will track their green foods on the study website daily. Participants will be recommended to enter their green foods at least once per day (at which time they would enter all green foods for the day), but ideally multiple times per day to reduce errors associated with recall.
10018715|NCT05047198|Active Comparator|Control|Catheter Ablation using invasive mapping
10018716|NCT05047198|Experimental|Treatment|Radio-ablation using non-invasive mapping
10018717|NCT05047159|Experimental|drug therapy group|Drug: drug therapy There is no restriction on the choice of therapeutic drugs.
10018718|NCT05047159|Experimental|drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group|"Device: rTMS Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
10018719|NCT05047159|Experimental|drug therapy combined with light therapy group|"Device: light therapy Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
10037463|NCT01825252|Active Comparator|Counsel, Test, and Treat|People in this arm will only receive standard-of-care counseling, testing, and treatment for HIV and STDs.
9477289|NCT03563729|Experimental|B: Pembrolizumab (Prednisolone >10 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
9803717|NCT03505424|Active Comparator|Group 1: Standard of Care|Parents of infants born from April -mid-August 2018 (Group 1)
10037464|NCT01825291||sleep apnea|
10018720|NCT05047159|Experimental|drug therapy combined with electroconvulsive therapy (ECT) group|"Device: ECT The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
10018721|NCT05047159|Experimental|drug therapy combined with magnetic seizure therapy (MST) group|"Device: MST A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.~Drug: drug therapy There is no restriction on the choice of therapeutic drugs."
10018722|NCT05046158|Active Comparator|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using Transforming Powder Dressing and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to other standard of care dressings used to treat diabetic foot ulcers.Surveys regarding pain and quality of life will be completed at each study visit.
10037465|NCT01825304|Active Comparator|esophageal pressure ,titrated setting|
10037466|NCT01825304|Other|ARDSNet recommendations,peep|
10018723|NCT05046158|Active Comparator|Standard of Care Dressing|Half of the subjects will be randomized to receive standard of care wound dressings to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using standard of care wound products, and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to transforming powder dressings used to treat diabetic foot ulcers. Surveys regarding pain and quality of life will be completed at each study visit.
10018724|NCT05045547||Patients with febrile illness|Febrile patients attending village malaria workers (VMWs)
10018725|NCT05045547||Health centre staffs|Health centre staffs from 12 rural health centres
10018726|NCT05045547||Key stakeholders|"Key stakeholders , for example health managers and health professionals:~the director, deputy-directors, and technical officers at the National Malaria Control Program;~the directors and deputy-directors of the Provincial Health Departments in Battambang and Pailin province;~health officers actively involved in community-based (malaria) programmes at the district levels in Battambang and Pailin provinces;~health workers (i.e., nurses or doctors) actively involved in community-based (malaria) programmes in Battambang and Pailin provinces;~community representatives and village malaria workers from villages in both Battambang Pailin province."
10036152|NCT01813162|Experimental|Vaginal product and Tenofovir 1% gel|"Tenofovir gel: Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.~In addition, Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen). Use of TFV gel will begin on day 15 of IVR use."
10036153|NCT01813175|Active Comparator|Intervention Group I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
10036154|NCT01813175|Active Comparator|Interventional Group II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
10036155|NCT01813175|Placebo Comparator|Control Group|Regular non-hydrolysed cow's milk based infant formula
10036156|NCT01813175|No Intervention|Reference Group|Exclusively breast-fed infants
10036157|NCT01813188|Experimental|ABM seeded onto a porous TCP and DBM|ABM seeded onto a porous TCP and DBM
10036158|NCT01813188|Active Comparator|autologous bone graft|autologous bone graft
10036159|NCT01813201|Active Comparator|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)
9477290|NCT03563729|Experimental|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
9803718|NCT03505424|Active Comparator|Group 2: NICU2HOME app|Parents of infants born from mid-August 2018- January 2019 (Group 2)
10018727|NCT05040971|Experimental|Semaglutide|Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks
10018728|NCT05040971|Placebo Comparator|Placebo (semaglutide)|Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks
10018729|NCT05040204|Experimental|Experimental Supplement 1|6 subjects will consume 12 grams of dietary supplement 1 daily for 4 weeks
10018730|NCT05040204|Experimental|Experimental Supplement 2|6 subjects will consume 12 grams of dietary supplement 2 daily for 4 weeks
10018731|NCT05040204|Experimental|Experimental Supplement 3|20 subjects will consume 50 grams of dietary supplement 3 daily for 4 weeks
10018732|NCT05040204|Placebo Comparator|Placebo Comparator 1|6 subjects will consume 12 grams of placebo dietary supplement daily for 4 weeks
10018733|NCT05040204|Placebo Comparator|Placebo Comparator 2|6 subjects will consume 50 grams of placebo dietary supplement daily for 4 weeks
10018734|NCT05039645|Other|Open Arm Study - All participants|"Study is open arm with no blinding or randomisation. Patients will receive standard care including frequent clinical visits, education, and preventative foot care/podiatry as required. Patients will also be given a DFS thermovisual scanner device. Patients will be instructed to use the DFS on a daily basis, at home, to record thermovisual data about the soles of their feet.~Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of >2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment)."
10018735|NCT05039476|Active Comparator|Retinol face cream|Retinol face cream on one half of the participant's face
10018736|NCT05039476|Placebo Comparator|Placebo face cream|Placebo face cream on one half of the participant's face
10018737|NCT05039450|Experimental|EFX 28 mg|
10018738|NCT05039450|Experimental|EFX 50 mg|
10018739|NCT05039450|Placebo Comparator|Placebo|
10018740|NCT05039411|Experimental|Human umbilical cord mesenchymal stem cells (UC-MSCs)|All patients to receive allogeneic UC-MSCs via intralesional injection
10018741|NCT05038787|Experimental|LY3473329|LY3473329 administered orally.
10018742|NCT05038787|Placebo Comparator|Placebo|Placebo administered orally.
10018743|NCT05038436|Experimental|Polyglucosamine L112|composed of (beta-1.4 polymer of D-glucosamine and N-acetyl-D-glucosamine)
10018744|NCT05038436|Placebo Comparator|Placebo|Dicalcium phosphate, cellulose
10018745|NCT05038176|Experimental|Active intervention group (AI)|The active intervention group (AI) receiving the active treatment (MANUP intervention) which include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
10018746|NCT05038176|Active Comparator|Delayed intervention group (DI)|"DI participants will only receive motivational text-messages. They will then flip and receive full intervention after the AI group has completed the program."
10018747|NCT05038150|Experimental|one arm|Cohorts of 3 patients will be enrolled, admitted to an infusion unit, and treated with a single IV infusion of SGN1 over 2 hours and closely evaluated for DLTs for 28 days after the infusion unit. Up to 5 cohorts will be evaluated.
10018748|NCT05037955||ILIT from trial NCT00470457|Patients who received ILIT in the original trial in 2005
10018749|NCT05037955||SCIT from trial NCT00470457|Patients who received SCIT in the original trial in 2005
10018750|NCT05037955||SCIT outpatient control|Patients who visited the allergy unit at the University Hospital Zurich and completed SCIT in the last 5 years
10018751|NCT05037669|Experimental|Cohort A: Acute Lymphoblastic Leukemia (ALL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Acute Lymphoblastic Leukemia (ALL)
10018752|NCT05037669|Experimental|Cohort B: Chronic Lymphocytic Leukemia (CLL) + Non-Hodgkin's Lymphoma (NHL)|Adult patients aged >18 with relapsed or refractory B cell malignancies - Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL).
10018753|NCT05036018|Active Comparator|Group 1|Patients treated with the ACURATE neo2 valve under isolated local anesthesia
10018754|NCT05036018|Active Comparator|Group 2|Patients treated with the ACURATE neo2 valve under local anesthesia with conscious sedation (CS)
10018755|NCT05036018|Active Comparator|Group 3|Patients treated with the Evolut Pro or Pro+ valve under isolated local anesthesia
10018756|NCT05036018|Active Comparator|Group 4|Patients treated with the Evolut Pro or Pro+ valve under local anesthesia with conscious sedation (CS)
10018757|NCT05035680|Active Comparator|Arm i - Seasonal influenza vaccine|Single 0.5 mL intramuscular (IM) injection of an unadjuvanted seasonal influenza vaccine
10018758|NCT05035680|Experimental|Arm ii - SWE and unadjuvanted seasonal influenza vaccine|Single 0.8 mL IM injection of SWE mixed with unadjuvanted seasonal influenza vaccine
10018759|NCT05035680|Active Comparator|Arm iii - MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
10018760|NCT05035082|Experimental|oral semaglutide|All participants are given tablets used in addition to metformin.
10018761|NCT05035082|Active Comparator|other oral glucose lowering medication|All participants are given tablets used in addition to metformin.
10018762|NCT05034068|No Intervention|control|the patients will be treated by using oral care only and evaluation will be done before cancer treatment and weekly till the treatment completed. In each weekly visit, oral sites will be examined, and a score was given to each site based on the degree of mucositis.
10018763|NCT05034068|Active Comparator|bezaydamine hydrochloride.|All patients were advised to rinse 15 mL of the solution benzydamine for 2 min, four to eight times daily before and during, and for 2 weeks after completion of cancer therapy. In case of any problem (e.g. burning or stinging), patients will be allowed to dilute the solution with water in the ratio 1:1 or 1:2. Study evaluations will be conducted before cancer treatment and weekly thereafter until 2 weeks after completion of the therapy .In each weekly visit, oral sites were examined and a score was given to each site based on the degree of mucositis.
10018764|NCT05034068|Active Comparator|low-level laser therapy|the patients will be treated by using a low-level laser therapy, the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2. The irradiations will be done intra-orally avoiding the tumor site, oral examinations will be recorded at each irradiation session and the degree of mucositis will be recorded.
10018765|NCT05033782||MS patients|"This group includes patients living in Ile de France, followed in the neurology department of the Pitié Salpêtrière Hospital in Paris for relapsing-remitting MS.~Clinical examination will be performed to evaluate the disability (EDSS scale), as part of the care (systematic for all MS consultations)~- A paper questionnaire is given to the patient during the consultation. The patient will be contacted by telephone within 15 days after the consultation by a health care staff to collect the answers to the questionnaire."
10018766|NCT05033743|Experimental|Treatment Group|Secnidazole treatment
9477291|NCT03563729|Experimental|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
9477292|NCT03563729|Experimental|E: BRAF/MEK -> ipi/nivo (prednisolone >10 mg)|Induction treatment with BRAF/MEK inhibitors (either the combination of encorafenib/binimetinib or dabrafenib/trametinib) orally for 28 days followed by intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
10018767|NCT05032274|Experimental|Single group|The study will include one group and each participant will perform home-based exercise for 8-weeks.
10018768|NCT05032040|Experimental|XmAb20717|
10018769|NCT05031195||1st tertile|
10018770|NCT05031195||2nd tertile|
10018771|NCT05031195||3rd tertile|
10018772|NCT05030870|Experimental|Capnographic monitoring group|In this group, in addition to the standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients, the capnographic is also monitored. The capnographic data of the patients are available for additional noninvasive assessment of ventilation.
10018773|NCT05030870|Active Comparator|Standard monitoring group|In this group, standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients. Capnographic data are not visible by closing the CO2 sampling line till the endoscopy end.
10018774|NCT05030025|Experimental|Group 1|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fasting conditions.
10018775|NCT05030025|Experimental|Group 2|single-dose pharmacokinetics will be characterized in twenty-four (24) healthy, adult males and females not of childbearing potential under fed conditions.
10018776|NCT05028361|Other|Simultaneous Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and IIV4 at Visit 1, saline placebo at Visit 2, and mRNA COVID-19 vaccine at Visit 3 for participants receiving their primary series of mRNA COVID-19 vaccine.
10018777|NCT05028361|Other|Sequential Vaccination Group|Subjects will receive a dose of mRNA COVID-19 vaccine (either as a study procedure or standard of care) and placebo at Visit 1, IIV4 at Visit 2, and mRNA COVID-19 vaccine at Visit 3 for participants receiving their primary series of mRNA COVID-19 vaccine.
10018778|NCT05027646|Experimental|Part 1 - Bioequivalence|Bioequivalence will be measured in approximately 42 healthy male and female subjects at a single center in the US to achieve at least 33 completers.
10018779|NCT05027646|Experimental|Part 2 - Adhesion|Adhesion will be measured in approximately 90 healthy male and female subjects are planned to be enrolled at a single center in the US.
10018780|NCT05025124||Method comparison|400 samples to be compared directly against the reference method. This is to get the bias estimate.
10018781|NCT05025124||Precision|30 samples will be each split into 10 individual samples to evaluate the precision of the Entia Liberty devices.
10018782|NCT05024903|Active Comparator|Control Group: (PWG 1.0)|Those randomized to PWG 1.0 would have already completed their serious illness medical planning. Further involvement in the trial will be solely for the purposes of the outcome data collection
10018783|NCT05024903|Active Comparator|Intervention group: PWG 2.0|Serious illness medical planning plus the novel e-health platform designed to help people more broadly think and plan ahead
10018784|NCT05024162|Experimental|Prospective Cohort|Sixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).
10036160|NCT01813201|Placebo Comparator|Saline isotonic solution (Placebo)|Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).
10036161|NCT01813240|Experimental|Minocycline, Spinal Tumor patients, quality of life|
10036162|NCT01813240|Experimental|Minocycline, Trauma patuents, quality of life|
10036163|NCT01813240|Placebo Comparator|Placebo, Trauma patients, quality of life|
9477293|NCT03563703|Experimental|Ultrasound imaging|Ultrasonography offers visual information about the size and depth of blood vessels, potentially facilitating intravenous placement of the needle in real time.
9477294|NCT03563703|Experimental|Near-infrared imaging|Near-infrared imaging devices project near-infrared light onto the skin, which is absorbed by deoxygenated hemoglobin. The invisible image of the underlying vascular pattern is captured by the device, processed and projected, in real time, back onto the patient's skin using visible green light. This technology allows hands-free visualization of a vascular map to guide catheter placement.
9477295|NCT03563677|No Intervention|Usual care|Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities
9477296|NCT03563677|Experimental|New Innovative Care|The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)
10018785|NCT05022550|Experimental|DEEPVR Experiment Group|Youth will be asked to experience an immersive virtual-reality simulation. Youth will wear a lightweight, ultra-high-resolution, wireless, head-mounted VR display (HTC Vive Pro Eye; HTC Corp., Taiwan). Each session will proceed through a series of three stages. First, participants will begin with a 5-min. acclimation period inside a demo VR environment. Second, baseline levels of physiological arousal will be captured over a 5 min. resting period where participants will be asked to sit quietly in a serene virtual environment. Physiological data will be collected using disposable gel-pad electrodes placed on the fingers (galvanic skin response) and torso (electrocardiography). Third, youth will progress through the DEEP VR experience for 15 minutes (see Behavioral Task), an underwater navigation video game wherein regularized, diaphragmatic breathing facilitates movement.
10018786|NCT05022524|Experimental|Transition-Age Adults|16-25 year old patients on stable dose of antipsychotic medication for treatment of depression or anxiety.
10018787|NCT05022511|Experimental|Intervention group|"All women aged 50-69 years attending breast cancer screening in the intervention unit on an intervention day. They will all be offered to receive information on their screening status in cerical cancer og colorectal cancer screening.~Women aged 50-64 years, who have not had a cervical cytology sample taken within 5 years and 6 months will be offered to receive a self-sample device for high risk human papilloma virus (hrHPV) screening by mail, or reminded to see her general practitioner (GP) to have a conventional cervical cytology sample taken.~Women aged 50-69 years, who have not had a Faecal Immunochemical Test (FIT) within 2 years and 4.5 months will be offered to receive a new self-sampling kit for FIT."
10018788|NCT05022511|No Intervention|Control group|Women in the control group will receive standard screening offers according to the national screening programme.
10018789|NCT05021991|Experimental|PRAX-944 (120 mg)|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
10018790|NCT05021991|Experimental|PRAX-944 (60 mg)|Once daily, oral dosing with titration to 60 mg: 3 days of 20 mg, 4 days of 40 mg, 49 days of 60 mg
10018791|NCT05021991|Experimental|PRAX-944 (20 mg)|Once daily, oral dosing: 56 days of 20 mg
10018792|NCT05021991|Placebo Comparator|Placebo|Once daily, oral dosing: 56 days of placebo
10018793|NCT05021809|No Intervention|Group A|control group will not receive any intracanal medication
10018794|NCT05021809|Active Comparator|Group B|Calcium hydroxide intracanal medication without iodoform (Metapaste )
10018795|NCT05021809|Active Comparator|Group C|Calcium hydroxide intracanal medication with iodoform (Metapex)
10018796|NCT05021224|Other|Engagement strategy groups|We anticipate that approximately 25 patients will receive an engagement strategy (~5 patients per strategy; only 1 strategy per patient). The exact strategies will be developed during the course of this R21 and cannot yet be specified. This is a non-control, pilot feasibility trial.
10018797|NCT05019924|Active Comparator|Intervention arm|Dietary supplement
10018798|NCT05019924|No Intervention|Control arm|No intervention given
10036164|NCT01813240|Placebo Comparator|Placebo, Spinal cord tumors, quality of life|
10036165|NCT01813253|Experimental|Irinotecan and nimotuzumab|Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
9803719|NCT03505424|Active Comparator|Group 3: SMART NICU2HOME app|Parents of infants born from February- June 2019 (Group 3)
10018799|NCT05019209|Experimental|Exposure to saline-dissolved house dust mite allergen and allergen-free air|Subjects are blinded to the sequence of interventions in the allergen challenge chamber (ACC). Overall, subjects will be in the ACC 4 times during the study. Of those, exposure to allergen-free air and HDM is allocated in a 2:2 ratio.
10018800|NCT05018026|No Intervention|Arm 1 (Control Arm)|A default NUSMart that mirrors a conventional web-grocery store in Singapore where some healthier products are displayed with Singapore's Healthier Choice Symbol (HCS) logos (Control).
10018801|NCT05018026|Experimental|Arm 2 (Nutri-Grade Arm)|Similar to Arm 1 except that beverages will be displayed with a color-coded and graded Nutri-Grade label.
10018802|NCT05017584|Experimental|Hyperbaric bupivacaine 10.5mg|
10018803|NCT05017584|Experimental|Hyperbaric bupivacaine 12mg|
10018804|NCT05017584|Experimental|Hyperbaric bupivacaine 13.5mg|
10018805|NCT05017584|Experimental|Hyperbaric bupivacaine 15mg|
10018806|NCT05016687|Experimental|Experimental Part I Cohort 1-5: CUR-N399|Healthy subjects 18-55 years will receive single ascending doses of CUR-N399. Planned doses for respective Cohorts: Cohort 1: 2.5 mg, Cohort 2: 7.5 mg, Cohort 3: 17.5 mg, Cohort 4: 35 mg, Cohort 5: 50 mg.
10018807|NCT05016687|Placebo Comparator|Experimental Part I Cohort 1-5: Placebo|Healthy subjects will receive Placebo to match treatment of CUR-N399.
10018808|NCT05016687|Experimental|Experimental Part IIa Cohort 1-3: CUR-N399|Healthy subjects 18-55 years will receive multiple ascending doses of CUR-N399 during a 7-day period. Planned doses for respective Cohorts: Cohort 1: 10 mg/day, Cohort 2: 25 mg/day, Cohort 3: 50 mg/day.
10018809|NCT05016687|Placebo Comparator|Experimental Part IIa Cohort 1-3: Placebo|Healthy subjects 18-55 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
10018810|NCT05016687|Experimental|Experimental Part IIb: CUR-N399|Healthy subjects >/= 65 years will receive multiple ascending doses of CUR-N399 during a 7-day period. The dose to be administered will determined based on safety results in Part IIa.
10018811|NCT05016687|Placebo Comparator|Experimental Part IIb: Placebo|Healthy subjects >/= 65 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
10018812|NCT05015803|Experimental|CBTi with Application|Device-based intervention facilitation and clinician interfacing for Cognitive Behavioral Therapy for Insomnia (CBTi).
10018813|NCT05015803|Active Comparator|CBTi|Standard CBTi delivered via video conferencing [Zoom Health].
10018814|NCT05015803|Active Comparator|Sleep Hygiene|Treatment as usual: Sleep hygiene education and training.
10018815|NCT05014776|Experimental|Arm A - Tadalafil, Pembrolizumab, Ipilimumab, CRS-207|
10018816|NCT05013567|Experimental|Ibuprofen gel 5%|
10018817|NCT05013567|Placebo Comparator|Placebo|
10018818|NCT05013502|Experimental|Empagliflozin 10mg PO daily for 12 weeks|Single arm trial
10018819|NCT05013229|Experimental|IcoSema|Participants will receive once weekly subcutaneous (s.c) injections of IcoSema during the 52-week treatment period.
10018820|NCT05013229|Active Comparator|Insuling glargine/insulin aspart|Participants will receive subcutaneous (s.c) injections of insulin glargine once daily combined with 2-4 times daily injections of insulin aspart.
10018821|NCT05012397|Experimental|Milademetan (RAIN-32)|260 mg once dailly orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
10018822|NCT05012358||Observational Cohort|no intervention
10018823|NCT05011409||Newly diagnosed breast cancer patients|Newly diagnosed breast cancer patients referred to Kazakh Institute of Oncology and Radiology or Almaty Oncology Center will be assessed on the prevalence of depression and anxiety symptoms.
10018824|NCT05011253||Intervention|The group which will receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria and makes recommendations for follow-up.
10018825|NCT05011253||Control|The group which will not receive the InBasket message to notify users that a patient has clinically significant microscopic hematuria. (Standard practice)
10018826|NCT05010915|Experimental|dorsolateral prefrontal cortex|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
10018827|NCT05010915|Experimental|ventrolateral prefrontal cortex|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
10018828|NCT05010915|Placebo Comparator|sham comparator|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
10018829|NCT05010408|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort|Full sweetness (sugar) for 6 months
10018830|NCT05010408|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
10018831|NCT05010408|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort|Reduced sweetness (moderate sugar level) for 6 months
10018832|NCT05010408|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
10036166|NCT01813253|Active Comparator|Irinotecan|Administration of irinotecan 150 mg/m2 IV once every 2 weeks
9480722|NCT05261698|Experimental|Assigned Interventions|Experimental group: in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
9803720|NCT03499483|Experimental|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
10018833|NCT05010408|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
10018834|NCT05010408|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
10018835|NCT05009732|Experimental|Proxalutamide (GT0918) plus standard of care|Participants receive 300mg once daily orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
10018836|NCT05009732|Placebo Comparator|Placebo plus standard of care|Participants will receive placebo tablets matching Proxalutamide (GT0918) orally plus standard of care for 7 days and can be extended up to 14 days per investigator discretion
10018837|NCT05008926|Experimental|Naloxegol|"Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.~Management of constipation and gastroparesis according to the recommendations."
10018838|NCT05008926|Placebo Comparator|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
10018839|NCT05007925|Experimental|Single-arm|
10018840|NCT05007821|Experimental|Arm A|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm A participants will take linezolid (LZD) once a day for the entire treatment period.~Weeks 1-26: LZD 600 mg once daily (QD)~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
9480723|NCT05261685|Experimental|Hyperopic patients planned to undergo single-step transepithelial PRK|Patients with moderate hyperopia or hyperopic astigmatism were planned to undergo bilateral transepithelial PRK using the new single-step StreamLight PRK Technology.
10018841|NCT05007821|Experimental|Arm B|"Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm B participants will take a higher dose of linezolid (LZD) once a day for 4 weeks and then continue taking that higher dose of LZD just three times a week for the rest of the treatment period.~Weeks 1-4: LZD 1200 mg once daily (QD)~Weeks 5-26: LZD 1200 mg three times per week (TIW)~Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD~Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD~Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD"
10018842|NCT05006144|Other|control group|control group
10018843|NCT05006144|Experimental|Experimental group|selective dorsal rhizotomy
10018844|NCT05006014||Patient with non restorable teeth|Patient with non restorable teeth located in smile line needs extraction with immediate implantation and immediate provisionalization to improve psychiatric effect of tooth loss
10018845|NCT05005026|Active Comparator|Virtual reality (VR) game 1|Participants will be asked to play a virtual reality game twice a day for 10 days.
10018846|NCT05005026|Active Comparator|Virtual reality (VR) game 2|Participants will be asked to play a virtual reality game twice a day for 10 days.
10036167|NCT01813266||Usual practice in screening for Hepatitis C virus.|Three clinics in this group will use this approach.
10036168|NCT01813266||USPTF risk factors to screen for chronic HCV infection.|3 internal medicine clinics will use this screening strategy.
10018847|NCT05004350|Experimental|Encorafenib and cetuximab|"Safety Lead-in (SLI) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~Randomized (Phase II) phase:~28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
10036169|NCT01813266||USPTF/CDC recommendations to screen for chronic HCV infection.|3 internal medicine clinics.
10036170|NCT01813279|Experimental|patients|
10018848|NCT05004350|Experimental|Irinotecan and cetuximab or FOLFIRI and cetuximab|"Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles.~Irinotecan and cetuximab:~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks and~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly~OR~FOLFIRI and cetuximab:~irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks~Folinic acid 400 mg/m² (120-minute infusion or to study site standards) or maximal dose tolerated in a prior regimen every 2 weeks~5-FU 400 mg/m² initial dose bolus (not to exceed 15 minutes), then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46 to 48 hours) continuous infusion or maximal dose tolerated in a prior regimen every 2 weeks and~cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly"
10018849|NCT05001373|Experimental|Study Group 1|eOD-GT8 60mer mRNA Vaccine (100µg)
10018850|NCT05001373|Experimental|Study Group 2|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
10018851|NCT05001373|Experimental|Study Group 3|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
10018852|NCT05001373|Experimental|Study Group 4|Core-g28v2 60mer mRNA Vaccine (100µg)
9477297|NCT03563664|Experimental|Study group|38 ovulatory patients with unexplained recurrent implantation failure were recruited. Pre-treatment endometrial biopsy and immunohistochemical examination for endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was done. After treatment with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks, post-treatment endometrial biopsy and immunohistochemical examination was repeated and compared with previous results.
10018853|NCT05001282|Experimental|ELU001|Dose Escalation: Escalating doses of ELU001 Dose Expansion: Recommended Dose for Expansion (or RP2D)
10018854|NCT05001022|Experimental|ALG-020572|Subcutaneous injections of ALG-020572 in HV or CHB subjects, up to 7 injections over the course of up to 29 days
10018855|NCT05001022|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 7 injections over the course of up to 29 days
10018856|NCT05000905|Experimental|Adaptive Attention Training|Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.
10018857|NCT05000905|Active Comparator|Low-dose Adaptive Attention Training|Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.
10018858|NCT05000645|No Intervention|Women, Infants, and Children (WIC)|Usual WIC counseling and food benefits for use in person at approved grocery stores.
10018859|NCT05000645|Experimental|WIC + grocery delivery|Usual WIC counseling and food benefits, as well as twice-monthly home deliveries of WIC-approved foods.
10018860|NCT05000645|Experimental|WIC + grocery delivery + unsweetened beverage delivery|Usual WIC counseling and food benefits as well as twice-monthly home deliveries of WIC-approved foods PLUS unsweetened beverages to replace their current sugar-sweetened beverages (SSB) intake.
10018861|NCT05000541||Armolipid-L/Armolipid Plus-L|Armolipid-L used for participants in Germany and Poland Armolipid Plus-L used for participants in Austria
10018862|NCT05000151||Patients|Hypermobile Ehlers-Danlos patients (n=21)
10018863|NCT05000151||Healthy subjects|Healthy subjects recruited from the clinic's staff (n=21) Age, Gender and BMI matched with hEDS patients
9480724|NCT05261672|Active Comparator|Group QL1|quadratus lumborum block will be done. 20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
9480725|NCT05261672|Active Comparator|Group QL2|quadratus lumborum block will be done. ) 20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
9480726|NCT05261646|Experimental|Hetrombopag|
10018864|NCT04999644|Experimental|Reduced Nicotine, Full Expectancy|Receive reduced nicotine cigarette expecting full
10018865|NCT04999644|Experimental|Full Nicotine, Full Expectancy|Receive full nicotine cigarette expecting full
10018866|NCT04999644|Experimental|Full Nicotine, Reduced Expectancy|Receive full nicotine cigarette expecting reduced
9480727|NCT05261646|Placebo Comparator|Matching placebo|
9480728|NCT05261633||Healthy Volunteers|
9480729|NCT05261633||Known Liver Metastases|
10018867|NCT04999644|Experimental|Reduced Nicotine, Reduced Expectancy|Receive reduced nicotine cigarette expecting reduced
10018868|NCT04999358|Experimental|Protein group|Participants in the protein group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the protein group will be provided with an additional targeted protein education session, which will aim to increase the amount of foods eaten with protein in them (≥1.2 g/kg protein/day) and improve the quality of protein sources that are eaten. The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD
10036171|NCT01813318|Placebo Comparator|Placebo/sugar pill|Placebo will be dosed similar to acamprosate, in terms of dosage form, frequency and duration.
10036172|NCT01813318|Active Comparator|Acamprosate|"Acamprosate: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.~Other Name: Campral"
10036173|NCT01813331||Chronic Heart Failure Patients|Chronic Heart Failure patients older than 65 years, which accept to participate to the study and give their informed written consent and consecutively refer to the A.R.C.A Campania Cardiologists in the pertaining healthcare districts.
10018869|NCT04999358|Placebo Comparator|Control group|Participants in the control group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the control group will receive an additional dietary education session that is similar to the standard practice sessions, containing only information that is usually provided in the cardiac rehabilitation programme.The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD.
10018870|NCT04998708|Experimental|Intervention|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM). We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
10018871|NCT04998708|No Intervention|Control|
10018872|NCT04998682|Experimental|Targeted Axillary Dissection (TAD)|During standard of care (SoC) surgery to remove breast cancer, study participants will undergo a sampling of lymph nodes in the axilla first and then complete removal of axillary lymph nodes under the arm.
10018873|NCT04997577|Experimental|Auditory training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios.
10018874|NCT04997577|Experimental|Auditory-cognitive training paradigm|Participants perform speech-in-noise perception tasks with real-world scenarios. A short-term memory component is added to the training paradigm to make the task more engaging and challenging.
10018875|NCT04997577|Sham Comparator|Active control of informational videos|Individuals are asked to watch informational videos.
10018876|NCT04997096|Experimental|Exercise|"Participants randomized to one of two groups with 2:1 ratio: exercise (n=20)~- Aerobic and Resistance Exercise for 16 weeks"
10018877|NCT04997096|Active Comparator|Attention Control|"Participants randomized to one of two groups with attention control (n=10).~-Attention Control for 16 weeks home-based stretching"
10018878|NCT04997044|Other|control group|control group
10018879|NCT04997044|Experimental|Experimental group|selective dorsal rhizotomy group
10018880|NCT04996758|Experimental|Toripalimab and Anlotinib Combination Treatment|Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity
10018881|NCT04994496|Experimental|Web-based intervention group|Two-week web-based intervention group
10018882|NCT04994496|Sham Comparator|Web-based control group|Two-week web-based sham comparator
10018883|NCT04994002|Experimental|Cohort 1: CERC-006 (0.5 mg)|Approximately 5 participants will receive CERC-006 at a dose of 0.5 mg twice daily for 28 days.
10018884|NCT04994002|Experimental|Cohort 2: CERC-006 (1 mg)|Following a safety review, if there are no clinically important safety findings in Cohort 1, a second cohort of approximately 5 participants will be enrolled to receive CERC-006 at a dose of 1 mg twice daily for 28 days.
10036174|NCT01813383||HLA-DR3-DQ2 patients|Patients with HLA-DR3-DQ2 haplotype
10018885|NCT04993703|Experimental|Kinesiotaping|"A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.~Additionally for this group, kinesiotaping will be applied by using carpal tunnel technique including button hole and I band technique of space correction; and with 25-50% tension in center of tape over dorsal carpal tunnel at the end of the each session. Patients will request to keep kinesiotaping at nights throughout the study."
10018886|NCT04993703|Experimental|Night splinting|"A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.~Additionally, night splinting will be advised. Patients will request to keep their splints at nights throughout the study."
10018887|NCT04993703|Experimental|Control group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.
10018888|NCT04993300|Experimental|transcranial magnetic stimulation (TMS)|This arm constitute of methamphetamine users who undergone abstinent period
10018889|NCT04992065|Experimental|Oral NNC0385-0434 15 mg once-daily (OD)|15 mg NNC0385-0434 co-formulated with 500 mg Salcaprozate sodium (SNAC) tablet once daily
10018890|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 15 mg)|15 MG placebo administered as tablets (without SNAC) once daily
10018891|NCT04992065|Experimental|Oral NNC0385-0434 40 mg OD|40 mg study drug co-formulated with 500 mg SNAC tablet once daily
10018892|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 40 mg)|placebo administered as tablets (without SNAC) once daily
10018893|NCT04992065|Experimental|Oral NNC0385-0434 100 mg|100 mg NNC0385-0434 co-formulated with 500 mg SNAC tablet once daily (51 participants)
10018894|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 100 mg)|placebo administered as tablets (without SNAC) once daily
10018895|NCT04992065|Active Comparator|Subcutaneous evolocumab 140 mg Q2W|140 mg evolocumab Subcutaneous (s.c.) injections every 2 weeks (51 participants). The s.c. evolocumab arm is open-label to limit unnecessary injections
10018896|NCT04991818|Experimental|Pregnant women or children 0-5 years of age|Pregnant women in third trimester or children 0-5 years of age
10018897|NCT04991077||patients group|patients with malignant hypertension
10018898|NCT04991077||Control group|patients with severe hypertension (Grade 2 or 3 hypertension)
10018899|NCT04990336|Experimental|DDC(Dachaihu decoction compound) Group|Treated with Dachaihu decoction compound and regular therapies
10018900|NCT04990336|Active Comparator|RSM(rhubarb single medicine) Group|Treated with rhubarb single medicine and regular therapies
10018901|NCT04990336|Other|N Group|Treated with regular therapies and without traditional Chinese medicine
10018902|NCT04989738|Experimental|THRIVE Condition|Specifically, parents will learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
10018903|NCT04989738|Active Comparator|Care As Usual - Healthy Steps Model|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
10018904|NCT04989725|Active Comparator|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
10018905|NCT04989725|Experimental|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
10036175|NCT01813383||HLA-DR7-DQ2 patients|Patients with HLA-DR7-DQ2 haplotype
10018906|NCT04989647|Experimental|A: Surgery only|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*. No further treatment will be administered.~*PLND can be avoided in patients with tumours < 4cm"
10018907|NCT04989647|Experimental|B: Surgery + radiothrerapy|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*, followed by adjuvant treatment.~*PLND can be avoided in patients with tumours < 4cm"
10018908|NCT04989621|Experimental|Orelabrutinib plus Rituximab followed by Maintenance with Orelabrutinib|"Induction therapy: Patients receive Orelabrutinib at a dose of 25 mg once daily on days 1-28 and rituximab at a dose of 375mg/m2 on day 1. Treatment cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~If patients achieve CR or PR or SD, they will be treated with maintenance therapy Maintenance therapy: Patients receive Orelabrutinib every day at a dose of 150mg for up to two years in the absence of disease progression or unacceptable toxicity."
10018909|NCT04989049|Active Comparator|intervention group or case group|topical folic acid on oral ulcers will be applied for 7 days and patients will be asked to visit after 7 days for follow up
10018910|NCT04989049|Placebo Comparator|control group|placebo drug for oral ulcers
10018911|NCT04988867|Experimental|Drug - trofinetide|Oral dose of trofinetide
10018912|NCT04988295|Experimental|Arm A: LACP (Lazertinib, Amivantamab, Carboplatin, and Pemetrexed)|Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as intravenous (IV) infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Lazertinib, Pemetrexed, and Amivantamab as maintenance until disease progression.
10018913|NCT04988295|Active Comparator|Arm B: CP (Carboplatin and Pemetrexed)|Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.
10018914|NCT04988295|Experimental|Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
10018915|NCT04987021|Experimental|Nucleus Smart App with Remote Assist Custom Sound Pro 6.3|Remote Assist Custom Sound Pro 6.3 to enable clinicians to use the App to remotely to program the recipients sound processors.
10018916|NCT04984993|Experimental|MED3000|MED3000 gel formulation topically applied to the glans penis
10018917|NCT04984993|Experimental|Tadalafil|Tadalafil (5 mg) tablets to be taken orally
10018918|NCT04984044|Active Comparator|Experimental|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
10018919|NCT04984044|Placebo Comparator|Control|This arm includes 36 Diabetic Peripheral Neuropathy patients receiving the antidiabetic medications
10036176|NCT01813396|Experimental|joint mobilization/massage|"joint mobilization: End-range joint mobilization~massage: massage twice a week on the identified muscle(s) of the involved shoulder about 6 minutes for each muscle for 3 months. The techniques of massage include petrissage for 3 minutes and rolling for 3 minutes of soft tissues"
10036177|NCT01813396|Experimental|joint mobilization/shoulder physical activity guide|joint mobilization: End-range joint mobilization shoulder physical activity guide: shoulder physical activity guide is based on the appropriate cut off activity level identified in the predication rule
10018920|NCT04984031||Generalized grade C periodontitis|generalized aggressive periodontitis ( generalized Grade C ,as in new classification) patients characterized with Bone loss/age index more than 1 and extent more 30 %
10018921|NCT04984031||Molar-incisor grade C periodontitis|localized aggressive periodontitis ( Molar-incisor pattern Grade C ,as in new classification) patients characterized with limited affection on molars and incisors and their Bone loss/age index more than 1.
10018922|NCT04983979|Experimental|SZC|3 month treatment using Sodium zirconium cyclocilicate. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
10018923|NCT04983979|Placebo Comparator|Placebo|3 month treatment using matched placebo. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
10018924|NCT04982081|Experimental|hiPSC-CM therapy low dosage|
10018925|NCT04982081|Experimental|hiPSC-CM therapy high dosage|
10018926|NCT04981912|Experimental|Arm A|HDMP + rituximab as a means of debulking prior to initiating venetoclax.
10018927|NCT04979780||Cancer patients with acute venous thromboembolism (VTE)|Cancer-associated thrombosis (CAT) patients treated with Rivaroxaban or any DOAC (Direct Oral Anticoagulants) or LMWH (Low molecular weight heparin).
10018928|NCT04979442|Experimental|RAIN-32 (Milademetan)|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle.
9477298|NCT03563638||GDM group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study,and excluded if they had multiple pregnancy, pre-gestational diabetes mellitus, hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness,and fetal abnormalities occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
9477299|NCT03563638||NGT group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. Women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (PGDM), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. if there were fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.those who not met the criteria were the NCT group.
10018929|NCT04979442|Active Comparator|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks.
10018930|NCT04979065|Experimental|Experimental Group|Probiotics and Vitamin D
10018931|NCT04979065|Placebo Comparator|Control Group|Placebo and placebo
9477300|NCT03563625|Active Comparator|Caudal block|Caudal block with 1mg/kg bupivacaine 0.25%.
9477301|NCT03563625|Active Comparator|Wound infiltration|Local wound infiltration with 1mg/kg bupivacaine 0.25%.
9477302|NCT03563612|Active Comparator|cpap first, differential ventilation later|
10018932|NCT04977635||600-cohort|"Patients with long-term (> 5 years) type 1 diabetes aged 16 years and older~As this is an observational study there is no intervention."
10018933|NCT04976946||Urologists|Local and international consultant Urologists and accredited Urology trainees.
9477303|NCT03563612|Active Comparator|differential ventilation first, cpap late|
9477304|NCT03563599|Experimental|Telacebec (Q203) tablet|
9477305|NCT03563599|Active Comparator|Rifafour e-275|
9477306|NCT03563586|Active Comparator|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
9477307|NCT03563586|Other|Bowel Preparation|Preoperative mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
9477308|NCT03563573|Active Comparator|Lidocaine-effective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
9477309|NCT03563573|Placebo Comparator|Lidocaine-effective ADHD: Placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
10018934|NCT04976946||Anaesthetists|Local and international consultant anaesthetists. Critical care physicians who are primarily Urological anaesthetists or have experience in complication reporting will be targeted.
10018935|NCT04976946||ICU specialists|Local and international consultant ICU specialists. Critical care physicians who are primarily Urological focused or have experience in complication reporting will be targeted.
9477310|NCT03563573|Active Comparator|Lidocaine-ineffective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
10018936|NCT04976738|Experimental|Treatment arm: Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 THC:CBD oil administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.
10018937|NCT04976244|Active Comparator|Brolucizumab|Arm B
10018938|NCT04976244|Active Comparator|Aflibercept|Arm A
10018939|NCT04976179|Experimental|FCM - Intravenous Ferric carboxymaltose|Intravenous Ferric Carboxymatlose administered in a single dose of 20mg/Kg to a maximum of 1000mg in 100mls of infusion given over minimum of 15 - 20 minutes at enrollment.
10018940|NCT04976179|Active Comparator|FS -Oral Ferrous sulphate|Oral Ferrous Sulphate (containing 65mg of elemental iron) to be taken as one 200mg tablet 3 times a day until delivery.
10018941|NCT04976166|Active Comparator|Conventional group|Videos and leaflets will be provided. Patients will have education using leaflets for 5 minutes in each hospital at months 0 and 2, respectively.
10018942|NCT04976166|Experimental|Extensive Informed Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients in the EIDM group will receive more informed and detailed education than those in the conventional group. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
10018943|NCT04976166|Experimental|Shared Decision Making group|Videos, leaflets, and intensive learning materials will be provided. Patients will check self-assessment items, and then have education according to the patients' preference using a self-developed counseling calendar. Patients will have education for more than 10 minutes at months 0 and 2, respectively.
10018944|NCT04976036|Experimental|Nintedanib|nintedanib 150 mg once a day for 2 weeks, then twice a day for 14 weeks
10018945|NCT04976036|Placebo Comparator|Placebo|placebo 150 mg once a day for 2 weeks, then twice a day for 14 weeks
9477311|NCT03563573|Placebo Comparator|Lidocaine-ineffective ADHD: placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
10018946|NCT04975802|Placebo Comparator|0 mg coffeeberry beverage|Appearance-matched to the other products
10018947|NCT04975802|Experimental|100 mg coffeeberry beverage|Appearance-matched to the other products
10018948|NCT04975802|Experimental|300 mg coffeeberry beverage|Appearance-matched to the other products
10018949|NCT04975802|Active Comparator|75 mg caffeine beverage|Appearance-matched to the other products
10036178|NCT01813448|Experimental|Cohort 1: Fidaxomicin low dose in Japanese males|
10036179|NCT01813448|Experimental|Cohort 2: Fidaxomicin high dose in Japanese males|
10036180|NCT01813448|Experimental|Cohort 3: Fidaxomicin high dose in Caucasian males|
10036181|NCT01813448|Placebo Comparator|Matching Placebo in Caucasian males|
10018950|NCT04975139||IDH-mutant astrocytoma or oligodendroglioma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
10018951|NCT04975139||IDH-wildtype astrocytoma|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
10018952|NCT04975139||Benign Brain Tumor|After enrollment and before beginning standard of care radiation therapy (RT), MRI will be obtained for RT planning as per standard of care (SOC), and the RS-fMRI sequences will be performed at the same time. At approximately 6 months, 2 years, 5 years, and 10 years from the completion of RT, RS-fMRIs will be performed.
10018953|NCT04974463||Persistent Opioid Use at 3 months|Patients who continue to use opioids about 3 months after their joint replacement surgery
10018954|NCT04974463||No Persistent Opioid Use at 3 months|Patients who do not use opioids after about 3 months following joint replacement surgery
10018955|NCT04974008|Experimental|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
10018956|NCT04973930|Active Comparator|Tele-Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy is a time-limited, affect-focused treatment of repeatedly demonstrated efficacy for major depression in the general population. It was also helpful to patients with comorbid depression and breast cancer in our prior randomized controlled trial. IPT focuses on the connection between upsetting life circumstances (e.g., diagnosis of breast cancer) and their effect on mood, and vice versa. We have considerable experience, enhanced by the Covid-19 lockdown, in delivering IPT as a HIPAA-secure tele-therapy.
10018957|NCT04973930|Active Comparator|Tele-Serotonin Reuptake Inhibitor|Both venlafaxine and escitalopram are FDA-approved treatments with demonstrated efficacy in treating major depression in the general population. Although little formal research has been done in treating patients with depression and breast cancer, these two are the favored treatments among serotonin reuptake inhibitors due to minimal interference with oncotherapy. The choice between prescribing these two study medications will depend upon prior treatment history. Venlafaxine XR will be serially titrated under expert psychopharmacologist tele-guidance from 75 mg to 300 mg daily, depending on clinical response and tolerance. Escitalopram will similarly be dosed between 5 mg and 30 mg daily.
10018958|NCT04972929|Experimental|Spinal Manipulation|The spinal manipulation (SM) group will receive manually delivered SM limited to the thoracic spine.
10018959|NCT04972929|Sham Comparator|Sham Spinal Manipulation|Sham-spinal manipulation will be delivered by setting the expansion control knob on an Activator II (Activator Methods®) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician. At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted.
10036182|NCT01813448|Placebo Comparator|Matching Placebo in Japanese males|
10036183|NCT01813461|Experimental|14C-labeled prodrug isavuconazonium sulfate|single dose
10036184|NCT01813487|Other|HBsAg vaccine with Entecavir|
10036185|NCT01813500||IBD Patients|Subjects with Crohn's Disease or Ulcerative colitis. IBD patients will be asked to provide a blood and stool sample.
10037467|NCT01825317|Active Comparator|NeuroAD|Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
10018960|NCT04972747|Experimental|Suggest skin care with sunflower oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and sunflower oil will be applied twice a day for 14 days.~Absorption of sunflower oil for preterm babies will be provided by using a baby massage application.~Before the massage, 3-4 ml of sunflower oil will be applied to the whole body surface except the genital area and scalp..~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
10018961|NCT04972747|Experimental|Suggest skin care with cocunut oil for preterm babies|"Before each application, preterm babies will be given skin care in the service routine and coconut oil will be applied twice a day for 14 days.~Absorption of coconut oil for preterm babies will be provided by using a baby massage application.~Before the massage, 3-4 ml of coconut oil will be applied to the whole body surface except the genital area and scalp.~12 hours after each application, the skin of the newborn will be evaluated using the Neonatal Skin Condition Assessment Scale (Appendix-2), and the measurement will be made with a DMM brand skin moisture meter and recorded in the follow-up form."
10018962|NCT04972552|Active Comparator|Watermelon Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus diet high in watermelon
10018963|NCT04972552|Active Comparator|Usual Diet & Coenzyme Q10|800-1200 mg of coenzyme Q10 daily plus no watermelon in diet
10018964|NCT04972552|Placebo Comparator|Watermelon Diet & Placebo|Placebo pill plus diet high in watermelon
10018965|NCT04972552|Placebo Comparator|Usual Diet & Placebo|Placebo pill plus no watermelon in diet
10018966|NCT04971811|Experimental|Lower-energy-dense Snack|Test snack with lower-energy-dense snack food
10018967|NCT04971811|Experimental|Higher-energy-dense Snack|Test snack with higher-energy-dense snack food
10018968|NCT04971499|Experimental|Dose Selection|Dapansutrile starting at 500 mg PO BID plus Pembrolizumab 200 mg IV every three weeks. Dose escalation is planned to a maximum of 1000 mg BID of dapansutrile + pembrolizumab.
10018969|NCT04971499|Experimental|Dose Expansion|Dapansutrile at the RP2D plus Pembrolizumab 200 mg IV every three weeks
10018970|NCT04971395|Experimental|Single IV infusion of 2 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
10018971|NCT04971395|Experimental|Single IV infusion of 4 mg/kg of XTMAB-16 or placebo|"Sentinel group: Each cohort will have a sentinel group of 2 participants (1:1 XTMAB-16 and placebo, respectively). dosed at least 48 hours before the remaining participants in the same cohort. (Up to 99 days)~After safety is confirmed, the remaining patients within the same cohort will be dosed.~Remaining group: Each cohort will then enroll 10 participants (8:2 XTMAB-16 and placebo, respectively) (Up to 99 days)"
10018972|NCT04970407|Experimental|Dysport®|40 Units (U) Intramuscular (IM) injection at day 1.
10018973|NCT04970407|Active Comparator|Botox®|16U IM at day 1.
10018974|NCT04970407|Active Comparator|Xeomin®|16U IM at day 1.
10018975|NCT04970212||Study Arm|Subjects will receive your standard liver ablation procedure, including ultrasound images. Data will be collected from the standard liver ablation procedure, including imaging. Subjects will receive a CT scan within 24 hours after the liver ablation procedure. There will then be an analysis of ultrasound images and research CT scan.
10018976|NCT04970134||Thyroid carcinoma|"Advanced and / or metastatic thyroid carcinoma with initial histological diagnosis date before January 1, 2021 of the types:~Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated carcinomas of the thyroid and the different corresponding variants.~Medullary thyroid carcinoma (MTC)."
10018977|NCT04969991|Experimental|Varespladib: 250 mg QD|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon and 1 placebo tablet in the evening.
10018978|NCT04969991|Experimental|Varespladib: 250 mg BID|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning and in the evening. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon.
10018979|NCT04969991|Experimental|Varespladib: 250 mg TID|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, in the afternoon, and in the evening.
10018980|NCT04969991|Placebo Comparator|Placebo|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, in the afternoon, and in the evening.
10018981|NCT04969783|Experimental|Ventilated Cigarette Filter|Filters with approximately 24-32% filter ventilation
10018982|NCT04969783|Experimental|Unventilated Cigarette Filter|Filters with approximately 0-5.0% filter ventilation
10018983|NCT04969562|Experimental|experiment|Individuals with multiple sclerosis in the experimental group will be included in six sessions of EFT at seven-day intervals, in which one session lasts 30-45 minutes. SUDS will be applied before and after each EFT session. At the same time, resting heart rate and blood pressure will be measured in the EFT group before and after each session.
10018984|NCT04969562|No Intervention|control|They will continue their routine treatment.
10018985|NCT04968782||Patients with acute appendicitis|
10018986|NCT04967352||Developed Persistent Opioid Use after 3 months following surgery|
10018987|NCT04967352||Did not develop persistent opioid use after 3 months following surgery|
10018988|NCT04967222|Experimental|Cognitive Reappraisal-by-Distancing (CRD)|Subjects will be coached to use cognitive reappraisal-by-distancing to downregulate their negative reactions to aversive emotional pictures usng practice pictures.
10018989|NCT04967222|Active Comparator|Control Downregulate Condition (CD)|Subjects will be coached to practice their customary emotion regulatory techniques in a treatment occurring twice a week for 6 weeks.
10018990|NCT04966858|Experimental|Individualized Caloric Refeeding (ICR)|Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal
10018991|NCT04966858|Active Comparator|Higher Calorie Refeeding (HCR)|Starting 2000 kcal/d, increasing by 200 kcal/d to goal
10018992|NCT04966585|Experimental|Posaconazole|Subjects administered posaconazole (Noxifil®, Merck) 300mg twice daily for 1 day followed by 300mg daily for 12 weeks
10018993|NCT04966585|Placebo Comparator|Placebo|Subjects administered three matching placebo tablets twice daily for 1 day followed by three tablets daily for 12 weeks
10018994|NCT04963790|Experimental|Tailored COVID-19 vaccine messaging|Based on the created segments of hesitant participants (reflecting age, language, education level, rurality, sex, gender, ethnicity, and attitudes or reasons for vaccine hesitancy) in the intervention group, a series of tailored messages that are meaningful to the recipients in the different segments will be created and sent to address the factors influencing the willingness to be vaccinated and persuade them to get the COVID-19 vaccine.
10018995|NCT04963790|Active Comparator|Other health-related messaging|Patients assigned to the control group will receive health messages unrelated to COVID-19.
10018996|NCT04962477||Pregnant|
10018997|NCT04962477||Non-pregnant|
10018998|NCT04961372||Healthcare Workers|All healthcare professionals working at Gümüşhane Şiran Government Hospital
10018999|NCT04961372||Non-Healthcare Workers|Twice the number of health workers included in the study, non-health worker volunteers
10019000|NCT04960683|Experimental|Robotic -assisted gait training group using Lokomat device|"5 sessions of 40 minutes of conventional therapy and~5 sessions of 40 minutes on Lokomat per week"
10019001|NCT04960683|Active Comparator|Traditional therapy group|• 5 sessions of 40 minutes of conventional therapy
10019002|NCT04960397|Experimental|Cohort 1|A cohort of influenza non-naïve 25 healthy children, 9-17 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1. N=45.
10036186|NCT01813500||Control Subjects|Subjects without Crohn's Disease or Ulcerative Colitis. Controls will also be asked to provide a blood and stool sample.
10019003|NCT04960397|Experimental|Cohort 2|A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive a single dose of 10^8 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1 intranasally. N= 45
10019004|NCT04960397|Experimental|Cohort 3|Once, there is sufficient evidence of safety and tolerability in Cohorts 1 and 2,and enrollment has completed of all 45 in each of these cohorts. Cohort 3 will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or placebo (N=10) at Day 1. N=25.
10019005|NCT04960397|Experimental|Cohort 4|Once, there is sufficient evidence of safety and tolerability in Cohort 3 and enrollment has been completed for this cohort, and fifth cohorts (Cohorts 4 and 5) will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive two doses of the 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or two doses of placebo (N=15) at Day 1 and Day 29. N=45.
10019006|NCT04960397|Experimental|Cohort 5|Participants in Cohort 4, will enroll concurrently. A cohort of influenza-naïve healthy children, 6-23 months old, will be randomized to receive two doses of 10^7 TCID50 of intranasal Sing2016 M2SR vaccine (N=6) or two doses of placebo (N=2) at Day 1 and Day 29. N=8.
10019007|NCT04960397|Experimental|Cohort 6|Once, there is sufficient evidence of safety in Cohort 5, Cohort 6 will begin enrollment. A cohort of influenza-naïve healthy children, 6-23 months old, where a lead-in group (N=20) will be randomly assigned to receive either two doses of 10^8 TCID50 of intranasal Sing2016 M2SR vaccine (N=6) or two doses of placebo (N=2) at Day 1 and Day 29. N=20. Once lead-in group completes Day 8, the SRC will review the safety and determine if Cohort 7 may begin enrollment. Additional group of children may continue to enroll during the SRC review, which will be assigned randomly to receive two doses of 10^8 TCID50 of intranasal Sing2016 M2SR (N=12) or two doses of placebo (N=6) at Day 1 and Day 29. N= 26
10019008|NCT04960397|Experimental|Cohort 7|Once, there is sufficient evidence of safety in Cohort 6, Cohort 7 will begin enrollment. A cohort of influenza-naïve healthy children, 6-23 months old, will be randomly assigned to receive two doses of 10^9 TCID50 dose of intranasal Sing2016 M2SR vaccine (N=18) or two doses of placebo (N=8) at Day 1 and Day 29. N=26
10019009|NCT04960202|Experimental|PF-07321332/ritonavir|Orally administered PF-07321332+ritonavir
10019010|NCT04960202|Placebo Comparator|Placebo|Orally administered placebo
10019011|NCT04958733|Active Comparator|Autologous Bone Grafting|Excess bone obtained from graft preparation and the coring reamer will be used to fill the patellar and tibial donor sites.
10019012|NCT04958733|Placebo Comparator|Control|The control group will have their patellar and tibial defects remain unfilled.
10019013|NCT04958265|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.
10019014|NCT04956172|Active Comparator|Tone A|Tone A uses an 80dB standard tone
10019015|NCT04956172|Experimental|Tone B|Tone B uses a 93dB standard tone
10019016|NCT04955405|Experimental|Seven telemedicine visits|Will receive the seven visit telemedicine protocol
10019017|NCT04955405|No Intervention|Control - Usual Care|Will not receive the protocol
10019018|NCT04952779||Xultophy®|Korean adults with type 2 diabetes mellitus (T2DM) initiating Xultophy® under routine clinical practice and according to approved label in Korea.
10036187|NCT01813513|Experimental|Group A: IDX719 then IDX719/Simeprevir|Healthy participants take IDX719 150 mg once daily (QD) on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
10019019|NCT04950998|Other|2-month Pilot Test|In this single-arm trial, participants will use a physical activity smartphone app for a two-month period. The app includes motivational messages, tips to increase the intensity level of everyday activities, and strategies to reduce sedentary behaviors. Users can also track their physical activity levels and sedentary activity.
10019020|NCT04950868|Experimental|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
10019021|NCT04950764|Experimental|Seladelpar 10 mg|Part A: Single oral dose 10 mg
10019022|NCT04950764|Experimental|Seladelpar 10 mg or less|Part B: Multiple oral dose of 10 mg or less
10019023|NCT04950582||UTI-high risk patients|patients who are at high risk for developing a urinary tract infection (UTI).
10019024|NCT04950075|Experimental|INBRX-109|IV every three weeks
10019025|NCT04950075|Placebo Comparator|Placebo|IV every three weeks
10019026|NCT04949854|Active Comparator|Control Arm B.Braun 6.35 cm 20 Gauge catheter|Device 6.35 cm 20 Gauge B. Braun catheter without guidewire
10019027|NCT04949854|Experimental|Experimental Arm B.D. Accucath 5.71 cm 20 Gauge catheter|Device BD 5.71 cm Accucath IV catheter with guidewire
10019028|NCT04948645|Active Comparator|ABBV-CLS-7262 LOW DOSE|
10019029|NCT04948645|Active Comparator|ABBV-CLS-7262 MEDIUM DOSE|
10019030|NCT04948645|Active Comparator|ABBV-CLS-7262 HIGH DOSE|
10019031|NCT04948645|Placebo Comparator|PLACEBO|
10019032|NCT04947137|Experimental|Subjects Free of Inflammatory Disease|The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
10019033|NCT04947137|Experimental|Healthy Controls and RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment.
10019034|NCT04945850||Covid negative|"20 patients undergoing ocular surgery who are COVID negative will be included as control patients and undergo the same procedures.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
10019035|NCT04945850||Covid positive|"60 patients undergoing ocular surgery with previous COVID infection will be stratified into three groups by time since diagnoses: 3, 6, 12 months ~ 20 patients per group.~All patients will get a vitreous tap from operative eye 0.1-0.2 ml fluid. This fresh sample will be tubed to the lab using a unique marked label. This will be performed after the trocar is placed~At the end of surgery, the BSS bag will be tubed to the lab using the same label."
10019036|NCT04944667|Other|TAVR standard|TAVR planning evaluated without VR and TAVR planning after VR analysis
10019037|NCT04943887|Experimental|PwMS eSupport Groups|12-weeks active treatment of eSupport Health's Weekly Group Sessions, a formal semi-structured program of psychoeducational support delivered in a small group format by licensed therapists who specialize in MS. The active treatment period will follow a 12-week waitlist period that will be used to enable a within-subject control design. Note that the very first group enrolled (N~10) will not have a 12-week waitlist period but will instead enter directly into the 12-week treatment.
10019038|NCT04943822|Placebo Comparator|conventional education service program|Including the written and verbal health education on preoperative preparation, stoma surgery and postoperative stoma care. At discharge, ET nurses offered teaching information and support for patients, including selection of pouching appliances, drug instructions, health education At each outpatient follow-up, both stomas and patients needed to be assessed. The condition of stoma and peristomal skin, nature and volume of effluent, date of pouch appliances and stoma complications were recorded by ET nurses.
10036188|NCT01813513|Experimental|Group B: Simeprevir then IDX719/Simeprevir|Healthy participants take simeprevir 150 mg QD on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
10036189|NCT01813513|Experimental|Group C: IDX719|Healthy participants take IDX719 150 mg QD on Days 1-14.
10036190|NCT01813513|Experimental|Group D: IDX719/Simeprevir|Participants from Groups A and B will be asked to return for Group D. Participants take IDX719 and simeprevir QD on Days 1-7 to determine the impact of food on single-dose (on Day 1) and steady state (Day 7) PK.
10019039|NCT04943822|Experimental|mobile care device|The participants in the intervention group were given the same routine care as the control group pre- and postoperatively. ET nurses taught patients and their family members how to use the home care mobile app before discharge. The home care mobile app was designed and developed for the discharged stoma patients by the research team and an information technology company in March 2021. Patients could receive stoma care from ET nurses through this mobile app at home, not just going to an outpatient clinic. The Major function modules of this mobile app were as follows: (a) appointment: The app users were able to complete the basic personal and medical information and make an appointment with the ET nurse; (b) photograph diagnosis: The ET nurses could make a diagnosis based on the patients' uploaded stoma photographs; and (c) consultation: Patients were able to contact their ET nurses for help and support. This mobile app was used to supplement the outpatient follow-up.
10019040|NCT04943796||Participants with ADHD|To collect information from participants who are underdiagnosed of ADHD with psychiatric disorders in daily clinical practice for up to 9 months.
10019041|NCT04942938|Experimental|Neubie Treatment|"Participants in this study will participate in intervention treatment with the Neubie for 6 weeks. Outcome measures objective and subjective will be collected at the beginning and end of the study. The treatments will include:~Manual activations to underactive, spastic or limited in sensory muscles/regions~Neubie Mapping mode scanning process to scan for 1) spots that stimulate movement they couldn't do before per initial assessment, 2) spots that allow movement which is a greater range than available before per initial assessment, 3) spots that lead to decreased spasticity, and 4) diminished sensation areas - drive signal to increase sensory nerves and become metabolically active.~Train using physical therapy exercises with Neubie in training mode and Hz current adjusted for tolerance (perceived 7/10) and ability to work through or decrease spasticity in (500 Hz) in the areas which show spasticity, contraction, are dead/diminished sensation, and hot spots."
10019042|NCT04941989|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 7 cohorts will be dosed. One or more subcutaneous injections of HTL0022562 will be administered. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
10019043|NCT04941989|Experimental|Part 2 Multiple Ascending Dose|Eight subjects in up to 4 cohorts will be dosed, following safety, tolerability and PK review of completed dose of Single Ascending Dose Cohort 5. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
10019044|NCT04941651|Experimental|OBE-COACH program|The OBE-COACH experimental group: access to the complete OBE-COACH program
10019045|NCT04941651|Active Comparator|e-learning program|The control group: access to an e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health) and provision of connected devices (auto-tensiometer and balance).
10019046|NCT04941521|Experimental|Exenatide and Drug Counseling|Participants will receive once weekly exenatide injections and drug counseling sessions.
10019047|NCT04940767|Experimental|Treatment Group A|Patients will concomitantly receive once daily treatment of oral isotretinoin and topical AMZEEQ® for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
10019048|NCT04940767|Experimental|Treatment Group B|Patients will receive once daily treatment of oral isotretinoin for 20 weeks, followed by a further 24 weeks of once daily AMZEEQ® only treatment.
10036191|NCT01813513|Experimental|Group E: High-Fat then Low-Fat PK|Participants from Group C will return to determine the PK of IDX719 after high-fat (Day 1) and low-fat (Day 7) meals (Days 2-6 are drug-free washout).
10019049|NCT04939597|Experimental|Arm I (memantine hydrochloride)|Patients receive memantine hydrochloride PO BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 30, and 60 months.
10019050|NCT04939597|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 30, and 60 months.
10019051|NCT04939116|Experimental|200 mg QD|200 mg of ANG-3070 will be taken once daily for 12 weeks.
10019052|NCT04939116|Experimental|400 mg QD|400 mg of ANG-3070 will be taken once daily for 12 weeks
10019053|NCT04939116|Experimental|300 mg BID|300 mg of ANG-3070 will be taken twice a day for 12 weeks.
10019054|NCT04939116|Placebo Comparator|Placebo|Placebo capsules will be taken once or twice daily for 12 weeks.
10019055|NCT04938804|Experimental|Screening group|
10019056|NCT04936854|Active Comparator|Sirolimus|Patients with active thyroid eye disease will receive 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
10019057|NCT04936854|Active Comparator|Corticosteroids|Patients with active thyroid eye disease will receive 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks.
10019058|NCT04935593|Experimental|Renew Intervention Group|Participants in the group will receive training to help children strengthen social, emotional and behavioral knowledge and resilience.
10019059|NCT04935593|No Intervention|Parallel Control Group|Participants in the group will receive the usual bible lessons and activities
10019060|NCT04933942|Active Comparator|Control group|Lomustine alone
10019061|NCT04933942|Experimental|Experimental group|Lomustine plus Romiplostim
10019062|NCT04933513||preoperative Parkinson' disease|pre DBS parkinson's disease patients responding to the DBS-PS scale preoperatively
10019063|NCT04930614||Transgender and non-binary people|Adult transgender and non-binary people in Flanders and Brussels (Belgium)
10019064|NCT04930445||Oxbryta Product Registry|
10019065|NCT04929405|Experimental|Intervention group|This group has access to the intervention (website for bereaved parents)
10019066|NCT04928677|Experimental|Codrituzumab|For Phase A of the study, we will use the 3+3 study design, with 2 planned dose levels, starting at 50% of the adult RP2D to confirm the pediatric RP2D/MTD. 6-9,43 Phase B will include an expansion cohort for patients with hepatoblastoma.
10019067|NCT04928144|Experimental|0.025% SHJ002|0.025% SHJ002 Sterile Ophthalmic Solution
10019068|NCT04928144|Experimental|0.080% SHJ002|0.080% SHJ002 Sterile Ophthalmic Solution
10019069|NCT04928144|Experimental|0.25% SHJ002|0.25% SHJ002 Sterile Ophthalmic Solution
10019070|NCT04928144|Experimental|SHJ002 - Maximum tolerated concentration|Maximum tolerated concentration of SHJ002
10019071|NCT04928014||Screening Mammogram|Individuals eligible for a screening mammogram.
10019072|NCT04927793|Experimental|Single arm EDP-938|
10019073|NCT04927377|Experimental|AI4DM Intervention Group|
10019074|NCT04927377|Active Comparator|Attention-control Group|
10019075|NCT04926701|Experimental|Single ascending dose|Single dose of inhaled ETD001/placebo on one occasion
10019076|NCT04926701|Experimental|Multiple ascending dose (7 days)|Daily doses of ETD001/placebo for 7 consecutive days
10019077|NCT04926701|Experimental|Multiple ascending dose (14 days)|Daily doses of ETD001/placebo for 14 consecutive days
10019078|NCT04926636|No Intervention|Standard Mobile App|This group will be supplied with Novidan DTC hearing aids and documentation following standard of care as a control. They will be provided with the mobile application allowing for the monitoring of data for study analysis and personal control of their hearing aids, but not Health and Wellness Coaching features.
10019079|NCT04926636|Experimental|Enhanced Mobile App with Health Coaching|This group will also be supplied with the Novidan DTC hearings aids and documentation, same as the control group, but will be supplied the enhanced mobile application that allows for participation in health coaching features. They will be assigned to a health coach and will have coaching sessions scheduled.
10019080|NCT04926181|Experimental|Single Arm: Apalutamide + Cetrelimab|Participants will be given Apalutamide tablets combined with infusions of Cetrelimab in 28-day cycles, for up maximum of two years.
9477312|NCT03563547|Active Comparator|Fat modified diet|Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
10019081|NCT04924348|Experimental|WALANT procedure|Local anesthesia of the WALANT type
10019082|NCT04924348|Active Comparator|Axial ALR|Axillary loco-regional anesthesia
10019083|NCT04924348|Active Comparator|Truncal ALR|Truncal loco-regional anesthesia
10019084|NCT04924088|Experimental|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
10019085|NCT04924088|Active Comparator|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
10036192|NCT01813513|Experimental|Group F: Low-Fat then High-Fat PK|Participants from Group C will return to determine the PK of IDX719 after low-fat (Day 1) and high-fat (Day 7) meals (Days 2-6 are drug-free washout).
10019086|NCT04922320|Experimental|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
10019087|NCT04922320|Placebo Comparator|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. PCPs will be trained to address the needs of UC participants based on their typical approach without the use of a facilitator or explicit process for identifying patient priorities. UC participants will not receive any additional preparation
10036193|NCT01813526|Experimental|Experimental Infant Formula|Experimental formula to be fed ad libitum.
10036194|NCT01813539|Experimental|Dose Escalation: Cohort 1|Participants will receive ARGX-110 as an intravenous infusion (IV) at dose level 1.
10019088|NCT04921527|Experimental|Chiauranib plus weekly paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most,Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
10019089|NCT04921527|Placebo Comparator|placebo plus weekly paclitaxel|Patients receive the combined treatment of placebo plus paclitaxel, 21 days for a cycle, 6 cycles at most,placebo is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15. After 6 cycles combined treatment, patients enter the single agent therapy of placebo.
10019090|NCT04921332|Experimental|Bright Light Therapy (BLT)|The intervention will consist of daily BLT sessions lasting 30 minutes at approximately 10AM (since many CF and COPD patients may not awaken until this time) starting on the day of admission through discharge for a goal of seven consecutive days. The intervention will use a 10,000-lux light box placed approximately 16-24 inches from the patient's face.
9477313|NCT03563547|Experimental|Fat modifed diet enriched with soy protein|"Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects in this arm were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
10019091|NCT04920123|Experimental|Game Intervention|Study participants play Neuro-World 30 minutes per day, twice a week for 12 weeks in your home settings (24 times).
10019092|NCT04920123|No Intervention|No Intervention|Study participants do not engage in any cognitive training.
9477314|NCT03563534|Active Comparator|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
9477315|NCT03563534|Active Comparator|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
9477316|NCT03563521||Atopic, eosinophilic|
9477317|NCT03563521||Atopic, non-eosinophilic|
9477318|NCT03563521||Non-atopic, eosinophilic|
9477319|NCT03563521||Chronic rhinosinusitis with/without nasal polyposis|
9477320|NCT03563521||Non-atopic, non-eosinophilic|
9477321|NCT03563521||Control|Without asthma, atopy and eosinophilia
9477322|NCT03563508||CBCT of Egyptian subpopulation|Cone-beam computed tomography (CBCT) of a sample of Egyptian subpopulation containing maxillary premolars for image assessment.
9477323|NCT03563495|Active Comparator|tissue engineered group|autogenous bone marrow derived and cultured stem cells loaded on collagen matrix was implanted in the alveolar cleft in the study group (1st arm)
9477324|NCT03563495|Active Comparator|autogenous bone graft group|autogenous cortico-cancellous bone graft harvested from the anterior iliac crest was implanted in the alveolar cleft of the control group (2nd arm)
10019093|NCT04919824|Experimental|Bipolar Knife|ESD procedure performed with Creo Medical Speedboat RS2.
9477326|NCT03563456|Experimental|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
9477327|NCT03563456|Active Comparator|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
9477328|NCT03563443||Bladder cancer patients|Diagnosed bladder cancer patients who are being monitored will be the experimental group to develop the LOI panel, and subsequent cohort will be used to confirm the sensitivity and specificity of this urinary analysis.
9477329|NCT03563443||Non-cancer participants|Patients being treated for other diseases but without any tumor or healthy participants will provide a negative control to provide data for developing the LOI diagnostic panel
9477330|NCT03563430|Experimental|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate.
9477331|NCT03563430|Experimental|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session.
10019094|NCT04919824|Active Comparator|Monopolar Knife|ESD procedure performed with monopolar knives.
10019095|NCT04919239|Experimental|RUTI® arm|A dose of 25 μg of of RUTI vaccine will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
9477332|NCT03563430|Experimental|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position.
9477333|NCT03563404||Portal Blood Flush|participants that receive the portal blood flush
9477334|NCT03563404||No Portal Blood Flush|participants that don't receive the portal blood flush
9477335|NCT03563391|Experimental|Evaluation of a new infant formula|To evaluate the effects of a new formula on the growth, safety and tolerance of infants with growth failure
10019096|NCT04919239|Placebo Comparator|Placebo arm|Placebo will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.
10019097|NCT04917367||Conventional surgery group|Conventional surgery with Preoperative foreign body localization
10019098|NCT04917367||New surgery group|new surgery with Intraoperative localization of foreign body
10019099|NCT04916743|Experimental|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
10019100|NCT04916743|No Intervention|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
10019101|NCT04916678|No Intervention|Control|The control period is a 5-day period during which no psychologist is available. ER cares will be provided as usual.
10019102|NCT04916678|Experimental|Intervention|The intervention period is a 5-day period during which trained psychologists are available in the ER and will provide a R-TEP EMDR intervention for patients selected with high risk of PCLS and who may provide psychotherapeutic care or reassurance to other patients should they be identified in need of help.
10019103|NCT04916470|Experimental|Semaglutide 2.4 mg once weekly (OW)|Participants will receive semaglutide injections for 52 weeks.
10019104|NCT04916470|Placebo Comparator|Semaglutide placebo OW|Participants will receive semaglutide placebo injections for 52 weeks.
10036195|NCT01813539|Experimental|Dose Escalation: Cohort 2|Participants will receive ARGX-110 as an IV infusion at dose level 2.
10036196|NCT01813539|Experimental|Dose Escalation: Cohort 3|Participants will receive ARGX-110 as an IV infusion at dose level 3.
10036197|NCT01813539|Experimental|Dose Escalation: Cohort 4|Participants will receive ARGX-110 as an IV infusion at dose level 4.
10036198|NCT01813539|Experimental|Dose Escalation: Cohort 5|Participants will receive ARGX-110 as an IV infusion at intermediate dose level at the conclusion of Cohort 4 prior to opening the safety expansion cohorts to participants enrolment.
10036199|NCT01813539|Experimental|Safety Expansion: Cohort 1|Participants with solid tumors will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
10036200|NCT01813539|Experimental|Safety Expansion: Cohort 2|Participants with hematological malignancies (all etiologies) will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
10036201|NCT01813539|Experimental|Safety Expansion: Cohort 3|Participants with cutaneous T-cell lymphoma (CTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
10036202|NCT01813539|Experimental|Safety Expansion: Cohort 4|Participants with peripheral T-cell lymphoma (PTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
10036203|NCT01813539|Experimental|Exploratory Efficacy: Cohort 5|Participants with relapsed/refractory CTCL will receive ARGX-110 as an IV infusion followed by a maintenance therapy at dose level 3.
10019105|NCT04914546|Experimental|LY3819469 (Part A)|Single ascending doses of LY3819469 administered subcutaneously (SC).
10019106|NCT04914546|Experimental|LY3819469 (Part B)|Single doses of LY3819469 administered SC in Japanese Participants.
10019107|NCT04914546|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
10019108|NCT04914546|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
10019109|NCT04914377|Experimental|Active Drug|Capsules containing TQ Formula
10019110|NCT04914377|Placebo Comparator|Placebo|Capsules containing corn oil
10019111|NCT04913064|Experimental|Prevention (white button mushroom)|Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.
10019112|NCT04911439|Active Comparator|Low Arousal|This group will see 25 affective images of the International Affective Picture System with low arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
10019113|NCT04911439|Active Comparator|Medium Arousal|This group will see 25 affective images of the International Affective Picture System with medium arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
10019114|NCT04911439|Active Comparator|High Arousal|This group will see 25 affective images of the International Affective Picture System with high arousal level during 8-12 randomly seconds each one at time and with randomly rest of 8-12 seconds between images.
10019115|NCT04911257||Degenerate Disc Disease|Subjects who will undergo spinal fusion surgery utilizing Stryker Interbody Systems.
10019116|NCT04911153||Aim 1: Physical Activity|250 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of physical activity on cardiometabolic health among veterans with and without PTSD.
10019117|NCT04911153||Aim 2: Diet Quality|200 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of diet quality on cardiometabolic health among veterans with and without PTSD.
10019118|NCT04911153||Supplemental Aim: Instrument Validation|100 participants will be recruited to examine the validity of a self-report clinical measure of physical activity against objectively measured physical activity obtained via accelerometry.
10019119|NCT04909541||Patient with ureteral stent|Patients with ureteral stent that meet the inclusion, exclusion criteria complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
10019120|NCT04909203|Experimental|iKinnect2.0|Parent-Youth dyads assigned to the iKinnect2.0 condition will be given access to the iKinnect2.0 app that has been developed for this study. Parent and youth will be asked to download the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
10019121|NCT04909203|Placebo Comparator|Attention-Control Placebo App & Supporting Materials|Parent-Youth dyads assigned to the control condition will be asked to download the free Life360 app to their phone during the baseline assessment process and will also be given access to an online suicide resources brochure. Participants will be asked to use the control-condition app and associated materials as often as they would like throughout the duration of the 16 week trial.
10019122|NCT04908800|Experimental|Part A single ascending dose (SAD) and Part B multiple ascending dose (MAD): KRP-A218|Administration Route: Oral
10019123|NCT04908800|Placebo Comparator|Part A (SAD) and Part B (MAD): Placebo|Administration Route: Oral
10019124|NCT04908800|Experimental|Part C drug-drug interaction (DDI): KRP-A218 and itraconazole|Administration Route: Oral
10019125|NCT04908176|Experimental|Patients with metastatic, unresectable GIST|Patients will receive 5 mg of midazolam orally on Day 1 and Day 18. Patients will receive avapritinib 300 mg, orally on Day 3 through Day 19.
10019126|NCT04907903|Experimental|RinasciMENTE|Participants will receive the internet-based intervention.
10019127|NCT04907903|No Intervention|Waiting-list|Participants will no receive the internet-based intervention.
10019128|NCT04907487||SEP|With Multiple Sclerosis as defined by McDonald's revised clinical or radiological spatial and temporal dissemination criteria
10019129|NCT04907487||NO SEP|For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease
10019130|NCT04904172||Acute ischemic stroke who undergo intravenous thrombolytic and / or endovascular thrombectomy|Patients with acute ischemic stroke who applied to Ege University Emergency Service and decided to undergo intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments by a Neurology Specialist.
10019131|NCT04903821|Experimental|Group A (Child- Pugh A)|Participants with mild impaired hepatic function (Child-Pugh A), including at least 2 female participants.
10019132|NCT04903821|Experimental|Group B (Child-Pugh B)|Participants with moderate impaired hepatic function (Child-Pugh B), including at least 2 female participants
10019133|NCT04903821|Experimental|Control A match controls for group A|Matched control participants for Group A with normal hepatic function.
10019134|NCT04903821|Experimental|Control B match controls for group B|Matched control participants for Group B with normal hepatic function
10019135|NCT04902235|Experimental|CRH administration|Experimental: CRH administration
10019136|NCT04902235|Placebo Comparator|Placebo administration|Control: Placebo administration
10019137|NCT04900688|Other|Ureteroscopy (URS) with the LithoVue 2.0 disposable flexible ureteroscope|Ureteroscopy will be done using the LithoVue 2.0 disposable flexible ureteroscope instead of the satandard ureteroscope
10019138|NCT04900480|No Intervention|Public subsidy to physiotherapy continue as usual|This control arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, where the access and public subsidy to physiotherapy continue as usual.
10019139|NCT04900480|Experimental|Direct access to publicly subsidized physiotherapy|This intervention arm consists of all physiotherapy clinics with registered provider numbers in two municipalities, introducing temporary exemption on the legal required general practitioner referral for public subsidy for treatment in general physiotherapy.
10019140|NCT04899843|Active Comparator|Experimental|This arm includes 61 acne vulgaris patients receiving topical retinoids
10019141|NCT04899843|Placebo Comparator|Control|This arm includes 61 acne vulgaris patients receiving topical retinoids
10019142|NCT04899687|Experimental|Group A: fluoxetine then fluoxetine plus dextromethorphan|Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.
10019143|NCT04899687|Experimental|Group B: fluoxetine plus dextromethorphan then fluoxetine|Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.
10019144|NCT04899284|Experimental|Infants eligible for Early Intensive Bimanual Stimulation|Infants between 3 and 12 months of age at the time of inclusion, with unilateral brain injury and clinical signs of underuse of one of the two upper limbs
10019145|NCT04899245|Experimental|School Staff|"50 school staff from Waisman Early Childhood Program (WECP) will be recruited to participate in this study. School staff will send a letter to all WECP staff inviting them to participate. Staff new to the school or who initially decline participation and then reconsider may join at any time.~Additionally, staff who are vaccinated will be asked to participate in testing."
10036204|NCT01813552|Experimental|Samatasvir + Ritonavir|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fed or fasted conditions with water. Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions with water.
10037468|NCT01825317|Sham Comparator|Sham NeuroAD|Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
10019146|NCT04899245|Experimental|Parent/Child with Children with medical complexity (CMC)|"65 children and their parents will be recruited to participate. School staff will send a letter to all parents with children enrolled in the Waisman Early Childhood Program (WECP) inviting them to participate. Families new to the school or who initially decline participation and then reconsider may join at any time. Participants will also be offered the option of as needed symptomatic home testing.~Additionally, parents who are vaccinated will be asked to participate in testing. Siblings may be enrolled in the study."
10019147|NCT04899206||ARBs only|Hypertensive patients under pharmacological treatment with ARBs
10019148|NCT04899206||ACEIs only|Hypertensive patients under pharmacological treatment with ACEIs
10019149|NCT04899206||ARBs + ACEIs|Hypertensive patients under pharmacological treatment with ARBs and ACEIs
10019150|NCT04899206||Other Antihypertensive Drugs|Hypertensive patients under pharmacological treatment with non-angiotensin agents (diuretics, calcium channel blockers and/or β-blockers alone or combined among them)
10019151|NCT04899206||Angiotensin Agents and Other Antihypertensive Drugs|Hypertensive patients under combined pharmacological treatment with Angiotensin Agents (ACEIs and/or ARBs) and Other Antihypertensives (non-angiotensin agents)
10019152|NCT04898036|Experimental|Sham First, then Experimental|Participants in this group will receive the sham treatment first, then the experimental treatment.
10019153|NCT04898036|Experimental|Experimental First, then Sham|Participants in this group will receive the experimental treatment first, then the sham treatment.
10019154|NCT04897802|Experimental|Experimental: GLP1-RA administration|A single dose of 10 mcg of GLP1-RA (exenatide) will be injected subcutaneously and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after GLP1-RA:placebo administration to assess OT secretory patterns
10019155|NCT04897802|Placebo Comparator|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than GLP1-RA (exenatide) administration
10019156|NCT04897061||Participants undergoing major pelvic organ prolapse surgery|
10019157|NCT04896632|Experimental|INE963|Part A is a single ascending dose (SAD) study with 4 planned cohorts Part B is a multiple dose (MD) study with 1 planned cohort q24h x 3 day of either INE963 or placebo
10019158|NCT04896632|Placebo Comparator|Placebo group|Part A is a single ascending dose (SAD) study with 4 planned cohorts Part B is a multiple dose (MD) study with 1 planned cohort q24h x 3 day of either INE963 or placebo
10019159|NCT04896385|Experimental|Ruxolitinib cream|Ruxolitinib cream will be administered twice a day (BID) for 24 weeks
10019160|NCT04896385|Placebo Comparator|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
10036205|NCT01813552|Experimental|Samatasvir + Omeprazole|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
10036206|NCT01813565|Experimental|Additional instillation of hyaluronic acid/chondroitin sulfate|Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
10036207|NCT01813565|Active Comparator|Transurethral resection of bladder ulcer|Transurethral resection of bladder ulcer
10036208|NCT01813578|Experimental|Intervention|An SSED study is an open-label design where the individual is his or her own control. All patients included received the same exercise intervention.
10036209|NCT01813591|Experimental|H.P. Acthar Gel 80IU|H.P. Acthar Gel of 80IU (1.0 ml)
10036210|NCT01813591|Experimental|H.P. Acthar Gel 40IU|H.P. Acthar Gel of 40IU (0.5 mL)
10037469|NCT01825330|Active Comparator|NeuroAD|NeuroAD treatment, synchronized TMS and cognitive training stimulation
10019161|NCT04896268|Experimental|Radiofrequency|Rafaelo's technique consists of delivering a low temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end. The intracellular water in the tissue and the injection of a locally injectable Xylocaine cushion serve as resistance to the vaporisation waves without releasing water vapour, thus avoiding the damage usually encountered in electrosurgery. The delayed phenomenon is cell volatilisation. Vaporisation of the tissue allows significant haemostasis without burns. Tissue changes will depend directly on the temperature emitted and the duration of exposure to the radiofrequence current. The fibrosis process starts during the session and continues for several days to weeks, allowing the reduction of the haemorrhoidal cushions.
10019162|NCT04896268|Active Comparator|Arterial ligation then recto-anal repair with Doppler|"Arterial ligation aims to de-arterialise the haemorrhoids by selectively decreasing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return. It is distinguished from mucopexy or recto anal repair (RAR®) which fixes the prolapsed hemorrhoidal plexus. Instead of excising the haemorrhoids, the principle is to reduce their size and to restore the anatomical relationships of the haemorrhoidal plexuses in the anal canal."
10019163|NCT04895150||Patients|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
10019164|NCT04895150||Healthy controls;|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
10019165|NCT04892862|Active Comparator|dorsal surgical approach|dorsal surgical approach
10019166|NCT04892862|Active Comparator|volar surgical approach|volar surgical approach
10019167|NCT04892628|Other|Aerobic training group|"The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.~Exercises will include:~Flexion, extension and abduction at the shoulder joint for anterior, middle and posterior fibers of deltoid~Flexion and extension at the elbow for biceps and triceps trachii~Flexion and extension at the knee joint for quadriceps and hamstring muscles~Plantar flexion at the ankle joint for gastrocnemius and soleus~Three sets of ten repetitions of each exercise will be done."
10019168|NCT04892628|Experimental|Resistance training group|"The intervention group will undergo a progressive resistance training program consisting of active muscle stretching and resistance training. Exercise for intervention group will consist of:~Resisted flexion, extension and abduction at the shoulder joint for anterior, middle and posterior deltoid, using dumbbells~Resisted flexion and extension at the elbow for biceps and triceps trachii, using dumbbells~Resisted flexion and extension of knee joint for quadriceps and hamstring muscles, using therabands~Resisted dorsiflexion and plantar flexion of gastrocnemius and soleus, using therabands~Resistance will be increased on basis of progressive overload principle. Three sets of ten repetitions will be performed per muscle group. Initial weight of the dumbbells will be 1kg and will be increased by 0.5kg per week."
10019169|NCT04891523|Other|Placebo-Probiotic|First receive placebo, then active probiotics.
10019170|NCT04891523|Other|Probiotic-Placebo|First receive active probiotics, then placebo.
10019171|NCT04889807||Patients who need fluid perfusion|
10019172|NCT04887948|Experimental|Coadministration Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
10019173|NCT04887948|Active Comparator|20vPnC-only Group|Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
10019174|NCT04887948|Active Comparator|BNT162b2-only Group|Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.
10019175|NCT04886596|Experimental|RSVPreF3_L1 Group|Participants in this group receive lot 1 of the RSVPreF3 OA vaccine (Dose 1).
10019176|NCT04886596|Experimental|RSVPreF3_L2 Group|Participants in this group receive lot 2 of the RSVPreF3 OA vaccine (Dose 1).
10019177|NCT04886596|Experimental|RSVPreF3_L3 Group|Participants in this group receive lot 3 of the RSVPreF3 OA vaccine (Dose 1).
10019178|NCT04886596|Experimental|RSVPreF3_L4 Group|Participants in this group receive lot 4 of the RSVPreF3 OA vaccine (Dose 1).
10019179|NCT04886596|Placebo Comparator|Placebo Group|Participants in this group receive 1 dose of placebo at day 1 and an additional dose of placebo every subsequent year.
10019180|NCT04886596|Experimental|RSV_L1_annual Group|Participants in this group are re-randomized from the RSVPreF3_L1 Group to receive an additional dose of the RSVPreF3 OA vaccine.
10019181|NCT04886596|Experimental|RSV_L2_annual Group|Participants in this group are re-randomized from the RSVPreF3_L2 Group to receive an additional dose of the RSVPreF3 OA vaccine.
10019182|NCT04886596|Experimental|RSV_L3_annual Group|Participants in this group are re-randomized from the RSVPreF3_L3 Group to receive an additional dose of the RSVPreF3 OA vaccine.
10019183|NCT04886596|Experimental|RSV_L4_annual Group|Participants in this group are re-randomized from the RSVPreF3_L4 Group to receive an additional dose of the RSVPreF3 OA vaccine.
10019184|NCT04886596|Experimental|RSV_L1_1dose Group|Participants in this group are re-randomized from the RSVPreF3_L1 Group to receive a dose of placebo.
10019185|NCT04886596|Experimental|RSV_L2_1dose Group|Participants in this group are re-randomized from the RSVPreF3_L2 Group to receive a dose of placebo.
10019186|NCT04886596|Experimental|RSV_L3_1 dose Group|Participants in this group are re-randomized from the RSVPreF3_L3 Group to receive a dose of placebo.
9477336|NCT03563378|Experimental|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
9477337|NCT03563378|Experimental|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
9477338|NCT03563365|Experimental|Replenix|Replenix power of 3 cream with Resveratrol applied twice daily
9477339|NCT03563365|Experimental|Replenix and Adapalene and Benzoyl Peroxide gel|Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
9477340|NCT03563365|Active Comparator|Adapalene and Benzoyl Peroxide gel|Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
9477341|NCT03563352||Observational (interview, survey)|Participants attend an interview over 15 minutes and complete surveys.
9477342|NCT03563339|Experimental|P-POD|All participants will complete the prevention for postpartum onset distress (P-POD)
9477343|NCT03563326|Experimental|CAR-T cell and chemotherapy|Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist
9477344|NCT03563326|Active Comparator|chemotherapy|Chemotherapy: determined by medical Oncologist
9477345|NCT03563300|Active Comparator|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
9477346|NCT03563300|Placebo Comparator|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
9477347|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs before surgery|
9477348|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery|
9477349|NCT03563261|Active Comparator|Collagen supplement group|Participants assigned in the collagen supplement group will drink the active product every morning before breakfast.
9477350|NCT03563261|Placebo Comparator|Placebo supplement group|Participants assigned in the placebo supplement group will drink the placebo every morning before breakfast.
9477351|NCT03563248|Active Comparator|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
9477352|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
9477353|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
9477354|NCT03563248|Experimental|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
9477355|NCT03563235|Experimental|Xulin Jiangu granules|Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
9477356|NCT03563235|Active Comparator|Calcitriol capsules|Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
9477357|NCT03563222|Experimental|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
9477358|NCT03563222|Active Comparator|Intralipid, 20%|Intralipid 20% is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
10019187|NCT04886596|Experimental|RSV_L4_1dose Group|Participants in this group are re-randomized from the RSVPreF3_L4 Group to receive a dose of placebo.
10019188|NCT04885985|Experimental|DEB catheter|Use DEB catheter to treat the stenosis or occlusion in below popliteal artery of experimental arm
10019189|NCT04885920||Participants With IBD|Participants diagnosed with moderately to severely active IBD (UC or CD) who initiated or are currently ongoing vedolizumab IV induction treatment in accordance with the current Summary of Product Characteristics (SmPC) or receiving vedolizumab ongoing or maintenance IV treatment with the option to switch to vedolizumab SC treatment, will be observed prospectively for at least 12 months.
10019190|NCT04884100|Other|PPG recording|arrhythmia recording using PPG monitor
10019191|NCT04883749|Experimental|Acalabrutinib|Acalabrutinib will be administered up to 24 cycles (= approx. 24 months total) until progression of disease (PD) or intolerable toxicity
10019192|NCT04883086||diabetic group ( Case)|Total of 91 participants diagnosed with diabetes type 2
10019193|NCT04883086||Non diabetic group (control)|Total of 91 participants healthy and not diagnosed with diabetes Mellitus
10019194|NCT04882384|Experimental|Peripheral Nerve Block (PENG)|Patients will receive the Pericapsular Nerve Group Block.
10019195|NCT04882332||metformin usage index and vitamin B12 level|Samples for correlation between metformin usage index and vitamin B1 level will be withdrawn from 108 type 2 diabetes patients
10019196|NCT04882202|Experimental|Acetaminophen group|patients receiving acetaminophen
10019197|NCT04882202|Placebo Comparator|Placebo group|patients receiving equal amount of normal saline
10019198|NCT04882189||Capsulorhexis|Capsulotomies conducted by Capsulorhexis
10019199|NCT04882189||ZEPTO Precision Capsulotomy Device|Capsulotomies conducted by ZEPTO Precision Capsulotomy Device
10019200|NCT04881617|Experimental|Lexical Retrieval Treatment|
10019201|NCT04881617|Experimental|Script Training|
10019202|NCT04881240|Experimental|Group A|Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.
10019203|NCT04881240|Experimental|Group B|Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.
10019204|NCT04880642|Experimental|C21|50 mg capsules, oral administration twice daily,for 14 days
10019205|NCT04880642|Placebo Comparator|Placebo|placebo capsules, oral administration twice daily,for 14 days
10019206|NCT04880473|Experimental|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
10019207|NCT04880460|Active Comparator|Experimental|45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets
10019208|NCT04880460|Placebo Comparator|Control|45 MDD patients were included in this arm who were received SSRIs and placebo tablets
10019209|NCT04879940|Experimental|Prostatic Artery Embolization (PAE)|Participants who receive PAE with Merit Medical Embospheres.
10019210|NCT04878913||C21|Subject treated with C21 in the VP-C21-006 trial
10019211|NCT04878913||Placebo|Subject treated with placebo in the VP-C21-006 trial
10019212|NCT04877990|Experimental|Long-Term Extension Rollover Study: BMS-986165|
10019213|NCT04877288|Experimental|Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap|Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)
10019214|NCT04877288|Active Comparator|Arm 2: Continue calcineurin inhibitor-based regimen|
10019215|NCT04876924|Experimental|BBP-711 for SAD|A single dose of BBP-711 will be administered orally.
10019216|NCT04876924|Placebo Comparator|Placebo for SAD|A single dose of matching placebo will be administered orally.
10019217|NCT04876924|Experimental|BBP-711 for MAD|A dose of BBP-711 will be administered orally for multiple days.
10019218|NCT04876924|Placebo Comparator|Placebo for MAD|A dose of matching placebo will be administered orally for multiple days.
10019219|NCT04876924|Experimental|BBP-711 for SAD Food Effect|A single dose of BBP-711 will be administered orally.
10019220|NCT04876924|Placebo Comparator|Placebo for SAD Food Effect|A single dose of matching placebo will be administered orally.
10019221|NCT04876248|Experimental|Treatment (belantamab mafodotin, lenalidomide)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-28. Treatment repeats every 8 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.
10019222|NCT04871607|Experimental|Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)|Patients receive 'cold' basiliximab IV followed by yttrium Y 90 basiliximab IV on day -14. Patients also receive carmustine IV on over 4 hours day -6, etoposide IV over 1 hours QD and cytarabine IV over 2 hours BID or QD on days -5 to -2, and melphalan IV over 1 hours on day -1. Patients then receive HPC-A product via infusion on day 0. Beginning day 5, patients receive G-CSF (or biosimilar) SC or IV until ANC > 500 for 3 consecutive days or according to the treating physician's best clinical judgement.
10019223|NCT04871425|Experimental|Ketamine|Participant will receive 2mg IV midazolam and 0.2-0.5mg/kg IV ketamine over 2 minutes, which can be repeated q5 minutes until appropriate analgesia is achieved.
10019224|NCT04871425|Active Comparator|Fentanyl|Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.
10019225|NCT04871217|Experimental|Acute ST-elevation myocardial infarction or chronic coronary artery occlusion|68-Ga-NODAGA-RGD PET after acute ST-elevation myocardial infarction or before and after re-opening of a chronic coronary artery occlusion
10019226|NCT04870944|Experimental|Treatment (CBL0137)|Patients receive CBL0137 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
10019227|NCT04869995||Intervention|Senior abdominal and pelvic cavity surgeons (i.e., visceral surgeons, gynecologist surgeons, and urologists) having completed their robot-assisted surgery training, and commonly doing laparoscopic surgery.
10019228|NCT04869813||Heart failure patients|"Inclusion criteria:~Age > or = 40 yrs~Stable chronic heart failure~Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less~Exclusion criteria:~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease~Contraindications to MRI such as:~Heart pacemaker/defibrillator~Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires~Cochlear implant or other ear implants~Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)~Programmable shunt~Aneurysm clips and coils~Stents • Filters (for example, blood clot filters)~Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
10036211|NCT01813604|Active Comparator|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
9477359|NCT03563196||Chest Radiograph|All the patients will undergo routine chest radiogram on day 1 after operation
10019229|NCT04869813||Healthy volunteers (Controls)|"Inclusion criteria:~Age > or = 40 yrs~No diagnosed heart failure or sarcopenia~Exclusion criteria~• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease~Contraindications to MRI such as:~Heart pacemaker/defibrillator~Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires~Cochlear implant or other ear implants~Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)~Programmable shunt~Aneurysm clips and coils~Stents~Filters (for example, blood clot filters)~Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)"
10019230|NCT04869345|Experimental|LARKSPUR intervention|Lessons in Affect Regulation to Keep Stress and Pain UndeR control
10019231|NCT04869345|No Intervention|Attention Control Condition|Daily emotion reporting/no intervention
10019232|NCT04867551|Experimental|KDT-3594|
9477360|NCT03563196||Lung Ultrasound|The same patient will undergo ultrasound evaluation of lungs on day 1 after operation
9665262|NCT05118945||START group: Change from conservative therapy to Control IQ|"The patients of the START group have a conservative Insulin therapy (MDI = multiple daily injections or CSII = Continuous subcutaneous insulin infusion) until the start of the study, but will switched to the Control IQ algorithm at study start."
10019233|NCT04865770|Experimental|Semaglutide 1.0 mg OW|Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).
10019234|NCT04865770|Placebo Comparator|Placebo (Semaglutide) 1.0 mg OW|Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).
10019235|NCT04864665|Experimental|Formula fed|0 - 6 months: a formula with prebiotics and milk fat (Stage 1); >6 - 12 months: a formula with prebiotics and milk fat (Stage 2); >1 - 2 years: a formula with prebiotics and milk fat (Stage 3)
10019236|NCT04864470|Experimental|Intervention|"Stroke Odysseys is a performing arts intervention for people who have had strokes which provides an opportunity for communication of experiences of stroke to an audience through acquired skills in movement, music, song and the spoken word.~Stroke Odysseys comprises three distinct stages:~weekly workshops over 12 weeks for stroke participants facilitated by an integrated team of expert artists and ambassadors from the charity Rosetta Life~a smaller group of ambassadors recruited from the workshops will be trained to become co-facilitators (stroke ambassadors)~a performance tour including education and taster workshops for audiences."
10019237|NCT04862975||Drug of Interest|Lactating moms receiving one or more antiretroviral drugs and their breastmilk fed infants per standard of care.
10019238|NCT04862221|Experimental|High-dose methylprednisolone|Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.
10019239|NCT04862221|Experimental|Equine anti-thymocyte globulin|Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.
10019240|NCT04862221|Placebo Comparator|Supportive care|Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.
10019241|NCT04861727|No Intervention|Group control|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will make MRPA and will receive the report and general guidance on blood pressure control and pharmacotherapy assessment
10036212|NCT01813604|Active Comparator|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
10019242|NCT04861727|Active Comparator|Intervention group|will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment, will also do MRPA whose result will guide pharmaceutical suggestions, when necessary, they will also receive a Referral Letter to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.
10019243|NCT04861350|Experimental|motor imagery with action observation|The subjects will perform the exercises mentally for 3 sets with video, 10 reps for 1 set.
10019244|NCT04861350|Experimental|physical training|The subjects will perform the exercise physically for 3 sets with supervision of investigator, 10 reps for 1 set.
10019245|NCT04861350|Experimental|combine physical training and motor imagery with action observation|The subjects will perform the exercise mentally with video for 1 set and physically with supervision of investigator for 2 sets, 3 sets totally, 10 reps for 1 set.
10019246|NCT04861259|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] C5 SNP (Single Nucleotide Polymorphism) Cohort - participants with documented C5 polymorphism.
10019247|NCT04860960|Experimental|Experimental|Intravenous administration of 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) (based on body weight) diluted with 0.5N saline over at least 6.5 hours every 2 weeks
10019248|NCT04860960|Placebo Comparator|Placebo comparator|Intravenous administration of 0.5N saline over at least 6.5 hours every 2 weeks
10019249|NCT04860960|Experimental|Open Label sub-study for Infants up to age 3|Up to 12 patients age 0 - 3 yrs in countries following EMA guidance may be enrolled in this open label sub-study. All patients will receive 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) diluted with 0.5N saline at the clinician's discretion over 6.5 hours every 2 weeks. Outcome measures are safety, clinician and caregiver impressions.
10019250|NCT04860791||Multiple Sclerosis patients|
10019251|NCT04860297|Experimental|mRNA-1273|"Part A: All participants (healthy participants and SOT participants) who were unvaccinated prior to enrollment will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29.~All SOT participants who were unvaccinated prior to enrollment will be offered the opportunity to receive a third primary dose of mRNA-1273 at Day 85 as per the emergency use authorization (EUA) Fact Sheet available at the time of protocol finalization.~SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the EUA prior to enrollment will receive Dose 3 on Day 1.~Part B: All eligible participants from Part A will be offered to receive a 100 µg booster dose of mRNA-1273 who are at least 4 months from the last dose. SOT recipients who completed primary COVID-19 vaccination series with a non-Moderna COVID-19 under EUA (outside of the mRNA-1273-P304 study) will receive a 100 µg booster dose on booster dose Day 1."
10019252|NCT04858750|Other|Cook D-J stent group|"Patients randomized to this group received Cook (Limerick, Ireland, USI-626-R) D-J stent.~Note: USI is an unexpandable acronym."
10019253|NCT04858750|Other|KYB anti-reflux D-J stent group|Patients randomized to this group received KYB (Shenzhen, China, 3201162) anti-reflux D-J stent.
10019254|NCT04858750|Other|Urovision trigonal D-J stent group|"Patients randomized to this group received Urovision (Bad Aibling, Germany, ST-230726) trigonal D-J stent.~Note: ST is an unexpandable acronym. Aibling is a German region name."
10019255|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Treatment|"Condition1: Treatment-first~Children with RSE and typical perception will be allocated to a randomized controlled trial measuring the efficacy of online visual-acoustic biofeedback treatment. Ten children with RSE will receive 10 weeks of visual-acoustic biofeedback training via video call."
10019256|NCT04858022|Experimental|Visual Acoustic Biofeedback for RSE via Telepractice-Wait|"Condition 2: Waitlist-first~Following the initial evaluation, 10 children with RSE will be allocated to a 10 week no treatment condition."
10019257|NCT04857580|Experimental|CTS device|
10019258|NCT04857580|No Intervention|Control|
10019259|NCT04857528||Retrospective (Participants Who Have Already Been Treated for HPV-Related Cancer Before Study)|This group will use medical records from participants who have already received chemoradiation for their HPV-related anal or cervical cancer at a time before this study started. Because they have already received treatment, these participants will provide previous blood/tumor tissue samples that contain detectable HPV DNA as well as at least one post-treatment sample that their doctor collected before the study. Data from these previously collected samples will be compared to current samples from participants who are actively enrolled in this study in present day (chart review).
10019260|NCT04857528||Prospective (Participants Who Will Receive Radiation Treatment for HPV-Related Cancer During Study)|This group is for participants who plan to receive radiation treatment (with or without chemotherapy) for their HPV-related anal or cervical cancer during the time this study will be conducted. Participants in this group will sign a consent form allowing researchers to collect their blood samples and analyze/compare them to the samples from the retrospective group of participants.
10019261|NCT04855097|Experimental|Standard care group|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will be blinded to the results and will choose between a low-moderate and high diuretic dose based on usual care clinical assessment of volume status.
10019262|NCT04855097|Experimental|BVA-guided treatment arm|Blood Volume Analysis will be performed at admission, during inpatient stay if warranted, and prior to hospital discharge. Treating physicians will receive the results and will choose between a low-moderate and high diuretic dose based on measured volume status.
10019263|NCT04855045|Experimental|Group 1 - open label|
10019264|NCT04855045|Experimental|Group 2 - open label|
10019265|NCT04855045|Experimental|Group 3: open label|
10019266|NCT04855045|Experimental|Group 4: double-masked, randomized to one of 2 dose cohorts|
10019267|NCT04853992|Experimental|Active - Placebo|Patients will receive active treatment for 7 days, followed by a washout period of 7 days and then placebo for 7 days
10019268|NCT04853992|Experimental|Placebo - Active|Patients will receive placebo for 7 days, followed by a washout period of 7 days and then active treatment for 7 days
10019269|NCT04853329|Experimental|PartA- Arm A|"Arm A 1-6 subjects will be enrolled at dose levels of CPO107 at (1, 3, 6, 12, 20 mg/kg).~Each subject group will receive multiple cycles of a weekly dose of CPO-107 (1 cycle=21 days=3 treatments)."
10019270|NCT04853329|Experimental|PartA- Arm B|Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks (1 cycle=21 days=1 treatment). The starting dose for Arm B will be the dose level below the Arm A level that provides an equivalent dose over a 3-week period.
10019271|NCT04853329|Experimental|Part B|Part B with either: second or greater relapse OR refractory patients, as defined by not achieving a CR after 2 cycles of a standard first line chemoimmunotherapy regimen or not achieving a CR following 1 cycle of a second line chemotherapy regimen.
10019272|NCT04850807|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting
10019273|NCT04850807|Experimental|Music & Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences at early signs of agitation
10019274|NCT04849728|Experimental|Lanifibranor (IVA 337) (800 mg/day)|2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --> once a day (quaque die, QD)
10019275|NCT04849728|Experimental|Lanifibranor (IVA 337) (1200 mg/day)|3 Lanifibranor tablets 400mg with food --> once a day (quaque die, QD)
10019276|NCT04849728|Placebo Comparator|Matching placebo|3 Placebo to match tablets with food --> once a day (quaque die, QD)
10019277|NCT04848740|Other|FRESH CORNEAL LENTICULE IMPLANTATION|"The aim in our study is to describe the importance of stroma as criteria of corneal thickness at implanting human fresh corneal lenticule in progressive corneal disease.~We have conclude that every biomechanical instability of corneal stroma function(abnormal increase collagen activity,decrease proteinase inhibitors,excessive premature keratocyte apoptosis) describe the role of stroma in corneal thickness."
10019278|NCT04848337|Experimental|Study Treatment Arm|Lenvatinib 20 mg Orally Day1-21 with Pembrolizumab 200 mg Intravenously (IV) over 30 minutes Day 1. Each cycle = 21 days
10019279|NCT04847193|Experimental|Placebo|Participants receive a study drink supplemented with a placebo over a time period of 5 days.
10019280|NCT04847193|Experimental|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol over a time period of 5 days.
10019281|NCT04847193|Experimental|Iso-alpha acids|Participants receive a study drink supplemented with Iso-alpha acids over a time period of 5 days.
10019282|NCT04847193|Experimental|Xanthohumol/Iso-alpha acids|Participants receive a study drink supplemented with a combination of Xanthohumol and Iso-alpha acids over a time period of 5 days.
10019283|NCT04844931|Experimental|RIC + PostC in addition to standard treatment|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery in addition to standard treatment.
10019284|NCT04844931|Active Comparator|Standard treatment|
10019285|NCT04844021|Experimental|Nudge|"Clinics randomized to the Nudge condition will receive the EHR prompt only. The investigators will add default language to the standard Well Child Visit workflow to serve as a reminder and allow for tracking of S.A.F.E. Firearm implementation. The clinician will be asked to denote whether the program was delivered (e.g., whether conversation around firearm storage was conducted, whether cable firearm lock was offered) to the parent during the visit. This EHR prompt will remain turned on from active implementation through the sustainment period."
10036213|NCT01813604|Active Comparator|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
10019286|NCT04844021|Experimental|Nudge+|This arm consists of Nudge as described above, as well as facilitation. Facilitation (i.e., external support delivered by health system employees not employed within the clinic site) will be offered for 12 months to each clinic, in keeping with other implementation trials. The investigators will use a train-the-trainer model to train facilitators at both health systems to ensure they achieve facilitator core competencies with an eye toward implementation of S.A.F.E. Firearm. The role of the facilitator is to engage with study clinics, to assist each clinic in setting change and performance goals around the implementation of S.A.F.E. Firearm, and to troubleshoot implementation barriers.
10036214|NCT01813604|Active Comparator|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
10036215|NCT01813604|Active Comparator|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
10036216|NCT01813617||Recent onset polymyositis and dermatomyositis|Patients in this cohort was diagnosed with polymyositis or dermatomyositis during 2003-2010 and was treated with corticosteroids and other immunosuppressive agents according to standard care. They were all diagnosed and treated at the Rheumatology Clinic, Karolinska University Hospital.
10036217|NCT01813630|Experimental|DA-3002|0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
10036218|NCT01813630|Active Comparator|Genotropin®|0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas
10036219|NCT01813643|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
10019287|NCT04843631|Experimental|Arm A: BFI-751|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL BFI-751
10019288|NCT04843631|Active Comparator|Arm B: EU-STELARA®|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL EU- STELARA®
10019289|NCT04843631|Active Comparator|Arm C: US-STELARA®.|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL US- STELARA®
10019290|NCT04843501|Experimental|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|The CMB curriculum is divided into four developmentally appropriate e-cigarette lessons (approximately 20-30 minutes each) for middle school aged youth (6th - 8th grade). A variety of educational strategies are used and include cooperative learning groups, large group discussions, interviews, role-play, media, reports, and goal setting. CMB will provide study materials to teachers and schools through a state-of-the art online delivery portal. A site-based management team will oversee program implementation. Teachers will be trained via webinar. Project staff will visit all participating schools to assemble and train the CATCH site-based management team, and answer questions about the study. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar with Dr. Kelder, which will be offered at multiple times to accommodate teaching schedules.
10019291|NCT04843501|Active Comparator|Texas Education Agency required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes online lessons and support materials.
10019292|NCT04840199|Experimental|Arm A: Letermovir|"Letermovir 480 mg will be administered by one of the following strategies:~Letermovir 240 mg tablets administered orally as two tablets once daily with or without food.~Letermovir 480 mg tablets administered orally as one tablet once daily with or without food.~Participants will be able to switch administration strategy during treatment duration based on availability of study supply."
10019293|NCT04840199|Other|Arm B: No anti-CMV treatment|
10019294|NCT04838977|Experimental|RESET|Children will view 8 educational modules online and participate in 8 sessions with a therapist via telehealth.
10019295|NCT04838977|No Intervention|Control|Children will receive usual post-trauma care.
10019296|NCT04838743||IDegLira|Real-world adult population with type 2 diabetes mellitus in Japan.
10019297|NCT04838197||Caregiver|If the caregiver agrees and consents to participating in the study, basic demographic and social data will be collected at baseline. The caregiver will also complete the caregiver burden questionnaire via telephone call at five different time points: pre-operatively, and post-operative 48 hours, 1 week, 2 weeks, and 1 month.
10019298|NCT04837521|Experimental|Therapist Delivered Unified Protocol|This is a five session psychotherapy designed to help people with problems such as anxiety and depression.
9477361|NCT03563170|Experimental|NANT Hepatocellular Carcinoma Vaccine|Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.
10019299|NCT04837521|Experimental|Self-Guided Unified Protocol|This is a five session treatment that patients can complete independently.
10019300|NCT04837092|Experimental|FR104 Treatment|
10019301|NCT04835844||Mapping with CARTO|CARTO (Biosense Webster) in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
10019302|NCT04835844||Mapping with RHYTHMIA|RHYTHMIA (Boston Scientific) in conjunction with the 64-electrodes ORION mini-basket catheter.
10019303|NCT04835584|Experimental|Part 1, KRT-232 combined with TKI (Dasatinib or Nilotinib) in patients with CML-CP|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.
10019304|NCT04835584|Experimental|Part 2, Arm A (KRT-232 combined with Dasatinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.
10019305|NCT04835584|Experimental|Part 2, Arm B (KRT-232 combined with Nilotinib in patients with CML-CP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.
10019306|NCT04835584|Experimental|Part 2, Arm C (KRT-232 combined with Dasatinib or Nilotinib in patients with CML-AP)|KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.
10019307|NCT04835168|Experimental|BT-11 500mg|Oral
10019308|NCT04835168|Experimental|BT-11 1000mg|Oral
9477362|NCT03563170|Active Comparator|Sorafenib Monotherapy|Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.
10019309|NCT04835168|Placebo Comparator|BT-11 Placebo|Oral
10036220|NCT01813643|Active Comparator|Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.
10019310|NCT04834973|Experimental|Single arm open label|Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2 given in combination with three weekly 200 mg intravenous doses of pembrolizumab.
9477363|NCT03563144|Experimental|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1~A combination of agents will be administered to subjects in this study:~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
10019311|NCT04834193|Experimental|WET-SUCTION|The stylet will be removed and the needle will be pre-flushed with 1-2mL of saline. The lesion will then be punctured, and suction will be applied using a 10-mL pre-vacuum syringe. The sample collected will be pushed into a formalin vial with saline.
10019312|NCT04834193|Active Comparator|SLOW-PULL|After puncturing the lesion, the stylet will be slowly and gradually withdrawn for at least 40cm. The sample will be pushed into formalin using the stylet.
10019313|NCT04834128|Experimental|γδ T cells (IMP, TCB008)|Patients will receive an infusion of γδ T cells (IMP, TCB008) following informed consent after admission to hospital for SARS-CoV-2 infection (COVID-19).
10019314|NCT04833010|Active Comparator|No cloth face mask|Cross-over randomization. Participants randomized to this arm will not wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
10019315|NCT04833010|Experimental|Cloth face mask|Cross-over randomization. Participants randomized to this arm will wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
10019316|NCT04831502|Experimental|Sequence 1: TAK 906 50 mg (Treatment A+Treatment B+Treatment A+Treatment B+Treatment C)|Participants will receive TAK-906 50 milligram (mg) as Treatment A (TAK-906 capsule) and Treatment B (TAK-906 tablet) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
10019317|NCT04831502|Experimental|Sequence 2: TAK-906 50 mg (Treatment B+Treatment A+Treatment B+Treatment A+Treatment C)|Participants will receive TAK-906 50 mg as Treatment B (TAK-906 tablet) and Treatment A (TAK-906 capsule) under fasted conditions and Treatment C (TAK-906 tablet) under fed conditions, orally, once on Day 1 of Periods 1 to 5. A washout interval of at least 3 days will be maintained between each Treatment Period.
10019318|NCT04831190|Experimental|Intervention|All participants will be involved in a tailored exercise intervention for 12 weeks.
10019319|NCT04830514|Experimental|Recommended dietary allowance (RDA) for protein|(RDA; 0.8g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
10019320|NCT04830514|Experimental|Habitual protein intake consistent with population level norms|(NHANES; 1.0g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
10019321|NCT04830514|Experimental|Optimal protein intake (OPI)|(OPI; 1.5g/kg/day) Protein intakes will be structured within two meals per day. A 2-day dietary lead-in will precede each dietary intervention. Study duration per subject will last about two weeks.
10019322|NCT04829929|Experimental|One arm|Patients with Non-Valvular Atrial Fibrillation and High Bleeding Risk
10019323|NCT04829474||Women consulting for spouse abuse|The study focuses on women consulting a doctor as part of spouse abuse, whatever the context (at the request of the police or not) or their motivation (medical or social).
10019324|NCT04828850|Experimental|EBUS-TBNA procedure|Single arm protocol. Invasive mediastinal staging with EBUS-TBNA in clinical N0 NSCLC patients candidate to surgical resection with systematic lymphadenectomy.
10019325|NCT04828434|Experimental|Virtual Individual Cognitive Stimulation Therapy|"Virtual Cognitive Stimulation Therapy (V-iCST), a psychosocial intervention, is a modified version of CST for people with mild to moderate dementia. Like the original CST, each of the 14 sessions will begin with a warm-up activity, which includes an orientation task and discussion of current affairs, followed by a main activity.~V-iCST will be prescribed to participants twice a week, for 7 weeks and each session is approx. 45 minutes. The intervention will be delivered by trained professionals, such as research staff, psychologists, and trainee clinical psychologists. All facilitators will have experience in dementia care and will have completed the CST training."
10019326|NCT04828434|No Intervention|Treatment as usual|Standard care.
10019327|NCT04826640||Pregnant women who receive COVID-19 vaccine|Pregnant women who receive COVID-19 vaccine
10019328|NCT04826523||Participants treated with Venetoclax|Participants who were prescribed venetoclax for the treatment of Acute Myeloid Leukemia (AML) will be enrolled for this study.
10019329|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 1|"A 3+3 dose escalation design will be used to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when combined with cemiplimab.~Participants will receive ASP8374 and Cemiplimab every 3 weeks for up to 2 years. ASP8374 will be available until October 31, 2022. Subjects may continue treatment with cemiplimab alone after that date."
10019330|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 2|"Upon determination of the MTD/RP2D of ASP8374 plus cemiplimab in Cohort 1, a dose expansion will be performed in which eligible participants who are candidates for surgical resection will enroll to Cohort 2 and will be randomized into one of two treatment groups (2A-2B).~Group 2A: IV ASP8374 plus cemiplimab within 14± 5 days prior to surgery at the MTD/RP2D established in Cohort 1.~Group 2B: No immune checkpoint therapy prior to surgery.~Post-operatively, all Cohort 2 participants will receive ASP8374 plus cemiplimab every 3 weeks administered at the MTD/RP2D established by Cohort 1~Per determination of treating clinician, participants will have 89Zr-Df-IAB22M2C administered prior to PET scans."
10019331|NCT04825964||Patients|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated at diagnosis and after 1-3 months.
10019332|NCT04825964||Healthy Controls|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated one time.
10019333|NCT04825847|Active Comparator|Electroencephalographic (EEG)-guided group|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
10019334|NCT04825847|Active Comparator|Standard Care (SC) group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at [0.8-1.2] MAC.
10019335|NCT04823858||Examination Group|There will only be one arm of subjects in this study. The arm will include subjects who plan to undergo a single-level TLIF stabilized with pedicle screws and meet all of the eligibility criteria.
10019336|NCT04823299|Active Comparator|Cryoballoon ablation|Cryoballoon Pulmonary Vein Isolation-Wide area circumferential ablation (WACA)
10019337|NCT04823299|Experimental|RF based WACA ± EP testing guided ablation of non-PV triggers of AF and low voltage area ablation|Radiofrequency wide area circumferential ablation (WACA) ± electrophysiological testing guided ablation of non-pulmonary vein triggers of AF and low voltage area ablation
10019338|NCT04822545|Other|Intervention Arm|"-Adult (≥ 18 years of age) hospitalized patients who have obesity (BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 if Asian/South Asian), as recorded in the medical chart, who have decision-making capacity and whose acute medical condition has been stabilized.~we will exclude patients who are enrolling in hospice/comfort care and the patients who are already enrolled in the CWM clinic. Non-English speaking patients. Patients who have opted out of research in their Epic EHR will be excluded from consideration for participation."
10019339|NCT04819854|Experimental|EP395|EP395 in ascending doses. Orally, once daily.
10019340|NCT04819854|Placebo Comparator|Placebo|Placebo, weight matched in ascending doses. Orally, once daily.
10019341|NCT04819815||Type 1 diabetes mellitus|"Patients~Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue (fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated."
10019342|NCT04819815||Healthy Controls|Maximal exercise capacity (Incremental shuttle walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance ( incremental threshold loading test), physical activity level (multi sensor activity monitor), quality of life (World Health Organization (WHO) well-being index), fatigue ( fatigue severity scale), shortness of breath (Modified Medical Research Council MMRC) will be evaluated.
10019343|NCT04819295||Latinx Adolescents|
9477364|NCT03563144|Active Comparator|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
9477365|NCT03563144|Active Comparator|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
9477368|NCT03563118||Group OSAS|We included 56 with OSAS [13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe
9477369|NCT03563118||control group|simple snoring
9477370|NCT03563105|Experimental|Desaturation|Vascular Occlusion Test
9477371|NCT03563092|Experimental|Lap Inguinal Hernia repair with Drain|A (14 French sizes) closed suction drain will be placed in preperitoneal space after laparoscopic inguinal hernia (TEP/TAPP) surgery.
9477372|NCT03563092|Active Comparator|Lap Inguinal Hernia repair without Drain|No drain will be placed after laparoscopic inguinal hernia (TEP/TAPP) surgery.
10019344|NCT04819295||Parents of Latinx Adolescents|
10019345|NCT04819295||Healthproviders|
9665263|NCT05117788||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study. The specimens will be tested with~Bioneer Accupower Q-FRIA assay using the Iron q-PCR instrument (investigational product)~Xpert MTB/RIF Ultra and Xpert MTB/XDR (comparators products)"
10019346|NCT04819035||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
10019347|NCT04818346|Experimental|INCB054707 Dose A followed by Dose C|Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
10019348|NCT04818346|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
10019349|NCT04818346|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
10019350|NCT04818346|Placebo Comparator|Placebo followed by INCB054707 Dose C|Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
10019351|NCT04818034|Experimental|Study Drug|The study drug Dapagliflozin
10019352|NCT04816747|Experimental|Autologous PRP|Participants with diagnosed lumbar DDD are planned to be managed via intradiscal injection of 0.5-1 ml autologous PRP, whereas participants with FJS will be injected with 0.5 ml of respective solution. All procedures will be performed in surgical theatre under constant fluoroscopic guidance.
10036221|NCT01813656|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
10019353|NCT04816149|Active Comparator|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
10019354|NCT04816149|Experimental|Treatment for Relationships and Safety Together (TR&ST)|TR&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
10019355|NCT04815967|Experimental|Phase 2; Low Dose MYOBLOC|Low Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
10019356|NCT04815967|Experimental|Phase 2; High Dose MYOBLOC|High Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
10019357|NCT04815967|Placebo Comparator|Phase 2; Placebo|Volume-matched placebo is a single treatment
10019358|NCT04815967|Experimental|Phase 3; MYOBLOC|MYOBLOC is a single treatment and will be compared to volume-matched placebo
10019359|NCT04815967|Placebo Comparator|Phase 3; Placebo|Volume-matched placebo is a single treatment
10019360|NCT04815070||Diabetic|A group of diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
10019361|NCT04815070||Non-Diabetic|A group of non-diabetic patients who have fasted for at least 8 hours undergoing staged bilateral total knee arthroplasty.
10019362|NCT04812912||Participants with Colon Cancer|This patient population will have hormone biomarker analysis, questionnaire (QOL) administration, and, if the patient is male, semen analysis
10019363|NCT04812912||Participants with Rectal Cancer|This patient population will have hormone biomarker analysis, QOL administration, and, if the patient is male, semen analysis
10019364|NCT04812015|Other|Dose Group 1|
10019365|NCT04812015|Other|Dose Group 2|
10019366|NCT04812015|Other|Dose Group 3|
10019367|NCT04812015|Other|Dose Group 4|
10019368|NCT04812015|Other|Dose Group 5|
10019369|NCT04812015|Other|Dose Group 6|
10019370|NCT04812015|Other|Dose Group 7|
10019371|NCT04812015|Other|Dose Group 8|
10019372|NCT04812015|Other|Dose Group 9|
10019373|NCT04811404|Experimental|Ethyl eicosapentaenoic acid|Ethyl eicosapentaenoic acid will be given at 1G by mouth twice per day
10019374|NCT04810884||Living kidney donors|"Aim 1: A survey about fractures and general bone health will be sent to 3000 prior living kidney donors.~Aim 2: Out of these 3000 subjects, 200 prior living kidney donors who are ≥10 years post kidney donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
10036222|NCT01813656|Placebo Comparator|Sugar pill|placebo arm,5mg/pill,10mg/day,last12weeks
10036223|NCT01813682|No Intervention|control group|preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
10019375|NCT04810884||Matched Controls|"Aim 1: A survey about fractures and general bone health will be sent to 3000 age, sex, race, and comorbidity-matched subjects who would have been eligible to donate but did not donate a kidney.~Aim 2: Out of these 3000 subjects, 200 control subjects who would be eligible to donate, but have not donated, and are matched by age, sex, race, and comorbidity to donors at the time of donation will be invited to Mayo Clinic Rochester for an assessment of bone health. Each subject will undergo lateral DXA with vertebral fracture assessment (VFA), bone density assessment of each hip, radius and spine by DXA scan, bone structure assessment by HRpQCT of the distal radius and tibia, finite element assessment (µFEA), skin AGEs measurement, and blood collection to measure markers of bone formation and resorption."
10019376|NCT04809012|Experimental|STI-3031|20 mg/kg STI-3031 administered intravenously Q2W
10019377|NCT04807985||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
10019378|NCT04807725||Peri-implant health|Includes patients with peri implant mucosa without inflammatory signs and absence of peri-implant bone loss.
10019379|NCT04807725||Peri-implantitis|Includes patients with bleeding and / or suppuration on probing, probing depth equal or greater than 6mm and bone loss equal to or greater than 3mm.
10019380|NCT04807595||Retrospective cohort|Patients with confirmed diagnosis of HER2-neg, unresectable and/or mBC regardless of hormone status dating back from 31 December 2017 - but no older than 01 January 2015 - who progressed on any systematic anti-cancer therapy will be involved in this study.
10019381|NCT04807387|Experimental|Healthy participants: acute|Healthy participants will wear one of two vaginal stents for 24 hours, followed by a 24 hour wash out period. They will then wear the second vaginal stent for 24 hours. After both stents have been worn, the participants will choose the most comfortable stent.
10019382|NCT04807387|Experimental|Healthy participants: chronic|Healthy participants will wear the stent chosen to be the more comfortable for 2 weeks without removal.
10019383|NCT04807387|Experimental|Pediatric participants: post vaginal surgery|Pediatric participants will wear the vaginal stent for 2 weeks after undergoing vaginal surgery.
10019384|NCT04807387|Experimental|Adult participants: post vaginal brachytherapy|Adult participants undergoing vaginal brachytherapy for cancer treatment will wear the stent for 2 weeks, be evaluated by a physician, and wear the stent for an additional 2 weeks.
10019385|NCT04807153||Patients|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
10019386|NCT04807153||Healthy Controls|Functional exercise capacity (6 minutes walk test), upper extremity exercise capacity (6 minutes Pegboard and Ring Test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), physical activity level (multi-sensor activity monitor), quality of life (European Cancer Research and Treatment Organization Quality of Life Scale (EORTC QOL C-30)), fatigue (Fatigue Severity Scale) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
10019387|NCT04806347|Experimental|Treatment arm|Participants will undergo a conditioning regimen, specific for the original disease, After that peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCRαβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems will be administered intravenously on Day 0 to all participants.
10019388|NCT04804241|Experimental|10 mg daily Senicapoc|10 mg daily Senicapoc for 52 weeks
10019389|NCT04804241|Placebo Comparator|Placebo Group|Placebo daily for 52 weeks
10019390|NCT04803643||Patients|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
10019391|NCT04803643||Healthy controls|"Upper extremity exercise capacity will be assessed using six minute pegboard ring test, functional exercise capacity using six minute walk test, muscle oxygenation using Moxy monitor, balance using Biodex Balance System® and Y balance test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, life quality using The Revised Cystic Fibrosis Questionnaire (CFQ-R) (Turkish version)."
10019392|NCT04802733|Experimental|MSK-DA01|
10019393|NCT04802707|Experimental|dC/dT100-400 Arm|Children 0-18 Y who takes the investigational product deoxynucleosides pyrimidine (mix of deoxycytidine and deoxythymidine), following the protocol.
10019394|NCT04802629||Term neonates|≥ 37+0 weeks of gestation
10019395|NCT04802629||Preterm neonates|≤ 36+6 weeks of gestation
10019396|NCT04801459|Experimental|Antiperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The isoperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was consistent.
10019397|NCT04801459|Active Comparator|Isoperistaltic direction of gastrointestinal anastomosis in Roux-en-Y reconstruction group|The antiperistaltic anastomosis represents the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
10019398|NCT04800107|Experimental|Treatment Group|Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.
10019399|NCT04800107|Placebo Comparator|Placebo Group|Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.
10019400|NCT04799405|Experimental|tDCS MDD|"A group of 5 participants with major depressive disorder (MDD).~tDCS, as a relatively simple and portable technology, is particularly well suited for remotely-supervised, home-based treatment, which would facilitate longer periods of treatment as well as offer a suitable therapeutic option at the present time as the investigators aim to deal with the COVID-19 pandemic."
10019401|NCT04798131|Experimental|Active|The visual feedback will correspond to instructions, adapted to the current hallucinatory state and decoded online from the fMRI signal.
10019402|NCT04798131|Sham Comparator|Sham|The visual feedback will correspond to random instructions independently of the fMRI signal.
10019403|NCT04797221||Veteran study group|The investigators will recruit approximately 20 Veterans who were identified as having elevated suicide risk while being treated in a VA Emergency Department.
10019404|NCT04797039||MR guided cryoablation|Focal MR guided cryoablation for low- to intermediate-grade prostate cancer
10019405|NCT04795440|No Intervention|Eya-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the ejaculate (control group).
10019406|NCT04795440|Experimental|Test-ICSI|Oocytes inseminated by ICSI technique with spermatozoa from the testicle (study group).
10019407|NCT04795141|Active Comparator|ABY-035 80mg Q2W SC injection|Group A
10019408|NCT04795141|Active Comparator|ABY-035 40mg Q2W SC injection|Group B
10019409|NCT04795141|Active Comparator|ABY-035 160mg Q4W SC injection|Group C
10019410|NCT04795141|Placebo Comparator|Placebo Q2W SC injection|Group D
10019411|NCT04794036|Experimental|Experimental Group|Telerehabilitation asynchronous programme at home
10019412|NCT04794036|Active Comparator|Control Group|Rehabilitation programme with an explanatory booklet at home
10019413|NCT04793867||CF and Non-CF Bronchiectasis|In the first arm (Aims 1 & 2) Up to 50 subjects will be recruited-approximately 25 with normal FEV1 (>85% predicted) and 25 with mild to moderate disease. All subjects will be asked to undergo longitudinal (i.e., approximately annually) 129Xe and UTE MRI, spirometry, and lung clearance index (LCI) measurement.
10019414|NCT04793867||Healthy Subjects|Up to 50 age and sex matched control subjects (i.e., subjects with no known cardiopulmonary disorders) may also be recruited to provide a reference data set from healthy subjects for comparison.
10019415|NCT04792957||Pyoderma Gangrenosum|Skin biopsies obtained from patients with pyoderma gangrenosum will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods.
10019416|NCT04792957||Hidradenitis Suppurativa|Skin biopsies obtained from patients with hidradenitis suppurativa, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
10019417|NCT04792957||Psoriasis|Skin biopsies obtained from patients with psoriasis, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods
10019418|NCT04792957||Healthy Subjects|Skin biopsies obtained from patients with healthy subjects, will be used to control group.
10019419|NCT04791969|Experimental|Naltrexone with ecological momentary intervention|Naltrexone Hydrochloride, 50 mg., intermittent with ecological momentary assessment (EMA)
10019420|NCT04791969|Placebo Comparator|Placebo with ecological momentary intervention|Placebo, intermittent with ecological momentary assessment (EMA)
10019421|NCT04791839|Experimental|Cohort A: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~Cohort A participants are those that have PD-L1 1-49%"
10019422|NCT04791839|Experimental|Cohort B: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~Cohort B participants are those that have PD-L1 ≥ 50%."
10019423|NCT04791735|Experimental|Laparoscopic approach for liver resection of HCC|
10019424|NCT04791735|Experimental|laparotomy|
10019425|NCT04791540||Patients with trachestomy|Patients, attending a respiratory rehabilitation program, who underwent tracheostomy decannulation
10019426|NCT04790773|No Intervention|Standard of care|Patient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
10019427|NCT04790773|Active Comparator|Alexa Education|Patient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.
10019428|NCT04790474|Experimental|ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment|Prospective study of ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment for patients with relapsed and refractory multiple myeloma (RRMM) previously treated with daratumumab, lenalidomide and bortezomib
10019429|NCT04790396||Patient presenting at emergent department with cardiac arrest|
10036224|NCT01813682|Experimental|treatment group1|preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
10019430|NCT04788953|Experimental|Solriamfetol (Sunosi)|"Participants will start at 75 mg and take that dose for 3 consecutive days. Participants will take their first 75mg dose on an early morning work day and take the next two 75 mg doses upon awakening regardless of their work schedule.~They will then move to 150mg on the next early morning work day and for all subsequent early morning shift work days. The drug/placebo will be taken orally within 30 minutes after awakening, before the start of each early morning shift. Prior to the end of study of visit (Visit 5), drug will be taken at home within 30 minutes of awakening."
10019431|NCT04788953|Placebo Comparator|Control|Participants randomized into the Control arm will receive a placebo
10019432|NCT04788511|Experimental|Semaglutide|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
10019433|NCT04788511|Placebo Comparator|Placebo (semaglutide)|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
10019434|NCT04788329|Experimental|Relaxation Group|This program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel.
10019435|NCT04788329|Experimental|Meditation Group|"This treatment group will be enrolled in Wim Hof Method, a meditation program. Patients in this group will take the online The Fundamentals Course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively"
10019436|NCT04788329|No Intervention|Standard Care Group|The control group will get the standard of care therapy after surgery.
10019437|NCT04788095|Experimental|Device feasibility (app-based mindfulness program)|Patients participate in a mindfulness-based program by using the Am app for 20-30 minutes every day, a minimum of 4 days each week over 4 weeks.
10019438|NCT04788004||Cohort 1|Participants in this group started their recovery process < 1 year ago
10019439|NCT04788004||Cohort 2|Participants in this group started their recovery process 1 to <2 years ago
10019440|NCT04788004||Cohort 3|Participants in this group started their recovery process 2 to <3 years ago
10019441|NCT04788004||Cohort 4|Participants in this group started their recovery process 3 to <4 years ago
10019442|NCT04788004||Cohort 5|Participants in this group started their recovery process 4 to <5 years ago
10019443|NCT04788004||Cohort 6|Participants in this group started their recovery process 5 to <6 years ago
10019444|NCT04788004||Cohort 7|Participants in this group started their recovery process 6 to <7 years ago
10019445|NCT04788004||Cohort 8|Participants in this group started their recovery process 7 to <8 years ago
10019446|NCT04788004||Cohort 9|Participants in this group started their recovery process 8 to <9 years ago
10019447|NCT04788004||Cohort 10|Participants in this group started their recovery process 9 to <10 years ago
10036225|NCT01813682|Experimental|treatment group2|preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
9477373|NCT03563079|Experimental|trial group|The treatment will be performed using two pieces of Instrument Assisted Soft Tissue Mobilization (IASTM) stainless steel in the neck, bilaterally, which comprise the following muscles: Upper Trapezius, Splenius, scalenes and Sternocleidomastoid. An established time of 3 minutes will be used in each region, using an angle of 30 to 60º with the instrument. As it is observed, through the instrument, regions of greater adhesion, the researcher will use most of this time to release this condition.
10019448|NCT04787653|Active Comparator|Otoband efficacy on Tinnitus|"Participants will wear the Otoband on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Each participant will select his/her preferred stimulation level. The OtoBand will be programmed to operate at one of three power levels that are thought to be effective. The OtoBand will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
10019449|NCT04787653|Placebo Comparator|Placebo device efficacy on Tinnitus|"The placebo device will use the same case, headband and battery as the OtoBand. The transducer in the OtoBand will be rotated 90 degrees, so that the placebo device will vibrate in a direction ineffectual at providing bone conducted vibrations. The vibrations will be in the horizontal plane, parallel to the skull, and will not have their energy penetrating the skull all the way to the vestibular system. Each participant will select his/her preferred stimulation level. The placebo devices will be made to vibrate at one of three power levels, none of which are thought to be effective. The placebo will record what power level is selected and how long it was operating at that power level as well as the date and time a usage started. The use log will be downloaded at Otolith's lab once the device is received. The participant will wear the device for 30 minutes and record their Tinnitus level in a Google Form."
10019450|NCT04787393||LOVE-HF-2 Participants|"Participants will have the Heartfelt device as well as a set of weighing scales installed at home.~Alerts will be raised for the patient to be seen at home or in clinic by clinician ( the clinician will be blinded to the type of alert). During this face-to-face encounter, the clinician will perform a detailed oedema assessment (recording pitting depth, time of recovery, height oedema, overall grading), ankle circumference measurement, weight measurements, and echo (Left ventricular ejection fraction, Left atrial volumes, inferior vena cava diameter, Diastolic function (E/A, E/E'), TAPSE and TR jet velocity + visually estimated mitral and tricuspid regurgitation)."
10019451|NCT04787380|Experimental|LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm A (Full data analysis mode of Heartfelt + weight + symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'full data analysis' mode and participants will follow standard care recommendations for weighing themselves and reporting their symptoms. 'Full data analysis' mode means that the device will be fully operational and will be detecting and reporting changes in foot volume over time. The device will have been allocated to the 'full data analysis' mode prior to shipping. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
10019452|NCT04787380|No Intervention|LOVE-HF Arm B (Technical checks only mode of Heartfelt + weight + symptoms reporting)|Participants in LOVE-HF Arm B (Technical checks mode of Heartfelt + weight + Symptoms reporting) will not know if they are assigned to LOVE-HF Arm A or LOVE-HF Arm B. The Heartfelt device will be in 'technical checks only' mode where the data analysis pipeline is blocked and changes in foot volume over time will not be processed or reported. However, technical checks on device functioning and image quality (e.g. camera being blocked) will be made as usual. The device will have been allocated to the 'technical checks only' mode prior to shipping. Participants will follow standard care recommendations for weighing themselves and reporting their symptoms. Participants will be provided with electronic, internet connected weighing scales that can transmit weight data. These weighing scales will be used as per usual advice given to patients, thus taking part in the study should not change their behaviour.
10019453|NCT04787198|Experimental|hypertonic saline|
10019454|NCT04787198|Placebo Comparator|isotonic saline|
10036226|NCT01813708|Experimental|Intensive Life-Style Counseling|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
10019455|NCT04787042|Experimental|Phase 1a, Dose Escalation|In phase 1 dose escalation will start at a dose level of 30ug/kg . Patients will be treated every week and the DLT evaluation period is 28 days. According to the mTPI schema initially there will be 2 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. Up to 12 patients will be treated at the RP2D
10019456|NCT04787042|Experimental|Phase 2, Expansion|Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and microsatellite instability-high (MSI-Hi) tumors at the RP2D.
10019457|NCT04785807|Experimental|Evaluation arm|
10019458|NCT04785781|Other|no mask|individuals perform cardiopulmonary test via cycle ergometer without mask till voluntary exhaustion
10019459|NCT04785781|Other|surgical mask|individuals perform cardiopulmonary test via cycle ergometer with surgical mask till voluntary exhaustion
10019460|NCT04785781|Other|N95/fpp2|individuals perform cardiopulmonary test via cycle ergometer with N95 mask till voluntary exhaustion
10019461|NCT04785352|No Intervention|Standard well-baby care|Children in this arm (control group), as well as children in the two intervention groups, will receive standard care as outlined in the Essential Package of Health Services by Haiti's Ministry of Public Health and Population (MSPP). This includes a World Health Organization (WHO) immunization schedule of vaccines, high dose vitamin A supplements, and growth monitoring and promotion.
10019462|NCT04785352|Experimental|Nutrition Intervention|Children in this arm will receive one egg per day for six months.
10019463|NCT04785352|Experimental|Grandi Byen|This arm comprises a multicomponent intervention on responsive parenting, nutrition, hygiene, and one egg per day for six months for children.
10019464|NCT04781907|Experimental|Home Expansion Group|Participants in home expansion group will perform the saline injection for their right tissue expander under clinic staff supervision on their 2nd and 3rd expansion. Beginning their 4th expansion, participants will perform saline injection at home prior to their regularly scheduled clinic visit.
10019465|NCT04781907|No Intervention|Control Group|Standard of Care
10019466|NCT04781647|Active Comparator|ABI-H0731 + ETV|Participants with cHBV will receive ABI-H0731 with ETV for 48 weeks, followed by ETV alone for 12 weeks
10019467|NCT04781647|Experimental|ABI-H0731 + ETV + Peg-IFNα|Participants with cHBV will receive ABI-H0731 with ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
10019468|NCT04781647|Active Comparator|ETV + Peg-IFNα|Participants with cHBV will receive ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks
10019469|NCT04781192|Experimental|Dose Finding Regorafenib|We will use a 3 + 3 design with two dose levels of 80 mg and 120 mg to discover the Maximum Tolerated Dose (MTD) for regorafenib
10019470|NCT04780763|Active Comparator|Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690|
10019471|NCT04780763|Placebo Comparator|Arm 2, Control: Milk-based non-fermented dairy product|
10019472|NCT04779320|Experimental|Induction Period: ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of ≥30 kg will be included in this arm group.
10019473|NCT04779320|Experimental|Induction Period: >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of >15 to <30 kg will be included in this arm group.
10019474|NCT04779320|Experimental|Induction Period: 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of 10 to 15 kg will be included in this arm group.
10019475|NCT04779320|Experimental|Maintenance Period: ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
10019476|NCT04779320|Experimental|Maintenance Period: ≥30 kg: Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
10019477|NCT04779320|Experimental|Maintenance Period: >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
10019478|NCT04779320|Experimental|Maintenance Period: >15 to <30 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
10037470|NCT01825330|Sham Comparator|Sham TMS+Cog|Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
10019479|NCT04779320|Experimental|Maintenance Period: 10 to 15 kg Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
10019480|NCT04779320|Experimental|Maintenance Period: 10 to 15 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
10019481|NCT04777279|Experimental|Individual physical exercise group|a 12-weeks physical exercise program (60 minutes/ three times weekly)
10019482|NCT04777279|Experimental|Individual Branched-Chain Amino Acids supplements group|a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
10019483|NCT04777279|Experimental|Combination of physical exercise and Branched-Chain Amino Acids supplements group|a 12-weeks physical exercise program (60 minutes/ three times weekly) and a 12-weeks Branched-Chain Amino Acids supplements (5 g Branched-Chain Amino Acids every day)
10019484|NCT04777279|No Intervention|Control group|no intervention
10019485|NCT04776382|Experimental|Study Group|Trainees of this group will watch an EMME (Eye Movement Modeling Examples) pre-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
10019486|NCT04776382|No Intervention|Control Group|Trainees of this group will not watch the pre-recorded video
10036227|NCT01813708|Active Comparator|Collaborative Educational|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
10036228|NCT01813747|Experimental|1440 nm wavelength laser with hand piece|To assess the effectiveness of the 1440 nm wavelength laser with handpiece for skin tightening and laser lipolysis for the mandibular and sub-mandibular areas
10036229|NCT01813760|Experimental|Diode laser|Diode laser to treat peri-orbital and peri-oral wrinkles
10036230|NCT01813773|Experimental|Group A - IAI every 4 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.
10036231|NCT01813773|Experimental|Group B - IAI every 8 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will receive IAI every 8 weeks, beginning week 24, through week 48.
10036232|NCT01813786|Experimental|755nm Alexandrite Laser with Handpiece 2|Focusing energy on skin
10036233|NCT01813786|Experimental|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
10036234|NCT01813786|Experimental|755nm Alexandrite laser with handpiece 1|Focusing energy on skin
10036235|NCT01813799|Experimental|DA-9801 300mg|
10036236|NCT01813799|Experimental|DA-9801 600mg|
10036237|NCT01813799|Experimental|DA-9801 900mg|
10036238|NCT01813799|Placebo Comparator|Placebo|
10036239|NCT01813812|Experimental|DA-6034 45mg|two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
10036240|NCT01813812|Experimental|DA-6034 90mg|two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
10036241|NCT01813812|Active Comparator|Rebamipide 300mg|two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
10036242|NCT01813825||Female >=45 years, negative margins, DCIS|
10019487|NCT04775966||The study population|Patients meeting eligibility criteria (see appropriate section).
10019488|NCT04775537||OssiMend™ Bioactive Moldable|Patients undergoing Lumber Spine Fusion
10019489|NCT04775394|Experimental|Pilot Part: Healthy subjects|3-5 healthy ex-smokers with normal lung function to establish methods
10019490|NCT04775394|Experimental|Main Part: COPD patients and Healthy Controls|8 subjects with COPD stage II and III who are ex-smokers and have a history of chronic cough and sputum production and 5-8 healthy, age-matched controls
10019491|NCT04774380|Experimental|Durvalumab - (cisplatin or carboplatin) - Etoposide|Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.
10019492|NCT04774328|Active Comparator|CA-008 (vocacapsaicin)|Single administration
10019493|NCT04774328|Placebo Comparator|Placebo|Single administration
10019494|NCT04774315|Experimental|Omalizumab|
10019495|NCT04773730|Active Comparator|Posterior transversus abdominus block|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A 12-14 MHz linear array transducer will be placed transversely between the iliac crest and costal margin then slided from medial-lateral to visualize the posterior most part of the external oblique, internal oblique, and transversus abdominus muscles~Then 20 mL of bupivacaine0.25% will be injected between the transverses abdominus muscle and the fascia deep to the internal oblique muscle~The same steps will be repeated on the other side"
10019496|NCT04773730|Active Comparator|Quadratus lumborum block type 2|"After the surgery end and while the patient in the supine position, with the side to be blocked is elevated~A2-5 MHz curved array transducer will be placed at the level of the antero-superior iliac spine then the external oblique muscle will be followed posterolaterally until its posterior border will be visualized The probe will be tilted down to identify a bright hyperechoic line After that 20 mL of bupivacaine 0.25% will be injected under direct visualization on the posterior surface of quadrates lumborum muscle~The same steps will be repeated on the other side"
9665264|NCT05117489|Experimental|Cohort 1 - 150 mg of miricorilant for 24 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 24 weeks.
10019497|NCT04773457||Spine Surgery|Pediatric patients presenting for elective spine fusion surgery at Boston Children's Hospital
10019498|NCT04773457||Abdominal Surgery|Pediatric patients presenting for elective abdominal surgery at Boston Children's Hospital
10019499|NCT04772456|Experimental|metabolic MRI|Single-arm study in patients who have Glioma Perform metabolic magnetic resonance imaging on patient have a Glioma cancer to understand if metabolic MRI can be safely performed on this population
10019500|NCT04769479|Experimental|acoramidis|
10019501|NCT04768361|Experimental|Behavioral Activation without Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and excludes terms and interventions from Third Generation Therapies.
10019502|NCT04768361|Experimental|Behavioral Activation with Mindfulness|Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and include mindfulness practices.
10019503|NCT04768335|Active Comparator|Patient group with schizophrenia|The schizophrenic subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
10036243|NCT01813838|Experimental|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of Acadesine 140mg/kg/d
10019504|NCT04768335|Active Comparator|Healthy control subjects|Healthy control subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
10019505|NCT04767802|Experimental|PTG-300|Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.
10019506|NCT04767503|Active Comparator|Propofol|Maintence of anesthesia during the operation using target control infusion with propofol 1mg/ml with bispetral index(BIS) in the range 40-60.
10019507|NCT04767503|Sham Comparator|Desflurane|Maintence of anesthesia during the operation using inhalational agent desflurane with 0.5 to 1.5 minimal alveolar concentration (MAC) with bispetral index(BIS) in the range 40-60.
10019508|NCT04766073|Experimental|New Closure Technique|This group will have the uterus closed after delivery of the fetus during cesarean section with a new technique.
10019509|NCT04766073|No Intervention|Regular closure technique|The usual method of closing the surgical incision is to suture the entire wall of the uterus with a stratafix suture without locking the suture.
9665265|NCT05117489|Experimental|Cohort 2 - 150 mg of miricorilant for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 12 weeks.
10019510|NCT04765761|Active Comparator|PLMA with Introducer'|PLMA placed in position with the help of the introducer-tool and then the introducer-tool retained in place throughout the institution and duration of positive pressure ventilation.
10036244|NCT01813838|Experimental|ACADESINE 210mg/kg/d|In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
10019511|NCT04765761|Active Comparator|PLMA without Introducer|PLMA placed in position with the help of the introducer-tool and then the introducer-tool removed before institution of positive pressure ventilation.
10019512|NCT04764305||Patients|Patients with Fontan circulation. No intervention planned (observational study)
10019513|NCT04764305||Controls|Healthy, biventricular controls. No intervention planned (observational study)
10019514|NCT04763564|Experimental|Liraglutide then Placebo|Participants will be randomly assigned to 6-week Liraglutide treatment. Then after a 5-day washout, treatment will continue with 6 weeks of placebo.
10019515|NCT04763564|Experimental|Placebo then Liraglutide|Participants will be randomly assigned to 6-week placebo treatment. Then after a 5-day washout, treatment will continue with 6 weeks of Liraglutide.
10019516|NCT04763252||Canadian|
10019517|NCT04762888|Experimental|Diagnostic (68Ga-PSMA PET/MRI or PET/CT)|Patients receive 68Ga-PSMA IV over 90 minutes. Patients then undergo PET/MRI over 60 minutes or PET/CT over 30 minutes.
10019518|NCT04762199|Experimental|Treatment (osimertinib, MRX-2843)|Patients receive osimertinib PO QD and MRX-2843 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10019519|NCT04761263|Active Comparator|Selected Physical Therapy group|will receive a selected physical therapy program for 90 minutes, 3 times/week for 3 successive months.
10019520|NCT04761263|Experimental|Task-oriented circuit training group|Children allocated to the study group will receive the same selected physical therapy program given to the control group for 45 minutes in addition to 45 minutes task-oriented circuit training program. The frequency of the whole program will be three times per week, for three months.
10019521|NCT04761159|Active Comparator|Ketofol1/1|Propofol 1 mg/kg + ketamin1 mg/kg (1/1 ratio) for group I to anesthesia induction.
10019522|NCT04761159|Active Comparator|Ketofol1/2|propofol 1,5 mg/kg + ketamin 0,75 mg/kg (2/1 ratio) for group II to anesthesia induction
10019523|NCT04761159|Active Comparator|Ketofol1/3|propofol 2 mg/kg +ketamin 0,66 mg/kg (3/1 ratio) for group III to anesthesia induction
10019524|NCT04761159|Active Comparator|propofol|propofol 3 mg/kg will perform for anesthesia induction
10019525|NCT04760496|Experimental|Experimental group|The experimental group will receive oxytocin at 4 mIU/mL
10019526|NCT04760496|Active Comparator|Control group|The control group will receive oxytocin at 2 mIU/mL
10019527|NCT04760288|Experimental|Arm A (Pralsetinib)|Participants will receive Pralsetinib at a dose of 400mg orally once daily (PO QD) in 28-day cycles.
10019528|NCT04760288|Active Comparator|Arm B (SOC: Cabozantinib/Vandetanib)|Participants will receive either one of the following SOC therapies, as determined by the treating investigator: Cabozantinib: 140mg PO QD in 28-day cycles; Vandetanib: 300mg PO QD in 28-day cycles.
10019529|NCT04759898|Active Comparator|Stimulation (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and transcranial direct current stimulation.
10019530|NCT04759898|Sham Comparator|Sham (noninvasive recording)|Patients with Parkinson's disease or chronic stroke will be assigned to undergo EEG recording and sham transcranial direct current stimulation.
10019531|NCT04759898|Experimental|Stimulation (invasive recording)|Patients with Parkinson's disease undergoing surgery for deep brain stimulation will be studied using electrocorticography combined with transcranial direct current stimulation
10019532|NCT04758611|Experimental|Treatment Arm|The Treatment Arm receives the eShunt implant
10019533|NCT04755816|Sham Comparator|Control Group|Standard heart failure educational information.
10019534|NCT04755816|Experimental|Dietary Sodium Intervention|The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
10019535|NCT04755816|Experimental|Clinical Worsening Intervention|The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
10019536|NCT04755816|Experimental|Dietary Sodium and Clinical Worsening|Full access to all content in the control, dietary sodium, and clinical worsening interventions.
10019537|NCT04754477|Experimental|Active Osseointegrated Steady-State Implant System (OSI)|
10019538|NCT04753216|Experimental|Treatment (bevacizumab, irinotecan sucrosofate)|Patients receive bevacizumab IV and irinotecan sucrosofate IV over 90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10019539|NCT04752033|Experimental|Morphine|Subjected to sequential up and down dose titration using biased coin method in parallel with the hydromorphone arm
10019540|NCT04752033|Experimental|Hydromorphone|Subjected to sequential up and down dose titration using biased coin method in parallel with the morphine arm
10019541|NCT04751487|Experimental|Itepekimab Q2W in former smokers|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
10019542|NCT04751487|Experimental|Itepekimab Q4W in former smokers|SC administration of Itepekimab every 4 weeks (Q4W) for 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
10019543|NCT04751487|Placebo Comparator|Placebo in former smokers|SC administration of matching placebo Q2W for 52 weeks
10019544|NCT04751487|Experimental|Itepekimab Q2W in current smokers|SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
10019545|NCT04751487|Placebo Comparator|Placebo in current smokers|SC administration of matching placebo Q2W for 52 weeks
10019546|NCT04750967|Experimental|Active|Greater occipital nerve and supraorbital nerve block with 1% lidocaine once a week for first four weeks then once a month for 5 months
10019547|NCT04750967|Active Comparator|Control|Amitriptyline 25 mg daily for 6 months
10019548|NCT04750642|Experimental|CI632D Investigational Medical Device (IMD)|
10019549|NCT04750642|Placebo Comparator|CI632 Comparator Device|
10019550|NCT04750239|Experimental|Nivatrotamab|Subcutaneous administration of nivatrotamab up to 13 cycles
10019551|NCT04749667|Experimental|Arm A - Crossover with MSCs at baseline and placebo at 6 months|Receives mesenchymal stem cells at baseline and placebo at 6 months
10019552|NCT04749667|Experimental|Arm B - Crossover with placebo at baseline and MSCs at 6 months|Receives placebo at baseline and mesenchymal stem cells at 6 months
10019553|NCT04749186|Active Comparator|Structured Didactic Model Group|A standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
10019554|NCT04749186|No Intervention|Standard Training Model|The standard local institutional teaching program
10019555|NCT04748497|Other|Parasportives of various disciplines|
10019556|NCT04748458||Congenital hip pathologies|Conical tapered stem for osteoarthritis due to congenital hip pathologies
10019557|NCT04745013|Experimental|PRIORITY|Patients randomized to the hybrid exercise intervention (PRIORITY) will receive a personalized exercise prescription generated by the EXPERT tool which will then be person-tailored by the physiotherapist during one-on-one physical activity consultation. Over a period of one year, patients will participate in 18 supervised center-based exercise sessions in adjunct to a remotely monitored and guided home-based exercise intervention.
10019558|NCT04745013|Placebo Comparator|Usual care|The usual care group will receive from the physiotherapist a personalized written exercise prescription that includes an individually tailored recommendation on frequency, intensity, type, time and volume of exercise. This exercise prescription will be generated by means of the EXPERT tool. No counselling or guidance on objective measures of physical activity by means of wearables or platform will be provided.
10019559|NCT04743908|No Intervention|Social Network Strategy (SNS Condition)|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walkthrough and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared."
10019560|NCT04743908|Experimental|Social Network Strategy + Messaging|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walk through and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared. Finally, community developed COVID-19 public health messages will be shared in the participant's preferred language."
10036245|NCT01813838|Experimental|ACADESINE 315mg/kg/d|In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients
10019561|NCT04742634|Experimental|Phase I Dose Level 1: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1, 2, 3 of a 28 day cycle."
10019562|NCT04742634|Experimental|Phase I Dose Level 2: DEC-C|"Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C.~35 mg decitabine/100 mg cedazuridine taken by mouth once daily on Days 1-4 of a 28 day cycle."
10019563|NCT04742634|Experimental|Phase II MRD Positive: DEC-C|"35 mg decitabine/100 mg cedazuridine taken by mouth once daily per the schedule determined in the Phase I portion of the study. Cycle 1 Day 1 may take place between Day 42 and Day 100 post-transplant. MRD-positive patients will receive up to 5 cycles of DEC-C prior to the Day 180 bone marrow evaluation.~Bone marrow biopsy with MyeloSeq-HD will be obtained on Day 180 post-transplant. If the Day 180 MyeloSeq-HD shows that MRD is still detectable in the opinion of the MGI board-certified molecular pathologist but below 0.5% and patient has tolerated initial treatment without toxicity, the patient may continue treatment. If it shows a lack of MRD, the patient will be moved to the post-treatment surveillance arm. If it shows any mutation detection prior to transplant that persists with a variant allele frequency of ≥ 0.5%VAF, the patient will receive up to an additional 6 cycles of DEC-C."
10019564|NCT04742634|Active Comparator|Phase II MRD Negative: Observation Arm|"In phase II, up to 77 patients who do not have MRD positivity on Day 30 post-transplant (i.e., the absence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.5%) will be placed on the observation arm and treated with standard of care.~Patients on the observation arm will be followed every 3 months for 2 years and every 6 months for 3 years for progression and survival"
10019565|NCT04741698|Active Comparator|Propranolol 2mg IV|"At the time of labor dystocia, patients randomized to the treatment arm of propranolol will receive a one-time administration of IV 2mg propranolol in pre-mixed syringes prepared by the pharmacy.~The propranolol IV administration recommended in clinical practice guidelines is 1 mg IV over 1 minute. Therefore, total administration time will be 2 minutes."
10019566|NCT04741698|No Intervention|No intervention|At the time of labor dystocia, patients randomized to the placebo arm will not receive any intervention
10019567|NCT04740567|Experimental|Cognitive Intervention|During hospitalization, enrolled patients assigned to the intervention arm will undergo two 20-minute cognitive training sessions daily, 7 days a week. After the patient is discharged from the hospital, cognitive rehabilitation will be administered once a week for 12-weeks at their place of residence. Goal Management Training will be the foundation for cognitive rehabilitation.
10019568|NCT04740567|No Intervention|Usual Care|Enrolled patients will undergo usual care during hospitalization and post-hospital discharge.
10019569|NCT04739956||Patient: point of care (POC) result not shared|Patients in this phase of the study will not be provided with the POC BhCG result. They will await the laboratory result. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
10019570|NCT04739956||Partner: point of care (POC) result not shared|Partners in this phase of the study will not be informed of the POC BhCG result. They will await the laboratory result to be provided to the patient. Simultaneously we will ascertain reliability of POC in clinical practice during this time.
10019571|NCT04739956||Patient: point of care (POC) result shared|Patients in this phase will be informed of the POC test result, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
10019572|NCT04739956||Partner: point of care (POC) result shared|Partners in this phase will be informed of the POC test result with the patient, which will reduce the time to which they receive the result. Prior to transfer to this phase, correlation between POC and laboratory BhCG levels will be calculated in order to confirm its reliability by creating a correlation curve using the data.
10019573|NCT04736875||Dialysis|Patients with hemodialysis-dependent end-stage renal disease and a newly created native arteriovenous fistula
10019574|NCT04736602|Experimental|Triptorelin Pamoate 15mg for injection|Triptorelin will be injected at day 1 and month 3.
10019575|NCT04736004||Athletes with COVID-19|
10019576|NCT04736004||Athletes without COVID-19 (control)|
10019577|NCT04735822|Experimental|Part 1: Belumosudil Sequence ABFCED|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen A (delivered by Vehicle 1); Regimen B (delivered by Vehicle 2); Regimen F (delivered by Vehicle 6); Regimen C (delivered by Vehicle 3); Regimen E (delivered by Vehicle 5); Regimen D (delivered by Vehicle 4);
10019578|NCT04735822|Experimental|Part 1: Belumosudil Sequence BCADFE|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen B (delivered by Vehicle 2); Regimen C (delivered by Vehicle 3); Regimen A (delivered by Vehicle 1); Regimen D (delivered by Vehicle 4); Regimen F (delivered by Vehicle 6); Regimen E (delivered by Vehicle 5)
10019579|NCT04735822|Experimental|Part 1: Belumosudil Sequence CDBEAF|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen C (delivered by Vehicle 3); Regimen D (delivered by Vehicle 4); Regimen B (delivered by Vehicle 2); Regimen E (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen F (delivered by Vehicle 6)
10019580|NCT04735822|Experimental|Part 1: Belumosudil Sequence DECFBA|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen D (delivered by Vehicle 4); Regimen E (delivered by Vehicle 5); Regimen C (delivered by Vehicle 3); Regimen F (delivered by Vehicle 6); Regimen B (delivered by Vehicle 2); Regimen A (delivered by Vehicle 1)
10019581|NCT04735822|Experimental|Part 1: Belumosudil Sequence EFDACB|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen E (delivered by Vehicle 5); Regimen F (delivered by Vehicle 6); Regimen D (delivered by Vehicle 4); Regimen A (delivered by Vehicle 1); Regimen C (delivered by Vehicle 3); Regimen B (delivered by Vehicle 2)
10019582|NCT04735822|Experimental|Part 1: Belumosudil Sequence FAEBDC|Subjects receive 1 dose of belumosudil 40 mg/mL in oral suspension in the following sequence: Regimen F (delivered by Vehicle 6); Regimen A (delivered by Vehicle 1); Regimen E (delivered by Vehicle 5); Regimen B (delivered by Vehicle 2); Regimen D (delivered by Vehicle 4); Regimen C (delivered by Vehicle 3).
10019583|NCT04735822|Experimental|Part 2: Belumosudil Sequence GHI|Subjects receive 1 dose in the following sequence; Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed)
10019584|NCT04735822|Experimental|Part 2: Belumosudil Sequence HIG|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed)
10019585|NCT04735822|Experimental|Part 2: Belumosudil Sequence IGH|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen G (belumosudil 200 mg tablet fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
10019586|NCT04735822|Experimental|Part 2: Belumosudil Sequence IHG|Subjects receive 1 dose in the following sequence: Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet fed)
10019587|NCT04735822|Experimental|Part 2: Belumosudil Sequence GIH|Subjects receive 1 dose in the following sequence: Regimen G (belumosudil 200 mg tablet fed); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed); Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted)
10019588|NCT04735822|Experimental|Part 2: Belumosudil Sequence HGI|Subjects receive 1 dose in the following sequence: Regimen H (powder for oral suspension or oral suspension belumosudil 200 mg fasted); Regimen G (belumosudil 200 mg tablet); Regimen I (powder for oral suspension or oral suspension belumosudil 200 mg fed);
10019589|NCT04735575|Experimental|EMB-06|"In Phase I part: participants enrolled at different time will receive EMB-06 by IV infusion at different ascending dose levels.~In Phase II part: participants will receive EMB-06 by IV infusion at previously defined RP2D."
10019590|NCT04735315||Born preterm|"Inclusion :~Born preterm ≤29 weeks Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
10036246|NCT01813851|No Intervention|control group|"Patients in the control group will receive:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day"
10036247|NCT01813851|Experimental|activity group|"Patients in the group exercise will:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day A program of physical activity consisting of progressive endurance and resistance training on a cycle ergometer, performed during the dialysis session under supervision and counseling by a qualified trainer"
10036248|NCT01813864|Experimental|CASPAR Resource Guide|Treatment Enhanced/CASPAR-- All counselors in this study will receive a training and take part in the experimental arm of the study in Phase 2.
10019591|NCT04735315||Born term|"Inclusion :~Born full-term at 37-41 weeks Birthweight ˃2500g Aged 18-40 years Participants with type-2 diabetes~Exclusion :~Currently pregnant due to administration of radionucleotides and impact on GFR Severe neurosensory deficit preventing test completion History of characterized kidney disease independent of preterm birth, including type-1 diabetes, glomerulopathies (e.g. nephrotic syndrome, glomerulonephritis), polycystic kidney disease, polycystosis, severe uropathy (Grade 4 or 5 RVU, severe hydronephrosis (SFU IV and V), posterior valve history), history of nephrectomy, exposure to radiotherapy or chemotherapy - given that we are interested in isolating the effects of preterm birth and that prevalence of these conditions is not increased in individuals born preterm In case of contra-indication to MRI scanning (which should be rare in the young population studied), the participant will still be given the opportunity to complete the other examinations."
10019592|NCT04734444|Experimental|SonoClear acoustic coupling fluid (ACF) mimicking brain tissue|SonoClear
10019593|NCT04733547||Donor hepatectomy|Live donors undergoing hepatectomy
10019594|NCT04731480|Active Comparator|CLADS group|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia.
10019595|NCT04731480|Active Comparator|Marsh model group|The target-controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
9480730|NCT05261620|Experimental|SoC + WISE|Candidates for surgery and habitual consumers of alcohol-containing beverages (7-21 alcohol-containing beverages per week) with a body mass index between 18 and 30 kg/m2. Subjects assigned to the Experimental Arm will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men.
10019596|NCT04731480|Active Comparator|Schnider model group|The TCI-pump will be programmed to will be programmed to Schnider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia.
10019597|NCT04731480|Active Comparator|Manual group|Propofol administration will be controlled manually using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
10019598|NCT04731298|Experimental|Emapalumab|"The first cohort of patients will receive a first infusion of 6 mg/kg at TD0, followed by a second infusion at 3 mg/kg after 3 days (treatment day 3 - TD3). Subsequent infusions of 3 mg/kg will be every 3 or 4 days from previous dose until dose 15 or until engraftment.~A maximum of 2 additional cohorts may be added to allow dosing regimen adaptation based on the PK/PD data observed from the previous cohort(s). Efficacy and safety data will also be considered before adding additional cohorts."
10019599|NCT04731155|Active Comparator|standard group|
10019600|NCT04731155|Experimental|experiment group|
10019601|NCT04731142|Experimental|T2DEx remote care service|
10019602|NCT04731142|Other|Matched control group|This study will create a matched control group using propensity score matching (PSM), a quasi-experimental method used to mimic the characteristics of a randomised control trial that has been shown to reduce biases. PSM uses statistical techniques to construct an artificial control group by matching each study participant with a non-treated participant of similar characteristics. PSM computes the probability that a person would enrol in a program based on pre-defined characteristics, giving a 'propensity score'.
10019603|NCT04730947|Experimental|Dapagliflozin Group|Subjects with HFpEF will take the study drug dapagliflozin daily
10019604|NCT04730947|Placebo Comparator|Placebo Group|Subjects with HFpEF will take a placebo daily
10019605|NCT04730921|Experimental|LBBAP group|AV block patients randomized to left bundle branch area pacing
10019606|NCT04730921|Active Comparator|RVP group|AV block patients randomized to right ventricular pacing group
10019607|NCT04727944|Experimental|MEG and EEG recordings on Healthy volunteers|"All subjects can participate in experiment 1 and/or 2. All analyses are intra-subject (no analyses are between-subject).~Experiment 1 will test the functional role of beta bursts in naturalistic action preparation, using a combined anatomical MEG-MRI approach which will be conducted in 2 sessions.~Experiment 2 will study the relationship between beta bursts and naturalistic action preparation using EEG."
10019608|NCT04727138|Experimental|EXS21546 Powder for Oral Suspension|EXS21546 Powder for Oral Suspension
10019609|NCT04727138|Placebo Comparator|Placebo|Placebo Powder for Oral Suspension
10019610|NCT04727138|Experimental|EXS21546 Granule in Capsule|EXS21546 Granule in Capsule
10019611|NCT04726124|Experimental|treatment group|Microwave Ablation Therapeutic Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous microwave therapy using Microwave Ablation Therapy Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months,12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
10019612|NCT04726124|Experimental|control group|Semiconductor Laser Treatment Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous laser treatment using Semiconductor Laser Treatment Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months, 12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
10019613|NCT04725539|Experimental|Intermittent hypoxia (IH) pre-conditioning|"The IH pre-conditioning program will be performed in a sitting position by inhaling a gas mixture with reduced O2 content via face masks.The program will include five sessions per week for 3 weeks. Each session consists of three to five hypoxic (14-10% inspired fraction of oxygen) periods, each lasting 3-5 min with 3-min normoxic intervals.~The control setting includes breathing room air via face mask."
10019614|NCT04725539|Experimental|Hypoxia pre-adaptation|The hypoxia pre-adaptation program consists of sleeping 1 night at 1900m. The control setting includes sleeping 1 night close to sea level.
10019615|NCT04723810|Experimental|Cohort 1|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has not been fully studied will be enrolled: glioma, breast cancer, colon cancer, rectal cancer, head and neck cancer, pulmonary metastasectomy (colorectal mets), thymoma, ovarian cancer, prostate cancer, renal cell carcinoma, thyroid cancer, parathyroid adenoma, mesothelioma, esophageal cancer, pancreas cancer, stomach cancer.
10019616|NCT04723810|Experimental|Cohort 2|Patients scheduled to undergo surgical resection for the following cancers (known or suspected) that the safety and dosing/timing of indocyanine green has been fully studied will be enrolled: non-small cell lung cancer, metastatic sarcoma to the lung, brain meningioma.
10019617|NCT04722744|Experimental|screwmented metal frameworks based on virtual implant position.|this group will receive a CAD CAM restoration based on virtually planned implant position.
10019618|NCT04722744|Active Comparator|screw-retained metal frameworks based on actual implant position.|this group will receive screw retained CAD CAM restoration based on actual implant position using conventional open tray impression.
10019619|NCT04722679||Patient|Elderly (defined as the ≥75 years old) patients with NVAF that are treated with a NOAC.
10019620|NCT04722679||Physician|Geriatricians (hospital or office-based).
10019621|NCT04721730|Experimental|PLH-YC|"The Parents will receive the optimised version of the Parenting for Lifelong Health for Young Children from 2-9 y. (PLH-YC) identified in Phase 2.~The groups will be conducted with 12 parents per group (with 2 facilitators). If local restrictions due to COVID-19 restrictions do not allow-in person meetings of this size, we will reduce the sample size (6 parents per group, and facilitator) and or conduct the groups online (e.g., using an online video software).~For each session, parents will receive a snack (or food voucher of same amount), childcare, transportation support (if needed), and a certificate at the end. Also, parents participating in at least four out of five PLH sessions will get a small gift. If the groups need be conducted online because of the COVID-19 pandemic, the parents will receive pre-paid data or another voucher of the same amount."
10019622|NCT04721730|Active Comparator|Lecture|"Parents will receive a lecture called Raising Healthy Children.~The lecture will be conducted with 12 parents per group (with one facilitator). If local restrictions due to COVID-19 pandemic will not allow in-person meetings, the groups will be online (e.g., using a video meeting software).~During the lecture, parents will receive a snack (or a food voucher of the same amount), childcare, transportation support (if needed), and a certificate at the end. If the lecture needs be conducted online because of the COVID-19 pandemic and associated restrictions, the parents will receive pre-paid data or another voucher of the same amount (instead of childcare, transport voucher and the snack)."
10019623|NCT04719390|Experimental|TMI Component On|Randomized at daily time point to ON, text messaging intervention gets sent to participant at that time
10019624|NCT04719390|No Intervention|TMI Component Off|Randomized at daily time point to OFF, text messaging intervention does not get sent to participant at that time
10019625|NCT04718961|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
10019626|NCT04718961|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
10019627|NCT04718961|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
10019628|NCT04716712|Active Comparator|Biannual mass oral azithromycin + child health days|Bi-annual Mass Azithromycin distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
10019629|NCT04716712|Placebo Comparator|Biannual mass placebo + child health days|Bi-annual Mass placebo distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
10019630|NCT04716712|Active Comparator|Resistance Sub Study: Azithromycin + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
10019631|NCT04716712|Placebo Comparator|Resistance Sub Study: Placebo + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
10019632|NCT04714905||Pregnant Cohort|Pregnant (up to and including 15 weeks), 18+ years of age.
10019633|NCT04714905||Pre-pregnancy Cohort|Anticipating to be pregnant, 18-40 years of age.
10019634|NCT04712968|Experimental|Group 1 (intervention group)|Regular exposure to morning daylight
10019635|NCT04712968|No Intervention|Group 2 (control group)|Treatment as usual.
10019636|NCT04711837|Experimental|HSK3486|HSK3486 for induction of general anesthesia.
10019637|NCT04711837|Active Comparator|Propofol|Propofol for induction of general anesthesia.
10019638|NCT04711603|Experimental|MR13A9/MR13A9|Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
10019639|NCT04711603|Placebo Comparator|Placebo/MR13A9|Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).
10019640|NCT04711317|Experimental|Preoxygenation with nasal high flow oxygen|Preoxygenation with nasal high flow oxygen
10036249|NCT01813877|No Intervention|Standard Diagnostics without PET|
10019641|NCT04711317|No Intervention|Control group|Standard preoxygenation according to hospital protocol with tight fitting facemask
10019642|NCT04709042|Experimental|Chordal tension measurement and cardiac Magnetic Resonance Imaging|All patient candidates for NeoChord implantation according to the standard of care will be considered for inclusion in this clinical study. Chordal tension measurement will be performed during Neochord implantation. Moreover, all patients will undergo cardiac Magnetic Resonance Imaging (MRI) exam before the surgery, as well as at 3 months follow-up.
10019643|NCT04707794||Elderly|Patients > 65 years age undergoing non-cardiac surgery will be administered general anesthesia maintained with sevoflurane or desflurane titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
10019644|NCT04707248|Experimental|Dose Escalation|Participants with ovarian cancer (OVC) or renal cell carcinoma (RCC) will receive an intravenous infusion of DS-6000a (starting dose 1.6 mg/kg).
10019645|NCT04707248|Experimental|Dose Expansion: Cohort B-1|Participants with RCC will receive an intravenous infusion of DS-6000a at the RDE.
10019646|NCT04707248|Experimental|Dose Expansion: Cohort B-2|Participants with OVC will receive an intravenous infusion of DS-6000a at the RDE.
10019647|NCT04707235||Sickle cell disease patients treated with Siklos|
10019648|NCT04707196|Experimental|Abemaciclib + NSAI or Fulvestrant|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally or Fulvestrant administered intramuscularly.
10019649|NCT04706676|Experimental|Integrative neuromuscular training + motivational counseling + usual care|General and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility.
10019650|NCT04706676|Active Comparator|Active control group + motivational counseling + usual care|home-based training program
10019651|NCT04706507|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by IV ganciclovir once daily until hospital discharge
10019652|NCT04706507|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by IV normal saline once daily until hospital discharge
10019653|NCT04704518|Experimental|Group 1; Lagricel® Ofteno PF|Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
10019654|NCT04704518|Active Comparator|Group 2; Thealoz® Duo|Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
10019655|NCT04703764|Experimental|HSG4112 480 mg|60 mg HSG4112 tablet, 8 tablets, once-daily, 14-day multiple oral administration
10019656|NCT04703764|Placebo Comparator|Placebo 480 mg|60 mg placebo tablet, 8 tablets, once-daily, 14-day multiple oral administration
10019657|NCT04703764|Experimental|HSG4112 720 mg|60 mg HSG4112 tablet, 12 tablets, once-daily, 14-day multiple oral administration
10019658|NCT04703764|Placebo Comparator|Placebo 720 mg|60 mg placebo tablet, 12 tablets, once-daily, 14-day multiple oral administration
10019659|NCT04703010|Experimental|All participants|All participants undergo the same measurements (longitudinal design)
10019660|NCT04702737|Experimental|Part 1: Dose Exploration|The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.
10019661|NCT04702737|Experimental|Part 2: Dose Expansion|Participants will received the recommended phase 2 dose (RP2D) identified in Part 1 (dose exploration) of the study.
10019662|NCT04702425|Experimental|VOB560-MIK665 - Part 1a|Part 1a - Patients with relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory multiple myeloma administered VOB560 and MIK665 as an intravenous (IV) infusion.
10019663|NCT04702425|Experimental|VOB560-MIK665 - Part 1b|Part 1b - Patients with relapsed/refractory acute myeloid leukemia administered VOB560 and MIK665 as an intravenous (IV) infusion.
10019664|NCT04702425|Experimental|VOB560-MIK665 - Part 2a|Part 2a - Patients with relapsed/refractory multiple myeloma with at least 10 patients with 1q gain cytogenetic abnormality and 10 patients with high risk R/R MM as defined in (Sonneveld et al 2016) administered VOB560 and MIK665 as an intravenous (IV) infusion.
10019665|NCT04702425|Experimental|VOB560-MIK665 - Part 2b|Part 2b - Patients with relapsed/refractory non-Hodgkin lymphoma with at least 10 patients with double-hit (DH) lymphoma, based on the overall bad prognosis and limited therapeutic options for patients with DH NHL administered VOB560 and MIK665 as an intravenous (IV) infusion.
10019666|NCT04702425|Experimental|VOB560-MIK665 - Part 2c|Part 2c - Patients with relapsed/refractory acute myeloid leukemia venetoclax refractory or insensitive with at least 6 patients M5 as proposed by French-American-British (FAB) group, based on the observation that venetoclax resistance in AML M5 can be caused by up-regulation of MCL1 administered VOB560 and MIK665 as an intravenous (IV) infusion.
10019667|NCT04702425|Experimental|VOB560-MIK665 - Part 2d|Part 2d - Patients with relapsed/refractory acute myeloid leukemia venetoclax naive patients administered VOB560 and MIK665 as an intravenous (IV) infusion.
10019668|NCT04702386||Focus groups|Children aged 8 years or more participating in a focus group with the study psychologist
10019669|NCT04702386||Individual interviews|All children who have an individual interview with the study psychologist
10019670|NCT04701983|Experimental|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
10019671|NCT04701983|Experimental|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) for 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
10019672|NCT04701983|Placebo Comparator|Placebo|SC administration of matching placebo Q2W for 52 weeks
10036250|NCT01813877|Experimental|Diagnostics with PET|All 18F-DOPA PET/CT studies will be interpreted qualitatively during a clinical readout session. Based on a previous study scans will be classified as positive if tumor regions defined on CT exhibited tracer uptake above the level of the contra-lateral caudate nucleus. Scans will be classified as negative if tumor 18F-FDOPA uptake is lower than that of the contra lateral caudate nucleus. Uptake at the level of the contra-lateral caudate will be considered equivocal for malignancy.
10036251|NCT01813903|Experimental|Nutrition|Intensified dietary counseling and use of web application.
10036252|NCT01813903|Experimental|Flexible mind|Use of mobile applications.
10036253|NCT01813903|No Intervention|Normal maternity clinic visits|In control maternity clinics, nurses continue their usual counseling.
10036254|NCT01813916|No Intervention|proteomic analysis|
10036255|NCT01813955|Experimental|Papaverine|Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)
10036256|NCT01813968|Experimental|Ischemic postconditioning|"Ischemic postconditioning via the cardioplegia line starting with 2 min of reperfusion followed by 2 min of ischemia x 3"
10036257|NCT01813968|No Intervention|Control|Standard operating technique
10036258|NCT01813981|Placebo Comparator|High roast coffee|110mg caffeine with 108 mg chlorogenic acid at start of study
10036259|NCT01813981|Active Comparator|Low roast coffee|110 mg caffeine with 235 mg chlorogenic acid at start of the study
10036260|NCT01813981|Placebo Comparator|Control|110 mg caffeine at start of study
10036261|NCT01813994|Placebo Comparator|Control group|Without simvastatin
10036262|NCT01813994|Experimental|Statin group|With simvastatin
10036263|NCT01814033|Experimental|LRU Pillow|Experimental: LRU Pillow
9480731|NCT05261620|No Intervention|SoC|Control Arm subjects adhere to diet free of any alcohol-containing beverages, as normally recommended by surgeons in their clinical practice
10036264|NCT01814033|Active Comparator|Control Group|Other: Control Group
10036265|NCT01814085|Experimental|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
10036266|NCT01814098|Experimental|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
10036267|NCT01814111|Experimental|renal sympathetic denervation|Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
10036268|NCT01814111|No Intervention|Drug Treatment Group|All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. AAD treatment is consistent in both arms.
10036269|NCT01814124|Active Comparator|Advice and home exercise|All participants will be given a handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week
10037471|NCT01825356|Active Comparator|Dorsal Cheilectomy no Amniotic Membrane Tissue Implantation|Dorsal cheilectomy is a surgery for hallux rigidus(degenerative arthritis and stiffness due to bone spurs that affect the joint at the base of the big toe). No amniotic membrane will be used for this group.
10019673|NCT04701866|Experimental|Music|Music will be provided for participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks).
10019674|NCT04701866|No Intervention|Usual Care|Participant's six 40 minute IV infusions of 0.5mg/kg ketamine administered over four weeks (biweekly for 2 weeks, then weekly for 2 weeks) will be administered as per usual care. That is, without music provided or permitted. Contact time with clinicians before, during, and after ketamine treatments will be matched.
10019675|NCT04700098|Experimental|Internet-based behavioral treatment for insomnia + HBPR|Internet version of cognitive-behavioral treatment for insomnia plus home-based pulmonary rehabilitation
10019676|NCT04700098|Experimental|HBPR only|Home-based pulmonary rehabilitation only
10019677|NCT04699695||Biologic Treatment|Subjects prescribed a biologic agent per standard of care
10019678|NCT04699695||Other Treatments|Subjects prescribed other treatment modalities exclusive of biologic therapy per standard of care
10019679|NCT04699461|Experimental|Loncastuximab Tesirine|Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.
10019680|NCT04699461|Active Comparator|Idelalisib|Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks.
10019681|NCT04699188|Experimental|Arm A|JDQ443
10019682|NCT04699188|Experimental|Arm B|JDQ443 in combination with TNO155
10019683|NCT04699188|Experimental|Arm C|JDQ443 in combination with tislelizumab
10019684|NCT04699188|Experimental|Arm D|JDQ443 in combination with TNO155 and tislelizumab
10019685|NCT04698564|Experimental|Single-arm study in patients who are suspected or known to have prostate cancer|Perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population
10019686|NCT04698096||metabolic syndrome|Patients with metabolic syndrome
10019687|NCT04698096||Healthy volunteers|Healthy volunteers
10019688|NCT04696380|Experimental|High nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 5% nicotine strength.
10019689|NCT04696380|Experimental|High nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 5% nicotine strength.
10019690|NCT04696380|Experimental|Low nicotine, preferred flavor|Participants will sample their preferred flavored JUUL e-cigarette at 3% nicotine strength.
10019691|NCT04696380|Experimental|Low nicotine, non-preferred flavor|Participants will sample their non-preferred flavored JUUL e-cigarette at 3% nicotine strength.
10019692|NCT04695847|Experimental|Part 1: M1231|Participants with solid tumors for whom no effective standard therapy exists will be included in this Part. Dose escalation of M1231 will be administered as single agent.
10019693|NCT04695847|Experimental|Part 2: Cohort A M1231: Metastatic NSCLC|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) expressing Epidermal Growth Factor Receptor (EGFR) and Mucin 1 (MUC1) on archival tumor tissue will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
10019694|NCT04695847|Experimental|Part 2: Cohort B M1231: Metastatic Esophageal Squamous Cell Carcinoma|Participants with metastatic esophageal squamous cell carcinoma will receive M1231 at the dose determined as recommended dose for expansion (RDE) in Part 1.
10019695|NCT04695366||Diffuse large B-cell lymphoma patients in year 1 and 2 of clinical follow-up|Patients (Diffuse Large B-cell Lymphoma) in complete remission after primary treatment and entering the regular follow-up program at the clinic. Baseline is defined as date of end-of-treatment visit.
10019696|NCT04694196|Experimental|Locate occlusal plane|Use anatomical landmark to locate OP in dentulous subjects.
10019697|NCT04692714|Experimental|Experimental knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented without additional cement using the MAKO robot
10019698|NCT04692714|Active Comparator|Conventional knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented with additional cement using the MAKO robot
10019699|NCT04692688|Experimental|APX3330|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
10019700|NCT04692688|Placebo Comparator|Placebo|Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
10019701|NCT04690855|Experimental|Study Treatment Arm|"All patients will be treated with induction talazoparib of 1mg PO daily starting Day 1. Patients will then receive 8 Gy x 3 fractions to 2-4 metastatic lesions beginning Day 12,13, or 14 and given QOD. 840 mg of atezolizumab will be given intravenously (IV) on Day 15 of the 1st cycle and then on Day 1 and Day 15 of the remaining cycles. The sequence of administration is not specified on the days in which talazoparib and atezolizumab are given on the same day. Each cycle equals 28 days. Treatment will continue until progression or severe toxicity.~A safety lead in of up to 6 patients will be performed. Immune-related and non-immune related adverse events will be tracked up to 12 weeks post initiation of atezolizumab, as the majority of treatment-related toxicities from talazoparib, radiation, and atezolizumab occur within this time period."
10019702|NCT04689074||ADPKD|Patients with ADPKD
10019703|NCT04689074||advanced CKD|Patients with advanced CKD
10019704|NCT04689074||DKD|Patients with DKD
10019705|NCT04689074||IgAN|Patients with IgAN
10019706|NCT04689074||Healthy volunteers|Healthy volunteers
10019707|NCT04688671|Experimental|ETX-018810|
10019708|NCT04688671|Placebo Comparator|Placebo|
10019709|NCT04685317|Experimental|Sentinel® Cerebral Protection System Group|Sentinel® Cerebral Protection System in patients undergoing AF catheter ablation
10019710|NCT04685317|No Intervention|Standard of Care Group|Standard of care (no cerebral protection device) in patients undergoing AF catheter ablation
10019711|NCT04684394|Experimental|GEM103 + SoC|
10019712|NCT04684394|Sham Comparator|Sham+SoC|
10019713|NCT04683588|Experimental|intervention arm|"Polyclinic: Pre-tests (pain, anxiety, self-care and daily living activities), General coaching, 60 minutes~Before Surgery: Nursing coaching, 30-45 minutes~Surgery Day: Nursing coaching, 30-45 minutes~Postoperative 1st Day: Nursing coaching, 30-45 minutes~Postoperative 2nd Day: Nursing coaching practice, 30-45 minutes~Day of discharge: Nursing coaching, 30-45 minutes.~15 days after discharge: Nursing coaching, 60 minutes~45 days after the operation: Nursing coaching, 60 minutes.~90 days after surgery: Nursing coaching, 60 minutes."
10019714|NCT04683588|No Intervention|Control arm|Patients in the control group will receive routine postoperative nursing care.
10019715|NCT04682574|Active Comparator|vitamin C|The dose would be 30 grams a day (10 grams TDS) for 2 days with standard treatment
10019716|NCT04682574|No Intervention|Placebo|Distill water in the same dose with same standard treatment
10019717|NCT04681859|Active Comparator|High Flow Nasal Oxygen (HFNO) treatment|
10019718|NCT04681859|Experimental|Continuous positive airway pressure (CPAP) therapy using OxyJet|
10019719|NCT04681066|Active Comparator|2.0 mg/kg (1.25 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
10019720|NCT04681066|Active Comparator|1.0 mg/kg (0.625 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
10019721|NCT04681066|Active Comparator|0.5 mg/kg (0.3125 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
10019722|NCT04681066|Placebo Comparator|Placebo (1.25, 0.625, or 0.3125 mL/kg)|patients randomized to placebo will receive one of three following volumes (1.25 mL/kg, 0.625 mL/kg, and 0.3125 mL/kg. although three volumes - all patients randomized to placebo will be analyzed together as one arm. administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
10019723|NCT04680975|Experimental|Belumosudil 200 mg PO BID|Subjects will receive open-label belumosudil 200 mg orally twice daily
10019724|NCT04678284|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
10019725|NCT04677660|Experimental|TAK-919|TAK-919 0.5 mL, intramuscular injection in the upper arm
10019726|NCT04677660|Placebo Comparator|Placebo|TAK-919 Matching Placebo, intramuscular injection in the upper arm
10019727|NCT04677517|Experimental|Implanted patients|All the participants are patients with post-lingual deafness and fitted with cochlear implants
10019728|NCT04677465|Experimental|RheOx Treatment|
10019729|NCT04677465|Sham Comparator|Sham Procedure|
10019730|NCT04677348|Experimental|PENG group|pericapsular nerve group (PENG) block before surgery
10019731|NCT04677348|Active Comparator|FICB group|suprainguinal fascia iliaca compartment block (FICB) before surgery
10019732|NCT04675320||Mutated BRCA epithelial ovarian cancer|
10019733|NCT04675320||Recurrent epithelial ovarian cancer|
10019734|NCT04674800|Experimental|Single, test arm|MYL-1701P- Subjects will receive 3 doses each of 2 mg at 8 weeks interval
10019735|NCT04673942|Experimental|Part 1: Dose Escalation Safety Run-In|Subjects will be treated with AdAPT-001 as a single injection, one time.
10019736|NCT04673942|Experimental|Part 2: Dose Expansion Single-Agent|6 subjects will be enrolled in the Lead In Cohort. A Safety Analysis will be performed after 6 subjects have received at least 4 doses. Upon Safety team review as a continuous reassessment of safety, an additional 19 subjects may be enrolled. All subjects in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
10019737|NCT04673123|Experimental|Core Stabilization Group|Core stabilization + Multifactorial Education Program (patient-specific upper and lower extremity stretching and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
10019738|NCT04673123|Active Comparator|Multifactorial Education Program Group|Multifactorial Education Program (patient-specific upper and lower extremity stretching, relaxation and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training)+ Informing about fall prevention (by verbal and written)
10019739|NCT04672772||Recurrent and/or metastatic SCCHN|Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
10019740|NCT04672161|Experimental|Vaccine Education|Patients randomized to the Experimental arm will receive a baseline educational intervention on vaccination following a vaccination history survey. Patients will be followed 6-months after the intervention to record prospective clinical data. Evidence of vaccination-status will be documented. Besides standard of care visits and testing, no additional procedures will be carried out for the purpose of this study.
10019741|NCT04672161|No Intervention|No Vaccine Education|Patients randomized to the No Intervention arm will not receive the Vaccine Education. They will only complete the survey on their vaccination history.
10019742|NCT04672083|Experimental|Cohort 1|6 subjects receiving a single subcutaneous injection of CPT31 (0.01 mg/kg) and 2 subjects receiving matching placebo SC injection
10019743|NCT04672083|Experimental|Cohort 2|6 subjects receiving a single subcutaneous injection of CPT31 (0.04 mg/kg) and 2 subjects receiving matching placebo SC injection
10019744|NCT04672083|Experimental|Cohort 3|6 subjects receiving a single subcutaneous injection of CPT31 (0.12 mg/kg) and 2 subjects receiving matching placebo SC injection
10019745|NCT04672083|Experimental|Cohort 4|6 subjects receiving a single subcutaneous injection of CPT31 (0.24 mg/kg) and 2 subjects receiving matching placebo SC injection
10019746|NCT04671485|Active Comparator|ARM A : standard care|standard care : Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
10019747|NCT04671485|Active Comparator|ARM B : standard care + Autohypnosis|"In addition to the standard care, the patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
10019748|NCT04671485|Active Comparator|ARM C : standard care + Musicotherapy|"In addition to the standard care, the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
9477374|NCT03563079|Active Comparator|group control|Treatment will be performed using manual Myofascial Release techniques. Release the upper Trapezius muscle bilaterally, sliding using roller with the dorsum of the fingers and ending with myofascial release. Sternocleidomastoid, sliding using roller with the dorsum of the fingers, ending with myofascial release. Afterwards the release of the scalenes muscles will be performed, with the fingers sliding and ending with the myofascial release. Soon afterwards techniques will be performed for the Splenius muscles, using finger slips and ending with posterior cervicothoracic release. The same time of 3 min will be used for the treatment bilaterally in each region.
10019749|NCT04671082|Experimental|Tolperisone 50 mg|Tolperisone 50 mg
10019750|NCT04671082|Experimental|Tolpersione 100 mg|Tolperisone 100 mg
9477375|NCT03563053|Experimental|active drug|~14-22 mg dexamethasone sodium phosphate (DSP)
9477376|NCT03563040|Experimental|Methoxsalen with the THERAKOS CELLEX Photopheresis System|Treatment will be performed according to a predefined protocol based on the consensus guidelines in patients with MF/SS. Treatment should be administered for one year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
10019751|NCT04671082|Experimental|Tolperisone 200 mg|Tolperisone 200 mg
10019752|NCT04671082|Placebo Comparator|Placebo|Placebo
10019753|NCT04670757|Experimental|CPL409116|"PART A. IMP is to be administered orally in single ascending dose in the groups consisting of 3 volunteers according to '3+3' design'. Dose escalation scheme is to be determined based on preclinical results and due to dose limiting observation (DLT).~PART A additional. Assessing the effect of food on bioavailability of CPL409116. IMP is to be administered orally in single dose in fasted and fed state in the group of 12 volunteers.There is to be one week wash-out between two treatment periods for this cohort."
10019754|NCT04670757|Experimental|PLACEBO|PART B. Two participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
10019755|NCT04669587|Experimental|Part A: Dose Escalation of ZB716 monotherapy (with Food Effect Cohort)|Cohorts will follow a 3+3 study design. Approx. 3 to 6 subjects will be enrolled in each dose cohort (6 subjects in Cohort A6; food-effect evaluation). (Dose levels: 50, 100, 200, 300, 400 mg, orally QD in a 28 day cycle) The overall DLT observation period of ZB716 monotherapy will be 4 weeks following the initial dose of study drug on Cycle 1 Day 1. There will be 2 ~ 6 days between dose escalations to allow sufficient time for an adequate safety review. The max. dose may be lower than 400 mg. In the first dosing group of Part A (Cohort A1), subject dosing will be staggered such that administration of the first dose is separated by at least 7 days between the first 2 subjects. In each of Cohorts A1 to A5, 3 to 6 subjects will receive ZB716 doses according to the assigned dose level in the fasted state. For Cohort A6, Period 1, doses will be administered in the fasted state in Treatment Period 1 and 2, doses will be given 30 min. after starting a standard high fat breakfast.
10019756|NCT04669587|Experimental|Part B: Dose Expansion of ZB716 monotherapy|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part B. For Part B, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined monotherapy RD of ZB716 (based on Part A) QD in a 28-day cycle. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
10019757|NCT04669587|Experimental|Part C: Dose Escalation of ZB716 in combination with palbociclib|Cohorts will follow a 3+3 study design. Approx. 6 to 12 subjects will be enrolled in the dose escalation phase of ZB716 in combination with Palbociclib. For Part C, doses will be administered at escalating doses starting with 1 dose level below the monotherapy RD (determined in Part A) and Palbociclib will be dosed at the fixed standard dose of 125 mg QD. ZB716 will be administered on a 28 day cycle and Palbociclib will be administered for 21 days in the cycle with 7 days off treatment. Administration of the higher dose level (at monotherapy RD) of ZB716 (with the standard dose of Palbociclib) to subsequent subjects will be based on the occurrence of DLTs during the DLT observation period (Cycle 1), until MAD of ZB716 with combination of Palbociclib is reached. Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison.
10019758|NCT04669587|Experimental|Part D: Dose Expansion of ZB716 in combination with palbociclib|"Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will come to the clinical site before the first dose of study drug to confirm eligibility. Cohorts will be enrolled sequentially based on an optional Simon 2-stage study design.~Approx. 29 subjects may be enrolled in the dose expansion cohorts of Part D. For Part D, doses will be administered (self-administered by subjects at home or administered by subjects under observation of clinical staff during clinic visits) at the determined RD of ZB716 QD for 28 days from Part C in combination with the standard dose of Palbociclib (125 mg QD for 21 days with 7 days off treatment). Doses will be administered in the dietary status for dosing as determined from Part A fed/fasted comparison."
10019759|NCT04668170||hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:~Patients with severe disease requiring on admission ICU management for SARS, Non-severe hospitalized patients with secondary clinical worsening requiring ICU management, Non-severe hospitalized patients without clinical worsening requiring ICU management."
10019760|NCT04668170||healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
10019761|NCT04668092|Experimental|Functional dry needling|Functional dry needling for shortened hamstring muscle
10019762|NCT04662359|Other|Ultrasound Assessment of Rheumatoid Arthritis Severity|All patients will receive an ultrasound scan to assess the severity of their arthritis. This scan will then be placed in their medical record to allow their rheumatologist to utilize the scan when making treatment recommendations.
10019763|NCT04661592|Experimental|Control|Neurologically healthy individuals will be recruited for the longitudinal study
10019764|NCT04661410|Experimental|Reward Re-Training|10 weekly sessions of Reward Re-Training Group Therapy.
10019765|NCT04661410|Active Comparator|Supportive Therapy|10 weekly sessions of Supportive Group Therapy.
10019766|NCT04661384|Experimental|Treatment (IL13Ralpha2-CAR T cells)|Patients receive IL13Ralpha2-CAR T cells ICV over 5 minutes on day 1. Treatment repeats every 7 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
10019767|NCT04660500|Experimental|PD Drivers Using AV Technologies On-road|Each driver will drive on-road, everybody will be exposed to two drives (Drive 1, Drive 2) one drive with and the other without in-vehicle technology. The order of technology (with vs. without IVIS or ADAS) and the order of the routes (Drive 1 vs. Drive 2) will be randomly allocated to control for order effects.
10019768|NCT04659941|Experimental|BCG vaccine|0.1 ml of the reconstituted vaccine to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
10019769|NCT04659941|Placebo Comparator|0.9% sodium chloride (NaCl) saline solution|0.1 ml of 0.9% NaCl saline solution to be administered intradermally in the lower insertion of the deltoid muscle, preferably on the right side, in only one occasion
10019770|NCT04659382|Experimental|Single arm|XELOX + bevacizumab + atezolizumab + SIRT (Therasphere)
10019771|NCT04658953|Experimental|Ultrasound-guided infiltration|The patient is positioned in the prone position with a block under his stomach. After disinfection of the lumbosacral region with alcoholic chlorhexidine 0.5%, the investigators position the convex probe of the ultrasound machine in the transverse plane. Once the spine has been located, the investigators look for the spinous processes of the lower lumbar vertebrae L4 and L5 with the mark on the cranial side and the side opposite the mark on the side of the sacrum. The latter is visualized as a continuous hyperechoic line. Then, the probe is tilted 90 ° to be in a transverse plane. A 22G needle is introduced in a transverse axis starting from the laterality by inserting it in the direction of the median bone contacts of the lower lumbar vertebrae L3, L4 and L5. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels).
10019772|NCT04658953|Experimental|Fluoroscopy-guided infiltration|"The patient is positioned in the prone position with a block under his stomach. The lumbosacral region is disinfected with alcoholic chlorhexidine 0.5%.~The C-shaped arm of a X-ray fluoroscopy is positioned around the patient in an antero-posterior view tilted ¾ in order to free the classic view called scotty dogs . The puncture point is determined by the positioning of the needle in so-called tunnel vision. The needle is thus brought to the bone contact corresponding to the eye of the scotty dog in tunnel vision, an area corresponding to the passage of the lumbar median branch. An infiltration will be unilaterally performed at three levels (L3-L4, L4-L5 and L5-S1 levels)."
10019773|NCT04658940|Experimental|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
10019774|NCT04658823|Experimental|HOV-12020|Palm tocotrienols complex Oral softgel capsule (containing 285mg mixed tocotrienols and tocopherol)
10019775|NCT04658823|Placebo Comparator|PLACEBO|Placebo Oral Softgel capsule (each capsule containing vitamin E stripped soybean oil)
10019776|NCT04657380|Active Comparator|Usual case management practices|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network of caring and non-caregiving professionals, working together with a view to the successful recovery of the patient. The patient and his or her family are at the center of care and receive proposals for psychoeducation and support throughout the different phases of the illness. This is concomitant with a regular evaluation of patients in order to update the care offer according to their clinical needs.
10019777|NCT04657380|Experimental|Mobile case-management application|"The intervention tested will be a mobile application used during consultations involving the patient and the case manager to define care objectives. The mobile application to be evaluated will result from the process of a co-design phase based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers. These stakeholders will define the content and form of the smartphone application during co-building workshops.~The main purpose of the final application will be to assist in the definition of patients' goals using an approach rooted in recovery theory, with the monitoring of goal achievement in three phases : 1) defining priorities for the patients, through a recovery oriented discussion with the patient and the case manager 2) Setting the concrete objectives and list concrete actions tho achieve them 3) evaluating the achievements."
10019778|NCT04657094|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with acalabrutinib may be continued beyond 12 cycles for a maximum of 36 cycles if, in the opinion of the treating physician, the patient might benefit from ongoing therapy.
10019779|NCT04657016|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
10019780|NCT04657016|Placebo Comparator|Placebo|Administered SC
10019781|NCT04656275|Experimental|BI 1323495 treatment group (part 1)|Part 1
10019782|NCT04656275|Experimental|BI 1323495 treatment group (part 2)|Part 2
10019783|NCT04656275|Placebo Comparator|Placebo group|Placebo
10019784|NCT04655885|Experimental|Optimization of cardiac flow by base water-electrolyte supply|Optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
10019785|NCT04655885|Other|Control arm|Increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
10037472|NCT01825356|Experimental|Dorsal Cheilectomy-Amniotic Membrane Tissue Implantation|Dorsal cheilectomy procedure with the addition of the amniotic membrane. Amniotic membrane represents a biologic therapy that has the ability to actively regulate myrofibroblast formation and activity within the joint space and surgical site
10019786|NCT04655573||Patient Derived Micro-Organospheres (PDMO)|Subjects will undergo image-guided biopsy as a standard of care clinical biopsy from which extra tissue is taken for research purposes. Following the biopsy, a PDMO will be generated and they will receive a chemotherapy regimen as determined by their treating physician. PDMO are successfully generated, and the patient begins treatment with a hemotherapy backbone. A patient will be considered evaluable if pathology results are available from the biopsy.
10019787|NCT04655144|Experimental|Dexamethasone Arm|A total of 5mg dexamethasone will be administered into each uterine artery (10mg total) prior to uterine artery embolization.
10019788|NCT04655144|Placebo Comparator|Saline Arm|A volume of normal saline, equal to the total volume delivered in the Dexamethasone Arm, will be administered into each uterine artery prior to uterine artery embolization.
10019789|NCT04655118|Experimental|Arm 1a, Relapsed/Refractory Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
10019790|NCT04655118|Experimental|Arm 1b, Relapsed/Refractory Myelofibrosis|"300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.~Note: Arm 1b is closed for enrollment. Subjects enrolled in Arm 1b will continue with the assigned TL-895 dose and schedule of Arm 1b."
10019791|NCT04655118|Experimental|Arm 1c, Relapsed/Refractory Myelofibrosis|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
10019792|NCT04655118|Experimental|Arm 2a, JAKi Intolerant Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
10019793|NCT04655118|Experimental|Arm 2b, JAKi Intolerant Myelofibrosis|"300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.~Note: Arm 2b is closed for enrollment. Subjects enrolled in Arm 2b will continue with the assigned TL-895 dose and schedule of Arm 2b."
10019794|NCT04655118|Experimental|Arm 2c, JAKi Intolerant Myelofibrosis|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
10019795|NCT04655118|Experimental|Arm 3a, JAKi Ineligible Myelofibrosis|150 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
10019796|NCT04655118|Experimental|Arm 3b, JAKi Ineligible Myelofibrosis|"300 mg of TL-895 will be administered orally, once daily (QD) continuously starting on Day 1 in a 28-day cycle.~Note: Arm 3b is closed for enrollment. Subjects enrolled in Arm 3b will continue with the assigned TL-895 dose and schedule of Arm 3b."
10019797|NCT04655118|Experimental|Arm 3c, JAKi Ineligible Myelofibrosis|300 mg of TL-895 will be administered orally, twice daily (BID) continuously starting on Day 1 in a 28-day cycle.
10019798|NCT04655118|Experimental|Arm 1 Expansion, Relapsed/Refractory Myelofibrosis|TL-895 administered orally at RP2D and schedule
10019799|NCT04655118|Experimental|Arm 2 Expansion, JAKi Intolerant Myelofibrosis|TL-895 administered orally at RP2D and schedule
10019800|NCT04655118|Experimental|Arm 3 Expansion, JAKi Ineligible Myelofibrosis|TL-895 administered orally at RP2D and schedule
10019801|NCT04649515|Experimental|TY027 1,500 mg|1,500 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
10019802|NCT04649515|Experimental|TY027 2,000 mg|2,000 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
10019803|NCT04649515|Placebo Comparator|Placebo|Placebo will be administered via IV infusion over a period of 30 minutes.
10019804|NCT04649476|Experimental|Neoadjuvant PD-1 blockade alone|The participants will receive 3 doses of neoadjuvant PD-1 blockade. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
10019805|NCT04649476|Experimental|Neoadjuvant PD-1 blockade plus TPF induction chemotherapy|The participants will receive 3 doses of PD-1 blockade and 2 courses of TPF induction chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
10019806|NCT04648787|Experimental|Intervention group: traditional nursing with family-integrated care|traditional nursing with family-integrated care
10019807|NCT04648787|Experimental|Control group: traditional nursing|traditional nursing
10019808|NCT04648371|Active Comparator|Cognitive Remediation and Active Transcranial Direct Current Stimulation|Cognitive Remediation (CR) is a form of group psychosocial intervention that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. Transcranial Direct Current Stimulation (tDCS): tDCS will be administered for 30 min/day, at the beginning of each group session. tDCS montage will be frontal with anode placed over Fz and the cathode over Iz. The direct current will be of 2 mA (current density = 0.57 A/m2). CR + tDCS is administered in groups consisting of 2-10 participants and one or two therapists. The groups meet 5 times per week for two hours per session over eight weeks, for a total of 40 sessions in induction phase. Afterwards 3 to 5 sessions per week on monthly boosters.
10019809|NCT04648371|Sham Comparator|Cognitive Remediation and Sham Transcranial Direct Current Stimulation|CR is identical to the one described under the Active Comparator Arm. However, sham tDCS will consist of active stimulation for only 1 min/day, at the beginning of each group session. tDCS montage and the frequency of the sessions and the boosters will be the same as for the Active Arm.
10019810|NCT04648241|Experimental|≥16 Years Old|TBE vaccine 0.5 mL (intramuscular injection).
10019811|NCT04648241|Experimental|1 to <16 Years Old|TBE vaccine 0.25ｍL (intramuscular injection).
10019812|NCT04648124||Patients for whom there is no planned implant surgery|
10019813|NCT04648124||Patients for whom implantation surgery is planned|
10019814|NCT04648124||case|
10019815|NCT04645342|Experimental|Baylis Versacross RF wire|Device: Baylis Versacross radiofrequency wire
10019816|NCT04645342|Active Comparator|Baylis RF Needle|Device: conventional Baylis radiofrequency needle
10019817|NCT04644770|Experimental|Part 1: Dose Escalation|Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
10019818|NCT04644770|Experimental|Part 2: Dose Expansion|Participants will receive intravenous (IV) injection of JNJ-69086420 at one of the RP2D(s) determined in Part 1.
10019819|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
10019820|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
10019821|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
10019822|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
10019823|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
10019824|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
10019825|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
10019826|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
10019827|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
10019828|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
10019829|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
10019830|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
10019831|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
10019832|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
10019833|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
10019834|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
10019835|NCT04640818||CLAD-GROUP|Patients with cladribine therapy
10019836|NCT04640818||CD20-GROUP|Patients with anti CD20 therapy (ocrelizumab or rituximab)
10019837|NCT04640493|Experimental|SGLT2-SDB|Patients with newly diagnosed SDB will be given dapagliflozin (standard dosage, 10mg)
10019838|NCT04638660|Experimental|Phentolamine Ophthalmic Solution 0.75%|One drop in both eyes at or near bedtime (8PM to 10PM)
10019839|NCT04638660|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop in both eyes at or near bedtime (8PM to 10PM)
10019840|NCT04637724|Experimental|active tDCS|active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.
10019841|NCT04637724|Sham Comparator|Sham tDCS|Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions
10019842|NCT04635449|Active Comparator|Intervention|age-specific information, complemented by a follow-up targeted telephone call
10019843|NCT04635449|No Intervention|Treatment as usual|usual information given at PICU discharge
10019844|NCT04635098|Experimental|dexmedetomidine|0.5μg/kg bolus injection in 10 minutes followed by 0.1µg/kg/hr pump infusion from 22:00 pm to 6:00 am
10019845|NCT04635098|Placebo Comparator|saline|the same rate as dexmedetomidine
10019846|NCT04634851|Experimental|Intervention|These participants will get virtual home visits with the urologist and dietitian
10019847|NCT04634851|No Intervention|Control|These participants will get standard urologist and dietitian counseling
10019848|NCT04633200|Experimental|Intervention|Participants in the intervention arm will receive a mobile app to support their daily PrEP adherence.
10019849|NCT04633200|No Intervention|Control|Participants in the control group will receive a 2-page PrEP patient education document based information about PrEP from on the CDC website.
10019850|NCT04632810|Experimental|Ketogenic diet + weight loss|
10019851|NCT04632810|Active Comparator|non-Ketogenic diet + weight loss|
10019852|NCT04632810|Active Comparator|Ketogenic eucaloric diet|
10019853|NCT04629963|Experimental|Pain Evaluation|Subjects receive the United Nations Istanbul Protocol (UNIP) evaluation. Subjects will complete the validated, self-administered pain questionnaire, the Brief Pain Inventory Short Form (BPISF). Subjects will receive a non-invasive physical exam and pain assessment by a pain specialist.
10019854|NCT04629339|Experimental|INCB086550|INCB086550 will be administered orally twice a day.
10019855|NCT04629053||Patients with an acute febrile illness|Patients with acute febrile illness, 4,800 children and 2,400 adults, divided equally across three countries (Laos, Myanmar and Bangladesh) and three age groups: >28 days to <5 years; ≥5 years to <15 years, and ≥15 years of age.
10019856|NCT04628065|Experimental|Intervention Arm|Participants will receive a text message everyday to build behavioral skills and practice self-monitoring of three behavior goals: (1) reduce TV time to less than 2 hours per day; (2) take 10,000 steps or more every day; (3) do 20 minutes or more of structures exercise like prenatal yoga or dance videos every day. Participants will also receive two health coaching mobile phone session; an introduction session and one problem solving session.
10019857|NCT04627662|Other|Care Partners|Based on previous work, we will recruit up to 75 Care Partners and their 75 care recipients with dementia. This allows for 20% attrition. We will recruit participants from three Alzheimer's Disease Research Centers (ADRCs) located at OHSU, University of Kentucky (UK) and Emory University. We anticipate we will recruit equal numbers from each site (e.g. 25 families from each site); however, these are not firm quotas. We may have more from one site than another.
10019858|NCT04627064|Experimental|Abemaciclib-Arm 1|"Arm 1~Abemaciclib will be taken at a standard recommended starting dose 2X daily during 28 day study cycles and will be taken until radiographic progression, unacceptable toxicity or withdrawal.~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both Arm 1 and Arm 2."
10019859|NCT04627064|Experimental|Abemaciclib and MK-6482-Arm 2|"Arm 2~Arm 2 will start enrolling only after there is experience with Arm 1 to see what abemaciclib effects are when given alone,~Dose escalation will occur following a 3+3 design.~Abemaciclib will be taken 2X daily uring 28 day study cycle~MK-6482 will be taken 1x daily during 28 day study cycle~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both arms."
10019860|NCT04626791|Experimental|Treatment (modified VR-CAP, acalabrutinib)|"CYCLES 1, 3, AND 5: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive bortezomib SC on days 1, 8, and 15, rituximab (or rituximab and hyaluronidase human) IV, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1, and prednisone PO on days 1-5.~CYCLES 2, 4, AND 6: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive rituximab (or rituximab and hyaluronidase human) IV on day 1 and cytarabine IV on days 1-2.~Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
10019861|NCT04626635|Experimental|Dose Escalation|Variety of mixed advanced solid tumor types
10019862|NCT04626635|Experimental|Dose Expansion A|Microsatellite-Stable Colorectal Cancer (MSS CRC)
10019863|NCT04626635|Experimental|Dose Expansion B|Triple Negative Breast Cancer (TNBC)
10019864|NCT04626635|Experimental|Dose Expansion C|Cutaneous Squamous Cell Carcinoma (CSCC)
10019865|NCT04626635|Experimental|Dose Expansion D|Non-Small Cell Lung Cancer (NSCLC)
10019866|NCT04626635|Experimental|Dose Expansion E|Head and Neck Squamous Cell Carcinoma (HNSCC)
10019867|NCT04626544||Dizziness|Patients with dizziness referred to a secondary referral center
10019868|NCT04626544||Healthy controls|Healthy controls without dizziness or neck pain symptoms for the last 3 months
9477377|NCT03563014||Radium-223 (Xofigo, Bay88-8223)|Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
10019869|NCT04625777|No Intervention|Waitlist control|In this waitlist control condition, participants will not receive any programming intervention. They will know that they have access to stress reduction programming after a certain date. They will also provide survey data at 3 time points and heart rate variability data at 2 time points while waiting. The survey questions will include a wide variety of stress items.
10019870|NCT04625777|Experimental|One of three stress reduction interventions|There are three stress reduction interventions: Mindfulness Based Stress Reduction, Daily Examen, and stress inoculation.
10019871|NCT04625504|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
10019872|NCT04625504|No Intervention|Wait-list Control (WL)|Patients Control receiving no treatment
10019873|NCT04625504|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
10019874|NCT04624087|Experimental|High Dose|Participants will perform the food-specific computerized go/no-go training four times per week for 4 weeks.
10019875|NCT04624087|Experimental|Low Dose|Participants will perform the food-specific computerized go/no-go training one time per week for 4 weeks.
10019876|NCT04624087|Active Comparator|Active Control|Participants will perform the generalized, nonfood-specific computerized go/no-go training one time per week for 4 weeks.
10019877|NCT04623775|Experimental|Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))|
10019878|NCT04623775|Experimental|Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))|
10019879|NCT04623775|Experimental|Part 2: Arm C (Nivolumab + Relatlimab Dose 1 or Dose 2 + PDCT)|
10019880|NCT04623775|Placebo Comparator|Part 2: Arm D (Nivolumab + Placebo + PDCT)|
10019881|NCT04622644|Experimental|Single Arm|All patients perform StrokeWave exam, after NCCT and before CTA acquisition.
10019882|NCT04622332|Experimental|SIR1-365|SIR1-365 dose 1 daily for 14 days
10019883|NCT04622332|Placebo Comparator|Matching placebo|Matching placebo dose 1 daily for 14 days
10019884|NCT04618692|Active Comparator|Surgical Loupes|In this group , patients will undergo biliary reconstruction using surgical loupe
10019885|NCT04618692|Active Comparator|Microscope|In this group , patients will undergo biliary reconstruction using microscope
10019886|NCT04617379|Experimental|Active Treatment Group|15 minutes daily stretch for 1 year
10019887|NCT04617379|No Intervention|Control Group|No stretches
10019888|NCT04616547|Experimental|Supportive care (tin Sn 117m DTPA)|Patients receive tin Sn 117m DTPA IV over 5-10 minutes on day 1. Treatment repeats every 8 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive tin Sn 117m DTPA for an additional 2 cycles if pain recurs within 6 months after a 16-week pain observation period and no disease progression on bone scans, or evidence of clinical progression.
9477378|NCT03563001|Experimental|Chronic Obstructive Pulmonary Disease Group|Patients with diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Disease(GOLD 2018) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
9477379|NCT03563001|Experimental|Asthma-Chronic Obstructive Pulmonary Disease Overlap Group|Patients with diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
9477380|NCT03562962|Other|Functional Analytic Psychotherapy|"Within the baseline (A), Supportive Listening (SL) will be provided, which has been widely utilized in randomized control trials (Cuijpers et al., 2012), including the only Randomized Control Trial (RCT) conducted in FAP (Maitland & Gaynor, 2016), as a control condition. SL is defined as a psychological treatment in which therapists do not engage in any therapeutic strategies other than active listening and offering support, focusing on participants' problems and concerns (Cuijpers et al., 2012, p. 281). In this therapy, the therapist reflects on clients' experiences and encourage them to share emotional experiences. Therapists are prohibited from giving advice, making interpretations, and providing feedback to clients (Cuijpers et al., 2012).~FAP will be introduced at phase B, where contingent reinforcement will be administered for increasing clients' alternative behaviors (CRB2) and differential reinforcement will be utilized to reduce clients' problem behaviors (CRB1)."
9477381|NCT03562949|Experimental|Test Product|Test Product, 40 mcg, 2 x daily
10019889|NCT04616027|Experimental|Healthy participants with normal renal function|This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
10019890|NCT04616027|Experimental|Participants with T2DM with normal renal function|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1
10019891|NCT04616027|Experimental|Participants with T2DM with mild renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
9477382|NCT03562949|Active Comparator|Reference Product|Reference Product, 40 mcg, 2 x daily
9477383|NCT03562949|Placebo Comparator|Placebo|Placebo Product 2 x daily
9477384|NCT03562923|Experimental|Test Product|Test Product, 100/50 mcg, 2 x daily
10019892|NCT04616027|Experimental|Participants with T2DM with moderate renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
10019893|NCT04616027|Experimental|Participants with T2DM with severe renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
10019894|NCT04614506||Subject with DS|Participants will complete two visits spaced out by 4 - 8 weeks to undergo neurophysiological assessments (Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]).
10019895|NCT04613830|Active Comparator|Erector spinae group|patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae.
10019896|NCT04613830|Placebo Comparator|Opioid GROUP|Patient in group T will intravenously administrate dose of 1 mg/kg/8hr tramal ( opioid) to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic.
10019897|NCT04611100|No Intervention|Conventional|Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice
10019898|NCT04611100|Experimental|Radiofrequency ablation|Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice
10019899|NCT04610892|Experimental|MEDI6570 Low dose|Monthly Subcutaneous administration.
10019900|NCT04610892|Experimental|MEDI6570 Medium dose|Monthly Subcutaneous administration.
10019901|NCT04610892|Experimental|MEDI6570 High dose|Monthly Subcutaneous administration.
10019902|NCT04610892|Placebo Comparator|Placebo Low dose|Monthly Subcutaneous administration.
10019903|NCT04610892|Placebo Comparator|Placebo Medium dose|Monthly Subcutaneous administration
10019904|NCT04610892|Placebo Comparator|Placebo High dose|Monthly Subcutaneous administration
10019905|NCT04609735|Experimental|Experimental: Electric DN, Manual therapy, exercise and US|Dry needling, manual therapy, exercise and ultrasound
10019906|NCT04609735|Active Comparator|Active comparator: Manual therapy, exercise and ultrasound|Active comparator: Manual therapy, exercise and ultrasound
10019907|NCT04609709|Experimental|thrust manipulation, electric dry needling and exercise|thrust manipulation, electric dry needling and exercise
10019908|NCT04609709|Active Comparator|non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|non-thrust mobilization, soft-tissue mobilization, exercise and TENS
10019909|NCT04609657|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
10019910|NCT04609657|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
10019911|NCT04609657|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
10019912|NCT04609657|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
10019913|NCT04609657|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
10019914|NCT04609657|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
10019915|NCT04609566|Experimental|Combination Therapy|brentuximab vedotin + pembrolizumab
10019916|NCT04608916|Active Comparator|Scalpel incision group|This group of patients will receive skin incision made with use of a scalpel blade.
10019917|NCT04608916|Experimental|Electrocautery incision group|This group of patients will receive skin incision made with use of electrocautery.
10019918|NCT04608682|Experimental|Sugammadex group|
10019919|NCT04608682|Sham Comparator|control group|
10019920|NCT04607876|Active Comparator|Standard of Care|The FAR Control Arm will involve risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
10019921|NCT04607876|Other|Enhanced Intervention|"This intervention will involve risk factor assessment and web based risk factor management.~Technological facilitators including a population health care management portal which will be used to facilitate risk factor management to monitor risk factor control, and to facilitate new symptom and complications management;~Telemedicine to allow FAR Coordinator and providers capability for evaluation and management in home/facility, which facilitates real time communication and collaboration and virtual evaluation of the subject when higher level of intervention is required~Educational portal provides a common educational platform for professional and subject education around stroke symptoms, complications, recovery and risk factor management, and lifestyle changes.~FAR EI teams will be coordinated at FAR Central where a centralized group of specialists initiate and monitor risk factor mitigation strategies tailored to the individual participant."
10019922|NCT04606797|Experimental|Nicotine Replacement Therapy|
10019923|NCT04606797|No Intervention|Control|
10019924|NCT04606784|Experimental|Ampion|Ampion
10019925|NCT04606784|Other|Standard of Care|Standard of Care
10019926|NCT04606602|Experimental|30 mg|
10019927|NCT04606602|Placebo Comparator|Placebo|
10019928|NCT04606602|Experimental|100 mg|
10019929|NCT04606602|Experimental|300 mg|
10019930|NCT04606602|Experimental|600 mg|
10019931|NCT04606602|Experimental|900 mg|
10019932|NCT04606602|Experimental|100 mg multi dose|
10019933|NCT04606602|Experimental|200 mg multi dose|
10019934|NCT04606602|Experimental|300 mg multi dose|
10019935|NCT04606602|Experimental|600 mg multi dose|
10019936|NCT04606602|Placebo Comparator|Placebo multi dose|
10019937|NCT04606160|Experimental|Single Session Problem-Solving Intervention|Participants will receive a single session problem-solving intervention during visit 2 of the 4 visit research study. During visit 3, participants will receive a review of the intervention from visit 2. During visits 1, 3, and 4, participants will complete measures.
10019938|NCT04606160|No Intervention|Control - Non Single Session Problem-Solving Intervention|These participants will complete measures at visits 1,2,3, and 4. They will also receive a visit during visit 2 of the 4 visit study, where they will only complete measures.
10019939|NCT04603690|Experimental|Complementary therapy group|This arm will receive a daily supplementation of 168 mg curcumin, 260 mg quercetin and 9 mcg/360 IU of vitamin D3 (cholecalciferol) as add-on to the standard of care for 14-days
10019940|NCT04603690|Active Comparator|Control group|This arm will receive standard care alone
10019941|NCT04602078|Experimental|AUREA single-arm|"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.~Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles."
10019942|NCT04598724||Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
10019943|NCT04598724||Care Givers for Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
10019944|NCT04598360|Experimental|Experimental: Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of cardiac surgery patients are studied before and during heart-lung-machine procedure using LC-MS / MS
10019945|NCT04597697|Experimental|Subjects with normal hepatic function|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
10019946|NCT04597697|Experimental|Subjects with mild hepatic impairment, child-pugh grade A|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
10019947|NCT04597697|Experimental|Subjects with moderate hepatic impairment, child-pugh grade B|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
10019948|NCT04597697|Experimental|Subjects with severe hepatic impairment, child-pugh grade C|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
10019949|NCT04596891|Experimental|Intervention|Remotely delivered psychotherapy combining exposure therapy with mindfulness
10019950|NCT04596631|Experimental|Semaglutide - max. tolerated dose|Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
10019951|NCT04596631|Placebo Comparator|Placebo (semaglutide)|Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
10019952|NCT04596098||Group A|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient not previously followed in Grenoble University Hospital for a chronic disease.
10019953|NCT04596098||Group B|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient followed in Grenoble University Hospital for a chronic disease.
10019954|NCT04595097|Experimental|Intervention Group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. IMT in both groups will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the intervention group will be set initially at a load of 50% of patients' maximal inspiratory mouth pressure (MIP). This initial load will be continuously and gradually increased to the highest tolerable intensity during each of the supervised sessions.
10019955|NCT04595097|Active Comparator|Control group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will perform endurance training or interval training at moderate to high intensities. Sham IMT will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the control group will be set at 10% baseline PImax and will be not modified throughout the intervention period.
10019956|NCT04594811|Experimental|Dose escalation|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.~Nivolumab will be administered on Day 1 of every 4 week cycle (Q4W)."
10019957|NCT04594811|Experimental|Phase 2: NT-I7 and Nivolumab|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W) at the recommended phase 2 dose (RP2D) identified during Dose escalation phase.~Nivolumab will be administered on Day 1 of every 4 week cycle (Q4W)."
10019958|NCT04594512|Other|LENTICULE IMPLANTATION|The present study may suggest that this procedure safely, reliably, and effectively increases corneal thickness and improves visual acuity with no adverse effects. It may even provide new avenues in the treatment of corneal ectasia. Stem cells and live keratocytes are well organized based on cornea transparency and in anterior segment OCT.
10019959|NCT04592874|Experimental|AL002 Dose 1|AL002 every 4 weeks
10019960|NCT04592874|Experimental|AL002 Dose 2|AL002 every 4 weeks
10019961|NCT04592874|Experimental|AL002 Dose 3|AL002 every 4 weeks
10019962|NCT04592874|Placebo Comparator|Placebo|Placebo every 4 weeks
10019963|NCT04590651|Experimental|Standard PHACO cataract surgery|In this group normal phacoemulsification cataract surgery will be preformed.
10019964|NCT04590651|Experimental|PHACO + extra aspiration|In this group an extra one minute anterior chamber angle aspiration will be preformed at the end of a standard cataract operation.
10019965|NCT04590326|Experimental|Module 1|REGN5668 and cemiplimab
10019966|NCT04590326|Experimental|Module 2|REGN5668 and REGN4018
10019967|NCT04590144|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead
10019968|NCT04589611|Experimental|Phase I single amobarbital/Gel-One dose|Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
10019969|NCT04589611|Active Comparator|Phase IIa Part 1 amobarbital/Gel-One dose|20 subjects will be randomized to amobarbital/Gel-One single dose.
10019970|NCT04589611|Placebo Comparator|Phase IIa Part 1 Placebo|10 subjects will be randomized to amobarbital/Gel-One single dose.
10019971|NCT04589611|Active Comparator|Phase IIa Part 2 amobarbital/Gel-One dose|20 subjects will be randomized to one dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
10019972|NCT04589611|Placebo Comparator|Phase IIa Part 2 placebo|20 subjects will be randomized to one dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
10019973|NCT04588857|Experimental|Active drug|dexamethasone 24 mg i.v., single dose
10019974|NCT04588857|Placebo Comparator|Placebo|saline i.v., single dose
10019975|NCT04586153|Experimental|Meplzaumb|This arm is combined with 3 groups, low dose, middle dose, and high dose. Low dose group: First dose: 0.12 mg/kg - Day 1; second dose: control - Day 8 Middle dose group: First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8 High dose group: First dose: 0.3 mg/kg - Day 1; second dose: 0.3 mg/kg - Day 8
10019976|NCT04586153|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
10019977|NCT04584684|Placebo Comparator|Saline|Subject participants will rinse mouth one time for 60 seconds with 10 mL of Isotonic Saline.
10019978|NCT04584684|Active Comparator|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 10 mL 27% ethanol plus essential oils.
10019979|NCT04584684|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 10 mL 0.075% Cetylpyridinium Chloride.
10019980|NCT04584684|Active Comparator|1.5% w/v Hydrogen Peroxide|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 1.5% w/v hydrogen peroxide rinse.
10019981|NCT04584684|Active Comparator|0.5% w/v Povidone-iodide|Subject participants will rinse mouth one time for 60 seconds with 10 mL .5% w/v povidone-iodide.
10019982|NCT04584684|Active Comparator|0.12% Chlorhexidine Gluconate|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 0.12% Chlorhexidine Gluconate.
10019983|NCT04582539|Experimental|INCB000928|INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
10019984|NCT04582435|Experimental|Insulin icodec|Participants will receive individualised weekly doses of insulin icodec
10019985|NCT04582409|Experimental|HSY244|HSY244 concentrate solution for injection via intravenous infusion
10019986|NCT04582409|Placebo Comparator|Placebo|Placebo concentrate solution for injection via intravenous infusion
10019987|NCT04580212|Experimental|Intervention arm|This arm received the poultry hygiene intervention.
9477385|NCT03562923|Active Comparator|Reference Product|Reference Product, 100/50 mcg, 2 x daily
9477386|NCT03562923|Placebo Comparator|Placebo|Placebo Product 2 x daily
10019988|NCT04580212|No Intervention|Control arm|This arm received no intervention.
10019989|NCT04579692|Experimental|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain called central lateral thalamic nucleus. Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
10019990|NCT04578639|Experimental|Rituximab|Rituximab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial dose; 1000 mg Subsequent doses; 500 mg
10019991|NCT04578639|Active Comparator|Ocrelizumab|Ocrelizumab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial and subsequent doses; 600 mg
10019992|NCT04577001|Experimental|Letrozole Group|Subjects with hepatopulmonary syndrome will get the study drug letrozole
9477387|NCT03562910|Experimental|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
10019993|NCT04577001|Placebo Comparator|Placebo Group|Subjects with hepatopulmonary syndrome will get the study placebo
10019994|NCT04576338||College Students|The cohort consists of Black and White college students at a university in a southeastern state in America.
10019995|NCT04575467|Experimental|CBL-514 320 mg|
10019996|NCT04575467|Experimental|CBL-514 480 mg|
10019997|NCT04575467|Experimental|CBL-514 640 mg|
10019998|NCT04575467|Experimental|CBL-514 800 mg|
10019999|NCT04574076||N8-GP|Patients with haemophilia A
10020000|NCT04573530|Experimental|We Walk Plus Intervention|The intervention group will receive a Fitbit, SMS and will be assigned to a private Fitbit community (4-5 participants per group) for 12 weeks. During the intervention, participants will receive weekly personalized SMS on their mobile phones including encouraging messages, reminders, and tips to increase steps, and weekly step goals. The investigators will use a secure, web-based platform, iCardia, to support continuous real-time remote monitoring of activity data from Fitbit devices and personalized communication via SMS based on incoming data. The investigators will set up the Fitbit networking settings on participants' phones to give notifications when there are posts to this group. Individual goals and a weekly team goal of steps will be set up by the research team. Each member will be awarded a badge upon reaching each individual's weekly goal. Teams will also be awarded badges when all team members reach their individual weekly goals.
10020001|NCT04573530|No Intervention|Attention control group|The attention control group will also receive a Fitbit and will be asked to continue with normal daily activities. During the initial in-person session, they will receive the same PA recommendations as the intervention group to walk at least 30 minutes for 5 days or more a week or 10,000 steps a day. However, a plan for improving PA will not be discussed.
10020002|NCT04573075|Other|no outlet|no outlet is used after colorectal resection and forming of a primary anastomosis
10020003|NCT04573075|Active Comparator|loop ileostomy|loop ileostomy is applied after colorectal resection and forming of a primary anastomosis
10020004|NCT04573075|Experimental|ghost ileostomy|ghost ileostomy or ghost stoma (synonyms) is performed after colorectal resection and forming of a primary anastomosis
10020005|NCT04572568||experimental group|"Treatment applied accordingly with the following standard criteria , patients are selected into this group:~Ruptured lesion：~Lesions not at the brainstem, thalamus, basal ganglia, or deep location，craniotomy can be performed;~Target embolization of aneurysms and arteriovenous fistulas should be applied;~Stereotactic radiosurgery for patients with a volume less than 10ml and not in the acute phase(< 3months) of intracranial hemorrhage.~Unruptured lesion:~Lesion is not located in the deep brain tissue, and is not located in an important functional area or the fiber bundle is more than 5mm away from the lesion, then surgery or combined surgery can be performed;~If there are bleeding-related risk factors (aneurysm or high-flow fistula), relevant risk factors should be actively treated with embolization;~Patients with no indications for craniotomy and poor symptom controlled, or with appropriate volume for radiosurgery or hybrid surgery (embolization +radiosurgery)."
10020006|NCT04572568||control group|Patients who received treatment that did not meet the standard group treatment plan were included in this control group.
10020007|NCT04570436|Experimental|gabapentin 600 mg|single dose
10020008|NCT04570436|Active Comparator|diazepam 20 mg|single dose
10020009|NCT04570436|Placebo Comparator|placebo|single dose
10020010|NCT04570436|Experimental|gabapentin 1200 mg|single dose
10020011|NCT04570436|Experimental|gabapentin 1800 mg|single dose
10020012|NCT04569734|Experimental|Experimental: Treatment Group|Determination for participation in the study is based on institutional standard of care practice for assessment of WATCHMAN eligibility. Patients that are being considered for LAA Closure with WATCHMAN device implant based on a history of non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2VASc score >2 but have an appropriate rationale to seek a non-pharmacologic alternative to anti-thrombotic therapy due to risks of anti-thrombotic therapy. Patients should be able to tolerate the WATCHMAN device implant procedure without the need for general anesthesia.
10020013|NCT04569448|Experimental|Patient|Individuals diagnosed with Bipolar Disorder Type I and suffering a major depressive episode who will receive an adjunctive and variable dose of Brexpiprazole treatment
10020014|NCT04568733|No Intervention|Resting|
10020015|NCT04568733|Experimental|Pilates exercise session|
10020016|NCT04568733|Active Comparator|Treadmill walking at 3.2 kph|
10020017|NCT04568733|Active Comparator|Treadmill walking at 4.8 kph|
10020018|NCT04567680|Experimental|Acceptance and Commitment Therapy to Improve Social Support|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
10020019|NCT04567680|Active Comparator|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
10020020|NCT04567264|Experimental|With stimulation|Implantation of device electrodes subcutaneous in lower tibia area; stimulation of posterior tibial nerves.
10020021|NCT04566887|Experimental|Acalabrutinib with R-CHOP chemotherapy|Acalabrutinib 100mg twice per day orally with standard of care R-CHOP chemotherapy by IV every 21 days for a maximum of six cycles.
10020022|NCT04564885|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis at 2 contiguous levels
10020023|NCT04564885|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc at 2 contiguous levels
10020024|NCT04564703|Experimental|cohort 1|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
10020025|NCT04564703|Experimental|cohort 2|Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
10020026|NCT04564703|Experimental|cohort 3|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
10020027|NCT04564547|Experimental|Group 1: ISL 20 mg + MK-8507 100 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD) [Part 1].
10020028|NCT04564547|Experimental|Group 2: ISL 20 mg + MK-8507 200 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 200 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
10020029|NCT04564547|Experimental|Group 3: ISL 20 mg + MK-8507 400 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 400 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
10020030|NCT04564547|Active Comparator|Group 4: BIC/FTC/TAF|Participants receive placebo to ISL + placebo to MK-8507 QW (Part 1) and BIC/FTC/TAF 50 mg/200 mg/25 mg QD (Parts 1 and 2).
10020031|NCT04564443|Experimental|(Medaxis Debritom+™) micro jet lavage|Medaxis Debritom+™ is a high-quality, micro water jet debridement device designed to remove fibrin, necrotic tissue, and biofilm from wound surfaces by mechanical cleaning and stimulation of the diabetic foot wound
10020032|NCT04564443|Active Comparator|Sharp Surgical Debridement|Use of a surgical scalpel or curette to remove fibrin, necrotic tissue and biofilm from wound surfaces by mechanically cleaning the wound
10020033|NCT04563130|Experimental|Cryocompression|Patients will be randomized to receive cryocompression on one hand and foot using ice bags and compression socks.
10020034|NCT04563130|No Intervention|Control|Patients will be randomized to receive no intervention on the opposite hand and foot.
10020035|NCT04562831|Experimental|Newly diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~Single dose EH301 (1000mg Nicotinamide riboside / 200mg Pterostilbene)~Placebo"
10020036|NCT04562831|Experimental|Earlier diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)~Placebo"
10020037|NCT04562766|Experimental|Rilzabrutinib|Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period
10020038|NCT04562766|Placebo Comparator|Placebo|Patients receive matching placebo 400mg orally twice daily for up to 24 weeks
10020039|NCT04561375|Active Comparator|Intervention Group|30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
10020040|NCT04561375|Placebo Comparator|Control Group|placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia
10020041|NCT04560972|Experimental|Treatment (LB-100, carboplatin, etoposide, atezolizumab)|"INDUCTION: Patients receive LB-100 IV over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
10020042|NCT04560179|Experimental|Treatment Arm - 78mg|The phase 1 trial will begin with a dose of 78mg. All treatment arms will administer study drug every 12 hours for up to 14 days (28 doses). Up to 6 infants in this arm will receive the 78mg dose of tobramycin solution for inhalation administered via vibrating mesh nebulizer. During the trial, infants in each treatment arm will undergo blood and tracheal aspirate sampling and respiratory mechanics measurements at pre-specified time points to assess dose safety and potential efficacy. Clinical data will also be recorded daily throughout the trial in all participants.
10020043|NCT04560179|Experimental|Treatment Arm - 150mg|If tolerability is demonstrated in the 78mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
10020044|NCT04560179|Experimental|Treatment Arm - 216mg|If tolerability is demonstrated in the 150mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
10020045|NCT04560179|Experimental|Treatment Arm - 300mg|If tolerability is demonstrated in the 216mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
10020046|NCT04560179|No Intervention|Observational Arm|Enrolled infants who are eligible to participate in the phase-1 trial may be enrolled in an untreated observational cohort at parental discretion. This cohort will undergo collection of clinical and respiratory mechanics data for 14 days after enrollment but will not receive the study drug.
10020047|NCT04558554|Experimental|Pharmacy-based PrEP delivery|Participants in this experimental arm (which includes all participants) will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) at community pharmacies in Kenya. During Phase Two of the study, participants will also have the option to initiate post-exposure prophylaxis (PEP) at the 12 study pharmacies, and in a subset of four study pharmacies, participants will have the option to undergo STI testing.
10020048|NCT04557735|Experimental|Ravulizumab plus Best Supportive Care|Participants will receive ravulizumab plus Best Supportive Care as background therapy.
10020049|NCT04557566|Active Comparator|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
10020050|NCT04557566|No Intervention|Control|Wait list control
10020051|NCT04557488|Experimental|Music therapy|The treatment group will receive social skill intervention using music therapy in groups of eight. A certified music therapist with prior experience with children with ASD and ID will be the trainer for the treatment group. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to facilitate the group activities, manage unexpected situations, and ensure the safety of the participants.
10020052|NCT04557488|Experimental|Behavioral-based social skill training|The control group will receive behavioral-based social skill training in groups of eight. The trainer will be a registered social worker with experience in providing social skill training for children with ASD and ID. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to provide support.
10020053|NCT04557189|Experimental|Group A|Prophylaxis with ondansetron placebo intravenous (IV) immediately before induction and 4 mg TAK 951 subcutaneous (SC) approximately 30 to 45 minutes before the end of surgery (wound closure).
10020054|NCT04557189|Experimental|Group B|Prophylaxis with 4 mg ondansetron IV immediately before induction and TAK-951 placebo SC approximately 30 to 45 minutes before the end of surgery (wound closure).
10020055|NCT04556097|Experimental|Early Training|Nurse care managers will be randomized to either early or delayed adapted Care Ecosystem training. The Early Training arm will be the first group to receive training and the first to have the opportunity to use the training in a clinical setting. We anticipate that each nurse care manager will manage 10 PWLD and we anticipate a 50% response rate/data availability, yielding 75 patients per arm.
10020056|NCT04556097|Active Comparator|Delayed Training|The Delayed Training arm will be the second group of nurse care managers to receive training.
10020057|NCT04551521|Experimental|BRAF V600E/K|
10020058|NCT04551521|Experimental|ERBB2|
10020059|NCT04551521|Experimental|ALK|
10020060|NCT04551521|Experimental|PI3K/AKT|
10020061|NCT04551521|Experimental|PI3K-AKT-TAX|
10020062|NCT04551521|Experimental|MAPK|
10020063|NCT04551521|Experimental|Immune evasion|
10020064|NCT04551300|Experimental|VS-505 500mg|VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
9477388|NCT03562884|Experimental|BLI800|BLI800 given orally as a split-dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m.- 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
9477389|NCT03562884|Active Comparator|Fortrans®|Fortrans® given orally as a split dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m - 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
9477390|NCT03562858|Active Comparator|Delayed dentine sealing|
10020065|NCT04551300|Experimental|VS-505 750mg|VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
10020066|NCT04551300|Experimental|VS-505 1500mg|VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
10020067|NCT04551300|Experimental|VS-505 2250mg|VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
10020068|NCT04551300|Active Comparator|Sevelamer Carbonate 1600mg|Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.
10020069|NCT04550741|Experimental|Telerehabilitation|Experimental group of 100 patients using the M-Réhab BPCO telerehabilitation solution. The solution will be provided during the fourth and final week of RR's stay during which patients will be trained to use all of the solution's features. Patients will carry out the entire post-rehabilitation using the remote rehabilitation solution and will benefit from medical assessments by teleconsultation at 1, 3, 6 and 12 months as well as assessments at 3, 6 and 12 months by filling. electronic auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
10020070|NCT04550741|No Intervention|Standard chronic care|following usual standard chronic care. Patients will receive during the last week of stay in the center, the usual advice to continue physical activity and nutritional advice at home. The evaluations at 3, 6 and 12 months will be done by electronic filling of auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
10020071|NCT04550247||Nivolumab treatment|Administered according to the market authorization in France
10020072|NCT04548648|Other|Open-label, single-arm|A multicenter open-label, single-arm, phase 2 study designed to investigate the antitumor effects of acalabrutinib in subjects with relapsed primary central nervous system lymphoma (PCNSL), and relapsed secondary CNS lymphoma (SCNSL) with no evidence of current systemic disease. Subjects will receive acalabrutinib at the dose of 100 mg every 12 hours. Prophylactic administration of broad spectrum triazole antifungal agent isavuconazole will be performed while subjects receive acalabrutinib.
10020073|NCT04545242|Active Comparator|Dexamethasone (low dose)|Dexamethasone: 6 mg/iv/day during 10 days.
10020074|NCT04545242|Active Comparator|Dexamethasone (moderate dose)|Dexamethasone: 20 mg/iv/ daily from day of randomization (day 1) during 5 days, followed by 10 mg/iv/ daily from Day 6 to Day 10 of randomization.
10020075|NCT04544930|Experimental|therapist-guided|Therapist-guided Internet treatment based on cognitive behavior therapy (ICBT).
10020076|NCT04543760|Other|[PP sequence 1] - Wash-out - [SP sequence 2]|
10020077|NCT04543760|Other|[SP sequence 1] - Wash-out - [PP sequence 2]|
10020078|NCT04543409|Experimental|Benralizumab|Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
10020079|NCT04543409|Placebo Comparator|Placebo|Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
10020080|NCT04543305|Experimental|PRT1419|PRT1419 will be administered orally
10020081|NCT04542980||SARS-CoV2 Positive|"Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus.~A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus."
10020082|NCT04542980||Control|Control tear and serum samples will be selected from Namida Lab's own biorepository.
10020083|NCT04541849||Critically ill patients|
10020084|NCT04540705|Experimental|Part 1A (Part 1): Nivolumab + Bempegaldesleukin + Axitinib|
10020085|NCT04540705|Experimental|Part 1B (Part 1): Nivolumab + Bempegaldesleukin + Cabozantinib|
10020086|NCT04540705|Experimental|Arm A (Part 2): Nivolumab + Bempegaldesleukin + Cabozantinib|
10020087|NCT04540705|Experimental|Arm B (Part 2): Nivolumab + Cabozantinib|
10020088|NCT04540315|Experimental|Intervention - MobiMD app|Intervention group will receive notifications to their smart device through MobiMD app. Participants will be asked to fill out reports and upload all clinically relevant data using the app. Engaging with the app will be in addition to the standard of care follow-up.
10020089|NCT04540315|No Intervention|Standard of Care|The standard of care control group will receive conventional postoperative care. Participants will receive reported outcome survey by email.
10020090|NCT04540133|Experimental|dexamethasone 0.5mg/5ml solution in Mucolox™ (group A)|Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
10020091|NCT04540133|Active Comparator|dexamethasone 0.5mg/5ml solution (Arm B)|Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks
10020092|NCT04539938|Experimental|Single Arm|Tucatinib + trastuzumab deruxtecan
10020093|NCT04539470|Experimental|Cohort A: Efmarodocokin Alfa Dosage Level 1|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
10020094|NCT04539470|Experimental|Cohort B: Efmarodocokin Alfa Dosage Level 2|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
10020095|NCT04539470|Experimental|Cohort C: Efmarodocokin Alfa Dosage Level 3|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
10020096|NCT04539223|Active Comparator|Drug (Evolocumab)|Individuals randomized to this arm will administer Evolocumab subcutaneously (SC) every two weeks (Q2W) for 26 weeks.
10020097|NCT04539223|No Intervention|No Drug (Standard of Care)|Individuals randomized to this arm will not administer a placebo.
10020098|NCT04537949|Experimental|Part A participants aged 18 to 55 years|Escalating dose levels
10020099|NCT04537949|Experimental|Part A participants aged 56 to 85 years (optional)|Escalating dose levels
10020100|NCT04537559||pre-COVID-19 period|Patients hospitalized between 1.3.2019 and 28.02.2020
10020101|NCT04537559||per-COVID-19 period|Patients hospitalized between 1.3.2020 and 28.02.2022
10020102|NCT04537559||post-COVID-19 period|Patients hospitalized between 1.3.2022 and 28.02.2023
10036270|NCT01814124|Experimental|Manual Therapy Plus Exercise|"Participants in this group will be given the same handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week.~Participants in this group will also receive 12 individualized physical therapy treatment sessions (2x/week for 6 weeks) consisting of both manual therapy and exercise directed at the hip and surrounding areas based upon findings from the initial examination. Participants will also be given additional exercises to be performed at home as directed by the treating physical therapist"
10036271|NCT01814150||Oncology Institute, Meir Medical Center|Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center
10020103|NCT04534972|No Intervention|Pre-Implementation|The control (pre-implementation) group will be burn patients admitted to the burn unit in ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
10020104|NCT04534972|Active Comparator|Post-Implementation Targeting Normoxemia in Burn ICU|The intervention (post-implementation) group will be patients admitted to the burn unit in ICU during the targeting normoxemia intervention period of the stepped-wedge design implementation process (up to 19 months).
10020105|NCT04534959|No Intervention|Pre-Implementation|The control (pre-implementation) group will be trauma patients admitted to the surgical/trauma ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
10020106|NCT04534959|Experimental|Post-Implementation Targeting Normoxemia in Trauma ICU|The intervention (post-implementation) group will be patients admitted to the surgical/trauma ICU during the targeted normoxemia intervention period of the stepped-wedge implementation process (up to 25 months).
9477391|NCT03562858|Experimental|Immediate dentin sealing|
10020107|NCT04534153|Experimental|Fexofenadine without SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
10020108|NCT04534153|Experimental|Fexofenadine and 3 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
10020109|NCT04534153|Experimental|Fexofenadine and 30 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
10020110|NCT04532619|Experimental|Intervention|6 weeks of Fathering Through Change videos and 3 individual coaching calls.
10020111|NCT04532619|No Intervention|Control|Links to parenting websites
10020112|NCT04531085|Active Comparator|RCT operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
10020113|NCT04531085|Active Comparator|RCT Non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
10020114|NCT04531085|Other|Patient preference operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
10020115|NCT04531085|Other|Patient preference non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
10020116|NCT04530825|No Intervention|Providers|"All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline~A subset of 5-10 providers will be recruited via email, at the baseline training,or by using snowball-sampling approach within the clinic to participate in qualitative in-depth interviews"
10020117|NCT04530825|No Intervention|Parents|-Semi-structured interviews
10020118|NCT04530825|Active Comparator|Patients - Wait-List Control|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~Up to 10 patients will also take part in semi-structured interviews~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
10020119|NCT04530825|Experimental|Patients - PREVENT tool|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered immediately following the clinic visit (within 48 hours) and 3-months after the clinic visit electronically and by mail~Up to 10 patients will also take part in semi-structured interviews~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
10020120|NCT04530435|Experimental|Treatment group|"The participants will be handed three airway resistances equivalent to a resistance of 10-20 cm H2O alongside one PEP flute. Two videos will guide the participants in use of the PEP flute; one with instructions of the rationale and how to use the flute, including how to choose the suitable resistance and one video, which gives instructions of hygienic maintenance.~Participants in the intervention group will be advised to continue use of their PEP flute in the active intervention period of 30 days or at least if they still have respiratory symptoms. They will receive daily text-messages to prompt their reporting and to use the PEP flute according to instructions."
10020121|NCT04530435|No Intervention|Control group|The participants in the control group will receive daily text-messages to prompt their reporting of CAT-scores. To avoid attrition of the trial due to early recovery of symptoms, the project manager will call the participants by phone at day 15 to ask them about their present condition (i.e. CAT-score) and address potential concerns of continued participation of the trial. Otherwise, they will only receive usual care.
10020122|NCT04530279||Referring hospital|Burn assessments performed in referring hospitals
10020123|NCT04530279||Burn centre|Burn assessments performed in the national burn centre
10020124|NCT04529980|Experimental|Lactobacillus rhanmosus GG(LGG®) Group|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge.
10020125|NCT04529980|Placebo Comparator|Placebo Control Group|Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge.
10020126|NCT04529499|Experimental|favipiravir + supportive care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets. Tablet Strength 200 mg. Dosage: 1,800 mg BID on Day 1 + 800 mg BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
10020127|NCT04529499|Placebo Comparator|Placebo with Standard of Care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets Dosage: 9 tablets for BID on Day 1 + 4 tablets BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
10020128|NCT04528433|Experimental|Medical-education-community Collaborated Intervention|
10020129|NCT04528433|Active Comparator|routine clinical care|
10020130|NCT04526132|Experimental|Experimental: group1|Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml
10020131|NCT04526132|Placebo Comparator|Experimental: group2|Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml
10020132|NCT04525014|Experimental|RRx-001, Temozolomide and Irinotecan|
10020133|NCT04524832|Experimental|Semaglutide D 50 mg|Participants will receive once daily semaglutide D formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
10020134|NCT04524832|Experimental|Semaglutide C 50 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
10020135|NCT04524832|Experimental|2 x Semaglutide C 25 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 2 x 25 mg (week 13-16)
10020136|NCT04524832|Experimental|Semaglutide E 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 16 weeks: A) Semaglutide C formulation: 2.4 mg (week 1-2), 5.6 mg (week 3-4) and 11.2 mg (week 5-8). B) Semaglutide E formulation: 25 mg (week 9-12) and 50 mg (week 13-16)
10020137|NCT04524832|Experimental|Semaglutide F 50 mg|Participants will receive once daily semaglutide F formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
10020138|NCT04523727|Experimental|Ferric citrate|Participants aged 12 to <18 years and 6 to <12 years will receive ferric citrate for 36 weeks at a starting dose based on body weight categories.
10020139|NCT04523428|Experimental|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
10020140|NCT04522895|Experimental|Consolidation Arm|Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
10020141|NCT04521920|Experimental|Medication and telemedicine follow up|All participants are provided with Suboxone and/or PrEP and follow up visits will be conducted via telemedicine
10020142|NCT04520776|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis
10020143|NCT04520776|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc
10020144|NCT04520698|Experimental|Nursing Home-level UPLIFT-AD intervention|The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.
10020145|NCT04520698|No Intervention|Usual Care|
10020146|NCT04519944||NVAF patients undergoing PCI|Patients with non-valvular atrial fibrillation (NVAF) who had successful percutaneous coronary intervention (PCI).
10020147|NCT04517864|Experimental|Treatment Arm: PF-06651600|ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm
10020148|NCT04517864|Other|Control Arm (Placebo) followed by active therapy extension|matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24
10020149|NCT04517734||Pregnant Adolescents|
10020150|NCT04517734||Pregnant Women Carrying Multiple Fetuses|
10020151|NCT04517487|Active Comparator|VMT recipients|"In order to prevent transfer of pathogens, sperm, or antibiotic-resistant commensals we will establish a vaginal fluid bank in which samples from suitable donors will be kept for future use:~Donors will be screened using a questionnaire addressing risk factors for potentially transmissible infections, undergo screening for cervico-vaginal infections, cervical cytology screening, and serology analysis for transmittable infections {see detailed screening in Lev-Sagie et al. Nat Med. 2019;25(10):1500-1504. doi: 10.1038/s41591-019-0600-6.}~The collected samples for VMT will be examined for bacteria,viruses and sperm.~Before transplantation, patients will be treated with intravaginal antibiotics. A frozen specimen will be thawed at room temperature and will be placed in the patient's vagina.~Following VMT, patients will be evaluated every 14 days for the first 2 months, then every month for additional 10 months."
10020152|NCT04517487|Placebo Comparator|Placebo|"Vaginal fluid of all recipients will be collected before initiation of the study using the same protocol, will be clearly labeled and will be kept frozen in similar conditions. These samples will be used in the placebo arm for autologous vaginal fluid transplantation.~Before transplantation, patients will be treated with intravaginal antibiotic.~Following Placebo, patients will be evaluated every 14 days for the first 2 months, then every month for additional 2-4 months.~After 4-6 months, patients who initially received placebo will be offered a VMT in case they are still symptomatic and fulfill inclusion criteria, in an open-label phase."
10020153|NCT04517370|Active Comparator|Laser treatment|Each patient will be treated once every 20-40 days, for a total of 3 laser treatments. In every visit during the study, patients will undergo gynecological examination and will complete questionnaires evaluating GSM symptoms, using a visual analogue scale (VAS) for each symptom (vaginal dryness, dyspareunia, discharge, itching and/or stinging, vaginal bleeding and dysuria) as well as treatment induced pain and side effects.
10020154|NCT04517370|Sham Comparator|Sham treatment|"Each patient will be treated once every 20-40 days, for a total of 3 Sham treatments, in a similar procedure not using an active laser energy. Patients will be assessed in a similar manner.~Following 3 Sham-treatments patients in the placebo group will be offered the laser treatment in an open-label study ."
10020155|NCT04516317||Group intravenous artesunate (around 300 patients)|Period 2011-2019
10020156|NCT04516317||Group intravenous quinine (around 300 patients)|Period 2000-2010
10020157|NCT04516252|Experimental|Intervention|Half of the BodyWorks families will be randomized to the intervention group, and will receive a PAT for the children, the parents, and the dogs at the beginning of the cycle; the children will respond to EMA surveys using a cell phone; the children and the parents will receive the Canine health literacy module in addition to the BW curriculum.
10020158|NCT04516252|Active Comparator|Control|Half of the BodyWorks participants will be randomized to the control group and will receive a PAT at the beginning of the cycle for the children, the parents, and the dogs, and the children will respond to EMA surveys using cell phones.
10020159|NCT04515147|Experimental|Part 1, Group 1: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
10020160|NCT04515147|Experimental|Part 1, Group 2: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
10020161|NCT04515147|Experimental|Part 1, Group 3: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants."
10020162|NCT04515147|Experimental|Part 1, Group 4: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants."
10020163|NCT04515147|Active Comparator|Part 1, Group 5: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
10020164|NCT04515147|Active Comparator|Part 1, Group 6: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
10020165|NCT04515147|Experimental|Part 2, Group 1: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
10020166|NCT04515147|Active Comparator|Part 2, Group 2: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
10020167|NCT04515147|Experimental|Part 2, Group 3: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
10020168|NCT04515147|Active Comparator|Part 2, Group 4: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
10020169|NCT04512794|Other|Non-randomized|All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.
10020170|NCT04508504|Experimental|Preop PENG Block|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL 0.5% ropivacaine in a manner consistent with Girón-Arango et al 2018 (PMID:30063657). Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence, in 5 mL increments with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
10020171|NCT04508504|Placebo Comparator|Placebo|Patients in the placebo group will receive a subcutaneous injection of 5 mL 0.9% normal saline. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, 1-2 cm beneath the skin, remaining in the subcutaneous tissue. 5 mL of 0.9% normal saline is injected, with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
10020172|NCT04507633|Experimental|ROMA therapy|ROMA therapy combines four elements including reminiscence, reality orientation, music, and art in the intervention.
10020173|NCT04507633|No Intervention|control group|usual care
10020174|NCT04506866|Other|Overactive Bladder Cohort|Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
10020175|NCT04506866|Other|Fecal Incontinence Cohort|Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.
10020176|NCT04506866|Other|Non-Obstructive Urinary Retention Cohort|Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
10020177|NCT04505280|Active Comparator|Active|%1 lidocaine injections to greater occipital nerve and cervical region once a week for 4 weeks
10020178|NCT04505280|Placebo Comparator|Placebo|0.9% saline injections to greater occipital nerve and cervical region once a week for 4 weeks
10020179|NCT04504825|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
10036272|NCT01814163||Paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
10036273|NCT01814176|Active Comparator|Macintosh Direct Laryngoscope|2 main forces - a 'lifting' force to elevate the structures not in the line of sight and a force exerted by the user's wrist to counterbalance the torque effect of the tongue tissues on the blade
10020180|NCT04504825|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
10020181|NCT04504825|Other|Concurrent Plasma Cell Dyscrasia Treatment|All patients will also receive concurrent treatment for Plasma Cell Dyscrasia (PCD) according to institutional SoC. Patients will have a planned first-line PCD treatment with a CyBorD regimen according to institutional SoC. The patient's PCD treatment may be initiated during the Screening period in consultation with the Medical Monitor and after screening laboratory samples are obtained. The patient may receive a maximum of 2 weeks of PCD treatment prior to randomization. For patients who receive the first dose of study drug prior to starting their PCD treatment, their PCD treatment must be initiated no later than 7 days after receiving the first dose of study drug. Patients can refer to the package insert or Summary of Product Characteristics (SmPC) for contraindications, warnings and precautions for PCD medications.
10020182|NCT04503382|Experimental|Kindness media|Short videos of kindness media. As part of a program entitled EnSpire®, this media consists of short videos that display acts of kindness and compassion that are edited together into a single reel.
10020183|NCT04503382|Active Comparator|Standard television|Children's commercial programming--as the control condition, participants watched commercial children's programming such as Disney, Nickelodeon, etc.
10020184|NCT04502719||Screened|Patients with liver cirrhosis screened for malnutrition.
10020185|NCT04501094|Experimental|1/Arm 1-Treatment with Bintrafusp alfa (M7824)|Treatment with Bintrafusp alfa (M7824)
10020186|NCT04501055|Experimental|Perineal nerve block|Man receive the perineal nerve block before under the transperineal prostate biopsy
10020187|NCT04501055|Active Comparator|Periprostatic block|Man receive the periprostatic block before under the transperineal prostate biopsy
10020188|NCT04498754|Experimental|Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants assigned to this arm will receive eight sessions of a well-established, evidence-based therapy called cognitive behavior therapy for insomnia (CBT-I).
10020189|NCT04498754|Other|Minimal Contact Control Condition|Participants assigned to this condition will be contacted every week for eight weeks and monitored regarding their insomnia symptoms.
10020190|NCT04496284|Experimental|Vitrification via slush nitrogen|Blastocyst stage embryos will be vitrified via slush nitrogen
10020191|NCT04496284|No Intervention|Vitrification via liquid nitrogen|Blastocyst stage embryos will be vitrified via conventional liquid nitrogen. This is the current standard of care.
10020192|NCT04495907||Group I|Group I- Asymptomatic patients with SARS-CoV-2 Infection
10020193|NCT04495907||Group II|Group II-Symptomatic patients with SARS-CoV-2 Infection
10020194|NCT04495179|Experimental|Arm A: AZD4635 + durvalumab|AZD4635 plus durvalumab (Arm A) will consist of participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
10020195|NCT04495179|Experimental|Arm B: AZD4635 + durvalumab + cabazitaxel|AZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
10020196|NCT04493034|Experimental|Art Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
10020197|NCT04493034|Experimental|Music Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
10020198|NCT04493034|No Intervention|Standard Of Care|A list of support services is provided. No requirement to attend sessions and no home assignments
10020199|NCT04492618|Experimental|Necrobiosis Lipoidica|Adults with cutaneous Necrobiosis Lipoidica (NL) up to 10% of the body surface area (BSA) treated with Ruxolitinib cream
9480732|NCT05261594|Other|Panic disorder|Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
10020200|NCT04491539|No Intervention|Adaptation|Site will inform the adaptation of the FRESH intervention.
10020201|NCT04491539|Experimental|First Receipt|Site will received the adapted FRESH intervention first.
10020202|NCT04491539|Experimental|Second Receipt|Site will received the adapted FRESH intervention second.
10036274|NCT01814176|Active Comparator|GlideScope Video Laryngoscope|The GlideScope has a 60º angulation anteriorly at the distal portion of the blade, allowing an anterior view of the larynx.
10036275|NCT01814189|Active Comparator|sumatriptan+promethazine (SPr)|The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg).
10020203|NCT04490707|Experimental|Azacitidine plus Lenalidomide (AZA+LEN)|"Arm 1(AZA+LEN): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA combined with LEN: AZA 50mg/m² per day for days 1-5 and LEN 10mg per day orally for days 6-26 , every 28 days for up to 12 cycles or progression.~AZA -Azacitidine, LEN- Lenalidomide"
10020204|NCT04490707|Experimental|Azacitidine(AZA)|"Arm 2 (AZA): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA 50mg/m² per day for days 1-5, every 28 days for up to 12 cycles or progression.~AZA -Azacitidine"
10020205|NCT04490707|No Intervention|Observation|Arm 3(Observation): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter observation.
10020206|NCT04489823|Experimental|Paravalvular Leak Closure|Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
10020207|NCT04489732|Experimental|Treatment with MSCs|A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia
10020208|NCT04489485||Primary Care Providers (PCP)|20 PCP who provide well child care to teens 12-18. After randomization, 10 PCPs in the enhanced care group will use the Teen Depression Module for care.
10020209|NCT04489485||Standard care teens|All teens coming for routine well child care to the control group PCPs will have routine depression screening and Youth Health Questionnaire without goals to inform treatment as usual. They will be offered a goals text messaging conversation. Suicide screening will be at the discretion of the PCP.
10020210|NCT04489485||Enhanced care teens|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, as well as Youth Health Questionnaire with goals and then they will receive treatment guided by the Teen Depression Module and offered a depression text messaging conversation. Suicide screening will be conducted.
10020211|NCT04489485||Standard care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the control group PCPs will complete a Pediatric Symptom Checklist and Short Moods and Feelings Questionnaire, plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
10020212|NCT04489485||Enhanced care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the enhanced group PCPs will complete a Pediatric Symptom Checklist plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
10020213|NCT04488913|Other|Standard of Care Treatment|Exposure to traditional evaluation for suspected acute coronary syndrome (ACS) with ECG, 0- and 3-hour troponin testing using the 99th percentile as the upper reference limit, and application of the History, EKG, Age, Risk factors, and troponin (HEART) score.
10020214|NCT04488913|Active Comparator|RACE-IT pathway|Exposure to new protocol for suspected ACS, which includes the use of 0- and 1-hour ECG and high-sensitivity troponin testing and application of the HEAR score (a modification of the HEART score)
10020215|NCT04487886|Experimental|Duvelisib|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive duvelisib for 14 days.
10020216|NCT04487886|Placebo Comparator|Placebo|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive a placebo to match duvelisib for 14 days.
10020217|NCT04487145|Experimental|HIV-infected children on EFV-based ART (E3)|30 HIV-infected children age 3 - 10 years on EFV-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
10020218|NCT04487145|Experimental|HIV-infected children on DTG-based ART (D3)|30 HIV-infected children age 11 - 17 years on DTG-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
10020219|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L1)|20 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take one oral dose DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
10020220|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L3)|30 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
10020221|NCT04487145|Active Comparator|HIV-uninfected children (C1)|20 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 1st dose. Control group for L1.
10020222|NCT04487145|Active Comparator|HIV-uninfected children (C3a)|30 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 3rd dose. Control group for E3 and L3.
10020223|NCT04487145|Active Comparator|HIV-uninfected children (C3b)|30 HIV-uninfected children age 11-17 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. Control group for D3.
9477392|NCT03562845||ARM 1-Bad vs Good Clinical Evolution|"This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:~Patients who, over previous months, have had a bad clinical evolution, in which rejection mechanisms were involved~Patients with a good and stable clinical evolution~IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences."
9477393|NCT03562845||ARM 2-Stable Renal Transplant Patients|This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
9477394|NCT03562819||NSCLC|Non-small cell lung cancer
9477395|NCT03562806|Experimental|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
9477396|NCT03562793|Experimental|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
9477397|NCT03562793|No Intervention|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
9477398|NCT03562780|Experimental|Fortolin Tab 500mg|During the study session, healthy subjects will be administered a single oral dose of Fortolin Tab 500mg after an overnight fast of approximately 10 hours.
9477399|NCT03562780|Active Comparator|Panadol Caplet 500mg|During the study session, healthy subjects will be administered a single oral dose of Panadol Caplet 500mg after an overnight fast of approximately 10 hours.
9477400|NCT03562754|Active Comparator|Control|
9477401|NCT03562754|Experimental|Prometheus System|
9477402|NCT03562741|Experimental|Fecal Microbiota Transplantation|Subjects receive intervention of stool transplanted to the colon via colonoscopy.
9477403|NCT03562715||Control group|Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.
9477404|NCT03562715||Preeclampsia group|Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
9477405|NCT03562702|Active Comparator|Standard IV Rehydration Therapy|Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
9477406|NCT03562702|Experimental|Oral Rehydration Therapy (ORT)|Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.
9477407|NCT03562676|Experimental|weightlessness|
9477408|NCT03562650|Experimental|Safety Behavior Fading|Participants are asked to pick their three most common safety behaviors from a list and then receive texts every other day for a month reminding them to fade those behaviors.
9477409|NCT03562650|Active Comparator|Present Centered|Participants receive texts every other day for a month asking them to try to focus on the present that day.
9477410|NCT03562624|Experimental|BAY98-7443 (low IND dose)|Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)
9477411|NCT03562624|Experimental|BAY98-7443 (middle IND dose)|Combi IUS Treatment, LNG with medium dose of IND
9477412|NCT03562624|Experimental|BAY98-7443 (high IND dose)|Combi IUS Treatment, LNG with highest dose of IND
9477413|NCT03562624|Active Comparator|Marketed comparator|Marketed comparator IUS
9477414|NCT03562611|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
9477415|NCT03562611|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
9477416|NCT03562611|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
10020224|NCT04486716|Experimental|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml) administered at baseline, Day 7, Day 14 and monthly thereafter
10020225|NCT04486170|No Intervention|Control group: Current hospital education practices|The control group will receive standard of care postpartum educational materials provided by the nursing and resident physician staff. The will be asked to complete a brief questionnaire to determine if they would be interested in receiving education in a video formal.
10036276|NCT01814189|Placebo Comparator|Sumatriptan+placebo (SP)|The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine.
10020226|NCT04486170|Experimental|Intervention group: Standardized video and pamphlet|The subjects enrolled in the invention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room. They will also be provided with a pamphlet with similar information that was discussed in the video. They will also be asked to complete a brief, anonymous survey to assess patient satisfaction with the video shown, no patient identifiers will be collected.
10020227|NCT04484935|Experimental|Nirsevimab|"1st RSV season: 50mg nirsevimab~st RSV season: 100mg nirsevimab~nd RSV season: 200mg nirsevimab"
10020228|NCT04484350|Experimental|Intensive Blood Pressure management|Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
10020229|NCT04484350|Active Comparator|Standard Blood Pressure management|Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
10020230|NCT04483479|Experimental|Active Treatment|Orally Administered ENT-01 25mg Tablet Once Daily (Dose dependent on ENT-01-030 dose level stratification)
10020231|NCT04482738||Lean subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
10020232|NCT04482738||Obese subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
10020233|NCT04482595|Experimental|BIO 300 Oral Suspension (genistein 1500 mg)|BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.
10020234|NCT04482595|Placebo Comparator|Placebo|BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.
10020235|NCT04482582|Experimental|Image-guided percutaneous ICN (pICN): Group A|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to percutaneous image-guided cryoneurolysis (pICN) group within 72 hours of presentation.
10020236|NCT04482582|Active Comparator|Standard-of Care : Group B|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to standard-of-care group within 72 hours of presentation.
10020237|NCT04481295|Active Comparator|High SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 94-96%, and a flow of 10 L/min).
10020238|NCT04481295|Active Comparator|Low SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 84-86%, and a flow of 10 L/min).
10020239|NCT04478994|Active Comparator|TEPEZZA 20mg/kg|Approximately 15 participants will receive 8 infusions of TEPEZZA q3W for a total of 21 weeks. TEPEZZA 10mg/kg will be administered on Day 1 and TEPEZZA 20mg/kg will be administered q3W for the remaining 7 infusions.
10020240|NCT04478994|Placebo Comparator|Placebo|Approximately 10 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
10020241|NCT04478578||Patients with febrile illness|Participants from approximately 650 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study.
10020242|NCT04477785||Clinical Observation|Up to 4500 participants will be followed clinically once identified, over the course of 5-8 years.
10020243|NCT04477330|Experimental|Priming+HIISTT|Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training
10020244|NCT04477330|Sham Comparator|Sham+HIISTT|Sham tDCS before high intensity interval speed based treadmill training
10020245|NCT04476901|Placebo Comparator|Genotype A administered with placebo Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.
10020246|NCT04476901|Experimental|Genotype A administered with hMSC Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.
10020247|NCT04476901|Placebo Comparator|Genotype B administered with placebo Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.
10020248|NCT04476901|Experimental|Genotype B administered with hMSC Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.
10020249|NCT04476901|Placebo Comparator|Genotype C administered with placebo Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.
10020250|NCT04476901|Experimental|Genotype C administered with hMSC Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.
10020251|NCT04476433|No Intervention|Control Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group).
10020252|NCT04476433|Experimental|Experimental Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 months of this evaluation the treatment program will be started. In the first contact session at 6 months after T1 all subjects (patients and relatives) will be re-evaluated (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 5 months). After the completion of the patient and family treatment sessions, a new diagnostic test pass will be performed (T3) (within an estimated maximum period of 15 days from the completion of treatment) in order to evaluate the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 months.
10020253|NCT04472468|Experimental|Treatment (pericardiotomy)|"Patient in this arm will receive balloon pericardiotomy before insertion of pericardiocentesis.~An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is used to dilate the pericardium.~Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.~Standard pericardiocentesis with prolonged drainage is performed afterwards.~Pericardial drain is removed when output is less than 100cc/day"
10020254|NCT04472468|No Intervention|Control (standard pericardiocentesis)|"Standard pericardiocentesis procedure is performed using standard pigtail pericardial drain. - Pericardial fluid is then tapped until dry on table.~Pericardial drain is removed when output is less than 100cc/day"
9477417|NCT03562585||Efficacy of immunoassay in liver fibrosis|efficacy of immunoassay in liver fibrosis in patients with CHB
10020255|NCT04471428|Experimental|Atezolizumab + Cabozantinib|Participants will receive atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on days 1-21 of each cycle.
10020256|NCT04471428|Active Comparator|Docetaxel|Participants will receive docetaxel on Day 1 of each 21-day cycle.
10020257|NCT04469842|Experimental|Immunosuppression with Extended-Release Tacrolimus|"LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
10020258|NCT04469842|Active Comparator|Immunosuppression with Intermediate Release Tacrolimus|"IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
10020259|NCT04469517||HHT|patients with HHT
10020260|NCT04469517||control|persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives
10020261|NCT04465201|Experimental|Subjects receiving the Impella/Impella® Hemodynamics platform|
10020262|NCT04464668||Wave 1 Only: Clinics using CARES Intervention|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics to implement the Colorectal Cancer Awareness, Research, Education & Screening (CARES) intervention.
10020263|NCT04464668||Wave 1 Only: Control Clinics|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics as control (usual care) clinics.
10020264|NCT04464668||All Clinics|For Wave 2, the 7 clinics in the control group will roll out as intervention clinic, thus, all 14 clinics will be exposed to the intervention by year 2.
10020265|NCT04464577|Experimental|Arm A: BMS-986235+Fluconazole|
10020266|NCT04464577|Experimental|Arm B: BMS-986235+ Bupropion|
10020267|NCT04464577|Experimental|Arm C: BMS-986235+ Itraconazole|
10020268|NCT04464187||Participants exposed to Elagolix-containing products|Pregnant participants exposed to Elagolix from 14 days after last menstrual period (LMP) or at any point during pregnancy.
10020269|NCT04464187||Participants not exposed to Elagolix-containing products|Pregnant participants with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of Elagolix-containing products not exposed to Elagolix from 14 days after LMP or at any point during pregnancy.
10020270|NCT04460924||MSM HIV-uninfected and ART naïve|Men who have sex with men without HIV infection, not receiving ART
10020271|NCT04460924||MSM HIV-infected starting ART|Men who have sex with men with HIV infection, starting ART
10020272|NCT04460924||MSM HIV-infected on ART with >500 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with >500 CD4 T cells/uL
10020273|NCT04460924||MSM HIV-infected on ART with <350 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with <350 CD4 T cells/uL
10020274|NCT04460924||MSM HIV negative patients starting PEP with INST|Men who have sex with men without HIV infection, starting post-exposure prophylaxis with raltegravir
10020275|NCT04459650|Experimental|Female Breast Cancer Pts|Participants include female breast cancer patients who either receive endocrine therapy and suffer from endocrine induced alopecia or suffer from post chemotherapy induced alopecia.
10020276|NCT04457622|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses
10020277|NCT04457271|Experimental|Goal Management Training (GMT)|Participants in this arm will attend 9 weekly, 2-hour group GMT appointments.
10020278|NCT04457271|No Intervention|Wait List|Participants in this arm will receive no treatment for approximately 21 weeks (at which point, they will be offered the same, standard GMT treatment).
10020279|NCT04454957|Experimental|Mastering Diabetes|Adults (hospital employees, their spouses, and community members) who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
10020280|NCT04454957|No Intervention|Usual care|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen not to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
10036277|NCT01814202|Experimental|PTM202|PTM202 is a medical nutrition product
10020281|NCT04454229|Experimental|Direct oral antibiotic challenge|Direct oral antibiotic (penicillin) challenge in patients with PEN-Fast less than 3.
10020282|NCT04454229|Active Comparator|Standard of care|Standard of care: skin testing and, if negative, oral challenge.
10020283|NCT04453709|Experimental|Problem Management Plus for Immigrants at family settings|PMP-I intervention aims to develop skills in coping adaptively in a new culture, seeking help and support for mental health problems, and other life skills opportunities that can help to improve their quality of life. PMP-I intervention includes stress management through breathing exercises and yoga, problem solving, behavioral activation, and skills to strengthen social support.
10020284|NCT04453709|Active Comparator|Talk program with Community Support Service Pamphlet (CSS)|Family receives pamphlet including list of community support service institutions that provide various health and well-being services.
10020285|NCT04453384|Experimental|Treatment arm|"Administrations of XAV-19~Phase 2a: XAV-19 at 0.5 mg/kg at D1 and D5(Group 1) or at 2 mg/kg at D1 and D5 (Group 2), or at 2 mg/kg at D1 (groupe 3)~Phase 2b: Selected dose from Phase 2a : one administration at 2 mg/kg on day1"
10020286|NCT04453384|Placebo Comparator|Placebo arm|"same administration as treatment arm~Phase 2a: two administrations of placebo (day 1 and day 5) for Group 1 and 2, one administration of placebo on day 1 for Group 3~Phase 2b: one administration of placebo on day 1"
10020287|NCT04451213|Experimental|experimental|
10020288|NCT04451044|Experimental|physiologically-guided arm|Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
10020289|NCT04451044|Active Comparator|angiographically-guided arm|Standard of care angiographically-guided PCI for determining the PCI strategy
10020290|NCT04449055|Experimental|Study arm|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TBS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use.
10020291|NCT04448938||optic neuritis|
10020292|NCT04448938||control|
10020293|NCT04445454|Experimental|MSC therapy for severe COVID-19 infection|After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.
10020294|NCT04444453|Experimental|Pedometer|Admitted patients who receive a pedometer to wear during their hospital stay to measure steps ambulated
10020295|NCT04444453|No Intervention|Control|Patients admitted to hospital who do not receive a pedometer, but receive all other usual standard of care
10020296|NCT04440774|Experimental|CHIK low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020297|NCT04440774|Experimental|CHIK mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020298|NCT04440774|Experimental|CHIK high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020299|NCT04440774|Experimental|ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020300|NCT04440774|Experimental|ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020301|NCT04440774|Experimental|ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020302|NCT04440774|Experimental|CHIK ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020303|NCT04440774|Experimental|CHIK ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020304|NCT04440774|Experimental|CHIK ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020305|NCT04440774|Placebo Comparator|Placebo|Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
10020306|NCT04435990|Experimental|Experimental:10,000 MM09|10,000 TU/mL of subcutaneous immunotherapy
10020307|NCT04435990|Experimental|Experimental: 30,000 MM09|30,000 TU/mL of subcutaneous immunotherapy
10020308|NCT04435990|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without any active ingredients.
10020309|NCT04434768|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke.
10020310|NCT04433975|Experimental|Psychosocial Pain Management (PPMI)|Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
10020311|NCT04433975|Active Comparator|Enhanced Usual Care (EUC)|Two individual telephone educational sessions with research study therapist.
10020312|NCT04433520||ASD/PFO cohort|Subjects indicated for atrial septal defect (ASD) closure with either the ASO or ASD-MF devices as well as subjects indicated for patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder.
10020313|NCT04433520||VSD cohort|Subjects indicated for ventricular septal defect (VSD) closure with either the MuscVSD or PIVSD occluders.
10036278|NCT01814202|Placebo Comparator|Placebo|The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor
10036279|NCT01814215|Experimental|Healthy Lifestyles Group|The Experimental Arm will receive the Keys to Healthy Family Child Care Homes intervention to be delivered over 9 months in 3 modules (3 months/module). The intervention group will be asked to participate in 3 workshops on 3 content areas. Participants will be asked to meet with a coach 3 times in-person, as well 3-9 times by phone/email, over the course of the 9-months. Three content areas are designed to help providers:(1) modify their own weight-related behaviors so they can role model healthy behaviors for children in their care (Healthy You module), (2) create environments that support children's physical activity and healthy dietary intakes (Healthy Home module), and (3) adopt sound business practices that will help them sustain the changes introduced (Healthy Business module).
10036280|NCT01814215|Placebo Comparator|Healthy Business Group|The Control Arm will receive the Healthy Business Education and Coaching program to be delivered over 9 months in 3 modules (3 months/module). The control group will be asked to participate in 3 workshops and a similar number of coaching contacts about their business practices. The focus on business topics is relevant, but not directly related to physical activity or nutrition.
10036281|NCT01814228|Experimental|right atrium ganglionated plexi transcatheter ablation|right atrium ganglionated plexi transcatheter ablation
10037473|NCT01825369|Experimental|IV L-carnitine|L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose ~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
10037474|NCT01825382|No Intervention|Accu-chek Meter|Patients receiving the Accu-chek nano meter for use during the study.
10037475|NCT01825382|Experimental|iBGStar meter interventional Arm|Subjects are given iBGstar meter along with iPhone to use as interventional meter.
10037476|NCT01825421|No Intervention|Control (continue antibiotics) group|The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
10037477|NCT01825421|Active Comparator|Study (discontinue antibiotics) group|The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.
10037478|NCT01825434|Active Comparator|Treatment Group|yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
10037479|NCT01825434|Placebo Comparator|Placebol group|regular yogurt, 1 time per day for 30 days.
10037480|NCT01825447|Placebo Comparator|Treatment A|
10037481|NCT01825447|Experimental|Treatment B|
10037482|NCT01825447|Active Comparator|Treatment C|
10037483|NCT01825460|Experimental|Manual Therapy Protocol|A protocol with five techniques on thoracic area applied twice a week.
10037484|NCT01825460|Active Comparator|Two manual techniques|Two manual therapies on thoracic area applied twice a week.
10037485|NCT01825473|Experimental|Erythromycin|50 mg/kg/day divided every 6 hours oral for 7 days
10037486|NCT01825473|Placebo Comparator|Placebo|Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
10037487|NCT01825486||accidental falls|
10037488|NCT01825499||Very low birth weight infants|Infants 401 to 1500 g or 22 to 29 weeks gestational age admitted to Vermont Oxford Network member centers within 28 days of birth
10037489|NCT01825525|Experimental|Cardiac device patients.|Exposure to ScopeGuide - patients with cardiac devices exposed to ScopeGuide as per study protocol
10037490|NCT01825538||COPD, pulmonary fibrosis|observational study, no interventions to be administered
10037491|NCT01825551|Active Comparator|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously
10037492|NCT01825551|Placebo Comparator|Placebo|normal saline 0.01 ml/kg/day for 5 days subcutaneously
10037493|NCT01825590||Subjects undergoing sodium alignment|Dialysate and serum sodium concentration aligned
10020314|NCT04430855|Experimental|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A for 12 weeks (Period 1) followed by Upadacitinib Dose A for 36 weeks (Period 2).
10020315|NCT04430855|Experimental|Placebo followed by Upadacitinib Dose B|Participants will receive placebo for 12 weeks (Period 1) followed by Upadcitinib Dose B for 36 weeks (Period 2).
10020316|NCT04430738|Experimental|Cohort 1A|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
10020317|NCT04430738|Experimental|Cohort 1B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
10020318|NCT04430738|Experimental|Cohort 1C|Tucatinib + trastuzumab + CAPOX given in 21-day cycles
10020319|NCT04430738|Experimental|Cohort 1D|Tucatinib + trastuzumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles and trastuzumab given every 21 days
10020320|NCT04430738|Experimental|Cohort 1E|Tucatinib + trastuzumab + pembrolizumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles, trastuzumab given in 21-day cycles, and pembrolizumab given in 42-day cycles
10020321|NCT04430738|Experimental|Cohort 1F|Tucatinib + trastuzumab + pembrolizumab + CAPOX. Tucatinib, trastuzumab, and CAPOX given in 21-day cycles and pembrolizumab given in 42-day cycles.
10020322|NCT04430738|Experimental|Cohort 1G|Tucatinib + trastuzumab + pembrolizumab. Tucatinib and trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
10020323|NCT04430738|Experimental|Cohort 2A|Tucatinib + trastuzumab + pembrolizumab + (FOLFOX or CAPOX). Either (1) tucatinib and FOLFOX given in 14-day cycles or (2) tucatinib and CAPOX given in 21-day cycles. Trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
10020324|NCT04430738|Experimental|Cohort 2B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles.
10020325|NCT04430517|Experimental|Mild Cognitive Impairment and Alzheimer's Dementia|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
10020326|NCT04427397|Experimental|Sulcular Bristle Tip Technique (SBTT)|This test group will receive formal instruction on the Sulcular Bristle Tip Technique (SBTT).
10020327|NCT04427397|No Intervention|User manual of the electric toothbrush (DFU)|This control group will be asked to read and use the instructions found in the user manual of the electric toothbrush (DFU). No formal instruction will be provided. The DFU accompany the electric toothbrush regardless of the subject's participation in the research.
10020328|NCT04424030||Multimodality imaging|Patients who have undergone echocardiography and cardiac MRI as part of their clinical management A research cardiac CT scan will be performed in eligible participants
10020329|NCT04422912|Experimental|DSG3-CAART|"Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (4-5 groups) administered as a single cycle.~Cohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (2 groups) administered as a single cycle.~Cohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle"
10020330|NCT04421963|Experimental|Olaparib|Treatment
10020331|NCT04421690|Experimental|Cognitive Training|8 week computerized cognitive training
10020332|NCT04421690|Active Comparator|Trivia Training|8 week computerized trivia training
10020333|NCT04421027|Experimental|Baricitinib + Standard of Care (SOC)|4 milligrams (mg) of baricitinib (given as two 2 mg tablets) administered orally every day (QD) with standard of care.
10020334|NCT04421027|Placebo Comparator|Placebo + SOC|Placebo (given as two placebo tablets) administered orally QD with standard of care.
10020335|NCT04419909|Experimental|Retreatment with CTL019/CTL119|All subjects will receive retreatment with CTL019/CTL119 and be followed per the schedule of procedures.
10020336|NCT04418362|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home 4-6 times per week for 8 weeks. Each session consists of 6 blocks of 5 minute training with a one minute rest period between each block.
10020337|NCT04417361|Experimental|Galcanezumab|The galcanezumab arm will self-administer a subcutaneous injection of galcanezumab. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of galcanezumab 120 mg. The injections will be with a pre-loaded syringe containing galcanezumab.
10020338|NCT04417361|Placebo Comparator|Placebo|The placebo arm will self-administer a subcutaneous injection of placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of placebo 120 mg. The injections will be with a pre-loaded syringe containing placebo.
10020339|NCT04417231|Experimental|Apheresis group|"10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts within 72 hours after infarction or, in case of an unclear time window, within presumed 72 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is <10 mg/l or if the patient has been discharged from hospital.~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours."
10020340|NCT04417231|No Intervention|Control group|10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.
10020341|NCT04417036|Experimental|Part A - Active Drug Dose 1|Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A
10020342|NCT04417036|Experimental|Part A - Active Drug Dose 2|Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A
10020343|NCT04417036|Placebo Comparator|Part A - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part A
10020344|NCT04417036|Experimental|Part B - Active Drug Dose|Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B
10020345|NCT04417036|Placebo Comparator|Part B - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part B
10020346|NCT04416867|Active Comparator|group-1 splint and home exercise|Patients in group 1 will be treated with splinting of the affected hand at night and a home exercise program. A wrist orthosis which held the wrist in the neutral position will be used for splinting at night time for a minimum of eight hours. Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
10020347|NCT04416867|Active Comparator|group 2 RESWT|Patients in group 2 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and a total of 3 sessions of RESWT at a frequency of one session per week using the Masterpuls ® mp200 radial shock wave therapy system (Elite-Storz Medical AG, Kreuzlingen, Switzerland). RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
10020348|NCT04416867|Active Comparator|group 3 physical therapy|Patients in group 3 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and two and 20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks.
10020349|NCT04415996|Experimental|HVLA L3/4 Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform the HVLA technique in L3/L4 joint articulation.~Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
10020350|NCT04415996|Sham Comparator|Control Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform a Sham technique. Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
10020351|NCT04415047|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System Intervention Device: JenaValve Pericardial TAVR System
10020352|NCT04414618|Active Comparator|opaganib|Study participants will receive opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
10020353|NCT04414618|Placebo Comparator|placebo|Study participants will receive placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
10020354|NCT04413097|Active Comparator|DCC and Low Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 .30, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
10020355|NCT04413097|Experimental|DCC and High Oxygen Concentration|During 90 seconds of delayed cord clamping, the infant will receive gentle stimulation and start CPAP by 30 seconds of life at an FiO2 1.0, with CPAP of 5 cmH20. If the infant is apneic or there is no Pedicap color change the team will begin positive pressure ventilation (starting PIP of 20 cmH20) by 60 seconds of life. The infant will remain on this support up until the umbilical cord is clamped at 90 seconds or greater. Once the cord is clamped the infant resuscitation will continue according to unit protocol.
10020356|NCT04412824|Active Comparator|Alcohol Beverage Cues|Participants will complete an MRI with alcohol beverage visual cues and oral alcohol session.
10020357|NCT04412824|Placebo Comparator|Non-Alcoholic Beverage Cues|Participants will complete an MRI with non-alcoholic beverage cues and oral alcohol session.
10020358|NCT04412369||Study group|Patients with COVID-19 and cardiac Troponin elevation
10020359|NCT04412057|Experimental|CERC-002|
10020360|NCT04412057|Placebo Comparator|Placebo|
10020361|NCT04409236|Experimental|Arm I (Quit2Heal app)|Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
10020362|NCT04409236|Active Comparator|Arm II (QuitGuide app)|Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
10020363|NCT04408807|Experimental|Study Group|ROPEE screening with speculum-free fundoscopy
10020364|NCT04408807|Active Comparator|Control Group|ROPEE screening with speculum fundoscopy
10020365|NCT04408677|Experimental|Normative data|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye
10020366|NCT04408677|Experimental|Repeatability|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye. After a 15 to 30 minutes break, same measurements repeated.
10020367|NCT04408677|Experimental|Inter-eye variability|Ocular oxygen saturation non-invasively measured at 3 eye fundus locations in the participant's right eye. After a 15 to 30 minutes break, same measurements repeated in the left eye.
10020368|NCT04408482|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy performed in difficult cannulation
10020369|NCT04408482|Active Comparator|Pancreatic sphincterotomy + pancreatic stent|Pancreatic sphincterotomy performed in difficult cannulation + pancreatic stent placement
10020370|NCT04405739|Experimental|EIDD-2801 twice daily (BID) for 5 days|EIDD-2801 orally twice daily (BID) for 5 days at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
10020371|NCT04405739|Placebo Comparator|placebo (PBO) twice daily (BID) for 5 days|Placebo (PBO) orally twice daily (BID) for 5 days matched for size and appearance to active IP
10020372|NCT04405115|No Intervention|No intervention arm|routine care only; will not be scheduled for comprehensive geriatric assessment
10020373|NCT04405115|Active Comparator|Active comparator arm|those that will be scheduled for comprehensive geriatric assessment with a geriatric nurse practitioner or physician
10020374|NCT04402658|Experimental|Physical performance test|After performing measurements of lung function by spirometry, participants will inhale either salbutamol or placebo. After 15 minutes of rest, a second spirometry will be performed before the participants warm-up by 10 minutes cycling. The exercise protocol will consist of 60 minutes of cycling at 70% of maximal oxygen consumption (VO2max) on the cycle ergometer followed by an all-out sprint. Several times during the exercise test, 30-second Wingate tests will be conducted. Participants will be blinded to feedback such as power (W), distance covered, and heart rate. Strong verbal encouragement will be given to each participant for them to perform their best. Measurements of lung function (spirometry), heart rate, arterial oxygen saturation and Borg ratings of perceived exercising will be recorded throughout the trials, as well as capillary blood sampled for analysis of [La-] and [Glucose].
10020375|NCT04402060|Experimental|180 mg APL-9 IV plus SOC|
10020376|NCT04402060|Placebo Comparator|Isotonic saline plus SOC|
10020377|NCT04399993|Experimental|Intervention Protocol in Diaphragm|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the intervention protocol in Diaphragm. Then, all the measurements described before, will be repeated by the assessor right after the technique."
10020378|NCT04399993|Sham Comparator|Sham Technique|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the Sham technique. Then, all the measurements described before, will be repeated by the assessor right after the technique."
10020379|NCT04398368|Experimental|Prevention (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU.
10020380|NCT04398160|Experimental|HVLA manipulation|"In the intervention of the experimental group, the investigator will be primarily on the right side of the volunteer and identify C3 through the cervical reference of jaw angle, which is at the disc level between C2/C3 and then contact with the phalanges of third metacarpal in the left transverse of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
10020381|NCT04398160|Sham Comparator|Sham technique|"The investigator will be primarily on the right side of the volunteer and identify the C3 vertebra, having as anatomical reference the angle of the jaw, which is at the disc level between C2/C3 and then contact, with the phalanges of the third metacarpal, the left transverse apophysis of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
10020382|NCT04398160|No Intervention|No intervention group|The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally.
10020383|NCT04396626||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
10020384|NCT04393766|Experimental|normal saline|
10020385|NCT04393766|Placebo Comparator|non normal saline|
10020386|NCT04391777|Experimental|CV-4 group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The CV-4 technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
10020387|NCT04391777|Sham Comparator|Control group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The sham technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
10020388|NCT04391179|Experimental|Dipyridamole 100 Milligram(mg)|100 milligrams (mg) by mouth (PO) four times a day (QID)
10020389|NCT04391179|Placebo Comparator|Placebo|Placebo given by mouth four times a day
10020390|NCT04388228|Experimental|Extended audit and feedback|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~A low cognitive load of the feedback where the results will be presented with the help of graphs.~Action plans to improve the quality of registration~A push system to minimize the effort the GP must make to consult the feedback."
10020391|NCT04388228|Active Comparator|Basic feedback|In the past, all GPs received basic feedback on the level of registration in the EHR and this form of feedback will still be provided in the control group. By providing all GPs a basic level of feedback, we do not change the former protocol and all GPs will receive the opportunity to improve their registration performance. Only the way of receiving feedback is more straightforward, the GP needs to login to HealthStat.be.
10020392|NCT04387656||Observational Cohort (data collection, biospecimen collection)|Patients undergo collection of medical information about COVID-19 symptoms, treatments/cancer treatments and outcomes, and results from laboratory tests and imaging scans performed as part of routine care for up to 2 years. Patients also undergo collection of blood samples at the same times they receive routine bloodwork up to 9 times for adults and up to 6 times for children. Patients who are hospitalized for COVID-19 undergo collection of blood samples at up to 6 additional times for adults and up to 3 additional times for children. Adult patients also complete quality of life questionnaire.
10020393|NCT04387227|Experimental|Treatment (carboplatin, pembrolizumab)|Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
10020394|NCT04387110||Ocrelizumab|Women receiving treatment for multiple sclerosis with ocrelizumab infusion between 2 and 36 weeks postpartum.
10020395|NCT04386304|Experimental|Dose escalation of (+)-epicatechin|Subjects will receive escalating doses of (+)-epicatechin starting at 75 mg/day and progressing to 150 mg/day and 225 mg/day with 2 months treatment duration for each dose. Subjects will continue treatment on the individual's maximum tolerated dose for another 6 months.
10020396|NCT04386096|Experimental|Mehealth for ADHD software with medication continuity tools|
10020397|NCT04386096|Active Comparator|Mehealth for ADHD software with no medication continuity tools|
10020398|NCT04385732|Experimental|Standard of Care plus Melanoma Surveillance Photography|Clinical surveillance standard of care with addition of 2D or 3D Melanoma Surveillance Photography and digital dermoscopy.
10020399|NCT04385732|No Intervention|Standard of Care|Clinical surveillance standard of care without Melanoma Surveillance Photography.
10020400|NCT04382911|Experimental|18F-fluoroestradiol PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
10036282|NCT01814254||Receiving hemodialysis|
10036283|NCT01814267|Experimental|Telemedicine|care and follow-up through telemedicine.
10020401|NCT04381169|Experimental|Aggressive fluid resuscitation|"Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h.~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours"
10020402|NCT04381169|Experimental|Moderate fluid resuscitation|"At recruitment:~A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h.~B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus).~At 12(±4) hours:~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours~Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours"
10020403|NCT04376827|Experimental|Guselkumab+Standard of Care|Participants will receive guselkumab Dose 1 intravenously (IV) at Weeks 0, 4 and 8 and guselkumab Dose 2 subcutaneous (SC) every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Participants who complete the assessments at Week 52 and have achieved complete renal response (CRR) may have the option to participate in the long-term extension (LTE).
10020404|NCT04376827|Placebo Comparator|Placebo+Standard of Care|Participants will receive placebo IV at Weeks 0, 4 and 8 and placebo SC q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Participants who complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
10020405|NCT04376684|Experimental|Part 1: Participants receiving otilimab|Participants (age >=18 years and <=79 years) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 1.
10020406|NCT04376684|Placebo Comparator|Part 1: Participants receiving placebo 1|Participants (age >=18 years and <=79 years) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 1.
10020407|NCT04376684|Experimental|Part 2: Participants receiving otilimab|Participants (age 70 years or above) will receive a single dose of otilimab administered as an IV infusion in addition to standard of care in Part 2.
10020408|NCT04376684|Placebo Comparator|Part 2: Participants receiving placebo 2|Participants (age 70 years or above) will receive a single dose of matching placebo administered as an IV infusion in addition to standard of care in Part 2.
10020409|NCT04375683|Experimental|Ph-positive ALLs|Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen. Subjects younger than 60 years are received flumatinib and hyper-CVAD regimen
10020410|NCT04375631|Experimental|Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)|"Patients receive filgrastim SC daily on days -9 to -4, cladribine IV over 2 hours daily on days -8 to -4, cytarabine IV over 2-4 hours daily on days -8 to -4, and mitoxantrone IV daily on days -8 to -6. If WBC > 20,000/uL, filgrastim on days -9 and -8 may be omitted at physician discretion. Patients undergo TBI and HCT on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours daily on days 3-4, cyclosporine IV over 1-2 hours BID on days 5-60, and mycophenolate mofetil IV or PO BID on days 5-28 (transplant with related donors) or TID on days 5-35 (transplant with unrelated donors). After day 60, patients continue to receive cyclosporine tapered through day 180 at the discretion of the treating physician in the absence of GVHD."
10020411|NCT04373603|Experimental|Intervention: HA plus TXA|HA will be diluted with TXA using a Leur-Lok hub in a ratio of 1.0 mL HA filler to 0.2 mL TXA (100mg/mL)
10020412|NCT04373603|Placebo Comparator|Control: HA plus Saline|HA will be diluted with saline in a ratio of 1.0 mL HA filler to 0.2 mL saline
10020413|NCT04372940|Experimental|Intervention Side: TXA Irrigation|2.5% tranexamic acid will be applied directly to the wound via bulb irrigation and left in place for 5 minutes in the wound bed
10020414|NCT04372940|Placebo Comparator|Control Side: Saline Irrigation|Contralateral side will serve as a control
10020415|NCT04372329|Experimental|CPAP4HealthySleep: System 1 (ABAB)|Participants in this group will first receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A). Next, they will receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B), re-introduction of type A for another two weeks, followed by re-introduction of type B for two weeks.
10020416|NCT04372329|Experimental|CPAP4HealthySleep: System 2 (BABA)|Participants in this group will first receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B). Next, they will receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A), re-introduction of type B for another two weeks, followed by re-introduction of type A for two weeks.
10020417|NCT04370704|Experimental|Phase 1 Part 1|Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
10020418|NCT04370704|Experimental|Phase 1 Part 2|Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
10020419|NCT04370704|Experimental|Phase 2|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
10020420|NCT04368832||Experimental group|During prenatal monitoring, at least one consultation by remote consultation (phone or teleconsultation)
10020421|NCT04368832||Control group|"Prenatal monitoring by face-to-face consultations adapted to confinement (absence of clinical signs or notion of travel, occupation, contact, clustering (TOCC), no attendant, limited movements inside the hospital and precautions of droplet and contact type)"
10020422|NCT04367987||Patients undergoing colorectal surgery|
10020423|NCT04367116|Experimental|spinal cord stimulation|the spinal cord stimulation was performed and operated
10020424|NCT04366219||2019|Data collection on patients with Lung cancer diagnosed between March 13, 2019 and August 28, 2019.
10020425|NCT04366219||2020|Data collection on patients with Lung cancer diagnosed between March 13, 2020 and August 28, 2020.
10020426|NCT04363905|Placebo Comparator|Placebo|100 mg lactose capsule
10020427|NCT04363905|Experimental|Ferrous sulfate|20 mg ferrous sulfate and lactose capsule
10020428|NCT04362891|Experimental|Juvéderm®|Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
10020429|NCT04362891|Experimental|Restylane®|Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
10020430|NCT04362891|Experimental|Belotero®|Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
10020431|NCT04362891|Experimental|Stylage®|Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 2-week follow-up).
10020432|NCT04362475|Active Comparator|Family Youth Intervention (FYI)|The primary objective of FYI is to evaluate the effectiveness of a theory-based, peer-supported family strengthening intervention on the primary outcomes in a sample of 120 parent-child pairs living in resource-poor urban neighborhoods in Birmingham. For FYI, we will utilize community health advisors (CHAs) to implement the intervention. CHAs will be recruited from each FYI neighborhood and will be trained in research ethics. CHAs will assist and support FYI participants in mastering the sequential skills of the 12 modules designed to improve maternal, youth, and family functioning. Additionally, CHAs will provide emotional social support that is helpful, hopeful, and trustful.
10020433|NCT04362475|Active Comparator|ESPI Environment: Social and Physical Intervention (ESPI)|ESPI will enroll 500 community members to examine the effect of blight elimination through lot recovery on primary outcomes of improved social interaction, social cohesion around common neighborhood norms, and collective efficacy to effect change in the neighborhoods . Neighborhood residents will select a cluster of lots (2-3) for lot recovery that are highly visible in the neighborhood (e.g. on a main thoroughfare). The community residents will lead the neighborhood projects. In some cases, neighborhood residents will personally undertake all or part of the greening projects.
10020434|NCT04362475|Other|Wait-List Control|The two communities will get ESPI, upon completion of the study.
10020435|NCT04362475|Active Comparator|FYI and ESPI|Two of the eight neighborhoods will receive both FYI and ESPI intervention.
10020436|NCT04362150||COVID-19 positive, recovered|Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).
10020437|NCT04360720|No Intervention|Dual Antiplatelet Therapy|"Subjects randomized to Dual Antiplatelet Therapy Control Group will be treated with a regimen of acetylsalicylic acid combined with ticagrelor or prasugrel for 12 months.~Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)"
10020438|NCT04360720|Experimental|Antiplatelet Monotherapy|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone for 12 months.~Ticagrelor alone (90 mg twice daily) Or Prasugrel alone (10 mg once daily)"
10020439|NCT04359784|Experimental|Prevention (anakinra, lisocabtagene maraleucel)|Patients receive anakinra SC daily on days 0-13 and lisocabtagene maraleucel via infusion on day 0.
10020440|NCT04357821|Experimental|Combination intervention arm|All volunteers will receive the combination intervention outlined above.
10020441|NCT04356742|Experimental|Dapagliflozin 10mg + Evogliptin 5mg + Metformin|
10020442|NCT04356742|Placebo Comparator|Dapagliflozin Placebo + Evogliptin 5mg + Metformin|
10020443|NCT04355780||Subgroup 1|Composed of HCT patients with respiratory failure requiring intubation and mechanical ventilation.
10020444|NCT04355780||Subgroup 2|Composed of oncology patients (solid tumor or leukemia patients) who have not undergone HCT and who have respiratory failure requiring intubation and mechanical ventilation.
9480733|NCT05261594|Other|Healthy controls|Participants will be randomized to start with either the caffeine condition or placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
10020445|NCT04355780||Subgroup 3|Composed of chimeric antigen T-cell receptor infusion recipients who have respiratory failure requiring intubation and mechanical ventilation.
10037494|NCT01825590||Subjects not undergoing sodium alignment|Dialysate and serum sodium concentration not aligned
10020446|NCT04353297|Experimental|BCI Group|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
10020447|NCT04353297|Active Comparator|Control Group|MI training without BCI support delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
10020448|NCT04353284|Experimental|Camostat mesylate|Camostat mesylate 200mg taken 7 days.
10020449|NCT04353284|Placebo Comparator|Placebo|Placebo taken for 7 days.
10020450|NCT04350892|Active Comparator|Roux-en-Y Gastric Bypass Surgery|
10020451|NCT04350892|Active Comparator|Sleeve Gastrectomy Surgery|
10020452|NCT04350892|Active Comparator|Very Low Calorie Diet|
10020453|NCT04349358|Other|FDG and FCH PET/CT|
10020454|NCT04348864|Experimental|Positive-Antigen swab test for SARS-COV-2|Subjects who have tested positive for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular test from nasal pharyngeal self-swab or a swab administered in a clinical setting at the point of care by a trained clinician. Parallel PCR-based testing occurs in an advanced laboratory to obtain Ct values for positive test results.
10020455|NCT04348864|Sham Comparator|Negative-Antigen swab test for SARS-COV-2|Subjects who have tested negative for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular nasal pharyngeal self-swab or a swab administered in a clinical setting by a trained clinician. PCR-based testing occurs in an advanced laboratory.
10020456|NCT04345367|Experimental|Abrocitinib 200 mg plus placebo injection|Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
10020457|NCT04345367|Active Comparator|Dupilumab 300 mg plus placebo tablets|Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26
10020458|NCT04344262|Active Comparator|control (C) group|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
10020459|NCT04344262|Experimental|minimal dose (M) group|"Intubating dose of muscle relaxant will be 0.2 mg/kg will be injected~boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal."
10020460|NCT04342390|Experimental|Exercise Group|Study participants in this group will be asked to complete 4 weeks of high-intensity interval training (HIIT).
10020461|NCT04342390|No Intervention|Control Group|Study participants in this group will not undergo HIIT exercise training during this study.
10020462|NCT04339621||Treatment Naive|20 patients with AIH will be recruited that will be treatment naive at the time of recruitment.
10020463|NCT04339621||Treatment cessation review|77 AIH patients will be recruited who will have been on treatment for the past 18-24 months and will be coming in to meet their physician to review treatment cessation options
10020464|NCT04339374||Ex vivo imaging|"Patients with known adenomatous polyps or malignancies in the colon or rectum undergoing resection will be considered for enrollment~Participation will include imaging of both normal and known pathologic portions of the specimen ex vivo immediately following resection. The specimen will then undergo fixation and standard pathologic evaluation, with subsequent correlation between imaging and pathologic findings.~This data will also be used to develop a convolutional neural network (CNN) to assist in interpreting photoacoustic imaging data."
10020465|NCT04339374||In vivo imaging|"Patients with distal rectal lesions (benign or malignant tumors within 15cm of the anal verge) will be enrolled for the in vivo imaging portion of the study~Participation will include an intraoperative, in vivo evaluation of the tumor with a novel endorectal photoacoustic ultrasound probe as well as ex vivo imaging post-resection as described above. Following the induction of anesthesia, patients will undergo a 20 minute endorectal imaging evaluation performed by their colorectal surgeon. After imaging, the patient will then undergo standard-of-care surgical resection of the rectum. The resection specimen will then be imaged ex vivo as performed in the ex vivo cohort of this study.~For this portion of the pilot, enrollment will be limited to 40 participants"
10020466|NCT04338100||Chest Ultrasound|Only one arm, all included patients having chest ultrasonography.
9480734|NCT05261581|Experimental|Intervention|Patients that will get ESPB, NSAID and exercise programme
10020467|NCT04337619|Experimental|Standard Behavioral Weight Loss Treatment|
10020468|NCT04337619|Experimental|Behavioral + Mindful Acceptance|
10020469|NCT04337619|Experimental|Behavioral + Values|
10020470|NCT04337619|Experimental|Behavioral + Mindful Awareness|
10020471|NCT04337619|Experimental|Behavioral + Acceptance + Values|
9480735|NCT05261581|Active Comparator|Control|Patients that will only get NSAID and exercise programme
10020472|NCT04337619|Experimental|Behavioral + Acceptance + Awareness|
10020473|NCT04337619|Experimental|Behavioral + Values + Awareness|
10020474|NCT04337619|Experimental|Behavioral + Acceptance + Values + Awareness|
10020475|NCT04337203|Experimental|SHARE-S|Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.
10020476|NCT04335799|Experimental|Weight Loss Plus Stress Management|Diabetes Prevention Program Intensive Lifestyle Intervention augmented with stress management training
10020477|NCT04335799|Active Comparator|Weight Loss Only|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics
10036284|NCT01814267|Active Comparator|Conventional care|care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)
10020478|NCT04332783||Healthy Typical Adults|Observers including radiologists and non-radiologists will be asked to participate in computer based tasks in which they visually search for, detect, localize, and categorize tumors in x-ray images.
10020479|NCT04331353|Active Comparator|Comparator 1 (tailored approach)|Multi-component intervention tailored to the participant's allergic profile.
10020480|NCT04331353|Active Comparator|Comparator 2 (insecticidal bait)|Insecticidal bait for cockroach reduction.
10020481|NCT04330807|Other|Patient with chronic kidney disease|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
10020482|NCT04330807|Other|CONTROL GROUP|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
9477418|NCT03562572|Experimental|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
10020483|NCT04328012|Experimental|Losartan|losartan 25 mg po QD X 14 days
10020484|NCT04328012|Placebo Comparator|Placebo|placebo QD X 14 days
10020485|NCT04325646||CORSER-1a|Subjects who had been to China in the weeks before the outbreak began
10020486|NCT04325646||CORSER-1b|Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
10020487|NCT04325646||CORSER-2a|Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
10020488|NCT04325646||CORSER-2b|Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
10020489|NCT04325646||CORSER-2c|"Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation.~study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise~study among pupils from 5 to 12 and their parents in elementary schools located in Oise~study among choir members"
10020490|NCT04325646||CORSER-2d|Staff of health care institutions
10020491|NCT04325646||CORSER-2e|Subjects in care, hospitalized or residing in health care facilities
10020492|NCT04325646||CORSER-3|Subjects returning from a humanitarian mission that started before 31/01/2020
10020493|NCT04325646||CORSER-2f|Subjects with two symptomatic episodes of SARS-CoV-2 infection
10020494|NCT04325646||CORSER-4|Subjects being vaccinated against COVID-19
10020495|NCT04325646||CORSER-5|Subjects with acute SARS-CoV-2 infection and uninfected controls
10020496|NCT04322539|Experimental|fruquintinib plus best supportive care|In this arm, subjects will receive active study drug plus best supportive care
10020497|NCT04322539|Placebo Comparator|placebo plus best supportive care|In this arm, subjects will receive placebo plus best supportive care
10020498|NCT04322318|Experimental|Arm I (Regimen UH-3)|See outline in detailed description section.
10020499|NCT04322318|Experimental|Arm II (Regimen ICE/Cyclo/Topo)|"CYCLES 1, 2, 4, 5, 7, AND 9: Patients receive carboplatin IV over 15-60 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and ifosfamide IV over 2-4 hours on days 1-3. Treatment repeats every 21 days during cycles 1, 2, 4, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.~CYCLES 3, 6, 8, AND 10: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan IV over 30 minutes on days 1-5. Treatment repeats every 21 days during cycles 3, 6, 8, and 10 in the absence of disease progression or unacceptable toxicity."
10020500|NCT04322058||Fathers or paternal caregivers to a child 0-18 years of age|Parenting and Healthy Relationship Education (10 Core 24/7 workshops covering- 15 hours of education), financial and economic mobility programming, comprehensive case management, and supplemental workshops utilizing the Within My Reach curriculum.
10020501|NCT04321993|Experimental|Baricitinib|Moderate and severe, not critical disease
10020502|NCT04321993|Experimental|Remdesivir|Moderate and severe, not critical disease
10020503|NCT04321993|Experimental|Remdesivir + baricitinib|Moderate and severe, not critical disease
10020504|NCT04321993|Experimental|Tocilizumab|Severe, critical disease
10020505|NCT04321993|No Intervention|Clinical standard of care|Moderate and severe, not critical disease AND severe, critical disease as applicable
10020506|NCT04316741|Experimental|Brief Intervention+Health Coaching|Brief intervention with social-media delivered health coaching
10020507|NCT04316741|No Intervention|Control|Enhanced usual care brochure plus attention control with social media messaging
10020508|NCT04315948|Experimental|Remdesivir|"Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.~n=475"
10020509|NCT04315948|Experimental|Lopinavir/ritonavir (stopped on June 29, 2020)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~n=620"
10020510|NCT04315948|Experimental|Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.~Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).~n=620"
10020511|NCT04315948|Experimental|Hydroxychloroquine (stopped on May 24, 2020)|Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620
10020512|NCT04315948|Active Comparator|Standard of care alone|Standard of care alone before March, 2021.
10020513|NCT04315948|Experimental|AZD7442|"Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1.~n=620"
10020514|NCT04315948|Active Comparator|Standard of care with placebo|Standard of care with placebo since April, 2021 n=620
10036285|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
10036286|NCT01814293|Active Comparator|Handheld humidifier|Study design is a nonblinded randomized controlled comparison study of pediatric patients presenting to the UCSF Emergency Department (ED) with upper respiratory infection (URI) symptoms for which the ED physician has recommended supportive care only (ie. non-prescription symptom relief). Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
10036287|NCT01814293|No Intervention|Control group|Subjects will manage cold symptoms with any desired supportive over the counter treatment, and complete surveys related to symptom scores and modalities used.
10036288|NCT01814306|Active Comparator|Supreme|Supreme LMA
10036289|NCT01814306|Active Comparator|Proseal|Proseal LMA
10036290|NCT01814319|Experimental|Probenecid|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
10036291|NCT01814319|Placebo Comparator|placebo|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.
10036292|NCT01814358|Experimental|Whey protein|Subjects on this arm will receive whey protein
10036293|NCT01814358|Active Comparator|Gelatin protein|Subjects on this arm will consume gelatin protein
10036294|NCT01814358|No Intervention|Control arm|Subjects on this arm will receive no intervention
10036295|NCT01814384|Other|Control group|Control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
10036296|NCT01814384|Other|Matched patient|Treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
10036297|NCT01814410|Placebo Comparator|intravenous ethanol placebo and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
10036298|NCT01814410|Active Comparator|intravenous ethanol 40% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
10036299|NCT01814410|Active Comparator|intravenous ethanol 100% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
10036300|NCT01814423|Experimental|Chloroquine-base 50 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.
10036301|NCT01814423|Active Comparator|Chloroquine-base 70 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.
10036302|NCT01814436|Experimental|scaffold-free SHED-derived pellet|
10036303|NCT01814449||Hypoxic Group|Higher 18FMISO uptake (Target to background Ratio, TBR>1.2) in Primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy Letrozole was given to the patients.
10036304|NCT01814449||Non-Hypoxic Group|Lower 18FMISO uptake (TBR<1.2)in primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy letrozole was given to the patients.
10036305|NCT01814462|Experimental|6 months CPAP|Application of continuous positive airway pressure (CPAP) therapy as established per routine clinical treatment. Home use of therapy for a period of 6 months.
10036306|NCT01814475|Active Comparator|A: Fludarabine + Busulphan|Conventional conditioning regimen with Fludarabine and Busulphan (Busilvex)for allogeneic stem cell transplantation in myelofibrosis
10036307|NCT01814475|Experimental|B: Fludarabine + Thiotepa|Reduced-intensity conditioning with Fludarabine and Thiotepa for allogeneic stem cell transplantation in myelofibrosis
10036308|NCT01814488|Experimental|allogenic transplant|The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias. Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.
10036309|NCT01814501|Experimental|Treatment (panitumumab, combination chemotherapy)|5-Fluorouracil, irinotecan, and panitumumab
10036310|NCT01814514|Active Comparator|Timolol-trusopt|Dosage:One drop/12hours,duration:3 months
10036311|NCT01814514|Placebo Comparator|placebo,Artificial tear|dosage:one drop/12 hours,duration:3 months
10036312|NCT01814527|Active Comparator|Docosahexaenoic acid|The experimental group will be given a standardized dose of omega-3 fatty acid containing 2200mg of DHA for 30 days after onset of concussion or longer for those with continued symptomatology. Brain Armor an over the counter DHA supplements that is independently tested and certified by the National Science Foundation Athletic Banned Substance Certified for Sport Program. The Docosahexaenoic acid supplement has 440mg of DHA per capsule and each subject will be given 5 capsules of Brain Armor once daily for a DHA dose of 2200mg/day.
10036313|NCT01814527|Placebo Comparator|Placebo|The placebo group will be given an equal amount of capsules.
10036314|NCT01814540|Placebo Comparator|Placebo Control, Glucose polymer|Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.
10020515|NCT04315246|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles.
10020516|NCT04310150|Experimental|Treatment arm label- Collastat®|
10020517|NCT04310150|Active Comparator|Control arm label- Floseal®|an marketed product is Floseal
10020518|NCT04307498|Other|Intensive Outpatient Program - Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks plus seven augmentations designed to maximize treatment outcomes. If necessary, the treatment window may be extended for another week.
10020519|NCT04307329|Experimental|Monalizumab + trastuzumab - low TILs (<5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
10020520|NCT04307329|Experimental|Monalizumab + trastuzumab - high TILs (>=5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
10020521|NCT04306848|Experimental|Pilot|Eligible subjects who have consented to the study, and have had the baseline data gathered as part of their participation in the Lifestyle Medicine Clinic, an intensive therapeutic lifestyle medicine program, will be given a CGMs device and supplies, and instructed in how to utilize these. They will set up the app on their smart phone to provide them with feedback on their glucose level to correlate with their lifestyle activities.
10020522|NCT04305444|Experimental|Disease-specific cohorts|Participants will be administered the oral triple-combination therapy, DTRM-555 (comprised of 200mg of DTRMWXHS-12, 5mg of everolimus and 2mg of pomalidomide), once-daily for 21 consecutive days every 28 days
10020523|NCT04303897||XEN Glaucoma Stent|
10020524|NCT04303663|Active Comparator|Fibular Plate|Open reduction and internal fixation of the fibular fracture Fixation of the fibular will be performed with a fibular plate +/- lag screws as judged intraoperatively
10020525|NCT04303663|Experimental|Fibular Nail|Percutaneous or mini-open reduction of the fibular fracture and fixation with a fibular nail.
10020526|NCT04299464|Placebo Comparator|Placebo|Participants will receive placebo matched to RO7017773 for approximately 12 weeks.
10020527|NCT04299464|Experimental|RO7017773 Low Dose|Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
10020528|NCT04299464|Experimental|RO7017773 High Dose|Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
10020529|NCT04299438|Active Comparator|Propranolol|IV Propranolol - 2mg; one possible repeat dose ≥2 hours later
10020530|NCT04299438|Placebo Comparator|Placebo|Normal saline placebo- 2 mL; one possible repeat dose ≥2 hours later
10020531|NCT04299061|Experimental|Study Group|
10020532|NCT04299009|Experimental|Retimer bright light therapy glasses|active bright light therapy in the green/blue spectrum range
10020533|NCT04299009|Sham Comparator|sham-Retimer bright light therapy glasses|bright light therapy with light in the red spectrum (not active)
10020534|NCT04298983|Experimental|Abemaciclib + ADT+ RT|Abemaciclib at 150 mg by mouth twice daily, androgen deprivation therapy (ADT), and radiation therapy in conjunction with ADT.
10020535|NCT04297683|Experimental|Regimen A - Zilucoplan|Participants are randomized to receive either active zilucoplan or matching placebo.
10020536|NCT04297683|Experimental|Regimen B - Verdiperstat|Participants are randomized to receive either active verdiperstat or matching placebo.
10020537|NCT04297683|Experimental|Regimen C - CNM-Au8|Participants are randomized to receive either active CNM-Au8 or matching placebo.
10020538|NCT04297683|Experimental|Regimen D - Pridopidine|Participants are randomized to receive either active Pridopidine or matching placebo.
10020539|NCT04297683|Experimental|Regimen E - SLS-005 Trehalose|Participants are randomized to receive either active SLS-005 Trehalose or matching placebo.
10020540|NCT04295772|Experimental|DOR/ISL|Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.
10020541|NCT04294914|Active Comparator|Fibromyalgia|Individuals with fibromyalgia.
10020542|NCT04294914|Experimental|Healthy controls|Healthy, pain-free individuals
10020543|NCT04294901|Experimental|Gabapentin (Gaba)|Patients prescribed gabapentin with a total daily dose >1800mg without exclusion criteria who have a primary care appointment with a provider in the Gaba cohort
10020544|NCT04294901|Experimental|Diabetes (DM)|Patients prescribed either insulin or a sulfonylurea meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the DM cohort
10020545|NCT04294901|Experimental|Proton Pump Inhibitor (PPI)|Patients prescribed a PPI meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the PPI cohort
10020546|NCT04294147|Experimental|Galcanezumab|Participants received a single subcutaneous (SC) dose of 240 milligram (mg) Galcanezumab.
10020547|NCT04294147|Active Comparator|Erenumab|Participants received a single SC dose of 140 mg Erenumab.
10020548|NCT04293276|Experimental|Treatment group|Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
10020549|NCT04292873|No Intervention|Control|
10020550|NCT04292873|Experimental|Vitamin D|Enteral supplement of 569,600 IU vitamin D
10020551|NCT04291079|Experimental|Part A1: Dose Escalation|Part A1 will determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of SRK-181 as a single agent and will determine the recommended Phase 2 dose (RP2D) of SRK-181 as a single-agent.
10020552|NCT04291079|Experimental|Part A2: Dose Escalation|Part A2 will determine the MTD or MAD of SRK-181 in combination with anti-PD-(L)1 antibody therapy and will determine the RP2D of SRK-181 in combination with anti-PD-(L)1 antibody therapy for use in Part B.
10020553|NCT04291079|Experimental|Part B: Dose Expansion|In Part B, parallel cohorts of patients with Non-small cell lung cancer (NSCLC), Urothelial Carcinoma (UC), Cutaneous melanoma (MEL), clear cell Renal cell carcinoma (ccRCC) or other advanced or metastatic solid tumor type that is not NSCLC, UC, MEL, or ccRCC will be enrolled to confirm the tolerability of the RP2D of SRK-181 (determined in Part A2) and to evaluate the anti-tumor activity of SRK-181 in combination with an anti-PD-(L)1 antibody therapy.
10020554|NCT04291079|Experimental|Long Term Extension Phase (LTEP)|"Patients may continue treatment in a LTEP:~Part A1: Patients may continue treatment with SRK-181 as a single agent at the RP2D in the LTEP following 3 cycles of treatment with SRK-181 as a single agent in Part A1.~Part A2: Patients may continue treatment with SRK-181 at the RP2D in combination with anti-PD-(L)1 antibody therapy in the LTEP following 3 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part A2.~Part B: Patients may continue treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy following 9 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part B"
10020555|NCT04290845|Experimental|Relief-Hybrid|Relief-Hybrid relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
10020556|NCT04290845|No Intervention|Referral to Mental Health/Usual Care|Continuation of medical attention and treatment provided by physicians and other medical professionals at the primary care practice. Referral for mental health based on clinical indication. Participants receive an educational booklet on pain.
10020557|NCT04290624|Experimental|Intervention Group|Participants will be instructed to use a dentifrice containing 0.454 percent (%) weight by weight (w/w) Stannous fluoride, COREGA denture foaming cleanser and mouth rinse containing 90 parts per million (ppm) sodium fluoride. Participants will brush with a strip of the dentifrice (full brush head) applied to the full length of the toothbrush head for 2 minutes followed by 2 pumps of denture cleanser foam brushed onto removable partial denture (RPD) for 90 seconds and 10 milliliter (ml) of mouth rinse for swished around the mouth for 1 minute. Participants will apply all these products twice daily (morning and evening) for 12 weeks.
10020558|NCT04290624|No Intervention|Reference Group|Participants will not be supplied any products and will continue with their existing dental/denture hygiene practices and should not make changes to either their established habits nor to the products they use following screening.
10020559|NCT04289454|Other|Effect of flavor modifiers|Intervention in the study: Subjects will taste model KE drinks with (control condition) and without (experimental condition) added flavors. Design is within-subjects (subjects will taste both the experimental and control drinks), with order counter-balanced across subjects.
10020560|NCT04285866||Durvalumab Group|Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
10020561|NCT04282642|Experimental|Cognitive Training|Computerized Cognitive Training
10020562|NCT04282642|Experimental|WLC|Waitlist Control
10020563|NCT04281485|Other|Cohort 1|Approximately two thirds of participants will be randomized to Cohort 1.
10020564|NCT04281485|Other|Cohort 2|Approximately one third of participants will be randomized to Cohort 2.
10020565|NCT04279158|Experimental|patients with optic ataxia (OA)|
10020566|NCT04279158|Experimental|patients with hemispatial neglect|
10020567|NCT04279158|Experimental|patients with attention-deficit hyperactivity disorder|
10020568|NCT04279158|Active Comparator|Healthy volunteers|
10020569|NCT04279067|Experimental|BCI-FES dorsiflexion therapy with physiotherapy|"Subjects will undergo placement of an EEG cap using standard technique connected to our custom BCI system. Subjects will provide 5 min of training EEG data as they engage in alternating epochs of idling and attempted foot dorsiflexion (of the paretic side). In the online phase, the subjects will perform 20-25 BCI-FES runs. A total of 12 sessions will be performed at a rate of 3x/week (over 4 weeks). Each BCI-FES therapy session will be followed by 1 hour of conventional physiotherapy.~Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises."
10020570|NCT04279067|Experimental|Dose-and intensity-matched physiotherapy|"Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.~In the dose-matched control group (Group 2), it will be 2 hours/session."
10020571|NCT04277611|Active Comparator|QLB|The patient is in the prone position, an ultrasound probe is placed in a transverse, oblique, and paramedian orientation approximately lateral to the posterior axillary line. The needle is then inserted in-plane from the medial side of the transducer and advanced laterally to enter the interfascial plane between the Quadratus Lumborum muscle and the kidney. We confirmed that the local anesthetic appeared to press down the kidney in the ultrasound image
10020572|NCT04277611|Active Comparator|ESPB|Using aseptic technique, an ultrasound probe is placed at the T9 vertebral level. After identifying the ribs and sliding towards the midline in a longitudinal parasagittal orientation, the overlying Erector Spinae is identified by visualization of the transition between the rib and transverse apophysis a block needle is inserted in plane with ultrasound beam and is advanced in a cephalo-caudal direction until the tip contacted the transverse process.
10020573|NCT04276311|Experimental|symptomatic patients with complex de novo FP arterial lesions|in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo FP arterial lesions (TASC C).
10020574|NCT04275557||Retrospective Cohort|Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases
10020575|NCT04275557||Prospective Cohort|Blood, tumor tissue samples and data will be collected.
10020576|NCT04273932|Experimental|Lithium aspartate 15mg a day|15mg of elemental lithium administered every morning by mouth.
10020577|NCT04273932|Experimental|Lithium aspartate 45mg a day|20mg every morning and 25mg every evening of elemental lithium administered by mouth.
10020578|NCT04273932|Experimental|Lithium carbonate|The dose will be titrated based on weekly blood tests to achieve a target serum level of 0.40-0.50mmol/L, which represents an elemental lithium dose of about 85-170mg a day.
10020579|NCT04273932|No Intervention|No lithium treatment|Control arm
10020580|NCT04272606|Active Comparator|Treatment|1:1 randomization, given tranexamic acid during surgery, visual acuity exam
10020581|NCT04272606|Placebo Comparator|Placebo|1:1 randomization, given standard of care treatment during surgery, visual acuity exam
10020582|NCT04271449|Experimental|Cerebellum tDCS|Cerebellum tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
10020583|NCT04271449|Experimental|Primary motor cortex|Primary motor cortex tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
10020584|NCT04271449|Sham Comparator|Sham tDCS|Sham tDCS arm will serve as a sham comparator for other experimental conditions. This arm will be subdivided into two groups depending on the localisation of the electrodes (cerebellum placement vs primary motor cortex placement).These two subgroups will be divided again in two subgroups depending on the task exposed (pointing vs throwing).
10020585|NCT04270188||anterior sacrospinofixation with autologous tissue|patients with middle and / or anterior prolapse ≥ II in the POP-Q classification and for whom an intervention by anterior sacrospinofixation by autologous tissues is planned.
10020586|NCT04269707|Other|IV Iron|The primary objective in this study is to allow participants who were randomized to receive oral iron in the 1VIT17044 trial and who had an unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol, increase in erythropoietin for any reason [Day 0 thru Day 35 of study protocol 1VIT17044], change in IBD treatment) to receive one course of FCM. This course of FCM will consist of two doses of FCM at 15 mg/kg (maximum single dose of 750 mg), separated by seven days.
10020587|NCT04268979|Experimental|eSNAP & Caregiver Navigator|eSNAP intervention plus questionnaires
10020588|NCT04268979|No Intervention|Waitlist Control Condition|Participants randomly assigned to the waitlist control condition will only complete questionnaires during the 8-week study period. After the 8 weeks, they will then have access to the eSNAP, including completion of questionnaires and 8 weeks of Caregiver Navigator sessions as needed.
10020589|NCT04268615|Experimental|Patients|Patients suffering from chronic bilateral vestibular hypofunction
10020590|NCT04268615|Active Comparator|healthy subject group|
10020591|NCT04266431|Experimental|EMPOWER|EMPOWER is a multichannel, behavioral lifestyle intervention delivered remotely. The goals of EMPOWER are to induce a loss of 5% or more of initial weight within 6 months and to maintain these improvements at 12 and 24 months, by meeting dietary and physical activity goals. Coach-participant contacts will occur by phone and email, without in-person visits. Coaching contacts will be weekly for the first 12 weeks and then monthly thereafter. Men will have access to a web-based system that (1) provides support for behavioral methods of weight management and (2) allows coaches to review participant self-monitoring data and monitor participant progress towards goals. Men will record diet, exercise, and weight on the web or on a smart phone application.
10020592|NCT04266431|No Intervention|Standard of Care|Men randomized to the standard of care group will continue to receive treatment from the mens' medical oncologist. These men will also be provided with a one page informative brochure on lifestyle recommendations adapted from the American Cancer Society Prostate Cancer Survivorship Care Guidelines, at the time of randomization. At the end of the trial, men in this arm will be offered a one-time counseling session with an intervention coach on healthy lifestyle.
10020593|NCT04266145|Active Comparator|intravenous dexmedetomidine|20 mL 0.25% levobupivacaine plus 1 mL normal saline will be administrated for adductor-canal-blockade while for intravenous solution; 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline will be prepared
10020594|NCT04266145|Active Comparator|adductor-canal-blockade dexmedetomidine|20 mL 0.25% levobupivacaine containing 1 mL of 0.5 mcg.kg-1 dexmedetomidine will be used for adductor-canal-blockade whereas, 20 mL 0.9% saline will be prepared for intravenous infusion
10020595|NCT04265573||Children under-five|Uncomplicated malaria case in this group will be managed using Pyronaridine-Artesunate at health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
10020596|NCT04265573||Individuals five years of age and above|Uncomplicated malaria case in this group will be managed using Dihydoartemisinin-Piperaquine health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
10020597|NCT04265573||Pregnant women|Uncomplicated malaria case in this group will be managed using Artemether-Lumefantrin health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
10020598|NCT04265534|Experimental|Telaglenastat with Pembrolizumab and Chemotherapy|The glutaminase inhibitor telaglenastat will be administered orally, twice daily with food, every day in combination with standard-of-care pembrolizumab plus chemotherapy by intravenous (IV) infusion every 3 weeks.
10020599|NCT04265534|Placebo Comparator|Placebo with Pembrolizumab and Chemotherapy|Placebo will be administered orally twice daily with food every day in combination with standard-of-care pembrolizumab plus chemotherapy by IV infusion every 3 weeks.
10020600|NCT04264637|Experimental|Azelastine hydrochloride 0.15% + Placebo|Each participant will receive a single dose (two sprays per nostril) of study intervention Azelastine hydrochloride 0.15% and Placebo at treatment period 1 and 2 respectively.
10020601|NCT04264637|Experimental|Placebo + Azelastine hydrochloride 0.15%|Each participant will receive a single dose (two sprays per nostril) of study intervention Placebo and Azelastine hydrochloride 0.15% at treatment period 1 and 2 respectively.
10020602|NCT04264234|Experimental|Placenta Previa|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.
10020603|NCT04263649||All subjects|patients who require a PICC
10020604|NCT04263246|Experimental|PhytoDyNAmic|Six capsules per day b.i.d.
10020605|NCT04263246|Placebo Comparator|Inulin|Six capsules per day b.i.d.
10020606|NCT04263207||anti-Tat Ab positive subjects|
10020607|NCT04263207||anti-Tat Ab negative subjects|
10020608|NCT04262908||Patients implanted with hip or knee prostheses|Patients who had hip or knee arthroplasty will be followed and asked at 3-months visit if they resumed their job or not. In both cases, further informations will be gathered
10020609|NCT04262713|Other|Patients implanted with Meije duo stem size 1 or 2|"Among this arm, patients that meet criteria ( weight>~60kg and / or a long neck / varus and / or a DEVANE score ≥ 4 ) will perform hip X ray"
10020610|NCT04262687|Experimental|Immunotherapy + chemotherapy|Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.
10020611|NCT04262336|Active Comparator|DB-020 for Injection, 12%/placebo|dosage
10020612|NCT04262336|Active Comparator|DB-020 for Injection, 25%/placebo|dosage
10020613|NCT04262206|Experimental|atorvastatin 40mg|40mg atorvastatin po qd from consent to study end
10020614|NCT04262206|Placebo Comparator|Placebo|matching placebo po qd from consent to study end
10020615|NCT04261439|Experimental|Arm 1|Single agent arm. NIZ985 is administered as a single agent (subjects may be treated with the NIZ985-Spartalizumab combination after their first disease re-evaluation)
10020616|NCT04261439|Experimental|Arm 2|Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1
10020617|NCT04259801|Experimental|NNC0480-0389 and semaglutide|"Part 1: 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.~Part 2: 12 subjects will receive 4 doses of s.c. NNC0480-0389 co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c semaglutide."
10020618|NCT04259801|Experimental|NNC0480-0389 and placebo (semaglutide)|"Part 1: 4 subjects will receive a single dose of s.c. NNC0480-0389 co-administered with semaglutide placebo.~Part 2: 4 subjects will receive 4 doses of s.c. NNC0480-0389, co-administered with semaglutide placebo after 8 weeks of dosing with semaglutide placebo."
10020619|NCT04259801|Active Comparator|Placebo (NNC0480-0389) with semaglutide|"Part 1: 2 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with s.c. semaglutide.~Part 2: 4 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c. semaglutide"
10020620|NCT04259801|Placebo Comparator|Placebo (NNC0480-0389) with placebo (semaglutide)|"Part 1: 3 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with semaglutide placebo.~Part 2: 2 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with semaglutide placebo, after 8 weeks of dosing with semaglutide placebo."
10020621|NCT04258813|Experimental|Control|40 PCP clinics; 400 patients
10020622|NCT04258813|Experimental|iGuide Intervention|40 PCP clinics; 400 patients
10020623|NCT04253977|Experimental|HEALTH-P2|Along with PAT National Center, parent educators affiliated with PAT sites in HEALTH-P2; with be trained to use the HEALTH-P2 training curriculum (implementation strategy).
10020624|NCT04253977|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual.
10020625|NCT04250597|Experimental|Part 1 Dose Escalation|Drug: GNX102 Dose Escalation: 21 day dosing interval
10020626|NCT04250597|Experimental|Part 2 Dose Escalation|Drug: GNX102 Dose Escalation: 7 day dosing interval
10020627|NCT04250597|Experimental|Part 3 Dose Expansion|Drug: GNX102 Dose Expansion: Selected dose level(s) and schedule(s) in expanded cohort(s)
10020628|NCT04248933|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRC-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention.
10020629|NCT04248595|Experimental|Azacitidine plus HAG|"Patients of denovo or relapsed AML(age≥60y) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), maintenance therapy with AZA+lenalidomide/AZA will be used every 4-6 weeks until progression or total of 12cycles.~AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF"
10020630|NCT04248595|Experimental|Azacitidine plus HIA|"Patients of denovo or relapsed AML(age<60y) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin"
10020631|NCT04248595|Experimental|Azacitidine plus HDA|"Patients of denovo or relapsed AML(age<60y) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Daunorubicin"
10020632|NCT04247243|Experimental|Rapid testing|Abbott ID NOW Strep A testing.
10020633|NCT04247243|Active Comparator|Reference testing|Culture-based testing.
10020634|NCT04246047|Experimental|Belantamab mafodotin and Bortezomib plus Dexamethasone (Arm A)|
10020635|NCT04246047|Active Comparator|Daratumumab and Bortezomib plus Dexamethasone (Arm B)|
10020636|NCT04245306|Experimental|Children with Autism Spectrum Disorders|A group of 25 children with autism spectrum disorders (ASD)
10020637|NCT04245306|Active Comparator|Typically Developing children|A larger group of 150 typically developing children (TD)
10020638|NCT04245306|Experimental|Children with Developmental Language Disorders|A group of 25 children with developmental language disorders (DLD)
10020639|NCT04244487|Experimental|intraoperative endoscopic variceal ligation group|intraoperative endoscopic variceal ligation group Every patient of vagus nerve-preserving group will receive the synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation procedure
10020640|NCT04244487|No Intervention|Non-intraoperative endoscopic variceal ligation group|Every patient of conventional group will receive single vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection without intraoperative endoscopic variceal ligation procedure
10020641|NCT04244240||Sickle cell disease patient|Adults with sickle cell disease (homozygous SS or heterozygous SC, Sβ0 or Sβ+) with cognitive complaint.
10020642|NCT04244175|Experimental|High Dose: CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Day 92 during the treatment period.
10020643|NCT04244175|Experimental|Low Dose: CVL-865 7.5 mg|Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg until Day 92 during the treatment period.
10020644|NCT04244175|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-865 tablets orally BID until Day 92 during the treatment period.
10020645|NCT04242992|Experimental|CETA (Common Elements Treatment Approach)|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based cognitive behavioral therapy (CBT) elements so the provider can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include Short Message Service (SMS) text reminders of their HIV care appointments, similar to the active control group.
10020646|NCT04242992|Active Comparator|Active control|Our comparison arm will be an active control receiving usual care for intimate partner violence. Short Message Service (SMS) text messages will be sent monthly to our control group participants to remind them of HIV care appointments.
10020647|NCT04242498|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
10020648|NCT04242498|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
10020649|NCT04242498|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
10020650|NCT04242498|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
10020651|NCT04241874|Experimental|Low PEEP and full inspiratory synchronization|PEEP = 5 cmH2O + clinically selected pressure support (PSVclin)
10020652|NCT04241874|Experimental|High PEEP and full inspiratory synchronization|PEEP = 15 cmH2O + clinically selected pressure support (PSVclin)
10020653|NCT04241874|Experimental|Low PEEP and inspiratory desynchronization|PEEP = 5 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
10020654|NCT04241874|Experimental|High PEEP and inspiratory desynchronization|PEEP = 15 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
10020655|NCT04241224|Experimental|Excimer Laser Photoablation|"Device: DABRA Laser System~Patients with symptomatic peripheral vascular disease undergoing an endovascular revascularization procedure utilizing the DABRA Laser System."
10020656|NCT04240197|Sham Comparator|Standard Pressure Transducer|Epidural pressure waveforms will be measured by using a standard invasive monitor pressure transducer
10020657|NCT04240197|Active Comparator|CompuFlo|Epidural pressure waveforms will be measured by using the CompuFlo Instrument
10020658|NCT04239976|Experimental|Supportive Care (scrambler therapy, sensory test, gait test)|Patients undergo scrambler therapy over 30-45 minutes QD Monday-Friday for 2 weeks. Patients also undergo a quantitative sensory test and a gait assessment test using a FitBit before receiving scrambler therapy, at the end of the first and second weeks of scrambler therapy, and 1 month after the last day of scrambler therapy.
10020659|NCT04239703||Kidney transplant biopsies for cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care.
10020660|NCT04239313|Experimental|Population I|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose vaccine.
10020661|NCT04239313|Active Comparator|Population II|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose adjuvant.
10020662|NCT04239313|Placebo Comparator|Population III|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo.
10020663|NCT04239079||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
10020664|NCT04239079||AD/aMCI and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Alzheimer's disease or Amnestic Mild Cognitive Impairment (aMCI)
10020665|NCT04238546|Experimental|Sirolimus-coated group|
10020666|NCT04238546|Active Comparator|Uncoated group|
10020667|NCT04238091|Active Comparator|Antibiotics prior to FMT|Participants will take a standardized regimen of antibiotics for three days prior to fecal transplant.
10020668|NCT04238091|Active Comparator|No Antibiotics prior to FMT|Participants will not take antibiotics before the transplant.
10020669|NCT04237350||severe visual impairment group|"The severe visual impairment group is defined as the BCVA of at least one eye outside the 99% referenced range or worse than light perception with structural abnormalities or other examination results."
10020670|NCT04237350||likely healthy group|"For the likely healthy group, the visual acuity of both eyes is in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
10020671|NCT04237350||mild visual impairment group|"The mild visual impairment group is defined as the BCVA in the 99% referenced range in both eyes with abnormalities of structure or other examination results."
10020672|NCT04237155|Other|Healthy controls involved in step 1|30 healthy individuals will complete a verbal material scoring questionnaire
10020673|NCT04237155|Other|Patients with schizophrenia involved in step 1|30 patients with schizophrenia will complete a verbal material scoring questionnaire
10020674|NCT04237155|Other|Healthy controls involved in step 2|30 healthy individuals will complete the source-monitoring task which will be created from step 1 as well as the task of reference
10020675|NCT04237155|Other|Patients with schizophrenia involved in step 2|30 patients with schizophrenia will complete the source-monitoring task which will be created from step 1 as well as the task of reference
10020676|NCT04236531|Experimental|individuals at ultra-high risk for psychosis (UHR)|"30 individuals meeting the UHR criteria according to the Comprehensive Assessment of at-risk mental state (CAARMS) will be recruited and will complete cognitive task and MRI scan"
10020677|NCT04236531|Experimental|patients with first episode psychosis (FEP)|30 patients with first episode psychosis (FEP) will be recruited and will complete cognitive task and MRI scan
10020678|NCT04236531|Sham Comparator|healthy controls|30 healthy individuals will be recruited and will complete cognitive task and MRI scan
10020679|NCT04236271|Experimental|patient|interventional group
10020680|NCT04233801|Experimental|Empagliflozin low dose|
10020681|NCT04233801|Experimental|Empagliflozin high dose|
10020682|NCT04233801|Placebo Comparator|Placebo|
10020683|NCT04233190|Experimental|Formoterol + budesonide Eurofarma (12/400mcg e 6/200mcg)|Formoterol 12mcg + budesonide 400mcg / Formoterol 6mcg + budesonide 200mcg
10020684|NCT04233190|Active Comparator|Alenia® (12/400mcg e 6/200mcg)|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
10020685|NCT04233112|Placebo Comparator|Placebo/Mock|Placebo capsules; mock osteogenic loading
10020686|NCT04233112|Experimental|Melatonin/Mock|Melatonin capsules; mock osteogenic loading
10020687|NCT04233112|Experimental|Placebo/Osteogenic loading|Placebo capsules/osteogenic loading
10020688|NCT04233112|Experimental|Melatonin/Osteogenic loading|Melatonin capsules/osteogenic loading
10020689|NCT04233034|Active Comparator|HCL and placebo|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
10020690|NCT04233034|Active Comparator|HCL and verapamil|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
10020691|NCT04233034|Active Comparator|non-HCL and verapamil|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
10020692|NCT04233034|Placebo Comparator|non-HCL and placebo|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
10020693|NCT04232566||Weight loss surgery|Gastric bypass surgery will be followed by weight loss as standard of care. Liver fibrosis by elastography will be determined before surgery.
10020694|NCT04231825|Experimental|Verum Stimulation|This group will receive 6-Hz tACS
10020695|NCT04231825|Active Comparator|Frequency Control|This group will receive 1-Hz tACS
10020696|NCT04230304|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10020697|NCT04226976|Experimental|Otoband efficacy on AUV|Participants will wear the Otoband during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Half the participants will be given the Otoband at power level 96db and half will be given the Otoband at power level 98db (all bone conduction levels re:1dyne). This will be randomized and neither the participant nor the investigator will know what power level the Otoband is set at. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
10020698|NCT04226976|Placebo Comparator|Placebo device efficacy on AUV|Participants will wear the placebo device during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. The placebo device will be set at a power level of 90db (bone conduction level re:1dyne). Neither the participant nor the investigator will know that this device is the placebo device. The participants will be fitted with the placebo device and will undergo the vestibular battery test. The investigator will record the outcome measurements.
10020699|NCT04226586|Active Comparator|Treatment Group|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.~Children in the treatment (intervention) arm will receive essential amino acids (EAA) twice a day.~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
10020700|NCT04226586|Placebo Comparator|Placebo|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.~Children in the placebo arm will receive placebo twice a day. EAA and placebo supplements will look and taste alike. The same flavoring ingredients (stevia blend, citric acid, malic acid, natural flavors, tartaric acid, fruit and vegetable juice for color) will be used in both products at the same amount.~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
10036315|NCT01814540|Experimental|Treatment 2: Low-Dose BMO|"Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
10036316|NCT01814540|Experimental|Treatment 3: High-Dose BMO|"Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
10036317|NCT01814579|Experimental|V-Loc Vaginal Cuff Closure|Patients in this arm will receive vaginal cuff closure with unidirectional barbed suture at time of their robotic hysterectomy.
10036318|NCT01814579|Active Comparator|Vicryl Vaginal Cuff Closure|Patients enrolled in this arm will have their vaginal cuff closed with polyglactin 910 (Vicryl) at the time of their robotic hysterectomy.
10036319|NCT01814592|Experimental|coronally mucosal thickness flap|coronally mucosal thickness flap plus connective tissue graft for root coverage (subepithelial connective tissue graft)
10036320|NCT01814592|Active Comparator|coronally partial thickness flap|coronally partial thickness flap plus connective tissue for root coverage (subepithelial connective tissue graft)
10036321|NCT01814605|Experimental|Subgluteal space group|"The patients in Subgluteal space group will receive sciatic block according to the approach described by Karmakar et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint will be designated with a marker and will be the site of needle entry.~A 50 to 90 mm 22 G insulated needle will be inserted at the midpoint previously designated and advanced under real time guidance in an out-of-plane approach until the needle reaches the subgluteal space."
10036322|NCT01814605|Active Comparator|Infragluteal space group|The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. After skin and transducer preparation, a curved 5 MHz(megahertz) transducer will be placed over the subgluteal region in a transverse plane to scan the sciatic nerve. A 50 to 90 mm 22 G needle is used and advanced under real time guidance in an out-of-plane approach until the needle tip is adjacent o the nerve.
10020701|NCT04224558|Experimental|HSCT after mobilization and conditioning|"Mobilization and leukopheresis allow for stem cell harvest. Then conditioning is provided prior to stem cell transplantation, followed by post-transplant conditioning.~Interventions include:~Stem cell mobilization~Leukopheresis~Preparative regimen~Peripheral blood stem cell infusion~Post-PBSC infusion conditioning"
10020702|NCT04223570|Active Comparator|Ameluz (amino-levulinic acid topical gel) Only|Ameluz is a topical gel approved for use in photodynamic therapy for treatment of actinic keratoses, among other skin conditions. It is being applied to all participants in this study to measure the levels of PpIX in different areas of skin as detailed in study description. This arm includes those participants who have not been prescribed photodynamic therapy and thus they will not receive any light treatment during this study.
10020703|NCT04223570|Active Comparator|Ameluz and Light Therapy|Ameluz is a topical gel approved for use in photodynamic therapy for treatment of actinic keratoses, among other skin conditions. It is being applied to all participants in this study to measure the levels of PpIX in different areas of skin as detailed in study description. For patients who have been prescribed photodynamic therapy, the investigators will perform one additional round of measurements of Protoporphyrin IX using our camera device, in addition to the other secondary outcomes including skin temperature.
10020704|NCT04223479|Experimental|Probiotic Formula Capsule|In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
10020705|NCT04223479|Placebo Comparator|Placebos|In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
10020706|NCT04221230|Experimental|BTRX-335140|BTRX-335140
10020707|NCT04221230|Placebo Comparator|Placebo|Placebo
10020708|NCT04219878|Active Comparator|Know@Home App or Website and Test Kit|Participants in this study arm will have access to Know@Home, a mobile HIV prevention app or website and will receive mail-out HIV self-testing kits.
10020709|NCT04219878|Active Comparator|Mail-Out Testing Kit Only|Participants in this study arm will receive mail-out HIV self-testing kits.
10020710|NCT04219826|Experimental|CK-3773274 - Cohort 1 (Obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
10020711|NCT04219826|Placebo Comparator|Placebo - Cohort 1 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
10020712|NCT04219826|Experimental|CK-3773274 - Cohort 2 (Obstructive HCM)|Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
10020713|NCT04219826|Placebo Comparator|Placebo - Cohort 2 (Obstructive HCM)|Subjects will receive placebo for up to 10 weeks
10020714|NCT04219826|Experimental|CK-3773274 & disopyramide - Cohort 3 (Obstructive HCM)|Subjects will receive doses 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
10020715|NCT04219826|Experimental|CK-3773274 - Cohort 4 (non-obstructive HCM)|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
10020716|NCT04219774|Experimental|Endovascular arm|Subjects meet all inclusion criteria and were randomized to intervention
10020717|NCT04219774|Active Comparator|Medical arm|Subjects meet all inclusion criteria and were randomized to best medical management
10020718|NCT04219774|Active Comparator|Non-Randomized Arm|Subject meets all inclusion criteria EXCEPT abnormal CTP. Subjects are not randomized and are eligible for only best medical management
10020719|NCT04219566|Active Comparator|Active VeNS|The VeSTAL device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
10020720|NCT04219566|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
10020721|NCT04218643|Active Comparator|Standard technique|Intravenous catheter inserted via standard technique
10020722|NCT04218643|Experimental|Ultrasound-guided technique|Intravenous catheter inserted via ultrasound guidance
10020723|NCT04217746|Experimental|High flow nasal cannula (HFNC) group|The HFNC group will receive heated (approximately 37 ⁰C) and humidified (100% relative humidity) oxygenated gas delivered at high flow at 50L/min. Flow could be decreased to as low as 30L/min and temperature to 31 ⁰C as per patient's tolerance.
10020724|NCT04217746|No Intervention|Conventional flow nasal oxygen (CFNO) group|The conventional flow nasal oxygen (CFNO) group is the control group which will receive ambient temperature and non-humidified oxygen delivered at flow rates of up to 8L/min (standard care).
10020725|NCT04216823||Sevoflurane Group|sevoflurane is used for anesthetic induction
10020726|NCT04216823||Propofol Group|intravenous anesthetic propofol is used for anesthetic induction
10020727|NCT04212117|Other|Arm 1 - Educational Platform, PALS|The Patient Activated Learning System is a free, health education platform written bu trusted MDs.
10020728|NCT04212117|Other|Arm 2 - WebMD|WebMD is a widely used educational platform for health information.
10020729|NCT04210947|Experimental|Foam-roller I-II-III|Participants will use foam roller in following order of 30RPM(I), 15RPM(II) and self-determined(III)
10020730|NCT04210947|Experimental|Foam-roller I-III-II|Participants will use foam roller in following order of 30RPM(I), self-determined(III) and 15RPM(II)
10020731|NCT04210947|Experimental|Foam-roller II-I-III|Participants will use foam roller in following order of 15RPM(II), 30RPM(I) and self-determined(III)
10020732|NCT04210947|Experimental|Foam-roller II-III-I|Participants will use foam roller in following order of 15RPM(II), self-determined(III) and 30RPM(I)
10020733|NCT04210947|Experimental|Foam-roller III-I-II|Participants will use foam roller in following order of self-determined(III), 30RPM(I) and 15RPM(II)
10020734|NCT04210947|Experimental|Foam-roller III-II-I|Participants will use foam roller in following order of self-determined(III), 15RPM(II) and 30RPM(I)
10020735|NCT04209387||Control|No PTSD, TBI, and Depression
10020736|NCT04209387||PTSD|Veterans ith PTSD
10020737|NCT04209114|Experimental|Arm A: Combination Therapy|Neoadjuvant (pre-surgical treatment) nivolumab + bempeg, followed by radical cystectomy (RC), followed by adjuvant (post-surgical treatment) nivolumab + bempeg
10020738|NCT04209114|Experimental|Arm B: Monotherapy|Neoadjuvant nivolumab, followed by RC, followed by adjuvant nivolumab
10020739|NCT04209114|Other|Arm C: Standard-of-care|RC alone, without neoadjuvant or adjuvant therapy
10020740|NCT04208529||CTX001|All subjects who complete or discontinue the parent study (CTX001-111 or CTX001-121) after CTX001 infusion will be asked to participate in this long-term follow-up study.
10020741|NCT04206735|Experimental|Interprofessional Education (IPE)|Each hospital needs to assign a 'COPD-NIV' team of champions to lead the implementation strategy at the local level. We will provide virtual or in-person (if safety permits) training for the COPD-NIV teams (one RT, one RN, and one MD). The training will consist of NIV knowledge and skills through the principles of IPE and teamwork. We will use the train the trainer method; after we train the COPD-NIV team champions, the champions will promote and hold training sessions for their peers in person (if safety permits, 2-3 times a month for 4 months). At present, we are providing these training sessions as prerecorded content available whenever the clinician is available. Champions will promote the training to their clinicians for the first 4 months and then at 6 and 12 months for new staff.
10020742|NCT04206501|Experimental|ICM guided Medical Management Group|A pre-specified management regimen based on standard clinical practice will be provided to the study team in which medical management including medication dosing (focusing on beta-blockers and diuretics) will be monitored and modified using Cardiac Implantable Electronic Devices (CIED) and OptiVol Monitor data. Based on CIED and patient engagement data, the study team will adjust medications and dosages, and optimize activity/exercise steps.
10020743|NCT04206501|No Intervention|Conventional Management Control Group|Non-study physicians will receive CIED/OptiVol data (as in usual care) and its use and the management strategy will be left to his/her discretion. To control for patient contact, patients in the conventional management group will have the same study visits as the interventional group and will include in-person device interrogation, and documentation of any medications changes.
10020744|NCT04203797|Experimental|dupilumab|A loading dose at the start of the treatment followed by once every two weeks (Q2W).
10020745|NCT04203797|Experimental|Matching placebo|Matching dupilumab
10020746|NCT04203433|Experimental|DLX105-DMP Multi-Dose Twice Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion twice weekly
10020747|NCT04203433|Experimental|DLX105-DMP Multi-Dose Once Weekly|4 Weeks of 1mg DLX105-DMP applied to a target lesion once weekly
10020748|NCT04203082|Experimental|Exposure Intervention|Participants randomized to receive the Exposure Intervention will be scheduled to come to clinic for a 1-hour session for the intervention. During this time, they will receive psychoeducation and behavioral exposure to the Cesarean section procedure.
10020749|NCT04203082|Other|Usual Care|Participants randomized to the Care as Usual condition will receive the typical standard of care that is offered in the center. This involves the anesthesiologist meeting with the patient during a delivery planning meeting to provide patients with the opportunity to review anesthetic technique and ask questions.
10020750|NCT04201197|Active Comparator|Inje Cocktail|Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)
10020751|NCT04201197|Experimental|Inje Cocktail + THC extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC
10020752|NCT04201197|Experimental|Inje Cocktail + THC/CBD extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC and 1350mg CBD
10020753|NCT04200651|Experimental|DEXTENZA® arm|This arm will receive the DEXTENZA® insert after cataract surgery and MIGS.
10020754|NCT04200651|Active Comparator|Prednisolone acetate 1% arm|This arm will receive the prescription for daily prednisolone acetate 1% eye drops after cataract surgery and MIGS.
10020755|NCT04200274||Mental Health Nurses in Germany|Nurses in Germany currently working with patients with mental disorders
10020756|NCT04200209|Experimental|Hospital|Twelve wards of the hospital will be evaluated at the same time.
10020757|NCT04198558|Experimental|Dose Level 1|MEDI0618 or placebo
10020758|NCT04198558|Experimental|Dose Level 2|MEDI0618 or placebo
10020759|NCT04198558|Experimental|Dose Level 3|MEDI0618 or placebo
10020760|NCT04198558|Experimental|Dose Level 4|MEDI0618 or placebo
10020761|NCT04198558|Experimental|Dose Level 5|MEDI0618 or placebo
10020762|NCT04198558|Experimental|Dose Level 6|MEDI0618 or placebo
10020763|NCT04198558|Experimental|Dose Level 7|MEDI0618 or placebo
10020764|NCT04198558|Experimental|Dose Level 8|MEDI0618 or placebo
10020765|NCT04198558|Experimental|Dose Level 9|MEDI0618 or placebo
10020766|NCT04198428|Experimental|Receives OUD-CDS|Clinics will have access to the OUD-CDS (Opioid Wizard)
10020767|NCT04198428|No Intervention|Does not Receive the OUD-CDS|"Clinics will not have access to the OUD-CDS (Opioid Wizard). These will be usual care clinics."
10020768|NCT04197999|Experimental|Single Ascending Dose followed by Multiple Doses|Up to 3 single ascending doses of GMI-1359 followed by the highest tolerated dose given for 3 consecutive days.
10020769|NCT04197544|Experimental|Intervention group|
10020770|NCT04197544|No Intervention|Control group|
10020771|NCT04196803|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
10020772|NCT04196803|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
10020773|NCT04196803|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
10020774|NCT04196803|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
9480736|NCT05261555|Experimental|Using the NoObesity app|"A mobile digital app (NoObesity) that enables families to set goals, track progress, play games, and access additional information and healthcare professionals to access training and monitor patients' progress."
9480737|NCT05261542||normal colorectal epithelium|Tissue samples from normal colorectal epithelium are collected during colectomy in every colorectal cancer patient
9480738|NCT05261542||cancer colorectal epithelium|Tissue samples from colorectal cancer are collected during colectomy in every colorectal cancer patient
9480739|NCT05261529|No Intervention|Control Group|Control Group with 30 patients diagnosed with SLE following their normal lifestyle in terms of dietary intake and physical exercise.
10020775|NCT04196686|Experimental|Ice bath Control then VR/AR|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
10020776|NCT04196686|Experimental|Ice bath with VR/AR then Control|Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
10036323|NCT01814618|No Intervention|Observation|These subjects did not have improved sense of smell after surgery and were randomized to this observation group or treatment group. These patients will be observed post-operatively but will not receive the trial medication.
10020777|NCT04196491|Experimental|Dose Escalation|"bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 800 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy with a planned starting dose of 450 x 10^6 CAR+ T cells.~Lenalidomide maintenance therapy is recommended for all patients and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later"
10020778|NCT04195399|Experimental|Treatment (nirogacestat)|Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9477419|NCT03562572|Active Comparator|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
10020779|NCT04193384||Group 1≤ (G1≤)|Group 1≤ (G1≤) - patients that performed bariatric surgery for ≤ 1 year
10020780|NCT04193384||Group 1> (G1>)|Group 1> (G1>) - patients that performed bariatric surgery for > 1 year
10020781|NCT04193189|Experimental|Group A, Arm 1: HEPLISAV-B (two injections)|Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.
9477420|NCT03562546|Experimental|Structured Resistance Exercise|12 week at home structured resistance exercise programme ('Strength From Within') using resistance bands. Under the supervision of an experienced exercise specialist.
9477421|NCT03562533||pegylated liposomal doxorubicin + carboplatin|carboplatin area under the curve [AUC] 5 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 every 4 weeks
9477422|NCT03562533||paclitaxel + carboplatin|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks
9477423|NCT03562520|Experimental|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
9477424|NCT03562507|Experimental|ESK981 Monotherapy|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
10020782|NCT04193189|Experimental|Group A, Arm 2: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
10020783|NCT04193189|Experimental|Group A, Arm 3: ENGERIX-B (three injections)|Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.
10020784|NCT04193189|Experimental|Group B: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
10020785|NCT04192630|Experimental|CVisc50 OVD|CVisc50 OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to IOL implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
10036324|NCT01814618|Experimental|Treatment|"These subjects did not have improved sense of smell after surgery and were randomized to this treatment group or the observation. These patients will be observed post-operatively and will receive a 3-month course of topical nasal steroids(budesonide respules).~Drug: Budesonide Respules~Other Names:~Pulmicort respules~Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months."
10036325|NCT01814631||Aloka|image quality and resolution
10036326|NCT01814644|Active Comparator|Standard Care|Individual assessment Lifestyle counseling
9802691|NCT05058404|Experimental|Experimental arm (B)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:~Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;~In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
9802692|NCT05054738|Experimental|Combined Recovery Program (CRP)+Treatment-as-usual (TAU)|Combined Recovery Program (CRP) is a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit. Attendance of CRP will be in addition to Treatment as Usual (TAU), that is, standard inpatient programming.
10036327|NCT01814644|Experimental|TRIMM Intervention|Individual assessment Lifestyle counseling Text messages
10036328|NCT01814657|Placebo Comparator|Normal Saline|Conscious sedation and sterile normal saline (placebo) paracervical block
10036329|NCT01814657|Active Comparator|Lidocaine|Conscious sedation and Lidocaine hydrochloride 1% solution paracervical block
10020786|NCT04192630|Active Comparator|ProVisc OVD|ProVisc OVD will be carefully injected into the anterior chamber using standard aseptic technique, during the surgical procedure. The duration of the treatment is anticipated to be approximately 15-20 minutes for the surgical procedure. The OVD may also be used to coat surgical instruments prior to IOL implantation (for example, the internal surfaces of an IOL inserter are typically filled and/or coated with the OVD to provide lubricity during IOL compression and delivery into the eye). Additional OVD of the same product, may be injected as needed throughout surgery to keep the anterior chamber fully formed and to re-inflate the capsular bag following cataract removal. At the end of the surgical procedure it is recommended that OVD be removed from the eye as completely as practical by thoroughly irrigating and aspirating with a sterile irrigating solution.
10020787|NCT04192318|Experimental|Hospital-based violence prevention with community initiative|Youth who are living in communities that receive Communities that Care Prevention System (CTC) will also receive Bridging the Gap (BTG), a hospital-based violence prevention program with 6-months of community case management.
9477425|NCT03562507|Experimental|ESK981 and Nivolumab|"ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles~Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle"
10020788|NCT04192318|Experimental|Hybrid hospital based violence prevention|Youth who do not live in a community that has CTC but will receive BTG.
10020789|NCT04192318|Active Comparator|Treatment as usual|Youth living in a community without the CTC program and will receive treatment as usual (TAU) in the hospital.
10020790|NCT04192318|Experimental|Treatment as usual with community initiative|Youth living in a community with the CTC program and will receive treatment as usual (TAU) in the hospital.
10020791|NCT04191460|Experimental|WP-I dose A|n=7. Injection of 0.05 mg/kg cRGD-ZW800-1, within 16-20 hours before imaging/surgery
9477426|NCT03562468|Placebo Comparator|Placebo|Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
9477427|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 300 mg/day|Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
9477428|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 1000 mg/day|Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
9477429|NCT03562455|Experimental|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
9477430|NCT03562455|Active Comparator|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
9477431|NCT03562442|Experimental|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).~Intervention: Smoking cessation"
9477432|NCT03562442|No Intervention|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
9477433|NCT03562429|Experimental|TGF group (study group)|Use TGF to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
9477434|NCT03562429|Placebo Comparator|TGFP group (placebo group)|Use TGFP to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
9477435|NCT03562416|Experimental|Nintedanib|Nintedanib 150 mg tablet by mouth twice daily for 24 months.
9477436|NCT03562416|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 24 months
9477437|NCT03562403|Experimental|DBS on patients with abnormal movement disorders|16 patients with intractable abnormal movement disorders (Parkinson's disease, Essential tremors and Dystonia)
9477438|NCT03562390|Experimental|Experimental group|124 women with locally recurrent or metastatic breast cancer who will receive treatment at 17 research centers in Liaoning Province and Heilongjiang Province of China. Irinotecan is administered intravenously on days 1 and 8 of each 3-week cycle.
9477439|NCT03562364|No Intervention|Standard of Care|The standard of care group will remain non-weight bearing for 10-12 weeks following definitive fixation and receive physical therapy in accordance with standard practice at the treating center.
9477440|NCT03562364|Experimental|Early Advanced Weight Bearing (EAWB)|The Early Advanced Weight Bearing (EAWB) group will receive early weight-bearing treatment using the antigravity AlterG treadmill. These sessions will begin 14-28 days following definitive fixation and last for a total of 10 weeks
9477441|NCT03562351|Experimental|Verbal Instructions on use of RM|Caregivers will undergo an educational intervention with typical training with verbal instructions and use of a rectal diazepam trainer.
9477442|NCT03562351|Experimental|Video on use of RM|Caregivers will undergo an educational intervention with training by watching an instructional video regarding rescue medication administration
9477443|NCT03562351|Experimental|Mannequin on use of RM|Caregivers will undergo an educational intervention with training by use of a mannequin to practice administering the rescue medication
9477444|NCT03562338|Experimental|Manual Therapy and Exercise|
9477445|NCT03562338|Active Comparator|Usual Care|
9477446|NCT03562325|Other|ACT|Acceptance & Commitment Therapy (ACT)
9477447|NCT03562312|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
9477448|NCT03562312|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
9477449|NCT03562299|Experimental|Experimental|Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
10020792|NCT04191460|Experimental|WP-I dose B|n=7. Injection of (to be determined) mg/kg RGD-ZW800-1, within (to be determined) hours before imaging/surgery.
9477450|NCT03562286|Experimental|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
9477451|NCT03562273||GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
10020793|NCT04191460|Experimental|WP-II selected dose|n=14: expansion cohort (n=14) will be added to the group of patients that had received the selected dose in WP-I. Injection of 0.05 ór (to be determined) mg/kg cRGD-ZW800-1, within 48 hours before imaging/surgery.
9477452|NCT03562260|Experimental|children who had bipolar release|children who had bipolar release are included
9477453|NCT03562247|Active Comparator|Usual Care of IPF|Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
10020794|NCT04191057|Experimental|Healthy twin|Free light chains of twins compared to non-twin siblings
10020795|NCT04190628|Experimental|Monotherapy Dose Escalation|"A classic 3+3 design will be used to determine MTD and RP2D. Three to six patients per treatment cohort will be assigned to receive sequentially higher oral doses of ABM-1310 on a twice daily schedule (bid) for 28-day cycles, starting at a dose of 25 mg bid. Patients will receive twice daily oral doses of ABM-1310 continuously until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
10020796|NCT04190628|Experimental|Combination Therapy Dose Escalation|"A classic 3+3 design will guide the dose escalation in Part B. At each dose level, ABM-1310 will be administered in combination with cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle. The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy."
10020797|NCT04187833|Experimental|Nivolumab + Talazoparib|Nivolumab 480mg intravenously every 4 weeks (28 days) + Talazoparib 1mg orally daily
10020798|NCT04186793|Experimental|Guided Grocery Shopping|Participants in this study arm will receive a guided grocery shopping intervention for four weeks.
10020799|NCT04186793|Experimental|Diet Provision Group|"Participants in this study arm will be provided with a diet low in free sugars. This intervention replaces the habitual diet with a low free sugars diet (goal of <3% of total calories)."
10020800|NCT04184635|Experimental|Experimental ECMO + IABP Arm|"VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.~An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible)."
10020801|NCT04184635|No Intervention|Control Conventional Treatment Arm|Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.
10036330|NCT01814683|Experimental|Primaquine 7 day|Standard blood schizontocidal therapy plus 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
10020802|NCT04183205|Placebo Comparator|Placebo only arm|For individuals who are placebo responders during the 2 week placebo lead in phase, they will remain on placebo for the duration of the study (i.e., the 12 weeks where the placebo non-responders are taking sertraline).
10036331|NCT01814683|Placebo Comparator|Placebo controlled arm|Standard blood schizontocidal therapy plus 14 days placebo.
10036332|NCT01814683|Active Comparator|Primaquine 14 day|Standard blood schizontocidal therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
10036333|NCT01814709|Experimental|Itraconazole Arm|
10036334|NCT01814709|Experimental|Rifampin Arm|
10036335|NCT01814735|Experimental|Brown rice|Brown Rice
10036336|NCT01814735|Active Comparator|White rice|White rice
10036337|NCT01814826|Experimental|MLN4924 and Azacitidine|
10036338|NCT01814839|Active Comparator|ALN-TTRSC (revusiran)|
10036339|NCT01814839|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
10020803|NCT04183205|Active Comparator|Sertraline arm|After the 2-week placebo lead-in phase, placebo-non responders will receive sertraline 25 mg daily for 2 weeks. Thereafter, sertraline will be increased flexibly by 25 to 50 mg per day (at a rate no higher than 50 mg per week) to achieve a total daily dose of 50 to 200 mg, based on clinical response and tolerability, with a maximum dose of 200 mg/d. Subjects unable to tolerate higher doses may be dropped back to the previous dose and remain at that dose for the remainder of the study.
10020804|NCT04182841|Other|RheOx Treatment|RheOx is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
10020805|NCT04181619|Experimental|Coffeeberry beverage|300 mg Coffeeberry extract in 300 ml beverage
10020806|NCT04181619|Placebo Comparator|Color and flavor matched beverage|0 mg Coffeeberry extract in 300 ml flavor and color-matched beverage
10020807|NCT04180085|Experimental|BELATACEPT|
10020808|NCT04179565|Active Comparator|Immediate intervention|The immediate education (IE) group will receive the intervention, Healthy Children, Healthy Families: Parents Making a Difference! in period 1. In period 2, IE will receive no education and will be followed longitudinally for periods 2 and 3.
10020809|NCT04179565|Active Comparator|Delayed intervention|The delayed education (DE) group will serve as controls in period 1, receiving no intervention. In period 2, the treatments will cross over, so DE will receive the Healthy Children, Healthy Families: Parents Making a Difference! intervention.
10020810|NCT04178772|Experimental|JJVC Marketed Contact Lens|Eligible subjects that have no experience with soft multifocal lenses for more than 2 years will be assigned to a single study lens type worn in both eyes daily for at least 6 hours per day, everyday for approximately 12 weeks.
10036340|NCT01814852|Experimental|Shockwaves|4 weekly sessions of low-intensity shockwave therapy
10036341|NCT01814852|Sham Comparator|Control Group|
10020811|NCT04178317||Venetoclax Participants|Participants receiving venetoclax for chronic lymphocytic leukemia according to the approved local label, and the decision to prescribe Venetoclax is independent from the enrollment into the study.
10020812|NCT04178187|Active Comparator|Lactolevure|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Probiotics
9477454|NCT03562247|Experimental|Telenursing|Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
9477455|NCT03562247|Experimental|Telenursing and Remote Monitoring|Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
9477456|NCT03562234||Pre-op Chemotherapy for CLM: MR & LiMAx|"Patients undergoing pre-operative chemotherapy for colorectal liver metastases being treated at the Christie NHS (National Health Service) Foundation Trust.~No intervention - participants will continue with standard care. Observation of changes in liver fat and liver function measured by MR (Magnetic Resonance) scan and LiMAx test (Maximum liver capacity)."
9477457|NCT03562182||Women Receiving Antenatal Steroids|Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.
9477458|NCT03562182||Normal Pregnancy Controls|1) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.
9477459|NCT03562169|Active Comparator|Conventional Autologous Stem Cell Transplant (ASCT)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0
9477460|NCT03562169|Experimental|Augmented Autologous Stem Cell Transplant (ASCT)|Melphalan 100mg/m2 IV infusion on Day -3 and -2 plus ixazomib 4mg capsules on Day -4 and -1. ASCT will then be given on Day 0.
9477461|NCT03562143|Experimental|Alternate-day iron supplementation|Patients taking iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) for 6 weeks.
9477462|NCT03562143|Active Comparator|Daily iron supplementation|Patients taking iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) for 6 weeks.
9477463|NCT03562130|Experimental|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
9477464|NCT03562104|Experimental|Minimally consciousness Patient|Wessex Head Injury Matrix scale and Videofluoroscopy for characterization of swallowing disorders in Minimally consciousness Patient
9477465|NCT03562078|Experimental|Tai Chi Quan for Type 2 Diabetes|diabetic patients care education and Tai Chi Quan training, including 10-minute warm-up, 40-minute Tai Chi lesson, and 10-minute cool-down exercise in the training, twice a week for 12 weeks.
9477466|NCT03562078|No Intervention|Control Group for Type 2 Diabetes|diabetic patients care education
9477467|NCT03562065|Experimental|mesenchymal stem cells|"Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~1.10^6 CSM / kg~2.10^6 CSM / kg~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
9477468|NCT03562039|Experimental|M-MIST (group A)|M-MIST(incomplete granulation tissue removal)
9477469|NCT03562039|Active Comparator|M-MIST (group B)|conventional M-MIST.
10036342|NCT01814865|Experimental|Abiraterone Acetate + Prednisone|Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
9477470|NCT03562000|Experimental|Intervention group on cough and ventilation assistance|Mechanical cough assistance during physiotherapy post-extubation in ICU and systematic indication of NIV.
9477471|NCT03562000|Other|Control group on cough and ventilation assistance|Control group of extubated patients receiving the current gold standard strategy during physiotherapy after extubation in ICU and with selected indications of NIV.
9477472|NCT03561987||Obese patients and bariatric surgery|"The investigators include men and women, over 18 years old, with morbid obesity and candidates for bariatric surgery, under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
10020813|NCT04178187|Placebo Comparator|Placebo|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Placebo
10020814|NCT04178122|Experimental|Immediate Results|Participants in the Immediate Results arm will receive their genetic testing results from a genetic counselor at baseline following randomization.
10020815|NCT04178122|Experimental|Delayed Results|Participants in the Delayed Results arm will receive their genetic testing results from a genetic counselor 6 months after randomization.
10020816|NCT04176874||Diastasis of the rectus abdominis muscles|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
10020817|NCT04175119|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses.
10020818|NCT04173572|Experimental|Walking Group|Participants will be walking two times a week in supervised virtual walking groups on a secure online platform (Zoom) and will also participate in independent walks done at a location of their own choosing outside group participation.
10036343|NCT01814865|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg PO OD x 2 weeks
10020819|NCT04173572|Active Comparator|Fitbit Alone|Participants will be provided with a Fitbit wristband and instructed how to use it. Participants will also be given information on current recommended physical activity guidelines and told that study staff may be contacting them on a weekly basis if it looks like participants are not wearing their Fitbit for a certain number of days or to troubleshoot any issues.
10020820|NCT04171141|Experimental|Dose Escalation|Single Agent Dose Escalation
10020821|NCT04171141|Experimental|Dose Finding Anti-PD-1 Combination|Part 1B PF-07062119 plus anti-PD-1
10020822|NCT04171141|Experimental|Dose Finding anti-VEGF Combination|Part 1B PF-07062119 plus anti-VEGF
10020823|NCT04171141|Experimental|Dose Expansion Arm A|PF-07062119 as a Single Agent in CRC
10020824|NCT04171141|Experimental|Dose Expansion Arm B|PF-07062119 in Combination with anti-PD-1 in CRC
10020825|NCT04171141|Experimental|Dose Expansion Arm C|PF-07062119 in Combination with anti-VEGF in CRC
10020826|NCT04171141|Experimental|Dose Expansion Arm D|PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
10020827|NCT04170023|Experimental|Open-label ALXN2050 Monotherapy|"Experimental: Open-label ALXN2050 Monotherapy ALXN2050 orally administered~Group 1: Patients with PNH who are treatment naïve~Group 2: Patient with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN)~Group 3: Patients with PNH who have received danicopan monotherapy during study ACH471-103"
10020828|NCT04169490|Experimental|FS2 Emulsion Moisturizer|The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.
10020829|NCT04169490|Experimental|Active Comparator + FS2 Emulsion Moisturizer|The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.
10020830|NCT04169451|Experimental|letrozole group|Women will be given IUI treatment with ovarian stimulation with letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days.
10020831|NCT04169451|No Intervention|natural cycle group|Women will be given IUI treatment without ovarian stimulation.
10020832|NCT04169438|Placebo Comparator|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Vehicle Cream Base Emulsion Moisturizer + Petrolatum
10020833|NCT04169438|Experimental|FS2 Emulsion Moisturizer + Petrolatum|FS2 Emulsion Moisturizer + Petrolatum
10020834|NCT04167618|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).
10020835|NCT04164472|Experimental|Friend to Friend with Coaching|Program for relationally aggressive girls and their classmates delivered by school personnel who have been coached by study team.
10020836|NCT04164472|No Intervention|Control|Referral to school counselor as needed as per standard practice.
10020837|NCT04164316|Sham Comparator|Kinesio Tape No Tension|Kinesio Tape No Tension
10020838|NCT04164316|Active Comparator|Kinesio Tape with Tension|Kinesio Tape with Tension
10020839|NCT04163328|Experimental|HydroEye®|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
10020840|NCT04163328|Placebo Comparator|Placebo|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
10020841|NCT04161040|Experimental|Relapse (experimental) Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. For the Relapse (experimental) Group, the second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Then, during the third phase, the incentives will be discontinued.
10020842|NCT04161040|Experimental|Fatigue Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. The second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Participants in this arm will continue to earn incentives during Phase 3 to control reductions in physical activity due to fatigue.
10020843|NCT04161040|No Intervention|No-Incentive Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. Participants in this arm will not earn incentives during any of the three phases to control for the possibility that participants will engage in some physical activity in the absence of incentives.
10020844|NCT04160494|Experimental|D2C7-IT (6920 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (6920 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
10020845|NCT04160494|Experimental|D2C7-IT (4613.2 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (4613.2 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
10020846|NCT04159818|Experimental|Control group|no induction treatment, nivolumab 240 mg flat-dose, every 2 weeks
10020847|NCT04159818|Experimental|Cisplatin induction|Cisplatin 40mg/m2, weekly for two weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
10020848|NCT04159818|Experimental|Low dose doxorubicin induction|Low dose doxorubicin 15mg flat dose, weekly for 8 weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
10020849|NCT04159779||Venetoclax Participants|Participants for whom the treating physician has decided to treat with venetoclax before enrollment in this study.
10020850|NCT04157881|Other|APO-Dabigatran|Single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
10020851|NCT04157881|Other|APO-Dabigatran and Rabeprazole|4-7 doses of rabeprazole followed by single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
10020852|NCT04157335|Experimental|Benralizumab|Benralizumab administered subcutaneously
10020853|NCT04157335|Placebo Comparator|Placebo|Placebo administered subcutaneously
10036344|NCT01814891|Experimental|Orange maize|"Children were fed orange maize and the intervention name was orange"
10020854|NCT04155489|Active Comparator|restrictive|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started.
10020855|NCT04155489|Experimental|Liberal|In the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
10020856|NCT04154683|Experimental|group using Cellvizio® optical biopsy|
10020857|NCT04154384|Experimental|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse. Participants will be followed for one year post operation. An official pain management protocol will be developed during the pilot portion of this study.
10020858|NCT04154384|Experimental|Life Care Specialist (LCS) Intervention|In addition to receiving current standard-of-care for pain management in the aftermath of trauma, participants will have the full communication of opioid risk - via the validated Opioid Risk Tool (ORT) and a detailed substance abuse and mental health screening. As part of the daily LCS intervention, the inpatients will engage in behavioral pain management, opioid education and harm-reduction strategies (naloxone education), while also being screened for eligibility for respective referrals for complex needs, such as mental health and substance use disorders. Upon discharge, each participant will be educated by the LCS on future available modes of contact (telephone, email, video-call, follow up- visits at 2-, 6- and 12-weeks).
10020859|NCT04154384|Active Comparator|Standard of Care with Clinical Coordination|Participants will receive the current standard-of-care for pain management in the aftermath of trauma, including a standardized prescription protocol, and hospital-system approved discharge instructions which provide written instruction on how to taper opioid use and links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
10020860|NCT04153929|Experimental|Dose group 1|
10020861|NCT04153929|Experimental|Dose group 2|
10020862|NCT04153929|Experimental|Dose group 3|
10020863|NCT04153929|Experimental|Dose group 4|
10020864|NCT04153929|Experimental|Dose group 5|
10020865|NCT04153929|Experimental|Dose group 6|
10020866|NCT04153929|Active Comparator|Dose group 7 (Semaglutide)|
10020867|NCT04152343|Experimental|RFA Physics Library- PGP|The RFA Physics Library will be used during during percutaneous liver RFA procedures.
10020868|NCT04152252||Baseline|No CPR feedback during CPR
10020869|NCT04152252||Real-time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
10020870|NCT04152252||Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
10020871|NCT04152018|Experimental|Dose Escalation|Single Agent Dose Escalation
10020872|NCT04152018|Experimental|Dose Finding Anti-PD-1 Combination 1|Part 1B PF-06940434 plus anti-PD-1
10020873|NCT04152018|Experimental|Dose Expansion Arm A|PF-06940434 with anti-PD-1 in SCCHN
10020874|NCT04152018|Experimental|Dose Expansion Arm B|PF-06940434 with anti-PD-1 in RCC
10020875|NCT04151563|Experimental|Arm A: cabozantinib + nivolumab + ipilimumab|
10020876|NCT04151563|Experimental|Arm B: cabozantinib + nivolumab|
10020877|NCT04151563|Experimental|Arm C: nivolumab + ramucirumab + docetaxel|
10020878|NCT04151563|Experimental|Arm D: lucitanib + nivolumab|
10020879|NCT04151563|Experimental|Arm E: nivolumab + docetaxel|
10020880|NCT04151563|Active Comparator|Arm F: docetaxel|
10020881|NCT04151550|Other|AVG LSM Procedure|Ace Vision Group LSM procedure performed on both eyes.
10020882|NCT04150900|Experimental|Pembrolizumab + Bavituximab|Pembro and Bavituximab for progressive recurrent/metastatic squamous cell carcinoma of head and neck
10020883|NCT04149691|Experimental|CPL304110|CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.
10020884|NCT04148651|Experimental|CO2RE® Treatment|All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.
10020885|NCT04146909|Active Comparator|Breast Feeding|This group will consist of women who exclusively or mostly breast-fed for at least 4-6 months (< 6 ounces of formula/24 hours at 6-9 weeks of delivery)1 and who delivered within the past 18 months.
10020886|NCT04146909|Active Comparator|Formula Feeding|This group will consist of women who exclusively or mostly formula-fed (no breastfeeding or < 3 weeks of breastfeeding)1 and who delivered within the past 18 months.
10020887|NCT04143711|Experimental|Monotherapy DF1001 Dose Escalation|Dose escalation cohorts of DF1001 in sequential ascending order.
10020888|NCT04143711|Experimental|Monotherapy DF1001 PK/PD Expansion|Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
10020889|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Urothelial Bladder Cancer|Monotherapy expansion cohort enrolling up to 40 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
10020890|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Metastatic Breast Cancer|Monotherapy expansion cohort enrolling up to 50 patients with metastatic breast cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
10020891|NCT04143711|Experimental|Monotherapy DF1001 Expansion in HER-2 High Expressing Cancers|Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented high levels HER-2 expression using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
10020892|NCT04143711|Experimental|Combination Therapy with DF1001 and nivolumab|Combination dose escalation of DF1001 in combination with a PD-1 checkpoint inhibitor in patients with select solid tumors.
10020893|NCT04143711|Experimental|Combination Therapy with DF1001 and Nab paclitaxel|Combination dose escalation of DF1001 in combination with a PD-L1 checkpoint inhibitor in patients with select solid tumors.
10020894|NCT04142736|Experimental|Prone position|Patients with acute hypoxemic respiratory failure from any cause
10020895|NCT04142736|No Intervention|Supine position|Patients with acute hypoxemic respiratory failure from any cause
10020896|NCT04142632||long term evaluation of hypospadias surgery|
10020897|NCT04141202||Exercise group|
10020898|NCT04141046|Sham Comparator|Sham Stimulation|This is a sham/placebo arm that receives some stimulation, mimicking the skin sensations associated with tACS to enhance success of patient blinding.
9480740|NCT05261529|Experimental|Oil Group|Group with 30 patients diagnosed with SLE that add to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, without changing their lifestyle in terms of physical exercise.
10036345|NCT01814891|Active Comparator|Blue vitamin A group|Received vitamin A in the form of retinyl palmitate in oil at the estimated average requirment.
10020899|NCT04141046|Active Comparator|Theta-tACS|This arm targets theta oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
10020900|NCT04141046|Experimental|Alpha-tACS|This arm targets alpha oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
10020901|NCT04138394|Experimental|Vitamin C|Patients will receive intravenous vitamin C at 200mg/kg in divided doses, every 6 hrs for 96 hrs.
10020902|NCT04138394|Placebo Comparator|Control group|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
10020903|NCT04137133|Experimental|collection of expectoration, stools and blood|
10020904|NCT04136990|Active Comparator|Isolated ACL reconstruction|Isolated ACL reconstruction only.
10020905|NCT04136990|Experimental|ACL + LEAT|ACL reconstruction combined with Lateral Extra-Articular Tenodesis (LEAT).
10020906|NCT04136756|Experimental|Dose Escalation|"Evaluation of NKTR-255 as:~Monotherapy~In combination with daratumumab~In combination with rituximab~This phase will help to determine the RP2D of NKTR-255"
10020907|NCT04136756|Experimental|Dose Expansion Cohort A|Evaluation of RP2D of NKTR-255 as monotherapy in patients with NHL relapsed after CAR-T
10020908|NCT04136756|Experimental|Dose Expansion Cohort B|Evaluation of RP2D of NKTR-255 as monotherapy and in combination with SC daratumumab in patients with R/R MM
10020909|NCT04136756|Experimental|Dose Expansion Cohort C|Evaluation of RP2D of NKTR-255 as monotherapy and in combination with rituximab in patients with R/R iNHL
10020910|NCT04136262|Experimental|Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
10036346|NCT01814891|Placebo Comparator|White|Received oil only at the same volume as the vitamin A group
10020911|NCT04136262|Placebo Comparator|TwHF (dummy) plus MTX|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
10036347|NCT01814904|Experimental|MCI-196-L|MCI-196 BSA eq 3g
10036348|NCT01814904|Experimental|MCI-196-M|MCI-196 BSA eq 6g
10036349|NCT01814904|Experimental|MCI-196-H|MCI-196 BSA eq 9g
10036350|NCT01814904|Active Comparator|CBPB|Calcium-based P binder
10036351|NCT01814917|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
9477473|NCT03561987||No obese patients and abdominal surgery|"The investigators include men and women, over 18 years old, without obesity and candidates for abdominal surgery (hernioplasty, cholecystectomy, fundoplication), under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
9477474|NCT03561974|Experimental|Humidification|
9477475|NCT03561974|No Intervention|Control group without humidification|
9477476|NCT03561961|Active Comparator|Moderate Hypo-fractionation|In arm 1 of the study, patients who are randomized to receive moderately hypo-fractionated RT will receive a total dose of 66-68 Gy in 25# to the primary over 5 weeks, with treatment being delivered daily. All patients will receive a dose of 50 Gy in 25# to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60-66 Gy/25# as a simultaneous integrated boost(SIB).
9477477|NCT03561961|Experimental|Extreme Hypo-fractionation|In Arm 2 of the study, patients who are scheduled to receive SBRT will receive a course of 5 fractions of radiation; each fraction size will be 7.00-7.25 Gy. The total dose will be 35-36.5 Gy. All patients will receive a dose of 25 Gy in 5 # to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30-35 Gy/5# as a simultaneous integrated boost(SIB).The 5 treatments will be scheduled to be delivered alternate day over approximately 7-10 days. An option of equivalent biological dose using 35-36.5 Gy in 5 weekly fractions may be allowed for multicentric accrual in the future.
9477478|NCT03561948|Experimental|Experimental group|Surgery and Intraperitoneal Chemotherapy
9477479|NCT03561948|Placebo Comparator|Control group|only surgery
9477480|NCT03561935|Experimental|Propafenone group|Prescribtion of propafenone for the management of premature ventricular complex
9477481|NCT03561935|Active Comparator|Indenol group|Prescribtion of indenol for the management of premature ventricular complex
9477482|NCT03561922|Experimental|RETINA IMPLANT Alpha AMS|All participants receive the subretinal device RETINA IMPLANT Alpha AMS
9477483|NCT03561909|Other|Platelet transfusion|HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
9477485|NCT03561857|Experimental|Confocal Laser Endomicroscopy|All included patients will undergo probe-based Confocal Laser Endomicroscopy during Robotic-Assisted Radical Prostatectomy (RARP) or Laparoscopic Radical Prostatectomy (LRP)
9477486|NCT03561844|Active Comparator|aromatherapy-scent|
9477487|NCT03561844|Active Comparator|aromatherapy-touch|
9477488|NCT03561844|No Intervention|waiting-list control|
9477489|NCT03561805|Other|Prolonged continuous ECG monitoring|Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
9477490|NCT03561792|No Intervention|traditional RSBI|the decision to continue SBT depends on the traditional RSBI (RSBI < 105 predicts successful weaning)
9477491|NCT03561792|Experimental|Diaphragmatic RSBI|diaphragm ultrasound was done to measure diaphragmatic displacement which is used to calculate DRSBI and The investigator takes the decision about SBT continuation based on the result of DRSBI (DRSBI < 1.3 predicts successful weaning)
9477492|NCT03561779|Experimental|YYD302|YYD302 (2ml)
9477493|NCT03561779|Active Comparator|Synovian Inj.|Synovian Inj. (3ml)
9477494|NCT03561753|Active Comparator|Group A (the standard 2HRZE/4HR regimen)|Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
9477495|NCT03561753|Experimental|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|Group B, PRS Regimen (4EZ [high dose] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
9477496|NCT03561740|Experimental|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
9477497|NCT03561740|No Intervention|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
9477498|NCT03561727|Experimental|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
9477499|NCT03561727|Active Comparator|Layered closure technique|Abdominal cavity will be closed with two separate layers of continuous sutures. The first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia. In case of incisions not exceeding the lateral border of rectus abdominis muscle, the second layer will involve only the anterior layer of the rectus abdominis muscle fascia. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer will include internal oblique abdominal muscle fascia, external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
9477500|NCT03561714||CMC-TI|Cardiometabolic Care Team Intervention
9477501|NCT03561714||Non-Intervention Comparator site|Non intervention comparator site with usual care
9477502|NCT03561688|Sham Comparator|Standard insole|a flat insole
10020912|NCT04135859|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
10020913|NCT04135859|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
10020914|NCT04134767|Experimental|Health Linkage|Research staff will: 1) meet with participants in a community setting, by phone, or video call to ask them questions about drug use and related behaviors, access to needed health and social services, and personal goals; provide overdose education and help develop a plan for reducing risks and accessing services; conduct saliva drug testing, offer HIV and hepatitis C testing and counseling, naloxone, and harm reduction supplies, and connect participants with needed services; 2) follow up with participants once a month for three months to help participants overcome challenges; and 3) six months after enrollment to the study, contact participants to conduct saliva drug testing. Participants will complete surveys at baseline, 3 months, and 6 months. The baseline will be conducted in jail for incarcerated participants preparing for re-entry, or in a community setting for those recruited in the community. The 3 and 6-month surveys will be conducted in a community setting.
9477503|NCT03561688|Experimental|Foot orthotics|Custom-made foot orthoses
10036352|NCT01814917|Active Comparator|CBPB|Calcium-based P binder
10036353|NCT01814930|No Intervention|Routine Care|Routine postpartum contraceptive counseling
10036354|NCT01814930|Experimental|Individual counseling|Brief standardized contraceptive counseling intervention
10036355|NCT01814943||Patients with prescription for low dose ASA (75-300 mg/day)|
10036356|NCT01814956|Experimental|1|i.v. lipid emulsion for parenteral nutrition
10036357|NCT01814956|Active Comparator|2|i.v. lipid emulsion for parenteral nutrition
9477504|NCT03561675|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9477505|NCT03561675|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
9477506|NCT03561662|Active Comparator|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
9477507|NCT03561662|Active Comparator|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
9477508|NCT03561662|Active Comparator|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
9477509|NCT03561649|Experimental|Adalimumab|"Adalimumab is not the experimental study drug. This treatment justifies the inclusion of patients and is used in accordance with its marketing authorization.~The patients will be seen as part of their follow-up consultation in Rheumatology.~Modality of administration: The baseline visit should take place no more than 4 weeks before the start of adalimumab treatment, 40mg every 2 weeks, subcutaneously, in accordance with Summary of Product Characteristics.~At baseline and 6 months follow-up visits, a single blood draw for the biomarker dosage will be added to the standard patient health care follow-up. The clinical examination will also be performed at these two visits, and the clinical response will be assessed after 6 months of adalimumab treatment at M6 follow-up visit."
9477510|NCT03561623||Patients with Post Polio Syndrome|Post Polio syndrome diagnosed according to March of Dimes Criteria; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
9477511|NCT03561623||Healthy controls|subjects age- and sex-matched; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
9477512|NCT03561610|Active Comparator|Study group 1|normal Nutrition + sip feed (covers individual energy and nutrient demands)
9477513|NCT03561610|Experimental|Study group 2|normal Nutrition + gumdrops (covers individual energy and nutrient demands)
9477514|NCT03561571|Active Comparator|Butter based breakfast|
9477515|NCT03561571|Active Comparator|Chocolate spread based breakfast|
10020915|NCT04134767|Other|Overdose Education|"The investigators will initiate the comparison group in Group 2 counties six months before the intervention begins. Research staff will conduct an overdose intervention with the comparison cohort. This will occur pre-release if individual is recruited in jail. The comparison group participants will watch a video on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit.~As in the intervention group, the comparison group participants will complete surveys at the baseline (in jail if recruited in jail, in a community setting if recruited in the community), and at 3 months and 6 months after the baseline. Surveys will be identical to those delivered to the intervention cohort."
10020916|NCT04133922|Active Comparator|GLP-1|GLP-1 infusion 1.2 pmol/kg/min for 150 min
9477516|NCT03561558|Experimental|Ibuprofen D, oral suspension|Ibuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
9477517|NCT03561558|Active Comparator|Nurofen® for Children, oral suspension|Nurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.
9477518|NCT03561545|Experimental|Functional capillary density|Functional capillary density during weightlessness
10020917|NCT04133922|Active Comparator|GLP-1 + Insulin clamp|GLP-1 infusion 1.2 pmol/kg/min for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min
9477519|NCT03561532|Active Comparator|FMT|50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum
9477520|NCT03561532|Placebo Comparator|Placebo|50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.
9477521|NCT03561519|Active Comparator|FMT|IBS patients randomized to receive FMT from a healthy donor.
9477522|NCT03561519|Placebo Comparator|Placebo|IBS patients randomized to receive autologous FMT (fecal suspension made of their own feces) as a placebo.
9477523|NCT03561506|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
9477524|NCT03561506|Active Comparator|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
9477525|NCT03561493|Experimental|zumba exercise group|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one h in length and a recovery period of at least 48 h was taken between classes.
9477526|NCT03561493|No Intervention|non zumba exercise group|The participants in the control group did not receive any intervention.
9477527|NCT03561480|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
9477528|NCT03561480|Active Comparator|Placebo group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
9477529|NCT03561454|Other|XOFT-Intra-Operative Radiation Therapy|XOFT-Intra-Operative Radiation Therapy
9477530|NCT03561441|Active Comparator|Tailored standard hydration|Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
10020918|NCT04133922|Active Comparator|Saline + Insulin clamp|Saline infusion at 30 ml/hr for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min.
9477531|NCT03561441|Experimental|Tailored aggressive hydration|Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
10020919|NCT04133077|Other|Succeed PDX|Genetic analysis will be performed in patients who got a successful PDX
10020920|NCT04132414|Experimental|NIRS open|Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia
10020921|NCT04132414|No Intervention|NIRS blinded|NIRS monitoring applied and masked for caregiver.
10020922|NCT04132232|Experimental|Treatment Group|"The patient will exhaled into the Smokerlyzer® device will at each visit~Exhaled carbon monoxide and fetal carboxyhemoglobin levels will be disclosed to the patient~Risks of adverse perinatal outcomes related to maternal carboxyhemoglobin and fetal carboxyhemoglobin level will be provided."
9477532|NCT03561415|Experimental|Universal posaconazole prophylaxis|Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.
10020923|NCT04132232|No Intervention|Control Group|"The patient will exhale into the Smokerlyzer® device at each visit.~Exhaled carbon monoxide and fetal carboxyhemoglobin level will NOT be disclosed to the patient~No risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin levels will be provided"
10020924|NCT04132050|Experimental|R788|Patients are administered R788 for 24 weeks (double-blind period), followed by R788 for up to 52 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
10020925|NCT04132050|Placebo Comparator|Placebo|Patients are administered Placebo for 24 weeks (double-blind period), followed by R788 for up to 28 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
10020926|NCT04129151|Experimental|PALBOCICLIB and GANITUMAB|"The research study procedures include screening for eligibility and study treatment including evaluations for testing and follow up visits.~The study treatment will be 12 months in duration and follow up will be one year from when the participant receives the last dose of study drug.~The names of the study drugs involved in this study are:~Palbociclib-Oral, per protocol pre determined dosage, once a day for 21 days~Ganitumab-Intravenous, per protocol predetermined dosage, twice per cycle~Cycle is 28 days"
10020927|NCT04129060|Experimental|Mecamylamine Challenge|One of the two study days will be the oral mecamylamine.
10020928|NCT04129060|Experimental|Placebo Challenge|One of the two study days will be the oral placebo.
10020929|NCT04128189|Active Comparator|Transplanted subject|In addition to receiving standard dose (2) of Shingrix prior to transplantation, participant may receive a 3rd dose several months after transplantation if they meet criteria related to no rejection.
10020930|NCT04128189|Sham Comparator|Non-Transplanted subject|Receives standard Shingrix dose (2), but not transplanted within 16 month time frame post-dose, so does not receive additional Shingrix dose.
10020931|NCT04127110|Experimental|Lorlatinib|"Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).~Lorlatinib will be taken continuously on a daily basis until disease progression, unacceptable toxicity, occurrence of any withdrawal criterion, whichever comes first."
10020932|NCT04126603|Placebo Comparator|Group A Placebo|Metformin + Placebo.
10020933|NCT04126603|Active Comparator|Group B Active|Metformin + Placebo
10020934|NCT04126486|Other|Zio®XT Monitor Arm|
10020935|NCT04126486|No Intervention|Usual Care Arm|
10020936|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)|
10020937|NCT04126200|Experimental|Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)|
10020938|NCT04126200|Experimental|Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)|
10020939|NCT04126200|Experimental|Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)|
10020940|NCT04126200|Experimental|Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)|
9477533|NCT03561415|Experimental|Pre-emptive posaconazole therapy|Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.
9477534|NCT03561402||Patients with active disease|From the cohort of patients receiving teriflunomide - 1 tablet (14 mg) daily, the investigators will identify patients that have active disease..
10020941|NCT04126200|Active Comparator|Belantamab mafodotin monotherapy cohort expansion|
10020942|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)|
10020943|NCT04126200|Experimental|Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)|
10020944|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat cohort expansion(Sub-study 3)|
10020945|NCT04126200|Experimental|Belantamab mafodotin+ dostarlimab cohort expansion(Sub-study 4)|
10020946|NCT04126200|Experimental|Belantamab mafodotin+ isatuximab cohort expansion(Sub-study 5)|
10020947|NCT04124497|Experimental|Daratumumab Pomalidomide dexamethasone|"Therapy consists in cycles of the DPd combination as follows:~Pomalidomide 4 mg once daily on days 1-21;~Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22;~Daratumumab 16 mg/kg intravenously at following schedule:~cycle 1 and 2: days 1, 8, 15, and 22~cycle 3 through 6: days 1, and 15~from cycle 7 until disease progression: day 1."
10020948|NCT04123314|Experimental|Psilocybin|Participants will complete an 8-week course of study treatment including weekly psychological support and two moderate to high dose psilocybin administrations in weeks 4 and 6.
9477535|NCT03561402||Patients with stable disease|From the cohort of patients receiving teriflunomide (as above), the investigators will identify patients that have stable disease.
10020949|NCT04123093|Experimental|Healthy Volunteers|The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.
10020950|NCT04123093|Experimental|Wound care|The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.
10020951|NCT04118049|Experimental|Vaginal Probiotic Arm|"BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) is offered over the counter. It contains a total of 5 billion lactobacilli: L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus.~RestoreTM gel: moisturizing personal lubricant.~We will recommend to participants to use the probiotic supplement and vaginal lubricant as a vaginal suppository three times weekly at night for 3 months."
9802693|NCT05054738|Active Comparator|CRP+ Stable & Able (S&A)+TAU|Combined Recovery Program (CRP) a six-session motivational enhancement and daily living skills therapy workshop provided while on the inpatient unit, plus a home telehealth program (Stable & Able) which begins on day 1 of hospital discharge. Attendance of CRP and S&A will be in addition to TAU, that is, standard inpatient programming.
10020952|NCT04118049|Other|Standard Care Arm|Women will perform standard care which includes follow up at 3 months for pessary removal/care.
10020953|NCT04117620||Patients|Patients from 7 to 17 years of age with vestibular deficiency.
10020954|NCT04117620||Controls|Subjects from 7 to 17 years of age without vestibular deficiency
10020955|NCT04117516|Active Comparator|Open surgery|30 patients will be operated with an open carpal tunnel release.
10020956|NCT04117516|Experimental|Percutaneous surgery|30 patients will be operated with a percutaneous carpal tunnel release.
10020957|NCT04116541|Experimental|HDM201 + Ribociclib|Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.
10020958|NCT04116541|Experimental|Cabozantinib|Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), KIT, RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB), Fms-like tyrosine kinase 3 (FLT3), TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation detected on tumor sample from primary tumor or metastatic lesion.
10020959|NCT04116541|Experimental|Alectinib|Patient with ALK alterations: translocation, mutation or amplification
10020960|NCT04115761|Other|Investigational Group|ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens. The total 10 doses (1 mL/dose; 2±0.5 × 10^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
10020961|NCT04115761|Other|Control Group|the conventional treatment (RT and chemotherapy) will be given after tumor resection, followed by subsequent evaluations by an approximately 8-week interval.
10020962|NCT04115371|No Intervention|Control|Standard emergency department care
10020963|NCT04115371|Other|Intervention|Standard emergency department are plus GEDI consult
10020964|NCT04115059|Experimental|Dasatinib|"-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.~Dasatinib: Oral Study Drug(s):~Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.~This will continue for up to 24 cycles."
9477536|NCT03561363|Experimental|Saturated high-fat diet|"In this intervention group, subjects ingest a saturated eucaloric high-fat diet (64 E%) with total fat content being similar to the polyunsaturated high-fat diet.~The diet is enriched in saturated fat (36 E%). The main saturated fatty acids in the diet are primarily palmitic acid (C16:0) and stearic acid (C18:0). The main food sources are milk products, high-fat meat and vegetables.~Carbohydrate comprise 20 E% and protein 15 E%."
9477537|NCT03561363|Experimental|polyunsaturated high-fat diet|In this intervention group, subjects ingest a polyunsaturated eucaloric high-fat diet (64 E%), with total fat content being similar to the saturated high-fat diet. The diet is enriched in polyunsaturated fat (32 E%). The main polyunsaturated fatty acids in the diet are primarily linoleic acid (C18:2 n-6) and alpha-linoleic acid (C18:3 n-3). The main food sources are vegetable oils, nuts and high-fat fish (e.g. salmon). Carbohydrate comprise 20 E% and protein 15 E%.
9477538|NCT03561337|Experimental|PROTEIN-CARBOHYDRATE|Intervention group receiving protein and carbohydrate supplement
9477539|NCT03561337|Placebo Comparator|CARBOHYDRATE|Intervention groups receiving carbohydrate supplement
9477540|NCT03561324|Experimental|Use of IntraOperative Imaging Probe|The sterilized (Imaging Beta Probe) IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins.
9477541|NCT03561311|Experimental|Remote ischemic conditioning group|
9477542|NCT03561311|Sham Comparator|Sham remote ischemic conditioning group|
9477543|NCT03561298|Experimental|Single Arm: BGB-3111 + Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
9477544|NCT03561285||Stroke with antiphospholipid|
9477545|NCT03561285||stroke without antiphospholipid|
9477546|NCT03561272|No Intervention|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
9477547|NCT03561272|Active Comparator|Smart Phone Application|Adherence assessment via phone app
9477548|NCT03561272|Experimental|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
9477549|NCT03561233|Experimental|proton pump inhibitor|omeprazole 20 mg twice daily
9477550|NCT03561181|Experimental|High dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
9477551|NCT03561181|Experimental|low dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
9477552|NCT03561168||Developmental Delay|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
9477553|NCT03561168||Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
9477554|NCT03561168||Developmental Delay and Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay and Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
9477555|NCT03561155|Experimental|Robot assisted treatment|The experimental group (EG) will undergo a robot-assisted arm training using Amadeo® (Tyromotion-Austria).
9477556|NCT03561155|Active Comparator|Conventional treatment|The conventional group (CG) will undergo robot unassisted treatment (Conventional treatment).
9477557|NCT03561142|Experimental|Radiochemotherapy -> chemotherapy.|Radiochemotherapy followed by consolidation chemotherapy. Deep regional hyperthermia can additionally be performed at the centers in Tübingen and Erlangen.
9477558|NCT03561116|Experimental|XAN|XAN (1 sachet of 12 mg/day)
9477559|NCT03561116|Placebo Comparator|Placebo|Placebo (1 sachet with excipient)
9477560|NCT03561077|Experimental|Mindfulness program|To study the feasibility in France of a mindfulness program with mindfulness-based interventions (MBI's) dedicated for adolescents with chronic pain.
9477561|NCT03561064|Experimental|Receiving CBT-I|This is a single arm study. All participants will receive CBT-I (cognitive behavioral therapy for insomnia).
9477562|NCT03561038|Active Comparator|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
9477563|NCT03561038|Active Comparator|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
9477564|NCT03561025|Active Comparator|18F-FDG-PET/MRI|
9477565|NCT03561025|Experimental|18F-GE180-PET/MRI|
9477566|NCT03561012|Experimental|Intervention arm|
9477567|NCT03561012|Active Comparator|Control Arm|
9477568|NCT03560973|Experimental|Gemcitabine + Ramucirumab|Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
9477569|NCT03560973|Placebo Comparator|Gemcitabine + Placebo|Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
9477570|NCT03560947|Experimental|Manual Therapy and Exercise|
9477571|NCT03560947|Active Comparator|Usual Care|
9480741|NCT05261529|Experimental|Oil + Exercise Group|Group with 30 patients diagnosed with SLE that besides adding to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, will follow a physical exercise multimodal program the 12 last weeks.
10020965|NCT04115033|Experimental|True CES|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to cranial electrical stimulation (CES), which involves transfer of current from the alpha-stim device using earclip electrodes. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The treatments can be self administered by the participants. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
10020966|NCT04115033|Sham Comparator|Sham CES|Veterans with fibromyalgia who meet study criteria and are randomized to the sham comparator group will receive standard therapy in addition to a CES device that does not deliver active electrical stimulation. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
10020967|NCT04114890|Experimental|Pregnant woman with second trimester and third trimester|
10020968|NCT04113252|Experimental|Group 1--Diary and Possible Opioid Return Incentive|Participants in this arm will be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
10020969|NCT04113252|Experimental|Group 2--Diary, Coaching, Possible Opioid Return Incentive|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
10020970|NCT04113252|Experimental|Group 3--Diary and coaching|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary.
10020971|NCT04111965|Experimental|Nanodrop® (PRO-176)|- Nanodrop®. 0.6% propylene glycol. Ophthalmic emulsion Laboratorios Sophia, S.A. from C.V. Route of administration: Ophthalmic.
10020972|NCT04111965|Active Comparator|Systane® Balance|"Systane® Balance. 0.6% propylene glycol. Ophthalmic emulsion Alcon Laboratories, Inc.~Route of administration: Ophthalmic."
10036358|NCT01814969|Experimental|Hyperfractionated Radiochemotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks with simultaneous two cycles of chemotherapy according to the scheme: 5FU-325mg/m2 (bolus) on 1-3 and 16-18 (last 3 days of radiotherapy).~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiochemotherapy (HRTCT)."
10036359|NCT01814969|Active Comparator|Hyperfractionated Radiotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks.~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiotherapy (HRT)."
9477572|NCT03560934|Experimental|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo.~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services."
9477573|NCT03560934|Experimental|Non Cannabis Users|Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
9477574|NCT03560921||Stored blood transfusion|measurement of urinary NGAL
9477575|NCT03560921||Fresh blood transfusion|measurement of urinary NGAL
9477576|NCT03560908|Experimental|Dasatinib plus chemotherapy|Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation
9477577|NCT03560895|Active Comparator|Group I|Patients will be anesthetized using low-volume cuffed Kimberly-Clark * MICROCUFF * endotracheal tube (Microcuff, Halyard Health Inc., Atlanta, GA, USA), with its outer diameter determined by ultrasonography.
9477578|NCT03560895|Active Comparator|Group II|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
9477579|NCT03560895|Active Comparator|Group III|Patients will be anesthetized using uncuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
9477580|NCT03560882|Experimental|Atorvastatin|Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
10020973|NCT04110743|Other|delayed imaging acquisition|10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
10020974|NCT04110743|Other|low FDG dose imaging|0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
10020975|NCT04110743|Other|comparison PET images reconstructed using CT-based attenuation|10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
10020976|NCT04109144|Experimental|Large Volume Paracentesis (LVP) with Fresh Frozen Plasma (FFP)|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the second drainage participants will receive 2 units, or about 500 ccs, of fresh frozen plasma intravenously, plus 1 bottle, or 50 ccs, of 25% albumin if more than 4 liters of fluid are removed
10020977|NCT04109144|Active Comparator|Large Volume Paracentesis (LVP) with Albumin|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the first and third drainage participants will receive 1 bottle, or 50 ccs, of 25% albumin intravenously for every two liters of fluid removed
10020978|NCT04108858|Experimental|Phase I, Phase II Arm I (copanlisib, trastuzumab, pertuzumab)|Patients receive copanlisib IV over 60 minutes on days 1 and 8. Patients also receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10020979|NCT04108858|Active Comparator|Phase II Arm II (trastuzumab, pertuzumab)|Patients receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10020980|NCT04107298|Experimental|SUNDANCE™ Drug Coated Balloon|SUNDANCE™ Drug Coated Balloon
10020981|NCT04104828||Grass/tree AIT with Allergovit|Collection of blood and data from patients that receive allergen-immunotherapy (AIT) with Allergovit, an aluminium-containing AIT preparations.
10020982|NCT04104828||Grass/tree AIT with Polvac|Collection of blood and data from Patients that receive AIT with Polvac, an MCT-containing AIT preparation.
10020983|NCT04104828||Grass/tree AIT with Pollinex Quattro|Collection of blood and data from patients that receive AIT with Pollinex Quattro, an MCT-MPLA containing AIT preparation.
10020984|NCT04101851|Experimental|No axillary SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery. Approximately 80% of these patients will be assigned to the single study arm (no axillary SLNB) due to breast pCR (ypT0) at the final pathology of lumpectomy.
10020985|NCT04099667|Experimental|Phase 2; Low Dose MYOBLOC|Low Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
10020986|NCT04099667|Experimental|Phase 2; High Dose MYOBLOC|High Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
10020987|NCT04099667|Placebo Comparator|Phase 2; Placebo|Volume-matched placebo is a single treatment
10020988|NCT04099667|Experimental|Phase 3; MYOBLOC|MYOBLOC is a single treatment and will be compared to volume-matched placebo
10020989|NCT04099667|Placebo Comparator|Phase 3; Placebo|Volume-matched placebo is a single treatment
10020990|NCT04099342|Experimental|A: FEAST|Focally Electrically-administered Seizure Therapy (FEAST) is a form of Electroconvulsive therapy (ECT) that combines unidirectional stimulation, control of polarity, and an asymmetrical electrode configuration.
10020991|NCT04099342|Experimental|B: RP FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Polarity (RP) utilizes the same electrode placement as FEAST but a reversed directionality of current flow.
10020992|NCT04099342|Experimental|C: RC FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Configuration (RC) utilizes the same current flow as FEAST but a reversed electrode configuration.
10020993|NCT04099251|Experimental|Nivolumab|
10020994|NCT04099251|Placebo Comparator|Placebo|
10020995|NCT04098484|Active Comparator|Normal-weight|Subjects with a BMI of 18-25 kg/m2
10020996|NCT04098484|Experimental|Obese|Subjects with a BMI of > 30 kg/m2
10020997|NCT04098198||Participants with an Inborn Error of Metabolism|Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years
10020998|NCT04096066|Experimental|KRd (Experimental Arm)|"Carfilzomib (K):~20 mg/m2 IV on day 1 of cycle 1;~56 mg/m2 IV on days 8 and 15 in cycle 1;~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~56 mg/m2 on days 1 and 15 from cycle 13 and onwards.~Lenalidomide (R):~- 25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.~Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration."
10020999|NCT04096066|Active Comparator|Rd (Control Arm)|"Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.~Until PD or intolerance."
10021000|NCT04093388|Experimental|Self-PAP|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the self-administered Papanicolaou (Pap) smear. They will be compared to each other for congruence and accuracy.
10021001|NCT04093388|Experimental|Traditional Pap|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the traditional, healthcare provider obtained Papanicolaou (Pap) smear specimen. They will be compared to each other for congruence and accuracy.
10021002|NCT04091308|Active Comparator|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
10021003|NCT04091308|Experimental|Usual Care with Protein Supl.|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
10021004|NCT04091308|Experimental|Individualized Physical Exercise Training with Protein Supl.|This group is also called EXER group, and will receive individually tailored physical exercise programs, based on their strength and weaknesses from the baseline testing.
10021005|NCT04091048||Primary Cohort|
10021006|NCT04090905||Cohort|
9477581|NCT03560856|Other|Fulvestrant 500mg + palbociclib 125 mg|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
9477582|NCT03560843|Experimental|MBSR treatment|MBSR will be administered over 8 week period.
9477583|NCT03560843|No Intervention|Control group|Usual care will continue for this group.
9477584|NCT03560830||Control|Sedentary control subjects with no medical or psychiatric disorder
9518144|NCT03299452|Experimental|Alphacait-guided therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.
10021007|NCT04089059|Other|Treatment Arm|Pulmonary Artery Pressure Guided Heart Failure Management (PAPGHFM) and Guideline Directed Medical Therapy (GDMT) considering daily Pulmonary Artery Pressure (PAP) measurements and vital signs collected by Cordella Heart Failure System (CHFS).
10021008|NCT04085614|Experimental|Dynamic Coronary Roadmap group|Patients will be treated via standard of care for PCI with navigation support of Dynamic Coronary Roadmap.
10021009|NCT04085614|Active Comparator|Control group|Patients will be treated via standard of care for PCI without navigation support of Dynamic Coronary Roadmap.
10021010|NCT04085042|No Intervention|Usual Care|Usual care during peripheral venous catheterization. Nurses will continue with the normal routine practice, by preparing all needed material individually.
10021011|NCT04085042|Experimental|PIVC pack|Nurses will use a sterile pack that includes all needed devices for peripheral intravenous catheterization according to the latest evidence (eg, cannula, swabs, disposable tourniquet, antiseptic).
10021012|NCT04084730|Experimental|Participants with Breast Cancer|Participants will have unicentric pathological stage I invasive ductal breast cancer or Grade 1 or 2 DCIS measuring <3cm in longest diameter on pathology and/or mammogram that is histologically confirmed at MSKCC.
10021013|NCT04084548|Experimental|Lidocaine and placebo|Lidocaine and placebo
10021014|NCT04084548|Experimental|Ketamine and placebo|Ketamine and placebo
10021015|NCT04084548|Experimental|Lidocaine and ketamine|Lidocaine and ketamine
10021016|NCT04084548|Placebo Comparator|Placebo and placebo|Placebo and placebo
10021017|NCT04084210|Active Comparator|Juul + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
10021018|NCT04084210|Active Comparator|Juul + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
10021019|NCT04084210|Active Comparator|VLNC + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
9518145|NCT03299426|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
9802694|NCT05054738|No Intervention|Treatment-as-usual only (TAU):|TAU will only receive the usual care on the inpatient unit including medical and medication management.
10021020|NCT04084210|Active Comparator|VLNC + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
9802695|NCT05054387|Experimental|Agalsidase beta|Agalsidase beta treatment at approved dose and regimen, administered once every 2 weeks as an IV infusion
9802696|NCT05044611|Experimental|Amiloride|the experimental arm will receive 5mg of amiloride twice daily during 2 months
10021021|NCT04084210|Other|No Product + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given no alternative nicotine delivery products but in Switch Week 1, participants will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
9477585|NCT03560830||POTS GWI|GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.
9477586|NCT03560830||START|"START = Stress Test Activated Reversible Tachycardia One third of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) BEFORE EXERCISE, but AFTER EXERCISE (submaximal exercise stress tests) they developed postural orthostatic tachycardia with changes in heart rate of 30 or more between recumbent and standing. The effect was transient as it lasted about 36 to 48 hr.~The START group had brainstem atrophy and reduced brain activation during a cognitive task compared to sedentary control and other GWI subjects."
9477587|NCT03560830||STOPP|"STOPP = Stress Test Originated Phantom Perception Two thirds of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) both before and after 2 submaximal exercise stress tests. STOPP did not develop postural orthostatic tachycardia. their changes were equivalent to the sedentary control group.~The STOPP group increased brain activation of the basal ganglia and anterior insula during a cognitive task compared to sedentary control subjects."
10021022|NCT04084210|Other|No Product + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given no alternative nicotine delivery products for two weeks but in Switch Week 1 participants will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
9802697|NCT05044611|Placebo Comparator|Placebo|the control arm will receive a placebo twice daily during 2 months
10021023|NCT04083781|Experimental|Arm 1: No prophylaxis|Haemophilia A with inhibitors (HAwI) and haemophilia B with inhibitors (HBwI) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension part, patients in arm 1 will receive daily concizumab subcutaneous (s.c., under the skin) injections.
10021024|NCT04083781|Experimental|Arm 2: Concizumab prophylaxis|HAwI and HBwI patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
10021025|NCT04083781|Experimental|Arm 3: Concizumab prophylaxis|The HAwI and HBwI patients enrolled into the concizumab phase 2 trial (NN7415-4310) at time of transfer will be offered enrolment into this trial. It is required that these patients are on concizumab prophylaxis up until enrolment into the trial. These patients will continue concizumab prophylaxis.
9802698|NCT05039840|Experimental|SAR441344|SAR441344 intravenous (IV) loading dose followed by subcutaneous (SC) doses, 24 weeks
10021026|NCT04083781|Experimental|Arm 4: Concizumab prophylaxis|Patients previously on prophylaxis with by-passing agents and on-demand patients who are screened at a timepoint where the required number of patients in arms 1 and 2 have been randomised. These patients will, if eligible, be enrolled into the trial and will initiate concizumab prophylaxis at visit 2a (week 0).
9477588|NCT03560817||breast cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
9477589|NCT03560817||colorectal cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
9802699|NCT05039840|Placebo Comparator|Placebo|Placebo IV loading dose followed by SC, 24 weeks
9802700|NCT05039281|Experimental|Treatment (atezolizumab, cabozantinib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9802701|NCT05036681|Experimental|futibatini|
9802702|NCT05036681|Experimental|pembrolizumab|
9802703|NCT05033821|Experimental|Intervention|Participants who receive the FOY+ImPACT intervention
9802704|NCT05033821|No Intervention|Control|Participants who receive standard library programing, but not the FOY+ImPACT intervention.
9802705|NCT05033301|No Intervention|Specialist-led Ned Clinic|Participants enrolled in specialist-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist for one year.
9802706|NCT05033301|Experimental|Nurse-led Ned Clinic|Participants enrolled in the nurse-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist. In addition, men will be asked to complete another set of PROs that will be monitored by a trained oncology nurse, in between their specialist visits.
9477590|NCT03560804|Active Comparator|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
9477591|NCT03560804|Active Comparator|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
9477592|NCT03560752|Experimental|Prevention(multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
9477593|NCT03560726|Experimental|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
9477594|NCT03560726|No Intervention|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
9477595|NCT03560713|Experimental|FES + combined exercise|The Functional Electrical Stimulation (FES) + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant) and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
9477596|NCT03560713|Sham Comparator|FES sham|The Functional Electrical Stimulation (FES) sham + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
9477597|NCT03560700|Experimental|lactobacillus probiotic strain|60 billion CFU/day
9477598|NCT03560700|Placebo Comparator|placebo|
9477599|NCT03560687|Experimental|CardioSIDERAL|Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
9477600|NCT03560687|No Intervention|Control|
9477601|NCT03560661||Amyotrophic lateral sclerosis (ALS) patients|
9477602|NCT03560661||Primitive Lateral Sclerosis (PLS) patients|
9477603|NCT03560661||Kennedy's disease (KD) patients|
9477604|NCT03560648|Other|Reference group|To define the normal muscle aging from HD-sEMG and accelerometer signals correlated to muscular parameters obtained from Dual Energy X-ray Absorptiometry (DEXA), handgrip strength and muscular echography. Data will be collected in healthy volunteers, aged 25 to 75 years old, physically active on IPAQ questionnaire.
9477605|NCT03560648|Other|Test group|"To evaluate the capacity of MFA to detect early muscle aging in  tests  individuals, sedentary volunteers within the same age group (45-55 years old)."
9477606|NCT03560622|Active Comparator|ET cohort|Ten adults with refractory ET (ET cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.
9477607|NCT03560622|Experimental|control cohort|Twenty adult healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)).
9477608|NCT03560596|Experimental|High Risk Latino Patients Adherence Intervention|74 high risk Latinos with uncontrolled hypertension
9477609|NCT03560596|Active Comparator|High Risk Latinos Usual Care|74 high risk Latinos with uncontrolled hypertension
9477610|NCT03560583|Experimental|Metoclopramide 10 mg BID|
9477611|NCT03560583|Placebo Comparator|Placebo 10 mg BID|
9477612|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
9477613|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
9477614|NCT03560570||Control|Healthy subject
9477615|NCT03560544|Experimental|Breaking up sitting time|A behaviour-change intervention to break up prolonged sitting in the workplace
9477616|NCT03560544|No Intervention|Control|The participants in the control group will continue their daily activities as normal without any form of information about the intervention.
10021027|NCT04083495|Experimental|ATLCAR.CD30 cells|The cellular product consisting of ATLCAR.CD30 cells will be administered via intravenous injection over 5 - 10 minutes through either a peripheral or a central line. The volume of infusion will depend upon the concentration of the cells when frozen and the size of the subject. Administration to eligible subjects will occur within 2 - 14 days after completing the lymphodepleting chemotherapy regimen
10021028|NCT04082676|Experimental|Height and weight based group|"Patients in Height and weight based group will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)"
10021029|NCT04082676|Active Comparator|Height based group|"Patients in Height based group will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)"
10021030|NCT04081233|Experimental|Early surgical stabilization|This arm will include early surgical stabilization (within 72 hours of admission) in addition to the usual care received for patients with multiple rib fractures. Usual care will involve pain management.
10021031|NCT04081233|Active Comparator|Usual care|This arm will be usual care only. Usual care will include pain managment.
10021032|NCT04080895|Experimental|group A|
10021033|NCT04080895|Experimental|group B|
10021034|NCT04078295|Experimental|Phase 1b: E7389-LF + Nivolumab|Participants will receive specified doses of E7389-LF (intravenous) and nivolumab (intravenous) on specified days.
10021035|NCT04078295|Experimental|Phase 2, Cohort-1: E7389-LF + Nivolumab|Participants with gastric cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
10021036|NCT04078295|Experimental|Phase 2, Cohort-2: E7389-LF + Nivolumab|Participants with esophageal cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
10021037|NCT04078295|Experimental|Phase 2, Cohort-3: E7389-LF + Nivolumab|Participants with small cell lung cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
10021038|NCT04075747|Experimental|Arm A|
10021039|NCT04075747|Experimental|Arm B|
10021040|NCT04075747|Experimental|Arm C|
10021041|NCT04074824||Necrotizing enterocolitis|Neonates diagnosed with NEC based on the Modified Bell criteria for NEC including clinical, radiological and Laboratory findings.
10021042|NCT04074824||Non-NEC|Neonates diagnosed with other conditions including low birthweight, prematurity, infection, metabolic, cardiovascular, CNS, respiratory or gastrointestinal problems.
10021043|NCT04074096|Experimental|Encorafenib + binimetinib + pembrolizumab|Encorafenib 450 mg oral route (PO) once daily (QD) + binimetinib 45 mg PO twice daily (BID) + pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W).
10021044|NCT04074096|Experimental|SRS followed by encorafenib + binimetinib + pembrolizumab|Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm); followed by encorafenib 450 mg PO QD + binimetinib 45 mg PO BID + pembrolizumab 200 mg IV Q3W. The treatment should be started more than 24 hours and less than 8 days (excluded) after the SRS
10021045|NCT04073667|Experimental|Early Rehabilitation Group|The first six weeks (1st-6th) will be followed as an exercise group and the second six weeks (7th-12th) will be followed as a control group without any intervention.
10021046|NCT04073667|Experimental|Late Rehabilitation Group|The first six weeks (1st-6th) will be followed as a control group without any intervention and the second six weeks (7th-12th) will be followed by exercise.
10021047|NCT04071366|Experimental|Part 1: Open Label Itacitinib Once Daily|During Part 1, all participants receive itacitinib 200mg once daily (open label) for 30 days. The study population will include participants receiving any approved IEC for an approved indication.
10021048|NCT04071366|Experimental|Part 2: Double-Blind Itacitinib Twice Daily|During Part 2, participants will be randomized to receive itacitinib 200mg or placebo twice daily for 30 days. The study population also includes participants who are receiving Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.
10021049|NCT04070131|No Intervention|Control Group|Regular follow ups.
10021050|NCT04070131|Experimental|Intervention Group|One weekly session (1 hour) of Horse-Assisted Rehabilitation, 24 weeks.
10036360|NCT01814982|Experimental|Part 1: JNJ-17299425|JNJ-1729425 will be administered once as 1 milligram (10 milliliter of a 0.1 milligram/milliliter (mg/ml) solution) intravenous bolus injection over 2 minutes in central vein. In case of no toxicity or Intra cranial pressure response, dose will be increased to a maximum of 200 milligram (mg).
10021051|NCT04069468||TheraSphere®|"Patients with HCC, iCC and mCRC will be treated. TheraSphere is administered in the liver through the hepatic artery. Treatment will be performed according to the Instructions for Use (IFU). Activity of administered TheraSphere is tailored in order to deliver an absorbed dose of 80 to150 gray (Gy) to the liver. Lung dose (D) will be calculated from the following formula: D=A*(1-S)*50/1. D=Planned dose absorbed by treated volume(Gy), A=Activity injected with microspheres (gigabequerel [GBq]), S=Percentage of pulmonary shunt, 1 assuming that the lung mass=1 kilograms [kg]). Number of treatments is up to Investigator's discretion while taking into account the cumulative dose to the liver and lung."
9477617|NCT03560505||Common fibular compression neuropathy|"Patients referred for electrophysiological assessment of common fibular compression neuropathy with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
10021052|NCT04069156|Placebo Comparator|Placebo Arm|LVAD Patients on the placebo arm will be given placebo medication
9477618|NCT03560505||Type 2 diabetes polyneuropathy|"Patients with type 2 diabetes referred for polyneuropathy involving the common fibular nerve with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
9477619|NCT03560492|Experimental|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
9477620|NCT03560492|Active Comparator|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
9477621|NCT03560479|Experimental|alpha1H, 7.4 mg/mL|alpha1H (7.4 mg/mL), solution for instillation, 30 mL
9477622|NCT03560479|Placebo Comparator|placebo|Placebo, 0.9% NaCl (sodium chloride), 30 mL
9477623|NCT03560479|Experimental|alpha1H, 37 mg/mL|alpha1H (37 mg/mL), solution for instillation, 30 mL
9477624|NCT03560479|Experimental|alpha1H, 74 mg/mL|alpha1H (74 mg/mL), solution for instillation, 30 mL
9477625|NCT03560453|No Intervention|Control|Attend assigned high school for 9 months
9477626|NCT03560453|Experimental|Project SEARCH plus ASD Supports|Attend Project SEARCH plus ASD Supports for 9 months
9477627|NCT03560440||Plasma exposure vancomycin|Pediatric patients treated with vancomycin
9477628|NCT03560427|Experimental|duloxetine+morphine|
9477629|NCT03560427|Placebo Comparator|placebo+morphine|
9477630|NCT03560414|Experimental|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
9477631|NCT03560414|Active Comparator|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
9477632|NCT03560414|Active Comparator|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
9477633|NCT03560401|Experimental|Brace group|After spinal surgery, patients in the brace group were instructed to wear a rigid brace (Knight-Taylor [chairback] brace) full-time for 12 weeks, except when bathing or lying in bed.
9477634|NCT03560401|No Intervention|No brace group|After spinal surgery, patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off.
9477635|NCT03560388|No Intervention|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
9477636|NCT03560388|Experimental|Touch/relaxation|Touch/relaxation treatment (pre-operative)
9477637|NCT03560388|Experimental|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
9477638|NCT03560375|Experimental|Circuit resistance training (CRT)|2-3 circuits * 10 exercises * 3 times per week
10021053|NCT04069156|Active Comparator|Active Arm|LVAD Patients on the active arm will be given 100mg Aspirin
10021054|NCT04067648|Experimental|S1 group|Sufentanil 0.3 μg/kg was intravenously given during anesthesia induction
10021055|NCT04067648|Experimental|S2 group|Sufentanil 0.4 μg/kg was intravenously given during anesthesia induction
10021056|NCT04067648|Experimental|S3 group|Sufentanil 0.5 μg/kg was intravenously given during anesthesia induction
9477639|NCT03560375|Experimental|Empagliflozin 10 MG|10 mg once daily
9477640|NCT03560375|Experimental|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources), aimed for sufficient protein from animal and mainly plant-based sources with carbohydrates limitation.
9477641|NCT03560362|Active Comparator|Bupivacaine with epinephrine|Patients will receive intraoperative intercostal nerve block with bupivacaine
10021057|NCT04066907|Experimental|Integrated Disease Management|Physicians randomized to intervention will attend a training session on the program standards and details of the IDM. Following the initial baseline interview a heart failure educator (HFE) will meet with subjects to obtain a detailed history of their HF, provide education, self-care management strategies (medication adherence, symptoms monitoring, dietary adherence, fluid restriction, exercise, weight management, smoking cessation) and review immunization status. A self-management action plan will be developed with the study physician and HFE to enable monitoring and management of HF by the participant.
10021058|NCT04066907|No Intervention|Usual Care|Subjects will receive HF care as usually provided by their physician as advised or as needed. Study commitments for the control group include the initial interview, the expected time allotment for this initial visit is 1 hour. Telephone follow-up will occur at 3 months and 9 months to collect exacerbation data and maintain contact with participant. At 6 months and 12 months telephone follow-up will be conducted by the research assistant and the questionnaires will be completed.
10021059|NCT04066062||Retrospective|A total of 700 vessel from 700 patients clinically indicated CCTA and IVUS or OCT performed within 3 months.
10021060|NCT04066062||Prospective|A total of 1,000 subjects will be enrolled in this Registry. This number of subject is expected to provide a maximum of 1,300 vessels. All CCTA and IVUS/OCT will be performed within 3 months
10021061|NCT04063241|No Intervention|Parent: Pre-implementation|Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized).
10021062|NCT04063241|Experimental|Parent: Post-Implementation|Doctors and nurses will be able to customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
10021063|NCT04063241|Other|Provider|Baseline measures will be assessed for providers. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. At the end of the study, assessments will be performed for those who use the health literacy-informed tool at least once during the study period.
10021064|NCT04060862|Experimental|Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant|
10021065|NCT04060862|Placebo Comparator|Phase 3: Placebo + Palbociclib + Fulvestrant|
10021066|NCT04060849|Experimental|Arm I (Nozin)|Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
10021067|NCT04060849|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
10021068|NCT04059965|Experimental|Intervention Arm|This cohort of patients will receive panel management through a customize software that integrates with the electronic health record
10021069|NCT04059965|Active Comparator|Control Arm|This cohort of patients will receive usual care
10021070|NCT04058756|Experimental|PDR001|All subjects in all combination will be entered in one arm
10021071|NCT04058639|Experimental|felt relief|"custom felt relief"
10021072|NCT04058639|Active Comparator|treatment as usual|standard treatment usually provided by the Surgical Outpatient Clinic
10021073|NCT04057001||Patients who received a HCV+ liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C+ virus positive tested liver transplant.
10021074|NCT04057001||Patients who received a HCV- liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C- virus positive tested liver transplant.
10021075|NCT04055818|Experimental|Nicotinamide|Oral Nicotinamide 1000 mg twice daily
10021076|NCT04055818|Experimental|THU Decitabine|Oral 250 mg THU and 5 mg decitabine Once per week
10021077|NCT04053569|Experimental|Diet with table grape|Table grape (5g/Kg) administered for four weeks with dietary recommendations. A strict restriction of fruits and the limitation of other foods containing polyphenols will be necessary.
10021078|NCT04053569|No Intervention|Specific dietary advice|Dietary recommendations (such as limitation of alcohol, caffeine), and low consumption of fruits.
10021079|NCT04053361|Active Comparator|Group A: Clinical ablation|"Cinical arrhythmia is fairly documented AF, pulmonary vein isolation will be performed. If AF persists after this step, electrical cardioversion will be performed.~If clinical arrhythmia is fairly documented type 1 AFL, cavo-tricuspid isthmus ablation will be performed.~If clinical arrhythmia is AT, it will be induced (if not persistent), identified by means of activation and/or entrainment mapping, and ablated.~If clinical arrhythmia is AT that is non-inducible during EP study, no ablation will be done.~If other incidental (or induced) AT is observed that can be qualified as non-clinical it will not be targeted unless considered important to ablate at discretion of operator.~No induction protocols for other, on top of already ablated, arrhythmias will be attempted."
10021080|NCT04053361|Experimental|Group B: Clinical plus substrate-based ablation|"- The initial ablation steps will be identical to those in patients from Group A.~Supplemental ablation will consist of:~Empirical lesion set within right atrium: superior vena cava isolation, posteroseptal bicaval line, and cavo-tricuspid isthmus ablation (if not already ablated)~AND~Homogenization of low-voltage zones (if any) in left / right atrium defined by bipolar voltage <0.5 mV in sinus rhythm or <0.2 mV in AF / AT. The threshold can be adapted in severely diseased atria to delineate reasonably smaller zones (<20% of atrial surface) achievable to ablate.~Arrhythmia induction protocol by10-second burst atrial pacing with cycle length of 300 ms decremented by 10 ms up to atrial refractoriness or cycle length of 200 ms.~Inducible ATs will be mapped and ablated if feasible. In case of inducible persistent (>5 min) AF, pulmonary vein isolation will be performed if not previously done as per protocol."
10021081|NCT04051346|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
10021082|NCT04051346|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
10021083|NCT04050189|Active Comparator|prenatal probiotic|will take probiotics every day from the 34th week of pregnancy until delivery; taking placebo for 10 days after delivery
10021084|NCT04050189|Active Comparator|postnatal probiotic|will take placebo every day from the 34th week of pregnancy until delivery; taking probiotics for 10 days after delivery
10021085|NCT04049669|Experimental|Core Regimen, sub-cohort A|For patients not eligible for re-irradiation; Start with Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
10021086|NCT04049669|Experimental|Core Regimen, sub-cohort B|For patients who are eligible for partial re-irradiation; Start with indoximod plus up-front re-irradiation, using a palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
10036361|NCT01814982|Experimental|Part 2: JNJ-17299425|JNJ-1729425 will be repeated once at a dose (which is, determined by Investigator in Part 1) as intravenous bolus injection over 2 minutes in central vein.
10021087|NCT04049669|Experimental|Core Regimen, sub-cohort C|For patients who are eligible for full-dose radiation; (All newly diagnosed DIPG patients and some relapsed ependymoma patients); Start with indoximod plus up-front radiation, using a palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
9477642|NCT03560362|Experimental|Lipossomal extended release bupivacaine|Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
9477643|NCT03560349|Experimental|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
9477644|NCT03560349|Placebo Comparator|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
9477645|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
9477646|NCT03560310|Experimental|Dual antiplatelet therapy|Ticagrelor 90 mg twice daily and ASA 75-100 mg daily for 12 months
9477647|NCT03560310|Active Comparator|Acetylsalicylic acid|ASA 75-160 mg daily for 12 months
9477648|NCT03560271|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 6 mg CHP
9477649|NCT03560271|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
9477650|NCT03560271|Placebo Comparator|Dose C|Placebo
9477651|NCT03560232|Active Comparator|Cefazolin + Gentamicin|"[Cefazolin]~Initial dose:~Cefazolin 2g IV x1 dose (patient weight < 120kg)~Cefazolin 3g IV x1 dose (patient weight >/= 120kg)~Subsequent dose:~Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min)~Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)~Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min)~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first"
9477652|NCT03560232|Active Comparator|Ceftriaxone|"Initial dose:~Ceftriaxone 2g IV x1 dose~Subsequent dose:~Ceftriaxone 2g IV every 24 hours~Duration:~One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first"
9477653|NCT03560232|Active Comparator|Ampicillin/Sulbactam|"Initial dose:~Ampicillin/Sulbactam 3g IV x1 dose~Subsequent dose:~Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min)~Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)~Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
9477654|NCT03560232|Active Comparator|Piperacillin/Tazobactam|"Initial dose:~Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes~Subsequent dose:~Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min)~Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
9477655|NCT03560232|Other|Clindamycin + Gentamicin|"Patients with known Penicillin allergy will receive:~[Clindamycin]~Initial dose:~Clindamycin 900mg IV x1 dose~Subsequent dose:~Clindamycin 600mg IV every 8 hours~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
9477656|NCT03560154|Experimental|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
9477657|NCT03560154|No Intervention|Home respiratory exercises|Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.
9477658|NCT03560089|Active Comparator|Rehabilitation with active serious game|25 patients will perform motor rehabilitation programme using the serious game
9477659|NCT03560089|Placebo Comparator|No active serious game|25 patients will not perform motor rehabilitation programme using the serious game
10021088|NCT04049669|Experimental|Salvage Regimen 1|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral metronomic cyclophosphamide and etoposide).
10021089|NCT04049669|Experimental|Salvage Regimen 2|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral lomustine and temozolomide).
9477660|NCT03560076||Group 1|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 1 implementation
9477661|NCT03560076||Group 2|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 2 (delayed) implementation
9477662|NCT03560063|Experimental|Corin OPS arm|Total hip replacement with use of Corin Optimised Positioning System to guide implant positioning
10021090|NCT04048824|Experimental|Inhibitory Learning-Based Exposure|Participants will receive exposure therapy aimed at increasing inhibitory learning.
10021091|NCT04048824|Active Comparator|Habituation-Based Exposure|Participants will receive exposure therapy aimed at reducing fear responding.
10021092|NCT04048642|Experimental|DASH diet; plant-based diet; DASH diet|Food is provided: 7 days of an ad libitum DASH diet, followed immediately by 7 days of an ad libitum whole food, plant based diet, followed immediately by 7 days of an ad libitum DASH diet again.
10021093|NCT04047836|Other|Low Nicotine|Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.
10021094|NCT04047836|Other|Medium or High Nicotine|The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.
10021095|NCT04045067||Group 1|A group of patients who have pulmonary vein isolation alone, without low-voltage areas identified.
10021096|NCT04045067||Group 2|A group of patients who have pulmonary veins isolation alone, with low-voltage areas identified but the complementary defragmentation will not be carried out.
10021097|NCT04045067||Group 3|A group of patients who have pulmonary veins isolation, with low-voltage areas identified and the complementary defragmentation will be carried out.
10021098|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 1|Custom neural anatomical target 1 defined by neuroimaging data
9477663|NCT03560063|Active Comparator|Standard care arm|Total hip replacement with standard templating to guide implant positioning
10021099|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 2|Custom neural anatomical target 2 defined by neuroimaging data
10021100|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 3|Custom neural anatomical target 3 defined by neuroimaging data
10021101|NCT04043442|Active Comparator|Active + Placebo rTMS for Left DLPFC Neural Target|"Neural anatomical target will be the Left Dorsolateral Prefrontal Cortex identified using the 5cm from the motor hot spot rule."
10021102|NCT04042168|Experimental|Intervention|Inappropriate use of inhalers and medication change. Pre-post intervention data will be compared.
10021103|NCT04041609|Experimental|LYR-210 (Low Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate low dose) in the middle meatus
10021104|NCT04041609|Experimental|LYR-210 (High Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate high dose) in the middle meatus
10021105|NCT04041609|Sham Comparator|Sham Procedure|In-office bilateral sham procedure
10021106|NCT04041479|Active Comparator|Standard of Care|FDA-cleared, standard-of-care iTBS repetitive Transcranial Magnetic Stimulation targeting the left dorsolateral prefrontal cortex (DLPFC), regardless of the depression subtype (biotype) determined by a magnetic resonance imaging (MRI) scan.
10021107|NCT04041479|Experimental|Targeted Side Arm|iTBS rTMS targeting the area of the brain (DLPFC or dorsomedial prefrontal cortex DMPFC)) that we hypothesize will be most effective for that subject's biotype (confirmation arm).
10021108|NCT04041479|Active Comparator|Opposite Side Arm|iTBS rTMS targeting the opposite site (DLPFC or DMPFC) than the one we hypothesize will be most effective for that subject's biotype (disconfirmation arm).
10021109|NCT04039607|Experimental|Nivolumab + Ipilimumab|
10021110|NCT04039607|Active Comparator|Sorafenib/lenvatinib|
10021111|NCT04038502|Active Comparator|Treatment Arm 1 - Carboplatin to Olaparib|Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.
10021112|NCT04038502|Active Comparator|Treatment Arm 2 - Olaparib to Carboplatin|Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.
10021113|NCT04037228||KneeAlign 2|Those of the group will be adopt KneeAlign 2: accelerometer-based navigation system at total knee arthroplasty.
9477664|NCT03560050|Experimental|Behavioral: Nutrition assistance|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
9477665|NCT03560050|Experimental|Behavioral: Children's environmental health|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
9477666|NCT03560037|No Intervention|Standard Colonoscopy|Patients randomly assigned to this group will receive standard colonoscopy without the use of a distal attachment.
9477667|NCT03560037|Experimental|Endocuff Vision Assisted Colonoscopy|Patients randomly assigned to this group will receive colonoscopy with the use of the Endocuff Vision distal attachment.
9477668|NCT03560024|Active Comparator|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
9477669|NCT03560024|Placebo Comparator|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
9477670|NCT03560011|No Intervention|Rituximab (375 mg/m²)|Single infusion of rituximab (375 mg/m²)
9477671|NCT03560011|Experimental|Rituximab followed by 5 injections of immunoglobulin IV|Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months
9477672|NCT03559985|Other|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
9477673|NCT03559985|Other|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
9477674|NCT03559972|Experimental|Treatment Group #1|"Subject in Treatment group 1 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~Hulk (cosmetic investigational)~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
9477675|NCT03559972|Experimental|Treatment group #2|"Subject in Treatment group 2 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~SkinMedica TNS Essential Serum~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
9477676|NCT03559959|Experimental|$0 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to redeem an HIV self-testing kit free of charge.
9477677|NCT03559959|Experimental|$0.5 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $0.5.
9477678|NCT03559959|Experimental|$1 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $1.
9477679|NCT03559959|Experimental|$2 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $2.
10021114|NCT04036994|Active Comparator|Experimental: Treatment group|
10021115|NCT04036994|No Intervention|Control group (no intervention)|
10036362|NCT01814995|Experimental|Nutrition/Physical Activity Intervention|There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
10036363|NCT01815021|Experimental|amorphous calcium carbonate|50, 100 and 200 mg elemental calcium tablets, according to the doctor's decision
10036364|NCT01815021|Active Comparator|crystalline calcium supplements|Tablets, according to the doctor's decision
10036365|NCT01815047|Experimental|200 IU Vitamin D3|A singular daily dose of 200 IU vitamin D3
10036366|NCT01815047|Experimental|2000 IU Vitamin D3|A singular daily dose of 2000 IU vitamin D3
10036367|NCT01815073|Experimental|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
10036368|NCT01815073|Experimental|Live Attenuated Varicella Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
10021116|NCT04033328|Experimental|Dose Escalation|ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.
10021117|NCT04033328|Experimental|Dose Expansion|RP2D dose
10021118|NCT04032782|Experimental|HM15136|
10021119|NCT04032782|Placebo Comparator|Placebo of HM15136|
10021120|NCT04030520|Experimental|intervention|participants will receive a behavioral intervention including counseling and offer of HIV oral fluid self test and PrEP
10021121|NCT04030520|Active Comparator|comparison|participants will be not be offered HIV oral fluid self test but receive counseling, condoms and offered PrEP
10021122|NCT04029623|Experimental|Partnered Rhythmic Rehabilitation (PRR)|Participants in this study are will receive the PRR intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
10021123|NCT04029623|Active Comparator|Group walking (WALK)|Participants in this study are will receive the WALK intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
10021124|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 1)|
10021125|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 2)|
10021126|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 1)|
10021127|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 2)|
10021128|NCT04026347|Experimental|Vesair|Subjects are treated with Vesair Balloon at enrollment (day 0)
10021129|NCT04026347|Sham Comparator|Sham|Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.
10021130|NCT04023812||Cohort 1|Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
10021131|NCT04023812||Cohort 2|Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
10021132|NCT04022200||Paclitaxel DCB for De Novo Coronary Lesions|we define de novo coronary artery lesions as the lesions never been treated with any interventional device, such as POBA, stent, rota ablation, laser etc.
10021133|NCT04021316|Active Comparator|Standard care arm|Compression bandaging therapy as per standard care
10021134|NCT04021316|Experimental|DCD Arm|DCD graft plus compression bandaging therapy as per standard care
10021135|NCT04020848||Patients with Alternating Hemiplegia of Childhood (AHC)|"Patients who fit the Aicardi Alternating Hemiplegia of Childhood clinical criteria of any age. The Aicardi Criteria are six (Heinzen et al 2015). (1) Paroxysmal hemiplegia episodes. (2) Bilateral hemiplegia or quadriplegia episodes. (3) Other paroxysmal manifestations, such as abnormal eye movements, nystagmus, strabismus, ataxia, dystonia, choreoathetosis, tonic spells, or autonomic disturbances. (4) Evidence of permanent neurological dysfunction, which can manifest as cognitive impairment, developmental delay, and/or persistent motor deficits such as spastic diplegia/quadriplegia, hypotonia, ataxia, choreoathetosis, or dystonia. (5) Sleep relieves symptoms, although attacks may resume soon after awakening. (6) First signs of dysfunction occur prior to the age of 18 months.~Patients having some but not all the above criteria and have the mutation in ATP1A3 gene can be included."
10021136|NCT04012177|No Intervention|Control Arm|Arm-A: Standard antenatal care (ANC) counseling, service provision and nutrition counseling (World Health Organization (WHO) standard)
10021137|NCT04012177|Experimental|Nutrition only Arm|Arm-B:Balanced-energy protein (BEP), ready-to-use utrition supplement for at least 6 months + Standard ANC counseling, service provision and nutrition counseling (WHO standard)
10021138|NCT04012177|Experimental|Nutrition plus Azithromycin Arm|Arm-C:Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + 2000 mg of Azithromycin at week 20 and 28 of pregnancy + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
10021139|NCT04012177|Experimental|Nutrition plus Choline and Nicotinamide Arm|Arm-D: Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + Choline 450 and Nicotinamide 100 mg (1 each once daily orally starting from week 20 until birth outcome) + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
10021140|NCT04011995|Experimental|Intermittent caloric restriction|
10021141|NCT04011995|Active Comparator|Low carbohydrate diet|
10021142|NCT04011189|Experimental|Videotaping|"First phase: Patients will be asked to complete questionnaires and pain scoring in pre-anaesthetic clinic. Their face and body pose will be videotaped. Patients are reviewed at 12-36 hrs, 36 hrs till before discharge post-operatively in the ward. They will be asked on pain scores and videotaping.~Second phase: Patients will be asked to complete questionnaires and pain scoring in preoperative/pre-procedural clinics/wards/rooms, inpatient/outpatient consultation waiting areas. Their face and body pose will be videotaped. The details after surgery/procedure/consultation are as below:~i) Surgery: After surgery, patients are reviewed at 12-36 hrs, and 36 hrs till before discharge post-operatively, with questionnaires, pain scoring and videotaping.~ii) Procedure: After the procedure, patients will be asked on questionnaires, pain scoring and videotaping.~iii) Consultation: Study team will follow up with patient on questionnaires, pain scoring and videotaping during next consultation."
10021143|NCT04009109|Experimental|Lenalidomide|12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.
10021144|NCT04009109|Experimental|Lenalidomide, Ixazomib, Daratumumab, and Dexamethasone|12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 year maintenance therapy.
10021145|NCT04008706|Experimental|Acalabrutinib|Participants will be enrolled into 3 cohorts. In the treatment-naive (TN) cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory (R/R) cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior Bruton tyrosine kinase inhibitor (BTKi) therapy cohort, up to 70 to 100 participants with Prior BTKi therapy will be enrolled.
10021146|NCT04007848|Experimental|Cobimetinib|Experimental group : 36 histiocytoses's patients without or with BRAF V600E will be randomised in cobimetinib group
10021147|NCT04007848|Placebo Comparator|Placebo|Control group : 18 histiocytoses's patients without or with BRAF V600E will be randomised in the placebo group
10021148|NCT04007289|Active Comparator|APIXABAN|Apixaban, 1 pill of 2.5 mg per os twice a day (one in the morning and one in the evening) for 24 months.
10021149|NCT04007289|Placebo Comparator|PLACEBO|Placebo, 1 pill per os twice a day (one in the morning and one in the evening) for 24 months.
10021150|NCT04004936|Active Comparator|Active Feedback|EQUIPPED with active provider feedback, implementing one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
10021151|NCT04004936|Active Comparator|Passive Feedback|EQUIPPED with passive provider feedback, implementing monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
10021152|NCT04004910|Experimental|Immunopheresis® - Arm 1|All patients will receive up to 16 weeks of initial treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient assigned to the treatment with LW-02 column-based Immunopheresis® will require central vascular access for the procedure. This part is alrady completed.
10036369|NCT01815073|Experimental|Live Attenuated JE Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
9477680|NCT03559959|Experimental|$3 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $3.
10036370|NCT01815086|Experimental|124I-labeled anti-amyloid mAb 11-1F4|124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.
10036371|NCT01815112|Experimental|Alzheimer|Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
10021153|NCT04004910|Experimental|Immunopheresis® combined with low dose chemotherapy - Arm 2|All patients will receive up to 16 weeks of treatment as per study arm assignment, which will include up to 48 LW-02 column-based Immunopheresis® treatments over a 4-month period (up to 3 procedures per week) though treatment can be extended based on certain protocol-specfied conditions. Each patient will require central vascular access for the procedure. Patients also will receive a low dose chemotherapy regimen administered iv or oraly. Patients treated with combination will be administered their chemotherapy following the first LW-02 column-based Immunopheresis® procedure of each week starting from week 2, assuming first week of study treatment serves as a run-in period confirming good tolerance of Immunopheresis® alone.
10021154|NCT04004910|Active Comparator|Chemotherapy - Arm 3|Patients who are assigned chemotherapy arm of the study will be treated with low dose chemotherapy alone. The chemotherapy will be administered intravenously or oraly depending on the regimen used.
10021155|NCT04004416|Placebo Comparator|Healthy Controls|
10021156|NCT04004416|Experimental|Early Psychosis patients|
9477681|NCT03559946|Sham Comparator|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
9477682|NCT03559946|Experimental|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
9477683|NCT03559920|Experimental|Sevoflurane group|Patients who are sedated using sevoflurane
9477684|NCT03559920|Active Comparator|Intravenous sedation group|Patients who are sedated using propofol
9477685|NCT03559907|Experimental|Cooking Matters for Parents|Trained instructors with a background in nutrition or culinary arts will lead six weekly, two-hour sessions to groups of 10 parent participants at local Family Support Centers.
9477686|NCT03559907|Experimental|Mealtime PREP|Trained group leaders with experience in pediatric occupational therapy will lead six weekly, two-hour, Mealtime PREP sessions to groups of 10 parent participants at local Family Support Centers.
9477687|NCT03559907|Experimental|Cooking Matters + Mealtime PREP|Parents will receive both programs in succession. They will attend Cooking Matters for Parents followed by Mealtime PREP. In total, this will equal 12 weekly, two-hour sessions delivered to groups of 10 parent participants at a local Family Support Center.
9477688|NCT03559881|No Intervention|Observation|Participants with a habitual protein intake >1.2 g/kg body weight/day will be allocated to the observational arm of the study
9477689|NCT03559881|Experimental|Intervention|Participants with a habitual protein intake <1.2 g/kg body weight/day will be allocated to the interventional arm of the study
9477690|NCT03559868|Active Comparator|Digoxin 3 mcg/Kg/day|Patients receiving oral digoxin 3 mcg/Kg/day
9477691|NCT03559868|Active Comparator|Digoxin 0.15 mcg|Patients receiving oral digoxin 0.15 mcg/Kg/day
9477692|NCT03559868|Placebo Comparator|Placebo|oral placebo
9477693|NCT03559842||Surgery patients|Obese patients undergoing laparoscopic sleeve gastrectomy
9477694|NCT03559842||Non-surgery patients|Obese patients not undergoing laparoscopic sleeve gastrectomy (delayed or refused proposed treatment)
9477695|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
9477696|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
9477697|NCT03559803|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
9477698|NCT03559777|Active Comparator|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~The widening drills can be sequentially used to widen the osteotomy site to the same level~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~The osteotome will be tapped gently to fracture up the sinus floor.~Xenograft will be added to the osteotomy as the grafting material.~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
10021157|NCT04004416|Experimental|Schizophrenia or Schizoaffective disorder patients|
10021158|NCT04004416|Experimental|Bipolar disorder patients|
9477699|NCT03559777|Experimental|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~Change the drill motor to reverse- densifying Mode~Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor.~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~densah burs (3.5mm) advance in the osteotomy.~Xenograft will be added to the osteotomy .~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
9477700|NCT03559764|Experimental|Anti-BCMA CAR T cells|Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
9477701|NCT03559751|Experimental|VLN Cigarettes (A)|Subjects will smoke VLN cigarettes
9477702|NCT03559751|Experimental|Usual Brand Cigarettes (B)|Subjects will smoke their usual brand cigarettes
9477703|NCT03559751|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
10021159|NCT04003311||Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
10021160|NCT04002934|Experimental|Group A|"Group A is the early-start group and will receive a total of 6 months of BZA -- 3 months of BZA, followed by 3 months BZA"
10021161|NCT04002934|Experimental|Group B|"Group B is the delayed-start group and will receive a total of 3 months of BZA -- 3 months of placebo, followed by 3 months of BZA"
10021162|NCT04002518||3.0mm and 4.0mm|Patients who have surgically been treated with a 3.0mm or 4.0mm screw.
10021163|NCT04002518||5.0mm|Patients who have surgically been treated with a 5.0mm screw.
10021164|NCT04002518||6.5mm and 8.0mm|Patients who have surgically been treated with a 6.5mm or 8.0mm screw.
10021165|NCT04000529|Experimental|TNO155 in combination with spartalizumab|TNO155 in combination with spartalizumab
10021166|NCT04000529|Experimental|TNO155 in combination with ribociclib|TNO155 in combination with ribociclib
10021167|NCT04000334|Experimental|Cerebral hypoperfusion (group A)|Cerebral hypoperfusion will be defined by an abnormal TCD at inclusion (t0) when two of the three measured values are abnormal using the following thresholds: Vm < 30 cm/s, Vd < 20 cm/s, PI > 1.4.
10021168|NCT04000334|Active Comparator|Normal cerebral perfusion (group B)|Normal cerebral perfusion will be defined by a normal TCD at inclusion (t0) when two of the three measured values are normal using the following thresholds: Vm > 30 cm/s, Vd > 20 cm/s, PI < 1.4.
10036372|NCT01815112|Experimental|Vascular dementia|Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
10021169|NCT04000282|Experimental|Part A: SAR442085 dose escalation|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
10036373|NCT01815112|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
9477704|NCT03559738||Patients With Upper Ureteric Stones|Patients with upper ureteral stones more than 1cm and 1000 HU
9477705|NCT03559725|Experimental|VLN Menthol Cigarettes (A)|Subjects will smoke VLN menthol cigarettes
9477706|NCT03559725|Experimental|Usual Brand Menthol Cigarettes (B)|Subjects will smoke their usual brand menthol cigarettes
9477707|NCT03559725|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
9477708|NCT03559712|Experimental|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
9477709|NCT03559712|No Intervention|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
9477710|NCT03559634|Experimental|Intervention group|Using an electronic application, participants answer survey questions about their sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception. Then, based on survey answers, they will be able to watch more in-depth educational videos on methods that they qualify for. Participants will only be offered methods that are considered low risk and without any contraindication based upon responses to survey screening. This may include, contraceptive implant, medroxyprogesterone acetate injection, microgestin pills, xulane patch, or intravaginal ring. Participants will then be given the opportunity to initiate contraception in the ED. All participants will be referred for follow up outpatient health services. Subjects who have medical contraindications to certain contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s) while in the ED.
9477711|NCT03559634|Other|Control Group|Using an electronic application, participants answer survey questions about their background, sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, based on participants medical history and contraceptive preferences they will be able to watch more in-depth counseling and educational videos on contraceptive methods that they qualify for. After these videos they will be given information on where they will be able to follow up to receive these contraceptive methods if they wish to start a method. Subjects who have medical contraindications to certain hormonal contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s), should this come up in future discussions with their providers.
9477712|NCT03559621|No Intervention|control group|Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.
9477713|NCT03559621|Other|intervention group|A mobile-based lifestyle intervention
9477714|NCT03559595|Experimental|Intervention group|All study participants will be exposed to the intervention
9477715|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
10036374|NCT01815112|Experimental|Healthy subjects (MRI)|Healthy subjects agreeing to undergo magnetic resonance imaging examination.
10021170|NCT04000282|Experimental|Part B: SAR442085 dose expansion|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
10021171|NCT03998462|Active Comparator|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
10021172|NCT03998462|Placebo Comparator|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
10021173|NCT03997643|Active Comparator|Standard Radiotherapy|Radiotherapy to all dissected areas
10021174|NCT03997643|Experimental|Radiotherapy to smaller treatment area|Omit radiation to pN0 neck
10021175|NCT03996850||Health service research (MIBI SPECT/CT, questionnaire)|Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.
10021176|NCT03993249|Other|Chemoradiotherapy|standard of care chemo-radiotherapy
10021177|NCT03993249|Experimental|Combination|standard of care chemo-radiotherapy + Nivolumab
10021178|NCT03991611|Experimental|IPREA3 program|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for at least 5 months
10021179|NCT03991611|Other|Intermediate group|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for less than 5 months
10021180|NCT03991611|Active Comparator|Standard care|Standard care
9477716|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
9477717|NCT03559556|Experimental|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
9477718|NCT03559504||Group 1|Infant period: 1 month-1 year old
9477719|NCT03559504||Group 2|Toddler period:1-3 years old
10021181|NCT03991611|Other|PTSD-REA_COVID cohort|ICU admission between March 1, 2020 and April 30, 2020.
10021182|NCT03991221|Other|Dental exam by orthodontic non-specialists|Detection of the presence of at least one malocclusion by orthodontic non-specialists with the graphic chart
10021183|NCT03991221|Other|Dental exam by orthodontic experts|Detection of the presence of at least one malocclusion by orthodontic experts
10021184|NCT03990883|Other|Treatment of device 1 on left side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF
10021185|NCT03990883|Other|Treatment of device 1 on right side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF
10021186|NCT03988634|Experimental|sacubitril/valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose at randomization will be determined based on the patient's previous dose of or lack of ACEi/ARB immediately prior to current WHF event (HFpEF decompensation), or at the time of post-decompensation randomization.~Study treatment will be titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active sacubitril/valsartan and one tablet of valsartan matching placebo pack)."
10021187|NCT03988634|Active Comparator|valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose at randomization will be determined based on the patient's previous dose of or lack of ACEi/ARB immediately prior to current WHF event (HFpEF decompensation), or at the time of post-decompensation randomization.~Study treatment will be titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active valsartan and one tablet of sacubitril/valsartan (LCZ696) matching placebo pack)."
10021188|NCT03984890|Experimental|Vitamin D Group|Vitamin D3 Supplementation plus traditional treatment of CGD and TB
10021189|NCT03984890|Other|Control Group|Traditional treatment of CGD and TB without Vitamin D Supplementation
10021190|NCT03982459|Experimental|Decision support tool|Patients in this single-arm study all receive training in use of a decision support tool by a trained coordinator.
10021191|NCT03982407|Experimental|Ga68 PSMA PET-MR|68Ga labeled PSMA -11 (or PSMA-HBED_CC) PET/MRI scan
10021192|NCT03980834|Active Comparator|Professional Learning, Program Training and Coaching|
10021193|NCT03980834|Active Comparator|Program for Parents of Pre-K Students|
10021194|NCT03980834|Active Comparator|Program for Pre-K Students|
9477720|NCT03559504||Group 3|Preschool age period:3-6 years old
9477721|NCT03559504||Group 4|School age period:7-18 years old
9477722|NCT03559504||Group 5|Adults:18-65 years old
9477723|NCT03559504||Group 6|Elderly:65-80 years old
9477724|NCT03559491||Macular Edema Patients|Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.
9477725|NCT03559478|Active Comparator|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
9477726|NCT03559478|Active Comparator|Treatment Group 2|Electrocautery for all dissection
9477727|NCT03559465|Experimental|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
9477728|NCT03559465|Sham Comparator|healthy subject|
10021195|NCT03978780|Placebo Comparator|Control Group|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.
10021196|NCT03978780|Experimental|Erector spinae plane (ESP) block group|Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
10021197|NCT03978546|Experimental|Non-Glaucoma Patient Arm|All participants will complete the same assessments
10021198|NCT03978546|Experimental|Glaucoma Patient Arm|All participants will complete the same assessments
10021199|NCT03978104|Experimental|Okara biscuits|Subjects will consume their habitual diet with daily okara biscuit consumption accounting to 20 grams/ day of dry okara powder for 21 days.
10021200|NCT03978104|Experimental|Bio-okara biscuits|Subjects will consume their habitual diet with daily bio-okara biscuit consumption accounting to 20 grams/ day of dry bio-okara powder for 21 days.
10021201|NCT03978104|Experimental|Control biscuits|Subjects will consume their habitual diet with daily control biscuit consumption for 21 days.
9477729|NCT03559452|No Intervention|Control|Immobilisation without prior exercise
9477730|NCT03559452|Experimental|Muscle damage|300 bilateral knee extensor eccentric contraction performed immediately prior to immobilisation
9477731|NCT03559439|Experimental|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
9477732|NCT03559426|Active Comparator|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
9477733|NCT03559426|Experimental|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
9477734|NCT03559413|Experimental|Intervention group|
9477735|NCT03559387|Experimental|ANF-RHO™|Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg as a subcutaneous injection.
10021202|NCT03973528|Experimental|traditional Chinese medicine|The experimental group use traditional Chinese medicine
10021203|NCT03973528|No Intervention|non- traditional Chinese medicine|The no intervention group no use traditional Chinese medicine.
10021204|NCT03971071|Placebo Comparator|Placebo|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
10021205|NCT03971071|Active Comparator|Erenumab 70 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
10021206|NCT03971071|Active Comparator|Erenumab 140 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
10021207|NCT03969693||The patients with mediastinal malignant lymphoma|Patients whose radiation therapy field essentially encompasses anterior mediastinum; namely, the majority of malignant lymphoma patients with mediastinal involvement.
10021208|NCT03969446|Experimental|Cohort I Arm I (pembrolizumab, decitabine)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10. Patients who achieve a CR receive decitabine on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
10021209|NCT03969446|Experimental|Cohort I Arm II (pembrolizumab, decitabine, venetoclax)|Patients with pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10 or 1-5. Patients who achieve a CR receive decitabine on days 1-5. Patients also receive venetoclax PO QD on days 1-14. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
9477736|NCT03559387|Active Comparator|Neulasta®|Neulasta® will be administered to the subjects at a dose of 6.0 mg in 0.6 ml as a subcutaneous injection.
9477737|NCT03559374||Pregnant women|Consenting women will provide samples to be tested with Vanadis NIPT system.
10021210|NCT03969446|Experimental|Cohort II (pembrolizumab, decitabine)|Patients with MDS receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine over 1 hour on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
10021211|NCT03968081|Experimental|Social exclusion|Participating at the cyberball game in exclusion condition in wich they will receive 2 time the ball in the 10 first throw then none of them in the last 20 throw.
10021212|NCT03968081|Active Comparator|Social inclusion|Participating at the cyberball game in inclusion condition in wich they will receive 33% of the throw : 10 in a total of 30
10021213|NCT03966742|Experimental|Treatment|Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
9477738|NCT03559361|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
9477739|NCT03559361|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
10021214|NCT03966638||Patients receiving platelet rich plasma|The group is composed of patients receiving an intra-meniscal injection of platelet-rich plasma, under echographic control, for isolated meniscal lesion.
10021215|NCT03965260||Bacteria-infected cirrhotic patients|All kind of etiologies for cirrhosis and all kind of bacterial infections (spontaneous bacterial peritonitis, urinary tract infections, pneumonia, skin and soft tissue infections and spontaneous bacteremia)
10021216|NCT03963388|Experimental|Intervention group|Speech therapy, right after T0 (baseline measurement).
10021217|NCT03963388|No Intervention|Control group|Patients will be on a waiting list for 8 weeks. After the primary endpoint (T1), patients will receive speech therapy.
10021218|NCT03960008|Other|Stereotactic Body Radiation Therapy (SBRT)|Radiation Therapy
10021219|NCT03960008|Other|Trans-Arterial Chemoembolization (TACE)|Procedure/Surgery - Chemoembolization Drug: Doxorubin
10021220|NCT03958552|No Intervention|Standard Care|Participants will receive the standard Medicare Skilled Nursing Facility care.
10021221|NCT03958552|Experimental|Palliative Care Consult|Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
10021222|NCT03956498|Other|Patients with cervix or vaginal cancer|
10021223|NCT03956394|Other|Active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
10021224|NCT03956394|Other|Non-active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
9477740|NCT03559361|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
10021225|NCT03955900||Participants with Multiple Myeloma (MM)|Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.
10021226|NCT03952182|Active Comparator|Spinal Orthosis (LSO, TLSO, etc)|Patient's in this arm will be given an orthosis for the treatment of their injury (TLSO for thoracic or upper lumbar injury, LSO for lumbar injury)
10021227|NCT03952182|Experimental|No Spinal Orthosis|the patient's in this arm will not be given an orthotic. They will be given a bending restriction and otherwise remain activities as tolerated.
10021228|NCT03949465|Experimental|Open label iTBS rTMS|Participants will receive repetitive transcranial magnetic stimulation (rTMS) as a treatment for depression
10021229|NCT03948893|Experimental|MORE|
10021230|NCT03948893|Active Comparator|CBT|
10021231|NCT03948776||Healthy volunteers|Adults without HF or prior heart transplantation
10021232|NCT03948776||Participants in our existing LVAD body composition study|Currently-enrolled LVAD body composition participants, who chose to participate in this study on the same day as a DXA scan already scheduled for study #12026
10021233|NCT03948776||Patients with heart failure, an LVAD or heart transplantation|Any patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation
10036375|NCT01815112|Experimental|Healthy subjects (PET)|Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
9477741|NCT03559348|Experimental|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
9477742|NCT03559335||Patients after colorectal cancer surgery|
9477743|NCT03559309|Other|Alirocumab|Medical Treatment (Clinical Routine)
9477744|NCT03559296||Study Group|patients with postmastectomy lymphedema who will undergo ultrasonographic assessment of postmastectomy lymphedema and circumferential tape measurement of arm
10021234|NCT03948776||Inpatients with heart failure, LVAD, heart transplantation|Patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation, currently admitted as inpatients at Tufts Medical Center. The 6/20/2019 protocol update includes these patients who will participate without a DXA scan (which can only be performed as an outpatient).
10021235|NCT03947190|Experimental|Group 1|Group 1 adults (n=20) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
10021236|NCT03947190|Experimental|Group 2|Group 2 adults (n=20) will be receiving 5x10^10 vp ChAd63 ME-TRAP and 2x10^8 pfu MVA ME-TRAP vaccines, 8 weeks apart, and then a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge, 4 weeks later.
10021237|NCT03947190|Experimental|Group 3|Group 3 adults (n=10) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intravenously (DVI) by inoculation of 3,200 PfSPZ Challenge.
10021238|NCT03947190|Experimental|Group 4|Group 4 adults (n=14) will be the control group receiving no vaccine, only a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
10021239|NCT03944941|Active Comparator|Arm I (Avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to Arm II.
10021240|NCT03944941|Experimental|Arm II (Avelumab, cetuximab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity.
10021241|NCT03940352|Experimental|treatment arm1: HDM201+MBG453|Phase Ib (escalation)
10021242|NCT03940352|Experimental|treatment arm2: HDM201+venetoclax|Phase Ib (escalation)
10036376|NCT01815125|Experimental|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
10036377|NCT01815125|Placebo Comparator|Placebo|The control group will receive a similar looking/ tasting pill of placebo.
10021243|NCT03939858||Cognitive Function Analysis|Cognitive function will be evaluated using a customized cognitive battery designed for brain tumor patients. Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
10036378|NCT01815164|Active Comparator|Hypnotherapy|Hypnotherapy
9477745|NCT03559283|Experimental|Walking and Record Cortical Activity|A sensor placement will be performed on the patient's forehead to record brain activity when walking, when performing a mental task, and when performing both tasks at the same time. In parallel, walking will be on a carpet that will record the spatio-temporal parameters of walking.
9477746|NCT03559244|Experimental|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
9477747|NCT03559244|Experimental|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
9477748|NCT03559244|Active Comparator|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
9477749|NCT03559231|Experimental|dFTRD|Endoscopic full-thickness resection of the duodenal adenoma with the 'duodenal Full-Thickness resection device' (dFTRD).
9477750|NCT03559231|Active Comparator|EMR|Endoscopic Mucosal Resection (EMR) of the duodenal adenoma (=standard therapy).
9477751|NCT03559166|Experimental|cohort 1a - starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
9477752|NCT03559166|Placebo Comparator|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
9477753|NCT03559166|Placebo Comparator|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
9477754|NCT03559166|Placebo Comparator|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
9477755|NCT03559166|Placebo Comparator|cohort 1e-4th SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
9477756|NCT03559166|Placebo Comparator|cohort 2a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
9477757|NCT03559166|Placebo Comparator|cohort 2b-2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
9477758|NCT03559166|Placebo Comparator|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
9477759|NCT03559166|Placebo Comparator|cohort 2d-4th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
9477760|NCT03559166|Placebo Comparator|cohort 2e-5th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
9477761|NCT03559166|Placebo Comparator|cohort 2F-6th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
9477762|NCT03559153|No Intervention|Control group|All workers will receive ergonomics instructions. Instruction for rest break.
9477763|NCT03559153|Experimental|Passive rest break - Shiatsu massage|"All workers will receive ergonomics instructions. The workers will be receive quick massage using shiatsu techniques."
9477764|NCT03559153|Active Comparator|Active rest break - Physical Exercise Program|All workers will receive ergonomics instructions. The workers will be receive exercises during the rest break.
9477765|NCT03559140|Experimental|Group A|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length.~After the procedure cryotherapy will be applied as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
10021244|NCT03935750|Experimental|BPTB + LET|Patients will undergo anterior cruciate ligament reconstruction (ACLR) using a bone patellar bone tendon (BPTB) autograft with lateral extra-articular tenodesis (LET).
10021245|NCT03935750|Active Comparator|BPTB alone|Patients will undergo ACLR using a BPTB autograft without LET.
10021246|NCT03935750|Experimental|QT + LET|Patients will undergo ACLR using a quadriceps tendon (QT) autograft with LET.
10021247|NCT03935750|Active Comparator|QT alone|Patients will undergo ACLR using a QT autograft without LET.
10021248|NCT03934398||ReNEW Clinical Cohort|Individuals evaluated in the ReNEW Clinic at Johns Hopkins University who join the ReNEW Clinic Cohort Study are eligible for this cross-sectional study. Tests will be done for all participants which includes Cardiovascular Assessments, Actigraphy and Laboratory assessments.
10021249|NCT03934255|Experimental|Constant Routine Protocol|Participants will be kept in constant conditions for 30 hours to observe circadian physiology in the absence of light, physical activity, and meals.
10021250|NCT03932682|Experimental|Seqirus QIVc|Cell-derived Quadrivalent Influenza Vaccine
10021251|NCT03932682|Active Comparator|Comparator|Non-influenza Comparator (NesiVac-C)
10021252|NCT03931655|Experimental|Spectroscopic photoacoustic imaging|Any suspicious lymph nodes identified through ultrasound will be imaged with spectroscopic photoacoustic imaging, which is a diagnostic test to measure saturated oxygen in the nodes.
9518146|NCT03299426|Active Comparator|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
10021253|NCT03931551|Experimental|Interventional Arm|Olaparib tablet 300mg bd po + Herceptin (IV 4 mg/kg body followed by weekly doses of 2 mg/kg, or SC 600 mg every 3 weeks) until progression or unacceptable toxicity.
10021254|NCT03930615|Experimental|Letermovir|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of LET (480 mg once daily alone or 240 mg once daily for participants on cyclosporin A) treatment.
10021255|NCT03930615|Placebo Comparator|Placebo|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of placebo treatment.
10021256|NCT03930576||Early Legal Terminations|Participants who receive a legal termination at <10 weeks gestation at a recruiting facility.
10021257|NCT03930576||Late Legal Terminations|Participants who receive a legal termination at 10+ weeks gestation at a recruiting facility.
10021258|NCT03930576||Turn-aways: Termination outside Legal Setting|Participants who receive a termination at another facility or outside the formal healthcare sector.
10021259|NCT03930576||Turn-aways: Birth|Participants who ultimately carry the pregnancy to term
10021260|NCT03929588|Experimental|Refraction with a Hand-held Device Supported by Mobile App.|BCVA with handheld device with app.
10021261|NCT03929588|Active Comparator|Manual Refraction|BCVA with phoropter
10021262|NCT03929588|Active Comparator|Automated Refraction|BCVA with autorefractoer
10021263|NCT03929289|Experimental|Social Facilitation|Cognitive tasks during the 2 functional Magnetic Resonance Imaging (fMRI) observed or not by a subject's known peer.
10021264|NCT03928847|Experimental|EGCG treatment|"Healthy volunteers: 450 mg, 600 mg, or 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth~Patients: 600 mg EGCG capsules once daily by mouth for two weeks"
10021265|NCT03928678|Active Comparator|thefast track (FTS group)|
10021266|NCT03928678|Placebo Comparator|Thecontrolgroup|
10021267|NCT03928600|Experimental|Combined method induction group|"25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)~After 4 hours of last misoprostol initiate oxytocin.~Cervical Foley will be removed after 12h of placement or when fails out."
10021268|NCT03928600|Placebo Comparator|Current department guidelines group|"Following current department guidelines, as usual, with the method considered more suitable.~If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.~If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place."
10021269|NCT03928509||Estrie CIUSSS|Subjects from the Estrie's Integrated Health and Social Services Centre
10021270|NCT03928509||Saguenay-Lac-Saint-Jean CIUSSS|Subjects from the Saguenay-Lac-Saint-Jean's Integrated Health and Social Services Centres
10021271|NCT03928314|Experimental|Dose Escalation (Part I)|ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.
10021272|NCT03928314|Experimental|Dose Expansion (Part II)|RP2D dose
10021273|NCT03927027|Active Comparator|Group I (ALND)|Patients receive isosulfan blue SC and undergo ALND.
10021274|NCT03927027|Experimental|Group II (ARM, ALND)|Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.
10036379|NCT01815164|Active Comparator|Educational intervention|Educational intervention
10036380|NCT01815177|Experimental|Arthroscopic transosseous fixation|Patients with torn rotator cuff randomized to experimental treatment receive a complete arthroscopic transosseous cuff repair
10036381|NCT01815177|Other|Repair using suture anchors|Patients randomized to this arm receive an arthroscopic rotator cuff repair using suture anchors.
10036382|NCT01815190||IgA-positive vasculitis|Patients with immune complex vasculitis who show perivascular deposits of IgA
10036383|NCT01815190||IgA-negative vasculitis|Patients with immune complex vasculitis who show no perivascular deposits of IgA
9477766|NCT03559140|Experimental|Group B|"Canals were prepared as in group A, Patients assigned to this group receive (application of criotherapy)~A final irrigation will be applied with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes. was applied. as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
9477767|NCT03559140|Experimental|Control Group (CG)|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length. Reciproc instruments were used in one tooth only (single use).~The group will receive the irrigant solution at room temperature. as follows:~they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes."
10036384|NCT01815203|Experimental|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
10021275|NCT03926533|Experimental|Telehealth ICU Recovery Program|Components of the ICU RC telehealth visit will be structured parallel to what is done during a typical in-person clinic visit. The telehealth intervention consists of 5 chronological components conducted during two 1.5 hour telehealth clinic visits (the same time required for an in-person visit). Upon completion of the pre-intervention baseline assessment, the study coordinator will contact patients randomized to the intervention arm to schedule the first telehealth visit. Study visits will occur at 3 weeks and 3 months following hospital discharge.
10021276|NCT03926533|No Intervention|Standard Recovery Conditions|participants assigned to the standard of care control group will be contacted by the study coordinator to ensure the patient has a primary care and/or specialist appointment scheduled. At this time, patients will also receive an electronic PICS guide for ICU survivors created by the Society of Critical Care Medicine. Patients will be directed to use the information provided in the PICS guide for ICU survivors to connect with resources.
10021277|NCT03926091|Experimental|4 cycles of TC adjuvant chemotherapy|4 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
10021278|NCT03926091|Active Comparator|6 cycles of TC adjuvant chemotherapy|6 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
10021279|NCT03924700|Experimental|Biportal endoscopic discectomy|Biportal endoscopic discectomy for lumbar herniated intervertebral disc
10021280|NCT03924700|Active Comparator|Microdiscectomy|Microdiscectomy for lumbar herniated intervertebral disc
10021281|NCT03924427|Experimental|BMS-986165|Given daily
10021282|NCT03922451||Pediatric patients supported on ECMO|
10021283|NCT03922217|Experimental|Mindfulness|This group will be given the Mindfulness mobile intervention, Mindful My Way (MMW)
10021284|NCT03921073|Experimental|Intralesional injection of T-VEC|Participants will undergo intralesional injections of up to 4 cc of 10^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.
10021285|NCT03918629|Experimental|Clostridium difficile vaccine - 3 dose|All 3 doses are the Clostridium difficile vaccine
10021286|NCT03918629|Experimental|Clostridium difficile vaccine - 2 dose|2 of the 3 doses are the Clostridium difficile vaccine with the other being placebo
10021287|NCT03918421||Immunogloblin M-anti myelin-associated-glycoprotein neuropathy|Patient group (25 subjects) presenting with an Immunogloblin M-anti myelin-associated-glycoprotein peripheral neuropathy
10021288|NCT03916419|Experimental|Safety lead-in: Chemoradiation + Durvalumab|"The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.~Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of treating physician) for up to 12 months."
10021289|NCT03916419|Experimental|Phase II: Chemoradiation + Durvalumab|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of the treating physician) for up to 12 months.
10021290|NCT03915574|Experimental|Dural Puncture Epidural|Participants will receive a dural puncture epidural block with a 25 gauge spinal needle followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
10021291|NCT03915574|Active Comparator|Standard Epidural|Participants will have standard epidural infusion followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
10021292|NCT03913442|Placebo Comparator|Placebo|Placebo in capsule identical to study drug
10021293|NCT03913442|Experimental|Colchicine|"0.6 or 0.8 mg orally once daily.~Because recent studies suggest that a dose of 0.6mg may be sufficient for chronic inflammatory suppression and may reduce the already low risk of toxicity of 0.8mg, for the remainder (second half) of the study the dosage will be switched from 0.8mg to a 0.6mg dose to allow comparison of the two doses."
10021294|NCT03910491|Experimental|Intervention|All participants who enroll in the study will be assigned to a PriCARE group program that will adhere to the approximately 9 hour PriCARE curriculum.The trainings are administered to groups of approximately 4-12 caregivers at a time and are led by 2 mental health providers trained in the PriCARE curriculum. The curriculum will be delivered in 2-6 sessions over a 2-20 week period.
10021295|NCT03910244|Experimental|Pomalidomide|Oral Pomalidomide will be provided as a capsule at 4 mg/day dose. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
10021296|NCT03910244|Placebo Comparator|Placebo|A placebo matching the study drug will be provided as a capsule. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
10021297|NCT03908073|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
10021298|NCT03908073|Placebo Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
10036385|NCT01815203|Placebo Comparator|Placebo|Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.
10021299|NCT03907735||2nd trimester|Second trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained primarily after second trimester surgical abortions or Dilation and Evacuation (D&E) procedures as well as after rare gravid hysterectomies or after late second trimester cesarean deliveries.
10021300|NCT03907735||Non-pregnant|Myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in non-pregnant women undergoing gynecologic surgery under anesthesia for laparoscopic tubal ligation.
10021301|NCT03907735||1st trimester|First trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained after first trimester surgical abortions or suction dilation and curettage (D&C).
10021302|NCT03907735||After term pregnancy (3rd trimester)|Third trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained at the time of cesarean delivery.
10021303|NCT03907397|Active Comparator|Treatment|Ingests peanut - . Depending upon reaction threshold, participants may begin with different starting amounts of store bought peanut butter measured with study-supplied kitchen measuring spoons.
10021304|NCT03907397|No Intervention|Avoidance|Avoids peanut, standard care
10036386|NCT01815216|Experimental|Bariatric surgery|patients participating in the intervention group , i.e. assessing effects of bariatric surgery on: Brain activity in resting state Memory performance
10021305|NCT03907332|Experimental|Intervention Arm|"Study group 1 - Home visits by a team made up of a CHW and CHN in addition to all existing usual care practices (see below).~Standardized educational Messages will be given during these scheduled home visits by the CHW-CHN including:~One visit during the second trimester of the pregnancy~Two visits during the third trimester of pregnancy"
10021306|NCT03907332|No Intervention|Control Arm|Study group 2 (Control) - Existing usual care practices. Usual Care includes at least four antenatal visits and care package which includes education on pregnancy, labour and delivery given at the health facility or at community settings to individuals and/or groups of pregnant women.
10021307|NCT03905330|Experimental|Maralixibat|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
10021308|NCT03905330|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
9518147|NCT03299413|Experimental|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
9477768|NCT03559127|Experimental|Group A. Cold Protocol with 6 oC|"Use of 20 mL cold (6 oC) sterile saline solution.~After the clinical procedure cryotherapy was applied. 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
9477769|NCT03559127|Experimental|Group B. Cold Protocol with 2.5 oC|"Use of 20 mL cold (2.5 oC) sterile saline solution~After the procedure cryotherapy was applied. 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
9477770|NCT03559127|Experimental|CG. Room temperature Protocol|"Use of 20 mL (at room temperature) sterile saline solution~The group will receive irrigant at room temperature. 5mL of 17% EDTA and 20 mL of sterile saline usingmetallic micro-cannula included in the Endo Vac System for five minutes."
9477771|NCT03559114|Active Comparator|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
9477772|NCT03559114|Placebo Comparator|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
9477773|NCT03559101|Active Comparator|Beverage 1 - Control|Distilled Water
9477774|NCT03559101|Experimental|Beverage 2|Medical Food 1 (8 amino acids, 60 mmol/L Na, 20 mmol/L K + citrate, Cl)
9477775|NCT03559101|Experimental|Beverage 3|Medical Food 2 (8 amino acids, 30 mmol/L Na, 10 mmol/L K + citrate, Cl)
9477776|NCT03559101|Experimental|Beverage 4|Pedialyte
9477777|NCT03559101|Experimental|Beverage 5|Gatorade
9477778|NCT03559088|Experimental|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
9477779|NCT03559088|No Intervention|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
9477780|NCT03559049|Experimental|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
9477781|NCT03559036||Locomotor Training|Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
9477782|NCT03559023|Active Comparator|Ultrasound Only|Ultrasound assisted epidural placement
9477783|NCT03559023|Active Comparator|Manometry Only|Manometry confirmation in epidural placement
9477784|NCT03559023|Active Comparator|Ultrasound Plus Manometry|Ultrasound Plus Manometry confirmation in epidural placement
9477785|NCT03559023|Sham Comparator|Usual Care/Management|Usual epidural technique placement
9477786|NCT03558984|Experimental|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
9477787|NCT03558984|Other|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
9477788|NCT03558971|Experimental|Patient self-administration of cortisol|Intervention is patient self-administration of cortisol.
9477789|NCT03558958|Experimental|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
9477790|NCT03558919|Experimental|Mirabegron|Mirabegron 25mg will give daily at night for 12 weeks
9477791|NCT03558919|Active Comparator|Solifenacin|Solifenacin Succinate 5mg will give daily at night for 12 weeks
9477792|NCT03558906||Aggressive Periodontitis|These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.
10021309|NCT03903315||medical treatment alone|Patients with central malignant airway obstructions undergoing medical treatment alone
10021310|NCT03903315||endoscopic + medical treatment|Patients with central malignant airway obstructions undergoing medical and endoscopic treatment
10021311|NCT03901807|Experimental|PMX Treatment|Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)
10021312|NCT03901807|No Intervention|Control|Standard medical care alone
9477793|NCT03558906||Chronic periodontitis|These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was >50% in the whole mouth.
9477794|NCT03558906||Gingivitis|Gingivitis patients exhibited no sites with CAL >2 mm and no detectable alveolar bone loss in the radiography. BOP was >50% in the whole mouth.
10021313|NCT03900221||Pregnant women with multiple sclerosis or related neurological|Children born to women with multiple sclerosis or related neurological syndromes.
10021314|NCT03899792|Experimental|LOXO-292|Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The MTD/recommended dose from Phase 1
10021315|NCT03898843|Experimental|Animal assisted therapy group|Patients included in this arm will have animal assisted therapy session in a specific room outside of the ICU. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires
10021316|NCT03898843|Active Comparator|Control Group|"Patients included in this arm will have a sham session : they will leave their hospital bedroom, to go in the AAT session room. There, no specific activity is planned. After 20 minutes, the patient will go back to his room. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires"
10021317|NCT03897088|Experimental|Tildrakizumab|
10021318|NCT03897088|Placebo Comparator|Placebo|
10021319|NCT03897088|No Intervention|PART 3: Observational Safety Follow-up|The subjects will not receive study treatment during the follow-up period
10021320|NCT03895541|Other|Stratification|All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity.
9477795|NCT03558906||Healthy|Periodontally healthy volunteers exhibited no sites with PD >3 mm and CAL >2 mm as well as no radiographic evidence of alveolar bone loss. BOP was <15% in the whole mouth.
9477796|NCT03558893|Experimental|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
9477797|NCT03558880|Active Comparator|Erector Spinae Plane Block|Before the general anesthesia Erector Spinae Plane Block was performed.
10021321|NCT03894891|Experimental|Docetaxel+Cisplatin+Nivolumab+Radioimmunotherapy|Docetaxel will be administered per standard institutional every 3 weeks Nivolumab will be administered intravenously every 3 weeks Cisplatin will be administered intravenously every 3 weeks Radioimmunotherapy will be conducted 3 weeks after the last cycle of TPN (docetaxel, cisplatin and nivolumab)
10021322|NCT03893916|Experimental|cohort|MEG - EEG HR
9477798|NCT03558880|Active Comparator|Tumescent Anesthesia|After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts
10021323|NCT03893448|Experimental|V114|Participants receive 4 total 0.5 mL intramuscular (IM) vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will receive other vaccinations (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
10021324|NCT03893448|Active Comparator|Prevnar 13™|Participants receive 4 total 0.5 mL IM vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will also receive other vaccines (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
9477799|NCT03558867|Placebo Comparator|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
9477800|NCT03558867|Active Comparator|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
9477801|NCT03558841|Experimental|Intervention Group|Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
9477802|NCT03558841|Active Comparator|Control Group|Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.
9477803|NCT03558828|Experimental|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
9477804|NCT03558828|Experimental|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
9802707|NCT05026385|Experimental|Intervention|"The intervention group will receive initial nutrition and exercise consultations with a Registered Dietitian (RD) and Clinical Exercise Physiologist (CEP) to personalize the study protocol and recommendations to their needs. The intervention period (3 months) includes: a) whole-body resistance training exercise sessions completed three-times per week (at-home with loaned equipment and/or in-person at the research gym); b) biweekly nutrition education provided through video conferencing; and c) biweekly OA self-management support provided through video conferencing.~After the 3 month intervention, participants will receive bimonthly phone calls from a study staff member to encourage continued behavior changes during the 6 month maintenance phase."
10021325|NCT03893253|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
10021326|NCT03893253|Active Comparator|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
10021327|NCT03893253|No Intervention|Control group|The control group will receive no booster teaching at all.
10021328|NCT03889314|Experimental|Rosuvastatin 20mg|Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
9802708|NCT05026385|No Intervention|Usual Care|The control group will follow standard care procedures, which includes their usual activities. The control group will receive bimonthly contact during the study period through phone calls with a study staff member to encourage retention. However no recommendations or advice on nutrition, exercise or self-management will be provided.
9802709|NCT05021848|Experimental|Experimental group|The experimental group (N=14) received a 90-minute partnered multicomponent exercises intervention once weekly for 12 weeks
9802710|NCT05021848|No Intervention|control group|The control group (N=14) carried out the usual activities without intervention. (After 12-wk, multicomponent exercises intervention will be given)
9802711|NCT05019144|Active Comparator|Face-to-face arm|Standard face-to-face burn care.
10021329|NCT03889314|Placebo Comparator|Placebo|
10021330|NCT03889314|No Intervention|No Treatment|7 day wash-out period between months
10021331|NCT03889275|Experimental|Sequential|MEDI5395 and durvalumab administered sequentially
10021332|NCT03889275|Experimental|Concurrent|MEDI5395 and durvalumab administered concurrently
9802712|NCT05019144|Experimental|TOBI arm|A novel smartphone application for burn wound care, called the Telemedicine Optimized Burn Intervention (TOBI), was recently developed to enable burn experts to direct burn wound care while the patient and caregiver are home through text messaging and video-conferencing. The app was designed to bring expert wound care directly to the patient's home to address barriers to healthcare, including high cost burden and time commitment (e.g., geographic limitations, transportation to burn centers, parking, lodging, meals, time away from school and work), particularly for patients/families in rural and medically underserved communities. TOBI is synced with a portal used by providers, as an adjunct to standard therapy. This burn app provides education through frequently asked questions, instructional burn dressing change videos in addition to direct communication between patient and burn expert through store-and-forward pictures and videoconferencing.
10021333|NCT03886909|Active Comparator|Home-Based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and periodical phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of transplant.
10021334|NCT03886909|Active Comparator|Prehabilitation Education|Will be offered a prehabilitation and stem cell education class at the Penn State Hershey Cancer Institute.
10021335|NCT03885817|Experimental|Exercise training and nutritional guide|Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.
10021336|NCT03885817|Active Comparator|Standard follow-up care|Standard recommendations regarding physical activity and nutrition.
9802713|NCT05017532|Experimental|Intervention|Intervention with RC2S+ that consists of 24 biweekly sessions
10021337|NCT03884998|Experimental|Treatment (copanlisib and nivolumab)|Patients receive copanlisib IV over 60 minutes on days 1, 8, and 15 and nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
10021338|NCT03884166||stroke|
10021339|NCT03884166||control|
10021340|NCT03884153|Experimental|CRP apheresis|"CRP apheresis by means of selective apheresis using the PentraSorb-CRP adsorber"
10021341|NCT03884049|Experimental|Embolization group|Group undergoes transcatheter arterial embolization of neovessels around the knee.
10021342|NCT03884049|Sham Comparator|Sham Embolization Group|Group undergoes sham embolization
10021343|NCT03884023||AD group|Alzheimer's disease
10021344|NCT03884023||aMCI group|Amnestic Mild Cognitive(MCI) impairment due to Alzheimer's disease
10021345|NCT03884023||NC group|Normal Control
10021346|NCT03880461|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve GWG within the range recommended by the Institute of Medicine. The lifestyle intervention will be delivered through 1 telephone counseling session with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and weekly e-mails of core lifestyle intervention sessions. Personalized text messages and 1:1 telephone coaching sessions will be given to those who are not meeting the GWG guidelines.
10021347|NCT03880461|No Intervention|Usual Care - Control|Usual Medical Care
10021348|NCT03880344|Experimental|Vibration Therapy + Normal Out-Patient Physiotherapy|Patients' randomized to this group will receive vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months. Regular out-patient department physiotherapy will also be given. They will be assessed 6 weeks and 6 months post operatively.
9477805|NCT03558828|Experimental|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
10021349|NCT03880344|Active Comparator|Normal Out-Patient Department Physiotherapy|Patients randomized to this group will receive regular out-patient department physiotherapy postoperatively for 6 months. They will be assessed 6 weeks and 6 months post operatively.
9477806|NCT03558815||Adults with mild, moderate, severe or profound ID|Adults with mild, moderate, severe or profound ID in contact with either a sheltered workshop and/ or sheltered living Institution in Saxony.
9477807|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
9477808|NCT03558776|Active Comparator|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) < 2.5 En% linoleic acid (n = 37)
9477809|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
9477810|NCT03558776|Placebo Comparator|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
9477811|NCT03558763|Active Comparator|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
9477812|NCT03558763|Active Comparator|Telemonitoring|"Twice a week subject will perform additional vital functions:~Blood pressure and heart rate will be measured using the Electronic Sphygmomanometers Track.~Weight will be taken using the Scale lite Oxygen saturation will be measured using Pulse Oximeter Air And~Complete two PRO´s (integrated in the application):~CAT MRC All this is estimated to take approximately 20-30 min each time.~For the first 4 weeks there will be weekly video calls with a COPD-center nurse discussing health condition and vital parameters.~Thereafter there will be monthly video calls with a COPD-center nurse for the remaining 5 months, i.e. 4 further calls. The video calls will take approximately 15 min."
9477813|NCT03558750|Experimental|Treatment (nivolumab, rituximab, lenalidomide)|Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
9477814|NCT03558724|Experimental|NIR endoscopy with 4.5 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
10021350|NCT03878849|Experimental|2X-121|Oral administration of 2X-121 once daily as 600 mg hard gelatin capsules in a 28 days cycle.
10021351|NCT03878823|Experimental|ODM-209 Part 1 Dose escalation|
10021352|NCT03878823|Experimental|ODM-209 Part 2 Dose expansion|
9802714|NCT05017363|Experimental|Intervention Group (ENGAGE)|Therapists will consist of pairs within sites providing similar interventions to similar children so that treatment and child characteristics other than the goal-setting intervention will be similar within each site. Therapists will use principles-based goal-setting approaches and strategies in the goal-setting toolbox. It is anticipated that treatment block lengths will vary from 3-8 sessions over 2-8 weeks, representing typical clinical variation.
9802715|NCT05017363|No Intervention|Usual Care Group (Control)|The control group will comprise usual care.
9477815|NCT03558724|Experimental|NIR endoscopy with 10 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
10021353|NCT03877211|Experimental|Cochlear implant users|Adult cochlear implanted patients wearing an Oticon Medical/Neurelec device will have speech audiometry test in noise, psychophysical tuning curves in forward masking and Electrically-evoked Auditory Brainstem Response (EABR) measurement
10021354|NCT03877211|Active Comparator|Normal-hearing subjects|Normal-hearing subjects will have speech audiometry test in noise, psychophysical tuning curves in forward masking, auditory canal examination and tonal audiometry
10021355|NCT03876808|Experimental|Convective pre-warming|Undergo convective warming during the preoperative preparations, completed for a minimum of 60 minutes prior to entering the operating room
10021356|NCT03876808|No Intervention|Standard of care|Undergo standard of care, which includes providing each patient with blankets and sheets, as well as more blankets on patient request.
10021357|NCT03874312||Calibration group|Patients with systolic chronic heart failure who undergo right heart catheterization (RHC) for heart transplant/left ventricular assist device workup.
9477816|NCT03558724|Experimental|NIR endoscopy with 25 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
9477817|NCT03558711|Experimental|study group|
9477818|NCT03558698|Other|Group 1|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
9477819|NCT03558698|Other|Group 2|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
9477820|NCT03558698|Other|Group 3|"One night of good ventilation with High CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
10021358|NCT03874312||Validation group|Patients with systolic chronic heart failure who undergo RHC for heart transplant/left ventricular assist device workup.
10021359|NCT03874052|Experimental|Treatment (ruxolitinib, venetoclax)|Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
10021360|NCT03873857||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
10021361|NCT03873792|Other|Allergy pregnant women|
10021362|NCT03873792|Other|Health pregnant women|
10021363|NCT03873194|Experimental|Meditation group|Patients who are going to practice meditation and will receive only the usual outpatient care, with the aim of observing reduction of systemic blood pressure in this period.
10021364|NCT03873194|Other|conventional treatment|Patients that will receive only the usual outpatient care, with the aim of observing the systemic blood pressure in this period.
9477821|NCT03558698|Other|Group 4|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
9477822|NCT03558698|Other|Group 5|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
10021365|NCT03872284||1|Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
10021366|NCT03870880|Experimental|Risperidone ISM 75 mg|"Patients assigned to this arm will receive 75 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
10021367|NCT03870880|Experimental|Risperidone ISM 100 mg|"Patients assigned to this arm will receive 100 mg of Risperidone ISM during the open label extensión (OLE).~Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients."
10021368|NCT03870334|Experimental|BT-11 1,000 mg|Eligible subjects will be randomly assigned, in a centralized manner, in a 1:1 ratio to 1 of 2 treatment groups, (omilancor) BT-11 1000 mg or placebo, through an interactive web-based response system (IWRS).
10021369|NCT03870334|Placebo Comparator|Placebo|Subjects in the (omilancor) BT-11 group will receive 1000 mg of BT-11 and subjects in the placebo group will receive matched placebo. Subjects will take study drug by ingesting 1 tablet per day with water.
10021370|NCT03863782||Sarcoid uveitis|The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
10021371|NCT03862261|No Intervention|Standard-of-Care|Pediatric TB services based on current routine approach (national standard of care)
10021372|NCT03862261|Experimental|Intervention|Integrated pediatric TB services
10021373|NCT03861377|Active Comparator|Remifentanil R2|Low dose Remifentanil induction dose (R2)
10021374|NCT03861377|Active Comparator|Remifentanil R4|Medium dose Remifentanil induction dose (R4)
10021375|NCT03861377|Active Comparator|Remifentanil R8|Medium dose Remifentanil induction dose (R8)
10021376|NCT03859167||Participants with AV block with pacemaker|Participants will have a stress test, and results will be collected and recorded.
10021377|NCT03858816|Experimental|Mixture probiotics|The probiotic contain 1 ×10^9 CFU/1 capsule of mixture probiotics, taking 1 probiotic capsule for up to 4 months after birth.
10021378|NCT03858816|Placebo Comparator|Placebo|Taking 1 placebo capsule for up to 4 months after birth.
10021379|NCT03857893|Active Comparator|Control Group : pH-Cream|Control Group will be only treated with a fixed amount (1g) of pH-cream (Cetomacrogol cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days and if deem necessary, additional doses can be applied and notified in the calendar provided).
9477823|NCT03558698|Other|Group 6|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
9477824|NCT03558685|Experimental|Diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10%monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
9477825|NCT03558659|Experimental|Positional Therapy Belt|Use of positional therapy belt (SlumberBUMP) during sleep.
9477826|NCT03558659|No Intervention|Standard Care|No positional therapy belt provided for use during sleep.
9477827|NCT03558620|Experimental|Group 1O2|A fitting mask is held by one hand -> one hand with an endoscopic bite block -> held by two hands
9477828|NCT03558620|Experimental|Group 12O|A fitting mask is held by one hand -> held by two hands-> one hand with an endoscopic bite block
9477829|NCT03558620|Experimental|Group O12|A fitting mask is held by one hand with an endoscopic bite block->by one hand -> by two hands
9477830|NCT03558620|Experimental|Group O21|A fitting mask is held by one hand with an endoscopic bite block -> by two hands-> one hand
9477831|NCT03558620|Experimental|Group 21O|A fitting mask is held by two hands -> one hand -> one hand with an endoscopic bite block
9477832|NCT03558620|Experimental|Group 2O1|A fitting mask is held by two hands ->one hand with an endoscopic bite block-> by one hand
9477833|NCT03558607|Experimental|Experimental arm|
9477834|NCT03558594|Experimental|Hypnosis|Participant will have one brief meeting with a clinician in which they will learn about hypnosis and be provided with an informational booklet and with audiorecordings of hypnosis exercises. Participants will be encouraged to listen to the hypnosis recordings as much as they would like, whenever they would like to listen. The recordings are short inductions followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the audio recordings that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
9518148|NCT03299400|Experimental|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
10021380|NCT03857893|Experimental|Dynamic Quadripolar Radio-Frequency treatment|"Experimental Group will be treated with Dynamic Quadripolar Radio-Frequency (DQRF) (with Eva™ Device) for 8 weeks (+ 4 weeks). The Dynamic Quadripolar Radio-frequency sessions will involve -5 sessions (one every 14-21 days), if necessary External treatment (vulvar - will be applied before internal treatment for more comfort) : 10 minutes (5 minutes left side, 5 minutes right side), and Internal treatment (VVA, Vaginal Laxity, Mild-Stress Urinary Incontinence (SUI)): 20 minutes.~In parallel, patients can also apply pH-cream (Cetomacrogol cream) (one dose of 1g) if they judge necessary but they are not allowed to use it during the seven days before radiofrequency session. If they use pH-cream, they must notify it in the calendar provided."
10021381|NCT03857048|Active Comparator|Control|Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
9477835|NCT03558594|Experimental|Mindfulness|Participant will have one brief meeting with a clinician in which they will learn about mindfulness meditation and be provided with an informational booklet and with audio recordings of mindfulness exercises. Participants will learn Vipassana meditation by listening to audio recordings, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.Participants will be encouraged to listen to the meditation recordings as much as they would like, whenever they would like to listen.
9477836|NCT03558594|No Intervention|No intervention|Participants will enroll in the study, but do not select a study intervention. They will complete study assessments on the same schedule as those participants who select either experimental arm.
9477837|NCT03558581|No Intervention|Control|Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
9477838|NCT03558581|Experimental|Intervention|After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
9477839|NCT03558568|Active Comparator|DBS off|
9477840|NCT03558568|Active Comparator|DBS on 60 Hz.|
9477841|NCT03558568|Active Comparator|DBS on 99 Hz.|
9477842|NCT03558568|Active Comparator|DBS on 130 Hz.|
9477843|NCT03558568|Active Comparator|DBS on 230 Hz.|
9477844|NCT03558542|Experimental|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
10021382|NCT03857048|Experimental|Reduced obese + diet + exercise|Persons with obesity randomized to a weight loss program consisting of caloric restriction, behavioral support, and supervised endurance exercise training. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
9477845|NCT03558490|Experimental|ZEMY software|
9477846|NCT03558477|Experimental|Set 1(YYD601 1 & Nexium)|Set 1: YYD601 1 & Nexium
9477847|NCT03558477|Experimental|Set 2(YYD601 2 & Nexium)|Set 2: YYD601 2 & Nexium
9477848|NCT03558477|Experimental|Set 3(YYD601 3 & Nexium)|Set 3:YYD601 3 & Nexium
9477849|NCT03558464|Experimental|Intervention|"Intervention (agriculture-focused package~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
10021383|NCT03857048|Active Comparator|Reduced obese + diet group|Persons with obesity randomized to a weight loss program consisting of caloric restriction and behavioral support. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
10021384|NCT03854461|Active Comparator|Educational material|Participants will be given written educational material to encourage dietary change towards a better quality diet. Educational material will be adapted from resources used in previous dietary intervention studies.
9477850|NCT03558464|Active Comparator|Control|(agriculture-focused package)
9477851|NCT03558451|Experimental|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
9477852|NCT03558451|Active Comparator|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
9477853|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
9477854|NCT03558425|Experimental|TR group|Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
9477855|NCT03558425|Experimental|RT group|Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
9477856|NCT03558412|Experimental|Arm A|Decitabine+CODOX-M/IVAC for patients with relapsed or refractory T-lymphoblastic lymphoma who used Hyper-CVAD or BFM-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B.
9477857|NCT03558399|Experimental|FET according to ERA|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the study arm, a single euploid embryo will be transferred at the time indicated by the ERA test results. Merely the timing of embryo transfer will distinguish the study from the control group.
9477858|NCT03558399|Active Comparator|FET according to standard protocol|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the control arm, a single euploid embryo will be transferred according to our standard FET protocol.
9477859|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
9477860|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
9477861|NCT03558347|Experimental|short implants with splinted crowns|Patients of that group received splinted crowns on the two adjacent implants Intervention: short implants with splinted crowns
9477862|NCT03558347|Experimental|short implants with non-splinted crowns|Patients of that group received single crowns on the two adjacent implants Intervention: short implants with non-splinted crowns
9477863|NCT03558334|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to preterm infants with BPD.
9477864|NCT03558334|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to preterm infants with BPD.
9477865|NCT03558321|Experimental|post menopausal bleeding|women with postmenopausal bleeding and endometrial thickness more than 5 mm
9477866|NCT03558308|Experimental|Brain+ with clinical support|Intervention: Computer based cognitive rehabilitation. This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
10036387|NCT01815216|Active Comparator|Control|"Patients in the control group will not undergo surgery during study.~These patients will be examined twice:~9 weeks before the operation (i.e. clinical intervention to reduce body weight has not started).~after 4 weeks of low-calorie diet (which will be a week before their surgery, when patients are in a catabolic metabolism because they eat much less energy than is needed) to assess effect of acute weight loss on: Brain activity in resting state Memory performance"
9477867|NCT03558308|Experimental|Cogmed with continuous support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
9477868|NCT03558308|Experimental|Brain+ without support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Brain+' but receive no support during the intervention period.
9477869|NCT03558308|Sham Comparator|Sham-training group|Intervention: Sham computerized gaming. This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
9477870|NCT03558282||Maxillary Anterior Implant|Subjects who have a single implant restoration in the maxillary anterior position with sufficient baseline data. Recession observation and crown contour observation of the implant will be completed.
9477871|NCT03558269|Experimental|Study group|This group will receive UCB after the first palliative surgery
9477872|NCT03558269|No Intervention|Control group|This group will not receive any treatment
9477873|NCT03558256|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
9477874|NCT03558256|Active Comparator|Medication|Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of depression (fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram).
9477875|NCT03558243|Active Comparator|Patent Hemostasis Arm|The TR Band (Terumo medical) will be placed on the sheath entry site, the air bladder of the TR Band will be filled with 18 mL of air to achieve initial hemostasis. The sheath will be removed, air will be withdrawn slowly until a pulsatile bleeding is observed through the sheath's orifice, once this phenomenon occurs, 2 ml of air will be added to the air bladder and the absence of bleeding will be corroborated, immediately afterwards a pulse oximeter will be placed on the index finger of the patient and transient manual compression of the ipsilateral ulnar artery will be performed, patency of the radial artery will be corroborated by means of oxygen saturation and adequate pulse curve (Barbeau reverse test), if it is not possible to achieve patent hemostasis, it will be retried deflating 1-2 ml of the TR Band every 15 minutes until a positive reverse Barbeau test with absence of bleeding is achieved. TR Band removal will be attempted 2 hours after the procedure.
9477876|NCT03558243|Experimental|ULTRA Arm|The TR Band will be placed at the sheath entry site, the ipsilateral ulnar artery will be compressed at the Guyon's canal by placing a cylindrical composite made by wrapping 4 inch x 4 inch gauze around a 1-inch plastic needle cap, and compressing it using a circumferentially applied Hemoband. After occlusive compression of ulnar artery is confirmed by means of plethysmography, patent hemostasis protocol will be used for radial artery hemostasis as described at the patent hemostasis arm. The needle cap and hemoband that compresses the ulnar artery will be removed 1 hour after the procedure. TR Band removal will be attempted 2 hours after the procedure.
9518149|NCT03299387|Active Comparator|Oral Nitrofurantoin|Participants will randomized to oral nitrofurantoin
10021385|NCT03854461|Experimental|Personalised dietary advice and educational material|Participants will also be given the educational material, but will be encouraged to make dietary change using individualized recommendations incorporating food markers of specific components of a high quality diet. Food markers of diet quality will be used to develop an algorithm to deliver personalized dietary advice. Based on biomarker data, a system of categorization of biomarker status will be developed, alongside dietary advice related to this biomarker categorization, and decision trees created, as previously described in the Food4Me study, to ensure standardized delivery of advice within this intervention arm.
10036388|NCT01815242|Experimental|Arm A|nab-Paclitaxel + gemcitabine
10036389|NCT01815242|Experimental|Arm B|nab-Paclitaxel + carboplatin
10036390|NCT01815255||tenofovir (TDF)|HIV-infected children who are currently on TDF-based regimen or are changing to TDF based on their clinical indication
9518150|NCT03299387|Active Comparator|Intravesical Gentamicin|Participants will be randomized to intravesical gentamicin
9477877|NCT03558243|Experimental|Hemostatic Disc Arm|The StatSeal hemostatic disc will be placed above sheath entry site, the TR Band will be placed above the disc, according to the manufacturer's specifications the air bladder will be filled with 8 ml of air, the sheath will be then removed, corroborating the absence of bleeding, 20 minutes later 3 ml of air will be removed, 20 minutes after that 5 ml of air will be removed, finally the investigators will try to remove the deflated TR Band 60 minutes after the procedure.
9518151|NCT03299374|Active Comparator|Falls Group|Falls prevention intervention
9518152|NCT03299374|Experimental|Pilates Group|Pilates intervention
10021386|NCT03852992|Experimental|Safety Group|"will participate in one visit, receiving laser assisted delivery of minoxidil and PK data. The safety group treatments will follow dose escalation as follows:~Safety Participant 1: Post-laser 5mg minoxidil (0.25ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 2: Post-laser 10mg minoxidil (0.5ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 3: Post-laser 20mg minoxidil (1mL of 20mg/mL sterile solution, applied post-laser procedure)"
10021387|NCT03852992|Placebo Comparator|Placebo|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Saline 0.9%: 2ml of sterile saline solution applied post-laser procedure"
9477878|NCT03558178|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated.
9477879|NCT03558178|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
10021388|NCT03852992|Experimental|Treatment A|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure"
10021389|NCT03852992|Experimental|Treatment B|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure~At-Home Minoxidil 5%: 2ml of 50mg/ml foam q24 h for duration of study"
9477880|NCT03558165||Stage IV Lung Adenocarcinoma|
9477881|NCT03558139|Experimental|Magrolimab + Avelumab (Part 1, Safety Run-in)|"Dose Level 1: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 30 mg/kg weekly for 4 doses (Cycle 1). Starting in Cycle 2, magrolimab 30 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.~Based on Dose Limiting Toxicities (DLTs) assessment in Dose Level 1 Cycle 1; additional participants will be enrolled and administered Dose Level 2.~Dose Level 2: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 45 mg/kg on Days 8,11,15, 22 and 29 for Cycle 1, continuing weekly in Cycle 2 on Days 1, 8, 15 and 22. Starting in Cycle 3, magrolimab 45 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.~Additional lower or higher dose levels may be explored after reviewing all available clinical data."
9477882|NCT03558139|Experimental|Magrolimab + Avelumab (Part 2, Ovarian Cancer Expansion)|After Part 1 Safety Run-in has completed and the recommended expansion dose(s) for magrolimab is determined, participants with ovarian cancer will be administered the recommended magrolimab dose(s) combined with avelumab 800 mg given once every 2 weeks.
9477883|NCT03558113|Other|visual tactile method|visual tactile method using the modified USHPS critiria
9477884|NCT03558100|Experimental|Reducing Fall Risks in Obesity|Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
9477885|NCT03558048||Men with Inflammatory Bowel Disease|Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
9477886|NCT03558035|Experimental|Induction chemotherapy and concurret chemoradiotherapy group|Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.
9477887|NCT03558035|Active Comparator|Concurrent chemoradiotherapy group|Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy
9477888|NCT03558022|Experimental|Salt Pills|One week on low salt diet plus salt pills
9477889|NCT03558022|Placebo Comparator|Placebo Pills|One week on low salt diet plus placebo pills
9477890|NCT03557996|Experimental|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
9477891|NCT03557996|Active Comparator|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
9477892|NCT03557983|Experimental|fenofibrate|Fenofibrate should be topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
9477893|NCT03557983|Placebo Comparator|Saline|Saline is topically spread three times per day for one week.
9518153|NCT03299348|Experimental|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
10021390|NCT03851133||All Participants|Blood samples, tumor samples and data will be collected from all participants as applicable.
10021391|NCT03850795|Experimental|HC-1119|Oral dose of 80 mg/day
10021392|NCT03850795|Active Comparator|enzalutamide|Oral dose of 160 mg/day
10021393|NCT03850444|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
10021394|NCT03850444|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
10021395|NCT03850288||Anorexia Nervosa|"Patients with a diagnosis of anorexia nervosa (According to the DSM-V criteria). These patients are characterized by a restriction of food intake leading to weight loss or a failure to gain weight resulting in a significantly low body weight of what would be expected for someone's age, sex and height. Moreover, there is a fear of becoming fat or of gaining weight.Then, these patients have a distorted view of themselves and of their condition."
10036391|NCT01815268|Experimental|HD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and provided free SD vaccine (Fluzone) for the staff.
10036392|NCT01815268|Experimental|HD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and not provided free vaccine for the staff.
10021396|NCT03850288||Bulimia Nervosa|"Patients with a diagnosis of bulimia nervosa. According to the DSM-V criteria, these patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time, an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode, recurrent inappropriate compensatory behaviour in order to prevent weight gain, such as self-induced vomiting, misuse of laxatives, diuretics, or other medications, fasting, or excessive exercise.~The binge eating and inappropriate compensatory behaviours both occur, on average, at least once a week for three months. Moreover, there is a self-evaluation influenced by body shape and weight."
10021397|NCT03850288||Binge Eating Disorder|Patients with a diagnosis of Binge Eating Disorder. These patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time (e.g. within any 2-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode. The binge eating episodes are associated with three or more of the following: eating much more rapidly than normal, eating until feeling uncomfortably full, eating large amounts of food when not feeling physically hungry, eating alone because of feeling embarrassed by how much one is eating, feeling disgusted with oneself, depressed or very guilty afterward,marked distress regarding binge eating is present. Moreover, binge eating occurs, on average, at least once a week for three months
10021398|NCT03848312|Experimental|Computerized Cognitive Training|Participants will complete computerized cognitive training.
10021399|NCT03848312|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities.
10021400|NCT03846570|Active Comparator|Formoterol-beclomethasone|Formoterol (fumarate dehydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler.
10021401|NCT03846570|Placebo Comparator|Placebo|Matching placebo (identically package) administered BID
10036393|NCT01815268|Active Comparator|SD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and provided free standard dose vaccine (Fluzone) for the staff.
10036394|NCT01815268|Active Comparator|SD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and not provided free vaccine for the staff.
10036395|NCT01815281|Experimental|Foot Mechanical Stimulation|The FMS stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
10021402|NCT03846050|Experimental|BAC Feedback, immediate onset|"Participants will receive aBAC Feedback/Warning intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
10021403|NCT03846050|Experimental|BAC Feedback, delayed onset|"Participants will receive the BAC Feedback/Warning intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
10036396|NCT01815281|Sham Comparator|Footh Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
10036397|NCT01815294|Experimental|Treatment A: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1
10021404|NCT03846050|Placebo Comparator|Minimal Assessment Control|"Participants will receive the No BAC Feedback/Warning intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions.~The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions."
10036398|NCT01815294|Experimental|Treatment B: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1
9477894|NCT03557957|Experimental|Standard care plus targeted correction of hyponatremia|Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.
9802716|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc1 [dose level 1 {DL1}] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab intravenously (IV) on Day 1 of Cycles 2 and 4 to 18, with or without background standard of care (SOC) chemotherapy as appropriate for the indication. A cycle is 42 days.
9477895|NCT03557957|Active Comparator|Standard care|Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
9477896|NCT03557944|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
9477897|NCT03557905|Active Comparator|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
9477898|NCT03557905|Active Comparator|Group II|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.5.
9477899|NCT03557892|Experimental|CSII+CGM|
9477900|NCT03557892|Active Comparator|MDI with degludec|
9477901|NCT03557879||Hearing impaired families|Samples from families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
9477902|NCT03557866|Experimental|pronated group|individuals with pronated foot
9477903|NCT03557866|Active Comparator|control group|individuals with normal foot posture
9477904|NCT03557853||Golimumab injection|Patients with ankylosing spondylitis and coxitis being treated with Simponi (golimumab) according to local clinical practice and label.
9477905|NCT03557840|Experimental|Temocillin treatment|Patients treated with temocillin and sampled as per the protocol
9477906|NCT03557827|Sham Comparator|control|Mechanical debridement by periodontal curets alone
9477907|NCT03557827|Active Comparator|Photodynamic Therapy|Mechanical debridement by periodontal curets and supplement with photodynamic appliance
9477908|NCT03557814|Active Comparator|LED01|Conventional non-surgical periodontal therapy plus LED light irradiation from T0-T1
9477909|NCT03557814|Active Comparator|LED02|Conventional non-surgical periodontal therapy plus LED light irradiation from T1-T2
9477910|NCT03557814|Sham Comparator|Control|Conventional non-surgical periodontal therapy without LED light irradiation
9477911|NCT03557762|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
10021405|NCT03844100|Experimental|Patients with Refractory Functional Dyspepsia|"Patients with FD diagnosed by the Rome IV criteria, patients with Refractory Functional Dyspepsia~Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week~Person with above symptoms that started at least 6 months before and continused for minimum 3 months~Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease~Person who do not respond to at least 2 general treatments for FD~Dyspepsia symptoms that can disrupt daily life (global overall symptom scale score =>5)"
10036399|NCT01813669|Experimental|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
9477912|NCT03557762|Other|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
10036400|NCT01813669|No Intervention|Waitlist Control|Participants in the waitlist condition will not receive any experimental intervention. They can continue any treatments as usual. The waitlist will be approximately 10-14 weeks in duration. At the end they will be offered the opportunity to participate in the intervention. If they elect to participate in the intervention, post-study data will also be collected from this group, approximately 13-weeks following the first group session.
10036401|NCT01815307|Experimental|Gemcitabine group|1000mg/m2, day 1 every 2 weeks
10036402|NCT01815307|Experimental|S-1 group|80mg/m2/day, day 1-28, every 6 weeks
10036403|NCT01815320|Experimental|Contrast-enhanced ultrasound (CE-US)|Ce-US is performed by contrast agent infusion SonoVue. The acquisition protocol will consist of two different administrations of SonoVue, performed 10 minutes apart. In the first session, SonoVue microbubbles will be administered as a fast 1.5 ml bolus immediately followed by 5 ml saline solution. In the second session, max 2 vials (9.6 ml) of SonoVue will be infused at an infusion rate between 0.5 and 1.0 ml/min.
10021406|NCT03842969|Experimental|RO7234292 (RG6042) Q8W|Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W.
9477913|NCT03557736|Experimental|Home-HIT|Home-based high-intensity interval training: participants performed 12 weeks of simple body weight exercises in a place of their own choosing 3x/week
10036404|NCT01815346|Experimental|Acupuncture Group - Twice a Week|Acupuncture 2 times a week for 6 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
10021407|NCT03842969|Experimental|RO7234292 (RG6042) Q16W|Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.
10021408|NCT03840668|Experimental|Dry eye|Participants who will be using the USB-powered eye mask.
10021409|NCT03838367|Experimental|Phase I-Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
10021410|NCT03838367|Experimental|Phase I-Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
9477914|NCT03557736|Experimental|Home-MICT|Home-based moderate-intensity interval training: participants performed 12 weeks of continuous exercise (running, swimming or cycling) in a place of their own choosing 3x/week
9477915|NCT03557736|Experimental|Lab-HIT|Laboratory-based high-intensity interval training: participants performed supervised cycle exercise under laboratory conditions 3x/week for 12 weeks
9477916|NCT03557710|Experimental|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
9477917|NCT03557710|Experimental|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
9477918|NCT03557710|Active Comparator|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
9477919|NCT03557671|Experimental|TRHF - Placebo|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
9477920|NCT03557671|Placebo Comparator|Placebo - TRHF|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
9477921|NCT03557645|Sham Comparator|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
9477922|NCT03557645|Experimental|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
9477923|NCT03557645|Experimental|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
9518154|NCT03299348|Placebo Comparator|Active Control Group|"This group will get a generic health education program, called the 10 Keys to Healthy Aging. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The health education program will only provide information related to some of the most important health conditions, such as cardiovascular disease, cancer, type 2 diabetes, and clinical depression, and how these conditions can be managed."
9518155|NCT03299335|Other|Early-stage sIMB patients|
9518156|NCT03299335|Other|Late-stage sIMB patients|
10021411|NCT03838367|Experimental|Phase I-Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
10021412|NCT03838367|Experimental|Phase II- MTD to be established for the combination treatment|MTD PRO 140 SC + AUC 5 Carboplatin in 30 subjects
9518157|NCT03299335|Other|Control subjects|
10021413|NCT03837925|Experimental|ATORVASTATIN|Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine
10021414|NCT03837925|Placebo Comparator|PLACEBO|Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm
10021415|NCT03836547|Experimental|Multicomponent Intervention for weight loss|12-week intervention that consists of Weight Watcher on-line program, Garmin Fitness Tracker, blue-tooth scale, and telephonic health coaching.
10021416|NCT03836547|Active Comparator|Wait-list Control|The participant will receive usual care for 12 weeks and then will compassionately be offered the active intervention.
9518158|NCT03299322|Placebo Comparator|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
10036405|NCT01815346|Experimental|Acupuncture Group - Three Times a Week|Acupuncture 3 times a week for 4 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
10036406|NCT01815359|Experimental|Appendiceal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
10021417|NCT03836144||Cystinuria|10 patients with cystinuria. Experimental. Urine collected before treatment initiation and 3 months after. Treatment: Usual alkalizing treatment using oral potassium citrate. The initial dosage will be 4 g/day divided into 3 to 4 oral daily doses. If the objective of urinary pH is not reached after the first two weeks of treatment, the dose will be increased by 2 grams (6 grams total). If the urinary pH remains below 7.5 after 2 weeks with 6 grams of potassium citrate per day, the alkalizing treatment will then be supplemented with oral sodium bicarbonate in the form of Vichy water or officinal preparation. This treatment is the usual treatment recommended for cystinuria .
10021418|NCT03836144||Non cystinuria nephrolithiasis|20 patients with a nephrolithiasis not due to cystinuria. Control group. Urine collected once to study biomarkers of inflammation No intervention.
10021419|NCT03836144||Inflammatory nephropathy|"10 patients with an inflammatory nephropathy of glomerular or tubulo interstitial origin (confirmed by renal biopsy).~Control group. Urine collected once to study biomarkers of inflammation. No intervention."
10021420|NCT03836066|Experimental|Experimental: Atezolizumab plus Bevacizumab arm|1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.
10021421|NCT03831347|Experimental|Hatha Yoga|12 weeks of modified Hatha Yoga specifically designed to be administered to teens with depression.
10021422|NCT03829735|Experimental|Children and their mothers|Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
10021423|NCT03829488|Experimental|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
10021424|NCT03829488|Active Comparator|0.9% SODIUM CHLORIDE 9g/L injection BP|0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
10021425|NCT03828331||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-55 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
10021426|NCT03826628|Experimental|0.5% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
10021427|NCT03826628|Experimental|1.0% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
10021428|NCT03826628|Placebo Comparator|Placebo|Placebo cream topical, applied once daily before bed on affected area for 26 weeks
10021429|NCT03826563|Placebo Comparator|Placebo|Subjects will receive pill placebo nightly
10021430|NCT03826563|Experimental|Melatonin|Subjects will receive oral melatonin tablets 2.5-10mg nightly for 2 weeks. All will receive melatonin 5mg for one week, then at the 1 week visit, the dose can be continued at 5mg or adjusted to 2.5mg or 10mg nightly based on clinical assessment of patient response and side effects.
10021431|NCT03825536|Experimental|Oral methamphetamine|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the experimental treatment arm, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later.
10021432|NCT03825536|Placebo Comparator|Placebo oral capsule|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the placebo treatment arm, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
10021433|NCT03819829|Other|Blood sample|Blood sample
10021434|NCT03819569|Active Comparator|Biopsy|Subjects receive a renal cell biopsy prior to making a decision about treatment
10021435|NCT03819569|Sham Comparator|No Biopsy|Subjects do not receive a renal cell biopsy prior to making a decision about treatment
10021436|NCT03817892|No Intervention|Unguided 2 minutes (U2)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines."
10021437|NCT03817892|Experimental|Unguided 4 minutes (U4)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)"
10021438|NCT03817892|Experimental|Guided 2 minutes (G2)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines.
9518159|NCT03299322|Experimental|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
9518160|NCT03299322|Experimental|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
9518161|NCT03299296|Experimental|Rivaroxaban arm|Rivaroxaban 10 Milligrams
9518162|NCT03299296|Active Comparator|Enoxaparin Arm|'Enoxaparin 40 Milligrams /0.4 Milliliters Prefilled Syringe
10021439|NCT03817892|Experimental|Guided 4 minutes (G4)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)
10021440|NCT03817398|Experimental|Basic Science (stop taking TKI, biospecimen collection)|Patients stop taking TKI medication within 10 days after enrollment. Patients undergo peripheral blood collection to monitor loss of MMR every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Patients who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.
10021441|NCT03816839|Experimental|SAR439859|administered orally once daily or twice daily as monotherapy in fasted or fed state
10021442|NCT03816397|Active Comparator|Continue adalimumab|Patients randomized to this arm will continue adalimumab at their current dose (either 20mg/0.2mL or 40mg/0.4mL) administered subcutaneously every other week.
10021443|NCT03816397|Placebo Comparator|Stop adalimumab|Patients randomized to this arm will receive a volume-matched placebo (0.8mL) administered subcutaneously every other week.
10021444|NCT03815643|Experimental|Avelumab|
10021445|NCT03814590|Experimental|Group Low Dose_PLAIN_A|Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021446|NCT03814590|Experimental|Group Medium Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021447|NCT03814590|Experimental|Group High Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021448|NCT03814590|Placebo Comparator|Group Placebo_A|Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021449|NCT03814590|Experimental|Group Low Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021450|NCT03814590|Experimental|Group Low Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021451|NCT03814590|Experimental|Group Low Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021452|NCT03814590|Experimental|Group Medium Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021453|NCT03814590|Experimental|Group Medium Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021454|NCT03814590|Experimental|Group Medium Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021455|NCT03814590|Experimental|Group High Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021456|NCT03814590|Experimental|Group High Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021457|NCT03814590|Experimental|Group High Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021458|NCT03814590|Placebo Comparator|Group Placebo_B|Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
10021459|NCT03812718|Active Comparator|ETT Group|"Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.~Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID)."
10021460|NCT03812718|Active Comparator|PLMA Group|Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.
10021461|NCT03811574|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue semaglutide 2.4 mg until week 68.
10021462|NCT03811574|Placebo Comparator|Placebo (semaglutide 2.4 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue placebo (semaglutide 2.4 mg) until week 68.
9802717|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc2 + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc2 [DL1] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab IV on Day 1 of Cycles 2 and 4 to 18, with or without background SOC chemotherapy as appropriate for the indication. A cycle is 42 days.
9518163|NCT03299283||Respiratory/Pharyngitis|Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue
9802718|NCT05016661|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
9802719|NCT05016661|Experimental|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles
9802720|NCT05013905|Experimental|PRA023|Participants to receive PRA023 administered by intravenous (IV) infusion.
9518164|NCT03299283||Gastrointestinal|Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
9802721|NCT05009706|Experimental|Self Care group|Patients who are randomized to the intervention Self Care group will get advice and support on physical excercise, nutrition and symptom management to perform at home for 12 weeks. Once a week, patients will come to the hospital for follow-up and to exercise with a physiotherapist.
9518165|NCT03299270||Group 1|Elderly patiences with solid malignancy
10021463|NCT03811574|Experimental|Semaglutide 1.7 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue semaglutide 1.7 mg until week 68.
9477924|NCT03557632|Experimental|TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)|Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
9477925|NCT03557632|Active Comparator|Control: Relapse Prevention Drug Education|Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
9477926|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
9477927|NCT03557580|Active Comparator|IS-5-MN R|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
9477928|NCT03557580|Experimental|IS-5-MN T1|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
9477929|NCT03557580|Experimental|IS-5-MN T2|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
9477930|NCT03557567||MO patients|
9477931|NCT03557567||OI patients|
9477932|NCT03557554|Experimental|Massage Therapy|Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.
9477933|NCT03557541|Experimental|Sardine group|
9477934|NCT03557541|Active Comparator|Control group|
9477935|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
9477936|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
9477937|NCT03557515|Experimental|CBT Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional CBT telephonic sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
9477938|NCT03557515|Experimental|Metta-Meditation Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional Metta-meditation sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
9477939|NCT03557502|Experimental|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
9477940|NCT03557502|Experimental|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
9477941|NCT03557489|Experimental|Experimental group|Patients use gel pad(in usual) in addition to(Mepilex Border Sacrum)foam pad during surgery.
9477942|NCT03557489|No Intervention|Control group|patients use gel pad(in usual) during surgery.
9477943|NCT03557463|Active Comparator|Soy protein|Low isoflavone soy protein powder: Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
9477944|NCT03557463|Experimental|Dairy protein|UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
9477945|NCT03557450|Experimental|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
9477946|NCT03557437|Active Comparator|Triple Therapy|Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
9477947|NCT03557437|Experimental|Bismuth Plus Triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
9477948|NCT03557424|Experimental|Polyglucosamine Glucomannan normal dose|Patients received the single dose Polyglucosamine und Glucomannan (0,5 g resp. 1 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
9477949|NCT03557424|Experimental|Polyglucosamine Glucomannan high dose|Patients received the higher dose of Polyglucosamine und Glucomannan (1 g resp. 1,34 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
10021464|NCT03811574|Placebo Comparator|Placebo (semaglutide 1.7 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue placebo (semaglutide 1.7) until week 68.
10021465|NCT03810196|Other|TBI regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
9477950|NCT03557424|Placebo Comparator|Placebo|Patients received Placebo three times per day over 65 days. The Placebo is administered according to the respective Intervention (Drug: Placebo Comparator: Placebo) as a powder which is dissolved in water. The solution is taken orally.
10021466|NCT03810196|Other|TBI or busulfan regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
10021467|NCT03809923|Experimental|Dexmedetomidine Combined With Lidocaine Infusion Affect PONV|
10021468|NCT03809923|Experimental|Effect of infusion saline on PONV|
10021469|NCT03809923|Experimental|Effect of infusion lidocaine on PONV|
10021470|NCT03809923|Experimental|Effect of infusion dexmedetomidine on PONV|
10021471|NCT03808961|Active Comparator|Group 1 ? Niacin Arm|Oral 100 mg fixed dose twice daily x 18-months (200 mg total / day) with assessments @ baseline, 6 month, 12 month and 18 months
10021472|NCT03808961|Active Comparator|Group 2 ? Niacinamide Arm|Oral 100 mg fixed dose twice daily (200 mg total / day) x 18-months with assessments @ baseline, 6 month, 12 month and 18 months
10021473|NCT03808961|Placebo Comparator|Group 3 ? Placebo Wait-listed Arm|Oral placebo twice daily x 18- months with assessments @ baseline, 6 month, 12 month and 18 months
10021474|NCT03806452|Experimental|Hydroxycarbamide|"Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
9477951|NCT03557411|Experimental|SHR-1210 +Hypofraction radiotherapy|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
9477952|NCT03557398|Experimental|Hydeal-D vaginal pessaries|Vaginal application of Hydeal-D vaginal pessaries
9477953|NCT03557268||On a GnRHa|Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
9477954|NCT03557268||Not on GnRHa|Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue
9477955|NCT03557255|Active Comparator|levosimendan|Levosimendan was prepared in a concentration of 25 µg/ml and infusion was commenced at a rate of 0.1 µg/kg/minute without loading and continued for 24 hours before surgery.The dose was doubled if an increase of > 20 mmHg in systolic blood pressure (SBP) could not be obtained within 2 hours after starting the infusion. Indications for dose reduction were the development of hypotension (SBP < 80 mmHg) or tachycardia (heart rate > 120 beats/min) persisting for more than 10 minute or (premature beats in a frequency exceeding 6/min or occurrence of a significant arrhythmia occurring in runs). The infusion medication would be discontinued should such occurrences persist despite dose reduction.
9477956|NCT03557255|Active Comparator|control|In the control group ,an identical saline infusion regimen was employed instead of levosimendan . Both patient and care giver were blinded for the study.
9477957|NCT03557229|Experimental|Melatonin|
9477958|NCT03557229|Experimental|Vitamin C|
9477959|NCT03557229|Experimental|Vitamin E|
9477960|NCT03557229|Experimental|N-acetylcysteine|
9477961|NCT03557229|No Intervention|Control|
9477962|NCT03557151|Active Comparator|Usual Care|Usual Care participants will receive the same excellent multidisciplinary care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
10021475|NCT03806452|Placebo Comparator|Placebo|"Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
10021476|NCT03804138||Patient|patient with COPD
10021477|NCT03804138||control group|patient without COPD
10021478|NCT03802019|Experimental|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will complete a 30-day experimental period when they will continue to receive their own preferred brand of cigarettes (i.e., control group).
10021479|NCT03802019|Experimental|LNC Cigarettes + Gray Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in standard investigational packaging (gray).
10021480|NCT03802019|Experimental|LNC Cigarettes + Red Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in red packaging.
10021481|NCT03802019|Experimental|LNC Cigarettes + Blue Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in blue packaging.
10021482|NCT03802019|Experimental|LNC Cigarettes + Plain Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in plain packaging.
10021483|NCT03801083|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic biliary tract cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
10021484|NCT03800420|Experimental|BBT-401-1S|BBT-401-1S, Oral capsule, QD
10021485|NCT03800420|Placebo Comparator|Placebo|Placebo, Oral capsule, QD
10021486|NCT03800407||EFV-based ART|ART-naïve HIV-infected children aged 3 - 14 years who initiate EFV-based ART
9518166|NCT03299257|Active Comparator|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
10021487|NCT03800407||Concurrent EFV-based ART plus anti-TB therapy|ART-naïve HIV-infected children aged 3 - 14 years with TB coinfection who initiate EFV-based ART while receiving first-line anti-TB therapy
10021488|NCT03796559|Experimental|Magseed marker|Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC.
10021489|NCT03796416|Active Comparator|misoprostol|"Induction using misoprostol:~Insert misoprostol 25 micrograms in the posterior fornix of the vagina digitally Repeat cervical exam every 4 hours"
10021490|NCT03796416|Experimental|Misoprostol and foley bulb|"Induction using Foley balloon combined with misoprostol:~A 26 French intracervical Foley balloon will be inserted above the internal os at the start of induction, inflated using 80cc of sterile water.~If a Foley balloon is not able to be inserted at the time of starting induction of labor, misoprostol 25microgram can be inserted in the posterior fornix of the vagina and the misoprostol protocol followed."
9518167|NCT03299257|Placebo Comparator|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
10021491|NCT03796221|Active Comparator|Control Group|Will receive standard pediatric obesity treatment
9665266|NCT05117489|Experimental|Cohort 3 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MWF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily for 2 weeks, followed by 100 mg of miricorilant every Monday, Wednesday and Friday for 10 weeks.
10021492|NCT03796221|Experimental|Intervention Group|Will receive standard pediatric obesity treatment and parenting videos
10021493|NCT03795558|Experimental|Etelcalcetide 2.5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
9665267|NCT05117489|Experimental|Cohort 4 - 100 mg daily miriorilant for 2 weeks, followed by 100 mg every MF for 10 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 2 weeks, followed by 100 mg of miricorilant every Monday and Friday for 10 weeks.
10021494|NCT03795558|Experimental|Etelcalcetide 5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
10021495|NCT03795558|Experimental|Etelcalcetide 7,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
10021496|NCT03795558|Experimental|Etelcalcetide 10 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
10021497|NCT03795558|Experimental|Etelcalcetide 12,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
10021498|NCT03795558|Experimental|Etelcalcetide 15 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
10021499|NCT03794206|Experimental|Treatment Arm|Single-arm of subjects who receive treatment with Vesair Balloon
10021500|NCT03790098|Experimental|Yoga Class Participants|Group 1 participants will meet twice per week for one hour to practice restorative-flow yoga with a certified yoga instructor. There will be a total of 24 classes. Group 1 participants will also receive an at-home supplemental booklet, a yoga video led by the class instructor, and encouragement to practice two additional days each week at home. They will be asked to fill out a form to record their at-home practice.
10021501|NCT03790098|No Intervention|No Classes|Group 2 participants will not attend yoga classes as part of the study and will be asked not to begin yoga classes outside the study. After the 24 classes, they will be given the 'at-home' supplemental materials.
10021502|NCT03785457|Experimental|Repetitive Trunk Extension|Participants with low back pain will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds, repeated five times with 15-second rest breaks
9477963|NCT03557151|Experimental|Transdisciplinary Care-In Person & Telehealth|In addition to all elements of Usual Care, TC-IP participants will have follow-up clinic visits in-person or by telehealth at approximately 3 month intervals during the study that will consist of simultaneous involvement of an advanced practice nurse, dietitian and psychologist who will see the parent and adolescent together. TC team members will have passed a competency exam following completion of a training course on each of the TC team professional disciplines.
9477964|NCT03557138|Experimental|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
9477965|NCT03557112|Experimental|the treatment group|TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
9477966|NCT03557112|Active Comparator|the control group|TPF regimen induction chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
9477967|NCT03557099|Experimental|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
9477968|NCT03557073|Experimental|Phone Call|Subjects in this study arm receive a post-operative phone call by a physician.
9477969|NCT03557073|No Intervention|No Phone call|Subjects in this study arm do not receive an additional post-operative phone call by a physician.
9477970|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
9477971|NCT03557021|Experimental|Individualized therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the followed therapy will be adjusted with in this setting available medications to the outcome of the resistance profile
9477972|NCT03557021|Active Comparator|standard therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the national defined standard therapy will be applied as second line treatment.
9477973|NCT03556995||Bariatric surgery patients|All patients above 18 that underwent bariatric surgery
9477974|NCT03556982|Experimental|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
9477975|NCT03556969||Propofol sedation after SA|Participants who undergo propofol sedation after spinal anesthesia
10021503|NCT03785457|Experimental|Sustained Trunk Extension|Participants with low back pain will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks
9477976|NCT03556930|Experimental|Movie Induced Sedation Effect|Pediatric Radiation Oncology with Movie Induced Sedation Effect monitored by an AlignRT system (VisionRT LTD, UK).
9477977|NCT03556917|Active Comparator|group 1|topical gel base + caffeine.
9477978|NCT03556917|Active Comparator|group 2|iontophoresis + caffeine
9477979|NCT03556917|Active Comparator|Group 3|iontophoresis
10021504|NCT03785106|Experimental|1HP|4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
10021505|NCT03785106|Active Comparator|3HP|12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
9477980|NCT03556878|Experimental|Fitted TranS-C|Fitted TranS-C involves 4 x 20-30 minute sessions. It involves selected cross-cutting, core and optional modules from Standard TranS-C.
9477981|NCT03556852|Active Comparator|CARBETOCIN|received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
9477982|NCT03556852|Active Comparator|MISOPROSTOL|received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.
10021506|NCT03782142||Group A NRTI + NNRTI|Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine
10021507|NCT03782142||Group B NRTI + boosted PI|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and a boosted Protease Inhibitor: Prezcobix- [darunavir+cobicistat combination]
10021508|NCT03782142||Group C NRTI + II|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an Integrase inhibitor (dolutegravir)
10021509|NCT03781791|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
10021510|NCT03781791|Placebo Comparator|Placebo Treatment|Placebo tablet will be taken once daily by mouth.
10021511|NCT03781323|Experimental|mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
10021512|NCT03778931|Experimental|Elacestrant|Subjects in Arm 1 will receive elacestrant
10021513|NCT03778931|Active Comparator|Standard of Care (SoC)|Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
10021514|NCT03776695|Experimental|2 mg/kg|Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
10021515|NCT03776695|Placebo Comparator|2 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10021516|NCT03776695|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
10021517|NCT03776695|Placebo Comparator|5 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10021518|NCT03776695|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
10021519|NCT03776695|Placebo Comparator|10 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
9477983|NCT03556839|Active Comparator|Arm A|Cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.
9477984|NCT03556839|Experimental|Arm B|cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.
9477985|NCT03556826|Experimental|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
9477986|NCT03556813||Group Vik|women over the age of 18 with breast cancer or remission
9477987|NCT03556813||Group physicians|women over the age of 18 with breast cancer or remission
9477988|NCT03556787|Experimental|Patients with knee pain|Adults patients suffering from osteoarthritis pain or general knee pain
9477989|NCT03556774|Experimental|With smoking cessation training|Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
9477990|NCT03556774|No Intervention|Without smoking cessation training|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
10021520|NCT03776695|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
10021521|NCT03776695|Placebo Comparator|20 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
10021522|NCT03772977|Experimental|Brain Health Champion (BHC)|"A health coach intervention with weekly phone calls"
10021523|NCT03772977|No Intervention|Standard of Care (SOC)|The current physician/provider counseling on brain health to reduce cognitive decline or incidence of cognitive impairment that occurs, per providers' own practice
10021524|NCT03770299|Experimental|Arm A|Nivolumab + SOC (chemotherapy in eligible participants or observation)
10021525|NCT03770299|Active Comparator|Arm B|SOC (chemotherapy in eligible participants or observation)
10021526|NCT03769415|Experimental|Intrinsic subtyping of Primary Breast Cancer|Intrinsic subtype of primary breast tissue from metastatic breast cancer subject will be determined
10021527|NCT03767244|Experimental|Apalutamide + ADT|Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy (RP) with pelvic lymph node dissection (pLND), followed by an additional six cycles of treatment.
10021528|NCT03767244|Experimental|Placebo + ADT|Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by RP with pLND, followed by an additional six cycles of placebo treatment.
10021529|NCT03766009|Active Comparator|Arm I (surgical consultation)|Prior to institutional crossover, participants receive care as per usual care.
10021530|NCT03766009|Experimental|Arm II (web-based breast cancer surgery decision aid)|Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..
10021531|NCT03762473|Experimental|Study Group|Post transplant patients (kidney transplant alone) with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, and negative BK screening at month 1, whom have a concentration/dose of < 1 and a steady state therapeutic level will be eligible. Patients will be converted to envarsus at 20% reduction in dose.
10021532|NCT03762473|Active Comparator|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
10021533|NCT03761849|Experimental|RO7234292 Q8W|RO4234292 is administered intrathecally every 8 weeks.
10021534|NCT03761849|Experimental|RO7234292 Q16W|RO7234292 is administered intrathecally every 16 weeks. Participants in this arm will also receive placebo at alternate weeks to keep the blind.
10021535|NCT03761849|Placebo Comparator|Placebo|Placebo will be administered every 8 weeks by IT injection.
10021536|NCT03761706|Experimental|Intervention Cohort|This is a one-arm intervention study that includes assessments and questionnaires at several time points as early stage breast cancer patients undergo chemotherapy and at 6 months post-chemotherapy. Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits to evaluate engagement in physical activity. Study participants will complete questionnaires, an exercise log, and submit blood samples as multiple time points.
10021537|NCT03761108|Experimental|REGN5458|Phase 1: Cohorts of multiple REGN5458 dose levels Phase 2: Until disease progression or other discontinuation criterion is met
10021538|NCT03760835|Experimental|Dual-release hydrocortisone|
10021539|NCT03760835|Active Comparator|Conventional glucocorticoids|
9477991|NCT03556748|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
10021540|NCT03759496|Experimental|Durvalumab treated patients|Subjects will receive up to 1000mg durvalumab (MEDI4736) via weekly intravesical administration, for up to a maximum of 6 weeks or until confirmed progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
10021541|NCT03759184|Experimental|Arm 1 -DOSE ESCALATION|DOSE ESCALATION: Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at escalating doses of 0.5, 1, and 2 mcg/kg/day on days 1-5 of each 4-week cycle (max 6 cycles), with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle, to determine the maximum tolerated dose (MTD)
10021542|NCT03759184|Experimental|Arm 2 - DOSE EXPANSION|DOSE EXPANSION: 3 to 6 patients to receive interleukin-15 (IL-15) by continuous intravenous (civ) infusion at the maximum tolerated dose (MTD) on days 1-5 of cycles 1-6 with Obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle (Total 9 patients at MTD)
10021543|NCT03758638|Experimental|Healthy Eating & Active Living Taught at Home|"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).~Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits."
10021544|NCT03758638|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual
9665268|NCT05117489|Experimental|Cohort 5 - 100 mg of miricorilant every MWF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday, Wednesday and Friday for 12 weeks.
10021545|NCT03757637|No Intervention|General module|"Control group will be case manager care only group. Eligible patients will also invite and receive their first time assessment as baseline during hospitalization. The usual cancer care group will receive routine cancer care in the inpatient wards through OPD visits."
9477992|NCT03556748|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
9477993|NCT03556735|Other|PEMF treatment|No sham group (placebo) was chosen. Treatment consisted of one active group in a multicenter study.
9477994|NCT03556722|Active Comparator|repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.
9477995|NCT03556722|Sham Comparator|Sham repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.
9477996|NCT03556709|Experimental|Treadmill Ankle Robot Training|
9477997|NCT03556670|Experimental|Total Worker Health Intervention|
9477998|NCT03556670|Active Comparator|Control|
9477999|NCT03556657|Experimental|Music Therapy Group|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
9478000|NCT03556657|No Intervention|Wait-List Control Group|Patient receives standard care alone. Patient will receive music therapy sessions following completion of the post-test.
9478001|NCT03556644|Other|Single arm study|70 patients with coronary artery disease will have CTCA imaging and 3 vessel intravascular imaging with NIRS-IVUS during percutaneous coronary intervention and the obtained imaging data will be used to assess the efficacy of CTCA in detecting plaque morphology and shear stress distribution.
9478002|NCT03556631|Experimental|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
9478003|NCT03556631|Placebo Comparator|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
9478004|NCT03556618|Experimental|Whole Person Care (WPC) Reentry Program|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated transition age youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Whole Person Care (WPC) Reentry Program will consist of community health workers (i.e. network coaches) who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved transition age youth pre- and post-release to increase youths' engagement in community SUD and mental health services. Participants in this branch will include youth exiting the adult justice system (ages 18-24)."
9478005|NCT03556618|No Intervention|Control|Participants in the control arm will receive usual care reentry healthcare planning, including correctional health provider and court-referred SUD and mental health treatment recommendations, medication prescriptions, written instructions for reinstating Medicaid, and written health discharge summaries. Participants in this branch will include youth exiting the adult justice system (ages 18-24) and youth exiting the juvenile justice system (ages 16-18).
9478006|NCT03556605|Other|Intervention Arm|A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
9478007|NCT03556605|Other|Control Arm.|A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
9478008|NCT03556592|Experimental|All subjects|"Tralokinumab - investigational medicinal product:~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.~CYP substrates - non-investigational medicinal products:~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
9478009|NCT03556566|Experimental|V3-OVA treatment arm|Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
10021546|NCT03757637|Experimental|NLSCP|NLSCP group will receive 5 section of NLSCP. Contents of scheduled intervention will be developed baed on the literature mentioned above. Ex 1 group, patients will receive at least 3 times face-to-face NLSCP, and two times by telephone calls for following up.
10021547|NCT03757637|Experimental|ICT supported HAP|The ICT supported HAP group will receive information or counseling through mobile phone App as the schedule intervention time. For this group, patients will receive two face to face interventions in the first two sections (pre-discharge from hospital and 5th week post-op). It will be delivered by research nurse to intervene patients and help them to build up the App system. Research nurse will also help patients to be familiar with the operation system. The rest parts of the intervention will all through Apps in the scheduled time. Patients can raise their questions and concerns through APPs. Patients in the HAP can raise their concerns or questions through APP and receive interventions or answers through App interactively.
10021548|NCT03757533|Experimental|Health Coaching|Participants in the Health Coaching (HC) arm will be assigned to a health coach for a period of 5 months along with receiving usual care (UC). An initial telephone call with the coach will include a discussion about the participant's self-assessment of health perceptions and goals. This self-assessment creates the foundation for the personalization of the behavioral intervention. From this point, the participant schedules the remaining 9 biweekly sessions (30-45 minute in length), for a total of 10 coaching calls over 5 months. Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record.
10021549|NCT03757533|Other|Control|Participants in the control arm will receive usual care (UC). Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record. To enhance recruitment, those subjects randomized to the usual care control group will be offered to participate in the health coaching arm of the study as well after a period of 6 months. If they refuse, they will continue in the usual care control group.
10021550|NCT03754725|Experimental|Deferiprone|This is the drug arm (deferiprone). Patients will receive oral deferiprone
10021551|NCT03754725|Placebo Comparator|Control|this group will only receive the placebo (sugar pill)
9478010|NCT03556553|Experimental|Vertise Flow|Superficial Class I cavities restored with Vertise Flow
10021552|NCT03751449|Experimental|Group I (active treatment)|Participants complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
10021553|NCT03751449|Active Comparator|Group II (waitlist)|Participants are placed on a waitlist for 12 weeks and then complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
10021554|NCT03750968|Experimental|Carotenoid group|The Carotenoid group will receive a commercially available prenatal vitamin/mineral tablet plus a softgel containing lutein/zeaxanthin, vitamin E and docosahexaenoic acid (DHA).
10021555|NCT03750968|Active Comparator|Control group|The Control group will receive the same prenatal vitamin/mineral tablet plus a softgel containing only vitamin E and DHA.
10021556|NCT03748784|Experimental|Dose 1|6E11 vg of ADVM-022
10021557|NCT03748784|Experimental|Dose 2|2E11 vg of ADVM-022
10021558|NCT03747640|Experimental|tDCS with mindfulness-based meditation|Self Transcranial Direct Current Stimulation (tDCS) with Mindfulness-Based Meditation
10021559|NCT03747640|Sham Comparator|sham tDCS with sham meditation|Sham self Transcranial Direct Current Stimulation (tDCS) with sham Meditation
10021560|NCT03744026|Experimental|SonoCloud-9 Ultrasound + Carboplatin|SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)
10021561|NCT03744013|Active Comparator|Perforated|Fortiva® 1mm perforated ADM
10021562|NCT03744013|Active Comparator|Non-perforated|Fortiva® 1mm non-perforated ADM
10021563|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material
9478011|NCT03556553|Experimental|LuxaFlow|Superficial Class I cavities restored with LuxaFlow
9802722|NCT05009706|No Intervention|Control group|Patients who are randomized to the Control group will receive ordinary health care (from an outpatient clinic), but will also be encouraged to follow recommendation of 150 minutes/week of moderate physical activity (12 weeks). To compensate for the extra attention received by the intervention group by the advice/support, the patients in the control group will be dialed with a nurse at 3, 6 and 9 weeks to discuss their current activity.
9802723|NCT05009602||Participating Centre|To complete all index tests and reference scan
9802724|NCT05009381|Experimental|Treatment group|Treatment group will receive STYLAGE® XXL at enrollment with an optional touch up injection 30 days later
9802725|NCT05009381|Experimental|control group|Control group will not be treated at enrollment visit. Subjects will receive STYLAGE® XXL at visit 6 months after randomization, if they are still eligible for chin augmentation with an optional touch up injection 30 days later.
9802726|NCT05009147|Experimental|experimental group|receive whole body manual massage
9802727|NCT05009147|No Intervention|control group|After experiment, receive whole body manual massage
9802728|NCT05006794|Experimental|Part A: GS-9716 Dose-Escalation|Participants will receive escalating doses of GS-9716 to establish MTD.
10021564|NCT03740724|Experimental|FCX-013 + veledimex|Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
9802729|NCT05006794|Experimental|Part A: GS-9716 Dose-Expansion|Participants will receive the MTD or below MTD of GS-9716.
9802730|NCT05006794|Experimental|Part B (Cohort B1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
10021565|NCT03737383|Experimental|Feasibility and Preliminary Efficacy|We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes.
10021566|NCT03737240|Experimental|IDegLira|Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
10021567|NCT03737240|Active Comparator|Basal-Bolus Insulin|Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
10021568|NCT03736889|Experimental|Tislelizumab (BGB-A317) Injection|
10021569|NCT03736876|Experimental|Treatment group|These students will receive About Us, an innovative, healthy relationship intervention. The program includes 10 lessons that blend group-based activities with online activities implemented in school-based health centers.
10021570|NCT03736876|No Intervention|Delayed intervention (control group)|These students will receive the business-as--usual condition (e.g., the standard health education that is provided by the school during the study period), and will receive the intervention once the study period has concluded.
10021571|NCT03736603|Experimental|Pathway Intervention 1|Hospitals randomized to group 1 receive PIPA Intervention Bundle 1.
9478012|NCT03556540|Placebo Comparator|Control|The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
10021572|NCT03736603|Experimental|Pathway Intervention 2|Hospitals randomized to group 2 receive PIPA Intervention Bundle 2, which adds a mobile app.
10021573|NCT03736603|No Intervention|Control|Hospitals are in the control arm (usual care) after January 2017 until active implementation begins, which includes 3-6 months of implementation preparation (identifying local multidisciplinary champions, educational sessions/webinars for local champions, one teleconference with an external practice facilitator).
10021574|NCT03736174||Compartment Pressure Testing|Patients who present with symptoms of CECS will be consented and tested per protocol with compartment pressure testing. Concurrently, patients will undergo a high frequency ultrasound to observe any patterns in structure to assist future research in noninvasively diagnosing CECS. Evaluation of ultrasonographic findings will be dependent on tissue density as measured by hypoechoic versus hyperechoic signal as well as muscle compartment thickness at its largest dimension.
9478013|NCT03556540|Experimental|Experimental|The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
9478014|NCT03556449||Patients|High resolution ultrasound
9478015|NCT03556449||Healthy subjects|High resolution ultrasound
9478016|NCT03556436|Experimental|Group 1|YH25448 240mg single dose in korean
9478017|NCT03556436|Experimental|Group 2|YH25448 240mg single dose in caucasian
9478018|NCT03556410|Placebo Comparator|sleep|Subject will undergo 5 days of shortened sleep and then 2 days of ad libitum sleep.
9478019|NCT03556410|Experimental|sleep+exercise|Subject will undergo 5 days of shortened sleep but also have 45 min of moderate exercise/day and then 2 days of ad libitum sleep
9478020|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - negative, no AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD
9478021|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - posit., AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)
9478022|NCT03556397|Experimental|cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD|Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)
9478023|NCT03556397|Experimental|cN1 after neoadjuvant therapy, SLNB, AD|Patients with cN1 after neoadjuvant therapy, SLNB, AD.
9478024|NCT03556384|Experimental|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
9802731|NCT05006794|Experimental|Part B (Cohort B2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
9802732|NCT05006794|Experimental|Part B (Cohort B3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
10021575|NCT03736174||Control|Control subjects will undergo exercise protocol and ultrasound, but will not have compartment pressure testing completed.
10021576|NCT03734666|Experimental|Mindfulness Based Relapse Prevention|Participants will receive Mindfulness Based Relapse Prevention (MBRP), an existing substance use treatment, which has been modified to focus explicitly on smoking cessation and reduced alcohol use, creating Mindfulness Based Relapse Prevention - Smoking and Alcohol (MBRP-SA).
10021577|NCT03734666|Active Comparator|Cognitive Behavioral Therapy|Participants will receive Cognitive Behavioral Therapy (CBT) a well-established and commonly used treatment for substance abuse behaviors that utilizes problem solving and coping skills.
10021578|NCT03733496||Participants from VY-AADC01 clinical studies:|Participants who have completed participation in VY-AADC01 clinical studies (PD-1101 or PD-1102) will be invited to participate in this extension study
10021579|NCT03731559|Active Comparator|DTG 50 mg OD with food|DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
10021580|NCT03731559|Active Comparator|DTG 50 mg BID|DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
10021581|NCT03731234|Experimental|Ibrutinib+R-CHOP|Screening phase for selection of Activated-B-Cell (ABC)-DLBCL Induction phase: R-CHOP21 x 5 cycles in combination with ibrutinib Maintenance phase: maintenance with Ibrutinib for 18 months for patients responding to the induction phase (CR or PR)
10021582|NCT03730974|Experimental|Experimental arm AB (Ball blanket + TAU)|"Participants will be randomized into either sequence AB or BA each lasting four weeks.~Patients that are randomized to the AB sequence receive intervention A (Protac Ball BlanketTM 7 kg Flexible) in the first two weeks and treatment B treatment as usual (TAU) in the second period."
10021583|NCT03730974|Experimental|Experimental arm BA (TAU + Ball blanket)|Patients that are randomized to the BA sequence receive treatment B (TAU) in the first period and intervention A in the second period (Protac Ball BlanketTM 7kg Flexible).
10021584|NCT03729349||Participants with Diagnosis of Rheumatoid Arthritis|Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.
10021585|NCT03727880|Experimental|Arm A - Pembrolizumab and Defactinib|
10021586|NCT03727880|Experimental|Arm B - Pembrolizumab|
10021587|NCT03727789|Experimental|Treatment (CBL0137)|Patients receive FACT complex-targeting curaxin CBL0137 IA over 15 minutes.
10021588|NCT03727750|Experimental|Gemtuzumab Ozogamicin (GO)|Patients will receive three doses of Gemtuzumab Ozogamicin (GO) 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
10021589|NCT03727152|Other|generic single tablet regimen of tenofovir alafenamide/e|HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen
10036407|NCT01815359|Experimental|Appendiceal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
10021590|NCT03726879|Experimental|Atezolizumab +ddAC-PacHP|Participants will receive atezolizumab (atezo) 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 & cyclophosphamide 600 mg/m2 IV), followed by atezo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8mg/kg IV loading dose) Q3W for 4 cycles, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant and adjuvant setting: atezo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezo+trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL dated 3 Feb 2021 treatment with atezo must be discontinued.
9478025|NCT03556371|Experimental|N-acetylcysteine Treatment|Oral administration of two capsules, containing 600 milligrams (mg) of N-acetylcysteine each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
9478026|NCT03556371|Placebo Comparator|Placebo oral capsules|Oral administration of two capsules, containing 600 milligrams (mg) of Placebo each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
9478027|NCT03556280|Experimental|Treatment Group|Will use the Active GammaSense Stimulation System.
9478028|NCT03556280|Sham Comparator|Control Group|Will use the Sham GammaSense Stimulation System.
9478029|NCT03556267|Other|spinal needle 27 gauqge|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
9478030|NCT03556267|Other|spinal needle 25 gauage|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
9478031|NCT03556254|Experimental|Genotypic resistance guided therapy|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given.
9478032|NCT03556254|Active Comparator|Susceptibility testing guided therapy|Tailored therapy according to the minimum inhibitory concentration result (susceptibility testing, E-test)
9478033|NCT03556241|Experimental|Intervention: No change group|Case management consists keeping patient's current pacemaker mode during surgery
9478034|NCT03556241|No Intervention|Control: Mode change group|Usual care consists changing pacemaker mode to VOO before surgery
9478035|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device and myringotomy|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy
9478036|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)
9478037|NCT03556215|Experimental|No effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy
9478038|NCT03556189|Experimental|Experimental|case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
9478039|NCT03556189|No Intervention|Control: Usual care|Usual care is provided with routine pacemaker interrogation.
9478040|NCT03556176|Active Comparator|5-HTTLPR or BDNF polymorphisms|
9478041|NCT03556176|Active Comparator|Control ( without 5-HTTLPR or BDNF polymorphisms )|
9478042|NCT03556163|Experimental|Test Group|Modified vertical internal mattress sutures + MWF surgery.
9478043|NCT03556163|Active Comparator|Control Group|Simple loop interrupted sutures + MWF surgery.
9478044|NCT03556150|Experimental|Manual Therapy protocol|Massages, mobilisation and stretching techniques in the most painful joint
9478045|NCT03556150|Active Comparator|Effleurage|Superficial massage in the most painful joint.
9478046|NCT03556137|Experimental|Pain Patients|Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.
9478047|NCT03556137|Experimental|Healthy Volunteers|Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.
9478048|NCT03556124|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
10021591|NCT03726879|Placebo Comparator|Placebo + ddAC-PacHP|Participants will receive placebo 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 & cyclophosphamide 600 mg/m2 IV), followed by placebo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W for 4 cycles & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W for 4 cycles. During adjuvant phase, participants will continue to receive following study treatments Q3W to complete up to 1 year HER2-target therapy inclusive of therapy given both in neoadjuvant & adjuvant setting: placebo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with initial 8-mg/kg IV loading dose) Q3W, & pertuzumab 420 mg IV (with initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles. In response to USM DIL, dated 3 Feb 2021 treatment with placebo must be discontinued.
10021592|NCT03724409|Experimental|Cohort 1|Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
10021593|NCT03724409|Experimental|Cohort 2|Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
9802733|NCT05006794|Experimental|Part B (Cohort B4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
10021594|NCT03724409|Experimental|Cohort 3|Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
10021595|NCT03724409|Experimental|Cohort 4|Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
10021596|NCT03724409|Experimental|Cohort 5|Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
10021597|NCT03724409|Experimental|Cohort 6|Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
10021598|NCT03724357|Experimental|Vaccination with Oral Cholera Vaccine (Vaxchora)|Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.
10021599|NCT03719417|Active Comparator|Unicompartmental Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty only
10021600|NCT03719417|Active Comparator|Extensive Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.
10021601|NCT03719170|Experimental|De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to the PPI de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
10021602|NCT03719170|No Intervention|No De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to usual care and will not receive the national de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
9802734|NCT05006794|Experimental|Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
10021603|NCT03718052|Experimental|Early valve surgery (EVS)|Cardiac surgery as soon as possible within 72 hours of randomization
10021604|NCT03718052|Active Comparator|Conventional care|Conventional care according to the 2015 European guidelines.
10021605|NCT03717428|Experimental|Daily Weighing Group|This group will be weighed and height measured in our metabolic unit at the beginning and end of the two year experimental period. In addition, the intervention in Daily Weighing Group is that they will be given an internet based scale and asked to weigh themselves immediately after rising from bed every morning for the duration of the two year experimental period.
10021606|NCT03717428|Active Comparator|Control Group|The only intervention for the control group is that they will be weighed and height measured at the beginning and end of the experimental period in our metabolic unit.
10021607|NCT03715829|Experimental|Cohort 1|Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
10021608|NCT03715829|Experimental|Cohort 2|Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
9478049|NCT03556124|Experimental|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
9802735|NCT05006794|Experimental|Part C (Cohort C1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
9478050|NCT03556124|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
10021609|NCT03715829|Experimental|Cohort 3|Maintenance dose A given QD for 24 weeks
10021610|NCT03715829|Experimental|Cohort 4|Maintenance dose B given QD for 24 weeks
10021611|NCT03715829|Experimental|Cohort 5|Maintenance dose C given QD for 24 weeks
10021612|NCT03715829|Placebo Comparator|Cohort 6|Placebo given QD for 24 weeks
10021613|NCT03715829|Experimental|Extension Cohort 1|4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
9478051|NCT03556124|Sham Comparator|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
10021614|NCT03715829|Experimental|Extension Cohort 2|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
10021615|NCT03715829|Experimental|Extension Cohort 3|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
10021616|NCT03715829|Experimental|Extension Cohort 4|Maintenance dose A given QD for 24 weeks
10021617|NCT03715829|Experimental|Extension Cohort 5|Maintenance dose B given QD for 24 weeks
10021618|NCT03715829|No Intervention|Extension Cohort 6|Observation period for 24 weeks
10021619|NCT03713411|No Intervention|No-catheter|after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones, patients in whom a urethral catheter wasn't placed
10021620|NCT03713411|Active Comparator|Catheter|urethral catheter placement after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones
10021621|NCT03713229||HIV-infected men who have sex with men|HIV-infected male patients who refer to conducting sexual risk practices that enable HPV transmission
9478052|NCT03556111|Experimental|anterior knife-edge maxilla graft (Without Xenograft Usage)|"The intervention will be a Sticky bone augmentation of defect. It is prepared using particulate autologous graft only along with fibrin glue and growth factors obtained from the patients' blood.~The sample is withdrawn and placed in plastic tubes which are spun twice in a centrifuge at a certain speed and time. The first spin to obtain the fibrin glue and the second to obtain the growth factors. The mixture is added to the harvested autogenous bone to form a semi-solid bone graft that is easily manipulated in the recipient site."
9478053|NCT03556111|Experimental|anterior knife edge maxilla graft (With Xenograft Usage)|"The intervention will be the sticky bone augmentation of the defect using both particulate autogenous and xenograft bovine bone.~The bone will be harvested from the donor, coupled with the bovine bone, the growth factors and the fibrin glue that is obtained from the patient's own blood sample.~The venous blood sample is placed in plastic tubes to be centrifuged at a certain speed and time to obtain the fibrin glue and growth factors.~The mixture is prepared until the bone is sticky and ready to be placed in the recipient defective maxilla"
9480742|NCT05261516|Active Comparator|Propofol|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given.~In patients in the propofol group, anesthesia will be induced and maintained with a total intravenous anesthesia pump following the model of Schnider et al, at a targeted effect-site concentration of 4 +/- 1 mcg/ml.~In patients in all groups, after induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TofScan device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital."
9480743|NCT05261516|Experimental|Isoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TofScan device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: isoflurane in this group."
9480744|NCT05261516|Experimental|Desflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TofScan device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: desflurane in this group."
9480745|NCT05261516|Experimental|Sevoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TofScan device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: sevoflurane in this group."
9480746|NCT05261477|Experimental|Intervention group|Intervention group receives one in person education session using the 1stBIEN booklet, video education via mobile phones and care coordination from a bilingual Patient Navigator-PN for 3-months. PN follow up patients weekly for the first month and once a month for two months. Video education is done weekly. Videos cover problem solving training, brain injury concepts, rehabilitation treatments and school resources individualized to patient and family needs. PNs facilitate transition to outpatient care, follow-up with specialists and primary care providers; use of community resources; and communication with teachers and school administrators. PN provides observational and experiential learning opportunities for parents, using three way calls for scheduling of services and interactions with clinics and schools. PN calls use a problem-solving training format, to reinforce parental experiential learning and improve self-efficacy. Expert MD providers (Co-investigators) will supervise PNs.
9480747|NCT05261477|No Intervention|Attention Control group|Attention Control group receives one in person education session using the 1stBIEN booklet, monthly well-child texts and usual post-injury care including routine follow-up by specialists and primary care providers, per guidelines at each recruiting institution. Control patients have access to a list of community resources included in the 1stBIEN booklet. While education using the 1stBIEN booklet is not part of the current usual care at participating institutions, providing all families with initial education at the time of discharge addresses ethical and practical considerations. It standardizes discharge processes at participating institutions while delineating differences in the intensity of education and care coordination activities.
9480748|NCT05261451|Experimental|Head Start Teachers|Participants will engage in three 1- hour workshops and optional consultations with an occupational therapist
10021622|NCT03713229||HIV-infected men|HIV-infected male patients who neglect conducting sexual risk practices that enable HPV transmission
10021623|NCT03713229||HIV-infected women|HIV-infected female patients disregarding sexual risk practices
10021624|NCT03712176||Cohort 1 : chemotherapy and radiotherapy|50 women aged between 18 and 65 with first non-metastatic breast cancer treated by surgery and adjuvant therapy (chemotherapy and radiotherapy)
10021625|NCT03712176||Cohort 2 : radiotherapy only|150 women aged between 18 and 65 with first non-metastatic breast cancer treated with surgery and adjuvant therapy (radiotherapy only).
10021626|NCT03711175|Other|Group A|The subscapularis is repaired. Receives device
10021627|NCT03711175|Other|Group B|The subscapularis is not repaired. Receives device
10021628|NCT03710928|Experimental|very low carbohydrate diet|Dietary Intervention, food delivery
10021629|NCT03710928|Active Comparator|standard diet|Dietary Intervention, food delivery
9478054|NCT03556098|Active Comparator|GIP|Infusion of Glucose-dependent insulinotropic peptide
9802736|NCT05006794|Experimental|Part C (Cohort C2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
10021630|NCT03710642|Active Comparator|Treatment (Prazosin)|"Eligible participants will be randomized using a 2:1 schedule to prazosin or placebo and stratified by site and gender, and will follow a fixed titration scheme for the first 15 days, followed by a flexible does titration from days 15-29, then a maintenance phase stable dose from days 29 to the end of the 12 weeks study period.~Prazosin Fixed titration dose schedule for Days 1 to 14 1 mg QHS for Days 1 to 3~1 mg QAM and 1 mg QHS for days 4 to 7~mg QAM and 2 mg QHS for days 8 to 10~mg QAM and 2 mg QHS for days 11 to 14~Prazosin Flexible titration dose schedule for Days 15 to 29. 3 mg QAM and 3 mg QHS on day 15, 4 mg QAM and 4 mg QHS on day 22, 4 mg QAH and 6 mg QHS on day 29,~Dose increases will be allowed only during the fixed and flexible dosing periods."
9478055|NCT03556098|Active Comparator|GIP[3-30]|Infusion of GIP[3-30]
10021631|NCT03710642|Placebo Comparator|Placebo oral capsule|Placebo medication will be administered in a titration schedule mimicking the active comparator treatment.
10021632|NCT03708627|Experimental|Bimatoprost in more proptotic eye|Patients instill Bimatoprost in their more proptotic eye one nightly
10021633|NCT03708627|No Intervention|Control|Bimatoprost is not instilled in the patient's fellow eye
9478056|NCT03556098|Placebo Comparator|Saline|Infusion of saline
10021634|NCT03707158|Active Comparator|Web-based CBT|The online, multimedia suite of Cool Kids CBT web-based programs for youth anxiety is a supported, largely self-administered online digital cognitive-behavioral therapy anxiety management intervention, with adjunctive therapist phone support. Treatment content runs directly parallel to that included in the therapist-led Cool Kids face-to-face suite of interventions. The online suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
10021635|NCT03707158|Active Comparator|Face-to-Face CBT|The Cool Kids suite of face-to-face (office-based or telehealth) CBT-based programs for youth anxiety is a well-supported therapist-led, clinic-based anxiety management intervention. The face-to-face cognitive-behavioral therapy treatment content runs directly parallel to that included in the Cool Kids online suite of interventions. The face-to-face suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
10021636|NCT03706170|Experimental|Vegetative State|For patients in vegetative state (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
10021637|NCT03706170|Experimental|Minimally Conscious State|For patients in minimally conscious state (n = 15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
10021638|NCT03706170|Experimental|Acquired Brain damaged patients without DOC|Acquired Brain damaged patients without disorder of consciousness (patients without DOC) For patients with acquired brain damage without disorder of consciousness (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography
10021639|NCT03706170|Experimental|Healthy subjects|For healthy subjects (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
10021640|NCT03704441|Other|bupivacaine 6mg|bupivacaine 6mg
10021641|NCT03704441|Other|bupivacaine 7mg|bupivacaine 7mg
10021642|NCT03704441|Other|bupivacaine 8mg|bupivacaine 8mg
10021643|NCT03704441|Other|bupivacaine 9mg|bupivacaine 9mg
10021644|NCT03704441|Other|bupivacaine 10mg|bupivacaine 10mg
10021645|NCT03704441|Other|bupivacaine 11mg|bupivacaine 11mg
10021646|NCT03704441|Other|bupivacaine 12mg|bupivacaine 12mg
10021647|NCT03703947||Watchful-waiting group|The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
10021648|NCT03703947||EVAR group|The prospective, longitudinal part of the study will include an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months after EVAR. CT will be conducted at baseline, at 1 month after EVAR and at 12 and 24 months after EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 1 month, at 12 and 24 months of follow-up after EVAR.
10021649|NCT03703947||Cross-sectional group (after EVAR)|A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
10021650|NCT03702725|Experimental|Dose Escalation|"Dose escalation will consist of three different drug levels of Ibrutinib, Lenalidomide, and Dexamethasone.~Dose Escalation (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
10021651|NCT03702725|Experimental|Dose Expansion|"Dosage of the combination will depend on the determine of maximum tolerated dose learned from the Dose Escalation phase.~Dose Expansion (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
10021652|NCT03701308|Active Comparator|Arm I (daunorubicin, cytarabine)|"INDUCTION: Patients receive daunorubicin IV on days 1-3 and cytarabine via CIVI over 168 hours on days 1-7. Patients with residual disease indicated by bone marrow examination receive a second induction including daunorubicin IV on days 1-3 and cytarabine CIVI over 12 hours on days 1-5.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
10021653|NCT03701308|Experimental|Arm II (uproleselan, daunorubicin, cytarabine)|"INDUCTION: Patients receive uproleselan IV QD on day 1 and then every 12 hours on days 2-10. Patients also receive daunorubicin IV on days 2-4 and cytrarabine CIVI over 168 hours on days 2-8 over 168 hours. Patients with residual disease indicated by bone marrow examination receive a second induction including uprleselan IV QD on day 1 and then every 12 hours on days 2-8, daunorubicin IV on days 2-3, and cytarabine CIVI over 120 hours on days 2-6.~CONSOLIDATION: Patients who achieve a CR or CRi receive uproleselan IV QD on day 1 and every 12 hours on days 2-8 and cytarabine IV over 3 hours on days 2-6. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
10036408|NCT01815359|Experimental|Colorectal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
10021654|NCT03696355|Experimental|Stratum A1|"Dose Escalation Phase:~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive single-agent oral GDC-0084 at one of the 4 dose levels once daily in cycles of 28 days. During cycle 1 only, a single dose of GDC-0084 will be withheld on day 2, for a total of 27 doses. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.~Dose Expansion Phase~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive the MTD dose established in the Stratum A dose escalation phase. Subjects who completed the first course of therapy may take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity."
9478057|NCT03556072||Intradiverticular papilla (IDP) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
9478058|NCT03556072||Juxtapapillary diverticulum (JPD) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
10037495|NCT01825603|Experimental|Treatment (ADH-1, cisplatin, gemcitabine hydrochloride)|Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride.
9478059|NCT03556059|Active Comparator|RNYGB|The role of EOSS for the surgical intervention: Roux-en-Y gastric bypass for severe obesity
10037496|NCT01825616|Experimental|Vitamin D2 mushroom powder|4000 IU/day vitamin D2 mushroom powder
10037497|NCT01825616|Placebo Comparator|Placebo|Mushroom powder without vitamin D2 (not exposed to UV radiation)
9478060|NCT03556059|Active Comparator|Sleeve|The role of EOSS for the surgical intervention: Sleeve Gastrectomy for severe obesity
9478061|NCT03556059|Active Comparator|MGB/OAGB|The role of EOSS for the surgical intervention: Mini/One anastomosis gastric bypass for severe obesity
9478062|NCT03556046|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
9478063|NCT03556033|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg capsule once daily for 8 weeks
9478064|NCT03556033|Placebo Comparator|Placebo oral capsule|Placebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
9478065|NCT03556007|Experimental|Cohort 1 - 3 μg/kg LY3471851|Participants received 3 microgram per kilogram (μg/kg) of LY3471851 or placebo on days 1, 15 and 29 by subcutaneous (SC) injection.
9478066|NCT03556007|Experimental|Cohort 1 - 6 μg/kg LY3471851|Participants received 6 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
9478067|NCT03556007|Experimental|Cohort 1 - 12 μg/kg LY3471851|Participants received 12 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
9478068|NCT03556007|Experimental|Cohort 1 - 24 μg/kg LY3471851|Participants received 24 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
9478069|NCT03555994|Experimental|MEDI0382 (Part A)|MEDI0382 administered subcutaneously (Part A)
9478070|NCT03555994|Placebo Comparator|Placebo (Part A)|Placebo comparator administered subcutaneously (Part A)
9478071|NCT03555994|Active Comparator|Liraglutide (Part B)|Active comparator administered subcutaneously (Part B)
9478072|NCT03555994|Experimental|MEDI0382 (Part B)|MEDI0382 administered subcutaneously (Part B)
9478073|NCT03555994|Placebo Comparator|Placebo (Part B)|Placebo comparator administered subcutaneously (Part B)
9478074|NCT03555981|Experimental|Early KMC|Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home
9478075|NCT03555981|Active Comparator|Standard care|Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at >24h of hospital admission until hospital discharge with encouragement of KMC at home
9802737|NCT05006794|Experimental|Part C (Cohort C3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
9802738|NCT05006794|Experimental|Part C (Cohort C4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
9802739|NCT05006794|Experimental|Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
9802742|NCT04998136|Experimental|Semaglutide 2.4 mg|
9802743|NCT04998136|Placebo Comparator|Placebo|
9802744|NCT04996797|Experimental|Cohort 1 PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
9802745|NCT04996797|Placebo Comparator|Cohort 1 Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
9478085|NCT03555955|Experimental|Cohort 1|Normal renal function
9478086|NCT03555955|Experimental|Cohort 2|Moderate renal impairment
9478087|NCT03555955|Experimental|Cohort 3|Severe renal impairment
9478088|NCT03555929|Experimental|Dexamethasone|Dexamethasone 8 mg/2cc I.V. 90 minutes after axillary block
9478089|NCT03555929|Placebo Comparator|Normal saline|Normal saline 2cc I.V., 90 minutes after axillary block
9478090|NCT03555916|Experimental|Drug|BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment
9478091|NCT03555916|Placebo Comparator|Placebo|2 mL of saline solution (0.9% NaCl) treatment
9478092|NCT03555903||Endometriosis cohort|The aim of the study is to advance the scientific knowledge of deep infiltrating endometriosis (DIE) and to evaluate the impact of surgery on the quality of life and the fertility of affected women.
9478093|NCT03555864||Obese|Patients need two intravenous access with infra red
9478094|NCT03555825|Active Comparator|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
9478095|NCT03555825|Experimental|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
9478096|NCT03555825|Active Comparator|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
9478097|NCT03555825|Experimental|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
9478098|NCT03555812|Experimental|Healthy volunteers|"a medical examination~10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
9802746|NCT04996797|Experimental|CDx+ Expansion Cohort PRA023|Participants randomized to receive PRA023 administered by intravenous (IV) infusion.
10021655|NCT03696355|Experimental|Stratum A2|Four to 12 weeks after the completion of standard RT, subjects will received the MTD dose established in the Stratum A1 dose escalation phase. Subjects who are unable to swallow capsules will initially be enrolled until the Stratum A1 expansion cohort is filled. Once the Stratum A1 expansion cohort has been filled, both subjects who are able to swallow capsules and those unable to swallow capsules may be enrolled. Subjects who are unable to swallow capsules will take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Subjects who have completed the first course of therapy and are able to swallow capsules may take GDC-0084 as capsules. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
10037498|NCT01825629|Experimental|Multidisplinary Therapy|The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
10021656|NCT03695471|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity. Patients receiving complete response during courses 2-9 are held for the remaining courses. If patients relapse while treatment is being held, the patient will then complete remaining courses.
10036409|NCT01815359|Experimental|Colorectal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
10021657|NCT03693677|Experimental|Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively|"Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months~Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.~Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
10036410|NCT01815372|Experimental|SPEDI|These are the patients that will be randomized to receive a SPEDI block of the sciatic and saphenous nerve with at single needle penetration of the skin
9802747|NCT04996797|Placebo Comparator|CDx+ Expansion Cohort Placebo|Participant randomized to receive placebo administered by intravenous (IV) infusion.
10021658|NCT03693677|Experimental|Nal-IRI/5-FU/LV|Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
10036411|NCT01815372|Active Comparator|Popliteal sciatic and mid-femoral saphenous|These are the patients that will be randomized to the administration of a popliteal sciatic nerve block combined with a mid-femoral saphenous nerve block with two separate injections
9802748|NCT04995419|Experimental|Enfortumab vedotin|Participants will receive enfortumab vedotin on Days 1, 8 and 15 of every 4-week (28 days) cycle.
10021659|NCT03693677|Active Comparator|Nab-paclitaxel/Gemcitabine|"Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
10021660|NCT03693430|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
10021661|NCT03693430|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
10021662|NCT03689595||Specimen Collection|"Samples of blood (2-4 tablespoons) from 3 tubes will be collected~Analysis will be performed on the blood to test for multiple myeloma precursor conditions once sent to outside labs at Mayo Clinic and the Broad Institute"
9478099|NCT03555812|Experimental|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:~a medical examination~3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
9478100|NCT03555799||Labor analgesia patients|Patients with clinical indication of labor epidural will have IVC diameter measurement with ultrasound before and after the epidural placement
9478101|NCT03555773|Experimental|Lipogems|Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract
9478102|NCT03555760||Surgery patient|Observation of informed consent form readings of all patients who are scheduled for surgery
9478103|NCT03555747|Other|Canine distalization by 75 g force|Canine was distalized using a continuous force of 75 g with nickel-titanium closed coil springs.
9478104|NCT03555747|Other|Canine distalization by 150 g force|Canine was distalized using a continuous force of 150 g with nickel-titanium closed coil springs.
9478105|NCT03555721||Oral examination followed by biopsy, CytID, and hpvID|Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID
9478106|NCT03555708|Experimental|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
9478107|NCT03555708|Experimental|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
9478108|NCT03555708|Experimental|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
9478109|NCT03555695|Experimental|Karate Class Participants|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD. Subjects will also complete an in-person pre-intervention focus group and post-intervention focus group, as well as a 6 month post-intervention follow up phone call.
9478110|NCT03555682|Placebo Comparator|Placebo|Placebo
9478111|NCT03555682|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
9478112|NCT03555682|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
9478113|NCT03555669|No Intervention|Screening Phase (Pre) Group|"Patients who screen positive on the PHQ-9 for depression during the pre period will comprise the comparison group. Participants will receive standard of care depression treatment at the providers discretion."
9478114|NCT03555669|Experimental|Treatment Phase (Post) Group|"Patients who screen positive during on the PHQ-9 for depression during the post period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score."
9478115|NCT03555656|Experimental|Repeated educational intervention|Repetition every 6 months of a group educational session
9478116|NCT03555656|Active Comparator|Control group|Initial single group educational session, with no repetition
9478117|NCT03555643||transient ischemic attack (TIA)|Patients with transient ischemic attack
9478118|NCT03555643||transient neurological attack (TNA)|Patients with transient neurological attack
9478119|NCT03555630||Post-cesarean preeclampsia|
9478120|NCT03555630||Post spontaneous vaginal delivery preeclampsia|
10036412|NCT01815398|Active Comparator|Computer skills training|26 sessions conducted 2-3 times a week to train in computer skills related to the workforce.
9802749|NCT04986657|Experimental|Patients: ChromoSeq|ChromoSeq will be performed on bone marrow DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
10036413|NCT01815398|Experimental|Cognitive Remediation|26 sessions conducted 2-3 times a week of cognitive remediation
10036414|NCT01815411|Experimental|Mushroom extract|The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
9478121|NCT03555617|Experimental|TD-1473 formulation bridging & food effect|Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.
9478122|NCT03555617|Experimental|TD-1473 with Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.
10036415|NCT01815411|No Intervention|Control group|The control group is selected by randomisation.
9802750|NCT04986657|No Intervention|Stakeholders (Treating Physicians)|-Stakeholders (treating physicians) will complete surveys/questionnaires
9802751|NCT04985929|Experimental|Healthy, Untrained|Untrained participants will be defined as having a V̇O2peak of 30-45 ml.kg-1.min-1 and will be between 18-40 years of age.
9802752|NCT04985929|Experimental|Healthy, Trained|Trained participants will be defined as having a V̇O2peak above 55 ml.kg-1.min-1 (females) and 60 ml.kg-1.min-1 (males) and will be between 18-40 years of age.
9802753|NCT04982224|Experimental|REGN5093-M114|
9802754|NCT04980391|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group receive a single dose of the RSV MAT vaccine administered intramuscularly between 24 and 36 weeks of gestation (Day 1) and are followed up until 180 days post-delivery.
9802755|NCT04980391|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group receive a single dose of placebo administered intramuscularly between 24 and 36 weeks of gestation (Day 1) and are followed up until 180 days post-delivery.
9478123|NCT03555617|Experimental|TD-1473 without Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.
9478124|NCT03555604||Scheduled cesarean section|Gastric ultrasound in term pregnant patients to correlate with NPO time in relation to body mass index
9478125|NCT03555539|Experimental|Part 1: Healthy Match|Single 200-milligram (mg) dose of danicopan on Day 1 in healthy participants (matched control group with normal hepatic function).
10036416|NCT01815437|Active Comparator|2000 IU Vitamin D3- Cholecalciferol|Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.
10036417|NCT01815437|Active Comparator|2000 IU Vitamin D2- Ergocalciferol|Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.
10036418|NCT01815437|Experimental|2000 IU Mushroom Vitamin D2|Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks
10036419|NCT01815437|Placebo Comparator|Mushroom Extract|Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.
10036420|NCT01815463||colorectal neoplasia|No interventions Record colorectal neoplasia
10036421|NCT01815476|Other|RT Positioning Intervention: Supine|Patient will be treated in a supine position as per standard of care/control.
10036422|NCT01815476|Experimental|RT Positioning Intervention: Prone|Patient will be treated in the prone position.
10036423|NCT01815528|Experimental|Catumaxomab|Catumaxomab treatment followed by an established chemotherapy regimen
10036424|NCT01815541|Experimental|teicoplanin|this group receive the teicoplanin
10036425|NCT01815554||DPS Cohort|All patients implanted with a DPS within the past 5 years at one of 6 collaborating sites will be included. Patients will be interviewed as they cross their 1st, 3rd, 5th or 7th anniversary with the DPS.
10036426|NCT01815567||controlled hypertension|hypertension with medication controlled
10036427|NCT01815567||uncontrolled hypertension|non-controlled hypertension
10036428|NCT01815567||hypertensive urgency|hypertensive urgency no previous history or antihypertensives
10036429|NCT01815567||asymptomatic normotensive|asymptomatic normotensive control group
10036430|NCT01815580|Active Comparator|Immediate ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at enrollment.
9802756|NCT04973059|Active Comparator|Summer Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the summer. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
9478126|NCT03555539|Experimental|Part 1: Moderate HI|Single 200-mg dose of danicopan on Day 1 in participants with moderate HI.
9478127|NCT03555526|Experimental|Genotypic resistance guided therapy|The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
9478128|NCT03555526|Active Comparator|Phenotypic resistance guided therapy|The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
9478129|NCT03555513||living kidney transplanted patients|Any patients over 18 who received kidney transplantation from living donor
9478130|NCT03555500|No Intervention|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
9478131|NCT03555500|Experimental|Non fasting group|Clear fluids and food up to the time of the procedure.
9478132|NCT03555487|Experimental|18F-choline PET|PET/CT
9478133|NCT03555474|Experimental|Theta burst stimulation & Physiotherapy|"Patients were given theta burst stimulation (intermittent TBS (iTBS) to the affected hemisphere and continuous TBS (cTBS) to the unaffected hemisphere) along with physiotherapy. TBS was delivered for 3 times in a week for 4 weeks.The stimulation was given with an intensity of 60% of RMT. The iTBS protocol of 10 bursts of high-frequency stimulation (3 pulses at 50 Hz) was applied at 5 Hz every 10 second for a total of 600 pulses.~Continuous TBS (inhibitory) was delivered to the unaffected hemisphere at the hot-spot with an intensity of 60% of RMT, 3 pulses at 50 Hz, repeated every 200 ms for a total of 600 pluses."
9478134|NCT03555474|Experimental|Functional stimulation & Physiotherapy|"Patients in the functional electrical stimulation (FES) group received the electrical stimulation with electrodes positioned according to pattern 3 [Grasp/Flexion/Extension, PATT (pattern movement)] of the FES (F) mode of the instrument. The electrodes were connected to a stimulator controller unit that delivers alternating current at a frequency of 35 Hz and a pulse width of 200 µs, intensity 10~50 mA.~The FES group stimulation session was given for 30 minutes for each day 3 times in a week (alternate days) for 4 weeks and it was concurrently synchronized with the physiotherapy."
9478135|NCT03555474|Active Comparator|Physiotherapy|"The following different physiotherapy regimens were followed for all the patients in the study.~Passive/Active Range of Motion (ROM); Weight bearing and supportive reaction; Reaching activities; Grasping, holding and release; Upper extremity activities of daily living (ADL). Physiotherapy intervention was given to all the patients 5 days per week for 1 month. In addition, all patients continued to receive in-home physiotherapy 1 to 2 times per week by a home physiotherapist who was guided by the research physiotherapist."
9478136|NCT03555370|Experimental|Standard of Care Group|"Standard of Care:~The standard of care protocol consists of standardized in office and at home behavioral management to include sleep, hydration, nutrition, and stress management interventions. Participants will also be assigned physical activity that they will complete during their visits and at home. Physical activity for the standard of care group will include 15 minutes of flexibility/range of motion exercises, and 10 minutes of aerobic-based daily physical activity (e.g.,walking, stationary cycle)."
10036431|NCT01815580|Placebo Comparator|Deferred ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at 24 weeks.
9480756|NCT05261412|Active Comparator|Standard Consent (Control)|Standard consent (written patient information leaflet (PIL) + verbal discussion with the responsible surgeon) for EVTA followed by signing of consent.
9480757|NCT05261412|Experimental|Digital health education tool (dHET)|dHET for EVTA + verbal discussion with the responsible surgeon followed by signing of consent.
10021663|NCT03685422|Experimental|Virtual Reality|"Patients will be given a VR Gear Headset fitted with a smartphone, and will be offered to choose the calming scenario they wish to experience from a set of predefined scenarios before the surgery. They will be given time to experience VR for up to 25 mins. After the VR session, patients will be given questionnaires, satisfaction with VR, and pain scores.~After the surgery is completed, patient will be transferred to recovery room. Patients may resume VR session for up to 25 mins. After the use of VR, they will be asked on their satisfaction towards the VR experience, and also fill in questionnaires.~On the same day of surgery (0-24 hours post-op), patients will be asked to have another two more VR sessions (up to 25 mins per session), with questionnaire filled in after the sessions.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given.~All the headsets will be disinfected following the hospital's infection control guideline."
10021664|NCT03685422|No Intervention|Non Virtual Reality|"Before the surgery, only questionnaires and pain scores will be documented. After the surgery is completed, patient will be transferred to recovery room. Only questionnaires and pain scores will be documented.~On the second day and third day of the surgery (48-72 hours post-op), questionnaires will be given."
10021665|NCT03684018|Experimental|IgPro10 (single dose)|
10021666|NCT03684018|Experimental|IgPro10 (multiple dose)|
10021667|NCT03683680|Experimental|MRiS|"The specimens to be collected will include at least five pleural biopsy samples~MPT test and the CLDN15/VIM test will be performed"
10036432|NCT01815593|Experimental|Enhanced External Counterpulsation|Men with erectile dysfunction receive Enhanced External Counterpulsation treatment
9480758|NCT05261373|No Intervention|Control (CG+INACT)|Participants who do not receive neither nutritional education nor exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
9802757|NCT04973059|No Intervention|Summer Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the summer no power assist.
10021668|NCT03680092|Experimental|Cyclophosphamide and abatacept|The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
9802758|NCT04973059|No Intervention|Winter Conditions activity measurement only|This arm is with the participant using their wheelchair during a week in the winter no power assist
10036433|NCT01815593|No Intervention|Control|Men with erectile dysfunction without Enhanced External Counterpulsation treatment
10021669|NCT03680092|Active Comparator|methotrexate and tacrolimus|The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus
10021670|NCT03678688|Active Comparator|Stage 1 and Stage 2: RHEZ|
10021671|NCT03678688|Experimental|Stage 1 Cohort 1|
10021672|NCT03678688|Experimental|Stage 1 Cohort 2|
10021673|NCT03678688|Experimental|Stage 1 Cohort 3|
10021674|NCT03678688|Experimental|Stage 1 Cohort 4|
10021675|NCT03678688|Experimental|Stage 2: OPC-167832/Delamanid|
10021676|NCT03678688|Experimental|Stage 2: OPC-167832/Bedaquiline|
10021677|NCT03678688|Experimental|Stage 2: OPC-167832/Delamanid/Bedaquiline|
10021678|NCT03678259|Experimental|124I-p5+14 Injection|A single-injection dose of 124I-p5+14 adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic amyloidosis of several sub-types.
10021679|NCT03677934|Experimental|PDS Implant Arm|Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
10021680|NCT03677934|Active Comparator|Intravitreal Arm|Participants will receive ranibizumab 0.5 mg monthly intravitreal injections of 10 mg/mL formulation at Day 1 and every month thereafter.
10021681|NCT03677817|Active Comparator|Lidocaine|perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
10036434|NCT01815606|Active Comparator|19 Gauge needle biopsy|biopsy with 19 gauge needle
10036435|NCT01815606|Active Comparator|25 gauge needle biopsy|biopsy with 25 gauge needle
10021682|NCT03677817|Placebo Comparator|Placebo|perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure
9478137|NCT03555370|Experimental|Vestibular Exercise Intervention Group|The vestibular group will complete the behavioral management activities described above, as well as prescribed in-office and at home vestibular exercises from each of four groups: 1) gaze stability training (i.e., integrated eye and head movements on fixed target), 2) visual motion training (i.e., integrated eye and head movements with busy visual background), 3) standing balance (i.e., standing in different stances), and 4) dynamic gait (i.e., walking with head turns). Participants will be prescribed to one of four levels of these four exercise groups based on presentation of symptoms/impairment as indicated on the VOMS. Progression through the four levels will be based on symptom tolerance and successful completion of all exercises at the current level.
9478138|NCT03555357|Active Comparator|PRP|Platelet Rich Plasma (PRP) injections into one half of the scar will be preformed. PRP is already considered an effective treatment for scar therapy.This will be randomly assigned by the clinical research coordinator .
10021683|NCT03677128|Experimental|mNavigator|Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
10021684|NCT03677128|No Intervention|Historical controls|BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.
10021685|NCT03676283|Experimental|Web-based psycho-educational support for family caregivers|Gaining access to the website (närstående.se) with supportive films and texts
10021686|NCT03676153|Experimental|Nurse-guided arm|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
10021687|NCT03676153|Active Comparator|Non nurse-guided arm|Integrative medicine treatment program, with no nurse-provided guidance on patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
9478139|NCT03555357|Experimental|PRF|Platelet Rich Fibrin (PRF) injections will be preformed the other half of the scar that is not treated with PRP. PRF has not been established as an effective scar treatment. The PRF will be considered experimental as this study seeks to evaluate if it is more effective than PRP.
10021688|NCT03674138|Active Comparator|DNA-guided choice of therapy|DNA-guided choice of antidepressant therapy
10021689|NCT03674138|Active Comparator|Clinical management|Clinical management
10021690|NCT03673826|Experimental|Arm A|Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
10021691|NCT03673826|Experimental|Arm B|KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
10021692|NCT03670680|Experimental|Lina LibrataTM|Use of the Lina LibrataTM
10021693|NCT03667014|Experimental|Dupilumab treatment|30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).
10036436|NCT01815619|Experimental|on-site evaluation of specimens by cytopathologist|The specimen will be evaluated onsite by a cytopathologist during the procedure to render a diagnosis
10036437|NCT01815619|Active Comparator|off-site specimen evaluation|The specimen will be evaluated offsite by a cytopathologist during the procedure and render a diagnosis
10036438|NCT01815632|Experimental|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
10036439|NCT01815632|Experimental|Late infusion of autologous marrow|Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
10036440|NCT01815658||Broken humerus shaft|Patients presenting with broken humerus shaft
10036441|NCT01815684|Experimental|ASP3652 Group 1|Dosed according to the following scheme: placebo, low dose, medium dose, high dose
10036442|NCT01815684|Experimental|ASP3652 Group 2|Dosed according to the following scheme: low dose, placebo, medium dose, high dose
10021694|NCT03663712|Experimental|Dose|"Drug: Talimogene Laherparepvec~There will be two parts to this phase I study: 1) Dose Escalation Cohort; 2.) Dose Expansion Cohort~In the Dose Escalation Cohort, three subjects will be enrolled at the starting dose of 4x106 PFU, and the dosing will continue in the standard '3+3' dose escalation scheme. If the starting dose is tolerated, enrollment will continue at 4x107 and 4x108 PFU. Once the MTD is determined, six subjects will be enrolled to the Dose Expansion Cohort at the MTD. All subjects will be dosed with talimogene laherparepvec intraperitoneal (IP) once every 2 weeks for up to 4 doses (in addition to the initial seroconversion dose, which all patients will receive)."
9478140|NCT03555344|Experimental|Mantra Chikitsa|Mantra chanting for 15 mins
9478141|NCT03555344|No Intervention|Wait list control|Rest for 15 Mins
10021695|NCT03663257||AneurysmFlow Observational Cohort|Subjects with unruptured, >5mm saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent enrolled at the centers participating in this CARO study.
9478142|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
10021696|NCT03662919||Flixabi|Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
10021697|NCT03662919||Imraldi|Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.
10021698|NCT03662685|Active Comparator|Goeckerman Therapy|Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
10021699|NCT03662685|Active Comparator|Phototherapy Only|Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
9478143|NCT03555318|Experimental|Geriatrician + Cardiologist|Patients randomized to a combined ambulatory follow up with a cardiologist and a geriatrician.
9478144|NCT03555318|Active Comparator|Cardiologist|Patients randomized to usual care (ambulatory follow up with a cardiologist).
9478145|NCT03555292|Experimental|PD without dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
9478146|NCT03555292|Experimental|PD with MCI|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
9478147|NCT03555292|Experimental|PD with dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
9478148|NCT03555292|Experimental|dementia with Lewy bodies|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
9478149|NCT03555292|Experimental|healthy control|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
9478150|NCT03555253|Experimental|PwMS and their Support Partner|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners.
9478151|NCT03555240||Patient with Rheumatoid Arthritis|Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis
9478152|NCT03555227|Active Comparator|Group X|"PECS group~USG PECS2 with Drug A (active) Wound infiltration with Drug P (placebo)"
9478153|NCT03555227|Active Comparator|Group Y|"LA (local anaesthetic) infiltration group~USG PECS2 with Drug P (placebo) Wound infiltration with Drug A (active)"
9478154|NCT03555214|Experimental|Manual Therapy based on soft tissue|
9478155|NCT03555214|Placebo Comparator|Control Group|
9478156|NCT03555214|Experimental|Manual Therapy based on structural techniques|
9478157|NCT03555214|Experimental|Manual Therapy based on soft tissue and structural techniques|
9478158|NCT03555201|Experimental|Manual therapy|Protocol of soft tissue techniques
9478159|NCT03555201|Active Comparator|Regular treatment control.|Regular treatment control.
9478160|NCT03555188|Experimental|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
9478161|NCT03555188|Placebo Comparator|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
9478162|NCT03555175|Other|Group one|This participants group must do eccentric exercise for 12 weeks
10021700|NCT03662685|Active Comparator|Crude Coal Tar Only|Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
10036443|NCT01815684|Experimental|ASP3652 Group 3|Dosed according to the following scheme: low dose, medium dose, placebo, high dose
9478163|NCT03555175|Other|Group two|This participants group must do proprioception exercise for 12 weeks
9478164|NCT03555175|Other|Group 3|This participants group mustn't do exercise extra
9478165|NCT03555162|Other|Tool Use|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when using tools. Here only the fMRI experimental session is necessary. Tasks proposed to the participants within the fMRI scanner will be related to tool use. They will have to solve mechanical problems, to judge the appropriateness of hand postures for using tools, and to judge if tools presented share the same context of use, the same functional goals, the same hand postures for using them.These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use tools.
9478166|NCT03555162|Other|Tool Evolution|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when we improve tools. Here the fMRI experimental session will be complemented by a cognitive psychology experiment, where participants will be given a tool to improve. Tasks proposed to the participants within the fMRI scanner will be related to cognitive functions that could be implicated in improving tools : creativity, technical reasinoning, logic, empathy. The BOLD measures realted to these experimental condfitions will be related to the ability of the participant to improve a tool, through General Linear Modeling.
9478167|NCT03555136||Patients initiating vortioxetine treatment|Patients with major depressive disorder initiating treatment with vortioxetine
9478168|NCT03555123|Experimental|SIMDAX|Levosimendan2.5mg/mL
9478169|NCT03555123|Placebo Comparator|SIMDAX Placebo|Water for injection
9478170|NCT03555110|Active Comparator|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
9478171|NCT03555110|Active Comparator|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:~Three evaluation and preparation sessions,~Eight EMDR sessions weekly with variable length of 60 minutes and~One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
9478172|NCT03555097|Experimental|COPD Group|incremental pressure support
10036444|NCT01815684|Experimental|ASP3652 Group 4|Dosed according to the following scheme: low dose, medium dose, high dose, placebo
10036445|NCT01815697|Experimental|Enhanced External Counterpulsation|Men with benign prostatic hyperplasia receive 35- 36 hours Enhanced External Counterpulsation treatment
10021701|NCT03662646||IBD patients|
10021702|NCT03662646||Healthy controls|
10021703|NCT03661320|Active Comparator|Arm A: Gemcitabine/Cisplatin (GC) Chemotherapy|
10021704|NCT03661320|Experimental|Arm B: Nivolumab + GC Chemotherapy|
10021705|NCT03660839|Experimental|Ferroquine 400 milligram (mg)|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.
10021706|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 300 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.
10021707|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 600 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.
10021708|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 1000 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.
10021709|NCT03660241|Experimental|PF-04965842|PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor
10021710|NCT03657667|Other|Ureteroscopy (URS) (standard treatment)|Endoscopic procedure used to remove kidney stones
10021711|NCT03656133|Active Comparator|Standard Fractionation|Standard Radiotherapy Fractionation
10021712|NCT03656133|Active Comparator|Hyperfractionation|Hyperfractionation
10021713|NCT03651271|Experimental|"Hot tumors for Advanced Metastatic Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
10021714|NCT03651271|Experimental|"Cold tumors for Advanced Metastatic Cancer"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
10021715|NCT03651271|Experimental|"Hot tumors for Advanced Prostate Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
10021716|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort A"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
10021717|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort B"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
10021718|NCT03651245||Participants with suspicion for Alpha-Mannosidosis|Participants with suspicion for Alpha-Mannosidosis based on their clinical symptoms aged from 2 months to 18 years
10021719|NCT03651102|Experimental|Thalidomide in combination with hydroxyurea|All the study patients refractory to hydroxyurea will be given thalidomide at an average dose of 2mg/kg/day (range 1-4mg/kg/day). Participants will also be continued on hydroxyurea at a dose of 10-20 mg/kg/day.
10021720|NCT03649841|Active Comparator|Arm I (ADT, abiraterone, prednisone)|Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
10021721|NCT03649841|Experimental|Arm II (ADT, abiraterone, prednisone, radiation therapy)|Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
10021722|NCT03649802|Placebo Comparator|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
10021723|NCT03649802|Active Comparator|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
10021724|NCT03645928|Experimental|Cohort 1A|LN-144 therapy in combination with pembrolizumab in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma with ≤ 3 prior lines of systemic therapy, excluding checkpoint inhibitors (CPI).
10021725|NCT03645928|Experimental|Cohort 1B|LN-145-S1 therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor or BRAF inhibitor with or without a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.
10021726|NCT03645928|Experimental|Cohort 1C|LN-144 Generation 3 (Gen 3) therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.
9478173|NCT03555084|Experimental|Device: Extension of Phonak Virto B-Titanium|The extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
9478174|NCT03555084|Active Comparator|Device: Phonak Virto B-Titanium|The Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
10021727|NCT03645928|Experimental|Cohort 2A|LN-145 therapy in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding CPIs.
10021728|NCT03645928|Experimental|Cohort 3A|LN-145 therapy in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III or Stage IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding CPIs or ≤ 4 prior lines if 2 or more of the lines are TKI therapy for those with tumors that harbored actionable mutations (eg, EGFR, ALK, ROS).
10021729|NCT03645928|Experimental|Cohort 3B|LN-145 therapy as a single agent in patients with Stage III or Stage IV NSCLC, who have previously received 1-3 lines of prior systemic therapy. Patients with known oncogene drivers (eg, EGFR, ALK, ROS) who have mutations that are sensitive to targeted therapies are not required to have received prior systemic therapy with CPIs.
10021730|NCT03645928|Experimental|Cohort 3C|LN-145 therapy in combination with ipilimumab and nivolumab in patients with Stage III or Stage IV NSCLC who have previously received 1 line of approved CPI monotherapy as the only prior line of systemic therapy.
10021731|NCT03645824|Experimental|Pacritinib treatment befor allo-SCT|The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.
10021732|NCT03643198|Sham Comparator|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
10021733|NCT03643198|Active Comparator|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
10021734|NCT03641664|Experimental|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
10021735|NCT03641664|Active Comparator|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
10021736|NCT03637595|Active Comparator|Positive Control Group|Acupuncture
10021737|NCT03637595|Sham Comparator|Negative Control Group|Sham Intervention
10021738|NCT03637595|Experimental|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
10021739|NCT03635385|Active Comparator|Plasma exchange (PE) technic patient group|
10021740|NCT03635385|Active Comparator|Immunoadsorption technic patient group|
10036446|NCT01815697|No Intervention|Control|Men with benign prostatic hyperplasia without Enhanced External Counterpulsation treatment as control
9478175|NCT03555071|Experimental|Experimental Group1|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
9478176|NCT03555071|Experimental|Experimental Group2|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
9478177|NCT03555071|Experimental|Experimental Group3|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
9478178|NCT03555071|Active Comparator|Control Group|"The control vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at trial-scale.~Intervention: Live attenuated varicella vaccine manufactured at trial-scale"
10036447|NCT01815710||Vomiting & Diarrhea|Alberta Health Services Acute Childhood Vomiting & Diarrhea Pathway
10021741|NCT03635073|Experimental|Soticlestat|Treatment: Soticlestat, tablets orally twice daily at optimized dose, titrated in up to 2 weeks of Dose Optimization Period, followed by Maintenance Period, which lasts until development is stopped by the sponsor, or the product is approved for marketing, or at any time at the discretion of the sponsor.
10021742|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted >72h at the Intensive Care Unit with the need of artificial Nutritional Support
10021743|NCT03634397|Experimental|Less-Impaired Arm Training|Intervention condition includes therapy of the less-impaired (ipsilesional) arm.
10021744|NCT03634397|Sham Comparator|Contralesional Arm Comparison|Comparison control condition includes therapy of the paretic (contralesional) arm.
10021745|NCT03634098|Experimental|Volunteers|"Exams performed on volunteers with other purpose than liver disease or diabetes in two centers:~MRI~Ultrasound AixPlorer These examinations are carried out in 2 differents centers at 1month intervals"
10021746|NCT03634098|Experimental|T2D liver test abnormalities's participants|"Exams performed on type 2 diabetic patients with liver test abnormalities :~sample for analysis and biocollection~MRI +/-Primovist~Ultrasound AixPlorer +Sonovue"
10021747|NCT03634098|No Intervention|T2D participants without liver test abnormality|type 2 diabetic participants without liver test abnormality and not undergoing liver biopsy
9478179|NCT03555058|Other|High risk- TDM|Treatment escalation per TDM and physician's decision.
9478180|NCT03555058|No Intervention|High risk- Follow Up|Patients randomized to this arm will keep with the follow-up regime. Treatment escalation will occur only upon worsening of symptoms.
9478181|NCT03555058|No Intervention|Low risk|Control group. Patients will be assigned to this group based on VCE results and will not undergo randomization.
10021748|NCT03631199|Experimental|canakinumab|canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy
10021749|NCT03631199|Other|canakinumab matching-placebo|canakinumab matching-placebo in combination with pembrolizumab and platinum-based doublet chemotherapy
10021750|NCT03626792|Other|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
10021751|NCT03626792|Other|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
10021752|NCT03623243|Experimental|Siponimod 2 mg|Siponimod 2mg tablets taken once daily after a 5 day titration
9478182|NCT03555045|Active Comparator|conducting the slanted recession technique|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
9478183|NCT03555045|Active Comparator|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
10036448|NCT01815710||Pediatric Asthma Clinical Pathway|Pediatric Asthma Clinical Pathway
10021753|NCT03620578|Experimental|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
10021754|NCT03616587|Experimental|AZD9833 monotherapy dose escalation|
10021755|NCT03616587|Experimental|AZD9833 monotherapy dose expansion|
10021756|NCT03616587|Experimental|AZD9833 with palbociclib dose escalation|
10021757|NCT03616587|Experimental|AZD9833 with palbociclib dose expansion|
10021758|NCT03616587|Experimental|AZD9833 with everolimus dose expansion|
10021759|NCT03616587|Experimental|AZD9833 with everolimus dose escalation|
10021760|NCT03616587|Experimental|AZD9833 with abemaciclib dose escalation|
10021761|NCT03616587|Experimental|AZD9833 with abemaciclib dose expansion|
10021762|NCT03616587|Experimental|AZD9833 with capivasertib dose escalation|
9478184|NCT03555032|Experimental|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
9478185|NCT03555019|Experimental|Formulaid|The intervention group will receive enteral supplementation with Formulaid containing ARA and DHA at a ratio of 2:1, from birth until 36 weeks PMA
9478186|NCT03555019|Active Comparator|MCT-oil|The control group will receive enteral supplementation with MCT oil containing coconut and/or palm kern oil, from birth until 36 weeks PMA
9478187|NCT03555006|Other|Local vs remote group|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation
9478188|NCT03555006|Other|Local vs local group|The examination will be interpreted by two department's radiologists
9478189|NCT03554993|Experimental|CC-99677 Under Fasted Conditions|CC-99677 Under Fasted Conditions
9478190|NCT03554993|Experimental|Placebo|Placebo under fasted conditions
9478191|NCT03554993|Experimental|CC-99677 Under Fed Conditions|CC-99677 Under Fed Conditions
10021763|NCT03616587|Experimental|AZD9833 with capivasertib dose expansion|
9478192|NCT03554980|Experimental|Group 1|"38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up at 0,1,3,6, 9 and 12.~SDF is a brush-on liquid."
10021764|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
10021765|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^3)|Participants will receive a single dose of rZIKV/D4Δ30-713 at study entry (Day 0).
10021766|NCT03611946|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
9478193|NCT03554980|Active Comparator|Group 2|5% sodium fluoride varnish will be applied four times annually and patients will be followed up at 0,1,3,6,9 and 12.
9478194|NCT03554941|Experimental|noise stimulation|noise stimulation
9478195|NCT03554928||Cocaine Dependent|Individuals with cocaine dependence
10021767|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^4)|Participants will receive a single dose of rZIKV/D4Δ30-713 or placebo at study entry (Day 0).
10021768|NCT03611556|Active Comparator|Arm A1|gemcitabine and nab-paclitaxel
10021769|NCT03611556|Experimental|Arm A2|oleclumab (MEDI9447), gemcitabine and nab-paclitaxel
10021770|NCT03611556|Experimental|Arm A3|oleclumab (MEDI9447), durvalumab (MEDI4736), and gemcitabine/nab-paclitaxel
10021771|NCT03611556|Active Comparator|Arm B1|mFOLFOX (oxaliplatin, leucovorin, 5-FU)
10021772|NCT03611556|Experimental|Arm B2|oleclumab (MEDI9447) and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
10021773|NCT03611556|Experimental|Arm B3|oleclumab (MEDI9447), durvalumab (MEDI4736), and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
10021774|NCT03607318|Experimental|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
10036449|NCT01815723|Experimental|FP187|500 mg FP187 daily (250 mg twice daily)
10036450|NCT01815723|Active Comparator|Dimethyl fumarate|720 mg Fumaderm® daily (240 mg three times daily)
10036451|NCT01815723|Placebo Comparator|Placebo|Matching FP187 and Fumaderm® placebo
10037499|NCT01825629|Placebo Comparator|One technique of myofascial release|"A physiotherapist administered 15 sessions of induction occipital once a week."
9478196|NCT03554928||Not Cocaine Dependent|Individuals without cocaine dependence
10021775|NCT03607318|Active Comparator|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
10037500|NCT01825642|Active Comparator|Control Group|nerve-sparing radical prostatectomy
10037501|NCT01825642|Active Comparator|Treatment Group|seminal vesicle-sparing radical prostatectomy
10037502|NCT01825668|Experimental|High cholesterol|600 mg cholesterol/day in 240 ml milk shake
10037503|NCT01825668|Experimental|Plant sterols|2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
9802759|NCT04973059|Active Comparator|Winter Conditions with SmartDrive|This arm is with the participant using the SmartDrive during a week in the winter. The SmartDrive is a manual wheelchair accessory that provide power assistance to reduce the necessary level of propulsion force. The goal is to increase participation by reducing propulsion effort.
9802760|NCT04972097|Experimental|IRE Treatment Arm|All patients enrolled in this trial will receive IRE treatment with the NanoKnife System
9802761|NCT04971993||Heart Failure NYHA Class II|Participants are diagnosed with NYHA Class II heart failure.
10037504|NCT01825668|Placebo Comparator|Placebo|50 mg cholesterol/day in 240 ml of milk shake
10021776|NCT03606980|Experimental|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
10021777|NCT03606980|Placebo Comparator|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
9802762|NCT04971993||Heart Failure NYHA Class III|Participants are diagnosed with NYHA Class III heart failure.
9802763|NCT04971993||At risk for arrythmias|Participants are indicated for an insertable cardiac monitor with no history of heart failure.
9802764|NCT04971161|Experimental|allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)|Application of IMP on patients wound
10021778|NCT03606980|Active Comparator|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
10021779|NCT03606538|Experimental|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
10021780|NCT03606538|Experimental|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
10037505|NCT01825681|Experimental|positive affect intervention|positive affect intervention
10037506|NCT01825681|No Intervention|wait list control|wait list control
9802765|NCT04971161|Placebo Comparator|Placebo|Application of IMP on patients wound
9802766|NCT04971161|Experimental|allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)|Application of IMP on patients wound
10021781|NCT03600116||Study Visit|After consent and enrollment, subjects with type 1 diabetes will arrive to the study visit having fasted the night before. Subjects will be given a meal, and will be given an insulin injection for this meal, calculated based on their prescribed meal to carbohydrate ratio as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL based on their prescribed insulin sensitivity factor. Following the insulin injection, subjects will eat breakfast and be observed in the clinic setting. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
10021782|NCT03599622|Experimental|BMS-986165 Dose 1|
10021783|NCT03599622|Experimental|BMS-986165 Dose 2|
10021784|NCT03599622|Placebo Comparator|Placebo|
10021785|NCT03598231|Sham Comparator|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
9478197|NCT03554915||Ketamine-based Protocol|The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
9478198|NCT03554915||Midazolam-based Protocol|The second 6 month period of the study will employ a midazolam-based protocol for prehospital agitation. There will again be a tiered dosing protocol based on degree of agitation.
10037507|NCT01825694|No Intervention|Standard of Care|The Standard of Care condition includes: 1) an individual session with the counselor, once per week; 2) a treatment group with the counselor, twice per week; and 3) parents of youth are invited to attend parent-only educational sessions weekly.
10037508|NCT01825694|Experimental|Trauma-focused Substance Abuse Intervention|See Intervention Arm description.
9478199|NCT03554889|Experimental|Experimental Group|Peripheral blood lymphocytes will be collected. The NK cell will be selected and expanded ex vivo, then adaptive transfer back into patients. A total of 5.0 x 10^8/L NK cells will be infused in one cycle.To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients. Nimotuzumab will be used 24 hours before infusion. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent.
9478200|NCT03554876|Active Comparator|Multi-Im Machined|Multi-Im Machined
9478201|NCT03554876|Experimental|Multi-Im® nanogolden|Multi-Im® nanogolden
9478202|NCT03554876|Experimental|Multi-Im T-Golden|Multi-Im T-Golden
9478203|NCT03554863|Active Comparator|Facial mask|
9478204|NCT03554863|Experimental|Optiflow anesthesia|
9478205|NCT03554824||Pre-Transfer Adolescents aged 10-16 years|
9478206|NCT03554824||Post-Transfer Young Adults aged 16-25 years|
9478207|NCT03554824||Parents/Guardians of Pre-Transfer Patients|
9478208|NCT03554811|Experimental|Functional electrical stimulation assisted supine cycling|Patients will start functional electrical stimulation assisted supine cycling (FESC) within 48 hours of ICU admission and will undergo up to 1 hour of supine cycling daily, 5 days per week for 28 days, or until discharge from ICU.
9478209|NCT03554811|Active Comparator|Conventional early exercise and mobility interventions|Patients will undergo standard ICU exercise and mobility interventions.
9478210|NCT03554785|No Intervention|Control/Usual Care|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
9478211|NCT03554785|Active Comparator|Intervention|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~CHC staff leadership key informant interviews (up to 5 at each site)~Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
9478212|NCT03554733|Experimental|Treatment|Re-Inventing Yourself after SCI protocol - 6-week educational sessions
9478213|NCT03554733|No Intervention|Control|No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
9478214|NCT03554694|Experimental|Start with prebiotics|Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
9478215|NCT03554694|Experimental|Start with placebo|Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.
9478216|NCT03554668||1|Post total knee replacement patients
9478217|NCT03554642|Experimental|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
9478218|NCT03554642|Active Comparator|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
9478219|NCT03554642|No Intervention|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
9478220|NCT03554603|Experimental|Modified Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
9478221|NCT03554603|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
9802767|NCT04971161|Experimental|allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)|Application of IMP on patients wound
10037509|NCT01825707|Experimental|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg
9478222|NCT03554590|Experimental|carbo-counters|carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy
9478223|NCT03554590|Active Comparator|control group|insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy
9478224|NCT03554577|Active Comparator|Hearing Aid without NR|Hearing Aid without Noise Reduction (NR) serves as reference condition.
9478225|NCT03554577|Experimental|Hearing Aid with NR_A|NR_A: Noise Reduction principle A
9478226|NCT03554577|Experimental|Hearing Aid with NR_B|NR_B: Noise Reduction principle B.
9478227|NCT03554577|Experimental|Hearing Aid with NR_C|NR_C: Noise Reduction principle C.
10021786|NCT03598231|Active Comparator|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
10021787|NCT03596684|Experimental|citrulline|citrulline 5g/d
10021788|NCT03596684|Placebo Comparator|Placebo|pure mixture of amino acids: alanine, aspartate, glycine, proline, serine, histidine
9478228|NCT03554564|Experimental|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
9478229|NCT03554564|Other|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
10021789|NCT03596450|Experimental|Semaglutide|Participants will receive semaglutide in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
10021790|NCT03596450|Active Comparator|Standard of care|Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
10021791|NCT03596385|Experimental|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
10021792|NCT03596385|No Intervention|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
10021793|NCT03595878|Active Comparator|Randomized Arm - Control Group|Patients randomized to this group will receive standard WBRT.
10021794|NCT03595878|Experimental|Randomized Arm - Intervention Group|Patients randomized to this group will receive parotid sparing WBRT.
10021795|NCT03595878|No Intervention|Observational Arm|Patients enrolled in this arm will be treated per their treating physician's choice.
10021796|NCT03591731|Experimental|Arm A : monotherapy arm|Nivolumab administered IV
10021797|NCT03591731|Experimental|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
10021798|NCT03590652|Experimental|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
10037510|NCT01825720|Experimental|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
10037511|NCT01825720|Active Comparator|normal saline group|same rate of normal saline
9478230|NCT03554551||Patients with Parkinsons disease|Disease duration > 4 years, Hoehn & Yahr stage 2-3, 50-85 years old
9478231|NCT03554551||Healthy controls|50-85 years
9478232|NCT03554538|Experimental|Web app exercises|An evidence based exercise program for the shoulder pain. Web application with multimedia animations with the tailored exercise program for each patient in this group.
9478233|NCT03554538|Active Comparator|Exercises|An evidence based exercise program for the shoulder pain.
9478234|NCT03554525|Experimental|Experimental product : FAT-BINDER DAMM|3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
9478235|NCT03554525|Placebo Comparator|Control product : PLACEBO|3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
9478236|NCT03554512|No Intervention|Standard of Care|No Intervention
9478237|NCT03554512|Experimental|Telehealth|Telehealth virtual appointment
9478238|NCT03554499|Experimental|Hydrodissection|Bichectomy with hydrodissection = infiltration of 15ml per side of a special solution (250ml of saline 0.9% + 1mg of epinephrine + 20ml of 2% Lidocaine, equivalent to 0.0555mg of epinephrine and 22.2mg of Lidocaine per side), prior to the incision with the following distribution: 1ml in the form of a wheal in the oral mucosa with a 22G needle 1cm behind the Stenon canal opening that corresponds to the incision site and 14 ml on the virtual space where the buccal fat pad is located.
9478239|NCT03554499|Active Comparator|Control|Bichectomy without hydrodissection = infiltration with 3ml per side of 2% Lidocaine with 1: 200,000 epinephrine ( equivalent to 0.015mg of epinephrine and 60mg of Lidocaine per side) at the operative site.
9478240|NCT03554460|Experimental|dual-limb NIV|A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
9478241|NCT03554447|Experimental|Pentoxifylline group|Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
9478242|NCT03554447|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
9478243|NCT03554421|Experimental|Posterior tibial nerve stimulation|Percutaneous tibial nerve stimulation. Stimulation av posterior tibial nerve via neuromodulator for 30 minutes. 10 sessions
9478244|NCT03554408|Experimental|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
9478245|NCT03554408|Experimental|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
9478246|NCT03554408|Experimental|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
9478247|NCT03554408|Experimental|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
9478248|NCT03554408|Experimental|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
9478249|NCT03554408|Experimental|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
9478250|NCT03554408|Experimental|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
9478251|NCT03554408|Experimental|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
9478252|NCT03554408|Experimental|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
9478253|NCT03554408|Experimental|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
9478254|NCT03554408|Experimental|Group 6|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
10037512|NCT01825733|Experimental|ramosetron|
10037513|NCT01825733|Active Comparator|palonosetron|
9478255|NCT03554408|Experimental|Group 7|HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
10021799|NCT03584711|Experimental|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
10021800|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
9478256|NCT03554408|Experimental|Group 8|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
9478257|NCT03554408|Experimental|Group 9|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
10021801|NCT03582475|Experimental|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10021802|NCT03582033|Experimental|Parts A and B: SEA-BCMA Monotherapy|SEA-BCMA
10021803|NCT03582033|Experimental|Part C: SEA-BCMA + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone
10021804|NCT03582033|Experimental|Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone + pomalidomide
10021805|NCT03582033|Experimental|Part E: SEA-BCMA + Nirogacestat + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone + nirogacestat
10021806|NCT03581721|No Intervention|The control group|"Control group according to usual practices: no active warming (no fluid warming). The fluid warmer device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
10021807|NCT03581721|Experimental|The warming group|"IV fluid warming with the enFlow® or Fluido®Compact IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® or Fluido®Compact device. The box will be also hidden. The fluid warmer will be turned off at the end of surgery, just before transfer to the PACU."
10021808|NCT03580824|Experimental|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm).
10021809|NCT03580824|Experimental|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
10021810|NCT03580824|Experimental|Group 3|"Group 3A infants 5-<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3B infants 5-<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3C infants 5-<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3D infants 5-<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3E infants 5-<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
10021811|NCT03579901|Other|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
10021812|NCT03579901|Other|Primary Breast Reconstruction|Subjects age 18 and over, Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
9478258|NCT03554395|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
9802768|NCT04966637||Individuals with COPD|"This retrospective annual analysis will use the following validated case definition to identify a cohort of individuals with COPD: an individual aged 35 years and older having at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44) between April 1, 2016 and March 31, 2019.~This is a retrospective descriptive study with administrative data and no intervention will be administered to the cohort"
10021813|NCT03579901|Other|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
9802769|NCT04962919||Public institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
9802770|NCT04962919||Private institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
9802773|NCT04955236|Experimental|Partial scalp block|Bilateral block of the greater lesser and third occipital nerves using bupivacaine 0.25% with epinephrine 1:200,000
9802774|NCT04955236|Active Comparator|Fentanyl group|Fentanyl infusion will be administered till time of dural closure
9802775|NCT04948736|Experimental|Combined exercise nutrition intervention group|Customized exercise and nutrition intervention by underlying disease and functional state for 12 weeks during intervention period.
9802776|NCT04948736|Active Comparator|Conventional medial care group|Conventional medical care service for 12weeks during intervention period.
9802777|NCT04944706|Experimental|Low dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
9802778|NCT04944706|Experimental|High dose group|The standard basic treatment is given according to the guidelines related to the underlying disease
9802779|NCT04944706|Experimental|Placebo group|The standard basic treatment is given according to the guidelines related to the underlying disease
9802780|NCT04943770||WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|"Patients will be randomised 4:4 to a specific stimulating rates order (A, B, C, D) for approx. 3-6 weeks per rate (12-24 weeks in total). Each period is followed by a wash-out phase.~At each frequency systematic assessment of the sweet-spot(s) will be performed. Various pulse width and amplitude values may be used to optimize therapy (up to 1KHz). These programmes will be saved in the subject's remote control based on the pre-generated rate randomization sequence."
9802781|NCT04943575|Active Comparator|Intervention 1|EZC Pak
9802782|NCT04943575|Active Comparator|Intervention 2|EZC Pak+D
9802783|NCT04943575|Placebo Comparator|Placebo|
10021814|NCT03579901|Other|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
10021815|NCT03579628|Experimental|AsiDNA|"Part A: AsiDNA as a single agent:~The study will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period.~Part B: AsiDNA combination with Carboplatin with or without Paclitaxel (Background treatments):~Part B1: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5.~Part B2: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5 and weekly Paclitaxel: 80 mg/m2 (full dose)."
10021816|NCT03579394|Active Comparator|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
10021817|NCT03579394|Experimental|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
10021818|NCT03579316|Active Comparator|Arm I (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10021819|NCT03579316|Experimental|Arm II (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10021820|NCT03579316|Experimental|Arm III (ceralasertib, olaparib)|Patient receive ceralasertib tablets by PO BID each day on Days 1-14. You will also take olaparib tablets by PO BID each day on Days 1-28.
10021821|NCT03576417|Active Comparator|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
10021822|NCT03576417|Experimental|RT+ cisplatin + nivolumab|"240 mg of nivolumab 3 weeks before RT-Cisplatin~360 mg of nivolumab on days 1, 22,43 of -RT-cisplatin~480 mg of nivolumab for maintenance"
9478259|NCT03554395|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
9478260|NCT03554395|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9480759|NCT05261373|Active Comparator|Moderate-intensity continuous training (CG+MICT)|Participants who do not receive nutritional education but are enrolled in a moderate-intensity continuous training exercise program.
10021823|NCT03575390|Placebo Comparator|control group|Control group will receive placebo medication therapy
10021824|NCT03575390|Experimental|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
10021825|NCT03575104|Experimental|Daridorexant 10 mg|
9478263|NCT03554343||All newborn from Southern Belgium|All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in survival motor neuron 1 (SMN1)
9478264|NCT03554330|Active Comparator|control group|Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.
9478265|NCT03554330|Experimental|single-RFA group|After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.
9478266|NCT03554330|Experimental|double-RFA group|The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).
9478267|NCT03554304|Experimental|WCK 5222|WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
9478268|NCT03554304|Placebo Comparator|Placebo (IV placebo matched toWCK 5222IV solution)|placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
9478269|NCT03554304|Active Comparator|Moxifloxacin 400-mg|positive control
9478270|NCT03554291|Experimental|Famotidine|"20mg of oral famotidine (pill) daily~Other names: Pepcid"
9478271|NCT03554291|Placebo Comparator|Placebo|Daily oral placebo (pill)
9478272|NCT03554252|Experimental|Frequencies|
9478273|NCT03554252|Experimental|Percentages|
9478274|NCT03554239|Other|Voriconazole treatment|Patients who start voriconazole treatment and receive benefits of genotyping
9478275|NCT03554213||Phase 1: TCV in 2018|Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.
9478276|NCT03554213||Phase 2: TCV in 2019|Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.
9478277|NCT03554200|Experimental|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
9478278|NCT03554200|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
9478279|NCT03554161|Experimental|Tocilizumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
10021826|NCT03575104|Experimental|Daridorexant 25 mg|
10021827|NCT03575104|Placebo Comparator|Placebo|
9802784|NCT04942535|Experimental|Social Incentive Gamification|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Incentive Gamification intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
10021828|NCT03574597|Experimental|Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
10021829|NCT03574597|Placebo Comparator|Placebo (semaglutide)|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
10021830|NCT03573557|Active Comparator|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
10021831|NCT03573557|Active Comparator|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
10021832|NCT03573557|Active Comparator|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
10021833|NCT03573115|Experimental|Acne patients|
10021834|NCT03572660|Other|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
10021835|NCT03569982|No Intervention|Control|Patients receiving best supportive care
10021836|NCT03569982|Experimental|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
10021837|NCT03569891|Experimental|AMT-061|"Single infusion of AMT-061~Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing."
10021838|NCT03569475|Experimental|Levomilnacipran ER 40-80 mg/day|Levomilnacipran extended release (ER) capsules, orally, 10 milligram per day (mg/day) on Days 1 to 3, 20 mg/day on Days 4 to 7, and 40 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by levomilnacipran ER 40 mg/day on Days 1 and 2, and then 20 mg/day from Day 3 through Day 7 in the Down-taper Period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day was permitted at Week 3 of the Double-blind Treatment Period.
10021839|NCT03569475|Active Comparator|Fluoxetine 20 mg/day|Fluoxetine capsule, orally, 10 mg/day at Week 1, and 20 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by fluoxetine 10 mg/day from Day 1 through Day 7 of the Down-taper Period.
9478280|NCT03554148||SSI|This group receives an additional swab of the surgical site infection. Follow up is terminated at the occurence of SSI.
9478281|NCT03554148||No SSI|This group is systematically followed up until 30 days after surgery (one year if a implant is implanted, e.g. mesh) by a third party (www.swissnoso.ch).
9478282|NCT03554122|Active Comparator|Shotblocker Group|Patients spinal injections were performed with Shotblocker placed onto injection site
9478283|NCT03554122|Placebo Comparator|Placebo Group|Patients spinal injections were performed without Shotblocker
10021840|NCT03569475|Placebo Comparator|Placebo|Matching placebo capsules once daily through 8 weeks in the Double-blind Treatment Period and Days 1 through 7 in the Down-taper Period.
9478284|NCT03554109|Experimental|Group A|"NANT Neoadjuvant Triple Negative Breast Cancer Vaccine~A combination of agents will be administered to subjects in this study:~cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, avelumab, aldoxorubicin HCl, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-051 and ETBX-061"
9478285|NCT03554109|Active Comparator|Group B|Standard treatment with a combination of doxorubicin, cyclophosphamide and paclitaxel.
9478286|NCT03554096|Experimental|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
9478287|NCT03554070|Experimental|Infravesical Obstruction|Patients with infravesical obstruction due to BPH (IPSS > 20, Qmax < 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.
10021841|NCT03565380|Experimental|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
10021842|NCT03565380|Experimental|Patients without intervention|usual post-operative care
10021843|NCT03565380|Experimental|Asymptomatic controls|untreated asymptomatic controls
10021844|NCT03562494|Experimental|VY-AADC02 (NBIb-1817)|Single administration of up to 3.6 x 10^12 vector genomes (vg) of VY-AADC02
10021845|NCT03562494|Placebo Comparator|Sham (Placebo) Surgery|Sham surgical procedure
10021846|NCT03560466|Experimental|Dupilumab|Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks
10021847|NCT03554798|Experimental|nOPV2 Candidate 1 (monovalent oral poliovirus type1)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.~Cohort B: 6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
10021848|NCT03554798|Experimental|nOPV2 Candidate 2 (monovalent oral poliovirus type2)|"Cohort A: IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.~Cohort B: Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
10021849|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
9478288|NCT03554031|Experimental|rhGH injection/Jintropin AQ|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
9478289|NCT03553992|Experimental|The Put It Out Project (POP-6):|a culturally tailored intervention developed for sexual and gender minority (SGM) young adults on Facebook
9478290|NCT03553992|Experimental|Tobacco Status Project (TSP-6):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
10021850|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected."
10021851|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
10021852|NCT03551951||Patients having surgery|Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
10021853|NCT03551951||Patients not having surgery|"Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations.~Lung cancer screening subjects"
10021854|NCT03551951||Healthy subjects|Healthy control subjects will have test for circulating tumor cells, DNA alterations
9480760|NCT05261373|Active Comparator|High-intensity interval training (CG+HIIT)|Participants who do not receive nutritional education but are enrolled in a high-intensity interval training exercise program.
9480761|NCT05261373|Active Comparator|Nutritional Education (EDU+INACT)|Participants who receive nutritional education but not an exercise program.
10021855|NCT03551249|Experimental|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
10021856|NCT03550144|Experimental|Awe Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
10021857|NCT03550144|Active Comparator|Control Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
10021858|NCT03548558|Experimental|"Arm 1 (group sessions)"|Group meetings only with some booster sessions
10021859|NCT03548558|Experimental|"Arm 2 (group+home sessions)"|Group meetings with a limited number of individual home visits and booster sessions
10021860|NCT03548558|No Intervention|Arm 3|This arm will serve as the control group to identify the effects of a parenting intervention and the most effective mode of delivery, as well as the sustained impacts from the intervention
10021861|NCT03548558|Experimental|Arm B (Father villages)|In one half of Arm 1 and Arm 2 villages above, fathers will be invited to attend the ECD sessions along with mothers.
10021862|NCT03548558|Other|Arm A (Mother-only villages)|In the other half of Arm 1 and Arm 2 villages, only mothers will be invited.
10021863|NCT03546556|Experimental|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
10021864|NCT03546556|Experimental|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
10021865|NCT03545191|Experimental|Daridorexant 25 mg|
10021866|NCT03545191|Experimental|Daridorexant 50 mg|
10021867|NCT03545191|Placebo Comparator|Placebo|
10021868|NCT03544281|Experimental|Arm A: Belantamab mafodotin+lenalidomide +dexamethasone|"Participants will receive SINGLE full dose of belantamab mafodotin as 2.5 mg/kg and 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 min infusion.~SPLIT: belantamab mafodotin will be administered in two equal divided doses, 2.5 mg/kg SPLIT dose of a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle.~STRETCH: belantamab mafodotin will be administered as 1.9 mg/kg dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on.) Participants will also receive Lenalidomide 25 mg or 10 mg orally daily, on Days 1-21 of each 28 day cycle with Dexamethasone, 40 mg weekly per oral (PO)/intravenously (IV) on Days 1,8,15, & 22 of each cycle."
10021869|NCT03544281|Experimental|Arm B: Belantamab mafodotin+bortezomib+dexamethasone|Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 & 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 & 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 & so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, & so on). Bortezomib will be administered at 1.3 mg/m^2 SC/IV on Days 1,4,8, & 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, & 12 of every 21-day cycle.
10021870|NCT03543813|Experimental|CX-2029 Escalation|Dose Escalation and Determination
10021871|NCT03543813|Experimental|CX-2029 Biomarker|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
10021872|NCT03543813|Experimental|CX-2029 Expansion|Evaluate antitumor activity of CX-2029
10021873|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
10021874|NCT03542175|Experimental|Rucaparib Administered With Radiation|"Treatment will consist of rucaparib at one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.~Radiotherapy will consist of 50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician."
10021875|NCT03537365|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
10021876|NCT03537365|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
10021877|NCT03534284|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.
10021878|NCT03534284|Active Comparator|Medication- Trazodone|Trazodone (50-100 mg):
10021879|NCT03534284|Placebo Comparator|Medication- Placebo|Placebo (for trazodone)
10021880|NCT03533712|Experimental|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
10021881|NCT03533712|Active Comparator|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
10021882|NCT03533582|Active Comparator|Group A1 (WDF)|Patients undergo observation.
10021883|NCT03533582|Experimental|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
10021884|NCT03533582|Experimental|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity.
10021885|NCT03533582|Experimental|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (2 pre-surgery, 4 post-surgery) in the absence of disease progression or unacceptable toxicity.
10021886|NCT03533582|Experimental|GROUP B2 (UNRESECTABLE)|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (4 pre-surgery, 2 post-surgery).
10021887|NCT03533582|Experimental|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
10021888|NCT03533582|Experimental|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
10021889|NCT03533582|Experimental|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9 during cycles 1 and 2 and days 1 and 2 during cycle 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
10037514|NCT01825746|Active Comparator|Early implementation practices|"9 practices that will initially field the MOHR assessment for up to 6 months. These practices will serve as intervention sites for the effectiveness outcomes measured by the patient experience survey."
9478291|NCT03553979|Experimental|Stress management program (SM)|The stress management program (SM) is a program which has been tailored to meet the specific needs of low-SES participants. The SM consists of 4-weekly sessions (1.5hours/session) and a follow-up session 8 weeks later. A core element of SM is its group-based format in which psycho-educative topics on stress responses and coping and motivation to stop smoking link up with cognitive and behavioural technique activities.
9480762|NCT05261373|Experimental|Nutritional Education Moderate-intensity continuous training (EDU+MICT)|Participants who receive nutritional education and are enrolled in a moderate-intensity continuous training exercise program.
9480763|NCT05261373|Experimental|Nutritional Education High-intensity interval training (EDU+HIIT)|Participants who receive nutritional education and are enrolled in a high-intensity interval training exercise program.
9478292|NCT03553979|Experimental|Stress management + Buddy program (SM-B)|The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
9478293|NCT03553979|No Intervention|Control|Participants in the control condition are instructed to continue with their normal daily behaviour. They will be invited to complete the questionnaires and objective measurements at the equivalent times as the intervention groups, thus at baseline, 4 weeks after baseline and 12 weeks after baseline. After the control period, participants in the control condition will be offered the intervention.
9478294|NCT03553966|Experimental|Tooth Brushing HAP+Restorative dentistry|"Arm Intervention: HA-Toothpaste Tooth Brushing HA Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite 3x daily over the duration of the study (336 days).~Procedure: Tooth Brushing HA"
10037515|NCT01825746|Other|Delayed implementation practices|"9 practices that will field the MOHR assessment for up to 6 months but starting 4 months after the early implementation practices. These practices will serve as control sites for the effectiveness outcomes measured by the patient experience survey. However, they will provide intervention data with respect to Reach and cost during the delayed phase."
9478295|NCT03553966|Active Comparator|Tooth Brushing F+Restorative dentistry|"Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (500 ppm F-), (three times daily over the duration of the study (336 days).~Intervention:~Procedure: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated toothpaste."
9478296|NCT03553953||Patients with recording from BIS device|One hundred screened adult patients and no more than 60 valid cases who undergo elective surgery under general anesthesia with recording from the BIS device at the same time and comply with the inclusions criteria
9478297|NCT03553927|Other|Low Energy Diet|Commercially available diet products
9478298|NCT03553927|Other|NHS advice on healthy eating|Dietary / lifestyle advice programme
9478299|NCT03553914|Experimental|12 mg/m^2 dose group|Subjects will receive PLM60 at 12 mg/m^2 dose.
9478300|NCT03553914|Experimental|16 mg/m^2 dose group|Subjects will receive PLM60 at 16 mg/m^2 dose.
9478301|NCT03553914|Experimental|20 mg/m^2 dose group|Subjects will receive PLM60 at 20 mg/m^2 dose.
9478302|NCT03553901|Experimental|Acupressure|Acupressure is applied before injection
9478303|NCT03553901|No Intervention|Control group|acupressure is not applied before injection
9478304|NCT03553888||HS patient|patients with HS
9478305|NCT03553888||no HS patients|patients without HS
9478306|NCT03553875|Active Comparator|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
9478307|NCT03553875|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
9478308|NCT03553862|No Intervention|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
9478309|NCT03553862|Experimental|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
9478310|NCT03553849|Experimental|Very Low Calorie Diet|If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
9478311|NCT03553849|No Intervention|Standard Preop Diet|The control group will continue a regular diet until the day before surgery.
9480764|NCT05261347|Experimental|intervention|mobilisation group
9480765|NCT05261347|Sham Comparator|control|sham control group
9480766|NCT05261321|Active Comparator|Cannabis oil with a high ratio of THC to CBD|Participants will be given a single dose of oral cannabis oil containing 10mg THC and 0.33mg CBD.
9480767|NCT05261321|Active Comparator|Cannabis oil with a high ratio of CBD to THC|Participants will be given a single dose of oral cannabis oil containing 10mg THC and 50mg CBD.
10037516|NCT01825759|Experimental|danshen dripping pill|danshen dripping pill 27mg ten pills by mouth every 8 hours for one year
10037517|NCT01825811|Experimental|TissueGene-C (Low dose)|TissueGene-C (1.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
10037518|NCT01825811|Experimental|Experimental: TissueGene-C (High dose)|TissueGene-C (3.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
10021890|NCT03533582|Experimental|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5, and carboplatin over 1 hour and etoposide IV over 2 hours on day 1 and 2 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
10021891|NCT03533582|Experimental|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
10021892|NCT03533582|Active Comparator|GROUP E1|Patients undergo observation only.
10021893|NCT03533582|Experimental|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
10021894|NCT03533582|Experimental|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 cycles of the treatment.
9480768|NCT05261321|Placebo Comparator|Placebo|Participants will be given a single dose of 2 mL placebo (carrier oil with botanical turpines) via oral route of administration.
9480769|NCT05261308|Experimental|prosthesis|The polyamide prosthesis
9480770|NCT05261295||Classical LMA|Patients who received general anesthesia with classical LMA
10021895|NCT03533582|Experimental|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of cycles 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of cycles 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 cycles of the treatment.
10037519|NCT01825824|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization
10037520|NCT01825850|Experimental|Gemigliptin|Gemigliptin 50mg q.d. during 7 days
9480771|NCT05261295||i-Gel|Patients who received general anesthesia with i-Gel
9665269|NCT05117489|Experimental|Cohort 6 - 100 mg of miricorilant every MF for 12 weeks|Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday and Friday for 12 weeks.
10021896|NCT03529838|Placebo Comparator|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
10021897|NCT03529838|Active Comparator|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
10021898|NCT03529838|Active Comparator|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
10021899|NCT03529396|Experimental|1a: Chloroquine + 5th-day Primaquine|[ARM HALTED PREMATURELY DUE TO SAFETY CONCERNS]
10021900|NCT03529396|Experimental|1b: Chloroquine + 8-week Primaquine|26 G6PD deficient patients. Directly observed therapy.
10021901|NCT03529396|Active Comparator|1c: Chloroquine + 12-week Chloroquine|26 G6PD deficient patients. Control group in terms of safety. Directly observed therapy.
9802785|NCT04942535|Experimental|Social Goals through Incentives to Charity|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Goals through Incentives to Charity intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
10021902|NCT03529396|Active Comparator|2: Standard chloroquine + primaquine|52 G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.
10021903|NCT03524911|Experimental|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
10037521|NCT01825850|Experimental|Irbesartan|Irbesartan 300mg q.d. during 7 days
10037522|NCT01825850|Experimental|Gemiglitin + Irbesartan|Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
10037523|NCT01825863|Active Comparator|Active abdominal wall block|60ml ropivacaine 0.375% single shot
10021904|NCT03523520|Active Comparator|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
10037524|NCT01825863|Placebo Comparator|Placebo abdominal wall block|60ml saline 9% single shot
9665270|NCT05117294|Experimental|ASP0367: Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
9665271|NCT05117294|Experimental|ASP0367: Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
10021905|NCT03523520|Active Comparator|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
9665272|NCT05117294|Experimental|ASP0367: Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
9665273|NCT05117294|Experimental|ASP0367: Normal Renal Function|Participants with normal renal function will receive a single dose of ASP0367 under fasting conditions on day 1.
9665274|NCT05116514|Experimental|Case manager group|
9665275|NCT05116514|No Intervention|Control|
10037525|NCT01825902|Experimental|Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)|Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
10021906|NCT03523520|Active Comparator|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
10021907|NCT03521830|Active Comparator|Previous Systemic Therapy Patients|Arm A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
10021908|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A) and Cohort C|Arm B: ipilimumab 1mg/kg IV q4 weeks x 4 doses + nivolumab 480mg IV q4weeks followed by nivolumab 480mg IV q4weeks for up to 48 total weeks of therapy.
10021909|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A)|Arm C: nivolumab 480 mg IV q4 weeks plus relatlimab 480 mg IV q4wks.
10037526|NCT01825915|Active Comparator|Laparoscopic Hysterectomy|Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
9665276|NCT05114655|Experimental|Intervention 1|Participants apply an herbaceous, earthy based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
10021910|NCT03518242|Experimental|Treatment (Specimen collection, chemotherapy)|"SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.~TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity."
9478312|NCT03553836|Experimental|Pembrolizumab|Pediatric participants receive 2 mg/kg (200 mg maximum) pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Adult participants receive 200 mg pembrolizumab by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of pembrolizumab and experience disease recurrence may be eligible to receive additional cycles of pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for unresectable disease recurrence. Participants with distant metastasis who undergo complete resection will receive 17 cycles (up to ~1 year) of pembrolizumab but can receive up to 35 cycles (up to ~2 years) of pembrolizumab under certain circumstances.
9478313|NCT03553836|Placebo Comparator|Placebo|Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of placebo and experience disease recurrence may be eligible to receive pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for disease that cannot be resected or metastatic disease.
9478316|NCT03553784|Experimental|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
9478317|NCT03553784|No Intervention|Control Group|No intervention.
9478318|NCT03553745|Experimental|Gentle Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
9478319|NCT03553745|Experimental|Rigorous Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
9478320|NCT03553745|Experimental|Cardiovascular Exercise Program|Program will meet twice a week for a 10-week period. Participants will be a part of cardiovascular exercise sessions led by instructors specializing in the area.
9478321|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
9478322|NCT03553693|Experimental|Intervention Clinics|RAPID-VL study intervention testing and counseling package, which includes near point-of-care viral load (VL) testing at local testing hubs, structured VL counseling, forms to track VL ordering and testing, with feedback and performance evaluations at regular intervals.
9478323|NCT03553693|No Intervention|Control Clinics|Standard of care VL testing and counseling procedures consistent with country guidelines.
9478324|NCT03553680|Experimental|Emotion-Focused CBT|Ten CBT sessions with a therapist.
10021911|NCT03511209|Experimental|CBTI plus Taper method A|Participants in this arm will receive CBTI plus the novel hypnotic tapering method.
10021912|NCT03511209|Active Comparator|CBTI plus Taper method B|Participants in this arm will receive CBTI plus the usual tapering method used by the VA.
10021913|NCT03508570|Experimental|Group I (nivolumab)|Patients receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
10021914|NCT03508570|Experimental|Group II (nivolumab and ipilimumab)|Patients receive nivolumab as in group I and ipilimumab i.p. on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
10021915|NCT03504397|Experimental|Arm A (zolbetuximab plus mFOLFOX6)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
9802786|NCT04942535|Active Comparator|Control|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive Daily Performance Feedback during the 12 month intervention and 6 month follow up."
9802787|NCT04937959||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
10021916|NCT03504397|Placebo Comparator|Arm B (Placebo plus mFOLFOX6)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
10021917|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
10021918|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
10021919|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
10021920|NCT03500549|Experimental|Pegcetacoplan|1080 mg pegcetacoplan administered subcutaneously twice-weekly or every three days.
10021921|NCT03500549|Active Comparator|Eculizumab|Complement (C5) Inhibitor.
10021922|NCT03498001|Experimental|Patients|
10021923|NCT03496181||Bilingual Participants with Glioma|"Bilingual (English and Spanish speaking) patients will be recruited from the clinical service of the Department of Neurosurgery of MSK. All patients on the Neurosurgery service scheduled to undergo a resection of a tumor in or adjacent to the primary language areas will be screened to participate in this study.~The study will be performed in concert with patient's regularly scheduled clinical care for his/her brain tumor. Clinical care (which will be performed whether or not the patient participates in the current study) will include: 1) pre-operative routine (anatomical) MRI and fMRI, 2) the surgery to remove the tumor, 3) intra-operative cortical stimulation to identify the essential motor and/or language areas. It should be stressed that neither the brain tumor surgery, nor the intra-operative cortical mapping will be changed in any way from routine practice."
10021924|NCT03496181||Healthy Volunteers|Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
10037527|NCT01825915|Active Comparator|Laparoscopic Supracervical Hysterectomy|Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
10037528|NCT01825928|Experimental|paliperidone|paliperidone arm,3mg/pill,3mg/day.last84 days.
9478325|NCT03553680|No Intervention|Wait List|Three visits for assessments only over the same time period of the Experimental Arm.
9478326|NCT03553667|Active Comparator|Standard group|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
10021925|NCT03495557|Sham Comparator|Control|Simple closure
10021926|NCT03495557|Experimental|Experimental|Simple closure + mesh
10021927|NCT03495427|Experimental|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
9478327|NCT03553667|Experimental|ClearSight|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
10021928|NCT03494049|Active Comparator|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
10021929|NCT03494049|Active Comparator|Standard HoLEP|Standard HoLEP TECHNIQUE as described by Elhilali et al 2010
10021930|NCT03490201|Active Comparator|Randomized - Control|
10021931|NCT03490201|Active Comparator|Randomized - Treatment|
9478328|NCT03553654|Experimental|CT monitoring arm|18-75 year old patients with newly-diagnosed cancer, scheduled to undergo anthracycline-based chemotherapy.
9478329|NCT03553628|Active Comparator|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
10021932|NCT03490201|Experimental|Non-randomized - Treatment|
10021933|NCT03486899|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection.
10021934|NCT03486899|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection.
10021935|NCT03486899|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection.
10021936|NCT03486899|Placebo Comparator|Placebo|Administered by subcutaneous injection.
10021937|NCT03482791|Experimental|Arm 1: Resectable (proton beam therapy)|"Proton beam therapy: total dose of 50 or 50.4 Gy~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~Surgery should ideally be performed no later than 8 to 10 weeks after completing chemoradiation~Patient-reported outcome measures (PROs) performed at several time points"
10037529|NCT01825928|Placebo Comparator|placebo|placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
9478330|NCT03553628|Active Comparator|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
9478331|NCT03553628|Experimental|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
10021938|NCT03482791|Experimental|Arm 2: Unresectable (proton beam therapy)|"Proton beam therapy: total dose of 59.4 or 60 Gy~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~Patient-reported outcome measures (PROs) performed at several time points"
10021939|NCT03481738||PKD Diagnosed|Participants diagnosed with PK deficiency by the presence of 2 or more PKLR gene mutations as well as clinical features.
10021940|NCT03481608|Active Comparator|Olive Oil Shake|"Intervention: No Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
10021941|NCT03481608|Experimental|Coconut Oil Shake|"Intervention: Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
10021942|NCT03480217|Experimental|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
10021943|NCT03480217|No Intervention|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
10021944|NCT03477500|Experimental|HSCT (Cyclophosphamide and ATG)|"Day 1: Cyclophosphamide 2.0 g/m2 body surface area Days 5-10: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight/day sc.~Day 11 and until apheresis is discontinued: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight x 2 sc/day.~HSCT days -5 to -2: Cyclophosphamide 50 mg/kg/day. HSCT days -5 to -1: Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be given iv on days -3,-2 and -1 over 10 hours.~HSCT day 0: Reinfusion of a minimum of 3,0 x 106 CD 34+ cells/kg body weight."
9478332|NCT03553628|Experimental|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
9478333|NCT03553615|Experimental|Oral treatment|12mg oral ivermectin treatment taken once a week for four weeks
9478334|NCT03553602|Experimental|HDR Brachytherapy + EBRT + STAD|"Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions.~6 months hormonal therapy(LHRH agonist and antiandrogen [until the end of radiotherapy])"
9478335|NCT03553589||Cases|Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
9478336|NCT03553589||controls|Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
9478337|NCT03553537|Experimental|Decitabine + CHOP regimen|decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles
9478338|NCT03553537|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles
9478339|NCT03553524|Experimental|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
9478340|NCT03553524|Experimental|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
9478341|NCT03553511|Experimental|Uterosacral ligaments suspension|Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.
9478342|NCT03553511|Active Comparator|McCall culdoplasty|Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.
9478343|NCT03553485|Experimental|taVNS|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
9478344|NCT03553485|Sham Comparator|Control|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
9478345|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
9478346|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
9478347|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
9478348|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
9478349|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
9478350|NCT03553472||Vedolizumab therarpy|12 IBD patients on vedolizumab maintenance therapy every 4-8 weeks
9478351|NCT03553472||Prednisone and Anti-TNF therapy|12 IBD patients on Anti-TNF maintenance therapy as combination or mono therapy along with at least 10mg of prednisone
10037530|NCT01825967||Acute Diverticulitis|We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
10037531|NCT01825993|Experimental|PCA endovenous|1mg/10 min Morphine
9478352|NCT03553459|Experimental|Trendelenburg Maneuver|Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
9478353|NCT03553446|Experimental|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
9478354|NCT03553433|Experimental|Verum|Apremilast 30mg bd
9478355|NCT03553433|Placebo Comparator|Placebo Oral Tablet|Excipiens
9478356|NCT03553407|Experimental|Low Level Laser - Pulse|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm², 25 Hz
10021945|NCT03477500|Active Comparator|Alemtuzumab|Alemtuzumab 12 mg iv daily on 5 consecutive days at first alemtuzumab treatment cycle, followed by 3 consecutive days at the second alemtuzumab treatment cycle 12 months later.
10021946|NCT03475888|Active Comparator|Group A|Patients who have undergone a successful percutaneous CTO recanalization
10021947|NCT03475888|Active Comparator|Group B|Patients who have undergone a failed percutaneous CTO recanalization
10021948|NCT03475888|Active Comparator|Group C|Patients with an untreated CTO
10021949|NCT03475186|Experimental|Ramipril|Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
10037532|NCT01825993|Active Comparator|PERIDURAL CATHETER|Peridural L-bupivacaine 0.25%
9802788|NCT04937959||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
10021950|NCT03474159|Other|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
10037533|NCT01825993|Active Comparator|TANSABDOMINAL BLOCK (TAP)|L-BUPIVACAINE im
10037534|NCT01826006|Active Comparator|Excimer laser|After wire crossing, Excimer Laser will be performed. Consequently, intracoronary adenosine will be selectively administered through the guiding catheter.
10021951|NCT03473483|Experimental|SREC only or cigarette only use|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; pharmacokinetic (PK) blood draws; ad libitum use of product; cardiovascular (CV) monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
9478357|NCT03553407|Experimental|Low Level Laser - continuous|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm²
9478358|NCT03553407|Placebo Comparator|Low Level Laser - Placebo|In this group the patient will receive the protocol with the equipment turned off.
9478359|NCT03553394|Active Comparator|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
9478360|NCT03553394|No Intervention|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
9478361|NCT03553381||obese without MS|BMI 25- 35 Kg/mq without metabolic syndrome (MS) submitted to hypocaloric balanced diet
9478362|NCT03553381||obese with MS|BMI 25- 35 Kg/mq with metabolic syndrome submitted to hypocaloric balanced diet
9478363|NCT03553368|Experimental|Step 1: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will be acquired without the use of HF-NIV, as a reference (MR)."
9478364|NCT03553368|Experimental|Step 2: Patients (arm A)|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard."
9478365|NCT03553368|Experimental|Step 2: Patients (arm B)|"Experimental intervention:~PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold).~Control intervention:~Data from the clinically indicated PET/CT acquisition will be used as reference.~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available."
9478366|NCT03553368|Experimental|Step 1 bis: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of CPAP (CPAP-MR).~Control intervention:~MRI data will be acquired without the use of CPAP, as a reference (MR)."
9478367|NCT03553355|Experimental|Infrared Laser Moxibustion Therapy|Each patient will receive this treatment twice per week for six weeks (12 sessions total).
9478368|NCT03553355|Sham Comparator|Sham Infrared Laser Moxibustion Therapy|The patients will receive treatment from sham laser moxibustion instrument.
9478369|NCT03553355|No Intervention|Waitlist Controls|The patients maintain their usual treatment and self-care,
9478370|NCT03553342|Experimental|Corticoids|
9478371|NCT03553342|Placebo Comparator|Placebo|
9478372|NCT03553316|Experimental|Sequence (1)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~Investigators Products(IPs) for Period1: A (Single)= PK101-002~IPs for Period2: B (Combination)= PK101-001, PK101-002"
9478373|NCT03553316|Experimental|Sequence (2)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~IPs for Period1: B (Combination)= PK101-001, PK101-002~IPs for Period2: A (Single)= PK101-002"
9478374|NCT03553303|Experimental|Intervention|Increasing doses of Sacubitril/Valsartan
9478375|NCT03553290|Sham Comparator|control|Mechanical debridement alone
9478376|NCT03553290|Active Comparator|lower-level laser Therapy|"Mechanical debridement with lower-level laser therapy~Device: A.R.C. FOX Laser-FOX Q-810nm Mechanical debridement with lower-level laser therapy"
9478377|NCT03553277|Experimental|Transfluthrin|transfluthrin
9478378|NCT03553277|Placebo Comparator|Placebo|inert ingredients
9478379|NCT03553264|Experimental|Head Mounted Device|"In addition to the Vestibular Rehabilitation protocol, each HMD group patient will perform Virtual Reality Rehabilitation by means of the game protocol Track Speed Racing 3D uninterruptedly for 20min/day, while sitting on a chair or sofa, after the smartphone accommodation into the HMD 'Revelation' 3D VR Headset. The game consists of a point-of-view race in which the car is steered from the cockpit by tilting the head to the left and to the right to avoid swerving off the road and to achieve all the goals before finishing the lap. During this real car experience, the visual background and the scenario change perspective according to the patients' left or right tilted head movements, possibly emulating eye-head exercises that induce visual-vestibular conflicts."
9665277|NCT05114655|Experimental|Intervention 2|Participants apply a light, citrus-based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
9665278|NCT05114655|Placebo Comparator|Placebo|Participants apply an inert blend including fractionated coconut oil to the jawline three times each day for 7 days.
10021952|NCT03473483|Experimental|Alternate product from Arm 1|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
10021953|NCT03473483|Experimental|Standardized Dual Use|Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
10021954|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
10021955|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
10021956|NCT03469960|Active Comparator|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
10021957|NCT03469960|Experimental|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
10021958|NCT03463018|Experimental|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
10021959|NCT03463018|Placebo Comparator|Placebo|Identical excipients as in the experimental arm, without the active ingredient
10021960|NCT03456700|Experimental|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
10021961|NCT03456453|Experimental|NIDA Standard via Facebook|30 participants will receive the NIDA Standard via Facebook
10021962|NCT03456453|No Intervention|Re-entry services as usual|30 participants will receive re-entry services as usual
10021963|NCT03456271||fracture group|
10021964|NCT03456271||non-fracture group|
10021965|NCT03455270|Experimental|Part 1: Dose Escalation (G1T48)|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
10021966|NCT03455270|Experimental|Part 1: Food Effect Cohort (G1T48)|"In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
10021967|NCT03455270|Experimental|Part 2: Monotherapy Dose Expansion (G1T48)|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
10021968|NCT03455270|Experimental|Part 3: Combination Dose Expansion (G1T48+palbociclib)|Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.
10037535|NCT01826006|Active Comparator|Manual Thrombus Aspiration|After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary adenosine will be selectively administered.
10021969|NCT03454165|Experimental|Single Arm|Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
10021970|NCT03447509|Active Comparator|Experiment 1a|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
9478380|NCT03553264|Active Comparator|Vestibular Rehabilitation|Patients will be actively involved in adapting the exercise program to suit their symptoms, capabilities, and lifestyle. Following previous protocols, the home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises, and all chronic unilateral vestibular hypofunction patients will be seen twice a week for 4 weeks for 30-45 min and monitored for adherence. Between supervised sessions, patients will perform a twice-daily home exercise program for a total of 30-40min/day.
9665280|NCT05114564|Experimental|Lens A (Test)|Subjects will be randomized to wear test lenses for one month and then cross over to wear control lenses for one month.
9665281|NCT05114564|Active Comparator|Lens B (Control)|Subjects will be randomized to wear control lenses for one month and then cross over to wear test lenses for one month.
10021971|NCT03447509|Active Comparator|Experiment 1b|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
10021972|NCT03447509|Active Comparator|Experiment 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and/or acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
10021973|NCT03445559|No Intervention|Control|No intervention
10021974|NCT03445559|Experimental|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
10021975|NCT03442465||Regenerative Osseous Surgery|Participants undergoing osseous reconstructive surgery (RegOS) for bone sarcoma. Study visits for post-op assessments will be annually after month-36.
10021976|NCT03442465||Other Reconstructive Surgery|Participants undergoing other reconstructive surgery for bone sarcoma. Study visits for post-op assessments will be annually after month-36.
9802789|NCT04937959||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9665282|NCT05113212|Active Comparator|Control arm|patients aﬀected by macular pucker or macular hole, whose internal limiting membrane peeling is performed using a traditional optical microscope (Leica F40)
9665283|NCT05113212|Experimental|Experimental arm|patients aﬀected by macular pucker or macular hole whose internal limiting membrane peeling is performed by 3D heads-up microscopy system (NGenuity 3D)
10021977|NCT03441776|Other|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
10021978|NCT03441776|Other|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
10021979|NCT03439228|Experimental|Brace|Lumbar brace wear prescribed for 3 months post-operation
10021980|NCT03439228|No Intervention|No brace|No lumbar brace prescribed
10021981|NCT03438838|Active Comparator|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
10021982|NCT03438838|Active Comparator|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
10021983|NCT03435185|Active Comparator|Blockade Group|Lidocaine injections. Procedure. Grater occipital nerve and supraorbital nerve were blocked with %2 lidocaine. These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
10021984|NCT03435185|Placebo Comparator|Placebo Group|Saline injections. Procedure. Grater occipital nerve and supraorbital nerve were injected with saline.These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
10021985|NCT03432494|Experimental|Study Arm 1|Subjects undergoing transcaval access for TAVR
10021986|NCT03432364|Experimental|ST-400 Investigational product|ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
10021987|NCT03430882|Experimental|Treatment (sapanisertib, paclitaxel, carboplatin)|Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10021988|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
10021989|NCT03427411|Experimental|1/Arm 1-M7824 1,200 mg intravenous (IV) once every 2 weeks|M7824 at a flat dose of 1,200 mg intravenous (IV) once every 2 weeks
10021990|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
10021991|NCT03423069|Experimental|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
10021992|NCT03423069|Active Comparator|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
10021993|NCT03421353|Experimental|Arm A1|Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every four weeks (Q4W). There will be a 1 week AZD9150 lead-in prior to durvalumab dosing.
10021994|NCT03421353|Experimental|Arm A2|Patients will receive AZD9150 once weekly (QW) + durvalumab every three weeks (Q3W) + Cisplatin on Day 1 + 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
10021995|NCT03421353|Experimental|Arm A3|Depending on the results of Arm A2, Arm A3 may not be conducted. If Arm A3 is conducted, patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + cisplatin on Day 1 + 5-flourouracil (5-FU) over Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
9518168|NCT03299231|Active Comparator|Aerobika|Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
10021996|NCT03421353|Experimental|Arm A4|"Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + gemcitabine on Days 1 and 8. This regimen will be repeated every 3 weeks. In addition, the following will be added to the regimen:~For cisplatin-eligible patients: cisplatin on Day 1 (every 3 weeks for up to 12-18 weeks); or~For cisplatin ineligible patients: carboplatin on Day 1 and Day 8 (every 3 weeks for up to 12-18 weeks).~There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing."
10021997|NCT03421353|Experimental|Arm A5|Patients will receive AZD9150 every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus carboplatin on Day 1 plus nab-paclitaxel on Days 1, 8, and 15 (every 3 weeks for up to 12-18 weeks). There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
10021998|NCT03421353|Experimental|Arm D: AZD9150 SC|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
10021999|NCT03421353|Experimental|Arm D: AZD9150 IV|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
9518169|NCT03299231|Sham Comparator|Sham device|Group of participants using the same looking device which is devoid from nebulizer port valve so it is not functioning (sham device). The sham arm is a control arm. It will be used as the active comparator three times daily for 10 to 20 minutes according to subject's effort
9518170|NCT03299218|No Intervention|Control|Receiving current Government of Punjab health services
9802790|NCT04937959||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9802791|NCT04934722|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab intravenously (IV) every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
9802792|NCT04934722|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
9802793|NCT04932759|No Intervention|control group|In the control group there will be no music listening
9802794|NCT04932759|Experimental|experimental group|In this group patients will listen to music while their dental treatments are being made.
10022000|NCT03417349||Aspiration thrombectomy|Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
10022001|NCT03415620|Experimental|Music listening|"Phase 1: Before and after surgery, 300 patients will be offered an ipod with earphone, in which the ipod is equipped with saved playlist of different music genres to select from pre-determined lists of music of different genres or patient choice. Patient will choose the desired playlist and listen to the music for about 30 minutes. Hospital Anxiety and Depression Scale (HADS) score, pain scores, analgesia usage, patient satisfaction, and quality of life measurement will be collected. Analysis of the type of music, duration of music listening, and the genre chosen will be analysed.~Phase 2: Ninety women undergoing Caesarean delivery assigned to experimental (music listening) group will listen to the music before, during and after surgery. Pain and psychological assessments and demographic data collection will be conducted before and after surgery."
9478381|NCT03553238|Experimental|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
9478382|NCT03553225|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsules regimen (1g)
9478383|NCT03553225|Active Comparator|Concord Grape Extract 1|1 g Concord Grape Extract in 2 capsules
9478384|NCT03553225|Active Comparator|Concord Grape Extract 2|500 mg Concord Grape Extract in 2 capsules
9478385|NCT03553212|Experimental|High dose external beam Radiotherapy|Image-guided tomotherapy
9478386|NCT03553199|Experimental|TRS|TRS, Tissue resection system
9478387|NCT03553186|Experimental|ivTXA + topical TXA|"TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
9518171|NCT03299218|Experimental|Cash-based transfers|Cash-based transfers only by BISP
9518172|NCT03299218|Experimental|Cash with SBCC|Cash-based transfers and Social & behaviour change communication (SBCC)
9518173|NCT03299218|Experimental|Cash with SNF (Wawamum)|Cash-based transfers and SNF (Wawamum)
10022002|NCT03415620|No Intervention|No Music Listening|Phase 2: Patients assigned to this group (n=45) will only have pain, psychological assessments and demographic data collection conducted before and after surgery.
10022003|NCT03414684|Experimental|Carboplatin + Nivolumab|"Nivolumab is administered every three weeks intravenously~Nivolumab dosage is 360mg~Carboplatin is administered every three weeks intravenously~Carboplatin dosage is pre-determined by the PI"
10022004|NCT03414684|Experimental|Carboplatin|"Carboplatin is administered every three weeks intravenously~Carboplatin dosage is pre-determined by the PI"
10022005|NCT03411889|Experimental|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
10022006|NCT03410342|Placebo Comparator|Low Fruits and Vegetables (LFV)|"1 portion of fruits plus 1 portion of vegetables, of commonly consumed types per day.~Intakes are at 25th percentile of UK consumption (NDNS) and will exclude citrus fruits, cruciferous and allium vegetables."
10022007|NCT03410342|Experimental|High Fruits and Vegetables (HFV)|4 portions of fruits plus 4 portions of vegetables, of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
10022008|NCT03410342|Experimental|High Citrus fruits and Cruciferous vegetables (CC)|4 portions of citrus fruits plus 4 portions of cruciferous vegetables per day excluding any other types of fruits and vegetables including allium vegetables.
10022009|NCT03408574|Experimental|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
10022010|NCT03408574|Experimental|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
10022011|NCT03408119|Experimental|Group A|100g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
10022012|NCT03408119|Experimental|Group B|50g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
10022013|NCT03408119|Placebo Comparator|Group C|800 IU vitamin D and 450 mg elemental calcium
10022014|NCT03407716|Experimental|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
10022015|NCT03407716|Placebo Comparator|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
10037536|NCT01826019|Experimental|Intervention|Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm [precise formulations used may differ in each country]; use of treatment supporters to reinforce adherence.
9518174|NCT03299218|Experimental|Cash,SNF (Wawamum) & SBCC|Cash-based transfers, SNF (Wawamum) and SBCC
10037537|NCT01826019|Other|Control - Usual Care|Participants in control communities will be referred to usual care.
9518175|NCT03299205|Experimental|Exercise|Aerobic exercise program using treadmill.
9478388|NCT03553186|Placebo Comparator|IV TXA + topical placebo|"Placebo solution (200 cc sterile normal saline + placebo TXA ampule (normal saline) (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
9478389|NCT03553173|Active Comparator|Control|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.~Prescribed treatments:~Bupropion pills + Psychological advice~Varenicline pills + Psychological advice"
9478390|NCT03553173|Experimental|Intervention|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.~Prescribed treatments:~Bupropion pills + Psychological advice + So-Lo-Mo~Varenicline pills + Psychological advice + So-Lo-Mo"
9478391|NCT03553160|Other|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
9478392|NCT03553147|Experimental|Group/Cohort 1|all patient SARC-F score, handgrip test and impedancemetry
9478393|NCT03553121|Active Comparator|Walk preoperativelying|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
9478394|NCT03553121|Active Comparator|not walking preoperatively|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will not walk preoperatively.
9478395|NCT03553108|Experimental|Olaparib Treatment Sequence ABCD|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg"
9478396|NCT03553108|Experimental|Olaparib Treatment Sequence BDAC|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg"
9478397|NCT03553108|Experimental|Olaparib Treatment Sequence CADB|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg"
9478398|NCT03553108|Experimental|Olaparib Treatment Sequence DCBA|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg"
9478399|NCT03553082|Active Comparator|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
9478400|NCT03553082|Active Comparator|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
9478401|NCT03553056|Experimental|Intervention|NZ Step Away app
9478402|NCT03553056|Active Comparator|Control|Modified NZ Step Away app
9478403|NCT03553043|Experimental|Energy Label 1|Alcoholic beverage displayed with Energy label 1
9478404|NCT03553043|Experimental|Energy Label 2|Alcoholic beverage displayed with Energy Label 2
9478405|NCT03553043|Experimental|Energy Label 3|Alcoholic beverage displayed with Energy Label 3
9478406|NCT03553043|Placebo Comparator|Unlabelled|Alcohol beverage displayed unlabelled.
9478407|NCT03553030||prediabetics|patients with diagnosed of prediabetes.
9478408|NCT03553030||normo glycemics (controls)|patients without diagnosed of prediabetes.
9518176|NCT03299192|Experimental|Tai Chi|twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
9518177|NCT03299192|Active Comparator|Health Education|twice weekly classes for 12 weeks
10022016|NCT03402945|Active Comparator|Arm 1|"cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day"
10022017|NCT03402945|Active Comparator|Arm 2|"cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days."
10022018|NCT03402945|Active Comparator|Arm 3|"cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
10022019|NCT03402945|Active Comparator|Arm 4|"cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
10022020|NCT03400137|Active Comparator|Healthy Volunteers|No family history (first degree relative) of glaucoma.
10022021|NCT03400137|Active Comparator|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness < 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
10022022|NCT03400137|Active Comparator|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
10022023|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Intravenous (IV)|Participants will receive IV infusion of Talquetamab at minimum anticipated biologic effect level (MABEL)-based starting dose until the completion of the end of treatment visit. Subsequent dose levels will be selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data.
10022024|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Subcutaneous (SC)|Participants will receive Talquetamab SC. The dose levels will be selected to identify safe and tolerable putative RP2D(s).
10022025|NCT03399799|Experimental|Part 2: Dose Expansion (Talquetamab)|Participants will receive IV infusion or SC injection of Talquetamab at each putative recommended Phase 2 dose(s) (RP2D[s]) as determined in Part 1.
10022026|NCT03398655|Experimental|Arm 1|VB-111 + Paclitaxel
10022027|NCT03398655|Active Comparator|Arm 2|Placebo + Paclitaxel
10022028|NCT03390322|Experimental|Duodenal Glycemic Control™|
10022029|NCT03387150|Experimental|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
10022030|NCT03387150|Experimental|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
10022031|NCT03387150|Experimental|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
10022032|NCT03387150|Experimental|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
10022033|NCT03387150|Experimental|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
10022034|NCT03387150|Experimental|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
10022035|NCT03387150|Placebo Comparator|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
10022036|NCT03385577|Experimental|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
10022037|NCT03383458|Experimental|Arm A|
10022038|NCT03383458|Placebo Comparator|Arm B|
10022039|NCT03383380|Experimental|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
10022040|NCT03382249|Placebo Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
10022041|NCT03382249|Experimental|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
10022042|NCT03375489|Experimental|Telehealth|"Patients will meet with the PC clinician in person within four weeks of enrollment~Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks~Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
10022043|NCT03375489|Active Comparator|In Person PC|"Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic~PC visits will be scheduled on the same day as an oncology visit if possible"
10022044|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
9478409|NCT03553017||Participants with eye disease|A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
10022045|NCT03373097|Experimental|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
10022046|NCT03370133|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
10022047|NCT03370133|Active Comparator|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
10022048|NCT03370133|Placebo Comparator|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
10022049|NCT03366792|Experimental|MRI Targeted Biopsy|
10022050|NCT03366337|Experimental|Bardoxolone Methyl - ADPKD|Participants with autosomal polycystic kidney disease (ADPKD) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
9478410|NCT03553004|Experimental|Niraparib Treatment|"Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)~(Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) [169.756 pounds (lbs)] or baseline platelet count is less than 150,000 microliters (µL))."
9518178|NCT03299192|Active Comparator|Usual Medical Care|the usual care to which participants are entitled by their health insurance
10022051|NCT03366337|Experimental|Bardoxolone Methyl - IgAN|Participants with IgA nephropathy (IgAN) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
10022052|NCT03366337|Experimental|Bardoxolone Methyl - T1D|Participants with Type 1 diabetes (T1D) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
10022053|NCT03366337|Experimental|Bardoxolone Methyl - FSGS|Participants with focal segmental glomerulosclerosis (FSGS) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
10022054|NCT03358303|Experimental|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
10022055|NCT03358303|No Intervention|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
10022056|NCT03358030|Placebo Comparator|Placebo|Participants receive placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
10022057|NCT03358030|Experimental|Cohort A: ISIS 416858, 200 mg|Participants receive ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
10022058|NCT03358030|Experimental|Cohort B: ISIS 416858, 250 mg|Participants receive ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
9478411|NCT03552991|Other|Agio arm|It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.
9478412|NCT03552978|Experimental|Tech-facilitated IC intervention|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.~Receive 8 video or telephone counseling sessions for smoking cessation. The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min.~Be asked to use the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation.~Be asked to use the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The Covita mobile app (compatible with iOS and Android) is used with the iCO Smokerlyzer to display CO readings."
10022059|NCT03358030|Experimental|Cohort C: ISIS 416858, 300 mg|Participants receive ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
10022060|NCT03350997|Experimental|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
10022061|NCT03350997|Experimental|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
10022062|NCT03348020|Experimental|Baseline Clinical Trial|Before blood donation, subjects will participate in a baseline clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
10022063|NCT03348020|Experimental|Post-Blood Donation Clinical Trial|1 month after blood donation, subjects will participate in post-blood donation clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
9518179|NCT03299153|Experimental|Intervention group|patients in this group were received 200 ml/d barberry juice for tow month
9518180|NCT03299153|No Intervention|control group|patients in this group received no intervention
9518181|NCT03299140|Other|Family Focused Therapy|Only 1 arm
10022064|NCT03346343|Experimental|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
10022065|NCT03344666|Experimental|First Treatment|Participants will be randomized to first treatment to compare Brief Intervention + Health Coach (Step 1 Treatment BI+HC) to Brief Intervention + Text Messages (Step 1 Treatment BI+TM). Participants in the BI+HC will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks. Participants in the BI+TM will receive a BI in the ED, followed by daily TMs for 4 weeks.
10022066|NCT03344666|Experimental|Second Treatment for Responders and Non-Responders|"Beginning in week 5, all participants will be classified as Responders or Non-Responders (based on weekly assessments) and re-randomized.~Step 2 Treatment Responders: Responders will be randomized to either stay the course or be stepped down. Specifically, participants in the BI+HC will either continue to receive the HC or stepped down to receive a control brochure; participants in the BI+TM will either continue to receive the TM or stepped down to receive a control brochure.~Step 2 Treatment Non-Responders: Non-Responders will be randomized to either stay the course or be stepped up. Specifically, participants in the BI+HC will either continue to receive the HC or stepped up to receive a HC+; participants in the BI+TM will either continue to receive the TM or stepped up to receive HC."
10022067|NCT03342053|Experimental|RO7234292 Monthly|RO7234292 is administered every 28 days intrathecally for 14 months.
9518182|NCT03299127|Experimental|imagery rescripting|bibliotherapy, intervention is provided by pdf-manual (either short or long version, i.e. 2 active arms, each 1/3 of sample receives either short or long version)
9518183|NCT03299127|No Intervention|wait-list control|wait-list control, participants receive intervention manual upon completion of post-assessment (1/3 of sample)
10022068|NCT03342053|Experimental|RO7234292 Bimonthly|RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.
10022069|NCT03340454|Active Comparator|Health systems-level intervention|using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;
10022070|NCT03340454|Active Comparator|CHW-led patient navigation program|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability
10037538|NCT01826032|Experimental|CPAP|"Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.~This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling."
10022071|NCT03331341|Experimental|Treatment (APVD)|"PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles."
10022072|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
10022073|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
10022074|NCT03330847|Active Comparator|Olaparib monotherapy|All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
10022075|NCT03330847|Active Comparator|Olaparib+Ceralasertib|All randomized patients will receive Olaparib 300 mg twice daily+Ceralasertib 160 mg once daily (OD).
10022076|NCT03330847|Active Comparator|Olaparib+adavosertib|All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
10037539|NCT01826032|Active Comparator|Standard care for OSA|Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
9518184|NCT03299114|Active Comparator|Intervention Group|Treated with warm whirlpool
9518185|NCT03299114|Placebo Comparator|Placebo group|Treated with sham whirlpool
10037540|NCT01826045|Experimental|Poly-gamma Glutamic Acid|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
10022077|NCT03325777|Experimental|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
10022078|NCT03325777|Sham Comparator|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
9478413|NCT03552978|Active Comparator|Treatment as usual (VA Quitline)|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.~Receive weekly proactive telephone sessions through the VA telephone Quitline, a proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor."
9478414|NCT03552965|Active Comparator|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
9478415|NCT03552965|Active Comparator|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
9478416|NCT03552952||Preterm infants|100 preterm infants
9478417|NCT03552952||Term infants|100 term healthy infants
9478418|NCT03552913||2015 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2015
9478419|NCT03552913||2017 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2017
9478420|NCT03552913||2015 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2015
9478421|NCT03552913||2017 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2017
9478422|NCT03552900|Active Comparator|App 1 Study group (7cups)|"Participants assigned to this group will be assigned a behavioral intervention, the mobile app (7cups) which allows participants access to direct online social support via the app."
9478423|NCT03552900|Active Comparator|App 2 Study Group (Bliss|"Participants assigned to this group will be assigned to a behavioral intervention, the mobile app ( Bliss ) which provides participants an informational app about mental health resources at Harvard."
9478424|NCT03552887||Postoperative patients|Cohort of patients undergoing cardiac surgery, aged ≥ 18 years old, who had received any physiotherapy intervention
10022079|NCT03325439|Experimental|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
9478425|NCT03552874||Patient Group|Children whose ages between 5-10 years with Duchenne Muscular Dystrophy.
9478426|NCT03552874||Healthy Group|Healthy peers
9478427|NCT03552861|Active Comparator|left and right DLPFC active treatment|Intervention: repetitive transcranial stimulation (rTMS) Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface.
9478428|NCT03552861|Active Comparator|left DLPFC active and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
10037541|NCT01826045|Placebo Comparator|Placebo|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.
10037542|NCT01826058|Experimental|Stereotactic body radiation therapy|"SBRT in one to four fractions~Irradiated total RT dose to gross tumor volume (GTV) according to fraction size~1 fx: 16 to 24 Gy~2 fx's: 20 to 26 Gy~3 fx's: 21 to 30 Gy~4 fx's: 24 to 36 Gy"
10037543|NCT01826071|No Intervention|Symptomatic Treatment|
10037544|NCT01826071|Experimental|Static Stretch|Home exercise program with static stretching
10037545|NCT01826071|Experimental|Active Elongation|Home exercise program with active elongation exercises
10037546|NCT01826097|Experimental|Vibration|Whole body vibration applied to a group of 20 bladder cancer patients.
10037547|NCT01826110|Experimental|[11C]PIB|[11C]PIB
9478429|NCT03552861|Active Comparator|left DLPFC sham and right DLPFC active treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
9478430|NCT03552861|Sham Comparator|left DLPFC sham and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks,the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
9478431|NCT03552848|Experimental|Mesenchymal stem cell|Patients in the MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.
9478432|NCT03552848|No Intervention|Control|Patients in the control arm will not be given MSC.
9478433|NCT03552835|Experimental|no caries removal|mandibular occlusal caries were treated with placement of stainless steel crown with no caries removal
9478434|NCT03552835|Experimental|partial caries removal upto soft dentin|mandibular occlusal caries were treated by partial caries removal upto soft dentin
9478435|NCT03552835|Experimental|partial caries removal upto firm dentin|mandibular occlusal caries were treated by partial caries removal upto firm dentin
9480984|NCT05129254|Experimental|Thulium laser (1927nm) and post-treatment topically administered platelet rich plasma (PRP)|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied autologous platelet rich plasma at monthly intervals for a total of 4 treatment. The total duration of laser application, venipuncture, PRP preparation, and topical administration will take approximately 30 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
9802795|NCT04931745|Experimental|Virtual Reality|The Oculus 2 headset will be used during port access. The device features a stereoscopic display mounted on a lightweight wireless head mounted display weighing 503 g with built-in 3D audio and an adjustable head strap and adjustable lens distance. The software used will be the Might Pebbles VR Game developed by ManageXR. It is a child-friendly VR game that does not require the use of hand controllers. It also provides an option to increase the cognitive load, making it appropriate for children of all ages. The experimental group will be given up to 10 minutes to familiarize themselves with the device, assisted by the research assistant and will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
9802796|NCT04931745|Active Comparator|Tablet|The child will watch a video on a tablet or iPad that is appropriate for their age during port access. They will begin using it 5-10 minutes prior to port access. The content of the video will be at the discretion of the child life specialist, nurse, or caregiver. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
10022080|NCT03323034|Experimental|Treatment (pevonedistat, temozolomide, irinotecan)|Patients receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan IV over 90 minutes on days 8-12 of cycle 1. Beginning cycle 2, patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, temozolomide PO daily on days 1-5, and irinotecan IV over 90 minutes on days 1-5. Treatment repeats every 28 days for cycle 1 and 21 days for subsequent cycles for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
10022081|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
10022082|NCT03314506|Experimental|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
9518186|NCT03299036|Experimental|Taiwan ACE Beads with doxorubicin|The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.
9480985|NCT05129254|Experimental|Platelet rich plasma injection|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with autologous platelet rich plasma injection at monthly intervals for a total of 4 treatment. The total duration of venipuncture, PRP preparation, and injection will take approximately 15 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
9480986|NCT05126823|Experimental|ACT face-to-face + app|Combines face-to-face ACT sessions with non-face-to-face activities and resources (mobile applications)
9480987|NCT05126823|Active Comparator|ACT face-to-face|face-to-face ACT sessions
9480988|NCT05126823|No Intervention|Waitlist|Waitlist group. After the second assessment of the two ACT groups (at post-treatment) this group will receive the face to face ACT intervention.
9478436|NCT03552809|Active Comparator|Conventional Frenectomy|For the conventional surgery, after application of local infiltration anesthesia of articaine HCL associated with epinephrine 1:100,000, the frenulum was grasped with a straight haemostat inserted into the depth of the vestibule; the tissue adjacent to the upper and lower surfaces of the haemostat was incised with a no.15 scalpel. After the diamond shaped resected portion of the frenulum was removed with the haemostat, muscle dilatations were excised on the submucosa of the lateral walls of the cavity. Horizontal incision was made on the periosteum with the help of a scalpel following the procedure. At the end of the operation, the wound was closed with absorbable sutures (4-0, Pegelak®, Doğsan Turkey).
9478437|NCT03552809|Experimental|Diode Laser Frenectomy|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
9478438|NCT03552809|Experimental|Laser Frenectomy with Incision|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenulum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum. Horizontal incision was made on the periosteum with the help of a scalpel, additionally. No sutures were necessary after procedure.
9478439|NCT03552783|Active Comparator|Fathers for a Lifetime (FFL) only|The participants in the comparison arm will receive the standard, 12-week program curriculum of Father For a Lifetime.
9478440|NCT03552783|Experimental|FFL + Cognitive Behavioral Therapy|The participants in the intervention will receive will the standard, 12-week program curriculum of Father For a Lifetime and the Cognitive Behavioral Therapy. The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP). In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program.
9480772|NCT05261282|Experimental|Mindful Hand Hygiene Intervention|"Participants in the Mindful Hand Hygiene Intervention will complete the same surveys as participants in the Control Arm at baseline, post-intervention, and 6-months post-intervention. Data will also be collected on baseline hand-hygiene rates during the habituation period, intervention period, and 3-12 months post-intervention. In addition, intervention participants will be asked to complete 3 mindfulness online educational modules and attend group-facilitated discussions on mindfulness. They will be offered the option of using a mobile application program Mindfulness Coach to enhance their mindfulness practices. A key message of the intervention is using hand hygiene as a prompt to practice mindfulness."
9480773|NCT05261282|No Intervention|Control Arm|Participants that are assigned to the control arm will be observed for hand hygiene adherence and duration during the habituation period, intervention period, and 3-12 months post-intervention. They will also be asked to complete study surveys at baseline, post-intervention and 6-months post intervention. They will not receive any of the intervention components.
9480774|NCT05261269|Experimental|Dose Escalation (DAN-222)|The starting dose of DAN-222 will be administered IV every week (QW) to subjects in the first cohort.
9480775|NCT05261269|Experimental|Dose Escalation (DAN-222 + niraparib)|The starting dose of DAN-222 will be administered IV every week (QW), in combination with daily oral niraparib.
9480776|NCT05261269|Experimental|Dose Expansion (DAN-222)|Single agent DAN-222 in HRD-positive or HRD-negative tumors.
9480777|NCT05261269|Experimental|Dose Expansion (DAN-222 + niraparib, HRD-positive)|Combination DAN-222 with niraparib in HRD-positive tumors.
9480778|NCT05261269|Experimental|Dose Expansion (DAN-222 + niraparib, HRD-negative)|Combination DAN-222 with niraparib HRD-negative tumors.
9480779|NCT05260398|Experimental|Mightier Now|8 weeks of use ad-libitum. Parents will be encouraged to have their children play Mightier games at least 3 times a week (totalling 45 minutes or more of play each week) for the 8-week duration.
9480780|NCT05260398|No Intervention|Mightier Later|8 weeks of wait list. Families in the Mightier Later condition will receive their Mightier shipment and will be encouraged to play Mightier after follow-up questionnaires have been completed 8 weeks after parents and teachers complete baseline questionnaires.
9480781|NCT05259956|Experimental|"3 plus 1 multidimensional exercise therapy"|The intervention consists of a Schroth-based exercise session and a manipulative therapy of pelvic asymmetry.
9480782|NCT05259956|Active Comparator|Schroth based scoliosis specific exercise|The intervention consists of the Schroth-based exercise session.
9480783|NCT05252962|Experimental|marine collagen peptide production process I|standardized to 10 g provided as single dose. Orally applied in water.
9480784|NCT05252962|Experimental|marine collagen peptide production process II|standardized to 10 g provided as single dose. Orally applied in water.
9480785|NCT05252962|Experimental|marine collagen peptide fish source I|standardized to 10 g provided as single dose. Orally applied in water.
9480786|NCT05252962|Experimental|marine collagen peptide fish source II|standardized to 10 g provided as single dose. Orally applied in water.
9480788|NCT05241522|Active Comparator|Tilmanocept Dose - 0.050 mg|
9480789|NCT05241522|Active Comparator|Tilmanocept Dose - 0.20 mg|
9478441|NCT03552770|Active Comparator|IVIBx1|Patients treated with a single intra-vitreous injection of bevacizumab (1.25 mg in 0.05 ml of solution) pro-re-nata repeated after monthly periodic monitoring of each patient
9478442|NCT03552770|Active Comparator|IVIBx2|Patients treated with two combined intra-vitreous injections of bevacizumab, (1.25 mg in 0.05 ml of solution) spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of each patient
9478443|NCT03552744|Experimental|Intervention group|
9478444|NCT03552744|No Intervention|Control group|
10022083|NCT03307356|Experimental|Uterine Transplantation|Women will undergo extensive medical and psychological screening. Five women that meet all inclusion and exclusion criteria will undergo ovarian stimulation, oocyte retrieval and will create embryos that will be stored for future use. Women will then undergo uterine transplantation from a donor. Following transplant women will be closely monitored for complications (including infection and rejection). If no complications arise, or complications that do arise can be treated, attempts at pregnancy will begin approximately 6 months after transplant. Pregnancy in the setting of uterine transplant requires directly placing embryos directly into the uterus.
9478445|NCT03552731||Subsequent|Patients who have been receiving chemotherapy more than once. A intervention survey will be administered.
9480790|NCT05241522|Active Comparator|Tilmanocept Dose - 0.40 mg|
10022084|NCT03307226|Experimental|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
9478446|NCT03552731||First Time|Patients who have been receiving chemotherapy first time. A intervention survey will be administered.
9478447|NCT03552718|Experimental|Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)|
9480989|NCT05115461||Radicular pain group|Patients presenting with lumbar radicular pain and MRI findings associated with radiculopathy
9478448|NCT03552705|Experimental|Tranexamic Acid|5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
9478449|NCT03552705|Placebo Comparator|Placebo|5-day course of placebo and intravenous saline during ACL reconstruction surgery
9478450|NCT03552679||LVAD recipients|Consecutive patients accepted for elective LVAD implantation in the context of routine care, will undergo routinely scheduled echocardiography before, within 1 week, 1 month, 3 months and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound machines that are capable of acquisition of two-, three-dimensional and Multiplane Echocardiography of the right ventricle. Invasive hemodynamic data will be collected in the perioperative period.
9478451|NCT03552666|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|A single oral dose of gummy vitamin D3 to monitor Vitamin D blood levels
9478452|NCT03552666|Active Comparator|Nature Made Vitamin D3 Tablet|A single oral dose of tablet vitamin D3 to monitor Vitamin D blood levels
9478453|NCT03552653|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|Single oral dose of gummy vitamin D3 to monitor vitamin D blood levels
9478454|NCT03552653|Active Comparator|Nature Made Vitamin D3 Tablet|Single oral dose of tablet vitamin D3 to monitor vitamin D blood levels
9478455|NCT03552627|Active Comparator|80% Oxygen|Patients will receive 80% oxygen throughout anaesthesia in accordance with current World Health Organisation Recommendations
9478456|NCT03552627|Active Comparator|55% Oxygen|Patients will receive 55% oxygen throughout anaesthesia in accordance with current UK clinical practice
9478457|NCT03552627|Experimental|30% Oxygen|Patients will receive 30% oxygen throughout anaesthesia in accordance with this research's hypothesis that lowering intraoperative oxygen concentrations may benefit patients
9478458|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
9478459|NCT03552601|Other|traditional speed|The target amount of every day's net negative fluid balance for the first three days is 1000mL.
9478460|NCT03552601|Other|faster speed|The target amount of every day's net negative fluid balance for the first three days is 1500mL.
9478461|NCT03552575|Experimental|Sacubitril/valsartan|24mg/26mg (dose level 1), 49mg/51mg (dose level 2) and 97mg/103mg (dose level 3) twice daily
9478462|NCT03552575|Experimental|Valsartan|40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.
9478463|NCT03552510|Active Comparator|Initial OPAMM|"At the start of the study, infants will receive mother's milk (to the maximum of 0.2 ml) to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for 24 hours.~Then, infants will receive regular gavage feeding only for the next 24 hours."
9478464|NCT03552510|Active Comparator|Initial Gavage|"At the start of the study, infants will receive regular gavage feeding only for 24 hours.~Then, infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for the next 24 hours."
9478465|NCT03552484|Active Comparator|Home Visit Arm|"Participants and their caregivers, when available, will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~[Completion of Home Visit Program]"
9478466|NCT03552484|Active Comparator|Usual Care Arm|"Participants and their caregivers, when available, will be asked to complete an initial online survey. Twelve months later, patients (and caregivers, if available) will be asked to complete an online follow-up survey.~[Completion of Usual Care/Online Survey]"
9478467|NCT03552458|Experimental|LR group|Lactobacillus Reuteri Oral Solution [BioGaia]
9478468|NCT03552458|Placebo Comparator|Placebo group|Placebos: The control agent will not contain the active agent
9478469|NCT03552445|Active Comparator|Tetanus-diphtheria (Td) and PCV13|
9478470|NCT03552445|Active Comparator|PCV13 alone|
9478471|NCT03552445|Active Comparator|Td alone|
9478472|NCT03552432|Experimental|Alirocumab therapy group|start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
9478473|NCT03552432|No Intervention|standard statin therapy group|start with only rosuvastatin 10mg per day
9478474|NCT03552419||Level Red|A level red refers to a case with an immediate threat to the life of the fetus or mother and may not be delayed under any circumstance.
9478475|NCT03552419||Level Orange|A level orange case requires the patient to arrive in the OR within 30 minutes from the time of decision with the approximate estimated time of arrival determined by the obstetrician.
9480990|NCT05115461||Control group|Age- and sex-matched control subjects without pain.
10022085|NCT03307226|Experimental|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)~Multiple Family Groups sessions focused on strengthening family relationships and mental health"
10022086|NCT03307226|No Intervention|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
9478476|NCT03552419||Level Yellow|A level yellow case requires operative intervention, but there is no maternal and/or fetal compromise at the time of evaluation. Timing to the OR is agreed upon by both the anesthesiology and obstetrical providers. The case may be delayed if a level red or orange case is identified. Possible
10022087|NCT03302520|Experimental|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
10022088|NCT03302520|Active Comparator|PEEK cage|PEEK cage for interbody fusion
10022089|NCT03301506|Experimental|Seladelpar 5 mg Capsules|
10022090|NCT03301506|Experimental|Seladelpar 10 mg Capsule|
9478477|NCT03552419||Level Green|A level green case is most dependent on the acuity of the OR suite and unit. The patient and/or fetus are stable with no threat to the health of either.
9478478|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 1)|1 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
9478479|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 2)|3 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
9478480|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 3)|5 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
9478481|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 4)|10 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
9478482|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 5)|20 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
10022091|NCT03301116|Experimental|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
9478483|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 1: Monotherapy)|ISU104 20 mg/kg to be administered every three weeks (Q3W) as monotherapy
10022092|NCT03301116|Active Comparator|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
10022093|NCT03300544|Experimental|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 4, 6, and 8. Patients receive 5-fluorouracil IV by bolus and over 46 hours, leucovorin IV bolus, and oxaliplatin IV over 2 hours on weeks 2 and 4. Patients also receive capecitabine orally PO BID followed by radiation therapy for 28 fractions on days 1-5 of weeks 8-13. Patients undergo resection surgery on weeks 21-25.
10022094|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
10022095|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
10022096|NCT03285789|Experimental|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
10022097|NCT03285789|Experimental|Dyslexics with normal visual attention span|
10022098|NCT03285789|Active Comparator|controls|
10022099|NCT03285139|Experimental|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
10022100|NCT03285139|Experimental|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
9802797|NCT04931745|Active Comparator|No or non-technologic distraction|This is no distraction or non-technologic distraction measures such as bubbles, etc., facilitated by the child life specialist, nurse, or caregiver during port access. The measure will be documented for the purposes of analysis. They will begin using it 5-10 minutes prior to port access. Most participants will receive topical anesthestic in the form of 4% amethocaine (Ametop), eutectic mixture of lidocaine and amethocaine (EMLA), or 4% lidocaine (Maxilene) as per standard practice at our institution. However, some participants may refuse this co-intervention.
9802798|NCT04931654|Experimental|Dose Escalation Part A: Non small cell lung cancer (NSCLC) Immuno-oncology (IO) acquired resistance|AZD7789 monotherapy
9478484|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 2: Combination therapy)|ISU104 20 mg/kg (or decreased dose) Q3W in combination with cetuximab* 250 mg/m2 QW (*Initial dose: 400 mg/m2)
9478485|NCT03552367|Experimental|Personalized structured exercise|"This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and personalized structured exercise prescription that will be offered on-site and online and monitored through the use of heart rate monitoring devices. The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters.~Intervention: Non-personalized non-structured exercise"
9478486|NCT03552367|Active Comparator|Non-personalized non-structured exercise|This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and non-personalized non-structured exercise prescription Intervention: Non-personalized non-structured exercise
9478487|NCT03552354|Experimental|Argatroban combined with antiplatelet|
9478488|NCT03552328|Experimental|Intervention|Seniors receiving daily meals from Meals on Wheels. Intervention: Lunch with Medical Student.
9478489|NCT03552328|Placebo Comparator|Control|Seniors receiving daily meals from Meals on Wheels
9478490|NCT03552315|Active Comparator|Water with amino acids and chromium|The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.
9478491|NCT03552315|Placebo Comparator|Carbonated water|The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.
9478492|NCT03552302||Cases|Yoga exercise for 12 weeks
9478493|NCT03552263|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 19 days."
9478494|NCT03552263|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 12 days followed by using four T89 capsules each time by oral administration twice daily for 7 days"
9478495|NCT03552263|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 19 days.
9478496|NCT03552250|Other|Parenting for Lifelong Health|"Parenting Programme Parenting for Lifelong Health for Young Children (PLH) for parents of children aged 2-9, 12 sessions"
9478497|NCT03552237|Experimental|dietary fiber intervention group|
9478498|NCT03552211||Patients treated with biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
9478499|NCT03552211||Control patients|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
9478500|NCT03552172||Prescription physical activity|
9478501|NCT03552172||No prescription for physical activity or suspension|
9478502|NCT03552159|Experimental|Behavioral Activation|For the first 4 weeks,participants received psychoeducation about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, t the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight bi-weekly behavioral activation sessions were administered, focusing pleasant event scheduling and effective communications.
9478503|NCT03552159|Active Comparator|Psychoeducation|For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
9478504|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
9478505|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
9802799|NCT04931654|Experimental|Dose Expansion Part B1: NSCLC IO acquired resistance|AZD7789 Monotherapy
10022101|NCT03285139|No Intervention|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
10022102|NCT03283241|Active Comparator|Zolidd One ExHex|Coated titanium implant
10022103|NCT03283241|Sham Comparator|One ExHex|Uncoated titanium implant
10022104|NCT03271034|Experimental|Baseline Lipedema characterization|Body composition and Fat distribution, adipose tissue biology, metabolic and immune function in women with Lipedema. Participants will receive a low-calorie diet therapy in the form of low calorie meals or shakes.
10022105|NCT03262909|Experimental|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
9478506|NCT03552133|Experimental|Smart CO2|Effects of rebreathe device over two sleep nights on sleep apnea, hypoxemia, sleep state, and blood pressure.
9478507|NCT03552133|No Intervention|No intervention|Effects of control night, i.e. no intervention on sleep apnea, hypoxemia, sleep state, and blood pressure.
9478508|NCT03552120|Experimental|Mindfulness-Oriented Recovery Enhancement|
9478509|NCT03552120|Active Comparator|Supportive Psychotherapy|
9478510|NCT03552107||Observational Group - Lorcaserin Treated|The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
10022106|NCT03262909|Other|Microfracture historical control arm|Microfracture historical control arm
10022107|NCT03261817|Experimental|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
9802800|NCT04931654|Experimental|Dose Expansion Part B2: NSCLC IO naive|AZD7789 Monotherapy
9802801|NCT04929249|Experimental|Inclisiran First|Inclisiran + usual care
9478511|NCT03552081|Experimental|fragmented DNA evaluation in blood and semen samples|20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking
9802802|NCT04929249|No Intervention|Usual Care|Usual care
9802803|NCT04926818|Experimental|ofatumumab - 20 mg injection/ placebo|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
10022108|NCT03261817|Sham Comparator|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
9478512|NCT03552042|Experimental|Counterclockwise Program|"Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to inhabit life in that era, making a psychological leap to be the person they were at the end of the 1980s."
9478513|NCT03552042|Active Comparator|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
9478514|NCT03552042|No Intervention|No-treatment control group|Non-treated participants will be assessed with the same timeline followed by the other groups. Participants will receive three coupons, for each assessment after the baseline (at T2, T3, and T4) for a two-night break in a location of their choice (among a selection of commercial services).
9478515|NCT03552029|Experimental|Part 1 - Quizartinib + Milademetan|Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
9478516|NCT03552029|Experimental|Part 2 - Cohort 1|Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
9478517|NCT03552029|Experimental|Part 2 - Cohort 2|Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
9478518|NCT03552016|Experimental|200 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 200 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
9478519|NCT03552016|Experimental|400 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 400 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
9478520|NCT03552016|Placebo Comparator|0 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 0 mg oral riboflavin (placebo) each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
10022109|NCT03261817|Active Comparator|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
9478521|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
9478522|NCT03551990|No Intervention|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
9478523|NCT03551990|No Intervention|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
9478524|NCT03551990|Experimental|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
10022110|NCT03261817|Sham Comparator|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
10022111|NCT03260504|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
10022112|NCT03259581|Experimental|Transarterial chemoembolization|Transarterial chemoembolization
10022113|NCT03254940|Experimental|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
10022114|NCT03254940|Experimental|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
10022115|NCT03254940|Experimental|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
10022116|NCT03254940|Experimental|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
10022117|NCT03254940|Experimental|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
9480995|NCT05110950|Active Comparator|No suction EBUS-TBNA|In this technique the stylet is slowly removed without any kind of device in order to avoid active suction.
10022118|NCT03254940|Experimental|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
10022119|NCT03254940|Experimental|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
10022120|NCT03254940|Experimental|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
10022121|NCT03254940|Experimental|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
10022122|NCT03254940|Experimental|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
10022123|NCT03254940|Experimental|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
10022124|NCT03254940|Experimental|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
9478525|NCT03551977|Experimental|Intervention group|The intervention group will receive the iCanCope with Pain app with all five components: (I) symptom trackers for pain, sleep, mood, physical, and social function; (II) goal setting to improve pain and function; (III) coping toolbox of pain self-management strategies; (IV) social support; (V) age-appropriate pain education
10022125|NCT03254940|Experimental|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
10022126|NCT03254940|Experimental|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
10022127|NCT03254940|Experimental|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
9478526|NCT03551977|Active Comparator|Control group|The control group will receive the iCanCope with Pain control app with only the first self-registration component (I) symptom trackers for pain, sleep, mood, physical, and social function.
9478527|NCT03551964|Experimental|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
9478528|NCT03551964|Active Comparator|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
9478529|NCT03551925|Experimental|Treatment as Usual Plus Occupational Therapy|The occupational therapy intervention will be guided by the Integrative Medication Self-Management Intervention (IMedS).The IMedS process guides the occupational therapist and client through an initial evaluation process and a three-step intervention plan to improve medication management.
9478530|NCT03551925|Active Comparator|Treatment as Usual (TAU)|Participants will receive only the TAU intervention which is provided by a clinical pharmacist and is the protocol at Jordan Valley Community Health Center. The intervention seeks to improve medication adherence in individuals with hypertension.
10022128|NCT03254940|Experimental|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
10022129|NCT03254940|Experimental|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
9478533|NCT03551860|Experimental|TQL Group|Administration of a single shot transmuscular quadratus lumborum (TQL) peripheral nerve block following spinal neuraxial blockade.
9478534|NCT03551860|Active Comparator|FIB Group|Administration of a single shot fascia iliac (FIB) peripheral nerve block following spinal neuraxial blockade.
9478535|NCT03551847|Experimental|Oral antibiotic therapy group|This group will receive preoperative oral antibiotic therapy tailored to the infecting organism (if identified) for two weeks before the time of revision surgery
9478536|NCT03551847|Active Comparator|No antibiotic therapy group|This group will not receive preoperative oral antibiotic therapy.
9478537|NCT03551834|Active Comparator|doing scleral patch graft glaucoma implantation|
9478538|NCT03551834|Active Comparator|Using short tunnel small flap technique|
9478539|NCT03551808|Active Comparator|installation of Ketorolac Tromethamine Eye Drop|
9478540|NCT03551808|No Intervention|not receiving placebo|
9478541|NCT03551795|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells.
9478542|NCT03551769|Experimental|Cohort 1, Period 1|Study drug administered concurrently with a standard meal
9478543|NCT03551769|Experimental|Cohort 1, Period 2|Study drug administered 30 minutes after a standard meal
9478544|NCT03551769|Experimental|Cohort 1, Period 3|Study drug administered 30 minutes after a high-fat meal
9478545|NCT03551769|Experimental|Cohort 1, Period 4|Study drug administered after an overnight fast
9478546|NCT03551769|Experimental|Cohort 2, Period 1|Study drug administered 30 minutes after a standard meal (Asian)
9478547|NCT03551769|Experimental|Cohort 2, Period 2|Study drug administered after an overnight fast (Asian)
9478548|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
9478549|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
9478550|NCT03551717||High cardiovascular risk patients|Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
9478551|NCT03551717||Low cardiovascular risk patients|"Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.~The age balance of the patients included in the two groups will be checked regularly."
9478552|NCT03551704|Active Comparator|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
9478553|NCT03551704|Experimental|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
9480996|NCT05110950|Active Comparator|Passive suction through dedicated EBUS-TBNA syringe|After rapid stylet removal, suction is applied through a vacuteiner syringe, without active aspiration.
10022130|NCT03254940|Experimental|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
9802804|NCT04926818|Experimental|siponimod - 0.5 mg, 1 mg or 2 mg/ placebo|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
9802805|NCT04926818|Active Comparator|fingolimod - 0.5 mg or 0.25 mg/ placebo|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
10022131|NCT03254940|Experimental|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
10022132|NCT03254940|Experimental|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
10022133|NCT03254940|Experimental|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
10022134|NCT03254940|Experimental|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
10022135|NCT03254940|Experimental|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
10022136|NCT03254940|Experimental|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
9478554|NCT03551678|Experimental|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
9478555|NCT03551652||Young patients|Patients aged 18 - 50 years
9478556|NCT03551652||Geriatric patients|Patients aged ≥ 80 years
9478557|NCT03551613|Active Comparator|honey group|malnourished children supplemented with honey in dose of 2ml/kg
9478558|NCT03551613|Placebo Comparator|malnourished control group|no honey supplementation only nutrition rehabilitation
9478559|NCT03551613|No Intervention|healthy children|healthy children with no suplementation
9478560|NCT03551600||Preterm, no PDA|"Babies </= 32 weeks gestation at birth with no symptoms of a patent ductus arteriosus (PDA) or echocardiogram confirmation of no PDA~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded"
9478561|NCT03551600||Preterm, moderate to large PDA|Babies </= 32 weeks gestation at birth with confirmed moderate to large PDA on echocardiogram Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded
9478562|NCT03551600||>/= 34 wk infants, no CHD|"Babies >/= to 34 weeks gestation at birth with no evidence of ductal dependent congenital heart disease (CHD)~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
9478563|NCT03551600||>/= 34 week infants, CHD|"Babies >/= to 34 weeks gestation at birth with ductal dependent CHD~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
9478564|NCT03551587|Experimental|Irrigant delivered by the Vibringe|"Experimental group:~The irrigant will be delivered and sonically activated with the Vibringe system."
9478565|NCT03551587|No Intervention|Irrigation by Conventional needle|"Control group:~Irrigation procedures will br performed with a conventional method using conventional gauge 24 needle."
9478566|NCT03551574||Macular involving retinal detachment|Patients with retinal detachments that have developed PVR when the macula has been involved
9480791|NCT05241496|Experimental|Marina Ramsis|In the other group, 70 women will be randomly assigned for ibuprofen; participants will take 1 tablet (400mg) immediately & clinicians will wait at least 45 minutes before inserting the copper IUD
9480792|NCT05240872|Active Comparator|Group A|Platelet Rich Plasm (PRP) injection group
9480793|NCT05240872|Active Comparator|Group B|Autologous Blood injection (ABI) group
9802806|NCT04926116|Experimental|AK3280 Cohort 1|Eligible subjects will be administered a single oral dose of 200 mg AK3280 under fasted conditions on Day 1. A multiple dosing period follows with daily 200 mg AK3280 b.i.d. administered with a concurrent low-fat meal intake from Day 4 to Day 16 and a 200 mg AK3280 q.d. dosing on Day 17.
10022137|NCT03254940|Experimental|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
10022138|NCT03254940|Experimental|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
10022139|NCT03254940|Experimental|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
10022140|NCT03254940|Experimental|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
10022141|NCT03254940|Experimental|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
9480997|NCT05110950|Active Comparator|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|After rapid stylet removal, suction is applied through Cameco syringe pistol, that can apply active suction manually.
10022142|NCT03254940|Experimental|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
10022143|NCT03254940|Experimental|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
10022144|NCT03254940|Experimental|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
10022145|NCT03251924|Experimental|BMS-986226|administered intravenously
10022146|NCT03251924|Experimental|BMS-986226 and Nivolumab|administered intravenously
10022147|NCT03251924|Experimental|BMS-986226 and Ipilimumab|administered intravenously
10022148|NCT03251508|Experimental|Peanut OIT/dietary peanut|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months. This is followed by daily ingestion of common dietary foods containing approximately 300 mg of peanut protein for an additional 6 months.
9480998|NCT05103384||PD Virtual Reality Cohort|
10022149|NCT03246230|No Intervention|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
10022150|NCT03246230|Other|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
10022151|NCT03246230|Other|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
9802807|NCT04926116|Experimental|AK3280 Cohort 2|The dose level of AK3280 for Cohort 2 will be determined by the SRC (Safety Review Committee) based on the safety and PK data gleaned in Cohort 1. Subjects will receive AK3280 following the same dosing schedule as that in Cohort 1, i. e., a single oral dose of AK3280 under fasted conditions on Day 1, multiple AK3280 b.i.d. administration with a concurrent low-fat meal intake from Day 4 to Day 16, and an AK3280 q.d. dose on Day 17.
9802808|NCT04926116|Experimental|AK3280 Optional Cohort|This is an optional dose cohort that the SRC will determine depending on the results of Cohorts 1 and 2, including the proposed dose level. Potential subjects in this cohort will also follow the same dosing scheme as those for Cohorts 1 and 2.
9478567|NCT03551561|Active Comparator|CSAAC group|The CSAAC group (chlorhexidine-based soap + ethyl alcohol + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB (Eosin Methylene Blue) media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
9478568|NCT03551561|Active Comparator|CSAC group|The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
9478569|NCT03551548|Placebo Comparator|Reference treatment|
9478570|NCT03551548|Experimental|experimental treatment|Spironolactone 25 mg
9478571|NCT03551535|Experimental|Physical Activity Intervention|Patients will be allocated to a physical activity intervention to be performed 3-5 days per week
9478572|NCT03551535|No Intervention|Control|Patients will receive standard counseling regarding activity recommendations in pregnancy
9478573|NCT03551483|Experimental|ArtontheBrain|ArtontheBrain application for about 30 to 45 minutes twice per week, over 6 weeks.
9478574|NCT03551483|Active Comparator|Seniors Online Victoria|Senior Online Victoria games for about 30 to 45 minutes twice per week, over 6 weeks (https://www.seniorsonline.vic.gov.au/services-information/games), after which they will participate in the ArtontheBrain intervention.
9478575|NCT03551483|Other|Waitlist Control|The waitlist control group will no treatment for 6 weeks, after which they will six weeks of the ArtontheBrain intervention.
9478576|NCT03551470||Synchronous colorectal cancer and liver metastases|Robotic (Da Vinci) one-stage colorectal and liver resection
9478577|NCT03551444|Active Comparator|Administration of DAA-based treatment (Arm 1)|"Arm 1 will be divided into 2 groups by randomization according to a 1:1 ratio into:~Group A: Administration of DAA-based treatment after 3 months of complete remission of HCC.~Group B: Administration of DAA-based treatment after 6 months of complete remission of HCC."
9478578|NCT03551444|Experimental|Control arm (Arm 2)|Not receiving DAAs after complete remission of HCC and to be kept on follow-up
9478579|NCT03551431|Experimental|Video EEG with verbal suggestion|
9478580|NCT03551431|Experimental|video EEG with verbal suggestion and tuning fork|
9478581|NCT03551431|Experimental|video EEG with verbal suggestion and cotton swab|
9478582|NCT03551418|Experimental|Repetitive video watching|Repetitively watching a video of an adult with Down Syndrome washing his hands
9802809|NCT04926116|Placebo Comparator|Control Arm|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
10022152|NCT03246230|Other|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
10022153|NCT03244644|Placebo Comparator|Group A|Placebo is an enema of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
10022154|NCT03244644|Experimental|Group B|RBX2660 is an enema of a microbiota suspension in a 0.9% sodium chloride irrigation USP solution and cryoprotectant
10022155|NCT03242772|Active Comparator|ESDM informed parent coaching + Amphetamine|Amphetamine regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.
10022156|NCT03242772|Placebo Comparator|ESDM informed parent coaching + Placebo Oral Tablet|Placebo regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The placebo contains no active drug and appears identical to the amphetamine (active drug).
10022157|NCT03237702|Experimental|MCS arm|The participants who will have Multi-Carotenoids for 8 weeks The intervention is Multi-Carotenoids 30 mg for 8 weeks.
10022158|NCT03236311|Placebo Comparator|Placebo|Matching placebo for 4 weeks.
10022159|NCT03236311|Experimental|SAR407899|SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).
9480794|NCT05240664|Experimental|ACP intervention|It is a theory-driven ACP programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model.
10022160|NCT03234686|Experimental|Deferiprone|Patients will orally receive the equivalent 15 mg/kg of 600mg delayed release Deferiprone tablets twice daily.
10022161|NCT03234686|Placebo Comparator|Placebo|Patients will receive matching placebo tablets designed to mimic the experimental treatment, twice daily
10022162|NCT03233204|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
10022163|NCT03229941|Experimental|Restrictive|Transfusion trigger: Hb<7gm/dl
10022164|NCT03229941|Experimental|Liberal|Transfusion trigger: Hb<10gm/dl
10022165|NCT03229629|Experimental|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
9478583|NCT03551405||Intensity accuracy|"The difference of the HU values in corresponding ROIs in the two image sets will be compared with zero using one sample t-test.~In addition, we will also use these patient cases to test the computational efficiency of our algorithm. Based on our preliminary study, it is expected that the computation time will be 5~10 sec per phase. The reconstruction time will be recorded in these patient cases and will be assessed."
9478584|NCT03551392|Active Comparator|NIR -Older Adult|Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
9478585|NCT03551392|Sham Comparator|No Dose NIR-Older Adult|Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
9478586|NCT03551392|Active Comparator|NIR -Parkinson|Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
9478587|NCT03551392|Sham Comparator|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
9478588|NCT03551379||Endoscopic procedure|A double balloon endoscopic platform will be used during an ESD procedure
9478589|NCT03551366|No Intervention|Control|Subjects in this group will continue with their usual PE curriculum for 15 weeks.
9478590|NCT03551366|Experimental|Linear|Subjects in this group will receive a linear PE curriculum for 15 weeks. Linear Pedagogy is underpinned by neuro-computation approach to motor learning such as information processing theory and prescribes that an ideal movement pattern exists for each task and that the teacher's role is to help learners recreate that pattern. Furthermore, theorists have suggested that learning is a gradual, linear process. This linear pedagogy is supported by a teaching and learning approach that includes both prescriptive and repetitive actions, utilising technical demonstrations that provide learners with a 'visual template or criterion model' for the desired skill . As a consequence, a PE pedagogy has developed whereby the teacher's role is to make all the decisions, and the learner's role is to follow their instructions on cue - a teacher-led approach to PE.
9478591|NCT03551366|Experimental|Nonlinear|Subjects in this group will receive a nonlinear PE curriculum for 15 weeks. Nonlinear pedagogy is grounded in Ecological Dynamics theory. Ecological dynamics regards learners as complex adaptive systems which afford opportunities for action from their environment and generate movement solutions to satisfy the combination of personal, environmental and task constraints imposed upon them. According to nonlinear pedagogy, the teacher's role is to design learning experiences that create behavioural symmetry between learning and the performance environment. The teacher is a facilitator and manipulates constraints to channel the learner's physical development, while learners are left free to experiment and select the movement solutions that best answer their individual needs. This child-focused, less prescriptive approach may enhance a child's intrinsic motivation by offering freedom to choose, and an emphasis on exploration and problem solving.
9480795|NCT05240664|Placebo Comparator|Attention-control health talks|Dyads of participants in the control group will receive health talks. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
10022166|NCT03229629|Experimental|Maternal BCC & Paternal BCC|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC *BCC: Behavior Change Communication"
10022167|NCT03229629|Experimental|Food voucher|"Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~Food voucher"
10022168|NCT03229629|Experimental|Maternal BCC & Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
9802810|NCT04925856|Experimental|Experimental|"4 différents cohorts:~Paclitaxel cohort (N=30)~Epirubicine - cyclophosphamide cohort (N=30)~Eribuline cohort (N=30)~Palbociclib (N=20) ou Abemaciclib (N=20) ou Ribociclib cohort (N=21)~Study diagram :~Inclusion and screening visite~Visit 1: J1C1~Visit 2 : J8C1 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C1 to Palbociclib ou Abemaciclib ou Ribociclib cohort~Visit 3 :J21C1~Visit 4 : J8C3 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C3 to Palbociclib ou Abemaciclib ou Ribociclib cohort~During these visits, we collect, before the start of treatment administration ;~Vital signs,~Concomitant treatments,~Blood sample:~1 heparinized tube (4 mL) for collection of plasma and storage~1 heparinized tube (4 mL) for immunophenotyping,~4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
10022169|NCT03229629|Experimental|Maternal BCC&Paternal BCC &Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC~Enrolled participants will receive monthly voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
10022170|NCT03229629|No Intervention|Control|Control group
10022171|NCT03229538|Experimental|Methylprednisolone Arm|IV Methylprednisolone
10022172|NCT03229538|Placebo Comparator|Placebo Arm|IV Isotonic Saline
10022173|NCT03229057|Active Comparator|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
10022174|NCT03229057|Active Comparator|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
10022175|NCT03229057|Experimental|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
10022176|NCT03226795|Experimental|interventional arm|
9478592|NCT03551353||Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
9478593|NCT03551353||Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
9478594|NCT03551340||Traditional methods|Patients, who consulted for gastro-intestinal symptoms between July 2016 and May 2017, and were investigated by traditional methods (stool microscopy and/or culture).
9478595|NCT03551340||Gastro-intestinal panel by PCR|Patients, who consulted for gastro-intestinal symptoms between July 2017 and May 2018,and were investigated by a gastro-intestinal panel by PCR
9478596|NCT03551327|Experimental|Intervention plus information|Participants in this arm will receive 6 telephone therapy sessions and 1 booster session. Participants will be followed up at 4 months and 6 months.
9478597|NCT03551327|Other|Information only|Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
9478598|NCT03551314|Active Comparator|Nasal Intermittent Positive Pressure|"In this group, soon after extubation, the newborns will be studied initially in NIPPV for one hour. Infants will be studied in supine while in their incubator.~NIPPV: Nasal Intermittent Positive Pressure Ventilation"
9478599|NCT03551314|Active Comparator|Continuous Positive Airway Pressure|"In this group, soon after extubation, the newborns will be studied initially in CPAP for one hour. Infants will be studied in supine while in their incubator.~CPAP: Continuous Positive Airway Pressure"
9478600|NCT03551288|Experimental|Food Effect Cohort|Twelve healthy male subjects 18 to 45 years of age, inclusive, will be administered a single oral dose of SUVN-911 on Day 1 (Period 1) and Day 8 (Period 2) with and without food in a crossover manner.
9478601|NCT03551288|Experimental|Gender Effect Cohort|Eight healthy female subjects 18 to 45 years of age, inclusive, will be administered a single dose of SUVN-911.
9478602|NCT03551288|Experimental|Age Effect Cohort|Eight healthy male subjects ≥ 65 years of age will be administered a single oral dose of SUVN-911.
9478603|NCT03551275|Experimental|Cohort no. 1, BCD-132, 100 mg, IV|"Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.~Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.2 is included."
9478604|NCT03551275|Experimental|Cohort no. 2, BCD-132, 250 mg, IV|"Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.~Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.3 is included."
9478605|NCT03551275|Experimental|Cohort no. 3, BCD-132, 500 mg, IV|"Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.~Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.4 is included."
9478606|NCT03551275|Experimental|Cohort no. 4, BCD-132, 1000 mg, IV|"Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.~Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion."
9478607|NCT03551262|Experimental|OTSC|Use of OTSC to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb, in first-line endoscopic haemostatic treatment.
10022177|NCT03226028|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
9802811|NCT04914403|Experimental|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
9802812|NCT04913272|Experimental|US-APR2020|Patients in this group will be administered US-APR2020 orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals, (for a total daily dose of 90 Billion CFUs).
9478608|NCT03551262|Active Comparator|TTS clip|Use of TTS clip to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb in first-line endoscopic haemostatic treatment
9478609|NCT03551223||Women undergoing cesarean delivery with general anesthesia|Preeclamptic parturients undergoing cesarean delivery under general anesthesia
9478610|NCT03551223||Women undergoing cesarean delivery with spinal anesth|Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia
9478611|NCT03551210|Experimental|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
9478612|NCT03551210|Active Comparator|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
9478613|NCT03551197|Experimental|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
9478614|NCT03551184|Active Comparator|Endotoxin|Endotoxin 0.6 ng/kg body weight injection
9478615|NCT03551184|Placebo Comparator|Placebo|Saline injection
9478616|NCT03551171|Experimental|ZL-2306 (niraparib)|Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.
9478617|NCT03551158|Other|Atrial fibrillation patients|Patients with atrial fibrillation who underwent cryoballoon ablation
9802813|NCT04913272|Placebo Comparator|Placebo|Patients in this group will be administered placebo orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals.
9802814|NCT04908956|Experimental|Osimertinib & SBRT|Osimertinib 80mg once daily p.o., until progression or unacceptable toxicity & locally ablative radiotherapy (SBRT) to the primary tumour and to all metastatic sites.
10022178|NCT03224767|Experimental|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
10022179|NCT03223974|Experimental|Paclitaxel DCB for MB and/or SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for >30 seconds
10022180|NCT03223974|Active Comparator|DES in MB|with regular techniques
10022181|NCT03223753|Active Comparator|Arm I (tracking device, limited version of device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the limited version of device app/website to get basic information related to their physical activity for 6 months.
10022182|NCT03223753|Experimental|Arm II (tracking device, interactive-reward based device)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the full version of the interactive-reward based device app/website to see their activity, earn activity points, see other's activity, and interact with other patients for 6 months.
10022183|NCT03223090|Experimental|Tool training group|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
10022184|NCT03223090|Active Comparator|Hand training group|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
10022185|NCT03222752|Active Comparator|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
9478618|NCT03551145|Experimental|Acellular collagen matrix|In a test group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Acellular collagen matrix will be adapted and suture to the vascular bed.
10022186|NCT03222752|Sham Comparator|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
10022187|NCT03220035|Experimental|Treatment (vemurafenib)|Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
10022188|NCT03216343|Experimental|Study Arm|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle until objective disease progression
10022189|NCT03211793|Experimental|MSC injections|Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
10022190|NCT03211793|Placebo Comparator|Placebo injections|Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
10022191|NCT03208153|Experimental|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
10022192|NCT03208153|Active Comparator|Conservative|In-hospital coronary angiogram only if poor clinical course
10022193|NCT03206476|Experimental|Intervention group|Nutritional intervention based on the SCT and the TM
10022194|NCT03206476|Active Comparator|Control group|Nutritional information
10022195|NCT03204916||Observational (cancer care delivery analysis)|"CHART REVIEW: Patient medical record data is abstracted and treatment plans are reviewed for consistency to NCCN guidelines. For each patient, induction and post-induction care is recorded as either concordant with NCCN guidelines or non-concordant with NCCN guidelines.~SITE QUESTIONNAIRE: Participating sites complete a questionnaire which is designed to capture facility-oriented data.~FOCUS GROUPS: Healthcare providers participate in focus groups over 2-3 hours to discuss facilitators and barriers to AYA ALL guideline concordance. Participants provide responses which will be recorded on a flip-chart or white board, followed by discussion of the ideas for clarification"
10022196|NCT03201939|Active Comparator|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
10022197|NCT03201939|Placebo Comparator|Placebo comparator (Control arm)|Matched placebo
10022198|NCT03200587|Experimental|Avelumab and cabozantinib, all patients|
10022199|NCT03196427|Experimental|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive vedolizumab 300 mg and participants with UC or CD having baseline weight of less than (<) 30 kg will receive vedolizumab 200 mg, IV infusion, every 8 weeks for up to 5 years.
9478619|NCT03551145|Active Comparator|Autogenous free gingival graft|In a control group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Free gingival graft will be harvested from the zone of the posterior palate, and then adapted and sutured to the vascular bed.
9478620|NCT03551132|Experimental|Group 1|"Experimental group A supervised progressive moderate-to-high RTC program designed to induce muscular hypertrophy was performed. EG followed a progressive moderate-to-high RTC program for 12-weeks. The training program incorporated resistance exercise of six major regions and consisted of 3 training sessions per week on non-consecutive days (Monday, Wednesday and Friday).~All subjects performed the sets with moderate-intensity (8 to 12 repetitions) in each exercise and 30-60 seconds rest between sets. The load was increased during the 12 weeks from 60% 1-RM to high-intensity 80% 1-RM. The training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions) followed the OMNI-RES scale and a hard effort perception level. Rest between sets was 1-2 minutes."
9478621|NCT03551132|No Intervention|Group 2|Control group The CG not participated in the RTC program.
9478622|NCT03551119|Experimental|Exercise|"Personnel experienced in training people with chronic conditions (exercise specialist) will supervise the exercise training. At each in-center session in phase 1, the patient's exercise will be monitored to assess whether they are achieving target levels. Training intensities will be prescribed based on the most recent exercise test.~Phase 1: an eight-week program of once weekly-supervised facility-based exercise sessions and twice weekly home-based sessions.~Phase 2: a 16-week home-based exercise program overseen by an exercise specialist. During this phase, participants will be progressed through their home-based exercise program from Phase 1 on an individual basis.~i. Frequency. A minimum of three exercise sessions per week. ii. Intensity. A moderate intensity (40-60% heart rate reserve) based on exercise testing.~iii. Time. 150 minutes of exercise per week. iv. Type. We will prescribe aerobic exercise supplemented with isometric resistance exercises."
9478623|NCT03551119|Other|Enhanced usual care|Participants in the control group will perform accelerometry. This is enhanced usual care because physical activity measurement is not routinely performed in CKD clinics. Control arm participants will only receive their accelerometry data after they have completed the study.
9478624|NCT03551106||Web based learning module|Laboratory prescriptions made by postgraduate students who were enrolled to follow the web based modules
9478625|NCT03551093|Experimental|Study Population|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
10022200|NCT03196427|Experimental|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of >= 30 kg will receive vedolizumab 150 mg and participants with UC or CD having baseline weight of < 30 kg will receive vedolizumab 100 mg IV infusion, every 8 weeks for up to 5 years.
9478626|NCT03551080|Active Comparator|Endotoxin|0.8 ng lipopolysaccharide/kg body weight injection
9478627|NCT03551080|Placebo Comparator|Placebo|Saline injection
10022201|NCT03192046|Experimental|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
10022202|NCT03192046|Active Comparator|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
10022203|NCT03191253|Experimental|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
10022204|NCT03191253|No Intervention|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
9478628|NCT03551067|Active Comparator|Dexmedetomidine|Patients received Dexmedetomidine (4 µg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
9478629|NCT03551067|Active Comparator|Midazolam/Ketamine|Patients received Midazolam (0.5 mg/kg) and Ketamine (1 mg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
9478630|NCT03551054|Experimental|Healthy for Two, Healthy for You|Remotely delivered behavioral health coaching in pregnancy and postpartum
9478631|NCT03551054|Active Comparator|Pregnancy Health Education|Single health education visit with study staff member
10022205|NCT03190369|Placebo Comparator|Placebo|Participants received a single IA injection of phosphate buffered saline on Day 1 and were observed for 26 weeks.
9478632|NCT03551028|Other|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
9478633|NCT03551015|Experimental|Intervention|The intervention arm will have outpatient review at 3 weeks and start 8 sessions of cardiac rehabilitation from 4 weeks, after hospital discharge following CABG.
9478634|NCT03551015|No Intervention|Control|This arm will have outpatient review 6 weeks after hospital discharge and start 8 sessions of cardiac rehabilitation from 8 weeks.
9478635|NCT03551002||Retrospective|
9478636|NCT03551002||Prospective|
9478637|NCT03550976|Experimental|High risk intervention group|
9478638|NCT03550976|No Intervention|High risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
9478639|NCT03550976|No Intervention|Low risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
9478640|NCT03550963|Other|rice-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group. The intervention of group one is that participants will be provided with rice-richen meal, meaning most of the calculated carbohydrates are from rice.
9478641|NCT03550963|Other|wheaten-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group.The intervention of group two is that participants will be provided with wheaten-richen meal, meaning most of the calculated carbohydrates are from wheaten.
9478642|NCT03550950|Experimental|Single Ascending Dose (SAD) IV Cohort|Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
9478643|NCT03550950|Experimental|Subcutaneous (SC) Cohort|Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
9478644|NCT03550924|Active Comparator|Low flow Oxygen Group|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
9478645|NCT03550924|Experimental|THRIVE Group|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
9478646|NCT03550898|Other|Dynamic ultrasonography|Dynamic ultrasonography was performed in all patients who underwent urodynamics, simultaneously.
9478647|NCT03550872|No Intervention|Control Group|Patients in the group who are continuously guided as the activities of daily living normally avoiding participation in any regular program of physical exercise does not proceed from the study.
9478648|NCT03550872|Experimental|Training Group|the patients randomized to the physical training group will undergo the supervised physical training program
9478649|NCT03550859|Experimental|Duowell Tab. 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
9478650|NCT03550859|Active Comparator|Micardis Tab. 40mg|Telmisartan 40mg qd for 48 weeks
9478651|NCT03550833||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years
9478652|NCT03550833||control patients|patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration…)
9478653|NCT03550794|Experimental|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
9478654|NCT03550794|Placebo Comparator|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
9478655|NCT03550781|Experimental|Anti-inflammatory treatment group|Prednisone and/or cyclophosphamide
9478656|NCT03550781|No Intervention|Control group|No intervention
9478657|NCT03550768||MDP|ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
9478658|NCT03550755|Experimental|V3-Cervix|Biological: V3-Cervix V3-Cervix is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood and tumor tissue from women with cervical cancer
9478659|NCT03550742|Experimental|Intervention|Daily administration of 5g of Fuco-N-Tetraose as a bolus for a period of 12 weeks.
10022206|NCT03190369|Experimental|Hylan G-F 20|Participants received a single IA injection of 6 mL Hylan G-F 20 (Synvisc-One) on Day 1 and were observed for 26 weeks.
9478660|NCT03550729|Experimental|Training|12-weeks of supervised endurance training program.
9478661|NCT03550716|Active Comparator|mTESE|Patients randomized to mTESE
10022207|NCT03190265|Experimental|CY, Nivolumab, Ipilimumab, GVAX, CRS-207|
10022208|NCT03190265|Experimental|Nivolumab, Ipilimumab, CRS-207|
10022209|NCT03188432|Experimental|Treatment - Carboplatin, CRS, HIPEC|Beginning 4-8 weeks after completion of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 90 minutes immediately following CRS.
10022210|NCT03186209|Experimental|Benralizumab|Benralizumab administered subcutaneously
10022211|NCT03186209|Placebo Comparator|Placebo|Placebo administered subcutaneously
10022212|NCT03186118|Experimental|Cohort A|Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
9802815|NCT04907227|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
9478662|NCT03550716|Active Comparator|TESA|Patients randomized to TESA
9478663|NCT03550703|Experimental|Single arm receiving V3-Myoma|A single oral pill of V3-Myoma therapeutic vaccine containing pooled antigens circulating in peripheral blood and within myoma tissues
9478664|NCT03550690||Large Volume Paracentesis|Patient has repeated large volume paracentesis for recurrent ascites secondary to cancer
10022213|NCT03186118|Experimental|Cohort B|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
10022214|NCT03186118|Experimental|Cohort C|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
10022215|NCT03186118|Experimental|Cohort D|Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
10022216|NCT03182998|Experimental|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
10022217|NCT03182998|Experimental|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
10022218|NCT03182998|Active Comparator|Arm C (Usual Care)|Patients undergo usual care.
10022219|NCT03178786|Experimental|Parkinson's Disease|
10022220|NCT03178786|Sham Comparator|Healthy Control Subjects|
10022221|NCT03178487|Experimental|Upadacitinib 15 mg|Participants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
10022222|NCT03178487|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
10022223|NCT03177187|Experimental|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
10022224|NCT03177187|Experimental|Phase II|"The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.~RECRUITING"
10022225|NCT03174379|Placebo Comparator|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
10022226|NCT03174379|Active Comparator|Treatment Group|60-minute treatment session twice a week for three weeks
10022227|NCT03172975|Experimental|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
10022228|NCT03172975|Experimental|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
9478665|NCT03550690||Semi-permanent drain|Patient has a semi-permanent drain (Rocket Indwelling Pleural Catheter) placed for recurrent ascites secondary to cancer
10022229|NCT03172975|Experimental|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
10022230|NCT03172975|Placebo Comparator|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
9478666|NCT03550677|Experimental|Group General Anesthesia|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen.
9478667|NCT03550677|Experimental|Group Ankle Block|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
9478668|NCT03550664|Experimental|Surgical intervention|Patients undergoing a surgical intervention within the CHU Brugmann with utilisation of rocuronium.
9478669|NCT03550651|Experimental|Licorice extract mouthrinse|10ml twice a day for 4 Days.
9478670|NCT03550651|Experimental|Hypertonic salt solution|10ml twice a day for 4 Days.
9478671|NCT03550651|Active Comparator|Essential oil mouthrinse|10ml twice a day for 4 Days.
9478672|NCT03550651|Active Comparator|Chlorhexidine Gluconate mouthrinse|10ml twice a day for 4 Days.
9478673|NCT03550651|Placebo Comparator|Distilled water|10ml twice a day for 4 Days.
9478674|NCT03550638|Experimental|group A|Coil system(Ton-bridgeMT)
9478675|NCT03550638|Active Comparator|group B|Axium Detachable Coil(Medtronic)
9478676|NCT03550625||Routine Colonoscopy Cohort|Photographies of polyps for creation of computer program
9478677|NCT03550612||Neonates with hypoxic ischemic encephalopathy|Cranial ultrasound,Magnetic resonant imaging and amplitude integrated encephalogram performed to All neonates with hypoxic ischemic encephalopathy in period between January 2010 to December 2015.
9478678|NCT03550599||patients accessing to Radiotherapy Unit|patients accessing to Radiotherapy Unit for oncologic treatment
9478679|NCT03550586||Parturients suffering from a PDPH|Parturients suffering form a PDPH following an accidental dural puncture between the years 2007-2017 will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
9480797|NCT05239052|Experimental|computer intervention group|stroke subjects with wheelchair users completed computer screen tasks with affected arm or bilateral arm movement
9480798|NCT05239052|Active Comparator|conventional long-term care services group|stroke subjects with wheelchair users receive conventional long-term care services
10022231|NCT03164889|Experimental|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
10022232|NCT03164889|Active Comparator|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
10022233|NCT03161444|Other|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
10022234|NCT03155932|Experimental|APD334|APD334 active treatment for 24 weeks.
10022235|NCT03147287|Active Comparator|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
10022236|NCT03147287|Experimental|Fulvestrant with Palbociclib|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
10022237|NCT03147287|Experimental|Fulvestrant with Palbociclib and Avelumab|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly~Avelumab will be administered intravebously once every 2 weeks"
10022238|NCT03147040|Experimental|Carboplatin/Atezolizumab|Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin
10022239|NCT03141190|Experimental|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
10022240|NCT03141190|Active Comparator|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
10022241|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
10022242|NCT03132636|Experimental|Group 1- metastatic BCC|Administration of cemiplimab in accordance with protocol dosing regimen
10022243|NCT03132636|Experimental|Group 2 - unresectable locally advanced BCC|Administration of cemiplimab in accordance with protocol dosing regimen
9518187|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
10022244|NCT03131817|Experimental|PD with mood disorder or impulsivity|This is a single-center study of the neurophysiology of non-motor symptoms such as anxiety, depression, and impulsivity that are comorbid in Parkinson's Disease.
10022245|NCT03128138|Experimental|25 mg SPH3127 tablet-Dose 1|"6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet."
10022246|NCT03128138|Experimental|50 mg SPH3127 tablet-Dose 2|"6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet."
10022247|NCT03128138|Experimental|100 mg SPH3127 tablet-Dose 3|"6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet."
10022248|NCT03128138|Experimental|200 mg SPH3127 tablet-Dose 4|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet."
10022249|NCT03128138|Experimental|400 mg SPH3127 tablet-Dose 5|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet."
10022250|NCT03128138|Experimental|800 mg SPH3127 tablet-Dose 6|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet."
10022251|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
10022252|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
10022253|NCT03126812|Experimental|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
10022254|NCT03122925||Control|Healthy subjects
10022255|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
10022256|NCT03117621||Patients initiating Blinatumomab|Patients initiating Blinatumomab after Country-Specific Reimbursement approval in routine clinical practice.
10022257|NCT03114319|Experimental|TNO155|TNO155 for oral administration
10022258|NCT03114319|Experimental|TNO155 in combination with EGF816 (nazartinib)|TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC
10022259|NCT03110432||Standard lipid lowering therapy|Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids (and any combinations of these agents)
10022260|NCT03110432||PCSK9 Inhibitor [EPC]|Evolocumab or alirocumab.
10022261|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
10022262|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
10022263|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
10022264|NCT03106779|Experimental|Asciminib|Patients were randomized to asciminib 40mg BID
10022265|NCT03106779|Active Comparator|Bosutinib|Patients were randomized to bosutinib 500mg QD
10022266|NCT03100747|Active Comparator|Bilamellar 3 mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
10022267|NCT03100747|Active Comparator|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
10022268|NCT03100747|Active Comparator|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
10022269|NCT03099564|Experimental|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
10022270|NCT03097146|Other|comprehensive multidisciplinary stroke care|
10022271|NCT03096834|Placebo Comparator|Placebo DB|Matching placebo subcutaneous injections administered every 4 weeks during Double-Blind Epoch
10022272|NCT03096834|Experimental|AMG334 140 mg DB|AMG334 70 mg subcutaneous injections (2) administered every 4 weeks during Double-Blind Epoch
10022273|NCT03096834|Experimental|AMG334 140 mg DB cont on AMG334 140 mg|AMG334 70 mg subcutaneous injections (2) during DB continued on AMG334 140 mg in Open-Label Epoch
10022274|NCT03096834|Experimental|Placebo in DB to AMG334 140 mg|Placebo in Double-Blind Epoch (DB) switched to AMG334 140 mg in Open-Label Epoch
10022275|NCT03095612|Experimental|Selinexor Monotherapy and in Combination with Docetaxel|"For the selinexor monotherapy cohort, 6 patients each will be treated in two dosing cohorts (weekly and biweekly). Selinexor once weekly oral (40mg, 60mg, 80mg) OR Selinexor twice weekly oral (60mg, 40mg, 60mg weekly).~Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks."
10022276|NCT03094312|Experimental|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
10022277|NCT03093116|Experimental|Repotrectinib (TPX-0005)|"Phase 1~Oral repotrectinib (TPX-0005):~Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.~Phase 2~Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts~EXP-1: ROS1 TKI-naïve ROS1+ NSCLC~EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC~EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)~EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)~EXP-5: TRK TKI-naïve NTRK+ solid tumors~EXP-6: TRK TKI-pretreated NTRK+ solid tumors"
9478680|NCT03550586||Parturients not suffering from a PDPH|This group will consistent of a control group of women receiving epidural analgesia on the same day as those women who suffered an ADP. This participants will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
9478681|NCT03550560||EUS-Guided drainage|Cancer patients in terminal phase with refractory malignant ascites
9478682|NCT03550547|Experimental|7 educational workshops|"Intervention: 7 educational workshops in addition to spa therapy :~Knowledge of the pathology ; Educational physical activity ( 2 workshops); Dietary; Management of pain, fatigue and the medical treatments; Articular hygiene and ergonomics; Technical assistance, an adaptation of the living condition"
9478683|NCT03550547|Active Comparator|spa therapy|Approved Spa therapy
9478684|NCT03550534|Experimental|Calcium Carbonate|Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks
9478685|NCT03550534|Placebo Comparator|Placebo oral capsule|Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks
9478686|NCT03550521|Experimental|Mindfulness condition|The brief mindfulness induction will be modeled after basic mindfulness skills commonly used in mindfulness-based interventions and tailored to target distressing thoughts and feelings.
9478687|NCT03550521|No Intervention|Control condition|"Participants assigned to the control task will be instructed to let your mind wander freely without trying to focus on anything in particular."
9478688|NCT03550508|Experimental|Anti-RANKL Monoclonal Antibody|Anti-RANKL Monoclonal Antibody is to be injected subcutaneously 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or 3.0 mg/kg.
9478689|NCT03550495|No Intervention|Control|Patients will undergo standard of care including the use of the ABCDEF bundle; psychiatry team will not be involved on daily ICU rounds.
9478690|NCT03550495|Experimental|Intervention|Patients will receive standard ICU care, including the use of the ABCDEF bundle, but will also receive the intervention of psychiatry involvement; the psychiatry team will participate in daily ICU rounds with the ICU team to help identify, prevent, and treat ICU delirium and identify other psychiatric disorders which may be otherwise undetected by the ICU team.
9478691|NCT03550482|Experimental|Oncoxin®|
9478692|NCT03550482|No Intervention|Control|
10022278|NCT03089853|Experimental|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
10022279|NCT03089853|No Intervention|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
10022280|NCT03089203|Experimental|Cohort 1|CART-PSMA-TGFβRDN cells 1-3x10^7 Day 0
10022281|NCT03089203|Experimental|Cohort 2|CART-PSMA-TGFβRDN cells 1-3x10^8 Day 0
10022282|NCT03089203|Experimental|Cohort -3|CART-PSMA-TGFβRDN cells 1-3x10^7 Day 0
10022283|NCT03089203|Experimental|Cohort 4|CART-PSMA-TGFβRDN cells 0.70-1.00 x 10^8 Day 0
10022284|NCT03089203|Experimental|Cohort 3|CART-PSMA-TGFβRDN cells at the MTD (established by Cohorts 1-2) on day 0
10022285|NCT03088813|Experimental|Experimental Arm|Irinotecan liposome injection
10022286|NCT03088813|Active Comparator|Control Arm|Topotecan
10022287|NCT03088241|Experimental|Intervention|switch to second-line ART
10022288|NCT03088241|No Intervention|Control|Standard of care: no switch to second-line ART
10022289|NCT03087058|Experimental|Cohort 1|Patiromer for age 12 - < 18 years
10022290|NCT03087058|Experimental|Cohort 2|Patiromer for age 6 - < 12 years
10022291|NCT03087058|Experimental|Cohort 3|Patiromer for age 2 - < 6 years
10022292|NCT03086993|Experimental|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
9478693|NCT03550469|Experimental|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
9478694|NCT03550469|No Intervention|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
10022293|NCT03086993|Active Comparator|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
10022294|NCT03085485|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
9478695|NCT03550456||ECC, ECC with CLE, speech therapy|"After the standard diagnostic (spirometry, body plethysmography, exhaled NO, skin prick test) all patients with dyspnea while exercising undergo exercise challenges in a cold chamber (ECC).~In case of a positive reaction in the ECC the patients get asthma medication (ICS/LABA combination).~Both groups negative and positive should fill out a symptom diary and the next visit will be booked 6 weeks later.~If they still have dyspnea while exercising with ICS/LABA combination or hat a negative ECC the patients undergo an ECC with continuous laryngoscopy. In case of an EILO diagnosis patients will be sent to speech therapy and checked at a follow up visit.~All patients and their parents should complete questionnaires for symptoms and quality of life at every visit."
9478696|NCT03550443|Experimental|RTA 402(Bardoxolone methyl)|Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
9478697|NCT03550443|Placebo Comparator|Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
10022295|NCT03085485|Placebo Comparator|Placebo|matching placebo
10022296|NCT03085277|Active Comparator|Preterm Formula|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
9478698|NCT03550430|Experimental|ADR neurofeedback|Ten ADR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions consists of five training blocks each. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
9478699|NCT03550430|Active Comparator|BTR neurofeedback|Ten BTR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions each consists of five training blocks. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
9478700|NCT03550430|Active Comparator|Diary Control Group|Daily diary completion for two weeks in the period between baseline and end-point assessments (total period baseline to end-point = four weeks).
9478701|NCT03550417||2011 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010.
9478702|NCT03550417||2013 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010. Comparison of 2011, 2013 cohorts & July16/June17.
10022297|NCT03085277|Experimental|Bovine Colostrum|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive Bovine Colostrum (BC), as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
10022298|NCT03083197|Active Comparator|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
10022299|NCT03083197|Active Comparator|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
10022300|NCT03083197|Active Comparator|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
10022301|NCT03082209|Experimental|Dose Escalation|ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).
10022302|NCT03082209|Experimental|Dose Optimization for KRAS-mutant CRC|Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.
10022303|NCT03082209|Experimental|Dose Optimization for Pancreatic Cancer|Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).
10022304|NCT03082209|Experimental|Dose Optimization: ABBV-621 + Venetoclax for DLBCL|Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.
10022305|NCT03082209|Experimental|Dose Optimization: ABBV-621 Monotherapy for AML|Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.
10022306|NCT03082209|Experimental|Dose Optimization: ABBV-621 + Venetoclax for AML|Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.
10022307|NCT03082209|Experimental|Chemotherapy combination: ABBV-621+FOLFIRI|Participants with RAS-mutant CRC who have received one prior line of therapy will be administered ABBV-621 in combination FOLFIRI.
10022308|NCT03082209|Experimental|Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab|Participants with KRAS-mutant CRC are administered with ABBV-621 in combination with bevacizumab plus FOLFIRI
9478703|NCT03550417||July2016/Jun17 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010 & 2014. Comparison of 2011, 2013 cohorts & July16/June17.
10022309|NCT03081806|Experimental|Group A|High dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
10022310|NCT03081806|Placebo Comparator|Group B|Low dose group: X0002, BID (approximately every 12 hours; n=102); Placebo, BID(approximately every 12 hours; n=102)
10022311|NCT03080883|Experimental|Group I (lower dose apixaban)|Patients receive lower dose apixaban PO BID for 365 days.
9803721|NCT03494621|No Intervention|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
9478704|NCT03550365|Experimental|Rye bran bread intervention|4 week rye bran bread diet intervention with dietary fibre intake of 30g
10022312|NCT03080883|Experimental|Group II (higher dose apixaban)|Patients receive higher dose apixaban PO BID for 365 days.
10022313|NCT03078361|Active Comparator|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
9802816|NCT04907227|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
9802817|NCT04906421|Experimental|TVB-2640 50 mg|Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.
9478705|NCT03550365|Experimental|Rye bread intervention|4 week rye bread diet intervention with dietary fibre intake of 30g
9478706|NCT03550365|Active Comparator|Wheat bread intervention|4 week wheat bread diet intervention with dietary fibre intake of 5-20g prior to two other arms
9478707|NCT03550352|Experimental|1) THC and CBD combined|TN-TC11M2 oral capsules (THC 2.5 mg / CBD 2.5 mg)
9478708|NCT03550352|Experimental|2) CBD alone|TN-C200M2 oral capsules (CBD 200 mg)
9478709|NCT03550339|Active Comparator|SURG|subjects attending bariatric surgery
9478710|NCT03550339|Active Comparator|DIET|subjects attending dietary weight loss program
10022314|NCT03078361|Active Comparator|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
10022315|NCT03078010|Active Comparator|Piperacillin-tazobactam|
10022316|NCT03078010|Experimental|cefepime|
10022317|NCT03070392|Experimental|IMCgp100 (tebentafusp, Kimmtrak)|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
10022318|NCT03070392|Active Comparator|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine~1 of 3 Investigator's Choice options: Systemic Ipilimumab~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
10022319|NCT03068819|Experimental|CIML NK cell after T cell DLT (Pilot Pediatric/Young Adult Cohort)|"The recipient will receive standard of care salvage chemotherapy consisting of fludarabine, cytarabine, and G-CSF (FLAG) to be started 2 to 4 weeks prior to the CIML NK cell infusion. 5-day decitabine is an acceptable alternative for FLAG, and another standard of care salvage chemotherapy regimen, if clinically appropriate and approved by the study PI, may be used.~The donor will undergo non-mobilized leukapheresis on Day -2 or -1. Standard of care DLI (1 x 106 CD3+ cells/kg) will be given fresh on day -1.~A second cycle of therapy may be administered > 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered."
10022320|NCT03068819|Experimental|CIML NK cell after T cell DLT (Phase 2 Adult Cohort)|"The recipient will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide beginning on day -7.~The donor will undergo non-mobilized leukapheresis on Day -2 or -1. Standard of care DLI (1 x 106 CD3+ cells/kg) will be given frozen for administration on day 30.~A second cycle of therapy may be administered > 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered. The date of the second NK cell infusion will be considered a second Day 0."
10036452|NCT01815762|Active Comparator|active arm of the study|The number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. The US B-line score (BLS) will be measured before dialysis. In patients presenting moderate to severe lung congestion (≥15 BLS pre-dialysis) LUS measurements will be repeated once a week until the treatment goal was achieved (<15 BLS pre-dialysis) and once a month thereafter. monthly monitoring frequency will be adopted also in patients without pulmonary congestion (BLS <15). Patients without evidence of lung congestion at baseline who developed pulmonary congestion (≥ 15 BLS) during the trial will received the same treatment contemplated for those with lung congestion at baseline during the trial.
10036453|NCT01815762|No Intervention|Standard care arm|In the control arm of the study, the dry weight will be assessed only clinically.Patients in the control arm of the study will be followed up and managed strictly with standard criteria according to current recommendations (implying optimization of fluids volume control on the basis of clinical criteria and the use of carvedilol, ACE inhibitors/sartans whenever deemed necessary); the use of lung US / bioimpedance assistance was not allowed in these patients.
10036454|NCT01815775|Experimental|Normal pressure hydrocephalus|Hydrocephalus patients planned for shunting surgery. They will undergo clinical and imaging examinations at day 1, 3 months and 1 year after their surgery.
10036455|NCT01815788|Experimental|Teo first|"Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000, 2000 Hz and 4000 Hz)~Patient 60 years of age and older,~No previous hearing aid"
10036456|NCT01815801|Experimental|Ventilated group|Lungs were mechanically ventilated during subclavian vein catheterization.
10036457|NCT01815801|Active Comparator|Control group|Lungs were not mechanically ventilated during subclavian vein catheterization.
10036458|NCT01815814|Experimental|Rolfing After 3-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 3 months after they start the study.
10036459|NCT01815814|Other|Rolfing After 6-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 6 months after they start the study.
10036460|NCT01815827|Active Comparator|Caucasian Healthy volunteers|
9478711|NCT03550339|Active Comparator|HAES|subjects attending Health At Every Size weight management program
10022321|NCT03068130|Experimental|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
9478712|NCT03550326||general anesthesia|Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management.
9478713|NCT03550300||Participants with CMT|Participants with CMT1A, CMT1B, CMT2A or CMTX1
9478714|NCT03550300||Control participants|Control participants
9478715|NCT03550274|Experimental|App-based exercise rehabilitation|Persons with Acute lateral ankle sprain (<48 hours) evaluated by a relevant health specialist in the hospital Emergency Department.
9478716|NCT03550248|Other|Intervention group|Participants will receive the intervention - Healthy Together (HT).
9478717|NCT03550118|Experimental|Adjustable Socket - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on socket size adjustments while walking.
9478718|NCT03550118|Experimental|Adjustable Socket - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on socket size adjustments while walking.
9478719|NCT03550118|Experimental|Adjustable Socket - Automatic Controls|An adjustable socket is tested where a control system is used to automatically control the adjustments. This arm focuses on socket size adjustments while walking.
9478720|NCT03550118|Experimental|Stress-Sensing Liner|An adjustable socket is tested in addition to a prosthetic liner with embedded stress sensors to measure mechanical stresses as the socket is adjusted.
10036461|NCT01815827|Experimental|Japanese Healthy volunteers|
9478721|NCT03550118|Experimental|Release/Recovery - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
9478722|NCT03550118|Experimental|Release/Recovery - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
10022322|NCT03067181|Experimental|Arm I (bleomycin, carboplatin, etoposide)|Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10022323|NCT03067181|Experimental|Arm II (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10022324|NCT03067181|Experimental|Arm III (bleomycin, etoposide, carboplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9478723|NCT03550105|Experimental|GJ-Only|Study Subjects with Baseline Glucose of > 150mg/dl, will have Gentle Jogger Only for 7 days
9478724|NCT03550105|Experimental|GJ-OGTT|Study Subjects with Baseline Glucose of < 150mg/dl, will have Oral Glucose Tolerance Test (OGTT) at baseline and after 7 days of Gentle Jogger
10022325|NCT03067181|Experimental|Arm IV (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
9478725|NCT03550079|Experimental|three screws fixation|femoral neck fractures were fixed with three converted screws
10022326|NCT03067181|Experimental|Low-Risk (observation)|Patients with low-risk stage I grade 2, 3 ovarian immature teratoma or stage I non-seminoma MGCTs undergo observation and can transfer to standard risk arm when eligibility criteria are met. Patients with stage I seminoma testicular MGCT undergo observation, and those with residual/recurrent disease are treated at the discretion of their physician.
9478726|NCT03550079|Experimental|four screws fixation|femoral neck fractures were fixed with four screws
9478727|NCT03550053|Active Comparator|Intraoperative plate bending|Plate will be bent intraoperatively, which is the standard of care, for this surgery
9478728|NCT03550053|Active Comparator|Preoperative plate bending|A 3D printed model of the patient's mandible will be used to bend the plate preoperatively by the surgeon. The pre-bent plate will be brought into the operating room on the day of surgery.
9478729|NCT03550040|Active Comparator|Robot assisted prostatectomy.|Intervention: radical prostatectomy
9478730|NCT03550040|Experimental|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
9478731|NCT03550027|Experimental|PleurX|Positioning of Pleurx drainage during surgical exploration if lung does not reinflate
9478732|NCT03550027|Experimental|Pleurocath|Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate
9478733|NCT03550014|Active Comparator|Low Back Only|Participants randomized to the Low Back Only arm will receive physical therapy as directed by the treating physical therapist targeting the lower back.
9478734|NCT03550014|Active Comparator|Low Back+Hip|Participants randomized to the Low Back+Hip arm will receive physical therapy as directed by the treating physical therapist targeting the lower back. In addition to that treatment, participants will received hands-on and exercise physical therapy interventions directed at the hip(s).
9478735|NCT03550001|Experimental|Injection CNP before NAT|Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.
9478736|NCT03550001|No Intervention|No injection|Do not inject carbon nanoparticle during the treatment.
9478737|NCT03549988||Control|"The group will receive current standard of care as the usual practice of the attending physician. Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on the baseline visit and month 6, 12 and month 18.~When endoscopy is performed biopsies should be taken and the endoscopic and histologic assessment will be recorded. If a fecal calprotectin is measured, every effort should be made to use the IBDoc with the result being sent to the central primary investigator via the IBDoc Web Portal. However, should a different fecal calprotectin measure be used, this will be recorded as part of the study documentation and will be included in the study data."
9478738|NCT03549988||Intervention: FC measurements with IBDoc|"Fecal Calprotectin (FC) measurements with IBDocTM home kits will be performed by participants in the intervention group every 2 months until final visit.~Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on baseline visit and month 6, 12 and month 18."
9478739|NCT03549975|Experimental|Botulinum toxin type A injection|Botulinum toxin type A injection followed by functional electrical stimulation
9478740|NCT03549936|Active Comparator|Low lactose formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula which arrives from milk lab labeled as formula A or formula B."
9478741|NCT03549936|Active Comparator|Regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive regular formula which arrives from milk lab labeled as formula A or formula B"
9478742|NCT03549923|Experimental|Simultaneous CRRT group|CRRT is initiated simultaneously (not late than 24 hours from the initiation of ECMO treatment), regardless of presentation of conventional indication of CRRT. CRRT lasts for 12 hours or more is recommended.The physician can decide when to withdraw CRRT based on the patient's condition.
9478743|NCT03549923|Experimental|Conventional-indication CRRT group|CRRT is not initiated unless conventional indication of CRRT is presented. The conventional indication of CRRT is as follow: KDIGO stage 3 AKI and one of the following criteria is met: severe hyperkalemia (> 6.5 mmol/L), metabolic acidosis (pH < 7.2), pulmonary edema, blood urea nitrogen level >112 mg/dL, or oliguria (urine output < 200 mL/12 h) for more than 72 hours.
9478744|NCT03549923|Experimental|Esmolol group|Patients will receive a continuous esmolol infusion in addition to routine management. The esmolol infusion commences at 25 mg/h and increases by 25 mg/h every 20-minute until the maximal tolerate dosage is reached or the heart rate reduced to 75±5 bpm, or an upper dose limit of 2000 mg/h is reached. Continue infusing esmolol to maintain the heart rate threshold or at the discretion of the physician until either ICU discharge or death. Oral beta-blockers should be considered before the withdrawal of esmolol.
9478745|NCT03549923|Experimental|Control group|All beta-blockers, including esmolol, should not be used during ICU treatment, unless the doctor thinks there's a strong indication.
9478746|NCT03549910|Experimental|Early use of APRVplus protocol in ARDS|physiology-driven APRVplus protocol
9478747|NCT03549910|Other|Low tidal volume ventilation|Low tidal volume lung protective ventilation
9478748|NCT03549897|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
9478749|NCT03549897|Active Comparator|90 mcg Reference Product|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
9478750|NCT03549897|Active Comparator|180 mcg Reference Product|One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
9478751|NCT03549897|Experimental|90 mcg Test Product|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
9478752|NCT03549884|Experimental|Delayed cord clamping (DCC)|Cord clamping will be performed after 60 seconds of life
9478753|NCT03549884|Active Comparator|Early cord clamping (ECC)|Cord clamping will be performed within 10 seconds of life
9802818|NCT04906421|Experimental|TVB-2640 75 mg|Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.
10022327|NCT03065465|Other|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis is performed using usual CURE hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1: 20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the SRH) of active bleeding or adherent clots (prior to snaring them off); coaptive coagulation with multipolar electrocautery (MPEC) probe and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by DEP. Hemostasis is performed until active bleeding stops and/or the SRH is obliterated. Residual blood flow after visually guided hemostasis is recorded, but not used as a guide for additional hemostasis in this study.
9480799|NCT05238987|Experimental|Healthy men (before-and-after (pre-post) study)|Partcipants will undergo a 75g oral glucose tolerance test (OGTT) to document baseline insulin secretion kinetics. One week later, OGTT will be repeated after administering a single dose of ferrous sulphate (120 mg of elemental iron) 2 hours prior to the test.
9480800|NCT05238753|Experimental|Intervention, stimulated|Electromagnetic stimulation of the phrenic nerve in critically ill patients.
10022328|NCT03065465|Experimental|Over-the-scope hemoclipping device|For those assigned OTSC, prior to use of the OTSC in UGI lesions with active bleeding or adherent clots, dilute epinephrine (1: 20,000) is injected around the SRH in 1-2 cc aliquots and the clots are cold guillotined off, as previously described (2, 4, 17). As a brief additional description, after initial diagnosis and preparation of the lesion and SRH (as described for standard hemostasis), the therapeutic sized endoscope is removed and this or a diagnostic panendoscope will be affixed with the OTSC of appropriate size for the endoscope and the target lesion. The endoscope is re-introduced and passed to the bleeding site. The SRH is centered in the field of view and within the cap of the OTSC device. Using high suctioning and firm pressure to center the SRH, the lesion and SRH is captured into the cap and the OTSC is deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue with mechanical hemostasis.
10022329|NCT03065192|Experimental|VY-AADC01 Single Dose|9.4 x 10^12 vector genomes of VY-AADC01
10022330|NCT03064854|Experimental|Group A: squamous, gem/cis+PDR001|
10022331|NCT03064854|Experimental|Group B: non-squamous, pem/cis+PDR001|
10022332|NCT03064854|Experimental|Group C: paclitaxel/carbo+PDR001|
9478754|NCT03549845|Experimental|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Health education sessions will include topics such as: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, and Appropriate use of 9-1-1. This intervention will be held in a common room in selected subsidized housing buildings.
9478755|NCT03549845|No Intervention|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
9478756|NCT03549832|Active Comparator|sof/sim/dac|Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin
9478757|NCT03549832|Active Comparator|sof/omb/parit|Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin
9478758|NCT03549819|Experimental|Cannabidiol (CBD) Oil Capsules|Pure CBD in sunflower lecithin oil, flexibly dosed at 200-800 mg per day
9478759|NCT03549819|Placebo Comparator|Sunflower Lecithin Oil in Capsule|1-4 capsules daily
9478760|NCT03549806||Prospective Cohort|No study intervention. Patients referred for ablation of atrial arrhythmias will be treated as per operator preference with no study intervention. Data will be collected in de-identified fashion.
9478761|NCT03549793|Experimental|dance thrapy|4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
9478762|NCT03549793|Active Comparator|exercises without dance|4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)
9478763|NCT03549780|Other|Stomal Occlusion|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
9478764|NCT03549767|Experimental|Springfusor|Women in this group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours through an IV infusion administered using a Springfusor pump.. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours.
9478765|NCT03549767|Active Comparator|Standard of care|The control group will have Magnesium sulphate administered using the Pritchard regimen, which involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours
9478766|NCT03549741|Experimental|study group|will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
9478767|NCT03549741|Active Comparator|control group|will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
9478768|NCT03549728|Experimental|Group A|Group A (N=44): women will receive intrauterine infusion of granulocyte colony-stimulating factor on the day of ovum-pick up during IVF cycle.
9478769|NCT03549728|Placebo Comparator|Group B|Group B (N=44): women will receive placebo intrauterine infusion of normal saline on the day of ovum-pick up during IVF cycle.
9478770|NCT03549702|Active Comparator|Povidone irrigation Group|Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
9478771|NCT03549702|No Intervention|Control Group|Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
9478772|NCT03549689|Experimental|Switch|Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
9478773|NCT03549689|Active Comparator|Continuation|Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
9480801|NCT05238753|No Intervention|Control, not stimulated|Control group, no stimulation of the phrenic nerve.
10022333|NCT03064854|Experimental|Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab|
9802819|NCT04906421|Placebo Comparator|Placebo|Subjects will receive matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.
9802820|NCT04905940|Experimental|Turmeric mouthwash|Evaluation of cost-effectiveness of turmeric mouthwash in controlling halitosis
9480802|NCT05238740|Active Comparator|Intervention group -5.4 cc ViviGen®|Biological: 5.4 cc ViviGen®The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 5.4 cc ViviGen®
9802821|NCT04905940|Active Comparator|Essential oil mouthwash|Evaluation of cost-effectiveness of essential oil mouthwash in controlling halitosis
9802822|NCT04905940|Placebo Comparator|Placebo mouthwash|Evaluation of cost-effectiveness of placebo mouthwash in controlling halitosis
9802823|NCT04905745||Facial palsy|Adulthood facial palsy patients group who receive Korean integrative medicine.
9802824|NCT04904549|Experimental|Stage 1: SARS-CoV-2 vaccine|2 injections of monovalent SARS-CoV-2 vaccine at Day 1 and Day 22
9802825|NCT04904549|Placebo Comparator|Stage 1: Placebo|2 injections of placebo at Day 1 and Day 22
10022334|NCT03064490|Other|Single arm interventional study|Single arm, non randomized, open label study. Subjects will receive three doses of neoadjuvant pembrolizumab (200 mg administered as an intravenous infusion over 30 minutes every 3 weeks). Pembrolizumab will be administered with weekly standard of care Carboplatin/Paclitaxel concurrent chemo-radiation therapy in the neo-adjuvant setting. Postoperatively, three additional cycles of pembrolizumab (200 mg every 3 weeks) will be administered as adjuvant therapy.
10022335|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
9478774|NCT03549676|Experimental|HSCT patients with refractory GVHD|Patients will accept FilmArray Gastrointestinal (GI) panel test before pre-treatment of HSCT and 28±3 days post-HSCT. Patients will receive 50ml fecal microbiota from unrelated healthy donors through nasojejunal tube and monitored under gastroscopy. Patients receiving FMT treatment will be followed for at least 6 months. The ideal follow up time is 2 year. Stool and blood samples will be serially collected and tested (before pre-treatment, 1/3/6/12 months after FMT).
9478775|NCT03549663|Experimental|Tacrolimus monotherapy|
9478776|NCT03549663|Active Comparator|Tacrolimus combined with hormone therapy|
9478777|NCT03549637|Experimental|Psychiatric population|"At inclusion: Patients will have A Lipid Panel Test, other biological analyzes and a clinical assessment. In case of a low LDL-C level (≤ 0, 50 g/L), genetic analyzes will be performed to screen for genetic forms of hypobetalipoproteinemia (HBL).~At 2- 4 weeks: for patients with HBL (LDL-C ≤ 0,50 g/L with no secondary cause of LDL-C reduction), another Lipid Panel Test will be performed to confirm the maintenance of the low LDL-C level.~At 6 months : Patients with a HBL will perform a full biological examination, and the LDL-C levels and genetic analyzes will be confirmed. A dietary survey will be performed, together with a psychiatric assessment. The same numbers of matched controls will performed a quick telephone interview to collect the psychiatric characteristics."
9478778|NCT03549624||Intervention group|"All adult (>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.~Patients will be treated with an perioperative regime/protocol consisting of:~Early so called NEWS-monitoring (measuring of standard physiological parameters);~Early start of antibiotics;~Rapid (within 6 hours) start of operation;~Goal-directed fluid therapy;~Intensified post-operative monitoring;~The presence of both surgical and anesthesiological specialists in the early care of the patients."
9478779|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
9478780|NCT03549611|Experimental|Multimodel Drug Regimen|"The patients randomized to this arm will receive the following multimodal oral drug regimen administered shortly before induction of general anesthesia~Tylenol, 975mg (3 tabs)~800mg Gabapentin~400mg Celecoxib~10mg Oxycodone"
9478781|NCT03549611|Active Comparator|Acetaminophen Only|"The patients randomized to this arm will receive oral acetaminophen only administered shortly before induction of general anesthesia~1. Tylenol, 975mg (3 tabs)"
10022336|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
10022337|NCT03057054|Experimental|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
10022338|NCT03057054|Placebo Comparator|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
9802826|NCT04904549|Experimental|Stage 2: SARS-CoV-2 vaccine|2 injections of bivalent SARS-CoV-2 vaccine at Day 1 and Day 22
9802827|NCT04904549|Placebo Comparator|Stage 2: Placebo|2 injections of placebo at Day 1 and Day 22
9802828|NCT04903977|Experimental|Impedance spectroscopy|ONIRY examination
9480803|NCT05238740|Active Comparator|Control group -4mg rhBMP-2|Biological: 4mg rhBMP-2The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 4mg rhBMP-2
9802829|NCT04903652|Experimental|Pyrotinib plus Vinorelbine|
10022339|NCT03056014|Active Comparator|N-acetylcysteine 600 mg|
10022340|NCT03056014|Active Comparator|N-acetylcysteine 1200 mg|
9478782|NCT03549572||Severe Traumatic Brain Injury|We will administer Coma Recovery Scale-Revised (CRS-R) and the Coma Recovery Scale Revised For Accelerated Standardized Testing (CRSR-FAST) to patients in the intensive care unit who have impaired level of consciousness resulting from a severe traumatic brain injury.
9478783|NCT03549546|Other|Patients undergoing lung cancer surgery|Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
9478784|NCT03549520|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of the contrast agent.
9478785|NCT03549455|Experimental|Exposure Therapy and Self Distancing|All subjects will have 2 introduction sessions and then receive Exposure therapy with Self-Distancing (2 weeks) following Exposure therapy without Self-Distancing (2 weeks) followed by 2 more weeks of Exposure therapy with Self-Distancing.
9478786|NCT03549442|Experimental|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
10022341|NCT03056014|Placebo Comparator|placebo|
10022342|NCT03056014|Active Comparator|PUFA 1000 mg|
10022343|NCT03056014|Active Comparator|PUFA 2000 mg|
10022344|NCT03056014|Placebo Comparator|Placebo|
10036462|NCT01815853|Experimental|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
10036463|NCT01815853|Active Comparator|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
10022345|NCT03054363|Experimental|Tucatinib in Combination with Palbociclib and Letrozole|During phase 1b part of this trial (N=20 patients), treatment will be administered in cycles of 28 days and consist of tucatinib 300 mg PO BID, palbociclib 125 mg PO daily for 21 days followed by 7 days off, and letrozole 2.5 mg PO daily. Dose modifications of tucatinib, palbociclib and letrozole will be allowed per protocol. There will be an interim safety analysis performed after enrollment of 10 patients. Safety analysis will take into account proportion of patients requiring dose modifications or interruption for therapy because of toxicity. If excessive toxicity or significant changes in PKs are found, further patients will be enrolled at a lower starting dose level. There will be a second interim safety analysis after enrollment of 20 patients in the study. Once the recommended phase II dose (RP2D) has been determined, testing of this drug combination will be expanded in the phase II part of this trial (N=20 patients) to determine the progression-free survival (PFS) rate.
10022346|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
10022347|NCT03052036|Other|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
10022348|NCT03052036|Other|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
9478787|NCT03549442|Experimental|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
10022349|NCT03050736|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
10022350|NCT03048578|Experimental|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
10022351|NCT03048578|Placebo Comparator|Placebo|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
10022352|NCT03042754|Other|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
10022353|NCT03034603|Experimental|Nutri-jelly with PEITC|Continuous intake of Nutri-jelly with PEITC for 200 milligrams per day, five days per week for 3 months.
9478788|NCT03549442|Experimental|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
10022354|NCT03034603|Placebo Comparator|Nutri-jelly|Continuous intake of Nutri-jelly for 200 milligrams per day, five days per week for 3 months.
10022355|NCT03029728||Participants with Hereditary Angioedema|Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years
10022356|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
10022357|NCT03026972|Experimental|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
10022358|NCT03026972|Experimental|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
10022359|NCT03026972|Experimental|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
10022360|NCT03026972|Experimental|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
10022361|NCT03026816|Experimental|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation
10022362|NCT03026218|Experimental|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
10022363|NCT03026218|Placebo Comparator|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
10022364|NCT03026218|Experimental|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
10022365|NCT03026218|No Intervention|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
10022366|NCT03019185|Experimental|Phase 2 Cohort|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
10022367|NCT03019185|Active Comparator|Phase 3 Bardoxolone Cohort|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
10022368|NCT03019185|Placebo Comparator|Phase 3 Placebo Cohort|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
10022369|NCT03017833|Experimental|Treatment (metformin, sapanisertib)|Patients receive metformin PO 1-3 times daily on days 1-42 and sapanisertib PO daily on days 15-42 of cycle 1. Patients then receive metformin PO daily and sapanisertib PO daily on days 1-28 of cycle 2 and beyond. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10022370|NCT03016065|Experimental|Pea Fiber|Snacks fortified with 10 g of pea hull fiber will be administered for two weeks, followed by a two-week washout, and a two-week period with control snacks.
10022371|NCT03016065|Placebo Comparator|Control|Control snacks will provided for 2 weeks, followed by a two-week washout, and snacks with 10 g/d of pea fiber for 2 weeks.
10022372|NCT03015792|Experimental|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
10022373|NCT03015194|Experimental|Laceration of Anterior Mitral Leaflet in Mitral Valve Failure Participants With no Surgical Option|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with transesophageal echocardiogram (TEE) or intracardiac echocardiography.
10022374|NCT03012815|Experimental|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
10022375|NCT03012815|Active Comparator|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
10022376|NCT03006432|Active Comparator|FOLFOX|Cycles every 15 days until progression desease
10022377|NCT03006432|Experimental|TFOX|Cycles every 15 days until progression desease
9480804|NCT05238480|Active Comparator|XC-XP-XP-XC Sequence|Use of the Xtreme Conventional mouthguard (XC) while playing rugby for first and fourth weeks and the Xtreme Pro mouthguard (XP) for the second and third weeks.
9478789|NCT03549442|Experimental|Phase A Expansion|Once safety of CART-BCMA/huCART19 combination therapy is established in Phase A, an expansion of Phase A will occur in which the Phase A target population (patients with relapsed/refractory multiple myeloma responding to a standard salvage therapy regimen) will receive both CART-BCMA and huCART19. Enrollment into the Phase A Expansion may occur concurrently with Phase B once opened.
9478790|NCT03549403|Experimental|Patient-centered telephone education|Patients receive the preoperative call home one week before the day surgery and postoperatively 3-8 days after the day surgery. On the day of surgery patients receive current education.
9478791|NCT03549403|No Intervention|Current education practice|Patient´s education is implemented in accordance with current practice, where day surgery adult patients receive preoperative education over the phone one week prior to day surgery and postoperative education during on the day of surgery.
9478792|NCT03549390|Experimental|Yoga|The yoga session will be held in a room where lighting, temperature and music can be regulated. The session will be led by a trained instructor and involve a combination of body postures, breathing techniques and meditation. There will be a series of progressive breath centred yoga poses named Sun Salutations A & B for participants to complete, which have been chosen based on PPI and current relevant yoga practices. Sun Salutations A & B will be completed in a continuous sequence and aim to be completed with one breath per pose, but can be modified based on participant ability.
9478793|NCT03549390|Experimental|Continuous exercise|The exercise will be 30 minutes of treadmill walking. During the initial stages of walking, participants will gradually be taken up to a speed that registers between 10 and 12 on the Borg Rating of Perceived Exertion (RPE) Scale, up to a maximum of 4.0 km/h. This speed will be fixed for the entire exercise period. This exercise intensity has been chosen as it is the exercise intensity matched to light-moderate physical activity.
9478794|NCT03549390|No Intervention|Control|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
9478795|NCT03549377||Rested|Based on Pittsburgh Sleep Quality Index, participants scoring in the top 10-20% will be assigned to the rested group and will experience deception as part of the delayed gratification task
9478796|NCT03549377||Sleep-deprived|Based on Pittsburgh Sleep Quality Index, participants scoring in the bottom 10-20% will be assigned to the sleep-deprived group and will experience deception as part of the delayed gratification task
9480805|NCT05238480|Active Comparator|XP-XC-XC-XP Sequence|Use of the Xtreme Pro mouthguard (XP) while playing rugby for first and fourth weeks and the Xtreme Conventional mouthguard (XC) for the second and third weeks.
9480806|NCT05238454|Experimental|Cohort 1: SCTV01C|
9480807|NCT05238454|Active Comparator|Cohort 1: Sinopharm inactivated COVID-19 vaccine|
9480808|NCT05238454|Experimental|Cohort 2: SCTV01C|
9480809|NCT05238454|Active Comparator|Cohort 2: Comirnaty|
9480810|NCT05238441|Experimental|SCTV01E and SCTV01E|SCTV01E on D0 and D180
9480811|NCT05238441|Active Comparator|Comirnaty and SCTV01E|Comirnaty on D0 and SCTV01E on D180
9480812|NCT05238441|Active Comparator|Comirnaty and Comirnaty|Comirnaty on D0 and D180
9480813|NCT05238324|Experimental|HMI-203 Low Dose Level Cohort 1|
9480814|NCT05238324|Experimental|HMI-203 Intermediate Dose Level Cohort 2|
9480815|NCT05238324|Experimental|HMI-203 High Dose Level Cohort 3|
9480816|NCT05237713|Other|Canakinumab treatment|200 mg canakinumab subcutaneously every three weeks
9480817|NCT05237557|Experimental|Interventional group|
9480818|NCT05237557|No Intervention|Control group|
9480819|NCT05237167|Experimental|Ultrasound|After randomization, these subjects will undergo diagnostic point-of-care ultrasound
9480820|NCT05237167|Active Comparator|Radiograph|After randomization, these subjects will undergo diagnostic plain radiograph
9480821|NCT05236933||Neuropathic|Individuals who report pain that is categorized as neuropathic will be assigned to this group.
9480822|NCT05236933||Nociceptive|Individuals who report pain that is categorized as nociceptive will be assigned to this group.
9480823|NCT05236829||Healthy group|Healthy women aged 18-55 who have not been diagnosed with any chronic disease and pituitary adenoma
9480824|NCT05236829||Patient with Prolactinoma group|Women between the ages of 18-55 diagnosed with Prolactinoma
9480825|NCT05236816|Experimental|Healthy|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
9480826|NCT05236478||CoviMouv' program|Patients who have benefited from the CoviMouv' program (supervised physical activity program + therapeutic education program) will be included.
9480827|NCT05236478||control group|Patients with autonomous physical activity at home or with a community-based physiotherapist will be included. They will have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
10022378|NCT03003065|Other|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
10022379|NCT03001011|Placebo Comparator|Placebo|Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (<=) 4.6 mg/dL (<=1.49 mmol/L).
9480828|NCT05236309||JGF (Jing-Guan-Fang): Traditional Chinese Medicine Decoction|JGF group: 100ml JGF decoction per day at least 1 week
9480829|NCT05236309||NO JGF|NO JGF group: None use traditional Chinese medicine(JGF)
9478797|NCT03549364|Experimental|Endurance race|"baseline investigations with CT and lab tests~the same CT and lab tests < 24h after an endurance race~CT and lab tests again about 1-2weeks after the race"
10022380|NCT03001011|Experimental|Renvela|Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus <=4.6 mg/dL (<=1.49 mmol/L).
10022381|NCT02999633|Experimental|Isatuximab|Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).
10022382|NCT02994030||Participants with Duchenne Muscular Dystrophy (DMD)|Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years
9802830|NCT04903080|Experimental|Treatment (HER2 CAR T cells), Phase I Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0. Treatment repeats every 8 to 12 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
10022383|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Concomitant Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
10022384|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Sequential Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Month 1 and Month 7. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the first 2 doses of CYD dengue vaccine.
9478798|NCT03549325|Experimental|Group 1|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner.~Follow up visits occur on Days 5, 14 and 32."
9478799|NCT03549325|Experimental|Group 2|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner.~Follow up visits occur on Days 15, 24 and 42."
9478800|NCT03549312|Experimental|Switch to Genvoya Followed By HCV Therapy Then Start Biktarvy|Oral Genvoya 150/150/200/10 mg & Epclusa 400/100 mg once daily. Once completed HCV therapy, switch anti-retroviral treatment to Oral Biktarvy 50/200/25 mg.
9478801|NCT03549299|Experimental|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10^4 cells per patient
9478802|NCT03549299|Experimental|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10^5 cells per patient
9478803|NCT03549299|Experimental|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10^5 cells per patient
9478804|NCT03549299|Experimental|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10^6 cells per patient
10022385|NCT02992418|Experimental|Concomitant Administration Group|Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.
10022386|NCT02992418|Experimental|Sequential Administration Group|Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.
10022387|NCT02984761|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
10022388|NCT02984761|Active Comparator|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
10022389|NCT02984124|Experimental|Intervention|Participants (n= approximately 100 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
10022390|NCT02984124|Placebo Comparator|Usual Care with Attention Control|Participants (n= approximately 100 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
10022391|NCT02980068|Experimental|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
10022392|NCT02980068|Experimental|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
10022393|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Concomitant Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
9518219|NCT03298633|Active Comparator|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
10022394|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Sequential Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
10022395|NCT02978911|Experimental|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
10022396|NCT02978716|Experimental|Group 1: Gemcitabine/Carboplatin (Days 1 and 8)|Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square [mg/m^2] and carboplatin area under the curve [AUC] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).
10022397|NCT02978716|Experimental|Group 2: Trilaciclib + Gemcitabine/ Carboplatin (Days 1 and 8)|Participants received IV infusion of trilaciclib 240 mg/m^2 plus GC chemotherapy (gemcitabine 1000 mg/m^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.
10022398|NCT02978716|Experimental|Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9)|Participants received IV infusion of trilaciclib 240 mg/m^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.
10036464|NCT01815866||CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
9478805|NCT03549286||pregnant women in the first trimester ultrasound consultation|Participation in the study will be offered to all pregnant patients, presenting for their first trimester ultrasound consultation in the obstetrics and gynecology department of the University Hospital of Reims. The study includes the consultations of all the certified doctors of the Maternity Department of the Reims University Hospital carrying out the first trimester ultrasounds. It will concern all the ranges of consultation regardless of the doctor who performs the consultation.
9478806|NCT03549260|Experimental|LIB003 150 mg or matching placebo|SC LIB003 150 mg or placebo every 4 weeks
9478807|NCT03549260|Experimental|LIB003 300 mg or matching placebo|SC LIB003 300 mg or placebo every 4 weeks
9478808|NCT03549260|Experimental|LIB003 350 mg or matching placebo|SC LIB003 350 mg or placebo every 4 weeks
10022399|NCT02977156|Experimental|Combination PexaVec + Ipilimumab|"PEXA-VEC (Pexastimogene devacirepvec): Oncolytic live replicating virus, Recombinant vaccinia virus GM-GCF of Classe 1, administered by Intra-tumoral injection with fixed-dosage regimen of 1x109 pfu (9.0 Log pfu)/ injection. Up to 5 IT injections, at Week 1 Day 1, Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed in case of disease progression following a documented objective response at W12. Provided by Transgene.~IPILIMUMAB: Anti-CTLA-4 monoclonal antibody (IgG1k) produced in CHO cells by recombinant DNA technology, administered by Intra-tumoral injection. Up to 4 IT injections at Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed In case of disease progression following a documented objective response at W12. Four dose levels of ipilimumab will be tested in dose escalation step: 2.5mg, 5mg, 7.5mg, 10mg, 20mg or 40 mg."
10022400|NCT02976220|Experimental|Digital Education|1 month digital education program
10022401|NCT02975934|Experimental|Rucaparib|Oral rucaparib (monotherapy).
10022402|NCT02975934|Active Comparator|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
10022403|NCT02974647|Experimental|rel/ref PTCLtumors are known to contain mutations associ|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
10036465|NCT01815879||Control Group|Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases
10036466|NCT01815892|Active Comparator|Withdrawal of Furosemide|The patient's Furosemide will be withdrawn
10022404|NCT02974647|Experimental|with rel/ref PTCL with functional evidence of JAK/STAT|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
10022405|NCT02974647|Experimental|with rel/ref PTCL who do not meet criteria for cohort 1 or 2.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours).Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
10022406|NCT02974647|Experimental|Rare sub-type expansion cohort: T-PLL and T-LGL and non-MF CTCL with JAK fusion mutations.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
9478809|NCT03549247||quality of life in periodontal healthy|250 individuals who have teeth pocket depth is at most 3 mm and there is no loss of attachment, no radiological bone loss and no gingival inflammation determeined for their quality of life
9478810|NCT03549247||quality of life in gingivitis|250 individuals who have teeth pocket depth in the mouth is at most 3 mm and there is no loss of attachment, no radiological bone loss and have chronic gingival inflammation with the sign of bleeding determeined for their quality of life
10022407|NCT02973321|Placebo Comparator|Placebo|Placebo (for SAR425899) subcutaneous (SC) injection once daily (QD) from Week 1 to Week 26, matching 3 SAR425899 dose levels of 0.12 mg, 0.16 mg and 0.20 mg.
10022408|NCT02973321|Experimental|SAR425899 0.12 mg|SAR425899 SC injection QD at maintenance dose of 0.12 mg for 25 weeks (Week 2 to Week 26) following 1 week dose increase step (0.06 mg at Week 1).
10036467|NCT01815892|Experimental|Administration of furosemide|The patient will receive furosemide 120 mgms daily
9478811|NCT03549247||quality of life in periodontitis|250 individuals who have more than 30% of teeth in the mouth which have pocket depths equal or more than 4mm and clinical attachment levels equal or more than 5mm and have radiologically detected bone loss determeined for their quality of life
9478812|NCT03549221|Experimental|MAC with adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
9478813|NCT03549221|No Intervention|MAC without adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
9478814|NCT03549208|Experimental|LBVE01|Multivalent pneumococcal conjugate vaccine
9478815|NCT03549208|Experimental|LBVE02|Multivalent pneumococcal conjugate vaccine
9478816|NCT03549208|Active Comparator|Prevnar13|Multivalent pneumococcal conjugate vaccine Prevnar13
9478817|NCT03549195|Active Comparator|ICG|
9478818|NCT03549195|Active Comparator|ICG-CP|CP, control peptide
9478819|NCT03549195|Experimental|ICG-TMTP1|also named as TMTP1-ICG
9478820|NCT03549182|Experimental|male TPH2-GG carriers with ATD then placebo group|male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.
9478821|NCT03549182|Experimental|male TPH2-GG carriers with placebo then ATD group|male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.
9478822|NCT03549182|Experimental|male TPH2-TTcarriers with ATD then placebo group|male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.
9478823|NCT03549182|Experimental|male TPH2-TTcarriers with placebo then ATD group|male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.
9478824|NCT03549169|Experimental|TOMAS|Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
9478825|NCT03549169|Other|Standard or regular attention|Regular attention is centered on education for therapeutic adherence
9478826|NCT03549156|Active Comparator|C-RUSF|Control/Standard RUSF
9478827|NCT03549156|Active Comparator|HIPRO RUSF|New RUSF product
9478828|NCT03549104|Experimental|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
9478829|NCT03549104|Active Comparator|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
9478830|NCT03549078|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
9478831|NCT03549065|Active Comparator|20 min active tDCS, and 20 min active rTMS|Applying active tDCS AND active TMS will reduce cue induced craving and opioid use, more than sham TMS AND sham tDCS and also either active TMS OR active tDCS alone. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), followed by 4000 pulses of real rTMS (10Hz over left Dorsolateral Prefrontal Cortex(DLPFC) for 20 minutes at 120%MT). There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS and the groups with only active tDCS OR active TMS.
9480999|NCT05101902||Overall Study|Participants will undergo antibody and genetic screen, initial pre-screening, eligibility monitoring and eligibility confirmation for potential transition to the treatment trial center once a treatment assignment in the study CAH-301 becomes available. Participation in Study CAH-300 is permitted to continue until treatment assignment is available in the treatment trial or unless, during eligibility monitoring or eligibility
10036468|NCT01815905|Active Comparator|Traditional therapy|Traditional rehabilitation therapy
9481000|NCT05101044|Experimental|Acceptance-based Behavioral Therapy (ABBT) Intervention|All recruited individuals will receive ABBT intervention. ABBT involves 2 sessions delivered within about a week of each other, consisting of a 20-25 minute session 1, and a 10 minute session 2.
10022409|NCT02973321|Experimental|SAR425899 0.16 mg|SAR425899 SC injection QD at maintenance dose of 0.16 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase step (0.06 mg at Week 1 and 0.12 mg at Week 2).
10036469|NCT01815905|Experimental|Mobile program|Mobile program for occupational and speech therapy
10036470|NCT01815931||ED patients|
10022410|NCT02973321|Experimental|SAR425899 0.20 mg|SAR425899 SC injection QD at maintenance dose of 0.20 mg for 23 weeks (Week 4 to Week 26) following 3 weeks dose increase step (0.06 mg at Week 1, 0.12 mg at Week 2 and 0.16 mg at Week 3).
10022411|NCT02973321|Active Comparator|Liraglutide|Liraglutide SC injection QD at maintenance dose of 1.8 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase steps (0.6 mg daily at Week 1 and by 1.2 mg daily at Week 2).
10022412|NCT02967250|Experimental|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
10022413|NCT02964585|Active Comparator|Active Arm|100 mg of Canagliflozin for 16 weeks
10022414|NCT02964585|Placebo Comparator|Placebo Arm|Placebo for 16 weeks
10022415|NCT02963844|Experimental|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
10022416|NCT02963844|Sham Comparator|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
10036471|NCT01815944|Active Comparator|0.75% Ropivacaine and normal saline|Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline
10036472|NCT01815944|Experimental|0.75% ropivacaine and dextrose 5%|Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%
10022417|NCT02962167|Experimental|Locally Recurrent Medulloblastoma/ATRT|Patients must have local recurrent disease (defined as negative spine MRI and negative cytology within 21 days prior to study registration) and undergo resection of local recurrence as part of their standard of care. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, directly into the tumor bed during standard of care resection.
10022418|NCT02962167|Experimental|Disseminated Recurrent MB/ATRT|Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
10022419|NCT02962167|Experimental|Disseminated Recurrent Medulloblastoma|Patients must have disseminated recurrent medulloblastoma (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
10022420|NCT02959320|Active Comparator|Direct Anterior Approach|All patients receiving a hip hemiarthroplasty through a Direct Anterior Approach (DAA) will have their surgeries performed with the aid of fluoroscopy on an OSI Hana table that allows the operative limb to be manipulated through range of motion and traction while keeping the pelvis stabilized. This table also has a radiolucent platform about the pelvis, enabling the surgery to be fluoroscopically assisted. The incision for the DAA will extend from a proximal point about 2 cm distal and 2 cm lateral to the ASIS to a point 8-12 cm distal and slightly lateral to this.
10022421|NCT02959320|Active Comparator|Anterolateral Approach|All patients receiving a hip hemiarthroplasty through an the Anterolateral Approach (ALA) will have their surgeries performed on a standard OR table in a contralateral lateral decubitus position. With the leg in the position of sleep, a straight 8-12 cm incision will be made, centered over the greater trochanter and femoral shaft with 1/3 of the incision extending superior to the tip of the greater trochanter.
10022422|NCT02950766|Experimental|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20~Ipilimumab will be injected within 1 cm of each NeoVax administration"
10022423|NCT02950766|Experimental|NeoVax alone|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)"
10022424|NCT02944188|Experimental|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
10022425|NCT02944188|Active Comparator|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
10022426|NCT02943785|Experimental|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet in case of transitioning at the end of treatment. Dosing must follow the locally approved label.
10022427|NCT02943785|Active Comparator|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
10022428|NCT02941705|Active Comparator|RECIEVED CELLS|this arm will receive the CDCs /CAP 1002 solution
10022429|NCT02941705|Placebo Comparator|CONTROL ARM|this arm will receive a solution during randomization but will not receive the CDCs
10022430|NCT02938143|Experimental|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
10022431|NCT02938143|Active Comparator|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
10022432|NCT02937818|Experimental|ARM A|
10022433|NCT02937818|Experimental|ARM B|
10022434|NCT02937818|Experimental|ARM C|
10022435|NCT02936947|Experimental|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
10022436|NCT02936947|Experimental|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
10022437|NCT02935946|No Intervention|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
10022438|NCT02935946|Experimental|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
10022439|NCT02935946|Experimental|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
10022440|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
10022441|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
10022442|NCT02933801|Experimental|Arm A: ODM-201|600mg ODM-201 BID (twice daily) and Best Supportive Care until progression
10022443|NCT02933801|Placebo Comparator|Arm B: Placebo|Placebo BID (twice daily) and Best Supportive Care until progression
10022444|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
10022445|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
10022446|NCT02932280|Experimental|Neratinib|There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
10022447|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
10022448|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
10022449|NCT02926768|Experimental|Daily dose of CK-101|Daily oral dose of CK-101
10022450|NCT02923674|Other|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3)."
10022451|NCT02923674|Other|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
9478832|NCT03549065|Active Comparator|20 min sham tDCS, and 20 min active rTMS|Applying sham tDCS AND active TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of real rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
9478833|NCT03549065|Active Comparator|20 min active tDCS, and 20 min sham rTMS|Applying active tDCS AND sham TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
9478834|NCT03549065|Sham Comparator|20 min sham tDCS, and 20 min sham rTMS|Applying sham tDCS AND sham TMS will not reduce cue induced craving and opioid use. We will apply 10 sessions of one hour of brain stimulation. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
9478835|NCT03549026|Experimental|duloxitine group|Patients will receive single oral dose of duloxetine capsule, 60 mg, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
9478836|NCT03549026|Placebo Comparator|placebo group|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
9478837|NCT03548974|Active Comparator|Interventiongroup1|passive, motor-driven movement therapy followed by intermittent active and passive training
9478838|NCT03548974|Active Comparator|Interventiongroup2|intermittent active and passive training followed by no intervention
9478839|NCT03548948|Other|High heme iron diet|
9478840|NCT03548948|Other|Low iron diet|
9478841|NCT03548948|Other|Plant-based high non-heme iron diet|
9478842|NCT03548922||Pectus carinatum|Demographic data (age, sex), pressure of correction, Tanner stage, Risser stage, Haller index, pectus carinatum protrusion measurements of patients with pectus carinatum will be recorded and association of them with pressure of correction will be investigated.
9478843|NCT03548909||ED Setting|An acute HF population enrolled at EDs. Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
9478844|NCT03548909||Outpatient Setting|A non-acute population enrolled at outpatient centers.Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
9478845|NCT03548896|Experimental|Dental Implants|Dental implants Titanium SLA treated surface of different dimensions according to the specific needs of the patient
9478846|NCT03548896|Experimental|Resorbable membrane|Resorbable membrane Cross link collagen membrane from porcine animal with a measure of 15 x 25 mm
9478847|NCT03548896|Experimental|Allograft|Allograft Bone from human source that is administered in a dosage of 1 cc per patient
10036473|NCT01815957|Experimental|Ranalozine|After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
10036474|NCT01815970|Experimental|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation
10036475|NCT01815996||Pregnant Women|"Females between the age of 18-80 who are pregnant~One time blood draw to look at patient's DNA"
9478848|NCT03548870|Experimental|Test with TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency TENS
9478849|NCT03548870|Sham Comparator|Test with sham-TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency sham-TENS
9478850|NCT03548857||COPD patients|COPD patients on the waiting list for a lung transplantation
9478851|NCT03548844|Experimental|local excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group)
10036476|NCT01815996||Pulmonary Embolism Patients|"Male and Female patients that have suffered a pulmonary embolism within the past 48 hours~One time blood draw to look at patient's DNA"
10022452|NCT02923674|Other|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
10022453|NCT02921971|Placebo Comparator|Placebo|Placebo (for SAR156597), single subcutaneous (SC) injection once in a week (QW) up to Week 24.
10022454|NCT02921971|Experimental|SAR156597|SAR156597 200 milligram (mg), single SC injection QW up to Week 24.
10022455|NCT02914912||GALS symptomatic patients group|Patents With symptoms of chronic mesenteric ischemia shall be investigated with GALS.
10022456|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
10022457|NCT02910986|No Intervention|Usual Care|Breast density notification using standard language reporting for dense and non-dense breasts within the mammogram results notification letter
10022458|NCT02910986|Active Comparator|Enhanced|Usual Care plus a written educational brochure
10022459|NCT02910986|Active Comparator|Interpersonal|Usual Care plus Enhanced plus interaction with a promotora (lay health educator)
10022460|NCT02908685|Experimental|Part 1 Group A: Adolescents and Adults (Risdiplam)|Adolescent and adult participants aged 12-25 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
10022461|NCT02908685|Placebo Comparator|Part 1 Group A: Adolescents and Adults (Placebo)|Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
9478852|NCT03548844|Active Comparator|total mesorectal excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (local excision group)
9478853|NCT03548831||MLH|Minilaparotomy Hysterectomy
9478854|NCT03548831||LAVH|Laparoscopic Assisted Vaginal Hysterectomy
9478855|NCT03548792|Other|RSA radiostereometric analysis|30 patients in each Group Persona or Nexgen will receive tantalus beads to achieve RSA analysis comparing micromevements in radiographs.
9478856|NCT03548792|Other|Clinical comparison|Clinical comarison using different patient reported outcome measures and objective measures (ActivePAL, walking speed)
9478857|NCT03548766|Experimental|Healthy Subjects|Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
9478858|NCT03548766|Experimental|Anemic Patients|Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
9478859|NCT03548753||Patients with Agatston score > 399|"Coronary computed tomography angiography with FFR-CT~Invasive coronary angiography with FFR"
9478860|NCT03548740||Group A|
9478861|NCT03548740||Group B|
9478862|NCT03548714|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
9478863|NCT03548714|Placebo Comparator|PT150 with placebo consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
9478864|NCT03548701||Emergency Department|Patients enrolled in the Emergency Department undergoing evaluation for threatened abortion abnormalities.
9478865|NCT03548701||Obstetric Clinic|Patients with normal pregnancies being treated at first obstetric visit in clinic.
9478866|NCT03548675|Experimental|Genotype-guided TCA treatment|Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
9478867|NCT03548675|Active Comparator|Standard TCA treatment|Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test
9478868|NCT03548662|Experimental|Platelet-Rich Plasma Protein (PRP) Group|Subjects in this group will receive PRP injection into tear site, followed by rehabilitative exercise
9478869|NCT03548662|Active Comparator|Hyaluronic Acid Group|Subjects in this group will receive one injection with hyaluronic acid followed by rehabilitative exercise
9478870|NCT03548649|Experimental|exoskeleton robot training group|subjects will receive exoskeleton robot training for 20 sessions (1 hr/session).
9478871|NCT03548636|Experimental|Single-Arm Feasibility Study|Participant determined 6-month physical activity program
9478872|NCT03548610|Experimental|Nanofat-seeded biological scaffold on surgical defect|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical & local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film & 3 layers of dressings. Topical application creates a fine <1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 & 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours & suture removal (if not absorbed) at 7 days.
9478873|NCT03548610|No Intervention|Standard of Care dressings|Immediately after surgical resection, each patient will be treated following the SOC, therefore with a local skin flap, rather than with a skin graft, based on surgeon assessment. Sutures, and moulage, if present, will be removed at 7 days and patient instructed to apply a daily silicone cream and sunscreen for 2 months.
9478874|NCT03548571|Experimental|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
9478875|NCT03548571|Active Comparator|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
9478876|NCT03548545|Experimental|CBT combined with active tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with active tDCS over the dorsolateral prefrontal cortex.
9478877|NCT03548545|Sham Comparator|CBT combined with sham tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with sham tDCS over the dorsolateral prefrontal cortex.
9478878|NCT03548506|Active Comparator|STN_O|Omnidirectional Deep Brain Stimulation of STN
9478879|NCT03548506|Experimental|STN_D|Directional Deep Brain Stimulation of STN
9478880|NCT03548493|Experimental|Magnesium (M) group|Magnesium (M) group (n=17) , in which magnesium sulphate is given as adjuvant to propofol for sedation
9478881|NCT03548493|Active Comparator|Fentanyl (F) group|Fentanyl (F) group (n=17), in which fentanyl is given as adjuvant to propofol for sedation
9478882|NCT03548480|Placebo Comparator|Placebo|
9478883|NCT03548480|Experimental|Probiotic|
10022462|NCT02908685|Placebo Comparator|Part 1 Group B: Children (Placebo)|Children aged 2-11 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
10036477|NCT01815996||Myocardial Patients|"Male and Female patients who have myocardial infarction in the past 48 hours.~One time blood draw to look at patient's DNA"
10022463|NCT02908685|Experimental|Part 1 Group B: Children (Risdiplam)|Children aged 2-11 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
10022464|NCT02908685|Placebo Comparator|Part 2: Placebo|Participants aged 2-25 years will receive placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants will be switched to risdiplam (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20) in a blinded manner and participants will continue with treatment until Month 24. After Month 24, participants will be offered the opportunity to enter the open-label phase.
10022465|NCT02908685|Experimental|Part 2: Risdiplam|Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20 kg), for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label phase.
10022466|NCT02908334|No Intervention|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
10022467|NCT02908334|Experimental|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
10022468|NCT02906397|Experimental|Experimental: Galunisertib/SBRT|Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28
10022469|NCT02905669|Experimental|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
9478884|NCT03548454|Experimental|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
9478885|NCT03548454|Experimental|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
9478886|NCT03548441||Surgery|Exposed
9478887|NCT03548441||Non-surgical management|Non-exposed
9518220|NCT03298633|Active Comparator|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
9518221|NCT03298620|Experimental|Intervention|Electric toothbrush
9518222|NCT03298620|Active Comparator|Control|New standard manual toothbrush
9518223|NCT03298607|Placebo Comparator|Placebo|2 capsules daily for 2 months containing inactive substances
9478888|NCT03548389|Experimental|Mother and newborn skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
9478889|NCT03548389|No Intervention|Conventional care|In the routine care group, the infant was delivered from the mother by a midwife, wrapped in blankets, taken to be routinely cared under a warmer, and then dried quickly. Afterwards, the Apgar score was determined immediately after the umbilical cord was cut. The infants were provided with all routine care by the midwife working in the delivery room. After the infants were weighed, dressed, and measured, they were handed to their mothers who were encouraged to begin breastfeeding.
9478890|NCT03548376|Experimental|One-group intervention|Hippotherapy sessions were delivered once a week for 30 minutes, during 6 months.
9478891|NCT03548363|Active Comparator|Gingest High|200 mg/d Gingest (powdered extract obtained from Ginger rhizomes) for 4-weeks
9518224|NCT03298607|Active Comparator|Serelys PMS|2 capsules daily for 2 months containing pollen extract
10022470|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 50mg twice daily|Monotherapy Part 1a: INCB001158 administered orally in patients with advanced/metastatic solid tumors. Escalating doses will be explored to determine the recommended phase 2 dose (RP2D).
9478892|NCT03548363|Active Comparator|Gingest low|100 mg/d Gingest (powdered extract obtained from Ginger rhizomes) + 100 mg maltodextrin for 4-weeks
9478893|NCT03548363|Placebo Comparator|Placebo|200 mg/d maltodextrin for 4-weeks
10022471|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 75mg twice daily|Monotherapy Part 2a: INCB001158 administered orally at the RP2D in patients with advanced/metastatic NSCLC (EGFR and Anaplastic Lymphoma Kinase (ALK) negative) previously treated with Standard of Care (SOC).
10022472|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 100mg twice daily|Monotherapy Part 2b: INCB001158 administered orally at the RP2D in patients with advanced/metastatic CRC previously treated with SOC.
10022473|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 150mg twice daily|Monotherapy Part 2c: INCB001158 administered orally at the RP2D in patients with Bladder Cancer, Gastric or Gastroesophageal Junction (GEJ) Cancer, Renal Cell Cancer (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Cell Cancer (UCC), or Melanoma, previously treated with SOC.
10022474|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 50mg twice daily|Monotherapy Part 2d: INCB001158 administered orally at the RP2D in patients with any tumor types in Parts 2a, 2b, or 2c.
10022475|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 75mg twice daily|Combination Part 1b: INCB001158 and Pembrolizumab administered in patients with advanced/metastatic NSCLC, Melanoma, Urothelial Cell Cancer, MSI CRC, MSS CRC, Gastric or Gastroesophageal Junction (GEJ) Cancer, SCCHN and Mesothelioma. Multiple dose levels will be explored to determine the recommended phase 2 dose (RP2D).
10036478|NCT01815996||Autoimmune Patients|"Male and Female patients that have been diagnosed with an Autoimmune disease~One time blood draw to look at patient's DNA"
10036479|NCT01815996||Healthy Controls|"Self-declared healthy adults (men and women).~One time blood draw to look at patient's DNA"
9518225|NCT03298594|Experimental|specific cervicograph|Specific cervicograph, including an alert line (normal progression of cervical dilation, i.e. 1 cm per hour) and an action line 2 hours after the alert line. This should be completed after the diagnose of active labor
10022476|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 100mg twice daily|Part 3a: INCB001158 and Pembrolizumab the combination RP2D in patients with advanced/metastatic NSCLC (EGFR and ALK negative) with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
10036480|NCT01816009|Experimental|6 weeks|the duration of antibiotic treatment will be six weeks.
9518226|NCT03298594|No Intervention|Usual cervicograph|The usual cervicograph in our unit is not having lines
9518227|NCT03298581|Experimental|Halobetasol propionate spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
10022477|NCT02903914|Experimental|INCB001158 50 mg BID in combination with pembrolizumab|Part C: evaluated a reduced dose of INCB001158 50 mg BID in combination with pembrolizumab with patients with moderately impaired renal function.
10022478|NCT02903615|Experimental|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
9802831|NCT04903080|Experimental|Treatment (HER2 CAR T cells), Surgical Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0 followed by surgical tumor resection 4-6 weeks following HER2 CAR T cell infusion. Treatment repeats every 8 to 15 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
9802832|NCT04899141||Coronary Artery Disease|
9478894|NCT03548350|Experimental|Intervention|"The experimental group will participate in a 24 week multi-component programme that includes four strands:~A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).~'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week~After schools club (not compulsory) featuring mind-set component delivered by external facilitators~Healthy kidz app with reward system"
9802833|NCT04895644|Experimental|No Hard Collar|Patient randomised to not wearing a Hard Collar for 12 weeks
10022479|NCT02903615|Placebo Comparator|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
10022480|NCT02902250|Experimental|Decompression|bone marrow decompression at fractured vertebral body
10022481|NCT02902250|Active Comparator|vertebroplasty|vertebroplasty for compression fracture
10036481|NCT01816009|Active Comparator|12 weeks|the duration of antibiotic treatment will be 12 weeks.
9478895|NCT03548350|No Intervention|Control|The control group will continue doing physical activity including physical education as is normal for their school
9478896|NCT03548324|Active Comparator|HHHFNC|Heated Humidified High Flow Nasal Cannulae
9478897|NCT03548324|Active Comparator|NCPAP|Nasal Continuous Positive Air Pressure
9478898|NCT03548311|Placebo Comparator|Placebo|intramuscular injection of saline solution
9478899|NCT03548311|Active Comparator|methylcobalamin|intramuscular injection of methylcobalamin
9478900|NCT03548298|Experimental|GERD without hiatal hernia|Participants with GERD without hernia hiatal will receive ARAT
9518228|NCT03298568|Experimental|DAOsin treatment|Patients suffering from histamine intolerance and a diamin oxidase activity below 10 Units/ml get a DAOsin treatment for one month 3 times a day.
10022482|NCT02901067|Experimental|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
10022483|NCT02901067|Placebo Comparator|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
10022484|NCT02900482||case group|Patients with a history of congenital hip dislocation
10022485|NCT02900482||control group|Patients with no history of congenital hip dislocation
10022486|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
10022487|NCT02895906|Experimental|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
10022488|NCT02890355|Experimental|Arm I (veliparib and mFOLFIRI)|Patients receive veliparib PO BID every 12 hours on days 1-7, irinotecan hydrochloride IV over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5.
10022489|NCT02890355|Active Comparator|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3.
10022490|NCT02890329|Experimental|Arm A (decitabine, ipilimumab)|"PRIMING PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
10022491|NCT02890329|Experimental|Arm B (decitabine, ipilimumab)|"PRIMING PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
10022492|NCT02887651|No Intervention|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
9802834|NCT04895644|No Intervention|Standard Care Arm - Hard Collar|Patient randomised to wearing a Hard Collar for 12 weeks - standard care
10022493|NCT02887651|Active Comparator|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
10036482|NCT01816035|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
10036483|NCT01816087|Experimental|brief assessment tool (BAT)|all participants will have a brief assessment tool (BAT) for the identification of geriatric syndromes performed by their general practitioner. Afterwards, all participants will have a full geriatric assessment performed by geriatricians
9518229|NCT03298555|Experimental|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
10022494|NCT02886286|Experimental|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
10022495|NCT02886286|Active Comparator|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.
10022496|NCT02876640|Experimental|Treatment (retinoid 9cUAB30)|Patients receive retinoid 9cUAB30 PO QD for 14 to 28 days. Patients then undergo tumor resection surgery.
10022497|NCT02874742|Experimental|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
9518230|NCT03298555|No Intervention|Control|This group will only receive standard care.
10022498|NCT02874742|Experimental|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
10022499|NCT02872259|Experimental|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
9802835|NCT04894188|Experimental|Neoadjuvant RT and ADT|"Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).~Gosereline 3.6mg sc injection at week 1, week 5, and week 9"
9802836|NCT04894188|Active Comparator|Neoadjuvant ADT|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
9478901|NCT03548272|Experimental|BiOSS LIM C|"Intervention: Percutaneous coronary intervention (PCI) with BiOSS LIM C stent implantation.~The BiOSS LIM C® is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 µm) releasing sirolimus (1.4 µg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids (PGLA). The degradation of the polymer lasts approximately 8 weeks. The BiOSS LIM C® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller. The proximal part is always a bit shorter than the distal one (avg. 1 mm)."
9478902|NCT03548272|Active Comparator|regular 2nd generation DES|"Intervention: Percutaneous coronary intervention (PCI) with regular drug-eluting stent implantation (rDES).~rDES well-tested and available on the market. Xience, Orsiro, Resulte Integrity"
9478903|NCT03548259|Experimental|Experimental|Platelet-rich plasma
9478904|NCT03548259|Placebo Comparator|Platelet-poor plasma|Platelet-poor plasma
9478905|NCT03548233|Other|bcg vaccinated|children under five year vaccinated by bcg vaccine
9478906|NCT03548220|Experimental|AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual's response in Part 1."
9478907|NCT03548220|Placebo Comparator|Placebo|"Part 1 (Dose Optimization Period): Participants will receive placebo matching AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of placebo matching AG-348 as determined by the individual's response in Part 1."
9478908|NCT03548194|Experimental|BNC210|Administered orally b.i.d. for 5 days.
9478909|NCT03548194|Placebo Comparator|Placebo|Administered orally b.i.d. for 5 days.
9478910|NCT03548181|Experimental|"Intervention group tele-rehabilitation"|"Each patient will have the opportunity to have minimum one Video Consultation (VC) per week the first month, one VC each second week the second month one VC a month the rest of the trial.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home. A digital diary will automatically register the data obtained by the system on patient's performance."
9478911|NCT03548181|Active Comparator|Control|Patients will be followed, but they do not get any other kind of treatment comparable to the intervention group treatment.
9478912|NCT03548168||Healthy Adults|Eligible healthy young adults, aged 18-30 years, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
9478913|NCT03548168||Low Back Pain|Eligible young adults, aged 18-30 years, with chronic low back pain will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
9478914|NCT03548168||Older Adults|Eligible healthy middle aged and older adults, aged 55 years and older, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
9478915|NCT03548168||Trunk Experts|Eligible healthy middle aged and older adults, aged 55 years and older, with high levels of trunk muscle control (ie. individuals with expertise in the Pilates Method of exercise) will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
9478916|NCT03548155|Experimental|berberine group|
9802837|NCT04892602||Rheumatiod arthritis patients|
9802838|NCT04892602||Psoaritic arthritis|
9802839|NCT04892602||Control group|
10022500|NCT02872259|Experimental|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
10022501|NCT02872259|Active Comparator|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
10022502|NCT02872259|Active Comparator|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
10022503|NCT02867384|Active Comparator|Obinutuzumab|"Obinutuzumab or will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
9478917|NCT03548155|Placebo Comparator|control group|
10022504|NCT02867384|Sham Comparator|Placebo|"Placebo will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
10022505|NCT02865187|Experimental|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
10022506|NCT02865187|Active Comparator|Vit D + non-hormonal contraception|600IU/day Vitamin D
9478918|NCT03548129|Active Comparator|Fosfomycin group (FG)|"Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.~The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.~Response to treatment will be assessed by post-treatment urine culture."
10022507|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
10022508|NCT02853214|Experimental|Identification of genetic factors in dysglobulinemia cases|
9478919|NCT03548129|Active Comparator|Culture specific group (CG):|"Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.~Response to treatment will be assessed by post-treatment urine culture."
9478920|NCT03548103|Experimental|Green Tea Extract|Green Tea Extract 500 mg per capsule
9478921|NCT03548103|Placebo Comparator|Placebo|Identical Placebo capsule
9478922|NCT03548090|Experimental|1|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
9478923|NCT03548090|Experimental|2|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
9478924|NCT03548090|Experimental|3|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
9478925|NCT03548090|Experimental|4|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
9478926|NCT03548090|Experimental|5|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
9478927|NCT03548090|Experimental|6|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
9478928|NCT03548090|Experimental|7|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
9478929|NCT03548090|Experimental|8|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
9478930|NCT03548090|Experimental|9|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
9478931|NCT03548090|Experimental|10|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
9478932|NCT03548090|Experimental|11|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
9478933|NCT03548090|Experimental|12|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
9478934|NCT03548090|Experimental|13|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
9478935|NCT03548090|Experimental|14|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
9478936|NCT03548090|Experimental|15|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
9478937|NCT03548090|Experimental|16|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
10022509|NCT02849496|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II.
10022510|NCT02849496|Experimental|Arm II (olaparib, atezolizumab)|Patients receive olaparib as Arm I and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022511|NCT02848001|Experimental|CC-90009 - Part A|Will be administered intravenously per dosing schedule in a 28-day cycle.
10022512|NCT02848001|Experimental|CC-90009 - Part B - AML and MDS patients|Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A
10022513|NCT02838927||Hypoparathyroidism|No intervention.
10022514|NCT02836249|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
10022515|NCT02836249|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
10022516|NCT02836249|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
10022517|NCT02833883|Experimental|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day & enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day & enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional in the expansion phase treated at 7.5 mg BID. Amended to treat expansion group with 5mg BID of CC-115.
10022518|NCT02832167|Experimental|Nivolumab|
10036484|NCT01816100|Experimental|exercise session|"6 months weight resistance session, with before/after evaluations by MEG and DTI. Fifty minute exercise sessions, twice weekly will be done. Each session will rotate between 3 separate exercise protocols: Static weights, free weights and balance. Exercises will be done with each extremity independently. For consistency and convenience, the resistance training will be performed at Fast Forward Gym, Omaha, NE.~The primary outcome exercise data include strength and endurance"
10036485|NCT01816113|Experimental|Group 1|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
10036486|NCT01816113|Experimental|Group 2A|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
10036487|NCT01816113|Experimental|Group 2B|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10^8 pfu 8 weeks later intramuscularly
10036488|NCT01816113|Experimental|Group 2C|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10^8 pfu 8 weeks later intramuscularly
10036489|NCT01816126||one-operator technique|
10036490|NCT01816126||two-operator technique|
10036491|NCT01816178|Experimental|communication training|Participants were instructed in the use of a voices output communication aid.
10036492|NCT01816191|Experimental|Diltiazem Hydrochloride|Topical cream and oral pill
10036493|NCT01816204|Experimental|Therapist assisted online treatment (TAO)|Students assigned to treatment with weekly online modules and weekly 10-15 minute video conference with counselor.
10036494|NCT01816204|Active Comparator|face-to-face individual therapy|weekly individual 50 minute psychotherapy sessions.
10036495|NCT01816217|Experimental|Intubated patient|Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)
10022519|NCT02829931|Experimental|Combination Therapy|"Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab.~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab"
10036496|NCT01816256|Other|Screening tests|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
10036497|NCT01816269||Patients with scaling and patients without scaling|No drug
10036498|NCT01816269||Helicobacter eradicated or non-eradicated|
10036499|NCT01816282|Experimental|Evicel|
9518231|NCT03298542|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
10036500|NCT01816282|No Intervention|Control|
10036501|NCT01816321|Experimental|Corifollitropin alfa followed by hpHMG|
9478938|NCT03548090|Experimental|17|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
9478939|NCT03548090|Experimental|18|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
9478940|NCT03548090|Experimental|19|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
9478941|NCT03548090|Experimental|20|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
9478942|NCT03548090|Experimental|21|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
9478943|NCT03548090|Experimental|22|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
9478944|NCT03548090|Experimental|23|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
9478945|NCT03548090|Experimental|24|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
9478946|NCT03548077|Experimental|Intervention group|Powerplay, a workplace wellness program designed for male-dominated work sites, is the intervention. The program focuses on physical activity, healthy eating, mental wellness, and smoking cessation as well as promoting changes in workplace environments to support employee health and wellness. Program delivery is supported with a detailed program manual and web-based resources. More information about the intervention is available here: http://www.powerplayatwork.com/
9518232|NCT03298542|Placebo Comparator|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
10022520|NCT02829918|Experimental|Nivolumab Treatment|This is a single arm study with two stage design using nivolumab in advanced biliary tract cancer (BTC), for participants who have failed or are intolerant to at least one line of therapy and no more than 2 lines of therapy. In the first stage, 18 participants will be accrued. If there is at least one response (or several participants with stable disease based on the study team's discretion), an additional 34 patients will be accrued for a total of 52 patients.
10022521|NCT02829723|Experimental|BLZ945 single agent|
10022522|NCT02829723|Experimental|BLZ945 + PDR001|
10022523|NCT02826707|Experimental|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
10022524|NCT02826707|No Intervention|Control group|Pragmatic no-contact control group
10022525|NCT02826512|Experimental|Niraparib|niraparib 300 mg QD continuously
10022526|NCT02824263|No Intervention|CPAP (Usual care)|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
10022527|NCT02824263|Experimental|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
10022528|NCT02824198|Experimental|CYD Dengue Vaccine booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD63).
10022529|NCT02824198|Placebo Comparator|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received an injection of a placebo at Day 0 in this study (CYD63).
10022530|NCT02823262|Experimental|Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.~-- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
10022531|NCT02823262|Active Comparator|No Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~Participant will receive Usual Care assistance when making treatment decisions.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
10022532|NCT02821754|Experimental|1/A1-Durvalumab + Tremelimumab|Durvalumab + Tremelimumab
10022533|NCT02821754|Experimental|2/A2 - Durvalumab + Tremelimumab + Trans-arterial Catheter Chemoembolization (TACE)|Durvalumab + Tremelimumab + TACE
10022534|NCT02821754|Experimental|3/A3 - Durvalumab + Tremelimumab+ Radiofrequency Ablation (RFA)|Durvalumab + Tremelimumab+ RFA
10022535|NCT02821754|Experimental|4/A4 - Durvalumab + Tremelimumab+ Cryoablation|Durvalumab + Tremelimumab+ Cryoablation
10022536|NCT02817126|Experimental|Robot-assisted surgery|Patients undergo robot-assisted resections.
10022537|NCT02817126|Active Comparator|Laparoscopic surgery|Patients undergo laparoscopic resections.
10022538|NCT02817074|Active Comparator|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
10022539|NCT02817074|Placebo Comparator|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
10036502|NCT01816321|Active Comparator|recombinant FSH|
10036503|NCT01816334|Active Comparator|methylprednisolone|administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
10036504|NCT01816334|Active Comparator|Ketoprofen|administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
10036505|NCT01816334|Placebo Comparator|sodium chloride|administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
10036506|NCT01816347||Routine PCI patients|
9478947|NCT03548051|Experimental|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
9478948|NCT03548051|Experimental|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
9478949|NCT03548038||Bariatric surgery patients|All subjects will be patients scheduled for bariatric surgery. There is only one arm in this study.
9478950|NCT03548025|Experimental|Treatment Group|Treated group of subjects, serves as its own control
9478951|NCT03548012|Experimental|The Carer Support Needs Assessment Tool (CSNAT) intervention|('Standard' basic palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
9478952|NCT03548012|No Intervention|Control|('Standard' basic palliative care). No intervention offered.
9478953|NCT03547986|Experimental|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
9478954|NCT03547986|Experimental|IVUS with Intraarterial pressure measurement (IAP)|Standard angiography and Intra-Vascular Ultrasound (IVUS) with Intraarterial pressure measurement (IAP) are performed on the same patients (paired data)
9478955|NCT03547960|Experimental|Guar gum in women with early GDM|5 g of Guar gum fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
9478956|NCT03547960|Placebo Comparator|Control/Cellulose in women with early GDM|5 g of Cellulose fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
9478957|NCT03547934|Experimental|Treatment Group|Treatment with the investigated device - High Intensity Focused ElectroMagnetic System
9478958|NCT03547921||operative|operative
9478959|NCT03547921||non operative|non operative
9478960|NCT03547895|Active Comparator|cases|"patients with decompensated cirrhosis~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)"
9478961|NCT03547895|Placebo Comparator|control group|the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion
9478962|NCT03547830|Experimental|Plerixafor/G-CSF|Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients
9478963|NCT03547817|Experimental|Optimal negative pulse pressure regime|The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber of the intermittent negative pressure device. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels. The order of the different negative pressure levels will be randomized to avoid causal interference.
9478964|NCT03547804|Experimental|experimental arm|apatinib 500 mg qd;The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events.Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
9478965|NCT03547791|Active Comparator|ACS (Group 1)|Intramuscular injection of betamethason sodium phosphate 12mg (3ml) twice 24hours apart
9478966|NCT03547791|Placebo Comparator|Placebo (Group 2)|Intramuscular injection of normal saline 3ml twice 24hours apart
9478967|NCT03547778|Experimental|Misoprostol group|Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).
9478968|NCT03547778|Placebo Comparator|Placebo group|Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.
9478969|NCT03547752|Active Comparator|Effective movement group|Observation of a video of neck movement at 100% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
9478970|NCT03547752|Experimental|Ineffective movement group|Observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
9478971|NCT03547713|Experimental|Study group|social feedback and neuropsychological assessment
9518233|NCT03298529|Experimental|Traditional egg pasta|"Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
10022540|NCT02810743|Active Comparator|ddAC-CP-Olaparib|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~CP; carboplatin/paclitaxel (CP) consisting of carboplatin (AUC 6) on day 1 and paclitaxel (80 mg/m2) on day 1,8 and 15 of a 21 days cycle. In total 4 courses of CP will be administered.~Olaparib will be administered in Dutch centers only, as monotherapy for one year at a dose of 300 mg BID, starting 3 weeks after adjuvant radiotherapy, or, if radiotherapy is not indicated, 3-5 weeks after the last CP cycle.~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
10036507|NCT01816360|Experimental|Aromatherapy group|20 sessions of olfactory aromatherapy using protocol.
10036508|NCT01816360|Experimental|Yogatherapy group|20 sessions of yogatherapy with aroma-placebo using protocol.
10036509|NCT01816360|Experimental|Aromatherapy-Yogatherapy group|20 sessions of yogatherapy with olfactory aromatherapy, using protocol.
10036510|NCT01816360|No Intervention|Control group|Control group in the waiting-list model (all volunteers were offered the treatment after the completion of data collection).
10036511|NCT01816373|Other|Vacuum Bell|Patients with pectus excavatum will be treated with the Vacuum Bell device
10036512|NCT01816386|Active Comparator|Acupuncture Regimen|Standard anaesthetic procedure plus press needle acupuncture
10022541|NCT02810743|Active Comparator|ddAC-mini CTC|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle~intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin (400 mg/m2; (or AUC=5 in patients with a calculated creatinine-clearance of <100 ml/min)) days 1,2 thiotepa 250 mg/m2 day 2~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
10022542|NCT02809586|Active Comparator|SMI + Incentives|A Social Media + Incentives (SMI + I) condition
10022543|NCT02809586|Active Comparator|SMI|A Social Media Intervention (SMI) condition
10022544|NCT02809586|No Intervention|Control|An Attention-Control E-News (CONTROL) condition
10022545|NCT02805803|Other|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:~SF12~Beck~WOMAC"
10022546|NCT02801045|Experimental|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
10022547|NCT02792114|Experimental|T-cell infusion|A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined & can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen & diphenhydramine, & administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.
10022548|NCT02791997|Experimental|Brain-damaged patients|
10022549|NCT02791997|Experimental|Control participants|
10022550|NCT02791997|Experimental|Migraine patients|
10022551|NCT02789098|Other|STEMI|All patients included in this study (1 arm)
10022552|NCT02787551|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|"Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.~Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted."
10022553|NCT02787551|Active Comparator|GLP-1 Receptor Agonist|Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily [BID], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
10022554|NCT02782871|No Intervention|Control|Manual ventilation with Mapleson C-circuit
10022555|NCT02782871|Experimental|Intervention|Pneupac VR1 portable ventilator
10022556|NCT02778685|Experimental|Cohort 3 (letrozole, palbociclib, fulvestrant, pembrolizumab)|Patients receive either letrozole PO QD on days -28 to -1 and days 1-28, or fulvestrant on days -28, -14, and day 1 of subsequent cycles. Patients also receive palbociclib PO QD for 3 weeks. Cycles with palbociclib, and letrozole or fulvestrant repeat every 28 days in the absence disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022557|NCT02778685|Experimental|Cohorts 1 and 2 (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Cycles with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022558|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
10022559|NCT02764541|Experimental|Arm A Tamoxifen followed by Endocrine Therapy|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
10022560|NCT02764541|Experimental|Arm B Letrozole Followed By Endocrine Therapy|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
10022561|NCT02764541|Experimental|Tamoxifen Followed By Endocrine Therapy and Palbociclib|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
10022562|NCT02764541|Experimental|Letrozole Followed By Endocrine Therapy and Palbociclib|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
10022563|NCT02763228|Experimental|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
10022564|NCT02763228|Active Comparator|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
10022565|NCT02757885|Other|Bone Marrow Donor|Participants who are related marrow donors and are 2-4 (out of 8) human leukocyte antigen (HLA) antigen mismatched and towards whom the recipient does not have donor specific antibodies.
10022566|NCT02757885|Experimental|Bone Marrow Recipient|Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) matched donor.
10022567|NCT02754011|Experimental|combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
10022568|NCT02753998|Experimental|Conventional angioplasty + paclitaxel-coated balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with paclitaxel-coated balloon
10022569|NCT02753998|Placebo Comparator|Conventional angioplasty + placebo balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with placebo balloon.
10022570|NCT02750319|Placebo Comparator|Amiodarone + Placebo|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading matching placebo; 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 NAC matched placebo continuously for 48 hours.
10022571|NCT02750319|Experimental|Amiodarone + N-Acetylcysteine|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading: 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 and then continuously for 48 hours.
9478972|NCT03547700|Experimental|Romidepsin plus Ixazomib|The phase I study includes three dose levels (DL) for romidepsin: DL4: 10 mg/m2 on Days 1, 8, 15; DL5: 14 mg/m2 Days 1, 8; DL6: 14 mg/m2 Days 1, 8, 15. Ixazomib is 4 mg PO Days 1, 8, 15. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study. Each cycle is 28 days and patients will receive treatment until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met.
9478973|NCT03547674|Active Comparator|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
9478974|NCT03547674|Active Comparator|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
9478975|NCT03547674|Active Comparator|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
9478976|NCT03547674|Experimental|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
9478977|NCT03547648|Active Comparator|Group I ( 30 cm H2O)|Patients will be applied 30 cm H2O peak airway pressure manually at the end of the surgery
9478978|NCT03547648|Active Comparator|Group II( 40 cm H2O)|Patients will be applied 40 cm H2O peak airway pressure manually at the end of the surgery
9478979|NCT03547648|Active Comparator|Group III(50 cm H2O)|Patients will be applied 50 cm H2O peak airway pressure manually at the end of the surgery
9478980|NCT03547622|Active Comparator|MAT taper with galantamine|Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
9478981|NCT03547622|Placebo Comparator|MAT taper with placebo|Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
9478982|NCT03547570|Experimental|Heavy shoulder resistance training|Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.
9478983|NCT03547557|Experimental|ExAblate MRgFUS|
10022572|NCT02747121|Other|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
10022573|NCT02747121|Experimental|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
10022574|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
10022575|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
10022576|NCT02741570|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
10022577|NCT02741570|Active Comparator|Extreme Regimen|Specified dose on specified days
9480836|NCT05235958|Experimental|Training intervention|8 weeks of non-linear periodized aerobic exercise; 3 sessions per week; 1 hour per session; standardized warm-up; individual training intensity according to cardiorespiratory fitness level
10022578|NCT02736669|Active Comparator|Fixed Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to reduce their food intake by a moderate amount and stay at this level of moderate reduction until their weight loss goal is achieved.
10022579|NCT02736669|Experimental|Variable Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to alternate between two levels of calorie reduction. One level will be a small amount of calorie reduction, while the other will be a more significant amount of calorie reduction. At the instruction of the research team, participants will periodically alternate back and forth between these two goals until their weight loss goal is achieved.
9802840|NCT04891770|Experimental|Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab|"Nucleos(t)ide(s) (NUC)-suppressed participants with chronic hepatitis B (CHB) will receive:~Tenofovir alafenamide (TAF) 25 mg once daily for 36 weeks (up to 84 weeks)~VIR-2218 200 mg once every 4 weeks for 24 weeks~At Week 12 the following will be added:~Selgantolimod (SLGN) 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Participants who are on TAF treatment and meet the criteria stopping at the end of trial (EOT) visit will stop all treatments, no later than follow-up (FU) Week 1 visit, and enter a treatment-free follow-up(TFFU) period"
9478984|NCT03547505|Experimental|R-Pilot®|"R-Pilot® was operated by an endomotor (VDW Silver, Munich, Germany) at Reciproc All setting."
10022580|NCT02736656|Experimental|Open-Label Treatment|"Subjects 6-11 yrs of age will be treated with 100 to 400 mg SPN-812 ER (100 mg capsule).~Subjects 12-17 yrs of age will be treated with 100 to 600 mg SPN-812 ER (100, 200 mg capsule).~Subjects are given a choice to extend their participation in the study every 6 months for up to 72 months."
10022581|NCT02736136|Experimental|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
10022582|NCT02736136|No Intervention|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
10022583|NCT02735044|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine 300 Units/milliliter [U/mL]) Subcutaneous(SC) injection once daily for 12 months.
10022584|NCT02735044|Active Comparator|Lantus|Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
10022585|NCT02732691|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.
10022586|NCT02725177|Experimental|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
10022587|NCT02724579|Experimental|Treatment (reduced radiation therapy and chemotherapy)|"RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks.~MAINTENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
10022588|NCT02724410|Active Comparator|home intravenous ertapenem and PICC|Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages <13; age 13 or greater, then 1 gm daily)
10022589|NCT02724410|Experimental|home oral amoxicillin-clavulanate|Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).
10022590|NCT02720744|Experimental|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
10022591|NCT02720744|Placebo Comparator|Placebo|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
10022592|NCT02718027||Participants with Alport Syndrome|Participants diagnosed with Alport syndrome aged between 2 months and 50 years
10022593|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 1)|Patients with recurrent/progressive GBM
10022594|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 2)|Newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide
10022595|NCT02716116|Experimental|Part 1: Dose Escalation Component|TAK-788 treatment for participants with advanced NSCLC.
10022596|NCT02716116|Experimental|Part 2: Expansion Cohort 1|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have either not received or not shown an objective response to an EGFR tyrosine kinase inhibitors (TKI), and who have no active, measurable central nervous system (CNS) metastases.
10022597|NCT02716116|Experimental|Part 2: Expansion Cohort 2|TAK-788 treatment for NSCLC participants with HER2 exon 20 activating insertions or point mutations and no active, measurable CNS metastases.
10022598|NCT02716116|Experimental|Part 2: Expansion Cohort 3|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active, measurable CNS metastases.
10022599|NCT02716116|Experimental|Part 2: Expansion Cohort 4|TAK-788 treatment for NSCLC participants with other targets against which TAK-788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions [with or without T790M mutations] and other uncommon EGFR activating mutations), without active CNS metastases.
10022600|NCT02716116|Experimental|Part 2: Expansion Cohort 5|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have previously shown an objective response to an EGFR TKI and subsequently progressed without active CNS metastases.
10022601|NCT02716116|Experimental|Part 2: Expansion Cohort 6|TAK-788 treatment NSCLC participants with EGFR exon 20 activating insertions, who have not received prior systemic anticancer treatment for locally advanced or metastatic disease without active CNS metastases
9478985|NCT03547505|Experimental|ProGlider®|ProGlider® was operated by an endodontic motor (X-Smart, Dentsply Sirona, Ballaigues, Switzerland) with 16:1 contra angle at the suggested settings (300 rpm on display, 5 Ncm).
9478986|NCT03547505|Experimental|Manual preparation|"In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with push and pull motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan)."
9478987|NCT03547492|Experimental|Language Intervention|"1. Baseline LENA recording 2. Review language curriculum and motor curriculum with study personnel 2. Direct linguistic feedback of baseline LENA recording 4. 2nd LENA recording completed and analyzed 5. Direct or mailed linguistic feedback of 2nd LENA recording 6. 16- Weekly text messages 7. 4 month LENA recording with mailed linguistic feedback 8. 12 month LENA recording with mailed linguistic feedback~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a book at each interaction."
9478988|NCT03547492|Active Comparator|Motor Control|"Baseline LENA recording~Review motor curriculum with study personnel~2nd LENA recording completed and analyzed~4- monthly text messages~4 month LENA recording~12 month LENA recording with mailed linguistic feedback of all recordings~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a toy at each interaction."
9478989|NCT03547479|No Intervention|Control|Participants receive current standard of care (DOTS)
9478990|NCT03547479|Experimental|VDOT only|Participants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
9478991|NCT03547479|Experimental|VDOT + mobile money incentives|Participants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
9478992|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI<25 kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
9478993|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI<25kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
9478994|NCT03547440||type 1 diabetes mellitus|Children with type 1 diabetes mellitus, usually not obese, with diabetic ketoacidosis. They could be with or without stationary metabolic profile. They are recruited at the onset of the T1DM into the Torino and Novara Pediatric Hospitals and then they are divided in relation to the ethnicity.
9478995|NCT03547440||Control healthy|Healthy children without relevant metabolic or systemic co-morbility. They are recruited from orthopedy department of the Torino and Novara Pediatric hospitals and then they are divided in relation to the ethnicity
9478996|NCT03547401||General anesthesia|Patient (15 to 40 years old) undergoing elective surgery requiring general anesthesia in supine position.
9478997|NCT03547388|Experimental|Single Arm|Additional application of weekly moderate whole-body hyperthermia concurrent to re-irradiation plus chemotherapy
9478998|NCT03547375|Experimental|treatment group|Apatinib 500mg/d po,28 days as one cycle
10022602|NCT02716116|Experimental|Part 2: Expansion Cohort 7|TAK-788 treatment for participants with solid tumors other than NSCLC with EGFR/HER2 mutations against which TAK-788 is active without active CNS metastases.
9478999|NCT03547362|Experimental|Casein|Single oral administration
9479000|NCT03547362|Experimental|Dairy protein blend 1|single oral administration
9479001|NCT03547362|Experimental|Whey protein|Single oral administration
9479002|NCT03547362|Experimental|Dairy protein blend 2|Single oral administration
9479003|NCT03547362|Experimental|Dairy protein blend 3|Single oral administration
9479004|NCT03547362|Experimental|Dairy protein blend 4|Single oral administration
9479005|NCT03547349|Active Comparator|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
9480837|NCT05235958|Sham Comparator|Control Intervention|Recommendation to continue with current lifestyle (especially physical activity habits) during the following 8 weeks. At the final assessment after 8 weeks, individualized exercise recommendations according to established standard procedures in exercise medicine and offer to attend the standard medical follow-up in our outpatient clinics subsequent to study termination
9480838|NCT05235282|Experimental|Usual care + IQoro|The intervention group receives usual training of swallowing function along with training 3 times each day with an IQoro oral screen
9480839|NCT05235282|Active Comparator|Usual care|The comparison group receives usual training of swallowing function
10022603|NCT02716116|Experimental|Part 3: Extension Cohort|TAK-788 treatment for participants with previously treated locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations.
10022604|NCT02714257|No Intervention|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
10022605|NCT02714257|Experimental|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
10022606|NCT02713867|Active Comparator|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
10022607|NCT02713867|Experimental|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
10022608|NCT02710383||Participants genetically diagnosed with Cystic fibrosis|Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years
10022609|NCT02706392|Experimental|Treatment (ROR1 CAR-specific autologous T-lymphocytes)|Patients receive chemotherapy comprising fludarabine phosphate and cyclophosphamide as determined by the referring physician in consultation with the protocol PI. Beginning within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive ROR1 CAR-specific autologous T-lymphocytes IV over 20-30 minutes. Patients may receive a second infusion of ROR1 CAR-specific autologous T-lymphocytes with or without additional cytoreductive therapy at the same (for those that received the highest cell dose) or up to the next highest dose level and there is persistent disease, there were no toxicities attributed to the first infusion, and the patient is at least 21 days from the first T cell infusion.
10022610|NCT02704403|Experimental|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
10022611|NCT02704403|Placebo Comparator|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
10022612|NCT02701751|Other|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
10022613|NCT02701738|Experimental|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
10022614|NCT02699697|Experimental|ARM I (palliative radiation therapy)|Patients undergo 1 fraction of EBRT over 30 minutes.
10022615|NCT02699697|Experimental|ARM II (palliative radiation therapy)|Patients undergo 2 fractions of EBRT over 30 minutes. The 2 fractions will be separated by 3-7 days.
10022616|NCT02699515|Experimental|MSB0011359C (M7824)|
10022617|NCT02695160|Experimental|Cohort 1|SB-FIX: Low Dose
10022618|NCT02695160|Experimental|Cohort 2|SB-FIX: Medium Dose
10022619|NCT02695160|Experimental|Cohort 3|SB-FIX: High Dose
10022620|NCT02694185|Experimental|Experimental Group|This group will undergo the intervention as described in the protocol
10022621|NCT02694185|No Intervention|Control Group|This group will not receive the intervention, they will receive usual care
10022622|NCT02692651|Active Comparator|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
10022623|NCT02692651|Active Comparator|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
10022624|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
10022625|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
10022626|NCT02688855|Experimental|Investigational Group|Standard Rigid Fixation + Active OL1000 device
10022627|NCT02688855|Sham Comparator|Control Group|Standard Rigid Fixation + Sham OL1000 device
10022628|NCT02688712|Experimental|LY2157299 + Chemoradiation + Surgery|Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
10022629|NCT02688140|Experimental|Arm A|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses."
10022630|NCT02688140|Active Comparator|Arm B (standard chemotherapy)|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7, oral tretinoin twice daily on day 1-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation I:~IDA 5 mg/m2 i.v. day 1-4 Ara-C 1000 mg/m2/3h i.v. day 1-4 ATRA 45 mg/m2 p.o. day 1-15~Consolidation II:~MTZ 10 mg/m2 i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Consolidation III:~IDA 12 mg/m2 i.v. day 1 Ara-C 150 mg/m2 every 8h i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Maintenance (duration 7 cycles = 2 years; one cycle lasts 106 days):~6-MP 50 mg/m2 p.o. Cycle 1-7: day 1-91 (followed by 15 days of ATRA on days 92-106)~MTX 15mg/m2 i.m./p.o. Cycle 1-7: once weekly for 91 days (followed by 15 days of ATRA on days 92-106)~ATRA 45 mg/m2 p.o. Cycle 1-6: day 92-106 Cycle 7: without ATRA Administration~(treatment break of 6-MP and MTX during ATRA administration)"
10022631|NCT02686658|Experimental|Dose Group 1|Zimura Dose Administration 1
10022632|NCT02686658|Experimental|Dose Group 2|Zimura Dose Administration 2
10022633|NCT02686658|Sham Comparator|Dose Group 3|Sham Administration 1
10022634|NCT02686658|Experimental|Dose Group 4|Zimura Dose Administration 3
10022635|NCT02686658|Experimental|Dose Group 5|Zimura Dose Administration 4
10022636|NCT02686658|Sham Comparator|Dose Group 6|Sham Administration 2
10022637|NCT02678572|Experimental|Melphalan/HDS|3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.
10022638|NCT02677688|Experimental|Autologous EBV specific CTL infusion|
9480840|NCT05235152|Active Comparator|Usual individual physiotherapy care|Participants with either low back pain, rotator cuff related pain, patellofemoral pain syndrome or lateral ankle sprain will received usual/individual physiotherapy care over a period of 12-weeks for the treatment of their musculoskeletal conditions if randomized in this group.
10022639|NCT02675699|Experimental|Optimisation + HENRY|
10022640|NCT02675699|Active Comparator|HENRY as standard|
10022641|NCT02674061|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A received 0-2 prior lines of treatment for recurrent ovarian cancer (ROC; 1-3 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year).
9479006|NCT03547349|Active Comparator|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
9479007|NCT03547349|Experimental|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
9479008|NCT03547336|Experimental|Theranova 400 Dialyzer|In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
10022642|NCT02674061|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B received 3-5 prior lines of treatment for ROC (4-6 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year)
10022643|NCT02672982|Experimental|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
10022644|NCT02672982|Active Comparator|standard NUT treatment|2-month of standard nutritional treatment only
10022645|NCT02671448||Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care.
10022646|NCT02659124|Other|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
10022647|NCT02656706|Experimental|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
10022648|NCT02654340||Participants with Tuberous Sclerosis Complex (TSC)|Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.
10022649|NCT02654314|Experimental|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
10022650|NCT02654314|Placebo Comparator|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
10022651|NCT02652676|Experimental|Reversible Pulmonary Artery Banding|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
10022652|NCT02652611|Experimental|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
10022653|NCT02652611|Experimental|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
10022654|NCT02642042|Experimental|Treatment (trametinib, docetaxel)|Patients receive trametinib PO on days 1-21. Patients also receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022655|NCT02634905|Experimental|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
10022656|NCT02634905|No Intervention|Control|
10022657|NCT02634710|Experimental|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
10022658|NCT02633891|Experimental|Balance exercise program|Participants will attend weekly group training sessions and will keep an exercise log of home activity during a three month exercise program designed to improve balance. Balance exercises will be performed three times per week in a home-based training program.
10022659|NCT02633891|Active Comparator|standard care|Participants will meet in person on a weekly basis for a general education class regarding health and fall prevention but will not participate in an exercise class.
10022660|NCT02629731|Experimental|ankle OA|inclusion criteria: 1) diagnosis of ankle OA or PTTD [non-control subjects only], 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m) with the primary impediment to pain-free ambulation being ankle OA or PTTD
10022661|NCT02629731|Experimental|flat foot|inclusion criteria: 1) diagnosis of flat foot, 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m)
10022662|NCT02629731|No Intervention|control|inclusion criteria: 1) between 18 and 80 years of age, and 2) ambulatory (able to walk at least 15 m)
10022663|NCT02628444|Experimental|STAGE-I Group 1: CYD Dengue Vaccine|Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).
10022664|NCT02628444|Experimental|STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)|Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).
10022665|NCT02628444|Experimental|STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)|Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).
10022666|NCT02628444|Experimental|STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)|Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
10022667|NCT02628444|Experimental|STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
10022668|NCT02628444|Experimental|STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
10022669|NCT02628444|Experimental|STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)|Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
10022670|NCT02628444|Experimental|STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
10022671|NCT02628444|Experimental|STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
9802841|NCT04891770|Experimental|Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab|"Viremic participants with CHB will receive:~VIR-2218 200 mg once every 4 weeks for 24 weeks~At Week 12, the following will be added:~SLGN 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study."
9802842|NCT04891770|Experimental|Cohort 2 Group B: SLGN + Nivolumab|"Viremic participants with CHB will receive:~SLGN 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study."
9802843|NCT04891770|Experimental|VIR-2218 + SLN + Nivolumab|"Cohort 3 will be initiated at the discretion of the sponsor after Cohort 2 has completed enrollment.~Viremic participants with CHB will recieve:~VIR-2218 200 mg once every 4 weeks for 24 weeks~SLGN 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study."
9802844|NCT04889430|Experimental|Iptacopan 200 mg b.i.d|Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses of iptacopan
9802845|NCT04887285|Experimental|Virtual reality (VR)|Subjects in the VR group will be fitted with an HTC headset and headphones with disposable ear covers. They will choose from a menu of 6 different programs. They will also receive 1% superficial anesthesia.
10022672|NCT02626962|Experimental|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
9479009|NCT03547336|Active Comparator|FX800|In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
9479010|NCT03547323|Experimental|Theranova 400 Dialyzer|One treatment session in an in-center setting.
9479011|NCT03547323|Active Comparator|FX80 Dialyzer|One treatment session in an in-center setting.
9479012|NCT03547310|Experimental|MyoBeatz|The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
9479013|NCT03547284|Active Comparator|81 patients,group 1|81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery .
9479014|NCT03547284|No Intervention|81 patients,group 2|81 patients will have traditional management(oral intake of clear fluids after hearing of first intestinal sounds or passage of flatus and regular diet after passage of stool)
9479015|NCT03547258||AML patients|Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
9479016|NCT03547232|Experimental|Indomethacin group|Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
9479017|NCT03547232|Sham Comparator|Standard group|Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
9479018|NCT03547219|Experimental|Escitalopram|Participants with depression were treated with escitalopram(ranging from 5mg to 30mg) for 8 weeks. Escitalopram was initiated at 5mg for 1 week, followed by an increase to 10mg at week 2. After week 2, doses of escitalopram were titrated according to symptoms and adverse effects. Specific, indicated psychotherapy for depression was not allowed during the study.
9479019|NCT03547206|Experimental|RPh201 Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
10022673|NCT02623998|Experimental|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
10022674|NCT02623998|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
10022675|NCT02623725|Experimental|CYD Dengue Vaccine Booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).
10022676|NCT02623725|Experimental|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).
10022677|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
10022678|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.08 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
10022679|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)|Participants receive the same dose (0.16 mg/kg/week) of NNC0195-0092 (somapacitan) during all 4 trial periods.
10022680|NCT02616562|Active Comparator|Open labelled daily Norditropin® (0.034 mg/kg/day)|Participants receive Norditropin during the main trial, the extension period and the safety extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the long-term safety extension periods.
10022681|NCT02612662|Experimental|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
10022682|NCT02612662|Experimental|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
10022683|NCT02612662|Experimental|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
10022684|NCT02612662|Experimental|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
10022685|NCT02612662|Experimental|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
10022686|NCT02612662|Experimental|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
9479020|NCT03547206|Placebo Comparator|Placebo Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
9479021|NCT03547206|Experimental|RPh201 Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
9479022|NCT03547206|Placebo Comparator|Placebo Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the vehicle control.
9479023|NCT03547180|Active Comparator|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
9479024|NCT03547180|Active Comparator|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
9802846|NCT04887285|Active Comparator|Sedation|Conscious sedation will be accomplished by the use of midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). All medications will be titrated to conscious sedation by a board-certified anesthesiologist. Subjects will also receive 1% superficial anesthesia.
9802847|NCT04887285|Other|Standard care|Patients in this arm will be administered only 1% lidocaine as superficial anesthesia, similar to the other 2 arms.
9802848|NCT04886622|Experimental|DT2216|DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year.
10022687|NCT02608684|Experimental|Cisplatin+Gemcitabine+Pembrolizumab|"2 cycles of 750mg gemcitabine and 30mg cisplatin chemotherapy (standard of care) followed by 4 cycles of gemcitabine and cisplatin combined with pembrolizumab in 21-day treatment cycles followed by single-agent pembrolizumab maintenance therapy for up to 2 years of treatment (6 cycles combination treatment + 28 cycles maintenance).~Gemcitabine 750 mg/m2 every 3 weeks (Q3W) x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle Standard of care~Cisplatin 30 mg/m2 Q3W x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle after gemcitabine Standard of care~Pembrolizumab 200 mg Q3W starting with cycle 3 IV infusion~-Day 1 of each 3 week cycle after gemcitabine and cisplatin Experimental"
10022688|NCT02603887|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
10022689|NCT02601378|Experimental|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
10022690|NCT02601378|Experimental|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
9479025|NCT03547180|Other|In-vivo exposure therapy|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
9479026|NCT03547141|Experimental|botulinum toxin 1U|
10022691|NCT02601209|Experimental|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9479027|NCT03547141|Experimental|botulinum toxin 5U|
10022692|NCT02601209|Experimental|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
10022693|NCT02599324|Experimental|Renal Cell Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with everolimus to determine the Recommended Phase 2 Dose (RP2D) of ibrutinib.~Phase 2: Patients will receive ibrutinib at the RP2D determined in Phase 1b in combination with everolimus."
10022694|NCT02599324|Experimental|Urothelial Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with paclitaxel to determine the RP2D of ibrutinib.~Phase 2: Subjects will receive paclitaxel at the RP2D determined in Phase 1b in combination with paclitaxel."
10022695|NCT02599324|Experimental|Gastric Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with docetaxel to determine the RP2D of ibrutinib.~Phase 2: Subjects will receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
10022696|NCT02599324|Experimental|Colorectal Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with cetuximab to determine RP2D of ibrutinib.~Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
9479028|NCT03547141|Experimental|botulinum toxin 15U|
9479029|NCT03547141|Experimental|botulinum toxin 30U|
9479030|NCT03547128||Parents with newborns recruited from 1992-5|Parents of newborns recruited from 8 Iowa hospitals in 1992-5
10022697|NCT02599324|Experimental|Urothelial Carcinoma Ibrutinib- Enrollment Closed|Phase 1b: Patients will receive ibrutinib at various dose levels to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b.
10022698|NCT02599324|Experimental|Urothelial Carcinoma with Pembrolizumab - Enrollment Closed|Phase 1b: Patients will receive ibrutinib at various dose levels in combination with pembrolizumab to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab.
10022699|NCT02595892|Active Comparator|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
10022700|NCT02595892|Experimental|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9479031|NCT03547102|Active Comparator|Cherry concentrate|8 weeks supplementation with montmorency cherry concentrate
9479032|NCT03547102|Placebo Comparator|Placebo concentrate|8 weeks supplementation with placebo isoenergetic cherry concentrate
9479033|NCT03547089|Experimental|Viveve treatment|Group of women who receive Viveve treatment
9479034|NCT03547063||Sleeve Gastrectomy (SG)|25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
9479035|NCT03547063||Lifestyle Intervention|25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
9479036|NCT03547063||Normal Weight|25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity
9479037|NCT03547050||Patients diagnosed with RE|People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.
9479038|NCT03547050||Controls|People without a lifetime history of seizures.
9479039|NCT03547024|Experimental|Part 1: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail on Day 1 followed by JNJ-55308942 high dose once daily from Day 3 to Day 14 and a single dose of drug cocktail on Day 12.
9479040|NCT03547024|Experimental|Part 2: JNJ-55308942 + Levonorgestrel/Ethinyl Estradiol|Participants will receive a single dose of levonorgestrel/ethinyl estradiol alone on Day 1 followed by JNJ-55308942 high dose once daily on Days 5 to 18 and a single dose of levonorgestrel/ethinyl estradiol on Day 14.
9479041|NCT03547024|Experimental|Part 3: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail alone on Day 1 followed by JNJ-55308942 low dose once daily on Days 3 to Day 14 and a single dose drug cocktail on Day 12.
10022701|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
10022702|NCT02592330|Experimental|Cultivated Autologous Limbal Epithelial Cell (CALEC) graft|Participants will have a corneal biopsy in their non-diseased eye, which will provide cells for the creation of the CALEC graft. The CALEC will be made at the Good Manufacturing Practice (GMP) Laboratory, Dana Farber Cancer Institute and transported to Mass. Eye and Ear Infirmary for application to the participant's diseased eye during their standard corneal reconstruction procedure.
9479042|NCT03547011|Active Comparator|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
10022703|NCT02587520|Experimental|Adolescents: SP0173 Formulation 1|Healthy participants aged 10-18 years received a single dose of the SP0173 Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccine.
10022704|NCT02587520|Experimental|Adolescents: SP0173 Formulation 2|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
10022705|NCT02587520|Experimental|Adolescents: SP0173 Formulation 3|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
10022706|NCT02587520|Experimental|Adolescents: SP0173 Formulation 4|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
10022707|NCT02587520|Active Comparator|Adolescents: Adacel®|Healthy participants aged 10-18 years received Adacel®.
10022708|NCT02587520|Active Comparator|Adolescents: Boostrix®|Healthy participants aged 10-18 years received Boostrix®.
10022709|NCT02587520|Experimental|Adults: SP0173 Formulation 1|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
10022710|NCT02587520|Experimental|Adults: SP0173 Formulation 2|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
10022711|NCT02587520|Experimental|Adults: SP0173 Formulation 3|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
10022712|NCT02587520|Experimental|Adults: SP0173 Formulation 4|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
10022713|NCT02587520|Active Comparator|Adults: Adacel®|Healthy participants aged 19-64 years received Adacel®.
10022714|NCT02587520|Active Comparator|Adults: Boostrix®|Healthy participants aged 19-64 years received Boostrix®.
10022715|NCT02587520|Experimental|Older Adults: SP0173 Formulation 1|Healthy participants aged greater than equal to (>=65) years received a single dose of the SP0173 Tdap vaccine.
10022716|NCT02587520|Experimental|Older Adults: SP0173 Formulation 2|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
10022717|NCT02587520|Experimental|Older Adults: SP0173 Formulation 3|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
10022718|NCT02587520|Experimental|Older Adults: SP0173 Formulation 4|Healthy participants aged >= 65 years received a single dose of the SP0173 Tdap vaccine.
10022719|NCT02587520|Active Comparator|Older Adults: Adacel®|Healthy participants aged >=65 years received Adacel®.
10022720|NCT02587520|Active Comparator|Older Adults: Boostrix®|Healthy participants aged >=65 years received Boostrix®.
10022721|NCT02587403|Active Comparator|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
10022722|NCT02587403|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
9479043|NCT03547011|Active Comparator|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
10022723|NCT02584829|Experimental|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
10022724|NCT02584829|Experimental|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
10022725|NCT02581306|Other|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
10022726|NCT02570308|Experimental|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen.
9479044|NCT03546985|Experimental|Group A|
10022727|NCT02570308|Experimental|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen.
10022728|NCT02567201|Experimental|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
10022729|NCT02567201|Experimental|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
10036513|NCT01816386|No Intervention|Standard Treatment Control|"Standard anaesthetic procedure plus No treatment.~All standardized medication according to the perioperative anaesthetic guideline, Department of Anaesthesiology, University of Munich, will be allowed. In special:~According to the guidelines, anxiolysis will be performed intravenously according to the standard guidelines with opioid immediately prior to the induction of anaesthesia.~Intraoperative anaesthesia will be performed according to our in-house guidelines: on general recommendations and guidelines of the German society for anaesthesiology (DGAI). Opioids and propofol will be administered via TCI pumps according to the standard protocol.~It is allowed to treat the subject for pain with metamizol (4*1.25 g/day) and additional piritramide (PCA; 2 mg each 10 minutes; maximum dosage 30 mg/4 hours) .~Variation of this guideline based regimen are allowed if medically indicated."
9479045|NCT03546985|Active Comparator|Group B|
9479046|NCT03546972|Active Comparator|Group A (DPP)|Participants take part in DPP once a week over 1 hour for 16 weeks.
10022730|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
9479047|NCT03546972|Experimental|Group B (DPP-HT)|Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.
9479048|NCT03546959|Experimental|Lycra sleeve after botulinum toxin|8 hours a day lycra sleeve wear plus rehabilitation (for five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
9479049|NCT03546959|Active Comparator|Rehabilitation after botulinum toxin|Rehabilitation (five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
9479050|NCT03546946|Experimental|Gaze-Contingent Music Reward Training|GCMRT for eight 20-minute sessions - twice per week over 4 weeks.
9479051|NCT03546946|Placebo Comparator|Control Training|Passive viewing task with continuous music for eight 20-minute sessions - twice per week over 4 weeks.
9479052|NCT03546946|No Intervention|No-Train Group|No active training.
9479053|NCT03546933||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
9479054|NCT03546920|No Intervention|Control Phase|Usual care for patients admitted to the SNF.
9479055|NCT03546920|Experimental|ALIGN Intervention Phase|ALIGN Intervention delivered by Palliative Care Social Workers in the SNF setting. The intervention consists of aligning patient/caregiver goals of care, completing advance care planning, and connecting to community resources and services to ensure smooth transition from facility to home setting.
9479056|NCT03546881|Experimental|Arm with fusion imaging guidance technology|arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
9479057|NCT03546881|Active Comparator|Arm without fusion imaging guidance technology|arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
9479058|NCT03546868|Experimental|Ulcerative Colitis|Patients with ulcerative colitis undergoing [18F]FSPG PET/CT scan
9479059|NCT03546868|Experimental|Crohn's disease|Patients with Crohn's disease undergoing [18F]FSPG PET/CT scan
9479060|NCT03546855|Experimental|treatment group|apatinib 500mg/d po.28d as one cycle
9479061|NCT03546803||Cohort A|Head and Neck Patients; Photon or Proton Treatment with product
9479062|NCT03546803||Cohort B|Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
9479063|NCT03546803||Cohort C|Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
10022731|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
10022732|NCT02559856|Active Comparator|Apixaban|10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.
9479064|NCT03546790|Experimental|Flavor 1|Grape flavored tobacco cigar wrapper
9479065|NCT03546790|Experimental|Flavor 2|Chocolate flavored tobacco cigar wrapper
9479066|NCT03546790|Experimental|Flavor 3|Tobacco flavored tobacco cigar wrapper
9479067|NCT03546764|Experimental|Percutaneous Catheter|14-French Percutaneous catheter (pigtail or non-pigtail) placed at bedside using Seldinger technique
9479068|NCT03546764|Active Comparator|Chest tube|Placement of 28-36F chest tube placed at bedside by an open cut-down technique (traditional)
9479069|NCT03546751|Experimental|CPAP|This arm will consist of patients with obstructive sleep apnea who will be asked to use CPAP nightly to treat their OSA for six months
9479070|NCT03546751|Active Comparator|Diet and Exercise|This arm will consist of patients with obstructive sleep apnea who will be asked to engage in dietary management and regular exercise for six months.
9479071|NCT03546738|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
9479072|NCT03546738|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
9479073|NCT03546725|Experimental|Leg with compression stocking|Leg wearing compression stocking during the flight
9479074|NCT03546725|No Intervention|Leg without compression stocking|Leg not wearing compression stocking during the flight
9479075|NCT03546673|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
10022733|NCT02559856|Active Comparator|Rivaroxaban|15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.
10022734|NCT02557321|Experimental|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
10022735|NCT02557321|Experimental|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
10022736|NCT02557321|Active Comparator|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
10022737|NCT02540200|Active Comparator|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
10022738|NCT02540200|Experimental|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
10036514|NCT01816386|Active Comparator|Acupressure Regimen|Standard anaesthetic procedure plus press plaster acupressure
10036515|NCT01816399||Routine coronary angiography patients|
10036516|NCT01816412|Experimental|LDCB|Paclitaxel Coated Balloon
10036517|NCT01816412|Active Comparator|PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter
10022739|NCT02536898|Experimental|Fracture liaison service|"Information, assessment & lifestyle advice~refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.~Blood samples~Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)~Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug~Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5~Fracture patients with reduced kidney function will be treated with anti-RANKL~Anti-osteoporosis drug prescribed by hospital physician~Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year~Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
10022740|NCT02536898|Other|Current treatment|Treatment as offered before intervention.
10022741|NCT02531295|Experimental|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
10022742|NCT02531295|Experimental|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
10022743|NCT02531295|Experimental|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
10022744|NCT02526901||No treatment|
10022745|NCT02516241|Experimental|Combination Therapy|MEDI4736 (Durvalumab) + Tremelimumab
10022746|NCT02516241|Experimental|Monotherapy|MEDI4736 (Durvalumab)
10022747|NCT02516241|Active Comparator|Standard of Care|Standard of Care Chemotherapy Treatment
10022748|NCT02514083|Experimental|Ibrutinib and short-course fludarabine|"Ibrutinib 420 mg PO daily for the duration of the study~Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4"
10022749|NCT02512172|Experimental|Oral CC-486 & MK-3475|Oral CC-486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
10022750|NCT02512172|Experimental|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
10022751|NCT02512172|Experimental|Oral CC-486 & Romidepsin & MK-3475|Oral CC-486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
10022752|NCT02510703|Other|Type 2 diabetes group|Type 2 diabetes group
10022753|NCT02510703|Other|no diabetes|no diabetes
10022754|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
10022755|NCT02500797|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
10036518|NCT01816425|Experimental|thermoplastic partial denture|The patients that need oral rehabilitation with partial denture will receive a thermoplastic partial denture as treatment
10022756|NCT02500797|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.
10022757|NCT02499367|Active Comparator|Radiation therapy|Radiotherapy on metastatic lesion
10022758|NCT02499367|Active Comparator|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
10022759|NCT02499367|Active Comparator|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
10022760|NCT02499367|Active Comparator|Cisplatin|40mg/m2, weekly for 2 weeks
10022761|NCT02499367|Active Comparator|No induction treatment|
10036519|NCT01816425|Active Comparator|CoCr partial denture|The patients that need oral rehabilitation with partial denture will receive a CoCr partial denture as treatment
10036520|NCT01816438||dysplasia or colorectal lesion|300 patients
10036521|NCT01816464|Experimental|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus.~Dose: Single Dose 0.5 mL of TIV from pre-filled syringe."
10036522|NCT01816503||Fentanyl matrix|
9479076|NCT03546673|Experimental|Self-regulation Condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
9479077|NCT03546673|Experimental|Emotional Disclosure condition|For the emotional disclosure condition, participants were asked to write about their deepest thoughts and feelings about their cancer experience for three weeks.
9479078|NCT03546660|Experimental|SECM capsule imaging|Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
9479079|NCT03546634|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
9479080|NCT03546634|Experimental|Two-dose schedule for Sabin IPV|Subjects first dose IPV vaccinate at 4 months of age, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
9479081|NCT03546608|Experimental|Part 1, Child-Pugh Class A: Tepotinib|
9479082|NCT03546608|Experimental|Part 1, Child-Pugh Class B: Tepotinib|
9479083|NCT03546608|Experimental|Part 1, Healthy Participants: Tepotinib|Healthy participants matched to Child-Pugh Class B participants.
9479084|NCT03546595|Experimental|Auricular acupoints acupressure|
9479085|NCT03546595|Sham Comparator|Sham auricular acupoints acupressure|
9479086|NCT03546543|Experimental|Supine|
9479087|NCT03546543|Experimental|Prone|
9479088|NCT03546530|Experimental|Interferon|Interferon 1.5ug/kg/week, 48weeks
9479089|NCT03546530|Experimental|Interferon+resveratrol|Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks
9479090|NCT03546517|Experimental|Intervention with DNHS technique|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
9479091|NCT03546517|Sham Comparator|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
9479092|NCT03546504|Experimental|dental procedures modification and OT|Modifying dental environment and procedures to reduce sensory stimulation. Occupational therapy provides desensitization techniques around the dental visit and home oral hygiene and habit training for oral hygiene activities.
9479093|NCT03546478|Experimental|99mTc-ABH2 SPECT/CT|The patients were injected with 370±54 MBq of 99mTc-ABH2 in one dose intravenously and underwent SPECT/CT scan 90-270 min later.
9479094|NCT03546465|Experimental|Cohorts 1C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 100 μg
9479095|NCT03546465|Experimental|Cohorts 1J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 100 μg
9479096|NCT03546465|Experimental|Cohorts 2C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 200 μg
9479097|NCT03546465|Experimental|Cohorts 2J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 200 μg
9479098|NCT03546465|Experimental|Cohorts 3C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 300 μg
9479099|NCT03546465|Experimental|Cohorts 3J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 300 μg
9479100|NCT03546465|Experimental|Cohorts 4C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 450 μg
9479101|NCT03546465|Experimental|Cohorts 4J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 450 μg
9479102|NCT03546452||malignant NSCLC hydrothorax|cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel
9479103|NCT03546426|Experimental|study treatment|Pembrolizumab in combination with Autologous dendritic cells and Interleukin-2
9479104|NCT03546400|Other|methylphenidate HCl ERCT|methylphenidate HCl ERCT
9479105|NCT03546361|Experimental|Treatment (Ad-CCL21-DC vaccine, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by autologous dendritic cell-adenovirus CCL21 vaccine by CT-guided or bronchoscopic IT injection on days 0, 21, and 42. Patients then receive pembrolizumab every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
9479106|NCT03546335|Experimental|1mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1mCi of 89Zr-DFO-CZP.
9479107|NCT03546335|Experimental|0.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
9479108|NCT03546335|Experimental|1.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
9479109|NCT03546335|Experimental|2mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
9479110|NCT03546322||Registry|Head and neck cancer patients monitored on registry
10022762|NCT02497612|Experimental|Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the body weight (BW), participants received orally a single dose of ferroquine (FQ) capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of artefenomel (OZ439) (maximum dose up to 800 milligrams [mg]) oral suspension as follows: BW greater than or equal to (>=) 35 kilograms (kg): FQ 400 mg + OZ439 800 mg; BW >=24 kg to less than (<) 35 kg: FQ 300 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 200 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 150 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 100 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 75 mg + OZ439 150 mg.
10022763|NCT02497612|Experimental|Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 600 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 450 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 300 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 225 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 150 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 115 mg + OZ439 150 mg.
10022764|NCT02497612|Experimental|Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 900 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 675 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 450 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 335 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 225 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 170 mg + OZ439 150 mg.
10022765|NCT02497612|Experimental|Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 1200 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 900 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 600 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 450 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 300 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 225 mg + OZ439 150 mg.
10022766|NCT02497131|Experimental|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
10036523|NCT01816516|Experimental|Healthy Babies|Participants receive the Healthy Babies curriculum via 6 in home lessons and 3 follow up telephone calls delivered by Extension paraprofessionals.
10036524|NCT01816516|Active Comparator|EFNEP|Participants receive the Expanded Food and Nutrition Education Program (EFNEP) curriculum via 6 in home lessons delivered by Extension paraprofessionals.
9802849|NCT04885244||Operative|Multicenter, prospective, nonrandomized analysis of ASD patients w/diagnosis of congenital, degenerative, idiopathic, neuromuscular, inflammatory or iatrogenic spinal deformity. Participants must be scheduled to have 3 or more levels of Percutaneous posterior spinal instrumentation or 3 level stand alone lateral surgery within next 6 months.
10022767|NCT02491333|Experimental|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
10022768|NCT02491333|Sham Comparator|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
10022769|NCT02491333|Active Comparator|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
10022770|NCT02490943|Active Comparator|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
9479111|NCT03546309|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
10022771|NCT02490943|Active Comparator|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
10022772|NCT02490943|No Intervention|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
10022773|NCT02488343|Experimental|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
10022774|NCT02488343|No Intervention|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
10022775|NCT02480257|Experimental|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
10022776|NCT02470286|Experimental|Cohort 1 (SA001 60mg or Placebo)|6 subjects receiving a single dose of 60mg SA001 and 2 subjects receiving placebo
10022777|NCT02470286|Experimental|Cohort 2 (SA001 120mg or Placebo)|6 subjects receiving a single dose of 120mg SA001 and 2 subjects receiving placebo
10022778|NCT02470286|Experimental|Cohort 3 (SA001 180mg or Placebo)|6 subjects receiving a single dose of 180mg SA001 and 2 subjects receiving placebo
10022779|NCT02470286|Experimental|Cohort 4 (SA001 240mg or Placebo)|6 subjects receiving a single dose of 240mg SA001 and 2 subjects receiving placebo
10022780|NCT02470286|Experimental|Cohort 5 (SA001 300mg or Placebo)|6 subjects receiving a single dose of 300mg SA001 and 2 subjects receiving placebo
10022781|NCT02469987|Experimental|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
10022782|NCT02469987|Active Comparator|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
10022783|NCT02469987|Active Comparator|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
10022784|NCT02460458||Type 3 Von Willebrand's Disease (VWD3)|Patients with diagnosis of Type 3 Von Willebrand's Disease
9479112|NCT03546309|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
9479113|NCT03546283|Placebo Comparator|Control|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebo group, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
9479114|NCT03546283|Experimental|CEGI treatment|The patients with hypertensive intracerebral hemorrhage will be randomized into giving drug CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
9479115|NCT03546257||EUS|group using conventional WLE and EUS
9479116|NCT03546257||ME-NBI|group using WLE and ME-NBI.
9479117|NCT03546244|Experimental|musical treadmill|4-week daily musical treadmill training, consisting in two session, 20 minute per session
9479118|NCT03546244|Active Comparator|traditional session|4-week daily traditional treadmill training, consisting in two session, 20 minute per session
9479119|NCT03546218|Experimental|Smartphone Application (SPSRS)|Participants watch motion picture using an application that displays positive-word stimuli.
9479120|NCT03546218|Active Comparator|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
9479121|NCT03546166|Experimental|TREATMENT|
9479122|NCT03546153|Experimental|Aerobic exercise program|Participants will complete 12 week exercise program.
9479123|NCT03546127||STS|Patients with advanced/metastatic soft-tissue sarcoma
9479124|NCT03546127||CCR|Patients with metastatic colorectal carcinoma
9479125|NCT03546114||Patients referring to an osteopathic clinic - CMO, Milan|Adults, age>18 years, first visit at osteopathic clinic (Centro di Medicina Osteopatica)
10022785|NCT02457559|Experimental|Tirabrutinib 40 mg once daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukemia (CLL) received tirabrutinib 40 mg once daily for up to 96 months from first dose in the parent study.
10022786|NCT02457559|Experimental|Tirabrutinib 80 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily for up to 96 months from first dose in the parent study.
9479126|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
10022787|NCT02457559|Experimental|Tirabrutinib 160 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
10022788|NCT02457559|Experimental|Tirabrutinib 320 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
10022789|NCT02457559|Experimental|Tirabrutinib 400 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily for up to 96 months from first dose in the parent study.
10022790|NCT02457559|Experimental|Tirabrutinib 500 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily for up to 96 months from first dose in the parent study.
9479127|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
9479128|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
9480841|NCT05235152|Experimental|Group-supervised physiotherapy training programs|Participants with either low back pain, rotator cuff related pain, patellofemoral pain syndrome or lateral ankle sprain will received group-supervised physiotherapy training programs over a period of 12-weeks for the treatment of their musculoskeletal condition if randomized in this group.
10022791|NCT02457559|Experimental|Tirabrutinib 600 mg once daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
10022792|NCT02457559|Experimental|Tirabrutinib 300 mg twice daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily for up to 96 months from first dose in the parent study.
10022793|NCT02457559|Experimental|Tirabrutinib 160 mg once daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 160 mg once daily for up to 96 months from first dose in the parent study.
10022794|NCT02457559|Experimental|Tirabrutinib 320 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily for up to 96 months from first dose in the parent study.
9479129|NCT03546088|Experimental|awake naso-tracheal intubation|The patients with obstructive oro and hypo-pharynx tumours will have their airway secured through awake fiberoptic naso-tracheal intubation with light sedation and topical anaesthesia with lidocaine. The sedation will be provided in small boluses until the desired level will be achieved not exceeding 0.05 mg/kg of midazolam and 3 mcg/kg fentanyl. The dose of lidocaine will be to a maximum of 7 mg/kg. The reinforced intubating tube will be lubricated with lidocaine gel.
9479130|NCT03546075|Experimental|500 mg Resveratrol|
9479131|NCT03546075|Experimental|250 mg Resveratrol|
9479132|NCT03546075|Placebo Comparator|Placebo|
9479133|NCT03546062||T2DM patients treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant.
9479134|NCT03546049|Active Comparator|US-guided percutaneous biliary drainage|The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
9480842|NCT05233839|Experimental|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
9480843|NCT05233839|Active Comparator|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
9480844|NCT05232916|Placebo Comparator|0.9% Normal Saline|"0.9% normal saline in HLA-A*02 positive and HER2/neu positive subjects~1 mL 0.9% normal saline intradermally, every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)"
10022795|NCT02457559|Experimental|Tirabrutinib 480 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily for up to 96 months from first dose in the parent study.
10022796|NCT02457559|Experimental|Tirabrutinib 600 mg once daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily for up to 96 months from first dose in the parent study.
10022797|NCT02455505||Risk Screening tool & Cognitive Interview|
10022798|NCT02453373|Experimental|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
10022799|NCT02453373|No Intervention|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
10022800|NCT02452697|Active Comparator|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
10022801|NCT02452697|Experimental|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
10022802|NCT02452697|Active Comparator|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
10022803|NCT02452697|Experimental|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
10022804|NCT02452268|Experimental|NIZ985|"Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.~Cycle length 28 days.~Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.~MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.~Following identification of the MTD / RDE, dose expansion will follow."
10022805|NCT02452268|Experimental|NIZ985 + PDR001|"The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.~On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.~Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual."
10022806|NCT02449837||Head and Neck Cancer|Patient with locally advanced head and neck cancer but no distant metastasis scheduled to receive radiotherapy to the head and neck region with or without chemotherapy/targeted therapy (palliative or curative intent).
10022807|NCT02449837||Cervical Cancer|Patients with locally advanced cervical cancer without distant metastasis scheduled for radiotherapy to the pelvic region with or without chemotherapy/targeted therapy (palliative or curative intent).
10022808|NCT02449837||Non-Small Cell Lung Cancer|Patients with stage I to III non-small cell lung cancer, without distant metastasis, scheduled to receive stereotactic body radiotherapy for early stage lung disease and/or external beam radiotherapy for locally advanced lung disease, with or without concurrent/sequential chemotherapy and/or targeted therapy (curative intent).
10022809|NCT02449837||Rectal Cancer|Patients with locally advanced rectal cancer (no distant metastasis) scheduled to receive neoadjuvant chemoradiotherapy (curative intent).
10022810|NCT02449837||Metastatic Prostate Cancer|Patients with metastatic prostate cancer scheduled for palliative radiotherapy, or biochemically recurrent prostate cancer following radical prostatectomy scheduled for salvage prostatic fossa radiotherapy, with or without androgen deprivation, or with high risk prostate cancer.
10022811|NCT02449837||Oligometastatic Disease|Patients with oligometastatic cancer, defined as any solid malignancy with< 5 measurable sites of metastatic disease, limited to a maximum of 3 anatomic organ systems, excluding the primary tumor and regional lymph nodes. At least 1 site of metastatic disease, but as many as all 5 sites, in addition to the primary tumor and regional lymph nodes, is amenable to local ablative therapy with external beam radiation, stereotactic cranial radiosurgery or stereotactic body radiotherapy. Treatment will be guided by multi-disciplinary evaluation and may also include surgery, chemotherapy or target agents at the discretion of the primary oncologists. Patients may present with oligometastatic disease or have oligometastatic disease recurrence after definitive therapy for localized disease.
9480845|NCT05232916|Experimental|GLSI-100|"GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects~1 mL GLSI-100 intradermally, every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)"
10022812|NCT02449837||Immunotherapy|Melanoma or metastatic NSCLC scheduled to receive ipilimumab, nivolumab, and/or pembrolizumab.
10022813|NCT02449837||Head and Neck Induction chemotherapy|Locally advanced head and neck cancer (HNSCC) scheduled to receive induction chemotherapy followed by radiotherapy.
10022814|NCT02449837||Metastatic Breast Cancer|Patients scheduled to receive any treatment, including radiation therapy, and/or systemic/hormonal therapy
10022815|NCT02449837||Endometrial Cancer|Patients with stage III endometrial cancer, being treated with adjuvant radiation
10022816|NCT02449031||TOBI® PODHALER® cohort|
10022817|NCT02449031||non-TOBI® PODHALER® cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
10022818|NCT02442349|Experimental|AZD9291|Once daily tablet 80 mg
10022819|NCT02439307|Active Comparator|Rifaximin|Patients will receive per day 1200 mg of rifaximin
10022820|NCT02439307|Placebo Comparator|Placebo|Patients will receive a placebo of rifaximin
10022821|NCT02437175|Placebo Comparator|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
10022822|NCT02437175|Experimental|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
10022823|NCT02434354|Experimental|neo-adjuvant/adjuvant pembrolizaumab 200 mg IV|All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year
10022824|NCT02424409|Active Comparator|1: Control|
10022825|NCT02424409|Experimental|2: Intervention|
10022826|NCT02420977|Experimental|DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
10022827|NCT02418039|Placebo Comparator|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
10022828|NCT02418039|Experimental|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
10022829|NCT02417974|Experimental|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
10022830|NCT02417974|No Intervention|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
10022831|NCT02404935|Experimental|Arm A cetuximab|cetuximab 500 mg/m2 (every 2 weeks) until progression
10022832|NCT02404935|Other|Arm B observation|observation until progression
10022833|NCT02393079|Experimental|Active helmet LED|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (ACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
10022834|NCT02393079|Sham Comparator|Sham group|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (INACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
10022835|NCT02392572|Experimental|Arm A (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every 3 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022836|NCT02392572|Experimental|Arm B (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO once every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022837|NCT02392572|Experimental|Arm C (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on the first two consecutive days of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022838|NCT02392572|Experimental|Arm D (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10022839|NCT02392572|Experimental|Arm E (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO twice weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10022840|NCT02390011||MRI|Day 1
10022841|NCT02385786|Experimental|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
10022842|NCT02381652|Experimental|Cingal/Cingal|Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
9479135|NCT03546049|Experimental|EUS-guided biliary drainage|The initial transluminal puncture of the bile duct is performed by endoscopic ultrasound guidance (longitudinal echoendoscope) with an 19 G access needle. After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance. Then, a 0.035 inch guide wire is introduced into the bile duct. After dilatation of the transluminal access route with a balloon catheter, a self-expandable metal stent is introduced as an antegrade biliary drainage, a transhepatic biliary drainage or a choledochal biliary drainage. The placement of the metal stent is controlled by fluoroscopic and endoscopic luminal guidance.
9479136|NCT03546036|Experimental|Weighted metal chain blanket|As experimental intervention, a weighted metal chain blanket of 8 kg was used during the night. Using a flexible dose protocol, participants who found the 8 kg blanket too heavy were allowed to change to a 6 kg weighted blanket (see below)
9479137|NCT03546036|Sham Comparator|Control plastic chain blanket|As sham comparator, light chain blankets were used, were plastic chains of the same shape and size as the metal chains in the weighted blanket were sewn in. The control blanket has a weight of 1535 grams. When checking the weight of standard blankets for sale in one of the largest stores in Stockholm, weight was ranging from 550 to 2389 grams (average 1332).
9479138|NCT03546010|Experimental|Oculometric and neuropsychological tests|Oculometric tests and neuropsychological tests
9479139|NCT03545997|Experimental|Montelukast|Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
9479140|NCT03545997|Placebo Comparator|Placebo|Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
9479141|NCT03545971|Experimental|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
9479142|NCT03545971|Experimental|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
9479143|NCT03545971|Experimental|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
9479144|NCT03545971|Experimental|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
9479145|NCT03545971|Experimental|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
9479146|NCT03545971|Experimental|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
9479147|NCT03545971|Experimental|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
9479148|NCT03545971|Experimental|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
9479149|NCT03545958|Experimental|High-intensity Interval Training (HIT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-minute HIT intervention.
9479150|NCT03545958|Active Comparator|Moderate-intensity Continuous Training (MCT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-min MCT intervention.
9479151|NCT03545945|Experimental|Study arm|Patients having office diagnostic hysteroscopy and endometrial biopsy
9479152|NCT03545945|Other|Control arm|Patients having only endometrial biopsy
9479153|NCT03545932|Experimental|Hydrogymnastics|Hydrogymnastics Program
9479154|NCT03545880|Experimental|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
9479155|NCT03545880|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
9479156|NCT03545867|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~45 min (duration of exercise performed in other arms). Following the intervention they are fed.
10022843|NCT02381652|Experimental|Cingal/Monovisc|Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
10022844|NCT02381652|Experimental|Cingal/Saline|Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
10022845|NCT02378259|Experimental|Bariatric surgery|Roux-en-Y gastric bypass surgery
10022846|NCT02378259|Active Comparator|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
10022847|NCT02367794|Experimental|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
10036525|NCT01816529|Experimental|Topical Diltiazem Hydrochloride 2% Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
9479157|NCT03545867|Experimental|Circuit resistance training (CRT)|Participants complete upper extremity resistance maneuvers (lifts) interspersed with low-load/high-speed arm cycling for a combined 30 repetitions of 6 lifts and ~20 min of arm cycling. During this time energy expenditure is measured via open-circuit indirect calorimetry. Following the intervention they are fed.
10036526|NCT01816529|Placebo Comparator|Vehicle Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
10036527|NCT01816529|Active Comparator|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
10036528|NCT01816529|Placebo Comparator|0.9% Saline|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
10036529|NCT01816542|Other|patch tests on healthy skin|
9479158|NCT03545867|Experimental|Moderate intensity continuous (MICT)|Participants complete continous arm cycling at a steady-state power output (intensity) matched to the energy expenditure (kcal/min) and duration of exercise (min) response during CRT. Following the intervention they are fed.
9479159|NCT03545867|Experimental|High intensity interval training (HIIT)|"Participants complete interval arm cycling at power output that varies between 2 min active and two min recovery periods. This interval exercise is matched to the total energy expenditure (accumulated kcals) response during CRT. Following the intervention they are fed."
9479160|NCT03545854|Experimental|T3 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T3 vertebral level
10036530|NCT01816555|Experimental|Vitamin D- Normal Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects have a normal level of Vitamin D(25-hydroxyVit D 30-100ng/mL), they will be assigned to this group.
10036531|NCT01816555|Experimental|Vitamin D- Insufficient or Deficient Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D <20ng/mL) Vitamin D levels, they will be assigned to this group.
9802850|NCT04882241|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
10036532|NCT01816568|Active Comparator|Group 1|SILS appendectomy
9479161|NCT03545854|Experimental|T3 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T3 vertebral level
10036533|NCT01816568|Active Comparator|Group 2|Three port laparoscopic appendectomy
10036534|NCT01816581|Active Comparator|Targin/OxyNorm|Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
10022848|NCT02367794|Experimental|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
10022849|NCT02367794|Active Comparator|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
10022850|NCT02367456|Experimental|Arm A|MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
10022851|NCT02367456|Experimental|Arm B|AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
9479162|NCT03545854|Experimental|T3 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T3 vertebral level
9479163|NCT03545854|Experimental|T12 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T12 vertebral level
9479164|NCT03545854|Experimental|T12 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T12 vertebral level
10022852|NCT02364323|Experimental|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
9479165|NCT03545854|Experimental|T12 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T12 vertebral level
9479166|NCT03545854|Experimental|L4 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the L4 vertebral level
9479167|NCT03545854|Experimental|L4 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the L4 vertebral level
9479168|NCT03545854|Experimental|L4 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the L4 vertebral level
9480846|NCT05232916|Experimental|GLSI-100, Open-label|"Small, open-label arm: GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects~1 mL GLSI-100 intradermally, every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)"
9480847|NCT05232903|Experimental|Group 1 SVF dose 0.5 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of stromal vascular fraction (SVF) dose 0.5 x 10^6/kg for 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
9480848|NCT05232903|Experimental|Group 2 SVF dose 1.0 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of stromal vascular fraction (SVF) dose 1.0 x 10^6/kg for next 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
9480849|NCT05232903|Experimental|Group 3 SVF dose 1.5 x 10^6/kg Intravenous infusion (IV)|Intravenous infusion of SVF stromal vascular fraction (SVF) dose 1.5 x 10^6/kg for final 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.
9480850|NCT05232890|Experimental|Datterino tomato purée from hydroponic technology|100% Italian datterino tomato purée deriving from hydroponic technology (soilless) with particular characteristics such as nickel free and zero residue.
9480851|NCT05232890|Active Comparator|Datterino tomato purée from conventional cultivation|100% Italian datterino tomato purée deriving from conventional cultivation.
9480852|NCT05232682|Experimental|Probiotic Arm|Probiotic arm
9480853|NCT05232097|Experimental|Behavioral therapy|Behavioral therapy consisting of diaphragmatic breathing exercises and physiotherapy to relax tensed abdominal and thoracic muscles
9480854|NCT05232071|Experimental|Lanifibranor (IVA337) (800 mg/day)|2 Lanifibranor tablets 400 mg with food --> once a day (quaque die, QD)
9480855|NCT05232071|Placebo Comparator|Matching placebo|2 Placebo to match tablets with food --> once a day (quaque die, QD)
9480856|NCT05232071|Experimental|Lanifibranor (IVA337) (800 mg/day) plus Empagliflozin (10mg/day)|2 Lanifibranor tablets 400 mg plus 1 Empagliflozin tablet 10mg with food --> once a day (quaque die, QD)
9480857|NCT05230719||dTRA group|Investigators perform percutaneous coronary intervention by dTRA for patients
9480858|NCT05230719||TRA group|Investigators perform percutaneous coronary intervention by conventional TRA for patients
9480859|NCT05229614|Experimental|Solid cancers with stable disease|"Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.~Patients diagnosed with NSCLC, HNSCC, melanoma and urothelial carcinoma will be eligible for the study."
9480860|NCT05228626|Placebo Comparator|Standard of care plus placebo arm|Will contain standard of care plus placebo
9480861|NCT05228626|Experimental|Stanadard of care plus COVIDEX arm|Will contain the standard of care plus the intervention given for 3 times daily for seven days
10022853|NCT02364323|Placebo Comparator|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
10022854|NCT02363998|Other|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
9480862|NCT05227898|Active Comparator|Attune™|Attune™ is a completely digital therapeutic intervention.
9480863|NCT05227898|Active Comparator|Cerena™|Cerena™ is a completely digital therapeutic intervention.
9480865|NCT05225220|Experimental|Transcutaneous Vagus Nerve Stimulation (t-VNS)|Participants will receive 60 minutes of t-VNS stimulation every day for 10 consecutive days while wearing a fitness tracker.
9480866|NCT05224401|Experimental|PAC treatment|
9480867|NCT05224401|Active Comparator|Standard treatment|
9480868|NCT05223179|Experimental|CODA-VAX H1N1|Live Attenuated Vaccine administered by Intramuscular Injection
9480869|NCT05223179|Active Comparator|Flucelvax Quad|Licensed Injectable Seasonal Influenza Vaccine
9480870|NCT05223179|Placebo Comparator|Saline|Normal Sterile Saline for Intramuscular Injection
10022855|NCT02358031|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months.
10036535|NCT01816581|Active Comparator|PCA|Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
10036536|NCT01816607||Rectal cancer|
9480871|NCT05223101|Experimental|Sequence A|TRTR
10036537|NCT01816620|Experimental|Lenalidomide, dexamethasone|Lenalidomide 10mg qd d1-21 & dexamethasone 40mg qw d1,8,15,22
9479169|NCT03545841|Experimental|HIT training|6 weeks of high-intensity interval training (HIT)
9480872|NCT05223101|Experimental|Sequence B|RTRT
10022856|NCT02358031|Experimental|Pembrolizumab + Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months; plus cisplatin 100 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
10022857|NCT02358031|Active Comparator|Cetuximab + Chemotherapy (Control)|Participants receive cetuximab on Day 1 at a dose of 400 mg/m^2 IV, and then 250 mg/m^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity; plus cisplatin 100 mg/m^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each 3-week cycle (6 cycle maximum for platinum-based therapy); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
10022858|NCT02355379|Experimental|GROUP1 -ARM A|LV5FU2 or capecitabine
10022859|NCT02355379|Experimental|GROUP1-ARMB|FOLFOX4 or XELOX
10022860|NCT02355379|Experimental|GROUP2- ARM C|Observation
10022861|NCT02355379|Experimental|GROUP2-ARM D|LV5FU2 or capecitabine
10022862|NCT02353832|Other|No Arm|Study did not have Arm(s)
10022863|NCT02353728|Experimental|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
10022864|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
10022865|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
10022866|NCT02345070|Placebo Comparator|Placebo qw|Participants received one injection of placebo (matched to SAR156597) subcutaneously once every week (qw) for 52 weeks.
9479170|NCT03545841|Experimental|Moderate intensity training|6 weeks of moderate-intensity continuous training (MICT)
10022867|NCT02345070|Experimental|SAR156597 200 mg q2w|Participants received one injection of SAR156597 200 mg subcutaneously once every 2 weeks (q2w) alternating with placebo (matched to SAR156597) for 52 weeks.
10022868|NCT02345070|Experimental|SAR156597 200 mg qw|Participants received one injection of SAR156597 200 mg subcutaneously qw for 52 weeks.
9479171|NCT03545828||Good neurological outcome|CPC 1 and 2 at 6 month after ROSC
9479172|NCT03545828||Poor neurological outcome|CPC 3 to 5 at 6 month after ROSC
9479173|NCT03545815|Experimental|anti-mesothelin CAR-T cells|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.~Patients receive anti-mesothelin-CAR T cells on day 0."
9479174|NCT03545802|Experimental|Training|6 weeks of home-based high intensity interval training
9479175|NCT03545789|Experimental|[18F]MNI-958|To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
9479176|NCT03545776||Educational program|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course that will be preceded by a pre-test evaluation and followed by delayed post-test evaluations.~Training will be followed by an online teaching consisting on additional questions and answers quizzes based on the 10 educational goals already described elsewhere.~In order to avoid any risk of intrasite contamination, all the learners benefiting from the training in the same department will be trained in a uniform time, with respect to the training schedule regarding post-test evaluations (day-1, day-15 and day-30). A final evaluation will be performed at day-90 after beginning of the training course."
9479177|NCT03545750||Regional citrate anticoagulation (RCA)|Those receiving regional citrate anticoagulation for CRRT
9479178|NCT03545750||Systemic heparin anticoagulation (SHA)|Those receiving systemic heparin anticoagulation for CRRT
9479179|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
9479180|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.~The depth of intubation = 0.1977* height-4.2423"
9479181|NCT03545724|Experimental|Neofitoroid®|Treatment is made by the application of Neofitoroid® 2 times a day for 10 days.
9479182|NCT03545711|Experimental|Anlotinib plus Irinotecan|
9479183|NCT03545698|Active Comparator|Telehealth Intervention|
9479184|NCT03545698|No Intervention|Non-Telehealth Intervention|
9479185|NCT03545685|Experimental|SMART|The subjects in SMART training group will receive add-on SMART intervention for 3 months. Subjects will play cognitive games for 1 hour per day, five days per week. SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities. Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time. Top 5 APS subjects who play the game for the most time in a week will be rewarded
9479186|NCT03545685|Other|Control group|Participants in this group will serve as control group
9479187|NCT03545672||PBC group|Patients have a definite PBC diagnosis.
9479188|NCT03545672||Control group|The healthy volunteers or patients in Renji Hospital whose medical examinations show no systemic disease, and the CMR examinations are normal.
9479189|NCT03545646|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
9479190|NCT03545633|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
9479191|NCT03545620||Difficult intubation,|Patients who underwent surgery under general anesthesia will be follow up. Patients predicted difficult intubation/airway or established difficult intubation/airway after anesthesia induction will be included. Which rescue technique will be used after unsuccessful direct laryngoscopy will be recorded.
9479192|NCT03545581|Other|Experimental diet Fru rich diet|Enriched fructose diet from day 1 to day 7.
9479193|NCT03545581|Other|Experimental low Fru diet|Low fructose diet from day 1 to day 7.
9479194|NCT03545568|Other|Experimental: sialic acid|
9479195|NCT03545555|Experimental|Kale Powder|"5 capsules with kale preparation kale powder per day for 8 weeks"
9479196|NCT03545555|Experimental|Kale Extract|"5 capsules with kale preparation kale extract per day for 8 weeks"
9479197|NCT03545555|Experimental|Flavonoid Extract|"5 capsules with kale preparation flavonoid extract (from kale) per day for 8 weeks"
9479198|NCT03545555|Placebo Comparator|Placebo|"5 capsules with placebo per day for 8 weeks"
9479199|NCT03545542|Experimental|Neuroblastoma group|"10 children with neuroblastoma. Inclusion after verification of diagnosis and informed consent.~Sampling of fecal microbiome (Initial microbiome, microbiome under chemotherapy, final microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds, fecal volatile organic compounds under chemotherapy and final fecal volatile organic compounds) and breath organic volatile compounds (initial breath organic compounds, breath volatile organic compounds under chemotherapy and final breath volatile organic compounds).~Samples will be taken after verifying diagnosis before initiation of chemotherapy, 1 week after completion of each cycle and 3 weeks after the end of chemotherapy."
9480873|NCT05222542||Patients after aneurysmal subarachnoid hemorrhage|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
9480874|NCT05219942|Placebo Comparator|low dose insulin infusion +Subcutaneous saline|low dose insulin infusion +Subcutaneous saline
10022869|NCT02332928|Active Comparator|20 mg Melatonin|RT (as clinically indicated) + melatonin (Subjects will receive 20-mg oral melatonin the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
10022870|NCT02332928|Placebo Comparator|Placebo|RT (as clinically indicated) + placebo (Subjects will receive 20-mg oral placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
10022871|NCT02325466|Placebo Comparator|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
10022872|NCT02325466|Active Comparator|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
10022873|NCT02325466|Active Comparator|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
10022874|NCT02323100|Active Comparator|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
10022875|NCT02323100|Active Comparator|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
10022876|NCT02323100|Placebo Comparator|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
10022877|NCT02322710|Active Comparator|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
10022878|NCT02322710|Active Comparator|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
10022879|NCT02316457|Experimental|ARM1 IVAC_W_bre1_uID|Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
10022880|NCT02316457|Experimental|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|Patients enrolled in ARM2 will optionally receive the WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
10022881|NCT02316457|Experimental|ARM3 IVAC_W_bre1_uID + RBLTet.1|Patients enrolled in ARM3 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumor sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient. RBLTet.1 RNA will be added to each RNA applied.
10022882|NCT02303678|Experimental|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
10022883|NCT02303548|Experimental|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
10022884|NCT02303548|Placebo Comparator|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
10022885|NCT02300493|Experimental|Experimental|weigh themselves daily
10022886|NCT02300493|Active Comparator|Control|Weigh themselves every six months
10022887|NCT02292654|Experimental|Olipudase alfa|Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.
10022888|NCT02285179|Experimental|tamoxifen and GDC-0032|20 mg tamoxifen QD and 4 MG GDC-0032 QOD
10022889|NCT02285179|Placebo Comparator|tamoxifen and placebo|20 mg tamoxifen QD and placebo QOD
10022890|NCT02283281|Experimental|Cannabis oil high dose|Single-dose, before anesthetic induction: 21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic
10022891|NCT02283281|Experimental|Cannabis oil low dose|Single-dose, before anesthetic induction: 10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
10022892|NCT02283281|Placebo Comparator|Control|Single-dose, before anesthetic induction: Dummy oromucosal spray containing alcohol vehicle without Cannabis oil .
10022893|NCT02257749|Experimental|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
10022894|NCT02257749|Active Comparator|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
10022895|NCT02255435|Experimental|Omaveloxolone Capsules 2.5 and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
10022896|NCT02255435|Experimental|Omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) Capsules, 10 mg taken orally once daily for 12 weeks
10022897|NCT02255435|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
10022898|NCT02255435|Experimental|Omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks
10022899|NCT02255435|Experimental|Omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks
10022900|NCT02255435|Experimental|Omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks
10022901|NCT02255435|Experimental|Omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks
10022902|NCT02255435|Experimental|Omaveloxolone Capsules 300 mg|omaveloxolone (RTA 408) Capsules, 300 mg taken orally once daily for 12 weeks
9480875|NCT05219942|Active Comparator|low dose insulin infusion +subcutaneous Glargine insulin|low dose insulin infusion +subcutaneous Glargine insulin
10022903|NCT02255435|Experimental|Omaveloxolone Capsules 150 mg|omaveloxolone (RTA 408) Capsules, 150 mg taken orally once daily for 24 weeks
10022904|NCT02251548|Experimental|Ibrutinib|"- Ibrutinib-~Oral, daily during each cycle~fludarabine-administered at standard dosing for up to 6 cycles~cyclophosphamide-administered at standard dosing for up to 6 cycles~rituximab-administered at standard dosing for up to 6 cycles"
10022905|NCT02243033||Visualase|MR-guided laser focal therapy
10022906|NCT02240498|Experimental|MB-PDT, 5 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 5 minutes.
9479200|NCT03545542|Other|Control group|"10 children without gastro-intestinal or pulmonary disease as age and sex matched controls to the neuroblastoma group. Patients will be recruited from paediatric surgery. Inclusion after informed consent.~Sampling of fecal microbiome (initial fecal microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds) and breath organic volatile compounds (initial breath volatile organic compounds).~Samples will be taken as age and sex matched controls for the neuroblastoma group. Sampling will be done once after obtaining informed consent."
9479201|NCT03545529|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (telealarm, numeric communication diary...) and from a strong accompaniment with a referent person who help better the patient.
9479202|NCT03545529|No Intervention|conventional supported|Patients benefit from usual care
9479203|NCT03545516|Placebo Comparator|Placebo|Wound infiltration with a placebo
9479204|NCT03545516|Experimental|Bupivacaine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL
9479205|NCT03545516|Experimental|Bupivacaine and Dexmedetomidine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .
9479206|NCT03545490|Experimental|Intervention oral or tube feeding group|Ensure 3 times/day
9479207|NCT03545490|No Intervention|Control oral or tube feeding group|Only nutrition education
9479208|NCT03545451|Experimental|Neurofeedback rehabilitation with videogames|Neurofeedback rehabilitation with videogames
9479209|NCT03545438|Placebo Comparator|cohort 1|LIB003 dose 1 SC
9479210|NCT03545438|Placebo Comparator|cohort 2|LIB003 dose 2 SC
9479211|NCT03545438|Placebo Comparator|cohort 3|LIB003 dose 4 SC
9479212|NCT03545438|Placebo Comparator|cohort 4|LIB003 dose 4 SC
9479213|NCT03545438|Placebo Comparator|cohort 5|LIB003 dose 5 SC
9479214|NCT03545438|Placebo Comparator|cohort 6|LIB003 dose 4 IV
9479215|NCT03545438|Placebo Comparator|cohort 7|LIB003 dose 5 IV
9479216|NCT03545438|Placebo Comparator|cohort 8|LIB003 dose 3 SC - statin treated
9479217|NCT03545438|Placebo Comparator|cohort 9|LIB003 dose 4 SC - statin treated
9479218|NCT03545425||Idiopathic Parkinson's Disease patients|Up to 30 Parkinson's Disease patients will be enrolled.
9479219|NCT03545425||Healthy Controls|Up to 30 Healthy Controls will be enrolled.
10022907|NCT02240498|Experimental|MB-PDT, 10 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 10 minutes.
9479220|NCT03545425||LRRK2 G2019S - Manifesting|Up to 30 LRRK2 G2019S Manifesting carriers will be enrolled.
9479221|NCT03545425||LRRK2 G2019S - Non-Manifesting|Up to 30 LRRK2 G2019s Non-Manifesting carriers will be enrolled.
9479222|NCT03545399|Experimental|Ulva Lactuca|The subject is given a capsule containing a concentrated fraction of freeze-dried and crushed hydrosoluble extract of seaweeds. The dose tested of extract of seaweeds is of 6.45mg per kg weight. The daily dose is 3 capsules per day for subjects weighing between 50 and 70kg, 4 capsules per day for subjects weighing between 70 and 90kg and 5 capsules per day for subjects weighing between 90 and 110kg. The duration of the treatment is 12 weeks.
10022908|NCT02240498|Experimental|MB-PDT, 15 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 15 minutes.
9479223|NCT03545399|Placebo Comparator|Placebo|The subject is given a capsule looking alike that of the active product but containing no extract of seaweeds.The duration of the treatment is 12 weeks.
9479224|NCT03545373|Experimental|Azithromycin|Azithromycin 500mg, oral, once daily for 3 days commencing on randomization day.
9479225|NCT03545373|Experimental|Amoxicillin|Amoxicillin 1g, oral, 3 times daily for 5 days commencing on randomization day.
10022909|NCT02240498|Experimental|MB-PDT, 20 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 20 minutes.
9479226|NCT03545373|No Intervention|Standard of care|The standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment, re-evaluate with sputum results)
9479227|NCT03545360|Experimental|Treatment Group|Treated group of subjects, serves as its own control
9479228|NCT03545347|Experimental|Nandrolone Decanoate|Physical therapy with strength training, protein-rich nutritional supplement plus Nandrolone decanoate.
9479229|NCT03545347|Placebo Comparator|Placebo (Sodium Chloride)|Physical therapy with strength training, protein-rich nutritional supplement plus placebo.
9479230|NCT03545334|Experimental|Comparison result lymphoscintigraphy with ICG lymphography|"The patient first receives a standard Tc-99m-based lymphoscintigraphy. The identified lymph nodes are not marked in the patients, so that the surgeons are not affected in lymph node identification during ICG and near infrared fluorescence imaging. The surgeon also has no access to lymphoscintigraphy images.~Transcutaneous ICG lymphography is then performed by intradermal injection of ICG around the scar of the primary tumor excision and transcutaneous fluorescence evaluation with the Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD) and results are compared."
9479231|NCT03545295|Experimental|QLB 2 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 10 ml coloring solution
9479232|NCT03545295|Experimental|QLB 2 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 20 ml coloring solution
9479233|NCT03545295|Experimental|QLB 2 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 30 ml coloring solution
10022910|NCT02240498|Experimental|MB-PDT, 25 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 25 minutes.
10022911|NCT02240498|Experimental|MB-PDT, 30 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, optical spectroscopy measurement, and laser illumination, 30 minutes.
10022912|NCT02239354|Experimental|Cohort 1|2 VC-01™ Combination Product implants
10022913|NCT02239354|Experimental|Cohort 2|4 or 6 VC-01™ Combination Product implants
10022914|NCT02234310|Experimental|Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)|Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
10022915|NCT02215980|Experimental|A|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance."
10022916|NCT02215980|Experimental|B|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.~Maintenance until progression or intolerance:~- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle"
9479234|NCT03545295|Experimental|QLB 3 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 10 ml coloring solution
9479235|NCT03545295|Experimental|QLB 3 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 20 ml coloring solution
9479236|NCT03545295|Experimental|QLB 3 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 30 ml coloring solution
9479237|NCT03545269|Experimental|CartiLife®|
9479238|NCT03545269|Active Comparator|Microfracture|
9479239|NCT03545243|Other|Pantoprazole 40mg in healthy volunteers|Peroral Pantoprazole 40mg once daily for 4 weeks
9479240|NCT03545243|Other|Pantoprazole 40mg in functional dyspepsia|Peroral Pantoprazole 40mg once daily for 4 weeks
9479241|NCT03545243|Other|PPI-withdrawal in functional dyspepsia|no PPI for 8 weeks
9479242|NCT03545230|Experimental|"children who recieved Four Not Techniques surgery"|":Four Not Techniques"
10022917|NCT02212015|Experimental|Pazopanib + Paclitaxel|Paclitaxel administered every 28 days at day 1, day 8 and day 15 as a 2h intravenous infusion in a dose of 70mg/m2 in combination with pazopanib in a daily oral dose of 800mg (2x400mg)
10022918|NCT02204241|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
10022919|NCT02196181|Experimental|Arm I (continuous dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
10022920|NCT02196181|Experimental|Arm II (intermittent dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
10022921|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
10022922|NCT02185820|Experimental|1|"Treatment schedule for 8 cycles of induction:~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
10022923|NCT02168829|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg daily
10022924|NCT02168829|Active Comparator|Acetylsalicylic acid (ASA)|ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)
10022925|NCT02163317|Experimental|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
10022926|NCT02162563|Experimental|Arm B: FOLFOXIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.~Intervention: FOLFOXIRI with bevacizumab"
10022927|NCT02162563|Active Comparator|Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
10022928|NCT02162563|Experimental|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.~Intervention: FOLFOX/FOLFIRI with panitumumab"
9479243|NCT03545217|Experimental|intervention group|
9479244|NCT03545217|No Intervention|control group|
10022929|NCT02162563|Active Comparator|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
10022930|NCT02158403|Other|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
10022931|NCT02158234|Experimental|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m^2
10036538|NCT01816633|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive AutoloGel treatment.
10036539|NCT01816646|Experimental|Cidofovir|Patients receive a single dose of 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours. Probenecid 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
9479245|NCT03545204|Other|Intervention Clusters|Community based Kangaroo Mother Care,KMC package in low birth weight infants of randomly selected union councils.
9479246|NCT03545204|Other|Control clusters|Essential newborn and routine standard care in low birth weight infants of randomly selected union councils.
9479247|NCT03545178||Diabetic patients using CGM/FGM|Evaluation of glucose control and application of hypoglycemia prediction models in diabetic patients wearing CGM and/or FGM devices for at least 50% of the time during the last 4 weeks prior to the medical consultation.
10036540|NCT01816659|Experimental|Metformin + Colon Surgery|Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
9479248|NCT03545152|No Intervention|comparison group|No procedure conducted between the pre- and the post-test evaluations, and they received an abridged version of the training after the post-test session.
10036541|NCT01816659|No Intervention|Colon Surgery Alone|Patients will not receive any study drug from the time of colonoscopy until surgery.
10036542|NCT01816672|Active Comparator|AutoloGel|AutoloGel treatment
10036543|NCT01816672|Other|Usual and Customary Care|Standard of care
10036544|NCT01816698|Active Comparator|Taurine|Interventions Drug: Taurine granule Arms: Group 1
10036545|NCT01816698|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
10036546|NCT01816724||Men with nocturia|Men older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
10036547|NCT01816724||Women with nocturia|Women older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
9479249|NCT03545152|Experimental|exercise group|The exercise program will include instructions on how to read the program, complete the activities, record their sessions, and exercise safely at first day. To promote incorporating exercising in their daily life routine during the 24-week period, we provided 2 group-based (5-8 participants with 2 instructors at community centers, 60' each) and one home-based (with the exercise program VCD and manual to bring home, 30') exercise program.
9479250|NCT03545152|Experimental|cognitive training group|Consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
9479251|NCT03545139|Experimental|NeoMTA (intervention group)|Revascularization with NeoMTA as coronal plug.
9479252|NCT03545139|Active Comparator|White MTA (Control group)|Revascularization with Conventional white mineral trioxide aggregate (White MTA) as coronal plug.
9479253|NCT03545113|Experimental|Upper extremity arteriovenous graft (AVG) - first|Participants randomized to receive an AVG will undergo surgery to have an AVG placed.
9479254|NCT03545113|Active Comparator|Upper extremity arteriovenous fistula (AVF) - first|Participants randomized to receive an AVF will undergo surgery to have an AVF created.
9479255|NCT03545100|Experimental|experimental group|motor control therapy
9479256|NCT03545100|Active Comparator|control group|regular physical therapy
9479257|NCT03545087|Experimental|Lanabecestat Control|Lanabecestat administered orally to participants with normal renal function
9479258|NCT03545087|Experimental|Lanabecestat Severe Renal Impairment|Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
9479259|NCT03545074|Experimental|Mindfulness Spanish|The MAPs program was developed at UCLA (Winston & Smalley, 2010 and Lopez-Maya, 2016) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
9479260|NCT03545074|Experimental|Mindfulness English|The MAPs program was developed at UCLA (Winston & Smalley, 2010) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
9479261|NCT03545074|Active Comparator|Health Education Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
9479262|NCT03545074|Active Comparator|Health Education English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
9480876|NCT05217511|Experimental|NMSE Group|Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points starting on the first day of randomization.The subjects also receive conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day during their stay in the ICU.
9480877|NCT05217511|No Intervention|CPT group|The subjects only receive conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day during their stay in the ICU.
10036548|NCT01816750|Experimental|Anatomical accuracy Cardiac GSI vs ICA|The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.
10036549|NCT01816750|Experimental|Stress perfusion Cardiac GSI vs MPI-SPECT|Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT
10036550|NCT01816750|Experimental|Delayed enhancement Cardiac GSI vs CMR|Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.
10036551|NCT01816789|Active Comparator|"Group A: age"|Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.
10022932|NCT02158091|Experimental|IPI-145|"Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation.~Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy.~Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing."
10022933|NCT02154568|Experimental|Hyperpolarized helium MRI of the chest|
10022934|NCT02152956|Experimental|Flotetuzumab dose escalation:|Participants will be assigned sequentially to escalating doses of flotetuzumab, up to the maximum tolerated dose (MTD).
9480878|NCT05216887|Active Comparator|Aducanumab IV|Participants will receive a single weight-based dose of aducanumab via IV infusion on Day 1.
10022935|NCT02152956|Experimental|Flotetuzumab dose expansion|Participants will receive flotetuzumab at the recommended phase 2 dose (RP2D) and schedule identified during dose escalation.
10022936|NCT02152956|Experimental|Flotetuzumab and ruxolitinib|Participants will receive flotetuzumab at the recommended phase 2 dose (RP2D) and schedule identified during dose escalation in combination with one of two escalating doses of ruxolitinib.
10022937|NCT02150902|Experimental|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
10022938|NCT02150902|Active Comparator|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
10022939|NCT02141542|Experimental|Tremelimumab and MEDI3617|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Tremelimumab-Fixed doses of Tremelimumab are given once per cycle~MEDI3617-MEDI3617 is administered twice per cycle"
10022940|NCT02139436|Experimental|FES-row-training|Subjects will perform 6 months of FES-row-training.
10022941|NCT02139436|Other|Wait-list time control|Subjects perform 6 months of their standard of care
10022942|NCT02139436|Active Comparator|Arms-only-row-training|Subjects will perform 6 months of arms-only row training
10022943|NCT02137850|Experimental|50 EDs (exposure days)|
9480879|NCT05216887|Experimental|Aducanumab SC|Participants will receive 2 fixed doses of aducanumab via SC injection on Days 1 and 15.
9480880|NCT05216809|Active Comparator|Young Adults|Equal sex distribution (6M/6F); ages 18-35 years old.
9480881|NCT05216809|Active Comparator|Older Adults|Equal sex distribution (6M/6F); ages 60-80 years old.
9480882|NCT05216211|Active Comparator|Group Caudal|Caudal block with 1 ml / kg, % 0.25 bupivacaine
9480883|NCT05216211|No Intervention|Group Control|No intervention
9479263|NCT03545048|Experimental|Intervention arm|"Interventional groups will have an assessment session with the experienced staff and NRS, QST, WOMAC, MSK-HQ, 30CST, TUG, PSQI, MSK-USS, urine and blood samples will be taken at baseline. Those who consent for aspiration of synovial fluid will go through the USGA procedure.~Interventional group will shortly after that receive a link via email, which will be used to log-in to Joint Academy online portal. After log-in has been achieved, the intervention starts. It consist of a 6-week internet-based physical therapy program. Interventional group will be given actigraphy device (a device to monitor sleeping pattern) which is CE marked. Therefore, their sleeping pattern can be recorded quantitatively.~Once exercises programme is finished in six weeks, the participants will fill in the same questionnaire and perform the physical tests, to enable evaluation."
9479264|NCT03545048|No Intervention|Control arm|Control group will continue with their routine self-management which is offered in the community setup. They will be assessed on NRS, QST, WOMAC, MSK-HQ, PSQI, 30CST, TUG, isometric muscles strengthen of quadriceps, MSK-USS, muscle mass of vastus lateralis, urine and blood samples at baseline. Control group will also get the actigraphy to monitor sleeping pattern of that group. They will be re-assessed after six weeks on the primary objective measures to see if they have made any difference by following self-management strategies in the community.
9479265|NCT03545035||Study group|All patients being observed during the study duration.
9479266|NCT03545022|Active Comparator|Active acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle.The needle measuring 0.25x30mm was used as an active needle. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle as well as the placebo needle were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
9479267|NCT03545022|Placebo Comparator|Placebo acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle. In the placebo needle, the needles were cut in 5mm, to measure 0.25x25mm. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle, as well as the placebo needle, were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
9479268|NCT03545009|Experimental|Beetroot Juice|
9479269|NCT03545009|Active Comparator|Beetroot Juice no Nitrate|
9479270|NCT03545009|Active Comparator|Sodium Nitrate|
9479271|NCT03545009|No Intervention|Control|
9479272|NCT03544996||TD Insulin Pilot|Test of novel transdermal insulin (TD Insulin) formulations
9479273|NCT03544983|Experimental|Proactive Outreach + Web Counseling|Web + Streamlined Telephone Genetic Counseling
9479274|NCT03544983|No Intervention|Usual Care|Participants in the usual care arm will not be provided with access to the web-based intervention nor will they have access to streamlined genetic counseling. They can pursue clinical genetic counseling on their own.
10022944|NCT02128802|Experimental|Surgical Gastric Bypass|Patients will undergo surgical gastric bypass according to standard institutional protocols
10022945|NCT02128802|Experimental|Medical Weight Loss Management|Patients will receive best practices medical management for weight loss under current institutional protocols
10022946|NCT02127086|Experimental|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
9479275|NCT03544944|Experimental|TJP-008-1|
9479276|NCT03544944|Experimental|TJP-008-2|
9479277|NCT03544944|Active Comparator|Coolprep powder|
10036552|NCT01816789|Experimental|"Group B: nomogram"|Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.
10036553|NCT01816802||In-vitro fertilization using Eeva|Patients undergoing in-vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.
9480884|NCT05214404||Ulcerative colitis group|Patients with ulcerative colitis as observation group
9480885|NCT05214404||Non-ulcerative colitis group|Non-ulcerative colitis as control group
10036554|NCT01816815|Experimental|BAY1002670 [0.1mg]|0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
10022947|NCT02127086|No Intervention|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
10022948|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
10022949|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
10036555|NCT01816815|Experimental|BAY1002670 [0.5mg]|0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
9479278|NCT03544931|Experimental|Root Instrumentation + EMD Application|"Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
9479279|NCT03544931|Active Comparator|Root Instrumentation|Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
9479280|NCT03544918||Patients with long QT syndrome.|Patents with Long QT syndrome hospitilized. To be followed over time with no intervention. Observational study.
9479281|NCT03544918||Patients in Telemark with normal QT time|Patients in Telemark with normal QT time. To be followed over time with no intervention. Observational study.
9479282|NCT03544905|Experimental|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
9479283|NCT03544892|Experimental|Experimental: Low carbohydrate diet|
9479284|NCT03544892|Active Comparator|Experimental: Standard of care diet|
9479285|NCT03544853|Experimental|Prosthetic socket evaluation|Intervention: Prosthetic socket for transtibial amputee. A subject's conventional prosthetic socket is compared to a novel prosthetic socket designed as part of the research. For standing and walking exercises the following will be assessed. 1) local skin contact pressures, 2) metabolic power, 3) gait parameters (symmetry indices for joint angles, positions, torques, and also ground reaction forces), and 4) the socket evaluation questionnaire.
9479286|NCT03544840|Experimental|Dynamic Standing Device|Home program using the Upsee
9479287|NCT03544827|Experimental|Atropine 0.01% then atropine 0.1%|Participants will be on topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
9479288|NCT03544827|Experimental|Atropine 0.1% then atropine 0.01%|Participants will be on topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
9479289|NCT03544814|Experimental|Concurrent therapy group|Icotinib combined with pemetrexed plus cisplatin.
9479290|NCT03544814|Experimental|Sequential therapy group|First icotinib and then pemetrexed plus cisplatin.
9479291|NCT03544801||sample group ,300|CSVD patients after symptomatic stroke
9479292|NCT03544801||control group,100|community population
9479293|NCT03544788|Experimental|Cirvo™ Therapy|
9479294|NCT03544775||Isolated General Anesthesia|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have not had a nerve block identified using physician billing codes.
9479295|NCT03544775||Peripheral Nerve Block|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have a nerve block identified using physician billing codes.
9479296|NCT03544762|Experimental|18F-FES PET|PET/CT
9479297|NCT03544749|Experimental|Ambu® AuraGain™ group|
9479298|NCT03544749|Active Comparator|I-gel group|
10036556|NCT01816815|Experimental|BAY1002670 [1.0mg]|1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
10036557|NCT01816815|Experimental|BAY1002670 [2.0mg]|2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
10036558|NCT01816815|Experimental|BAY1002670 [5.0mg]|5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
9479299|NCT03544723|Experimental|Ad-p53 with anti-PD-1/anti-PD-L1 100% of patients|Up to 40 patients, all patients treated with intra-tumoral Ad-p53 (dose determined by tumor size) in combination with IV physician's choice of approved immune checkpoint inhibitor
10022950|NCT02120079|Active Comparator|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
10022951|NCT02120079|Active Comparator|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
10022952|NCT02114229|Experimental|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
9479300|NCT03544710|Experimental|Bathing|Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
9479301|NCT03544710|No Intervention|No bathing|"No intervention done for participants in this arm. They go through the routine ward procedure as below.~Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
9479302|NCT03544697||Skin expansion and repair with flaps|The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients.
9479303|NCT03544684|Experimental|Control day with no exercise|glycaemic profile will be assessed using continuous glucose monitors following a single 24-hour period in which participants performed no exercise
9479304|NCT03544684|Experimental|High intensity interval training (HIT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of high-intensity interval training (HIT) in the morning under fasted conditions
9479305|NCT03544684|Experimental|moderate intensity continuous training (MICT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of moderate-intensity continuous training (MICT) in the morning under fasted conditions
9479306|NCT03544671|Experimental|400 IU/d vitamin D2|Children received 1mililiter (dosage applicator) containing 400 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
9479307|NCT03544671|Experimental|800 IU7d vitmin D2|Children received 2 mililiter (dosage applicator) containing 800 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
9479308|NCT03544671|Experimental|1000 IU vitamina D3|Children received 1drop (dosage applicator) containing 1000 IU of vitamin D3 per day. dosage form (1 drop), frequency (daily) and duration 16 weeks
9479309|NCT03544671|Placebo Comparator|Multiple vitamin|Children received 1 mililiter of a supplement with multiple vitamins (dosage applicator) frequency (daily) and duration 16 weeks
9479310|NCT03544658|Experimental|Dental prophylaxis|Visit 1: tooth color assessment (by patient, dentist and spectrophotometer) and professional dental prophylaxis Visit 2: tooth color assessment (by patient, dentist and spectrophotometer)
9479311|NCT03544645|Active Comparator|control group|"This group received a printed material brochure as an educational material"
9479312|NCT03544645|Experimental|intervention group|"This group received an audiovisual material video as an educational material"
9479313|NCT03544606|Experimental|isosorbide mononitrate group|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
9479314|NCT03544606|Placebo Comparator|placebos group|70 patients induced by placebo (pyridoxine) placebo tablet of the same size and shape as the isosorbide mononitrate. administered in the posterior vaginal fornix at 36, 24 , 12 before induction
9479315|NCT03544580|Experimental|immediate implant with dentin chips|using the tooth structure presented in socket either as remaining root or as unrestorable tooth structure remove all periodontal ligaments & scraping all enamel & cementum using a stone also to cut it into slices then putting it in acid to demineralize the dentine ; then using a bone mill to transform dentine into small particles or chips to be used in jumping gap between implant & thin buccal bone
9479316|NCT03544580|Active Comparator|immediate implant with xenograft|after surgical removal of entire badly decayed tooth we immediately put implant and in jumping gap we use xenograft
9479317|NCT03544567|Experimental|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
9479318|NCT03544554|Experimental|Intervention group and control group|This research is planned with semi experimental design
9479319|NCT03544528|Experimental|Regeneration|This treatment aims to regenerate pulp-like tissue within the root canal space after inducing an influx of stem cells from the apical papilla that results in reestablishment of pulp protective functions.
9479320|NCT03544528|No Intervention|Apexification|Traditional method. The application of Mineral Trioxide Aggregate (MTA) as an artificial apical barrier; also refer as the MTA apical plug method.
9479321|NCT03544515|Sham Comparator|Scaling and use of inactive Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an inactive fashion
10036559|NCT01816815|Placebo Comparator|Placebo|Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
10036560|NCT01816828|Experimental|Immediate|In the immediate arm, participants will begin the 8 session group motivational interviewing intervention, Gay Poz Sex, within 2 weeks of randomization.
10036561|NCT01816828|Active Comparator|Wait List/Standard of Care|Participants in the wait list/standard of care group will be given active referrals to existing community resources available to HIV+ MSM. For ethical reasons, participants randomized to the control group will have the option to attend the Gay Poz Sex program after a 6-month wait period.
10022953|NCT02114229|Experimental|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.~Interventions:~B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.~B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
10036562|NCT01816841|Experimental|Diagnostic (COE and DVFE)- Arm I|Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
10036563|NCT01816841|Experimental|Arm II - Comparison of surgical margins using COE vs. DVFE|Comparison of surgical margins using COE vs. DVFE
10036564|NCT01816854||Patients with PAD|
10036565|NCT01816867||Patients with a ventral hernia|
9802851|NCT04882241|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 3 cycles."
9479322|NCT03544515|Experimental|Scaling and use of active Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an active fashion
9479323|NCT03544502|Experimental|Music group|Music group (group M, n=35) patients applied CD player. One CDs were prepared with 5 children's songs (classic music) for the study. CD player opened during anesthesia induction and continued until postoperative 15 minute
9479324|NCT03544502|Experimental|Silence group|"silence group (group S, n=35) patients received the independent anesthesiologist applied earplugs into the patients' ears during anesthesia induction and the earplugs were removed immediately before tracheal tube extubation.~During each measurement, noise level recordings were performed using CEL-480 Sound Level Meter Sonometre."
9479325|NCT03544502|Placebo Comparator|Noise group|"noise group (group N, n=35) patients were exposed to the ambient operating room noise.~Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.Postoperatively, Emergence delirium (ED) was assessed as a Pediatric Anesthesia Emergence Delirium (PAED) Score ≥ 10."
9479326|NCT03544489|Experimental|E-ICD Intervention|E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Digi-walker, Borg scale, and exercise logs), and 3) telephone coaching by clinic RNs. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months. Participants will record walking sessions each week in the exercise logs that will be collected again at 6 months.
9479327|NCT03544489|No Intervention|Usual Care|"Usual Care will receive treatment as usual from their health care clinicians with outcomes measured at baseline, 3 and 6 months. Participants will not be discouraged from physical activity, but will be asked not to change their current level of activity for 6 months while in the study. Usual care involves ICD interrogation and follow-up every 3 months, measured either in-person or with home telephonic transmissions. Because participants in usual care may choose to participate in another exercise program, we will monitor those who participate in exercise programs and use the StepWatch monitor to quantify the amount and timing of physical activity. To control for group differences in attention, investigators will telephone usual care participants requesting information about health care utilization twice during the study at 3 and 6 months."
9479328|NCT03544476|Experimental|Mobile phone TB treatment support app|Daily use of the mobile phone TB treatment support app plus usual care. Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
9479329|NCT03544476|Active Comparator|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
9479330|NCT03544463|Experimental|Treated|iNAP® Sleep Therapy System Treatment Intervention
9479331|NCT03544463|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline condition
9479332|NCT03544450|Experimental|Psychosocial counselling + Enhanced usual care (EUC)|This arm receives psychosocial counselling from the counsellor as well as enhanced usual care from health worker
9479333|NCT03544450|Active Comparator|Enhanced Usual Care (EUC)|This arm receives enhanced usual care from health worker
9479334|NCT03544424||Study cohort|People over 60 years of age with a Medtronic CareLink® compatible CIED in situ recruited from the Manchester University NHS Foundation Trust, England, UK
9479335|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 1|The group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
9479336|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 2|this group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
9479337|NCT03544398|Active Comparator|exoskeleton|We will use exoskeleton type robot assisted gait training for spinal cord injury rehabilitation
10022954|NCT02114229|Experimental|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
10022955|NCT02112526|Experimental|Acalabrutinib|
10022956|NCT02106195|Experimental|Belumosudil 200 mg|Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days
10022957|NCT02104180|Active Comparator|TulleGras M.S.|
10022958|NCT02104180|Active Comparator|Urgotul|
10022959|NCT02102243|Experimental|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
10022960|NCT02102243|Experimental|Initial Saline Infusion|"We will perform the following procedures:~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
10022961|NCT02097550|Experimental|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
10022962|NCT02097550|No Intervention|Standard of care|These patients will receive the standard of care from their physician.
10022963|NCT02075840|Experimental|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
10022964|NCT02075840|Active Comparator|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
9479338|NCT03544398|Active Comparator|end-effector|We will use end-effector type robot assisted gait training for spinal cord injury rehabilitation
9479339|NCT03544398|Placebo Comparator|conventional physiotherapy|
9479340|NCT03544385|Experimental|Treatment Group|
9479341|NCT03544385|Placebo Comparator|Placebo Group|
9480886|NCT05214378|Experimental|Treatment Arm|The investigators will test an alternative pattern of sacral root stimulation in individuals who are already implanted with the device. Study participants will act as their own controls.
10022965|NCT02066181|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
10022966|NCT02066181|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
10022967|NCT02061423|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
10022968|NCT02059681|Experimental|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
10036566|NCT01816880||Healthy Elderly|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study Blood sample of approximately 20mL is drawn.
10036567|NCT01816919|Experimental|eNose breath samples|
10022969|NCT02050919|Experimental|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
10022970|NCT02040857|Experimental|Palbociclib With Adjuvant Endocrine Therapy|"Palbociclib 125 mg PO qd 21 days on, 7 days off~Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
9479342|NCT03544346||Retired professional rugby players|"Rugby Players will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
9479343|NCT03544346||Retired professional rowers|"Rowers will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
9480887|NCT05212259|Experimental|Collagen type II (40 mg/day)|4 capsules per day for 180 days
10022971|NCT02036476|Experimental|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
10022972|NCT02001142|Experimental|Exercise|
10022973|NCT02001142|No Intervention|Sedentary Control|
10022974|NCT01997463|No Intervention|Regular Therapy|Regular Asthma Therapy
10022975|NCT01997463|Experimental|Supervised Therapy|Supervised asthma therapy in schools
9479344|NCT03544320|Active Comparator|Activity Monitoring-Wrist worn wearable|Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.
10022976|NCT01996267|Active Comparator|FEC-T +Pertuzumab|Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days
10022977|NCT01996267|Active Comparator|PTC+Pertuzumab|Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days
10022978|NCT01994252|Active Comparator|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
10022979|NCT01994252|Active Comparator|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
10022980|NCT01979393|Experimental|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
10022981|NCT01979393|Experimental|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
10022982|NCT01976754|Other|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
10022983|NCT01950390|Active Comparator|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning cycle 8, patients receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
10022984|NCT01950390|Experimental|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning cycle 8, patients also receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
10022985|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
10022986|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
10022987|NCT01943825|Experimental|CYD Dengue Vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
9480888|NCT05212259|Experimental|Collagen type II (80 mg/day)|4 capsules per day for 180 days
10022988|NCT01943825|Experimental|CYD Dengue Vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
10022989|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
10022990|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 4|Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
10022991|NCT01940471|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
10022992|NCT01940471|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
10022993|NCT01940471|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
10022994|NCT01926184|Experimental|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
10022995|NCT01926184|Placebo Comparator|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
10022996|NCT01916317|No Intervention|Arm B:Control|: No peritumoral Local Anesthesia prior to excision
10022997|NCT01916317|Active Comparator|Arm A: Intervention|Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
10022998|NCT01913951|Experimental|Treatment (vosaroxin, azacitidine)|Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
10022999|NCT01913730|No Intervention|No prolonged therapy is scheduled|
10023000|NCT01913730|Experimental|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
10023001|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
10023002|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
10023003|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
10023004|NCT01909453|Experimental|LGX818 450 mg + MEK162|LGX818 450 mg QD + MEK162 45 mg BID
9480889|NCT05212259|Experimental|Collagen type II (120 mg/day)|4 capsules per day for 180 days
10023005|NCT01909453|Active Comparator|Vemurafenib|Vemurafenib 960 mg BID
10023006|NCT01909453|Experimental|LGX818 300 mg + MEK162|LGX818 300 mg QD + MEK162 45 mg BID
10023007|NCT01909453|Experimental|LGX818|LGX818 300 mg QD
10036568|NCT01816958||chronic depression and/or pain|co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
10023008|NCT01904123|Experimental|Treatment (STAT3 inhibitor WP1066)|Patients receive STAT3 inhibitor WP1066 PO BID on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10023009|NCT01898117|Active Comparator|Carbo/cyclo|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
10023010|NCT01898117|Active Comparator|Carbo/cyclo + Atezolizumab|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
10023011|NCT01898117|Active Comparator|Paclitaxel|Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
10023012|NCT01898117|Active Comparator|Paclitaxel + atezolizumab|Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
10023013|NCT01895660|Experimental|Group with continuous constraint and daily therapy|
10023014|NCT01895660|Experimental|Group with continuous constrainit and 3 days a week therapy|
10023015|NCT01895660|Experimental|Group with part-time constraint and daily therapy|
10023016|NCT01895660|Experimental|Group with part-time constraint and 3 days a week therapy|
10023017|NCT01895660|Active Comparator|Usual and customary treatment group|
10023018|NCT01892371|Experimental|Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10023019|NCT01892371|Experimental|Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10023020|NCT01874353|Experimental|Olaparib 300mg tablets|Taken orally twice daily
10023021|NCT01874353|Placebo Comparator|Placebo tablets|Taken orally twice daily
10023022|NCT01864460|Experimental|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
10023023|NCT01864460|Active Comparator|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
10023024|NCT01863186|Active Comparator|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
10023025|NCT01863186|Active Comparator|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
10023026|NCT01863186|Placebo Comparator|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
10023027|NCT01863186|Other|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
9479345|NCT03544320|Active Comparator|Activity Monitoring-Waist-worn wearable|Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.
9479346|NCT03544294||Group|Consecutive patients treated with very thin stents on ULM and bifurcation
9480890|NCT05212259|Active Comparator|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day for 180 days
9480891|NCT05212259|Placebo Comparator|Placebo|4 capsules per day for 180 days
9480892|NCT05209061||Colo-rectal cancer patients|Patients receiving right colectomy or ileo-ceacal resection for colorectal cancer
9480893|NCT05205109|Experimental|ATG-037|The dose escalation plan for evaluating ATG-037 monotherapy will utilize the Bayesian Optimal Interval (BOIN) design, starting with 3 subjects at the first dose level (20 mg BID) followed by a cohort size of 6 subjects for the subsequent dose levels, in order to obtain a broader dataset on PK/PDx
9480894|NCT05204485|Active Comparator|Fibular intramedullary nail|Randomized in the OR to ankle fracture repair with fibular intramedullary nail
9480895|NCT05204485|Active Comparator|Open reduction and internal fixation (ORIF)|Randomized in the OR to ankle fracture repair with ORIF
9480896|NCT05204446|Experimental|Experimental|Live interactive telehealth-based group meetings will be held for 30 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=6-8 per cohort) and a parent group (n=6-8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week.
9480897|NCT05204446|No Intervention|Control Group|(Care-As-Usual): Participants assigned to the control group (n=30 dyads) will receive care as usual, which consists of appointments in the Celiac Disease Clinic (at diagnosis, 3 months post-diagnosis, 6 months post-diagnosis, and annually after diagnosis thereafter). These appointments consist of a gastrointestinal physician or nurse practitioner, dietitian, GFD educator, and psychologist for 40-minute consultations each.
9480898|NCT05203523|Experimental|Group 1 (G1)|Participants will receive active tACS simultaneously with cognitive exercises.
9480899|NCT05203523|Sham Comparator|Group 2 (G2)|Participants will receive sham tACS simultaneously with cognitive exercises.
9480900|NCT05201300|Experimental|Remimazolam 6|Remimazolam starts at 6 mg/kg/hr until loss of consciousness
9480901|NCT05201300|Experimental|Remimazolam 12|Remimazolam starts at 12 mg/kg/hr until loss of consciousness
9480902|NCT05201300|Active Comparator|Propofol|Propofol starts at a target controlled infusion 4 µg/ml until loss of consciousness.
10023028|NCT01860404|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 21 days
10023029|NCT01860404|Experimental|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
10023030|NCT01860404|Experimental|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
9480903|NCT05200676||Main group|"All included in the study will offered to participate in:~ePatch-monitoring~Blood pressure measurement~Cardial vagal tone~Questionnaire-assessment"
9480904|NCT05200676||Subgroup|"Part of the study-population will be offered to participate in en examination with a SmartPill. The Smartpill measures pressure, pH, temperature and movement in the gut. These measurements gives an indication of the function of the autonomic nervous system (ANS) of the participant. Although measured in the gut, this is relevant as ANS-dysfunction may cause arrhythmias.~Only a subgroup of the study population will be offered to participate due to the cost of this examination."
9480905|NCT05198648||Postoperative myocardial injury|
9480906|NCT05198648||Non postoperative myocardial injury|
9480907|NCT05197439|Active Comparator|DEX group|Dexmedetomidine will be given at the beginning of the second step of DBS and last for 48 hours by electronic pump.
10023031|NCT01860404|Experimental|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
10023032|NCT01860404|Experimental|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
9479347|NCT03544229|Experimental|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, twice daily (BID) for up to 12 weeks.
9479348|NCT03544229|Experimental|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, twice daily for up to 12 weeks.
9479349|NCT03544229|Experimental|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, twice daily for up to 12 weeks.
9802852|NCT04882241|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
9479350|NCT03544229|Placebo Comparator|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily for up to 12 weeks.
10023033|NCT01857115|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.~Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
10023034|NCT01856192|Experimental|Arm A (rituximab, combination chemotherapy, lenalidomide)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1; prednisone PO on days 1-5; and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
10023035|NCT01856192|Active Comparator|Arm B (rituximab, combination chemotherapy)|Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
10023036|NCT01853748|Active Comparator|Trastuzumab emtansine (T-DM1)|T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks
10023037|NCT01853748|Active Comparator|Paclitaxel + Trastuzumab|paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments
10023038|NCT01843374|Experimental|Tremelimumab|Tremelimumab
10023039|NCT01843374|Placebo Comparator|Placebo|Placebo
9479351|NCT03544177|Experimental|BFR-Walking|Interval walking training with blood flow restriction.
9479352|NCT03544177|Active Comparator|Conventional therapy|Conventional therapy
9480908|NCT05197439|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively and postoperatively the same duration just like the DEX group would do.
10023040|NCT01841736|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10023041|NCT01841736|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I.
10023042|NCT01828840|Active Comparator|morphine, epidural|Epidurally administrated morphine
10023043|NCT01828840|Active Comparator|fentanyl, epidural|epidurally administrated fentanyl
10023044|NCT01828840|Active Comparator|methadone, epidural|epidurally administrated methadone
10023045|NCT01828840|Active Comparator|morphine, intervenous|intravenously administrated morphine
10023046|NCT01822834||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
10023047|NCT01822834||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
10023048|NCT01817751|Experimental|Treatment (sorafenib tosylate, valproic acid, sildenafil)|"Sorafenib 400 mg orally twice a day;~Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;~Sildenafil 50 mg orally twice a day~A cycle consists of 4 weeks.~*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)"
10023049|NCT01817426|Active Comparator|infliximab|Patients in this arm are randomized to continue IFX therapy at an unchanged dosage and frequency.
10023050|NCT01817426|Placebo Comparator|Placebo|Patients in this arm are randomized to receive matching placebo.
9479353|NCT03544125|Experimental|Treatment (olaparib, durvalumab)|Participants receive olaparib PO twice a day BID for 28 days in the absence of disease progression or unacceptable toxicity. Participants then receive olaparib PO BID on days 1-28 and durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants may continue on therapy beyond disease progression at the discretion of the investigator.
9479354|NCT03544112||ED and OUD treatment providers and staff|"ED patients will be recruited to participate in interviews or focus groups.~ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.~Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc."
9479355|NCT03544112||Community Stakeholders|"Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.~Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups."
9479356|NCT03544112||Patients|ED patients will be recruited to participate in interviews or focus groups.
9479357|NCT03544086||test group|First group is the first 10 patients
9479358|NCT03544086||study group|following 150 patients
9479359|NCT03544073|Placebo Comparator|Saline Solution for Injection|This arm will receive a one-time subcutaneous injection of 0.4mL normal saline solution at the time of embryo transfer. This arm will continue to receive all the same treatments that everyone routinely receives for the IVF cycle, e.g. estrogen and progesterone supplements.
9479360|NCT03544073|Experimental|Leuprolide Acetate|This arm will receive a one-time subcutaneous injection of 0.4U (0.2mg=0.4mL) Leuprolide acetate at the time of embryo transfer. This arm will continue to receive all the same routine treatments for the IVF cycle, e.g. estrogen and progesterone supplements.
9479361|NCT03544047|Experimental|Experimental arm|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
9479362|NCT03544034|No Intervention|Pre-intervention|Routine/ standard care and retrospective chart review for identifying preventable and ameliorable Adverse drug events as baseline
9479363|NCT03544034|Experimental|Post-intervention|Hometeam toolkit interventions (including improved discharge education, proactive medication safety assessment in daily rounds and handoffs, safety briefings) applied in all hospitalist services.
9479364|NCT03544021|Experimental|CART-19|The relapsed/refractory ALL patients will receive allogenic or autologous CD19-Targeted CAR-T cells infusion after FC chemotherapy.
9479365|NCT03543995||Enuresis nocturna|Patients aged 6 to 15 years with at least one night-time wetting weekly
9479366|NCT03543995||Normal population|Patients who were admitted to the urology clinic with a complaint of abdominal or lateral pain, who had no NE and had a direct abdominal x-ray examination
9479367|NCT03543982|Experimental|Oral probiotic product|
9479368|NCT03543969|Experimental|BRAF-MEK Inhibitor Therapy|"Vemurafenib twice a day and cobimetinib daily, 3 weeks on / 2 weeks off / 3 weeks on, for an 8-week cycle.~After 8 week cycle, response to these study drugs will be analyzed based on several parameters to determine if participants will proceed in the study.~Participants will be invited for post-treatment follow-up visits for up to 5 years."
9479369|NCT03543956||Systemic Sclerosis patient|patients affected by SSc according to EULAR 2013 criteria
9479370|NCT03543930||Major open vascular surgery|Surgical procedures on the abdominal aorta requiring median abdominal incision
9479371|NCT03543930||Endovascular aortic repair|Abdominal aortic repair with endovascular approach
9479372|NCT03543917|Experimental|New Medication Combination|Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
9479373|NCT03543904|Experimental|Pre-operative physiotherapy education|Pre-operative education regarding post-operative physiotherapy intervention and post-operative physiotherapy intervention in children with abdominal surgery
9479374|NCT03543904|Experimental|Post-OP PT without Pre-OP education|Post-operative physiotherapy intervention without pre-operative education in children with abdominal surgery
9479375|NCT03543891||Control group|50 healthy volunteers were included in the healthy control group
9479376|NCT03543891||Thyroid cancer group|50 patients of thyroid cancer were included
9479377|NCT03543826|Other|Protocol|Patients will have perioperative nuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed subjectively at adductor pollicis with standard train-of-four stimulation of the ulnar nerve.
10023051|NCT01813695||Preemptive|Patients with genotype testing entered into electronic medical record for consideration and opioid administration postoperatively.
10023052|NCT01813695||Control|Genetic sample taken but withheld from electronic medical record.
10023053|NCT01804179|Active Comparator|Standard Intervention (SI)|"At Baseline Visit, Participants in the standard intervention (SI) condition will get: I-FOBT kit and Screen for Life brochure, a mailed reminder card at two weeks post-intervention to remind them about FOBT testing and follow up assessments at 12 months."
10023054|NCT01804179|Experimental|CARES Intervention|Colorectal Cancer Awareness, Research, Education and Screening (CARES). At Baseline Visit, Participants in the CARES intervention will receive: I-FOBT kit, a newly developed DVD and booklet, and a mailed reminder card at two weeks post-intervention to remind them about FOBT testing, and follow-up assessments at 12 months.
9479378|NCT03543800|Experimental|ABP|(test treatment)
9479379|NCT03543800|Active Comparator|PRP|(active control)
9479380|NCT03543774|Active Comparator|simvastatin treatment|
10023055|NCT01790152||Ancillary-Correlative (laboratory biomarker analysis)|Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.
10023056|NCT01741103|Experimental|Sitagliptin|
10023057|NCT01741103|Placebo Comparator|Placebo|
10023058|NCT01736956|Experimental|Fetal Aortic Valvuloplasty|Subjects will undergo fetal aortic valvuloplasty
10023059|NCT01736956|No Intervention|Control|Control group. Will receive standard prenatal and postnatal care.
9479381|NCT03543774|Sham Comparator|EZE/simvastatin 10/20 mg treatment|
9479382|NCT03543774|Sham Comparator|EZE/simvastatin 10/40 mg treatment|
9479383|NCT03543761|Sham Comparator|A|Sham group
9479384|NCT03543761|Active Comparator|B|LiST active treatment group
9479385|NCT03543761|Active Comparator|C|LiST active treatment group
9479386|NCT03543748|Experimental|TMS|The Transcranial Magnetic Stimulation course consisted of daily sessions of 2,000 stimuli for the left DLPFC (50 trains of 40 stimuli at 10 Hz for 10 days),
10023060|NCT01722331|Experimental|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
10023061|NCT01722331|Experimental|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
10023062|NCT01722331|Placebo Comparator|Placebo|Matching placebo administered SC once a week at Weeks 0 and 4.
10023063|NCT01716117|Experimental|Surpass Flow Diverter|The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
10023064|NCT01698905|Experimental|Nilotinib|Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening
10023065|NCT01697930|Experimental|[18F] 4-L-Fluoroglutamine (2S,4R)|This pilot, first in-human microdose PET trial of the positron-emitting agent [18F] 4-L-Fluoroglutamine (2S,4R) will be an open-label study. The [18F] 4-L-Fluoroglutamine (2S,4R) agent will be administered by bolus intravenous injection. In all study patients, the pharmacokinetics, metabolism, and biodistribution of [18F] 4-L-Fluoroglutamine (2S,4R) will be evaluated by non-invasive blood- and PET-based assays, at multiple time points (see Table 1,) during one day. Eligible patients optionally can participate in the study twice, on a separate date, receiving a second radiotracer microdose of [18F] 4-L-Fluoroglutamine (2S,4R), followed by non-invasive blood- and PET-based assays. At the discretion of the investigator, scan 3 can be waived.
10023066|NCT01676350|No Intervention|Standard of care|If you are assigned to this group, ultrasound-guided IV will be used to obtain vascular access.
10023067|NCT01676350|Experimental|IO access using EZ-IO®|If you are assigned to this group, you will receive an IO line in the humeral head of the shoulder. IO lines are placed using an FDA-approved device called an EZ-IO®.
10023068|NCT01670500|Active Comparator|Doxorubicin-Cyclophosphamide|Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4
10023069|NCT01670500|Active Comparator|Cisplatin|Cisplatin q 3 wk x 4
9479387|NCT03543748|Sham Comparator|SHAM|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
9479388|NCT03543735|Experimental|Wisepill+SMS|
9479389|NCT03543735|Active Comparator|Wisepill-only|
9479390|NCT03543735|No Intervention|Disulfiram-only|
9479391|NCT03543709||Behcet and fibromyalgia|Women with Behcet's disease with fibromyalgia
10023070|NCT01662453||SUDEP Group|The SUDEP group refers to epileptic patients that had a sudden unexplained death; excludes trauma, drowning, status epilepticus, or other known cause, but there is often evidence of an associated seizure.
10023071|NCT01662453||Control Group|We will recruit living patients with epilepsy for the control group. In particular, epileptic patients with Dravet Syndrome of Idic 15.
9479392|NCT03543709||Behcet|Women with Behcet's disease without fibromyalgia
9479393|NCT03543696|Experimental|Single Dose Radiotherapy (SDRT)|Single Dose Radiotherapy (SDRT) at a prescription dose of 24 Gy to all detectable metastatic lesions
10023072|NCT01657591|Experimental|Dose Escalation|The treatment period will include dosing (taking a certain amount on a regular schedule) with vemurafenib along with the study drug, XL888. Everyone in the study will receive both drugs, but the XL888 will be given at different doses (different amounts). Everyone in this study will be given vemurafenib at the standard dose (the amount of the drug that is given as standard treatment) of 960 milligrams (mg) twice per day, unless the first people in the study have severe side effects when taking the lowest dose of XL888 along with vemurafenib. If that happens, the next people in the study may be given a lower dose of vemurafenib (720 mg twice per day) along with the lowest dose of XL888.
9479394|NCT03543683||osimertinib and aspirin|Osimertinib starting at a dose of 80 mg once a day, orally with meals.The intervention is aspirin which is starting at a dose of 100 mg once a day, orally with meals.Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
9479395|NCT03543683||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
9479396|NCT03543670|Experimental|Oncoxin-Viusid|
9479397|NCT03543657|Experimental|Molidustat group|Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
9479398|NCT03543657|Active Comparator|Darbepoetin alfa group|Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
9479399|NCT03543644|Active Comparator|Sugar-sweetened beverage (SSB)|"The SSB intervention will consist the participants' consuming their usual serving of cans SSBs (each 355 ml, 42 grams sugar) per day. The calories of the SSB group will not be matched to allow for real-world substitutions using products available on the market."
9479400|NCT03543644|Experimental|Non-nutritive sweetened beverage (NSB)|"The NSB intervention consists of substituting the participants' usual serving of cans SSBs with NSBs (each 355 ml, 0 grams sugar) per day. The calories of the NSB group will not be matched to allow for real-world substitutions using products available on the market."
9479401|NCT03543644|Experimental|Water|"The water intervention consists of substituting the participants' usual serving of cans SSBs with bottles or cans of still or sparkling water (each 355 ml bottle or can, 0 grams sugar) per day. The calories of the water group will not be matched to allow for real-world substitutions using products available on the market."
9479402|NCT03543618|Sham Comparator|Control|Installation of conventional design dental implant
9479403|NCT03543618|Active Comparator|Sloped|Installation of sloped design dental implant
9479404|NCT03543592|Other|3 dimensional power Doppler|100 women suffering post-menopausal bleeding (occurred after at least 12 months of amenorrhea) will be included in the study and 3 dimensional ultrasonography and Doppler will be done for them
9479405|NCT03543579||Multiple myeloma patients|Patients with multiple myeloma and an indication to receive carfilzomib
9479406|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
9479407|NCT03543553||HC|Healthy control participants
9479408|NCT03543540|Experimental|Nexvax2 (Arm A)|
9479409|NCT03543540|Experimental|Nexvax2 (Arm B)|
9479410|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm C)|
9479411|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm D)|
9479412|NCT03543527||Takayashu|
9479413|NCT03543501|Experimental|Real-time ultrasound imaging group|See intervention
9479414|NCT03543501|Experimental|PBU group|See intervention
9479415|NCT03543488||Rheumatoid Arthritis Patients|Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.
9479416|NCT03543488||Healthy Women|Thirty-five healthy women, age- and body size-matched to the RA patients, were recruited as controls (CG).
9479417|NCT03543475|Experimental|Pessary|Silicon device applied on the cervix
9479418|NCT03543475|Active Comparator|No Pessary|standard care, no pessary
9479419|NCT03543462|Sham Comparator|Arm A: Chest tube positioning YES|Patients enrolled for chest tube positioning
9479420|NCT03543462|No Intervention|Arm B: Chest tube positioning NO|Patients enrolled for diaphragm closure without chest tube positioning
9479421|NCT03543436|Experimental|Intravenous temocillin|Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h)
9479422|NCT03543436|Active Comparator|Intravenous meropenem or imipenem|Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy
9479423|NCT03543423|Experimental|Oral glucose tolerance test|Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.
9479424|NCT03543423|Experimental|Liquid mixed meal test|Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min
10023073|NCT01646034|Experimental|intensified alkylating chemotherapy|a course chemotherapy with high dose cyclophosphamide, G-CSF and peripheral blood progenitor cell (PBPC) harvest followed by tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
10023074|NCT01646034|Active Comparator|three cycles of chemotherapy|"three cycles of chemotherapy depending on previously received agents~chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclophosphamide previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
10023075|NCT01644591|Experimental|Treatment (SRS)|Patients undergo SRS on day 1.
10023076|NCT01630590|Experimental|Cabozantinib + Androgen Ablation Therapy|Patients receive Cabozantinib at starting dose of 60 mg by mouth every day. Study cycles 3 weeks in duration. Patients stay on treatment as long as they are benefitting. Patients receive androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration. Study doctor will decide what hormone therapy patient will receive.
9479425|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
9479426|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
9479427|NCT03543332||Cardiac arrest|
9479428|NCT03543332||Myocardial infarction|Myocardial infarction without cardiac arrest
9479429|NCT03543267|Experimental|epileptic Patients|
10023077|NCT01619085|Experimental|All subjects|patient to receive a capsule containing Nintedanib twice a day
10023078|NCT01612663|Active Comparator|deep needle non-site specific|
10023079|NCT01612663|Active Comparator|contralateral elbow to the knee pain|
10023080|NCT01612663|Active Comparator|Energy of Living Systems Needling|
10023081|NCT01612663|Placebo Comparator|Sham acupuncture|
10023082|NCT01606098|Active Comparator|Systemic treatment|First-line fluoropyrimidine-based chemotherapy with bevacizumab initiated within 4 weeks of randomization, followed by salvage therapy upon progression at the discretion of the local investigator. Surgery of primary tumour will be performed only when indicated by local signs or symptoms.
10023083|NCT01606098|Experimental|Surgery followed by systemic treatment|Surgery within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy upon progression at the discretion of the local investigator
10023084|NCT01582802||Pregnant women carrying multiples|Healthy pregnant women carrying twins, triplets and quadruplets will be recruited.
10023085|NCT01517945||Breast cancer survivors and Rare cancer survivors|This is a Cycle for Survival and Center for Translational Science Center (CTSC)-funded intervention development and pilot clinical trial of a psychosocial intervention to address fear of cancer recurrence in breast cancer survivors (BCS) and rare cancer survivors (RCS). BCS form the largest survivor cohort of any cancer, with approximately 2.5 million living in the United States. About 50 percent of people with cancer have a rare cancer. Even though they account for about half of all cancer diagnoses when combined, research aimed at supporting RCS is sparse, leaving RCS with limited support after treatment.
9479430|NCT03543254|Experimental|BoNT-A injected|BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration
10037548|NCT01826123|Active Comparator|Conventional laboratory testing|"After being randomized to the group conventional coagulating testing, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
9479431|NCT03543241||MyoStrain|Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.
9480909|NCT05195775|Experimental|Tadalafil plus BOLD-MRI (Schedule A)|The intervention is the same as in Schedule B; this arm will use BOLD-MRI as the technique to monitor drug impact on skeletal muscle.
9479432|NCT03543228||MyoStrain|During standard chemotherapy and/or targeted treatment for breast cancer or lymphoma, MyoStrain will be used during standard cardiac magnetic resonance imaging to evaluate the change in myocardial contraction regionally and globally to detect cardiotoxicity and management of myocardial dysfunction.
9479433|NCT03543202|Experimental|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
9479434|NCT03543202|Active Comparator|Local infiltration anesthesia|will receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
9479435|NCT03543202|Sham Comparator|Intravenous patient control analgesia|will not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
9479436|NCT03543163|Active Comparator|subepithelial connective tissue graft|Subepithelial Connective Tissue graft from the hard palate with Coronally Advanced flap at the site of gingival recession.
9479437|NCT03543163|Experimental|non pedicled buccal fat pad graft|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap at the site of gingival recession
9479438|NCT03543150||Subjects receiving BOTOX|Subjects with a diagnosis of spasmodic dysphonia, for which BOTOX is indicated, will be included.
9479439|NCT03543111|Experimental|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
9479440|NCT03543111|No Intervention|Control|No intervention
9479441|NCT03543072||exposure group|exposed to some factors
9479442|NCT03543072||control group|not exposed to some factors
9479443|NCT03543059||exposure group|exposed to some factors
9479444|NCT03543059||control group|not exposed to some factors
9479445|NCT03543046|Experimental|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
9479446|NCT03543046|No Intervention|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
9479447|NCT03543033|Experimental|Treatment|Patients will receive a corticosteroid epidural injection within 2 weeks of their scheduled lumbar surgery
9479448|NCT03543033|No Intervention|Control|Patients will not receive a corticosteroid injection within 2 weeks of their scheduled lumbar surgery.
9479449|NCT03543020||Patients|Patients undergoing Radiation therapy to brain
9479450|NCT03542981|Active Comparator|Interferential Current Treatment|Interferential Current group received interferential current treatment 30 minutes, 2 times a day for 5 days after the surgery.
9479451|NCT03542981|Sham Comparator|Sham Interferential Current Treatment|In the sham interferential Current treatment, no electrical stimulation was applied to the probes with the same pads for the same time.
9479452|NCT03542968|Experimental|4D magnetic resonance imaging|MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).
9479453|NCT03542968|Sham Comparator|2D magnetic resonance imaging|MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI
9479454|NCT03542955|Active Comparator|ActiPatch Group|Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.
9479455|NCT03542955|Placebo Comparator|Control Group|Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.
9479456|NCT03542942|Other|treatment with EXIT-target volume|The radiotherapeutic treatment plan is based on an EXIT-target volume in which the non-involved uterus is excluded from the target volume. All other delineations are performed conform standard of care.
9479457|NCT03542929|Active Comparator|healthy elderly|healthy elderly were use the Whole body vibration intervention during 10 minutes
9479458|NCT03542929|Experimental|diabetic elderly|diabetic elderly were use the Whole body vibration intervention during 10 minutes
9479459|NCT03542916|Experimental|CJ-40001|CJ-40001 60ug SC, IV injection
9479460|NCT03542916|Active Comparator|NESP|NESP 60ug SC, IV injection
9479461|NCT03542903|Active Comparator|Short ECT arm|In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
9479462|NCT03542903|Active Comparator|Long ECT arm|In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.
9479463|NCT03542890||Baska Mask|It has a non-inflatable cuff, which is moulded to take up the shape of the supraglottic airway, potentially reducing the risk of oropharyngeal tissue and/or nerve damage induced by cuff over inflation, a known complication with other supraglottic airways.
9479464|NCT03542890||I-gel|The I-gel is a single use (SADs) composed of a soft ,gel-like, non-inflatable cuff made from a thermoplastic elastomer. It has a widened , flattened stem with a rigid bite block that acts as a buccal stabilizer to reduce axial rotation and mal-positioning and a port for gastric tube insertion. It is a latex free device that does not require digital insertion into mouth of patient.
9479465|NCT03542864|Experimental|Nasogastroduodenal Protocol|Evaluation of a protocol for the treatment of excess body fat through duodenal nutrition
9479466|NCT03542864|Active Comparator|Controls|Change from Baseline Body Composition values at 1 and 3 months
9479467|NCT03542864|Other|Data analysis|Analysis and publication of data
9479468|NCT03542851|Experimental|Subject Receives BTD001 first|
9479469|NCT03542851|Experimental|Subject Receives Placebo first|
9479470|NCT03542838|Experimental|Resiniferatoxin|Resiniferatoxin is administered as a one-time dose, intra-articularly at a dose level of 5ug, 12.5ug, 20ug, 25ug, or 30ug.
9479471|NCT03542838|Placebo Comparator|Saline|Saline is administered as a one-time dose, intra-articularly.
9479472|NCT03542825|Active Comparator|Iron Sulphate|ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.
9479473|NCT03542825|Active Comparator|Amino acid Chelated|amino acid chelated iron capsule 15mg for 3 consecutive months.
9479474|NCT03542825|Active Comparator|Lactoferrin|lactoferrin 100 mg sachets once daily for 3 consecutive months.
9479475|NCT03542799|Experimental|3|anti-tumor response of EGFR IL12 CART
9479476|NCT03542786|Experimental|i3.1|This group will have their habitual antiretroviral therapy (integrase inhibitor (INI), protease inhibitor (IP), reverse transcriptase inhibitor (ITINAN)) combined with the research product (probiotic i3.1). The prebiotic will be taken once a day during 6 months.
9479477|NCT03542786|Experimental|i3.1 + ProSeed|This group will have their habitual antiretroviral therapy combined with the probiotic (i3.1) and the prebiotic (ProSheed). The prebiotic and probiotic will be taken once a day during 6 months.
9479478|NCT03542786|Placebo Comparator|Placebo|This group will only have their habitual antiretroviral therapy. The placebo will be taken once a day during 6 months.
10023086|NCT01503086|Experimental|Arm I (interactive training program)|Patients undergo a home-based, computerized, interactive training program comprising 3-5 sessions of 15-45 minutes every week for 5-9 weeks. The program contains twelve visually engaging and interesting exercises that target skills involving visual-spatial and verbal WM. The program is adaptive in a way that each difficulty task is automatically adjusted on a trial-by-trail basis to match a patient's current WM. Each patient has an interventional coach who has online access to patient's training sessions and outcomes (pass or fail). Coaches are able to modify the training sequence or make suggestions to patients and/or parents about how progress can be maximized. Coaches also have telephone meetings with patients and/or families once a week to ensure compliance, track progress, provide feedback, and answer questions that arise during training.
10023087|NCT01503086|Experimental|Arm II (non-adaptive training program)|Patients undergo a home-based, computerized, interactive, non-adaptive training program comprising 3-5 sessions of 15-45 minutes a week for 5-9 weeks. Each patient also has an interventional coach as in arm I. Patients in both arms complete a brief neuropsychological/behavioral assessment comprising the WIS-IV, the CMS, and the CVLT-C at baseline, after completion of study, and at 6 months after completion of study. Additionally, parents complete a parent-report questionnaire to gather information about patient's behaviors, thoughts, emotions, adaptive skills, and social and functional impairment. Parents and children also complete surveys about the program regarding technical feasibility, adherence, ease-of-use, and satisfaction.
10023088|NCT01499095|Experimental|HOE901-U300|
10023089|NCT01499095|Active Comparator|Lantus|
10023090|NCT01499082|Experimental|HOE901-U300|
10023091|NCT01499082|Active Comparator|Lantus|
9479479|NCT03542760||Primary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia that is symptomatic (eg, exhibiting sleepiness, cyanosis, dizziness, etc) or with measured methemoglobin levels > 30%.
9479480|NCT03542760||Secondary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia with measured methemoglobin levels ≤ 30 and lack of clinical symptoms
9479481|NCT03542747|Experimental|Time to ventilation with the iLTS|Measuring the time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
9479482|NCT03542747|Experimental|Time to ventilation with the Fastrach|Measuring time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
9479483|NCT03542734||Individuals with SVDs|Individuals with at least one following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
9479484|NCT03542734||Individuals without SVDs|Individuals without any following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
9479485|NCT03542721|Placebo Comparator|Placebo of DA-5515 Capsule|Placebo of DA-5515 (three times a day)
9479486|NCT03542721|Experimental|DA-5515 Capsule|Garlic oil, Gingko biloba ex.,Crataegus berry ex.,Melissa officinalis ex., (three times a day)
9479487|NCT03542656|Experimental|amyloid PET|PET/CT
10023092|NCT01496976|Experimental|Immunotherapy|Combination Regimen Followed by Consolidative Therapy: Ofatumumab/High Dose Methylprednisolone (HDMP) plus Ofatumumab/Lenalidomide
9479488|NCT03542643|Active Comparator|N-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
9479489|NCT03542643|Placebo Comparator|Placebo|olive oil ethyl esters
10023093|NCT01488890|Experimental|CYD Dengue vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months.
10023094|NCT01488890|Experimental|CYD Dengue vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months.
9802853|NCT04882241|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.~Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
9802854|NCT04875416||Primary participants|Patients that have or are suspected to have ALS or a related neurodegenerative disease
9802855|NCT04875416||Secondary Participants|Family members of primary participants enrolled in the study
10023095|NCT01488890|Experimental|CYD Dengue and Yellow Fever vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0.
10023096|NCT01488890|Active Comparator|Yellow Fever vaccine: Group 4|Participants received single dose of YF vaccine at Day 0.
10023097|NCT01452074|Other|Exercise Training with Weight Loss|"During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week~After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight"
10023098|NCT01452048||Obese Sedentary Adults, but otherwise healthy|
10023099|NCT01451970|Other|High Monounsaturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
10023100|NCT01451970|Other|High Saturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
9479490|NCT03542630||fertile, without periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
9802856|NCT04873934|Experimental|Inclisiran with Usual Care|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
9802857|NCT04873934|No Intervention|Usual Care|Usual Care Alone
9802858|NCT04870112|Experimental|Patients with NSCLC|Patients with Non-Small Cell Lung Cancer
10023101|NCT01436396|Experimental|CYD Dengue Vaccine Group|Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month [M] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
9802859|NCT04870112|Experimental|Patients with SCLC|Patients with Small Cell Lung Cancer
9479491|NCT03542630||fertile, with periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do have periodontitis.~Interventions:~salivary MMP8 test;periodontal examination;blood tests"
9802860|NCT04867135||No Sepsis / Sepsis|To compare amikacin PK / PD models of newborns with a confirmed diagnosis of sepsis (clinical or microbiological) and with ruled out sepsis.
10023102|NCT01436396|Experimental|Placebo Group|Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
10023103|NCT01428973|Active Comparator|Arm 1|GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
10023104|NCT01428973|Experimental|Arm 2|GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
10023105|NCT01415882|Experimental|Arm A (ixazomib citrate and dexamethasone, closed to accrual)|Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10023106|NCT01415882|Experimental|Arm B (ixazomib citrate and dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9802861|NCT04866420||Poststroke fatigue|Participants who are experiencing fatigue post stroke.
9802862|NCT04865887|Experimental|Pembrolizumab with Lenvatinib|
10023107|NCT01415882|Experimental|Arm C (higher-dose ixazomib citrate and dexamethasone)|Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9802863|NCT04863716|Active Comparator|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered to this group.
10023108|NCT01415882|Experimental|Arm D (ixazomib citrate, dexamethasone, and cyclophosphamide)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO (cycles 1-18 only) and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9479492|NCT03542630||infertile, without periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination;blood tests"
9479493|NCT03542630||infertile, with periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
10023109|NCT01415882|Experimental|Arm E (ixazomib citrate, cyclophosphamide, daratumumab)|Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO (cycles 1-12 only) on days 1, 8, 15, 22, and daratumumab IV on days 1, 8, 15, 22 (cycles 1-2), days 1 and 15 (cycles 3-6), and day 1 in all subsequent cycles. Patients also receive dexamethasone IV or PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10023110|NCT01414777|Experimental|ondansetron|ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
10023111|NCT01414777|Placebo Comparator|Placebo|Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
10023112|NCT01411241|Experimental|CYD Dengue Vaccine Group 1|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a measles, mumps, rubella (MMR) vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), a booster dose of Pentaxim vaccine was administered concomitantly with the second injection of CYD dengue vaccine at Month 6 (15 to 18 months of age), placebo at Month 7 (16 to 19 months of age) to maintain the blind, and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
9479494|NCT03542617|Placebo Comparator|Normal Saline Solution|The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .
9479495|NCT03542617|Active Comparator|10 mg Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia
9479496|NCT03542617|Active Comparator|40 mg Dexamethasone|The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia
9479497|NCT03542604|Experimental|CBT-I + BWL|Cognitive behavioral therapy intervention for insomnia: 6 sessions over 8-week period combining education and behavioral techniques to reduce insomnia. Sleep intervention followed by behavioral weight loss intervention.
9479498|NCT03542604|Placebo Comparator|EDU + BWL|Program will parallel the CBT-I intervention in number and length of sessions. Intended to disseminate basic information about sleep, including behavioral treatment information that is widely available to patients and practitioners.Will be followed by behavioral weight loss intervention.
9479499|NCT03542591||Participants of the VegMed congress (Berlin, April 2018)|
9479500|NCT03542552|Active Comparator|Nifidipne|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
9479501|NCT03542552|Experimental|Magnisum sulphate|Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
9480910|NCT05195775|Experimental|Tadalafil plus Doppler ultrasound (Schedule B)|The intervention is the same as in Schedule A; this arm will use Doppler ultrasound as the technique to monitor drug impact on skeletal muscle.
9802864|NCT04863716|Active Comparator|Control Group|No regional anesthesia technique will be applied to the control group.
9802865|NCT04861766|Experimental|Treatment group Stylage L ®|"Each subject will receive STYLAGE® L in both NLFs.~STYLAGE® L will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
9802866|NCT04861766|Active Comparator|Control group Active Comparator|"Each subject will receive the Active Comparator in both NLFs.~Active Comparator will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
9802867|NCT04860661|Placebo Comparator|N group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline
9480911|NCT05193799|Experimental|Investigational device#1 = Kolmi® Op-AirTM KALM|
9480912|NCT05193799|Experimental|Investigational device#2 = Kolmi® Op-Air OneTM|
9802868|NCT04860661|Experimental|Es group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.
9479502|NCT03542487|No Intervention|1: Control|A randomly selected half of primary care practices in the study sample at Inova Health Care Services will not receive any intervention and patients/physicians located at these practices will continue with business as usual.
9480913|NCT05193799|Experimental|Investigatonal device#3 = Kolmi® Op Air-Pro® Oxygen|
10023113|NCT01411241|Experimental|CYD Dengue Vaccine Group 2|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a MMR vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), the Pentaxim vaccine was administered concomitantly with placebo at Month 6 (15 to 18 months of age) to maintain the blind, a second injection of CYD dengue vaccine at Month 7 (16 to 19 months of age), and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
9518234|NCT03298529|Experimental|Pasta with only eight egg whites/kg flour|"Pasta with only eight egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only eight egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
10023114|NCT01407263|Experimental|Lymphadenectomy vs. no lymphadenectomy|In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.No lymph nodes will be removed in patients randomized to the no PLND arm.
10023115|NCT01407263|Experimental|Transverse versus vertical closure of the port site incision (Closed as of 9/30/2021)|
9517153|NCT03309046|Active Comparator|Education Webinar|For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
10023116|NCT01407263|Experimental|One vs. three days of antibiotic prophylaxis (Closed as of 9/30/2021)|
9517154|NCT03308994||Oral first line disease modifying treatments|
10023117|NCT01396408|Active Comparator|Sunitinib|
10023118|NCT01396408|Active Comparator|Temsirolimus|
10023119|NCT01380938|No Intervention|Arm C. Standard duration|"Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment."
10023120|NCT01380938|Experimental|Arm A|"Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight < 75 kg or 1200 mg/day for those with a body weight > 75 kg.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)"
10023121|NCT01380938|Experimental|Arm B|"Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)"
10023122|NCT01374516|Experimental|CYD Dengue Vaccine Group|Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.
10023123|NCT01374516|Placebo Comparator|Placebo Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
10023124|NCT01373281|Experimental|Dengue Vaccine Group|Participants were to receive CYD dengue vaccine at 0, 6, and 12 months.
10023125|NCT01373281|Placebo Comparator|Control Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
10023126|NCT01357668||Patients with JIA who are treated with Abatacept|Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
10023127|NCT01346787|Experimental|Carfilzomib Cyclophosphamide Dexamethasone|The treatment period includes administration of Carfilzomib Cyclophosphamide Dexamethasone for 9 courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled carfilzomib administration. The response will be assessed after each cycle.
10023128|NCT01340105|Experimental|Microwave|Hepatocellular carcinoma treated with microwave ablation
10023129|NCT01340105|Active Comparator|Radiofrequency|Hepatocellular carcinoma treated with radiofrequency ablation
10023130|NCT01302847|Experimental|Cohort I|Adolescents 12 to younger than 18 years of age who received DTG film-coated tablets
10023131|NCT01302847|Experimental|Cohort IIA|Children 6 to younger than 12 years of age who received DTG film-coated tablets
10023132|NCT01302847|Experimental|Cohort IIB|Children 6 to younger than 12 years of age who received DTG granules for suspension
10023133|NCT01302847|Experimental|Cohort III|Children 2 to younger than 6 years of age who received DTG granules for suspension
10023134|NCT01302847|Experimental|Cohort IV|Children 6 months to younger than 2 years of age who received DTG granules for suspension
10023135|NCT01302847|Experimental|Cohort III-DT|Children 2 to younger than 6 years of age who received DTG dispersible tablets
9802869|NCT04859218|Experimental|ABO non-identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
10023136|NCT01302847|Experimental|Cohort IV-DT|Children 6 months to younger than 2 years of age who received DTG dispersible tablets
10023137|NCT01302847|Experimental|Cohort V-DT|Infants 4 weeks to younger than 6 months of age who received DTG dispersible tablets
10023138|NCT01287611|Active Comparator|Purse string closure technique|Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
10023139|NCT01287611|Active Comparator|Continuously locked closure technique|Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.
10023140|NCT01275677|Active Comparator|Arm I (chemotherapy)|"GROUP IA: Patients receive docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.~GROUP IB: Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-3 weeks after last dose of doxorubicin hydrochloride and cyclophosphamide, patients also receive paclitaxel IV over 60 minutes once weekly for 12 doses in the absence of disease progression or unacceptable toxicity."
10023141|NCT01275677|Experimental|Arm II (chemotherapy, trastuzumab)|"GROUP IIA: Patients receive docetaxel and cyclophosphamide as in Group IA. Patients also receive trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity.~GROUP IIB: Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in Group IB. Patients also receive trastuzumab IV over 30-90 minutes weekly for 12 doses and then every 3 weeks for subsequent doses. Treatment repeats every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity."
9517155|NCT03308994||Injectable first line disease modifying treatments|
9517156|NCT03308981|Experimental|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
9517157|NCT03308981|Active Comparator|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
10023142|NCT01272037|Experimental|Arm I (chemotherapy and endocrine therapy)|Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
9479503|NCT03542487|Experimental|2a: Practice Orientation- No Reminder|In the other randomly selected half of primary care practices in the study sample at Inova Health Care Services, practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2a will receive no additional reminder messaging to enter glucose measurements in the electronic flowsheets.
9479504|NCT03542487|Experimental|2b: Practice Orientation- Standard Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2b will receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets.
9479505|NCT03542487|Experimental|2c: Practice Orientation- Gift Card Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2c will receive generic biweekly reminders to enter data, addressed from Inova Medical Group, that will also notify that the patient will be entered to win a $50 gift card for each day entering data.
9517158|NCT03308981|No Intervention|Wait-list|Participants will not receive any intervention.
9517159|NCT03308955|Active Comparator|Grup B|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
10023143|NCT01272037|Experimental|Arm II (endocrine therapy)|Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
10023144|NCT01254422|Experimental|CYD Dengue vaccine group|Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.
10023145|NCT01254422|Placebo Comparator|Placebo Group|Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.
10023146|NCT01247207|Experimental|Ataluren|Participants will receive 3 doses of ataluren oral suspension per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).
10036569|NCT01816971|Experimental|Treatment (dexamethasone, carfilzomib, lenalidomide)|"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..~TRANSPLANT: Patients undergo autologous stem cell transplant.~CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity."
10036570|NCT01816997|Placebo Comparator|Control|IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
10036571|NCT01816997|Active Comparator|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
10036572|NCT01816997|Experimental|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
10036573|NCT01817010|Experimental|Multi-Component Rehabilitation (CMC)|The CMC group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after THA.
10023147|NCT01229878|Active Comparator|Arm 1|Hemodialysis Patients randomized to take Vitamin D supplements
10023148|NCT01229878|Placebo Comparator|Arm 2|Hemodialysis Patients randomized to take placebo pills
10023149|NCT01218776||Male, Female, Kidney Disease, Elderly|Non-interventional patient registry
10023150|NCT01204242|Placebo Comparator|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
10036574|NCT01817010|Active Comparator|Control (CON)|The CON group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same CMC rehabilitation intervention beginning 10 weeks after THA.
10023151|NCT01204242|Experimental|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
10023152|NCT01196390|Experimental|Arm I (radiotherapy, chemotherapy, trastuzumab)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, 22, 29, 36, and 57 and paclitaxel intravenously IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Beginning 21-56 days after surgery, patients receive trastuzumab IV over 30-90 minutes. Treatment repeats every 21 days for 13 courses in the absence of disease progression or unacceptable toxicity.
10023153|NCT01196390|Experimental|Arm II (radiotherapy and chemotherapy)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive paclitaxel IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
10023154|NCT01194570|Experimental|Placebo|Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
10023155|NCT01194570|Placebo Comparator|Ocrelizumab 600 mg|Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
10023156|NCT01190787|Experimental|VMP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
10023157|NCT01190787|Experimental|VCP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
10023158|NCT01190787|Experimental|VP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
10023159|NCT01187433|Experimental|Dengue Vaccine Group|Participants will receive Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus vaccine
10023160|NCT01187433|Placebo Comparator|Control Group|Participants will receive a placebo, NaCl 0.9%.
10023161|NCT01166113|Experimental|PCP|
10023162|NCT01163487|Experimental|Dichloroacetate (DCA)|25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.
10023163|NCT01160107|Experimental|RP followed MPR|
10023164|NCT01153035|Other|Surgery followed by RFA|
10023165|NCT01150045|Active Comparator|Arm A - FOLFOX and placebo (12 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
10023166|NCT01150045|Experimental|Arm B - FOLFOX and celecoxib (12 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
10023167|NCT01150045|Active Comparator|Arm C - FOLFOX and placebo (6 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
10023168|NCT01150045|Experimental|Arm D - FOLFOX and celecoxib (6 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
9479506|NCT03542487|Experimental|2d: Practice Orientation- Physician Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2d will receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT).
9479507|NCT03542461|Experimental|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
9479508|NCT03542461|Other|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
9479509|NCT03542448||Study group|"97 eye of 49 normal Egyptian volunteers were divided into groups according to age, AL, SE of refractive error, minimum corneal thickness (MCT) and mean corneal power as follow:~Age into 3 groups:~Group A: from 18 to 30 years old Group B: from 31 to 40 years old Group C: > 40 years old~Axial length into 3 groups:~Group A: from 22 to less than 24 mm Group B: from 24 to 26 mm Group C: > 26 mm~Spherical equivalent of refractive error into :~Group A : from zero to - 2 D Group B : from - 2 to > - 4 D Group C : from - 4 to > - 6 D Group D: from - 6 to - 8 D~Minimum corneal thickness (MCT) into 3 groups:~Group i: < 500 um Group ii: from 500 to 540 um Group iii: > 540 um~Refractive power of cornea (Mean K) into 3 groups:~Group 1: 41 to less than 44 D Group 2: 44 to 46 D Group 3: > 46 D"
9479510|NCT03542435|Experimental|SXC-2023|Dose Escalation
9479511|NCT03542435|Placebo Comparator|Placebo|Dose Escalation
9479512|NCT03542422|Experimental|Apatinib|Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
9479513|NCT03542396|Experimental|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
9479514|NCT03542396|No Intervention|Control|Participants do not receive any intervention. Participants receive treatment as usual, which means they are on a waiting list of an outpatient unit to receive individual psychotherapeutic treatment
9479515|NCT03542357|Active Comparator|Sumatriptan|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
9479516|NCT03542357|Placebo Comparator|Placebo|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment
9479517|NCT03542344|Experimental|BI 1015550|
9479518|NCT03542344|Placebo Comparator|Placebo|
9479519|NCT03542331|Other|Control group|The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush
9479520|NCT03542331|Experimental|Intervention group|The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle
9479521|NCT03542318||Active group (Experimental)|Total of 60 patients were enrolled. All patients were referred for PR from the outpatient clinics of the local general hospital. Pulmonary fibrosis was confirmed through a high resonance computed tomography scan and pulmonary function testing. Participants who required modifications to their drug therapy due to exacerbations were excluded from the study. Each participant was classified according to the modified Medical Research Council dyspnoea scale
10023169|NCT01144507||Group A|Approximately 60 subjects with a heterogeneous echo pattern of the liver on abdominal ultrasound (HTG US).
10023170|NCT01144507||Group B|Approximately 680 subjects with a normal echo pattern on abdominal ultrasound (NL US). Of these subjects, approximately 110 will be matched 1:1 with Group A participants and followed for the duration of the study. The remaining unmatched subjects will not be followed beyond their initial visit.
10023171|NCT01144507||Group C|An estimated 30 subjects with cirrhosis pattern on abdominal ultrasound. These subjects will be followed in the study.
10023172|NCT01144507||Group D|An estimated 30 subjects with diffusely homogeneous echogenic pattern at screening ultrasound will be followed in the study.
9517160|NCT03308955|Sham Comparator|Grup S|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
9802870|NCT04859218|Active Comparator|ABO identical transfusion|All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
9802871|NCT04858776|Experimental|Treatment|
9802872|NCT04858776|Sham Comparator|Control|
9802873|NCT04855721|Experimental|AUR101 400 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
10023173|NCT01142427||Ancillary-Correlative (classification)|Patients undergo blood sample collection and bone marrow biopsies at baseline and during and after induction therapy for immunophenotyping for ALL confirmation and classification, DNA ploidy, genomic variation, and cytogenetic (BCR-ABL, trisomies 4+10, and molecular testing for translocations) analysis by flow cytometry and FISH. Immunophenotype results obtained on this study are used to determine patient's assignment to specific clinical-trial treatments. Some samples (leukemic and germline) may be banked for current and/or future analyses.
10023174|NCT01098032|Active Comparator|Systemic alone therapy group|Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
10023175|NCT01098032|Experimental|RenalGuard System group|Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow <300 ml/h.
10023176|NCT01096368|Experimental|Arm I (radiotherapy, chemotherapy)|Patients receive vincristine IV over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
10036575|NCT01817023|Experimental|RT alone|SIB-IMRT was given to the patients with a regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
9802874|NCT04855721|Experimental|AUR101 200 mg PO BID|Patients will receive AUR101 / placebo in double blind, double dummy manner
9802875|NCT04855721|Experimental|AUR101 400 mg PO QD|Patients will receive AUR101 / placebo in double blind, double dummy manner
9802876|NCT04855721|Placebo Comparator|Placebo|Patients will receive AUR101 / placebo in double blind, double dummy manner
9517161|NCT03308916|Experimental|Liver stiffness measurement|Transient elastography in fasting state
10023177|NCT01096368|Experimental|Arm II (radiotherapy, chemotherapy)|Patients undergo conformal radiotherapy over 6-7 weeks. Patients then receive vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
9517162|NCT03308890|Active Comparator|Arm 1|0.5mg Entecavir QD for 6 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
10023178|NCT01096368|Active Comparator|Arm III (radiotherapy, observation)|Patients undergo conformal radiotherapy over 6-7 weeks and then undergo observation.
10023179|NCT01093196|Active Comparator|Rd|Induction treatment with oral Lenalidomide and low dose dexamethasone followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
10023180|NCT01093196|Experimental|MPR|Induction treatment with oral Lenalidomide, Prednisone and Melphalan followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
10023181|NCT01093196|Experimental|CPR|Induction treatment with oral Lenalidomide, Cyclophosphamide and Prednisone for followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone.
10023182|NCT01054248|Experimental|MAS3|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
10023183|NCT01054248|Active Comparator|ALN+|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet)
10023184|NCT01054248|Experimental|DP|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
10023185|NCT01050855|Experimental|RIC: Distal Campath|"Day Treatment~Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) (subcutaneously) over 2 hours~Day - 21 to-19 Alemtuzumab IV/ SQ (subcutaneously)~Day - 7 to -3 Readmission to hospital Fludarabine IV~Day - 2 Melphalan IV~Day - 1 Begin cyclosporine infusion~Day 0 Transplant: Bone marrow or cord blood infusion"
10023186|NCT01050855|Experimental|RIC:Intermediate Campath|"Day Treatment~Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 to -3 Fludarabine IV~Day - 2 Melphalan 140 mg/m2 IV~Day - 1 Cyclosporine infusion starts~Day 0 Transplant: Bone marrow or cord blood infusion"
9802877|NCT04854512|Experimental|Investigational Arm (Metformin DR plus metformin IR placebo)|Group A will receive 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2×placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
10023187|NCT01050855|Experimental|RIC: Mini Busulfan|"Day Treatment~Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV~Day - 3 Fludarabine IV~Day - 2 Fludarabine IV Cyclosporine infusion~Day - 1 Rest~Day 0 Transplant: Bone marrow or cord blood infusion"
10023188|NCT01040806|Experimental|Health coaching|Patients with poorly controlled diabetes will receive counseling from a peer health coach -- a patient with diabetes trained in health coaching
10023189|NCT01040806|Active Comparator|Usual care|Patients will receive usual care
10023190|NCT01034306|Experimental|CF101 1 mg|piclidenoson (CF101) 1 mg tablet oral, Q12h for 12 weeks
9479522|NCT03542318||Inactive control group|A total of 60 patients were enrolled in a control group. All were referred for PR from the outpatient clinics of the local general hospital. In this group patients who requested not to carry out the intervention but participate in the investigations were enrolled. Each participant was classified according to the modified Medical Research Council dyspnoea scale, and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities
9479523|NCT03542292|Experimental|placental drainage group|In study group; umbilical cord was clamped from fetal side but unclamped from maternal side. After that unclamped side of umblical cord was left open to drain the blood until the flow ceased. The blood was collected in the metal bowl and measured using a measuring jar. Care was taken not to mix the drained blood from the cord with the blood lost during the third stage.
9479524|NCT03542292|Active Comparator|no placental drainage group|In control group the umblical cord was clamped both sides.
9479525|NCT03542279|Experimental|Early PE group|PE (3-5 times in each course) combined with high-dose glucocorticoid, and IVIG after PE.
9479526|NCT03542279|Active Comparator|Non-early PE group|IVIG (0.4 g/kg/d for each course for 5 d) combined with high-dose glucocorticoid, and PE after IVIG 2 weeks.
9479527|NCT03542253||Age|
9479528|NCT03542253||Sex|
9479529|NCT03542253||triglyceride|
9479530|NCT03542253||Lipoprotein|
9479531|NCT03542253||CT|Target Reconstruction
9479532|NCT03542253||micorRNA-A Plasma exocrine|
9479533|NCT03542253||micorRNA-A Paracancerous tiusse|
9479534|NCT03542253||pathologic diagnosis|
9479535|NCT03542253||hemolysis|
9479536|NCT03542253||ct-DNA|
9479537|NCT03542253||micorRNA-A in plasma|
10023191|NCT01034306|Placebo Comparator|Placebo|placebo tablet to match the active, oral dosage, Q12h for 12 weeks
9479538|NCT03542253||Sample quality control|
9479539|NCT03542253||positive|
9479540|NCT03542253||negative|
9479541|NCT03542253||micorRNA-R in plasma|
9479542|NCT03542253||micorRNA-R in Plasma exocrine|
9479543|NCT03542253||Surgery|
9479544|NCT03542240|Experimental|Curcumin|
9479545|NCT03542214|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for inoperabel colorectal cancer
9479546|NCT03542201|Experimental|PLS|Plain abstract about the Cochrane systematic review.
9479547|NCT03542201|Experimental|Blogshot|Blogshot presentation of the results of Cochrane systematic review.
9479548|NCT03542162|Experimental|Healaflow group|The Healaflow group consists of patients with primary RRD, but exclude proliferative vitreoretinopathy grade C or more, dialysis, retinoschisis, eyes with secondary RRD, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than RRD.
9479549|NCT03542149|Experimental|A|"200mg of OZ439 and 480 mgPQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
9479550|NCT03542149|Experimental|B|"200mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
9479551|NCT03542149|Experimental|C|"400mg of OZ439 and 480 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
9479552|NCT03542149|Experimental|D|"400mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
9479553|NCT03542136|Other|Patients receiving chemotherapy treatment with oxaliplatin.|
9479554|NCT03542123|Experimental|NeuroTronik CANS Therapy® System|
9479555|NCT03542110|Active Comparator|Alirocumab 150 MG/ML subcutaneous injection|Alirocumab 150 mg subcutaneously every 2 weeks
10023192|NCT01015833|Experimental|Arm I (doxorubicin hydrochloride, sorafenib tosylate)|Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
10023193|NCT01015833|Experimental|Arm II (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10023194|NCT01013857|Active Comparator|Health coaching|Phone patients every week to discuss medication adherence
10023195|NCT01013857|Experimental|Health coaching plus home-titration|Health coaches call patients every week to discuss medication adherence and to intensify medications if appropriate according to physician-created algorithm
10036576|NCT01817023|Active Comparator|CCRT group|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume and cisplatin 100mg/m2 was given at d1, d22,d43 during radiotherapy.
10036577|NCT01817036|Placebo Comparator|Placebo|5 placebo pills per day, 16 weeks
10036578|NCT01817036|Experimental|400 IU|(4 placebo pills + 1 vitamin D pill) per day, 16 weeks
9802878|NCT04854512|Placebo Comparator|Placebo Arm (Metformin DR placebo plus metformin IR placebo)|Group B will receive placebo for 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2× placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
9802879|NCT04854512|Active Comparator|Active Control Arm (Metformin DR placebo plus metformin IR)|Group C will receive placebo for 1800 mg Metformin DR qAM + 1500 mg metformin IR in divided doses (2× metformin IR 500 mg qAM and 1× metformin IR 500 mg qPM).
9802880|NCT04854213|Other|Liquid biopsy|Blood samples for liquid biopsy
9802881|NCT04853238||Cohort 1: Participants with newly and previously diagnosed stable disease|
10023196|NCT01005745|Experimental|TIL With High Dose IL-2|"Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours.~Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days.~Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused.~Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion."
10023197|NCT01000753||Observational (specimen collection)|See Detailed Description
10023198|NCT00993447|Experimental|CYD Dengue Vaccine Group|Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
9802882|NCT04853238||Cohort 2: Participants with moderate acute exacerbation not requiring hospitalization|
9802883|NCT04853238||Cohort 3: Participants requiring hospitalization for an acute exacerbation|
10023199|NCT00993447|Sham Comparator|Control Vaccine Group|
10023200|NCT00986661|Experimental|PV-10 Injection (Intralesional)|Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.
10023201|NCT00959283||Ancillary-correlative|Patients undergo peripheral blood collection periodically for biomarker analysis. Samples are analyzed for GATA1 mutations by real-time PCR, polymorphisms, cytogenetics, and K-RAS mutations, gene expression, drug sensitivity patterns, and minimal residual disease by flow cytometry.
10023202|NCT00945009|Experimental|Arm 1 (Bilateral Wilms Tumors)|Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
10023203|NCT00945009|Experimental|Arm 2 (Unilateral High Risk tumors bilaterally predisposed)|Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.
10023204|NCT00945009|Experimental|Arm 3 (DHPLN)|Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
9479556|NCT03542110|Placebo Comparator|Matching Placebo subcutaneous injection|Matching placebo subcutaneously every 2 weeks
10023205|NCT00942877|Experimental|Cediranib (AZD2171) Treatment|"Adult participants will be treated with 30 mg by mouth once a day for 28 days (28-day cycles).~Pediatric participants (<16 years old) will be treated with 12 mg/m^2/day once a day for 28 days (28-day cycles)."
10036579|NCT01817036|Experimental|800 IU|(3 placebo pills + 2 vitamin D pills) per day, 16 weeks
10036580|NCT01817036|Experimental|1200 IU|(2 placebo pills + 3 vitamin D pills) per day, 16 weeks
10036581|NCT01817036|Experimental|2000 IU|5 vitamin D pills per day, 16 weeks
10023206|NCT00942331|Active Comparator|Arm I (gemcitabine hydrochloride, cisplatin, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
10023207|NCT00942331|Experimental|Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab)|Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
10023208|NCT00919269||Ancillary-Correlative (specimen collection)|Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or relapse) and, if applicable, at the development of a second primary tumor. Specimens are used for research purposes. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
10023209|NCT00904241||Ancillary-Correlative (cytology specimen collection)|Patients undergo collection of blood, tissue, and bone marrow samples for analysis via RT-PCR, quantitative PCR, flow cytometry, and FISH.
10023210|NCT00899990||Observational (biomarker sampling)|Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.
9802884|NCT04852666||IBD Partners cohort|IBD Partners is an internet-based cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the University of North Carolina School of Medicine in conjunction with the Crohn's & Colitis Foundation. There is no intervention for this study.
10023211|NCT00899275||Ancillary-correlative|After the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. Patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). Autopsy tumor samples may also be submitted.
10023212|NCT00896389|Other|Salt-loading and thiazide diuretic (HCTZ)|Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week
9802885|NCT04852666||SPARC-IBD cohort|SPARC-IBD is a multi-center cohort study of patients with Crohn's disease (CD) and ulcerative colitis (UC). It is coordinated by the Crohn's & Colitis Foundation. There is no intervention for this study.
9802886|NCT04851496||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9802887|NCT04851496||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
9802888|NCT04851496||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
9802889|NCT04851496||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
10023213|NCT00887146|Experimental|Arm A (RT, procarbazine, lomustine, vincristine)|Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10036582|NCT01817049|Experimental|HAPA intervention|Coaches will receive a 3.5 hour HAPA-based coach education workshop prior to the start of the first study season.
10023214|NCT00887146|Experimental|Arm B (RT, temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO QD on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
10023215|NCT00880893|Experimental|CYD Dengue Vaccine Group|Participant's received the CYD Dengue Vaccine at 0, 6, and 12 months as first, second, and third vaccinations, respectively.
10023216|NCT00880893|Sham Comparator|Placebo Group|All participants received a placebo at first vaccination (Month 0). Participants <12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants >= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.
10023217|NCT00875901|Experimental|Peripherally located lung tumor|12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent
10023218|NCT00875901|Experimental|Centrally located lung tumor|6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent
10023219|NCT00866918|Experimental|Standard Risk (WBC < 10000/uL)|See Detailed Description
10023220|NCT00866918|Active Comparator|High Risk (WBC > 10000/uL)|See Detailed Description
9479557|NCT03542097||Temozolomide and Irinotecan treatment|The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done
9479558|NCT03542084|Experimental|Intervention: Unsolicited e-consult|The PCP of intervention arm patients will receive an unsolicited e-consult by an endocrinologist offering clinical guidance on how to optimize the patients' glycemic control
9479559|NCT03542084|No Intervention|Control|Control arm patients will receive usual care
9479560|NCT03542071|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
9479561|NCT03542071|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
9479562|NCT03542058|Experimental|Treatment Group|Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
9479563|NCT03542058|No Intervention|Control Group|Study participant will not receive any cardiac medication, apart from standard cancer care.
9479564|NCT03542032|Other|jaw-thrust|"the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
9479565|NCT03542032|No Intervention|classic group|"In the classic group, the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place. This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
9479566|NCT03542006|Experimental|Topical brinzolamide|Brinzolamide ophthalmic, given bd for 3 months
9479567|NCT03541993|Experimental|Resveratrol Hypoxia|500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
9479568|NCT03541993|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
9479569|NCT03541993|Experimental|Resveratrol Normoxia|500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
9479570|NCT03541993|Placebo Comparator|Placebo Normoxia|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
9479571|NCT03541967|Other|ADHEAR-PONTO|The ADHEAR system will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system. Then the patient will be fitted with the PONTO 3 SUPER POWER on softband and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband.
9479572|NCT03541967|Other|PONTO-ADHEAR|The PONTO 3 SUPER POWER on softband will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband. Then the patient will be fitted with the ADHEAR system and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system.
9479573|NCT03541954|Other|Patient with pelvic or perineal pain with sensitization|Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria > 5)
9479574|NCT03541954|Other|Patient with pelvic or perineal pain without sensitization|Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria < 5)
9479575|NCT03541928|Experimental|Gene Therapy, ADT, RT, and Surgery|"The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10[11] virus particles (1.25 x 10[11] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.~The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).~The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).~Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months."
9479576|NCT03541915|Experimental|Mg group|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
9479577|NCT03541915|Placebo Comparator|Control group|Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.
10023221|NCT00845390||ICD Patients|ICD patients
10023222|NCT00809991|Experimental|Hypofractionated radiation therapy in prostate adenocarcinoma|Participants with histologically confirmed, locally confined adenocarcinoma of the prostate receive 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions).
10023223|NCT00786760||1. Men ages 18 - 44 years|
10023224|NCT00786760||2. Men ages 45 - 70 years|
10023225|NCT00782574|Experimental|1|"Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator.~Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid).~The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions."
10023226|NCT00779961|Experimental|Group A|Early Cleft Palate Repair (Age group 6-10 months)
10023227|NCT00779961|Active Comparator|Group B|Sick Kids Routine cleft palate repair (age group 10-14 months)
10023228|NCT00770380|Experimental|Hypnosis for relapse prevention|The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
10023229|NCT00770380|Active Comparator|Behavioral relapse prevention counseling|In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
10023230|NCT00769379|Experimental|Arm I (standard WBI)|Patients undergo standard WBI over 5-6 weeks.
10023231|NCT00769379|Experimental|Arm II (WBI, trastuzumab)|Patients receive trastuzumab IV over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
10023232|NCT00753545|Experimental|1|AZD2281
10023233|NCT00753545|Placebo Comparator|2|matching placebo
10023234|NCT00750841|Experimental|1|Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
10023235|NCT00622583||Observation Group|Subjects who meet the inclusion/exclusion criteria who have had a hernia repair.
10023236|NCT00603330|Experimental|1|MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
10023237|NCT00603330|Experimental|2|MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
10023238|NCT00603330|Experimental|3|MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
10023239|NCT00588770|Active Comparator|Arm IA (docetaxel, cisplatin)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10023240|NCT00588770|Experimental|Arm IB (docetaxel, cisplatin, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.
10023241|NCT00588770|Active Comparator|Arm IIA (docetaxel, carboplatin)|Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10023242|NCT00588770|Experimental|Arm IIB (docetaxel, carboplatin, bevacizumab)|Patients receive bevacizumab as in Arm IB and docetaxel and carboplatin as in Arm IIA.
10023243|NCT00588770|Active Comparator|Arm IIIA (cisplatin, fluorouracil)|Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10023244|NCT00588770|Experimental|Arm IIIB (cisplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.
10023245|NCT00588770|Active Comparator|Arm IVA (carboplatin, fluorouracil)|Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10023246|NCT00588770|Experimental|Arm IVB (carboplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.
10023247|NCT00587314||1|Patients with Barrett's Esophagus or early esophageal adenocarcinoma who will or have had ablation therapy will be enrolled in this long term follow up study
10023248|NCT00587301|Experimental|Lap-Band|Lap-band surgery in treatment of morbidly obese adolescents
9802890|NCT04851327|Experimental|High energy|"Child will be given a high energy drink: a flavoured high energy milk or juice-based drink, used clinically to supplement the diet of preschool children (either Pediasure plus or Duocal). This will provide 1.5 kcals per ml in various flavours as preferred. The amount given will supply 10% of the child's daily energy requirements per Kg - for example for a 2-year-old child weighing 15 KG this would be 80 mls of drink supplying 120 Kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing a range of pre-packaged foods of known energy content suitable for their age, chosen in consultation with the parents."
10023249|NCT00582296||1|multi-organ follow-up
10023250|NCT00582296||2|control follow-up
10023251|NCT00579527|Experimental|Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
10023252|NCT00579527|Experimental|CTTI with Parathyroid Transplantation w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.
10023253|NCT00579072||Longitudinal Study|Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
10023254|NCT00579072||Group Comparison|Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
10023255|NCT00576836|Experimental|Cultured Thymus Tissue Implantation w Parathyroid Transplant|"Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue and parathyroid tissue."
10023256|NCT00576836|Experimental|Cultured Thymus Tissue Implantation|"Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue.~."
10023257|NCT00576407|Experimental|Cultured Thymus Tissue Implantation in Complete DiGeorge|"Participants with Complete DiGeorge Syndrome, who were eligible, received cultured thymus tissue implantation (CTTI).~No specific dose was assigned. There was a one time administration of the cultured thymus tissue."
10023258|NCT00557193|Experimental|Arm A (standard risk MLL-G)|Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
10023259|NCT00557193|Active Comparator|Arm B (IR/HR MLL-R chemotherapy)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
9479578|NCT03541902|Experimental|Group 1 (cabozantinib)|Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
9479579|NCT03541902|Experimental|Group 2 (sunitinib malate)|Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
10023260|NCT00557193|Experimental|Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
10023261|NCT00551928|Active Comparator|A|Oral therapy with Lenalidomide Melphalan and Prednisone.
10023262|NCT00551928|Active Comparator|B|High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)
10023263|NCT00547339|Experimental|Phase 1: Stereotactic Body Radiation Therapy (SBRT) 45 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated - 45 Gy
10023264|NCT00547339|Experimental|Phase 1: Stereotactic Body Radiation Therapy (SBRT)- 47.5 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated- 47.5 Gy
10023265|NCT00547339|Experimental|Phase 1: Stereotactic Body Radiation Therapy (SBRT)- 50 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated- 50 Gy
10023266|NCT00547339|Experimental|Phase 2: Stereotactic Body Radiation Therapy (SBRT)- 50 Gy|The dose of SBRT is escalated - 50 Gy in Phase 2
10023267|NCT00543348|Active Comparator|1|CUTTING BALLOON ANGIOPLASTY
10023268|NCT00543348|Placebo Comparator|2|Balloon angioplasty with a high pressure balloon
10023269|NCT00531232|Experimental|Clofarabine 55 mg/day|Participants received Clofarabine 55 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
10023270|NCT00531232|Experimental|Clofarabine 35 mg/day|Participants received Clofarabine 35 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
10023271|NCT00531232|Experimental|Clofarabine 25 mg/day|Participants received Clofarabine 25 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
10023272|NCT00512122|Experimental|EN only|Withholding PN during the first week of ICU stay
10023273|NCT00512122|Active Comparator|EN plus early PN|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E Parenteral nutrition targeted at covering calculated needs together with the enteral nutrition intake that is achieved
10023274|NCT00478712||Families with Hirschsprung Disease|Individuals with Hirschsprung disease and their affected and unaffected relatives.
10023275|NCT00476606||Long-term pediatric cohort|Long-term follow-up cohort since 2003
10023276|NCT00467103||Chronic Stroke patients with Nonfluent Aphasia|patients with left hemisphere (LH) stroke who have chronic nonfluent aphasia
10023277|NCT00389844|No Intervention|1|Routine care
10023278|NCT00389844|Active Comparator|2|Exercise only
10023279|NCT00389844|Active Comparator|3|Motivation only
10023280|NCT00389844|Experimental|4|Exercise plus motivation
10023281|NCT00379340|Experimental|Stage IV and rapid complete response (RCR) of lung metastases|Stage IV and rapid complete response (RCR) of lung metastases continuously treated with DD4A after 6 weeks of DD4A
10023282|NCT00379340|Experimental|Stage IV and slow incomplete response (SIR) of lung metastases|Stage IV and slow incomplete response (SIR) of lung metastases treated with Regimen M after 6 weeks of DD4A
9479580|NCT03541889|Experimental|Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
9479581|NCT03541889|Experimental|Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
9479582|NCT03541876||children with H. pylori infection|
9479583|NCT03541863||Endocrine therapy|use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus
9479584|NCT03541863||Chemotherapy|use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based
9479585|NCT03541837|Other|peri operative analgesia|Post operative regional analgesia by Erector Spinae bilateral catheters with infusion of ropivacaine
9479586|NCT03541824|Experimental|Body Acceptance Program|The Body Acceptance Program (BAP) is the active condition. Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
9479587|NCT03541824|No Intervention|Waitlist control|Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
9479588|NCT03541811||patients with hemophilia (16-45y)|not applicable (no intervention administered)
9479589|NCT03541811||peer-matched healthy control|not applicable (no intervention administered)
9517163|NCT03308890|Active Comparator|Arm 2|0.5mg Entecavir QD for 12 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
10023283|NCT00379340|Other|Stage III/IV with LOH 1p and 16q treated with Regimen M|Stage III/IV with LOH 1p and 16q treated with Regimen M
10023284|NCT00379340|Other|Stage IV with non-lung disease treated with Regimen M|Stage IV with non-lung disease treated with Regimen M
10023285|NCT00379340|Other|Stage IV with lung metastases|Stage IV with lung metastases treated with DD4A for less than 6 weeks and/or response inevaluable at week 6
10023286|NCT00365326|Experimental|Treatment with autologous bone marrow (BM)-derived CD133+ stem cell therapy|The Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia.
9802891|NCT04851327|Experimental|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink, made either of skim milk or sugar free fruit juice, with a similar sugar free flavour; for above example this will supply 25 kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of pre-packaged foods as above."
10023287|NCT00304070|Experimental|Stratum I (surgery, observation)|Patients undergo conventional surgery (primary tumor resection and retroperitoneal lymph node sampling) followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
10023288|NCT00304070|Experimental|Stratum II (exploratory surgery, observation)|Patients undergo conventional surgery (primary tumor resection and extended regional lymph node dissection) followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
10023289|NCT00304070|Experimental|Stratum III (chemotherapy, surgery)|Patients receive combination chemotherapy with a total of 8 cycles of chemotherapy with cisplatin, etoposide and doxorubicin hydrochloride, filgrastim (G-CSF). The first 2 to 4 cycles are called the induction phase, followed by mitotane alone for an additional 2 months. Some patients undergo conventional surgery after chemotherapy course 2 or 4. Some patients undergo additional conventional surgery after finishing all chemotherapy.
10023290|NCT00265525|Experimental|Cardio fit|
10023291|NCT00265525|No Intervention|Usual Care|
10023292|NCT00195052||Epilepsy Patients|
10023293|NCT00066950|No Intervention|Counseling Only|Oral Health Counseling Only
10023294|NCT00066950|Experimental|CHX+Counseling (caregiver) + FV (child)|Oral Health Counseling plus Chlorhexidine for caregiver plus fluoride varnish every 6 months from 12mo to 30mo of age for child
10023295|NCT00004935|Active Comparator|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
9517164|NCT03308890|No Intervention|Arm 3|No consolidation arm and observation only and clinical observation for up to 6 months after the end of study follow-up.
10023296|NCT00004935|Active Comparator|Herceptin™+Chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
10023297|NCT00001322|Experimental|Phase 1 - Lupron|Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
10023298|NCT00001322|Experimental|Phase 2, Arm 1 - Estradiol, then progesterone|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
10023299|NCT00001322|Experimental|Phase 2, Arm 2 - Progesterone, then estradiol|12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
10023300|NCT01694134|Active Comparator|Corticoids|A group of patients will receive an intradiscal injection of Hydrocortancyl.
10023301|NCT01694134|Sham Comparator|Local anaesthetic|A group of patients will receive an intradiscal injection of Lidocaine.
10023302|NCT01694147||patients with sepsis related ALI/ARDS.|Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.
10023303|NCT01694160|Experimental|Paricalcitol|Paricalcitol 2 ug/daily for 48 weeks
10023304|NCT01694160|No Intervention|no intervention|
9517165|NCT03308877|Experimental|Brief Motivational Intervention (BMI)|
10023305|NCT01694173|Experimental|Stem cell therapy - SPD artery|Stem cells will be infused into the superior pancreaticoduodenal artery.
10023306|NCT01694173|Active Comparator|Stem cell therapy - splenic artery|Stem cells will be infused into the splenic artery.
9479590|NCT03541798|Active Comparator|Traditional sitting position|"Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
9479591|NCT03541798|Experimental|Harmstring stretch position|"the patients sit up from supine position with the legs remaining on the operating table, knees are maximally extended.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
9479592|NCT03541798|Experimental|Squatting position|"the patients sit up from supine position with the legs remaining on the operating table, hips and knees are maximally flexed .~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
10023307|NCT01694173|Active Comparator|Stem cell therapy-intravenous|Stem cells will be given intravenously.
10023308|NCT01694173|Placebo Comparator|Normal saline placebo -sham procedure|Sham procedure with infusion of normal saline.
10023309|NCT01694212|Experimental|Diclofenac|Patients with diabetic retinopathy having preoperative treatment with diclofenac
10023310|NCT01694212|Placebo Comparator|Placebo|Control group having placebo treatment
10023311|NCT01694225|Experimental|bubble package for monthly prescription|use of bubble packaging for monthly prescription
9479593|NCT03541772|Experimental|Oncoxin-Viusid®|Radiotherapy + Chemotherapy + Oncoxin-viusid®
10023312|NCT01694238|Active Comparator|Cruciate incision|Cruciate incision in the abdominal wall fascia
10023313|NCT01694238|Experimental|Circular incision|Circular incision in the fascia
10023314|NCT01694238|Experimental|Mesh enforced cruciate incision|Mesh enforcement and then cruciate incision in the abdominal wall fascia
10023315|NCT01694264|Experimental|Experimental Group|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
10023316|NCT01694264|Placebo Comparator|Control Group|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
10023317|NCT01694290|Experimental|Chemical Ice packs to neck, groin, axillae|Chemical ice packs will be changed out every 9 minutes
10023318|NCT01694290|Experimental|Chemical Ice Packs to cheeks, palms, soles|Chemical Ice packs will be changed out every 9 minutes
10023319|NCT01694290|No Intervention|no chemical ice packs|
10023320|NCT01694303|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
10023321|NCT01694303|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
10023322|NCT01694316|Active Comparator|Engaging in Computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
10023323|NCT01694316|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
10023324|NCT01694329||2006-2010 cohort|cohort of children born between 2006 and 2010, and living in Nunavik
10023325|NCT01694355|Experimental|Vitamin D treatment|We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.
10023326|NCT01694381|Experimental|mutant pro-urokinase (M5) alone|In the first study part subjects in cohorts of 4 will receive ascending doses of either M5 (3 subjects) or M5-placebo (1 subject) without C1-inhibitor.
10036583|NCT01817049|Placebo Comparator|Attention control|Coaches will receive a 3.5 hour workshop prior to the start of the first study season, consisting of innocuous sport nutrition and sport psychology information as an attention control.
10036584|NCT01817062||Neonates|Neonates with very low birth weight and surgery therapy of acute abdomen
10023327|NCT01694381|Experimental|Mutant pro-urokinase (M5) and its inhibitor, C1 inhibitor|"In the second study part subjects in cohorts of 5 will receive ascending doses of either M5 or M5-placebo, preceded by a single intravenous dose of C1-inhibitor or C1-inhibitor-placebo. Each subject will randomly be allocated to one of the following treatment arms within one cohort:~C1-inhibitor followed by M5 (3 subjects);~C1-inhibitor followed by M5-placebo (1 subject);~C1-inhibitor-placebo followed by M5-placebo (1 subject).~Dose levels of both M5 and C1-inhibitor within each cohort will be chosen based on the available safety, pharmacokinetic and pharmacodynamic data of the preceding cohorts."
10023328|NCT01694394||Cohort|Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
10023329|NCT01694407|Active Comparator|TFV Alone Vaginal Tablet|
10023330|NCT01694407|Active Comparator|Emtricitabine (FTC) Alone Vaginal Tablet|
10023331|NCT01694407|Active Comparator|TFV Combined with FTC Vaginal Tablet|
10023332|NCT01694407|Placebo Comparator|Placebo Vaginal Tablet|
9479594|NCT03541772|Placebo Comparator|Placebo|Radiotherapy + Chemotherapy + Placebo
9479595|NCT03541759|Active Comparator|Hydromorphone|Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) > 5.
9517166|NCT03308877|Active Comparator|Standard Care (SC)|
10023333|NCT01694446|Experimental|Intraduodenal glucose or fructose|
10036585|NCT01817088|Experimental|New targeting procedure without electrophysiology|Patients with the high precision procedure under general anesthesia alone without electrophysiological stimulation
10036586|NCT01817088|Active Comparator|Classical neurosurgical procedure|patients with a first step of electrode implantation under awake surgery with electrophysiological control followed by a second step under general anesthesia
10036587|NCT01817101|Active Comparator|Dietary Supplement capsule|One capsule at meals (3 each day) during 1 year with Omega-3 fatty acid supplementation
10036588|NCT01817101|Placebo Comparator|Empty gelatine capsule|One capsule at meals (3 each day during 1 year)
10036589|NCT01817114|Experimental|Chronic Remote Ischemic Conditioning|Remote ischemic conditioning will be induced using an AutoRIC device (occluding arm bloodflow exactly like manual bloodpressure cuff). With the participant in a supine or seated upright position, the AutoRIC device will be placed on the right arm and will inflate to a pressure of 200mmHg for 5 minutes (ischemia). The device will then auto-deflate (reperfusion), completing one cycle of ischemia-reperfusion. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
10036590|NCT01817114|Sham Comparator|SHAM Remote Ischemic Conditioning|Sham conditioning will involve the AutoRIC device being placed on the right arm and will inflate to a pressure of 10mmHg for 5 minutes (ie. no limb ischemia will occur). The device will then auto-deflate, completing one cycle. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
10036591|NCT01817127||Main Study|Women enrolled in this cohort of the study will collect their breast milk, infant urine and stool, and their urine and stool samples. Blood and saliva will be collected from these participants by study personnel.
10036592|NCT01817127||Gestational Diabetes Mellitus Cohort|Women who have been diagnosed with gestational diabetes mellitus, type 2 diabetes mellitus or impaired glucose tolerance will be enrolled in this cohort. Participants will be asked to report their fasting and postprandial blood glucose levels if they are monitoring these outcomes at home with a glucometer.
10036593|NCT01817127||Fresh Milk Cohort|Women enrolled in this cohort will provide fresh milk samples (stored in the refrigerator and picked up by study personnel within 1 hour of collection) for analysis of glycan composition and gene expression of glycan metabolizing enzymes of somatic cells in milk.
10036594|NCT01817127||RNA Milk Fat Cohort|Women enrolled in this cohort must have given birth to sons and will collect a fresh milk sample for transcriptomic analysis compared against non-human primate milk.
10036595|NCT01817127||Skin Study|This cohort includes mothers and their infants who will provide milk and infant stratum corneum cells to act as the control group for a different study designed to investigate skin function in premature infants.
10036596|NCT01817127||BMMI Project|Subjects enrolled in this cohort will be part of the control group for the BMMI Project.
10036597|NCT01817140||Patient MRI|Adult patients with possible maxillofacial and/or mandibular bone invasion with oral cancer or osteoradionecrosis who are scheduled for surgery. All eligible and consented participants will have MRI scans obtained using 3T and 4T magnets prior to their surgery.
10036598|NCT01817140||Normal MRI|Healthy adult volunteers recruited to test the comfort of the coil apparatus and to determine configurations which lead to satisfactory image acquisition.
10036599|NCT01817153|Placebo Comparator|placebo|10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
10036600|NCT01817153|Active Comparator|hydrocortison|50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
10036601|NCT01817179|Experimental|FES neuroprosthesis to dorsiflexors on affected side|Participants will use FES neuroprosthesis to dorsiflexors on affected leg for 3 months at home.
10023334|NCT01694459|Active Comparator|Standard dose heparin|Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) > 300 sec. during the procedure
10023335|NCT01694459|Experimental|Low-dose heparin|Bolus of 50 UI/Kg heparin with a target ACT during the procedure of >200 sec.
10023336|NCT01694472|Experimental|MAGE-A4 TCR Gene-Modified T Cells|
10023337|NCT01694498|Active Comparator|A. Desmopressin 25 µg|1 orally disintegrating tablet every night during study period
10023338|NCT01694498|Active Comparator|B. Desmopressin 50 µg|1 orally disintegrating tablet every night during study period
10023339|NCT01694498|Placebo Comparator|C. Placebo|1 orally disintegrating tablet every night during study period
10023340|NCT01694511|Active Comparator|Introductory conventional endoscopy|Conventional endoscopy followed by HRME+CVC after 30 days.
10023341|NCT01694511|Active Comparator|Introductory HRME+CVC|HRME+CVC followed by conventional endoscopy after 30 days.
10023342|NCT01694537|Placebo Comparator|placebo|The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
10023343|NCT01694537|Experimental|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
10023344|NCT01694550||Pacemaker mode programming|High grade AV-block
10023345|NCT01694576|Experimental|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
10023346|NCT01694576|No Intervention|Observation|Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation
10023347|NCT01694589|Experimental|LDE-225|LDE-225: dose - 800 mg, taken by mouth once daily for 2 weeks.
10023348|NCT01694602||Newly Diagnosed NSCLC patients|In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).
10023349|NCT01694615|Active Comparator|Cryoprobe biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
10023350|NCT01694615|Active Comparator|Forceps Biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
10023351|NCT01694628|Experimental|CLIMB (COPD Lifestyle, Mood, and Behavior)|Counseling sessions for COPD and depression
10023352|NCT01694628|No Intervention|Control|Usual Care
10023353|NCT01694680|Active Comparator|Lutein-enriched-egg beverage|Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
10023354|NCT01694680|Placebo Comparator|Placebo|Powder in sachet to prepare beverage
10023355|NCT01694693||RA patients treated by Orencia|RA patients treated by Orencia according to usual practice from June 1st 2007
10023356|NCT01694719|Experimental|Behavioral Activation + Cognitive Control Training|Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.
9479596|NCT03541759|Active Comparator|Piritramide|Piritramide 15mg s.c. 2 times after surgery as basic medication. Piritramide 7.5mg s.c. maximum 2 per 24h when numeric rating scale (NRS) > 5.
10023357|NCT01694719|Active Comparator|Behavioral Activation Therapy plus Control Task|Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.
10023358|NCT01694732|Experimental|varenicline with counselling|Active varenicline associated with intensive smoking cessation counselling
10023359|NCT01694732|Placebo Comparator|Placebo with counselling|Placebo of varenicline associated with intensive smoking cessation counselling
10023360|NCT01694758||Patients with diabetes type 2|
10023361|NCT01694784|Experimental|Quantitative|In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet. Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
10023362|NCT01694784|Active Comparator|Qualitative|In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
10023363|NCT01694784|Experimental|Narrative|In the narrative arm, we will present harms using patient narratives (i.e. descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet. To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
10023364|NCT01694784|Experimental|Framed|In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e. use a gain frame). In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
10023365|NCT01694797|Experimental|Metoprolol Succinate ER Tablets, 50 mg|Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd
10023366|NCT01694797|Active Comparator|TOPROL-XL ER Tablets 50 mg|TOPROL-XL ER Tablets 50 mg of AstraZeneca
10023367|NCT01694810|Experimental|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
10023368|NCT01694810|Experimental|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel once daily for 4 weeks
10023369|NCT01694810|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel once daily for 4 weeks
10023370|NCT01694810|Experimental|8% NVN1000 Topical Gel|8% NVN1000 8% Topical Gel applied once daily for 4 weeks
10023371|NCT01694823|Experimental|CS-ACI|"Group/Cohort Label： pretherapy post-treatment~Group/Cohort Description ：The CS-ACI is used to prepare cell sheet and implant to the Cartilage defects.The arm of safety and efficacy are compared preoperative observation with postoperative observation."
10023372|NCT01694836|Experimental|Depigoid Birch 5.000 DPP/ml|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
10023373|NCT01694836|Placebo Comparator|Placebo|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
10023374|NCT01694849|Experimental|GFT505 80mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
10023375|NCT01694849|Experimental|GFT505 120mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
10023376|NCT01694849|Placebo Comparator|Placebo|hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
10023377|NCT01694862|Experimental|Integrated FP /PNC service delivery|Clinic or district identified as 'intervention' in which FP and PNC services are (theoretically) being provided together with HIV services (counselling, testing, treatment etc.) and in which the procedural intervention has been applied.
10023378|NCT01694862|No Intervention|Non-integrated FP/PNC service delivery|Clinic or district where FP and PNC services are not (theoretically) being provided together with HIV services, and in which no procedural intervention has been applied.
10023379|NCT01694875||No Treatment|
9479597|NCT03541746|Experimental|Study Group|Platelet Rich Plasma
9479598|NCT03541746|Active Comparator|Control Group|Intrauterine Foley's Catheter
9479599|NCT03541733|Experimental|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
10023380|NCT01694888|Experimental|midwifery students|all midwifery students studying at last term (except one who was absent) (27) in Mashhad school of nursing and midwifery in April 2011
10023381|NCT01694901||SmartPilot® system|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia using the SmartPilot® system
10023382|NCT01694901||Standard arm|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia according to the standard operating procedures of the department, i.e. manually controlled clinical anesthesia and EEG-derived parameters of anesthetic depth
10023383|NCT01694914|Experimental|Animal Compound Free Medium|Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium
10023384|NCT01694914|Active Comparator|organ culture medium containing 2% of fœtal calf serum|Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum
10023385|NCT01694927|Experimental|Mesenchymal Stem cells|
10023386|NCT01694940||Mitochondrial Disease Patients|Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.
10023387|NCT01694953||Patients with MNGIE|Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.
10023388|NCT01694979||Single group: pelvic floor and breathing|This is a single group with repeated measures during variable breathing effort
10023389|NCT01694992|Experimental|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after stroke, five times per week for 30 plus a time spent out of bed (sitting).
10023390|NCT01694992|No Intervention|Control|The Control Group will follow within the routines of the hospital as is usually done.
10023391|NCT01695005|Experimental|LY3039478 - Dose Escalation|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams [mg] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression
10023392|NCT01695005|Experimental|LY3039478 - Cohort Expansion|Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
10023393|NCT01695005|Experimental|Dose 1 LY3039478 + Prednisone|Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
10023394|NCT01695005|Experimental|Dose 2 LY3039478 + Prednisone|Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.
10023395|NCT01695018||p16 methylation positive|48 patients with mild or moderate oral epithelial dysplasia containing methylated p16.
10023396|NCT01695018||p16 methylation negative|104 patients with p16 mild or moderate oral epithelial dysplasia NOT containing methylated p16.
10023397|NCT01695031|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions of web-based, tailored asthma management
10023398|NCT01695031|Active Comparator|Generic web-based education|Teens in the control group will receive generic, web-based asthma education.
10023399|NCT01695057|Experimental|Treatment (vorinostat and surgery)|Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.
10036602|NCT01817205|Other|TACE with Hyperthermia treatment|Interventions: TACE to all liver lesions and two sessions of systemic hyperthermia performed at 24 hours and 48 hours respectively after TACE.
10023400|NCT01695070|Experimental|Melatonin|Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.
10023401|NCT01695096|Experimental|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
10023402|NCT01695096|Placebo Comparator|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to > 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
10023403|NCT01695109|Placebo Comparator|Placebo|
10023404|NCT01695109|Active Comparator|Liraglutide|
10023405|NCT01695122|Experimental|valproic acid|
10023406|NCT01695148|Active Comparator|White Maize Flour|Children will receive 2 meals a day (~200 g of white maize flour), 6 days a week for 6 months.
10023407|NCT01695148|Experimental|β-Carotene Biofortified Maize|Children will receive 2 meals a day (~200 g of beta-carotene biofortified maize flour), 6 days a week for 6 months.
10023408|NCT01695148|No Intervention|Non-Intervened|Children will receive no food for the duration of the study, but families in this group will receive an equivalent ration of food items at the end of the trial.
10023409|NCT01695161||mucopolysaccharidosis|mucopolysaccharidosis
10023410|NCT01695161||Fabry disease|Fabry disease
10023411|NCT01695161||healthy controls|healthy controls
10023412|NCT01695174|Experimental|Xifaxan|Xifaxan 550 mg two times per day for three months
10023413|NCT01695187|Experimental|NB-001 (0.3%)|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and two surfactants: polysorbate (Tween) 20 and cetylpyridinium chloride (CPC).
10023414|NCT01695187|Placebo Comparator|Vehicle|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and one surfactant: polysorbate (Tween) 20.
10023415|NCT01695200|Experimental|Omega-3 Fatty Acids|15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)
10023416|NCT01695213|Active Comparator|HA-Omnifit|Patients who receive a HA-Omnifit uncemented hip stem
10023417|NCT01695213|Active Comparator|Symax hip stem|Patients with the Symax uncemented hip stem
10023418|NCT01695226|Placebo Comparator|placebo|pre-operative placebo twice daily for two to three weeks
10023419|NCT01695226|Experimental|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
10023420|NCT01695252|No Intervention|S-Sup|Standard supervision
10023421|NCT01695252|Experimental|MEMOS|Patient informed clinical outcomes supervision
10023422|NCT01695265|Experimental|Exercie oronasal breathing (ONB)|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
10023423|NCT01695265|Experimental|Exercie nasal breathing through the FB|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
10023424|NCT01695278|Active Comparator|Standard Care|Participants will receive standard care from physicians for monitoring and treating their diabetes. They are placed on a wait list to receive the intervention.
10023425|NCT01695278|Experimental|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
10023426|NCT01695343|Experimental|KB001-A|KB001-A administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.
10023427|NCT01695343|Placebo Comparator|Placebo Comparator|Placebo administered up to 5x intravenously
10023428|NCT01695356|Active Comparator|290-400 nm sunscreen|"Sunscreen containing Mexoryl SX, Mexoryl XL, Titanium Dioxide, Octocrylene, Tinosorb S, Avobenzone, and Ethylhexyl triazone.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
9479600|NCT03541733|No Intervention|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
9479601|NCT03541720|Experimental|Injection of 18F-DA|18F-DA will be injected into a vein in the arm or leg, or via central venous access line.
10023429|NCT01695356|Experimental|290-800 nm sunscreen|"Sunscreen containing Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide, and iron oxide.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
10023430|NCT01695382|Experimental|Navigation|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy. In addition they will have 5 navigator initiated home visits to review the educational materials and help patients and families address barriers to palliative care through education, advocacy, and activation.
10023431|NCT01695382|No Intervention|Control|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy.
10023432|NCT01695395||Intellectual disabled adults without a mental disorder|
10023433|NCT01695395||Intellectual disabled adults with a mental disorder|
10023434|NCT01695421|Experimental|Functional electrical stimulation|Burst modulated alternating rectified current with a 10 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
10023435|NCT01695421|Experimental|Medium-frequency alternating current|Burst modulated alternating current with a 2500 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
10023436|NCT01695421|Experimental|Burst-modulated alternating current|Burst modulated alternating current with a 4000 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts.
10023437|NCT01695421|Placebo Comparator|Placebo|Training with the intensity of 5 mA.
10023438|NCT01695434||Copaxone MRI|Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI.
10023439|NCT01695434||Healthy Controls MRI|Subjects who are otherwise healthy, without neurological disorders, will have a MRI.
10023440|NCT01695447|Experimental|duct-to-mucosa|duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
10023441|NCT01695447|Active Comparator|invagination|invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
9479602|NCT03541707|Active Comparator|Active Therapy|
9479603|NCT03541707|Sham Comparator|"As if Stimulation"|
10023442|NCT01695460|Active Comparator|Vitamin D|"The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.~D3 Vitamin ® consists of small white tablets, which are easy to swallow.~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products."
10023443|NCT01695460|Placebo Comparator|Placebo|Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
10023444|NCT01695499||Immunosuppressed ICU Patients with lung infiltrates|Immunosuppressed ICU Patients with lung infiltrates
10023445|NCT01695499||Control Group|BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population.
10023446|NCT01695512||Immunocompromised Patients|Patients with acute leukemia undergoing induction chemotherapy or undergoing allogeneic stem cell transplantation
10023447|NCT01695512||Control Group|Patients underdoing bronchoscopy and diagnostic BAL without immunosuppression and without signs of infection (Sarcoidosis, Lung Cancer)
10023448|NCT01695525|Experimental|Yoga|Participants will be asked to practice Yoga 3 times per week at a minimum, and daily at a maximum. Participants will receive training in different Yoga techniques including breathing exercises, postures and meditation. Participants will be asked to practice 1 hour Yoga sessions comprised of breathing exercises, postures and meditation.
10023449|NCT01695538|Experimental|Yoga|Participants will be asked to practice yoga 3 days per week, at a minimum and encouraged to practice 7 days per week, for 1 year.
10023450|NCT01695551||Ventricular Tachycardia|Participants in cohort will have implantable defibrillators in-situ and are undergoing ablation procedure for ventricular tachycardia.
10023451|NCT01695564||WATCHMAN|Patients that had the WATCHMAN device implanted
10023452|NCT01695564||LARIAT LAA Device|patients that had LARIAT LAA device implanted
10023453|NCT01695577|Experimental|Multidisciplinary evaluation and VR|Vestibular rehabilitation and balance training. Twice a week for eight weeks.Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
10023454|NCT01695577|Active Comparator|Multidisciplinary evaluation and no VR|Multidisciplinary evaluation. Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
10023455|NCT01695590|Experimental|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
10023456|NCT01695603|No Intervention|Standard mode of controlled ventilation|Each brain injured patient will be ventilated during two hours with a standard mode of controlled ventilation.
10023457|NCT01695603|Experimental|Intellivent arm|Each brain injured patient will be ventilated during two hours with an automated mode of ventilation, the Intellivent mode.
10023458|NCT01695616|Placebo Comparator|Placebo|Patients enrolled in this arm will take a tablet twice a day
10023459|NCT01695616|Active Comparator|Passiflora incarnata and isoflavona combination|Patients enrolled in this arm will take a tablet twice a day
10023460|NCT01695629||None to Mild|Subjects with Diabetes with none to mild peripheral neuropathy
10023461|NCT01695629||Severe|Subjects with diabetes with severe neuropathy
10023462|NCT01695642||Microkeratome|mechanical microkeratome
10023463|NCT01695642||Intralase|femtosecond laser
9479604|NCT03541681|Active Comparator|Glucocorticoid Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections with glucocorticoid (1 ml Dexamethasone) within 3 months.
10023464|NCT01695655||PKP|Subjects undergoing penetrating keratoplasty
10023465|NCT01695681|Other|Dietary instruction|Gluten-free diet
10023466|NCT01695694|Active Comparator|community support group|
10023467|NCT01695694|Experimental|supporting positive and healthy relationships|
10023468|NCT01695707|Placebo Comparator|Placebo|"Subjects randomized to placebo will receive opaque size 00 gelatin capsules containing 240mg lactose. As with the intervention group, 1 capsule will be taken by each day throughout the treatment period."
10023469|NCT01695707|Experimental|Pioglitazone|"Subjects randomized to pioglitazone will receive opaque size 00 gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose.~One capsule will be taken by each day throughout the treatment period."
10023470|NCT01695720|Experimental|VisionScope Imaging (VSI) Exam|A VisionScope Imaging (VSI) Exam is diagnostic arthroscopic procedure. Through a natural or surgical opening, an endoscope is inserted through a cannula to illuminate and visualize the interior cavity of a joint.
10023471|NCT01695733|Experimental|Schedule A|Influenza vaccination on the first day of chemotherapy
10023472|NCT01695733|Experimental|Schedule B|Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy
10023473|NCT01695759|Experimental|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
10023474|NCT01695759|Active Comparator|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
10023475|NCT01695785||Healthy weight|greater than or equal to the 5th to less than the 85th BMI percentile
10023476|NCT01695785||Obese|greater than or equal to the 95th BMI percentile
10023477|NCT01695798|No Intervention|Chronic malnourished bOPV|This arm will receive only bOPV
10023478|NCT01695798|Experimental|Malnourished IPV+bOPV|This arm will receive IPV and bOPV
10023479|NCT01695798|No Intervention|Normally nourished bOPV|This arm will receive only bOPV
10023480|NCT01695798|Experimental|Normally nourished IPV+bOPV|This arm will receive both IPV and bOPV
10023481|NCT01695811||FLAK|FLAK
10023482|NCT01695811||PKP|Retrospective
10023483|NCT01695824|Active Comparator|LAA occluder|
10023484|NCT01695824|Active Comparator|Warfarin|
10023485|NCT01695837|Experimental|Group A-dietary counseling month 0-6|"Group A Visit #1 - Weight, height, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the primary care physician (PCP) reviewed the results of the fasting lipid panel and diet test with the patient; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #2 - Same as visit #1. Weekly automatic emails sent to patient reminding to visit the counseling website.~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
10023486|NCT01695837|Other|Group B- Dietary counseling month 3-6|"Group B Visit #1: Weight, height, blood pressure and pulse were measured at the beginning of the visit. Follow up visit and lab order were scheduled for 3 months. No blood test or diet test results were reviewed with the patient.~Visit #2 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the two fasting lipid panels ; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
10023487|NCT01695850|Experimental|MZRW|MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
10023488|NCT01695850|Active Comparator|Senna|Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
10023489|NCT01695850|Placebo Comparator|Placebo|Placebo MZRW and Placebo Senna
10023490|NCT01695863|Experimental|miralax|miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
10023491|NCT01695863|Experimental|moviprep split dose|Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen
10023492|NCT01695876|Experimental|AMG 357|AMG 357 is a small molecule for treatment of inflammatory disease
10023493|NCT01695876|Placebo Comparator|Placebo|Matching placebo to AMG 357 containing no active drug
10023494|NCT01695902|Experimental|Levosert-20|Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
10023495|NCT01695902|Active Comparator|Mirena®|Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
10023496|NCT01695915||Healthy|Transabdominal ultrasound
10023497|NCT01695915||Constipated|Transabdominal ultrasound
10023498|NCT01695928|Active Comparator|Extracorporeal shockwave therapy (ESWT)|Active treatment
10023499|NCT01695928|Placebo Comparator|ESWT Placebo|No extracoporeal shockwave therapy
10023500|NCT01695967|Experimental|Turbinate Cauterization|Turbinate Cauterization will be completed.
10023501|NCT01695967|No Intervention|control|no turbinate cauterization
10036603|NCT01817218|Experimental|PRP (Platelet Rich Plasma)|PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.
10023502|NCT01696019|Experimental|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
10023503|NCT01696019|Active Comparator|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
10023504|NCT01696019|Active Comparator|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
10023505|NCT01696019|Placebo Comparator|Contact and testing only|The fourth group received no intervention. Contact was maintained by phone during the intervention period to reduce dropout. Participants were called four times during the 40 weeks intervention period by the study coordinator.
10023506|NCT01696097|Other|Dietary Counseling|Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure
10023507|NCT01696110|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
10023508|NCT01696110|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
10023509|NCT01696110|Active Comparator|heparin plus tirofiban|heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.
10023510|NCT01696123|Experimental|MLC601|MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore) (0.4 g per capsule) was prescribed as one capsule three times daily without an escalation dose.
10023511|NCT01696136|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
10023512|NCT01696136|Active Comparator|AF-Ablation with single-tip electrode|Regular AF-ablation with a regular single-tip ablation catheter
10023513|NCT01696149|Experimental|electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz transcutaneous electrical nerve stimulation session, a 110 Hz transcutaneous electrical nerve stimulation session, and a control (off-transcutaneous electrical nerve stimulation) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period
10023514|NCT01696162|Active Comparator|PDF exercise sheets|Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
10023515|NCT01696162|Active Comparator|Limited Exercise Videos|"Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks.~A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety."
10023516|NCT01696162|Experimental|Algorithm based Exercise Videos|Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
10023517|NCT01696175||PICU admittance|Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
10023518|NCT01696201|No Intervention|Control group|Sedentary pregnant women
10023519|NCT01696201|Experimental|Exercise group|Exercise program
10023520|NCT01696227||Nissle 1917|In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
10023521|NCT01696240|Placebo Comparator|Placebo|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
10023522|NCT01696240|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
10023523|NCT01696253||Subjects at risk for Alport sydrome|
10023524|NCT01696253||Newly identified subjects with Alport syndrome|
10023525|NCT01696266||Insulin-treated patients with diabetes|
10023526|NCT01696305|Experimental|Hyalobarrier|ACP200 (Auto-crosslinked polysaccharide:inner ester of hyaluronic acid) 30mg/ml*10ml/syringe and 5cm-cannula
10023527|NCT01696305|Active Comparator|Guardix-SG|Poloxamer/sodium alginate mixture 6g/syringe
10023528|NCT01696318|No Intervention|Educational program|Educational Program with Professional Physical Education, Pharmacist and Nutritionist
10023529|NCT01696318|Experimental|Educational program and individual care|Educational program and individual care with professional Physical Education; Pharmacist and Nutritionist
10023530|NCT01696331|Experimental|Text Message Reminder|
10023531|NCT01696344||Cohort 1|No additional ablation after AF termination(PVAI only)
10023532|NCT01696344||Cohort 2|Additional ablation of extra-PV triggers before and after isoproterenol-challenge after AF termination (PVAI + ablation of extra-PV triggers)
10023533|NCT01696370|Active Comparator|Trimetazidine|
10023534|NCT01696370|Placebo Comparator|Placebo capsule|
10023535|NCT01696383|Experimental|DuoTrav|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
10023536|NCT01696409||Arm A|400 IU vitamin D3 once a day for 2 months
10023537|NCT01696409||Arm B|2000 IU Vitamin D3 once/day for 2 months
10023538|NCT01696422|Experimental|Step A: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC
10023539|NCT01696422|Active Comparator|Step A:dengue liquid vaccine|TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC
10023540|NCT01696422|Placebo Comparator|Step A: Placebo|Placebo comparator Two doses with a six-months interval, SC
10023541|NCT01696422|Experimental|Step B: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
10023542|NCT01696422|Placebo Comparator|Step B: Placebo|Placebo comparator Single dose, SC
10023543|NCT01696448|Experimental|Experimental Group|CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
10023544|NCT01696448|Placebo Comparator|Control Group|3 placebo capsules, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
10023545|NCT01696461|Experimental|Related donors receiving plerixafor|Collection of sufficient CD34+ cells using plerixafor as the mobilizing agent.
9479605|NCT03541681|Active Comparator|Local Anesthetic Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections without glucocorticoid (Dexamethasone) within 3 months.
10023546|NCT01696474|Experimental|Bortezomib therapy|A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
10023547|NCT01696487|Experimental|Healthy Volunteers|Volunteers will be challenged with oral 150g Fructose per day for 28 days.
10023548|NCT01696487|No Intervention|NAFLD|Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.
10023549|NCT01696487|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.
10023550|NCT01696487|No Intervention|Hepatitis C genotype 1 (HCV-GT1)|Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group
10023551|NCT01696500|Experimental|NPB-01|
10023552|NCT01696526|Experimental|vitamin D fortified fish|Human volunteers receiving vitamin D fortified fish, 4 weeks
10023553|NCT01696526|Placebo Comparator|conventional fish|consumption of conventional fish , 4 weeks
10023554|NCT01696539|Experimental|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
10023555|NCT01696539|Active Comparator|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
9479606|NCT03541668|Experimental|Group A|Recombinant human urokinase (rhPro-UK)
9479607|NCT03541668|Active Comparator|Group B|Alteplase(rt-PA)
10023556|NCT01696552|Active Comparator|TKR with Positioning Guides (PSPG)|Use of PSPG (Signature, Materialise) in TKR (Vanguard Total Knee System, Biomet)
10023557|NCT01696552|Active Comparator|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet), Conventional Technique
10023558|NCT01696565|Experimental|125 mg/day Treatment Arm|125 mg/day PG2 treatment continuously for 7 days
10023559|NCT01696565|Experimental|250 mg/day Treatment Arm|250 mg/day PG2 treatment continuously for 7 days
10023560|NCT01696565|Experimental|500 mg/day Treatment Arm|500 mg/day PG2 treatment continuously for 7 days
10023561|NCT01696578|Experimental|BF-CBT and group physiotherapy|Multivitamin+10 sessions of biofeedback supported cognitive behavioral therapy (BF-CBT) and 10 sessions of group physiotherapy
10023562|NCT01696578|Active Comparator|Waiting list|The waiting list group receives only multivitamin pills while being waiting and will receive the same intervention 3 months later
10023563|NCT01696591||NEUROSTEM®-AD|"A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery~DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain"
10023564|NCT01696591||Control Group|"A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:~Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.~For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
10023565|NCT01696604|Experimental|Part A: Cohort 1-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.01, 0.03, 0.1, and 0.3 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period.
10023566|NCT01696604|Experimental|Part A: Cohort 1-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
10023567|NCT01696604|Experimental|Part A: Cohort 2-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.3, 1, 3, and 10 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period in one of the 4 treatment periods.
10023568|NCT01696604|Experimental|Part A: Cohort 2-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
10023569|NCT01696604|Experimental|Part B: Cohort 3-GSK2849466 (Repeat dose 1)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo.
10023570|NCT01696604|Experimental|Part B: Cohort 3-Placebo (Repeat dose 1)|The subjects will receive repeat dose of matching placebo.
10023571|NCT01696604|Experimental|Part B: Cohort 4-GSK2849466 (Repeat dose 2)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo. In Cohort 4 subjects will be dosed in the fasted state on Days 1 and 14 and in the fed state on Day 7.
10023572|NCT01696604|Experimental|Part B: Cohort 4-Placebo (Repeat dose 2)|The subjects will receive repeat doses of matching placebo.
10023573|NCT01696604|Experimental|Part B: Cohort 5-GSK2849466 (Repeat dose 3)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo
10023574|NCT01696604|Experimental|Part B: Cohort 5-Placebo (Repeat dose 3)|The subjects will receive repeat doses of matching placebo.
10023575|NCT01696617|Experimental|Aripiprazole 8-week group|Adjunctive aripiprazole 8-week treatment
10023576|NCT01696617|Active Comparator|Aripiprazole 6-week group|Adjunctive aripiprazole 6-week treatment
10023577|NCT01696630|Active Comparator|Desflurane|Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase
10023578|NCT01696630|Experimental|Xenon|Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase
10023579|NCT01696656||Intestinal insufficiency|Patients with variable categories of major intestinal resection due to benign diseases,suffering from intestinal insufficiency and maintained with home nutritional support. Only clinically stable and nonhospitalized subjects will be recruited.
10036604|NCT01817218|Active Comparator|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
9479608|NCT03541642|Experimental|Enhanced Intervention|Women who are eligible and randomized to the Enhanced Intervention will receive targeted PrEP counseling; targeted written/visual materials, follow up supportive text messages, and distribution of PrEP at the syringe exchange
9479609|NCT03541642|Active Comparator|Basic Intervention|"Women who are eligible and randomized to the Basic Intervention will receive usual care with general messaging from medical personnel, reminder text messages, and distribution of PrEP at the syringe exchange"
9479610|NCT03541616||Enrolled Patients|
9479611|NCT03541603|Experimental|Levosimendan 2.5mg/mL Injectable Solution|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
9479612|NCT03541603|Placebo Comparator|Matching Placebo|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
9479613|NCT03541577||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo FFR measurement with the TruePhysioTM Microcatheter and the Pressure Wire
9479614|NCT03541564|Experimental|BMS-986165 Dose 1 oral administration|BMS-986165 therapeutic single dose
9479615|NCT03541564|Experimental|BMS-986165 Dose 2 oral administration|BMS-986165 supratherapeutic single dose
10023580|NCT01696669|Experimental|Chemotherapy + Surgery + Radiotherapy|"Standard risk patients: MP6 Treatment:~CHEMOTHERAPY: 2 cycles of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide. SURGERY: Ideally within 21 days after chemotherapy.~CHEMOTHERAPY: 1 cycle of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide.~RADIOTHERAPY: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%.~High risk patients:~CHEMOTHERAPY: Window phase with 2 cycles of gemcitabine + docetaxel. MP6 TREATMENT. CHEMOTHERAPY: Maintenance therapy for 1 year with gemcitabine + docetaxel."
9479616|NCT03541564|Active Comparator|Moxifloxacin Dose 3 oral administration|Moxifloxacin positive control single dose
9479617|NCT03541564|Placebo Comparator|Placebo Dose 4 oral administration|Placebo single dose
9479618|NCT03541538|Active Comparator|Global manipulation|Manual therapy performed in the cervical region in a non-specific way.
9479619|NCT03541538|Experimental|Especific manipulation|manual therapy performed specifically on the C6-7 segment
9479620|NCT03541525||Affected patients|Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
9479621|NCT03541525||Non affected relatives|Biological samples of blood for all relatives.
9479622|NCT03541512|Active Comparator|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
9479623|NCT03541512|Active Comparator|Education only|Educational materials only
10023581|NCT01696682|Experimental|Narrow Gastric Conduit|The group in which narrowed gastric conduit will be performed during minimally invasive esophagectomy
10023582|NCT01696682|Experimental|Wide Gastric Conduit|The group in which widened gastric conduit will be performed during minimally invasive esophagectomy
9479624|NCT03541473|Active Comparator|Peptamen® 1.5 Vanilla|
9479625|NCT03541473|Placebo Comparator|Boost Plus® Vanilla|
9479626|NCT03541434||Healthy|Children with no history of adenotonsillar hypertrophy, recurrent tonsillitis, or middle ear effusion. They presented to the clinic for examination or a scheduled procedure.
9479627|NCT03541434||Recurrent tonsillitis|Children with a history of recurret tonsillitis but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and complete blood count. They presented to the clinic for a sceduled tonsillectomy.
9479628|NCT03541434||Middle ear effusion|Children with chronic middle ear effusion but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and tympanometry. They presented to the clinic for scheduled myringotomy with or without adenoidectomy.
10023583|NCT01696708|Other|Patients|31-Phosphorus RMN Spectroscopy
9479629|NCT03541434||Adenotonsillar hypertrophy|Children with tonsillar and/or adenoidal hypertrophy. Diagnosis was based on physical exam and partly on x-ray of nasopharynx or nasopharyngoscopy. They presented to the clinic for scheduled tonsillectomy and/or adenoidectomy.
10023584|NCT01696708|Other|Volunteers|31-Phosphorus RMN Spectroscopy
10023585|NCT01696721||Pediatric Patients Treated with Protons|Proton Radiation Therapy
10023586|NCT01696786|Experimental|Oocyte cryopreservation|
10023587|NCT01696799|Experimental|Econazole Nitrate Foam|Investigational Drug Product
10023588|NCT01696799|Placebo Comparator|Vehicle Foam|Vehicle Foam Comparator
10023589|NCT01696799|Active Comparator|Econazole Nitrate Cream|Active comparator cream product
10023590|NCT01696812|Experimental|electrode position, STN DBS, Parkinson' disease|To determine the electrode positions with the relationship of the STN from the fused images of the preoperative MRI and the postoperative CT via web-site.
10023591|NCT01696825|Experimental|Diazepam Tablet, 5 mg, Vaginal|
10023592|NCT01696825|Experimental|Diazepam Suppository, 5 mg, Vaginal|
10023593|NCT01696825|Experimental|Diazepam Cream, 5 mg, Vaginal|
10023594|NCT01696825|Active Comparator|Diazepam Tablet, 5 Mg, Oral|
10023595|NCT01696838|Experimental|EA group|Electroacupuncture group
10023596|NCT01696838|Experimental|MOX group|Herbs-partitioned moxibustion group
10023597|NCT01696851||wheelchair rugby players with tetraplegia|
10023598|NCT01696851||other routine sport participants with tetraplegia|
10023599|NCT01696864|Experimental|stroke patients - hand|stroke patients with the ability to move their hand
10023600|NCT01696864|Experimental|stroke patient - arm|stroke patients with the ability to move their arms
10023601|NCT01696890|Active Comparator|integrated care|telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
10023602|NCT01696890|Active Comparator|standard care|telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
10023603|NCT01696903|No Intervention|Conventional anastomosis|"Conventional anastomosis: The pancreaticojejunostomy is carried out in a traditional way according to Cattell's duct-to-mucosa technique."
10023604|NCT01696903|Active Comparator|Novel anastomosis|Novel anastomosis: This the active comparator to the conventional anastomosis. A new pancreaticojejunostomy technique is used for the reconstruction. The pancreas is intubated into the jejunum.
10023605|NCT01696916|Experimental|exercise testing|6-minute walking test with pCO2 and pO2 measurement
10023606|NCT01697007|Experimental|2 injections of DNA administered by Zetajet|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml
10023607|NCT01697007|Experimental|2 injections DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device.
10036605|NCT01817231||breast cancer cases|breast cancer cases versus controls
10023608|NCT01697007|Experimental|1 injection DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device.
10023609|NCT01697020|Experimental|Arm 1|Mercaptopurine 20mg/ml Oral Suspension
10023610|NCT01697020|Active Comparator|Arm 2|Mercaptopurine 50mg tablets
10023611|NCT01697046|Experimental|Isentress+Truvada|All participants will receive the intervention
10023612|NCT01697059|Experimental|Piperacillin + Amoxicillin|Piperacillin/Tazobactam (Zosyn®) 100 mg/kg, up to adult dose of 3 g, i.v. q 6 hours x 2 doses, followed by Ampicillin/Clavulanate (Augmentin®) 50 mg/kg/d p.o. in 3 divided doses for 1 week.
10023613|NCT01697085|Experimental|Sea buckthorn oil|3 g (6 capsules)/day for three months
10023614|NCT01697085|Placebo Comparator|Placebo oil|3 g (6 capsules)/day for three months
9479630|NCT03541421|Experimental|Intervention|The patients administers own drugs during hospital stay.
10023615|NCT01697098|Experimental|12 hours Dexamethasone|Those patient will be given 12 hours dexamethasone after randomization
10023616|NCT01697098|Experimental|24 hours Dexamethasone|Those patient will be give 24 hours dexamethasone after randomization
10023617|NCT01697111|Experimental|Arm 1|
10023618|NCT01697111|Experimental|Arm 2|
10023619|NCT01697111|Active Comparator|Arm 3|
10023620|NCT01697124|Experimental|SPARK-EC|SPARK-EC curriculum for preschoolers offered instruction and practice in a comprehensive program designed to promote motor development through increased physical activity.
10023621|NCT01697137|No Intervention|Usual Care|Following enrollment, participants will visit with their primary care provider per usual.
10023622|NCT01697137|Experimental|Participant Video and Provider Cueing|Participants will watch a video prior to meeting with their provider. Participants will then cue their providers to discuss organ donation with them.
10023623|NCT01697150|Experimental|Control to Range Testing|Subjects will spend two nights in a non hospital setting while the DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is remotely monitored from an adjacent room. DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
10023624|NCT01697163||Iressa|Lung cancer patients with EGFR mutation
10023625|NCT01697189|Experimental|Fatigue management training|Experimental group subjects participated in a single half-day fatigue management training session.
10023626|NCT01697189|No Intervention|No fatigue management training|The control group subjects did not participate in the fatigue management training.
10023627|NCT01697202||no intervention|
10036606|NCT01817244|Experimental|care management type 1|2-month care management
10036607|NCT01817244|Active Comparator|care management type 2|6-month care management
10023628|NCT01697215||Oral or nasal endotracheal intubation|Oral or nasal endotracheal intubation, anticipated to last at least 48 hours Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm Subject must be at least 18 years old (no upper age limitation) English speaking patients/decision makers.
10023629|NCT01697228|Other|Immediate treatment group|This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months.
10023630|NCT01697228|Other|Delayed treatment group|This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months.
10023631|NCT01697241|Experimental|Supervised exercise and patient education|The entire duration of the intervention is 12 weeks, and consists of 24 sessions each lasting 60-70 minutes. Patients will receive two types of exercises, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX) in groups with progression guided by the patient's neuromuscular function (12 sessions). The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load (12 sessions).
10023632|NCT01697241|Other|Patient Education|The patient education program is designed to educate the patients about hip OA during 3 sessions of 90 min. duration
10023633|NCT01697280|Experimental|Educational messages only|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization
9479631|NCT03541421|No Intervention|Control|The patients receive medications from the medicine room dispensed by a nurse (standard care). No intervention
9479632|NCT03541408|Placebo Comparator|Control|Subjects will receive anesthesia
10023634|NCT01697280|Experimental|Immunization status verification only|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
10023635|NCT01697280|Experimental|Education and vaccine verification|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization, identify and record details of un/under-vaccinated children in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
10023636|NCT01697280|No Intervention|Status quo|No interventional activity will take place in this group. Therefore, the status quo (routine services) will be maintained during Polio NID
10036608|NCT01817257|Experimental|A: Continue treatment|Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
10036609|NCT01817257|No Intervention|B: Discontinue treatment|Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
10023637|NCT01697293|Experimental|Treatment (chemotherapy, surgery)|"COURSES A 1-12 (PHASE I & II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.~COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy."
10023638|NCT01697306|Active Comparator|Gemcitabine-arm|7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year
10023639|NCT01697306|Active Comparator|BCG-arm|7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months
10023640|NCT01697384|Experimental|one histrelin acetate 50 mg implant|The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.
10023641|NCT01697410|Experimental|terlipressin|
10023642|NCT01697410|Active Comparator|norepinephrine|
10023643|NCT01697423|Experimental|platelet-rich plasma|
10023644|NCT01697423|Active Comparator|durolane|
10023645|NCT01697436|Experimental|Crossover Period 1|
10023646|NCT01697436|Experimental|Crossover Period 2|
10023647|NCT01697436|Experimental|Crossover Period 3|
10023648|NCT01697436|Experimental|Crossover Period 4|
10023649|NCT01697475|Experimental|Intervention Group|Motivational text messaging
10023650|NCT01697475|No Intervention|Control Group|Step count
10023651|NCT01697488||Cohort|Overall sample
10023652|NCT01697488||Subgroup|Patients aged >/= 70 years
10023653|NCT01697514|Experimental|Part A: LY2940680 (Dose Escalation)|LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter [mg/m^2] up to 370 mg/m^2) for two 28 day cycles. Lower dose levels (23 mg/m^2 and 46 mg/m^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
10023654|NCT01697514|Experimental|Part B: LY2940680 (Dose Confirmation)|LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
10023655|NCT01697553|Experimental|Home automation pack coupled to teleassistance service|
10023656|NCT01697553|Active Comparator|Home without automation pack coupled to teleassistance service|
10023657|NCT01697566|Experimental|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
10023658|NCT01697566|Experimental|Placebo + Lifestyle Intervention|Placebo taken by mouth twice daily for 4, 30 day cycles. Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
10023659|NCT01697566|Experimental|Metformin + Lifestyle Intervention|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.~Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period."
10023660|NCT01697566|Placebo Comparator|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
10023661|NCT01697605|Experimental|BGJ398|Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
10023662|NCT01697618|Experimental|BIAsp 30|
9517167|NCT03308864|Experimental|Interpersonal Psychotherapy for Adolescents (IPT-A)|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
10023663|NCT01697618|Active Comparator|BHI 30|
10023664|NCT01697631|Experimental|BIAsp|
10023665|NCT01697631|Experimental|Insulin aspart|
10023666|NCT01697644|Experimental|Low dose|
10023667|NCT01697644|Experimental|High dose|
9479633|NCT03541408|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable~Minimized fentanyl usage intraoperatively~Intubation + GA adjunct total: 1-2 mcg/kg~Sedation: 0-0.25 mcg/kg~Post-op: 0.5-1 mcg/kg~Avoid morphine~Avoid ketamine~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine~Avoid H2-blockers (cimetidine, ranitidine, famotidine)~Avoid polypharmacy intraoperatively if possible (i.e. >5 new medications)~Fluid repletion based on maintenance and losses"
9479634|NCT03541395|Other|Testosterone|A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
9479635|NCT03541382|Active Comparator|HIVST campaign arm|Community representatives will be supported to plan and administer an HIVST campaign linked to HIV care and prevention services in their communities.
9479636|NCT03541382|No Intervention|SOC arm|Standard HTS will be provided by MoH at health facilities.
9479637|NCT03541343|Experimental|GreenBone|All patients will receive the GreenBone implant instead of bovine xenograft.
9479638|NCT03541330|Other|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
9479639|NCT03541291|Experimental|SMART-SYNC LM03|All participants
9479640|NCT03541278|Experimental|IM-SLNB with MIT|The radiotracer was injected with our modified injection technique (MIT) (periareolar intraparenchymal, high volume and ultrasonographic guidance). Internal mammary sentinel lymph node biopsy (IM-SLNB) was performed for patients with internal mammary visualized.
10023668|NCT01697657|Experimental|Detemir|
10023669|NCT01697657|Active Comparator|NPH|
10023670|NCT01697670|Experimental|Photodynamic therapy with Gliolan|Intervention: Laser light illumination with a cylindrical light diffuser (Model RD, Medlight SA) is performed 3 hours after administration of 15 mg/kg 5-aminolevulinic acid (5-ALA, Gliolan)
10023671|NCT01697683|Active Comparator|Probiotic Rhamnosus Lactobacilli|
10023672|NCT01697683|Placebo Comparator|Sugar pill|
10023673|NCT01697722||Step-up as FDC ICS/LABA|ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).
10023674|NCT01697722||Step up as separate therapies|ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).
10023675|NCT01697722||Qvar step-up|ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate
10023676|NCT01697735|Experimental|Berberine;Atorvastatin or Rosuvastatin|Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
10023677|NCT01697735|Active Comparator|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
9479641|NCT03541265|Experimental|Adductor block protocol|An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
9479642|NCT03541265|Active Comparator|peri-articular injection|Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.
9479643|NCT03541239|Active Comparator|non-ischemic preconditioning|The participants will have the cuff attached to the arm, however not be inflated for the 4 cycles of remote ischemic conditioning: 1 cycle is 5 minutes of inflation followed by 5 minutes of deflation. The ischemic reperfusion injury was induced by cuff inflation by the Single Cuff Tourniquet 8000 to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
9517168|NCT03308864|Active Comparator|Treatment as Usual|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
10023678|NCT01697761|Experimental|Treatment Group|treat by moxibustion and acupuncture
10023679|NCT01697761|Experimental|Control Group|treat by Sham acupuncture and moxibustion
10023680|NCT01697787|Other|Amodiaquine-Artesunate|ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
10023681|NCT01697787|Other|Artemether-Lumefantrine|AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
10023682|NCT01697826|Active Comparator|ClinSupV3 -soft gelatin capsule|Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days
10023683|NCT01697826|Active Comparator|ClinSupV3ER- Extended release tablet|ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.
10023684|NCT01697852|Experimental|LLIN plus IRS|LLIN by universal coverage campaign 2 rounds of indoor residual spraying with bendiocarb insecticide
10023685|NCT01697852|Active Comparator|LLIN only|LLIN by universal coverage campaign
10023686|NCT01697865|Active Comparator|Transfer group|The first surgical technique includes a concomitant latissimus and teres major transfer (transfer group).
10023687|NCT01697865|Active Comparator|Control group|The second technique does not include a concomitant latissimus and teres major transfer (control group).
10023688|NCT01697878|Experimental|Randomization Group 1|CPAP first followed by standard of care
10023689|NCT01697878|Active Comparator|Randomization group 2|Standard of care followed by CPAP
9802892|NCT04848662|Experimental|A/B - Treatment with BDA MDI (PT027) 160/180 μg followed by treatment with Pulmicort Respules 1mg|Subjects randomized to receive a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 2, and a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 3.
10023690|NCT01697891|Experimental|ALTENS|Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
10036610|NCT01817270|Experimental|Live Attenuated Varicella Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
10036611|NCT01817283|Placebo Comparator|placebo + cART|combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months
10036612|NCT01817283|Experimental|Triptolide + cART|combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.
10036613|NCT01817296|Experimental|Single arm|
9517169|NCT03308851|Experimental|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
10023691|NCT01697904|Experimental|Low Oxygen Strategy|"Resuscitation was initiated with room air (21% O2) for LOX infants. Supplemental oxygen was given if 1) the heart rate (HR) was less than 100 bpm after 30 seconds of effective ventilation, 2) the lower limits of goal saturations were not met. Targeted goal Pre-ductal saturations after birth were derived by approximation of the interquartile values for healthy term infants as reported by Kamlin et al and Dawson et al.FiO2 was increased or decreased by 10% in 30 second intervals as needed. If HR < 60 bpm after 30 seconds of effective ventilation , FiO2 was increased to 100% until the heart rate was stabilized.~Targeted Pre-ductal SpO2 After birth~min 60%-65%~min 65%-70%~min 70%-75%~min 75%-80%~min 80%-85%~10 min 85%-94%"
10023692|NCT01697904|Active Comparator|Traditional Oxygen strategy ( TOX)|Resuscitation for TOX infants was started with 100% O2 and adjusted every 30 seconds by 10% to meet the target oxygen saturation range of 85-94%
10036614|NCT01817309|Experimental|Study group|endotoxin assay in peritoneal dialysis effluent
10036615|NCT01817322|Experimental|Myfortic® (Enteric-coated Mycophenolate Sodium)|reduced cyclosporine+steroids+standard dose of myfortic
10036616|NCT01817322|Active Comparator|Myfortic|Conventional Dose+cyclosporine+steroid+Reduced Dose of Myfortic
9517170|NCT03308851|No Intervention|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
10023693|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
10023694|NCT01697943|Experimental|Roux-En-Y Pouch Reconstruction or Roux-En-Y Reconstruction|
10023695|NCT01697982|Experimental|Living with Hope Program|"Participants will receive the Living with Hope Program (LWHP). The LWHP involves viewing a short film and choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
10023696|NCT01697982|Experimental|LWH Film|Participants will viewing a short film entitled Living with Hope (LWH), which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope
10023697|NCT01697982|No Intervention|Usual Care|Participants in the usual care group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
10023698|NCT01697995||Lexiscan-Echo echo subjects|No Intervention: Observational study
10023699|NCT01697995||Lexiscan-Echo control subjects|No intervention: observational study
10023700|NCT01698034|Experimental|Volunteering|Weekly volunteering with elementary school children in after school programs
10023701|NCT01698034|No Intervention|Control|Wait-list control
10036617|NCT01817335|Experimental|Supportive care (psycho-educational program)|Patients participate in a psycho-educational program focused on medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks.
10023702|NCT01698047|Experimental|Resiliency Class|"Resiliency Classes (study group) Study participant randomized to the Resiliency classes will be offered and assigned a time and date to attend the classes. Each class will have up to 10 participants. Classes will be 90-120 minutes in duration and will be held weekly for six weeks. At the classes, participants will be offered a copy of the Resiliency Class Manual. And at each class, light snacks and refreshments will be offered.~The Resiliency Class manual covers the following topics:~Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation"
10023703|NCT01698047|Active Comparator|Case Management|Case management phone calls (control group) Study participants randomized to the case management phone calls will be told that they will receive two calls over two months by study staff to offer them referrals based on their perceived need for services to local health care, mental health, substance use, social services, child welfare, housing, and food. In addition, study participants in this arm of the study will be told that if the study determines that the resiliency classes are better at improving mood than the case management calls, they will receive a call to invite them to participate in resiliency classes for free at the B-RICH partner agencies.
10023704|NCT01698060|Experimental|Intestinal Delivery|ND1.1
10023705|NCT01698073|Experimental|mCOL|mCircle of Life is a culturally-based HIV-prevention intervention designed for American Indian and Alaska Native 10-12 year-olds. It includes both online and facilitated material.
10023706|NCT01698073|Active Comparator|AS+|After-School Science Plus is a curriculum designed for youth to teach science and literacy using everyday materials. It helps youth see how science is a part of everyday life and provides role models of scientists who come from different backgrounds and ethnicities.
10023707|NCT01698086|Experimental|Experimental group|Participants who are randomized to the Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions (Figure 1). The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report.
10023708|NCT01698086|No Intervention|Wait-listed Control group|The Wait-listed Control group will not receive treatment; however, participants in the Wait-listed Control group will undergo the same outcome measurement plan as the Experimental group. If interested, participants from this group will be placed on a wait-list and will have the opportunity to receive instructions in how to perform the vestibular rehabilitation program following their completion of the study.
10023709|NCT01698112|Experimental|Flaxseed High Dose|
10023710|NCT01698112|Experimental|Flaxseed Low Dose|
10023711|NCT01698112|No Intervention|Flaxseed control|
10023712|NCT01698125||Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
10023713|NCT01698138|Placebo Comparator|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
10023714|NCT01698138|Active Comparator|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
10023715|NCT01698164|Active Comparator|estradiol plus MPA|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle"
10023716|NCT01698164|Experimental|estradiol plus progesterone|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box"
10023717|NCT01698164|Experimental|Ximingting tablet|1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years.
10023718|NCT01698177|Active Comparator|Group A|This group will receive the influenza vaccine preoperatively.
10023719|NCT01698177|Active Comparator|Group B|Group B will receive the influenza vaccine postoperatively, prior to hospital discharge.
10023720|NCT01698177|No Intervention|Group C|Group C subjects have already received the seasonal flu vaccine.
10023721|NCT01698177|Placebo Comparator|Group D|Group D subjects have refused the vaccine, but agree to have serum titers drawn.
10023722|NCT01698190|Active Comparator|Fine needle aspiration (FNA)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a standard FNA needle
10023723|NCT01698190|Active Comparator|Fine needle biopsy (FNB)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a new Core needle (Procore; Fine Needle Biopsy).
10023724|NCT01698203|Experimental|ropivacaine|
10023725|NCT01698203|Placebo Comparator|placebo|
10023726|NCT01698216||Consta Sustenna switching|The patients group who switched to paliperidone palmitate from risperidone long acting injection
10023727|NCT01698229||Group 1|Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
10023728|NCT01698242|Experimental|Enhanced Training|The Enhanced Training intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. Randomization occurs at the PCP-level, that is, patients are assigned to the Enhanced Training group only if their PCP has been enrolled and randomized to this group. Descriptions of the intervention on the PCP-level and patient-level are provided in the intervention section.
10023729|NCT01698242|Active Comparator|Enhanced Education|The Enhanced Education intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention strategy revolves around providing nominal information through the mail. Randomization occurs at the PCP-level; that is, patients are assigned to the Enhanced Education group only if their PCP already has been enrolled and randomized to this group. Description of the intervention on the PCP-level and patient-level is provided in the intervention section.
9479644|NCT03541239|Experimental|ischemic preconditioning|The blood supply to the distal part of the arm will be occluded by inflation of a single cuff to 200mmHg, by the help of the Single Cuff Tourniquet 8000, for 5 minutes separated from 5 minutes of deflation, a cycle that happens 4 times in total. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
9479645|NCT03541213|Other|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
9517171|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
10023730|NCT01698255|Experimental|ENGAGE|"ENGAGE is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression. The steps of ENGAGE are:~basic social and physical engagement, which has been found to be a very effective depression strategy for most older adults;~the addition of strategies to address clinical features of depression interfering with treatment engagement, namely affect regulation, pessimism, and disorganization."
10023731|NCT01698255|Active Comparator|Standard of Care Psychotherapy|The comparison group for this study will be the current standard of care psychotherapy offered by Westchester Jewish Community Services (WJCS) therapists. This type of psychotherapy is often supportive or eclectic in nature. Therapists will focus on helping the subject to express feelings and focus on strengths and abilities in working through current difficulties and transitions. Therapists assigned to provide standard psychotherapy to eligible participants will receive training and supervision from WJCS staff consistent with agency practice.
10023732|NCT01698294|Experimental|Group I (flaxseed)|"Participants receive flaxseed PO daily for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group II."
10023733|NCT01698294|Active Comparator|Group II (usual diet)|"Participants maintain a usual diet for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group I."
10023734|NCT01698346|No Intervention|control|50 unvaccinated pregnant women
9479646|NCT03541213|Other|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
10023735|NCT01698346|Active Comparator|Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)|50 pregnant women vaccinated with pertussis vaccine
10023736|NCT01698372|Experimental|Prevena device (Group A)|Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
9479647|NCT03541213|Other|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
10023737|NCT01698372|No Intervention|Conventional dressing (Group B)|Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
10023738|NCT01698385|Active Comparator|Lifestyle counseling|
10023739|NCT01698385|No Intervention|Control, just measurements|
10023740|NCT01698398|Experimental|CF-LVAD pumpspeed.|Optimal pumpspeed setting of CF-LVAD during exercise on ergometric bicycle.
10023741|NCT01698437|Other|Transcranial MR-Guided Focused Ultrasound for Brain Tumors|
10023742|NCT01698450|Other|Focused Ultrasound for Movement Disorders|
10023743|NCT01698476|Active Comparator|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
10023744|NCT01698476|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
10023745|NCT01698515||Anti-TNF subgroup|"anti - TNF subgroup~20 subjects with RA, who are starting TNF inhibitors based on the decision of their treating rheumatologist, will be recruited from the clinic. Patients will be starting commercially available anti-TNF agents that have already been authorized for insurance coverage. We are not requesting anti-TNFs or other drugs specifically for patients enrolled in this study from any pharmaceutical company. Patients will also continue on their background MTX and corticosteroids if they are taking these agents, and MTX will be required for patients taking Infliximab or Golimumab as per approved indication. No medications will be supplied through the study.~--------------------------------------------------------------------------------"
10023746|NCT01698541|Experimental|Tacni|Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center
9802893|NCT04848662|Experimental|B/A - Treatment with Pulmicort Respules 1 mg followed by treatment with BDA MDI (PT027) 160/180 μg|Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 3.
9802894|NCT04838782|Experimental|Repeat Surgical Resection|Standard surgical operative management according to local practices.
10023747|NCT01698541|Active Comparator|Prograf|Tacrolimus administered as Prograf in according to standard protocol at the transplant center
10023748|NCT01698567|Active Comparator|Antithrombin III|"Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a."
10023749|NCT01698567|Placebo Comparator|Placebo|placebo (normal saline)
10023750|NCT01698580|Active Comparator|usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
10023751|NCT01698580|Experimental|Multifactorial Falls Prevention Program|12 week intervention for 10 to 12 participants with sessions once a week, lasting for 2 hours, consisting of: On-site exercises (progressive body balance exercise program),Home-based exercise program, Educational and Behavioural sessions and management of modifiable risk factors.
10023752|NCT01698593|Active Comparator|Ring Finger Nerve Block|
10023753|NCT01698606|Active Comparator|Secondary lifestyle intervention arm|6-month wait list group. Second arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling, following of completion of main 6-month intervention for arm 1.
10023754|NCT01698606|Experimental|Primary lifestyle intervention arm|First arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling
10023755|NCT01698619||Climbers on Mount Aconcagua|The Cohort consists of volunteers climbing Mount Aconcagua.
10023756|NCT01698632||benign-looking adnexal masses|
10023757|NCT01698645||PecFent®|
10023758|NCT01698658|Experimental|Diagnostic (SoftVue ultrasound tomography)|Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.
10023759|NCT01698671|Other|InterGard Synergy Vascular Graft|
10023760|NCT01698697|Active Comparator|U100|
10023761|NCT01698697|Experimental|U200|
10023762|NCT01698723|Active Comparator|Ribavirin|1000 mg (5 capsules)
10023763|NCT01698723|Placebo Comparator|Placebo|5 capsules of placebo
10023764|NCT01698736|Active Comparator|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
10023765|NCT01698736|Experimental|Semiselective IA + membrane filtration|Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration
10023766|NCT01698749|Experimental|Ozurdex in diabetic macular edema|Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months
10023767|NCT01698762||Osteoarthritis (OA)|"One OA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
10023768|NCT01698762||Osteoporosis (OP)|"One OP group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OP group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
10023769|NCT01698762||Rheumatoid Arthritis (RA)|"One RA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One RA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
10023770|NCT01698788|Experimental|TPHM removal without ozurdex|Comparison of taut posterior hyaloid removal with (Group B)and without intraoperative ozurdex(Group A)
10023771|NCT01698788|Experimental|TPHM removal with ozurdex|Comparison of TPHM removal with (Group B) and without (Group A)Ozurdex
10023772|NCT01698827||Kangaroo|"20 patients managed by Kangaroo gastrostomy tubes. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
10023773|NCT01698827||Cook|"20 patients receiving Wilson Cook gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
10023774|NCT01698827||Silmag|"20 patients managed by Silmag gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
10023775|NCT01698827||Freka|"20 patients carrying Freka gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
10023776|NCT01698827||Bard|"20 patients using the Bard gastrostomy tube. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
10023777|NCT01698866|Experimental|vaccin GenHevac B Pasteur|vaccin GenHevac B Pasteur (Suspension for injection in pre-filled syringe / 20 μg microgram(s)Per day). In total, 3 injections at M0, M1 and M6
10023778|NCT01698892|Experimental|I.V. sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
10023779|NCT01698892|Active Comparator|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
10023780|NCT01698931|Experimental|Treatment period 1|
10023781|NCT01698931|Active Comparator|Treatment period 2|
10023782|NCT01698931|Placebo Comparator|Treatment period 3|
10023783|NCT01698944|Experimental|Somatropin|
10023784|NCT01698957||UA Doppler Velocimetry|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
10023785|NCT01698970|Experimental|1 = Tested product|
10023786|NCT01698970|Placebo Comparator|2 = Control product|
10023787|NCT01698996|Active Comparator|No Packing|No Packing
10023788|NCT01698996|Experimental|Packing|Packing
10023789|NCT01699009|Experimental|Vegan diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
10023790|NCT01699009|Placebo Comparator|Supplement group|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
10023791|NCT01699035||stroke survivors|stroke survivors who have either returned to work, have thought about returning to work, or have tried to return to work
10023792|NCT01699048|Other|Hybrid group|Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with the left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50)
10023793|NCT01699048|Other|PCI|Multi-vessel PCI with DES (MV-PCI group, n=50)
10023794|NCT01699048|Other|CABG|Coronary artery bypass graft (CABG) treatment (CABG group, n=50)
9479648|NCT03541187|Experimental|G. cockroach allergenic extract|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
9479649|NCT03541187|Placebo Comparator|Placebo|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
9479650|NCT03541161||Early rehabilitation group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
9479651|NCT03541161||Conventional protocol group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from May 2016 to Dec 2016. Following conventional protocol, patients were asked to immobilize their shoulder for more than 4 weeks and then undergo self-exercise program.
9479652|NCT03541148|Experimental|Oncoxin-Viusid|Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
9479653|NCT03541122||Experimental group|Patients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
9479654|NCT03541109|Experimental|Polypill|Polypill group will receive a fixed dose combinations of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg), prescribed once daily by moth for 34 months
9479655|NCT03541109|No Intervention|Control|The usual care arm will receive regular drug order at the time of discharge from the hospital.
9479656|NCT03541096|Experimental|Winter Swimmers|4 Months of supervised winter swimming.
9479657|NCT03541096|Placebo Comparator|Control group|No winter swimming activities.
9479658|NCT03541070|Experimental|Kinesiology taping|For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
9479659|NCT03541031|Experimental|Micronutrient & Fish oil|Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
9479660|NCT03541031|Placebo Comparator|Olive oil & Safflower oil|Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
9479661|NCT03541018|Experimental|Posterior canalolithiasis|Type of repositional maneuvre
9479662|NCT03541018|Experimental|Lateral cupulolithiasis|Type of repositional maneuvre
9479663|NCT03540979|Active Comparator|Estrogen|Endometrial preparation: Estrogen supplements (Estradiol 6mg/d) will be started at the 2nd-3rd day of the cycle. First US scan will be performed after 10 days. If necessary, adjusting the estradiol doses will be performed according to the physician decision. After achieving trilinear endometrial thickness ≥8mm progesterone supplements (Endometrin 100mg*3/d) will be administrated. Embryo transfer will be performed after completing 5 days of progesterone supplements (at the 6th day after starting the progesterone supplements).
9802895|NCT04838782|Active Comparator|Management Without Re-operation|Non-surgical management with standard care according to local practices.
9802896|NCT04838717|Active Comparator|BPG Arm|BPG injections will be performed at the participating center
9802897|NCT04838717|Experimental|Doxycycline Arm|Dispensing of Doxycycline 100 mg is carried out at one time at V0 - Inclusion visit.
9802898|NCT04836520|Experimental|SHR6390+anatrozole|Hormone receptor positive, HER2 negative participants will receive SHR6390 in combination with anatrozole before surgery.
10023795|NCT01699061|Placebo Comparator|Placebo|Placebo tablet administered with a meal twice a day on Day 1
10023796|NCT01699061|Experimental|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
10023797|NCT01699074|Experimental|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
10023798|NCT01699074|Experimental|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
10023799|NCT01699074|Experimental|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
10023800|NCT01699074|Placebo Comparator|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
10023801|NCT01699074|Active Comparator|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
10023802|NCT01699100|Experimental|device|In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
10023803|NCT01699126|Experimental|CPAP, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP on OSA
10023804|NCT01699126|Active Comparator|CPAP and statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP plus statin on OSA patients
10023805|NCT01699126|Active Comparator|OSA, statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after statin treatment on OSA
10023806|NCT01699126|No Intervention|Placebo|We will also measure the FMD, blood pressure and inflammation on patients with only life style modification as in all other patients
10023807|NCT01699139|Active Comparator|positional device|
10023808|NCT01699139|Sham Comparator|lumbar corset|
10023809|NCT01699152|Experimental|TG02 citrate|TG02 citrate capsules given orally.
10023810|NCT01699165|Sham Comparator|Placebo Nasal filter|Placebo treatment
10023811|NCT01699165|Active Comparator|Nasal Filter|Active treatment
10023812|NCT01699191|Active Comparator|Probiotic Mixture|Probiotic mixture
9517172|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
9517173|NCT03308812|Active Comparator|Health360x|Participants will use the Health360x application for 6 months.
9517174|NCT03308812|Experimental|Health360x plus health coach|Participants will use the Health360x application and received personalized health coaching for 6 months.
10023813|NCT01699191|Placebo Comparator|Placebo|Placebo
10023814|NCT01699204|Placebo Comparator|Filtered air with placebo|Exposure for 2 hours to filtered air and placebo tablets 3 times daily for 6 days
10023815|NCT01699204|Active Comparator|Diesel exhaust with placebo|Exposure for 2 hours to diesel exhaust and placebo tablets 3 times daily for 6 days
10023816|NCT01699204|Experimental|Diesel exhaust with N-acetylcysteine|Exposure for 2 hours to diesel exhaust and N-acetylcysteine tablets (600 mg) 3 times daily for 6 days
10023817|NCT01699230|Experimental|Omega 3 supplemented patients|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
10023818|NCT01699230|No Intervention|Control group|
10023819|NCT01699243||Epidural|subjects under epidural anesthesia
10023820|NCT01699256|Experimental|Enhanced strategy|Enhanced implementation strategy
10023821|NCT01699256|Active Comparator|Strategy as usual|Normal implementation strategy
10023822|NCT01699269|Other|brain tumor|
10023823|NCT01699282|Experimental|Group thorough VKA (antivitamin K)education|
10023824|NCT01699282|Active Comparator|control group|
10023825|NCT01699295|Experimental|A+PAAC|Lessons delivered using A+PAAC
10023826|NCT01699295|Active Comparator|CON|Regular sedentary lessons
9802899|NCT04834557|Placebo Comparator|Control|Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 24 weeks.
10023827|NCT01699308|Experimental|Genotropin|10 persons with TBI and GHD will receive daily rhGH injections titrated to bring their GH levels into the normal range for one year. Treatment is initiated using Genotropin (rhGH) at an initial daily dose of 200mcg/day subcutaneously with a titration schedule calling for an increase in daily dosage by 200 mcg every two months until the target daily dose, 600 mcg/day, is achieved. The 10 GHD subjects will be assessed at baseline with EEG, fMRI and DTI and neuropsychological measures, again at 6 months, and a third time at 12 months.
10023828|NCT01699308|No Intervention|Control|5 demographically-matched TBI with normal GH subjects will be assessed at baseline (with EEG, fMRI and DTI, and neuropsychological measures) and at 12 months.
9517175|NCT03308786|Experimental|IL2 treatment|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for five consecutive days every 8 weeks for 8 weeks, in addition to combination antiretroviral therapy.
10023829|NCT01699321|Experimental|Your Move (physical activity)|The Your Move intervention is a multi-level, theory and evidence-based intervention that will include the following components: monthly handbills with community resources, newsletters, contests (shop and customer level), tailored health feedback report, and monthly phone calls from the research team.
10023830|NCT01699321|Other|Your Money (financial empowerment)|The Your Money program is an attention control intervention. Owners and barbers will receive 3 workshops that focus on financial health. Customers will receive monthly handbills and newsletters about different financial health topics.
10023831|NCT01699334|Experimental|Psychoeducational video|
10023832|NCT01699334|Active Comparator|Relaxation video|
10023833|NCT01699347|Experimental|OK432|Intracystic injection of OK432 under US guiding
10023834|NCT01699360|Experimental|Cyclosporine A, Tacrolimus, Sirolimus|"Cyclosporine A：soft capsule,2-6mg/kg/d, the same twice daily dose at least five days.~Tacrolimus:capsule,0.15-0.3mg/kg/d, the same twice daily dose at least five days.~Sirolimus:tablet,2mg/d, once a day."
10023835|NCT01699386|Active Comparator|Control Study Formula|protein hydrolysate formula
10023836|NCT01699386|Experimental|Experimental Study Formula|free-amino acid-based medical food
10023837|NCT01699399|Experimental|water immersion|infuse water during insertion phase of colonoscopy instead of air insufflation; remove the water during withdrawal phase.
10023838|NCT01699399|Experimental|water exchange|infuse and remove water during the insertion phase of colonoscopy. Air insufflation is used only in the withdrawal phase
10023839|NCT01699399|Active Comparator|air insufflation|standard colonoscopy using traditional air insufflation during insertion
10023840|NCT01699412|Experimental|Dexamethasone|Patients under topical treatment with solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL
10023841|NCT01699412|Experimental|Clobetasol|Patients under topical treatment with solution of clobetasol 0.05% associated with nystatin 100,000 UI/mL
10023842|NCT01699425|Experimental|Ajust|Experimental group: surgery to treat stress urinary incontinence with the sling Ajust®
10023843|NCT01699425|Active Comparator|Classical transobturator tape|Control group: surgery to treat stress urinary incontinence with the Align® sling.
10023844|NCT01699438|Experimental|Mesalazine|
10023845|NCT01699438|Placebo Comparator|Placebo|
10023846|NCT01699477|Other|Trancranial MRg Focused Ultrasound for Neuropatic Pain|
10023847|NCT01699490|Experimental|Fluoxetine + Valsartan|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to 40 mg per day of valsartan"
10023848|NCT01699490|Active Comparator|Fluoxetine + Placebo|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to placebo"
10023849|NCT01699516||Intestinal graft vs host disease|Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant
10023850|NCT01699516||Control group|In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.
10023851|NCT01699529|Experimental|Renal Denervation|
9517176|NCT03308747|Experimental|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: > 2.0 mg/L.
9517177|NCT03308747|Active Comparator|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: < 1.7 pg/ml and hs-CRP: < 1.0 mg/L.
10023852|NCT01699555|Experimental|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
10023853|NCT01699555|Placebo Comparator|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
10023854|NCT01699568|Experimental|Vulcano Actives|Implants 4mm x 10mm Vulcano Actives (anodized surface)(AR Torque Vulcano actives), Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
10023855|NCT01699568|Active Comparator|Porous|Implants 4mm x 10mm Porous (dual acid-etched surface treatment)(AR Torque Porous, Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
10023856|NCT01699581|Experimental|Nestle Impact Advanced Recovery|"Nestle Impact Advanced Recovery~1 dose of Nestle Impact Advanced Recovery orally three times a day"
10023857|NCT01699594|Experimental|Mannitol|This arm will assess the allergen induced change in airway responsiveness to mannitol bronchoprovocation.
10023858|NCT01699594|Active Comparator|Methacholine Chloride|This arm will assess the allergen induced change in airway responsiveness to methacholine bronchoprovocation.
10023859|NCT01699620|Experimental|Dermatome|BAHA implant insertion with Dermatome technique
10023860|NCT01699620|Experimental|Linear incision|BAHA implant insertion with linear incision
10023861|NCT01699646|Active Comparator|CTG + FBS|intrapartum surveillance with CTG+FBS
9802900|NCT04834557|Experimental|Digoxin|Participants in this arm will receive digoxin 0.25 mg every other day + DMARDs for 24 weeks.
10023862|NCT01699646|Active Comparator|Neoventa S 21 ST-ANalysis of fetal heart|intrapartum surveillance with CTG + STAN
10023863|NCT01699672|Experimental|Group and Individual information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
9802901|NCT04834557|Experimental|Ursodeoxycholic acid (UDCA)|Participants in this arm will receive ursodeoxycholic acid (UDCA) 500 mg/day + DMARDs for 24 weeks.
10023864|NCT01699672|No Intervention|Individual information|Standard information about disease and treatment from doctor and nurse given at 2 occasions.
10023865|NCT01699711|Active Comparator|Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
10023866|NCT01699711|Placebo Comparator|Placebo|No active treatment is given.
10023867|NCT01699724|Active Comparator|JZoloft|Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft ® tablet) 50 mg as a single oral dose under fasted conditions
10023868|NCT01699724|Experimental|ODT without water|sertraline ODT 50 mg without water as a single oral dose under fasted conditions
10023869|NCT01699724|Experimental|ODT with water|sertraline ODT 50 mg with water as a single oral dose under fasted conditions
10023870|NCT01699776|Active Comparator|Ivabradine|Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
10023871|NCT01699776|Active Comparator|Digoxin|Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.
10023872|NCT01699802|Experimental|Inhaled anaesthetic agent|The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
10023873|NCT01699828|Experimental|Buspirone 120 mg|Buspirone 120 mg (encapsulated).
10023874|NCT01699828|Experimental|Buspirone 60 mg|Buspirone 60 mg (encapsulated)
10023875|NCT01699828|Placebo Comparator|Placebo|Placebo (encapsulated)
10023876|NCT01699828|Experimental|Buspirone 30 mg|Buspirone 30 mg (encapsulated).
10023877|NCT01699841||HIV+ and HIV- mothers and their infants|
10023878|NCT01699854|Active Comparator|capsaicin patch|
10023879|NCT01699854|Placebo Comparator|placebo patch|
10023880|NCT01699880||conventional high FiO2 bag reservoir facemask|this group of patients is intubated according to our current practice that requires the use of a high FiO2 nonrebreathing with bag reservoir facemask to ensure preoxygenation in patients requiring tracheal intubation. a small nasal catheter is inserted just before laryngoscopy to ensure a low oxygen flow to allow oxygenation during laryngoscopy.
10036618|NCT01817348|Experimental|Lidocaine group|"1% lidocaine 5ml intra-articular injection to shoulder joint + physiotherapy three times weekly~Injection is performed if pain during intervention equals to or greater than 7cm in a 10-cm VAS scale.~Injection frequency is not greater than twice per week and total injection time is limited to 10 times in the whole course~In each week, patient will receive 3 times of PT with or without intra-articular lidocaine injection."
10036619|NCT01817348|Placebo Comparator|PT group|- Apply to every patient, each by the same physical therapist, 3 times weekly for 3 months or till the patients gain satisfactory results.
9479664|NCT03540979|Experimental|Letrozole|Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
9479665|NCT03540966|Experimental|Group A|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies plus CapulinTM on-demand treatment period
9479666|NCT03540966|Placebo Comparator|Group B|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies on-demand treatment period
9479667|NCT03540953|Other|Endoscopic injection of Mitomycin C|Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer
9479668|NCT03540940|Experimental|zero positive end expiratory pressure|
9479669|NCT03540940|Experimental|Positive end expiratory pressure|
9517178|NCT03308734|Experimental|Exercise Intervention Group|Reduced-Exertion High-Intensity Interval Training Following baseline testing, participants will start a 6-week training protocol involving reduced-exertion high-intensity training on a cycle ergometer based in a gym in Gloucestershire used by the Macmillan Cancer Support's Next Steps project.
10036620|NCT01817387|Experimental|PRIME + CT|4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
10023881|NCT01699880||high flow nasal cannula oxygen|we wish to change our standard practice of preoxygenation and expand our use of high flow nasal cannula oxygen therapy to the tracheal intubation setting. Currently, used of high flow oxygen nasal cannula oxygen therapy to ensure oxygenation during intubation is limited to the patients already under high flow nasal cannula oxygen. the change of practice consists in the systematic use of high flow nasal cannula oxygen therapy in all patients requiring tracheal intubation in the ICU.
10023882|NCT01699893|Experimental|unique arm|"At V0: 1500 will be screened~At V1: 1000 subjects will be performed following samples: blood, nasal swab,stool. 500 subjects among 1000 will be performed one additional sample (Skin Biopsy)~At V2: only the 500 subjects having performing the skin biopsy at V1 will come at V2 to perform blood, nasal swab and stool samples"
10023883|NCT01699906|Experimental|Dietary intervention|Diet regimen to induce weight loss
10023884|NCT01699919|Active Comparator|intravenous lignocaine|Intravenous lignocaine will be given as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr throughout surgery and till one hour post surgery.
10023885|NCT01699919|Placebo Comparator|normal saline|Normal saline will be given as a bolus at the time of intubation and saline infusion given to patients in the control group during the surgery and till one hour post surgery.
10023886|NCT01699932|Experimental|Arm 1|24-week treatment period: starting dose will be of 2/1000 mg or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M® ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M® , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
10023887|NCT01699945||Verbal Autopsies|The study involves filling of verbal autopsies for still births and deaths in women of reproductive age group.
9528731|NCT03208283|Active Comparator|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
10023888|NCT01699958|Experimental|Problem-solving intervention|2 individual sessions teaching problem-solving skills with the use of videos, handouts, and worksheets.
10023889|NCT01699958|No Intervention|Control: Standard Care|Control arm participants will receive standard of care from their primary care provider.
10023890|NCT01699971|Active Comparator|Lichtenstein|Hernia repair with lichtenstein propylene mesh
10023891|NCT01699984||Hospitalized patients|All patients hospitalized in 4 inpatient facilities in Northern Italy during 4 index-months.
10023892|NCT01699997|Experimental|Oxytocin|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of OXT Spray, which contains approximately 40 international units (IU) of OXT
10023893|NCT01699997|Placebo Comparator|Placebo vial|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of placebo Spray, which contains all OXT Spray ingredients except for oxytocin.
10023894|NCT01700010|Experimental|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
9528732|NCT03208309|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
9528733|NCT03208309|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
10023895|NCT01700023||patients with leg-edema|patients with decompensated heart failure presenting with leg-edema
10023896|NCT01700062|Experimental|Medium calorie|
9528734|NCT03208244|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet
10023897|NCT01700062|Experimental|standard calorie|
10023898|NCT01700075|Active Comparator|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
10023899|NCT01700075|Experimental|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
10023900|NCT01700088||Oxygen cannular|After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes
10023901|NCT01700127|Other|Breastfeeding|Breastfeeding Encouraged
10023902|NCT01700127|Active Comparator|Breastfeeding Withheld|Breastfeeding Withheld
10023903|NCT01700153|Experimental|Experimental: Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of robotic-assisted therapy.
10023904|NCT01700153|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of classical rehabilitation.
10023905|NCT01700166|Experimental|Biologic; Cord Blood Stem Cells; Intravenous injection|Autologous Human Umbilical Cord Blood derived Stem Cell injection
10023906|NCT01700218|Other|telemonitoring|patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
10023907|NCT01700218|Other|control|patients in the control arm will not record any vital parameter
10023908|NCT01700231||Liver resection ,Liver Dysfunction|100 patients will be monitored perioperatively, in a subset of 40 patients hepatic venous pressure gradient will be monitored
10023909|NCT01700244|Experimental|Pacemaker|
10023910|NCT01700257|Other|CT scan & Early CDT Lung test|Every study participant receives a CT scan & Early CDT-Lung test (biomarker blood test) for lung cancer screening purposes.
10023911|NCT01700270|Experimental|dovitinib (TKI258)|dovitinib, 5 days on / 2 days off dose schedule
10023912|NCT01700283|Experimental|exercise education and walking program|
10023913|NCT01700283|No Intervention|maintain their daily activity|
10023914|NCT01700296|No Intervention|Standard Care|"Standard Care: finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP. In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic. The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the Best care group"
10036621|NCT01817387|Experimental|Daily Goals + CT|4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training
10023915|NCT01700296|Experimental|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
10023916|NCT01700309|No Intervention|Control group|Treatment as usual
10023917|NCT01700309|Experimental|Young and Active|This arm will recieve web-based health counselling through the web-site Young and Active.
10023918|NCT01700322|Active Comparator|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
10023919|NCT01700322|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
10023920|NCT01700322|Active Comparator|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
10023921|NCT01700361||No treatment|This is an observational study. Women in this study are not receiving any treatments.
10023922|NCT01700374||Women without Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 0 or 1 adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
10023923|NCT01700374||Women with Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 2 or more adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
10023924|NCT01700400|Experimental|Experimental Phase I Dose Escalation|"Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3~Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3~Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3~Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3"
10023925|NCT01700413|Experimental|Idarubicin|Cohort 1: Idarubicin 14 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 2: Idarubicin 16 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 3: Idarubicin 18 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day
10023926|NCT01700426|Active Comparator|iron|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
10023927|NCT01700426|Active Comparator|iron 2|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
10023928|NCT01700452||patients suspected of having lung cancer|Subjects presenting with 0.8 - 3 cm solitary pulmonary nodules with high probability for malignance. The subject must be scheduled for a lung biopsy procedure to determine clinical diagnosis.
10023929|NCT01700465||Hemodialysis|Patients undergoing hemodialysis
9517179|NCT03308734|No Intervention|Control Group|Following baseline testing, participants will receive usual care only.
10023930|NCT01700478|Experimental|Misoprostol + vasopressin, Vasopressin|Misoprostol 400ug given rectally one hour before surgery.
10023931|NCT01700491|Active Comparator|Epidural Catheter 0.2% ropivacaine|Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
10023932|NCT01700491|Active Comparator|Paravertebral Catheter 0.4% ropivacaine|Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.
10023933|NCT01700504|Experimental|Gentamicin lavage|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
10023934|NCT01700504|Active Comparator|Normal saline lavage|Patients undergoing 2 axillary lavages with 500ml of normal saline
10023935|NCT01700543||1|Patients indicated for hemi or total shoulder arthroplasty with good bone stock who fulfill all inclusion and none of the exclusion criteria.
10023936|NCT01700556|Active Comparator|Usual Care|"150 patient-caregivers will receive a light support in the form of paper brochures and 3 preventive home visits by a nurse"
10023937|NCT01700556|Experimental|UP Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker and receiving 3 preventive home visits by a nurse
10023938|NCT01700556|Experimental|UP-TECH Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker, receiving an intervention based on assistive technologies and 3 preventive home visits by a nurse
10023939|NCT01700569|Experimental|Folinic Acid|"Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a 3x3 method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg."
10023940|NCT01700582||Patients with advanced lung cancer|Patients with advanced lung cancer
10023941|NCT01700595|Experimental|new technical intervention|''new technical intervention'' represents the surgical procedure which is applied for the patients assigned to this group because of their certain characteristics. Namely, pediatric patients with broad axillary, anterior chest wall, mammary and neck scars are treated with this surgical approach.
10023942|NCT01700608||plerixafor treated patients|lymphoma and myeloma patients
10023943|NCT01700634||OA patients with HIGH central sensitization|Central sensitization will be defined by the presence of both spreading sensitization and temporal summation to repeated pressure pain stimulation (Arendt-Nielsen et al. 2010, Graven-Nielsen et al. 2010, Woolf 2010, Imamura et al. 2008, Nijs et al. 2010).
10023944|NCT01700634||OA patients with LOW central sensitization|
10023945|NCT01700634||Control subjects|
10023946|NCT01700647||smoking controls|patients referred for bronchoscopy who have detailed axamination and do not have any dysplasia proven by bronchoscopy and laryngoscopy Breath test- sampling using ENose
10023947|NCT01700647||In Situ carcinoma larynx|Biopsy proven in situ carcinoma larynx proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
10023948|NCT01700647||Advanced Larynx Cancer|Biopsy proven stage 3/4 larynx cancer proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
10023949|NCT01700660||VIO|Patients operated under VIO.
10023950|NCT01700660||Control|Patients operated without VIO.
10023951|NCT01700686||Obese subjects|Meal test and dexa scan
10023952|NCT01700699||Sorafenib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sorafenib
10023953|NCT01700699||Axitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Axitinib
10023954|NCT01700699||Pazopanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Pazopanib
10023955|NCT01700699||TKI|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with different type of tyrosine kinase inhibitor
10023956|NCT01700699||Motesanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Motesanib
10023957|NCT01700699||Sunitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sunitinib
10023958|NCT01700712|Active Comparator|L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU|2 tablets a day for 2 weeks
10023959|NCT01700712|Placebo Comparator|Sugar pill|2 tablets a day for 2 weeks
10023960|NCT01700738|Experimental|gastric ring surgery|in this group a gastric ring will be put by surgery.
10023961|NCT01700738|Active Comparator|nutritional help|the usual treatment of obesity in France with nutritional care will be dispensed for this arm
10023962|NCT01700751|Experimental|Dose Level 0 (starting dose)|brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
10023963|NCT01700751|Experimental|Dose Level 1|brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
10023964|NCT01700751|Experimental|Dose Level 2|brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
10023965|NCT01700751|Experimental|Dose Level 3|brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
9528735|NCT03208296|Experimental|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
10023966|NCT01700751|No Intervention|Control Dose Level|The first 3 patients will not receive brentuximab vedotin.
10023967|NCT01700777|Experimental|Intensive rehab group|"A group of children will beneficiate of HABIT-ILE treatment in an intensive way (camp) for 90h."
10023968|NCT01700777|Active Comparator|Regular treatment group|A group of children with hemiplegic cerebral palsy will beneficiate from conventional training at a regular frequency (1 to 6 hours / week) for 90hours.
10023969|NCT01700790|Experimental|Lopinavir/ritonavir and ritonavir|Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.
10023970|NCT01700803|Experimental|Povidone Iodine 10%|Using Povidone Iodine 10% hand scrub before caesarian section
10023971|NCT01700803|Experimental|Povidone Iodine 7.5% hand scrub|Using Povidone Iodine 7.5% hand scrub before caesarian section
10023972|NCT01700855|Experimental|Electroacupuncture|Patients received electroacupuncture stimulation
10023973|NCT01700855|Sham Comparator|Non-electroacupuncture|Patients received sham electroacupuncture
10023974|NCT01700868|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
10023975|NCT01700868|Active Comparator|American Diabetes Association guidelines|Participants will follow ADA diet according to ADA regulations. This group will also receive weekly nutrition classes.
10023976|NCT01700881|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
9517180|NCT03308708|No Intervention|Control group|
9517181|NCT03308708|Experimental|NE group|
10023977|NCT01700881|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
10023978|NCT01700894|Experimental|Walking Program + motivational interviewing calls|"The Women's Walking Program (WWP) core included a lifestyle PA prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every week for 5 weeks in the 1st 24 weeks and 1 3 months later) targeted to increase lifestyle PA in AA women.~Participant in the WWP plus motivational interviewing telephone call arm receives 11 motivational interviewing telephone calls from an interventionist, with two calls in between each of the group-visits. Motivational interviewing calls are tailored to the individual and intended to sustain intervention effects between group-visits"
10023979|NCT01700894|Experimental|Walking Program + automated calls|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP plus automated telephone call arm receive 11 automated calls with two calls sent between each group-visit. The automated calls are intended to supplement and sustain the intervention effects of the group-visits."
10023980|NCT01700894|Experimental|Walking Program|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP receive no telephone calls."
10023981|NCT01700920|Experimental|Mesenchymal Stem Cell|"Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.~Pharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
10023982|NCT01700933|Active Comparator|High-dosage-group|
10023983|NCT01700933|Active Comparator|Low-dosage-group|
10023984|NCT01700946|Active Comparator|Standard Risk|"Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
10023985|NCT01700946|Active Comparator|High Risk|"Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
10023986|NCT01700972|Experimental|Imaging at 10-minute vs. 30-45-minutes|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
10023987|NCT01700998|Placebo Comparator|Placebo|250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr for 3 days repeated during ICU stay if hypomagnesemia occurs.
10023988|NCT01700998|Experimental|Magnesium|48 mEq Magnesium diluted in 250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr. Therapy is continued for 3 days and repeated if hypomagnesemia occurs during ICU stay
10023989|NCT01701050||Blood collection|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
10023990|NCT01701076|Experimental|Bendamustine|All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
10023991|NCT01701089|Experimental|RO4602522 Group 1|
10023992|NCT01701089|Experimental|RO4602522 Group 2|
10023993|NCT01701128|Experimental|Speed TT|Walk on treadmill with progressive increases in speed
10023994|NCT01701128|Experimental|Mixed TT|Walk on treadmill with progressive increases in speed and incline
10023995|NCT01701128|Active Comparator|Control|Light-intensity exercise group, work flexibility and coordination
10023996|NCT01701141||Individuals with MDD|Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.
10023997|NCT01701141||Healthy Controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment
10023998|NCT01701154||Pompe|Adults and children with Pompe disease.
10023999|NCT01701180|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
10024000|NCT01701180|Placebo Comparator|Placebo|Intranasal application, sodium chloride solution, 3 puffs per nostril
9517182|NCT03308682|Experimental|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
10024001|NCT01701206|Experimental|HIV intervention Group|Experimental arm receives peer-led HIV information on social media
10024002|NCT01701206|No Intervention|Control arm|
10024003|NCT01701219|Other|Cohort A|S. aureus on at least 1 blood culture within 72 hours of beginning study drug
10024004|NCT01701219|Other|Cohort B|MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment
10024005|NCT01701232|Active Comparator|MabThera|Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
10024006|NCT01701232|Experimental|BCD-020|Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
10024007|NCT01701284|Experimental|Right-Sided Low-Frequency rTMS|Participants will have rTMS administered at 1Hz to the right dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
10024008|NCT01701284|Experimental|Left-Sided High-Frequency rTMS|Participants will have rTMS administered at 10Hz to the left dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
10024009|NCT01701297|Active Comparator|Co-trimoxazole|Co-trimoxazole 960mg daily po
10024010|NCT01701297|Experimental|VSL#3 active|VSL#3 active 2 sachets/daily
10024011|NCT01701297|Placebo Comparator|VSL#3 placebo|VSL#3 placebo 2 sachets/daily
10024012|NCT01701310|Experimental|Ferric carboxymaltose|
10024013|NCT01701310|Active Comparator|Ferrous Sulphate|
10024014|NCT01701323|Experimental|Treatment (Ex-vivo expanded cord blood progenitors)|Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
10024015|NCT01701336|Experimental|Unique Arm|"Ad6NSmut~MVA-NSmut~15 subjects receiving 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination"
10024016|NCT01701349|Active Comparator|Fosbretabulin + paclitaxel + carboplatin|"Six 21 day cycles of:~Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2"
10024017|NCT01701349|Placebo Comparator|Placebo + paclitaxel + carboplatin|"Six 21-day cycles of:~Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2"
10024018|NCT01701388|Experimental|Ekso Safety and Efficacy|Observational study on the first time use of a robotic exoskeleton.
10024019|NCT01701427||1|1. Healthy, un-operated, groin-hernia free, pain-free and medicinal free males
10024020|NCT01701453|Experimental|6 months group|6 months duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
10024021|NCT01701453|Experimental|12 months or longer group|12 months or longer duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
10024022|NCT01701466|Experimental|Arm B: standard of care plus NeoVIDERM cream|Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
10024023|NCT01701466|Active Comparator|Arm A: standard skin care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
10024024|NCT01701479|Experimental|Experimental arm|"Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).~A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
10024025|NCT01701479|Active Comparator|Comparator arm|"A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
10036622|NCT01817400|Experimental|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
10036623|NCT01817400|Experimental|Anti-inflammatory treatment|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
10024026|NCT01701492||Stem Cell Transplant Survivors|All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
10024027|NCT01701492||Normal control participants|Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
10024028|NCT01701518|Other|Ozurdex|Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
10024029|NCT01701531|Experimental|RBCPF|Treatment intervention arm
10024030|NCT01701544|Sham Comparator|NBM DBS Off|NBM DBS switched off
9517183|NCT03308656||Induced labor in term pregnancies|100 singleton nulliparous patients are planning to complete the study period. Study group constitute of third trimester pregnancies between 37-40 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
10024031|NCT01701544|Active Comparator|NBM DBS On|NBM DBS Switched On
10024032|NCT01701557|Active Comparator|slow fluid rate|bolus 10 ml/kg of NS followed by 1.25 times maintenance rate
10024033|NCT01701557|Active Comparator|Fast fluid rate|bolus 20 ml/kg of NS followed by 1.5 times maintenance rate
10024034|NCT01701570|Active Comparator|An Active Comparator exercise training intervention|The Active Comparator Groupwill participate in an exercise training intervention to distinguish the relative roles of objective factors (lactate level) and subjective factors (self-efficacy) in mediating pre-post change in RPE during low, moderate, and vigorous exercise.
10024035|NCT01701570|Placebo Comparator|A Placebo Attention Control|The placebo attention control group will receive monthly diabetes education and phone calls phone calls to monitor their blood glucose levels. Participants will receive an accelerometer to wear for one week.
10024036|NCT01701583|Experimental|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
10024037|NCT01701596|Experimental|Rotational atherectomy (RA)|Immediate rotational atherectomy (RA) in the treatment with nondilatable calcified lesion complicated by coronary dissection
10024038|NCT01701596|Active Comparator|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
10024039|NCT01701609|Experimental|Cognitive Remediation Therapy|CRT: Frontal/Executive Program. The program has a duration of 40 sessions, with two session for week. Is is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
10024040|NCT01701635|Experimental|Disclosure intervention|In the disclosure intervention plus usual care arm the adherence and disclosure specialist will meet with caregiver at each clinic visit and provide information, education, disclosure skills, and support till disclosure occurs.
10024041|NCT01701635|Active Comparator|Usual care|"In the enhanced usual care (control) arm the disclosure specialist will meet with caregiver at each clinic visit and provide them will general health education and no mention or effort will be made to improve disclosure skills of caregiver."
10024042|NCT01701648|Active Comparator|1|
10024043|NCT01701661|Active Comparator|conservative treatment|Compression stockings class II
10024044|NCT01701661|Active Comparator|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refloating trunk
10024045|NCT01701687||Decompensated Alcoholic Cirrhosis|Recruited patients will have diagnosed liver cirrhosis (histological, radiological or accepted clinical parameters)admitted with an episode of decompensation. Patients must still be drinking hazardous alcohol quantities (>14 units for women, >21 units for men) at study enrollment
10024046|NCT01701700|Experimental|portable electronic magnifier|Use of a prescribed electronic magnifier plus existing optical aids for a period of 2 months
9517184|NCT03308643|Experimental|Oxytocin infusion|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
10024047|NCT01701700|Active Comparator|optical aids|Use of existing optical aids for 2 months
10024048|NCT01701713|Experimental|TDCS - DKI ED2011|TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues
10024049|NCT01701713|Sham Comparator|Sham-TDCS|Sham-TDCS session is followed by a behavioral naming therapy with different cues
10024050|NCT01701726|Experimental|Acupuncture|Two types of acupuncture are given, one is acupuncture at affected meridian points, the other is at non-affected. For the first type, We select the acupoints from the affected meridians.Patients in this group are divided into two subgroups according meridian syndrome differentiation(jue-yin style,yang-ming style).Patients pertaining to Jue-yin-style are treated with taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6) .Patients pertaining to Yang-ming-style: taichong(LR3), renying(ST9), zusanli(ST36), quchi(LI11). For the second,We select the acupoints from the non-affected meridians.Patients assigned into the non-affected meridian acupuncture group will be treated with Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), xuehai (SP10).
10024051|NCT01701726|Sham Comparator|Sham acupuncture|"we use sham acupoints:~The edge of the tibia (1-2cm lateral and horizontal to the zusanli (ST36))~Half way between the tip of the elbow and the axilla~On the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.~2cm superior to fu tu(LI18)"
10024052|NCT01701726|No Intervention|Waiting list|Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
10024053|NCT01701739|Experimental|aleglitazar / digoxin|
10024054|NCT01701752|Active Comparator|Group 1|Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
10024055|NCT01701752|Active Comparator|Group 2|Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
10024056|NCT01701752|Active Comparator|Group 3|Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
10024057|NCT01701752|Active Comparator|Group 4|Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
10024058|NCT01701752|Active Comparator|Group 5|Day 1: Adjuvant + TIV ; Day 29: Placebo
10024059|NCT01701752|Active Comparator|Group 6|Day 1: Placebo + TIV ; Day 29: Placebo
10024060|NCT01701765||Patients in residential facilities|All patients staying in September 2010 in 23 medium-long term RFs of the St John of God Order in Northern Italy with a primary psychiatric diagnosis and younger than 65 years recruited.
9517185|NCT03308643|Placebo Comparator|Placebo|Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.
9517186|NCT03308630|Experimental|Energy Alignment and Mantra|
9517187|NCT03308604|Experimental|Patients with locally advanced cervical cancer|
10024061|NCT01701778|Experimental|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
10024062|NCT01701778|Experimental|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg~Anesthesia was induced and maintained with sevoflurane"
10024063|NCT01701778|Placebo Comparator|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
10024064|NCT01701791|Experimental|Computerized Decision Support System (CDSS)|GPs will use a CDSS with treatment algorithms, supervision from a consultant psychiatrist, and despatch to patients of reminders via mobile texting or automatic mobile (or landline) phone calls to improve adherence to the treatment prescribed.
10024065|NCT01701791|No Intervention|Treatment as usual|GPs will provide TAU, will make their own decisions and will therefore not use the CDSS. Patients will not receive any reminders.
10024066|NCT01701804||integrative treatment|
10024067|NCT01701817||Patients with Atrial Fibrillation (AF)|(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
10024068|NCT01701830||Case Group|Patients with chronic kidney disease of stage 3-4.
10024069|NCT01701830||Control group|30 healthy subject
10024070|NCT01701843|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
10024071|NCT01701843|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)
10024072|NCT01701856|Experimental|Interferon beta-1b|Interferon beta-1b 250 mcg s.c. every other day
10024073|NCT01701869||NTHi positive|No intervention, this is an observational study
10024074|NCT01701869||NTHi negative|No intervention, this is an observational study
10024075|NCT01701869||Healthy Control|No intervention, this is an observational study
10024076|NCT01701882|Experimental|tenofovir/emtricitabine/rilpivirine|A one pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
10024077|NCT01701921|Experimental|Pregabalin 75|Pregabalin 75mg by mouth one hour before surgery
10024078|NCT01701921|Active Comparator|Pregabalin 150|Pregabalin 150mg by mouth one hour before surgery
10024079|NCT01701921|Placebo Comparator|Sugar pill|Placebo : Sugar pill manufactured to mimic pregabalin capsule by mouth one hour before surgery
10024080|NCT01701934|Experimental|Roflumilast|Roflumilast 500 mcg, once daily for 6 months
10024081|NCT01701934|Placebo Comparator|Placebo pill|Placebo pill, once daily for 6 months
10024082|NCT01701960||Group 1|This cohort will be injected with 1% lidocaine with 1:100,000 of epinephrine into the nasal mucosa at the time of nasal surgery
10024083|NCT01701960||Group 2|This group will be injected with 1% lidocaine with 1:200,000 of epinephrine into the nasal mucosa at the start of nasal surgery.
10024084|NCT01702012|Experimental|Almased Meal Replacement Powder|Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
10024085|NCT01702012|Active Comparator|Lifestyle Intervention|Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
10024086|NCT01702038|Experimental|Rituximab|Participants will receive an intravenous infusion of rituximab on Days 0 and 14
10024087|NCT01702051||1|patients with chronic pancreatitis treated with total or subtotal pancreatectomy
10024088|NCT01702051||2|patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
10024089|NCT01702051||3|patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
10024090|NCT01702051||4|patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck
10024091|NCT01702064|Experimental|Nilotinib with Ruxolitinib|"The starting dose of ruxolitinib will be 5mg by mouth (PO) twice a day (BID) and will increase by 5 mg increments in each cohort, to a maximum dose of 15 mg PO BID. Nilotinib will be given at a dose ranging from 300 mg PO BID to 400 mg PO BID, depending on the participant's dose prior to enrollment on the trial.~Dose Level 1: Ruxolitinib 5 mg twice a day (BID); Nilotinib 300 mg or 400 mg BID.~Dose Level 2: Ruxolitinib 10 mg BID; Nilotinib 300 mg or 400 mg BID.~Dose Level 3: Ruxolitinib 15 mg BID; Nilotinib 300 mg or 400 mg BID."
10024092|NCT01702077|Experimental|Neurofeedback first|Neurofeedback then sham feedback
10024093|NCT01702077|Experimental|Sham first|Sham feedback then neurofeedback
10024094|NCT01702090|Experimental|TMC114/ritonavir|
10024095|NCT01702103|Experimental|Mometasone|Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
10024096|NCT01702103|Active Comparator|Nasonex®|Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
10024097|NCT01702116|Experimental|extralevator APR|"This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
10024098|NCT01702116|Active Comparator|standard APR|conventional abdominoperineal resection (APR)
10024099|NCT01702129|Experimental|anti-EGFR Immunoliposomes|anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.
10024100|NCT01702142||NIATx Only|NIATx (Network for the Improvement of Addiction Treatment) organization change model only
10024101|NCT01702142||NIATx and Advancing Recovery|Organizational and system changes
10024102|NCT01702155|Experimental|DFP-10917|"7-day continuous infusion (in the vein): Starting dose 4 mg/m^2~14-day continuous infusion (in the vein): Starting dose 10 mg/m^2~Phase II Only: 6 mg/m^2 for the 14-day continuous infusion (in the vein)"
10024103|NCT01702168||CBT Training|
10024104|NCT01702181|Placebo Comparator|Placebo|Matching placebo.
10024105|NCT01702181|Active Comparator|Tacrolimus|Tacrolimus 0.1% ointment twice daily for 28 days.
10024106|NCT01702181|Experimental|OPA-15406|
10024107|NCT01702194|Experimental|TD-1211 IV [C14]|TD-1211 IV [C14]
10024108|NCT01702194|Experimental|TD-1211 PO [C14]|TD-1211 PO [C14]
10024109|NCT01702207|Active Comparator|Once Daily Tacrolimus|Treatment Arm - Subjects are switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
10024110|NCT01702207|Active Comparator|Twice Daily Tacrolimus|Control Arm - Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
10024111|NCT01702220|Experimental|CBT|
10024112|NCT01702220|Active Comparator|Enhanced Community Care (ECC)|
10024113|NCT01702272||Dengue Virus|
10024114|NCT01702285|Experimental|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
10024115|NCT01702324|Experimental|DD-25|A concentration of 0.025% of topical DD-25 cream.
10024116|NCT01702337||HPV-1 Group|Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.
10024117|NCT01702337||HPV-2 Group|Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.
10024118|NCT01702350|Experimental|Study Drug Formulation A|Enterric Coated Tablet Formulation of GSK2251052
10024119|NCT01702350|Experimental|Study Drug Formulation B|Modified Release Table Formulation of GSK2251052
10024120|NCT01702350|Experimental|Study Drug Formulation C|Enterric Coated Powder for Oral Suspension Formulation of GSK2251052
10024121|NCT01702350|Experimental|Study Drug Formulation D|Immidiate Release Table Formulation of GSK2251052
10024122|NCT01702350|Experimental|Study Drug Formulation E|Oral Solution Formulation of GSk2251052
10024123|NCT01702376|Experimental|Retosiban 100 mg|Each subject will be randomized to single dose of retosiban 100 mg in one of the four treatment sequences.
10024124|NCT01702376|Experimental|Retosiban 800 mg|Each subject will be randomized to single dose of retosiban 800 mg in one of the four treatment sequences
10024125|NCT01702376|Placebo Comparator|Placebo|Each subject will be randomized to single dose of matching placebo in one of the four treatment sequences
10024126|NCT01702376|Active Comparator|Moxifloxacin 400 mg|Each subject will be randomized to single dose of moxifloxacin 400 mg in one of the four treatment sequences
10024127|NCT01702389|Experimental|Remifentanil|The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.
10024128|NCT01702402|Experimental|Intervention Arm|Intervention activities will include behaviour change communications on healthy timing and spacing of pregnancy, couples counselling, social networking and expansion of contraceptive options for postpartum women, including provision of oral contraceptive pills and condoms in the home.
10024129|NCT01702402|Other|Comparison|A comparison area received standard government health services.
10024130|NCT01702415|Placebo Comparator|Placebo|Placebo
10024131|NCT01702415|Experimental|Zoledronic acid|Active IMP
10024132|NCT01702467|Experimental|GSK2647544|The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).
10024133|NCT01702467|Placebo Comparator|Placebo|Matching placebo
10024134|NCT01702480|Experimental|Part 1: GSK2981710 10 gram (g)|Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.
10024135|NCT01702480|Experimental|Part 1: GSK2981710 20 g|Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.
10024136|NCT01702480|Experimental|Part 1: GSK2981710 30 g|Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.
10024137|NCT01702480|Experimental|Part 1: GSK2981710 40 g|Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.
10024138|NCT01702480|Placebo Comparator|Part 1: Placebo|Eight subjects will receive single dose of matching placebo daily for 14 days.
10024139|NCT01702480|Experimental|Part 2: GSK2981710 (dose to be decided from Part 1)|The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.
10024140|NCT01702480|Placebo Comparator|Part 2: Placebo|The subjects will receive single dose of matching placebo daily for 14 days..
10024141|NCT01702493|Active Comparator|Part 1: Cap SRT2104|500 mg SRT2104 (in the form of two, 250 mg capsules) will be administered as a single oral dose in the fasting state
10024142|NCT01702493|Experimental|Part 1: Tab SRT2104 (slow release)|500 mg SRT2104 (in the form of two, 250 mg slow release tablets) will be administered as a single oral dose in the fasting state.
10024143|NCT01702493|Experimental|Part 1: Tab SRT2104 (intermediate release)|500 mg SRT2104 (in the form of two, 250 mg intermediate release tablets) will be administered as a single oral dose in the fasting state.
10024144|NCT01702493|Experimental|Part 1: Tab SRT2104 (fast release)|500 mg SRT2104 (in the form of two, 250 mg fast release tablets) will be administered as a single oral dose in the fasting state.
10024145|NCT01702493|Experimental|Part 2A: SRT2104 500 mg single-dose|500 mg SRT2104 (formulation selected from Part 1) will be administered as a single oral dose in the fed state.
10024146|NCT01702493|Experimental|Part 2B: SRT2104 single alternative dose|An alternative dose (other than 500 mg, but not to exceed 2000 mg) of SRT2104 (formulation selected from Part 1) will be administered as a single oral dose.
10024147|NCT01702493|Experimental|Part 2C: SRT2104 500 mg daily for 7 days|500 mg SRT2104 (formulation selected from Part 1) will be administered daily for 7 days.
10024148|NCT01702506|Experimental|Fasted|Dacomitinib administered under fasted conditions
10024149|NCT01702506|Experimental|Fed|Dacomitinib administered under fed conditions
10024150|NCT01702506|Experimental|Antacid|Dacomitinib administered under antacid treatment
10024151|NCT01702584||stent assisted embolization|stent assisted embolization of intracranial aneurysm
10024152|NCT01702597|Experimental|WBV|Patients will receive supervised physical therapy using a whole body vibration device (Galileo® Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 minutes per session, for 6 weeks.
10024153|NCT01702597|Active Comparator|Physiotherapy|Patient will receive the current gold standard treatment protocol: supervised physical therapy, twice a week, 30 minutes per session, for 6 weeks.
10024154|NCT01702610|Experimental|Temozolomide, Accelerated Hypofractionated RT|Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
10024155|NCT01702623|Active Comparator|Oxcarbazepine first, then Trileptal|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)
10024156|NCT01702623|Active Comparator|Trileptal first, then Oxcarbazepine|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period
10024157|NCT01702636|Active Comparator|Tranexamic Acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
10024158|NCT01702636|Placebo Comparator|Placebo|Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
10024159|NCT01702649|Experimental|RPX2003 (Biapenem)|Single and multiple dose of RPX2003 (Biapenem).
10024160|NCT01702649|Placebo Comparator|Normal Saline|Single and multiple doses of normal saline.
10024161|NCT01702662|Experimental|Photopill treatment|Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
10024162|NCT01702675|Experimental|ACH15 - 50mg capsule|ACH15 50mg capsule by mouth single dose (Group 1)
10024163|NCT01702675|Experimental|ACH15 - 250 mg capsule|ACH15 250mg capsule by mouth as single dose(Group 2)
10024164|NCT01702675|Experimental|ACH15 - 500mg capsule|ACH15 500mg capsule by mouth in a single dose(Group 3)
10024165|NCT01702675|Experimental|ACH15 - 1000 mg (two 500mg capsule)|ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
10024166|NCT01702675|Experimental|ACH15 - 2000 mg (four 500 mg capsule)|ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
10024167|NCT01702675|Experimental|ACH15 - 500 mg (twice a day for 7 days)|ACH15 500mg capsule by mouth twice a day for seven days (Group 6)
10024168|NCT01702675|Placebo Comparator|Placebo - 250 mg capsule|Placebo 250mg capsule by mouth single dose (Group 2)
10024169|NCT01702675|Placebo Comparator|Placebo - 500 mg capsule|Placebo 500mg capsule by mouth in a single dose(Group 3)
10024170|NCT01702675|Placebo Comparator|Placebo - 1000 mg (two 500mg capsule)|Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
10024171|NCT01702675|Placebo Comparator|Placebo 2000 mg (four 500mg capsule)|Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
10024172|NCT01702675|Placebo Comparator|Placebo - 500 mg (twice a day for 7 days)|Placebo 500mg capsule by mouth twice a day for seven days (Group 7)
10024173|NCT01702701|Active Comparator|Montelukast|patients will receive 10 mg po montelukast daily for 12 weeks.
10024174|NCT01702701|Active Comparator|Fluticasone|patients will receive 440mcg fluticasone po bid for 12 weeks
10024175|NCT01702714|Experimental|RO5083945 + carboplatin + paclitaxel|
10024176|NCT01702714|Experimental|RO5083945 + cisplatin +gemcitabine|
10024177|NCT01702727|Experimental|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
10024178|NCT01702727|Active Comparator|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
10024179|NCT01702727|Experimental|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
10024180|NCT01702740|Experimental|Part A, 1 mg/kg CNTO 136|
10024181|NCT01702740|Experimental|Part A, 4 mg/kg CNTO 136|
10024182|NCT01702740|Experimental|Part A, 10 mg/kg CNTO 136|
10024183|NCT01702740|Experimental|Part B, 10 mg/kg CNTO 136/placebo|
10024184|NCT01702753|Active Comparator|Bifidobacterium animalis subsp. lactis|
10024185|NCT01702753|Placebo Comparator|Placebo|
10024186|NCT01702766|Active Comparator|Bifidobacterium animalis subsp. lactis|
10024187|NCT01702766|Placebo Comparator|Placebo|
10024188|NCT01702779|Other|optiflow|
10024189|NCT01702779|Other|O2|
10024190|NCT01702792|Experimental|Tumor Vaccine|1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.
10024191|NCT01702818||HSDD group|Women with a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
10024192|NCT01702818||Control Group|Women without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
10024193|NCT01702831|Experimental|BuMel + lenalidomide Maintenance|I.V. Busulfan + I.V. Melphalan for conditioning prior ASCT, followed by Lenalidomide maintenance at day 100 after ASCT.
10024194|NCT01702857|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
10024195|NCT01702857|Experimental|TDENV-PIV AS03B|1 µg TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
10024196|NCT01702857|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
10024197|NCT01702857|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
10024198|NCT01702857|Experimental|TDENV-PIV AS01E|1 µg TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
10024199|NCT01702870||Suspected myositis|Participants with suspected myositis based on clinical criteria (Bohan and Peters criteria) referred for Magnetic resonance imaging
10024200|NCT01702870||Controls|Normal volunteers without myositis, who will undergo MR imaging to establish normal ranges of MR signal in health muscle
10024201|NCT01702974|Active Comparator|Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
10024202|NCT01702974|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
10024203|NCT01703052|Experimental|CHF 6001 SD or placebo|Single administration of CHF 6001 dose levels 1 to 7 or placebo
10024204|NCT01703052|Experimental|CHF 6001 MD or placebo|Multiple administration of CHF 6001 dose levels 1 to 5 or placebo
10024205|NCT01703078|Active Comparator|Ingenol mebutate gel 0.05%|once daily for two consecutive days
10024206|NCT01703078|Experimental|Ingenol derivative concentration 1|once daily for two consecutive days
10024207|NCT01703078|Experimental|Ingenol derivative concentration 2|once daily for two consecutive days
10024208|NCT01703078|Experimental|Ingenol derivative concentration 3|once daily for two consecutive days
10024209|NCT01703104|Active Comparator|Paludrine + Folic Acid|This arm uses routine drugs, Paludrine + Folic Acid
10024210|NCT01703104|Active Comparator|Paludrine + Folic Acid + Jobelyn|This group uses Paludrine + Folic Acid + Jobelyn
10024211|NCT01703130|Experimental|Local Anesthestic Dose|
10024212|NCT01703143|Experimental|Laser Ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
10024213|NCT01703156|Experimental|Non-Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a patient has contraindications to any medications, they will not be administered. If a statin contraindication exists, other cholesterol-lowering medications may be administered. Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
10024214|NCT01703156|Active Comparator|Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a statin contraindication exists, other cholesterol-lowering medications may be administered. All patients will undergo noninvasive stress testing. Results of individual stress tests will be reviewed by a cardiologist. Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered. Likewise, medical treatment may be adjusted.
10024215|NCT01703182||leg amputation|Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement
10024216|NCT01703195|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
10024217|NCT01703234|Experimental|Ramipril|
10024218|NCT01703247|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
10024219|NCT01703247|Active Comparator|PVI+GP|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
10036624|NCT01817400|Experimental|Insulin-lowering therapy|We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
10036625|NCT01817413|Active Comparator|Apexification with MTA|"The control group will receive:~Visit 1: root canal dressing with calcium hydroxide Visit 2: apexification with mineral trioxide aggregate (MTA), followed by obturation of the root canal with gutta percha.~Treatment will be carried out over two visits, two weeks apart."
10024220|NCT01703273|Experimental|low key intervention|
10024221|NCT01703273|Active Comparator|routine care|
10024222|NCT01703299||imipenem-treated patients|imipenem-treated patients
10024223|NCT01703299||ertapenem-treated patients|ertapenem-treated patients
10024224|NCT01703312|Experimental|QGE031|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.
10024225|NCT01703312|Active Comparator|omalizumab|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.
10024226|NCT01703312|Placebo Comparator|placebo|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).
10024227|NCT01703325|Active Comparator|triamcinolone injection (10 mg/ml)|"Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection"
10024228|NCT01703325|Active Comparator|Topical 0.05% clobetasol ointment|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months
10024229|NCT01703325|No Intervention|Controlled group|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group
10024230|NCT01703338||Lumbar spinal surgery|The study included participants who were diagnosed by a neurological surgeon and received lumbar surgery according to relevant imaging findings
10024231|NCT01703351|Experimental|Drug: 0.5% ropivacaine|
10024232|NCT01703351|Active Comparator|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|
10024233|NCT01703364|Experimental|Lenalidomide/Fludarabine/Rituximab|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
10024234|NCT01703390|Experimental|ERCC-1 low|modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
10024235|NCT01703390|Experimental|ERCC-1 high|FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
10024236|NCT01703416||1|
10024237|NCT01703429||Individuals with MS|
10024238|NCT01703442||Ovarian cancer patients|Perioperative primary epithelial ovarian cancer patients
9479670|NCT03540927|Experimental|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
9479671|NCT03540927|Active Comparator|Control|The control arm will receive a cash transfer only to support them in their businesses.
9479672|NCT03540914|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9479673|NCT03540914|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
10024239|NCT01703455|Experimental|Sorafenib 400 mg twice daily|Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
10024240|NCT01703468|Active Comparator|Oxcarbazepine then Trileptal|600 mg suspension
9528736|NCT03208296|Experimental|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
10024241|NCT01703468|Active Comparator|Trileptal then Oxcarbazepine|600 mg suspension
10024242|NCT01703481|Experimental|Part 1|Dose Escalation, Part 1: Participants will be enrolled in sequential cohorts to determine recommended Phase 2 doses (RP2D).
10024243|NCT01703481|Experimental|Part 2|Dose Confirmation, Part 2: Tumor biopsy cohorts will confirm RP2D.
10024244|NCT01703481|Experimental|Part 3, Cohort A|First dose expansion, Part 3: Participants with squamous non-small cell lung cancer.
10024245|NCT01703481|Experimental|Part 3, Cohort B|First dose expansion, Part 3: Participants with small cell lung cancer.
10024246|NCT01703481|Experimental|Part 3, Cohort C|First dose expansion, Part 3: Participants with breast cancer.
10024247|NCT01703481|Experimental|Part 3, Cohort D|First dose expansion, Part 3: Participants with solid tumors (consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme [GBM], ovarian or prostate).
10024248|NCT01703481|Experimental|Part 4, Cohort E|Second dose expansion, Part 4: Participants with non-small cell lung cancer.
10024249|NCT01703481|Experimental|Part 4, Cohort F|Second dose expansion, Part 4: Participants with solid tumors (consisting of one of the following: breast, urothelial, GBM).
10024250|NCT01703494|Active Comparator|Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal Microbiota Transplant (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
10024251|NCT01703494|Sham Comparator|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute severe C. difficile infection, subjects will receive a 300 mL infusion of a sham (autotransfusion) fecal solution at colonoscopy.
10024252|NCT01703546|Experimental|LAGB & LGCP|"All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB & LGCP).~The percent of Excess Body Weight Loss will be monitored at all post op visits."
10024253|NCT01703559|Placebo Comparator|Placebo|Administered once daily in both eyes for 15 days
10024254|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 0.5%|Administered once daily in both eyes for 15 days
10024255|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 1.0%|Administered once daily in both eyes for 15 days
10024256|NCT01703572|Experimental|OMP-52M51|
10024257|NCT01703585||metastatic breast cancer|
10024258|NCT01703585||metastatic colorectal cancer|
10024259|NCT01703585||metastatic gynecological cancer|
10024260|NCT01703585||metastatic melanoma|
10024261|NCT01703611|Experimental|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBPGN) (www.guidelines.gov)
10024262|NCT01703611|Active Comparator|Usual Nutrition Care|Visits for usual nutrition therapy (diet and lifestyle changes) provided by dietitians over a 12 month period.
10024263|NCT01703624|Experimental|glycopyrronium bromide 12.5mcg|glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
10024264|NCT01703624|Experimental|glycopyrronium bromide 25mcg|glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
10024265|NCT01703624|Experimental|glycopyrronium bromide 50mcg|glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
10024266|NCT01703624|Experimental|glycopyrronium bromide 100mcg|glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
10024267|NCT01703624|Placebo Comparator|placebo|placebo single dose via pressurised metered dose inhaler (pMDI)
10024268|NCT01703637|Experimental|Sitagliptin|Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks
10024269|NCT01703637|Experimental|Vildagliptin|Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks
10024270|NCT01703637|Experimental|Saxagliptin|Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks
10024271|NCT01703650||Resectable pancreas cancer|patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
10024272|NCT01703650||Locally advanced Pancreas cancer|Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
10024273|NCT01703676||Patients|Klinefelter Patients
10024274|NCT01703676||Parents|Parents of Klinefelter Patients
10024275|NCT01703676||Controls M|Healthy Male Control with normal karyotype
10024276|NCT01703676||Controls F|Healthy female controls
10024277|NCT01703689|Experimental|strong intervention group (SIG)|Nursing homes that received audit and feedback information on quality indicators and benefited of cooperative work meetings with hospital geriatricians
10024278|NCT01703689|Active Comparator|intervention group (LIG)|Nursing homes that only received audit and feedback information on quality indicators
10024279|NCT01703715||Patients aged 65 years and over|All patients aged 65 years and over admitted to acutely to medical wards
10024280|NCT01703728||Highly purified menotropin (HP-hMG) treatment|Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
10024281|NCT01703754|Experimental|Ad-RTS-hIL-12 and veledimex|Experimental study drug monotherapy arm (A)
10024282|NCT01703754|Experimental|Ad-RTS-hIL-12 and Palifosfamide|Study drug combination therapy arm (C)
10024283|NCT01703767||Gulf War 1 Veterans|Persian Gulf War 1 Veterans (GW1V) who are currently treated by a primary care physician at the VA Salt Lake City Health Care System. GW1V will assess their primary care satisfaction before and after their providers receive a Provider Education Workshop.
10024284|NCT01703780||resistant hypertension|blood pressure remaining above goal (< 140/90 mm Hg for the general population and < 130/80 mm Hg for patients with diabetes or renal disease) despite using optimal doses of 3 antihypertensive agents of different classes(including a diuretic) for half to one year.
10024285|NCT01703780||controllable hypertension|blood pressure can reach 130/80 mm Hg or less in half year by use of optimal dose of less than 3 antihypertensive agents of different classes
10024286|NCT01703780||healthy control|"Age>50 years old~Blood pressure ≤ 120/80 mm Hg( 24-hour blood pressure monitor or home blood pressure measurement at 6-9 am and 5-8pm, twice)~No cardiovascular diseases: coronary artery disease(coronary angiography or CTA), cerebrovascular diseases(history, MRI-Lacunar brain stem), Carotid ultrasound~No peripheral angiopathy (ABI<0.9 or lower extremity vessels Doppler ultrasound)~No major cardiovascular risk factors:~Dyslipidemia~Diabetes~Smoke within one year"
10024287|NCT01703793|Placebo Comparator|Vehicle|Vehicle (placebo) treatment, twice a week for four weeks.
10024288|NCT01703793|Experimental|Test Product 10156|Product 10156 treatment, twice a week for four weeks.
10024289|NCT01703793|Experimental|Test Product 49778|Product 49778 treatment, twice a week for four weeks.
10024290|NCT01703884|Experimental|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively.
10024291|NCT01703884|No Intervention|SP|At ANC and labor wards for women in the control area, there will be no change from routine approaches.
10024292|NCT01703897||Obese patients|
10024293|NCT01703910|Active Comparator|Arm A|Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.
9517188|NCT03308591|Experimental|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
10024294|NCT01703910|Experimental|Arm B|Treatment guided by the gene expression profiles obtained from the CTC
10024295|NCT01703936|Experimental|agricultural training program|Three to four month residential agriculture and life skills training program.
10024296|NCT01703936|No Intervention|Control group|
10024297|NCT01703962||Patients with IDH1 R132H or wild type IDH1/IDH2 glioma|
10024298|NCT01703975|No Intervention|Single training|Students training alone on the simulator
10024299|NCT01703975|Experimental|Training in pairs (Dyad Training)|Students training in pairs on the simulator
10024300|NCT01704001|Experimental|Renal impairment grade 0|
10024301|NCT01704001|Experimental|Renal impairment grade 1|
10024302|NCT01704001|Experimental|Renal impairment grade 2|
10024303|NCT01704001|Experimental|Renal impairment grade 3|
10024304|NCT01704014||α1-ARA Group|All patients on α1-ARA(α1-adrenergic receptor antagonists) medication who underwent cataract surgeries.
10024305|NCT01704014||Control Group|Age and sex-matched control subjects
10024306|NCT01704027|Experimental|Radiotherapy|Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation
10024307|NCT01704040|Experimental|Part 1: Healthy participants (CNTO 3157 + HRV-16)|
10024308|NCT01704040|Placebo Comparator|Part 1: Healthy participants (placebo + HRV-16)|
10024309|NCT01704040|Experimental|Part 2: Asthmatic patients (CNTO 3157 + HRV-16)|
10024310|NCT01704040|Placebo Comparator|Part 2: Asthmatic patients (placebo + HRV-16)|
10024311|NCT01704092||Group High-dose|Dexmedetomidine loading dose 1μg/kg Dexmedetomidine maintenance dose 0.6μg/kg/h
10024312|NCT01704092||Group Low-dose|Dexmedetomidine loading dose 0.6μg/kg Dexmedetomidine maintenance dose 0.3μg/kg/h
10024313|NCT01704092||Group Control|Dexmedetomidine loading dose and Dexmedetomidine maintenance dose were placed with the same amount of 0.9% saline as placebo
10024314|NCT01704105|Active Comparator|Water Quality|100 clusters, approximately 1,000 newborns
10024315|NCT01704105|Active Comparator|Sanitation|100 clusters, approximately 1,000 newborns
10024316|NCT01704105|Active Comparator|Handwashing|100 clusters, approximately 1,000 newborns
10024317|NCT01704105|Active Comparator|Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
10024318|NCT01704105|Active Comparator|Nutrition|100 clusters, approximately 1,000 newborns
10024319|NCT01704105|Active Comparator|Nutrition + Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
10024320|NCT01704105|No Intervention|Active control arm|200 clusters, approximately 2,000 newborns. Village-level promoter will visit household and will strictly engage in recording the child's MUAC, which will also be conducted in all active comparator arms as well.
10024321|NCT01704105|No Intervention|Passive control arm|100 clusters, approximately 1,000 newborns. No intervention.
10024322|NCT01704118|Experimental|I-gel|I-gel (Intersurgical Ltd, Wokingham, Berkshire, UK) is a disposable supraglottic airway device with a non-inflatable cuff in which part of that is fixed on glottis is made of thermoplastic elastomer, unlike other laryngeal masks
9517189|NCT03308591|Active Comparator|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
10024323|NCT01704118|Active Comparator|ProSeal Laryngeal mask|ProSeal laryngeal mask (PLMA) (LMA North America, Inc., San Diego, USA) is a modified type of LMA (larger and deeper bowl and enlarged and softer cuff) with gastric drainage tube.
10024324|NCT01704131||children > 6 months|children > 6 months of age
10024325|NCT01704131||children < 6 months|children < 6 months
10024326|NCT01704157|Other|Open Treatment|Treatment with Cryo-Touch III Device
10024327|NCT01704170|Experimental|Renal Denervation Using Externally Focused Ultrasound Therapy|
10024328|NCT01704222||Child in nursery|Children older than 3 months and less than 6 years kept in nurseries retained, regardless of the duration of custody of the child in the manger concerned.
10024329|NCT01704235||Primary health care providers|medical physicians and nurse practitioners
10024330|NCT01704248|Placebo Comparator|Routine self-instillation technique|The participants first use the Routine self-instillation technique for two weeks and then switch to the Eye Drop Guide technique for another two weeks.
10024331|NCT01704248|Experimental|Eye Drop Guide technique|The participants first use the Eye Drop Guide technique for two weeks and then switch to the Routine self-instillation technique for another two weeks.
10024332|NCT01704274|Placebo Comparator|Placebo|Placebo patch
10024333|NCT01704274|Experimental|Low dose GTN 0.0285 mg/hr|Low dose GTN
10024334|NCT01704274|Experimental|High Dose GTN 0.057 mg/hr|High Dose GTN
10024335|NCT01704300||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
10024336|NCT01704313|Experimental|Interrupted|Interrupted suturing technique used around heel of anastomosis
10024337|NCT01704313|Active Comparator|Continuous|Continuous suturing technique used for the anastomosis
10024338|NCT01704339|Experimental|QUTENZA|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
10024339|NCT01704352|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment consisting of sleep restriction therapy, psychoeducation about sleep, stimulus control, stabilizing circadian rhythm and challenging beliefs and perception of sleep.
10024340|NCT01704352|No Intervention|Treatment as usual|Treatment as usual (TAU) consists of pharmacological and supportive psychosocial treatment according to the needs of the patient.
10024341|NCT01704378|Experimental|BIAsp|
10024342|NCT01704391||Aortic aneurysm patients|10 patients with a CT verified diagnosis of aortic aneurysm demanding open elective surgical correction with insertion of vascular prosthesis
10024343|NCT01704391||Aortic occlusive disease patients|10 patients with CT verified aortic occlusive disease demanding open elective surgical correction with insertion of vascular prosthesis
10024344|NCT01704417|Experimental|IDeg followed by IGlar|
10024345|NCT01704417|Experimental|IGlar followed by IDeg|
10024346|NCT01704430|Experimental|Glutamine|Oral/enteral glutamine 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
10024347|NCT01704430|Placebo Comparator|Maltodextrin|Oral/enteral maltodextrin 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
10024348|NCT01704443|Experimental|Immediate treatment|Women in the Immediate treatment arm will receive the Group Psychoeducational treatment in the next available group. There will be 8-9 womenper group and each session will be 2.25 hours in duration and there will be 4, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
10024349|NCT01704443|Experimental|Waitlist Control- delayed treatment|Women in the Waitlist Control arm will receive no treatment for a period of approximately 8 weeks. After the waitlist period they will receive the same Group Psychoeducational treatment as the participants in the immediate treatment arm of the study.
10024350|NCT01704469|Experimental|The local anesthetic injection group|
9518235|NCT03298529|Experimental|Pasta with four eggs/kg flour|"Pasta with four eggs/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with four eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
10024351|NCT01704482|Experimental|N-acetylcysteine|N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
10024352|NCT01704482|Placebo Comparator|Glucose 5%|equivalent volume over the same period.
10024353|NCT01704508|Active Comparator|Artemether-lumefantrine|6-dose regime will be used:
10024354|NCT01704508|Active Comparator|Dihydroartemisinin-piperaquine|A 3 dose regime will be used
10024355|NCT01704534|Experimental|Ustekinumab|Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28
10024356|NCT01704560|Experimental|Coversheet to Informed Consent|Coversheet attached to Informed Consent.
10024357|NCT01704560|No Intervention|No Coversheet|Standard, full permission form, without the coversheet.
10024358|NCT01704573||NMR by abstinence status|"This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2* nAChR availability using 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine (2-[18F]FA) PET imaging.~Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.~All participants who complete both PET scans will also complete an anatomical MRI scan."
10024359|NCT01704586|Active Comparator|Radioiodine|Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
10024360|NCT01704586|Active Comparator|I-124|I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.
10024361|NCT01704612|Active Comparator|Diabete group|Patient with type 2 diabete received 20 mL ropivacaine
10024362|NCT01704612|Sham Comparator|Control group|no diabete reveived 20 mL ropivacaine
10024363|NCT01704625|Experimental|Osteopathic Manipulative Treatment|The osteopathic treatment group will have performed on them 3 standardized osteopathic manipulative treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT
10024364|NCT01704625|Sham Comparator|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
10024365|NCT01704638|Experimental|2677TT|Plasma kinetics of fluvoxamine and digoxin in this genotype
10024366|NCT01704638|Other|2677GG|plasma kinetics of fluvoxamine and digoxin in this genotype
10024367|NCT01704664|Active Comparator|I - Nutritional therapy only during the postoperative period.|Postoperative nutritional therapy administered in group I will not include immunomodulating factors. Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), starts 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
10024368|NCT01704664|Active Comparator|II - parenteral glutamine in postoperative time|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
10036626|NCT01817413|Experimental|Pulp revascularisation|"The experimental group will receive:~Visit 1: root canal dressing with triple antibiotic paste Visit 2: pulp revascularisation procedure Treatment will be carried out over two visits, two weeks apart."
10036627|NCT01817439|Experimental|oral amiodarone, group A|oral amiodarone 400 mg three times a day for 2 days
10024369|NCT01704664|Active Comparator|III - perioperative oral immunonutrition|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they will be administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
10024370|NCT01704664|Active Comparator|IV - Perioperative parenteral immunonutrition|Nutritional therapy of group IV will be based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids will be administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will be started at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
10024371|NCT01704677|Experimental|Surgery|Replacement of the degenerative intervertebral lumbar disc with an artificial lumbar disc device (degeneration had to be restricted to the two lower levels (L4/L5 and/or L5/S1))
10024372|NCT01704677|Active Comparator|Multidiciplinary rehabilitation|
10024373|NCT01704690|Experimental|S-1 and Paclitaxel|Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
10024374|NCT01704690|Active Comparator|Paclitaxel and Cisplatin|"Patients in these arm will receive combination treatment of paclitaxel and cisplatin.~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days"
10024375|NCT01704690|Active Comparator|5-FU and Cisplatin|Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
10024376|NCT01704703|Experimental|Experimental|FOLFIRI + panitumumab
10024377|NCT01704716|Experimental|R0: COJEC plus G-CSF|Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.
10024378|NCT01704716|Active Comparator|R0: COJEC|Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF
10024379|NCT01704716|Active Comparator|R1: BuMel MAT|"The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.~In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)"
10024380|NCT01704716|Experimental|R1: CEM MAT|The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course
10024381|NCT01704716|Active Comparator|R2: ch14.18/CHO|ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses
10024382|NCT01704716|Experimental|R2: ch14.18/CHO plus Aldesleukin|Patients randomised to receive ch14.18/CHO plus Aldesleukin
10024383|NCT01704716|Active Comparator|R3: COJEC Induction|"Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:~Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide"
10024384|NCT01704716|Experimental|R3: Modified N7|The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).
10024385|NCT01704716|Active Comparator|R4: cnt inf ch14.18/CHO|ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO
10024386|NCT01704716|Experimental|R4: cnt inf ch14.18/CHO plus Aldesleukin|"ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.~In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion"
10024387|NCT01704729|Other|group2|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
10024388|NCT01704729|Other|group3|"Cycloplegic subjective refraction by a vision technician trained in the Zhongshan Ophthalmic Center's Rural Refractionist Program"
10024389|NCT01704729|Other|group4|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
10024390|NCT01704729|Other|group1|Non-cycloplegic self-refraction using First Generation, Child-Specific fluid-filled adjustable spectacles and updated self-refraction protocol
10024391|NCT01704742||No treatment|
10024392|NCT01704768|Experimental|COPE/Healthy Lifestyles TEEN Program|COPE is a manualized 15-session educational and cognitive-behavioral skills building program guided by Cognitive Behavioral Theory with physical activity as a component of each session.
10024393|NCT01704768|Placebo Comparator|Healthy Teens Attention Control Program|Healthy Teens is an attention control program that controls for the time spent with the adolescents in the COPE group is essential to determining the efficacy of the experimental program.
10024394|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (500mg)|Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
10024395|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (250mg.)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily
10024396|NCT01704794|Active Comparator|Folic Acid + Paludrine + Jobelyn (2mg)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily
10024397|NCT01704807|Active Comparator|Intervention, Custom Orthotics|Wearing custom foot orthotics
10024398|NCT01704807|Sham Comparator|Sham Foot Orthotic|Wearing sham or flat shoe insoles
10024399|NCT01704820|Experimental|Retroflexion arm|Retroflexion arm: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the hepatic flexure with removal of all visible colon polyps
10024400|NCT01704820|Placebo Comparator|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the hepatic flexure and all visible colon polyps are removed.
10024401|NCT01704833|Experimental|Cognitive Behavioral Therapy|This group receives 15 weeks of Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) in addition to standard care.
10024402|NCT01704833|No Intervention|Treatment as Usual|This group receives standard care only.
10024403|NCT01704872|Experimental|dose level finding ch14.18/CHO|A dose escalation design based on Phase I rules starting at 10 mg/m2/day ch14.18/CHO. This is 50% below the dose of ch14.18/SP2/0 used in a large cohort of patients. Dose escalation will be adapted to a modified Fibonacci series aiming at 10, 20 and 30 mg/m2 of ch14.18/CHO. Since this study is a bridging study aiming at a reassessment of the toxicity and determination of the pharmacokinetics of ch14.18/CHO, only a limited number of dose escalation steps (3) is implemented in the design.
10024404|NCT01704885|Sham Comparator|Active Control Group|Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
10036628|NCT01817439|Experimental|IV amiodarone, Group B|"Amiodarone:~IV loading of 300 mg for 30 min in 100cc glucose 5% IV infusion with 900 mg/24h in 1000cc glucose 5%"
10024405|NCT01704885|Experimental|Play Intervention|"children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session."
10024406|NCT01704898|Other|Efavirenz 600 Test-Stocrin 600 Reference|Efavirenz 600 mg will be randomly assigned.
10024407|NCT01704898|Other|Stocrin 600 Reference-Efavirenz 600 Test|Stocrin 600 mg will be randomly assigned.
10024408|NCT01704911|Experimental|Transradial Coronary Intervention|Transradial Coronary Intervention
10024409|NCT01704911|Experimental|Transfemoral Coronary Intervention|Transfemoral Coronary Intervention
10024410|NCT01704924|Active Comparator|Prevena|Incision with prevena device overlying
10024411|NCT01704924|Active Comparator|Standard of Care dressing|Prevena device is not used
10024412|NCT01704937|Experimental|Colonoscopy|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy"
10024413|NCT01704937|Experimental|Nasogastric Tube (NGT)|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT"
10024414|NCT01704963|Experimental|PCI-32765|Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
10024415|NCT01704989|Active Comparator|Laser pathway|Arm in which patients first randomised to receive SLT laser
10024416|NCT01704989|Active Comparator|Topical therapy|Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
10036629|NCT01817452|Experimental|Arm A|Trastuzumab + Pertuzumab
10036630|NCT01817452|Active Comparator|Arm B|Trastuzumab + Pertuzumab + Paclitaxel
10036631|NCT01817465|Experimental|Motilione®|30 mg is administered with a tablet of placebo (Pantoline®)
10036632|NCT01817465|Active Comparator|Pantoline®|40mg is administered with a tablet of Motilitone®
10036633|NCT01817465|Active Comparator|Motilitone® and Pantoline®|Both drugs are administered at once
10036634|NCT01817478|Experimental|medical staff|
10036635|NCT01817517|Experimental|Deep Brain Stimulation implant|Unblinded treatment arm, thalamic DBS for Tourette syndrome.
10036636|NCT01817543|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
10036637|NCT01817556|Experimental|Stillen Tab.|administered three times daily for four weeks
10036638|NCT01817556|Active Comparator|Mucosta Tab.|administered three times daily for four weeks
10036639|NCT01817569||Byetta|
10036640|NCT01817595|Active Comparator|BG Star (Conventional Meter)|25 patients will use the (conventional) BG star meter in which patients will upload their readings onto a computer and send in their readings via email.
10036641|NCT01817595|Active Comparator|IBG Star Group (iPhone)|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
10036642|NCT01817621|Experimental|Experimental Intervention|
10036643|NCT01817621|Active Comparator|TAU Condition|
10036644|NCT01817634|Experimental|Food supplement Intervention - Capsule Intervention|Omega 3 food supplement + Omega 3 capsule.
10036645|NCT01817634|Experimental|Food Supplement Intervention - Capsule Control|Omega 3 food supplement + Control Capsule.
10036646|NCT01817634|Experimental|Food Supplement Control - Capusle Intervention|Food supplement control + Omega 3 Capsule.
10024417|NCT01705002|Experimental|Cohort A: Promitil 0.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
10024418|NCT01705002|Experimental|Cohort B: Promitil 1.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
9479674|NCT03540888|Experimental|Deep Transverse Friction Massage group|Deep transverse friction massage group. Participants were taught by one of the examiners how to sit and perform pre-exercise self-massages on their tested leg musculotendinous junction (MTJ). The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur. One examiner carefully monitored how the technique was performed to assure the precision of the application. This massage technique was applied over a duration of 30 seconds.
9479675|NCT03540888|Active Comparator|Dynamic stretching intervention|The dynamic stretching intervention was included for its positive effects on agility and muscle strength. Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
9479676|NCT03540888|Active Comparator|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
9479677|NCT03540862||NPV|a hospital-based maintenance NPV program including NPV support, breathing training and an educational program (relaxation techniques, and home pacing walking exercise) in daily clinical practice. Patients received NPV with breathing training via the cuirass ventilator (Philips Respironics Lifecare NEV-100) settings for 60 min. The ventilator was set to control model with frequency of 12 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot) and delivered negative pressures ranging -20 to -30 cm H2O. In the NPV group, patients underwent the hospital-based NPV once every week as the maintenance program.
9479678|NCT03540862||Control|If patients do not wish to enter the hospital-based NPV program, they are placed in the control group and are trained to perform breathing training, relaxation techniques and home pacing walking exercise.
9479679|NCT03540849|Experimental|BV after allogeneic hematopoietic stem cell transplantation|
9479680|NCT03540836|Experimental|Relacorilant 3x100mg softgel capsules|Relacorilant (3x100 mg softgel capsules)
9479681|NCT03540836|Experimental|Relacorilant 3x100mg hard-shell capsules|Relacorilant (3x100 mg hard-shell capsules)
9479682|NCT03540836|Experimental|Relacorilant 6x50mg hard-shell capsules|Relacorilant (6x50mg hard-shell capsules)
9528737|NCT03208296|Experimental|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
10024419|NCT01705002|Experimental|Cohort C: Promitil 1.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
10024420|NCT01705002|Experimental|Cohort D: Promitil 2.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
10024421|NCT01705002|Experimental|Cohort E: Promitil 2.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
10024422|NCT01705002|Experimental|Cohort F: Promitil 3.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
10024423|NCT01705002|Experimental|Cohort G: Promitil 3.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
10024424|NCT01705002|Experimental|Cohort H: Promitil 4.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
10024425|NCT01705002|Experimental|Expanded Cohort|"Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.~Only for mCRC patients."
10024426|NCT01705002|Experimental|Combination Cohort|"Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.~Only for mCRC patients."
10024427|NCT01705002|Experimental|Triple combination Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.~Only for mCRC patients."
10024428|NCT01705002|Experimental|3 Weekly Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.~Only for mCRC patients."
10036647|NCT01817634|Active Comparator|Food Supplement Control - Capsule Control|Food supplement control + Control Capsule.
10036648|NCT01817647||PCT|Patients undergoing colorectal surgery with an anastomosis performed
10024429|NCT01705015|Experimental|UCFit plus direct feedback about exercise|Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs. These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged. Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters. Graphical displays that can be used for feedback will be available at the patient's bedside. The staff, patient and family will be able to view these bar graphs.
10024430|NCT01705015|Placebo Comparator|UCFit plus encouraged exercise|These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs. The coordinator will only encourage these subjects to try to increase their total cycling time. These bar graphs will not be posted, but will be left by the bedside.
10024431|NCT01705041|Experimental|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
10024432|NCT01705054||Outpatient Coronary Artery Disease Patient|CAD patients being seen in a participating cardiology office for a scheduled clinic visit who agree to take the survey.
10024433|NCT01705093|Experimental|Flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
10024434|NCT01705093|Placebo Comparator|macronutrient- matched control powder|50g macronutrient-matched control powder that will lack strawberry flavonoids
10024435|NCT01705119|Experimental|Mechanically Ventilated|
10024436|NCT01705158|Experimental|carboplatin and liposomal doxorubicin|carboplatin and liposomal doxorubicin in ovarian cancer in realapse
10024437|NCT01705171||IBS patients with fructose intolerance|analysis of biopsies
10024438|NCT01705171||Control group: no IBS or fructose intolerance|analysis of biopsies
10024439|NCT01705184|Experimental|BUCiL|"Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --> Sequence 2~Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
10036649|NCT01817660|Active Comparator|Open Surgery|In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
10036650|NCT01817660|Active Comparator|Endovascular Surgical repair (EPAR)|In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).
10036651|NCT01817673|Experimental|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
10024440|NCT01705197|Active Comparator|Avanfil 100 or 200mg|All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization. When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed. For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
10024441|NCT01705197|Placebo Comparator|Placebo 100mg or 200mg|When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
10024442|NCT01705210||Diabetes mellitus type 2 (DM2)|
10024443|NCT01705210||metabolic syndrome (MetS)|
10024444|NCT01705210||healthy controls|
10024445|NCT01705223|Experimental|group A|DNA vaccine prime at week 0,4,8 and rTV boost at week 16
10024446|NCT01705223|Experimental|group B|DNA vaccine prime at week 0,4,8 and rTV boost at week 24
10024447|NCT01705223|Experimental|group C|DNA vaccine prime at week 0,4,8 and rTV boost at week 32
10024448|NCT01705223|Experimental|group D|DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24
10024449|NCT01705249|Experimental|estradiol / norethisterone acetate|
10024450|NCT01705262||u-65 M|Male patients under 65
10024451|NCT01705262||u-65 K|Female patients under 65 years old
10024452|NCT01705262||o-65 -K|Female patients over 65 years
10024453|NCT01705262||O-65 M|Male patients over 65 years
10024454|NCT01705275|Experimental|ONO-8539 BID|ONO-8539
10024455|NCT01705275|Placebo Comparator|Placebo BID|0mg
10024456|NCT01705301||Deep Brain Stimulation|Patient's undergoing the clinical procedure of Deep Brain Stimulation will have the experimental protocol that involves, after implantation of the DBS electrodes, a single electrochemical recording electrode, from the WINCS system, implanted along the same trajectory path as the electrophysiology and the DBS electrode
10024457|NCT01705314|Experimental|vitamin D supplements|children and adolescents that are randomized to the intervention will receive 7 mls of D-drops (14,000U/week of vitamin D) for eight months
10024458|NCT01705314|Placebo Comparator|vitamin D placebo|children and adolescents that are randomized to placebo will receive 7 mls of placebo drops for eight months
9479683|NCT03540823|Experimental|Patients with rheumatic diseases|Patients with diagnosis of adult and juvenile systemic lupus erythematosus (SLE and JSLE) and Sjogren syndrome (SSp)
9479684|NCT03540823|Other|Healthy controls|Healthy children and adults
9479685|NCT03540810|Active Comparator|Hydroxychloroquine|All patients randomised in this arm will receive hydroxychloroquine with their usual treatment, which is antivitamin K anticoagulants
9479686|NCT03540810|Placebo Comparator|Placebo|All patients randomised in this arm will receive a placebo with their usual treatment, which is antivitamin K anticoagulants
10024459|NCT01705327||Parkinson's Disease Subjects|
10024460|NCT01705327||Healthy Control Subjects|
10024461|NCT01705340|Experimental|Treatment (MK2206, lapatinib ditosylate, trastuzumab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10024462|NCT01705366||Knee Arthroplasty|"Patients undergoing total knee arthroplasty. This may be Non-MAKO® Robot Assisted Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty or MAKO® Robot Assisted Medial and PF Knee Arthroplasty~The Non-MAKO® Robot Assisted Total Knee Arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System. The MAKO® Robot Assisted Arthroplasty uses the RESTORIS Multicompartmental Knee System ."
10024463|NCT01705379||MenACWY-CRM|2 years of age and older
10024464|NCT01705392|Experimental|Bevacizumab plus propranolol|Bevacizumab 10mg/kg q2w plus propranolol 80 mg x 1
10024465|NCT01705392|Experimental|Bevacizumab plus enalapril|Bevacizumab 10mg/kg q2w plus enalapril 5 mg x 1
10024466|NCT01705392|Active Comparator|Dacarbazine|Dacarbazine 1000mg/m2 q3w
10024467|NCT01705405|Experimental|medical device|medical device to acquire ultrasound and endoscopic images during surgery
10024468|NCT01705431|Experimental|Support for students with EBD|
10024469|NCT01705431|No Intervention|Control|Participants continue with services as usual
10024470|NCT01705444|Other|Foley catheter and The Spanner Insertion|Quality of life questionnaire after using the Foley catheter and the Spanner
10024471|NCT01705457|Active Comparator|with Multiple Sclerosis, vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
10024472|NCT01705457|Placebo Comparator|with multiple sclerosis,placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
9479687|NCT03540797||Intensive care unit (ICU) patients with sepsis|
10024473|NCT01705470|Experimental|arm1|will receive 60 mg (6 ml) of intra-venous furosemide before administration of the blood transfusion (250-300 ml of packed cells).
10024474|NCT01705470|Experimental|arm2|will receive 6 ml of normal saline (NaCl 0.9%) before administration of the blood transfusion (250-300 ml of packed cells).
10024475|NCT01705483|Experimental|Part 1: ASP9853 with docetaxel|2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
10024476|NCT01705483|Experimental|Part 2: ASP9853 with paclitaxel|Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
10024477|NCT01705522||IBD patients|patients with ulcerative colitis or crohn's disease, in remission
10024478|NCT01705535|Experimental|Pelvic floor muscle exercises|Individual supervised pelvic floor muscle exercises. Standard information and guidance
10024479|NCT01705535|Active Comparator|Masage of the neck and back|Massage of the neck and back. Standard information and guidance
10024480|NCT01705548|Experimental|Hypofractionated Radiosurgery|"HR (Hypofractionated Radiosurgery) delivered in 5 fractions, with a minimum of 2 and a maximum of 3 fractions being delivered per week, to patients with brain metastases or resection cavity greater than 3 cm and less than 6 cm.~Dose escalation will proceed according to the Escalation with Overdose Control (EWOC) method with a planned total enrollment of 24 patients, in 8 patient cohorts with 3 patients per cohort. A 4 month observation period will occur for each completed cohort prior to dose escalation, with a goal timeline for trial completion of 4 years from first patient enrollment."
10024481|NCT01705600|Experimental|Pain Verbalization Repression Rules|This group will wear a bracelet with a set of rules which will restrict ones verbalization of pain complaints
10024482|NCT01705626||Participants diagnosed with small fiber polyneuropathy|Participants aged between 18 and 85 years, diagnosed with small fiber polyneuropathy of no obvious etiology, without diagnosis of alcoholism and not undergoing chemotherapy for cancer
10024483|NCT01705639|Experimental|Melatonin|melatonin 4mg od for 3 months
10024484|NCT01705665||Aspirated Coronary Thrombi During AMI|
10024485|NCT01705678|Active Comparator|Krill oil|Krill oil will be compared to fish oil as an active comparator
10024486|NCT01705678|Active Comparator|Fish oil|Fish oil 500 mg of DHA/EPA
10024487|NCT01705704||Cohort|
10024488|NCT01705743|Active Comparator|Group 1 Sevoflurane+Nitrous oxide|
10024489|NCT01705743|Active Comparator|Group 2 Sevoflurane|
10024490|NCT01705756|Placebo Comparator|Vehicle|•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
10024491|NCT01705756|Experimental|Kineret (Anakinra)|Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
10024492|NCT01705769|Experimental|RUTF-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company
10024493|NCT01705769|Experimental|RUTF-Locally produced|Ready to Use Therapeutic Food-Locally produced by the study team at each study site
10024494|NCT01705769|Active Comparator|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
10024495|NCT01705782|No Intervention|Saline|Only saline is given.
10024496|NCT01705782|Placebo Comparator|+ Saline|Endotoxin is given + Placebo (Saline)
10024497|NCT01705782|Active Comparator|+ amino acids|Endotoxin is given + amino acids (intravenously)
10024498|NCT01705795|Active Comparator|Mepolizumab|Mepolizumab 750 mg four times one month apart.
10024499|NCT01705795|Placebo Comparator|Placebo|Placebo (saline) four times one month apart
10024500|NCT01705808|Experimental|Protein C concentrate|
10024501|NCT01705808|Placebo Comparator|Placebo|
10024502|NCT01705821||Skull Base Surgery Candidate|Patient with a skull base lesion will undergo use of standard surgical curette with force sensor built into shaft. 6-axis force and torque data will be collected during the surgical procedure.
10024503|NCT01705834||Arthritis patients|Patients with Rheumatoid Arthritis
10024504|NCT01705847|Experimental|GS-9820|Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
10024505|NCT01705860||Assessment|All subjects will receive same assessments.
10024506|NCT01705873||LPV/r|LPV/r based HAART
10024507|NCT01705873||Efavirenz|EFV first line based HAART
10024508|NCT01705886||Knee Arthroplasty|"Patients undergoing knee replacement surgery. This may be a Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty.~The MAKO® Robot Assisted surgeries use the RESTORIS Multicompartmental Knee System.~The total knee arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System."
10024509|NCT01705899|Experimental|Subjects with preserved kidney function|Subjects with preserved renal function that have not previously received a kidney transplant will be treated with Human Pancreatic Islets (in the form of islets alone - IA).
10024510|NCT01705899|Experimental|Subjects with prior kidney transplant|Subjects with renal failure secondary to diabetes who have received a prior kidney transplant at least 6 months previously and have stable renal function on a steroid-free immunosuppressive regimen will receive Human Pancreatic Islets (in the form of islets after kidney - IAK).
10024511|NCT01705912|Experimental|Training|Complete intervention i.e. basic intervention + individual training program.
10024512|NCT01705912|Active Comparator|Control|Basic intervention.
10024513|NCT01705938|Active Comparator|Group 1|SP-333 0.1 mg & Placebo, one tablet by mouth, single dose
10024514|NCT01705938|Active Comparator|Group 2|SP-333 0.3 mg & Placebo, 3 tablets by mouth, single dose
10024515|NCT01705938|Active Comparator|Group 3|SP-333 1 mg & Placebo, one tablet by mouth, single dose
10024516|NCT01705938|Active Comparator|Group 4|SP-333 3 mg & Placebo, 3 tablets by mouth,single dose
10024517|NCT01705938|Active Comparator|Group 5|SP-333 10 mg & Placebo, 1 tablet by mouth, single dose
10024518|NCT01705938|Active Comparator|Group 6|SP-333 30 mg & Placebo, 3 tablets by mouth, single dose
10024519|NCT01705938|Active Comparator|Group 7|SP-333 60 mg & Placebo, 6 tablets by mouth, single dose
10024520|NCT01705951|Experimental|Group 1: Resistance Training/Nicotine Replacement|
10024521|NCT01705951|Experimental|Group 2: Resistance Training only|
10024522|NCT01705951|Experimental|Group 3: Nicotine Replacement Therapy only|
10024523|NCT01705951|No Intervention|Group 4: Control; no RT and no NRT|
10024524|NCT01705990|Experimental|Group A: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
10024525|NCT01705990|Experimental|Group B: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
10024526|NCT01705990|Experimental|Group C: Ad35-GRIN followed by SeV-G(NP)|Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
10024527|NCT01705990|Experimental|Group D: SeV-G(NP) only|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)
10024528|NCT01706016|Experimental|Patients with breast cancer smaller than 20mm|
10024529|NCT01706042|Placebo Comparator|white bread|White bread (based on 35 g available carbohydrates)
10024530|NCT01706042|Active Comparator|Legume meal|Legumes are consumed as a late evening meal(based on 35 g available carbohydrates)
10024531|NCT01706055||Group 1|
10024532|NCT01706094|Experimental|lying flat head position|positioning the head of the bed at zero degrees during the first 48 hours from admission of patients with acute ischemic stroke Active Comparator: upright position of the head of the bed during 48 hours from admission of patients with acute ischemic stroke
10024533|NCT01706120|Other|First-line chemotherapy with bevacizumab|"Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
10036652|NCT01817673|Placebo Comparator|placebo (dextrose)|20 g/d for 5 d followed by 5 g/d throughout the trial
10036653|NCT01817686|Experimental|Comfort Default|ADs with pre-selected defaults that focus on providing comfort at end-of-life.
10036654|NCT01817686|Experimental|Life Extension Default|ADs with pre-selected defaults that focus on extending life.
10024534|NCT01706133|No Intervention|Basal phase|Integrated measurement of all variables involved impact and frequency of prior use of health services and specifically to the emergency room, service access, patient characteristics, features for the classification of frailty, cognitive impairment and depression, why consultation, triage scale level on admission to the service and to the service variables in terms of length of stay, diagnosis and medical management, and related services with internal consultants percentage of inpatients discharged or deceased, in further analysis the researchers undertake group estimating frequency of use and the identification of factors associated with the use of emergency departments and adverse events
10024535|NCT01706172|Active Comparator|Dextrose 20 % Injection|Injecting 20 % Dextrose and 0.2 % lidocaine intra-articularly into the TM Joint
10024536|NCT01706172|Active Comparator|Sterile Water Injection|Injection of Sterile water in 0.2 % lidocaine intra-articularly into the TM joint
10024537|NCT01706185||Cancer Group|
10024538|NCT01706211|Experimental|BRL 49653C|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
10024539|NCT01706211|Placebo Comparator|placebo|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
10024540|NCT01706224||Group A|Subjects in this group will be all physicians actively working at hospital centres in Spain.
10024541|NCT01706224||Group B|Subjects in this group will be all nurses actively working at hospital centres in Spain.
10024542|NCT01706224||Group C|Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.
10024543|NCT01706224||Group D|Subjects in this group will be all midwives actively working at hospital centres in Spain.
10024544|NCT01706237|Experimental|Shield|A shield (similar to a contact lens) is placed on the eye after myopic LASIK procedure.
10024545|NCT01706289||diabetic mellitus screen|
10024546|NCT01706302||Cohort Group|
10024547|NCT01706315|Experimental|Cohort 1 - GSK2140944 400 mg|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days
10024548|NCT01706315|Placebo Comparator|Cohort 1 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
9479688|NCT03540784|No Intervention|Control group|usual care treatment
9479689|NCT03540784|Experimental|Nutrition|high-protein nutrition therapy
9479690|NCT03540784|Experimental|EMS+Nutrition|WB-EMS Training (2x/week á 20 min) + high-protein nutrition therapy
9479691|NCT03540745|Experimental|TES Treatment|Where subject is randomized to TES.
9479692|NCT03540745|Placebo Comparator|TES-SHAM Treatment|Where subject is randomized to a SHAM condition
9479693|NCT03540693||RYGB-longitudinal|Longitudinal group of subjects studied before and after Roux-n-Y gastric bypass surgery
9479694|NCT03540693||SG_longitudinal|Longitudinal group of subjects studied before and after sleeve gastrectomy surgery
10024549|NCT01706315|Experimental|Cohort 2 - GSK2140944 800 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1
10024550|NCT01706315|Placebo Comparator|Cohort 2 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
10024551|NCT01706315|Experimental|Cohort 3 - GSK2140944 1500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2
10024552|NCT01706315|Placebo Comparator|Cohort 3 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
10024553|NCT01706315|Experimental|Cohort 4 - GSK2140944 2500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3
10024554|NCT01706315|Placebo Comparator|Cohort 4 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
10024555|NCT01706315|Experimental|Cohort 5 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4
10024556|NCT01706315|Placebo Comparator|Cohort 5 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
10024557|NCT01706315|Experimental|Cohort 6 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5
10024558|NCT01706315|Placebo Comparator|Cohort 6 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
10024559|NCT01706341|Active Comparator|acetate Ringer's solution|Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml
10024560|NCT01706341|Active Comparator|acetate Ringer's solution with 1% glucose|Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)
10024561|NCT01706354|Active Comparator|Local anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
10024562|NCT01706354|Experimental|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
10024563|NCT01706367|Experimental|Low dose C diff vaccine|
10024564|NCT01706367|Experimental|Low dose C diff vaccine + adjuvant|
10024565|NCT01706367|Experimental|Mid dose C diff vaccine|
10024566|NCT01706367|Experimental|Mid dose C diff vaccine + adjuvant|
10024567|NCT01706367|Experimental|High dose C diff vaccine|
10024568|NCT01706367|Experimental|High dose C diff vaccine + adjuvant|
10024569|NCT01706380|Experimental|Interactive voice response with personal feedback|Interactive voice response follows the client twice weekly for 3 months with respect to symptoms and substance use, in both arms. This intervention group also receives a personalized and automated feedback describing whether the symptom status of the patient is better, worse or equal, compared to the preceding follow-up.
10024570|NCT01706380|Active Comparator|Interactive voice response without personal feedback|This control group is also followed with identical interactive voice response follow-up, addressing symptoms and substance use, but without the personal feedback.
10024571|NCT01706393|Experimental|probiotics|"Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
10024572|NCT01706393|Placebo Comparator|placebo|"Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
10024573|NCT01706406|Experimental|1 treatment|"Women randomized into the treatment group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment"
10024574|NCT01706406|Other|2 waitlist|"Women randomized to the waitlist group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months). They will undergo pretreatment testing and treatment on the same schedule as women in the treatment group."
10024575|NCT01706419|No Intervention|no school meal|control group receiving no school meal
10024576|NCT01706419|Placebo Comparator|normal school meal|school meal without fortified rice, placebo group
10024577|NCT01706419|Experimental|cold extruded fortified rice|school meal with fortified rice using cold extrusion kernels
10024578|NCT01706419|Experimental|warm extrusion|school meal with fortified rice using warm extrusion kernels
10024579|NCT01706419|Experimental|hot extruded|school meal with fortified rice using hot extrusion kernels
10024580|NCT01706445|No Intervention|Control|
10024581|NCT01706445|Other|intervention|Exercise training
10024582|NCT01706471|Experimental|Everolimus + Low dose CsA +PD|
10024583|NCT01706471|Active Comparator|Myfortic+ Standard CsA + PD|
10024584|NCT01706484|Experimental|80 mg BNO 1016 und placebo|2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily
10024585|NCT01706484|Experimental|160 mg BNO 1016|2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily
10024586|NCT01706484|Placebo Comparator|placebo|2 tablets (each without BNO 1016) by mouth 3 times daily
10024587|NCT01706510|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
10024588|NCT01706510|Active Comparator|Clopidogrel|Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days
10024589|NCT01706523|Experimental|STX209|Active treatment with STX209
10024590|NCT01706562||Itraconazole|
10024591|NCT01706601||Hemorrhoids|Patient with hemorrhoids
10024592|NCT01706627|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
10024593|NCT01706627|Active Comparator|Drug: 10 mg Melatonin|10 mg melatonin gelatin capsule
10024594|NCT01706627|Active Comparator|Drug: 20 mg Melatonin|20 mg melatonin gelatin capsule
10024595|NCT01706653|Active Comparator|Intervention 1|Polyphenol-enriched fruit-based drink - low
10024596|NCT01706653|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - medium
10024597|NCT01706653|Active Comparator|Intervention 3|Polyphenol-enriched fruit-based drink - high
10024598|NCT01706653|Placebo Comparator|Intervention 4|Very low polyphenol fruit based drink (control)
10024599|NCT01706679|Active Comparator|Maximum therapeutic dose of ATX-101|ATX-101 10 mg/ml
10024600|NCT01706679|Active Comparator|Supratherapeutic dose of ATX-101|ATX-101 20 mg/ml
10024601|NCT01706679|Active Comparator|Moxifloxacin|moxifloxacin (400mg)
10024602|NCT01706679|Placebo Comparator|Placebo vehicle|placebo vehicle (PBS)
10024603|NCT01706692||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
10024604|NCT01706692||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
10024605|NCT01706692||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
10024606|NCT01706692||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
10024607|NCT01706692||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
10024608|NCT01706692||Fumaric acids|Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
10024609|NCT01706692||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
10024610|NCT01706692||Other anti-psoriatic systemic treatments|e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
10024611|NCT01706718|Placebo Comparator|Control white bread|
10024612|NCT01706718|Experimental|Beetroot bread|
10024613|NCT01706731|Active Comparator|TAU plus Cognitive-behavioral Therapy|Participants randomized to this group will receive treatment as usual plus cognitive behavioral therapy (CBT) provided by trained Buddhist monks.
10024614|NCT01706731|Sham Comparator|TAU plus routine counselling|Participants randomized into this group will receive treatment as usual (TAU) plus plus routine psychological support from non-CBT monks.
10036655|NCT01817686|Experimental|Standard Default|ADs without pre-selected defaults.
10036656|NCT01817699|No Intervention|Low Hb target without cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL
10036657|NCT01817699|Active Comparator|Low Hb target with cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL Cholecalciferol: 1,000 IU/day
10036658|NCT01817699|Active Comparator|High Hb target without cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL
10036659|NCT01817699|Experimental|High Hb target with cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL Cholecalciferol: 1,000 IU/day
10024615|NCT01706744|Experimental|Intermediate care unit|Follow-up treatment and care in a intermediate care unit after discharge from hospital
10024616|NCT01706744|Active Comparator|Local health care 1|Discharge from hospital to usual care as provided by the local health and social care (Verdal)
10024617|NCT01706744|Active Comparator|Local health care 2|Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
10024618|NCT01706757|Experimental|with go-cart|conducts exercises with the help of a go-cart
10024619|NCT01706757|No Intervention|without go-cart|conduct exercises without go-cart
10024620|NCT01706783|Experimental|NNC0195-0092 (somapacitan)|
10024621|NCT01706783|Active Comparator|Norditropin NordiFlex®|
10024622|NCT01706796|Experimental|PF-06273340 Oral Solution Fasted|
10024623|NCT01706796|Experimental|PF-06273340 Immediate Release Tablet Fasted|
10024624|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fasted|
10024625|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fasted|
10024626|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fed|
10024627|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fed|
10024628|NCT01706809||Biomarkeres|
10024629|NCT01706848|Active Comparator|Celotres|Scar halves randomized to treatment with device, opposite side treated per standard of care.
10024630|NCT01706848|Active Comparator|Standard surgical wound closure|Scar halves randomized to treatment with device, opposite side treated per standard of care.
10024631|NCT01706861|Other|Celotres|Celotres following surgical removal of earlobe keloid.
10024632|NCT01706874||Periodontal prophylaxis|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.
10024633|NCT01706874||Control|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients
10024634|NCT01706887|Experimental|Diet Amiloride|One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).
10024635|NCT01706900|Placebo Comparator|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
10024636|NCT01706900|Experimental|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
10024637|NCT01706913|No Intervention|No consult|Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
10024638|NCT01706913|Active Comparator|Dermatology Consult|The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
10024639|NCT01706939|Experimental|Reduced Dose Radiation|Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin
10024640|NCT01706939|Active Comparator|Standard Dose Radiation|Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin
10024641|NCT01706991||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
9479695|NCT03540693||LAGB_longitudinal|Longitudinal group of subjects studied before and after laparoscopic gastric banding surgery
9479696|NCT03540693||Weight-loss success|Subjects who lost ≥40% body weight by 2-5 years post-surgery
9479697|NCT03540693||Weight-loss failure|Subjects who lost <25% body weight (or lost more but then regain weight so that now are at <25%) by 2-5 years post-surgery
9479702|NCT03540667||Single group study|The study population will include patients presenting for primary elective unilateral total hip and knee arthroplasty.
9479703|NCT03540654||Patients with CML discontinuing TKI treatment|
9479704|NCT03540641|Active Comparator|1500 pulses|This group will receive 1500 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions
9479705|NCT03540641|Sham Comparator|1500 pulses sham|this group will receive the sham modality of the protocol of 1500 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
10024642|NCT01706991||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
10024643|NCT01706991||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
10024644|NCT01707017|Active Comparator|High-load strength training|
10024645|NCT01707017|Active Comparator|Low-load strength training|
10024646|NCT01707017|Active Comparator|Low-load + moderate-load strength training|
10024647|NCT01707056|Active Comparator|Black coffee|Synthroid will be administered with 12 ounces of black coffee for a period of 6 weeks.
10024648|NCT01707056|Active Comparator|Coffee with Milk|Synthroid will be administered with 12 ounces of coffee and 2 ounces of 2% milk for a period of 6 weeks.
10024649|NCT01707056|Active Comparator|Black Tea|Synthroid will be administered with 12 ounces of black Lipton tea for a period of 6 weeks.
10024650|NCT01707056|Placebo Comparator|Water|Synthroid will be administered with 12 ounces of water for a period of 6 weeks.
10024651|NCT01707069|Experimental|Group 1: 4mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who are skin test negative to Japanese Red Cedar pollen or Mountain Cedar pollen and have no reactive Cry J 2 antibodies.~Group 1: will receive 4mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered to be the optimal DNA vaccine dose based on historical clinical data from other DNA vaccine studies). The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) of a 4 mg dose at 14 day intervals."
10036660|NCT01817738|Active Comparator|CV9104|CV9104 intradermal injection
10036661|NCT01817738|Placebo Comparator|Placebo|Placebo intradermal injection
10024652|NCT01707069|Experimental|Group 2: 2mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four half (2 mg) dose dosing regimen.~Group 2: will receive 2 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection(considered ½ of the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive three (3) additional 2 mg doses at 14 day intervals between doses (4 doses in total)."
10024653|NCT01707069|Experimental|Group 3: 4 mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four full (4 mg) dose dosing regimen.~Group 3: will receive 4 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive 3 additional 4 mg doses at 14 day intervals between doses (4 doses in total)."
10024654|NCT01707082|Experimental|Part A Cohort 1|
10024655|NCT01707082|Experimental|Part A Cohort 2|
10024656|NCT01707082|Experimental|Part A Cohort 3|
10024657|NCT01707082|Experimental|Part A Cohort 4|
10024658|NCT01707082|Experimental|Part A Cohort 5|
10024659|NCT01707082|Experimental|Part B Cohort 1|
10024660|NCT01707082|Experimental|Part B Cohort 2|
10024661|NCT01707121||Surgical patients|Patients with planned surgery for breast cancer, colorectal cancer and gall bladder disease
10024662|NCT01707134|Experimental|insulin aspart|
10024663|NCT01707134|Active Comparator|human insulin|
10024664|NCT01707160|Experimental|Treatment period 1|
10024665|NCT01707160|Active Comparator|Treatment period 2|
10024666|NCT01707173|Other|Standard Education|Control group participants will receive standard educational materials published by the CDC or American Academy of Pediatrics as an intervention along with a generic infant safety DVD
10024667|NCT01707173|Experimental|Tailored education|Parents/caregivers will receive educational materials tailored to their specific beliefs and barriers about infant supine sleep along with a DVD detailing standard guidelines along with specific solutions and facilitators to infant supine sleep as the intervention.
10024668|NCT01707186||Group 1A|Early phase, requiring change in treatment
10024669|NCT01707186||Group 2|Established phase, stable treatment
10024670|NCT01707186||Group 2A|Established phase, requiring a change in treatment
10024671|NCT01707186||Group 1|Early phase, stable treatment
10024672|NCT01707199|Experimental|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
10024673|NCT01707212|Experimental|Pain management education|Education about pain management during infant immunization
10024674|NCT01707212|Other|No pain management education|Control - general information about immunization only
10024675|NCT01707251|Experimental|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
10024676|NCT01707251|Placebo Comparator|Saline|IV saline every 6 hours starting preoperatively (5 doses).
10024677|NCT01707277|Experimental|Inspiratory muscle training|Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)
10024678|NCT01707277|Active Comparator|Usual care|Pharmacological treatment
10024679|NCT01707303|Other|Usual Care|Usual hospital rehabilitative services
10024680|NCT01707303|Experimental|Early ICU Rehabilitation Strategy|Early ICU physical therapy will be applied in this arm
10024681|NCT01707316|Experimental|Sequence 1: Treatment A-B-C|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
10024682|NCT01707316|Experimental|Sequence 2: Treatment B-C-A|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
10024683|NCT01707316|Experimental|Sequence 3: Treatment C-A-B|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
10024684|NCT01707329|Active Comparator|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
10024685|NCT01707329|Experimental|Icotinib+Chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
10024686|NCT01707342|Experimental|Simeprevir (TMC435)|Treatment A: single oral dose of simeprevir (TMC435) 50 mg; and Treatment B: single oral dose of simeprevir (TMC435) 150 mg. A single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram will be followed 5 hours later after administration of Treatment A and Treatment B in Period 1 and Period 2, respectively.
10024687|NCT01707355|Active Comparator|invention with poster|intervention - poster
10024688|NCT01707355|No Intervention|control|control - no poster
10024689|NCT01707394|Experimental|Group 1: Apixaban (low dose)|
10024690|NCT01707394|Experimental|Group 2A: Apixaban (low dose)|
10024691|NCT01707394|Experimental|Group 2B: Apixaban (low dose)|
10024692|NCT01707394|Experimental|Group 3: Apixaban (low dose)|
10024693|NCT01707394|Experimental|Group 4: Apixaban (low dose)|
10024694|NCT01707394|Experimental|Group 5: Apixaban (low dose)|
10024695|NCT01707394|Experimental|Group 2A (higher dose): Apixaban (low dose)|
10024696|NCT01707407|Experimental|Pomalidomide|
10024697|NCT01707407|Experimental|Pomalidomide plus Ketoconazole|
10024698|NCT01707407|Experimental|Pomalidomide plus Ketoconazole plus Fluvoxamine|
10024699|NCT01707407|Experimental|Pomalidomide plus Carbamazepine|
10024700|NCT01707433||Diagnosis of hip disease|Diagnosed with spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease, or bilateral proximal femoral epiphyseal dysplasia
10024701|NCT01707446|Active Comparator|Near-infrared reflectance spectroscopy|Bilateral NIRS (The INVOS® Cerebral/Somatic Oximeter)will be used to measure rSO2 intraoperatively and during the 24h postoperative period in the intensive care unit. In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established.
10024702|NCT01707446|No Intervention|Blinded Near-infrared reflectance spectroscopy|In the control group, the NIRS monitor screen will be electronically blinded, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in NIRS application and unaware of the study design.
10024703|NCT01707498|Experimental|Tetraplegic patients|Scanning device RoBIK Brain-Computer Interface
10024704|NCT01707498|Experimental|Healthy volunteers|RoBIK Brain-Computer Interface
10024705|NCT01707524|Experimental|Trans-radial approach|Randomized left versus right radial artery approach
10024706|NCT01707524|No Intervention|Trans-femoral approach|Observational
10024707|NCT01707537|Experimental|Euvichol|Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
10024708|NCT01707550||Cohort|
10024709|NCT01707563|Other|Marfan patients|Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
10024710|NCT01707563|Other|control patients|Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
10024711|NCT01707576|Other|screening of adolescent mental suffering. Management|screening of adolescent mental suffering consultant to emergencies. Management and later monitoring
10024712|NCT01707589|Experimental|Neonates admitted to the NICU|Neonates admitted to the NICU for a variety of medical reasons will be the cohort group. Those whose parents give informed consent will compose the subjects of the study
10024713|NCT01707602|Experimental|Arm A|Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
10024714|NCT01707602|Active Comparator|Arm B|Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
10024715|NCT01707602|Active Comparator|Arm C|Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
10024716|NCT01707615|Other|control group|In the control group, all patients were enrolled in a lifestyle intervention
10024717|NCT01707615|Active Comparator|GSPE group|GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention.
10024718|NCT01707628|Active Comparator|Early group after rituximab|"Patients who received rituximab last dose 3-6 months before influenza vaccination will be the early group."
10024719|NCT01707628|Active Comparator|Late group after rituximab|"Patients who received rituximab last dose 9-12 months before influenza vaccination will be the late group."
10024720|NCT01707628|Active Comparator|Control group|Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
10024721|NCT01707641|Active Comparator|CD#2|patients will be asked to melt slowly in the mouth 6 lozenges per day, containing Lactobacillus brevis CD2
10024722|NCT01707641|Active Comparator|bicarbonate sodium mouthwash|patients will be asked to wash their mouth with bicarbonate several times per day
10024723|NCT01707680||Dexmedetomidine|Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
10024724|NCT01707680||Propofol|Here, patients to be included are those being sedated with propofol as primary sedative.
10024725|NCT01707680||Midazolam|Here, patients to be included are those being sedated with midazolam as primary sedative
10024726|NCT01707706|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
10036662|NCT01817803|Active Comparator|1) Add furosemide/no spironolactone|
10036663|NCT01817803|Active Comparator|2) Add metolazone/no spironolactone|
10036664|NCT01817803|Active Comparator|3) Add furosemide/spironolactone|
10036665|NCT01817803|Active Comparator|4) Add metolazone/spironolactone|
10024727|NCT01707706|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Forearm [1 inch lateral to the middle point between HE3 and HE7] , Upper arm [1 inch lateral to LU 3 ], and Lower leg [0.5 inch dorsal to GB39]; for head, the non-acupoints include bilateral Head [middle point between GB8 and ST8], Forehead [middle point between ST8 and GB14], Neck [middle point between TB16 and SI17], and Ear [the point on the helix, inferior to the apex]. The points selected have been used in previous acupuncture studies as sham control. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
10024728|NCT01707706|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
10024729|NCT01707719||Alzheimer's disease|
10024730|NCT01707719||Non demented subjects|
10024731|NCT01707732|Active Comparator|Enoxaparin 40mg/ day|Enoxaparin administrated at the following dose : 40mg/ day
10024732|NCT01707732|Experimental|Enoxaparin 60 mg/day|Enoxaparin administrated at the following dose : 60 mg/day
10024733|NCT01707745|Other|Avastin|Bevacizumab(Avastin) 0.75mg in 0.03 ml
10024734|NCT01707758||pancreatic cancer|This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
10024735|NCT01707771|Active Comparator|Roux-en-Y gastric bypass|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
10024736|NCT01707771|Active Comparator|diet and lifestyle modifications|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
10024737|NCT01707784||Women with gestational diabetes|Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
10024738|NCT01707784||Women without gestational diabetes|Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
10024739|NCT01707797||Healthy children aged 9-15 months|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status and/or race/ethnicity to ensure a diverse representation. Each child will be paired with the primary caregiver, whom the investigators expect to most likely be the adult parent or legal guardian.
10024740|NCT01707810|Sham Comparator|Conventional method|In the conventional method IVC was clamped during the anhepatic phase and venous return was maintained by a portal femoral axillary venovenous bypass with a centrifugal pump. In these cases, IVC reconstruction was performed by end-to-end anastomosis above and below the liver.
10024741|NCT01707810|Experimental|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
10024742|NCT01707823|Experimental|Prevention (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO for 7 days.
10024743|NCT01707836||Family|Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
10024744|NCT01707849|Active Comparator|MMF arm|"MMF arm (n=20)~They will receive immunosuppression as stipulated by hospital protocol:~Tacrolimus (levels 8-10ng/mL) and Mycophenalate mofetil 1mg bid(levels 1-3ng/mL)."
10024745|NCT01707849|Experimental|EVL arm|"EVL arm (n=20):~Tacrolimus (levels 8-10ng/ml) + everolimus 1mg bid (levels 2-4 ng/mL)"
10024746|NCT01707875||fetal ventricle brain asymmetry|
10024747|NCT01707888||major lung resection|Patients undergo major lung resection by thoracoscopy/VATS.
10024748|NCT01707901|Experimental|ONO-8539|ONO-8539
10024749|NCT01707901|Placebo Comparator|Placebo|Placebo
10024750|NCT01707914|Experimental|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
10024751|NCT01707914|Placebo Comparator|Placebo|Consume 500 mL placebo/d (250 mL placebo twice daily)
10024752|NCT01707927||Trifecta|Degenerated aortic valve with indication for aortic valve replacement
10024753|NCT01707927||mosaic Ultra|Need a aortic valve replacement
10024754|NCT01707940|Experimental|BI 144807|subjects receive an oral single dose of BI 144807
10024755|NCT01707940|Experimental|BI 144807 plus Ketoconazole|subjects receive bid ketoconazole plus an oral single dose of BI 144807
10024756|NCT01707953|Experimental|Midodrine|Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.
10024757|NCT01707953|Placebo Comparator|Placebo|Placebo administered as capsule 5- and 23 hours after end of surgery.
10024758|NCT01707966|Experimental|Orteronel and best supportive care|Arm A: 300mg Orteronel twice daily and best supportive care until occurrence of an event.
10024759|NCT01707966|Placebo Comparator|Placebo and best supportive care|Arm B: Placebo twice daily and best supportive care until occurrence of an event.
10024760|NCT01707979||Diabetic neuropathy|Male participants, type1 diabetic with diabetic neuropathy
10024761|NCT01707979||Diabetes without neuropathy|Male participants, type1 diabetic without diabetic neuropathy
10024762|NCT01707979||Non diabetic control|Male participants, control group non diabetic
10024763|NCT01708005|Active Comparator|Intervention|80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
10024764|NCT01708005|Placebo Comparator|Placebo|"80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks.~Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week."
10024765|NCT01708018|No Intervention|Control group|Prior and post intervention period (on days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). Survey concerning birth.
10024766|NCT01708018|Experimental|Intervention group|Prior and post intervention (days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). After the second intervention(day 4): qualitative questionnaire for intervention-group only. Survey concerning birth.
10024767|NCT01708031|Experimental|stress inducing task|Normal subjects without history medication presently will be participated. Stress induced through stress inducing task (mental arithmetic task), the physiological signals collected before and during the task simultaneously. All the subjects will be participating only once in this MAT based study. Because, the stress will not be possible to induce when the subject is more familiar with the stress inducing task.
10024768|NCT01708044|Experimental|Pramlintide 6 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
10024769|NCT01708044|Experimental|Pramlintide 9 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
10024770|NCT01708044|Experimental|Pramlintide 12 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
10024771|NCT01708044|Placebo Comparator|Placebo|
10036666|NCT01817816|Experimental|Botox_A|receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)
10024772|NCT01708070|Active Comparator|Asthma self-management experimental|The intervention will involve a self-management workbook, contracting to improve self-management behaviors, instruction in using of a peak flow meter, and follow-up discussions based on the workbook.
10024773|NCT01708070|Other|Asthma self-management control|The control state will involve a self-management workbook and contracting to improve self-management behaviors.
10024774|NCT01708083||Type 2 Diabetes and BMI>35|Patients with type 2 diabetes and body mass index 35 or more.
10024775|NCT01708083||BMI>35|Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
10024776|NCT01708083||BMI 18-27|Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
10024777|NCT01708096|Active Comparator|Modifast|treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass,
10024778|NCT01708096|Placebo Comparator|Normal diet|normal diet 2 weeks before gastric by-pass surgery
10024779|NCT01708109|Experimental|Biliary calculus remain|biliary calculus, less than or equal to 6 mm, remains
10024780|NCT01708109|Experimental|Biliary calculus removed|biliary calculus, less than or equal to 6 mm, removed
10024781|NCT01708135|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in preparing for bariatric surgery.
10024782|NCT01708148|Active Comparator|Lactobacilli|30 Participants with verum
10024783|NCT01708148|Placebo Comparator|Placebo|30 Participants
10024784|NCT01708200|Experimental|Memory Intervention|Two types of memory protocols (psychoeducational vs computerized) will be compared in a population of individuals with mental illness.
10024785|NCT01708226|Experimental|Attention Modification Program|Attention Modification Program
10024786|NCT01708239||Pregnant women|Pregnant women with suspected DVT assessed by the LEFt rule, D-dimer measurement and complete ultrasonography.
10024787|NCT01708252|Experimental|Ulthera treatment group|All subjects will receive an Ulthera System Treatment
10024788|NCT01708265|Active Comparator|Early mitral valve repair|Early mitral valve repair
10024789|NCT01708265|Active Comparator|Watchful waiting|Watchful waiting
10024790|NCT01708304|Other|RDAD|Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
10024791|NCT01708330|Placebo Comparator|Placebo gel|Placebo gel applied topically to the cervix
10024792|NCT01708330|Experimental|Lidocaine gel|2% lidocaine gel applied topically to the cervix
10024793|NCT01708343|Sham Comparator|Placebo-sham|Placebo-sham twice a week during four weeks
10024794|NCT01708343|Active Comparator|Lidocaine injection|Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
10024795|NCT01708343|Experimental|DIMMST|"DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).~Twice a week during four weeks"
10024796|NCT01708356|Experimental|Normal cycling|Cycling on a residential and downtown route (crossover design)
10024797|NCT01708369|Active Comparator|Oseltamivir & Placebo|Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
10024798|NCT01708369|Experimental|Oseltamivir & Ethanol|Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
10024799|NCT01708369|Active Comparator|Aspirin & Placebo|Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
10024800|NCT01708369|Experimental|Aspirin & Ethanol|Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
10024801|NCT01708382|Experimental|Ultherapy treatment on the elbows|All enrolled subjects will receive one Ultherapy treatment to the elbows.
10024802|NCT01708395||Cohort 1|First 50 patients
10024803|NCT01708395||Cohort 2|2nd group of 50 patients
10024804|NCT01708408||community|
10024805|NCT01708434|Experimental|Ulthera® treatment of the knees|Bilateral treatment of the knees using the Ulthera® System
10024806|NCT01708447|Active Comparator|Topical anesthetic - L.M.X.4.® cream|Topical anesthetic cream, L.M.X.4.® cream, applied to one side of the face and neck prior to Ulthera System treatment.
10024807|NCT01708447|Placebo Comparator|Placebo cream|A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment.
10024808|NCT01708460|Experimental|Ulthera-treated subjects|All enrolled subjects will receive one Ultherapy treatment to one side of the body in the lateral buttock region. Following study completion, subjects may elect to receive a balancing treatment to the other side of the body.
10024809|NCT01708473|Active Comparator|Advil with Ultherapy|Subjects randomized to this study arm will receive Advil prior to an Ulthera System Treatment.
10024810|NCT01708473|Active Comparator|Lortab with Ultherapy|Subjects randomized to this study arm will receive Lortab prior to an Ulthera System Treatment.
10024811|NCT01708486||Adolescents' with asthma using inhalation devices|Asthmatic adolescents will record their opinion for their inhalation devices by replying to FSI-10 questionnaire
10036667|NCT01817816|Placebo Comparator|placebo_A|receiving placebo injection at both aLE & aUE ; receiving Botox-A at both aLE & aUE at 6-month.
10036668|NCT01817816|Experimental|Botox_B|receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.
10036669|NCT01817816|Placebo Comparator|placebo_B|receiving placebo injection at both aLE & aUE ; receiving Botox-A only at aLE at 6-month.
10024812|NCT01708499|Experimental|Study treatment|All enrolled subjects will receive one Ulthera System Treatment.
10024813|NCT01708512|Experimental|Ultherapy™ study treatment|Each subject will receive a customized, high-density, vectored Ulthera System Treatment.
10024814|NCT01708538|Active Comparator|Epithelium on|Epi not removed during CXL treatment
10024815|NCT01708538|Active Comparator|Epithelium off|Epi removed before CXL treatment
10024816|NCT01708564|Experimental|Cohort 1|10 patients administered a single low dose of rhFVIIa
10024817|NCT01708564|Experimental|Cohort 2|10 patients administered a single intermediate dose of rhFVIIa
10024818|NCT01708564|Experimental|Cohort 3|10 patients administered a single high dose of rhFVIIa
10024819|NCT01708577|Experimental|IPANEMA validation without water intake|The one group is restricted to the water intake during the Indoor phase during testing the IPANEMA measurement system. The other group is not restricted to the water intake.
10024820|NCT01708577|Experimental|IPANEMA validation with water intake|The one group is restricted to the water intake during the Indoor phase, the other group is not restricted to the water intake.
10024821|NCT01708616|Placebo Comparator|Placebo + risperidone|
10024822|NCT01708616|Placebo Comparator|Placebo +placebo|
10024823|NCT01708616|Active Comparator|RO5285119 + placebo|
10024824|NCT01708616|Experimental|RO5285119 + risperidone|
10024825|NCT01708642|Experimental|Adrenaline|Intraoperative low-dose adrenaline infusion
10024826|NCT01708642|Placebo Comparator|Placebo|Placebo: Isotonic Saline
10024827|NCT01708655|Other|Sweat Evaporimeter measurement|"0.1 ml Carbachol, intraocular solution - diluted to 0.1 µg/ml in normal saline- dose 0.01 µg~0.2 ml Atropine sulphate, injection solution - diluted to 44 µg/ml in normal saline - dose 8.8 µg.~0.2 ml of the Beta cocktail injection solution diluted to 44 µg/ml atropine, 22 µg/ml isoproterenol and 4.6 mg/ml aminophylline in normal saline - dose:~4.4 µg Isoproterenol hydrochloride, injection solution~0.93 mg Aminophylline injection solution~8.8 µg Atropine, injection solution"
10024828|NCT01708668|Active Comparator|1|Epidural analgesia (EA) with continuous epidural infusion(CEI)
10024829|NCT01708668|Active Comparator|2|Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)
10024830|NCT01708668|Active Comparator|3|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
10024831|NCT01708668|Active Comparator|4|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
10024832|NCT01708668|Active Comparator|5|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
10024833|NCT01708668|Active Comparator|6|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
10024834|NCT01708668|Active Comparator|7|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
10024835|NCT01708668|Active Comparator|8|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
10024836|NCT01708681|Experimental|Lean seafood|Cross-over design, half of the subject will receive lean seafood in study period I and the other half in study period II
10024837|NCT01708681|Active Comparator|Meat, egg, milk|Cross-over design, half of the subject will receive meat, egg, milk in study period I and the other half in study period II
10024838|NCT01708694|Placebo Comparator|Placebo Starch|Yogurt with about 45 g/day of placebo starch (amylopectin).
10024839|NCT01708694|Experimental|Experimental Starch|Yogurt with about 45 g/day of slowly digestible starch (amylose).
9479706|NCT03540641|Active Comparator|5000 pulses|This group will receive 5000 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions.
10024840|NCT01708707|Active Comparator|Oral morphine sulfate|Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine
10024841|NCT01708707|Experimental|Buprenorphine|Sublingual Buprenorphine 15.9 µg/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome
10024842|NCT01708720|Experimental|Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
10024843|NCT01708720|Experimental|Adjuvanted Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
10024844|NCT01708720|Active Comparator|IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose
10024845|NCT01708733|Placebo Comparator|KSY diluted|KSY diluted, 100mg decoction by mouth per day for 6 weeks
10024846|NCT01708733|Experimental|KSY|KSY, 100mg decoction by mouth per day for 6 weeks
10024847|NCT01708746||Enrolled subjects|
10024848|NCT01708746||Historic control|
10024849|NCT01708759||Sepsis|Forty patients developed septic complication during ICU stay (sepsis group).
10024850|NCT01708759||SIRS|Forty patients were critically ill without evidence of infectious organism (SIRS group).
10024851|NCT01708772||Sepsis|Forty five patients developed septic complication during ICU stay (sepsis group).
10024852|NCT01708772||SIRS group|Forty five patients were critically ill without evidence of infectious organism (SIRS group).
10024853|NCT01708785|Active Comparator|Single context|Subjects will be exposed to food cues in a single context.
10024854|NCT01708785|Experimental|Multiple contexts|Subjects will be exposed to food cues in multiple contexts.
10024855|NCT01708785|Active Comparator|8 treatment sessions|Subjects receive 8 treatment sessions.
10024856|NCT01708785|Experimental|16 treatment sessions|Subjects receive 16 treatment sessions
10024857|NCT01708798|Placebo Comparator|Placebo|"One tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to one tablet by mouth daily."
10024858|NCT01708798|Experimental|Eplerenone|"Eplerenone 25 mg tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily."
10024859|NCT01708824|Experimental|dietary|"Dietary intervention to meet the target of~1.<5 servings of red/processed meat weekly; <2 servings would be processed meat 2.2 servings of refined grains daily"
10024860|NCT01708824|Experimental|physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
9479707|NCT03540641|Sham Comparator|5000 pulses sham|this group will receive the sham modality of the protocol of 5000 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
9479708|NCT03540628|No Intervention|Placebo Arm|The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care to care for septic shock. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
9479709|NCT03540628|Experimental|Thiamine and Vitamin C administration Arm|The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
9479710|NCT03540615|Experimental|BAY1830839|Single Dose escalations
10024861|NCT01708824|Experimental|dietary and physical activity|Meeting both the dietary and physical activity targets
10024862|NCT01708824|No Intervention|usual care|Follow the general lifestyle advice in accordance with the recommendations of the Department of Health in Hong Kong available in the public domain
10024863|NCT01708837|Other|deep anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 30-45
10024864|NCT01708837|Other|light anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 45-60
10024865|NCT01708850|Other|Rivaroxaban|Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
10036670|NCT01817829|Active Comparator|paracetamol|paracetamol 2 tablets1000mg PO.
10024866|NCT01708863||Children with Hypoplastic Left Heart Syndrome (HLHS)|HLHS patients requiring Stage II Glenn surgery
10024867|NCT01708876|Active Comparator|Artesunate-mefloquine|3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
10024868|NCT01708876|Active Comparator|Chloroquine|4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.
10024869|NCT01708889|Experimental|Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2
10024870|NCT01708889|Experimental|Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2
9479711|NCT03540615|Placebo Comparator|Placebo|Matching Placebo
9479712|NCT03540602|Placebo Comparator|Placebo|Rice flour capsule
10024871|NCT01708889|Experimental|Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2
10024872|NCT01708889|Experimental|Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2
10024873|NCT01708889|Experimental|Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR < 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)
10024874|NCT01708928|Active Comparator|Group A|Subjects who have previous history of submentoplasty and or rhytidectomy
10024875|NCT01708928|Active Comparator|Group B|Subjects naïve to submentoplasty and or rhytidectomy
10024876|NCT01708980|Experimental|Six different strength training exercises|Six different strength training exercises are investigated. Four repetitions of each exercise are performed with a relative loading of 10 RM.
10024877|NCT01708993|Active Comparator|Arm A: Pemetrexed and Reolysin (and safety run-in)|
10024878|NCT01708993|Active Comparator|Arm B: Pemetrexed|
10024879|NCT01708993|Active Comparator|Arm C: Docetaxel and Reolysin (and safety run-in)|
10024880|NCT01708993|Active Comparator|Arm D: Docetaxel|
10024881|NCT01709006|Other|Radiation therapy|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
10024882|NCT01709019|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
10024883|NCT01709019|Experimental|Group B|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
10024884|NCT01709019|Experimental|Group C|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
10024885|NCT01709019|Experimental|Group D|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
10024886|NCT01709019|Placebo Comparator|Group E|Placebo (Day 0 & Day 28); Seasonal TIV (Day 28)
10024887|NCT01709045||Patients scheduled for CEA|All patients who are scheduled for carotid endarterectomy (CEA)
10024888|NCT01709058|Experimental|Intramuscular/paravertebral injections of Oxygen-Ozone|"This group will be treated with Intramuscular/paravertebral injections of Oxygen-Ozone twice a week for six weeks"
10024889|NCT01709058|Other|Simulated treatment|"The Simulated intramuscular/paravertebral injections will mimic the Oxygen-Ozone injections in the area to be treated by pricking the skin with the needle without drilling. These simulated injections will be performed twice a week for six weeks."
10024890|NCT01709071|Experimental|Low dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
10024891|NCT01709071|Experimental|Low dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
9479713|NCT03540602|Active Comparator|Polyphenol Rich Supplement|NordicCherry Tart Cherry Extract Powder 500 mg in capsule form
10024892|NCT01709071|Experimental|Middle dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
10024893|NCT01709071|Experimental|Middle dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
10024894|NCT01709071|Experimental|High dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
10024895|NCT01709071|Experimental|High dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
10024896|NCT01709071|Active Comparator|Conventional IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.~Infants receive three injections with an interval of 8 weeks between doses."
10024897|NCT01709097||With Med-O-Wheel™|Kidney Transplant Recipient with Med-O-Wheel™
10024898|NCT01709097||With out Med-O-Wheel™|Kidney Transplant Recipient with out Med-O-Wheel™
10024899|NCT01709123|Placebo Comparator|placebo|Placebo supplementation in pill form for 3 months following randomization after a placebo run-in period.
10024900|NCT01709123|Experimental|chromium niacinate|Chromium niacinate supplementation (200ug or 500ug/day) in pill form for 3 months following randomization after a placebo run-in period
10024901|NCT01709175|Experimental|Once-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the once-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet ONCE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
10024902|NCT01709175|Experimental|Twice-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the twice-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet TWICE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
10024903|NCT01709188|Experimental|Musical Dual Task Training|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the Musical Dual Task Training session, participant will be asked to sing familiar songs, play simple percussive musical instruments such as paddle drums and shakers, sing while walking, and play instruments while walking.
10024904|NCT01709188|Active Comparator|Walking and Talking|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the walking and talking session, participant will be asked to read a newspaper article prior to a walk and have a conversation with the music therapist based on the content of the news while walking.
10024905|NCT01709201|No Intervention|Treatment as Usual|Those in the Treatment as Usual group will not receive the brief intervention for substance use but will receive a brief health education brochure.
10024906|NCT01709201|Experimental|Brief Intervention|Those in the Brief Intervention group will receive a brief motivational intervention aimed at encouraging the participant to decrease their substance use.
10024907|NCT01709240|Experimental|BioWeld1 System|
10024908|NCT01709253|Experimental|Arm 1|27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
10024909|NCT01709253|Experimental|Arm 2|27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
10024910|NCT01709253|Experimental|Arm 3|27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
10024911|NCT01709253|Experimental|Arm 4|27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
10024912|NCT01709266|Experimental|Probiotics|Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
10024913|NCT01709266|Placebo Comparator|Placebo|Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.
10024914|NCT01709279|Other|adipose tissue derived stromal cells|
10024915|NCT01709292|Experimental|Vemurafenib - (Presurgery)|All Groups: Vemurafenib 960 mg by mouth 2 times a day for 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56 +/- 7 days).
10024916|NCT01709292|Experimental|Vemurafenib (Post Surgery) - Group A|Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
10024917|NCT01709292|No Intervention|Post Surgery - Group B|Post Surgery - Group B: Patients discontinue vemurafenib after surgery but will be restaged with CT neck 8 weeks after surgery.
10036671|NCT01817829|Placebo Comparator|placebo|placebo 2 tablets containing Starch PO
10024918|NCT01709292|Experimental|Vemurafenib - Group C|Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56, Vemurafenib 960 mg by mouth twice a day unless there is evidence of progressive disease on day 56 CT scan. Patients evaluated for resectability after each CT scan is performed. If scheduled for resection, patient continues vemurafenib until surgery and follows same treatment schema as patients in Groups A and B.
10024919|NCT01709344|Experimental|PS-OT|Problem-solving Occupational Therapy
9802902|NCT04834336|Experimental|Physical training plus inspiratory muscle training|"Inspiratory Muscle Training (IMT) will be implemented by using the Power Breathe® device. IMT training will begin with mild to moderate intensity of maximal inspiratory pressure. It will be performed 6 to 10 breaths, 4 sets, and twice daily during the hospitalization when as soon as hemodynamic stability is provided.~Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided."
10024920|NCT01709344|Other|Usual care|Access to all supportive and rehabilitative services available at DHMC
10024921|NCT01709357|Experimental|Muscle energy technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the muscle energy technique of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
10024922|NCT01709357|Experimental|Ischemic compression technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed ischemic compression technique on the latent trigger point.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
10024923|NCT01709357|Experimental|Passive stretching technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the passive stretching of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
10024924|NCT01709357|Sham Comparator|Sham technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, for the sham technique, the therapist only contacted with his hands the head and the shoulder of the subject, without executing any movement, for 30 seconds.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
9518236|NCT03298529|Experimental|Hyperproteic pasta (with added gluten and albumin)|"Hyperproteic pasta (with added gluten and albumin). 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with added gluten and albumin. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
10024925|NCT01709357|No Intervention|No intervention group|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next,the subject was lying for 30 seconds, without intervention.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
10024926|NCT01709370|Experimental|Letrozole plus PD 0332991|Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery
10024927|NCT01709396|Experimental|18 cGY ED-TBI|18 cGY ED-TBI followed by an allogenic done marrow transplant
10024928|NCT01709435|Experimental|Treatment (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10024929|NCT01709487|Experimental|HIPEC surgery with chemotherapy|"3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks~Debulking surgery~HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery~3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
10024930|NCT01709526|Other|Improvement after psychiatric inpatient treatment|
10024931|NCT01709552|Experimental|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
10024932|NCT01709552|Sham Comparator|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
10024933|NCT01709565||No hepatic dysfunction|No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
10024934|NCT01709565||Hepatic dysfunction|Hepatic dysfunction, total plasma bilirubin > 2.0 mg/dl
10024935|NCT01709591|No Intervention|No Prenatal education|These subjects will be randomized to receive routine prenatal epidural class (control group).
10024936|NCT01709591|Active Comparator|Receives Prenatal Education|Subjects randomized to this group will receive educational video addressing the cultural and perceptions regarding the myths on epidural in either English or Spanish (Keeping an Open Mind: choices in Labor Anaglesia: an educational produce of the Society for Obstetric Anesthesia and perinatology)
10024937|NCT01709604||continuous venovenous hemofiltration|Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
10024938|NCT01709604||Standardized therapy regimens|The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
10024939|NCT01709617|Experimental|Glucose-glucose|Glucose ingestion
10024940|NCT01709617|Active Comparator|Glucose-Fructose|glucose-fructose ingestion
10024941|NCT01709617|Active Comparator|disaccharide|Disaccharide ingestion
10024942|NCT01709630||Neonatal|Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection.
10024943|NCT01709630||Maternal|Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection
10024944|NCT01709643|Other|High fat breakfast lean subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
10024945|NCT01709643|Other|High fat breakfast,obese subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
10024946|NCT01709643|Other|HF breakfast with protein,lean subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
10024947|NCT01709643|Other|HF breakfast with protein,obese subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
10024948|NCT01709656|Experimental|MSC plus NSAID|"human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os).~Duration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
10024949|NCT01709656|Experimental|NSAID|"non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
10024950|NCT01709669||Enrolling by invitation|
10024951|NCT01709682|Active Comparator|AAD therapy|Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
10024952|NCT01709682|Active Comparator|re-ablation procedure|"Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs."
10024953|NCT01709734|Experimental|Dose Confirmation|"Dose A - galeterone tablets once daily PO for three months + extension~Dose B - galeterone tablets once daily PO for three months + extension~Dose C - galeterone tablets once daily PO for three months + extension"
10024954|NCT01709734|Experimental|Dose Expansion|Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
10024955|NCT01709760|Experimental|methotrexate & ENIA11|ENIA11 25 mg, sc twice weekly
10024956|NCT01709760|Active Comparator|methotrexate & Placebo|Placebo, sc twice weekly
10024957|NCT01709773|Experimental|Focal treatment arm|
10024958|NCT01709812|Other|1 standard care|standard care
10024959|NCT01709812|Experimental|2 individualized PSP|individualized patient support program
10024960|NCT01709825|Placebo Comparator|Sugar Pill|Sugar Pill will be taken as a capsule once daily for 6 weeks.
10024961|NCT01709825|Experimental|Probiotic- Bifidobacterium bifidum|Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
10024962|NCT01709825|Experimental|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
9802903|NCT04834336|Active Comparator|Physical training|Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided.
10024963|NCT01709825|Experimental|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
10024964|NCT01709851||Type 1 Diabetes - vMD and sMD|Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)
9802904|NCT04832659|Active Comparator|CEASE|Those assigned to the Active Comparator arm will receive the CEASE intervention.
10024965|NCT01709851||Type 1 diabetes - vMD|Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)
10024966|NCT01709877|Active Comparator|Traditional multiport laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy performed by the traditional multiport technique
10024967|NCT01709877|Experimental|Single port laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using the reusable ENDOCONE system with dedicated curved coaxial instruments
10024968|NCT01709890||Airway catheter during sedation|
10024969|NCT01709916||Glaucoma patients|Glaucoma patients treated with eye drops to lower the IOP.
10024970|NCT01709929|Experimental|Insulin detemir|
10024971|NCT01709942|Experimental|degarelix group|group of patients treated with long acting GnRH antagonist
10024972|NCT01709942|Active Comparator|Cetrorelix 0.25mg|patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
10024973|NCT01709955|Experimental|Gucomannan|
10024974|NCT01709955|Placebo Comparator|Placebo pill|
10024975|NCT01709968|Experimental|MAGNOX 520®|MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
10024976|NCT01709968|Placebo Comparator|Similarly looking placebo.|Similarly looking placebo. Oral administration once daily for 4 weeks.
10024977|NCT01709994|Active Comparator|aspirin|Aspirin dosage 100 mg/day
10024978|NCT01709994|No Intervention|standard medication|the patients will continue with standard medication
10024979|NCT01710007|Experimental|1PC002|2 mg 1PC002 once daily for 12 weeks.
10024980|NCT01710007|Active Comparator|Lipitor|10 mg atorvastatin once daily for 12 weeks.
10024981|NCT01710059|Experimental|Experimental: Intervention Group|"Experimental: Intervention Group~1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma."
10024982|NCT01710072|Experimental|aspirin|aspirin 81 mg po every day
10024983|NCT01710072|No Intervention|no aspirin|
10024984|NCT01710085|Experimental|Diffusion weighted imaging, Recurrence|
10024985|NCT01710098||Degarelix|adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year
10024986|NCT01710111|Experimental|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
9518237|NCT03298529|Experimental|Pasta with only four egg whites/kg flour|"Pasta with only four egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only four egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
10024987|NCT01710111|No Intervention|Control Recipients|No face shield and no repeat hand hygiene measures
10024988|NCT01710124|Experimental|Incentive|Subjects in this group will receive financial incentives for using grocery coupons to purchase healthy foods.
10024989|NCT01710124|No Intervention|No incentive|Subjects in this group will receive no financial incentives.
10024990|NCT01710150|Placebo Comparator|CTI ablation only|subjects undergoing cavo-tricuspid isthmus (CTI) ablation alone for Atrial flutter
10024991|NCT01710150|Active Comparator|CTI ablation and PVI.|subjects undergoing cavo-tricuspid isthmus (CTI) ablation for Atrial flutter and pulmonary vein isolation (PVI) for Atrial Fibrillation.
10024992|NCT01710163|Experimental|Lithium|Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)
10024993|NCT01710163|Experimental|Aripiprazole|Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)
10024994|NCT01710189|Experimental|TicoVac immunisation - right deltoid muscle|IM immunisation right deltoid muscle
10024995|NCT01710189|Experimental|TicoVac immunisation - upper anterolateral thigh|IM: right upper anterolateral thigh
10024996|NCT01710202||Placebo|Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
10024997|NCT01710202||Experimental: Hydrocortisone|Group will receive 20mg oral hydrocortisone
10024998|NCT01710215|No Intervention|Usual Care|"No outreach mailed invitations.~Ordering of colonoscopy or FIT for screening at the discretion of the primary provider.~Follow up of abnormal tests and results reporting to the patient at the discretion of primary and specialty providers."
10024999|NCT01710215|Experimental|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
10025000|NCT01710215|Experimental|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
10025001|NCT01710228|Placebo Comparator|Methylprednisolone placebo|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
10025002|NCT01710228|Experimental|methylprednisolone|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
10025003|NCT01710267||Observation group|This group includes all volunteers of this observation study.
10025004|NCT01710280|Active Comparator|Native palm olein|75 g native palm olein
10025005|NCT01710280|Experimental|Interesterified palm olein|75 g interesterified palm olein
10036672|NCT01817842|Experimental|mEX support|Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support. Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
10025006|NCT01710293|Experimental|Communication of Patients Lost to Follow-up to Providers|This intervention will consist of two related, continuous steps over at least a 12-month period. In the first step, the investigators will query the VA's Corporate Data Warehouse (CDW, a repository of near real-time patient data from all VA medical centers) weekly to identify possible lost to follow-up events in a pre-specified time period and for a random sample of about half of the providers at the investigators' study sites. These identified patient charts will be reviewed by Facility Recipients/Cancer Trackers at each site who will then communicate patients truly found to be lost to follow-up to the appropriate provider/care team.
10025007|NCT01710293|No Intervention|Usual Care|In the usual care group, providers will continue to use the existing notification system to receive abnormal test results in accordance with institutional norms, policies, and procedures. There are no formal patient-tracking programs currently at our study sites for all abnormal test results. The investigators will apply our computerized surveillance tools in the usual care arm only when the investigators are ready to conduct the final chart reviews on intervention patients and identify these patients in similar time periods as in the intervention arm. If persistent delays are found, the investigators will inform the patients' primary care providers.
10025008|NCT01710319||smoker with lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
10025009|NCT01710319||smoker without lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
10025010|NCT01710319||nonsmoker with lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
10025011|NCT01710319||nonsmoker without lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and do not have lung cancer
10025012|NCT01710371|Experimental|Arginine Stimulation Testing|Establish the methodology for glucose enhanced arginine stimulation testing (AST).
10025013|NCT01710371|Experimental|PET Imaging|Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD) and Type 2 Diabetes mellitus (T2DM).
10025014|NCT01710384|Experimental|betamethasoneb, 34-36 weeks, preterm labor|betamethasone 12 mg 2 injections will be given 24-hours apart.
10025015|NCT01710384|No Intervention|preterm labor, 34-37 weeks|betamethasone 12 mg 2 injections will be given 24-hours apart.
10025016|NCT01710397|No Intervention|Standard group, non-pregnant adults|Comparison group (prospective enrollment)
10025017|NCT01710397|No Intervention|Standard group, pregnant women|Comparison group (retrospective record review)
10025018|NCT01710397|Experimental|Rapid group, non-pregnant adults|Rapid ART initiation
10025019|NCT01710397|Experimental|Rapid group, pregnant women|Rapid ART initiation
10025020|NCT01710410|Experimental|DLPFC tDCS (left anode/right cathode)|Active transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
10025021|NCT01710410|Experimental|DLPFC tDCS (left cathode/right anode)|Active transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
10025022|NCT01710410|Sham Comparator|DLPFC tDCS|Sham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
10025023|NCT01710423|Experimental|Immediate Intervention|Peer mentoring intervention ('Cooking with Friends')
10025024|NCT01710423|No Intervention|Delayed Entry Control|
10025025|NCT01710436||Low dose - Wild genotype (LW)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
10025026|NCT01710436||Low dose - Variant genotype (LV)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
10025027|NCT01710436||High dose - Wild genotype (HW)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
10025028|NCT01710436||High dose - Variant genotype (HV)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
10025029|NCT01710449|Experimental|Normal|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
10025030|NCT01710449|Experimental|Lung Disease|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
9518238|NCT03298516|Experimental|Arm A: DCLL9718S|Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
10025031|NCT01710462|Experimental|Pantoprazole + Domperidone|The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma. For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
10025032|NCT01710462|Active Comparator|Pantozol® (Takeda)|The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg. For this study will be used 20 mg tablets.
10025033|NCT01710488|Active Comparator|Levofloxacin 1 tablet 500 mg once a day|Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
10025034|NCT01710488|Experimental|Prulifloxacin 1 tablet 600 mg once a day|Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
10025035|NCT01710540|Other|Metformin GSK 850mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 850mg
10025036|NCT01710540|Other|Glucophage 850mg|open label, crossover, two period, two treatment, two sequence, single dose
10025037|NCT01710553|Other|Metformin GSK 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 1000mg
10025038|NCT01710553|Other|Glucophage 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Glucophage 1000mg to asset bioequivalence
10025039|NCT01710566|Experimental|Group 1|600 mcg oral misoprostol
10025040|NCT01710566|Experimental|Group 2|10 IU oxytocin in Uniject
10025041|NCT01710579|Other|ARM 1 Healthy Volunteers|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
10025042|NCT01710579|Other|ARM 2: Patients with fecal incontinence|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
10025043|NCT01710579|Other|ARM 3 Patients with constipation|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
10025044|NCT01710592|Active Comparator|Epirubicin, Oxaliplatin, Capecitabine|"Epirubicin 50mg/m2 (day 1) bolus injection~Oxaliplatin 130mg/m2 (day 1) in 250mls of 5% dextrose. i.v. over 2 hours~Capecitabine 625mg/m2 (days 1-21) b.d. orally~8 x 3-weekly cycle"
10025045|NCT01710592|Active Comparator|Docetaxel, Oxaliplatin|"Docetaxel 20mg/m2 (days 1, 8 & 15)in 250mls of 5% dextrose. i.v. over 30mins (Dexamethasone 8mg i.v, Chlorpheniramine 10mg i.v,Ranitidine 50mg i.v. to be given 30 minutes prior to Docetaxel)~Oxaliplatin 85mg/m2 (days 1 & 15)in 250mls of 5% dextrose. i.v. over 2 hours~6 x 4-weekly cycle"
10025046|NCT01710605|Active Comparator|Standard|Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.
10025047|NCT01710605|Experimental|Circulating Tumor Cells|"Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :~If <5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy"
10025048|NCT01710631|Experimental|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
10025049|NCT01710631|Placebo Comparator|placebo|placebo tablet
10025050|NCT01710670|Experimental|Ethanol + Brivaracetam|Treatment A: Ethanol + Brivaracetam
10025051|NCT01710670|Experimental|Ethanol Placebo + Brivaracetam|Treatment B: Ethanol Placebo + Brivaracetam
10025052|NCT01710670|Experimental|Ethanol + Brivaracetam Placebo|Treatment C: Ethanol + Brivaracetam Placebo
10025053|NCT01710683||Control group|Median age 45 years, 18-63.
10025054|NCT01710683||Intervention group|Median age 46 years, 18-62.
10025055|NCT01710696|Experimental|Individual dose|
10025056|NCT01710696|Experimental|Fixed dose|
10025057|NCT01710722|Experimental|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
10025058|NCT01710722|Experimental|leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
10025059|NCT01710722|Experimental|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
10025060|NCT01710735|Experimental|Dry needling (deep)|Subjects receive dry needle insertion deeper than 1,5cm below the skin of the Trapezius.
10025061|NCT01710735|Active Comparator|Dry needling (superficial)|Insertion of dry needle less than 1cm.
10025062|NCT01710748|Active Comparator|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
10025063|NCT01710748|Experimental|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
10025064|NCT01710761|Active Comparator|Nitrate supplement with caffeine|
10025065|NCT01710761|Placebo Comparator|Placebo|
10025066|NCT01710774|No Intervention|Traditional follow-up|Traditional follow-up with standard consultations at the Section of Endocrinology. For some patients, this will include follow-up from nurses in the home care or general practice office related to wound care. However, this is not the standard procedure and will not take place in combination with telemedicine follow-up.
10025067|NCT01710774|Active Comparator|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
10025068|NCT01710813||pompe safety sub-registry|patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry
10025069|NCT01710826|Experimental|Genz-682452|This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
10025070|NCT01710826|Placebo Comparator|Placebo|Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
10025071|NCT01710852|Experimental|Group A|ISIS CRP Rx followed by Placebo
10025072|NCT01710852|Experimental|Group B|Placebo followed by ISIS CRP Rx
10025073|NCT01710865|Experimental|Ultraseal Sealant|Both Ultraseal XT Hydro and Ultraseal XT Plus will be applied on patients.
10025074|NCT01710878|Other|Intergard Synergy Graft|
10025075|NCT01710917||Targinact® (oxycodon/naloxon)|
10025076|NCT01710930|Experimental|Study of predictive factors|
9528738|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
9802905|NCT04832659|Experimental|CEASE + BIO|Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).
10025077|NCT01710943|Experimental|Web-based Cognitive Behavioral Treatment|"Participants who are randomly assigned to the treatment condition will receive the same standard care as those in the control condition and they will also receive access to the web-based CBT intervention. Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial."
10025078|NCT01710943|No Intervention|Treatment as Usual|TAU consists of the usual Veterans Integrated Service Network 2 (VISN) primary care services. As we have described, all of the participants will be recruited from patients presenting for treatment typically for physical complaints in primary care clinics in VA's VISN 2 (Upstate NY). VISN 2 officially practices a co-located, collaborative care model of integrated (behavioral health and physical health) in its primary care clinics. This integrated model has been implemented widely in both VA and non-VA primary care clinics in the United States .
10025079|NCT01710956|Experimental|Arm 1(with twice-daily TRT)|
10025080|NCT01710956|Experimental|Arm 2 (with once-daily TRT)|
10025081|NCT01710969|Experimental|Individual Intervention|behavioral - children receive the Coping Power program in an individual, face-to-face format
10025082|NCT01710969|Experimental|Group Intervention|behavioral - children receive the Coping Power program in a small group format (5-6 children per group)
10025083|NCT01710982|Active Comparator|TZP-101|TZP-101
10025084|NCT01710982|Placebo Comparator|Placebo|Placebo
10025085|NCT01710995|Active Comparator|Zegerid 20mg capsule|Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
10025086|NCT01710995|Active Comparator|Zegerid 20mg powder for oral suspension|Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
10025087|NCT01710995|Active Comparator|Losec 20mg capsule|Losec 20mg capsule (20mg omeprazole)
10025088|NCT01711008|Placebo Comparator|No Breakfast|Water only
10025089|NCT01711008|Active Comparator|20g Cereal|20g Kelloggs Special K cereal with 83ml semi-skimmed milk
10025090|NCT01711008|Active Comparator|40g Cereal|40g Kelloggs Special K cereal with 166ml semi-skimmed milk
10025091|NCT01711034|Experimental|OPB-111077|"In escalation stage of study, treatment with a once daily dose of OPB-111077 during cycles 1 and 2 on day 1, followed by 2-day treatment free interval, and then resuming daily dosing on day 4 through day 28. For cycle 3 and beyond, OPB-111077 will be administered for 28 continuous days per cycle until MTD is reached.~In expansion portion of study, established dose of 250mg administered once daily for 28 consecutive days for each cycle. Patient in expansion are defined as those who meet eligibility criteria and have a diagnosed malignancy that is presumed to be susceptible to inhibition by OPB-111077"
10025092|NCT01711047|Active Comparator|PVI + Linear ablation|Arm A: patients have PVI and roof and mitral isthmus lines
10025093|NCT01711047|Active Comparator|PVI + linear ablation + CFAE|Arm B: patients have PVI + roof and mitral isthmus lines and CFAE ablation
10025094|NCT01711060|Experimental|oxytocin|
10025095|NCT01711060|Experimental|balloon catheter|Dufour 1859H18
10025096|NCT01711073|Experimental|Mobilization with G-CSF plus Mozobil|Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)
10025097|NCT01711086|Active Comparator|Inspiromatic followed by Aerolizer|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler.
10025098|NCT01711086|Active Comparator|Aerolizer followed by Inspiromatic|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler.
10025099|NCT01711099|Experimental|ESMR treated|
10025100|NCT01711112|Experimental|docetaxel|Days 1 & 8 Docetaxel 35 mg/m2 IV
10025101|NCT01711125|Experimental|Arm 1|Baclofen low dose
10025102|NCT01711125|Experimental|Arm 2|Baclofen high dose
10025103|NCT01711125|Placebo Comparator|Arm 3|Placebo
10025104|NCT01711138||Intervention|Intervention group is geographically located near a built environment intervention (neighbourhood redevelopment).
10025105|NCT01711138||Comparison|Comparison group is not exposed to the built environment intervention according to their geographic location.
10025106|NCT01711151||Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
10025107|NCT01711151||Non Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
10025108|NCT01711151||Sarciodosis|Questionnaire evaluation
10025109|NCT01711151||Healthy Controls|Questionnaire evaluation
10025110|NCT01711164||patients|Chronic HCV patients who undergo antiviral therapy
10025111|NCT01711164||Healthy controls|healthy controls who are willing to give blood and liver tissue samples
9802906|NCT04830709||PARPi maintenance cohort (PMC)|patients who received at least one dose of PARPi as 1L MTX after 1L platinum-based CTX
10025112|NCT01711203|Experimental|Motor Control|"Pilates-based exercise with verbal cues to facilitate motor control Plank progression, use of feedback tool VERBAL CUES FOR MOTOR CONTROL GROUP (could also include above cues) Maintain neutral spine Not too arched, not too flexed Remember your pilates position Inhale, exhale Let me hear your breath"
10025113|NCT01711203|Active Comparator|General strengthening|"Patient group that will receive active strengthening without specific verbal cueing to recruit deeper abdominal musculature. Core strengthening and lower quarter strengthening is the focus of this group.~Verbal cuing will include:~VERBAL CUEING FOR NON-MOTOR CONTROL GROUP~Keep your back straight Don't slouch Don't arch your back Don't let your body move Nothing should move but your arms tighten up your abs suck in your stomach feet shoulder-width apart, knees bent, shoulders back, hold your stomach tight Time will be kept the same as the intervention group."
10025114|NCT01711229|Active Comparator|Group I: IV acetaminophen|Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair
10025115|NCT01711229|Active Comparator|group 2|Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery
9528739|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
10025116|NCT01711242|Experimental|capecitabine/Oxaliplatin/radiotherapy|"sequence chemoradiotherapy following radical resection~sequence chemoradiotherapy two cycles of XELOX + concurrent chemoradiotherapy + two cycles of XELOX.~Postoperative radiotherapy regimen: Radiotherapy consisted of 4500 centigray of radiation at 180 centigray per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Concurrent chemotherapy regimen: capecitabine 825 mg/m² twice daily Postoperative chemotherapy regimen: see arm 2"
10025117|NCT01711242|Active Comparator|capecitabine/Oxaliplatin|"chemotherapy alone following radical resection~Drug: chemotherapy alone following radical resection Postoperative chemotherapy regimen: The XELOX regimen was administrated: Oxaliplatin, 130mg/m2/day on day1, i.v. 2h; Capecitabine 1000mg/m²/day twice daily d1-14; every 21 days repeated, for 4 cycles."
10025118|NCT01711255||Multiple Sclerosis|Subjects who have been diagnosed with clinically definite or probable multiple sclerosis as defined and recorded by board certified neurologist.
10025119|NCT01711255||Healthy controls|Adults age 18 and older who have not been diagnosed with any neurological, endocrine, or other chronic health condition. They must also be free of any recent acute illness that can impact inflammation/clotting.
10025120|NCT01711281|Experimental|Intracardiac Impedance Measurement|
10025121|NCT01711307|Experimental|non-operative|cast applied within 48 hours
10025122|NCT01711307|Active Comparator|operative|cast applied within 48 hours and surgery within 14 days
10025123|NCT01711320|Placebo Comparator|Placebo|oral dose of Placebo combined with two dose of Metformin (OGTTs)
10025124|NCT01711320|Experimental|Omeprazole|oral dose of Omeprazole (80 mg) combined with two dose of Metformin (OGTTs)
10025125|NCT01711333|Experimental|Pletaal SR capsule|
10025126|NCT01711385|No Intervention|Standard practice|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the basic/control intervention, are informed that it is important to follow-up with their physician regarding their test results. They are contacted by phone once to schedule their 6-month recall visit."
10025127|NCT01711385|Experimental|Enhanced intervention|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit."
10025128|NCT01711398|Experimental|IPP204106N|
10025129|NCT01711437|Experimental|PEG-S|polyethylene glycol 4000 solution with simethicon
10025130|NCT01711437|Experimental|PEG-CS + Bisacodyl|PEG-CS is a new sulphate-free iso-osmotic formulation of PEG-4000 with citrates and simethicone
10025131|NCT01711437|Experimental|PEG-ASC|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
10025132|NCT01711437|Experimental|picoprep|sodium picosulphate plus magnesium oxide and citric acid
10025133|NCT01711450|Experimental|Paravertebral block|Paravertebral space will be needled and an anesthetic agent will be injected.
10025134|NCT01711450|Placebo Comparator|Control sham procedure|Paravertebral space will be needled, but only normal saline injected.
10025135|NCT01711463|Experimental|FF/VI|50/25 mcg, 100/25 mcg or 200/25 mcg
10025136|NCT01711463|Placebo Comparator|Placebo|matching placebo
10025137|NCT01711476|Active Comparator|Lifestyle counseling ARM 1|Arm 1 Breakfast Diet The arm 1 will be assigned to eat High calorie breakfast (800kcal) and reduced dinner (200 kcal) During 90 days from baseline to the end of the trial (day 90)
10025138|NCT01711476|Placebo Comparator|Lifestyle counseling ARM 2|Lean PCOS women in the Arm 2 will be assigned to do a dinner diet from day 0 to day 90 of the trial
10025139|NCT01711489|Experimental|isavuconazole and mycophenolate mofetil|Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
10025140|NCT01711502||Female patients diagosed with metastatic breast cancer|
10025141|NCT01711515|Experimental|Treatment (cisplatin, radiation therapy, and ipilimumab)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36, undergo extended beam radiation therapy 5 days a week for 6 weeks, and then undergo intracavitary brachytherapy for approximately 2 weeks. Within 2 weeks, patients receive ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks.
10025142|NCT01711528|Experimental|Schedule I (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10025143|NCT01711528|Experimental|Schedule II (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10025144|NCT01711567|Active Comparator|entecavir|standard drugs
10025145|NCT01711567|Active Comparator|tenofovir|study drugs
10025146|NCT01711580||Re-irradiation, high grade glioma|EORTC QLQ-C30 EORTC QLQ-BN20 Hopkins Verbal Learning Test-Revised (HVLT-R) Trail Making Test (TMT) Stroop color-word test Controlled oral word association test (COWA) Jamar hand dynamometer EORTC QLQ- FA13 Short Form health survey (SF-36)
10025147|NCT01711593|Experimental|Allergic Asthmatic, Non-allergic non-asthmatics(HC)|Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
10025148|NCT01711606||unselected Fragile-X patients|
10025149|NCT01711632|Experimental|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
10025150|NCT01711671|Experimental|DKN-01 300mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
10025151|NCT01711671|Experimental|DKN-01 600mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
10025152|NCT01711671|Active Comparator|Standard of Care|Lenalidomide (Revlimid)/dexamethasone
10025153|NCT01711684|Experimental|Diphenylcyclopropenone (DPCP)|Subjects will have DPCP in a topical gel formulation applied to their cutaneous metastatic lesions.
10025154|NCT01711697|Experimental|Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)|Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
10025155|NCT01711710|Experimental|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant
10025156|NCT01711723|Experimental|Renal Impaired Group|Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
10025157|NCT01711723|Experimental|Healthy Control Group|Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
10025158|NCT01711749|Active Comparator|Sequence 1|01 tablet, single dose, of Reference Product in period 1 and 01 tablet, single dose, of Test Product in period 2.
10025159|NCT01711749|Active Comparator|Sequence 2|01 tablet of Test Product in period 1, and 01 tablet, single dose, of Reference Product in period 2.
10025160|NCT01711762|Experimental|GDC-0973 Single Arm|
10025161|NCT01711775|Experimental|Aleglitazar|
10025162|NCT01711788|Experimental|Intrabone umbilical cord blood tranplant|Intrabone infusion of umbilical cord blood stem cells
10025163|NCT01711801|Placebo Comparator|Part 1: Placebo|
10025164|NCT01711801|Experimental|Part 1: RO5545965|
10025165|NCT01711801|Experimental|Part 2: Food effect|
10025166|NCT01711814|Experimental|ASP015K|Experimental
10025167|NCT01711827|Experimental|Isavuconazole and Prednisone|Single dose of prednisone on Days 1 and 9, isavuconazole 3 times a day (TID) on Days 5-6, isavuconazole once a day (QD) on Days 7-10
9528740|NCT03208400|Other|virtual reality exposure|one-session exposure conveyed via virtual reality technology
10025168|NCT01711840||Symbicort|
10025169|NCT01711892|Active Comparator|Soccer Training|12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
10025170|NCT01711892|No Intervention|Control group|Usual care
10025171|NCT01711905|Experimental|Vitamin D3|cholecalciferol 20 µg per day for 12 weeks
10025172|NCT01711905|No Intervention|Placebo|Placebo for 12 weeks
10025173|NCT01711931|Active Comparator|Everolimus-eluting bioresorbable vascular scaffold stents|
10025174|NCT01711931|Active Comparator|Everolimus-eluting stent|
10025175|NCT01711931|Active Comparator|Biolimus-eluting stent|
10025176|NCT01711944|Experimental|Online PSST|An online version of Problem-Solving Skills Training (PSST) will be compared to standard (face-to-face) PSST
10025177|NCT01711944|Active Comparator|Face-to-Face PSST|This is an 8-session face-to-face Problem-Solving Skills Training intervention
10025178|NCT01711957||Liver disease and liver transplantation|Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
10025179|NCT01711970|Experimental|VB-111|
10025180|NCT01711996||UPJO|0-3 year old hydronephrosis patients without ureter dilatation who undergo pyeloplasty
10025181|NCT01711996||Hydronephrosis|0-3 year old hydronephrosis patients without ureter dilatation who does not meet the indication of pyeloplasty
10025182|NCT01711996||Normal|0-3 year old children without hydronephrosis
10025183|NCT01712022||Dry Eye|clinical diagnosis of dry eye
10025184|NCT01712022||Contact Lens|routine wear of contact lens
10025185|NCT01712022||Normal|Not having history of dry eye or contact lens wear or corneal pathology or surgery
10025186|NCT01712035||Treatment-active NVAMD|Patients with NVAMD who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
10025187|NCT01712035||Treatment-naive NVAMD|Individuals who have not received any treatment for neovascular AMD in the study eye
10025188|NCT01712048|Active Comparator|Submucosal Injection EMR|"For patients who are randomized to the submucosal injection arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
10025189|NCT01712048|Active Comparator|Underwater EMR|"For patients who are randomized to the underwater arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
10025190|NCT01712087||MedStream System Implants|All subjects presenting for a de novo programmable pump implant or replacement of an implantable, programmable infusion pump for the treatment of severe spasticity with intrathecal Baclofen.
10025191|NCT01712100|Experimental|irbesartan|300 mg tablet
10025192|NCT01712100|Active Comparator|Avapro|300 mg tablet
10025193|NCT01712113|Experimental|irbesartan|300 mg tablet
10025194|NCT01712113|Active Comparator|Avapro|300 mg tablet
10025195|NCT01712126|Experimental|Irbesartan and Hydrochlorothiazide|300 mg and 25 mg tablet
10025196|NCT01712126|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg
10025197|NCT01712139|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg tablet
10025198|NCT01712139|Experimental|Irbesartan and Hydrochlolothiazide|300 mg irbesartan and 25 mg hydrochlorothiazide tablet
10025199|NCT01712165|Active Comparator|ANMUM Materna|75g milk powder in 400 ml water daily for 12 weeks.
10025200|NCT01712165|Placebo Comparator|Control|75g of milk powder in 400 ml water for 12 weeks.
10036673|NCT01817842|Active Comparator|Device Control|Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
10025201|NCT01712243|Active Comparator|Dim light|15 minutes of very dim (<1 lux) light during the night
10025202|NCT01712243|Active Comparator|Room light|15 minutes of normal room light (~100 lux) during the night
10025203|NCT01712243|Experimental|Colored light|15 minutes of colored light during the night
10025204|NCT01712269|Experimental|Weight-loss (bariatric) surgery|All subjects enrolled will undergo bariatric surgery to assist weight-loss
10025205|NCT01712282|Experimental|High dose training|2 x 30 minutes/day on a weight-bearing treadmill
10025206|NCT01712295|Experimental|17% Salicylate with Ethyl Pyruvate|Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.
10025207|NCT01712295|Active Comparator|17% salicylate|subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks
9802907|NCT04830709||Bevacizumab maintenance cohort (BMC)|patients who continue to receive at least one dose of bevacizumab after 1L platinum-based CTX and who have not received PARPi MTX treatment
10025208|NCT01712321|Experimental|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
10025209|NCT01712321|Placebo Comparator|Placebo|Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
10025210|NCT01712347||mCRC Participants|mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
10025211|NCT01712373|Active Comparator|Ginseng|Ginseng, tablet, 250 mg, twice, 3 months
10025212|NCT01712373|Placebo Comparator|Placebo|Placebo, tablet
10025213|NCT01712386|Experimental|COPD|
10025214|NCT01712412|Experimental|IW-9179|Oral IW-9179 taken daily for two weeks
10025215|NCT01712412|Placebo Comparator|Placebo|Oral placebo taken daily for two weeks
10036674|NCT01817868||Group 1|
10025216|NCT01712425|Experimental|0-24 week prime/boost regimen (ARM A)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen
10025217|NCT01712425|Experimental|0-8 week prime/boost regimen (ARM B)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen
10025218|NCT01712425|No Intervention|Arm A control (ARM C)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
10025219|NCT01712425|No Intervention|Arm B control (ARM D)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
10025220|NCT01712464|Other|Cross over Oxytocin and Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
10025221|NCT01712464|Other|Cross over Placebo and Oxytocin|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
10025222|NCT01712477|Active Comparator|Intravenous sedation with propofol|Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
10025223|NCT01712477|Active Comparator|Intravenous sedation with midazolam|Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels
10025224|NCT01712503|Experimental|Toric intraocular lens|TFlex Lens (623T)
10025225|NCT01712503|Placebo Comparator|Monofocal intraocular lens|Superflex Aspheric Lens (920H)/Cflex Aspheric Lens (970C)
10025226|NCT01712529|Experimental|Supervised physical exercise|Walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
10025227|NCT01712529|No Intervention|No supervised physical exercise|No intervention for 16 weeks
10025228|NCT01712555|Experimental|fat grafting with PRP to anophthalmic orbits|There is only one arm to this study. People with orbital atrophy and loss of an eye are to be injected with autologous fat mixed with autologous PRP (platelet rich plasma) and observed for at least one year for evidence of retention of the injected fat
10025229|NCT01712568|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
10025230|NCT01712568|Experimental|Reference Product|Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
10025231|NCT01712581|Experimental|Healthy volunters|175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
10025232|NCT01712594|Active Comparator|Closed Loop Procedure AB|Closed loop procedure with normal calibration first followed by closed loop procedure B with calibration error induced.
10025233|NCT01712594|Active Comparator|Closed loop Procedure BA|Closed loop procedure with an induced calibration error first followed by closed loop procedure with normal calibration.
10025234|NCT01712607|Experimental|Warm-Up|Surgery after warm-up task Preoperative Warm-Up training
10025235|NCT01712607|No Intervention|No Warm-up|Surgery without warm-up exercise
9479714|NCT03540589|Experimental|Video distraction|A video will be available as soon as the child is randomized to this group, thus enabling the child to become more involved with distraction. A tablet will be delivered to the parents in the reception room to be viewed by the child before entering the vaccine room. After entering the room, the parents will keep the child entertained with the videos. There will be several videos, and it may be optional for the parents to choose according to their preferences.
9479715|NCT03540589|Experimental|Vibration device|Buzzy® specific vibration device will be placed by the professional or caregiver at the application site, 15 to 45 seconds before the procedure.
10025236|NCT01712698||Cervical spinal cord injury|Those patients with an acute cervical spinal cord injury evaluated with DTI MRI
10036675|NCT01817894|Other|split-face eflornithin vs. no treatment|Eflornithine cream 11.5 W/W% applied twice daily to one side of the face for six months
10036676|NCT01817920|Experimental|integrated multidisciplinary fall prevention program|
10036677|NCT01817933|Experimental|Physical therapy|
9479716|NCT03540589|Experimental|Distraction plus vibration|Combination of the two interventions described above
10025237|NCT01712724|Active Comparator|Aerobic Training|Walking, elliptical, stationary recumbent or upright cycling will be the modes of AT prescribed depending on individual ability and access to equipment when away from the Centre. Treadmill or overground walking will be considered for those who can sustain high enough speeds and durations to achieve aerobic benefit. Cycle ergometer exercise (upright or recumbent) will be prescribed to patients in addition to walking when stroke-related deficits preclude a sufficient walking speed. The AT group will complete AT 5 d∙wk-1.
10025238|NCT01712724|Experimental|Combined Resistance and Aerobic Training|The AT+RT group will complete AT 3 d∙wk-1 + RT 2 d∙wk-1.The RT exercises will be task specific, incorporating muscle actions that are performed during daily activities. Resistance will be provided by hand-held dumbbells, exercise bands (wrist/ankle attachments), or patients' body weight. A weight load equivalent to 50-60% of 1 repetition maximum will be prescribed on the non-affected limb. On the hemiparetic limb ≥50% of 1 repetition maximum and/or a resistance rated as 13-14 on the Rating of Perceived Exertion scale on the last repetition of the set will be prescribed
10025239|NCT01712737|Experimental|Snack foods: raisins|children were given ad libitum access to raisins for 15 min
10025240|NCT01712737|Experimental|Snack foods: grapes|children were given ad libitum access to grapes for 15 min
10025241|NCT01712737|Experimental|Snack foods: a mix of almonds with raisins|children were given ad libitum access to a mix of almonds with raisins for 15 min
10025242|NCT01712737|Experimental|Water control|children were given ad libitum access to water
10025243|NCT01712750||VOT on bypass|
10025244|NCT01712802|Experimental|Denture Adhesives: Cream|Parallel arm that receives application of Cream denture adhesives.
10025245|NCT01712802|Experimental|Denture Adhesives: Powder|Parallel arm that receives application of powder denture adhesive.
10025246|NCT01712802|Placebo Comparator|control|Parallel arm that receive placebo.
10025247|NCT01712815|Experimental|Diagnostic (fluorine F 18-clevudine PET/CT)|Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.
10025248|NCT01712828|Experimental|Lenalidomide plus Quinidine|
10025249|NCT01712828|Experimental|Lenalidomide plusTemsirolimus and Diphenhydramine|
10025250|NCT01712841||Severe NEAMD|Presence of definite central or noncentral geographic atrophy within 3000 microns of the foveal center
10025251|NCT01712841||Moderate/Intermediate NEAMD|Presence of large drusen (>125µ) and pigmentary changes without geographic atrophy
10025252|NCT01712841||Mild/Early NEAMD|Presence of small or medium drusen without geographic atrophy
10025253|NCT01712867|Experimental|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
10025254|NCT01712867|Active Comparator|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
10025255|NCT01712880|Active Comparator|open debridement with modular exchange|
10025256|NCT01712880|Active Comparator|one stage exchange|
10025257|NCT01712893|Experimental|Zoladex combined with chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy
10025258|NCT01712893|Active Comparator|Zoladex after chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy
10025259|NCT01712906|Experimental|3.50±0.25logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.
10025260|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
10025261|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
10025262|NCT01712906|Placebo Comparator|0 logCCID50/ml in adults|0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.
10025263|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.
10025264|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
10025265|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
10025266|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (5-15 years old)|0 logCCID50/ml in 18 children aged 5-15 years old on day 0.
10025267|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.
10025268|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
10025269|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
10025270|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (2-4 years old)|0 logCCID50/ml in 18 children aged 2-4 years old on day 0.
10025271|NCT01712906|Active Comparator|Attenuated Mumps vaccine in children (2-4 years old)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.
10025272|NCT01712906|Experimental|3.50±0.25logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.
10025273|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
10025274|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
10025275|NCT01712906|Placebo Comparator|0 logCCID50/ml in infants|0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.
10025276|NCT01712906|Active Comparator|Attenuated Mumps vaccine in infants|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.
10025277|NCT01712919|Experimental|cetuximab|Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
10025278|NCT01712945|Experimental|Palifermin (and Alemtuzumab)|Palifermin (Kepivance®), at the maximum identified tolerated dose will be administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose. Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
10025279|NCT01712945|Placebo Comparator|Placebo (and Alemtuzumab)|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
10025280|NCT01712971||OPD|standard open pancreaticoduodenectomy
10025281|NCT01712971||LPD|laparoscopic pancreaticoduodenectomy
10025282|NCT01712997|Experimental|Combination therapy|combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.
10025283|NCT01712997|Active Comparator|monotherapy|Bosentan,125mg,po,bid.
9802908|NCT04830709||No maintenance cohort (NMC)|patients who never received any 1L MTX treatment (PARPi or bevacizumab)
10025284|NCT01713023|Experimental|Glucose solution|Solution containing 75g of glucose diluted in 200 mL of water
10025285|NCT01713023|Experimental|Fructose solution|Solution containing 75g of fructose diluted in 200 mL of water
10025286|NCT01713049|Other|18F-FLT|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
10025287|NCT01713075||Symbicort|
10025288|NCT01713088|Experimental|Multisystemic therapy|MST is a family- and community-based intervention that establishes close contact with families to understand and deal with the factors that cause the young person's antisocial behaviour. The intervention targets the individual's adjustment, family relationships, school functioning and peer group affiliations. Therapists help caretakers develop skills to intervene and operate changes in important domains such as young person's individual adjustment, their family relationships, school functioning, and peer group affiliations.
10036678|NCT01817946||Genetic testing|All participants determined eligible for the study will be placed into genetic testing arm.
10025289|NCT01713088|Active Comparator|YOT (usual services)|YOT intervention consisted of services currently available to young offenders in accordance with the Youth Justice Board National Standards.These services included supporting the young person to re-engage with education, with substance misuse problems and anger management; training them in social problem-solving skills; and programs to decrease vehicle-crime, violent-offending and knife crime. The treatments were delivered by professional social workers, specialist therapists or probation officers.
10025290|NCT01713101|Experimental|Early intravenous tranexamic acid administration|"Early intraveous administration of tranexamic acid~(1g IV bolus over 10 minutes followed by 1g slow infusion over 8 hours"
10025291|NCT01713101|Placebo Comparator|Placebo group|Normal saline (placebo) administration instead of tranexamic acid solution
10025292|NCT01713114|Experimental|Low carbohydrate|
10025293|NCT01713114|Experimental|Moderate carbohydrate|
10025294|NCT01713114|Experimental|Higher Carbohydrate|
10025295|NCT01713114|Placebo Comparator|Meal Skipping|
10025296|NCT01713127|Placebo Comparator|Placebo|5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
10025297|NCT01713127|Active Comparator|remifentanil|0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth
10025298|NCT01713140|Experimental|1 strength training set performed until contraction failure|Knee extensions until contraction failure will be performed, using a relative loading of 10 repetition maximum (RM).
10025299|NCT01713153|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
10025300|NCT01713153|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
10025301|NCT01713166|Active Comparator|Plasmalyte solution|Plasmalyte solution infusion to meet the fluid requirements.
10025302|NCT01713166|Experimental|Hextend|6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
10025303|NCT01713179|Experimental|ambroxol|"Ambroxol hydrochloride (Mucopect®, trans-4[2-amino-3.5-dibrombenzylamino]-cyclohexanhydro-chloride, 60 mg, Boehringer Ingelheim) was administered orally to subjects in the ambroxol group immediately after initial examination (10 AM).~one dose for one day"
10025304|NCT01713179|No Intervention|control|
10025305|NCT01713192||Cardiac surgery|
10025306|NCT01713218|Experimental|Gemcitabine+Vismodegib|Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery
10025307|NCT01713231|Active Comparator|standard-dose vitamin D|one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
10025308|NCT01713231|Experimental|high-dose vitamin D|One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
9479717|NCT03540589|No Intervention|Usual care|The vaccine will be carried out according to the routine of the Vaccine Center. Lidocaine plus prilocaine, non-nutritive sucking or breastfeeding may be used.
9479718|NCT03540563|Other|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
9479719|NCT03540550|Experimental|Dietary intervention|
9479720|NCT03540537|Other|PCA for Open Hepatectomy|Patient-controlled intravenous analgesia in Open hepatectomy (PCA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing)
9479721|NCT03540537|Experimental|QLB for Open Hepatectomy|Bilateral quadratus lumborum block with 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
9479722|NCT03540537|Experimental|TPVB for Open hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
9479723|NCT03540537|Other|PCA for Laparoscopic Hepatectomy|Patient-controlled intravenous analgesia in Laparoscopic hepatectomy (same as PCA for Open hepatectomy Arm)
9479724|NCT03540537|Experimental|QLB for Laparoscopic Hepatectomy|Bilateral quadratus lumborum block 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
9479725|NCT03540537|Experimental|TPVB for Laparoscopic Hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
10025309|NCT01713244|Active Comparator|Hepatectomy|Using Hepatectomy for the treatment of advanced HCC
10025310|NCT01713244|Experimental|RFA assisted Hepatectomy|Ablating the liver tissue around the tumor before hepatectomy.
10025311|NCT01713257|Experimental|Immunoenhancing diet|Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
10025312|NCT01713257|Active Comparator|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
10025313|NCT01713270|Experimental|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter was introduced into each renal artery. This was then maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 60 seconds each were performed in both renal arteries. After renal sympathetic denervation, patients with persistent AF accepted direct-current cardioversion immediately.
10025314|NCT01713270|Active Comparator|drug therapy|Patients in the drug treatment group will be followed-up at 3, 6, 9 and 12 months after randomization. All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. Antiarrhythmic drugs treatment is consistent in both arms.
10025315|NCT01713296|Experimental|Pazopanib|
10025316|NCT01713309|Active Comparator|Filgrastim|Filgrastim 300 microgr/day subcutaneously for 7 days
10025317|NCT01713309|Placebo Comparator|NaCl 0.9%|Corresponding placebo once daily, subcutaneously for 7 days
10025318|NCT01713322|Experimental|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
10025319|NCT01713322|Other|No pain management education|Control - parents receive general information about childhood immunization.
10025320|NCT01713361|Experimental|ISIS-FXIRx Dose 2|Group B: ISIS-FXIRx Dose #2
10025321|NCT01713361|Experimental|ISIS-FXIRx Dose 3|Group C: ISIS-FXIRx Dose #3
10025322|NCT01713361|Active Comparator|Enoxaparin|Enoxaparin (40mg)
10025323|NCT01713374|Active Comparator|Myogenic activation|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of myogenic activation
10025324|NCT01713374|Active Comparator|Cold pressure test|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of cold pressure test
10025325|NCT01713374|Active Comparator|mental stress|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of mental stress
10025326|NCT01713374|Active Comparator|Control|Control visit - no intervention performed - subjects will undergo endothelial function measurement twice at a distance of 45 minutes
10025327|NCT01713387|Experimental|gemcitabine , S-1|Level-2 Gem 800mg/msq, S-1 50mg/msq Level-1 Gem 800mg/msq, S-1 65mg/msq Level 1 Gem 1000mg/msq, S-1 65mg/msq Level 2 Gem 800mg/msq, S-1 80mg/msq
10025328|NCT01713413|Active Comparator|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
10025329|NCT01713413|Active Comparator|nasal cannula|Using first the conventional nasal cannula and 24 h later the Oxymizer
10025330|NCT01713426|Experimental|Qutenza|Cutaneous patch
10025331|NCT01713426|Active Comparator|Pregabalin|Oral capsule
10025332|NCT01713439|Experimental|Injection of allogeneic neuroblastoma cells|Retrovirally transduced allogeneic neuroblastoma cell lines secreting the human interleukin-2 and lymphotactin genes are frozen and, when needed, are thawed, mixed and irradiated. Relapsed or refractory patients are then treated with a course of four injections of their gene-modified tumor cells according to the following schedule: The first two injections will be given at week 1 and week 2. Patients will then have a two-week rest and the remaining two injections will be given at week 4 and week 5. A complete evaluation for evidence of toxicity and response will be performed at week 8 after a 3 week rest. At the 8 week evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
10025333|NCT01713452|Active Comparator|Purse string closure|Patients undergo a purse string closure of their old stoma site.
10025334|NCT01713452|Active Comparator|Primary closure|Patients have their stoma sites close primarily with staples.
10025335|NCT01713465|Experimental|1 CBMP|CBMP: Computer based Metabolic syndrome program
10025336|NCT01713478|Experimental|cirrhotic patients|"Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis~Routine blood samples~Electrocardiogram (12 leads)~Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.~Comprehensive Echocardiography"
10025337|NCT01713478|Active Comparator|normal controls|50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers
10025338|NCT01713491||Cognitively normal|Patients with IQCODE score of 52 or less
10025339|NCT01713491||Cognitively impaired - no dementia|IQCODE score 53 - 63
10025340|NCT01713491||Demented|IQCODE score 64 or more
10025341|NCT01713504|Experimental|Hypereosinophilic syndrome unexplained|
10025342|NCT01713504|Active Comparator|Hypereosinophilic syndrome explained|
10025343|NCT01713504|Sham Comparator|Normal rate of eosinophilic|
10025344|NCT01713517|Active Comparator|Universal coverage of Long Lasting Insecticidal Nets (LLIN)|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons
10025345|NCT01713517|Experimental|LLIN Plus Indoor Residual Spraying|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons plus indoor residual spraying with insecticide of interior walls of all houses twice yearly.
10025346|NCT01713543|Experimental|Intervention Group|The intervention consists of a tailored physical therapy focused on progressive strength, balance and gait training for a period of 3 months.
10025347|NCT01713543|No Intervention|Control Group|Usual care by physician.
10025348|NCT01713556|Experimental|Propranolol + reactivation|they have a script-driven mental imagery of the traumatic event white drug
10025349|NCT01713556|Placebo Comparator|Placebo + reactivation|They have a script-driven mental imagery of the traumatic event with placebo
10025350|NCT01713569|Active Comparator|Subject 1|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side.
10025351|NCT01713569|Active Comparator|Subject 2|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side.
10025352|NCT01713569|Active Comparator|Subject 3|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side.
10025353|NCT01713569|Active Comparator|Subject 4|Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side.
10025354|NCT01713569|Active Comparator|Subject 5|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side.
10025355|NCT01713569|Active Comparator|Subject 6|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side.
10025356|NCT01713595|Experimental|Hypertonic Saline Aerosol|a single 5ml dose of 7% Saline aerosol
10025357|NCT01713634|Experimental|Low Apro/K Diet|Subjects consume a prescribed diet for 4 days with a low ratio of animal protein to potassium (0.3-0.6 g/mEq).
10025358|NCT01713634|Experimental|High Apro/K Diet|Subjects consume a prescribed diet that has a high ratio of animal protein to potassium (1.0-1.3 g/mEq) for 4 days.
10025359|NCT01713647|Experimental|LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon|"Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
10025360|NCT01713647|Active Comparator|NORVASC & HYZAAR (100/12.5 mg)|"Subjects will be fasted overnight and receive one tablet of Norvasc &HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
10025361|NCT01713673|Experimental|Active Treatment|Subjects receive Ulthera System Treatments according to the pre-defined Ulthera® System energy settings.
10025362|NCT01713673|Sham Comparator|Sham Treatment|Subjects will receive Sham treatments using the Ulthera® System with the energy set to 0.00 Joules.
10025363|NCT01713699|Other|diagnostic|Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
10025364|NCT01713712|No Intervention|Routine Obstetric Care|
10025365|NCT01713712|Experimental|Nutritional Counseling|Patients will receive an initial 90 minute nutritional consult followed by 60 minute follow up consults every 2 weeks to monitor weight gain and nutritional status.
10025366|NCT01713725|Active Comparator|Omalizumab 300 mg|"Subcutaneous route~300 mg dose (independent from total IgE, weight or high)"
10025367|NCT01713725|Placebo Comparator|Placebo|"Saline serum~Subcutaneous route~0.6 ml saline serum with same volume as an active treatment"
10025368|NCT01713738|Experimental|rituximab|
10025369|NCT01713751|Active Comparator|Interrupted suturing Group|Includes women who have their skin closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
10025370|NCT01713751|Active Comparator|Subcuticular suturing Group|Includes women who have their skin closed with subcuticular stitches using non-absorbable polypropylene [Prolene®].
10025371|NCT01713764|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate diet: carbohydrate intake 10-50 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
10025372|NCT01713764|Active Comparator|American Diabetes Association Diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
10025373|NCT01713777|Experimental|"Lamotrigine Generic A/Generic B"|"Crossover trial. Each arm will receive generic A for two periods and generic B for two periods."
10025374|NCT01713777|Experimental|"Lamotrigine Generic B/Generic A"|"Crossover trial. Each participant will have two periods of generic A and two periods of generic B"
10025375|NCT01713790|Experimental|Training group|T0 - Intervention program 3x/ week over 10 weeks: Stochastic resonance whole-body vibration + Exergame + leg press - T1
10025376|NCT01713803|Placebo Comparator|Sugar pill|
10025377|NCT01713803|Experimental|buprenorphine and nalaxone|
10025378|NCT01713816||Elderly control|Healthy elderly subjects age and gender matched to the AD cohort, predominantly male
10025379|NCT01713829|Experimental|Cranberry Beverage|Cranberry Beverage is provided in an 8 oz daily beverage consumed once daily for 12 weeks
10025380|NCT01713829|Placebo Comparator|Placebo Beverage|The placebo beverage looks like the active arm and is given in the same way but contains no active ingredient.
10025381|NCT01713842|Experimental|TCZ|Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion
10025382|NCT01713881||post-registry|"Registry Group:~Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry.~Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013)."
10025383|NCT01713881||pre-registry|Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006.
10025384|NCT01713894|Other|Decision Aid|In this arm of the study, parents will be counseled using a decision aid.
10025385|NCT01713894|Other|Standard|In this arm of the study, parents will be counseled using current standard methods.
10025386|NCT01713907|Experimental|Ulthera® treatment|All enrolled subjects will receive one full face and neck Ulthera® treatment.
10025387|NCT01713920|Experimental|SEVIKAR|Subjects who are eligible for the inclusion and exclusion criteria will be treated with Sevikar 5/20mg for 4 weeks. If subjects fail to reach the SBP threshold of SeSBP≥ 140mmHg after 4-week treatment, they will receive Sevikar 5/40mg for 4 weeks. At the end of 4-week treatment, subjects who fail to reach SBP threshold will receive Sevikar 10/40mg for 4 weeks. Subjects who can reach SBP threshold will continue to treat with current dose until 12 weeks.
10025388|NCT01713959|Experimental|Group A - Split Body Treatment|Active treatment of one axilla with the Ulthera System Treatment; Sham treatment of one axilla.
9802909|NCT04826692|Experimental|Metformin|Therapeutic group: Biguanidines (antidiabetic) Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
10025389|NCT01713959|Active Comparator|Group B: Ulthera System Treatment w lido|Subjects receive a bilateral Ulthera System Treatment, with one axilla receiving a subcutaneous lidocaine injection.
10025390|NCT01713972|Experimental|Treatment (dabrafenib, pazopanib hydrochloride)|Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10025391|NCT01713972|Other|Correlative Studies|"Pharmacokinetic studies: Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
10025392|NCT01713985|Active Comparator|Group A|Ulthera System Treatment Right, Thermage Left
10025393|NCT01713985|Active Comparator|Group B|Ulthera System Treatment Left, Thermage Right
10036679|NCT01817972|Placebo Comparator|Certolizumab pegol-Placebo Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine placebo tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets. This is not active Azathioprine.
10036680|NCT01817972|Active Comparator|Certolizumab pegol plus Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets.
10036681|NCT01817985|Experimental|Cohort 1|(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816.
10036682|NCT01817985|Experimental|Cohort 2|(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816.
10036683|NCT01817998|Experimental|High Intensity Endurance Physical Exercise|High Intensity endurance physical exercise, intensity measured on Borg Scale with progression from Borg 10-13 (50% of maximum) to 17-18 (80 % of maximum). One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
10036684|NCT01817998|Active Comparator|Low Intensity Endurance Physical Exercise|Low Intensity endurance physical exercise, intensity measured on Borg Scale, Borg 10-13 (50% of maximum) with no progression in intensity. One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
10036685|NCT01818011|Experimental|Part A GSK1322322 single dose Arm|Subjects will receive single dose of one of the following 4 GSK1322322 treatments in 4 treatment periods (one per period) with an aqueous suspension of a low dose of GSK1322322F (stable isotope labeled drug substance) PO in a fed condition: 1500 mg (fit for purpose formulation), 1500 mg (intended commercial formulation), 1500 mg (over granulated formulation), and 2000 mg (intended commercial formulation)
10036686|NCT01818011|Experimental|Part B Cohort 1- GSK1322322 Oral Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Cohort 1 will receive following GSK1322322 (intended commercial formulation) doses po in fed state: 1000 mg, 1500 mg and 2000 mg
10036687|NCT01818011|Experimental|Part B Cohort 2 -GSK1322322 IV Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Part B Cohort 2 will receive following GSK1322322 IV fasted doses (one per period): 600 mg, 900 mg and 1200 mg
10036688|NCT01818011|Experimental|Part C GSK1322322 Arm|Subjects in this arm will receive repeat doses of GSK1322322 as following: GSK1322322 1200 mg IV fasted for 4 days twice a day (BID), followed by GSK1322322 2000 mg orally fed for 6 days BID
10036689|NCT01818011|Placebo Comparator|Part C Placebo Arm|Subjects in this arm will receive repeat doses of Placebo IV fasted for 4 days BID, followed by placebo po fed for 6 days BID
10036690|NCT01818024|Experimental|Part 1: Cohort 1a|Single IV dose of GSK2862277 as a continuous infusion over 2 hours.
10036691|NCT01818024|Experimental|Part 1: Cohort 1b|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
10036692|NCT01818024|Experimental|Part 1: Cohort 1c|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
10036693|NCT01818024|Experimental|Part 2: Cohort 2a GSK2862277|Single IV dose of GSK2862277 as a continuous infusion over 1 hour.
10036694|NCT01818024|Experimental|Part 2: Cohort 2a Placebo|Matching placebo will be administered as a continuous IV infusion over 1 hour.
10036695|NCT01818024|Experimental|Part 2: Cohort 2b GSK2862277|Single IH dose of GSK2862277.
10036696|NCT01818024|Experimental|Part 2: Cohort 2b Placebo|Matching placebo will be administered.
10036697|NCT01818024|Experimental|Part 3: Cohort 3a GSK2862277|IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.
10036698|NCT01818024|Experimental|Part 3: Cohort 3a Placebo|Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.
10036699|NCT01818024|Experimental|Part 3: Cohort 3b GSK2862277|Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.
10025394|NCT01714011|Active Comparator|Ziprasidone|Ziprasidone is a psychotropic agent with chemical name: 5-[2-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.Ziprasidone is a potent antagonist of both serotonin 5-HT2A and dopamine D2 receptors, although its affinity for 5-HT2A receptors is about 10 times higher than for D2 receptors.
10025395|NCT01714011|Active Comparator|Aripiprazole|Aripiprazole is a psychotropic drug that is available as tablets for oral administration. Aripiprazole is 7-[ 4-[ 4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3-4-dihydrocarbostyril. Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha 1-adrenergic and histamine H1 receptors and moderate affinity for serotonin reuptake site (Ki = 98nM).
10025396|NCT01714037|Experimental|Cisplatin, Pemetrexed, Debio 0932|Cisplatin, Pemetrexed, Debio 0932
10025397|NCT01714037|Experimental|Cisplatin, Gemcitabine, Debio 0932|Cisplatin, Gemcitabine, Debio 0932
10025398|NCT01714037|Experimental|Docetaxel, Debio 0932|Docetaxel, Debio 0932
10025399|NCT01714050|Experimental|Cognitive-Behavioral Therapy (CBT)|"The CBT is a SAD-tailored version of Beck et al.'s (1979) cognitive therapy for depression called Coping with the Seasons (Rohan, 2008). The rationale addresses environmental changes, thoughts, and behaviors in SAD onset and maintenance. It seeks to change behaviors and thoughts to improve coping with winter. Behaviors that promote enjoyment in the winter are increased. Negative thoughts that interfere with self-esteem and negative thoughts about winter are identified and addressed. A relapse-prevention component addresses early identification of negative anticipatory thoughts about winter and SAD-related behavior changes, using the CBT skills learned to cope with subsequent winter seasons, and development of a personalized relapse-prevention plan. The CBT sessions are administered twice a week over 6 weeks (total of 12 sessions) with 4-8 participants per group. The CBT is led by one of three licensed Ph.D.-level psychologists working on the project."
10025400|NCT01714050|Experimental|Light Therapy (LT)|LT will be initiated at 30-minutes in the morning at home, first thing upon awakening, using a light box with an ultraviolet shield that emits 10,000-lux of white fluorescent light. After the first week, an M.D. light therapy consultant will recommend individually-tailored, clinical adjustments to the duration and timing of light use to maximize response and reduce any reported side effects. For each of the 6-weeks of LT, LT participants will complete a Light Therapy Side Effects Questionnaire to assess side effects attributed to LT. Participants will keep daily LT compliance diaries to record the timing and duration of LT. After the 6-weeks of monitoring, participants may choose to continue using the light box through April. We will offer LT participants who wish to use light therapy in the next fall/winter season access to our light boxes if they agree to followup with a physician or other qualified professional for monitoring and side effects management.
10036700|NCT01818024|Experimental|Part 3: Cohort 3b Placebo|Matching placebo will be administered as IH daily for 5 days.
9479726|NCT03540524|Experimental|Cohort A - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)
9479727|NCT03540524|Experimental|Cohort B - F508del heterozygous/potentiator nonresponsive|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)
10025401|NCT01714076||cohort isolation|patients with bronchiolitis are cohorted together irrespective of viral agent diagnosed, thus respiratory syncytial virus (RSV)-positive patient stay in the same room as RSV-negative patients
10025402|NCT01714089|Experimental|RNS60 125 ml|125 ml of RNS60 administered weekly by IV infusion
10025403|NCT01714089|Experimental|RNS60 250 ml|250 ml of RNS60 administered weekly by IV infusion
10025404|NCT01714089|Active Comparator|Interferon beta-1a|Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.
10025405|NCT01714102|Placebo Comparator|Placebo|Placebo for 30 days
10025406|NCT01714102|Active Comparator|Resveratrol|1000 mg PO BID for 30 days
10025407|NCT01714128|Other|Optional Diagnostic Imaging|Optional diagnostic imaging FES-PET/CT imaging
10025408|NCT01714141|Experimental|Multi-component, technology based intervention|2 tailored, computer-delivered motivational interviewing sessions targeting adherence to asthma control medications + tailored text messaged reminders to take medications between sessions.
10025409|NCT01714141|Active Comparator|Asthma education active control|Control condition consists of active control matched to intervention for delivery-method and time-- 2 sessions of computer-delivered asthma education + daily text messaged facts about asthma.
10025410|NCT01714154|Experimental|A: setrobuvir|
10025411|NCT01714154|Experimental|B: setrobuvir + DNV/r|
10025412|NCT01714167|Active Comparator|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation
10025413|NCT01714167|No Intervention|conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
10025414|NCT01714180||Obese Patients|
10025415|NCT01714180||Non-obese Patients|
10025416|NCT01714193|Experimental|Canagliflozin + oral contraceptive|Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin.
10025417|NCT01714206|Active Comparator|Treatment A|Each volunteer will receive digoxin once daily on Days 1 through 7.
10025418|NCT01714206|Experimental|Treatment B|Each volunteer will receive digoxin once daily on Days 1 through 7 in combination with canagliflozin (JNJ-28431754) once daily on Days 1 through 7.
10025419|NCT01714219|Experimental|Posterior reconstruction|"New posterior reconstruction, which entails opposition of the median dorsal fibrous raphe solely to the posterior counterpart of the detrusor apron~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
10025420|NCT01714219|No Intervention|No posterior reconstruction|"No posterior reconstruction~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
10025421|NCT01714258|Experimental|non invasive cardiac output measure|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients 20 times, throughout a period of about 45 min
10036701|NCT01818037||Microphthalmos with congenital cataract|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract surgery between January 2003 and June 2008.
10036702|NCT01818050|Other|Wing stent arm|There is only one arm in this study. Intervention: checking liver function tests to evaluate stent patency
10036703|NCT01818089||Lung Sound Analyzer|Patient with pneumonia admitted to hospital will receive additional auscultation with lung sound analyzing stethoscope
10036704|NCT01818102|Experimental|Width 1000 HU/Level -450 HU|
10025422|NCT01714271|Experimental|Home environs-based lifestyle counseling|Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
10025423|NCT01714271|Experimental|Cancer early detection|Cancer Early Detection Spanish-speaking health educators will interact with study participants via a home visit and four telephone calls. The focus of the health education will be on practical strategies to detect cancer early to help prevent death from cancer. Cancer sites of interest will be: breast, cervical, skin, colon, prostate and testicular cancers. In addition, study participants will be provided two group education classes that will focus on the basics of the cancer process and why early detection and intervention can be life-saving.
10025424|NCT01714284|Experimental|Diet and Exercise|
10025425|NCT01714284|Sham Comparator|Informative|
10025426|NCT01714297|Active Comparator|dalteparin 5000IU s.c.|5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
10025427|NCT01714297|Placebo Comparator|saline|Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
10025428|NCT01714375|Active Comparator|QuietDose device VOLUNTARY|"This group of employees will voluntarily use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
10025429|NCT01714375|No Intervention|No QuietDose device|"This group of employees will not use the QuietDose units and maintain use of their regular hearing protection which may be either ear plugs or ear muffs."
10025430|NCT01714375|Active Comparator|QuietDose Device REQUIRED|"This group of employees will be required to use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
10025431|NCT01714388|Experimental|Remifentanil, Vagotonic response|1 microgram/kg remifentanil given iv over at least 30 sec. at the beginning of induction of general anaesthesia
10036705|NCT01818102|Active Comparator|Width 400 HU/Level 25 HU|
9479728|NCT03540524|Experimental|Cohort C - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)
9802910|NCT04826692|Placebo Comparator|Placebo|Therapeutic group: NA Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
10025432|NCT01714401|Active Comparator|Salbutamol 2,5 mg|25 mechanically ventilated patients to receive 2,5mg of nebulised salbtamol (Ventolin) duration of nebulisation - 20 minutes
10025433|NCT01714401|Active Comparator|Salbutamol 5mg|25 mechanically ventilated patients 5 mg of nebulised salbutamol (Ventolin) duration of nebulisation - 20 minutes
10025434|NCT01714414|Experimental|FZD 600mg twice daily|FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
10025435|NCT01714414|Experimental|FZD 800mg once daily|FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
10025436|NCT01714414|Experimental|FZD 1200mg once daily|FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
10025437|NCT01714414|Active Comparator|AZT twice daily|1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
10025438|NCT01714427|Active Comparator|Dexamethasone|
10025439|NCT01714427|Placebo Comparator|Sterile isotonic saline|
10025440|NCT01714440||Transplant Recipients Cohort|Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
10025441|NCT01714440||Transplant Donors Cohort|Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
10025442|NCT01714440||Activity&mRNA Expression Substudy Cohort|A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.
10025443|NCT01714466|Experimental|Part A, arm 1|Evening dose of TF048. Morning dose of TF043
10025444|NCT01714466|Experimental|Part A, arm 2|Evening dose of TF043. Morning dose of TF048
10025445|NCT01714466|Experimental|Part A, arm 3|Evening dose of TF047. Morning dose of TF043
10025446|NCT01714466|Active Comparator|Part A, arm 4|MOVIPREP (Both evening and morning dose)
10025447|NCT01714466|Experimental|Part B, arm 1|IMP selected based on the optimal dosing sequence and volume identified from Part A
10025448|NCT01714466|Experimental|Part B, arm 2|IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
10025449|NCT01714466|Active Comparator|Part B, arm 3|IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
10025450|NCT01714466|Experimental|Part B, arm 4|MOVIPREP used in both evening and morning dose
10025451|NCT01714479|Placebo Comparator|Load Carriage - Control|Load Carriage - with a calorie-free placebo
10025452|NCT01714479|Experimental|Load Carriage - leucine-enriched nutrition supplement|Load Carriage with leucine-enriched amino acid supplementation
10025453|NCT01714479|Placebo Comparator|Conventional Exercise - Control|Conventional Exercise with a calorie-free placebo
10025454|NCT01714479|Active Comparator|Conventional Exercise - Leucine-enriched Nutrition Supplement|Conventional Exercise with leucine-enriched Amino Acid supplementation
10025455|NCT01714518||ILD diagnosis|Patients subjected to Cryobiopsy and/or VATS for diagnosis of interstitial lung disease
10036706|NCT01818115|Experimental|IOL placement with Hydrus Implant|Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant
10036707|NCT01818115|Active Comparator|IOL placement only.|Cataract Extraction with IOL placement only.
10036708|NCT01818128|Active Comparator|Neutral shape of bronchial tip|
9479729|NCT03540498|Experimental|Probiotics|The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
9479730|NCT03540498|Placebo Comparator|Control|The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
9479731|NCT03540485|Experimental|Melatonin|Daily administration of 300 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
9479732|NCT03540485|Placebo Comparator|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
9479733|NCT03540472|Experimental|efficiency of tacrolimus on PRCA|"A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
9479734|NCT03540446|Experimental|Standard stimulation|Group A will be treated with First Relief Treatment at standard stimulation.
9479735|NCT03540446|Experimental|sweep stimulation|Group B will be treated with First Relief Treatment at sweep stimulation.
9479736|NCT03540446|Experimental|Placebo|Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no electrical stimulation)
9479737|NCT03540407|Experimental|Oncoxin-Viusid®|will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
9479738|NCT03540407|Placebo Comparator|Placebo|will receive a Placebo concomitant to the onco-specific treatment
9479739|NCT03540381||Identified neoatherosclerosis group|From the patients treated with coronary stents, the investigators functionally evaluated their HDL by measuring the CUC. the investigators also performed follow-up OCT to evaluate the presence of neoatherosclerosis. Consecutive patients were divided into two groups. The patients with neoatherosclerosis were identified neoatherosclerosis group and the remaining were not-identified neoatherosclerosis group. After that, clinical follow-up was performed to assess TLR and the investigators examined the relation between CUC, neoatherosclerosis and TLR.
9479740|NCT03540381||Not-identified neoatherosclerosis group|
9479741|NCT03540368|Experimental|Tranexamic acid injection|Group with tranexamic acid injection
9479742|NCT03540368|Placebo Comparator|Placebo|Group with Placebo
9479743|NCT03540355|Experimental|Cipros 20|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Cipros 20 association; and~1 tablet crestor placebo. Oral, once a day"
9479744|NCT03540355|Active Comparator|Crestor|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Crestor 20 mg; and~1 tablet cipros association placebo. Oral, once a day"
9479745|NCT03540342|Experimental|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
9479746|NCT03540342|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
9479747|NCT03540329|Active Comparator|I-A Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in patients in growing age.
9479748|NCT03540329|Active Comparator|I-A External distraction|External osteogenesis distractor in congenital mandibular deformities in patients in growing age.
9479749|NCT03540329|Active Comparator|I-B Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in adult patients.
9479750|NCT03540329|Active Comparator|I-B External distraction|External osteogenesis distractor in congenital mandibular deformities in adult patients.
9479751|NCT03540329|Active Comparator|II-A Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in patients in growing age
9479752|NCT03540329|Active Comparator|II-A External distraction|External osteogenesis distractor in acquired mandibular deformities in patients in growing age
9479753|NCT03540329|Active Comparator|II-B Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in Adult patients.
9479754|NCT03540329|Active Comparator|II-B External distraction|External osteogenesis distractor in acquired mandibular deformities in Adult patients.
9479755|NCT03540316|Active Comparator|Two short implants and 2 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and Low level laser therapy (LLLT) for 2 minutes .
9479756|NCT03540316|Active Comparator|Two short implants and 4 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
9479757|NCT03540316|Active Comparator|Four short implants and 2 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
9479758|NCT03540316|Active Comparator|Four short implants and 4 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 4 minutes .
9479759|NCT03540303|Experimental|CAR19 T cells carrying cytoplasmic activated PD-1|patients with refractory/relapsed B-NHL receive a preconditioning before infusion of CAR T cells.
9479760|NCT03540290|Active Comparator|Mechanical instrumentation and oral hygiene instructions|
9479761|NCT03540290|Experimental|Modification of the implant supported prostheses|
9479762|NCT03540264|Active Comparator|Composite resin|Restoration with composite resin has shown good clinical performance and limited occlusal wear. The Clearfil Majesty will be used in the present study.
9479763|NCT03540264|Active Comparator|Polymer-infiltrated-ceramic-network|This hybrid material seems to be a promising material that imitates natural tooth properties. The VITA-Enamic® will be used in this study.
10036709|NCT01818128|Experimental|Bent shape of bronchial tip|
10036710|NCT01818180|Experimental|Urell|
10025456|NCT01714531|Experimental|Telephone-Based Goal Management Training|The GMT intervention targets cognitive deficits in executive functioning that impact a person's ability to carry out daily tasks. Participants learn how to recognize and stop absentmindedness and automatic pilot and how to reduce daily errors and 'slips' through goal setting. The telephone-based GMT condition includes 7 sessions delivered over the phone for 10 weeks.
10036711|NCT01818180|Placebo Comparator|Placebo|
10036712|NCT01818206|Experimental|Cystic fibrosis (CF) patients|Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
10025457|NCT01714531|Active Comparator|Telephone-Based Attention-Control|The attention group receives an educational intervention that is matched to the GMT intervention in terms of session length and contact with the study therapist. The telephone-based attention condition includes 7 sessions delivered over 10 weeks. Sessions address education on brain function and cognitive principles of memory, attention, language, perception, and motor skills. Education on stress reduction, sleep hygiene, energy management, exercise, communication, and nutrition are also provided
10025458|NCT01714531|No Intervention|Usual Care Control|Participants in the control group will receive usual care as determined by the treating surgeon. Usual care may include referral to a physical therapist, occupational therapist, psychiatrist, and/or psychologist and utilization of health services will be recorded during follow-up assessments.
10025459|NCT01714557|No Intervention|No prophylaxis|
10025460|NCT01714557|Active Comparator|piperacillin|
10025461|NCT01714557|Experimental|piperacillin/tazobactam|
10025462|NCT01714570|Experimental|piperacillin/tazobactam|
10025463|NCT01714570|Active Comparator|imipenem/cilastatin|
10025464|NCT01714583||High PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) greater than or equal to 12cm.
10025465|NCT01714583||Low PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) less than 12cm.
10025466|NCT01714596|Active Comparator|Oral Antibiotic|Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.
10025467|NCT01714596|Active Comparator|IV Antibiotic|Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.
10025468|NCT01714622||metabolic syndrome|gastric cancer patients with metabolic syndrome
10025469|NCT01714622||metabolic disease|gastric cancer patients with metabolic disease
10025470|NCT01714622||normal|gastric cancer patients without metabolic syndrome or metabolic disease
10025471|NCT01714648|Experimental|OHSS high risk patients|Triptorelin 0.2 mg
10025472|NCT01714661|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
10025473|NCT01714661|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
10025474|NCT01714661|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
10025475|NCT01714674|Placebo Comparator|Placebo beverage|the impact of placebo (no active substance) on exercise-induced cTnT release
10025476|NCT01714674|Active Comparator|Dietary nitrate beverage|The impact of dietary nitrate (active substance) on exercise-induced cTnT release
10025477|NCT01714700|Active Comparator|High protein diet, Resistance exercise|High protein diet, Resistance exercise total calories 2400 Kcal/day, 55% carbohydrate, 30% protein, and 15% fat
10036713|NCT01818219|Experimental|Study|
10025478|NCT01714700|Placebo Comparator|Standard diet, Resistance exercise|total calories 2400 Kcal/day, 60% carbohydrate, 15% protein, and 25% fat; ST group
10025479|NCT01714713|Experimental|EVP-6124 low dose|low dose Tablet, Once Daily, Day 1 through Day 182
10025480|NCT01714713|Experimental|EVP-6124, high dose|high dose Tablet, Once Daily, Day 1 through Day 182
10025481|NCT01714752|Experimental|exercise|Patients perform exercise and pression measure is performed
10025482|NCT01714765|Other|Dovitinib and Everolimus|No Arms
10025483|NCT01714778||e-Cigarette|Smokers attempting to quit with behavioural support and e-Cigarettes.
10025484|NCT01714791|Active Comparator|Usual care|Patients following the outpatient cardiac rehabilitation program.
10025485|NCT01714791|Experimental|Usual care and Osteopathic treatment|Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.
10025486|NCT01714817|Experimental|BMS-188667 + Mycophenolate mofetil + Prednisone|BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
10025487|NCT01714817|Placebo Comparator|Placebo + Mycophenolate mofetil + Prednisone|Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
10025488|NCT01714830|Sham Comparator|sham group|the same protocol is applied but with the probe being turned off.
10025489|NCT01714830|Sham Comparator|treatment group|patients will be treated by ESWT once a week for 4 weeks
10025490|NCT01714843|Experimental|ASP0456 lowest dose group|oral
10025491|NCT01714843|Experimental|ASP0456 low dose group|oral
10025492|NCT01714843|Experimental|ASP0456 middle dose group|oral
10025493|NCT01714843|Experimental|ASP0456 high dose group|oral
10025494|NCT01714843|Placebo Comparator|placebo group|oral
10025495|NCT01714856|Experimental|Test Product|Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fed conditions
10025496|NCT01714856|Experimental|Reference Product|Single oral dose of REQUIP XL Tablets 2mg under fed conditions
10025497|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
10025498|NCT01714882|Experimental|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
10025499|NCT01714882|Active Comparator|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
10025500|NCT01714895|Other|High plasma insulin-Low plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
10025501|NCT01714895|Other|Low plasma insulin-High plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
10025502|NCT01714908|Experimental|Erlotinib w Concurrent Radiotherapy|erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.
10025503|NCT01714908|Active Comparator|etoposide/cis-platin (EP) w Concurrent Radiotherapy|etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.
10025504|NCT01714934||IPF|IPF patients diagnosed according to clinical and radiological findings
10025505|NCT01714934||NON IPF|Other interstitial lung diseases such as sarcoidosis or hypersensitivity pneumonitis diagnosed as per clinical and radiological findings
10025506|NCT01714960|Experimental|Healthy volunteers low dose|MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.
10025507|NCT01714960|Experimental|Healthy volunteers high dose|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
10025508|NCT01714960|Experimental|Glaucoma patients|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
10025509|NCT01714960|Placebo Comparator|Placebo|Placebo eye drops, 1-3 drops three times per day, duration: 16 days.
10025510|NCT01714973|Experimental|ST266 intact|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The first cohort will receive ST266 and saline placebo applied to intact skin beginning immediately following the first radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
10025511|NCT01714973|Experimental|ST266 inflamed|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The second cohort will receive ST266 and saline placebo applied to inflamed skin (after inflammation is first noted) beginning immediately following the radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
10025512|NCT01714986|Active Comparator|Affect School|Psychological group education intervention
10025513|NCT01714986|Active Comparator|Body Awareness Therapy|Physiotherapeutic psychosomatic intervention
10025514|NCT01714999|Experimental|Bursectomy: Vienna|At the Department of Trauma Surgery, Medical University of Vienna, bursectomy is considered the gold standard in case of traumatic laceration of the OB or PB bursa.
10025515|NCT01714999|Experimental|Bursal reconstruction: Munich|At the Department of Trauma Surgery, Medical University of Munich, the treatment regime is a primary bursa-preserving therapy.
10025516|NCT01715025|Experimental|E2/Nomac|Women with demonstrated HMB at baseline will be assigned to 3 cycles of a E2/Nomac combined pill 1 daily for 24 days followed by 1 placebo pill daily for 4 days per cycle.
10025517|NCT01715038|Experimental|Comprehensive|"Comprehensive LNS: LNS-PLW provided daily to mothers during pregnancy and postpartum lactation (a total of at least 11 months, starting by 20 weeks gestation and ending at 6 months post-partum) and LNS developed for infants and young children (LNS-child) provided daily to their infants (beginning at 6 months of age for a period of 18 months i.e., from 6-24 months of age)."
10025518|NCT01715038|Experimental|Child-only LNS|"Child-only LNS: Daily LNS-child supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
10025519|NCT01715038|Experimental|Child-only MNP|"Child-only MNP: Daily MNP supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
10025520|NCT01715038|Active Comparator|Control: IFA|Control: No additional nutrient supplementation for the child will be provided through the study, but the regular nutrition education and visits provided by the program frontline staff will continue. Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum.
10025521|NCT01715051|Active Comparator|D-serine|Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
10025522|NCT01715051|Placebo Comparator|Placebo|The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
10025523|NCT01715077|Experimental|Ipilimumab|The recommended induction dose of ipilimumab is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of four doses, as guided by laboratory tests and patient assessment.
10025524|NCT01715090|Experimental|Web-based insulin titration|An online web-based insulin titration algorithm to guide patients in self-titration
10025525|NCT01715090|No Intervention|Standard care|
10025526|NCT01715103|Other|Healthy women volunteers|Healthy women volunteers with vaginal swabs by washing and cytobrush
10025527|NCT01715103|Other|HIV-1 infected women|HIV-1 infected women with vaginal swabs by washing and cytobrush
10025528|NCT01715116|Experimental|Enhanced ICD programming|
10025529|NCT01715142|Experimental|Gemcitabine+Abraxane|Chemotherapy combining gemcitabine and Abraxane during 4 weeks (1 cycle) before surgery (cohort 1: resectable patients) and during at least 8 weeks (2 cycles or more in case of response of stable disease) (cohort 2: locally advanced and metastatic patients)
10025530|NCT01715155||Female patients diagnosed with metastatic breast cancer|Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
10025531|NCT01715168|Active Comparator|DOXIL/CAELYX or Doxorubicin Hydrochloride (Lipspome)|Current Standard of care and/or reference product in Europe (Caelyx) and US (Doxorubicin Hydrochloride (Liposome) and Doxil)
10025532|NCT01715168|Experimental|ATI-0918|Investigational drug arm which will be compared to Doxil/Caelyx and Hydrochloride Doxorubicin (Liposome) arms for bioequivalence analysis
10025533|NCT01715181|No Intervention|Usual care|Individuals will receive usual care
10025534|NCT01715181|Experimental|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
10025535|NCT01715194|Active Comparator|Telemedicine intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if~CPAP was used <4h/ night for 2 consecutive night~the median leakage was above 0.4 L/sec on 2 consecutive nights The nurse informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions are discussed according to the ELF facts sheet (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits, appendix 1). The patient is encouraged to use CPAP every night. In the case of regular use and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail (for procedural rules, see appendix 4)."
10025536|NCT01715194|No Intervention|Control (without telemedicine)|In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
10025537|NCT01715220|Active Comparator|Sublingual nitroglycerine|Sublingual nitroglycerine followed by pain assessment and if necessary second dose of sublingual nitroglycerine
10036714|NCT01818232|Experimental|[14C]-LX4211|400 mg LX4211 administered orally
10025538|NCT01715220|Placebo Comparator|placebo|sublingual placebo followed by pain assessment and if necessary second dose of sublingual placebo
10025539|NCT01715246|Placebo Comparator|Starter infant formula without HMO|Volumes of feed depend on age, weight and appetite.
10025540|NCT01715246|Active Comparator|Starter infant formula with 2 HMOs|Volumes of feeds depend on age, weight and appetite
10025541|NCT01715246|No Intervention|Breasfed reference group|
10025542|NCT01715259|Experimental|Abiraterone acetate|
10025543|NCT01715272|Active Comparator|Fleet enema|This group will receive Fleet enema as their treatment
10025544|NCT01715272|Experimental|TF037|This group will receive TF037 as their treatment
10025545|NCT01715311|Experimental|Indacaterol|Indacaterol once daily
10025546|NCT01715311|Placebo Comparator|Placebo|Placebo for indacaterol and placebo for tiotropium once daily
10025547|NCT01715311|Active Comparator|Tiotropium|Tiotropium
10025548|NCT01715337|Other|pulmonary rehabilitation|
10025549|NCT01715350|Placebo Comparator|Placebo group|"• Drug : Placebo 2 tablet~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
10025550|NCT01715350|Experimental|Dose group 1|"Drug : Placebo 1 tablet + Study drug 1 tablet~Study drug(650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
10025551|NCT01715350|Experimental|Dose group 2|"Drug : Study drug 2 tablet~Study drug (650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
10025552|NCT01715363|Experimental|FOLFOX + surgery + FOLFOX|"Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery~resection of the colorectal tumor during surgery~Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
10025553|NCT01715376||Integrative Chinese and western medicine|Integrative Chinese and western medicine group treat with western medical therapy for CHD refering to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.TCM should be confirmed by the physicians, according to the syndrome differentiation and the treat plan recommended in this study.
10036715|NCT01818271|Active Comparator|conventional physical Therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
9479764|NCT03540251|Active Comparator|Therapeutic auricular points treatment|Therapeutic auricular points treatment including auricular points:CO18、TF2、TF4、AT4、CO15（with complaint of sweating）or CO12(with symptom of heart palpitation)in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets. In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points.
9479765|NCT03540251|Sham Comparator|Placebo auricular points treatment|Placebo auricular points treatment including auricular points AH9、AH11、TG3、AT2、LO4 in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing placebo auricular points treatments.
9479766|NCT03540225|Experimental|Early Low-dose Arm|Start from 11-14 week: 200 mg self-administered vaginal progesterone daily
9479767|NCT03540225|Experimental|Early High-dose Arm|Start from 11-14 week: 400 mg self-administered vaginal progesterone daily
9479768|NCT03540225|Experimental|Late Low-dose Arm|Start from 20-24 week: 200 mg self-administered vaginal progesterone daily
9479769|NCT03540225|Experimental|Late High-dose Arm|Start from 20-24 week: 400 mg self-administered vaginal progesterone daily
9479770|NCT03540212|Experimental|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
9479771|NCT03540199|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
9479772|NCT03540199|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
9479773|NCT03540199|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9479774|NCT03540186|Experimental|Epigenorm Antivir and acupuncture arm|Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.
9479775|NCT03540173||Training Cohort|In the training cohort, we evaluated the impact of patient-related factors on the pain during the colonoscopy. In univariatelogistic regression analysis, All factors associated with the pain during colonoscopy (p<0.1) were included in multivariate analysis.
10025554|NCT01715376||Western medicine|western medical therapy for CHD can refer to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.
10025555|NCT01715389|Experimental|Intervention|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
10025556|NCT01715389|No Intervention|Control|The control group will be signed up for MyChart but not use the MyAsthma Patient Portal. This group will be referred to asthma educational content on the CHOP website, complete study measures and otherwise, receive standard care.
10025557|NCT01715402||operated patients|this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure
10025558|NCT01715428||Liraglutide|administration of liraglutide at 1.2 mg/daily
10025559|NCT01715441|Active Comparator|Irinotecan monotherapy|Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
10025560|NCT01715441|Active Comparator|Sorafenib monotherapy|Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
10025561|NCT01715441|Experimental|Sorafenib and irinotecan combination|"Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m² at C3 in the same conditions~Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
10025562|NCT01715480|Experimental|Broccoli sprout homogenate ingestion|Subjects will ingest broccoli sprout homogenate in the form of a shake.
10025563|NCT01715493|Experimental|Lysozyme 90 mg|
10025564|NCT01715493|Placebo Comparator|Placebo|
10025565|NCT01715506|Experimental|Educational intervention|Educational intervention with two days of lecture/course for the whole staff in the selected department in each nursing home and six monthly sessions of counselling in smaller groups
10025566|NCT01715519|Experimental|Treatment (Viibryd)|10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
10025567|NCT01715519|Placebo Comparator|Placebo|will be compared to the treatment group (viibryd)
10025568|NCT01715532|Experimental|Huachansu + TACE|Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
10025569|NCT01715532|Active Comparator|TACE|Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
10025570|NCT01715545||day-3 poor quality embryos|
10025571|NCT01715545||developmental stage|day3 poor quality embryos day4 morular day-5/6 blastocyst
10025572|NCT01715558||RYTHMIQ study group|
10025573|NCT01715558||Historical control from OPTI-MIND|
10025574|NCT01715584|Other|Angiotensin Converting Enzyme Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm.~Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)"
10025575|NCT01715584|Other|Angiotensin Receptor Blocker Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs).~Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)"
10025576|NCT01715584|Other|Non ACE/ARB Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm."
10025577|NCT01715597|Experimental|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 2hours before the operation
10025578|NCT01715597|Placebo Comparator|Control|Normal saline 500ml IV infusion for 2hour
10025579|NCT01715610|Active Comparator|Antibiotic Clavulin or Clindamycin|Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
10025580|NCT01715610|Placebo Comparator|Placebo|Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
10025581|NCT01715623||Children with HSP|children with Purpura of Henoch-Schönlein with or without renal complication
10025582|NCT01715623||healthy volunteers|healthy volunteers without allergy
9802911|NCT04826237|Experimental|Statin|"Methylprednisolone+statin (identity and dose to be determined before Trial Begins) Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day;~Oral statin 1 dose per day for 7 days, beginning with the first dose of methylprednisolone:~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
10025583|NCT01715623||subjects with allergy|subjects with peanut allergy or hymenoptera venom allergy
10025584|NCT01715623||lymphoma|lymphoma-proliferation with chromosome 14 translocation
9479776|NCT03540173||Validation group|The validation cohort was used to verify the intubation discomfort score.
10025585|NCT01715636|Other|Eviplera|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
10025586|NCT01715649|No Intervention|Control-usual care|Nurse care coordination in a telephonic diabetes disease management program
10025587|NCT01715649|Experimental|Intervention paired testing and remote monitoring|Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
10025588|NCT01715662|Experimental|Wii.n.Walk|Subjects (n=12) in the experimental arm (Wii.n.Walk) will be trained using the Wii Fit for 40-minute sessions, 3 times a week for a period of 4 weeks. Subjects will stand on the Wii Fit balance board and interact with the games through weight shifting or using the Wii remote controller. The intervention protocol includes: 1) Yoga (static single and double leg exercises), 2) Balance games (lateral and poster/anterior weight shifting exercises in standing), 3) Aerobics (running on spot and step class), and 4) Strength training (dynamic single and double leg exercises). The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic training sessions, a trained research assistant will administer the intervention and will provide external cueing and correction of the pose if the participants use unsafe technique.
10025589|NCT01715662|Placebo Comparator|Control|Subjects (n=12) in the control arm will play cognitive computer games using Wii Big Brain for the same frequency and duration as the Wii.n.Walk arm. The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic sessions, a research assistant will administer the intervention and will provide supervision. Wii Big Brain is a low-cost commercially available gaming software to improve cognitive function.
10025590|NCT01715675|Active Comparator|plant stanol|
9479777|NCT03540121|Experimental|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
10025591|NCT01715675|Placebo Comparator|control|
10025592|NCT01715688|Active Comparator|Alkalinized lidocaine|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
10025593|NCT01715688|Placebo Comparator|Saline|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
10036716|NCT01818271|Experimental|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
10036717|NCT01818310|Experimental|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
9479778|NCT03540121|No Intervention|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
10025594|NCT01715701|Experimental|Paravertebral nerve blockade|A multilevel thoracic paravertebral nerve block will be performed by the anaesthesiologist prior to the induction of general anesthesia. Prior to the block, the anaesthesiologist will locate and mark each level and then, infiltrate the skin with lidocaine 2% (0.5-1 mL). Subsequently, using a Tuohy needle 22G, 5 mL of ropivacaine 0.5% will be injected at each level between T4 and T8. At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
10025595|NCT01715701|Active Comparator|Intercostal nerve blockade|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will also infiltrate the skin with lidocaine 2% (0.5-1 mL). A multilevel intercostal nerve block will be performed by the surgeon at the end of surgery before skin closure. Five mL of ropivacaine 0.5% will be injected at each level between T4 and T8. A PCA device will be installed upon arrival in the recovery room.
10025596|NCT01715701|Active Comparator|Patient Controlled Analgesia (PCA)|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will infiltrate the skin with lidocaine 2% (0.5-1 mL). At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
10025597|NCT01715714|Active Comparator|Statin Recapture Therapy|Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin* on admission. (*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)
10025598|NCT01715714|Placebo Comparator|Placebo|Placebo given orally 12 hrs and 2 hrs before CABG
10025599|NCT01715727||Parkinson's Disease for follow-up|"Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Early to moderate stage defined as Hohen and Yahr stage 1-3,"
10025600|NCT01715727||"Parkinsonss Disease with severity match"|"Parkinsonss Disease with severity match: 30 subjects~Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Severity matched with PSP (subjects = 15)/MSA (subjects= 15), the severity was judged by Hohen and Yahr stage"
10025601|NCT01715727||Healthy age matched controls|"Healthy age matched controls: subjects = 112~Healthy subjects without a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.~Able to understand and provide signed informed consent.~Age range and gender matched with Parkinsonss Disease for follow up."
10025602|NCT01715727||Parkinson Plus Syndrome Group M|"MSA Patients should fulfill the NINDS Consensus statement for the clinical diagnosis of probable MSA~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent"
10025603|NCT01715727||Parkinson Plus Syndrome Group P|"PSP Patients should fulfill the NINDS-SPSP and Litvan criteria(4) for probable PSP~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent."
10025604|NCT01715740|Experimental|Chinese herbal medicine (CHM)|Subject in CHM group will receive CHM capsules, 8 capsules (4 gm) four times a day, total 16 gm a day, combined with levocetiricine 1PC once a day for 1 month.
10025605|NCT01715740|Placebo Comparator|Control|Subjects in control group will receive the placebo capsules, which has the similar look, smell and taste. The dosage, frequency and duration are the same as CHM group, in which 8 placebo capsule (4gm) 4 times a day, total 16 gm a day, combined with levocetiricine 1PC once a day, for 1 month.
10025606|NCT01715753|Active Comparator|Weight Loss Control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
10025607|NCT01715753|Experimental|Weight Loss-High Protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
10025608|NCT01715779||Patients who experienced a thromboembolic event|Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials.
10025609|NCT01715792||Group 1|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant rejection reported during the overall study period (01 September to 31 October 2010).
10025610|NCT01715818|Experimental|Aleglitazar|
10025611|NCT01715818|Placebo Comparator|Placebo|
10025612|NCT01715844|Active Comparator|L-citrulline|3-gr/day of L-citrulline effervescent powder mix
10025613|NCT01715844|Placebo Comparator|Placebo|3 gr of Placebo/day matching L-citrulline effervescent powder
10025614|NCT01715870||"Population of the Epidemiological study on AMD."|
10025615|NCT01715909|Experimental|Oseltamivir: Standard dose|Participants will receive standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight. Infants <1 year of age will receive oseltamivir at a dose of 3 milligrams per kilogram (mg/kg).
10025616|NCT01715909|Experimental|Oseltamivir: Triple dose|Participants will receive three times the standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight and age. Infants <1 year will receive standard dose at 3 mg/kg.
10025617|NCT01715922|Other|oral treatment|"Drug: Fluconazole and flucytosine~Induction treatment for 2 weeks:~Fluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
10025618|NCT01715935|Experimental|everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
10036718|NCT01818310|Experimental|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
10036719|NCT01818310|Experimental|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
10036720|NCT01818310|Other|Group D: Control-standard treatment|Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
9479779|NCT03540108|Experimental|Experimental: L. plantarum ECGC 13110402 (LPLDL®)|Lactobacillus plantarum ECGC 13110402 (LPLDL®) equivalent to 4 x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
9479780|NCT03540108|Placebo Comparator|Placebo Comparator: Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
9479781|NCT03540095|Experimental|Erector Spinae Plane Block|The patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
9479782|NCT03540095|Experimental|Paravertebral Nerve Block|The patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
9479783|NCT03540082|Active Comparator|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
9479784|NCT03540082|No Intervention|Control|Written instructions will be provided on the correct way to fall without physical practice.
9479785|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
9479786|NCT03540056||Boys without varicocele|Boys thoroughly examined but without diagnose of varicocele
9479787|NCT03540056||Boys with a varicocoele|Boys with a diagnosed varicocele of any stage possible.
9479788|NCT03540043|Placebo Comparator|Placebo|Administration of Placebo
9479789|NCT03540043|Experimental|PUR0110 (Thykamine) 0.05%|Administration of PUR0110 (Thykamine) 0.05%
9479790|NCT03540043|Experimental|PUR0110 (Thykamine) 0.10%|Administration of PUR0110 (Thykamine) 0.10%
9479791|NCT03540043|Experimental|PUR0110 (Thykamine) 0.25%|Administration of PUR0110 (Thykamine) 0.25%
9479792|NCT03540017|Experimental|HIPEC|Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
9479793|NCT03539991|Experimental|Supportive care (online course, virtual meeting)|Participants complete an online course focusing on different aspects of tobacco prevention and cessation over 1 hour each per week for 4 weeks. They also engage in 6 virtual meetings over 1 hour about tobacco use once per month.
9479794|NCT03539978||SM-THINk Unit|Two of the three inpatient floors will use the SM-THINk enhanced discharge method. This is part of a clinical practice change and not for research. Parents will complete a questionnaire at the time of the patient's discharge from the hospital.
9479795|NCT03539978||Control Unit|One of the three inpatient floors will use the usual discharge method. Parents will also complete a questionnaire at the time of the patient's discharge from the hospital.
10036721|NCT01818349|Active Comparator|isokinetic lower-limb training|3 times/week for 6 weeks
10025619|NCT01715961|Other|anthropometric measurement|"The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months~anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)~albuminemia, transthyretin, orosomucoid, CRP~functional test to attest the muscular strength: hand grip test, unipodal test, up and go test~hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2~OS and PFS at 18 and 24 months~GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis"
10025620|NCT01715974|Placebo Comparator|CONTROL|patients with recurrent implantation failure treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
10025621|NCT01715974|Experimental|G-CSF group|patients with recurrent implantation failure treated with G-CSF (60 micrograms/day) from the day of embryo transfer through the day of beta hCG test
10025622|NCT01715987||Tenofovir Disoproxil Fumarate|Patients who are taking Tenofovir Disoproxil Fumarate.
10025623|NCT01715987||Entecavir|Patients who are taking Entecavir.
10025624|NCT01716000|Experimental|2 mL vaginal gel|2 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
10025625|NCT01716000|Experimental|4 mL vaginal gel|4 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
10025626|NCT01716026|Active Comparator|3 Month Load with 9 month p.r.n.|3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit
10025627|NCT01716026|Experimental|Single Dose Load Phase|Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol
10025628|NCT01716091||saline irrigation|irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed
10025629|NCT01716130||IM vaccine in the past 3 years|Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
10025630|NCT01716130||no IM vaccine in the past 3 years|Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
10025631|NCT01716130||vaccine administrators|Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
10025632|NCT01716143|Other|catheter ablation|
10025633|NCT01716182||transacral lumbar interbody fusion procedure|
10025634|NCT01716182||transforaminal lumbar interbody fusion procedure (TLIF)|
10025635|NCT01716247|Experimental|pts at risk for breast cancer|Women at increased risk for breast cancer who are being referred for screening MRI will be offered and consented for CESM at the same time. The 2 examinations will be performed on the same day when at all possible and if not we will make every attempt to perform CESM before MRI. Patients with outside MRI performed within 30 days and of adequate quality will also be eligible for CESM.
10025636|NCT01716260||Chloroquine and Primaquine|Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days
10036722|NCT01818349|Placebo Comparator|isokinetic uppe-limb training|3 times/week for 6 weeks
10025637|NCT01716273|Experimental|Chronic & Acute infected wounds|Wound will be cleaned with normal saline or tap water and Granulated sugar will be applied directly to the wound and covered with an absorbent pad and held in place with a bandage and tape.
10025638|NCT01716273|Active Comparator|Chronic and Acute infected wounds|Wound will be cleaned with normal saline or tap water and an appropriate debridement dressing (Aquacel or Sorbsan) is applied to the wound and secured with a bandage and surgical tape.
10025639|NCT01716286|Experimental|yoghurt type|low fat yoghurt vs. essence yoghurt
10025640|NCT01716325|Experimental|Weight loss - ICT support|Weight loss - ICT support
10025641|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
10025642|NCT01716338|Active Comparator|Glyburide|1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
10025643|NCT01716338|Placebo Comparator|Sugar Pill (Capsule)|Matching placebo capsule by mouth every day with breakfast for 7 days
10025644|NCT01716351|Experimental|Adapted Yoga Intervention Group|Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.
10025645|NCT01716351|No Intervention|Control|Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.
10025646|NCT01716364|Experimental|Anti-LeY- scFv-CD28-ζ vector.|Anti-LeY- scFv-CD28-ζ vector, a non-pathogenic, replication-incompetent retroviral vector specifically designed for this study and produced by EUFETS under GMP-conditions.
10025647|NCT01716377|Placebo Comparator|Placebo|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
10025648|NCT01716377|Active Comparator|Venlafaxine|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
10025649|NCT01716390|Active Comparator|Drink that contains plant stanols|Dietary supplement: Plant stanol
10025650|NCT01716390|Placebo Comparator|Placebo drink|Dietary supplement: Placebo
10025651|NCT01716403||HCV tritherapy and anemia|HCV-genotype 1 infected patients
10025652|NCT01716416|Experimental|Dose Level 1|"Pazopanib 200 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
10025653|NCT01716416|Experimental|Dose Level 2|"Pazopanib 400 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
10025654|NCT01716416|Experimental|Dose Level 3|"Pazopanib 600 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
10025655|NCT01716416|Experimental|Dose Level 4|"Pazopanib 800 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
10025656|NCT01716416|Experimental|Part 2 Dose|"Pazopanib (dose to be determined in Part 1 of study) mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
10025657|NCT01716429|Active Comparator|Low Calorie|Participants in this arm will be instructed on how to reduce their caloric intake and follow a low calorie diet
10025658|NCT01716429|Experimental|Vegan diet|Participants in this arm will follow a very low fat diet (~10% kcals from fat) and also a diet that has a low glycemic index and is free of animal products (vegan)
10025659|NCT01716442|Active Comparator|steroid-resistant|Steroid-resistant group: n=27 , enroll all for treatment
10025660|NCT01716442|Active Comparator|steroid-dependent-rituximab|steroid-responsive group: n=38
10025661|NCT01716442|Placebo Comparator|steroid-dependent-placebo|steroid-responsive group: n=23
10025662|NCT01716481|Experimental|Mesenchymal stem cell treatment|
10025663|NCT01716481|No Intervention|Standard treatment|
10025664|NCT01716494||Severe Asthma|Subjects with severe asthma (SARP protocol definition)
10025665|NCT01716494||Well controlled asthma|Subjects with well controlled asthma
10025666|NCT01716494||Normal control|Subjects that are healthy normals
10025667|NCT01716507|Other|20 gauge pars plana vitrectomy|20 gauge pars plana vitrectomy for retinal detachment repair
10025668|NCT01716507|Other|23 gauge pars plana vitrectomy|23 gauge pars plana vitrectomy for retinal detachment repair
10025669|NCT01716546|Experimental|1|Panitumumab plus DCF
10025670|NCT01716572|Active Comparator|gastric lavage|gastric lavage by nasogastric tube with 1 liter saline before the endoscopy
10025671|NCT01716572|Active Comparator|erythromycin|administration of 250mgr of erythromycin before the endoscopy
10025672|NCT01716598|Experimental|Treatment|Targeted Lung Denervation Therapy (TLD Therapy)
9462654|NCT03700281|No Intervention|Control|No intervention
9462655|NCT03700281|Experimental|Messaging|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail
9462656|NCT03700281|Experimental|Messaging plus incentive|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail, and will be eligible to receive a gift card as incentive for receiving flu vaccine
9462657|NCT03700268|Experimental|Manual fitting|The patient is receiving the classical treatment : 10 sessions of 1 hour during one year where the clinician programs manually the Cochlear implant.
9462658|NCT03700268|Experimental|Artificial Intelligence|The patient is receiving the new treatment : 4 sessions of 1 hour during one year where the clinician programs the Cochlear implant with the FOX (Fitting to Outcome eXpert) software using artificial intelligence.
9462659|NCT03700255|Experimental|Group A|Group A will undergo the PickUpSimTM simulation training program
9462660|NCT03700255|No Intervention|Group B|Group B will only have the classic training with no simulation.
9802912|NCT04826237|Placebo Comparator|Placebo|"Methylprednisolone+ placebo. Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral placebo 1 dose per day for 7 days, beginning with the first dose of methylprednisolone~If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart."
9802913|NCT04825990|Experimental|Single Arm Treatment|Patients will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week dosing cycle (Q3W) and olaparib 300 mg capsules twice a day (BID) every day starting from Day 1 of Cycle 1. Treatment with protocol therapy will continue until objective disease progression, any prohibitive toxicity or until a maximum of 35 treatment cycles (up to 2 years).
9802914|NCT04820530|Experimental|LNP023|Participants will receive LNP023 at a dose of 200 mg orally b.i.d
9802915|NCT04817618|Experimental|iptacopan 200mg b.i.d.|iptacopan 200 mg b.i.d.
10025673|NCT01716611|Active Comparator|Tolvaptan group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
10025674|NCT01716611|Placebo Comparator|Placebo group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
10025675|NCT01716624|Active Comparator|Oxybutynin|
10025676|NCT01716624|Experimental|Botulinum Toxin A injection|
10025677|NCT01716637|Active Comparator|Etanercept|25 mg administered weekly for 6 weeks
10025678|NCT01716637|Active Comparator|Nutritional Supplements|Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
10025679|NCT01716650||Saphenous nerve block|Data collection after saphenous nerve block placement
10025680|NCT01716676|Active Comparator|Standard CPAP follow-up|
10025681|NCT01716676|Experimental|Telemedicine CPAP follow-up|
10025682|NCT01716689|Experimental|Patients with advanced sarcoma|
10036723|NCT01818362|Experimental|Group 2|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
9462666|NCT03700229|Experimental|Bortezomib +Rituximab|Bortezomib +Rituximab
9462667|NCT03700203||Early cardiac arrest patients|Cases will be consecutive adult patients with EMS-treated OHCA and transport to the 14 emergency departments of participating hospitals. A prospective OHCA patient cohort will be developed and all survived OHCA cases will be followed at 1-month and 6-month after ED discharge by telephone. During the study period, the investigators aim to recruit a total 1,780 cases (200 cases between September 2017 and August 2018, 600 cases between September 2018 and August 2020, 80 cases between September 2020 and December 2020, and 900 cases between January 2021 and December 2023).
9462668|NCT03700203||Matched community-based controls|Matched community-based controls (2:1 matching) will be selected from two health screening centers. Controls are those who visit the participating health screening centers for their annual routine physical examinations. During the study period, the investigators aim to recruit a total 3,560 controls (400 controls between September 2017 and August 2018, 1200 controls between September 2018 and August 2020, 160 controls between September 2020 and December 2020, and 1800 controls between January 2021 and December 2023).
9462669|NCT03700177|Active Comparator|ropivacaine + dexamethasone|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).
9462670|NCT03700177|Placebo Comparator|ropivacaine + placebo|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml placebo (NaCl 0,9%).
9462671|NCT03700164|Experimental|Cold exposure|Participants will be wrapped in a water-perfused suit. The temperature of the suit will be lowered to 10°C. From the onset of shivering, the participants will remain in the suit for 1 hour.
9462672|NCT03700164|Other|Thermoneutral (Control)|"Participants will be wrapped in a water-perfused suit. The temperature of the suit will remain at a thermoneutral temperature (32°C) to avoid shivering and excessive sweating.~The duration will be matched to that during the cold exposure."
9462673|NCT03700151|Experimental|Children with SSD|Participants will receive a piloted treatment programme for children with severe speech sound disorders, especially childhood apraxia of speech.
9462674|NCT03700138|Experimental|Privigen|TThe treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 6 weeks, with a total of 3 perfusions administered (W0, W4, W8).
9462675|NCT03700138|Placebo Comparator|Placebo|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
9462676|NCT03700125|Experimental|ECMO resuscitation|6 patients who meet the eligibility criteria will be treated by pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable and can establish ECMO flow within 30 minutes of collapse
9462677|NCT03700112|Experimental|JUUL Virginia Tobacco flavored 5.0% ENDS|"Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed using 10 puffs delivery method~Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed Ad-libitum delivery method"
9462678|NCT03700112|Experimental|PMI iQOS Heat sticks|"Administration of PMI iQOS Heat sticks - Regular consumed using 10 puffs delivery method~Administration of PMI iQOS Heat sticks - Regular consumed ad-libitum delivery method"
9462679|NCT03700112|Experimental|Reynolds VUSE Solo ENDS - Original|"Administration of Reynolds VUSE Solo ENDS - Original consumed using 10 puffs delivery method~Administration of Reynolds VUSE Solo ENDS - Original consumed using ad-libitum delivery method"
9462680|NCT03700112|Experimental|Imperial MyBlu ENDS - Original|"Administration of Imperial MyBlu ENDS - Original consumed using 10 puffs delivery method~Administration of Imperial MyBlu ENDS - Original consumed using ad-libitum delivery method"
9462681|NCT03700112|Experimental|Altria MarkTen ENDS - Bold Classic|"Administration of Altria MarkTen ENDS - Bold Classic consuming using 10 puffs delivery method~Administration of Altria MarkTen ENDS - Bold Classic consuming using ad-libitum delivery method"
10025683|NCT01716702|Experimental|Couples Prostate Cancer Support Group|"The participants in the support group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
10025684|NCT01716702|No Intervention|Wait-List Control|Participants will be asked to complete questionnaires at three time points: 1)week 1 2) week 7, and 3) week 13.
10025685|NCT01716728|No Intervention|Enzyme analysis|Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis
10025686|NCT01716741|Other|Enzyme analysis|Patients invited for evaluation will undergo glucocerebrosidase enzyme analysis
10025687|NCT01716767|Experimental|Menthol|Biofreeze topical gel containing 3.5% menthol
10025688|NCT01716767|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
10025689|NCT01716780|No Intervention|Routine care|"Patients allocated to the control group will undergo their 'usual care'; they will be given pain medication when they specifically request it or when their oncology doctor/ nurse or GP considers it appropriate to prescribe it, either at the oncology clinic visit or at any time during the course of the study."
10025690|NCT01716780|Experimental|Intervention|"Patients allocated to the intervention group will be reviewed by the pain/palliative care team and will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care."
10025691|NCT01716793|Other|Risk-adapted postremission treatment|Ara-C, autologous transplantation, Allogeneic HLA-identical sibling transplantation depending on risk factors (cytogenetics, courses to CR)and availability of an HLA-identical sibling, CD34+ selection.
10025692|NCT01716819|Other|Abdominal obesity|"Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :~Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring"
10025693|NCT01716832|Experimental|Mindfulness walking|
10025694|NCT01716832|No Intervention|No intervention (waiting list)|
10025695|NCT01716845||Development group 1|
10025696|NCT01716845||Development group 2|
10025697|NCT01716845||Development group 3|
10025698|NCT01716845||Validation group|
10025699|NCT01716858|Experimental|A single-arm study|
10025700|NCT01716871|Active Comparator|cryotherapy using Cold pack®|"patients with lateral ankle sprain who have been randomized in the cold packs® group.~Application of cryotherapy with Cold pack® or ice-cubes pack in the sprained ankle during 20 minutes 4 times a day, 3 days long."
9462682|NCT03700112|Experimental|MLV PHIX ENDS - Original Tobacco|"Administration of MLV PHIX ENDS - Original Tobacco consumed using 10 puffs delivery method~Administration of with MLV PHIX ENDS - Original Tobacco consumed using ad-libitum delivery method"
9462683|NCT03700112|Experimental|NJOY Daily EXTRA ENDS - Rich Tobacco|"Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puffs delivery method~Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using delivery method and ad-libitum"
9802916|NCT04817618|Placebo Comparator|Placebo to iptacopan 200mg b.i.d.|Placebo to iptacopan 200mg b.i.d.
9462684|NCT03700112|Experimental|Altria Marlboro combustible cigarette - Red|Administration of Altria Marlboro combustible cigarette - Red consumed using 10 puffs delivery method Administration of Altria Marlboro combustible cigarette - Red consumed using ad-libitum delivery method
10025701|NCT01716871|Active Comparator|cryotherapy using Neurocryostimulation|"Patient with lateral ankle sprain randomized in the neurocryostimulation group.~Application of neurocryostimulation with Duo-cryo® device during 1 minute on the sprained ankle, 2 times a day, 3 days long"
9462685|NCT03700099|Other|Study cohort|Docetaxel 75 mg/m2 i.v. every 3 weeks for 6-10 cycles. Upon disease progression after docetaxel, participants will receive enzalutamide 160 mg p.o. daily until limiting toxicity or disease progression.
9462686|NCT03700086|Experimental|Negative wound pressure device (PICO)|The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
9462687|NCT03700086|Active Comparator|Standard sterile dressing|The OPsite post-op visible standard sterile dressing will be used to cover the midline incision. Dressing is changed q48h. Data are collected on POD3, POD7 and POD30.
9462688|NCT03700073|Experimental|Walk training plus virtual reality|Experimental group (GTVR): The intervention consisted of treatment with the robotic CL1Walker gait training system in combination with virtual reality
9462689|NCT03700073|Active Comparator|Walk training|Control group (GT): The intervention consisted of treatment with the robotic CL1Walker gait training system
9462690|NCT03700060||General Practice|Volunteering General Practices who registers contacts from nursing homes on residents with suspected UTI
9462691|NCT03700034|Experimental|mHealth Integrated Antenatal Care|The mIRA trial intervention will consist of an electronic decision support system (EDSS), provided to healthcare providers at primary-level facilities in India and Nepal to deliver enhanced ANC with improved detection and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM) and anemia.
9462692|NCT03700034|No Intervention|Routine Antenatal Care|In the control clusters, pregnant women will receive the existing standard of care (usual care) from Frontline Health Workers (FHWs).
10025702|NCT01716897|Other|50 mg E2609 capsule formulation in fasted state|50 mg E2609 capsule formulation
10025703|NCT01716897|Other|50 mg E2609 tablet formulation in fasted state|50 mg E2609 tablet formulation in fasted state
10025704|NCT01716897|Other|50 mg tablet formulation in fed state|50 mg E2609 tablet formulation in fed state
10025705|NCT01716910|Placebo Comparator|Maltodextrin|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day
10025706|NCT01716910|Active Comparator|Synbiotic|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day + 10e9 CFU
10025707|NCT01716923|Experimental|S-303 Treated Red Blood Cells|Patients receive S-303 treated red blood cells (RBCs).
10025708|NCT01716923|Active Comparator|Conventional, untreated Red Blood Cells|Patients receive conventional, untreated red blood cells (RBCs).
10025709|NCT01716936||MAGEC Implant|All patients implanted with the MAGEC System will be reviewed for inclusion into this retrospective study.
10025710|NCT01716949|Experimental|HyRec|Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin
10025711|NCT01716962||ARDS with acute circulatory failure|acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
10025712|NCT01716975|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
10025713|NCT01716975|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
10025714|NCT01716975|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
10025715|NCT01716988||Micafungin|
10025716|NCT01717027|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10025717|NCT01717027|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10025718|NCT01717027|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10025719|NCT01717027|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
10025720|NCT01717066|Experimental|the ginsenoside Rg3|320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence
10025721|NCT01717066|Placebo Comparator|the placebo|160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group
10025722|NCT01717079|Active Comparator|Effective arm|Effective coil
10025723|NCT01717079|Placebo Comparator|Placebo arm|Placebo coil
9462693|NCT03700008|Other|Participants with mental illness|"Participant with pre known or actually diagnosed mental disorder, especially affective or neurodevelopmental disorder.~Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements."
10025724|NCT01717092||Consecutive patients with acute PE|
10025725|NCT01717105||metastatic non-small cell lung cancer|Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
10025726|NCT01717118|Active Comparator|Tetravalent Vaccine|"Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
10036724|NCT01818362|Experimental|Group 3|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
10036725|NCT01818362|Experimental|Group 4|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
10025727|NCT01717118|Active Comparator|Bivalent Vaccine|"Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
10025728|NCT01717131|Active Comparator|Surgery for standard axillary node dissection|Standard axillary dissection
9462694|NCT03700008|Other|Participants without any mental illness|Participant with never diagnosed mental disorder, in a healthy mental state. Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements.
9462695|NCT03699982|Experimental|Cystic fibrosis patients|Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
9462696|NCT03699969|Experimental|Hypofractionated dose escalated VMAT|Hypofractionated dose escalated VMAT radiotherapy
9462697|NCT03699969|No Intervention|Conventional concurrent chemoradiation|Conventional concurrent chemoradiation
10025729|NCT01717131|Experimental|No axillary lymph node dissection|No surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial)
10025730|NCT01717144|No Intervention|traditional medical care|patients benefiting of a traditional medical care
10025731|NCT01717144|Experimental|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
10025732|NCT01717157|Experimental|Treatment sequence 1 (AEBD)|
10025733|NCT01717157|Experimental|Treatment sequence 2 (BACE)|
10025734|NCT01717157|Experimental|Treatment sequence 3 (CBDA)|
10025735|NCT01717157|Experimental|Treatment sequence 4 (EDAC)|
10025736|NCT01717157|Experimental|Treatment sequence 5 (DECA)|
10025737|NCT01717157|Experimental|Treatment sequence 6 (EADB)|
10025738|NCT01717157|Experimental|Treatment sequence 7 (ABEC)|
10025739|NCT01717157|Experimental|Treatment sequence 8 (BCAD)|
10025740|NCT01717170|Experimental|Tocilizumab (4 mg/kg)|Tocilizumab (4 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
10025741|NCT01717170|Experimental|Tocilizumab (8 mg/kg)|Tocilizumab (8 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
10025742|NCT01717183|Experimental|URGO 310 3113 dressing - new|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
10025743|NCT01717183|Placebo Comparator|URGO 310 3113 dressing|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
10025744|NCT01717196|Experimental|DIFFERENT VOLUME ASPIRATION BIOPSY|The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
10025745|NCT01717222|Active Comparator|Intraperitoneal (IP) group|Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
9462698|NCT03699956|Experimental|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks~Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
9479796|NCT03539965||Single-arm cohort|Initially, patients will be analyzed in a single group. After determining the status of the biomarkers, the patient sample will be divided into specific groups for comparative purposes.
10025746|NCT01717222|Active Comparator|Intravenous (IV) group|Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.
10025747|NCT01717235|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
10025748|NCT01717235|Experimental|Reference Product|REQUIP XL Tablets (containing Ropinirole hydrochloride CR 2mg Tablets)under fasting conditions
10025749|NCT01717248|Experimental|GCS-100|GCS-100 will be administered once weekly by a ten minutes injection.
10025750|NCT01717261|Experimental|Single Pre-Operative Radiation Therapy|
10025751|NCT01717274|Experimental|Hot saline irrigation|Hot saline is prepared by first placing 2 litres of sterile normal saline (0.9%) into a basin (IntraTemp Therma BasinTM) that is wrapped in a sterile disposable drape (IntraTemp Therma Basin DrapeTM). The basin is then placed in a medical grade warmer (IntraTemp Fluid Warming SystemTM). The warmer is set to heat the saline up to a temperature of 50 degrees Celsius. An external digital thermometer is placed in the saline at all times to ensure that the temperature is between 45-50 degrees.
10025752|NCT01717274|No Intervention|Room temperature saline irrigation|Room temperature saline is prepared in the same manner as the experimental arm except that the warmer is switched off and the temperature of the saline in the basin is left to equilibrate to the temperature of the operating room.
10025753|NCT01717300|Experimental|Anacetrapib 100 mg|
10025754|NCT01717300|Experimental|Anacetrapib 25 mg|
10025755|NCT01717300|Placebo Comparator|Placebo|
10025756|NCT01717339|Other|Normal Subjects|Non-OSA (Obstructive sleep apnea) patients
10025757|NCT01717339|Other|OSA subjects|(Obstructive sleep apnea) OSA subjects
10025758|NCT01717352|Active Comparator|Weight Loss Education|Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
10025759|NCT01717352|Active Comparator|Sleep and Eating Routine|Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
10025760|NCT01717365||OTs|Occupational therapists
10025761|NCT01717378||Potential research participants|UCSF Registry represents a single recruitment pool of individuals who have consented to be contacted about future studies for which they may be eligible based on self-reported health information.
10025762|NCT01717404|Experimental|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
10025763|NCT01717417||group 1|Patient treated with Trans Palatal Arch as anchorage for canine traction
10025764|NCT01717417||Group 2|Patient treated with miniscrew as anchorage for canine traction
10025765|NCT01717430||Corticosteroid injection|Consecutive patients receiving initial or repeated sacroiliac joint or single or multi-level epidural corticosteroid injections as part of their management plan for SI joint, neck, back, or radicular pain. Injections will be performed using 0.5 mL bupivacaine 0.25% and 15 mg dexamethasone sodium phosphate.
9462699|NCT03699956|Active Comparator|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
9462700|NCT03699943|Active Comparator|CaverStem 1.0 - Low|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc
9462701|NCT03699943|Active Comparator|CaverStem 1.0 - High|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc
9462702|NCT03699943|Active Comparator|Caverstem 2.0 - Clinical Registry|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
10025766|NCT01717443||Women, renal disease, transplantation|Women with end-stage renal disease, whose eligibility for renal transplantation is assessed
10025767|NCT01717469|Active Comparator|RV Pacing|Right ventricular pacing
9462705|NCT03699904|Experimental|Active arm|Valaciclovir 1 gram orally three times daily for 8 weeks.
9462706|NCT03699904|Placebo Comparator|Placebo arm|Matching placebo capsules (containing Avicel blend). Two capsules three times daily for 8 weeks.
10025768|NCT01717469|Experimental|LV Pacing|Left ventricular pacing through coronary sinus tributaries
9462707|NCT03699878||patients undergoing robotic esophagectomy|Patients 20 years or older who undergo robotic esophagectomy
9462708|NCT03699852|Experimental|LED group|The study had two groups of participants: the LED group (GL) and the control group (GC), both with Membracel®, a porous membrane that regenerates crystalline cellulose, as the primary cover in the donor area of the skin graft (no secondary cover was used) ). In one of the groups (GL), a light-emitting diode (LED) plate was applied, which was covered with sterile waterproof and transparent film to prevent contamination. The participant was positioned so that the skin graft donor area was accessible. The LED plate covered the entire skin donor area and was irradiated with a radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED plate was applied in contact with the skin graft donor area in the immediate postoperative period and on Membracel® on the 1st, 3rd, 5th and 7th postoperative days. The primary coverage remained until spontaneous removal.
9462709|NCT03699852|Other|Control group|The participants remained and were evaluated under the same conditions. The only difference between the groups is that no LED photobiomodulation session was applied to the control group.
9462710|NCT03699839|Experimental|High dose influenza vaccine|Administration of high-dose influenza vaccine
9462711|NCT03699839|Experimental|MF59-adjuvanted influenza vaccine|Administration of MF59-adjuvanted vaccine
9462712|NCT03699839|Active Comparator|Standard influenza vaccine|Administration of standard intramuscular influenza vaccine
9462713|NCT03699826|Experimental|TMS|
9462714|NCT03699813||scoliosis bleeding management based on aPTT/PT|"Bleeding and coagulopathy during surgery managed by clinical approach and aPTT/PT tests.~Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed."
9462715|NCT03699813||scoliosis bleeding management based on ROTEM|Bleeding and coagulopathy during surgery managed by ROTEM. Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed.
9462716|NCT03699800|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
9462717|NCT03699800|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
9462718|NCT03699787|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
10025769|NCT01717495||Implantation Procedures|Patients submitted to initial pacemaker or ICD implantation
10025770|NCT01717495||Reoperation Procedures|Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
10036726|NCT01818362|Experimental|Group 1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
10036727|NCT01818362|Experimental|Group 5|ChAdOx1 NP+M1 2.5 x 10¹⁰vp
10036728|NCT01818362|Experimental|Group 6|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
9462719|NCT03699787|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
9462720|NCT03699774|Experimental|All Participants|"In treatment Period 1 (Day 1 through Day 4), on Day 1, participants receive a single dose of rosuvastatin 10 mg orally with food, and in Period 2 (Day 1 through Day 16), starting on Day 1, participants receive DS-8500a 75 mg orally qd with food for 16 days with concomitant administration of a single dose of rosuvastatin 10 mg qd on Day 14.~In both the periods, rosuvastatin and DS-8500a are administered after an overnight fast of 8 hours and within 10 minutes after consuming a standardized breakfast of 500 calories."
9462721|NCT03699761|Experimental|Pelvic Peritonization|
9462722|NCT03699761|No Intervention|Without Pelvic Peritonization|
9462723|NCT03699735|Active Comparator|Hearing Aid with beam form principle_A|Device: Hearing Aid beam former principle_A (simulation of real ear condition). Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
9462724|NCT03699735|Experimental|Hearing Aid with beam form principle_B|Device: Hearing Aid beam former principle_B. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
9462725|NCT03699735|Experimental|Hearing Aid with beam form principle_C|Device: Hearing Aid beam former principle_C. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
9462726|NCT03699722|Experimental|Education + Activities|12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
9462727|NCT03699722|Active Comparator|Information|PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
9462728|NCT03699696||65-75 years of age|Patients who are between the ages of 65 and 75, including 65 but not including 75, and receive propofol for induction of anesthesia.
9462729|NCT03699696||75-85 years of age|Patients who are between the ages of 75 and 85, including 75 but not including 85, and receive propofol for induction of anesthesia.
9462730|NCT03699696||85+ years of age|Patients who are 85 years of age or older, and receive propofol for induction of anesthesia.
9462731|NCT03699683|Experimental|Physical Combined Activity Program|Before and after a 6-months supervised and individualized program that combined aerobic and resistance training were performed in post bariatric patients. Body composition, physical fitness and cardiovascular risk factors were measured before, after the physical activity program and 6 months later (13 months sinde the program started)
9462732|NCT03699657|Active Comparator|RFA with DSM mode|RFA is performed in dual switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
9462733|NCT03699657|Active Comparator|RFA with SSM mode|RFA is performed in single switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
9462734|NCT03699618||Anti-VEGF injection only|Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
10025771|NCT01717508|Other|Cognitive Behavioral Therapy|12 weekly sessions of cognitive behavioral therapy
10025772|NCT01717508|No Intervention|Healthy Controls|
10025773|NCT01717534|Experimental|Heat-treated lactobacilli|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
10025774|NCT01717534|Placebo Comparator|Maltodextrin|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
10025775|NCT01717547|Experimental|Yoga|Yoga-based treatment - manualized group treatment - classes will be held twice per week for approximately 85 minutes for a period of eight weeks.
10025776|NCT01717560|Experimental|Collaborative multidisciplinary integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
10025777|NCT01717573|Active Comparator|Deferred stenting|During primary PCI in STEMI, when TIMI 3 flow has been re-established with guide-wire, aspiration thrombectomy and/or balloon angioplasty, stenting is then deferred for a period of 4-16 hours following reperfusion. During this time, patients remain in the Coronary Care Unit and will receive intravenous tirofiban and subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg)
10025778|NCT01717573|Sham Comparator|Conventional treatment|Conventional treatment in STEMI, with immediate stenting
10025779|NCT01717599|Experimental|Diclofenac group|
10025780|NCT01717599|Placebo Comparator|Placebo(normal saline) group|
10025781|NCT01717612|Active Comparator|Histoacryl group|the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
10025782|NCT01717612|Experimental|thrombin group|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
9462735|NCT03699618||Hemorrhage displacement + Anti-VEGF|Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24
10025783|NCT01717625|Experimental|Montelukast|"montelukast sodium~dosage~< 1000g : 0.5 mg/D QD~1000g~1500g : 1.0 mg/D QD~1500g~2000g : 1.5 mg/D QD~> 2000g : 2mg/D QD~medication period : to discharge or GA 36wks"
9462736|NCT03699605|Experimental|VESMP|"Participants used VESMP at least half hour session thrice a week over an average of 4 months. The instruction before every domain included using it independently on the participant's own smart phone, or with a trained person either in the clinic or on their phone brought to the participant's home.~Total 25 patients with diagnosis of severe non-fluent aphasia included, ages 40+, at least 3 months post-onset of single unilateral CVA affecting the language dominant hemisphere at the time of baseline testing also including, Participant demographics, aphasia classification and severity. All subjects participated in an intensive 2-week VESMP treatment program prior to beginning the individualized programs."
9462737|NCT03699605|Active Comparator|Traditional Therapy|Control group received traditional therapy total 25 patients with diagnosis of severe non-fluent aphasia included, All subjects participated in an traditional therapy group in routine and received language therapy for 4 months of periods with three sessions per week.
10025784|NCT01717625|No Intervention|Control|Standard treatment of BPD and preterm infants
10025785|NCT01717651||CPM device|a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.
10025786|NCT01717664|Experimental|RHB-104|5 RHB-104 capsules administered orally BID
9462738|NCT03699592|No Intervention|Control|
9462739|NCT03699592|Experimental|Reach Home and Read|This arm will receive the Reach Home and Read early literacy intervention
10025787|NCT01717677|Experimental|radical prostatectomy|Procedure/Surgery: radical prostatectomy
10025788|NCT01717677|Experimental|percutaneous radiation therapy|Radiation: percutaneous radiation therapy
9462740|NCT03699566||Healthy volunteers|"Individuals aged 18-65 without chronic disease.~Interventions: Assessment of Respiratory Muscle Strength, Spirometer, Trunk Muscles Endurance Tests"
9462741|NCT03699514||Subject who completed or will complete a BNA test|
9479797|NCT03539939|Experimental|Smoker Group|This group included smoker gingival recession patients.
10025789|NCT01717677|Experimental|permanent seed implantation|Radiation: permanent seed implantation
10025790|NCT01717677|Experimental|Active Surveillance|Procedure/Surgery: Active Surveillance
10025791|NCT01717690|Active Comparator|CHG antiseptic body cleanser|"One randomly selected intervention unit in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with an antiseptic body cleanser (CHG).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed.~Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic solution."
10025792|NCT01717690|No Intervention|Non-antiseptic body cleanser|"Two control units in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with a non-antiseptic body cleanser (Comfort Bath ®).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed."
10025793|NCT01717703|Experimental|Water Control|Water Control
10025794|NCT01717703|Experimental|Fruit drink|Fruit drink
10025795|NCT01717703|Experimental|Cola|Cola
10025796|NCT01717703|Experimental|1% chocolate milk|1% chocolate milk
10025797|NCT01717716|Experimental|Calorie-free control|Calorie-free control
10025798|NCT01717716|Experimental|HFCS-55 drink|HFCS-55 drink
10025799|NCT01717716|Experimental|Glucose drink|Glucose drink
10025800|NCT01717716|Experimental|Sucrose drink|Sucrose drink
10025801|NCT01717729|Experimental|RFA-125I group|The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125.
10025802|NCT01717729|Active Comparator|RFA-only group|(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe.
10025803|NCT01717755|No Intervention|Best medical management.|"Best medical management consists of the standard of care of patients with acute ischemic stroke according to existing local protocols and guidelines, and may include IV thrombolysis.~If treated with IVT as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO."
10025804|NCT01717755|Experimental|Additional intra-arterial treatment.|Best medical management followed by intra-arterial treatment and best medical management
10025805|NCT01717781|Experimental|Thunderbeat|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to incise the bladder peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to dissect the bladder and develop rectovaginal septum, to unroof the ureter, to cut parametria, and to divide the uterosacral ligaments. Monopolar hook is used in the culdotomy. Thunderbeat is also used to perform pelvic lymphadenectomy."
9479798|NCT03539939|Active Comparator|Non-smoker Group|This group included non-smoker gingival recession patients.
9479799|NCT03539926|Experimental|Lit-control®pH Meter|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
10025806|NCT01717781|Active Comparator|Standard|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
10025807|NCT01717794|Active Comparator|Standard bipolar electrosurgery|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
9462742|NCT03699462|Active Comparator|Plasma A group|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
9462743|NCT03699462|Experimental|Albumin group|The group receiving receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
9462744|NCT03699449|Experimental|olaparib + cediranib|olaparib+cediranib combination therapy
9462745|NCT03699449|Experimental|durvalumab + olaparib|durvalumab + olaparib combination therapy
9462746|NCT03699449|Experimental|durvalumab + chemotherapy|durvalumab +chemotherapy
9462747|NCT03699449|Experimental|durvalumab + tremelimumab + chemotherapy|durvalumab + tremelimumab + chemotherapy
9462748|NCT03699449|Experimental|durvalumab + tremelimumab + paclitaxel|durvalumab + tremelimumab + paclitaxel
9462749|NCT03699449|Experimental|durvalumab +chemotherapy|durvalumab +chemotherapy
9462750|NCT03699436|Experimental|Electric Stimulation Therapy Group|The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
9462751|NCT03699436|Active Comparator|Control Group|The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
9462752|NCT03699423|Active Comparator|0.01% atropine eye drops|Participants will receive one drop per eye every night for two weeks
9462753|NCT03699423|Active Comparator|0.02% atropine eye drops|Participants will receive one drop per eye every night for two weeks
9462754|NCT03699423|Active Comparator|0.03% atropine eye drops|Participants will receive one drop per eye every night for two weeks
9462755|NCT03699397|Experimental|Dry electrode cap EEG|In this diagnostic accuracy study, all patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
9462756|NCT03699384|Experimental|Azacitidine and Avelumab|All enrolled patients will receive 1 cycle of AZA followed by cycles of combination AZA+Avelumab.
9462757|NCT03699371|Experimental|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of continuous renal replacement therapy (CRRT) 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU for the purpose of the study.
9462758|NCT03699371|No Intervention|Late Supplemental Parenteral Nutrition|Control group: would receive EN reaching up to 20 % of daily nutritional requirements and late (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day ) in SPN on 7th day of stay in ICU if it is not already met via enteral route.
9462759|NCT03699358||Group 1: Myeloid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
9462760|NCT03699358||Group 2: Lymphoid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
9462761|NCT03699345||Edwards CENTERA THV|
10025808|NCT01717794|Experimental|Thunderbeat technology|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to coagulate the fallopian tubes, to coagulate and divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to incise the bladder peritoneum, to dissect the bladder, to develop rectovaginal septum, to cut parametria, and to divide the uterosacral ligaments. Thunderbeat is also used to perform the pelvic lymphadenectomy and, if necessary, the para-aortic lymphadenectomy."
10025809|NCT01717807||lung cancer; advanced pancreatic cancer|
10025810|NCT01717820|Experimental|Freeze-dried whole-grape powder|Freeze-dried whole-grape powder (46g/day)will be provided to participants for 12 weeks.
10025811|NCT01717833|Experimental|NEMS group|
10025812|NCT01717833|Sham Comparator|Sham group|
10025813|NCT01717846|Experimental|Arm 1|Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
10025814|NCT01717846|Other|Arm 2 or group 2|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
10025815|NCT01717885||HIV+children on LPV/r|HIV+ children who are stabilized on a LPV/r based ART regimen
9462762|NCT03699332|Experimental|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
9462763|NCT03699306|Active Comparator|Conventional r blinded|the participants were allocated to have NG tube inserted in a conventional or blind method.
9462764|NCT03699306|Active Comparator|Brake cable|the participants were assigned to have NG tube inserted by use of a bike brake cable as a guide wire.
9462765|NCT03699306|Active Comparator|High way man's hitch|they were selected to have NG tube inserted by use of silk thread knot.
9462766|NCT03699293|Active Comparator|ASA and Celecoxib|Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
9462767|NCT03699293|Active Comparator|ASA and Naproxen|Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)
9462768|NCT03699280|Experimental|Virtual Reality|VR video to be played during the procedure
9462769|NCT03699280|No Intervention|Standard Procedure|Routine protocol outpatient hysteroscopy
9462770|NCT03699267||UBR TRAM / GBA|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
9462771|NCT03699267||UBR TRAM / GBA + TAP|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
9462772|NCT03699267||M + UBR TRAM / GBA|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
9462773|NCT03699267||M + UBR TRAM / GBA + TAP|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
9462774|NCT03699254|Active Comparator|Control|"Control Group (universal prophylaxis + pre-emptive therapy; 6+6): The recommendation of the Spanish Consensus Document will be followed according to the strategy described below:~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +6. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend on each center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of patients will depend oneach center's clinical practice.~Pre-emptive therapy guided by viral load from month +6 to month +12. For a viral load above> 38 copies/mL (> 35 IU/mL) and depending on each center's clinical practice, treatment with valganciclovir may be initiated (900 mg/12h, corrected for renal function)."
9462775|NCT03699254|Experimental|Experimental|"Experimental Group (reduced prophylaxis + immuno-guided prophylaxis; 3+9):~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +3. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend oneach center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of the patients will depend on the each center's clinical practice.~Immuno-guided prophylaxis. This will consist of a monthly determination of cellular immunity by QF-CMV from month +3 to month +12."
9462776|NCT03699241|Placebo Comparator|Group 1|HIV-Uninfected participants
9462777|NCT03699241|Placebo Comparator|Group 2|HIV-Uninfected participants
9462778|NCT03699241|Placebo Comparator|Group 3|HIV-Uninfected participants
10025816|NCT01717885||HIV+ children on nevirapine|HIV+ children who are stabilized on an nevirapine based ART regimen
10025817|NCT01717885||HIV+ children on efavirenz|HIV+ children who are stabilized on an efavirenz based ART regimen
10025818|NCT01717885||HIV+ pregnant women on LPV/r|HIV+ pregnant women who are stabilized on an LPV/r based ART regimen
10025819|NCT01717885||HIV+ pregnant women on NVP|HIV+ pregnant women who are stabilized on an nevirapine based ART regimen
10025820|NCT01717885||HIV+ pregnant women on EFV|HIV+ pregnant women stabilized on an efavirenz based ART regimen
10025821|NCT01717885||HIV negative children|HIV negative children that will serve as a control for HIV positive children on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
10025822|NCT01717885||HIV negative adults|HIV negative adults that will serve as a control for comparing results to HIV negative children and HIV negative pregnant women
10025823|NCT01717885||HIV negative pregnant women|HIV negative pregnant women who will serve as a control for HIV positive pregnant women on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
10025824|NCT01717911|Active Comparator|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
10025825|NCT01717911|Experimental|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
10025826|NCT01717911|Experimental|Insulin|In the insulin therapy group (Insulin glargine), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Daily dose was administrated before breakfast.
10025827|NCT01717924|Active Comparator|peri-operative chemotherapy|Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery
10025828|NCT01717924|Experimental|surgery first with adjuvant chemotherapy|Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy
10025829|NCT01717937||PVOCT|Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.
9462779|NCT03699241|Placebo Comparator|Group 4|HIV-Uninfected participants
9462780|NCT03699241|Placebo Comparator|Group 5|HIV-Uninfected participants
9462781|NCT03699215|Placebo Comparator|placebo|solution for intravenous infusion, with similar organoleptic characteristics than active treatment.
9462782|NCT03699215|Experimental|levosimendan|Concentrate for solution for perfusion. Pack with a 5 ml vial
9462783|NCT03699202|Experimental|100mg AK0529 Arm|Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
10025830|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel®|
10025831|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
10025832|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
10025833|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel®|
10025834|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
9462784|NCT03699202|Experimental|200mg AK0529 Arm|Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.
9462785|NCT03699202|Experimental|300mg AK0529 Arm|Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.
9462786|NCT03699202|Placebo Comparator|Placebo Arm|Patients randomised into this arm will be orally administered with placebo q.d. for five days.
9462787|NCT03699189|Experimental|Immediate ANAIS|Participants that attend the training course immediately.
10025835|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
9462788|NCT03699189|No Intervention|Delayed ANAIS|Participants that attend the training course a year later.
9462789|NCT03699176|Experimental|Vilaprisan|2 treatment periods of 12 weeks without a break
10025836|NCT01717963|Experimental|Naltrexone intramuscular suspension|Extended release naltrexone injections 380mg
9462790|NCT03699176|Placebo Comparator|Placebo|2 treatment periods of 12 weeks without a break
9462791|NCT03699150||Postmenopausal women|Outpatients referred to the Gynecologic Endocrinology, FTGM
9462792|NCT03699137||Cases with confirmed ACS|Cases with confirmed diagnosis of acute coronary syndrome in the MINAP database (national registry of ACS patients). No interventions apply to this group as this is an observational study.
9462793|NCT03699137||EMS personnel|Emergency Medical Service (EMS) personnel will take part in the focus group. No intervention applies to this group in this qualitative component of the study.
10025837|NCT01717963|Active Comparator|Buprenorphine-naloxone|Flexible oral dose 4-24 mg daily
10025838|NCT01718002|Other|Educational video on oral hygiene|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
10025839|NCT01718015||Patients with diabetic polyneuropathy|
10025840|NCT01718015||Patients with diabetes without peripheral nerve disorder|
10025841|NCT01718015||Patients with polyneuropathies not due to diabetes|
10025842|NCT01718015||Patients not suffering from diabetes or nerve disease|Control subjects
10025843|NCT01718015||Patients with unspecified nerve disease|
10025844|NCT01718041|Experimental|VRS-317|Active treatment arm
10025845|NCT01718054|Active Comparator|vascular|In this intervention period children will receive a vascular ready-to-use supplementary food with added L-Arginine & L-Citrulline plus daily chloroquine
10025846|NCT01718054|Active Comparator|regular|In this intervention period children will receive a regular ready-to-use supplementary food plus weekly dose of chloroquine
10025847|NCT01718067|Experimental|Vakum|VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique
10025848|NCT01718067|Active Comparator|Control|conventional manual ELTGOL technique
10025849|NCT01718080||Group A|Healthy lean children before puberty
10025850|NCT01718080||Group B|Otherwise healthy overweight children before puberty
10025851|NCT01718080||Group C|Healthy lean adolescents in mid to late puberty
10025852|NCT01718080||Group D|Otherwise healthy overweight adolescents in mid to late puberty
10025853|NCT01718093|Active Comparator|Insulin plus sitagliptin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily
10025854|NCT01718093|Active Comparator|Insulin plus metformin|The subjects continued their usual insulin regimen throughout the study. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
10025855|NCT01718093|Active Comparator|Insulin plus sitagliptin and metformin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
10025856|NCT01718106|Active Comparator|Single long bioabsorbable polymer DES|Patients with long coronary stenosis treated by a single long bioabsorbable polymer DES
10025857|NCT01718106|Active Comparator|Two bioabsorbable polymer DES in overlapping|patients with long coronary artery stenosis tretaed by 2 bioabsorbable polymer DES with minimal overlapping
10025858|NCT01718119|Experimental|DA-3803|subjects treated with DA-3803(r-hCG)
10025859|NCT01718119|Active Comparator|Ovidrel|subjects treated with Ovidrel(r-hCG)
10025860|NCT01718132||postoperative patients|
10025861|NCT01718171||Group I, Group II, Group III, Group IV|Values and results of the Systemic Inflammatory Response and C-reactive protein to appendicitis
10025862|NCT01718184|Experimental|Sulcoflex|Sulcoflex intraocular lens implantation
9462794|NCT03699085|Experimental|ED-LINC Intervention Condition|Patients in this arm will receive the ED-LINC intervention. Elements of ED-LINC are based on evidence-based treatments and are central components of collaborative care. ED-LINC will be supported by a novel Emergency Department Information Exchange (EDIE) technology platform that allows for the creation of ED care plans and electronic alerts and will assist in care coordination of this complex population.
10025863|NCT01718197||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
10025864|NCT01718197||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to ICS, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past"
10025865|NCT01718197||Healthy Controls|Those without asthma or other chronic lung disease.
10025866|NCT01718210|Experimental|GM-CSF medium|patient's embryos are incubated after fertilization with mediun supplemented with GM-CSF
10025867|NCT01718210|Placebo Comparator|CONTROL|50 women with recurrent implantation failure (at leat three previous IVF attempts failed with at least 8 good embryos transferred in uterus)that the obtained with IVF are incubated with a standard medium for IVF, and utilized as control group.
10025868|NCT01718223|Experimental|Treatment (interstitial photodynamic therapy using temoporfin)|Patients receive temoporfin IV over at least 6 minutes on day 1 and undergo interstitial photodynamic therapy on day 3. Within 4-6 weeks, patients undergo surgical resection.
10025869|NCT01718236|Experimental|Rocuronium + sugammadex|Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
9462795|NCT03699085|No Intervention|Usual Care Condition|Patients in this arm may receive a spectrum of consulting services visits including social work services, psychiatric consultation, inpatient psychiatry consult, rehabilitation psychology consultation, addiction intervention services, pain team consultation services that include MD psychiatric and PhD psychologist providers, spiritual care or other consulting services which shall count as usual care.
9462796|NCT03699059|Other|Health Care Professionals|A purposeful sample of 5 HCP's from the transplant team will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
10025870|NCT01718236|Experimental|Succinylcholine + Neostigmine|Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
10025871|NCT01718249|Other|deep brain stimulation|
10025872|NCT01718275||Non-operative Group|Patients and caregivers who agree to receive non-operative management with antibiotics alone
9462797|NCT03699059|Other|Kidney Transplant Patients|A purposeful sample of 10 kidney transplant patients will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
9462798|NCT03699046|Active Comparator|Subchondroplasty and Knee Arthroscopy|Patients randomized to the Subchondroplasty and Knee Arthroscopy group will receive the subchondroplasty procedure before or after knee arthroscopy that will be completed based on current standard of care guidelines.
9462799|NCT03699046|Sham Comparator|Knee Arthroscopy Alone|Patients randomized to the Knee Arthroscopy Alone group will receive the knee arthroscopy that will be completed based on current standard of care guidelines.
9462800|NCT03699033|Experimental|Radiation|2.5 Gy/Fraction
9462801|NCT03699007|Experimental|Graded Exposure Therapy (GET Living)|GET Living is jointly delivered by a pain psychologist and a physical therapist. The GET Living treatment was based on a published graded in-vivo exposure treatment manual for adults with adaptations to target a pediatric audience.
9462802|NCT03699007|Active Comparator|Typical Pain Management (TPM)|TPM is a treatment intervention that is representative of current standards of care in a multidisciplinary pain clinic setting. It consists of Cognitive Behavioral Therapy (CBT) and Physical Therapy (PT) sessions, delivered separately by a pain psychologist and a physical therapist.
9462803|NCT03698981|Experimental|Mothers Moving towards Empowerment (MME)|The MME intervention arm will complete our 8-session intervention, weekly for 60-70 minutes per session. Homework will be assigned each week and reviewed the next session. Certificates will be issued to participants who complete the intervention. Fidelity assessments for each session will be evaluated by local research personnel.
9462804|NCT03698981|No Intervention|Treatment As Usual (TAU)|Control condition participants will receive Treatment as usual (TAU), including using free ART and antenatal services as they wish. Control condition participants are assessed on all 'Primary outcomes' at the same time points as the MME intervention group.
9462805|NCT03698968|Other|Single prospective intervention|
9462806|NCT03698955|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
10025873|NCT01718275||Surgery Group|Patients and caregivers who decide to undergo appendectomy that permit us to track their standard treatment course
10025874|NCT01718288|Experimental|iloprost + standard treat.(aspirin)|1B - patients unsuitable to surgical or endovascular vascular therapy: treatment with iloprost intravenous infusions for 10 days every 3 months, in addition to conventional treatment
10025875|NCT01718288|Active Comparator|Standard Treatment (aspirin....)|"1A - patients unsuitable to surgical or endovascular vascular therapy: conventional treatment~Conventional Treatments:correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
10025876|NCT01718288|Experimental|Vascular surgery patients + iloprost|2B - patients suitable to vascular surgical or endovascular therapy: treatment with intravenous infusions iloprost for 10 days every 3 months, in addition to conventional treatment
10025877|NCT01718288|Active Comparator|Vasc. Surg.+ standard treat. (aspirin..)|2A - patients suitable to vascular surgical or endovascular therapy + standard treatment (aspirin...)
10025878|NCT01718301|Experimental|boceprevir + ribavirin + peginterferon|boceprevir 800 mg three times a day (v.o.) in combination with peginterferon (alfa-2b or alfa-2a) and ribavirin
10025879|NCT01718314|Experimental|Sublingual Misoprostol & Lidocaine placebo|Misoprostol 200 µg sublingually single dose and Lidocaine spray placebo
10025880|NCT01718314|Experimental|Lidocaine Pump Spray & Misoprostol placebo|Lidocaine Pump spray, 6 sprays to cervix (60 mg totally) and sublingual misoprotol placebo
9462807|NCT03698955|Active Comparator|Mediterranean diet|The diet group will be asked to follow a Mediterranean diet for 16 weeks.
10025881|NCT01718327|Experimental|open label, single arm|single arm: sunitinib until progresion or unacceptable toxicity
10025882|NCT01718340|Experimental|Metformin|The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive
10025883|NCT01718366|Experimental|ferritin level >300ng/ml and < 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level >300ng/ml and < 1000ng/ml, will be included in Group 1.~Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
9462808|NCT03698929|Active Comparator|Dietary Effect of Cholesterol - Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the egg phase participants will consume two egg yolks a day for four weeks. Each week, participants will be given a week's worth of baked goods containing two egg yolks each.
10025884|NCT01718366|Experimental|ferritin level > 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level > 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
10025885|NCT01718379|Experimental|Arm A|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
10025886|NCT01718379|Experimental|Arm B|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
10025887|NCT01718392|Experimental|Training|24 weeks combined exercise programme (supervised)
9462809|NCT03698929|Placebo Comparator|Dietary Effect of Cholesterol - No-Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the no-egg phase participants will consume an egg-free product for four weeks. Each week participants will be given a week's worth of egg-free baked goods.
10025888|NCT01718392|No Intervention|Control|sedentary/habitual lifestyle
10025889|NCT01718405|Experimental|Exercise Group|Each individual subject will give a blood sample for genetic analysis and undertake an exercise session and a rest session as a control. Cognitive function will be tested before and after each session.
10025890|NCT01718418|Experimental|+ ind.CHO + prebiotics|test meal: intrinsic indigestible carbohydrates in combination with a combined probiotic supplement.
10025891|NCT01718418|Experimental|+ ind.CHO - prebiotics|test meal: intrinsic indigestible carbohydrates in combination with placebo probiotic supplement.
10025892|NCT01718418|Experimental|- ind.CHO - prebiotics|reference: no ind. carbohydrates and no probiotic supplement
10025893|NCT01718431|Experimental|indigestible carbohydrates|test meal: indigestible carbohydrates
10025894|NCT01718431|Experimental|reference|reference meal: no indigestible carbohydrates
9462810|NCT03698903|Experimental|Take a STAND 4 Health: Immediate|Receives the coaching calls + mHealth intervention first, then receives only the mHealth intervention after the 4 week assessment.
10025895|NCT01718457|Experimental|Endobarrier device insertion|
10025896|NCT01718470|Active Comparator|Endotracheal tube|At the end of surgery, emerge from anesthesia with the ETT still in place
10025897|NCT01718470|Active Comparator|Laryngeal mask|At the end of surgery,emerge from anesthesia after ETT had been replaced by an LMA.
10025898|NCT01718496|Active Comparator|Morphine|Patient with advance COPD who will randomly receive single dose oral Morphine
9462811|NCT03698903|Active Comparator|Take a STAND 4 Health: Delayed|Will receive no intervention for the first 4 weeks but then after assessment will be provided the opportunity to receive the full coaching calls + mHealth intervention.
10025899|NCT01718496|Placebo Comparator|Placebo|patient with advanced COPD who will receive Placebo
9462812|NCT03698890|No Intervention|Control|Usual care of 3 to 6-monthly clinic visit
9462813|NCT03698890|Experimental|Intervention|Network-based home blood pressure monitor (Fora P20b Blood Pressure Monitor) and telephone consult with care team
9462814|NCT03698864|Experimental|PCS499 900mg twice a day|
9462815|NCT03698851|Experimental|Test Group|Guidor® and Guidor easy-graft® CRYSTAL Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CRYSTAL (Test).
9462816|NCT03698851|Active Comparator|Control Group (C)|Guidor® and Guidor easy-graft® CLASSIC Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CLASSIC (Test).
9479800|NCT03539926|Placebo Comparator|Reactive strips|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
9462817|NCT03698838||McDESPOT Study Group|Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
9462818|NCT03698838||Control Model|Control model derived from a linear mixed-effects model (Spader et al 2013)
10025900|NCT01718548|Active Comparator|CS and Lingzhi|CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
9462819|NCT03698825|Experimental|Dose Escalation of TEW-7197|TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks
9462820|NCT03698812||CTL group|control group
9462821|NCT03698812||EXP group|Colonoscope
9462822|NCT03698799||LPV|Patients receive LPV strategy at the initiation of MV support. The LPV strategy is defined as ventilation with tidal volume of <8 mL/kg of PBW plus applying PEEP of at least 5 cm H2O.
9462823|NCT03698799||Non-LPV|Patients do not receive LPV strategy at the initiation of MV support.
9462824|NCT03698786||European males|"This study will involve a cohort of 15 White European men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
9462825|NCT03698786||South Asian males|"This study will involve a cohort of 15 South Asian (India, Pakistan, Sri Lanka, Nepal, Bangladesh, Maldives and Bhutan), men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
9462826|NCT03698773|Active Comparator|Baseline Group|Access to existing educational materials about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
9802917|NCT04816474|Experimental|Education and Phone Counseling Service|Patients in this group will be trained online for 6 weeks. After the online training is over, a telephone consultation service will be provided once a week for 6 weeks.
9802918|NCT04816474|No Intervention|Control|No application will be made to patients in this group for 12 weeks. Pre-test and post-test will be applied.
9802919|NCT04812626|Experimental|Group A: Intralesional (IL) triamcinolone acetonide (TAC) alone;|Group A: 1 ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline. 5 units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units,covering an area of 0.5X0.5 cm2 of scar. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs( maximum dose=2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
9802920|NCT04812626|Experimental|Group B: Intralesional triamcinolone acetonide and 5-fluorouracil (5-FU) combination|"Group B: 1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU.~Injection Method: Five units (0.125ml) of the mixture will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. (maximum dose 2ml). Follow up Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks), Post treatment follow up: at 12 weeks."
9802921|NCT04810494|Experimental|test drug|2% Lidocaine
9802922|NCT04810494|Placebo Comparator|Placebo|0.9% Normal Saline
9802923|NCT04809298|Other|Free-hand lumbar punction|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the free-hand method.
9802924|NCT04809298|Active Comparator|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
9802925|NCT04804033|Active Comparator|BHV-3500 200mg|Zavegepant 200mg oral soft gel capsule.
9802926|NCT04804033|Placebo Comparator|Placebo 200mg|Matching placebo 200mg oral soft gel capsule.
9802927|NCT04804033|Active Comparator|BHV-3500 100mg|Zavegepant 100mg oral soft gel capsule.
9802928|NCT04804033|Placebo Comparator|Placebo 100mg|Matching placebo 100mg oral soft gel capsule.
9802929|NCT04803747|Active Comparator|Tranexamic acid (TXAl Arm|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
9802930|NCT04803747|Placebo Comparator|Placebo Arm|Placebo 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
9802931|NCT04797156|Experimental|High Dose Intravenous TXA (hTXA group)|Patients assigned to hTXA group will receive 50mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
9802932|NCT04797156|Experimental|Low Dose Intravenous TXA (lTXA group)|Patients assigned to lTXA group will receive 20mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
9462827|NCT03698773|Experimental|Website Group|Access to a tablet computer set to display an educational website (thepainlesspush.com) with information about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
9462828|NCT03698760|Experimental|Mild stage Alzheimer group|Participants with mild stage Alzheimer's disease
9462829|NCT03698760|Experimental|Control Group|Participants without cognitive disorders
9479801|NCT03539913|Active Comparator|Saccharomyces boulardii|Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
9462830|NCT03698747||mTBI Study Group with McDESPOT sequence|Study group (30 subjects) of football players diagnosed with mTBI (scan at diagnosis, 3-month follow-up scan, genetic screening, concussion assessment at both interaction)
9462831|NCT03698747||Control Group|Control group (30 subjects) of age match non-contact sport players (scan, genetic testing, concussion assessment)
9462832|NCT03698734|Active Comparator|Evening primrose oil|
9462833|NCT03698734|Placebo Comparator|placebo|
9462834|NCT03698695|Experimental|THN201|THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days
9462835|NCT03698695|Active Comparator|Donepezil|Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days
9462836|NCT03698695|Placebo Comparator|Placebo|Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days
9462837|NCT03698682|Experimental|Short treatment group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
9462838|NCT03698682|Experimental|Standard treatment group|1 tablet of Levofloxacin 500mg prescribed for 7days
9462839|NCT03698669|Experimental|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
9462840|NCT03698669|Active Comparator|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
9462841|NCT03698630|Experimental|Dexamethasone|Single dose of 0.3 mg/kg dexamethasone (rounded off to the nearest 2 mg, max. 12 mg) prescribed on day 1
9462842|NCT03698630|Active Comparator|Prednisolone|1 mg/kg prednisolone (rounded off to the nearest 5 mg, max. 40 mg) prescribed daily for three days from day 1
9462843|NCT03698617|Experimental|HSK3486|"Dose Escalation Cohort:~0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg."
9462844|NCT03698617|Active Comparator|Propofol|Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg
9462845|NCT03698604|Active Comparator|Total Laparoscopic Hysterectomy|The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
9462846|NCT03698604|Active Comparator|Total Abdominal hysterectomy|The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
9462847|NCT03698578|Experimental|group 1 combat fight|Consisting of professional, high-performance paratletas. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
9462848|NCT03698578|Experimental|group 2 combat fight|Constituted by amateur paratroopers. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
9462849|NCT03698565|Experimental|PPI and ANI measurements|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
9462850|NCT03698526|Active Comparator|Palliative care I|Palliative care
9462851|NCT03698526|Active Comparator|Control II|Patients with mamma carcinoma and (neo-) adjuvant radiotherapy
9462852|NCT03698526|Active Comparator|Control III|Patients before colonoscopy
10025901|NCT01718548|Placebo Comparator|Placebo|Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
10025902|NCT01718561|No Intervention|Control|Usual clinical airway evaluation and usual registration in Danish Anaesthesia Database (without SARI registration)
10025903|NCT01718561|Experimental|SARI|Registration of Modified SARI score and predictors for difficult mask ventilation in Danish Anaesthesia Database
10025904|NCT01718574|Experimental|Self-help book|
10025905|NCT01718574|No Intervention|Usual Care Control|
10025906|NCT01718587|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
10025907|NCT01718587|Active Comparator|antiviral therapy|"Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).~Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
9462853|NCT03698513|Experimental|BMS-986177 + Aspirin + Clopidogrel (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
10025908|NCT01718600||Neuroimaging Correlates|Carotid revascularization can significantly reduce the risk of stroke in patients with severe carotid stenosis; however, it has been associated with cognitive decline in 25% of the older adults who undergo the procedure. Neuroimaging techniques that characterize white matter integrity and regional hypoperfusion have the potential to provide sensitive brain structure indicators that may be associated with memory decline following revascularization procedures. In this proposal, we hope to determine the risk factors and cognitive effect of microembolization following carotid revascularization procedures.
10025909|NCT01718613|Active Comparator|Norepinephrine|
10025910|NCT01718613|Active Comparator|Vasopressin|
10025911|NCT01718626|Active Comparator|S1+Docetaxel|
10025912|NCT01718626|Experimental|S1+Docetaxel followed by S1|
9462854|NCT03698513|Experimental|BMS-986177 (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5)
9462855|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin + Clopidogrel (Part 1)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)
9462856|NCT03698513|Experimental|BMS-986177 (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5)
10025913|NCT01718639|Active Comparator|IQP-LH-101 tablet|4 chewable tablets to be chewed thoroughly before swallowing
10025914|NCT01718639|Active Comparator|IQP-LH-101 liquid|2 liquid sachets to be emptied into the mouth and consumed.
9462857|NCT03698513|Placebo Comparator|BMS-986177 placebo + Clopidogrel (Part 2)|BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
9462858|NCT03698513|Experimental|BMS-986177 + Clopidogrel (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
9462859|NCT03698513|Experimental|BMS-986177 (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5)
9462860|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin (Part 3)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
9462861|NCT03698513|Experimental|BMS-986177 + Aspirin (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
10025915|NCT01718639|Placebo Comparator|Placebo|1 tablet to be swallowed with water.
10025916|NCT01718652|Experimental|Canagliflozin + cyclosporine|Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.
10025917|NCT01718678|Active Comparator|Melatonin|Melatonin, Tablet, 3 mg, once, one month
10025918|NCT01718678|Placebo Comparator|Placebo|Placebo, tablet
10025919|NCT01718704|Experimental|Viberect device|Men in this group will begin using the Viberect device 3 days after Foley catheter removal after surgery on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting.
9462862|NCT03698500|Other|Patients with intestinal colitis and control patients|Device: qPCR diagnostic of specific microRNAs in peripheral blood (10 ml)
10025920|NCT01718704|No Intervention|No Viberect|Men in this group will not be provided with the Viberect device
10025921|NCT01718717|Active Comparator|6 days TEA|Postoperative analgesia for the first six postoperative days with TEA and daily monitoring for arrhythmia
10025922|NCT01718717|Active Comparator|3 days TEA and 3 days intravenous morphine|Postoperative analgesia for the first three postoperative days with TEA followed for the next three days with intravenous morphine, and daily monitoring for arrhythmia
9462863|NCT03698474|Active Comparator|SPMC-S|Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy
9462864|NCT03698474|Active Comparator|SPMC-D|Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
9462865|NCT03698474|Active Comparator|PEGA-S|Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy
9462866|NCT03698474|Active Comparator|PEGA-D|Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
10025923|NCT01718730||Mild depression|Subjects with mild, but clinically significant depression
10025924|NCT01718730||Moderate to Severe MDD|Subjects with moderate to severe major depressive disorder who have not yet initiated treatment with an SSRI
10025925|NCT01718730||MDD with response to SSRI|Subjects with moderate to severe major depressive disorder that has responded to an SSRI
10025926|NCT01718730||MDD without response to SSRI|Subjects with moderate to severe major depressive disorder which has not responded to treatment with an SSRI
10025927|NCT01718756|Placebo Comparator|Placebo|The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
10025928|NCT01718756|Active Comparator|Scheduled|They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
10025929|NCT01718756|Active Comparator|Continuous infusion|They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
10025930|NCT01718769|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
10025931|NCT01718769|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
10025932|NCT01718782|Active Comparator|laryngeal mask Ambu AuraOnce|laryngeal mask Ambu AuraOnce
10025933|NCT01718782|Active Comparator|laryngeal mask LMA Supreme|laryngeal mask LMA Supreme
10025934|NCT01718795|Active Comparator|Bag-valve mask ventilation|"Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?~Intervention is Bag-valve mask ventilation during CPR"
9462867|NCT03698474|Active Comparator|SULF-S|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy
9462868|NCT03698474|Active Comparator|SULF-D|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy
9462869|NCT03698461|Experimental|Atezolizumab, Bevacizumab, FOLFOX|Atezolizumab 1200mg IV Once, Atezolizumab (840mg IV D1 of C1-12) + Bevacizumab (5mg/kg IV D1 of C1-12) + FOLFOX(Oxaliplatin 85mg/m2 IV D1 of C1-12, Levoleucovorin 200mg/m2 IV D1 of C1-12, 5-FU - bolus 400mg/m2 IV D1 of C1-12, - infusional 2400mg/m2 IV continuous(46 hours) D1-3 of C1-12)
10025935|NCT01718795|Active Comparator|Laryngeal Tube|"Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?~Intervention is Ventilation through laryngeal tube during CPR"
10025936|NCT01718808|Active Comparator|Arm A: Cetuximab|Cetuximab 500 mg/m2 every 2 weeks
9462870|NCT03698448|Placebo Comparator|Placebo DPI|Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID
9462871|NCT03698448|Active Comparator|Low dose OligoG DPI|17.5 mg OligoG dry powder for inhalation. 10 capsules, BID
9462872|NCT03698448|Active Comparator|medium dose OligoG DPI|27.5 mg OligoG dry powder for inhalation. 10 capsules, BID
10025937|NCT01718808|Active Comparator|Arm B: Cetuximab and Capecitabine|"Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks~* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
10025938|NCT01718821||Advanced upper GI cancer patients|Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
9462873|NCT03698448|Active Comparator|High dose OligoG DPI|37.5 mg OligoG dry powder for inhalation. 10 capsules, BID
9462874|NCT03698435||Prophylaxis|Patients who receive (val)ganciclovir for prophylaxis of cytomegalovirus
10025939|NCT01718834|Active Comparator|prophylactic vaccine|6 monthly doses each of 648 ug of prophylactic vaccine subcutaneously injected to healthy volunteers
10025940|NCT01718834|Active Comparator|therapeutic vaccine|6 monthly doses each of 648 ug subcutaneously injected to chronic HCV patients
9462875|NCT03698435||Treatment|Patients who receive (val)ganciclovir for treatment of cytomegalovirus
9462876|NCT03698422||Healthy controls|"Estimated glomerular filtration rate (eGFR) > 60 mL/min for > 3 months and no known current or chronic medical or surgical conditions.~Blood and urine samples are collected for every 3rd hour during 24 hours"
9462877|NCT03698422||Predialysis CKD subjects|"Estimated glomerular filtration rate (eGFR) between 30 and 15 mL/min for > 3 months (i.e. CKD stage 4).~Blood and urine samples are collected for every 3rd hour during 24 hours"
9462878|NCT03698422||ESKD subjects|"Maintenance haemodialysis treatment for > 3 months for ESKD and with anuria (urine excretion < 100 mL/day).~Blood and urine samples are collected for every 3rd hour during 24 hours"
9462879|NCT03698409|No Intervention|Botox in preservative-free saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative-free saline, as recommended by the manufacturer. 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites)
9462880|NCT03698409|Active Comparator|Botox in preserved saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative saline (i.e. bacteriostatic saline). 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites).
9462881|NCT03698396|Experimental|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cell will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
9462882|NCT03698383|Experimental|Herzuma plus Gedatolisib|
9462883|NCT03698370|Experimental|Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2|Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
9462884|NCT03698370|Experimental|Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)|Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
9462885|NCT03698357|Experimental|Interactive video balance-based exercise|Fifteen participants in group A will undergo 30 minutes a day and 3 days a week interactive video balance-based exercise intervention for four weeks.
10025941|NCT01718847|Experimental|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
10025942|NCT01718860||Postoperative Residual Paralysis|Patients with train-of-four ratio less than 0.9 measured in the postanesthesia care unit
10025943|NCT01718860||No Postoperative Residual Paralysis|Patients with train-of-four ratio greater than 0.9 measured in the postanesthesia care unit
10025944|NCT01718873|Experimental|bevacizumab before chemotherapy|Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
10025945|NCT01718873|Active Comparator|bevacizumab with chemotherapy|Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
10025946|NCT01718886||Obalon Gastric Balloon|Patients received 1-3 Obalon Gastric Balloons over a period of 12 weeks
10025947|NCT01718899|Experimental|PVX-410, .4 mg dose|Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
10025948|NCT01718899|Experimental|PVX-410, .8 mg dose|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
10025949|NCT01718899|Experimental|PVX-410 plus lenalidomide|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
10025950|NCT01718912|Other|Metronidazole-nystatin oral rinse, regular oral hygiene|Week 1: daily brushing with suction brush. Week two: daily brushing with a mixture of metronidazole-nystatin suspension.
9462886|NCT03698357|Active Comparator|Conventional physiotherapy|Another 15 participants allocated to the group B will receive 30 minutes a day and 3 days a week conventional rehabilitation for four weeks.
9462887|NCT03698344|Experimental|Biodiesel exhaust exposure|A single arm study in which first a filtered air baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute biodiesel exhaust will start.
10025951|NCT01718925||Inflammatory Bowel Disease|Ulcerative Colitis and Crohns's disease patients will be recruited from sqeduled outpatient follow-up
10025952|NCT01718925||Irritable Bowel Syndrome|Irritable Bowel patients will be recruited from sqeduled outpatient follow-up
10025953|NCT01718925||Rheumatoid Arthritis|Rheumatoid Arthritis patients will be recruited from sqeduled outpatient follow-up
10025954|NCT01718925||Diabetes Mellitus|Diabetes mellitus patients will be recruited from sqeduled outpatient follow-up
10025955|NCT01718951|Active Comparator|golimumab|golimumab 50mg subcutaneous every 4 weeks
10025956|NCT01718951|Active Comparator|pamidronate|Pamidronate (60mg) intravenously every 4 weeks
10025957|NCT01718964|Other|A|Cortisol 20 mg /Placebo Mannitol
9462888|NCT03698318|Experimental|Subject sequence 1|Subject allocation sequence 1. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462889|NCT03698318|Experimental|Subject sequence 2|Subject allocation sequence 2. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
10025958|NCT01718964|Other|B|Placebo Mannitol/Cortisol 20mg
10025959|NCT01718977|Experimental|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
9462890|NCT03698318|Experimental|Subject sequence 3|Subject allocation sequence 3. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462891|NCT03698318|Experimental|Subject sequence 4|Subject allocation sequence 4. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462892|NCT03698318|Experimental|Subject sequence 5|Subject allocation sequence 5. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462893|NCT03698318|Experimental|Subject sequence 6|Subject allocation sequence 6. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462894|NCT03698318|Experimental|Subject sequence 7|Subject allocation sequence 7. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9479802|NCT03539913|Active Comparator|Bacillus clausii|Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
9479803|NCT03539887|Experimental|Intranasal ketamine|Intranasal ketamine
10025960|NCT01718977|Active Comparator|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
10025961|NCT01718990||Patients with Idiopathic Pulmonary Fibrosis (IPF)|Sixty patients with IPF will be included in this prospective cohort;15 IPF patients per year for years 1-4.
10025962|NCT01718990||Healthy Volunteers|Sixty normal controls will be recruited from volunteers.
10025963|NCT01719016||Cardiac PET, Coronary catheterization|"Cardiac PET scan:~Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.~Injection of Lexiscan.~Coronary catheterization:~Pressure and flow readings using Combowire~Injection of Adenosine."
10025964|NCT01719029|Experimental|Conventional Diet|Low carbohydrate/higher fat diet: 40% carbohydrate, 45% fat, 15% protein
10025965|NCT01719029|Experimental|Complex Carbohydrate Diet|High complex carbohydrate/lower fat diet: 60% complex carbohydrate, 25% fat, 15% protein
10025966|NCT01719042|Active Comparator|Zofran (8mg)|Participant will take Zofran (8mg) once per day before taking their antibiotic regimen
10025967|NCT01719042|Active Comparator|Ensure|Subject will drink a can of Ensure before taking their antibiotic regimen
10025968|NCT01719068||Workers exposed to asbestos|
9802933|NCT04797156|Placebo Comparator|Combined Intravenous and Topical TXA group (cTXA group)|Patients assigned to cTXA group will received 20mg/kg V TXA loading dose with a 5mg/kg/hr maintenance dose, and 2g topical TXA poured over 5 minutes at the would prior to closure
10025969|NCT01719081|Experimental|Ultrasound Guided SIJ Injection|Needle placement will be performed under US guidance. Fluoroscopy will be used to confirm needle placement prior to medication injection.
10025970|NCT01719081|Active Comparator|Xray Guided SIJ Injection|Needle placement will be performed under fluoroscopy.
10025971|NCT01719094||Childhood Cancer Surviviors|
10025972|NCT01719094||Adolescent/young adults with no cancer history|
10025973|NCT01719094||Newly diagnosed cancer patients|
10025974|NCT01719107|Active Comparator|L. reuteri DSM 17938 chewable tablets|The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
10025975|NCT01719107|Placebo Comparator|Placebo chewable tablets|The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
10025976|NCT01719120|Experimental|Self-help CBT with tel. consultation|Self-help CBT with tel. consultation (SHTC)group will receive telephone consultation provided by the investigator in addition to self-help cognitive-behavioral therapy once per week for 6 consecutive weeks.During the consultation, the investigator will answer questions about the treatment content, monitor whether the subjects read the assigned materials and comply with the tasks and procedures, and provide encouragement and support.
10025977|NCT01719120|Experimental|Self-help CBT|The subjects will receive self-help cognitive-behavioral therapy (SH)once per week for 6 consecutive weeks.
10025978|NCT01719120|No Intervention|Waiting-list control (WL)|Subjects in this group will not receive any kind of treatment during the waiting period. They will receive the treatment identical to the self-help group within 3 months from the baseline.
10036729|NCT01818375|Experimental|Goal Directed Fluid Therapy (GDFT)|"During surgery, patients in the Goal Directed Fluid Therapy (GDFT) will receive:~maintenance infusion of intravenous infusion of ringer lactate at a rate of 1.5 ml/Kg/hr to compensate insensible blood loss and fluid shift during surgery as recommended by perioperative fluid management guidelines for patients undergoing surgery with an enhanced recovery program and receiving a GDFT approach;~intraoperative intravenous boluses of colloids (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride-Voluven) guided by an algorithm based on Esophageal Doppler (ED) estimation of the stroke volume (SV) provided by the manufacture, and also used in other clinical trials."
10036730|NCT01818375|Active Comparator|Standard Fluid Therapy|During surgery, patients will receive a maintenance infusion of intravenous infusion of ringer lactate as recommended by international guidelines and anesthesia text-books (Standard Fluid Therapy). In the Standard Fluid Therapy arm, the Esophageal Doppler (ED) monitor will be turned away from the anesthesia care provider, and the screen will be covered with an opaque card. The ED variables will be collected by an independent research personnel. Hemodynamic variables triggering extra fluid administration (Ringer Lactate or Voluven) will be decided based on the clinical judgment of the anesthetist in charge and will include: urinary output less than 0.5/ml/kg/hr, an increase in heart rate more than 20% above baseline or more than 110 beats/min, a decrease in mean systolic blood pressure less than 20% below baseline or less than 90 mmHg and intraoperative blood loss. Boluses of 200 ml of intravenous fluid will be administered until the above targets will be restored
9462895|NCT03698318|Experimental|Subject sequence 8|Subject allocation sequence 8. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462896|NCT03698318|Experimental|Subject sequence 9|Subject allocation sequence 9. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462897|NCT03698318|Experimental|Subject sequence 10|Subject allocation sequence 10. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
9462898|NCT03698305|Experimental|ASP5354 Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, 4 subjects will be randomized to receive escalated doses of ASP5354. Each subject will receive a single intravenous bolus injection under fasting conditions.
9462899|NCT03698305|Placebo Comparator|Placebo Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, two subjects will be randomized to receive placebo.
9462900|NCT03698292|Active Comparator|First group|Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days
9462901|NCT03698292|Active Comparator|Second Group|Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days
9802934|NCT04795856|Active Comparator|chronic compensated moderate-severe primary mitral regurgitation (PMR)|
9802935|NCT04795856|Active Comparator|Healthy Volunteers|
9802936|NCT04793516|Experimental|VR-based spatial retraining|Game-like therapy activities will be taken place in a virtual environment, provided through an immersive head-mounted display.
9462902|NCT03698266|Other|All Enrolled Patients|Receive needle knife fistulotomy as a starting technique to gain access to the biliary system
9479804|NCT03539887|Experimental|Intranasal ketamine in alcohol abuse|Intranasal ketamine
9479805|NCT03539887|Placebo Comparator|Placebo|non-active placebo
9479806|NCT03539887|Placebo Comparator|Placebo in alcohol abuse|non-active placebo
9479807|NCT03539874||Confirmed paternity|Sperm sample from men with confirmed paternity
9479808|NCT03539874||Intrauterine insemination|Sperm sample from men in intrauterine insemination process
9479809|NCT03539874||In vitro fertilization|Sperm sample from men in in vitro fertilization process
10025979|NCT01719133|Other|All subjects|placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5
10025980|NCT01719146||UofL Subjects|Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY
10025981|NCT01719146||Duke Subjects|Subjects undergoing Specimen Collection at Duke University, Durham, NC
10025982|NCT01719146||WNERTA Subjects|Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA
10025983|NCT01719159|Experimental|Rituximab|Rituximab, 25 mg, is administrated intrathecal three times one week apart
10025984|NCT01719185|Experimental|Phentermine and B12|Those in the experimental group will take 37.5 mg of phentermine daily as well as receive 1000 mg intramuscular injections of B12 weekly.
9462903|NCT03698253|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followedby Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted doseage of 120 mg daily for 3 weeks in a 4-week cycle."
9462904|NCT03698240|Experimental|Mindfulness-based program|Children and parents receive the program
9462905|NCT03698240|No Intervention|Waiting-list|Children and parents receive no-interventions.
9462906|NCT03698227|Experimental|Study treatment|"Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.~Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles~Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles~Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle"
9462907|NCT03698214||isolated traumatic brain injury|Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index < 1 or reversed shock index ≥ 1.
9462908|NCT03698188|Experimental|Injectable platelet-rich fibrin|A platelet concentrate will be prepared from the patient's own blood in plain plastic tubes, without the use of anticoagulants, and applied immediately within the root canal before coagulation.
9462909|NCT03698188|Active Comparator|Platelet-rich plasma|A platelet concentrate will be prepared from the patient's own blood in tubes containing anticoagulants to maintain the fluid consistency and applied within the root canal.
9462910|NCT03698175|Experimental|Three good things exercise|
9462911|NCT03698175|Placebo Comparator|Unspecific childhood memory recall exercise|
9462912|NCT03698149|Experimental|Electrocorticography-based brain computer interface|
9462913|NCT03698136|Experimental|Stimulation of denervated muscle|direct muscle stimulation 5 times a week for 33 minutes 3 minutes warm up 30 minutes treatment
9462914|NCT03698110|Experimental|Intervention Group|Participated in one introductory session, in the four sessions of PUEDES program during four weeks and in a closing session.
9462915|NCT03698110|No Intervention|Control Group|Participated in one introductory session and in a closing session.
9462916|NCT03698058|Experimental|A2 Growing Up Milk|
9462917|NCT03698058|No Intervention|Traditional non-A2 milk|
9462918|NCT03698058|Active Comparator|Other Growing Up Milk|
9462919|NCT03698045|Experimental|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
10025985|NCT01719185|Active Comparator|Phentermine|Those in the control group will take phentermine 37.5 mg daily as well as receive 1000 mg intramuscular injections of saline weekly.
10025986|NCT01719237|Active Comparator|Ropivacine and Cholroprocaine mixture|20 ml's of 1% ropivacaine + 10 ml's of 3% 2-chloroprocaine + 0.1 ml of 1 mg/ml epinephrine
10025987|NCT01719237|Sham Comparator|Ropivacine only|30 ml syringe with either 20 ml's of 1% ropivacaine + 10 ml's of normal saline + 0.1 ml of 1mg/ml epinephrine
10025988|NCT01719250|Experimental|Treatment (buparlisib)|Patients receive buparlisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10025989|NCT01719263|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
10025990|NCT01719263|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
10025991|NCT01719276|Active Comparator|Graded Activity|Exercise treadmill, Strengthening of the lower limbs and trunk
10025992|NCT01719276|Active Comparator|Supervised exercises|Stretching, Strengthening, Motor Control
10025993|NCT01719289|Experimental|PROGRAVIDA|All women in this arm receive a stepped-care program for depression based on psycho-education and problem solving techniques.
9462920|NCT03698032|Active Comparator|Water Arm|Participants will consume water only as the intervention
9462921|NCT03698032|Active Comparator|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
9462922|NCT03698032|Active Comparator|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
9462923|NCT03697954||overactive bladder patients|Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation
9462924|NCT03697941||Surgical cut-down and arterial puncture under direct vision|
9462925|NCT03697941||Percutaneous arteriotomy closed with closure device|
9462926|NCT03697928||CrAT subjects|"13 healthy adult men, with a wide range of maximal aerobic capacity will be included.~Subjects will be classified as trained, physical active and untrained according to their VO2max.~Subject will perform one-legged knee extension and flexion exercise inside the MRS scanner and cycling outside the scanner"
9462927|NCT03697915|Experimental|Experimental group|Experimental group, in which a physical therapy programme supplemented by the James lift system was applied
9462928|NCT03697915|Placebo Comparator|Control|Control group, in which a conventional physical therapy programme was applied.
9462929|NCT03697889|Experimental|Treatment Sequence AB|Participants will receive Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 1 followed by Treatment B (reference product Nalgesin, 1 x 275 mg) dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
9462930|NCT03697889|Experimental|Treatment Sequence BA|Participants will receive Treatment B (reference product Nalgesin, 1 x 275 mg) at dosing period 1 followed by Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
10025994|NCT01719289|No Intervention|Treatment as usual|Primary health care professionals in charge of prenatal care are notified by the research team about all women with depression receiving pre-natal care and included in the trial. Primary health care professionals decide how to treat these women without any interference from the research team.
10025995|NCT01719302|Experimental|cohort 1|
10025996|NCT01719315||MDD with Hypersomnia|Participants with Major Depressive Disorder and co-morbid hypersomnia
9462931|NCT03697863||Noninvasive Adjusted Ventilatory Assist|
9462932|NCT03697863||Noninvasive Pressure Support|
9462933|NCT03697850|Experimental|atezolizumab|Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.
10025997|NCT01719315||MDD without hypersomnia|Participants with Major Depressive Disorder but without co-morbid hypersomnia
10025998|NCT01719315||BPAD with hypersomnia|Participants with Bipolar Affective Disorder and co-morbid hypersomnia
10025999|NCT01719315||BPAD without hypersomnia|Participants with Bipolar Affective Disorder without co-morbid hypersomnia
10026000|NCT01719315||Primary Hypersomnia|Patients with primary hypersomnia (idiopathic hypersomnia)
10026001|NCT01719315||Primary Insomnia|Patients with primary insomnia
10026002|NCT01719315||Narcolepsy|Subjects with narcolepsy
10026003|NCT01719315||Healthy Controls|healthy participants
10026004|NCT01719328|Experimental|Vinyasa yoga|Group administered 60 minute vinyasa yoga classes delivered twice weekly for 8 weeks
10026005|NCT01719354|Experimental|Community Health center|Aftercare in a community Health center
10026006|NCT01719354|Active Comparator|Control|AFtercare as usual in hospital/Mental health centers of District Psychiatric Service (DPS.
10026007|NCT01719406|Experimental|Intervention, behavioral lifestyle education|Pregnant women will participate in 20 educational sessions designed to promote daily exercise, vegetable and fruit intake, maintain a diet that is relatively lower in fat and rich in whole grains.
10026008|NCT01719406|No Intervention|Control|Standard medical care
9479810|NCT03539861|Other|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:~Treatment 1 will be standard hemodialysis (no device).~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
9479811|NCT03539835|Experimental|Resistance training|
9479812|NCT03539835|Active Comparator|Cognitively-based compassion training|
9479813|NCT03539809|Experimental|BCAA Ratio|Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.
9479814|NCT03539783||PARDS|Children <18 years of age with PARDS and expected duration of hospitalization seven days or greater.
10026009|NCT01719419|Experimental|Placebo|Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.
10026010|NCT01719419|Experimental|Orlistat|Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.
10026011|NCT01719432||Obese patients|
9479815|NCT03539783||Control|Children <18 years of age without PARDS or other lung disease and expected duration of hospitalization 7 days or greater.
9479816|NCT03539770||AIS|Adolescent idiopathic scoliosis subjects undergoing posterior spinal fusion.
9479817|NCT03539770||Control|Children without scoliosis
9479818|NCT03539757||Fontan patients|Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.
9479819|NCT03539731|Active Comparator|Group I ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
9479820|NCT03539731|Experimental|Group II ([18F]DASA-23, PET)|Intracranial tumor participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
9479821|NCT03539731|Experimental|Group III ([18F]DASA-23, PET)|Patients with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan. These patients will undergo one [18F]DASA 23 PET/MRI scan before the initiation of therapy, and a second/final [18F]DASA 23 PET/MRI scan within 2-6 weeks after initiation of therapy for their GBM.
10026012|NCT01719432||Non-obese patients|
10026013|NCT01719445||RFPM/Paper and Pen Method|
10026014|NCT01719471||Smokers|Nicotine dependent individuals otherwise medically healthy
10026015|NCT01719471||Healthy|Medically healthy individuals who do not smoke
10026016|NCT01719484||Healthy|Subjects deemed to be medically healthy
10026017|NCT01719484||Obese|Subjects deemed to be medically obese
10026018|NCT01719497||Alcohol|Subjects diagnosed with alcohol dependence
10026019|NCT01719497||Obese|Subjects diagnosed with obesity
10026020|NCT01719497||High Stress|Subjects diagnosed with high stress
10026021|NCT01719497||Healthy|Subjects deemed medically healthy
10036731|NCT01818388||IVTM system, therapeutic hypothermia|Induced therapeutic hypothermia post cardiac arrest
9462934|NCT03697837|Experimental|Parent Management Training|Parents will receive a web-based parenting intervention for tantrums and disruptive behavior in young children
9462935|NCT03697824|Experimental|GSK3377794+pembrolizumab|After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.
9462936|NCT03697811|Experimental|DE-117 Ophthalmic Solution 0.002%|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
9462937|NCT03697798|Active Comparator|Children aged between 7-10 years of age|Healthy children from 7 up to 10 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country. They will receive Boostrix®-IPV combination vaccine.
9462938|NCT03697798|Active Comparator|Children aged between 11-15 years of age|Healthy children from 11 up to 15 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country aiming for comparable numbers of participants with aP vs wP vaccination background. They will receive Boostrix®-IPV combination vaccine.
9462939|NCT03697798|Active Comparator|Adults aged between 20-34 years of age|Healthy young adults from 20 up to 34 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
9462940|NCT03697798|Active Comparator|Adults aged between 60-70 years of age|Older adults from 60 up to 70 years of age determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
9462941|NCT03697785|Experimental|Beacon Caresystem with weaning advice|Beacon care system set up to give weaning advice and options to accept or reject advice.
9462942|NCT03697785|Other|Beacon Caresystem for monitoring only|Beacon care system attached but only for data collection purposes. No advice will be given.
10026022|NCT01719510|Other|Positive Group B Streptococcus vaginal sample|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For all women included will be achieved in the delivery room:~a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.~For mothers, the collection of milk when breastfeeding."
10026023|NCT01719523|Experimental|EPI-743|EPI-743- Participants will receive 200mg three times a day of EPI-743 for 2 weeks and then receive 300mg of EPI-743 for an additional 2 weeks.
10026024|NCT01719536|Experimental|Icotinib|Icotinib 125mg is administered orally three times per day.
10026025|NCT01719536|Active Comparator|Chemotherapy|Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.
10026026|NCT01719549|Experimental|Dovitinib|
10026027|NCT01719575|Other|Motilitone|take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week
10026028|NCT01719575|Other|Placebo|take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week
10026029|NCT01719588||Prolonged release tapentadol|Patients will be taking prolonged release tapentadol hydrochloride as per the product insert approved in Philippines.
10026030|NCT01719601||Immediate release tapentadol|Patients will be taking immediate release tapentadol hydrochloride as per the product insert approved in Philippines.
10026031|NCT01719614|Experimental|Rilpivirine+Metformin|All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15).
10026032|NCT01719627|Experimental|MVC 300 mg|MVC 300 mg in unique dose
10026033|NCT01719627|Active Comparator|TVD 300/200 QD|TVD 300/200 QD during 7 days.
10026034|NCT01719627|Experimental|Maraviroc 600mg|MVC 600mg in unique dose
10026035|NCT01719640|Experimental|BMMSC+BMMNC|infusion of BMMSC+BMMNC and insulin injection
10026036|NCT01719640|Active Comparator|BMMNC|infusion of BMMNC and insulin injection
10026037|NCT01719640|Active Comparator|Insulin|insulin injection
10026038|NCT01719679|Experimental|School Located Vaccine (SLV) Program|A vaccine program carried out by a community vaccinator will be conducted in a limited number of participating schools. The program will be open to the students enrolled at the participating schools
10026039|NCT01719679|No Intervention|no School Located Vaccine (SLV) Program|Schools that are part of the non-intervention arm of the study will not have a school-located vaccine program.
10026040|NCT01719692|Experimental|Rituximab A group|375mg/m2 for once
10026041|NCT01719692|Active Comparator|Rituximab B group|100mg/week for four weeks
10026042|NCT01719705|Placebo Comparator|Placebo|receive two identical placebo capsules
9462943|NCT03697772||multmorbid patients|patients with 2 chronic diseases (medical conditions requiring management for more than 6 months)
9462944|NCT03697759|Experimental|Usual care + selfBACK|Participants will use the selfBACK system and app
9462945|NCT03697746|Active Comparator|Paracetamol|1000 mg Paracetamol vial intravenously
9462946|NCT03697746|Active Comparator|Dexketoprofen Trometamol|50 mg Dexketoprofen Trometamol vial intravenously
9462947|NCT03697746|Active Comparator|Ibuprofen|400 mg Ibuprofen vial intravenously
10026043|NCT01719705|Active Comparator|Pregabalin 150 mg group|one capsule of pregabalin 150 mg
10026044|NCT01719705|Active Comparator|Pregabalin 300 mg group|two capsules of pregabalin 150 mg
10026045|NCT01719718|Active Comparator|Closure|
10026046|NCT01719718|Sham Comparator|Non-Closure|
10026047|NCT01719731|Placebo Comparator|Non-Education|This group will not receive the psychosocial education.
9462948|NCT03697733|Experimental|Oral Etoricoxib group|Subjects will receive oral Etoricoxib120 mg 30 minutes before fractional curettage then added intravenous Propofol 2 mg/kg when start the procedure
9462949|NCT03697733|Placebo Comparator|Intravenous Fentanyl group|Subjects will receive oral placebo [folic acid] 1 tab 30 minutes before the procedure then added intravenous Propofol 2 mg/kg and Intravenous Fentanyl 1 microgram/kg when start the procedure
10026048|NCT01719731|Active Comparator|Education|This group will receive the psychosocial education
9462950|NCT03697707|Experimental|Cohort 1: Low dose|patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
9462951|NCT03697707|Experimental|Cohort 2: High dose|patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
9462952|NCT03697694|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
9462953|NCT03697694|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
9462954|NCT03697681|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
9462955|NCT03697681|Placebo Comparator|Placebo|placebo
9462956|NCT03697668|Experimental|imatinib-Dihydroartemisinin-piperaquine|triple combination
9462957|NCT03697668|Active Comparator|Dihydroartemisinin-piperaquine|standard of care
9462958|NCT03697655|Experimental|PREDATOR-BR Cohort A|n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
9462959|NCT03697655|No Intervention|PREDATOR-BR Cohort B|n=46, Control Group, Observation (no treatment)
9462960|NCT03697655|Experimental|PREDATOR-MRD Cohort A|n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
9462961|NCT03697655|No Intervention|PREDATOR-MRD Cohort B|n=59, Control Group, Observation (no treatment)
9462962|NCT03697642|Experimental|NG tube placement with nasopharyngeal tube|
9462963|NCT03697642|Active Comparator|NG tube placement without nasopharyngeal tube|
9462964|NCT03697616|Experimental|Ridge augmentation with sticky bone and GBR|Ridge augmentation using Autologous concentrated Growth factors (CGF) enriched bone graft matrix (sticky bone) and guided bone regeneration using native collagen membrane in horizontally deficient maxilla
9462965|NCT03697603|Experimental|Brexpiprazole 1mg|Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
9462966|NCT03697603|Experimental|Brexpiprazole 2mg|Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
10026049|NCT01719770|Active Comparator|Rocuronium|Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
10026050|NCT01719770|Placebo Comparator|Placebo|Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
10026051|NCT01719796|Experimental|Bilateral TAP catheter|Ultrasonography guided bilateral TAP catheter insertion.
10026052|NCT01719796|No Intervention|No TAP catheter|
10026053|NCT01719822|No Intervention|Usual Care|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week and a written home exercise plan/diary.
10026054|NCT01719822|Experimental|Intervention|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
10026055|NCT01719835|Experimental|Chemotherapy GEM-P|Gemcitabine, Methylprednisolone, Cisplatin
10026056|NCT01719835|Active Comparator|Chemotherapy CHOP|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
9462967|NCT03697603|Placebo Comparator|Placebo|Tablets, Oral, once daily, 14 weeks
9462968|NCT03697590|Experimental|PDT with no curettage|
10026057|NCT01719848||Preoperative airway examination|patients undergoing general anesthesia for any surgery
10026058|NCT01719874|Experimental|TCN-032|single-dose, administered intravenously
10026059|NCT01719874|Placebo Comparator|Placebo (saline)|single-dose, administered intravenously
10026060|NCT01719887|Active Comparator|Conservative treatment|Conservative treatment with functional brace and physiotherapy.
10026061|NCT01719887|Experimental|Operative treatment|Operative treatment with open reduction and internal fixation with 4,5mm locking compression plate. Physiotherapy at 3 and 9 wks.
10026062|NCT01719913|Active Comparator|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
9462969|NCT03697590|Active Comparator|Standard PDT|
9462970|NCT03697564|Experimental|gemcitabine +nivolumab + cabiralizumab|
9462971|NCT03697538|Experimental|Adductor Canal Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
9462972|NCT03697538|Active Comparator|Femoral Nerve Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
9479822|NCT03539731|Active Comparator|Group IV ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET/MRI brain scan for 60 mins
10026063|NCT01719913|Placebo Comparator|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
10026064|NCT01719926|Experimental|Capecitabine/Oxaliplatin|Patients receiving Capecitabine/Oxaliplatin chemotherapy
9462973|NCT03697525|Experimental|Vibration Group (VG)|VG participants undergo rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
9462974|NCT03697525|Sham Comparator|Control Group (CG)|CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients were only subject to the faint buzzing sound of the vibrator. Sham rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
9462975|NCT03697499|Experimental|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
9462976|NCT03697499|Sham Comparator|fish oil and shame exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
9462977|NCT03697499|Placebo Comparator|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
9462978|NCT03697499|Other|soy oil and shame exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
9462979|NCT03697486|Experimental|High Protein|(40,6% protein)
9462980|NCT03697486|Experimental|Moderate Protein|(23.5% protein)
9462981|NCT03697486|Experimental|Low Protein|(12.4% protein)
9479823|NCT03539718|Experimental|cases|Cases, taurolidine heparin 500 will be used at end of session
9479824|NCT03539718|Active Comparator|control|Controls, Heparin Sodium 5000 will be given at end of session
10026065|NCT01719926|Experimental|Cisplatin + Xeloda(Capecitabine) or Gemcitabine|Patients receiving Cisplatin regimen
10026066|NCT01719952|Experimental|Carbetocin|Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal
10026067|NCT01719952|Active Comparator|Oxytocin|Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
10026068|NCT01719965||Health Workers|"Worked in SMRU for at least 6 months~Clinic assistants, medics or home visitors"
10026069|NCT01719965||Researchers|"Worked in SMRU for at least 6 months~Physician or scientist"
10026070|NCT01719965||CAB members|- Member of the CAB for at least 3 months
10026071|NCT01719965||Community members|- Lived in the border area (area served by SMRU or Mae Sot) for at least 6 months
10026072|NCT01719965||Research subjects|- Participants who are currently enrolled in an SMRU study
10026073|NCT01719978|Active Comparator|Hyaluronidase|Lower Third Molar Extraction -- 3.6mL 2% Mepivacaine with 1:100,000 epinephrine + Hyaluronidase
10026074|NCT01719978|Placebo Comparator|Placebo|Lower Third Molar Extraction -- Anesthetic: 3.6 mL of the LA 2% HCl mepivacaine with 1:100,000 epinephrine + Placebo (0.9% saline)
10026075|NCT01719991|Experimental|Nurse case management and self-management support|The first component of the intervention is the monitoring offered under the case management process. The second component of the intervention consists of group meetings (10-12 people) for self-management support in accordance with the stanford model. A sample of patients in each of the four FMGs (n = 126) will be recruited. These patients will receive the intervention for six months.
10026076|NCT01719991|No Intervention|Control group|Patients in the control group (n = 121) will receive the usual care for six months and then the same intervention as the experimental group for the next five months (waiting list control group).
10026077|NCT01720004|Experimental|Repeated Use of Hands-and-Knees|The intervention was repeated use of hands-and-knees position during labour. Participants were asked to try it for at least 15 minutes every hour, from randomization until delivery. They were not required to use it for delivery.
10026078|NCT01720004|No Intervention|Usual care|Participants were asked to refrain from using hands-and-knees position at any time from randomization to delivery. They were free to use any other position.
10026079|NCT01720017|Active Comparator|Inservice Training Only|Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
10026080|NCT01720017|Experimental|Inservice and Manikin Training|Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.
10026081|NCT01720030|Placebo Comparator|Conventional therapy|Standard of care as protocolized locally
10026082|NCT01720030|Experimental|Levosimendan|The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.
10026083|NCT01720056|Active Comparator|Verapamil|Verapamil 2.5 mg/mL injection sc intralesionally
10026084|NCT01720056|Active Comparator|Kenalog 10|Kenalog 10 mg/mL injection sc intralesionally
10026085|NCT01720082|Active Comparator|Single incision laparoscopic appendectomy|Acute appendicitis with surgical indication
9462982|NCT03697473|Active Comparator|Nordic Hamstring Exercise Group|Participants were required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they could no longer lower themselves as such, they were instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touched the ground they were instructed to immediately return to the starting position by pushing up with their hands.
9462983|NCT03697473|Experimental|Hip Extension Exercise Group|The participant lay on an exercise bench at a 45° angle with their hips held just over the top of the bench, their trunk erect and hips extended and their heel supported. Participants slowly flexed their hip until they reached 90° from the starting position and were then required to return to the starting position by extending through the hip while maintaining a neutral pelvic and trunk posture throughout. This exercise was then repeated on the opposite leg
9462984|NCT03697447|Experimental|Endermotherapy treated scar|Endermotherapy massage treatment
10026086|NCT01720082|Active Comparator|Multiport Laparoscopic appendectomy|Acute appendicitis with surgical indication
10026087|NCT01720095|Experimental|Niaspan|these are the first episode psychosis patients that are randomized to receive niaspan
9462985|NCT03697447|No Intervention|Control scar|No intervention, standard of care
9462986|NCT03697434|Experimental|Palliative Care referral|Participants with specific uncontrolled symptoms or critical events in course of their Parkinson disease will be referred to a palliative care specialist for supportive care.
9462987|NCT03697408|Experimental|Itacitinib and everolimus|
9462988|NCT03697382|Experimental|Very Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 2,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
9462989|NCT03697382|Experimental|Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 5,000 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
9462990|NCT03697382|Experimental|Moderate Steps|Subjects will be asked to undergo reduced daily stepping to a level of 7,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
9462991|NCT03697369||Observation group|Individuals with T1D ages 0-20 years who switched management modality from MDI to pump as part of their clinical care and were followed up prospectively in the next 12 months.
9462992|NCT03697343|Other|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and no margin as defined by the RTOG 9005
9462993|NCT03697343|Other|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm margin
9462994|NCT03697330|Active Comparator|Ringer's lactate 18-20 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group L:will receive 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
9462995|NCT03697330|Active Comparator|Ringer's lactate 4-6 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group R: will receive 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
9462996|NCT03697317|Experimental|Televideo Lifestyle Coaching|
9462997|NCT03697317|Active Comparator|Enhanced Usual Care|
9462998|NCT03697291|Experimental|PS wire|self-invented iECG wire
10026088|NCT01720095|No Intervention|healthy control|this is the group of healthy controls for cognitive outcome measures
10026089|NCT01720095|No Intervention|first episode control group|first episode psychosis patients who are randomized to no intervention
10026090|NCT01720108|Active Comparator|rivaroxaban|rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
10026091|NCT01720108|Experimental|ASA|ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
9462999|NCT03697291|Active Comparator|Certodyn|Commercially available iECG system - Certodyn
9463000|NCT03697265|Experimental|Sepranolone (UC1010) low dose|Sepranolone (UC1010) low dose administered subcutaneously (SC) during the luteal phase
9463001|NCT03697265|Experimental|Sepranolone (UC1010) high dose|Sepranolone (UC1010) high dose administered subcutaneously (SC) during the luteal phase
9463002|NCT03697265|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) during the luteal phase
9463003|NCT03697239|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
10026092|NCT01720121|No Intervention|Control group|The control group received the guidelines orientation provide by nursing team
10026093|NCT01720121|Experimental|Guidelines printed group|The patient received the informative material in details about the cardiac catheterization provide by the researchers
10026094|NCT01720121|Experimental|Guidelines digital video disc group|Guidelines digital video disc group: The patient received the informative provide by digital video disc in details about the cardiac catheterization
10026095|NCT01720134||after legislation 1st july 2003|2003-2006
10026096|NCT01720134||before legislation 1st july 2003|1999-2003
9463004|NCT03697226|Experimental|Dose 1|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
9463005|NCT03697226|Experimental|Dose 2|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
9463006|NCT03697226|Experimental|Dose 3|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
10026097|NCT01720186|Experimental|SPI Medical device|SPI medical device used during PET/CT 4D imaging in a synchronized mode centered on the thorax.
10026098|NCT01720186|Active Comparator|reference medical device : RPM|Reference medical device (RPM) used simultaneously during PET/CT 4D imaging in a synchronized mode centered on the thorax.
10026099|NCT01720199|Experimental|Intervention group|Preadolescents allocated to the Diario della Salute (DDS) intervention.
10026100|NCT01720199|No Intervention|Control group|
9463007|NCT03697226|Experimental|Dose 4|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
9463008|NCT03697226|Experimental|Dose 5|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
9463009|NCT03697213||General Practitioners|Registered General Practitioners in one of the six participating countries.
10026101|NCT01720212|Experimental|Single dose group|
10026102|NCT01720212|Experimental|Multiple dose group|
10026103|NCT01720238||Group 1|Entecavir Therapy
10026104|NCT01720238||Group 2|Lamivudine plus Adefovir Dipivoxil Therapy
10026105|NCT01720290|Experimental|Rep|
10026106|NCT01720290|Active Comparator|Met|
10026107|NCT01720290|Active Comparator|Rep + met|
10026108|NCT01720303|Experimental|Rep + NPH|
10026109|NCT01720303|Active Comparator|Premixed insulin/NPH|
10026110|NCT01720329|Active Comparator|Probiotics|Participants randomized to probiotics will receive 2 capsules supplemented with 10 billion cfu of Lactobacillus rhamnosus GG on a daily basis for six months
10026111|NCT01720329|Placebo Comparator|Probiotic placebo|Participants randomized to placebo will receive 2 capsules of matching placebo on a daily basis for six months
10026112|NCT01720342||Aortic valve stenosis, aortic valve insufficiency|Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.
10026113|NCT01720368||1st Group of 50 patients|
10026114|NCT01720368||2nd Group of 50 patients|
10026115|NCT01720394|Experimental|Cervical ripening balloon|primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.
10026116|NCT01720394|Active Comparator|Propess|Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)
10026117|NCT01720407|Experimental|Imiquimod|
10026118|NCT01720407|Placebo Comparator|Placebo|
10026119|NCT01720420|Experimental|Mandible|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
10026120|NCT01720420|Experimental|Maxilla|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
9463010|NCT03697200|Active Comparator|Auricular Point Acupressure (APA)|Patients with active points related to Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). The points for AIMSS include (1) points corresponding to body pain location and (2) three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex)
9463011|NCT03697200|Sham Comparator|Sham APA control|The same procedure of APA will be applied but the tapes/seeds will be placed on different points (points not related to AIMSS). Participants in the Sham APA Control will receive APA on the five ear points comprising mouth, stomach, duodenum, internal ear, and tonsils. These points are chosen for the Sham APA Control for two reasons: First, they are distinct from the zones of the ear (and the points therein) associated with AIMSS and correspond to body regions in which BCS (Breast Cancer Survivors) are usually pain-free; second, they are equivalent in number to those points used in the APA treatment group and no negative impacts have been observed among these points in our pilot study.
9479825|NCT03539679|Experimental|Encouraging physical activity|Encouraging physical activity by using motion sensor and feedback.
10026121|NCT01720433|Experimental|intervention|In the intervention group, in addition to the above, the patient was placed in the Trendelenburg position (30°) and a pulmonary recruitment maneuver utilized, consisting of two manual inflations to a maximum pressure of 60 cm H2O. This was performed by the Anaesthetist, who held each positive pressure inflation for five seconds, with the valves on the operative ports fully open.
10026122|NCT01720433|No Intervention|control arm|In the control group residual carbon dioxide pneumo-peritoneum was evacuated at the end of the procedure by passively allowing the abdomen to decompress by opening the operative ports.
10026123|NCT01720459|Active Comparator|Micronized trans-resveratrol|Micronized trans-resveratrol
10026124|NCT01720459|Placebo Comparator|Placebo|
10026125|NCT01720472||Community, Physical Performance|
10026126|NCT01720485|Experimental|Desloratadine + Prednisolone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.~Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.~Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication."
10026127|NCT01720485|Active Comparator|Dexchlorpheniramine + Betamethasone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication."
10026128|NCT01720498|Experimental|Male|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
10026129|NCT01720498|Experimental|Female|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
10026130|NCT01720511|Experimental|Purple Rice|Twice a day given purple rice with 5mg of resveratrol.
10026131|NCT01720511|Active Comparator|Brown RIce|Plain Purple rice given twice a day
10026132|NCT01720537|Experimental|Cohort 1|
10026133|NCT01720537|Experimental|Cohort 2|
10026134|NCT01720537|Experimental|Cohort 3|
10026135|NCT01720537|Experimental|Cohort 4|
10026136|NCT01720537|Experimental|Cohort 5|
10026137|NCT01720537|Experimental|Cohort 6|
10026138|NCT01720550|Experimental|PG2 High Dose|Astragalus Polysaccharides 500 mg
10026139|NCT01720550|Experimental|PG2 Low Dose|Astragalus Polysaccharides 250 mg
10026140|NCT01720563|Placebo Comparator|Control|Placebo
10026141|NCT01720563|Experimental|Treatment|Astragalus polysaccharides 500 mg
10026142|NCT01720576|Experimental|Cohort 1|Dose 1 of REGN1033 (SAR391786) or Placebo
9479826|NCT03539679|No Intervention|CONTROL GROUP|No intervention.
9463012|NCT03697200|Other|Education Control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Educational sessions are intended to reflect usual standard medical care per guidelines from the American Society of Clinical Oncology (ASCO), while also meeting the needs of trial participation, including (1) the knowledge of hormonal therapy and side effects; (2) assessment and management of physical long-term and late effects; (3) assessment and management of psychological long-term and late effects; and (4) dietary (developed by Co-I, van Londen) and physical activity in Breast Cancer Survivors (BCS) (developed by Co-I, Stearns). These materials have been used by the research team, and clinical practice. Materials will be tailored so that they can be delivered within 15 minutes for each session.
9463013|NCT03697187||Hereditary Angioedema|Patients with Hereditary Angioedema who are receiving treatment with Ruconest (rhC1INH).
10026143|NCT01720576|Experimental|Cohort 2|Dose 2 of REGN1033 (SAR391786) or Placebo
10026144|NCT01720576|Experimental|Cohort 3|Dose 3 of REGN1033 (SAR391786) or Placebo
10026145|NCT01720589|Experimental|Melt (test oil)|Participants will consume a muffin containing 20 g of dietary fat provided by the test oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the test oil and their food intake at an ad libitum meal will be measured 1 hour later.
10026146|NCT01720589|Active Comparator|Corn oil (control)|Participants will consume a muffin containing 20 g of dietary fat provided by the control oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the control oil and their food intake at an ad libitum meal will be measured 1 hour later.
10026147|NCT01720615|No Intervention|Propofol or Sevoflurane|General anesthesia
9463014|NCT03697174|Experimental|Exposure group|Subjects in exposure group will be exposed to 200 ppb ozone for 2 hours in a chamber.
10026148|NCT01720628||Behçet's patients|Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
9463015|NCT03697174|Sham Comparator|Control group|Subjects in control group will be exposed to 0 ppb ozone (clean air) for 2 hours in a chamber.
9463016|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 1|Once Daily
10026149|NCT01720641|No Intervention|Control|Standardized partner notification counseling
10026150|NCT01720641|Experimental|Internet Notification|Standardized partner notification counseling and referral to internet-based partner referral website.
10026151|NCT01720641|Experimental|Referral Card|Standardized partner notification counseling and provision of 5 printed partner referral cards.
10026152|NCT01720641|Experimental|Internet and Referral Card|Standardized partner notification counseling and referral to internet-based partner referral website and provision of 5 printed partner referral cards.
10026153|NCT01720654|No Intervention|Control|Standardized partner notification counseling.
10026154|NCT01720654|Experimental|EPT|Standardized partner notification counseling and provision of 5 partner treatment (EPT) packets.
9463017|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 2|Twice Daily
10026155|NCT01720693|Experimental|hypoperfusion|Hypoperfusion of the renal artery
10026156|NCT01720706|Experimental|Acute|The RFA Loosely wound thermal coil electrode will be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed group'. Energy will be delivered using the single timed heating cycle. Treatment will be monitored with B mode US. Once the cycle is completed, the probe will be removed and the planned surgery will continue with partial or radical nephrectomy.
10026157|NCT01720706|Experimental|Delayed|Using an electrically insulated 12ga introducer with trocar is inserted percutaneously into the renal tumor. The needle tip will be placed 20mm from the center of the target. The trocar is removed and co-axially (i.e. within the introducer), a core biopsy of the lesion is performed with a 14-18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode is then optimally positioned and locked into the introducer. On approximately day 6-10, a partial or radical nephrectomy will be performed in the usual way.
10026158|NCT01720719|Active Comparator|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
10026159|NCT01720719|Experimental|Atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
10026160|NCT01720732|Experimental|Lifeline NET|Lifeline-NET (Short Version of NET)
10026161|NCT01720732|No Intervention|TAU|Treatment as Usual
10026162|NCT01720745||EUS FNA|Patients undergoing endoscopic ultrasound for solid mass lesions with a 22 G needle at University of Minnesota Medical center and Aurora St.Luke's Medical Center, Milwaukee, WI
10026163|NCT01720771|Active Comparator|Probiotic tablet|a tablet with three probiotic streptococci strains (S. uberis KJ2, S. oralis KJ3 and S. rattus JH145) at a concentration of 3x108 CFU
10026164|NCT01720771|Placebo Comparator|Sugar pill|The same tablet but without active probiotic bacteria
10026165|NCT01720784|Placebo Comparator|Placebo|
10026166|NCT01720784|Experimental|Low dose (1.5 g DF)|
10026167|NCT01720784|Experimental|High dose (2.25 gDF)|
9463018|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 3|Three Times Daily
9463019|NCT03697135||Seed Contacts|Initial participants who will invite previous injecting contacts to take a hepatitis C test using a respondent driven sampling method
9463020|NCT03697135||Initial Nominations for Testing|Contacts of initial participants who consent to be tested and enrol in the study using a respondent driven sampling method
9463021|NCT03697135||Second Level Nominations for testing|Contacts of wave one participants who consent to be tested and enrol in the study using a respondent driven sampling method
9463022|NCT03697096|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
9479827|NCT03539640|Active Comparator|PEEP level of 5 cmH2O|During second part of the study (MRI) Diaphragm position
10036732|NCT01818401|Other|Control group|The control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
10036733|NCT01818401|Other|Matched patient|The treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
9463023|NCT03697096|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for UTI in non-ICU patients in the first 3 days of hospitalization.
9463024|NCT03697070|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
9463025|NCT03697070|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for PNA in non-ICU patients in the first 3 days of hospitalization.
9463026|NCT03697057||patients|Patients scheduled for elective ambulatory gynaecological surgery, which was performed under standardised general anaesthesia
9463027|NCT03697057||healthy volunteers|Female healthy volunteers matched to the patient group regarding the age
9463028|NCT03697018|Experimental|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material, enriched with zirconia (10% by weight), the material offers natural esthetics with successful outcome.
9463029|NCT03697018|Active Comparator|monolithic zirconia|Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
9463030|NCT03697005|Experimental|BioHPP PEEK single posterior crowns|BioHPP PEEK copings veneered with composite resin
9463031|NCT03697005|Active Comparator|zirconia-based single posterior crowns|yttria stabilized tetragonal zirconia used as copings to be veneered with porcelain
10026168|NCT01720823|Experimental|home polysomnography and standard polysomnography|home polysomnography (GETEMED) and standard polysomnography (BRAINNETII) are both carried out in children during 1 night.
10026169|NCT01720836|Experimental|Stage IA or I/II NSCLC|Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
9463032|NCT03696979|Active Comparator|myofascial induction|Twice a week for 8 weeks. Lumbar interfacial field stroke application, Lumbar interfacial field to deep application, Lumbar region cross-hands induction technique, Hip flexor region induction.
9463033|NCT03696979|Active Comparator|Therapeutic Pain education|Pain education,twice a week for 8 weeks. The mechanism of pain,Pain processing in the center, How sensitive the central nervous system is in chronic pain, Pain becomes chronic with the contribution of factors, Problems related to fear of pain will be explained in detail.
9463034|NCT03696966|Active Comparator|Continuous Calorie Restriction|Daily calorie restriction: follow low-calorie diet (1,200-1,500 calories) daily using portion-controlled meals
9463035|NCT03696966|Experimental|Intermittent Very-Low Calorie Diet|Intermittent Restriction: follow very-low calorie diet (500-800) with portion-controlled meals three days per week and structured healthy eating on other days
9463036|NCT03696953|Experimental|Probiotic|"Florajen3 Combination Probiotic Product 15 billion CFU per capsule~1 capsule daily from 28 weeks until the time of birth."
9463037|NCT03696953|No Intervention|Placebo|Microcrystalline Cellulose
9463038|NCT03696940|Experimental|Experimental Group|2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
9463039|NCT03696940|Active Comparator|Control Group|2 tablets of: Atorvastatin 10 mg
9463040|NCT03696927|Experimental|User Focus Group Participants|Target user population will be human subjects with spinal cord injury at levels C3 to C5, and ASIA Impairment Scale (AIS) A, B, or C.
9463041|NCT03696914||Eosinophilic|Asthmatic patients showing 3% or more sputum eosinophils
9463042|NCT03696914||Non-eosinophilic|Asthmatic patients showing less than 3% sputum eosinophils
10026170|NCT01720836|Experimental|Stage IB/II/IIIA|Resection and adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
10026171|NCT01720836|Experimental|Stage IIIA or IIIB|Concomitant chemo-irradiation followed by 3 cycles of vaccine + PolyICLC.
10026172|NCT01720849||Fampyra group|
10026173|NCT01720862||Episodic migraineurs|Those with migraines >2 and < 12 times per month.
10026174|NCT01720862||Chronic migraineurs|Those with migraines greater than 14 days per month.
10026175|NCT01720862||Controls|Those without headaches other than occasional hangover, cold, flu headaches.
10026176|NCT01720875|Experimental|Vorinostat Velcade Dexamethasone (VVD)|"Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.~Cycles 1-8 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11~Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12~Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)~Vorinostat: 400mg PO on 1-4 and 15-18"
10026177|NCT01720888|No Intervention|Maximal medical therapy|Maximal medical therapy which comprises of optimal pharmacological therapy
10026178|NCT01720888|Experimental|Maximal medical therapy and BM-MSCs|Autologous Bone marrrow-derived mesenchymal stem cells implantation
10026179|NCT01720901|Experimental|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
10026180|NCT01720914||Critically ill patient|
10026181|NCT01720927||Acute Pharyngitis|Subjects presenting with acute pharyngitis
10026182|NCT01720940|Experimental|continuous vancomycin infusion|
10026183|NCT01720940|Active Comparator|intermittent vancomycin infusion|vancomycin in this arm will be administered as intermittent infusion
10026184|NCT01720953||Healthy control subjects|Matched healthy control subjects will be assessed at 6 month intervals to compare changes in DNA methylation, BDNF serum levels, salivary cortisol levels, and neuropsychological test performance. Healthy control subjects will within the 1-year study period also undergo continuous assessment for comparative changes in symptoms of dissociation, depression, and personality dysfunction.
10026185|NCT01720966||Laparoscopy|Patients who will undergo liver resection who have a laparoscopically performed colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
10026186|NCT01720966||Laparotomy|Patients who will undergo liver resection who have an open colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
10026187|NCT01720979||Patients with traumatic injuries|Children that were admitted to the hospital after traumatic injuries to body parts below the clavicles (traumatic control injury) and children that were admitted to the hospital after traumatic brain injury as diagnosed by a physician (TBI).
10026188|NCT01720992|Experimental|Group A|A theory-based action planning toolkit will be distributed to Group A participants.
10026189|NCT01720992|Other|Group B|Group B is a wait list control
9463043|NCT03696901||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in Germany
9463044|NCT03696888|Experimental|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
9463045|NCT03696888|Active Comparator|TeleCoach control|A web-app giving information on health-related consequences of alcohol consumption.
9463046|NCT03696875|Experimental|Multilevel Guided Discharge Planning|
9463047|NCT03696875|Active Comparator|Standard of care|
9463048|NCT03696862|Experimental|collagen plug|collagen plug used to seal the socket after atraumatic extraction of the badly deacayed teeth with immediate implant placement and bone graft
9463049|NCT03696849|Active Comparator|glazed emax Press|
9463050|NCT03696849|Experimental|Polished emax Press|
9463051|NCT03696836|Experimental|Trammpolin® meniscus prosthesis|The patients will be implanted with the Trammpolin® meniscus prosthesis
9463052|NCT03696745|Placebo Comparator|Placebo|preterm infants with severe hypoxic ischemic encephalopathy receive only 0.9% Sodium-chloride
10026190|NCT01721005|Other|pulse palpation education|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model
10026191|NCT01721018|Experimental|HSV1716|Single Arm Phase I/II study of intra-pleural HSV1716 administration.
9463053|NCT03696745|Experimental|infusion|preterm infants with severe hypoxic ischemic encephalopathy will receive up to 4 infusions of their own volume reduced cord blood stem cells. The number of doses will be determined by the amount of available cord blood stem cells. The dose for each infusion is 5x107 cells/kg
9463054|NCT03696732||Women undergoing cesarean section|Women undergoing cesarean section under spinal anesthesia with prophylactic phenylephrine drip.
9463055|NCT03696719|Active Comparator|Undergoing surgery under general anesthesia|Patients will undergo the surgery under general anesthesia, anesthetic regime will be according to standard clinical practice.
9463056|NCT03696719|Active Comparator|Undergoing surgery under regional anesthesia|Patients will undergo the surgery under neuroaxial anesthesia.
9463057|NCT03696706|Active Comparator|LED group|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
9463058|NCT03696706|Placebo Comparator|Placebo group|For the placebo group, all measures described for the LED group will be adopted, however, the equipment will be switched off.
9463059|NCT03696706|No Intervention|Control group|In this group, the participants will only be evaluated. No intervention will take place.
9463060|NCT03696693||children with chronic rhinosinusitis|Children aged 6-18 years presented with symptoms of chronic rhinosinusitis will be recruited from the otorhinolaryngology out-patient clinic and department at Assiut University Hospital from October, 2018 to October, 2019.
9463061|NCT03696693||children without chronic rhinosinusitis|Children have the same age and number in the study group which are presented with vocal symptoms and have not chronic rhinosinusitis will be recruited for the same duration.
9463062|NCT03696680|Experimental|FSRT Stereotactic radiation therapy|Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
9479828|NCT03539640|Active Comparator|PEEP level of 10 cmH2O|During second part of the study (MRI) Diaphragm position
10026192|NCT01721031|Experimental|DPNB|Patients receive DPNB 30min before extubation at the end of operation.
10026193|NCT01721031|Active Comparator|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
10026194|NCT01721083|Experimental|Z-Track immunization|Subject receives Intramuscular injection by z-track method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
10026195|NCT01721083|Active Comparator|Bunch immunization|Subject receives Intramuscular injection by bunch method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
10026196|NCT01721135|Experimental|GSK2190915 100mg|GSK2190915 100mg on days 1-5; moxifloxacin placebo on day 5
10026197|NCT01721135|Experimental|GSK2190915 1000mg|GSK2190915 1000mg on days 1-5; moxifloxacin placebo on day 5
10026198|NCT01721135|Active Comparator|moxifloxacin 400mg|placebo tablet on days 1-5; moxifloxacin 400mg on day 5
10026199|NCT01721135|Placebo Comparator|placebo|placebo tablet on days 1-5; moxifloxacin placebo on day 5
9479829|NCT03539640|Active Comparator|PEEP level of 15 cmH2O|During second part of the study (MRI) Diaphragm position
10026200|NCT01721148|Other|Cohort Dose Escalation|open label dose escalation study of ASLAN002 administered orally on a once daily schedule to subjects with advanced or metastatic solid tumours, who have either progressed on standard therapy or for whom standard therapy is not known
10026201|NCT01721174|Active Comparator|SEMS only|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
10026202|NCT01721174|Active Comparator|EBRFA and SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.
10026203|NCT01721187||Low disinhibition|fMRI during fed and fasted states
10026204|NCT01721187||High disinhibition|fMRI during fed and fasted states
10026205|NCT01721213||Patients using Trobalt™|Use of Trobalt™ current use or at least one prescription filled within the previous three months.
10026206|NCT01721213||Physicians prescribing AEDs|Physicians (neurologists) who prescribed AEDs at least once in the three months prior to the survey.
10026207|NCT01721213||Physicians Prescribing Trobalt™|Physicians (neurologists) who have had experience of prescribing Trobalt™ specifically, from among those who have prescribed AEDs at least once in the three months prior to the survey.
10026208|NCT01721239|No Intervention|Control group|No intervention
10026209|NCT01721239|Experimental|Standardized Followup program|Standardized written information, patient photos and three follow-up consultations.
10026210|NCT01721291|Experimental|SALBUTAMOL 1.5 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
10026211|NCT01721291|Experimental|SALBUTAMOL 3 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
10026212|NCT01721291|Experimental|SALBUTAMOL 6 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
10026213|NCT01721291|Active Comparator|SALBUTAMOL 200 MICROGRAMS|DOSAGE FORM- SALBUTAMOL INHALED VIA METERED DOSE INHLAER;DOSAGE- 200 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT ONE VISIT INHALE SLOWY)
10026214|NCT01721304|Experimental|Adaptive Conjoint Analysis|Computerized survey to elicit preferences
9463063|NCT03696667|Active Comparator|Affective BCI training|15 participants in the intervention group will undergo 24 sessions of BCI-based emotion regulation training over an 8-week period. Each session will take about 30-minute to complete where participants will listen to music with audio feedback to regulate emotions toward positive affect.
9463064|NCT03696667|No Intervention|Control group|15 participants in the control group will take part in 24 music sessions (with no audio feedback) over an 8-week period. Each session will take about 30-minute to complete.
9463065|NCT03696654|No Intervention|Before treatment|
9463066|NCT03696654|Active Comparator|After treatment|
9463067|NCT03696641|Active Comparator|glazed IPS e.max|lithium disilicate glazed crowns that proved to have a good color stability
9463068|NCT03696641|Experimental|polished IPS e.max|polished lithium disilicate crowns with the polishing kit
9463069|NCT03696628|Other|Healthy children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
10026215|NCT01721304|No Intervention|Usual care|Patients are counseled by their physician as usual
10026216|NCT01721356||Healthy individuals|Healthy individuals ranging in age, race, ethnicity, socioeconomic status, and years of education
10026217|NCT01721382|Experimental|Sitagliptin|Treatment with sitagliptin
10026218|NCT01721395|Placebo Comparator|Colored, Flavored water|The placebo will be colored to approximate the reddish amber color of the agave syrup. The placebo will use the same flavoring used in the agave syrup. The placebo will be created in a GMP facility
10026219|NCT01721395|Experimental|Agave Syrup|The formulation of pasteurized agave syrup consists of pasteurized agave syrup and natural flavoring.
10026220|NCT01721395|Sham Comparator|Air-filled oral syringe|Air-filled oral syringe to match experimental and placebo arm
10026221|NCT01721421|Experimental|Extended Treatment time|Extended treatment time of 6 hours
10026222|NCT01721421|Active Comparator|standard treatment time|Standard Treatment time of 4 hours
10026223|NCT01721434|Experimental|Levosimendan|Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.
10026224|NCT01721434|Placebo Comparator|Placebo|Similar coloured placebo intravenous for a single 7 hours
10036734|NCT01818440|Active Comparator|A|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method
9463070|NCT03696628|Other|Cardiomyopathic children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
9463071|NCT03696615|Experimental|Tabata Kettlebell Swings|"Participants in this group performed:~A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)~Receive instruction on the kettlebell swing~Performed a high-intensity workout in a Tabata Kettlebell Swings format, which involves 20 seconds of all out effort followed by 10 seconds of rest, repeated for a total of 8 times."
9463072|NCT03696615|Active Comparator|Control Group|"Participants in this group performed:~1. A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)"
9463073|NCT03696602||test with methacholine|
9463074|NCT03696602||test with exercise|
9463075|NCT03696563|Active Comparator|Control group|In this group, the - usual care based upon BLS-PCS with manual titration of oxygen. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
9463076|NCT03696563|Experimental|FreeO2 group|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration to reach the SpO2 target set by paramedic.
10026225|NCT01721499|Experimental|Mindfulness intervention|"The mindfulness intervention consists of weekly group format mindfulness instruction and skills development, weekly individual therapy sessions, and 6 nutritional sessions.~The control group receives 6 nutritional sessions only."
10026226|NCT01721499|Active Comparator|Nutrition Control Group|The control group receives 6 nutritional counseling sessions.
9463077|NCT03696524|Experimental|Intervention Group|This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
9463078|NCT03696524|No Intervention|Usual Care|The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
9463079|NCT03696511|Active Comparator|group 1:maxillary insertion|Orthodontic miniscrew insertion; maxillary insertion. buccal
9463080|NCT03696511|Active Comparator|group 2: mandible insertion|Orthodontic miniscrew insertion; mandible insertion.
9463081|NCT03696511|Active Comparator|group 3: palatal insertion|Orthodontic miniscrew insertion; palatal insertion
9463082|NCT03696498|Experimental|Partial caries excavation (1 step)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Local anaesthesia shall be used. as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: A permanent resin restoration is placed on top of the remained caries."
9463083|NCT03696498|Active Comparator|Partial caries excavation (2 steps)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Before randomisation, the participants receive the first excavation procedure as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: After randomisation, a calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months, the temporary restoration is removed, final excavation is carried out with hand excavators until firm but stained dentine remains, and a permanent resin restoration is placed."
9463084|NCT03696485|Experimental|group 1: low dose|One intrathecal (IT) administration of SCM-010 at baseline visit
9463085|NCT03696485|Experimental|group 2: high dose|One intrathecal (IT) administration of SCM-010 at baseline visit
9463086|NCT03696472|Experimental|robotic-assisted left colonic resection|Standard left colonic resection assisted by Davinci Robotic
9463087|NCT03696472|Active Comparator|laparoscopic left colonic resection|Standard laparoscopic left colonic resection
9463088|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 1|Participants will receive single oral dose of JNJ-53718678, 2000 milligram (mg) suspension or matching placebo on Day 1, under fasted conditions.
9463089|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 2|Participants will receive single oral dose of JNJ-53718678, of maximum 3000 mg suspension or matching placebo on Day 1, under fasted conditions.
10026227|NCT01721512||Breast-fed infants|80 infants of mothers who plan to exclusively breastfeed for at least 6 months.
9463090|NCT03696459|Experimental|Part 1 (Dose escalation): Panel 3|Participants will receive single oral dose of JNJ-53718678 4500 mg suspension (this dose may be used in Part 2, Treatment F) or matching placebo on Day 1, under fasted condition.
9463091|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 4 (Optional)|Participants will receive single oral dose of JNJ-53718678 (dose to be decided [this dose may be used in Part 2, Treatment F]) suspension or matching placebo on Day 1, under fasted condition, if 4500 mg dose in Panel 3 is considered safe and tolerable and if pharmacokinetic data require further dose escalation to reach the target exposure.
9463092|NCT03696459|Experimental|Part 2 Group 1: Treatment Sequence EHFG|Participants will receive single oral dose of JNJ-53718678, 500 mg suspension with single oral dose of moxifloxacin placebo and JNJ 53718678 placebo (Treatment E) in Period 1, then participants will receive single oral dose of moxifloxacin 400 mg with single oral dose of JNJ-53718678 placebo (Treatment H) in Period 2 then will receive single oral dose of JNJ-53718678, 4500 mg (dose will be based on review of safety, tolerability, and PK data obtained in Part 1 [either from Panel 3 or 4], this dose may be lower/higher) suspension with single oral dose of moxifloxacin placebo (Treatment F) in Period 3 followed by single oral dose of JNJ-53718678 placebo with single oral dose of moxifloxacin placebo (Treatment G) in Period 4, on Day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
9463093|NCT03696459|Experimental|Part 2 Group 2: Treatment Sequence FEGH|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment G in Period 3 followed by Treatment H in Period 4 on Day 1 of each treatment period.
9463094|NCT03696459|Experimental|Part 2 Group 3: Treatment Sequence GFHE|Participants will receive Treatment G in Period 1, then Treatment F in Period 2, then Treatment H in Period 3 followed by Treatment E in Period 4 on Day 1 of each treatment period.
9463095|NCT03696459|Experimental|Part 2 Group 4: Treatment Sequence HGEF|Participants will receive Treatment H in Period 1, then Treatment G in Period 2, then Treatment E in Period 3 followed by Treatment F in Period 4 on Day 1 of each treatment period.
9802937|NCT04790578|Experimental|ZoeInsights Application Arm|Participants will receive free access to the ZI app for the 12-week intervention. After completing initial set-up, participants will be asked to record physical activity and symptoms regularly via scheduled in-app routines. Further use of ZI (eg. Custom daily routines, additional graphing, medication tracking, accessing linked health resources) during the intervention will be possible ad libitum. After the initial 12-weeks of the EXCEL+ZI intervention, participants have continued free access to the ZI app for up to 1 year.
9802938|NCT04790578|Active Comparator|Waitlist control|During the 12-week intervention the participants will only take part in an online delivered EXCEL exercise class and will not have access to the ZI app. After completion of the 24-week test, the participants will be granted access to the ZI app.
10026228|NCT01721512||Formula-fed infants|"Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.~Mother consents to her infant receiving trial infant formula for 12 months"
10026229|NCT01721525|Experimental|afatinib, ribavirin, and weekly carboplatin/paclitaxel|This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.
9463096|NCT03696420||DBS surgery targeting the VIM|Patient who underwent a DBS surgery targeting the VIM at Bordeaux University Hospital
9463097|NCT03696394|No Intervention|Group I|Group I consists of 5 patients receiving a microfracture as per standard of care.
9463098|NCT03696394|Active Comparator|Group II|Group II consists of 10 patients receiving a microfracture with BioCartilage®.
9463099|NCT03696381|Experimental|Real tRNS|Real tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
9463100|NCT03696381|Sham Comparator|Sham tRNS|Sham tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
9463101|NCT03696329|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
9463102|NCT03696329|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
9463103|NCT03696290|Active Comparator|Aztreonam lysine, 3 doses per day|3 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
9463104|NCT03696290|Placebo Comparator|Placebo, 3 doses per day|3 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
9463105|NCT03696290|Active Comparator|Aztreonam lysine, 2 doses per day|2 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
9463106|NCT03696290|Placebo Comparator|Placebo, 2 doses per day|2 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
9463107|NCT03696277|Experimental|Stereotactic ablative body radiation (SABR)|SAbR will be used to treat all sites of measurable metastases. New sites of metastasis will be treated if deemed appropriate by both medical and radiation oncologists with SAbR.
9463108|NCT03696264|Experimental|Resistance-trained, adult males|Subjects receive varying levels of amino acid intakes ranging from 0.2-3.0g/kg/d
10026230|NCT01721538|Experimental|Therapy arm|Non-drug therapeutic weight reduction program (15 weeks)
9463109|NCT03696251||master's nursing program|the graduates of master's nursing program in recent three years in Taiwan
9463110|NCT03696238|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
10026231|NCT01721538|Placebo Comparator|Control arm|Lecture on healthy nutrition (1 hour)
10026232|NCT01721551|Experimental|Exercise training|HD patients will receive a 9 months intradialytic exercise training program
10026233|NCT01721551|Placebo Comparator|No exercise|HD patients will not participate in any type of systematic exercise training
10026234|NCT01721577|Experimental|AXL1717|In the first phase, 10-20 patients will be enrolled and treated with 300-520 mg BID of AXL1717 for 28 days. The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 and to assess the safety and toxicity of AXL1717. The study has a 3+3 design and the first cohort will be treated with 400 mg AXL1717 BID for 28 days repeated in up to 5 cycles. The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RP2D. Non-progressing patients may be treated for a total of five 28-day cycles (24 weeks).
10026235|NCT01721590|Placebo Comparator|Control|Placebo，3 capsules/time，3times/day for 1 year
10026236|NCT01721590|Experimental|Tongxinluo|Tongxinluo 3 capsules/time 3times/day for 1 year
10026237|NCT01721616|Active Comparator|Cefazolin|single antibiotic
10026238|NCT01721616|Active Comparator|Cefazolin + Azitrhromycin|double antibiotic
10026239|NCT01721629|Other|Sudden wean of nasal CPAP|The CPAP is taken off at the morning ward round. If the discontinuation of the CPAP fails according to prespecified failure criteria, CPAP is recommenced and continued for at least 24 hours. Then a new evaluation takes place and if the infant again meets the inclusion criteria another attempt of sudden wean can be undertaken. Infants are considered successfully weaned if they are off CPAP for three days.
10026240|NCT01721629|Other|Gradual wean of nasal CPAP pressure|The reduction of the CPAP pressure begins at the morning ward round and the pressure is reduced in steps with 1 cmH2O maximum once a day. Each time the pressure is to be reduced the infant needs to be evaluated according to the inclusion criteria and only if these are still met, will the pressure be reduced. When a CPAP pressure at 4 cmH2O is reached the infant is treated with this pressure for 24 hours and then the CPAP is discontinued. Infants are considered successfully weaned if they are off CPAP for three days.
10026241|NCT01721642|Experimental|Apica Cardiovascular ASC Device|Access, stabilisation and closure with the Apica Cardiovascular ASC Device
9463111|NCT03696238|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
9463112|NCT03696212|Experimental|grapiprant and pembrolizumab combination|Participants will be treated with grapiprant in combination with pembrolizumab.
9463113|NCT03696186|Active Comparator|Luminal type-1|Standard treatment
9463114|NCT03696186|Experimental|Luminal type-2|Experimental treatment
9463115|NCT03696186|Active Comparator|Neuroendocrine type-1|Standard treatment
9463116|NCT03696186|Experimental|Neuroendocrine type-2|Experimental treatment
9463117|NCT03696186|Active Comparator|Atypical type-1|Standard treatment
9463118|NCT03696186|Experimental|Atypical type-2|Experimental treatment
9463119|NCT03696173||Participants taking abatacept|
9463120|NCT03696173||Participants taking abatacept with methotrexate|
10026242|NCT01721655|Active Comparator|Spironolactone|Oral spironolactone suspension dosed at 3 mg/kg/day will be administered once-daily to the patients assigned to the treatment arm.
10026243|NCT01721655|Placebo Comparator|Placebo suspension|An oral placebo suspension dosed at 3 mg/kg/day administered once-daily will be given to patients in the placebo arm.
9463123|NCT03696121|Experimental|Intervention|Desmopressin injection
9463124|NCT03696121|Placebo Comparator|Control|Normal Saline
9463125|NCT03696095|Active Comparator|Continous infusion ropivacaine|Continuous infusion via peri-neural femoral nerve catheter of Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode) at rate of 6ml/h + patient controlled bolus of 3ml ...
9463126|NCT03696095|Experimental|PIB ropivacaine|Programmed intermittent bolus of Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode) : 6ml each 60min + patient controlled bolus 3ml ...
9463127|NCT03696056|Experimental|Kirtan Kriya meditation|Participants will mediate for 12 minutes a day for 8 consecutive weeks.
9463128|NCT03696056|Active Comparator|Relaxing instrumental music|Participants will relax listening to music for 12 minutes a day for 8 consecutive weeks.
9479830|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
9479831|NCT03539588|Active Comparator|Treatment group 1|In this group participants will receive trigger point dry needling with electrical stimulation first and receive trigger point needling by itself second. Only MYOTECH dry needles will be used in this study. However we are not studying the equipment.
9479832|NCT03539588|Active Comparator|Treatment Group 2|In this group the participants will receive trigger point dry needling first and receive trigger point dry needling with electrical stimulation second. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
10026244|NCT01721668|Experimental|MSR - Music Supported Rehabilitation|Behavioral: Music Supported Rehabilitation
10026245|NCT01721668|Active Comparator|CU/ET|Experimental: CU/ET (Conventional Upper Extremity Therapy)
10026246|NCT01721694|Experimental|azithromycin 1.5%/Loteprednol 0,5% + placebo|fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops
10026247|NCT01721694|Active Comparator|azithromycin 1.5% + Loteprednol 0,5% (separately)|azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)
10026248|NCT01721707|Experimental|Latanoprost+Brinzolamide combination|Latanoprost 0.005%(50 mg/ml)+brinzolamide 1%(10mg/ml) eye drops
10026249|NCT01721707|Active Comparator|Latanoprost|Latanoprost 0.005% (50 mg / ml)
10026250|NCT01721785||Primary staging group I|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME.~Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI."
10026251|NCT01721785||Restaging group II|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group II are patients that will be stratified for a long course of chemoradiotherapy.~Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI."
10026252|NCT01721798|Active Comparator|Copper T-380a IUD|Copper T-380a IUD
10026253|NCT01721798|Active Comparator|Mirena Levonorgestrel IUD|Mirena levonorgestrel IUD
10026254|NCT01721811|Experimental|Healthy|Healthy study participanats
10026255|NCT01721811|Experimental|Diabetes|Patients with diabetes
10026256|NCT01721824|Experimental|IPS-MA|"The IPS-MA method consists of five basic services for the participants. 1)Individual mentor support, based on psychiatric knowledge. 2)Coordination by the mentor of activities, internal as well as from external providers. 3)Career counseling aimed at people with mental illnesses. 4)Impartial help to clarify private economy. 5) Contact to employers to help participants obtain jobs, and keep them.~Participants will receive the IPS-MA method in addition to treatment as usual."
10026257|NCT01721824|No Intervention|Control group|"Participants randomised to the control group will receive treatment as usual only. This means the standard support offered by the social- and health services in Denmark."
10026258|NCT01721863|Experimental|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
10026259|NCT01721863|No Intervention|control group|Control group conducted the usual care
10026260|NCT01721889||Radiostereometric analysis - Intact fusion|Clinically fused per classical radiographic assessment (≤ 2 degrees angular motion and evidence of bone bridging)
10026261|NCT01721889||Radiostereometric analysis - Symptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis (not fused, ˃ 2 degrees angular motion or absence of bone bridge) and scheduled for surgical exploration
10026262|NCT01721889||Radiostereometric analysis - Asymptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis without scheduled surgical exploration.
10026263|NCT01721902|Active Comparator|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of autologous CD133+ cells in suspension.
10026264|NCT01721902|Placebo Comparator|Carrier Solution|Intra-myocardial inception of carrier solution.
10026265|NCT01721915|Experimental|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
10026266|NCT01721915|Placebo Comparator|Placebo|the placebo group will receive oily drops without vitD
10026267|NCT01721928||ICU patients with AKI|ICU patients with AKI treated with continuous venovenous hemodialysis
10026268|NCT01721928||ICU patients without AKI|ICU patients without AKI defined as RIFLE group O and R
10026269|NCT01721941|Experimental|Phase I dose level -1|TH-302 25mg; Doxorubicin 50mg
10026270|NCT01721941|Experimental|Phase I Dose level 1|TH-302 50mg; doxorubicin 50mg
10026271|NCT01721941|Experimental|Phase I Dose level 2|TH-302 100mg; doxorubicin 50mg
10026272|NCT01721941|Experimental|Phase 1 Dose level 3|TH-302 150mg; Doxorubicin 50mg
10026273|NCT01721980|Other|50 mg GLPG0974 or placebo|50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
10026274|NCT01721980|Other|100 mg GLPG0974 or placebo|100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days
10026275|NCT01721980|Other|200 mg GLPG0974 or placebo|200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
10026276|NCT01721980|Other|400 mg GLPG0974 or placebo|400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
10026277|NCT01721993|Experimental|T121E01F|
10026278|NCT01721993|Active Comparator|zoledronic acid IV|
10026279|NCT01722006||Pairing group|Paired, high reward, oral methamphetamine (20 mg) vs placebo Paired, low reward, oral methamphetamine (20 mg) vs placebo Paired, no reward, oral methamphetamine (20 mg) vs placebo Unpaired, oral methamphetamine (20 mg) vs placebo
9463129|NCT03696030|Experimental|Treatment (HER2-CAR T cells)|Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.
10026280|NCT01722019|Active Comparator|radiofrequency ablation with VNUS closure fast|Radiofrequency ablation will be performed with VNUS closure fast.
10026281|NCT01722019|Experimental|laser ablation and Tulip fiber|Laser ablation with a 1470 nm wave length in combination with a new fiber, the Tulip fiber.
10026282|NCT01722032|Experimental|Treatment|"The intervention centers' menus were modified to include more fresh fruit, fresh vegetables, low-fat (1%) or skim milk, water, less juice, and less simple carbohydrate snacks. The centers were also encouraged to incorporate fresh fruits and vegetables as often as possible for snack and meal time.~Physical Activity. Physical activity was promoted for at least 60 minutes per day. TV viewing, watching movies and playing computer games were logged and limited to 30 minutes or less per day. Schools adopted Best-Practice Policies."
9463133|NCT03696004|Active Comparator|Retros FEC-100 +BRS|Contains record of already treated patients with six cycles of FEC-100 Fluorouracil ,Epirubicin and Cyclophosphamide and later had Breast conservative Surgery(BRS)
9463134|NCT03696004|Active Comparator|PROS 30 FEC-100 +BRS|These are new patients who will be treated with six cycles of FEC-100 (Flourouracil,Epirubicin and Cyclophosphamide) and will undergo Breast Conservative Surgery (BRS)after 6 weeks
9463135|NCT03695991||Study group|Patients will be recruited from out-patient clinics and in-patient sectors of Assiut Urology and Nephrology hospital
9463136|NCT03695965||study group|patients with history of ankle trauma or chronic lateral ankle pain
9463137|NCT03695952||Hepatocellular carcinoma|Hepatocellular carcinoma patients treated with nivolumab
9463138|NCT03695952||Biliary Tract Cancer|Biliary tract cancer patients treated with pembrolizumab
9463139|NCT03695926|Experimental|[18F]MNI-1054|To measure blood metabolites, dynamic uptake, and washout of [18F]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.
9463140|NCT03695900|Other|Targeting SpO2 at 93-95% followed by targeting at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
9802939|NCT04785300|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).
10026283|NCT01722032|No Intervention|Control|Those schools randomized to the control arm received a safety curriculum and some child care center locations received an attention control consisting of three visits from the University of Miami Safety Van which provided parents and teachers with home, car and child seat safety information. The control group received all the same pre-post measures as the intervention arms. They also received the same incentives as the intervention arms to foster involvement and ensure retention/reduce loss to follow up.
10026284|NCT01722058|Experimental|peptide application|
10026285|NCT01722084|Experimental|Community-eùbedded reproductive health interventions|Members of communities that belonged to the intervention arm were exposed to complex interventions addressing different target groups (adolescents, parents, authorities and health providers) and focusing on various behaviours that were related to communication about sexuality, information seeking, access to health care and safe sexual intercourse.
10026286|NCT01722084|No Intervention|Community members without intervention|
9463141|NCT03695900|Other|Targeting SpO2 at 90-92% followed by targeting at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours.
9463142|NCT03695887|Experimental|Nitrous Oxide Inhalant Product|Nitrous oxide
9463143|NCT03695887|Placebo Comparator|Placebo|placebo comparator
9463144|NCT03695874||Phase 1: statistical purification|"400 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
9463145|NCT03695874||Phase 2: statistical validation|"200 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
9463146|NCT03695861|Experimental|Whole-body 18F-FDG PET-CT scan|
9463147|NCT03695835||Adenocarcinoma treated with MyVaccx|MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
9463148|NCT03695822|Experimental|Mirabegron|OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
9463149|NCT03695796|Other|Single arm|Only one arm because diagnostic study evaluating non-invasive tests using liver biopsy as reference
9463150|NCT03695770|Experimental|target population|All the target population should be included in the experimental arm
9463151|NCT03695757|Experimental|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
9463152|NCT03695757|Experimental|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
9479833|NCT03539562||Accepted Morphine Sulfate|Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.
10026287|NCT01722110|Experimental|Indomethacin Extended-Release Capsules USP 75 mg|Indomethacin Extended-Release Capsules USP 75 mg of Ipca Laboratories Limited, India
9463153|NCT03695744|Experimental|Daratumumab Bortezomib Dexamethasone|IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
9463154|NCT03695731|Experimental|Patients without Neuropathy|activation of cold induced brown adipose tissue
9463155|NCT03695731|Experimental|Patients with Neuropathy|activation of cold induced brown adipose tissue
10026288|NCT01722110|Active Comparator|Indomethacin Extended Release Capsules USP 75 mg|Indomethacin Extended Release Capsules USP 75 mg of Epic Pharma, USA.
10026289|NCT01722123|No Intervention|DLST Only|Patients will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
10026290|NCT01722123|Experimental|Contemplate only|Patients will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
9463156|NCT03695705|Other|Primary prophylaxis arm|28 Patients with decompensated cirrhosis without past history of SBP were randomised to receive Rifaximin at dose 550 mg twice daily.29 Patients with decompensated cirrhosis without past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
9463157|NCT03695705|Other|Secondary prophylaxis arm|26 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Rifaximin at dose 550 mg twice daily.33 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
10026291|NCT01722123|Experimental|Decide with advice|Patients will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, patients will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
9463158|NCT03695692|Experimental|Connective tissue massage group|Pelvic floor exercises and connective tissue massage have been applied
9463159|NCT03695692|Experimental|Control group|Pelvic floor exercises alone have been applied
9463160|NCT03695679|Experimental|Intervention group|Interactive computer-based intervention
9463161|NCT03695679|No Intervention|Control group|An one-page online information about procedures and tips of condom use with minimal intervention
9463162|NCT03695666||Cycle 1|Counted number of patients booked into clinic. No individual patient data collected.
9463163|NCT03695666||Cycle 2|Counted number of patients booked into clinic. No individual patient data collected.
10026292|NCT01722123|Experimental|Decide without advice|Patients will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
10026293|NCT01722136|Experimental|Low Dosage|Exercise dose of 8kcal/kg/week
9463164|NCT03695653|Active Comparator|Drink Tracking (MA) Condition|Ps will receive weekly mobile assessment trick tracking described above for six months in addition to the guidelines on safe drinking.
9463165|NCT03695653|Experimental|TA Intervention|The TA intervention is tailored but will adapt over time too
9463166|NCT03695653|Experimental|Tailored Content Only (TO)|The TO treatment arm includes tailored text messages sent at 6pm daily based on the baseline assessment.
9463167|NCT03695640|Active Comparator|Group L|continuous femoral nerve block with levobupivacaine
9463168|NCT03695640|Experimental|Group LM|continuous femoral nerve block with levobupivacaine and magnesium sulfate
9463169|NCT03695627|Experimental|Meditation Group|Participants in the meditation group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks
9463170|NCT03695627|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
9463171|NCT03695614|Experimental|Cognitive Remediation|CR is a form of group therapy that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. CR is administered in groups consisting of 2-8 participants and one or two therapists. The CR groups meet twice per week for two hours per session over twelve weeks, for a total of 24 sessions.
9463172|NCT03695601||HeartCare|Diagnostic Test: Heart Care 2300 patients managed with HeartCare (AlloMap® and AlloSure-Heart® )
9463173|NCT03695601||Control|A historical control group will be matched to the estimated 1150 HeartCare group patients who complete at least two years of HeartCare surveillance use and inclusive of year 3 post-transplant clinical follow-up for outcome. The criteria for the matched controls will be based on allograft donor type, age, gender, ethnicity/race, and other clinical factors. Propensity scores will be used to perform the matching.
9463174|NCT03695588|Active Comparator|Quadratus lumborum block|Bilateral posterior QLB with 20ml 0.25% L-Bupivacaine.
9463175|NCT03695588|Sham Comparator|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle. Patient blinded due to residual spinal anaesthetic block.
9463176|NCT03695575|Other|Study sample|A repeated-measures model will be used. This means that participants in a single arm will be tested in all conditions. Speech recognition and listening effort outcomes will be measured in two conditions: with and without a bone-conduction headset.
9463177|NCT03695562|Experimental|implant placement using sequential drilling|patient with vitamin D deficiency using sequential drilling technique
9463178|NCT03695562|Active Comparator|implant placement using single drilling|Patient with vitamin D deficiency using single drilling technique
9463179|NCT03695549|Active Comparator|intervention|CAF+ APRF
10026294|NCT01722136|Experimental|High Dosage|Exercise dose 14kcal/kg/week
10026295|NCT01722149|Experimental|Adoptive Transfer of re-directed T cells|Adoptive Transfer of re-directed FAP specific T cells in the pleural effusion
9463180|NCT03695549|Active Comparator|control|CAF+SCTG
10026296|NCT01722175|Experimental|Arm I (ALPPS)|Patients undergo Associating Liver Partition with Portal Vein Ligation (ALPPS) step 1 surgery on day 0 and step 2 surgery 7-14 days later, based on patient's liver size.
9463181|NCT03695536||ultrasound use during resuscitation|The group with ultrasound integrated into the resuscitation efforts.
10026297|NCT01722175|Active Comparator|Arm II (PVO)|Patients undergo portal vein occlusion (PVO) step 1 on day 0 and step 2 surgery 6-8 weeks later, based on patient's liver size.
9463182|NCT03695536||no ultrasound use during resuscitation|The group without ultrasound integrated into the resuscitation efforts.
9463183|NCT03695523|Experimental|PLAY (PhysicaL ActivitY) Policy Intervention|The childcare physical activity policy will be adopted for 8 weeks within participating toddler and preschool classrooms of facilities allocated to the experimental group.
9463184|NCT03695523|No Intervention|Control group|Childcare centres will maintain their typical daily programming and standard of care for the duration of the 8-week intervention period.
9463185|NCT03695497|Experimental|Direct anterior approach|total hip arthroplasty with direct anterior approach
9463186|NCT03695497|Experimental|Direct Lateral Approach|total hip arthroplasty with direct lateral approach
9463187|NCT03695458|Placebo Comparator|Placebo-Control|Photobiomodulation Therapy with the placebo program will be applied in both legs.
9463188|NCT03695458|Active Comparator|irradiation effect Local|Photobiomodulation Therapy with the active irradiation will be applied on the exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the non-exercised leg.
10026298|NCT01722188||Optim Leads|
10026299|NCT01722201|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
10026300|NCT01722201|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
10026301|NCT01722214|Experimental|Group Adalimumab|A total of 53 patients with moderate to severe psoriasis will randomized in the adalimumab group. At Day 0 patients will receive adalimumab. It will be administered sub-cutaneously as described in the Canadian product monograph (80mg followed by 40mg at Week 1 and 40mg every other week). At Week 16, all patients will received two injections of placebo. As of Week 17, patients randomized to the adalimumab group will receive 40 mg adalimumab every other week until Week 51.
10026302|NCT01722214|Placebo Comparator|Placebo Group|A total of 53 patients with moderate to severe psoriasis will be randomized in the placebo group. At Day 0 these patients will receive the placebo. It will be administered sub-cutaneously as described in the Canadian product monograph of adalimumab. At Week 16, all these patients will received two injections of adalimumab. As of Week 17, patients randomized to the placebo group will receive 40 mg adalimumab every other week until Week 67.
10026303|NCT01722227|Active Comparator|Liraglutide 0.6mg|Daily Injection
10026304|NCT01722227|Placebo Comparator|Placebo|Daily Injection
10026305|NCT01722240|Active Comparator|Liraglutide 1.8mg|Daily Injection
10026306|NCT01722240|Placebo Comparator|Placebo|Daily Injection
10026307|NCT01722253||placebo, electroacupuncture|"Electroacupuncture before and after surgery (40min and 60 min respectively) with frequency 2 Hz, and 'frequency scanning mode'.~Placebo electroacupuncture, in which the needles are secured (without penetrating the skin) and connected to the electrical device, which is not functional."
10026308|NCT01722279||Bariatric surgery patients, at least 5 years post-surgery|Survey participants had bariatric surgery at the St. Vincent Bariatric Center of Excellence at least 5 years before completing survey.
10026309|NCT01722305|Experimental|Treatment (pomalidomide, dexamethasone)|Patients receive pomalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10026310|NCT01722344|Experimental|Individual Placement and Support (IPS)|
10026311|NCT01722344|Experimental|IPS plus|Individual Placement and Support plus cognitive remediation and work-related social skills training
10026312|NCT01722344|No Intervention|Standard intervention|
10026313|NCT01722357|Experimental|Pedometer + Exercise Counseling|
10026314|NCT01722357|Experimental|Pedometer|
10026315|NCT01722357|No Intervention|Usual Care|"Self-help information provided on physical activity (WIN:Weight Control Network Active At Any Size provided by National Institute of Diabetes and Digestive and Kidney Diseases, 2006)."
10026316|NCT01722370|Placebo Comparator|Medical air equivalent|Oxygen-nitrogen mix equivalent to medical air when inhaled from a cylinder at 2l/min
10026317|NCT01722370|Experimental|Oxygen|Ambulatory oxygen delivered at 2l/min on any activity performed by the patient, using a blinded cylinder
10026318|NCT01722383||Chronic kidney disease|Stages 3-5 chronic kidney disease (pre-dialysis)
10026319|NCT01722396|Experimental|Vitamin D|
10026320|NCT01722409|No Intervention|sevoflurane and saline infusion|After induction of general anesthesia, Group S received a placebo infusion of normal saline.
10026321|NCT01722409|Experimental|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
10026322|NCT01722409|Experimental|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
10026323|NCT01722422|Placebo Comparator|normoxia and isotonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
10026324|NCT01722422|Active Comparator|normoxia and 3% hypertonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days.
10026325|NCT01722422|Active Comparator|hyperoxia and isotonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with isotonic saline during 3 days."
10026326|NCT01722422|Active Comparator|hyperoxia and 3% hypertonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
10026327|NCT01722448|Experimental|Choline|Phosphatidyl choline
10026328|NCT01722448|Placebo Comparator|Placebo|Vegetable oil
10026329|NCT01722461|Experimental|Active treatment|Ulthera System treatment
9463189|NCT03695458|Active Comparator|irradiation effect Systemic|Photobiomodulation Therapy with the active program will be applied on non-exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the exercised leg.
10026330|NCT01722461|Sham Comparator|Sham treatment|Ulthera System delivering no ultrasound energy
10026331|NCT01722474|Experimental|ASI Device|Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
10026332|NCT01722500||10 year old children|500 children with mean age 10.5 years from each of 12 countries
10026333|NCT01722513|Experimental|Alprostadil, Control|Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography
10026334|NCT01722526|Experimental|Recombinant human acid sphingomyelinase|Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.
10026335|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine|"Sulfadoxine-Pyrimethamine every Four months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
10026336|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine+Piperaquine|"Sulfadoxine-Pyrimethamine every 4 months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Piperaquine every four months Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.~Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
10026337|NCT01722539|Active Comparator|Control|"Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
10026338|NCT01722565|Experimental|Mesh Group|Patients receiving conventional sigmoid end colostomy plus a preperitoneal lightweight mesh Physiomesh® by laparoscopic procedure
10026339|NCT01722565|No Intervention|Control Group|Patients receiving conventional sigmoid end colostomy by laparoscopic procedure, without mesh
10026340|NCT01722578|Experimental|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
10026341|NCT01722578|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
10026342|NCT01722591|Experimental|Cardiapex device|Use of the Cardiapex device in the context of transapical TAVI procedures
10026343|NCT01722617|No Intervention|DAS 28|Patients in this group will be asked to fill basic questionnaires, but without the FLARE questionnaires.
10026344|NCT01722617|Active Comparator|DAS 28 + FLARE questionnaires|Patients in this group will be asked to fill basic questionnaires and FLARE questionnaires.
10026345|NCT01722617|Active Comparator|DAS 28+FLARE + information to doctor|Patients in this group will fill basic and FLARE questionnaires which then will be transmitted to physician.
10026346|NCT01722630|No Intervention|control|Patients received intravenously saline solution at 5 ml/Kg/h
10026347|NCT01722630|Experimental|dopamine|Patients received intravenously saline solution at 5 ml/Kg/h and dopamine at 3 mcg/Kg/min
10026348|NCT01722630|No Intervention|crystalloids|Patients received intravenously saline solution at 10 ml/Kg/h
10026349|NCT01722656|Other|Aflibercept|All subjects will receive aflibercept
10026350|NCT01722682|Active Comparator|A: intraportal islet infusion|Patients will received islet into the liver through the portal venous circulation (standard procedure)
10026351|NCT01722682|Experimental|B: intra BM islet infusion|Patients will received an intra BM islet infusion at the level of the iliac crest. The direct intra BM administration will be performed following the same procedures that our institution utilizes for administration of cord-blood cells in patients with acute leukemia (Lancet Oncol. 2008;9:831). The procedure is easy and reproducible: a standard needle for BM aspiration is inserted in the iliac crest and cells are gently infused.
10036735|NCT01818440|Experimental|B|Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy
10036736|NCT01818453|Active Comparator|Computerized self-help program for depression|Participants will have access to a computerized self-help program for depression, called deprexis, for 8 weeks.
10036737|NCT01818453|No Intervention|Wait List Control|"Participants randomly assigned to a wait list control condition will wait 8 weeks after assignment before they can access the deprexis program."
10036738|NCT01818479|Experimental|All participants|
9463190|NCT03695445||Peripheral Norepinephrine|Patients who will undergo surgery with need for vasopressor support.
9463191|NCT03695432|Experimental|Vaccine|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
9463192|NCT03695432|Experimental|Probiotic|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic
10026352|NCT01722695|Other|Revaclear followed by FX|
9463193|NCT03695432|Placebo Comparator|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
9463194|NCT03695432|Placebo Comparator|Placebo probiotic|capsul
9463195|NCT03695354|Experimental|Whole body vibration plus conventional therapy group|conventional therapy + whole body vibration training for 40 minutes per day, five days per week for two-week period.
9463196|NCT03695354|Active Comparator|conventional training group|conventional therapy (passive range of motion exercise and walking exercise) for 40 minutes per day, five days per week for two-week period.
9463197|NCT03695341||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
9463198|NCT03695341||Everolimus plus Exemestane|Everolimys 10 mg or 5 mg daily; Exemestane 25mg per day
9463199|NCT03695328||physical activity level|Children categorized either in the group with moderate to vigorous physical activity or in the group with low physical activity according the accelerometer's measures
10026353|NCT01722695|Other|FX followed by Revaclear|
10026354|NCT01722708|Experimental|clindamycin|
10026355|NCT01722708|Experimental|metronidazole|
9463200|NCT03695328||dietary intake|Childrens' 24th dietary recalls for 7 days analyzed for protein, calcium, vitamin D and phosphorus intake and they categorized according the RDAs above or below them.
9463201|NCT03695315||OSA with hypoxia|People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure
9463202|NCT03695315||OSA without hypoxia|People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure
9463203|NCT03695289|Experimental|iOTA-SMI|Participants randomized to iOTA-SMI arm will participate in a 16 week interactive obesity treatment approach (iOTA) program approach.
9463204|NCT03695289|Active Comparator|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly in-person health coaching visits for 16 weeks.
9463205|NCT03695276|Experimental|PuSHCon model|A health coach will contact patients with poorly controlled asthma or COPD. The health coach will gather information from the patient and medical record and review the case with a pulmonary specialist. The specialist will provide recommendations to the primary care clinician based on the case review; the specialist may request an in-person patient visit if needed. The health coach will follow up with the primary care clinician and will support implementation of recommendations that the the primary care clinician accepts,
9463206|NCT03695276|Active Comparator|Usual care|Patients with poorly controlled asthma or COPD will receive the standard of care, which usually means management within primary care. The study team will provide in-service sessions on COPD and asthma guidelines to primary care clinicians in both arms. As in standard practice, a primary care clinician may refer a patient for specialty consultation or diagnostic testing at any time.
10026356|NCT01722747|Experimental|Intervention Condition|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
10026357|NCT01722747|No Intervention|Delayed Intervention Control condition|Receives abbreviated 3-month delayed intervention after final data collection time point
10026358|NCT01722760||Term and preterm infants|Term and preterm infants
10026359|NCT01722773|Active Comparator|Bipap|Bipap
10026360|NCT01722773|No Intervention|Standard of care|No intervention
10026361|NCT01722786||DOA|"Expected number of patients estimated by study duration~N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding~N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical intervention"
10026362|NCT01722786||VKA|"Expected number of patients estimated by study duration~N= 90 treated with vitamin K antagonists (VKA) with acute bleeding~N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention"
10026363|NCT01722799|Experimental|Drug elluting Balloon (DEB)|Is a coronary dilating device with Paclitaxel ® drug delivery, for dilatation and provisional spot bare metal stenting (BMS).
10026364|NCT01722799|Active Comparator|Drug elluting coronary stent (DES)|The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm.
10026365|NCT01722812|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion on left bodyside), Cromoglicate (on a lesion on right bodyside)
10026366|NCT01722812|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion on right bodyside), Cromoglicate (on a lesion on left bodyside)
10026367|NCT01722825|Experimental|LY2157299|80 up to 150 milligrams of LY2157299 administered orally, twice daily for 14 days, followed by 14 days with no study drug (2 weeks on/2 weeks off schedule) for at least two 28 day cycles. Participants receiving clinical benefit may continue receiving treatment until discontinuation criterion is met.
9463207|NCT03695263|Experimental|N-of-1 Trial|Multiple crossovers between one of the available intervention options (mindfulness meditation, gratitude journaling, physical activity, laughter therapy, or random acts of kindness) and usual activities
9463208|NCT03695224||Group A|Subjects with normal topological perception
9463209|NCT03695224||Group B|Subjects with abnormal topological perception
9463210|NCT03695211|Active Comparator|LM group|LM group use conventional landmark technique, which selects the midpoint of the posterior border of the sternocleidomastoid muscle as the puncture point of superficial cervical plexus block
9463211|NCT03695211|Experimental|GAN Group|This group firstly locate the superficial cervical plexus by ultrasound scanning of the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle (GAN Point). GAN Group apply the precise block technique, selects the GAN Point as the puncture point of superficial cervical plexus block
9463212|NCT03695198|Experimental|LY3361237 - Subcutaneous (SC)|LY3361237 administered SC
9463213|NCT03695198|Placebo Comparator|Placebo - SC|Placebo administered SC
9463214|NCT03695198|Experimental|LY3361237 - Intravenous (IV)|LY3361237 administered IV
9463215|NCT03695198|Placebo Comparator|Placebo - IV|Placebo administered IV
9463216|NCT03695133|Experimental|intervention group|"Group-based interventions Group-based interventions include physical activity, sightseeing, picnics, theater, cinema, group educations.~Individual interventions Individual interventions include interventions in the Omaha System Nursing Interventions Scheme that is specific to health problems of elderly women."
9463217|NCT03695133|No Intervention|control group|The control group will not take any intervention, the post-tests will be collected at the end of 12 weeks.
9463218|NCT03695120|No Intervention|Full Dose ACEI/ARB or Home Dose Group|This group will receive the full dose of ACEI/ARBs.
9463219|NCT03695120|Active Comparator|No ACEI/ARB Group|This group will not receive the full dose of ACEI/ARBs for the first 72 hours of hospitalization.
9463220|NCT03695107||XBDP1-|
9463221|NCT03695107||XBDP2-|
9463222|NCT03695055|Experimental|Arm 1|Rituximab maintenance
10026368|NCT01722838|Experimental|B-ME intervention|Men will receive behavioral HIV prevention intervention, B-ME.
10026369|NCT01722838|No Intervention|Control Arm|Men in this arm will receive monthly text or telephone voice messages relaying general health messages.
9463223|NCT03695055|Active Comparator|Arm 2|DPP/DCEP-G alternation regimen
9463224|NCT03695055|No Intervention|Arm 3|
9463225|NCT03695042|Experimental|BFR THEN without BFR|Will perform exercises with BFR at the first visit and without BFR at the second visit
9463226|NCT03695042|Experimental|Without BFR THEN with BFR|Will perform exercises without BFR at the first visit and with BFR at the second visit
9463227|NCT03695029|Experimental|treatment group|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
10026370|NCT01722903||Stage IV colorectal cancer|CTCs will be drawn during liver and/or lung metastasectomy for colorectal cancer
10026371|NCT01722942|Active Comparator|ICD group|ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.
10026372|NCT01722942|Active Comparator|Amiodarone Group|"Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen:~Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis;~After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted."
10026373|NCT01722955|Experimental|Pre-warmed fluids|Pre-warmed fluids will be prepared for 8hous in 41℃ set hot cabinet.
10026374|NCT01722955|Experimental|Room temperature fluids|Room temperature fluids will be stored at ambient temperature.
10026375|NCT01722968|Active Comparator|Arm A|Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly.
9463228|NCT03695029|No Intervention|control group|control group receive no drug, only follow-up
9463229|NCT03695016|Experimental|Immediate Intervention|Participants will receive the ActiveGOALS 13 week, online self-directed intervention for increasing aerobic physical activity and decreasing time spent sitting. The intervention is based on social-cognitive theory models of behavior changes and utilizes barrier recognition, problem solving, and monitoring of behavior to initiate behavior change. They will also receive weekly feedback from a coach and be provided with online, paper, and wearable tracking devices. They will also be provided with links to tools that support physical activity.
9463230|NCT03695016|Other|Wait-listed Control|This group will receive a monthly newsletter with general health advice during the wait period (3 months). After the three month follow-up visit/ collection of outcomes they will be offered the ActiveGOALS intervention in its entirety.
9463231|NCT03695003|Active Comparator|600 mg sage/polyphenol combination|600 mg of this sage/polyphenol combination will be consumed, via capsule, per day for 29 days.
9463232|NCT03695003|Placebo Comparator|Placebo|The same number of aesthetically similar capsules will be consumed per day for 29 days.
9463233|NCT03694990||Short-term|Patients will be scheduled for PO follow-up visits 2 weeks, and 8 weeks after surgery.
9463234|NCT03694990||Intermediate|Patients will be scheduled for PO follow-up visits 4 weeks, and 8 weeks after surgery.
9463235|NCT03694990||Long-term|Patients will be scheduled for PO follow-up visits 8 weeks after surgery.
9463236|NCT03694977|Experimental|MCS110/PDR001 combination|
9463237|NCT03694964|Experimental|Supplementation with Citrulline|Patients will receive citrulline (ProteoCIT®) 10 mg by day during 45 days
9463238|NCT03694964|Placebo Comparator|Placebo|Patients will receive placebo (one tablet by day) during 45 days
9463239|NCT03694951|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of reducing their daily sedentary behaviour to <7 hours per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for reducing their daily sedentary behaviour. Strategies may include: setting an alarm while studying to break up sedentary behaviour, to stand rather than sit on transit, and/or to achieve an active step profile (i.e., ≥10,000 steps a day) through pedometer self-monitoring.
9463240|NCT03694951|No Intervention|Control Group|The control group will not receive any behavioural intervention.
9463241|NCT03694912||Aggressive RCC Group|RCC with synchronous metastasis, recurrence, or cancer-specific death
9463242|NCT03694912||Non-aggressive RCC Group|RCC without synchronous metastasis, recurrence, or cancer-specific death
9463243|NCT03694899|Experimental|one|acetaminophen 650 mg three times/day ibuprofen 600 mg three times/day opioid dose based on use in hospital day prior to discharge
9479834|NCT03539562||Declined Morphine Sulfate|Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.
10026376|NCT01722968|Active Comparator|Arm B|Arm B: Paclitaxel 80mg/m2 iv weekly.
10036739|NCT01818505||Gouty arthritis|Patient with gouty arthritis
10036740|NCT01818505||Asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia
9463244|NCT03694886|Active Comparator|Caffeine with small sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
9463245|NCT03694886|Active Comparator|Caffeine with large sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 5 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
9463246|NCT03694886|Placebo Comparator|No caffeine with small sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
9463247|NCT03694886|Placebo Comparator|No caffeine with large sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
9463248|NCT03694873|Experimental|tramadol|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
9463249|NCT03694873|Active Comparator|celecoxib|one tablet of Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
10026377|NCT01722981|Active Comparator|Direct laryngoscopy|Performing percutaneous tracheostomy as accepted in our institute: By placing the tube higher up near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
10026378|NCT01722981|Active Comparator|Real time sonography|"Percutaneous tracheostomy will be guided by real time sonography (with the visualization of the needle path) using acoustic shadows of the cricoid and the tracheal rings.~In both methods, in order to identify the anatomic location of the needle prick- after passing the guide wire, the front elevation will be verified by optical means, which will be drawn out immediately afterwards."
9463250|NCT03694847||Asthma with CRSwNP|Asthmatic patients with a diagnosis of CRSwNP
9463251|NCT03694847||Asthma without CRSwNP|Asthmatic patients without a diagnosis of CRSwNP
9463252|NCT03694808|Active Comparator|Fluad Vaccine|A single adjuvanted dose (AD) intramuscular injection
9463253|NCT03694808|Active Comparator|Fluzone Vaccine|A single high dose (HD) intramuscular injection
9463254|NCT03694782||Experimental group|Gardeners starting gardening in a community garden in Montpellier (France)
9802940|NCT04778904|Experimental|Group 1 (MVA-HBV)|Day 0: MVA-HBV 1 x 10^8 pfu IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection
10026379|NCT01722981|Active Comparator|Bronchoscopy|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
10026380|NCT01723007|Experimental|Other: Apple|Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
10026381|NCT01723007|Active Comparator|Other: oatmeal cookies|A another group with nineteen women were asked to ingest three oatmeal cookies a day, approximately 60g and similar caloric content to experimental group (approximately 120 kcal) between meals (breakfast, lunch and dinner).
10026382|NCT01723007|Active Comparator|Other: Pear|Women were supplemented with pear. Sixteen women were asked to ingest daily three pears (approximately 120 kcal) between meals daily (breakfast, lunch and dinner).
9463255|NCT03694782||Control Group|Volunteers living in the same neighborhoods but with no experience in community gardening.
9463256|NCT03694769||All participants|Semi-structured interview and drop attack diary
9463257|NCT03694743|Experimental|2Shape rotary system|root canal preparation using 2Shape rotary system in mandibular molars with symptomatic pulpitis
9463258|NCT03694743|Active Comparator|Protaper Next rotary system|root canal preparation using Protaper Next rotary system comparing to 2Shape rotary system in mandibular molars with symptomatic pulpitis
9463259|NCT03694730|Experimental|Pain-guided Activity Modification|Participants in the Pain guided Activity Modification group will receive an exercise program consisting of progressive patellar tendon loading exercises Outside of physical therapy treatment, these participants will modify activity based on the Pain-Monitoring Model.
10026383|NCT01723020|Experimental|AMG 232|AMG 232 is an anti-cancer agent.
10026384|NCT01723033||EEG acquisition|15 PTSD patients and 15 OCD patients who will, while wearing a net of electrodes for EEG acquisition on their heads, perform three error detection tasks.
10026385|NCT01723033||Control|Previously collected healthy student's data
10026386|NCT01723046|Experimental|Training with the device|Training with new upper limb robot assisted therapy device
10026387|NCT01723046|No Intervention|Control group|The control group is treated with conventional therapy.
10026388|NCT01723059|Other|Standard triple therapy|Gold standard for management of H pylori is amoxicillin 1 gm twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 10 days.
10026389|NCT01723059|Active Comparator|Sequential Therapy|Amoxicillin 1 gm twice daily and omeprazole 20 mg twice daily for 5 days followed by metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 5 days.
10026390|NCT01723085||Open myomectomy|All patients belong to the same group Description includes the surgical technique
10026391|NCT01723098|No Intervention|Control|Sedentary pregnant women
10026392|NCT01723098|Experimental|Exercise group|
10026393|NCT01723111||Peritoneal dialysis|start PD
10026394|NCT01723111||Hemodialysis|start HD
10036741|NCT01818505||OA without hyperuricemia|Patient of osteoarthritis but without hyperuricemia and gout
10036742|NCT01818544|Experimental|BAY85-8501|
10026395|NCT01723124|Experimental|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
10026396|NCT01723137||In pain|Patients who report pain greater than or equal to 3 out of 10 are eligible for this study.
9463260|NCT03694730|Active Comparator|Pain-free Activity Modification|Participants in the Pain-free Activity Modification group will receive an identical exercise program to the Pain-guided Activity Modification group. However, participants will not be allowed to participate in activities that cause patellar tendon pain or excessively load the patellar tendon (e.g. jumping) outside of physical therapy treatment.
9463261|NCT03694717||Patients|The patients will receive a 500 ml fluid expansion over a standardized 10 minutes period
9463262|NCT03694704|Experimental|CI with FineHearing Strategy|cochlear implant with FineHearing strategy
9463263|NCT03694691|Experimental|Biopsy|Biopsies taken at protocol specified time points
9463264|NCT03694678|Experimental|Recovering Together|Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.
9463265|NCT03694678|No Intervention|Health Education|Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.
9463266|NCT03694665|Other|Morbidly anesthetized obese|Morbidly obese patients undergoing bariatric surgery (single-arm study) will receive a Lung recruitment maneuver to treat atelectasis..
9463267|NCT03694652|Experimental|PACE+DApp|Participants in this group will receive combined intervention and a mobile phone app.
9463268|NCT03694652|Active Comparator|PACE+Dface-to-face|Participants in this group will receive combined intervention and in person/phone communication.
9463269|NCT03694639|No Intervention|Pregabaline group|where patients received pregabaline 150 mg twice daily.
9463270|NCT03694639|Active Comparator|Pregabaline plus ganglion impar block group|where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.
9463271|NCT03694626|Active Comparator|Healthy Control subjects|
9463272|NCT03694626|Active Comparator|TBI Patients without photosensitivity|
9463273|NCT03694626|Active Comparator|Migraine patients without photosensitivity|
9463274|NCT03694626|Active Comparator|Migraine patients with photosensitivity|
9463275|NCT03694626|Active Comparator|TBI patients with photosensitivity|
9463276|NCT03694600||men or women between 21-84|Multi-analyte blood test screening alone and as combination with multi-analyte Test and Ultrasound in subjects diagnosed with liver cirrhosis
9463277|NCT03694587|Active Comparator|Test IMP|
9463278|NCT03694587|Active Comparator|Reference IMP|
9463279|NCT03694574|Other|Low schizotypy|Schizotypy score < 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
10026397|NCT01723150|Experimental|Oral antibiotics|The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
10026398|NCT01723150|Active Comparator|Intravenous antibiotics|The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
10026399|NCT01723176||Patients in Cardiopulmonary Failure|patients in cardiopulmonary failure
10026400|NCT01723189||Central Apnoeas Patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of central apnoea (central apnoea index> 10 / h, or Cheyne-Stokes breathing for more than 30% of total sleep time or mixed apneas with central apnoeas> 50% of total apneas)
10026401|NCT01723189||Obstructive apnoea patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of obstructive sleep apnea (apnea-hypopnea index> 20 / h)
10026402|NCT01723189||No SDB patients|• 30 patients diagnosed with TIA / stroke within 7 days of admission and no evidence of sleep respiratory disorders at polysomnography
10026403|NCT01723189||Healthy controls|• 30 healthy controls matched for age, sex, race and BMI.
10026404|NCT01723215|Active Comparator|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
10026405|NCT01723215|Active Comparator|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
10026406|NCT01723215|No Intervention|Control|Control: will not receive any intervention
10026407|NCT01723215|Placebo Comparator|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
10026408|NCT01723241|Experimental|XAF5|
10026409|NCT01723241|Placebo Comparator|Placebo|
10026410|NCT01723267|Active Comparator|3D follicles assessment|During IVF treatment all ultrasound examinations will use 3D- SonoAVC technology. Timing of hCG injection and oocyte collection will be based on follicle volume and 3D-volume based diameter.
10026411|NCT01723267|Active Comparator|2D follicles assessment|During IVF treatment all ultrasound examinations will use standard 2D ultrasound. Timing of hCG injection and oocyte collection will be based on follicle diameter.
10026412|NCT01723280||80% oxygen group|
10026413|NCT01723280||30% oxygen group|
10026414|NCT01723293|No Intervention|Control|Sedentary pregnant women
10026415|NCT01723293|Experimental|Exercise group|
10026416|NCT01723306|Experimental|2nd Generation Designer T Cells|All participants will receive gene modified T cells, with concomitant IL2 for 30 days post infusion.
10026417|NCT01723319|Experimental|1|deep TMS treatment
10026418|NCT01723319|Sham Comparator|2|inactive treatment
10026419|NCT01723332|Experimental|Intervention|Clinical based educational and self management intervention.
9463280|NCT03694574|Other|High schizotypy|Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
9463281|NCT03694561||Late-Onset Pompe disease|Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS
9463282|NCT03694535|Experimental|Bladder wall thermochemotherapy|Mitomycin-C application with bladder wall thermochemotherapy system after TUR bladder tumor in intermediate and high risk non muscle invasive bladder cancer
9463283|NCT03694522|Active Comparator|bemarituzumab (FPA144)+mFOLFOX6|"15mg/kg of bemarituzumab (FPA144) given intravenously and mFOLFOX6 administered after the end of the bemarituzumab (FPA144) infusion~*Cycle 1 will consist of a one-time dose of 7.5 mg/kg of bemarituzumab (FPA144) given intravenously on Day 8~Treatment is repeated every 2 weeks."
9463284|NCT03694522|Placebo Comparator|Placebo+mFOLFOX6|"Placebo given intravenously and mFOLFOX6 administered after the end of the placebo infusion~* Cycle 1 will consist of a one-time dose of placebo given intravenously on Day 8~Treatment is repeated every 2 weeks."
9463285|NCT03694509|Experimental|Breakfast tea with full fat milk|Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
9463286|NCT03694509|Active Comparator|Water|Water 250ml
9463287|NCT03694496|Experimental|peer-led theory-based intervention group|2-6 students (depending on the headcount of the grade 2 students of the school) will be selected as peer leaders and they will receive oral health training first. After being trained and qualified, they will deliver oral health talks and workshops to their peers. The peer leaders will be requested to conduct six activities during 6 months, including health talks, workshops, information leaflets, etc.
9463288|NCT03694496|No Intervention|Control group|Participants in the control group will continue their present practice, and no additional interventions will be given except oral health pamphlets delivery. We will record their present practice in detail. As the control group is in different schools, so they will have very low opportunity to get access to the peer-led activities conducted in the intervention group. Contamination will be quite minimum.
9463289|NCT03694444|Active Comparator|AMY-101 treatment|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
9463290|NCT03694444|Placebo Comparator|Placebo|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
9463291|NCT03694431|Active Comparator|Standard HBPC|Patients and caregivers in standard HBPC will continue to receive usual care from the palliative care team which includes home visits
9463292|NCT03694431|Experimental|Tech-supported HBPC|Patients and caregivers in tech-supported HBPC will receive synchronous video visits with a provider (physician or nurse practitioner) while the nurse is in the patient's home. Home visits by the palliative care team will be determined based on patients/caregivers' needs.
9463293|NCT03694379|Experimental|Apneic Oxygenation|Participants receiving apneic oxygenation
9463294|NCT03694379|No Intervention|No Apneic Oxygenation|Participants not receiving apneic oxygenation
9463295|NCT03694366||Five facilities in Bassar District|Estimated population of 34,676 served by five public sector facilities in Bassar District.
9463296|NCT03694366||Seven facilities in Binah District|Estimated population of 31,027 served by seven public sector facilities in Binah District.
9463297|NCT03694366||Four facilities in Dankpen District|Estimated total population of 40,165 served by four public sector facilities in Dankpen District.
9463298|NCT03694366||Five facilities in Kéran District|Estimated total population of 31,866 served by five public sector facilities in Kéran District.
9463299|NCT03694340|Other|Re-programming of cochlear implant|The cochlear implant is programmed with a new MAP based on behavioral measurements of T- and C-levels and used by the participant for 4 months before follow up.
10026420|NCT01723332|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
10026421|NCT01723345|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
10026422|NCT01723345|No Intervention|control|just receive standard treatment
9463300|NCT03694314|Experimental|Omega-3 fatty acids|Both the mother and child will receive omega-3 supplements in the form of a 200 mL drink to be taken once daily. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
9802941|NCT04778904|Experimental|Group 2 (ChAdOx1-HBV, MVA-HBV)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection
9802942|NCT04778904|Experimental|Group 3 (ChAdOx1-HBV, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
9802943|NCT04778904|Experimental|Group 4 (ChAdOx1-HBV and nivolumab, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection + nivolumab 0.3 mg/kg IV infusion Day 28: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
10026423|NCT01723358|Experimental|Neuromuscular electrical stimulation (NMES)|
10026424|NCT01723371|Experimental|Carvedilol|
10026425|NCT01723410|Experimental|Writing condition|Subjects will be asked to write about other individuals in their lives.
10026426|NCT01723410|Placebo Comparator|Writing|Subjects will be asked to write about places or objects in their lives.
10026427|NCT01723423||Expander/Implant|Patients receiving expander/implant breast reconstruction procedures.
10026428|NCT01723423||Lat Dorsi|Patients receiving latissimus dorsi breast reconstructions with or without implant.
10036743|NCT01818544|Placebo Comparator|Placebo|
10026429|NCT01723423||PTRAM|Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
10026430|NCT01723423||FTRAM|Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
10026431|NCT01723423||DIEP|Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
10026432|NCT01723423||SIEA|Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
10026433|NCT01723423||S-GAP|Patients receiving superior gluteal artery perforator breast reconstruction.
10026434|NCT01723423||I-GAP|Patients receiving inferior gluteal artery perforator breast reconstruction.
10026435|NCT01723436|No Intervention|DLST Only|Surrogates will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
10026436|NCT01723436|Experimental|Contemplate only|Surrogates will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
10026437|NCT01723436|Experimental|Decide with advice|Surrogates will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, surrogates will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
10026438|NCT01723436|Experimental|Decide without advice|Surrogates will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
9463301|NCT03694314|Placebo Comparator|Placebo|The mother and child will both receive a placebo drink to take daily, with no known effect on the brain. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
10026439|NCT01723475|Experimental|BAY2010112 (s.c.)|
10026440|NCT01723475|Experimental|BAY2010112 (c.i.v.)|
10026441|NCT01723488|Experimental|Tau diagnostic|Experimental: Tau diagnostic [F18] T808
10026442|NCT01723501|Placebo Comparator|sterile water|sterile water wipes
10026443|NCT01723501|Experimental|0.25% chlorhexidine|0.44% chlorhexidine digluconate wipes which will release 0.25% free chlorhexidine
9463302|NCT03694288|Active Comparator|Removal Group|The implant removal group will have surgery scheduled 6 months after their initial surgical fixation.
9463303|NCT03694288|No Intervention|Retention Group|The implant retention group will retain their implant for a minimum of 2 years from the time of their initial surgery.
9479835|NCT03539510|Experimental|HF-ACP Website|The HF-ACP website leads participants through 4 e-learning modules. Each module contains 3 core elements: (1) educational content which provides information and support to help patients complete the module (2) interactive tools for documenting their thoughts and progress and (3) motivational video clips that encourage behavior change by validating participants ambivalence, suggesting strategies to help participants complete the task and to encourage and reassure participants that they can do this.
9479836|NCT03539510|No Intervention|Usual Care|"The standard of care for advance care planning at our institution is the Speak Up booklet and the Power of Attorney workbook from the Attorney General's Office - Ontario. Patients randomized to the Control arm will be asked to register on a separate research portal where participants will have electronic access to both of the booklets and a link to the Speak Up online Interactive workbook. There is no specific information on HF or HF treatments. Participants in the control arm will be asked to complete the ACP using the interactive workbook. Participants in the control arm will not receive any additional communication from the research team about their progress."
9479837|NCT03539471||psychiatric resident in NTUH|
9802944|NCT04775628|Experimental|inferior glide|Inferior glide of the right humerus till no motion is visual on the imaging
9802945|NCT04771481|Experimental|metoclopramide|Metoclopramide 10mg with normal saline up to 10 ml IV slowly push in 5minutes.
10026444|NCT01723527|Experimental|Therapeutic Workplace|Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention. All phases of this intervention include employment-based drug abstinence reinforcement contingencies. Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis. Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment. Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace. Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
10026445|NCT01723527|Active Comparator|Diversion to treatment (Usual Care)|Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management. All services will be provided in the treatment clinics. There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site. In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments. As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days. It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
10026446|NCT01723540|Experimental|Minilaparotomy cholecystectomy with ultrasonic scissors|Minilaparotomy vs laparoscopy
10026447|NCT01723540|Active Comparator|Laparoscopic cholecystectomy|Minilaparotomy vs laparoscopy
10026448|NCT01723553|Experimental|PiB positron emission tomography (PET)|All subjects will receive PET imaging with C-11 PiB on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
10026449|NCT01723592|Placebo Comparator|Placebo|30 participants in this group receive a oral lactose placebo
10036744|NCT01818557|No Intervention|Every day blood glucose testing|Patients will test their blood glucose values 4 times every day
10036745|NCT01818557|Experimental|Every other day blood glucose testing|Patients will test their blood glucose 4 times every other day
10026450|NCT01723592|Active Comparator|Probiotics|"30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:~L.rhamnosus/ LbV96 (DSM 22560)~L.jensenii /LbV 116 (DSM 22567)~L.crispatus/ Lbv88 (DSM 22566)~L.gasseri /LbV 150N (DSM 22583)"
9802946|NCT04771481|Placebo Comparator|placebo|Normal saline 10 ml IV slowly push in 5 minutes.
10026451|NCT01723605|Experimental|insitu repair|insitu repair of the uterine incision during caeserean section
9463304|NCT03694249|Experimental|Group 1 (ifetroban)|ifetroban capsule (250mg) will be taken by mouth daily.
9463305|NCT03694249|Placebo Comparator|Group 2 (placebo)|Placebo capsule (250mg) will be taken by mouth daily.
9463306|NCT03694236|Experimental|durvalumab|This study is single arm phase II study to evaluate efficacy and safety of durvalumab and chemoradiotherapy (paclitaxel and carboplatin) in treatment-naïve clinical stage II/IIIa NSCLC.
9479838|NCT03539445|Experimental|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
9479839|NCT03539445|Placebo Comparator|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
9802947|NCT04769544|Active Comparator|Medial pivot group|Device used: medial pivot total knee arthroplasty design
10026452|NCT01723605|Active Comparator|exteriorisation of the uretus|uterine closure during caeserian section with exteriorisation of the uterus
9802948|NCT04769544|Active Comparator|Conventional group|Device used: conventional total knee arthroplasty design
10026453|NCT01723618|Experimental|CRD007 10 mg|CRD007, 10 mg tablet, single dose
10026454|NCT01723618|Experimental|CRD007 25 mg|CRD007, 25 mg tablet, single dose
10026455|NCT01723618|Experimental|CRD007 40 mg|CRD007, 40 mg tablet, single dose
10026456|NCT01723631|Other|Relapsing Multiple Sclerosis- group 1|Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
10026457|NCT01723631|Other|Relapsing Multiple Sclerosis- group 2|Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
10026458|NCT01723631|Other|secondary progressive multiple sclerosis- Group 3|Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
10026459|NCT01723631|Other|primary progressive multiple sclerosis- group 4|Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
10026460|NCT01723631|Other|control 1|healthy volunteers
10026461|NCT01723631|Other|Control 2|Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
10026462|NCT01723631|Other|Control 3|Patients having an autoimmune pathology
10026463|NCT01723644|Other|PCT guidance|"Group of patient  Procalcitonin  where the initiation and the stop of the antibiotic treatment are made according to a strategy guided by the PCT"
10026464|NCT01723644|Other|clinical reassessment|Group of patient where the initiation and the stop of the antibiotic treatment make following on clinical criteria and paraclinic not including the PCT.
10026465|NCT01723657|Other|Risk-adapted postremission treatment.|Ara-C, G-CSF, Autologous peripheral blood stem cell transplantation, Allogeneic matched related or unrelated donor transplant, G-CSF Priming, CD34+ selection, Myeloablative or reduced intensity conditioning, Mylotarg purging before autologous PBSC transplantation.
10026466|NCT01723670|Experimental|CHF 5074 1x|oral tablet, multidose
10026467|NCT01723670|Experimental|CHF 5074 2x|oral tablet, multidose
10026468|NCT01723670|Placebo Comparator|Placebo|placebo, oral tablet, multidose
10026469|NCT01723683|Experimental|MISTCPAP group|MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP.
10026470|NCT01723683|Active Comparator|INSURE group|INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP.
10026471|NCT01723735|Experimental|Alirocumab + Ezetimibe Placebo|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
10026472|NCT01723735|Experimental|Alirocumab + Ezetimibe|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
10026473|NCT01723735|Experimental|Alirocumab + Fenofibrate|Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate
10026474|NCT01723748|Active Comparator|surgery treated|"10 patients with well-controlled acromegaly for at least 6 months after surgery alone.~Stimulated with genotropin"
10026475|NCT01723748|Active Comparator|SA treated|10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin
10026476|NCT01723774|Experimental|Arm 1: PIK3CA Wild Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
10036746|NCT01818570|Placebo Comparator|Placebo solution|A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
10026477|NCT01723774|Experimental|Arm 2: PIK3CA Mutant Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
10026478|NCT01723774|Experimental|Arm 3: Endocrine Resistant Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
10026479|NCT01723787||Infantile Spasms|Participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
10026480|NCT01723787||biological parents|Biological parents of participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
10026481|NCT01723800|Experimental|Treatment (pemetrexed, carboplatin, PI3K inhibitor BKM120)|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
10026482|NCT01723813|Experimental|Group 1 : peptides + GM-CT-01 IV|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections
9463307|NCT03694223|Experimental|Booklets|Health education delivery method: Booklet. Patients will be given 2 leaflets on the low FOMDAP diet produced by the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London. These booklets have been produced by dietitians and are commonly used in clinical practice across the UK.
9463308|NCT03694223|Experimental|Mobile application|Health education delivery method: Mobile application. Patients will be asked to download an application on their mobile phones or tablets. This application has been produced by dietitians from the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London.
9463309|NCT03694223|Active Comparator|One to one consultation with dietitian|Health education delivery method:One-to-one consultation with dietitian. Patients will attend a clinic visit for a one-to-one consultation with a dietitian. As per current clinical practice, the initial visit will last for 1 hour. During the visit, tailored information on the low FOMDAP diet will be given to match patients' individual needs. During the visit, either the leaflets (used in group 1) or the application (used in group 2) will be used to facilitate the visit. The choice of using the leaflets or the app during the visit will be based on the dietitian's judgment based on the patients' needs.
10026483|NCT01723813|Experimental|Group 2 : peptides + GM-CT-01 IV+PT|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections and Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
10026484|NCT01723852|Active Comparator|Vitamin D supplement|Vitamin D supplement according to national guidelines (10 ug/day) from 2 weeks to 2 years of age
10026485|NCT01723852|Active Comparator|Vitamin D supplement at 30 ug/day|Vitamin D supplement at 30 ug/day from 2 weeks to 2 years of age
9463310|NCT03694145||Diabetic patients w. risk of retinopathy|The 300-500 patients to be enrolled for the study are diabetic patients normally seen by the Los Angeles County Department of Health Services (LACDHS) Teleretinal Diabetic Retinopathy Screening Program and Reading Center. In addition to receiving their recommended LACDHS annual teleretinal screening, for the study, participants will receive an additional in-person eye examination.
9463311|NCT03694132|Experimental|functional MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical and mechanical stimuli of ADM proprioceptors
9463312|NCT03694132|Experimental|structural MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have diffusion MRI acquisition to evaluate their brain structures
9463313|NCT03694132|Experimental|EEG/MEG|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical stimuli of ADM proprioceptors
9463314|NCT03694119|Active Comparator|Phenelzine|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Phenelzine arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 31, then receiving Phenelzine 15mg BID plus ozanimod placebo QD from Days 32 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
9463315|NCT03694119|Placebo Comparator|Placebo|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Placebo arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
9463316|NCT03694119|Experimental|ozanimod|Following tyramine challenging in Period 1, eligible subjects randomly assigned to ozanimod arm are receiving Phenelzine placebo BID plus ozanimod 1.84mg QD from Days 11 to 38, including dose escalation days. Subjects receive second tyramine challenge from Day 39 to up to Day 49
9463317|NCT03694093||Patients with Hyperhidrosis|Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.
10026486|NCT01723865||Conventional|Patients with heart failure having an ICD-CRT implanted, followed by conventional visits.
10026487|NCT01723865||Remote Monitoring|Patients with heart failure having an ICD-CRT implanted, followed by remote monitoring.
10026488|NCT01723878||Cohort|
10026489|NCT01723891|Active Comparator|Surfolase capsule & HT-002-01|
10026490|NCT01723891|Active Comparator|HT-002-01 & Surfolase capsule|
10026491|NCT01723917|Experimental|PhytoSERM 50 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
10026492|NCT01723917|Experimental|PhytoSERM 100 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
10026493|NCT01723917|Placebo Comparator|Placebo tablet|Dietary supplement: placebo tablet to be taken once per day for 12 weeks
10026494|NCT01723943|Active Comparator|Arm I (educational booklet)|"Participants receive the What's Happening to the Woman I Love? booklet, which focuses on ways to understand and deal with marital communication and relationship issues arising from breast cancer diagnosis."
9463318|NCT03694080|Experimental|Calcium Electroporation treatment|Calcium electroporation for colorectal cancer as a preoperative treatment before elective surgery.
10026495|NCT01723943|Experimental|Arm II (Helping Her Heal program)|"Participants undergo the Helping Her Heal educational counseling program comprising 5 1-hour sessions 2 weeks apart.~SESSION I: Participants learn stress management skills and discover ways stress affects themselves and their partner.~SESSION II: Participants practice attentive listening and reduce the tendency to try to distract patients from talking about sad or difficult aspects of the cancer experience.~SESSION III: Patients learn to help their spouse talk when she is quiet or withdrawn, to add to their understanding of what she is thinking and feeling, and to add to their ways of supporting her during especially difficult times with the cancer.~SESSION IV: Participants learn strategies for physically reconnecting with spouses.~SESSION V: Participants review skills from prior sessions, identify strategies he or she will continue to use to manage their personal stress, and identify ways to maintain connection and support."
10026496|NCT01723956|Active Comparator|Arm B|LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
10026497|NCT01723956|Experimental|Arm A|Cryotherapy treatment of CIN 2/3 cervical lesions
10026498|NCT01723969||Colo-rectal cancer|Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
10026499|NCT01723982|Experimental|A. FE 200440|Barusiban (FE 200440) Solution for Injection for Subcutaneous use
10026500|NCT01723982|Placebo Comparator|B. Placebo|Placebo Solution for Injection for Subcutaneous use
10026501|NCT01723995|Experimental|low-level laser on nipples|Application of laser light from the device in direct contact with the nipple injury, equipment connected and set up at a dose of 5J/cm2 (Epoint = 0.2J/cm2) for both groups, three consecutive doses of 5J/cm2 (ETotal = 0.6J/cm2) along the entire length of the injury.
10026502|NCT01723995|Placebo Comparator|low-level laser off on nipples|Laser with modified standard operation - shutdown of InGaAIP semiconductor diode and installation of a visible red light emitting diode with optical power of 0mW (LED - Light Emitting Diode - maximum power with standard nozzle).
9463319|NCT03694067||Androgenetic alopecia patients|Two 1 mm scalp punch skin biopsy will be taken per patient
9463320|NCT03694054|Experimental|Care coordination patients, caregivers|Patients and caregivers enroll in using care coordination tool during oncology care and treatment.
9463321|NCT03694054|No Intervention|Standard of care patients, caregivers|Patients and caregivers receive oncology care and treatment.
9463322|NCT03694054|Experimental|Oncology Care Providers|Oncology care providers with patients enrolled in care coordination tool.
9463323|NCT03694041|Experimental|SAD: APX-115|Experimental: APX-115 SAD group
9463324|NCT03694041|Placebo Comparator|SAD: Placebo|Experimental: Placebo group
9463325|NCT03694041|Experimental|MAD: APX-115|Experimental: APX-115 MAD group
9463326|NCT03694041|Placebo Comparator|MAD: Placebo|Experimental: Placebo group
9463327|NCT03694041|Active Comparator|Food effect - Fasting condition|Experimental: APX-115 under fasting condition
9463328|NCT03694041|Active Comparator|Food effect - fed condition|Experimental: APX-115 under fed condition
9463329|NCT03694041|Placebo Comparator|Drug Interaction - metabolic probe|Experimental: metabolic probe
9463330|NCT03693976||Ectoin Rhinosinusitis Nasal Spray|application of 1-2 sprays of SNS01 into each nostril several times a day
9463331|NCT03693976||Xylometazoline nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
9463332|NCT03693976||Xylometazoline + Ectoin Nasal Spray|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day
9463333|NCT03693963|Other|Single Arm, treated with Serranator|Subjects treated with Serrantor
9463334|NCT03693911|Experimental|Prevention group|AcceptME- digital gamified Acceptance and Commitment Therapy prevention program
9463335|NCT03693911|No Intervention|Waitlist control|Waitlist control group
9463336|NCT03693898|Other|Persons with collagen VI defect|Observational
9463337|NCT03693885|Experimental|OCT-group|Oxytocin challenge test: Oxytocin 5 IU/500 ml Ringer® lactate will be infused at a rate of 12 ml/h and doubled every 10 min until it induced three uterine contractions per 10-min interval at which point it will stopped.
9463338|NCT03693885|No Intervention|Control|standard procedure before planned caesarean section
9463339|NCT03693872|Other|Apomorphine|Withdrawal of dopaminergic agonists at pump initiation
9463340|NCT03693872|Other|Dopaminergic Agonist + Apomorphine|Continuation of dopaminergic agonists at pump initiation
9463341|NCT03693859|Experimental|Behavioral Weight Loss + Gaming|Treatment will consist of 12-weekly, one-hour group sessions of approximately 15 participants per group. Participants will provide logs of serious gaming (intervention).
9463342|NCT03693859|Active Comparator|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks. Participants will provide logs of video segment watching (control).
10026503|NCT01724034|Experimental|Daily Lung Ultrasound|"If there is no lung sliding - evaluation for pneumothorax or mainstream intubation.~If lung ultrasound shows normal pattern - search for reversible airway obstruction or venous embolism. If the patient has COPD, non invasive ventilation must be used as mode of discontinuing mechanical ventilation.~If lung ultrasound shows intersticial syndrome - evaluate the need to negativate hydric balance before the next spontaneous breathing trial.~If findings are asymmetrical - search for new or uncontrolled infection. If there is simple pleural effusion - researchers should determine a negativation of hydric balance or perform thoracocentesis.~If there are signs of complicated pleural effusion - a new image technique should be performed as evaluated by the surgical team."
9463343|NCT03693833|Experimental|Intervention|10mg Cannabidiol (CBD) tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
9463344|NCT03693833|Placebo Comparator|Placebo|10mg Placebo Oral tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
10026504|NCT01724034|No Intervention|Control Group|
10026505|NCT01724047|Experimental|Playground Intervention|Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed 2) Waitlist treatment, where the training will begin the following school year. The initial delivery will occur for 30 minutes three times for a period of two to three weeks, then 30 minutes two times for a period of two weeks, then 30 minutes once a week for up to 16 sessions, within a period of 3 months, then a 30 minute follow up will occur 3 months later. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment, and 3-month follow-up. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
9463345|NCT03693820|Active Comparator|the infiltration group|a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline. We will administrate 5 ml lidocaine at each port site before incision, then immediately after the creation of the pneumoperitoneum, the surgeon will spray 50-75 ml of the total solution on the upper surface of the liver under the right sub-diaphragmatic space and another 50-75ml over the parietal peritoneum. The Trendelenburg position will be maintained for 2 minutes. Then 50 ml will be infiltrated in the bladder bed and pedicle after clamping of the cystic duct and artery. Infiltration will be through a laparoscopic suction needle, diameter 0.9 /330 mm (Zhejiang, China).
9463346|NCT03693820|Placebo Comparator|the control group|the same technique but the 50 ml for gallbladder infiltration will be replaced by saline.
9463347|NCT03693755|Active Comparator|In-plane Group|In this Group the femoral nerve catheter will be placed with the in-plane technique.
9463348|NCT03693755|Active Comparator|Out-of-plane Group|In this Group the femoral nerve catheter will be placed with the out-of-plane technique.
9463349|NCT03693729|Experimental|Active DLPFC during task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
10036747|NCT01818570|Active Comparator|PPC-5650|"PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days."
9463350|NCT03693729|Active Comparator|Active DLPFC after task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min after the memory and metamemory task and during a filler task.
9463351|NCT03693729|Sham Comparator|Sham DLPFC during task|Sham HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
9463352|NCT03693716|Experimental|Dynamic Anterior Stabilization|Arthroscopic Dynamic Anterior Capsular Stabilization with Trans subscapular Long Head of the Biceps Tenodesis
9463353|NCT03693703|Experimental|bi-parametric MRI|Patients will undergo axial T2-weighted and diffusion-weighted imaging (no contrast agent injection)
9463354|NCT03693703|Active Comparator|multi-parametric MRI|Patients will undergo multiparametric MRI including morphological study (T2- and T1-weighted imaging) and functional acquisitions (diffusion-weighted and dynamic contrast-enhanced imaging)
9463355|NCT03693651||Parent of a Premature infant / PP|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
9463356|NCT03693651||Parent of a baby born on time / PT|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
9463357|NCT03693638|Active Comparator|Single dose (SD)|2,5 ml total anesthetic drug dose (Bupivacaine-fentanyl) were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
9463358|NCT03693638|Active Comparator|Fractionated dose (FD)|1,5 ml of total anesthetic drug dose (Bupivacaine-fentanyl) followed by 1 ml remaining dose after 90 s interval were given
9463359|NCT03693612|Experimental|Part 1: feladilimab +tremelimumab|In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
9463360|NCT03693612|Experimental|Part 2: feladilimab +tremelimumab|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
9463361|NCT03693612|Active Comparator|Part 2: SOC|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
9463362|NCT03693599|Experimental|carbetocin|600 women received single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
9463363|NCT03693599|Active Comparator|Syntometrine|600 women received one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 micrograms of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
9463364|NCT03693573|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab in combination with bevacizumab.
9463365|NCT03693560|Experimental|vildagliptin / metformin|Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
10026506|NCT01724047|Experimental|STAT Intervention|Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. The intervention will be over a period of 6 weeks, with baseline, treatment, and a follow up visit totaling 18 weeks at the school site. Each visit is approximately 30 minutes. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
10026507|NCT01724047|No Intervention|Playground Waitlist Control|Waitlist Control
10026508|NCT01724047|No Intervention|STAT Waitlist Control|Waitlist Control
10026509|NCT01724073|Experimental|Leafy vegetable-fish sauce|one meal per day, 6 days a week, with leafy vegetable-fish sauce + tô, a local cereal-based paste
10026510|NCT01724073|Experimental|Leafy vegetable-fish/liver sauce|one meal per day, 6 days a week, 5 days with leafy vegetable-fish sauce + tô, 1 day with leafy vegetable-liver sauce + tô
10026511|NCT01724073|Experimental|Misola|one meal per day, 6 days a week, with gruel prepared with the fortified Misola flour
10026512|NCT01724073|No Intervention|no test food|control group receiving no test food
10026513|NCT01724086|Experimental|Panel 1|10 chronic HCV genotype 1a (GT1a) infected treatment-naive patients/prior relapsers who will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
9463366|NCT03693560|Experimental|glimepiride / metformin.|Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
9463367|NCT03693547|Experimental|utidelone|Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC
10026514|NCT01724086|Experimental|Panel 2 Arm 1|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
9463368|NCT03693534||Long Antagonist Protocol|Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.
9463369|NCT03693534||Long Agonist Protocol|Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.
9463370|NCT03693521|Experimental|Intervention group|Standard care at yearly check-up by diabetes-nurse in primary care. Handgrip strength measurement bilaterally. Measurement of physical activity level.
9463371|NCT03693521|Active Comparator|Control group|Standard care at yearly check-up by diabetes-nurse in primary care. Measurement of physical activity level.
9463372|NCT03693508|Experimental|Arm 1|Naive HIV patients with severe immunosuppression.
9802949|NCT04769310|Other|Patient arm|"All patients will undergo a CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
9802950|NCT04767750||HCC patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
10026515|NCT01724086|Experimental|Panel 2 Arm 2|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
9463373|NCT03693495|Experimental|ellume·lab Group A Streptococcus Test|"ellume·lab Group A Streptococcus Test~Pharyngeal samples from participants will be tested with:~ellume.lab Group A Streptococcus Test; Polymerase Chain Reaction (PCR) and bacterial culture."
10026516|NCT01724086|Experimental|Panel 3 - Arm 1|8 chronic HCV GT1a infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir + ribavirin.
10026517|NCT01724086|Experimental|Panel 3 - Arm 2|8 chronically HCV GT1b infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
9463374|NCT03693469|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during immunization.
9463375|NCT03693469|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
9463376|NCT03693456|Experimental|Responders Without Epinephrine|Subjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
9463377|NCT03693456|Experimental|Responders With Epinephrine|Subjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
9463378|NCT03693456|Experimental|Non-Responders|Subjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
9463379|NCT03693417|Active Comparator|Control|
9463380|NCT03693417|Experimental|Heat|
9463381|NCT03693404|Experimental|Spinal Anesthesia|Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
9463382|NCT03693404|Active Comparator|General Anesthesia|The control group will receive no injection into area surrounding the fracture site
10026518|NCT01724086|Experimental|Panel 4 - Arm 1|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (30 mg once daily)
10026519|NCT01724086|Experimental|Panel 4 - Arm 2|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (60 mg once daily)
10026520|NCT01724099|Experimental|Euiiyin-tang|powder type, 3 times per day before the meal, 12 weeks total
10026521|NCT01724099|Placebo Comparator|Placebo|powder type, 3 times per day before the meal, 12 weeks total
10026522|NCT01724125|Experimental|Case|Assigned a Personal Electronic Health Record
10026523|NCT01724125|Active Comparator|Control: Usual Care|Assigned to control arm, continued to receive care as usual in community. Was issued information on community health resources, but did not use research study personal health record.
9463383|NCT03693391|Experimental|Cohort 1: JNJ-64140284|Participants in cohort 1 will receive single oral dose of JNJ-64140284 at a starting dose of 0.5 milligram (mg) under fasted conditions. The dose levels of JNJ-64140284 will be escalated sequentially based on the decisions of an independent Data Review Committee (iDRC), the clinical team and the investigator. First 3 participants will also receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq). Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent positron emission tomography-computed tomography (PET-CT) scan.
9802951|NCT04767750||T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
9802952|NCT04767750||HCC & T2DM patients|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
9463384|NCT03693391|Experimental|Cohort 2: JNJ-64140284|Participants in cohort 2 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
9463385|NCT03693391|Experimental|Cohort 3: JNJ-64140284|Participants in cohort 3 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
10026524|NCT01724138|Experimental|Deferasirox|The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to <6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
9479840|NCT03539419||Patients with plaque psoriasis on apremilast|Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
10026525|NCT01724151||Healthy adults|Healthy adults, over 45 years old
10026526|NCT01724151||Mild cognitive impairment|subjects with mild cognitive impairment
10026527|NCT01724151||Alzheimer's disease|subjects with Alzheimer's disease
10026528|NCT01724164|Experimental|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
10026529|NCT01724164|Experimental|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
10026530|NCT01724164|Active Comparator|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
10026531|NCT01724164|Experimental|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
10026532|NCT01724164|Placebo Comparator|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
9802953|NCT04767750||Controls|Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
10026533|NCT01724190|Active Comparator|Vitamin D|Subjects will receive oral vitamin D supplementation, 3000 IU daily over the course of 9 months.
10026534|NCT01724190|Placebo Comparator|Placebo|Subjects will receive a placebo solution daily over the course of 9 months.
10026535|NCT01724203|Active Comparator|Lactobacillus rhamnosus|Formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20) at least three times daily for 12 weeks.
10026536|NCT01724203|Active Comparator|Bifidobacterium animalis subsp. lactis|Formula containing 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10) at least three times daily for 12 weeks.
10026537|NCT01724203|Placebo Comparator|Placebo|Placebo formula without probiotics at least three times daily for 12 weeks.
9463386|NCT03693391|Experimental|Cohort 4: JNJ-64140284|Participants in cohort 4 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
9463387|NCT03693352||Patients undergoing surgeries|Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning.
9463388|NCT03693339|Experimental|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
9463389|NCT03693326|Experimental|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
9463390|NCT03693313|Experimental|CrossFit KAMP Group 1|14 weeks of CrossFit Kids exercise program
9463391|NCT03693313|Active Comparator|CrossFit KAMP Wait-list Group|Waitlist group that waits 14 weeks while group 1 does exercise program. After first 14 weeks will then participate in 14 weeks of CrossFit Kids exercise program
9463392|NCT03693287|Active Comparator|Personalized-Parenteral Nutrition (P-PN)|"These patients will receive personalized parenteral nutrition (PN) as it is customary in the participating centers.~Dosing range: glucose from 9 to 13 g/kg/d, AA from 2.0 to 3.0 g/kg/d, and FAT from 1.5 to 2.5 g/kg/d.~Intravenous macronutrient intakes:~PN day 1: 2.0 g/kg of AA, 1.6 g/kg of FAT and 9 g/kg of glucides.~PN day 2: 2.5 g/kg of AA, 2.0 g/kg of FAT and 11 g/kg of glucides.~PN day 3 and the days after: 3.0 g/kg of AA, 2.5 g/kg of FAT and 13 g/kg of glucides.~Intravenous vitamins will be supplied according to local clinical practice. Variations in macronutrient intakes will be tolerated within ±20%.~Nutritional goal: to ensure at least 2.5 g/kg/d of AA and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
9463393|NCT03693287|Experimental|Standardized-Parenteral Nutrition (S-PN)|"These patients will receive standardized parenteral nutrition (PN) by using a triple chamber bag (Numeta G13%E®).~Dosing range: 80-300 ml/d. Intravenous macronutrient intakes: 65 ml/kg at PN day 1, 80 ml/kg at PN day 2 and then 100 ml/kg from PN day 3.~Nutritional goal: to ensure at least 2.5 g/kg/d of amino acids (AA) and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
9463394|NCT03693274|Experimental|Mindfulness Course|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center and will also be given access to BreatheAware for Pain Management, a 16- week web-based mindfulness course.
9463395|NCT03693274|No Intervention|Usual Care|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center.
9463396|NCT03693261||Coronary Artery Disease (CAD)|Patients with clinically and angiographically established coronary artery disease (CAD) who require CABG, as part of the standard medical care.
9463397|NCT03693261||controls|Control group will be formed by subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography).
9463398|NCT03693248|Experimental|Two cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Two cycles of neoadjuvant chemotherapy and four cycles of adjuvant chemotherapy."
9463399|NCT03693248|No Intervention|Three cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Three cycles of neoadjuvant chemotherapy and three cycles of adjuvant chemotherapy."
9463400|NCT03693235|Experimental|70 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 70 degrees.
9479841|NCT03539406|Experimental|NK-cells without preparative regimen|NK-cells without preparative regimen
10026538|NCT01724229|Other|treatment with OTC drug products|"Body Wash & Shampoo applied directly to the skin or cloth; soiled area gently wiped clean. No rinsing necessary.~Moisture Barrier Cream: Once area cleansed and dried thoroughly, a thin coat is gently applied to the area of the skin exposed to moisture twice daily for two weeks or as directed by doctor.~2-in-1 Cleanser: applied directly to the skin or a cloth and skin gently wiped clean. No rinsing necessary.~Antifungal Cream: Once reddened area cleansed and dried thoroughly a thin layer is applied over the affected area twice daily for two weeks or as directed by doctor."
10026539|NCT01724242|Experimental|Vaginal DHEA|Vaginal DHEA 0.5%(6.5mg)inserted nightly
10026540|NCT01724242|Placebo Comparator|Placebo|
10026541|NCT01724255||staple removal day 4 dressing removal day 1|early staple removal and early dressing removal
10026542|NCT01724255||staple removal day 4 dressing removal day 4|early staple removal and day 4 dressing removal
10026543|NCT01724255||staple removal day 7, dressing removal day 1|late staple removal and early dressing removal
10026544|NCT01724255||staple removal day 7, dressing removal day 7|late staple removal and late dressing removal
10026545|NCT01724255||staple removal day 7, dressing removal day 4|late staple removal and day 4 dressing removal
10026546|NCT01724268|Experimental|Pred + Meth|"Prednisolone : 10 mg daily~+ Methotrexate : 25 mg/ day~ARM 1 Treatment Arm"
10026547|NCT01724268|Active Comparator|Anti TNF + Meth|"Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg~+ Methotrexate 25 mg per day Control Arm"
10026548|NCT01724281||pregnant women between 19-30 weeks gestational age|No intervention, only follow up
10026549|NCT01724294||Cohort|
10026550|NCT01724307|Active Comparator|Asthma positive to Methacholine Challenge Testing|Asthma diagnosis by positive Methacholine Challenge Testing
10026551|NCT01724307|Active Comparator|Asthma positive to Eucapnic voluntary hyperventilation testing|Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
10026552|NCT01724320|Experimental|OTX008|Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
10026553|NCT01724333||Group 1- in active treatment|Questionnaires only
10026554|NCT01724333||Group 2 - 2-6 months post-treatment|Questionnaires only
10026555|NCT01724333||Group 3 - 6 mos-3yrs post-treatment|Questionnaires only
10026556|NCT01724333||Group 4 - Palliative treatment|Questionnaires only
10026557|NCT01724333||Group 5 - Referred to dentist/oral team|Questionnaires only
10026558|NCT01724346|Other|Arm A Post-Chlorambucil Therapy Followup|Patients randomized to Chlorambucil in the parent study(PCYC-1115-CA) who have not progressed at the time of parent study closure will be transferred to this Arm. Follow-up will continue until PD, unacceptable toxicity, or other reason for treatment discontinuation.
10026559|NCT01724346|Experimental|Arm B Ibrutinib|Patients randomized to Ibrutinib in the parent study (PCYC-1115-CA) who have not experienced PD at the time of parent study closure will be transferred to this Arm to continue on Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
10026560|NCT01724346|Experimental|Arm C Second-line Ibrutinib|Patients who received Chlorambucil in the parent study (PCYC-1115-CA) and experienced PD are transferred to this Arm for Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
10026561|NCT01724346|Other|Arm D Alternative Anticancer Therapy|At the Investigator's discretion, alternative anticancer treatment is a therapeutic option for patients who experienced PD during Ibrutinib treatment or during or after Chlorambucil treatment. This Arm can also be considered if drug is discontinued for other reasons (e.g., intolerability or adverse event [AE]) or prior to experiencing PD).
9463401|NCT03693235|Experimental|80 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 80 degrees.
9463402|NCT03693235|Experimental|90 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 90 degrees.
9463403|NCT03693222|Experimental|tramadol use|Cases were assessed as intravenous opioid with 1 mg/kg tramadol hydrochloride
10036748|NCT01818583|Experimental|Potassium|Potassium chloride infusion at a rate of 15 mmol/h (60 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.05 mmol/mL, flow rate 265 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.
10036749|NCT01818583|Placebo Comparator|Placebo|5% glucose (flow rate 265 ml/h) as placebo infusion.
9463404|NCT03693222|Experimental|quadratus lumborum block|Cases were assessed asquadratus lumborum block for postoperative analgesia
10036750|NCT01818609|Experimental|Step Reduction|"Step reduction:~Take less than 1500 steps/d~No disease"
10036751|NCT01818622|Experimental|Patient-group blue-blockers|N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
9463405|NCT03693209|Experimental|General trigger|"VHS with one general trigger: If I am getting angry... and 10 strategies (e.g. Then I will take deep breaths). Participants are instructed to link trigger with strategies."
10036752|NCT01818622|Placebo Comparator|Patient group clear-lensed goggles|N= 21 (Patient group) clear-lensed goggles from 06 p.m. to 08 a.m. in addition to TAU.
10036753|NCT01818622|Experimental|Non-bipolar control-group blue-blockers|N= 42 For baseline day 1-7: Actiwatch Spectrum worn at the wrist of dominant hand, day 8-14 continued wearing of Actiwatch spectrum + blue-blocking goggles from 6 p.m. to 08 a.m. In addition to selfreport forms described in the outcome section self report forms Horne-Ostberg Morningness-Eveningness Questionaire (HOMEQ)and Seasonal Pattern Assessment Questionaire (SPAQ).
9463406|NCT03693209|Experimental|Specific triggers|"VHS with a list of 10 specific situations that can act as anger triggers (e.g. If I am getting angry when people act like they know it all) and 10 strategies. Participants are instructed to link triggers with strategies."
9463407|NCT03693209|No Intervention|Control|List of 10 specific situations that can act as anger triggers and 10 strategies. Participants are instructed to select most encountered triggers and most useful strategies.
9463408|NCT03693196|Other|Straumann®|Titanium implants the surfaces of which were roughened with SLA (sandblasted and acid-etched titanium surface) (Straumann®, Basel, Sweden). Immunological parameters (PICF, Perio-paper®) , microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
9463409|NCT03693196|Other|Astra Tech, OsseoSpeed™|Implants the surfaces of which were roughened by modifying with fluorine (Astra Tech, OsseoSpeed™, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
9463410|NCT03693196|Other|Nobel Biocare, Replace®|Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
9463411|NCT03693183|Experimental|Ketorolac/HPMC|"Drug: Ketorolac/HPMC Ophthalmic Solution~1 drop administered in each eye 4 times per day for 2 days"
9463412|NCT03693183|Active Comparator|HPMC|"Drug: 0.80% Hydroxypropyl Methylcellulose(HMPC) Ophthalmic Solution~1 Drop administered in each eye 4 times per day for 2 days"
9463413|NCT03693183|Placebo Comparator|Vehicle|"Drug: Vehicle Ophthalmic Solution~1 drop administered in each eye 4 times a day for 2 days"
9463414|NCT03693170|Experimental|1 Arm|encorafenib plus binimetinib plus cetuximab
9463415|NCT03693144|Experimental|Intervention Group 1 Full LIITA3H App|Participants will be given the LIITA3H app, which is a combination product consisting of 3 main features that will track their visits to fast food restaurants (using the ELI feature), send tailored text messages to prompt healthy choices when they are in a fast food restaurant (using the POP feature), and allow them to submit pictures of their food (using the SNAP feature).
9463416|NCT03693144|Active Comparator|Control Group 2 Partial LIITA3H App|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) and they will submit pictures of their food (using the SNAP feature). However, they will not receive tailored text messages.
9479842|NCT03539406|Experimental|NK-cells with preparative regimen|NK-cells with preparative regimen
10026562|NCT01724372|Experimental|Antidepressant|Fluoxetine
10026563|NCT01724372|Active Comparator|Antipsychotic|Aripiprazole
10026564|NCT01724385|Experimental|intravitreal bevacizumab injection|intravitreal injection of bevacizumab 1.25 mg
10026565|NCT01724398|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 48 study visit.
9463417|NCT03693144|Other|Control Group 3 LIITA3H Location only|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) but they will not receive tailored messages or submit pictures of their food.
9463418|NCT03693131|Experimental|MND-2119 2 g|MND-2119 2 g, orally, once daily after breakfast for 12 weeks.
9463419|NCT03693131|Experimental|MND-2119 4 g|MND-2119 4 g, orally, once daily after breakfast for 12 weeks.
9463420|NCT03693131|Active Comparator|EPADEL CAPSULES 300 1.8 g|EPADEL CAPSULES 300 0.9 g, orally, twice daily after breakfast and dinner for 12 weeks.
9463421|NCT03693131|Active Comparator|EPADEL CAPSULES 300 2.7 g|EPADEL CAPSULES 300 0.9 g, orally, three-times daily after each meal for 12 weeks.
9463422|NCT03693118|Experimental|Grup1, Grup2|
9463423|NCT03693118|Experimental|Grup1,Grup2|
9463424|NCT03693105|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
9463425|NCT03693105|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
9463426|NCT03693079|Experimental|Wet Cupping|wet cupping therapy will be applied to all participants
9463427|NCT03693066|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
9463428|NCT03693066|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
9463429|NCT03693066|Active Comparator|Control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
9463430|NCT03693040|Experimental|DHFS with IS-Truvada|Digital Health Feedback System (DHFS) with IS-Truvada 1 capsule daily for 12 weeks
9463431|NCT03693027|Experimental|PTx800|Qualified subjects will dissolve one oral lozenge (PTx800 lozenges) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
9463432|NCT03693027|Placebo Comparator|Placebo|Qualified subjects will dissolve one oral lozenge (placebo control) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
9463433|NCT03693001|Experimental|IC/FM Patients|All patients had been diagnosed with fibromyalgia and were suffering from IC by standard criteria.
9463434|NCT03692988|Experimental|Interventiongroup|Dignity Therapy. Patients receive dignity-therapy-Intervention after randomization
9463435|NCT03692988|No Intervention|Waitinggroup|Patients receive dignity-therapy-Intervention after a waiting time of 3 months post randomization
9463436|NCT03692975|Experimental|CIS patients|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially suggestive of multiple sclerosis (MS) whatever the mode of presentation
9463437|NCT03692975|Active Comparator|Control|50 Healthy controls
10026566|NCT01724398|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.
10026567|NCT01724398|Experimental|Conventional plus PE treatment|Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.
10026568|NCT01724398|Experimental|Conventional plus UC-MSC and PE therapy|Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit.
10026569|NCT01724411|Experimental|Resistant Starch 3|Resistant Starch Type 3:dose of 26g/day males and 22g/day female during 11 days of the maintenance period. (C ActiStar 11700, Tapioca Maltodextrin, Cargill, Belgium)
9463438|NCT03692962|Sham Comparator|Sleep restriction without acoustic stimulation|
9802954|NCT04766502|Experimental|Blood sample (20ml) and Quality of Life Survey|
9802955|NCT04764162|Active Comparator|Choline supplementation|Participants will consume 1000 mg of choline per day for 4 weeks.
9802956|NCT04764162|Placebo Comparator|Placebo supplementation|Participants will consume 1000 mg of placebo per day for 4 weeks.
10026570|NCT01724411|No Intervention|Control Non- RS3|Non-Resistant Starch type 3 food items during 11 days of the maintenance period.
10026571|NCT01724424|Experimental|melatonin 20mg|2 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
10026572|NCT01724424|Experimental|melatonin 30mg|3 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
10026573|NCT01724424|Experimental|Melatonin 50mg|5 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
10026574|NCT01724424|Experimental|Melatonin 100mg|10 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
10026575|NCT01724437|Active Comparator|Loss of pace capture|Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved
9463439|NCT03692962|Experimental|Sleep restriction with acoustic stimulation|
9463440|NCT03692949|Experimental|LY3451838 Part A|Single ascending doses, administered intravenously (IV)
9463441|NCT03692949|Experimental|LY3451838 Part B|Single doses administered subcutaneously (SC)
9463442|NCT03692949|Placebo Comparator|Placebo Part A|Matching single doses administered intravenously (IV)
9463443|NCT03692949|Placebo Comparator|Placebo Part B|Matching single doses administered subcutaneously (SC)
9463444|NCT03692923|No Intervention|control group|participants received ordinary prenatal care.
9463445|NCT03692923|Experimental|virtual community group|participants were invited to join a virtual community to interact with peers in addition to their ordinary prenatal care.
9463446|NCT03692871|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of double-blind V114 at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
9463447|NCT03692871|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
9463448|NCT03692858|Active Comparator|Group A|
9463449|NCT03692858|Active Comparator|Group B|
9463450|NCT03692845|Other|O-TLIF group|Spinal fusion ,Transforaminal lumbar interbody fusion procedure will be performed through open surgery.
10026576|NCT01724437|Active Comparator|Conventional|Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.
10026577|NCT01724450|Active Comparator|Carvedilol|
10026578|NCT01724450|Placebo Comparator|Control|
10026579|NCT01724463||Electronically Screened Sepsis Patients|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
10026580|NCT01724476|Active Comparator|folate with B12|Subjects randomized to the folate with B12 group will take 1 capsule of 400mcg per day of folate with B12.
10026581|NCT01724476|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 1 capsule of placebo per day.
10026582|NCT01724502|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
10026583|NCT01724502|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
10026584|NCT01724502|Experimental|Healthy Control Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
10026585|NCT01724515|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
10026586|NCT01724515|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
10026587|NCT01724515|Experimental|Healthy Control Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
10026588|NCT01724554|Experimental|Every Month Treatment|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
10026589|NCT01724554|Experimental|Every Month, then Every Other Month|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.
10026590|NCT01724567|Experimental|Weight Loss|12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
10026591|NCT01724567|Experimental|Interval Training|12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
10026592|NCT01724593||Observational Cohort|No Intervention
10026593|NCT01724619|Experimental|Healthy Volunteers|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
10026594|NCT01724619|Experimental|Prostate Cancer Patients|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
10026595|NCT01724632|Active Comparator|Group Treatment|Participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. Participants will be weighed individually at the start of each group meeting.
10026596|NCT01724632|Active Comparator|Individual Treatment|Participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months.
10026597|NCT01724632|Experimental|Smartphone Treatment|Participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. They will also attend one-on-one sessions with a weight loss counselor every month for 18 months.
10026598|NCT01724645|Experimental|Korean traditional diets|Korean traditional diets (calorie 2,100kcal) for 12weeks
10026599|NCT01724645|Active Comparator|Control group|"Control group : told to eat as usal diet) for 12weeks"
10026600|NCT01724658|Experimental|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
10026601|NCT01724658|Placebo Comparator|placebo|placebo twice a week with progynova 1 mg oral daily
10026602|NCT01724671||Cefatroline|Investigators will retrospectively capture patient cases that have been treated for MRSA with ceftaroline. Cases will only be included if the isolate was tested against vancomycin and ceftaroline
10026603|NCT01724671||Vancomycin|Investigators will retrospectively capture patient cases that were been treated for MRSA with Vancomycin.
10026604|NCT01724684|Other|Telehealth program|Telehealth program service
10026605|NCT01724684|Other|Usual care|Usual care service
10026606|NCT01724697|Active Comparator|conventional treatment|conventional treatment & antivrial treatment.
10026607|NCT01724697|Experimental|BMSC transplantation|conventional treatment & antiviral treatment & autologous bone marrow stem cell transplantation via hepatic artery
10026608|NCT01724710||chronic ulcer|1x1cm2 tissue from chronic ulcer wound
9463451|NCT03692845|Other|MI-TLIF group|Spinal fusion,Transforaminal lumbar interbody fusion procedure will be performed through minimally invasive surgery using a tubular retractor.
9463452|NCT03692819|Active Comparator|placebo|Periodontal debridement treatment will be performed in a single session after the therapy will be administered the Placebo Oral Tablet twice a day for 21 days.
9463453|NCT03692819|Experimental|Metronidazole and Amoxicillin|Periodontal debridement treatment in a single session Metronidazole 400mg + Amoxicillin 500mg every 8 hours for 7 days.
9463454|NCT03692819|Experimental|Lactobacillus reuteri|Periodontal debridement treatment in a single session Lactobacillus reuteri Oral Drops twice a day for 21 days.
9463455|NCT03692806|Experimental|Stablor|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
9463456|NCT03692806|Placebo Comparator|placebo|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
9463457|NCT03692793|Experimental|Pulmonary rehabilitation|The PRP (24-session, three times for week) will be delivered according to ATS/ERS (Spruit et al, 2013),
9463458|NCT03692780|Experimental|Careseng 1370|
9463459|NCT03692780|Placebo Comparator|Matched Placebo|
9463460|NCT03692767|Experimental|Anti-CD22 CAR NK cells|Total dose of 50-600 thousand /kg Anti-CD22 CAR NK cells will be administered at day0
9463461|NCT03692754|Active Comparator|AT with 10 mg/d|The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
9463462|NCT03692754|Active Comparator|AT with 20 mg/d|The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
10026609|NCT01724710||normal skin|1x1x0.1 cm3 normal skin from graft
10026610|NCT01724723|Experimental|Entecavir group|Study treatment for only treatment group: entecavir (BARACLUDE®) 0.5 mg per day during and within 6 months after anti-tuberculous treatment.
10026611|NCT01724723|No Intervention|Control group|Not receiving entecavir (BARACLUDE®)
10026612|NCT01724736|Placebo Comparator|Placebo Comparator:|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
10026613|NCT01724736|Active Comparator|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
10026614|NCT01724749||Healthy control subjects|"Age: 21 - 80 years~No prior history or symptoms of cardiovascular disease~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80."
10026615|NCT01724749||Subjects with cardiovascular disease|"Age: 21 - 80 years~HeartSCORE > 0%~Symptoms of angina pectoris~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80. Also, the investigators aim to include patients in 3 strata of HeartSCORE risk: low risk (1-4%), mild risk (5-9%) and high risk (> 9%)"
10026616|NCT01724762|Experimental|Nursing orientation|Patients who received nursing orientation and read the informative manual concerning bed bath
10026617|NCT01724775||CME surgery for colon cancer|
10026618|NCT01724775||non-CME surgery for colon cancer|
10026619|NCT01724788|Experimental|Furosemide PO - IV|Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)
10026620|NCT01724788|Experimental|Furosemide IV - PO|IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)
10026621|NCT01724801|Experimental|icotinib|icotinib administered orally at a dose of 125 mg 3 times daily
10026622|NCT01724801|Active Comparator|Whole brain irradiation|Whole brain irradiation 30Gy/3Gy/10 fractions plus concurrent or sequential chemotherapy for 4-6 cycles
10026623|NCT01724814|Experimental|Cohort S1|HM12460A Dose 1 (1.2 nmol/kg) or placebo
10026624|NCT01724814|Experimental|Cohort S2|HM12460A Dose 2 (2.4 nmol/kg) or Placebo
10026625|NCT01724814|Experimental|Cohort S3|HM12460A Dose 3 (4.8 nmol/kg) or Placebo
10026626|NCT01724814|Experimental|Cohort S4|HM12460A Dose 4 (9.6 nmol/kg) or Placebo
9463463|NCT03692754|Experimental|Dexamethasone|The patients will be given dexamethasone 40mg/d for 4 days.
9463464|NCT03692728||CC children|CC children were registered members of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH). All of them were diagnosed with CC by two experienced pediatric ophthalmologists based on a comprehensive evaluation of the onset age (within one year after birth), morphological features of lens opacity, family history, and detailed medical records.
9463465|NCT03692728||NV children|NV children were recruited from the Optometry Department of the ZOC as the control group. NV was defined as BCVA ≥0.3 (log MAR) in children between 3-5 years old or BCVA ≥0.15 (log MAR) in children older than 5 years. Children with strabismus and high refractive error (myopia or hyperopia: >6.0 Diopters; astigmatism: >3.0 Diopters) were excluded from NV group.
9463466|NCT03692702|Experimental|WE PLAY|Teachers in this condition received the WE PLAY training.
9463467|NCT03692702|No Intervention|Control|Preschools in this condition received the same physical activity equipment that preschools in the WE PLAY condition received. Teachers were not provided with any specific instructions or information about physical activity.
9463468|NCT03692689|Experimental|SCT200|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
9463469|NCT03692663|Experimental|anti-PSMA CAR NK cells treatment group|
10026627|NCT01724814|Experimental|Cohort S5|HM12460A Dose 5 (14.4 nmol/kg) or Placebo
10026628|NCT01724814|Experimental|Cohort S6|HM12460A Dose 6 (19.2 nmol/kg) or Placebo
10026629|NCT01724827|Active Comparator|ceramic|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
10026630|NCT01724827|Active Comparator|composite|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
10026631|NCT01724840|Experimental|GraftJacket|GraftJAcket is used as interpositional material
10026632|NCT01724840|Active Comparator|Tendon Interposition|Flexor carpi radialis tendon is used as interpositional material
9463470|NCT03692637|Experimental|anti-Mesothelin Car NK Cells|Total dose of 0.5-3 million /kg cells will be administered at day0
9463471|NCT03692624|Experimental|Intervention Group|Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
9463472|NCT03692624|No Intervention|Control Group|To control for the laboratory environment or other potential placebo effects, a control group will receive their usual follow-up care for their cancer diagnosis and will complete baseline and post-baseline outcome assessments without any HRV-B training.
9463473|NCT03692598|Experimental|MIA Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach
9463474|NCT03692598|Experimental|MIA Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach
10026633|NCT01724853|Other|Surgery|Preferred surgery
9479843|NCT03539367|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9479844|NCT03539367|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9479845|NCT03539354|Active Comparator|CABG + b-blockers|Standart coronary artery bypass grafting is performed with b-blockers treatment. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
9479846|NCT03539354|Experimental|CABG + b-blockers + temporary SCS|Before coronary artery bypass grafting in the experimental group, 3 days of temporary spinal cord stimulation is performed than device turned off and coronary artery bypass grafting procedure is made. The device for spinal cord is turned on in intensive care unit for 7 days. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
10026634|NCT01724853|Other|Conservative|Conservative treatment
10026635|NCT01724892|Active Comparator|Loteprednol etabonate|Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks
10026636|NCT01724892|Active Comparator|Dexamethasone|Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks
10026637|NCT01724905|Experimental|Modified Stop Light Diet|
10026638|NCT01724905|Active Comparator|Recommended Care for Weight Reduction|
10026639|NCT01724918|Other|100 mg IV|100 mg IV lacosamide infused over 30 minutes
10026640|NCT01724918|Other|200 mg IV|200 mg IV lacosamide infused over 30 minutes
10026641|NCT01724918|Other|400 mg IV|400 mg IV lacosamide infused over 30 minutes
10026642|NCT01724931|Placebo Comparator|Placebo|Placebo once weekly
10026643|NCT01724931|Experimental|3 mg LD-Aminopterin|3 mg LD-aminopterin once weekly
10026644|NCT01724931|Experimental|1 mg LD-aminopterin|1 mg LD-aminopterin once weekly
10026645|NCT01724944|Experimental|Systematic Lymphadenectomy|
10026646|NCT01724957||Patients with coronary bifurcation lesions|Only one group will be studied. The patient will be a slef-reference.
10026647|NCT01724970|Experimental|PLMA|ProSeal
10026648|NCT01724970|Experimental|SLMA|Supreme LMA
10026649|NCT01724983|Experimental|ketamine|patients will receive ketamine at induction
10026650|NCT01724983|Active Comparator|fentanyl|patients will receive fentanyl at induction
10026651|NCT01725009|Experimental|Levetiracetam IV infusions in Japanese|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects
10026652|NCT01725009|Experimental|Levetiracetam IV infusions in Caucasian|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects
10026653|NCT01725022|Experimental|Home Care|This is the arm for patients who receive their transplant care in their homes.
10026654|NCT01725022|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
10026655|NCT01725022|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
10026656|NCT01725035||Fatty liver|
10026657|NCT01725035||Non Fatty liver|
10026658|NCT01725048|Active Comparator|Mirtazapine|Treatment with oral mirtazapine, dosed once daily, for 9 weeks, with starting dose of 7.5 milligrams (mg) daily up to 30mg daily.
10026659|NCT01725048|Active Comparator|Citalopram|Treatment with Citalopram, once daily, for 9 weeks, with dosages starting at 10mg once daily to 40mg once daily.
10026660|NCT01725074|Experimental|"Case Management CM CHD"|The intervention consists of a biweekly telephone or personal contact by trained case managers over the first 6-months and monthly contact over the second 6-months to assess well-being, everyday life (positive, neutral and negative daily events), and to inquire after health and personal problems on which basis the case manager offers practical or emotional support or a referral to the general practitioner if deemed necessary. During the contacts also medical control measures like blood pressure or weight are taken, and other study outcome measures like need for medical treatment.
10026661|NCT01725074|Experimental|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures.
10026662|NCT01725074|No Intervention|Control Group|Patients assigned to the control group received usual care (no additional contact/support) and therefore stays under the standard supervision of the general practitioner i.e. as participant in the normal disease management program for CHD (quarterly check-ups).
10026663|NCT01725087|Placebo Comparator|Matching Placebo|Twice daily oral administration of matching placebo for 14 weeks
10026664|NCT01725087|Experimental|Low Dose GRT6005|Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.
10026665|NCT01725087|Experimental|Medium Dose GRT6005|Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.
10026666|NCT01725087|Experimental|High Dose GRT6005|Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.
10026667|NCT01725087|Active Comparator|Tapentadol|Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.
10026668|NCT01725100|Experimental|Treatment A: GSK1120212B (Standard DMSO content)|Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
10026669|NCT01725100|Experimental|Treatment B: GSK1120212B (Lower DMSO content)|Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
9463475|NCT03692572|Active Comparator|Nitrate supplementation|Nitrate rich (6.8 mmol) beet root juice (70ml) twice a day
9463476|NCT03692572|Placebo Comparator|Placebo|Nitrate depleted (0.04 mmol) placebo juice (70ml) twice a day
10026670|NCT01725113|Experimental|Calcitriol|Patients will be converted from paricalcitol to calcitriol according to published package inserts which describe a 10mcg:3mcg ratio.
10026671|NCT01725113|Active Comparator|Paricalcitol|Continuation of intravenous paricalcitol that patient was originally on at the time of recruitment.
10026672|NCT01725139|Experimental|Cohort 1-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 (0.25 mg twice daily [bid]) or placebo for approximately 8 days (7 to 10 days dosing)
10026673|NCT01725139|Placebo Comparator|Cohort 1-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing)
10026674|NCT01725139|Experimental|Cohort 2-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 1 and which could be escalated or deescalated or repeated from Cohort 1 dosing.
10026675|NCT01725139|Placebo Comparator|Cohort 2-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
10026676|NCT01725139|Experimental|Cohort 3- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 2 and which could be escalated or deescalated or repeated from Cohort 2 dosing.
10026677|NCT01725139|Placebo Comparator|Cohort 3-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
10026678|NCT01725139|Experimental|Cohort 4- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 3 and which could be escalated or deescalated or repeated from Cohort 3 dosing.
10026679|NCT01725139|Placebo Comparator|Cohort 4- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
10026680|NCT01725139|Experimental|Cohort 5- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 4 dosing.
10026681|NCT01725139|Placebo Comparator|Cohort 5- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
9463477|NCT03692559|Experimental|full sterile dressing|Patients receive full sterile dressing
9463478|NCT03692559|No Intervention|usual standard care|Patients receive usual standard care
9463479|NCT03692546|Experimental|Liposomal Bupivacaine (LB)|Administration of 20 ml of LB diluted with an additional 40 ml of saline was injected into a triangular soft tissue surgical field block, along with standard bupivacaine interscalene block
9463480|NCT03692546|No Intervention|Interscalene Block Alone (ISB)|Administration of 20mL of 0.5% standard bupivacaine interscalene block with no additional soft tissue surgical field block
9463481|NCT03692533|Active Comparator|Group A|Group (A) [study cases] Adult patients who will undergo radical or partial nephrectomy.for primary renal cell carcinoma.
9463482|NCT03692533|Active Comparator|Group B|Group (B) [control cases] Adult patients who will undergo simple nephrectomy for benign causes
9463483|NCT03692520|Experimental|SCT200|Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression
9463484|NCT03692507|Experimental|HMB only|Taking HMB supplements three times a day
9463485|NCT03692507|Experimental|Protein and HMB|Drinking Ensure Enlive shakes
10026682|NCT01725139|Experimental|Cohort 6- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 5 dosing.
10026683|NCT01725139|Placebo Comparator|Cohort 6- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
10026684|NCT01725178|No Intervention|Standard care|No intervention besides usual care
10026685|NCT01725178|Active Comparator|Cognitive and physical training|Patients will undergo the comprehensive program of cognitive and physical training.
10026686|NCT01725191|Experimental|Treatment (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9463486|NCT03692507|Experimental|Current ERAS (High Protein)|Drinking Ensure surgery shakes + Ensure pre-surgery
9463487|NCT03692481|Experimental|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
9463488|NCT03692468|Experimental|Intervention Group|Participants will engage in a 5 session psychotherapy intervention focused on improving pain and mood.
9463489|NCT03692468|No Intervention|Control Group|Patients will receive treatment as usual from their care providers.
9463490|NCT03692455|Experimental|BPG Group|Patients will be submitted to Roux-en-Y Bypass Gastric Surgery.
9463491|NCT03692455|Experimental|Sleeve Group|Patients will be submitted to Vertical Sleeve Gastrectomy Surgery.
9463492|NCT03692442||immunotherapy effective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
10026687|NCT01725204|Experimental|Dasatinib + PegIFN|Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.
10026688|NCT01725230|Experimental|Rosuvastatin|Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
9463493|NCT03692442||immunotherapy ineffective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
9463494|NCT03692429|Experimental|CYAD-101 with FOLFOX|Infusion after standard FOLFOX chemotherapy
9463495|NCT03692429|Experimental|CYAD-101 with FOLFIRI|Infusion after standard FOLFIRI chemotherapy
9463496|NCT03692416|Active Comparator|Ibuprofen|"Patients in this group will receive:~Ibuprofen~Oral~At a dosage of 30 to 40 mg/kg/day, divided into 3 or 4 doses/day, max 2400 mg/day, given with food, in the form of suspension or tablets.~Duration of therapy: 4 - 6 weeks."
9463497|NCT03692416|Active Comparator|Prednisone Oral or Methylprednisolone IV|"Steroids:~Pednisone (for mild/moderate cases):~Oral~Single daily morning dosage of 0.05-2.0 mg/kg/day, or in 2 - 4 divided doses, max 80 mg/d.~Duration: 4 - 6 weeks, with gradual tapering to the lowest effective dose.~Methylprednisolone (for severe/acute cases):~IV~10-30 mg/kg/dose (max 1 g), over 1 hr daily for 1-5 days, followed by oral prednisone, with gradual tapering to the lowest effective dose.~The duration is variable according to the condition of the patient."
9463498|NCT03692416|Active Comparator|Methotrexate|"Patients in this group will receive:~Methotrexate~Oral~At a dosage of 10 to 20 mg/m2/wk (0.35 to 0.65 mg/kg/wk), max dose 25 mg/wk.~Duration of therapy: 6 - 12 weeks."
9463499|NCT03692390|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app while undergoing procedural sedation
9463500|NCT03692390|No Intervention|Standard-of-Care|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
9463501|NCT03692377||Children Aged 2-6|Children 2 to 6 years of age who are arriving with a guardian to the Emergency Department with a low acuity condition (Canadian Triage scale (CTAS) 4 or 5) and are waiting to be seen by the doctor, or are waiting for test results.
9463502|NCT03692364|Active Comparator|Metal-on-conventional polyethylene|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a CoCr prosthetic femoral head and an acetabular liner made of intermedially cross-linked polyethylene polyethylene (Duration, Stryker, Mahwah, NJ, US).
9463503|NCT03692364|Experimental|Ceramic-on-ceramic|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a prosthetic femoral head and an acetabular liner made of alumina ceramic (Biolox Forte, Ceramtec, Plochingen, Germany).
9463504|NCT03692351|Active Comparator|Cup with screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US), screw fixation (2 or 3 screws)
9463505|NCT03692351|Experimental|Cup without screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US) without screw holes, press-fit fixation
9463506|NCT03692338|Experimental|12 week supervised exercise program|"Patients will be asked to complete 3 30-minute supervised exercise sessions/week under the guidance of the study exercise physiologist. The preferred mode will be treadmill walking, however, alternatives such as cycling or stair climbing machines will be used. For these sessions, patients will be asked to wear a heart rate monitor. Following a 5 minute warm-up, the exercise physiologist will increase speed to correspond with an intensity of approximately 80% VO2peak for 1-minute before returning to a lower speed for 1-minute (50% VO2peak). Patients will complete up to 20 of each 1-minute interval, then cool-down for 5 minutes. At the end of each higher intensity interval patients will be asked to rate their perceived exertion (RPE).~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
10026689|NCT01725230|Experimental|Simvastatin|Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
10026690|NCT01725243|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg IV, once following delivery.
9479849|NCT03539328|Other|Standard treatment|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion
9479850|NCT03539328|Experimental|Pembrolizumab|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion plus Pembrolizumab 200 mg d1 q 21 iv infusion in 30 minutes
10026691|NCT01725243|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg IV, once following delivery.
10026692|NCT01725243|Active Comparator|Carbetocin 40mcg|Carbetocin 40mcg IV, once following delivery.
10026693|NCT01725243|Active Comparator|Carbetocin 60mcg|Carbetocin 60mcg IV, once following delivery.
10026694|NCT01725243|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg IV, once following delivery.
10026695|NCT01725243|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg IV, once following delivery.
10026696|NCT01725243|Active Comparator|Carbetocin 120mcg|Carbetocin 120mcg IV, once following delivery.
10026697|NCT01725243|Active Comparator|Carbetocin 140mcg|Carbetocin 140mcg IV, once following delivery.
10026698|NCT01725256|Experimental|80mg AIR001 four times daily|80mg AIR001 nebulized four times daily for 16 weeks
10026699|NCT01725256|Experimental|46mg AIR001 four times daily|46mg AIR001 nebulized four times daily for 16 weeks
10026700|NCT01725256|Experimental|80mg AIR001 once daily|80mg AIR001 nebulized once daily for 16 weeks
10026701|NCT01725269|Experimental|80mg AIR001, nebulized four times daily|AIR001, 80 mg into nebulizer
10026702|NCT01725269|Experimental|46 mg AIR001, nebulized four times daily|AIR001, 46 mg into nebulizer
10026703|NCT01725269|Experimental|80mg AIR001, nebulized once daily|AIR001, 80 mg into nebulizer
10026704|NCT01725295|Experimental|NST|A form of physical therapy to relieve symptoms of fibromyalgia
10026705|NCT01725295|Active Comparator|Hydrotherapy|An alternate form of physical therapy to relieve symptoms of fibromyalgia
9463507|NCT03692338|Experimental|12 week semi-supervised exercise program|"This cohort will complete 12 weeks of a semi-supervised exercise program independently. Patients will be scheduled for an exercise session with a study exercise physiologist during clinical appointments to complete a sample intensity and time specific exercise session. The preferred mode will be walking, however cycling is also permitted. For each session the patient will wear a heart rate monitor. Following a 5 minute warm-up, patients will increase the intensity of exercise to reach a heart rate corresponding to approximately 60% VO2peak, and will continuously maintain this intensity for their individualized duration to elicit the desired energy expenditure. Each week, the exercise physiologist will call the patient and discuss how to approach the next set of exercise sessions.~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
9463508|NCT03692338|No Intervention|Control cohort|Participants will have routine care for 12 weeks. This will consist of nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks.
9463509|NCT03692299|Active Comparator|Saccaromyces boulardii oral tablet|Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
9463510|NCT03692299|Active Comparator|Metronidazole plus S. boulardii|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
10026706|NCT01725321||Narrow band imaging|Colonoscopy with new narrow band imaging
10026707|NCT01725334|Experimental|Nucleus Accumbens/Ventral Striatum (NAcc/VS) Stimulation|The first 3 patients will have the DBS device target the NAcc/VS, which has been found to be hypoactive in patients with primarily negative symptoms.
9463511|NCT03692299|Active Comparator|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.
9463512|NCT03692286|Active Comparator|AgNP/Ca(OH)|Patients receiving combined Silver nanoparticle/Calcium hydroxide administered as intracanal medication at the first visit after cleaning and shaping
9463513|NCT03692286|Active Comparator|AgNP|Patients receiving silver nanoparticles in gel form administered as intracanal medication at the first visit after cleaning and shaping
9463514|NCT03692286|Active Comparator|Ca(OH)|Patients receiving calcium hydroxide intracanal medication at the first visit after cleaning and shaping
10026708|NCT01725334|Experimental|Ventral Tegmental Area (VTA) Stimulation|For 3 patients, the DBS device will target the VTA, which has been found to be hypoactive in patients with primarily negative symptoms.
10026709|NCT01725347||African American Girls|-25% of sample is African American Girls
10026710|NCT01725347||African American Boys|-25% of sample is African American Boys
10026711|NCT01725347||Hispanic American Girls|-25% of sample is Hispanic American Girls
9463515|NCT03692273|Experimental|Laser|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz.
9463516|NCT03692273|Experimental|0.5mm punch biopsy|0.5mm punch biopsy area. This area will receive 0.5mm punch biopsies 75 per cm2 at a depth of 5mm.
9463517|NCT03692273|No Intervention|No treatment|3x3cm2 area designated as no treatment that will serve as a control
9463518|NCT03692260|Active Comparator|intervention group|3D stent in Herbert screw insertion vs titanium plate
10026712|NCT01725347||Hispanic American Boys|-25% of sample is Hispanic American Boys
10026713|NCT01725360|Experimental|montelukast|A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
10026714|NCT01725373||Angioplasty of left main|"Patients with:~stable or unstable angina and/or documented ischemia~de novo ≥50% stenosis in the left main stem referred for angioplasty"
10026715|NCT01725399|Placebo Comparator|Water|Water will be given as the study subject's first oral intake after emergence from general anesthesia.
10026716|NCT01725399|Experimental|Apple Juice|Apple juice will be given as the study subject's first oral intake after emergence from general anesthesia.
10026717|NCT01725412|Experimental|Thiamine Supplementation|
10026718|NCT01725412|Placebo Comparator|Placebo|
10026719|NCT01725438|Experimental|Pregnant women accepting an invasive prenatal diagnosis|Pregnant women accepting an invasive prenatal diagnosis and a sample blood (non invasive diagnosis)
10026720|NCT01725464|Experimental|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
10026721|NCT01725477|Experimental|Dye& normal saline/ 20ml methylene blue +50 ml normal saline|first arm:20 ml methylene blue washing with50 ml normal saline
10026722|NCT01725477|Active Comparator|injection of 20ml metheylen blue|20 ml methylene blue injected without washing
10026723|NCT01725490|Experimental|metformin 500mg daily (arm A)|
10026724|NCT01725490|Experimental|metformin 1500mg daily (arm B)|
10026725|NCT01725490|Placebo Comparator|an identical- appearing placebo (arm C)|
10026726|NCT01725503|Experimental|Creatine and amino acid supplement|
10026727|NCT01725516|Experimental|Myofascial release technique|
10026728|NCT01725542|Experimental|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|"Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin~Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin"
10026729|NCT01725555|Experimental|Fasted treatment|
10026730|NCT01725555|Experimental|Fed treatment|
10026731|NCT01725568||Implantable cardiac monitor diagnostics|Patients has standard indication for implantable cardiac monitor diagnostic.
10026732|NCT01725581||Inexperienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
10026733|NCT01725581||Experienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
10026734|NCT01725581||Junior Doctors|Pre Royal College of Obstetric and Gynaecology registered junior doctors with experience in Obstetrics and Gynaecology
10026735|NCT01725594|Experimental|Cohort A1, Dose Level 1: CAT 2003 or placebo fasting|Single dose
10026736|NCT01725594|Experimental|Cohort A2, Dose Level 2: CAT 2003 or placebo fasting|Single dose
10026737|NCT01725594|Experimental|Cohort A3, Dose Level 3: CAT 2003 or placebo fasting|Single dose
9463519|NCT03692260|No Intervention|control group|titanium plate
9463520|NCT03692247|Other|Quantitative Sensory Testing|After answering brief questionnaires assessing psychosocial factors related to anxiety, catastrophizing, and pain, participants will undergo quantitative sensory tests where they will use a simple numeric rating scale (0-10) to rate pain and anxiety at several points during two QST sessions. During the second QST session, participants will use Unwind, a smartphone-based music intervention.
9463521|NCT03692234|Placebo Comparator|placebo|placebo capsules containing lactose - oral once weekly administration for six month
9463522|NCT03692234|Active Comparator|homoarginine|125 mg L-homoarginine supplement - oral once weekly administration for six month
9463523|NCT03692221|Experimental|MSC treatment group 1|Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution
9463524|NCT03692221|Active Comparator|MSC treatment group 2|High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution
9463525|NCT03692221|Active Comparator|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
10026738|NCT01725594|Experimental|Cohort A4, Dose Level 4: CAT 2003 or placebo fasting|Single dose
10026739|NCT01725594|Experimental|Cohort A5, Dose Level 5: CAT 2003 or placebo fasting|Single dose
10026740|NCT01725594|Experimental|Cohort A2: Dose Level 2: CAT 2003 or placebo fed|Single dose
10026741|NCT01725594|Experimental|Cohort A3: Dose level 3:CAT 2003 or placebo fed|Single dose
10026742|NCT01725594|Experimental|Cohort B1: Dose level 6: CAT 2003 or placebo|Multiple dose for 14 days
10026743|NCT01725594|Experimental|Cohort B2: Dose level 7: CAT 2003 or placebo|Multiple dose for 14 days
10026744|NCT01725594|Experimental|Cohort B3: Dose level 8: CAT 2003 or placebo|Multiple dose for 14 days
10026745|NCT01725594|Experimental|Cohort B4: Dose level 9: CAT 2003 or placebo|Multiple dose for 14 days
10026746|NCT01725607|No Intervention|the control group (Group C)|general anesthesia
10026747|NCT01725607|Experimental|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
10026748|NCT01725607|Experimental|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
10026749|NCT01725620|Experimental|Group 1|Enbrel, LBEC0101
10026750|NCT01725620|Experimental|Group 2|LBEC0101, Enbrel
10026751|NCT01725646|Active Comparator|Omacor® 4 g|Subjects in this group will take 4 g of Omacor® everyday.
10026752|NCT01725646|Active Comparator|Omacor® 2 g|Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
10026753|NCT01725646|Placebo Comparator|Placebo|Subjects in this group will take 4 g of placebo everyday.
10026754|NCT01725659|Experimental|Motor Learning|subjects are provided with intensive motor learning training of the upper limb
9463526|NCT03692195|Experimental|Week WHOOP is worn|Participants will wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
9463527|NCT03692195|Placebo Comparator|Week WHOOP is not worn|Participants will not wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
9463528|NCT03692182||Study group|Participants enrolled in PACE who received an antipsychotic medication.
9463529|NCT03692169||CSC patients|Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns. This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
9463530|NCT03692143||teriparatide group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide
9463531|NCT03692143||PVP group plus alendronate|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with vertebroplasty. Then alendronate was prescribed.
9463532|NCT03692143||teriparatide and PVP group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide after vertebroplasty
9463533|NCT03692130|Active Comparator|New Treatment|"The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called Mindfulness, Acceptance and Commitment-Therapy for depressive Patients."
10026755|NCT01725659|Experimental|Robotics and Motor Learning|subject are provided with intensive motor learning and robotics training of the upper limb
10026756|NCT01725659|Experimental|Motor learning and FES|subjects are provided with intensive motor learning and surface FES (Functional Electrical Stimulation) of the upper limb
10026757|NCT01725672|Active Comparator|Part A and B:Arm 1: 500 mg metformin XR / 1 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 500 mg metformin XR and 1 mg glimepiride IR on Day 1 of the respective period per randomized sequence
10026758|NCT01725672|Active Comparator|Part A and B:Arm 2: 1000 mg metformin XR / 2 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 1000 mg metformin XR and 2 mg glimepiride IR on Day 1 of the respective period per randomized sequence
10026759|NCT01725672|Experimental|Part A:Arm 3: 500 mg metformin XR and 1 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
10026760|NCT01725672|Experimental|Part A:Arm 4: 1000 mg metformin XR and 2 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
9463534|NCT03692130|Sham Comparator|Known Treatment|"The participants will be treated with a relaxation-treatment, long time established as jacobson muscle relaxing technique."
9463535|NCT03692091|Active Comparator|Anterior portal|Injection in to subacromial space from anterior portal
9463536|NCT03692091|Active Comparator|Lateral portal|Injection in to subacromial space from lateral portal
9463537|NCT03692078|No Intervention|GROUP 1: Continue Smoking|Subjects will be asked to continue smoking their OB cigarettes ad libitum for 7 days.
9463538|NCT03692078|Experimental|GROUP 2: OTDN product 1|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
9463539|NCT03692078|Experimental|GROUP 3: OTDN product 2|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
10026761|NCT01725672|Experimental|Part B:Arm 5: 500 mg metformin XR and 1 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC3) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
10026762|NCT01725672|Experimental|Part B:Arm 6: 1000 mg metformin XR and 2 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC4) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
10026763|NCT01725685|Experimental|Treatment A - FF 400 microgram (mcg)|Subjects will be randomized to single dose of FF 400 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
10026764|NCT01725685|Experimental|Treatment B - UMEC 500 mcg|Subjects will be randomized to single dose of UMEC 125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
9463540|NCT03692078|Experimental|GROUP 4: OTDN product 1|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
9802957|NCT04755699|Active Comparator|Healthy Volunteers|This arm consists of healthy volunteers receiving transcutaneous electrical stimulation to the arms, legs, and/or spinal column to evoke various arm/hand and leg/foot movements.
10026765|NCT01725685|Experimental|Treatment C - FF/UMEC 400/500 mcg|Subjects will be randomized to single dose of FF/UMEC 100/125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
10026766|NCT01725698|Experimental|Stemcell|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
10026767|NCT01725711|Experimental|Implant System|
10026768|NCT01725724|Active Comparator|Allogeneic blood|Allogeneic blood transfusion. Patients in this group will receive allogeneic red cell transfusions.
10026769|NCT01725724|Experimental|Autologous blood|Autologous blood transfusion. Patients in this arm will receive per- and postoperatively collected autologous blood collected with the Sangvia Blood Collection System. If teh amount of autologous blood is too small for the clinical need, additional allogeneic blood will be transfused.
10026770|NCT01725737|Placebo Comparator|Placebo|
10026771|NCT01725737|Active Comparator|GlyTI-M|GlyTI-M: 0.03gm/kg/day
10026772|NCT01725763|Other|suspected PH|60 minute Cardiac MRI
10026773|NCT01725776|Experimental|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg(as for the injectable solution)
10026774|NCT01725789|Experimental|Ferinject® Group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
10026775|NCT01725789|Placebo Comparator|Placebo Group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
10026776|NCT01725802|Experimental|levodopa and carbidopa|levodopa and carbidopa solution
10026777|NCT01725802|Placebo Comparator|placebo to levodopa and carbidopa|saline
9463541|NCT03692078|Experimental|GROUP 5: OTDN product 2|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
9463542|NCT03692078|Experimental|GROUP 6: Tobacco Cessation|Subjects will completely stop all tobacco product usage for 7 days.
9463543|NCT03692065|Active Comparator|Apixaban film coated tablets 2.5 mg|Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.
9463544|NCT03692065|Active Comparator|Apixaban film coated tablets 5 mg|Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.
9463545|NCT03692039|Experimental|M-pro files|Instrumentation using M-pro files in rotating motion
9463546|NCT03692039|Active Comparator|ProTaper Next files|Instrumentation using ProTaper Next files in rotating motion
9463547|NCT03692026|Experimental|Study group|Immediate implant placement in fresh extraction sockets with addition of Hyaluronic acid and Melatonin mixture to the implant surface, into the extraction socket and to the peri-implant area.
9463548|NCT03692026|Active Comparator|Control group|Immediate implant placement in fresh extraction sockets without adding any material.
9463549|NCT03692013|Experimental|nighttime group|patients with nocturnal hypertension taking losartan at nighttime
9463550|NCT03692013|Active Comparator|daytime group|patients with nocturnal hypertension taking losartan at daytime
10026778|NCT01725828|Experimental|External Palpation group|External Palpation group will consist of 109 patients, who's CTM will be marked using traditional palpation technique of identifying the Cricothyroid membrane.
10026779|NCT01725828|Experimental|Ultrasound group|"Ultrasound group will consist of 114 patients, who's CTM will be marked using, ultrasonography to identify the CTM.~The Intervention by using the Ultrasound to determine the CTM."
10026780|NCT01725854|Experimental|Relaxation Response Training|The Military tailored RR training program will consist of six weekly small group sessions which involve group presentations, in-group skill building exercises, and at-home assignments. Groups will contain 5-8 participants who are active-duty Soldiers enrolled in either Respect-MIL or the Interdisciplinary Pain Management Center (IPMC).
10026781|NCT01725854|No Intervention|Standard of Care|Participants randomized to the control group will receive standard care through their providers at Respect-MIL or at the IPMC. Participants randomized to the control group will remain on the wait list for further standard care. After the collection of the final data point, these participants will also have the option to participate in an abbreviated, two-hour version of the RR training.
10026782|NCT01725867|Experimental|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
9463551|NCT03692000||Men with a history of prostate cancer|Men with a history of prostate cancer invited to participate in design-workshops , interviews or usabilitytesting.
9463552|NCT03691987|Experimental|Preprocessed thawed donor FMT|"The active transplants are processed in a 2-3 weeks period before treatment of the first participant. Fifty to eighty grams of freshly delivered feces from donors is mixed with 100 mL isotonic saline and 25 mL 85% glycerol, homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60 ml luerlock syringes and stored at -40°C.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the FMT-syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in an enema bag prior to installation."
10026783|NCT01725867|Active Comparator|Splint group|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
9463553|NCT03691987|Placebo Comparator|Preprocessed thawed autologous FMT|"The placebo transplant from each participant is prepared during the inclusion process four to six weeks before intervention and stored at -40°C. Fifty to eighty grams of freshly delivered feces from participants is mixed with 100 mL isotonic saline and 25 mL 85% glycerol is homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60ml Luerlock syringes.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the Luerlock syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in the enema bag prior to installation."
9463554|NCT03691935|Experimental|Ropivicaine|Erector Spinae Block of 20ml 0.5% ropivicaine bolus, connected to a pump containing 0.2% ropivicaine receiving 15ml every 3 hrs.
9463555|NCT03691935|Sham Comparator|Normal Saline|Erector Spinae Block of 20ml normal saline placebo bolus, then connected to pump of normal saline receiving 15ml every 3 hrs.
9463556|NCT03691922|Active Comparator|ESP Block|Preoperative US guided active Erector Spinae Plane (ESP) block and a saline PAI
9463557|NCT03691922|Other|PAI with LA|Preoperative US guided ESP blockade with saline and an active Periarticular Infiltration (PAI)
9463558|NCT03691896|Experimental|Lower dose|cholecalciferol 400UNT, oral solution
9463559|NCT03691896|Active Comparator|Middle dose|cholecalciferol 800UNT, oral solution
10026784|NCT01725880||No treatment|Observation
10026785|NCT01725906|Active Comparator|Empirical therapy|selection of antibiotic according to medication history
9463560|NCT03691896|Experimental|Higher dose|cholecalciferol 1200UNT, oral solution,
10026786|NCT01725906|Experimental|Genotypic resistance guided therapy|selection of antibiotics according to genotypic resistance
9463561|NCT03691883||TB patients|TB patients diagnosed and followed-up in Barcelona, at the following Hospitals/Clinics: Servicios Clínicos, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron-Drassanes, Hospital del Mar.
9802958|NCT04755699|Experimental|Individuals with a Spinal Cord Injury|This arm consists of individuals with a spinal cord injury receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
9802959|NCT04755699|Experimental|Individuals with a Stroke|This arm consists of individuals with a stroke receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
9802960|NCT04755699|Experimental|Individuals with other Brain or Nerve Injuries|This arm consists of individuals with a other brain and nerve injuries receiving transcutaneous electrical stimulation to the arms/hand, legs/foot, and/or spinal column to evoke various arm/hand or leg/foot movements.
9802961|NCT04755140||Endoprosthesis|Patients with a endoprosthesis
9802962|NCT04753827|Experimental|Experimental Group Stent only|Stents were implanted in MV and SB respectively, and DKcrush or Culotte technology was selected according to the lesion characteristics.
9802963|NCT04753827|Experimental|Experimental Group Stent+DCB|The MV was stented and the SB were treated with just drug-coated balloon(DCB)
9802964|NCT04753827|Experimental|Experimental Group L-Sandwich|Stents were implanted in the MV and the shaft of side branch SB respectively, then a DCB was applied to the ostium of the SB
9802965|NCT04753658||Pediatric Neuroblastoma Patients Treated with Lorlatinib|
10036754|NCT01818648|Experimental|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
9802966|NCT04751201|Experimental|Receiving mindfulness open and circular program|
9802967|NCT04745910|Experimental|Treatment (pegloticase)|Patients receive pegloticase IV over 120 minutes. Patients whose serum uric acid does not drop below 6 mg/dL within 24 hours receive a second dose of pegloticase IV over 120 minutes on day 2. Patients whose serum uric acid does not drop below 6 mg/dL after two doses of pegloticase receive standard of care rasburicase IV QD for 5 days.
9802968|NCT04742556|Experimental|BI 3011441|
9802969|NCT04742179|Experimental|Experimental group|The children belonging to the classes of the school complex undergoing the maintenance intervention.
9802970|NCT04742179|No Intervention|Control group|The children belonging to the classes of the school complex that will not undergo the maintenance intervention.
9802971|NCT04733417|Experimental|SHR6390+famitinib|Participants will receive SHR6390 in combination with famitinib.
10026787|NCT01725919|Experimental|Immediate CI therapy|
10026788|NCT01725919|Active Comparator|Delayed CI therapy|
10026789|NCT01725932|Experimental|Culturally adapted CBT based Self Help|Culturally sensitive cbt based self help intervention, which consists of 6 regular chapters and 2 additional chapters. The self help intervention involves family to improve compliance with the intervention
9463562|NCT03691870|Active Comparator|standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment.~The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
10026790|NCT01725932|No Intervention|Care As Usual|Control Group
10026791|NCT01725945|No Intervention|Usual Care|Usual Care
10026792|NCT01725945|Experimental|DASH Intervention|Dietary Approaches to Stop Hypertension dietary pattern. Usual care in combination with a DASH intervention consisting of 8 group and 3 individual sessions over 3 months, followed by 3 monthly phone consultations.
9463563|NCT03691870|Experimental|Trans-Venous Embolization (TVE) (+/- Arterial) strategy|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.~It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion)."
10026793|NCT01725958|Experimental|Dietary Supplement|"Treatment Regimen~-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake."
10026794|NCT01725971||Control group|Group of nonsmokers individuals without respiratory disease.
9463564|NCT03691818|Experimental|Low-dose test drug group|X0002 Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
9463565|NCT03691818|Active Comparator|Low-dose active drug control group|Ibuprofen Tablet 400 mg/time, 3 times /day; X0002 Placebo Spray 1 Spray/time/Knee, 2 times/day.
9463566|NCT03691818|Placebo Comparator|Low-dose placebo control group|Placebo Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times/day.
9463567|NCT03691818|Experimental|Medium-dose test drug group|X0002 Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
10026795|NCT01725971||normal exam|subjects with silicosis , but with normal spirometric data
9463568|NCT03691818|Active Comparator|Medium-dose active drug control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
9463569|NCT03691818|Placebo Comparator|Medium-dose placebo control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
9463570|NCT03691818|Experimental|High-dose test drug group|X0002 Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
9463571|NCT03691818|Active Comparator|High-dose active drug control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
9463572|NCT03691818|Placebo Comparator|High-dose placebo control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Placebo Tablet 400 mg/time, 3 times /day.
9463573|NCT03691805|Active Comparator|anodal tDCS over rDLPFC|Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).
9463574|NCT03691805|Sham Comparator|sham tDCS|Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.
10026796|NCT01725971||mild obstruction|subjects with silicosis with mild obstruction in spirometric data
10026797|NCT01725971||moderate to severe obstruction|subjects with silicosis with moderate to severe obstruction in spirometric data
10026798|NCT01725997|Active Comparator|Operative treatment|Operative treatment with hook plate.
10026799|NCT01725997|Active Comparator|Conservative treatment|Physiotherapy
10026800|NCT01726010|Experimental|22-G Procore Needle|
10026801|NCT01726062|Experimental|Motivational Interviewing plus Incentives|
10026802|NCT01726062|Other|Conventional Care (CC)|
10026803|NCT01726075|Experimental|COLIRIOBCN070660|COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution. One drop/eye administered twice a day.
10026804|NCT01726075|Placebo Comparator|Placebo|Placebo Eye drops, solution. One drop/eye administered twice a day.
10026805|NCT01726075|Experimental|Brimonidine|Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.
10026806|NCT01726088|Active Comparator|modafinil|Study participants randomized to the active arm of the study will take modafinil 100mg capsules orally each day for 4 weeks.
10026807|NCT01726088|Placebo Comparator|Sugar Pill|Study participants randomized to the placebo arm of the study will take matching capsules orally each day for 4 weeks.
10026808|NCT01726114|Experimental|Non-invasive Optical Glucose Monitor™|Test device
10026809|NCT01726127|Experimental|Broccoli and Brussels Sprouts|Subjects will consume broccoli or Brussels sprouts (40g daily) for 8 weeks.
10026810|NCT01726127|Experimental|Cruciferous Complete|Subjects will take Cruciferous CompleteTM supplements (2 capsules, 3 times daily) for 8 weeks.
10026811|NCT01726127|Placebo Comparator|Placebo|Subjects will take placebo capsules (2 capsules, 3 times daily) for 8 weeks.
10026812|NCT01726140|Experimental|TREATMENT|Helmet CPAP
10026813|NCT01726140|Active Comparator|CONTROL|Venturi Mask
10026814|NCT01726153|No Intervention|Web sites|Individuals assigned to this arm are given a list of websites where they can view additional information relating to condom use.
9463575|NCT03691792|Experimental|Cognitive-Behavioral Therapy (CBT-SAD)|12 1.5-hour group sessions at a rate of 2 sessions per week over 8 weeks.
9463576|NCT03691792|Active Comparator|Light Therapy|6 weeks of daily light therapy at home, using a 10,000-lux light box beginning at 30 minutes upon waking, with dose subsequently adjusted per treatment algorithm.
9463577|NCT03691766|Experimental|Photobiomodulation Therapy|Experimental: Photobiomodulation Therapy comprising 640 nm, 875 nm, and 905 nm light (red lights)
10026815|NCT01726153|Experimental|Condom-HIM|Individuals assigned to this arm must follow an on-line one session tailored intervention.
10026816|NCT01726166|Active Comparator|Suprapubic Aspiration|A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
9463578|NCT03691766|Placebo Comparator|Control|Placebo device with different wavelengths of light without known physiologic effect.
9463579|NCT03691753|Experimental|Experimental arm|Patients will be treated with Fitaya Vena Cava Filter System.
9463580|NCT03691753|Active Comparator|Control arm|Patients will be treated with Aegisy Vena Cava Filter.
9463581|NCT03691740|Experimental|Experimental|Ocular light will be applied via a mask. The participants allocated to the experimental group will receive blue light
9463582|NCT03691740|Placebo Comparator|Control|Ocular light will be applied via a mask. The participants allocated to the control group will receive red light
9463583|NCT03691701|Experimental|Strict SBP Target|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
9463584|NCT03691701|No Intervention|Usual SBP Target|Usual care, no home SBP target
9463585|NCT03691688||Aspirin|Aspirin 100mg
9463586|NCT03691688||Clopidogrel|Clopidogrel 75mg
9463587|NCT03691675|Experimental|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
9463588|NCT03691662|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
9463589|NCT03691662|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
10026817|NCT01726166|Active Comparator|Urinary Catheterization|"The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat)."
10026818|NCT01726192|Active Comparator|HLOC|Placement of a femoral catheter with the hydrolocalization technique
10026819|NCT01726192|Active Comparator|NS|Placement of a femoral neurostimulating catheter
10026820|NCT01726205|Active Comparator|pregabalin|perioperative pregabalin starting the evening before surgery, and for five days postoperatively
10026821|NCT01726205|Active Comparator|pregabalin and continuous wound infusion|Pregabalin as previous group and continuous infusion of ropivacaine 0.2% via a wound catheter
10026822|NCT01726205|Placebo Comparator|placebo|Placebo drug and normal saline infusion
10026823|NCT01726218||Stroke patients|
10026824|NCT01726218||Healthy Control|
10026825|NCT01726244|No Intervention|Control group|Habitual Clinical Practice
9463590|NCT03691649|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
9463591|NCT03691649|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
9463592|NCT03691636|Experimental|Eyelash Prostheses|Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
9463593|NCT03691636|Active Comparator|5.0% Lifitegrast Ophthalmic Solution|Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
9463594|NCT03691623|Experimental|EDP-938 Arm A|Subjects will take EDP-938 Dose 1 oral suspension for 5 days
9463595|NCT03691623|Experimental|EDP-938 Arm B|Subjects will take EDP-938 Dose 2 oral suspension for 5 days
9463596|NCT03691623|Placebo Comparator|Placebo Arm C|Subjects will take matching placebo oral suspension for 5 days
9463597|NCT03691623|Experimental|EDP-938 Arm D|Subjects will take EDP-938 Dose 3 oral suspension for 5 days
9463598|NCT03691623|Experimental|EDP-938 Arm E|Subjects will take EDP-938 Dose 4 oral suspension for 5 days
9463599|NCT03691623|Placebo Comparator|Placebo Arm F|Subjects will take matching placebo oral suspension for 5 days
9463600|NCT03691597|Active Comparator|Adhesive resin cement|type of cement used for cementation of crowns have a good adhesion bond
9463601|NCT03691597|Experimental|Bioactive cement|recent cement improve the marginal integrity
9463602|NCT03691558|Experimental|Ketogenic diet|Subjects followed 5 weeks of ketogenic diet
9463603|NCT03691558|Active Comparator|Western Diet|Subjects followed 5 weeks of a western diet
9463604|NCT03691545|Experimental|Intervention Group|(1) 12 weekly interactive sessions with a health coach to help them set goals and make changes toward becoming physically active and consuming the recommended number of fruits and vegetables.
9463605|NCT03691532|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~60 min (duration of exercise performed in other arm). Following the intervention they are fed a liquid meal.
9463606|NCT03691532|Experimental|Arm cycle exercise (ACE)|Participants complete continuous arm cycle exercise (ACE) for ~60 min. Following the intervention they are fed a liquid meal.
9463607|NCT03691506|Active Comparator|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
9463608|NCT03691506|Experimental|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
10026826|NCT01726244|Experimental|Intervention Group|Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
10026827|NCT01726283||low risk subjects for developing post-operative ectasia|Patients undergoing vision correction surgery who are not at a higher risk for developing post-op ectasia
9463609|NCT03691493|Experimental|Radiation, palbociclib, hormone therapy|Patients undergo radiation therapy over 5-10 days and receive palbociclib PO QD on days 1-21. At the discretion of treating physician, patients also receive letrozole, anastrozole, exemestane, or tamoxifen PO QD on days 1-28, or fulvestrant IM on days 1 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9463610|NCT03691480|Experimental|simple exsufflation|
9463611|NCT03691480|Experimental|Fuhrman catheter and ambulatory care|
10026828|NCT01726283||Subjects at Risk for Ectasia|Patients undergoing vision correction surgery who are at a higher risk for developing post-operative ectasia
10026829|NCT01726296|Experimental|Health services research (educational intervention)|Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.
10026830|NCT01726348||Darunavir|Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
9463612|NCT03691467|Experimental|immediate implant with hyaluronic acid.|immediate dental implant with topical application of hyaluronic acid.
9463613|NCT03691467|Active Comparator|immediate implant.|immediate dental implant placement with placebo gel
10026831|NCT01726361|Experimental|MTFC|Out of home placement in MTFC family program
10026832|NCT01726361|Active Comparator|TAU|Other kind of out of home placement
9463614|NCT03691454|Experimental|DOS|Docetaxel+Oxaliplatin+S-1
9463615|NCT03691454|Active Comparator|SOX|Oxaliplatin+S-1
9463616|NCT03691441|Experimental|Resection/adjuvant radio(-chemo)therapy|"Transoral surgical resection within 4 weeks after randomization~Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization~6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery"
9463617|NCT03691441|Active Comparator|Adjuvant radio(-chemo)therapy/salvage neck dissection|"6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization~70-72 Gy, SIB possible~Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33~+/- Salvage neck dissection 12±2 weeks after treatment"
9463618|NCT03691415||BELKYRA Inj.|Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.
9463619|NCT03691376|Experimental|Treatment (autologous NY-ESO-1 engineered T and HSC)|Patients receive melphalan IV over 30 minutes on day -1. Patients then receive autologous NY-ESO-1 CD4-TCR CD34+ HSC IV on day 0 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21. Patients also receive aldesleukin SC BID for 14 days on the following day after the T cell infusion (between days 8 and 22).
9463620|NCT03691363|Experimental|M-STEP|Mobile exercise intervention
9463621|NCT03691350|Active Comparator|Group I (usual cigarette brand)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Participants continue to smoke their usual brand of cigarettes. Participants undergo a second bronchoscopy on day 71.
9479851|NCT03539315|Experimental|Intervention: ARCHES|All women attending facilities assigned to the intervention arm receive the Addressing Reproductive Coercion within Healthcare Settings (ARCHES) intervention.
10026833|NCT01726374|Experimental|One cycle adjuvant BEP(500)|Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
9463622|NCT03691350|Experimental|Group II (SREC with nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC with nicotine for 2 weeks and switch completely to the SREC with nicotine starting day 15 for 8 weeks. Participants undergo a second bronchoscopy on day 71.
9463623|NCT03691350|Experimental|Group III (SREC without nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
10026834|NCT01726387|Experimental|Psychosocial Counseling|A Counseling Assistant offers a low-threshold intervention (self-management support, counseling, active guidance). This nurse practitioner collaborates extensively with the general practitioner, re-adjusting the intervention in order to meet the patient's needs.
10026835|NCT01726387|Placebo Comparator|Usual Care|Depending on the conditions, patients get usual care of their general practitioner.
10026836|NCT01726400||Interferon and ribavirin|Treatment with standard of care pegylated interferon alpha and ribavirin.
10026837|NCT01726413|Experimental|Test Arm|GRC17356 for daily administration
9463624|NCT03691350|Experimental|Group IV (usual cigarette brand, nicotine-containing SREC)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the nicotine-containing SREC for 2 weeks and use both their usual brand of cigarettes and the nicotine-containing SREC starting day 15 for 8 weeks with the intention of smoking reduction to 5 cigarettes or less per day. Participants undergo a second bronchoscopy on day 71.
10026838|NCT01726413|Placebo Comparator|Placebo|Matching placebo for daily administration
10026839|NCT01726426|Experimental|Patients of palmer arsenical keratosis|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
10026840|NCT01726426|Active Comparator|Arsenic exposed controls|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
9463625|NCT03691350|Experimental|Group V (NRT)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 2 days before the day 15 quit date, participants stop smoking using NRT comprising either patch, gum, or lozenge for 8 weeks. Participants undergo a second bronchoscopy on day 71.
9463626|NCT03691337|Active Comparator|Low dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.11 mL x subject height)
9463627|NCT03691337|Active Comparator|High dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.22 mL x subject height)
9463628|NCT03691337|Placebo Comparator|Placebo|Preoperative fascia iliaca block with Sodium Chloride 0.9% (0.11 mL x subject height)
9463629|NCT03691324|Experimental|Intervention|Patients receive an inhalation technique education based on standardized procedure developed by The Norwegian Pharmacy Association. In addition they are offered a discharge service day before or the day of discharge; a second inhalation training and dispensing of their prescribed COPD- medicines.
9463630|NCT03691324|No Intervention|Standard care|Patients receive standard care and follow up of their COPD-treatment
9463631|NCT03691298||Arthroscopic hip repair|
9463632|NCT03691285|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
9463633|NCT03691285|Active Comparator|Two-implant mandibular overdenture|Participants allocated to this group will have two implants placed in the inter-foraminal region after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
9463634|NCT03691272|Experimental|rTMS- Real Air Film Coil|Patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. The DLPFC will be located through MNI coordinates (-48, 20, 34). Electromyography (EMG) electrodes will be attached to the right abductor digiti minimi (ADM) muscle. The resting motor threshold (RMT) is determined as the minimal stimulation intensity required to elicit motor-evoked response of 50 microvolts peak-to-peak amplitude in at least 5 out of 10 consecutive trials of the ADM (contralateral to stimulation).
9463635|NCT03691272|Sham Comparator|rTMS- Sham coil|The same procedure for determining RMT as described above will be employed for the Sham Arm. However, a sham coil will be used when the treatment over the left DLPFC is applied.
9463636|NCT03691259|Experimental|Dance Group|Dance group will participate in one-hour ballet classes twice per week for 10 weeks
9463637|NCT03691259|No Intervention|Control Group|The control group will not participate in the ballet classes
10026841|NCT01726426|Active Comparator|Heathy volunteers|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
10026842|NCT01726439||CHB patients who are naive to NUC treatment|CHB patients who are naive to NUC at enrollment and be treated at hospitals at tier 2 cities in China
10026843|NCT01726465|Experimental|N-acetylcysteine|Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.
10026844|NCT01726465|Experimental|Methylprednisolone|Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
10026845|NCT01726465|Placebo Comparator|Placebo|Patients were randomized to this arm will receive placebo (Ringer's acetate) in an hour after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
10026846|NCT01726478|Active Comparator|2.5 units oxytocin|Administration of 2.5 units of oxytocin intravenously after clamping of umbilical cord
10026847|NCT01726478|Placebo Comparator|10 units oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
10026848|NCT01726491||Insulin resistance epigenetics|"This experiment will use the Infinium methylation assay to perform epigenome mapping and define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. We will test the hypotheses that~(1) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (2) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (3) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance."
9463638|NCT03691220|Experimental|Telemetric Intervention Arm|Adolescent with MLVI>2 to receive the telemetric intervention.
9463639|NCT03691220|No Intervention|Standard of Care Arm|Adolescent with MLVI>2 to receive standard of care.
9463640|NCT03691194|Experimental|fresh orange juice|Subject will take 8 ounces of fresh orange every day for 28 days.
9463641|NCT03691194|Active Comparator|concentrated orange juice|Subject will take 8 ounces of concentrated orange juice every day for 28 days.
9463642|NCT03691181|Experimental|Open Ambulatory Ventilation|"monitoring with the use of the Life2000 Open Ventilation System for a period of six months with measures of nutrition, feeling of breathlessness, exercise tolerance, and quality of life.~BODE Index B - BMI - BMI stands for body mass index, a calculation made by comparing height vs weight.~O - Airway obstruction - Airway obstruction is measured by evaluating FEV1 - the amount of air that can be forcefully exhaled in 1 second after a deep breath.~D - Dyspnea - Dyspnea refers to the degree of breathlessness someone experiences while living with COPD.~E - Exercise tolerance - Exercise testing refers to how well some does on a 6-minute walk test.~Modified Medical Research Council Dyspnea Scale"
9463643|NCT03691142||Women with Hereditary Haemorrhagic Telangiectasia|Women with Hereditary Haemorrhagic Telangiectasia with at least one full term pregnancy
10026849|NCT01726491||Single bout of exercise|"This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and~Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise."
10026850|NCT01726491||Eight weeks of exercise|"This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes,~There is altered methylation of genes involved in inflammation and cytoskeletal structure."
9463646|NCT03691116|Experimental|Digital Health Profile|A digital health check-up, with questions, brief feedback and information about alcohol, tobacco, diet and exercise, as a complement to treatment as usual. (Psychological assessment and treatment)
9463647|NCT03691116|Active Comparator|Treatment as usual|Psychological assessment and treatment as usual.
9463648|NCT03691090|Experimental|SHR-1210 + paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
9463649|NCT03691090|Active Comparator|placebo+paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance
9463650|NCT03691077|Experimental|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
9463652|NCT03691038|Active Comparator|Pregabalin 75mg bid|The patients who were prescribed according to the conventional flexible dose regimen
9463653|NCT03691038|Experimental|pregabalin 25mg,50mg|The patients who were prescribed according to the new flexible dose regimen.
9463654|NCT03691025||RALPD|
9463655|NCT03690999|Placebo Comparator|Placebo group|Placebo product
9463656|NCT03690999|Experimental|Prebiotic Supplement, low dose|
9463657|NCT03690999|Experimental|Prebiotic Supplement, high dose|
9463658|NCT03690973|Active Comparator|Alveolar socket preservation with graft and flap surgery|
9463659|NCT03690973|Experimental|Immediate implant placement with bone using flapless surgery|
9463660|NCT03690973|Experimental|Immediate implant placement with bone and flap surgery|
9463661|NCT03690973|Experimental|Alveolar socket preservation with graft and flapless surgery|
9463662|NCT03690960|Experimental|electrospun TAP nanofibers|Revascularization procedure with Electrospun TAP nanofibers as as an intracanal medicament for immature necrotic teeth
9463663|NCT03690960|Active Comparator|modified TAP paste|Revascularization procedure with modified TAP paste as an intracanal medicament for immature necrotic teeth
9479852|NCT03539315|No Intervention|Control|All women attending facilities assigned to the control arm receive the standard of care (no intervention).
9479853|NCT03539289|Other|MUFA Diet|Monounsaturated Fatty Acids Diet
9479854|NCT03539289|Other|SFA Diet|Saturated Fatty Acids Diet
9479855|NCT03539276|No Intervention|Pre-intervention|Usual care
9479856|NCT03539276|Experimental|Post-intervention|One 90-minute interdisciplinary knowledge exchange including the provision of a validated list of appropriate and inappropriate medications for severe dementia long-term care residents.
9479857|NCT03539263|Experimental|Group 1|the subjects are treated with probiotics: Bifihappy
9463664|NCT03690947|Experimental|Combination Therapy Group|
9463665|NCT03690947|Active Comparator|Intravitreal Ranibizumab Group|
9463666|NCT03690934|Experimental|Fistula-tract laser closure (FiLAC™)|The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.
10026851|NCT01726530|Active Comparator|Transdermal fentanyl patch|Transdermal fentanyl patch, 50 mcg/hour, was attached to the patient's chest wall at 10 pm the day before surgery
10026852|NCT01726530|Placebo Comparator|Placebo|Placebo patch was attached to the patient's chest wall at 10 pm the day before surgery
9463667|NCT03690934|Active Comparator|Fistula monopolar cogulation|The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.
9802972|NCT04732663||Persistently Symptomatic Covid-19 (PS-CoV)|PS-CoV will be defined as individuals with a history of molecular testing confirmed COVID-19 infection, recovered from acute infection but with ongoing symptoms (self-reported, pulmonary, cardiac, musculoskeletal or other symptoms) of at least 4 weeks' duration. Recovery from acute infection will be defined according to provincial health guidelines: at least 10 days' (14 in those hospitalized; 21 in those with immunocompromise) from onset of symptoms with at least 24 hours without a fever, without taking anti-pyretic medications and improvement of other symptoms.
9802973|NCT04732663||Recovered Covid-19|Recovered Covid-19 Survivors will be defined as individuals without complaint of a persisting covid-19 symptom. Recovered Covid-19 survivors will be matched to PS-CoV for age, sex, body mass index and time post corona virus infection.
10026853|NCT01726543|Active Comparator|Canaloplasty and phacoemulsification|
10026854|NCT01726543|Active Comparator|Non-penetrating deep sclerectomy and phacoemulsification|
10026855|NCT01726556|Active Comparator|Rigid thoracoscopy|Rigid thoracoscopy would be done using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany.
9463668|NCT03690921|Experimental|Treatment (LET-IMPT, chemotherapy)|Patients undergo linear energy transfer-optimized intensity modulated proton therapy 5 times per week for 5-6 weeks. Patients also receive standard cisplatin and fluorouracil IV weekly for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
9463669|NCT03690908||IgG4-related orbital inflammation|patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy
9463670|NCT03690908||non IgG4-related orbital inflammation|patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy
9463671|NCT03690895||Cases|
9463672|NCT03690882||Cases of unclassified acute cervical pain|
9463673|NCT03690856|Experimental|depressiv people|
9463674|NCT03690830|Experimental|Case group RIF|blood samples, analyzing endometrial cells
9463675|NCT03690830|Experimental|Case group IRPL|blood samples, analyzing endometrial cells
9463676|NCT03690830|Active Comparator|Control group|blood samples, analyzing endometrial cells
9463677|NCT03690817||Bilateral vestibulopathy|Patients with bilateral vestibulopathy, according to the Barany Criteria (2017, Strupp).
10026856|NCT01726556|Active Comparator|Semirigid thoracoscopy|The semirigid thoracoscope employed is a model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan.
10026857|NCT01726582|Other|Pre surgery targeted chemo|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm A:~Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging:~see link to protocol Figures A & C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
9463678|NCT03690817||Healthy controls|Subjects without vestibular or neurological diseases (DHI<5), and with normal hearing thresholds according to their age.
9463679|NCT03690804|Experimental|newborn is above 28 weeks of gestational age|40 parent-newborn duos in which the newborn is above 28 weeks of gestational age and less than 3 months of life and hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France)
9463680|NCT03690791|Active Comparator|MediCabilis CBD Oil|
9463681|NCT03690791|Placebo Comparator|Placebo Oil|
9463682|NCT03690778|Experimental|Group I|"Period I: administration of Metformin and Rosuvastatin seperately Period II: JLP-1310"
9463683|NCT03690778|Experimental|Group II|"Period I: JLP-1301 Period II: administration of Metformin' and Rosuvastatin seperately"
9463684|NCT03690752|Sham Comparator|weighted|"The weighted group uses the same Alter-G Treadmill as the unweighted group but were not allowed to use the unweighting function of the treadmill.~Intervention: unweighting using Alter-G Anti-Gravity Treadmill"
9463685|NCT03690752|Experimental|unweighted|"The unweighted group uses the same Alter-G Anti-Gravity Treadmill as the weight group but is allowed to adjust their weight using the weight control feature.~Intervention: normal weight using Alter-G Anti-Gravity Treadmill"
9463686|NCT03690739|Active Comparator|platinum-based chemotherapy|According to the investigator's discretion
9463687|NCT03690739|Active Comparator|PLD + Trabectedin|PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21
9463688|NCT03690726|Experimental|Active rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to active treatment arm receive consecutive treatment sessions with rTMS directed at cranium and cortex regions as described in protocol.
9463689|NCT03690726|Sham Comparator|Sham rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to sham/control arm receive consecutive treatment sessions with coil from rTMS that fires at other spot (pillow/mattress) as described in protocol.
9463690|NCT03690713||Patient and Vessels underwent physiologic evaluation|The total 1397 patients (1694 vessels) which evaluated using pressure-temperature sensor wire and measured FFR, CFR, and IMR.
9463691|NCT03690700|Active Comparator|active BFRE|14 consecutive paraplegic SCI patients are block-randomized to active arm
9463692|NCT03690700|Sham Comparator|sham BFRE|14 consecutive paraplegic SCI patients are block-randomized to sham arm
10026858|NCT01726582|Other|Pre surgery cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm B:~Before surgery: Chemoradiotherapy (cRXT); restaging:~see link to protocol Figure C and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
10026859|NCT01726582|Other|Pre surgery targeted chemo, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C1:~Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging~see link to protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
9463693|NCT03690687||Group I. Primary anastomosis|Resection of the small bowel to place primary anastomosis into small intestine or transverse colon during relaparotomy.
9463694|NCT03690687||Group II. Delayed anastomosis|Resection of the small intestine to place delayed anastomosis. After the closure of the afferent and efferent loops of the small intestine, anastomosis was not applied. A decompression probe was introduced into the upper small intestine. In 24-36 hours, delayed anastomosis was placed into the small intestine or transverse colon during the planned relaparotomy with arrested postoperative peritonitis.
9463695|NCT03690687||Group III. Enterostomy|Resection of the small intestine with enterostomy. In case there was no postoperative peritonitis relief and was organ dysfunction progression, anastomosis was not placed. The surgery was completed with enterostomy to perform open abdomen.
9463696|NCT03690661|Experimental|Intervention Video Game|Participants will play the Intervention Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
9463697|NCT03690661|Placebo Comparator|Control Video Game|Participants will play the Control Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
9463698|NCT03690648||Saliva collection|"Clinical examination;~Quality of life survey;~Saliva collection for genetical analysis"
9463699|NCT03690648||Saliva and Blood collection|"Clinical examination;~Quality of life survey;~Saliva and blood collection for genetical analysis"
9463700|NCT03690635|Experimental|VISTA technique|evolution of a newer approach known as Vestibular Incision Subperiosteal Tunnel Access (VISTA) was proposed to avoid some of the potential complications occurring with other intrasulcular tunneling techniques
9463701|NCT03690635|Active Comparator|tunneling technique|Several modifications of tunnel technique have been described in order to preserve esthetics, avoid relapse of gingival recession and maintain papillary integrity. These modifications also attend to avoid scar formation and delayed healing related to vertical releasing incision
9463702|NCT03690622|Sham Comparator|BSS|Balanced salt solution
9463703|NCT03690622|Active Comparator|Dexmedetomidine|dexmedetomidine (0.0055%)
9463704|NCT03690609|Active Comparator|Nutraceutical intervention, 3 capsules daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 3 capsules daily in the morning.
9463705|NCT03690609|Active Comparator|Nutraceutical intervention, 2 capsules twice daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 4 capsules daily: Two in the morning and two later in the day.
9463706|NCT03690583|Experimental|Zinc group|Zinc sulfate 10 mg in children younger than 1 year old, 20 mg in children older than 1 year old
9463707|NCT03690583|Placebo Comparator|Placebo group|Glucose
9463708|NCT03690557|Experimental|IncentaHealth|All patients who decide to join the weight loss program will be enrolled in the commercially-available IncentaHealth program - a comprehensive, evidence-based, behavioral weight management program designed to help patients initiate and maintain weight loss. The program is delivered completely online, via website, emails, mobile app, and (if requested by the participant) text messaging over 12 months. Each participant will be given a digital scale that wirelessly syncs with a smartphone app. Participants' weights are automatically uploaded to the Incentahealth online portal. In the informed consent process, participants will need to agree to release their weight data to researchers at the University of Nebraska Medical Center in order to participate in this program.
9463709|NCT03690531||Take Pause Virtual Reality Head Set|The mbVR intervention arm will be a Take-Pause virtual reality simulation will be for 5 minutes shown through a virtual reality goggle, headset and iPhone.
9463710|NCT03690531||Passive Distraction Group_IPAD|The Passive Distraction group will utilize the standard or passive distraction technique of using an IPAD lasting 5 minutes.
9463711|NCT03690505|Other|Assessment|Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
9463712|NCT03690492|Experimental|The Box 2.0|Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
9463713|NCT03690492|No Intervention|Controls|Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.
10026860|NCT01726582|Other|Pre surgery FOLFIRINOX, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C2:~standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging:~see link at protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
10026861|NCT01726582|Other|After surgery targeted chemo, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D1:~After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
10026862|NCT01726582|Other|After surgery Gemcitabine, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D2:~Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
9463714|NCT03690479|Active Comparator|Ball Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the new trial tip (ball-end probe, 0.6mm diameter).
10026863|NCT01726582|Other|After surgery cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm E:~After surgery: chemoradiotherapy (cXRT); restaging:~see lint to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
9463715|NCT03690479|Active Comparator|Florida Probe Straight Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip (straight-end probe, 0.45mm diameter).
9463716|NCT03690414|Active Comparator|Experimental BHVI2 eye drops|20 participants will receive one drop per eye every night for four weeks.
9463717|NCT03690414|Active Comparator|0.02% Atropine eye drops|20 participants will receive one drop per eye every night for four weeks.
9463718|NCT03690414|Active Comparator|Experimental BHVI2 plus 0.02% atropine|20 participants will receive one drop per eye every night for four weeks.
9463719|NCT03690362|Experimental|Group 1 - Control|Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment
9463720|NCT03690362|Experimental|Group 2 - Mild Renal Impairment|Mild renal impairment
9463721|NCT03690362|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
9463722|NCT03690362|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
9463723|NCT03690362|Experimental|Group 5 - ESRD|End Stage Renal Disease undergoing chronic intermittent hemodialysis
9463724|NCT03690349||Skin test in severe asthma exacerbation|Skin test in asthmatic children hospitalized due to severe asthma exacerbation in a preceding year
10026864|NCT01726582|Other|After surgery targeted chemo|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F1:~Targeted chemotherapy after surgery: 8 weeks targeted chemotherapy; restaging; 8 weeks targeted chemotherapy; restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
10026865|NCT01726582|Other|After surgery Gemcitabine|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F2:~Gemcitabine after surgery : 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
9463725|NCT03690349||skin test in outpatient|Skin test in asthmatic children without severe asthma exacerbation in a preceding year
9463726|NCT03690323|Experimental|RFA|"RFA: laparotomy is performed followed by radiofrequency ablation of the tumor.~After recovery of the RFA patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel + gemcitabine or gemcitabine monotherapy"
9463727|NCT03690323|Active Comparator|Chemotherapy|"Patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel plus gemcitabine or gemcitabine monotherapy"
9463728|NCT03690310|Experimental|Anti-CD19 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19 CAR NK cells will be administered at day0
9463729|NCT03690297|Experimental|LCI|Linked Color Imaging
9463730|NCT03690297|Active Comparator|WL|White Light
9463731|NCT03690271||Groupe 5-5|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way : 5 ml~dose to be administered every hour by the patient : 5 ml"
9463732|NCT03690271||groupe 6-6|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way : 6 ml~dose to be administered every hour by the patient : 6 ml"
9463733|NCT03690271||groupe 7-7|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way :7 ml~dose to be administered every hour by the patient :7 ml"
9463734|NCT03690258|Experimental|Variable load exercise|"Variable load intervention (The nHANCE-squat ultimate - iso-inertial load, with power output in watts performed 3 x per week) will being performed to determine whether this training approach is an effective countermeasure to attenuate for rapid declines in muscle power, function, contractile capacity that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in seniors.~Data available at: http://nhance.se/"
9463735|NCT03690258|Experimental|Variable load intervention|"This study is being conducted to determine whether this variable load (The nHANC dead lift - eccentric overload performed 3 x per week for 4-6 weeks) intervention is an effective countermeasure to modulate blood pressure in seniors. Since age-related incline in resting blood pressure (hypertension) is accelerated already after short bouts of physical inactivity, any attempt to counteract age-related and disuse-related decline have high clinical significance. In addition, we aim to examine endothelial function via non-invasive flow mediated dilatation (FMD) technique.~Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in this specific population. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system, especially for reducing economic burden."
9463736|NCT03690245|Active Comparator|Control|Infants will have immediate cord clamping and respiratory support afterwards
9463737|NCT03690245|Experimental|Initiation of Resuscitation While Attached to the Cord|Infants will receive respiratory support for 120 seconds while attached to the cord.
9463738|NCT03690232|Experimental|Glucose group|The glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment
9463739|NCT03690232|Active Comparator|hyaluronic acid group|The HA group was administered intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment.
9479858|NCT03539263|Placebo Comparator|Group 2|the subjects are treated with a placebo
10026866|NCT01726582|Other|After surgery no additional treatment|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm G:~No additional therapy after surgery:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
10026867|NCT01726595||severe sepsis|Patients with severe sepsis or septic shock
9463740|NCT03690193|Experimental|Ketogenic Diet Arm|All participants will be assigned to the 3-month ketogenic diet intervention. Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein). Participants will be provided medium chain triglyceride oil with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
9463741|NCT03690180||Diabetics with microalbuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
9463742|NCT03690180||Diabetics with normal albuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
9463743|NCT03690167|Active Comparator|Concentrated Growth Factor (CGF)|Participants with impacted lower third molar
9463744|NCT03690167|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|Participants with impacted lower third molar
9463745|NCT03690167|Sham Comparator|Control|Participants with impacted lower third molar
9463746|NCT03690141|Experimental|tomivosertib (eFT508)|Tomivosertib (eFT508) is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics, Inc. as an anticancer therapy. Tomivosertib (eFT508) down regulates AR and acts by inhibiting mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK1) and MNK2.
9463747|NCT03690128|Active Comparator|Control Arm - standard EWS procedure|Standard use of the current implement Early Warning System, based on the principles of the National Early Warning Score and with a standard escalation protocol.
10026868|NCT01726595||non-infected critically ill|Patients with severe non-infectious systemic inflammatory response syndrome
10026869|NCT01726595||healthy|healthy volunteers
9463748|NCT03690128|Active Comparator|Intervention Arm - I-EWS|"Implementation of Individual Early Warning Score (I-EWS) with a systematic clinical assessment with a standard escalation protocol as intervention 7 parameters (Respiration rate, pulse, saturation, systolic blood pressure, consciousness, temperature, Oxygen) are registered , an aggregated score is generated. In the electronic patient journal (Sundhedsplatformen), the nursing staff is asked to reevaluate the aggregated score based on their clinical assessment of the patient. The aggregated score can be upgraded with up to 6 points and downgraded with up to 4.~This new I-EWS score interacts with the standard escalation protocol which defines the observation frequency and relevant clinical actions."
9463749|NCT03690115|Experimental|Experimental|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
9463750|NCT03690102|Experimental|No BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario before attending the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
9463751|NCT03690102|Experimental|With BLS course. No T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will not receive T-CPR."
9463752|NCT03690102|Experimental|With BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
9463753|NCT03690076||Control|patients with normal weight (23 < BMI < 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
9463754|NCT03690076||Endocarditis|patients with normal weight (23 < BMI < 27) carriers of endocarditis with surgery indication
9463755|NCT03690076||Obese|obese patients (BMI > 30 with waist to hip ratio > or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
10026870|NCT01726608|Active Comparator|Radiofrequency neurotomy|Active Radiofrequency Neurotomy
10026871|NCT01726608|Placebo Comparator|Sham|Sham radiofrequency neurotomy
10026872|NCT01726634|Experimental|Elastic Tapping|
10026873|NCT01726647||No product is tested|No intervention
10026874|NCT01726660|Experimental|IMT Robotic Arm Therapy: Aim training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for aim training, 3x/week for 12 weeks.
10026875|NCT01726660|Experimental|IMT Robotic Arm Therapy: Smoothness Training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for smoothness training, 3x/week for 12 weeks.
10026876|NCT01726660|Experimental|IMT Robotic Arm Therapy: Impairment training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole-arm, impairment training, 3x/week for 12 weeks.
10026877|NCT01726660|Experimental|IMT Robotic Arm Therapy: Functional training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole arm, functional training, 3x/week for 12 weeks.
10026878|NCT01726686|Active Comparator|Ropivacaine in the pump|The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
10026879|NCT01726686|Placebo Comparator|Placebo in the pump|The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
10026880|NCT01726699||Cancer Diagnosis|
10026881|NCT01726712|No Intervention|Routine Care|
10026882|NCT01726712|Active Comparator|Supportive Contact|
10026883|NCT01726725||hemifacial spasm, lateral spread, motor evoked potentials|EMG recordings from facial muscles of HFS patients during MVD surgery will be compared during total intravenous anesthesia (propofol), 0.5 MAC desflurane and 1.0 MAC desflurane
9463756|NCT03689998|Experimental|implant placement with melatonine|immediate implant placement with melatonine
10026884|NCT01726751|Other|Early off-stimulation (group B)|Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
10026885|NCT01726751|Other|Early on-stimulation (group A)|Early SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group A starting with SCS for a period of six weeks (A) followed by a period of no SCS (off-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
10026886|NCT01726764|Experimental|Metformin|"7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.~Minimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
10026887|NCT01726777|Placebo Comparator|Control|30g normal cheddar cheese once per week
10026888|NCT01726777|Experimental|Vitamin D|30g cheddar cheese containing 28,000IU vitamin D once per week
10026889|NCT01726816|Experimental|Probucol 250mg/day|Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks
10026890|NCT01726816|Experimental|Probucol 500mg/day|Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks
10026891|NCT01726816|Placebo Comparator|Placebo|Placebo group: placebo 2 tablets, 16 weeks
10026892|NCT01726829|Experimental|MD-Logic Artificial Pancreas (MDLAP) system|four consecutive outpatients overnight sessions at home under closed loop MD-Logic Artificial Pancreas (MDLAP) system
10026893|NCT01726829|Active Comparator|Standard treatment with sensor augmented pump therapy|four consecutive outpatients overnight sessions at home under standard treatment with sensor augmented pump therapy
9463757|NCT03689998|Active Comparator|immediate implant placement alone|immediate implant placement alone
9463758|NCT03689985|Experimental|General|One arm study: smART Feeding Tube System.
9463759|NCT03689972|Experimental|Part 1: Standard Interval Dosing (SID) IV|Participants will receive natalizumab 300 milligram (mg) intravenous (IV) infusion every 4 weeks (-2/+5 days) up to Week 72.
9463760|NCT03689972|Experimental|Part 1: Extended Interval Dosing (EID) IV|Participants will receive natalizumab 300 mg IV infusion every 6 weeks (-2/+5 days) up to Week 72.
9463761|NCT03689972|Experimental|Part 2: EID SC, then EID IV|Participants will receive natalizumab 300 mg SC injection every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg IV infusion every 6 weeks from Week 132 through Week 150.
9463762|NCT03689972|Experimental|Part 2: EID IV, then EID SC|Participants will receive natalizumab 300 mg IV infusion every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg SC injection every 6 weeks from Week 132 through Week 150.
9463763|NCT03689959|Experimental|Patients|13 child with fixed knee flexion deformity more than 10° on one or both sides with 12 months or more predicted growth remaining subjected to eight plate hemiepiphysiodesis of the distal femur
10026894|NCT01726842||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
10026895|NCT01726842||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
10026896|NCT01726842||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
10026897|NCT01726855||dorsal fascial flap|combined with standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger palmar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons.
10026898|NCT01726855||standard modified Kessler technique|
10026899|NCT01726868|Experimental|Liposorber LA-15 System|
10026900|NCT01726881|Experimental|Fresh Spinal Cord Injury patients|Spinal Cord Injury patients that are currently admitted to the rehabilitation unit with three weeks or less since injury that will over go several tests and will fill out several questionnaires.
9463764|NCT03689933|Experimental|root analog implant|The tooth indicated for extraction will be extracted atraumatically using periotome, socket preservation using Iodoform packing strips, and then optical scanning of the remaining tooth structure with optical scanner will be made to obtain a 3D virtual model, this model will be modified by addition of macro-retentions strictly to the interdental area to avoid any fracture in thin cortical bone, the cervical portion of implant circumference will be decreased by 0.1 to 0.2 mm to avoid pressure resorption of alveolar crest of bone and addition of prepared crown stump for the future crown to be placed.
9463765|NCT03689933|Active Comparator|conventional stock root-form titanium implant|Using a conventional implant as a comparator as it's the gold stander in restoring the non-restorable teeth.
9463766|NCT03689907||Allogeneic Stem-Cell Transplant Recipients|"At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.~At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients."
9463767|NCT03689894|Experimental|Ibrutinib plus Rituximab|"Rituximab~*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)~Ibrutinib~420 mg (140 mg capsule x3) by mouth daily~May be given beyond 3-6 months (for maintenance)."
9463768|NCT03689881|Experimental|Tomosynthesis|Tomosynthesis of SI joints
9463769|NCT03689868|Experimental|Virtual Reality|
10026901|NCT01726881|Experimental|Chronic Spinal Cord Injury patients|Spinal Cord Injury patients with one year or more since injury that will over go several tests and will fill out several questionnaires
10026902|NCT01726881|Active Comparator|Healthy volunteers|Healthy subjects that will over go several tests and will fill out several questionnaires
10026903|NCT01726894|Experimental|Irreversible Electroporation|
10026904|NCT01726907|Experimental|Robotic SMG resection|Robot-assisted SMG resection
10026905|NCT01726907|Active Comparator|Endoscopic SMG resection|Endoscope-assisted SMG resection
10026906|NCT01726920|Experimental|naratriptan + naproxen|Fixed-dose combination of naratriptan + naproxen
9463770|NCT03689868|No Intervention|Control|
9463771|NCT03689829|Experimental|MOR106 Single Dose A, i.v. infusion, Part 1|A single dose of MOR106 will be administered by i.v. infusion.
9463772|NCT03689829|Experimental|MOR106 Single Dose B, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
9463773|NCT03689829|Experimental|MOR106 Single Dose C, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
9463774|NCT03689829|Experimental|MOR106 Single Dose D, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
9463775|NCT03689829|Experimental|MOR106 Repeated Doses E, s.c. injection, Part 2|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
9463776|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 2|Corresponding Placebo will be administered by s.c. injection.
9463777|NCT03689829|Experimental|MOR106 Repeated Doses F, s.c. injection, Part 3|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
9463778|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 3|Corresponding Placebo will be administered by s.c. injection.
9463779|NCT03689816|Experimental|bone density|bone density
9463780|NCT03689803|Active Comparator|Lipidemia|
9463781|NCT03689790|Active Comparator|liver function|liver function
9463782|NCT03689777|Active Comparator|Glomerular Filtration Rate|
9463783|NCT03689764|Experimental|Group A|Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
9463784|NCT03689764|Experimental|Group B|Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
9463785|NCT03689751|No Intervention|LSCS Control Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
10026907|NCT01726920|Active Comparator|naratriptan|
10026908|NCT01726920|Active Comparator|naproxen|
10026909|NCT01726933|Experimental|LAS41008|up to 6 tablets/ day for 16 weeks double blind treatment period, randomized gastric resistant tablet
10026910|NCT01726933|Placebo Comparator|Placebo|up to 6 tablets/ day for 16 weeks randomized, double blind gastric resistant tablet
10026911|NCT01726933|Active Comparator|LASW1835|double blind, randomized gastric resistant tablet up to 6 tablets/ day for 16 weeks
9463786|NCT03689751|Experimental|LSCS Intervention ArmIntervention Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (LSCS Video) as an additional educational resource.
9463787|NCT03689751|No Intervention|TVT/TOT Control Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
9463788|NCT03689751|Experimental|TVT/TOT Interventional Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (TVT/TOT Video) as an additional educational resource.
9463789|NCT03689738|Experimental|Potato condition|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g RS per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
9463790|NCT03689738|Active Comparator|Control condition|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
9463791|NCT03689725|Experimental|Preterm music group|Music exposure with headphones
9463792|NCT03689725|No Intervention|Preterm control group|headphones without music
9463793|NCT03689725|No Intervention|Full-term control group|
9463794|NCT03689699|Experimental|Arm A: Nivolumab alone|Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
9463795|NCT03689699|Experimental|Arm B: Nivolumab plus BMS-986253|Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
9463796|NCT03689686|Experimental|Patients|Fifteeen children with Acute Respiratory Failure admitted to a PICU, needing noninvasive respiratory support
9463797|NCT03689647|Experimental|Single Group Experimental|Each participant will act as their own control with variables of interest measured while walking without the assistive device and while walking with the assistive device.
9463798|NCT03689634|Experimental|Move For Surgery Preconditioning Program Intervention Group|
9463799|NCT03689634|No Intervention|Standard Preoperative Care Group|
9463800|NCT03689621|Active Comparator|Transcutaneous vagal nerve stimulation (tVNS)|tVNS administered for 4 hours each day and behaviour is recorded.
9463801|NCT03689621|Placebo Comparator|Baseline|tVNS worn but not switched on whilst collecting behavioural data.
9463802|NCT03689569|Experimental|Exercise|Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.
9802974|NCT04732663||Control|Covid Naïve Controls will be defined as individuals who have no known history of covid-19. Control participants will be matched to PS-CoV for age, sex and body mass index.
10026912|NCT01726959||Methotrexate|Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly
10026913|NCT01726985||Patients hospitalized with CHF|Patients hospitalized with CHF Parameter Based Clinical Disposition
10026914|NCT01726998|Experimental|Lokomat Group|
10026915|NCT01726998|Active Comparator|conventional gait training group|
10026916|NCT01727037|Experimental|BIABI arm|Patients will undergo intrabullous autologous blood instillation
9463803|NCT03689569|Experimental|Resistant Starch|Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training
9463804|NCT03689569|Experimental|Exercise & Resistant Starch|Exercise & resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period
9463805|NCT03689569|Placebo Comparator|Starch|Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks
9463806|NCT03689556||FLT PET/CT|Patients with locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) will receive FLT PET/CT scans before CIRT and after completion of CIRT.
9463807|NCT03689517|Experimental|placebo arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. Participants took placebos (pills made by starch) that were told to be an effective analgesic
9463808|NCT03689517|Sham Comparator|sham arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. But participants do not take placebos
9463809|NCT03689491|Experimental|rTMS+visual feedback|10-minute rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
9463810|NCT03689491|Active Comparator|sham rTMS+visual feedback|10-minute sham rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
9463811|NCT03689491|Active Comparator|sham rTMS+traditional training|10-minute sham rTMS and then a 30-minute traditional rehabilitation training,3 times a week, for 4 weeks
9463812|NCT03689465|Active Comparator|PTCy-ATG group|PTCy-ATG group refers to treatment with PTCy-ATG protocol as GVHD prophylaxis at a total dose of 4.5mg/kg ATG, a dose of 50mg/kg/d cyclophosphamide (CTX), a dose of 2.5mg/kg/d Ciclosporin A （CsA）, and a dose of 1.0g/d Mycophenolate Mofetil(MMF).
9463813|NCT03689465|Active Comparator|ATG group|ATG group refers to treatment with ATG protocol as GVHD prophylaxis at a total dose of 7.5mg/kg ATG, a dose of 2.5mg/kg/d Ciclosporin A （CsA）, a dose of 1.0g/d Mycophenolate Mofetil(MMF) and methotrexate (MTX, on days +1, +3 and +6).
9463814|NCT03689413|Experimental|1 mg/kg|"For '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
9463815|NCT03689413|Active Comparator|2 mg/kg|"For '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
9463816|NCT03689361|Other|with migraine aura.|patient with migraine aura detected by MRI, then MRI control 3 month after
9463817|NCT03689361|Other|without migraine aura|patient without migraine aura detected by MRI, then telephone consultation 3 month after
9463818|NCT03689348|Placebo Comparator|Placebo|Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
9463819|NCT03689348|Experimental|300mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x2 placebo capsules (described above) and x1 300mg capsule of Avena sativa per day for 28 days.
9463820|NCT03689348|Experimental|600mg Avena sativa|If in the 600mg of Avena sativa group, participants will consume x1 placebo capsule (described above) and x2 300mg capsule of Avena sativa per day for 28 days.
9463821|NCT03689348|Experimental|900mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x3 300mg capsule of Avena sativa per day for 28 days.
9463822|NCT03689335|Active Comparator|Operative|Surgical fixation of the humeral shaft fracture
9463823|NCT03689335|Active Comparator|Non-operative|Conservative treatment of the humeral shaft fracture, using a humeral brace
10026917|NCT01727050|Active Comparator|Mechanical stapling|
10026918|NCT01727050|Active Comparator|Fibrin sealant spray|
10026919|NCT01727063|Experimental|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
10026920|NCT01727063|No Intervention|Placebo|Saline injection
10026921|NCT01727076|Experimental|Treatment (recombinant interleukin-15)|Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10026922|NCT01727115|Active Comparator|NUTRAMIGEN®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Nutramigen® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Nutramigen®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
10026923|NCT01727115|Experimental|ALTHERA®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Althera® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Althera®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
10026924|NCT01727128|Experimental|Mild Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - mildly hepatically impaired
10026925|NCT01727128|Experimental|Moderate Hepatic Impaired group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - moderately hepatically impaired
9463824|NCT03689322|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
9463825|NCT03689322|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
9463826|NCT03689322|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
9463827|NCT03689309|No Intervention|1. Classic SBT (C-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but oxygen delivered through a heat humidifier filter that is usually connected on tracheotomy.
10026926|NCT01727128|Experimental|Severe Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - Severely hepatically impaired
10026927|NCT01727128|Experimental|Control Group|Matching healthy control subjects who do not have hepatic impairment and are matched to the hepatic impaired subjects by sex, age, gender and BMI
10026928|NCT01727206|Experimental|Tocilizumab|Tocilizumab 8 mg/kg intravenously every month for six months
10026929|NCT01727232||Standard regimen|Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab
10026930|NCT01727232||Rheumatoid arthritis regimen|Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab
10026931|NCT01727245|Other|Obese|Obese patients undergoing gastric by-pass surgery
10026932|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
9463828|NCT03689309|Experimental|2. High Flow Oxygen SBT (HFO-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
9463829|NCT03689296||Users|Person with a long-term mental disorder
9463830|NCT03689296||Caregivers|Adult helping a person with a long-term psychological disorder
9463831|NCT03689296||Primary care professionals|Primary care professional in practice following at least one person with a long-term mental disorder
9463832|NCT03689296||Psychiatric professionals|Psychiatric specialist working in a hospital or in private practice
9463833|NCT03689283|Experimental|Dry Needling Group|Individuals in the DN arm will receive two treatment sessions of DN to latent trigger points of the gastrocnemius muscle.
9463834|NCT03689283|Sham Comparator|Control Group|Individuals in the control group will receive two treatment sessions of sham dry needling.
9463835|NCT03689270||Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
9463836|NCT03689270||Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
9463837|NCT03689218|No Intervention|Control|The control arm will receive routine public and private health services available in the area.
9463838|NCT03689218|Experimental|Intervention|Pregnant women in intervention arm will receive 30 sachets of Maamta (Nutritious Food Supplement) during pregnancy and first six months of lactation. Children 6-24 months of age will receive 30 sachets of Wawamum (Lipid-Based Nutrient Supplement) every month during the study.
9463839|NCT03689205||Patients that BMI> 30kg / m2 (Group A)|Venous puncture pain on patients that Body mass index > 30kg / m2
9463840|NCT03689205||Patients that BMI< 30kg / m2 (Group B)|Venous puncture pain on patients that Body mass index < 30kg / m2
9463841|NCT03689192|Experimental|ARG1-18,19,20 peptide vaccine|One ARG1-vaccine every third week for 45 weeks.
9463842|NCT03689179|Experimental|Treatment with Follow-up (Group A)|"After an initial orientation/control period (4 weeks), group A will receive access to the Time for Living & Caring (TLC) intervention for 8 weeks, followed by an optional 8-week control period where they can continue to use the TLC intervention if they choose."
10026933|NCT01727271|Active Comparator|Tenofovir Monotherapy|Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)
9463843|NCT03689179|Experimental|Wait-List Control w/Treatment (Group B)|"After the initial 4-week orientation period, Group B will receive 8 weeks of waitlist (no treatment) control, followed by access to the Time for Living & Caring (TLC) intervention for 8 weeks."
9479859|NCT03539250|Experimental|IMRT with and without chemotherapy|Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
9479860|NCT03539237|Experimental|"Video-group"|"Video group: Individuals in this group receive the intervention Video demonstration of physical activity intensity levels. They watch a 3-minute-video explaining and visualizing light-, moderate-, and vigorous-intensity levels of physical activity before completing a tablet PC-supported physical activity assessment at the DZHK-examination center.The video can not be skipped."
9479861|NCT03539237|No Intervention|"No video-group"|"No video group: Individuals in this group do not receive the intervention Video demonstration of physical activity intensity levels. They complete a tablet PC-supported physical activity assessment at the DZHK-examination center without receiving a 3-minute-video explaining and visualizing the different intensity levels of physical activity."
10026934|NCT01727271|Experimental|PegIFN-2b/Tenofovir Sequential Therapy|Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
10026935|NCT01727271|Experimental|Peg-IFN-2b + Tenofovir Combination Therapy|Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
10026936|NCT01727349|Other|Type 2 diabetic subject|Subject with type 2 diabetes
10026937|NCT01727349|Other|healthy subject|Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
10026938|NCT01727362|Active Comparator|Usual care + acupuncture|
10026939|NCT01727362|Active Comparator|Usual care|
10026940|NCT01727375|No Intervention|Standard light|In this arm patients receive standard lightening conditions
10026941|NCT01727375|Experimental|Ciradian light|In this arm patients receive artificial ceiling light (circadian light) at the bedside.
9463844|NCT03689153|Experimental|Cohort 1: JNJ-63733657 or Placebo|Participants will receive a single intravenous (IV) low dose of JNJ-63733657 or matching placebo.
9463845|NCT03689153|Experimental|Cohort 2: JNJ-63733657 or Placebo|Participants will receive a single IV middle dose of JNJ-63733657 or matching placebo.
9463846|NCT03689153|Experimental|Cohort 3: JNJ-63733657 or Placebo|Participants will receive a single IV high dose of JNJ-63733657 or matching placebo.
9463847|NCT03689127|Active Comparator|Control|Heated breathing circuit will be turned off.
9463848|NCT03689127|Experimental|Heat|Heated breathing circuit will be turned on.
9463849|NCT03689114|Experimental|Low dose|Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
9463850|NCT03689114|Active Comparator|Standard dose|Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
9463851|NCT03689088|Experimental|Investigational device (Goldfish)|IOP will be monitored for 24 h in the Goldfish eye
9463852|NCT03689088|Active Comparator|Tonometry|IOP will be acquired by standard tonometry at specific times in the the fellow eye
9463853|NCT03689075|No Intervention|Immediate release tacrolimus|Patients will continue on immediate release tacrolimus
9463854|NCT03689075|Active Comparator|Extended release tacrolimus|
9463855|NCT03689062|Active Comparator|conservative group|patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .
9463856|NCT03689062|Experimental|active group|Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.
9463857|NCT03689049|Experimental|SPIDER|QI Learning Collaboratives.
9463858|NCT03689049|Placebo Comparator|Usual Care|Standard primary care.
9463859|NCT03689023|Experimental|A controlled multimodal intervention|A uniform and systematic patient education about cardiovascular risk factors, physical activity and a healthy diet lifestyle starting early in the primary rehabilitation process with 6 months of follow up.
9463860|NCT03689010|Active Comparator|Azelaic acid foam 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
9463861|NCT03689010|Active Comparator|Finacea® (azelaic acid) Foam, 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
9802975|NCT04728217|Experimental|Patients receiving Efmoroctocog alfa|For long term prophylaxis, the recommended starting dose is 50 IU of factor VIII per kg body weight at intervals of 3 to 5 days. The dose may be adjusted based on patient response in the range of 25 to 65 IU/kg. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
9802976|NCT04725695|Experimental|Viscous lidocaine|Oral viscous lidocaine 20 mg/ml, 10 ml
9802977|NCT04725695|Placebo Comparator|Placebo|Oral viscous solution without active drug, 10 ml
10026942|NCT01727388|Experimental|lateral decubitus|The digital rectal examination is performed in lateral decubitus i.e. curled up position . The patient in left lateral decubitus if the examiner is right handed and right lateral decubitus if the examiner is left handed.
10026943|NCT01727388|Active Comparator|supine decubitus|The digital rectal examination is performed supine, spread legs, feet on the examination table. The examiner is in the patient's right side if he is right handed and in the patient's left side if he is left-handed.
10026944|NCT01727401|Experimental|Fondaparinux|Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
10026945|NCT01727427||Anticoagulants, aspirin|Parenteral or oral anticoagulants: heparin, fondaparinux, vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors; aspirin. Any dosage, frequency and duration
9463862|NCT03689010|Placebo Comparator|Vehicle of the test product|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
9463863|NCT03688997|Experimental|Experts|"For the novice group, the investigators recruited 30 residents within their first year of surgical residency (Post-Graduate Year [PGY]-1) in general surgery, vascular surgery, plastic surgery, orthopedic surgery, cardio-thoracic surgery, gynecology and urology.~The intervention administered was the use of a simulator by the participants."
9479862|NCT03539224|Experimental|Dolutegravir (DTG) + Lamivudine (3TC)|Eligible subjects will receive one 50 mg tablet of DTG plus 300 mg 3TC tablet orally once daily upto 48 weeks
9802978|NCT04724980|Experimental|Dose Levels 1 and 2|Adjuvant PRGN-2012 at escalating doses
10026946|NCT01727453|Active Comparator|Bemiparin|Group 1 (low molecular weight heparin: bemiparin), which is the study group: after passing the bleeding episode, will receive low molecular weight heparin (bemiparin) in anticoagulant dose. Check should be made by measurement of anti-factor Xa.
10026947|NCT01727453|Active Comparator|Warfarin|which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
10026948|NCT01727466|Experimental|Facing Your Fears|FYF is a group CBT approach to managing anxiety symptoms in children with high-functioning autism spectrum disorders and anxiety.
10026949|NCT01727479|Experimental|Ribose|After each of the 3km time trial (3 in total), consumption of ribose incorporated in a sports drink.
10026950|NCT01727479|Placebo Comparator|Placebo|After each of the 3km time trial (3 in total), consumption of placebo incorporated in a sports drink.
9463864|NCT03688997|Experimental|Novice|"The expert's group included 15 attending surgical faculty members in the general surgery, vascular surgery, cardio-thoracic surgery and gynecology services.~The intervention administered was the use of a simulator by the participants."
9463865|NCT03688984|Experimental|Cognitive Behavioural Therapy for Insomnia|Six sessions of in person Cognitive Behavioural Therapy for Insomnia (CBT-I)
9463866|NCT03688984|No Intervention|Treatment As Usual|Participants will receive regular care in the Treatment As Usual (TAU) condition. Participants will be offered CBT-I at the completion of the trial.
9463867|NCT03688971|Experimental|Omiganan Topical Gel|Omiganan 1.75%
9463868|NCT03688971|Active Comparator|Ketoconazole Topical Cream|Ketoconazole 2.0%
9463869|NCT03688971|Placebo Comparator|Vehicle|
9463870|NCT03688958|Placebo Comparator|Early Cancer placebo|"The daily supplement of a vegetable colored water solution (drops) for 7 to 35 days in early breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the activity of placebo on tumor size, and molecular tumor response, as well as side effects attenuation"
9463871|NCT03688958|Experimental|Early Cancer Iodine|The daily supplement of an iodine solution (drops, 5 mg/day) for 7 to 35 days in early breast cancer diagnosticated woman
9463872|NCT03688958|Placebo Comparator|Advanced Cancer FEC/TE placebo|"The daily supplement of an vegetable colored water solution (drops) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the adjuvancy of placebo in FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation."
9463873|NCT03688958|Experimental|Advanced Cancer FEC/TE + Iodine|"The daily supplement of an iodine solution (drops, 5 mg/day) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman Drug: Iodine solution (5 mg/day). Evaluate the adjuvancy of I2 on FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation.~Other Name: evaluating the adjuvancy of iodine supplement in FEC/TE treatment"
9463874|NCT03688945|Experimental|Arm I (art sessions)|Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
9463875|NCT03688945|Active Comparator|Arm II (standard of care)|Participants receive standard of care for 2 years.
9463876|NCT03688932|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
9463877|NCT03688932|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
9463878|NCT03688932|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
9463879|NCT03688919|No Intervention|Comparison|Adolescents and their families in this group will not receive any of the interventions.
10026951|NCT01727492|Placebo Comparator|sugar pill|
10026952|NCT01727492|Active Comparator|Antioxidantia|Dosage: 600mg n-acetylcystein and 200mg magnesium intake: 1 hour before leisure noise exposure above 100dB of at least 30 minutes frequency: 4 separate events (2x placebo, 2x antioxidants)
10026953|NCT01727518||Reference Population|No Intervention
10026954|NCT01727531|Experimental|CQ Arm|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks.
10026955|NCT01727544|Active Comparator|Surgical Group|patients will undergo a primary transmastoid and tegmen mini-craniotomy cartilage cap occlusion surgery.
9463880|NCT03688919|Experimental|Self-Regulation Intervention|This arm will use a computer-based working memory training game (NBack) targeting Executive Functioning and in-person relaxation and biofeedback training targeting Emotion Regulation. As well, adolescents will receive Future Orientation training by being asked to envision and describe future events they are looking forward to, using concrete, vivid descriptive language.
9463881|NCT03688893|Experimental|Laser Application|35% Hydrogen Peroxide (Whitening HP, FGM SC Brazil) 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes Laser Application and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. Experimental
9463882|NCT03688893|No Intervention|No Laser Application|35% Hydrogen Peroxide (Whitening HP FGM SC Brazil), 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes waiting and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. No Laser Application No Intervention
9463883|NCT03688854|Placebo Comparator|Placebo|Placebo are capsules containing cellulose.
9479863|NCT03539198||Locoregional|Patients with recurrent locoregional head and neck cancer
10026956|NCT01727544|No Intervention|Non Surgical Group|patients meet the same criteria but will elect not to undergo surgery
10026957|NCT01727557|Active Comparator|Local anesthesia|
10026958|NCT01727557|Active Comparator|regional anesthesia|
10026959|NCT01727570|No Intervention|Nutrition Counselling|Patients will be asked to fill out a three day record of all food and drink consumed. Patients will be given an appointment with the nutritionist approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of their diet
10026960|NCT01727570|Active Comparator|Nutrition Supplementation|Patients will be asked to fill out a three day record of all food and drink consumed. An appointment with the nutritionist will be given approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of the diet. Patients will also be given a supply of nutritional supplements to take orally (by mouth) every day. These supplements include a whey protein isolate (Immunocal®, Immunotec Inc), omega-3 fatty acids from fish oil, and vitamins/minerals.
10026961|NCT01727583|Active Comparator|Lipid 1|Meal intake
10026962|NCT01727583|Placebo Comparator|Lipid-free|Maltodextrine + proteins
10026963|NCT01727583|Active Comparator|Lipid 2|Meal intake
10026964|NCT01727583|Active Comparator|Lipid 3|Meal intake
10026965|NCT01727583|Active Comparator|Lipid 4|meal intake
10026966|NCT01727596|Experimental|1|
9463884|NCT03688854|Experimental|SCFA mixture low dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 10 grams of fiber.
9463885|NCT03688854|Experimental|SCFA mixture high dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 20 grams of fiber.
10026967|NCT01727609|Active Comparator|Slower milk feed increment|Increase milk feeds by 18 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
10026968|NCT01727609|Experimental|Faster milk feed increment|Increase milk feeds by 30 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
10026969|NCT01727622||Controls|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
9463886|NCT03688841|Experimental|Bridged V.A.C.® with compression therapy|A vacuum assisted closure device will be placed on the ulcer. A compression dressing will be placed over the V.A.C.® device
9463887|NCT03688841|Active Comparator|Conventional compression therapy|A Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings will be applied and changed once to three times per week (dependant on exudate).
9463888|NCT03688815||Patients with ischemic heart disease|Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
9463889|NCT03688789|Experimental|Hydrocortisone supplementation|
10026970|NCT01727622||Mild Cognitive Impairment|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
10026971|NCT01727635|Experimental|counseling|body-mind-spirit group therapy
10026972|NCT01727648|Experimental|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
10026973|NCT01727648|Experimental|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
10026974|NCT01727648|Experimental|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
10036755|NCT01818648|Placebo Comparator|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
9463890|NCT03688776|Experimental|1805AA, 1805AB Use Group|Use of product 1805AA exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AB exclusively for approximately 3 days prior to a PK assessment.
9463891|NCT03688776|Experimental|1805AB, 1805AA Use Group|Use of product 1805AB exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AA exclusively for approximately 3 days prior to a PK assessment.
9479864|NCT03539198||Metastatic|Patients with recurrent metastatic head and neck cancer
9463892|NCT03688737|Placebo Comparator|control group|"A) Control group:~Has Surgical procedures von Langenbeck technique  to repair cleft palate and will come for follow up visit at day of surgery, 1st day and 3rd day for placebo device like LLL and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
9463893|NCT03688737|Active Comparator|study group|"B) Study group:~This group will be subjected to the same surgical procedure von Langenbeck technique to repair cleft palate but low level laser Therapy will be at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
10026975|NCT01727648|Active Comparator|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
9463894|NCT03688698||PAH|
9463895|NCT03688698||Controls|
10026976|NCT01727661||type 1 diabetes mellitus|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
10026977|NCT01727661||healthy controls|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
10036756|NCT01818661|Experimental|Tau positron emission tomography (PET)|All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.
10036757|NCT01818674|Experimental|Group A - Microclinic Behavioral Health Enhanced Program|Group A received the Microclinic Behavioral Health Full Program (structured social interactions + fully interactive classroom education curriculum; parallel clinical screenings)
10036758|NCT01818674|Experimental|Group B - Microclinic Behavioral Health Basic Program|Group B received the Microclinic Behavioral Health Basic Program (no social structured interactions; basic classroom education; parallel clinical screenings)
10036759|NCT01818674|No Intervention|Group C - Controls with Parallel Monitoring|Group C only received standard care, and only received parallel risk factor screening measurements; not participation in classroom or any social activities.
10036760|NCT01818687|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
9463896|NCT03688659|Other|vancomycin,gentamycin in endocarditis|patients with infective endocarditis will recieve intravenous infusion Vancomycin 30 mg/kg/day for 4:6 weeks and intravenous Gentamycin 3mg/kg/day for 2 weeks
9463897|NCT03688646|Experimental|Intervention group|Intensive nutrition intervention group receiving standardised oral nutrition supplement provided once daily throughout cancer treatment with 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement
9463898|NCT03688646|No Intervention|Control group|Routine care were given to this group inclusive of 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement and also prescription of oral nutrition supplement where needed. Oral nutrition supplement was not provided
9463899|NCT03688607||POKE|All babies in NICU at Intermountain Healthcare hospitals
9463900|NCT03688594|Experimental|couple : man and pregnant women|
9463901|NCT03688568|Experimental|Imatinib Mesylate Arm|Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.
9463902|NCT03688516|Experimental|Atypical development|30 children with Williams-Beuren syndrome will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
9463903|NCT03688516|Sham Comparator|Typical development|30 control children matched for mental age will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
9463904|NCT03688503|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
9463905|NCT03688503|Placebo Comparator|placebo|placebo supplement
9463906|NCT03688477|Experimental|iovera°|Patients will receive iovera° prior to stand of care ACL
9463907|NCT03688477|No Intervention|Standard of Care|Patients will receive standard of care ACL procedure without iovera° treatment.
9802979|NCT04724980|Experimental|RP2D|Adjuvant PRGN-2012 at the RP2D
10036761|NCT01818713|Experimental|2B3-101|A single dose of 2B3-101 (a glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) will be administrated intravenously once per cycle. To minimize the risk of infusion reactions, 5% of the total dose of 2B3-101 (in mg) will be administrated over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes
10036762|NCT01818778|Experimental|Stimulation Group|Cognitive Stimulation Group: One-on-one (one volunteer visiting one resident at a time), stimulation-group residents and stimulation-group volunteers met 3 times each week, for 8 weeks, to work through a variety of memory, reasoning, and selective attention exercises. Each visit was 20 minutes in length.
10026978|NCT01727687|Experimental|Patients with Parkinson's disease|Using simulated traffic scene system to help patients with Parkinson's disease improve crossing road behaviors.
9463908|NCT03688464|Active Comparator|Melatonin Treatment|Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
10026979|NCT01727739|Active Comparator|PLLA bioscrew|poly-L-lactic acid bioscrew
9463909|NCT03688464|Active Comparator|Diphenhydramine Treatment|Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
9463910|NCT03688464|Placebo Comparator|Placebo|Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
9463911|NCT03688451|Experimental|Intrathecal rituximab|Cohort 1: 10 mg dose, day 1 chemotherapy cycles 2-5 Cohort 2: 20 mg dose, day 1 chemotherapy cycles 2-5
9463912|NCT03688438|No Intervention|Standard of Care|Standard of care wound closure and dressing No active interventions
9463913|NCT03688438|Experimental|WoundVAC (CINPT)|Closed-Incision Negative-Pressure Therapy
9463914|NCT03688412||Cook lead extraction devices|The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
9463915|NCT03688386|Experimental|Language Intervention|"1. Review language and infant bonding curriculum 2. 1st LENA recording and heart rate variability of mother reading to infant 3. Provide LENA linguistic feedback and review curriculum 4. 2nd LENA recording and heart rate variability of mother reading to infant 5. Provide LENA linguistic feedback and review curriculum 6. 3rd LENA recording and heart rate variability of mother reading to infant 7. Provide LENA linguistic feedback~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
9463916|NCT03688386|Active Comparator|Infant bonding|"1. Review infant bonding curriculum with mother 2. 1st LENA recording and heart rate variability of mother holding infant 3. Review infant bonding curriculum 4. 2nd LENA recording and heart rate variability of mother holding infant 5. Review infant bonding curriculum 6. 3rd LENA recording and heart rate variability of mother holding infant 7. Provide linguistic feedback of all 3 LENA recordings~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
9463917|NCT03688373|Experimental|Exposure-in-big-steps|In the big steps exposure sessions the adolescent moves in three a set pace of big steps from bottom to top (1-5-10) in their fear hierarchy. From 0-5 in the first session and from 5-10 in the second session.
9463918|NCT03688373|Experimental|Exposure-in-small-steps|In the small steps exposure sessions the adolescent moves in a step-by-step pace of their own choice from bottom to top in their fear hierarchy, for example from 1 to 2 to 3 to in the first session and from 4 to 5 to 6 etc. in the second session.
9463919|NCT03688360|Experimental|Therapist-guided in-session|The participants will engage in 2 x 45 minutes of exposure exercises conducted together with the therapist in the mental health care centre. In addition, they will conduct 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
9463920|NCT03688360|Experimental|Self-guided out-session|The participants will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
9463921|NCT03688360|Experimental|Parent-guided out-session|The participants and one of their parents will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises together with their parent out of session as a homework assignment.
9463922|NCT03688334|Active Comparator|IPF patients|Supplementation of oxygen treatment (40% FiO2) during steady state cardiopulmonary exercise testing
9463923|NCT03688334|Sham Comparator|IPF patients (crossover)|Supplementation of medical air (sham Oxygen) during steady state cardiopulmonary exercise testing
9463924|NCT03688321|Active Comparator|Probiotic capsule GR-1 and RC-14|The intervention for study group is taking 2 capsules containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
9463925|NCT03688321|Placebo Comparator|Placebo capsule|The intervention for placebo group is taking 2 capsules not containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
9463926|NCT03688308|Experimental|Shoulder arthroscopy with BMAC|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair along with 3-4cc of BMAC produced from the Harvest/Terumo BCT system
9463927|NCT03688308|Active Comparator|Shoulder arthroscopy alone|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair without administration of BMAC.
9463928|NCT03688295|Other|experimental group|no antibiotherapy post surgery for complicated acute appendicitis (CAA)
9463929|NCT03688295|Active Comparator|control group|antibiotherapy post surgery for complicated acute appendicitis (CAA)
9463930|NCT03688269|Experimental|Intravenous dexamethasone|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 8mg/2ml Dexamethasone during the regional anesthesia"
9463931|NCT03688269|Placebo Comparator|Intravenous saline|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 2ml Saline 0.9% during the regional anesthesia"
9479865|NCT03539185|Active Comparator|Airtraq|Awake tracheal intubation using airtraq videolaryngoscope.
10026980|NCT01727739|Active Comparator|PLLA+TCP bioscrew|poly-l-lactic acid with beta tricalcium phosphate bioscrew
10026981|NCT01727752|Active Comparator|Surgical decompression|Surgical decompression
10026982|NCT01727752|Active Comparator|coflex Interlaminar Technology|Surgical decompression followed by implantation of coflex Interlaminar Technology.
10026983|NCT01727778|Experimental|Antibody treatment|Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
10026984|NCT01727804|Experimental|Laser|
10026985|NCT01727817|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
9463932|NCT03688230|Experimental|Abituzumab + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
9463933|NCT03688230|Placebo Comparator|Placebo + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
10026986|NCT01727817|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
9463934|NCT03688217|Experimental|Philani Intervention Model+MOVIE (PIM+M)|Participants will receive the standard PIM perinatal home visiting program together with the MOVIE intervention (13 entertainment-education videos about infant feeding). The PIM is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others. The MOVIE videos will be integrated into the regular home visiting program.
9463935|NCT03688217|Active Comparator|Philani Intervention Model (PIM)|Participants will receive the standard PIM perinatal home visiting program, which is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
9463936|NCT03688191|Experimental|Study Group|participants who received sirolimus treatment
9463937|NCT03688178|Experimental|Gr1: DC vaccine (DC pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 1 patients will receive autologous unpulsed DC vaccines administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine as pre-conditioning.
9463938|NCT03688178|Experimental|Gr2: DC Vaccine (Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site.
9463939|NCT03688178|Experimental|Gr3:DC Vaccine+varlilumab(Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 3 patients will receive the first 3 DC vaccines every 2 weeks, same as Groups 1 and 2, but they will also receive varlilumab intraveneously (IV) 7 days before vaccine #1 and again at the same visit as vaccine #1, as well as 7 days before every DC vaccine except vaccine #2. Prior to the 4th vaccine, patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side.
9463940|NCT03688165||Treadmill-based Robotic Gait Training|The Treadmill-based Robotic Gait Training (TRGT) period will last 20 sessions, 3-5 days/week for at least 400' of exercise totally. The parameters to be respected for the robotic training will be the following for all patients: 0.9 km / h starting speed up to a maximum of 2.5 km / h; weight support not exceeding 40-45% of the body weight at the beginning and gradual progressive reduction depending on the case; for Lokomat: maximum assistance required at the start of treatment and gradual decrease during the treatment. The TRGT will always be associated with the traditional gait rehabilitation, and will be part of the Individual Rehabilitation Project which normally includes 3 hours of rehabilitation treatments for patients in the subacute phase, 60' of treatment for those in chronic phase.
9463941|NCT03688165||Traditional Over-ground Gait Training|"The Traditional Over-ground Gait Training (TOGT) period will last 20 sessions, 3-5 days / week for a total time that corresponds to the same total time of traditional overground gait training, or at least 400' totally at the end of the period.~By Traditional Therapy we mean any technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids."
9463942|NCT03688152|Experimental|INCB053914 + INCB050465|INCB053914 in combination with INCB050465.
9463943|NCT03688113|Experimental|Treatment|
9463944|NCT03688113|Other|Wait list|
10026987|NCT01727843|Experimental|tranexamic acid|3000mg/mL tranexamic acid in saline applied directly to the wound at the end of the surgical procedure.
10026988|NCT01727843|Placebo Comparator|saline|3000mg/mL saline applied directly to the wound at the end of the surgical procedure
9463945|NCT03688087|Placebo Comparator|placebo|"Smartphone application placebo"
9463946|NCT03688087|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
9463947|NCT03688061|Experimental|Group 1 (low dose/healthy volunteers)|5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10*7 pfu) IM at week 8
9463948|NCT03688061|Experimental|Group 2 (higher dose/healthy volunteers)|10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10*8 pfu) IM at week 8
10026989|NCT01727856||Rehabilitation Measurement Tool|This single arm consists of all subjects which will interact with the tool under invstigation.
9463949|NCT03688061|Experimental|Group 3 (higher dose/HCV cured volunteers)|10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10*8 pfu) IM at week 8
9463950|NCT03688048|Experimental|Bright light treatment|Single-dose bright light treatment (1 hour, 10 000 lux)
9463951|NCT03688048|Placebo Comparator|Sham placebo|Deactivated negative ion generator in conjunction with a plausible cover story
9463952|NCT03688022|Experimental|MT-7117 BA and DDI (fasted)|MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)
9463953|NCT03688022|Experimental|MT-7117 food effect and DDI (fed)|MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)
9463954|NCT03688009|Experimental|Mindfulness-Based Family Psycho-Education (MBFBE)|A programme focuses on non-judgmental attitudes, collaborative inquiry and self-care, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
9463955|NCT03688009|Active Comparator|Family Psycho-Education (FPE)|A programme focuses on information giving, problem-solving and mutual support, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
9463956|NCT03687983|Experimental|Intervention arm|Participants will be treated with GoldenFlow Peripheral Stent System.
10026990|NCT01727869|Experimental|Cohort 1|Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
10026991|NCT01727869|Experimental|Cohort 2|Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
9463957|NCT03687931|Experimental|Arm 1|Dexamethasone suspension dose level 1
9463958|NCT03687931|Experimental|Arm 2|Dexamethasone suspension dose level 2
9463959|NCT03687905||Lupus nephritis III or IV/chloroquine|receiving chloroquine with daily dose 5 mg/kg
9463960|NCT03687905||Lupus nephritis III or IV/hydroxychloroquine|receiving hydroxycholorquine with daily dose 5 mg/kg
10026992|NCT01727869|Experimental|Cohort 3|Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
10026993|NCT01727882|Experimental|Daily Assessments & Brief Feedback|Daily assessments during 30 days after parole and a feedback intervention based on these daily assessments.
9463961|NCT03687905||Systemic lupus erythematosus|not received hydroxychloroquine nor chloroquine .
9463962|NCT03687892|Experimental|continuous Theta Burst Stimulation|The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
9463963|NCT03687892|Experimental|intermittent Theta Burst Stimulation|The investigators will perform two applications of 40s of intermittent Theta Burst Stimulation (iTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
9463964|NCT03687853|Experimental|Intrahepatic Arterial Infusion chemotherapy|chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.
9463965|NCT03687853|No Intervention|control|chemotherapy through Peripheral venous is one of the regularly used method.
10026994|NCT01727882|Active Comparator|Daily assessments|Daily assessments during 30 days after parole.
10026995|NCT01727908|No Intervention|Endoscopy without staining of the mucosa|
10026996|NCT01727908|Experimental|Endoscopy with staining of the mucosa.|
10026997|NCT01727921|Active Comparator|22 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 22 gauge ProCore biopsy needle.
10026998|NCT01727921|Active Comparator|25 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 25 gauge ProCore biopsy needle.
9463966|NCT03687840|Other|Study Group|Spatio-Temporal gait analysis of subjects with unilateral lower extremity burn injuries due to diabetic polyneuropathy.
9463967|NCT03687840|Other|Control Group|Spatio-Temporal gait analysis of subjects with only diabetic polyneuropathy.
9463968|NCT03687801|Experimental|Online hearing support|The intervention group will have access to online hearing support for five weeks. The online hearing support will include a program that consists of three elements: 1) reading material; 2) reading instructions and weekly assignments related to the reading material; and 3) online and telephone interaction with a professional.
9463969|NCT03687801|Active Comparator|Standard care|"The control group will have access to traditional support that the Hearing Organization provides (standard care)."
9463970|NCT03687788|Experimental|Intervention Group|Intervention group received laughter therapy twice a week for six weeks.
9463971|NCT03687788|No Intervention|Control Group|The control group did not take part in the laughter therapy program. This group received the routine care given by the nurses in the center.
10026999|NCT01727934|Experimental|Miravirsen sodium|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg.
10027000|NCT01727947|Experimental|MSOME|Couples in which the sperm cells were analysed through MSOME
10027001|NCT01727960||Korean Male Adolescents|students from two academic high schools
10027002|NCT01727973|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
10027003|NCT01727986|Experimental|RoActemra/Actemra|
10027004|NCT01727999||TPO responder|Patients with therapeutic response to TPO
10027005|NCT01727999||TPO non-responder|Patients not responding to TPO agonists
10027006|NCT01728012||eGFR >=60ml/min/1.73m2|Patients with an estimated glomerular filtration rate of >=60 ml/min/1.73m2.
9463972|NCT03687775||DSG-Stabi|The group consists of patients with primary trapeziometacarpal osteoarthritis and an indication for trapeziectomy alone or in combination with the resection-suspension-interposition arthroplasty.
9802980|NCT04724772|Experimental|Blepharoplasty patient|Patient receives LA in one eye and LA with TXA in the other eye. They are blinded. They compare eyes without knowing which one received the TXA.
10027007|NCT01728012||eGFR 45-60ml/min/1.73m2|Patients with estimated glomerular filtration rate >=45 ml/min/1.73m2 and <60ml/min/1.73m2.
9463976|NCT03687749||Women with breast cancer-related lymphedema|Individuals with upper limb lymphedema developed after breast cancer treatment
9463977|NCT03687749||Healthy control subjects|Healthy individuals without breast cancer-related lymphoedema.
9463978|NCT03687697|Experimental|Global vs. G-TL Media|Global medium will be compared with G-TL (Time-Lapse) medium.
9463979|NCT03687697|Experimental|Global vs. Cornell's C3 Media|Global medium will be compared with Cornell's C3 single step medium.
9463980|NCT03687697|Experimental|Global vs. Cornell's sequential Media|Global medium will be compared with Cornell's C1/C2 sequential medium.
9463981|NCT03687671|Experimental|Animal-assisted therapy|The intervention is animal-assisted occupational therapy, animal-assisted physiotherapy or animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
9463982|NCT03687671|Active Comparator|Treatment as usual (activation program)|As control intervention patients receive treatment as usual (TAU) in speech therapy, occupational therapy or physiotherapy. The control intervention is named activation program.
10027008|NCT01728025|Experimental|Ranolazine|Ranolazine 500-1000 mg twice a day as tolerated
10027009|NCT01728038|Experimental|Cessation Counseling|Parental smokers will be given a brief cessation intervention consisting of counseling, nicotine replacement therapy and Quitline connection.
10027010|NCT01728090|Experimental|Hand sanitizer|"Intervention classrooms received alcohol-based hand sanitizer and a programme educational.~Characteristics of the hydroalcoholic gel (ALCO ALOE GEL): chlorhexidine digluconate at 20% solution, phenoxyethanol 1%, benzalkonium chloride 0.%. aloe Barbadensis 5%, Renat ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 65 - 70% degrees, pondus Hydrogenium (pH) = 7-7,5."
10027011|NCT01728090|No Intervention|Control|No hand sanitizer or educational programme were used
10027012|NCT01728103||No Treatment|
10027013|NCT01728129|Experimental|Concussed|Subjects who are diagnosed with a concussion by a clinician will be assessed with the MACE and DANA Rapid every 24 hours for up to 72 hours post-injury.
10036763|NCT01818778|Active Comparator|Control Group|"Standard Friendly Visit: Control-group residents and control-group volunteers, one-on-one, met for 8 weeks, 3 times each week, for friendly visits. Each visit was 20 minutes in length."
9463983|NCT03687658|Experimental|Binge Eating Group|All participants in the study will be invited to use Laddr, described in the intervention section.
9463984|NCT03687658|Experimental|Smoking Group|All participants in the study will be invited to use Laddr, described in the intervention section.
9463985|NCT03687645|Experimental|Prostate Cancer|Patients with biopsy-proven prostate cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
10027014|NCT01728129|Active Comparator|Non-concussed|Subjects will have been exposed to a potentially concussive event but be clinically evaluated and found not to have sustained a concussion. Control subjects from this arm will take both the MACE and DANA Rapid twice: once within 24 hours of potentially concussive event, and again on the day of return to duty.
10027015|NCT01728142|Active Comparator|Non-concussed|Control group; individuals assigned to this group will be either healthy volunteers or individuals sustaining an injury that does not involve concussion. Participants will take both the ANAM and DANA Brief twice at minimum.
9463986|NCT03687645|Experimental|Renal Cancer|Patients with biopsy-proven renal cell carcinoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
9463987|NCT03687645|Experimental|Breast Cancer|Patients with biopsy-proven breast cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
9463988|NCT03687645|Experimental|Lymphoma|Patients with biopsy-proven lymphoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
9463989|NCT03687619|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a top-down approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
10027016|NCT01728142|Experimental|Concussed|Individuals who have been diagnosed with a concussion by a clinician. Participants will take both the DANA and ANAM twice at minimum.
10027017|NCT01728155|No Intervention|Group1|initial observation (chemotherapy is only given if there is subsequent progression)
9463990|NCT03687619|Experimental|Conductive Education|Conductive Education is a down-top approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
10027018|NCT01728155|Active Comparator|Group 1: chemotherapy|chemotherapy and surgery
9463991|NCT03687606|Active Comparator|Human Chorionic Gonadotropin alone|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for 3 years.
9463992|NCT03687606|Experimental|hCG alone for 6 months then hMG added|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for six months, then 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
9463993|NCT03687606|Experimental|hCG and hMG|Human Chorionic Gonadotropin 2000U~6000U and 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
10027019|NCT01728155|Experimental|Group 2|chemotherapy and surgery
9463995|NCT03687515|Experimental|budesonide inhalation suspension|
9463996|NCT03687515|Active Comparator|budesonide aqueous nasal spray|
9463997|NCT03687515|Active Comparator|oral steroids|
9463998|NCT03687502|Experimental|Experimental|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, up to 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
10027020|NCT01728155|Experimental|Group 3|chemotherapy and surgery
10027021|NCT01728155|No Intervention|Group 4|Observation
10027022|NCT01728155|Experimental|Group 5|chemotherapy
10027023|NCT01728155|Experimental|Group 6|chemotherapy and surgery
10027024|NCT01728155|Experimental|Group 7|chemotherapy and surgery
10027025|NCT01728155|Experimental|Group 8|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
10027026|NCT01728155|Experimental|Group 9|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
10027027|NCT01728155|Experimental|Group 10|chemotherapy, surgery,
10027028|NCT01728168||Atopic|Subjects with either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of Erlangen (>10 points).
10027029|NCT01728168||Non-atopic|Subjects without atopy.
10027030|NCT01728181|Experimental|Phase I|Will receive Tivozanib and Erlotinib treatment.
10027031|NCT01728181|Other|Phase II Group 1 (Standard of Care)|"Group 1: VeriStrat® predicts the chance of no benefit from erlotinib~• The patient will get standard-of- care"
10027032|NCT01728181|Active Comparator|Phase II Group 2 (arm 1)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 1: Patient will get the study drugs Erlotinib and Tivozanib"
10027033|NCT01728181|Placebo Comparator|Phase II Group 2 (arm 2)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 2: Patient will get the study drug erlotinib and placebo"
10027034|NCT01728207|Experimental|IMMU-114|IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.
10027035|NCT01728233|Experimental|Dacomitinib (PF-00299804)|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
9463999|NCT03687489|Experimental|Intervention arm|Participants will be treated with Abdominal Aortic Aneurysm Stent Graft System
9464000|NCT03687476|Experimental|VTS-270 (Part A)|VTS-270 200 milligram per milliliter (mg/mL) will be administered intrathecally by lumbar puncture every 2 weeks followed by dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. The highest tolerable dose is considered as clinically relevant dose which will be administered throughout the remaining duration of the 20-week treatment period of Part A.
9464001|NCT03687476|Experimental|VTS-270 (Part B)|VTS-270 200 mg/mL will be administered intrathecally by lumbar puncture every 2 weeks in Part B followed by a re-challenge to dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. In case of intolerance, the dose should be returned to previously tolerable dose and should be continued throughout the duration of Part B (end of study).
9464002|NCT03687424|Active Comparator|Normal weight 18<BMI<30 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
10027036|NCT01728272|Experimental|blood concentration of metoprolol|how does off-pump miniperfusion and perfusion CABG influence the absorption of metoprolol after CABG
10027037|NCT01728285|Active Comparator|Electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
10027038|NCT01728285|No Intervention|No electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
10027039|NCT01728298|Active Comparator|SLITone ULTRA low dose|SLITone ULTRA HDM immunotherapy
10027040|NCT01728298|Active Comparator|SLITone ULTRA medium dose|SLITone ULTRA HDM immunotherapy
10027041|NCT01728298|Active Comparator|SLITone ULTRA high dose|SLITone ULTRA HDM immunotherapy
10027042|NCT01728311|Experimental|Arm 1|
10027043|NCT01728350|Experimental|Treatment|Participants in this arm will participate in a novel structured volunteering intervention called HOPE - Helping Others through Purpose and Engagement. This intervention involves orientation, training, volunteer placement assistance, and problem solving and support.
10027044|NCT01728350|No Intervention|Control|Participants who are randomized to the control arm will be offered the HOPE intervention at the conclusion of study.
9464003|NCT03687424|Active Comparator|Obese 30<BMI<40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
9464004|NCT03687424|Active Comparator|Morbidly obese BMI ≥40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
9464005|NCT03687424|Experimental|Normal weight 18<BMI<30 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
9464006|NCT03687424|Experimental|Obese 30<BMI<40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
9464007|NCT03687424|Experimental|Morbidly obese BMI ≥40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
10027045|NCT01728363|Experimental|Ticarcillin-clavulanate antibiotic|"Cohort Gestational Age (GA) Postnatal Age (PNA) Dose~<30 weeks <14 days: 75 mg/kg Q12 hrs x 6 doses~<30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-90 days 75 mg/kg Q 6 hours x 6 doses~Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs & both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth & clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better."
10027046|NCT01728363|Experimental|Rifampin generic antibiotic|"Cohort GA PNA Dose~<32 weeks <14 days 10 mg/kg Q 24 hours x 4 doses~<32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks <14 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses~The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus & staphylococcus epidermis."
9464008|NCT03687398||control|does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
9464009|NCT03687398||patient|has laparoscopically proven endometriosis
9464010|NCT03687385|Active Comparator|ASA I / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
9464011|NCT03687385|Active Comparator|ASA II / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
9464012|NCT03687385|Active Comparator|ASA III / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
9464013|NCT03687385|Experimental|ASA I / HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
9464014|NCT03687385|Experimental|ASA II/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
9464015|NCT03687385|Experimental|ASA III/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
9464016|NCT03687294||Group I|patients suffering from malignant salivary gland tumors.
9464017|NCT03687294||Group II|patients suffering from benign salivary gland tumors.
9464018|NCT03687281||Male patients living with HIV and having sex with men|Male patients living with HIV and having sex with men followed at Universitary Hospital Center of Reunion Island
9479866|NCT03539185|Active Comparator|Fiberoptic|Awake nasotracheal tracheal intubation using flexible fiberoptic bronchoscope.
9479867|NCT03539172|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
10027047|NCT01728363|Experimental|Clindamycin Generic Antibiotic|"Cohort GA PNA Dose~<30 weeks <14 days 10 mg/kg Q 12 hours x 6 doses~<30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-120 days 10 mg/kg Q 6 hours x 6 doses~The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections."
10027048|NCT01728389|Experimental|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
9479868|NCT03539159|Experimental|Allogeneic conventional sized serum eye drops|
9479869|NCT03539159|Experimental|Allogeneic micro sized serum eye drops|
9479870|NCT03539146|Active Comparator|Control yogurt|Treatment with a control yogurt with cascara but no dietary fiber.
9479871|NCT03539146|Experimental|Yogurt with fiber|Treatment with yogurts containing cascara and 3%, 7% and 13% of dietary fiber.
9480914|NCT05190315|Experimental|Chlorpromazine with standard of care chemoradiation|"Each patient will undergo 3 phases of treatment.~Concurrent Phase: includes concurrent radiation Monday - Friday (60 Gy total radiation dose in 2 Gy fractions), oral temozolomide (75 mg/m2/day) daily for a maximum 49 days starting Day 1 of radiation, and oral chlorpromazine (25 mg for first 3 patients, then escalate to 50 mg if no DLT) daily starting 7 days prior to radiation start.~Interim Phase: Continue oral chlorpromazine daily dose post-radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: 28 days after radiation fini (+/- 5 business days), Start oral temozolomide (starting dose 150 mg/m2/day and escalated to 200 mg/m2/day if no treatment related adverse events noted) once daily for 5 consecutive days of a 28 day cycle, and continue oral daily chlorpromazine seven days a week per cycle. The adjuvant phase treatment will continue for up to 6 cycles. Cycle length is 28 days."
10027049|NCT01728415|Experimental|A: Exercise|High intensity interval exercise training (3 x 3 minutes of intensity abow 85% og Heart rate peak)
10027050|NCT01728415|Active Comparator|B: Execise|Moderate continuous exercise training
10027051|NCT01728415|No Intervention|C: Controll|Usual care without exercise training
10027052|NCT01728441|Experimental|Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.
10027053|NCT01728441|Active Comparator|Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.
10027054|NCT01728467|Experimental|RVX000222, 200 mg daily|
10027055|NCT01728467|Placebo Comparator|Placebo|
9464019|NCT03687268|Placebo Comparator|Placebo|
10027056|NCT01728480|Experimental|Treatment (entolimod, IMRT, cisplatin)|Patients undergo IMRT 5 times per week for 7 weeks, receive cisplatin IV once weekly for 7 weeks, and entolimod SC on days 1, 8, 15, 22, 29, 36, and 43.
10027057|NCT01728493||Part 1|- newly diagnosed hypertensive patients in general practice
9464020|NCT03687268|Experimental|Naloxone 24 mg|
10027058|NCT01728493||Part 2:|"newly diagnosed hypertensive patients with primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
9464021|NCT03687268|Experimental|Naloxone 48 mg|
9464022|NCT03687255|Experimental|cefepime/AAI101 combination|Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)
9464023|NCT03687255|Active Comparator|piperacillin/tazobactam|Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)
9464024|NCT03687242|Experimental|SPR001|SPR001 at Dose A
9464025|NCT03687229||Patient|"Chronic HCV patients before treatment & 3 months after starting of treatment. not known to be:~Cirrhosis~Diabetes Mellitus.~Hemochromatosis~HBV~HIV.~Hepatocellular carcinoma (HCC)~Chemotherapy~Organ transplantation"
9464026|NCT03687229||Control|Apparently healthy individuals
9464027|NCT03687216|Experimental|HVPG group|HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)
9464028|NCT03687216|Active Comparator|Routing group|Routing therapy (EVL plus NSBB)
9464029|NCT03687177|Other|Control group|Nurses from intensive care informed on the prevention of VAP and without visual cue to estimate the angle of elevation of the head of intubated patients
9464030|NCT03687177|Other|Experimental group|Nurses from intensive care informed on the prevention of VAP with visual cue to estimate the angle of elevation of the head of intubated patients.
9464031|NCT03687164|Experimental|Group Medical Visits|Group visits which will provide aspects of support, empowerment, education and medical care.
9464032|NCT03687164|No Intervention|Usual Care|Usual clinical office visits
9464033|NCT03687151||patients with a diagnosis of invasive or in situ cancer|patients with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur since 2005
9464034|NCT03687138||Control 1|This is the control population. The analysis will be done with a 24h urin sample. We will compare this population with the other two.
9464035|NCT03687138||Control 2|This is the control LES population. The analysis will be done with a 24h urin sample. We will compare this population with the other control population and the study population.
9464036|NCT03687138||Study population|This is the study population. The analysis will be done with a 24h urin sample. We will compare this population with the other two controls populations.
9464037|NCT03687112||Alzheimer desease and related disorders|Alzheimer desease and related disorders
9464038|NCT03687086|Experimental|Program A|cognitive behavioral therapy type A plus medications in packaging type A
10027059|NCT01728493||Part 3:|"newly diagnosed hypertensive patients with normokalemic primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
10027060|NCT01728506|Experimental|Weight Loss & Exercise|Single arm intervention of a 24 week weight loss and exercise intervention.
10027061|NCT01728519|Experimental|AllerT SC|AllerT subcutaneous injections
10027062|NCT01728519|Placebo Comparator|Placebo SC|placebo subcutaneous injections
10027063|NCT01728519|Experimental|AllerT ID|AllerT intra-dermal injections
10027064|NCT01728519|Placebo Comparator|Placebo ID|placebo intra-dermal injections
9464039|NCT03687086|Active Comparator|Program B|cognitive behavioral therapy type B plus medications in packaging type B
9464040|NCT03687073|Experimental|Single-dose PK study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil once at the study center. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will also be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
9464041|NCT03687073|Experimental|Multi-dose PK Study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
9464042|NCT03687073|Experimental|Safety Study|Safety data will be generated during the multi-dose PK and PD study, as DLT is not anticipated in the single-dose PK study. Enrollment into dose cohorts 1 and 2 can occur on a continuous basis. Enrollment for dose cohorts 3 and 4 will be done sequentially using a modified 3+3 design (see Section 8.2). The first three subjects enrolled into a dose cohort must complete at least 21 days of the multi-dose PK/PD study without a DLT before the remaining 4 subjects in the cohort can be enrolled.
9464043|NCT03687073|Experimental|Cohort 4 PD Study|The effect of I3C, Sil, or I3C + Sil on the pharmacodynamic endpoints listed under the Secondary Objectives in Section 1.2 will be characterized. This PD study will be done concurrently with the multi-dose PK study. Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Nasal epithelium, oral cavity cells, buccal cells, blood, and urine will be collected at the time points described in the study calendar in Section 4.0.
9479872|NCT03539107|Experimental|Spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
9479873|NCT03539107|Active Comparator|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
10027065|NCT01728532|Active Comparator|Pulp Canal Sealer (Kerr)|zinc oxide eugenol sealer
10027066|NCT01728532|Experimental|PA0903|type C implant according to ISO 7405:2008 and ISO 10993 guidelines.
9464044|NCT03687047|Experimental|New complete dentures|"Steps: 1) Preliminary impressions will be done using stock trays and impression compound; 2) primary casts will be fabricated to make custom trays for definitive impressions; 3) definitive impressions will be made using zinc oxide eugenol impression paste;4) definitive impressions will be poured with type III dental stone to obtain mastercasts; 5)jaw relations will be recorded, and the casts will be mounted on the articulator; 6) the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up. After denture insertion, post-denture insertion instructions such as oral hygiene will be explained to the patients.~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and at 3, 6, 9, 12 and 18 months after treatment."
10027067|NCT01728558|Other|Early Goal Directed Sedation|"Early Goal Directed Sedation process of care involves:~Early delivery of proposed intervention, shortly after initiating mechanical ventilation;~Effective analgesia provided simultaneously and early (analgesia first).~Regular and frequent assessment of patient wakefulness/sedative state;~Avoidance of benzodiazepines and minimisation of use of propofol;~Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.~Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment."
10036764|NCT01818791|Active Comparator|Making Proud Choices alone|These sites will be trained in Making Proud Choices.
9464045|NCT03687034|Experimental|BRCX014|Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
9464046|NCT03687021|No Intervention|endometriosis|tissue biopsy from patients (n=10) with endometriosis
9464047|NCT03687021|No Intervention|without endometriosis|tissue biopsy from patients (n=10) without endometriosis
9464048|NCT03687021|Experimental|Intramuscular progesterone|Intramuscular progestin(20mg)
9464049|NCT03687021|Experimental|vaginal progesterone|vaginal progestin (90mg)
9464050|NCT03687021|Experimental|oral progesterone|oral progestin(40mg)
9464051|NCT03687008|Experimental|Adolescents with SVHD|All adolescents will receive the intervention Cogmed. This is an in home, computer based, cognitive intervention to improve working memory, supervised by trained coaches, [25 sessions, each 30-45 minutes, 5 days a week / 5 week duration].
9464052|NCT03686982|Experimental|Active Nitrate Bar|include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
9464053|NCT03686982|Placebo Comparator|Placebo Bar|Containing no active ingredients
9464054|NCT03686956|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
9464055|NCT03686956|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
9464056|NCT03686943||Elderly|Patient over 75 years seen with the mobile extra hospital geriatric team
9464063|NCT03686917||CHAT-P|Survey
9464064|NCT03686904|Placebo Comparator|SOC GROUP [Cohort A]|Debridement, SOC irrigation & SOC topical gel
9464065|NCT03686904|Active Comparator|SOC TOPICAL GEL & TORRENT X GROUP [Cohort B]|Debridement, benzalkonium irrigation & SOC topical gel
9464066|NCT03686904|Active Comparator|BLASTX and SALINE (SOC) GROUP [Cohort C]|Debridement, SOC saline irrigation & benzalkonium gel
9464067|NCT03686904|Active Comparator|BLASTX and TORRENTX GROUP [Cohort D]|Debridement, benzalkonium irrigation & benzalkonium gel
9464068|NCT03686878|Experimental|Intervention Group|Lifitegrast 5% ophthalmic solution group
9464069|NCT03686865||dental implants|
9464070|NCT03686852|Active Comparator|group A|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A).
9464071|NCT03686852|Active Comparator|groppo B|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 150IU (Group B)
10027068|NCT01728558|Active Comparator|Standard care Sedation Arm|Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.
10027069|NCT01728571|Active Comparator|Vitamin D3 + fish oil|Dietary Supplement: vitamin D3 Drug: omega-3 fatty acids (fish oil)
9464072|NCT03686852|Active Comparator|Group C|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 250IU (Group C) of recFSH (Puregon®, MSD).
9464073|NCT03686839|Experimental|SMR neurofeedback training to MCI|"Sensorimotor rhythm neurofeedback protocol consisted of 20 individual sessions, twice a week, during 11 weeks maximum. For each subject MCI, NF was planned and conducted by a neuropsychologist experienced in neurophysiology and neurofeedback. Each session lasted 1h10-15min and was conducted as follows:~Preparation and installation of the electrodes, verification of the impedance, adjustment of the calibration and thresholds (15 minutes).~NF training (tasks and video described below) (45 minutes).~Feedback and debriefing about the session (15 minutes)."
10027070|NCT01728571|Active Comparator|Vitamin D3 + fish oil placebo|Dietary Supplement: vitamin D3 Dietary Supplement: fish oil placebo
9464074|NCT03686826||multiple sclerosis patients|
9464075|NCT03686826||healthy volunteers|
10027071|NCT01728571|Active Comparator|Vitamin D3 placebo + fish oil|Drug: omega-3 fatty acids (fish oil) Dietary Supplement: vitamin D3 placebo
10027072|NCT01728571|Placebo Comparator|Vitamin D3 placebo + fish oil placebo|Dietary Supplement: vitamin D3 placebo Dietary Supplement: fish oil placebo
9464076|NCT03686800|Experimental|Rivelin® plain patches|This is an open label study with the objectives to establish information on adhesion time, tolerability and usability of Rivelin® plain patches when applied to VLS lesions. Furthermore, the design of the Rivelin® plain patch will also be evaluated.
9464077|NCT03686774|Experimental|Memantine group|Memantine will be given orally for four weeks starting two weeks before surgery. Memantine will be given in increasing doses: 5 mg/day for 3 days; 10 mg/day for 3 days; 15 mg/day for 3 days and 20 mg/day for 5 days.
10027073|NCT01728597||healthy volunteers|MR compliant volunteers with no history of cardiovascular diseases
10027074|NCT01728610|Active Comparator|Active high|Probiotic, high dose
10027075|NCT01728610|Active Comparator|Active low|Probiotic, low dose
10027076|NCT01728610|Placebo Comparator|Placebo|Placebo
10027077|NCT01728649|No Intervention|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA approved devices. After which patient will be started on normothermia attempting to keep core body temp between 38 and 36.5 degrees centigrade. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
10027078|NCT01728649|Experimental|Mild Hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA cleared device. Patient will also have a Quattro catheter placed in the femoral vein and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours and then be rewarmed very slowly. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
9464078|NCT03686774|Other|Usual care group|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment."
10027079|NCT01728662|Experimental|ELVR Procedure|A single subsegmental AeriSeal System treatment consists of the administration of 10 mL Foam Sealant administered through a standard fiberoptic bronchoscope via an administration syringe and bronchoscopic catheter into the target area of damaged lung
10027080|NCT01728675|Experimental|Young group|Participants will underwent two isokinetic eccentric exercise sessions
10027081|NCT01728675|Experimental|Elderly group|Participants will underwent two isokinetic eccentric exercise sessions
10027082|NCT01728688|Active Comparator|Conventional|conventional treatment & antiviral treatment
10027083|NCT01728688|Experimental|conventional & PBSC transplantation|After three days G-CSF mobilization, Patients randomized to the intervention arm will receive autologous PBSCs transplantation at day1, and receive conventional treatment and antiviral treatment through the one year study visit and followed until one years study visit.
9464079|NCT03686761|Experimental|Study|A Involvement with the osteotomy site of the surgery, osteotomy was performed then GCF were collected from teeth neighboring the
9464080|NCT03686761|Active Comparator|Control|Involvement with the osteotomy site of the surgery, surgical osteotomy was performed then GCF were collected from teeth away from the osteotomy site
9464081|NCT03686748|Experimental|Two-point intervention|Two point discrimination training.
9464082|NCT03686748|Active Comparator|One-point intervention|One point discrimination of size of probe
9464083|NCT03686748|No Intervention|Healthy Controls|Observational component of differences in discrimination between chronic pain patients and healthy controls.
9464084|NCT03686735||Satisfaction measure 1|25% of the cohort
9464085|NCT03686735||Satisfaction measure 2|25% of the cohort
9464086|NCT03686735||Satisfaction measure 3|25% of the cohort
9464087|NCT03686735||Satisfaction measure 4|25% of the cohort
10027084|NCT01728701|Experimental|Grp 1: 75,000 PfSPZ Challenge, 3 immunizations|Grp 1 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 1 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 1 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
10027085|NCT01728701|Placebo Comparator|Grp 2: Normal Saline (NS)|Grp 2 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 2 gets ID injections of normal saline, on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 2 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
9464088|NCT03686722|Active Comparator|Metformin|Subjects administered Metformin 500mg(Glucophage tablets) twice daily till day(4) then Metformin 1000mg twice daily till day(7)
9464089|NCT03686722|Experimental|Metformin and Daclatasvir|Subjects Coadministered Metformin 500mg(Glucophage tablets) twice daily and Daclatasvir 60mg tablets once daily till day (4) then Metformin 1000mg twice daily and Daclatasvir 60mg tablets once daily till Day(7)
9464090|NCT03686709|Experimental|SIR-Spheres Therapy Selection|Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
9464091|NCT03686709|Experimental|TheraSpheres Therapy Selection|Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
9464092|NCT03686696|No Intervention|No Beta blocker and no ACEI/ARB|No Beta blocker and no ACEI/ARB
9464093|NCT03686696|Experimental|Beta blocker and ACEI/ARB|Beta blocker and either ACE inhibitor or Angiotensin receptor blocker
9464094|NCT03686696|Experimental|Beta blocker alone|Beta blocker alone
9464095|NCT03686696|Experimental|ACEI/ARB alone|Either ACE inhibitor or Angiotensin receptor blocker alone
9464096|NCT03686657|No Intervention|Healthy adults with NGT|Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.
9464097|NCT03686657|Active Comparator|Metformin-Drug naive patients & Patients with inadequate glycemic control with Metformin|Patients receive metformin once daily
9464098|NCT03686657|Experimental|RK-01 Low|Patients receive valsartan, celecoxib and metformin (low dose) once daily
9464099|NCT03686657|Experimental|RK-01 High|Patients receive valsartan, celecoxib and metformin (high dose) once daily
9464100|NCT03686644|Experimental|Children with Cerebral Palsy|Children with Cerebral Palsy (CP) will be included. They will have to wearing of night splint ankle foot orthoses (phase A) and then no wearing of night splint ankle foot orthoses (phase B). The phases A and B will be repeated twice. In more, they will have an ultrasound, isokinetic dynamometer and measure of quality of night sleeping.
9464101|NCT03686631|No Intervention|Passive Arm|This arm uses a passive tracking device to assess the number of times a patient uses their prescribed incentive spirometer.
9464102|NCT03686631|Experimental|Smartphone Arm|This arm uses a smartphone connected device and smartphone application to remind and encourage patients to use the spirometer as well as track the number of times they utilize the spirometer.
10027086|NCT01728701|Experimental|Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations|Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
9464103|NCT03686618|No Intervention|Cohort X|no secretin administered. All observations
9464104|NCT03686618|Active Comparator|Cohort 1|32 mcg (<50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)
9464105|NCT03686618|Active Comparator|Cohort 2|32 mcg (<50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)
9464106|NCT03686618|Active Comparator|Cohort 3|32 mcg (<50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)
9464107|NCT03686605||Cancer pain patients|
9464108|NCT03686592|Experimental|pancreatectomized patients|Patients with pancreatic cancer who underwent a pancreatectomy at Institut Paoli Calmettes
9464109|NCT03686592|Active Comparator|Volunteers|
9464110|NCT03686579||chest trauma|"Early detection and diagnosis of associated thoracic injuries .~decrease of costs required for investigations . 3- sensitivity and specificity of the investigations"
9464111|NCT03686566||13C-glucose infusion|Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
9464112|NCT03686566||No 13C-glucose infusion|Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
9464113|NCT03686553||infected, with SSI|patients with SSI
9464114|NCT03686553||non-infected|patients without SSI
9464115|NCT03686527||Echocardiography|
9464116|NCT03686527||MRI Fibrosis|
9464117|NCT03686501|Experimental|PF-06412562|To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of PF-06412562.
9464118|NCT03686475|Experimental|Biodentine pulpotomy|Biodentine (Septodont, France) Pulpotomy for primary molars Clinical and radiographic evaluation Follow up at 1,3,6 and 12 months
9464119|NCT03686475|Active Comparator|MTA pulpotomy|"MTA (Angelus- Londrina, Brazil) Pulpotomy for primary molars . it is fine hydrophilic powder consisting of tricalcium silicate, tricalicum aluminate, tricalcium oxide, silicate oxide and bismuth oxide11.~It is currently being used in pulpotomy of primary molars with a high rate of success.~Clinical and radiographic evaluation. Follow up at 1,3,6 and 12 months"
10027087|NCT01728701|Placebo Comparator|Grp 4: Normal Saline (NS)|Grp 4 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 wks(98 days). In this time, Grp 4 gets ID injections of NS, on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 4 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will receive 1 additional immunization (immunization 4), consisting of ID injections of NS, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 4 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
10027088|NCT01728714||Adults over 18 years old|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year
10027089|NCT01728714||Adults with HbA1c <= 8,5%|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year
9464120|NCT03686462|Experimental|Virtual reality-based interactive treadmill training|In this group, the subjects will receive virtual reality (VR)-based interactive treadmill training. During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
9464121|NCT03686462|Sham Comparator|Treadmill training without VR-based interaction|The subjects in this group will receive the treadmill gait training. Virtual reality environment will be provided during the gait training but no feedback and interaction will be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of treadmill-based training.
9464122|NCT03686449|Experimental|study group 1|Non-cultured Autologous Keratinocyte Suspension
10027090|NCT01728727|Active Comparator|conventional|conventional treatment & antiviral treatment
10027091|NCT01728727|Experimental|UC-MSC transplantation|Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit
10027092|NCT01728740|Experimental|Acarbose/Metformin FDC|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)
10027093|NCT01728740|Active Comparator|Acarbose+Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg
10027094|NCT01728740|Active Comparator|Acarbose|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg
10027095|NCT01728740|Active Comparator|Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg
10027096|NCT01728766||Infants under-6 months and their mothers|Small for gestational age at delivery. Post-term Infant, Not Heavy-for-dates.
9464123|NCT03686449|Experimental|study group 2|Adipose-Derived Stem cell-Keratinocyte Suspension
9464124|NCT03686449|Active Comparator|Control group|Split skin graft
9464125|NCT03686410|Experimental|1. Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
9464126|NCT03686410|Active Comparator|2. Convetional Tretament|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
9464127|NCT03686397|Experimental|SVT-15652|1 vial twice daily
9464128|NCT03686397|Placebo Comparator|Placebo|1 vial twice daily
9464129|NCT03686384|Experimental|SVT-15652|1 vial twice daily
9464130|NCT03686384|Placebo Comparator|Placebo|1 vial twice daily
9464131|NCT03686319|No Intervention|control groups|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
9464132|NCT03686319|Experimental|"intervention (foot reflexology)"|Reflexology was performed in those in the intervention group after CS on right foot for 10 min and left foot for 20 min as continuing 30-min seances three times per day every eight hours for three days. The procedure was started at mean 3rd hour after mothers became stable. Reflexology was performed for none of those in the control group.
9464133|NCT03686293|Experimental|Paracetamol and breakfast|One tablet of paracetamol (500 mg) and a standardized breakfast will be consumed within 15 minutes one morning upon 10 hours of fasting
9464134|NCT03686280|Experimental|Robot in combination with traditional reeducation|
9464135|NCT03686280|Active Comparator|Standard rehabilitation|
10027097|NCT01728818|Experimental|Arm A|
10027098|NCT01728818|Active Comparator|Arm B|
10027099|NCT01728857|Experimental|Fat Reduction|
10027100|NCT01728870|Experimental|Unique Diet+Partial Enteral Nutrition|"Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:~Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.~Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet."
10027101|NCT01728870|Active Comparator|Exclusive Enteral Nutrition (Modulen)|"Exclusive Enteral Nutrition(EEN): This group will receive as follows:~Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet."
10027102|NCT01728883||Diagnosed DR/DME requiring treatment|Patients diagnosed as diabetic retinopathy(DR) and/or diabetic macular edema (DME) and requiring treatment at the time they are recruited into the Study. Patients will be home vision monitoring using myVisionTrack®.
9464136|NCT03686267|Experimental|intervention (I1)|Lithium disilicate crowns over titanium abutments covered by a layer of opaque porcelain
10027103|NCT01728896|Experimental|Patient-controlled oral refeeding|Patients will be allowed to drink and eat hospital food freely as tolerated.
10027104|NCT01728896|No Intervention|Conventional management|
10027105|NCT01728909|Experimental|Oxytocin|40 IU Oxytocin
10027106|NCT01728909|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
10027107|NCT01728922|Active Comparator|Healthy control - 5,000 IU vitamin D|13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
10027108|NCT01728922|Active Comparator|Healthy control - 10,000 IU vitamin D|13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
10027109|NCT01728922|Placebo Comparator|CIS - placebo|15 patients will be administered placebo and all outcome measures will be assessed.
9464137|NCT03686267|Experimental|Intervention (I2)|Lithium disilicate crowns over titanium abutments covered by lithium disilicate (high opacity) coping
9464138|NCT03686267|Active Comparator|Lithium disilicate crowns over uncovered titanium abutments|Lithium disilicate crowns over uncovered titanium abutments directly without masking
9464139|NCT03686254|Active Comparator|The control Arm|bevacizumab and second-line chemotherapy
9464140|NCT03686254|Experimental|The experimental Arm|RFA, bevacizumab and second-line chemotherapy
9464141|NCT03686189|Experimental|Intervention arm|Participants will be treated with Iliac Bifurcation Stent Graft System
9464142|NCT03686163|Experimental|IN-NGF group|Patients who underwent acute ischemic stroke will be chosen to receive NGF randomly
9464143|NCT03686163|Placebo Comparator|Control group|Patients who underwent acute ischemic stroke will be chosen to receive normal saline randomly
9464144|NCT03686137||Institut Paoli-Calmettes patients undergoing liver surgery|
9464145|NCT03686124|Experimental|Dose Escalation|Dose escalation of IMA203
9464146|NCT03686124|Experimental|Extension Cohort A|IMA203 at MTD
9464147|NCT03686124|Experimental|Extension Cohort B|IMA203 at MTD + atezolizumab
9464148|NCT03686111||infertile patientes with medical assistance to procreation|
9464149|NCT03686111||Infertile patientes with induction of ovulation to give their|
9464150|NCT03686098|Experimental|Dietary Soy Arm|Participants will be asked to increase soy in their diet by an equivalent of 50mg/day for 12 months
9464151|NCT03686098|Active Comparator|Soy Supplement Arm|Participants will consume 2 tablets of 50mg each per day for 12 months
9464152|NCT03686098|No Intervention|Control Arm|No diet or supplement changes
9464153|NCT03686085|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
9464154|NCT03686085|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
9464155|NCT03686072|Other|Cataract surgery with goniosynechialysis|
9464156|NCT03686059|Experimental|punctal plug|SOFT PLUG® Preloaded Silicone Plugs by OASIS®
9464157|NCT03686059|Experimental|Combined|SOFT PLUG® Preloaded Silicone Plugs by OASIS® plus Daily intake of DHA (docosahexaenoic acid)
10027110|NCT01728922|Active Comparator|CIS - 5,000 IU vitamin D|15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.
10027111|NCT01728922|Active Comparator|CIS - 10,000 IU vitamin D|15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.
10027112|NCT01728922|Placebo Comparator|Healthy control - placebo|13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.
10027113|NCT01728935|Other|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
10027114|NCT01728948||Group 1|
9464158|NCT03686059|No Intervention|control|no medication was given
9464159|NCT03686046||Exploratory use|Brief (2 hour) exploratory use of prototype self-adjusted wearable Master Hearing Aid
9464160|NCT03686020||Group I|participants suffering from oral potentially malignant lesions
9464161|NCT03686020||Group II|participants suffering from diagnosed oral malignant lesions
9464162|NCT03686020||Group III|healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
9464163|NCT03685994||the patients who will undergo TIPS|
9464164|NCT03685981|Experimental|Incentives information provided|
9464165|NCT03685981|No Intervention|No incentives information provided|
9464166|NCT03685955||Genitourinary Reconstruction with Amniotic Membranes|Patients who undergo genitourinary reconstruction with amniotic membranes
9464167|NCT03685916|Other|Control|50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
9464168|NCT03685916|Experimental|Cumin Rice|50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
9464169|NCT03685916|Experimental|Cumin Drink|50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
9464170|NCT03685916|Experimental|Cornsilk Rice (Low dose)|50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
9464171|NCT03685916|Experimental|Cornsilk Rice (High dose)|50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
10027115|NCT01728961|Active Comparator|ARM A: AL + NVP -based ARV treatment|AL given to children who test positive for malaria and are already taking NVP as prescribed by their healthcare provider
10027116|NCT01728961|Active Comparator|ARM B: AL with No ARV treatment|AL given to children who do not meet national guidelines for beginning ARV treatment
10027117|NCT01728974|Experimental|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
10027118|NCT01728987|Active Comparator|cholecalciferol|vitamin d (cholecalciferol) will be given as a capsule of 20.000 Iu twice a week
10027119|NCT01728987|Placebo Comparator|placebo|the placebo capsules are looking identical to the vitamin d capsules and contain medium chain triglycerides and arachis oil
10027120|NCT01729000|No Intervention|Hand hygiene|All staff that have interaction with subjects will perform hand hygiene with all patient contact and before all contact with the intravenous line.
10027121|NCT01729000|Experimental|Hand hygiene plus gloving|All staff that have interaction with subjects will perform hand hygiene and wear gloves with all patient contact and before all contact with the intravenous line.
9464172|NCT03685916|Experimental|Cornsilk Drink (Low dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
9464173|NCT03685916|Experimental|Cornsilk Drink (High dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
9464174|NCT03685916|Experimental|Tamarind Rice|50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
9464175|NCT03685916|Experimental|Tamarind Drink|50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
9464176|NCT03685903|Experimental|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
9464177|NCT03685890|Experimental|ILP + Nivolumab|The day before planned ILP, the patient will receive one infusion of nivolumab 480mg
9464178|NCT03685890|Placebo Comparator|ILP + Placebo|The day before planned ILP, the patient will receive one infusion of placebo
9464179|NCT03685864|Experimental|Suture Embedding Acupuncture|Suture Embedding Acupuncture 1 time for two weeks, total 3 times.
9464180|NCT03685864|Sham Comparator|Sham acupuncture|Sham Acupuncture 1 time for two weeks, total 3 times.
9464181|NCT03685851||UT-DSAEK|With graft 6 months thick less than 100 µm
9464182|NCT03685851||DSAEK|With graft thicker than 100 µm
10027122|NCT01729013||subjects previously given placebo|
9464183|NCT03685838|Active Comparator|Compression|Patient will receive Class II above knee compression stockings, and will be asked to wear it for 1 week. This would involve wearing the stocking during daytime but patients will be allowed to take it off at night whilst in bed.
10027123|NCT01729013||subjects previously given vitamin D|
10027124|NCT01729052|Experimental|Acupuncture and standard treatment|"Acupuncture at Neiguan (Pericardium-6) bilaterally with Seirin needles no 3 (0.20x15 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed before they are fully awake.~Standard treatment: general anaesthesia"
10027125|NCT01729052|No Intervention|Standard treatment|General anaesthesia
10027126|NCT01729065|No Intervention|Home Program|Participants perform home program only.
10027127|NCT01729065|Experimental|Physical Therapy Intervention|Physical therapy intervention provided for first 12 weeks following surgery.
10027128|NCT01729078|Experimental|high fat ( MUFA) diet|intervention using high fat diet.
10027129|NCT01729078|Experimental|high carb/high fiber|diet using high carb-high fiber with dry beans
10027130|NCT01729078|Experimental|high carb/low fat|Habitual diet
10027131|NCT01729104|Experimental|Phase I: Carfilzomib + Lenalidomide + Rituximab|Phase I: Four primary dose levels of carfilzomib plus lenalidomide (carfilzomib 20 mg/27 mg + lenalidomide 20 mg, carfilzomib 20 mg/36 mg + lenalidomide 20 mg, carfilzomib 20mg/45 mg + lenalidomide 20 mg, carfilzomib 20 mg/56 mg + lenalidomide 20 mg,) evaluated with a fixed dose of rituximab (375 mg/m2 weekly for 4 weeks). Alternate dose levels using 15 mg of lenalidomide in combination with carfilzomib and rituximab evaluated if MTD is exceeded with 20 mg of lenalidomide.
10027132|NCT01729104|Experimental|Phase II: Mantle Cell Lymphoma Group|"Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
10036765|NCT01818791|Experimental|Making Proud Choices+Getting To Outcomes|These sites will receive training in Making Proud Choices and receive the Getting To Outcomes intervention.
10036766|NCT01818817||TPVB group|In this group of patients thoracic paravertebral block is performed.
10036767|NCT01818817||GA group|In this group of patients general anesthesia is performed.
9464184|NCT03685838|No Intervention|No Compression|Patient will not receive any compression stockings.
9464185|NCT03685812||patients with patellofemoral pain syndrome , Auto Cad software|Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
9464186|NCT03685799||DHG on Barrett's esophagus|patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection
9464187|NCT03685786|Experimental|Experimental: CART19 cell and auto-HSCT|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
9464188|NCT03685695|Experimental|Supportive care (physical activity)|Participants wear Fitbit Charge 2 to monitor physical activity for 3 courses (9-12 weeks). Participants then increase their activity minutes to 30 minutes, 5 times a week or by 30% for 6 additional months.
9464189|NCT03685682|Experimental|VZV seronegative Transplant Patients|recombinant subunit Herpes zoster vaccine
9464190|NCT03685669||Lung nodule group|
9464191|NCT03685669||Healthy Control group|
9464192|NCT03685656|Experimental|ANACA3|ANACA3 slimming gel
10027133|NCT01729104|Experimental|Phase II: Follicular, Marginal Zone, DLBCL Group|"Group consists of : Patients with follicular lymphoma (FL) grade 1 - 3, marginal zone lymphoma (MZL), or non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL).~Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
10027134|NCT01729117|Other|Meal Replacement|Meal Replacements will be provided to participants randomized to the MR group
10027135|NCT01729117|Other|Standard Care|Standard Care participants will receive standard care but no meal replacements
10027136|NCT01729130||Group 1 Pancreas/kidney transplant|Group 1 of patients with End Stage Renal Disease (ESRD) and Diabetes Mellitis who will receive a pancreas and kidney transplant. An adipose tissue biopsy and blood samples are collected at time of transplant surgery. A repeat adipose tissue needle biopsy and blood samples are collected between 3-12 months post transplant.
10027137|NCT01729130||Group 2 DM with kidney transplant|Group 2 are patient with DM and ESRD and who will receive only a kidney transplant.
10027138|NCT01729130||Group 3 No DM and kidney transplant|Group 3 will be patients who do not have DM but do have the diagnosis of ESRD and will receive only a kidney transplant.
9464193|NCT03685656|Placebo Comparator|Placebo|Slimming gel contening no active ingredient
10027139|NCT01729143|Active Comparator|Black pepper|During the black pepper study day, subjects consumed 1.5g of black pepper (0.5g/meal) in 60.8g of vegetable juice. Black pepper was consumed was a meal on each occasion. 24-hour energy expenditure and substrate utilization will be measured.
10027140|NCT01729143|Placebo Comparator|No pepper control|During the no pepper control study day, subjects consumed an identical menu without black pepper. 60.8g of vegetable juice (vehicle) was consumed at each of the three study meals. 24-hour energy expenditure and substrate utilization will be measured.
10027141|NCT01729169||Sarcoidosis patients|Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
9464194|NCT03685630|Experimental|Brivaracetam|Subjects in this arm will receive open-label Brivaracetam.
9464195|NCT03685617|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
9464196|NCT03685617|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
9464197|NCT03685604|Active Comparator|Cardiothoracic surgery - PI disinfection|
9464198|NCT03685604|Active Comparator|Cardiothoracic surgery - CHX disinfection|
9464199|NCT03685604|Active Comparator|Abdominal surgery - PI disinfection|
9464200|NCT03685604|Active Comparator|Abdominal surgery - CHX disinfection|
10027142|NCT01729182||Nexium|
10027143|NCT01729195|Experimental|Single-arm|The syndesmosis injury of the patients will be fixed with a ciprofloxacin containing bioabsorbable PLGA bone screw or a stainless steel metal screw
10027144|NCT01729221||HCV infected patients treated by stem cell therap|Hepatitis C virus infected patients treated by stem cell therapy
10027145|NCT01729221||HCV infected patients treated by standared line of care|Hepatitis C virus infected patients treated by standared line of care
10027146|NCT01729234|Experimental|Nitrate|150µmol /Kg bodyweight /day
9464201|NCT03685565|Experimental|Dermabond with underlying steristrips|
9464202|NCT03685565|Active Comparator|Dermabond|
9479876|NCT03539081|Experimental|Subjects with RLS|"Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Intervention: Use of epidural spinal cord stimulation."
9479877|NCT03539081|Other|Subjects without RLS|"Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Intervention: Use of epidural spinal cord stimulation."
10027147|NCT01729234|Placebo Comparator|PLacebo|150µmol /Kg bodyweight /day
10027148|NCT01729260|Experimental|Mebendazole|All study participants will receive study drug; Mebendazole.
9479878|NCT03539081|Other|Continous BP Monitoring|"This arm consists of subjects from arm Subjects with RLS, Subjects without RLS, and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only.~Intervention: Use of epidural spinal cord stimulation."
9479879|NCT03539055|Experimental|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
10027149|NCT01729273|Experimental|Diet and Exercise Intervention|"Tests will include EndoPAT analysis to assess endothelial function, applanation tonometry to assess arterial stiffness, carotid artery imaging to assess the wall thickness of the carotid arteries, exercise testing to assess the physical exercise capacity of these children and blood work to evaluate the lipid profile and inflammation status (CRP).~The Home Exercise Program will be 3 days a week for 12 weeks and participants will connect with the trainer to perform 45-60 minutes of a combination of strength training and aerobic activity via Skype. The Dietary Approaches to Stop Hypertension(DASH) eating pattern will be prescribed to all participants in the treatment group and specific strategies to achieve goals will be discussed weekly by the participant over the phone."
9479880|NCT03539029||Control group|age and sex matched healthy control persons
9464203|NCT03685552|Experimental|Prog: Purify-2|All subjects will be participating in a diet life style modification program (High Phytopro dietary program) ( a modified Mediterranean style low glycemic load food plan) and will be receiving a supportive nutritional supplements over a 4 week period.
9464204|NCT03685526|Experimental|Interventional arm|Patients will be treated with Cinenses Lung Volume Reduction Reverser System.
9464205|NCT03685513|Active Comparator|Metal ceramic single posterior crowns|Metal copings veneered with feldspathic porcelain
9464206|NCT03685513|Experimental|BioHPP PEEK-based single posterior crowns|BioHPP PEEK copings veneered with composite resin
9464207|NCT03685500|Active Comparator|Arm 1|Patients who postpone switching from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) four weeks
10027150|NCT01729286|Active Comparator|PriMatrix Moist Wound Therapy|sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
10027151|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
10027152|NCT01729299|Placebo Comparator|saline|Saline: 0.9% saline solution
10027153|NCT01729299|Experimental|ghrelin and exendin (9-39)|Ghrelin+Ex-9: Combination of ghrelin and Ex-9,
10027154|NCT01729299|Experimental|Exendin (9-39)|Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min
10027155|NCT01729299|Experimental|ghrelin|synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,
10027156|NCT01729325|Experimental|Preventive Narrative Exposure Therapy|Treatment with Pre-NET before deployment in peace-keeping mission
10027157|NCT01729325|No Intervention|No treatment control|
9464208|NCT03685500|Experimental|Arm 2|Patients who switch from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) during the baseline visit
9464209|NCT03685474|Experimental|Facing Your Fears-School Based (FYF-SB)|This group will receive the Facing Your Fears - School Based intervention during the fall semester
10027158|NCT01729351||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
10027159|NCT01729351||IPDI FP|Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
10027160|NCT01729351||IPDI NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
10027161|NCT01729351||IPDA EF HFA-BDP|Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
10027162|NCT01729351||IPDA FP|Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
10027163|NCT01729351||IPDA NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
10027164|NCT01729364|Experimental|crystalloid|crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes
10027165|NCT01729364|Experimental|colloid|colloidal fluids administration, HES 6% (130/0,4) 7ml/kg under 30 minutes
10027166|NCT01729377||Suicidal older persons and their families|Suicidal older persons and their families will be interviewed
10027167|NCT01729390|Experimental|Std ED Control|100% energy density and 133% portion size
10027168|NCT01729390|Experimental|Inc ED Control|133% energy density and 133% portion size
10027169|NCT01729390|Experimental|Std ED and Std PS|100% energy density and 100% portion size
10027170|NCT01729390|Experimental|Std ED and Inc PS|100% energy density and 133% portion size
10027171|NCT01729390|Experimental|Inc ED and Inc PS|133% energy density and 133% portion size
10027172|NCT01729390|Experimental|Inc ED and Std PS|133% energy density and 100% portion size
10027173|NCT01729416|Experimental|Water Exchange Colonoscopy|The intervention will be water exchange colonoscopy in patients who are randomized to have screening colonoscopy with water exchange colonoscopy.
10027174|NCT01729416|Active Comparator|Air colonoscopy|The intervention will be colonoscopy using the traditional air method in patients who are randomized to have screening colonoscopy with air colonoscopy.
10036768|NCT01818830||SIRS group|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
9464210|NCT03685474|Active Comparator|Usual Care (UC)|This group will receive usual care of anxiety treatment during the fall semester, but will be in the FYF-SB arm the following spring semester.
10036769|NCT01818830||sepsis|SIRS+infection
10036770|NCT01818830||normal control|For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
10036771|NCT01818843|Experimental|Safety and Adverse Reaction in CO|Inhaled Carbon Monoxide
10036772|NCT01818856|Experimental|Telaprevir interactions|"Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.~Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours"
10036773|NCT01818869|Experimental|AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
10036774|NCT01818869|Placebo Comparator|Placebo to match AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
10036775|NCT01818882|Active Comparator|Standard care|"Patients randomized to this arm will receive standard care.~Intervention: Standard care."
10036776|NCT01818882|Experimental|Standard care + ultrasound|"Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.~Intervention: Standard care + ultrasound"
10036777|NCT01818895||Withdrawal of mechanical ventilation|
9479881|NCT03539029||Surgery|patients with ankle fracture treated surgically
9479882|NCT03539029||Conservative treatment|patients with ankle fracture treated conservatively
9479883|NCT03539003|Experimental|sevoflurane (Group S)|general anesthesia with sevoflurane
10027175|NCT01729429|Active Comparator|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
9464213|NCT03685435||Non-fasting patients|We will examine non-fasting patients using bedside ultrasound. First we examine the gaster in a supine position. Then we repeat the procedure in a right lateral position.
9464214|NCT03685409|Active Comparator|Metformin-Group|Metformin hydrochloride tablets 500 mg taken orally once daily for 3 months
10027176|NCT01729429|Experimental|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
10027177|NCT01729442|Other|Patients referred for first-line prostate HIFU ablation|10 patients
10027178|NCT01729442|Other|Patients referred for first-line HIFU hemi-ablation|10 patients
10027179|NCT01729442|Other|Patients referred for salvage HIFU after radiotherapy|10 patients
10027180|NCT01729468|Experimental|Aspirin|Aspirin 160 mg per day
9464215|NCT03685409|Placebo Comparator|Placebo-Group|Starch placebo tablets taken orally once daily for 3 months
9464216|NCT03685383|Experimental|intervention group: eCPR + CytoSorb|In addition to standard treatment in patients undergoing eCPR in the intervention group the CytoSorb removal column will be added to the ECLS-system (intervention: CytoSorb removal column in eCPR).
10027181|NCT01729468|Placebo Comparator|Placebo|Placebo 160 mg per day
9464217|NCT03685383|Active Comparator|control group: eCPR - CytoSorb|Patients in the control group will receive standard treatment established for eCPR patients on our ICU. This standard treatment includes, among others, targeted temperature management (TTM) for the first 72 hours. For the use of ECLS as well as TTM we are following well established standard operating procedures (control: standard eCPR (va-ECMO)).
9464218|NCT03685370|Active Comparator|LOS group|Patients randomized to recieve epidural catheter placement with LOS technique, without any Rx control
9464219|NCT03685370|Experimental|X-ray group|Patients randomized for X-ray placement of epidural catheter
10027182|NCT01729481|Experimental|RASH positive|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~Thereafter Treatment in patients with RASH-positve outcome after 4 weeks."
10027183|NCT01729481|Active Comparator|RASH-negative|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX:~Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion"
10027184|NCT01729507|Active Comparator|Treatment with tDCS|This group will receive 7x verum treatment with tDSC. All participants receive standardised behavioural therapy ('The smoke-free programme')
10027185|NCT01729507|Placebo Comparator|7x sham treatment|This group will receive 7x sham treatment. All participants will receive standardised behavioural therapy ('The smoke-free programme')
10027186|NCT01729520|Experimental|Knee extension strength training|
10027187|NCT01729533|Active Comparator|ICSI|In this arm, patients will be provided with standard intracytoplasmic sperm injection (ICSI), in which sperm selection is performed under an overall magnification of x400.
9464220|NCT03685357||Idiopathic Parkinson's|"Oral glucose tolerance test~The Unified Parkinson's Disease Rating Scale (UDPRS)."
9464221|NCT03685357||Diabetics receive sulphonylurea group|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
9464222|NCT03685357||Diabetics on sulphonylurea and metformin|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
9464223|NCT03685357||Healthy|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score~Oral glucose tolerance test"
9464224|NCT03685331|Experimental|Phase I Level 0|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1"
9464225|NCT03685331|Experimental|Phase I Level 1|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
10027188|NCT01729533|Experimental|IMSI|In this arm, patients will be provided with a modified intracytoplasmic sperm injection (ICSI) procedure, the IMSI, in which sperm selection is performed under an overall magnification of x6600.
10027189|NCT01729572|Experimental|Experimental: Tele-medicine monitoring|Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
10027190|NCT01729572|No Intervention|No Intervention: Control Rutine out-patient treatment|routine out-patient treatment will be given to the control group
10027191|NCT01729585|No Intervention|control group|control group
10027192|NCT01729585|Active Comparator|Massage therapy|Treatment group receives pre-determined massage therapy protocol x 5 over 10-12 weeks. massage therapy protocol includes a blend of Swedish strokes and myofascial trigger point therapy. Initially, dosing will be more frequent. Treatments will be spaced out to determine the ability of the body to maintain a more efficient musculoskeletal system, especially related to respiratory and postural efforts. Each session will end with resting hands and relaxation strokes to signal the end of the session. This protocol invites increased mobility in the musculoskeletal system. The ultimate goal is to return connective tissue (including muscles and fascia) to a more relaxed and neutral state, thus allowing expansion and ease of movement of the areas of the musculoskeletal system being worked.
9464226|NCT03685331|Experimental|Phase I Level 2|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
9479884|NCT03539003|Active Comparator|desflurane (Group D)|general anesthesia with desflurane
9479885|NCT03539003|Active Comparator|total intravenous anesthesia (Group T)|general anesthesia with total intravenous anesthesia
9464227|NCT03685331|Experimental|Phase II|"(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
9464228|NCT03685318|Active Comparator|Conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
9464229|NCT03685318|Active Comparator|Shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo for two weeks. The shortened mouthguard is designed with the palatal margin at 2 mm from the cervical line.
9464230|NCT03685292||Group A|Subject(s): A Subgroup
9464231|NCT03685292||Group B|Subject(s): B Subgroup
9464232|NCT03685292||Group C|Subject(s): C Sub Group
10027193|NCT01729611||Scleroderma|60 patients with scleroderma - 30 with and 30 without Pulmonary Arterial Hypertension
10027194|NCT01729611||Cirrhosis|60 patients with cirrhosis - 30 with and 30 without Pulmonary Arteria Hypertension
10027195|NCT01729650|Experimental|Physical and diet educational group|group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
10027196|NCT01729650|No Intervention|Usual clinical care|
10027197|NCT01729663|Active Comparator|Interferon alpha 2 b|Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks and then 5 MU (3t/w) for 23 months.
10027198|NCT01729663|Experimental|CSF470 vaccine, BCG, Molgramostim|"CSF470 vaccine, BCG, Molgramostim~CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.~Each vaccine consist of a mixture of 17,6.106 melanoma cells , from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rhGM-CSF (Molgramostim 400 µg, fractionated in four days doses) will be used."
10027199|NCT01729676||Group A|Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
10027200|NCT01729689|Experimental|Supportive care (cognitive behavioral therapy)|Participants undergo cognitive behavioral therapy over 1 hour once weekly for a total of 6 sessions. Sessions are tailored to patient and caregiver cognitions and approach and avoidance behaviors.
10027201|NCT01729702|Other|single group - consecutive patients|
10027202|NCT01729715|Experimental|Internet|Internet site that offers parents tips on promoting sleep in infants and toddlers
10027203|NCT01729715|Experimental|DVD|DVD that offers parents tips on promoting sleep in infants and toddlers
10027204|NCT01729715|No Intervention|No treatment|
10027205|NCT01729741|No Intervention|No drain|No drain was inserted after Thyroid surgery
10027206|NCT01729741|Experimental|Drain|A drain was inserted after thyroid surgery
10027207|NCT01729767|Experimental|Acyclovir|Acyclovir 400 mg tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
10027208|NCT01729767|Placebo Comparator|Placebo|Placebo tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
10027209|NCT01729780|Sham Comparator|Sham EEG-NF|Subjects who will undergo sham EEG-NF.
10027210|NCT01729780|Active Comparator|True EEG-NF|Subjects who will undergo true EEG-NF training in order to lessen their anxiety symptoms.
10027211|NCT01729793|Active Comparator|Digestive Enzyme #2|A proprietary blend of dietary supplement enzymes in a capsule
10027212|NCT01729793|Placebo Comparator|Placebo|Capsule identical to active arm containing only microcrystalline cellulose
10027213|NCT01729806|Experimental|Arm A (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
10027214|NCT01729806|Experimental|Arm B (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
10027215|NCT01729832|Experimental|Supportive care (image-guided breast reconstruction)|Patients undergo DIEP flap breast reconstruction using the StealthStation navigation system.
10027216|NCT01729897|Experimental|Etomidate & Fentanyl|"4 min before procedure: fentanyl 1 μg/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, etomidate was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of etomidate would be administrated separately when duration of procedure was prolonged."
9464233|NCT03685279|Experimental|NHA Group|"Six-week, online intervention with weekly, sequential, content knowledge and skills practice. Each week included recorded, slide presentations (narrated by the developer of the NHA, Howard Glasser); readings from The Transforming the Intense Child Workbook by Howard Glasser with Melissa Lowenstein; participants' skills practice, web postings, and live sessions with Howard Glasser and Advanced NHA Trainers."
9464234|NCT03685279|Other|Control Group|The Control Group received the same intervention after the collection of NHA Group post-intervention surveys.
9464235|NCT03685266||Pediatric Residents|Participating pediatric residents from first postgraduate year (PGY-1) through third postgraduate year (PGY-3) will be observed over a 12 month timeframe.
9464236|NCT03685240|Experimental|Intervention|AI-enabled camera fall detection with Human-in-the-Loop (HIP) review
9464237|NCT03685240|No Intervention|Control|No camera detection
9464238|NCT03685227|No Intervention|Control|Participant will lie quietly for 90 minutes. They will be allowed to sleep.
10027217|NCT01729897|Placebo Comparator|Propofol & Fentanyl|"4 min before procedure: fentanyl 1 g/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, propofol was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of propofol would be administrated separately when duration of procedure was prolonged."
9464239|NCT03685227|Experimental|Yoga Nidra|Participant will practice yoga nidra (using a recording) during the first 30 minutes of the 90 minute measurement period. Then they will be allowed to sleep.
9464240|NCT03685214|Experimental|0.9% saline|We use 0.9% saline for resuscitation fluid in ICU septic patients
9464241|NCT03685214|Experimental|Balanced Crystalloids|We use acetated Ringer's solution for resuscitation fluid in ICU septic patients
9464242|NCT03685201|Active Comparator|Orange Juice1|100% orange juice
9464243|NCT03685201|Experimental|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
9464244|NCT03685201|Placebo Comparator|Raw Orange|raw orange
9464245|NCT03685149|Active Comparator|Flecainide|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
9464246|NCT03685149|Placebo Comparator|Placebo|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
9464247|NCT03685123|Experimental|PA-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the minimum physical activity recommendations
9464248|NCT03685123|Experimental|WM-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the weight maintenance recommendations
9464249|NCT03685097||Cardiac surgery patients|Patients undergoing elective cardiac surgery requiring cardiopulmonary bypass.
9464250|NCT03685084|Placebo Comparator|0.9% saline infusion|Saline 0.9% infusion
9464251|NCT03685084|Experimental|AAI101 i.v.|"600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.~Drug-Drug Interaction:~Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.~Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v."
9464252|NCT03685084|Experimental|Piperacillin i.v.|Piperacillin 3 g
9464253|NCT03685084|Experimental|Cefepime i.v.|Cefepime 1 g
9464254|NCT03685058|Active Comparator|The control group|A total of 88 non-cavitated proximal carious lesions treated with standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish (Vanish 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate, 3M ESPE, St. Paul, MN, U.S.A.), oral hygiene instruction, and dietary counseling applied at initial, six-months follow-up, and 12-months follow-up visits.
9464255|NCT03685058|Experimental|The test group|Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
9464256|NCT03685032|Experimental|The study group (Gr. D)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. D was administered 4 mg of dexamethasone in 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. D received ondansetron 4 mg in 2 ml iv."
9464257|NCT03685032|Placebo Comparator|the control group (Gr. N)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. N received normal saline 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. N received normal saline 2 ml iv."
9464258|NCT03685019|Experimental|Valgus stress - lateral compartment|Valgus stress radiograph. Joint space width measured in lateral compartment.
9464259|NCT03685019|Experimental|Varus stress - medial compartment|Varus stress radiograph. Joint space width measured in medial compartment.
9464260|NCT03685019|Experimental|0 degree flexion - medial compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
9464261|NCT03685019|Experimental|0 degree flexion - lateral compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
9464262|NCT03685019|Experimental|20 degree flexion - medial compartment|20 degree flexion radiograph. Joint space width measured in medial compartment.
9464263|NCT03685019|Experimental|20 degree flexion - lateral compartment|20 degree flexion radiograph. Joint space width measured in lateral compartment.
9464264|NCT03685019|Experimental|45 degree flexion - medial compartment|45 degree flexion radiograph. Joint space width measured in medial compartment.
9464265|NCT03685019|Experimental|45 degree flexion - lateral compartment|45 degree flexion radiograph. Joint space width measured in lateral compartment.
9464266|NCT03684993|Experimental|Arabic gum extract|natural product Arabic gum (acacia gum) prepared as a mouthwash
9464267|NCT03684993|Experimental|Licorice root extract|natural product Licorice (Glycyrrhiza Glabra) root extract prepared as a mouthwash
9464268|NCT03684993|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
9464269|NCT03684967|Experimental|fruquintinib|Fruquintinib treatment: administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.
9464270|NCT03684954|Other|Used of PRF in clsed sinus lifting|Used of PRF in closed sinus lifting with implant placement
9464271|NCT03684954|No Intervention|Closed sinus with xenograft|used of xenograft in closed sinus lift with implant placement.
9464272|NCT03684941|Experimental|Treatment Period One|LoFric, hydrophilic urinary catheter for single use. The study device is based on commercially available hydrophilic urinary catheters for intermittent catheterization, but with a different coating process than the comparator. Treatment Period One will last 1 week.
10027218|NCT01729910|Experimental|Parent education / behavioral counseling|Parents of children in the intervention group will be invited to participate in four group visits and two individual visits with their primary care provider as well as four follow-up phone calls with study personnel (project coordinator or registered dietician). Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls.
9464273|NCT03684941|Active Comparator|Treatment Period Two|CE-marked LoFric®, hydrophilic urinary catheter for single use. The comparator product is today commercially available and produced by WHC. Treatment Period Two will last 1 week.
9464274|NCT03684915|Experimental|rotary files|"Pre-operative radiograph showing all roots and their apices.~Local anaesthetic (to enable use of rubber dam clamp).~Rubber dam isolation.~Removal of caries.~Removal of roof of pulp chamber.~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece.~Identify root canals.~Irrigate with normal saline (0.9%)~Estimate working lengths of root canals keeping 2 mm short of the radiographic apex.~Insert rotary files into canals and debride the canals lightly and gently.~Irrigate the root canals.~Dry canals with pre-measured paper points, keeping 2 mm from root apices.~Canals will be dried with paper points, obturated by injecting Metapex. (Meta Biomed - Metapex Root Canal Filling Material)~Stainless steel crown will be performed"
9464275|NCT03684915|Active Comparator|manual files|All steps as that of intervention group are to be followed except step (j) instead of it; a manual files will be inserted into the canals for debridement lightly and gently
10027219|NCT01729910|Placebo Comparator|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
10027220|NCT01729936|Experimental|Sitting time Change Intervention|"Sitting time Change Intervention: recommendation to substitute Sitting time by doing the regular activities standing or walking.~Duration: 6 month. Frequency: 1 time each 15 days during the first 4 month and 1 time each month the last 2 months."
10027221|NCT01729936|No Intervention|Active Control|Control visits to the Primary Health Care Center
10027222|NCT01729949|Active Comparator|Active Treatment Beverage|Strawberry powder and Blackcurrent extract
10027223|NCT01729949|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
10027224|NCT01729962||Agreement Cohort|All subjects in the agreement portion of the study will have a single measurement performed with each device, the Nidek optical biometer, predicate device and ultrasound reference device. Each device will be operated by a different operator.
10027225|NCT01729962||Precision Cohort|All subjects in the precision portion of the study will each be paired with one Nidek optical biometer and with one predicate device for a total of three Nidek optical biometer/predicate device pairs. Each of the three device pairs will be designated one and only one operator. All subjects in the precision portion of the study will have their measurements repeated three times on each of three Nidek optical biometer and predicate device pairs.
10027226|NCT01729975||18-28 years old Non-pathologic|
10027227|NCT01729975||29-80 years old Non-Pathologic|
10027228|NCT01729975||29-80 years old pathologic corneal disease|
9464276|NCT03684902|Experimental|xpolration|women who underwent emergency midline laprotomy
9464277|NCT03684863|No Intervention|Standard therapy|
9464278|NCT03684863|Experimental|capecitabine|
9464279|NCT03684850|Active Comparator|Exercise therapy group|(n = 40)
10027229|NCT01729988|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
10027230|NCT01730001|Active Comparator|Early Intubation|Early intubation is defined as prehospital intubation on the scene of the patient illness/injury, or where the EMS physician first meets the patient (e.g en route to hospital). Intubation includes drug assisted and/or rapid sequence intubation (RSI) with endotracheal tube.
10027231|NCT01730001|Active Comparator|Late intubation|Late intubation is defined as on-scene prehospital high-flow (> 10 L/min) supplemental oxygen by mask, assisted bag-mask-ventilation by EMS physician if required and stable recovery position during transport to hospital. Intubation should be done on arrival in the emergency department.
10027232|NCT01730014|Experimental|Trial part 1|
10027233|NCT01730014|Experimental|Trial part 2, treatment A|
10027234|NCT01730014|Experimental|Trial part 2, treatment B|
10027235|NCT01730066|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria preoperatively and given the same study product enterally postoperatively
10027236|NCT01730066|No Intervention|Control|No intervention.What has been the standard procedure so far
10027237|NCT01730118|Experimental|1/Part I dose escalation|AdHER DC vaccine administered at escalating doses
10027238|NCT01730118|Experimental|2/Part I dose expansion|AdHER DC vaccine administered at a next lower dose or the highest dose
10027239|NCT01730118|Experimental|3/Part II dose escalation|AdHER DC vaccine administered at Dose Level 1
10027240|NCT01730118|Experimental|4/Part II dose expansion|AdHER DC vaccine administered at Arm 1 MTD
10027241|NCT01730157|Experimental|Treatment (yttrium Y 90 glass microspheres, ipilimumab)|Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10027242|NCT01730183|Experimental|Bone marrow derived stem cells|Autologous Bone Marrow derived Stem Cells(BMSC) transplanted intrathecally into patients with spinal cord injury.
10027243|NCT01730196|Experimental|Fit Body and Soul|Faith-based adaptation of the Group Life Style Program
10027244|NCT01730196|Active Comparator|Wellness education|A health education program developed from the list of topics provided by the Centers for Disease Control and Prevention (CDC) Guide to Community Prevention Services
10027245|NCT01730209|Experimental|Everolimus|Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml
10027246|NCT01730209|Placebo Comparator|Placebo|Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.
10027247|NCT01730222|Experimental|PAXG regimen|cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
10027248|NCT01730222|Active Comparator|gemcitabine + nab-paclitaxel|gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks
10027249|NCT01730235||Case Group|Group receiving access to MyMediHealth web site.
9464280|NCT03684850|Experimental|Knee brace and exercise group|(n = 40)
9464281|NCT03684850|Experimental|Footwear device group|(n = 40)
9464282|NCT03684837|Active Comparator|D vitamine|a dose for week
9464283|NCT03684837|Placebo Comparator|D vitamine placebo|a dose for week
9464284|NCT03684824|Other|obese group|100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility
9464285|NCT03684798|Experimental|Mental Contrasting with Implementation Intentions (MCII)|"Mental Contrasting with Implementation Intentions (MCII) combines two methods: Mental Contrasting and Implementation Intentions.~Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality (Oettingen, 2000, 2014; Oettingen, Pak, & Schnetter, 2001) in order to increase goal commitment when expectations of success are high (Gollwitzer, 2014). Implementation Intentions on the other hand specify when, where, and how to strive for a goal in form of an if-then-plan, e.g. If situation Y is encountered, then I will perform the goal-directed response Z (Gollwitzer, 2014; Wieber, Thürmer, & Gollwitzer, 2015)."
10027250|NCT01730235||Control Group|Children completing baseline and week two measures, but without any additional intervention.
10027251|NCT01730248|Experimental|JAK Inhibitor Naive|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period ( 6 or more cycles of 28 days, with visits every 28days for 6 cycles and then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine maximum tolerated dose (MTD) / Recommended Phase II dose (RPIID) & an Expansion Phase
9464286|NCT03684798|Active Comparator|Treatment as usual|The control group receive a control training, which consists of an exercise from treatment as usual. Thus, patients in the control group are supported in their intention for abstinence and in the reappraisal of risk situations and relapse, while no individual motivational strategies are planned or provided
9464287|NCT03684772|Experimental|ICVT|Digoxin and Furosemide (0.125%)
10027252|NCT01730248|Experimental|Prior JAK Inhibitor|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period (6 or more cycles of 28 days, with visits every 28 days for 6 cycles then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine MTD / RPIID & an Expansion Phase
10027253|NCT01730261|Experimental|Online Emotional Regulation Treatment|Participants will receive 24 treatment sessions, with baseline, post-treatment screening and follow-up screening, and bi-weekly assessments
10027254|NCT01730274||patients|children operated on a cerebellar tumor
10027255|NCT01730274||healthy subjects|healthy volunteers
9464288|NCT03684772|Experimental|Furosemide|Furosemide (0.125%)
9464289|NCT03684772|Experimental|Digoxin|Digoxin (0.125%)
9464290|NCT03684772|Placebo Comparator|Placebo|Vehicle Gel
9464291|NCT03684746||Medial Experts|Including doctors- surgeons - consultants
9464292|NCT03684746||Care specialist|including nurses - before/after care staff
9464293|NCT03684733||Arm 1: Cohort 1 - Retrospective Analysis|Participants attending MRI & XRM for a clinical indication with at least one normal breast
9464294|NCT03684733||Arm 2: Cohort 2 - Retrospective Analysis|"BRCA1 or BRCA2 mutation carriers attending MRI & XRM for breast screening:~Genetic risk of breast cancer"
9464295|NCT03684733||Arm 2: Cohort 3 - Retrospective Analysis|"Participants attending MRI & XRM for breast screening post mantle radiotherapy:~Environmental risk of breast cancer"
9464296|NCT03684733||Arm 2: Cohort 4 - Prospective|"General population attending XRM for breast investigation:~Population risk of breast cancer MRI"
9464297|NCT03684720|Experimental|Discover followed by direct instruction [DD]|The intervention group which will be taught suturing using guided-discovery-learning
10027256|NCT01730287|Experimental|Control|No lining applied in group1.
10027257|NCT01730287|Experimental|CEM cement|CEM cement applied over remained caries in group4.
10027258|NCT01730287|Experimental|Mineral Trioxide Aggregate (MTA)|MTA applied over remained caries in group3.
9464298|NCT03684720|No Intervention|Instruction followed by practice [IP]|The control group which will be taught suturing using traditional instructional teaching.
9464299|NCT03684707|Active Comparator|Metformin Hcl 500Mg 24Hr Sa Tab|Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient
9464300|NCT03684707|Placebo Comparator|control|starch tablets
9464301|NCT03684681|Other|Peer Navigator|Current standard of care
10027259|NCT01730287|Experimental|Calcium Hydroxide|Calcium Hydroxide applied over remained caries in group2.
10027260|NCT01730313|Experimental|Pyridoxine (B6)|Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks
10027261|NCT01730313|Experimental|Phenytoin|Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks
10027262|NCT01730313|Experimental|Sodium Valproate|Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks
10027263|NCT01730313|Placebo Comparator|Placebo|Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm
10027264|NCT01730326|Experimental|Paracetamol|Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
10027265|NCT01730326|Active Comparator|Dexketoprofen|Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
9464302|NCT03684681|Other|Social Worker|Current standard of care
9464303|NCT03684668|Experimental|Psychoeducational intervention|The psychoeducational intervention, with the use of meta-universes,consists of three sessions in which techniques based on three of the four sources of self-efficacy described are applied.
10027266|NCT01730352|No Intervention|H. pylori no treatment|Observational group, with clinical and platelet count follow-up
10027267|NCT01730352|Experimental|H. pylori triple therapy|Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
10027268|NCT01730365||Histological biopsy procedures|Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
10027269|NCT01730391||Study cohort|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and Vietnam.
9464304|NCT03684668|No Intervention|Control|The control arm will not receive the psychoeducational intervention. Students in this group will complete the questionnaires before the beginning of the intervention and after its end.
10027270|NCT01730404|Experimental|CHF6001|CHF6001 DPI (Dry Powder Inhaler) once daily
10027271|NCT01730404|Active Comparator|Roflumilast|Roflumilast, tablet, once daily
10027272|NCT01730404|Placebo Comparator|placebo|Placebo
10027273|NCT01730417|Experimental|Radiation dosimetry|no carrier added metaiodobenzylguanidine
10027274|NCT01730430||Collection of CSF|"Those with Alzheimer's disease~Those with non-Alzheimer's disease dementia~Healthy elderly volunteers"
9464305|NCT03684629|Experimental|the response of KPI and corresponding suggestion|The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month. The multifaceted quality improvement interventions include: 1) implementation of standardized templates of medical record, evidence-based clinical pathway, and written care protocols; 2) feedback system of performance measures; 3) expert online consultation.
9464306|NCT03684629|No Intervention|a control arm|The control group indicated that the hospitals will not be provided with the multifaceted quality improvement interventions. They just provide patients with routine care.
9464307|NCT03684616||Statin treatment prior to cardiac arrest|
9464308|NCT03684616||No Statin treatment prior to cardiac arrest|
9464309|NCT03684603|Active Comparator|Acoustic cueing|The melody will be played during training and during slow wave sleep.
9464310|NCT03684603|Sham Comparator|Control|The melody will be played during training.
9464311|NCT03684577|Experimental|Hypnotherapy for Agoraphobia|A total of 8-12 individual sessions of hypnotherapy over 12 weeks will be delivered. Hypnotherapy consists of hypnotic activation and reinforcement of the patient's own resources, the use of relevant positive and negative experiences from the biography, and the development of positive solution imagery. The central technique is the work with a symptom regression and the resolution of old and actual experiences. Furthermore, formal trance induction, utilisation techniques, indirect techniques such as the use of metaphors or the representative technique, or work with time progression will be used.
9464312|NCT03684577|No Intervention|Wait-list control group|Patients in the wait-list control group will receive 8-12 sessions of individual hypnotherapy after a waiting period for 12 weeks.
9464313|NCT03684564|Experimental|Rivaroxaban (Treatment Arm)|
9464314|NCT03684564|Active Comparator|Warfarin (Control Arm)|
9464315|NCT03684551|Active Comparator|No dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. The supervisory feedback session for CHWs in the control arm was not facilitated by a visual Dashboard tool or any personalised quantitative feedback on quantity, speed, or quality of care. CHW supervisors were instructed to continue providing CHWs in the control arm with feedback informed by patient perspectives and direct observation during the individual supervision visit.
9464316|NCT03684551|Experimental|Dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. For CHWs randomised to the intervention arm, a visual feedback tool, the CHW Performance Dashboard, was employed during individual supervision, starting in January 2016. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month. The feedback provided to CHWs in the intervention arm, therefore, was both quantitative, informed by the Dashboard, and qualitative, informed by patient perspectives and direct observation of CHW service provision during the individual supervision visit.
9480915|NCT05186129|Experimental|Clopid® 75 mg(Clopidogrel)Tablet of Ferozsons Laboratories Ltd. Pakistan|Single dose of Clopid® 75 mg Tablet administered under fasting condition
10027275|NCT01730443||On progesterone treatment|The group assigned to progesterone treatment.
10027276|NCT01730443||group assigned to placebo|The group that will not be receiving progesterone treatment
10027277|NCT01730456|Experimental|RoActemra/Actemra|
10027278|NCT01730469|Experimental|AT1001 150 mg|Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
10027279|NCT01730482|Experimental|[14C] AT1001 Arm|Each subject will receive a single oral dose of 150 mg of [14C] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.
10027280|NCT01730495|Experimental|Etanercept|
10027281|NCT01730508||Chronic Hepatitis B Participants|Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.
10027282|NCT01730521||Difference in Iron bioavailabilty exercise and resting phase|the subjects will act as their own control during the study
10027283|NCT01730547|Active Comparator|Early treatment with mesenchymal stem cells|
10027284|NCT01730547|Active Comparator|Delayed treatment with mesenchymal stem cells|
10027285|NCT01730560|Experimental|Arm 1:Treatment A|Treatment A (active) followed by treatment B (neutral)
10027286|NCT01730560|Experimental|Arm 2: Treatment B|Treatment B (neutral) followed by treatment A (active)
10027287|NCT01730573|Active Comparator|Interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
9464317|NCT03684538|Experimental|Group Probiotics|Patients in this group will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive probiotics (Saccharomyces boulardii) one dose per day.
9464318|NCT03684538|Experimental|Group Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
9464319|NCT03684538|Active Comparator|Group Probiotics & Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive a combination of probiotics (Saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
9464320|NCT03684525|Experimental|Extraction of primary canines only|"A total of 43 patients with unilateral mesioangular displaced maxillary canines Interceptive treatment: Extraction of both maxillary primary canines will be held at baseline visit At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
9464321|NCT03684525|No Intervention|Control group- no extraction|"A total of 43 patients with unilateral mesioangular displaced maxillary canines At Baseline (T0): Clinical examinatiion + CBCT scan , no extraction At 6 month follow-up (T1): Clinical examination At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
9464322|NCT03684512|Experimental|Adolescent Only|Remote based physical activity intervention delivered to adolescents only. Adolescents will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity.
9480916|NCT05186129|Active Comparator|Plavix® 75mg Tablet of Sanofi Winthrop Industrie France for Sanofi Pakistan.|Single dose of Plavix® 75 mg Tablet administered under fasting condition
10027288|NCT01730573|Active Comparator|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
10027289|NCT01730599||PD patients|PD patients carriers of the G2019S mutation in the LRRK2 gene
10027290|NCT01730625|Experimental|ABMT + CBT|CBT and ABMT
10027291|NCT01730625|Other|CBT Alone|CBT alone (compare/control group)
10027292|NCT01730625|Placebo Comparator|ABMT placebo + CBT|ABMT placebo training and CBT
10027293|NCT01730651|Experimental|Tomotherapy|"Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
10027294|NCT01730664|Experimental|ertapenem|single dose ertapenem
10027295|NCT01730677|Experimental|Lapatinib+Vinorelbine|lapatinib 1000mg, once daily vinorelbine 20mg/m2, D1 and D8, every 3 weeks
10027296|NCT01730677|No Intervention|Vinorelbine|vinorelbine 30mg/m2, D1 and D8, every 3 weeks
10027297|NCT01730703||Adults ages 65 and older|
10027298|NCT01730716|Experimental|Surgery|There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
10027299|NCT01730742|Experimental|Sleep deprivation|Total sleep deprivation: participants were required to stay up for the entire night before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
10027300|NCT01730742|Experimental|Sleep|Sleep: participants had an 8-h sleep opportunity before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
10027301|NCT01730794|Other|Conventional Lung Protective Ventilation|In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level <30 cmH2O.
10027302|NCT01730794|Other|NAVA Ventilation Group|In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
10027303|NCT01730807|Experimental|IntellaTip XP MiFi|Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
10027304|NCT01730859|Experimental|Balance exrercise and ankle taping|"Balance Exercises:Balance exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for training group.~Ankle taping: Ankle joint taping was performed for 6 weeks and was renewed three times a week."
10027305|NCT01730885|Other|BGStar|Comparision
10027306|NCT01730898|Active Comparator|Control capsule|2 capsules
10027307|NCT01730898|Experimental|Experimental capsule|2 capsules
10027308|NCT01730911|No Intervention|ParaGard, paper diaries|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries on paper.
10027309|NCT01730911|Active Comparator|ParaGard, text message|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries via text message.
9464323|NCT03684512|Active Comparator|Adolescent and Parent|Remote based physical activity intervention delivered to adolescents and their parent. Adolescents and a parent will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity. Parents will have access to a Parent Facebook group.
9464324|NCT03684499|Other|study group (1)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
9480917|NCT05181449|Experimental|Twin Precision Treatment (TPT)|Twin Precision Treatment (combination of AI and lifestyle coaching)
9480918|NCT05181449|No Intervention|Usual Care (UC)|Usual care prescribed by Cleveland Clinic diabetes specialists and primary care physicians
10027310|NCT01730911|No Intervention|Mirena, paper diaries|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries on paper.
10027311|NCT01730911|Active Comparator|Mirena, text message|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries via text message.
10027312|NCT01730924|Other|Contact force available|
10027313|NCT01730924|Other|Contact force not available|
10027314|NCT01730963||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
10027315|NCT01730963||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
10027316|NCT01730963||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
10027317|NCT01730976|Experimental|Vitamin D 2,000 I.U. daily|Study subjects will take 2,000 I.U. vitamin D daily for three months
10027318|NCT01730989|Experimental|Estromineral Serena Plus|"Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.~1 tablet oad for 12 weeks"
10027319|NCT01730989|Active Comparator|Estromineral|"Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.~1 tablet oad for 12 weeks"
10027320|NCT01731015|Experimental|Normal Subject|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
10027321|NCT01731015|Experimental|Subjects with Lung/or Airway Disease|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
10027322|NCT01731028||Somatropin|Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization
10027323|NCT01731067|Active Comparator|CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors|Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs
10027324|NCT01731067|Active Comparator|CYP2D6 and P-gp inhibitor|Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs
10027325|NCT01731067|Active Comparator|CYPs and P-gp inducer|Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs
10027326|NCT01731067|Experimental|Probe cocktail alone|"Oral intake of the cocktail probe drugs :~bupropion 25 mg~flurbiprofen 25 mg~omeprazole 5 mg~dextromethorphan 5 mg~midazolam 1 mg~fexofenadine 25mg~Caffeine (a cup of coffee)"
10027327|NCT01731080||Pseudoxanthoma Elasticum|Patients with genetically and clincally proven PXE
10027328|NCT01731080||chronic kidney disease|Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
10027329|NCT01731080||Diabetes|patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
10027330|NCT01731093|Experimental|AT-001|AT-001
10027331|NCT01731093|Placebo Comparator|Placebo|Matching placebo.
10027332|NCT01731132||Group 1|
10027333|NCT01731145|Experimental|SNUMAP assessment|Uses SNUMAP motion sensing system to quantify tremor symptom.
10036778|NCT01818908|Experimental|DA-EPOCH|"Infused agents:~Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;~Bolus agents:~Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;~The details of dose adjustment are described in ref 1.~If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
10036779|NCT01818934|Active Comparator|expert clinical exam only|all babies assigned to this group had expert clinical examination only, no hip ultrasound
10036780|NCT01818934|Active Comparator|selective hip ultrasound screening|all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
10036781|NCT01818934|Active Comparator|universal hip ultrasound screening|All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination
10036782|NCT01818947||Gefitinib|
10036783|NCT01818960|Active Comparator|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
10036784|NCT01818960|Active Comparator|IRA-PCI|IRA only PCI with planned staging for non-IRA lesions
9464325|NCT03684499|No Intervention|control group( 2)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
9464326|NCT03684486|Experimental|rehabilitation by effort|8 sessions of rehabilitation by effort in sports medicine
9464327|NCT03684460|Experimental|Bright Light|"Intervention: Daytime Bright Light~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 09:00 to 13:00 starting on study day 2 and continuing through study day 5 or MICU discharge whichever is longer up to 30 days. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor, if the patient is transferred (prior to study day 5). Feasibility metrics will also be collected."
9464328|NCT03684460|Active Comparator|Usual Light|"Intervention: Usual Care~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise, have usual care."
9464329|NCT03684447|Experimental|Propofol High Dose|high propofol injectable, individually dosed, three times per week
9464330|NCT03684447|Experimental|Propofol Low Dose|low propofol injectable, individually dosed, three times per week
9464331|NCT03684434|Experimental|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
9464332|NCT03684434|Active Comparator|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
9464333|NCT03684421||Long Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Long Antagonist Protocol for COS
9464334|NCT03684421||Classical Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Classical Antagonist Protocol for COS
9480919|NCT05179057|Experimental|Posoleucel + SoC|Posoleucel + SOC; then placebo + SOC for patients who meet optional protocol-defined crossover criteria
9480920|NCT05179057|Placebo Comparator|Placebo + SoC|Placebo + SOC; then Posoleucel + SOC for patients who meet optional protocol-defined crossover criteria
10027334|NCT01731158|Other|arm A|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (Sutent, Nexavar or Votrient) (third-line)"
10027335|NCT01731158|Other|arm B|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), a TKI (Sutent, Nexavar or Votrient) (second-line) and Afinitor (third-line)"
10027336|NCT01731184|Experimental|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
10027337|NCT01731184|Placebo Comparator|Placebo|Placebo at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
10027338|NCT01731197|Experimental|Test ISP-10|10 grams of the test ISP will be consumed as a dry-blended beverage
10027339|NCT01731197|Experimental|Test ISP-20|20 grams of the test ISP will be consumed as a dry-blended beverage
10027340|NCT01731197|Active Comparator|Control ISP-10|10 grams of the control ISP will be consumed as a dry-blended beverage
10027341|NCT01731197|Active Comparator|Control ISP-20|20 grams of the control ISP will be consumed as a dry-blended beverage
10027342|NCT01731223|Experimental|Group treatment for insomnia|Group treatment for insomnia.
9480921|NCT05175495||Normal young|Aged less than 45 years old,no underlying heart disease
10027343|NCT01731223|No Intervention|No intervention|Treatment as usual
10027344|NCT01731236|Active Comparator|Carnitine (No antibiotics, No aspirin)|L-Carnitine 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
10027345|NCT01731236|Active Comparator|Choline (No Antibiotics, No aspirin)|Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
10027346|NCT01731236|Active Comparator|Antibiotics|"Antibiotics (Ciprofloxacin, Vancomycin, Metronidazole and Neomycin) Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)~Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)~Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)~Drug: Neomycin 1 gram, po, four times daily for 7 days (Other Names: Aminoglycoside)"
10027347|NCT01731236|Active Comparator|Choline and Aspirin|"Choline supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
10027348|NCT01731236|Active Comparator|Carnitine and Aspirin|"Carnitine supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Carnitine supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
10027349|NCT01731249|Placebo Comparator|Placebo|Placebo sublingual solution
10027350|NCT01731249|Experimental|Birch pollen allergen extract|Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years
10027351|NCT01731262||RA group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
9464335|NCT03684408|Other|RFID and Wire Localization|Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader.
9464336|NCT03684408|Experimental|RFID Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
9464337|NCT03684408|Active Comparator|Wire Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
9464338|NCT03684395||DOACs (Direct Oral Anticoagulants)|
9464339|NCT03684395||Standard of care|
10027352|NCT01731262||control group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
10027353|NCT01731275|Experimental|E6011|
10027354|NCT01731275|Placebo Comparator|E6011 Matching Placebo|
9464340|NCT03684382|Experimental|NeW-I group|Participants engage in a weekly structured writing task of 15-30 minutes which provides them an opportunity to reflect on the emotional, practical and financial demands of caregiving, and the means to cope with these challenges (week 1), explore avenues where they can seek information and resources for caregiving (week 2), explore the sources of support which they have within their network of family and friends (week 3) and examine how they (and their children) can rise above illness-related challenges and live their lives as fully as possible (week 4). After participants complete their weekly writing task, the written narrative will be reviewed and edited by the therapist within the next 3-4 days. The revised draft will be shared with the participant along with constructive feedback, empathic support and psychoeducation. In week 5, participants will receive a 'legacy' document and engage in a voice call with the therapist to receive psychosocial support and for closure of therapy.
9464341|NCT03684382|No Intervention|Control group|Participants engage in a weekly unstructured writing task of 15-30 minutes with a single open-ended question for each week which allows them to respond in any manner they find acceptable. Simple empathic weekly feedbacks are provided by the therapist to encourage continuous participation. In week 5, a consolidated document that includes all unedited journal writings together with a brief summary statement of appreciation by the therapist will be given to participants to indicate conclusion of participation.
9464342|NCT03684369|Experimental|Augmented TENS|Transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions.
9464343|NCT03684369|Sham Comparator|Sham|Transient (10 s) application of transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions .
9464344|NCT03684356|Experimental|experimental|immediate implant with socket shield technique
9464345|NCT03684356|Active Comparator|control|immediate implant placement with filling the buccal gap with xenograft
9464346|NCT03684330|Active Comparator|Vitamin D supplementation|
9464347|NCT03684330|Placebo Comparator|Vitamin D placebo|
9464348|NCT03684291||Group V|The patients in this group are ventilated using VCV (Volume Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute, I/E ratio: 1/2, PEEP not applied)
10027355|NCT01731288||vulvodynia|Women with vulvodynia
10027356|NCT01731288||control|Women without vulvar pain
10027357|NCT01731301|Experimental|Ribavirin, peginterferon, boceprevir|The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
9464349|NCT03684291||Group P|The patients in this group are ventilated using PCV-VG (Volume Guaranteed Pressure Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute (EtCO2 kept between 35-40 mmHg), Pressure limit: 30 cm H2O, I/E:1/2, PEEP not applied)
10027358|NCT01731327|Experimental|Experimental Treatment A|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
10027359|NCT01731327|Experimental|Experimental Treatment B|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
10027360|NCT01731340|Active Comparator|Supplemental Calcium|"750 mg Calcium Citrate per day~800 IU Vitamin D3 per day~Low Dietary Calcium (450 mg per day)"
10027361|NCT01731340|Active Comparator|Dietary Calcium|"400 IU Vitamin D3 per day~High Dietary Calcium (1200 mg per day)"
10027362|NCT01731340|No Intervention|Usual Diet|"400 IU Vitamin D3 per day~Unrestricted Dietary Calcium"
10027363|NCT01731353||Emerging fungal infections|Web-based registry of invasive infections by emerging fungi
10027364|NCT01731366|Placebo Comparator|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
9464350|NCT03684252|Other|Control|Treatment as usual
9464351|NCT03684252|Experimental|Intervention|CBT-based intervention
10027365|NCT01731366|Active Comparator|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
10027366|NCT01731379||Surgical resections|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy, patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
10027367|NCT01731392|Experimental|Milk with Bifidobacteria|duration of the treatment is 5 months
10027368|NCT01731392|Active Comparator|Milk with non replicating lactobacilli|duration of the treatment is 5 months
9464352|NCT03684239|Experimental|G-CBT group|G-CBT group has 40 patients, maybe will be divided them into 4 groups. Every group has 8-10 patients. Every group receive 10 times CBT group therapy and 1 times a week for 120 minutes each time.
10027369|NCT01731392|Placebo Comparator|Semi skimmed milk|duration of the treatment is 5 months
10027370|NCT01731405||Formats A,B,C; medicines Ritalin, Morphine Sulfate, Aranesp|All patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
9464353|NCT03684239|Active Comparator|Conventional treatment group|Conventional treatment group has 40 patients, received routine outpatient treatment. Once every two weeks for 45 minutes each time, including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
9464354|NCT03684200|Experimental|Copenhagen adductor exercise|20 players allocated to the Copenhagen adductor exercise group complete a progressive strengthening programme comprising of the Copenhagen adductor exercise over a period of 6 weeks. They will complete two exercise sessions a week consisting of one set of the Copenhagen adductor exercise. The exercise will be performed on each side. The training load will increase from 5 repetitions in week 1, to 15 repetitions in week 6. The exercise programme is performed at the end of the warm-up of a regular football training session.
10027371|NCT01731405||There is not another group|
9464355|NCT03684200|No Intervention|Control|19 players allocated to the control group will be asked not to perform the Copenhagen adductor exercise or any other specific strength training for the adductor muscles and to continue to play football as usual.
10027372|NCT01731418|Other|Treamtent-as-usual|Treatment-as-usual can be defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive psychotherapy.
10027373|NCT01731418|Experimental|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a standardized short-term approach based on the principles of cognitive behavioral exposure therapy and testimony therapy for the treatment of PTSD resulting from organized violence.
10027374|NCT01731431|Active Comparator|Insulin|standard protocol of insulin treatment for gestational diabetes
10027375|NCT01731431|Experimental|Glyburide|initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
10027376|NCT01731444|Experimental|Phenylephrine|20 ug/cc
10027377|NCT01731444|Active Comparator|Epinephrine|1:1000000
10027378|NCT01731457|Experimental|Etanercept|
10027379|NCT01731457|No Intervention|Control|
9464356|NCT03684187|Experimental|Stress in Control for Healthy Liver (SynC-HL) Intervention:|This mindfulness based intervention to target healthy liver focuses on teaching skills of mindfulness, yoga and self-control to improve lifestyle choices and decision making.
9464357|NCT03684161||Surgically closed VSDs|Patients born with a ventricular septal defect, which have been closed in early childhood.
9464358|NCT03684161||Small, persistent VSDs|Patients born with a small, hemodynamically insignificant ventricular septal defect.
10027380|NCT01731496|Experimental|Telephone reminder|Telephone message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
10027381|NCT01731496|Experimental|Text Message reminder|Text message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
9464359|NCT03684161||Healthy controls|Healthy control subjects.
9464360|NCT03684148|Experimental|Motor imagery practice|In addition to routine physical therapy patients that will be included in the motor imagery practice (MIp) group will receive an additional intervention based on motor imagery beginning immediately after the TKA procedure.
9464361|NCT03684148|No Intervention|Control group|Patients from the control group will underwent the same post-surgery rehabilitation program, but will not be engaged in MI practice.
9464362|NCT03684135|Experimental|Use of cosmetics during chemotherapy and thermal cure|Use of cosmetics during chemotherapy and post-treatment thermal cure
9464363|NCT03684122|Experimental|Injection of Umbilical cord derived MSCs|Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
9464364|NCT03684122|Experimental|Injection of MSCs differentiated into neural stem cells NSCs|Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
10027382|NCT01731496|No Intervention|Control: Telephone|
10027383|NCT01731496|No Intervention|Control: Text Message|
10027384|NCT01731509|Active Comparator|Standard FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 26 0/7 weeks and 28 6/7 weeks.
10027385|NCT01731509|Experimental|Early FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 22 0/7 weeks and 24 6/7 weeks.
10027386|NCT01731535||Prior bisphosphonate users|Patients with record of using bisphosphonate medication
10027387|NCT01731548|Experimental|study arm|"For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy（1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks）"
9464365|NCT03684096|Active Comparator|non-estrogenic pollen extract PCC-100|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
9464366|NCT03684096|Placebo Comparator|placebo|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
9464367|NCT03684083||Case|patients having received heterologous stem cell transplantation (HSCT)
9464368|NCT03684083||Control|patients without HSCT
9464369|NCT03684057|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
9464370|NCT03684057|Other|Wait list control|Individuals in the wait list group will complete the assessments without an intervention. (Note: participants will be transitioned to the Unwinding Anxiety program following the 2-month wait list control)
9464371|NCT03684031|Experimental|Cognitive Control Training|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
9464372|NCT03684031|Sham Comparator|Sham Cognitive Control Training Program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
9464373|NCT03684005|Other|Single-Arm Smartphone App Use|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
9464374|NCT03683979|Experimental|Interpretation bias modification program|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
9464375|NCT03683979|Sham Comparator|Control training program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
9464376|NCT03683953|Placebo Comparator|Placebo|0.9% sodium chloride intratracheal instillate on 14 days after birth
9464377|NCT03683953|Experimental|mesenchymal stem cells|mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg
10027388|NCT01731548|Active Comparator|control arm|"For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
9464379|NCT03683927|Experimental|Probiotics|Probiotics consist on Bacillus clausii in a plastic vial that will be administered to the infant 4 times a week
10027389|NCT01731561|Experimental|Rituximab infusion according biological parameters|Rituximab infusion based on ANCA and CD19 lymphocytes
10027390|NCT01731561|Active Comparator|Systematic rituximab infusion|Semestrial rituximab infusion until 18 months
10027391|NCT01731574|Active Comparator|Dapivirine Ring + Miconazole|Dapivirine Ring + miconazole
10027392|NCT01731574|Experimental|Dapivirine Ring|Dapivirine Ring
10027393|NCT01731587|Experimental|L-BLP25 plus Cyclophosphamide (CPA)|
10027394|NCT01731613|Active Comparator|Standard Fortification|receive human milk fortified with human milk fortifier(HMF) in the standard amount (4 packs /100 ml of HM) throughout the study
10027395|NCT01731613|Experimental|Adjustable fortification|encompasses increasing/decreasing the amount of human milk fortifier(HMF) and adding supplemental protein guided by periodic determinations of the protein concentration of human milk (PCHM), body weight, blood urea nitrogen(BUN)
10027396|NCT01731639|Experimental|MSOME|The samples will be evaluated under high magnification
10027397|NCT01731652|Experimental|TMX-101|TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
10027398|NCT01731665||The Songpa-Kangdong cohort of IBD|Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
10027399|NCT01731704|Active Comparator|Stereotactic Radiosurgery (SRS)|Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
10027400|NCT01731704|Active Comparator|Whole Brain Radiation Therapy (WBRT)|whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
10037549|NCT01826123|Active Comparator|POC testing (ROTEM and Multiplate)|"After being randomized to the group POC testing, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
9464380|NCT03683927|Placebo Comparator|Placebo group|Sterile water contained in a plastic vial will be administered to the infant 4 times a week
9464381|NCT03683914|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
9464382|NCT03683914|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
9464383|NCT03683888|Experimental|Healthsnap|50 patients will receive HealthSnap assessment in addition to their current treatment regardless of their participation into the study
9464384|NCT03683888|Active Comparator|Diet|50 patients will receive standard of care dietary counselling in addition to their current treatment regardless of their participation into the study
9464385|NCT03683862|Experimental|Thermoplastic Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
9464386|NCT03683862|Active Comparator|Hawley Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
10027401|NCT01731717|Experimental|Stepped care intervention (SCM)|"Patients within the stepped care intervention are screened by general physician using the PHQ-9 (inclusion criterion: >4 points) and diagnosed according to International Classification of Diseases (ICD-10) criteria. Patients receive differentially intensive treatment according to depression severity.~Patients with mild depression receive:~Step I: Active monitoring or Step II: II.a. Bibliotherapy or II.b. Online self-help (Deprexis®) or II+: Telephone-based psychotherapy~Patients with moderate depression receive:~Step III: III.a. Outpatient psychotherapy or III.b. Psychopharmacological treatment~Patients with severe depression receive:~Step IV: Combined psychotherapy and psychopharmacological treatment, optionally in inpatient setting."
9464387|NCT03683849|Experimental|Dancing group|Dance intervention group, inspired by the rhythm of Salsa. Training will be administered for an hour twice a week, for six months.
10027402|NCT01731717|Active Comparator|Control group: treatment as usual|Patients in the control group are screened by their general physician using the PHQ-D-9 depression scale. Patients included in the study then receive treatment as usual from general physician or other health service providers.
10027403|NCT01731743|Other|implantation of a trifocal IOL (AT LISA tri 839MP)|
10027404|NCT01731756|Experimental|Palmer arsenical keratosis (study)|Leaf extract of A. indica plus salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
10027405|NCT01731756|Placebo Comparator|Palmer arsenical keratosis (control)|Salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
10027406|NCT01731769|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
10027407|NCT01731769|Experimental|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
10027408|NCT01731782|Active Comparator|bupivacaine|bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
10027409|NCT01731782|Placebo Comparator|normal saline|Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
10027410|NCT01731795|No Intervention|No dexamethasone|Patients will be treated with conventional treatment
10027411|NCT01731795|Active Comparator|Dexamethasone|Conventional treatment plus dexamethasone
10027412|NCT01731808|No Intervention|Standard care|All participants received three specially-developed brochures with information regarding the diabetic foot condition. The brochures contained explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home. The participants who were randomized in the control group received standard care. Standard care consisted of either physician-prescribed inpatient or outpatient wound care.
10027413|NCT01731808|Experimental|Nursing counseling|
10027414|NCT01731821|Experimental|Nonstented stump-closed anastomosis|Nonstented stump-closed anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
10027415|NCT01731821|Active Comparator|Duct-to-mucosa anastomosis|Duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy.
10027416|NCT01731834|Active Comparator|Aspiration of secretion|10 children are evaluated at rest, during and after aspiration technique secretion
10027417|NCT01731834|Experimental|Vibrocompression|10 children will be assessed at rest, during and after the maneuver vibrocompression
10027418|NCT01731847|Experimental|The combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
10027419|NCT01731860|Experimental|Patients receiving PET/CT|Patients already scheduled for a clinically necessary PET/CT scan.
10027420|NCT01731899||agomelatine|patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
10027421|NCT01731925|Experimental|Sunitinib|Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
10027422|NCT01731925|Placebo Comparator|Placebo|Placebo (for sunitinib). Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
10027423|NCT01731964|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD
10027424|NCT01731977|Experimental|Strengths-based family psychoeducation|Family psychoeducation in addition to treatment as usual
10027425|NCT01731977|No Intervention|Waiting list|Treatment as usual
10037550|NCT01826136|Experimental|Acapella|use of the Acapella device postoperatively
10037551|NCT01826136|No Intervention|Control|
10027426|NCT01732003|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
10027427|NCT01732003|Placebo Comparator|Placebo Pill|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
10027428|NCT01732016|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric (sea-level atmospheric pressure) hypoxia (low oxygen) by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (around 4500 m).
9464388|NCT03683849|Active Comparator|Strength training group|Strength training group. Training will be administered for an hour twice a week, for six months.
10027429|NCT01732029|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric hypoxia by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (about 4500 m).
10027430|NCT01732055|Active Comparator|Partner-Assisted Interpersonal Psychotherapy|Partner-Assisted Interpersonal Psychotherapy is an 8-week series of psychotherapy sessions attended by the patient and her identified partner.
10027431|NCT01732055|Other|Treatment as Usual|Treatment prescribed for subjects by the UNC Perinatal Psychiatry clinic physicians according to the clinic algorithm.
9464389|NCT03683849|No Intervention|Control|Control group
9464390|NCT03683836||Study Group|
9464391|NCT03683810|Experimental|Lactoferrin|Participants will receive 4gr lactoferrin per day for a duration of 3 months + standard treatment for anemia
9464392|NCT03683810|Active Comparator|Standard treatment|Participants will receive only the standard treatment for anemia
9464393|NCT03683797|Experimental|Post-discharge call|Patients in this arm will receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
9464394|NCT03683797|No Intervention|No post-discharge call|Patients in this arm will not receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
9464395|NCT03683784||Males|Male diabetics or male subjects proved to be diabetics
9464396|NCT03683784||Female|Female diabetics or male subjects proved to be diabetics
9479886|NCT03538990|Experimental|DASH Eating Pattern|The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. During the intervention phase of the study, all participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.
10027432|NCT01732068|Experimental|Corifollitropin alfa+hMG|
10027433|NCT01732081||Patients with chronic hepatitis B virus infection|Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France
9479887|NCT03538977|Active Comparator|Conventional physiotherapy (GP)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
9479888|NCT03538977|Experimental|GP + hydrotherapy (GH)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
10027434|NCT01732094|Experimental|Corifollitropin Alfa + hMG|
10027435|NCT01732120|Experimental|Off-clamp partial nephrectomy|Partial nephrectomy will be performed without clamping of the renal blood vessels.
10027436|NCT01732120|No Intervention|Traditional partial nephrectomy|Partial nephrectomy will be performed with clamping of the renal blood vessels.
10027437|NCT01732133|Experimental|Measurement of arterial pressure|
10027438|NCT01732146|Active Comparator|Erythropoietin beta|1000 to 1500 U/kg/dose X 3 every 24 hours
10027439|NCT01732146|Placebo Comparator|Placebo|0.2 ml saline solution X 3 given every 24 hours
10027440|NCT01732159|Experimental|Administration of the checklist|Patients will be contacted by phone for administration of the checklist
10027441|NCT01732159|No Intervention|No contact by phone|Patients who will not be contacted by phone
10027442|NCT01732172|Experimental|Patient Group|Patient with urethritis
10027443|NCT01732172|Other|Control group|Subjects with no urethritis and no history urogenital infection
10027444|NCT01732185|Other|Patient|congenital cystic adenomatoid malformations
9479889|NCT03538964|Active Comparator|Toric intraocular lens (IOL)|toric intraocular lens for low astigmatism correction
9479890|NCT03538964|Sham Comparator|Non toric intraocular lens (IOL)|non toric intraocular lens
9464397|NCT03683745||Maryland|Maryland is a county in southeast Liberia. Survey clusters based on catchment populations served by community health volunteers (CHVs) around 24 district health facilities (primary sampling unit). Clusters will constitute ~600 people (~100 households) with population-weighted cluster selection applied. In total, 80 clusters will be required. CHVs would conduct house-to-house visits to develop a full census and listing of all possible cases using broad case definitions. Full details of all potential cases will then be passed to an expert verification team based at the closest health facility. Suspected cases will arrive at the health facility over a 10-day verification period to receive a diagnosis using clinical examination and/or laboratory confirmation.
9464398|NCT03683732||Frenchteenagers|
9464399|NCT03683706|Active Comparator|Intervention|Participants in this arm will receive 12 sessions of LTP in My Own Way Plus interventions.
9464400|NCT03683706|No Intervention|Treatment as Usual|Participants in this arm will be getting their usual treatment
9464401|NCT03683693|No Intervention|Standard of Care group|Historical Group = Standard of Care group. Decision for stopping antibiotics taken by ICU physician: assessment on the basis of the clinical picture and traditional inflammatory biomarkers such as crp and leucocytosis
9464402|NCT03683693|Experimental|Procalcitonin group|ICU physician gets on regular base PCT value, what can be used as additive tool in the decision-making for stopping antibiotics.
10027445|NCT01732198|Experimental|NU300 and Prevnar 13|NU300 at a single dose of 0.5 mL IM
10027446|NCT01732198|Active Comparator|ActHIB and Prevnar 13|ActHIB at a dose of 0.5 ml IM
9464403|NCT03683667|Placebo Comparator|Placebo & Control|Placebo / Nutrition education
9464404|NCT03683667|Experimental|Placebo & Protein Supplement|Placebo / Protein-rich blended food / Nutrition education
9464405|NCT03683667|Placebo Comparator|Placebo & Isocaloric Supplement|Placebo / Isocaloric blended food / Nutrition education
9464406|NCT03683667|Experimental|Placebo & Egg|Placebo / Egg / Nutrition education
9464407|NCT03683667|Experimental|Azithromycin & Control|Azithromycin / Nutrition education
9464408|NCT03683667|Experimental|Azithromycin & Protein Supplement|Azithromycin / Protein-rich blended food / Nutrition education
9464409|NCT03683667|Experimental|Azithromycin & Isocaloric Supplement|Azithromycin Isocaloric blended food Nutrition education
9464410|NCT03683667|Experimental|Azithromycin and Egg|Azithromycin Egg Nutrition education
9464411|NCT03683641|Active Comparator|Shock Wave group|Applying shock wave to patient's Achilles tendon insertion
9464412|NCT03683641|Sham Comparator|Sham Control group|Applying sham shock wave to patient's Achilles tendon insertion
9464413|NCT03683615|Other|patients with traumatic recent orbital blow out fractures|
9464414|NCT03683602|Experimental|PNF group|PNF techniques, patterns, re-education of postural control, once a day 10 days,
9464415|NCT03683602|Active Comparator|Manual therapy group|traction, joints mobilization, pos-isometric relaxation, once a day 10 days
9464416|NCT03683589||Study group|"Participants will receive deuterated water for 10 days before undergoing bariatric surgery.~Liver biopsy collected, lipids extracted and DNL measured via GC/MS."
10027447|NCT01732224|Experimental|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
10027448|NCT01732224|Active Comparator|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
10027449|NCT01732237|Experimental|JNJ-42396302|Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
10027450|NCT01732237|Experimental|JNJ-42692507|Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
10027451|NCT01732237|Experimental|JNJ-53773187|Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
10027452|NCT01732250|Experimental|Colistin and Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
10027453|NCT01732250|Active Comparator|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
10027454|NCT01732276|Experimental|gefitinib|gefitinib tablet 250mg/day by mouth until disease progression
10027455|NCT01732289|Experimental|A|
10027456|NCT01732302|Experimental|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
10027457|NCT01732302|No Intervention|Delayed educational intervention|Primary health care centers in the delayed intervention group will receive the same intervention as described above with 9 months delay.
10027458|NCT01732315|Experimental|Vaccination Email Reminder|This group of parents in the study will receive email notifications about due/overdue vaccines for their adolescents. Vaccination records will be reviewed to identify adolescent patients in both practices who are newly eligible for a vaccine and/or overdue for a vaccine at the start of every other month. Email notifications will then be sent to the parents of these children.
9464417|NCT03683563|Active Comparator|4% citrate|dialysis catheter locked with 4% sodium citrate
9464418|NCT03683563|Experimental|30% citrate|dialysis catheter locked with 30% sodium citrate
9464419|NCT03683550|Experimental|SPEC/CT|SLNE with preoperative hybrid SPECT/CT
9464420|NCT03683550|Active Comparator|Standard|Standard SLNE (with planar preoperative lymphoscintigraphy)
9464421|NCT03683537||Delayed Neurocognitive decline|Patients in whom there is Delayed Neurocognitive Recovery (DNR) after surgery, based on neuropsychological tests or clinically. DNR is defined as follow: 1)decrease of scores of neuropsychological test scores for more than 1 standard deviation (SD) of these tests; 2)clinically - inability of patient to perform test after surgery because of neurocognitive impairment.
9479891|NCT03538951|Experimental|Cohort 1|10% VDA-1102
9464422|NCT03683537||Normal postop neurocognitive function|Patients in whom there is no clinical signs of DNR, defined as in previous group.
9464423|NCT03683498|Experimental|Regulatory T-cell enriched infusion|"Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:~Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg"
9464424|NCT03683485|Experimental|long duration EPBD group|Balloon dilation was performed using wire-guided hydrostatic balloon catheters. An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy. Stones were removed by standard techniques, including balloon or basket catheters.
9464425|NCT03683485|Active Comparator|endoscopic sphincterotomy (EST) group|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage.
9464426|NCT03683472|No Intervention|Treatment as usual (TAU)|Individuals will receive treatment as usual
9464427|NCT03683472|Active Comparator|TAU and Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals unlearn/extinguish worry at a core mechanistic level."
9464428|NCT03683459|Experimental|interventional arm|Participants will be treated with FemFlow Drug-Eluting Peripheral Balloon Catheter.
10027459|NCT01732315|No Intervention|Usual Care|This group of parents in the study will not receive email notifications about due/overdue vaccines for their adolescents.
10027460|NCT01732328|Placebo Comparator|placebo|Inactive pill (microcrystalline cellulose and corn starch) taken daily
10027461|NCT01732328|Active Comparator|Calcium plus vitamin D|600mg of calcium and 200 international units (IU) vitamin D taken daily
10027462|NCT01732341|Experimental|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
10027463|NCT01732341|Active Comparator|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
10027464|NCT01732367|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
10027465|NCT01732367|Experimental|Tenofovir|Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy
10027466|NCT01732380|Active Comparator|Radiotherapy|Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
10027467|NCT01732380|Experimental|Raltitrexed/Oxaliplatin Plus Radiotherapy|Raltitrexed 2.5mg/㎡ d1,Oxaliplatin 100mg/㎡ d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
10027468|NCT01732393|Active Comparator|oral quercetin capsules|Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
10027469|NCT01732393|Placebo Comparator|oral placebo capsules|Patients in the placebo group received two placebo capsules containing lactose .
10027470|NCT01732497|Experimental|Single Group miraDry Treatment|This is a single group study where each enrolled subject will receive active miraDry treatment in each axilla.
10027471|NCT01732523||No treatment|No intervention
10027472|NCT01732562|No Intervention|Control|Patient receives the standard of care.
10027473|NCT01732562|Experimental|Patient e-Learning educational tool|Patient receives the standard of care and access to patient e-Learning educational tool.
10027474|NCT01732575|Experimental|Enrichment|Enrichment with meaning-generating activities
10027475|NCT01732575|No Intervention|Rehabilitation as usual|The ongoing, normal day center program.
10027476|NCT01732601|Experimental|Intensive Outpatient CBT|Intensive CBT for both parents and adolescents as well as family sessions to increase communication.
10027477|NCT01732601|Active Comparator|Standard Care|Standard Treatment in the Community
10027478|NCT01732614|Experimental|Topcon Endpoint Management Laser|
10027479|NCT01732653|Experimental|TT+VR|The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
10027480|NCT01732653|Active Comparator|TT alone|The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
10027481|NCT01732666|Placebo Comparator|group L|receives 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
10027482|NCT01732666|Placebo Comparator|group H|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
10027483|NCT01732666|Experimental|group N|20mg of nefopam mixed in 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
10027484|NCT01732679||stroke patients|specialized rehabilitation in a multidisciplinary team, Sunnaas International Network
10027485|NCT01732705|Experimental|HIT (trained leg) DM|High intensity interval training for one leg (trained leg) (randomized) in patient with type 2 diabetes
10027486|NCT01732705|No Intervention|Control leg, DM|Control leg (untrained leg)in patient with type 2 diabetes
10027487|NCT01732705|Experimental|HIT (trained leg), Control subject|High intensity interval training for one leg (trained leg) (randomized) in control subject
10027488|NCT01732705|No Intervention|Control leg, Control subject|Control leg (untrained leg)in control subject
10027489|NCT01732731|Experimental|treadmill training|children will receive home-based treadmill training with supervision from a physical therapist
10027490|NCT01732731|No Intervention|no treadmill training|children will not receive treadmill training
10037552|NCT01826149|Experimental|Propofol 1.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.
10027491|NCT01732744|Placebo Comparator|Physiological solution|"1)Negative Control: physiological solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
10027492|NCT01732744|Active Comparator|Sodium hypochlorite|"2)active Comparator 1: Sodium hypochlorite, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
10027493|NCT01732744|Active Comparator|Peroxide alkaline|"2)Active Comparator 2: Alkaline peroxide (Polident), for 5 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
9464429|NCT03683446||Laparoscopic Rectal Surgery|A minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon. For abdominal entry, at the beginning of the procedure, the abdomen is inflated with carbon dioxide gas to provide a working and viewing space for the surgeon. For both, the laparoscope transmits images from the abdominal cavity or anus to high-resolution video monitors to allow the surgeon detailed images of the abdomen on the monitor.
9464430|NCT03683446||Open Rectal Surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
9464431|NCT03683433|Experimental|Treatment (azacitidine, enasidenib mesylate)|Patients receive azacitidine SC or IV over 30 minutes on days 1-7 and enasidenib mesylate PO QD beginning on day 1. Cycles repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
9464432|NCT03683420|Experimental|Group I (music)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. The study consists of a presurvey, active listening period, and a post-survey.
9464433|NCT03683420|No Intervention|Group II (control)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. Participants and caregivers in the control condition complete a presurvey and post survey but do not listen to music during infusion session .
9464434|NCT03683407||Chemotherapy Group|All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy.
9464435|NCT03683381|Experimental|intervention|Patients in the intervention group will receive a 6-week app-based intervention to treat insomnia
9464436|NCT03683381|Experimental|patient education|Participants in the patient education group will receive weekly information on insomnia symptoms
9464437|NCT03683368|Experimental|Soft cannula first|Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.
9464438|NCT03683368|Experimental|Steel cannula first|Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.
9464439|NCT03683342|Active Comparator|Ankle Block|Ankle block will be performed under ultrasound guidance.
10027494|NCT01732744|Experimental|Castor bean solution|"3)Experimental: castor bean solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
10027495|NCT01732848||Subjects treated with BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered
10027496|NCT01732848||Subjects treated with Placebo matching BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered
10027497|NCT01732861|Experimental|CC-292 + Lenalidomide|
10027498|NCT01732887|Other|Immediate cognitive fitness training|"After the initial baseline evaluation, the immediate treatment group participants will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants in this group will switch to a 20 week no intervention period where they receive only standard of care treatment."
10027499|NCT01732887|Other|Delayed cognitive fitness training|"After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks (no intervention period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment."
10027500|NCT01732900|Active Comparator|Morphology|Embryos selected for transfer will be based on morphology alone.
10027501|NCT01732900|Experimental|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
10027502|NCT01732939||AT|Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
10027503|NCT01732939||AT-NP|docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles
10027504|NCT01732952||regions,hospitals,age, gender, risk levels, comorbidity,|
10027505|NCT01732965|Placebo Comparator|NB-UVB phototherapy|NB-UVB alone
10027506|NCT01732965|Experimental|phototherapy and photochemotherapy|NB-UVB and PUVA
10036785|NCT01818973|Experimental|Single Arm|"Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).~Followed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.~6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.~3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
9464440|NCT03683342|Active Comparator|Popliteal sciatic nerve block (PSNB)|PSNB will be performed under ultrasound guidance, along with a saphenous nerve block at the ankle
10036786|NCT01818986|Experimental|arm one|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR)
9464441|NCT03683329|Experimental|Antibiotic de-escalation|"According to the results of the antibiogram of the suspected causative bacteria, the ''pivotal'' antibiotic (antipseudomonal betalactam) used for empirical treatment is switched to an antibiotic with a spectrum as narrow as possible according to the targeted pathogens,~Stop the companion antibiotic (aminoglycoside, fluoroquinolone, macrolide) between day 2 and day 3 of antibiotic treatment as much as possible,~Stop the empirical antibiotic directed against methicillin-resistant staphylococcus aureus (MRSA) or an enterococcus in the absence of these bacteria in the culture."
9464442|NCT03683329|Active Comparator|Standard treatment without de-escalation|"The companion antibiotic is stopped between day 3 and day 5 of antibiotic treatment as much as possible and according to the local prescription,~Empirical antibiotics directed against MRSA or enterococcus were used according to local prescription and/or international guidelines,~The pivotal antibiotic of the empirical treatment is continued for the entire duration of the treatment, independently of microbiological results. For prolonged treatment, the physician has the choice of de-escalating after 8-15 days of treatment."
9464443|NCT03683316||all infants|"There will be one arm for this study. All infants will receive a similar intervention during their routine kangaroo mother care (KMC). KMC is a national and international standard of care. This is an observational study of how infants breath while participating in KMC compared to how they breath while in a crib or incubator. Work of breathing will be measured at baseline and then during KMC. Mothers will participate in KMC regardless of participation in the study. Work of breathing will be measured by using Respiratory Inductance Plethysmography (RIP). This scientifically measures work of breathing (specifically phase angles) by placing soft bands around the abdomen and chest. The actual intervention is a standard of care and something that the mother infant dyad will do regardless of the study. Each mother / infants pair is expected to be actively enrolled for approximately 2 hours."
9464444|NCT03683303|Experimental|mobile applications (APP)|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
9464445|NCT03683303|Active Comparator|oral education|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
9464446|NCT03683277|Experimental|Ixazomib/Pomalidomide/Dexamethasone|"Single arm treatment organized in 2 separate phases~Induction phase : association of Ixazomib, Pomalidomide & Dexamethasone (IPD) 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Maintenance phase : association of Ixazomib and Pomalidomide (IP) 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
9479892|NCT03538951|Experimental|Cohort 2|20% VDA-1102
9479893|NCT03538925|Experimental|Treatment Group|AAC Generative Language Intervention
9479894|NCT03538925|Active Comparator|Business as Usual|Standard of Care / Business as Usual
10036787|NCT01818999|Experimental|arm one|IXABEPILONE and STEREOTACTIC BODY RADIATION THERAPY (SBRT)
10036788|NCT01819012|Experimental|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
10036789|NCT01819012|Experimental|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
10036790|NCT01819012|Experimental|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
10036791|NCT01819025|Experimental|4 face-to-face and smartphone-app|Four face-to-face therapy sessions and smartphone app as a complement and support to the four sessions.
10036792|NCT01819025|Active Comparator|TAU|10 sessions of face-to-face therapy, full behavioral activation
10036793|NCT01819038|Experimental|High NGAL and early RRT|NGAL level > 400 ng/ml and start continuous renal replacement therapy early
10036794|NCT01819038|Experimental|High NGAL and late RRT|NGAL > 400 ng/ml and start continuous renal replacement therapy late
10036795|NCT01819038|Active Comparator|Low NGAL|NGAL < 400 ng/ml and starting continuous renal replacement therapy follow with absolute indication
10036796|NCT01819051|Experimental|Plasma|Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
10036797|NCT01819064||Children less than 5Kg.|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 5Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
10027507|NCT01732978|Other|Babies|Any child born in the University Hospital of Saint Etienne (inborn) whatever its term birth, hospitalized in a neonatal unit at the time of registration (after 37 weeks of gestation for preterm infants) or maternity
10027508|NCT01732991|Experimental|prostatic photo-vaporization|prostatic photo-vaporization (PVP) surgery with laser Greenlight
10027509|NCT01733004|Experimental|Arm A|MM-141 monotherapy
10027510|NCT01733004|Experimental|Arm B|MM-141 and Everolimus
10027511|NCT01733004|Experimental|Arm C|MM-141 and Abraxane and Gemcitabine
10027512|NCT01733017|Experimental|sodium reduction, omega-3, lycopene|combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
10027513|NCT01733017|Placebo Comparator|Control|Limited nutritional counseling, juice without lycopene, rice oil capsules
10027514|NCT01733030||250 mg Seromycin|Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
10027515|NCT01733030||500 mg Seromycin|Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
10027516|NCT01733030||Placebo|Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
10027517|NCT01733043|Experimental|Dexmedetomidine infusion|Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes
10027518|NCT01733043|Placebo Comparator|Placebo|Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate
9464447|NCT03683264|Other|Vacuum delivery|Deliveries completed using vacuum instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The vacuum was a metal vacuum (Bird's cup 50 mm, 80 kPa) was used to perform fetal extraction. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in vacuum delivery following Valme's University Hospital clinical practice guideline for instrumental deliveries.
9464448|NCT03683264|Other|Forceps delivery|Deliveries completed using forceps instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The forceps used for the instrumentation was the forceps of Kielland. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in VD following Valme's University Hospital clinical practice guideline for instrumental deliveries.
9464449|NCT03683225|Experimental|CTC-413|Pramipexole with/with out aprepitant orally once daily
9464450|NCT03683212|Experimental|Intervention period : early and comprehensive care bundle|
9464451|NCT03683212|No Intervention|acute heart failure standard therapy|
9464452|NCT03683199|Experimental|Cleft lip nasal deformity|"•Anthropometric evaluation of the nose (will be measured pre and post-operative) This represents the objective evaluation. It will be done by measuring the angles and ratios of the nose and its relation to the face. Common parameters will be measured from the photos (frontal, oblique, lateral and basal views) for all the patients to compare the pre-operative measures with the post-operative ones.~MSCT flesh mode will be used to measure nose related angels and ratios. It also gives idea about nasal skeleton pre-operative for proper design of the operative strategy, and it will be done post-operative for assessment and comparizon."
9464453|NCT03683160|Experimental|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
9464454|NCT03683147|Experimental|Control (online sessions, content manual, CD after 6 weeks)|Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
9464455|NCT03683147|Experimental|Intervention (online sessions, content manual, relaxation CD)|Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation CD.
9464456|NCT03683134|Experimental|Mediterranean diet group|Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
9464457|NCT03683134|Active Comparator|American Heart Association group|Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
9464458|NCT03683121||the traditional follow-up group|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding
9464459|NCT03683121||Non-traditional follow-up|The dose and notes for the use of the Non-selective beta blockers were informed during telephone or WeChat follow-ups for the patients with a history of esophageal variceal bleeding
9464460|NCT03683121||Combine of Group1 and Group2|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding,and the patients were followed up by telephone or WeChat again on the same day.
9464461|NCT03683108|Experimental|Resveratrol and Carbossimetyl Beta Glucan|
10027519|NCT01733082||Cohort|
10027520|NCT01733095|Experimental|ambrisentan|In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months.
10027521|NCT01733108|Experimental|Canagliflozin (JNJ-28431754) + glyburide|Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.
10027522|NCT01733134|Experimental|Standard therapy plus Tolvaptan|Patient in the interventional group will receive tolvaptan in addition to standard therapy
10027523|NCT01733134|Placebo Comparator|Standard therapy plus placebo|
10027524|NCT01733173||mass in posterior fossa, either benign or malignant|A pilot study will be performed. We will perform fMRI and DTI in children before and after surgery for posterior fossa brain tumors. Each subject will receive the standard of care for their brain tumors in terms of surgical resection, radiation therapy and/or chemotherapy.
10027525|NCT01733199|Experimental|BA-|Patient with no secondary behavioural addiction
10027526|NCT01733199|Experimental|BA+/DDS-|Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
10027527|NCT01733199|Experimental|BA+/DDS+|Patients with secondary behavioural addiction and dopamine dysregulation syndrome
10027528|NCT01733290|Experimental|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
10027529|NCT01733290|Placebo Comparator|Control arm-Normal saline instillation|Normal saline instillation
10027530|NCT01733303|Experimental|Exercise|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality.
10027531|NCT01733342|Active Comparator|Celsite|patients received celsite chemoport implantation under local anesthesia
10027532|NCT01733342|Experimental|Humanport|patients received Humanport chemoport implantation under local anesthesia
10027533|NCT01733355|Experimental|Tau diagnostic|[F18] T807
9464462|NCT03683108|Placebo Comparator|Saline solution|
9464463|NCT03683095||Lymphovenous bypass|Patients with extremity lymphedema treated with lymphovenous bypass.
9464464|NCT03683082|Active Comparator|PAH patients|Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask
9464465|NCT03683082|Sham Comparator|PAH patients (crossover)|Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask
9464466|NCT03683056|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
9464467|NCT03683056|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
9464468|NCT03683043|Active Comparator|Transabdominal guided transfer|In the trans-abdominal guided embryo transfer group, the patients' bladder were filled by 500-700 ml saline; in order to enhance the visualization. The trans-abdominal probe is applied on pelvis by an assistant nurse or the attending gynecologist intern
9464469|NCT03683043|Active Comparator|Transvaginal guided transfer|the trans-vaginal guided embryo transfer group had their bladder emptied by the gynecologist via catheter prior to transfer or else the patient was asked to void. The speculum is applied followed by insertion of the outer sheath of the transfer catheter. The speculum is removed with caution; to maintain the outer sheath in place. The TVUS probe is applied vaginally and endometrium is visualized before transfer. The transfer is done through an inner catheter applied to the already inserted outer sheath
9464470|NCT03683017|Experimental|I-OP2.0|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
9479895|NCT03538912|Other|Biomarker group|patient follow the Biomarker strategy
9479896|NCT03538912|Other|Routine group|patient follow the routine strategy
10027534|NCT01733381||Barefoot runners|This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
10027535|NCT01733381||Shoed runners|This group of individuals will run in normal running shoes. Participants will be runners who consistently run in regular running shoes (that are not considered by industry standards to be minimal shoes) at least 20 miles per week.
10027536|NCT01733394|Experimental|Generic A - Generic B - Brand - Generic A - Brand - Generic B|Sequence 1
10027537|NCT01733394|Experimental|Generic B - Brand - Generic A - Generic B - Generic A - Brand|Sequence 2
10027538|NCT01733394|Experimental|Brand - Generic A - Generic B - Brand - Generic B- Generic A|Sequence 3
10027539|NCT01733446|No Intervention|Standard anesthesia regimen|Positive pressure ventilation will be stopped at the same time infusions of anesthetic agents and spontaneous ventilation employed until emergence from anesthesia is observed. (This is standard protocol for everyday anesthesia management of this population.)
10027540|NCT01733446|Experimental|Continuation of High Frequency Jet Ventilation ( HFJV)|In Group B after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
10027541|NCT01733459|Experimental|Treatment I|1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
10027542|NCT01733459|Active Comparator|Treatment II|1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
10027543|NCT01733485|Active Comparator|Aspirin|
10027544|NCT01733485|Active Comparator|Indomethacin|
10027545|NCT01733485|No Intervention|Control|
10027546|NCT01733511||admitted to emergency department|
10027547|NCT01733511||patients admitted to surgical ward|
10027548|NCT01733524|Sham Comparator|Picture of a fish|Participants will receive a picture of a betta fish.
10027549|NCT01733524|Active Comparator|Pet fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
10027550|NCT01733537|Experimental|Vest and Education|Motorcycle Taxi Drivers provided with a reflective, fluorescent vest and basic education about recommended measures to increase their visibility
9464471|NCT03683017|Experimental|I-OP2.1|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.
9464472|NCT03683017|Experimental|F-OP2.0|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
9464473|NCT03683004||CRC patients (Ctx+ group)|Postoperative CRC patients scheduled to begin CTX
10027551|NCT01733537|Other|Education Alone|Motorcycle Taxi Drivers provided with basic education about recommended measures to increase their visibility
10027552|NCT01733550||Glaucoma patients|Intraocular pressure is measured by Home iCare performed by the study nurse, by the patient it self and by Goldmann applanation tonometry.
10027553|NCT01733563|Experimental|fructose sweetened beverage|"Soft drink consumption:~Subjects have to drink a fructose sweetened beverage (3x 200ml per day, 13.3g fructose/100ml) during 7 weeks"
9464474|NCT03683004||CRC patients (CT- group)|Postoperative CRC patients who do not receive CTX
9464475|NCT03683004||Healthy control group|Study participants that are demographically matched to CRC study patients and meet all inclusion criteria
9464476|NCT03682991|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
9464477|NCT03682991|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
9464478|NCT03682978|Experimental|Arbaclofen|"Arbaclofen is provided as orally disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg.~A flexible dose titration schedule will be utilized during the first 5 weeks of the Treatment Period. Dosing regimens will be stratified by age. The total up-titration to 15 mg TID or 20 mg TID, and dose adjustment period to the optimal dose will be 35 days. If a participant does not tolerate a dose increase, he or she should return to the previous dose level and must remain at the dose level for the remainder of the Treatment Period. No changes should be made to dosing after 5 weeks, unless for safety.~5-11 years: Week 0 (BID) 5mg; Week 1 (BID) 5mg; Week 2 (TID) 10mg; Week 3 (TID) 10mg; Week 4-16 (TID) 15mg.~12-17 years: Week 0 (QD) 5mg; Week 1 (BID) 10mg; Week 2 (BID) 10mg; Week 3 (TID) 15mg; Week 4-16 (TID) 20mg."
9464479|NCT03682978|Placebo Comparator|Placebo|"Placebo tablets will have similar form, colour, smell and taste compared to the Arbaclofen tablets, and will be provided in non-distinguishable packaging.~Dosage level is n/a."
9464480|NCT03682952|Experimental|Experimental group|Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.
9464481|NCT03682952|No Intervention|Anemia control group|Anemia patients
9464482|NCT03682952|No Intervention|Control group|Healthy person
9464483|NCT03682939|Experimental|Single arm|Single arm, open-label, all participants will receive both Bexsero® (meningitis B vaccine) and Menveo® (meningitis ACWY vaccine) vaccines.
9464484|NCT03682926|Experimental|electrostimulation individualized|Selective electrostimulation for tonic fiber, phasic fiber FIa and FIIb and different stimulus times. Muscle fibers (Tonic) with a frequency of 20Hz, pulse width (t) of 700μs to 1ms, time of rise and fall of the wave of 1.0 seconds, duration of contraction and repetition was based on the perineal evaluation But the resting time was twice as long as sustained. For the IIa (phasic) fibers the frequency was 50 Hz with a pulse width of 400μs to 500μs, for 3 seconds of sustentation and 6 seconds of relaxation, time of rise of 0,5 seconds and 0,5 seconds of descent. E for type IIb (phasic) fibers, 80 Hz frequency, pulse width 250μs to 400μs, 1 second contraction for 3 seconds rest and 0.2 seconds rise and fall time.
10027554|NCT01733563|Experimental|glucose sweetened beverage|"Soft drink consumption:~Subjects have to drink a glucose sweetened beverage (3x 200ml per day, 13.3g glucose/100ml) during 7 weeks"
10027555|NCT01733563|Experimental|sucrose sweetened beverage|"Soft drink consumption:~Subjects have to drink a sucrose sweetened beverage (3x 200ml per day, 13.3g sucrose/100ml) during 7 weeks"
10027556|NCT01733563|Experimental|No change of eating habits|"No Soft drink consumption (no soft drink diet):~Subjects do not change their eating habits during 7 weeks"
10027557|NCT01733576|Sham Comparator|Sham HD-tDCS|
10027558|NCT01733576|Active Comparator|Active HD-tDCS 1|
10027559|NCT01733576|Active Comparator|Active HD-tDCS 2|
10027560|NCT01733576|Active Comparator|Active HD-tDCS 3|
10027561|NCT01733589|Experimental|Recombinant Human Endostatin|All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.
10027562|NCT01733602|Experimental|active tDCS and cognitive training|Transcranial direct current stimulation combined with cognitive training
10027563|NCT01733602|Active Comparator|sham tDCD and cognitive training|Sham transcranial direct current stimulation combined with cognitive training
10027564|NCT01733615||Mucopolysaccharidosis IVA|Patients with the condition.
10027565|NCT01733654|Active Comparator|RO4995819 5mg|RO4995819 5mgX6wks
10027566|NCT01733654|Active Comparator|RO4995819 15mg|RO4995819 15mg X 6 weeks
10027567|NCT01733654|Active Comparator|RO4995819 30mg|RO4995819 30mg X 6 weeks
10027568|NCT01733654|Placebo Comparator|Placebo|Placebo X 6 weeks
10027569|NCT01733667|Experimental|MediENT|Right or left sinus cavity where MediENT will be place after randomization.
10027570|NCT01733667|Active Comparator|MeroPack|Right or left sinus cavity where MeroPack will be placed after randomization of MediENT is assigned.
9464485|NCT03682926|Active Comparator|electrostimulation with fixed protocol|Intervention -Electro-stimulate all fibers with a single electrical parameter. Pulse width 700μs, rise and fall time of 2 seconds each, sustain time of 4 seconds and rest 8 seconds for 20 minutes, the intensity will be modulated, as in the previous group by patient tolerance in milliamperes.
9464486|NCT03682913|Experimental|P-CIT protocol|OCD patients who receive the P-CIT intervention.
9464487|NCT03682913|Placebo Comparator|Placebo|OCD patients who don't receive the P-CIT intervention.
9464488|NCT03682900|Experimental|Click City Tobacco Prevention Program|Click City program used as part of school curriculum
9464489|NCT03682900|No Intervention|Usual Tobacco Prevention Curriculum|Will vary by school district.
9464490|NCT03682887|Active Comparator|Cryoballoon PV isolation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm cryoballoon catheter will be used.~Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and ablation times will be evaluated.~The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
9464491|NCT03682887|Experimental|Cryoballoon PV isolation w/ RA linear ablation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter as the same as cryoballoon PV isolation group.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional SVC-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local RF ablation will be followed.~The procedure and ablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
9464492|NCT03682861|Placebo Comparator|Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
9464493|NCT03682861|Experimental|Carbohydrate drinks|Sweet corn derived starch mixed in water at three different concentrations (6%, 12% and 18%) will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
9464494|NCT03682835|Placebo Comparator|Placebo treatment arm|Placebo: 2 capsules per dose, 2 doses per study day.
9464495|NCT03682835|Experimental|POCO treatment arm|FDGard Capsule containing a combination of peppermint oil (41,5mg) and caraway oil (50mg); 2 capsules per dose, 2 doses per study day.
9464496|NCT03682822|Experimental|Early artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
9464497|NCT03682822|Active Comparator|Delayed artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
9464498|NCT03682796|Experimental|Escalation|Estimated to be <31 subjects across multiple centers
9464499|NCT03682796|Experimental|Expansion|Estimated to be <121 subjects across multiple centers
9464500|NCT03682783||Fundus Image|Glaucomatous and Non-glaucomatous fundus images that have been taken from the last 5 years in Shanghai General hospital.
9464501|NCT03682757||Severe Injury/Shock|Severely injured trauma patients presenting with shock, as defined by an Injury Severity Score (ISS)>=25, and base deficit (BD)>=6.
9464502|NCT03682757||Without Severe Injury/Shock|Not severely injured trauma patients presenting without shock, as defined by an Injury Severity Score (ISS)<25, and base deficit (BD) <6.
9464503|NCT03682757||Healthy Controls|Uninjured healthy volunteers
9464504|NCT03682718|Experimental|vaginal misoprostol and intracervical Foley catheter|participants will receive misoprostol by the same dose and method. Transcervical Foley catheter (size 16F, with 30ml balloon capacity) will be passed. The catheter will deﬂated, removed and cervix re-assessed if no spontaneous expulsion occurred at 12 hours post- insertion. A new catheter will be passed for another 12 hours, if the Bishop score is less than 8 this will be considered as failure of induction.
9464505|NCT03682718|Active Comparator|vaginal misoprostol|"Misoprostol group; participants will receive 50 μg intravaginal in the posterior vaginal fornix, 25 μg will be given every 4 hours for another two doses, if a satisfactory Bishop score of 8 not reached, patient will take an overnight rest and she will continue induction by the same doses on the next day-provided that there is no ROMs- (this is according to Ain Shams University Protocol) The maximum dose of Misoprostol is 200 μg.~Oxytocin infusion will not started until 6 hours after the last dose or if there is no adequate contractions obtained."
9464506|NCT03682692|Experimental|ACEI/CCB|
9464507|NCT03682692|Experimental|ACEI/DIU|
9464508|NCT03682666|Active Comparator|KT group|the patients will perform Kinesiotaping for 5 days per week for 3 weeks
9464509|NCT03682666|Sham Comparator|mCIMT group|"the unaffected limb will be constraint for 2 hours a day, 5 days a week for three weeks.~And they will receive sham taping on the affected limb."
9464510|NCT03682666|Experimental|KT+mCIMT group|the patients will perform Kinesiology taping for 5 days per week for 3 weeks, and while being taped, the modified Constraint Induced Movement Training would be also executed.
9464511|NCT03682653|Active Comparator|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
10027571|NCT01733706|Active Comparator|Standard counseling|a psychologist will provide standard counseling
10027572|NCT01733706|Experimental|No nicotine electronic cigarette|patients will receive standard counseling as well as an electronic cigarette
9464512|NCT03682653|Placebo Comparator|Placebo|a single dose of placebo will be administered to infants between their 8-27th days of life
9464513|NCT03682640|Experimental|AIDIT protocol|"Treatment as usual with the addition of:~i) Azithromycin Monohydrate, three times a week (≥ 48 h between doses) during 52 weeks. 500 mg if body weight ≥ 30 kg, 250 mg if body weight < 30 kg.~ii) Extra intensive insulin treatment periods for maximum beta-cell rest with Insulin lispro (Sanofi). This treatment will be given i.v. for one episode of 72 hours in the first week after inclusion and s.c. on seven 6-8 h occasions during the study year. The dose will be individually titrated to reach target blood glucose 4.0±0.5 mmol/L.~ii) Dietician support; Extra advice and support from the study dietician within the first week after randomization and after 1.5 and 4 months."
10027573|NCT01733719|Active Comparator|ER plus RFA|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or RadioFrequency Ablation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
10027574|NCT01733719|Active Comparator|ER plus APC|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or Argon Plasma Coagulation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
10027575|NCT01733771||CAM with standard care|Symptomatic hospitalized people referred by the medical team to CAM treatments on top of standard of care
10027576|NCT01733771||Standard care only|Symptomatic patients who are referred to CAM treatments but are not interested in such treatments
9464514|NCT03682640|No Intervention|Control|Patients will receive treatment as usual (TAU). All patients will receive standard therapeutic treatment consisting of insulin replacement with insulin analogues aiming for normoglycemia from diagnosis. Rapid acting insulin analogue will be administered via insulin pump (continuous subcutaneous infusion) with access to insulin injections in case of malfunction in the pump system.
9464515|NCT03682627|Active Comparator|preventive fenestration|Fenestration is performed at the time of kidney transplantation
9464516|NCT03682627|Experimental|preventive fenestration and clipping|Fenestration and clipping of the edges are performed at the time of kidney transplantation
9464517|NCT03682601|Placebo Comparator|Placebo|"15 postmenopausal women will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
9464518|NCT03682601|Active Comparator|5% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 5% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
9464519|NCT03682601|Active Comparator|10% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 10% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
9464520|NCT03682588|Experimental|Functional exercise group|Functional exercise program with 14 exercises, two times/week, during 14 weeks. Two sets of 10 repetitions each, with 30 seconds interval.
9464521|NCT03682588|Active Comparator|Stretching exercise group|Stretching exercise program with 17 exercises, two times/week, during 14 weeks and each movement was repeated by three times and held for 20 seconds each
9464522|NCT03682575||Infants WITH diagnosis of bronchopulmonary dysplasia (BPD)|Preterm infants who were on oxygen at 28 days of life.
9464523|NCT03682575||Infants WITHOUT diagnosis of bronchopulmonary dysplasia (BPD|Preterm infants who were not on oxygen at 28 days of life.
9464524|NCT03682562||Oral Cancer|Patients diagnosed clinically and histopathologically as having oral cancer.
9464525|NCT03682562||Premalignant Oral Lesions|Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
9464526|NCT03682562||Normal Subjects|"Patients who give a history of:~No smoking~No alcohol~No systemic disease; and who on conventional oral examination have:~No visible oral lesions on conventional oral examination .~Good oral hygiene."
10027577|NCT01733784|Experimental|Viscoelastic properties of the airway|
10027578|NCT01733797|Experimental|Wooden spatula|
10027579|NCT01733797|Experimental|Therabite|
10027580|NCT01733810|Experimental|Reflux Patients|Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.
10027581|NCT01733823|Experimental|Group A|Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
10027582|NCT01733823|Experimental|Group B|PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
10027583|NCT01733823|Experimental|Group C|PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
10027584|NCT01733823|Experimental|Group D|PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
10027585|NCT01733836|Experimental|Metformin|850mg BID
10027586|NCT01733836|Placebo Comparator|Placebo|
10027587|NCT01733849||Group Bulgaria|Subjects in this group include infants/children from Bulgaria, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
10027588|NCT01733849||Group Latvia|Subjects in this group include infants/children from Latvia, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
10027589|NCT01733862||Group Japan|Children less than five years of age, hospitalized for RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE, between November 2007 and October 2016 (i.e., before and after the introduction of RV vaccination in Japan) in any of the selected hospitals.
10027590|NCT01733875|Experimental|CC-220 0.03 mg|
10027591|NCT01733875|Experimental|CC-220 0.1 mg|
9464527|NCT03682549||HCV positive Patients|"patients will be recruited from the outpatient's viral hepatitis clinic~The patients will be diagnosed as HCV positive through (antiHCV-Ab) and (HCV-PCR) tests"
9464528|NCT03682549||Successfully treated former HCV patients|Patients formerly diagnosed as HCV positive who received DAA treatment successfully.
9464529|NCT03682549||Normal Individuals|healthy volunteers recruited from the outpatient clinic of the Faculty of Dentistry- Cairo University
9464530|NCT03682523|No Intervention|Control Group|Fitted with an accelerometer to measure time spent out of bed while in hospital. Otherwise, participants in the control group will receive usual care from the hospital medical team during their hospital stay. Daily activities of participants will not be restricted if patients are assigned to the control group.
9464531|NCT03682523|Experimental|Intervention Group|Fitted with accelerometer to measure time spent out of bed while in hospital; daily goals set for time spent out of bed; real-time feedback on goal attainment provided on bedside tablet; mobilization feedback real-time feedback on goal attainment; hands on mobilization by physiotherapist for participants in late afternoon for participants who do not meet daily goal.
9464532|NCT03682510|Active Comparator|stepwise devascularization|routine stepwise devascularization
9464533|NCT03682510|Active Comparator|B-Lynch Transverse Compression Suture|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side."
9464534|NCT03682510|Experimental|N&H technique|"In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade. As follow:~(i) 100-cm Vicryl no. 1 was thrown to form two nearly equal parts (each 50 cm) on a blunt semicircular 70-mm needle, the curve of the needle was straightened.~(ii) The needle transfixed the right side of the uterine wall from anterior to posterior, about 2 cm below the hysterotomy incises posterior, then the needle transfixed the left side of the uterine wall from posterior to anterior, about 2 cm below the hysterotomy incision."
9464535|NCT03682497|Active Comparator|Spironolactone|Spironolactone treatment for 28 days
9464536|NCT03682497|Experimental|AZD9977|AZD9977 treatment for 28 days
9464537|NCT03682484|Experimental|MA-0211 Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
9464538|NCT03682484|Placebo Comparator|Placebo Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
9464539|NCT03682484|Experimental|MA-0211 Single Ascending Dose (food effect)|A single cohort of 8 participants will be started on a fixed single dose of MA-0211, within 30 minutes after the start and 5 minutes after the completion of an US Food and Drug Administration (FDA) high fat breakfast.
9464540|NCT03682484|Experimental|MA-0211 Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
9464541|NCT03682484|Placebo Comparator|Placebo Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
9464542|NCT03682471||Deoxycholic Acid Injection, 5 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 5 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
9464543|NCT03682471||Deoxycholic Acid Injection, 10 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 10 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
9464544|NCT03682471||Placebo|Non-treatment observational follow-up study: Participants were previously treated with placebo in studies ATX-101-10-16 or ATX-101-10-17.
10027592|NCT01733875|Experimental|CC-220 0.3 mg|
10027593|NCT01733875|Experimental|CC-220 1 mg|
10027594|NCT01733875|Experimental|CC-220 2 mg|
10027595|NCT01733875|Experimental|Placebo|In each arm, 6 subjects will receive a dose of CC-220 and 2 subjects will receive placebo depending on the randomization schedule.
10027596|NCT01733875|Experimental|CC-220 4 mg|
10027597|NCT01733875|Experimental|CC-220 6 mg|
10027598|NCT01733875|Experimental|CC-220 1 mg (Part 2 only)|
10027599|NCT01733888|Active Comparator|Office Bleaching|
10027600|NCT01733888|Experimental|Resin Infiltration|
10027601|NCT01733888|Experimental|Resin Infiltration twice|
10027602|NCT01733888|Experimental|Office Bleaching + Resin Infiltration|
10036798|NCT01819064||Children weighing 5Kg to 15Kg|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh between 5Kg and 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
10036799|NCT01819077||TMMR|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE
10027603|NCT01733901|Active Comparator|RSD+PCI+Medicine|We will recruit 300 randomised CHD patients who meet the inclusion criteria. First undergo percutaneous coronary intervention, and then perform the renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. After renal sympathetic denervation traditional secondary prevention of coronary heart disease is recommend. Finally we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
10027604|NCT01733901|Placebo Comparator|PCI+Medicine|We aslo will recruit 300 randomised CHD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will perform percutaneous coronary intervention firstly, then give traditional secondary prevention of coronary heart disease just like the RSD+PCI+Medicine group. Third we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
10027605|NCT01733914|Experimental|Acupuncture|Experimental group
10027606|NCT01733914|Sham Comparator|Waiting list|Control group
9464545|NCT03682445|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
9464546|NCT03682445|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
9464547|NCT03682445|No Intervention|Control group|The participants in the control group will make stretching exercise at home
9464548|NCT03682419|Experimental|VKA Patients|Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy
9464549|NCT03682419|Experimental|non-Vka Patients|Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy
9464550|NCT03682380|Experimental|Part 1: Seltorexant High Dose|In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
9464551|NCT03682380|Experimental|Part 2: Seltorexant High Dose|Participants will receive the following treatments: Treatment G: Two low doses of seltorexant tablets (Reference formulation), Treatment H: High dose or two low doses of seltorexant tablet (Test formulation 1), Treatment I: High dose of seltorexant tablet (Test formulation 2), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-3). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
9464552|NCT03682380|Experimental|Part 3: Seltorexant Low Dose or High Dose|Part 3 will have 3 subparts (Part 3A, Part 3B, and Part 3C). In Part 3A and 3B, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7) respectively in a different food conditions on Day 1 in each treatment Periods (Periods 1-5). In Part 3C, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7 ) on Day 1 in each period (Period 1 and 2). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
9464553|NCT03682354|Active Comparator|Intercostal Nerve Block with PCIA|Intercostal Nerve Block with patient-controlled intravenous analgesia
9464554|NCT03682354|Experimental|Erector Spinae Plane Block (ESPB)|Continuous Erector Spinae Plane Block
10027607|NCT01733927|Experimental|Rapid testing for HIV|The intervention consisted in administer an oral rapid test for HIV (OQA) to people that also had taken an ELISA test to compare their tests results. Group 1 consisted of 344 participants who did not know their HIV status; Group 2 consisted of 153 participants who were previously confirmed to be HIV positive. The participants were instructed to obtain their own oral fluid sample using the testing devices provide by the OQA rapid test kits. Project team members, certified to interpret OQA results, registered each test outcome on a data form using the same code number that the participant was assigned for the ELISA test.
9464555|NCT03682341||Group A|Patients with ovarian endometriosis cyst
9464556|NCT03682341||Group B|Patients with ovarian teratoma cyst
9464557|NCT03682328|Active Comparator|vertebroplasty|Patients will be managed by equipment of vertebroplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
9464558|NCT03682328|Active Comparator|kyphoplasty|Patients will be managed by equipment of kyphoplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
9464559|NCT03682315|Active Comparator|Biphasic phycogenic biomaterial|Biphasic phycogenic biomaterial and Autogenous cortical bone
9464560|NCT03682315|Experimental|Xenograft bovine hydroxyapatite|Xenograft bovine hydroxyapatite and Autogenous cortical bone
9464561|NCT03682276|Experimental|Treatment Group|Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
9464562|NCT03682237|No Intervention|A) Standard diabetes training (control)|"More specifically, group training in general diabetes health issues, how to do experienced based dosing, how to handle sick days, exercise etc. in general terms. The group will not be taught in carbohydrate counting or bolus calculation. They will be encouraged to measure SMBG at least 4 times daily with patients own preferred glucose meter.~Patients will be offered 6 months treatment with FGM after study end."
9464563|NCT03682237|Active Comparator|B) Carbohydrate counting, automated bolus calculation|
10027608|NCT01733940|Experimental|"Tegaderm CHG Dressing"|This arm is receiving a clorhexidine dressing for intravascular catheters.
10027609|NCT01733940|Active Comparator|"Tegaderm IV dressing"|Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
10027610|NCT01733966|Experimental|Secnidazol-Ciprofloxacin|2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
10027611|NCT01733966|Active Comparator|Amoxicillin-Clavulanic Acid|3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days
9464564|NCT03682237|Active Comparator|C) Flash glucose monitoring (FGM)|Group training with same content as for group A.
9464565|NCT03682237|Active Comparator|D) Carbohydrate counting, automated bolus calculation, FGM|Group training as group B. A more sophisticated education concept will be developed for how FGM should be used to adjust settings and suggestions from the automated bolus calculator (MySugr app).
9464566|NCT03682211|Experimental|Active Intranasal Fentanyl|Subjects will receive 50 μg/ml intranasal fentanyl citrate and a placebo matched to intravenous morphine (1 ml water for injection) at time 0
9464567|NCT03682211|Active Comparator|Active IV Morphine|Subjects will receive 10 mg/ml intravenous morphine sulphate and a placebo matched to intranasal fentanyl (2 ml water)
9464568|NCT03682198|Other|One strategy for all enrolled patients:|All patients will participate in three substudies, in which they also act as controls, with exposure to the same three interventions: 1) NIRS-measurement on skin, skull and dura, 2) Phenylephrine 0.1 mg iv., and 3) inspired oxygen fraction of 0.3 vs. 0.8
9464569|NCT03682185|Experimental|Timed Activity Intervention Protocol|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem solving approaches, and provide education.
9464570|NCT03682185|Active Comparator|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
9464571|NCT03682172|Experimental|GLP-2 (10pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min
9464572|NCT03682172|Experimental|GLP-2 (1pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
9464573|NCT03682172|Experimental|Placebo|A single four hour intravenous infusion with saline water (placebo)
9464574|NCT03682159|No Intervention|control|
10027612|NCT01733979|Experimental|Heme-Iron Polypeptide|
10027613|NCT01733979|Placebo Comparator|Placebo|
10027614|NCT01733979|Active Comparator|Heme-Iron|
10027615|NCT01733979|Active Comparator|Organic Iron|
10027616|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
10027617|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
10027618|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
10027619|NCT01733992|Placebo Comparator|Placebo|Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
10027620|NCT01734005|Experimental|Red Ginseng|
10027621|NCT01734005|Placebo Comparator|Placebo|
10027622|NCT01734018||Cohort|
10027623|NCT01734044|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rhTPO in combination with dexamethasone at the indicated dose.
10027624|NCT01734044|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
10027625|NCT01734057|Experimental|combinant treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with rhTPO at the indicated dose.
10027626|NCT01734057|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
10027627|NCT01734070|Experimental|Cherry consumption|Volunteers will supplement their diets with 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories. We will prefer that the subjects split the cherries into three equal portions and consume one with each meal; however, this will not be mandatory.
10027628|NCT01734083|Experimental|Whole body vibration exercise|The experimental group will receive 2 sessions of whole body vibration exercise training and conventional exercise per week for a period of 9 weeks. The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration frequency and amplitude used will be 30 Hz and 1 mm, respectively.
10027629|NCT01734083|Active Comparator|Conventional exercise|This group will receive 2 sessions of conventional exercise training per week for a period of 9 weeks.
10027630|NCT01734096|Active Comparator|control group|healthy volunteer
10027631|NCT01734096|Active Comparator|obesity group|Patients with BMI >30 Kg/m2
10027632|NCT01734096|Active Comparator|white coat hypertension group|Patients with office blood pressure >140/90 mmHg and ambulatory daytime blood pressure <135/85 mmHg
10027633|NCT01734096|Active Comparator|Resistant hypertension|Patients with ambulatory blood pressure > 135/85 mm Hg (day) or >120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking.
9464575|NCT03682159|Experimental|intervention|
9464576|NCT03682146|Experimental|R-LRPE|robot-assisted laparoscopic prostatectomy
9464577|NCT03682146|Experimental|LRPE|conventional radical laparoscopic prostatectomy
9464578|NCT03682133||Prehabilitation|The care as given in a participating hospital is according to the local guideline and will not be changed for this study. Whether prehabilitation is applied in a participating hospital is based on a predefined definition of oncological surgical prehabilitation.
9464579|NCT03682133||Usual care|Guideline based colon cancer surgery, without prehabilitation.
9479897|NCT03538886|Active Comparator|Percutaneous coronary intervention (PCI)|Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
10027634|NCT01734109|Placebo Comparator|Standard of Care - Wound Care|Standard, acceptable local wound care management, consisting of topical treatments, chemical debriders, or light bedside debridement.
9464580|NCT03682081|No Intervention|Usual care|Usual care groups will receive standard swallowing interventions identified by the Speech-Language Pathologist as appropriate to treat the patient's dysphagia and common in clinical practice. Such treatment would likely consist of dietary (e.g., thickened liquids or pureed foods) or postural compensatory strategies (e.g., chin down posture while swallowing). No progressive lingual strengthening approaches or regimented salivary substitute protocols are utilized.
9464581|NCT03682081|Experimental|Saliva Substitute Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied to the oral cavity regularly for 8 weeks.
9464582|NCT03682081|Experimental|Lingual Strengthening Intervention|Patient-caregiver dyads will be trained in the lingual strengthening protocol and patients will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
9464583|NCT03682081|Experimental|Saliva Substitute and Lingual Strengthening Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied regularly to the oral cavity for 8 weeks. Each dyad will also be trained in the lingual strengthening protocol and will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
9464584|NCT03682055|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|VK-2019 QD in Accelerated Titration dose escalation cohorts enrolling EBV+ NPC
9464585|NCT03682055|Experimental|Phase 1 Dose Escalation (Rolling Six)|VK-2019 QD in Rolling Six dose escalation cohorts enrolling EBV+ NPC.
10027635|NCT01734109|Active Comparator|Quantum NPWT|Intervention with Quantum NPWT to Standard III/IV pressure ulcers for 12 weeks.
10027636|NCT01734109|Active Comparator|Quantum NPWT with Irrigation|NPWT with the Quantum device, with the addition of simultaneous irrigation using 0.25% acetic acid.
9464586|NCT03682055|Experimental|Phase 1 Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified criteria for clinical and/or biological activity.
9464587|NCT03682055|Experimental|Phase 2a Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified efficacy criteria in Phase 1 Dose Escalation cohorts.
9479898|NCT03538886|Experimental|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.
9479899|NCT03538873|Active Comparator|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
9479900|NCT03538873|No Intervention|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
9479901|NCT03538769|No Intervention|Baseline group|This will be the pre and post alert phase where e-alerts will not be sent to providers
9479902|NCT03538769|Other|Alert group|This will be the phase when e-alerts will be sent to the provider
10027637|NCT01734122||Essential Tremor|Patients with severe, medication-refractory Essential Tremor
10027638|NCT01734122||Parkinsonian Tremor|Patients with severe, medication-refractory, tremor-dominant Parkinsons
10027639|NCT01734135|No Intervention|Usual Care|Usual care
10027640|NCT01734135|Experimental|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
10027641|NCT01734148|Experimental|Experimental group (RELAX TO SLEEP program)|
10027642|NCT01734148|No Intervention|Control group (Usual Care)|
10027643|NCT01734174||cardiac patients|Patients having elective coronary artery bypass grafting surgery, valve repair or replacement surgery, aortic repair or replacement surgery, or any combination of these surgeries will be recruited for this study to validate measurements of left ventricular volume and ejection fraction (a quantitative measure of general heart function) as assessed by 3-dimensional transesophageal echocardiography (3D TEE) as compared to 3-dimensional transthoracic echocardiography (3D TTE). Secondarily, we will also compare the 3D TEE assessment to the 2D TEE and TTE assessment, which is routinely performed simultaneously. Last, we will compare this assessment to a third method of quantification of cardiac function via a pulmonary artery catheter using thermodilution.
9479903|NCT03538756|Experimental|Group A--Walkasins On Then Off|"Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
9479904|NCT03538756|Experimental|Group B--Walkasins Off Then On|"Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
9479905|NCT03538730|No Intervention|Attention Control|Similar to previous narrative and memory interventions, parents in the control group will receive instructions from a researcher for 20 minutes on how to engage in child-directed play. Importantly, they will not talk about pain or the past surgery experience.
9464588|NCT03682042|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
9464589|NCT03682042|No Intervention|Early Cord Clamping|The umbilical cord is clamped immediately after the delivery (within 60 seconds).
9464590|NCT03682029|Experimental|Vitamin C|Vitamin C (ascorbic acid) 500 mg/capsule. Ingestion of 2 capsules (1000 mg) daily for 12 months.
9464591|NCT03682029|Placebo Comparator|Placebo|Placebo capsule. Ingestion of 2 capsules daily for 12 months. Placebo will be prepared as capsules that look and taste identical to the vitamin C supplement capsules. The content of the placebo is lactose, potato starch, gelatin, magnesium stearate, and talc.
9464592|NCT03681990|Experimental|3M CHG/IPA Prep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
9464593|NCT03681977|Experimental|Zimmer MP Persona|Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
10027644|NCT01734187|Experimental|Fermented Cinnamon Vine Powder|
10027645|NCT01734187|Placebo Comparator|Placebo|
9464594|NCT03681977|Active Comparator|Zimmer Persona Knee-PS|Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
9464595|NCT03681977|No Intervention|Healthy Participants|The control group for the kinematic assessment
9464596|NCT03681938||Intensification treatment: Autograft|
9464597|NCT03681938||Standard chemotherapy (without autograft)|
9464598|NCT03681925|Experimental|Intervention|Dietitians randomized to the intervention arm will have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and base their intervention on these results.
9464599|NCT03681925|No Intervention|Control|Dietitians randomized to the control arm will not have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and will provide the standard-of-care intervention for their patients.
9464600|NCT03681899||Subjects aged of 65 years or older|Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.
9464601|NCT03681873|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose exams
9464602|NCT03681860|Other|Group 1 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
9464603|NCT03681860|Other|Group 2 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
9464604|NCT03681860|Other|Group 3 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
9464605|NCT03681860|Other|Group 4 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
9464606|NCT03681860|Experimental|Group 5/6 Randomised Comparison|30 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp followed by MVA85A boost versus 30 adolescents who are EMaBS participants, to receive BCG revaccination
9464607|NCT03681847|Active Comparator|normal saline|Patients will receive normal saline 0.9% 15 ml/kg over 15-20 minutes.
9464608|NCT03681847|Active Comparator|Hydroxyethyl starch|Patients will receive hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
10027646|NCT01734200|Experimental|Eriobotyra Japonica Lindley Extract|
10027647|NCT01734200|Placebo Comparator|Placebo|
10027648|NCT01734213|Experimental|Eriobotyra Japonica Lindley Extract|
10027649|NCT01734213|Placebo Comparator|Placebo|
10027650|NCT01734226|Experimental|Prunus Mume Extract|
9464609|NCT03681847|Active Comparator|Hypertonic saline|Patients will receive hypertonic saline 3% (7ml/kg) over 15-20 minutes.
9464610|NCT03681821|Experimental|The intervention group|Patients in the intervention group receiving the follow-up TTM-based intervention sessions.
10027651|NCT01734226|Placebo Comparator|Placebo|
10027652|NCT01734252|No Intervention|Standard Treatment|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
10027653|NCT01734252|Experimental|Treatment with Argatroban|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.
10027654|NCT01734265|Experimental|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
10027655|NCT01734265|Experimental|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
10027656|NCT01734278||Asenapine|Patients prescribed asenapine for any indication.
9464611|NCT03681821|No Intervention|The control group|No interventions except conventional care were performed for the control group.
9464612|NCT03681795|Experimental|patient|patients with Gilles de la Tourette syndrome
9464613|NCT03681795|Experimental|Control|healthy control
9464614|NCT03681756|No Intervention|Group 1|Participants will receive an in-person session and an activity monitor
10027657|NCT01734291|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the patients.
10027658|NCT01734291|Placebo Comparator|Treatment as usual(TAU)|Treatment as usual administered by physician and counseling administered by nurse.
9464615|NCT03681756|Experimental|Group 2|Participants will receive an in-person session, an activity monitor, and social support through BAND
9464616|NCT03681743|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
10027659|NCT01734304|Experimental|DC vaccination|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
10027660|NCT01734330|Experimental|Cognitive behavior therapy|Cognitive behavior therapy for 6 weeks associated to nicotine replacement for 12 weeks
10027661|NCT01734330|Other|Nicotine replacement|Nicotine replacement for 12 weeks
10027662|NCT01734343|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
10027663|NCT01734343|Other|PhysIOL microAY|eyes with implanted intraocular lens PhysIOL microAY
9464617|NCT03681743|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors and/or parents.
9464618|NCT03681730|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
9464619|NCT03681730|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
9464620|NCT03681717|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during laceration repair with sutures.
9464621|NCT03681717|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
9464622|NCT03681704|Experimental|HuangQi Decoction|HuangQi Decoction 150ml by mouth ,twice a day for 24 weeks
9464623|NCT03681704|Placebo Comparator|HuangQi Decoction placebo|HuangQi Decoction placebo 150ml by mouth, twice a day for 24 weeks
9464624|NCT03681691|Experimental|Post menopausal women with diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes
9464625|NCT03681691|Experimental|Post menopausal women without diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.
9464626|NCT03681665||Abscess|Patients group with abdominal abscess
9464627|NCT03681652||Azathioprine or 6MP|Patients treated with thiopurines for post-operative prophylaxis.
9464628|NCT03681652||Anti-TNF drug|Patients treated with anti-TNF alpha monotherapy for post-operative prophylaxis.
9464629|NCT03681639|Experimental|Patients who received Metasul Monoblock in hip resurfacing|Patients who received the Zimmer Hip Resurfacing System utilising the Metasul Monoblock Component™ Cup in a Hip Resurfacing Application with the Durom® Hip Resurfacing Femoral Component and whose Serum metal ion levels is being measured.
9464630|NCT03681626|Active Comparator|tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed with a standardized tracheal suction.
9464631|NCT03681626|Experimental|no tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed without tracheal suction.
10027664|NCT01734356|Other|inherited arrhythmias|6 patient with inherited arrhythmias
10027665|NCT01734356|Other|valvulopathies|6 patient with valvulopathies
10027666|NCT01734356|Other|controle|8 healthy people for these pathologies
10027667|NCT01734408|Experimental|alum-adjuvant 160U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
9464632|NCT03681613|Experimental|Exercise Therapy With CNS Treatment|NEMEX program combined with a CNS-focused protocol
9464633|NCT03681613|Experimental|Exercise Therapy alone|NEMEX program alone
10027668|NCT01734408|Placebo Comparator|placebo A|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
10027669|NCT01734408|Experimental|alum-adjuvant 320U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
10027670|NCT01734408|Placebo Comparator|placebo B|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
10027671|NCT01734408|Experimental|alum-adjuvant 640U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
10027672|NCT01734408|Placebo Comparator|placebo C|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
10027673|NCT01734408|Experimental|adjuvant-free 640U /0.5ml EV71 vaccine|A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
10027674|NCT01734408|Placebo Comparator|placebo D|A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
10027675|NCT01734421|Other|Control group|Habitual deshabituation in the control group following the guidelines of the primary health care institution.
10027676|NCT01734421|Active Comparator|Cell phone Aplication for Smarth Phone|Cell phone 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application
10027677|NCT01734447|Experimental|1.2, continuous treatment|
10027678|NCT01734447|Experimental|1.2, non-continuous treatment|
9464634|NCT03681574|Experimental|Placebo Group|The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
9464635|NCT03681574|Experimental|GABA 15mg/kg Group|The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
10027679|NCT01734447|Experimental|2.4, non-continuous treatment|
9464636|NCT03681574|Experimental|GABA 30mg/kg Group|The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
9464637|NCT03681548|Active Comparator|Reference Product - R|Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).
9464638|NCT03681548|Experimental|Test Product - T|Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).
10027680|NCT01734460||third trimester pregnant women|no intervention
10027681|NCT01734473|Experimental|Study day 1|Hydrolyzed casein protein. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
9464639|NCT03681535|Experimental|Single arm interventional study|RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
9464640|NCT03681522|Experimental|Pelvic plexus block|The injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
9464641|NCT03681522|Active Comparator|Periprostatic nerve block|The injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle.
9464642|NCT03681509|Experimental|Pramipexole|Maximum daily dose: 1.0 mg of pramipexole salt
9464643|NCT03681509|Placebo Comparator|Placebo|Lactose
9464644|NCT03681470|Experimental|Patients with Acne Vulgaris|Acne Vulgaris in Patients With Skin of Color
9464645|NCT03681457|Other|Group 1 - Normal Hepatic Function|Normal hepatic function - Control - control group
10027682|NCT01734473|Experimental|Study day 2|Hydrolyzed casein protein + carbohydrates. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
10027683|NCT01734473|Experimental|Study day 3|Hydrolyzed casein protein + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
10027684|NCT01734473|Experimental|Study day 4|Hydrolyzed casein protein + carbohydrates + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
9464646|NCT03681457|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment - Child-Pugh A (Score 5-6)
10027685|NCT01734473|Experimental|Study Day 5|4 levels of hydrolyzed casein protein + carbohydrates
10027686|NCT01734486|Experimental|Low dose|
10027687|NCT01734486|Experimental|High dose|
9464647|NCT03681457|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment - Child-Pugh B (Score 7-9)
9464648|NCT03681457|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment - Child-Pugh C (score 10-15)
10027688|NCT01734499|Experimental|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. Quality of Life survey completed at 5 time points after informed consent."
10027689|NCT01734499|Active Comparator|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program, (2)Local support groups centered at community cancer centers, (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation.Quality of Life surveys completed at 5 time points after informed consent.
10027690|NCT01734538|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories, Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
10027691|NCT01734538|Placebo Comparator|Placebo Capsule|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
10027692|NCT01734564|Experimental|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
10027693|NCT01734564|Experimental|Hiltonol, dendritic cells and radiation|Hiltonol, dendritic cells and radiation.
10027694|NCT01734577|Active Comparator|Dry needling|Monofilament needles will be inserted into each subject's left multifidus muscle and stimulated mechanically for a local twitch response
10027695|NCT01734577|Sham Comparator|Sham needling|Monofilament tubes will be pressed into the left multifidus muscle and mechanically manipulated to give the sensation that needling is occuring.
10027696|NCT01734590|Experimental|Carbohydrate based food mix 1|Slowly digestible carbohydrate
10027697|NCT01734590|Experimental|Carbohydrate based food mix 2|Slowly digestible carbohydrate
10027698|NCT01734590|Active Comparator|Control carbohydrate based food|Rapidly digestible carbohydrate
10027699|NCT01734603|Active Comparator|conventional rehabilitation program|conventional rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with complete rest.
9464649|NCT03681444|Experimental|Regular diet|no dietary restriction
9464650|NCT03681444|Placebo Comparator|Clear fluid diet|no solid material
9464651|NCT03681444|Experimental|Low residue diet|easy digestible food
9464652|NCT03681431|Experimental|Ceftriaxone 4g/ 24h|Single intravenous dose of Ceftriaxone 4g/ 24h
9464653|NCT03681431|Active Comparator|Ceftriaxone 2g/ 12h|Two intravenous doses of Ceftriaxone 2g/ 12h
9464654|NCT03681418|Other|Patients with operable breast cancer|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.
9464655|NCT03681366|No Intervention|Single vision soft contact lens|single vision, spherical soft contact lens
9464656|NCT03681366|Experimental|DISC3.5 Plus lens|A soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
9464657|NCT03681340|Experimental|Hydroxyapatite toothpaste|4 weeks toothbrushing with a hydroxyapatite toothpaste
9464658|NCT03681340|Active Comparator|Fluoridated toothpaste|4 weeks toothbrushing with a fluoridated toothpaste
9464659|NCT03681314|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
9464660|NCT03681314|No Intervention|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
9464661|NCT03681301|Experimental|Interventional|Additional self-directed learning and practice using virtual reality simulator, after conventional training session
9464662|NCT03681301|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
10027700|NCT01734603|Experimental|experimental rehabilitation program|experimental rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with active recovery (no stop walking).
10027701|NCT01734616|No Intervention|Young|Young subjects to be controlled to older individuals with interventions
9464663|NCT03681288|Experimental|MSC|Mindful Self-Compassion Intervention
9464664|NCT03681275|Experimental|Tofacitinib|Patient will receive two days treatment with tofacitinib prior to the surgery.
9464665|NCT03681275|Placebo Comparator|Placebo|Patient will receive two days treatment with placebo prior to the surgery.
9464666|NCT03681262|Experimental|High frequency spinal cord stimulation|Implant of the device that can deliver high frequency waveform to spinal cord
9464667|NCT03681262|Experimental|Burst spinal cord stimulation|Implant of the device that can deliver burst waveform to spinal cord
9464668|NCT03681249|Experimental|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml by mouth, twice a day for 24 weeks
9464669|NCT03681249|Placebo Comparator|ShenqiDihuang Decoction placebo|ShenqiDihuang Decoction placebo 150ml by mouth, twice a day for 24 weeks
9464670|NCT03681236|No Intervention|No alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O
9464671|NCT03681236|Active Comparator|Alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O. In addition to this, performing alveolar recruitment maneuver at 2 moments: before surgical incision, end of pneumoperitoneum
9464672|NCT03681197|Active Comparator|Metformin Group|Will receive metformin plus clomiphene citrate
9464673|NCT03681197|Placebo Comparator|Placebo|Will receive placebo plus clomiphene citrate.
9464674|NCT03681171|Experimental|Children with CP|Children with CP (9-15 years old) participated in a therapeutic dance program to improve physical, physiological and cognitive outcomes.
10027702|NCT01734616|No Intervention|Old|Older individuals to compare to young and other older intervention groups
9464676|NCT03681145|Experimental|Group A-Intervention|Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
9464677|NCT03681145|Experimental|Group B-Wait-list|Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
9464678|NCT03681132|Other|Low-threshold re-start|Re-start antiviral therapy if HBV DNA viral load >2000 IU/ml and ALT >80 U/L.
9464679|NCT03681132|Other|High-threshold re-start|"Re-start antiviral therapy if:~ALT >100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR~ALT >400 U/L persisting for more than 2 months in consecutive assays."
9464680|NCT03681106|Experimental|Kinesiotape|Kinesio Tex taping treatment for 10 days + usual care
9464681|NCT03681106|No Intervention|Control|usual care
9464682|NCT03681080|No Intervention|lying|cognitive tests are performed during lying in all groups (SFN, AAN, EDS, POTS and controls)
10027703|NCT01734616|Experimental|Old Exercise|Older individuals studied after an intervention of 20 weeks fully-supervised resistance exercise training
9464683|NCT03681080|No Intervention|standing|cognitive tests are performed during active Standing in all groups (SFN, AAN, EDS, POTS and controls)
9464684|NCT03681080|Experimental|crossed legs|cognitive tests are performed during leg crossing in all groups (SFN, AAN, EDS, POTS and controls)
10027704|NCT01734616|Experimental|Old Acute Cocoa|Older individuals studied with the addition of cocoa flavanols during their acute study
10027705|NCT01734616|Experimental|Old 7 Day Cocoa|Older individuals studied after 7 day supplementation of cocoa flavanols
10027706|NCT01734629||Coronary CT Spirometry Cohort|Patients refereed to coronary CT enrolled in the study.
9464685|NCT03681067|Experimental|GSK10708060|Humanised antibody GSK1070806
9464686|NCT03681067|Placebo Comparator|Placebo - sodium chloride|Placebo
9464687|NCT03681054|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
9464688|NCT03681054|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
9464689|NCT03681002|Other|structured lifestyle program|individual counseling focusing on Lifestyle habits
9464690|NCT03680989|Placebo Comparator|Natural Light|"Participants will use a therapy light that provides ~500 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
9464691|NCT03680989|Active Comparator|Bright Light|"Participants will receive Bright Light Exposure using a therapy light that provides ~10,000 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
10027707|NCT01734642||PATIENT HOSPITALIZED|ALL THE PATIENTS HOSPITALIZED IN THE INVOLVED UNITS WHO GAVE THEIR INFORMED CONSENT. PATIENTS HOSPITALIZED DURING THE WEEK-END WILL BE ENROLLED ON the next MONDAY
9464692|NCT03680976|Experimental|10-nitro-octadeca-9-enoic acid (CXA-10)|CXA-10 150 mg tablet taken orally once a day for 12 weeks
10027708|NCT01734681|Experimental|Treatment with G-202|G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
10027709|NCT01734694|Active Comparator|Vancomycin|
10027710|NCT01734694|Active Comparator|Comparator|
10027711|NCT01734707|Active Comparator|Allicor|Allicor 150 mg tablet by mouth two times a day
9464693|NCT03680976|Placebo Comparator|Placebo|Placebo 150 mg tablet taken orally once a day for 12 weeks
10027712|NCT01734707|Placebo Comparator|Sugar pill|Placebo tablet 150 mg by mouth two times a day
9464694|NCT03680963|Experimental|Non-invasive strategy|Non-invasive strategy consisting of blood pressure monitoring by non-invasive automated cuff measurements
9464695|NCT03680963|Other|Control strategy|Usual strategy of systematic indwelling arterial catheter insertion in the early hours of acute circulatory failure
9464696|NCT03680950|Experimental|Upper Gastrointestinal Monitoring System|Participants who meet criteria of enrollment and is willing to join in this study will wear a real-time upper gastrointestinal monitoring system for checking whether upper gastrointestinal rebleeding occurs continuously for 3 days.
10027713|NCT01734720||common bile duct stone|Patients undergoing cholecystectomy
10027714|NCT01734733|Experimental|NTCELL|"NTCELL 40 microcapsules (+/- 20%)~The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging."
9464697|NCT03680937||Immature oocytes vitrified before in vitro maturation|Immature oocytes will be vitrified using closed system vitrification with a semiautomatic method. After warming, a maturation culture will be performed during 36 hours
9464698|NCT03680937||Immature oocytes vitrified after in vitro maturation|A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
10036800|NCT01819090|Active Comparator|No ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an usual (with no ventilation switch control) Elysee 150 ventilator while speaking
10036801|NCT01819090|Active Comparator|Ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an Elysee 150 ventilator with a ventilation switch control allowing them to control ventilation while speaking
10036802|NCT01819103||Acute myocardial infarction|Drug Adherence
10036803|NCT01819142|Experimental|AutoloGel|Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment
10036804|NCT01819155|Experimental|adjTIV|Children randomized to receive adjTIV
10036805|NCT01819155|Experimental|TIV|Children randomized to receive TIV
9464699|NCT03680937||Fresh oocytes|The culture of immature oocytes will be performed during 36 hours
9464700|NCT03680898|Experimental|revogene Testing|The swab will be used for the testing on the revogene using the GenePOC Carba assay.
9464701|NCT03680898|Active Comparator|Reference Method|The other swab will be used in the Reference Method.
9464702|NCT03680885|Active Comparator|Reports getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
9464703|NCT03680885|Active Comparator|Reports trouble getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
9464704|NCT03680833|Other|prospective cohort study|"Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.~The intervention is the detection and removal of sentinel lymph nodes"
9464705|NCT03680807||Older adults with knee osteoarthritis (>50 years)|
9464706|NCT03680807||Healthy older adults (> 50 years)|
9464707|NCT03680794|Experimental|Patients with ophthalmic surgery|
9464708|NCT03680755|Experimental|Tr1 group|Participants assigned to Tr1 will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
9464709|NCT03680755|Experimental|Tr2 group|Participants assigned to Tr2 will complete the experimental dental anxiety management program, which will be facilitated by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
10036806|NCT01819155|Placebo Comparator|Placebo|Children randomized to receive Placebo
10036807|NCT01819207|Experimental|TEG group|
10036808|NCT01819220|Active Comparator|amlodipine/valsartan|
10036809|NCT01819220|Experimental|hydrochlorothiazide/telmisartan|
10036810|NCT01819246|Active Comparator|Pheresis Treatment Arm|
10036811|NCT01819246|Sham Comparator|Control Arm|
10036812|NCT01819259|Active Comparator|ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
10036813|NCT01819259|Active Comparator|Non-ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
10027715|NCT01734759|Experimental|Taste Test|
9464710|NCT03680755|No Intervention|Active control|Participants assigned to the control group, will not complete the experimental dental anxiety management program at this time. They will complete study paperwork and watch a non-dental video for 45 minutes before their scheduled dental appointment. Immediately after the dental appointment, they will complete a brief interview with the research staff person.
9464711|NCT03680716|Experimental|IPACK block|Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
9464712|NCT03680716|Active Comparator|Local infiltration analgesia|Periarticular infiltration by surgeon
9464713|NCT03680703|Experimental|Internet|Guided self-help behavioral weight loss treatment delivered via the internet
10027716|NCT01734798|Experimental|Arm 1|post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
9464714|NCT03680703|Experimental|Internet Plus Phone|Guided self-help behavioral weight loss treatment delivered via the internet with weekly phone consultations
10027717|NCT01734798|Experimental|Arm 2|adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
10027718|NCT01734798|Experimental|Arm 3|Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
9464715|NCT03680690||Group A|women with normal uterus,detected by hysteroscopy.
9464716|NCT03680690||Group B|Women with detected or corrected uterine cavitary lesions by hysteroscopy.
9464717|NCT03680664|Experimental|Active tDCS + MBSR|"Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice."
9464718|NCT03680664|Sham Comparator|sham tDCS + MBSR|"The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice."
9464719|NCT03680638|Sham Comparator|Control (Lactated Ringer's)|This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
9479906|NCT03538730|Experimental|Memory Reframing Intervention|Parents in the intervention group will spend 20 minutes with a researcher and receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods.
9802981|NCT04721691|Active Comparator|IP|Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Epidiolex at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
10027719|NCT01734824|Active Comparator|Teriparatide|daily subcutaneous injection of teriparatide 20µg for three months
10027720|NCT01734824|Placebo Comparator|Placebo Teriparatide|daily subcutaneous teriparatide placebo injection
10027721|NCT01734824|Active Comparator|Denosumab|one subcutaneous injection of denosumab
10027722|NCT01734824|Active Comparator|Placebo Denosumab|one subcutaneous injection of denosumab placebo
10027723|NCT01734863|Experimental|Radiotherapy Arm|"this study arm will take External Beam radiotherapy as follows :~Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy [IMRT] is allowed.~Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
10027724|NCT01734863|No Intervention|No Radiotherapy Arm|"this arm will not take radiotherapy and their inclusion criteria as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
10027725|NCT01734876|Experimental|Tactile Touch|Tactile Touch is given to the active arm
10027726|NCT01734876|Active Comparator|Rest To Music|Rest to Music. Rest for 30-60 minutes, aroma therapy, quit music in the background, well temepered room, lying position
10027727|NCT01734915||NSCLC|Subjects with advanced NSCLC, will undergo blood draw
10027728|NCT01734941|Active Comparator|TSO 2500|2500 TSO every other week
10027729|NCT01734941|Active Comparator|7500 TSO|7500 TSO every other week
10027730|NCT01734941|Placebo Comparator|Placebo|placebo every other week.
10027731|NCT01734954|Experimental|Sciatic nerve blockade at bifurcation|Ultrasound-guided block at the bifurcation of the sciatic nerve
10027732|NCT01734954|Experimental|Sciatic block 2 cm beyond bifurcation|Ultrasound-guided block of the sciatic nerve 2 cm beyond of the bifurcation
10027733|NCT01734967|Experimental|needle based CLE & EUS-FNA|The study will prospectively include patients referred to our department for EUS and EUS-FNA of suspected pancreatic masses during a 12 months period. The indication for this investigation will be based on the patient's clinical history and previous imaging studies (abdominal ultrasound, CT scan, MRI).
10027734|NCT01734980|Experimental|Endobronchial Ultrasound|EBUS-TBNA is a procedure that allows accurate sampling of mediastinal lymph nodes and peribronchial lesions
9464720|NCT03680638|Experimental|Tempol|This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
9464721|NCT03680638|Experimental|Apocynin|This site will only be infused with apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone; 100µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
9464722|NCT03680638|Experimental|Allopurinol|This site will only be infused with tempol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
9464723|NCT03680612|Experimental|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg
9464724|NCT03680612|Active Comparator|cefepime monotherapy|cefepime 1 g or cefepime 2 g
9464725|NCT03680599|Experimental|Connection to Health for Smokers|Participants in this arm will participate in the Connection to Health for Smokers Arm of the study, wherein an electronic survey will be administered and participants will be guided through an evidence-based action planning sequence, taking into account each patient's unique social environment, health related behaviors, and behavioral health status, with multimodal follow up.
9464726|NCT03680599|Active Comparator|Enhanced Standard of Care|Participants in this arm will participate in Enhanced Standard Care, wherein participants will receive a brief electronic survey and receive standard smoking cessation program that does not include formal action planning and multimodal follow up.
9464727|NCT03680573|Active Comparator|Control- Lactated Ringers|This site will serve as the control site and will receive lactated Ringer's (saline solution) at an infusion rate of 2 µl/min.
9464728|NCT03680573|Experimental|Apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone)|This site will receive 100 µM apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone) at an infusion rate of 2 µl/min.
9464729|NCT03680573|Experimental|Allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)|This site will receive 10 µM allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)at an infusion rate of 2 µl/min.
9464730|NCT03680573|Experimental|BH4 ((6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride)|This site will receive 10 mM (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) at an infusion rate of 2 µl/min.
9464731|NCT03680560|Experimental|ACTR T cell product in combination with trastuzumab|
9464732|NCT03680534|Experimental|Reciproc Blue|Patients in which root canal from a lower premolar was prepared with the Reciproc Blue technique.
9464733|NCT03680534|Experimental|WaveOne Gold|Patients in which root canal from a lower premolar was prepared with the WaveOne Gold technique.
9464734|NCT03680534|Experimental|XP EndoShaper|Patients in which root canal from a lower premolar was prepared with the XP EndoShaper technique.
9464735|NCT03680508|Experimental|TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)|Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9464736|NCT03680495||AECOPD with Respiratory Failure|The AECOPD cohort will be hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure requiring invasive or non-invasive mechanical ventilation. We will be following patients from admission through to discharge, and during a follow-up visit (~2 months from discharge). During the follow-up visit we will be administering 60mg of methylprednisolone once to study possible steroid resistance.
9464737|NCT03680495||Stable COPD|The Stable COPD cohort will not have had an AECOPD within the past 6 months and will be frequency matched to the AECOPD cohort. The Stable COPD cohort will have one research visit where we will administer 60mg of methylprednisolone once to study possible steroid resistance.
9464738|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose.
9464739|NCT03680482|No Intervention|Intervention ingest a water (control group)|Subjects with type 2 diabetes who ingest a water (control group)
9464740|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
9464741|NCT03680469|Active Comparator|standard early rehabilitation|The standard early rehabilitation program after acute stroke is an intervention regularly utilized in the stroke center of National Taiwan University Hospital.
9464742|NCT03680469|Experimental|adding early out-of-bed mobilization|The adding early out-of-bed mobilization treatment will be defined as the patients with acute ischemic stroke who receive out-of-bed mobilization treatment in addition to standard early rehabilitation care.
9464743|NCT03680430|Experimental|limb soft tissue sarcoma|
10027735|NCT01735006|Experimental|HPV vaccine|This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
10027736|NCT01735006|Placebo Comparator|HEV vaccine|commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant
10027737|NCT01735019|Experimental|group 1|administration of remifentanil with target-controlled infusion (TCI) system at a given concentration during anesthetic emergence
10027738|NCT01735045|Experimental|Test Group myopia control|Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control
9464744|NCT03680417|Active Comparator|Safety Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
9464745|NCT03680417|Active Comparator|Sub Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
9464746|NCT03680404|Active Comparator|Control (Phenylephrine)|Subjects will be administered phenylephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
9464747|NCT03680404|Experimental|Phenylephrine + Apocynin|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and apocynin (10^-4 M) at the same rate and for the same time as the control arm.
9464748|NCT03680404|Experimental|Phenylephrine + Allopurinol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and allopurinol (10^-5 M) at the same rate and for the same time as the control arm.
9464749|NCT03680404|Experimental|Phenylephrine + Tempol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and Tempol (10^-5 M) at the same rate and for the same time as the control arm.
9464750|NCT03680391||early postoperative feeding|103 patients will have early postoperative oral fluids and semisolid food after 6 hours of cesarean section irrespective to intestinal sounds ,flatus or stool passage
9464751|NCT03680391||Late postoperative feeding|97 patient will start oral fluids 6 hours with no solid or semi solid until after passage of flatus or stool
9464752|NCT03680378|Experimental|Cefepime 2 gram + AAI101 1 gram|cefepime 2 grams in combination with AAI101 1 gram intravenous infusion
9464753|NCT03680352|Experimental|cefepime/AAI101 combination|Investigational drug
9464754|NCT03680339|Active Comparator|Routine ecbolic group|100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
9464755|NCT03680339|Active Comparator|Misoprostol group|The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
9464756|NCT03680326||OCT|only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis
9479907|NCT03538704|Experimental|BMI≥25 group with metformin|Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,
9479908|NCT03538704|No Intervention|BMI≥25 group without metformin|Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.
9479909|NCT03538691|Experimental|Brexpiprazole & Citalopram Hydrobromide|Brexpiprazole: oral tablet; 2 to 3 mg/day Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
9479910|NCT03538691|Placebo Comparator|Placebo & Citalopram Hydrobromide|Placebo: daily oral tablet Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
9479911|NCT03538691|Experimental|Brexpiprazole & Escitalopram|Brexpiprazole: oral tablet; 2 to 3 mg/day Escitalopram: oral tablet; 10 or 20 mg/day
10027739|NCT01735045|Active Comparator|Myopia Control|Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control
10027740|NCT01735058|Active Comparator|Sodium hyaluronate|Ultrasound guided injection of sodium hyaluronate
10027741|NCT01735058|Placebo Comparator|Normal saline|Ultrasound guided injection of normal saline
9479912|NCT03538691|Placebo Comparator|Placebo & Escitalopram|Placebo: daily oral tablet Escitalopram: oral tablet; 10 or 20 mg/day
9479913|NCT03538691|Experimental|Brexpiprazole & Fluoxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Fluoxetine: oral capsule; 20 or 40 mg/day
9479914|NCT03538691|Placebo Comparator|Placebo & Fluoxetine|Placebo: daily oral tablet Fluoxetine: oral capsule; 20 or 40 mg/day
10027742|NCT01735071|Experimental|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
10036814|NCT01819285|Active Comparator|Immediate Endocrine Therapy|Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
9479915|NCT03538691|Experimental|Brexpiprazole & Paroxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
9479916|NCT03538691|Placebo Comparator|Placebo & Paroxetine|Placebo: daily oral tablet Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
9479917|NCT03538691|Experimental|Brexpiprazole & Sertraline|Brexpiprazole: oral tablet; 2 to 3 mg/day Sertraline: oral tablet; 100, 150 or 200 mg/day
9479918|NCT03538691|Placebo Comparator|Placebo & Sertraline|Placebo: daily oral tablet Sertraline: oral tablet; 100, 150 or 200 mg/day
9479919|NCT03538691|Experimental|Brexpiprazole & Duloxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
9479920|NCT03538691|Placebo Comparator|Placebo & Duloxetine|Placebo: daily oral tablet Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
9479921|NCT03538691|Experimental|Brexpiprazole & Venlafaxine extended-release (XR)|Brexpiprazole: oral tablet; 2 to 3 mg/day Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
9479922|NCT03538691|Placebo Comparator|Placebo & Venlafaxine extended-release (XR)|Placebo: daily oral tablet Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
9479923|NCT03538574|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
10036815|NCT01819285|Experimental|Delayed Endocrine Therapy|Orchiectomy or LHRH Therapy plus (initially) Antiandrogen Therapy. BSRL; CPTR. Treatment delayed until onset of symptoms.
9464757|NCT03680313||Hypertension group|"All adult patients (above 18 year of age) were recruited between May, 2016 and June 2017, at Duc Giang General Hospital. The inclusion criteria are as followed:~Patients have never been diagnosed with hypertension.~Has been diagnosed with primary hypertension, but not take any treatment."
9464758|NCT03680313||Control group|A group of normal people with the similar age to hypertension group was recruited as control group at the same time
9464759|NCT03680300|Experimental|Post Facilitating Stretch|Each patient in group A will be given with hot pack along with Tens for 20 mins then the patient will receive post facilitation stretch only, for about one month on daily basis.
9464760|NCT03680300|Experimental|Post Isometric Relaxation|Each patient in group B will receive hot pack along with Tens for 20 mins then the patients will receive post isometric relaxation alone for about one months on daily basis.
9464761|NCT03680300|Experimental|Frictional Massage|Frictional massage will be given to 3rd group
9464762|NCT03680261|Experimental|Adjuvant chemoradiotherapy group|Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
9464763|NCT03680261|Active Comparator|Adjuvant chemotherapy group|Adjuvant chemotherapy (6 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
9464764|NCT03680248|Experimental|Healthy subjects, Fat|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention
9464765|NCT03680248|Experimental|Steatosis, Fat|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention
9464766|NCT03680248|Other|Healthy subjects, Fasting|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting
9464767|NCT03680248|Other|Steatosis, Fasting|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting
9464768|NCT03680248|Experimental|Healthy subjects, Fat+Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration
9464769|NCT03680248|Experimental|Steatosis, Fat+Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration
9464770|NCT03680248|Experimental|Healthy subjects, Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration
9464771|NCT03680248|Experimental|Steatosis, Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration
9464772|NCT03680248|Experimental|Healthy subjects, Fat+Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration
9464773|NCT03680248|Experimental|Steatosis, Fat+Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration
9464774|NCT03680248|Experimental|Healthy subjects, Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration
9464775|NCT03680248|Experimental|Steatosis, Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration
10036816|NCT01819298||bacteria colonization in CAT less 20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores less than 20
10036817|NCT01819298||the PPM in change of CAT >2|the change of potential pathogenic microorganism in CAT difference more than 2 while follow-up
9464776|NCT03680235|Active Comparator|Group I: (standard information about pregnancy, breastfeeding)|Participants receive standard information about pregnancy and breastfeeding. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
9464777|NCT03680235|Experimental|Group II (information about breastfeeding and cancer)|Participants receive standard information about pregnancy and breastfeeding as well as information about breastfeeding and breast cancer. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
9464778|NCT03680222|No Intervention|Standard method|Standard method recommended by the guide
9464779|NCT03680222|Experimental|Reversed Tracking Method|Reversed Tracking Method
9464780|NCT03680183||Pre-exposure|Entecavir 1Mg Oral Tablet
9464781|NCT03680183||Post-exposure|Entecavir 1Mg Oral Tablet
9464782|NCT03680170|Experimental|Working memory updating training|"Training with web-based program on the internet for 30 sessions (4-5 times a week). The result of the training is registered.~Intervention Device: web-based cognitive training"
9464783|NCT03680170|Placebo Comparator|Placebo training|"Low dose, short term memory training. Intervention: Training with computer based program on the internet for 30 sessions (4-5 times a week).~Intervention Device: Web-based cognitive training"
9464784|NCT03680144|Experimental|Diagnostic (MRI, DSC-MRI)|Participants undergo diagnostic magnetic resonance imaging (MRI) with and without contrast and treatment planning dynamic susceptibility contrast-MRI (DSC-MRI) series before receiving SRS at 4-6 weeks after SRS, and then every 3 months unless clinically indicated sooner.
9464785|NCT03680118|Experimental|autogenous rings with GBR and autogenous graft with ti-mesh|Augmentation with autogenous onlay ring blocks covered by guided bone regeneration (GBR) using collagen membrane and autogenous bone graft using titanium mesh (ti-mesh) only
9464786|NCT03680079|Other|Youth with type 1 diabetes|A group of 16 teens (ages 13-18) with poorly -controlled type 1 diabetes will be recruited to participate in this study.
9464787|NCT03680066|Experimental|Foods with traces|Oral food challenge with foods with traces
9464788|NCT03680027|No Intervention|Control Group|In 'Control group' participants had 6 week follow-up without any intervention.
9480922|NCT05175495||Young people diagnosed with coronary heart disease|Aged less than 45 years old,Diagnosed coronary heart disease;Confirmed by coronary angiography;Diagnosed myocardial infarction;Typical symptom of ischemic chest pain with positive stress test;
9464789|NCT03680027|Experimental|Interventional Group|In 'Interventional group' participants had 6 week follow-up and during that period of time, they were asked to consume 40g/day walnut. Participants in intervention group was ensured to consume all 40g of walnut every day, during their snack times for 6 weeks.
9464790|NCT03680014||1|Capable of independent of daily activities and able to mobilise unaided. No previous of falls.
9464791|NCT03680014||2|Capable of independent of daily activities and able to mobilise unaided. With a previous of atleast one fall.
9464792|NCT03680014||3|Requires help with most daily activities, mobilises with a single walking stick. No previous falls.
9464793|NCT03680014||4|Requires help with most daily activities, mobilises with a single walking stick. With a previous of atleast one fall.
9464794|NCT03680014||5|Requires help with most daily activities. Mobilise with frame or roller frame. No previous falls.
9464795|NCT03680014||6|Requires help with most daily activities. Mobilise with frame or roller frame. Previous history of at least one fall.
9464796|NCT03679962|Experimental|Triple Chronotherapy|Four-day intervention, with 24-hour total sleep deprivation, 3-days of sleep phase advancement and daily bright light therapy.
9464797|NCT03679962|Active Comparator|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
9464798|NCT03679949|Placebo Comparator|Placebo|Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
10027743|NCT01735071|Experimental|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
10027744|NCT01735084|Experimental|Prevenar13|The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
10027745|NCT01735084|Experimental|Synflorix|The booster vaccination schedule consists of one dose of 0.5 ml with an interval of at least 1 month between doses.
10027746|NCT01735097|Experimental|Arsenical keratosis (Study)|Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks
10027747|NCT01735097|Active Comparator|Arsenical keratosis (Control)|Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks
10027748|NCT01735110|Active Comparator|Femoral approach group|PCI through Femoral approach
10027749|NCT01735110|Experimental|radial approach group|PCI through radial approach
10027750|NCT01735123|Experimental|extensively hydrolyzed casein formula|The investigators plan to randomize 60 out of 120 infants to be weaned to an extensively hydrolyzed casein formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
10027751|NCT01735123|Experimental|cow's milk based infant formula|The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
10027752|NCT01735136|Experimental|InSan Bamboo Salt|
10027753|NCT01735136|Placebo Comparator|Placebo|
10027754|NCT01735149|Experimental|Kochujang Pills|
10027755|NCT01735149|Placebo Comparator|Placebo|
10027756|NCT01735162||Very high risk|Very high risk PICU patients are on mechanical ventilation and at least one inotrope or vasopressor at time of admission
10027757|NCT01735162||High Risk|High risk PICU patients have a history of transplantation (solid organ or bone marrow)
9464799|NCT03679949|Experimental|Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
9464800|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0)|Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
9464801|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
9464802|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
9464803|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
9464804|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
9464805|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
9464810|NCT03679923|Experimental|NEM® brand eggshell membrane|NEM, 500 mg, #0 capsule, once daily orally for 2 weeks
9464811|NCT03679923|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks
9464812|NCT03679910||Group 1|pancreatic cancer patients (50 patients)
9464813|NCT03679910||Group2|A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
9464814|NCT03679897|Experimental|Ropivacaine group|BPB with 0.375% ropivacaine solution
9464815|NCT03679897|Active Comparator|Levobupivacaine group|BPB with 0.25% levobupivacaine solution
9464816|NCT03679871|Other|Questionnaire validation|"22-items questionnaire Spiritual Resources and Distress"
9464817|NCT03679858||Platelet function test in patients|Platelet function test in patients on antiplatelet therapy
9464818|NCT03679858||Platelet function test in healthy|Platelet function test in healthy subjects
9464819|NCT03679845|Experimental|Sarilumab Arm|200 mg of sarilumab every two weeks
9464820|NCT03679832||Historical Group 1|Patients admitted at UMC between September 2015 and October 2016
9464821|NCT03679832||Historical Group 2|Patients admitted at UMC between November 2016 and up to the beginning of the QIP
9464822|NCT03679832||Nutrition-Focused QIP|Patients admitted at UMC that meet eligibility criteria and prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption 30-days post discharge
9464823|NCT03679819||HR-TRUS|HR-TRUS for the detection of prostate cancer in men scheduled for radical prostatectomy for localized prostate cancer
9464824|NCT03679806|Experimental|Halliwick|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
9464825|NCT03679806|Experimental|Aquatic Plyometric Exercise|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase included.
9464826|NCT03679793|Active Comparator|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger.
9464827|NCT03679793|Experimental|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
9464828|NCT03679754|Experimental|Ad-RTS-hIL-12 + veledimex|Intratumoral Ad-RTS-hIL-12 and oral veledimex
9464829|NCT03679728||First trimester|Group of children from mother affected by Zika virus in the first trimester of pregnancy.
9464830|NCT03679728||Second trimester|Group of Children from mother affected by Zika virus in the second trimester of pregnancy.
9464831|NCT03679715|Experimental|Intervention group|The participants in the Intervention group will be participants of the museum participatory art-based activity.
9464832|NCT03679715|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the museum participatory art-based activity.
9464833|NCT03679702|Other|Active treatment|
9464834|NCT03679689|No Intervention|Control group|no changes in their alimentary habits
9464835|NCT03679689|Experimental|intervention group|no intake of artificially sweetened beverages
9464836|NCT03679676|Other|Cohort A: Omalizumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with placebo
9464837|NCT03679676|Other|Cohort B: Omalizumab/Dupilumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab.
10027758|NCT01735162||Moderate risk|Moderate risk PICU patients are all other admissions to the ICU (may have either mechanical ventilation or inotropy/vasopressor use but not both). Cannot have a history of transplant. Minimum expected stay 48 hours.
10027759|NCT01735188||Living|
9464838|NCT03679676|Other|Cohort C: Dupilumab|Participants will be treated with placebo for 8 weeks, followed by 24 weeks of treatment with dupilumab.
10027760|NCT01735188||Deceased|
10027761|NCT01735227|Experimental|omeprazole group|omeprazole group:all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and taking omeprazole 20mg/d(1 month).on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) .
10027762|NCT01735227|Experimental|pantoprazole group|pantoprazole group: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term),taking pantoprazole 20mg/d(1 month).
10027763|NCT01735240|Experimental|First AZD5069, then Ketoconazole + AZD5069|AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone (on 2 days)
10027764|NCT01735253|Experimental|gastric bypass, duodenojejunal bypass|
10027765|NCT01735266|Active Comparator|Air colonoscopy|Air was insufflated during whole procedure of colonoscope insertion.
10027766|NCT01735266|Experimental|Whole-colon water exchange colonoscopy|The air pump was turned off before colonoscopy. During the whole procedure of the scope insertion, residual air in lumen was suctioned and 37°C (maintained with a water bath) water was infused with a peristaltic pump to obtain lumen visualization. Air was insufflated until cecum was reached or appendix opening was seen.
9464839|NCT03679663|No Intervention|Palpation|Anesthesia performed without ultrasound
9464840|NCT03679663|Experimental|Ultrasound|Anesthesia performed after ultrasound
9464841|NCT03679637|Experimental|Intervention group|Each participant will receive a tablet-based aphasia therapy
9464842|NCT03679598|Active Comparator|Alvelestat (MPH966)|Alvelestat (MPH966) 120mg (4 30mg tablets) twice daily by mouth for 12 weeks
9464843|NCT03679598|Placebo Comparator|Placebo|4 Placebo tablets twice daily by mouth for 12 weeks
9464844|NCT03679585|Experimental|Supportive Care (social media intervention)|Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
9480923|NCT05175495||Coronary heart disease|Older than 65 years, diagnosed with coronary heart disease
10027767|NCT01735266|Experimental|left-colon water exchange colonoscopy|In the left side of colon (including descending colon, sigmoid colon and rectum), water was infused instead of air to obtain lumen visualization as described above in whole-colon water exchange colonoscopy group.
10027768|NCT01735305||Antiplatelet therapy|patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.
10027769|NCT01735318|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
10027770|NCT01735318|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
10027771|NCT01735331||VEGF level|VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
10027772|NCT01735331||control group|Patients with Abnormal Uterine Bleeding
10027773|NCT01735344|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
10027774|NCT01735344|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
10027775|NCT01735357|Placebo Comparator|Olive oil (BP specification)|5g per day
9464845|NCT03679572|Experimental|Robot assisted partial nephrectomy super-selective clamping|The Da Vinci robot (device) allows to use near-infrared fluorescence in order to clamp precisely the branches of the vascularization for the partial nephrectomy. The healthy parenchyma ischemia is avoided.
9464846|NCT03679572|Active Comparator|Robot assisted partial nephrectomy with renal artery clamping|The partial nephrectomy with robotic assistance is performed using a renal artery. It's the conventional method.
9802982|NCT04721691|Placebo Comparator|Placebo|Placebo is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe. The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Placebo at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
9802983|NCT04721665||NAFLD patients|No intervention
10027776|NCT01735357|Experimental|DHA-rich oil|Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
10027777|NCT01735357|Experimental|EPA-rich oil|Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
9464847|NCT03679559|Experimental|Arm I (home-based walking program, resistance training)|Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
9464848|NCT03679559|Experimental|Arm II (home-based Zumba program, resistance training)|Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
9464849|NCT03679559|Experimental|Arm III (HIIT, resistance training)|Participants wear Fitbit and attend supervised HIIT exercise sessions 3 days per week over 12 weeks. Participants receive resistance training as in Arm I.
9464850|NCT03679559|Active Comparator|Arm IV (supervised moderate intensity walking program)|Participants wear Fitbit and attend supervised moderate intensity walking sessions weekly for 50-60 each over 12 weeks. Participants undergo resistance training as in Arm I.
9464851|NCT03679559|Active Comparator|Arm V (usual physical activity)|Participants wear Fitbit and continue their usual physical activity over 12 weeks.
10027778|NCT01735370|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
10027779|NCT01735370|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
10027780|NCT01735383|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
10027781|NCT01735383|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
10027782|NCT01735409|Experimental|1-day regimen|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
10027783|NCT01735409|Experimental|2-day regimen|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
10027784|NCT01735409|Experimental|3-day regimen|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
10027785|NCT01735422|Experimental|r-hLH (825 International Units [IU])|
10027786|NCT01735422|Experimental|r-hLH (2750 IU)|
10027787|NCT01735422|Experimental|r-hLH (5500 IU)|
10027788|NCT01735422|Experimental|r-hLH (11000 IU)|
10027789|NCT01735422|Experimental|r-hLH (22000 IU)|
10027790|NCT01735422|Active Comparator|u-hCG (5000 IU)|
10027791|NCT01735435|No Intervention|Group 2 (Control group)|Group 2(Control group)-patients in this group received nutrition according to the standard hospital dietary regimen.
10027792|NCT01735435|Experimental|Group 1 (Indirect Calorimetry)|Group 1(Indirect Calorimetry)-The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
10027793|NCT01735448||Aboriginal smoker, male, Adelaide|Focus group: Aboriginal smoker, male from Adelaide
10027794|NCT01735448||Aboriginal smoker, female, Adelaide|Focus group: Aboriginal smoker, female, from Adelaide
10027795|NCT01735448||Aboriginal ex/non-smoker, male, Adelaide|Focus group: Aboriginal ex/non-smoker, male, from Adelaide
10027796|NCT01735448||Aboriginal ex/non-smoker, female, Adelaide|Focus group: Aboriginal ex/non-smoker, female, from Adelaide
10027797|NCT01735448||Healthcare workers, Adelaide|Focus group: Healthcare workers who are based in Adelaide and work with Aboriginal patients
10027798|NCT01735448||Healthcare workers, Murray Bridge|Focus group: Healthcare workers who are based in Murray Bridge and work with Aboriginal patients
10027799|NCT01735448||Aboriginal smoker, male, Murray Bridge|Focus group: Aboriginal smoker, male, from Murray Bridge
10027800|NCT01735448||Aboriginal smoker, female, Murray Bridge|Focus group: Aboriginal smoker, female, from Murray Bridge
10027801|NCT01735448||Aboriginal ex/non-smoker, male, Murray Bridge|Focus group: Aboriginal ex/non-smoker, male, from Murray Bridge
9464852|NCT03679546|Experimental|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
10027802|NCT01735448||Aboriginal ex/non-smoker, female, Murray Bridge|Focus group: Aboriginal ex/non-smoker, female, from Murray Bridge
9464853|NCT03679546|Experimental|Vedolizumab|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
9464854|NCT03679533|Active Comparator|Active Cranberry Study Food|
9464855|NCT03679533|Placebo Comparator|Placebo Study Food|
9464856|NCT03679520|Experimental|New programme|A new programme of antenatal parental preparation provided by midwives to groups with 8-16 individuals. It will include 5 sessions á 2 hours and start in gestational week 25.
9464857|NCT03679520|Active Comparator|Regular programme|A regular programme of antenatal parental preparation provided by midwives to groups of 8-16 individuals and encompassing between 5 and 7 hours of antenatal parental preparation.
9464858|NCT03679507|Active Comparator|Group A|The first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device
9464859|NCT03679507|Placebo Comparator|Group B|"Will be treated with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light."
9464860|NCT03679507|Active Comparator|Group B1|The first patient group will receive high CBD oil applied topically to the affected knee joint.
9464861|NCT03679507|No Intervention|Group B2|This group of patients will not receive high CBD oil to the affected joint.
9464862|NCT03679481|Experimental|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
9464863|NCT03679481|Placebo Comparator|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
10027803|NCT01735448||Key community stakeholders|One-on-one interviews with 10 key Aboriginal community stakeholders
10027804|NCT01735448||Respiratory physicians|One-on-one interviews with 10 Respiratory physicians
10027805|NCT01735448||Consultants and General Practitioners|One-on-one interviews with 10 consultants and/or GP's
10027806|NCT01735461|Experimental|Dietary supplement|Calcium Carbonate
9464868|NCT03679455|Experimental|Treatment arm|Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.
9464869|NCT03679442|Experimental|Healthy individuals|Healthy individuals received intravenous N-acetylcysteine (NAC) treatment to investigate its actions on macrophage activation assessed by the markers soluble CD163 and CD206
9464870|NCT03679429||Control group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
10027807|NCT01735474|Placebo Comparator|Placebo|30 people are recruited in order to the inclusion criteria for the study. Placebo controlled.
10027808|NCT01735474|Active Comparator|Manual technique|30 people are recruited in order to the inclusion criteria for the study. Experimental group.
10027809|NCT01735487|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
10027810|NCT01735487|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
10027811|NCT01735487|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
10027812|NCT01735487|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
10027813|NCT01735487|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
10027814|NCT01735500||CAG without PCI|
10027815|NCT01735500||CAG with PCI|
10027816|NCT01735513|Experimental|Transaortic TAVI with EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation with the use of the embolic protection device EmbolX"
10027817|NCT01735513|Active Comparator|Transaortic TAVI without EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation without the use of the embolic protection device EmbolX"
10027818|NCT01735539|Experimental|Old Bolus|15g EAA bolus
10027819|NCT01735539|Experimental|Old Arginine|15g EAA Bolus supplemented with 3g Arginine
10027820|NCT01735539|Experimental|Young Bolus|15g EAA bolus
10027821|NCT01735539|Experimental|Young Pulse|4 x 3.75g Mixed EAA Pulses
10027822|NCT01735539|Experimental|Old Pulse|4 x 3.75g Mixed EAA Pulses
10027823|NCT01735552||Infants requiring PRBCs|Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.
10027824|NCT01735565||Post bone marrow transplant|Patients who are undergoing bone marrow transplant, as well as patients who have completed a bone marrow transplant within the previous year.
10027825|NCT01735578||Premature infants with anemia|Inpatient premature infants at the University of Utah Neonatal Intensive Care Unit (NICU) with Hct < or = to 28 who are being fed and are stable.
9464871|NCT03679429||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined by using the NBI function of the scope.
9464872|NCT03679403||ADHD Probands|Subjects with DSM-IV ADHD who received the same MRI and CANTAB+CPT assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at the estimated age of 15-25.
10027826|NCT01735591|Experimental|Probiotic|Capsules with 3x10^9 colony forming units (Lactococcus lactis PB 411 - 50%; Lactobacillus casei PB 121 - 25%; Lactobacillus acidophilus PB 111 - 12,5%; Bifidobacterium bifidum PB 211 - 12,5%). 1 capsule a day from inclusion until liver transplantation
10027827|NCT01735591|Placebo Comparator|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
10027828|NCT01735604|Experimental|anti-CD20-CAR T cell|Arm 1 Patients receive anti-CD20-CAR lentiviral vector-transduced autologous T cells with 41BB vector for 3-5 days in the absence of disease progression or unacceptable toxicity.
10027829|NCT01735643|Experimental|interactive videogame intervention|
10027830|NCT01735643|Experimental|waiting group|
10027831|NCT01735656|Experimental|DK-culotte & Resolute stents|Double kissing culotte technique for true bifurcation lesion with Resolute stents
9464873|NCT03679403||Unaffected siblings of ADHD|The unaffected siblings received the MRI and CANTAB+CPT assessments during 2013.8-2015.7 (NCT01682915) will be recruited and assessed.
9464874|NCT03679403||Neurotypicals Follow-up|Subjects without any lifetime diagnosis of DSM-IV ADHD or other psychiatric disorders as the control group of the ADHDFU group around 4-8 years ago when they received the same MRI and neuropsychological assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at their estimated age of 15-25.
9464875|NCT03679390|Experimental|10-20 y/o|We will include the teenagers who need intravenous general anesthesia(IVGA), and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
9464876|NCT03679390|Experimental|20-40y/o group|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
9464877|NCT03679390|Experimental|>70 y/o|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
9464878|NCT03679377|Experimental|Mandibular slotplate|Mandibular slotplates are placed during BSSO surgery and their clinical usefullness is tested. Afterwards the plates are removed and the osteotomy is fixated by three bicortical screws.
9464879|NCT03679364||LUOTAI group|LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.
9464880|NCT03679364||Control group|Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.
9464881|NCT03679338|Other|Ablation Therapy With Bipolar Radio Frequency|
9464882|NCT03679325|Active Comparator|vitamine D|a dose once a week
9464883|NCT03679325|Placebo Comparator|vitamine D placebo|a dose once a week
9464884|NCT03679286||All subjects|No intervention
9464885|NCT03679273|Experimental|Abound supplement|The participant will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
9464886|NCT03679273|No Intervention|Traditional supplement|The participant will take traditional diabetes-specific formula as provided by dietitians.
9464887|NCT03679234|Experimental|Intervention|Routine infant formula
10027832|NCT01735656|Active Comparator|DK-crush & Resolute stents|Double kissing crush technique for true bifurcation lesion with Resolute stents
9464888|NCT03679208|Experimental|Stage 1 Safety cohort|Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.
9464889|NCT03679208|Experimental|Stage 2 Performance (test group)|One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.
9464890|NCT03679208|Active Comparator|Stage 2 Performance (control group)|One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.
9464891|NCT03679195|Experimental|NO Ultra (Nitric Oxid Ultra Capsules)|764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline. Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
9464892|NCT03679195|Placebo Comparator|Placebo (Cellulose Capsules)|Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
9464893|NCT03679182|Experimental|Olanzapine|Olanzapine 5 mg at 0, 12, 24 and 36 hours
9464894|NCT03679169|Experimental|Group RAMPS|Radical antegrade modular pancreatosplenectomy
9464895|NCT03679169|Active Comparator|Group SPS|standard pancreatosplenectomy
10027833|NCT01735669|Experimental|Remifentanil|External cephalic version at term under Remifentanil perfusion
10027834|NCT01735669|Active Comparator|Nitrous oxide|External cephalic version at term under Nitrous oxide inhalation
10027835|NCT01735682|Experimental|Whole body vibration|This group will receive whole body vibration and conventional exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
10027836|NCT01735682|Active Comparator|Conventional exercise|This group will receive convention exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
10027837|NCT01735682|Active Comparator|Control|This group will have exercise training that involve only the upper limbs (about 30 minutes per session, 3 sessions per week, for 8 consecutive weeks).
9464896|NCT03679143|Experimental|ZSP1273(single dose)-100 mg(Cohort 1)|ZSP1273 100 mg /Placebo
9464897|NCT03679143|Experimental|ZSP1273(single dose)-200 mg(Cohort 2)|"ZSP1273 200mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1."
9464898|NCT03679143|Experimental|ZSP1273(single dose)-400 mg(Cohort 3)|"ZSP1273 400mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2."
9464899|NCT03679143|Experimental|ZSP1273(single dose)-600 mg(Cohort 4)|"ZSP1273 600 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3."
9464900|NCT03679143|Experimental|ZSP1273(single dose)-900 mg(Cohort 5)|"Drug:ZSP1273 900 mg/Placebo 900mg；~Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4."
9464901|NCT03679143|Experimental|ZSP1273(single dose)-1200 mg(Cohort 6)|"ZSP1273 1200 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5."
9464902|NCT03679143|Experimental|ZSP1273(Food Effect)-Cohort 7|"Drug:ZSP1273 /Placebo； Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8."
9464903|NCT03679143|Experimental|ZSP1273(multiple doses)-Low Dose(Cohort 8)|"while fasted or fed according to the results of Cohort FE~ZSP1273 /Placebo for 5 Days."
10027838|NCT01735708|Placebo Comparator|Health Education|Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
10027839|NCT01735708|Active Comparator|HIVPASS Intervention|Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.
9464904|NCT03679143|Experimental|ZSP1273(multiple doses)-Median Dose(Cohort 9)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
9464905|NCT03679143|Experimental|ZSP1273(multiple doses)-High Dose(Cohort 10)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
9464906|NCT03679130|Experimental|Structured exercise training (EXE)|Structured supervised exercise training (EXE) contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
9464907|NCT03679130|Experimental|Motivational counseling (MOT)|Motivational counseling supported by health technology (MOT) contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
9464908|NCT03679130|No Intervention|Control group (CON)|Control group receiving standard treatment.
9464909|NCT03679117|Experimental|Mindfulness Training|Phone-delivered mindfulness training
9464910|NCT03679117|No Intervention|Treatment as Usual|Prenatal care
9464911|NCT03679104|Active Comparator|Endoscopic clips|Closure of mucosotomy using endoscopic clips
9802984|NCT04720443|Experimental|SAD Part 1 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 10 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
10027840|NCT01735721|Active Comparator|Open Sinus Lift with DFDBA|In each patient, one sinus was chosen at random and filled with DFDBA (Tissue Regeneration Corporation, Iran).
9464912|NCT03679104|Active Comparator|OverStitch™ suturing device|Closure of mucosotomy using OverStitch™ suturing device
9464913|NCT03679065|Active Comparator|P (Paracetamol) group:(n=100)|
9464914|NCT03679065|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
9464915|NCT03679065|Placebo Comparator|Placebo|
9464916|NCT03679052|Active Comparator|Group I (Mirtazapine group): (n=100)|
9464917|NCT03679052|Active Comparator|Group II (Clonidine group): (n=100)|
9464918|NCT03679052|Placebo Comparator|Group III (Control group): (n=100)|
9464919|NCT03679013|Other|Opoid based standard of care regimen.|Inova Heart and Vascular Institute (IHVI) opioid based standard of care regimen given for post operative cardiac surgery pain.
9464920|NCT03679013|Experimental|Opioid sparing pain regimen.|Multimodal pain regimen consisting of PO Gabapentin paired with intravenous Acetaminophen given for post operative cardiac surgery pain.
9464921|NCT03679000||The reproductive health of couples|The study is a prospective cohort study, and its participants are childbearing couples who are seeking assisted reproductive technologies for having a baby in the reproductive center in Tongji Hospital.The study is a observational study.
9464922|NCT03678987||SSc on MMF|"Patients with systemic sclerosis using mycophenolate mofetil (mycophenolic acid, MMF) since >3 months.~During a 6 hour time period, P-MPA concentration will be measured 4 times."
9464923|NCT03678974|Experimental|Exercise|Subjects will receive metabolic testing, exercise prescription, YMCA memberships, and physician based on Intensive Behavioral Therapy for Obesity utilizing CardioCoach app.
9464924|NCT03678961||Group N|Neutral position
9464925|NCT03678961||Group E|External rotation of leg by 45 degrees
9464926|NCT03678961||Group EF45|External rotation of leg by 45 degrees, hip flexion by 45 degrees, and knee flexion by 45 degrees
9464927|NCT03678961||Group EF15|External rotation of leg by 45 degrees, hip flexion by 15 degrees, and knee flexion by 15 degrees
9464928|NCT03678948|Active Comparator|Radiofrequency-Based Debridement|The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
9464929|NCT03678948|Active Comparator|Mechanical Debridement|
9464930|NCT03678935|Active Comparator|Low FODMAP diet (LFD)|The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
10027841|NCT01735721|Experimental|Open Sinus Lift with Algipore|The contra lateral sinus was filled with Algipore (Dentsply, USA).
10027842|NCT01735734||Capillary malformation|
10027843|NCT01735747|Experimental|Temozolomide, Nedaplatin, Vincristine, Radiotherapy|The newly diagnosed PCNSL patients will be given concurrent temozolomide (75mg/m2, orally) daily during WBRT. Then, the TNV regimen will be given after four weeks. TNV regimen consisted of temozolomide (200mg/m2 orally, days 1-5), nedaplatin (80mg/m2 i.v., day 1), vincristine (1.4mg/m2 i.v., day 1). Each cycle was 4 weeks and a maximum of six cycles were applied.
10027844|NCT01735760||Palpation|The group using palpation as primary attempt at localizing the cricothyroid membrane
10027845|NCT01735760||Ultrasonography|The group using ultrasound for their primary approach to localizing the cricothyroid membrane
10027846|NCT01735773||Hemodialysis group|Patients on chronic hemodialysis program
10027847|NCT01735773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
10027848|NCT01735773||Pre-dialysis group|Patients with chronic kidney disease stage-4
9464931|NCT03678935|No Intervention|Control|Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
10027849|NCT01735773||Control group|Healthy volunteers
10027850|NCT01735786||Treatment group|Subjects in this group will received Endoclot treatment immediately after EMR.
10027851|NCT01735786||Control group|Subjects in this group will not received any hemostasis treatment after EMR.
10027852|NCT01735812|Experimental|symptomatic UF|
10027853|NCT01735825|Experimental|paclitaxel-coated balloon|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter (iopomide coating)
9464932|NCT03678909||Hypoplastic Left Heart Disease|Patients with congenital hypoplastic left heart disease who will undergo surgical palliation with Norwood procedure or DKS or Damus-Kaye-Stansel procedure
9464933|NCT03678896|Experimental|CrewD Program approach|"The aim was to increase education about the disease by using narrative skills through the CrewD Program. The sessions were conducted by two group leaders: a health professional and a literature professor manager of creative writing groups.~Each session had a title, which parallels the classical structured educational approach (active comparator condition), which was known in advance by the subjects: a) Who I am in Diabetes?; b) Nutrition; c) The body where I live; d) Fears; e) Can attention change things?; and f) Roots.~Team leaders directed a discussion of different texts used in the sessions with the participants focusing on their feelings and on how the texts relate to themselves and to their diabetes. Patients were encouraged to participate and freely express their opinion."
9464934|NCT03678896|Active Comparator|Classical structured education|"Each session was 90 minutes long, with a similar internal structure in all of them. Each session included the following topics: a) Chronic Disease; b) Nutrition; c) Exercise; d) Complications; e) Self-management; and f) Diabetic foot. The sessions were held in a large room, in which the seats were arranged in circle. Every session was chaired by two healthcare providers, who worked as group leaders.~There was a different visual presentation in each session, with relevant theoretical information. A board with sheets of paper was available for use in the discussion along with brochures about the disease.~Patients were encouraged to actively participate and take part in group-problem solving. Group leaders guided the discussion by asking questions and encouraging the discussion."
9464935|NCT03678857|Experimental|Creatine Before|Receives Creatine before and placebo after training.
9464936|NCT03678857|Experimental|Creatine After|Receives creatine after and placebo before training.
9464937|NCT03678844|Experimental|Taekwondo practice|
9464938|NCT03678844|Placebo Comparator|CONTROL|
9464939|NCT03678831||Arthritic patients with knee prosthetic replace|Arthritic post-menopausal patients with knee prosthetic replacement Each patient is her own control since the two cell types are compared within the same patient The main criteria is based on a comparison of two cell types from the same patient. The secondary criteria are based on a comparison of cell types according to a grouping of patients according to different metabolic parameters.
9464940|NCT03678818|Experimental|Handling Medium Supplemented with Latrunculin A|
9464941|NCT03678818|No Intervention|Handling Medium as it is.|
9464942|NCT03678792|Other|Buprenorphine-Naloxone|Standard of Care
9464943|NCT03678792|Experimental|Morphine|
9464944|NCT03678792|Experimental|Tramadol|
9464945|NCT03678779|Experimental|Incentive|Each week parents received one $5 grocery store gift card per child in the household, intended for the purchase of healthy snacks, donated to the study by a partnering grocery store
9464946|NCT03678779|Experimental|Education|Parents received brief weekly nutrition education videos (approximately one minute in length, uploaded on YouTube and viewable on most operating systems and on mobile devices
9464947|NCT03678779|Experimental|Combined|Parents received both the Incentive and Education arm interventions
9464948|NCT03678714|Experimental|Exercise Intervention|Structured exercise intervention will be undertaken for 12 weeks
9464949|NCT03678714|Experimental|Lifestyle Physical Activity|Increased lifestyle physical activity undertaken for 12 weeks
9464950|NCT03678714|No Intervention|Control|Resting control
9464951|NCT03678701|Experimental|Protein group|The protein group will consume 30g of 100% whey protein shake 1 hour before lunch and before dinner, for 12 weeks
9464952|NCT03678701|No Intervention|Control group|Control group will not consume any protein supplements. They will continue the usual feeding habits
9464953|NCT03678675|No Intervention|Standard Protocol|Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain.
9464954|NCT03678675|Experimental|Ketorolac Protocol|Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 5 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room.
9464955|NCT03678662|Experimental|hyperalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-enhancing effects.
9464956|NCT03678662|Experimental|hypoalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-diminishing effects.
9464957|NCT03678662|Active Comparator|Neutral|In this group the subjects expectations are not manipulated
10027854|NCT01735825|Active Comparator|drug eluting stent|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
10027855|NCT01735825|Other|seal-wing paclitaxel-eluting balloon catheter|"Observational, non-randomised arm:~Pts with ISR treated by seal-wing paclitaxel-eluting balloon catheter"
10036818|NCT01819298||the change of CAT<=2|the change of potential pathogenic microorganism in CAT difference less than or equal to 2 while follow-up
10036819|NCT01819298||PPM in CAT>=20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores more than or equal to 20
10036820|NCT01819324|Experimental|Targeting the Teachable Moment|Receiving Targeting the Teachable Moment Intervention materials (focusing on health behaviors and issues specific to breast cancer survivors) every other week for 4 months
9464958|NCT03678649|Experimental|the treatment arm|"1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .~it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
9464959|NCT03678649|No Intervention|the control arm|clinical observation
10027856|NCT01735851|Active Comparator|Thoracic epidural analgesia|Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
10027857|NCT01735851|Experimental|Bilateral Paravertebral block|Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
9479924|NCT03538574|Experimental|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
9479925|NCT03538548|Experimental|Treatment|Participants receive a standard 12-week course of Cognitive Behavioral Therapy for Relapse Prevention (CBT-RP; Carroll, 1998). The treatment protocol will be implemented over 12 weeks, with two 1-hour sessions per week for the first two weeks and one 1-hour session per week thereafter (i.e., a total of 14 sessions).
9479926|NCT03538535|Experimental|Go/No-Go Active Learning (GOAL)|Adaptation of Behavioral Activation, focused on reinforcement learning strategies.
9479927|NCT03538522|Experimental|Low-dose N-831(Traneurocin)- 10 mg QD|Oral administration of 10 mg of NA-831 (Traneurocin) per day for 24 weeks
9479928|NCT03538522|Experimental|Medium-dose NA-831(Traneurocin)- 20 mg QD|Oral administration of 20 mg of NA-831(Traneurocin) per day for 24 weeks
10027858|NCT01735864|Active Comparator|Indirubin 200 μg/g|per gram of ointment contains 200 μg of indirubin
10027859|NCT01735864|Active Comparator|Indirubin 100 μg/g|per gram of ointment contains 100 μg of indirubin
9479929|NCT03538522|Experimental|High-dose NA-831(Traneurocin)- 40 mg QD|Oral administration of 40 mg of NA-831(Traneurocin) per day for 24 weeks
9479930|NCT03538522|Placebo Comparator|Placebo|Oral administration of placebo per day for 24 weeks
9479931|NCT03538496|Active Comparator|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine
10027860|NCT01735864|Active Comparator|Indirubin 50 μg/g|per gram of ointment contains 50 μg of indirubin
9479932|NCT03538496|Active Comparator|ultrasound guided paravertebral block|ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine
10027861|NCT01735864|Active Comparator|Indirubin 10 μg/g|per gram of ointment contains 10 μg of indirubin
10027862|NCT01735890|Experimental|CJ Amlodipine/Valsartan 10/160mg|
9479933|NCT03538483|Active Comparator|ultrasound guided serratus plane block|Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
9479934|NCT03538483|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
9479935|NCT03538470|Experimental|Spa treatment|Mineral water cares in Contrexéville thermal cure center, massage, cataplasm.
9479936|NCT03538418|Experimental|WAT group|The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
9479937|NCT03538418|No Intervention|Control group|The control group will receive a 3-month exercise training programme without a WAT, which also includes 12 weekly exercise training sessions (an hour each) in addition to 7 face-to-face and telephone sessions offering support for BCTs.
9479938|NCT03538405|Experimental|all participants|All participants received the same interventions, there were no subgroups interventions: supporting cushions and harmonic techniques
9479939|NCT03538392||PAD|
9479940|NCT03538392||AV Fistula|
9479941|NCT03538392||AV Graft|
9479942|NCT03538379|Active Comparator|Combat Application Tourniquet (CAT)|The combat application tourniquet (CAT) is the type of commercial tourniquet taught in the B-Con course as administered by the investigators. It will serve as the control group to which all other types of tourniquets, which are not explicitly taught in the course, are compared to.
9479943|NCT03538379|Active Comparator|Sof Tourniquet (Sof-T)|The Sof-Tourniquet (Sof-T) is a commercial windlass type tourniquet similar to the CAT tourniquet in that it is based on a windlass mechanism. Its application not explicitly taught in the B-Con course.
9479944|NCT03538379|Active Comparator|Stretch-Wrap-And-Tuck (SWAT) Tourniquet|The Stretch-Wrap-And-Tuck (SWAT) Tourniquet is a commercial elastic tourniquet. Its application not explicitly taught in the B-Con course.
10027863|NCT01735890|Active Comparator|Novartis Exforge 10/160mg|
9464962|NCT03678623||Office-based workers|Individuals working in an office environment with their main tasks involving use of a computer, reading, phoning, making presentations and participating in meetings, who perform more than 30 hours per week mostly sitting at a computer.
10027864|NCT01735968|Experimental|STI571 (imatinib mesylate) and BYL719|The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
9464963|NCT03678610|Experimental|ICSI medium supplemented with Ionomycin and Latrunculin A|
9464964|NCT03678610|No Intervention|ICSI medium as it is|
9464965|NCT03678597|Experimental|Handling Medium Supplemented with Latrunculin B|
9464966|NCT03678597|No Intervention|handling Medium as it is.|
9464967|NCT03678584|Experimental|Handling Medium Supplemented with Chaetoglobosin A|
9464968|NCT03678584|No Intervention|handling Medium as it is.|
9464969|NCT03678571|Experimental|Latrunculin A supplemented vitrification medium|
9464970|NCT03678571|No Intervention|Vitrification medium with no supplementation|
9464971|NCT03678558|Experimental|Cytochalasin B supplemented vitrification medium|
9464972|NCT03678558|No Intervention|Vitrification medium with no supplementation|
9464973|NCT03678532|Experimental|Daily interruption of sedation (control group)|Control group received daily interruption of sedation. After intubation, patients received IV infusion of midazolam. 1-2 mg / hour with increments 1-2 mg/hr gradually increasing dose till RASS reached -4 or -5. Infusion stopped at 7:00 AM. If the patient is awake no need for resuming infusion. If signs of discomfort occurred, infusion resumed at half of the prior dose, targeting conscious sedation (RASS 0: -3)
9464974|NCT03678532|Experimental|No sedation|Intervention group were managed by no-sedation strategy. Patients received bolus doses of midazolam (1-5 mg) only when needed, after atrial to control agitation by correcting the underlying cause. If the patient needed more than 3 bolus doses , IV infusion of midazolam was given by the daily interruption protocol as in the control group. No crossover was allowed between groups. Analysis was done by intension-to-treat principle.
9464975|NCT03678519||Exposed workers|Flour mills workers exposed to health hazards
9464976|NCT03678480|Experimental|HTD1801 500 mg BID (twice daily), or 1000 mg/day|HTD1801 tablets in double-blind capsules, 250 mg
9464977|NCT03678480|Active Comparator|Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day|UDCA tablets in double-blind capsules, 250 mg
9464978|NCT03678467|Experimental|EB-CMF Implant|Subject receiving EB-CMF implant
9464979|NCT03678441|Experimental|Group I (BrainCheck and paper and pen cognitive assessment)|Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.
9464980|NCT03678441|Active Comparator|Group II (pen and paper and BrainCheck cognitive assessment)|Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.
9464981|NCT03678428|Experimental|FUDR/Oxaliplatin HAI plus irinotecan|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
9464982|NCT03678428|Active Comparator|FOLFOXIRI|"Patients will receive Systemic FOLFOXIRI every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15."
9464983|NCT03678415|Experimental|Control|In the control arm, the community healthcare providers serve usual health education like counseling as they provided in perinatal period of enrolled mothers regular follow up basis. This health education is different from developed intervention. But service provider does not know. The investigators select community clinic before provide training regarding training manual. For this, the investigators selected 11 cluster randomly among the 23 community clinics' in the primary health care in study area and provide common health education instructions to the enrolled mothers. But service providers does not know the intervention package services that will provide in intervention arm's service providers.
9464984|NCT03678376|Other|complaint, cognitive and functional assessments|All patients will be included in a single arm. They will complete an evaluation with their General Practitioner, followed by an evaluation at the Memory Clinic with a specialist (neurologist, geriatrician or psychiatrist).
10027865|NCT01736007|Sham Comparator|Liquid light guide tip on laser|Excimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
9464985|NCT03678363|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
10027866|NCT01736007|Active Comparator|308-nm excimer laser to alopecia patch|Laser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
10027867|NCT01736020|Placebo Comparator|Placebo|Placebo
10027868|NCT01736020|Experimental|Dexmedetomidine|Dexmedetomidine intravenous infusion during scan.
10027869|NCT01736020|Experimental|Propofol|Propofol intravenous infusion during scan.
10027870|NCT01736020|Experimental|Ketamine|Ketamine intravenous infusion during scan.
10027871|NCT01736020|Experimental|Nitrous Oxide|Nitrous Oxide inhalation during scan.
10027872|NCT01736033|Placebo Comparator|Tamsulosin + Placebo|Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression
10027873|NCT01736033|Active Comparator|Tamsulosin + Finasteride|Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression
9464986|NCT03678363|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
10027874|NCT01736046||Crohn's Disease patients|All patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
10027875|NCT01736072|Active Comparator|Laparoscopic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Standard Laparoscopic Surgery.
9464987|NCT03678337||Observational cohort with plasma samples|
9464988|NCT03678324|Other|Fabry|Must be 18 or older and able to have an MRI.
9464989|NCT03678272|Active Comparator|HERNIOPLASTY WITH PANAVALE MESH|Preformed polypropylene mesh.
9464990|NCT03678272|Active Comparator|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Mesh consisting of mono lament polyester with a resorbable polylactic acid (PLA) microgrip technology.
9464991|NCT03678272|Active Comparator|HERNIOPLASTY WITH ADHESIX MESH|Self-adhesive mesh.
9464992|NCT03678272|Active Comparator|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh.
9464993|NCT03678246|Experimental|LSFOI (Ramped)|LSFOI (Ramped)
9464994|NCT03678246|Active Comparator|LSFOI (Supine)|LSFOI (Supine)
9464995|NCT03678233|Active Comparator|Intervention|AndroGel® AndroGel 16.2 mg/L will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women
9464996|NCT03678233|No Intervention|Control|In the control group, AndroGel will not be administered.
9464997|NCT03678220|Experimental|Patients using LapAR system|
9464998|NCT03678207||Potential Undiagnosed HTN|
9464999|NCT03678194|Experimental|Smartphone application|This group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up). The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence…
9465000|NCT03678194|No Intervention|Standard services|This group of patients receives conventional treatment only. Clinical evaluations are provided at the same endpoint. Patients still receive standard services for depression.
9465001|NCT03678168|Other|Control|Standard care (Throat pack) which will be used as a control.
9465002|NCT03678168|Experimental|Intervention|Pharyngeal tampons which will be used as a comparator against throat pack.
9465003|NCT03678155|Active Comparator|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
9465004|NCT03678155|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
9465005|NCT03678116|Placebo Comparator|Sugar Pill (Placebo)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
9465006|NCT03678116|Experimental|Caffeine (plus Teacrine and Cayenne)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
9465007|NCT03678116|Experimental|Caffeine (plus Teacrine)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
9465008|NCT03678090|Active Comparator|tPA standard dosage|Tissue Plasminogen Activator (tPA) dose of 10 to 25 mg.
9465009|NCT03678090|Experimental|tPA low dosage|tPA dose of 2.5mg
9465010|NCT03678077||Mild traumatic brain injury|"Patients between 18-60 years, who were hospital admitted, emergency or outpatient treated with mild traumatic brain injury (ICD-10 S06.0). Data were extracted from the Danish national patient register from January 2003 - December 2007.~Patients who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
9465011|NCT03678077||Matching controls|"Matching controls without concussion of the same age, from the same municipality and of same gender as the included cases. Controls were included during 2003 - 2007. Data were extracted from the population register.~Controls who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
9465012|NCT03678064|Experimental|Lokomat|16 sessions total. Provided by study PT twice weekly for 8 weeks.
9465013|NCT03678051|Active Comparator|Treatment as Usual (TAU)|Standard of care
9465014|NCT03678051|Experimental|TAU+CBT4CBT|TAU with access to the CBT4CBT program
9465015|NCT03678038|Experimental|rotator interval injection|patient received ultrasound-guided steroid injection via rotator interval
9465016|NCT03678038|Active Comparator|posterior recess injection|patient received ultrasound-guided steroid injection via posterior recess
9465017|NCT03678012|Active Comparator|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
9465018|NCT03678012|Placebo Comparator|Hydrogen peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
9465019|NCT03678012|Sham Comparator|Water|Sham solution (water; negative control)
9465020|NCT03677999||Brain tumor patients with Glioma|"Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.~Passed the safety screen for MRI~Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI."
9465021|NCT03677960|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
9465022|NCT03677960|Experimental|Dose 2 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
9465023|NCT03677960|Experimental|Dose 3 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
9465024|NCT03677921|Experimental|Investigational Group- Bio-Germanium|"Ingredient: Bio-Germanium~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~Duration of use: 8 weeks"
10027876|NCT01736072|Active Comparator|Robotic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Robotic Assisted Laparoscopic Surgery.
9465025|NCT03677921|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Corn starch~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day~Duration of use: 8 weeks"
9465026|NCT03677908||13 high|High-Density ElectroEncephaloGraphy analysis of 13 healthy premature infants
9465027|NCT03677908||15 low|Low-Density ElectroEncephaloGraphy analysis of other 15 healthy premature infants
10027877|NCT01736098|Experimental|High Energy Flux|Energy Flux Exercise Intervention: 7kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
10027878|NCT01736098|Experimental|Medium Energy Flux|Energy Flux Exercise Intervention: 3.5kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
10027879|NCT01736098|No Intervention|Low Energy Flux|No Intervention: maintain normal lifestyle
10027880|NCT01736111|Experimental|Personal feedback|"This arm will receive all intervention components of Active Comparator group, plus the following:~Text messages to prompt participant to reply with self-monitoring entries~Human coach uses system to send personalized text messages with feedback on self-monitoring entries"
10036821|NCT01819324|Active Comparator|Standardized Lifestyle Management|Receiving Standardized Lifestyle Management materials (focusing mostly on health behaviors) every other week for 4 months
10036822|NCT01819324|No Intervention|Usual Care|Receiving SLM materials at the end of the 7 months
9465028|NCT03677895|Experimental|patients with rotator cuff disorders|patients with rotator cuff disorders, including impingment, rotator cuff disorders and rotator cuff tear receiving hyaluronic acid injection over subacromial bursa
9465029|NCT03677882|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
9465030|NCT03677882|Experimental|Treatment As Usual with Mind-Body Bridging (TAU + MBB)|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator.
9465031|NCT03677856|Experimental|Paravertebral Blockade|Anaesthesia to single side of the patient's chest
9465032|NCT03677856|Active Comparator|Thoracic epidural block|Anaesthesia to both sides of the patient's chest
9465033|NCT03677843||cerebral palsy|They are included in GMFCS level 3, 4, 5. and they have diplegia or quadriplegia
9465034|NCT03677778|Placebo Comparator|Placebo group|This control group will have no normal saline injected into their nerve catheter (no intervention). This group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
9465035|NCT03677778|Active Comparator|Treatment group|This group will have 30ml normal saline injected into their nerve catheter. The treatment group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
9465036|NCT03677765|Active Comparator|Infraclavicular group|In the infraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle.
9465037|NCT03677765|Active Comparator|Supraclavicular group|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
9465038|NCT03677752|Experimental|GP_Posit|Participants allocated to this arm will receive the GP_Posit intervention.
9465039|NCT03677752|No Intervention|Control|Participants in the control arm will receive usual care.
9465040|NCT03677726|Experimental|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
9465041|NCT03677726|Active Comparator|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise of eight weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
9465042|NCT03677687|Experimental|Mindfulness for Physical Activity|A 6-week mindfulness programme (2 hours per week) aimed at increasing physical activity in underactive participants.
9465043|NCT03677674|Experimental|dehydrated|The participants will be dehydrated (at least 2% of their body weight) before performing the Sterkowicz test.
9465044|NCT03677674|No Intervention|euhydrated|The participants will be normally hydrated (= euhydration) before performing the Sterkowicz test (i.e. no specific intervention will be implemented).
9465045|NCT03677661|Active Comparator|Conventional approach|Graded aerobic exercise and advice for graded cognitive stimulation approach based on the 2016 Berlin consensus
9465046|NCT03677661|Experimental|Personalized rehabilitation program|Cervico-vestibular rehabilitation personalized patient-centered clinical program combined with the exercise and advice of the conventional approach
9465047|NCT03677635|Experimental|Intervention|Guided autobiographical memory recall to enhance specificity and links to the future.
9465048|NCT03677635|No Intervention|Control|Recall without prompts or psychoeducation video.
9465049|NCT03677622|Experimental|Stroke volume (SV) group|"As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:~A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%.~The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery."
9465050|NCT03677622|Active Comparator|Restricted group|"Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml.~Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.~Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.~In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.~Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis."
9465051|NCT03677609|Experimental|Intervention|Physicians will receive a training or trainings to improve their communication and interaction with patients. The primary trainings will involve teaching physicians how to understand and leverage patient psychology as part of clinical care. Impact on patient health will then be assessed.
9465052|NCT03677609|No Intervention|Control|
9465053|NCT03677583|Experimental|Duckweed|daily lunch with 150-180g wet weight duck weed
9465054|NCT03677583|Active Comparator|Spinach|daily lunch with 150-180g wet weight spinach
9465055|NCT03677570||Female athletes|A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
9465056|NCT03677570||Healthy Control|15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
9465057|NCT03677557|Other|Cutaquig Intervention|Participants with primary or secondary immunodeficiency disease who are currently on subcutaneous immunoglobulin treatment but have developed adverse events including allergic reaction and are willing to change the treatment product to 16.5% Cutaquig.
9465058|NCT03677544||exploratory cohort (A)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation. procedures were performed between 1980 and 2013
9465059|NCT03677544||exploratory cohort (B)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
9465060|NCT03677531|Experimental|Other (radiation therapy, videos)|Participants undergo daily radiation therapy and watch videos/movies of their choice during treatments.
9465061|NCT03677505|Experimental|KoMAC group|Orotracheal intubation with KoMAC videolaryngoscope
9465062|NCT03677505|Active Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscope
9465063|NCT03677492|Experimental|Handling Medium Supplemented with Cytochalasin D|
9465064|NCT03677492|No Intervention|Handling Medium as it is.|
9465065|NCT03677479|Experimental|socket preservation with camelline bone|natural hydroxyapatite derived from camels prepared by investigator
9465066|NCT03677479|Active Comparator|socket preservation with bovine bone|natural hydroxyapatite derived from cows (Bio-Oss)
9465067|NCT03677466|Experimental|Pharmaco-invasive strategy|Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
9465068|NCT03677466|Active Comparator|Primary PCI|Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
9465069|NCT03677453|Active Comparator|IPTP|Patients will have access to the web-based interactive teaching tool.
9465070|NCT03677453|No Intervention|Non-IPTP|Patients will not have access to the web-based interactive teaching tool.
9465071|NCT03677440|Experimental|Treadmill Walking Exercise Training|"This condition will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise training based on ACSM guidelines for maximizing adaptations with exercise training. Exercise intensities will be prescribed based on percent oxygen consumption reserve (% VO2R) using values derived from the baseline graded exercise test.~The exercise training itself will be led by trained exercise leaders who are not involved in the collection of outcome assessments. At the outset of each session, participants will be fitted with a Polar HR Monitor (Oy, Finland), and HR will be monitored continuously throughout each session. Each session will begin with a 5-10 min warm-up, followed by the exercise; the target heart rate reserve (HRR) range associated with the VO2R range will be maintained for as long as possible during each exercise period. This will be followed by a 5-10 min cool-down."
9479945|NCT03538379|Active Comparator|Rapid Application Tourniquet (RAT)|The Rapid Application Tourniquet (RAT) is a commercial elastic tourniquet similar to a bungee cord. Its application not explicitly taught in the B-Con course.
9479946|NCT03538379|Active Comparator|Improvised Tourniquet|The improvised tourniquet arm will involve participants being given supplies to enable them to fashion a tourniquet. The supplies will include a leather belt, gauze, shoestring, and a rod to act as a windlass.
9479947|NCT03538366|Experimental|Donor FMT|Fecal transplant from unrelated, healthy volunteers
9479948|NCT03538353|Other|Pain Education Video|Participants will watch a pain education video and then answer several questions.
9479949|NCT03538340|Active Comparator|Control Arm|Control Arm: Surgery without intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
9465072|NCT03677440|Active Comparator|Stretching-and-Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities using the same frequency and duration of the treadmill walking exercise condition. These activities will be based on a manual provided by the National Multiple Sclerosis Society and sessions will be led by trained exercise leaders who are not involved in the collection of outcome assessments. Activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. The progression of activities over the 3-month period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands that provide minimal resistance. Each session is designed to last up to 60 minutes in total. Each session will begin with a warm-up of up to 10 minutes, followed by stretching-and-toning (following the same duration as the treadmill walking exercise training condition) activities, and a cool-down of up to 10 minutes.
9465073|NCT03677427|Experimental|5 fractions|
9465074|NCT03677427|Experimental|15 fractions|
9465075|NCT03677362|Experimental|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
10027881|NCT01736111|Active Comparator|One Way Text|"Printed handouts from the Aim for a Healthy Weight booklet, which is published by National Heart, Lung, and Blood Institute and is frequently included in control conditions in primary care-based weight loss studies.~Other handouts will discuss the use of prepackaged foods as well as setting goals for calorie intake, physical activity, and weight loss.~One to three text messages per week, based on topics from Aim for a Healthy Weight and other sources. The text messages will be pre-scheduled, automated, non-tailored, and one-way (no reply will be requested). The total dose of contact will be low because each text message is limited to 160 characters. The condition is comparable in intensity to control conditions in other weight loss trials in the primary care setting.~Usual medical care from the PCP.~Education on symptoms of hypoglycemia, hypotension, and cardiovascular disease, with instructions to contact their PCP in the event of those symptoms."
10027882|NCT01736137||Chronic Heart failure group|All chronic heart failure group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
9465076|NCT03677349|Experimental|Resensitized group|Patients with resensitized free flap by neurorrhaphy
9465077|NCT03677349|Experimental|Non Resensitized group|Patients without resensitized free flap by neurorrhaphy.
9465078|NCT03677336|Other|Group l: 1st cycle MVP/placebo OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=d1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized vaginal progesterone 200 mg capsules 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): 'Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo 'Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days."
9465079|NCT03677336|Other|Group ll: 1st cycle placebo MVP/OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=day 1): Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized progesterone 200 mg intravaginal capsules 3 times daily, for 8 days."
9465080|NCT03677323|Experimental|Virtual reality|The virtual reality device will consist of the virtual reality headset and headphones for full immersion.
9465081|NCT03677323|Active Comparator|Drug sedation|The sedation group will benefit from drug sedation used in current practice, that is to say an association of Sufentanil, Droleptan and Propofol.
9465082|NCT03677310|Experimental|3% sodium chloride|Subjects in this group will receive 3% sodium chloride over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
9465083|NCT03677310|Sham Comparator|Normal Saline|This group will receive normal saline over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
9465084|NCT03677297|Experimental|ROSUVASTATIN|1.2% Rosuvastatin Gel. Insertion in infrabony defects once
9465085|NCT03677297|Placebo Comparator|placebo|No intervention used on control site
9465086|NCT03677271|Other|Physical Activity|
9465087|NCT03677258|Experimental|Collagen injections|30 females with aging facial problems from 35 to 65 years old prescribed collagen ingection once every 3 weeks, cours of therapy - 3 procedures
9465088|NCT03677258|Active Comparator|Hyaluronic acid injections|30 females with aging facial problems from 35 to 65 years old prescribed hyaluronic acid ingection once every 3 weeks, cours of therapy - 3 procedures
9465089|NCT03677232||Hong Kong Chinese adolescents with CHD|Hong Kong Chinese adolescents with CHD aged 12-18 who are able to read and write chinese
9465090|NCT03677219|No Intervention|Control|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, and do not view an educational video.
9465091|NCT03677219|Experimental|Video|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, then view a 2 minute educational video and respond to a second survey.
10036823|NCT01819350|Experimental|G4 and G5|Application of antibiotic group of pediatric medicines and control group (sucrose 10 %)on dental biofilm.
9465092|NCT03677206|Sham Comparator|Exposure to white LED light.|Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks
9465093|NCT03677206|Experimental|Exposure to green LED light|Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks.
9465094|NCT03677206|Other|Cross over|Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks.
10027883|NCT01736137||Control Group|All control group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
10027884|NCT01736150|Experimental|Sevelamer carbonate|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
9465095|NCT03677193|Experimental|Experimental arm|
9465096|NCT03677167|Experimental|walking on a treadmill barefoot group|26 Patients in this group will walk barefoot on the treadmill and will be asked to walk barefoot at home and report the time of barefoot walking at home
10027885|NCT01736150|Placebo Comparator|Placebo|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
10027886|NCT01736163||Thyrogen and 131I|Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.
10027887|NCT01736163||Thyroid Hormone Withdrawal and 131I|Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.
9465097|NCT03677167|Active Comparator|Walking on a treadmill with shoes group|26 Patients in this group will walk with shoes on the treadmill
10027888|NCT01736202|Active Comparator|Palm oil orally|oral fat load
10027889|NCT01736202|Active Comparator|Canola oil orally|Oral fat load
9465098|NCT03677050|No Intervention|Control|patients receiving standard care (verbal and written instructions) before colonoscopy
9465099|NCT03677050|Experimental|Intervention|Patients instructed to use a smart phone patient education app in addition standard care
9465100|NCT03677037|Experimental|Short-term MBT|The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
9465101|NCT03677037|Active Comparator|Long-term MBT|The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
9465102|NCT03677024|Experimental|SLN arm|"Experimental:~Intra-operative sentinel lymph node (SLN) mapping with indocyanin green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceeds to a total hysterectomy.~If only unilateral SLN are detected, surgeons will proceed to pelvic lymphadenectomy on the opposite side.~If non SLN are detected, surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy."
9465103|NCT03677024|No Intervention|Lymphadenectomy arm|Surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy.
9465104|NCT03676998|Other|Measurement of diaphragm function|Patients will be followed up from admission to weaning with twice a week a diaphragm function multimodal evaluation (ultrasound, phrenic nerves stimulation technique)
9465105|NCT03676985|Experimental|ZKAB001 5 mg/kg/time|Three or six patients will treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
9465106|NCT03676985|Experimental|ZKAB001 10 mg/kg/time|Three or six patients will treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
10027890|NCT01736202|Placebo Comparator|Water orally|oral water administration as control
10027891|NCT01736228|Experimental|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
10027892|NCT01736280|Other|1|Standard of Care. Participants will be evaluated and treated for their particular digestive disorder or presenting symptoms.
10027893|NCT01736306||Volunteers|Volunteer milk donors
10027894|NCT01736345||Telephone Disclosure|Telephone Disclosure: Participants randomized to telephone disclosure will be asked to provide a personal identifier that the participant will be asked at the time of their telephone disclosure to ensure their identity.
10027895|NCT01736345||In Person Disclosure|Individuals opting out of randomization but still willing to participate in the research will be placed in the self-select in-person arm.
10027896|NCT01736371|Sham Comparator|Total Intravenous Anesthesia|Only propofol infusion is used for maintenance of anesthesia keeping Bispectral Index (BIS) between 45-55.
10027897|NCT01736371|Active Comparator|1% Sevoflurane|1% Sevoflurane with propofol infusion is used for maintenance. BIS is kept between 45-55 by adjusting propofol infusion.
10027898|NCT01736371|Active Comparator|Sevoflurane|Only Sevoflurane is used for maintenance keeping BIS between 45-55
10027899|NCT01736384||Obesity|Gastric bypass surgery and non-obese controls undergoing cholecystectomy
9465107|NCT03676985|Experimental|ZKAB001 15 mg/kg/time|Three or six patients will treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
10027900|NCT01736410|Other|IHC method|
10027901|NCT01736410|Other|FISH method|
10027902|NCT01736423|Experimental|Female Patients with D-IBS|
10027903|NCT01736436|Experimental|100 mg APG101 weekly over 12 weeks|Single arm open label study. Patient receive 100 mg APG101 i.v. weekly over 12 weeks with a 6 monthly follow-up phase
10027904|NCT01736449|Placebo Comparator|Pterygium Excision Alone|
10027905|NCT01736449|Experimental|Pterygium Excision with Bevacizumab Injection|
10027906|NCT01736462|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%
10027907|NCT01736488|Experimental|Fimasartan 60mg|60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
10027908|NCT01736488|Active Comparator|Atenolol 50mg|50mg/day of Atenolol will be oral administered for the study period (8 weeks)
10027909|NCT01736501|No Intervention|Baseline1-demographics|Baseline survey- demographics only
10027910|NCT01736501|Other|Baseline1 w/genetics|Genetics education, baseline interest in genome screening - 1
10027911|NCT01736501|Other|Baseline2-demographics|Baseline survey- demographics only
10027912|NCT01736501|Other|Baseline2 w/genetics|Genetics education, baseline interest in genome screening - 2
10036824|NCT01819350|Experimental|G1, G2 and G3|Application of Nutritional, Respiratory and Endocrine groups medicines pediatric on dental biofilm
10036825|NCT01819363||Study group|Patients with Malignant pleural effusion according to inclusion and exclusion criteria.
9465108|NCT03676959|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
9465109|NCT03676959|Experimental|ZKAB001 10 mg/kg|Three or six patients will be treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
9465110|NCT03676959|Experimental|ZKAB001 15 mg/kg|Three or six patients will be treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
9465111|NCT03676946|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
9465112|NCT03676946|Experimental|ZKAB001 10mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
9465113|NCT03676946|Experimental|ZKAB001 15mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
9465114|NCT03676933|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
9465115|NCT03676933|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
9465116|NCT03676920|Experimental|Intervention Arm|This feasibility study includes only one arm. All enrolled patients will be asked to use the intervention.
9465117|NCT03676907|No Intervention|single layer suturation technique|in this arm we use single layer suturation technique to suture uterine incision
9465118|NCT03676907|Experimental|double layer suturation technique|in this arm we use double layer suturation technique to suture uterine incision
9465119|NCT03676894|Sham Comparator|Sham Treatment|Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.
9465120|NCT03676894|Active Comparator|Intravaginal Treatment|Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.
9465121|NCT03676894|Experimental|Intravaginal and intraurethral Treatment|Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.
9465122|NCT03676881||Mild Cognitive Impairment (MCI)|30 MCI patients their study partners will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 MCI with their study partners will be part of The NeuroCatch™ Platform (NCP) project.
9465123|NCT03676881||Cognitively normal subjects (CN)|30 CN participants who are cognitively normal that will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 CN will be part of The NeuroCatch™ Platform (NCP) project.
10036826|NCT01819376|Experimental|Intervention: Facebook updates|The experimental group will be encouraged to update their Facebook status regarding healthy lifestyle decisions at least once a day.
10036827|NCT01819376|No Intervention|Control: No Facebook|This group will be encouraged not to share their healthy lifestyle decisions on Facebook.
10036828|NCT01819389|Experimental|Imatinib and nilotinib combination|All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.
10036829|NCT01819402|Active Comparator|Active Comparator: 1|up to 30 mg pioglitazone, tablet, orally, once daily
9465124|NCT03676855|Active Comparator|bladder dissection before uterine incision|
9465125|NCT03676855|Experimental|bladder dissection after uterine incision|
9465126|NCT03676842|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
9479950|NCT03538340|Experimental|Study Arm|Study Arm: Surgery with intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
10036830|NCT01819402|Sham Comparator|Sham Comparator: 1|up to 4 mg/day glimepiride, tablet, orally, once daily
10036831|NCT01819428|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib)12mg PO daily administration
10036832|NCT01819441|Sham Comparator|Normal Azelnidipine/Perindopril|Systole blood pressure controlled between 130 mmHg~140 mmHg(with or without hydrochlorothiazide).
10036833|NCT01819441|Experimental|Intensive Azelnidipine/Perindopril|Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).
9465127|NCT03676829|Experimental|Arterial Embolization of the Shoulder (AES)|Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.
9465128|NCT03676816|Experimental|Vaginal self-sampling and provider performed endocervical sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
9465129|NCT03676790|Experimental|Group I|(in the first month, continuous ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
9465130|NCT03676790|Experimental|Group II|(in the first month, pulsed ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
9465131|NCT03676790|Experimental|Group III|(in the first month, the continuous ultrasound was applied three times a week and in the second month, three times a week, the continuous ultrasound associated with exercises was applied)
9465132|NCT03676790|Experimental|Group IV|(in the first month, the pulsed ultrasound was applied three times a week and in the second month, three times a week, the pulsed ultrasound associated with exercises was applied)
9465133|NCT03676790|Experimental|Group V|(patients received only exercise sessions three times a week for eight weeks)
9465134|NCT03676777||Infection|Patients admitted or developed bacterial/fungal infection while hospitalization
9465135|NCT03676777||Non-infection|Patients without bacterial/fungal infection
9479951|NCT03538327|Experimental|Silybin|50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the OGTT.
9479952|NCT03538314|Experimental|Experimental Treatment|UV1/GM-CSF
9479953|NCT03538288|Experimental|Twenty sessions of rTMS|Twenty sessions of rTMS will be applied to treatment seeking participants.
9479954|NCT03538275||Unipolar depression cohort|
9479955|NCT03538275||Bipolar depression cohort|
9479956|NCT03538275||Healthy Control cohort|
9479957|NCT03538262||former phase 3 PD trial participants|The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.
9479958|NCT03538249|Experimental|Aerobic training|Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.
9479959|NCT03538249|Experimental|Inspiratory muscle training|The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.
9479960|NCT03538249|Experimental|Resistance training|The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training.
9479961|NCT03538249|No Intervention|Control|The control group patients were allocated to a non-training time period, during which they were told to continue their life as before enrollment.
9479962|NCT03538249|Experimental|Aerobic and Inspiratory training|Note that the Aerobic and Inspiratory group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
9479963|NCT03538249|Experimental|Combined|Note that the Aerobic, Inspiratory and resistance group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
9479964|NCT03538236|Active Comparator|Lifestyle intervention alone|All patients included in the study will undergo an evaluation by a nutritionist and will undergo diet and lifestyle intervention.
9479965|NCT03538236|Experimental|Intragastric balloon with lifestyle|Patients who do not reach the 10% weight loss with lifestyle intervention alone after 6 months will be offered to have intragastric balloon insertion for 6 months. Regardless of whether an intragastric balloon is inserted, all patients will continue with the same lifestyle changes described above for another 6 months.
9479966|NCT03538184|Experimental|Piezosurgery|Osteotomy preparation entirely with piezosurgery tips and equicrestal placement of a 4.1 mm implant in the piezosurgery (test) group were performed as follows: 1.15 mm initial MB1 tip, 1.95 mm MB2 tip, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm MB3 tip, 2.8 mm MB4 tip, 2.8 mm paralleling pin, 3.05 mm MB5 tip, 3.3 mm MB6 tip, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm-wide healing abutment.
9479967|NCT03538184|Active Comparator|Drill|Preparation of an implant recipient site entirely with relevant drills were performed as follows: Osteotomy preparation and equicrestal placement of a 4.1 mm diameter implant in the drill (control) group were performed as follows: initial trispade drill, 2.0 mm pilot drill, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm drill, 2.8 mm drill, 2.8 mm paralleling pin, 3.5 mm drill, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm wide healing abutment.
9479968|NCT03538171|Active Comparator|ARM Entinostat+Exemestane|Patients receive Exemestane orally (PO) once daily (QD) on days 1-28 and Entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9479969|NCT03538171|Placebo Comparator|ARM Placebo+Exemestane|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10027913|NCT01736514|Experimental|febuxostat group|oral
10027914|NCT01736514|Active Comparator|allopurinol group|oral
10027915|NCT01736592|Other|Long Term Follow up|Long term follow up in all patients who received SAR422459 in previous study TDU13583
10027916|NCT01736605|Active Comparator|Massage|Daily massage for 20 minutes the first 3 days following surgery.
10027917|NCT01736605|Active Comparator|Massage combined with meditation|Daily massage for 20 minutes combined with meditation the first 3 days following surgery.
9465136|NCT03676764|Active Comparator|Biannual mass oral azithromycin|Bi-annual Mass Azithromycin distribution to all children 1-60 months old in participating communities
10027918|NCT01736631|Experimental|Cognitive behavioural therapy|Cognitive behavioural therapy for social phobia in people with bipolar disorder
10027919|NCT01736644|Placebo Comparator|Electrocautery|Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
9465137|NCT03676764|Placebo Comparator|Biannual mass oral placebo|Bi-annual Mass Placebo distribution to all children 1-60 months old in participating communities
9465138|NCT03676764|Placebo Comparator|Targeted oral placebo|Targeted placebo to children 5 to 12 weeks old at vaccine visit or other healthy child visit
10027920|NCT01736644|Active Comparator|Bipolar Sealer Aquamantys|Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
10027921|NCT01736670|Experimental|Acute Steroid Responsive dermatitis|10 patients with acute steroid-responsive dermatoses
10027922|NCT01736670|Experimental|Chronic Steroid Responsive Dermatits|10 patients with chronic steroid-responsive dermatoses
10027923|NCT01736670|Active Comparator|Control, Otherwise healthy|10 healthy controls
10027924|NCT01736709|Experimental|trivalent seasonal influenza vaccine|2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen
10027925|NCT01736722|Experimental|MRI-guided laser induced thermal therapy|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
10027926|NCT01736735|Experimental|CLP|CLP BID
9465139|NCT03676764|Active Comparator|Targeted oral azithromycin|Targeted azithromycin to children 5 to 12 weeks old at vaccine visit or other healthy child visit
9465140|NCT03676738||In-patient spine surgery|Scheduled for an in-patient, elective spine surgery where subject will receive general anesthesia
9465141|NCT03676738||Non-surgical spine care|Presenting to spine clinic and undergoing conservative, non-surgical management of spine disorder
9465142|NCT03676712|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months
9465143|NCT03676686|Experimental|Nåva Foot Cream|Topical Nåva foot cream administered twice daily.
9465144|NCT03676673||ASD group|120 patients with clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
9465145|NCT03676673||Unaffected siblings of ASD|40 unaffected siblings of ASD probands
9465146|NCT03676673||TD group|40 healthy age/gender-matched TD controls according to age and neighborhood distribution of the ASD group after interviewed by the Chinese K-SADS-E-DSM-5
9465147|NCT03676621|Experimental|study group|patients will receive buccal misoprostol
9465148|NCT03676621|Active Comparator|control group|patients will receive intravenous oxytocin
9465149|NCT03676608|Experimental|Bee wax mammary areolae|"Usual educational care plus the product.~The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams."
9465150|NCT03676608|Active Comparator|Control|Usual educational care.
9465151|NCT03676595|Experimental|Group A|Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
9465152|NCT03676595|Experimental|Group B|Group B had no exercise in the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
9465153|NCT03676569|Experimental|Experimental group|Autologous ADRC transplantation in autoimmune refractory epilepsy
9465154|NCT03676556|Active Comparator|Topical lidocaine|23 patients will recieve lidocaine solution before wound treatment
9465155|NCT03676556|Placebo Comparator|Saline serum|23 patients will recieve saline solution before wound treatment
9465156|NCT03676543|Experimental|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
9465157|NCT03676530|No Intervention|Relative Rest (Control)|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. No compression. Standard of care therapy includes relative extremity rest, stretches and graduated run program.
9465158|NCT03676530|Experimental|Compression Garments|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. Standard of care therapy includes compression garments worn, stretches and graduated run program.
9465159|NCT03676517|Experimental|Preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
9465160|NCT03676504|Experimental|Stratum I|Adult patients with relapsed or refractory ALL
9465161|NCT03676504|Experimental|Stratum II|Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL
9465162|NCT03676504|Experimental|Stratum III|Pediatric patients with relapsed or refractory ALL
10027927|NCT01736735|Placebo Comparator|Placebo|BID powder
10027928|NCT01736748|Experimental|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
10027929|NCT01736748|Other|Traditional PA counseling|In this arm, while children will wear the same sensors as in the intervention arm, the intervention will not rely on data gathered using the wearable sensors. Rather, a traditional physical activity counseling strategy will be adopted in this control group.
10027930|NCT01736761|Experimental|Darunavir, Ritonavir, Rilpivirine|Darunavir 800 mg once daily, Ritonavir 100 mg once daily and Rilpivirine 25 mg once daily
9465163|NCT03676491|Experimental|Experimental Group|"Music Intervention: Participants listen to music minimum 30 minutes at bedtime for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer"
9465164|NCT03676491|No Intervention|Waitlist Control Group|"No intervention: Participants are monitored for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer."
9465165|NCT03676478|No Intervention|start enteral support @ POD1|The standard of care (SoC) in our department consists of enteral nutritional support of maximum 1000 kilocalories (kCal) through a peroperatively placed jejunostomy feeding tube started at POD 1. Oral caloric intake is resumed at POD 4.
9465166|NCT03676478|Active Comparator|delayed start enteral support @ POD5|As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of 4.000 kCal in the immediate postoperative course.
10027931|NCT01736774|Experimental|Usual care intervention|Primary care as required including medication
9465167|NCT03676452|Experimental|Intervention group|Participants of the intervention group train for 16 weeks (three times per week) with a multicomponent virtual reality-based exergame at their home. The Active@Home exergame contains strength training with Tai Chi-based exercises, balance training with dancing and a cognitive training with specific cognitive-motor games. Each training session lasts about 30 to 40 minutes.
9465168|NCT03676452|No Intervention|Control group|Participants of the control group go on with their usual daily life. After post-measurements, they get the Active@Home exergame to use the training system at home. They don't have to follow a specific training plan.
9465169|NCT03676439|Active Comparator|Treated Arm: Magnetic Spinal Stimulation plus PKT|Three months of kinesthetic and phoniatric treatment, and Magnetic Spinal Stimulation, 80% of the cervical muscles's motor threshold, 100 pulses at 10Hz, lasting 10 seconds, repeated during 30 minutes, twice a week for 3 months on cervical lateral location, focalized on the Lateral Spinal Cord.
9465170|NCT03676439|Placebo Comparator|Sham comparator|They will receive kinesthetic and phoniatric treatment, and during 3 months,with equal periodicity, they will receive a sensible false magnetic stimulation, of equal localization that other arm, with insufficient intensity, to blind clinical experience.
10027932|NCT01736774|Experimental|Physiotherapy treatment|Exercise and manipulative therapy
9465171|NCT03676426|Experimental|Web-based AD|Patients will be encouraged to use the web platform for advance care planning/advance directive to document their care preferences..
9465172|NCT03676426|Active Comparator|Paper AD|Patients will be given the standard advance directive and encouraged to complete on their own.
10027933|NCT01736787|Experimental|Cauliflower Mushroom extract|
10027934|NCT01736787|Placebo Comparator|Placebo|
10027935|NCT01736800|Experimental|Temozolomide/Topotecan|Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
9465173|NCT03676413|Experimental|Test (T)|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals
9465174|NCT03676413|Active Comparator|Reference (R)|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
9465175|NCT03676413|Placebo Comparator|Placebo|
9465176|NCT03676400|Experimental|NGF-574H|"NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss.~NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks."
9465177|NCT03676400|Placebo Comparator|placebo|Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
9465178|NCT03676387|No Intervention|Aged based group (group AB) (n = 27)|ETT size was determined according to age
9465179|NCT03676387|Active Comparator|Ultrasound based group (group UB) (n = 27): ETT was determined|ETT was determined according to the subglottic transverse diameter that was estimated with ultrasonography.
9465180|NCT03676374|Experimental|Prucalopride|Prucalopride 2mg once a day as add-on for PPI 2x/d
9465181|NCT03676374|Placebo Comparator|Placebo|Placebo once a day as add-on for PPI 2x/d
9465182|NCT03676361|Experimental|Desmopressin|All ten subjects will be evaluated pre and post nephrectomy at 6 months.
9465183|NCT03676335|Experimental|0.3 g: 0.15 mg（1)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
10027936|NCT01736813||CCR5-inhibitor at 300 mg/bid|colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
10027937|NCT01736826||Group P: pregnancy w/complications|"The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).~100 patients will be included.~Interventions to be administered: Bloodwork, baseline"
10027938|NCT01736826||Group T1: Healthy volunteers|"Healthy volunteers with no history of chronic or neoplastic disease.~30 healthy volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
10027939|NCT01736826||Group T2: Pregnancy, no complications|"Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.~50 pregnant volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
10027940|NCT01736826||Group T1x: 15 Healthy volunteers|"15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.~Interventions to be administered: Blood work, Months 1 & 2"
10027941|NCT01736826||Group T2x: 15 Pregnancy, no complications|"15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.~Interventions to be administered: Bloodwork, Months -1 to -6"
10027942|NCT01736839||CF adults colonized with Pseudomonas aeruginosa|
10027943|NCT01736878|Experimental|Sorafenib tablets|Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity
10027944|NCT01736878|Placebo Comparator|Placebo tablets|Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator
10027945|NCT01736891|Experimental|Rasagiline|Rasagiline 0.5 mg by mouth every day for 2 weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
10027946|NCT01736891|Placebo Comparator|Placebo|placebo 0.5 mg by mouth every day for two weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
10027947|NCT01736904|Active Comparator|FOLFIRI|FOLFIRI regimen
10027948|NCT01736904|Experimental|wXELIRI regimen|wXELIRI
9465184|NCT03676335|Experimental|0.3 g: 0.15mg（2)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
9465185|NCT03676335|Experimental|0.3 g: 0.3 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
9465186|NCT03676335|Active Comparator|0.4 ml: 0.2 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
9465187|NCT03676322|Experimental|Part A: M5049|
9465188|NCT03676322|Placebo Comparator|Part A: Placebo|
9465189|NCT03676322|Experimental|Part B: M5049|
9465190|NCT03676322|Placebo Comparator|Part B: Placebo|
9465191|NCT03676322|Experimental|Part C: M5049|
9465192|NCT03676309|Placebo Comparator|placebo|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
9465193|NCT03676309|Active Comparator|nutraceutical oral capsule|nutraceutical oral capsule 920 mg twice a day for 12 weeks
9465194|NCT03676296|Experimental|Puerarin|Puerarin (90.2 mg daily) in granules
9465195|NCT03676296|Placebo Comparator|Placebo|Placebo in granules
9465196|NCT03676244|Experimental|immediate implant placement in anterior esthetic zone|extraction of badly broken anterior maxillary teeth with immediate implant placement
9465197|NCT03676231|Experimental|High-dose SGM-1019|
9465198|NCT03676231|Experimental|Low-dose SGM-1019|
9465199|NCT03676231|Placebo Comparator|Placebo|
9465200|NCT03676205|Experimental|Platelet-Rich Plasma|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 6-7 ml of PRP .~After 4-5 days from the injury the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will recived the second infiltration of 6-7 ml of PRP."
10027949|NCT01736969|Experimental|RD047-023|RD-047-023
10027950|NCT01736969|Active Comparator|Predicate Device|legally marketed predicate device
10027951|NCT01736982|Active Comparator|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)], breath sample monitoring, standard smoking cessation counseling
10027952|NCT01736982|Experimental|Standard of Care plus Contingency Management|Standard smoking cessation intervention plus contingency management
10027953|NCT01736995|Experimental|Motivational/Cog Beh Tx-Contingency Mgmt|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
9465201|NCT03676205|Other|Traumel ®|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 4 ml of a homeopathic product (Traumeel ®) After 4-5 days from the date of injury, the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will receive the second infiltration of 4 ml of a homeopathic product."
9465202|NCT03676192|Experimental|CT-P16|Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
9465203|NCT03676192|Active Comparator|Avastin|Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
9465204|NCT03676179|Active Comparator|unicompartment knee arthroplasty and patella denervation|UKA and patella denervation
9465205|NCT03676179|Experimental|unicompartment knee arthroplasty and patella non-denervation|UKA and patella non-denervation
9465206|NCT03676166|Experimental|0mg THC smoked cannabis|placebo smoked cannabis
9465207|NCT03676166|Experimental|10mg THC smoked cannabis|smoked cannabis containing 10mg THC
9465208|NCT03676166|Experimental|25mg THC smoked cannabis|smoked cannabis containing 25mg THC
9465209|NCT03676166|Experimental|0mg THC vaporized cannabis|placebo vaporized cannabis
9465210|NCT03676166|Experimental|10mg THC vaporized cannabis|vaporized cannabis containing 10mg THC
9465211|NCT03676166|Experimental|25mg THC vaporized cannabis|vaporized cannabis containing 25mg THC
9465212|NCT03676140|Active Comparator|Separate Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 8'
9465213|NCT03676140|Experimental|Co-Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 1'
9465214|NCT03676127||Study Group|ultrasonographic dermal thickness measurements in patients with unilateral breast cancer related lymphedema
9465215|NCT03676114|Experimental|ketamine group|
9465216|NCT03676114|Placebo Comparator|normal saline group|
10027954|NCT01736995|Experimental|Functional Family Tx- Contingency Mgmt|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
10027955|NCT01736995|Experimental|Motivational/Cog Beh Tx|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
10027956|NCT01736995|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
10027957|NCT01737008|Experimental|Dacomitinib with Radiotherapy|Dacomitinib, 15mg to 45mg orally, once daily. Radiotherapy, once daily (Monday to Friday) over six weeks.One day on weeks 2 to 6 the participants will receive treatment twice daily (bid).
10027958|NCT01737008|Experimental|Dacomitinib and Chemoradiotherapy|Dacomitinib: 15mg to 45mg orally, once daily. Radiotherapy: Once daily (Monday to Friday) over seven weeks. Twice daily (bid) treatments may be introduced to compensate for treatment days missed due to statutory holidays, or machine maintenance. Cisplatin: 100mg/m2 intravenously; weeks 1, 4, and 7.
10027959|NCT01737034|Experimental|low GI, low GI|low GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
10027960|NCT01737034|Experimental|low GI, high GI|low GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
10027961|NCT01737034|Experimental|high GI, low GI|high GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
9465217|NCT03676101|Experimental|9-valent HPV Recombinant Vaccine|
9465218|NCT03676101|Placebo Comparator|Placebo|
9465219|NCT03676088|Experimental|Test group - rhPDGF-BB+MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The test group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB
9465220|NCT03676088|Active Comparator|Control group - MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The control group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft alone
9465221|NCT03676062|Active Comparator|stabilization exercise group|Spinal stabilization exercise were applied all patients additional with hotpack, TENS application in this group accompanied by physiotherapist.
9465222|NCT03676062|Active Comparator|yoga group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing exercises, warm up, asana and relaxation.
9465223|NCT03676062|Active Comparator|home exercise group|Home exercise were applied all patients in this group supervised, controlled by physiotherapist every week.To make compliance easier for patients; a booklet including suggestions to prevent low back pain and description of exercises, were given. Prescribed exercises were selected in this booklet and checked&progressed in each control sessions.
9465224|NCT03676036|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 28 days: DS107E taken topically twice a day
9465225|NCT03676036|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and Vehicle taken once a day Next 28 days: Vehicle taken topically twice a day
9465226|NCT03676023||Pulmonary Hemorrhage|Patients treated for pulmonary hemorrhage with inhaled Transexamic Acid
9465227|NCT03676010||Sarcoma and GIST|
9465228|NCT03676010||Breast cancer|
9465229|NCT03676010||Pancreatic cancer|
9465230|NCT03676010||Renal cell carcinoma|
9465231|NCT03676010||Colon Cancer (adjuvant setting)|
9465232|NCT03676010||Solid tumours undergoing image-guided tumor ablation|
9465233|NCT03675997||Autografted patients|Patients hospitalized in the hematological department of the Institute will complete the first day of conditioning and then weekly HAD (Hospital Anxiety and Depression) scale.
9465234|NCT03675984|Experimental|asymmetrical stabilization exercise group|'asymmetrical stabilization exercise' patient learn asymmetrical stabilization exercise according to the asymmetrical paraspinal muscles weakness and curve type
9465235|NCT03675971|Experimental|Medical Cannabis|Drug: Cannabidiol
9465236|NCT03675971|Placebo Comparator|Placebo|Placebo comparator
9465237|NCT03675958|Experimental|GJPS + S|Experimental group: (GJPS + S) : Application Johnstone´s Pressure Splint plus Stretching in in 4 different treatment postures.
9465238|NCT03675958|Active Comparator|GS|Control group (GS): Just Stretching in 4 different treatment postures.
10027962|NCT01737034|Experimental|high GI, high GI|high GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
9465239|NCT03675932|Experimental|Cycling Intervention|Single-arm trial. All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
9465240|NCT03675906||preoperative albumin levels <3.8|
9465241|NCT03675906||preoperative albumin level >3.8|
9465242|NCT03675906||postoperative Day 2 albumin level <2.9|
9465243|NCT03675906||postoperative Day 2 albumin level >2.9|
9465244|NCT03675893|Experimental|Cohort 1A|"Abemaciclib is administered by mouth twice daily~Letrozole is administered by mouth once daily"
9465245|NCT03675880|Experimental|1.25mg(0.05ml) single-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose
9465246|NCT03675880|Experimental|2.00mg(0.08ml) single-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose
9465247|NCT03675880|Experimental|2.50mg(0.10ml) single-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose
9465248|NCT03675880|Experimental|1.25mg(0.05ml) multiple-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose
9465249|NCT03675880|Experimental|2.00mg(0.08ml) multiple-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose
9465250|NCT03675880|Experimental|2.50mg(0.10ml) multiple-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose
9465251|NCT03675867||Obese teenagers|
10027963|NCT01737047||HIV positive over 50 years of age|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
10027964|NCT01737047||HIV positive under the age of 50|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
10027965|NCT01737047||HIV negative over the age of 50|All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
10027966|NCT01737073|Experimental|IVR self management|cognitive behavioral based self management training for chronic pain delivered by interactive voice response (IVR)
9465252|NCT03675854|Experimental|Extended Group|3 weeks of antibiotics
9465253|NCT03675854|Active Comparator|Conventional Group|2 weeks of antibiotics
9465254|NCT03675841|Experimental|0.1% single-dose pre|Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
9465255|NCT03675841|Experimental|0.1% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
9465256|NCT03675841|Experimental|0.3% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose
9465257|NCT03675841|Experimental|0.5% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose
9465258|NCT03675828|Experimental|Virtual Visit|In this arm, the 7-day post discharge visit will be completed by a scheduled virtual visit with a member of the study team using the Cleveland Clinic Online Express Care application on a computer or a tablet/phone.
9465259|NCT03675828|No Intervention|Outpatient Clinic|In this arm, the 7-day post discharge visit will be completed by a standard-of-care, in-person outpatient visit with a member of the study team in the heart failure clinic.
9465260|NCT03675815|Active Comparator|Standard of care|darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd
9465261|NCT03675815|Experimental|Dolutegravir + tenofovir (TDF) + either lamivudine (3TC) or emtricitabine (FTC)|dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd
9465262|NCT03675815|Experimental|Dolutegravir + darunavir|dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd
9465263|NCT03675802|Active Comparator|Arm number one ,misoprostol|
9465264|NCT03675802|Active Comparator|Arm number 2 dinoprostone|
9465265|NCT03675789||STEMI|50 STEMI patients treated with standard therapy undergoing to primary percutaneous coronary internention (PPCI). Thromboaspiration will be performed whenever possible (when the anatomy of the coronary artery - curve and size- allowed it) in all patients with a TIMI Flow 0 and in all patients with a visible thrombus if TIMI Flow was 1 or more.
10027967|NCT01737073|Experimental|Opioid monitoring|monthly interactive voice response (IVR) monitoring of prescription opioid use with feedback to the prescribing physician
10027968|NCT01737073|Experimental|IVR self management plus opioid monitoring|Cognitive behavioral based self management training for chronic pain delivered by IVR plus monthly IVR monitoring of prescription opioid use with feedback to the prescribing physician
10027969|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tips via IVR
10027970|NCT01737086|Experimental|ORS with probiotic and zinc|Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
10027971|NCT01737086|Placebo Comparator|Standard ORS|Standard oral rehydration solution
10027972|NCT01737099|Experimental|DHA-O|
9465266|NCT03675789||Stable angina|50 stable angina (SA) patients on standard therapy, undergoing to intracoronary blood aspiration during elective diagnostic and/or interventional coronary procedure, matched for age, sex and comorbidities with the 50 STEMI patients.
9465267|NCT03675789||Controls|50 outpatients without coronary heart disease, matched for age gender and comorbidities like diabetes and hypertension with the 50 STEMI patients. Peripheral blood samples will be collected during routine patient monitoring.
9465268|NCT03675659|Active Comparator|intra-articular injection|intra-articular injection with magnesium sulfate at weekly interval for four weeks
9465269|NCT03675659|Placebo Comparator|control|intra-articular injection with saline
9465270|NCT03675646|Experimental|Morphine group M|Experimental group M were administered preservative-free morphine 250 mcg in 2.5 ml NS intrathecal using 25 G needle in L1/2 - L5/S1 interspaces.
9465271|NCT03675646|No Intervention|Control group C|No intervention
9465272|NCT03675633||FEUrea in decompensated liver cirrhosis|FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS
10027973|NCT01737099|Active Comparator|Fish oil|
10027974|NCT01737099|Placebo Comparator|Placebo|
10027975|NCT01737112|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and evaluation of lung cancer patients.
10027976|NCT01737138|Active Comparator|RSD+Medicine|The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria. First undergo renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. At the same time, we will use optimal medication to protect renal function. Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
10027977|NCT01737138|Placebo Comparator|Medicine|The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
10027978|NCT01737151|Active Comparator|Arm I (standard stereotactic body radiation therapy (SBRT)|Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
10027979|NCT01737151|Experimental|Arm II (four fraction split-course SBRT)|Patients undergo 2 fractions of SBRT in weeks 1 and 4
10027980|NCT01737164|Experimental|Aerobic Exercise - Older Subjects|Subjects aged 65 and higher will perform 16 weeks of moderate intensity exercise
10027981|NCT01737164|Experimental|Aerobic Exercise - Young Subjects|Subjects 18-30 years old will perform 16 weeks of moderate intensity exercise
10027982|NCT01737177|Experimental|Bendamustina, Lenalidomide, Rituximab|1 arm for all patients
10027983|NCT01737190|Experimental|PEEP guided by Esophageal pressure + Recruitment maneuver.|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
9465273|NCT03675620|Active Comparator|Standard Rehabilitation (Control Group)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to this group will begin with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for for the first 6 weeks of post-operative care. Standard rehabilitation will continue until discharge.
10027984|NCT01737203|Active Comparator|Viagra|Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra® tablet) 50 mg as a single oral dose under fasted conditions
10027985|NCT01737203|Experimental|ODT without water|Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions
9465274|NCT03675620|Experimental|Blood Flow Restriction (BFR)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to the BFR group will begin combining BFR with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for the first 6 weeks post-operative care. Standard rehabilitation will continue until discharge.
9465275|NCT03675607||Caregivers infants <2years old|Caregivers of infants under 2 years of age (parents or other), of any gender, who prepare complementary feeding regularly (more than once a week).
9465276|NCT03675594|Experimental|intervention arm|the group of participants will take the CAD/CAM titanium denture bases and assessment during and after the first 3 months after delivery of the first type.
9465277|NCT03675594|Experimental|intervention arm 2|the same group of participants will take the CAD/CAM cobalt/chromium denture bases and assessment during and after the second 3 months after delivery of the second type.
9465278|NCT03675568|Experimental|study group|Non-Cultured autologous keratinocyte suspension
9465279|NCT03675568|Active Comparator|Control group|Split skin Graft
9465280|NCT03675555|Active Comparator|M (Mirtazapine) (Merta) group:(n=100)|
9465281|NCT03675555|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
9465282|NCT03675555|Placebo Comparator|C (Control) group: (n=100)|
9465283|NCT03675542|Experimental|Study medication|HSP90 inhibitor (CUDC-305)
10027986|NCT01737203|Experimental|ODT with water|Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions
10027987|NCT01737216|Experimental|Zoledronic acid plus First-line chemotherapy|
9465284|NCT03675529|Experimental|High Intensity Interval Training bout|Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax. Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
9465285|NCT03675529|No Intervention|Controls (usual care)|Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
9465286|NCT03675503|No Intervention|Control|No change in the standard of care.
9465287|NCT03675503|Experimental|Fall Prevention Decision Support|"Nursing assesses patient using the Assistive Device Checklist and provides assistive devices to patients, if appropriate.~Decision support aimed at preventing hospital falls and empowering nurses."
9465288|NCT03675490|Experimental|Exercise|Participants will engage in a physiotherapist-prescribed home exercise program with ABLE, the interactive technology. The exercises that will be prescribed are designed to improve functional mobility via challenging lower extremity strength and balance in a multicomponent exercise program. The difficulty of each exercise will be chosen at the discretion of the physiotherapist based on the participants' performance on the baseline assessments. The exercises will be prescribed at a moderate intensity (moderate balance challenge, 8-12 repetitions for strength exercises with the last few repetitions being challenging) and will be progressed over the study duration to ensure they remain a moderate challenge.
9465289|NCT03675477|Active Comparator|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 16.
9465290|NCT03675477|Active Comparator|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 16.
10027988|NCT01737216|Active Comparator|First-line chemotherapy|
9465291|NCT03675477|Active Comparator|SHR0302 dose C|Participants randomized in this arm will receive dose D of SHR0302 until end of study at week 16.
9465292|NCT03675477|Placebo Comparator|palcebo|Participants randomized in this arm will receive placebo until week 8, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 16.
10027989|NCT01737229|Experimental|Direct pulp capping/carious exposure|symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
10027990|NCT01737229|Experimental|Direct pulp capping/dental trauma|• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
10027991|NCT01737229|Experimental|Repairing root canals/pulp chamber floor|"Iatrogenic perforation of the pulpal floor, with or without LEO.~Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.~Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO."
10027992|NCT01737229|Experimental|Retrograde endodontic surgery - adults|"Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.~Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option"
9465293|NCT03675438|Experimental|Sub-epitheilal TCA Inlay|Implantation of a sub-epithelial presbyopia corrective inlay using TCA technology
9465294|NCT03675425|Experimental|Group 1: non chest shielding|non chest shielding generic name: non dosage: non frequency and duration: in first 48 h eco with pad diameter will be measured in before and after phototherapy,
10027993|NCT01737229|Experimental|Pulpotomy in primary molars - children (3 to 12 years )|"Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.~Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years."
10027994|NCT01737229|Experimental|Apexification - children (7 to 18 years) + adults|"Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.~Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.~Apical Root Resorption"
10027995|NCT01737294||Treatment with QUTENZA|Patients with Peripheral Neuropathic Pain
10027996|NCT01737307|Experimental|Fluoride Varnish|Fluoride varnish was used once in this group. Fluoride varnish(NaF 5%,Sultan,USA)
10027997|NCT01737307|Experimental|Oral hygiene|Oral hygiene followed twice daily. No F varnish or CPP-ACP applied.
9465295|NCT03675425|Placebo Comparator|Group 2: chest shielding|chest shielding generic name: Phototrephy dosage: non frequency and duration: in first 48 h echo with pad diameter will be measured in before and after phototherapy,
9465296|NCT03675399|Experimental|Supra-threshold isometric exercise|Participants will perform 10 isometric external rotation supra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
9465297|NCT03675399|Experimental|Infra-threshold isometric exercise|Participants will perform 10 isometric external rotation infra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
9465298|NCT03675399|No Intervention|Control|Participants will remain resting.
9465299|NCT03675373|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
9465300|NCT03675373|Active Comparator|control group|Alcohol brief intervention
9465301|NCT03675360|Experimental|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
9465302|NCT03675360|No Intervention|Usual Diet|"No dietary intervention.~At baseline, participants will receive written information with standard dietary advice and standard physical activity recommendations."
9465303|NCT03675334|Active Comparator|Test Group|"Active comparator: gingival recession~the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions"
9465304|NCT03675334|Placebo Comparator|Control Group|the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions. The control group was treated with the same technique as the collagen matrix graft.
9465305|NCT03675295|Active Comparator|Comparator: Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
9465306|NCT03675295|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
9465307|NCT03675269|Experimental|Treatment|HBOT
9465308|NCT03675269|Active Comparator|Control|Standard wound care
10027998|NCT01737307|Experimental|CPP-ACP|CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
10027999|NCT01737320|Experimental|short-course|antibiotic treatment stopped on day 7 if the patient has been afebrile for 48 hours and clinically stable. Continued hospitalization will be left to the discretion of the treating physician. Antibiotics will be restarted if fever recurs in at least 2 consecutive measurements above 38 or in cases of clinically or microbiologically documented infections.
9465309|NCT03675230|Active Comparator|3DCRT|This arm will be planned by 3DCRT to the treatment of the Medulloblastoma
9465310|NCT03675230|Experimental|Tomotherapy HD，TOMO|This arm will be planned by TOMO to the treatment of the Medulloblastoma
9465311|NCT03675217|Experimental|PE and PCFPC|Physical Exercise and primary care family caregivers program
9465312|NCT03675217|Active Comparator|Usual Care|Usual Care: PCFPC (primary care family caregivers program)
9465313|NCT03675191|Experimental|orlistat|Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
9465314|NCT03675191|Placebo Comparator|placebo|placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
10028000|NCT01737320|Active Comparator|accepted prolonged antibiotic treatment|"antibiotic treatment continued for 14 days according to accepted hospital local guidelines. Duration of hospital stay will also be left to the discretion of the treating physician.~Type of empiric antibiotic treatment and later, specific antibiotic treatment, will be chosen by the treating physicians in consultation with the infectious diseases unit.~The decision on timing of switch to oral antibiotic therapy will also be left to the discretion of the treating physician."
10028001|NCT01737346|Experimental|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
9465315|NCT03675178|Experimental|treatment group|Anerning particle +ceftriaxone sodium
9465316|NCT03675178|Placebo Comparator|control group|Anerning particle placebo+ceftriaxone sodium
10028002|NCT01737359|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
10028003|NCT01737359|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
9465317|NCT03675165|Experimental|Intervention|Participants receive a tailored version of Laura King's 'Best Possible Self' intervention: a brief, self-administered, psychological intervention. It is fundamentally a writing exercise, whereby recipients are asked to spend 10 minutes writing about their best possible future self and the steps they need to take to become that person. This helps the individual set goals while facilitating positive affect. Our version of the task has people focus on their health-related goals in particular.
9465318|NCT03675165|No Intervention|Waiting List Control|Participants are informed that they are on a waiting list and will receive the intervention at the end of the study.
10028004|NCT01737359|Active Comparator|tenofovir DF 300 mg qd|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
10028005|NCT01737372||Secondary Progressive MS (SPMS)|Secondary Progressive MS participants
10028006|NCT01737372||Clinically Isolated Syndrome (CIS)|Clinically isolated syndrome participants
10028007|NCT01737372||Healthy participants|No immunological or neurological illnesses.
10028008|NCT01737385||Type 1|One segment fracture
10028009|NCT01737385||Type 2|Two segment fracture
10028010|NCT01737385||Type 3|Three segment fracture
10028011|NCT01737385||Type 4|Four segment fracture
9465321|NCT03675113|Experimental|upper extremity aerobic group|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be 3 day per a week through 6-weeks.
9465322|NCT03675113|Sham Comparator|control group|Deep breathing exercises combination with arm movements will be given as a home program in the control group. Training duration will be 3 day per a week through 6-weeks.
9465323|NCT03675100|Sham Comparator|IBS group|Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.
9465324|NCT03675100|Active Comparator|Control group|Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.
9465325|NCT03675074|Experimental|Treatment|A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device.
10028012|NCT01737411|Active Comparator|solifenacin|10 mg solifenacin per day for three months
10028013|NCT01737411|Experimental|cesa/vasa|repair of USL
10028014|NCT01737424|Placebo Comparator|Placebo|Placebo
10028015|NCT01737424|Experimental|LC28-0126|LC28-0126(IV)
10028016|NCT01737437|Experimental|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
9479973|NCT03538080|Experimental|ACCUVEIN plus ultrasound|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with Accuvein and ultrasound
9479974|NCT03538080|Sham Comparator|Ultrasound only|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with ultrasound only.
9479975|NCT03538067||Paired sample group|Patients with symptomatic coronary artery disease (stable, NSTEACS) undergoing planned percutaneous coronary intervention with intravascular ultrasound (IVUS) guidance
9479976|NCT03538054|Experimental|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
10028017|NCT01737437|Placebo Comparator|group C|0.9% normal saline was applied to trachea and laryngoscope blade in Group C.
10028018|NCT01737437|Experimental|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
10028019|NCT01737437|Experimental|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
10028020|NCT01737450|Experimental|BKM120|Full dose=100 mg/day (oral route) One study cycle equals 28 days. Patients will be treated until disease progression, unacceptable toxicity, or willingness to stop.
10028021|NCT01737463|Active Comparator|Group A|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was inserted immediately after the excision."
10028022|NCT01737463|Active Comparator|Group B|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was not inserted immediately after the excision."
10028023|NCT01737476|Sham Comparator|control|control-sham
10028024|NCT01737476|Active Comparator|Deep TMS PFC Lt|Deep TMS PFC left
10028025|NCT01737476|Active Comparator|DEEP TMS PFC Rt|DEEP TMS PFC Rt
10028026|NCT01737476|Active Comparator|Superficial TMS PFC Lt|Superficial TMS PFC Lt
10028027|NCT01737476|Active Comparator|superficial TMS PFC Rt|superficial TMS PFC Rt
10028028|NCT01737489|Active Comparator|LACE ( Listening And Communication Enhancement )|use the commercially available auditory training program which is administered by computer as daily lessons.
10028029|NCT01737489|Active Comparator|NOOK (Electronic reader)|will use an electronic reader (NOOK device) to do speech tracking
9465326|NCT03675061|Other|Control group|Current care : The management of the preterm delivery risk without biochemical test, with hospitalization of the patient, initiation of tocolysis and a complete corticosteroid treatment.
9465327|NCT03675061|Other|PartoSure group|"Each women have a biochemical test = PartoSure Test.~PartoSure test negative : For a negative test, the patient will be able to benefit from a nifedipine tocolysis, if the uterine contractions require it, then she will return home with a control by a midwife at home twice a week up to 34 weeks of amenorrhea.~PartoSure test positive : For a positive test, the patient will be hospitalized 7 days with a care identical to the control group."
10028030|NCT01737489|No Intervention|Control|
10028031|NCT01737515||Main group|Consecutive patients undergoing colorectal surgery for benign or malignant colorectal disease without any diversion from the standard of care
10028032|NCT01737528||TAVR Patients|Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.
10028033|NCT01737541|Experimental|Fluoxetine|fluoxetine per os 20 mg daily
10028034|NCT01737541|Placebo Comparator|Placebo|per os daily
10028035|NCT01737554||Participants|"Participants include children with cancer and hematologic disorders who, as part of their standard clinical care, have a central venous access device (CVAD) used for infusion, withdrawal of blood, or hemodynamic monitoring.~Intervention: Catheter resistance monitoring"
10028036|NCT01737567|Experimental|Bright Narrow Band Imaging|Use of B-NBI to detect colonic adenomas.
10028037|NCT01737567|Active Comparator|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
10028038|NCT01737580|Active Comparator|Intanza+resiquimod gel|Intanza 15mcg intradermal injection + resiquimod gel applied to the vaccination site immediately post vaccination.
10028039|NCT01737580|Placebo Comparator|Intanza + placebo gel|Intanza 15mcg intradermal injection + placebo gel applied to the vaccination site immediately post vaccination.
10028040|NCT01737606|Experimental|echography|Fast Cerebral Pulsatility Imaging
10028041|NCT01737632|Experimental|Multidimensional Family Therapy (MDFT)|MDFT is an intensive, in-home family-based drug abuse treatment for adolescent substance abusers. MDFT views family factors in their context -in terms of the network (individual, familial, peer, community) or multiplicity of influences on drug use and change.
10028042|NCT01737632|Other|Adolescent Residential Treatment|"The Adolescent Treatment Program (ATP) is a residential dual diagnosed substance abuse treatment program that is staff secure. It is based on a social learning approach which emphasizes positive reinforcement for appropriate coping behavior and social skills, and incorporates a levels system which allocates privileges and responsibilities according to the individual's behavioral capacities."
10028043|NCT01737645||obese patients|BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
10028044|NCT01737645||Thin patients|BMI less than or equal to 30 kg/m2
10028045|NCT01737658|Other|Exercise Program upon enrollment|Subject will receive exercise intervention immediately upon enrollment to study
10028046|NCT01737658|Other|Exercise Program 6 months after enrollment|Subject will be enrolled into study and then receive exercise intervention 6 months after enrollment.
9465328|NCT03675048|Experimental|Intervention group|The intervention group will receive 5 drops (10^8 cfu Lactobacillus reuteri DSM 17938) twice daily during feeding for 4 weeks.
10028047|NCT01737671|Experimental|Methotrexate Infusion|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle is 4 consecutive daily doses of intraventricular methotrexate with minimum 2 weeks between cycles. If any serum methotrexate level is > 0.3 micromolar, then Leucovorin therapy administered (5 mg/square meter per dose) every 6 hours by vein or mouth.
10028048|NCT01737723||Study population|Stroke patients
10028049|NCT01737736||Patients undergoing cartoid endarterectomy surgery|
10028050|NCT01737749||Patients undergoing cardiac surgery|
10028051|NCT01737775|Experimental|Abdominal laparoscopic surgery (C group)|
10028052|NCT01737775|Experimental|Abdominal surgery by laparotomy (L group)|
10028053|NCT01737775|Experimental|Head and neck surgery (O group)|
10028054|NCT01737788|Experimental|Therapeutic Trial|Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (<25mm)
10028055|NCT01737788|Experimental|Prophylactic Trial|Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency
10028056|NCT01737801|Experimental|Lung function test|Lung function test
10028057|NCT01737814|Experimental|MST-188|MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
10028058|NCT01737814|Placebo Comparator|Saline|Saline administered as a continuous infusion for up to 49 hours
10028059|NCT01737853||Ganfort's Group|"Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)"
10028060|NCT01737853||Krytantek's Group|"Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)"
10028061|NCT01737866|Experimental|Group 1|End Stage Renal Diseas (ESRD) requiring hemodialysis
9465329|NCT03675048|Placebo Comparator|Placebo group|The placebo group will receive 5 drops twice daily during feeding for 4 weeks. Placebo composition will be identical to that of the study drug but will not contain L. reuteri.
9465330|NCT03675048|No Intervention|Control group|The infants from the control group will comply with the same requirements and will undergo the same procedures as participants from the main group except for randomization and treatment.
9465331|NCT03675035|Experimental|Endomina|Reduction trough sutures of the gastro-jejunal anastomosis
9465332|NCT03675022|Experimental|Dupilumab|Dupilumab injections every 2 weeks.
9465333|NCT03675009|Other|Early Intervention|Educational curriculum will be delivered earlier in the timeframe after IAQ monitoring has initiated.
9465334|NCT03675009|Other|Late Intervention|Educational curriculum will be delivered later in the timeframe after IAQ monitoring has initiated.
9479977|NCT03538054|Placebo Comparator|Placebo|Participants will take one placebo capsule in the morning and at night.
9465335|NCT03674996|Experimental|Same day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 12 hours after the surgery.
9465336|NCT03674996|Experimental|Next-day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 24 hours after the surgery.
9465337|NCT03674996|Other|2-days discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 48 hours after the surgery.
10028062|NCT01737866|Experimental|Group 2|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
10028063|NCT01737866|Experimental|Group 3|Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)
9465338|NCT03674983|Experimental|CEI Group|CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
9465339|NCT03674983|No Intervention|SOC Group|SOC Group will receive the standard of care only (information, prescription, free PrEP.)
9465340|NCT03674931|Experimental|musical practice|Intensive weekly musical keyboard training over 12 months
10028064|NCT01737866|Experimental|Group 4|Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)
9465341|NCT03674931|Active Comparator|music education|Recreative weekly musical courses without practice over 12 months
9465342|NCT03674918||persons with arterial hypertension|patients referred to consultation cardiology for hypertension. They get a 24 h blood pressure monitoring to define the exact mean arterial blood pressure
10028065|NCT01737866|Experimental|Group 5|Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)
10028066|NCT01737866|Experimental|Group 6|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
9465343|NCT03674905|Other|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
9465344|NCT03674905|Other|Peripheral nerve block|Pre-operative peripheral nerve block.
9465345|NCT03674879|No Intervention|Phone Call|Follow up contact is attempted via phone call.
10028067|NCT01737918|Experimental|trans obturatorial tape (TOT)|placement of a sub-urethral tape
10028068|NCT01737918|Active Comparator|solifenacin|10 mg per day
10028069|NCT01737957|Experimental|Low-fluence|Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy
10028070|NCT01737957|Active Comparator|Full-fluence|Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy
10028071|NCT01737983|Experimental|Lactobacillus reuteri (LR) ATCC55730|The tested probiotic, Lactobacillus reuteri, was administered in 5 drops per day (10^10 colony-forming units) for 6 months
9465346|NCT03674879|Experimental|Text Message|Follow up contact is attempted via text message.
9465347|NCT03674866||Patients with diabetes|Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
10028072|NCT01737983|Placebo Comparator|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation for 6 months During the test period, patients were not allowed to consume any other product that contained probiotics or prebiotics
10028073|NCT01738022|Experimental|Gas mixture administration|Subjects will breathe different gas mixtures with different densities and viscosity for brief periods in order to promote changes in peak inspiratory flow
10028074|NCT01738035|Experimental|NEFECON 8 mg/day|NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months
10028075|NCT01738035|Experimental|NEFECON 16 mg/day|NEFECON 16 mg/day (4 active capsules daily) for 9 months
10028076|NCT01738035|Placebo Comparator|Placebo|Placebo (4 placebo capsules daily) for 9 months
10028077|NCT01738048||Mastectomy|Patients treated with mastectomy without reconstruction
10028078|NCT01738048||Reconstruction|Patients treated with mastectomy followed by reconstruction
10028079|NCT01738061|No Intervention|reference group|They continued their daily routine.
10028080|NCT01738061|Experimental|Multidimensional lifestyle intervention|The multidimensional lifestyle intervention program received motivational activities to improve awareness of the impact of lifestyle on chronic diseases and the importance of self-health management.
10028081|NCT01738074|Experimental|trivalent rotavirus genetic reassortment vaccine|2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
10028082|NCT01738074|Placebo Comparator|Placebo|2ml of placebo by mouth every month for three month
10028083|NCT01738087|Experimental|NEXThaler 100/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg
10028084|NCT01738087|Experimental|NEXThaler 200/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg
10028085|NCT01738087|Placebo Comparator|NEXThaler placebo|Single dose (4 inhalations)
10028086|NCT01738087|Experimental|NEXThaler 100/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg
9465348|NCT03674853|Experimental|Wuling Capsule group|Patients who were treated with Wuling Caspule
9465349|NCT03674853|Active Comparator|Oryzanol group|Patients who were treated with oryzanol
9465350|NCT03674840|Other|control group|Subjects in this group will go through a cataract surgery with SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
9465351|NCT03674840|Experimental|design group|Subjects in this group will go through a cataract surgery with SBL-3 implantation based on kappa angle(described by Pentacam HR preoperatively) guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
9465352|NCT03674814|Experimental|Dose Level|Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
9465353|NCT03674788||TAVI|Transcatheter Aortic Valve Implantation
9465354|NCT03674788||TMVI|Transcatheter Mitral Valve Intervention
9465355|NCT03674788||TTVI|Transcatheter Tricuspid Valve Intervention
9465356|NCT03674775|Active Comparator|Intervention Group Providers|DART QI Program Participation
9465357|NCT03674775|No Intervention|Control Group Providers|Usual Care
9465358|NCT03674762|Experimental|dental implants|microgrooved dental implants submerged
9465359|NCT03674762|Experimental|dentale implants|microgrooved dental implants nonsubmerged
9465360|NCT03674749|Active Comparator|Hyperbaric Oxygen|Hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks
10028087|NCT01738087|Experimental|NEXThaler 200/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg
9465361|NCT03674749|Experimental|Meditation with Hyperbaric Oxygen|Meditation session combined with each hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks,
10028088|NCT01738087|Active Comparator|Flixotide Accuhaler 500 mcg|Single dose (2 inhalations) of fluticasone propionate
10028089|NCT01738100|Experimental|Ticagrelor + Intracoronary Morphine|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.
9465362|NCT03674723|Experimental|Arms|Methionine bioavailability in Mung beans Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods). You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or a Mung bean stew with or without rice or wheat, which will be provided by the investigators
9465363|NCT03674710|Experimental|Group A|"Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
9465364|NCT03674710|Experimental|Group B|"Patients assigned to group B will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
9465365|NCT03674710|Experimental|Group C|"Patients assigned to group C will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
9465366|NCT03674710|Experimental|Group D|"Patients assigned to group D will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
9465367|NCT03674710|Experimental|Group E|"Patients assigned to group E will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
9465368|NCT03674710|Experimental|Group F|"Patients assigned to group F will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
9465369|NCT03674684||hydroxyethyl starch|Patients who received hydroxyethyl starch
9465370|NCT03674684||gelatin|Patients who received gelatin
9465371|NCT03674684||crystalloids|Patients who received crystalloids
9465372|NCT03674671|Experimental|Intravenous Ketamine|
10028090|NCT01738100|Experimental|Ticagrelor + Intracoronary Saline|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.
10028091|NCT01738100|Experimental|Clopidogrel + Intracoronary Morphine|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.
10028092|NCT01738100|Active Comparator|Clopidogrel + Intracoronary Saline|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.
10028093|NCT01738113|Experimental|open kinetic chain exercise|Open kinetic chain exercise
10028094|NCT01738113|Experimental|Closed Kinetic chain exercise|Closed kinetic chain exercise
10028095|NCT01738139|Experimental|Treatment (ipilimumab, imatinib mesylate)|Patients receive ipilimumab IV over 90 minutes on day 1 and imatinib mesylate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10028096|NCT01738152|Experimental|HLA treatment|This is a single arm prospective longitudinal clinical trial investigating the feasibility of a hyaluronic acid (HLA) vaginal gel (HyaloGYN®; Cebert Pharmaceuticals, Inc.; Birmingham, Alabama) to improve estrogen deprivation vaginal and vulvar health symptoms in post-menopausal women with a history of hormone-receptor positive cancer with estrogen deprivation symptoms of vaginal dryness and discomfort.
10028097|NCT01738178|Placebo Comparator|Control - Placebo|These participants will receive placebo tablets during the first 5 years
10028098|NCT01738178|Active Comparator|Caffeine group|This group of participants will receive caffeine tablets.
10028099|NCT01738217|Experimental|Fluobeam|
10028100|NCT01738243|Experimental|Unilateral Upper Eyelid Retraction|"This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection"
9465373|NCT03674671|Active Comparator|Electroconvulsive Therapy|
9465374|NCT03674658|Experimental|A drug|Rhynorm(A drug)
9465375|NCT03674658|Active Comparator|B drug|Rytmonorm (B drug)
9465376|NCT03674632|Experimental|relaxation meditation tape|Participants in this arm will be asked to use the relaxation therapy during the feed at least once a day. Participants will be given a diary to record when it is used. Participants will be encouraged to use the tape as often as they find it helpful.
9465377|NCT03674632|No Intervention|Normal care|Participants in this arm will receive normal care from the Beijing Children Hospital
9465378|NCT03674619|Active Comparator|Surgical treatment|Anterior discectomy
9465379|NCT03674619|Active Comparator|Conservative treatment|Patients will attend an experienced specialist in physical medicine and rehabilitation and a physiotherapist.
9465380|NCT03674606|Experimental|Routine low-dose aspirin|Subjects shall receive standard antenatal care as well as taking oral low-dose aspirin from the eligibility visit until 36-week gestation once daily, as prescribed by the research clinician. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
10028101|NCT01738243|Experimental|Bilateral Upper Eyelid Retraction|"This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection"
9465381|NCT03674606|No Intervention|No aspirin|No low-dose aspirin will be prescribed. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
9465382|NCT03674606|Active Comparator|Test-indicated low-dose aspirin|The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk > 1:8 must start low-dose aspirin treatment immediately. Participants with a risk < 1:8 will be excluded.
10028102|NCT01738256|Experimental|Face-to-Face|Group meetings face-to-face using intervention for wellbeing with ACT principles.
10028103|NCT01738256|Experimental|Mobile|Intervention for wellbeing via mobile phone application with ACT principles.
9465385|NCT03674580||Suicidal patients|No intervention. Follow-up of the suicidal patients
9465386|NCT03674554|Experimental|titanium bases group|full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
9465387|NCT03674554|Experimental|transmucosal abutment group|a full-arch screw-retained implant prosthesis with transmucosal abutment
9465388|NCT03674541|Active Comparator|Study Drug - Pyridostigmine|Pyridostigmine 60 mg by mouth as a one time dose
9465389|NCT03674541|Placebo Comparator|Placebo|Placebo by mouth as a one time dose
9465390|NCT03674515|Placebo Comparator|placebo|"Smartphone application placebo"
9465391|NCT03674515|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
9465392|NCT03674502|Experimental|ADU-1604|ADU-1604 administered as an IV infusion
9465393|NCT03674489|Active Comparator|Neurodynamic Slider Mobilization|
9465394|NCT03674489|Active Comparator|Neurodynamic Tensioner Mobilization|
9465395|NCT03674489|Sham Comparator|Sham Neurodynamic Mobilization|
10028104|NCT01738256|Experimental|Internet|Intervention for wellbeing via Internet (Virtual Health Check and Coaching).
10028105|NCT01738256|Experimental|Control|Control group, no intervention.
10028106|NCT01738269||Apparently healthy subjects|
10028107|NCT01738269||Non-malignant conditions subjects|
10028108|NCT01738269||Malignant conditions subjects|
10028109|NCT01738282|Experimental|Baclofen|Baclofen 20mg tablet. Titration:increasing dosage regimen to reach the target dosage of 180 mg (9 tablets)in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
10028110|NCT01738282|Placebo Comparator|Placebo|Placebo tablet Titration:increasing dosage regimen to reach the target dosage of 9 tablets in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
10028111|NCT01738295|Active Comparator|Donepezil|Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
10028112|NCT01738295|Placebo Comparator|Lactose pill|Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
10028113|NCT01738308|Experimental|Healing Touch Treatment|"Healing Touch Treatment~When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
10028114|NCT01738308|Sham Comparator|Sham Healing Touch Treatment|Usual standard of post operative care plus a sham Heal Touch treatment upon entering the post anesthesia care unit. Treatment done by untrained study staff using same hand locations.
10028115|NCT01738308|No Intervention|Control- No treatment done|Usual standard of post operative care with no additional intervention
10028116|NCT01738334|Active Comparator|Healthy subjects|"The active control group of healthy individuals was subjected to the practice of meditation for eight weeks."
10028117|NCT01738334|No Intervention|Standby|The control group of participants (patients and healthy subjects) who was not practice anything for eight weeks.
10028118|NCT01738334|Experimental|Meditation|A Group of Patients with ADHD was participate of the meditation practices for eight weeks.
10036834|NCT01819454|Experimental|pH monitoring sinusitis no polyps|30 patients with chronic rhinosinusitis without nasal polyposis, without asthma bronchiale or ASA syndrome
10036835|NCT01819454|Experimental|pH monitoring sinusitis with polyp|30 patients with chronic rhinosinusitis with nasal polyposis, without asthma bronchiale or ASA syndrome
10036836|NCT01819454|Experimental|pH monitoring sinusitis, polyps, asthma|30 patients with chronic rhinosinusitis with nasal polyposis and with asthma bronchiale and/or ASA syndrome
10037553|NCT01826149|Experimental|Propofol 2.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.
10037554|NCT01826149|Experimental|Propofol 3.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.
10037555|NCT01826162|Experimental|sigmoidoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the proximal colon (sigmoidoscopy)
10037556|NCT01826162|Experimental|colonoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the distal colon (colonoscopy)
10037557|NCT01826175|Experimental|Ticagrelor|Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
9465396|NCT03674476|Experimental|Mild Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
9465397|NCT03674476|Experimental|Moderate Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
9465398|NCT03674476|Experimental|Severe Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
9465399|NCT03674476|Other|Normal|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
9465400|NCT03674463|Experimental|LCAR-B4822M treatment group|r/r multiple myeloma patients will be treated with LCAR-B4822M CAR-T cells with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
9465401|NCT03674450|Experimental|Interventional|
9465402|NCT03674424|Experimental|DD-MVAC + avelumab|"Methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) given in combination with Avelumab.~DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2. Each cycle is given every 2 weeks for a maximum of 4 administrations Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 2 every 2 weeks.~Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
9465403|NCT03674424|Experimental|CG+ avelumab|"Cisplatin, gemcitabine (CG) consists of Gemcitabine 1000 mg/m2 iv in day 1 and day 8 and Cisplatin 70 mg/m2 iv in day 1. Each cycle is given every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
9465404|NCT03674424|Experimental|PG+ avelumab|"Paclitaxel, gemcitabine (PG) consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15. Each cycle is repeated every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
9465405|NCT03674424|Experimental|Avelumab|"Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (iv) infusion once every 2 weeks. Dose reductions are not allowed.~Avelumab will be given alone for 4 administrations. Cystectomy will be performed 2 weeks after the last administration of avelumab"
9465406|NCT03674411|Experimental|FLU, CY, TBI + MGTA-456 infusion|
9465407|NCT03674411|Experimental|BU/ FLU/ MEL + MGTA-456 infusion Suspended: No|
9465408|NCT03674398|Experimental|Exercise+CT|Aerobic exercise for 30 minutes and smart-phone delivered cognitive training application for 20 minutes, 3 times per week for 4 weeks
9465409|NCT03674398|Active Comparator|Exercise only|Aerobic exercise for 30 minutes and smart-phone delivered videos for 20 minutes, 3 times per week for 4 weeks
9465410|NCT03674385|Experimental|vitamin E group|30 patient
9465411|NCT03674385|Active Comparator|control group|clomiphene
9465412|NCT03674372|Experimental|Fetuses with Left CDH (O/E LHR < 25%)|Fetuses with Left CDH (O/E LHR < 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
9465413|NCT03674372|Experimental|Fetuses with L- sided CDH with O/E LHR <30%.|Fetuses with Left CDH (O/E LHR < 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
10028119|NCT01738347|Experimental|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
10028120|NCT01738360|Experimental|Arsenic trioxide|Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).
10028121|NCT01738399|Experimental|Coffee|Subjects take 4 cups of coffee mix per day for 24 weeks
10028122|NCT01738399|Placebo Comparator|Placebo|Subjects take 4 cups of placebo per day for 24 weeks
10028123|NCT01738412||Study population|Stroke patients
10028124|NCT01738425|Experimental|GIC-1001 oral tablets|GIC-1001; 125 mg oral tablets; Single ascending doses (SAD) from 125 mg to 1000 mg; multiple ascending dose (MAD) from 125 mg to 500 mg TID over 7 successive days
10028125|NCT01738425|Placebo Comparator|GIC-1001 matching placebo|Matching placebo, single or multiple dosing
10028126|NCT01738451|Experimental|Part 1(Cohort 1): GSK2118436 225 mg|GSK2118436 (3 capsules of 75 mg) will be administered orally at the dose of 225 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal.
10028127|NCT01738451|Experimental|Part 1(Cohort 2): GSK2118436 300 mg|GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
10028128|NCT01738451|Experimental|Part 2: GSK2118436 300 mg (or highest tolerated dose)|Subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single dose on the 9th day. There will be 1 day when a placebo will be given. All doses will be administered under fasted conditions, either 1 hour before or 2 hours after a meal.
10028129|NCT01738464||Pelvic Pain|Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, and Overactive Bladder patients will be compared to Healthy and Depressed patients.
10028130|NCT01738464||Controls|Healthy patients will be used as controls to compare to patients diagnosed with Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Depressed patients.
10028131|NCT01738464||Major Depression|Major Depression patients will be compared to Controls and Pelvic Pain cohorts.
10028132|NCT01738490|Other|Wide diameter implant|Bone anchored hearing implant For the wide diameter arm (test group), the Ponto wide implant (diameter 4,5mm, length 4mm) and abutment 6mm developed by Oticon Medical AB (Gothenburg, Sweden) will be installed.
10028133|NCT01738490|Other|Control group|Bone anchored hearing implant For the control group, the previous generation Ponto implant (diameter 3,75mm, length 4mm) and 6mm abutment (Oticon Medical AB, Gothenburg, Sweden) will be installed.
10028134|NCT01738516|Other|epileptic patients|Electroencephalography
10028135|NCT01738516|Other|Healthy Volunteers|Electroencephalography and additional experimental tasks
10028136|NCT01738529|Active Comparator|CLE ileocolonoscopy on Crohn patients|Patients known with Crohn´s disease
10028137|NCT01738529|Sham Comparator|CLE ileocolonoscopy on control patients|CLE ileocolonoscopy on patients without known IBD
10028138|NCT01738542|Experimental|Antiaggregants & Statins & Antihypertensives & Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy
10028139|NCT01738542|Active Comparator|Antiaggregants & Statins & Antihypertensives|Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy
10028140|NCT01738555|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
10028141|NCT01738555|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
10028142|NCT01738568|Experimental|Exercise|Aerobic exercise
9465414|NCT03674372|Experimental|Fetuses with R- sided CDH with O/E LHR < 45%|Fetuses with Right CDH (O/E LHR < 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
9465415|NCT03674359||Cohort|Patients hospitalized in intensive care, meeting the inclusion criteria. BDG analysis
10028143|NCT01738607|Placebo Comparator|Placebo|"basic recipe for juice and muffin recipe~abbreviated PLB"
10028144|NCT01738607|Experimental|Carboxymethylcellulose|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated CMC"
9465416|NCT03674346|Experimental|Hypnoanalgesia group|It is performed by a radiologist technologist who has been trained in Ericksonian hypnoanalgesia in the Hospices Civils de Lyon and has been practicing it regularly for 1 year.
9465417|NCT03674346|Other|MEOPA Group|The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA)
10028145|NCT01738607|Experimental|Gum Arabic|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated GA"
9465418|NCT03674333|Experimental|Group A|Folic acid 1mg daily will be given to the participants of Group A.
10028146|NCT01738607|Experimental|Psyllium|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated as PSY"
10028147|NCT01738620|Experimental|psychological counseling+prevention of sleep disorders in ICU|patients will receive both psychological counseling and interventions to prevent sleep disorders during their ICU stay
10028148|NCT01738620|Experimental|psychological counseling|patients will receive psychological counseling
10028149|NCT01738620|Experimental|prevention of sleep disorders in ICU|interventions to prevent sleep disorders during their ICU stay
10028150|NCT01738620|No Intervention|standard care|patients will receive standard care
10028151|NCT01738633|Experimental|nutritional + respirology counseling|patients will receive both nutritional and respirology counseling
10028152|NCT01738633|Experimental|nutritional counseling|patients will receive nutritional counseling alone
10028153|NCT01738633|Experimental|respirology counseling|patients will receive respirology counseling alone
10028154|NCT01738633|No Intervention|standard care|patients will receive standard care
10028155|NCT01738659|Experimental|normal sodium diet (120 mmol/die)|active comparator: low sodium diet (80 mmol/die)
10028156|NCT01738685|Other|Control.|Nutritional Education.
10028157|NCT01738685|Other|Behavioral Intervention|Behavioral Intervention.
10028158|NCT01738711|Active Comparator|Cognitive Behavioural Therapy|Patient in this arm receive 2-6 sessions of cognitive behavioural therapy
10028159|NCT01738711|Placebo Comparator|Written information on CBT|Patients in this arm do not receive sessions of CBT but receive written information on anxiety control as per standard practice
10028160|NCT01738724|Experimental|Dienogest|Dienogest 2mg pills daily during 6 months
10028161|NCT01738724|Experimental|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
10028162|NCT01738724|Active Comparator|Desogestrel|Desogestrel 75mcg pills daily during six months
10028163|NCT01738763|Experimental|Low dose (2.5 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
10028164|NCT01738763|Experimental|Intermediate dose (4.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
10036837|NCT01819467|Active Comparator|Treatment Group|Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
10036838|NCT01819467|No Intervention|Control Group|This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method
9465419|NCT03674333|Placebo Comparator|Group B|A Placebo (a sugar pill) will be given to the participants of the Group B.
9465420|NCT03674307|Experimental|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
9465421|NCT03674307|Active Comparator|Regular screening|Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
9465422|NCT03674294|Experimental|Palonosetron/Dexamethasone/Aprepitant|
9465423|NCT03674294|Placebo Comparator|Palonosetron/Dexamethasone/Placebo|
9479978|NCT03538028|Experimental|INCAGN02385|Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
10028165|NCT01738763|Experimental|High dose (6.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
10028166|NCT01738776||Cases|Hip fracture patients participating in a randomised controlled trial (RCT) of orthogeriatric care (ClinicalTrials.gov NCT01009268)
10028167|NCT01738776||Controls|A group of voluntary elderly persons without a history of hip fracture, recruited specifically for this purpose
10028168|NCT01738802|Experimental|Anti-oxidant and micronutrient|This group will take the anti-oxidant and micronutrient supplement.
10028169|NCT01738802|Placebo Comparator|Placebo|This group will take the placebo.
10028170|NCT01738815|Experimental|valproic acid|Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
10028171|NCT01738828||Subjects with CAD|
10028172|NCT01738828||Subjects without CAD|
10028173|NCT01738841||Cohort Group|Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician.
10028174|NCT01738854|Experimental|intra-cuff pressure 40 cmH2O|
9465424|NCT03674255||1|Participants in group 1 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained, in addition to venous blood samples obtained from the cannula inserted as part of the standard clinical procedure. These blood samples will be collected before and after the stress echocardiogram. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
10028175|NCT01738854|Active Comparator|intra-cuff pressure 60 cmH2O|
10028176|NCT01738854|Active Comparator|intra-cuff pressure 80 cmH2O|
10028177|NCT01738867|Placebo Comparator|Treatment A|Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
10028178|NCT01738867|Experimental|Treatment B|Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
10028179|NCT01738867|Experimental|Treatment C|Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
10028180|NCT01738880|Active Comparator|group C|intraoperative fluid management based on CVP
10028181|NCT01738880|Experimental|group S|intraoperative fluid management based on SVV
10028182|NCT01738893|Experimental|A (test)/ B (reference)|initial administration of test and cross-over to reference
10028183|NCT01738893|Experimental|B (reference/ A (test)|initial administration of reference and cross-over to test
10028184|NCT01738906|Experimental|Alcohol placebo and MSF|175 mL orange juice with 31 g Fantomalt maltodextrin and modified sham feeding of 40 g butter cake
10028185|NCT01738906|Experimental|Alcohol and MSF|65 mL vodka with 135 mL orange juice (ca 20 g alcohol)and modified sham feeding of 40 g butter cake
10028186|NCT01738906|Experimental|Alcohol placebo and consumption|175 mL orange juice with 31 g maltodextrin and consumption of 40 g butter cake
10028187|NCT01738906|Experimental|Alcohol and consumption|65 mL vodka with 135 mL orange juice and consumption of 40 g butter cake
10028188|NCT01738906|Experimental|Alcohol placebo and control|175 mL orange juice with 31 g maltodextrin and no oral exposure to butter cake
10028189|NCT01738906|Experimental|Alcohol and control|65 mL vodka with 135 mL orange juice and no oral exposure to butter cake
10028190|NCT01738932||Patients|women with histologically verified endometriosis
10028191|NCT01738932||Controls|Healthy Danish blood donors
10028192|NCT01738945|Other|Amlodipine|Amlodipine 10 mg/day for 12 weeks
10028193|NCT01738958|Active Comparator|Probiotic lactobacilli|L. reuteri, two times a day for 6 weeks
10028194|NCT01738958|Placebo Comparator|Placebo|Placebo tablets, two times a day for 6 weeks
10028195|NCT01738997|Experimental|Group A|Dilation 10 sec
10028196|NCT01738997|Active Comparator|Group B|Dilation 2 min
10028197|NCT01739023|Experimental|Autologous Human Schwann Cells|
10028198|NCT01739036|Active Comparator|Group 4|Unvaccinated control volunteers who undergo controlled human malaria infection.
10028199|NCT01739036|Active Comparator|Group 3|Controlled human malaria infection administered at an interval of approximately 8-12 months after the initial controlled human malaria infection that the volunteers received in the VAC045 clinical trial.
10028200|NCT01739036|Active Comparator|Group 2|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp and ChAd63 AMA1 5 x 1010 vp followed by intramuscular administration of a mixture of MVA ME-TRAP 1.33 x 108 pfu and MVA CS 1.33 x 108 pfu and MVA AMA1 1.33 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
10028201|NCT01739036|Active Comparator|Group 1|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp, followed by intramuscular administration of a mixture of MVA ME-TRAP 2 x 108 pfu and MVA CS 2 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
10028202|NCT01739049|Experimental|Liraglutide and lifestyle counselling|"Liraglutide 0.6mg od for 1st week, then 1.2mg od for 2nd week then 1.8mg od until 12 weeks.~Diet and Exercise"
10028203|NCT01739049|Active Comparator|Lifestyle counselling|Diet and Exercise
10028204|NCT01739062|Experimental|Genetic risk assessment|At least 40 SNP (single nucleotide polymorphisms)increase the risk of PCa. The individual risk of PCa accumulates with the increasing number of these genetic variants. The risk is doubled if patient has familial disposition as well. In retrospective studies, non-genetic risk-prediction models were compared to risk-prediction models containing both non-genetic factors and SNPs analyses. The genetic models had a significantly higher specificity than the non-genetic models. It has been argued that genetic PCa risk assessment could reduce the inexpedient use of PSA tests, saving it for patients at high risk of PCa.
10028205|NCT01739062|No Intervention|Familial disposition risk assessment|
10036839|NCT01819480|Experimental|Transoral robotic surgery|Transoral robotic surgery
9465425|NCT03674255||2|Participants in group 2 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
10028206|NCT01739088|Experimental|Remote ischemic preconditioning stimulus|The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
10028207|NCT01739088|Sham Comparator|Sham Ischemic Pre-conditioning|In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
10028208|NCT01739101|Experimental|Intervention group|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
10028209|NCT01739101|No Intervention|Control group 1|The control group 1 answered a baseline questionnaire in the waiting room and received standard care.
10028210|NCT01739101|No Intervention|Control group 2|The control group 2 received standard care.
9465426|NCT03674255||3|Participants in group 3 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
9465427|NCT03674255||4|Participants in group 4 will be recruited at their stress echocardiogram appointment, regardless of the type of investigation. A simplified data set and an anonymised version of the stress echocardiography report will be collected as a part of this registry phase. Participants will be followed up over a 10-year period.
10028211|NCT01739114|Experimental|"SI group"|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cm H2O.~After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cm H2O and PEEP of 5 cm H2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided."
10028212|NCT01739114|Active Comparator|IPPV group|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
10028213|NCT01739127||Aripiprazole|Participants receiving treatment with at least 10mg aripiprazole per day, as prescribed to them by their psychiatrists.
10028214|NCT01739127||Risperidone/Quetiapine|Participants receiving treatment with either risperidone or quetiapine, as prescribed to them by their psychiatrists.
9465428|NCT03674242|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with~Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.~Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8."
9465429|NCT03674242|Active Comparator|Chemotherapy alone|Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle
9465430|NCT03674229|Active Comparator|Group I (information about weight management programs)|Participants receive information about commercially-available weight management programs and encouragement to participate in one of the programs for 6 months.
10028215|NCT01739127||Control|Healthy participants who are not taking any antipsychotic medications.
9465431|NCT03674229|Experimental|Group II (information, call from patient navigator)|Participants receive information about commercially-available weight management programs encouragement to participate in one of the programs for 6 months. Participants also receive 6 phone calls over 20-30 minutes each from an assigned patient navigator for 6 months.
9465432|NCT03674203|Experimental|Application of platelet-rich plasma|The patients received three sessions of PRP application, at intervals of 15 days between each of them. It was applied by means of a 32G needle to introduce the PRP by means of superficial micro-injections via the mesotherapy technique (approximately 1.5-2.0 mm deep) and it was deposited in the papillary dermis of the rosotro.
9465433|NCT03674190|Experimental|Anterior Lumbar Interbody Fusion|Surgical treatment Anterior Lumbar Interbody Fusion
9465434|NCT03674190|Active Comparator|Total disc replacement|Surgical treatment total disc replacement in the lumbar spine
9465435|NCT03674151|Active Comparator|Device: Silver Nylon dressing|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
9465436|NCT03674151|Active Comparator|Device: Manuka-Honey|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
9465437|NCT03674151|Active Comparator|Device: Povidone-Iod (PVP-Iod)|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
9465438|NCT03674151|Active Comparator|Device: Hydrogel|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
9465439|NCT03674125|Experimental|Group 1|GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost)
9465440|NCT03674125|Experimental|Group 2|GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost)
9465441|NCT03674125|Experimental|Group 3|GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost)
9465442|NCT03674125|Experimental|Group 4|GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost)
9465443|NCT03674099|Experimental|Imatinib|Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.
10028216|NCT01739140|Experimental|Yoga|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
10028217|NCT01739153|Experimental|CARB diet|The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
10028218|NCT01739153|Experimental|CHEESE diet|The CHEESE diet will contain cheese in amounts corresponding to 120 g/day on a 10 MJ diet (approx. 1.8 MJ from cheese). A high dose of cheese is chosen to provoke effects within this short time frame. The cheese types used in this study will be Danbo (45+) and Cheddar (50+) which will be supplied in equal amounts. The CHEESE diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
9465444|NCT03674099|Active Comparator|Methylprednisolone|Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.
9465445|NCT03674086||First-time hearing aid user|Using hearing aids less than or equal to three months.
9465446|NCT03674086||Existing hearing aid user|Using hearing aids for 6 months or more.
9465447|NCT03674073|Experimental|Microwave Ablation + Neoantigen Vaccines|The HCC patients will be treated firstly by Microwave Ablation, and then treated by courses of Neoantigen Vaccines.
9465448|NCT03674073|Active Comparator|Microwave Ablation|The HCC patients will be treated only by Microwave Ablation.No vaccine will be used.
9465449|NCT03674060|Experimental|SYO-1644 100mg|SYO-1644 tablet, PO, 1 100mg tablet
9465450|NCT03674060|Experimental|SYO-1644 150mg|SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
9465451|NCT03674060|Experimental|SYO-1644 200mg|SYO-1644 tablet, PO, 2 100mg tablet
9465452|NCT03674060|Active Comparator|Nexavar|Nexavar 200mg/tablet, PO, 1 tablet
9465453|NCT03674047|Experimental|newly-diagnosed BOS|-Participants will take ruxolitinib twice every day
9465454|NCT03674047|Experimental|Established BOS|-Participants will take ruxolitinib twice every day
9465455|NCT03674034||term|50 CTscan and MRI images of children aged at term
9465456|NCT03674034||one month|50 CTscan and MRI images of children aged one month
9465457|NCT03674034||two months|50 CTscan and MRI images of children aged two months
9465458|NCT03674008|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
9465459|NCT03674008|Active Comparator|Propofol|1.5mg/kg/0.75mg/kg
9465460|NCT03673995|Experimental|Myo-inositol+L-tyrosine|One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.
9465461|NCT03673982|Experimental|iCASK Group|Materials and support to aid transitions.
9465462|NCT03673969|Active Comparator|MGB|Mini gastric bypass
9465463|NCT03673969|Active Comparator|Roux enY gastric bypass|Roux enY gastric bypass
9465464|NCT03673943|Experimental|PET/CT imaging with 64Cu-DOTATATE|64Cu-DOTATATE is an investigational radioactive drug that binds to somatostatin receptors on NETs cancer cells.
9465465|NCT03673930|Active Comparator|Zanthozylum armatum|fruit extract
9465466|NCT03673930|Placebo Comparator|Placebo|placebo
9465467|NCT03673917|Experimental|Educational video|The educational video on skin cancer for cosmetologists
9465468|NCT03673917|Active Comparator|Control video|A publicly accessible healthy lifestyle video on YouTube, which did not contain any information on skin cancer
9465469|NCT03673904||Prediabetics|Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
9465470|NCT03673904||Newly diagnosed type 2 diabetes|Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/d Hb A1C > 6.5%
9465471|NCT03673891|No Intervention|Control|After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
9465472|NCT03673891|Experimental|LifeFlow group|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
9465473|NCT03673839|Active Comparator|Animal proteins (crossover)|
9465474|NCT03673839|Experimental|Plant-based protein blends type 1 (crossover)|
9465475|NCT03673839|Experimental|Plant-based protein blends type 2 (crossover)|
9465476|NCT03673839|Experimental|Plant-based protein blends type 3 (crossover)|
10028219|NCT01739153|Experimental|MEAT diet|The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
10028220|NCT01739166|Experimental|Practice-tailored intervention - Early/Phase 1|During the 6 month Intervention Phase the Practice Facilitator works with each practice to create changes that are tailored to their individual preferences and methods of operation. Sites randomized to Early/Phase 1 start their 6 month intervention immediately after randomization.
9465477|NCT03673761||Cushing's syndrome|"a) Patients with Sd Cushing (SC): 40 women (25-60 years) with SC, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
9465478|NCT03673761||acromegaly|"b) Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / Insulin-like-Growth Factor (IGF-I) controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
9465479|NCT03673761||Healthy controls|"Controls: n = 40; normal healthy control paired by age, sex and BMI will be included.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
9465480|NCT03673748|Experimental|Mesenchymal stromal cells (MSC)|Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid
9465481|NCT03673748|Placebo Comparator|Placebo|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups.
9465482|NCT03673735|Experimental|Experimental Arm|Patients will receive 1 infusion of 1500 mg Durvalumab within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with Durvalumab will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
9465483|NCT03673735|Placebo Comparator|Control arm|Patients will receive 1 infusion of placebo within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with placebo will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
9465484|NCT03673722|Experimental|MDP only|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern through interaction with the online LEAP2 platform
9465485|NCT03673722|Experimental|MDP plus PA|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern AND to increase Physical Activity using a mixture of structured and non-structured activities through interaction with the online LEAP2 platform
9465486|NCT03673722|Placebo Comparator|Control|Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and British Heart Foundation (BHF) guidelines
9465487|NCT03673696|Experimental|50 mg single dose|It includes two group, one group is pilot study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=2) . Another group is formal study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
9465488|NCT03673696|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
9465489|NCT03673696|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg HEC74647PA capsule (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
9465490|NCT03673696|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
9465491|NCT03673696|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
9465492|NCT03673696|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
9465493|NCT03673696|Experimental|100 mg multiple doses|Healthy subjects, receiving 100 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
9465494|NCT03673696|Experimental|200 mg multiple doses|Healthy subjects, receiving 200 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
9465495|NCT03673696|Experimental|400 mg multiple doses|Healthy subjects, receiving 400 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
9465496|NCT03673683|Active Comparator|Usual Care|Sedation and ventilation weaning that is non-protocol-based and primarily medically-driven.
9465497|NCT03673683|Experimental|SANDWICH protocol|A protocol-based intervention for managing sedation and ventilation weaning.
9465498|NCT03673657|Experimental|A|"ONS from the start of radiotherapy; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
9465499|NCT03673657|Experimental|B|"ONS from the time of grade 2 radiation esophagitis; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
9465500|NCT03673657|Experimental|C|ONS from the start of radiotherapy; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
9465501|NCT03673657|Experimental|D|ONS from the time of grade 2 radiation esophagitis; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
10028221|NCT01739166|Experimental|Practice-tailored intervention - Late/Phase 2|The Phase 2 group will start the practice-tailored intervention with the study facilitator 4 months post-randomization and continue through post-randomization month 10.
10028222|NCT01739179||1|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
10028223|NCT01739179||2|VP Shunt Surgery for open insertion of the peritoneal catheter
10028224|NCT01739192|Placebo Comparator|Arm 1|Placebo oral daily for approximately six (6) weeks.
10028225|NCT01739192|Experimental|Arm 2|Naltrexone (25 mg) oral daily for approximately six (6) weeks.
9465502|NCT03673644||Primary Open-Angle Glaucoma|"Two following two questionnaires will be administered:~Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.~Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions."
9465503|NCT03673631||NFHC-O2 Group|NFHC-O2 therapy alone with gas flow at least 40L/min,
9465504|NCT03673631||NIV/Standard-O2 Group|NIV sessions with at least 30% FiO2 and standard oxygen therapy
9465505|NCT03673631||NFHC-O2/NIV Group|combination of NIV sessions and NFHC-O2 therapy,
9465506|NCT03673618|Experimental|PROMOTIR soluble corn fiber|Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
9465507|NCT03673618|Placebo Comparator|Malodextrin|Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
9465508|NCT03673605|Experimental|Rivaroxaban|
9465509|NCT03673605|Active Comparator|Warfarin|
9465510|NCT03673592||Euploid embryos analyzed by PGT-A|Embryos with a normal chromosome copy number. This embryos will be transferred to the uterus.
9465511|NCT03673592||Low-grade mosaic embryos (PGT-A)|Embryos with a lower aneuploidy percentage (<50%). This embryos will be considered for transfer to the uterus.
9465512|NCT03673592||High-grade mosaic embryos (PGT-A)|Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
9465513|NCT03673592||Aneuploid embryos analyzed by PGT-A|Embryos with an abnormal number of chromosomes. This embryos will be discarded for transfer.
9465514|NCT03673579|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
9465515|NCT03673579|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
9465516|NCT03673579|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
9465517|NCT03673566|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
10028226|NCT01739192|Experimental|Arm 3|Naltrexone (50 mg) oral daily for approximately six (6) weeks.
10037558|NCT01826175|Active Comparator|Clopidogrel|Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
9465518|NCT03673566|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
9465519|NCT03673566|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
9465520|NCT03673553||Association of people with fibromyalgia|Control group included people affiliated to the FM Patient Association of Terres de l'Ebre, Spain.
9465521|NCT03673553||Multimodal treatment of patients with FM|The intervention group was made up of patients from the specialist FM Unit in the Hospital of Lleida, Spain.
10037559|NCT01826188|Active Comparator|THC 5 mg/ml and CBD 50 mg/ml.|olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
10037560|NCT01826188|Placebo Comparator|Placebo|olive oil but without any active ingredients.
9465522|NCT03673540|Experimental|CBT with smartphone application (EMI on)|CBT with CBT+ smartphone application (EMI on)
9465523|NCT03673514|Active Comparator|THA Posterior Approach|The posterior approach to the hip has been described by many authors and yields good results. Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
9465524|NCT03673514|Active Comparator|THA Direct anterior approach|The modified Hueter approach, based on the Smith-Peterson approach, was performed for the direct anterior minimally invasive surgery. This approach could have some advantages as it is a muscle sparing approach, hence yielding a faster recovery. A traction table was used for DAA as surgeons were trained to use this method. No intra-operative fluoroscopy was used for implant confirmation.Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
9465525|NCT03673501|Experimental|DCC-2618|150 mg QD DCC-2618
9465526|NCT03673501|Active Comparator|sunitinib|50 mg QD sunitinib
9465527|NCT03673488||TephaFlex™ mid-urethral sling for SUI|P4HB material ( TephaFlex ™) will be implanted in 25 women with confirmed Stress Urinary Incontinence (SUI).
9465528|NCT03673475||fluid responsiveness|Assessment of fluid responsiveness using pleth variebility index and jugular vein distensibility in patients undergoing major abdominal surgery
10028227|NCT01739205|Experimental|Lifestyle counseling|"CALM-D Intervention Session Topic Weekly~I Welcome to the CALM-D Program. Getting Started Being Active, Losing Weight and Managing Stress~I Negative Thoughts and Emotions~G Where's the Fat?/Three Ways to Eat Less Fat~G Taking Your Medications/Stress and You Bi weekly~G Move Those Muscles/Being Active: A Way of Life~G Challenging and Changing Negative Thoughts~G Healthy Eating~G Problem Solving Monthly~G Four Keys to Healthy Eating Out~G Social Support/Communication~G Take Charge of What's Around You/Tip the Calorie Balance~G The Slippery Slope of Lifestyle Change~G Jump Start Your Activity Plan~G Assertiveness/Make Social Cues Work for You.~G You Can Manage Stress~G Life Goals~G Ways to Stay Motivated Abbreviations: I = Individual session; G = Group session"
10028228|NCT01739218|Experimental|Carboplatin + Paclitaxel + Bevacizumab|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5).
10028229|NCT01739218|Active Comparator|Carboplatin + Paclitaxel|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26.
10028230|NCT01739244|Experimental|SYL040012 eye drops dose A|Ocular topical administration of SYL040012 eye drops dose A
9465529|NCT03673449|Experimental|SilkBridge treatment|Surgery for digital nerve reconstruction with SilkBridge
9465530|NCT03673436||Patients with low back pain|Cohort of 200 low back pain patients, 18 years+, who have been undergoing a lumbar spinal fusion
9465531|NCT03673410|Active Comparator|Laparoscopic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.
9465532|NCT03673410|Experimental|Robotic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.
9465533|NCT03673397|Experimental|Aerobic exercise|Patients allocated to the intervention group will perform a single bout of supervised aerobic exercise. The starting time will be approximately 1630 hrs. The exercise mode will be a bicycle ergometer. After a warm-up period, during which the intensity is gradually increased, an intensity of 80% of the individual anaerobic threshold will be maintained for 30 minutes. The intensity level was chosen based on clinical experience that this corresponds to an approximate rate of perceived exertion of 13 (on a scale from 6-20) in this population.
9465534|NCT03673397|No Intervention|Control|Individuals allocated to the control group will be placed in a room with analogous conditions to the exercise group concerning light, temperature and absence of music at the same time as individuals performing the exercise intervention. The control group will be asked to remain seated and read magazines.
9479979|NCT03537989|Experimental|Restricted group|"Oral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules.~Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.~Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase.~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
9479980|NCT03537989|Active Comparator|Standard group|"Oral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.~Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
9479981|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
9479982|NCT03537950|Experimental|PLC, CBD, CBDV|Dose order: PLC, CBD, CBDV
9479983|NCT03537950|Experimental|PLC, CBDV, CBD|Dose order: PL, CBDV, CBD
9479984|NCT03537950|Experimental|CBD, PLC, CBDV|Dose order: CBD, PLC, CBDV
9479985|NCT03537950|Experimental|CBD, CBDV, PLC|Dose order: CBD, CBDV, PLC
9479986|NCT03537950|Experimental|CBDV, PLC, CBD|Dose order: CBDV, PLC, CBD
9479987|NCT03537950|Experimental|CBDV, CBD, PLC|Dose order: CBDV, CBD, PLC
9479988|NCT03537937|Active Comparator|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
9479989|NCT03537937|Active Comparator|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
9479990|NCT03537937|Active Comparator|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
10028231|NCT01739244|Experimental|SYL040012 eye drops dose B|Ocular topical administration of SYL040012 eye drops dose B
9479991|NCT03537924|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
10028232|NCT01739244|Experimental|SYL040012 eye drops dose C|Ocular topical administration of SYL040012 eye drops dose C
10028233|NCT01739244|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
10028234|NCT01739257|Experimental|Theater|"1-hour dramatic reading of The Most Massive Woman Wins"
10028235|NCT01739257|Active Comparator|Lecture|1-hour lecture on the medical management of obese patients
10028236|NCT01739270|Active Comparator|dexamethasone with levobupivacaine|25ml 0.5% levobupivacaine plus 4mg Dexamethasone are given for supraclavicular brachial plexus block for upper extremity surgery
9465535|NCT03673384|Experimental|experimental group|"Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate."
9465536|NCT03673384|Placebo Comparator|Control group|received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
9465537|NCT03673371||Women Veterans with Lower Limb Amputations|Questionnaire
9465538|NCT03673358|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
9465539|NCT03673358|No Intervention|No intervention- - control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
9465540|NCT03673332|Experimental|treatment including immune checkpoint inhibitors|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
9465541|NCT03673319|Experimental|Positive expectative|"Participants in the positive expectation group will be told that DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
9465542|NCT03673319|Experimental|Neutral expectatives|"Participants in the neutral expectation group will be told that DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
9465543|NCT03673306||Pregnant cohort|Women with one or more pregnancies any time after breast cancer diagnosis
9465544|NCT03673306||Non-pregnant cohort|Women with no subsequent pregnancies after breast cancer diagnosis
9465545|NCT03673280|Placebo Comparator|Classical spinal anesthesia|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + placebo quadratus lumborum block.
9465546|NCT03673280|Experimental|Spinal anaesthesia with block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg + quadratus lumborum block.
9465547|NCT03673280|Experimental|Classical anaesthesia plus block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + quadratus lumborum block.
9465548|NCT03673267|Experimental|Nutricity|
9465549|NCT03673241|No Intervention|Control Group|The Control Group will receive the standard support surface mattresses/bed surfaces and recovery chairs without the non-invasive perfusion enhancement system (The Guardian System)
9465550|NCT03673241|Experimental|Study Arm|The Study Arm will have the non-invasive perfusion enhancement system placed on their beds and recovery chairs. Patients will be utilizing the systems while lying in bed or sitting in the chair.
9465551|NCT03673215|Experimental|A|
9465552|NCT03673215|Experimental|B1|
9465553|NCT03673215|Placebo Comparator|B2|
9465554|NCT03673215|Experimental|C1-1|
9465555|NCT03673215|Placebo Comparator|C1-2|
9465556|NCT03673215|Experimental|C2-1|
9465557|NCT03673215|Placebo Comparator|C2-2|
9465558|NCT03673215|Experimental|C3-1|
9465559|NCT03673215|Placebo Comparator|C3-2|
9465560|NCT03673202||UC monitoring patients|Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.
9465561|NCT03673189|Experimental|Healthy volunteers|Sensors assigned for 3 weeks
9465562|NCT03673189|Experimental|Patients with arythmic disease or peripheral vascular disease|Sensors assigned for 3 weeks
10028237|NCT01739270|Active Comparator|levobupivacaine|25ml 0.5% levobupivacaine plus 1ml 0.9% saline are given for supraclavicular brachial plexus block for upper extremity surgery
9465563|NCT03673176|Experimental|Stereotactic Ablative Radiotherapy|Experimental stereotactic ablative radiation treatment
9465564|NCT03673163|Experimental|Lidocaine|Lidocaine treatment
9465565|NCT03673163|Placebo Comparator|Control|Placebo treatment
9465566|NCT03673150||women with breast cancer|women who gave birth in 2002/2005 with cord blood collection and developed invasive or non-invasive breast cancer in the following years (2005- O6/2018) to the exclusion of another cancer.
9465567|NCT03673150||women without breast cancer|Controls will be obtained by matching by date of delivery, location, age (woman's date of birth), parity at the time of cord collection and not having had breast cancer
9465568|NCT03673137|Experimental|Synchronous treatment group|Gemcitabine was administered over 30 minutes immediately following percutaneous irreversible electroporation. Gemcitabine was then given once weekly for 2 weeks, followed by a week of rest from treatment. Subsequent cycles consisted of once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
9465569|NCT03673137|Active Comparator|Traditional treatment group|The initial gemcitabine administration was on day 7 following IRE treatment. Once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
9465570|NCT03673111|Experimental|1.0 mg|Y14 single dose, subcutaneous
9465571|NCT03673111|Experimental|2.0 mg|Y14 single dose, subcutaneous
9465572|NCT03673111|Experimental|6.0 mg|Y14 single dose, subcutaneous
9465573|NCT03673111|Experimental|9.0 mg|Y14 single dose, subcutaneous
9465574|NCT03673111|Experimental|18.0 mg|Y14 single dose, subcutaneous
9465575|NCT03673111|Experimental|36.0 mg|Y14 single dose, subcutaneous
9465576|NCT03673111|Placebo Comparator|Placebo|0.9% saline
9465577|NCT03673111|Experimental|26.0 mg (B1)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 12mg on day 8, 16mg on day 15, 20mg on day 22 and 26mg on day 29.
10028238|NCT01739283|Experimental|hyperglycemia|Hyperglycemic clamping
10028239|NCT01739283|Experimental|hypoglycemia|Hypoglycemic clamping
9465578|NCT03673111|Experimental|36mg (B2)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
10028240|NCT01739296|Experimental|Wedge|Lateral wedge insole with subtalar strapping Use of lateral wedge insoles with subtalar strapping for 5 to 10 hours daily
10028241|NCT01739296|Sham Comparator|Neutral|Neutral insole with subtalar strapping (sham) Use of neutral insoles with subtalar strapping for 5 to 10 hours daily
10028242|NCT01739322|Experimental|1|"Four concentrations of Platanus acerifolia allergen extract (10, 1, 0.1, 0.01 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
9465579|NCT03673111|Experimental|36mg (B3)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 12mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
9465580|NCT03673098|Experimental|Intervention Group: Adapted 3RP|The intervention condition will consist of the 10-week adapted 3RP intervention.
9465581|NCT03673098|No Intervention|Control Group: Supportive Psychotherapy|The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
9465582|NCT03673085|Experimental|Group 1-1|The dose of CN128 is 2.5 mg/kg bw.
9465583|NCT03673085|Placebo Comparator|Group 1-2|The dose of placebo is 2.5 mg/kg bw.
9465584|NCT03673085|Experimental|Group 2-1|The dose of CN128 is 5 mg/kg bw.
9465585|NCT03673085|Placebo Comparator|Group 2-2|The dose of placebo is 5 mg/kg bw.
9465586|NCT03673085|Experimental|Group 3-1|The dose of CN128 is 10 mg/kg bw.
9465587|NCT03673085|Placebo Comparator|Group 3-2|The dose of placebo is 10 mg/kg bw.
9465588|NCT03673085|Experimental|Group 4-1|The dose of CN128 is 15 mg/kg bw.
9465589|NCT03673085|Placebo Comparator|Group 4-2|The dose of placebo is 15 mg/kg bw.
9465590|NCT03673085|Experimental|Group 5-1|The dose of CN128 is 20 mg/kg bw.
9465591|NCT03673085|Placebo Comparator|Group 5-2|The dose of placebo is 20 mg/kg bw.
9465592|NCT03673085|Experimental|Group 6-1|The dose of CN128 is 30 mg/kg bw.
9465593|NCT03673085|Placebo Comparator|Group 6-2|The dose of placebo is 30 mg/kg bw.
9465594|NCT03673085|Experimental|Group 7-1|The dose of CN128 is 45 mg/kg bw.
9465595|NCT03673085|Placebo Comparator|Group 7-2|The dose of placebo is 45 mg/kg bw.
9465596|NCT03673085|Experimental|Group 8-1|The dose of CN128 is 60 mg/kg bw.
9465597|NCT03673085|Placebo Comparator|Group 8-2|The dose of placebo is 60 mg/kg bw.
9465598|NCT03673072|Experimental|Arm A (gemcitabine plus cisplatin)|Patients assigned to arm A will receive treatment with gemcitabine plus cisplatin. Chemotherapy will be administered for 3 cycles preoperatively (neoadjuvant part) and for 3 cycles postoperatively (adjuvant part).
9465599|NCT03673072|Active Comparator|Arm B (standard postoperative management)|Patients assigned to arm B will receive surgery directly, without receiving perioperative chemotherapy (Standard of Care / SOC). After surgery, adjuvant chemotherapy can be administered by investigator's choice.
9465600|NCT03673059|Experimental|OTC Eczema Moisturizer Regimen|Subjects who were assigned to use an over-the-counter (OTC), oatmeal-containing eczema therapy moisturizing cream. The product is classified as an OTC monograph drug.
10028243|NCT01739374|Experimental|Device - Reduced mesh implants|Patients treated with reduced mesh implants for POP reconstruction
10028244|NCT01739387||Breath actuated inhaler (BAI)|Placebo. Two to nine puffs on one day only
10028245|NCT01739387||Flutiform® pMDI|Placebo. Two to nine puffs on one day only
10028246|NCT01739413|Active Comparator|General Anesthesia|Patients will receive general anesthesia alone followed by intravenous morphine for postoperative pain control. This techniques is safe and is standard procedure for colorectal surgery.
10028247|NCT01739413|Experimental|Epidural Anesthesia|Patients will receive general anesthesia plus epidural anesthesia followed by epidural analgesia for postoperative pain control. This techniques is safe and standard procedure for colorectal surgery.
9465601|NCT03673059|Experimental|Cosmetic Moisturizer Regimen|Subjects who were assigned to use a non-fragranced, dry skin daily moisturizer classified as a cosmetic (i.e. non-OTC).
9465602|NCT03673046|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
9465603|NCT03673046|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
9465604|NCT03672994||Asthma|Patients with prior confirmed diagnosis of bronchial asthma
9465605|NCT03672994||Chronic Obstructive Pulmonary Disease|Patients with prior confirmed COPD
9465606|NCT03672994||Pneumonia|Patients with X-ray confirmed community acquired pneumonia
9465607|NCT03672994||Heart failure|Patients with confirmed heart failure
9465608|NCT03672994||Healthy volunteers|Healthy participants with no otherwise known cardiorespiratory condition
9465609|NCT03672981|Experimental|Supportive Care (aerobic exercise and resistance training)|Patients undergo moderately intense aerobic/cardiovascular exercise over 30-60 minutes and complete 1-2 sets of 8 to 10 resistance/strength training exercises, 8 to 12 repetitions of each exercise, 3 days per week for 12 weeks. Patients also participate in weekly phone calls with an exercise physiologist to ensure adherence to the program and to provide support.
9465610|NCT03672942|Experimental|Communication Skills|Male and female participants will listen to a description of John Gottman's Gentle Start-up communication skills training exercise and practice the technique in the lab for approximately 8 minutes.
9465611|NCT03672942|Experimental|Mindfulness|Male and female participants will listen to a script about Acceptance/Willingness of unwanted emotions written by Amie Zarling and practice this technique in the lab for approximately 8 minutes.
9465612|NCT03672942|Placebo Comparator|Placebo|Male and female participants will listen to music in lieu for 8 minutes.
9465613|NCT03672903|Experimental|Intervention|Subjects in this arm will carry heavy weight vests for three weeks.
10028248|NCT01739426|Experimental|Study population|"The population is composed of patients with a confirmed Zenker's diverticulum.~Intervention: Repair w/LigaSure"
10028249|NCT01739439|Experimental|Treatment (chemoradiation and radiosurgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
10028250|NCT01739452||erythropoiesis-stimulating agents|Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents.
9465614|NCT03672903|Placebo Comparator|Control|Subjects in this arm will carry light weight vests for three weeks.
9465615|NCT03672890||Pre-Telestroke|Retrospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
9465616|NCT03672890||Post-Telestroke|Prospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
9465617|NCT03672877|Experimental|Immediate training group|Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
9465618|NCT03672877|No Intervention|Delay training group|Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
9465619|NCT03672864|Experimental|Immediate Group|The intervention is intensive exercise, delivered over 12 weeks beginning on admission to the study. The group will then be followed for 9 months post intervention.
9465620|NCT03672864|No Intervention|Delay Group|The group will be followed for 6 months with no intervention. After 6 months the group will be given the opportunity to receive the same intensive exercise intervention as the Immediate group. The group will be followed for 3 months following the intervention.
9465621|NCT03672851|Experimental|anti-CD123 CAR-T treatment|
9465622|NCT03672838|Active Comparator|Cohort 1|Patients with NF1
9465623|NCT03672838|Active Comparator|Cohort 2|Patients with NF2
9465624|NCT03672812|No Intervention|placebo|0,5ml
9465625|NCT03672812|Experimental|liraglutide|0,5ml
9465626|NCT03672799|Experimental|Rehabilitation Planning Consult (RPC)|"The RPC is a trans-disciplinary, consultative intervention. In the RPC, individualized rehabilitation needs are established, goals are set, strategies to achieve the goals are developed, and follow-through with strategies and goal attainment is facilitated by a rehabilitation professional who consults and collaborates with the survivor. The Rehabilitation Consultant does not provide hands-on treatment, but rather determines the survivors' priority individualized rehabilitation goals, and then helps devise a plan for the survivor to meet those goals independently.~Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consultant and second consultation 2 to 12 weeks later."
9465627|NCT03672799|Active Comparator|Wait list control (WLC)|"There is no standard rehabilitation care for survivors of head and neck cancer at the Princess Margaret Cancer Centre.~Participants allocated to WLC will enter a 12 week waiting period after which they will crossover to the RPC group."
9465628|NCT03672786|Active Comparator|Control Group|Sedentary: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
9465629|NCT03672786|Experimental|Experimental Group|Athletes: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
9465630|NCT03672760|Active Comparator|IMT PowerBreath|"Participants will have PowerBreath device for IMT adjusted for 30% of maximal inspiratory pressure and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will provide re-adjustment of load through maximal inspiratory pressure performance"
9465631|NCT03672760|Placebo Comparator|IMT PowerBreath Placebo|"Participants will have PowerBreath device for IMT with no load and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will not re-adjustment the load though maximal inspiratory pressure performance will be performed"
10028251|NCT01739452||Transfusion support|A control group of patients who received only transfusional support.
9465632|NCT03672760|Active Comparator|CardioBreathApp|CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 10 minutes for five weeks An once a week meeting will provide re-adjustment of respiratory rate to perform exercises
9465633|NCT03672747|Active Comparator|Anodal|Participants will receive occipital anodal stimulation using high-definition tDCS
9465634|NCT03672747|Active Comparator|Cathodal|Participants will receive occipital cathodal stimulation using high-definition tDCS
9465635|NCT03672747|Placebo Comparator|Sham|Participants will receive occipital sham stimulation (placebo) using high-definition tDCS
9465636|NCT03672721|Experimental|IA Carbo + radiation|Intraarterial carboplatin + radiation
9465637|NCT03672708|Other|Cresyl violet|
9465638|NCT03672682||DLBCL with chemoresistance|15 patients with DLBCL with chemoresistance or relapsed less than 2 years after completion of first-line therapy
9465639|NCT03672682||DLBCL with chemosensitivity|15 patients with DLBCL with chemosensitivity without relapse within 2 years following the end of first-line therapy.
9465640|NCT03672682||Healthy patients|15 healthy patients
9465641|NCT03672669|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF was applied into the tooth socket after mandibular third molar surgery.
9465642|NCT03672669|Active Comparator|Leukocyte- and platelet-rich fibrin (L-PRF)|L-PRF was applied into the tooth socket after mandibular third molar surgery.
9465643|NCT03672656|Experimental|pattern scanning laser system Pascal|
9465644|NCT03672656|Active Comparator|conventional laser|
9465645|NCT03672617||Children and adolescents|Children and adolescents, who administer growth hormone (GH) themselves (self-injections) will be asked to complete the questionnaire.
10028252|NCT01739465|Active Comparator|Self expanding metallic stent （SEMS ）placement only|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
9465646|NCT03672617||Parents/legal guardians|Parents/legal guardians who administer the GH to their child will be asked to complete the questionnaire.
9465647|NCT03672604|Placebo Comparator|Part A: Single Dose|"Cohort 1 = 0.25 mg NLY01 Cohort 2 = 0.8 mg NLY01 Cohort 3 = 2.5 mg NLY01 Cohort 4 = 5 mg NLY01 Cohort 5 = 10 mg NLY01~All cohorts include 8 subjects randomized to receive a single dose of NLY01 or placebo (6 active, 2 placebo)."
9465648|NCT03672604|Placebo Comparator|Part B: Multiple Dose|"In Part B, NLY01 or placebo will be administered once-weekly for 4 doses. There will be 3 sequentially-enrolled, ascending-dose cohorts of 8 subjects (6 active, 2 placebo). Doses in Part B will be a fraction of the maximum tolerated dose (MTD) established in Part A.~Cohort 6 = 15% of the single-dose MTD Cohort 7 = 35% of the single-dose MTD Cohort 8 = 70% of the single-dose MTD"
9465649|NCT03672604|Placebo Comparator|Part C:Multiple Dose|"In Part C, NLY01 or placebo will be administered once-weekly for 6 doses.~Cohort 10 = 2.5 mg NLY01 Cohort 11 = 5 mg NLY01"
9465650|NCT03672591||HFpEF patients|Patients suffering from heart failure with preserved ejection fraction
9465651|NCT03672591||Control group|Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
9465652|NCT03672578|Experimental|Loss-frame, text-only, no attribution|Label participants will see is loss-frame, text-only, and with no attribution
10028253|NCT01739465|Experimental|Endoscopic radiofrequency ablation plus SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
9802985|NCT04720443|Experimental|SAD Part 1 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 30 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
10028254|NCT01739465|Experimental|Photodynamic therapy plus SEMS|Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
10028255|NCT01739478|Experimental|Non-packing of abscess cavity|
10028256|NCT01739478|Other|Packing of abscess cavity|Current practice
9465653|NCT03672578|Experimental|Gain-frame, text-only, no attribution|Label participants will see is gain-frame, text-only, and with no attribution
10028257|NCT01739491||Bendamustine hydrochloride|Adult Filipino patients with chronic lymphocytic leukemia will be taking bendamustine hydrochloride as per the dosing regimen given on product insert approved in Philippines.
10028258|NCT01739504|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Intervention: AD-SVF infusion directly into affected joints.
10028259|NCT01739517|Experimental|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
10028260|NCT01739530|Experimental|Repaircell|allogenic differentiated adipocyte
10028261|NCT01739543|Experimental|Investigational|Subject receives Hem-Avert Device.
9465654|NCT03672578|Experimental|Loss-frame, icon, no attribution|Label participants will see is loss-frame, icon, and with no attribution
9465655|NCT03672578|Experimental|Grain-frame, icon, no attribution|Label participants will see is gain-frame, with an icon, and with no attribution
9465656|NCT03672578|Experimental|Loss-frame, icon, attribution|Label participants will see is loss-frame, icon, and with attribution
9465657|NCT03672578|Experimental|Gain-frame, icon, attribution|Label participants will see is grain-frame, icon, and with attribution
9465658|NCT03672578|Experimental|Loss-frame, text-only, attribution|Label participants will see is loss-frame, text-only, and with attribution
10028262|NCT01739543|No Intervention|Control|Subject does not receive Hem-Avert Device.
10028263|NCT01739556|Experimental|Intervention Arm|Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
9465659|NCT03672578|Experimental|Gain-frame, text-only, attribution|Label participants will see is gain-frame, text-only, and with attribution
9465660|NCT03672578|Placebo Comparator|No label|Participant will not see a label
9465661|NCT03672565|Active Comparator|Hospital setting|ERPs may be conducted in various settings on hospital grounds (e.g., cafeteria, hallways) but will not be conducted off property.
9465662|NCT03672565|Active Comparator|Community setting|Community ERP sessions will be conducted locations deemed most relevant to the child's symptom presentation such as in the home or at other community locations (e.g., church, downtown).
9465663|NCT03672552|Experimental|FFWP and Improved Oral Care|Receiving dental hygienist cleaning with supervised tooth brushing and FFWP (plain, unmodified water).
9465664|NCT03672552|No Intervention|Standard Care|This group has assessments and standard oral care with no dental hygienist cleaning, no FFWP or supervised tooth brushing and continuing with agreed upon diet texture and fluid modification.
10028264|NCT01739556|No Intervention|Standard Treatment|Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
10028265|NCT01739569|Experimental|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
10028266|NCT01739569|No Intervention|Habitual meals|Dietary treatment with habitual diet
9465665|NCT03672539|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and days 1 and 3 of cycle 2 and gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~CONSOLIDATION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and gemtuzumab ozogamicin over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~MAINTENANCE CYCLE: Patients receive gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
9465666|NCT03672526|Experimental|device compuflo|
9465667|NCT03672513|Placebo Comparator|Placebo Supplemented Group|Placebo control
9465668|NCT03672513|Experimental|Magnesium Supplemented Group|Magnesium Group
9465669|NCT03672513|Experimental|Zinc Supplemented Group|Zinc Group
9465670|NCT03672500|Active Comparator|Bupivacaine arm|The edges of the 2PT/Epi will be infiltrated with 10ml of Bupivacaine 0.5%+Epinephrine 50mcg prior to suture placement.
9465671|NCT03672500|Sham Comparator|Control arm|Sham injection will be done using a syringe filled with 10ml of NaCl 0.9%, but the fluid will not be injected to the edges of the laceration but discarded. The sham injection will last no less than 10 seconds.
9465672|NCT03672474|Experimental|Photobiomodulation REGEnLIFE RGn530 device group|
9465673|NCT03672474|Sham Comparator|Sham REGEnLIFE RGn530 device group|
9465674|NCT03672461|Experimental|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population. The study will feature a therapeutic program based primarily on Iyengar yoga, a form of Hatha yoga that is known for its potential therapeutic applications.
9465675|NCT03672461|Active Comparator|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants. Similar to postures in the yoga intervention program, the exercises in the stretching/strengthening program have been selected for their potential to be performed safely by women across a range of ages and flexibility levels."
9465676|NCT03672448||Neurocognitive disorder|Dementias
9465677|NCT03672448||Normal Aging|Normal Aging with normal cognitive function
9465678|NCT03672435||proparacaine|Received topical proparacaine 0.5% with routine antibiotic-steroid ointment in operative eye(s) following strabismus surgery
9465679|NCT03672435||No proparacaine|Received no topical proparacaine 0.5% but did receive routine antibiotic-steroid ointment in the operative eye(s) following strabismus surgery
9465680|NCT03672422||Acute Recurrent Pancreatitis|At least 2 episodes of acute pancreatitis with complete resolution of pain and a >1 month pain-free interval between episodes.
9465681|NCT03672422||Chronic Pancreatitis|"Children with at least:~1) One irreversible structural change* in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes.~*irreversible structural changes:~Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).~Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2 months) on any imaging.~Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP.~Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)."
9465682|NCT03672409|Other|Intervention in knowledge|All participants will be offered learning sessions to improve knowledge in diabetes
9465683|NCT03672383|Experimental|BAY987534 (Treated Arm)|Subjects with quiescent atopic dermatitis. Right or left volar forearm with test product applied.
9465684|NCT03672383|No Intervention|Untreated Arm|Subjects with quiescent atopic dermatitis. Right or left volar forearm without test product applied.
9465685|NCT03672357|Experimental|Laparoscopic liver resection|Laparoscopic hepatectomy
9465686|NCT03672357|Other|Open liver resection|Open hepatectomy
9465687|NCT03672344|Active Comparator|BioStream Training|
9465688|NCT03672344|Placebo Comparator|Alternative Game|
9465689|NCT03672305|Other|c-Met/PD-L1 CAR-T cells treating group|Intervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 * 10^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.
9465690|NCT03672266||Neurological Disorder|Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia
9465691|NCT03672266||Neurotypical|Healthy individuals with no known neurological disorders
10028267|NCT01739582|Experimental|Androxal|Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule. Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2.
10028268|NCT01739608|Experimental|CT Colonography (CTC)|Invitation to screening. Subject who consent to participate in the study undergo to low dose CTC examination with limited bowel preparation.
9465692|NCT03672253|Experimental|CAR-T Re-treatment group|Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
10028269|NCT01739608|Active Comparator|Sigmoidoscopy (FS)|Invitation to screening. Subjects who consent to participate in the study undergo to FS.
9465693|NCT03672240|Experimental|APL-1202|"APL-1202 will be administered orally at daily 750 mg (250 mg, TID) for 5-7 days prior to the first intravesical BCG treatment and continue for additional 11 weeks (a total 12 weeks of dosing with APL-1202).~Standard intravesical BCG induction course (once weekly for 6 weeks) 50 mg TICE BCG in 50 mL sterile saline (or a full dose standard vial of BCG) will be initiated on Week 2."
9465694|NCT03672214|Experimental|Without placement of a catheter|No placement of indwelling catheter prior to Caesarean section
10028270|NCT01739621|Experimental|Proellex 12 mg|Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months
10028271|NCT01739621|Experimental|Proellex 24 mg|Telapristone acetate, 1 vaginally inserted capsule, twice a day, for 4 months
10028272|NCT01739634|Experimental|Active Drug|After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.
10028273|NCT01739647|Experimental|AZD3293|Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg
9465695|NCT03672214|Active Comparator|With placement of a catheter|Placement of indwelling catheter prior to Caesarean section
9465696|NCT03672201|Active Comparator|The Integrated Care Pathway (ICP) Arm|The ICP consists of 1) a cleanup phase during which a thorough assessment of pharmacotherapy to discontinue unnecessary medications, is performed; 2) Structured non-pharmacological interventions, which would have started as soon as randomization occurred and would continue before any pharmacological intervention for 2 weeks as stand-alone interventions; and 3) a pharmacological intervention phase: in this phase the medications algorithm for AD-AA is initiated.
9465697|NCT03672201|No Intervention|Treatment-As-Usual (TAU) Arm|Following eligibility and baseline assessments, half of the participants will be randomized to TAU. TAU will consist of the typical care that the interdisciplinary team provides at each site for AD-AA. No predetermined cleanup phase, non-pharmacological interventions, algorithmic pharmacological interventions will be systematically part of TAU.
10028274|NCT01739647|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
9465698|NCT03672162|Active Comparator|Gabapentin Group|Subjects will receive Gabapentin 600 mg (two capsules of Gabapentin 300 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
9465699|NCT03672162|Active Comparator|Celecoxib Group|Subjects will receive Celecoxib 400 mg (two capsules of Celecoxib 200 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
9465700|NCT03672162|Placebo Comparator|Placebo group|Subjects will receive Placebo (two capsules of placebo) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
9465701|NCT03672149|Other|Infection needing cefazolin|a) If a patient requires antimicrobial therapy for a proven or suspected infection at the time of CRRT initiation or at any time receiving CRRT, they are eligible for inclusion. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic and safety data of administering cefazolin via the CRRT solution and infection treatment related data. For this indication, pharmacokinetic and safety data will be obtained for the duration the patient receives cefazolin via the CRRT solution(s) for the proven or suspected infection as dictated by the primary team caring for the patient.
9465702|NCT03672149|Other|Infection not needing cefazolin|b) If a patient is deemed a candidate for CRRT and requires therapy with any anti-microbial for a proven or suspected infection not requiring cefazolin as part of the anti-microbial drug regimen, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
9465703|NCT03672149|Other|No infection|c) If a patient is deemed a candidate for CRRT and does not require any anti-microbial therapy, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
9465704|NCT03672136|Experimental|Concurrent Chemoradiotherapy+Anlotinib|"Radiotherapy: Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy. If radiotherapy and chemotherapy are conducted in the same day, chemotherapy should be priority to radiotherapy.~Chemotherapy: Platinum based dual drug regime determined by researcher.After finishing concurrent chemoradiotherapy, there is no need of maintenance chemotherapy.~Anlotinib: Combined with 12mg/d QD Anlotinib on the first, second weeks and fourth, fifth weeks of radiotherapy, that is on the day1~14, day22~36.~Maintenance therapy: One month after finishing concurrent chemoradiotherapy, 12mg/d QD Anlotinib can be administrated, each cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. The treatment can continue until disease progression or treatment intolerance, but should not exceed 24 months.~During the course of study, it's not allowed to receive other anti-tumor therapy."
9465705|NCT03672123||APE with RVD|RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria
9465706|NCT03672123||APE without RVD|RVD defined according to ESC criteria
9465707|NCT03672110|Active Comparator|Standard tacrolimus group|Control group: Advagraf will be administered as usual (0.2mg/kg bodyweight), trough levels will be measured every day in the first week after kidney transplantation (TX) and Advagraf dose will be adjusted accordingly.
10028275|NCT01739660|Experimental|Pegloticase|Pegloticase 8 mg single intraveneous dose
10028276|NCT01739673|Experimental|Ultraviolet-A and riboflavin|
10028277|NCT01739686|Experimental|CASA Intervention|"The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
10028278|NCT01739686|No Intervention|Usual Care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. If patients self-report depression on baseline surveys, this information will be given to their provider, and patients will be given resources. Patients will have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency.
10028279|NCT01739712|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
10028280|NCT01739712|Sham Comparator|Fixed Sleep Duration|All youth in this condition are asked to maintain their baseline sleep duration.
9465708|NCT03672110|Experimental|Fixed dose tacrolimus group|Study group: Advagraf will be administered per fix dose 5mg/day, trough levels will be blinded during the first week, there will be no adjustments in the first week after TX.
9465709|NCT03672071|Other|Group E|If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Ephedrine i.v. will be administered to patient will be performed. In the case of hypotension,
9465710|NCT03672071|Other|Group NE|.If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Noradrenaline, i.v. will be administered to patient will be performed. In the case of hypotension,
9465711|NCT03672071|Other|Group N|. If a 20% decrease in parameter compared to their baseline levels is sustained, necessary interventions mg Ephedrine + 2.5 mg Noradrenaline i.v. will be administered to patient will be performed. In the case of hypotension,
9465712|NCT03672058|Experimental|Fitbit plus personalised text messaging & Goal Setting|
9465713|NCT03672058|Active Comparator|Fitbit Only|
9465714|NCT03672045|Active Comparator|Carbetocin 10mcg|Patient is given 10 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9465715|NCT03672045|Active Comparator|Carbetocin 20mcg|Patient is given 20 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9465716|NCT03672045|Active Comparator|Carbetocin 40mcg|Patient is given 40 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9465717|NCT03672045|Active Comparator|Carbetocin 60mcg|Patient is given 60 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9465718|NCT03672045|Active Comparator|Carbetocin 80mcg|Patient is given 80 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9465719|NCT03672045|Active Comparator|Carbetocin 100mcg|Patient is given 100 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
9465720|NCT03672019||Patients Undergoing Percutaneous Biliary Drainage|Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
9465721|NCT03671993|Experimental|EPNS group|Electrical pudendal nerve stimulation (EPNS) is a type of conservative treatment which can directly modulate the pudendal nerve and produce a regulation effects on both the sensory fibers and the motor fibers of pudendal nerve.
9465722|NCT03671993|Active Comparator|II group|Intravesical instillation (II) are mixture solution administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects.
9465723|NCT03671980|Experimental|Web-intervention|30 participants using a self-management website and home faecal calprotectin smartphone monitoring instead of usual outpatient follow up as a means of managing their inflammatory bowel disease for 6 months after stopping an IBD medication.
9465724|NCT03671954|Experimental|TKA Intervention Group|The TKA intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy.
9465725|NCT03671954|Active Comparator|TKA Control Group|The TKA control group will receive standard physical therapy alone.
9465726|NCT03671954|Active Comparator|Healthy Control Group|The Healthy Control Group, aged 49-85 years without any signs of degenerative joint, disease will undergo the preoperative assessments only.
9465727|NCT03671941|Active Comparator|Group A|D578 Tab. 1T
9465728|NCT03671941|Experimental|Group B|CKD-357 Tab. 1T
9465729|NCT03671928|Other|bowel ischemia|
10028281|NCT01739725|Experimental|Helical stent insertion|Study participants will receive the helical stent
10028282|NCT01739738||no Ureteral Stent - control group|non-stented volunteers to receive ultrasound for peristalsis changes detection
9465730|NCT03671928|Other|non-digestive abdominal pain|
9465731|NCT03671915|Active Comparator|Usual System (Open-loop)|In open loop: sensor-augmented pump (SAP) therapy using standard insulin pump setting combined with the six-generation glucose sensor (Dexcom G6).
9465732|NCT03671915|Experimental|DIABELOOP System (Closed-loop)|"In the closed loop: Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.~A remote monitoring system managed by specialized nurse on behalf diabetologist, is provided in closed-loop session."
9465733|NCT03671902|Other|Lower Body Negative/Positive Pressure|
9465734|NCT03671876|Active Comparator|Intervention plus therapy|"Case group:~A population that suffered a stroke and treated to improve mobility with the Selfit system (25 patients) for twice a week, at least 30 minutes per session, for a period of 3 weeks.~Intervention with the Selfit system include a set of mobility task exercises."
9465735|NCT03671876|No Intervention|Therapy and no intervention|"Control group:~A population that suffered a stroke and is being treated in the hospital without any interventions with the Selfit system."
9465736|NCT03671863||Infants who are treated for clubfoot|Infants who are treated for clubfoot in the reference reeducation center
9465739|NCT03671837|Experimental|Oyxgen|Nasal Insufflation with 15 L/min O2 and a nasopharyngeal airway
9465740|NCT03671837|Active Comparator|Air|Nasal Insufflation with 15 L/min air and a nasopharyngeal airway
9465741|NCT03671824||Lean|BMI ≤ 30 kg/m2
9465742|NCT03671824||Obese|BMI ≥30 kg/m2
10028283|NCT01739738||Ureteral stent|patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
9465743|NCT03671811|Experimental|Arm I (pterostilbene, megestrol acetate)|Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
9465744|NCT03671811|Experimental|Arm II (megestrol acetate)|Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
9465745|NCT03671798||REM sleep behavior disorder (RBD)|Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep. 2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring. 4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
9465746|NCT03671798||Controls|Subjects with 1) No RBD symptoms and PSG characteristics. 2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology. 3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test. 4) No history of mental illnesses or use of antidepressants
10028284|NCT01739751|No Intervention|Control Group|Patients without feedback of a pedometers, followed for 3 months
10028285|NCT01739751|Experimental|Pedometers|With a program of physical activity enhancement using pedometers as a feedback
9465747|NCT03671772||FDRs of idiopathic RBD patients|First-degree relatives of idiopathic RBD patients
9465748|NCT03671772||FDRs of controls|First-degree relatives of controls
9465749|NCT03671759|Experimental|Experimental: N-of-1|"Participants will be randomized in two-day blocks to consume then avoid caffeine (Start: On Caffeine) or avoid then consume caffeine (Start: Off Caffeine). Using an N-of-1 strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, participants will receive instructions and answer questions to help us understand the relationship between caffeine and heart rhythm."
9465750|NCT03671746|Placebo Comparator|Standard of Care without NSAID|Polytrauma participants will receive standard of care in addition to saline solution according to standard ATLS and standard ICU routine medical care.
9465751|NCT03671746|Experimental|Standard of Care with NSAID|Participants in the group will receive Ketorolac in addition to standard of care for the standard ATLS or ICU routine medical care.
9465752|NCT03671733|Experimental|Liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
9465753|NCT03671733|Experimental|Exenatide|Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
9465754|NCT03671733|Experimental|Exenatide Microspheres for Injection|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
9802986|NCT04720443|Experimental|SAD Part 1 Cohort 3|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 100mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
10028286|NCT01739777|Experimental|ucMSC|Umbilical cord derived mesenchymal are injected intravenously to Patients.
10028287|NCT01739777|Placebo Comparator|Controls|Intravenous placebo solution are administrated to Patients.
10028288|NCT01739816|No Intervention|Control group|Patients get no intervention at study start, but only at study end after seven months.
10028289|NCT01739816|Active Comparator|Intervention group|At the beginning and at the end of the study, this group receives a pharmacist's led medication review focusing on daily medicines use (= Polymedication Check).
10028290|NCT01739816|Other|Observational arm|If participants after recruitment violate inclusion criteria (e.g. change from autonomous medication management to external home care) or insists on intervention despite being randomised to control group or patient condition forces pharmacist to provide a PMC.
9465755|NCT03671720|Experimental|personalized vaccine|
9465756|NCT03671707|Experimental|Intervention group|Brief AWARD advice + Nicotine replacement therapy sampling + Active referral
9465757|NCT03671707|Active Comparator|Control group|Very brief advice (VBA) + Leaflet
9479992|NCT03537924|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
9479993|NCT03537911|Experimental|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
9479994|NCT03537898|Active Comparator|Lactated Ringer's|Patients in a MICU block randomized to lactated Ringer's will receive lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
10028291|NCT01739829|Experimental|DIABECELL group 1|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
10028292|NCT01739829|Experimental|DIABECELL group 2|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
9479995|NCT03537898|Active Comparator|Normosol|Patients in a MICU block randomized to Normosol will receive Normosol-R pH 7.4 whenever isotonic intravenous fluid administration is ordered by the treating provider.
10028293|NCT01739842|Active Comparator|Kudzu extract treatment|"Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
10028294|NCT01739842|Placebo Comparator|Placebo|"Placebo will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day."
10028295|NCT01739855|Active Comparator|Calcium/Vitamin D|"All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:~daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)"
10028296|NCT01739855|No Intervention|No Calcium/Vitamin D|All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
10028297|NCT01739894|Experimental|IP Paclitaxel|Paclitaxel will be administered intraperitoneally at 40mg/m2 on Days 1 and 8 in a 21-day cycle in patients receiving intravenous oxaliplatin 100mg/m2 on Day 1 and capecitabine 1000mg/m2 twice daily on Days 1-14.
10028298|NCT01739907|Experimental|Iron-fortified dairy product|Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet
10028299|NCT01739907|Experimental|Iron and vitamin D dairy product|Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet
9465758|NCT03671694|Active Comparator|laser treatment|Erbium-YAG laser treatment to the vagina
10028300|NCT01739920|Experimental|Povidone-iodine|1 drop of povidone-iodine 5% will be instilled at time zero, 20-minute and 28-minute study period.
9465759|NCT03671694|Placebo Comparator|sham treatment|sham treatment with laser placebo
9465760|NCT03671681|Experimental|MT group|Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and six group sessions of 45 minutes of mindfulness-based treatment.
9465761|NCT03671681|Other|MED group|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (i.e. clinical features, previous failures and contraindications)
9465762|NCT03671668|Active Comparator|Screw retained prosthesis on transmucosal abutments|
9465763|NCT03671668|Experimental|Screw retained prosthesis on titanium bases|
9465764|NCT03671655|Experimental|Drug-eluting stent|Drug-eluting stent is nitinol stent coated with Paclitaxel drug Other Names: Zilver PTX stent Zilver Paclitaxel stent
9465765|NCT03671655|Active Comparator|Bare metal stent|Bare metal stentis Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
9465766|NCT03671642|Experimental|Perfusion assessment|Q-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
9465767|NCT03671629|Experimental|Intervention group|In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital.
9465768|NCT03671629|No Intervention|Control group|This group receives standard care, which might include a medication review at the hospital.
9465769|NCT03671616|Experimental|IPV-Al SSI|Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination
9465770|NCT03671577|Experimental|Active Treatment|four week computerized intervention designed to reduce fear of intimacy
9465771|NCT03671577|No Intervention|Wait List Control|Participants will continue as usual and will be given the option to receive the active treatment after completion of the study
9465772|NCT03671564|Experimental|Dose Escalation - Milademetan|All participants enrolled for dose escalation receive a single oral dose of 90 mg milademetan, followed by escalated doses, based on mCRM with EWOC
9465773|NCT03671551||Psychomotor/psychological evaluation|Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.
9465774|NCT03671538|Experimental|Anlotinib Plus Pemetrexed and Cisplatin|pemetrexed 500mg/m2 and Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
9465775|NCT03671512|Experimental|Periodontal Structure Repair (PSR)|Periodontal pockets treated with PSR
9465776|NCT03671512|Active Comparator|Standard Root Planing (SRP)|Periodontal pockets treated with SRP
9465777|NCT03671499|Experimental|Social Cognitive Theory based text messages|The study only contains 1 arm. All participants will receive the same experimental protocol. Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
9465778|NCT03671460|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
9465779|NCT03671447|Active Comparator|ICU usual care|control condition
9465780|NCT03671447|Experimental|"Intervention ERIC"|intervention condition
10028301|NCT01739920|Active Comparator|Povidone-iodine and Saline Solution|1 drop of saline solution 0.9% will be instilled at time zero and 20-minute. At 28-minute will be instilled 1 drop of Povidone-iodine 5%.
10028302|NCT01739946||Implanted subject|Subjects with Interstim implanted
10028303|NCT01739946||Controls|Subjects without Interstim implanted
10028304|NCT01739959||Necrotizing fasciitis proven|Histological evidence of necrotizing fasciitis at initial surgical debridement
10028305|NCT01739959||Not necrotizing fasciitis|A composite of those with no histological tissue necrosis at initial surgical debridement, and those clinically judged not to be a necrotizing infection who therefore did not undergo surgery.
9465781|NCT03671408||periodontitis|periodontitis patients which were diagnosed based on clinical parameters
9465782|NCT03671408||gingivitis/healthy|gingivitis healthy patients which were diagnosed based on clinical parameters
9465783|NCT03671382|Experimental|Intervention Arm|Communication Training Program and Patient Prompt Sheet
9465784|NCT03671382|No Intervention|Control Arm|Oncologists will not receive the communication skills training program and their patients will not receive the Patient Prompt Sheet
9465785|NCT03671369||Cervarix Group|The study group comprises of 9-25 year-old male and female subjects who will be administered 3 doses of Cervarix vaccine, according to a 0, 1, and 6 months schedule, as per locally approved prescribing information (PI) in Korea. The 9-14 years old subjects can be vaccinated with 2 doses, according to a 0 and 6-12 months schedule. In the 2-dose schedule, if the second dose is administered before 5 months after the first dose, the third dose vaccination is required. In the 3 doses schedule, if the vaccination schedule requires flexibility, the second dose can be administered between 1 and 2.5 months and the third dose can be administered between 5 and 12 months after the first dose.
9465786|NCT03671343|Experimental|Intervention : Physical rehabilitation|"The Arm Physical rehabilitation will benefit from the implementation of the Loss of Mobility Prevention program set up in the Department of Aging Medicine of the Center Hospitalier Lyon Sud (CHLS) of Pr BONNEFOY."
9465787|NCT03671343|No Intervention|Control : optimized medical treatment|"The Arm Optimized medical treatment will not benefit from the implementation of the Loss of Mobility Prevention program."
9465788|NCT03671317|Experimental|Intervention group|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
10028306|NCT01739972|Active Comparator|Levothyroxine|Levothyroxine in the capsule form, once daily, appropriate dosage to keep TSH at the normal range.
10028307|NCT01739972|Active Comparator|Desiccated thyroid extract|Desiccated thyroid extract in capsule form, once daily, appropriate dosage to keep TSH in the normal range.
10028308|NCT01739985|Active Comparator|Dexamethasone + ondansetron + Placebo|dexamethasone + ondansetron + Placebo
9465789|NCT03671317|No Intervention|Non-intervention group|This arm will continue usual care with no intervention from medical clowns. They will be asked to complete pre and post surveys about the blood draw process.
9465790|NCT03671291|Experimental|Recently infected with HIV|Men and women recently infected with HIV and have been eligible for PrEP based on the recommendation of french national regulatory agency regarding the prescription of Truvada® in prophylaxis to HIV exposure. The potential reasons behind these missed opportunity of Pre-exposure prophylaxis will be studied through a self-administrated questionnaire.
9465791|NCT03671278|Other|STarT Back Screening Tool Approach|After baseline consultation, all patients will receive usual care from their medical doctors as well as an educational booklet and weekly videos containing information on the prognosis of back pain and how patients could deal with their problems. Six weeks after baseline consultation all patients will be screened by the STarT Back Screening Tool (SBST) and will receive a stratified care according to their SBST classification.
9465792|NCT03671265|Experimental|SHR-1210 + Chemotherapy + Radiotherapy|"Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.~SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.~Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.~Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )"
9465793|NCT03671252|Experimental|Experimental: Group 1|Patient will receive FOLFOXIRI regimen every two weeks for 4-6 cycles within 2-3 months.Two weeks after completing 3 and 6 cycles of FOLFOXIRI regimen,patients will have two efficacy evaluations according to RECIST criteria and toxicity evaluation .If the tumor is defined as no progression without severe toxicity at the first efficacy evaluation, the rest of 3 cycles of FOLFOXIRI regimen will be performed.If it is defined as progression of primary tumor or it is defined as progression of primary tumor and MRF(+)at the second efficacy evaluation,patients are assigned into active comparator group. If distant metastasis occurred during chemotherapy, patients are treated according to the guidelines for metastatic colorectal cancer.Chemotherapy is initiated at 3-4 weeks after R0 resection. XELOX regimen is performed post-operatively (about 4-6 cycles). If postoperative pathology confirmed as positive margin, postoperative chemoradiotherapy was given.
9465794|NCT03671252|Active Comparator|Active Comparator:Group 2|The patients are scheduled to receive chemoradiotherapy. After 5 weeks from the end of chemoradiotherapy, patients will have a efficacy evaluation according to RECIST criteria. If the tumor is defined as CR、PR or SD, and the TME operation is conducted within 5-10 weeks after chemoradiotherapy completion. If tumor is defined as progressive disease with the possibility of R0 resection, the operation was also conducted within 5-10 weeks after chemoradiotherapy . If tumor is defined as progressive disease without possibility of R0 resection, the palliative chemotherapy was performed . If distant metastasis occurred during chemoradiotherapy, patients are treated according to the guidelines for metastatic colorectal cancer. Adjuvant chemotherapy of XELOX is performed post-operatively (about 4-6 cycles).
9465795|NCT03671239|Other|Product Sequence A|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
9465796|NCT03671239|Other|Product Sequence B|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
9465797|NCT03671239|Other|Product Sequence C|Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period.
9802987|NCT04720443|Experimental|SAD Part 1 Cohort 4|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 300 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
9802988|NCT04720443|Experimental|SAD Part 1 Cohort 5|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 600 mg)or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
10028309|NCT01739985|Experimental|Dexamethasone + ondansetron + Droperidol|dexamethasone + ondansetron + Droperidol
10028310|NCT01739998|Experimental|functional oil|Treatment consisted of consuming 5 ml of functional oil [olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15% EPA) Orange flavour] during the day by 8 weeks.
10028311|NCT01739998|Placebo Comparator|Placebo|Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks
10028312|NCT01740011|Experimental|Group A|Laparoscopic surgery with AirSeal CO2 pressure insufflation
10028313|NCT01740011|Active Comparator|Group S|Laparoscopic surgery with standard CO2 pressure insufflation
10028314|NCT01740024|Experimental|1 (Dose-Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations Positive control Negative control
10037561|NCT01826240|Experimental|MBCT+SPI|Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
10037562|NCT01826253||Hypovolemia|Fluid expansion
10037563|NCT01826266|Placebo Comparator|PER977-Dose 1|Dose titration
10037564|NCT01826266|Placebo Comparator|PER977-Dose 2|Dose Titration
10037565|NCT01826266|Placebo Comparator|PER977-Dose 3|Dose Titration
10028315|NCT01740037|Experimental|Specialized AF-clinic|Management of AF patients in specialized outpatient AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by a nurse practitioner/ physician assistant/ specialised cardiovascular nurse, cardiologist, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®). The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.
10028316|NCT01740037|Active Comparator|Usual Care|Usual care provided by cardiologists at the regular outpatient clinic.
9465798|NCT03671239|Other|Product Sequence D|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period.
9465799|NCT03671239|Other|Product Sequence E|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
9465800|NCT03671239|Other|Product Sequence F|Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
9465801|NCT03671226|Experimental|Supportive Care (questionnaire)|Patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.
9465802|NCT03671187|Experimental|Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
9465803|NCT03671187|Experimental|Ex- Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
9465804|NCT03671174|Experimental|Prednisone + hydroxychloroquine + anticoagulation|Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
9465805|NCT03671174|Experimental|Hydroxychloroquine + anticoagulation|Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
9465806|NCT03671174|Active Comparator|Anticoagulation|Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
10028317|NCT01740050|Active Comparator|Roux- and Y bypas surgery (RYGB)|"One subject group will lose 10% of initial body weight using RYGB. RYGB is an operation that first divides the stomach into a small upper pouch and a much larger lower remnant pouch and then re-arranges the small intestine to connect to both, in this way bypassing part of the small intestine."
10028318|NCT01740050|Active Comparator|Laparoscopic adjustable gastric banding (LAGB)|One subject group will lose 10% of initial body weight using LAGB. With LAGB an inflatable band is placed around the upper part of the stomach to create a smaller stomach pouch. This slows and limits the amount of food that can be consumed at one time giving the opportunity for the sense of satiety to be met. It does not decrease gastric emptying time.
10028319|NCT01740050|Active Comparator|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
10028320|NCT01740063|Experimental|DAS181-F02 formulation|DAS181 10 mg dose for three days of the F02 formulation
10028321|NCT01740063|Experimental|DAS181-F04 formulation|DAS181 20 mg dose group for three days of the F04 formulation,
10028322|NCT01740063|Placebo Comparator|Placebo|placebo group
10028323|NCT01740076|Experimental|soy nuts|25 g of soy nuts provided daily to the subjects and they were counseled to replace 25 g of protein in their therapeutic lifestyle change (TLC) diet with the soy. TLC diet consisted of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
10028324|NCT01740076|Other|Therapeutic lifestyle change diet|Counseling on therapeutic lifestyle change diet consisting of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
10028325|NCT01740102|Experimental|RIPC|Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
10028326|NCT01740102|No Intervention|No RIPC|Patients in the control group will not receive remote ischemic preconditioning before the surgery.
10028327|NCT01740141|Other|Plexus before surgery|Plexus brachialis before surgery
10028328|NCT01740141|Other|Plexus after surgery|Plexus brachialis performed after surgery
10028329|NCT01740167|Experimental|Lifestyle program|health promotion lifestyle program : individual counseling, once a month, total 3 times.
10028330|NCT01740180||CLIPPERS patients|"The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).~Intervention: Data entry"
10028331|NCT01740193|Active Comparator|TAP Block|
10028332|NCT01740193|Active Comparator|Ilioinguinal/iliohypogastric blockade|
10028333|NCT01740219|Experimental|Capacity Enhancement|
10028334|NCT01740219|Active Comparator|Standard Dissemination|
10028335|NCT01740232|Active Comparator|Trephination|A 1 x 10 mm pricker are used for the trephination of the meniscus before normal meniscal repair.
9465807|NCT03671161|Experimental|Patients with poorly controlled diabetes type 1|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day swithced to Insulin Pump and flash glucose monitoring
9465808|NCT03671135|Experimental|TCA Intrastromal Inlay|A monocular intrastromal corneal inlay will be implanted.
9465809|NCT03671109|Experimental|IPTp-DHA-PPQ|Monthly IPTp-DHA-PPQ over three days plus daily ARVs and cotrimoxazole prophylaxis
9465810|NCT03671109|Placebo Comparator|IPTp-Placebo|Monthly IPTp-placebo over three days plus daily ARVs and cotrimoxazole prophylaxis
9465811|NCT03671096|Experimental|Intrastromal TCA Inlay|Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
9465812|NCT03671083||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
9465813|NCT03671083||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
9465814|NCT03671070|Active Comparator|Low dose Epinephrine boluses|Patients suffering from acute hypo-tension will receive low dose IV epinephrine boluses ≤ 5 μg/kg/dose, 3 doses, within 3 hours
9465815|NCT03671070|Placebo Comparator|Traditional management of shock|Patients suffering from acute hypo-tension will be managed according to Traditional algorithm of Hypotension
9465816|NCT03671057|Experimental|HospiAvontuur|Intervention group - Non-pharmacological (HospiAvontuur) preparation HospiAvontuur is a simple point and click adventure game on a I-pad. The game describes the pathway which a child and his parents will take before, during and just after a hospital admission for an elective otorhinolaryngeal procedure under general anaesthesia.
9465817|NCT03671057|Active Comparator|Midazolam|control group: The children of the control group will not play the game HospiAvontuur as an at home preparation for surgery. These children will be prepared for surgery according to the current practice at the Jessa hospital. Children receive only the basic information during the consultation with the surgeon. There is no specific at home preparation required. When admitted at the hospital, children receive a pharmacological preparation, 45 - 60 minutes prior to the induction of the anaesthesia. The medication is administered orally by a small syringe in the mouth and contains Dormicum 0.3mg/kg body weight and atropine 0.02mg/kg body weight supplemented with raspberry syrup.
9465818|NCT03671044|Experimental|Nanosomal Docetaxel Lipid Suspension - 75 mg/m2|Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
9465819|NCT03671044|Experimental|T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
9465820|NCT03671044|Active Comparator|R, Taxotere® (100 mg/m2)|Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
9465821|NCT03671031||isolated roux loop|isolated roux loop reconstruction following pancreaticoduodenectomy as the first group.
9465822|NCT03671031||single loop|single loop reconstruction following pancreaticoduodenectomy as the second group.
9465823|NCT03671005|Experimental|Mindfulness-based group therapy (MBGT)|The mindfulness-based group therapy (MBGT) involves a four-week manual with three group therapy sessions per week in addition to TAU. The therapy represents the first German group-based mindfulness manual for psychosis. One sixty-minute session was held by a certified psychotherapist who is experienced in mindfulness-based therapy. A trained co-therapist implements two 30-minute sessions. On a weekly basis, a new theme is discussed in the three sessions to ensure the internalization of different mindfulness concepts. Namely, the topics Mindfulness of the Breath (1), Mindfulness of the Senses in the Context of Nature (2), Mindfulness of Detachment (3), and Mindfulness in the Context of Bodily Awareness (4) are addressed during the group-sessions.
9465824|NCT03671005|Active Comparator|treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
9465825|NCT03670992||Pancreatic Metastases|Patients with only pancreatic metastases from RCC
9465826|NCT03670992||extra-pancreatic metastases|patients with extra pancreatic metastases from RCC
9465827|NCT03670979|Experimental|bone swaging alone|xenograft alone
9465828|NCT03670979|Experimental|bone swaging plus EDTA|bone swaging with EDTA
9465829|NCT03670953|Experimental|IPX203 ER CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to investigational product IPX203 ER CD-LD and IR CD-LD placebo.~IR CD-LD active and placebo are tablets and IPX203 ER CD-LD active is capsules. Dosage and frequency is patient specific."
10028336|NCT01740232|Placebo Comparator|Normal meniscal repair|standard operation. Normal meniscalrepair.
10028337|NCT01740245|Active Comparator|Chlorhexidine|
10028338|NCT01740245|Experimental|Polyhexamethylene biguanide|
10028339|NCT01740271|Experimental|Epirubicin|Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4.
10028340|NCT01740284|Active Comparator|Grazax + Aerius|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (desloratidine) 2.5 mg
10028341|NCT01740284|Placebo Comparator|Grazax + Placebo|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (Placebo)
10037566|NCT01826266|Placebo Comparator|PER977-Dose 4|Dose Titration
10037567|NCT01826266|Placebo Comparator|PER977-Dose 5|Dose Titration
10028342|NCT01740310|Experimental|High Elaboration Video Arm|Women randomized to this arm will be exposed to a handheld/electronic tablet device-based video with detailed vaccine-related information designed to invoke a high level of attention to the message and thought (elaboration) while processing information.
10028343|NCT01740310|Experimental|High Elaboration Interactive Tutorial Arm|Women will be exposed to a handheld/electronic tablet device-based intervention designed to invoke a high level of attention to the message and thought (elaboration) while processing information through an interactive question/answer format.
10028344|NCT01740310|Placebo Comparator|Low Elaboration / Control Arm|Women randomized to the control arm will be provided standard CDC vaccine information statements that will likely lead to low elaboration information processing.
9465830|NCT03670953|Active Comparator|IR CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to IPX203 placebo and IR CD-LD active comparator.~IR CD-LD active is tablets and IPX203 active and placebo are capsules. Dosage and frequency is patient specific."
9465831|NCT03670940||COPD patients|COPD patients without bronchiectasis
9465832|NCT03670940||COPD and bronchiectasis patients|COPD patients with bronchiectasis
9465833|NCT03670927||Cases|Cases (incident patients with a diagnosis of primary sarcoma and histologically confirmed by an expert pathologist of the RRePS or ResOs networks in the 15 districts of France participating to this study) Environmental, occupational and lifestyle-related exposures
10028345|NCT01740336|Experimental|A: Paclitaxel, GDC-0941|Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
10028346|NCT01740336|Placebo Comparator|B: Paclitaxel, Placebo|Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
10028347|NCT01740349||30 children with UC|This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.
10028348|NCT01740375|No Intervention|Arm B: observation:|No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
10028349|NCT01740375|Experimental|Arm A: esophagectomy|Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
10028350|NCT01740453|No Intervention|Single (no catheter)|ropivacaine single injection : 5 mg/ml 15 ml
10028351|NCT01740453|Experimental|Continuous infusion|Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h
10028352|NCT01740466||Ocular diseases|Observational
10028353|NCT01740479|Active Comparator|Complete Revascularization Strategy|"Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor)."
9465834|NCT03670927||Controls|"Subjects never diagnosed with a primary sarcoma and individually-matched by sex, age (5-years group), and districts of residence and randomly selected from electoral list.~Environmental, occupational and lifestyle-related exposures"
9465835|NCT03670914|Experimental|WatchPAT 200 and In-Lab Study|Patients who are referred to the sleep center for an overnight study that are narcotic users will be offered to the opportunity to participate in the study. Patients who fulfill the inclusion exclusion criteria and have given informed consent will undergo a standard in-lab polysomnography while simultaneously wearing the WatchPAT200 device.
9465836|NCT03670901|Experimental|JHL1101|375 mg/m2 of JHL1101 is given intravenously on D1 of each cycle
10028354|NCT01740479|No Intervention|Optimal Medical Therapy Alone|"Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor)."
10028355|NCT01740492|Experimental|LDK1: Low dose Ketamine (0.15mg/kg)|"Participants randomized to the first group, LDK1, will receive an intravenous injection of low dose ketamine (0.15mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
10037568|NCT01826266|Placebo Comparator|PER977-Dose 6|Dose Titration
9465837|NCT03670901|Active Comparator|MabThera|375 mg/m2 of Rituximab is given intravenously on D1 of each cycle
9465838|NCT03670888|Experimental|JHL1101|Single dose IV infusion of 375 mg/m2 of JHL1101
9465839|NCT03670888|Active Comparator|Rituxan|Single dose IV infusion of 375 mg/m2 of Rituximab
9465840|NCT03670875|Experimental|Agave inulin|Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
9465841|NCT03670875|Experimental|Curcumin|Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.
9465842|NCT03670875|Experimental|Omega 3 Fatty Acids|O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
9465843|NCT03670875|Other|Control|Recommendations to decrease calories intake an do exercise.
9465844|NCT03670862||stroke|Ischemic stroke patients with sympton onset in 24 hours
9465845|NCT03670849|Experimental|Patients using LapAR system|
9479996|NCT03537885|Experimental|TMS, EEG, and tDCS Group|"Participants will wear a cap fitted with Electroencephalography (EEG) electrodes to detect the brain's activity during the task. Transcranial Magnetic Stimulation will be used to evaluate the brain's responsiveness to Transcranial Direct Current Stimulation.~All study participants will receive the same study procedures - TMS, tDCS, and EEG."
9465846|NCT03670836|Experimental|Dilapan group|"Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed."
10028356|NCT01740492|Experimental|LDK2: Low dose Ketamine (0.3mg/kg)|"Participants randomized to the second group, LDK2, will receive an intravenous injection of low dose ketamine (0.3mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
10028357|NCT01740492|Placebo Comparator|0.9% Normal Saline|This group will receive a placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
9465847|NCT03670836|Experimental|Misoprostol group|Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.
9465848|NCT03670823||Healthy subjects|50 healthy subjects for a control group
9465849|NCT03670823||Patients with Major Depression|50 patients with major depression for a research group
9465850|NCT03670797||controlled diabetic patients|
9465851|NCT03670797||uncontrolled diabetic patients|
9465852|NCT03670784||Women_KPNC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Northern California (KPNC).
9465853|NCT03670784||Women_KPSC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Southern California (KPSC).
9465854|NCT03670758||Group 1|Will include 30 women with unexplained primary infertility; will be recruited from the outpatient infertility clinic
9465855|NCT03670758||Group 2|another 30 fertile women who got pregnant and delivered at least once in the previous year with no history of recurrent abortions; will recruited from outpatient gynecology clinic as control
9465856|NCT03670732|Active Comparator|CPAP first|The intervention is application of continuous positive airway pressure (CPAP). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
9465857|NCT03670732|Active Comparator|NIPPV first|The intervention is application of nasal intermittent positive pressure ventilation (NIPPV). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
10028358|NCT01740505|Experimental|Timing and Coordination|
9465858|NCT03670719|Experimental|Manual Therapy and Exercise Group|Combination of manual therapy and exercises for chronic cervical pain
10028359|NCT01740505|Experimental|Aerobic Walking|
10028360|NCT01740505|Active Comparator|Stretching and Relaxation|
10028361|NCT01740518||PEG + ascorbic acid|Those who taken PEG 2L + ascorbic acid
10028362|NCT01740518||PEG 4L|Those who taken PEG 4L alone
10028363|NCT01740531|Experimental|S-303 Treated Red Blood Cells (RBC)|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
10028364|NCT01740531|Active Comparator|Conventional, untreated Red Blood Cells|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
10028365|NCT01740544|Experimental|Cathodal tDCS in young study participants|Cathodal tDCS in young study participants
10028366|NCT01740544|Experimental|Cathodal tDCS in elderly study participants|Cathodal tDCS in elderly study participants
10028367|NCT01740544|Sham Comparator|Sham tDCS in young study participants|Sham tDCS in young study participants
10028368|NCT01740544|Sham Comparator|Sham tDCS in elderly study participants|Sham tDCS in elderly study participants
10028369|NCT01740570|Experimental|Cabazitaxel|"Cabazitaxel by vein on day 1 of each 3 week cycle.~Phase I: Up to 5 dose levels of cabazitaxel tested. Two (2) dose levels will be given over 60 minutes, and 3 will be given over 30 minutes. First group of participants receive the lowest dose level. Each new group receives a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.~Phase II: Cabazitaxel at the highest dose that was tolerated in Phase I."
10028370|NCT01740583|Experimental|annuloplasty|All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
10028371|NCT01740596|Experimental|C-Pulse® System|C-Pulse® System Counterpulsation
10028372|NCT01740596|No Intervention|Control Arm|Optimal Medical Therapy
10028373|NCT01740609|Placebo Comparator|1. Placebo|Placebo
9465859|NCT03670719|Active Comparator|Exercise Group|Only exercises for chronic cervical pain
9465860|NCT03670706|Active Comparator|Group A|Exercise training, then crossover to analgesic optimisation
9465861|NCT03670706|Active Comparator|Group B|Analgesic optimisation, then crossover to exercise training
9465862|NCT03670706|No Intervention|Group C|Control group
9465863|NCT03670693|Experimental|Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) suffering from fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 >14, and a score of >4 in the Fatigue questionnaire.)
10028374|NCT01740609|Experimental|2.0|
10037569|NCT01826266|Placebo Comparator|PER977-Dose 7|Dose Titration
10037570|NCT01826279|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for 1 month
10037571|NCT01826279|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for 1 month
9465864|NCT03670693|Experimental|Non-Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) without fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 <14, and a score of <4 in the Fatigue questionnaire.)
9465865|NCT03670693|Experimental|Healthy Volunteers|Age,gender,muscle mass, and physical activity-matched healthy controls.
9465866|NCT03670667||RA patients treated with abatacept|
9465867|NCT03670667||RA patients treated with anti-TNFi's|
9465868|NCT03670667||RA patients treated with other biologics|
9465869|NCT03670654|Active Comparator|Pilates Method|The intervention of active comparator will be Pilates Method exercises.
9465870|NCT03670654|Sham Comparator|Muscle stretching exercises|The intervention of sham comparator will be muscle stretching exercises.
9465871|NCT03670602|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future cues that will be accessed via an electronic app to engage in EFT.
9465872|NCT03670602|Other|Control Thinking|Participants will generate or be provided with non-future cues.
9465873|NCT03670589||radiosurgery gammaknife group|Patient treated by radiosurgery gammaknife for a one side vestibular schwannoma
9465874|NCT03670589||microsurgery resection group|Patient treated by microsurgery resection for a one side vestibular schwannoma
9465875|NCT03670576||Case|A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.
9465876|NCT03670576||Control|Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.
9465877|NCT03670563|Experimental|Exercise 1|Short foot exercise protocol instructed utilizing verbal instruction, passive modeling, active-assisted modeling, and active modeling.
9465878|NCT03670563|Active Comparator|Exercise 2|Short foot exercises plus NMES. Short foot exercise protocol instructed utilizing verbal instruction, passive modeling assisted by neuromuscular electric stimulation (NMES), active-assisted modeling assisted by neuromuscular electric stimulation, and active modeling.
9465879|NCT03670563|No Intervention|Control|No exercise intervention; continue normal physical activity, but do not start any new exercise programs
9465880|NCT03670550|Experimental|Knee Brace|"ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy.~Dynamic X-ray imaging of the knee will take place prior to surgery, and again upon clearance from physical therapy 7-9 months after surgery. The injured knee will be imaged with and without the brace, and the contralateral limb will be imaged for use as a control."
9465881|NCT03670524|Experimental|Targeted neighborhoods for Greenness|Using greenness as a therapeutic intervention, we will plant shrubs, grasses, young and mature trees (40-50 ft in height), so that we can evaluate changes in health and pollution, 2 years after planting.
9465882|NCT03670524|No Intervention|Control Group|No intervention
9465883|NCT03670511|Experimental|sit-to-stand|
9465884|NCT03670511|Active Comparator|six minute walking test|
9465885|NCT03670498|Experimental|4 channel Electrical Stimulation(revised sequential)|apply 4 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it sequentially Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
10028375|NCT01740622|Experimental|Injury Intervention Group|In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq.ft.) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1-meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years.
10028376|NCT01740622|No Intervention|Control Group|Participants who are assigned to the control group will have their medical claims examined related to injury in the home. Households in this control condition will also be provided with information sheets on child safety developed by the American Academy of Pediatrics, The Injury Prevention Program (TIPP). These age-based recommendations for child safety are provided as standard of care at many pediatric offices.
10028377|NCT01740635|Experimental|EPIC WheelS Training Program|The EPIC WheelS program includes a comprehensive, structured library of educational material and training activities, organized in a hierarchy from simple to complex. Experimental group subjects will attend 2 training sessions with an expert Trainer. The Trainer will individualize a structured home training program, delivered via a computer tablet, and subjects will train at home for 1 month.
9465886|NCT03670498|Active Comparator|2 channel Electrical Stimulation(classical)|apply 2 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it simultaneously suprahyoid m (ch 1), thyrohyoid m (ch 2) with 2 channel electrical stimulation device.
9465887|NCT03670485|Experimental|Revised sequential activation protocol|"Apply 4 channel electrical stimulation device with a revised sequential activation protocol.~It sequentially activates Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device."
9465888|NCT03670485|No Intervention|control subject|Apply 4 channel electrical stimulation device without any stimulation
9465889|NCT03670459|Experimental|Group 1|Patients in G1 will receive traditional physical therapy program (balance exercises) for twelve sessions; day after day
10037572|NCT01826305|Active Comparator|Formal Rehabilitation Therapy|Patients randomized to the formal rehabilitation therapy cohort will receive a prescription for therapy for twelve weeks following their primary knee replacement.
9465890|NCT03670459|Experimental|Group 2|Patients in G2 will receive Cawthorne Cooksey Exercises in addition to traditional physical therapy program for twelve sessions; day after day .
9465891|NCT03670459|Experimental|Group 3|Patients in G3 will receive vestibular habituation exercises in addition to traditional physical therapy program for twelve sessions; day after day.
9465892|NCT03670446|Experimental|Pharmacists' intervention|A group of participants assigned to a pharmaceutical intervention
9465893|NCT03670446|No Intervention|Routine therapy|A group of participants assigned to a control (routine therapy)
9465894|NCT03670433||Patients admitted in the Polyvalent Internal Medical Unit|"Patients over 65 years old admitted in the Polyvalent Internal Medical Unit (UMIP) of Rennes University Hospital between 09/04/2017 and 10/31/2017 or going back home or to a rehabilitation service during the same period.~Cost analysis of medication reconciliation."
9465895|NCT03670420|Experimental|Medical honey in addition to standard care|In addition to the usual care provided by the maternity unit, women allocated to this group apply honey on first and second degree perineal tears, episiotomies and anterior vulvar tears twice a day for four days from randomization.
9465896|NCT03670420|No Intervention|Standard care|This group benefits from the standard care offered by the maternity: hygiene advice, analgesics, ice packs, buoys and positioning.
9465897|NCT03670407|No Intervention|Control group|Participants who opt not to go ahead with ovarian fragmentation.
9465898|NCT03670407|Experimental|Study group|Participants who opt for ovarian fragmentation.
9465899|NCT03670381||ASD group|ASD patients with HDAC4 CNVs
9465900|NCT03670381||TD group|Typically developing controls without lifetime ASD or a family history of ASD
9465901|NCT03670329|Experimental|URGO2875|Dressing
9465902|NCT03670316|Experimental|Algorithm Treatment plus referral to quitline (AT)|will be assigned a pharmacotherapy treatment regimen recommended to their provider.
9465903|NCT03670316|Active Comparator|Quitline (eTAU)|will be referred to quitlines, telephone-based tobacco cessation services.
9465904|NCT03670303|Experimental|Intervention group|This group will include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance will be assessed at 6 months follow-up after baseline assessment than educational intervention will be given. Six months after intervention compliance will be assessed again.
9465905|NCT03670303|No Intervention|Control group|This group will also include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance towards spectacle use will be assessed at 6 months after baseline assessment. No intervention will be given in this group. Compliance will be assessed again at the same time when assessed in intervention group 6 months after the intervention.
9465906|NCT03670290||Group 1|Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
10028378|NCT01740635|No Intervention|Cognitive games|To provide a comparable level of investigator attention, control group subjects will receive two 1-hour social visits. To control for Trainer bias, the experimental and control groups will have separate Trainers. During social visits, the Trainer will discuss subjects' current community activities and their experience using the wheelchair, and provide verbal information related to barriers encountered. Subjects will receive a computer tablet with cognitive stimulation games to account for activity and tablet device exposure. Participants in the extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week (total 75 minutes/week) and document these on a simple calendar-style form provided. To minimize attrition, control subjects will receive a DVD with a condensed MWC skills education program after the post-intervention data collection is complete.
10028379|NCT01740661|Experimental|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
10028380|NCT01740661|Placebo Comparator|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
10028381|NCT01740674|Experimental|Electronic data collection|The group of participants who will complete questionnaires via the internet
10028382|NCT01740674|No Intervention|Paper data collection|The group of participants who will continue to complete paper based questionnaires, as has been the practice for this longitudinal study.
10028383|NCT01740687||Essure+NovaSure|The group of women relying on Essure micro-inserts for permanent birth control when NovaSure is performed following a successful Essure Confirmation Test
10028384|NCT01740700|Experimental|p-Branch®|
10028385|NCT01740739||Cardiac Risk|Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.
10028386|NCT01740752|Experimental|UCAN+CBT|This condition includes 22 UCAN sessions and 22 CBT sessions, totaling 44 psychotherapy sessions. UCAN is a manualized, 22-session Cognitive Behavioral Couple Therapy (CBCT) intervention that engages the couple to target the core psychopathology of AN and address the uniquely challenging stress that AN places on intimate relationships. The CBT proposed for this study is a 22 session adaptation of the manualized intervention that has been employed successfully as an outpatient post-hospitalization therapy and in an National Institute of Mental Health multisite study of fluoxetine with elements from the CBT manual used in McIntosh et al (PubMed 15800147).
10028387|NCT01740752|Experimental|CBT|"In this condition, participants will receive a higher dose of individual CBT, with 44 total sessions. Our experience with patients in the pilot strongly suggests that a higher dose of CBT will allow for further, fruitful discussion and exploration of key individual issues and is unlikely to be experienced as diluted or a slow approach to treatment. Most of these patients have complicated histories, long-standing eating disorders, and complex comorbid conditions."
10028388|NCT01740765|Experimental|Eucaloric Feeding|Subjects will complete an initial eucaloric feeding study day. During this study day, subjects will receive 100% of their calorie requirements. 24-hour energy expenditure will be measured.
10028389|NCT01740765|Experimental|Underfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the underfeeding study arm, subjects will receive 50% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
10028390|NCT01740765|Experimental|Overfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the overfeeding study arm, subjects will receive 150% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
10028391|NCT01740778||Study Group 1|Aurora vs. Microlet 2
10028392|NCT01740778||Study Group 2|Aurora vs. SoftClix
10028393|NCT01740778||Study Group 3|Aurora vs. One Touch Comfort
10028394|NCT01740778||Study Group 4|Aurora vs. Multiclix
9465907|NCT03670290||Group 2|Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
9465908|NCT03670290||Group 3|Group III will receive 10 ml of Bupivacaine 0.25% solution through the epidural catheter.
9465909|NCT03670238|Experimental|Orogastric intubation|Orogastric intubation using a polyurethane enteral tube followed by fixation of the tube tip to a superior molar.
10028395|NCT01740830|Active Comparator|Anodal tDCS|
10028396|NCT01740830|Sham Comparator|Sham tDCS|
10028397|NCT01740843|Active Comparator|Low intensity anodal tDCS|tDCS will be administered for 10 min at 1mA
9465910|NCT03670238|Active Comparator|Nasogastric intubation|Nasogastric intubation using a polyurethane enteral tube followed by fixation of the tube to the patient face.
9465911|NCT03670225|Other|Invia Motion Endure|
10028398|NCT01740843|Experimental|High intensity anodal tDCS|tDCS will be administered for 10 min at 2.5mA
9465912|NCT03670212|Placebo Comparator|Placebo|The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
9465913|NCT03670212|Experimental|Acute Stress|During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
9465914|NCT03670199|Experimental|Experimental group|nutritional and functional management coordinated by dieticians and physiotherapists, with adapted nutritional and physical advice and support, realized with the use of Nutrimus booklet in order to facilitate coordination and delivration of cares proposed to the patients
9465915|NCT03670199|Active Comparator|Control group|usual preoperative advice for patients who undergoing surgical procedure concerning nutritional cares and physical activity
9465916|NCT03670186|Experimental|V66V-HIIT|Val/Val carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
9465917|NCT03670186|Experimental|V66M-HIIT|Val/Met carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
10028399|NCT01740843|Sham Comparator|Sham tDCS|Sham will be administered for 10 min at 0 mA
10028400|NCT01740856|Experimental|Rest three hours|Rest three hours
10028401|NCT01740856|Experimental|Rest five hours|Rest five hours
10028402|NCT01740869|Experimental|Experimental: Patients|Children who will receive intrathecal autologous stem cells
10028403|NCT01740869|Other|Control/Crossover|We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
10028404|NCT01740908||Hyperbaric Oxygen Treatment|Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.
10028405|NCT01740908||Baseline|Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.
10028406|NCT01740921|Active Comparator|Liraglutide|Liraglutide (Victoza) daily injections
10028407|NCT01740921|Placebo Comparator|diet|reduction in calorie intake
10028408|NCT01740921|Placebo Comparator|Aspirin|Aspirin 300mg once daily
10028409|NCT01740934|Active Comparator|Anatabloc Cream|Twice daily use of active facial cream
9465918|NCT03670173|Experimental|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year. One course of osalmid treatment lasts four weeks. Response will be assessed at the end of each treatment course, and patients who have achieved MR (minor remission) or more than MR at the end of the fourth course will continue to take 1.0g tid osalmid daily for consolidation / maintenance therapy. Otherwise, patients who have not achieved MR at the end of the fourth course and patients who are assessed for PD (progression of disease) at the end of each course will receive salvage treatment, such as a combined treatment of osalmid and dexamethasone or the VCD (bortezomib, cyclophosphamide and dexamethasone) regimen.
9465919|NCT03670108||patients receiving an individualized SMS|
9465920|NCT03670108||patients receiving a standard SMS|
9465921|NCT03670095|Experimental|Lactose-free memantine tablet|(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state
9465922|NCT03670095|Experimental|Lactose-containing memantine tablet (Ebixa®)|(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state
9465923|NCT03670082|Experimental|Group 1: Fasting condition in Period I|Subjects will be in fasting condition in Period I and in a fed condition in Period II.
9465924|NCT03670082|Experimental|Group 2: Fed condition in Period I|Subjects will be in fed condition in Period I and in fasting condition in Period II.
10028410|NCT01740934|Placebo Comparator|Placebo Cream|Twice daily use of placebo facial cream
9465926|NCT03670043|Active Comparator|Metformin ER|The subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)
9465927|NCT03670043|Experimental|Psyllium|The subjects developing GI-related symptoms with metformin will be randomized to Psyllium
9465928|NCT03670004||Unilateral Below Knee Amputation|Individuals who walk with a below knee prosthesis
9465929|NCT03670004||Non-Impaired|Able-bodied controls
10028411|NCT01740947|No Intervention|Standard treatment|Standard treatment for colorectal cancer
10028412|NCT01740947|Experimental|Selective decontamination of the digestive tract (SDD)|"Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively."
10028413|NCT01740960|Active Comparator|delta-9-tetrahydrocannabinol|Subjects will be randomized to receive 3 doses Namisol® (3 mg, 5 mg, 6,5 mg)
10028414|NCT01740960|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product.
10028415|NCT01740973||SILC cholecystectomy|No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
10028416|NCT01740973||and conventional lap. cholecystectomy|no intervention.Patients are also mailed a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
10028417|NCT01740986|Experimental|SA09012 Low dose|
9465930|NCT03669978||Patients with chronic occlusive arthritis of the Lower Limbs|"Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.~Creation of a bone and arterial panorama using EndoNaut® software."
9479997|NCT03537872|Experimental|Miner-Friendly (MF) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.~Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies."
9479998|NCT03537872|Active Comparator|Public Sector (PS) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.~Public Sector (PS) Health Facilities TB/HIV Integration Strategies"
10028418|NCT01740986|Experimental|SA09012 High dose|
9479999|NCT03537859|Experimental|Augmented Reality (AR)|Books with augmented reality plus an electronic tablet.
9480000|NCT03537859|Other|Non Augmented Reality (NoAR)|Conventional children book. No electronic device will be given to children.
9480001|NCT03537846||Osteoporosis and women|Patient women over thirty years old
9480002|NCT03537820||before nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, before nurses formation and installation of a noise warning device
9480003|NCT03537820||after nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, after nurses formation and installation of a noise warning device
9480004|NCT03537794||Treatment Resistant Depression|Unmedicated Individuals with Treatment Resistant Depression
9480005|NCT03537794||Major Depressive Disorder|Unmedicated Individuals with Major Depressive Disorder
9480006|NCT03537794||Healthy Control|healthy controls with no previous psychiatric disorders
10028419|NCT01740986|Placebo Comparator|Placebo|
10028420|NCT01740999|Experimental|silicone arthroplasty|silicone arthroplasty
10028421|NCT01740999|Active Comparator|arthrodesis|arthrodesis
10028422|NCT01741025|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
10028423|NCT01741025|Active Comparator|conservative management|Medications, physical therapy, information
10028424|NCT01741038|Experimental|AlloStim® treatment|The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
10028425|NCT01741038|Other|Physician's Choice (PC)|All subjects will be assigned Physician's Choice (PC) therapy. PC can consist of best supportive care (BSC) or any US-FDA-approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated.
9480007|NCT03537781|Experimental|Food label available, hungry state|foods will be displayed with food labels present and when participants had nothing to eat
9480008|NCT03537781|Experimental|food label available, satiated|foods will be displayed with food labels present and when participants had already eaten breaksfast
9480009|NCT03537781|Experimental|food label unavailable, hungry state|foods will be displayed without food labels present and when participants had nothing to eat
9480010|NCT03537781|Experimental|food label unavailable, satiated|foods will be displayed without food labels present and when participants had already eaten breakfast
10028426|NCT01741051|Experimental|HEPA Filter|HEPA filter(s) placed in the participant's home from approximately 10 weeks gestation until birth.
10028427|NCT01741051|No Intervention|Control|
10028428|NCT01741064||PTH below target iPTH in CKD|iPTH at one year post transplantation below target range of iPTH by stage of CKD (KDOQI-guidelines).
10028429|NCT01741064||iPTH within target range of iPTH in CKD|iPTH at one year post transplantation within target range of iPTH by stage of CKD (KDOQI-guidelines).
10028430|NCT01741064||iPTH above target range of iPTH in CKD|iPTH at one year post transplantation above target range of iPTH by stage of CKD (KDOQI-guidelines).
10028431|NCT01741077||pregnant women|pregnant women taking 1 mg folic acid;
10028432|NCT01741077||non-pregnant women|non-pregnant women taking 0mg folic acid;
10028433|NCT01741077||non-pregnant women 2|non-pregnant women taking 1 mg folic acid
10028434|NCT01741077||non-pregnant women 3|non-pregnant women taking 5 mg folic acid
10028435|NCT01741090|Experimental|MSC injection|This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
10028436|NCT01741116|Experimental|TKI258, inhibitor of RTKs|"Intervention: TKI258~Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:~- Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off."
10037573|NCT01826305|Experimental|Independent Exercise Cohort|Patients randomized to the independent exercise cohort will receive online access to a twelve-week protocol of exercises to perform at home to strengthen and improve function of the replaced knee.
9480011|NCT03537768|Active Comparator|UPA 30mg|
9480012|NCT03537768|Active Comparator|LNG 1.5 mg|
9480013|NCT03537768|Active Comparator|LNG 3.0|
9480014|NCT03537742|Experimental|alirocumab|alirocumab 150mg subcutaneous every other week for one year following start of study drug
9480015|NCT03537742|Placebo Comparator|placebo|placebo to match alirocumab every other week for one year following start of study drug
9465931|NCT03669965|Experimental|Part A Arm 1|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
9465932|NCT03669965|Experimental|Part A Arm 2|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
9465933|NCT03669965|Experimental|Part A Arm 3|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
9465934|NCT03669965|Experimental|Part B KRT-232 Arm|Recommended KRT-232 dose and schedule from Part A
9465935|NCT03669965|Active Comparator|Part B Ruxolitinib Arm|Ruxolitinib per approved prescribing label
9465936|NCT03669965|Experimental|Part A Arm 4b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
9465937|NCT03669965|Experimental|Part A Arm 2b|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
9465938|NCT03669952||Invasive ductal carcinoma|Patients with Invasive ductal carcinoma
9465939|NCT03669939||Communication strategy|Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers
9465940|NCT03669939||Standard of Care|Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines
9465941|NCT03669926|Other|DBT+SM|Digital Breast Tomosynthesis+synthetic mammography (DBT+SM) All women are screened with DBT+SM. All examinations are independently double read. Consensus used to decide whether or not to recall.
9465942|NCT03669913|Experimental|Intervention|Intervention arm will receive a pre evaluation survey, 11 lessons on CSE sequentially in a period of one year and a post evaluation survey
9465943|NCT03669913|No Intervention|Control arm|This is a control arm that receives no intervention but will have and pre and post evaluation in one year
9465944|NCT03669900|Other|a minimally invasive surgery (SERI)|The surgery consisted of varus traction, skin incision, metatarsal osteotomy and K- wire insertion. All the cases were done by the senior consultant orthopedic surgeon, including preoperative planning, the osteotomy itself and the follow up in the clinic. Another orthopedic surgeon was involved in collecting the data, doing all the measurements preoperative and postoperative and assisting the primary surgeon during the surgery.
9465945|NCT03669848||Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO) Measurements are taken with a noninvasive method by placing a sensor on a patient, usually on the fingertip.
9465946|NCT03669835|Experimental|Dietary supplement and standard therapy.|Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month.
9465947|NCT03669835|Other|Standard therapy only.|Patients would be given standard treatment for 1 month.
9465948|NCT03669809||male, non-obese|male with BMI<28
9465949|NCT03669809||male, obese|male with BMI≥28
9465950|NCT03669809||female, non-obese|female with BMI<28
9465951|NCT03669809||female, obese|female with BMI≥28
9465952|NCT03669796|Experimental|supplementary Marine protein hydrolysate|20 mg powder per kg body weight of Marine protein hydrolysate (MPH)
9465953|NCT03669796|Placebo Comparator|control|20 mg powder per kg body weight of casein/maltodextrin
9465954|NCT03669783|Active Comparator|treatment VAD|Vincristin, Actinomycin-D and Doxorubicin
9465955|NCT03669783|Experimental|treatment VCE|Vincristin, Carboplatin and Etoposide
9465956|NCT03669757|Experimental|LEO 134310 Dose A|Once daily application
9465957|NCT03669757|Experimental|LEO 134310 Dose B|Once daily application
9465958|NCT03669757|Experimental|LEO 134310 Dose C|Once daily application
9465959|NCT03669757|Experimental|LEO 134310 Dose D|Once daily application
9465960|NCT03669757|Placebo Comparator|LEO 134310 vehicle|Once daily application
9465961|NCT03669757|Active Comparator|0.1% betamethasone valerate ointment (class III steroid)|Once daily application
9465962|NCT03669744||Patients with trigeminal neuralgia resistant|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018
9465963|NCT03669731|Experimental|Group 1|Urinary urea 24 hours and food diary
9465964|NCT03669731|Experimental|Group 2|Urinary urea 24 hours and food diary
9465965|NCT03669731|Experimental|Group 3|Urinary urea 24 hours and food diary
9465966|NCT03669692|Active Comparator|Control|Patients in the control group will be assigned to a free diet (ad libitum), according to the Spanish Association of Urology lifestyle recommendations for patients with LUTS
9465967|NCT03669692|Experimental|Caloric Restriction|"Patients in the experimental group will be assigned to intermittent caloric restriction, based on an early time restricted eating, with a 16/8 fasting/feeding scheme.~The patients in this group will have a RC progressive scheme until achieve a maximum of 5 days a week of fasting."
9465968|NCT03669679|Active Comparator|Group A|"participants undergoing superomedial pedicle breast reduction Hall-Findlay technique"
9465969|NCT03669679|Active Comparator|Group B|"participants undergoing inferior pedicle breast reduction Robbins technique"
9465970|NCT03669666||control group|10 normal healthy subjects are conducted for cardiac magnetic resonance imaging examination
10028437|NCT01741129|Active Comparator|Nasal Continuous Positive Airway Pressure (CPAP)|"After 2 hours evaluation:~Infants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of >88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
9465971|NCT03669666||case group|25 patients with valvular heart disease diagnosed clinically and by echocardiography are conducted for cardiac magnetic resonance imaging examination
9465972|NCT03669653|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
10028438|NCT01741129|Active Comparator|Nasal Intermittent Mandatory Ventilation (IMV)|"After 2 hours evaluation:~Infants needed invasive MV or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of > 88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
10028439|NCT01741142|Experimental|ABT-436|Subject receiving ABT-436
10028440|NCT01741142|Active Comparator|Escitalopram|Subject receiving escitalopram.
10028441|NCT01741142|Placebo Comparator|Placebo|Subject receiving placebo
10028442|NCT01741168|Active Comparator|TLSO|TLSO brace 8-10 weeks
9465973|NCT03669653|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
9465974|NCT03669601|Experimental|Continuous AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily for 21 days of a 28 day cycle. Dose range from 40mg to 120mg."
9465975|NCT03669601|Experimental|Intermittent AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily and intermittently for up to 12 days of a 28 day cycle. Dose range from 40mg to 120mg."
9465976|NCT03669575|Experimental|omega 7 - placebo|Receiving the active first then switch to the placebo after three weeks
9465977|NCT03669575|Active Comparator|placebo - omega 7|Receiving the placebo first then switch to the active after three weeks
9465978|NCT03669562|Experimental|Alprostadil liposome|
9465979|NCT03669562|Placebo Comparator|Placebo|
9465980|NCT03669510|Active Comparator|computer gaiuded IAN|Computer guided surgical technique
9465981|NCT03669510|Experimental|Classical technique|Non computer guided surgical technique
9465982|NCT03669484|Experimental|Remimazolam|"The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.~Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation to 2 mg/kg/h maximum; In case of loss of consciousness was not registered in 2.5 minutes of continuous intravenous infusion: drug administration was terminated. If loss of consciousness was not registered during 30 seconds, other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed: intravenous bolus infusion (maximum level of 12 mg/kg/h for 1 minute). If signs of awakening remained remimazolam administration was discontinued and other sedatives were used."
9480016|NCT03537729|No Intervention|Control|There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
9480017|NCT03537729|Experimental|Salient Cues|Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
10028443|NCT01741168|Experimental|No Orthosis|No Orthosis
10028444|NCT01741181|Active Comparator|Vitamin D supplementation|Vitamin D3 tablets (cholecalciferol)
10028445|NCT01741181|Placebo Comparator|Placebo pill|Placebo pill
10028446|NCT01741207|No Intervention|control|control This group is without N-acetylcystein : just receives standard treatment
10028447|NCT01741207|Active Comparator|N-acetylcystein|receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
10028448|NCT01741220||anesthetists|German-speaking intensive-care providers and anesthetists
10028449|NCT01741233|Experimental|UV-B irraditation|VitDgen
10028450|NCT01741246||Control|Headache-free subjects.
10028451|NCT01741246||Episodic migraine|Patients with less that 15 headache days per month that fulfill International Classification of Headache Disorders 2R (ICHD-2nd edition Revised)- criteria for Episodic Migraine.
10028452|NCT01741246||Chronic migraine|Patients that fulfill International Classification of Headache Disorders (ICHD)-2R criteria for chronic migraine (more than 15 days per month).
10028453|NCT01741285|Active Comparator|Fluticasone|Two weeks treatment with HFA-Fluticasone 250 microgram twice daily
10028454|NCT01741285|Active Comparator|Clenil|Two weeks treatment with HFA-Clenil 200 microgram 2 inhalations twice daily.
10028455|NCT01741285|Experimental|QVAR|Two weeks treatment with QVAR 2 times 100 microgram twice daily
10028456|NCT01741298|Experimental|Lifestyle counseling|CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
10028457|NCT01741311|Experimental|3H+ Group|3H+ (Holistic for HIV) group patients will receive the standard of drug treatment care (i.e., methadone maintenance treatment and case management) plus four weekly 60-minute HIV risk reduction groups, and a 60-minute booster session at 12 weeks, led by two facilitators trained and supervised by a licensed clinical psychologist. 3H+ is an HIV risk reduction and ART adherence intervention that provides coping skills training and is delivered in a group modality, addressing high risk drug- and sex-related HIV risk behaviors and ART adherence for opioid-dependent individuals living with HIV.
10037574|NCT01826318|Experimental|intervention|"Participants received a 10 minute instruction to cope with stress by loudly posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention group)"
10037575|NCT01826318|No Intervention|Control|Students in the control group did not receive any further instructions.
10028458|NCT01741311|Active Comparator|HHRP+ Group|HHRP+ (Holistic Health Recovery Program) is comprised of 12 two-hour weekly manual-guided group sessions with comprehensive HIV risk reduction content that addresses the medical, emotional, and spiritual needs of opioid-dependent individuals living with HIV. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators, who address potential motivational conflicts of HIV+ individuals by providing them with self-protective as well as altruistic reasons for examining and changing their HIV risk behaviors and improving adherence behavior. Material is presented using cognitive remediation strategies.
10028459|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
9465983|NCT03669484|Active Comparator|Propofol|"The induction of anesthesia: intravenous infusion of 1.5-2.5 mg/kg for about 1 minute.~Maintenance of anesthesia: intravenous infusion for a total dose of 4-12 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation.~In case of loss of consciousness was not registered other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed and propofol dose adjustment had not resulted in the desired effect and signs of awakening were saved: the use of propofol was discontinued and other sedatives were used."
9465984|NCT03669471||FAIS group|Subjects who have had a hip arthroscopy for femoroacetabular impingement during the preceding 6-30 months
10028460|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
10028461|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
10028462|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
10028463|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
10028464|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
10028465|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
9465985|NCT03669458|Experimental|Arm 1: BTK intervention with SPUR/DCB|Below the knee peripheral intervention using SPUR/DCB.
9465986|NCT03669458|Experimental|Arm 2: BTK intervention using SPUR Only|Below the knee peripheral intervention using SPUR only.
9465987|NCT03669458|Experimental|ARM 3: BTK intervention using DCB Only|Below the knee peripheral intervention using DCB only.
10028466|NCT01741324|Placebo Comparator|Malmö, placebo, dark skin,|Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
9465988|NCT03669445|Experimental|four drugs combination|21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab
9465989|NCT03669432|Experimental|Intensity Modulated radiotherapy|"In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
9465990|NCT03669432|Other|Surgery alone|In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
9465991|NCT03669406|Experimental|Autograft fat|Paraplegic patients with healed pelvic eschar
9465992|NCT03669393|Experimental|THR-317|
10028467|NCT01741324|Placebo Comparator|Malmö, placebo, light skin|Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
10028468|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
10028469|NCT01741337|Experimental|Patients treated by ventilation|Adaptive servo-ventilation post-operative treatment for 6 months
10028470|NCT01741337|No Intervention|Patients not treated by ventilation|Patients not treated during 6 months by an adaptive servo-ventilation
10028471|NCT01741363|Experimental|one-day sampling with one-year interval|FIT one-day sampling with one-year interval
10028472|NCT01741363|Active Comparator|one-day sampling with two-year interval|FIT one-day sampling with two-year interval
10028473|NCT01741363|Experimental|two-day sampling with one-year interval|FIT two-day sampling with one-year interval
10028474|NCT01741363|Experimental|two-day sampling with two-year interval|FIT two-day sampling with two-year interval
10028475|NCT01741363|Experimental|Hp stool antigen (HpSA)+FIT|HpSA for detection of upper gastrointestinal tract diseases and upper endoscopy for H. pylori carriers; HPSA combined with FIT
10028476|NCT01741376|Placebo Comparator|Placebo + Placebo|Two placebos are given for 84 days.
10028477|NCT01741376|Active Comparator|Progesterone + Placebo|Progesterone (200 mg twice daily) and a placebo are given
10028478|NCT01741389|Placebo Comparator|Sleep only|Placebo given at night to tetraplegic individuals before going to sleep,
10028479|NCT01741389|Active Comparator|Melatonin|Melatonin given at night to tetraplegic individuals before going to sleep.
10028480|NCT01741402|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
10028481|NCT01741402|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
10028482|NCT01741415|Experimental|SIDI|Skills for Improving Distress Intolerance treatment protocol: individual, manualized treatment aimed at improving distress intolerance
10037576|NCT01826331|No Intervention|Control Group|Participants will be incentivized for assessments only
10028483|NCT01741415|Placebo Comparator|SC|supportive counseling; psychological placebo/talk therapy - aimed at controlling for non-specific therapeutic factors
10028484|NCT01741428|Active Comparator|Intervention (INT1)|The participants will join a 5-days course at the Feiring Heart Clinic.
10028485|NCT01741428|No Intervention|Control (KTR1)|The participants in the Control Group will receive care as usual at their local Doctors Office
10028486|NCT01741428|Active Comparator|Subgroup Intervention (INT2)|Subgroup of 200 participants from the (INT1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
10028487|NCT01741428|No Intervention|Subgroup control (KTR2)|Subgroup of 200 participants from the (KTR1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
10028488|NCT01741441||WAR and MR patients|Consecutive patients with MR and WAR selected for laparoscopic total fundoplication (LTF) were included in a prospective clinical study. Gastroesophageal function was assessed by clinical validated questionnaires, upper endoscopy, esophageal manometry and 24-h impedance pH monitoring before and 12 and 60 months after LTF. Gastric scintigraphy was preoperatively performed in all patients.
9465993|NCT03669380||conservative treatment|Conservative treatment consisted of bowel rest, intravenous fluid therapy, nutritional support, strict blood pressure control, anticoagulation (with or without antiplatelet) and close observation
9465994|NCT03669380||Interventional and surgical treatment|Interventional and surgical treatment
10028489|NCT01741467|Experimental|RT-CGM|Patients using the RT-CGM for the intervention portion of the study.
10028490|NCT01741493|Experimental|Healthy Volunteers (ABT-494)|Multiple dosing of ABT-494 in healthy volunteers
10028491|NCT01741493|Experimental|Rheumatoid Arthritis Patients|Multiple dosing of ABT-494 in patients with rheumatoid arthritis
10028492|NCT01741493|Placebo Comparator|No treatment|Placebo administration in healthy volunteers and patients with rheumatoid arthritis
10028493|NCT01741493|Other|Healthy Volunteers (tofa)|Multiple dosing of tofacitinib in healthy volunteers
9465995|NCT03669341|Experimental|Deep Inspiration Breath Hold (DIBH)|DIBH extended by prior hyperventilation while breathing 100% O2
9465996|NCT03669341|Active Comparator|High Frequency Percussive Ventilation (HFPV)|passive Ventilation by a jet ventilator
9465997|NCT03669328||Group 1|patients of 2016, June with locoregional anesthesia
9465998|NCT03669328||Group 2|patients of 2018, June with locoregional anesthesia
9465999|NCT03669315|Active Comparator|Active cTBS treatment|Active cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. TBS consists of bursts of 3 pulses separated by 20ms (i.e. 50 Hz), with each triplet being repeated every 200 ms (i.e. 5 Hz). Stimulus intensities will be set at 80% of AMT. The investigators will use 2 trains of 600 pulses each separated by 1 minute (a total of 1200 pulses).
9466000|NCT03669315|Sham Comparator|Sham cTBS treatment|Sham cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same active cTBS configuration will be used.
9466001|NCT03669302|Sham Comparator|Robotic gait training|Robotic gait training only
9466002|NCT03669302|Experimental|Robotic gait training & low-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at low frequency (0.3 Hz).
9466003|NCT03669302|Experimental|Robotic gait training & high-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at high frequency (30 Hz).
9466004|NCT03669289|Experimental|Enhanced model of primary care|
9466005|NCT03669263|Experimental|Fentanyl buccal soluble film (FBSF)|Single arm
9466006|NCT03669250|Active Comparator|CVN058, low dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 15mg or 75mg substitution of 15mg.
10028494|NCT01741506|Experimental|Dalteparin (Fragmin®)|Dalteparin (Fragmin®) 5000 IU (International Unit) once daily
10028495|NCT01741506|No Intervention|No treatment|No treatment
9466007|NCT03669250|Active Comparator|CVN058, high dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
10028496|NCT01741506|Other|Open surgery arm|Dalteparin (Fragmin®) 5000 IU once daily
10028497|NCT01741519|Experimental|LDLL600|Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
10028498|NCT01741519|Active Comparator|Brevibloc|Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
10028499|NCT01741558|Experimental|Methotrexate|Established treatment associated with methotrexate
10037577|NCT01826331|Experimental|Incentives for Participation|Participants will be incentivized for each assessment and for each smoking cessation session they complete
9466008|NCT03669250|Placebo Comparator|Placebo|Matching placebo.
9466009|NCT03669237|Experimental|end-to-side anastomosis|
9466010|NCT03669237|No Intervention|end-to-end anastomosis|
9466011|NCT03669224|Experimental|Nano Care Gold|Silver and Gold nano particles suspended in 70 % isopropyl alcohol. It will be used for cavity pre-treatment. This arm will be compared with no intervention (negative control).
9466012|NCT03669224|Active Comparator|Chlorhexidine|2% chlorhexidine gluconate solution will be applied to prepared cavity followed by adhesive system then resin composite. This arm will be compared with no intervention (negative control).
9466013|NCT03669211|Experimental|Cardiac stress test|
9466014|NCT03669198|Active Comparator|NT-pro BNP group|Subjects who be included in NT-pro BNP group examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group can be discharged if the NT-pro BNP level decreased ≥ 30% from baseline. If the target percent decline is not met, we will do intensification of therapy according to the algorithm
9466015|NCT03669198|No Intervention|Control group|Patients in the control group were managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not was determined by cardiologist in charge of the patient based on clinical assessment.
9466016|NCT03669185|Placebo Comparator|Placebos|Placebos, 2 times daily 1 tablet, intake max. 133 days
10028500|NCT01741558|Placebo Comparator|Placebo (Riboflavin)|Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
10028501|NCT01741571|Active Comparator|EBUS guided FNA with suction|"Device/procedure: lymph node tissue collection using fine needle aspiration with suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
10028502|NCT01741571|Experimental|EBUS guided FNA without suction|"Device/procedure: lymph node tissue collection using fine needle aspiration without suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
10028503|NCT01741584|Experimental|stationary bike exercise|6 months of exercise (60% of anaerobic threshold)
10028504|NCT01741584|Placebo Comparator|aerobic|6 months of exercise <30% anaerobic threshold
10028505|NCT01741597|Experimental|Diagnostic (DCE-MRI, tumor-homing peptide iRGD)|Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
10028506|NCT01741610|Placebo Comparator|No coloading (Group E)|Placebo comparator
9466017|NCT03669185|Active Comparator|Pentalong|Pentalong, 2 times daily 1 tablet, intake max. 133 days
9466018|NCT03669172|Experimental|NK cells infusion|NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor
9466019|NCT03669120|Active Comparator|Arm I (mainstream instructional care)|Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of NRT in the form of nicotine patches, and intensive print materials to promote smoking cessation.
10028507|NCT01741610|Active Comparator|Cristalloid (Lactated Ringer) Coloading|Cristalloid (Lactated Ringer's) Coloading (Group L)
9466020|NCT03669120|Experimental|Arm II (tailored intensive care)|Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.
10028508|NCT01741610|Active Comparator|Colloid (HES) coloading|Colloid (HES) coloading (Group C)
9466021|NCT03669107|Experimental|Gum chewing|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at 30 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
9466022|NCT03669107|No Intervention|Control group|no gum
9466023|NCT03669068||Elective endoscopy|Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.
9466024|NCT03669068||Gastrointestinal bleeding|Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately
9466025|NCT03669055|Experimental|Pre-operative and post operative Magnetic Resonance Imaging|Realization of an angio-MRI with 4D phase contrast sequence before and after the endovascular treatment of the aortic dissection
9466026|NCT03669042|Experimental|Treatment|All patients will undergo a vascular repair or reconstruction surgery, which requires the use of PhotoFix. The surgical procedures will vary by patient and by underlying etiology. Therefore, PhotoFix implant sites will also vary. In all cases, PhotoFix will be implanted per the Instructions for Use (IFU).
9466027|NCT03669029|Experimental|Week 6 Responders|In patients with clinical response at week 6, serum golimumab levels and anti-golimumab antibody levels will be correlated with clinical response.
9466028|NCT03669029|Experimental|Week 6 Non Responders|In patients without clinical response at week 6, golimumab treatment will be optimized.
9466029|NCT03669016|Experimental|Face-to-face group-based mindfulness|8 weeks training.
9466030|NCT03669016|Experimental|Internet-based mindfulness|8 weeks training.
9466031|NCT03669016|No Intervention|Waiting-list control group|No training during the study.
10028509|NCT01741623|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
10028510|NCT01741623|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
10028511|NCT01741636|Experimental|Supportive care (survivorship plan)|Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.
10028512|NCT01741649|Experimental|Clorhexidine|Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
10028513|NCT01741649|Experimental|Povidone|Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
10037578|NCT01826331|Experimental|Incentives for Cessation|Participants will be incentivized for each assessment and biochemically confirmed abstinence at 12 and 24 months
9466032|NCT03669003|Experimental|Gelfoam|Gelfoam slurry will be injected at the end of the biopsy procedure.
9466033|NCT03669003|Active Comparator|Standard procedure|Standard procedure of lung biopsy
9466034|NCT03668990|Other|persons with Multiple Sclerosis (MS)|"25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
9466035|NCT03668990|Other|stroke patients|"25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
9466036|NCT03668990|Other|Healthy controls|"50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
9466037|NCT03668977|No Intervention|Routine care|"In all four groups, the following antenatal and post-natal interventions will be offered:~Women encouraged to enroll in routine antenatal care at their local health post/center.~A clean birthing kit consisting of a clean blade, string, and plastic disc for cutting the cord, a plastic sheet, a bar of soap, and a tube of chlorhexidine ointment for application to the umbilical stump.~Women encouraged to deliver at a certified birthing facility and participate in the government's incentive scheme.~Nutritional, hygiene, and infant care counseling.~Tetanus toxoid (if needed) and iron-folic acid supplements."
9466038|NCT03668977|Experimental|Supplementation-pregnancy|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing throughout pregnancy. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
9466039|NCT03668977|Experimental|Supplementation-lactation|A daily fortified balanced protein-energy nutritional supplement beginning after delivery and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
9466040|NCT03668977|Experimental|Supplementation-pregnancy & lactation|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
9466041|NCT03668964|Experimental|Vitamin B2|Daily dose of 75 mg Vitamin B2
9466042|NCT03668964|Experimental|Vitamin C|Daily dose of 500 mg Vitamin C
9466043|NCT03668964|Experimental|Vitamin B2 + C|Daily dose of 75 mg Vitamin B2 and 500 mg Vitamin C
9466044|NCT03668964|Experimental|Vitamin A|Daily dose of 250 µg Vitamin A
9466045|NCT03668964|Experimental|Vitamin D3|Daily dose of 60 µg Vitamin D3
9466046|NCT03668964|Experimental|Vitamin E|Daily dose of 100 mg Vitamin E
9466047|NCT03668964|Placebo Comparator|Placebo|Daily dose of 575 mg microcrystalline cellulose
9466048|NCT03668938|Experimental|intervention|The occupational therapy intervention provides a treatment aimed at improving autonomy in the activities chosen by the patient
9466049|NCT03668938|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
9466050|NCT03668925|Experimental|"Group Case"|patient diagnosed with hidrosadenitis suppurativa
9466051|NCT03668925|Active Comparator|"Group control"|patient without hidrosadenitis suppurativa
9466052|NCT03668912|Experimental|Guided participation group|
9466053|NCT03668912|No Intervention|Usual care group|
9466054|NCT03668899|Experimental|Chitosan NPs group|irrigation with Chitosan nanoparticles (final flush)
9466055|NCT03668899|Experimental|Chlorhexidine group|irrigation with CHX (final flush)
9466056|NCT03668899|Experimental|Combination group|irrigation with CHX/ nano Chitosan combination (final flush)
9466057|NCT03668899|Active Comparator|Hypochlorite group|irrigation with NaOCL (final flush)
9466058|NCT03668886|Experimental|multimodal exercise program|Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
9466059|NCT03668886|No Intervention|Control group|Elderly in this group will continue to attend community activity as usual. The activity includes active activity is 60 minutes and frequency is 2 times/week.
9466060|NCT03668873|Experimental|Sleep Parent Training|The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-weeks. In addition to the five sessions, there are three home visits conducted via Express Care Online (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
10028514|NCT01741662|Other|group psychopathological|
10028515|NCT01741675|Experimental|Monetary incentive|The intervention group will receive a postal questionnaire together with a voucher worth €15 for the largest supermarket chain in Denmark. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
10028516|NCT01741675|Other|Control|The control group will only receive a postal questionnaire. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
10028517|NCT01741714|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active chiropractic spinal manipulative treatment
10028518|NCT01741714|Sham Comparator|Sham manipulation|Sham chiropractic manipulative therapy
10028519|NCT01741714|No Intervention|Control group|No intervention, follow headache diary
10028520|NCT01741727|Experimental|ABT-414|Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
10028521|NCT01741740||retrospective surgical patients|consecutive elective umbilical hernia repair patients during two years from two hospitals,- retrospective id with prospective follow up
10028522|NCT01741753|Experimental|Treatment Arm|BKM120+Abiraterone+Prednisone
10028523|NCT01741766|Experimental|Stretching Training|Whole body stretching exercises 3 times per wk for 8 weeks
10028524|NCT01741766|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
10028525|NCT01741779|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
9466061|NCT03668873|Active Comparator|Sleep Parent Education|SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.
9466062|NCT03668860|Active Comparator|Treatments A & B (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
9466063|NCT03668860|Active Comparator|Treatments B & A (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
9466064|NCT03668860|Active Comparator|Treatments C & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
9466065|NCT03668860|Active Comparator|Treatments D & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))"
9466066|NCT03668860|Active Comparator|Treatments E & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
9466067|NCT03668860|Active Comparator|Treatments D & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
10028526|NCT01741779|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
10028527|NCT01741779|Experimental|Whole body vibration training & diet|Lower-body exercise training on a vibration platform and diet
10028528|NCT01741779|Experimental|Whole body vibration training|Lower-body exercises 3 times per wk for 12 wk in a vibration platform
10028529|NCT01741805||Severe Asthma|Patients with severe asthma as specified under inclusion, exclusion criteria
10028530|NCT01741818||Group B|CVP less than 8cmH2o
10028531|NCT01741831||Darunavir|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
10028532|NCT01741844||Etravirine|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.
10028533|NCT01741857|Experimental|human umbilical cord derived MSC|human umbilical cord derived MSC transplantation for SLE
10028534|NCT01741870|Placebo Comparator|Control|No intervention was given. All subjects received routine care
10028535|NCT01741870|Active Comparator|Received nutrition supplement as needed|Subjects in this group received 50 g/day soy protein-based nutritional supplement (containing 9.5 g protein, 250 kcal energy and all essential micro-nutrients) whenever subjects BMI is below 24 and MNA score also below 24.
10028536|NCT01741883|No Intervention|Standard Medical Care and Information|Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
10028537|NCT01741883|Experimental|Side effect prevention training (SEPT)|Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
10028538|NCT01741883|Active Comparator|Attention Control group (ACG)|Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.
9466068|NCT03668860|Active Comparator|Treatments C & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)"
10028539|NCT01741896|Active Comparator|RIPC|Patients in the RIPC arm will undergo a period of upper limb ischaemic preconditioning before their contrast enhanced CT scan. The RIPC stimulus involves four cycles of ischaemia/reperfusion (5 minutes of blood pressure cuff induced upper limb ischaemia with 3 minutes reperfusion). This will start at a time of 30 - 40 minutes before the administration of contrast. The cuff is inflated to 15mmHg above systolic pressure at each inflation.
10028540|NCT01741896|No Intervention|Control arm|Patients in the control arm will undergo no extra intervention.
10028541|NCT01741909|Experimental|Before, After|The intervention is educational
10028542|NCT01741922|Experimental|ASA evening&placebo morning|Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.
10028543|NCT01741922|Active Comparator|ASA morning&placebo evening|Patients will receive acetylsalicylic acid (100 mg) in the morning and placebo in the evening
9466069|NCT03668860|Active Comparator|Treatments E & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)"
9466070|NCT03668834|Active Comparator|Dermabrasion with NCES|Intervention-Dermabrasion with autologous non cultured epidermal cell suspension Recipient site preparation using dermabrasion followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
9466071|NCT03668834|Active Comparator|Dermaroller with NCES|Intervention-Dermaroller with autologous non cultured epidermal cell suspension Recipient site preparation using dermaroller system followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
9466072|NCT03668834|Active Comparator|Liquid nitrogen induced blister with NCES|Liquid nitrogen induced blister with autologous non cultured epidermal cell suspension Recipient site preparation using liquid nitrogen induced blister followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
9466073|NCT03668821||Carotid Artery Disease|Patients with Carotid Artery Disease. Quality of life and frailty questionnaires
9466074|NCT03668821||Aneurysmal Disease|Patients with Aneurysmal Disease. Quality of life and frailty questionnaires
9466075|NCT03668821||Peripheral Artery Disease|Patients with Peripheral Artery Disease. Quality of life and frailty questionnaires
9466076|NCT03668808|Experimental|Insulin Degludec|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.
9466077|NCT03668808|Active Comparator|Insulin Glargine U100|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.
9466078|NCT03668782||immediate cord clamping|Tthe umbilical cord of neonates was cut and clamped.
9466079|NCT03668782||umbilical cord milking.|Tthe umbilical cord of neonates was milked.
9466080|NCT03668769|Experimental|Prevention (smoking reduction, Quitting Schedule mobile app)|"AIM I: Participants follow an individually tailored gradual reduction of smoking schedule for 5 weeks while MDACC eHealth adapts WebCASSI into a smartphone app: Quitting Schedule.~AIM II: Participants pre-test the Quitting Schedule mobile smartphone app for 5 weeks."
9466081|NCT03668756||Computer-Assisted Navigation TKA|the patients who were received CAS TKA in one limb
9466082|NCT03668756||Conventional TKA|the patients who were received conventional TKA in one limb
9466083|NCT03668730|Experimental|Reduced dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome, Cisplatin and 5-Fluorouracil, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive cisplatin once per three week for 3 cycles.
9466084|NCT03668730|Experimental|Standard dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome,Cisplatin and 5-Fluorouracil, patients undergo standard-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cisplatin once per three week for 3 cycles.
9466085|NCT03668704||Medial Bicompartmental Knee Arthroplasty|Patient who have received a robotic-arm assisted medial and patellofemoral knee arthroplasty.
10028544|NCT01741948||First time users of hormonal contraceptive|
10028545|NCT01741961||glaucoma, surgery, Ahmed valve|Patients with uncontrolled glaucoma undergoing Ahmed glaucoma valve implantation for intraocular pressure reduction.
10028546|NCT01741974|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
10028547|NCT01741974|Placebo Comparator|Sugar pill|Placebo tablet 500 mg by mouth three times a day
10028548|NCT01741987|Active Comparator|optive® eye drop|
10028549|NCT01741987|Placebo Comparator|fresh tears ® eye drop|
10028550|NCT01742000|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
10028551|NCT01742000|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
10028552|NCT01742013|Placebo Comparator|Placebo|NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks
10028553|NCT01742013|Experimental|GCJBP Laennec Inj.|GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks
10028554|NCT01742039||b-blocker|
10028555|NCT01742039||amiodarone|
10028556|NCT01742039||atrial pacing|
10028557|NCT01742039||amiodarone plus atrial pacing|
10028558|NCT01742052|Experimental|MT-1303-Low|MT-1303-Low Dose
10028559|NCT01742052|Experimental|MT-1303-Middle|MT-1303-Middle Dose
10028560|NCT01742052|Experimental|MT-1303-High|MT-1303-High Dose
10028561|NCT01742052|Placebo Comparator|Placebo|Placebo
10028562|NCT01742130|Experimental|Sodium bicarbonate|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
10028563|NCT01742130|Active Comparator|Saline|Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
9466086|NCT03668678|Experimental|iGrow Readers Curriculum|The iGrow Readers nutrition and physical activity curriculum was implemented in early-childhood classrooms assigned to the IGrow Readers intervention group.
10028564|NCT01742156||Presence of coronary disease|All patients with or without coronary disease who are followed in coronary clinics or wards
10028565|NCT01742156||coronary disease|Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics
10028566|NCT01742169|Experimental|Outreach and Reminder Intervention|Participants randomized to this arm will receive the Outreach and Reminder intervention.
9466087|NCT03668678|No Intervention|Standard Curriculum|The standard curriculum was provided within early-childhood classrooms assigned to the control group.
9466088|NCT03668665|Active Comparator|Conventionell Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~1st half: conventional treatment with moist dressings (mepilex and fixomull)"
9466089|NCT03668665|Experimental|Treatment with Ready Medical Post Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~2nd half: conventional treatment with moist dressings (mepilex and fixomull) and additional treatment with ready medical post treatment"
9466090|NCT03668652|Experimental|Focal prostate cancer treatment by HIFU|Patients with target lesion distance < 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion > 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO.
9466091|NCT03668652|Active Comparator|Radical Prostatectomy|Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.
9466092|NCT03668626|No Intervention|Term infants|Healthy term infants
9466093|NCT03668626|No Intervention|Usual care program (UCP)|In-hospital and after-discharge intervention (telephone calls)
10028567|NCT01742169|No Intervention|Usual Care|Patients assigned to this arm will receive usual care.
10028568|NCT01742182|No Intervention|Control|
10028569|NCT01742182|No Intervention|PD patients without sleep problems|
10028570|NCT01742182|Active Comparator|PD patients with sleep problems|light exposure
10028571|NCT01742182|Placebo Comparator|PD patients with sleep problem|light exposure
10028572|NCT01742195|Other|Nasal EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
10028573|NCT01742195|Other|Oral EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
10028574|NCT01742221|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
10028575|NCT01742221|Placebo Comparator|Placebo|Single subcutaneous dose
10028576|NCT01742234||Kidney Donors|People who will donate a kidney at the University of Minnesota, Mayo Clinic, or University of Alabama
10028577|NCT01742234||Lung Donors|People who will donate a lung at the Washington University School of Medicine or the University of Southern California
10028578|NCT01742247|Experimental|Physiogel, Laser therapy, Moisturizer|"Experimental: Physiogel treated & Non-treated~1 Palmitoylethanolamide, Physiogel 3 times a day for 2 weeks"
10028579|NCT01742260|Experimental|Repair of cranial defect|Repair of cranial defects by tissue engineering
9466094|NCT03668626|Experimental|Family-centered intervention program (FCIP)|In-hospital and after-discharge intervention (clinic and home visits)
9480018|NCT03537729|Experimental|Spaced retrieval education|This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.
10028580|NCT01742273|No Intervention|standard treatment (usual care)|standard treatment (usual care)
10028581|NCT01742273|Experimental|Vitamin K1|Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)
10028582|NCT01742312||oesophageal adenocarcinoma|DEXA scan cardio-pulmonary exercise testing (CPEX) muscle biopsy
10028583|NCT01742325|Other|Lifestyle counseling|To test an intervention program (two 20-minute sessions of walking around the nurse's station daily, five days a cycle) to reduce the symptoms of fatigue and pain and increase quality of sleep.
10028584|NCT01742338|Active Comparator|Low Dose Corticosteroids|"10 mg IV q8hrs x 3 days*, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop.~*If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days."
10028585|NCT01742338|Experimental|High Dose Corticosteroids|Methylprednisolone 40 mg IV q8hrs x 3 days*, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. *If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.
10028586|NCT01742351|Experimental|Guided internet-based cognitive behavior therapy (CBT)|
10028587|NCT01742377||Patients with GerdQ positive|Gerd Q positive was defined as score equal or more than eight.
10028588|NCT01742377||Patients with GerdQ negative|Gerd Q neegative was defined as score less than eight.
10028589|NCT01742377||Normal volunteers|Normal volunteers was defined as population without dyspeptic symptom.
9466095|NCT03668574|Experimental|Aerobic exercise group|Patients will firstly warm up for 5 minutes and begin training on the treadmill. There will be two weekly sessions, lasting 40 minutes, for 6 weeks, reaching a total of 12 sessions. The exercise intensity will vary from 60 to 90% of the maximum heart rate (HRmax) predicted by the percentage formula HR = HR rep + percentage (HRmax - HR rep), where HRmax = 220-age (years) and HR rep = HR obtained for five minutes of rest. Heart rate and level of subjective perception of the effort will be monitored during all sessions. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
10028590|NCT01742390|Experimental|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
10028591|NCT01742390|Active Comparator|risperidone or paliperidone|Stay on risperidone (RIS) or paliperidone (PALI)
10028592|NCT01742403|Experimental|R/T gating kV intrafraction monitoring|"Intervention: Recruitment will be performed in 2 phases:~Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction)."
10028593|NCT01742416|Experimental|Ultrasound|
10028594|NCT01742416|Active Comparator|Palpation Method|
10028595|NCT01742429|Experimental|Levofloxacin-bismuth therapy|14 day levoﬂoxacin and bismuth-containing therapy:PPI,bismuth, amoxicillin, levoﬂoxacin
9466096|NCT03668574|Placebo Comparator|Placebo Group|Patients will received a detuned pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes, twice weekly for 6 weeks. The devices will be used with disconnected internal cables to obtain the placebo effect; however, it will be possible to manipulate the devices and adjust the doses and alarms as if they were connected, in order to simulate the pragmatism of clinical practice as well as to increase the credibility of the use of these devices in patients. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
9466097|NCT03668561|Experimental|Treatment (CALIGALOC)|Wearing of the Caligaloc orthosis
9466098|NCT03668548|Experimental|Leucine group|To receive leucine on a daily basis for 10 weeks
9466099|NCT03668548|Placebo Comparator|Control group|To receive a placebo supplement on a daily basis for 10 weeks
10028596|NCT01742429|Active Comparator|classical quadruple therapy|14 day classical quadruple therapy:PPI,bismuth, metronidazole, tetracycline
10028597|NCT01742442||Older cancer patients|Older cancer patients 70 years or older referred to specialist oncology outpatient clinics
10028598|NCT01742468|Experimental|Dietary supplement: n-3 LC-PUFA|Name: microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany; rich in docosahexaenoic acid (DHA); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
10028599|NCT01742468|Placebo Comparator|Dietary supplement: sunflower oil|Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
10028600|NCT01742481|Experimental|Education and empowerment program|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
10028601|NCT01742481|Placebo Comparator|self-guided empowerment and education|participants have information packet but receive no individualized support or assistance
10028602|NCT01742494|Active Comparator|Water-jet POEM|POEM were performed by the use of Erbe Hybrid knife (WJ group)
10028603|NCT01742494|Active Comparator|Conventional POEM|POEM were performed by the conventional technique using injection and triangle tip knife (C group).
10028604|NCT01742507|Active Comparator|Medtronic Resolute Integrity Stent|Medtronic Resolute Integrity Stent
10028605|NCT01742507|Active Comparator|Biomatrix stent|Biomatrix stent
10028606|NCT01742520|Active Comparator|Formula or Breast Milk|Breast milk or formula prior to every painful procedure.
10028607|NCT01742520|Active Comparator|Multiple doses of sucrose|Infants in this group will be treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure
10028608|NCT01742533|Experimental|Group1 : HRT plus hUCMSCs treatment:|Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
10028609|NCT01742533|Experimental|Group 2: HRT plus hCBMNCs and hUCMSCs therapy|Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
10028610|NCT01742533|Experimental|Group3 : HRT plus hCBMNCs treatment:|Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
10028611|NCT01742533|Experimental|Group 4:Hormone Replacement Therapy|Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
10028612|NCT01742546|Experimental|Therapeutic ultrasound combine TENS|"Use therapeutic ultrasound with simultaneous TENS for 10 minutes/session for 10 sessions/course.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius), this device has treatment head described by the manufacturers as having surface area as 5.8 cm2, ERA (Effective Radiating Area) of 5.0 cm2 and BNR (Beam Non-uniform Ratio) as max. 5.0. For electrotherapy unit which composes of 2 channels, output characteristics are constant current (CC) or constant voltage (CV), resolution of output signal is in steps of 0.2 mA and timer is limited to 30 minutes during ultrasound and combination therapy are operated."
10028613|NCT01742546|Sham Comparator|Therapeutic ultrasound with sham TENS|Use the same therapeutic ultrasound machine and place the electrode as experimental group but turn-off electrical current during treatment period
10037579|NCT01826383|Experimental|Active Video|This is a five-minute video that coaches parents about how to soothe their infant post-immunization.
10037580|NCT01826383|Placebo Comparator|Placebo Video|This is a video identical to that of the active video, except no specific instructions regarding how to soothe an infant post-immunization are given.
9466100|NCT03668535|Active Comparator|Bladder Filling arm|Group A have triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
9466101|NCT03668535|Active Comparator|Bladder deflation arm|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
9466102|NCT03668522||children|age<=17
9466103|NCT03668522||adult|age>17
10028614|NCT01742559|Experimental|Anterior middle superior alveolar|The AMSA technique was performed in the test group according to Friedman & Hochman (1997). The needle was introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the periodontal procedure.
10028615|NCT01742559|Active Comparator|Supraperiosteal technique|The supraperiosteal technique at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the SRP procedure.
9466104|NCT03668509|Experimental|Cohort 1|oral adminstration of SHR1459, dose 1
10028616|NCT01742572|Experimental|Vegan|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
10028617|NCT01742572|Experimental|Vegetarian|A vegetarian diet is one that does not contain meat, fish, or poultry but does contain eggs and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
10028618|NCT01742572|Experimental|Pesco-Vegetarian|A pesco-vegetarian diet is one that does not contain meat or poultry but does contain fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
10028619|NCT01742572|Experimental|Semi-Vegetarian|A semi-vegetarian diet is one that contains all foods, including meat, poultry, fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. However, red meat is limited to one time per week and poultry is limited to 5 times per week or less. We will also ask you to keep foods low in fat and low in glycemic index.
10028620|NCT01742572|Active Comparator|Omnivorous|An omnivorous diet contains all food groups. However, as part of this study, we will ask participants in this group to keep foods low in fat and low in glycemic index. Participants in this group will not need to attend weekly meetings but will receive information via e-mail each week.
10028621|NCT01742585|Experimental|ASP1585 group|
9466105|NCT03668509|Experimental|Cohort 2|oral adminstration of SHR1459, dose 2
9466106|NCT03668509|Experimental|Cohort 3|oral adminstration of SHR1459, dose 3
9466107|NCT03668496|Experimental|SHR-1210 +chemotherapy|subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
9466108|NCT03668496|Active Comparator|chemotherapy|carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
9466109|NCT03668483|Experimental|Pulmonary Rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
9466110|NCT03668470|Experimental|Dulaglutide|Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
9466111|NCT03668470|Placebo Comparator|placebo|Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
9466112|NCT03668457|Experimental|Intervention to Patients|Only patients receive intervention
9466113|NCT03668457|Experimental|Intervention to Psychiatrists|Psychiatrists receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
9466114|NCT03668457|Experimental|Mixed Intervention|Patients and Psychiatrists associated with these patients receive intervention
9466115|NCT03668457|Other|Control|Psychiatrists provide the usual care Patients receive usual care
9466116|NCT03668444|Experimental|TXS- Supportive Text Group|Participants randomized to this arm (TXS) of the study will receive care as usual within the Drug Treatment Court (DTC) system plus supportive daily text messages which will be delivered at specific times each day for 30 days and will be signed by the judge for their specific DTC. (TXS) Group receives text messages for drug treatment compliance.
9466117|NCT03668444|Placebo Comparator|TAU- Treatment As Usual Group|Participants randomized to the (TAU) arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive motivational text messages for 30-days.
9466118|NCT03668431|Experimental|PDR001, Dabrafenib, Trametinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive PDR001, Dabrafenib, Trametinib. Treatment will be administered on an outpatient basis.~After the screening procedures confirm participation in the research study:~Dabrafenib will be taken twice a day for 28 consecutive days~Trametinib will be taken once a day for 28 consecutive days~PDR001 will be administered IV every 28 days."
9466119|NCT03668418||Colorectal cancer|Patients operated for colorectal cancer with or without liver metastasis undergoing a chemotherapy treatment after surgery
9466120|NCT03668418||Esophagus/gastric cancer|Patients operated for esophagus/gastric cancer undergoing a chemotherapy treatment after surgery
10028622|NCT01742585|Placebo Comparator|placebo group|
10028623|NCT01742598|Experimental|Portico Implant|
10028624|NCT01742611|Experimental|ASP1585 group|
10028625|NCT01742624|Experimental|Advagraf group|
10028626|NCT01742624|Active Comparator|Prograf group|
10028627|NCT01742637|Experimental|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)
10028628|NCT01742637|Active Comparator|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)
10028629|NCT01742637|Placebo Comparator|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)
10028630|NCT01742650|Active Comparator|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
10028631|NCT01742650|Active Comparator|TightRope|TightRope transfixation of syndesmosis
10028632|NCT01742663|Experimental|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
10028633|NCT01742663|Active Comparator|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
10028634|NCT01742663|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
10028635|NCT01742676|Experimental|ADVAGRAF group|
10028636|NCT01742676|Active Comparator|PROGRAF group|
10028637|NCT01742689|Experimental|Desmopressin intranasal spray|Patients in this arm will receive 40 microgram desmopressin intranasal spray & 100 milligram indomethacin suppository
9466121|NCT03668418||Biliary duct cancer|Patients operated for biliary duct cancer undergoing a chemotherapy treatment after surgery
9466122|NCT03668418||Pancreatic cancer|Patients operated for pancreatic cancer undergoing a chemotherapy treatment after surgery
9466123|NCT03668405|Experimental|Lu AF20513 high dose|
9466124|NCT03668379|Active Comparator|Behavioral Activation Therapy|"During the initial stage treatment, the active comparator arm is the behavioral activation (BAT) program intervention. BAT is informed by behavioral theory and has been shown to be a highly efficacious treatment for depression. A total of five, 1-hour sessions will be delivered every two weeks. During Session 1, the focus will be on providing an introduction to BAT, as well as building confianza (mutual trust) between the patient and provider. Sessions 2 & 3 will review the initial session, introduce high value activities and barriers to BAT protocols. Sessions 4 & 5 will review progress, challenges & maintenance strategies."
9466125|NCT03668379|Experimental|Behavioral Activation Therapy & mHealth|"During the initial stage treatment, the experimental arm will deliver a BAT program identical to the active comparator arm, as well as a mobile health (mHealth) component in the form of one-way and two-way SMS text-messages. Direct personalized text-messages will be delivered twice a week to facilitate engagement with the BAT intervention activities. One-way messages will be sent as appointment and BAT adherence reminders. Two-way messages will be sent once a week during a set block of protected hours, creating a mobile drop-in clinic where messages can be sent and received."
9466126|NCT03668366|Experimental|S-1 arm|The patients in the S-1 arm will receive IMRT (66-70.4Gy to GTV, 57-60.8Gy to CTV1, 54-56Gy to CTV2, given in 30-32 fractions). During the IMRT course, S-1 will be administered orally according to body surface area (BSA<1.25m2, 30mg; BSA: 1.25-1.5m2, 40mg; BSA>1.5m2, 50mg) twice per day for 30-32 days. The dose modifications of S-1 will not be permitted during concurrent chemotherapy unless progression of the disease, toxicities of grade 4 or patient's refusal.
9466127|NCT03668353|Experimental|treatment 1|Recombinant SeV-hFGF2/dF Injection 2×10 8CIU
9466128|NCT03668353|Experimental|treatment 2|Recombinant SeV-hFGF2/dF Injection 1×10 9CIU
9466129|NCT03668353|Experimental|treatment 3|Recombinant SeV-hFGF2/dF Injection 5×10 9CIU
9466130|NCT03668353|Experimental|treatment 4|Recombinant SeV-hFGF2/dF Injection 1×10 10CIU
9480019|NCT03537716|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic system
9480020|NCT03537703|Experimental|Active tDCS + Auditory Training|Cathodal tDCS plus concurrent active auditory training exercise
9480021|NCT03537703|Active Comparator|Active tDCS + Control Condition|Cathodal tDCS plus concurrent control condition
10028638|NCT01742689|Placebo Comparator|Placebo intranasal spray|Patients in this group will receive placebo nasal spray & 100 milligram indomethacin suppository
10028639|NCT01742702||DYNAMIC (ongoing)|Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
10028640|NCT01742702||AERO-DYNAMIC (recordings completed)|Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.
10028641|NCT01742702||Liquorice (recordings completed)|Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.
10028642|NCT01742702||Milk polypeptides (recordings completed)|Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.
10028643|NCT01742702||Bisoprolol (recordings completed)|Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.
10028644|NCT01742702||Aortic stenosis (ongoing)|Subjects with aortic stenosis confirmed by echocardiography
10028645|NCT01742702||Methodological (recordings completed)|35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner
9480022|NCT03537703|Active Comparator|Sham tDCS + Auditory Training|Sham tDCS plus concurrent active auditory training exercise
9480023|NCT03537677|Experimental|Sedentary Behavior Intervention|A behavioral intervention that targets prolonged sitting and encourages frequent activity breaks.
9480024|NCT03537638|Experimental|Multicomponent Intervention|Rheumatologist and internist receive a multicomponent intervention
9480025|NCT03537638|No Intervention|Control|Rheumatologist and internist provide the usual care
9480026|NCT03537625|Experimental|Green tea|Green tea extract 2 gram per day
9480027|NCT03537625|Experimental|Fermented green tea|Fermented green tea extract 2 gram per day
9480028|NCT03537625|Placebo Comparator|Placebo|Placebo
9466131|NCT03668340|Experimental|Part A: AZD1775|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
9466132|NCT03668340|Experimental|Part B: AZD1775 in Carcinosarcoma|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
9466133|NCT03668340|Experimental|Part C: AZD1775 in Uterine Serous with biopsiable disease|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
9466134|NCT03668314|Experimental|Cohort 1:1 - 1:6 RDN-929|RDN-929 single dose capsule
9466135|NCT03668314|Placebo Comparator|Cohort 1:1 - 1:6 placebo|Placebo single dose capsule
10028646|NCT01742702||Participants of Ironman Triathlon|Altogether 80 athletes participating in a full length Ironman competition. Non-invasive recordingds are performed under normal conditions during the training period and after completion of a full-length Ironman competition.
9466136|NCT03668314|Experimental|Cohort 2:1|Fed/Fast RDN-929
9466137|NCT03668314|Experimental|Cohort 3:1- 3:4 RDN-929|RDN-929 multiple dose capsules once daily for 12 days
10028647|NCT01742715|Experimental|PEEP by Best oxygenation|"Set Positive End Expiratory Pressure (PEEP) at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg Ideal Body Weight (IBW). fraction of inspired oxygen (FiO2) is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with arterial blood gas (ABGs), and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% Partial Oxygen tension (PaO2) PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
10028648|NCT01742715|Experimental|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
10028649|NCT01742715|Experimental|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
9466138|NCT03668314|Placebo Comparator|Cohort 3:1- 3:4 placebo|placebo multiple dose capsules once daily for 10 days
10028650|NCT01742728||Nagasaki|Sample collection
10028651|NCT01742728||Tokushima|Oxidative stress, cytokine
10028652|NCT01742728||Kanagawa|oxidative stress
10028653|NCT01742741|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs)system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct the hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
10028654|NCT01742741|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
10028655|NCT01742754|Experimental|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.
10028656|NCT01742767|Active Comparator|Cis (D1) + Pem (D1)|Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21
10028657|NCT01742767|Experimental|CIS (D1+8) + Pem (D!)|Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21
9466139|NCT03668301||Group CPB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery with cardiopulmonary bypass
9466140|NCT03668301||Group OPCAB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery without cardiopulmonary bypass
9466141|NCT03668301||Group CPB-C|Control patients undergoing cardiac surgery with cardiopulmonary bypass
9466142|NCT03668301||Group OPCAB-C|Control patients undergoing cardiac surgery without cardiopulmonary bypass
9466143|NCT03668288||PID patients|Adults with primary or secondary immunodeficiency for whom human immunoglobulin-assisted recombinant human hyaluronidase treatment is initiated
9466144|NCT03668275|Experimental|Intervention|(partial) oncological home-hospitalization
9466145|NCT03668275|No Intervention|Control|standard oncological ambulatory hospital care
9466146|NCT03668262||0.15mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.
9466147|NCT03668262||0.1mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
10028658|NCT01742780|Active Comparator|Standard Vidacare Site Identification Method|Palpate up the proximal humerus towards the anterior shoulder just above the surgical neck, to the greater tubercle of the proximal humerus. Insert the needle set perpendicular to skin with a slight downward angle at the most prominent aspect of greater tubercle to establish proximal humerus intraosseous vascular access.
10028659|NCT01742780|Active Comparator|Saussy Site Identification Method|Palpate the proximal humerus to locate the intertubercular groove; rotate the forearm medially and laterally to isolate the groove. Move one finger breadth laterally from the groove to the greater tubercle. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
9466148|NCT03668262||0.07mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
9466149|NCT03668262||0.05mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
9466150|NCT03668262||0.03mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
9466151|NCT03668262||0.02mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
10028660|NCT01742780|Active Comparator|Campbell Site Identification Method|"With the fingers on both hands fully extended similar to a karate chop, place one hand into the anterior joint space (acromioclavicular joint) of the patient. Place the second karate chop hand along the midline of the patient's lateral shoulder; touch the pinkie fingers over the superior aspect of the patient's shoulder. Overlap the thumbs on the patient's shoulder, which will be at the most prominent aspect of the greater tubercle. Insert the needle set perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
10037581|NCT01826396|Experimental|high dose irinotecan|high dose irinotecan based on UGT1A1 genotype, 5-fluorouracil, and leucovorin (FOLFIRI) for first-line treatment of locally advanced colon cancer
9466152|NCT03668249||All Participants|Participants diagnosed with CD from approximately 12 to 15 investigational sites will be observed retrospectively for previous 5 years.
9466153|NCT03668210||Patients with contralateral ACL after Ligamentoplasty|"Athletic patients who have consulted in Sports Medicine Department at the Rennes University Hospital, victims of an ACL rupture during sports activity and who declared a contralateral ACL after the ligamentoplasty.~Isokinetic evaluation."
9466154|NCT03668210||Patients without contralateral ACL rupture|"Athletic patients who have consulted in Sports Medicine Department at Rennes University Hospital, without ACL rupture.~Isokinetic evaluation."
9466155|NCT03668171|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks
9466156|NCT03668171|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2
9466157|NCT03668158||recurrent HCC|recurrent HCC after LT
9466158|NCT03668158||non-recurrent HCC|non- recurrent HCC after LT
9466159|NCT03668145|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.
9466160|NCT03668145|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.
9466161|NCT03668132||Left damage|Have the ischemic brain damage and the location of the damage ,and in the left brain
9466162|NCT03668132||Right damage|Have the ischemic brain damage and the location of the damage ,and in the right brain
9466163|NCT03668132||Normal control|Not have the ischemic brain damage
9466164|NCT03668106|Active Comparator|swim up method|Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
9480029|NCT03537612|Experimental|Opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
10037582|NCT01826409|Experimental|Fermented red ginseng|
10028661|NCT01742780|Active Comparator|Davlantes Site Identification Method|"Using one hand, place the thumb on the acromioclavicular joint in the natural recess or pocket between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
9466165|NCT03668106|Active Comparator|sperm gradient centrifugation|"PureSperm gradients 40 % and 80 % were used for the experiment. All procedures were conducted under sterile conditions. Using a sterile pipette, 2.0 mL of the lower layer (80% PureSperm gradient) was transferred into a conical centrifuge tube.~Using a new sterile pipette, 2.0 mL of the upper layer (40% PureSperm gradient) was gently dispensed on top of the lower layer. A liquefied semen sample was then placed on top of the upper layer and the tube was centrifuged for 20 minutes at 300g. The upper and lower layers were carefully aspirated without disturbing the pellet. Using a transfer pipette, 2-3 mL of Ham's F10 +10% HAS was added to the pellet and the resuspended pellet was centrifuged for 7 minutes at 300g. The supernatant was then removed and the pellet was suspended in a volume of 0.5 mL of Ham's F10 + FCS 10%. Aliquots of the detached sperm were dealt with like previous arm"
10028662|NCT01742793|Experimental|Arm L: subjects with lymphoma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with lymphoma who are eligible to enter Arm L:~Dose Level Arm L Lenalidomide dose Oral Romidepsin Dose Intravenous~2 10mg D1-7, D15-21 6mg D1, 8, 15~1 10mg D1-7, D15-21 8mg D1, 8, 15~10mg D1-21 8mg D1, 8, 15 2 15mg D1-21 8mg D1, 8, 15 3 15mg D1-21 10mg D1, 8, 15 4 15mg D1-21 12mg D1, 8, 15 5 15mg D1-21 14mg D1, 8, 15 6 25mg D1-21 14mg D1, 8, 15~The first patient in arm L will be entered into the study at dosing level one."
10028663|NCT01742793|Experimental|Arm M: subjects with myeloma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with myeloma who are eligible to enter Arm M:~Dose Level Arm M Lenalidomide dose Oral Romidepsin Dose Intravenous Dexamethasone~2 15mg D1-7, D15-21 6mg D1, 8, 15 20mg D1,8,15,22~1 15mg D1-7, D15-21 8mg D1, D8, 15 20mg D1,8,15,22~15mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 2 25mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 3 25mg D1-21 10mg D1, 8, 15 20mg D1,8,15,22 4 25mg D1-21 12mg D1, 8, 15 20mg D1,8,15,22 5 25mg D1-21 14mg D1, 8, 15 20mg D1,8,15,22~The first patient in arm M will be entered into the study at dosing level one."
10028664|NCT01742806|No Intervention|control|not to use bio-absorbable felt(NEOVEIL®)
10028665|NCT01742806|Experimental|NEOVEIL®|To use bio-absorbable felt
10028666|NCT01742819||Advanced glaucoma|Patients with MD < -6 or visual field loss within the central 10 degrees of the visual field.
10028667|NCT01742845|Active Comparator|control group|landmark-based superficial cervical block is used. After insertion of the needle superficially below the skin, 20 to 30 ml of 4.75 mg/ml ropivacaine are injected fan-like in the subcutaneus plane.
10028668|NCT01742845|Experimental|echo group|ultrasound-guided intermediate cervical block was performed. The probe is placed perpendicular to the skin, in the horizontal plane at the C3-C4 level. Needle is inserted in-plane. 10 ml ropivacaine 4.75mg/ml are injected under ultrasound control, 5 ml injected when needle is withdrawn under ultrasound control, 5 ml in the subcutaneous plane.
10028669|NCT01742858||Adolescents|15-18 years old
10028670|NCT01742858||Young adults I|19-24 years old
10028671|NCT01742858||Young adults II|25-30 years old
10028672|NCT01742871||controls|Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults
10028673|NCT01742871||kaskadil|Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
10028674|NCT01742884|Experimental|Thealoz|Treatment with Thealoz (Trehalose) 3% for 1 month
10028675|NCT01742884|Placebo Comparator|Treatment with Thealoz´s vehicle|Treatment with Thealoz´s vehicle for 1 month
10028676|NCT01742910|Other|Tecnis ZCB00|eyes with implantation of Tecnis ZCB00
10028677|NCT01742910|Other|Acrysof SA60AT|eyes with implantation of Acrysof SA60AT
10028678|NCT01742923|Placebo Comparator|Usual care|Usual care
10037583|NCT01826409|Placebo Comparator|Placebo|
9466166|NCT03668106|Active Comparator|zeta method|"sperm samples were diluted 5 million in 1 ml. To induce a positive charge, the tube was placed inside a latex glove up to the cap and grasping the cap, the tube was rotated two or three turns and rapidly pulled out. Each tube was kept at room temperature for 1 minute to allow adherence of the charged sperm to the wall of the centrifuge tube.~Tubes were hold by the cap to avoid grounding of the tube. After 1 minute the tubes were centrifuged at 200g for 5 minutes. Then, the medium and pellet were discarded in order to discard non adhering sperm and other cells. The surface of tube was washed by 0.2ml of Ham's F10+ FCS 10% in order to neutralize the charge on the wall of the tube and detach the adhering sperm.~The collected medium at the bottom of each tube was repipetted and used to rinse the wall of the same tube several times to increase the number of recovered sperm . Aliquots of the detached sperm were dealt with like previous arm"
9466167|NCT03668093|Experimental|ICCMS|Intervention
9466168|NCT03668093|Active Comparator|CAMBRA|Comparator
9466169|NCT03668080||surgical residents|Surgical specialties included general surgery, plastic surgery, urology, vascular surgery, obstetrics and gynecology, orthopedic surgery, pediatric surgery, cardiothoracic surgery and otolaryngology.
9466170|NCT03668080||non-surgical residents|Non-surgical specialties included cardiology, rheumatology, neurology, pulmonary disease, endocrinology, nuclear medicine, pediatrics, psychiatry, internal medicine, oncology, nephrology, hygiene and preventive medicine, anesthesiology, child and adolescent psychiatry, radiology, radiation oncology, infectious disease, dermatology, pathology, microbiology, hematology, gastroenterology, geriatric medicine, medical genetics, sports medicine, occupational and environmental medicine.
9466171|NCT03668067||2WIN|Accommodation, refraction and ocular alignment are estimated by infrared photoscreener using the 2WIN photoscreener device. Photoscreener screening makes use of light crescent quantification from off-axis flash-to-lens in a camera.
9466172|NCT03668067||school bus skiascopy|Refractive error estimated by child-friendly skiascopy rack holding lenses from +1.00 D to +10.00 D and -5.00 D. Skiascopy is a common, old-fashioned form of retinoscopy.
10028679|NCT01742923|Experimental|Complex tailored intervention|"The interventions consists of 3 elements:~Medication review with recommendations focused on antihypertensives and statins and adherence to guidelines and patient´s adherence to medications~Consultation with a pharmacist using motivational interviewing techniques~Follow-up telephone calls one month and six months after inclusion"
10028680|NCT01742962||Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
10028681|NCT01742975|Experimental|Arm A: Applying Ifabond|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.
10028682|NCT01742975|No Intervention|Arm B: without Ifabond|The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.
9466173|NCT03668054|Experimental|Bevacizumab (Lumiere®)|Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
9466174|NCT03668041|Active Comparator|Trazodone|Participants who are assigned to take trazodone, an active study medication.
10028683|NCT01742988|Experimental|Fimepinostat - Continuous Once Daily|Fimepinostat 30-60 mg/day
10028684|NCT01742988|Experimental|Fimepinostat - 2x/week|Fimepinostat 60-240 mg/day
9466175|NCT03668041|Active Comparator|Eszopiclone|Participants who are assigned to take eszopiclone, an active study medication.
9466176|NCT03668041|Active Comparator|Gabapentin|Participants who are assigned to take gabapentin, an active study medication.
9466177|NCT03668041|Placebo Comparator|Placebo|Participants who are assigned to take a placebo, a non-active study medication.
9466178|NCT03668028|Experimental|TPX-114|Subjects undergo arthroscopic rotator cuff repair with TPX-114.
9466179|NCT03668028|Placebo Comparator|Placebo|Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
9466180|NCT03668015|Experimental|Group A (Xylitol then sorbitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol"
10028685|NCT01742988|Experimental|Fimepinostat - 3x/week|Fimepinostat 60-180 mg/day
9466181|NCT03668015|Experimental|Group B (Sorbitol then xylitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol"
9466182|NCT03668002|Placebo Comparator|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
9466183|NCT03668002|Active Comparator|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
10028686|NCT01742988|Experimental|Fimepinostat - 4x/week|Fimepinosta 60-180 mg/day
10028687|NCT01742988|Experimental|Fimepinostat - 5x/week|Fimepinostat 60-180 mg/day
10028688|NCT01742988|Experimental|Fimepinostat - Expansion 5x/week|Fimepinostat 60 mg on the 5 days on/2 days off
10028689|NCT01742988|Experimental|Fimepinostat - Expansion 3x/week|Fimepinostat 120 mg 3 days on/4 days off
9466184|NCT03667989|Other|123I-MIBG CZT SPECT|Patients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.
9466185|NCT03667976|No Intervention|Control Group|All participants in the control group will receive a study pedometer and a physical activity logbook. Participants will also receive the Canadian Society of Exercise Physiology/ParticipACTION physical activity guidelines for adults ages 18 to 64.
10028690|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ rituximab|Fimepinostat 60 mg 5 days on.2 days off plus rituximab
10028691|NCT01742988|Experimental|Fimepinostat 120 mg - Combination w/ rituximab|Fimepinostat 120 mg 3x/week plus rituximab
10028692|NCT01742988|Experimental|Fimepinostat - Biocomparability Arm|Biocomparability Arm
10028693|NCT01742988|Experimental|Fimepinostat 30 mg - Combination w/ venetoclax|Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
10028694|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ venetoclax|Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
10028695|NCT01742988|Experimental|Fimepinostat - Combination w/ venetoclax and rituximab|Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle
10028696|NCT01743014|Active Comparator|ramipril|Ramipril 10 mg tablets. Each dose will be taken orally with water once daily.
10028697|NCT01743014|Active Comparator|clopidogrel and ramipril|clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily
10028698|NCT01743053|Other|Control: Standard Care|The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).
10028699|NCT01743053|Experimental|ReCell|The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).
9466186|NCT03667976|Experimental|Intervention Group|All participants in the intervention group will receive a study pedometer and a physical activity logbook. Participants will also receive the South Asian women Together in a Health Initiative (SATHI) intervention which consists of a gender and culturally specific South Asian physical activity education booklet and video and 2) a matched peer. Peers will encourage physical activity and provide motivation and suggestions for incorporating physical activity into daily life of a South Asian woman based on Bandura's Self-Efficacy construct. Peer contact will occur via telephone, text/email messaging or in person at least once weekly and more often as determined by participants.
9466187|NCT03667963|Other|Low Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
9466188|NCT03667963|Other|High Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
9466189|NCT03667950|Experimental|hyperspectral imaging|diagnostic hyperspectral Imaging of the gastrointestinal anastomosis and calculating the anastomotic Perfusion measures
10028700|NCT01743066|Experimental|Arsenicosis patients|Vitamin E (200 IU, caplet) daily orally for 20 weeks
10028701|NCT01743066|Active Comparator|Arsenic exposed controls|vitamin E (200 IU, caplet) daily orally for 20 weeks
10028702|NCT01743066|Active Comparator|Heathy volunteers|Vitamin E (200 IU, caplet) daily orally for 20 weeks
9466190|NCT03667937|Experimental|CUTIMED|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
10028703|NCT01743079|Experimental|Telbivudine|Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
10028704|NCT01743079|Experimental|Lamivudine|Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
10028705|NCT01743079|No Intervention|No antiviral treatment|Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis
10028706|NCT01743105|Experimental|Study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Interventions: Diaphragm excursion measures 1, Diaphragm excursion measures 2"
10028707|NCT01743118|Experimental|Psoriasis Plaque Test|SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex® ointment
10028708|NCT01743144|Active Comparator|Magnesium sulphate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
9466191|NCT03667937|Active Comparator|AQUACEL silver|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
9466192|NCT03667911|No Intervention|Control Group|Only routine patient education on bowel preparation of colonoscopy. Give oral instructions on bowel preparation(including definition, significance, correct steps as well as dietary limitations) by a well-trained nurses or doctors. Written instructions are offered, which have the some contents.
9466193|NCT03667911|Experimental|Virtual-reality Group|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
9466194|NCT03667898|Experimental|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
9466195|NCT03667898|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
10028709|NCT01743144|Placebo Comparator|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
10028710|NCT01743157|Experimental|Biochemo + Bevacizumab then Ipilimumab|Single arm: Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.
10028711|NCT01743170|No Intervention|Control group|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
10028712|NCT01743170|Experimental|Intervention group|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
10028713|NCT01743183|Experimental|threshold|Held inspiratory muscle strengthening for 5 weeks with Threshold, charging 30% of maximal inspiratory pressure, 7 days a week, one supervised and unsupervised 6.
10028714|NCT01743196||Normal weight|Women with BMI 18.5 to 24.9 kg/m2
10028715|NCT01743196||Obese|Women with BMI > 30 kg/m2
10028716|NCT01743222|Experimental|eASC|"eASC~First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.~Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells."
9466196|NCT03667885||Small renal Masses|patients with a renal mass of 4 cm or less. Typically incidentally found. Blood and urine samples will be collected from each patient at baseline before a biopsy of the tumor is collected and 14 days later. In addition, all patients will be offered a Multi planar MRI before the biopsy. Patients elected for curative treatment for malignant tumors will have another set of blood and urine samples collected at 1 month and 6 months after the intervention.
9466197|NCT03667872|Experimental|Device|MRI compatible and LFP recordable implantable stimulator
9466198|NCT03667859||Women undergoing Brachytherapy|Women with either uterine or cervical malignancy treated primarily by brachytherapy.
9466199|NCT03667859||Women undergoing Pelvic Radiation|Women with either uterine or cervical malignancy treated primarily by pelvic radiation.
10028717|NCT01743222|Placebo Comparator|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node"
10028718|NCT01743235|Experimental|Placebo|30 subjects administered a placebo
10028719|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combination drug|30 subjects are given combination drug (0.25 mg Testosterone + 5 mg Buspirone hydrochloride)
10028720|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combinat|30 subjects are given combination drug (0.25 mg Testosterone + 10 mg Buspirone hydrochloride)
10028721|NCT01743235|Experimental|Testosterone + Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 5 mg Buspirone hydrochloride)
10028722|NCT01743235|Experimental|Testosterone +Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 10 mg Buspirone hydrochloride)
10028723|NCT01743235|Experimental|Testosterone|30 subjects are given 0.5 mg Testosterone
10028724|NCT01743235|Experimental|Buspirone|30 subjects are given 10 mg Buspirone hydrochloride
10036840|NCT01819493|Active Comparator|Standard Family-Based intervention|"Families randomized to the Standard Family-based Intervention will receive three-month family YMCA memberships, one orientation training session, access to available equipment and programming at the YMCA, and receive diabetes educational materials from the Power to Prevent curriculum via email. Based on our previous experience with AA adults, the investigators anticipate that all families will have access to email either at home or at work. Educational materials will be mailed to families without access to email. The study will also maintain contact with participants by sending holiday and birthday cards, as well as postcard reminders of scheduled data collection visits."
9466200|NCT03667833|Experimental|shoulder brace with comfortable tension|"Self-comfortable tension of strap will be adjusted by subject's feedback with comfortable feeling as please feel postural correction by shoulder brace without tight pressure."
9466201|NCT03667833|Experimental|shoulder brace with forced tension|Forced tension, the self-comfortable tension of strap will be increased till forced tension of strap using buckles.
10036841|NCT01819493|Experimental|Lifestyle Intervention|"The lifestyle intervention for adults will involve a dietary weight loss program and an increase in caloric expenditure through moderate PA. Parents will be encouraged to decrease caloric intake in a sound manner to produce a total weight loss of 5%. The PA component will be to promote an increase in family home-based activity.~Children. The study will promote healthy eating behaviors, rather than restrictive eating plans with caloric restrictions."
10036842|NCT01819519|No Intervention|Standard Prenatal Care|Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.
9466202|NCT03667820|Experimental|Osimertinib|Osimertinib in combination with Stereotactic Ablative Radiation (SABR)
9466203|NCT03667807|Experimental|rTMS condition 1|
9466204|NCT03667807|Experimental|rTMS condition 2|
9466205|NCT03667807|Experimental|rTMS condition 3|
9802989|NCT04720443|Experimental|SAD Part 1 Cohort 6|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet at 900 mg) or placebo. In each cohort, to mitigate any unforeseen safety issues, the first 2 subjects (1 active + 1 placebo) will be admitted and dosed, and at least 48 hours apart from the other 6 subjects. The remaining 6 subjects of each cohort will be dosed after review of the safety data of the first 2 subjects.
9466206|NCT03667794||PH patients|Patients with known or first diagnosis of PH
9466207|NCT03667794||healthy controls|Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.
9466208|NCT03667794||non-healthy controls|Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.
9466209|NCT03667781||Patients Interviewed|Patients in cardiology clinic with uncontrolled hypertension despite being on 2 medications
9466210|NCT03667781||Providers Interviewed|Providers in cardiology clinic
9466211|NCT03667781||Patients Blood Draw|Patients seen in interventional clinic for post PCI followup will have a venous blood draw which will be sent for therapeutic drug monitoring
9466212|NCT03667768|Experimental|Glass ionomer sealant|Two hand-mixed glass ionomer cements (GICs) available in the dental market were used, and they were mixed according to the manufacturer's instructions (powder/liquid ratio 1:1). The molars were cleaned with a toothbrush and wet cotton wool pellets. Isolation was performed with cotton wool rolls and the occlusal surface was conditioned with GIC liquid (20s), rinsed with wet cotton wool pellets and dried with dry cotton wool pellets. GIC was placed on the occlusal surface and pressed into the pits and fissures using the press-finger technique. The excess of material was removed and the occlusion checked and adjusted. Sealant was protected with a new layer of petroleum jelly and the children were instructed not to eat for at least one hour. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
9466213|NCT03667768|Other|Non-sealant (toothbrushing)|No sealant was performed. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
9466214|NCT03667755|Experimental|fast track recovery|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Subjects are given a specific drink to their group on the evening prior to surgery and three hours before operation. The CHO-P group received 474ml (evening drink) or 237ml (3 hours prior to operation drink) of a lactose-free clear tea-colour fruit flavoured fluid contains 14% whey protein, 86% carbohydrates and 0% lipids. Participants fast for solids for 6 hours from the operation. Participants will be given clear fluid (2 packs Resource peach) within 24 hours post-surgery (without present of bowel sound) and reviewed by dietitian. Staff nurse in-charged will monitor anesthetic risk of drinking whey protein and ensure subject to finish specific drinks prior surgery. When they tolerated at least 500ml of clear fluids, they were given a regular solid diet.
9466215|NCT03667755|No Intervention|conventional|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Participants followed conventional operation procedure whereby fasting start 12am until operation. On the first day of post-operation day, participants will be reviewed by gynaecologist and dietitian. They are allowed for clear fluid once there is bowel sound. After tolerated clear fluid, they will proceed for nourishing fluid, then soft diet and they were given a regular solid diet.
9466216|NCT03667729|Experimental|progressive muscle relaxation|The experimental group received PMR once a week for a total of 12 weeks. Subjects completed measures at baseline, 3-month, and 3-month follow-up.
10028725|NCT01743261|Active Comparator|usual care|In this arm patients were managed according to the organization of the management model which took on the care of the patient. The organization of these models is characterized by one or two professional figures (physiatrists, neurologist), with hierarchical relationships, in spaces limited to a specific pathology; access is determined by clinical stability; the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas; the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty.
9466217|NCT03667729|No Intervention|Control group|treatment-as-usual(TAU)
9466218|NCT03667703|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.
9466219|NCT03667703|Active Comparator|Study Drug|Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants < 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
9466220|NCT03667677|Experimental|Group 1|Tandospirone + Amlodipine
9466221|NCT03667677|Experimental|Group 2|Tandospirone placebo + Amlodipine
9466222|NCT03667677|Experimental|Group 3|Tandospirone + Amlodipine placebo
9466223|NCT03667677|Placebo Comparator|Group 4|Tandospirone placebo + Amlodipine placebo
9466224|NCT03667664|Other|Prevention of loss of autonomy|Lifestyle counseling for elderly people about physical exercises and nutrition in a preventive way
9466225|NCT03667651|Active Comparator|Twice daily use treatment with EpiCeram|They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.
9466226|NCT03667651|No Intervention|Standard skin care|Parents are to follow standard skin care practices
10028726|NCT01743261|Experimental|Graded intensive rehabilitation|"Instruments of governance are the diagnostic-therapeutic rehabilitation. pathways (DTRP), the Quality system and product standards.~Medical care process with result-oriented autonomy. Technology support of vital signs. Multidisciplinary intervention"
9466227|NCT03667638|Experimental|PRP Intervention|PRP injection into wound border
10028727|NCT01743274|No Intervention|Control Group|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups. In the Control Group, the angioplasty procedure will be guided by traditional fluoroscopy alone.~In both groups, fractional flow reserve (FFR) will be measured at the end of the procedure, once the operator considers the result of the angioplasty to be optimal. The average of three consecutive FFR measures will be recorded."
10028728|NCT01743274|Experimental|Optical Coherence Tomography|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups.~In the OCT group, OCT will be performed to optimise the results of angioplasty. The procedure will be performed according to usual practice, with or without pre-dilation before implantation of one or more stents (drug-eluting or bare metal). In the OCT group, OCT will be performed after initial coronary angiography and at the end of the procedure and the operator will have the possibility to change procedural strategy according to the data immediately available on the OCT images, with the possibility of additional interventions (additional balloon inflations, addition stent implantation, use of GPIIb/IIIa inhibitors and/or thromboaspiration and/or rotational atherectomy)."
9466228|NCT03667625|Experimental|Aquatic group|Aquatic multidimensional mobility exercises were given in the treatment pool at Balcova Thermal Centre, Izmir, Turkey. Group of 6-7 patients was instructed by a specialized physiotherapist twice in a week for eight weeks. The water temperature was 33-340C and the depth was between 110-140 cm, patients were asked to keep T11 level submersion during vertical exercises. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
9466229|NCT03667625|Experimental|Land group|Multidimensional mobility exercises were given at exercise unit of Dokuz Eylul University School of Physical Therapy, Izmir, Turkey. Group of 6-7 patients were instructed by a specialized physiotherapist twice in a week for eight weeks. The room temperature was 23-240C. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
10028729|NCT01743287|Experimental|Imotun capsule|Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks
9466230|NCT03667625|Active Comparator|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks.
9466231|NCT03667612||Patients with breast cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres~Realization of tumor samples series of cuts and paraffin shavings for:~Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
9466232|NCT03667612||Patients with colorectal cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments~Realization of series of cuts and paraffin shavings of the tumor samples for:~Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
10028730|NCT01743287|Placebo Comparator|Imotun capsule placebo|Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks
10028731|NCT01743300|Active Comparator|Grapefruit juice arm|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment
10028732|NCT01743300|Active Comparator|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment.
9466233|NCT03667586|Experimental|Group Cognitive Behavioral Therapy|Cognitive behavioral psychotherapy sessions will be conducted at an appropriately accommodated office of the Psychiatry Department in groups of 6-10 patients and will be coordinated by a qualified psychologist of the research team. Each session will be of 90 minutes duration. The initial two sessions will be psycho-educational and the remaining sessions will be based on the principles of Cognitive Behavioral Therapy (CBT). In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months.
9466234|NCT03667586|Placebo Comparator|Standard care|Regular brief follow-ups by the gastroenterologists and the nurse of the research team
9466235|NCT03667560|Experimental|Dermacell ADM without basement membrane|Dermacell ADM without a basement membrane
9466236|NCT03667560|Active Comparator|FlexHD|FDA-approved FlexHD Pliable
9466237|NCT03667521||non-nerve-sparing laparaoscopic sacrocolpopexy.|
9466238|NCT03667521||nerve-sparing laparaoscopic sacrocolpopexy.|
9466239|NCT03667508|Experimental|Rapid Maxillary Expansion|Patients will undergo Rapid Maxillary Expansion using a rapid maxillary expanding device, i.e. a Hyrax expander (modified by McNamra).
10028733|NCT01743313||Hip and knee replacement recipients|"Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826)."
9466240|NCT03667508|Active Comparator|Slow Maxillary Expansion|Patients will undergo Slow Maxillary Expansion using a slow maxillary expanding device, i.e. a removable appliance with a central screw.
9466241|NCT03667495||Relapse|Patients who suffered colorectal cancer or adenoma relapse after curative surgery
9466242|NCT03667495||Remission|Patients who get remission after curative surgery
10028734|NCT01743326|Experimental|RFD-group|Radio Frequency Denervation
10028735|NCT01743326|Active Comparator|Local Anesthesia-group|Local Anesthesia-group
10028736|NCT01743339|Active Comparator|Control|Control (brief check-in calls) and Cognitive Processing Therapy (12 individual weekly sessions)
9466243|NCT03667469|Experimental|Stapleless one anastomosis gastric bypass|Laparoscopic stapleless-separated one anastomosis (mini-) gastric bypass procedures
9466244|NCT03667469|Active Comparator|Staple use mini-gastric bypass|Laparoscopic stapler-separated one anastomosis (mini-) gastric bypass procedures
9466245|NCT03667469|Active Comparator|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
9466246|NCT03667456|Experimental|Self-rehabilitation by digital support|"Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.~Monitoring and regulation of remote self-reeducation by tele-reeducation. Evaluation of the acceptance of the tool and the quality of life of the patients by questionnaire at day 0, and two and twelve months after."
9466247|NCT03667430|Experimental|Normal weight subjects|Healthy normal weight (BMI 20-25) men 18-35 year. Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 Total study time 21 days
9480030|NCT03537612|Experimental|Sub-opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
9480031|NCT03537612|Active Comparator|Opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
10028737|NCT01743339|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (4 individual therapy sessions over 5 weeks) and Cognitive Processing Therapy (12 individual weekly sessions)
10028738|NCT01743352||Hypertension patients|Local common carotid artery pulse wave velocity is compared in patients with hypertension and healthy volunteers.
10028739|NCT01743352||Healthy Volunteers|Local common carotid artery pulse wave velocity is compared in hypertension patients and healthy volunteers
10028740|NCT01743365|Experimental|Cisplatin-5FU-Afatinib|"Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (Weekday on, Weekend off) for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
10028741|NCT01743378|Experimental|TAP Block Ropivacaine 0,75 %|Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 %
10028742|NCT01743378|Placebo Comparator|TAP Block Saline 0,9 %|Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 %
9466248|NCT03667430|Experimental|Subjects with obesity|Obese otherwise healthy men (BMI 30-45) 18-35 year Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 The dose of Silica 3gx3 for additional 10 weeks Total study time 84 days
10028743|NCT01743404|Active Comparator|Inflaminat|Inflaminat 500 mg tablet by mouth three times a day
10028744|NCT01743404|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
9466249|NCT03667417||subjects carrying a BRCA gene mutation|subjects carrying a BRCA gene mutation
9466250|NCT03667378||supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinician
9466251|NCT03667378||without supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinicianTo receive the investigational cancer treatment alone (control arm) no monthly visit with a supportive care clinician.
10028745|NCT01743417|Experimental|Cognitive intervention|Children in this arm will receive computerised cognitive rehabilitation training for 24 sessions lasting 45 minutes. The Captain's log brain training software is programmed to increase in difficulty as child progresses through the training levels.
10028746|NCT01743417|Active Comparator|Active control|Children in this arm will receive 24 sessions of computerised cognitive rehabilitation training. Captain's log, the brain training software will not be programmed to increase in difficulty with each successive level in this arm.
10028747|NCT01743417|No Intervention|Passive control|No computer training or games will be provided to this group
9466252|NCT03667365|Experimental|aortic valve replacement|
10028748|NCT01743430|Experimental|telerehabilitation|telerehabilitation via internet
9466253|NCT03667365|Active Comparator|strict clinical surveillance|
9466254|NCT03667352|Experimental|Scalp & TAP Block (Group T)|Group T received 0.2% Ropivacaine + clonidine 1µg/kg mixture, for ipsilateral scalp block (10ml),TAP block under USG guidance (20ml) and intravenous saline 0.1ml/kg/hr (sham infusion) for continuous infusion.
9466255|NCT03667352|Active Comparator|Intravenous Fentanyl (Group C)|Group C received saline, for ipsilateral scalp block (10ml) and TAP block under USG guidance (20ml) and I.V fentanyl 1 µg/kg/hr as analgesic.
9466256|NCT03667339||outpatients group|Patient schedulded to undergo outpatient Direct Anterior Total Hip Arthroplasty
9466257|NCT03667339||inpatients group|Patient schedulded to undergo inpatient Direct Anterior Total Hip Arthroplasty
9466258|NCT03667326|Active Comparator|Low-Dose Aspirin (LDA) Intervention Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.
9466259|NCT03667326|Placebo Comparator|Placebo Control Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.
10028749|NCT01743430|No Intervention|conventional|conventional therapy
10028750|NCT01743443|Experimental|Sensitiviy|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
10028751|NCT01743456|No Intervention|Current practice (BIS and rSO2 blinded)|
10028752|NCT01743456|Experimental|Targeted intra-operative depth of anaesthesia|
10028753|NCT01743482|Experimental|Pazopanib|Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.
10028754|NCT01743495|Other|Functional Services|The program consists of up to 10 home-based functional services sessions over 4 months.
9466260|NCT03667313|Experimental|sirolimus-eluting balloon (SEB)|treatment of bare-metal (BMS) or drug-eluting in-stent restenosis (DES-ISR) with SEB
10028755|NCT01743508|Active Comparator|Misoprostol by physician|Misoprostol treatment by midwife
10028756|NCT01743508|Experimental|Misoprostol by midwife|Misoprostol treatment by midwife
10028757|NCT01743534||Conservation of praxies and form plates|
10028758|NCT01743547|No Intervention|No Intervention; Arm A; Control Group|24 subjects who declined yoga but agreed to data collection
10028759|NCT01743547|Active Comparator|Active Comparator; Arm B; Intervention Group|24 subjects participating in 8 weeks of Yoga and agreed to data collection
10028760|NCT01743573|Experimental|yoga training|Yoga training
10028761|NCT01743573|No Intervention|control|no yoga training
10028762|NCT01743586|No Intervention|Control|
10028763|NCT01743599||Diabetic men|
10028764|NCT01743599||Non-diabetic men|
10028765|NCT01743612|Experimental|Sclerodermic patients|patients with systemic sclerosis according to Leroy's classification
10028766|NCT01743612|Experimental|Primary Raynaud's phenomenon|without secondary disease
10028767|NCT01743612|Experimental|Healthy subjects|18 years old or more
10028768|NCT01743638|Experimental|MR-Guided Laser Ablation|
9466261|NCT03667313|Active Comparator|paclitaxel-eluting balloon (PEB)|treatment of BMS- or DES-ISR with PEB
9466262|NCT03667300|Active Comparator|Evogliptin Group|Intervention group will take daily evogliptin 5mg per oral, not linagliptin 5mg per oral
9466263|NCT03667300|Active Comparator|Linagliptin Group|Control group will take daily linagliptin 5mg per oral, not evogliptin 5mg per oral
9466264|NCT03667287|Experimental|Full-thickness skin graft|Repair of parastomal hernia with full-thickness skin graft, placed intraperitoneally, as reinforcement.
9466265|NCT03667287|Active Comparator|Synthethic mesh|Repair of parastomal hernia with best available conventional method, using synthetic mesh material as reinforcement
10028769|NCT01743664|Experimental|Eye Movement Desesitization Reprocessing|The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
9466266|NCT03667261|Active Comparator|cover screw|extraction of hopeless mandibular molars followed by immediate implants that will be covered using cover screw
10028770|NCT01743664|Active Comparator|relaxation|Relaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
10028771|NCT01743690|Active Comparator|fluocinolone, placebo|fluocinolone, placebo
10028772|NCT01743690|Experimental|fluocinolone, probiotic|fluocinolone, Probiotic lactobacilli reuteri
10028773|NCT01743690|Active Comparator|Nystatin, placebo|Nystatin, placebo
10028774|NCT01743690|Experimental|nystatin, probiotic|nystatin, Probiotic lactobacilli reuteri
10028775|NCT01743703|Other|whole body MRI|diagnostic whole body MRI, and skeletal imaging following guidelines (whole body radiographic and scintigraphic screening)
9466267|NCT03667261|Experimental|sealing socket abutment|extraction of hopeless mandibular molars followed by immediate implants that will be covered using sealing socket abutment
9466268|NCT03667222|Experimental|BPX-04 Active|BPX-04 1% minocycline topical gel
9466269|NCT03667222|Placebo Comparator|BPX-04 Vehicle|BPX-04 topical gel vehicle
9466270|NCT03667209|Experimental|Traditional exercise and pain neuroscience education|Will include exercises of the neck and scapular regions using traditional methods and pain neuroscience education
10028776|NCT01743716||MDD Mothers|Adult women with a history of major depressive disorder (MDD) and a healthy adolescent daughter between the ages of 12-14
10028777|NCT01743716||Healthy Control Mothers|Adult women with no history of psychopathology and an adolescent daughter between the ages of 12-14
10028778|NCT01743716||High Risk Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the MDD Mothers cohort
9466271|NCT03667209|Active Comparator|Suspension exercise and pain neuroscience education|Will include suspension exercises of the neck and scapular regions using traditional methods and pain education.
9466272|NCT03667196||Observational|
10028779|NCT01743716||Healthy Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the Healthy Control Mothers cohort.
10028780|NCT01743742|Experimental|Oral vitamin E, vitamin C|Single dose of vitamin E drops 200 IU within 6 hours of birth and vitamin C tablet 250 mg in pulverised form (2 doses at 24 hr interval) via infant feeding tube
10028781|NCT01743755|Active Comparator|Dexamethasone|
10028782|NCT01743755|Placebo Comparator|Placebo|Placebo tablet, once daily for four consecutive days
10028783|NCT01743768|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using inhalation device.~Administered dose: 10 mg hgd40 in 2 mL solution (5.0 mg/mL).~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
10028784|NCT01743768|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using inhalation device.~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
10028785|NCT01743781|Experimental|intervention group|view a 10-minute informational video about comprehensive eye examination
10028786|NCT01743781|No Intervention|control group|No intervention
10028787|NCT01743794|Experimental|ropivacaine 0.2%, wound infusion|
10028788|NCT01743794|Placebo Comparator|saline solution 0.9%, wound infusion|
10028789|NCT01743807|Experimental|Dose Level 1|GNKG168 0.25 mg/kg/day on days 1 through 5
9466273|NCT03667183|Experimental|Pilates Group|Female adolescents with eating disorders who receive Pilates for 10 weeks.
9466274|NCT03667157|Active Comparator|moderate-to-severe Graves Orbitopathy|active, moderate-to-severe Graves Orbitopathy according to EUGOGO.
9466275|NCT03667157|Active Comparator|Dysthyroid Orbit Neuropathy|Dysthyroid Orbit Neuropathy according to EUGOGO
9466276|NCT03667131|Experimental|Enalapril Maleate|Enalapril Maleate 5 mg every 12 hrs for 90 days.
9466277|NCT03667131|Experimental|Placebo|Substance that lacks in itself therapeutic action.
9466278|NCT03667118|Experimental|Food Supplement|Infants who received the active food supplement powder
10028790|NCT01743807|Experimental|Dose Level 2|GNKG168 0.75 mg/kg/day on days 1 through 5
10028791|NCT01743807|Experimental|Dose Level 3|GNKG168 1.5 mg/kg/day on days 1 through 5
9466279|NCT03667118|Placebo Comparator|Placebo|Infants who received the placebo powder
9466280|NCT03667105|Experimental|CAF+XDM|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous dermal collagen matrix graft (AXDM - Mucoderm®, Botiss,) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
9466281|NCT03667105|Experimental|CAF+MC|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Mucograft®, Geistlich Pharma) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
9480032|NCT03537612|Active Comparator|Sub-opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
9466282|NCT03667105|Active Comparator|CAF|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Then, the flap will be coronally positioned and sutured to completely cover the graft. This group will be the control group.
9466283|NCT03667092|Experimental|Non-drug intervention type|"Exploration of gene transcript variation on seriate blood samples before treatment, before and after the 2nd and the 4th Lu-Dotatate injection and before and after the 6 month post treatment follow-up.~Measures of stability and reproducibility of selected gene transcripts and miRNA as radio sensitivity genes or progressive metastatic midgut neuroendocrine tumors genetic signatures before and during Lu-177 Dotatate internal vectorized therapy, as well as on the 6-month follow-up."
10028792|NCT01743807|Experimental|Dose Level 0|If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
10028793|NCT01743820|Active Comparator|dihydroartemisinin-piperaquine only|dihydroartemisinin -piperaquine (DP) only
9466284|NCT03667079|Experimental|Integrated|Intervention 'integrated delivery of deworming and vaccination' will be delivered to this arm of the study
9466285|NCT03667079|Active Comparator|Deworming only|Intervention 'Mass deworming only' will be delivered to villages in this arm of the study
9466286|NCT03667079|Active Comparator|Rabies vaccination only|Villages assigned to this arm received mass vaccination of dogs against rabies only
9466287|NCT03667040|No Intervention|Control Group|75 participants will take part in three visits (baseline, 30days and 60days)
9466288|NCT03667040|Active Comparator|Intervention|75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions
9466289|NCT03667001|Experimental|Lidocaine Hydrochloride|"1.5 mg/kg lean body mass lidocaine (lidocaine 1%) bolus I.V. as general anesthesia steady state concentration is accomplished~1.5 mg/kg lean body mass/h lidocaine I.V. with beginning of surgical procedures~after completion of surgery: transfer to PACU, pain evaluation for 48 hours~duration of intervention: lidocaine infusion up to four hours from completion of surgery, or till transfer to surgical ward"
9466290|NCT03667001|Placebo Comparator|Saline Solution|"0.15 ml/kg lean body mass saline 0.9% bolus I.V. as general anesthesia steady state concentration is accomplished~0.15 ml/kg lean body mass/h saline 0.9% I.V. with beginning of surgical procedure~after completion of surgery: transfer to PACU, pain evaluation for 48 hours~duration of intervention: saline infusion up to four hours from completion of surgery, or till transfer to surgical ward"
9466291|NCT03666988|Experimental|Part 1: GSK3368715 dose escalation|Eligible participants with solid relapsed/refractory tumors will receive escalating doses of GSK3368715 at a starting dose of 50 mg, administered orally once daily.
9466292|NCT03666988|Experimental|Part 1: GSK3368715 PK/PD/Metabolite/Biomarker|Additional participants in Part 1, treated at or close to the expected the maximum tolerated dose (MTD)/RP2D, will be evaluated for metabolic and biomarker profiling. Participants may be enrolled into this cohort(s) even after MTD/RP2D has been identified and Part 2 has been initiated.
9466293|NCT03666988|Experimental|Part 1: GSK3368715 Food effect|Eligible participants will receive single dose of GSK3368715 at starting dose of 50 mg tablet orally in fasted state followed by fed state in Period 1 and Fed followed by fasted state in Period 2.
9466294|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion - DLBCL participants|Eligible participants with relapsed/refractory DLBCL will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
9466295|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion-solid tumor participants|Eligible participants with relapsed/refractory solid tumors (pancreas cancer, NSCLC, and bladder cancer) will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
9466296|NCT03666975|Experimental|LIV 30 Hz, 0.4 g|LIV 30 Hz, 0.4 g Low intensity vibration to short leg 3x / week x 10 wks
9466297|NCT03666975|Experimental|LIV 30 Hz, 1.0 g|LIV 30 Hz, 1.0 g Low intensity vibration to short leg 3x/week x 10 wks
9466298|NCT03666962||case group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
9466299|NCT03666962||control group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
9466300|NCT03666949|Other|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
9466301|NCT03666949|Other|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
10028794|NCT01743820|Experimental|DP and 0.125 mg/kg primaquine|DP and single dose oral 0.125 mg/kg primaquine
10028795|NCT01743820|Experimental|DP and 0.5 mg/kg primaquine|DP and single dose oral 0.5 mg/kg primaquine
10028796|NCT01743820|Experimental|DP and 0.25 mg/kg primaquine|DP and a single dose oral 0.25 mg/kg primaquine
10028797|NCT01743820|Experimental|DP and 0.0625 mg/kg primaquine|DP and a single dose oral 0.0625 mg/kg primaquine
10028798|NCT01743833|Active Comparator|Thoracic HVLAMT, Postive Message|Thoracic HVLAMT with a positive message given prior to the intervention.
10028799|NCT01743833|Active Comparator|Thoracic HVLATM, Neutral Message|Thoracic HVLAMT with a neutral message given prior to the intervention.
10028800|NCT01743833|Active Comparator|Scapular HVLATM, Positive Message|Scapular HVLAMT with a positive message given prior to the intervention.
10028801|NCT01743833|Active Comparator|Scapular HVLATM, Neutral Message|Scapular HVLAMT with a neutral message given prior to the intervention.
10028802|NCT01743846||Major Surgery|Patients undergoing major surgery
10028803|NCT01743872|Active Comparator|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
10028804|NCT01743872|Active Comparator|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
10028805|NCT01743872|Active Comparator|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
10028806|NCT01743885|Active Comparator|propanolol|Propanolol (Syprol:oral solution)
10028807|NCT01743885|Active Comparator|Acebutolol|Acebutolol (Sectral:oral solution)
10028808|NCT01743898||Experimental|Patient taking FDA approved dose of rivaroxaban
10028809|NCT01743898||Control Group|Patient not taking any form of anticoagulation
10028810|NCT01743911|Placebo Comparator|sugar pill|Intervention: sugar pill
10028811|NCT01743911|Active Comparator|tadalafil|Intervention: tadalafil
9466302|NCT03666936|Experimental|Intervention|Social-health care intervention
9466303|NCT03666923|Experimental|THR-687 dose level 1|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1
10028812|NCT01743924|Experimental|Raw|Broccoli,200 grams
10028813|NCT01743924|Experimental|cooked|Microwaved, 200 grams
10028814|NCT01743937|Active Comparator|Ticagrelor|Coronary occlusion with balloon inflation
10028815|NCT01743937|Active Comparator|Clopidogrel|Coronary occlusion with balloon inflation
9466304|NCT03666923|Experimental|THR-687 dose level 2|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2
9466305|NCT03666923|Experimental|THR-687 dose level 3|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3
9466306|NCT03666910||children of rheumatic diseased mothers not on treatment|
9466307|NCT03666910||children of rheumatic diseased mothers on antimalarial drugs|
9466308|NCT03666910||children of normal mothers|
9466309|NCT03666897|Other|DTI Outcomes and Biomarkers|Imaging and Lab Collection
9466310|NCT03666884|Active Comparator|dry eye patients 1|dry eye patients treated for 1 month and patient symptoms after 1 month
9466311|NCT03666884|Active Comparator|dry eye patients 2|dry eye patients treated for 1 month and patient symptoms after 1 month
9466312|NCT03666845||Sciatic nerve block|Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic kidney disease
9466313|NCT03666832|Experimental|Arm1|TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
10028816|NCT01743950|Active Comparator|Bevacizumab-naïve with recurrent glioblastoma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
10028817|NCT01743950|Active Comparator|Bevacizumab-exposed with refractory recurrent glioblastoma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
10028818|NCT01743950|Active Comparator|Bevacizumab-naïve with recurrent anaplastic glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
10028819|NCT01743950|Active Comparator|Bevacizumab-exposed with recurrent anaplastic glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
10028820|NCT01744002|Experimental|Shoulder Treatment with Neck Mobilization|The experiment group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and Unlateral Posterior Anterior Mobilization to the cervical spine; applied as 3 X 30 seconds, to each comparable (stiff or painful) segment.
9466314|NCT03666819|Experimental|Treatment (carbon dioxide fractional laser)|Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9466315|NCT03666806|Experimental|Influenza vaccine|Influenza vaccine: An inactivated influenza vaccine (split virion) shall be used during the study. The product information is attached as an appendix to the proposal. Brief description of the type of influenza vaccine to be used for the study, mechanism of action, dose justification, efficacy, safety and its use in the population.
9466316|NCT03666806|Placebo Comparator|Normal saline|Placebo: Placebo will be normal saline which shall be prepared by the pharmacist for injection by the immunization nurse in a similar syringe as the investigational product.
9466317|NCT03666793|No Intervention|Control|Standard healthcare procedures
9466318|NCT03666793|Experimental|experimental: Reconciliation group|medical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital
9480033|NCT03537586|Experimental|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells. Evaluation of the sublingual microvasculature with a side stream dark field imaging video microscope will be performed.
9480034|NCT03537573|Active Comparator|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
10028821|NCT01744002|Active Comparator|Control Group|The control group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
10028822|NCT01744015|Experimental|Patient Decision Making Tool|Patients will be given an opportunity to use a decision making tool to assist in decision making of their care
10028823|NCT01744015|Active Comparator|Standard of care|Control group consisting of normal care
10028824|NCT01744028|Experimental|Remote patient monitoring|Remote patient monitoring system including the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) tool can use changes in daily scores over a certain threshold level to alert notification to the clinical site. The site will contact the patient in order to determine the clinical significance associated with the change in score, and to treat the patient based on clinical judgment and clinical practice.
10028825|NCT01744028|Experimental|Usual care|This group of patient will continue on their usual standard care as close to real life situation as possible.
10028826|NCT01744054|Other|PET/MR or PET/CT|"Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT~Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver"
10028827|NCT01744067|Active Comparator|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.
10028828|NCT01744067|Placebo Comparator|Placebo|Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.
10028829|NCT01744080|Active Comparator|Early Surgery|
9466319|NCT03666767||Oesophageal atresia (OA) +/- tracheo-oesophageal fistula (TOF)|
9466320|NCT03666767||Congenital diaphragmatic hernia (CDH)|
10028830|NCT01744080|Experimental|Regular Wait Time|
10028831|NCT01744106|Experimental|pseudoephedrine hydrochloride 30 mg tablets|Test product
10028832|NCT01744106|Placebo Comparator|placebo tablets|Placebo
9466321|NCT03666767||Intestinal atresia (IA)|
9466322|NCT03666767||Gastroschisis|
9466323|NCT03666767||Exomphalos|
9466324|NCT03666767||Anorectal malformation (ARM)|
9466325|NCT03666767||Hirschsprung's disease|
9466326|NCT03666728|Experimental|SHR-1210+BP102|Subjects receive SHR-1210 200 mg and BP102 15 mg/kg in day 1 intravenously every 3 weeks, until disease progression or unacceptable toxicity.
9466327|NCT03666715||Participants with Schizophrenia|Participants diagnosed with schizophrenia who switched from oral antipsychotics (OAPs) to Paliperidone Palmitate 1-month formulation (PP1M), with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment, and who switched to PP1M at least 6-months after it was available for reimbursement in Portugal will be observed. The primary data source for this study will be the medical records of each participant.
9466328|NCT03666702|Experimental|Upper limb physiotherapy programme|A progressive, individualised four week upper limb physiotherapy intervention programme delivered via web-based physiotherapy lasting up to 30 minutes/session, five times per week + usual care.
9466329|NCT03666702|Active Comparator|Usual care|An average of 4 to 5 physiotherapy sessions per week, lasting approximately 45 minutes each.
10028833|NCT01744119||Abdominal Aortic Aneurysm|
10028834|NCT01744132|Experimental|Aim 3: Contract|Half of patients screened in the pharmacy are selected to a contract group, which encourages patients to review the results of the screen, share the results with their PCP, and schedule and attend a follow-up appointment with an ophthalmologist if the results are abnormal.
10028835|NCT01744132|No Intervention|Aim 3: Control|No contract is signed for half of the patients screened in Aim 3.
10028836|NCT01744145|Active Comparator|Interventional 40-60|Interventional group aged 40-60
10028837|NCT01744145|Placebo Comparator|Control 40-60|Control group aged 40-60
10028838|NCT01744145|Active Comparator|Interventional 60 and above|Interventional group aged 60 and above
10028839|NCT01744145|Placebo Comparator|Control 60 and above|Control group aged 60 and above
10028840|NCT01744158||Children with cerebral palsy|No intervention applicable
10028841|NCT01744171|Experimental|Treatment (recombinant hsp110-gp100 chaperone complex vaccine)|Patients receive recombinant hsp110-gp100 chaperone complex vaccine ID on days 1, 15, and 43 in the absence of unacceptable toxicity.
10028842|NCT01744184|Active Comparator|Midazolam|"midazolam sedation combined with pharyngeal anaesthesia~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy."
10036843|NCT01819519|Experimental|Educational Intervention|This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
10036844|NCT01819532|Active Comparator|Immediate umbilical cord clamping|The umbilical cord will be clamped immediately after delivery.
10036845|NCT01819532|Experimental|Cord milking group|"The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes."
9466330|NCT03666689||MHV reconstruction|Both ends of middle hepatic vein tributaries V8 and/or V5 of modified right lobe graft will be anastomosed to side of a single synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice.
9466331|NCT03666689||Separate tributaries reconstruction|End of V8 middle hepatic vein tributary of modified right lobe graft; if present, will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice, and end of V5; if present; will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's Inferior Vena Cava directly.
9466332|NCT03666650|Other|Rotem|
9466333|NCT03666598|No Intervention|No tourniquet|No use of tourniquet during surgery
9466334|NCT03666598|Experimental|Tourniquet|Use of tourniquet during surgery. The cuff will be inflated to 300mmHg
9466335|NCT03666585|Active Comparator|mobile application actuated rehabilitation exercise guidance|
9466336|NCT03666585|Active Comparator|routine rehabilitation exercise guidance|
9466337|NCT03666572|Active Comparator|B. infantis alone (Bif) in SAM infants|B. infantis alone (Bif) in Severe Acute Malnourished infants
10028843|NCT01744184|Experimental|Entonox|"Entonox combined with pharyngeal anaesthesia.~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner."
10028844|NCT01744210||CHF|
10028845|NCT01744236|Experimental|Liraglutide (main study, long-term intervention)|This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks
10028846|NCT01744236|Experimental|Sitagliptin (main study, long-term intervention)|This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks
10028847|NCT01744236|Placebo Comparator|Placebo (main study, long-term intervention)|This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks
10028848|NCT01744236|Experimental|Exenatide (main study, acute intervention)|Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).
10028849|NCT01744236|Placebo Comparator|Placebo (main study, acute intervention)|Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).
10028850|NCT01744236|Other|Acute MRI intervention study|In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.
10028851|NCT01744236|Other|Pilot-study|In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.
10028852|NCT01744249|Experimental|Axitinib + Sandostatin LAR|Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
10028853|NCT01744249|Placebo Comparator|Placebo + Sandostatin LAR|Placebo BID + Sandostatin LAR 30mg/28 days
10028854|NCT01744262|Active Comparator|Inhalational anesthesia group|
10028855|NCT01744262|Experimental|Total intravenous anesthesia group|
10028856|NCT01744275|Placebo Comparator|Placebo|Placebo
10028857|NCT01744275|Experimental|Omega 3 fatty acids supplementation|Omega 3 fatty acids capsules
10028858|NCT01744288|Experimental|1|Ticagrelor with Platelet transfusion
10028859|NCT01744288|Experimental|2|Ticagrelor without Platelet transfusion
10028860|NCT01744288|Active Comparator|3|Clopidogrel with Platelet transfusion
10028861|NCT01744288|Active Comparator|4|Clopidogrel without Platelet transfusion
10028862|NCT01744301||All patients newly prescribed PPI|All patients newly prescribed PPI
10028863|NCT01744301||All patients newly prescribed H2RA|All patients newly prescribed H2RA
10028864|NCT01744314|Experimental|drug|The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent). The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
10028865|NCT01744314|Placebo Comparator|placebo|The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control. The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
10028866|NCT01744327||Chronic Plaque type psoriasis|Patients with plaque type psoriasis
10028867|NCT01744366|Experimental|Degarelix|Degarelix 240/80 mg
10028868|NCT01744366|Active Comparator|Goserelin|Goserelin 3.6 mg
10028869|NCT01744379|Experimental|200 mg lesinurad|200 mg lesinurad or placebo fasted and fed
10028870|NCT01744379|Experimental|400 mg lesinurad|400 mg lesinurad or placebo fasted and fed
10028871|NCT01744379|Experimental|100 mg lesinurad|100 mg lesinurad or placebo fasted and fed
10028872|NCT01744379|Experimental|50 mg lesinurad|50 mg lesinurad or placebo fasted and fed
10028873|NCT01744379|Experimental|600 mg lesinurad|600 mg lesinurad or placebo fasted and fed
10028874|NCT01744405||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating
9466338|NCT03666572|Active Comparator|B. infantis + prebiotic Lacto-N-neotetraose [LNnT]|B. infantis + prebiotic Lacto-N-neotetraose [LNnT] (Bif+prebiotic) in Severe Acute Malnourished infants
10028875|NCT01744431||No treatment|
10028876|NCT01744444|Experimental|Memantine first|
10028877|NCT01744444|Experimental|Gabapentin first|
10028878|NCT01744457|Other|20 patients with dry eye syndrome|Patients with dry eye syndrome defined as outlined in the inclusion and exclusion criteria
10028879|NCT01744457|Other|20 healthy control subjects|age- and sex-matched controls
10028880|NCT01744470|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
10028881|NCT01744470|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
10028882|NCT01744509|Other|Diagnosis of CRC|All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
10028883|NCT01744522||Leech therapy|Patients receiving leech therapy in the outpatient clinic
10028884|NCT01744535|Active Comparator|Paper food diary|
10028885|NCT01744535|Active Comparator|Online food diary|
10036846|NCT01819545||Alzheimer's disease|no intervention
10036847|NCT01819545||Mild cognitive impairment|no intervention
10036848|NCT01819545||Normal aging|no intervention
9466339|NCT03666572|Placebo Comparator|Placebo (Lactose)|Placebo (Lactose) in Severe Acute Malnourished infants
9466340|NCT03666572|Active Comparator|B. infantis alone (Bif) in Not SAM Infants|B. infantis alone (Bif) in not Severe Acute Malnourished infants
9466341|NCT03666546|Experimental|Laevolac crystals 20 g|Lactulose crystals, oral intake, 20 g single dose
9466342|NCT03666546|Experimental|Laevolac crystals 30 g|Lactulose crystals, oral intake, 30 g single dose
10028886|NCT01744535|Experimental|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users can select foods from the large Weight Loss Resources food database. Instant nutritional feedback is provided along with weekly feedback by text message."
10028887|NCT01744548|Experimental|tCBT treatment|Participants randomised to the tCBT treatment arm will receive 12 individual, 1-hour tCBT sessions based upon Barlow et al.'s (2011) Unifed Protocol for emotional disorders (UP).
9466343|NCT03666546|Experimental|Laevolac liquid 20 g|Lactulose liquid, oral intake, 20 g single dose
9466344|NCT03666546|Experimental|Laevolac liquid 30 g|Lactulose liquid, oral intake, 30 g single dose
9466345|NCT03666546|Active Comparator|Glucose 30 g|Glucose Monohydrate, oral intake, 33 g single dose
9466346|NCT03666546|Placebo Comparator|Water|Still water, oral intake, 250 mL single dose
10028888|NCT01744548|No Intervention|7-week delayed tCBT treatment|Participants randomised to the delayed-treatment arm will receive a brief telephone call and complete the Hospital Anxiety and Depression Scale (HADS) in order to monitor risk and symptom deterioration during the 7-week delayed treatment phase. They will also receive TAU (e.g. Community Mental Health Team appointments, case reviews, etc) during this time. At the end of 7 weeks, participants in the delayed-treatment arm will crossover into the treatment arm and receive the tCBT intervention. This arm will serve as a control condition in order to enable between-group comparisons.
9466347|NCT03666520||Control Group|Clinician not prompted to change the drug from intravenous to oral equivalent.
9466348|NCT03666520||Cohort with clinician being prompted to convert drug|This arm would include the provider being prompted to change the intravenous drug to the oral equivalent.
9466349|NCT03666507||Brain stem associated tumors|Brain stem associated tumors
9466350|NCT03666507||Tumors without brain stem assocation|Tumors without brain stem assocation
9466351|NCT03666494|Active Comparator|Control Arm|As part of the patient's anesthetic induction, they will receive propofol and fentanyl.
9466352|NCT03666494|Active Comparator|Ketamine Arm|As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.
9466353|NCT03666481|Experimental|MPAI group|Patients in this group participated in a 6-months Motivational Physical Activity Intervention (MPAI) to explore its effects on different variables related to PA levels and psychosocial aspects of life of bariatric patients. Concretely, the fundamental goals of the MPAI group were three: to increase the self-determined forms of motivation of the patients towards exercise or reduce those related to non-self-determined motivation; to improve post-operative levels of PA with respect to pre-operative levels, and; transfer the benefits of the intervention on different variables related to the perceived health-related quality of life.
9466354|NCT03666481|No Intervention|Control group|Patients in this group did not participate in any intervention, but the same measurements were made in them as in the MPAI group in the same temporal spaces.
9466355|NCT03666468|Experimental|PlayMed|"PlayMed, a highly immersive role-playing computer game~- Focus on Paediatric Asthma and Seizure management"
9466356|NCT03666468|Active Comparator|Online Package (OP)|"Online package (OP) of NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
9466357|NCT03666468|Placebo Comparator|Paper Guidelines|"Paper NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
9466358|NCT03666455|Experimental|Acceptance and Commitment Therapy|The intervention consists of eight individual (one-on-one) acceptance and commitment therapy sessions approximately one week apart over a 12-week period.
9466360|NCT03666429|Active Comparator|Bulb suction|Patients in this arm will be given bulb suction to treat nasal congestion. This group will contain participants who have used bulb suction in the past.
9466361|NCT03666429|Experimental|NoseFrida|Patients in this arm will be given the NoseFrida to treat nasal congestion. This group will contain participants who will trial the NoseFrida in the emergency department.
9480035|NCT03537573|Experimental|Guideline + Opioid Justification (OJ)|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
10028889|NCT01744561|Experimental|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
10028890|NCT01744561|No Intervention|Control|Keep activity level constant
10028891|NCT01744587|Placebo Comparator|Placebo|Placebo qd (2# bid) for 3 years
10028892|NCT01744587|Experimental|Epigallocatechin Gallate (EGCG)|EGCG 600 mg qd (2# bid) for 3 years
10028893|NCT01744600|Experimental|Music Therapy|Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
10028894|NCT01744600|No Intervention|Control|Participants in the control group will receive normal, standard daily care for the 22 week period.
10028895|NCT01744613||Group A|Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
10028896|NCT01744613||Group B|Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
10028897|NCT01744626|Experimental|CC-292 with Rituximab|Dose Escalation
10028898|NCT01744639|Experimental|HCC under treatment with radioablation|Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.
10036849|NCT01819558|Experimental|immune therapy|6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.
10036850|NCT01819571|Experimental|Normal diastolic function group|
10028899|NCT01744652|Experimental|Arm A - Crizotinib + Dasatinib|"Arm A: Patients receive dose of crizotinib plus an increasing dose of dasatinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle.~Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib Expansion Dose: MTD from dose escalation group."
10028900|NCT01744652|Experimental|Arm B - Dasatinib + Crizotinib|"Arm B: Patients receive dasatinib plus an increasing dose of crizotinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Dasatinib 140 mg by mouth daily in a 28 day cycle. Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle.~Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
10028901|NCT01744678|Experimental|Access to experimental break room|"Subjects will visit the experimental break room 4 times per Orbit 1 shift:~first, prior to the beginning of the work shift~second, during an operationally feasible 20-min break during the 1st half of the work shift~third, once during an operationally feasible 20-min break during the 2nd half of the work shift~fourth, immediately after the end of the work shift~In the break room, subjects will be passively exposed to blue-wavelength enriched ceiling lights during all four visits for each work shift.~Also in the break room, subjects will perform 10-minutes of mild exercise during the first three visits to the break room during each work shift."
10028902|NCT01744717||Critically ill uncommunicative patients|Critically ill non-communicative patients, on mechanical ventilation
10028903|NCT01744743|Active Comparator|preconception|Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
9466362|NCT03666416|Experimental|Sprint Interval Training|Participants will be scheduled for two in-lab experimental appointments: sprint interval training (SIT) and Non-SIT. During the SIT appointment, the researcher will lead the participant through a set of stretches and three minutes of low-intensity cycling on a Schwinn AD2 Airdyne leg-cycling and arm-cranking ergometer to warm up and increase blood flow to active muscles. Participants will then complete 16 minutes of SIT, consisting of eight bouts of 20 seconds of cycling followed by 100 seconds of rest. Participants will complete computer-based tests of sustained attention and working memory during both the SIT (15 minutes following the exercise) and Non-SIT appointments.
9466363|NCT03666403|Experimental|Patients|This prospective one-year study enrolled consecutive 30 children of ≤3 years-old with suspected major airway diseases and therefore scheduled for diagnostic FB. During FB, PIP measurements and associated lumen images were obtained at six airway locations using three studied NIV modes, including 1) NIV rate: 0/min, 2) NIV rate: 10-20/min, 3) NIV rate: 5-10/min.
9466364|NCT03666390|Experimental|0.5mg/kg Ketamine|Anesthesia
10036851|NCT01819571|Active Comparator|Diastolic dysfunction group|
9466365|NCT03666390|Active Comparator|0.045mg/kg Midazolam|Benzodiazepine
9466366|NCT03666364|Experimental|Magnetic nanoparticle selection for teratozoospermia|
9466367|NCT03666364|No Intervention|Density gradient centrifugation for teratozoospermia|
10036852|NCT01819584||Patients below 15 years old|
10036853|NCT01819584||Patients above 15 years old|
10036854|NCT01819610|Experimental|SPRIX|Subjects will be administered open label SPRIX according to subject weight.
10036855|NCT01819623|Experimental|Non-pharmacological therapy|This group will be supervised nonpharmacologic therapy
10036856|NCT01819623|No Intervention|Control|This group will receive the standard treatment for mild cognitive impairment
9466368|NCT03666351|Experimental|The intensive care group|"The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
9466369|NCT03666351|Experimental|The usual care group|"The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
9466370|NCT03666338|Active Comparator|Early, goal-directed mobilization|Early goal-directed mobilization with (1) SOMS algorithm and (2) facilitator
9466371|NCT03666338|No Intervention|Standard of Care|Standard of Care regarding mobilization
10028904|NCT01744743|Active Comparator|early conception|Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
10028905|NCT01744743|Placebo Comparator|late conception|Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
10028906|NCT01744756|Experimental|Subconjunctival Bevacizumab|One aplication of subconjunctival Bevacizumab 0,5 ml
10028907|NCT01744769||Hypothyroidism for RAI|The group of patients who experience hypothyroidism after thyroid hormone withdrawal for radioactive iodine(RAI) therapy
10028908|NCT01744795|Experimental|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the CardioQ and thermodilution technique.
10028909|NCT01744808|Active Comparator|EB-1020 SR1|Sustained release formulation
9466372|NCT03666325|Experimental|Pembrolizumab|Pembrolizumab 200 mg, IV infusion on Day 1 of each 3 week cycle. After 3 cycles patient will be evaluated. In case of disease control (SD, PR, CR) the patient will continue to receive pembrolizumab. In case of progression the patient will receive also Cetuximab (250 mg/m2 after loading dose of 400mg/m2 IV infusion every week.
9466373|NCT03666312||Cohort A|The study will include patients from the two main Italian liver transplantation centers (Ospedale Le Molinette, Torino and Azienda Ospedaliera Pisana, Pisa), allowing to enroll 220 patients in the first 18 months of the proposed study. More in details, all >18-years-old patients listed for and undergoing liver transplantation will be included in the study after signing an informed consent. Each patient will then be prospectively followed one year.
9466374|NCT03666312||Cohort B|A second cohort of 55 patients will then be enrolled in the following 6 months as internal validation sample, and will be analogously monitored until the end of the 3-years-long study.
9466375|NCT03666299|Experimental|Lidocaine|Lidocaine treatment
9466376|NCT03666299|Placebo Comparator|Control|Placebo treatment
9466377|NCT03666286||Intensive Care Patients|Patients >24h on intensive care
9466378|NCT03666260|Experimental|Quadratus Lumborum Block arm|
9466379|NCT03666260|Active Comparator|Femoral block arm|
9466380|NCT03666247|Experimental|HealthMindr Application|Participants in this study arm will have access to the mobile messaging platform (HealthMindr) for 3 months.
9466381|NCT03666247|Other|Waitlist|Participants in this study arm will not have access to the mobile messaging application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr.
9466382|NCT03666221|Experimental|Nimotuzumab plus IMRT|Patients with recurrent nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent intensity modulated radiation therapy(IMRT) , folowing weekly nimotuzumab (200 mg/week) for totally 8 weeks concurrent with IMRT.
9466383|NCT03666208|Experimental|Thrombosed Arteriovenous Graft|Single arm pilot study to investigate effect of sirolimus coated balloon in thrombosed arteriovenous graft
9466384|NCT03666195|Active Comparator|Group A|complete dentures will be fabricated using poly methyl methacrylate resin denture base material modified with 5%wt titanium dioxide nanoparticles.
9466385|NCT03666195|No Intervention|Group B|complete dentures will be fabricated with poly methyl methacrylate resin denture base material.
9466386|NCT03666182||Whole Sample|Female, Caucasian participants aged 18-65 years.
9466387|NCT03666169||Whole Cohort|UK Citizens, aged 18-65 years
9466388|NCT03666156||Whole Sample|Female, caucasians, aged 18-65 years
9466389|NCT03666130|Active Comparator|endoscopic septoplasty|in this arm the participants will undergo endoscopic septoplasty for correction of the deviated nasal septum
9466390|NCT03666130|Active Comparator|conventional septoplasty|in this arm the participants will undergo conventional septoplasty operation for correction of the deviated nasal septum that will done by surgical traditional septoplasty technique using head lamb and anterior rhinoscopy
9466391|NCT03666117||Study group|children and adolescents with type 1 diabetes
9466392|NCT03666078||normal vaginal delivery|
9466393|NCT03666078||assisted vaginal delivery|
9466394|NCT03666078||elective cesarean delivery|
9466395|NCT03666078||emergency cesarean delivery|
9466396|NCT03666065|Active Comparator|Aspart-U100 Insulin|Standard Concentration Rapid Acting Insulin
9466397|NCT03666065|Experimental|Aspart-U25 Insulin|Diluted Concentration of Rapid Acting Insulin
9466398|NCT03666039|Experimental|Sensorimotor training|The participants will receive a tablet-based app for at home training that contains sensorimotor components.
9466399|NCT03666039|Active Comparator|Control training|The participants will receive a tablet-based app for at home training that contains relaxing components.
9466400|NCT03666013||Young healthy subjects|20-30 years old, max 1h of exercise per week
9466401|NCT03666013||Elderly with a normal physical function|65-80 years old, max 1h of exercise per week
9466402|NCT03666013||Elderly with a decreased physical function|65-80 years old, max 1h of exercise per week, SPPB under 9 or frailty score lower then 10
9466403|NCT03666013||Active elderly|65-80 years old, minimal 3h of exercise per week
10028910|NCT01744808|Active Comparator|EB-1020 SR2|Sustained Release Formulation
10028911|NCT01744808|Active Comparator|EB-1020 SR3|Sustained Release Formulation
10028912|NCT01744808|Active Comparator|EB-1020 IR|Immediate Release Formulation
9802990|NCT04720443|Experimental|MAD Part 2 Cohort 1|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage TBD) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Three dose levels (low dose, medium dose, and high dose) proposed for MAD part will be determined based on the doses evaluated in SAD part (including a dose higher than 900 mg if it is indicated).
9802991|NCT04720443|Experimental|MAD Part 2 Cohort 2|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage TBD) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Three dose levels (low dose, medium dose, and high dose) proposed for MAD part will be determined based on the doses evaluated in SAD part (including a dose higher than 900 mg if it is indicated).
10028913|NCT01744808|Placebo Comparator|Placebo|Placebo Formulation
10028914|NCT01744847|Active Comparator|DGT, Tracer Metro® Direct™ Wire Guide|Double guide wire technique was performed by Tracer Hybrid® Wire Guides and Tracer Metro® Direct™ Wire Guide
10028915|NCT01744847|Active Comparator|TPS, Tracer Hybrid® Wire Guides|trans pancreatic sphincterotomy was performed by Tracer Hybrid® Wire Guides
10028916|NCT01744873|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
9466410|NCT03665987||properative assessment clinic group|The treatment group will be seen in the preoperative clinic before hospitalization.
9466411|NCT03665987||Control group|The control group will get anesthetic consultation after hospitalization without clinic service.
9466412|NCT03665974||Women with gestational diabetes mellitus|GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
9466413|NCT03665974||Women non gestational diabetes mellitus|Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
9466414|NCT03665961||Central obesity|Cases with central obesity as defined by waist circumference cut-offs ≥ 90 cm in men and ≥ 80 cm in women for Asians
9466415|NCT03665961||No central obesity|Controls with no central obesity
9466416|NCT03665948|Experimental|Ketogenic Diet (KD)|Group consuming very low carbohydrate ketogenic diet. The ketogenic diet model was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement up to 5% of energy from carbohydrates. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with fats (fats covered more than 75% of the daily energy requirement). Each of the subjects in this group received 10-day menus.
9466417|NCT03665948|Active Comparator|Low-Glycemic Index Diet (CHO-LGI)|Group consuming carbohydrate, low-glycemic index diet. The carbohydrate diet model with a low glycemic index was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement of 25% of fat. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with carbohydrates (carbohydrates covered about ~55% of the daily energy requirement). The glycemic index of individual meals as well as the daily diet was calculated in accordance with the appropriate recommendations. Each of the subjects in this group received 10-day menus.
9466418|NCT03665896|Active Comparator|VivaSight DLT group|Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.
9466419|NCT03665896|Placebo Comparator|Standard DLT group|Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.
9466420|NCT03665883|Active Comparator|Diathermy preferred|Monopolar energy is the preferred dissection approach in this group of patients undergo TEP. Total time of activation of monopolar machine will recorded by specially designed device
9466421|NCT03665883|Active Comparator|Blunt dissection preferred|Blunt dissection is the preferred dissection approach in this group of patients undergo TEP. Use of monopolar energy for haemostasis is still allowed upon surgeons' decision. Total time of activation of monopolar machine will recorded by specially designed device
9466422|NCT03665870|Experimental|Intervention Arm|Hypoglycemia Education: Participants will receive educational support to prevent repeat episodes of hypoglycemia.
10028917|NCT01744873|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
10028918|NCT01744886|Active Comparator|lung surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
10028919|NCT01744886|Active Comparator|port-access cardiac surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
10028920|NCT01744899||Prolonged sitting|Includes individuals who spent an average of at least 6 hours a day sitting over the past year.
10028921|NCT01744899||Control|Includes individuals who spent 4 hours or less/day sitting over the past year.
9466423|NCT03665857|Experimental|multicomponent intervention|"Schools in the intervention arm will receive a multicomponent intervention at the school-, parent- and student-level, with a mobile application to promote the collaboration between investigators, school teachers, parents and students.~The school-level intervention elements will include school policies and health education for teachers.~The parent-level intervention elements will include health education for parents and promoting students' physical activity at home.~The student-level intervention elements will include health education for students, promoting students' physical activity in school and monthly monitoring of weight and height."
10036857|NCT01819636|Experimental|Sparkling highly mineral bicarbonated sodium water|1.25 liter a day of sparkling highly mineral bicarbonated sodium water
9466424|NCT03665857|No Intervention|usual-care control|Schools assigned to the control group will have usual education provision throughout their participation in the trial, and after finishing the study they will be offered the health education package, policy suggestion and materials as the schools in the multicomponent intervention group.
9466425|NCT03665844|Placebo Comparator|SmartSleep Boost Off|Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.
9466426|NCT03665844|Active Comparator|SmartSleep Boost On|Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.
9466427|NCT03665831|Experimental|Active H1 Coil deep rTMS active treatment|
9466428|NCT03665818|Experimental|Oral appliance intervention|
9466429|NCT03665818|No Intervention|Without oral appliance intervention|
9466430|NCT03665779|Experimental|isosorbide mono-nitrate group|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
9466431|NCT03665779|Placebo Comparator|placebo group|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.
9466432|NCT03665766||IFN group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Cyclosporine A as primary immunosuppression ,this was routinely taken not as intervention according to local practice
9466433|NCT03665766||IFN group received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Tacrolimus as primary immunosuppression ,this was routinely taken not as interventing according to local practice
9466434|NCT03665766||Sof plus Rbv group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
9466435|NCT03665766||Sof plus Rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
9466436|NCT03665766||Sof,dac pus ribavirin received cyclosporine|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
9466437|NCT03665766||sof,dac plus rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
9466438|NCT03665753|Experimental|Ketorolac 10mg|Subjects will be administered 10 mg of Ketorolac.
9466439|NCT03665753|Experimental|Ketorolac 20mg|Subjects will be administered 20 mg of Ketorolac
9466440|NCT03665753|Experimental|Ketorolac 30mg|As a part of standard care, subjects will be administered 30 mg of Ketorolac.
9466441|NCT03665740|Experimental|Resveratrol|Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
9466442|NCT03665740|Placebo Comparator|Placebo|Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
9466443|NCT03665727|Experimental|Mindfulness|15 minute mindfulness session
9466444|NCT03665727|Experimental|Suggestion|15 minute therapeutic suggestion session
9466445|NCT03665727|Active Comparator|Psychoeducation|15 minute psychoeducation session
9466446|NCT03665727|No Intervention|Usual Care|The usual care comparison group was comprised of patients who underwent total joint arthroplasty of the hip or knee at the same academic medical center during the study period but who did not attend Joint Academy.
9466447|NCT03665714|Experimental|Impact Oral|"Preoperatively:~1 bottle each time (250ml/bottle), 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~1 bottle (250 ml each) per day of test product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~2 bottles (250 ml each) per day of test product on D 3 and D 4 post surgery, corresponding to 707Kcal.~3 bottles (250 ml each) per day of test product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
9466448|NCT03665714|Active Comparator|Enteral nutrition Emulsion(TPF-T)|"Preoperatively:~272ml each time, 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~272ml of control product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~544ml of control product on D 3 and D 4 post surgery, corresponding to 707Kcal.~816ml of control product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
10036858|NCT01819636|Placebo Comparator|Sparkling low mineralized water|1.25 liter a day of sparkling low mineralized water
10036859|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d|
10036860|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d|
9466449|NCT03665701|Experimental|Inhibitory effects of Fevipiprant|in vitro experiments: The reaction of the innate lymphoid cells by cytokine secretion in response to the stimulation by Prostagalandin D2 metabolites and the measurement of a potential suppressive effect of Fevipiprant will be assessed.
10028922|NCT01744912|Experimental|Ublituximab + Lenalidomide|"4 cohorts, with 3 - 6 patients per cohort, as follows:~Cohort 1: Ublituximab 450 mg + Lenalidomide 10 mg~Cohort 2: Ublituximab 450 mg + Lenalidomide 15 mg~Cohort 3: Ublituximab 600 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)~Cohort 4: Ublituximab 900 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)~Ublituximab is an IV infusion on days 1, 8, and 15 of cycles 1 & 2 followed by a planned maintenance with a single infusion on day 1 of cycles 3 thru 6.~Lenalidomide is taken orally on days 9 - 28 of cycle 1 followed by daily administration on Days 1 - 28 for cycles 2 thru 6. Non-hodgkins lymphoma patients may have up to a 7 day rest period (Days 21-28) in any cycle."
9466451|NCT03665662|Experimental|Intervention|Patients in this arm will receive patient-selected music through headphones throughout their procedure.
10028923|NCT01744925|Active Comparator|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
10028924|NCT01744925|Experimental|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
9466452|NCT03665662|No Intervention|Control|Patients will be wearing headphones during their procedure (for the purpose of blinding the care team), but will not receive any music, sounds or sound-cancelling effects through the headphones.
9466453|NCT03665649|Other|CD133+ human donors|CD133+ cells isolation
9466454|NCT03665610||Mandatory Safety Population|All subjects who enrolled in studies RPC01-1912, RPC01-1913, or RPC01-1914 and received at least one dose of ozanimod or IP (per parent studies), excluding subjects who discontinued during Period 1 of study RPC01-1913.
9466455|NCT03665610||Optional pharmacokinetic(s) and pharmacodynamics(s) population|Subjects in study RPC01-1913 have completed the study at least through Period 2 and completed the 7 ± 2 days postdose follow-up assessments; or subjects in study RPC01-1914 have completed the study through the 7 ± 2 days postdose follow-up and had no major protocol violations in the parent studies that are deemed to impact PK or PD assessments.
9466456|NCT03665584|Active Comparator|FxCO2 Laser|FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
9466457|NCT03665584|Sham Comparator|Sham Laser|Sham laser treatment will be performed by scanning across the entire affected anogenital region. The sham treatment will be performed using 4W (power), 400us (dwell time), and 1500um (spacing). The laser has no effect on the vulvar tissue using these parameters.
9466458|NCT03665571||Conventional Activation method|NK cell was incubated with either K562 cells
9466459|NCT03665571||Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
9466460|NCT03665558|No Intervention|Aortic dP/dt in sinus rhythm|Left ventricular and aortic dP/dt values were recorded at baseline condition while patients are on sinus rhythm.
9466461|NCT03665558|Active Comparator|Aortic dP/dt during DDD pacing|Patients will be their own control. Aortic and ventricular pressures will be recorded under temporary DDD pacing again and these data collected at every pacing steps will be compared to the pressures recorded at baseline condition.
9466462|NCT03665545|Active Comparator|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
9466463|NCT03665545|Experimental|IMA950/Poly-ICLC and pembrolizumab|Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly- ICLC administered subcutaneously
9466464|NCT03665532|Experimental|Interactive 2-way texting|Biweekly text message communications with counselors for problem solving
9466465|NCT03665532|Active Comparator|Passive text reminders|Automated weekly text message health care reminders
9466466|NCT03665519|Experimental|Dietary supplement and ursodeoxycholic acid therapy.|Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.
9466467|NCT03665519|Other|Ursodeoxycholic acid therapy only.|Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.
9466468|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications ON|Idiopathic Parkinson's patient's with Hoehn and Yahr score of 1.5- 2 i.e. in an early stage of the disease, under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
9466469|NCT03665493|Experimental|PD patients H&Y=3 Medications ON|Parkinson's patient's with Hoehn and Yahr score of 3, i.e. in moderate-to-advanced stages of the disease under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
9466470|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications OFF|Same as above described
9466471|NCT03665493|Experimental|PD patients H&Y=3 Medications OFF|Same as above described
9466472|NCT03665493|Experimental|Healthy age-matched controls|Healthy controls. Right-handed healthy subjects (it will be assessed by the Edinburgh handedness inventory) with normal or corrected-to-normal vision, without a history of neurological diseases. Age range: 40-70.
10028925|NCT01744938|No Intervention|early surgery|only receiving pancreaticoduodenectomy without preoperative biliary drainage
10028926|NCT01744938|Experimental|preoperative biliary drainage|percutaneous preoperative biliary drainage before pancreaticoduodenectomy guided by CT scan
10036861|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d|
10036862|NCT01819649|Placebo Comparator|Yeast tablet|
10036863|NCT01819662|Placebo Comparator|Standard management|No echocardiogram
10036864|NCT01819662|Active Comparator|Enhanced standard management|Echocardiogram performed, with results to GP
9466473|NCT03665480|Experimental|G-CSF treatment|In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
9466474|NCT03665480|No Intervention|G-CSF-free|In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
9466475|NCT03665454|Experimental|PF-06412562|Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
9466476|NCT03665454|Active Comparator|Standard of Care carbidopa/levodopa|Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
9466477|NCT03665441|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed every 2 weeks in combination with~Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle as follows:~Abraxane (125 mg/m2) IV~Gemcitabine (1000 mg/m2) IV~Or~Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle as follows:~Onivyde 70 mg/m2 (irinotecan freebase) IV (recommended dose in patients homozygous for UGT1A1*28 is 50 mg/m2)~Leucovorin 400 mg/m2 IV~5 FU 2400 mg/m2~Or~FOLFIRI: Irinotecan 180 mg/m2 IV~Leucovorin 400 mg/m² IV~5 FU 400 mg/m² IV bolus~5 FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5 FU"
9466478|NCT03665441|Other|Chemotherapy alone|Standard treatment: Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle Or Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle
9466479|NCT03665428|Experimental|PAMB group|PAMB treatment (modified quadruple therapy) for 14 days
9466480|NCT03665428|Active Comparator|PMBT group|PBMT treatment (bismuth-containing quadruple therapy) for 14 days
9466481|NCT03665415|Other|Formative|This stage represents an initial formative phase to implement the NDGame Squad intervention with small samples of youth in order to make any modifications necessary before embarking on the full pilot in both sites in the next phase. Three (n=3) participants from the school site only will participate in an initial 4-week Game Squad intervention in the first formative phase. Participant feedback including barriers to engagement and suggestions for improvements will be obtained via parent/caregiver and child interviews post-intervention.
9466482|NCT03665415|Experimental|Pilot Intervention|Participants in the pilot intervention arm will receive either 10 or 14 weeks of the NDGameSquad intervention. School site participants will receive 10 weeks during the school year, followed by another 4 weeks during summer vacation. Clinic site participants will receive 10 weeks only.
9466483|NCT03665415|Other|Pilot Waitlist Control|Participants at both sites randomized to the waitlist control arm will be asked to maintain current physical activity levels during the first 10-week period. They will then be provided the intervention equipment and training. School site control arm participants will then participate in a 4-week, unsupported summer NDGame Squad intervention. Clinic site control arm participants will not be required to participate in the NDGameSquad intervention.
9466484|NCT03665402|Active Comparator|Rapid metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
9466485|NCT03665402|Active Comparator|Slow metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
9466486|NCT03665402|Experimental|Slow metabolizer (PGx treatment)|Decreased isoniazid dose regimen (200 mg qd)
9466487|NCT03665389|Other|Single Arm|Among patients who undergo TAVR at the kobe university hospital, those who are found to have moderate or severe stenosis on cCTA performed before surgery and judged to clinically require ischemia evaluation will be included in this study.
9802992|NCT04720443|Experimental|MAD Part 2 Cohort 3|Eight subjects will be randomized at a ratio of 3:1 in each cohort to receive either NIP292 (oral tablet dosage TBD) or placebo. All subjects will receive either NIP292 or placebo on an empty stomach for 7 days (from Day 1 to Day 7), and dosing frequency will be identical and either QD, Q12H, or Q8H (depending on the observed PK data in Part 1). Three dose levels (low dose, medium dose, and high dose) proposed for MAD part will be determined based on the doses evaluated in SAD part (including a dose higher than 900 mg if it is indicated).
9802993|NCT04717518||Lower Anchor Survey|Patients will likely rate their pain lower.
10028927|NCT01744951|Experimental|ADAPT|ADAPT is a manualized intervention with eight treatment modules designed as an early intervention for children, ages 5-14, who are being adopted from foster care and their adoptive parent/s.
10028928|NCT01744951|No Intervention|Care as usual|Children, ages 5-14, and their adoptive parent/s will receive care as usual in the treatment setting.
10028929|NCT01744964|Placebo Comparator|Saline|Assessment of experimental pain models before and after treatment
9466488|NCT03665376|Experimental|ERAS arm|Preoperative: Counseling and education about the ERAS program; Oral intake until 6 hours before the surgery; Carbohydrate drinks load; No mechanical bowel preparation; Antithrombotic prophylaxis (Tinzaparin 3500 IU) Intraoperative: Spinal anaesthesia (15 mg hyperbaric Bupivacaine + 200mcg intrathecal Morphine); Intravenous Ceftriaxone 2g, Metronidazole 500mg / Gentamycin 160mg, Ondansetron 8mg and Dexamethasone 8mg; Crystalloid fluid 10 to 20ml/Kg; Adrenaline 200mcg in each 500 ml of intravenous fluid; Avoidance of abdominal drains; Postoperative: Early oral intake; Nasogastric tube and urinary catheter removed immediately after the surgery; Early enteral nutrition; Chewing gum for 2 to 4 hours after surgery; Oral sips 8 hours postoperatively; Intravenous fluids discontinued at four hours after transfer to the ward.
9466489|NCT03665376|No Intervention|Control arm|Preoperative: No carbohydrate drink loads, no antithrombotic prophylaxis; Mechanical bowel preparation as needed; Spinal anaesthesia, fluid therapy and antibiotherapy done according to standard hospital practice. The urinary catheter and drains were removed at the discretion of the surgeon. Postoperative: Enteral feeding delayed by the auscultation of bowel sounds. The standard hospital practices involve keeping active the nasogastric tube, fasting patients postoperative, strict bed rest… Pain control was managed with medication of choice by surgeon and anesthesiologist.
9802994|NCT04717518||Higher Anchor Survey|Patients will likely rate their pain higher.
9802995|NCT04716322|Other|Adapted Physical Activity|A 16-week health-adapted physical activity program and 5-year follow-up
10028930|NCT01744964|Active Comparator|Apomorphine|Assessment of experimental pain models before and after treatment
9466490|NCT03665350|No Intervention|non insulin|standard care + antidiabetic therapy non insulin
9466491|NCT03665350|Experimental|Insulin|standard care including insulin
9466492|NCT03665337|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
9466493|NCT03665337|Active Comparator|Control|Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.
9466494|NCT03665324||Veteran athletes with Supraventricular arrhythmias|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) with documented paroxysmal supraventricular arrhythmias.
9466495|NCT03665324||Veteran athletes without supraventricular arrhythmia|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) without documented supraventricular arrhythmia.
9466496|NCT03665311|Placebo Comparator|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED and another 100 mL 0.9% Normal Saline after 4 hours of treatment
9466497|NCT03665311|Active Comparator|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of SLED and another 100 mL 25% Albumin fluid after 4 hours of treatment
9466498|NCT03665298|Experimental|Needle X|Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.
9466499|NCT03665285|Experimental|NC318|NC318 for IV infusion of various dose strengths administered in 14 day dosing cycles. Alternative dosing schedules may be explored once RP2D has been determined.
9466500|NCT03665272|Experimental|fixation by tissue adhesive|In this group, deepithelialized gingival grafts were fixed by tissue adhesive without any suture.
9466501|NCT03665272|Experimental|fixation by sutures|In this groups, deepithelialized gingival grafts were fixed by 4.0 round vicryl sutures.
9466502|NCT03665259|Active Comparator|Pure oxygen group|The patients receive 100% oxygen therapy during the induction phase of induction
9466503|NCT03665259|Experimental|Lower oxygen group|The patients received 60% oxygen therapy during the induction phase of induction
9466504|NCT03665246|Experimental|Intervention (iMBC/ECD + C-PrES)|The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
9466505|NCT03665246|No Intervention|Control (C-PrES)|The control group of women/children dyads who consent will have exposure to 14 sessions of the C-PrES curriculum which promotes the adoption of key MNCHN behaviors (e.g. newborn care, exclusive breastfeeding, etc.). Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages.
9466506|NCT03665233|Sham Comparator|Sh-group|The patients in this arm get standard treatment, together with a sham version of a VR session.
9466507|NCT03665233|Active Comparator|VR-group|These patients get a VR session with the standard treatment
9480036|NCT03537573|Experimental|Guideline + Provider Comparison (PC)|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
9480037|NCT03537573|Experimental|Guideline + OJ + PC|This arm will include the guideline, opioid justification, and provider comparison described above.
9480038|NCT03537547|Experimental|GeneSight Psychotropic test|Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
9480039|NCT03537547|Active Comparator|Treatment As Usual|Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
9480040|NCT03537534|Experimental|Experiment|Lidocaine jelly (2%) 5mL x 1 dose only
9480041|NCT03537534|Placebo Comparator|Placebo|Surgilube 5mL x 1 dose only
10028931|NCT01744990|Other|Interventional single arm|Single group of children undergoing the same investigations and follow up
10028932|NCT01745003|Experimental|Fibromyalgia|Investigate biochemical, functional, and structural neuroimaging changes following non-invasive brain stimulation in patients with chronic widespread pain: fibromyalgia (FM). We will be using tDCS as intervention.
10028933|NCT01745016|Placebo Comparator|Placebo|placebo
10028934|NCT01745016|Experimental|Beta-Alanine|beta-alanine
10028935|NCT01745029||Ulcerative Colitis|
10028936|NCT01745042||android postmenopausal women|Clinical exams
10028937|NCT01745042||gynoid postmenopausal women|Clinical exams
10028938|NCT01745068|No Intervention|Control group|
10028939|NCT01745068|Experimental|Integrated program|Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
10028940|NCT01745081|Experimental|Mannitol|Bolus mannitol 20% at skin incision
10028941|NCT01745081|Experimental|Hypertonic saline|Hypertonic saline 3% at skin incision
10028942|NCT01745107|No Intervention|surgery alone|No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm
10028943|NCT01745107|Experimental|surgery plus radiation|Prophylactic postoperative radiation therapy is developed in this arm
9466508|NCT03665220|Experimental|Ergonomic adjustment group|Ergonomic intervention program at home for post-stroke patients. The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form.
10028944|NCT01745159|Experimental|continued tacrolimus treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
9466509|NCT03665220|Experimental|Kinesiotherapy + ergonomics group|A Kinesiotherapy plus ergonomic adjustments program for post-stroke patients. This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
9466510|NCT03665220|Active Comparator|Healthcare education|A conservative intervention program for post-stroke patients
9466511|NCT03665194|Experimental|Cortexolone 17α-propionate 7.5% solution|
9466512|NCT03665194|Placebo Comparator|Vehicle solution|
9466513|NCT03665181||without modification of dose and without bismuth mask|The cranial CT imaging presrcibed in usual care will be performed without modification of dose and without bismuth mask
9466514|NCT03665181||with modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and with bismuth mask
9466515|NCT03665181||without modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed without modification of dose and with bismuth mask
9466516|NCT03665181||with modification of dose and without bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and without bismuth mask
9466517|NCT03665168||Patients in the palliative stage|Adult patients in various settings will be included (General Practioners practices, home care facilities, general and academic hospitals, hospices) and with any underlying life-limiting disease.
9466518|NCT03665142|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 36 participants were taped for the TTH.50-mm wide and 0.5-mm thick KT was applied to the upper trapezius muscle with one I-shaped tape. The tape was measured from the acromion to the hairline at the back, and the upper trapezius fibers were extended in the extended position, ie the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation position.
9466519|NCT03665142|Placebo Comparator|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
9466520|NCT03665103|Experimental|Laser-assisted ICSI|
9466521|NCT03665103|No Intervention|conventional ICSI|
9466522|NCT03665025|Experimental|immediate implant placement with xenograft|Immediate implant placement with the use of xenograft as grafting material
9466523|NCT03665025|Experimental|immediate implant using mixed allograft and xenograft|Immediate implant placement with using mixture of allograft and xenograft material
9466524|NCT03664999||Parturients physiologic pregnancy|Parturients undergoing caesarean delivery with physiologic pregnancy
9466525|NCT03664999||Parturients with risk pregnancy|Parturients undergoing caesarean with risk of complications (pre-eclampsia, HELLP syndrom, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
9466526|NCT03664986|Experimental|Exparel pudendal block|This group will have intra-operative pudendal block performed with Liposomal Bupivacaine (EXPAREL) solution.
9466527|NCT03664986|No Intervention|Comparison group|This group will be those to receive current standard treatment with no pudendal block performed.
9466528|NCT03664973|Experimental|continuous|continuous local anesthetic infusion (ropivacaine 0.2%)on the serratus plane for at least 72h adds to a Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml.
9466529|NCT03664973|Active Comparator|single-shot|Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml
9802996|NCT04712019|Experimental|Closed Incision Negative Pressure Therapy (ciNPT) Dressing|Prevena Restor Arthro-Form Dressing with Prevena Plus Therapy Unit
9802997|NCT04712019|Active Comparator|Standard Silver-containing Dressing|
9802998|NCT04711135|Experimental|GEP-NET and PPGL|All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
9802999|NCT04705623|Experimental|Intervention|The intervention group receives weekly 90 minute yoga classes over a course of 12 weeks. They are also asked to do two 45-minute yoga classes at home each week and document these in a Diary.
9803000|NCT04705623|No Intervention|Control|The control group receives an assessment of their biofunctional status at the beginning and the end of the study (same as the intervention group).
9466530|NCT03664960|Experimental|1 to 3.0 mg/kg of AK002|Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg
9466531|NCT03664947|Experimental|exercise|The exergaming training programs have included recent daily living activities in games. In our study we have planned the Nintendo Wii Fit Plus Game Console in the therapy training.
9466532|NCT03664947|No Intervention|control|No exercise training applied for the control group.
9466533|NCT03664908|Experimental|serum samples of SLE patients without LN|100 serum samples coming from systemic lupus erythematosus (SLE) patients without lupus nephritis (LN).
9466534|NCT03664908|Experimental|serum samples of Lupus nephritis (LN) patients|100 serum samples coming from systemic lupus erythematosus(SLE) patients with lupus nephritis (LN)
9466535|NCT03664908|Experimental|healthy voluntary blood donors (control group)|100 serum sample coming from 100 healthy voluntary blood donors (provided by Regional blood center of Reims). This arm will be our control group.
9466536|NCT03664895|No Intervention|observation arm(TMX, MDR≥5%)|keep go on TMX
9466537|NCT03664895|No Intervention|control arm(TMX, MDR<5%)|keep go on TMX
9466538|NCT03664895|Active Comparator|OFS add arm(TMX + OFS, MDR<5%)|OFS add on to TMX
9803001|NCT04702711||Patients with symptoms of generalized anxiety in primary health care|Patients (18 years or older) with symptoms of generalized anxiety at a primary health care center.
9803002|NCT04702711||Health care professionals|Health care professionals working with patients with symptoms of generalized anxiety in a primary health care center.
9803003|NCT04699149|Active Comparator|real stimulation|The PD patients randomized in the experimental group will receive VBT each time preceded by a real rTMS stimulation.
9803004|NCT04699149|Sham Comparator|sham stimulation|The PD patients randomized in the control group will receive VBT each time preceded by a sham TMS.
9466541|NCT03664869|Active Comparator|Group A|"BCG instillation therapy with induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used."
10028945|NCT01745159|No Intervention|no additional treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
9466542|NCT03664869|Experimental|Group B|"Sequential BCG and EMDA mitomycin C treatment with nine weekly instillations of BCG, BCG, EMDA-MMC x3 followed by nine monthly instillations of EMDA-MMC, EMDA-MMC, BCG x3~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.~Mitomycin C dosage is 40 mg of MMC with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water"
9466543|NCT03664856|Experimental|experimental group|Subject suffering from a locally advanced or metastatic cancer therefore falling under palliative care as defined by the definition of the French Society of Support and Palliative Care An interview will be performed
10028946|NCT01745172|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
10028947|NCT01745185||Fabry disease switch group|Subjects will include individuals with Fabry disease who are switching from agalsidase alfa to agalsidase beta
10028948|NCT01745185||Control Group|Controls will include individuals with Fabry disease who have only received agalsidase beta as treatment in their lifetime.
10028949|NCT01745198||Treatment Group|This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin®/CerefolinNAC® in the past or are currently being treated with Cerefolin®/CerefolinNAC®.
9466544|NCT03664843||The chemotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
10028950|NCT01745198||Non-Treatment Group|This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin®/CerefolinNAC®.
9466545|NCT03664843||The radiotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
9466546|NCT03664843||The targeted therapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
9466547|NCT03664817|Experimental|social capital intervention|This group will receive intervention developed from Phase 1 study and based on photovoice project
9466548|NCT03664817|Active Comparator|group-based health promotion intervention|"The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)"
9466549|NCT03664791||Vanguard Rocc knee implant|Patient in need for a total knee arthroplasty and who met the inclusion/ exclusion criteria and received the Vanguard Rocc implant
9466550|NCT03664726|Experimental|Episodic Future Thinking (EFT)|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months)
9466551|NCT03664726|Active Comparator|Episodic Recent Thinking (ERT)|Participants will complete an episodic task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties). ERT participants will list positive recent events that have already happened and that they have enjoyed, at different general recent time points (e.g., a few hours ago, 1 day ago, 2-6 days ago, 7-12 days ago)
9480042|NCT03537521||DOA|N= 130 patients treated with direct oral anticoagulants (DOAC) with acute bleeding N= 65 patients treated with direct oral anticoagulants (DOAC) with urgent surgical intervention
9480043|NCT03537521||VKA|N= 130 patients treated with vitamin K antagonists (VKA) with acute bleeding N= 65 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention
9803005|NCT04696614|Experimental|aerobic exercise to aerobic exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise
10028951|NCT01745224|Experimental|Revlite Q switched Nd:YAG laser|Revlite Q switched Nd:YAG laser 1064 nm
10028952|NCT01745224|Experimental|TriVantage Q switched Nd:YAG laser|TriVantage Q switched Nd:YAG laser 1064nm
10028953|NCT01745250|Experimental|Emervel Lips|Emervel Lips
10028954|NCT01745250|Experimental|Juvederm Ultra Smile|Juvederm Ultra Smile
10028955|NCT01745263|Active Comparator|VitD-Omega3-StrengthExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
10028956|NCT01745263|Active Comparator|VitD-Omega3-FlexibilityExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
10028957|NCT01745263|Active Comparator|Placebo-Omega3-StrengthExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
10028958|NCT01745263|Active Comparator|Placebo-Omega3-FlexibilityExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
9466552|NCT03664713|Experimental|EMDR plus TAU|Individual Eye Movement Desensitization and Reprocessing (EMDR) Therapy: This consists of 25 individual sessions of 60 minutes each, applying the standard protocol with the existing validated modifications for specific pathologies. The standard EMDR protocol consists of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation.
9466553|NCT03664713|No Intervention|TAU only|Treatment As Usual (TAU): The patients in this condition will participate in the psychosocial activities proposed by the inpatient unit (with a focus on autonomy, psychoeducation, treatment adherence, insight, functioning and family interventions). Patients who receive EMDR therapy will also participate in these activities.
10028959|NCT01745263|Active Comparator|VitD-Placebo-StrengthExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
10028960|NCT01745263|Active Comparator|VitD-Placebo-FlexiblityExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
10028961|NCT01745263|Active Comparator|Placebo-Placebo-StrengthExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
10028962|NCT01745263|Sham Comparator|Placebo-Placebo-FlexibilityExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
9466554|NCT03664700||LMA Protector|The LMA Protector will be used
9466555|NCT03664674|Experimental|OTO-104|
9466556|NCT03664674|Placebo Comparator|placebo|
9466557|NCT03664661|Experimental|experimental group|BCMA nanobody CAR-T cells
9466558|NCT03664635|Experimental|Phase I - Safety Dose Level|In phase I three (3) + 3 patients will be treated with 1x10^5 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the preceding safety dose level
9466559|NCT03664635|Experimental|Phase I - Dose Level 1|In phase I six (6) + 3 patients will be treated with 1x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 1
9466560|NCT03664635|Experimental|Phase I - Dose Level 2|In phase I six (6) + 3 patients will be treated with 3x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 2
9466561|NCT03664635|Experimental|Phase II|The number of additional patients who will be treated with MB-CART20.1 cells in Phase II is depending on the number of evaluable patients treated with the maximum tolerated dose (MTD) level and the results in Part I
9466562|NCT03664622|Experimental|group K|patients with a ketamine infusion intraoperative
9466563|NCT03664622|Experimental|group M|patients with a Morphine infusion intraoperative
9466564|NCT03664596|Experimental|Dietary supplement only|Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.
9466565|NCT03664596|Other|Dietary supplement and ursodeoxycholic acid therapy|Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.
9466566|NCT03664596|Active Comparator|Ursodeoxycholic acid therapy only|Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.
9803006|NCT04696614|Experimental|aerobic exercise to interval training|first 8-week: aerobic exercise second 8-week: interval training
9803007|NCT04696614|Experimental|aerobic exercise to aerobic exercise +resistance exercise|first 8-week: aerobic exercise second 8-week: aerobic exercise +resistance exercise
10028963|NCT01745276|Experimental|External pins coated by biphosfonate.|External pins coated by biphosfonate.
10028964|NCT01745276|Active Comparator|External pins coated by hydroxylapatite.|External pins coated by hydroxylapatite.
10028965|NCT01745302||TCM plus EGFR-TKIs|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day, six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day ，until progression or unacceptable toxicity;
10028966|NCT01745302||Placebo plus EGFR-TKIs|TCM Placebo:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day ,six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day until progression or unacceptable toxicity;
10028967|NCT01745315|Active Comparator|LigaSure (advanced bipolar device)|Laparoscopic hysterectomy will be done with LigaSure in 15 patients.
9466569|NCT03664570|Experimental|Condition A|"Infusion rate = 25 ml/h~Radiography: confirmation balloon position~VIPUN Balloon Catheter~13C-Octanoate Breath Test o"
9466570|NCT03664570|Experimental|Condition B|"Infusion rate = 75 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Test"
9466571|NCT03664570|Experimental|Condition C|"Infusion rate = 250 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Testt"
9803008|NCT04696614|Experimental|interval training to interval training|first 8-week: interval training second 8-week: interval training
9803009|NCT04696614|Experimental|interval training to aerobic exercise|first 8-week: interval training second 8-week: aerobic exercise
9803010|NCT04696614|Experimental|interval training to aerobic exercise+resistance exercise|first 8-week: interval training second 8-week: aerobic exercise +resistance exercise
9803011|NCT04696289|Experimental|Standardized catheterization assessment|Assessment of pulmonary veins including angiography, intravascular ultrasound, pressure assessment and compliance testing.
9803012|NCT04683003|Experimental|Prophylactic Cohort: TAK-755|"Participants who are non-naïve (continuing from the study 281102 [NCT03393975]) will receive prophylactic treatment with TAK-755 intravenous (IV) infusions once every week or once every other week for the duration of the study.~Participants who are naïve will receive an initial IV dose of 40 IU/kg TAK-755 to allow measurement of the pharmacokinetics of TAK-755, followed by prophylactic treatment with TAK-755 by IV infusion once every week or once every other week for the duration of the study."
10028968|NCT01745315|Active Comparator|Halo PKSforceps(advanced bipolar device)|Laparoscopic hysterectomy will be done with Halo PKS cutting forceps in 15 patients.
10028969|NCT01745315|Active Comparator|EnSeal (advanced bipolar device)|Laparoscopic hysterectomy will be done with EnSeal in 15 patients.
10028970|NCT01745328|Active Comparator|LVX-AMX|subject is treated with LAV-AMX, then followed by placebo.
10028971|NCT01745328|Active Comparator|TCM treatment|subject is treated with TCM
10028972|NCT01745341||vitreoretinal surgery patients|Patients undergoing vitreoretinal surgery under monitored anesthesia care. They will be observed during surgery and no interventions will be administered.
9466572|NCT03664557|Experimental|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
9466573|NCT03664531|Experimental|Gluten, ATIs, nocebo|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
9466574|NCT03664531|Experimental|Gluten, nocebo, ATIs|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of nocebo muesli bars (with nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
9466575|NCT03664531|Experimental|ATIs, gluten, nocebo|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
9466576|NCT03664531|Experimental|ATIs, nocebo, gluten|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of nocebo muesli bars (containing nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
9803013|NCT04683003|Experimental|On-Demand Cohort: TAK-755|In the on-demand cohort, all participants will receive daily IV infusions of TAK-755 when experiencing an acute thrombotic thrombocytopenic purpura (TTP) event until 2 days after the acute TTP event is resolved. Upon resolution of the acute TTP event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study.
10028973|NCT01745354|Experimental|SD-101 + Combined with Local Radiation|
10028974|NCT01745406||Doctor and nurse|
10028975|NCT01745406||Doctor without nurse|
10028976|NCT01745419||COPD Frequent Exacerbators|COPD patients having experienced at least two episodes of acute exacerbations in the former 12 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
10028977|NCT01745419||COPD non- exacerbators|COPD patients who have not experienced exacerbations in the former 24 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
10028978|NCT01745432|Experimental|ADBLOCK +laparoscopic surgery|Adhesion Barrier System is site-specific sprayable adhesion barrier gel administered on the surgical field to reduce risk of adhesion formation.
10028979|NCT01745432|No Intervention|laparoscopic surgery|Laparoscopic surgery only without use of adhesion barrier
10028980|NCT01745445|Experimental|radiotherapy alone arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; All patients will be radiated by external beam radiation, using 3-D conformal radiation technique.
10028981|NCT01745458|Experimental|SB-659032|250 mg non-enteric coated SB-659032
10028982|NCT01745458|Placebo Comparator|Placebo|matched placebo QD for 14 days
10028983|NCT01745484|Experimental|Arm 1|SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
10028984|NCT01745510|Experimental|DHA Group|"DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.~They will receive one dose, administered by enteral feeding every 24 h during 14 days"
10028985|NCT01745510|Placebo Comparator|Control Group (Placebo)|"Control group will receive sunflower oil which is the excipient of the DHA in this study.~They will receive one dose every 24 h during 14 days."
10028986|NCT01745523|Experimental|Vitrified oocytes using HPC+Trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
10028987|NCT01745523|Active Comparator|Vitrified oocytes using SSS+ Sucrose|Oocytes are vitrified using the SSS containing HSA and sucrose
10028988|NCT01745536|Experimental|Vitrified oocytes using closed Cryotop®|Oocytes are vitrified/stored using a closed device
10028989|NCT01745536|Active Comparator|Vitrified oocytes using open Cryotop®|Oocytes are vitrified/stored using an open device
10028990|NCT01745549|Experimental|needle 4 mm gauge 33|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
10028991|NCT01745549|Active Comparator|needle 4 mm gauge 32|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
9466577|NCT03664531|Experimental|Nocebo, ATIs, gluten|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars containing non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
9466578|NCT03664531|Experimental|Nocebo, gluten, ATIs|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
9466579|NCT03664518|Experimental|Eltrombopag|58 enrolled patients are picked up to take eltrombopag at the indicated dose.
9466580|NCT03664505|Active Comparator|Garment based on manual measurement|Garment based on manual measurement is used on burn scar
9466581|NCT03664505|Experimental|Garment based on scan measurement|Garment based on scan measurement is used on burn scar
9466582|NCT03664492|Other|Educational Whiteboard video|All the interested participants contacting us will be provided an info email and an internet link via email to access the study through REDCap. Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
10028992|NCT01745562|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
10028993|NCT01745562|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
10028994|NCT01745575|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
9466583|NCT03664479|Experimental|classical electrical stimulation protocol|"apply 4 channel electrical stimulation device with protocol 1.~It will simultaneously stimulate suprahyoid, thyrohyoid and sternothyroid m with 4 channel electrical stimulation device.~during apply the device, we evaluate the manometry and videofluoroscopic swallowing study for evaluation of deglutition function."
10028995|NCT01745575|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
10028996|NCT01745601|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
10028997|NCT01745601|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
10028998|NCT01745614|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
9466584|NCT03664479|Experimental|revised sequential activation protocol|"apply 4 channel electrical stimulation device with protocol 2~Is a revised sequential activation protocol, it sequentially stimulate bilateral suprahyoid m (channel 1), pharyngeal constrictors (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.~during apply the synchronized electrical stimulation device, we will evaluate the parameters same as group 1."
9466585|NCT03664453|Experimental|Food Effect (Fasted)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fasted state (Period 1) with a crossover and then in the fed state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
9466586|NCT03664453|Experimental|Effect (Fed)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fed state (Period 1) with a crossover and then in the fasted state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
10028999|NCT01745614|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
10029000|NCT01745640|Experimental|POMALIDOMIDE and dexamethasone treatment|All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
10029001|NCT01745653|Experimental|Low level laser therapy|Low level laser (970nm) will be delivered on the mucous membrane in regard to the first molar teeth on which rings of the quadhelix have been settled.
10029002|NCT01745653|Sham Comparator|sham procedure|Same procedure than experimental arm except that the laser is not activated.
10029003|NCT01745653|No Intervention|no intervention|no intervention : Patient received the quadhelix with nothing else
9466587|NCT03664453|Experimental|Dose Proportionality|"Subjects will be randomly assigned to one of two omaveloxolone dosages. A single dose of omaveloxolone (in either 50 mg or 100 mg) will be administered to the subjects in 50 mg capsules in a fasted state.~Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 6."
9466588|NCT03664440|Placebo Comparator|continuation arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of NVP 200 mg twice daily plus TDF/3TC (group A1) and plus TDF/FTC (groupB1)
9466589|NCT03664440|Active Comparator|switch arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers to switch from NVP to RPV 25 mg once-daily plus TDF/3TC (group A2) and plus TDF/FTC (groupB2)
10029004|NCT01745666|Experimental|patients with KCNQ1 or KCNH2 mutation|
10029005|NCT01745666|Other|patients WITHOUT KCNQ1 or KCNH2 mutation (control group)|
10029006|NCT01745679|Experimental|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
10029007|NCT01745692|Active Comparator|Intravenous rtPA|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms
10029008|NCT01745692|Experimental|Intravenous rtPA and Mechanical Thrombectomy|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms + additional mechanical thrombectomy procedure to commence within 90 minutes of start of IV rtPA infusion
10029009|NCT01745705|Experimental|Cervical Spine Manipulation|Subjects will lie supine on a treatment table and receive a high velocity low amplitude thrust joint manipulation to their cervical spine in rotation to each side of the neck.
10029010|NCT01745705|Sham Comparator|Manual Contact|Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
10029011|NCT01745718|Other|MRI and targeted biopsies|All patients receive the same level/number of diagnostic procedures. They all undergo targeted biopsies which are compared to the cytological imprints.
10029012|NCT01745731|Experimental|Experimental|Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
10029013|NCT01745731|No Intervention|Control|Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
10029014|NCT01745744|Experimental|Low dose|- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.
10029015|NCT01745744|Experimental|High dose|- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.
10029016|NCT01745744|No Intervention|Control|Conventional treatment
10029017|NCT01745770|Experimental|A|
10029018|NCT01745770|Active Comparator|B|
10029019|NCT01745796||Intubated ICU patients|
10029020|NCT01745809||Severe Asthmatics|Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
10029021|NCT01745809||Healthy non-smokers|Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
9466590|NCT03664414|Placebo Comparator|Placebo group|Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
10029022|NCT01745835|Active Comparator|2L Coolprep®|
9466591|NCT03664414|Active Comparator|Pentoxifylline group|Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
9466592|NCT03664401|Experimental|Kerecis Oral™|The Fish Skin Graft will be is cut to shape of wound bed and placed directly on the appropriate prepared recipient wound bed. The Fish skin graft has the smooth side down and the scaly side facing out. The graft will be sutured in place at either coronal end with resorbable sutures and may be secured apically if needed. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.
9466593|NCT03664401|Active Comparator|Autogenous Free Gingival Graft|"The recipient bed will be prepared at the appropriate sequential time as described. The graft will be harvested from the same side that the Free Gingival Graft is to be placed. A measurement will be made to determine the size of the donor tissue needed to be placed at the recipient site. Local anesthetic will be administered. The donor tissue will be harvested using the usual techniques. The width will be 5 mm and the length will match the predetermined measurement. The graft will be thinned as is usual practice.~The harvested palatal graft will be centered on the study tooth and placed on the appropriately prepared recipient wound bed. The graft will be sutured with resorbable sutures on the mesial and distal aspects of the tooth. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed."
10029023|NCT01745835|Experimental|1L Coolprep® and Bisacodyl|
10029024|NCT01745861|Active Comparator|Lipidem® (BBraun)|Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)
10029025|NCT01745861|Placebo Comparator|Lipofundin® MCT/LCT 20%|Lipid emulsion containing medium and long chain triglycerides
10029026|NCT01745887|Active Comparator|EBI-005-2 5mg/ml|Administration: 3 times per day
10029027|NCT01745887|Active Comparator|EBI-005-2 20 mg/ml|Administration: 3 times per day
10029028|NCT01745887|Placebo Comparator|EBI-005-2 Placebo|Administration: 3 times per day
9466594|NCT03664375|Experimental|Experimental Group|The experimental group received botulinum toxin type A. After one week of Botox administration, a specially made task specific training program was started for these patients. It was provided for a duration of one hour and for three times per week for a total of 12 weeks by a trained physiotherapist.
9466595|NCT03664375|Placebo Comparator|Control Group|The control group received only task specific training program with the same protocol as for the experimental group; for a duration of one hour and for three times per week up to a total of 12 weeks by a trained physiotherapist
9466596|NCT03664349||Older Adult Participants and Informal/Formal Caregiver Pairs|A sub-cohort of approximately 10 participant-caregiver pairs will utilize SE9000 and communication strategies over a 4-6-week period between LVR visits.
9466597|NCT03664349||Older Adult Participants|The pilot cohort of approximately 100 adults over age 60, with vision impairment, will complete the Hearing Handicap Inventory for the Elderly (HHIE), an assessment of perceived impact of hearing impairment, and an objective hearing evaluation.
9466598|NCT03664349||Formal/Informal Caregivers|Identified persons who assist willing and eligible older adult pilot participants with two or more ADLs/IADLs.
9466599|NCT03664323||Group 1 Sequential strategy|Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).
9466600|NCT03664323||Group 2 Concomitant strategy|Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).
9466601|NCT03664310|Experimental|FSET Anxiety and Sleep Treatment|The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
10029029|NCT01745926||CPR|MECHANICAL CHEST COMPRESSION
10029030|NCT01745939|Active Comparator|Lumbar manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying
10029031|NCT01745939|Sham Comparator|Sham manipulation|Patients will receive oscillations into slight rotation, without cavitation, in side lying
9466602|NCT03664310|Active Comparator|Control|The control condition is the Physical Health Education Treatment (PHET) used in several of our laboratory's prior studies (Schmidt, Capron, Raines, & Allan, 2014). PHET is also a 45-minute computerized intervention, including audio and visual features as well as comprehension quizzes.
9466603|NCT03664297|Experimental|SHR1459|Oral administration, once a day, 28 days for a cycle, until the disease progression or the intolerable toxicity occurs.
9466604|NCT03664284|Active Comparator|intervention group|
9466605|NCT03664284|No Intervention|control group|
9466606|NCT03664271|Experimental|in-clinic video intervention|Intervention: Caregivers will watch an educational video in clinic, and also be given information about how to access the video from home (ideal condition). The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
10029032|NCT01745965|Experimental|T-DM1|single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)
10029033|NCT01745965|Experimental|T-DM1 + endocrine therapy|Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage).
10029034|NCT01745965|Active Comparator|Trastuzumab + endocrine therapy|The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage).
10029035|NCT01745978|Experimental|the knob-tipped knife|the knob-tipped knife using for precut papillotomy in difficult CBD cannulation
9466607|NCT03664271|Active Comparator|at home video intervention|Intervention: Caregivers will be given information about how to watch the video at home, but will not watch it in clinic (real-world condition).The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
10029036|NCT01745978|Active Comparator|the needle knife|the needle knife using for precut papillotomy in difficult CBD cannulation
10029037|NCT01745991||Biliary Atresia undergoing Kasai op|Randomisation for the use of CoSeal at the time of Kasai and assessment at the time of Transplantation.
10029038|NCT01746004|Experimental|[^14C]-LY2157299|Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug
10029039|NCT01746030||Questionnaires|No treatment
10029040|NCT01746056|Active Comparator|Heat Patch Continuous|applied 2 hrs daily for 12 weeks
9466608|NCT03664271|No Intervention|usual care|Control: Caregivers will not watch the educational video, but will be given access to it at the conclusion of the study.
9466609|NCT03664245||experimental group|Critically ill patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
9466610|NCT03664219|Active Comparator|isolation of IAN nerve with collagen membrane|
9466611|NCT03664219|Experimental|without isolation of the IAN with collagen|
9466612|NCT03664206||Patients|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
9466613|NCT03664206||Healthy subjects|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
9466614|NCT03664167|Experimental|intervention|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
9466615|NCT03664167|No Intervention|control|usual care
9466616|NCT03664154|Experimental|Stress and Feeding (SAFE)|The SAFE intervention is grounded in a general theory of guided participation (GP) that posits learning will be facilitated by an emotionally regulated state of the mother. Efforts to help mothers manage stress will better position them to learn and attend to feeding their infants. GP links the two components: stress management (SM) and guided feeding (GF). SM provides skills to manage perceived stress and regulate emotion. GF provides education with skill building to help mothers become more sensitive and responsive to their infant. SAFE is delivered through a secure, password-protected responsive website with practice opportunities.
9466617|NCT03664141|Placebo Comparator|Placebo group|1 drop of regular oil for food labeled as 3% cannabis oil once a day during 3 months
9466618|NCT03664141|Experimental|Cannabis oil group|1 drop of 3% cannabis oil once a day during 3 months
9466619|NCT03664128||pregnant women positive for anxiety|"100 pregnant women who screen positive for anxiety symptoms (>21 on the Perinatal Anxiety Screening Scale). Participants are matched for age, parity, and gestational age at enrollment.~Coping with Anxiety through Living Mindfully (CALM) Pregnancy: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants)"
9466620|NCT03664128||healthy pregnant controls|100 matched healthy pregnant women. Participants are matched for age, parity, and gestational age at enrollment.
9466621|NCT03664115|Experimental|Itraconazole Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles + itraconazole 200 mg oral tablet daily, on a 21-day cycle.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
9466622|NCT03664115|Active Comparator|Control Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
9466623|NCT03664102||Sutures with hand-tied knots|Minimally-invasive isolated aortic valve replacement with Sutures were secured with hand-tied knots
9466624|NCT03664102||Sutures with automated fastener device (Cor-Knot)|Minimally-invasive isolated aortic valve replacement with Sutures were secured with automated fastener device (Cor-Knot)
9466625|NCT03664089|Experimental|Intervention|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
10029041|NCT01746056|Active Comparator|Heat Patch Noncontinuous|applied 2 hrs daily 2 weeks on and 2 weeks off for 12 weeks
10029042|NCT01746069|Placebo Comparator|health advice|clinical practice routine
10029043|NCT01746069|Experimental|Quit smoking combined cessation programme|Health advice and support sms messages to patient's mobile phone + clinical routine practice
10029044|NCT01746121||Amelogenesis Imperfecta|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
10029045|NCT01746121||healthy family members|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
10029046|NCT01746134||Cohort|
10029047|NCT01746147||Patients with MDS and AML prior to allogeneic SCT|
10029048|NCT01746160|Experimental|C1 Implant|Patient having C1 implant installed.
10029049|NCT01746186||21-35 years of age|200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area.
10029050|NCT01746199|Experimental|cotrimoxazole daily prophylaxis|cotrimoxazole daily prophylaxis
10029051|NCT01746199|Active Comparator|Intermittent Preventive sulphadoxine-pyrimethamine Treatment|Referent treatment given according WHO recommendations
10036865|NCT01819662|Active Comparator|Optimised heart failure management|Echocardiogram, followed by referral to comprehensive heart failure program for those with left ventricular dysfunction
10036866|NCT01819675|Experimental|High frequency (10Hz) rTMS|<high frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
9466626|NCT03664089|Placebo Comparator|Control|All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
9466627|NCT03664063|Active Comparator|Azithromycin for Yaws|Patients will receive standard treatment for yaws alone
9466628|NCT03664063|Active Comparator|IDA for Lymphatic Filariasis|Patients will receive standard IDA (Ivermectin & Diethylcarbamazine & Albendazole) treatment for Lymphatic Filariasis alone
9466629|NCT03664063|Experimental|Combination Therapy of Azithromycin for Yaws and IDA for LF|Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.
9466630|NCT03664050|Experimental|Group A Letrozole group|2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.
9466631|NCT03664050|Active Comparator|Group B laparoscopic ovarian drilling group|bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
9466632|NCT03664037|Active Comparator|D group, (n=55)|
9466633|NCT03664037|Placebo Comparator|C group, (n=55)|
10029052|NCT01746212||Degenerative Disc Disease|Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
9466634|NCT03664011|Experimental|All Subjects|
9466635|NCT03663998|Active Comparator|A|CN54ENV IM EP 400 g
9466636|NCT03663998|Active Comparator|B|CN54ENV IM EP 1000 g
9466637|NCT03663998|Active Comparator|C|CN54ENV IM EP 4000 g
9466638|NCT03663998|Active Comparator|D|CN54ENV ID EP 600 g
10029053|NCT01746251|Active Comparator|Concise Afatinib|Afatinib oral daily dose for 3 months
10029054|NCT01746251|Active Comparator|Prolonged Afatinib|Afatinib oral daily dose for 2 years
9466639|NCT03663998|Active Comparator|E|CN54ENV ID EP 1200 g
10029055|NCT01746277|Other|combined group|combined group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
10029056|NCT01746277|Other|sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
9466640|NCT03663998|Active Comparator|F|CN54ENV ID EP 1800 g
9466641|NCT03663998|Active Comparator|G|"CN54ENV IM1 EP~+ pIL-12 (500 g)"
9466642|NCT03663998|Active Comparator|H|"CN54ENV IM1 EP~+ pIL-12 (1500 g)"
9466643|NCT03663998|Active Comparator|I|"CN54ENV IM1 EP~+ ID2 EP"
10029057|NCT01746290|Experimental|PulsePoint notification|Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
10029058|NCT01746290|No Intervention|Usual Care|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures but no PulsePoint notification will be sent to nearby PulsePoint users.
10029059|NCT01746303|Experimental|Omega 3 and Blueberry powder|This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)
10029060|NCT01746303|Experimental|Omega-3 and placebo powder|This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)
9466644|NCT03663972|Active Comparator|Motoric Arm|Children will participate in an intervention based on traditional articulation approaches to speech therapy.
9466645|NCT03663972|Active Comparator|Phonologic Arm|Children will receive intervention that targets the conceptual representation of sounds.
9466646|NCT03663959||Vaginal Sacrospinous Fixation group|Women who had vaginal sacrospinous fixation procedure with Dr.Aksakal's Desta suture carrier in our clinic between January 2014 and June 2018.
9466647|NCT03663959||Laparoscopic Pectopexy Group|Women who had Laparoscopic Pectopexy procedure in our clinic between January 2014 and June 2018
9466648|NCT03663907|Experimental|Telemonitoring|Structured follow-up in the basis of using telemedicine. Telemedicine will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
9466649|NCT03663907|No Intervention|Usual Care|Patients with usual care follow-up in a heart failure program.
9466650|NCT03663881|Experimental|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
9466651|NCT03663868|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
9466652|NCT03663868|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
9466653|NCT03663868|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
10029061|NCT01746303|Experimental|Placebo oil and blueberry powder|This group will receive placebo oil and blueberry powder for 24 weeks (6 months).
9466654|NCT03663842|Experimental|Neural tissue management|Myofascial release technique; Hip joint mobilization technique; Cross-fiber friction over the sacroiliac joints; Neural mobilization to improve sciatic nerve excursion.
9466655|NCT03663803|Experimental|Intervention|Participants in the intervention group received the offer of four 2h group sessions during five weeks, and two further sessions after one and six months. The attendance rates of the sessions were 95%, 88%, 87%, 73%, 67% and 51%, respectively. The course was delivered by health care staff in the Holstebro Health Care Centre, including a dietitian and an occupational therapist, both with health pedagogic competences. It was delivered to seven intervention groups, which varied in size from 5 to 15 participants.
9466656|NCT03663803|No Intervention|Control|Usual practice
9466657|NCT03663777|Experimental|Isometric Handgrip Training|Experimental group will perform home-based bilaterall handgrip exercise and will be recommended to increase daily physical activity levels.
10029062|NCT01746303|Placebo Comparator|Placebo oil and placebo powder|This group will receive placebo oil and placebo powder for 24 weeks (6 months)
10029063|NCT01746329|Experimental|Tea|Oral intake of tea containing 75 grams of glucose
10029064|NCT01746329|Experimental|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
10029065|NCT01746329|Placebo Comparator|Placebo|Oral intake of 75 grams of glucose in water
9466658|NCT03663777|Other|Control group|Control gorup will be recommended to increase daily physical activity level
9466659|NCT03663751|Experimental|Treatment|The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (>98%).
10029066|NCT01746342|Active Comparator|Effective CPAP|Continuous positive airway pressure: effective fixed level determined by polysomnographic titration
9466660|NCT03663738|Active Comparator|health mobile app for T2DM patients|It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
9466661|NCT03663738|No Intervention|Control|Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)
9466662|NCT03663725|Experimental|Intensified protocol|Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ
9466663|NCT03663725|Active Comparator|Stupp protocol|Concomitant Temozolomide (TMZ) Adjuvant TMZ
9466664|NCT03663699|Experimental|Exergaming|24 week access to the exergaming platform PlayPulse
9466665|NCT03663699|No Intervention|Control|Asked to continue with their normal daily routine
9466666|NCT03663686|Placebo Comparator|25mg single doses|Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
9466667|NCT03663686|Placebo Comparator|50mg single doses|Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
9466668|NCT03663686|Placebo Comparator|100mg single doses|Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
9466669|NCT03663686|Placebo Comparator|200mg single doses|Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
9466670|NCT03663686|Placebo Comparator|400mg single doses|Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
9466671|NCT03663686|Placebo Comparator|600mg single doses|Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
9466672|NCT03663686|Placebo Comparator|800mg single doses|Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
9466673|NCT03663673|Other|Clinical pilot study|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
9466674|NCT03663660||before the OIPP|Period 1 : Children hospitalized before the OIPP implementation
9466675|NCT03663660||after the OIPP implementation|Period 2 :Children hospitalized after the OIPP implementation
9466676|NCT03663634|Experimental|Handling Medium Supplemented with Cytochalasin B|
10029067|NCT01746342|Sham Comparator|Sham CPAP|Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure
10029068|NCT01746355|Active Comparator|rTMS-active|patients undergoing of rTMS real
10029069|NCT01746355|Sham Comparator|rTMS-Sham|patients undergoing to placebo rTMS
10029070|NCT01746381|Experimental|IVAPS mode of non-invasive ventilation|Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
10029071|NCT01746381|Active Comparator|BIST mode of non-invasive ventilation|Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
10029072|NCT01746394|Experimental|Parents as Teachers Enhanced|Participants in the Parents as Teachers Enhanced (PaTE) intervention arm will receive the enhanced diet and activity maternal, infant, and early childhood home visiting program
9466677|NCT03663634|No Intervention|Handling Medium as it is.|
9466678|NCT03663621||Initial survey and interview (Aim 2)|Participants in Aim 2 will be asked to complete an initial 15-minute survey and 20-30 minute semi-structured interview. The purpose of this study is to learn the best ways to support healthful behaviors and weight loss prior to pregnancy. Researchers are also interested in what motivates or prevents women of reproductive age from engaging in a structured weight loss program.
9466679|NCT03663621||Formal weight loss program (Aim 3)|Participants in Aim 3 have expressed interest in referral to the Mass General Weight Center. The purpose of this study is to learn what motivates or prevents women of reproductive age from engaging in a structured weight loss program. Researchers will ask for no more than a half hour of participant's time to complete a 5- minute interview following Orientation at the Weight Center and another 10-minute interview after a participant has participated in a program offered at the Weight Center.
9466680|NCT03663556||Very Preterm Infants|Newborn infants with less than 32 weeks admitted in the NICU.
9466681|NCT03663543|Active Comparator|Active Arm|Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
9466682|NCT03663543|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
9466683|NCT03663517||pregnant women|pregnant women in Hong Kong
9466684|NCT03663491|Experimental|Unsedated Nasal Gastroscopy|Transnasal Endoscopy. No sedation used. Use of local anesthesia.
9466685|NCT03663491|Active Comparator|Oral Gastroscopy, unsedated|Transoral Endoscopy. No sedation used. Use of local anesthesia.
9466686|NCT03663491|Active Comparator|Oral Gastroscopy, sedated|Transoral Endoscopy. Intravenous sedation used.
9466687|NCT03663478|Active Comparator|Intervention|Ropivacaine
9466688|NCT03663478|Placebo Comparator|Control|Isotonic saline
9466689|NCT03663465|Experimental|Hawthorn and SGAs|SGAs has a dose of 3-20 gm/day, Hawthorn at a dose of 3 gm/day for six months.
10029073|NCT01746394|Active Comparator|Parents as Teachers|Participants in the Parents as Teachers (PaT) control arm will receive the standard maternal, infant, and early childhood home visiting program
9466690|NCT03663465|Active Comparator|Hawthorn|Hawthorn at a dose of 3 gm/day for six months.
10029074|NCT01746433|Active Comparator|Hanging Triangle Bar|"The patients randomized to this group will use a hanging triangle bar for aid in sitting up exercises.~No particular brand of hanging bar is targeted."
9466691|NCT03663452|Active Comparator|Prolonged exposure training|
9466692|NCT03663452|Experimental|TACTICS|
9466693|NCT03663439|Experimental|modified shell technique|block of bone from the mandibular ramus divided into two shells ,grafting one shell in the anterior maxilla to increase width
9466694|NCT03663439|Active Comparator|onlay bone graft|grafting block of bone from the mandibular ramus in the atrophic anterior maxilla
9466695|NCT03663426|Active Comparator|control group opioid anesthesia|standard anesthesia using opioids
9466696|NCT03663426|Experimental|study group opioid free anesthesia|opioid free anesthesia and high dose glucocorticoids
9466697|NCT03663413||BIS|Monitored with BIS (bispectral index) monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
9466698|NCT03663413||Narcotrend|Monitored with Narcotrend monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
9480044|NCT03537495|No Intervention|Control arm|"Subjects in this arm will only receive high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.~High-dose rifampicin will consist of weight-banded fixed-dose combination (FDC), including rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) according to international guidelines, combined with 900 mg rifampicin (≤37 kg: two 450 mg tablets) or 1200 mg rifampicin (>37 kg: two 600 mg tablets) to reach ~35 mg/kg rifampicin in total."
9480045|NCT03537495|Experimental|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
9480046|NCT03537495|Experimental|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
9480047|NCT03537469|Experimental|CTU Mega 20 real device|A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
10029075|NCT01746433|Experimental|Ergonome|"The patients randomized to this group will use the l'ERGONOME device for aid in sitting up exercises.~Commercial name of the device: SAM ERGONOM (TM)~Manufacturer: Medicatlantic groupe Winncare, Le Pas du Château, 85680 Saint-Paul-Mont-Penit"
10029076|NCT01746446|Experimental|Care team|Patients are offered the support and services of the care team.
10029077|NCT01746446|No Intervention|Usual Care|Patients receive usual care.
10029078|NCT01746459|Active Comparator|Low Low|Low Intensity, Low Frequency Reminder System
10029079|NCT01746459|Active Comparator|Low, High|Low Intensity, High Frequency Reminder System
10029080|NCT01746459|Active Comparator|High, Low|High Intensity, Low Frequency Reminder System
10029081|NCT01746459|Active Comparator|High, High|High Intensity, High Frequency Reminder System
10029082|NCT01746472|Experimental|2 - B-passive|
10029083|NCT01746472|Experimental|3 - B-active|
10029084|NCT01746472|Experimental|4 - B-active, B-passive|
10029085|NCT01746472|Experimental|6 - z, B-passive|
10029086|NCT01746472|Experimental|7 - z, B-active|
10029087|NCT01746472|Experimental|8 - z, B-active, B-passive|
10029088|NCT01746472|Experimental|10 - t, B-passive|
10029089|NCT01746472|Experimental|11 - t, B-active|
10029090|NCT01746472|Experimental|12 - t, B-active, B-passive|
10029091|NCT01746472|Experimental|14 - t, z|
10029092|NCT01746472|Experimental|15 - t, z, B-active|
10029093|NCT01746472|Experimental|16 - t, z, B-active, B-passive|
10029094|NCT01746485|Experimental|UT-15C|
9466699|NCT03663387||Normal subjects|70
10029095|NCT01746498|Active Comparator|Group 1|11 patients We Applied real anodal tDCS on the left dorsolateral prefrontal cortex (DLPFC)20 minutes every day for 10 consecutive days.
10029096|NCT01746498|Active Comparator|Group 2|11 patients we applied cathodal tDCS on left DLPFC for 20 minutes every day for 10 consecutive days.
10029097|NCT01746498|Sham Comparator|Group 3|11 patients We applied sham stimulations(anodal tDCS) on the left DLPFC for few seconds the stop stimulations 2 mA every day for 10 days.
10029098|NCT01746524||CR FB|Subjects receiving Cruciate Retaining Fixed Bearing configuration of ATTUNE Primary Knee Implant
10029099|NCT01746524||PS FB|Subjects receiving Posterior Stabilized Fixed Bearing configuration of ATTUNE Primary Knee Implant
10029100|NCT01746524||CR RP|Subjects receiving Cruciate Retaining Rotating Platform configuration of ATTUNE Primary Knee Implant
10029101|NCT01746524||PS RP|Subjects receiving Posterior Stabilized Rotating Platform configuration of ATTUNE Primary Knee Implant
9466700|NCT03663374|Experimental|Odelepan|One tablet once daily
9466701|NCT03663374|Placebo Comparator|Placebo|One tablet once daily
10029102|NCT01746550|Experimental|MD-12-001 Stent Arm|This study includes a single arm, the MD-12-001 Stent Arm.
10029103|NCT01746563|Experimental|Ranibizumab|Ranibizumab 0,05 mg intravitreal injection
9466702|NCT03663322|Experimental|OMT Protocol|Subjects assigned to this arm will have selected osteopathic manipulative treatment techniques administered during the treatment sessions
9466703|NCT03663322|Sham Comparator|OMT-Sham Protocol|Subjects assigned to this arm will have sham-osteopathic manipulative treatment techniques administered during the treatment sessions
10029104|NCT01746563|Active Comparator|Laser Therapy|Laser Therapy alone
10029105|NCT01746576|Other|All|All subjects will undergo spontaneous ventilation through an impedance threshold device and ScvO2 will be recorded before and after
9466704|NCT03663309||study group|"Children and adolescents aged 2-17 years, reported to be on gluten free diet for at least a year, diagnosed with celiac disease~Children and adolescents aged 2-17 years that are reported to be noncompliant with gluten free diet, diagnosed with celiac disease for at least 1 year."
9466705|NCT03663309||control group|Healthy controls aged 2-17 years old matched for age and sex.
9466706|NCT03663296|Experimental|Interventional|Additional 30 minutes of self-directed learning and practice using the mobile application, after conventional training session
9466707|NCT03663296|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
9466708|NCT03663270|Active Comparator|Intervention arm|HPI monitoring to predict hypotension
9466709|NCT03663270|No Intervention|Control arm|blinded HPI monitoring
9466710|NCT03663244|Experimental|MindfulnessBasedStressReduction(MBSR)|Standardised, curriculum-based MBSR-programme: 2.5-hour weekly group sessions over 8 weeks; one 6-hour silence retreat day; and 45 minutes daily homework 6 days a week.
9466711|NCT03663244|Experimental|Local Stress Reduction (LSR)|Local stress reduction programme ; developed and delivered by two local psychologists. This programme is delivered in groups of 12 participants, in 2.5-hour weekly sessions over 8 weeks and includes approximately 10 minutes daily homework between the sessions.
9466712|NCT03663244|No Intervention|Wait-list|Usual practice
9480048|NCT03537469|Sham Comparator|CTU Mega 20 sham device|A single-session of sham CTU Mega 20 on the corresponding primary right-hand motor area (magnetic field = 0 Tesla; intensity = 0 J; frequency of impulses = 7Hz; duration = 15 minutes). The sham stimulation did not provide a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
10029106|NCT01746589|Other|myopic LASIK procedure|All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
10029107|NCT01746602|Experimental|healthy subjects I|20 healthy subjects
10029108|NCT01746602|Experimental|healthy subjects II|20 healthy subjects
10029109|NCT01746602|Experimental|healthy subjects III|20 healthy subjects
10029110|NCT01746602|Experimental|healthy subjects IV|20 healthy subjects
10029111|NCT01746602|Experimental|healthy subjects V|20 healthy subjects
10029112|NCT01746602|No Intervention|healthy subjects VI|20 healthy subjects
10029113|NCT01746628|Placebo Comparator|Hysterectomy without FloSeal|Endometrial curettage Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
10029114|NCT01746628|Active Comparator|Hysterectomy with FloSeal|Endometrial curettage FloSeal placement into uterine cavity Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
10029115|NCT01746641|Active Comparator|Remifentanil|"Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
10029116|NCT01746641|Active Comparator|Propofol|"Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
10029117|NCT01746654|Experimental|P128-0.1 mg|Three healthy adult volunteers will be enrolled to P128-0.1 mg single dose-cohort 1 (Part A) Three healthy adult volunteers will be enrolled to P128-0.1 mg multiple doses-Cohort 4 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.1 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.1 mg single dose (Part D)
9466713|NCT03663218|Other|Single Arm|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
9466714|NCT03663153||SEMA4C high value follow-up group|Postoperative SEMA4C value is higher than 5.00 ng/ml.
9466715|NCT03663153||SEMA4C low value follow-up group|Postoperative SEMA4C value is lower than 5.00 ng/ml.
9466716|NCT03663140||Group 1-Health periodontal|This group created by individuals with healthy periodontal tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
9466717|NCT03663140||Group 2- Healthy peri-implant|This group created by individuals with healthy peri-implant tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
9466718|NCT03663140||group 3- Gingivitis|This group created by individuals with gingivitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
9466719|NCT03663140||Group 4-Peri-implant Mucositis|This group created by individuals with peri-implant mucositis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
9466720|NCT03663140||Group 5-Periodontitis|This group created by individuals with periodontitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
9466721|NCT03663140||Group 6-Periimplantitis|This group created by individuals with peri-implantitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
9466722|NCT03663127|Experimental|Beauty Drink|"Subjects receive two bottles Beauty Drink per day for 8 weeks of a stage."
9466723|NCT03663127|Placebo Comparator|Placebo|Subjects receive two bottles placebo per day for 8 weeks of a stage.
9466724|NCT03663114||Lenvatinib|Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.
9466725|NCT03663075|Experimental|Group 1|This group will receive the intervention Group information (GI).
10029118|NCT01746654|Experimental|P128-0.3 mg|Three healthy adult volunteers will be enrolled to P128-0.3 mg single dose-Cohort 2 (Part A) Three healthy adult volunteers will be enrolled to P128-0.3 mg multiple doses-Cohort 5 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.3 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.3 mg single dose (Part D)
10029119|NCT01746654|Experimental|P128-1.0 mg|Three healthy adult volunteers will be enrolled to P128-1.0 mg single dose-Cohort 3 (Part A) Three healthy adult volunteers will be enrolled to P128-1.0 mg multiple doses-Cohort 6 (Part B) Ten chronic kidney disease patients will be enrolled to P128 1.0 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-1.0 mg single dose (Part D)
10029120|NCT01746654|Placebo Comparator|Placebo|Three healthy adult volunteers will be enrolled to placebo single dose-Cohort 1-3 (Part A) Three healthy adult volunteers will be enrolled to placebo multiple doses-Cohort 4-6 (Part B) Ten chronic kidney disease patients will be enrolled to placebo multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to placebo single dose (Part D)
10029121|NCT01746667|Experimental|Exposure in vivo|This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing & Emmelkamp (1993).
10029122|NCT01746667|Experimental|Virtual Reality Exposure Therapy|"This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.~The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
10029123|NCT01746667|No Intervention|Wait-list|Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
10029124|NCT01746680|Experimental|Tacrolimus with Methotrexate|Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks
10029125|NCT01746706|Experimental|patients|
10029126|NCT01746706|Experimental|volunteers|
10036867|NCT01819675|Experimental|Low frequency (1Hz) rTMS|<low frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
10036868|NCT01819675|Sham Comparator|Sham rTMS|<Sham rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp
10036869|NCT01819701|Placebo Comparator|Placebo|starch
10036870|NCT01819701|Experimental|LC and Coenzyme Q10|L-carnitine: 1000 mg/d and 2000 mg/d Coenzyme Q10: 150 mg/d and 300 mg/d
10036871|NCT01819714|Experimental|Study population|Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
10036872|NCT01819740||patients with suspected prostate cancer|
10036873|NCT01819753|Active Comparator|Single access|It was performed only single access standard PCNL in this group.
10029127|NCT01746719|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
10029128|NCT01746719|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
10029129|NCT01746758|Experimental|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
10029130|NCT01746758|No Intervention|Comparison arm|No intervention will be implemented in intervention arm. Data on reproductive health conditions and treatments and data on referrals from drug stores in this arm will be obtained directly from ministry of health registers filled and filed at the dispensary and health centres, plus a tailor-made form which is filled by the dispensary and health centre clinicians whenever they receive a patient in the eligible categories.
10029131|NCT01746771|Experimental|HM781-36B, Paclitaxel, Trastuzumab|HM781-36B(Poziotinib): QD*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg
9466726|NCT03663075|Experimental|Group 2|This group will receive the intervention Group information (GI) followed by Structured person-centered support (PCS)
10029132|NCT01746797||Women currently taking antidepressants|Women who have selected to stay on antidepressant medication while undergoing infertility treatment.
10029133|NCT01746797||Women not on antidepressants|Women who decided to discontinue their antidepressants while undergoing fertility treatments.
9466727|NCT03663075|Experimental|Group 3|This group will receive the intervention Structured person-centered support (PCS)
9466728|NCT03663075|No Intervention|Group 4|This is a control group.
9466729|NCT03663049|No Intervention|Usual care|These patients will continue as statins as usual.
9466730|NCT03663049|Experimental|Discontinue statin|Patients randomized to this group will stop using the statins they are currently prescribed and will not use their statin medication for 12 weeks.
9466731|NCT03663036|Experimental|FL-ASCR|Magnetic Resonance Imaging of the shoulder Radiograph of the shoulder
10029134|NCT01746810|Experimental|Stereotactic Body RT and IRGA|Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.
9466732|NCT03662984|Active Comparator|Ciprofibrate|1dd100mg at breakfast
9466733|NCT03662984|Placebo Comparator|Placebo|1dd0mg at breakfast
9466734|NCT03662971|Experimental|0.0005% single-dose|Two subjects will be treated with Germinal peptide eye drops 0.0005% single dose.
9466735|NCT03662971|Experimental|0.001% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.001% single dose (eight treatment and two placebo).
9466736|NCT03662971|Experimental|0.002% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% single dose (eight treatment and two placebo).
9466737|NCT03662971|Experimental|0.004% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% single dose (eight treatment and two placebo).
9466738|NCT03662971|Experimental|0.008% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% single dose (eight treatment and two placebo).
9466739|NCT03662971|Experimental|0.002% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% multiple dose (eight treatment and two placebo).
9466740|NCT03662971|Experimental|0.004% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% multiple dose (eight treatment and two placebo).
9466741|NCT03662971|Experimental|0.008% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% multiple dose (eight treatment and two placebo).
9466742|NCT03662958|Experimental|Lutrate|a novel leuprolide acetate 3.75mg depot
9466743|NCT03662958|Active Comparator|Enantone|market reference leuprolide acetate 3.75 mg depot
9466744|NCT03662945|Experimental|Intervention group|Mobile Geriatric Team intervention including physicians and nurses with the aim of developing person-centered, safe, sustainable and coordinated care plans. These care plans are developed in collaboration with the patient, his/her relatives and staff from the municipality. Among the main ambitions of this concept are improved communication flows between patients, their relatives and healthcare providers in combination with the delivery of medical as well as care measures. Other ambitions are to avoid unnecessary traditional healthcare utilization in the form of inpatient care and EMR visits, for example.
9466745|NCT03662945|No Intervention|Control group|Standard care including primary care units, home care and home help.
9466746|NCT03662932|Experimental|Early intensive mobilization|Progressed mobilization from postoperative day 0.
9803014|NCT04678414||Observational (focus group, survey)|"FOCUS GROUP: Patients attend an audiotaped focus group over 90 minutes to provide feedback for survey development.~SURVEY VALIDATION: Patients complete an online survey over 15-30 minutes at baseline and 2 days later.~TELEPHONE SURVEY: Patients complete a telephone survey."
9803015|NCT04677647|Experimental|OurChild|
9466747|NCT03662893|Sham Comparator|Behavioural therapy with written guideline|Patients were instructed to apply only written guideline forms of behavioural therapy which were the same as those in the checklist over six-month period.
9466748|NCT03662893|Active Comparator|Behavioural therapy with checklist|Patients were instructed to apply behavioural therapy with a written checklist for patients to fully complete over six-month period.
9466749|NCT03662893|Active Comparator|antimuscarinic drug plus verbal behavioural therapy|Patients received medical treatment (once or twice per day) plus behavioural therapy without checklist over six-month period.
9466750|NCT03662893|Active Comparator|antimuscarinics plus checklist|Patients received medical treatment (once or twice per day) with a written checklist to fully complete over six-month period.
9803016|NCT04671433|Experimental|Experimental - Immediate Treatment|RPGR4e11
9466751|NCT03662880|Other|Cardiac Magnetic Resonance &Trans-esophageal echo|patients undergo Percutaneous Mitral Commissurotomy will do cardiac magnetic resonance and trans esophageal echo for detection of left atrial thrombus
9803017|NCT04671433|Other|Deferred Treatment|Deferred Treatment
9803018|NCT04671433|Active Comparator|Experimental Immediate Treatment|RPGR2e11
10029135|NCT01746823||Controls, Keratoconus|Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
10029136|NCT01746875|Experimental|Treatment|aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
10029137|NCT01746875|No Intervention|Observation|
10029138|NCT01746888||Older Adults|Adults 65 years and older who present to the Emergency Department.
9466752|NCT03662867|Experimental|Family-based mindfulness intervention|Family-based mindfulness intervention is a parallel-group intervention containing one parent program and one child program. The parent mindfulness program lasts for 6 weeks, one session per week, and each session lasts for 1.5 hours. The child mindfulness program lasts for 8 weeks, one session per week, and each session lasts for 1 hour. In the fourth and sixth sessions of the parent program, 30-minute joint practice of parents and children is incorporated. All sessions are implemented by qualified instructors.
10029139|NCT01746914||Lung transplantated patients|Patients undergone lung transplantation
10029140|NCT01746927||cricoid pressure|
10029141|NCT01746966||Rheumatoid Arthritis|20 patients age of 20-60 with Rheumatoid Arthritis according to ARA 1987 revised criteria and disease activity Disease Activity Score (DAS) 3-5
10029142|NCT01746966||Healthy controls participants|Healthy controls age of 20-60 according to conclusion of preventive medicine department
10029143|NCT01746992|Experimental|pirarubicin|3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate
10029144|NCT01746992|Active Comparator|doxorubicin|8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)
10029145|NCT01747005||Conventional therapy|
10029146|NCT01747005||ERAS|Oral intake of solid food restriction 6 hours before surgery. Oral intake clear fluids restriction 2 hours before surgery. Intravenous 5% Dextrose-500 ml 1 hour before surgery. Intravenous dexamethasone -4mg before anesthesia. Combined spinal-epidural anesthesia. Intraoperatively 10 ml/kg intravenous of crystalloids. Paracetamol intravenous 1g. Early mobilization of patient. Oral solid food intake 4 hour postoperative. Postoperative continuous epidural analgesia.
10029147|NCT01747018|Experimental|Platelet-rich Plasma|From all the patients who participated in the clinical trial, 27 ml of blood sample was collected with a 20-G needle from an antecubital vein so that the ratio of the blood and the anti-coagulant became 10:1. The collected blood samples were transferred to a prepared separation kit (Prosys PRP, Seoul, Korea) and underwent centrifugation at the speed of 3,000 RPM for three minutes. The buffy coat layer and the plasma of the upper portion of the layer were obtained and were transferred to a concentration kit (Prosys PRP, Seoul, Korea) using a 10-ml syringe. They again underwent centrifugation at the speed of 3,300 RPM for three minutes in order to obtain concentrated PRP. The injection area was sterilized aseptically and 3-4 cc of PRP were percutaneously injected into the knee joints.
9466753|NCT03662867|Other|Wait-list control|Intervention group participants were assessed at baseline (T1) and after the intervention (T2). Control group participants were assessed at the same time with the intervention group, and would receive the same program after posttest of intervention groups.
9466754|NCT03662854|Experimental|Hair Stimulating Complex|Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
9466755|NCT03662854|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
9466756|NCT03662802||ECG Data|Coded data including; wavelengths, amplitude, intervals, timing, frequence
9466757|NCT03662763|Placebo Comparator|Placebo|
9466758|NCT03662763|Experimental|Extended-release Guanfacine Hydrochloride (SPD503)|
9466759|NCT03662737||Group 1 -Chronic cannabis use|Individuals between 18 and 50 years old who have been using at least 2 joints per day for at least 3 years. They should have used cannabis during the last 24h but not during the 3h prior to participation to the study and they should test positive for cannabis in their urine. Individuals with another substance use or severe mental disorder will be excluded (except tobacco use)
9466760|NCT03662737||Group 2 - Alcohol dependence|Individuals between 18 and 50 years old diagnosed with alcohol use disorder according to DSM-V criteria and have been consuming alcohol for at least 3 years. Individuals who are diagnosed with another substance use or severe mental disorder will be excluded (except tobacco use).
9466761|NCT03662737||Control Group|Individuals matched in gender and age with the experimental groups and with no diagnosis of substance use or severe mental disorder (except tobacco use)
10029148|NCT01747031|Experimental|Single arm study|Single arm study.The investigators will conducte computed tomography,angiography and FFR measurement during angiography in this single arm.
10029149|NCT01747044|Active Comparator|Milnacipran|Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
10029150|NCT01747044|Placebo Comparator|Capsules of lactose|placebo over a period of 8 weeks to 24 weeks
9466762|NCT03662711|Active Comparator|Long-acting beta-agonist (LABA) or LABA/LAMA|long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities
9466763|NCT03662711|Experimental|Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS|Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities
9466764|NCT03662698|Experimental|Guided Imagery|The GI intervention will include direct, written, and audio delivery of one of three GI vignettes (depiction).The patient will be able to choose one of the three vignettes.
9466765|NCT03662698|Active Comparator|Treatment as Usual|The control, or treatment as usual condition, will include an orientation to RT from the clinic nurse coordinator.
9466766|NCT03662633||Breast cancer group|Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
9466767|NCT03662633||Benign breast tumor group|Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
9466768|NCT03662620|Experimental|ARM1|"In ARM1, 32 subjects will be assigned and the subjects will be administered comparator drug at Day1/Day43 and study drug at Day22/64."
10029151|NCT01747057|Experimental|Dynamic guide resuscitation|This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.
9466769|NCT03662620|Experimental|ARM2|"In ARM2, 32 subjects will be assigned and the subjects will be administered study drug at Day1/Day43 and comparator drug at Day22/64."
9466770|NCT03662607|No Intervention|Control|Standard pre-procedural education for cardiac catheterization.
9466771|NCT03662607|Experimental|Treatment|Standard pre-procedural education plus virtual reality experience for cardiac catheterization.
9466772|NCT03662594|Other|ECMO tube|
9466773|NCT03662581|Experimental|Mindfulness Group Program|A primary care mindfulness-based rolling admissions program where subjects must attend 4 of 8 consecutive group sessions, to be considered to have completed the program.
9466774|NCT03662568|Experimental|Part A:Group A|Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.
9466775|NCT03662568|Experimental|Part A:Group B|Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.
9466776|NCT03662568|Experimental|Part B:Group C|Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.
9466777|NCT03662568|Experimental|Part B:Group D|Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.
9466778|NCT03662555|Experimental|NMES and BFR (80%)|Group 1, participants will undergo NMES and BFR (80% pressure) applied to the quadriceps for 25 min.
9466779|NCT03662555|Experimental|NMES and BFR (40%)|Group 2, participants will undergo NMES and BFR (40% pressure) applied to the quadriceps for 25 min.
9466780|NCT03662555|Active Comparator|NMES alone|Group 3, participants will undergo NMES applied to the quadriceps for 25 min.
9466781|NCT03662529|Experimental|Mind Freedom Plan therapy sessions|The Four-Session Mind Freedom Plan (MFP) is cognitive behavioral therapy (CBT)-based, client-centered, manualized individual therapy that functions as part of intensive outpatient substance abuse treatment. The MFP model is based on efficacious brief interventions, with content and format driven from military veteran feedback. The four 60-minute MFP sessions were one-on-one private consultations with a therapist that were focused on identifying and changing unhealthy thinking and behavioral patterns as core elements of CBT, but with an emphasis on problem-solving, coping skills, goal setting, and psychosocial functioning. At each session, structured worksheets were utilized and homework was assigned to facilitate this CBT-based skill building.
9466782|NCT03662529|Active Comparator|Treatment as usual therapy|The four 50-minute TAU sessions were one-on-one individual therapy sessions. Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed. Veterans were also connected with community-level psychosocial supports as appropriate.
9466783|NCT03662516|Other|Sequence 1|In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (EE and LN) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.
9466784|NCT03662516|Other|Sequence 2|In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
9466785|NCT03662503||nutrition not aggressive group|"Children will be grouped according to their calorie and protein during the first week of life. The tertile 1 will represent the group of children with the lowest nutritional intake (called the nutrition not aggressive )"
9466786|NCT03662503||aggressive nutrition group|"Children will be grouped according to their calorie and protein during the first week of life. the tertile 3 will define the group of children presenting the contributions highest nutritional levels (called the aggressive nutrition group)"
9466787|NCT03662490||patient|Patient who performed a High resolution oesophageal manometry (HRM) for the diagnosis of oesophageal motility disorder.
9466788|NCT03662477|Experimental|EGFR+NK+|The EGFR mutation positive patients were with the principles of randomized and NK cells treatment.
9466789|NCT03662477|No Intervention|EGFR+NK-|The EGFR mutation positive patients were with the principles of randomized and without NK cells treatment .
9466790|NCT03662477|Experimental|EGFR-NK+|The EGFR mutation negative patients were with the principles of randomized and NK cells treatment .
9466791|NCT03662477|No Intervention|EGFR-NK-|The EGFR mutation negative patients were with the principles of randomized and without NK cells treatment.
9466792|NCT03662451|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
9466793|NCT03662451|Active Comparator|Robotic multi-site hysterectomy|Robotic multi-site hysterectomy is performed in this arm
9466794|NCT03662438|Other|Study Participants|"This is a self-controlled study where participants will serve as their own controls. All participants will be enrolled into a 10 week home-based physiotherapy program which will include a total of 2 home visits by a physiotherapist at the start and midpoint of the program. Participants will also receive weekly telephone calls by a research coordinator to provide encouragement for patient on the programme and enquire about compliance to the home exercise regimen and safety (e.g. falls and healthcare utilisation).~Patients will also be prescribed a lightweight portable oxygen concentrator to facilitate exercise therapy and mobility in the community. They will receive familiarisation and training in its usage as part of the home-based physiotherapy program."
10029152|NCT01747057|Active Comparator|Standard resuscitation|This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.
9466795|NCT03662425|Experimental|schizophrenia with oxytocin|Participants self-administered the oxytocin twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of oxytocin.
9466796|NCT03662425|Placebo Comparator|schizophrenia with Placebo|Participants self-administered the placebo twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of placebo.
9466797|NCT03662412|Experimental|Sirolimus treatment|Oral solution of sirolimus, 2mg, once a day. The trial will be terminated when a serious adverse reaction occurred, or the tumor progressed rapidly twice in a row, or when the patient did not want to continue.
9466798|NCT03662399|Experimental|Insole A|Investigational product - Insole A
9466799|NCT03662399|Experimental|Insole B|Investigational product - Insole B
9466800|NCT03662399|Experimental|Insole C|Investigational product - Insole C
9466801|NCT03662399|Experimental|Insole D|Investigational product - Insole D
9466802|NCT03662399|Experimental|Insole E|Investigational product - Insole E
9466803|NCT03662399|Experimental|Insole F|Investigational product - Insole F
9466804|NCT03662399|Experimental|Insole G|Non-Investigational product - Standard shoe
9466805|NCT03662373||carbon ions radiation therapy|the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
9466806|NCT03662373||protons radiation therapy|the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
9466807|NCT03662321||sexual behavior on the internet|this group of teenagers use internet for sexuality
9466808|NCT03662321||not sexual behavior on the internet|this group of teenagers doesn't use internet for sexuality
9466809|NCT03662269|Experimental|indomethacin treatment group|indomethacin (75mg, bid) + omeprazole (20mg, qd)
9466810|NCT03662269|Placebo Comparator|placebo treatment group|placebo (75mg, bid) + omeprazole (20mg, qd)
9466811|NCT03662256|Active Comparator|Current Primary Care Referral Process|In communities randomized to the current primary care process, families will be notified if their children refer hearing screening in exactly the same method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. Per current practice, most preschools also give the list of referred children to the Norton Sound Audiology Department, whose staff then reaches out to families to schedule appointments during the next available audiology clinic.
9466812|NCT03662256|Experimental|Expedited Telemedicine Referral|In communities randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
9466813|NCT03662243||Acquired brain injury participants|People with acquired alexia and/or agraphia secondary to brain injury who participate in the reading/writing intervention.
9466814|NCT03662217|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
9466815|NCT03662217|Other|ADA- based diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard American dietary approach for treating diabetes
9466816|NCT03662204||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466817|NCT03662204||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
10029153|NCT01747070|Active Comparator|tDCS and EAC sham|Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
10029154|NCT01747070|Placebo Comparator|tDCS sham and EAC sham|The subjects will receive 05 sessions of tDCS sham and EAC sham. The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC sham consists of placement of rubber electrodes in the same areas of active stimulation (beside the spinous processes of L1 to S2, muscles vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus). The electrodes are connected to the same device electro, for 30 minutes, but without passage of electrical stimulation to the patient. The device is kept on and in front of the patient, with the lights blinking.
10036874|NCT01819753|Active Comparator|Multiple access|It was performed multiple access standard PCNL in this group
10036875|NCT01819766||IBD or PSC|Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
10036876|NCT01819779|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
9466818|NCT03662204||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466819|NCT03662204||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
10029155|NCT01747070|Active Comparator|tDCS sham and EAC|Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
10029156|NCT01747070|Experimental|tDCS and EAC|Subjects will receive 05 sessions of transcranial direct current stimulation(tDCS) and electroacupuncture(EAC). The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline. The electroacupuncture consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
10029157|NCT01747083|Experimental|A|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition
9466820|NCT03662204||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466821|NCT03662204||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466822|NCT03662204||Kidney & Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466823|NCT03662204||Pancreatic|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466824|NCT03662204||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466825|NCT03662204||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466826|NCT03662204||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466827|NCT03662204||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
9466828|NCT03662191|Experimental|Treatment A|4 × 20 mg commercial tafamidis meglumine administered as soft gelatin capsules under fasted conditions
9466829|NCT03662191|Experimental|Treatment B|10 mgA tafamidis free acid administered as a wet-milled suspension under fasted conditions
9466830|NCT03662191|Experimental|Treatment C|a dose of tafamidis free acid projected to be an equivalent of 4 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
9466831|NCT03662191|Experimental|Treatment D|a dose of tafamidis free acid projected to be an equivalent of 5 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
9466832|NCT03662165|Experimental|Intervention|"The primary intervention consisted of a text message informing participants that HIV self-test kits were available at all North Star Alliance clinics in Kenya. The message was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority."
9466833|NCT03662165|Experimental|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
9466834|NCT03662165|Active Comparator|Traditional Standard of Care|"Those randomized to the traditional SOC arm received the SOC message one time sent simultaneously in both Kiswahili and English. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
9466835|NCT03662152|Experimental|Foam roller|Non-Vibration Foam Rolling (NVFR) Group: subjects performed the FR protocol using a custom-made foam roller composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long).
9466836|NCT03662152|Experimental|vibration foam roller|Vibration Foam Rolling (VFR) Group: subjects performed the same protocol using a foam roller with vibration (frequency: 18 Hz) composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long) (Hyperice ®).
9466837|NCT03662113|Experimental|Experimental: Domperidone|5ml domperidone prior to VCE
9466838|NCT03662113|Other|Control: water|5ml warm water prior to VCE
10029158|NCT01747083|Experimental|B|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition
10029159|NCT01747109|Experimental|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
10036877|NCT01819779|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
9466839|NCT03662100|Experimental|LY3074828 Reference 1|Solution formulation in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm
9466840|NCT03662100|Experimental|LY3074828 Reference 2|Solution formulation in PFS administered as SC injection in thigh
9466841|NCT03662100|Experimental|LY3074828 Reference 3|Solution formulation in PFS administered as SC injection in abdomen
9466842|NCT03662100|Experimental|LY3074828 Test 1|Solution formulation administered SC via an auto-injector (AI) in arm
9466843|NCT03662100|Experimental|LY3074828 Test 2|Solution formulation administered SC via an AI in thigh
9803019|NCT04670198|Experimental|Intervention|The intervention arm will receive the Youth Empowerment Skills (YES) programme.
9466844|NCT03662100|Experimental|LY3074828 Test 3|Solution formulation administered SC via an AI in abdomen
10029160|NCT01747109|Active Comparator|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol."
10029161|NCT01747122|Experimental|Wound catheter|Wound catheter
10029162|NCT01747122|Active Comparator|Epidural|Standard epidural, pre-operative insertion, to be run for 48 hours
9466845|NCT03662087|Experimental|HMA+DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day +60 post-transplantation, HMA and DLI were given. DLI was given 48 hours after administration of HMA. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, HMA and DLI were given as shown above.
9466846|NCT03662087|Experimental|DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60 post-transplantation. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day+60 post-transplantation, DLI was given. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, DLI was given as shown above.
9466847|NCT03662048|Active Comparator|intervention at 1 month + usual care|Parents will send the study team photographs of their infant sleeping during the night at ages 1 and 2 months.
9466848|NCT03662048|Placebo Comparator|usual care|Parents will send the study team photographs of their infant sleeping during the night only at at age 2 months.
9466849|NCT03662035|Experimental|single-arm|Apatinib and S-1 Patients will be offered with Apatinib (500mg/d) and S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2) until their disease have progressed.
9466850|NCT03661957|Active Comparator|Non grafted maxillary sinus floor elevation with implant pacem|
9466851|NCT03661957|Experimental|using short dental implants for posterior atrophic maxilla|
9466852|NCT03661944||Symptomatic group|There is no intervention in this group, only functional assessments and general physical examinations will be done
10029163|NCT01747135|Experimental|Open label|
10029164|NCT01747161|Experimental|botulin toxin|botulin toxin
10029165|NCT01747161|Placebo Comparator|physiological water|physiological water
10029166|NCT01747174|Experimental|Std PCI + Intra-coronary (IC) Adenosine|IC Adenosine in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
10029167|NCT01747174|Experimental|Std PCI + IC Sodium Nitroprusside (SNP)|IC SNP in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
10029168|NCT01747174|Active Comparator|Std PCI|Standard PCI only
9466853|NCT03661944||Healthy control group|There is no intervention in this group, only functional assessments and general physical examinations will be done
9466854|NCT03661931|Experimental|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a User Experience Questionnaire for each dietary assessment method.
9466855|NCT03661918|Other|Group 1|In-person first session, no second caregiver, no wifi-enabled scale
9466856|NCT03661918|Other|Group 2|In-person first session, no second caregiver, wifi-enabled scale
9466857|NCT03661918|Other|Group 3|In-person first session, second caregiver, no wifi-enabled scale
9466858|NCT03661918|Other|Group 4|In-person first session, second caregiver, wifi-enabled scale
10029169|NCT01747187||Septic shock|
9466859|NCT03661918|Other|Group 5|No in-person first session, no second caregiver, no wifi-enabled scale. 10 core coaching calls only
9466860|NCT03661918|Other|Group 6|No in-person first session, no second caregiver, wifi-enabled scale
9466861|NCT03661918|Other|Group 7|No in-person first session, second caregiver, no wifi-enabled scale
9466862|NCT03661918|Other|Group 8|No in-person first session, second caregiver, wifi-enabled scale
9466863|NCT03661905|Experimental|Cognitive Therapy|A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
10029170|NCT01747226|Placebo Comparator|Fluoride rinse|A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.
10029171|NCT01747226|Active Comparator|Halita|Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)
10029172|NCT01747226|Active Comparator|Meridol Halitosis|This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).
10029173|NCT01747226|Sham Comparator|Water|To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.
10029174|NCT01747239|Experimental|Cabazitaxel|25 mg/m2 IV every three weeks
10029175|NCT01747252|Experimental|RGC1|RGC containing the equivalent of 50 mg resveratrol
9803020|NCT04670198|Other|Waiting-list control|The waiting-list control arm will receive usual care for six months before receiving the Youth Empowerment Skills (YES) programme.
9803021|NCT04669002|Experimental|Phase 2A Cohort 1|Patients with advanced platinum resistant ovarian cancer who have received no more than 1 prior line of therapy which must be platinum-based chemotherapy
9803022|NCT04669002|Experimental|Phase 2A Cohort 2|Patients with advanced ovarian cancer who have received at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by a PARP inhibitor as maintenance treatment as their last treatment regimen
9466864|NCT03661905|Active Comparator|Behavioural Therapy|Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
9466865|NCT03661892|Experimental|Treatment (Syndros)|All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks).
9466866|NCT03661879|Experimental|NNC9204-1706|Participants will receive NNC9204-1706 for 10 weeks. There will be a 2-week follow-up period after the treatment period.
9466867|NCT03661879|Placebo Comparator|Placebo (NNC9204-1706)|Participants will receive placebo (NNC9204-1706) for 10 weeks. There will be a 2-week follow-up period after the treatment period.
9466868|NCT03661853|Active Comparator|Control|This microintervention is intended to control for the effect of nonspecific therapy factors such as therapeutic alliance, time spent with a therapist, talking about alcohol, and/or effects related to assessment reactivity, and consists of 60 minutes of psycho-education on alcohol and drugs. The therapist will talk about historical and scientific information on different types of alcohol and drugs and will not overlap with CBT treatment. The participants will not be encouraged to personalize this information, make any behavioral changes, or do homework. The control does not have any active interventions that would specifically target or affect our outcome variables.
9466869|NCT03661853|Experimental|Functional Analysis|"Functional Analysis (FA) is a core intervention in Cognitive Behavioral Therapy (CBT) for AUD, and helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use. The FA microintervention teaches the patient to think and behave in new, more controlled ways in response to triggers, to identify maladaptive, impulsive behavior chains and to replace them with more deliberate ones."
10029176|NCT01747252|Active Comparator|Resveratrol|The equivalent of 150 mg resveratrol
10029177|NCT01747252|Experimental|RGC2|RGC containing the equivalent of 150 mg resveratrol
10029178|NCT01747278|No Intervention|Placebo|Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).
10029179|NCT01747278|Experimental|TMP/SMX|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.
9466870|NCT03661853|Experimental|Cognitive Restructuring|"Cognitive Restructuring of Thoughts About Alcohol (CR) is a core technique in CBT to help patients identify automatic (habituated) thoughts that happen quickly and are often not noticed, and change automatic thoughts occurring in response to alcohol triggers."
9466871|NCT03661853|Experimental|Dealing with Cravings|Dealing with Cravings (DC) is designed to directly target the reward and arousal systems, helping the patient accept the nature of cravings as time limited and deflated by continued abstinence so that craving is no longer associated with urgency. DC also teaches skills to reduce cravings by conjuring images such as a spider floating in a glass of wine, or of older versions of oneself sitting alone and dejected in a bar. Distraction techniques and breathing skills to reduce physiological arousal occurring in response to alcohol cues are also taught.
9466872|NCT03661788|Experimental|First placebo, than atomoxetin|Patients receive a placebo in the first of the two 14-day treatment intervals and atomoxetin in the second 14-day treatment intervals. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
10029180|NCT01747291||Atypical femur fracture cohort|
10029181|NCT01747304||Screening population|Healthy post-menopausal women attending bone mineral density screening clinic with leg/hip/groin pain/discomfort/weakness an has been on anti-resorptive therapy for at least 5 years.
10029182|NCT01747304||Comparator Group|Control group from Toronto CaMOS cohort willing to participate.
10029183|NCT01747304||AFF group|participants in the AFF Cohort study at UHN
10029184|NCT01747317|Experimental|Single arm study|Single arm study.The investigators will conduct computed tomography,angiography and FFR measurement during angiography in this single arm.
10029185|NCT01747356|Experimental|Resolute stent treatment group|"All patients will receive Resolute stent implantation to cure severe coronary atherosclerotic lesions.~RESOLUTE stent system specification (eluted zotarolimus 1.6μg/mm2):~After stent implantation, each patient will be followed up at time point of 30-day, 6-month and 12-month.~Follow-up window:~Duration of hospital stay Follow-up 1: 30days after procedure (±7 days) Follow-up 2: 6-month after procedure (±30 days) Follow-up 3: 12-month after procedure (±30 days)"
10029186|NCT01747395|No Intervention|Control Group|No exercise group (sedentary)
10029187|NCT01747395|Experimental|Aerobic Exercise Training|Group undergoing isolate aerobic exercise training 3 times/week, during 40 minutes, for 04 mouths
10029188|NCT01747395|Experimental|Inspiratory Muscle Training|Group undergoing isolate inspiratory muscle training 7 times/week, during 30 minutes, for 04 mouths
10029189|NCT01747395|Experimental|Aerobic+Inspiratory Muscle Training|Group undergoing aerobic exercise training (3 times/week during 40 minutes) associate inspiratory muscle training (7 times/week during 30 minutes) for 04 mounths
10029190|NCT01747408|Experimental|25% human albumin|Subjects will be entered into one of 4 increasing dosages of 25% human albumin sequentially. Once the first 20 subjects have been enrolled and the DSMB reviews data and approves moving to the next dosage tier patients will be entered into the following dosage tier.
10029191|NCT01747512|Active Comparator|C-PERT|45 patients with cancer
10029192|NCT01747512|Active Comparator|G-PERT|65 patients with cancer
10036878|NCT01819792|Other|patient with Acute Myeloïd Leukemia|
10029193|NCT01747525||NIRS/IVUS of coronary artery|All patients will have an epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.
9466873|NCT03661788|Experimental|First atomoxetin, than placebo|Patients receive atomoxetin in the first of the two 14-day treatment intervals and a placebo in the second 14-day treatment interval. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
9466874|NCT03661775|Experimental|controlled group|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour
10029194|NCT01747538|Placebo Comparator|Placebo|
10029195|NCT01747538|Experimental|Dose 1 gevokizumab|
10029196|NCT01747538|Experimental|Dose 2 gevokizumab|
10029197|NCT01747564|Experimental|mirabegron group|
10029198|NCT01747577|Experimental|Solifenacin group|
10029199|NCT01747577|Placebo Comparator|Placebo group|
10029200|NCT01747590|Experimental|Zolpidem, Alprazolam, Caffeine, and Placebo|The 4 medications are given in a counterbalanced design.
10029201|NCT01747603|No Intervention|Current management of LPTB|The current pragmatic, but non-systematic, pattern of management of LPTB infants. Growth measurements, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, and basic developmental milestones (as itemized in the Rourke Developmental screening tool) will be recorded by families and primary health care providers as itemized in the Memory Book at the assessments made at the discretion of the health care providers.
10029202|NCT01747603|Experimental|Specialized LPTB Clinic|Additional 6 specialized LPTB follow-up clinic visits attended by pediatricians and neonatologists. Detailed findings from physical examination, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, basic developmental milestones (as itemized in the Rourke Developmental screening tool) and physician recommendations will be recorded at each appointment. These will be compared to those obtained from families and primary health care providers as itemized in the Memory Book.
10029203|NCT01747616|Experimental|12 subjects wearing soft contact lenses|The medical test device will be administered with the contact lenses inserted
10029204|NCT01747616|Experimental|12 subjects wearing rigid contact lenses|The medical test device will be administered with the contact lenses inserted
10029205|NCT01747616|Experimental|12 subjects with soft contact lenses|The medical test device will be administered before insertion of the contact lenses
10029206|NCT01747616|Experimental|12 subjects with rigid contact lenses|The medical test device will be administered before insertion of the contact lenses
10029207|NCT01747642|Active Comparator|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
10029208|NCT01747642|Active Comparator|Oncoxin & Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
10029209|NCT01747642|No Intervention|Supportive treatment|Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
9466875|NCT03661775|Experimental|Experimental group|group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
9466876|NCT03661749|Experimental|Clean catch|women in this group will collect urine for PR/CR using a clean catch technique
9466877|NCT03661749|Placebo Comparator|Non-clean catch|women in this group will not employ clean catch technique
9466878|NCT03661684|Experimental|Prednisone in subjects with Diabetes|Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
9466879|NCT03661684|Experimental|Prednisone in control subjects|Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
10029210|NCT01747668|Placebo Comparator|Control Supplement|soft-gel placebo capsules, 2 capsules from the placebo bottle per day
10029211|NCT01747668|Experimental|Experimental Supplement A|soft-gel capsules; 1 capsule from the experimental bottle and 1 capsule from the placebo bottle per day
10029212|NCT01747668|Experimental|Experimental Supplement B|soft-gel capsules; 2 capsules from the experimental bottle per day
9466880|NCT03661671|Experimental|LCI+white light|Using white light firstly to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
9466881|NCT03661671|No Intervention|White light|Using white light only.
9466882|NCT03661658|Active Comparator|Inferior alveolar nerve lateralization with implant placement|
9466883|NCT03661658|Experimental|Using short dental implant with atrophic mandible|
9466884|NCT03661619|Experimental|Control Group|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
9466885|NCT03661619|Experimental|Test Group|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
10029213|NCT01747681||Microfracture|Microfracture of articular chondral defect
10029214|NCT01747694|Experimental|Multi-respiratory muscle training|Patients will perform multi-repiratory muscle training programe for 12 weeks
10029215|NCT01747694|No Intervention|Diaphragmatic breathing|Patients will be taught diaphragmatic breathing technique routinely. To practice at home lasting 12 weeks
9466886|NCT03661606|Experimental|Monitoring arm|Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.
9466887|NCT03661593|Experimental|Cataract guideline|In this patients we follow cataract guideline and correct the patients ametropia during the cataract surgery
9466888|NCT03661593|No Intervention|Standard refraction|The patients gets an IOL ensuring his preoperatively refraction
9466889|NCT03661580|Experimental|Behavioural Activation|Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
10029216|NCT01747707|Experimental|docetaxel, cisplatin and S-1 (DCS)|All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2.
10029217|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 1000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months
10029218|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 2000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months
9466890|NCT03661580|Active Comparator|Treatment as Usual|Participants in this arm will receive no change to the care they usually receive at the CDAT service.
9466891|NCT03661567|Experimental|Methylprednisolone|Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
9466892|NCT03661567|Active Comparator|Observation|Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).
9466893|NCT03661554|Experimental|single arm|"This clinical study, BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research, is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups."
9466894|NCT03661515|Experimental|Fludarabine-Idarubicine-Cytarabine- Selinexor|"fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:~Level -1: Selinexor 40 mg/day, once weekly~Level 1: Selinexor 60 mg/day, once weekly~Level 2: Selinexor 80 mg/day, once weekly~Level 3: Selinexor 100 mg/day, once weekly"
9466895|NCT03661502|Experimental|variable tidal volume ventilation (VVV)|the intervention is using a ventilation mode with variable tidal volume. The average tidal volume is 6 ml/kg and respiratory rate adapted to reach an end tidalCO2 concentration between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
10029219|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 3000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months
10029220|NCT01747720|Placebo Comparator|Placebo|daily, for 12 months
10029221|NCT01747733||Endoscopy patients|Patients undergoing endoscopy in the endoscopy unit in HUCH (Helsinki University Central Hospital).
9466896|NCT03661502|Experimental|Pressure controlled ventilation (PCV)|the intervention is using ventilation mode with constant pressure and constant tidal volume. The tidal volume is 6 ml/kg and respiratory rate is adapted to reach end tidal CO2 concentrations between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
9466897|NCT03661489|Experimental|Intravenous Remimazolam 50 mg|"For induction of general anesthesia, remimazolam is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia remimazolam is titrated to effect. Administration of boluses of remimazolam is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
9466898|NCT03661489|Active Comparator|Intravenous Propofol 2%|"For induction of general anesthesia, propofol is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia propofol is titrated to effect. Administration of boluses of propofol is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
10029222|NCT01747746|Active Comparator|Rivaroxaban|Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days
9480049|NCT03537456|Experimental|mRDX-02-17|"mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:~Hypotrophic tissues~Tissue hypotonicity~Crow's feet~Glogau III - IV~Fiztpatrick I - VI~WSRS (Wrinkle Severity Ranking Scale): 2-5"
9480050|NCT03537443|Placebo Comparator|Group A (Placebo)|Children whose mothers were randomized to receive a weekly dose of placebo from 17-24 weeks of gestation to 26 weeks postpartum.
9480051|NCT03537443|Experimental|Group B (4200:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 4200 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
10029223|NCT01747746|Other|Warfarin and Enoxaparin|Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
10029224|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
10029225|NCT01747759|Other|Fisher exact test|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
10029226|NCT01747785||Healthy controls|Individuals without history of cardiovascular disease and at least 18 years of age will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 3 visits over a 12 week period.
10029227|NCT01747785||Patients at risk of heart failure|Individuals at risk of heart failure and a preserved ejection fraction of at least 50% will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a baseline cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 6 visits over a 12 week period. A cardiac rehabilitation exercise program will also occur over 12 weeks.
9803023|NCT04660799|Active Comparator|Rituximab IV+CHOP|Participants will receive 8 cycles of IV rituximab in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
10029228|NCT01747798|Experimental|Treatment (auranofin)|Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10029229|NCT01747824||Agitation Group|Patients that are evaluated to have an altered mental status score greater than 1 will be enrolled in the Agitation Group.
10029230|NCT01747824||Pain Group|Patients that report severe pain secondary to a long bone fracture or dislocation and report a visual analog scale pain score greater than 7 will be enrolled in the Pain Group.
10029231|NCT01747863||Mild NE|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia.
9466899|NCT03661476|Experimental|Oculo-Motor Exercises (OME)|10 repetitive four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
10029232|NCT01747889|Experimental|Electronic system|patients managed with an electronic chest drainage system
10029233|NCT01747889|No Intervention|traditional system|patients managed with a traditional analogue chest drainage system
10029234|NCT01747902|Other|Biceps tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
10029235|NCT01747902|Other|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
10029236|NCT01747941|Experimental|Cohort 1|Single ascending oral doses in fasted conditions
10029237|NCT01747941|Experimental|Cohort 2|Single ascending oral doses in fasted conditions
9466900|NCT03661463|Experimental|Aspirin|Aspirin (Acetylsalicylic Acid [ASA]) tablets, 300mg once a day, for 90 days.
9466901|NCT03661463|No Intervention|No Treatment|No medical treatment
9466902|NCT03661450||PICU-Patients|Pediatric patients admitted after 01.08.2018
9466903|NCT03661437|Experimental|Arm I (BWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
9466904|NCT03661437|Experimental|Arm II (DWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
9466905|NCT03661424|Experimental|Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)|Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
10029238|NCT01747941|Experimental|Cohort 3|Single ascending oral doses in fed conditions
10029239|NCT01747954|Experimental|Bag Squeezing|"20% increase in FiO2~Inflation pressure of 30 cm H2O + 10l O2/min~0.5 ml saline 0.9%~10 Manual Hyperinflation~10 vibrocompression~Aspiration Tracheal"
10029240|NCT01747954|Active Comparator|Thoracic vibrocompression|"20% increase in FiO2~0.5 ml saline~10 vibrocompression toracica on the right and left~Aspiration Tracheal"
10029241|NCT01747967|Experimental|Meal test|Both new-onset T1D children and adults will be recruited and followed up through 4 meal tests at 0, 6, 12 , 18, 24 and 30 months.
10029242|NCT01747980|Experimental|PRX-112|250 mL of resuspended carrot cells administered orally in a vehicle
10029243|NCT01747993|Experimental|tamsulosin|Tamsulosin (0.4 mg/j) (1 tablet / day for 6 days)
10029244|NCT01747993|Placebo Comparator|placebo|1 tablet / day for 6 days
10029245|NCT01748006||Blood and urine samples|
9466906|NCT03661398|Experimental|Transcatheter Mitral Valve Replacement|Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System
9466907|NCT03661385|Active Comparator|Intervention arm|• Intervention arm will receive nitric oxide 20 parts per million (ppm) into the oxygenator of a cardio-pulmonary bypass circuit
9466908|NCT03661385|No Intervention|Control arm|Control arm will not receive nitric oxide, they will receive standard bypass as per local policy
9466909|NCT03661359|Experimental|Social Determinants of Health|Intervention will be the Social Determinants of Health Referrals.
9466910|NCT03661307|Experimental|Treatment (decitabine, quizartinib, venetoclax)|Patients receive decitabine IV over 1 hour on days 1-10, quizartinib PO every day beginning on day 1 of cycle 1, and venetoclax PO on days 1-14 (days 1-21 if persistent leukemia). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9466911|NCT03661294|Other|GE Healthcare Metabolic Oxygenator|The actual and predicted energy expenditure of tetraplegic (ventilated/non-vent) and paraplegic patients will be measured at three time points during the patient's rehabilitation in hospital.
9466912|NCT03661281|Experimental|Simulated Thumb Arthrodesis|Subjects will have their thumb immobilized in 2 prefabricated wrist splints to simulate 2 different fusion positions tested: one splint to simulate the MCP fusion and one to represent the IP fusion. Patients will complete hand function tests in each of the splints to evaluate hand function.
9466913|NCT03661268|Experimental|Septic shock|Patients (at least 18 years of age, no more than 75 years old) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of pulmonary artery catheter. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
9803024|NCT04660799|Experimental|Rituximab SC+CHOP|Participants will receive 1 cycle of IV plus 7 cycles of SC in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
10029246|NCT01748019|Experimental|ST1968|"ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks~--------------------------------------------------------------------------------"
10029247|NCT01748032|Other|Alternative Uses Training|In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
10029248|NCT01748032|Other|Word Association Training|In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.
10029249|NCT01748058|Experimental|Active video games|Exercise based on active video gaming
10029250|NCT01748058|No Intervention|Routine care|
10029251|NCT01748084|Placebo Comparator|NaCl|NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone
10029252|NCT01748084|Experimental|Rituximab|Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone
9466914|NCT03661255|Experimental|PC CARES Intervention|Participants will attend 1-4 sessions of the PC CARES curriculum. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
9466915|NCT03661255|No Intervention|No intervention|This group will not attend the PC CARES sessions. Investigators will collect data from this group at baseline and follow-up
10029253|NCT01748097|Experimental|IV bicarbonate 4.2% 20 cc|injecting 20cc 4.2% to a newly administered IV line
10029254|NCT01748097|Placebo Comparator|IV normal saline|injecting 20 cc normal saline to a newly administered IV line
9466916|NCT03661242|No Intervention|Standard of care|No intervention
10029255|NCT01748110|No Intervention|Local Control Group|This arm is for patients in the District of Columbia (DC), (Maryland) MD, (Virginia) VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
10029256|NCT01748110|Experimental|Local TRIMM Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
10029257|NCT01748110|Experimental|Local Intensive Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to undergo intensive in-person fitness interventions according to the Look AHEAD model. This will involve attendance at weekly support group meetings and personal monthly meetings with a health care provider/
10029258|NCT01748110|No Intervention|Distant Control Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
10029259|NCT01748110|Experimental|Distant TRIMM Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
10029260|NCT01748123|Active Comparator|Chlorthalidone|25mg daily orally for 8 weeks
10029261|NCT01748123|Active Comparator|Hydrochlorothiazide|50mg daily orally for 8 weeks
10029262|NCT01748136||Single Arm|CT Scan Arm
10029263|NCT01748188|Active Comparator|Ultrasound + Exercises + Cryotherapy|Ultrasound of 1 Megahertz (MHz), intensity 2 W/cm2, 5 minutes, for 20 sessions.
10029264|NCT01748188|Experimental|Phonophoresis + Exercises + Cryotherapy|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
10029265|NCT01748188|Experimental|Iontophoresis + Exercices + Cryotherapy|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 milliamperes (mA), 20 minutes, for 20 sessions.
10029266|NCT01748201|Experimental|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
10029267|NCT01748214||Nasal CPAP|Infants received nasal CPAP as standard of care.
10029268|NCT01748214||High Flow Nasal Cannual|Infants received high flow nasal cannula as standard of care.
10029269|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (morning)|
10029270|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (bedtime)|
10029271|NCT01748266||microcirculatory reactivity|Patients were studied during the first 48 postoperative hours. Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
10029272|NCT01748279|Active Comparator|Atorvastatin|40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
10029273|NCT01748279|Placebo Comparator|Lactose tablet|One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.
10029274|NCT01748305|Experimental|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
10029275|NCT01748318|Experimental|NM Regional Honey|15 ml of NM Honey applied directly to wound
10029276|NCT01748318|Active Comparator|Bactrim DS|Standard of Care Oral Antibiotic
9466917|NCT03661242|Active Comparator|Shared care|Clinic visit with Clincal Exercise Physiologist or physical therapist who does assessment and prescripes individulized physical activity plan
9466918|NCT03661229|Experimental|CVInsight Monitoring|Single group arm: All participants receive the same intervention/treatment CVInsight non-contact device and CVInsight contact device application.
9466919|NCT03661216|Placebo Comparator|Placebo|3g of non-GMO maltodextrin
9466920|NCT03661216|Active Comparator|Nephure|3g of Nephure
9466921|NCT03661203||Qualitative cohort|The cohort consists of MSM with late HIV diagnosis. The person from this cohort will participate to round table called also focus group or individual interview.
9466922|NCT03661203||Quantitative cohort|MSM community will be invited to participate to an online self questionnaire established from the information gathered from the previous cohort.
9466923|NCT03661190|Other|Grammatical Reasoning|This group will complete a short-term Intensive Grammatical Reasoning cognitive task delivered online by Wesnes Cognition Ltd (START). Participants will be encouraged to complete the START training once a day for six-weeks.
9466924|NCT03661190|Other|Control - Card Pairs|The control group will complete a basic picture-matching task that will provide the same level of engagement, but without the learning effects.
9466925|NCT03661177|Experimental|Diet intervention|
9466926|NCT03661177|No Intervention|Control|
9466927|NCT03661151||Antireflux surgery following PPI|A single cohort with the GERD patients who had acid suppressive medication with proton pump inhibitor (PPI) followed by laparoscopic antireflux surgery
9466928|NCT03661125|Experimental|Saracatinib or placebo|In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.
9466929|NCT03661125|Experimental|Placebo or Saracatinib (Cross-over)|The groups will now cross over i.e. the group that had the study drug in the first arm will get the placebo in the second arm and the group that had the placebo in the first arm will have the study drug in the second arm.
9466930|NCT03661112||All of Us Research Program (AoURP) consortium members|
9466931|NCT03661073|Experimental|Stroke|The investigator will include patients with stroke (either hemorrhagic or ischemic) with or without neglect in the experimental group.
10029277|NCT01748331|Other|Strict fluid restriction < 1 L/day|20 patients will be randomized to strict fluid restriction < 1 L/day
10029278|NCT01748331|Other|Moderate fluid restriction < 2.5 L/day|20 patients will be randomized to moderate fluid restriction < 2.5 L/day
10029279|NCT01748344|Experimental|Experimental 1|High dose ONO-4053
9466932|NCT03661073|Sham Comparator|Healthy subjects|The investigator will include healthy subjects aged-matched to participants of the experimental group in the control group.
9466933|NCT03661034|Experimental|Cohort 1, Arm A|Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)
9466934|NCT03661034|Experimental|Cohort 1, Arm B|Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)
10029280|NCT01748344|Active Comparator|Cetirizine|10mg Cetirizine
9466935|NCT03661034|Experimental|Cohort 2, Arm C|Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
9466936|NCT03661034|Experimental|Cohort 2, Arm D|Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
9466937|NCT03661008||Adolescents with paternal involvement|
10029281|NCT01748344|Experimental|Experimental 2|Low dose ONO-4053
9466938|NCT03661008||Adolescents without paternal involvement|
9466939|NCT03660995|Experimental|SLI children|
10029282|NCT01748344|Placebo Comparator|Placebo|Placebo
9466940|NCT03660995|Active Comparator|Control children|
9466941|NCT03660982||FDRs of RBD cases|FDRs of RBD cases. The diagnosis of RBD is based on ICSD-II criteria, as confirmed by v-PSG and with the aid of REM sleep behaviour disorder questionnaire (RBDQ-HK). RBD cases which are secondary to narcolepsy, neurodegenerative diseases or other neurological diseases are excluded.
9466942|NCT03660982||FDRs of non-RBD controls|FDRs of non-RBD controls. Non-RBD control probands are free of narcolepsy, significant clinical RBD symptoms and other neurological diseases.
9466943|NCT03660956|Experimental|Exercise and back counselling group|
9466944|NCT03660956|Active Comparator|Back counselling group|
9466945|NCT03660917|Experimental|Riluzole|Riluzole 50 mg twice daily for 12 months in the treated group. In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (RHDD; 100 mg).
9466946|NCT03660917|Placebo Comparator|Placebo + riluzole|Placebo twice daily for 6 months and riluzole 50 mg twice daily for the following 6 months in the comparison group
9466947|NCT03660904|Experimental|Home made media|home made vitrification & thawing kit
10029283|NCT01748357||Tuberculosis group|Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis >1 week are excluded.
10029284|NCT01748357||Inflammation group|Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.
10029285|NCT01748357||Healthy group|Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.
10029286|NCT01748370|Experimental|Vitamin D hypogonadal|Vitamin D supplementation in hypogonadal men
10029287|NCT01748370|Experimental|Vitamin D eugonadal|Vitamin D supplementation in eugonadal men
9466948|NCT03660904|Active Comparator|Commercial media|commercially available vitrification & thawing kit
9466949|NCT03660852||Before dedicated MRI|
9466950|NCT03660852||After dedicated MRI|
9466951|NCT03660813|Experimental|HCG triggering|Ovitrelle ( hCG 250 mcg)
9466952|NCT03660813|Experimental|Dual triggering|Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 )
9466953|NCT03660800|Experimental|CTAP101 Capsules 450mcg/weekly fasted|
9466954|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fasted|
9466955|NCT03660800|Experimental|CTAP101 Capsules 1800mcg/weekly fasted|
9466956|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fed|
9466957|NCT03660774||Patients with hemophilia|Children and young adults with hemophilia A or B, all severities, treated in the hemophilia treatment center (comprehensive care) setting, including participation of caregivers/parents completing questionnaires designed to evaluate neurologic, neurocognitive and neurobehavioral function and development.
9466958|NCT03660761|Experimental|apatinib 500mg|
9466959|NCT03660748|Experimental|Lower BMI|Use of MET-2 in subjects with BMI of 30.0 to 34.9
9466960|NCT03660748|Experimental|Higher BMI|Use of MET-2 in subjects with BMI of 35 to 39.9
9466961|NCT03660735||Male Factor Subfertility|Participant is undergoing first or second cycle of IVF and ICSI for male factor subfertility
9466962|NCT03660735||Recurrent Implantation Failure|Participant is undergoing an IVF cycle to treat subfertility with a history of Recurrent Implantation Failure (RIF).
10029288|NCT01748370|Placebo Comparator|Placebo hypogonadal|Vitamin D supplementation in hypogonadal men
10029289|NCT01748370|Placebo Comparator|Placebo eugonadal|Vitamin D supplementation in eugonadal men
10029290|NCT01748383|Experimental|Transplantation of BMMCs|Autologous BMCs aspiration and transplantation of these cells
10036879|NCT01819805||Patients taking tramadol hydrochloride and acetaminophen|
9466963|NCT03660735||Female Subfertility|Participant is undergoing an IVF cycle to treat at least 1 year of subfertility
9466964|NCT03660709|Experimental|Intervention|enhanced version of HIV testing and counseling
10029291|NCT01748383|Experimental|Transplantation of CD 133+ cells|Autologous CD 133+ BMCs aspiration and transplantation of CD 133+ cells
10029292|NCT01748383|Active Comparator|stenting of IRA|The only stenting of IRA
10029293|NCT01748396|Experimental|Calcitriol + CaCO3|Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks
10029294|NCT01748396|Active Comparator|Calcitriol|Calcitriol 0.25mcg 1cap daily for 8 weeks
10029295|NCT01748422||Experimental: Qutenza|Single treatment with Qutenza (topical capsaicin8%) transdermal patch
10029296|NCT01748435||Qutenza|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
10029297|NCT01748448|Active Comparator|Vitamin D|Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs
10029298|NCT01748448|Placebo Comparator|arachides oleum raffinatum|Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs
9466965|NCT03660709|Active Comparator|Control|standard-of-care HIV testing and counseling
10036880|NCT01819818||Paliperidone palmitate|
10036881|NCT01819857|Active Comparator|Droperidol 0.625 mg intravenously|
10036882|NCT01819857|Active Comparator|Droperidol 1.25 mg intravenously|
9466966|NCT03660670|Experimental|Interventional Arm|Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs
9466967|NCT03660670|Sham Comparator|Standard of care|Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.
9466968|NCT03660644|Experimental|WhatsApp, Pedometer and Step Diary|Pedometer, step diary and WhatsApp following pulmonary rehabilitation
9466969|NCT03660644|No Intervention|Control|Usual care following pulmonary rehabilitation.
9466970|NCT03660631|Experimental|CVRS Early Intervention|Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
9466971|NCT03660631|Other|CVRS Delayed Intervention|Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
9466972|NCT03660618|Other|Clinic Subjects|cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.
9466973|NCT03660605|Experimental|Rhythmic Auditory Stimulation|Participants will walk on treadmill to metronome set at 85% of typical cadence, followed by overground walking with metronome set at 115% of typical cadence.
9466974|NCT03660579|No Intervention|HIIT-CON|No intervention: Control
9466975|NCT03660579|Experimental|HIIT-AB Group|"Intake:~330ml (women) or 2x300 ml (men) of beer with 5.4% alcohol. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
9466976|NCT03660579|Experimental|HIIT-NAB Group|"Intake:~330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%). The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
9466977|NCT03660579|Experimental|HIIT-SW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
10036883|NCT01819857|Active Comparator|Ondansetron 8 mg intravenously|
10036884|NCT01819870|Experimental|Dilatrend SR capsule 32mg|
10036885|NCT01819870|Active Comparator|Dilatrend IR tablet 25mg|
10036886|NCT01819896||pacemakers and defibrillators|
10036887|NCT01819948|Experimental|single-arm|Two capsules in the morning, one at night, every day for a month, taken with a glass of water.
10036888|NCT01819961|Experimental|MCT/LCT|Structural Fat Emulsion Injection 250ml per day, for 7 days
10036889|NCT01819961|Experimental|MCT/LCT and fish oil|Structural Fat Emulsion Injection 250ml and fish oil 100ml for 7 days.
10036890|NCT01819974|No Intervention|Control|The normal procedure at the ward
10036891|NCT01819974|Active Comparator|Stratified medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist in patients with highest medication error risk
10036892|NCT01819987|Active Comparator|Mailing information|Participants in the mailing information group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
10029299|NCT01748461|Active Comparator|Structured intervention|Supervised cycle ergometer program
10029300|NCT01748461|Active Comparator|Coach intervention|Non-supervised cycle ergometer program
10029301|NCT01748461|No Intervention|Control group|No cycle ergometer program
10029302|NCT01748474|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
10029303|NCT01748474|Placebo Comparator|Sham room air|Room air will be applied similarly to oxygen
10029304|NCT01748487|Experimental|OZURDEX|24 patients will receive an intravitreal injection of OZURDEX at the end of cataract surgery.
9466978|NCT03660579|Experimental|HIIT-ASW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water with 5.4% alcohol.The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
9466979|NCT03660566|Experimental|Test - Implant with L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement with the use of Leucocyte- and Platelet-rich fibrin (L-PRF) membranes.
9466980|NCT03660566|Active Comparator|Control - Implant without L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement only.
9466981|NCT03660540|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
10029305|NCT01748500|Experimental|Pantoprazole, Docetaxel, Prednisone|
10029306|NCT01748513||preoperative venous return optimizing|Morbidly obese patients scheduled for bariatric surgery
9466982|NCT03660540|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
9466983|NCT03660527||6-17 year old|
9466984|NCT03660527||18-44 year old|
9466985|NCT03660527||45-59 year old|
9466986|NCT03660527||above 60 year old|
9466987|NCT03660514|No Intervention|Standard Family Planning|Counseling Clients receive standard FP counseling services.
9466988|NCT03660514|Experimental|Jovenes Sanos Intervention in FP Counseling|Clients receive the Jovenes Sanos intervention in addition to standard FP counseling services.
9466989|NCT03660488|Active Comparator|Benzathine Penicillin G|"Patients of the Penicillin Group will receive the standard of care treatment. This is one intramuscular injection of 2.4 million units Benzathine Penicillin G. The group will consist of 50 patients."
9466990|NCT03660488|Experimental|Cefixime Group|"Patients of the Cefixime Group will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.~The group will consist of 50 patients."
9466991|NCT03660475|Experimental|Naltrexone|Naltrexone Ophthalmic Solution 0.002%
9466992|NCT03660475|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
9466993|NCT03660462|Active Comparator|FeSO4 fortified rice test meal|
9466994|NCT03660462|Experimental|FePO4 fortified rice test meal|
9466995|NCT03660462|Experimental|HiFePO4 1 fortified rice test meal|
9466996|NCT03660462|Experimental|HiFePO4 2 fortified rice test meal|
9466997|NCT03660449|Experimental|Experiment|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
9466998|NCT03660436|Experimental|BMS-986165 + MMF|Oral administration
10029307|NCT01748526|Experimental|Treatment A|Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
10029308|NCT01748526|Experimental|Treatment B|Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.
9466999|NCT03660423|Experimental|Dance Group|Dance group will participate in a 60 minute integrative dance class two times per week
9467000|NCT03660423|No Intervention|Control Group|The Control group will continue with normal activities, not participating in the dance intervention.
9467001|NCT03660410||Yanomamis|Yanomami Indians, Anamnesis and oral clinical examination
9467002|NCT03660410||Macuxi|Macuxi Indians, Anamnesis and oral clinical examination
9467003|NCT03660410||Wapixana|Wapixana Indians, Anamnesis and oral clinical examination
10029309|NCT01748539|Experimental|KHK4827 70mg SC|
9467004|NCT03660397|Experimental|Intervention|Selective endovascular chemical ablation of adrenal gland after adrenal angiography.
9467005|NCT03660397|Active Comparator|Control|No intervention, but treated with standard antihypertensive drugs
9467006|NCT03660358|Experimental|Kinesiotape|Kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
9467007|NCT03660358|No Intervention|Control|No kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
9467008|NCT03660332|Active Comparator|IL-6 infusion|Healthy young men will receive IL-6 infusion
9467009|NCT03660332|Placebo Comparator|Placebo infusion|Healthy young men will receive saline infusion
9467010|NCT03660319|Experimental|Environmental Music Therapy|Music Therapy Intervention (EMT)
9467011|NCT03660319|No Intervention|Control|Control - No Environmental Music Therapy. Does not experience Environmental Music Therapy during wait time in radiation oncology waiting room.
10029310|NCT01748539|Experimental|KHK4827 140mg SC|
10029311|NCT01748539|Experimental|KHK4827 210mg SC|
10029312|NCT01748539|Placebo Comparator|Placebo SC|
10029313|NCT01748565||premature infants|Infants born prematurely between 23-0/7 and 27-6/7 weeks post-menstrual age with and without bronchopulmonary dysplasia
10029314|NCT01748578|Active Comparator|EBI-005-1 5mg/mL|Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
10029315|NCT01748578|Active Comparator|EBI-005-1 20 mg/mL|Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
9467012|NCT03660306||opioid anesthesia|classical anesthesia using sufentanil to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
9467013|NCT03660306||opioid free anesthesia|anesthesia using non opioids like dexmedetomidine, lidocaine, magnesium and ketamine to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
9467014|NCT03660293|No Intervention|diabetic- no cardioprotectives|25 child with type 1 diabetes mellitus will not receive any cardio protective drug
9467015|NCT03660293|Experimental|diabetic-Atorvastatin|25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
9467016|NCT03660293|Experimental|diabetic-Captopril|25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
9467017|NCT03660293|Experimental|diabetic-L-Carnitine|25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
9467018|NCT03660293|No Intervention|Controls|50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
9467019|NCT03660267|Experimental|coffee group|caffeine coffee
9467020|NCT03660267|Experimental|decaffeinete coffee group|decaffeinete coffee group
9467021|NCT03660267|Experimental|water group|
9467022|NCT03660254|Experimental|one group has exercise intervention|tai chi exercise intervention，two times a week and each time costs one hour
9467023|NCT03660254|No Intervention|no intervention|no intervention
9467024|NCT03660202|Experimental|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
9467025|NCT03660189|No Intervention|Usual care|Usual care with a one bag system of IV fluids, as recommended in the American Diabetes Association consensus statement guidelines from 2009.
9467026|NCT03660189|Experimental|Two bag system|A two bag system of IV fluids will be used during insulin infusion administration.
9467027|NCT03660176|Active Comparator|routine management|Children in the control group receive no additional treatment
9467028|NCT03660176|Experimental|EXP GROUP|children receiving butyrate enemas + routine management butyrate enemas every day before Curative surgery
9467029|NCT03660137|Experimental|MOLLI Localization|All patients will be implanted with a MOLLI magnetic seed in addition to the standard-of-care RSL seed. Both systems will be use to localize the respective seeds during the lumpectomy surgery.
9467030|NCT03660124|Experimental|Deep Brain Stimulation Treatment|
9803025|NCT04655365|Experimental|Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging Subjects|Enrolled subjects will receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL Injection followed by a single PET/CT scan acquired at 1-2 hours post-dosing. After initial 18F-DCFPyL PET/CT, the patients with positive 18F-DCFPyL PET/CT imaging will be treated with enzalutamide (160 mg po id) for M0CRPC disease within less than two weeks. 18F-DCFPyL PET/CT scan will then be repeated 90 days after the start of enzalutamide treatment.
10029316|NCT01748591||PICOPREP treatment|PICOPREP powder for oral solution according to standard clinical practice
10029317|NCT01748604|Active Comparator|Standard trimodality therapy with MLD|Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
9803026|NCT04651010|Experimental|Multimodal MRI|
9467031|NCT03660111|Other|spirometry|single spirometry: only a routine diagnostic test
9467032|NCT03660072||Empliciti combination therapy|Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
9467033|NCT03660046||Depot medroxyprogesterone acetate (DMPA)|This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
9467034|NCT03660046||Etonogestrel implant (Eng-Implant)|This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
9467035|NCT03660046||Levonorgestrel IUD (Lng-IUD)|This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.
9467036|NCT03660033|Experimental|With ECG|These teams will have access to ECG monitoring (intervention) during the scenario
9467037|NCT03660033|No Intervention|Without ECG|These teams will NOT have access to ECG monitoring during the scenario
9467038|NCT03660020|Sham Comparator|local anaesthetic group|
9467039|NCT03660020|Active Comparator|hyalorounidase group|
9467040|NCT03660007||Fresh embryo transfer|This exposure is an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation
9467041|NCT03660007||Frozen embryo transfer|This exposure is an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle
9467042|NCT03660007||Natural pregnancy|Spontaneous pregnancy without IVF
9467043|NCT03659994|Experimental|Vitabeard High Dose|3 capsules of multivitamin Vitabeard
9467044|NCT03659994|Experimental|Vitabeard Mid-Dose|2 Capsules of multivitamin Vitabeard, 1 Capsule of Placebo
9467045|NCT03659994|Experimental|Vitabeard Low-Dose|1 Capsule of multivitamin Vitabeard, 2 Capsules of Placebo
9467046|NCT03659994|Placebo Comparator|Placebo|3 Capsules of Placebo
9467047|NCT03659981|Experimental|MS Patients|Multiple sclerosis patients MRI 7T will be performed
9467048|NCT03659968|Experimental|EXPERIMENTAL GROUP|patients in advanced phase of pediatric cancer Physical activity training will be performed in drug development
9467049|NCT03659942||Experimental group|New child arriving in detention CAST questionnaire will be performed
9467050|NCT03659916|Experimental|A4250|Capsules for oral administration (120 ug/kg) once daily for 72 weeks
9467051|NCT03659903||younger patients (age < 80)|age < 80 patients， All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
9480052|NCT03537443|Experimental|Group C (16800:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 16800 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
10029318|NCT01748604|Experimental|Trimodality therapy with LPD|Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
10029319|NCT01748604|Experimental|Bimodality therapy without MLD|intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
10029320|NCT01748617|Experimental|Pomegranate Juice|Acute ingestion of pomegranate juice with high fat meal.
10029321|NCT01748617|Placebo Comparator|Control|Acute ingestion of juice-free sweetened beverage with high fat meal.
10029322|NCT01748630|Active Comparator|Dexmedetomidine, Midazolam|dexmedetomidine (group DEX); starting dose, 0.4 μg•kg-1•h-1,with intermittent fentanyl
9803027|NCT04648878|Experimental|Group A - Hybrid combination|Group A (n=12) will receive 18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks.
10029323|NCT01748630|Active Comparator|Midazolam|midazolam (group MDZ); starting dose, 0.1 mg•kg-1•h-1
9467052|NCT03659903||older patients (age≥ 80 )|age ≥ 80 years-old patients，All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
9467053|NCT03659890|Placebo Comparator|Low nucleotide|2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose
9467054|NCT03659890|Experimental|High nucleotide|2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose
9467055|NCT03659890|Experimental|High nucletide + Ribose|2 week supplementation with a high nucleotide mycoprotein drink, with added ribose
9467056|NCT03659877|Experimental|Heart failure patients|Patients will be required to perform a number of physical activity tasks such as laying down, sitting and walking. During these activities, acceleration, oxygen consumption, rating of perceived exertion and heart rate will be recorded.
9467057|NCT03659864|Sham Comparator|Exposure 1|filtered air
9467058|NCT03659864|Experimental|Exposure 2|nanoparticle 1 (either DEP or s-GO depending on group)
9467059|NCT03659864|Experimental|Exposure 3|nanoparticle 2 (either CB or us-GO depending on group)
9467060|NCT03659851||Levosimendan before LVAD implantation|Levosimendan use 24 hrs. before LVAD implantation
9467061|NCT03659851||Dobutamine/milrinone before LVAD implantation|Dobutamine/milrinone use 24 hrs. before LVAD implantation
9467062|NCT03659838||Participants|Schoolchildren from the canton of Zürich aged 6 to 16 years
9467063|NCT03659825|Placebo Comparator|Placebo + Normoxia|Taste, volume and appearance matched drink given before cognitive testing in normoxia
9467064|NCT03659825|Placebo Comparator|Placebo + Hypoxia|Taste, volume and appearance matched drink given before cognitive testing in hypoxia
9467065|NCT03659825|Experimental|Ketone Ester + Normoxia|Ketone ester drink given before cognitive testing in normoxia
9467066|NCT03659825|Experimental|Ketone Ester + Hypoxia|Ketone ester drink given before cognitive testing in hypoxia
9467067|NCT03659812|Experimental|MACS is applied to the sperm sample|Previous to the AID technique, the sperm sample undergoes capacitation through Percoll density gradient and MACS
9467068|NCT03659812|No Intervention|MACS is not applied to the sperm sample|Previous to the AID technique, MACS only undergoes capacitation through Percoll density gradient, but not MACS technique
9467069|NCT03659786|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
9467070|NCT03659786|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo)
9467071|NCT03659786|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo)
9467072|NCT03659773|Experimental|hematopoietic stem cell transplant (HSCT)|immune biomarkers to evaluate vaccine response in HSCT recipients
10029324|NCT01748656|Active Comparator|AVAPS|AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night
10029325|NCT01748656|Active Comparator|IVAPS|IVAPS mode(STELAR 150-RESMED)1 night
9480053|NCT03537443|Experimental|Group D (28000:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
9480054|NCT03537443|Experimental|Group E (28000:28000 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by the same dose (28000 IU/week vitamin D3) from delivery to 26 weeks postpartum.
9480055|NCT03537430|Other|TNT Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent TNT uniportal VATS mediastinal tumor resection
9480056|NCT03537430|Other|Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent traditional uniportal VATS mediastinal tumor resection
9480057|NCT03537417||Tension pneumothorax group|Patients undergoing intentional pneumothorax for thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
9480924|NCT05175001|Placebo Comparator|Group R|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine in saline was administered under real-time ultrasound monitoring
10029326|NCT01748669|Experimental|Patients of palmer arsenical keratosis|One soft capsule of garlic oil (10 mg) daily for 12 weeks
10029327|NCT01748669|Active Comparator|Arsenic exposed controls|One soft capsule of garlic oil (10 mg) daily for 12 weeks
9467073|NCT03659760|Experimental|Group Isolated|Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)
9467074|NCT03659760|No Intervention|Group Disrupted|Group Disrupted (Group I) (exposed to ambient light and noise)
9467075|NCT03659747|Experimental|Probiotic|"6 g sachet containing probiotic powder (1.8 x 10^12 colony forming units (CFU) Probiotic) in sachet~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
9467076|NCT03659747|Active Comparator|Lactrase|"6 g sachet containing 4500 FCC units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
9467077|NCT03659747|Placebo Comparator|Placebo|"6 g sachet containing placebo powder (maltodextrin) in sachet~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
9467078|NCT03659734|Experimental|Motivational Interviewing and Gradual Opioid Weaning|
9467079|NCT03659734|Experimental|Enhanced Usual Care|
9467080|NCT03659734|No Intervention|Observation|
9467081|NCT03659708|Experimental|Lyon-VTE score|"300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the Lyon-VTE score :~The Lyon score classifies patients into 3 risk categories and directs the preventive LMWH prescription:~A score strictly less than 3 indicates a moderate thrombotic risk: the patient does not receive LMWH in ante-partum;~A score between 3 and 5 indicates a high thrombotic risk: a preventive dose LMWH is introduced in the third trimester (from the beginning of the 7th month);~A score greater than or equal to 6 indicates a very high thrombotic risk: LMWH at a preventive dose is prescribed throughout the ante-partum.~All patients receive an elasto-compression prescription and daily physical activity is recommended throughout pregnancy (except obstetric contraindication).~All patients also receive systematic preventive LMWH treatment postpartum for 6 weeks."
9467082|NCT03659708|Experimental|recommendations currently available|300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the last ACCP guidelines or UK guidelines or Canadian recommendations or French recommendations, according to the habits of the center.
9467083|NCT03659695|Experimental|Grape Powder|69 g/d freeze dried grape powder
10029328|NCT01748669|Active Comparator|Heathy volunteers|One soft capsule of garlic oil (10 mg) daily for 12 weeks
9467084|NCT03659695|Placebo Comparator|Placebo powder|69 g/d placebo powder matched for taste and appearance
9467085|NCT03659682|Active Comparator|semaglutide|Ozempic- 1.0 mg administered subcutaneously once weekly
10029329|NCT01748682|Experimental|Liquid Diet Group|The group followed a very low calorie liquid diet for two weeks
10029330|NCT01748682|Active Comparator|Control Group|The group followed a very low calorie diet of normal consistency for two weeks.
9467086|NCT03659682|Placebo Comparator|placebo|Placebo, 1.0 mg administered subcutaneously once weekly
9467087|NCT03659656|Other|Fitbit (FB)|The Fitbit only (FB) group will receive the Fitbit monitor to use for 3 months.
9467088|NCT03659656|Experimental|Fitbit + Health coaching (FB+)|The Fitbit + Health coaching (FB+) group will receive a Fitbit, weekly personalized physical activity report and health coaching by phone. The 3-month intervention will be delivered through health coaching (1-time per week for month 1, 1-time every other week for month 2 and 1 time for month 3) and use of a Fitbit activity monitor.
9467089|NCT03659643||Retrospective MCI cohort|EEG with SPR analysis of the group from the study 2011-2013 is evaluated in relation to the status of current cognitive impairment
9467090|NCT03659643||Prospective MCI cohort|New individuals diagnosed with MCI. EEG with SPR analysis is performed during the diagnostic work-up and evaluated in relation to changes in cognitive status during the following two years.
9467091|NCT03659630|Experimental|Intervention group|The intervention group receives the MyCompass intervention, an automated self-help intervention for mild to moderate mental ill-health.
9467092|NCT03659630|Placebo Comparator|Comparison group|The control group receives a brief email each week, describing the most common mental health issues.
9467093|NCT03659591|Active Comparator|Cognitive Behaviour Therapy|10 week, manual-based group CBT treatment for depression and anxiety, followed by optional booster sessions
9467094|NCT03659591|Active Comparator|Adaptive Psychological Training|5 week, manual-based group APT treatment for depression and anxiety, followed by optional booster sessions
9467095|NCT03659565|Experimental|Enhanced Pre-Visit Consultation|Patients and caregivers will participate in an enhanced pre-visit consultation using Zoom for remote video and audio conferencing with screen sharing capabilities.
10029331|NCT01748708|Experimental|Magnetic seizure therapy|
10029332|NCT01748708|Active Comparator|Electroconvulsive therapy|
10029333|NCT01748721|Experimental|Treatment (MORAb-004)|Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
10029334|NCT01748734|Experimental|Supportive care (cognitive behavioral therapy)|Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
10029335|NCT01748747|Experimental|Arm I (MART-1 antigen, Gag:267-274 peptide vaccine)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 1.
10029336|NCT01748747|Experimental|Arm II (MART-1 antigen, resiquimod, Montanide ISA 51 VG)|Patients receive MART-1 antigen emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
10029337|NCT01748747|Experimental|Arm III (MART-1 antigen, Gag:267-274 peptide, resiquimod)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine peptide vaccine emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
9467096|NCT03659565|Active Comparator|Usual Care Control|Patients continue to receive usual care from their cardiologist.
9467097|NCT03659552|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.
9467098|NCT03659526||Control|Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
9467099|NCT03659526||Deformation imaging|Significant coronary disease (diameter stenosis >50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
9467100|NCT03659526||High p(CAD)|Intermediate-to-high probability of significant epicardial coronary disease (>50%).
10029338|NCT01748773|Experimental|Combination Therapy|Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.
9467101|NCT03659526||All comers|Probability of severe disease ranging from 15 to 85%.
9467102|NCT03659500||Four-week routine bloodwork|Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014
9467103|NCT03659500||Six-week routine bloodwork|Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015
9467104|NCT03659487|Active Comparator|Nissen|Surgery of GERD with 360 degrees total fundoplication
9467105|NCT03659487|Active Comparator|Toupét|Surgery of GERD with 270 degrees partial fundoplication
9467106|NCT03659474|Experimental|cryotherapy by compression|maximum dynamic intermittent compression, programmed to maintain a temperature at 1 ° C
9467107|NCT03659474|Experimental|ice pack|the ankle joint was surrounded by three plastic bags containing crushed ice.
9467108|NCT03659474|Experimental|cold water immersion|articulation of the ankle submerged in cold water at approximately 10 ° C, being controlled by the thermal camera.
9467109|NCT03659448|Active Comparator|Treatment|"Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both standard white light conditions and then NIR."
9467110|NCT03659448|No Intervention|No Treatment|"Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light conditions only."
9467111|NCT03659435|Experimental|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
9467112|NCT03659435|Active Comparator|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
9467113|NCT03659422|Other|Intervention Arm|Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
9467114|NCT03659409|Experimental|Mindfulness Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
9467115|NCT03659409|Other|Treatment Waitlist Group|Participants will receive no intervention, except for a baseline follow-up at the start and again at the end of the first phase. 2 months after the end of the first intervention phase, participants in this group will receive the same mindfulness-based intervention for 4 weeks.
9467116|NCT03659396|Experimental|individualized Tai Chi|patient received individualized Tai Chi program training.
9467117|NCT03659396|Active Comparator|Entire Tai Chi|patient received Entire Tai Chi program training.
9803028|NCT04648878|Experimental|Group B - Powered Exoskeleton only|Group B (n=12) will receive 18 visits of powered exoskeleton only, three times a week for approximately 6 weeks.
10029339|NCT01748786|Experimental|Mindfulness Emotion Regulation|12 on-line modules targeting social and emotional regulation through mindfulness training
10029340|NCT01748786|Placebo Comparator|Placebo|12 on-line modules providing information regarding health behaviors
10029341|NCT01748838|Experimental|Part 1: CTX-4430|
10029342|NCT01748838|Placebo Comparator|Part 1: Placebo + Mannitol|
9467118|NCT03659396|Placebo Comparator|home-based program|patient received home-based program training.
9467119|NCT03659383|Experimental|Optimal hypoglycemic treatment|The patients will receive optimal hypoglycemic treatments, including adjustment of insulin dose and oral antidiabetic agents
9467120|NCT03659370|Active Comparator|Fumigation Full|Full Fumigation after acupuncture, 2 times per week, for 4 weeks.
9467121|NCT03659370|Active Comparator|Fumigation 1/16|1/16 Fumigation after acupuncture, 2 times per week, for 4 weeks.
9467122|NCT03659370|Active Comparator|Acupuncture|Acupuncture only, 2 times per week, for 4 weeks.
9467123|NCT03659357||A-first CTE examination|
9467124|NCT03659357||B-first MRE examination|
9467125|NCT03659344|Active Comparator|Vicryl plus|In this group, vicryl plus(Triclosan coated) sutures were used to close flaps
9467126|NCT03659344|No Intervention|vicryl|In this group, vicryl sutures were used to close flaps
10029343|NCT01748838|Experimental|Part 2: CTX-4430|
10029344|NCT01748838|Placebo Comparator|Part 2: Placebo + Mannitol|
10029345|NCT01748851|Experimental|XELOX|Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks
10029346|NCT01748851|Active Comparator|FOLFOX|Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks
10029347|NCT01748864|Experimental|Single Arm - Healthy Volunteers|Etarfolatide (EC20)
9467127|NCT03659331|Experimental|unexplained elevation of liver enzymes|patients over the age of 18 referred for unexplained elevation of liver enzymes and carry a single mutation in the ATP7B gene. After a washout period of 3 months these patients will be re-checked for liver enzymes and if high will receive zinc therapy at a dose of 300 mg / day for 6 months, after which the liver enzymes will be checked again.
9467128|NCT03659318|Experimental|Robot|TKA is done with robotic-assisted manner. Final implantation of implants is done by surgeons, same as the conventional way. Robotic-assisted TKA for this arm.
10029348|NCT01748877|Experimental|NXN-462|capsule, 200 mg, bi.d. 28-days
10029349|NCT01748877|Placebo Comparator|Placebo|capsule, b.i.d. 28-days
10029350|NCT01748903||Target 360°, 2D, Nano Coils|Subjects will undergo embolization using Target 360°, 2D, Nano Coils for the treatment of their intracranial aneurysm.
10029351|NCT01748929|Experimental|Albendazole|single dose 400 mg tablet of albendazole
9467129|NCT03659318|Active Comparator|Conventional|TKA is done with conventional instruments. Conventional TKA for this arm.
10029352|NCT01748929|Placebo Comparator|Placebo|Placebo Manufactured by Hersil Laboratories in Lima, Peru
9467130|NCT03659305|Experimental|RPH-001|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
9467131|NCT03659305|Active Comparator|Avastin|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
9467132|NCT03659292|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
9467133|NCT03659292|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
9467134|NCT03659279|Experimental|Let's Get Organized|Group intervention with 10 weekly sessions, each lasting 1.5 hours.
9803029|NCT04648878|Experimental|Group C - Physical Therapy only|Group C (n=12) will receive 18 visits of physical therapy, three times a week for approximately 6 weeks. Upon completion of the data collection portion of the study, group C will receive 9 sessions, three times a week for approximately three weeks of powered exoskeleton therapy. Data will not be collected or reported during this phase, but but may be retained for future approved use.
10029353|NCT01748968||Veterans with HIV/AIDS|Veterans with HIV/AIDS
10029354|NCT01748981|Other|Physical training|Exercise intervention.
10029355|NCT01748981|Other|As usual|Controls
10029356|NCT01749007||Veterans with HIV/AIDS|
9467135|NCT03659266|Active Comparator|Group 1|"D0: Injection of Botulinum toxin A in triceps surae, according to pre-established modalities (no influence of the experimental protocol on this stage) W2-W4: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization)"
9467136|NCT03659266|Active Comparator|group 2|"D0: Injection of Botulinum toxin A in triceps surae W2-W4: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization)"
9467137|NCT03659253|Experimental|Oral Fluid Based Self Testing|All study participants that received intervention and meet inclusion criteria intervention that will be offered OFT
9467138|NCT03659253|No Intervention|Control Group|All HIV Patients in the clinic that not received any intervention
9803030|NCT04646213|Experimental|Therapy|psychotherapeutic intervention
9803031|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 1|Randomised participants will receive oral inhalation of AZD1402 Dose 1 via DPI.
10029357|NCT01749020|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
10029358|NCT01749020|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
10029359|NCT01749046|Experimental|Remegal|Remegal 1500 mg
10029360|NCT01749046|Placebo Comparator|Placebo|Placebo
10029361|NCT01749059||Congenital Heart Defect|
10029362|NCT01749072|Other|Gefitinib|Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
10029363|NCT01749072|Other|Vinorelbine-Ifosfamide|VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
10029364|NCT01749085|Experimental|Sequence 1|
10029365|NCT01749085|Experimental|Sequence 2|
9467139|NCT03659253|Experimental|Simplified ART Initiation|All study participants that received intervention and meet inclusion criteria intervention that will be offered SAI
9467140|NCT03659253|Experimental|CBO AND BROTHEL-BASED ART SERVICE|All patients coming to brothel or Community Based Organization services will be offered to get tested and received ART
10029366|NCT01749098|Experimental|PF-04958242|PF-04958242 and ketamine
10029367|NCT01749098|Placebo Comparator|Placebo|Placebo and ketamine
10029368|NCT01749111|Experimental|Arm A|Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4
10029369|NCT01749111|Active Comparator|Arm B|In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis
9467141|NCT03659253|Experimental|SMS Reminder|"All patients that recently found HIV Positive HIV Naive offered to get SMS Reminder"
9467142|NCT03659253|Experimental|Motivational Interviewing|PWID in Jakarta and Bandung that recently found HIV Positive or lost to follow up ARV offered MI intervention
9467143|NCT03659240|Experimental|Cranberry beverage|
9467144|NCT03659240|Placebo Comparator|Placebo beverage|
10029370|NCT01749124|Experimental|My Coach Connect|"To evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare. Clients will use this tool to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. Providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as word clouds generated from the text. Word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently."
9467145|NCT03659214||Treated group|Patients with proven CF (sweat-test > 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)
9467146|NCT03659214||Control group|Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
9467147|NCT03659201|Experimental|Neosil complete|"The patient will take the tablets, as follow:~3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and~2 tablets of Neosil Oral, per day - during the last 12 weeks."
9467148|NCT03659201|Experimental|Pantogar|"The patient wil take the tablets, as follow:~3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and~3 tablets of Pantogar, Oral, per day - during the last 12 weeks."
9467149|NCT03659201|Experimental|Neosil|"The patient will take the tablets, as follow:~2 tablets of Neosil Oral, per day - during the 12 weeks."
10029371|NCT01749150|Experimental|with cirrhosis|
10029372|NCT01749150|Experimental|without cirrhosis|
9467150|NCT03659188|Experimental|Corticotomy with drills|Patients will undergo orthodontic treatment plus an acceleration procedure employing corticotomy with drills.
9467151|NCT03659188|Experimental|Traditional Corticotomy|Patients will undergo orthodontic treatment plus an acceleration procedure employing traditional corticotomy.
9467152|NCT03659188|No Intervention|Control|Patients will undergo orthodontic treatment in which canine retraction will be accomplished using the standard sliding mechanism without any acceleration procedures.
9467153|NCT03659175||male elderly with SIBO|"male elderly who was diagnosed as SIBO via 'lactulose breath test' (LBT). At the same time, they meet the following criteria:~no use of antibiotics in the past 1 month.~no use of prokinetic drugs and probiotics in the past 1 week.~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
9467154|NCT03659175||male elderly without SIBO|"male elderly without SIBO after 'lactulose breath test'. At the same time, they meet the following criteria:~no use of antibiotics in the past 1 month.~no use of prokinetic drugs and probiotics in the past 1 week.~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
9467155|NCT03659162||neutropenic cancer patient recieving azoles .|neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation & identification of causative agent & it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
9467156|NCT03659149|Experimental|Group 1|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Test drug 2(CKD-333 formulation II) Period 3: Reference drug(CKD-330 + D086)
9467157|NCT03659149|Experimental|Group 2|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 2(CKD-333 formulation II)
9467158|NCT03659149|Experimental|Group 3|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 1(CKD-333 formulation I)
9467159|NCT03659149|Experimental|Group 4|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Reference drug(CKD-330 + D086)
9467160|NCT03659149|Experimental|Group 5|Period 1: Reference drug(CKD-330 + D086) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Test drug 2(CKD-333 formulation II)
9467161|NCT03659149|Experimental|Group 6|Period 1: Reference drug(CKD-330 + D086) Period 2: Test durg 2(CKD-333 formulation II) Period 3: Test drug 1(CKD-333 formulation I)
9803032|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 2|Randomised participants will receive oral inhalation of AZD1402 Dose 2 via DPI.
9803033|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 3|Randomised participants will receive oral inhalation of AZD1402 Dose 3 via DPI.
10029373|NCT01749163|Experimental|Control|Saline will be coninfused during the pancreatic clamp
10029374|NCT01749163|Experimental|GIP|GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min
10029375|NCT01749163|Experimental|GLP-1|GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min
10029376|NCT01749176|Experimental|SMS texting intervention|Behavioral text messages will be sent at random times throughout the week reagarding Healthy nutrition tips, benefits of physical activity, benefits of medication adherence and requests to check blood sugar and send back results.
10029377|NCT01749176|Placebo Comparator|Control-Usual Care|Participants will continue to receive their usual care in their primary care home. They will return at months 3 and 6 to conduct behavioral and laboratory assessments to compare results with the intervention group.
9467162|NCT03659123|Experimental|Intervention|"The intervention is designed to be implemented at different times of patients' care~During the prehabilitation time:~Nutritional care~Total-body rehabilitation~Pharmaceutical conciliation During peri-operative time~Management of enhances rehabilitation of the elderly. During rehabilitation time~Nutritional, medication conciliation and functional follow-up During hospital-home transition time~Nutritional and functional follow-up~Optimisation of symptoms management: abdominal pain, nausea, vomiting…"
10029378|NCT01749189|Placebo Comparator|Placebo|Placebo dry blended beverage (carbohydrate)
10029379|NCT01749189|Experimental|Blend|A dry blended beverage containing a protein blend of soy, whey and casein
10029380|NCT01749189|Active Comparator|Whey|A dry blended beverage containing Whey protein
9467163|NCT03659110||1000 subjects receive the HPV 4 vaccine|
9467164|NCT03659097|Experimental|Periodontally accelerated osteogenic orthodontics|Patients in this group will undergo orthodontic treatment plus periodontally accelerated osteogenic orthodontics in order to induce tooth movement.
10029381|NCT01749202|Placebo Comparator|Negative Control|
10029382|NCT01749202|Active Comparator|Positive Control|
9467165|NCT03659097|No Intervention|Traditional orthodontics|Patients in this group will undergo traditional orthodontics without any surgical interventions
9467166|NCT03659071|Experimental|DONORS|donors from the siblings of survivors of acute childhood leukemia who have received hematopoietic stem cell transplantation questionnaire VSP-A will be performed
10029383|NCT01749202|Experimental|Active|
10029384|NCT01749228|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
10029385|NCT01749228|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
10029386|NCT01749241|Experimental|Loteprednol etabonate ointment|This is the arm which contains loteprednol steroid
10029387|NCT01749241|Other|Vehicle Ointment|This arm contains vehicle only.
9467167|NCT03659071|Other|NON DONORS|non-donor siblings. questionnaire VSP-A will be performed
9467168|NCT03659058|Active Comparator|study group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents
9467169|NCT03659058|Placebo Comparator|control group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention
9467170|NCT03659045|Experimental|Mifegyne® 600MG|Patients assigned to this group will receive three 200 mg tablets of Mifegyne® taken during the consultation Patients will answer to a scale of pain
9467171|NCT03659045|Placebo Comparator|Mifegyne® 200MG|"Patients assigned to this group will receive one 200 mg Mifegyne® tablet and two placebo tablets that will be taken during the consultation.~Patients will answer to a scale of pain"
9467172|NCT03659032|Experimental|Pediatric Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
9467173|NCT03659032|Active Comparator|Control Group|"Only Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
9467174|NCT03659019||ventilatory paralysis|dependence on mechanical ventilatory support
9467175|NCT03659019||central hypoventilation|documented permanent or nocturnal hypoventilation
9467176|NCT03659006|Experimental|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
9467177|NCT03658993|Active Comparator|Rifaxamine 550 mg|Study drug Oral Rifaximin 550 mg TID for 4 weeks .
9467178|NCT03658993|Placebo Comparator|Placebo|Placebo TID for 4 weeks
9467179|NCT03658980|Experimental|Health Education Intervention|Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
9467180|NCT03658980|No Intervention|Control Group|No Intervention will be conducted in this control group
9467181|NCT03658941|Experimental|No dural tenting sutures|No dural tenting techniques
9467182|NCT03658941|Active Comparator|Dural tenting sutures|Dural tenting techniques
9803034|NCT04643158|Placebo Comparator|Part 1 and Part 2: Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
9803035|NCT04642287|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
10029388|NCT01749254||Acute Coronary Syndrome|40 patients admitted with ACS (NSTEMI/STEMI) will be recruited undergo 18F NaF PET, 18F FDG and CTCA within 1 month of the event.
10029389|NCT01749254||Stable angina cohort|40 patients with previously diagnosed coronary artery disease and listed to undergo elective coronary angiogram will be recruited. VH-IVUS will be attempted in all patients. Selected patients will undergo PET scan after stent implantation.
10029390|NCT01749267|Experimental|partial caries removal|partial caries removal only at enamel dentin junction (EDJ) without carious tissue removal at the pulpal site
10029391|NCT01749280||Abdominal Aortic Aneurysms|Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
10029392|NCT01749306|Other|ABH001|ABH001 application plus wound care dressings.
10029393|NCT01749306|Other|Control|Control wound treatment
10029394|NCT01749319|Active Comparator|Oral Baclofen|
10029395|NCT01749319|Experimental|Intervenous baclofen|Crossover study that eacg subject is given both oral and intervenous baclofen
9467183|NCT03658915||Osteoarthritis|"Thirty symptomatic knee with osteoarthritis will be recruited according to the following criteria:~INCLUSION CRITERIA:~Referred with a confirmed diagnosis of unilateral or bilateral OA of the knee based on the following criteria.~1.1. Morning stiffness < 30 minutes, 1.2. Crepitus on active knee movement. 1.3. Bony enlargement either palpable or visible in radiographs. 1.4. Bony tenderness.~Age 40-60 years old.~EXCLUSION CRITERIA:~Steroid injection within the past 2 months.~Presence of neurologic disorders.~Presence of of orthopedic diseases or trauma in the lower extremity or spine within the past year.~6. Severe pain with active movement 7. Poor memory or cognitive function"
9467184|NCT03658915||Control|Thirty asymptomatic knee will be recruited for this study. Control group participants will be age-matched to the osteoarthritis group, and should have no pain or other relevant clinical symptoms in lower quadrant.
9467185|NCT03658863|Active Comparator|Endoscopy first|Endoscopic ultrasound is used to evaluate bile ducts. If stones in extrahepatic bile ducts are seen ERCP and stone evacuation is performed during the same anaesthesia. Laparoscopic cholecystectomy is performed after endoscopic procedures in two days.
10029396|NCT01749332|Experimental|Pts having liver or colon surgery|Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
10029397|NCT01749358|Experimental|High Therapy Dose|Sixty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
9467186|NCT03658863|Active Comparator|Cholecystectomy first|Laparoscopic cholecystectomy with intraoperative cholangiography is performed. If stones are found postoperative ERCP with stone evacuation is applied (during cholecystectomy if common bile duct is completely blocked or as soon as possible).
9467187|NCT03658850|Active Comparator|Intervention|the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.
9467188|NCT03658850|Placebo Comparator|Control|placebo group will receive one tablet or equivalent volume of enteral solution of inert substance
9467189|NCT03658824|Other|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
9467190|NCT03658824|Other|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
9467191|NCT03658824|Other|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
9467192|NCT03658824|Other|6 week wait|Participant waits for 6 weeks after their baseline assessment before commencing therapy.
9467193|NCT03658824|Other|7 week wait|Participant waits for 7 weeks after their baseline assessment before commencing therapy.
9467194|NCT03658824|Other|8 week wait|Participant waits for 8 weeks after their baseline assessment before commencing therapy.
9467195|NCT03658798|Experimental|FES-Garment|All participants will take part in 40 sessions of 1 hour of Functional Electrical Stimulation
9467196|NCT03658785|Experimental|TIL,IL-2,Cyclophosphamide,Fludarabine|"Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).~Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.~Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days."
9467197|NCT03658746|Experimental|Antimicrobial susceptibility guided therapy|"Patients in this group will receive a 14-day quadruple therapy for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin, and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d, 2.Colloidal Bismuth Pectin 200mg bid for 14d, 3.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 500mg qid for 14d."
9467198|NCT03658746|Active Comparator|Empirical therapy according to medication history|"Patients in this group will receive a 14-day quadruple therapy based on personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics chosen according to medication history. If the patient hasn't been treated with levofloxacin in the previous eradication regimen, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and levofloxacin 500mg qd for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
9480058|NCT03537391|Experimental|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:~Traditional imaging (clinical standard imaging);~Whole-body contrast enhanced computer tomography~Planar bone scintigraphy~Novel imaging (investigational imaging);~SPECT/CT (investigational imaging)~18F-PSMA-PET/CT (investigational imaging)~Whole-body MRI (investigational imaging)~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
10029398|NCT01749358|Experimental|Moderate Therapy Dose|Thirty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
9467199|NCT03658733|Experimental|Esomeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole,amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. esomeprazole 40mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
9467200|NCT03658733|Active Comparator|Rabeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 20mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
9467201|NCT03658720|Experimental|Single tablet|Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
9467202|NCT03658720|Experimental|Two tablets|Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
9467203|NCT03658681|Experimental|Test meal 1: Saturated fat 14.9 E%|Test meal with saturated fat 14.9 E%
9467204|NCT03658681|Experimental|Test meal 2: Polyunsaturated fat 13.6 E%|Test meal with polyunsaturated fat 13,6 E%
9467205|NCT03658655|Experimental|Stem Cells From Human Exfoliated Teeth|According to the weight of 0.1IU /kg with Stem Cells From Human Exfoliated Teeth, three injections will be given respectively at the time of enrollment, one week and four weeks after enrollment.
9467206|NCT03658642|Experimental|Clinical Decision Support for BUP|The Clinical Decision Support (CDS) will be available for clinician use for Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) with referral for ongoing medication assisted treatment (MAT) if: ED chief complaint or urine drug screen indicate opioid use. The clinician will then be prompted to complete DSM-5 checklist for OUD. If DSM-5 OUD Score>5 and urine drug screen is positive for opioids, then the clinician is prompted to complete COWS scale. If COWS score >12, then the clinician is prompted to order BUP. Regardless of COWS score, the clinician will be prompted to schedule an MAT appointment with BUP provider. The CDS will interface with outside MAT facilities so that making an appointment is easy and to capture data on whether an appointment has been scheduled.
9467207|NCT03658642|No Intervention|Usual Care|The CDS will not be activated and patients will receive care as usual.
9467208|NCT03658603|Experimental|Study group|Thoracodorsal artery perforator flap
9467209|NCT03658603|Active Comparator|control group|Conventional free flaps
9467210|NCT03658590|Active Comparator|Group D|including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
10029399|NCT01749358|Experimental|Low Therapy Dose|Fifteen total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
9467211|NCT03658590|Placebo Comparator|Group P|including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
10029400|NCT01749358|Other|Active Monitoring|This is an observation only group.
9467212|NCT03658564|Experimental|Oral carbohydrate|fast from midnight the night before surgery, and patients consume 400 ml Preoperative oral carbohydrate preOp®(12.5% carbohydrates, 0.5%kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
9467213|NCT03658564|No Intervention|Fasting|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
10029401|NCT01749371|Experimental|Early Vitamin E|Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.
10029402|NCT01749371|Experimental|Delayed Vitamin E|Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.
10029403|NCT01749384|Experimental|Treatment (bevacizumab, tivantinib)|Patients receive bevacizumab IV over 30-90 minutes on days -15, 1, and 15 (day -15 of course 1 only) and tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10029404|NCT01749397|Experimental|Treatment (veliparib and floxuridine)|Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9467214|NCT03658538|Active Comparator|Active Treatment|The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
9467215|NCT03658538|Sham Comparator|Control Arm|Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status. The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
9467216|NCT03658525|Experimental|MR LINAC RADIOTHERAPY|RADIOTHERAPY DELIVERED ON MR LINAC
10029405|NCT01749423||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
10029406|NCT01749436||Lung ultrasound imaging|Lung ultrasound imaging examinations performed during the perioperative period for the monitoring of atelectasis associated with laparoscopic surgery
10029407|NCT01749449|Experimental|High protein 3 meals/day|35% protein intake eaten as 3 meals per day
9467217|NCT03658512||TUEDID cohort|
9467218|NCT03658499|Experimental|Experimental|"Those assigned to the experimental condition will be provided with treatment as usual (the two day skills group) and exposure to the video intervention adjuncts.~two day skills group plus treatment adjuncts"
9467219|NCT03658499|Other|control|"Those in the control condition will be provided with treatment as usual (the two day skills group) without access to the video intervention adjuncts.~two day skills group control group"
9467220|NCT03658473|Active Comparator|Treatment A|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
9467221|NCT03658473|Active Comparator|Treatment B|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole 1x daily over 7 days.
9467222|NCT03658473|Active Comparator|Treatment C|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
9467223|NCT03658473|Placebo Comparator|Treatment D|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
9467224|NCT03658447|Experimental|177Lu-PSMA + Pembrolizumab|200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
9467225|NCT03658434|Experimental|feasibilty|Palliative Radiotherapy
9467226|NCT03658421|Experimental|H group|H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
9803036|NCT04642287|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
10029408|NCT01749449|Experimental|High carbohydrate consumed 3 meals/day|High carbohydrate 3 meals/day
10029409|NCT01749449|Experimental|High protein consumed 6 meals/day|35% protein 6 meals/day
10029410|NCT01749462||Oxis|
10029411|NCT01749475||midazolam|
10029412|NCT01749475||hypnosis|
10029413|NCT01749488|No Intervention|Control intensive care wards|This is a randomized cluster trial. The centers randomized into this arm will serve as controls. No interventions will be implemented for these centers.
10029414|NCT01749488|Experimental|Experimental intensive care wards|"This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.~Intervention: Designated dietitian for the ward"
10029415|NCT01749514|Experimental|ACE-536|Subjects assigned to 1 of 7 possible dosing groups.
9467227|NCT03658421|Experimental|L group|L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
9467228|NCT03658421|Experimental|LD group|LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
9467229|NCT03658408|Experimental|4-aminopyridine|Participants with recent prostatectomies receiving 4-aminopyridine
9467230|NCT03658408|Placebo Comparator|Placebo|Participants with recent prostatectomies receiving placebo
9467231|NCT03658395|Active Comparator|LSCP Only|A Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, is used utilizing robot-assisted Laparoscopic Sacrocolopopexy.
9467232|NCT03658395|Active Comparator|LSCP + PR|"The Laparoscopic Sacrocolopopexy involves a Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, utilizing robot-assisted Laparoscopic Sacrocolopopexy.~In addition, patients will receive posterior repair. Posterior repair is performed by midline fascial plication. Plication of superficial perineal muscles (perineorrhaphy) is performed in conjunction with posterior repair. All repairs are performed using polydioxanone 2/0 for fascial repair and 4/0 polyglactin suture for skin closure."
9467233|NCT03658382|No Intervention|Telephone Results Disclosure|
9467234|NCT03658382|Experimental|Virtual Visit Results Disclosure|
9467235|NCT03658369|Active Comparator|Lanconone®|Lanconone®: 2 Capsules once a day after breakfast
10029416|NCT01749527|Other|24-hour pad test|decreased activity
10029417|NCT01749540|Experimental|ACE 536|ACE-536 - 1 of 7 possible dose levels.
9467236|NCT03658369|Placebo Comparator|Methyl Crystalline Cellulose|2 Capsules once a day after breakfast
10029418|NCT01749553|Experimental|sleeper stretch|
9467237|NCT03658356|Placebo Comparator|Verbal Instruction on Urine collection|"At initial prenatal visit, pregnant patients will be given verbal instructions on how to collect a urinary sample for culture.~Intervention: Pt will be given verbal instruction to collect urine"
9467238|NCT03658356|Active Comparator|Video instruction on urine collection|"At initial prenatal visit, pregnant patients will watch a video on how to collect a urinary sample for culture~Intervention: Patient will be asked to watch a video on how to collect a urine sample"
9467239|NCT03658343|Experimental|T2* Imaging|Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
9467240|NCT03658330|Experimental|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
9467241|NCT03658317|Active Comparator|cases|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
9467242|NCT03658317|Active Comparator|controls|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
9467243|NCT03658291|Experimental|Sanjin tablets group|Sanjin tablets+ levofloxacin simulants
9467244|NCT03658291|Placebo Comparator|Levofloxacin group|Sanjin tablets simulants +levofloxacin
9467245|NCT03658291|Active Comparator|Sanjin tablets+ Levofloxacin group|Sanjin tablets+ levofloxacin
9467246|NCT03658278|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
9467247|NCT03658278|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
9803037|NCT04639960|Experimental|Risperidone|
10029419|NCT01749553|No Intervention|no intervention|
10029420|NCT01749566|Active Comparator|Group A (standard maraviroc dosing)|maraviroc 300mg po bid x 7 days
10029421|NCT01749566|Active Comparator|Group B (reduced maraviroc dosing)|maraviroc 300mg po daily x 7 days
10029422|NCT01749566|No Intervention|Group C (no drug)|No additional drug
10029423|NCT01749579|Experimental|Propofol|The patients will receive propofol for sedation in addition to fentanyl
10029424|NCT01749579|Active Comparator|Midazolam|The patients will receive midazolam for sedation in addition to fentanyl
10029425|NCT01749592|Experimental|Cochlear Implant|Surgical Implantation of a Cochlear Implant
10029426|NCT01749618|No Intervention|No education or feedback|Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
10029427|NCT01749618|Experimental|Education and Feedback|Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
10029428|NCT01749644||CF patients with chronic pseudomonas infection|
10029429|NCT01749657|Active Comparator|Off-the-shelf Device and shoe|subjects will wear an off-the-shelf orthotic device (AirLift PTTD Brace) and standard Edge shoe (Aetrex Co) for 12 weeks
9467248|NCT03658265|Active Comparator|7 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
9467249|NCT03658265|Experimental|7 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
9467250|NCT03658265|Experimental|3 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
9467251|NCT03658265|Experimental|3 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
9467252|NCT03658252|Experimental|Intervention|"Participants in the intervention arm will be shown a 2 minute educational video, and given an information leaflet on topical steroids. At 1 month of follow up, a link encouraging participants to sign up for a pre-selected, disease specific, moderated online support group would be sent to their emails.~Participants will continue to receive standard medical care and counselling by their dermatologists as clinically indicated."
9467253|NCT03658252|No Intervention|Control|Patients in the control arm will receive only standard medical care and counseling by their dermatologist as clinically indicated.
9467254|NCT03658239|Experimental|Experimental|"Subjects will undergo 4-5 visits total over the course of 6 months. There will be 3-4 visits that will be done at the Flaum Eye Institute. During these sessions the subject will be measured with a stationary topographer (GALILEI G4), with a rotatable topography measurement (Oculus Topographer) and a Tonometer. The subject's heart rate and blood pressure will also be measured (using a commercially available blood pressure and heart rate meter).~The GALILEI measurement will only be done once. The rest of the measurements will be done up to 4 times. Once at the start of the study session then, after the subject has been inverted using a commercially available inversion table to first 135 degrees, then 150 degrees and finally to 165 degrees.~The blood pressure and heart rate will be monitored to ensure subject safety.~There will also be one visit at the Massachusetts General Hospital. The visit will be 2 hours and will involve a Brillouin Microscopy measurement."
9467255|NCT03658226|Experimental|Therapy|Psychodynamic Interpersonal Therapy (PIT)
10029430|NCT01749657|Experimental|Custom Device - standard and Shoe|subjects will wear a custom (standard) orthotic device (Arizona Co) and Edge shoes (Aetrex Co.) for 12 weeks.
9467256|NCT03658213|Experimental|ZOLADEX 10.8 mg depot group|• ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
9467257|NCT03658213|Active Comparator|ZOLADEX 3.6 mg depot group|• ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks
9467258|NCT03658200|Active Comparator|FAST software|Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
9467259|NCT03658200|Active Comparator|Control|Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
9467260|NCT03658187|Placebo Comparator|Placebo|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
9467261|NCT03658187|Experimental|IP|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
9480059|NCT03537378|Experimental|Hybrid APC Therapy Group|1) Patients are diagnosed as early central lung neoplasms (severe dysplasia, carcinoma in situ, microinvasive carcinoma，mucoepidermoid carcinoma.etc.) by inquiry of the first doctor, CT test, endoscopy and histopathology. Patients who meet inclusion/exclusion criteria are not suitable for or refuse surgery.
9480060|NCT03537352||Surgical Disorders|"A. Surgical Disorders:~Current Hospitalization at the Surgical Inpatient Department or at the Inpatient Department of Otorhinolaryngology or at the Inpatient Department of Cardiology OR~Current Follow-up at the Surgical Outpatient Department or at the Outpatient Department of Otorhinolaryngology or at the Outpatient Department of Cardiology due to a disorder for which any appropriate surgical treatment (surgery) is a treatment option."
9480061|NCT03537352||Non-Surgical General Medical Disorders|"Current Hospitalization at the Internal Medicine Inpatient Department or at the Inpatient Department of Cardiology OR~Current Follow-up at the Internal Medicine Outpatient Department or at the Outpatient Department of Cardiology due to a disorder for which surgery is not a treatment option and any appropriate drug or non-drug treatment excluding surgery is a treatment option."
9480062|NCT03537339||Observation|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on
9480063|NCT03537326|Experimental|Budesonide|Healthy women, aged between 18 and 45 years old, with weigh between 50 and 75 kg and with IMC included between 19 and 27 kg/m². Patients will be given, on an empty stomach since 10 hours minimum, a single dose of 3 mg of Budesonide, in the form of Entocord ® tablets. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
9480925|NCT05175001|Experimental|Group RD|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine plus 4.67mg Diprospan in saline was administered under real-time ultrasound monitoring
9480926|NCT05174754|Experimental|Inflammatory Bowel Disease Exercise Group|The exercise group will be randomized to a 20-week physician-prescribed exercise programme following the principles of Frequency, Intensity, Time, and Type (FITT) in addition to best medical therapy with the aim of increasing physical fitness levels, inflammatory response, quality of life/fatigue improvements and favorable body composition changes.
9480927|NCT05174754|Other|Inflammatory Bowel Disease Control Group|The IBD control group will be randomized to best medical therapy alone.
9480928|NCT05174754|No Intervention|Healthy Control Group|A group of healthy controls without inflammatory bowel disease will be included in the study for comparison of inflammatory markers including cytokine analysis and body composition.
10029431|NCT01749657|Experimental|Custom Articulated device and Shoe|subjects will wear a custom articulated device (Arizona Co) and Edge shoe (Aetrex Co)for 12 weeks
10029432|NCT01749657|Experimental|Custom Extended Device and Shoe|subjects will wear a custom extended foot plate orthotic device (Arizona Co) and Edge shoe (Aetrex Co) for 12 weeks.
10029433|NCT01749670||Autism|Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
10029434|NCT01749670||Control|Age- and gender-matched controls with typical neuropsychological developmental patterns
10029435|NCT01749696||Patients with pelvic organ prolapse|Patients, who were operated on because of pelvic organ prolapse.
10029436|NCT01749696||Patients without pelvic organ prolapse|Patients, who had hysterectomy due to other reasons than pelvic organ prolapse.
9480929|NCT05172167||Early vaccinated against COVID-19|80 subjects with less than 4 months after being fully vaccinated against COVID-19
10029437|NCT01749722|Experimental|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
9480930|NCT05172167||Late vaccinated against COVID-19|80 subjects with more than 4 months after being fully vaccinated against COVID-19
9480931|NCT05172167||COVID-19 infection|40 patients diagnostic of COVID-19
9803038|NCT04639960|Placebo Comparator|Placebo|
9803039|NCT04638413|Experimental|Walking regimen (W)|
9803040|NCT04638413|Experimental|Gamified inhibitory control training (PolyRules!)|
10029438|NCT01749748|Other|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy for asymptomatic women breasts.
10029439|NCT01749761|Placebo Comparator|Hemodialysis without biofeedback|Patients will be randomized to receive hemodialysis without biofeedback for a period of 8 weeks.
10029440|NCT01749761|Active Comparator|BioLogic RR biofeedback|Patients will receive 8 weeks of HD with BioLogic RR Blood pressure guided biofeedback.
10029441|NCT01749774|Experimental|Physical activity counseling|
10029442|NCT01749787|Experimental|1.5 mcg/kg|PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks
10029443|NCT01749787|Experimental|3.0 mcg/kg|PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks
10029444|NCT01749787|Experimental|6.0 mcg/kg|PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks
10029445|NCT01749787|Experimental|12.0 mcg/kg|PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks
10029446|NCT01749787|Experimental|240 mcg|PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
10029447|NCT01749787|Placebo Comparator|Placebo|Placebo administered via infusion once per week for 5 weeks
10029448|NCT01749787|Experimental|420 mcg|PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
10029449|NCT01749852|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
10029450|NCT01749852|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
10029451|NCT01749865|Experimental|A, CIK|Biological/Vaccine: Cytokine-Induced Killer Cells
9467262|NCT03658174|Active Comparator|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
10029452|NCT01749865|No Intervention|B, CONTROL|Regular follow up with no intervention
10029453|NCT01749878|Experimental|Group A: Cohorts 1 through 6|"Group A:~Cohorts 1 through 3 will receive REGN1500 subcutaneous (SC) or placebo Cohorts 4 through 6 will receive REGN1500 intravenous (IV) or placebo"
9467263|NCT03658174|Placebo Comparator|Nitrate-free beetroot juice|70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
9467264|NCT03658161|Experimental|CASCADE|Oncology providers will receive the CASCADE coaching intervention.
9467265|NCT03658148||Study Group|Neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease (CHD) between 2008-2017.
10029454|NCT01749878|Experimental|Group B|Group B will receive REGN1500 IV or placebo
9467266|NCT03658135|Experimental|BIIB092|The investigational drug, BIIB092, will be given intravenously, every 4 weeks for 20 weeks
9467267|NCT03658135|Placebo Comparator|Placebo|Inactive ingredient
9467268|NCT03658122|Experimental|Parent-Child Care Treatment|Participants receive PC-CARE treatment immediately following the pre-treatment assessment.
10029455|NCT01749878|Experimental|Group C: Cohorts 1 and 2|"Group C:~Cohort 1 will receive REGN1500 SC or placebo Cohort 2 will receive REGN1500 IV or placebo"
10029456|NCT01749891|Experimental|Arm 1.5 mg ALG - 1001|Arm 1.5 mg ALG- 1001 per 50ul
10029457|NCT01749891|Experimental|Arm 2.5 mg ALG -1001|Arm 2.5 mg ALG -1001 per 50ul
10029458|NCT01749891|Experimental|Arm 4.0 mg ALG -1001|Arm 3 4.0 mg ALG -1001 per 50ul
10029459|NCT01749917|Active Comparator|Control group|30 people are recruited in order to the inclusion criteria for the study. The study include subjects who can complete the assessment battery of tests at the beginning and end in order to perform the control intervention.
10029460|NCT01749917|Experimental|Exercise program group|30 people are recruited, diagnosed with Parkinson attending to the Parkinson Association of Granada aged between 40 and 65 years. No sex differences. The study include subjects who can complete the assessment battery of tests at the beginning and end.
10029461|NCT01749943||EDSS Score 0-3.5|21 Subjects Total : 7 with normal to mildly limited walking
10029462|NCT01749943||EDSS Score 4.0-5.5|21 Subjects total: 7 subjects with moderately limited walking ability.
10029463|NCT01749943||EDSS Score 6.0-7.5|21 Subjects total: 7 subjects with severely limited walking ability
10029464|NCT01750008|Other|Global Fibroid Ablation|Global Fibroid Ablation
10029465|NCT01750008|Other|Laparoscopic Myomectomy|Myomectomy via laparoscopy
9467269|NCT03658122|Other|Waitlist Control then Parent-Child Care|Participants wait approximately 2 months with no intervention before completing another pre-treatment assessment (post-waitlist assessment) and receiving PC-CARE treatment.
9467270|NCT03658109|Active Comparator|Lidocaine Bolus Infusion|"Patients will also undergo a loading dose of lidocaine, followed by continuous lidocaine infusion in the lidocaine group.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block."
9467271|NCT03658109|Active Comparator|QL Block & Saline Bolus Infusion|"Patients will undergo a posterior QL block.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will receive a saline bolus infusion."
10029466|NCT01750021|Experimental|High fat low carbohydrate diet|High fat low carbohydrate diet
10029467|NCT01750021|Experimental|Low fat high carbohydrate diet|Low fat high carbohydrate diet
10029468|NCT01750034|Active Comparator|Closed method|Burn patients randomized to closed method of burn wound care.
10029469|NCT01750034|Experimental|Open method|Burn patients randomized to the open method of burn wound care.
10029470|NCT01750060|Active Comparator|Fentanyl citrate IV infusion & Naltrexone|Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
10029471|NCT01750060|Experimental|Fentanyl Study System (170 mcAmps) & Naltrexone|Two consecutive 40 mcg fentanyl doses each delivered over 10 minutes by the Study System (170 mcAmps) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
9467272|NCT03658109|No Intervention|Intrathecal Morphine Alone|"Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block.~Patients will receive a saline bolus infusion."
9467277|NCT03658070|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg;Include single dose treatment and multiple dose phase
9467278|NCT03658070|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg;Include single dose treatment and multiple dose phase
9467279|NCT03658070|Experimental|XY0206-37.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：37.5mg;Include single dose treatment and multiple dose phase
9467280|NCT03658070|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg;Include single dose treatment and multiple dose phase
9467281|NCT03658070|Experimental|XY0206-75mg|Drug:XY0206;Dosage form:Tablet;Dosage：75mg;Include single dose treatment and multiple dose phase
10029472|NCT01750060|Experimental|Fentanyl, Study System (140 mcAmp) & Naltrexone|Two consecutive 35 mcg fentanyl doses, each delivered over 10 minutes by the Study System (140 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
10029473|NCT01750060|Experimental|Fentanyl, Study System (200 mcAmp) & Naltrexone|Two consecutive 50 mcg fentanyl doses, each delivered over 10 minutes by the Study System (200 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
10029474|NCT01750060|Experimental|Fentanyl, Study System (230 mcAmp) & Naltrexone|Two consecutive 54 mcg fentanyl doses, each delivered over 10 minutes by the Study System (230 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
9467282|NCT03658070|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg;Include single dose treatment and multiple dose phase
9467283|NCT03658057|Active Comparator|ROC|Neuromuscular blockade is performed in the ROC group by administering rocuronium 0.4~0.8mg/kg before the insertion of laryngeal airway.
9467284|NCT03658057|No Intervention|Control|Neuromuscular blockade is not performed.
9467285|NCT03658044|Experimental|Participation in the internet forum|Other: Patients will be encouraged to participate in an internet forum communicating with other patients at least once per week. Participation in the internet forum
9467286|NCT03658044|Active Comparator|No participation in the internet forum|"Placebo Patients will not be able to enter or read in the forum, but will be able to read general information on the webpage where the forum is placed."
10036893|NCT01819987|Experimental|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
9467287|NCT03658031|Experimental|Dapagliflozin|Dapagliflozin 10mg per/day in prediabetes cases with MI before breakfast
9467288|NCT03658031|No Intervention|Placebo|Antiplatelet, ACEI and Betablockers
9467289|NCT03658018|Experimental|Intracept System Ablation|
9467290|NCT03658005||Study cohort|"Adult (>18 years, <90 years) patients admitted and treated for acute myocardial infarction, and whose treatment includes ticagrelor in association with aspirin.~Blood samples will be taken at 3 timepoints between two doses of ticagrelor (taken at 12 hours interval)."
9467291|NCT03657979|Experimental|Ropivacaine|Conventional PCA morphine +TAP-block ropivacaine 0.2%
9467292|NCT03657979|Placebo Comparator|TAP-block with placebo|Conventional PCA morphine treatment with TAP-block with placebo
9467293|NCT03657966|Experimental|Standard of care chemotherapy + DCVAC/Ov|Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa
9467294|NCT03657953|Active Comparator|anterior (MI-A) surgical approach|The minimally invasive anterior surgical approach was carried out using a modified Smith-Petersen access as described by Bender et al. (Bender et al. 2009) with the patient in supine position.
9467295|NCT03657953|Active Comparator|anterolateral (MI-AL) surgical approach|For the minimally invasive anterolateral surgical approach, a modified Watson-Jones approach according to Röttinger (Rottinger et al. 2006) was applied with the patient in supine position.
9467296|NCT03657953|Active Comparator|direct lateral (DLA) surgical approach|The direct lateral surgical approach was performed according to the technique described by Hardinge et al. (Hardinge et al. 1982) with the patient positioned supine
9467297|NCT03657940|Experimental|Exercise intervention|multicomponent exercise training program [VIVIFRAIL],
9467298|NCT03657940|No Intervention|Usual Care|Participants randomly assigned to the usual care group will receive normal outpatient care, which includes physical rehabilitation when needed.
9467299|NCT03657927|Active Comparator|C-MAC Videolaryngoscope|Morbidly obese patients intubated with C-MAC Videolaryngoscope
9467300|NCT03657927|Active Comparator|McGrath MAC Videolaryngoscope|Morbidly obese patients intubated with McGrath MAC Videolaryngoscope
9467301|NCT03657914|Experimental|Inflatable mediastinal mirror|Patients with especially esophageal squamous cell carcinoma ( ESCC ) who meet the inclusion criteria and do not meet the exclusion criteria will undergo radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, and will be followed up until 3 years after discharging from the hospital.
9467302|NCT03657901|Experimental|Breathing|Guided slow breathing for 30 minutes before sleep onset
9467303|NCT03657901|Active Comparator|Music listening|Guided music listening for 30 minutes before sleep onset
9467304|NCT03657862|Experimental|SDF treated|application of 38% silver diamine fluoride solution
9467305|NCT03657862|Placebo Comparator|Placebo|application of a placebo (tonic water)
9467306|NCT03657836|Experimental|Dietary supplement and antibiotics|Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
9467307|NCT03657836|Other|Antibiotics only|Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
9467308|NCT03657823||Fetal growth cohort|Longitudinal measurements of fetal growth, fetal circulation and maternal circulation
9467309|NCT03657823||Hypertensive cohort|Retrospective cohort of women with heart disease that underwent oregnancy and childbirth
9467310|NCT03657784|Experimental|Cohort 1|P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
9803041|NCT04638413|Experimental|Walking regimen + gamified inhibitory control training (W+PolyRules!)|
9803042|NCT04637763|Experimental|Dose Escalation of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
9467311|NCT03657784|Experimental|Cohort 2|P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
9467312|NCT03657784|Experimental|Cohort 3|P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
10029475|NCT01750099|Experimental|Combined spinal-epidural|After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
10029476|NCT01750099|Placebo Comparator|Continuous lumbar epidural|After identifying the epidural space with the loss of resistance technique, a standard flexible epidural catheter will be threaded 4 cm into the epidural space. A standard test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000 will be given through the catheter. If positive for vascular or intrathecal placement, procedure to be repeated at different interspace. If negative, catheter will be secured and slowly dosed with 5-10 mL of 0.25% bupivicaine through epidural catheter with a goal dermatome level of T6. After obtaining the dermatome level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a PCEA option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
10029477|NCT01750112|Experimental|Macrolane VRF20|All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity.
9467313|NCT03657784|Experimental|Cohort 4|P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
9467314|NCT03657784|Experimental|Cohort 5|P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
9467315|NCT03657771|Active Comparator|DED|Diet eliminating dairy
10029478|NCT01750125||Healthy subjects|In these health subjects we will measure ascending aortic blood flow with pulse wave Doppler and also record the raw audio of the Doppler signal
10029479|NCT01750138|Experimental|Glutamine|Glutamine powder given preoperatively for five days
10029480|NCT01750138|Active Comparator|Placebo|dextrose powder for 5 days pre-operatively
10029481|NCT01750151|Experimental|Glucose beverage|Glucose beverage
10029482|NCT01750151|Experimental|Control beverage and video game playing|Control beverage and video game playing
10029483|NCT01750151|Experimental|Glucose beverage and video game playing|Glucose beverage and video game playing
10029484|NCT01750151|Experimental|Control beverage|Control beverage
9467316|NCT03657771|Active Comparator|FREE|Diet eliminating dairy and food additives
9467317|NCT03657758|Active Comparator|EPA and statin therapy group|After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
10036894|NCT01820000|Experimental|Diffusion Weighted Imaging with MRI scans|Subjects will undergo a MRI (magnetic resonance imaging) scan where DWI (diffusion weighted imaging) will be performed. Subjects will not receive contrast during this sequence, but will receive contrast as standard MRI protocol.
10036895|NCT01820013|Experimental|Customised Orthoses|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)
9467318|NCT03657758|Active Comparator|High dose statin therapy group|After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.
9467319|NCT03657758|No Intervention|low dose statin therapy group|After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.
9467320|NCT03657745||Participants who adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants adhere to the protocol if they exercise with AlzLife the minimum of 1hour/week.
9467321|NCT03657745||Participants who do not adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants do not adhere to the protocol if they exercise with AlzLife less than 1hour/week.
9467322|NCT03657732||Familial Alzheimer's disease group|Familial Alzheimer's disease with the known mutation presenilin1 (PSEN1), presenilin2 (PSEN2) and amyloid precursor protein (APP) including mutation carriers and noncarriers, presymptomatic and symptomatic.
10036896|NCT01820013|Active Comparator|Rigid 'off the shelf' pelvic support|Serola Sacroiliac Belt.
10036897|NCT01820026|Experimental|Imipenem & Vancomycin & Azithromycin|"Tienam combined with vancomycin (1g/12 h) for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of a source of infections.~Tienam combined with vancomycin (1g/12 h)and azythromycin (500 mg/24 h)for pneumonia"
9467323|NCT03657732||Normal control group|Normal cognitive control people
9467324|NCT03657719|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
9467325|NCT03657719|Active Comparator|Active Comparator: GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
9467326|NCT03657706|Active Comparator|group A|tunnel procedure with subepithelial connective tissue graft (sCTG)
9467327|NCT03657706|Active Comparator|group B|tunnel procedure with modified free gingival graft (mFGG)
9467328|NCT03657693||BPD|Infants born premature requiring oxygen
9467329|NCT03657693||Controls|
9467330|NCT03657680||ATQ Group|Convenience sample of patients from Porto Alegre (RS, Brazil) who were experiencing unilateral hip osteoarthritis and were submitted to THA in referral hospitals at least five months previously to data collection. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
9467331|NCT03657680||Control Group|The control group was composed of asymptomatic individuals from the community. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
10029485|NCT01750164||Invasive breast cancer with metastatic disease|
10029486|NCT01750177|Experimental|Television Viewing|Television viewing before mealtime
10029487|NCT01750177|Experimental|Video Game Playing|Video Game Playing before mealtime
10029488|NCT01750177|Experimental|Computer Use|Computer Use before mealtime
9467332|NCT03657654||Thyroidectomy|Patients that are clinically referred for a thyroidectomy for known or potential cancer.
9467333|NCT03657654||Other surgeries|Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
9467334|NCT03657641|Experimental|Treatment (pembrolizumab, regorafenib)|Participants receive pembrolizumab IV over 30 minutes on day 1 and regorafenib PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9467335|NCT03657615|Active Comparator|Control|Hearing Aid Fitting Patients with hearing loss but no tinnitus paired by age and hearing loss degree Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
9467336|NCT03657615|Experimental|Tinnitus|Hearing Aid Fitting Patients with tinnitus and hearing loss associated Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
9467337|NCT03657602|Experimental|Contraceptive Kyleena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
9467338|NCT03657602|Experimental|Contraceptive Mirena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
9467339|NCT03657589||patients with 1 missing tooth|Patients with 1 missing anterior or premolar tooth and planned for implant surgery were recruited. Gingiva and alveolar bone were ultrasound scanned and compared to CT scans and direct measures during implant surgery.
9467340|NCT03657563|Experimental|Intervention group|Nurses with burnout are recruited in the intervention group and participate in positive psychological intervention.
9467341|NCT03657563|No Intervention|Control group|Nurses with burnout are recruited in the control group and none interventions are conducted to them.
9467342|NCT03657550|Other|Test Drug - Reference Product - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
9467343|NCT03657550|Other|Reference Product - Test Drug - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
9467344|NCT03657537|Experimental|Hyperketonemia - Placebo|Participants are randomly assigned to initially receive ketone infusion and then saline infusion
9467345|NCT03657537|Experimental|Placebo - Hyperketonemia|Participants are randomly assigned to initially receive saline infusion and then ketone infusion
10029489|NCT01750177|Experimental|Sitting Quietly|Sitting Quietly before mealtime
10029490|NCT01750203||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
10029491|NCT01750216||Cohort|
10029492|NCT01750307|Experimental|Fatty acid supplementation|4 capsules to be taken daily
10029493|NCT01750307|Placebo Comparator|Medium Chain Triglyceride (MCT) oil softgel|4 capsules to be taken daily
10029494|NCT01750320|Experimental|Koning Breast CT - guided Biopsy|
10029495|NCT01750333||Lean children|
10029496|NCT01750333||Overweight Children (OW)|
10029497|NCT01750333||Obese children (Ob)|
9467346|NCT03657524|Experimental|Resuscitation patients|
9467347|NCT03657524|Active Comparator|healthy volunteers|
9467348|NCT03657511|Other|Educational Interventions to Promote Tobacco Cessation|
9467349|NCT03657498|Experimental|Study group|Combined orthodontic-orthognathic treatment
9467350|NCT03657498|No Intervention|Control Group I|No intervention
9467351|NCT03657498|Active Comparator|Control Group II|Standard orthodontic treatment
9467352|NCT03657485|Experimental|interventional|In the interventional group we supplemented the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFbaby, IBSS Biomed SA, Poland) orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
9467353|NCT03657485|No Intervention|control|No intervention. Feeding with mother milk
9467354|NCT03657485|No Intervention|comperative|Comparing stool composition of vaginally born newborns
9467355|NCT03657472|Experimental|Sequence 1(RTR)|
9467356|NCT03657472|Experimental|Sequence 2(RRT)|
9467357|NCT03657472|Experimental|Sequence 3(TRR)|
9467358|NCT03657446|Experimental|Treatment sequence ABC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
9467359|NCT03657446|Experimental|Treatment sequence ACB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn
9467360|NCT03657446|Experimental|Treatment sequence BAC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
9467361|NCT03657446|Experimental|Treatment sequence BCA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
9467362|NCT03657446|Experimental|Treatment sequence CBA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
9467363|NCT03657446|Experimental|Treatment sequence CAB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
9467364|NCT03657433|Experimental|Ferumoxyltol|"Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
10029498|NCT01750359|Active Comparator|curcumin|
10029499|NCT01750359|Placebo Comparator|placebo|
9467365|NCT03657433|Active Comparator|Ferrous Sulfate|"Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
9467366|NCT03657420|Experimental|ABI-009 + Pomalidomide + Dexamethasone|"Pomalidomide is given orally daily on days 1-21, 7 days off~ABI-009 is given intravenously on days 1, 8, and 15~Dexamethasone is given orally weekly on days 1, 8, 15, 22"
9467367|NCT03657394|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC.
9467368|NCT03657394|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
9467369|NCT03657381|Experimental|F520 0.2mg/kg single-dose|F520 0.2mg/kg single-dose
9467370|NCT03657381|Experimental|F520 1.0mg/kg single-dose|F520 1.0mg/kg single-dose
9467371|NCT03657381|Experimental|F520 3.0mg/kg single-dose|F520 3.0mg/kg single-dose
9467372|NCT03657381|Experimental|F520 200mg/times single-dose|F520 200mg/times single-dose
9467373|NCT03657381|Experimental|F520 10mg/kg single-dose|F520 10mg/kg single-dose
9467374|NCT03657381|Experimental|F520 1mg/kg multiple dosing, every 2 weeks|F520 1mg/kg every 2 weeks
9467375|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 2 weeks|F520 3mg/kg every 2 weeks
9467376|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 2 weeks|F520 200mg/times every 2 weeks
9467377|NCT03657381|Experimental|F520 10mg/kg multiple dosing, every 2 weeks|F520 10mg/kg every 2 weeks
10029500|NCT01750372||Persons with lower limb amputation|Persons with amputation below the hip and at or above the ankle
10029501|NCT01750385|Active Comparator|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
10029502|NCT01750385|Active Comparator|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
10029503|NCT01750411||Asthma|Severe Asthma Not severe Asthma
10029504|NCT01750424|Experimental|Fat Grafted|The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.
10029505|NCT01750424|Placebo Comparator|Non-fat grafted|The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.
10029506|NCT01750437|Experimental|YH1885L 33.3 mg|TID, Subject takes it for 4 week.
10029507|NCT01750437|Experimental|YH1885L 50mg|BID, Subject takes it for 4 week.
10029508|NCT01750437|Experimental|YH1885L 66.6 mg|TID, Subject takes it for 4 week.
10029509|NCT01750437|Experimental|YH1885L 100mg|BID, Subject takes it for 4 week.
10029510|NCT01750437|Active Comparator|Esomeprazole 20mg|QD, Subject takes it for 4 week.
9467378|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 3 weeks|F520 3mg/kg every 3 weeks
9467379|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 3 weeks|F520 200mg/times every 3 weeks
9467380|NCT03657355|Experimental|50 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
9467381|NCT03657355|Experimental|100 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
9467382|NCT03657355|Experimental|150 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
9467383|NCT03657355|Active Comparator|150 mg suvorexant|Suvorexant will be administered as tablets for oral use.
9467384|NCT03657355|Active Comparator|30 mg zolpidem|Zolpidem will be administered as tablets for oral use.
9467385|NCT03657355|Placebo Comparator|Placebo|Placebo will be administered as tablets for oral use.
9467386|NCT03657329|Experimental|Suspicion of sleep-disordered breathing|Dreem
9467387|NCT03657316|Experimental|experimental school 1|"The experimental school 1 will receive the following:~Nutritional and physical activity educational workshop~Enhanced physical education~Involvement of the morning broadcast~Educational brochure will be sent to the parents~A monthly telephone call or a text message will be sent to the parents~Message to school administration to prevent selling of soft drinks and to sell healthy food~A monthly session (3 months)"
9467388|NCT03657316|Experimental|experimental school 2|The experimental school 2 school will receive a nutritional and physical activity educational workshop; that will be held on three days through one week; one hour session each day
9467389|NCT03657316|No Intervention|control|The control school will receive no intervention
9467390|NCT03657290|Active Comparator|Treatment A|vadadustat 3 X 150 mg Tablets in fasted subjects
10029511|NCT01750450||Elective left heart cath|Patients undergoing elective left heart catheterization will be consented for this study
9467391|NCT03657290|Active Comparator|Treatment B|Vadadustat 1 X 450 mg Tablets in fasted subjects
10029512|NCT01750463||Arm A|"Critically ill pediatric patients admitted to PICU requiring hemoglobin monitoring.~Patients admitted to PICU requiring hemoglobin monitoring will have a reading total hemoglobin (SpHb) assessment done with the Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor,prior to standard laboratory blood draw and hemoglobin analysis."
10029513|NCT01750476||Depo-Provera|Women who choose to initiate Depo-Provera
10029514|NCT01750476||Mirena|Women who choose to initiate Mirena (intrauterine device)
10029515|NCT01750476||Oral contraception|Women who choose to initiate oral contraception
10029516|NCT01750489|No Intervention|COPD|
10029517|NCT01750489|Experimental|COPD with non-invasive ventilation (NIV)|Starting non-invasive ventilation with the patient's own device during registration of MSNA.
10029518|NCT01750489|No Intervention|Healthy control subjects|
10029519|NCT01750515|Experimental|Intervention group - acupuncture treatment|
10029520|NCT01750515|No Intervention|Control group|
10029521|NCT01750528||Ankylosing spondylitis|patients aged 18 years or more who meet the 1984 modified New York criteria
10029522|NCT01750528||Control|age- (± 3 years) and gender-matched volunteers who do not have inflammatory arthropathy.
10029523|NCT01750541|Active Comparator|Haloperidol|Haloperidol 5mg intramuscular injection
9467392|NCT03657290|Active Comparator|Treatment C|vadadustat 1 X 450 mg Tablets in fed subjects
10029524|NCT01750541|Active Comparator|Valproate|Valproate single Infusion; 400 mg (weigh<60 kg), 500 mg (weight>60 Kg)
10029525|NCT01750554|Experimental|bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
10029526|NCT01750554|No Intervention|No bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
9467393|NCT03657251||CureCloud Direct to Patient|
9467394|NCT03657238|Experimental|Experimental|Doses were escalated from 0.2μg/kg up to 4.8μg/kg
9467395|NCT03657238|Placebo Comparator|Placebo|
9467396|NCT03657225|Active Comparator|Mini CPB (ECCO, Sorin, Italy)|Utilization of the mini CPB circuit (Extra Corporeal Circuit Optimized; Phisio, Sorin Group, Italy)
9467397|NCT03657225|Placebo Comparator|Conventional|Use of conventional CPB circuit
9467398|NCT03657212|Active Comparator|Nap/5mg Zolpidem|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
9467399|NCT03657212|Placebo Comparator|Nap/Placebo|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
9467400|NCT03657199||Bypass graft failure|Patients with at least one detected graft failure after routine cardiac computed tomography before discharge
9467401|NCT03657199||No bypass graft failure|Patients without occluded bypass grafts after routine cardiac computed tomography before discharge
9467402|NCT03657186|Experimental|ProbioSatys™|
9467403|NCT03657186|Placebo Comparator|Placebo|
10029527|NCT01750580|Experimental|Arm 1: Lirilumab + Ipilimumab|Lirilumab and Ipilimumab on specific days
10029528|NCT01750593|Experimental|radiofrequency ablation of thyroid nodule|Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation
10029529|NCT01750606||pre-THA|Patients who are planned but have not yet received a total hip arthroplasty. No intervention or treatment - blood draw only to be used as a surrogate baseline for metal ion exposure.
10029530|NCT01750606||Metal-on-Poly|Patients receiving a Biomet metal on poly hip implanted between January 1, 2003 and December 31, 2006.
10029531|NCT01750606||M2a Magnum hip|Patients receiving a Biomet M2a Magnum hip implanted between January 1, 2006 and January 1, 2011.
10029532|NCT01750606||M2a38 hip|Patients receiving a Biomet metal on metal M2a38 hip implanted between January 1, 2004 and December 31, 2006.
10029533|NCT01750606||M2a Ringloc hip|Patients receiving a Biomet M2a Ringloc metal on metal hip implanted between January 1, 2002 and December 31, 2004.
10029534|NCT01750606||M2a Taperloc hip|Patients receiving a Biomet M2a Taperloc metal on metal hip implanted between January 1, 2002 and December 31, 2003.
10029535|NCT01750632|Experimental|Orchiectomy|The patients undergo subcapsular orchiectomy
10029536|NCT01750645||Intervention Group|
10029537|NCT01750645||Control Group|
9467404|NCT03657160|Experimental|Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background graft-versus-host disease (GvHD) prophylaxis regimen.
9467405|NCT03657160|Placebo Comparator|Placebo|Vedolizumab placebo-matching, intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background GvHD prophylaxis regimen.
10029538|NCT01750658||COPD|"COPD patients admitted in any of the participating ECOS hospitals due to a COPD exacerbation.~- External factors. The episodes of COPD exacerbations are associated to exogenous factors (pollution, change of ambient temperature, humidity, infections). The prevalence of environmental contamination and infections is higher than expected.~- Endogenous factors. These factors (hyperinflation, pulmonary embolism, cardiac dysfunction, mucus hypersecretion) are present in a proportion higher than expected~- During exacerbations of COPD serum markers of inflammation and autoimmunity are high relative to baseline in COPD and decrease progressively during the follow-up, after controlling the acute episode"
10029539|NCT01750723|Active Comparator|Acetazolamide|Acetazolamide 1 g in 10 ml saline, i.v. infusion
10029540|NCT01750723|Placebo Comparator|Saline|Saline, 10 ml i.v. infusion
9467406|NCT03657147|Experimental|Question Prompt List and Video|Participants will watch an educational video and question prompt list will be provided. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
9467407|NCT03657147|No Intervention|Usual Care|The usual care group will not receive any intervention. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
9467408|NCT03657082|Experimental|Arm A|In this arm, patients will receive the experimental condition first, then the sham condition
9467409|NCT03657082|Experimental|Arm B|In this arm, patients will receive the sham condition first, then the experimental condition
10029541|NCT01750736|Experimental|Augmented Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a specific exercise to augment the specific manual treatment provided.
10029542|NCT01750736|Active Comparator|General Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a general neck range of motion exercise.
10029543|NCT01750749|Experimental|Autologous BMDC implantation at the venous ulcer|Autologous BMDC implantation at the venous ulcer in conjunction with SOC treatment (advanced wound management plus pressure therapy)
9467410|NCT03657069|Experimental|Supportive care (Blossom Smart Expander Technology)|After mastectomy, participants undergo 2-staged IBR with the Blossom Smart Expander Technology comprising of the Blossom syringe assist device connected to the Mentor SPECTRUM adjustable saline breast implant.
9467411|NCT03657056|Experimental|BX Pulsar 1002|Low-Intensity Focused Ultrasound Pulsation (LIFUP) sonications will be conducted using the LIFUP experimental device BX Pulsar 1002 produced by the Brainsonix Corporation. For the purposes of safety LIFUP sonications will be initiated at the FDA limit for diagnostic ultrasound. However, the minimally effective dose in humans applications, according to (Lee et al., 2015), when derated is approximately 1125mW/cm2.
9467412|NCT03657030|Active Comparator|Single Ascending Dose|The planned dose levels will be 1, 5, 25, 75, and 225 mg CVN424 and matching placebo.
9803043|NCT04637763|Experimental|Expansion of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
10029544|NCT01750762|Experimental|Lenalidomide|Dose escalation. Starting dose is 10 mg/day for 3 weeks followed by 1 week off (1 cycle). Subject will receive a total of 3 cycles.
10029545|NCT01750775|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
10029546|NCT01750775|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
10029547|NCT01750788||Group 1|
10029548|NCT01750801|Active Comparator|Propolis|alcohol-free mouthwash containing 5% green propolis (MGP 5%) on the control of plaque and gingivitis.
10029549|NCT01750801|Active Comparator|chlorhexidine|chlorhexidine used on the control of plaque and gingivitis.
10029550|NCT01750814|Active Comparator|GC FLU inj.|Influneza vaccine, single-dose vial
10029551|NCT01750814|Experimental|GC3102C|Influneza vaccine, multi-dose vial
10029552|NCT01750827|Experimental|SB-659032|Single dose open label
10029553|NCT01750853|Experimental|Group 1|"Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally."
10029554|NCT01750853|Experimental|Group 2|"Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally."
10029555|NCT01750853|Experimental|Group 3|"Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period)."
10029556|NCT01750866|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. Treatment will continue until disease progression, intolerable side effects, or a maximum of 10 cycles of therapy.
10029557|NCT01750892|Active Comparator|Group 1: Control|Group 1 will be the control group. They will complete questionnaires but will otherwise receive usual care from their Primary Care Provider (PCP). At the end of the study period they will be given the Study Materials for participating.
9467413|NCT03657030|Active Comparator|Multiple Ascending Dose|The planned dose levels will be 25, 75, and 150 mg CVN424 and matching placebo.
9467414|NCT03657017|Other|PET/MR|Patients are examined with PET/MR.
9467415|NCT03656991|Experimental|0 month group|Receive the bicycle intervention at 0 months after enrollment.
9467416|NCT03656991|Experimental|2 month group|Receive the bicycle intervention at 2 months after enrollment.
9467417|NCT03656991|Experimental|4 month group|Receive the bicycle intervention at 4 months after enrollment.
9467418|NCT03656991|Experimental|6 month group|Receive the bicycle intervention at 6 months after enrollment.
9467419|NCT03656978|Active Comparator|Dynamic|Keep moving the probe for needle tip visualization during the puncture procedure.
9467420|NCT03656978|Placebo Comparator|Regular-triangle|Needle access along the hypotenuse of the regular triangle formed by the vascular depth and puncture point.
9467421|NCT03656965|Experimental|Antiviral Drug with Chemoradiotherapy|Antiviral therapy Acyclovir 800 mg per day during the whole course of treatment.
10029558|NCT01750892|Experimental|Group 3: Group Intervention|Group 3 (Group Intervention) will receive the Study Materials at the beginning of the study and will also be invited to attend two REACH for Independence group sessions.
10029559|NCT01750892|Experimental|Group 4: Full Intervention|Group 4 (Full Intervention) will receive the Study Materials at the beginning of the study, will be invited to attend the REACH for Independence group sessions, and will be invited to a Transition Consult with an MD and social worker.
10029560|NCT01750892|Experimental|Group 2: Basic Intervention|Group 2 (Basic Intervention) will receive the Study Materials at the beginning of the study but will otherwise continue with their usual PCP care.
10029561|NCT01750905|Active Comparator|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
10029562|NCT01750905|Placebo Comparator|Placebo|Placebo: Vehicle (D5W) SQ
10029563|NCT01750944|Experimental|Healthy Volunteers 1|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: ankle first"
10029564|NCT01750944|Experimental|Healthy Volunteers 2|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: toe first"
10029565|NCT01750970|Experimental|Resection under blue light|
10029566|NCT01750970|Active Comparator|Resection under white light|
10029567|NCT01750983|Experimental|Ipilimumab + Lenalidomide|"Dose Escalation Group Ipilimumab Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Escalation Group Lenalidomide Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab and Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Groups."
10029568|NCT01750996|No Intervention|Usual Care control (Parenting tips)|Participants randomized to usual care will have access to a brief information website containing brief parenting tips but will not receive Strongest Families Intervention
10029569|NCT01750996|Experimental|Strongest Families|Strongest Families intervention
10029570|NCT01751009|Experimental|Vitamin A supplements|Sprinkles with Vitamin A
10029571|NCT01751009|Active Comparator|Sprinkles without Vitamin A|Made of other micronutrients without Vitamin A
10029572|NCT01751035|Placebo Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers. This could include individual and/or group therapy using a variety of treatment models.
9467422|NCT03656965|Other|Chemoradiotherapy|Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
9467423|NCT03656952|Experimental|Seq 1|PF-06700841-> placebo-> moxifloxacin
9467424|NCT03656952|Experimental|Seq 2|PF-06700841->moxifloxacin->placebo
9467425|NCT03656952|Experimental|Seq 3|Placebo->PF-06700841->moxifloxacin
9467426|NCT03656952|Experimental|Seq 4|Placebo->moxifloxacin->PF-06700841
9467427|NCT03656952|Experimental|Seq 5|Moxifloxacin->PF-06700841->placebo
9467428|NCT03656952|Experimental|Seq 6|Moxifloxacin->placebo->PF-06700841
9467429|NCT03656913|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose CT exams
9467430|NCT03656900|Experimental|BA9/BA46|
9467431|NCT03656900|Experimental|BA46/BA9|
9467432|NCT03656874|No Intervention|Usual Care|Usual care, practitioners review clinical guidelines for tobacco during consent process.
9467433|NCT03656874|Experimental|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care.
9467434|NCT03656861||Athletes|122 were athletes (41 females and 81 males). Of the 41 female athletes, 32 were endurance athletes, and 9 strength athletes. From 81 male athletes, 56 were endurance athletes, and 25 were strength athletes.
9467435|NCT03656861||Non-athletes|29 were non-athletes (14 females and 15 males)
9467436|NCT03656835|Experimental|Diagnostic (ILN biochip testing)|Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
9467437|NCT03656822||Routine imaging such as CT or MRI|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging,
9467438|NCT03656822||Routine imaging (CT or MRI) with a 3D printed model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D printed anatomical mode
9467439|NCT03656822||Routine imaging (CT or MRI) with a VR model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D VR anatomical model
9467440|NCT03656796|Experimental|PD with freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
9467441|NCT03656796|Experimental|PD without freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
9467442|NCT03656796|Experimental|Healthy subjects (Control)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
9467443|NCT03656783|Other|HIV patients on stable therapy|Open-label, multicenter, single-arm study
9467444|NCT03656770|No Intervention|V1: Control|This version of the survey questionnaire depicts a young woman with no symptoms of mental illness.
9467445|NCT03656770|Experimental|V2: Schizophrenia|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic schizophrenia."
9467446|NCT03656770|Experimental|V3: Schizophrenia + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with complete response."
9480064|NCT03537313|No Intervention|Control-douching group|No preoperative vagina douching
9480065|NCT03537313|No Intervention|Control-painting group|No intra-operative vagina painting
10029573|NCT01751035|Experimental|RRFT|RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy. Please see intervention description for more detail about the model.
10029574|NCT01751048|Experimental|Group #1|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE)
10029575|NCT01751048|Experimental|Group #2|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 10 mcg Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE)
9467447|NCT03656770|Experimental|V4: Schizophrenia + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with partial relapse."
9467448|NCT03656770|Experimental|Version 5: Bipolar|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic bipolar disorder."
10029576|NCT01751048|Experimental|Group #3|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + Stable oil-in-water Emulsion (SE)
9467449|NCT03656770|Experimental|V6: Bipolar + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with complete response."
9467450|NCT03656770|Experimental|V7: Bipolar + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with partial relapse."
10029577|NCT01751074|Experimental|Part A|All subjects will be of Caucasian descent and will receive single dose of Rosuvastatin 10 mg for 1 day (Day 1) during treatment period 1, then will receive Darapladib 160 mg once daily (QD) for 10 days (Day 5 to 14) in treatment period 2. Immediately following this, all subjects will receive the combination of Darapladib 160 mg and Rosuvastatin 10 mg for 1 day (Day 15) and continued Darapladib dosing of 160 mg QD for additional 3 days (Days 16 to 18) in treatment period 2.
10029578|NCT01751074|Experimental|Part B|The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A. Part B will consist of a cohort of healthy subjects of Far-East Asian descent and will be conducted similar to Part A.
9467451|NCT03656770|Experimental|V8: Depression|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic major depressive disorder."
9467452|NCT03656770|Experimental|V9: Depression + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with complete response."
9467453|NCT03656770|Experimental|V10: Depression + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with partial relapse."
9467454|NCT03656731|Experimental|Intervention group (n=50)|Patients in the intervention group will receive standard care and a 12-week exercise-based intervention.
10029579|NCT01751100|Active Comparator|HIV Test Offer|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
9467455|NCT03656731|No Intervention|Control group (n=50)|Patient in the control group will receive standard care.
9467456|NCT03656679|Active Comparator|Pectoralis Blockade(PECs)|Participants undergo pectoralis nerve block (PEC II) will received anesthesia between the pectoralis major and minor in the chest while lying flat.
9803044|NCT04634149|Experimental|Group A: Moderate Hepatic Impairment|
10029580|NCT01751100|Experimental|General Health Screen Offer|In Group 2 (Intervention), a free general health screening is offered that may include a blood pressure check, blood glucose measurement, a Hepatitis C (HCV) test, and an HIV test.
10029581|NCT01751191||Training set-chronic response to propranolol|
10029582|NCT01751191||Validation set-chronic response to propranolol|
10029583|NCT01751191||Acute response to propranolol|
10029584|NCT01751204|Active Comparator|Calcium tablet|250 mg calcium/tablet
10029585|NCT01751204|Experimental|Calcium ion water (250mg)|250 mg calcium in 200 ml water
10029586|NCT01751204|Experimental|Calcium ion water (125mg)|125 mg calcium in 200 ml water
10029587|NCT01751217|Experimental|Funct Family Tx/Video Teleconf (FFT-V)|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Adolescents and parents assigned to the FFT-V condition will receive a Verizon netbook laptop computer equipped with the Microsoft Windows 7 operating system, webcam, and VTC software for use in the family home. The VTC software is designed to stream live video between therapists and participants, to record video, and to store recorded videos as digital mpeg files. All family sessions will take place via video teleconference.
10036898|NCT01820026|Active Comparator|Cefotaxime & Amoxicillin & Azithromycin|Cefotaxime IV(2g/12 h): for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of specific site of infection Amoxicillin/clavulanic acid (2,2 g/8 h)or Ciprofloxacin (500 mg/12 h: urinary tract infections Amoxicillin/clavulanic acid (2,2 g/8 h)and azithromycin (500 mg/24 h): pneumonia Amoxicillin/clavulanic acid (2,2 g/8 h)for skin or soft tissue infection
9467457|NCT03656679|Active Comparator|Paravertebral Blockade (PVB)|Participants undergoing paravertebral nerve block (PVB) consisting of receiving anesthesia in the back while sitting upright.
9480066|NCT03537313|Experimental|Vaginal douching group|Preoperative vaginal douches with povidone-iodine solution
9480067|NCT03537313|Experimental|Vaginal painting group|Intra-operative vaginal painting with povidone-iodine solution
9480068|NCT03537300|Experimental|experimental group|
9803045|NCT04634149|Experimental|Group B: Severe Hepatic Impairment|
10029588|NCT01751217|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Families in the FFT condition will not be provided with the laptop and internet access described above. Instead, adolescents and parents in this condition will receive the FFT intervention face-to-face from an FFT therapist who will travel to the family home for each session.
10029589|NCT01751217|Active Comparator|Services as Usual|The main CYFD service provider for adjudicated youth in both Sandoval and Valencia counties is Youth Development Incorporated (YDI) which is a private not-for-profit youth service organization serving adolescents in New Mexico . YDI provides an array of services for youth including tutoring, after-school activities, gang intervention, school drop-out prevention, family counseling services, an emergency teen shelter, parenting skills training, youth leadership development, community corrections services, GED studies, substance abuse and AIDS education, etc. The YDI juvenile corrections services include intensive supervision, educational and employment assistance, community service, victim restitution, and institutional transition services.
10029590|NCT01751243|Placebo Comparator|Group 0|Haploidentical transplantation of hematopoietic progenitors
10029591|NCT01751243|Experimental|Group 1|Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg
10029592|NCT01751243|Experimental|Group 2|Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg
10029593|NCT01751243|Experimental|Group 3|Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg
10029594|NCT01751243|Experimental|Group 4|Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg
10029595|NCT01751243|Experimental|Group 5|Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg
10029596|NCT01751256|Experimental|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
9467458|NCT03656666|Active Comparator|Apremilast|"Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.~Initial titration:~Day 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily."
9467459|NCT03656666|Placebo Comparator|Placebo + Apremilast|Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.
9467460|NCT03656653|Experimental|Future-based recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future without cocaine use
10029597|NCT01751256|No Intervention|Control|Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
10029598|NCT01751269|Experimental|Ascending Single and Multiple dose of RPX7009|Ascending Single and Multiple dose of RPX7009
10029599|NCT01751269|Placebo Comparator|Normal Saline|Ascending Single and multiple dose of normal saline.
9467461|NCT03656653|Experimental|Future-based cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future where cocaine is causing significant distress
9467462|NCT03656653|Experimental|Past recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event without cocaine use
9467463|NCT03656653|Experimental|Past cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event where cocaine use has caused significant distress
9467464|NCT03656640||Patients Receiving Gammanorm®|Patients Receiving Gammanorm®
9467465|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 1|"Arms determined by autoimmune type. First cohort consists of patients with:~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
10029600|NCT01751282|Placebo Comparator|Standard therapy and control saline spray|Conventional standard therapy and control saline spray
10029601|NCT01751282|Sham Comparator|standard therapy and fibrin spray|Conventional standard therapy and fibrin spray
10029602|NCT01751282|Experimental|Conventional standard therapy and MSCs|Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
10029603|NCT01751295|Active Comparator|atorvastatin|PCI with atorvastatin pre-treatment group
10029604|NCT01751295|No Intervention|control|PCI without atorvastatin pre-treatment group
10029605|NCT01751321|Other|sitagliptin, metformin, placebo|"group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day~group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day"
10029606|NCT01751334|Experimental|Mobile Bearing|Mobile bearing total knee arthroplasty
9803046|NCT04634149|Experimental|Group C: Normal Hepatic Function|
10029607|NCT01751334|Active Comparator|Fixed Bearing|Fixed Bearing total knee arthroplasty
10029608|NCT01751347|Active Comparator|Lidocaine|Subjects randomized to this treatment arm will receive lidocaine during their elective hand surgery.
10029609|NCT01751347|Experimental|Bupivacaine|Subjects randomized to this treatment arm will receive bupivacaine during their elective hand surgery.
9467466|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 2|"Arms determined by autoimmune type. Second cohort consists of patients with:~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
9467467|NCT03656614||sugammadex 0.125|Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
9480069|NCT03537300|Active Comparator|control group|
9467468|NCT03656614||Sugammadex 0.25|Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
10029610|NCT01751360|Experimental|SYR-472 100mg|SYR-472 100mg
10029611|NCT01751373|Active Comparator|Standard Therapy|Coupling focal BoNT-A injections with a therapy program comprising of functional tasks.
10029612|NCT01751373|Experimental|Optimal Muscle Activation Therapy|Coupling focal BoNT-A injections with a motor training program that focuses on developing and maintaining activation patterns in the muscle treated with BoNT-A.
10029613|NCT01751425|Experimental|Treatment (TKIs, ruxolitinib)|Participants receive commercially available TKIs (imatinib mesylate, nilotinib, or dasatinib) as they had been receiving during the last 6 months and ruxolitinib PO BID. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
9467469|NCT03656614||Sugammadex 0.5|Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
9467470|NCT03656614||Sugammadex 1.0|Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
9467471|NCT03656614||Sugammadex 2.0|Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
9467472|NCT03656614||Neostigmine 10|Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
9467473|NCT03656614||Neostigmine 25|Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
9467474|NCT03656614||Neostigmine 40|Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
9467475|NCT03656614||Neostigmine 55|Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
9467476|NCT03656614||Neostigmine 70|Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
9467477|NCT03656614||Placebo|Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3
9467478|NCT03656601||Vaginal delivery|Women that had only vaginal delivery
9467479|NCT03656601||Cesarean-section|Women that had only cesarean-section
9467480|NCT03656601||Nulliparous|Women without delivery
9467481|NCT03656588|Active Comparator|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by|
9467482|NCT03656588|Active Comparator|b. Iodine scrub and ChloraPrep alone|
9467483|NCT03656575|Active Comparator|intra-articular alpha-2-macroglobulin|intra-articular injection of 1 mL of the 40 mg/ml strength (1 vial)
9467484|NCT03656575|Active Comparator|intra-articular Platelet-rich Plasma (PRP) injection|Standard of care PRP treatment
9467485|NCT03656575|Active Comparator|Intra-articular corticosteroid|Standard of Care steroid treatment
9467486|NCT03656549|Experimental|Impaired renal function|patients will be treated with pemetrexed, with dosing based on renal function.
9480070|NCT03537287|Active Comparator|17 alpha hydroxyprogestrone caproate Group|Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.
9480071|NCT03537287|Active Comparator|Vaginal progesterone Group|Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.
9480072|NCT03537287|Active Comparator|Oral dydrogesterone Group|Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks
10029614|NCT01751438|Experimental|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST). Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
10029615|NCT01751438|Experimental|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy (BST) in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice. Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
10029616|NCT01751464|Experimental|WrapAround Care|
10029617|NCT01751477||Probiotics (Infloran)|Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life
10029618|NCT01751477||Control|Very low birth weight Infants who did not receive Infloran (historical cohort)
10029619|NCT01751490|Active Comparator|physiotherapy alone|patients undergoing physiotherapy only
10029620|NCT01751490|Active Comparator|surgery and physiotherpay|patients receiving surgical treatment followed by physiotherapy
10036899|NCT01820039|Experimental|FertiScreen|all patients between 18 and 38 years, consulting their general practitioner for infertility will be asked to use FertiScreen.
10036900|NCT01820052|Active Comparator|Oral Iron|Patient will receive 230 mg of oral elemental iron daily for 3 months
9480073|NCT03537248|Experimental|Asepticys investigational ASP-57 Multi-Purpose Solution|ASP-57 Multi-Purpose contact lens care solution used as a rub care regimen (Test)
9480074|NCT03537248|Active Comparator|ReNu® Multiplus Contact Lens Solution|ReNu® Multiplus Contact Lens Solution used as rub care regimen (Control)
9480075|NCT03537235|Experimental|Libramed|3 tablets of Libramed 2 twice a day 15 minutes before meals for 3 months.
9480076|NCT03537235|Placebo Comparator|Placebo|3 tablets of Placebo 2 twice a day 15 minutes before meals for 3 months.
9480077|NCT03537196|Other|All patients|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
9480078|NCT03537196|Other|HIV/HCV co-infected patients|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day (sofosbuvir 400 mg and daclatasvir 90 mg)
9480079|NCT03537196|Other|Cirrhosis|In case of cirrhosis : ribavirin will be added to sofosbuvir / daclatasvir 12 weeks
9480080|NCT03537196|Other|Cirrhosis with ribavirin contra-indication|In case of cirrhosis with ribavirin contra-indication : sofosbuvir and daclatasvir for 24 weeks
9480081|NCT03537157|Experimental|Rifaximin delayed release tablets|Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
9480082|NCT03537157|Placebo Comparator|Placebo|Two placebo tablets twice a day for 26 weeks
9480083|NCT03537144|Active Comparator|Indomethacin|Indomethacin as drug to treat PDA.
9480084|NCT03537144|Experimental|Acetaminophen|Acetaminophen as drug to treat PDA.
10036901|NCT01820052|Placebo Comparator|Oral Placebo|Oral Placebo tablets will be administered daily for 3 months
9467487|NCT03656523||Acute Coronary Syndrome|Patients with Aute coronary syndrome trated with Percutaneous Coronary Intervention plus Stent implantation and Atrial Fibrillation
9467488|NCT03656484|Active Comparator|Tetracycline-Metronidazole (TM) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.
9467489|NCT03656484|Experimental|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.
9467490|NCT03656471||Clear aligner group|Patients receiving clear aligner treatments for their malocclusions
9467491|NCT03656471||Fixed appliance group|Patients receiving fixed appliance treatments for their malocclusions
9467492|NCT03656458|Active Comparator|Control Group A|Warm Up followed by Conventional Balance Training (Internal and External Perturbations)
9467493|NCT03656458|No Intervention|Control Group B|Control group. No intervention given to participants.
9467494|NCT03656458|Experimental|Experimental Group|Warm Up followed by Biodex Balance Training
9467495|NCT03656445|Active Comparator|Group A - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
9467496|NCT03656445|Active Comparator|Group B - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
9467497|NCT03656445|Active Comparator|Group C - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively
9467498|NCT03656432|Experimental|CPP-ACP paste|MI Paste represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
9467499|NCT03656432|Experimental|CPP-ACP containing fluoride|MI paste plus contains fluoride 0.2% (900 ppm) that is very similar to the amount of fluoride in the toothpaste binds to the tooth surfaces and plaque and provides biocompatible calcium, phosphate and fluoride in a localized way. So, it provides all the ions needed to build fluorapatite crystals that are more resistant to the acid attack compared to hydroxyapatite
9467500|NCT03656432|Active Comparator|toothpaste contains fluoride|Fluoridated Toothpaste are the most significant and worldwide spread forms of caries control used globally as the greater acceptability of toothpaste makes its regular use more likely, thereby improving effectiveness
9467501|NCT03656419|Experimental|aPDT group|For photodynamic therapy will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² .One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points, considering the scattering halo and the effectiveness of aPDT. The LED apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
9467502|NCT03656419|Active Comparator|Tongue Scraper|Tongue scraper 10 times in the tongue, from the back to the front.
9467503|NCT03656419|Experimental|aPDT and tongue scraper|Tongue scraper 10 times in the tongue, from the back to the front. For aPDT will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² . One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points. Based on previous studies carried out with the aPDT for the treatment of halitosis the apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
9467504|NCT03656393|Experimental|Gefitinib therapy group|Patients are treated with Gefitinib (250 mg, orally, every day) for 56 days and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
9467505|NCT03656393|Active Comparator|Vinorelbine combination therapy group|Patients are treated with vinorelbine (60 mg/m2, orally, Once every three weeks) plus carboplatin (AUC5, intravenously drip, once a week) for 6 weeks and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
9467506|NCT03656341|Experimental|2 Feet 4 Life|Intervention group will receive one hour intervention weekly for four consecutive weeks. Outcomes will be measured at baseline (before the intervention), immediately after the intervention (1 month), three months post-intervention, and six months post-intervention
9467507|NCT03656341|No Intervention|True control group|Will complete the same four assessment visits as the intervention group.
9467508|NCT03656341|No Intervention|Bias control group|Will complete outcome assessments at baseline and the final assessment.
9467509|NCT03656328|Experimental|Lactobacillus Reuteri 4659|This Arm received standard antibiotic therapy, consisting of ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for seven days, with supplementation with the probiotic L. reuteri 4659 twice a day for 10 days
9467510|NCT03656328|Placebo Comparator|Placebo|This arm received the same standard antibiotic therapy and a matching placebo for the same periods.
9467511|NCT03656315|Other|Airway assessment|All patients recruited will be entered into this arm of the study. Airway assessment including Ultrasound scan will be performed
10036902|NCT01820065||Patients undergoing phacoemulsification|Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)
10036903|NCT01820078|Experimental|Paricalcitol, Daily treatment, CKD|Experimental Arm
10036904|NCT01820078|Other|Daily treatment for CKD|Comparator Arm
10029621|NCT01751503|Active Comparator|Interosseous route of TPTT|The investigators will have two groups of patients, one who had their tendon transfer using the extra membranous route and other group which had their tendon transfer through the interosseous route. Patients will be randomized to either groups before the surgery and both the patients and the assessors will be blinded to the technique used. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors.
9467512|NCT03656302||Case offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having at least one biological parent with a lifetime or current diagnosis of bipolar disorder; 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder; 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
9467513|NCT03656302||Control offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having no biological parent(s) with lifetime or current diagnosis of mood disorders. 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form.~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder. 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
9467514|NCT03656289|Experimental|Etonogestrel Contraceptive|Etonogestrel contraceptive implant; consists of a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. The implant must be removed no later than by the end of the third year.
9467515|NCT03656276||Group A: Oncologists (wait list control)|Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
9467516|NCT03656276||Group B: Oncologists (training)|Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
9467517|NCT03656263||High risk cardiac surgery patients|"Defined as either:~Multiple surgical procedures planned and/or,~EuroSCORE ≥ 5% and/or,~Known pulmonary hypertension (mPAP>25 mmHg or sPAP > 40 mmHg)"
9467518|NCT03656250||Chemo Patients with Nasopharyngeal cancer|The standard chemoradiation treatment (total 7000 cGy in 35 fractions at 200 cGy/fraction) for 7 weeks with 3 cycles of chemo followed by 3-month chemotherapy.
9467519|NCT03656237|Experimental|Usual training + Audits + LDHF training|"Usual training of health workers, in classroom, following standard curriculum~+ Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits"
9467520|NCT03656237|Experimental|Audits + LDHF training|Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits
9467521|NCT03656237|Active Comparator|Usual Training|Control Arm exposed to usual training of health workers, in classroom, following standard curriculum
9467522|NCT03656224||Observational (survey)|Participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.
9467523|NCT03656211||Patients with UAVM|"All patients who have been diagnosed with UAVM (symptomatic or non-symptomatic) between January 1, 2000 and March 30, 2017, and confirmed by an imaging examination.~Telephone interview"
9467524|NCT03656198|Experimental|Vaccine group|Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.
9467525|NCT03656198|Placebo Comparator|Control group|The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).
9467526|NCT03656172||Haemoglobin measure|Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
9467527|NCT03656146|Active Comparator|Tablet Screening|Food insecurity screening conducted via electronic tablet
9467528|NCT03656146|Active Comparator|Verbal Screening|Food insecurity screening conducted via verbal face-to-face interview
9467529|NCT03656120|Experimental|0.2mg group|Participants are taking 0.2mg thienorphine hydrochloride table once a day for 12 weeks.
9467530|NCT03656120|Experimental|0.5mg group|Participants are taking 0.5mg thienorphine hydrochloride table once a day for 12 weeks.
9467531|NCT03656120|Placebo Comparator|placebo control group|Participants only taking placebo once a day for 12 weeks.
9467532|NCT03656107|Experimental|Cognitive training|Participants selected to brain training will be given instructions on how to access and use the program at home for 15-30minutes, 3-5 times per week for 8-12 weeks.
9467533|NCT03656107|No Intervention|Waiting-list control|Control participants will be waiting listed to receive the brain training program at the end of the study. control participants will undergo usual care.
9467534|NCT03656094|Experimental|Pembrolizumab plus chemotherapy|Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
9467535|NCT03656094|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
9467536|NCT03656042|Experimental|G-CSF|Subjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
9467537|NCT03656042|No Intervention|No-treatment|No-treatment group is used to control evaluation bias and potential time effect.
9467538|NCT03656029|Placebo Comparator|Placebo|Participants will smoke a single smoked placebo (<0.1% THC) cannabis cigarette
9467539|NCT03656029|Active Comparator|low dose|Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
9467540|NCT03656029|Active Comparator|middle dose|Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
10029622|NCT01751503|Active Comparator|Extra membranous route of TPTT|Extramembranous or circumtibial route of Tibialis Posterior tendon transfer.Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
9467541|NCT03656029|Active Comparator|high dose|Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette
9467542|NCT03656016||study group|patients with congenital and acquired disorders that can alter the CSF dynamics will undergo phase-contrast magnetic resonance imaging
9467543|NCT03656016||control group|age matched healthy individuals will undergo phase-contrast magnetic resonance imaging
9467544|NCT03656003|Experimental|Procore needle|EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
9467545|NCT03656003|Active Comparator|Conventional needle|Conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
9467546|NCT03655977|Experimental|Cervical cancer patients|This pilot study includes 25 women with histologically proven advanced stage primary cervical cancer (FIGO stages ≥IB2-IVA), planned for treatment with radio-chemotherapy.
9467547|NCT03655964|Experimental|Olmesartan|20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)
9467548|NCT03655964|Experimental|Nebivolol|20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)
9467549|NCT03655964|Experimental|No antihypertensive treatment|20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke
9467550|NCT03655925||Patients with Chronic Heart Failure (CHF)|Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction <40
10029623|NCT01751529|Experimental|Contrast-enhanced Ultrasound|
10029624|NCT01751542|Experimental|Mindfulness + residential treatment|Mindfulness and Acceptance Group Therapy + residential treatment
10029625|NCT01751542|Active Comparator|Residential Treatment|Residential treatment alone
10029626|NCT01751555|Experimental|TDF/3TC/EFV Treatment HIV/HBV Co-infection|TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection
10029627|NCT01751581|Active Comparator|Habitual Sleep|Women sleep 8 h/night throughout the study phase
10029628|NCT01751581|Experimental|Short Sleep|Women sleep 4 h/night throughout the study phase
10029629|NCT01751594|Active Comparator|H4L Comparison Intervention|
10029630|NCT01751594|Experimental|MOVE Intervention|
10029631|NCT01751607||genetic variants|AFib patients with or without the genetic variants
10029632|NCT01751620|Experimental|Project ACCEPT|Participants randomized to the intervention (Project ACCEPT) arm.
10029633|NCT01751620|Active Comparator|HEALTH|Participants randomized to the comparison (HEALTH) arm.
10029634|NCT01751633||Surgical treatment|"Surgical treatment according to one of the following:~Posterior open approach~Posterior minimally-invasive surgery (MIS) approach The choice of the approach will be left upon the surgeon's discretion"
10029635|NCT01751633||Conservative treatment|Conservative treatment according to hospital's standard of care
10029636|NCT01751659||Phase I|"Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians.~The total duration of Phase 1 is expected to last approximately nine months, including data analysis."
10029637|NCT01751659||Phase II|"Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1).~The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey."
10029638|NCT01751659||Phase III|"Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians.~The total duration of Phase 3 will last approximately six to nine months."
10029639|NCT01751672|Active Comparator|SBIRT|Screening, Brief Intervention, and Referral to Treatment
10029640|NCT01751672|Experimental|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment
10029641|NCT01751685|Experimental|Kyphosis-specific spinal exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
10029642|NCT01751685|Placebo Comparator|Control|Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
10029643|NCT01751698|Active Comparator|JASP-EMT|JASP-EMT (Joint Attention, Symbolic Play and Enhanced Milieu Teaching) focuses on creating a context for joint engagement within naturally occurring child-led play routines. There is evidence of the effects of these interventions with children with ASD, and pilot data showing effects with minimally verbal children.
9467551|NCT03655912|Active Comparator|Patch|Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
9467552|NCT03655912|Experimental|Electronic Devices|Eye patch on the fellow eye and a electronic tablet
9467553|NCT03655912|Experimental|Red/Green Glasses|Red/green glasses and a electronic tablet
9467554|NCT03655886|Experimental|Radical prostatectomy|
9467555|NCT03655886|Experimental|Radiotherapy|
9467556|NCT03655873|Experimental|HEC30654AcOH capsule|"single ascending-dose study: Including 7 dose groups(5-、10、15-、30-、60-、90-、120mg)，Day1 ante meridiem(AM) 8:00 (±1h) with 240ml warm water to taking the experiment drug，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 Post Meridiem(PM) (±1h), with 240ml warm water to take the experiment drug On an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the experiment drug，On an empty stomach."
9480085|NCT03537131|Active Comparator|arm B1- Dapagliflozin once only dose|Participants who will take one tablet of Dapagliflozin 10 mg on the day of the exercise challenge.
10029644|NCT01751698|Active Comparator|DTT|CORE-DTT (discrete trial training for core features of ASD) emphasizes didactic adult-led instruction and is considered the current evidenced-based 'standard of care' for children with autism (NRC, 2001).
10029645|NCT01751737|Experimental|Prostate Cancer Imaging|"Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.~In addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.~Patients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
10029646|NCT01751750|Other|Grape|
10029647|NCT01751763||Group 1|
10029648|NCT01751776|Experimental|BI 655064 Part 1|3 different doses plus placebo in healthy volunteers
10029649|NCT01751776|Experimental|BI 655064 Part 2|2 different doses plus placebo in rheumatoid arthritis patients
10029650|NCT01751789|Active Comparator|Linkage|Participants will receive Suboxone during their inpatient detoxication and be given outpatient appointments to continue Suboxone treatment after completing inpatient detoxification
9467557|NCT03655873|Placebo Comparator|placebo capsule|"single ascending-dose study: Including 6 dose groups(10、15-、30-、60-、90-、120mg)，Day1 morning 8:00 (±1h) with 240ml warm water to taking the placebo capsule，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 PM (±1h), with 240ml warm water to take the placebo capsule on an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the placebo capsule，on an empty stomach."
10029651|NCT01751789|Placebo Comparator|Detoxification|Participants will receive Suboxone to detoxify from opioids and the standard treatment offered by the inpatient detoxification program
10029652|NCT01751815|Experimental|Acu-TENS|
10029653|NCT01751815|Sham Comparator|Placebo-TENS|
10029654|NCT01751828|Experimental|Sertraline|Open-label sertraline, 8 week trial, dosing from 50mg to 200mg daily.
10029655|NCT01751854|Experimental|SSRI|SSRI alone or with training
10029656|NCT01751854|Placebo Comparator|Placebo|Placebo alone or with training
10029657|NCT01751880|Experimental|Exercise Group|
10029658|NCT01751893|Experimental|Henna arm|Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
10029659|NCT01751893|Placebo Comparator|Placebo|Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hours and then the mixture will be rinsed with fresh water.
10029660|NCT01751919|Other|Group 1 (RT)|"Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)~Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
10029661|NCT01751919|Other|Group 2 (TR)|"Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)~Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
9467558|NCT03655860|Experimental|SIMEOX|
9467559|NCT03655847|Experimental|Dexmedetomidine|Drug: Dexmedetomidine dexmedetomidine, 0.1ug/kg up or down Other Name: precedex
9467560|NCT03655834|Experimental|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
9467561|NCT03655821|Active Comparator|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
9467562|NCT03655821|Experimental|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
9467563|NCT03655808|Experimental|BBCs transplantation|Autologous Bronchial basal cells transplantation
9467564|NCT03655795|Experimental|Bronchial basal cells|Autologous transplantation of bronchial basal cells
9467565|NCT03655756|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:~Noncellular, Therapeutic Cancer Vaccine > Immunomodulator~Route of Administration:~Intratumoral injection of cutaneous, subcutaneous or nodal lesions~Mechanism of Action:~Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.~Physiological Effect:~This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
10029662|NCT01751932|Experimental|CGM Monitoring|Fitting of Dexcom G4 Platinum CGM monitor and Medtronic Enlite CGM monitor
10029663|NCT01751945|Experimental|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
10029664|NCT01751945|No Intervention|Standard of care|Standard care as per national policy
10029665|NCT01751958|Experimental|Epidural Steroid injection|Group-Epidural Steroid injection (Intermittent)
10029666|NCT01751958|Experimental|Epidural Steroid Injection2|Group-injection under angiography (continuous)
10029667|NCT01751997|Active Comparator|Transplants from 8/8-matched unrelated|Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
9467566|NCT03655730|Experimental|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
10029668|NCT01751997|Experimental|Transplants from family-mismatched/haploidentical donors|Participants will receive FMT using a reduced intensity conditioning regimens.
9467567|NCT03655730|Experimental|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
9467568|NCT03655717|Experimental|Placebo Dronabinol + Ethanol|single dose of Placebo Dronabinol + Ethanol See protocol for dosing
9467569|NCT03655717|Experimental|Dronabinol + Placebo Ethanol|single dose of Dronabinol + Placebo Ethanol See protocol for dosing
9467570|NCT03655717|Experimental|Dronabinol + Ethanol|single dose of Dronabinol + Ethanol See protocol for dosing
9467571|NCT03655717|Placebo Comparator|Placebo Dronabinol + Placebo Ethanol|single dose of Placebo Dronabinol + Placebo Ethanol See protocol for dosing
9467572|NCT03655665|Experimental|Treatment Ear|Participants will serve their own control. Participants will receive 3 drops of ofloxacin otic solution intra- and post-operatively 3 times per day for 3 days in ONE ear. Ear sidedness will be randomized by participant.
10029669|NCT01752010|Active Comparator|Acupuncture Treatment|Traditional Chinese acupuncture.
10029670|NCT01752010|Active Comparator|Tennant™ Biomodulator Treatment|
10029671|NCT01752010|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) Treatment|
10029672|NCT01752075||REVLIMID|Taiwanese patients treated with REVLIMID
10036905|NCT01820091|Experimental|Cohort 1 - Fusilev - 20 doses|"5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle~Days 2 and 16: 4 doses/day~Days 3 and 17: 4 doses/day~Days 4 and 18: 2 doses/day~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
10036906|NCT01820091|Experimental|Cohort 2 - Fusilev - 12 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
10036907|NCT01820091|Experimental|Cohort 3 - Fusilev - 8 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
10036908|NCT01820091|Experimental|Cohort 4 - Fusilev - 4 doses|"5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
10036909|NCT01820091|Experimental|Cohort 5 - Fusilev - 2 doses|"5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
10036910|NCT01820104|Placebo Comparator|Placebo|oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
10036911|NCT01820104|Experimental|Combination of lansoprazole and sitagliptin|oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
10036912|NCT01820117||Hodgkin lymphoma|"Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
10036913|NCT01820117||Normal control|"A group of healthy individuals matched for age, sex and race.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
10036914|NCT01820130|Experimental|Spinal Cord Stimulation system therapy|St Jude Medical EON mini rechargeable system
10036915|NCT01820143|Experimental|Treatment sequence ADBC|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
10036916|NCT01820143|Experimental|Treatment sequence BACD|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
10036917|NCT01820143|Experimental|Treatment sequence CBDA|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
10036918|NCT01820143|Experimental|Treatment sequence DCAB|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
9467573|NCT03655665|No Intervention|No Intervention|Participants will serve their own control. Participants will receive no intervention in the ear contralateral to the treated ear. Ear sidedness will be randomized by participant.
9467574|NCT03655639||Premature Birth|Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
9467575|NCT03655626|Experimental|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
9467576|NCT03655613|Experimental|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
10036919|NCT01820156|Experimental|HRP-PSG|First performance three nights of HRP and following one night of laboratory PSG
9467577|NCT03655613|Experimental|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
9467578|NCT03655600|Active Comparator|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
9467579|NCT03655600|No Intervention|Usual care|Usual care
9467580|NCT03655587|Experimental|Solid ankle foot orthotic|This is a leg brace that is made to fit the contour of the patient's foot, ankle, and lower leg. The two pull solid ankle AFO is fabricated from a rigid polypropylene outer boot and a more flexible silicone inner boot. It is commonly used in rehabilitation to improve gait in pediatric and adult populations. A certified orthotist fabricates the device. This device is lawfully marketed in the United States. It is not regulated by the FDA.
10029673|NCT01752127|Active Comparator|DM arms|comparison of two different stents(Xience prime and Resolute integrity)
10029674|NCT01752127|Active Comparator|Small vessel arms|comparison of two different stents(Xience prime and Resolute integrity)
10029675|NCT01752140|Active Comparator|10-core prostate biopsy protocol group|Ultrasound guided prostate biopsy with extraction of 10 cores
10029676|NCT01752140|Active Comparator|Vienna nomogram prostate biopsy protocol group|Ultrasound guided prostate biopsy performed according to the Vienna nomogram
10029677|NCT01752153|Experimental|Silymarin (Legalon)|Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
10029678|NCT01752153|Experimental|Combined therapy (Deaferrioxamine+Silymarin (Legalon)|In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
10029679|NCT01752166||Blood culture|Subjects have had a blood culture ordered, per routine standard of care
10029680|NCT01752179|Experimental|kinesio tape|kinesio Tape : Width 5cm ,Length 35cm Y shape
9467581|NCT03655587|Active Comparator|Resting night splint|An ankle resting night spring (RNS) is an off-the-shelf device that provides static sagittal plane dorsiflexion. The RNS is worn nocturnally to provide maximal stretch/length to the gastrocsoleus to maintain or increase dorsiflexion ROM and/or to prevent further regressions in ankle range. It is not regulated by the FDA.
9467582|NCT03655574|Experimental|Motivational + Family Check-up (MET+FCU)|"The MET individual session covers three constructs; 1) intentions to use marijuana; 2) normative beliefs about peer substance use; and 3) attitudes towards peer substance use. These same three constructs are also addressed with respect to truancy. In addition, motivation to abstain from substance use is discussed.~The FCU session with teens and parents/caregivers begins by collecting self-report measures and conducting a videotaped Family Assessment Task (FAsTask) to assess parent-teen interactions. The FAsTask is the basis of FCU feedback. There are four specific phases of the feedback session: 1) Self-assessment, 2) Support and clarification, 3) Feedback, and, 4) Action plan."
9467583|NCT03655574|Placebo Comparator|Psychoeducation|An interventionist will review a set of educational materials with the parents regarding teen marijuana use, effects of marijuana on the brain, body and behavior, risks associated with marijuana use, how to tell if a teen is engaging in marijuana use or truancy, and parenting skills. A comparable set of materials will be reviewed with the adolescent.
9467584|NCT03655535|Experimental|BTI320|4 g BTI320 administered 10 min before breakfast, lunch, and dinner
9467585|NCT03655535|Placebo Comparator|Placebo|Placebo administered 10 min before breakfast, lunch, and dinner
9467586|NCT03655522|Active Comparator|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
9467587|NCT03655522|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
9467588|NCT03655509|Other|ACTH stimulation test|
9467589|NCT03655496|No Intervention|Control group|Subject to standard care.
9467590|NCT03655496|Experimental|Intervention group|Exposed to the home-based tool.
9467591|NCT03655483|Experimental|GLS-010|GLS-010
9467592|NCT03655470|Experimental|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
9467593|NCT03655470|Active Comparator|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
9467594|NCT03655457|Experimental|group 1 Poractant alfa|Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours
10029681|NCT01752179|No Intervention|Control group|without using Kinesio tape
10029682|NCT01752192|Experimental|Telerehabilitation programme|Telerehabilitation programme: Each patient will use a telehealth monitor and measure blood pressure, pulse and weight once or twice a week over a 3 months periods with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital step-counter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with healthcare professionals. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound. The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
10029683|NCT01752192|No Intervention|Control group traditional rehabilitation|The control group of heart patients follow traditional rehabilitation activities for a period of 3 months.The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
10029684|NCT01752205|Active Comparator|Chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ，dosing schedule: 45mg/m2/w.
10029685|NCT01752205|Experimental|Erlotinib and chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.
10029686|NCT01752218|Experimental|Arcuate Incision|Study arm will consist of patients who show cataract and corneal astigmatism.
9467595|NCT03655457|Active Comparator|group 2 beractant|beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours
9467596|NCT03655431|Experimental|Telerehabilitation|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment. The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package. Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
9467597|NCT03655418|Experimental|Intervention|The prevention program RECUR will be administered.
9467598|NCT03655418|No Intervention|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
9467599|NCT03655392|Experimental|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 monthly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
9467600|NCT03655392|Experimental|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 montly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
9467601|NCT03655379|Experimental|Nasal Doppler|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns
9467602|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
9467603|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
9467604|NCT03655353|Experimental|ABY-PET|68Ga-ABY-025 is used as tracer for PET scan
9467605|NCT03655327||stroke patients|stroke patients with upper limb paresis
9467606|NCT03655327||healthy control group|healthy participants with no motor disability of the upper limb
9467607|NCT03655314|Active Comparator|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
10029687|NCT01752231||DCE-MRI (dynamic contrast-enhanced MRI)|Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
9467608|NCT03655314|Placebo Comparator|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
9467609|NCT03655275|Active Comparator|Group(A): PRP|PRP prolotherapy injections with 2.5ml of PRP at an interval of 2 weeks. Intraticular and pericapsular
9467610|NCT03655275|Active Comparator|Group (B): saline|Saline prolotherapy injections with 2.5ml of saline at an interval of 2 weeks.intrarticular and pericapsular
9467611|NCT03655249|Experimental|Asl + CPT|Aerosotherapy + Autogenic drainage
9467612|NCT03655249|Active Comparator|Asl|Aerosoltherapy alone
9467613|NCT03655210|Experimental|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
10029688|NCT01752244|Experimental|Alfacalcidol|Alfacalcidol
10029689|NCT01752244|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram: were given to the intervention group once a day for 8 weeks
10029690|NCT01752257|Other|EF5 Hypoxia|EF5 administered at 21mg/kg
10029691|NCT01752270|Experimental|diane-35|Diane-35 pretreatment from the third day of menstrual cycle
10029692|NCT01752270|No Intervention|blank control|
10029693|NCT01752283|Experimental|Hypnosis and local anesthesia|video-assisted thyroidectomy under hypnosis and local anesthesia.
10029694|NCT01752283|Active Comparator|General anesthesia|Video-assisted thyroidectomy under general anesthesia
10029695|NCT01752309||Rheumatoid Arthritis, ultrasound, persistence disease activity|Patients diagnosed with early Rheumatoid Arthritis will be assessed three times in one year with ultrasound to evaluate the predictive value of ultrasound.
10029696|NCT01752322|Experimental|Lidocaine plaster|Topical hydrogel plaster
10029697|NCT01752322|Placebo Comparator|Placebo plaster|Topical hydrogel plaster
10029698|NCT01752335|Other|tocilizumab|"All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.~Usually 8mg/kg (not minor than 480 mg), once each 4 weeks."
10029699|NCT01752348|Placebo Comparator|Placebo (isotonic saline)|Endotoxin + isotonic saline. Reference for model of acute inflammatory illness
10029700|NCT01752348|Experimental|Acipimox + Placebo (isotonic saline)|Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.
10029701|NCT01752348|Experimental|Acipimox + free fatty acids|Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids
10029702|NCT01752348|Experimental|Acipimox + 3-hydroxybutyrate|Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate
10029703|NCT01752361||Ulcerative Colitis|
10029704|NCT01752374||Palonosetron group|Patient recieving Palonosetron/granisetron and ramosetron
10029705|NCT01752374||Granisetron group|
9467614|NCT03655210|Placebo Comparator|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
9467615|NCT03655184||MOH group|Patients with medication overuse headache
9467616|NCT03655184||Episodic migraine group|Patients with episodic migraine
9467617|NCT03655184||Healthy group|No headache or other special medical history
9467618|NCT03655171||H&Y 0|"Age-matched non-disease population, or prodromal Parkinson's patients with no noticeable motor symptoms.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
9467619|NCT03655171||H&Y 1|"Hoehn and Yahr disability stage was 1: Unilateral involvement only usually with minimal or no functional disability.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
9467620|NCT03655171||H&Y 2|"Hoehn and Yahr disability stage was 2: Bilateral or midline involvement without impairment of balance.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
9467621|NCT03655171||H&Y 3|"Hoehn and Yahr disability stage was 3: Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
9467622|NCT03655171||H&Y 4|"Hoehn and Yahr disability stage was 4: Severely disabling disease; still able to walk or stand unassisted.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
10029706|NCT01752374||Ramosetron group|
10029707|NCT01752439|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation
10029708|NCT01752439|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation
10029709|NCT01752439|No Intervention|Control group|
10029710|NCT01752465|Active Comparator|Standard Care|Patients in the standard care group will receive standard clinical care from their attending psychiatrist, including pharmacotherapy and education. Study assessments will be done at baseline, and once a month thereafter at Months 1, 2, 3, and 6.
10029711|NCT01752465|Experimental|Health Coaching|Patients in the Health Coaching group will receive both Health Coaching, and standard care. In addition to routine clinical appointments, patients receiving Health Coaching will attend Health Coaching sessions twice a month during Months 1, 2, and 3, and once a month during Months 4, 5, and 6. Study assessments will be conducted at baseline, and once a month thereafter during Health Coaching sessions at Months 1, 2, 3, and 6.
10029712|NCT01752504|Experimental|Intervention group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members..
10029713|NCT01752517||refractory SCLC|NI group vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days; every 3 weeks; up to the maximum cycles (total:6);
10029714|NCT01752530|Experimental|Computer program C8 + treatment as usual|Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
10029715|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
10029716|NCT01752543|Active Comparator|Conivaptan|10 patients will be randomized to conivaptan treatment
10029717|NCT01752543|Placebo Comparator|Dextrose|10 patients will receive placebo treatment (dextrose)
10029718|NCT01752556|Active Comparator|Hospital diagnosis|diagnosis of Sleep Apnea and therapeutic decision will perform according to polysomnography
9467623|NCT03655158|Experimental|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
10029719|NCT01752556|Experimental|Home diagnosis|diagnosis of Sleep Apnea and therapeutic decision will be perform according to home respiratory polygraphy
10029720|NCT01752569|Experimental|Selumetinib treatment|Phase I is a dose-finding study to discover the maximum tolerated dose of selumetinib in combination with HAART. Phase II will consider the efficacy of selumetinib for treating Kaposi's sarcoma at the recommended phase II dose discovered in phase I.
10029721|NCT01752582|Other|BuMA stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~BuMA stent Arm:About 35 patients will undergoing implantation of BuMA stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
10029722|NCT01752582|Other|EXCEL stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~EXCEL stent Arm:About 35 patients will undergoing implantation of EXCEL stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
10029723|NCT01752595|No Intervention|Standard|Subjects randomized to this group will receive standard, usual care with no intervention.
10036920|NCT01820156|Experimental|PSG-HRP|First perform laboratory PSG and following three nights of HRP
10036921|NCT01820169|Experimental|Single arm|
9467624|NCT03655158|No Intervention|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
9467625|NCT03655145|Experimental|Haploidentical donor stem cell transplantation|The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
9467626|NCT03655145|Active Comparator|HLA 10/10 MUD stem cell transplantation|The stem cell source will be peripheral blood stem cell for HLA-matched unrelated transplantation.Peripheral blood stem cell (PBSC) for HLA-matched unrelated SCT will be mobilized by G-CSF (Neupogen®) administered to the donor from Day-4 to Day-1 subcutaneously (10µg/kg/day) with the minimal target dose of 4.106 CD34+ cells/kg.
9467627|NCT03655132|No Intervention|Waitlist Control Group|Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
10029724|NCT01752595|Active Comparator|Preference Based Music Intervention|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods.
10029725|NCT01752595|Active Comparator|Preference Based Rhythmic Auditory Stimulation Music|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods. Rhythmic Auditory Stimulation (accentuation of beats, frequencies) will be added to the music subliminally.
10029726|NCT01752608|Experimental|eCBT Mood|Electronic cognitive behavioral therapy application running on the iPhone and iPod Touch.
9467628|NCT03655132|Experimental|VACT-CP Group|Veterans randomized to VACT-CP will receive 8 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.
9467629|NCT03655093||Patients with multiple sclerosis|Patients with MS according to the diagnostic criteria of 2010 Validation of AMSQ questionnaire
9467630|NCT03655041|Experimental|Beta-Alanine|6.4 g/day of beta-alanine for 24 weeks
9467631|NCT03655041|Placebo Comparator|Placebo|6.4 g/day of maltodextrin for 24 weeks
9467632|NCT03655002|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2)|Patients receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
9467633|NCT03654989|Experimental|Treprostinil iontophoresis|"Gel of treprostinil 1 mg/mL (target concentration)~Part 1: 1 administration/day, on separate days, with 72h between two doses. Ascending doses are 0.025 mg/mL, 0.05mg/mL, 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.7 mg/mL, and 1 mg/mL. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~Part 2: 1 administration/day at the maximum tolerated dose (MTD) for 10 days; dressing will be changed by a trained nurse every 2 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
9467634|NCT03654989|Placebo Comparator|Remodulin® Placebo iontophoresis|Placebo will be made from the placebo of Remodulin® incorporated into hydrogel (Suprasorb® G). The route and frequency of administration will be the same as for the investigational drug (topical administration by iontophoresis).
9467635|NCT03654989|No Intervention|Standard care|subjects randomized to the standard of care group (no iontophoresis) will only undergo standard blood test at visit 0 or 1, unless tests <1 month before inclusion are available This group is not double blind Standard care consists on debridement and dressings
9467636|NCT03654976|Experimental|Active treatment|Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet
9467637|NCT03654976|Placebo Comparator|Placebo|Subject's ICS or ICS/LABA background medication plus placebo oral tablet
9467638|NCT03654963|No Intervention|Control|Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
9467639|NCT03654963|Experimental|Medication reconciliation|The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking. To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members. The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor. The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
10029727|NCT01752608|No Intervention|Mood Tracker|Mood monitoring application running on the iPhone and iPod Touch
10029728|NCT01752621||acromegaly|patients with acromegaly
10029729|NCT01752621||comparison population|matched background population
10029730|NCT01752647|Experimental|Low dose computed tomography|Patients will have one baseline LDCT scan.
10029731|NCT01752660|Experimental|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
10029732|NCT01752660|Active Comparator|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
10029733|NCT01752673|Experimental|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
10029734|NCT01752673|Active Comparator|Didactic review pulmonary embolism lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
10029735|NCT01752686|Experimental|carboplatin chemotherapy|At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.
10029736|NCT01752686|No Intervention|Observation arm|In this observation arm, patients should be follow up with regular interval without treatment.
10029737|NCT01752699|Experimental|Methadone|in this arm patients will take methadone 5mg.
10029738|NCT01752699|Experimental|Placebo|in this arm patients will take placebo pills.
9467640|NCT03654937|Active Comparator|2h|The participants were asked to report for their vaccination immediately after an intensive bout of training (not later than two hours after). The influenza vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
10029739|NCT01752725|Experimental|BiCision Arm|Coagulation with BiCision
9467641|NCT03654937|Active Comparator|26h|The athletes of the second group were vaccinated after an entire day (between 24 and 26 hours) after their last training session.The vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
9467642|NCT03654924|Experimental|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
9467643|NCT03654911||aMCI subjects|EEG recording, ApoE testing
9467644|NCT03654885|Active Comparator|XEN group|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation
9467645|NCT03654885|Active Comparator|Trabeculectomy|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.
9467646|NCT03654846|No Intervention|Conventional emergency call|"Emergency call with conventinal cell phone:~verbal description of location~telephone-assisted CPR"
9467647|NCT03654846|Experimental|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:~automated geolocalisation~video-assisted CPR"
9467648|NCT03654820|Experimental|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
9467649|NCT03654820|Active Comparator|SDF treated|Annual application of 38% SDF solution
9467650|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.~Cell pharmacokinetics of tacrolimus"
9480086|NCT03537131|Active Comparator|arm B2- Dapagliflozin daily administration|Participants who will take a daily dose of Dapagliflozin 10 mg before and after the exercise challenge.
9480087|NCT03537118|Experimental|Fluoroscopic + Ultrasound Guidance|
9480088|NCT03537118|No Intervention|Fluoroscopic Guidance Alone|
9480089|NCT03537105|Experimental|Sclerodermic patients|Sclerodermic patients presenting cutaneous fibrosis
9480090|NCT03537079|Placebo Comparator|normoxia conditioning|exercise training in normoxia and rest conditioning in normoxia
9480091|NCT03537079|Active Comparator|exercise hypoxia|exercise training in hypoxia and rest conditioning in normoxia
9480092|NCT03537079|Active Comparator|rest hypoxia|exercise training in normoxia and rest conditioning in hypoxia
9480093|NCT03537066|Other|CPAP treatment|All included OSA patients are going to be treated by CPAP
9480094|NCT03537053|Experimental|A plan to Move a Little and Often|"The intervention will consist of 3 components: a short video will raise awareness about the impact of sedentary behaviours, a booklet, and an online forum on Facebook to encourage participants to support each other.~At the end of the baseline data collection, participants will be asked to watch the video. They will then be given the booklet and invited to join the Facebook group. A minimum of 5 participants must be recruited prior to running the Facebook group."
9480095|NCT03537040|Other|Method of Levels|Talking therapy- duration and frequency of sessions to be determined by participant
9480096|NCT03537027|Experimental|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
9480097|NCT03537001||Penthrox|Administration of Penthrox at the beginning of the management of the traumatized adult patient
9480098|NCT03536988|Experimental|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of proctectomy with IPAA will be performed.
9480099|NCT03536988|Active Comparator|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of proctectomy with IPAA will be performed.
10029740|NCT01752725|Active Comparator|Ultracision Arm|Coagulation with Ultracision
10029741|NCT01752751||Cancer Patients Age 65 or above|Cancer patients age 65 years or above with a diagnosis of head and neck cancer or lung cancer with radiotherapy or chemoradiotherapy planned as part of curative standard treatment.
10029742|NCT01752764|Experimental|Test product|Test product: Salad with high dosage fat
10029743|NCT01752764|Other|Control product|Control product: Salad with low dosage fat
10029744|NCT01752777|Experimental|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
10029745|NCT01752777|Sham Comparator|General Health Improvement|Participants in this condition receive education conducted in one office session followed by 4 cell-phone-based sessions. The education sessions focus on raising awareness of health services and health improvement strategies.
10029746|NCT01752790|Experimental|Top-down|patients randomized on top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus azathioprine (2 mg/Kg per os/day). During maintaining phase, patients will receive subsequent infusions of infliximab (5 mg/kg every 8 weeks), starting 8 weeks after the end of the induction phase (week 14). At 12 motnhs patients will stop azathioprine and continue infliximab (5 mg/kg every 8 weeks)
10029747|NCT01752790|Active Comparator|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day). Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop).
10029748|NCT01752803|Experimental|probiotic|subjects in this arm will receive probiotic supplementation for 12 weeks.
9480100|NCT03536975|Other|Platform|"Group with access to the web platform CAREGIVERSPRO-MMD"
9480101|NCT03536975|No Intervention|Control|Group without any access to the web platform
9480102|NCT03536910|Other|General anesthesia|
9480103|NCT03536910|Other|Spinal anesthesia|
9467651|NCT03654781|Active Comparator|Triple therapy|Conventional triple antibiotic treatment would be applied to all patients (consisted of a 10-day course of Lansoprazole (a proton pump inhibitor) combined with amoxicillin ( 2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
9467652|NCT03654781|Experimental|Combined treatment|"Periodontal treatment would be administered in addition to triple therapy consisted of a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).~Periodontal treatment consisted of supra and sub gingival scaling and root planing, oral hygiene instruction"
9467653|NCT03654768|Active Comparator|Arm I (dasatinib, nilotinib)|Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9467654|NCT03654768|Experimental|Arm II (ruxolitinib phosphate, dasatinib, nilotinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10029749|NCT01752803|Placebo Comparator|placebo|subjects in this arm will receive placebo in identical sachets similar to probiotics which only differs in the codes mentioned on the label of sachets.
10029750|NCT01752816|Active Comparator|endurance training|40 min bicycle or treadmill training at 60% maximal oxygen uptake
10029751|NCT01752816|Experimental|Strength following endurance training|20 minutes bicycle or treadmill training at 60% maximal oxygen uptake followed by 20 minutes stength training increasing from 15RM to 10RM
10029752|NCT01752868|Experimental|supplement|
10029753|NCT01752868|No Intervention|control|
10029754|NCT01752881|Experimental|AdimFlu-S|
10029755|NCT01752894|Active Comparator|Angio guided PCI|
9467655|NCT03654755|Experimental|ASN002 40 mg|ASN002 40 mg
9467656|NCT03654755|Experimental|ASN002 60 mg|ASN002 60 mg
9467657|NCT03654755|Experimental|ASN002 80 mg|ASN002 80 mg
10029756|NCT01752894|Experimental|OCT-guided PCI|
10029757|NCT01752894|Active Comparator|BES|
10029758|NCT01752894|Experimental|EES|
9467661|NCT03654716|Experimental|ALRN-6924 -- Cohort A|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~ALRN-6924 will be administered intravenously.~Participants with otherwise unselected TP53 wild type solid tumors and lymphoma will participate in this cohort."
9467662|NCT03654716|Experimental|ALRN-6924 -- Cohort B|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~ALRN-6924 will be administered intravenously.~Participants with solid and CNS tumors and lymphoma with specific diagnoses or molecular features will participate in this cohort."
9467663|NCT03654716|Experimental|ALRN-6924 -- Cohort C|"Patients will receive ALRN-6924 in combination with cytarabine on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.~Cytarabine is administered intravenously.~ALRN-6924 will be administered intravenously.~Participants with TP53 wild type acute leukemia will participate in this cohort."
10029759|NCT01752894|Active Comparator|Keep dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
10029760|NCT01752894|Active Comparator|Discontinue Dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
10029761|NCT01752959|Active Comparator|Remifentanyl|Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva
10029762|NCT01752959|Experimental|esmolol|Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion
10029763|NCT01752972|Experimental|Palmer arsenical keratosis|Spirulina 10 g/day orally for 12 weeks
10029764|NCT01752972|Active Comparator|Arsenic exposed controls|Spirulina 10 g/day orally for 12 weeks
10029765|NCT01752972|Active Comparator|Heathy volunteers|Spirulina 10 g/day orally for 12 weeks
10029766|NCT01752998|Active Comparator|TOPPS Intervention|Individuals randomized into this arm will receive 7 individual sessions of the Treating Opioid Patients' Pain and Sadness (TOPPS) intervention, designed to reduce symptoms of pain and depression.
10029767|NCT01752998|Placebo Comparator|Health Education|Individuals randomized into this arm will receive 7 individual sessions on general health education.
10029768|NCT01753011||Stress Urinary Incontinence|Stress Urinary Incontinence
10029769|NCT01753024||Sepsis-PEST|septic patients with enteral nutrition and pancreatic enzyme supplementation therapy
10029770|NCT01753024||Sepsis-NPEST|Septic patients with enteral nutrition only
10029771|NCT01753024||DM-PEST|Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy
10029772|NCT01753024||DM-NPEST|Diabetic patients with enteral nutrition only
10029773|NCT01753024||PCAS-PEST|Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy
10029774|NCT01753024||PCAS-NPEST|Patients suffering from cardiac arrest receive enteral nutrition only
10036922|NCT01820182|Experimental|capsocam capsula|capsocam capsula readings
9467664|NCT03654703|Experimental|Cyclophophamide|Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.
9467665|NCT03654703|Experimental|Placebo|5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline
9467666|NCT03654690|No Intervention|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
9467667|NCT03654690|Active Comparator|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
9467668|NCT03654690|Experimental|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
9467669|NCT03654677|Experimental|inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 500U(Name of viral strain: TZ84)
9467670|NCT03654677|Active Comparator|Havrix Inj|1440 ELISA/mL_Adult Inj.(Name of Viral strain: HM175 Inj)
9467671|NCT03654664|Experimental|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
9467672|NCT03654664|Active Comparator|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
10029775|NCT01753024||ARF-PEST|Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy
10029776|NCT01753024||ARF-NPEST|Patients with acute renal failure receive enteral nutrition only
10029777|NCT01753037|Active Comparator|DHEA Group|Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
10029778|NCT01753037|Placebo Comparator|Placebo Group|Oral administration of an identical capsule containing placebo for 5 days.
10029779|NCT01753050|No Intervention|Standard care|No specific hemodynamic optimization measures
10029780|NCT01753050|Experimental|Hemodynamic optimization|Hemodynamic optimization by stroke volume monitoring
9467673|NCT03654651|Experimental|Evening Peanut Consumption|Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).
9467674|NCT03654651|Active Comparator|Evening Snack|Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).
9467675|NCT03654625|Experimental|Standard Written Exposure|Four writing sessions at the laboratory
10029781|NCT01753063|Experimental|Patient Expectations|At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
10029782|NCT01753102|Experimental|Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
10029783|NCT01753102|Active Comparator|Reference: Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
10029784|NCT01753102|Placebo Comparator|Placebo|Intravaginal self-administration of study medication once daily for 14 days.
10029785|NCT01753128|Active Comparator|imipramine|
10029786|NCT01753141|Experimental|Active|Cognitive Behavioral Therapy for smoking cessation plus anxiety sensitivity reduction.
9467676|NCT03654625|Experimental|Enhanced Written Exposure|Four writing sessions at the laboratory
9467677|NCT03654625|Placebo Comparator|Control Condition|Four writing sessions at the laboratory
9467678|NCT03654612|Experimental|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
9467679|NCT03654599|Experimental|Baseline and Digital Stories (DS)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
9467680|NCT03654599|Active Comparator|Baseline and Information Control (IC)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
9467681|NCT03654586|Active Comparator|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
9467682|NCT03654586|Experimental|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
9467683|NCT03654586|Experimental|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
9467684|NCT03654586|Experimental|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
9467685|NCT03654534|Experimental|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
9467686|NCT03654534|No Intervention|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
10029787|NCT01753141|Active Comparator|Control|Cognitive Behavioral Therapy for smoking cessation.
10029788|NCT01753154|Experimental|Solution B (balance PD solution)|Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)
10029789|NCT01753154|Active Comparator|Solution A (conventional PD solution)|Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)
10029790|NCT01753180|Experimental|collagenase|
10029791|NCT01753180|Placebo Comparator|saline|
10029792|NCT01753219|Experimental|Onstep|Participants in this group will have a inguinal hernia repair ad modum Onstep.
10029793|NCT01753219|Active Comparator|Lichtenstein|Participants in this group will receive a inguinal hernia repair ad modum Lichtenstein.
10029794|NCT01753232||DALI-adsorber, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system
10029795|NCT01753232||MONET-Filter, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter
10029796|NCT01753245||Non-Metabolic Syndrome|Patients without Metabolic Syndrome criteria (OMS).
10029797|NCT01753245||Metabolic Syndrome|Patients with Metabolic Syndrome criteria (OMS).
10029798|NCT01753258||Definite diagnosis of dyspareunia|Patients who report dyspareunia, and whose dyspareunia was evaluated prior to delivery by a caregiver experienced with sexual pain disorders, with definite diagnosis.
10029799|NCT01753258||No definite diagnosis of dyspareunia|"Patients who report dyspareunia but were not evaluated prior to delivery or were evaluated inappropriately (i.e. yeast infection without cultures, inflammation and other vague definitions)."
10029800|NCT01753258||Patients without dyspareunia|Patients without dyspareunia- those who report non painful sexual intercourse. This group of patients will be used as a control group.
10029801|NCT01753271|Experimental|Thoracic Mobilization|thoracic mobilization in addition to shoulder mobilization plus exercise
9467687|NCT03654521|Active Comparator|Diabetes group|Women with gestational or pre-gestational diabetes mellitus.
9467688|NCT03654521|Active Comparator|Control group|Women without gestational or pre-gestational diabetes mellitus.
9467689|NCT03654508|Active Comparator|ADRB2-genotype guided treatment arm|In the genotype-stratified arm, children will be treated based on their ADRB2 genotype. Children homozygous for the risk variant Arg16 and heterozygotes (Arg16Gly) will be treated with doubling dosages of their ICS. Children homozygous for the wild type allele (Gly16Gly) will receive LABA.
10029802|NCT01753271|Active Comparator|exercise only|shoulder mobilization plus exercise alone
9467690|NCT03654508|Active Comparator|Control arm|In the control arm, genotyping will be performed for retrospective analysis, but the genotype information will not be used to guide treatment. Children in this study arm will proceed randomisation between doubling ICS dosage (n=75) or LABA treatment (n=75), the two most commonly preferred add-on options among paediatric pulmonologists in the Netherlands. The investigators choose to randomize between both treatments options, since international guidelines do not agree on the preferred treatment option.
10029803|NCT01753349||Idiopathic cervical dystonia|Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia. BoNT-A injections, 3-4 times yearly.
10029804|NCT01753375|Active Comparator|Vitamin D3|Administered orally on weekly basis
10029805|NCT01753375|Placebo Comparator|Placebo|To be administered orally on weekly basis
10029806|NCT01753388|Experimental|Treatment by the Liberty Stent|
10029807|NCT01753440|Other|Stem cells implantation|Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF ≤40% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age <75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF ≤40 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization.
10029808|NCT01753453|Active Comparator|G-CSF alone|Patients will receive G-CSF for 5 consecutive days
10029809|NCT01753453|Experimental|G-CSF plus plerixafor|Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF
10029810|NCT01753466|Experimental|Hydration|Participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 L water per day, depending on sex and weight, in addition to usual consumed beverages, for 6 weeks
9467691|NCT03654495|Experimental|Exergame Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. In addition training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train different aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.
9467692|NCT03654495|Active Comparator|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation.
9467693|NCT03654482|Experimental|SuperSeton arm|
9467694|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
10029811|NCT01753466|No Intervention|Control|
10029812|NCT01753479|Experimental|Test subject|
10029813|NCT01753492|Experimental|Ologen implantation (single arm)|Ologen implantation as an adjunctive to trabeculectomy
10029814|NCT01753505|Experimental|MDCTA|
9467695|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
9467696|NCT03654443|Experimental|Group Painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a painful stimulus (IT0), during the painful stimulus (IT1) and soon afterwards (IT2)
9467697|NCT03654443|Experimental|Group Non-painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a non-painful stimulus (IIT0), during the painful stimulus (IIT1) and soon afterwards (IIT2)
9467698|NCT03654430|Other|Healthy Newborns|
9467699|NCT03654391|Active Comparator|InnoSlim|Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
10029815|NCT01753531||Flu Symptoms|
9467700|NCT03654391|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
10029816|NCT01753583|Experimental|10 patients with corneal abrasions|
10029817|NCT01753583|Experimental|10 patients with corneal infiltrates|
10029818|NCT01753596|Experimental|30 healthy subjects|Subjects will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
10029819|NCT01753596|Experimental|30 patients with dry eye syndrome|Patients will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
10029820|NCT01753609|Experimental|Tulip capsule|swallowing Tulip capsule for up to 29 days
10029821|NCT01753622|No Intervention|Control group|Sedentary Obese and overweight pregnant women
10029822|NCT01753622|Experimental|Exercise group|Physical exercise program
10029823|NCT01753635|Experimental|Baska mask|In this arm the Baska mask will be used as the airway management device
10029824|NCT01753635|Active Comparator|single use laryngeal mask airway device (LMA)|in this arm a single use LMA device will be used for airway management.
10029825|NCT01753661|Experimental|Project ASPIRE Treatment Condition|The Project ASPIRE Treatment condition will receive the Project ASPIRE intervention program which includes the linguistic feedback reports and the multimedia education sessions. This group will complete the same assessments as the control group.
10029826|NCT01753661|Active Comparator|EI-As-Usual Condition|As an ethical decision, eligible participants may roll over to the experimental group after satisfactory completion of this treatment.
10029827|NCT01753674|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
10029828|NCT01753674|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
10029829|NCT01753687|Other|50 patients with dry eye syndrome|
10029830|NCT01753700|Experimental|UHT treated milk|1,5 L of 1,5% UHT milk pr day for 3 weeks (21days)
10029831|NCT01753700|Placebo Comparator|Paseurised milk|1,5 L 1,5% pasteurised milk pr day for 3 weeks (21 days)
10029832|NCT01753726|Experimental|Experimental group|43 people are recruited in order to the inclusion criteria for the study. They are healthy people. A diaphragm stretching technique was employed in this experimental group.
10029833|NCT01753726|Placebo Comparator|Placebo group|37 healthy people were recruited in order to the inclusion criteria.
9467701|NCT03654365|Active Comparator|Control|Pts in the control arm receive usual care. Usual care includes a EHR based reminder of single HCV testing for patients who are in the birth cohort. (routine alerting)
9467702|NCT03654365|Experimental|Intervention|Pts in the intervention arm receive bulk messaging and bulk ordering of the HCV ab test.
9467703|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
9467704|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
9467705|NCT03654339|Experimental|experimental group|"Group A-15 patients were allocated to the microsurgical group for root coverage. following scaling and root planning, the laterally repositioned flap was done using the microsurgical approach~Group B-15 Patients were allocated to the conventional group for root coverage following scaling and root planning, the laterally repositioned flap was done using the macrosurgical approach"
9467706|NCT03654313|Experimental|Part A MEDI6570 Cohort 1|Part A MEDI6570 Cohort 1 dose level
10029834|NCT01753752|Experimental|Chitosan-N-acetylcystein|Instillation into the study eye
10029835|NCT01753752|Placebo Comparator|Placebo|Instillation into the fellow eye
9467707|NCT03654313|Experimental|Part A MEDI6570 Cohort 2|Part A MEDI6570 Cohort 2 dose level
9467708|NCT03654313|Experimental|Part A MEDI6570 Cohort 3|Part A MEDI6570 Cohort 3 dose level
9467709|NCT03654313|Experimental|Part A MEDI6570 Cohort 4|Part A MEDI6570 Cohort 4 dose level
9467710|NCT03654313|Placebo Comparator|Part A Placebo|Part A Placebo
9467711|NCT03654313|Experimental|Part B MEDI6570 Cohort 1|Part B MEDI6570 Cohort 1 dose level
9467712|NCT03654313|Experimental|Part B MEDI6570 Cohort 2|Part B MEDI6570 Cohort 2 dose level
9467713|NCT03654313|Experimental|Part B MEDI6570 Cohort 3|Part B MEDI6570 Cohort 3 dose level
9467714|NCT03654313|Placebo Comparator|Part B Placebo|Part B Placebo
9467715|NCT03654313|Experimental|Part A MEDI6570 Cohort 5|Part A MEDI6570 Cohort 5 Dose level
9467716|NCT03654313|Experimental|Part A MEDI6570 Cohort 6|Part A MEDI6570 Cohort 6 dose level
9467717|NCT03654287||Treatment with CPFA|The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.
9467718|NCT03654287||Treatment with TPE+CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.
9467719|NCT03654287||Treatment with CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.
10029836|NCT01753765|Experimental|Treatment|Study treatment with Cryo-Touch III device at Day 0.
10036923|NCT01820195|Active Comparator|Intravenous N Acetyl Cystein|1200 mg IV N- Acetyl Cystein half an hour before contrast administration. This group will also take oral placebo
10036924|NCT01820195|Placebo Comparator|Placebo|Patients on both oral placebo and IV placebo just like patients on oral and IV N-acetyl cystein groups in regard of dose and timing.
10036925|NCT01820195|Active Comparator|Oral N Acetyl Cystein|Patients on 600 mg oral N-Acetyl Cystein bid started at the day before contrast exposure and continue until the next day of contrast exposure.These patients will also take IV placebo
9467720|NCT03654287||Treatment without CRRT/ECMO|The critically ill children who are not treated by CRRT or ECMO.
9467721|NCT03654287||Treatment with ECMO|The critically ill children who are treated by ECMO whether treated by CRRT
9467722|NCT03654274|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 80 weeks.
9467723|NCT03654235|Experimental|PNE and PE program|Pain neuroscience education (Health education) and Physical exercise program.
9467724|NCT03654235|Active Comparator|Usual care in Primary Care Physiotherapy|Usual care in Primary Care Physiotherapy Units
10036926|NCT01820208|Placebo Comparator|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
10036927|NCT01820208|Experimental|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
10036928|NCT01820221|Active Comparator|Arm 1: Skin closure with suture|Subjects in this group will be randomized to suture for skin closure with computer generated random card draw.
10036929|NCT01820221|Active Comparator|Arm 2: Skin closure with staples|Subjects randomized to skin closure with staples with computer generated random card draw.
10036930|NCT01820234|Other|In-person dermatology evaluation|Health care modality
10036931|NCT01820234|Other|Store-and-forward teledermatology evaluation|Health care modality
10036932|NCT01820247|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
10036933|NCT01820247|Experimental|tripterygium glycosides|The patients receive treatment of tripterygium glycosides only.
10036934|NCT01820247|Experimental|tripterygium glycosides and enteral nutrition|The patients receive treatment of tripterygium glycosides and enteral nutrition.
10036935|NCT01820286|Experimental|Positive psychology intervention|4-week positive psychology intervention of 1 positive psychology exercise per week. Exercises will include 1) recalling 3 good events, 2) writing a letter of thankfulness, 3) using a personal strength, 4) envisioning a best possible future.
9467725|NCT03654222||Cardiac surgery|Direct procedures in heart
9467726|NCT03654222||Organ preservation|Mainly renal autograft
9467727|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
9467728|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
9467729|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
9467730|NCT03654222||Other|Any surgery that does not include the previous ones
10029837|NCT01753778|Experimental|Treatment|Treatment with Cryo-Touch III Device at Day 0
10029838|NCT01753791|Experimental|Cohort 1|
9467731|NCT03654196|Experimental|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
9467732|NCT03654196|Active Comparator|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
10029839|NCT01753791|Experimental|Cohort 2|
9467733|NCT03654170|Experimental|All Subjects|BI 425809 mixed with [C14] BI 425809
9467734|NCT03654144|Experimental|Study group|women will receive dienogest
9467735|NCT03654144|Active Comparator|control group|women used combined oral contraceptive pills
9467736|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points~Phone follow-up"
9467737|NCT03654105|Experimental|Smoking cessation and Antinflammatory|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
9467738|NCT03654105|Experimental|Smoking cessation|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
9467739|NCT03654105|Experimental|Antinflammatory|reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
9467740|NCT03654105|Other|Control Group|standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
9467741|NCT03654066|Active Comparator|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
9467742|NCT03654066|Active Comparator|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
9467743|NCT03654053|Experimental|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
9467744|NCT03654053|Placebo Comparator|Placebo|Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
9467745|NCT03654040|Experimental|arTreg|"arTreg: alloantigen-reactive T regulatory cells~The investigational product is donor alloantigen-reactive regulatory T cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <90 x10^6 total cells will be included in intent-to-treat analysis."
10029840|NCT01753791|Experimental|Cohort 3|
10029841|NCT01753791|Experimental|Cohort 4|
10029842|NCT01753804||Study participants|All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.
10029843|NCT01753817||Study cohort|Cohort of patients who have previously undergone transradial catheterization with the use of a 7F vascular sheath
10029844|NCT01753843|Active Comparator|early cord clamping|cord clamping within 20 sec
10029845|NCT01753843|Experimental|brief delay in cord clamping|cord clamping delayed by 30 to 60 seconds
10029846|NCT01753869|Active Comparator|ACTs after HTS inhalation:|ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
10029847|NCT01753869|Active Comparator|ACTs during HTS inhalation|ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).
10029848|NCT01753882|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training for 4 weeks (3X week) with Lexapro (10 mg SSRI), wash out period of 1 week, gait training for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
9467746|NCT03654027|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
10029849|NCT01753882|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
10029850|NCT01753908|Experimental|Arm I (broccoli sprout extract)|Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.
10029851|NCT01753908|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-14 immediately prior to surgery.
10029852|NCT01753921||DKA Group|Subjects who presented in diabetic ketoacidosis.
10029853|NCT01753921||Healthy control|Control subjects without diabetes.
10029854|NCT01753947|Experimental|Deliberate Practice|Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.
10029855|NCT01753947|No Intervention|Conventional Feedback|Residents in the control group received informal feedback as they performed the initial laparoscopic cholecystectomy in the operating room. This was left up to the discretion of the staff surgeon supervising the operation. This corresponds to the routine teaching and feedback practices that occur during conventional surgical residency training
10029856|NCT01753960||Control group|Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
10029857|NCT01753960||SpHb group|Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
10029858|NCT01753986|Experimental|Brief Alcohol Intervention plus Standard Batterer intervention|Brief Alcohol Intervention plus 40 hours of Standard Batterer intervention
10029859|NCT01753986|Placebo Comparator|General Health Improvement plus Standard batterer intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer intervention
10029860|NCT01754012|Experimental|Dietary Intervention|This group will follow for a year the NU-AGE whole diet approach elderly-specific and will be supplemented with 10micrograms per day of Vitamin D (cholecalciferol) from MCOHealth.
10029861|NCT01754012|No Intervention|Control Group|This group will follow the habitual diet.
9467747|NCT03654027|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
9467748|NCT03654014|Experimental|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
9467749|NCT03654014|Placebo Comparator|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
9467750|NCT03654014|Sham Comparator|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
9467751|NCT03654001|Experimental|Albumin + Balanced|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Balanced crystalloid solutions~According to the preference and the standard use of the participating center:~Ringer Lactate~Ringer Acetate~Crystalsol"
9467752|NCT03654001|Experimental|Albumin + Saline|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl)."
9467753|NCT03654001|Experimental|Balanced|Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)
9467754|NCT03654001|No Intervention|Saline|Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).
9467755|NCT03653975||Nodding syndrome|"I) probable Case of Nodding Syndrom (according to the WHO epidemiologic surveillance case definition) *reported head nodding ** in a previously healthy person with at least 2 major and 1 minor criteria~Major criteria~Age 3 to 18 y at onset of head nodding~Nodding frequency 5 to 20 times per min~Minor criteria~Other neurologic abnormalities~Clustering in space or time with similar cases~Triggering by eating or cold weather~Delayed sexual or physical development~Psychiatric manifestations~As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). ** Repetitive involuntary drops of the head toward the chest on >2 occasions."
9467756|NCT03653975||epilepsy and onchocerciasis|"II) People with epilepsy (PWE) and onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
10029862|NCT01754025||Cancer patients with T790M|Have a diagnosis of cancer of any type. Have an EGFR T790M mutation identified on either genotyping of their cancer at diagnosis OR on quantitative plasma genotyping with evidence of high level (>40% allelic fraction) EGFR T790M. OR another EGFR mutation previously reported as germline detected on tumor genotyping of their cancer.
10029863|NCT01754025||Relatives of Carriers|Have a relative known to carry a germline EGFR mutation (either T790M or other novel germline EGFR mutation)
10029864|NCT01754025||Individuals known to be carriers|Have a known germline EGFR mutation (either T790M or other novel germline EGFR mutation)
10029865|NCT01754038||Integrative Medicine Clinic Attendees|All patients attending a participating Integrative Medicine clinic for clinical services will be invited to participate in the PRIMIER Registry
10029866|NCT01754051||Treatment by the PC 400 coils|Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use.
10029867|NCT01754064||Cardiac Rhythm Management device|Implanted with implantable defibrillator or pacemaker system
9467757|NCT03653975||epilepsy, no onchocerciasis|"III) People with epilepsy (PWE) without onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
9467758|NCT03653975||no epilepsy but onchocerciasis|"IV) Controls with onchocerciasis, otherwise healthy (n= 50)~no evidence for epilepsy or other neurological diseases~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
9467759|NCT03653975||no epilepsy, no onchocerciasis|"V) Healthy Controls without onchocerciasis (n= 50)~no evidence for epilepsy or other neurological diseases~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
9467760|NCT03653975||controls for Wechsler Nonverbal (WNV)|"Healthy Controls for cognitive assessment only, (n= 750)~no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
9467761|NCT03653962|Active Comparator|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
9467762|NCT03653962|Experimental|video assisted group|The second group got an additional information video presentation and then the same quiz.
9467763|NCT03653949|Experimental|High Intensity Interval Training|The subjects will participate of an educational intervention and a High Intensity Interval Training.
10029868|NCT01754077|Experimental|Thirty Million Words Project|The participants in the intervention group receive the LENA linguistic feedback reports intervention and the home visiting educational session intervention. Participants in this arm complete the same assessments as participants in the control group.
10029869|NCT01754077|Other|Control Group|The control group receives the Childhood Nutrition Education intervention. Participants in this group completed the same assessments as the treatment group. Following participation in the control group, eligible families were offered the opportunity to continue into the experimental group.
10029870|NCT01754090|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
10029871|NCT01754090|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
10029872|NCT01754103|Experimental|Functional Connectivity MRI|Functional Connectivity will be measured by MRI, we will perform one T1WI run as well as three resting state bold based runs. Bold runs parameters: TE 30ms, TR 3000ms, flip angle 90º, gap 0mm, 124 time points, voxel size 3mm, duration 6min18s each, FOV 240x240x141.
10029873|NCT01754116|Experimental|Lead In Period GSK1265744 30 mg + midazolam 3mg|During the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
10029874|NCT01754116|Experimental|Lead in Period GSK1265744 30mg|On Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
10029875|NCT01754116|Experimental|Treatment A|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
10029876|NCT01754116|Experimental|Treatment B|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
10029877|NCT01754116|Experimental|Treatment C|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
10029878|NCT01754142||Type 2 diabetes mellitus subjects initiating Kombiglyze XR|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled
10029879|NCT01754155|Other|Vitamin E Polyethylene and RSA|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
10029880|NCT01754181|Experimental|Proposed treatment by Diabeloop algorithm|the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
10029881|NCT01754181|No Intervention|usual treatment|
10029882|NCT01754220|Active Comparator|Montelukast|Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks
10029883|NCT01754233|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
10029884|NCT01754246|Experimental|Alexandrite Laser for Skin Toning|755 nm Alexandrite Laser for Skin Toning
10029885|NCT01754246|Experimental|Alexandrite Laser for Pigmented Lesions|755nm Alexandrite Laser for Epidermal Pigmented Lesions
10029886|NCT01754272||FOLFIRI + Aflibercept|Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
10029887|NCT01754272||FOLFIRI + Placebo|Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.
10029888|NCT01754285|Experimental|LF-PB 10 mg|2 IM injections = placebo + 10 mg
10029889|NCT01754285|Experimental|LF-PB 20 mg|2 IM injections = placebo + 20 mg
10029890|NCT01754285|Experimental|LF-PB 30 mg|2 IM injections = 10 mg + 20 mg
10029891|NCT01754285|Placebo Comparator|Placebo|2 IM injections of placebo
9467764|NCT03653949|Active Comparator|Control Group|The subjects will participate of an educational intervention.
9467765|NCT03653923|Experimental|Waiting-List|
9467766|NCT03653923|Experimental|Treatment|
10029892|NCT01754298|Active Comparator|Retro-articular drilling|Retro-articular drilling goes through the cortical margin of the affected condyle, thereby sparing the articular surface and physes.
10029893|NCT01754298|Active Comparator|Trans-articular drilling|Trans-articular drilling penetrates the articular cartilage through multiple sites to create subchondral penetrations.
10029894|NCT01754311||HTLV-1 infected patients|HAM/TSP patients and HTLV-1 Asymtomatic patients
10029895|NCT01754311||control|Blood donors
10029896|NCT01754324||Methadone|All infants requiring pharmacological treatment of their NAS symptoms are treated with a standardized protocol utilizing oral methadone. This treatment protocol has been the standard of care for infants with NAS at our institution for many years. Infants enrolled in this study will have blood samples drawn at predetermined times in order to obtain information regarding the pharmacokinetics of oral methadone in this population.
10029897|NCT01754337|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels.
10029898|NCT01754337|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels.
9467767|NCT03653923|No Intervention|Healthy Controls|Not randomized healthy control group for comparison to normal functioning
9467768|NCT03653910|Experimental|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
9467769|NCT03653910|Active Comparator|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
9467770|NCT03653897|Experimental|ID-Capsules- Active|Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded.
10029899|NCT01754337|Active Comparator|Insulin pump therapy|Patient's conventional treatment will be implemented.
9467771|NCT03653871|Experimental|Intervention|Performing arts instruction delivered 1 hour/week for 8 weeks.
10029900|NCT01754415|No Intervention|control|Do exercise at home with video program designed by our team.
10029901|NCT01754415|Experimental|hydraulic resistance circuit training|Intervention:12 weeks resistance training
10029902|NCT01754454|Experimental|Human Umbilical Cord Derived MSC|"Human Umbilical Cord Derived MSC:~Patients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
10029903|NCT01754506|Experimental|EPA+DHA|EPA+DHA (fish oil)
10029904|NCT01754506|Placebo Comparator|Placebo|mineral oil
10029905|NCT01754532||Schizophrenia patients|
10029906|NCT01754545|Experimental|Octaplas infusion and placebo (group 1)|Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.
10029907|NCT01754545|Experimental|Octaplas infusion and placebo (group 2)|Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks
10029908|NCT01754558|Experimental|Ajust sling|The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane
10029909|NCT01754558|Experimental|TVT/TVT-O, polypropylne slings|TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.
10029910|NCT01754571|Experimental|CBT treatment|
10029911|NCT01754597|Experimental|Peptide Natriurétique de type B|Peptide Natriurétique de type B
9467772|NCT03653871|No Intervention|Wait List Control|Control group. Performing arts instruction delivered upon completion of control period.
10029912|NCT01754636||Elderly patients|patients aged 65 years old or older : no intervention
10029913|NCT01754636||"Young patients"|patients aged 18-64 years (added by amendment n°3 -02/2014) : no intervention
10029914|NCT01754649|Active Comparator|misoprostol vaginal 200 mcg|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
10029915|NCT01754649|Placebo Comparator|placebo|The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
10029916|NCT01754662|Experimental|Soy protein with isoflavones and cocoa|Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
10029917|NCT01754662|Experimental|Soy protein alone with cocoa|Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
10029918|NCT01754662|Experimental|Soy protein with soy isoflavones|Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
9467773|NCT03653858|Experimental|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF* (for max. 3 months) or continued DBS for another 6 months. *DBS OFF until worsening of clinical depression, event (defined as > 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
10029919|NCT01754662|Experimental|Soy protein alone|Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
10029920|NCT01754662|Placebo Comparator|Placebo|Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
10029921|NCT01754675|Experimental|Soccer|Watching the soccer match at the time that the favorite team is playing
10029922|NCT01754675|Placebo Comparator|Movie|Watching a movie at the time that the favorite team is playing
9467774|NCT03653858|Sham Comparator|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.~2ND STAGE: See group A."
9467775|NCT03653845|Experimental|Intevention|Patients in this group will be treated with endovascular chemical ablation of adrenal glandp by endovascular injection of dehydrated alcohol. Sequenced antihypertensvie drugs with titrated dosage(amlodipine 5-10 mg/d ; terazosin 2-6mg/d) will be prescribed if home blood pressure (HBP) exceeds ≥160/100 mmHg.
9467776|NCT03653845|Active Comparator|Control|Patients in this group will be treated only with sequenced antihypertensvie drugs with titrated dosage(amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d→→plus amlodipine 10 mg/ d →plus terazosin 2-6mg / d) if home blood pressure (HBP) exceeds ≥160/100 mmHg.
9467777|NCT03653819|Other|HIIT + compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session with compression garments/second without.
9467778|NCT03653819|Other|HIIT - compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session without compression garments/second with
9467779|NCT03653793|Experimental|LivRelief Varicose Veins Cream|"Intervention:~All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use."
9467780|NCT03653780|Experimental|Ekso GT gait training|20-minute Ekso GT gait training
10029923|NCT01754701|Experimental|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
10029924|NCT01754701|Experimental|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
10029925|NCT01754740|Experimental|Study Group|19 patients whom received topical medication of urea 10%
10029926|NCT01754740|Placebo Comparator|Control Group|19 patients whom received placebo
10029927|NCT01754792|Experimental|Normal fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
10029928|NCT01754792|Experimental|Impaired fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
10029929|NCT01754792|Experimental|Diabetic subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
10029930|NCT01754805|Experimental|ASP015K and methotrexate|Patients receive a single dose of methotrexate on day 1 and day 8 and ASP015K (twice daily) on days 3 through 8 plus the morning of day 9.
10029931|NCT01754818|Placebo Comparator|Placebo|Placebo, oral capsule, no active study drug, single dose
10029932|NCT01754818|Experimental|Bendavia 10mg|Bendavia, oral capsule, 10mg, single dose
10029933|NCT01754818|Experimental|Bendavia 50mg|Bendavia, oral capsule, 50mg, single dose
10029934|NCT01754818|Experimental|Bendavia 100mg|Bendavia, oral capsule, 100mg, single dose
10029935|NCT01754831|Other|Fluoride varnish|Topical fluoride
10029936|NCT01754844|Experimental|Group 1-5, single ascending dose AZD7624|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
10029937|NCT01754844|Placebo Comparator|Placebo|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
10029938|NCT01754870|Experimental|Bendamustine + Rituximab-->Rituximab and Lenalidomide|"Induction chemoimmunotherapy:~Bendamustine 70 mg/m2 IV days 1 & 2 every 28 days X 6 cycles~Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)~Maintenance phase:~Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.~Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day."
10029939|NCT01754883|Experimental|Lithium Augmentation|Open-label trial - active treatment
10029940|NCT01754896|Experimental|Mail-out/Mail-back|Mailing of FIT kit directly to patient. Mailing completed kits in for processing.
10029941|NCT01754896|Experimental|Mail-out/Drop-off|Mailing of FIT kit directly to patient. Dropping completed kits at lab for processing.
10029942|NCT01754896|Experimental|Pick-up/Mail-back|Mailed invitation to pick up lab requisition and then kit. Mailing completed kits in for processing.
10029943|NCT01754896|Experimental|Pick-up/Drop-off|Mailed invitation to pick up lab requisition and then kit. Dropping completed kits at lab for processing.
10029944|NCT01754961|Placebo Comparator|Placebo|Placebo will be given on Day 1 orally
10029945|NCT01754961|Active Comparator|Vitamin D|Administration of 500,000 IU Vitamin D orally on Day 1
10029946|NCT01754974|Experimental|Peginterferon Lambda-1a + Ribavirin|Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
10029947|NCT01754974|Active Comparator|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
10029948|NCT01755000|Other|Aim 1: Hemodynamically Healthy Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will perform the USCOM second scan within five minutes of Nurse 1's scan and record the values of Vpk and SV on the clinical data sheet.~Nurse 1 and 2 will be blinded to each other's scans by using separate clinical data forms"
10036936|NCT01820286|Active Comparator|Recollection intervention|4-week recollection intervention of 1 recollection exercise per week. Exercises will include recalling events related to 1) daily activities, 2) health, 3) social life, 4) morning and evening.
9467781|NCT03653767|No Intervention|Control Group|The control group will use conventional school furniture.
9467782|NCT03653767|Experimental|Adjustable Furniture Group|The experimental group will use adjustable ergonomic school furniture.
10029949|NCT01755000|Other|Aim 2: Hemodynamically Unstable Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will also be notified of the hypotensive event, will then perform the USCOM second scan within five minutes of PI's scan and record the values of Vpk and SV on the clinical data sheet.~The two USCOM scans will be completed within 10 minutes of the hypotensive episode.~Nurse 1 and Nurse 2 will be blinded to each other's scans by using separate clinical data forms."
10029950|NCT01755000|Other|Aim 3: Hemodynamically Unstable Patients + Fluid Bolus|"At the time that an enrolled patient meets one of the following criteria; SBP drops below 95 mmHg or MAP drops below 65 mmHg the PI will be notified to PI to perform the USCOM scan and record the Vpk, SV, systolic blood pressure and mean arterial pressure on the clinical data sheet within 10 minutes of the hypotensive episode, prior to the patient receiving a fluid bolus (fluid bolus is part of standard of care).~The USCOM scan will then be repeated within 5 minutes after fluid bolus delivery.~Before the hemodynamically unstable patient receives subsequent fluid boluses (multiple boluses are common standard of care), the PI will perform an USCOM scan. Then within 5 minutes after the delivered fluid bolus, the PI will perform another USCOM scan. This will continue, until no further boluses are prescribed."
10029951|NCT01755013|Experimental|PDT Group|Subjects who receive Photodynamic therapy with plastic optic diffuser.
10029952|NCT01755039||Patients with invasive out-of-hospital ventilation|
10029953|NCT01755065||Teenager laparoscopic patients|
10029954|NCT01755078|Experimental|Sevelamer HCl|Sevelamer HCl regular treatment 1-3 tablets TID
10029955|NCT01755078|Active Comparator|Calcium-based binder|Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID
9467783|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
9467784|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
10029956|NCT01755104|Experimental|Stablor|dietary supplement Stablor
10029957|NCT01755104|Placebo Comparator|Placebo|dietary supplement Placebo
10029958|NCT01755117|Active Comparator|TKR, sciatic, femoral, obturator|TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
10029959|NCT01755117|Active Comparator|TKR sciatic nerve block, posterior lumbar plexus block|TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
10029960|NCT01755130|Experimental|Diagnostic (LOUISA 3D)|Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.
10029961|NCT01755182|Active Comparator|Pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy alone
10029962|NCT01755182|Experimental|TAE and pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy and TAE
10029963|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|"Restech pH probe placement at initial clinic visit; Subject returns 24 hours later for probe removal~Proton pump inhibitor (PPI) therapy; Subject starts PPI medication (omeprazole 40mg once daily) and returns for follow-up visit 8-12 weeks later~Optional second pH probe placement at follow up visit; Subject returns 24 hours later for probe removal; Subject continues PPI medication for 2 more weeks"
10029964|NCT01755247|Placebo Comparator|Topical Gel Vehicle|Once daily application of topical gel vehicle to forehead for 3 days
10029965|NCT01755247|Active Comparator|8% NVN1000 Topical Gel|Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
10029966|NCT01755247|Active Comparator|8% NVN1000 Topical Gel and moisturizer|Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
10029967|NCT01755260|No Intervention|oral intake|The patients at this arm were allowed to take food through mouth
10029968|NCT01755273|No Intervention|Standard pancreaticoduodenectomy|Cases receiving pancreaticoduodenectomy with standard enteral bypass
10029969|NCT01755286|Experimental|4 mg OTO-201|
9467785|NCT03653728||Traumatic brain injury with cerebral contusions|
10029970|NCT01755286|Experimental|12 mg OTO-201|
10029971|NCT01755286|Placebo Comparator|Vehicle for OTO-201|
9467786|NCT03653702|Experimental|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
9467787|NCT03653689|Active Comparator|FODMAPs|Dietary supplement: FODMAPs 50 grams three servings per day for seven days.
9467788|NCT03653689|Active Comparator|Gluten|Dietary supplement: Gluten 17.3 grams three servings per day for seven days.
9467789|NCT03653689|Placebo Comparator|Placebo|Dietary supplement: Placebo rice porrige three servings per day for seven days.
9467790|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
9467791|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
9467792|NCT03653663|Placebo Comparator|Placebo|8 weeks treatment with placebo (or until muscle symptoms appear for at least 1 week or are unbearable)
9467793|NCT03653663|Active Comparator|20 mg simvastatin|8 weeks treatment with 20 mg simvastatin daily (or until muscle symptoms appear for at least 1 week or are unbearable)
9467794|NCT03653650|Experimental|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
9467795|NCT03653650|Active Comparator|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
9467796|NCT03653650|Active Comparator|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
9467797|NCT03653598||AF patients|Patients with Atrial Fibrillation
9467798|NCT03653585||Lesion negative hemisphere in Healthy Controls (HC)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in age and sex matched healthy voluntary participants
9467799|NCT03653585||Lesion negative hemisphere in patients (PT-N)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in MS patients
10029972|NCT01755286|Sham Comparator|Sham|
10029973|NCT01755299|Active Comparator|Active ingredient|"Regular 5-hour Energy"
9467800|NCT03653585||Lesion positive hemisphere in patients (PT-P)|"Lesion positive hemisphere in patients:~Data grouped as a lesioned primary sensorimotor cortical hemisphere in MS patients"
9467801|NCT03653572|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
9467802|NCT03653559|Experimental|"Home meals condition"|The recommendation consists of menus with examples of breakfast, lunch and dinner based on typical preparations plus a prescription of the number of portions of the food groups that provides 1200 kcal with a distribution of 50-60% carbohydrates, 15-20% protein and < 30% lipids.
10029974|NCT01755299|Active Comparator|Active ingredient-2|"5-hour Energy Decaf"
10029975|NCT01755299|Active Comparator|Active ingredient-3|Compounded caffeine product 135 mg/2 ounces
10029976|NCT01755299|Placebo Comparator|Placebo|Flavored placebo
10029977|NCT01755312|Experimental|medication reminder|medication reminder
9467803|NCT03653559|Active Comparator|"Healthy meals condition"|"The recommendation consists of the educative graphic tool Eatwell plate plus a prescription of the same number of portions of the food groups for a isocaloric diet with the same macronutrient distribution as the home meals condition."
9467804|NCT03653546|Experimental|AZD3759 Group|AZD3759 group will receive a 200 mg twice daily dose of AZD3759
9467805|NCT03653546|Active Comparator|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
10029978|NCT01755312|Placebo Comparator|Placebo|Placebo
10029979|NCT01755325|Experimental|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
9467806|NCT03653533|Other|MiniMed™ 640G alone|MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
9467807|NCT03653533|Other|MiniMed™ 640G + Captor CGM Enlite®|insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
9467808|NCT03653533|Other|MiniMed™ 640G + Captor + SmartGuard®|insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
9467809|NCT03653520|Active Comparator|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
9467810|NCT03653520|Active Comparator|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
9467811|NCT03653520|Experimental|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
9467812|NCT03653494|Experimental|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
9467813|NCT03653494|Active Comparator|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
9467814|NCT03653481|Experimental|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
9467815|NCT03653481|Placebo Comparator|Placebo|Maltodextrin placebo administered for 8 weeks
10029980|NCT01755325|Placebo Comparator|placebo|"placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib 0.4g qd"
9467816|NCT03653468|No Intervention|Control group|No-exercise
9467817|NCT03653468|Experimental|Endurance training plus resistant training|Concurrent training
9467818|NCT03653455|Experimental|Pre-operative discussion group|At a pre-operative visit, patients and their care provider will discuss what assigned surveys are and why they are important. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
9467819|NCT03653455|Experimental|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
9467820|NCT03653455|Experimental|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
9467821|NCT03653455|Experimental|control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
9467822|NCT03653403|Experimental|IDP-126 Gel|Component A
9467823|NCT03653403|Active Comparator|Control Gel|Gel
9467824|NCT03653377||Patients with self-administered questionnaire|
9467825|NCT03653338|Experimental|Hematopoietic Stem Cell Transplantation|"All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost.~Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy."
9480932|NCT05169385|Experimental|Parent SMART|Parent SMART is a technology-assisted parenting intervention combining an off-the-shelf computer program (Parenting Wisely), up to four telehealth coaching sessions, and access to an app-based networking forum.
10029981|NCT01755338|Active Comparator|Methylprednisolone|Methylprednisolone i.v. 15mg/kg x 1 intraoperative Aortic Valve Replacement
10029982|NCT01755338|Placebo Comparator|Placebo (NaCl)|Placebo i.v., x1, intraoperative Aortic Valve Replacement
10029983|NCT01755364|Experimental|AdimFlu-V|
10029984|NCT01755377||No Chagas Disease|Participants with no Chagas Disease will be evaluated as a Control Group
10029985|NCT01755377||Chagas Disease|Participants diagnosed with Chagas Disease will be followed-up as a Case Group
10036937|NCT01820299|Experimental|Grape Seed Extract and Vitamin D|All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64. For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU.
9467826|NCT03653325|Experimental|interventional arm|"In the interventional arm of the study clinicians will be encouraged to titrate oxygen FiO2 according to the following table:~Interventional arm (FiO2 adaptation every 2-3 min) :~ORI >0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.2 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.1 ORI >0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.1 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.05 ORI=0 et SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1~In the absence of a ORI measurement reading FiO2 will be adapted as in the observational arm according to SatO2 only."
9467827|NCT03653325|Active Comparator|Observational arm|"Observational arm (adaptation every 2-3 min):~oxygen saturation measurement SatO2>98% and FiO2>0.5 reduction of FiO2 by 0.1 SatO2>98% and FiO2≤0.5 reduction of FiO2 by 0.05 SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1"
9467828|NCT03653312|Active Comparator|NMES|"2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.~Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair."
9467829|NCT03653312|No Intervention|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.
9467830|NCT03653299|Experimental|Group A - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy A will receive the programs in the following order 1, 2, 3 and 4, before the tests."
9467831|NCT03653299|Experimental|Group B - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy B will receive the programs in the following order 2, 3, 4 and 1, before the tests."
10029986|NCT01755390|Experimental|Cabazitaxel|"IV escalation part:~XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.~Oral bioavailability part:~XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration."
10029987|NCT01755403|Other|Benznidazole|
10029988|NCT01755442|Active Comparator|AMG 151|
10029989|NCT01755442|Placebo Comparator|Placebo|
9467832|NCT03653299|Experimental|Group C - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy C will receive the programs in the following order 3, 4, 1 and 2, before the tests."
9467833|NCT03653299|Experimental|Group D - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy D will receive the programs in the following order 4, 1, 2 and 3, before the tests."
9467834|NCT03653286|Experimental|NMES and Run|NMES and run
9467835|NCT03653286|Other|Only Run|Only Run
9467836|NCT03653260|Experimental|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
9467837|NCT03653260|Placebo Comparator|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
9467838|NCT03653234|Experimental|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
9467839|NCT03653234|No Intervention|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
9467840|NCT03653221|Experimental|standardized patients with VRNET|The medical students examine the standardized patients who have neurological deficits which presented by VRNET.
9467841|NCT03653221|Placebo Comparator|standardized patients|The medical students examine the standardized patients who have neurological deficits which presented by words or pictures.
9467842|NCT03653195|Other|Pre-injury|Each participant will act as their own control. Pre-injury samples were collected.
9467843|NCT03653195|Active Comparator|Post-injury|Post-injury samples were collected at the same time and within 72 hours of injury.
9467844|NCT03653182||normal|A normal constitution condition in TCM.
9467845|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
9467846|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
9467847|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
9467848|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
9467849|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
9467850|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
9467851|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
9467852|NCT03653182||Special|One of an abnormal constitution condition in TCM.
9480933|NCT05169385|Active Comparator|Treatment as Usual|The active comparator is defined as residential treatment services as usual.
10029990|NCT01755468|Active Comparator|Continuous metformin|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
10029991|NCT01755468|Experimental|Intermittent insulin therapy|After a 3-week course of intensive insulin therapy, participants will receive intermittent intensive insulin therapy for 2 weeks every 3 months. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months
10029992|NCT01755481|Experimental|Probiotics F19|F19 in an infant formula
10029993|NCT01755481|Experimental|Whey protein concentrate|Whey protein concentrate in an infant formula
9467853|NCT03653156||Mild cognitive impairment (MCI) and its subtypes|MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
9467854|NCT03653156||Sporadic Alzheimer's disease (SAD)|SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
9467855|NCT03653156||Familial Alzheimer's disease (FAD)|FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
9467856|NCT03653156||Vascular dementia(VaD）|VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
9467857|NCT03653156||Normal control|Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
10029994|NCT01755494|Experimental|Lower dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)
10029995|NCT01755494|Experimental|Higher dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)
10029996|NCT01755507|Experimental|B|norUDCA
10029997|NCT01755507|Experimental|C|norUDCA
10029998|NCT01755507|Placebo Comparator|placebo|Placebo
10029999|NCT01755507|Experimental|A|norUDCA
10030000|NCT01755520|Experimental|Ticagrelor|Intervention: Drug: Ticagrelor verum + Aspirin placebo
10030001|NCT01755520|Active Comparator|Aspirin|Intervention: Drug: Aspirin verum + Ticagrelor placebo
9467858|NCT03653156||Non-Alzheimer degenerative dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.
9467859|NCT03653130|Experimental|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
9467860|NCT03653130|No Intervention|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
10030002|NCT01755533|Experimental|Rural curriculum|Receive rural version of curriculum
9467861|NCT03653130|No Intervention|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
9467862|NCT03653117|Experimental|TPLA|TPLA procedure
10030003|NCT01755533|Experimental|Classic curriculum|Receive classic version of curriculum
10030004|NCT01755533|No Intervention|Control|Continue normal prevention activities
9467863|NCT03653104|Experimental|Melodica Intervention|An 8-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
9467864|NCT03653104|Active Comparator|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
9467865|NCT03653104|No Intervention|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
9467866|NCT03653104|No Intervention|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
9467867|NCT03653091|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
10030005|NCT01755559|Other|Artesunate-amodiaquine|Efficacy estimates at 95%
10030006|NCT01755559|Other|Dihydroartemisinin-piperaquine|Efficacy estimates at 95%
10030007|NCT01755559|Other|Artemether-lumefantrine|Efficacy estimates at 95%
10030008|NCT01755572|Experimental|Liraglutide|Liraglutide 0.6mg for 7 days, liraglutide 1.2mg for 7 days, liraglutide 1.8mg for 7 days
10030009|NCT01755572|Placebo Comparator|Placebo|Placebo 0.6mg sc for 3 weeks, Placebo 1.2mg sc for 3 weeks, Placebo 1.8mg for 3 weeks.
10030010|NCT01755585||C/T-RT group|Chemotherapy (C/T) is applied in the morning. After 2-4 hrs, radiotherapy (RT) is delivered (according to the clinical practice)
10030011|NCT01755585||RT-C/T group|Radiotherapy (RT) is delivered in the morning. After 2-4 hrs, chemotherapy (C/T) is applied (according to the clinical practice).
10036938|NCT01820325|Experimental|Buparlisib + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib for up to 6 cycles, followed by blinded buparlisib maintenance
10036939|NCT01820325|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib-matching placebo for up to 6 cycles, followed by blinded placebo maintenance
10036940|NCT01820338|Experimental|Behavioral Family Intervention|Child and Parent attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
10036941|NCT01820338|Experimental|Behavioral Parent-Only Intervention|Only parents attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
10036942|NCT01820338|Active Comparator|Education Control|Child and parent attend intervention that includes only nutrition and physical activity education; no instruction or assistance in the use of behavioral strategies are included in this condition
10037584|NCT01826435|Experimental|Electronic Intervention|Over the three months, participants will receive a technology intervention. This will include text or email encounter notifications associated with appropriate mobile or online self-management information for medication adherence and behavior change.
10030012|NCT01755611|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
10030013|NCT01755611|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
10030014|NCT01755624|Experimental|NovoTTF-100A device|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
9467868|NCT03653091|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
9467869|NCT03653078|Experimental|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
9467870|NCT03653078|No Intervention|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
9480104|NCT03536897||IORT|All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome. Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered. Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery. After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
9480105|NCT03536871|Active Comparator|Multinutrient Supplement|Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (protein and creatine sachet and omega-3 oil) or placebo during a 12 week home-based exercise program and we will assess the influence on the primary and secondary outcomes.
9480106|NCT03536871|No Intervention|Age biological and chronological|The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
9480107|NCT03536871|No Intervention|Sarcopenia grades|The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
9480108|NCT03536871|Experimental|Exercise - home based programme|Each of the older participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.
9480109|NCT03536858|Active Comparator|Centrality|The patients at clinic one who receive hemodialysis on Tuesday, Thursday, Saturday and the patients on the Monday, Wednesday, Friday schedule at clinic two, will be assigned to the Centrality arm. Two patients per hemodialysis shift with the highest centrality will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patients selected by centrality will have a centrality greater than 1 standard deviation (SD) from the mean of the other patients on their hemodialysis clinic shift and a clustering less than 1 SD from the mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
9480110|NCT03536858|Active Comparator|Clustering|The patients at clinic one who receive hemodialysis on Monday, Wednesday, Friday and the patients on the Tuesday, Thursday, Saturday schedule at clinic two, will be assigned to the Clustering arm.Two patients per hemodialysis shift with the highest clustering coefficient will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patient selected by clustering coefficient, will have a clustering coefficient greater than 1 SD from the mean of the other patients on their hemodialysis clinic shift and centrality 1 SD less than a mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
9480111|NCT03536845|Active Comparator|400 IU|
9480112|NCT03536845|Active Comparator|1000 IU|
9480113|NCT03536832|Active Comparator|cesarean section with Vicryl|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Vicryl.
9480114|NCT03536832|Active Comparator|cesarean section with prolene|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Prolen.
9480115|NCT03536806|Placebo Comparator|Placebo Comparator: Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. After drug administration the patient will be observed for 2 hours after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
10030015|NCT01755624|Active Comparator|Best Standard of Care|Patients will be treated as the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
10030016|NCT01755650|Experimental|D-18F FPM|
10030017|NCT01755650|Experimental|L-18F FPM|
10030018|NCT01755663|Experimental|Ivabradine|Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
10030019|NCT01755663|Active Comparator|metoprolol|Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
10030020|NCT01755676|Experimental|Orlistat 60 mg|
10030021|NCT01755676|Placebo Comparator|Placebo|
10030022|NCT01755689|Experimental|Nimenrix+Cervarix (1,2,7-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 1, Month 2 and Month 7. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
10030023|NCT01755689|Experimental|Nimenrix+Cervarix (0,1,6-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
9467871|NCT03653052|Experimental|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
9467872|NCT03653039|Experimental|Tritube|
9467873|NCT03653039|Active Comparator|Standard endotracheal tube|
9467874|NCT03653000|Experimental|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
9467875|NCT03652974|Experimental|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: sodium valproate with Clozapine"
9467876|NCT03652974|Experimental|Modified electroconvulsive therapy with clozapine|"12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
9467877|NCT03652974|Experimental|amisulpride|"amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: amisulpride with Clozapine"
9467878|NCT03652974|Placebo Comparator|placebo|"The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: placebo with Clozapine"
9467879|NCT03652961|Other|Open Label|Open Label abatacept for Intravenous Infusion Abatacept intravenous will be administered as a 30-minute intravenous infusion utilizing the weight range-based dosing. Following the initial intravenous administration, an intravenous infusion will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for a total of 7 doses.
9467880|NCT03652948|Experimental|Meru Health Ascend Program|"The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.~Study 2 is examining a revised version of the Meru Health Ascend Program that is 12 weeks long and incorporates sleep and nutrition information in addition to the 8-week program."
9467881|NCT03652935|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week. A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups. Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga. Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
9467882|NCT03652935|Active Comparator|Health Education Series|The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program. Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better). The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
9467883|NCT03652922|Experimental|Propranolol|
9467884|NCT03652922|Placebo Comparator|Placebo|
9467885|NCT03652896|Experimental|anatomical liver resection|resect the tumor located liver segment or lobe
9467886|NCT03652896|Experimental|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
9467887|NCT03652883|Experimental|ItFits-toolkit|A generic 'Integrated Theory-based Framework for Implementation Tailoring Strategies' toolkit (the ItFits-toolkit) functions as an online self-help toolkit by which users are guided through the process of tailoring site-specific implementation strategies. The ItFits-toolkit includes four modules that implementers need to work through: 1) identifying and prioritising implementation goals and determinants of practices, 2) matching up implementation determinants to strategies, 3) designing a plan for carrying out strategies in a local context, and 4) applying strategies, and reviewing progress. In each of these four modules, evidence-informed materials such as iCBT relevant determinants of practices and implementation strategies, are included as well as methods for engaging with stakeholders.
9480116|NCT03536806|Experimental|Experimental: canrenone|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After administration of canrenone: dose 200 mg (1 ampule a 10 ml) within 2-3 minutes the patient will be observed for 2 hours after the dose with exit ECG and BP measure taken at the end of observation.
10030024|NCT01755689|Experimental|Cervarix Group|Subjects in this group received 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6, administered intramuscularly (IM) in the deltoid region of the arm.
10030025|NCT01755689|Experimental|Nimenrix+Cervarix+Boostrix Group|Subjects in this group received 1 dose each of Nimenrix and Boostrix vaccines at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. All vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
10030026|NCT01755689|Experimental|Boostrix+Cervarix Group|Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
10030027|NCT01755715|No Intervention|Control group|Insertion of IUD at 2-4 weeks after abortion.
10030028|NCT01755715|Experimental|Immediate IUD insertion|Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta.
10030029|NCT01755728|No Intervention|No known PDA|For all infants, we do echo cardiogram study only if they are suspected of having PDA, due to sings and symptoms. Hence, we do not do echo cardiogram study to most of the infants.
10037585|NCT01826461|Experimental|PDI-192 Foam, 0.1%|topical foam, 0.1% concentration, twice daily
9467888|NCT03652883|Active Comparator|Implementation as Usual|Implementation-as-Usual (IAU) refers to any existing approaches and efforts to embed and integrate iCBT within an organisation. All implementation sites included in IMA are engaged in and conducting IAU. IAU activities can be, but are not necessarily planned or guided by scientific evidence and often emerge from practice experiences and other sources of information. No standardisation in IAU across the sites is applied except for the implementation objective. That is, all implementation sites pursue the goal of increasing the number of patients treated by the iCBT service.
10030030|NCT01755728|Active Comparator|Ibuprofen|If there is a PDA, that should be treated, and the infant is less than 2 weeks of age, we use ibuprofen, as this is the gold standard in literature.
10030031|NCT01755728|Active Comparator|Surgical closure of PDA|Infants with symptomatic PDA, who had to be treated, but could not be treated by ibuprofen, either due to age (> 2 weeks) or due ibuprofen contraindications (thrombocytopenia or renal failure), whose could not be treated by paracetamol (either because of parents' refuse or because they were on nothing per os protocol due to other disease), for whom surgery was the treatment of choice to close the arterial duct.
9467889|NCT03652870|Active Comparator|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
9467890|NCT03652870|Active Comparator|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
9467891|NCT03652870|Placebo Comparator|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
9467892|NCT03652857|Experimental|Apatinib Combined With Vinorelbine|Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
9467893|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) 1.0|
9467894|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) Diluted|
9467895|NCT03652831|Active Comparator|Soft Tissues mobilization with Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques and Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
9467896|NCT03652831|Active Comparator|Soft Tissues mobilization without Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques.~Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
9467897|NCT03652805|Experimental|IPL344|IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg
9467898|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
9467899|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
9467900|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
9467901|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
9467902|NCT03652779|Experimental|Tecarfarin 10mg|
9467903|NCT03652779|Experimental|Tecarfarin 20mg|
9467904|NCT03652779|Experimental|Tecarfarin 30mg|
9467905|NCT03652779|Experimental|Tecarfarin 40mg|
10030032|NCT01755728|Experimental|Paracetamol|Infants with symptomatic PDA who could not be treated with ibuprofen, and their parents agreed and they could be treated with paracetamol.
10030033|NCT01755728|No Intervention|DA closed spontaneously|Infants with PDA, who did not get any treatment for it, and the duct was closed spontaneously.
10030034|NCT01755741|Experimental|Placebo Vaginal Ring|Placebo vaginal ring with condom use
9467906|NCT03652766|Other|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
9467907|NCT03652753|Experimental|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
9467908|NCT03652753|Placebo Comparator|Saline|Injection of saline at the time of external fixation
9467909|NCT03652727|Experimental|ECG-EM Guidance|PICC insertion using electrocardiographic and electromagnetic guidance [Site~Rite® 8 Ultrasound System with integrated SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS)]
9467910|NCT03652727|Active Comparator|FX Guidance|PICC insertion using fluoroscopic guidance
9467911|NCT03652714|Experimental|Local anesthetic|
9467912|NCT03652714|Placebo Comparator|Isotonic NaCl|
9467913|NCT03652701|Experimental|Hair Up|
9467914|NCT03652701|Placebo Comparator|Placebo|
9467915|NCT03652688|Experimental|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
9480117|NCT03536780|Experimental|Avelumab and Gemcitabine|
9480118|NCT03536767|Experimental|Open-Label|
9480119|NCT03536754|Placebo Comparator|Group A|Placebo (N=10)
9467916|NCT03652688|Sham Comparator|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
10030035|NCT01755741|Other|Condom|Male condoms during vaginal intercourse in presence and absence of the vaginal ring.
10030036|NCT01755754|Experimental|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
9467917|NCT03652649|Experimental|3:1 Ketogenic Complete Meal Replacement|Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day complete meal replacement ketogenic diet
9467918|NCT03652636|Other|One: Patient population with hepatic lesion(s)|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
9467919|NCT03652623|Experimental|TDF/FTC and cs-HT|Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.
9467920|NCT03652597|Active Comparator|Left|Subjects are ascribed to left hemispheric stimulation
9467921|NCT03652597|Active Comparator|Right|Subjects are ascribed to right hemispheric stimulation
10030037|NCT01755754|Experimental|Female Condom|This trial will test the performance of female condoms when used concurrently with a placebo vaginal ring
10030038|NCT01755780||Left interscalene block|Left interscalene block on hypotension and bradycardia during beach chair positioning
10030039|NCT01755780||Right interscalene block|Right interscalene block on hypotension and bradycardia during beach chair positioning
10030040|NCT01755806||aortic root dimension change|those without aortic valve calcification
10030041|NCT01755806||aortic root dimension change, aortic valve calcium score|those with aortic valve calcification
10030042|NCT01755819|Other|Biocomposite interference screw|Thirty patients treated with ACL reconstruction and graft fixation is performed using Biocomposite interference screw on tibial and femoral side. Patients are randomized to one of the two study arms.
10030043|NCT01755819|Other|Extracortical ACL Tightrope fixation|Thirty patients treated with ACL reconstruction and graft fixation is performed using extracortical ACL Tightrope fixation on tibial and femoral side. Patients are randomized to one of the two study arms.
9467922|NCT03652584|Experimental|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
9467923|NCT03652584|Active Comparator|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
9467924|NCT03652571|Experimental|Nortriptyline|"Nortriptyline in an escalating dose regimen:~Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily"
9467925|NCT03652571|Placebo Comparator|Placebo|Placebo
9467926|NCT03652558|Experimental|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
9467927|NCT03652558|No Intervention|non-ozone group|Only active periodontal therapy was performed
9467928|NCT03652545|Experimental|TAA-T|"Three different dosing schedules will be evaluated.~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2~Group A patients (DIPG): The first TAA-T dose will be infused any time more than or equal to 14 days after completion of radiotherapy.~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time more than or equal to 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.~Ideally, patients should not receive other systemic antineoplastic agents for at least 42 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
9467929|NCT03652532|Experimental|Alternate Day Fasting and Exercise|
9467930|NCT03652532|Experimental|Alternate Day Fasting|
9467931|NCT03652532|Experimental|Exercise|
9467932|NCT03652532|No Intervention|Control|regular eating and exercise habits for 8 weeks
9480120|NCT03536754|Experimental|Group B|CCX140-B 5 mg once daily (N=10)
9480121|NCT03536754|Experimental|Group C|CCX140-B 10 mg twice daily (N=10)
9480122|NCT03536754|Experimental|Group D|CCX140-B 15 mg twice daily (N=10)
9480123|NCT03536741|Experimental|ALR|
10030044|NCT01755832||Pool exercise group|Patients with inflammatory rheumatic disease
10030045|NCT01755845|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
10030046|NCT01755845|Active Comparator|Arm 2|Patients receive chemoradiotherapy as in arm 1.
10030047|NCT01755871|Experimental|Fingolimod|Gilenya 0,5mg per day, oral
10030048|NCT01755884|Experimental|Wheat oral immunotherapy|Well-cooked wheat spaghetti is given daily to the patients starting from a minimal dosage (0,0003 g of wheat protein) and increasing the dosing in every 1-2 weeks until a dosage corresponding the size of one meal.
10030049|NCT01755897|Experimental|Adjuvant Chemotherapy (Arm A)|Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.
10030050|NCT01755897|Active Comparator|Concurrent radiochemotherapy, CCRT (Arm B)|Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.
10030051|NCT01755910||Left thoaracic paravertebral block|Surgery in the left breast under left thoracic paravertebral block and HRV
10030052|NCT01755910||Right thoracic paravertebral block and HRV|Surgery in the right breast under right thoracic paravertebral block and HRV
10030053|NCT01755923|Experimental|Gefitinib|Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
10030054|NCT01755923|Active Comparator|Docetaxel|Docetaxel 75mg/m2,d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
9480124|NCT03536741|Active Comparator|EV|
10030055|NCT01755936||Controls|Patients will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
10030056|NCT01755936||Aortic Stenosis patients|All patients who agreed to study will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
10030057|NCT01755962|Experimental|Low Glycemic Load + Resistance Training|12-week intervention diet + resistance training (1 hour, 3 times per week)
9467933|NCT03652519|Experimental|High-intensity Interval Training (HIIT)|Participants of the HIIT group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the HIIT group will perform 5x one-and-a-half Minute high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 minutes with the aim to achieve 60% HRmax.
9467934|NCT03652519|Active Comparator|Moderate Continous Training (ST)|Participants of the ST group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the ST group will exercise 30 minutes continuously at 65% of HRmax. This moderate continous training program represents the standard care at the local rehabilitation clinic.
10030058|NCT01755962|Experimental|High Glycemic Load + Resistance Training|12-week control diet + resistance training (1 hour, 3 times per week)
10030059|NCT01755962|Experimental|Low Glycemic Load|12-week intervention diet
9467935|NCT03652506|Active Comparator|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
9467936|NCT03652506|Active Comparator|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
9467937|NCT03652506|Active Comparator|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
10030060|NCT01755962|Other|High Glycemic Load|12-week control diet
10030061|NCT01755988|No Intervention|Usual care|
9467938|NCT03652493|Experimental|CARBOPLATIN|CARBOPLATIN in Intraveinous Dose AUC 5 according to Calvert every 3 weeks, for a duration of 6 to 9 cycles
9467939|NCT03652467|Experimental|Deferoxamine|Patients are treated with deferoxamine and conventional TACE.
9467940|NCT03652467|Active Comparator|Conventional TACE|Patients are treated with conventional TACE.
9467941|NCT03652441|Experimental|Maintenance|Brentuximab Vedotin will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
9467942|NCT03652428|Other|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:~Gemcitabine + nab-paclitaxel:~• Administered per institutional standard every 7 days for 3 weeks~Part II:~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.~Part III:~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy~OR~Chemo per discretion of MD if not resectable"
10030062|NCT01755988|Experimental|Educational website.|Educational website (in addition to usual care).
10030063|NCT01755988|Experimental|Website and interactive platform with telemonitoring.|Adjusted care pathway, including both the educational website and an interactive web-based platform with telemonitoring facilities. In this arm all routine consultations with heart failure nurses and general practitioner will be substituted by this combination of telemonitoring facilities connected to an interactive web-based platform plus the Dutch version of the European Society of Cardiology (ESC) website on heart failure.
9467943|NCT03652389|Experimental|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
9467944|NCT03652389|Active Comparator|Usual Care|Standard Diabetes Treatment
9467945|NCT03652376|Experimental|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
9467946|NCT03652363|Placebo Comparator|Placebo|Placebo administered via convection enhanced delivery
9467947|NCT03652363|Experimental|glial derived neurotrophic factor|Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF), administered via convection enhanced delivery
9467948|NCT03652350|Experimental|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
9467949|NCT03652337|Experimental|BlephEx|The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.
9467950|NCT03652337|Experimental|Manual debridement|The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.
10030064|NCT01756001||Control Arm|Arm 1 will be the Control arm, in which subjects will be instructed to use the GlowCap for their chronic disease medication but will not be provided with any specific incentive for taking the medication or with any aid in remembering to do so.
10030065|NCT01756001||Reminder Arm|Arm 2 will be the Reminder arm with daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
9467951|NCT03652324|Other|randomized|
10037586|NCT01826461|Experimental|PDI-192 Foam, 0.15%|topical foam, 0.15% concentration, twice daily
10030066|NCT01756001||Incentives Arm|Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
10030067|NCT01756001||Incentives and Reminders Arm|Arm 4 will be the financial incentives and reminders arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform. They will also receive daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
9467952|NCT03652311|Experimental|TNM Device Group|In this arm participants will receive 5 sessions of twice daily treatments of 15 minutes of caloric vestibular stimulation (CVS) using the ThermoNeuroModulation TNM Device. In addition, participants will continue with the standard therapy that they are receiving.
10030068|NCT01756014||Controls|Age matched healthy subjects
10030069|NCT01756014||Mild DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class II
9467953|NCT03652311|Sham Comparator|Sham CVS Group|In this arm participants will receive 5 sessions of twice daily sessions of 15 minutes of sham stimulation with the ThermoNeuroModulation TNM Device. The ThermoNeuroModulation TNM device will be fitted and turned on in a random paradigm that has no demonstrated efficacy. Participants will continue with the standard therapy that they are receiving.
10030070|NCT01756014||Severe DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class III/IV
9467954|NCT03652298|Experimental|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
9467955|NCT03652298|Other|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
9467956|NCT03652259|Experimental|Cohort 1: SRP-9003|Participants will receive a single intravenous (IV) infusion of SRP-9003 at a prespecified dose.
9467957|NCT03652259|Experimental|Cohort 2: SRP-9003|Participants will receive a single IV infusion of SRP-9003. Dose will be determined based on the findings from Cohort 1.
9467958|NCT03652233|Experimental|Afatinib and Nivolumab|
9467959|NCT03652220|Experimental|Intervention|"8 weeks Minimal treatment + MBLM 16 weeks Multimodal specific treatment + MBLM Consolidation~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
9467960|NCT03652220|Active Comparator|Control I|"8 weeks Minimal treatment 16 weeks Multimodal specific treatment~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
9467961|NCT03652220|Active Comparator|Control 2|"Definitions 24 weeks Multimodal specific treatment~Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
9467962|NCT03652207|Placebo Comparator|Sucrose|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
9467963|NCT03652207|Experimental|Palatinose(TM)|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
9467964|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
9467965|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
9467966|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin > 8µg/ml)
10030071|NCT01756027|Active Comparator|Group A|Ulthera System providing one treatment per cheek
10030072|NCT01756027|Active Comparator|Group B|Ulthera System providing two treatments per cheek
10030073|NCT01756040|Other|Lactulose - rhamnose solution|Preterm Infants age 24-32 weeks gestation
10030074|NCT01756066|Active Comparator|A|Participant has 50% subsidy, i.e. gets a 50% discount off regular price of the program
9467967|NCT03652168|Experimental|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
9467968|NCT03652168|No Intervention|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
9467969|NCT03652155||Orthognathic Surgery Patients|The study cohort will be patients undergoing orthognathic surgery for correction of an existing dentofacial deformity.
9467970|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
9467971|NCT03652129|Experimental|Laser Group|Disinfection using biostimulating LASER
10030075|NCT01756066|Experimental|B|Participant has 100% subsidy, i.e. program attendance is free
9467972|NCT03652129|Experimental|Nano irrigant Group|Disinfection using Nano irrigant
9467973|NCT03652129|Active Comparator|Conventional irrigation protocol group|disinfection using normal irrigation protocols
9467974|NCT03652116|Active Comparator|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
9467975|NCT03652116|Active Comparator|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
9467976|NCT03652103|No Intervention|GCont|Only dressing will be applied to patients without actually nerve catheter performed
9467977|NCT03652103|Experimental|GBlock|"Ultrasound Guided Erector Spinae Plane Block Catheter will be applied: 20ml Bupivacaine 0.25% Injectable Solution* will be administered initially.~20 ml Bupivacaine %0.25 Injectable Solution** will be administered 30 minutes before ambulation at postoperative day(POD) 0 and before removal of nephrostomy at POD 2~*10ml %0,5 Bupivacaine will be diluted with 10ml Saline solution."
9467978|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
9467979|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
10030076|NCT01756066|Experimental|C|Participant has 80% subsidy; i.e. gets 80% discount off regular price of the program
10030077|NCT01756066|Experimental|D|Participant has 50% subsidy up front (i.e. pays 50%), with possibility for 100% subsidy based on attaining monthly participation goals
10030078|NCT01756092|Experimental|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
9467980|NCT03652090||healthy control|subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling
10030079|NCT01756105|Experimental|treatment by Metformin plus insulin if needed|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
10030080|NCT01756105|Active Comparator|treatment by insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
10030081|NCT01756118|Experimental|BEZ235|
10030082|NCT01756131|Experimental|Cohort 1|100 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
10030083|NCT01756131|Experimental|Cohort 2|200 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
10030084|NCT01756131|Experimental|Cohort 3|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
10030085|NCT01756131|Experimental|Cohort 4|800 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
10030086|NCT01756131|Experimental|Cohort 5|100 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
10030087|NCT01756131|Experimental|Cohort 6|200 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
10030088|NCT01756131|Experimental|Cohort 7|400 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
10030089|NCT01756131|Experimental|Cohort 8|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
10030090|NCT01756131|Experimental|Cohort 9|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
10030091|NCT01756144|Active Comparator|Autologous bone grafting|autologous bone of the iliac crest
10030092|NCT01756144|Experimental|rhBMP-2|Inductos, recombinant human bone morphogenetic protein
10030093|NCT01756170|Active Comparator|Arm 2|Patients receive radiotherapy alone as in arm 1.
10030094|NCT01756170|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.
10030095|NCT01756183|Experimental|S-1 + Paclitaxel Chemotherapy|"S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Paclitaxel: 150 mg/m2, iv, 3h, at D1"
10030096|NCT01756196||Steroid Injection|Reactions associated with spinal steroid injection
10030097|NCT01756248||Group 1|
9467981|NCT03652038|Experimental|TD-8236 for SAD (Part A)|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
9467982|NCT03652038|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
10030098|NCT01756261||Group 1|
10030099|NCT01756287|Experimental|Standardized Chinese ocular exercise|The participants are trained with standardized Chinese ocular exercise which contains accurate positions of acupuncture points and appropriate pressure on the points.
10030100|NCT01756287|Sham Comparator|Nonstandardized ocular exercise|The participants are trained with nonstandardized ocular exercise performed on wrong positions where no acupuncture points at all.
9467983|NCT03652038|Experimental|TD-8236 for MAD (Part B)|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236.
10030101|NCT01756287|No Intervention|Eye closure|The participants are told to close eyes and don't do ocular exercise at all.
10030102|NCT01756313|Experimental|Laser+Methylaminolevulinat|It's a single arm. Intervention as described in the detailed description.
9467984|NCT03652038|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo.
9467985|NCT03652038|Experimental|TD-8236 for Biomarker (Part C)|8 subjects in each of 2 biomarker cohorts will be randomized to receive TD-8236.
9467986|NCT03652038|Placebo Comparator|Placebo for Biomarker (Part C)|8 subjects in 1 biomarker cohort will be randomized to receive placebo.
9467987|NCT03652025|Experimental|Study group|perimenopausal women
9467988|NCT03652012|Experimental|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
9467989|NCT03652012|Active Comparator|Healthy Controls|"Participants who are matched for age and gender.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
9467990|NCT03651999||dream workshop|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse anesthetist, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; The nurse anesthetist explains the hospitalization process and will help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...); the child will be able to customize his mask and choose the blanket he wants to take along; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
9467991|NCT03651999||control|"No dream workshop"
10030103|NCT01756326|Experimental|PREOB® Implantation|Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.
10030104|NCT01756326|Active Comparator|Bone Autograft|Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.
9467992|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
10030105|NCT01756365|Experimental|CECA|
10030106|NCT01756378|Experimental|Muligan mobilization with movement|"Interventions are:~medial glide mobilization with movement lateral glide mobilization with movement rotation mobilization with movement dorsal glide with active knee flexion"
10030107|NCT01756378|Active Comparator|traditional physical therapy program|Infra-red, stretching exercises, strengthening exercises,
10030108|NCT01756404|Experimental|Cohort 1|Each volunteer will receive a total daily dose of 30 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
9467993|NCT03651973|Experimental|With learning workshops|Patients in experimental arm will attend learning workshops, one before breast cancer surgey and one after surgery. Patients will be educated by physiologist to self massages and self stretching. Each workshop will last around 2 hours.
9467994|NCT03651973|Other|Without learning workshops|Standard follow-up. Patients randomized in this arm won't attend Learning workshops and will be followed in a standard way.
9467995|NCT03651960|Experimental|Robot|ROBOT PROTOTYPE
10030109|NCT01756404|Experimental|Cohort 2|Each volunteer will receive a total daily dose of 100 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
10030110|NCT01756404|Experimental|Cohort 3|Each volunteer will receive a total daily dose of 300 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
10030111|NCT01756404|Experimental|Cohort 4|Each volunteer will receive a total daily dose of 600 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
10030112|NCT01756404|Experimental|Cohort 5|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) twice daily (600 mg total daily dose) or placebo (inactive medication) twice daily on Days 1 through 14.
10030113|NCT01756417|Experimental|Metformin + canagliflozin (JNJ-28431754)|Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
10030114|NCT01756430|Experimental|Carvedilol SR 32mg, 64mg|•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.
10030115|NCT01756430|Active Comparator|Carvedilol IR 25mg|•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.
10030116|NCT01756443|Active Comparator|Premixed group|Patients will receive sciatic nerve block with premixed 7.5 mls of 2% lidocaine/adrenaline and 7.5 mls of 0.5% bupivacaine followed by an interval of 90 seconds with an injection of same amount of both drugs.
10030117|NCT01756443|Experimental|Sequential Group|Patients will receive a sciatic nerve block with 15 mls of 2% lidocaine/adrenaline followed by an interval of 90 seconds with 15 mls of 0.5% bupivacaine.
10030118|NCT01756469|No Intervention|Control|non-alcohol related information about nutrition
10030119|NCT01756469|Active Comparator|Intervention|Behavioral Intervention for Alcohol Use
10037587|NCT01826461|Placebo Comparator|Vehicle Foam|topical foam, 0% concentration, twice daily
9467996|NCT03651947|Experimental|QL1206|QL1206 injection (120mg) by subcutaneous injection once on the first day.
9467997|NCT03651947|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day.
10030120|NCT01756495|Experimental|Losmapimod 7.5 mg|Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
9467998|NCT03651934|Experimental|Normal iron|
9467999|NCT03651934|Experimental|Weak iron|
9468000|NCT03651934|Experimental|Normal selenium|
9468001|NCT03651934|Experimental|Weak selenium|
9468002|NCT03651921|No Intervention|Usual care|Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).
9468003|NCT03651921|Experimental|Usual care and CTS-BC-CH|CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.
10030121|NCT01756495|Experimental|Losmapimod 20 mg|Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
10030122|NCT01756495|Active Comparator|Moxifloxacin 400 mg|Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
10030123|NCT01756495|Placebo Comparator|Placebo|Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
10030124|NCT01756508|Experimental|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
9468004|NCT03651908|Experimental|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
9468005|NCT03651908|Active Comparator|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
10030125|NCT01756508|No Intervention|control|No intervention will be applied instead eculizumab infusion
10030126|NCT01756521|Experimental|Moxifloxacin 400mg|moxifloxacin 400mg
10030127|NCT01756521|Experimental|Moxifloxacin 800mg|moxifloxacin 800mg
10030128|NCT01756521|Placebo Comparator|Placebo(No treatment)|Only drink water
10030129|NCT01756534|No Intervention|CONVENTIONAL HEMOSTASIS|patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis
10030130|NCT01756534|Active Comparator|SURGICEL|patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone)
9468006|NCT03651882|Active Comparator|Oxytocin|
9468007|NCT03651882|Active Comparator|Carbetocin|
10030131|NCT01756547|Experimental|Potassium citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
10030132|NCT01756547|Placebo Comparator|Placebo|Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.
10030133|NCT01756599|Experimental|leukaemia during childhood or adolescence|
10030134|NCT01756612||Chronic Kidney Disease Participants|Participants for whom the treating physician has decided to initiate treatment with MIRCERA for medical reasons prior to study start, will be observed for 9 months.
10030135|NCT01756625||First line WT KRAS mCRC|
10030136|NCT01756638|Experimental|Abiraterone plus Prednisolone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
10030137|NCT01756651|Experimental|Intranasal Fentanyl 100mcg|fentanyl pectin nasal spray 100mcg
10030138|NCT01756651|Experimental|Intranasal Fentanyl 200mcg|fentanyl pectin nasal spray 200mcg
10030139|NCT01756664|Placebo Comparator|Control|Vaseline has been used on the first day after laser treatment
10030140|NCT01756664|Active Comparator|Sunscreen|Sunscreen has been used on the first day after laser treatment
9468008|NCT03651869|Experimental|Condition 1|
10030141|NCT01756703|Experimental|MT-3995 Low group|
10030142|NCT01756703|Experimental|MT-3995 High group|
10030143|NCT01756703|Placebo Comparator|Placebo group|
10030144|NCT01756716|Experimental|MT-3995 Low group|
10030145|NCT01756716|Experimental|MT-3995 High group|
10030146|NCT01756716|Placebo Comparator|Placebo group|
10030147|NCT01756729|Active Comparator|Best Standard of Care|Patients recruited to the BSC group will be treated according to the BSC practiced at each center.
10030148|NCT01756729|Experimental|NovoTTF-100A (monotherapy)|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
10030149|NCT01756742|Experimental|Respiratory physiotherapy|54 people according to the inclusion criteria were recruited to have a respiratory physiotherapy treatment added to their medical intervention.
10030150|NCT01756742|Placebo Comparator|Conservative treatment|49 people were recruited in this group. These participants received conservative medical treatment intervention
9468009|NCT03651869|Experimental|Condition 2|
9468010|NCT03651869|Experimental|Condition 3|
9468011|NCT03651869|Experimental|Condition 4|
9468012|NCT03651843||Healthy subjects|
9468013|NCT03651817|Active Comparator|6ml/kg volume|Patients ventilation will provided with a tidal volume of 6ml/kg
9468014|NCT03651817|Active Comparator|8ml/kg volume|Patients ventilation will provided with a tidal volume of 8ml/kg
9468015|NCT03651791|Experimental|USPIO labeled MSC injection|USPIO labeled MSC injection
9468016|NCT03651765|Experimental|Setmelanotide|Once daily subcutaneous injection
9468017|NCT03651752|Other|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
10030151|NCT01756755|No Intervention|Control|Treat with severe sepsis / septic shock practice guideline
10030152|NCT01756755|Experimental|PMX HP|Treat with severe sepsis / septic shock practice guideline Treat with PMX-20R Hemoperfusion [Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood].
10030153|NCT01756768|Experimental|Radio-labeled Dose Arm|
9468018|NCT03651739||TKR Patients|Any patient undergoing total knee arthroplasty and will use the Knee Connect during their knee classes at the Holland Centre
10030154|NCT01756781|Experimental|Sequence 1|Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
9468019|NCT03651726|Experimental|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
9468020|NCT03651726|Placebo Comparator|Placebo|"Double-blind phase:~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
9468021|NCT03651713|Experimental|GLU+EX|Subjects will consume a 75g glucose beverage three times daily for seven days while participating in five structured aerobic exercise sessions throughout the experimental protocol.
9468022|NCT03651713|Active Comparator|GLU|Subjects will consume a 75g glucose beverage three times daily for seven days without participating in structured aerobic exercise.
9468023|NCT03651700|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
9468024|NCT03651700|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
9468025|NCT03651674|Active Comparator|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
9468026|NCT03651674|Sham Comparator|Drug treatment|Patients only received antipsychotic drugs during observation period.
10030155|NCT01756781|Experimental|Sequence 2|Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone.
10030156|NCT01756794|Other|Transplantation of alcoholic hepatitis|Patients of this arm will be selected for early liver transplantation for severe alcoholic hepatitis not responding to medical therapy. Selection process will be based on a specific algorithm and follow-up time will be 2 years
10030157|NCT01756794|Other|Transplantation for alcoholic cirrhosis|Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
10037588|NCT01826474|Experimental|PRO045, cohort 1|0.15 mg/kg until dose-titration
10037589|NCT01826474|Experimental|PRO045, cohort 2|1.0 mg/kg until dose-titration
10037590|NCT01826474|Experimental|PRO045, cohort 3|3.0 mg/kg until dose-titration
10037591|NCT01826474|Experimental|PRO045, cohort 4|6.0 mg/kg until dose-titration
9468027|NCT03651661|Active Comparator|nasal insulin|160 U of human insulin as nasal spray
9468028|NCT03651661|Placebo Comparator|nasal placebo|placebo as nasal spray
9468029|NCT03651635||Medical ICU Patients|All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period
9468030|NCT03651609|Experimental|UNE at HUA_HUA release|Patients with UNE under the HUA randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. Control neurological examination will be performed every 3 months and identical protocol as at the time of diagnostic evaluation at 1 year follow-up.
9468031|NCT03651609|Active Comparator|UNE at HUA_conservative treatment|Patients with UNE under the HUA randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA control neurological examination will be performed every 3 months. Criteria for surgical HUA release will be clinical deterioration or lack of clinical improvement after 12 months. Prior to surgical HUA release and at 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
9468032|NCT03651609|Experimental|UNE at RTC_HUA release|Patients with UNE in the RTC groove randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
10030158|NCT01756807|Experimental|The Combo Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
9468033|NCT03651609|Active Comparator|UNE at RTC_conservative treatment|Patients with UNE in the RTC groove randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
9468034|NCT03651596|Active Comparator|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
10030159|NCT01756820|Active Comparator|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|Single-portal Endoscopic Carpal Tunnel Release (Microaire®) will be used, according to the endoscopic technique described by Agee at al.
10030160|NCT01756820|Active Comparator|Knifelight®|A mini-open technique will be performed, using the Knifelight® (Stryker).
10030161|NCT01756859||Patients with HVPG measurements|Patients having HVPG measurements for clinical reasons will be recruited to undergo research MRI scan.
10030162|NCT01756872||Ovarian reserve study participants|Measurements of ovarian reserve for women attending the Oxford Fertility Unit having their first IVF/IVF-ICSI cycle.
10030163|NCT01756911|Experimental|Thotaco-abdominal aneurysm|MFM
9468035|NCT03651596|Experimental|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
9468036|NCT03651583|Other|Pilot Trial|Behavioral Intervention Kiko exercises-combines breathing and movement all study subjects no placebo or control group
9468037|NCT03651570|Experimental|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
10030164|NCT01756937|Active Comparator|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
9468038|NCT03651570|Placebo Comparator|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
9468039|NCT03651570|No Intervention|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
10030165|NCT01756937|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
9468040|NCT03651557|Experimental|Neu2000KWL high dose|
9468041|NCT03651557|Experimental|Neu2000KWL low dose|
9468042|NCT03651557|Placebo Comparator|saline|
9468043|NCT03651544|Experimental|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
10030166|NCT01756950|Experimental|Cohort 1 - CR8020|2 mg/kg CR8020
10030167|NCT01756950|Placebo Comparator|Cohort 1 - Placebo|5% dextrose in water
10030168|NCT01756950|Experimental|Cohort 2 - CR8020|5 mg/kg CR8020
10030169|NCT01756950|Placebo Comparator|Cohort 2 - Placebo|5% dextrose in water
9468044|NCT03651544|Experimental|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
10030170|NCT01756950|Experimental|Cohort 3 - CR8020|15 mg/kg CR8020
9468045|NCT03651544|Experimental|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
9468046|NCT03651531|Active Comparator|insulin|
9468047|NCT03651531|Active Comparator|insulin and metformin|
10030171|NCT01756950|Placebo Comparator|Cohort 3 - Placebo|5% dextrose in water
10030172|NCT01756950|Experimental|Cohort 4 - CR8020|30 mg/kg CR8020
10030173|NCT01756950|Placebo Comparator|Cohort 4 - Placebo|5% dextrose in water
10030174|NCT01756950|Experimental|Cohort 5 - CR8020|50 mg/kg CR8020
10030175|NCT01756950|Placebo Comparator|Cohort 5 - Placebo|5% dextrose in water
10030176|NCT01756950|Experimental|Cohort 6 - CR8020|30 mg/kg CR8020
10030177|NCT01756950|Placebo Comparator|Cohort 6 - Placebo|5% dextrose in water
10030178|NCT01756963||IBD-SL cohort|
10030179|NCT01756989|Experimental|Thalidomide, etoposide, celecoxib|Single arm study,phase II
10030180|NCT01757002|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
10030181|NCT01757002|Active Comparator|Control|Teens in the control group will receive generic, web-based asthma education.
10030182|NCT01757015|Placebo Comparator|Placebo|Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
10030183|NCT01757015|Experimental|NVA237|NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
10030184|NCT01757054|Experimental|Probiotic group|
9468048|NCT03651466|Experimental|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
10030185|NCT01757054|No Intervention|Control group|This is a non-supplemented control group that will follow the same dietary and medication restrictions. The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure.
10030186|NCT01757080|Experimental|Diabetic-hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
10030187|NCT01757080|Active Comparator|Hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
10030188|NCT01757093|Experimental|Automatic tube compensation plus CPAP|The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
10030189|NCT01757093|Active Comparator|Continuous Positive Airway Pressure|The patients is going to undergo a trial of spontaneous breathing with continuous positive airway pressure and later with automatic tube compensation plus continuous positive airway pressure, during 30 minutes each.
10030190|NCT01757106|Experimental|Drug: Xenon|gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
9468049|NCT03651466|Experimental|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
9468050|NCT03651466|Experimental|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
10030191|NCT01757106|Active Comparator|Drug: Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery
10030192|NCT01757119|Experimental|Drug|
9468051|NCT03651466|Experimental|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
9468052|NCT03651466|Experimental|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
9468053|NCT03651466|Experimental|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
10030193|NCT01757132|Other|Implantable Miniature Telescope|Post approval study
9468054|NCT03651453|Active Comparator|Standard Care|Participants will receive standard information about harm reduction as available at the drug treatment centers.
9468055|NCT03651453|Experimental|Decision aid|Participants in this arm will receive the adapted decision aid for PrEP.
9468056|NCT03651440|Experimental|lumbar stabilization training|lumbar stabilization training exercises
10030194|NCT01757145|Experimental|Eltrombopag|"Eltrombopag will be given orally as a single daily dose. From day +1 after cord blood transplantation, start eltrombopag 100 mg/d. If primary end point not reached on day +14,then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d (maximal dose). If dose not tolerated, return to last tolerated dose.~Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.~In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks.~After 4 weeks we will re-attempt to hold the drug."
10030195|NCT01757158|Experimental|Cs-131 brachytherapy seeds|sub-lobar resection plus cesium-131 brachytherapy
10030196|NCT01757223|Experimental|Part A, Group 1 - 10^8 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units.
10030197|NCT01757223|Experimental|Part A, Group 2 - 10^9 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units.
10030198|NCT01757223|Experimental|Part A, Group 3 - 10^10 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units.
10030199|NCT01757223|Experimental|Part B, Group 1 - AdVEGF-All6A+|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
10030200|NCT01757223|Experimental|Part B, Group 2 - AdNull placebo|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
10036943|NCT01820377|Experimental|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4 students, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s act as the intervention group.
10037592|NCT01826474|Experimental|PRO045, cohort 5|9.0 mg/kg until move to 48 week treatment phase
9468057|NCT03651440|Experimental|PNF training|PNF training exercises
9468058|NCT03651440|Experimental|physical therapy|HP,TENS US
9468059|NCT03651440|Sham Comparator|control|NO APPLİCATİON
9468060|NCT03651427|Experimental|Transgender Women|"Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.~If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.~After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition."
9468061|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
9468062|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
10030201|NCT01757236|Active Comparator|Treatment A|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
10030202|NCT01757236|Experimental|Treatment B|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).~The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
10030203|NCT01757236|Experimental|Treatment C|IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
10030204|NCT01757249|Experimental|Group 1 OCP|Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
10030205|NCT01757249|No Intervention|Group 2 Control|Control Group - no intervention
9468063|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
9468064|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
10030206|NCT01757262|Experimental|Ticagrelor|90 mg Ticagrelor
9468065|NCT03651375|Experimental|Sequential chemoradiotherapy|1xAI (doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm) + 5x5 Gy radiotherapy + 2xAI + surgery
9468066|NCT03651349|Placebo Comparator|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
9468067|NCT03651349|Experimental|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
9468068|NCT03651349|Experimental|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
9468069|NCT03651349|Experimental|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
9468070|NCT03651349|Experimental|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
10030207|NCT01757262|Active Comparator|Clopidogrel|75mg Clopidogrel
10030208|NCT01757314||CA 1 and 2 anethesia residents|palpation technique
10030209|NCT01757314||Ca1 and 2 residents|ultrasound guided technique
10030210|NCT01757327|Experimental|Arm I (erismodegib [LDE225])|400 mg daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
10030211|NCT01757327|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
10030212|NCT01757340|No Intervention|Weight maintenance|Weight maintenance with normal protein and leucine intake
10030213|NCT01757340|Active Comparator|Weight loss with normal protein intake|
10030214|NCT01757340|Experimental|Weight loss with leucine supplementation|
10030215|NCT01757353|Active Comparator|Self-directed: Information only|Participants in this arm will complete a baseline assessment, followed by a 50-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students; BASICS) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
10030216|NCT01757353|Active Comparator|BASICS motivational interview|Participants in this arm will complete a baseline assessment, immediately after which they will be administered alcohol-related informational sheets. These participants will participate in follow-up assessment sessions at approximately 3 and 9 months.
10036944|NCT01820377|No Intervention|Control Group|This group acts as a control, and are not apart of the Aboriginal Youth Mentorship Program
10037593|NCT01826474|Experimental|PRO045, cohort 6|48 week treatment phase
9468071|NCT03651349|Experimental|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
9468072|NCT03651349|Experimental|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
9468073|NCT03651349|Experimental|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
9468074|NCT03651310|No Intervention|Control Group|waiting in preoperative area without music listening.
9468075|NCT03651310|Active Comparator|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
9468076|NCT03651297|Experimental|Younger Adults|First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
10030217|NCT01757353|Experimental|BASICS plus normative enhancement motivational interview|Participants in this arm will complete a baseline assessment, followed by a 60-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students, with a normative enhancement module) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
10030218|NCT01757366|Experimental|experimental|Ginsenoside Rg3 plus First-line Chemotherapy
10030219|NCT01757366|Active Comparator|Active Comparator|First-line Chemotherapy
10030220|NCT01757379|Experimental|13C-labeled acetate|
10030221|NCT01757379|Experimental|13C-labeled propionate|
10030222|NCT01757379|Experimental|13C-labeled butyrate|
10030223|NCT01757379|Experimental|Inulin|
10036945|NCT01820403|Experimental|portion size small|400 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
10036946|NCT01820403|Experimental|portion size medium|800 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
10036947|NCT01820403|Experimental|portion size large|1600 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
10036948|NCT01820403|No Intervention|control|no box lunch provided to participants.
10036949|NCT01820429||First 48 hours|Patients in the first 48 hours of non ST-elevation acute coronary syndromes.
10036950|NCT01820429||3 months after discharge|Patients with 3 months after hospital discharge for non ST-elevation acute coronary syndromes.
10036951|NCT01820442|Active Comparator|Lofexidine Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
9468077|NCT03651297|Experimental|Older adults|Second group will include 20 older adults with a self-reported history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
9468078|NCT03651284|Experimental|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
9468079|NCT03651284|Other|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools for three months, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
9468080|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
9468081|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
9468082|NCT03651232|Experimental|yoga|weekly prenatal yoga group class
9468083|NCT03651232|Active Comparator|support|weekly group support class
9468084|NCT03651219|Experimental|experimental group|Patients use Apatinib Mesylate tablets combined with Irinotecan.
9468085|NCT03651219|Active Comparator|controlled group|Patients use Irinotecan
9468086|NCT03651193||AOSD|Patients fulfill Japan's Yamaguch AOSD classification
9468087|NCT03651193||Control|Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
9468088|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
10036952|NCT01820442|Placebo Comparator|Placebo Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g., Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) to mimic titration for subjects randomized to lofexidine.
9468089|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
9468090|NCT03651141|Experimental|Neurodynamic Sliding|neurodynamic sliding consists of 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets.
9468091|NCT03651141|Experimental|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
9468092|NCT03651141|Sham Comparator|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
9468093|NCT03651115||Neonates with gentamicin|
10036953|NCT01820455|Active Comparator|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal Mupirocin ointment daily for 5 days
10036954|NCT01820455|Placebo Comparator|Soap baths, Lubricating jelly|Soap and water baths with lubricating jelly to each nare daily for 5 days
9468094|NCT03651115||Neonates with vancomycin|
9468095|NCT03651089|Active Comparator|SP16 0.0125|0.0125 mg/kg of SP16 will be administered by subcutaneous injection once
10036955|NCT01820468|Experimental|Adapted critical time intervention team|Community-based team will help facilitate early inpatient discharge and re-entry into the community.
10036956|NCT01820468|No Intervention|Regular inpatient care|
10036957|NCT01820481|Experimental|Treatment 1|
10036958|NCT01820481|Experimental|Treatment 2|
10036959|NCT01820481|Experimental|Treatment 3|
10036960|NCT01820481|Placebo Comparator|Placebo|
10036961|NCT01820494|Experimental|Experimental Infant Formula|Complete amino acid-based infant formula
10037594|NCT01826500||Patients|"Patients having any of the following criteria:~Patients with embryo transfer fresh or frozen~Patients from an IVF cycle,~Patients supported surgically for endometriosis"
10030224|NCT01757418|Experimental|Immune Globulin Intravenous|IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
10030225|NCT01757418|Placebo Comparator|Normal saline|An equivalent volume (weight-based)of normal saline
10030226|NCT01757431|Other|ECULIZUMAB|
10030227|NCT01757444|Experimental|BiPAP - A40|BiPAP with AVAPS AE mode
9468096|NCT03651089|Active Comparator|SP16 0.050|0.050 mg/kg of SP16 will be administered by subcutaneous injection once
9468097|NCT03651089|Active Comparator|SP16 0.20|0.20 mg/kg of SP16 will be administered by subcutaneous injection once
9468098|NCT03651089|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once
9468099|NCT03651076|Experimental|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
9468100|NCT03651076|No Intervention|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
9468101|NCT03651037|Experimental|Thrivors+BH|For Thrivors+BH, a module will be developed for users to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, users will be able upload and send videos of themselves exercising for feedback and assessment. This version will contain bone health educational content, mindfulness and nutrition resources.
9468102|NCT03651037|Experimental|Thrivors Basic|A Thrivors Basic version that lacks customization and video content will be developed. This version will contain bone health educational content, mindfulness and nutrition resources.
9468103|NCT03651024|Other|Treating Patients with ED|Treatment of patients with ED
9468104|NCT03650998|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
9468105|NCT03650998|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
9468106|NCT03650985|Experimental|TOCTD|Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent, will be involved. Fetoscope technique will be administered in suitable patients.
9468107|NCT03650972|No Intervention|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
9468108|NCT03650972|Active Comparator|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
9468109|NCT03650959|Experimental|Faculty-led|
9468110|NCT03650959|Experimental|Peer tutor-led|
9468111|NCT03650959|Experimental|Computer augmented self-directed learning|
9468112|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
9468113|NCT03650946||2|men with rising PSA after local definitive treatments
9468114|NCT03650946||3|m0CRPC with a PSA >1.0 or 2.0
9468115|NCT03650933|Experimental|G-CHOP|GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
9468116|NCT03650933|Active Comparator|R-CHOP|Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
10030228|NCT01757444|Active Comparator|BiPAP- ST|Patients receiving BiPAP- ST at home
10030229|NCT01757457|Experimental|Intracoronary abciximab|Intracoronary administration of an abciximab bolus during primary PCI
9468117|NCT03650907|Experimental|Group exercise program by coach|
9468118|NCT03650907|Sham Comparator|Self exercise|
9468119|NCT03650881|Experimental|Neutrogena ® Light Therapy Acne Mask (MASK)|Over-the-counter powered light-based device for the treatment of acne
9468120|NCT03650881|Active Comparator|Topical benzoyl peroxide 2.5% gel and OTC adapalene|Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel
9468121|NCT03650868|No Intervention|Control Group|No intervention will be applied to control group
9468122|NCT03650868|Experimental|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
9468123|NCT03650790|Active Comparator|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
9468124|NCT03650790|Active Comparator|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
10030230|NCT01757457|Active Comparator|Intravenous abciximab|Intravenous standard administration of an abciximab bolus during primary PCI
10030231|NCT01757470||Caprelsa Patient|All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
10030232|NCT01757470||Caprelsa Prescriber|All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
9468125|NCT03650790|Active Comparator|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
10030233|NCT01757483||Prescribers|
10030234|NCT01757496|Experimental|Cough Assist|These children will receive 2 Cough Assist sessions daily.
10030235|NCT01757496|No Intervention|Control group|These children receive standard care but no physiotherapy.
10030236|NCT01757509|Other|Intervention group|Participants in this group will receive a set dancing intervention along with their usual care.
10030237|NCT01757509|No Intervention|Control Group|The control group will continue with their usual medical regime, activities of daily living and exercise habits and at the end of the study participants in this group will be offered the set dancing intervention.
10030238|NCT01757522||ARDS group|Patients under mechanical ventilation since less than 24 hours at inclusion and presenting acute respiratory distress syndrome criteria.
10030239|NCT01757522||ALI group|Patients under mechanical ventilation and presenting acute lung injury criteria.
9468126|NCT03650751||stroke patients；neurologic impairment|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
9468127|NCT03650738|Experimental|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
9468128|NCT03650699|Experimental|Self-Directed Tongue Strengthening Rehab|"8 sessions of self-directed tongue strengthening exercises followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
9468129|NCT03650699|Experimental|SLP Directed Face-to-Face Rehab|"8 sessions of SLP-directed face-to-face rehabilitation program followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
9468130|NCT03650660||Patients with liver cirrhosis|
9468131|NCT03650647|Active Comparator|Indirect Pulp Capping|"Nonselective removal to hard dentine (formerly complete excavation or complete caries removal) : removal of soft dentin, only hard dentine is left on the cavity, so that demineralized dentine free of bacteria is completely removed.~Intervention: Total soft and leathery caries removal. Carious dentin removal"
9468132|NCT03650647|Experimental|Stepwise excavation|"Stepwise removal is carious tissue removal in 2 stages, i.e., visits. Soft carious tissue is left over the pulp in the first step, while peripheral dentine is prepared to hard dentine to allow a complete and durable seal of the lesion. A provisional restoration is placed, which should be sufficiently durable to last up to 6 months to allow changes in the dentine and pulp to take place. After this period, a second excavation is done and, if there is hard dentin formed, the tooth is restored.~Intervention: Part of the soft caries is removed. Final restoration is placed on the second visit. Carious dentin removal"
9468133|NCT03650647|Experimental|Selective caries removal|"Selective caries removal: only part the soft dentine is removed, so soft carious tissue is left over the pulp, while peripheral enamel and dentine are prepared to hard dentine, to allow a tight seal and placement of a durable restoration.~Intervention: Part of the soft caries is removed. Final restoration is place over the soft dentin. Carious dentin removal"
9468134|NCT03650621|Experimental|Intervention - Magnetic acupuncture|"Infants randomized to the intervention arm will have 5 magnetic stickers placed on both ears approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
9468135|NCT03650621|Placebo Comparator|Control - Placebo control|"In this arm the infants will have 5 stickers (magnets removed) placed on their ear approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
10030240|NCT01757522||Control Group|Patients under mechanical ventilation for a non-respiratory cause
9468136|NCT03650608|Experimental|Cohort 1: HL217 Ophathalmic Solution QD|HL217 3mg/mL, Ophthalmic solution, two drop once a day
9468137|NCT03650608|Experimental|Cohort 2: HL217 Ophathalmic Solution BID|HL217 3mg/mL, Ophthalmic solution, two drop twice a day
9468138|NCT03650608|Experimental|Cohort 3: HL217 Ophthalmic Solution QID|HL217 3mg/mL, Ophthalmic solution, two drop four times a day
9468139|NCT03650608|Placebo Comparator|Placebo Ophthalmic solution|Placebo Ophthalmic solution, two drop once or twice or four times a day
9468140|NCT03650595|Experimental|Single arm prospective clinical trial|This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time
9468141|NCT03650582|Experimental|Glucagon|Glucagon, 0.7mg, intranasal, single dose
9468142|NCT03650582|Placebo Comparator|Placebo|Placebo, intranasal, single dose
10030241|NCT01757548|Experimental|open operation|high ligation of spermatic vein by open operation
9468144|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 1|"This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days."
9468145|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 2|"This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 *1/*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 *1/*2 or *1/*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 *2/*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner."
9468146|NCT03650530|Experimental|The Family Talk Intervention|These families will participate in a psychosocial support program.
10030242|NCT01757548|Experimental|microsurgery|high ligation of spermatic vein by microsurgery
10030243|NCT01757574|Experimental|Alemtuzumab|Open label study of alemtuzumab
10030244|NCT01757587|Active Comparator|Vildagliptin|
10030245|NCT01757587|Placebo Comparator|Placebo|
10030246|NCT01757600||Macular Hole|
10030247|NCT01757613|Active Comparator|AK 3012 a for topical use|
10030248|NCT01757613|Active Comparator|AK 3012 b for topical use|
10030249|NCT01757613|Active Comparator|AK 3012 c for topical use|
10037595|NCT01826500||Controls|Controls
10030250|NCT01757626|Experimental|Hu3F8 with GM-CSF|The phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. The expansion phase II single arm trial assesses the anti-NB activity of hu3F8+GM-CSF.in 3 groups of patients: Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123I-MIBG scan. Group 2 patients are in ≥2nd CR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123I-MIBG scan. Ph II: Groups 1 & 3 pts can continue to get cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved.
10030251|NCT01757626|Experimental|expansion phase II single arm trial|Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123^I-MIBG scan. Group 2 patients are in >2nd CR/VGPR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123^I-MIBG scan. GM-CSF can be omitted if patients have a history of an allergy to GM-CSF or develop an allergic reaction to GM-CSF after initiating therapy while on the protocol.
10030252|NCT01757639|Experimental|Treatment (ipilimumab)|"INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 12 weeks after last dose of induction ipilimumab, patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
10030253|NCT01757743||Interventional closure|Interventional catheterization closure
10030254|NCT01757743||Open Heart Surgery|Surgery for Atrial septal defect
10030255|NCT01757756|Experimental|Arm Label Pf-05175157, placebo, midazolam|
10030256|NCT01757769|Experimental|Silodosin|Silodosin capsule 8 mg daily for 24 weeks
9468147|NCT03650517||Robotic Right Colectomy with ICA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
9468148|NCT03650517||Robotic Right Colectomy with ECA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
9468149|NCT03650517||Laparoscopic Right Colectomy with ICA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
9468150|NCT03650517||Laparoscopic Right Colectomy with ECA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
9468151|NCT03650504|Experimental|Above Artery Group|
9468152|NCT03650504|Active Comparator|Between Artery and Vein Group|
9468153|NCT03650478|Experimental|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
9468154|NCT03650478|Experimental|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
9468155|NCT03650465|Experimental|CT/BTP|Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck & Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
9468156|NCT03650465|Experimental|REBT|Cognitive-behavioral therapy (CBT) in the form of REBT was based on the approach of Dryden & DiGiuseppe (1990), having as a central tenet changing dysfunctional emotions (e.g., anxiety) into functional ones (e.g., healthy anxiety/concern) by changing irrational beliefs into rational beliefs using cognitive, emotive, and behavioral techniques. The structure of an REBT session parallels the CT/BTP session structure including the same elements, but often with a different content. In its elegant/specific form, used here, REBT is focused on changing the core irrational beliefs (i.e., evaluative beliefs/appraisals) seen as the fundamental etiopathogenetic mechanism of GAD.
9468157|NCT03650465|Experimental|ACT/ABBT|Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
9468158|NCT03650426|Active Comparator|Onlay patellar resurfacing technique|
9468159|NCT03650426|Experimental|Inlay patellar resurfacing technique|
9468160|NCT03650361|Experimental|Test Product|Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
9468161|NCT03650361|Active Comparator|Reference Product|Adapalene Gel 0.3%, , applied for 84 days
9468162|NCT03650361|Placebo Comparator|Placebo Control|Vehicle of the test product, applied for 84 days
10030257|NCT01757782|Active Comparator|Oral Sildenafil|In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
9468163|NCT03650348|Experimental|PRS-343 in Combination with Atezolizumab|
9468164|NCT03650335||group I|with a total of 20 mL 0.25% bupivacaine injection to be administered
9468165|NCT03650335||group II|with a total of 30 mL 0.25% bupivacaine injection to be administered
9468166|NCT03650322|Experimental|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
9468167|NCT03650322|Active Comparator|Stretching and Toning|This 12 week, progressive stretching and toning course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
9468168|NCT03650322|Experimental|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
9468169|NCT03650309|Experimental|Deep Brain Stimulation|All patients will receive deep brain stimulation (DBS) targeting two brain areas involved in the pathophysiology of obesity. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
9468170|NCT03650296||Resusci Baby|Resusci Baby used for the simulated emergency scenario
9468171|NCT03650296||MegaCode-Kid|MegaCode-Kid used for the simulated emergency scenario
9468172|NCT03650296||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
9468173|NCT03650270|Experimental|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
9468174|NCT03650270|Active Comparator|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
9468175|NCT03650257|Experimental|gp96 group|"Patients receive standard treatment with radiation and temozolomide after surgery.~Then 6 times of autologous gp96 vaccination are administered via subcutaneous injection in 25μg doses at the 2nd week after the end of postoperative radiotherapy.~( gp96 is administered once a week for the first 4 weeks, the 5th injection is administered 2 weeks after the 4th injection, and the 6th injection is administered 3 weeks after the 5th injection. )~The first adjunctive temozolomide startes on the day of the fifth gp96 injection.~(150-200 mg/m2/day for 5 days, then stop for 23 days, one cycle is 28 days for a total of 6 cycles)"
9468176|NCT03650257|Active Comparator|control group|Patients receive standard treatment with radiation and temozolomide after surgery. Then only adjuvant treatment with temozolomide is administered.
9468177|NCT03650244||Patients fitted with REMEEX|
9468178|NCT03650218|Experimental|THIODERM STRONG|"THIODERM STRONG injected into the upper arm (cohort 1)~THIODERM STRONG injected into nasolabial folds (cohort 2)"
9468179|NCT03650205|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.
9468180|NCT03650205|Placebo Comparator|Placebo|Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.
9468181|NCT03650179||Patients enrolled in the cohort|Patients over 18 years old, consulting for functional digestive disease, without neurologic or urologic disease, and performing an urodynamic examination in neuro-urology and functional explorations department.
9468182|NCT03650166|Active Comparator|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
9468183|NCT03650166|Experimental|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
9468184|NCT03650153|Active Comparator|Trans-rectal MRI targeted Biopsy|Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
9468185|NCT03650153|Active Comparator|Trans-perineal MRI targeted Biopsy|Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
9468186|NCT03650140|Active Comparator|Tart cherry concentrate 60 mL|Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
9468187|NCT03650140|Active Comparator|Tart cherry concentrate 120 mL|Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
9468188|NCT03650088|Experimental|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
9468189|NCT03650075|Placebo Comparator|Single Ascending Dose (SAD)|
9468190|NCT03650075|Placebo Comparator|Multiple Ascending Dose (MAD)|
9468191|NCT03650075|Experimental|Food Effect Part|
10030258|NCT01757782|Placebo Comparator|Distilled water|In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
9468192|NCT03650023|Experimental|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.
10030259|NCT01757795|Experimental|SP-8203|Active arm
10030260|NCT01757795|Placebo Comparator|Placebo|Matching Placebo
10030261|NCT01757808|Experimental|Ranolazine|
10030262|NCT01757808|Placebo Comparator|Placebo|
10030263|NCT01757834|Experimental|SWUS Elastography|This is a noninvasive technique using focused ultrasonic beams (pushing beams.) Several pushing beams at increasing depths are transmitted to generate a quasi-plane shear wave frame that propagates throughout the imaging area. After generating the shear wave, an ultrafast imaging sequence is performed to acquire successive raw radiofrequency dots at a very high frame rate (up to 20,000 per second). A tissue elasticity assessment can be derived from shear wave propagation speed. A color-coded image is displayed; softer tissue in blue and stiffer tissue in red. Quantitative information is delivered by drawing regions of interest on the thyroid and surrounding tissues which is the Elasticity Index expressed in kilo-Pascal (kPa). Due to the lack of manual compression and known value of the strength of pushing beam, SWUS gives an objective number to stiffness within the nodule.
10030264|NCT01757860|Experimental|CARD-024|CARD-024 oral administered: 3, 9, 27 or 81 mcg.
10030265|NCT01757860|Placebo Comparator|Drug Carrier|Placebo: 20% ethanol:80% propylene glycol solution oral administered.
10030266|NCT01757873|Experimental|Z160|375 mg BID
10030267|NCT01757873|Placebo Comparator|Placebo|matching placebo control
10030268|NCT01757886||ST-elevation acute coronary syndrome|ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty
10030269|NCT01757899|Active Comparator|Methylprednisolone Arm|"The patients in this arm will receive methylprednisolone, which is available in vials containing 125 mg/2mL after dilution, as it follows:~Day 0 Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day"
9468193|NCT03650023|Placebo Comparator|White egg|White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.
9468194|NCT03649997|Experimental|Part 1 (Single Ascending Dose [SAD]): Cohort 1|Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.
9468195|NCT03649997|Experimental|Part 1 SAD: Cohort 2|Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.
10030270|NCT01757899|Placebo Comparator|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
10030271|NCT01757912|Experimental|Cuff pressure after positioning|The patient will be positioned in 16 distinct body positions. Immediately after correct positioning, the cuff pressure is measured.
10030272|NCT01757925|Experimental|Active Gaming|Participants will receivce a weight management program plus active gaming device
10030273|NCT01757925|Active Comparator|Control Group|Participants will receive a weight management program without active gaming
10030274|NCT01757938|Experimental|Shang Ring Guided Circumcision|The Shang Ring (SR) (Wuhu Santa Medical Devices Technology Co Ltd, China) male circumcision performed by study surgeon (study PI). In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine. The surgeon measured participants in the SR group to determine ring size. Patients for whom a suitable ring size was not available crossed over to the FG group, but remained in the SR group for intention to treat (ITT) analyses.
10030275|NCT01757938|Active Comparator|Forceps Guided Circumcision|Standard forceps guided adult male circumcision was performed. In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine.
10030276|NCT01757951|Experimental|Unimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
10030277|NCT01757951|Active Comparator|Bimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
10030278|NCT01757977|Experimental|Vivasight DL|placement and intraoperative use of Vivasight DL double lumen endobronchial tube
10030279|NCT01757977|Active Comparator|standard DLT|placement and intraoperative use of a standard double lumen endotracheal tube.
10030280|NCT01757990|Experimental|Stevioside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Stevioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
10030281|NCT01757990|Experimental|Rebauside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
10030282|NCT01757990|Sham Comparator|Saccarosio|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
10030283|NCT01758029||Testosterone Undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
10030284|NCT01758042|Other|Haploidentical Bone Marrow/Kidney|Single Arm Study
10030285|NCT01758055|Experimental|Autologous MSCs transplantation|intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once
9468196|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence CDEF|Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
9468197|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence DFCE|Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.
10030286|NCT01758068|Experimental|Coconut Oil Application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
9468198|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence ECFD|Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.
9468199|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence FEDC|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.
9468200|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence GHIJ|Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.
10030287|NCT01758068|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
10030288|NCT01758094||Hypogonadotropic hypogonadism patients|Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
10030289|NCT01758107|Experimental|Sirolimus with Prednisolone|Sirolimus with Prednisolone, and withdraw cyclosporine
10030290|NCT01758107|No Intervention|Sirolimus with Cyclosporine with Prednisolone|
10030291|NCT01758120|Experimental|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)
10030292|NCT01758120|Experimental|prednisone alone|prednisone alone: prednisone(0.5mg/kg/day*6 months)
10030293|NCT01758133||Mothers exposed to medical clowns|Mothers of premature infants who have been exposed to medical clown activities
10030294|NCT01758133||Mothers not exposed to medical clown activity|
10030295|NCT01758146|Experimental|Arm A- Letrozole|Aromatase inhibitor- letrozole 2.5mg once daily for 5 years
10030296|NCT01758146|Active Comparator|Arm B- Tamoxifen|Tamoxifen 20 mg once daily for 5 years
10030297|NCT01758159|Experimental|CFR group|The children in this group will receive complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
10030298|NCT01758159|Experimental|Fe group|The children in this group will receive iron supplementation 2mg/kg/day of ferric Na EDTA (in the form of syrup) daily for 24 weeks duration.
10030299|NCT01758159|Experimental|CFR + Fe group|The children in this group will receive both local food-based complementary feeding according to CFR and Iron supplementation for 24 weeks duration
10030300|NCT01758159|Placebo Comparator|Control group|The children in this group will receive basic health services and placebo syrup.
10030301|NCT01758172|Active Comparator|Albumin|albumin was administered to reach CVP up to 7mmHg
10030302|NCT01758172|Experimental|6% hydroxyethyl starch 130/0.4|6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg
10030303|NCT01758185|Placebo Comparator|recombinant hepatitis b vaccine|0.5ml intramuscular
10030304|NCT01758185|Experimental|Aleph influenza vaccine|0.5ml intramuscular
10030305|NCT01758198|Experimental|Group 1: Abatacept + Methotrexate (MTX)|"Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
10030306|NCT01758198|Placebo Comparator|Group 2: Placebo matching with Abatacept + Methotrexate|"Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
10030307|NCT01758211|Experimental|fMRI guided resection of AVM|fMRI Navigation AVM resection in AVM patients
10030308|NCT01758211|Active Comparator|conventional AVM resection|conventional resection of AVM
10030309|NCT01758224|Experimental|Functional Magnetic Stimulation|This group will receive magnetic stimulation of the respiratory (breathing) muscles that may improve the breathing function in subjects with MS. The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes).
9468201|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence HJGI|Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.
9468202|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence IGJH|Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.
9468203|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence JIHG|Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.
9468204|NCT03649997|Experimental|Part 3 Cohort 5: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.
9468205|NCT03649997|Experimental|Part 3 Cohort 6: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.
9468206|NCT03649984|Experimental|Symptom Navi© Program|Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers
9468207|NCT03649984|No Intervention|Standard care|Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.
9468208|NCT03649945|Active Comparator|Test Group 1|Docetaxel plus Nedaplatin combined with Endostar
9468209|NCT03649945|Active Comparator|Test Group 2|Docetaxel plus Nedaplatin
9468210|NCT03649945|No Intervention|Control Group|No medicine intervention
9468211|NCT03649919||1 spinal muscular atrophy, SMA|Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
9468212|NCT03649919||2 DMD|Progressive muscular dystrophy (DMD) is a group of hereditary skeletal muscle degeneration diseases. It is clinically characterized by slow and progressive development of muscle atrophy and muscle weakness. The inheritance can be divided into sexual chain recessiveness. Genetic type. For children with high suspected DMD/BMD, the current DMD diagnosis is preferred by MLPA method for detection of DNA in peripheral blood; MLPA diagnostic kit can only detect about 65% of large gene deletions or repeat types, thus detecting undetected gene mutations.
9468213|NCT03649919||3 X-linked adrenoleukodystrophy X-ALD|X-linked adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive hemiplegia are more common symptoms.
9468214|NCT03649919||4 tuberous sclerosis complex，TSC|Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease involving multiple systems. About 1 in every 6,000-10,000 people in TSC suffer from tuberous sclerosis, and children in the neurology department are diagnosed with developmental delay or seizures, and about 2/3 have no positive family history. Nearly 2 million people worldwide suffer from TSC, and there are about 200,000 in China.
10030310|NCT01758224|Active Comparator|Resistive Expiratory Muscle Training|Participants in this group will perform breathing exercises using a resistive breathing device. The training will take place in the FMS lab. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home.
10030311|NCT01758237|Experimental|Superior Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the superior aspect of the iris in the eye being treated. This will be in the 11 to 1 o'clock position.
10030312|NCT01758237|Experimental|Temporal Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the temporal aspect of the iris in the eye being treated. The position will be in the 2 to 4 o'clock in the left eye and 8 to 10 o'clock in the right eye.
10030313|NCT01758250||Systemic Sclerosis|Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
10030314|NCT01758250||GVHD|Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.
9468215|NCT03649906|Experimental|Optimized Localization Group|Subjects have small pulmonary nodules. In order to facilitate the search for nodules during surgery, it is necessary to indwelling markers pre-operative.
10030315|NCT01758250||Undergoing HSCT|Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.
9468216|NCT03649893|No Intervention|Control Group|The control group will use conventional siiting-desk office.
9468217|NCT03649893|Experimental|Active Office Group|The experimental group will use active offfice, including sit-to-stand desk, bike desk, seddle chair and active breask.
9468218|NCT03649828|Experimental|kefir group|The kefir group (KG) received orally probiotic milk fermented with kefir grains and was compared with the control group (CG) that received only curd
9468219|NCT03649828|Experimental|control group|control group (CG) that received only curd
9468220|NCT03649789||No Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of greater than 0.1 mL saliva/min.
9468221|NCT03649789||Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of less than 0.1 mL saliva/min.
9468222|NCT03649763|Active Comparator|Lidocaine distal forearm|Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
9468223|NCT03649763|Active Comparator|Bupivacaine distal forearm|Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
9468224|NCT03649763|Active Comparator|Lidocaine distal and proximal forearm|Lidocaine 1%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Lidocaine 1%. Volume injected is 3 mL/nerve; 12 mL total
9468225|NCT03649763|Active Comparator|Bupivacaine distal and proximal forearm|Bupivacaine 0.5%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Bupivacaine 0.5 %. Volume injected is 3 mL/nerve; 12 mL total.
9803047|NCT04633993|Experimental|PCSMP|Patient-centered self-management program for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
9803048|NCT04633993|No Intervention|Usual Care|Routine care.
10030316|NCT01758250||Controls|Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.
10030317|NCT01758250||Sickle cell disease|Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
10030318|NCT01758250||Cutaneous fibrosing disorder|Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.
10030319|NCT01758263||Metoprolol to Nebivolol|Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
10030320|NCT01758276||Non smokers|Women who did not report smoking in pregnancy
10030321|NCT01758276||Smokers in pregnancy|Women who report smoking in pregnancy
10030322|NCT01758302|Active Comparator|No physical task + Taste cookies|Participants in this arm do not engage in a physical activity task. They are asked to taste test chocolate chip cookies.
10030323|NCT01758302|Active Comparator|No physical task + Taste vegetable|Participant does not complete a physical activity. Asked to taste test raw celery or radishes.
10030324|NCT01758302|Active Comparator|Simple physical task + Taste vegetables|Participants are asked to complete a simple physical task and are asked to taste test raw celery or radishes.
10030325|NCT01758302|Active Comparator|Complex physical task + Taste vegetables|Participants complete a more complex physical task that is novel and challenging. They are asked to taste test raw celery or radishes.
10030326|NCT01758315|Experimental|Improvement Sessions|We will implement a context-sensitive collaborative improvement model that will emphasize training and in-office coaching by quality improvement, efficiency and safety experts, as well as shared learning methods to develop, test and implement changes in the following four key risk areas: medication management; test and lab results management; follow-up and referral management; and communication - within and between practices as well as with patients.
10030327|NCT01758315|No Intervention|Control|Control practices will not receive training or in-office coaching.
10030328|NCT01758341|Experimental|Malignant biliary obstruction|All patients who underwent endoscopic radiofrequency ablation with the HabibTM EndoHBP as a treatment for malignant biliary obstruction in Austria between November 2010 and December 2012.
10030329|NCT01758354|Experimental|Pompe disease newborn screening|newborns will be tested if they were affected by Pompe disease
10030330|NCT01758367|Experimental|Decitabine+DLI|Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.
10030331|NCT01758380|Experimental|Vildagliptin + placebo to Gliclazide|Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
10030332|NCT01758380|Active Comparator|Gliclazide + placebo to Vildagliptin|Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
10030333|NCT01758393|Experimental|Medium Dose|Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
9468226|NCT03649737|Experimental|Supportive care (exercise)|Participants attend supervised group exercises classes twice per week during weeks 1-6 and once per week during weeks 7-12. Participants also attend home-based unsupervised exercise sessions via an instructional DVD once per weeks over for 30 minutes during weeks 1-6 and twice per week during weeks 7-12.
9468227|NCT03649724|Placebo Comparator|Placebo|0.25 ml of sterile normal saline administered subcutaneously / 12 weeks
10030334|NCT01758393|Experimental|High Dose|Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
10030335|NCT01758406|Experimental|cardiac stem cell transplantation|The patients with heart failure that underwent cardiac stem cell transplantation.
9468228|NCT03649724|Experimental|Leuprolide|Eligard 22.5mg administered subcutaneously / 12 weeks
9468229|NCT03649711|Experimental|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
9468230|NCT03649711|Active Comparator|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
9468231|NCT03649711|Active Comparator|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
9468232|NCT03649698|Experimental|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
9468233|NCT03649698|Experimental|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
9468234|NCT03649698|Experimental|2 Anabolic interventions|Home-based training program and high quality protein supplement
9468235|NCT03649698|Experimental|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
9468236|NCT03649698|Placebo Comparator|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
9468237|NCT03649685|Active Comparator|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
9468238|NCT03649685|Experimental|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
9468239|NCT03649685|Experimental|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
9468240|NCT03649685|Sham Comparator|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
9468241|NCT03649659|Experimental|Silver Diamine Fluoride (SDF)|SDF will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
9468242|NCT03649659|Placebo Comparator|Placebo|The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
9468243|NCT03649620|Experimental|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
9468244|NCT03649620|Placebo Comparator|Placebo|Placebo for 12 weeks
9803049|NCT04633278|Experimental|CMP-001 and Pembrolizumab|All subjects will receive CMP-001 IT and pembrolizumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
10030336|NCT01758406|Placebo Comparator|Placebo|The patients with heart failure that underwent placebo injection.
10030337|NCT01758419||Tomotherapy|Breast cancer female s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT. Comparing the clinical follow-up data between different groups (left-sided s/p tomography, left-sided s/p conventional RT, and right-sided RT), respectively.
10030338|NCT01758445|Experimental|Proton Radiotherapy|Proton Radiotherapy
10030339|NCT01758471|Experimental|Acarbose|The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month. With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)<7.0,PBG(postprandial blood glucose)<10.0
10030340|NCT01758471|Active Comparator|glipizide|There is no fixed dosage of glipizide to control hyperglycemia for patients in this group. As long as the targeted blood glucose concentration is reached, FBG< 7.0, PBG< 10.0, patients will have the least dosage of glipizide according to their glucose level.
10030341|NCT01758484|Experimental|Supportive care (palliative care support)|Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center.
10030342|NCT01758497|Active Comparator|Ropivacaine|US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
10030343|NCT01758497|Sham Comparator|Saline|US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
10030344|NCT01758510|Experimental|HYNR-CS-Allo|HYNR-CS-Allo inj. 2 times by intrathecal administration with 28 days interval.
10030345|NCT01758536|Placebo Comparator|Placebo Pills|"12 g each time, twice daily.~3 months"
10030346|NCT01758536|Experimental|Huatuo Zaizao Pills|"12 g each time, twice daily.~3 months."
10030347|NCT01758549|Experimental|Aggressive Intravenous Hydration Group|Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.
10030348|NCT01758549|Active Comparator|Standard Fluids Arm|Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.
10030349|NCT01758562|No Intervention|State-of-the-art mouth care|
10030350|NCT01758562|Active Comparator|Mouth rinse Caphosol|Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.
10030351|NCT01758575||antiangiogenic tyrosine kinase inhibitors|Sunitinib: 50 mg orally once daily Sorafenib: 400 mg orally twice daily Pazopanib: 800 mg orally once daily
10030352|NCT01758575||EGFR inhibitors|Cetuximab 250 mg/m2 intravenously, weekly Panitumumab 6 mg/Kg intravenously, every 2 weeks
10030353|NCT01758575||mTOR inhibitors|Everolimus 10 mg orally once daily
10030354|NCT01758575||BRAF inhibitor|Vemurafenib 960 mg orally twice daily
10030355|NCT01758575||anti-CTL4 antibody|Ipilimumab 3 mg/kg intravenously, every 3 weeks
10030356|NCT01758601|Experimental|Fish - no fish|The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Then switched to previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood.
10030357|NCT01758601|Active Comparator|No fish - fish|Patients were on previous diet except for the avoidance of fish and any other seafood for 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
9468245|NCT03649607|Other|Accelerated Resolution Therapy|Participants will complete a clinical intake assessment before meeting with the therapist and initiating the ART® protocol. Participants will receive the ART intervention over a 21-day period, where imaginal exposure and imagery re-scripting will be used replace previous traumatic experiences. The ART intervention will be assessed through pre- and post-test measures at 60-days post enrolment.
9468246|NCT03649594||TAVI and no therapeutic anticoagulation|Subjects in this group do not have an indication for therapeutic anticoagulation.
9468247|NCT03649594||TAVI and therapeutic anticoagulation|Subjects in this group have an indication for therapeutic anticoagulation such as atrial fibrillation.
9468248|NCT03649581|Experimental|patient with schizophrenia and periodic catatonia|
9468249|NCT03649581|Experimental|patient with schizophrenia and hebephrenia|
10030358|NCT01758627|No Intervention|Peritoneal dialysis group|
10030359|NCT01758627|Experimental|Conventional treatment group|medical treatment such as diuretics
10030360|NCT01758640|Active Comparator|Pregnant|Group of Pregnant patients who will receive either warfarin or phenindione according to the study design
10030361|NCT01758640|Active Comparator|Non Pregnant|Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design
9468250|NCT03649581|Active Comparator|healthy volunteers|
9468251|NCT03649568|Experimental|Pork|1 ounce lean pork
9468252|NCT03649568|Active Comparator|Egg|1 large whole egg
9468253|NCT03649568|Experimental|Black beans|0.5 cups cooked black beans
9468254|NCT03649568|Experimental|Almonds|1 ounce almonds
9480125|NCT03536689|Experimental|Upright maternal position change|The participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the upright position for 5 minute. After 5 minute of upright position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after upright position.
9480126|NCT03536689|Experimental|Left lateral decubitus maternal position change|the participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the left lateral decubitus position for 5 minutes. After 5 minutes of left lateral decubitus position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after left lateral decubitus position.
9480127|NCT03536650|Experimental|DMR procedure|
9480128|NCT03536637|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
9480129|NCT03536637|Experimental|Study Treatment 2|DMT310 Powder mixed with Placebo Diluent
9480130|NCT03536637|Experimental|Study Treatment 3|Placebo powder mixed with Hydrogen Peroxide
9480131|NCT03536637|Placebo Comparator|Control|Placebo powder mixed with Placebo Diluent
9480132|NCT03536624|Experimental|Experimental group|"Participants will be involved in a short-term spa residential program of 6 days combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.~After the program, participants will be followed for 12 months."
9480133|NCT03536611|Experimental|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
9480134|NCT03536611|Active Comparator|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
9480135|NCT03536598|Experimental|Test|Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
10030362|NCT01758653||Biorepository|Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
10030363|NCT01758666|Experimental|Methotrexate and Calcium folinate|
9480136|NCT03536598|Active Comparator|Reference 1|Amlodipine 10mg + Valsartan 160mg
9480137|NCT03536598|Active Comparator|Reference 2|Valsartan 160mg + Rosuvastatin 20mg
9480138|NCT03536533|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
9480139|NCT03536494|Experimental|Mirabegron intervention|Review the use of mirabegron and its discontinuation
9480140|NCT03536494|No Intervention|Control group|Usual care
9480141|NCT03536481|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.
10030364|NCT01758679|Experimental|Licartin，Licartin and CIK|Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
10030365|NCT01758692||Able-bodied Controls|"10 controls between the ages of 18 and 65 of either gender; free of cardiovascular disease and/or medication.~An addition 40 controls ages 18-89 of either gender, will perform the non-invasive manipulations only."
10036962|NCT01820507|Experimental|High Flow Conditioned Oxygen Therapy|Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
10036963|NCT01820507|Active Comparator|Standard Oxygen Therapy|The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.
10030366|NCT01758692||Spinal Cord Injury|"40 subjects to perform the pharmacological and non-invasive manipulations; between the ages of 18 and 65 years old in stable health for the last 6 months, non-smoker, and level of injury from C1 - S4 for over 1 year and an AIS classification of A, B, C. Free of arrhythmia, hypertension, cardiovascular disease, kidney disease, diabetes, neuropathies, neuromuscular disease, and sulfite allergies or hypersensitivity.~60 subjects to perform the non-invasive manipulations only; between 18-89 years of age in stable condition (>6 months), non-smoker. Level of injury from C1-S4 for over a year with a AIS classification of A, B, or C. No history of diabetes, autonomic neuropathy, parkinson's disease, or acute illness or infection. An additional 30 will perform the non-invasive testing before and after completion of an ambulatory training protocol."
10030367|NCT01758705||Cohort 1|Cohort 1
9468255|NCT03649555|Experimental|[18F]-FTC-146|[18F]-FTC-146
9468256|NCT03649542|Active Comparator|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
9468257|NCT03649542|No Intervention|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
9468258|NCT03649529|Experimental|GPA-TriMAR-T|Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.
9468259|NCT03649516|Experimental|iCKD APP Group|Use iCKD APP
9468260|NCT03649516|No Intervention|Traditional Care Group|Accept traditional care
9468261|NCT03649464|Experimental|OKN-007|Oral OKN-007
9468262|NCT03649425||hydroxyapatite coated pins|Patients submitted to surgical treatment with external fixators using pins coated with hydroxyapatite.
9468263|NCT03649425||uncoated steel pins|Patients submitted to surgical treatment with external fixators using uncoated steel pins.
9468264|NCT03649399|Experimental|Patients with pancreatic stent|abdominal ultrasound and x-ray for stent detection.
9468265|NCT03649386|Active Comparator|Control|Heated breathing circuit will turned off.
9468266|NCT03649386|Experimental|Heat|Heated breathing circuit will be turned on.
9468267|NCT03649373||ED Patients|We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
9468268|NCT03649334|Other|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
9468269|NCT03649334|Other|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
10030368|NCT01758718|Active Comparator|Entropion with Down's syndrome|Eyelash resection surgery was performed for entropion with Down's syndrome
10030369|NCT01758744|Experimental|Treprostinil|Inhaled prostanoid therapy with Treprostinil
10030370|NCT01758757|Active Comparator|Proliferative diabetic retinopathy|
10030371|NCT01758783|Placebo Comparator|placebo group|
10030372|NCT01758783|Experimental|Glutamine group|
10030373|NCT01758809|Active Comparator|Bupivacaine|
10030374|NCT01758809|Other|Intravenous Patient Controlled Analgesia|postoperative pain control with intravenous patient controlled analgesia
10030375|NCT01758822|Experimental|No Endotracheal suction|In the experimental group, endotracheal suction will not be performed during the initial steps of resuscitation of non-vigorous meconium stained neonate
10030376|NCT01758822|No Intervention|Endotracheal suction|In the No intervention group endotracheal suction will be performed during the initial steps of resuscitation of non - vigorous meconium stained neonate
10030377|NCT01758835|Active Comparator|Splint 3 weeks|Removable ankle brace/splint
10030378|NCT01758835|Active Comparator|Cast 3 weeks|Below-the-knee cast (glass fiber)
10030379|NCT01758835|Active Comparator|Cast 6 weeks|Below-the-knee cast (glass fiber)
10030380|NCT01758861|Experimental|EPO group|EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.
10030381|NCT01758861|Placebo Comparator|Placebo group|Placebo group received normal saline via intravenous bolus administration after induction of anesthesia.
10030382|NCT01758874|No Intervention|Non phlebotomy group (control group)|"• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation.~We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups.~Non phlebotomy arm has no phlebotomy treatment."
10030383|NCT01758874|Experimental|PH (study group)|"The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.~Procedures for therapeutic phlebotomy~Inject heparin 5000 units to prevent blood clot during phlebotomy~Inject volume expander equivalent to 5% of blood volume~Remove 5% of whole blood~Monitor the vital sign of the patient during the phlebotomy~They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc.~We will compare amputation and mortality between control and study groups."
10030384|NCT01758887||Controls|Healthy control
10030385|NCT01758887||patients|clinical high risk subjects for psychosis
10030386|NCT01758913|Experimental|Ibuprofen|Infant who was assigned to ibuprofen, an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours respectively as a course was given.
10030387|NCT01758926||Inflammatory bowel disease|Patients previously diagnosed as having IBD
9468270|NCT03649308|Experimental|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
9468271|NCT03649308|Active Comparator|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
10030388|NCT01758926||Health control|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
9468272|NCT03649295|Experimental|Functional Electrical Stimulation|"- Functional electrical stimulation device obeying the following steps: Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure. Conventional therapy should be performed in conjunction with functional electrostimulation~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
10030389|NCT01758939||Hepatitis C virus infected patients|
10030390|NCT01758952||Beijing Chaoyang Hospital|2000 cases
10030391|NCT01758952||Peking University Hospital|2000 cases
9468273|NCT03649295|Placebo Comparator|Placebo|"Sham.The electrodes are placed at 0 Hz~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
9468274|NCT03649282|Experimental|HFNC/NCPAP|HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
9468275|NCT03649282|Experimental|NCPAP/HFNC|NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
9468276|NCT03649269|Experimental|PC-300 tea|Patients that received the Eryngium heterophyllum + Amphipterygium adstringens tea, one cup half an hour before eating.
9468277|NCT03649269|Active Comparator|Bezafibrate|Patients that received fibrate (bezafibrate) 200 mg/day.
9468278|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
9468279|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
10030392|NCT01758952||Zhongshan Hospital of Fudan University|2000 cases
10030393|NCT01758952||Tongji Hospital, Wuhan|2000 cases
10030394|NCT01758952||Tangdu Hospital, Xi'an|2000 cases
10030395|NCT01758952||The Prince Welsh Hospital|1000 cases
10030396|NCT01758965|Experimental|combination therapy of H2RA and surgicel|H2RA and surgicel
10030397|NCT01758965|Experimental|Monotherapy of PPI|PPI
10030398|NCT01758978|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test)."
10030399|NCT01758978|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)."
10030400|NCT01758991|Active Comparator|real tDCS|"patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.~tDCS will be applied during swallowing therapy, during 20 minutes"
10030401|NCT01758991|Placebo Comparator|sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
10030402|NCT01759004|Active Comparator|patient with lipoedema|"Lipedema group:~diagnosed with lipedema following the criteria of Wold~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
10030403|NCT01759004|Active Comparator|patients with obesity|"Obesity group:~BMI ≥ 30~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
10036964|NCT01820520|Experimental|Double staining with brilliant blue G during vitrectomy|
10036965|NCT01820533||smokers|
9468280|NCT03649243||Propolis group|The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
9468281|NCT03649243||control group|the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
9468282|NCT03649191|Other|Intervention ACP Group|The BABEL Approach to Advance Care Planning in Nursing Homes
9468283|NCT03649191|Other|Control ACP Group|Control group Advance Care Planning
10036966|NCT01820598|Other|m-NMES first|Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
10036967|NCT01820598|Other|c-NMES first|Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
10036968|NCT01820611||With Bonemaster HA|100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite
10036969|NCT01820611||Without BoneMaster HA|100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite
10036970|NCT01820624|Experimental|Treatment (tretinoin, lithium carbonate)|Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10036971|NCT01820663|Experimental|Modified Atkins Diet|Patients will receive a 14 day menu consisting of the Modified Atkins diet, a low-carbohydrate, high protein, high fat diet.
10036972|NCT01820663|Placebo Comparator|Control Diet|Patients will receive a diet (e.g. regular, low cholesterol, diabetic) determined by the attending physician.
10036973|NCT01820676||iUni G2+|iUni G2+ in all patients
10036974|NCT01820689|Experimental|Tympanometry measurement|
10036975|NCT01820702|Active Comparator|defined training programme|
10036976|NCT01820702|No Intervention|Control|
10030404|NCT01759017||Infliximab responders|Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
10030405|NCT01759017||Infliximab non-responders|Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery
10030406|NCT01759030|Active Comparator|MabThera (F. Hoffmann-La Roche Ltd.)|"Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15).~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
10030407|NCT01759030|Experimental|BCD-020 (CJSC BIOCAD)|"Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15.~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
10030408|NCT01759043|Experimental|guiding catheter|a single transradial guiding catheter for coronary angiography and intervention in patients with STEMI
9468284|NCT03649165|Experimental|Treatment Sequence 1|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
9468285|NCT03649165|Experimental|Treatment Sequence 2|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
9468286|NCT03649165|Experimental|Treatment Sequence 3|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
10030409|NCT01759043|Active Comparator|Diagnostic catheter|Diagnostic catheter followed by guiding catheter selection for transradial primary PCI
10030410|NCT01759056|Active Comparator|AVX 470|AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
9468287|NCT03649165|Experimental|Treatment Sequence 4|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
9468288|NCT03649152|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
9468289|NCT03649152|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
9468290|NCT03649139|Active Comparator|artemisia annua (sweet sagewort) allergen extract drops|Drug: sublingual immunotherapy drops
9468291|NCT03649139|Placebo Comparator|Placebo drops|Drug: sublingual placebo drops
9468292|NCT03649126||Dutch pathologists hospital I|"Pathologists in hospital I using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
9468293|NCT03649126||Dutch pathologists hospital II|"Pathologists in hospital II using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
9468294|NCT03649126||Dutch pathologists hospital III|"Pathologists in hospital III using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
9468295|NCT03649126||Dutch pathologists hospital IV|"Pathologists in hospital IV using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
9468296|NCT03649126||Dutch pathologists hospital V|"Pathologists in hospital V using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
9468297|NCT03649126||Dutch pathologists hospital VI|"Pathologists in hospital VI using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
9468298|NCT03649113|Experimental|sclerotherapy arm|Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
10030411|NCT01759056|Placebo Comparator|Placebo|Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
10030412|NCT01759069|Experimental|treatment with microscope|treatment with microscope
10030413|NCT01759069|Experimental|treatment without microscope|treatment without microscope
10030414|NCT01759095|No Intervention|Control|At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
10030415|NCT01759095|Experimental|Electronic Multidrug Blister Pack|
9468299|NCT03649100|Experimental|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
10030416|NCT01759108|Experimental|Rebamipide|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of rebamipide for 12 weeks together with their usual therapy
10030417|NCT01759108|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of placebo for 12 weeks together with their usual therapy.
9468300|NCT03649100|Active Comparator|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
9468301|NCT03649074|Experimental|AKL-T01|AKL-T01 digital treatment.
10030418|NCT01759121|Active Comparator|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
10030419|NCT01759121|Experimental|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
10030420|NCT01759134|Experimental|Post Discharge Formula|Babies will be given formula for first three months post discharge
9468302|NCT03649061|Active Comparator|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
9468303|NCT03649061|Experimental|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
9468304|NCT03649048|Active Comparator|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
9468305|NCT03649048|Active Comparator|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
9468306|NCT03649009|Placebo Comparator|Normal Saline|"Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days for placebo group after recruitment and randomization done.~If patients develop rashes or redness after normal saline administration, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
9468307|NCT03649009|Active Comparator|IV Thiamine|"IV Thiamine 200mg diluted in 50mls normal saline infused over 1 hour 3 times per day for total 3 days for Thiamine group after recruitment and randomization done.~If patients develop nausea after thiamine administration, IV metoclopramide (antiemetic)10mg stat dose will be given. If patients develop redness and rashes after Normal Saline infusion, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
9468308|NCT03648996|Experimental|Low-fructose diet, isocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose while maintaining baseline body weight.
9468309|NCT03648996|Experimental|Allopurinol|Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)
9468310|NCT03648996|Placebo Comparator|Placebo|Subjects assigned to this arm will receive placebo
9468311|NCT03648996|Experimental|Low-fructose diet, hypocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose with a 500 Calorie energy reduction.
9468312|NCT03648970|Experimental|Pravastatin Treatment Group|In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
9468313|NCT03648970|No Intervention|Control Group|"In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.~In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group"
9468314|NCT03648957|Experimental|Behavioral intervention|Usual stroke service care plus additional lifestyle counselling focusing on smoking cessation, physical activity, and adherence to preventive medication. Regular follow-up sessions (3-4 weeks intervals). Physical activity is monitors by an activity tracker.
9468315|NCT03648957|Active Comparator|Usual care|Usual stroke service care; including computed tomography brain scan, neurological evaluation, and relevant cardiological/vascular evaluation (48-72 hour telemetry, echocardiography, carotic ultrasound imaging). At discharge all patients will receive written and verbal encouragement to a healthy lifestyle.
9468316|NCT03648944|Experimental|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
9468317|NCT03648944|Active Comparator|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
9468318|NCT03648931||Pregnant or Breastfeeding Women|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
9468319|NCT03648931||Male Partners|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
10030421|NCT01759147|Experimental|Surgery|Surgical repair of acromioclavicular dislocation.
10030422|NCT01759173||college athletes|
10030423|NCT01759186||None interventional|
10030424|NCT01759199|Experimental|The six minute Stepper Test|Experimental : The six minute Stepper Test with a Conventional respiratory rehabilitation
10030425|NCT01759212|Experimental|Stem cells implantation|Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.
10030426|NCT01759225||Cardiovascular Disease Patients|
10030427|NCT01759238|Experimental|Chemoradiation|Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)
9468320|NCT03648931||Grandmothers|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
9468321|NCT03648931||Key Informants|No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures.
10030428|NCT01759303|Experimental|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
10030429|NCT01759316|Active Comparator|heliox|Heliox is use in this group
10030430|NCT01759316|Placebo Comparator|Placebo|Oxygen is used in this group
10030431|NCT01759329|Experimental|test coffee|test coffee
10030432|NCT01759329|Active Comparator|control coffee|control coffee
10030433|NCT01759342|Experimental|Comprehensive exercise program|Moderate to high intensity aerobic, resistance, flexibility, posture and balance exercise program
10030434|NCT01759342|Active Comparator|Usual care exercise|30 minutes/day of self selected mode and intensity of aerobic exercise
10030435|NCT01759355||Surgery|Participants undergoing surgical intervention will receive a PET/MR scan prior and following surgery for a total of two (2) scans.
10030436|NCT01759355||Chemoradiation|Participants undergoing chemoradiation intervention will receive a PET/MR scan prior, during, and following chemoradiation for a total of three (3) scans.
10030437|NCT01759394|Experimental|Avatrombopag maleate 40 mg|
10030438|NCT01759459|Experimental|Lidocaine|1% Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
10030439|NCT01759459|Experimental|Buffered Lidocaine|"1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm~Buffered lidocaine is compounded by the following process:~2.3 mLs of 8.4% sodium bicarbonate is added to a vial of 1% lidocaine"
10030440|NCT01759459|Experimental|Bacteriostatic Normal Saline|Bacteriostatic Normal Saline for injection, 0.50 mL administered one time intradermally in peripheral forearm
9468322|NCT03648866||Physicians|interview physicians who have conducted compassion rounds
9468323|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
9468324|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
9468325|NCT03648866||Patients|interview patients who have participated in compassion rounds
9468326|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
9468327|NCT03648801||Hypertention, Dyslipidemia|NA (Observation study)
9468328|NCT03648762|Other|Heart failure patients|Patients diagnosis with heart failure will be assessed for the study
9468329|NCT03648749|Experimental|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided
9468330|NCT03648736||HOCM patients|selected for routine TASH procedure
9468331|NCT03648723||Diabetic nephropathy|Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
9468332|NCT03648723||Non-diabetic nephropathy|This group consisted of diagnosis with nephropathy without diabetes mellitus.
9468333|NCT03648710|No Intervention|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
9480142|NCT03536481|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.
9480143|NCT03536481|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.
10030441|NCT01759472||montelukast，vitamin C pill|leukotriene receptor antagonist:(montelukast)，montelukast (10 mg, once per night)，56 days vitamin C pill:100mg，once per night，56 days
10030442|NCT01759472||montelukast, vitamin C pill|montelukast:10 mg, once per night，56 days vitamin C pill:100mg，once per night，56 days
10030443|NCT01759485|Active Comparator|Vitamin D|Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment
10030444|NCT01759485|Placebo Comparator|Placebo|Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment
10030445|NCT01759498|Experimental|HYDRO 2|Subjects in the second experimental group will follow the procedures of first experimental group with additional administration of hydrogen-rick packs 6 times per day for 20 minutes throughout the study.
10030446|NCT01759498|Active Comparator|ACTIVE|During the period of 2 weeks subjects will receive traditional treatment protocol after the soft-tissue injury, consisting of RICE protocol during the first 48 h (e.g. rest, ice packs for 20 minutes every 2 hours, compression with elastic bandage, elevation of the injured area above the level of the heart at all possible times) and sub-acute protocol thereafter (e.g. passive stretching 3 times per day for 90 sec, isometric strength exercise with 3 sets with 15 repetitions, 30 min of pain-free weight-bearing exercise).
10030447|NCT01759498|Experimental|HYDRO|Subjects in the first experimental group will follow the PLA procedures with additional administration of oral hydrogen-rich capsules (4 capsules three times per day) throughout the study.
10036977|NCT01820715|Experimental|600㎍ of DA-3030 Injection|600㎍ of DA-3030 is injected once a day, for 5 continuous days.
9468334|NCT03648710|Experimental|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
9468335|NCT03648710|Experimental|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
9468336|NCT03648697|Experimental|EBV-TCR-T cells(YT-E001)|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered."
9468337|NCT03648684|Experimental|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
9468338|NCT03648684|Placebo Comparator|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
10030448|NCT01759524|Experimental|Group L|40 mls of 2% lidocaine + 1.5 mcg/kg will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
10030449|NCT01759524|Active Comparator|Group B|40 mls of 0.5% bupivacaine will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
10030450|NCT01759537|Experimental|Implants placed at sub-crestal position.|Ankylos dental endosseous implants-sub-crestal
9468339|NCT03648684|No Intervention|Control|
9468340|NCT03648671||PD with PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
10030451|NCT01759537|Active Comparator|Epi-crestal implants.|Ankylos dental endosseous implants-Epi-crestal
10030452|NCT01759550||LigaSure Device|In this prospective observational study, 60 patients scheduled to undergo a Roux-en-Y or gastric reduction procedure (sleeve gastrectomy or plication) will have hemostasis controlled with LigaSure Advance ™ Pistol Grip or LigaSure™ Blunt Tip, respectively. Both devices are regularly used at Duke in the Bariatric Surgery division. The surgeon will select which device is used. There will be no randomization. The device decision tree will be based upon the procedure. Cases that require enterotomy will utilize the AdvanceTM pistol grip. Cases which don't need enterotomy will utilize the 5 Blunt Tip. The LigaSure AdvanceTM pistol grip and LigaSureTM Blunt Tip are used exclusively with the Force TriadTM Energy platform. There is no simultaneous use.
10030453|NCT01759563|Other|single arm study|
9468341|NCT03648671||PD without PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
9468342|NCT03648671||PD with PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
9468343|NCT03648671||PD without PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
9468344|NCT03648658|Experimental|Paracetamol 15mg/kg|
9468345|NCT03648619|Other|Oncologic patients|Oncologic patients with a previous PET/CT for whole-body staging
9468346|NCT03648593|Experimental|behavioral|work recovery intervention
9468347|NCT03648593|Experimental|waiting list control|work recovery intervention after 6 months
9468348|NCT03648580|Experimental|Intervention group|Give the verbal nutrition education and supply Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
10030454|NCT01759576|Experimental|Group 1 (normal kidney function)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
10030455|NCT01759576|Experimental|Group 2 (mild kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
10030456|NCT01759576|Experimental|Group 3 (moderate kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
10030457|NCT01759576|Experimental|Group 4 (severe kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
9468349|NCT03648580|Other|Control group|just give the verbal nutrition education.
9468350|NCT03648554|Experimental|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
9468351|NCT03648554|Sham Comparator|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
9468352|NCT03648528|Experimental|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
9468353|NCT03648528|Placebo Comparator|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
9468354|NCT03648515||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~Then, digital images of the dental arches of each patient will be taken using a dedicated camera with very high resolution. Finally, digital images of models that were poured with gypsum will be taken also with the same camera and in the same conditions."
10030458|NCT01759576|Experimental|Group 5 (hemodialysis)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis. Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
10030459|NCT01759589|Placebo Comparator|propofol (Group P)|The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
10030460|NCT01759589|Active Comparator|remifentanil and propofol (Group R)|Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
10030461|NCT01759589|Active Comparator|sevoflurane (Group S)|In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.
10030462|NCT01759615|Experimental|Early enteral feeding|Early enteral feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
10030463|NCT01759615|Active Comparator|Late enteral feeding|Late enteral feeding group was kept NPO for a period of 48 hours followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
10030464|NCT01759628|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
10030465|NCT01759628|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
10030466|NCT01759641||Hypotension-prone patients|The study group included all patients treated with standard HD prone to acute intradialytic hypotension.
10030467|NCT01759654|Experimental|AdimFlu-V|
10030468|NCT01759667|Experimental|A standard mixed Meal|The standard mixed meal was composed of a chicken salad sandwich and 200ml of coconut water, totalling 260 kcal, distributed among carbohydrates (62%), proteins (12%) and lipids (26%).
10030469|NCT01759680|Experimental|Whole Body Vibration Group|The whole body vibration group received 3 training sessions every week composed of 5 series of 15 seconds of vibrations at 30 Hz intensity.
10030470|NCT01759680|No Intervention|Control Group|The control group had a normal daily life for the whole study period
10030471|NCT01759693||Skin disease|Patients with urticaria or atopic dermatitis
10030472|NCT01759693||Control|Healthy volunteers
10030473|NCT01759706|Experimental|Enhanced Recovery After Surgery (ERAS)|Patients treated with enhanced recovery after surgery protocol: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia with naropin + sufentanil, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV prophylaxis with ondansetron + dexamethasone, hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, postoperative mobilization program, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
10030474|NCT01759706|Active Comparator|Standard perioperative care (Control)|Patients treated with standard care perioperative protocol: epidural analgesia with naropin + sufentanil, pre-anesthetic medication with diazepam, Preoperative bowel preparation with sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
10030475|NCT01759719||PtCr stent PCI treated patients|patients treated with PCI in whichat least 1 PtCr stent was used
10030476|NCT01759732|Experimental|HAPLO|
10030477|NCT01759745||Blepharospasm|Blepharospasm, patient's group
10030478|NCT01759745||Control|Healthy control subjects
10030479|NCT01759758|Active Comparator|Plaster Ulnar Gutter Splint|Patients will have their hand placed in a conventional Plaster ulnar gutter splint. This immobilizes all joints of the ring and small fingers and the wrist
9468355|NCT03648502|Experimental|dementia (D-HI)|hearing impaired dementia
9468356|NCT03648502|Other|Mild cognitive impairment (MCI-HI)|MCI with hearing loss
9468357|NCT03648502|Active Comparator|normal (N-HI)|normal cognition with hearing loss
9468358|NCT03648476|Experimental|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
9468359|NCT03648476|Other|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
9468360|NCT03648463|Experimental|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
9468361|NCT03648463|Active Comparator|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
10030480|NCT01759758|Experimental|Thermoplastic Splint|Patients will be fitted with a custom molded thermoplastic splint that stabilizes the metacarpals of the injured hand but does not immobilize any joints
10030481|NCT01759771|Experimental|Arm 1|4,000 IU of VD3 for one year
10030482|NCT01759771|Placebo Comparator|Arm 2|placebo for one year
10030483|NCT01759784|Experimental|stem cell recipient|The patients who underwent mesenchymal stem cell transplantation.
10030484|NCT01759797|Experimental|stem cell reciepient|the patients with ALS who underwent intravenous injection of mesenchymal stem cell.
9468362|NCT03648437|Experimental|Pedea 5mg/mL and Paracetamol 10mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
10036978|NCT01820715|Placebo Comparator|Placebo|Placebo(a salin drip) is injected once a day, for 5 continuous days.
10030485|NCT01759810|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
10030486|NCT01759810|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
10030487|NCT01759823|Experimental|mesenchymal stem cell transplantation|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
9468363|NCT03648437|Placebo Comparator|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
9468364|NCT03648437|Experimental|Indomethacin 25mg/mL and Paracetamol10mg/mL|Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
9468365|NCT03648437|Placebo Comparator|Indomethacin 25mg/mL and 0.45 sodium chloride|Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
9468366|NCT03648424||Linagliptin|Patients who initiate Linagliptin with no use in the prior 180 days
9468367|NCT03648424||Glimepiride|Patients who initiate Glimepiride with no use in the prior 180 days
9468368|NCT03648411||Shwegyin|Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
9468369|NCT03648411||Pinlebu|Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
9468370|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
9468371|NCT03648346|Experimental|Cohort 1: HL217 Ophathalmic Solution BID|Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
9468372|NCT03648346|Experimental|Cohort 2: HL217 Ophathalmic Solution QID|High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
9468373|NCT03648346|Placebo Comparator|Placebo Ophathalmic Solution|Placebo: two drops of placebo in one eye twice a day or 4 times a day
9468374|NCT03648333|Experimental|Lodivixx tab. 5/160mg|S-amlodipine nicotinate (5mg as S-amlodipine), valsartan 160mg
9468375|NCT03648333|Active Comparator|Exforge tab. 10/160mg|amlodipine besylate (10mg as amlodipine), valsartan 160mg
9468376|NCT03648320|Experimental|Peanut oral immunotherapy|Desensitisation using peanut flour
9468377|NCT03648307||Trauma splenectomized|Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
9468378|NCT03648307||Bowel resection|Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
9468379|NCT03648242|Experimental|Interruptive Clinical Decision Support|
9468380|NCT03648229|Experimental|SLT|The study eye will undergo 360-degree selective laser trabeculoplasty (SLT), followed, if needed, by repeat 360-degree SLT.
10030488|NCT01759823|Sham Comparator|Control|vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
10030489|NCT01759823|Experimental|MNC's TRANSPLANTATION|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
10030490|NCT01759849||Allergen challenge|Determination of the effects of a β-chain monoclonal antibody (MAb) on the function of cells naturally activated by in vivo allergen exposure, from donors with allergen-induced asthma
10030491|NCT01759875|Active Comparator|Ritonavir-boosted Atazanavir|
10030492|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole|
10030493|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl|
9468381|NCT03648229|Active Comparator|MED|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided at no cost to the subject.
10030494|NCT01759888|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 60 PD patients, including 20 LRRK2 G2385R, 20 PARK6, and 20 idiopathic PD. Subjects will be evaluated sequentially with 18F-DTBZ during a 36 month period. 18F-DTBZ PET scans will be performed twice, at baseline, and 24 (21~27) months following the start of their participation in the study.
10030495|NCT01759914||Potent topical steroid-treated|Patients treated with potent topical steroids
10030496|NCT01759914||Superpotent topical steroid-treated|Patients treated with superpotent topical steroids
10030497|NCT01759927|No Intervention|Control condition|Physically inactive employees are measured on anthropometrics, fitness and psycho-social variables.
10030498|NCT01759927|Experimental|Physical Activity Coaching|Physically inactive employees receiving a 12-week behavioural support intervention grounded in self-determination theory.
10030499|NCT01759940|Experimental|ropivacaine 0,375%|In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
9468382|NCT03648229|Active Comparator|RX|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
9468383|NCT03648216|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to <5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
9468384|NCT03648216|No Intervention|Control Group|The control group will not receive any behavioural intervention or instruction.
9468385|NCT03648203|Experimental|TEAMS|Routine asthma care, as provided in the University of Rochester Medical Center Medicine Clinic, will be augmented by three intervention components over a six-month pilot period : (1) Patient subject smartphone asthma monitoring; (2) Nursing telemedicine follow up (virtual home visits); (3) EMR custom programming to guide nursing assessment and management.
9468386|NCT03648190||Inherited qualitative platelets defect|"Clinical manifestations in the form of mucocutaneous bleeding or hemorrhage.~Bleeding patients with acquired bleeding disorders, coagulation defects, and those on antiplatelet drugs will be excluded from the study."
9468387|NCT03648190||Control|Normal healthy participants, with no manifestations of bleeding disorders.
9468388|NCT03648177|Active Comparator|Treatment as Usual|"Active Comparator: (n=15) Treatment as Usual~The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain which allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic, non-pharmacologic approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
10030500|NCT01759940|Active Comparator|ropivacaine 0,75%|In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
10030501|NCT01759953|Active Comparator|InsuOnline game|Playing the InsuOnline game, on the web, in the player´s own time and rhythm, until its end, as already described previously.
10030502|NCT01759953|Active Comparator|Traditional CME|Traditional learning session as used for Continuing Medical Education, on insulin therapy, including a short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
10030503|NCT01759966||Heart transplant recipients|Patients receiving orthotopic heart transplant in the enrollment period
10030504|NCT01759966||Healthy controls|Healthy control subjects, having the same age and sex distribution as the heart transplant recipients
10030505|NCT01759979|Experimental|Laser and mechanical lithotripsy|Bile duct stones with be treated with cholangioscopy guided laser therapy in addition to mechanical basket and balloon techniques.
10030506|NCT01759979|Active Comparator|Mechanical lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloon for removal of large stones.
10030507|NCT01759992|No Intervention|Control group|Usual care
10030508|NCT01759992|Experimental|Treatment group|Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
10030509|NCT01760005|Experimental|Gantenerumab|
10030510|NCT01760005|Experimental|Solanezumab|
10030511|NCT01760005|Placebo Comparator|Matching placebo (Gantenerumab)|
10030512|NCT01760005|Placebo Comparator|Matching Placebo (Solanezumab)|
10030513|NCT01760005|No Intervention|Cognitive Run-in|
10030514|NCT01760005|Active Comparator|Gantenerumab Open Label Extension|Subcutaneously every 4 weeks at escalating doses
10030515|NCT01760018|Experimental|Desflurane group|
10030516|NCT01760018|Active Comparator|TIVA(total intravenous anesthesia) group|
10030517|NCT01760031||Subjects with impaired renal function|Subjects with baseline impaired renal function undergoing cardiac catheterization with contrast-medium exposure
10030518|NCT01760044|Experimental|Tissue oxygenation monitoring|Tissue oxygenation monitoring
10030519|NCT01760057|Placebo Comparator|Health promotion message|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
10030520|NCT01760057|Experimental|Combined Web-based HIV intervention|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging
10030521|NCT01760070|Experimental|Hybrid knife|O-type Hybrid knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
10030522|NCT01760070|Active Comparator|IT knife|IT knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
10030523|NCT01760083|Active Comparator|Biolimus-eluting stent implantation|PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.
10036979|NCT01820728|Experimental|DA-3801 injection|Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days
10036980|NCT01820728|Active Comparator|Gonal-F®|75 IU/day is injected for 14 days
10036981|NCT01820767|Experimental|Paricalcitol|SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.
9468389|NCT03648177|Experimental|IPGT|"Experimental: IPGT (n=15) Integrated Psychosocial Group Treatment~IPGT consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. The intervention also entails an education session on knowledge pertaining to overdose education and naloxone distribution. Topics covered in IPGT include: Pacing and goal setting, negative thinking, coping with stress and anxiety, sleep enhancement techniques, managing set-backs, and chronic pain and your life."
9468390|NCT03648138|Active Comparator|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
9468391|NCT03648138|Experimental|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, type 2 diabetes, and tooth decay. The calorie label will also appear on all beverages.
9468392|NCT03648138|Experimental|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
9468393|NCT03648138|Experimental|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks for each sugary beverage, along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
9468394|NCT03648125|Other|Rowing training session|"Power tests, balance and tonicity tests are performed eyes opened and eyes closed :~with artificial occlusal disturbance and~without artificial occlusal disturbance"
9468395|NCT03648112|Active Comparator|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
9480144|NCT03536481|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.
10030524|NCT01760083|No Intervention|Medical therapy|Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.
10030525|NCT01760096|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
10030526|NCT01760096|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
10030527|NCT01760096|Active Comparator|Glucocorticoids|Glucocorticoids
10030528|NCT01760109|Experimental|Piperacillin Sodium and Sulbactam Sodium|"Drug:xintemie 1.5-3.0g,iv,bid 7-14 days~serious infections 6.0-12.0g,iv,tid for 7-14 days"
10030529|NCT01760122|Experimental|Ypeginterferon Alfa-2b|
10030530|NCT01760122|Active Comparator|Pegasys|
10030531|NCT01760135|Experimental|low calory|15kcal/kg caloric supplement
10030532|NCT01760135|Active Comparator|high calory|25kcal/kg
10030533|NCT01760148||Interferon and ribavirin|All the patients followed the standard treatment protocol.
10030534|NCT01760161|Active Comparator|Ropivacain|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
10030535|NCT01760161|Placebo Comparator|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
10030536|NCT01760174|Active Comparator|Bupivacain-infusion in epidural catheter|Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
10030537|NCT01760174|Active Comparator|Ropivacaine bolus in transversus abdominis plane catheter|Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
10030538|NCT01760200||Drug eluting balloon angioplasty|Drug eluting balloon angioplasty
10030539|NCT01760200||Drug eluting stent group|Drug eluting stent intervention
10030540|NCT01760213|Experimental|Treatment|intervention delivered via internet
10030541|NCT01760213|No Intervention|Control|
10030542|NCT01760226|Experimental|DA-EPOCH-R for DLBCL, PTLD & PMBCL|"Minimum of 6 cycles (cycle=3 weeks), possibly 8. Dosages of the drugs will be determined by the subject's weight and height for cycle 1. Thereafter, the dosages of some drugs will be adjusted up or down for the next cycle, dependent on the blood tests results.~DA-EPOCH-R for 2 cycles then two more cycles of DA-EPOCH-R. If complete response (CR), then DA-EPOCH-R for more 2 cycles. If no CR, DA-EPOCH-R for 4 more cycles."
10030543|NCT01760252|Experimental|CAPOXIRI Chemotherapy Regimen|"Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)~The proposed chemotherapy regimen CAPOXIRI is:~Capecitabine 1000mg/m2 p.o. bid on days 1-7~Oxaliplatin 85mg/m2 intravenously (IV) on day 1~Irinotecan 150mg/m2 IV on day 1"
10030544|NCT01760278|Experimental|Study Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured by time-lapse imagery technique (embryoscope) and analysis would be done using patients receive rFSH (Gonembryo viewer equipped with latest software.
10030545|NCT01760278|Active Comparator|Control Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured in conventional culture environment and analysis would be done using established subjective morphological criteria.
10030546|NCT01760317|Active Comparator|Midline|Midline Lumbar Epidural Steroid Injection
10030547|NCT01760317|Active Comparator|Parasagittal|Parasagittal Lumbar Epidural Steroid Injection
10030548|NCT01760330|Active Comparator|IV acetaminophen|IV acetaminophen administered q 4 hrs. for a total of 24 hrs.
10030549|NCT01760330|Placebo Comparator|Placebo|Normal saline administered IV every 4 hrs. for a total of 24 hrs.
9468396|NCT03648112|Active Comparator|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~These oat flakes were roasted at 150°C for 20 minutes.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
9468397|NCT03648112|Active Comparator|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
9468398|NCT03648112|Active Comparator|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
9468399|NCT03648112|Placebo Comparator|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
9468400|NCT03648099|Experimental|Labor Dance and music groups|"Labor Dance; The pregnant women performed labor dance when the cervical dilatation reached 4-5 cm. The dance was performed in the company of music played through headphones.~The pregnant women listened to music for 30 minutes when the cervical dilatation reached 4-5 cm. They took any position they wanted while listening to music."
9468401|NCT03648099|No Intervention|Control group|The control group: No intervention was made to relieve the labor pain and reduce the fear of childbirth in the control group of the study. They were administered routine hospital applications.
10030550|NCT01760343|Experimental|Berinert, then CSL830|A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU.
10030551|NCT01760343|Experimental|CSL830, then Berinert|A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU.
10030552|NCT01760356||Healthy Volunteers No treatment|This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
10030553|NCT01760356||Liver Transplant Patients on Tacrolimus|"To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 50."
10030554|NCT01760356||Waiting List for Liver Transplantation|"To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions.~The number proposed is 12."
10030555|NCT01760356||Liver Transplant Patients on Cyclosporine|"To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 10."
10030556|NCT01760356||Longitudinal Cohort|"Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses.~The number proposed is 20."
10030557|NCT01760382||STEMI network Primary PCI patients|Patients with STEMI brought to the Hub Hospital by the STEMI network ambulance and treated by primary PCI.
10030558|NCT01760382||STEMI Hospital ED Primary PCI patients|Patients with STEMI who reached by themselves the Hub Hospital, where they were admitted for STEMI and tretated by Primary PCI
10030559|NCT01760408||Home PN - pediatric|Pediatric patients (under 18) on Home PN
10030560|NCT01760408||Adult patients on Home PN|Adult patients on Home PN
10030561|NCT01760421|Experimental|Hydroxychloroquine|Receive treatment with hydroxychloroquine
10030562|NCT01760434|Other|Long-Term Outcomes|Patients will be recruited who were diagnosed with adolescent idiopathic scoliosis prior to age 18 and before 1994 (minimum 20 year outcomes) with available xrays. Patients will be included who were treated with surgery, observation, or bracing. Patients will return for a one-time visit for new xrays, physical exam, health-related quality of life surveys, and pulmonary function testing.
10030563|NCT01760460|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
10030564|NCT01760460|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.
10030565|NCT01760486|Active Comparator|Shape Up Rhode Island|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive periodic newsletters throughout the 12 month trial.
10030566|NCT01760486|Experimental|Shape Up Rhode Island + Professional Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a professional weight loss coach and will be incentivized for submitting information to their coach and meeting weight goals.
10030567|NCT01760486|Experimental|Shape Up Rhode Island + Peer Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a peer coach and will be incentivized for reporting to their coach and meeting weight goals.
10030568|NCT01760499|Experimental|Immunotherapy Followed by Surgery|PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
10030569|NCT01760512|Experimental|Robot-assisted surgery|Robot-assisted (da Vinci surgical system) gastric bypass
10030570|NCT01760512|Active Comparator|Conventional laparoscopy|Laparoscopic gastric bypass
10030571|NCT01760525|Experimental|CGM097 - Dose escalation|
10030572|NCT01760525|Experimental|CGM097 - Dose Expansion at MTD or RP2D|
10030573|NCT01760538|Experimental|exercise group|exercise training
10030574|NCT01760538|Active Comparator|Control|usual care
10030575|NCT01760551||Patients assessed with AMA guide fifth edition|
10030576|NCT01760551||Patients assessed with AMA guide sixth edition|
10030577|NCT01760564|Experimental|Miglustat|miglustat 200mg tid
10030578|NCT01760577|Experimental|The Botulinum Toxin A group|The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.
10030579|NCT01760577|Active Comparator|The hyaluronate group (Hyalgan, Italy)|The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .
10036982|NCT01820767|Active Comparator|Paricalcitol, Atorvastatin|SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)
10036983|NCT01820767|Active Comparator|Atorvastatin|SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)
10036984|NCT01820780|Experimental|intensive disease management|Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
10036985|NCT01820780|Active Comparator|usual disease management|usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
10036986|NCT01820793|Experimental|cefoxitin|this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.
10036987|NCT01820806|Experimental|[14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
9468402|NCT03648086|Experimental|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
9468403|NCT03648086|No Intervention|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
9468404|NCT03648060|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
9468405|NCT03648047|Experimental|Experimental group|Patients in this group will receive a mixed home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist (with decreasing periodicity depending on program stage) as well as sessions performed with a digital kinematic biofeedback system.
9468406|NCT03648047|Active Comparator|Conventional rehabilitation|Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
9468407|NCT03648034|Experimental|ropivacaine|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.5% ropivacaine
9468408|NCT03648034|Placebo Comparator|saline|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.9% saline
9468409|NCT03648008|Active Comparator|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg*kg-1
9468410|NCT03648008|Experimental|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg*kg-1
9468411|NCT03648008|Experimental|Group BH|Drug: Hydromorphone Background: 0.002 mg*kg-1*h-1 Bolus infusion: 0.002 mg*kg-1
9468412|NCT03647995|Active Comparator|Probiotic-receiving group|The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
9468413|NCT03647995|Placebo Comparator|Placebo|The placebo group will receive once daily, identical capsules containing 0 Bn CFU.
9468414|NCT03647982|Experimental|botulinum toxin 1U|
9468415|NCT03647982|Experimental|botulinum toxin 3U(25U/1ml)|
9468416|NCT03647982|Experimental|botulinum toxin 5U|
9468417|NCT03647982|Experimental|botulinum toxin 10U|
9468418|NCT03647982|Experimental|botulinum toxin 3U(50U/1ml)|
9468419|NCT03647982|Experimental|botulinum toxin 3U(12.5U/1ml)|
9468420|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab A/A1|"Nivolumab 240mg Flatdose i.v. d1 over 30 min every 2 weeks followed by Ipilimumab 1mg/kg i.v. d1 over 30 min every 6 weeks followed by FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment."
9480145|NCT03536468||Patients pending complete tooth loss|Will be recruited patients pending tooth loss, ages between 18 and 65 years, whose dental conditions have previously been identified
9480146|NCT03536442||Intervention (CBT)|"As there is only one arm in this trial, this will be described in intervention."
10036988|NCT01820819||Registered or not on the transplantation national waiting list|
10036989|NCT01820832|Experimental|Calcitriol|General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
9480147|NCT03536403|Experimental|healthy volunteers|EOS X-rays is done with et without a kyphosis induced corset and 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
10036990|NCT01820832|No Intervention|Control|General treatments.
9468421|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab sequential A2|"3 cycles of induction chemotherapy with FOLFOX: FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks followed by immunotherapy consisting of: 4 administrations of Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks and 2 administrations of Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks~Sequence as described may be repeated starting two weeks after last administration of immunotherapy once, or, if medically reasonable, for an unlimited number of repetitions upon investigator decision. After discontinuation of chemotherapy, immunotherapy will be continued consisting of:~Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks and Ipilimumab at 1mg/kg i.v. d1 every 6 weeks until disease progression or inacceptable toxicity or end of study treatment."
10030580|NCT01760590|Experimental|Manual Manipulation|Patients will be randomized to receive a thrust manipulation
10030581|NCT01760590|Experimental|Manual Mobilization|Patients will be randomized to receive mobilization
9468422|NCT03647969|Active Comparator|mFOLFOX B|FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment.
10030582|NCT01760603|Experimental|ISFF|The patients performed ischia spinous fascia fixation surgery.
9468423|NCT03647969|Experimental|FLOT/Nivolumab C|"Nivolumab 240mg Flatdose i.v. d1 every 2 weeks followed by FLOT: Docetaxel 50mg/², Oxaliplatin 85 mg/m², leucovorin 200 mg/m² on day 1 and fluorouracil 2600 mg/m² IV continuous infusion over 24 hours every 2 weeks until disease progression or inacceptable toxicity or end of study treatment. After completion or discontinuation of chemotherapy, immunotherapy may be continued consisting of: Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks Chemotherapy can also be administered per local standard."
10030583|NCT01760616|Experimental|Test group|Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
10030584|NCT01760616|No Intervention|Control group: adjuvant therapy|Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.
9468424|NCT03647956|Experimental|Arm 1|Using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
9468425|NCT03647930|Experimental|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
9468426|NCT03647930|No Intervention|Control|No MPH
9468427|NCT03647904|Experimental|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
9468428|NCT03647904|Other|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
9468429|NCT03647891|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
9468430|NCT03647891|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
9468431|NCT03647865|Experimental|Patients need genioplasty|
9468432|NCT03647839|Experimental|Arm 1|Nivolumab and BNC105
9468433|NCT03647839|Experimental|Arm 2|Nivolumab and BBI-608
9468434|NCT03647826|Experimental|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
10030585|NCT01760629|Experimental|Cooling arm|Whole body cooling to 33 to 34 C rectal temperature
10030586|NCT01760642|Experimental|Midazolam|"period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days."
10030587|NCT01760655|Experimental|Treatment (RIC and stem cell transplant)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, thiotepa IV over 2 hours on days -15 to -13, donor lymphocyte infusion (DLI) on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28."
9468435|NCT03647826|Experimental|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
9480148|NCT03536390|Placebo Comparator|Placebo|one chewable tablet once daily in morning.
9480149|NCT03536390|Experimental|Methylphenidate Hydrochloride Extended Release Chewable Tablet|one chewable tablet once daily in morning.
9480150|NCT03536377|Experimental|very low calorie liquid diet|Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence
9480151|NCT03536364|Experimental|Prediabetes|manipulation of food order during a meal on postprandial in subjects with prediabetes
9480152|NCT03536351|Experimental|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists, and target understanding emotion, intentions and appropriate social interactions.
9480153|NCT03536338|Active Comparator|Control|Sit-to-stand training alone
9480154|NCT03536338|Experimental|Treatment|Sit-to-stand training combined with Spinal Stimulation
9480155|NCT03536325|Experimental|Cohort 1: Guselkumab Dose 1 or Placebo|Participants will receive Dose 1 of guselkumab or matching placebo as an intravenous (IV) infusion on Day 1.
9480156|NCT03536325|Experimental|Cohort 2: Guselkumab Dose 2 or Placebo|Participants will receive Dose 2 of guselkumab or matching placebo as an IV infusion on Day 1.
10030588|NCT01760668||Turner syndrome (TS)|TS verified by genotyping Age > 18 years awaiting operation due to aortic dilation
10030589|NCT01760668||Marfan syndrome (MS)|Females with MS verified clinically or by genotyping Age > 18 years awaiting operation due to aortic dilation
10030590|NCT01760668||Bicuspid aortic valve|females with bicuspid aortic valve Age > 18 years awaiting operation due to aortic dilation
9480157|NCT03536325|Experimental|Cohort 3: Guselkumab Dose 3 or Placebo|Participants will receive Dose 3 of guselkumab or matching placebo as an IV infusion on Day 1 based on safety data results received from Cohort 1 and 2.
10030591|NCT01760668||Controls|Men/females who died from conditions other than aortic dilation or dissection. Age 20-60 years.
10030592|NCT01760681|Experimental|H coil DTMS|20 daily deep TMS treatments
9480160|NCT03536299|Active Comparator|Single-Task Gait|The Single-Task Gait group will be provided with gait training without the Dual-Task cognitive tasks.
9480161|NCT03536299|Experimental|Dual-Task Gait|The Dual-Task Gait group will be provided with gait training AND secondary cognitive tasks during gait training.
9480162|NCT03536286|Experimental|Encouragement Zone 3|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
10030593|NCT01760681|Sham Comparator|inactive stimulation|20 daily sham deep TMS treatments
10030594|NCT01760694|Experimental|Resectable Patients|Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
10030595|NCT01760694|Experimental|Marginally Resectable Patients|2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
10030596|NCT01760707|Experimental|Exercise Training|aerobic exercise training
10030597|NCT01760707|Active Comparator|Control|
10030598|NCT01760720|No Intervention|control|Standard care
10030599|NCT01760720|Experimental|intervention|The MMT CARE intervention has 3 session/modules: 1) MMT protocol and procedures, understanding stigma and its impact; 2) effective communication with clients, introducing motivational interviewing; 3) application of motivational interviewing, motivating clients for behavior change. The intervention contents reflect challenges faced by service providers working at MMT clinics and the impact of these challenges on their clients. Sessions will occur once a week for three weeks, with each session featuring a different set of themes and relevant activities. Each session will be 90-100 minutes long and will be conducted with a group of 5 to 7 providers.
10030600|NCT01760746||PDR, Avastin/Lucentis, randomization, humour, inflamation|Patients will be randomized to receive pre-treatment with either bevacizumab or ranibizumab . Sample of aqueous humour will be taken before injection and before surgery.Both the patient and the treating physician will be masked to the identity of the study drug.
10030601|NCT01760759|No Intervention|Usual care|Patients receive usual care from their medical providers.
10030602|NCT01760759|Experimental|Usual care plus cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
10030603|NCT01760759|Experimental|Usual care, reminders & contingency management for adherence|Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
10030604|NCT01760772|Placebo Comparator|Saline|0.9% saline
10030605|NCT01760772|Experimental|Exendin-9 (Ex-9)|Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
10030606|NCT01760772|Experimental|GLP-1|GLP-1 infusion at 0.3 pmol/kg/min
10030607|NCT01760798|Active Comparator|Daily Teriparatide group|This group will recieve 20µg of teriparatide by subcutaneous route daily at 8 pm for 1 year
9468436|NCT03647813|Active Comparator|Photobiomodulation group|Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
9468437|NCT03647813|Placebo Comparator|Placebo group|Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
9468438|NCT03647774|Experimental|Extended release naltrexone|Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.
9468439|NCT03647774|No Intervention|Treatment As Usual (TAU)|Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.
9468440|NCT03647761|No Intervention|Control|Standard of care
9468441|NCT03647761|Experimental|Treatment|Tetra-grip applied
9468442|NCT03647748|No Intervention|Cellulize 532nm|Cellulize device using 532nm Green Light.
9468443|NCT03647748|Sham Comparator|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.~Sham Device, or Placebo."
9468444|NCT03647735|Experimental|Group PCS|Patients in Group PCS (patient-controlled sedation) received intravenous (IV) propofol via a patient controlled analgesia (PCA) infusion pump. The machine was set to deliver a demand bolus dose of 0.25 mg/kg with 1-minute lockout interval, without basal infusion.The patient was instructed to press on a hand-held device as often as required, to achieve their desired level of comfort or sedation.
9468445|NCT03647735|Active Comparator|Group TCIS|Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
9468446|NCT03647722||Lemtrada treated - 6 month|Patients that received their first course of treatment with Lemtrada approximately 6 months prior.
9468447|NCT03647722||Lemtrada treated - 12 month|Patients that received their first course of treatment with Lemtrada approximately 12 months prior but who have not received the second course of treatment.
9468448|NCT03647722||Lemtrada treated - 18 month|Patients that received their first course of treatment with Lemtrada approximately 18 months prior and their second course of treatment with Lemtrada approximately 6 months prior.
9468449|NCT03647722||Lemtrada treated - 24 month|Patients that received their first course of treatment with Lemtrada approximately 24 months prior and their second course of treatment with Lemtrada approximately 18 months prior and who have not received any further treatment.
9468450|NCT03647722||Lemtrada qualified - untreated|Patients that are qualified to start treatment with Lemtrada but have not yet being untreated.
9468451|NCT03647683|Experimental|Self-Compassion|After pretreatment heat pain assessment, participants are introduced to the concept of self-compassion. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily self-compassion audio-interventions. Afterwards, the follow-up pain assessment is conducted.
9468452|NCT03647683|Experimental|Acceptance|After pretreatment heat pain assessment, participants are introduced to the concept of acceptance. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily acceptance audio-interventions. Afterwards, the follow-up pain assessment is conducted.
10030608|NCT01760798|Experimental|Weekly Teriparatide group|This group will recieve 60µg of teriparatide by subcutaneous route weekly at 8pm on Sunday for 1 year
10030609|NCT01760811|Other|Cetuximab ,neoadjuvant administration|Drug administration ,Cetuximab(merck Serono )given neoadjuvant ,3 courses prior surgery followed by post operatve radiation and Cetuximab
10030610|NCT01760824|Experimental|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
10030611|NCT01760824|Active Comparator|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days
10030612|NCT01760837|Other|baked milk products, cow's milk allergy|to offer baked milk products to cow's milk allergic patients and to follow them for tolerance and if this intervention may have any impact on the natural history of milk allergy
10030613|NCT01760850|Experimental|Arm I (Esperanza y Vida)|Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer.
10030614|NCT01760850|Active Comparator|Arm II (control)|Participants engage in an educational information session for diabetes.
10030615|NCT01760863|Experimental|Oral Antibiotics|Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.
10030616|NCT01760863|No Intervention|No oral antibiotics|No oral antibiotics.
10030617|NCT01760902|Experimental|Diet and Physical Activity|Participants convene weekly for 12 consecutive weeks and then once per month for 9 months. Each sessions is 90 minutes
10030618|NCT01760928||Asthma patients|all
10030619|NCT01760967|Active Comparator|Dexmedetomidine|administer dexmedetomidine (0.1-0.7ug/kg/h) from the beginning of ICU treatment
10036991|NCT01820845||Cohort of children with scoliosis surgery|
10030620|NCT01760967|Active Comparator|non-Dexmedetomidine|administer sedatives except Dexmedetomidine
10030621|NCT01760980|Experimental|Test product (B)|B: Subjects receive Exemestane 25 mg tablets under fasting conditions
9468453|NCT03647683|Experimental|Distraction|After pretreatment heat pain assessment, participants are introduced to the concept of distraction. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily distraction audio-interventions. Afterwards, the follow-up pain assessment is conducted.
10030622|NCT01760980|Active Comparator|Reference product (A)|A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
10030623|NCT01761032||Infrequent tanners|Individuals who tan less than twice a week and do not meet modified DSM-IV criteria for tanning addiction.
10030624|NCT01761032||Compulsive Tanners|Individuals who tan more than 3 times per week in a tanning bed. Tanning must cause disruption in daily functioning. Must meet modified DSM-IV criteria for tanning addiction
9468454|NCT03647670|Other|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
9468455|NCT03647670|Other|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
9468456|NCT03647644||Acute Normovolemic Hemodilution Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. If clinically indicated and appropriate per the discretion of the anesthesiologist, Acute Normovolemic Hemodilution (ANH) blood, about 2 units, will be withdrawn from the patients and stored carefully at room temperature per standard protocol. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients prior to re-infusing the ANH blood and after the blood has been infused per standard institutional protocol.
9468457|NCT03647644||Control Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. In this arm, ANH would be clinically appropriate, however, the anesthesiologist determined they would not have ANH preformed. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients and again 30 minutes later to mirror the time lapse in the ANH group.
9468458|NCT03647631||Patients affected to porocarcinoma|
9468459|NCT03647631||patients affected to porocarcinoma in our centre|
9468460|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
9468461|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
9468462|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
9468463|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
9468464|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
9468465|NCT03647605|Experimental|VR Mind|Two VR Mind sessions using experimental virtual reality scenarios. During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
9468466|NCT03647579|Active Comparator|midazolam plus ketamine|
9468467|NCT03647579|Active Comparator|dexmedetomidine plus ketamine|
9468468|NCT03647540|Experimental|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
9468469|NCT03647540|Active Comparator|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
9468470|NCT03647514|Experimental|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
10030625|NCT01761045|Active Comparator|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
9480163|NCT03536286|No Intervention|Control Zone 3|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
10030626|NCT01761045|Active Comparator|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
10030627|NCT01761045|Placebo Comparator|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
10030628|NCT01761071|Experimental|group KO|(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)
10030629|NCT01761071|Active Comparator|group DO|(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)
10030630|NCT01761097|Active Comparator|Endocuff assisted colonoscopy|Endocuff attachment
10030631|NCT01761097|Placebo Comparator|Control standard colonoscopy|Standard colonoscopy
10030632|NCT01761110|No Intervention|Pre-intervention|Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
10030633|NCT01761110|Experimental|Post-intervention|Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
10030634|NCT01761123|Experimental|VXA-A1.1|Intestinal Delivery
10030635|NCT01761136|Active Comparator|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
9468471|NCT03647462|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
10030636|NCT01761136|Experimental|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
10030637|NCT01761149|Active Comparator|Remifentanil (Low dose)|remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
10030638|NCT01761149|Experimental|Remifentanil (High dose)|The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
9468472|NCT03647462|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
9468473|NCT03647449|Experimental|Juice fast|"In the juice fasting arm, participants will be given vegetable/fruit pressed juices and be instructed to engage in a three-day juice fast diet totaling 800-900 kcal-per-day. The specific juices will be assigned for each day in order to maintain the calorie level."
9468474|NCT03647449|Experimental|Caloric restriction via Plant-based meals|"In the caloric restriction diet arm, participants will be on a whole-food plant-based diet totaling 800-900 kcal-per-day (matching the daily calories of juice fasting)."
9468475|NCT03647449|Experimental|Juice plus ad hoc|"In the juice plus ad hoc arm, participants will be given the same juice for three days but continue with their usual diet in addition to the juice. For this arm, there is no restriction of caloric intake or restriction to liquid only."
9468476|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
9468477|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
9468478|NCT03647423|Experimental|NANT Chordoma Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
9468479|NCT03647423|Active Comparator|Controlled Arm - Radiation|SBRT
9468480|NCT03647410||lumbopelvic fixation|sacral fractures fixed with lumbopelvic fixation
10030639|NCT01761188|Experimental|STABLE-SR|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm ( STABLE-SR)
10030640|NCT01761188|Experimental|Control Group|conventional stepwise ablation approach for persistent AF(CPVI + Lines +CFE) .
10030641|NCT01761201|Experimental|levofloxacin|Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
10030642|NCT01761201|Active Comparator|Isoniazid|"Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months"
10030643|NCT01761214|Active Comparator|Fluroquinolones|The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
10030644|NCT01761214|Active Comparator|Beta-lactamase inhibitor|In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.
9468481|NCT03647410||novel adjustable plate|sacral fractures fixed with novel adjustable plate
9468482|NCT03647397|Experimental|PECO|All pediatric patients admitted for respiratory distress will have the intervention of Photo Electrochemical Oxidation (PECO) for Air Purification.
9468483|NCT03647384|Experimental|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
9468484|NCT03647384|Active Comparator|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
10030645|NCT01761227|Experimental|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
9468485|NCT03647371|Other|Macintosh laryngoscope|direct laryngoscope - laryngoscope with Macintosh blade
9468486|NCT03647371|Other|McGrath videolaryngoscope|McGrath Videolaryngoscope
10030646|NCT01761227|Placebo Comparator|Placebo|3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
10030647|NCT01761240|Experimental|Study Drug|
10030648|NCT01761253||Assessing costs & cost-variability|Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
10030649|NCT01761305|Experimental|Brace|Hypercorrective night-time brace worn 8 hours per night. A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions regarding physical activity will be delivered during a one hour session.
10030650|NCT01761305|Experimental|Scoliosis specific exercises.|Scoliosis specific exercises. The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. An additional session will be provided every 6 months for the entirety of the study. A prescription of general physical activity will be provided at a dose of 60 minutes per day.
10030651|NCT01761305|Active Comparator|Self-mediated physical activity.|A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions will be delivered during a 1 hour session.
10030652|NCT01761318|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
10030653|NCT01761318|Placebo Comparator|Liraglutide-placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dosage: same as Liraglutide~Duration: 26 weeks"
10030654|NCT01761331|Active Comparator|Group A: Standardized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Intervention: Infants in the standardized acupuncture group get minimal acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
9468487|NCT03647345|Experimental|Experimental 1: Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
9468488|NCT03647345|Experimental|Experimental 2: Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
9468489|NCT03647345|Active Comparator|Active Comparator: Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
9468490|NCT03647332|Active Comparator|Cooled RFA treatment|
9468491|NCT03647332|Active Comparator|Steroid injection|
10030655|NCT01761331|Active Comparator|Group B: Individualized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Infants in the individualized acupuncture group get acupuncture in points chosen by the acupuncturists according to symptoms: maximum 5 needles are inserted about 3 mm in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
10030656|NCT01761331|No Intervention|Group C: No acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. The nurse hold the infant´s hand and talks to it but no acupuncture is given.
10030657|NCT01761344|Experimental|Intraoperative measurement of cortisol|Intervention: During a routine procedure intraoperative cortisol is measured. Upon unsuccessful sampling, the sampling will be repeated.
10030658|NCT01761370|Active Comparator|Treatment|AHA diet plus exercise with BIB placement
10030659|NCT01761370|Sham Comparator|Sham control|AHA diet plus exercise with sham BIB placement
10030660|NCT01761383|Experimental|Nintendo Wii and Chronic Schizophrenia|Participants enrolled in the study will be provided with the Nintendo Wii console and Nintendo Wii Fit Plus video games to use for the duration of the study (6 months) with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life with the use of self report questionnaires and psychiatric assessment.
9468492|NCT03647319|Experimental|Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
9468493|NCT03647319|Experimental|Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
9468494|NCT03647319|Active Comparator|Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
9468495|NCT03647293|Active Comparator|Control Group|Neonates who underwent a peripherally inserted central catheter
9468496|NCT03647293|Active Comparator|Intervention Group|Neonates who underwent an Ultrasound Guided Central Catheter Insertion
9468497|NCT03647280|Experimental|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
10030661|NCT01761396|Experimental|CBT|Cognitive behavioral therapy
10030662|NCT01761396|Active Comparator|UC|Usual care
10030663|NCT01761422||SLE active flare|Patients who are having an active flare of their lupus confirmed by labs
9468498|NCT03647254|Experimental|Patient Education Group|A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls
10030664|NCT01761435|Experimental|Influenza vaccine, second administration after 5 weeks|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
10030665|NCT01761435|Active Comparator|Influenza vaccine|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
10030666|NCT01761448|Experimental|Device Guided Exercise|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities of patients.
10030667|NCT01761461|Experimental|Arm A|S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles
10030668|NCT01761461|Active Comparator|Arm B|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles
10030669|NCT01761461|Active Comparator|Arm C|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles → S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) → Rest for 4 weeks → {S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles
10030670|NCT01761474||1. Carbon dioxide insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
10030671|NCT01761474||2. Carbon dioxide insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
10030672|NCT01761474||3. Air insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
10030673|NCT01761474||4. Air insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
10030674|NCT01761487|Other|One arm only - Gentamicin and polymyxin E|All subjects will receive:Gentamicin and polymyxin E paste applied on buccal surface four times daily + gentamicin + polymyxin E PO + Strict contact precautions
10030675|NCT01761500|Other|Modified BFM-90 protocol|Using the Modified BFM-90 protocol to treat Chinese children and adolescents with NHL
10030676|NCT01761513|Experimental|Sequence 1|
10030677|NCT01761513|Experimental|Sequence 2|
10030678|NCT01761513|Active Comparator|Sequence 3|
10030679|NCT01761513|Active Comparator|Sequence 4|
10030680|NCT01761526|Experimental|Rotigotine in Healthy Japanese|"Rotigotine transdermal patch~Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects~Transdermal patch over 24 hours"
10030681|NCT01761526|Experimental|Rotigotine in Caucasian|"Rotigotine transdermal patch~Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects~Transdermal patch over 24 hours"
10030682|NCT01761539|Experimental|Aggressive Hydration|Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
10030683|NCT01761539|Active Comparator|Moderate Hydration|Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
10030684|NCT01761552|Experimental|Sugammadex (tradename Bridion)|
10030685|NCT01761552|Active Comparator|Traditional reversal or spontaneous recovery:|Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade.
10030686|NCT01761578|Experimental|ART18Z Bioresorbable stent|
10030687|NCT01761591|Experimental|Acrobat|Device: PCI with Svelte Acrobat
10030688|NCT01761591|Active Comparator|Control BMS|Device: PCI with other BMS
10030689|NCT01761604|Other|Nasal ganglion block for TN|Sphenopalatine ganglion block using the Tx360™ device
10030690|NCT01761617|Active Comparator|Yoga Class Twice Per Week|Participants attend two hatha yoga classes each week for 12 weeks.
10030691|NCT01761617|Active Comparator|Yoga Class Once per Week|Participants attend one hatha yoga class each week for 12 weeks.
10030692|NCT01761630||Severe Asthma|"We will classify subjects as having severe asthma using the following stages:~Stage 1: Subjects must have asthma which requires treatment with high-dose inhaled corticosteroids plus a 2nd controller, or systemic corticosteroids with or without a 2nd controller to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy~Stage 2: Assess for uncontrolled asthma by any one of the following criteria:~Poor symptom control evidenced by an Asthma Control Questionnaire score consistently > 1.5 or an Asthma Control Test Score < 20 or not well controlled by NAEPP or GINA asthma treatment guidelines~Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids (> 3 days each) in the previous 12 months~Serious exacerbations reflected by at least one hospitalization, ICU stay or mechanical ventilation in the previous 12 months~Presence of airflow limitation evidenced by FEV1 < 80% predicted (in the face of reduced FEV1/FVC)"
10030693|NCT01761630||Non-severe Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
9468499|NCT03647254|No Intervention|Control group|Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate.
9468500|NCT03647241|Experimental|Self-Ligating Brackets|Patients will be treated using self-ligating brackets to achieve proper alignment of teeth
9468501|NCT03647241|Experimental|Self-Ligating Brackets with Corticotomy|Patients will be treated using self-ligating brackets with corticotomy (alveolar cortical cuts) in order to accelerate orthodontic treatment.
9468502|NCT03647241|Active Comparator|Traditionally-Ligated Brackets|Patients in this group will be treated using traditionally-ligated brackets to achieve proper alignment of teeth
9468503|NCT03647228|Experimental|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
9468504|NCT03647228|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
10030694|NCT01761630||Healthy Control|"The purpose of the SARP Control Sub-study is to generate reference data for outcomes measured in biospecimens collected from asthmatic subjects enrolled in the SARP Longitudinal Protocol.~Seven healthy subjects between the ages of 18-65 will be enrolled."
10030695|NCT01761656|Experimental|loading dose atorvastatin|For the arm of loading dose atorvastatin, patients will be treated with 80 mg atorvastatin 12 hours before PCI and 40 mg atorvastatin 2 hours before PCI and then 20mg/d after PCI.
10030696|NCT01761656|Active Comparator|conventional dose atorvastatin|For the arm of conventional dose atorvastatin, patients will be treated with 20 mg atorvastatin 12 hours before PCI and then 20mg/d after PCI.
9468505|NCT03647215||All Participants|Participants with CML and Ph+ALL who are being treated with their first or subsequent TKI therapy. CML patients must meet the ELN criteria for warning and failure ) or have high SOKAL score (>0.8) or presence of additional chromosomal abnormalities (ACAs) and have detectable BCR-ABL levels. Ph+ALL patients need detectable BCR-ABL levels only.
10030697|NCT01761669||healthy voulnters|
10030698|NCT01761682||Ph-ALL|Diagnosed as ALL with Philadelphia-negative
9468506|NCT03647202|Experimental|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
10030699|NCT01761682||Ph+ALL|Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
10030700|NCT01761682||Other ALL|Diagnosed as ALL of other type, including Burkitt leukemia
10030701|NCT01761695||CML CP|Diagnosed as CML with chronic phase
10030702|NCT01761695||CML AP|Diagnosed as CML with accelerated phase
10030703|NCT01761695||CML BC|Diagnosed as CML with blast crisis
10030704|NCT01761695||CML other|Diagnosed as CML, which is not included in any of other category
10030705|NCT01761708||umbilical, epigastric and trocar-site hernia|
10030706|NCT01761721||RAHL|Women suspected of endometrial cancer planned to be treated by robotic assisted laparoscopy hysterectomy
10030707|NCT01761734|Experimental|text message|receipt of text message
10030708|NCT01761734|No Intervention|usual care|usual care
10030709|NCT01761760|Experimental|Contingent|"Patients will earn game-based incentives contingent on meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
10030710|NCT01761760|Active Comparator|Non-contingent|"Patients will earn game-based incentives independent of meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
10030711|NCT01761773|Experimental|Group 1|Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.
10030712|NCT01761773|Experimental|Group 2|Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.
9468507|NCT03647202|Experimental|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
9468508|NCT03647202|Experimental|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
9468509|NCT03647202|Experimental|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
9468510|NCT03647202|Experimental|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
9468511|NCT03647202|Experimental|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
9468512|NCT03647189|Experimental|Treatment Arm|Subjects will be treated with hybrid fractional laser
9468513|NCT03647189|Placebo Comparator|Control Arm|
9468514|NCT03647176|Active Comparator|small polyps|Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (5-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
9468515|NCT03647176|Experimental|large polyps|Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
9468516|NCT03647150|Other|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
10030713|NCT01761773|Experimental|Group 3|Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.
10030714|NCT01761773|Experimental|Group 4|Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.
10030715|NCT01761786|No Intervention|Control group|CYP2C19 genotyping will be performed after end of study. Patients will be treated with prasugrel or ticagrelor, according to local protocol.
10030716|NCT01761786|Active Comparator|Intervention group|CYP2C19 genotyping will be performed <48h after PCI and antiplatelet treatment will be chosen based on genotyping results.
10030717|NCT01761799|Experimental|P3 Vaccine Promotion Package|The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
10030718|NCT01761799|No Intervention|No P3 vaccine promotion package intervention|The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
10030719|NCT01761812|Experimental|Single arm study|
10030720|NCT01761825|Active Comparator|Ivabradine|Ivabradine 10 mg once
10030721|NCT01761825|Placebo Comparator|placebo|
10030722|NCT01761838|Experimental|SMT for low back pain patients|To investigate the effects of high velocity, low amplitude lumbopelvic spinal manipulative therapy on spinal stiffness and back muscle activity.
10030723|NCT01761838|Other|Asymptomatic arm|To investigate the sequential changes in spinal stiffness and back muscle activity of asymptomatic participants over time without any intervention. Participants of this arm can volunteer for an additional experimental pain protocol after their third visit (at 1 week) to investigate the effects of experimental pain on the changes of spinal stiffness and back muscle activity using a randomized crossover design (injecting 5% hypertonic saline or 0.9% isotonic saline to the interspinous ligaments at L3 to L5 levels in random order in two additional visits).
10030724|NCT01761838|Other|Low back pain participants without SMT|To investigate the temporal changes in lumbar disc diffusion within a 1-hour period without SMT
10030725|NCT01761851||Cases|Liver cirrhosis
10030726|NCT01761864|Experimental|intervention group|academic detailing receiver
10030727|NCT01761864|No Intervention|control group|not receiving an academic detailing intervention
10030728|NCT01761877|Experimental|Sulindac (Clinoril)|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will receive 150 mg of sulindac twice daily for 12 months. They will receive up to 4 MRI within 12 months.
10030729|NCT01761877|No Intervention|Observational|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will continue their treatment, and will be monitored with MRI and standard of care tests every 6 months for up to 12 months.
10030730|NCT01761903||Primary Focal Dystonia|Volunteers with primary focal dystonia
10030731|NCT01761903||Healthy Controls|'Healthy' volunteers, consisting of people of the same age as the PFD volunteers, w/o a diagnosis of PFD.
10030732|NCT01761916|Experimental|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
10030733|NCT01761916|Active Comparator|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral CAPTOPRIL (25mg)
10030734|NCT01761929|Experimental|Stereotactic Body Radiation Therapy|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
10030735|NCT01761942|Placebo Comparator|placebo ,anorexia nervosa|2x3 placebo capsules with olive oil
10030736|NCT01761942|Experimental|fatty acids preparation- eye-q|2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).
10030737|NCT01761955|Experimental|High Dairy|Consuming four or more servings of dairy per day.
9468517|NCT03647150|Experimental|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.
10030738|NCT01761955|Placebo Comparator|Control, Low Dairy|Participants consumed less than 2 servings of low fat dairy per day.
10030739|NCT01761968|Experimental|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
9468518|NCT03647137||Parkinson's disease with FoG|Subjects with Parkinson's disease that have freezing of gait (FoG) who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
9468519|NCT03647137||Parkinson's disease without FoG|Subjects with Parkinson's disease that do not have freezing of gait who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
10030740|NCT01761994|Active Comparator|M100|heparin free CRRT group
9468520|NCT03647124||Lenalidomide treated R/R-MCL patients in Denmark and Sweden|Retrospective data collection for Lenalidomide treated R/R-MCL patients from Nordic registries and national health databases
10030741|NCT01761994|Experimental|HF1000|CRRT with nafamostat mesilate anticoagulation group
10030742|NCT01762007||6Mo-2Yr old penile hypospadias patients before operation|
10030743|NCT01762007||6Mo-2Yr old male patients without hypospadias|
10030744|NCT01762007||penile hypospadias patients under the age of 5 Yr|penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed
10030745|NCT01762007||2Yr-5Yr old male patients without hypospadias|
10030746|NCT01762020|Active Comparator|3M Cavilon No Sting Barrier Film|Two of four regions of the breast will be randomly chosen to receive 3M Cavilon No Sting Barrier Film treatment twice per week.
9468521|NCT03647124||Lenalidomide treated R/R-MCL patients in the rest of EU|Retrospective data collection for Lenalidomide treated R/R-MCL patients from sites in the rest of European Union
9468522|NCT03647072|Active Comparator|CHOP|CHOP only
9468523|NCT03647072|Active Comparator|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
9468524|NCT03647072|Active Comparator|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
9468525|NCT03647059||LSCM examination|
9468526|NCT03647007|No Intervention|Standard group|The Standard programme on the Christmas Seal Homes.
9468527|NCT03647007|Experimental|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
9468528|NCT03646955|Active Comparator|Partial breast irradiation|External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks
9468529|NCT03646955|No Intervention|No partial breast irradiation|No radiation therapy
9468530|NCT03646942|Active Comparator|Lingual orthodontics|Patients will be treated with lingual braces without being irradiation with low level laser therapy. Treatment will go forward in the normal manner. Archwires will be changed in the traditional way.
9468531|NCT03646942|Experimental|Low level laser therapy|Patients will be subjected to low level laser therapy during their orthodontic treatment using lingual braces.
9468532|NCT03646929|Other|healthy individuals and patients with multiple sclerosis|MEP in healthy individuals and patients with multiple sclerosis are measured using standard facilitation technique
9468533|NCT03646929|Other|patients with multiple sclerosis|MEP in patients with multiple sclerosis are measured using modified facilitation technique
9468534|NCT03646916|Active Comparator|Dexamethasone|
10030747|NCT01762020|Placebo Comparator|Standard preparations|Standard treatment
10030748|NCT01762033|Experimental|ASONEP|ASONEP will be administered by intravenous infusion over 90 minutes at 15 mg/kg once a week every 4 consecutive weeks per cycle
10030749|NCT01762046|Other|Glipizide and Metformin|On day 1, subjects will receive a single oral dose of glipizide 5 mg, and will have blood drawn at various time points for up to 240 minutes. During study days 2-7, the participants will fill out a dietary intake food record, including 3 weekdays and one weekend day. During days 6-8, the subject will receive a short-course metformin treatment of four 500-mg doses. On the morning of study day 8, 60 minutes after taking the fourth metformin dose, the subject will do a 75g Oral Glucose Tolerance Test. Blood draws will again be taken at time points for 120 minutes.
10030750|NCT01762072|Placebo Comparator|vitaminB12|VitB12 group (VitB12, n=10) receives 8 weeks of treatment with daily oral doses of 1000 μg of vitamin B12 (one capsule)
9468535|NCT03646916|No Intervention|Non-treatment|
9468536|NCT03646903|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using mental health services (e.g., Seeking help for my problems means I am weak). Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced (e.g., That's right! You are correct!). Participants in this condition will complete three separate 15-minute CBM-HS sessions."
9468537|NCT03646903|Placebo Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a similar CBM task with neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
9468538|NCT03646903|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration of self-directed psychoeducation will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
10030751|NCT01762072|Experimental|Fish oil|Fish oil group (FO, n=10)receives 8 weeks of treatment with daily oral doses of 2g of fish oil in the form of two capsules of fish oil) .
10030752|NCT01762072|Experimental|Fish oil+vitaminB12|VitB12+Fish oil group (VitB12+FO, n=10) receives 8 weeks of treatment with daily oral doses of a combination of 1000 μg of vitamin B12 and 2g of fish oil
10030753|NCT01762085|Placebo Comparator|healed DFU control arm|"clinic-specific usual best care"
10030754|NCT01762085|Experimental|healed DFU surgical intervention|"clinic-specific best care plus nerve decompression at 4 known sites of lower leg fibro-osseous entrapment"
10030755|NCT01762098||Recurrent miscarriages|
10030756|NCT01762098||Repeated embryo implantation failures|
9468539|NCT03646877|Experimental|Ozone (O3)|The O3 level during the exposures will be 200 ppb, which has previously been used in human exposure studies without short or long term, untoward side effects (and comparable to peak levels attained during the summer in the Raleigh-Durham area of North Carolina) (REF - Bromberg review).
10030757|NCT01762124|Experimental|Native Outflow Tract TPV|Implantation of the Native Outflow Tract TPV
10030758|NCT01762137|Active Comparator|Coiling|Coiling
9468540|NCT03646877|Placebo Comparator|Filtered Air (FA)|Control will be treadmill walk with filtered room air in chamber.
10030759|NCT01762137|Active Comparator|Flow Diversion|Flow Diversion
10030760|NCT01762150|Experimental|sorafenib combined with chemotherapy|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.
10030761|NCT01762163|Experimental|Qizhitongluo Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.~intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks."
10030762|NCT01762163|Active Comparator|Naoxintong Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.~intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks."
10030763|NCT01762163|Placebo Comparator|Placebo|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.~intervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks."
10036992|NCT01820858|Experimental|Adjuvant Chemotherapy|Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.
10036993|NCT01820858|Active Comparator|Adjuvant Radiotherapy|"Histopathological grade G3 and <50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;~Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;~≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times."
9468541|NCT03646864|Experimental|Treatment A|ACT-541468 50 mg from Day 1 to Day 5 of Period A
9468542|NCT03646864|Placebo Comparator|Treatment B|Placebo from Day 1 to Day 5 of Period B
9468543|NCT03646851|Experimental|COPD|COPD patients GOLD stage III and IV
9468544|NCT03646825||Treatment group|Male patients exposed to antioxidant for 12 weeks
10036994|NCT01820871|Experimental|application arm|"The patients of application arm have the smartphone application (android) for management of type 2 DM.~The application contains action plans and alarm system for each situation of serum fasting glucose, blood pressure, body weight, exercise amount, calori intake, medication, etc."
10036995|NCT01820871|Active Comparator|conventional arm|The patients of conventional arm have the booklet for management of type 2 DM. The application contains general medical guideline and knowledge for management of type 2 DM such as,exercise amount, calori intake, medication, etc.
10036996|NCT01820884|Experimental|Total Hysterectomy (TH)|Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
10036997|NCT01820884|Active Comparator|TH and bilateral salpingo-oophorectomy (TH/BSO)|Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
10036998|NCT01820897|Experimental|Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim, placebo|Fosfomycin-Trometamol 3 grams every 10 days for 6 months Plus Sulfamethoxazole trimethoprim 800/160 mg monday, wednesday and friday for 6 months Plus Placebo of Sulfamethoxazole trimethoprim Tuesday,thursday, saturday and sunday for 6 months.
10036999|NCT01820897|Active Comparator|Sulfamethoxazole trimethoprim, placebo|Sulfamethoxazole trimethoprim 800/160 mg every day for 6 months plus Placebo of Fosfomicyn-trometamol every 10 days for 6 months
9468545|NCT03646799|Experimental|Group 1|Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)
10037000|NCT01820910|Experimental|Doxycycline|
10037001|NCT01820923|Experimental|Brain stimulation|"Brain stimulation will consist of 4 types of intervention:~real transcranial direct current stimulation (two weeks, five days a week)~a week of wash-out~Sham transcranial direct current stimulation (two weeks, five days a week)~two weeks of wash-out~real repetitive transcranial magnetic stimulation (two weeks, four days a week)~a week of wash-out~Sham repetitive transcranial magnetic stimulation (two weeks, three days a week)~Stimulations will be counterbalanced between patients."
10037002|NCT01820936|Experimental|Treatment A: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 30 minutes after completing a high-fat breakfast
10037003|NCT01820936|Experimental|Treatment B: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water after fasting for at least 10 hours and 30 minutes before starting a high-fat breakfast
10037004|NCT01820936|Experimental|Treatment C: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 2 hours after completing a high-fat breakfast
10037005|NCT01820936|Experimental|Treatment D: PCI-32765|420 mg capsules administered with 240 mL noncarbonated water after fasting at least 10 hours
9468546|NCT03646799|Experimental|Group 2|Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)
9468547|NCT03646760|Experimental|Hybrid Cardiac Rehabilitation (HYCR)|
9468548|NCT03646760|Active Comparator|Center Based cardiac Rehabilitation (CBCR)|
10030764|NCT01762176|Active Comparator|Usual care group|Usual care
10030765|NCT01762176|Active Comparator|Intensive care group|Protocolized intensive treatment
10030766|NCT01762202|Experimental|Study therapy|
10030767|NCT01762215|Experimental|PLM|Upon consenting to the study, participants will be asked to register an account on PatientsLikeMe; no personal identifiers will be required. As part of registration patients create a user name and password for the website and share their email with PatientsLikeMe. Participants will be asked to provide a set of demographic variables and to complete a survey assessing elements of self-management, disease knowledge, social support, and quality of life. Paticipants will then use the PatientsLikeMe website for 6 weeks as much as they wish. After 6 weeks the participants are asked to complete a second survey.
9468549|NCT03646747|Experimental|MRI scan|"10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout.~Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours."
10030768|NCT01762228|Active Comparator|Transcutaneus electrical stimulation|Sensorial transcutaneous electrical stimulation to the pharynx and larynx will be used 1 hour/day during 5 days/week for 2 weeks.
10030769|NCT01762228|Active Comparator|TRPV1 agonist|Sensorial stimulation of TRPV1 receptors into the oropharynx of patients will be used 3 times/day (before meals) during 5 days/week for 2 weeks.
10030770|NCT01762241|Experimental|Intervention group|12 weeks systematically home based training 3 times per week one hour at the time using the Xbox Kinect system.
10030771|NCT01762241|No Intervention|Control group|No systematically training/standard of care
10030772|NCT01762254|Active Comparator|incisionless laparoscopic colectomy|incisionless laparoscopic colectomy: Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
10030773|NCT01762254|Active Comparator|conventional laparoscopic colectomy|conventional laparoscopic colectomy: The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
10030774|NCT01762267|Active Comparator|diet intervention, DASH diet|intervention: nutrition intervention: DASH diet
10030775|NCT01762267|No Intervention|not intervention, control diet|control weight loss diet
10030776|NCT01762280|Experimental|Famitinib Malate|Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily
9468550|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
9468551|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
9468552|NCT03646721|Experimental|[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
9468553|NCT03646721|Placebo Comparator|[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
9468554|NCT03646721|Experimental|[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
9468555|NCT03646721|Placebo Comparator|[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
9468556|NCT03646721|Active Comparator|[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
9468557|NCT03646695|Experimental|ILM flap|vitrectomy with ILM flap transposition and gas-tamponade will be performed
9468558|NCT03646695|Active Comparator|ILM peeling|vitrectomy with ILM peeling and gas-tamponade will be performed
9468559|NCT03646682|Experimental|caffeine group|180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling
9468560|NCT03646682|Active Comparator|control group|no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general
9468561|NCT03646643|Active Comparator|PVI, non-PV triggers|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
9468562|NCT03646643|Active Comparator|PVI, non-PV triggers & CS-LA connection|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.
9480934|NCT05168891|Experimental|Test group (TG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. Finally, the patients will be enrolled in a peri-implant maintenance therapy (PIMT) program every 3 months.
10030777|NCT01762293|Experimental|Famitinib|Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
10030778|NCT01762293|Placebo Comparator|Placebo|Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
9468563|NCT03646630|Active Comparator|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, ~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
10030779|NCT01762306|Experimental|Diclofenac Potassium|Diclofenac Potassium 50 mg PO 1 hour prior to fractional curettage
10030780|NCT01762306|Placebo Comparator|Folic Acid|Folic acid 5 mg PO 1 hour prior to fractional curettage
10030781|NCT01762319|Experimental|Misoprostol|200 mcg Misoprostol SL 1 hour prior to fractional curettage
10030782|NCT01762319|Placebo Comparator|Vitamin B6|100 mg Vitamin B6 SL 1 hr prior to fractional curettage
9468564|NCT03646630|Active Comparator|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
9468565|NCT03646591||Neoadjuvant chemotherapy|"FLOT Chemotherapy regimen~A cycle consist of Day 1: 5-fluorouracil (5-FU) 2600mg/M2 intravenous Via peripherally inserted central catheter (PICC) for 24 hour Day 1: Leucovorin 200mg/M2 intravenous Day 1: Oxaliplatin 85mg/ M2 intravenous Day 1: Docetaxel 50mg/M2 intravenous Repeated every 15th day"
9468566|NCT03646552|Experimental|THX-110|All participants will be titrated up on THX-110 (Dronabinol) dose during the first week of the trial (2.5mg Dronabinol for 3 days, 5mg Dronabinol for 3 days to 7.5mg Dronabinol for 3 days and finally increasing to 10mg for the remainder of the trial). Dronabinol will only be increased if the subject is tolerating the previous dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving 800mg PEA concomitantly.
9468567|NCT03646539|Experimental|Smartphone use + treatment as usual|Participants will receive treatment as usual and use the smartphone app for the management of mood.
9468568|NCT03646539|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
9468569|NCT03646526|Experimental|Fast group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under fasting condition .~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
9468570|NCT03646526|Experimental|Feeding group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under feeding condition.~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
9468571|NCT03646513||SMF Short Modular Femoral Stem Implanted Subjects|Subjects who have been implanted with the SMF Short Modular Femoral Stem for primary total hip arthroplasty.
9468572|NCT03646500|Experimental|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
9468573|NCT03646500|Active Comparator|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
9468574|NCT03646487|Experimental|Probiotic LP299v|Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.
9468575|NCT03646487|Placebo Comparator|Placebo|Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
9468576|NCT03646474|Active Comparator|tranexamic acid group|
9468577|NCT03646474|Placebo Comparator|placebo group|
9468578|NCT03646435|Experimental|Wearable device (Fitbit Charge 2)|The Fitbit Charge 2 is the wearable of interest for this pilot study. All 50 study participants will be requested to wear the electronic device for the duration of their stay in the hospital (maximum of 6 days). The Fitbit will passively collect health information of patients which will be tracked on mobile devices by the study investigators.
9468579|NCT03646409||Patients with esophageal cancer receiving chemotherapy|Patients > 18 years with esophageal cancer receiving neoadjuvant chemotherapy
9468580|NCT03646396|Experimental|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
9468581|NCT03646357|Active Comparator|Betablocker|Patients receiving a betablocker. Any other treatment or management is to be given as per usual care.
9468582|NCT03646357|Experimental|Non-Betablocker|No betablocker is given to this arm. Any other treatment or management is to be given as per usual care.
9468583|NCT03646344|Active Comparator|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
9468584|NCT03646344|Placebo Comparator|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
10030783|NCT01762332|Active Comparator|Low opioid level|Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014)
10030784|NCT01762332|Active Comparator|High opioid level|Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014)
10030785|NCT01762332|Other|chronic beta-blocker treatment|"Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization.~Continue recruitment."
9468585|NCT03646331|Experimental|Tablet A in Session 1 and Tablet B in Session 2|Tablet A = reference product Tablet B = test product
9468586|NCT03646331|Experimental|Tablet B in Session 1 and Tablet A in Session 2|Tablet A = reference product Tablet B = test product
10030786|NCT01762358|Active Comparator|Standard Therapy|Standardized physiotherapy for 12 times (15 patients)
10030787|NCT01762358|Experimental|Standard + Khalifa|Initial one hour Khalifa therapy followed by twelve times standardized Physiotherapy (15 patients)
10030788|NCT01762371|Experimental|K-Pat|Getting one time one hour of Khalifa's therapy for ACL injury treatment.
9468587|NCT03646318|Experimental|Ketanserin|Ketanserin is a serotonin type 2-receptor blocker (5-HT2). In normal endothelium, the 5-HT1 effects (vasodilation) are the most prominent [Dabire 1990]. In endothelium that is damaged, which is the case in sepsis, the 5HT2 effects (vasoconstriction) surpass the 5-HT1 effects. Blocking the 5-HT2 receptor with ketanserin can attenuate this pathological vasoconstriction. In addition, ketanserin has favourable α1-adrenergic blocking properties in the endothelium (vasodilation) that may further reverse the pathological vasoconstriction. In these ways ketanserin can reduce vasoconstriction and can improve the microcirculation.
9468588|NCT03646318|Placebo Comparator|Placebo|The placebo is a standard glucose 5% solution.
10030789|NCT01762384|Active Comparator|LSC|procedure: laparoscopic sacral colpopexy.
9468589|NCT03646292|Experimental|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 6 months
9468590|NCT03646292|Experimental|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 6 months
9468591|NCT03646292|Experimental|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg + Empagliflozin 10mg combination 1T daily for 6 months
9468592|NCT03646266|Experimental|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
9468593|NCT03646266|No Intervention|Control|Standard of care
9468594|NCT03646253||Patients with proximal humerus fracture|
9468595|NCT03646240|Experimental|Dosing arm|
9468596|NCT03646214|Experimental|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
9468597|NCT03646214|No Intervention|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
9468598|NCT03646201|Experimental|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family food environment, mothers' own eating behaviors, and food parenting practices.
9468599|NCT03646201|No Intervention|Control Group|Data are collected at baseline and post intervention session.
10030790|NCT01762384|Active Comparator|Modified PFRS|procedure: modified pelvic floor reconstructive surgery with mesh.
10030791|NCT01762397|Experimental|PMK-S005|
10030792|NCT01762410|Experimental|P7170|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
10030793|NCT01762423|Experimental|Active Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with Velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Active Devices The device will be activated at the time of placement. The active devices are programmed to automatically deliver treatment. Each treatment duration is 15 minutes. The active device delivers treatment every 2 hours. A light will flash on the device when the PEMF begins and will continue to flash every second until the end of the treatment. Between treatments the device will be in sleep mode and the light will flash every 5 seconds."
9468600|NCT03646188|Placebo Comparator|Placebo-containing MNA|Placebo
9468601|NCT03646188|Experimental|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
9468602|NCT03646188|Experimental|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
10030794|NCT01762423|Sham Comparator|Sham Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Sham Devices The sham devices mirror the active device with the exception of the delivery of the PEMF. The sham device will be activated at the time of placement. A light will flash on the device when the SHAM PEMF begins and will continue to flash every second until the end each treatment interval. While in sleep mode the device will not deliver treatment and the light will flash every 5 seconds."
10037006|NCT01820936|Experimental|Treatment E: PCI-32765|840 mg capsules administered with 240mL noncarbonated water 30 minutes after completing a high-fat breakfast
10037007|NCT01820949||Control cohort|Standard care before implementation (pre-implementation)
9468603|NCT03646188|Experimental|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
9468604|NCT03646188|Experimental|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
9468605|NCT03646149||Housing Skills Training Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care.
9468606|NCT03646136|Experimental|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
9468607|NCT03646136|Active Comparator|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
9468608|NCT03646110|Experimental|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
9468609|NCT03646110|Active Comparator|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
10030795|NCT01762436|Experimental|bisoprolol|initially received 5 mg of bisoprolol (Concor®, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
9468610|NCT03646097|Active Comparator|Blinded-group|Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care)
9468611|NCT03646097|Active Comparator|OCT-group|Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings
9468612|NCT03646097|Experimental|ACR-group|Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings
9468613|NCT03646084|Experimental|Sleep Intervention Program (SCIP)|Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
9468614|NCT03646084|Active Comparator|Control|Rehabilitation according to current clinical practice.
9468615|NCT03646045||Transpyloric feed|Preterm infant receiving transpyloric feeding.
9468616|NCT03646045||Control|Preterm infants receiving gastric feeding
9480164|NCT03536286|Experimental|Encouragement Zone 4|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
9480165|NCT03536286|No Intervention|Control Zone 4|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
9480166|NCT03536273|Experimental|Functional Movement Screen|
9480167|NCT03536273|Experimental|Posture Analysis|
9480168|NCT03536273|Experimental|Depression Level|
9480169|NCT03536273|Experimental|Quality of Life|
9480170|NCT03536260|Active Comparator|Immediate implant with Xenograft|
9480171|NCT03536260|Active Comparator|Immediate implant with Nanobone|
9480172|NCT03536247|Active Comparator|Intraductal lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
9480173|NCT03536247|Active Comparator|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
9480174|NCT03536234|Experimental|Triptorelin (GnRH analogue)|
9480175|NCT03536234|No Intervention|Control group|
9480176|NCT03536208|Experimental|Warfarin|Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin
9667785|NCT02988661|No Intervention|Usual Care|African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.
10030796|NCT01762436|Active Comparator|atenolol|initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
10030797|NCT01762449||Patients who received cyclophosphamide|Patients who received cyclophosphamide on the Scleroderma Lung Study
10030798|NCT01762449||Patients who received placebo|Patients who received placebo on the Scleroderma Lung Study
10030799|NCT01762462|Experimental|SAR302503|single treatment with oral dose up to 300 mg of SAR302503
10037008|NCT01820949||PBM cohort|After implementation of PBM program (post-implementation)
10037009|NCT01820962|Active Comparator|A: heparin (Heparin LEO)|After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
10037010|NCT01820962|Experimental|B: concentrated citrate (Citralock)|locking the central venous catheter with concentrated citrate after each use
10030800|NCT01762475|Experimental|Experimental: Group 1--Symptomatic TBI|"Experimental Group, Group 1, will consist of twenty-four male and female adult participants who have persistent TBI symptoms lasting more than six months.~Participants in the experimental group will be randomized in a 1:1 ratio, assigned to group a or b.~Participants randomized into Group 1a will take placebo twice daily for 8 weeks, followed by 8 weeks of sildenafil 25 mg twice daily with a 2-week washout period between the two 8-week periods.~Participants randomized into Group 1b will take sildenafil 25 mg twice daily for 8 weeks, followed by 8 weeks of placebo twice daily with a 2-week washout period between the two treatment periods."
10030801|NCT01762475|Active Comparator|Active Comparator: Group 2--Healthy Controls|Group 2 will be comprised of twenty male and female adult participants who have never experienced a TBI or concussion to serve as age and gender-matched healthy controls. Participants in Group 2 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
10030802|NCT01762475|Active Comparator|Group 3--Recovered TBI|Group 3 will be comprised of twenty male and female adult participants who have experienced a TBI, have recovered, and are asymptomatic at the time of screening, to serve as age and gender-matched asymptomatic TBI controls. Participants in Group 3 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
10030803|NCT01762488|Active Comparator|Renal denervation by ablation of the renal arteries|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.
10030804|NCT01762488|Sham Comparator|Control|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.
9468617|NCT03646032|Experimental|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
9468618|NCT03646032|Active Comparator|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
9468619|NCT03646019||Normal coronary arteries|
9468620|NCT03646019||Non significant coronary artery disease|
9468621|NCT03646019||Significant coronary artery disease|
9468622|NCT03646006|Experimental|Pre-sacral nerve block|10 mL bupivacaine (5mg/mL)
9468623|NCT03646006|Sham Comparator|Sham block|10 mL normal saline
9468624|NCT03645993||Early-Onset Alzheimer's disease|Patients ages 45-60 with Early-Onset Alzheimer's disease
9468625|NCT03645993||Negative Control|Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
9468626|NCT03645980|Experimental|DKN-01 300 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg , depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
9468627|NCT03645980|Experimental|DKN-01 600 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
10030805|NCT01762514|No Intervention|Program I|Patients with American Joint Cancer Committee/Union Internationale Contre le Cancer (UICC/AJCC) 2010 Stage I and II; Radiotherapy applied
10030806|NCT01762514|Experimental|Program II|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine every-other-day regimen
10037011|NCT01820975|Experimental|High protein intake|High protein intake: large bolus of protein in teh diet the day before testing
9468628|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
9468629|NCT03645889|Experimental|Paediatric Lung Tonic (PLTG)|Traditional Chinese Medicine (TCM) in granules dosage form to be dissolved for consumption.
9468630|NCT03645889|Placebo Comparator|PLTG Placebo|Starch granules with 10% TCM to mimic the colour, taste and smell of active TCM.
9468631|NCT03645876|Experimental|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
9468632|NCT03645850|Experimental|Investig. device:Vismed Gel Multi 0.3%|Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
9468633|NCT03645850|Active Comparator|Comparative device: Vismed Multi 0.18%|Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
9468634|NCT03645837|Experimental|10 minutes|Compression clamp release start after 10 minutes
9468635|NCT03645837|Experimental|20 minutes|Compression clamp release start after 20 minutes
9468636|NCT03645837|Active Comparator|30 minutes|Compression clamp release start after 30 minutes
9468637|NCT03645798|Experimental|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
9468638|NCT03645798|Other|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
9468639|NCT03645772|Experimental|Plyometric exercise|12-week progressive exercise program, consisting of plyometric exercises such as countermovement jump, forward and sideways step-up.
9468640|NCT03645772|Active Comparator|Resistance exercise|12-week resistance exercise program for the leg muscles (2-4 sets of 8-15 repetitions at 8-15RM, leg press, leg extension, calve extension).
9468641|NCT03645772|Active Comparator|Walking|12-week progressive walking program.
10030807|NCT01762514|Active Comparator|Program III|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine everyday regimen
10030808|NCT01762514|No Intervention|Program IV|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied
9468642|NCT03645746|Experimental|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
9468643|NCT03645746|Experimental|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
9468644|NCT03645746|Experimental|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
9468645|NCT03645746|Experimental|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
9468646|NCT03645746|Experimental|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
9468647|NCT03645746|Experimental|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
9468648|NCT03645746|Experimental|Cohort 7|Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
9468649|NCT03645733|No Intervention|Control Group|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months
9468650|NCT03645733|Experimental|Lower Temperature Group|These patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study.
9468651|NCT03645733|No Intervention|Caregivers|Patients, who consent for the study, will be asked to identify the most suitable carer to participate in the study who could be approach in person, over the phone or by post as deemed suitable by the research team and convenient by the carer. Patient's permission to contact their identified carer will be recorded. Carers of consenting patients will be approached in the same manner as above after obtaining patients consent to contact their carers. Patients will still be able to take part in the study even if their carer declines consent.
9468652|NCT03645720|No Intervention|Metal needle gruop|puncture using metal needle
9468653|NCT03645720|Experimental|plastic cannula|puncture using plastic cannula
9468654|NCT03645681|Experimental|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
9468655|NCT03645668|Experimental|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
9468656|NCT03645668|Other|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
9468657|NCT03645655||hepatoblastoma|The diagnosis of hepatoblastoma is based on enhanced CT scanning and/or histopathology.
9468658|NCT03645655||hepatic hemangioendothelioma|The diagnosis of hepatic hemangioendothelioma is based on enhanced CT scanning and/or histopathology.
9468659|NCT03645655||Healthy control|The healthy control group consist of people undergoing routine medical examination.
10030809|NCT01762514|Experimental|Program V|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine every-other-day regimen
10030810|NCT01762514|Active Comparator|Program VI|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine everyday regimen
10030811|NCT01762527|Experimental|ART|Online adaptive radiotherapy
10030812|NCT01762540|Placebo Comparator|Calcium supplement|Capsule with tablet of calclium supplement
10030813|NCT01762540|Active Comparator|Glucocorticoids|Capsule with tablet of Prednisolone 37,5mg
10030814|NCT01762553|Experimental|intervention|The TEA intervention program will be implemented for the intervention group. The TEA intervention has three modules (healthy body & healthy mind, family interaction, and quality of life) logically connected to each other and implemented at three levels from individual, family to the community: 1) TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; 2) TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; 3) TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
10037012|NCT01820975|Placebo Comparator|No protein intake|No protein in the diet the day before testing
10037596|NCT01826526|Active Comparator|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
9468660|NCT03645642|Experimental|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
9468661|NCT03645642|Active Comparator|Albumin with diuretics|Albumin(20g/l) and diuretics.
9468662|NCT03645629|Active Comparator|Food skin tests at 0 month|the skin test results of food extract at time 0 months after preparation
9468663|NCT03645629|Active Comparator|Food skin tests at 3 month|the skin test results of food extract at time 3 months after preparation
9468664|NCT03645629|Active Comparator|Food skin tests at 6 month|the skin test results of food extract at time 6 months after preparation
10030815|NCT01762553|No Intervention|Control|In order to tease out the impact of the proposed intervention from the impact of attention in general, we will add limited activities to the control group condition. The differences between the intervention and control conditions consist in both contents and formats. For the control group, there will only be group sessions once a week for three weeks starting after baseline assessment. The content of the sessions for the control group will focus on basic care, health education and promotion, nutrition, personal and family hygiene. The Essential Care Package (ECP), a set of education materials originally developed by the World Health Organization (WHO) and supported by the Global Fund Project, will be used and explained in these group sessions. Health workers from villages in the control group will also visit participating families once a week for the initial three weeks and once a month for 12 months.
10030816|NCT01762566|Active Comparator|wheat|wheat is administered blindly versus placebo in capsules once
10030817|NCT01762566|Placebo Comparator|xylose|placebo (xylose) will be administered blindly versus wheat in capsules once
10030818|NCT01762592|Experimental|Iodine (124I) Girentuximab|Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0.
10030819|NCT01762618|Experimental|Cognitive Behavioral Therapy Group|14 therapy sessions, once a week for one and a half hours.
9468665|NCT03645616|Experimental|Functional Tests|Participants undertook 6-minute walk test, 10 meters walk test and 30 second sit to stand test.
9468666|NCT03645590|Experimental|Stroke Ready Community intervention|We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
9468667|NCT03645538||Parkinson's disease patients|"PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).~The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
9468668|NCT03645538||No drug - Control group|PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
9468669|NCT03645525|Experimental|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
9468670|NCT03645525|Placebo Comparator|placebo|saline without mesenchymal stem cell
9468671|NCT03645512|Experimental|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
9468672|NCT03645512|No Intervention|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
9468673|NCT03645499|Experimental|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
9468674|NCT03645499|Experimental|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
9468675|NCT03645499|Experimental|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
9468676|NCT03645499|Experimental|Topical TA-102 D|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
9468677|NCT03645499|Experimental|Topical TA-102 E|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
9468678|NCT03645486|Experimental|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
9468679|NCT03645473|Experimental|Monarch device settings assessment group|"Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study.~The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures."
9468680|NCT03645460|Experimental|TYF-ADA-modified autologous stem cells|Autologous hematopoietic and/or mesenchymal stem cells transduced with lentiviral vector carrying the ADA gene
9468681|NCT03645447|Experimental|Taste test|Participants will be presented with a series of tastants of 4 different modalities (sweet, salt, sour, bitter) of 9 different concentrations in pseudo-random order. The threshold at which each participant reliably identifies the taste is determined for each tastant. Mood Questionnaires will be used to determine whether a participant is clinically depressed.
9468682|NCT03645395|Experimental|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
9468683|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 3x a week|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
10030820|NCT01762618|No Intervention|Control Group|Social support for caregiver (through the social worker) as usual. The social worker gives information when they considered that there is a social economic risk or upon request by the caregiver.
10030821|NCT01762644|Experimental|Arm 1|Immune Tolerance and Proton Pump Inhibitor
10030822|NCT01762644|Active Comparator|Arm 2|Proton Pump Inhibitor
10030823|NCT01762657|Experimental|Oral CyclosporineA and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day in two divided dosages given with Lansoprazole dosed at 30 mg per day in two divided dosages for subjects aged 8-15 year and 60 mg per day for those aged 16-60.
10030824|NCT01762657|Placebo Comparator|Placebos|
10030825|NCT01762670|Active Comparator|Metronidazole|Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
9468684|NCT03645395|Experimental|MT-3724 20 mcg/kg-LEN 3x a week|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
9468685|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 2x a week|MT-3724 25 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
9468686|NCT03645395|Experimental|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
9468687|NCT03645382|Placebo Comparator|baked barley powder consumption|Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
9468688|NCT03645382|Experimental|jeju steam onion powder consumption|Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
9468689|NCT03645369|Experimental|Mechano-Analgesia|The first SC heparin injections were applied from the right abdominal region using ShotBlocker®.
9468690|NCT03645369|Experimental|Cold Application|The second SC heparin injections were applied from the left abdominal region with an ice pack
9468691|NCT03645369|No Intervention|Control|The second SC heparin injections were applied from the lower abdominal region without any additional application
9468692|NCT03645343|Active Comparator|Activator|Patients will be treated using the Activator appliance for one and a half year
9468693|NCT03645343|Experimental|Twin Block|Patients will be treated using the Twin Block appliance for 18 months on average
9468694|NCT03645343|No Intervention|Control|Patients will be monitored until the last assessment times in the other groups. This group will serve as a control group
9468695|NCT03645317|Other|Single arm|Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)
9468696|NCT03645304|Experimental|Ropivacaine group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .
9468697|NCT03645304|Placebo Comparator|0.9% Saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
9468698|NCT03645291|Active Comparator|Skin test with local extract|Skin prick test and intradermal test with local stinging insect allergen extracts that develop in Immunological division of Siriraj hospital, mahidol University
9468699|NCT03645291|Sham Comparator|Skin test with commercial extract|Skin prick test and intradermal test with commercial stinging insect allergen extracts that order from ALK company
9468700|NCT03645278|Experimental|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
9468701|NCT03645278|Experimental|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
9468702|NCT03645265|Experimental|Gestures|Use of hand gestures to improve speech rhythm and speech production
9468703|NCT03645265|Experimental|Auditory|Use of auditory cues to improve speech rhythm and speech production
10030826|NCT01762670|Experimental|GoldenCare|GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.
10030827|NCT01762683|Experimental|pre-conceptional obesity with a scheduled cesarean section|
10030828|NCT01762683|Active Comparator|non-obese women with a scheduled cesarean section|
10030829|NCT01762683|Active Comparator|women entering labour|women entering labour for vaginal delivery and for vaginal delivery
10030830|NCT01762696|Active Comparator|MET only|Motivational Enhancement Therapy only
10030831|NCT01762696|Experimental|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
10030832|NCT01762709|Active Comparator|The VT 4 ml/kg group|Use of tidal volume of 4 ml/kg during one lung ventilation
10030833|NCT01762709|Active Comparator|The VT 6 ml/kg group|Use of tidal volume of 6 ml/kg during one lung ventilation
10030834|NCT01762709|Experimental|The VT 8 ml/kg group|Use of tidal volume of 8 ml/kg during one lung ventilation
10030835|NCT01762735|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
10030836|NCT01762735|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
9468704|NCT03645252|Active Comparator|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
10030837|NCT01762748|Experimental|S. boulardii 200mg (Floratil®)|"The patients received S. boulardii every 8h during 30 days as an oral capsule formulation which contained 200 mg lyophilized S. boulardii-17 (Floratil®).~The patients enrolled in the study were evaluated immediately before the beginning of treatment, after a thirty-day period of treatment with probiotic and at the end of the second study month (after a thirty-day period without treatment with probiotic)."
10030838|NCT01762761|Experimental|Eltrombopag (ETB115)|Thrombopoietin- receptor (TPO-R) agonist
10030839|NCT01762761|Placebo Comparator|Placebo|Placebo
10030840|NCT01762774|Experimental|Cohort 1|Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
9468705|NCT03645252|Active Comparator|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
10030841|NCT01762774|Experimental|Cohort 2|Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
10030842|NCT01762774|Experimental|Cohort 3|Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
10030843|NCT01762774|Experimental|Cohort 4|Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.
10030844|NCT01762787|Active Comparator|Effect of Aspirin|Positive control as previously used in the cantharidin blister experimental model of inflammation
9468706|NCT03645226||Early PD subjects converted from iRBD|"Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging will be used for severity grading.~Onset of PD symptoms of <5 years~In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
9468707|NCT03645226||iRBD subjects|"Age-and sex-matched with PD subjects~Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
9468708|NCT03645226||First degree relatives of patients with iRBD|"First degree relatives of patients with iRBD;~Age-and sex-matched with PD subjects~Chinese aged 40 or above;~Absence of dream enactment behaviors;~Not cohabiting with proband"
9468709|NCT03645226||Healthy Controls|"Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Without a personal history or a family history of PD or RBD;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Absence of RSWA as measured by v-PSG."
9468710|NCT03645226||Spouses of patients with iRBD|"Spouses of patients with iRBD;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
9468711|NCT03645226||First degree relatives of healthy controls|"First degree relatives of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 40 or above ;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;"
9468712|NCT03645226||Spouses of healthy controls|"Spouses of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
10030845|NCT01762787|Experimental|Effect of steroid - Prednisolone|Prednisolone selected as steroids should provide the most robust positive control anti-inflammatory therapy
10030846|NCT01762787|Experimental|Cantharidin exposure to optimise blister formation|Cantharidin exposure to optimise blister formation
10030847|NCT01762813||open and laparoscopic surgery|Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
9468713|NCT03645213|Experimental|Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a head-mounted VR box in the VR group.
9468714|NCT03645213|Experimental|Non- Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a computer tablet in the non-VR group. The computer tablet was the 10 centimeters far from the child.
10030848|NCT01762826||Placebo control|Diet pills of 400 mcg of acid folic daily
10030849|NCT01762826||D-chiro-inositol / Myo-inositol|Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily
10030850|NCT01762826||D-chiro-inositol|Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily
10030851|NCT01762826||Myo-inositol|Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily
10030852|NCT01762839|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
10030853|NCT01762839|Placebo Comparator|Placebo|IV placebo
9468715|NCT03645213|No Intervention|Control|There was no additional intervention in the control group. Venipuncture procedures was the same other groups. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's.
9468716|NCT03645200|Experimental|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
9468717|NCT03645187|Active Comparator|FOLFERI|FOLFERI regien
9803050|NCT04622228|Experimental|LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with atezolizumab. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
9803051|NCT04622163|Experimental|Secondary Mentor Plus Career Development Resources|Subjects will be assigned a secondary mentor for 6 months. Subjects will also receive career development resources.
9803052|NCT04622163|Other|Career Development Resources Alone|Subjects will not be assigned a secondary mentor. Subjects will receive career development resources only.
9803053|NCT04618055|Experimental|NiTiDent Tuah Porous NiTi Dental Implants|
9468718|NCT03645187|Active Comparator|FOLFERI and celecoxib|FOLFERI and celecoxib
9468719|NCT03645174|Active Comparator|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
9468720|NCT03645174|Experimental|Long tube|Fiberoptic-guided intubation through LMA, using long tube
9468721|NCT03645161|Active Comparator|Local rat and mouse skin test|All patients receive local skin prick test for mouse and rat. The result were recorded and compared to the imported one.
9468722|NCT03645161|Active Comparator|Imported rat and mouse skin test|All patients receive imported skin prick test for mouse and rat. The result were recorded and compared to the local one.
9468723|NCT03645135|No Intervention|Control|Patients in the control group will be asked to complete a demographics survey and assess their perceived involvement in care after their visit
9468724|NCT03645135|Experimental|Goal elicitation|Patients in the intervention group will be asked to list 2 goals for their visit. They will also be asked to complete a demographics survey and access their perceived involvement in care after their visit.
9468725|NCT03645109|Experimental|Vitamin D|Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks
9468726|NCT03645109|Placebo Comparator|Placebo|Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks
9468727|NCT03645083|Experimental|Telephone call|Participants receive a telephone call reminder three days after their initial visit
9468728|NCT03645083|Experimental|Text message|Participants receive a text message reminder three days after their initial visit
10030854|NCT01762839|Active Comparator|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a moxifloxacin tablet and will not receive a placebo infusion.
10030855|NCT01762852|Experimental|Belimumab Arm|Subjects will receive belimumab 10 mg/kg intravenous infusion [will last for 1 hour (hr)] on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
10030856|NCT01762852|Placebo Comparator|Placebo Arm|Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
10030857|NCT01762878|Experimental|GSK2269557 100 mcg arm|Each subject will receive 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 100 mcg in one of the 4 treatment periods.
9468729|NCT03645083|No Intervention|Control|Participants do not receive any intervention after their initial visit
9468730|NCT03645057|Experimental|Crisaborole|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
9468731|NCT03645057|Active Comparator|Tacrolimus 0.03%|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
9468732|NCT03645031|Experimental|ALS Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
9468733|NCT03645031|Experimental|Healthy Control Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
9468734|NCT03645018|Experimental|diagnosis with tomosynthesis (DTS)|"Single arm.~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
9468735|NCT03645005|Experimental|My Guide (psychoeducation & self-management program)|
9468736|NCT03645005|Active Comparator|My Health (health education program)|
9468737|NCT03644992||Thromboembolic Disease|the patients who undergo gynecological operations but develop thromboembolic disease
9468738|NCT03644979|Experimental|Skydiving|Tandem skydiving
9803054|NCT04618055|Active Comparator|Control Implant|
9803055|NCT04610645||Head and Neck Cancer Patients|Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer
10030858|NCT01762878|Experimental|GSK2269557 500 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 500 mcg in one of the 4 treatment periods
10030859|NCT01762878|Experimental|GSK2269557 3000 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 3000 mcg in one of the 4 treatment periods
10030860|NCT01762878|Placebo Comparator|Placebo arm|The subjects will receive single dose of placebo in each treatment period of part A and repeat doses of placebo in Part B of the study.
10030861|NCT01762878|Experimental|Part B GSK2269557 arm|The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
9468739|NCT03644979|No Intervention|Negative control|No skydiving
9468740|NCT03644966|Experimental|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
9468741|NCT03644966|Active Comparator|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
9468742|NCT03644940|Experimental|Subpopulation-specific Algorithm|
9468743|NCT03644940|No Intervention|Control Algorithm|
9468744|NCT03644914|Experimental|Intervention Group (Reading Program)|First graders who will receive the 10-week reading program (a total of 20 hours), twice weekly in 1-hour sessions, and will continue to receive typical classroom reading instruction.
9468745|NCT03644914|No Intervention|Control Group|First graders who will not take part in the reading program but will continue to receive typical classroom reading instruction.
9468746|NCT03644901||Patients whose blood type is A|Applying nonsurgical periodontal treatment (scaling and root planning).
9468747|NCT03644901||Patients whose blood type is B|Applying nonsurgical periodontal treatment (scaling and root planning).
9468748|NCT03644901||Patients whose blood type is AB|Applying nonsurgical periodontal treatment (scaling and root planning).
9468749|NCT03644901||Patients whose blood type is O|Applying nonsurgical periodontal treatment (scaling and root planning).
9468750|NCT03644888|Active Comparator|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
9468751|NCT03644888|Experimental|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
9468752|NCT03644888|Sham Comparator|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
9468753|NCT03644836|Experimental|Retraining with respiratory effort+ amino acids|
9468754|NCT03644836|Placebo Comparator|Retraining with respiratory effort+ placebo|
9468755|NCT03644823|Experimental|PDL1-inhibitor and radiotherapy|PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)
9468756|NCT03644810|Active Comparator|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
9468757|NCT03644810|Active Comparator|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
9468758|NCT03644797||Patients|Patients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
9468759|NCT03644784||Yamaguchi University Hospital|
9468760|NCT03644784||Erasmus Medical Center|
9468761|NCT03644784||Academic Medical Center - Amsterdam|
9468762|NCT03644784||Segeberger Kliniken Gruppe|
9468763|NCT03644784||McGill University - Montreal|
9468764|NCT03644758||professional and voluntary firefighter|Professional and voluntary firefighter in Service Departmental Fire and Rescue of Loire will be included. They will have to answer at the self-administrated questionnaires. It is composed of 5 parts: socio-demographic data and personal medical history, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Insomnia Severity Index (ISI) and stop-BANG questionnaire.
9468765|NCT03644745|Experimental|VM @ Home Usability|We will pilot our customer engagement and physical exercise system in the homes of up to 20 participants for 3 months. Participants will interact with the system on their own computers, smart phones, and/or televisions and wear an activity tracker throughout the study. Interactions include physical exercise, system usage, and video conferencing.
9468766|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
9468767|NCT03644719|Experimental|Cognitive behavior skills training|The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.
10030862|NCT01762891|Experimental|Celecoxib|Celecoxib 200mg/day oral rout Intervention: celecoxib 200mg oral rout administered durng 15 days and followed by administration of rofecoxib 25mg/day during 15 days, placebo 15 days and acetaminophen 3g/day during 15 days.
9468768|NCT03644719|No Intervention|Education as usual|The EAU group received six hours of informational lectures about ketamine, its effects on the brain, relevant regulations and laws, and the risks and modes of transmission of infectious diseases, including HIV and hepatitis C.
9468769|NCT03644706|Active Comparator|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
9468770|NCT03644706|Placebo Comparator|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
9468771|NCT03644693|Experimental|Investigational|Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
9468772|NCT03644693|Placebo Comparator|Placebo|Subjects assigned to this arm will receive the Placebo Formulation.
9468773|NCT03644680|Experimental|Nasal Provocation with Birch Extract|Birch allergic patient receiving 3 consecutive nasal challenges with birch extract (Allergopharma). Total dose of 1.5ug of Bet v 1 per challenge
9468774|NCT03644680|Placebo Comparator|Nasal Provocation with NaCl 0.9%|Birch allergic patient receiving 3 consecutive nasal challenges with sterile NaCl 0.9%. Total dose of 100ul per nostril per challenge
9468775|NCT03644667|Experimental|Tocilizumab + Standard of Care Triple IS|"Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
9468776|NCT03644667|Placebo Comparator|Placebo + Standard of Care Triple IS|"Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
9468777|NCT03644654|Active Comparator|Standard care group|Fluid management will be done according standard care
9468778|NCT03644654|Experimental|Noninvasive monitoring group|Fluid management will be provided using noninvasive hemodynamical monitor ClearSight (Edwards)
9468779|NCT03644641|Experimental|Desflurane Group|Induction and anesthesia will be held by using desflurane
10030863|NCT01762917||Obstruction|Patients suffering from pulmonary obstruction
9468780|NCT03644641|Experimental|Propofol Group|Induction and anesthesia will be held by using target-control anesthesia with propofol
9468781|NCT03644628|Active Comparator|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
9468782|NCT03644628|Experimental|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
9468783|NCT03644602|Active Comparator|IBD patients|"All subjects with Crohn's disease in clinical remission (defined in the presence of a Crohn's Disease Activity Index, CDAI <150), and with Ulcerative colitis in clinical remission (defined in the presence of <3 evacuations / day without blood, in the absence of endoscopic alterations) received a low FODMAPs diet.~The low FODMAPs diet was administered for 3 months."
9468784|NCT03644602|Active Comparator|Coeliac patients|Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
9468785|NCT03644602|Active Comparator|IBS patients|Patients with Irritable Bowel Syndrome received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
9468786|NCT03644589|Experimental|Treatment (pembrolizumab, cisplatin)|"Participants receive pembrolizumab and cisplatin once every 3 weeks for a total of 6 doses. Both drugs are given by vein (IV). Participants that are responding to the study treatment will continue to receive pembrolizumab alone beyond 6 cycles for up to 24 months until disease gets worse, having bad side effects, no longer wish to be in the study, or have become pregnant (whichever comes first).~Participants receive pembrolizumab over 30 minutes and cisplatin on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants without disease progression after 6 courses may continue on pembrolizumab IV on day 1 every 21 days for up to 24 months (or 35 courses) in the absence of disease progression or unacceptable toxicity."
9468787|NCT03644576|Experimental|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
9468788|NCT03644576|Placebo Comparator|ozanimod placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
9468789|NCT03644537|Other|heavy force 100gm|heavy intrusive force is to be applied on a first premolar on one side
9468790|NCT03644537|Other|medium force 25 gm|medium intrusive force is to be applied on a first premolar on one side
10030864|NCT01762917||Restriction|Patients suffering from pulmonary restriction
10030865|NCT01762917||Controls|Pulmonary healthy controls
10030866|NCT01762930|Active Comparator|Shanchol stored at 2-8oC|Vaccines will be stored at 2-8oC before administration.
10030867|NCT01762930|Experimental|Shanchol stored at 25oC|Vaccines will be stored at 25oC for 14 days before administration.
10030868|NCT01762930|Experimental|Shanchol stored at 37oC|Vaccines will be stored at 37oC for 14 days before administration.
10030869|NCT01762930|Experimental|Shanchol stored at 42oC|Vaccines will be stored at 42oC for 14 days before administration.
10030870|NCT01762956|Experimental|Training group (TG)|The group of patients undergoing radiotherapy and submitted to pelvic floor muscles training.
10030871|NCT01762956|No Intervention|Control group(CG)|The group of patients undergoing radiotherapy only.
10030872|NCT01762969|Experimental|Modified by molecular response|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
9468791|NCT03644537|Other|light force 10 gm|light intrusive force is to be applied on a first premolar on one side
9468792|NCT03644524|Experimental|Heat Therapy|Subjects assigned to heat therapy underwent 30 1-hour hot tub sessions over 8-10 weeks (3-4 per week). The hot tub was set to 40.5 Celsius, and core temperature and heart rate were monitored throughout each session.Subjects were instructed to not make any other dietary or lifestyle changes.Cardiovascular and metabolic health assessments were made Pre (0 heat sessions), mid (after 14-16 heat sessions, ~4-5 weeks), and post (after all 30 heat sessions; ~8-10 weeks).
10030873|NCT01762995|Experimental|Cohort 1|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment B = single dose DTG 50 mg + Calcium Carbonate 1200 mg fasted. Treatment C = single dose of DTG 50 mg + Calcium Carbonate 1200 mg fed. Treatment D = single dose DTG 50 mg 2 hours prior to single dose Calcium Carbonate 1200 mg fasted
10030874|NCT01762995|Experimental|Cohort 2|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment E = single dose DTG 50 mg + Ferrous Fumarate 324 mg fasted. Treatment F = single dose of DTG 50 mg + Ferrous Fumarate 324 mg fed. Treatment G = single dose DTG 50 mg 2 hours prior to single dose Ferrous Fumarate 324 mg fasted
9468793|NCT03644524|No Intervention|Time Control|Subjects were monitored at matched timepoints (start of study, 4-5 weeks, and 8-10 weeks) but not exposed to any intervention. Subjects were instructed to not make any dietary or lifestyle changes.
9468794|NCT03644511||Patients with HCC|Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment
9468795|NCT03644498||Adults treated with a CPI therapy for cancer|
9468796|NCT03644459|Experimental|LYN00101|Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.
9468797|NCT03644446||Bisoprolol 5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
9468798|NCT03644446||Bisoprolol 7.5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
9468799|NCT03644446||Bisoprolol 10mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
9468800|NCT03644433|Placebo Comparator|Single layer|Single layer closure
9468801|NCT03644433|Active Comparator|Double layer with resection|Double layer closure after resection uterine scar
9468802|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:~Clinical evaluation~Radiographic assessment of osteoarthritis~Magnetic resonance imaging (MRI)~Histological evaluation of the surgical piece"
9468803|NCT03644394|Other|Implantation|Surgical Implantation of IMES sensors
9468804|NCT03644381|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
9468805|NCT03644381|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
9468806|NCT03644355|Experimental|Diet and Nutrition Education|Lifestyle counseling plus nutrition education and counseling and protein sparing modified fast diet plus supplementation of vitamins and minerals, followed by a balanced, hypo-caloric diet and nutrition education provided by a registered dietician
9468807|NCT03644355|Active Comparator|Exercise Instruction|Lifestyle counseling plus moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
9468808|NCT03644355|Active Comparator|Combined Diet and Exercise|Lifestyle counseling plus dietary intervention including nutrition education and counseling and a protein sparing modified fast diet and nutrition education combined with the exercise intervention including a moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
9468809|NCT03644355|No Intervention|Control|Delayed intervention (waiting list) group receives no intervention for 12 weeks followed by the Diet plus Exercise intervention.
9480177|NCT03536182|Active Comparator|Arm A: Carbon ion radiotherapy|"The dose calculation algorithms used in Japan and Europe (local effect model, LEM) are different, so the total dose must be modified to ensure consistency~Japan : 55.2 GyE in 4.6 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of each CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose.~European: . Patients treated in Europe should receive 57.6 GyE in 4.8 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose. This evaluation will occur in the LEM system"
10030875|NCT01763008||Doripenem|Patients will be administered doripenem as per the dosing regimen given on product insert approved in Philippines.
10030876|NCT01763021|Experimental|PCI-32765 + Rifampin|Participants will recieve a single oral dose of PCI-32765 560 mg on Day 1 and Day 11 along with rifampin; and rifampin 600 mg from Day 4 to Day 13.
10030877|NCT01763034|Sham Comparator|limb ischemia|
10030878|NCT01763060||ECMO survivors|CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function
10030879|NCT01763073||Medical Students|Fourth-year students in accredited US medical schools who have applied to, but not yet been matched with, residency programs in obstetrics and gynecology.
9468811|NCT03644329|Other|Control group, CT|In the CT, the postmenopausal breast cancer survivers does not perform exercise.
9468812|NCT03644329|Experimental|Lower-load resistance training (LL)|In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).
9468813|NCT03644329|Experimental|Higher-load resistance training (HL)|In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).
9468814|NCT03644329|Experimental|Higher-volume resistance training (HV)|In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).
9468815|NCT03644316|Experimental|BandGrip|Topical skin closure device
10030880|NCT01763086|Experimental|Mesenchymal stem cells|Mesenchymal stem cells 1×10^6 cells/kg, intravenously
10030881|NCT01763099|Experimental|Mesenchymal stem cells|Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)
9468816|NCT03644303|Experimental|SBRT + ADT|Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
9468817|NCT03644290|Experimental|Cognitive training|Semantic categorization training sessions
9468818|NCT03644290|Active Comparator|Control condition|Five sessions of behavioral control condition with information and education
9468819|NCT03644264|Experimental|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
10030882|NCT01763099|Experimental|Mesenchymal stem cells and cord blood|Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1×10^6 cells/kg) and cord blood
10030883|NCT01763112|Placebo Comparator|Placebo group|This group will not do any specific training baseline and week 4 investigation will be done only
10030884|NCT01763112|Active Comparator|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
10030885|NCT01763125||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions. Blood samples will be taken."
10030886|NCT01763125||Benign controls|"Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.~Blood samples will be taken."
9468820|NCT03644264|Active Comparator|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
9468821|NCT03644251|Experimental|AMUC Dosage 1|25mg amniotic and umbilical cord matrix
9468822|NCT03644251|Experimental|AMUC Dosage 2|50mg amniotic and umbilical cord matrix
9468823|NCT03644251|Experimental|AMUC Dosage 3|100mg amniotic and umbilical cord matrix
10030887|NCT01763125||Healthy controls|"People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.~Blood samples will be taken."
10030888|NCT01763138|Other|pamphlet and reminder|pictorial oral health pamphlet comprising of instructions on child's oral hygiene and feeding practices and a oral health education reminder phone call after a period of one month.
10030889|NCT01763138|Other|pamphlet only|oral health education pictorial pamphlet would be provided to mothers however there will be no reminder phone calls.
9468824|NCT03644238|Experimental|Experimental intervention|Oral Glucose Tolerance Test and physical activity
9468825|NCT03644238|Other|Control intervention|Oral Glucose Tolerance Test and inactivity.
9468826|NCT03644225|Other|Healthy Control|Healthy controls, who signed an informed consent, age ≥18 years old will be age and sex matched to the SSc patients
9468827|NCT03644225|Other|Systemic sclerosis patients|"SSc patients who signed an Informed consent~Age ≥18 years old~Diagnosis of systemic sclerosis according to the ACR/EULAR 2013 criteria~Skin thickening diagnosed by clinical expert"
9468828|NCT03644199|Other|OGTT test|Comparison of responses to a OGTT between CF subjects and health control subjects
9468829|NCT03644199|Other|Mixed meal|Comparison of responses to a mixed meal through the day between CF subjects and health control subjects
9468830|NCT03644147|Experimental|Treatment|Patients in this group will receive 1 gram of acetaminophen intravenously after the end of surgery.
9468831|NCT03644147|No Intervention|Control|Patients in this group will receive 100 ml of normal saline intravenously after the end of surgery.
9468832|NCT03644134|Experimental|Intervention Group|Assessment of physiological stress and sleep pattern intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns
9468833|NCT03644134|No Intervention|Control Group|The control protocol only includes (i) information session (ii) pre-assessment (initial assessment and (iii) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
9468834|NCT03644082|Experimental|Epilepsy Patients|
9468835|NCT03644069|Experimental|Nexvax2|
9468836|NCT03644069|Placebo Comparator|Placebo|
9468837|NCT03644056|Experimental|IMC-001|Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)
9468838|NCT03644043||Early stage of MCI symptoms|Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results.
9468839|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
10030890|NCT01763138|No Intervention|control|no oral health education or reminder phone calls will be provided to mothers.
10030891|NCT01763151|Active Comparator|toric IOL|aspherical, toric acrylic IOL (Lentis L-312T, Oculentis, Germany)
10030892|NCT01763151|Active Comparator|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with OCCI
10030893|NCT01763177|No Intervention|No oxygen|No given oxygen at post-anesthetic care unit
10030894|NCT01763177|Active Comparator|Oxygen|Oxygen nebulizer via face mask, Fraction of inspired oxygen (FiO2) 0.4, flow 8 liter per minute (LPM) for 30 minutes
10030895|NCT01763190|Experimental|SAR302503|single treatment of 300 mg oral dose of SAR302503
9468840|NCT03643991|Experimental|Weighted Blanket Cohort|First 15 subjects enrolled have access to sleep with weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).
9468841|NCT03643991|No Intervention|Control Cohort|Last 15 subjects enrolled receive treatment as usual while inpatient.
10030896|NCT01763216|Experimental|Road Tour|Road Tour was designed to improve the efficiency and accuracy of visual information processing and the ability to perform complex visual attention tasks. It focuses on improving the speed and accuracy with which users identify and locate visual information using a divided attention format. Over time, the difficulty and complexity of each task is systematically increased as users attain specified performance criteria. Difficulty is increased by reducing visual stimuli duration, adding visual distracters, increasing similarity between target and distracter stimuli, and presenting visual targets over a broader spatial expanse.
10030897|NCT01763216|Sham Comparator|Boatload of Crosswords|Boatload of Crosswords offers the user a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also provides optional help features that the user may select, like filling in a letter or word to minimize frustration levels often associated with puzzle completion. Boatload of Crosswords was chosen for this study because it is computerized, it is very popular and easy to use, and many older adults enjoy doing crossword puzzles. Boatload of Crosswords, however, does not improve speed of processing because it does not focus on central discrimination and peripheral target location. Indeed, Boatload of Crosswords is not designed to train on any aspect of cognitive ability associated with visual speed of processing.
10030898|NCT01763229|Experimental|transthoracic echocardiography|
10030899|NCT01763242|Active Comparator|EMAN|Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required
9468842|NCT03643978|Experimental|Decision Aid Group|These patients review a decision aid.
9468843|NCT03643978|No Intervention|Control Group|These patients do not review a decision aid.
9468844|NCT03643926|Experimental|Arthroscopic Brostrom|
9468845|NCT03643926|Active Comparator|Open Brostrom|
9468846|NCT03643913|Active Comparator|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
10030900|NCT01763242|No Intervention|Control|Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy
10030901|NCT01763255|Experimental|CD133 transplantation|The patients with cerebral palsy that underwent CD133 transplantation.
9468847|NCT03643913|Experimental|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
10030902|NCT01763255|No Intervention|Control|The patients with cerebral palsy that underwent regular observation.
10030903|NCT01763268|Experimental|Trivivac|Children who receive Trivivac vaccine
9468848|NCT03643900|Experimental|indomethacin with stenting group|Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
9468849|NCT03643900|Active Comparator|indomethacin group|Rectal indomethacin 100mg at preoperative 30min in 100 patients
10030904|NCT01763281|Active Comparator|CRH|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
9468850|NCT03643887|Experimental|FMT Capsule DE|FMT Capsule DE
9468851|NCT03643887|Placebo Comparator|Placebo Oral Capsule|Placebo Capsule
9468852|NCT03643874|Experimental|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
9468853|NCT03643874|Active Comparator|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
9468854|NCT03643835|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
9468855|NCT03643835|Active Comparator|Forearm Ice Towels|Participants, following exercise-induced hyperthermia, will be cooled using forearm ice towels. Cotton-blend towels will be doused in ice-water and then wrapped around participant's forearms (elbow to wrist). The towels will be rotated (re-wetted) every 2 minutes)
10030905|NCT01763281|Placebo Comparator|Normal Saline (0.9%)|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
9468856|NCT03643835|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
9468857|NCT03643783||Bariatric Obese Patients|Obese patients, including men and women, White (Caucasians), Africa American, and Hispanic or Latino racial categories, and ages 18-70 years, who are enrolled and planning to undertake bariatric surgery in the Outpatient Bariatric Surgery Clinic at Tulane University, HSC (Christopher G. Ducoin, MD, MPH; Chair of Bariatric Surgery Clinic and Surgeon, and Shauna Levy, MD, Bariatric Surgeon Specialist).
10030906|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min|Apply 1 session of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
10030907|NCT01763294|Active Comparator|Nicolet Endeavor CR: 60min|Apply 1 session of 2 milliampere intensity for 60 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
10030908|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 3 days|Apply 3 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
10030909|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 5 days|Apply 5 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
10030910|NCT01763294|Placebo Comparator|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
10030911|NCT01763307|Experimental|RECONVAL CREAM|half face treated with RECONVAL CREAM
9468858|NCT03643783||Lean Control Patients|Plasma samples from lean control patients that have already been collected and are available as part of the Tulane Obesity-Endocannabinoids Study (Tina Thethi, M.D, Collaborator).
10030912|NCT01763307|Placebo Comparator|PLACEBO|half face treated with PLACEBO cream
9468859|NCT03643770|No Intervention|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
9468860|NCT03643770|Active Comparator|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
9468861|NCT03643770|Active Comparator|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
9468862|NCT03643770|No Intervention|Sham AIH therapy|Sham hypoxia
9468863|NCT03643757|Active Comparator|Thoracic Epidural Analgesia|Population to whom thoracic epidural analgesia with bupivacaine as a component of multimodal analgesia was administered.
9468864|NCT03643757|Active Comparator|Intravenous analgesia|Population to whom combined intravenous analgesia was administered.
9468865|NCT03643731|Experimental|HeatTens|"After baseline measurements and during 4 weeks of follow up~Composition and dosing of the device:~HeatTens (HV-F311-E) 2 - 108 Hz (modulation), 100 microsec (pulse duration) for 30 minutes."
9468866|NCT03643731|No Intervention|Control group|No intervention
9468867|NCT03643679|Experimental|Kwit smartphone app|This arm will receive the Kwit smartphone app.
9468868|NCT03643666|Placebo Comparator|control group|this group will include 25 patients receiving intraperitoneal 40 ml of normal saline only at the end of laparoscopic cholecystectomy
9468869|NCT03643666|Active Comparator|dexamethasone group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone in 40 ml saline at the end of laparoscopic cholecystectomy
9468870|NCT03643666|Active Comparator|dexamethasone plus magnesium sulphate group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone plus 2 gm magnesium sulphate at the end of laparoscopic cholecystectomy
9468871|NCT03643640|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
9468872|NCT03643640|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
9468873|NCT03643627|Placebo Comparator|Placebo|
9468874|NCT03643627|Experimental|1 mg/kg|
10030913|NCT01763385|Experimental|Erlotinib & secondary brain radiotherapy|Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.
10030914|NCT01763385|Other|Erlotinib & concurrent brain radiotherapy|Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons
9468875|NCT03643627|Experimental|3 mg/kg|
9468876|NCT03643627|Experimental|10 mg/kg|
9468877|NCT03643627|Experimental|30 mg/kg|
10030915|NCT01763398||non-Hodgkin's lymphoma|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by CHOP-like regimen and primary G-CSF prophylactic therapy
10030916|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN60D3 IOL)|No Intervention: Multifocal Spheric IOL implantation
9468878|NCT03643614|Experimental|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
9468879|NCT03643601||Non-Dialysis (ND) Patients|For the ND patients, data are captured on each clinic visit during the course of the year (2-4 times per year), the last available record for 2015 will be used.
9468880|NCT03643601||Dialysis (DD) Patients|For the DD patients, data are input from a randomly selected visit to the hospital in September to October 2015; the evaluation will be based on this record.
9468881|NCT03643588|Experimental|HYAJOINT Plus group|The HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
10030917|NCT01763411||Monofocal Spheric Intraocular Lens (AcrySof SN60AT IOL)|No Intervention: Monofocal Spheric IOL implantation
10030918|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMA00 IOL)|No intervention Multifocal IOL implantation
10030919|NCT01763411||Monofocal Aspheric Intraocular Lens (AcrySof SN60WF IOL)|No Intervention: Monofocal IOL implantation
10030920|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMB00 IOL)|No intervention Multifocal IOL implantation
9468882|NCT03643588|Active Comparator|Hyalgan group|The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
9468883|NCT03643549|Experimental|Bortezomib and Temozolomide|Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
9468884|NCT03643536|Experimental|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
9468885|NCT03643536|Active Comparator|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
10030921|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN6AD1 IOL)|No intervention Multifocal IOL implantation
10030922|NCT01763424|Active Comparator|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
9468886|NCT03643523||ALbumin level|Detection of serum albumin levels in postoperatory of colorectal surgery
9468887|NCT03643510|Experimental|Fulvestrant in Combination with Abemaciclib|Eligible patients will take Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28. Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles. Each cycle will be 28 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.
9468888|NCT03643497||Children with the usage of anti-infective drugs|Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
9468889|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
10030923|NCT01763424|Experimental|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
10030924|NCT01763437|No Intervention|Observation|30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
10030925|NCT01763437|Experimental|Tetracycline|30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
9468890|NCT03643445|Experimental|Motivational Interviewing (MI) Treatment|Motivational interviewing is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices. Patients assigned to these MI-trained therapists will be in the motivation-oriented condition. All individual meetings patients have with their therapist while they are in the program will entail sessions that are guided by MI principles. That is, revisiting patients' motivation to recover and overcoming obstacles to ambivalence or low motivation.
9480178|NCT03536182|Active Comparator|Arm B: Photon radiotherapy|50.4-56 Gy in 1.8-2.0 Gy per fraction in 28 fractions delivered 5 days a week. The plan should be normalized such that 100% of the PTV receives at least 48.9 Gy (i.e. 97% of 50.4 Gy). In addition, 100% of the GTV should receive at least 50.4 Gy. The maximum dose allowed to a point volume (0.03 mL) is 115% of the prescribed dose.
10030926|NCT01763450|Experimental|Bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
10030927|NCT01763463||Patients with COPD who develop severe pneumonia|Patients with COPD who develop severe pneumonia
10030928|NCT01763463||Patients with COPD who do not develop severe pneumonia|Patients with COPD who do not develop severe pneumonia
10030929|NCT01763476|Active Comparator|Paclitaxel-coated balloon angioplasty|Target lesion to be treated with paclitaxel-coated balloon
9468891|NCT03643445|Active Comparator|Psychoeducation-Oriented Treatment|"The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. Two staff members in the eating disorders program will deliver the psychoeducation-infused interventions, which are intended to be equivalent to treatment-as-usual in many eating disorder programs, but in a structured and standardized way, and with the use of the self-help manual. Psychoeducation is a very common intervention, often used as part of cognitive-behavioural treatment for eating disorders. The idea is that information about eating disorders and their health risks facilitates recovery and allows patients to buy in to treatment."
9468892|NCT03643419|Sham Comparator|Laminectomy|
9468893|NCT03643419|Experimental|Laminectomy & Irradiation|
9468894|NCT03643406|Experimental|Mental Fatigue Condition|
9468895|NCT03643406|Placebo Comparator|Control Condition|
10030930|NCT01763476|Active Comparator|Atherectomy + paclitaxel-balloon|Target lesion to be treated with atherectomy (TurboHawk, ev3) and paclitaxel-coated balloon
10030931|NCT01763489|Experimental|ASSIST tool group|Surgeons will assess the applicability of a trial using the ASSIST
9468896|NCT03643393|Other|incarceration rectal prolapse|
9468897|NCT03643380|Experimental|Investigational SNS device|
10030932|NCT01763489|Active Comparator|Synopsis Group|Surgeons will assess the applicability of a trial using the synopsis presented in a case vignette
10030933|NCT01763502|Experimental|FOOD|Food transfer linked to preschool enrollment
10030934|NCT01763502|Experimental|CASH|Cash transfer linked to preschool enrollment
9468898|NCT03643367|Experimental|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
9468899|NCT03643367|Active Comparator|Propofol Sedation|Patients randomized into Control Group will get continued intravenous sedation with propofol
10030935|NCT01763502|No Intervention|CTRL|No transfer linked to preschool enrollment
9468900|NCT03643354|Experimental|Evaluation of prevalence of BPPV|Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device.
9468901|NCT03643341|Experimental|Family Healthy Living Intervention|Children aged 8-12 and at least one caregiver will meet for 10 weekly face-to-face and online intervention sessions (1.5 hours per session). Four biweekly maintenance sessions will follow the main program.
9468902|NCT03643341|No Intervention|Wait-list control group|Children aged 8-12 will be randomly assigned to the wait-list control group until after the study.
9468903|NCT03643328|Experimental|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
9468904|NCT03643315|Experimental|Exercise and Meal (EX)|The EX protocol will involve a 30 minute acute bout of high intensity intermittent exercise on a stationary exercise bike followed by an ad-libitum test meal.
9468905|NCT03643315|Experimental|No-Exercise and Meal (NEX)|The NEX protocol will involve a 30 minute period of rest (to match the exercise period in EX) where participants will be provided a video/movie. Following this, participants will be provided ad-libitum access to a test meal (as per EX energy intake assessment protocol)
9468906|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of airway clearance and bronchoalveolar lavage.
9468907|NCT03643302||Fundamental treatment group|In the control group,fundamental treatment was adopted according to the guidelines
10030936|NCT01763515|Experimental|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
10030937|NCT01763528|Active Comparator|nutrition intervention|high protein diet
9468908|NCT03643289||Cohort A|Patients with stage 4 melanoma due to commence immunotherapy. Patients should be naïve to immunotherapy.
9468909|NCT03643289||Cohort B|Patients with stage 3 melanoma who are naïve to immunotherapy
10030938|NCT01763528|No Intervention|control group|control diet
9468910|NCT03643276|Active Comparator|pB: early (non-)HR-standard/MR-standard|"Induction (5 wks): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)~Consolidation (6 w/4 w): Consolidation extended (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
9468911|NCT03643276|Experimental|pB: early HR-exp./MR-standard|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
10030939|NCT01763541|Other|Testosterone|"To determine the effect of testosterone on the NP responses to acute and chronic salt loading.~One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days.~Intervention: Leuprolide acetate and anastrozole"
10030940|NCT01763541|Other|Estradiol|"To determine the effect of estradiol on the NP responses to acute and chronic salt loading.~Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks.~Intervention: leuprolide acetate"
10030941|NCT01763580|Experimental|Tacrolimus with low-dose corticosteroid|Oral
10030942|NCT01763580|Active Comparator|High-dose corticosteroid alone|Oral
9480179|NCT03536143|Experimental|Topical beremagene geperpavec|HSV1-COL7A1 vector (KB103)
10030943|NCT01763593||Aurosleek blades|Patients having cataract will undergo surgery by using Aurosleek blades
10030944|NCT01763619|Experimental|Freedom Cervical Disc|
10030945|NCT01763658|Experimental|Antioxidant, drug therapy for ITP|interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
9468912|NCT03643276|Experimental|pB: early (non)HR-standard/MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
9468913|NCT03643276|Experimental|pB: early HR-exp./MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX,IT MTX~Reinduction (6 weeks): Protocol II with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
9468914|NCT03643276|Active Comparator|pB: early (non-)HR-standard/HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): Protocol III given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)."
9468915|NCT03643276|Experimental|pB: early HR-exp./HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
9468916|NCT03643276|Experimental|pB: early (non-)HR-standard/HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
9480180|NCT03536130|Experimental|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter.
9803056|NCT04605159|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group will receive a single dose of RSV MAT vaccine at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm.
9803057|NCT04605159|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group will receive a single dose of Placebo at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm.
9803058|NCT04605094|Experimental|Benralizumab|
9803059|NCT04605094|Experimental|Placebo / Benralizumab|
10030946|NCT01763658|Active Comparator|drug therapy for ITP|drug therapy for ITP according to ASH, 2011 guidelines.
10030947|NCT01763671|Active Comparator|Docetaxel|
10030948|NCT01763671|Experimental|Paclitaxel - Bevacizumab|
10030949|NCT01763697|Active Comparator|Morhpine/Taste acuity|Taste acuity assessment after 1mg subcutaneous morphine injection
10030950|NCT01763697|Placebo Comparator|Placebo/Taste acuity|Taste acuity assessment after subcutaneous placebo injection
10030951|NCT01763697|Active Comparator|Morphine4/Taste acuity|Taste acuity assessment after 4mg subcutaneous morphine injection
10030952|NCT01763710|Active Comparator|Arm A|Paclitaxel 80 mg/m2 days 1, 8 and 15
10030953|NCT01763710|Experimental|Arm B|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
10030954|NCT01763710|Experimental|Arm C|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
10030955|NCT01763710|Experimental|Arm D|Nab-paclitaxel 150 mg/m2 days 1 and 15
10030956|NCT01763723|Experimental|IPL after UV-exposure|8 UV-exposures followed by 3 weekly IPL exposures
9468917|NCT03643276|Experimental|pB: early HR-exp./HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
10030957|NCT01763736|Experimental|Music|Everyone enrolled with receive music sessions.
10030958|NCT01763749|Experimental|Closone|75mg/100mg per day, 4weeks, PO
9468918|NCT03643276|Other|pB: early non-HR/SR|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Consolidation short with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
9468919|NCT03643276|Active Comparator|T: early non-SR-standard/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (4 w): Protocol IB regular (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
9480181|NCT03536130|No Intervention|Traditional device|Patients in the no intervention (traditional) arm are connected to traditional drain system with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with traditional devices (requiring connection to wall suction) are managed by applying suction (-20 cmH2O) until the morning of POD 1 and are subsequently disconnected from suction thereafter.
9480182|NCT03536117|Experimental|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
9480183|NCT03536117|Experimental|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
10030959|NCT01763749|Active Comparator|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
10030960|NCT01763762|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.5 Hz and an intensity (45~55 mA) as high as the patient can tolerate without discomfort; 60 minutes three times a week for a total of four weeks
10030961|NCT01763762|Active Comparator|PFM training with Transvaginal ES|"PFM training: EMG-biofeedback assisted PFMT was performed by specially trained therapists, 20 min three times a week for a total of four weeks. Patients conduct 30 maximal high intensity PFM contractions for 2-6 sec (with 2-6 sec rest), three sessions a day at home for a total of four weeks.~Transvaginal ES: At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min three times a week for a total of four weeks."
10030962|NCT01763775|Experimental|Transtek 125X|Which measured by DUT (Transtek 125X): GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B.
10030963|NCT01763775|Experimental|Transtek 950D|Measured by Reference (Transtek 950D): GBF-950-D.
10030964|NCT01763788|Experimental|Necitumumab + Gem and Cis|"Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.~Phase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
10030965|NCT01763788|Active Comparator|Gemcitabine + Cisplatin|Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles .
10030966|NCT01763801|Active Comparator|P-Max group|Includes cases in which the catheter tip was considered correctly positioned when the Maximal P wave was obtained
10030967|NCT01763801|Active Comparator|P-Submax group|Includes cases in which the catheter tip was considered correctly positioned when the Submaximal P wave was obtained
10030968|NCT01763814|Active Comparator|Single shot femoral nerve block|A ultrasound probe will be used to identify the nerve, and correct needle placement.
10030969|NCT01763814|Active Comparator|Femoral nerve block non stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered off.
10030970|NCT01763814|Active Comparator|Femoral nerve block stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered on.
10030971|NCT01763840|Experimental|Contrast enhanced Ultrasound|Presence and grade of solid organ injury on contrast enhanced ultrasound
10030972|NCT01763853|Other|albumin|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
10037013|NCT01820988||Sarcopenic vs. non-sarcopenic|Participants are classified as sarcopenic/non-sarcopenic according to the criteria of the European Working Group of Sarcopenia in Older People (EWGSOP).
10030973|NCT01763853|Other|crystalloid|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
10030974|NCT01763879|Active Comparator|The PCV-VCV group|The dependent lung will be ventilated with pressure controlled (PCV) followed by the volume-controlled ventilation (VCV)
10030975|NCT01763879|Active Comparator|The VCV-PCV group|The dependent lung will be ventilated with volume-controlled ventilation (VCV) followed by the pressure controlled (PCV)
10030976|NCT01763892||Children admitted to hospital with a TBI|non-intervention study
10030977|NCT01763944|Active Comparator|Low carbohydrate, lifestyle counseling|The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months.
10030978|NCT01763944|No Intervention|Control|The control arm will receive no dietary intervention.
10030979|NCT01763957|Active Comparator|Pelvic Floor Muscle Training (PFMT)|
9468920|NCT03643276|Experimental|T: early non-SR-exp/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (6 w): Protocol IB long (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
9468921|NCT03643276|Other|T: early SR/non-HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Protocol IB regular with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
9468922|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
9468923|NCT03643250|Experimental|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
9468924|NCT03643250|Experimental|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
9468925|NCT03643250|Experimental|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
10030980|NCT01763957|Active Comparator|Paula Method|
9468926|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
9468927|NCT03643237|Experimental|Video game-based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 45 minutes long that will be administered at a rate of 1 per week with between-session homework.
9468928|NCT03643237|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
9468929|NCT03643120|Other|Development of diagnostic typology|One main goal is to Development a typology of sub-types of gender dysphoria.
9468930|NCT03643107|Experimental|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
9468931|NCT03643094|Experimental|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
9468932|NCT03643081|Experimental|"use of camera Fluobeam"|
9468933|NCT03643081|No Intervention|"Without use of the camera Fluobeam"|
9468934|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
9468935|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
9468936|NCT03643055||MTC 18F-fluorocholine PET/CT|Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
9468937|NCT03643016|Experimental|Group with Virtual Epileptic Patient brain access data|
9803060|NCT04604444|Experimental|Multimodal Intensive Rehabilitation of Aphasia/AOS (MIRAA)|A minimum of 3 hour speech-language training daily during 10 days.
10030981|NCT01763983|Experimental|Aerobic Exercise|12-week structured and monitored aerobic exercise program
10030982|NCT01763983|Experimental|CBT and Aerobic Exercise|Combined 12-week individual Cognitive Behavioural Therapy and Exercise Program
10030983|NCT01763983|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
10030984|NCT01764009|Experimental|Plasmid AMEP electrotransfer in muscle|
10030985|NCT01764035|Active Comparator|Brief Supportive Psychotherapy (SP)|30 people will be randomized to receive Brief Supportive Psychotherapy.
10030986|NCT01764035|Experimental|Body Scan (BS) Meditation Intervention|30 people will be randomized receive the Body Scan Meditation Intervention.
9468938|NCT03643016|No Intervention|Group without Virtual Epileptic Patient brain access data|
9468939|NCT03643003|Experimental|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
9468940|NCT03643003|Placebo Comparator|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
9468941|NCT03642990|Experimental|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
9468942|NCT03642977||Allogeneic HSCT recipients|"Adult patients receiving allogeneic hematopoietic stem cell transplant (HSCT) at University Hospitals of Geneva and who are enrolled in the Cohort of infectious disease in hematopoietic stem cell transplant patients."
9803061|NCT04604210|Experimental|Dysphoric target|"The dysphoric target is a region in the dorsolateral prefrontal cortex. TMS targeted to this region has been shown to be more effective for depression than anxiety."
10030987|NCT01764048|Experimental|Fix protocol|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
9468945|NCT03642938|Experimental|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
10030988|NCT01764048|Experimental|medications following demand protocol|The same combinations will be given as in the fixed protocol however only after patient request
10030989|NCT01764074|Experimental|Brief Sleep Intervention|Every participant in the study will complete a 3-session sleep intervention with a clinician to improve sleep problems such as insomnia or hypersomnia.
10030990|NCT01764087|Experimental|KX2-391 and Paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)~The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
10030991|NCT01764100|Experimental|Mesenchymal Stromal Cells (MSC)|Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight
10030992|NCT01764113|Experimental|Mindful Eating|Subjects and at least one of their parents will receive mindful eating based behavioral modification program
10030993|NCT01764113|Active Comparator|Standard Dietary Couseling|Subjects and their parents will receive standard nutritional counseling provided by a registered dietician
10030994|NCT01764126|Active Comparator|Pneumococcal protein vaccine|Pneumococcal protein vaccine
10030995|NCT01764126|Placebo Comparator|Placebo|Placebo
10030996|NCT01764139||Knee pain patients with minimal knee changes|Male & no pregnant female age between 18-40 yrs.
10030997|NCT01764152|Experimental|Nasopharyngeal sample|one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days.
10030998|NCT01764165|Active Comparator|oxygen|nocturnal oxygen of 2 L/min
10030999|NCT01764165|Experimental|High Flow of room air|Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
10031000|NCT01764178|Experimental|Livalo fixed combination drug|Livalo fixed combination drug(Pitavastatin + Valsartan)
10031001|NCT01764178|Active Comparator|Pitavastatin + Valsartan|Pitavastatin, Valsartan
10031002|NCT01764204||Qingkailing Injection|
10031003|NCT01764230|Experimental|case group|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
10031004|NCT01764230|No Intervention|control group|no intervention
10031005|NCT01764243|Experimental|MT-4666 Low Dose|low dose
10031006|NCT01764243|Experimental|MT-4666 High Dose|high dose
10031007|NCT01764243|Placebo Comparator|Placebo|placebo
10031008|NCT01764269|Other|inactivated influenza vaccine (IIV)|Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)
10031009|NCT01764269|Other|Live attenuated influenza vaccine (LAIV)|Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)
10031010|NCT01764282|Experimental|Intervention|comprehensive intervention components
10031011|NCT01764282|No Intervention|Usual|According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.
10031012|NCT01764295|Experimental|DWJ1276|Once daily, administered orally, 8 week
10031013|NCT01764295|Active Comparator|Olmesartan|Once daily, administered orally, 8 week
10031014|NCT01764295|Active Comparator|Rosuvastatin|Once daily, administered orally, 8 week
10031015|NCT01764295|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
10031016|NCT01764308|Experimental|O3FA|Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
10031017|NCT01764308|Placebo Comparator|Placebo|4 tablets twice a day for 24 weeks
9468946|NCT03642938|Experimental|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
9468947|NCT03642938|Experimental|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
9468948|NCT03642938|Sham Comparator|Control|The Control group will perform quiet rest, three times per week for one week.
10031018|NCT01764321||Certolizumab Pegol treatment|Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
10031019|NCT01764321||Other Tumor Necrosis Factor TNF inhibitor treatment|Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
10031020|NCT01764334|Active Comparator|Fractional flow reserve|"Fractional flow reserve - guided group:~The initial treatment decision and the coronary arteries for fractional flow reserve (FFR) measurement will be established and recorded before randomization. FFR will then be measured by the cardiologist immediately after randomization and the FFR result will used to guide treatment decisions based on a threshold of 0.80. An FFR ≤ 0.80 should result in a treatment decision for revascularization by PCI or CABG combined with optimal medical therapy and an FFR>0.80 should result in treatment with optimal medical therapy alone. Changes in treatment compared to the treatment plan prior to FFR disclosure will be recorded at the time."
10031021|NCT01764334|Placebo Comparator|Angiography-guided|FFR is measured by but not disclosed to the clinical team. Treatment decisions are therefore guided by angiography but not by FFR. The patient and the clinical team, including the cardiologists and nurses, will be blinded to FFR. The RadiAnalyzer Xpress (St Jude Medical) will be turned away from the clinical team who will not see the pressure wire data. FFR will not be displayed on any other monitor. Quality control checks, such as assessments of equalized pressure, will be done in the usual way, by the unblinded clinical research team. These steps will be followed for all FFR measurements. Adherence to the blinding protocol, including any non-protocol FFR disclosure at any time, will be prospectively recorded and blinding procedures will be monitored with site visits.
10031022|NCT01764347|Experimental|Diagnostic (MRI-TRUS fusion image-guided biopsy)|Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies.
10031023|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will be randomized at different timepoints to receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
10031024|NCT01764373|Experimental|16-Week Exercise Program|Subjects to participate in 16-week3 supervised aerobic exercise 3 times per week. Exercise sessions to last between 30 and 60 minutes.
10031025|NCT01764399|Experimental|Care4U intervention|Care4U intervention with 6 weekly sessions focusing on physical activity, healthy eating, self-management, emotional responses.
10031026|NCT01764399|No Intervention|Information group|The information group receives 6 weekly socialization sessions.
10031027|NCT01764412||Healthy women|Non interventional
10031028|NCT01764425|Active Comparator|P7435|Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
10031029|NCT01764425|Placebo Comparator|Placebo|Placebo tablets for oral administration
10031030|NCT01764438||very early or early staged patients|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT
10031031|NCT01764451|Experimental|Simvastatin|20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
9803062|NCT04604210|Experimental|Anxiosomatic target|"The anxiosomatic target is a region in the dorsomedial prefrontal cortex. TMS targeted to this region has been shown to be more effective for anxiety than depression."
10031032|NCT01764451|No Intervention|No Treatment|
10031033|NCT01764477|Experimental|PRI-724 and Gemcitabine|This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
10031034|NCT01764516||Zinc level (micro gram per deciliter)|In all cases
10031035|NCT01764516||Selenium level (micro gram per deciliter)|In all cases
10031036|NCT01764516||Zinc level in male (micro gram per deciliter)|
10031037|NCT01764516||Selenium level in male (micro gram per deciliter)|
10031038|NCT01764516||Zinc level in Female (micro gram per decilitre)|
10031039|NCT01764516||Selenium level in Female (micro gram per decilitre)|
10031040|NCT01764542|Other|Endoscopy and biopsy|Endoscopy with biopsy taken Endoscopy and biopsy Blood samples Questionnaire
10031041|NCT01764555|Experimental|normal weight patients|normal weight patients receiving acetaminophen 2 g instead of 1 g
10031042|NCT01764555|Experimental|mobidly obese patients|morbidly obese patients receiving acetaminophen 2 g instead of 1 g
10031043|NCT01764568|Experimental|Metacognitive Training for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Metacognitive Training twice weekly for 8 weeks (16 sessions).
10031044|NCT01764568|Experimental|Cognitive Remediation for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
10031045|NCT01764568|No Intervention|Treatment as Usual for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will continue to receive treatment as usual (TAU) as defined by their health care team (i.e., medication, other therapies) while still taking part in baseline, midpoint, and end-point assessments.
10031046|NCT01764581|Experimental|Tacrolimus dose regulation|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.
10031047|NCT01764581|No Intervention|Control|immunosuppressive therapy is managed either by standard practice at our center (Control)
10031048|NCT01764594|Experimental|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
10031049|NCT01764594|Placebo Comparator|Placebo|Placebo
10031050|NCT01764620|Other|Control|In this session, the athletes will be evaluated before and after the fatigue protocol, without any taping application.
10031051|NCT01764620|Experimental|Kinesio taping|A kinesio taping technique for facilitating lower trapezius muscle function will be applied just before fatigue protocol and removed after in the end of the evaluation session.
10031052|NCT01764620|Sham Comparator|Sham|A similar technique, using the same tape, will be applied but without any tension (tension is considered to be the therapeutic effect). The tape will be applied just before the fatigue protocol and removed in the end of the session.
9468949|NCT03642925|Experimental|Meal replacement diet|Obese subjects (BMI>27; n=50, male 23, female 27) were requested to replace (intervention) two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks
9468950|NCT03642899||Patients with anterior ischaemic optic neuropathy|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
10031053|NCT01764646|Experimental|9 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
10031054|NCT01764646|Experimental|28 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
10031055|NCT01764672|Experimental|Attention Deficit Hyperactivity Disorder|Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
10031056|NCT01764672|Experimental|Healthy adults|Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
10031057|NCT01764698|Experimental|CALM-SUD|Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
10031058|NCT01764698|Active Comparator|Treatment as usual|Participants in this arm receive the standard Intensive Outpatient treatment for their substance use disorder at a community addictions treatment facility.
9468951|NCT03642899||control group. Normal eyes|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
9468952|NCT03642886|No Intervention|Continued Strenuous Exercise|Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period
9468953|NCT03642886|Experimental|Prescribed Detraining|"Detraining period of 8-weeks which is defined as:~a 75% decrease in the amount of exercise (from baseline)~a 50% decrease in the intensity of exercise as measured in METS (from baseline)~Mitchell Classification classes 1A, 2A, 2B of activity are permitted"
9468954|NCT03642860|Experimental|Active treatment|Triheptanoin oil
9468955|NCT03642860|Placebo Comparator|Placebo treatment|Safflower oil
9468956|NCT03642847|Active Comparator|Prevnar 13|13 valent Pneumococcal Conjugate
9468957|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
9468958|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
9468959|NCT03642834|Experimental|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
9468960|NCT03642756|Placebo Comparator|20 gauge|
10031059|NCT01764724||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
10031060|NCT01764737|Experimental|VX15/2503|
10031061|NCT01764737|Experimental|Placebo|
10031062|NCT01764750|Experimental|Low Dose Intrasite Vancomycin|10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
10031063|NCT01764750|Experimental|Mid-dose Intrasite Vancomycin|10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
10031064|NCT01764750|Experimental|High-dose Intrasite Vancomycin|10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
10031065|NCT01764750|Active Comparator|Optimally-dosed IV Vancomycin|10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)
10031066|NCT01764763||non epiaortic group|non epiaortic group ( n=1019)
10031067|NCT01764763||epiaortic group|epiaortic group ( n=1273)
10031068|NCT01764776|Experimental|LDE225|LDE225
10031069|NCT01764789|Experimental|Supportive care (psychosocial intervention)|Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.
9468961|NCT03642756|Active Comparator|22 gauge|
9468962|NCT03642756|Active Comparator|24 gauge|
9468963|NCT03642743|Experimental|Two and six week follow up|Patients will be assigned to routine two and six week postoperative follow up appointments
9468964|NCT03642743|Experimental|Six week follow up only|Patients will be assigned to a single six week postoperative follow up appointment
9468965|NCT03642730|Experimental|Scanned patients|Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
9468966|NCT03642730|Experimental|Non-expert scanning volunteers|Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
9468967|NCT03642704|Experimental|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
9480184|NCT03536117|Experimental|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
9480185|NCT03536117|Active Comparator|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
9480186|NCT03536104||Controls|"This group will include healthy person."
10031070|NCT01764802|Active Comparator|Arm I (enhanced standard care)|Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.
10031071|NCT01764802|Experimental|Arm II (psychological intervention)|Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.
10031072|NCT01764815|Experimental|Directional lead|
10031073|NCT01764828|Experimental|Refametinib (BAY86-9766)+ Gemcitabine|Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2
10031074|NCT01764867|Active Comparator|Algorithm Guided Treatment (AGT)|Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
10037014|NCT01821001|Experimental|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
9468968|NCT03642678|Experimental|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is < 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
9468969|NCT03642678|No Intervention|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
9468970|NCT03642665|Experimental|Natural cycle|no medication
9468971|NCT03642665|Active Comparator|Artificial cycle|"Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.~Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy."
9468972|NCT03642652|Experimental|SMS|"Each patient in the intervention group also received an automated text message up to a week after the positive FOBT result. The text read: Hello. There is a lab test result ready for you. Contact your physician for an explanation of the findings. Two additional automated text message reminders were sent to the patient at 2 weeks and 1 month reading, Hello, This is a reminder. It is essential that you contact your physician if you have not already done so."
9468973|NCT03642652|No Intervention|Control|Routine care
9468974|NCT03642626||ARM A: Refractory/relapsed B-cell acute lymphoblastic leukemia (ALL)|
9468975|NCT03642626||ARM B: Yescarta for Refractory diffuse large B cell lymphoma (DLBCL)|
9468976|NCT03642626||ARM C: Kymriah for Refractory diffuse large B cell lymphoma (DLBCL)|
9468977|NCT03642626||Arm D: Tecartus CAR-T product for Mantle Cell Leukemia (MCL)|
9468978|NCT03642600|Active Comparator|dietary advice plus myo-inositol and folic acid|2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS
9468979|NCT03642600|Active Comparator|dietary advice plus liraglutide pen injector|liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS
9468980|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
9468981|NCT03642574|Experimental|PMS group|Subjects in the PMS group will have blastocyst biopsy and whole genome bisulfate sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by DNA methylation level.The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
9468982|NCT03642574|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
9480187|NCT03536104||Parkinson's patient|This group will include Parkinsonian patients
9480188|NCT03536104||patients with a related disease.|This group will include patients with a related disease.
9480189|NCT03536078|No Intervention|Phototherapy at hospital|Newborns with icterus that receive treatment while being admitted to hospital.
9480190|NCT03536078|Experimental|Home phototherapy|Newborns with icterus receiving phototherapy at home.
9480191|NCT03536065|Active Comparator|Pre-Intervention|Current practice (unchanged)
9480192|NCT03536065|Experimental|Post-Intervention|Reduction of opioid prescription based on Pre-Intervention data, implementation of a discharge sheet and nursing education.
10031075|NCT01764867|Active Comparator|Treatment As Usual (TAU)|This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement.
10031076|NCT01764880|Experimental|SST0001 (Roneparstat)|"SST0001 once daily for 5 or 10 days in a cycle of 28 days. Starting dose 25 mg, to be escalated in subsequent cohorts.~Duration of treatment depending on toxicities observed or until documentation of disease progression or other discontinuation criteria are met."
9468983|NCT03642561|Experimental|RFA group|Patients in RFA group will accept RFA treatment
9468984|NCT03642561|Active Comparator|TACE group|Patients in TACE group will accept TACE treatment
10031077|NCT01764893|Active Comparator|PTNS and solifenacin|PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
10031078|NCT01764893|Placebo Comparator|PTNS and placebo|PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks
10031079|NCT01764906|Experimental|Novosis|Bongros/rhBMP-2
10031080|NCT01764906|Active Comparator|Iliac crest bone graft|Iliac crest bone graft
10031081|NCT01764932|Other|Thoracic epidural catheter insertion|Fluoroscopic imaging. For patients undergoing thoracic epidural analgesia (TEA) with catheter placement for pain associated with thoracic or upper abdominal surgery
10031082|NCT01764958||preterm infants and their mothers|"Inclusion criteria are: preterm infants born between 26-34 weeks of gestation, whose mothers speak and write Hebrew fluently. Exclusion criteria are: preterm infants who suffer from perinatal asphyxia, genetic or metabolic diseases, necrotizing colitis that requires operation, intra uterine growth retardation, deafness, retinopathy of prematurity (ROP) or major congenital defects.~Infants and their mothers will be recruited from child developmental centers and Pediatric Clinics of Maccabi. No intervention is included in the research."
9468985|NCT03642548|Experimental|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
9468986|NCT03642548|Placebo Comparator|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
9468987|NCT03642535|Experimental|ALA for all face group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
9468988|NCT03642535|Active Comparator|ALA for AK lesion group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
9468989|NCT03642522|Experimental|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
9480193|NCT03536052|Experimental|Virtual Heart Guided Ablation|
10031083|NCT01764971||chronic itp and cerebral dysfunction|patients with chronic itp and had behavioral and or cognitive dysfunction
10031084|NCT01764971||chronic itp only|chronic ITP patients without cerebral dysfunction
10031085|NCT01764984|Experimental|Trabecular metal|Primary Total Knee Arthroplasty is performed with a non cemented trabecular metal tibial baseplate.
10031086|NCT01764984|Active Comparator|Titanium|Primary total knee arthroplasty is performed with cemented titanium traditional tibial base plate
10031087|NCT01765010|Placebo Comparator|Placebo control|Placebo control
10031088|NCT01765010|Active Comparator|Cholecalciferol 1000IU|Cholecalciferol 1000IU qd for 8 weeks
10031089|NCT01765010|Experimental|alfacalcidol|alfacalcidol 0.5ug qd for 8 weeks
10031090|NCT01765010|Experimental|Calcitriol|Calcitriol 0.25ug qd for 8 weeks
10031091|NCT01765023|Experimental|Part A|single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
10031092|NCT01765023|Experimental|Part B|single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
10031093|NCT01765036|Experimental|SonoVue®|"Non randomised study~Sonovue 4,8 ml intravenous administration, in 1 bolus, during the EUS examination"
10031094|NCT01765062||Before Rapid Maxillary Expansion|T0
10031095|NCT01765062||3 months After Rapid Maxillary Expansion|T1
10031096|NCT01765062||One year After Rapid Maxillary Expansion|T2
10031097|NCT01765075||Patients undergoing cardiac ablation for permanent AF|
10031098|NCT01765088|Active Comparator|temozolomide|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)
10031099|NCT01765088|Experimental|temozolomide +α-IFN|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles
10031100|NCT01765101|Experimental|customized insoles|"customized full-length lateral wedged shoe insoles~1 month and 3 months study the immediate, short-term and intermediate-term therapeutic effects"
9468990|NCT03642509|Experimental|LAAO group|Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
10031101|NCT01765101|Placebo Comparator|ready made insoles|"ready-made full-length lateral wedged shoe insoles at 1 and 3 months~study the immediate, short-term and intermediate-term therapeutic effects"
9468991|NCT03642509|Experimental|NOAC group|Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
9468992|NCT03642496|Experimental|The low dose group|
10031102|NCT01765114|Experimental|PEG-Formulation|PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
10031103|NCT01765127||Asenapine|Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.
10031104|NCT01765166|Experimental|Control(ChO)|Children receive traditional SSGRIN child treatment with no parent involvement
10031105|NCT01765166|Experimental|Parent attention control(PAC)|Children will participate in traditional SSGRIN treatment, and parents will participate in a weekly support group to meet with other parents regarding their child's peer relations and behavior. The support group will meet for a parallel amount of time (1 hour/week for 10 weeks) and be facilitated by two parents with no SSGRIN or Parent Guide experience. The PAC condition will reflect the social support functions of a parenting group, but no therapeutic skills training or other instructional materials will be provided.
9468993|NCT03642496|Experimental|The middle dose group|
9468994|NCT03642496|Experimental|The high dose group|
10031106|NCT01765166|Experimental|Parent Guide-Home Study(PG-HS)|Children will receive traditional SSGRIN treatment, and parents will receive the Parent Guide to SSGRIN training by participating in the online Parent Guide Home Study (PG-HS) course. The PG-HS course will include all instructional content and materials for the in-person Parent Guide course, but parent will receive the training online.
10031107|NCT01765166|Experimental|Parent Guide(PG)|Children will receive traditional SSGRIN treatment and parents will receive parallel traditional in-person SSGRIN-Parent Guide treatment.
9468995|NCT03642444|Active Comparator|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
10031108|NCT01765205||Newborns with Pulse oximetry|Up to 50 healthy newborn participants will receive 15 minutes of pulse oximetry to determine the effectiveness of measuring somatic oxygen saturation.
10031109|NCT01765205||CHD infant with pulse oximetry|Up to 10 infants diagnosed with congenital heart disease will receive 15 minutes of pulse oximetry using the INVOS Cerebral/Somatic Oximeter to determine the effectiveness of measuring somatic oxygen saturation.
10031110|NCT01765231|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
10031111|NCT01765231|Active Comparator|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
10031112|NCT01765244|Experimental|Anterior lamellar nanostructured artificial human cornea|Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface
9468996|NCT03642444|Active Comparator|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
9468997|NCT03642444|No Intervention|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
9468998|NCT03642405||Methylphenidate-Group|The group is examined before and after intake of Methylphenidate
9468999|NCT03642405||Methylphenidate and know QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
9469000|NCT03642405||Methylphenidate and non-QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
9469001|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
9469002|NCT03642366|Active Comparator|Active Arm 1|
9469003|NCT03642366|Active Comparator|Active Arm 2|
9469004|NCT03642366|Sham Comparator|Sham Arm|
9469005|NCT03642353|Experimental|G1: Triclosan/health children|Children from health parents will use the triclosan toothpaste for 45 days.
9469006|NCT03642353|Placebo Comparator|G2: Placebo/health children|Children from health parents will use the placebo toothpaste for 45 days.
9469007|NCT03642353|Experimental|G3: Triclosan/GAP children|Children from GAP parents will use the triclosan toothpaste for 45 days.
9469008|NCT03642353|Placebo Comparator|G4: Placebo/GAP children|Children from GAP parents will use the placebo toothpaste for 45 days.
9469009|NCT03642327|Active Comparator|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
9469010|NCT03642327|Experimental|Maintenance of Certification (MOC)|MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
9469011|NCT03642314|Experimental|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
9469012|NCT03642314|No Intervention|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
9469013|NCT03642288|Experimental|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
9469014|NCT03642288|Active Comparator|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
9469015|NCT03642275|Experimental|iCardia4HF|Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
9469016|NCT03642275|No Intervention|Control Group|Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
9469017|NCT03642249|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration); and~delirium care OSCE and reflective activity (30 minutes in duration)."
9469018|NCT03642249|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration)"
9469019|NCT03642236|Experimental|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
9469020|NCT03642236|Active Comparator|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
9469021|NCT03642223|Active Comparator|normal-weight|
10031113|NCT01765244|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.
10031114|NCT01765257|Experimental|rasagiline|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
10031115|NCT01765257|Placebo Comparator|placebo|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
10031116|NCT01765283|Experimental|Hepastem Low dose|12.5x106cells/kg
10031117|NCT01765283|Experimental|Hepastem Intermediate dose|50x106cells/kg
10031118|NCT01765283|Experimental|Hepastem High dose|200x106cells/kg
10031119|NCT01765296|Active Comparator|Celecoxib|Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
10031120|NCT01765296|Placebo Comparator|Placebo|Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
10031121|NCT01765296|Experimental|CG100649|CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)
10031122|NCT01765309|Experimental|Bilateral mastectomy with reconstruction|The trial was a comparison between each breast in a single patient undergoing bilateral mastectomy with reconstruction
10031123|NCT01765322|Experimental|Assisted hatching group (AH group)|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
10031124|NCT01765322|No Intervention|Control group|The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
10031125|NCT01765335|Experimental|NICaS system efficacy in HF patients|NICaS system efficacy in HF patients
10031126|NCT01765348|Experimental|Sentence combining|
10031127|NCT01765348|Active Comparator|Narrative based method|
10031128|NCT01765374|Experimental|rituximab|Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
10031129|NCT01765387|Experimental|Spa therapy|A cycle of 3 Vichy shower and whirlpool baths are applied during 30-minutes period. Vichy sedative shower is applied for 90-120 sec to the sides of the trunk and the abdomen, avoiding as much as possible the gall bladder area, at a temperature of 36-38ºC. A short, partial jet spray followed the shower. A whirlpool bath is administered where subjects immersed the body until their clavicle level for a 10min period with a water temperature ranging 33.5-35.5 ºC. Aromatherapy application using lavender and chamomile oils is used in all Spa therapy sessions.
10031130|NCT01765387|No Intervention|Control group|"The control group perform a rest session in supine position in a room with neutral temperature condition with a same duration to Spa session. Participants of both groups are encouraged to drink water ad libitum to prevent dehydration."
10031131|NCT01765400|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 2 weeks
9469022|NCT03642223|Experimental|peripheral adiposity|
9469023|NCT03642223|Experimental|central adiposity|
9480194|NCT03536039|Experimental|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
10031132|NCT01765400|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily for 2 weeks
10037015|NCT01821014|Experimental|Telemedicine First|Patients whose first physician visit during the clinic was using videoconference, a form of telemedicine, and whose second physician visit during the clinic was with a physician in-person.
10037016|NCT01821014|Experimental|Telemedicine Second|"Patients whose first physician visit during the clinic was with a physician in-person, and whose second physician visit during the clinic was using videoconference, a form of telemedicine. This is the reverse order of visits of the Telemedicine fist arm."
10037017|NCT01821014|Active Comparator|Two physician visits|Patients who had two sequential visits with different in-person physicians.
10037018|NCT01821027|Experimental|Canagliflozin + simvastatin|Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
10037019|NCT01821040|Experimental|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
10031133|NCT01765413|Experimental|Varilrix|Participants receive one dose of 'Varilrix' varicella-zoster vaccine.
10031134|NCT01765413|Experimental|Stamaril|Participants receive one dose of 'Stamaril' yellow fever vaccine.
9469024|NCT03642197|Experimental|Support Figure Attended (SFA)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is support figure attendance. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
9469025|NCT03642197|No Intervention|SFA - Treatment as Usual (SFA-TAU)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
9469026|NCT03642197|Experimental|Partner Attended (PA)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
9469027|NCT03642197|No Intervention|PA - Treatment as Usual (PA-TAU)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
9469028|NCT03642184|Active Comparator|Empagliflozin|Jardiance 10mg/25mg Film-coated tablets， once daily
9469029|NCT03642184|Active Comparator|Linagliptin|Trajenta 5mg Film-coated tablets， once daily
10031135|NCT01765413|Placebo Comparator|Placebo|Participants receive one injection of placebo.
10031136|NCT01765439|Experimental|CD resected|Patients with Crohn´s disease with the history of single resection (<60 cm) of distal leum.
10031137|NCT01765439|Experimental|UC unoperated|Patients with ulcerative colitis without history of gut resection.
10031138|NCT01765439|Experimental|UC IPAA|Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).
10031139|NCT01765439|Experimental|Healthy volunteers|Subjects without any sign of disease of the digestive tract.
10031140|NCT01765452|Experimental|Closone|75mg/100mg per day, 8weeks, PO
10031141|NCT01765452|Active Comparator|Plavix with Astrix|75mg per day, 8weeks, PO 100mg per day, 8weeks, PO
10031142|NCT01765478|Experimental|Treatment A Period 2|40mg HM71224 single dose
10031143|NCT01765478|Experimental|Treatment B Period1|20mg HM71224 single dose
10031144|NCT01765478|Experimental|Treatment A Period1|10mg HM71224 single dose
10031145|NCT01765478|Experimental|Treatment B Period2|80mg HM71224 single dose
10031146|NCT01765478|Experimental|TreatmentA Period3|160mg HM71224 single dose
10031147|NCT01765478|Experimental|TreatmentB Period3|200mg HM71224 single dose
10031148|NCT01765478|Experimental|Food effect period1|active 4subjects + placebo 4subjects
10031149|NCT01765478|Experimental|Food effect period2|active 4subjects + placebo 4subjects
10031150|NCT01765478|Experimental|TreatmentC|HM71224 Xmg multiple dose for 14days
10031151|NCT01765478|Experimental|TreatmentD|HM71224 Ymg 14days multiple dose
10031152|NCT01765478|Experimental|TreatmentE|HM71224 Zmg 14days multiple dose
10031153|NCT01765491|Experimental|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy.
10031154|NCT01765491|Active Comparator|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy.
10031155|NCT01765517|Experimental|Probiotics|Probitoics
10031156|NCT01765517|Placebo Comparator|Placebo|Placebo
10031157|NCT01765556|Experimental|Ketoconazole treatment|
10031158|NCT01765556|Experimental|Vemurafenib treatment|
10031159|NCT01765595|Experimental|DDI+|DDI+ Incorporated in routine ambulatory practice
10031160|NCT01765595|No Intervention|Control|Standard care
10037020|NCT01821040|Active Comparator|Prednisone IR|Prednisone IR 15mg daily start dose (immediate release) administered in the morning
10037021|NCT01821053||pregestational type 1 diabetes|It is an observational study. No intervention is made.
10031161|NCT01765608|Experimental|Zonisamide|Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
10031162|NCT01765608|Active Comparator|Placebo|Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
9469030|NCT03642158|Active Comparator|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
9469031|NCT03642158|Sham Comparator|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
9469032|NCT03642145|Experimental|Arm A: Deflazacort 0.9 mg/kg|Participants will receive approximately 0.9 mg/kg deflazacort once daily orally for 52 weeks in Period 1 and for 52 weeks in Period 2. The target dose could be varied +/- 20 percent (%) depending upon the available tablet strengths and change in participant's weight.
9469033|NCT03642145|Experimental|Arm B: Deflazacort 0.45 mg/kg|Participants will receive approximately 0.45 mg/kg deflazacort once daily orally for 52 weeks in Period 1. Participants will either continue to receive 0.45 mg/kg deflazacort or escalated dose of deflazacort (0.9 mg/kg) once daily orally in Period 2 at the investigator's discretion and in consultation with the caregiver. The target dose could be varied +/- 20% depending upon the available tablet strengths and change in participant's weight.
9469034|NCT03642145|No Intervention|Natural History Control Group|Control participants matching to the study population as closely as possible, will be used as a comparator to characterize the safety and tolerability of deflazacort.
9469035|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
9469036|NCT03642093|Experimental|Frail|Subjects assessed and determined to be Frail and meet trial eligibility criteria will be enrolled on Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
9469037|NCT03642093|Active Comparator|Not Frail|Subjects assessed and determined to be Not Frail and meet trial eligibility criteria will be enrolled on Not Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
9469038|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
9469039|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
9469040|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
9469041|NCT03642015|Experimental|listening music|The participants in the music group selected the music they preferred from different genres. During the 15-min intervention period before the gastroscopy procedure, the experimental group rested by listening to music and sitting on a comfortable chair
9469042|NCT03642015|No Intervention|Control|control group rested only by sitting on a comfortable chair
9469043|NCT03642002|Experimental|Toning|Vocal Tonal Holding
9469044|NCT03642002|Other|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
10031163|NCT01765608|Active Comparator|nCPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
10031164|NCT01765621|Experimental|DDI+ and Pharmacogenetic data|DDI+ System and Pharmacogenetic data
10031165|NCT01765621|No Intervention|Standard Care|Control
9469045|NCT03642002|Experimental|SOK|Song of kin with lyric content
9469046|NCT03642002|Experimental|Process|Processing of experience
10031166|NCT01765634|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)each week, four times for a cycle
9469047|NCT03642002|Experimental|Holding Harmonic Container|
9469048|NCT03641989|Active Comparator|Plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
9469049|NCT03641989|Placebo Comparator|Non-plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the over-the-counter, non-plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
9469050|NCT03641976|Experimental|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
10031167|NCT01765634|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
10031168|NCT01765660|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
9469051|NCT03641976|Active Comparator|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
10031169|NCT01765660|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)every two weeks, four times for a cycle
10031170|NCT01765686|Active Comparator|Harmonic|Harmonic scalpel uses ultrasound technology to coagulate and to cut tissues.
10031171|NCT01765686|Active Comparator|Small Jaw|Small Jaw device uses bipolar electrical energy and pressure to form a seal and a micro blade to divide the sealed tissues.
10031172|NCT01765699||Primary knee arthroplasty|Patients with osteoarthritis of the knee undergoing primary knee arthroplasty
9469052|NCT03641963|Experimental|Stroke patients with ICP measurement|All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.
10031173|NCT01765725|No Intervention|Control group|The control group will be offered to take part in the patient education group as soon as they have completed the last outcome evaluations
10031174|NCT01765725|Experimental|Patient education program|Patient education program
10031175|NCT01765738|Active Comparator|Antibiotic coated PICC|Cook Medical Spectrum Turbo-Ject Minocycline/Rifampin Power-Injectable PICC (5fr double lumen or 6fr triple lumen)
10031176|NCT01765738|Active Comparator|Non-antibiotic coated PICC|Bard Access PowerPICC Power Injection PICCs (6fr double lumen or 6fr. triple lumen)
10031177|NCT01765790|Experimental|Malignant Solid Tumor (Arm 1)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
9469053|NCT03641950|Experimental|Botulinum Toxin Type A (Botulax)|Botulinum Toxin Type A (Botulax)
9469054|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR>0.8) are assessment by intravascular ultrasound.
9469055|NCT03641885|Experimental|mother and adolescents|an intervention group in which mothers and adolescents receive the intervention and questionnaires via Telegram social media
9469056|NCT03641885|Experimental|adolescents|an intervention group in which adolescents receive the intervention and questionnaires via Telegram social media
9469057|NCT03641885|Active Comparator|active control|mothers and adolescents are in active control group and only receive the questionnaires
9469058|NCT03641872||Acute-on-Chronic Liver Disease|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT > 3 ULN(upper limited of normal),AST > 3 ULN or TB > 2 ULN within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding and/or jaundice(TB > 5 ULN) within 1 month before enrollment)].~Standary therapy for chronic liver disease with ATI and/or AD"
9469059|NCT03641846|Active Comparator|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
9469060|NCT03641846|Placebo Comparator|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
9469061|NCT03641807|Experimental|Acupuncture|
9469062|NCT03641807|Sham Comparator|Sham acupuncture|
9469063|NCT03641794|Experimental|DN1406131|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
9469064|NCT03641794|Placebo Comparator|Placebo|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
9469065|NCT03641781|Active Comparator|Isometric strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
9469066|NCT03641781|Active Comparator|Isokinetic strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOK group isokinetic training group randomly. ISOk group participants were involved in Training at speed of 30 deg/sec, 90deg/sec, 150/deg/sec 210deg/sec, 270deg/sec 5 repetition for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
9469067|NCT03641781|No Intervention|Healthy control group|Data for outcome parameters including Peak torque average peak torque average power agonist antagonist ratio by using biodex isokinetic system for both by isometric contraction method and isokinetic method. For performance test were recorded for healthy control of same age group to compare the training effect with healthy control values.
9469068|NCT03641768|Active Comparator|Healthy volunteers|Volunteers with no trauma history
9469069|NCT03641768|Active Comparator|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
10031178|NCT01765790|Experimental|Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
10031179|NCT01765816|Experimental|high intensity interval training|one interval training session with 1 x 4 and 4 x 4 minutes interval training at 90-95% of peak heart rate
10031180|NCT01765816|Active Comparator|moderate intensity training|45 minutes of moderate continuous training at 75% of maximal heart rate
10031181|NCT01765829|Active Comparator|Antipsychotic treatment|"Antipsychotic treatment according to common clinical practice~Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone."
10031182|NCT01765829|Experimental|Discontinuation antipsychotic treatment|Dose reduction of antipsychotic treatment (25% every 4 weeks).
10031183|NCT01765842|Active Comparator|Rituximab (1 cycle)|"1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
9469070|NCT03641768|Active Comparator|PTSD only|Volunteers with PTSD but no traumatic brain injury
9469071|NCT03641768|Active Comparator|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
9469072|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
9469073|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
9469074|NCT03641729|Other|Intervention|Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
9469075|NCT03641703|Experimental|FLT180a|Participants who have received gene therapy vector (FLT180a)
9469076|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
9469077|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
9469078|NCT03641651|Experimental|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
9469079|NCT03641638||Low level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 34-102 IU/ml.
9469080|NCT03641638||Medium level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 103-204 IU/ml.
9469081|NCT03641638||High level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb >205IU/ml.
9469082|NCT03641638||Control group|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of negative Thyroid antibody, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L.
9469083|NCT03641625|Experimental|Intervention|In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
9803063|NCT04602858|Experimental|Reactive Balance Training|"Participants randomised to the intervention group will initially undertake 3 x 40 min training sessions of reactive balance training over 3 weeks followed by 3-monthly retraining sessions at 3, 6 and 9 months, and final assessment at month 12.~During the training, participants will be exposed to unpredictable slips and trips whilst they are walking on the Trip and Slip Walkway (Okubo et al. 2019). They will be required to consistently walk at their normal walking pace using our gait regulation protocol (i.e. individually adjusted stepping tiles and metronome). Each training session will involve up to 30 trips and slips which progress in unpredictability.~Participants will also receive a Staying active and on your feet fall prevention booklet containing guidance regarding fall risk factors including exercise, diet, vision, footwear, medications and home safety."
9469084|NCT03641625|No Intervention|Control|Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.
9469085|NCT03641612|Experimental|one shape|single file rotary system
9469086|NCT03641612|Active Comparator|protaper next|multiple file rotary system
9469087|NCT03641599||heart failure with preserved ejection fraction|
9469088|NCT03641599||heart failure with mid range ejection fraction|
9469089|NCT03641599||heart failure with reduced ejection fraction|
9469090|NCT03641586|Experimental|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
9469091|NCT03641586|Experimental|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
9469092|NCT03641586|Experimental|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
9469093|NCT03641573|Experimental|[14C] ASN002|[14C] ASN002
10031184|NCT01765842|Experimental|Rituximab (2 cycles)|"A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)"
10031185|NCT01765855|Experimental|Single Arm Oral Betrixaban|
10031186|NCT01765868|Experimental|Single Arm Oral and IV Betrixaban|
9469095|NCT03641534||Sepsis|
9469096|NCT03641534||Severe malaria|
10031187|NCT01765881|Experimental|Misoprostol|one 25 micrograms capsule all 4 hours by intravaginal route
9469097|NCT03641534||Uncomplicated malaria|
9469098|NCT03641521|Experimental|Intervention|The intervention consisted of an enhanced Cooking Matters® for Families program that included behavioral strategies derived from behavioral economics, to be implemented by parents at home for increasing vegetable intake of low-income 9-12 year old children
9469099|NCT03641521|No Intervention|Control|The control arm consisted of the enhanced Cooking Matters® for Families program alone--without lessons about the behavioral strategies for the parents
9469100|NCT03641495|Experimental|Pain education plus exercise therapy (PE + ET)|"Pain education according to the book Explain Pain written by Lorimer Moseley and David Butler~Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations."
9469101|NCT03641495|Active Comparator|Exercise therapy (ET)|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.
9469102|NCT03641482|Active Comparator|NBF|Propolis Extract, Ascorbic Acid, Tocopherol Acetate, Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
10031188|NCT01765881|Active Comparator|Dinoprostone|one unique intravaginal sustained released of 10 milligrams
10031189|NCT01765894||Normal glucose tolerance subjects|Healthy controls. If any medication then paused 3 days prior to test days. BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description.
9469103|NCT03641482|Placebo Comparator|Placebo|Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
9469104|NCT03641456|Experimental|VRD for Followed by VR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib 1.3mg/m2 on days 1 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
10031190|NCT01765894||DM2|"Type 2 diabetics in diet treatment or type 2 diabetics who have paused their oral medication for 3 whole days.~Insulin treatment is an exclusion criteria. If any other medication then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description."
10031191|NCT01765894||DM2 + Metformin|"Type 2 diabetics in metformin treatment. Insulin treatment is an exclusion criteria. If any other medication (besides from metformin) then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description"
10031192|NCT01765907|Experimental|HIFU|
10031193|NCT01765933|Experimental|DMAA|Single oral dose 25 mg DMAA
10031194|NCT01765946|Experimental|Metformin|Metformin tablets 500 mg tid for 2 months
10031195|NCT01765946|Placebo Comparator|Placebo|Placebo tables tid for 2 months
10031196|NCT01765959|Active Comparator|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
10031197|NCT01765959|Active Comparator|Cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 How to solve problems, planning for the future"
10031198|NCT01765985|Experimental|Intercurrent PSORIAMED|5 minutes twice a day for 12 weeks
9469105|NCT03641443|Experimental|Non-invasive measurement of intracranial pressure|Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement
10031199|NCT01765985|Active Comparator|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
10031200|NCT01765998|Experimental|Probiotic|To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
9469106|NCT03641430|Experimental|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
10031201|NCT01765998|Placebo Comparator|placebo|This will be the comparison group to the experimantal group that recives Probiotic.
10031202|NCT01766011|Experimental|study pre-term formula|Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles
9469107|NCT03641417|Experimental|GLWL-01|Oral administration of GLWL-01 300mg BD for 10 days
9469108|NCT03641417|Placebo Comparator|Placebo|Identical oral capsules with no active ingredient, administered BD for 10 days
9469109|NCT03641404|Experimental|Ergothioneine|Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
9469110|NCT03641404|Placebo Comparator|Placebo|Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
9469111|NCT03641391|Experimental|Direct electrical stimulation|Intraoperative direct cortical electrical stimulation or intraoperative direct subcortical electrical stimulation on language or language-associate areas, and the participants' after-discharge activity would be monitored. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
9469112|NCT03641378|Experimental|Inpatient Palliative Care Intervention|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent~Palliative Care Intervention~Therapeutic Relationship~--Develop a strong therapeutic relationship with patients and caregivers~Assessment and Treatment of Patient Symptoms~--Clarify the symptoms the patient will likely experience and offer reassurance about the methods for reporting and treating symptoms~Managing Patients and Caregivers Expectations~--Address early on patients and caregivers' concerns about the trajectory of illness during HCT and treatment side effects~Coping with Illness and HCT --Introduce strategies to help improve adjustment (e.g., behavioral, cognitive, and spiritual approaches; accepting illness while maintaining hope; social support)"
9469113|NCT03641378|Experimental|Transplant Care Alone|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent.~Standard Transplant Care"
9469114|NCT03641365|Experimental|Test group|Test group: Surgical template without metallic sleeves. In this case the surgical template has all been designed and fabricated in acrylic material by mean of stereolitographic technology.
9469115|NCT03641365|Active Comparator|Control group|Control group: Surgical template with metallic sleeves. Surgical template has designed and fabricated in acrylic material by mean of stereolitographic technology and metallic sleeves have been bonded after its production.
9469116|NCT03641352|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
9469117|NCT03641352|Placebo Comparator|Placebo|Placebo
9469118|NCT03641300|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
9469119|NCT03641300|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q
9469120|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
9469121|NCT03641261|Experimental|Therapeutic Patient Education program|All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose
9469122|NCT03641248|Experimental|Enteric coated Devil's Claw|H. procumbens 100 mg in enteric coated capsules
9469123|NCT03641248|Active Comparator|Non-enteric coated Devil's Claw|H. procumbens 100 mg in non-enteric coated capsules
9469124|NCT03641235||exacerbating COPD patients needing ICU admission|sputum collection
9469125|NCT03641222|Experimental|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
9469126|NCT03641222|Active Comparator|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
9469127|NCT03641209|Experimental|Paracetamol|Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days
9469128|NCT03641209|Placebo Comparator|Placebo|0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug
9469129|NCT03641196|No Intervention|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
9469130|NCT03641196|Active Comparator|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
9469131|NCT03641196|Active Comparator|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
9469132|NCT03641170|Experimental|Experimental intervention|Fixed diet and physical activity.
9803064|NCT04602858|Active Comparator|Control|"After exposing the control group to one trip and one slip at baseline, participants will then be provided with the Staying active and on your feet fall prevention booklet, an educational booklet providing guidance on fall risk factors including exercise, diet, vision, footwear, medications and home safety. The control group will then return for a reassessment after 12 months."
10031203|NCT01766063||Group 1|
10031204|NCT01766089|Active Comparator|Dexmedetomidine|dexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
10031205|NCT01766089|Placebo Comparator|Remifentanil|remifentanil intravenous infusion rate of 0.1 µg/kg/min
10031206|NCT01766115|Experimental|Telaprevir|750 mg oral tablet of telaprevir will be given three times per day for 4 weeks within a five (5) day period from health care worker exposure.
10031207|NCT01766141|No Intervention|Acute versus chronic low back pain|No manipulative intervention. Phlebotomy for inflammatory biomarker determinations to compare acute versus chronic at baseline.
10031208|NCT01766141|Experimental|Spinal manipulation (SMT)|Inflammatory biomarker determinations after a course of 6 SMT interventions over the period of 2 weeks; a single SMT per treatment.
10031209|NCT01766141|No Intervention|No treatment controls|Asymptomatic subjects. Biomarker determinations at time zero and again two weeks later.
10031210|NCT01766154|Experimental|Subjects with normal renal function given tirofiban|Subjects with normal renal function (CrCl >90 mL/min)
10031211|NCT01766154|Experimental|Subjects with moderate renal insufficiency given tirofiban|Subjects with moderate renal insufficiency (CrCl 30-59 mL/min)
10031212|NCT01766154|Experimental|Subjects with severe renal insufficiency given tirofiban|Subjects with severe renal insufficiency (CrCl <30 mL/min).
10031213|NCT01766167|Experimental|MP-424|
10031214|NCT01766180|No Intervention|Placebo / Placebo|In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
9469133|NCT03641170|Other|Control intervention|Fixed diet and inactivity.
9469134|NCT03641157||Group I Easy Intubation|Pediatric patients ages 0-3 years Easy Intubation (Cormach-Lehane score I-II)
9469135|NCT03641157||Group II Difficult intubation|Pediatric patients ages 0-3 years Difficult intubation (Cormach-Lehane score III-IV)
9469136|NCT03641144|Experimental|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
9469137|NCT03641144|Active Comparator|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
10031215|NCT01766180|Active Comparator|Fruitflow-II / Placebo|In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
10031216|NCT01766180|Active Comparator|Placebo / resVida|In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
10031217|NCT01766180|Active Comparator|Fruitflow-II / resVida|In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
9469138|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
9469139|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
9469140|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
9469141|NCT03641105||lung adenocarcinoma|patients with lung adenocarcinoma
9469142|NCT03641079|Experimental|brinjal peel extract containing cream|intervention-brinjal peel extract containing cream, dose-twice daily for 12 weeks
9469143|NCT03641066|Experimental|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
9469144|NCT03641053|Experimental|Honey|0.05 cc of honey (Madu Nusantara®) per 1 cm of laceration, given every predetermined wound care schedule
9469145|NCT03641053|Active Comparator|Povidone-iodine|0.05 cc of povidone-iodine per 1 cm of laceration, given every predetermined wound care schedule
9469146|NCT03641053|Active Comparator|Paraffin gauze|1 layer of paraffin gauze, given every predetermined wound care schedule
10031218|NCT01766193||vaginal birth|women whose first child was born by spontaneous vaginal delivery
10031219|NCT01766193||cesarean section|women whose first child was born by cesarean section
10031220|NCT01766193||forceps|women whose first child was born by forceps extraction
10031221|NCT01766193||vacuum|women whose first child was born by vacuum extraction
10031222|NCT01766232||Obstructed nasolacrimal drainage group|This group of patients is clinically identified as having epiphora due to an obstruction of the lacrimal drainage system.
10031223|NCT01766232||Ectropion group|This group of patients is clinically determined to have functional epiphora due to ectropion and a patent lacrimal drainage system.
10031224|NCT01766245|Experimental|Formulation A followed by Formulation B|
10031225|NCT01766245|Active Comparator|Formulation B followed by Formulation A|
10031226|NCT01766258|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
10031227|NCT01766258|Experimental|ODM-101 65mg Carbidopa|levodopa/carbidopa/entacapone
10031228|NCT01766258|Experimental|ODM-101 105mg Carbidopa|levodopa/carbidopa/entacapone
10031229|NCT01766271|Experimental|Standard Risk Assessment (SRA) Only|
10031230|NCT01766271|Experimental|SRA plus Health Coaching|
10031231|NCT01766271|Experimental|SRA plus Genetic Testing|
9469147|NCT03641040|Experimental|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
9469148|NCT03641040|Active Comparator|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
9469149|NCT03641014|Experimental|Sequential pH culture (7.23 then 7.35)|A split embryo at day 3 to continue culture at a pHe of 7.23±0.02 or to be cultured at a pH of 7.35±0.02 and monitor the effect on blastocyst development.
9469150|NCT03641014|No Intervention|Continuously pH culture at 7.23|Embryo culture from day 0 to 5 or 6 at 7.23
9469151|NCT03640975||case : eosinophilic esophagitis|Children with symptoms suggestive of EoE and requiring an upper gastrointestinal endoscopy with biopsies of the esophageal mucosa
9469152|NCT03640975||control|Children in whom an endoscopy performed to explore symptoms of EoE revealed another condition (peptic oesophagitis, achalasia), or children in whom an endoscopy with biopsies has been performed to explore chronic abdominal or epigastric pain or suspected chronic inflammatory bowel disease
9469153|NCT03640936||Healthy|Healthy controls, without asthma or allergy (negative prick test)
9469154|NCT03640936||Allergic asthma|Patients with allergic asthma sensitized to Dermatophagoides pteronyssinus, tested by prick test or specific IgE
9469155|NCT03640936||Non-allergic asthma|Patients with asthma not sensitized to Dermatophagoides pteronyssinus, with negative prick test or specific IgE
10031232|NCT01766271|Experimental|SRA plus Health Coaching plus Genetic Testing|
10031233|NCT01766284|Experimental|Niris 1300e OCT imaging|OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.
10031234|NCT01766297|Experimental|Proton Radiotherapy|Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
10031235|NCT01766323|Placebo Comparator|Arm Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
10031236|NCT01766323|Active Comparator|Arm-Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
10031237|NCT01766349||esophagus cancer patients|Respiratory muscle performance will be followed in patients with esophagus cancer during CCRT or RT treatments.
10031238|NCT01766362|Experimental|A session|
10031239|NCT01766362|Other|Four sessions|Every session are spaced out of month
10031240|NCT01766375|Experimental|IDBUCY|"Idarubicin: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
10031241|NCT01766375|Active Comparator|BUCY|"Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
10031242|NCT01766388||Pregnant women|Pregnant women of 13-22 weeks gestation
10031243|NCT01766414|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
10031244|NCT01766414|Placebo Comparator|Placebo|Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
10031245|NCT01766427||morning electroacupuncture with pills|
10031246|NCT01766427||afternoon EA with pills|
10031247|NCT01766427||no EA group with pills|
10031248|NCT01766453|No Intervention|Non exercise control|Non exercise control will undergo baseline testing and follow up testing but will not participate in an exercise intervention.
10031249|NCT01766453|Experimental|Standard Exercise|The standard exercise group will attend exercise sessions under the supervision of a Certified Personal Trainer. Intensity will increase every four weeks by 10% from 50-80% of maximal heart rate to ensure that exercise is progressive in nature. Participants will be provided with a heart rate monitor during their exercise sessions and have the option to perform the aerobic training on a treadmill, upright bike, elliptical machine or recumbent bike as long as heart rate is kept within the prescribed training intensity. Intensity, duration, resting and exercise heart rates will be recorded for each exercise session for the duration of the intervention to ensure compliance to the exercise program.
10031250|NCT01766453|Experimental|Bhangra Dance Exercise|Bhangra dance classes taught be a certified instructor progressing in difficulty over the 12 week period. Bhangra dance is an Indian folk dance that consists of jumping and kicking of a high intensity. This group will attend exercise sessions under the supervision of a Bhangra Dance Instructor. The intensity of bhangra dance will be tracked through heart rate monitors worn by participants.
10031251|NCT01766479|Experimental|Family Degree-relatives of pts. with CRC|Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day.
10031252|NCT01766492||male (age > 18 y/o) with prostate cancer|Men received Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer
9469156|NCT03640923|Experimental|experimental group|Child with a proven infection of the mother or both biological parents known to HIV antenatal a swab of mucous membrane will be withdrawed
9469157|NCT03640910|Experimental|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
9469158|NCT03640910|Active Comparator|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
9469159|NCT03640897|Experimental|Liniderm|"Oleocalcareous liniment Liniderm:~The product will be applied on the diaper area by parents/ caregivers at each diaper change."
9469160|NCT03640897|Active Comparator|Wipes|Free-fragrance baby wipes The product will be used on the diaper area by parents/ caregivers at each diaper change.
9469161|NCT03640897|Active Comparator|Water|Water and cotton pads The product will be used on the diaper area by parents/ caregivers at each diaper change.
9480195|NCT03536026|Experimental|Bronchoscopic evaluation and biopsy|-Bronchoscopy will be performed by pulmonary and/or critical care fellows who have performed fewer than 10 bronchoscopies (inexperienced bronchoscopists) under direct supervision by an attending Interventional Pulmonologist. The inexperienced bronchoscopist will attempt to navigate to the targeted peripheral pulmonary lesion without virtual bronchoscopic navigation, using only standard axial CT images as a reference. The attending physician will directly observe, but will provide no guidance during this period, which will last no longer than 10 minutes. If the lesion is located and confirmed with radial probe endobronchial ultrasound prior to 10 minutes, biopsies will be performed as per routine clinical practice. If the 10 minute time period elapses prior to localization of the peripheral pulmonary lesion, virtual bronchoscopic navigation will be used.
9480196|NCT03536013|Experimental|Treatment|91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
9480197|NCT03536013|No Intervention|Control|91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.
9480198|NCT03536000||Healthy women|"200 Pregnant women~Over 18 years~Healthy~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
10031253|NCT01766505|Experimental|Candemore tablet|Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
10031254|NCT01766505|Active Comparator|Cozzar tablet|Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
10031255|NCT01766518|Experimental|MY-REPT capsule|MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally
10031256|NCT01766531|Experimental|Body bioelectrical impedance|comparison with four methods for assessing nutritional status. ; compare length of mechanical ventilation, length in ICU and energy expenditure rest between malnourished and non-malnourished patient
10031257|NCT01766544|Active Comparator|Standard practice group (SPG)|Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
10031258|NCT01766544|Active Comparator|Targeted Intervention Strategy (TISG)|interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.
10031259|NCT01766557|Experimental|Semi-controlled intervention with fish protein diet|Women with polycystic ovarian syndrome who are assigned to a 12 weeks experimental diet containing cod as the protein source.
10031260|NCT01766557|Active Comparator|Semi-controlled intervention with other animal proteins|Women with polycystic ovarian syndrome who are assigned to a 12 week experimental diet containing beef, pork, veal, eggs and milk products (BPVEM) as protein sources.
10031261|NCT01766570|Experimental|Phenol|Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.
10031262|NCT01766570|Placebo Comparator|Control|Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.
10031263|NCT01766583|Experimental|CC-292 + lenalidomide|Combination of CC-292 + lenalidomide
10031264|NCT01766596|Other|3C cohort|
10031265|NCT01766609|Active Comparator|A: Triamcinolone acetonide|Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
10031266|NCT01766609|Placebo Comparator|B: Normal saline|Bacteriostatic normal saline will injected into one half of the vitiligo patch.
10031267|NCT01766648|Experimental|Far Cortical Locking screw fixation|Far Cortical Locking screw fixation
10031268|NCT01766648|Active Comparator|Standard locking screw fixation|Standard locking screw fixation
10031269|NCT01766661|Active Comparator|Coloanal anastomosis with ileostomy|Hand-sewn coloanal anastomosis protected by a loop ileostomy
9469162|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
9469163|NCT03640871|Experimental|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing (AWC=Advanced Wound Care)
9469164|NCT03640858|Experimental|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
9469165|NCT03640845|Experimental|experimental group|Patient living in nursing homes a tele-expertise will be performed
9469166|NCT03640845|No Intervention|control group|Patient living in nursing homes will performed a normal care.
9469167|NCT03640819|Experimental|Tattooing of biopsied node|The biopsied node will be tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or separate visit under ultrasound guidance.
9469168|NCT03640806|Experimental|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
9469169|NCT03640806|No Intervention|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
9469170|NCT03640780||cataract extraction (CE)|Patients received CE without IOL implantation in the first surgical stage, and received IOL implantation at secondary surgical stage.
9469171|NCT03640780||cataract extraction and IOL implantation|Patients received CE and IOL implantation in the first surgical stage.
9469172|NCT03640767|Experimental|message-based lifestyle intervention|The intervention group will receive 4 mobile phone messages per week for 24 weeks.
9469173|NCT03640767|No Intervention|Control|no intervention
9469174|NCT03640741||Laparoscopy|The group consists of patients who undergoes laparoscopy procedure during which changes in cerebral oxygenation are estimated.
9469175|NCT03640728||ETV|patients receive entecavir 0.5 mg/day orally.
9469176|NCT03640728||TDF|patients receive Tenofovir Disoproxil Fumarate 300 mg/day orally.
9469177|NCT03640728||TAF|patients receive Tenofovir alafenamide 25 mg/day orally.
9469178|NCT03640715|Other|group A|Group A: no vulnerability according to expert with no indication of any PASS marker care
9469179|NCT03640715|Other|group B|Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
9469180|NCT03640715|Other|group c|Group C: high vulnerability according to the expert with indication of at least two care markers PASS
9469181|NCT03640702||Prolonged second stage of labor|Women with prolonged second stage of labor as specified before.
9469182|NCT03640689|Experimental|Intervention Group|Endovenous ablation + iliac US +/- iliac stenting
9469183|NCT03640689|Active Comparator|Control Group|Endovenous ablation of Great Saphenous Vein
9469184|NCT03640676|Sham Comparator|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
9469185|NCT03640676|Active Comparator|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
10031270|NCT01766661|Experimental|Two stage Turnbull-Cutait anastomosis|Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
10031271|NCT01766674|Experimental|Kyphosis spinal exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
10031272|NCT01766674|No Intervention|Control|Control group will be enrolled in the usual care waitlist group
10031273|NCT01766687|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
10031274|NCT01766687|No Intervention|Control|
10031275|NCT01766700|Experimental|No calorie beverages|2 no calorie beverages per day.
10031276|NCT01766700|Active Comparator|Water|2 water beverages per day.
10031277|NCT01766726||Healthy control subjects|Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to arterial inflammation and coronary atherosclerotic plaque. Prospectively recruited healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to lipid and immune function.
9469186|NCT03640663||Midwife led continuity model of care|Women who received antenatal care from midwives from the hospital reaching out to the rural villages
9469187|NCT03640663||Regular care group|Women who received care from doctors, nurses or midwives employed at primary Health care centres in rural villages
10031278|NCT01766726||ART-naïve HIV+ patients starting QUAD/Stribild|ART-naïve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy.
10031279|NCT01766752|Experimental|GlucoTab System|Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward.
9469188|NCT03640650|Experimental|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
9469189|NCT03640650|Active Comparator|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
10031280|NCT01766752|No Intervention|no intervention|standard care
10031281|NCT01766765|Experimental|Early jejunostomy nutrition|
10031282|NCT01766765|Active Comparator|Early oral nutrition|
10031283|NCT01766791|Experimental|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1 Repetition Maximum (1RM)
10031284|NCT01766791|Experimental|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - <75% 1RM
10031285|NCT01766791|Experimental|HIT-exercise with protein|High Intensity Resistance Exercise Training with protein supplementation
10031286|NCT01766791|Placebo Comparator|Control|No physical exercise intervention
9469190|NCT03640637||Suspected IBD|A prospective study of 50 pediatric patients suspected of IBD. Participants will undergo routine diagnostic procedures for evaluation of pediatric IBD including blood samples, faecal samples, endoscopies (colonoscopy and gastroscopy with biopsy/histology) and MRI of the abdomen. In addition, a PET scan will be performed in this protocol and combined with MRI. For accuracy measures, PET/MRI scan will be compared to the combined findings of endoscopy, histology and severity of inflammation by clinical scoring systems (weighted Pediatric Crohn's Disease Activity Index (wPCDAI) for CD and Pediatric Ulcerative Colitis activity Index (PUCAI) for CU), faecal calprotectin and biochemistry.
10031287|NCT01766804|Experimental|Bovine colostrum|A daily supplement of bovine colostrum powder.
10031288|NCT01766804|Placebo Comparator|Placebo|A daily placebo supplement consisting of whole milk powder and whey protein.
10031289|NCT01766830|Experimental|Phase 3 Diagnostic|A total of 10 RDTs will be assessed in the patients cohort for the respective target condition
10031290|NCT01766843|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
10031291|NCT01766843|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
10031292|NCT01766843|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
10031293|NCT01766843|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
10031294|NCT01766856||children undergoing myringoplasty/tympanoplasty|child having repair of eardrum because of hole in eardrum after tube extruded or after tube removal
9469191|NCT03640637||Treatment response group|A pilot study of 10-15 patients previously diagnosed with CD who will undergo PET/MRI scan as an investigational procedure before initiation of biological treatment with an anti-TNF-alpha antibody (infliximab, adalimumab) because of disease relapse or steroid dependent disease. Patients will be scheduled for a PET/MRI again after one month. This study will evaluate if PET/MRI can diagnose a flare in CD and if PET/MRI is a reliable imaging tool to monitor intestinal inflammation. In this study the patient will act as his/her own control.
10031295|NCT01766882|Experimental|Treatment|"Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day~Lower dialysate sodium at 137 mmol/L.~Progressive Challenge to Post Dialysis Weight:~The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments."
10031296|NCT01766882|No Intervention|Control|Usual care in addition to Blood pressure monitoring and and Hydration status monitoring
10031297|NCT01766895||uremic patients|blood sampling of viral hepatitis in uremic patients
10031298|NCT01766908|Active Comparator|Cord Clamp 20 Seconds After Delivery|Intervention is cord clamp at 20 seconds following vaginal or cesarean delivery
10031299|NCT01766908|Active Comparator|Cord Clamp 40 seconds After Delivery|Timing of cord clamp at 40 seconds following vaginal or cesarean delivery.
10031300|NCT01766908|Active Comparator|Cord Clamp 60 seconds After Delivery|Intervention is timing of cord clamp at 60 seconds following vaginal or cesarean delivery
10031301|NCT01766947|Experimental|Triggerfish|Device : Sensimed Triggerfish
10031302|NCT01766960|Experimental|Healthy volunteers|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
9469192|NCT03640598|Other|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
9469193|NCT03640598|Other|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
10031303|NCT01766960|Experimental|Advanced nonalcoholic fatty liver disease patients|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
10031304|NCT01766973||Chronic back pain|Adults, >6months duration
9469194|NCT03640585|Experimental|Music therapy|Children listened to Classical music disc for 45 minutes.Children treated by neurodevelopmental therapy while listening to this music.A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients.
9469195|NCT03640585|Placebo Comparator|Control|Only the neurodevelopmental therapy was applied in the control group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
9469196|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
9469197|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
9469198|NCT03640533|Experimental|Nanit-Insights intervention group|Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
9469199|NCT03640533|No Intervention|Nanit-monitor control group|Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.
9469200|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
9469201|NCT03640468|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
9469202|NCT03640468|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
9469203|NCT03640442|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
9469204|NCT03640442|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
9469205|NCT03640416|Other|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit® Charge HR smart watch
9469206|NCT03640403|Experimental|DP|Dihydroartemisinin-piperaquine (DP), antimalarial drug to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
9469207|NCT03640403|Active Comparator|ASAQ|Artesunate-amodiaquine (ASAQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
10031305|NCT01766973||Control|Age and sex matched controls
10031306|NCT01766999||SpMetHb > 8%|hemoximetric MetHb measurements triggered
10031307|NCT01767012|Active Comparator|Polylens EC-Y10-PAL (uncoated)|hydrophobic acrylic IOL (no coating) implantation during cataract surgery
10031308|NCT01767012|Active Comparator|Polylens EC-Y10H-PAL (coated)|hydrophobic acrylic heparin-coated IOL implantation during cataract surgery
10031309|NCT01767025|Experimental|Oxytocin|Oxytocin 24 IU (3 puffs) per nostril
10031310|NCT01767025|Placebo Comparator|Sea water|Sea water 3 puffs per nostril
10031311|NCT01767051||Children born from mothers who are diagnosed with PCOS|Children at the age of 2.5-4 years or at the age of 6-8 years born from mothers who are diagnosed with PCOS at the University Medical Centre in Utrecht (UMCU) in the period 2004-2012 (n=891) will be asked to participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU will be asked to participate too. All mothers have been diagnosed with PCOS according to standardised extensive diagnostic work-up and have given informed consent to be approached for future research purposes.
9469208|NCT03640403|No Intervention|Control|No intervention drugs will be given, but normal routine standard of care will be provided.
9469209|NCT03640390|Experimental|Dexmedetomidine group|This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour
9469210|NCT03640390|Active Comparator|Magnesium Sulphate group|This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour
10031312|NCT01767051||Children who participated in the WHISTLER study|Children who participated in the WHISTLER 3 (11-163) and WHISTLER/Cardio study (10-194) in 2002-2012. The children were born from mothers with a regular cycle prior to conception who conceived naturally. The children were examined at the age of 2.5-4 years or at the age of 7-8 years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.
10031313|NCT01767077|Placebo Comparator|Butter oil|Daily intake of 40 g butter oil
10031314|NCT01767077|Active Comparator|Cream|Daily intake of 100 g cream (40%)
9469211|NCT03640390|Placebo Comparator|Saline group|This group will receive normal saline infusion
9469212|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose only baseline treatment|150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
9469213|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose only baseline treatment|150 children will receive 80 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
9469214|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose at baseline and 6 months|150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.
9469215|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose at baseline and 6 months|150 children will receive 80 mg/kg Praziquantel at baseline and again six months later.
9469216|NCT03640351|Active Comparator|Preservative free diquafosol group|The subjects use preservative free diquafosol ophthalmic solution after cataract surgery
9469217|NCT03640351|Active Comparator|Preservative containing diquafosol group|The subjects use preservative containing diquafosol ophthalmic solution after cataract surgery
9469218|NCT03640351|Active Comparator|Preservative free sodium hyaluronate group|The subjects use preservative free sodium hyaluronate ophthalmic solution after cataract surgery
9469219|NCT03640338|Experimental|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
9469220|NCT03640338|No Intervention|Standard care (ice-pack)|Patients will use disposable ice-pack as per standard of care
9469221|NCT03640299|Experimental|ERAS procedure|"In this arm, ERAS perioperative cares patients planned to undergoing laparoscopic surgery, following the ERAS protocols.~Extensive preoperative counselling and education by surgeon and anesthetists.~No Bowel preparation.~6 h fast for solid food and carbohydrate loading with clear fuilds 2h before surgery.~Oral nonselective NSAIDs premedication.~Total Intravenous Anesthesia via TCI, wound infiltration and the transversus abdominis plane (TAP).~Minimally invasive surgery.~Maintenance of normothermia.~Avoidance of surgical drains and nasogastric tubes.~Nonselective NSAIDs postoperative medication.~Postoperative nausea and vomiting active control.~Early oral feeding and ambulation.~VTE prophylaxis postoperative."
9803065|NCT04597996|Experimental|Web Based Education|A pre-test will be applied. Web-based education will be conducted. The post-test will be applied twice, the first one to be performed 4 weeks after Web-based education is completed and the second one 3 months after Web-based education is completed.
10031315|NCT01767090|Placebo Comparator|Placebo|Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
10031316|NCT01767090|Experimental|ASP1707 lowest dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
10031317|NCT01767090|Experimental|ASP1707 low dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
10031318|NCT01767090|Experimental|ASP1707 medium dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
10031319|NCT01767090|Experimental|ASP1707 high dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
10031320|NCT01767090|Active Comparator|Leuprorelin acetate|Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks
10031321|NCT01767181|No Intervention|A|Control group without intervention
10031322|NCT01767181|Experimental|B|Intensive light therapy during the first half of the night shift
10031323|NCT01767181|Experimental|C|Exercise before the beginning of the night shift
10031324|NCT01767181|Experimental|D|Exercise after the end of the night shift
10031325|NCT01767207||screening for mental disorders|screening for mental disorders
10031326|NCT01767220|Active Comparator|Strategy 1- endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial.
10031327|NCT01767220|Active Comparator|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and ablation are done from endocardial and epicardial.
10031328|NCT01767233|Experimental|Pancreatic stenting|Pancreatic stenting versus observation
10031329|NCT01767246|Experimental|PFS algorithm treatment|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
10037597|NCT01826526|Placebo Comparator|Saline solution 0.9%|"5 ml of saline will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of saline administration in this trial will be 12 months."
9469222|NCT03640299|No Intervention|Traditional treatment procedure|"In this arm, control patients planned to undergoing laparoscopic surgery, following the traditional treatment protocols.~Conventional preoperative visits and education.~Mechanical bowel preparation.~Fasting overnight, and no fluids before surgery.~No oral nonselective NSAIDs premedication.~Continuous epidural anesthesia is administered before surgery. Sevoflurane and sufentanil maintain the depth of anesthesia.~Minimally invasive surgery.~No maintenance of normothermia.~Drainage tube insertion if needed.~Postoperative patient-controlled intravenous analgesia.~Postoperative Nausea Control if needed.~Conventional oral feeding and mobilization.~No bowel routine.~VTE prophylaxis postoperative."
9469223|NCT03640273|Experimental|Prapchompoothaweep|Group 1 will be received Prapchompoothaweep remedy 1,000 mg for 3 times before meals (for 6 weeks).
9469224|NCT03640273|Experimental|Loratadine|Group 2 will be received Loratadine 10 mg per day before meals (for 6 weeks)
9469225|NCT03640260|Experimental|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
9469226|NCT03640260|No Intervention|controlled|
9469227|NCT03640247|Other|Narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours~Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg."
9803066|NCT04597996|No Intervention|No Intervention Group|The control group will not have any intervention during the study.
10031330|NCT01767246|Active Comparator|Multimodal Treatment|Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
10031331|NCT01767259|Other|Valsartan 160 mg alone|Valsartan alone
10031332|NCT01767259|Other|Hydrochlorothiazide 12.5 mg alone|Hydrochlorothiazide alone
10031333|NCT01767259|Other|Valsartan160 mg + Hydrochlorothiazide12.5 mg|Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
10031334|NCT01767259|Other|Valsartan / Hydrochlorothiazide 160 mg/12.5mg|Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
10037022|NCT01821066|Experimental|Two-Period Fixed-Sequence Arm|This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
10037023|NCT01821079|Experimental|PF-05175157 PIC in fed state|200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
10037024|NCT01821079|Experimental|PF-05175157 tablet in fed state|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
10037025|NCT01821079|Experimental|PF-05175157 tablet in fed state (repeat)|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
10037026|NCT01821079|Experimental|PF-05175157 tablet in fasted state|200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
10037027|NCT01821092|Active Comparator|standard implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in healed ridge, prosthetic connection with switching platform
10037028|NCT01821092|Active Comparator|immediate implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in immediate post-extraction sites, prosthetic connection with switching platform
10037029|NCT01821131|Experimental|30g ground flaxseed per day|consume 1 muffin containing 30g ground flaxseed every day for 4 weeks
10037030|NCT01821131|Experimental|20g ground flaxseed per day|consume 1 muffin containing 20g ground flaxseed every day for 4 weeks
10037031|NCT01821131|Placebo Comparator|0g ground flaxseed per day|consume 1 muffin containing 0g ground flaxseed every day for 4 weeks
10037032|NCT01821144|Other|Control|No salt awareness education
10037033|NCT01821144|Experimental|Salt reduction|Salt reduction
10037034|NCT01821157|Active Comparator|Flapless|Flapless: Gingivectomy and osteoplasty, as necessary, will be performed without flap elevation.
10037035|NCT01821157|Active Comparator|Open-flap|Gingivectomy and osteoplasty, as necessary, will be performed with flap elevation
9803067|NCT04595968|Experimental|Vestal DM active device|100 subjects randomised to receive active device plus lifestyle intervention for 24 weeks
9803068|NCT04595968|Sham Comparator|Vestal DM sham device|100 subjects randomised to receive sham device plus lifestyle intervention for 24 weeks.
9803069|NCT04594239|Experimental|Treatment, needle|
9803070|NCT04594239|Experimental|Treatment, cannula|
10037036|NCT01821170|Experimental|Cognitive remediation|
10037037|NCT01821170|Active Comparator|Supportive psychotherapy|
10037038|NCT01821170|Active Comparator|Methylphenidate|
10037039|NCT01821183||hip rotators muscle strength|
10037040|NCT01821183||control group|no intervention
10037041|NCT01821196|Experimental|biopsy|Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient.
10037042|NCT01821209|No Intervention|Control|Standard robot assisted radical prostatectomy
10037043|NCT01821209|Experimental|Sling|Placement of sling at time of robot assisted radical prostatectomy
10037044|NCT01821222|Experimental|Wired mothers intervention|The wired mothers' intervention consisted of two components: an automated short messaging service (SMS) system providing wired mothers with unidirectional text messaging and a mobile phone voucher system providing the possibility of direct two-way communication between wired mothers and their primary health care providers. While only women with registered phone numbers received text messages, all women in the intervention group were given mobile phone vouchers to contact their local primary health care provider.
10037045|NCT01821222|No Intervention|Control|The control group received standard care
10037046|NCT01821235|Experimental|Neurontin® (gabapentin) batch A|
10037047|NCT01821235|Experimental|Neurontin® (gabapentin) batch B|
9469228|NCT03640247|Active Comparator|Non-narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours"
9469229|NCT03640221|Experimental|Experimental|will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide.
9469230|NCT03640221|Active Comparator|Active Comparator|will receive two bottles of Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)
9469231|NCT03640195|Experimental|Experimental group|Transcutaneous nerve electrical stimulation and Auricular acupressure.
10031335|NCT01767272|Other|fexofenadine 60 mg|First dose strength
10031336|NCT01767272|Other|fexofenadine 120 mg|Second dose strength
9469232|NCT03640195|No Intervention|Control group|without intervention
9469233|NCT03640182|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
9469234|NCT03640169|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
9469235|NCT03640156|Experimental|Oxytocin (OXT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
9469236|NCT03640156|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
9469237|NCT03640143||experimental group|children with clinical expression of lead poisoning data about venous blood lead will be reported
9469238|NCT03640130|Experimental|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
9469239|NCT03640104|Experimental|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
9469240|NCT03640104|Other|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
9469241|NCT03640091|Experimental|Pre-extractive inter-radicular implant bed preparation|
9469242|NCT03640078|Experimental|experimental group|Vasculitis patients The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis of serum. (acquisition imaging)
9469243|NCT03640065|Experimental|freeze-dried probiotic sachets|
9469244|NCT03640065|Active Comparator|fermented dairy product (yogurt)|
9469245|NCT03640039|Experimental|study group: 3d strut plate fixation without post op IMMF.|Open reduction and internal fixation with 3d strut plate without post operative IMMF.
9469246|NCT03640039|Active Comparator|control group: 3d srut plate fixation with post op IMMF.|Open reduction and internal fixation with 3d strut plate with post operative IMMF for 15 days.
9469247|NCT03640026|Experimental|Tacrolimus treatment|
9469248|NCT03640013|Experimental|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
9469249|NCT03640013|Other|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
9469250|NCT03640000|Experimental|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
10031337|NCT01767272|Other|fexofenadine 180 mg|Third dose strength
10031338|NCT01767272|Other|fexofenadine 240 mg|Fourth dose strength
10031339|NCT01767272|Other|fexofenadine 360 mg|Fifth dose strength
10031340|NCT01767298|Other|Valsartan 320 mg alone|Valsartan alone
9469251|NCT03639974|Active Comparator|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
9469252|NCT03639974|Active Comparator|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
9469253|NCT03639974|Sham Comparator|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
9469254|NCT03639961|Experimental|Staff of facilities for intervention|Intervention: Participants have been trained two times in six months period with integrated leading, managing and governing for results model.
9469255|NCT03639961|Active Comparator|Staff of facilities for control|Intervention: Participants have been trained two times in six months period with traditional model.
9469256|NCT03639922|Active Comparator|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
9469257|NCT03639922|Placebo Comparator|Placebo|2 placebo tablets per day for 6 days
9469258|NCT03639909||MSA-P|Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
9469259|NCT03639909||PD patients|Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
9469260|NCT03639896|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
9803071|NCT04594239|Other|Untreated-control / delayed-treatment, needle|
10031341|NCT01767298|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide alone
10031342|NCT01767298|Other|Valsartan 320 mg + Hydrochlorothiazide 25 mg|Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg
10037048|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch A|
9469261|NCT03639896|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
10031343|NCT01767298|Other|Valsartan / Hydrochlorothiazide 320 mg/25mg|Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg
9469262|NCT03639883|Placebo Comparator|0.033% versus Vehicle|One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
9469263|NCT03639883|Placebo Comparator|0.1% versus Vehicle|One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
9469264|NCT03639883|Placebo Comparator|0.3% versus Vehicle|One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
9469265|NCT03639883|Placebo Comparator|1% versus Vehicle|One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
9469266|NCT03639870|Experimental|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
9469267|NCT03639831|Experimental|Active group|Proprietary, standardized botanical extract
9469268|NCT03639831|Placebo Comparator|Placebo group|Placebo (maltodextrin)
9469269|NCT03639818|Experimental|experimental group|HIV patients
9469270|NCT03639805|Active Comparator|non interventional arm|Standard Of Care
9469271|NCT03639805|Experimental|interventional arm|Standard of Care + music therapy program MUSIC CARE®
9469272|NCT03639753|Experimental|Parent-Teen Intervention|Parent health coaching session and supportive materials, teen on road driver assessment with feedback.
9469273|NCT03639753|Other|Usual Practice|
9469274|NCT03639740|Other|Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor|Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor
9469275|NCT03639727|Active Comparator|Citric acid aerosol bronchial challenge|Inhaled citric acid aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is citric acid aerosol challenge.
9469276|NCT03639727|Active Comparator|Mannitol aerosol bronchial challenge|Inhaled mannitol aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is mannitol aerosol challenge.
9469277|NCT03639714|Experimental|Phase 1|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
9469278|NCT03639714|Experimental|Phase 2 Cohorts|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
9469279|NCT03639701|Experimental|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
9469280|NCT03639688|Active Comparator|Left sided|
9469281|NCT03639688|Active Comparator|Right sided|
9469282|NCT03639662|Experimental|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
9469283|NCT03639662|No Intervention|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
9469284|NCT03639649|Experimental|STHLM3|
9469285|NCT03639649|Active Comparator|PSA|
9469286|NCT03639636|Other|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
9469287|NCT03639597|Experimental|Study device|VytronUS Ablation System
9469288|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
9469289|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
9469290|NCT03639584||Group 3|Patients admitted to ICU 3~7 days. Take blood sample on the day of enrollment.
9469291|NCT03639584||Group 4|Patients admitted to ICU 8~14 days. Take blood sample on the day of enrollment.
9469292|NCT03639584||Group 5|Patients admitted to ICU 15~28 days. Take blood sample on the day of enrollment.
10031344|NCT01767311|Experimental|Core Study: Lecanemab 2.5 mg/kg biweekly|2.5 mg/kg biweekly
10031345|NCT01767311|Experimental|Core Study: Lecanemab 5.0 mg/kg biweekly|5.0 mg/kg biweekly
10031346|NCT01767311|Experimental|Core Study: Lecanemab 10 mg/kg biweekly|10 mg/kg biweekly
10031347|NCT01767311|Experimental|Core Study: Lecanemab 5.0 mg/kg monthly|5.0 mg/kg monthly
10031348|NCT01767311|Experimental|Core Study: Lecanemab 10 mg/kg monthly|10 mg/kg monthly
10031349|NCT01767311|Placebo Comparator|Core Study: Lecanemab-matched Placebo|Matching placebo biweekly
9469293|NCT03639571|Experimental|Test|Ibuprofen 200mg TEPI medicated plaster
9469294|NCT03639571|Placebo Comparator|Placebo|Placebo TEPI Plaster
9469295|NCT03639558|Active Comparator|Haloperidol + Promethazine + Chlorpromazine|
9469296|NCT03639558|Experimental|Haloperidol + Promethazine|
9469297|NCT03639545|Active Comparator|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
9469298|NCT03639545|Active Comparator|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
9469299|NCT03639545|Active Comparator|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
9469300|NCT03639545|Placebo Comparator|*placebo*|placebo for 12 weeks, once daily with water, by mouth
9469301|NCT03639532|Experimental|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
9469302|NCT03639532|Active Comparator|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
9469303|NCT03639519|Experimental|Ascorbic acid|Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
9469304|NCT03639519|Placebo Comparator|Placebo group|will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.
9469305|NCT03639506|Experimental|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
9469306|NCT03639506|Active Comparator|ICSI|only has intracytoplasmic sperm injection (ICSI)
9469307|NCT03639493|Experimental|Sequence 1|"Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg~Period 2: receive CJ-30060 10/160/20mg"
9469308|NCT03639493|Experimental|Sequence 2|"Period 1: receive CJ-30060 10/160/20mg~Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg"
9469309|NCT03639480|Experimental|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
9469310|NCT03639480|Active Comparator|Reference 1|Amlodipine 10mg+Valsartan 160mg
9469311|NCT03639480|Active Comparator|Reference 2|Valsartan 160mg+Atorvastatin 40mg
9469312|NCT03639467|Experimental|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
9469313|NCT03639454|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9469314|NCT03639454|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9469315|NCT03639441|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9469316|NCT03639441|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9469317|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
10031350|NCT01767311|Experimental|Extension Phase: Lecanemab 10 mg/kg|All participants who fulfill Extension phase inclusion and exclusion criteria will have the option to participate in the Extension phase to receive lecanemab 10 mg/kg biweekly for up to 60 months or until the drug is commercially available in the country where the subject resides, or until the benefit-to-risk ratio from treatment with lecanemab is no longer considered favorable, whichever comes first.
10031351|NCT01767324|Experimental|Injection to deltoid|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
10031352|NCT01767324|Experimental|Injection to forearm|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
10031353|NCT01767324|Experimental|Injection to thigh|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
10031354|NCT01767337|Experimental|injection of 0.1 mL saline|deliver from FluGen 101.2 device
10031355|NCT01767337|Experimental|injection of 0.25 mL saline|deliver from FluGen 101.2 device
10031356|NCT01767337|Experimental|Injection of 0.5 mL saline|deliver from FluGen 101.2 device
10031357|NCT01767350||children with organ transplant|Subjects who received an solid organ transplant at our institution at the age of 0-19 yrs and who were subject to pharmacokinetic evaluation during their follow up. Additional blood withdrawal for DNA will be performed
10031358|NCT01767363||5-alpha reductase inhibitors with or without alpha-blockers|Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
10031359|NCT01767363||Alpha-blockers|Men using alpha-blockers over the course of the study period.
10031360|NCT01767389||Type 2 diabetes patients taking antidiabetic agents|Subjects should also have at least 1 claim of T2D diagnosis identified using ICD-9 codes 250.x0 or 250.x2 (excluding 250.x1 and/or 250.x3 - Type 1 diabetes and 648.0x - gestational diabetes).
10031361|NCT01767402|Experimental|PhtD Group 1|Subjects will receive PhtD vaccine formulation 1 without any adjuvant.
10031362|NCT01767402|Experimental|PhtD Group 2|Subjects will receive adjuvanted PhtD vaccine formulation 2.
10031363|NCT01767402|Experimental|PhtD Group 3|Subjects will receive adjuvanted PhtD vaccine formulation 3.
10031364|NCT01767402|Experimental|PhtD Group 4|Subjects will receive adjuvanted PhtD vaccine formulation 4.
10031365|NCT01767402|Experimental|PhtD Group 5|Subjects will receive adjuvanted PhtD vaccine formulation 5.
10031366|NCT01767402|Active Comparator|23 PPV Group|Subjects will receive the Pneumovax 23TM vaccine and NaCl.
10031367|NCT01767428|Experimental|Experimental Paracetamol Tablet|Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water.
9469318|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
9469319|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
10031368|NCT01767428|Active Comparator|Standard Paracetamol Tablet (500 mg)|Standard paracetamol tablet (500 mg) administered with 240 mL of water.
10031369|NCT01767441||Roux-en-Y-gastric bypass|morbidly obese subjects undergoing gastric bypass surgery
9469320|NCT03639415|Experimental|controlled-release oxycodone group|"Patients with moderate to severe pain accept CR oxycodone treatment and if any follow situations appears, then change the dose frequency from every 12 hours to every 8 hours or 6 hours.~Patients are satisfied with the pain control, but unable to tolerate nausea、vomit or dizziness, and can't get satisfactory pain control if reducing the CR oxycodone dose.~Patients are unsatisfied with the pain control, but can't increase the CR oxycodone dose because of intolerable nausea、vomit or dizziness."
10031370|NCT01767441||gastric banding|morbidly obese subjects undergoing laparoscopic adjustable gastric banding
9469321|NCT03639402|Experimental|Health education classes|"Intervention consist of 2 rounds. Round 1: Locally selected mothers who have children 1-9 years old are trained by research team (peer mothers). Peer mothers conduct 4 education classes each for approximately 10 eligible mothers in their neighbourhood (fellow mothers).~Round 2: After one month gap one meeting for recapitulation and feedback is conducted by research team for peer mothers. Similarly, peer mothers conduct one meeting with fellow mothers."
9469322|NCT03639402|No Intervention|No health education classes|Community is exposed to health-related information, which is provided by the regular health system of Nepal
9469323|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
9469324|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
9469325|NCT03639363|Experimental|Intervention Arm|daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
9469326|NCT03639363|Active Comparator|Control Arm|daily bathing with standard soap
9469327|NCT03639350|Experimental|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
9469328|NCT03639350|Active Comparator|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
9803072|NCT04594239|Other|Untreated-control / delayed-treatment, cannula|
10031371|NCT01767441||sleeve gastrectomy|morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
10031372|NCT01767441||control group|morbidly obese subjects not undergoing bariatric surgery, on diet treatment
10031373|NCT01767454|Experimental|Doublet arm|Subjects will be started with dabrafenib 150 mg twice daily (BID) orally for 2 weeks (run-in). The doublet arm will comprise 2 cohorts. Cohort A1 (Dabrafenib 150 mg BID + ipilimumab). Cohort A-1 (Dabrafenib 100 mg BID +ipilimumab). Ipilimumab will be administered as 3 mg/kg every 3 weeks (Q3W) for a total of 4 infusions over approximately 12-16 weeks. Dabrafenib will be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
10031374|NCT01767454|Experimental|Triplet arm|This arm will be initiated using dabrafenib and ipilimumab doses established in the doublet dose-finding. Subjects will be started with dabrafenib and trametinib orally for 2 weeks (run-in), followed by ipilimumab 3 mg/kg Q3W for a total of 4 infusions over approximately 12-16 weeks. The triplet arm will comprise 3 planned cohorts. Cohort B-1: Dabrafenib 100 mg BID + trametinib 1 mg once daily + ipilimumab, Cohort B1: Dabrafenib 150 mg BID + trametinib 1 mg once daily+ ipilimumab, Cohort B2: Dabrafenib 150 mg BID + trametinib 2 mg once daily + ipilimumab. Dabrafenib and trametinib wil be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
10031375|NCT01767480|Experimental|Higher-intensity RT group|All participants received a duration-matched intervention for 90-120 minutes/day, 5 days/week for 4 consecutive weeks. For the RT groups, they will receive RT training together with functional rehabilitation trainings. Within 1 training session, each patient in the higher-intensity RT group will use Bi-Manual-Tract to practice 400-600 repetitions of the mode 1 and 800-1000 repetitions of mode 2, totaling 1200-1600 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 100-200 repetitions in mode 3, if application.
10031376|NCT01767480|Experimental|Lower-intensity RT group|Patients in the lower-intensity RT received half the number of the repetitions per unit of time than patients in the higher-intensity RT group. Within 1 training session, patients in the lower-intensity RT group will practice 200-300 repetitions of the mode 1 and 400-500 repetitions of mode 2, totaling 600-800 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 50-100 repetitions in mode 3, if application.
10031377|NCT01767480|Active Comparator|Conventional rehabilitation (CR) group|The CR group will be designed to control for the duration of therapeutic activities. CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
10031378|NCT01767532|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
10031379|NCT01767532|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
10031380|NCT01767545|Active Comparator|Dexamethasone-implant (Group 1)|Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.
10031381|NCT01767545|Active Comparator|Bevacizumab/Dexamethasone-implant (Group 2)|Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.
10037049|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch B|
10031382|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
10031383|NCT01767571|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
9469329|NCT03639337|Experimental|Allergic Children|"Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo.~Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63"
10031384|NCT01767571|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
10031385|NCT01767584|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
10031386|NCT01767584|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
10031387|NCT01767610|Experimental|micronized fenofibrate|
10031388|NCT01767610|Experimental|pitavastatin Ca|
9469330|NCT03639337|No Intervention|Not confirmed Allergic Children|Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.
9469331|NCT03639337|No Intervention|Controls|Healthy controls ages between 10 and 14 months
9469332|NCT03639298|Experimental|training|children submitted to the Intendu training with motion based cognitive video games software
9469333|NCT03639298|No Intervention|no training|children not submitted to the training, entering the study as a control group
10031389|NCT01767610|Experimental|micronized fenofibrate plus pitavastatin Ca|
10031390|NCT01767623|Active Comparator|Cohort 1: Participants with Normal Liver Function|Participants with normal liver function (according to National Cancer Institute [NCI] liver dysfunction criteria) will receive vemurafenib 960 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
10037050|NCT01821248|Experimental|Gemcitabine, Cisplatin, S-1|1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7
10037598|NCT01826539|Other|Innervated finger flap|donor nerve attached with the flap for finger pulp reconstruction
9469334|NCT03639259||Post-stroke fatigue|Participants fulfilling criteria for presence of fatigue after cerebral stroke
9469335|NCT03639233|Other|Arm 1|Intervention access
9480199|NCT03536000||Intrauterine Growth restriction|"Pregnant women~Over 18 years~Intrauterine Growth Reestriction(IUGR): fetuses with percentile Growth <p3 or <p10 with vascular Doppler alteration.~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
9480200|NCT03536000||Preeclampsia|"Pregnant women~Over 18 years~Preeclampsia: elevated blood pressure + Ratio Prot/Creatinin in urine> 30 mg / mmol creatinin~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
9480201|NCT03536000||Diabetes Mellitus type 1|"Pregnant women~Over 18 years~Diabetes mellitus type1~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
9480202|NCT03535987||Observational|To determine the feasibility of using myocardial PET imaging
9480203|NCT03535961|Other|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
9480204|NCT03535935|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin
9480205|NCT03535935|Experimental|Add on astragalus powder|3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.
9480206|NCT03535896|Experimental|HSR and injection|HSR and corticosteroid injection
9480207|NCT03535883||patients taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
9480208|NCT03535883||patients not taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).
9480209|NCT03535870|Experimental|Fluticasone propionate/salmeterol|fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study
9480210|NCT03535870|Active Comparator|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
9480211|NCT03535870|Placebo Comparator|Placebo|placebo inhaled powder twice a day by inhalation throughout the study
9480212|NCT03535831|Experimental|18F-DCFPyL PET/ MR or PET/CT imaging|"Will use a newer technology called PET-MR that combines a Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. This new combined imaging test, where PET and MRI data is gathered at one time, will be performed on an integrated PET-MR scanner located at Toronto General Hospital.~Or technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.~Choice of imaging method (PET/CT or PET/MR) will be made by one of the study PIs, based on clinical judgement taking into account the specific exam indication, prior recent imaging, and suitability for MR imaging."
9480213|NCT03535818|Active Comparator|Redo pulmonary vein isolation|
10031391|NCT01767623|Experimental|Cohort 2: Participants with Severe Liver Dysfunction|Participants with severe liver dysfunction (according to NCI liver dysfunction criteria) will receive vemurafenib 720 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
10031392|NCT01767649||Caesarean|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
10031393|NCT01767649||Vaginal Delivery|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
10031394|NCT01767662|Experimental|manipulation|home program for parents manipulation
10031395|NCT01767662|Placebo Comparator|observe|observation
10031396|NCT01767714|Experimental|G-CSF + plerixafor|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.
10031397|NCT01767714|Placebo Comparator|G-CSF + Placebo|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.
10031398|NCT01767727|Other|Surgical flap|Surgical flap is based on the dorsal branch of the digital artery, and is used for soft tissue coverageof multiple finger defects.
10031399|NCT01767740|Experimental|ULTRABRAID PLUS SUTURE|ULTRABRAID Plus Suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
9469336|NCT03639220|Active Comparator|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
9469337|NCT03639220|Placebo Comparator|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
9469338|NCT03639207||1|Patients treated with ledipasvir/sofosbuvir in the Kaiser Permanente Northern California
9469339|NCT03639181|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
9469340|NCT03639168|Experimental|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
9469341|NCT03639155|Experimental|Regimen A|vadadustat reference tablets
9469342|NCT03639155|Experimental|Regimen B|vadadustat test tablets
9469343|NCT03639142|Experimental|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
9469344|NCT03639142|Active Comparator|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
9469345|NCT03639129|Experimental|Contrast-enhanced mammography (CME)|-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
9469346|NCT03639077|Experimental|Allograft bone alone|
9469347|NCT03639077|Experimental|Allograft and xenograft mixture|
9469348|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
9469349|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
9469350|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
9469351|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
9469352|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
9469353|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
9469354|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
9469355|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
9469356|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
9469357|NCT03639012|Active Comparator|Carbohydrate loading|Patients to receive an oral preoperative carbohydrate drink
9469358|NCT03639012|No Intervention|No Carbohydrate loading|Current standard of care
10031400|NCT01767740|Active Comparator|ULTRABRAID SUTURE|ULTRABRAID Suture is a marketed suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
10031401|NCT01767753|Experimental|Triggerfish|Device: Sensimed Triggerfish
9469359|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
9469360|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
9469361|NCT03638973|Experimental|Biopsy with Er: YAG|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser under previous local anesthesia
9469362|NCT03638973|Active Comparator|Biopsy with Scalpel|Biopsies taken with Er: YAG are compared with biopsies taken with a scalpel in patients with lichenoid or leukoplakic changes of the oral mucosa.
9469363|NCT03638960|Active Comparator|Bupivacaine|Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine.
9469364|NCT03638960|Experimental|Liposomal bupivacaine|Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.
9469365|NCT03638947|No Intervention|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
9469366|NCT03638947|Active Comparator|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
9469367|NCT03638934|Experimental|Videos about ACP|Subjects in experimental group get three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish watching the materials, they fill out the questionnaire.
9469368|NCT03638934|Active Comparator|Brochure for Life-Sustaining Treatment|Subjects in the group get 13-page brochure entitled, Understanding the Life-Sustaining Treatment Act. After they finish watching the materials, they fill out the questionnaire.
9480214|NCT03535818|Active Comparator|Ganglionated plexus ablation + redo pulmonary vein isolation|
10031402|NCT01767766|Experimental|TGR-1202|TGR-1202 Daily Oral Dose
10031403|NCT01767779||seizure free infants with dx of TSC|infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC
10031404|NCT01767779||Parents or family guardian of cohort 1|Parent or family guardian of infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC.
10031405|NCT01767805|Other|Type of incubator|Embryos are cultured in a standard incubator or a mini-incubator
10031406|NCT01767805|Other|Oxygen concentration|Embryos are cultured in an incubator with a gas mixture with 20% oxygen or with 5% oxygen
10031407|NCT01767818||Previously treated PD patients|220 subjects with PD treated and responsive to dopaminergic medication
10031408|NCT01767818||Previously untreated PD|20 subjects with de-novo, previously untreated PD confirmed by I-123 Ioflupane SPECT
9469369|NCT03638921|Experimental|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
9469370|NCT03638895|Active Comparator|ECAL group|Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
9469371|NCT03638895|Placebo Comparator|SC group|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
9469372|NCT03638882|Experimental|Duolingo Spanish Course|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
9469373|NCT03638882|Active Comparator|BrainHQ|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
9469374|NCT03638882|Placebo Comparator|Passive Control|No intervention.
9469375|NCT03638869|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
9469376|NCT03638869|Experimental|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469377|NCT03638869|Experimental|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469378|NCT03638869|Experimental|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469379|NCT03638856|Experimental|Misoprostal group|Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy
9469380|NCT03638856|No Intervention|Placebo group|Patients were take placebo 2 tab per oral 3 hour before hysteroscopy
9469381|NCT03638843|Experimental|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
9469382|NCT03638830|Experimental|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
9469383|NCT03638830|Experimental|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
9469384|NCT03638830|Placebo Comparator|Group 3|placebo (like full dose) in combination with the drug Maxipime®
9469385|NCT03638804|Experimental|89Zr-KN035 injection|
9469386|NCT03638778|Active Comparator|Oral semaglutide (reference)|Participants will receive oral semaglutide (reference) for 10 days.
9469387|NCT03638778|Experimental|Oral semaglutide formulation B|Participants will receive oral semaglutide formulation B for 10 days.
9469388|NCT03638778|Experimental|Oral semaglutide formulation C|Participants will receive oral semaglutide formulation C for 10 days.
9469389|NCT03638778|Experimental|Oral semaglutide formulation D|Participants will receive oral semaglutide formulation D for 10 days.
9469390|NCT03638765|Experimental|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
9469391|NCT03638752|Experimental|Comprehensive education group|"The details of Comprehensive education are as follows:~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
9469392|NCT03638752|No Intervention|standard education|"The details of standard education are as follows:~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
9469393|NCT03638739|Experimental|Exercise|Participants will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS for 12 weeks at McMaster University. Following this, they will return to their normal daily activities for a further 12 weeks.
9469394|NCT03638739|Experimental|Wait-list Control|Participants will engage in their usual daily activities for the first 12 weeks of the study, then will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS at McMaster University for the 2nd 12 weeks.
10031409|NCT01767818||Healthy age-matched controls|46 age-matched healthy controls will be studied.
10037599|NCT01826552|Experimental|Orsiro|The Patient group who are treated with Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
10031410|NCT01767831||Group A: CGM monitoring (1) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
9469395|NCT03638726|Experimental|Atropine sulfate and Epinephrine|Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).
10031411|NCT01767831||Group B: CGM monitoring (2) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
10031412|NCT01767844|Experimental|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
10031413|NCT01767844|Placebo Comparator|Fruit powder drink|A regular fruit flavoured powder that has no benefits
10031414|NCT01767870|Experimental|FIT-Sigmoidoscopy|This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.
10031415|NCT01767870|Experimental|Colonoscopy|This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.
9469396|NCT03638726|Other|Topical cyclopentolate and phenylephrine|Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.
9469397|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ angled tip|Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
9469398|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ angled tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
9469399|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ straight tip|Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
9469400|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ straight tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
9469401|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
9480215|NCT03535805|Experimental|Mind My Mind (MMM)|Mind My Mind (MMM)
10031416|NCT01767883|Experimental|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation"
10031417|NCT01767883|Active Comparator|Clinical Decision Support Only|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support System~Academic detailing concerning the rationale for the algorithms"
10031418|NCT01767896|Experimental|ASP7374 group|cell-culture-derived vaccine group
10031419|NCT01767896|Active Comparator|TIV group|approved egg-derived TIV group
10031420|NCT01767922|Experimental|Extramel 10 mg - 140 UI SOD|This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
10031421|NCT01767922|Placebo Comparator|Placebo - exipients only|This arm receives daily one capsule Placebo containing excipients only.
10031422|NCT01767948|Experimental|Patients with mild hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
10031423|NCT01767948|Experimental|Patients with moderate hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
10031424|NCT01767948|Experimental|Patients with severe hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
10031425|NCT01767948|Experimental|Patients with normal hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
10031426|NCT01767961|Experimental|Diagnostic (modified barium swallow)|Patients undergo the modified barium swallow, comprising swallowing boluses of thin liquid barium, barium honey, barium pudding, and barium crackers while undergoing fluoroscopic imaging.
10031427|NCT01767974||Non-Small Cell Lung Cancer|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
10031428|NCT01768026||No treatment|Subjects diagnosed with Dystrophic Epidermolysis Bullosa
10031429|NCT01768039|Active Comparator|Vitamin D|treatment with weekly 50000IU vitamin D
10031430|NCT01768039|Placebo Comparator|Placebo|Treatment with placebo
10031431|NCT01768052||functional Near Infrared Spectroscopy|Noninvasive functional Near Infrared Spectroscopy (fNIRS) monitoring will take place during patients' clinical rTMS treatment sessions.
10031432|NCT01768065|Experimental|Nasal Expiratory Positive Airway Pressure Devices|Nasal Expiratory Positive Airway Pressure Device
10031433|NCT01768065|Sham Comparator|placebo sham|A sham device
10031434|NCT01768078|Experimental|with corticoids|
10031435|NCT01768078|Other|without corticoids|
10031436|NCT01768091|Experimental|POEM|POEM for patients with esophageal achalasia
10031437|NCT01768091|Active Comparator|Pneumatic dilation|Pneumatic dilation for patients with esophageal achalasia
9469402|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
9469403|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
9469404|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
10031438|NCT01768104|Experimental|ESTD|Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
9469405|NCT03638661|Experimental|n-3 fatty acid enriched formula|"Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).~vegetable (canola, flaxseed) derived n-3 fatty acid"
9469406|NCT03638661|Placebo Comparator|soybean oil used formula|"Patients assigned to the control group received a soybean used formula by tube feeding.~soybean used formula"
9469407|NCT03638648|Active Comparator|Low risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk receiving capecitabine.
9469408|NCT03638648|No Intervention|Low risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk NOT receiving any additional chemotherapy.
9469409|NCT03638648|Experimental|High risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk receiving capecitabine.
9469410|NCT03638648|No Intervention|High risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk NOT receiving any additional chemotherapy.
9469411|NCT03638609|No Intervention|Control|Group of patients not receiving IABP
9469412|NCT03638609|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
9469413|NCT03638596|Experimental|Contingency Management|Incentive delivery contingent upon maintaining transdermal alcohol concentration below cut-off
9469414|NCT03638596|Placebo Comparator|Control|Incentive delivery not contingent on transdermal alcohol concentration
9480216|NCT03535805|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU)
10031439|NCT01768104|Active Comparator|VATS|Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
10031440|NCT01768143||Nurse Trainees|unexperienced endoscopy nurses
10031441|NCT01768143||Nurse Experts|Educated endoscopy Nurses
10031442|NCT01768156|Experimental|Study arm|
10031443|NCT01768169||fish oil capsule|10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
10031444|NCT01768182|Experimental|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
10031445|NCT01768182|Placebo Comparator|Placebo|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
10031446|NCT01768195|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
10031447|NCT01768208|Experimental|Saxagliptin|
10031448|NCT01768221|Other|Caregiver intervention|
10031449|NCT01768234|Experimental|Supplemental water|This arm receives up to 2 L of supplemental water during the course of the testing day.
10031450|NCT01768234|No Intervention|Control|No supplemental water provided
10031451|NCT01768247|Experimental|HCG priming|Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
10031452|NCT01768260|Active Comparator|Enhanced External conterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
10031453|NCT01768260|Active Comparator|aspirin|The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
10031454|NCT01768273|Experimental|Midazolam and 824|2 mg midazolam (oral syrup) Day 1 and Day 17. 400 mg PA-824 once daily Day 4 - 17.
10031455|NCT01768299|Experimental|Mifepristone at home 24 hours before miso dosing starts|"All women will receive study packet one containing mifepristone to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
10031456|NCT01768299|Experimental|Mifepristone and first dose of misoprostol simultaneously.|"Will receive study packet one containing placebo to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
10031457|NCT01768312|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
10031458|NCT01768312|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
10031459|NCT01768338|Experimental|Ofatumumab combined with SB-485232|Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
10031460|NCT01768351|Active Comparator|Control|Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
10031461|NCT01768351|Experimental|Paricalcitol|Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.
10031462|NCT01768364|Active Comparator|Antibiotics|will receive antibiotics
10031463|NCT01768364|Active Comparator|No antibiotics|will not receive antibiotics
10031464|NCT01768377|Active Comparator|Intubation with sedation|Sedation with midazolam and analgesia with fentanyl
9803073|NCT04581343|Experimental|Canakinumab, spartalizumab, nab-paclitaxel and gemcitabine|Spartalizumab (PDR001),IV infusion, 400 mg, D1 of each 28-day cycle; Canakinumab (ACZ885), s.c. injection, 250 mg, Day 1 of each 28- day cycle; Gemcitabine, IV Infusion, 1000 mg/m2, Days 1, 8, 15 of each 28-day cycle; Nab-paclitaxel, IV Infusion, 125 mg/m2, Days 1, 8, 15 of each 28-day cycle.
10031465|NCT01768377|Experimental|Intubation with Nerve block|Laryngeal plus supraglottic plus intratracheal nerve block plus sedation with midazolam
9803074|NCT04580771|Experimental|Treatment (radiation therapy, cisplatin, PDS0101)|Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin IV over 4 hours QW during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity. Patients also receive PDS0101 SC on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
9469415|NCT03638557|Experimental|Intervention|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
9469416|NCT03638544|Active Comparator|Reduced Gluten-Normal Gluten|
9469417|NCT03638544|Active Comparator|Normal Gluten-Reduced Gluten|
9469418|NCT03638531|Experimental|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
9469419|NCT03638531|Sham Comparator|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
9469420|NCT03638518|Experimental|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
9469421|NCT03638518|Experimental|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
9469422|NCT03638518|No Intervention|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
9469423|NCT03638505||patients|patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
9469424|NCT03638505||caregiver|the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
9469425|NCT03638492|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
9469426|NCT03638492|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
9469427|NCT03638479||Parkinson's Disease|Participant's diagnosed with Parkinson's Disease
9469428|NCT03638479||Essential Tremor|Participant's diagnosed with Essential Tremor or other Movement Disorders
9803075|NCT04579211||Adults with a diagnosis of CF with history of negative NTM sputum cultures|Male or female participants age 18 or greater at time of enrollment with diagnosis of CF consistent with the 2017 CFF Guidelines and NTM culture status of negative, as defined by a review of at least 3 year or more years of culture data and at least 3 NTM negative cultures with one of those negative cultures being within the last 3 years and no known history of previous positive cultures for pathogenic NTM by chart review.
9469429|NCT03638479||No Parkinson's Disease and No Essential Tremor|Participant's with no diagnosis of PD, ET or other Movement Disorders
9469430|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
9469431|NCT03638414|Experimental|Group 1 - Interventional Treatment|This group will be given the ePainQ questionnaire and an interview.
10031466|NCT01768390|Experimental|5000 Test|Twice daily use of a toothpaste containing 5,000 ppm fluoride
10031467|NCT01768390|Active Comparator|1450 GCP|Twice daily use of a toothpaste containing 1,450 ppm fluoride
10031468|NCT01768429|Experimental|Fatty fish|Four fatty fish meals per week
10031469|NCT01768429|Experimental|Lean Fish|Four lean fish meals per week
9469432|NCT03638414|No Intervention|Group 2 - Usual care|This group will be receiving normal routine care without the study intervention
9469433|NCT03638401|No Intervention|Standard treatment|
9469434|NCT03638401|Active Comparator|Intervention arm|
10031470|NCT01768429|Experimental|Alpha-linolenic acid|10 g of alpha-linolenic acid daily from camelina sativa oil
9469435|NCT03638388|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
9469436|NCT03638388|Active Comparator|Dry Needling with Intramuscular electrical stimulation (DNES)|"Subjects will receive dry needling treatment with electrical stimulation, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
10031471|NCT01768429|Experimental|Control diet|Limited fish and alpha-linolenic acid intake
10031472|NCT01768455|Experimental|Gemigliptin and Glimepiride|Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride
10031473|NCT01768455|Experimental|Glimepiride|Single administration of glimepiride
10031474|NCT01768468|Experimental|LAYLA|Drug : LAYLA tablet/ bid
9469437|NCT03638375|Experimental|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
10031475|NCT01768468|Active Comparator|JOINS|Drug : JOINS tablet/ tid
10031476|NCT01768481|Experimental|Statin|Atorvastatin 10 mg every day for one year
9469438|NCT03638375|Experimental|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.~IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
9469439|NCT03638362|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
9469440|NCT03638362|Experimental|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
9469441|NCT03638336|Experimental|flexible ureteroscopy|
9469442|NCT03638310|Experimental|ITG (intratympanic gentamicin) group|Patients who underwent prehabituation by gentamicin prior to surgery for vestibular schwannoma. They underwent intratympanic application of gentamicin and microsurgical removal of vest. schwannoma.
9469443|NCT03638310|Active Comparator|control group|patients without prehabituation before surgery. They underwent microsurgical removal of vest. schwannoma.
9469444|NCT03638297|Experimental|PD-1 antibody + cox inhibitor|BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
9469445|NCT03638284|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
9469446|NCT03638271|Other|nonischemic cardiomyopathic patient|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging.
9469447|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
9469448|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
9469449|NCT03638232||Patients with multiple myeloma|"Data to be collected are :~Drug exposition data~Administrative data~Medical data"
10031477|NCT01768481|Placebo Comparator|Sugar pill|Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
10031478|NCT01768507|Placebo Comparator|Placebo|no medication
10031479|NCT01768507|Experimental|Resveratrol|Trans-resveratrol (Resveratrol - Terraternal®): 5 g (10 capsules) as single oral dose on day 1 of the investigation period.
10031480|NCT01768533||Survey|A lifestyle survey was administered to primary-care givers or legal guardians who take their children 4-10 y/o to the pediatric well-child visits.
10031481|NCT01768546|Experimental|Video on Demand (VOD)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD arm of the study received access to a paper tracker to track food and activity during the program.
10031482|NCT01768546|Experimental|Video on Demand Plus (VOD+)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD+ arm of the trial received access an interactive tracking and problem solving web portal offered by SparkPeople™ (Cincinnati, Ohio).
10031483|NCT01768585|Active Comparator|Ivabradine|Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor
10031484|NCT01768585|Placebo Comparator|Placebo|Drug: Placebo bid placebo Other Name: Placebo control
10031485|NCT01768598||Fracture - Boys|Boys who have sustained a distal radius fracture
10031486|NCT01768598||Fracture - Girls|Girls who have sustained a distal radius fracture
10031487|NCT01768598||Non Fracture - Boys|Boys who have not sustained a distal radius fracture
10031488|NCT01768598||Non Fracture - Girls|Girls who have not sustained a distal radius fracture
10031489|NCT01768611||Withou Diabetic Nephropathy|Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).
10031490|NCT01768611||Incipient Nephropathy|Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
10031491|NCT01768611||Overt Diabetic Nephropathy|Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.
10031492|NCT01768624||Stage 5 chronic kidney disease|Patients receiving home hemodialysis Patients receiving home peritoneal dialysis Patients receiving center-based hemodialysis Patients who had a pre-emptive kidney transplant Patients who planned for renal conservative care
10031493|NCT01768650|Experimental|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
10031494|NCT01768650|Experimental|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
10031495|NCT01768663|Experimental|Treatment Group (Cohort 1)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21.
10031496|NCT01768663|Experimental|Treatment Group (Cohort 2)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21.
10031497|NCT01768663|Experimental|Treatment Group (Cohort 3)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24.
10031498|NCT01768663|Experimental|Treatment Group (Cohort 4)|Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days.
10031499|NCT01768689|No Intervention|Run-in period|First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
10031500|NCT01768689|Experimental|Adherence-encouraging period|"Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions:~adherence-encouraging interventions - Group meetings~adherence-encouraging interventions - Individual meetings~adherence-encouraging interventions - Monthly phone calls~Patient will receive routine treatment for CML according to the physician discretion."
10031501|NCT01768702|Sham Comparator|Control|Sham, no injection
10031502|NCT01768702|Experimental|C3BS-CQR-1 Treated|Injection of C3BS-CQR-1
10031503|NCT01768715||Good response|Patients with severe alcoholic hepatitis and good response to therapy.
10031504|NCT01768715||Non transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation, according to the specified criteria.
10031505|NCT01768715||Transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation, according to the specified criteria.
10031506|NCT01768728|Active Comparator|Laparoscopic left hemihepatectomy group|Group of patients that are operated with laparoscopic left hemihepatectomy
10031507|NCT01768728|Active Comparator|Open left hemihepatectomy|Group of patients operated with open left hemihepatectomy
10031508|NCT01768741|Active Comparator|Laparoscopic liver resection group|
10031509|NCT01768741|Active Comparator|Open liver resection|
10031510|NCT01768754||COPD patients|Usual and Fast Walking Speeds
10031511|NCT01768767|Experimental|Ketamine/Lithium|Participant will receive ketamine/lithium
10031512|NCT01768767|Active Comparator|Ketamine|Participant will receive ketamine
10031513|NCT01768767|Placebo Comparator|Placebo|Participant will receive placebo
10031514|NCT01768780|Experimental|sensory nerve block level of spinal anesthesia|This test group and the control group. Because within the group in two ways to check the level after spinal anesthesia will be.
10031515|NCT01768793|Experimental|Parents As Teachers + Lifestyle Int.|Participants assigned to this group will receive Parents As Teachers Plus (PAT+). This will be a diet and physical activity lifestyle intervention integrated within the standard Parents As Teachers home visiting curriculum. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
10031516|NCT01768793|Active Comparator|Standard Parents as Teachers (PAT)|Participants assigned to this group will receive the standard Parents As Teachers (PAT) home visiting curriculum, focusing on parenting and child development. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
10031517|NCT01768806|Experimental|P.L.A.Y. Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
9469450|NCT03638206|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
9469451|NCT03638193|Experimental|CART-meso cells|A single dose of CART-meso T cells will be administered intravenously.The dose is 1-3×10^7/m^2 CART positive cells(chort 1)or 1-3×10^8/m^2 CART positive cells(chort 2).
9469452|NCT03638180|Experimental|Single Ascending Doses|Single ascending doses, 6 dose levels
9469453|NCT03638180|Experimental|Multiple Ascending Doses|Multiple ascending doses, 3 dose levels
9469454|NCT03638154|Placebo Comparator|GroupI|safety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
9469455|NCT03638154|Active Comparator|GroupII|"safety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane.~(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
9469456|NCT03638115|Experimental|VaSecure™ Drug Coated PTA Balloon Catheter|
10031518|NCT01768806|Active Comparator|Special Education Pre-school|Special education pre-school services include 10-12 hours per week of special education preschool, occupational therapy, and speech and language therapy. No intensive intervention is provided.
10031519|NCT01768819|Experimental|Intervention Group|Physical Activity
9469457|NCT03638102|Experimental|Sleep intervention|Sleep extension
9469458|NCT03638102|Active Comparator|Healthy living|Health education
9469459|NCT03638089|Experimental|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
9469460|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，bid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.
9469461|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，tid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg three times daily for 48 weeks .
9469462|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
9469463|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
9469464|NCT03638063||Control|healthy controls
9469465|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
9469466|NCT03638037||Study|69 women, delivered preterm babies (less than 37weeks).
9469467|NCT03638037||Control|69 women, delivered at term (38-42 weeks) of full tem babies.
10031520|NCT01768819|No Intervention|Control Group|
10031521|NCT01768884|Experimental|Nitric oxide inhalation + standard treatment|Inhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
10031522|NCT01768884|Placebo Comparator|Standard treatment|Standard treatment
10031523|NCT01768897|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|"Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
10031524|NCT01768910|Experimental|Healthy controls|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
10031525|NCT01768910|Experimental|MS with OAB|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
9469468|NCT03638024||Study group|Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
9469469|NCT03638024||Control group|Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
9469470|NCT03637998|Experimental|PROPEL|The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
9469471|NCT03637985|Experimental|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
9469472|NCT03637985|Experimental|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
10031526|NCT01768910|Experimental|MS without OAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
10031527|NCT01768910|Experimental|NNOAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
10031528|NCT01768910|Experimental|SCI with neurogenic detrusor overactivity|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
10031529|NCT01768923|Active Comparator|SDAI remission group|SDAI remission
10031530|NCT01768923|Active Comparator|Minimal disease activity group|Minimal disease activity remission
10031531|NCT01768936||eliminated infectious abdominal focus|
10031532|NCT01768936||persisting/progressing infectious abdominal focus|
10031533|NCT01768949|Other|Echocardiography|An echocardiography will be systematically realised in all the patients included in the study in order to evaluate whether any echocardiographic criterion exploring the right ventricle can predict the efficacy and/or safeness of recruitment maneuvers in patients suffering from acute respiratory distress syndrome.
10037051|NCT01821261|Experimental|Mouth Rinse 19668-012|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
10037052|NCT01821261|Active Comparator|Mouth Rinse 500347078842|"Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 10 ml of mouth rinse 500347078842 for 60 seconds and spit it out - do not swallow.~Attention: Toothpastes can stop mouth rinse from working. Rinse your mouth thoroughly with water and wait 5 minutes after brushing your teeth before using the mouth rinse. You can also use the mouthwash at a different time of day."
10037053|NCT01821261|Other|Toothpaste 035000513007|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner. Subjects in this arm will not use any mouth rinse.
9469477|NCT03637946|Experimental|SHOFU Beautifil II LS|Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)
9469478|NCT03637933|Active Comparator|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
10037054|NCT01821274|Experimental|topical Diltiazem Hydrochloride 2% Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
10037055|NCT01821274|Placebo Comparator|Vehicle Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
10037056|NCT01821274|Active Comparator|0.2% sodium lauryl sulfate (SLS)|0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
10037057|NCT01821274|Placebo Comparator|0.9% saline|0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
10037058|NCT01821287||CHD Infants|Infants with a single ventricle (Congenital Heart Disease) CHD admitted to Cincinnati Children's Hospital Medical Center (CCHMC) for neonatal medical management or surgical palliation
10037059|NCT01821287||Normal Controls|Healthy newborns (full-term infants with no known medical problems) recruited from Cincinnati Children's Hospital Medical Center (CCHMC) and private practices
10037060|NCT01821313|Experimental|Moderate exercise|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The moderate exercise group will begin with a five-minute warm-up, cycling at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the moderate group will cycle for 30 minutes at 65-70% of maximal heart rate. The subject will then complete a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
10037061|NCT01821313|Active Comparator|High Intensity Interval Exercise (HIIE)|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The subjects in the HIIE group will begin with a five-minute warm-up at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the HIIE group will perform 10, two-minute exercise bouts at 90-95% of maximal heart rate, with one minute of active recovery at 55% of maximal heart rate between each interval for a total of 30 minutes. They will complete the test with a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
10037062|NCT01821404|Placebo Comparator|Placebo|Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
10037063|NCT01821404|Experimental|Atorvastatin|Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
10037064|NCT01821430|Experimental|Pregabalin|Pregabalin 400mg / Day
10037065|NCT01821430|Placebo Comparator|Placebo Control|Placebo Tablet
10037066|NCT01821443|Experimental|Stereotactic Radiosurgery (SRS)|Stereotactic radiosurgery technique via Gamma Knife® Perfexion™ radiosurgical system
10037067|NCT01821456||Antiinfectives|To analyze the efficacy of antiinfectives at high risk patients
10037068|NCT01821469|Experimental|psychoeducation|psychoeducation (12 weeks)
10037069|NCT01821482|Experimental|A|After complete resection or TACE, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) (every 4 weeks)
10037070|NCT01821482|No Intervention|B|After complete resection or TACE, Patient only regularly follow up
10037071|NCT01821495|No Intervention|B|After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
10031534|NCT01768962|Active Comparator|Sequence A|2 weeks, 6 week washout, 2 weeks
10031535|NCT01768962|Active Comparator|Sequence B|2 weeks, 6 week washout, 2 weeks
10031536|NCT01768988|Experimental|Group I|Conventional analgesic treatment + pregabalin.
10031537|NCT01768988|Placebo Comparator|Group II|Conventional analgesic treatment + placebo.
10031538|NCT01769027|Active Comparator|SSRI+AB|Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ). Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
9469479|NCT03637933|Experimental|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
10031539|NCT01769027|Placebo Comparator|SSRI+placebo|Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
9469480|NCT03637920||transmen|Biological women, who identify as men and are seeking gender reassignment.
9469481|NCT03637894|Active Comparator|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
9469482|NCT03637894|Placebo Comparator|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
9469483|NCT03637894|Other|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.~The breastfeeding infants were the reference group"
9469484|NCT03637894|Active Comparator|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
9469485|NCT03637894|Placebo Comparator|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
9469486|NCT03637894|Other|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.~The breastfeeding infants were the reference group."
9469487|NCT03637881||Other|Daily or non-daily Consumers
9469488|NCT03637868|Experimental|Eribulin|eribulin 1.4 mg/m² administered intravenously between 6 and 7 cycles.
9469489|NCT03637829|Placebo Comparator|Control|250 mL of water
9469490|NCT03637829|Active Comparator|White Chocolate|White chocolate (40 g)
9469491|NCT03637829|Experimental|Dark chocolate 1|Dark chocolate (40 g)
9469492|NCT03637829|Experimental|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
9469493|NCT03637803|Experimental|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
9469494|NCT03637790|Other|PF 04965842|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
9469495|NCT03637790|Other|Rifampin and PF 04965842|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
9803076|NCT04579120||African American|African American participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
9803077|NCT04579120||Non-Hispanic White|Non-Hispanic White participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
9469496|NCT03637751|Experimental|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
10031540|NCT01769040|Experimental|Rifaximin|Rifaximin tablets for oral ingestion, 550 mg twice daily for 28 days.
10031541|NCT01769040|Placebo Comparator|Placebo tablets|Placebo tablets similar in shape and size to intervention treatment, 1 tablet twice daily for 28 days.
10031542|NCT01769053|Active Comparator|Variable Ventilation|Patients are ventilated with variable pressure support mode.
10031543|NCT01769053|No Intervention|Conventional (non-variable) Ventilation|Patients are ventilated with non-variable(conventional) pressure support ventilation mode.
10031544|NCT01769066|Experimental|Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1 Gefitinib PO. 250mg DAY3-16
9469497|NCT03637751|Experimental|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
9469498|NCT03637738|Experimental|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
9469499|NCT03637738|Active Comparator|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
9469500|NCT03637712|Experimental|Screening Colonoscopy|Patients undergoing standard screening or surveillance colonoscopy will be included
9480217|NCT03535792|Active Comparator|Fentanyl/Hyperbaric Bupivacaine|"Group F:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg) and will have Tibial internal fixation."
9469501|NCT03637634||NPC survivors|Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
9469502|NCT03637634||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.
10031545|NCT01769066|Active Comparator|Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1
9469503|NCT03637582|Active Comparator|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 4% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 4% lidocaine gel. The subject will then perform the second uroflow study.~Complex urodynamics with the use of lidocaine hydrochloride 4% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
9469504|NCT03637582|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
9469505|NCT03637569||Cancer patients|Newly diagnosed pancreatic, bile duct or GB cancer patients at samsung medical center.
9469506|NCT03637543|Experimental|PD-L1 Positive|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
10031546|NCT01769079|Active Comparator|oral nitrate|In nitrate group will be provided the same prescribed dose for this drug. One group remains on nitrate use and other on placebo (same number of pills) use.
10031547|NCT01769079|Placebo Comparator|Placebo|In the placebo group will be given the same dose and frequency prescribed nitrate.
9469507|NCT03637543|Experimental|PD-L1 Negative|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
9469508|NCT03637530|Experimental|intervention group|in this group of patients, inverse ratio ventilation is provided during general anaesthesia
9469509|NCT03637530|No Intervention|control group|in this group of patients, conventional ventilation is provided during general anaesthesia
10031548|NCT01769092|Experimental|Fish Oil|Each capsule contains 625 mg of fish oil (100 mg EPA & 250 mg DHA). Participants will take 12 capsules per day over 6 months.
10031549|NCT01769092|Placebo Comparator|Safflower Oil|Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
9469510|NCT03637504|Experimental|Interventional|web-based, mobile medication management application [MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
9469511|NCT03637504|No Intervention|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
10031550|NCT01769118||Caffeine|caffeine will be given according to clinical judgment
10031551|NCT01769131||Allis|
10031552|NCT01769131||Tenaculum|
10031553|NCT01769144|Active Comparator|Acticoat Absorbent|Acticoat Absorbent wound dressing
10031554|NCT01769144|Experimental|BCT wound dressing|wound dressing
10031555|NCT01769157|Active Comparator|L-carnitine|L-carnitine 330mg, 3 tablet twice daily
10031556|NCT01769157|Placebo Comparator|Placebo|placebo drug, 3 tablet twice daily
10031557|NCT01769183|Experimental|Squalamine|Study eyes will be assigned to receive Squalamine. The dose will be one drop twice daily. If neovascularization fails to regress at week one or if neovascularization returns within the study, the dose will be increased to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Patients will continue administering study drug until week 20.
10031558|NCT01769235|Experimental|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
10031559|NCT01769235|Active Comparator|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
10031560|NCT01769235|Placebo Comparator|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)
10031561|NCT01769261|Experimental|Internet, eligible patients|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
10031562|NCT01769261|Active Comparator|Telephone, eligible patients|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
10031563|NCT01769261|Other|" Non eligible patients"|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
10031564|NCT01769287||Surgical operation|The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.
9469512|NCT03637504|Other|Optional Extension|web-based, mobile medication management application [MedActionPlan® (MAP)]
9469513|NCT03637478|Experimental|Enhanced Systems of Care Team|The four intervention sites have been selected based on their size: taken together, their pediatric populations comprise over 80% of the total number of children receiving care at Cambridge Health Alliance. At the four intervention sites, the study will involve: 1) an integrated child mental health assessment done by the E-SOC team within primary care, 2) active follow-up, collaboration with specialty providers and support to families, 3) School, child welfare and other community linkages as appropriate.
9469514|NCT03637465|Experimental|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
9469515|NCT03637465|No Intervention|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
9803078|NCT04578834|Experimental|LNP023 200mg b.i.d|
9803079|NCT04578834|Placebo Comparator|Placebo to LNP023 200mg b.i.d|
9803080|NCT04571060|Active Comparator|BHV-3500|Zavegepant (BHV-3500)
10031565|NCT01769300|No Intervention|Control practices|Practices that do not use the ADHD clinical decision support
10031566|NCT01769300|Experimental|Clinical decision support|Electronic health record-based clinical decision support for ADHD medication titration.
10031567|NCT01769313|Experimental|Group A|In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
10031568|NCT01769313|Active Comparator|Group B|Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
9469516|NCT03637452||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
9469517|NCT03637452||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
9469518|NCT03637439|Experimental|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera & Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
9469519|NCT03637439|Sham Comparator|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
9469520|NCT03637426|Placebo Comparator|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
9469521|NCT03637426|Experimental|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
9469522|NCT03637426|Experimental|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
9469523|NCT03637426|Experimental|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
9469524|NCT03637413|Experimental|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
9469525|NCT03637400|Experimental|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
9469526|NCT03637400|Experimental|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (>100 kg) and four additional placebo tabs will be given to subjects > 100 kg randomized to doxycycline.
9469527|NCT03637387|Experimental|BIIB074|Administered orally three times daily (TID)
9469528|NCT03637387|Placebo Comparator|Placebo|Placebo matching BIIB074
9469529|NCT03637374|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
9480218|NCT03535792|Active Comparator|Nalbuphine/Hyerbaric Bupivacaine|"Group N:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt) and will have Tibial internal fixation."
10031569|NCT01769417|Placebo Comparator|Placebo|
10031570|NCT01769417|Active Comparator|MEDI4893|
10031571|NCT01769430||Community acquired respiratory infection|Measurement of exhaled breath aerosol
10031572|NCT01769482|Experimental|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
9469530|NCT03637374|Other|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
9469531|NCT03637361|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
9469532|NCT03637361|Experimental|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469533|NCT03637361|Experimental|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469534|NCT03637361|Experimental|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469535|NCT03637361|Experimental|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469536|NCT03637361|Experimental|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
9469537|NCT03637335|Experimental|irradiation + carboplatin|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
9469538|NCT03637335|Placebo Comparator|irradiation + placebo|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
9469539|NCT03637283|Experimental|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
10031573|NCT01769482|Placebo Comparator|Placebo|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
10031574|NCT01769495|No Intervention|Control|Standard post ED care
10031575|NCT01769495|Experimental|2-3 day return appointment|Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge.
10031576|NCT01769521|Experimental|Triggerfish|Device: Sensimed Triggerfish
10031577|NCT01769547|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
10031578|NCT01769560|No Intervention|Centers for Disease Control and Prevention (CDC) Fact Sheet|Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
10031579|NCT01769560|Experimental|MeFirst Intervention|Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
10031580|NCT01769599||Grid Treatment|30 patients that were treated with laser grid treatment
10031581|NCT01769599||Avastin Treatment|patients that were treated with Avastin injections
10031582|NCT01769625|Placebo Comparator|placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
10031583|NCT01769625|Active Comparator|placebo & cholecalciferol 2,000 IU|Placebo & cholecalciferol 2,000 IU
10031584|NCT01769625|Experimental|celecoxib 400mg & cholecalciferol 2,000 IU|celecoxib 400 mg & cholecalciferol2,000 IU
9469540|NCT03637283|Active Comparator|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
9469541|NCT03637270|Experimental|PRO group|Participants in PRO group receive dietary supplementation with protein-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
9469542|NCT03637270|Active Comparator|CHO group|Participants in CHO group receive dietary supplementation with carbohydrate-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
9469543|NCT03637257|Experimental|Nasal cannula / Guedel|Record of capnography using a standard nasal cannula followed by use of a modified Guedel airway
9469544|NCT03637257|Experimental|Guedel / nasal cannula|Record of capnography using a modified Guedel airway followed by use of a standard nasal cannula
9480219|NCT03535779||Group 1|Healthy volunteers receiving Tetanus (Td/IVP) vaccine were enrolled onto the study for 1 month with no additional follow up visits.
9480220|NCT03535779||Group 2|Healthy volunteers receiving the Hepatitis B (HBsAg) vaccine were enrolled onto the study for 2 months with no additional follow up visits.
9480221|NCT03535753|Experimental|Decitabine and R-GDP|ALL patients will be treated with Decitabine and R-GDP
10031585|NCT01769638|Experimental|SPO1101|
10031586|NCT01769638|Experimental|SPO1101D|
10031587|NCT01769651||Drug service users|Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
10031588|NCT01769664|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)
10031589|NCT01769664|Active Comparator|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)
10031590|NCT01769664|Placebo Comparator|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)
10031591|NCT01769677|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test)."
10031592|NCT01769677|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference)."
10031593|NCT01769690|Experimental|DBS stimulator setting alteration|
10031594|NCT01769703|Experimental|Dabigatran|
10031595|NCT01769716|Experimental|Umbilical cord blood transplantation|Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.
10037072|NCT01821495|Experimental|A|After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
10037073|NCT01821508|Active Comparator|Clinical treatment|Best and most modern clinical treatment of type 2 diabetes mellitus.
10031596|NCT01769729|Experimental|PEPP + care management|"This 4-month collaborative psychotherapy, entitled Program for Emotional and Physical Pain (PEPP), will include 1 joint meetings with the behavioral health specialist (BHS), primary care provider (PCP), and patient, 10 psychotherapy sessions, and continued collaboration between the BHS and the PCP to assure a shared treatment plan.~Care management will include monthly calls with a depression care manager."
10031597|NCT01769729|Active Comparator|Care management alone|Care management will include monthly calls with a depression care manager.
10031598|NCT01769742|Experimental|Early mobility bundle|Delivery of early targeted physiotherapy to patients on the interventional wards; to comprise assessment and communication of mobility to ward staff and patient, provision of mobility aids, guidance and encouragement to patient and staff to allow patient to dress and mobilise independently if clinically safe to do so
9469545|NCT03637244|Experimental|Experimental Condition|Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will be asked to use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.
9469546|NCT03637231|Other|Standard and ultra-low-dose CAC scoring|
10031599|NCT01769742|No Intervention|Usual care|Usual physiotherapy service only
10031600|NCT01769755|Experimental|Human Placenta-Derived Cells PDA001 Intravenous Infusion|Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours.
10031601|NCT01769755|Placebo Comparator|Vehicle controlled placebo|Intravenous infusion of Vehicle Controlled Placebo over the course of 2 hours
10031602|NCT01769768|Experimental|LDE225+Warfarin|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
10031603|NCT01769768|Experimental|LDE225+Bupropion|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
10031604|NCT01769781|Experimental|anastrazole|women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
10031605|NCT01769781|Active Comparator|GnRH analog alone|women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
9469547|NCT03637218|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
9469548|NCT03637218|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
10031606|NCT01769794|Active Comparator|Western therapy & Placebo|Western therapy(oral care, skin care and reducing temperature) Placebo for JET(Jinlianqingre Effervescent Tablets )
9469549|NCT03637205|Experimental|ECLS|PCI (or CABG) plus medical treatment + ECLS
10031607|NCT01769794|Experimental|Western therapy & JET|Jinlianqingre Effervescent Tablets plus western therapy
10031608|NCT01769807|Experimental|CPAP treatment|67 consecutive male patients with OSA were recruited: 36 with mild-moderate OSA and 31 with severe OSA. Data were collected in all subjects at baseline and after 1 month of CPAP.
9469550|NCT03637205|Active Comparator|No ECLS|PCI (or CABG) plus medical treatment
9469551|NCT03637192|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
9469552|NCT03637192|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
9469553|NCT03637179|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
9469554|NCT03637179|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
9469555|NCT03637166|Experimental|Order A|"The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)"
10031609|NCT01769820|Active Comparator|Dexamethasone|Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
10031610|NCT01769820|Placebo Comparator|Placebo|Placebo
10031611|NCT01769833|Active Comparator|PEG-interferon-alfa 2A|PEG-interferon-alfa 2A
10031612|NCT01769833|Placebo Comparator|Nucleosides|Nucleosides
10031613|NCT01769846|Experimental|Early Mobilization protocol|Early Mobilization protocol: Patients in the treatment group additionally received a progressive cycling exercise session 7 days a week, until the last day of ICU stay, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). Cycling exercise will be realized during 30 consecutive minutes, initially in continuos and passive (classified patients with RASS - 4) exercise, at a fixed pedaling rate of 20 cycles/min and after in actively (classified patients with RASS 0), with an exercise intensity of 3-5 on the Borg rate of perceived exertion scale.
10031614|NCT01769846|No Intervention|Control group|Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
10031615|NCT01769872|Experimental|Autologous Adipose Tissue derived MSCs|
10031616|NCT01769885|Experimental|Treatment (tivozanib and surgery)|Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
10031617|NCT01769898|Placebo Comparator|Placebo+formoterol-budesonide|"Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.~Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
9469556|NCT03637166|Experimental|Order B|"The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level)."
9469557|NCT03637153|Experimental|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
9469558|NCT03637153|Experimental|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
9469559|NCT03637140|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
9469560|NCT03637140|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
9469561|NCT03637127|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
9469562|NCT03637127|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
9469563|NCT03637114|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
9469564|NCT03637114|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
9469565|NCT03637088|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
9469566|NCT03637088|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
9469567|NCT03637075|Placebo Comparator|Placebo|Intranasal placebo administration
9469568|NCT03637075|Active Comparator|Intranasal insulin|Intranasal insulin administration
9469569|NCT03637049|Experimental|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
9803081|NCT04571060|Placebo Comparator|Placebo|Matching placebo
9803082|NCT04568993|Experimental|proximal phalangeal level|injection in the the tendon sheet over proximal phalanx of finger
10031618|NCT01769898|Experimental|Theophylline+formoterol-budesonide|"Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.~Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
10031619|NCT01769911|Experimental|Treatment (gene modified peripheral blood cell transplant)|"CONDITIONING: Patients receive carmustine IV over 3 hours on day -7, cytarabine IV over 2 hours BID and etoposide IV over 2 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.~TRANSPLANTATION: Patients receive an autologous PBSC infusion and/or infusion of autologous transduced hematopoietic cells on day 0.~Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. Patients achieving > 10% gene marking and CD4 count of >= 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection."
10031620|NCT01769937|Experimental|H.P. Acthar Gel SQ injection|Patients will administer single dose (80 units) of Acthar subcutaneously every day for 10 days (with a possible 5 day dosing rescue).
10031621|NCT01769950|Experimental|Choline-PET arm|Every eligible patient will be scanned with Choline-PET at the time of diagnosis of prostate cancer. MRI will also be obtained as it is the current standard of care. CT scan will be obtained as part of the same procedure while procuring the Choline-PET scan with PET-CT dual imaging hardware.
10031622|NCT01769963|Experimental|Dietary intervention|All participants will be fed a high AGE diet followed by a low AGE diet (single arm study)
10031623|NCT01769976|Experimental|Daily energy restriction|25% reduction in daily energy intake
10031624|NCT01769976|Active Comparator|Energy balance diet|Diet provides 100% of energy requirements and is designed to achieve weight stability
9469570|NCT03637036|Other|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
9469571|NCT03637036|Other|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
9469572|NCT03637036|Other|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
9469573|NCT03637036|Other|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
9469574|NCT03636997|Active Comparator|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
10031625|NCT01769976|Experimental|Periodic fasting with weight loss|Fast 3 days per week, and consume 1.5 times usual amount of food on other days
10031626|NCT01769976|Experimental|Periodic fasting without weight loss|Fast 3 days per week, and consume double usual amount of food on other days
10031627|NCT01769989|Active Comparator|Eletrodermabrasion|The side treated with electrodermabrasion will be burned with an electric cautery machine to remove the outermost layer of skin as well as the lumps and bumps and a small area of surrounding skin.
10031628|NCT01769989|Active Comparator|Dermabrasion|The side treated with dermabrasion will be scraped with a sterile piece of sandpaper until the outermost layer of skin and lumps and bumps have been removed and a small layer of surround skin.
10031629|NCT01770002|Active Comparator|Everted suture technique|Technique that everts the skin; the edges will sit up against each other in a little peak, raised above the surrounding skin.
9469575|NCT03636997|Active Comparator|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
9469576|NCT03636984||rheumatoid arthritis patients|subjects with rheumatoid arthritis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
9469577|NCT03636984||ankylosing spondylitis patients|subjects with ankylosing spondylitis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
9469578|NCT03636971|Experimental|hyaluronic acid with mannitol|
9469579|NCT03636971|Experimental|hyaluronic acid with sorbitol|
9469580|NCT03636971|Active Comparator|saline|
9469581|NCT03636958|Active Comparator|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
10031630|NCT01770002|Active Comparator|Non-everted suture technique|Surgical wound will be approximated such that the suture line is flat relative to the surrounding skin.
10031631|NCT01770015|Experimental|ventilated patient|"all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization.~HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration"
10031632|NCT01770028||Intervention partners|Partners of pregnant women randomized to lifestyle intervention. Note: There is no intervention in partners of pregnant women.
9469582|NCT03636958|Experimental|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
9469583|NCT03636945|Experimental|Medullary thyroid carcinoma|Patients with MTC who have serum calcitonin> 150 pg / ml at initial diagnosis and have performed baseline imaging examinations within the last 3 months will be included in the study A PET at 18F-FDOPA will be performed according to a very powerful acquisition protocol
10031633|NCT01770028||Standard care partners|Partners of pregnant women randomized to Standard Care. Note: There is no intervention in partners of pregnant women.
10031634|NCT01770041||Liver resection group|Patients undergoing liver resection and receiving paracetamol (observation of routine administration)
10031635|NCT01770054||obtention of a blood sample|all Atahualpa residents aged 40 years or more
10031636|NCT01770080|Active Comparator|Euminz®|Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
10031637|NCT01770080|Placebo Comparator|Placebo|Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
9469584|NCT03636932|Active Comparator|N-acetylcysteine (NAC) group|
9469585|NCT03636932|Placebo Comparator|Placebo group|
9469586|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
9469587|NCT03636906|Experimental|1 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Bexsero vaccine
10031638|NCT01770093||Parents of Pediatric Inpatients|
9469588|NCT03636906|Experimental|2 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Bexsero vaccine
10031639|NCT01770106|Experimental|Denosumab|Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
10031640|NCT01770106|Active Comparator|Standard treatment|Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.
10031641|NCT01770119|Experimental|MMR vaccination|MMR vaccine to seronegative pediatric SOT recipients
10031642|NCT01770132|Experimental|porfimer sodium, EUS-PDT, gemcitabine|Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.
10031643|NCT01770171|Experimental|Carboplatin-paclitaxel-bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg every 3 weeks until disease progression
9469589|NCT03636906|Active Comparator|Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive the Bexsero vaccine comparator and placebo
9469590|NCT03636906|Experimental|1 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Nimenrix vaccine
9469591|NCT03636906|Experimental|2 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Nimenrix vaccine
9469592|NCT03636906|Active Comparator|Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Nimenrix comparator vaccine and placebo.
9469593|NCT03636906|Experimental|1 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Menveo vaccine
10031644|NCT01770171|Active Comparator|carboplatin-paclitaxel|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
10031645|NCT01770184|Experimental|Intervention Group|The intervention group will receive the rehabilitation services and support that is recommended and provided in the current health care structure. The intervention group will also receive the Chronic Disease Self-Management Program (CDSMP). The CDSMP is an education program based on the concept of self-management. Self-management refers to the ability of an individual to manage the day-to-day responsibilities of living with a chronic condition. The CDSMP will be delivered in two and a half hour sessions, once a week, for six weeks, in group format.
10031646|NCT01770184|No Intervention|Usual Care Group|The usual care group for this study will receive the rehabilitation services and support that is recommended and provided in the current health care structure. No additional intervention will be provided to the usual care group within this study.
10031647|NCT01770197||recombinant tissue plasminogen activator|Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
9469594|NCT03636906|Experimental|2 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Menveo vaccine
9469595|NCT03636906|Active Comparator|Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Menveo comparator vaccine and placebo.
9469596|NCT03636906|Experimental|1 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive1 dose of the experimental GSK3389245A vaccine followed by placebo and Synflorix vaccine
9469597|NCT03636906|Experimental|2 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive2 doses of the experimental GSK3389245A vaccine followed by Synflorix vaccine
9469598|NCT03636906|Active Comparator|Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Synflorix comparator vaccine and placebo
9469599|NCT03636906|Experimental|1 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 1 dose of the GSK3389245A experimental vaccine followed by placebo.
10031648|NCT01770197||rt-PA|One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
10031649|NCT01770210||Cardiovascular events|Patients on atorvastatin treatment hospitalised due to cardiovascular events
10031650|NCT01770223|Experimental|Boceprevir + PegIFN-2b + RBV|All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).
10031651|NCT01770236|Experimental|IV acetaminophen|Patients in this group will receive intraoperative intercostal block + IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)
10031652|NCT01770236|No Intervention|On-Q Pain Pump catheter|Patients in this group will receive the current standard care which includes an intraoperative intercostal block + On-Q Pain Pump catheter (continuous dosing).
10031653|NCT01770262||Osteoporosis|Hospitalized subjects diagnosed with osteoporosis
9469600|NCT03636906|Experimental|2 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 2 doses of the GSK3389245A experimental vaccine followed by placebo.
9469601|NCT03636906|Placebo Comparator|Placebo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Placebo vaccine
9469602|NCT03636880|Experimental|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
9469603|NCT03636880|Active Comparator|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
9469604|NCT03636867||data and specimen collection|consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia
9469605|NCT03636854|Experimental|Concentric Exercises|2 different concentric exercises will be done 3 times a week for 8 weeks.
9469606|NCT03636854|Experimental|Eccentric Exercises|2 different eccentric exercises will be done 3 times a week for 8 weeks.
9469607|NCT03636841|Experimental|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
9469608|NCT03636841|Active Comparator|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
9469609|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
9469610|NCT03636776|Experimental|quality of life in metastatic BC|"Patients benefit from a longitudinal follow-up determined according to the treatments.~Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment.~The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre.~The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II)."
9469611|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
9469612|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
9469613|NCT03636750|Experimental|HB002.1T 2mg/kg|Participants received a 2mg/kg dose of HB002.1T via intravenous injection.
9469614|NCT03636750|Experimental|HB002.1T 4mg/kg|Participants received a 4mg/kg dose of HB002.1T via intravenous injection.
10031654|NCT01770262||Healthy|
10031655|NCT01770275||patients with esophageal cancer|Patients with esophageal cancer who underwent esophagectomy
9469615|NCT03636750|Experimental|HB002.1T 8mg/kg|Participants received a 8mg/kg dose of HB002.1T via intravenous injection.
10031656|NCT01770288|Experimental|Anaerobic Performance|
10031657|NCT01770301|Active Comparator|A - Paclitaxel|patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor
10031658|NCT01770301|Experimental|B - Paclitaxel + Bevacizumab followed by Bevacizumab|patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year
10031659|NCT01770327|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
10031660|NCT01770327|Experimental|Group 2 (Intervention) - Milk|This group will drink Non-Fat Milk in 1st trial
9469616|NCT03636750|Experimental|HB002.1T 12mg/kg|Participants received a 12mg/kg dose of HB002.1T via intravenous injection.
9469617|NCT03636750|Experimental|HB002.1T 16mg/kg|Participants received a 16mg/kg dose of HB002.1T via intravenous injection.
9469618|NCT03636750|Experimental|HB002.1T 20mg/kg|Participants received a 20mg/kg dose of HB002.1T via intravenous injection.
9469619|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
9469620|NCT03636724|Experimental|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
9469621|NCT03636724|No Intervention|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
9469622|NCT03636711||experimental group|• Patient admitted to emergency for infectious syndrome Description of antibiotic protocol, according to a syndromic approach will be performed
9469623|NCT03636698||Chorioamnionitis Group|preterm infants were born to mothers with chorioamnionitis
9469624|NCT03636698||Control Group|preterm infants were born to mothers without chorioamnionitis
9469625|NCT03636685|Experimental|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I~Anlotinib combined with pemetrexed and carboplatin, phase II"
9469626|NCT03636685|Experimental|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I~Anlotinib combined with paclitaxel and carboplatin, phase II"
9469627|NCT03636672|Experimental|experimental|Perturbation training during stationary bicycle riding
9469628|NCT03636672|Active Comparator|control|stationary bicycle riding training
9803083|NCT04568993|Active Comparator|volar MCP level|injection above the A1 pulley volar to the MCP joint
10031661|NCT01770327|Experimental|Group 3 (Intervention) - Orange Juice|This group will drink Orange Juice in 1st trial
10031662|NCT01770327|Experimental|Group 4 (Intervention) - Iced Tea|This group will drink Iced Tea in 1st study
10031663|NCT01770340|Sham Comparator|Control group|Radical prostatectomy without implantation of allograft
10031664|NCT01770340|Experimental|Treatment group|Radical prostatectomy with implantation of allograft
10031665|NCT01770405||pancreatic cysts|Patient indicated for a first endoscopic ultrasound fine needle aspiration (EUS-FNA) for a pancreatic cyst,
10031666|NCT01770418|Experimental|Proton Radiotherapy with Chemotherapy|
10031667|NCT01770444|Experimental|Low-dose cardiac CT|Patients randomized to this group will be assessed by low-dose cardiac CT protocol.
10031668|NCT01770444|Other|Conventional cardiac CT|Patients randomized to this group will be assessed by conventional cardiac CT protocol.
10031669|NCT01770470||Patients receiving chronic hemodialysis|Dialysis patients chewing chitosan-containing gum
10031670|NCT01770496|No Intervention|No reminder / recall notice|No childhood vaccination reminder / recall notification sent. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
10031671|NCT01770496|Experimental|mailed reminder / recall notice|Childhood vaccination reminder / recall notification sent by postal mail. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
10031672|NCT01770548|Experimental|Autism|Analysis of the glutamate synapse in autism
10031673|NCT01770548|Other|Relative|Analysis of the glutamate synapse in autism
10031674|NCT01770548|Other|Major control|DNA collection
10031675|NCT01770548|Other|Minor control|auditory evoked potentials
10031676|NCT01770561|Experimental|Integrated sensor and infusion set.|All subjects must have been previously diagnosed Type 1 Diabetics and being used to sensor augumented pumps
10031677|NCT01770574|Experimental|ReproBone|calcaneal lengthening
10031678|NCT01770574|Active Comparator|Autologous bone graft|calcaneal lengthening
9469629|NCT03636659|Experimental|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
9469630|NCT03636659|Active Comparator|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
10031679|NCT01770587|Experimental|Behavioral Insomnia Treatment|Brief Behavioral Insomnia Treatment
10031680|NCT01770600|Active Comparator|Risperidone|Administer pill of risperidone 1 mg once a day by mouth for 5 days.
10031681|NCT01770600|Placebo Comparator|Placebo|Administer pill of placebo once a day by mouth for 5 days.
10031682|NCT01770613|Experimental|Stem Cells|ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
10031683|NCT01770613|Placebo Comparator|Control|Lactated Ringer's Solution
9469633|NCT03636620|Active Comparator|TACE group|Transcatheter arterial chemoembolization
9469634|NCT03636620|Experimental|TACE+RFA/MV group|Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
9469635|NCT03636594|Experimental|Dance|This was a single arm study with all participants receiving the same intervention.
9469636|NCT03636555|Active Comparator|Oxytocin|Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
9469637|NCT03636555|Placebo Comparator|Placebo|Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
9469638|NCT03636542|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
9469639|NCT03636542|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
9469640|NCT03636529|Active Comparator|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
9469641|NCT03636529|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
9469642|NCT03636516|Active Comparator|jj stent yes|
9469643|NCT03636516|Active Comparator|jj stent no|
9469644|NCT03636477|Experimental|Ad-RTS-hIL-12 + veledimex in combination with nivolumab|Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
9469645|NCT03636412|Experimental|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
9469646|NCT03636412|No Intervention|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
9469647|NCT03636399|Experimental|Standard GIST|Standard Group Interactive Structured Treatment.
9469648|NCT03636399|Other|Waitlist control/Intensive GIST|After a wait list control period of nine months the participants receive Intensive Group Interactive Structured Treatment.
9469649|NCT03636373|Experimental|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
9469650|NCT03636373|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
9469651|NCT03636360|Experimental|LED - Sunlike|LED lighting with spectral pattern similar to that of sunlight
9469652|NCT03636360|Active Comparator|Fluorescent|Fluorescent light at same illuminance (lux) as LED light
9469653|NCT03636360|Placebo Comparator|Dim|"Dim fluorescent light with same spectrum as Fluorescent condition"
9469654|NCT03636360|Active Comparator|LED|Standard LED lighting
9469655|NCT03636334|Experimental|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
9469656|NCT03636334|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
9469657|NCT03636321|Experimental|intraductal stent|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis with internal biliary stent
9803084|NCT04566016|Experimental|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1).
10031684|NCT01770626|No Intervention|Single arm|evaluate the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis
10031685|NCT01770639||MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
10031686|NCT01770665||Mesothelioma|
10031687|NCT01770665||all cancer types|
10031688|NCT01770678|Experimental|Constraint induced movement therapy (prolonged restraint)|Constraint induced movement therapy(prolonged restraint)consists of a combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
10031689|NCT01770678|Active Comparator|Constraint induced movement therapy(manual restraint)|Constraint induced movement therapy(manual restraint)consists of a combination of manual restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
10031690|NCT01770704||Patients diagnosed with bipolar disorder I or II|
10031691|NCT01770717||Pressure Ulcer Formation|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
10031692|NCT01770730|Experimental|LAM plus standard care|Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site
9469658|NCT03636321|Active Comparator|stentless|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done without internal biliary
10031693|NCT01770730|No Intervention|Standard care|Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site
10031694|NCT01770756|Experimental|Enhancing willpower using active skills|This group will use active tasks such as learning skills using hands to enhance willpower.
10031695|NCT01770756|Experimental|Enhancing willpower using passive tasks|This group will use passive tasks such as taking still postures to enhance willpower.
10031696|NCT01770769|Active Comparator|Internal fixation - standard treatment|Internal fixation with two parallel cancellous screws (Hip Pins(R)) Current standard treatment
10031697|NCT01770769|Experimental|Hemi - arthroplasty|cemented Hemi - arthroplasty (Exeter(R)) modular system V40 by Stryker. Refobacin cement.
10031698|NCT01770782|Other|Laser Scanner|Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
10031699|NCT01770782|Other|SARME|Surgically Assisted rapid Maxillary Expansion -SARME was used for the treatment of transverse maxillary deficiency.This procedure is a combination of a surgical procedure and orthopedic expansion of the maxilla.
10031700|NCT01770795|Experimental|Genexol-PM/Gemcitabine|
10031701|NCT01770808|Experimental|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
9469659|NCT03636308|Experimental|AS：Nanoparticle albumin-bound paclitaxel，S-1|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle.~S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle."
9469660|NCT03636308|Active Comparator|AG：Nanoparticle albumin-bound paclitaxel，Gemcitabine|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8 of each 21 day cycle.~Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21 day cycle."
9469661|NCT03636230|Active Comparator|Remote Patient Management|Remote monitoring only
9469662|NCT03636230|Placebo Comparator|Standard of Care|In-clinic visits
9469663|NCT03636217|Experimental|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
9469664|NCT03636217|Experimental|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
9469665|NCT03636217|Experimental|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
9469666|NCT03636204|Experimental|AL001|Up to six single ascending doses of AL001
9469667|NCT03636204|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
9469668|NCT03636191|Experimental|Probiotic|
9469669|NCT03636191|Placebo Comparator|Placebo|
9469670|NCT03636178|Other|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
9469671|NCT03636178|Other|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
9469672|NCT03636139|Experimental|Anodal stimulation|transcranial DC stimulation : anodal
9469673|NCT03636139|Sham Comparator|Sham stimulation|transcranial DC stimulation : sham
9469674|NCT03636126|Experimental|VR + TACS|"Complete one chapter of the virtual reality game Land's End while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).~Use the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment"
9469675|NCT03636126|No Intervention|No Intervention for 2 Weeks|For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention.
9469676|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
9469677|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
9469678|NCT03636087|Active Comparator|Conventional|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
9469679|NCT03636087|Experimental|Enhanced sterile protocol|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Changing gloves before obturation Disinfecting rubber dam The use of new instruments at time of obturation Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
9469680|NCT03636048|Experimental|Spinal anesthesia group|Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
9469681|NCT03636048|Active Comparator|General anesthesia group|General anesthesia is used for operation with wound patient-controlled device for pain control. propofol (10milligram/ML) 1.5-2 mg/ml is used as bolus intravascular injection for induction of anesthesia. 0.5% ropivacaine is used for postoperative pain control with continous infusion through wound catheter.
9469682|NCT03636035|Experimental|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
9469683|NCT03636009|Experimental|Concurrent traction|Concurrent traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
9469684|NCT03636009|Active Comparator|Sequential traction|Sequential traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
10031702|NCT01770808|Experimental|AquaPT|AquaPT are produced by Marigot Ltd. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
10031703|NCT01770808|Placebo Comparator|Placebo|Produced by Marigot Ltd
10031704|NCT01770821|Active Comparator|Standard physical training & standard nutrition|Standard of care
10031705|NCT01770821|Experimental|Tailored physical training and sipdrink|Tailored physical training and sipdrink (Protein nutridrink, 200 ml x 2)
10031706|NCT01770821|Experimental|Tailored physical training and standard nutrition.|Standard physical training provided by the hospital and standard hospital nutrition
10031707|NCT01770821|Experimental|Standard physical training and sip drink|Standard physical training provided by the hospital and sipdrink (Nutridrink protein, 200 ml x2)
10031708|NCT01770834||Cohort|
9469685|NCT03635970|Placebo Comparator|conventional treatment|receive the best conventional therapy
9469686|NCT03635970|Active Comparator|experimental treatment|The best medical treatment possible plus celular therapy
9469687|NCT03635944||Group A|Infants born in Lyon (France)
9469688|NCT03635944||Group B|Infants born in Stockholm (Sweden)
9469689|NCT03635931|Active Comparator|Concentrated Growth Factor|plaque control, scaling and root planing if required, surgical application of CGF
10031709|NCT01770847||Healthy controls|Healthy age matched controls
10031710|NCT01770847||Chronic kidney diease|Chronic kidney disease patients stage 2-4
9469690|NCT03635931|No Intervention|Control Group|plaque control, scaling and root planing if required
9469691|NCT03635918|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a benchmark HSAT monitor.
9469692|NCT03635905|Experimental|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
9469693|NCT03635905|Placebo Comparator|Placebo|
9469694|NCT03635879|Active Comparator|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
9469695|NCT03635879|Active Comparator|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
9469696|NCT03635879|Active Comparator|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
9469697|NCT03635879|Active Comparator|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
9469698|NCT03635879|Active Comparator|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
9469699|NCT03635879|Experimental|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
9469700|NCT03635866|Experimental|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
9469701|NCT03635853|Experimental|patients with palmar arsenical keratosis|patients are given an ointment containing extract from cock's comb twice daily for three months
9469702|NCT03635840|No Intervention|Control|Group of patients not receiving IABP
9469703|NCT03635840|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump prior to revascularization
9469704|NCT03635827|Active Comparator|NBTX-001|
10031711|NCT01770873|Experimental|Take Charge 2|Receipt of BBBS mentoring plus youth and parent violence prevention curriculum
10031712|NCT01770873|No Intervention|Control|Standard emergency room protocol followed
9469705|NCT03635827|Placebo Comparator|Placebo|
9469706|NCT03635814|Experimental|YD312 drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
9469707|NCT03635814|Placebo Comparator|YD312 placebo drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
9469708|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.~An ECG is performed under controlled conditions."
9469709|NCT03635762|Experimental|Be In Charge|behavioral + nutrition education program
9469710|NCT03635736||Severe brain injury|ICU-patients suspect to severe brain injury, measurement with multiple-spectral-sonography as acustocerebrography (ACG
9480222|NCT03535714|Active Comparator|MANTR-a group|"Patients who are in the MANTR-a group attend the MANTR-a treatment program, which consists of 20 once-weekly therapy sessions. Caregivers can be invited to 2 sessions. After 20 weeks, therapy continues with four monthly booster-sessions. In sum, each patient (whose bodyweight is above the 3rd BMI percentile) can attend 24 therapy sessions. In patients whose bodyweight is below the 3rd BMI percentile treatment will be extended to 30 once-weekly and 4 monthly booster sessions. Besides therapy the patients are in nutritional consultation by a dietician and under regular medical care to monitor the physical health and weight gain.~Patients who who have already an existing psychotherapy are attached to the control group."
9480223|NCT03535714|No Intervention|control group|Patients of the control group receive treatment as usual (TAU). It consists of medical care and monitoring, psychotherapy in a single or family setting, parents counselling and dietetics.
9480224|NCT03535701|Active Comparator|Arm I (standard of care)|Patients receive standard of care therapy with paclitaxel.
9480225|NCT03535701|Experimental|Arm II (standard of care, ketogenic diet)|Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.
9480226|NCT03535662|Experimental|Orvepitant|Orvepitant single 20mg dose
9480227|NCT03535662|Experimental|Orvepitant and itraconazole|Orvepitant single 20mg dose in combination with repeat dose itraconazole
10031713|NCT01770886|Active Comparator|UE2343|Oral capsule
10031714|NCT01770886|Placebo Comparator|Placebo|Oral capsule
10031715|NCT01770899|Experimental|Montelukast|Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
10031716|NCT01770899|Placebo Comparator|Placebo|One placebo capsule given every 24h
10037074|NCT01821508|Active Comparator|Roux-En-Y gastric bypass surgery|"A metabolic surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus [SCHULMAN, 2009]."
10037075|NCT01821521|Experimental|AGSPT_L20|tablet, q.d.
10037076|NCT01821521|Active Comparator|Pantoloc 40mg|tablet, q.d.
10037077|NCT01821573|Experimental|Botox Injection|Patients treated by botulinum toxin.
10031717|NCT01770925|Active Comparator|n-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
10031718|NCT01770925|Active Comparator|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
9469711|NCT03635697|Experimental|Mindfulness Intervention Group|Participants in this group will listen to a short mindfulness audio clip during 6 of their NST appointments.
9469712|NCT03635697|No Intervention|Control Group|Participants in this group will have the regular standard of care for their NST appointments.
9469713|NCT03635684|Experimental|SC Acetaminophen|Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
9469714|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
9469715|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
9469716|NCT03635658|Active Comparator|titanium mesh|using non resorbable titanium mesh to fix and cover the onlay bone graft mixture to the atrophic maxillary ridge.
9469717|NCT03635658|Experimental|collagen membrane(Sausage technique)|using resorbable collagen membrane with the sausage technique to fix the onlay bone graft mixture to the resorbed atrophic maxillary ridge
9469718|NCT03635593|Active Comparator|CBD|10mg capsules Cannabidiol (CBD)
9469719|NCT03635593|Active Comparator|CBD+THC|10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
9469720|NCT03635593|Placebo Comparator|Placebo|10mg capsules placebo
9469721|NCT03635580|Experimental|rhGH/Jintropin AQ|Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.
9469722|NCT03635567|Experimental|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
9469723|NCT03635567|Placebo Comparator|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin AUC 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
9469724|NCT03635541||observational group of NAFLD|Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.
9469725|NCT03635528|Experimental|Test 1\Test 2\Control 2\Test 3\Control 1\Test 4\Test 5|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469726|NCT03635528|Experimental|Test 2\Test 3\Test 1\Test 4\Control 2\Test 5\Control 1|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469727|NCT03635528|Experimental|Test 3\Test 4\Test 2\Test 5\Test 1\Control 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469728|NCT03635528|Experimental|Test 4\Test 5\Test 3\Control 1\Test 2\Control 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469729|NCT03635528|Experimental|Test 5\Control 1\Test 4\Control 2\Test 3\Test 1\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469730|NCT03635528|Experimental|Control 1\Control 2\Test 5\Test 1\Test 4\Test 2\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469731|NCT03635528|Experimental|Control 2\Test 1\Control 1\Test 2\Test 5\Test 3\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469732|NCT03635528|Experimental|Test 5\Test 4\Control 1\Test 3\Control 2\Test 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469733|NCT03635528|Experimental|Control 1\Test 5\Control 2\Test 4\Test 1\Test 3\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469734|NCT03635528|Experimental|Control 2\Control 1\Test 1\Test 5\Test 2\Test 4\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469735|NCT03635528|Experimental|Test 1\Control 2\Test 2\Control 1\Test 3\Test 5\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9803085|NCT04566016|Active Comparator|General anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
9803086|NCT04565743|Active Comparator|Intervention|Multiprofessional education for health professionals in primary care on secondary prevention of osteoporotic fractures. Identification and referral of patients with recent osteoporotic fracture.
10037078|NCT01821573|Placebo Comparator|Saline Solution|Patients treated with saline solution.
10031719|NCT01770925|Active Comparator|NIPPV|o The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water, peak inspiratory pressure of 15cm of water, RRof35 and Ti of 0.32
10031720|NCT01770938|Active Comparator|Effective light-emitting diode therapy and training|Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
10031721|NCT01770938|Placebo Comparator|Placebo light-emitting diode therapy and training|Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
10031722|NCT01770964|Other|Training Type A, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type A
10031723|NCT01770964|Other|Training Type B, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type B
10031724|NCT01770964|Other|Training Type A, placebo|Subjects randomized to receive placebo at a site that received training Type A
10031725|NCT01770964|Other|Training Type B, placebo|Subjects randomized to receive placebo at a site that received training Type B
10031726|NCT01770977|Active Comparator|Effective Light-emitting diode therapy|Effects of light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
10031727|NCT01770977|Placebo Comparator|Placebo light-emitting diode therapy|Effect of placebo light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
10031728|NCT01770990|Active Comparator|Tel-PT without mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) without additional motivating letters.
10031729|NCT01770990|Experimental|Tel-PT including mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) with an additional motivating letter after every telephone session.
10031730|NCT01771003|Placebo Comparator|Without CellAegis' autoRIC™ Device|patients will have a blood pressure cuff attached to their arm that will not inflate/deflate as in the active group
9469736|NCT03635528|Experimental|Test 2\Test 1\Test 3\Control 2\Test 4\Control 1\Test 5|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469737|NCT03635528|Experimental|Test 3\Test 2\Test 4\Test 1\Test 5\Control 2\Control 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469738|NCT03635528|Experimental|Test 4\Test 3\Test 5\Test 2\Control 1\Test 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
9469739|NCT03635502||Stroke Group|
9469740|NCT03635502||Healthy Group|
9469741|NCT03635463|Experimental|twin block appliance|this group will receive conventional twin block appliance and followed up every month for 9 months.
9469742|NCT03635463|Experimental|modified twin block appliance group|modified twin block appliance group , this group will receive the modified appliance and followed up every month for 9 months
9469743|NCT03635450|Experimental|First cohort of 3 subjects enrolled|The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
9469744|NCT03635450|Experimental|Second cohort of 3 subjects enrolled|If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
9469745|NCT03635437|Experimental|Low dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 200 mg daily for 6 months
9469746|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 600 mg daily for 6 months
9469747|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA) + Alprazolam|Oral Alprazolam treatment 0.5 mg daily combined with oral GABA treatment 600 mg daily for 3 months. Alprazolam treatment thereafter ended, and study subjects will continue with oral GABA treatment 600 mg daily only for another 3 months.
10031731|NCT01771003|Active Comparator|With CellAegis' autoRIC™ Device|Patients will have the CellAegis' autoRIC™ Device attached and it will inflate to 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles (while under general anesthetic)
10031732|NCT01771042|Experimental|Normal glucose tolerant|"Weight loss attained by 25% caloric restriction.~This arm will be both a glycemic and time control. Initially they will undergo a 4-month weight maintenance phase (acting as time control), followed by 4 month weight loss."
9469748|NCT03635411|Experimental|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
9469749|NCT03635411|Placebo Comparator|Placebo|Placebo given twice daily for 90 days
9469750|NCT03635398|Experimental|Intranasal Midazolam by SipNose device|
9469751|NCT03635398|Active Comparator|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
9469752|NCT03635398|Active Comparator|oral administration of midazolam|
9469753|NCT03635372|Experimental|Alginate|10 cc of Alginate peroral
9469754|NCT03635372|Experimental|Sucralfate|10 cc of Sucralfate peroral
9469755|NCT03635372|Experimental|Hydrotalcite|10 cc of Hydrotalcite peroral
9469756|NCT03635359||positive for fetal aneuploidy|
9469757|NCT03635359||negative for fetal aneuploidy|
9469758|NCT03635333|Experimental|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
9469759|NCT03635333|Experimental|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
9803087|NCT04565743|No Intervention|Control|No intervention from study. No restrictions regarding education or the local organization of care for the prevention of osteoporotic fractures.
9469760|NCT03635333|Experimental|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
9469761|NCT03635333|Experimental|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
9469762|NCT03635333|Experimental|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
9469763|NCT03635333|Experimental|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
9469764|NCT03635307||Operated patients with volume expansion|
9469765|NCT03635294|Experimental|Blood sample|Blood sample for analyses
10031733|NCT01771042|Experimental|Impaired glucose tolerant|"Weight loss using 25% caloric restriction.~Impaired glucose tolerant subjects will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
10031734|NCT01771042|Experimental|Type 2 diabetic hyperinsulinemic|"Weight loss using 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
9469766|NCT03635281|Experimental|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
9469767|NCT03635281|Experimental|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
10031735|NCT01771042|Experimental|Type 2 diabetic hypoinsulinemic|"Weight loss via 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
10031736|NCT01771068|No Intervention|Waiting list|
10031737|NCT01771068|Experimental|Parenting Discussion Group|Two-hour discussion group on child noncompliance. Groups were composed by a maximum of 10 parents and were facilitated by the principal researcher, who is an accredited practitioner. The groups were interactive and discussion based, and a power point presentation with embedded-video clips was used to aid the facilitator. The key points covered in the discussion group included reasons for disobedience, parenting traps, encouraging good behaviour, and managing disobedience. Parents also received a workbook that included the content covered in the discussion group and 2 follow up telephone calls to check how they were doing after the discussion groups.
10031738|NCT01771081||Group1|
9469768|NCT03635242|Active Comparator|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
9469769|NCT03635242|Experimental|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
10031739|NCT01771094|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
10031740|NCT01771094|Experimental|"Group 3 (Intervention) - Low Sucralose"|This group will drink Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage in 1st trial
9469770|NCT03635138|Experimental|Adhesives Cu/Zn nanoparticles doped|Adhesive dopped with Zn Oxide + Cu nanoparticles in a ( 5% / 0.2% concentration )
10031741|NCT01771094|Experimental|"Group 2(Intervention)-High Sucralose"|This group will drink Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage in 1st trial
10031742|NCT01771120||Asthma Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
9469771|NCT03635138|Active Comparator|Adhesive control|Adhesive conventional
9469772|NCT03635125|No Intervention|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
9469773|NCT03635125|Active Comparator|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
9469774|NCT03635125|Active Comparator|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
9469775|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
9469776|NCT03635099|Experimental|Dose group A|
9469777|NCT03635099|Experimental|Dose group B|
9469778|NCT03635099|Experimental|Dose group C|
9469779|NCT03635099|Experimental|Dose group D|
9469780|NCT03635099|Placebo Comparator|Placebo|
9469781|NCT03635099|Experimental|Dose group V|
9803088|NCT04559711|Experimental|Intervention arm|Strengthening coverage and quality of nutrition services including MMS during ANC
9803089|NCT04559711|No Intervention|Comparison arm|Existing provision of nutrition services during ANC.
10031743|NCT01771120||Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
10031744|NCT01771120||Asthma and Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
10031745|NCT01771120||Healthy Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
10037079|NCT01821586|Experimental|Modified ORS-1|Modified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
10037080|NCT01821586|Experimental|Modified ORS-2 (ReSoMal)|Modified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
10037081|NCT01821586|Experimental|Modified ORS-3 (Benefibre)|Modified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
9469782|NCT03635099|Experimental|Dose group U|
9469783|NCT03635099|Placebo Comparator|Placebo W|
9469784|NCT03635060|Active Comparator|Dorsal Bridge Plating|The intervention is surgery with dorsal distraction plating with or without any additional fragment specific fixation.
9469785|NCT03635060|Active Comparator|Volar Locking Plating|The intervention is surgery with open reduction and internal fixation with non-spanning fixation.
9469786|NCT03635047|Active Comparator|AL002|AL002 by intravenous (IV) infusion
9469787|NCT03635047|Placebo Comparator|Saline Solution|placebo by intravenous (IV) infusion
9469788|NCT03635034|Experimental|No Bladder catheter|"Subjects will not have bladder catheter inserted during their ablation procedure.~Intervention: No catheter"
9469789|NCT03635034|Active Comparator|Bladder catheter inserted|"Bladder catheter will be inserted prior to starting ablation procedure after the subject is under general anesthesia.~Intervention: bladder catheter inserted"
10031746|NCT01771133|No Intervention|Lifestyle and nutrition control group|The control arm will receive routine prenatal care in the prenatal clinic. They will receive regular phone calls and mailings, token gifts and some useful information from data collected in the study, such as physical activity, feedback on behavior throughout the study. To additionally promote adherence (since they will have less contact with study staff), we will include 2 pre-partum and 1 post-partum group sessions meant to increase bonding between participants and retention of control participants. These sessions will include general pregnancy information not related to our interventions.
9469790|NCT03635008|Experimental|Anodal tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
10031747|NCT01771133|Active Comparator|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
10031748|NCT01771146|Other|Neoadjuvant FOLFIRINOX Regimen|Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection
9469791|NCT03635008|Placebo Comparator|sham tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
9469792|NCT03634995|Experimental|Single Dose|Ascending single doses of BMS-986256
9469793|NCT03634995|Experimental|Multiple Dose|Ascending multiple doses of BMS-986256
9469794|NCT03634995|Experimental|Sequential Dose|Sequential multiple doses of BMS-986256
9469795|NCT03634969|Experimental|Normal Renal Function|
9469796|NCT03634969|Experimental|Mild Renal Impairment|
10031749|NCT01771159|Experimental|Population|All subjects will undergo the implantation of the TBC.
10031750|NCT01771185|Active Comparator|Best medical treatment|Metformin 2 g/day; gliclazide 30 mg
10031751|NCT01771185|Active Comparator|Duodenal jejunal bypass plus sleeve gastrectomy|Duodenal jejunal bypass plus sleeve gastrectomy is a metabolic surgical procedure
9469797|NCT03634969|Experimental|Moderate Renal Impairment|
9469798|NCT03634969|Experimental|Severe Renal Impairment|
9469799|NCT03634969|Experimental|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
9469800|NCT03634956|Experimental|Group I.IONM in thyroid surgery|Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.
9469801|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
9469802|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
9803090|NCT04555226|Active Comparator|Standard treatment group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
10031752|NCT01771198|Experimental|SIMVASTATIN 40mg|SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment
10031753|NCT01771211|Experimental|anodal tDCS|anodal tDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left inferior frontal gyrus
10031754|NCT01771211|Sham Comparator|sham tDCS|sham tDCS will be administered to the left inferior frontal gyrus
9469803|NCT03634917|Active Comparator|Acamprosate|"1 capsule with Acamprosate calcium~oral use~3 times / day (morning, noon, evening)~666 mg per capsule~14 - 19 days"
9469804|NCT03634917|Active Comparator|Calcium Carbonate|"1 capsule with Calcium Carbonate~oral use~3 times / day (morning, noon, evening)~1500 mg Calcium Carbonate (= 600 mg Calcium 2+)~14 - 19 days"
9469805|NCT03634917|Placebo Comparator|Placebo|"1 capsule placebo,~oral use~3 times / day (morning, noon, evening)~14 - 19 days"
9469806|NCT03634904|Experimental|Drug Blood sampling|"Drug Blood sampling~Pharmacokinetic study measuring total and free ceftazidime concentrations"
9469807|NCT03634878|Experimental|Perineal ultrasound to visualize the strips and their position|
9469808|NCT03634852|Active Comparator|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
9469809|NCT03634852|Active Comparator|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
9469810|NCT03634787||Acute pancreatitis|First time acute pancreatitis. No later than 2 days since the clinical symptoms started.
9469811|NCT03634787||Healthy|No major systemic illness
9469812|NCT03634774|Experimental|Step 1 CHOICE+|Receives the intervention first
9469813|NCT03634774|Other|Step 2 CHOICE+|Received intervention four months after baseline
9469814|NCT03634774|Other|Step 3 CHOICE+|Receives intervention eight months after baseline
9469815|NCT03634761|Experimental|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
9469816|NCT03634761|Active Comparator|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
9469817|NCT03634735|Active Comparator|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
9469818|NCT03634735|Placebo Comparator|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
9469819|NCT03634722|Experimental|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
9469820|NCT03634722|No Intervention|The observational group|routine nursing
9469821|NCT03634709|Experimental|Memory Flexibility Training (MemFlex)|The MemFlex programme has been adapted from the initial format addressing depression-related memory distortions to facilitate completion with individuals experiencing posttraumatic stress. The workbook and associated materials have also been translated from English to Farsi. The programme consists of one researcher-facilitated session and eight self-guided workbook-based sessions that train memory retrieval skills and are completed over a one month period.
10031755|NCT01771224|Experimental|palmitoleic acid|Palmitoleic acid: 720 mg/day for 56 days
10031756|NCT01771224|Placebo Comparator|Sugar pill|Sugar pill: 720 mg/day for 56 days
10031757|NCT01771237|Experimental|MyPeeps Manualized Group Intervention|Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
9469822|NCT03634709|No Intervention|Waitlist control|After randomisation, the waitlist control group will be informed that they have been placed on a waiting list for the intervention. The participants will complete the baseline assessment and receive no further contact from the researcher until the post assessment one month later, followed by the follow-up assessment three months later. After the three month assessment, wait listed participants will receive the intervention. No further assessments will be completed.
9469823|NCT03634683|Experimental|LioCyx|"This is a single-arm study.~Patients will receive escalating doses of LioCyx on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle."
10031758|NCT01771237|Active Comparator|Standard Sexual Health Education|Educational group intervention focused on HIV and STI knowledge using a lecture-based format in 6 sessions. Non-tailored to YMSM.
9469824|NCT03634657|Active Comparator|Plain X-ray protection shield|
9469825|NCT03634657|Experimental|Protection shield & X-ray protective strips|
9469826|NCT03634657|Experimental|Protection shield & protective strips & patient cut-outs|
9469827|NCT03634644|Active Comparator|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
9469828|NCT03634644|Placebo Comparator|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
9469829|NCT03634618|Experimental|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
9469830|NCT03634618|Experimental|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
9469831|NCT03634605|Experimental|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
9469832|NCT03634605|Placebo Comparator|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
9469833|NCT03634566|Active Comparator|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
9469834|NCT03634566|Placebo Comparator|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
9469835|NCT03634553|Experimental|Intervention|Training with e-health product The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
9469836|NCT03634553|Active Comparator|Control|usual care, i.e. participates in regular training regime at the physiotherapy department
9469837|NCT03634540|Experimental|Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)|Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.
10031759|NCT01771263|Other|iControl-RP|iControl-RP is a system which performs controlled delivery of both remifentanil and propofol infusions.
10031760|NCT01771276|Experimental|Ultimate Anchor|Use of the g-Cath Suture Anchor Delivery Catheter and accessories in placing the ultimate number of anchors for weight loss.
10031761|NCT01771289|Experimental|chemoradiation|
10031762|NCT01771302|Active Comparator|Bio-Oss|the xenograft is of bovine origin where the organic phase has been eliminated.
10031763|NCT01771302|Experimental|calcium phosphate ceramic|is a calcium phosphate biomaterial
10031764|NCT01771315|Experimental|telephone follow-up|Nurse led follow-up in form of consultation by telephone 4 days and 2weeks after discharge, respectively as a supplement to conventional admission course.
9469838|NCT03634540|Experimental|Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)|Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.
10031765|NCT01771315|No Intervention|Usual treatment|All patients follow conventional admission course which implies preoperative seminar and a discharge planning consultation on the day of discharge. The patients are discharged to home, referred to physiotherapy in the community and a scheduled follow-up by the surgeon after 3 month in the orthopedic outpatient clinic.
10031766|NCT01771328|Active Comparator|hydrocortisone|Treatment B ( Solu-Cortef) the initial standard dose of 10mg/m2/24hrs. Hydrocortisone infusate will be given as Solu-Cortef Act-o-Vial 50mg/ml, produced by Pfizer. Treatment will take 4 months.
10031767|NCT01771328|Active Comparator|cortisone acetate|Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
10031768|NCT01771341|Placebo Comparator|Pressure support|
10031769|NCT01771341|Experimental|NAVA|
10031770|NCT01771354|Placebo Comparator|Placebo|Placebo
10031771|NCT01771354|Active Comparator|Vaccine|Engerix B vaccine
10031772|NCT01771367|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine.
10031773|NCT01771367|Active Comparator|Agrippal|Participants receive one dose of Agrippal vaccine.
10031774|NCT01771367|Placebo Comparator|Placebo|Participants receive one dose of saline placebo.
10031775|NCT01771380||Subjects with impaired glucose tolerance|
10031776|NCT01771393|Experimental|CBCT prior to MDCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the CBCT performed prior to the MDCT.
10031777|NCT01771393|Experimental|MDCT prior to CBCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the MDCT performed prior to the CBCT.
10031778|NCT01771406|Experimental|Nebivolol then CPAP|8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
10031779|NCT01771406|Experimental|CPAP then Nebivolol|8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
10031780|NCT01771419|Experimental|loop-tip arm|The cannulation of CBD will be obtained using the loop-tip wire (Cook Medical inc.)
9469839|NCT03634527|Experimental|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
9469840|NCT03634527|Sham Comparator|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
9469841|NCT03634514|Experimental|Application of Biomatrop|A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
9469842|NCT03634514|Active Comparator|Application of Hormotrop|A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
10031781|NCT01771419|Active Comparator|Control arm|The cannulation of CBD will be obtained with a Cook Medical sphincterotome CT-25 mm (tradictional technique)
10031782|NCT01771432|Active Comparator|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
10031783|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
9469843|NCT03634501|Experimental|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
9469844|NCT03634475|Experimental|PP-001|Single intravitreal injection of 3 up to 4 doses of PP-001
10031784|NCT01771445|Active Comparator|IL-1Ra|
10031785|NCT01771445|Placebo Comparator|Placebo|
10031786|NCT01771458|Active Comparator|Standard chemotherapy|Treatment choice is based on Investigator decision.
10031787|NCT01771458|Experimental|Personalized treatment|"Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)~Elligible therapies in this trial are :~Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
10031788|NCT01771471|Experimental|NuQu treatment|single administration
9469845|NCT03634462|Experimental|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
10031789|NCT01771471|Other|Saline|single administration
10031790|NCT01771484|Experimental|Low Sodium Diet|participants will consume a diet (10 milliequivalent Na+/day)for 4-5 days prior to study day.
10031791|NCT01771484|Experimental|High sodium diet|Participants will consume a diet high in sodium (300 milliequivalent Na+/day) for 4-5 days prior to study intervention.
10031792|NCT01771497||Women undergoing neoadjuvant therapy|
10031793|NCT01771523|Active Comparator|Group 1|thyroidectomy
10031794|NCT01771523|Active Comparator|Group 2|thyroidectomy use of drain
10031795|NCT01771536|Active Comparator|PCI Choice decision|Decision Aid intervention is provided to clinician to share with patient
10031796|NCT01771536|No Intervention|Usual Care|
10031797|NCT01771549||Group 1|Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.
10031798|NCT01771549||Group 2|Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.
10031799|NCT01771575|Experimental|Treatment Arm|PoNS™ device
10031800|NCT01771575|Placebo Comparator|Placebo Arm|placebo device
10031801|NCT01771588|Experimental|New human milk fortifier|New human milk fortifier
10031802|NCT01771588|Active Comparator|Currently marketed fortifier|Currently marketed fortifier
9469846|NCT03634462|Experimental|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
9469847|NCT03634449|Experimental|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
9469848|NCT03634449|Active Comparator|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
9469849|NCT03634436|Experimental|Cohort 1|A single subcutaneous injection of SHR-1209 dose 1 versus placebo
9469850|NCT03634436|Experimental|Cohort 2|A single subcutaneous injection of SHR-1209 dose 2 versus placebo
9469851|NCT03634436|Experimental|Cohort 3|A single subcutaneous injection of SHR-1209 dose 3 versus placebo
9469852|NCT03634436|Experimental|Cohort 4|A single subcutaneous injection of SHR-1209 dose 4 versus placebo
9469853|NCT03634423|Experimental|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
9469854|NCT03634423|Experimental|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
9469855|NCT03634423|Experimental|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
10031803|NCT01771588|Experimental|New human milk fortifier with new Ca source|a subgroup of patients will receive the new milk fortifier containing a new source of calcium.
10031804|NCT01771601||Near-infrared spectroscopy sensors|Term infants born by elective Caesarean section
9469856|NCT03634423|Experimental|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
9469857|NCT03634423|Experimental|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
9469858|NCT03634423|Experimental|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
9469859|NCT03634423|Experimental|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
9469860|NCT03634423|Experimental|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
9469861|NCT03634423|Experimental|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
9469862|NCT03634423|Experimental|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
9469863|NCT03634423|Experimental|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
9469864|NCT03634423|Experimental|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
9469865|NCT03634410||Employed|people aged +50 and currently employed
9469866|NCT03634410||Unemployed|people aged +50 and currently unemployed
9469867|NCT03634410||Early retirement|people aged +50 and currently on early retirement
9469868|NCT03634410||Disability pension|people aged +50 and currently on disability pension
10031805|NCT01771614|Experimental|Normoglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
10031806|NCT01771614|Experimental|Steady-State Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
10031807|NCT01771614|Experimental|Fluctuating Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, fluctuating hyperglycemia (~8-15 mM) will be induced by intravenously injecting 0.15 g/kg boluses of 20% dextrose every 30 minutes. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
10031808|NCT01771640|Experimental|stem cell reciepient|The patients with ALS that underwent mesenchymal stem cell transplantation
10031809|NCT01771653||Previously treated|Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
10031810|NCT01771653||Previously untreated|Records of patients who have never received anti-HCV treatment.
10031811|NCT01771679|Experimental|Allogeneic Mesenchymal Bone Marrow Cells|1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)
10031812|NCT01771692|Active Comparator|Conventional ligation|Modules ligated in a conventional manner (figure of 0)
10031813|NCT01771692|Active Comparator|Figure of 8 ligation|Modules ligated in a figure of 8 configuration
10031814|NCT01771705|Experimental|Dose adjust group (NFAT)|Within 4 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is <20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
9469869|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
9469870|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
9469871|NCT03634371|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
9469872|NCT03634371|Active Comparator|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
9469873|NCT03634358|Active Comparator|Bipolar scissors group|Group of male infants undergoing circumcision using bipolar scissors to separate the foreskin
9469874|NCT03634358|Active Comparator|Classic scalpel group|Group of male infants undergoing circumcision using classic scalpel to separate the foreskin, and sutures to control bleeding
9469875|NCT03634345|Experimental|PF-04965842|investigational drug
9469876|NCT03634332|Experimental|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
9469877|NCT03634293|Placebo Comparator|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
9469878|NCT03634293|Active Comparator|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
9469879|NCT03634280|Placebo Comparator|Splinting|Splinting was applied to the patients' ankle in the second group(n=120). Splint were kept on the patients for 5 days for 23 hours a day. In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
9469880|NCT03634280|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 120 participants were taped for a lateral ankle sprain. 50-mm wide and 0.5-mm thick KT was applied to the tendinomuscular meridian around the ankle with three I-shaped tapes. Initially, one I-shaped tape was applied along the course of the tibialis anterior muscle, and another I-shaped tape was then applied to the peroneus longus and brevis muscles. The third I-shaped tape was applied from the abductor digiti minimi muscle and wrapped around the ankle in a figure-of-eight shape to the abductor hallucis muscle, surrounding the ankle over the medial and lateral malleoli. The tape was applied to the skin by applying zero tension, and skin problems were avoided.
9469881|NCT03634267|Experimental|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
9469882|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
9469883|NCT03634215||Multiple Trauma patients|
9469884|NCT03634202|Experimental|IMRT + oral chemotherapy|Radiotherapy = IMRT with SIB. The overall duration of irradiation is 5 to 7 weeks Chemotherapy = oral capecitabine. Chemotherapy is taken in concomitance as radiotherapy days
9469885|NCT03634189|Experimental|HF- ACC/AHA stage A-C + CBD|Patients with HF stages A-C + Cannabidiol
9469886|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
10031815|NCT01771705|No Intervention|Standard of care group|A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.
10031816|NCT01771718||Human skin|Multiphoton microscopy imaging to collect information about changes in skin cells and fibrilar structure.
10031817|NCT05318443|Experimental|Experimental|SIBP04 & Paclitaxel & Carboplatin
9469887|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
9469888|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
10031818|NCT05318443|Active Comparator|Control group|Avastin & Paclitaxel & Carboplatin
9469889|NCT03634163|Experimental|Immediate|Quality of Life Assessment plus facilitated implementation of neighbourhood exchange and personal care support
9469890|NCT03634163|Active Comparator|Delayed|Quality of Life Assessment
9469891|NCT03634137|Experimental|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
9469892|NCT03634137|Experimental|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
10031819|NCT05318430|Experimental|Experimental group|the closed-suction drainage device will be placed subcutaneously when closing the incision
10031820|NCT05318430|No Intervention|Control group|the closed-suction drainage device will not be placed subcutaneously when closing the incision
10031821|NCT05318404|No Intervention|Conventinal feeding group|Start oral feeding 5-7 days after esophagectomy and discharge with soft blended diet as major energy source
10031822|NCT05318404|Experimental|Delayed feeding group|Start clear liquid fluid diet 5-7 days after esophagectomy and discharge with jejunostomy feeding as the major energy source. Start oral feeding at postoperative 1st visit
10031823|NCT05318391||Group/Cohort|Retrospective Cohort： Participants who diagnosed with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients and treated with BTK inhibitor or lenalidomide and its biosimilars.
10031824|NCT05318378|Experimental|student|Twenty fifth-year medical students were asked to participate in the study
9469893|NCT03634111|Active Comparator|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
9469894|NCT03634111|Placebo Comparator|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
9469895|NCT03634072|Other|PVR Arm|PVR arm will undergo PVR via catheter or surgery
10031825|NCT05318378|Active Comparator|senior surgeon|As controls, we asked 3 independent board-certified orthopedic surgeons to participate in the study following the same conditions as described previously.
10031826|NCT05318365|Active Comparator|Treatment of constipation and/or faecal incontinence|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition
10031827|NCT05318365|Active Comparator|Treatment of constipation and/or faecal incontinence combined with urotherapy|Medical treatment of bowel symptoms in accordance with the guidelines of The European Society for Paediatric Gastroenterology, Hepatology and Nutrition combined with standard urotherapy in accordance with International Children's Continence Society (ICCS)
10031828|NCT05318352|Experimental|Transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive tDCS over the right and left prefrontal cortex (F3 and F4 areas) with a constant current of 1.5 mA intensity that lasts for 20 minutes, 3 times a week for 2 weeks in daytime.
9469896|NCT03634072|No Intervention|No PVR|No PVR group will continue with medical management
9469897|NCT03634059|Experimental|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
9469898|NCT03634046|Experimental|PTED group|Percutaneous transforaminal endoscopic discectomy (PTED). Use German Joimax company production of intervertebral foramen mirror operation system, the prone position, by preoperative X-ray locating the skin into the needle point, intervertebral level away from the spine line 8 ~ 10 cm, 18 g needle insertion, the Kambin security triangle directly through the middle of pathological changes of intervertebral disc. After the success of the puncture, remove the needle core, injection of contrast agent, methylene blue (9:1) mixture disk imaging, replace the godet, slight rotation step by step to insert the expansion sleeve, X-ray perspective to determine work under the correct position. Radiofrequency ablation is used to form nucleus pulposus and fibrous ring and stop bleeding.
9469899|NCT03634046|Active Comparator|RA group|Radiofrequency ablation (RA). Patients in prone position, local infiltration anesthesia, the puncture point for lesion clearance level, is apart from the spine line distance is 8 to 10 cm, in the perspective of the C-shaped arm X-ray machine; After the puncture needle was reached, the needle core was removed and the radiofrequency head was pierced through the puncture channel to the nucleus pulposus. In accordance with the method of melt into the shrinking exit, the intensity of the treatment by band 2, increased to 3 file again, according to the needle round mouth of 2, 4, 6, 8, 10, 12 o'clock to this process is repeated six times.
9469900|NCT03634033|Experimental|MiCAP with IF|MiCAP with Internal Facilitation will receive MiCAP (implementation strategies). Internal facilitators will be waiver site clinicians with exemplary clinical practice and/or supervisory experience, who are expected to be early adopters of CAPABLE; and will be selected by their supervisors.
9469901|NCT03634033|Experimental|MiCAP with IF and EF|MiCAP with Internal Facilitation and External Facilitation will receive MiCAP (implementation strategies) and the addition of external facilitation. The external facilitators will be Super-Champion waiver program site clinicians from prior work who were trained and early adopters of CAPABLE; and will be selected by the research team to perform external facilitation.
10031829|NCT05318352|Sham Comparator|Sham transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive sham tDCS over the right and left prefrontal cortex.
10031830|NCT05318339|Experimental|Trastuzumab + Pyrotinib|"Patients receive a loading dose of trastuzumab IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes every three weeks.~Meanwhile, patients also receive pyrotinib 400mg PO daily. Treatment may continue till unacceptable toxicity or disease progression occurs."
10031831|NCT01771744||Morbidly obese patients|48 morbidly obese patients with revisional gastric bypass
10031832|NCT01771744||48 morbidly obese patients|with primary gastric bypass
9469902|NCT03634020|Experimental|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
9469903|NCT03633994|Experimental|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
9469904|NCT03633994|Placebo Comparator|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
10031833|NCT01771783|Experimental|ACEI-ARB-RI|angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
9469905|NCT03633968|Active Comparator|maxillary sinus lift small antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall. round diamond bur will be used to make small antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
10031834|NCT01771783|Experimental|ARB-RI-ACEI|ARB-RI-ACEI
10031835|NCT01771783|Experimental|RI-ACEI-ARB|RI-ACEI-ARB
10031836|NCT01771796|Experimental|Aerobic and muscle resistance training|
9469906|NCT03633968|Active Comparator|maxillary sinus lift large antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall round diamond bur will be used to make large antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
10031837|NCT01771796|No Intervention|Usual care group|All patients (intervention and usual care group) are patients with lung cancer who underwent a resection surgery.
10031838|NCT01771822|Experimental|Ibuprofen 5% topical gel|
10031839|NCT01771822|Experimental|Topical gel vehicle|
9480228|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.~A BMI under 35 and no pregnancy."
9480229|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
9480230|NCT03535610|Experimental|Embolization|Uterine Embolization with PVA Microspheres
9480231|NCT03535597|No Intervention|Arm 1|Standard of Care (TR Band)
10031840|NCT01771822|Active Comparator|Sodium lauryl sulfate 0.2%|
10031841|NCT01771822|Sham Comparator|Sodium chloride solution 0.9% (saline)|
9480232|NCT03535597|Experimental|Arm 2|Quikclot Radial pad with Coban Bandage to hold the pad in place
9480233|NCT03535597|Experimental|Arm 3|Quikclot Radial Pad with Tegaderm dressing to hold the pad in place
9480234|NCT03535558||Cohort 1: FQ With Uncomplicated Sinusitis or Bronchitis|A target cohort which includes participants exposed to an oral fluoroquinolone (FQ) with an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
9480235|NCT03535558||Cohort 2: FQ With Uncomplicated Acute Urinary Tract Infection|A target cohort which includes participants exposed to an oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
9480236|NCT03535558||Cohort 3: AZ with Uncomplicated Acute Sinusitis or Bronchitis|A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
9480237|NCT03535558||Cohort 4: ST with Uncomplicated Acute Urinary Tract Infection|A comparator cohort which includes participants exposed to oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
9803091|NCT04555226|Experimental|Experimental group|Open/minimally invasive pelvic and para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
10031842|NCT01771835||Diabetes patients|Patients with diabetes mellitus type I + II, without diabetic retinopathy
10031843|NCT01771848|Experimental|Grp 1-10ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 1 (n=6): 2,500 PfSPZ administered IM in a volume of 10 µL in 2 sites (one injection of 10µL containing 1,250 PfSPZ in each deltoid)."
10031844|NCT01771848|Experimental|Grp 2-50ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 2 (n=6): 2,500 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50µL containing 1,250 PfSPZ in each deltoid)."
10031845|NCT01771848|Experimental|Grp 3-250ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 3 (n=6): 2,500 PfSPZ administered IM in a volume of 250 µL in 2 sites (one injection of 250 µL containing 1,250 PfSPZ in each deltoid)."
10031846|NCT01771848|Experimental|Grp 4-50ul x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 4 (n=6) (control group) 25,000 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50 µL containing 12,500 PfSPZ in each deltoid)."
10037082|NCT01821599|Active Comparator|Conventional group|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
10031847|NCT01771848|Experimental|Grp 5-Optimal vol Part A x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 5 (n=6) 25,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 12,500 PfSPZ in each deltoid).~If the optimal volume in Part A is 50µL, then Group 5 will be modified to avoid duplication of regimens between groups 4 and 5. In this case, volunteers in group 5 will be administered a dose of 25,000 PfSPZ administered intradermally in four 10 µL injections. (Every volunteer will receive 4 ID injections of 6,250 PfSPZ in a volume of 10 µL each, with 2 injections in each arm respectively)."
10031848|NCT01771848|Experimental|Grp 6-Optimal vol Part A x 2; 125,000* PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 6 (n=6) 125,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 62,500 PfSPZ in each deltoid) if the volume is 50 µL or 250 µL.~*If the optimal volume in Part A is 10 µL, then Group 6 will receive 100,000 PfSPZ (2 inoculations of 50,000 PfSPZ) instead of 125,000 PfSPZ."
10031849|NCT01771861||Seriously injured or potentially seriously injured patients|
10031850|NCT01771874|Experimental|MDMA, bupropion, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject. The four treatment conditions are placebo-placebo, bupropion-placebo, placebo-MDMA, and bupropion-MDMA.
10031851|NCT01771887|Experimental|education program|education program in 6 hours for groups of 10 people. The content will be divided into 2 sessions with an interval of 2 weeks, the duration of each session is 3 hours. Means active learning, teaching materials in Arabic accompany the content masterful discussions on flipcharts, situation analysis, computer-assisted presentation, demonstration, 150 photos of Lebanese dishes. After, patients receive a 10-page illustrated book, a logbook of diabetes control. 2 weeks after the second education session, each participant will receive 5 calls every 15 days in 2 months. During each call, the research assistant will ask the patient about diet, exercise and self-monitoring, medication and foot care and this according to a checklist.
10031852|NCT01771900|Experimental|Heart Camp Group|
9469907|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
9469908|NCT03633916|Experimental|Intervention|Classroom sensitization session (plus school-level sensitization activities)
9469909|NCT03633916|Active Comparator|Control|School-level sensitization activities only
9469910|NCT03633890|Experimental|DaZhu Rhodiola Rosea Capsule|
9469911|NCT03633890|Placebo Comparator|DaZhu Rhodiola Rosea Simulation Capsule|
9469912|NCT03633877|Experimental|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
9469913|NCT03633877|Experimental|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
9469914|NCT03633864|Experimental|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
9469915|NCT03633851|Experimental|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
9469916|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
10031853|NCT01771900|Experimental|Attention Control Group|
10031854|NCT01771926|Experimental|High Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
10031855|NCT01771926|Experimental|Low Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
10031856|NCT01771926|Placebo Comparator|Other Carbohydrate Source|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
10031857|NCT01771939|Experimental|idiopathic epiretinal membranes|Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)
10031858|NCT01771939|Active Comparator|idiopathic epiretinal membrane|Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only
10031859|NCT01771978|Placebo Comparator|Arm1: control group|Received 250 ml of a 5% dextrose solution as placebo drug
10031860|NCT01771978|Experimental|Arm 2: diltiazem group|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
10031861|NCT01771978|Experimental|Arm 3: acetylcystein group|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
10031862|NCT01771978|Experimental|Arm 4: diltiazem and acetylcystein group|"Received a combination of drug :~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
10031863|NCT01772017|Experimental|Device Treatment|Tongue Advancement Retainer Device
10031864|NCT01772030|Other|Recurrent Atrial Fibrillation|
10031865|NCT01772043||Duchenne muscular dystrophy|
10031866|NCT01772056|Experimental|Fluticasone, cream|fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant.
10031867|NCT01772056|Placebo Comparator|Placebo, cream|Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant.
9469917|NCT03633812||Beta blocker group|ESLD recipients who had beta blocker during more than 1 month before the liver transplantation
9803092|NCT04554667|Experimental|Exercise Intervention|Single exercise arm
10031868|NCT01772082|Active Comparator|Pedometer alone|pedometer
10031869|NCT01772082|Experimental|Pedometer plus website|pedometer and website
10031870|NCT01772095||Patients with Dementia|Patients diagnosed with dementia and evaluated by specific Alzheimer disease scales
10037083|NCT01821599|Experimental|Accelerated group|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
10031871|NCT01772108|Experimental|MitraClip Device|Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
9469918|NCT03633812||Non-Beta blocker group|ESLD recipients who had not taken beta blocker more than 3 month before the liver transplantation
9469919|NCT03633773|Experimental|MUC-1 CART|Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy. After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
9469920|NCT03633760|Experimental|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
9469921|NCT03633760|Experimental|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
9469922|NCT03633747|Experimental|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
9469923|NCT03633734|Experimental|Sequential treatment|"One cycle of sequential treatment lasts for 56 days.~Stage 1(28 days): AG regimen. Nab-paclitaxel (Abraxane) 125mg/m^2 + gemcitabine 1000mg/m^2 (days 1, 8, 15, 28)~Stage 2(28 days)：mFolfirinox regimen. Fluorouracil 2400 mg/m^2 continuous intravenous drip 46h + calcium folinate 400 mg/m^2 + irinotecan 135 mg/m^2 + oxaliplatin 68 mg/m^2 (day 1, 15, a total of 28 days).~Repeat the cycle above until progression or intolerance of toxicity."
9469924|NCT03633695|Experimental|IC-8 IOL|The AcuFocus IC-8 intraocular lens will be surgically implanted in one eye of each subject. A monofocal or monofocal toric intraocular lens will be surgically implanted in the fellow eye of each subject.
9469925|NCT03633695|Active Comparator|Monofocal|A monofocal or monofocal toric intraocular lens will be surgically implanted in both eyes of each subject.
9469926|NCT03633682|Experimental|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
9469927|NCT03633682|Other|No Engagement Support|Participants in this group will receive no text message support.
9469928|NCT03633669|Active Comparator|Tight control|Group that will receive fecal calprotectin testing every 3 months
9469929|NCT03633669|Placebo Comparator|Standard care|Routine clinical care
9469930|NCT03633656|Experimental|Treatment|Model predictive control recommendation of iron dosing in combination with an erythropoietic stimulating agent.
9469931|NCT03633630|Experimental|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
9469932|NCT03633630|Placebo Comparator|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
10031872|NCT01772108|No Intervention|Control|Subjects randomized to the Control group will receive optimal standard of care therapy alone.
10031873|NCT01772121||HCV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HCV infection
10031874|NCT01772121||HBV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HBV infection
9469933|NCT03633591|Experimental|Modified Release Prototypes of Tolcapone|
9469934|NCT03633578|Experimental|Interventional group|Patients are asked to walk ont a treadmill in four conditions: with and without distraction (virtual environment) and at different speed (comfortable vs high).
9469935|NCT03633565|Active Comparator|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
9469936|NCT03633565|Active Comparator|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
9469937|NCT03633565|Experimental|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
9469938|NCT03633552|Experimental|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
9469939|NCT03633552|Active Comparator|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
9469940|NCT03633539|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（multi-ports）.
9469941|NCT03633539|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
9469942|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
9469943|NCT03633513||Caregivers|Environmentally matched healthy control subjects
9469944|NCT03633500|Placebo Comparator|Sterile water|Sterile water: Started by six hours of age, In the control arm, 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
9480238|NCT03535545|Experimental|Healthy Individuals|Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
9480239|NCT03535545|Experimental|Lung Cancer Subjects|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
10031875|NCT01772173||subjects with diabetes developing hypertension|subjects with diabetes not developing hypertension
10031876|NCT01772186|No Intervention|Without real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system but not receive the real-time somatosensory cue during freezing-of-gait episodes.
10031877|NCT01772186|Experimental|With real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system and receive the real-time somatosensory cue during freezing-of-gait episodes.
10037084|NCT01821612|Other|mFOLFIRINOX, chemoradiation, surgery and gemcitabine|"Each patient will receive mFOLFIRINOX therapy administered every other week for a total of 4 cycles. Each treatment cycle is a total of 14 days. This treatment program consists of four drugs (oxaliplatin 85 mg/m^2 IV over 2 hours on day 1 followed by irinotecan 180 mg/m^2 IV over 90 minutes on day 1 followed by, leucovorin 400 mg/m^2 IV over 2 hours on day 1 followed by 5-FU 2400 mg/m^2 IV over 46-48 hours).~Two to six weeks following treatment with the mFOLFIRINOX, if the tumor has not spread to other parts of the body then the patient will receive capecitabine 825 mg/m^2, twice daily for 28 days along with radiation therapy. Patients will have surgery within 4-10 weeks of the last dose of chemoradiation if the tumor has gotten smaller or stayed the same.~Within 6-8 weeks following surgery, patients will receive gemcitabine for 2 cycles (1 cycle is 28 days). Gemcitabine will be given IV on days 1, 8 and 15 of every 28 day cycle."
10037085|NCT01821638||Older adults with heart failure|Older adults with heart failure
10037086|NCT01821651|Experimental|HeartNavigator|Group with HeartNavigator-Software
10037087|NCT01821651|Active Comparator|Control|Control-group without HeartNavigator-Software
9469945|NCT03633500|Experimental|Breastmilk|Breastmilk. This is started at 6 hours of age at the earliest; breast milk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
9469946|NCT03633474|Experimental|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (>350 volunteers to date).
9469947|NCT03633474|Placebo Comparator|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
9469948|NCT03633435|Experimental|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
9469949|NCT03633409||IBD patients and healthy volunteers|We will recruit IBD patients and healthy volunteers
9469950|NCT03633396|Placebo Comparator|Placebo|Placebo as subcutaneous (SC) injection every 4 weeks
9469951|NCT03633396|Experimental|Group 1|ANB019 subcutaneous (SC) injection every 4 weeks
9469952|NCT03633383||Transfemoral Approach|
9469953|NCT03633383||Transapical Approach|
9469954|NCT03633370|No Intervention|Control Group|Usual management of patients according to international guidelines. Protocols of call acceptance, phone advice and sending of emergency services are not modified
9469955|NCT03633370|Other|Test Group|"Multifaceted intervention~Training using distance learning for medical regulation assistants to recognise cardiac arrest on phone~Activation of the location-software application to send bystanders on cardiac arrest location before the arrival of emergency medical services (EMS)~Motivation feed-back Volunteers will received feed-back regarding CPR initiated before EMS arrival and survival"
9469956|NCT03633357|Experimental|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
9469957|NCT03633357|Placebo Comparator|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
9469958|NCT03633318||IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
9469959|NCT03633318||Control Group|Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
9469960|NCT03633292|Active Comparator|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
9469961|NCT03633292|Experimental|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
9469962|NCT03633266|Experimental|anti-VEGF|experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF
9469963|NCT03633266|Active Comparator|PRP|Control group: vitreoretinal surgery combined with intraoperative PRP
9469964|NCT03633227|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|
9469965|NCT03633227|Placebo Comparator|Placebo|
9469966|NCT03633214|Active Comparator|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
10037088|NCT01821651|Experimental|EchoNav|Group with EchoNav-Software
10037089|NCT01821651|Active Comparator|Conrol|Control-group without EchoNav-Software
10037090|NCT01821664||Prosthetic vascular graft implantation, follow up|
10037091|NCT01821677|Experimental|Low Dose Danazol|Low Dose Danazol
10037092|NCT01821677|Placebo Comparator|Placebo|Placebo
9469967|NCT03633214|No Intervention|No training module (Control)|
9469968|NCT03633188|Experimental|Patients treated by antibiotherapy|35 Patients treated by antibiotherapy for acute and subacute post-operative implant-associated BJI infections and among them 10 patients with Staphylococcus. aureus treated with antibiotics as part of their standard treatment procedure for metagenomic procedure.
9469969|NCT03633175|Active Comparator|Vaginal progesterone group|Women will receive vaginal progesterone 400 mg [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).
9469970|NCT03633175|No Intervention|Control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
9469971|NCT03633149|Experimental|Computer tablet-delivered C4H|Two session CHOICES4Health intervention delivered by a computer tablet to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
10031878|NCT01772199|Experimental|GSK239512 Arm|GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
9469972|NCT03633149|Experimental|Person-delivered C4H|Two session CHOICES4Health intervention delivered by a counselor to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
9469973|NCT03633149|Active Comparator|Brief Advice|Women will receive advice and educational material from a research assistant about risk drinking, smoking, marijuana, and contraception, depending on their specific risk behaviors, as well as information about women's health. In addition, the women will receive referrals to the Harris Health System's SBIRT clinic if needed.
10031879|NCT01772199|Placebo Comparator|Placebo Arm|Placebo once daily orally
10031880|NCT01772212|Experimental|A(test)/B(reference)|Initial administration of test and crossover to reference
9469974|NCT03633136|No Intervention|standard education|Standard of care education provided at each transplant center
9469975|NCT03633136|Experimental|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
9469976|NCT03633123|Other|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
9469977|NCT03633123|Experimental|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
9469978|NCT03633097|Experimental|Acupuncture + Usual care|Acupuncture with Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
9469979|NCT03633097|Active Comparator|Usual care|Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
9469980|NCT03633032|Other|UTE MRI|
9469981|NCT03633019|Experimental|high-dose rhTPO|rhTPO (300-600U/kg/day), ih, until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L
9469982|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.~A second blood draw will be collected at 12 months."
9469983|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.~Diagnostic information will be collected to confirm the final diagnosis."
9469984|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.~Subject will be enrolled and provide a blood sample."
9469985|NCT03632980|Experimental|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
9469986|NCT03632967|Experimental|Device: TriCinch Coil System treatment|
9469987|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
9469988|NCT03632915||No study intervention|No study intervention
9469989|NCT03632876|Active Comparator|Lower Dose Vitamin A|Subjects with SCD-SS in the lower dose Vitamin A arm receive 3000IU of retinyl palmitate daily for 8 weeks.
9469990|NCT03632876|Active Comparator|Higher Dose Vitamin A|Subjects with SCD-SS in the higher dose Vitamin A arm receive 6000IU of retinyl palmitate daily for 8 weeks.
9469991|NCT03632876|No Intervention|Healthy Comparison Arm|Healthy subjects receive no intervention and undergo comparisons to the two vitamin A supplementation arms at baseline.
9469992|NCT03632837|Experimental|Treatment|Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
9469993|NCT03632837|No Intervention|Control|ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation
9469994|NCT03632824|Experimental|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
9469995|NCT03632824|Placebo Comparator|comparative group|expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected
9469996|NCT03632772|Experimental|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
9469997|NCT03632772|Experimental|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
9469998|NCT03632772|No Intervention|Control: non treatment|Control: non treatment.
9469999|NCT03632733|Active Comparator|Tetracycline group|Tetracycline cream twice daily for three months
9470000|NCT03632733|Active Comparator|Clotrimazole group|Clotrimazole cream twice daily for three months
9470001|NCT03632733|Active Comparator|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
9470002|NCT03632733|Placebo Comparator|Placebo group|participants will be provided a cream containing no active drug ingredients
9470003|NCT03632694|Experimental|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
9470004|NCT03632694|Active Comparator|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
10031881|NCT01772212|Experimental|B(reference)/A(test)|Initial administration of reference and crossover to test
10031882|NCT01772225||Deceased Group|Subjects in this group will include the deceased patients from each of the three countries.
10031883|NCT01772225||Living Group|Subjects in this group will include living patients aged 18 years or older from each of the three countries.
10031884|NCT01772238|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
10031885|NCT01772238|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
10031886|NCT01772251|Experimental|Oshadi Icp & placebo|
10031887|NCT01772264|Experimental|Arm A - active treatment|
10031888|NCT01772264|Placebo Comparator|Arm B - placebo|
9470005|NCT03632694|No Intervention|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
10031889|NCT01772277||MMC group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy with intraoperative MMC
10031890|NCT01772277||Control group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy without intraoperative MMC
10031891|NCT01772290|Active Comparator|A: Vismodegib|
10031892|NCT01772290|Experimental|B: Rabeprazole + Vismodegib|
10031893|NCT01772290|Experimental|C: Itraconazole + Vismodegib|
10031894|NCT01772290|Experimental|D: Fluconazole + Vismodegib|
10031895|NCT01772303|Experimental|HO/03/03 10-40 micro gram|Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
10031896|NCT01772329|Experimental|4 weekly CT sessions - in person|4 weekly CT sessions; all will be 1-hr individual cognitive therapy sessions with the psychology staff (under the supervision of John Burns, PhD).
10031897|NCT01772329|Experimental|8 weekly CT sessions|"8 weekly CT sessions; 1st and 8th will be 1-hr individual cognitive therapy session with the psychology staff (under the supervision of John Burns, PhD). The intermediate CT sessions will be by telephone call or video/Skype. Our group will purchase and setup a web camera and headphone/microphone for the subjects in the CT groups that use Skype. The 1-hr CT protocol was adapted from Dr. Beverly E. Thorn's CT manual (Cognitive Therapy for Chronic Pain: A Step-by-Step Guide; Thorn, 2004; with the Client and Therapy Workbooks."
10031898|NCT01772329|Experimental|4 weekly CT sessions - Tele-video|"4 weekly CT sessions; 1st and 4th will be 1-hr individual cognitive therapy session with the psychology staff. The intermediate CT sessions will be by telephone call or video/Skype."
10031899|NCT01772329|Placebo Comparator|Routine care|Routine care; no CT sessions
10031900|NCT01772342|Experimental|Nocturnal Air Purification|"Hepa Filtration with PureNight~SHAM with PureNight"
10031901|NCT01772355|Other|tissue core|semi automated core needle biopsy of the orbital tumors
10031902|NCT01772381|Experimental|Dexamethasone|Dexamethasone, im , 12 mg twice, 12 hrs apart, 48 hrs before elective cesarean section
10031903|NCT01772394|Active Comparator|Cognitive Remediation Therapy (CRT)|Active : CRT
10031904|NCT01772394|Sham Comparator|Sham Therapy (ST)|Sham : ST
10031905|NCT01772407||1|laparoscopic surgery in right colon cancer operations
10031906|NCT01772407||2|open surgery in right colon cancer operations
10031907|NCT01772420|Experimental|Arm A (lenalidomide, eltrombopag olamine)|"Patients with baseline platelet counts >= 50,000 receive lenalidomide PO daily or QOD on days 1-21. If platelet counts fall below 50,000, patients discontinue lenalidomide and receive eltrombopag olamine PO daily or QOD until platelet count is maintained above 50,000 for 2 weeks. Patients then resume lenalidomide PO daily or QOD. If platelets fall below 50,000 again, patients receive eltrombopag olamine as before. When platelet counts are maintained above 50,000 for 2 weeks, patients resume lenalidomide concurrently with eltrombopag for all subsequent courses.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
10031908|NCT01772420|Experimental|Arm B (eltrombopag olamine, lenalidomide)|"Patients with baseline platelet counts < 50,000 receive eltrombopag olamine PO daily or QOD on days 1-28 until platelet count is maintained above 50,000 for 2 weeks. Patients then receive treatment as in Arm A.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
10031909|NCT01772433|Placebo Comparator|Phonophoresis Gel|The Phonophoresis gel will be used as placebo
10031910|NCT01772433|Experimental|Olive Oil|Olive oil will be used as a replacement to phonophoresis gel in this arm
10031911|NCT01772446|No Intervention|CONTROL GROUP|ROUTINE CLINICAL PRACTICE
10031912|NCT01772446|Experimental|SMS MESSAGING|SMS MESSAGES TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED HEMOGLOBIN
10031913|NCT01772459||Paper/Paper|This group will complete paper questionnaires at baseline and two week follow up.
10031914|NCT01772459||Paper/Internet|This group will complete paper questionnaires at baseline and internet questionnaires at two week follow up.
10031915|NCT01772459||Internet/Paper|This group will complete internet questionnaires at baseline and paper questionnaires at two week follow up.
10031916|NCT01772459||Internet/Internet|This group will complete internet questionnaires at baseline and two week follow up.
10031917|NCT01772485|Experimental|Cognitive Training|Training group participants will engage in 30 hours of at-home online training on the novel neuroplasticity-based cognitive training program ('Rewired') in 30 minute sessions completed approximately 3-5 days per week, for a total training period lasting 12-20 weeks. Both visual and auditory exercise forms will be practiced daily. Level progression criteria will be flexibly set to assure that almost all individuals can reach them in a reasonable time. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely, and analyzed over secure online servers to assure that subjects are completing their training as scheduled and to deal with any unexpected road-blocks in training.
10031918|NCT01772485|Active Comparator|Active Control|The active control group shall engage in an at-home computer game suite, as used in a prior cognitive training trial in a psychiatric population (Fisher et al., 2009), for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with clinical research personnel and monetary rewards. Compliance will be monitored via an online data portal.
10037093|NCT01821703|Experimental|LY3045697|Escalating dose (0.1 milligrams [mg] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods
10031919|NCT01772498|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training administered in eight, individual, weekly, one hour sessions. There will also be 20 minutes a day of resonant frequency breathing to be conducted at home. This intervention involves teaching subjects how to breath at their resonant frequency in a relaxed, diaphramatic manner.
10031920|NCT01772511||Questionnaire|Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
9470006|NCT03632681|Active Comparator|Insulin|In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
9470007|NCT03632681|Placebo Comparator|Placebo|In this arm a single-dose intranasal placebo will be administrated
9470008|NCT03632668|Experimental|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
9470009|NCT03632642|Active Comparator|Benzylpenicillin arm|Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
9470010|NCT03632642|Active Comparator|Flucloxacillin arm|Patients randomised to flucloxacillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 2g Q6H IVI or 2g Q4H for deep-seated or criticial illness infections.
10031921|NCT01772524|Experimental|ALD403|Single IV Dose on Day 0
10031922|NCT01772524|Placebo Comparator|Saline|Single IV infusion on Day 0
10031923|NCT01772563|Experimental|volasertib + itraconazole|administration of volasertib alone and in combination with itraconazole
10031924|NCT01772589|Active Comparator|New saw blade|New saw blade
9470011|NCT03632629|Active Comparator|study group|3 months of individualized interactive cognitive training, 2 times per week, 15 min per session, a total of 24 sessions, in addition to traditional rehabilitation programs.
10031925|NCT01772589|Active Comparator|Reprocessed saw blade|Reprocessed saw blade
10031926|NCT01772615|Experimental|ciprofloxacin-EcN|
10031927|NCT01772615|Experimental|ciprofloxacin-placebo|
9470012|NCT03632629|No Intervention|control group|3 months of traditional rehabilitation programs, without individualized interactive cognitive training.
9470013|NCT03632603|Experimental|Radiotherapy 20 Gy / 4 F|Radiotherapy 20 Gy / 4 F
9470014|NCT03632603|Active Comparator|Radiotherapy 30 Gy/ 10 F|Radiotherapy 30 Gy/ 10 F
9470015|NCT03632590|Experimental|Magnesium Citrate|450 mg of Magnesium Citrate per day
9470016|NCT03632590|Experimental|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
10031928|NCT01772615|Experimental|placebo-EcN|
10031929|NCT01772615|Placebo Comparator|placebo-placebo|
10031930|NCT01772628|Experimental|Promoting parent-child communication|This is the arm in which all interventions of Promoting parent-child communication on selected sexual and reproductive health issues among young secondary school adolescents in Kampala and Wakiso Districts were implemented. The interventions included; classroom-based component, STI/HIV prevention education, parenting component and homework assignment component.
10031931|NCT01772628|No Intervention|Comparison|The 11 comparison schools did not receive any form of intervention. Instead the students continued with the official standard school curriculum and regular parent/guardian involvement in school activities. No homework assignments were given to the senior one students.
10031932|NCT01772641|Experimental|Scheduled Gradual Reduction + Varenicline|Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
9470017|NCT03632590|Experimental|Magnesium Oxide|450 mg of Magnesium Oxide per day
9470018|NCT03632590|Placebo Comparator|Placebo|
9470019|NCT03632577|Experimental|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
9470020|NCT03632577|Active Comparator|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
9470021|NCT03632564|Experimental|Stimulation Arm|REVIVIEW dichoptic audio-visual stimulation
9470022|NCT03632551|Active Comparator|Symmetrical hearing|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
9470023|NCT03632551|Experimental|Single-sided deafness|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
10031933|NCT01772641|Experimental|Scheduled Gradual Reduction + Placebo Drug|Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
10031934|NCT01772641|Experimental|Basic Advice + Varenicline|Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
10031935|NCT01772641|Placebo Comparator|Basic Advice + Placebo Drug|Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.
10031936|NCT01772667|No Intervention|Usual care|Usual care during the whole study period without pulmonary rehabilitation. The patients will perform their normal daily life.
10031937|NCT01772667|Active Comparator|Inpatient Rehabilitation|3-week inpatient multimodal pulmonary rehabilitation program, including daily exercise training, breathing therapy, medical treatment and psychological support. In the following 3 month, the patients will perform their normal daily life.
10031938|NCT01772680|Experimental|Zinc Supplementation|25 mg elemental Zinc as Zn sulfate in capsule form taken daily for 3 months
10031939|NCT01772706|Experimental|laser low-level energy functional|The material used will be a diode laser of 100 mW, with a wavelength of 658 nm. Application will be made after each radiotherapy session in an adapted room (low light intensity, possibility of ENT examination) on all grade superior or equal to 2 stomatitis injuries. The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be determined by an abacus.
10031940|NCT01772706|Placebo Comparator|laser low-level energy nonfunctional|The procedure is identical to the one used in arm A but the laser will not be functional. The period of application will be around one minute.
10031941|NCT01772732|Experimental|Simotinib Treatment|"3+3 design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
10031942|NCT01772745|Active Comparator|Group 1|SILS cholecystectomy
10031943|NCT01772745|Active Comparator|Group 2|TPCL cholecystectomy
9470024|NCT03632551|Experimental|Bilateral profound hearing loss treated|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
9470025|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
9470026|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
9470027|NCT03632525|Experimental|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
9470028|NCT03632512|Experimental|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
9470029|NCT03632512|Placebo Comparator|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
9470030|NCT03632486||Suspected Dengue|Children with fever and two of the following criteria: anorexia and nausea, rash, aches and pains, warning signs, leukopenia, positive tourniquet test will all receive a diagnostic bedside ultrasound.
9470031|NCT03632460|Active Comparator|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
9470032|NCT03632460|Active Comparator|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
9470033|NCT03632447|Experimental|Leva Arm|Subjects will undergo pelvic floor muscle training using the leva device (a vaginal probe) which provides immediate visual feedback via smartphone regarding the motion of pelvic floor muscles. Subjects will perform exercises 2 1/2 minutes twice daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later subjects will undergo pelvic floor muscle testing using the PFDx device and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device. They will be further randomized to receive reminder text messages or no messages over 10 months. Subjects will be asked to complete follow up surveys at 6- and 12-months.
9470034|NCT03632447|Active Comparator|Kegel Arm|Subjects in this arm will perform pelvic floor muscle exercises (Kegels) for the treatment of stress or mixed urinary incontinence. Subjects will be asked to perform exercises three times daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later, subjects will undergo pelvic floor muscle testing (using the PFDx device) and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device.
9470035|NCT03632434|Experimental|tDCS|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
9470036|NCT03632382|Other|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
9470037|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
9470038|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
9480240|NCT03535545|Experimental|Pulmonary Fibrosis Subjects|Idiopathic pulmonary fibrosis patients or patients with other types of interstitial lung disease with a fibrotic component will receive [68Ga]CBP8 and undergo PET imaging.
10031944|NCT01772771||Ancillary-correlative (biospecimen collection, chart review)|Patients' previously collected tissue samples are analyzed. Patients may also undergo collection of blood, saliva or buccal samples for analysis. Patients' medical records are reviewed.
10031945|NCT01772784|Experimental|phenolic acids|Maltodextrine + Phenolic acids
10031946|NCT01772784|Placebo Comparator|placebo|Maltodextrine
10031947|NCT01772784|Experimental|phenolic acid|Maltodextrine + Phenolic acids
10031948|NCT01772784|Active Comparator|polyphenol|
10031949|NCT01772797|Experimental|LDK378 and AUY922|
10031950|NCT01772810|Experimental|Surgical implantation of human spinal cord stem cells|Surgical implantation of human spinal cord derived neural stem cells.
9470039|NCT03632356|Experimental|Stepped Care Intervention (STEP)|In a stepped-care model, all patients start with an evidence-based intervention of low intensity as a first treatment step. Progress is monitored and patients who do not respond adequately can subsequently be 'stepped up' to a higher intensity treatment. This model is now being recommended as the best strategy for treating panic attacks and panic disorder.
9470040|NCT03632356|Active Comparator|Screening only|Screening only for panic attacks and panic disorder using a gold standard clinical interview that provides coverage of the core symptoms of panic attacks and panic disorder.
9470041|NCT03632343|Experimental|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
9470042|NCT03632343|Experimental|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
9470043|NCT03632343|No Intervention|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
9470044|NCT03632330||Dexmedetomidine|Dexmedetomidine group
9470045|NCT03632330||Midazolam|Midazolam group
9470046|NCT03632330||propofol|propofol group
10031951|NCT01772836|Placebo Comparator|Normal saline|Single and multiple dose of normal saline
10031952|NCT01772836|Experimental|Single dose IV of biapenem or RPX7009|Single dose IV infusion of biapenem or RPX7009
10031953|NCT01772836|Experimental|Single dose of biapenem or RPX7009|Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
10031954|NCT01772836|Experimental|Biapenem and RPX7009 in combination|Single dose followed by a multiple dose of biapenem and RPX7009 in combination
10031955|NCT01772849|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
10031956|NCT01772849|No Intervention|Standard educational programme|The children receive the standard of care with respect to education this include education in the hospitals school or at home without a class mate and no specific activity to secure continuous linkage with community school and class mates
10031957|NCT01772862|No Intervention|Only conventional supportive care|The children receive conventional supportive care with respect to physical training
10031958|NCT01772862|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
10031959|NCT01772875|Active Comparator|lavage Isobetadine Dermicum solution|Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline
10031960|NCT01772875|Active Comparator|lavage Acetic Acid solution|Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline
10031961|NCT01772875|Sham Comparator|lavage with saline|patients will receive during 5 consecutive days a bladder lavage with 100cc saline
10031962|NCT01772875|Active Comparator|lavage Urotainer Suby G|patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G
10031963|NCT01772888||Patients with ALS|All subjects aged > 18 years, diagnosed with an ALS and included in the multidisciplinary follow-up of the HUG at time of diagnosis will be considered and included, if possible, at their first visit.
10031964|NCT01772888||Healthy age and gender-matched subjects|Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
10031965|NCT01772901|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
10031966|NCT01772901|Experimental|Influenza Vaccine Intervention|The intervention group will receive a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions.
10031967|NCT01772927||Very low birth weight infants,|Parenteral nutrition
10031968|NCT01772940|Active Comparator|nevirapine and tenofovir/emtricitabine|nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
10031969|NCT01772940|Experimental|lopinavir/r and tenofovir/emtricitabine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
10031970|NCT01772940|Active Comparator|Nevirapine and zidovudine/lamivudine|nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
9470047|NCT03632330||Midazolam/Propofol|Midazolam and Propofol group
9470048|NCT03632317|Experimental|Panobinostat and Everolimus|Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
9470049|NCT03632304|No Intervention|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
9470050|NCT03632304|Active Comparator|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
9470051|NCT03632291|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
9470052|NCT03632291|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
9470053|NCT03632291|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
9470054|NCT03632291|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
9470055|NCT03632291|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
9470056|NCT03632278|Experimental|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
9470057|NCT03632278|No Intervention|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney & Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
9470058|NCT03632226||1|Healthy Volunteers
9470059|NCT03632213|Active Comparator|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
9470060|NCT03632213|Placebo Comparator|Placebo|Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
9470061|NCT03632200|Experimental|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
9470062|NCT03632200|No Intervention|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
9470063|NCT03632187|Experimental|Experimental group|Subcutaneous abatacept every weeks during 3 months (W0 to W11). Then, at W12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients wont receive any treatment until a flare.
9470064|NCT03632187|Placebo Comparator|Control group|Subcutaneous placebo every week during 3 months (W0 to W11). Then, at week 12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients won't receive any treatment until a flare.
9470065|NCT03632174|Experimental|Topical Ointment with L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
9470066|NCT03632174|Experimental|Topical Ointment without L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
9470067|NCT03632161|Active Comparator|Dexmedetomidine|Dexmedetomidine is added to bupivacaine the paravertebral block
9470068|NCT03632161|Other|Bupivacaine|Bupivacaine only in the paravertebral block
9470069|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
9480241|NCT03535532|Experimental|unilateral laparoscopic adrenalectomy|subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
9480242|NCT03535532|Active Comparator|standard medical treatment|subjects allocated in standard medical treatment group will be given conservative medicine treatment.
9480243|NCT03535493|Active Comparator|Acceptance and Commitment Therapy (ACT)|
9480244|NCT03535493|Active Comparator|Float REST|
9480245|NCT03535493|Experimental|ACT + Float REST|
9480246|NCT03535480|Experimental|G-CSF|Only receives G-CSF subcutaneously five days for stem cell mobilization
9480247|NCT03535480|Experimental|ASCOT|Receives G-CSF subcutaneously five days and then plasmapheresis for hematopoietic stem cell collection and catheterism for infusion in ovarian artery
9480248|NCT03535467||Conventional Rehabilitation|
9480249|NCT03535467||Robotic Therapy|
9480250|NCT03535454||Factory workers|
9480251|NCT03535454||Nurses|
9480252|NCT03535454||Janitors|
9480253|NCT03535454||Data automation employees|
9480254|NCT03535441||voluteer group|No treatment, only blood sample collection
9480255|NCT03535441||hemorrhagic shock group|HS was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more. Exclusion criteria were pregnancy, <15 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital
9480256|NCT03535428||VENOUS exploration|
9480257|NCT03535415|Experimental|rhGH Injection|rhGH 0.05mg/kg/d by subcutaneous injection
9470070|NCT03632096|Active Comparator|Photobiomodulation group|Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
9470071|NCT03632096|Sham Comparator|Sham group|The placebo group will have a simulation of application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
9470072|NCT03632070||Stroke|Patients with ischemic or hemorrhagic stroke who were admitted to Samsung Medical Center and transferred to the Department of Physical and Rehabilitation Medicine
9470073|NCT03632057|Active Comparator|Fixed Tilt (65%)|This is the control group, so device programming for shock energy is the default setting
9470074|NCT03632057|Active Comparator|Fixed Pulse Width|This is the Study group.
9470075|NCT03632044|Experimental|Suprazygomatic maxillary nerve blockade|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.
9470076|NCT03632044|Sham Comparator|25 Gauge needle|Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
9470077|NCT03632031||Patients with chronic non-healing wounds|Patients with chronic non-healing wounds with planned use of OASIS Extracellular Wound Matrix
9470078|NCT03632018|Active Comparator|Standard Cardiac Rehabilitation|Participants in the STANDARD condition will receive the standard of care cardiac rehabilitation, consisting of 36 sessions across 12 weeks of prescribed, supervised exercise sessions.
10031971|NCT01772940|Experimental|Lopinavir/r and zidovudine/lamivudine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
9470079|NCT03632018|Experimental|HEART-PLAY|Participants in the HEART-PLAY will receive standard CR and additionally receive pedometers, resistance bands, and the National Institute of Aging (NIA) exercise guide. They will further receive counseling from peer health coaches, social support from group education sessions, and supplemental educational materials. After the 12 weeks of prescribed, supervised exercise sessions, HEART-PLAY group participants will continue to receive support from peers and clinic staff with check-in calls, feedback on pedometer goals, and twice weekly group events including walks and/or resistance band group exercise classes.
9470080|NCT03632005|Other|Sterile Dressing|Standard of care treatment - Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
10031972|NCT01772953|Experimental|treosulfan, fludarabine and low-dose TBI prep regimen|"Treosulfan: 10-14 g/m2/day IV over 120 minutes on days -6, -5 and -4. Treosulfan will be administered prior to fludarabine on days -6 to -4 to facilitate PK testing.~Fludarabine: 30 mg/m2 IV for patients > 10 kg (or 1 mg/kg IV for patients < 10 kg) once daily per institutional infusion standards on days -6 through -2 for a total dose of 150 mg/m2 (or 5 mg/kg).~A single fraction of 200 cGy TBI will be administered on day -1. Stem cell infusion on day 0"
10031973|NCT01772966|Experimental|Spinal manipulation|Participants will receive spinal manipulation delivered as segmental thrust to a specific site in the neck. They will receive three intervention sessions over 7-10 days.
10031974|NCT01772966|Sham Comparator|Control manipulation|Participants will receive spinal manipulation delivered as non-segmental thrust to the neck. They will receive three intervention sessions over 7-10 days.
10031975|NCT01772979|Experimental|Trabectedin|"Trabectedin 1.3 mg/m2 q 21 days~Patients will receive trabectedin until disease progression or unacceptable toxicity"
10031976|NCT01772992|No Intervention|Control group (iVCT)|Male couples randomized to the control group (iVCT) will each receive individual HIV counseling and testing, separately.These couples in the control group (iVCT) will return every 6 months, up to 18 months, for individual visits, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted separately.
10031977|NCT01772992|Experimental|Experimental group (CVCTPLUS)|Male couples randomized to the experimental group (CVCTPLUS) will each receive HIV counseling and testing as a couple. These couple will return for two additional visits that members of the control arm do not get, for two one-hour sessions of the Partner-STEPS. Couples in the experimental group (CVCTPLUS) at 8 and 10 weeks after the initial enrollment. They will also return every 6 months, up to 18 months, for visits in which they will be seen as a couple, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted for the couples together.
10031978|NCT01773005|Sham Comparator|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
10031979|NCT01773005|Active Comparator|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
10037094|NCT01821703|Active Comparator|Spironolactone|25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods
10037095|NCT01821703|Placebo Comparator|Placebo|Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods
9470081|NCT03632005|Active Comparator|Vacuum Assisted Closure|The Prevena™ System, a type of vacuum assisted closure, is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
9470082|NCT03631992|Experimental|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
10031980|NCT01773018|Experimental|Volitinib(HMPL-504)|"There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.~An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504)."
10031981|NCT01773031||Autoimmune pancreatitis|Patients with autoimmune pancreatitis based on clinical and CT findings
9470083|NCT03631992|Sham Comparator|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
9470084|NCT03631979|Experimental|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
9470085|NCT03631979|No Intervention|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
9470086|NCT03631966|Experimental|BTX-A injection|
9470087|NCT03631953|Experimental|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
9470088|NCT03631914|Active Comparator|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
9470089|NCT03631914|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
9470090|NCT03631901|Active Comparator|Melatonin|melatonin 0.3mg/kg/8 hours, orally. Given only during the febrile illness.
9470091|NCT03631901|Active Comparator|Diazepam|oral diazepam 1mg/kg/day divided into 3 doses. Given only during the febrile illness.
9470092|NCT03631888||patients scheduled for elective laparoscopic surgery|
9470093|NCT03631875|Placebo Comparator|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LM conditions insertion.
9470094|NCT03631875|Active Comparator|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LM conditions insertion.
9480258|NCT03535415|No Intervention|Non-treatment control group|Only follow-up without treatment
10031982|NCT01773044|Active Comparator|alkalinized lidocaine & lidocaine|
10031983|NCT01773044|Active Comparator|alkalinized lidocaine &Placebo|
10031984|NCT01773057|Experimental|Active decision support|Regular NHGDoc domains plus NHGDoc domain heart failure
10031985|NCT01773057|No Intervention|Passive decision support|Regular NHGDoc domains
10031986|NCT01773096|Experimental|Study group|Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
10031987|NCT01773096|Active Comparator|Institutional bowel protocol|Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
10031988|NCT01773148|Experimental|Arstasis Access System (AXERA) placement|Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
10031989|NCT01773161||Cerebral palsy, post hip surgery|Children between the ages of 4-18 undergoing surgical treatment for hip subluxation or dislocation secondary to cerebral palsy.
10031990|NCT01773174|Experimental|dabigatran etexilate|single dose treatment with dabigatran oral solution
10031991|NCT01773200||Aneurysmal Subarachnoid Hemorrhage|Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage
10031992|NCT01773213|Other|Bladder dysfunction, ice-water-test|
10031993|NCT01773213|Other|Bladder dysfunction, warm water-test|
10031994|NCT01773239|Experimental|TARA computer-based exercises|"TARA is a computerized social cognitive (SC) remediation program consisting of a set of specific SC exercises. The program creates a game-like experience where the participant is encouraged to earn points and in-game rewards to further advance in each 'game'. Participants perform tens to hundred of trials over the course of their session, with each trial providing auditory and visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each trial, the difficulty of the next trial is updated to ensure that within each session, the participant gets ~85% of trials correct. Summary screens including game metrics (points, levels) and exercise metrics (usage, progress) are shown to the participant at the end of each session.~Participants in the TARA computer-based exercises arm will complete baseline- assessments, 24 hours of TARA computer based-exercises, and repeat post-assessments."
10031995|NCT01773252|Experimental|TEE|Within patient comparison of TEE, FDS and a TCD from select study sites
10031996|NCT01773304|Experimental|Meal rich in dairy protein|
10031997|NCT01773304|Experimental|Meal rich in meat protein|
10031998|NCT01773317|Experimental|Perturbation|Subjects complete the training protocol and peturbation training exercises
10031999|NCT01773317|Experimental|Control|Subjects will complete the training protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
10032000|NCT01773330|Experimental|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
9470095|NCT03631862|Experimental|Apatinib combined with CHOP regimen|Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
10032001|NCT01773343|Active Comparator|CO2 laser at 1 month interval|CO2 laser treatment of mild to severe acne scars at 1 month interval
10032002|NCT01773343|Active Comparator|CO2 laser at 3 monrths interval|CO2 laser treatment of mild to severe acne scars at 3 month intervals
9470096|NCT03631862|Experimental|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
9470097|NCT03631849|Experimental|Peri implantitis patients|
9470098|NCT03631849|Active Comparator|not peri implantitis patient|
9470099|NCT03631836|Experimental|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
9470100|NCT03631823||Radio/Chemotherapy group|The participants in this group receive the concurren radio/chemotrherapy
10032003|NCT01773356|Placebo Comparator|Placebo 0 mg/d|0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
10032004|NCT01773356|Active Comparator|Dihydrocapsiate 9 mg/d|9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
10032005|NCT01773369|Experimental|Early treatment group|These children will undergo the intervention (i.e., early leg training) shortly after recruitment. Measures will be taken before, during and after the intervention.
10032006|NCT01773369|Experimental|Delayed treatment group|These children will undergo the intervention (delayed leg training) after a delay of ~3 months, during which outcome measures will be taken so that they can serve as a control for the early treatment group. Their intervention is identical to the Immediate treatment group.
10032007|NCT01773369|No Intervention|Control group|These children will be recruited close to the age of 4 years old, and will only undergo gait analysis and GMFM-66 scoring.
10032008|NCT01773369|Experimental|Parent training group|These children will undergo the intervention (i.e., parent leg training) shortly after recruitment. Parents will be trained to provide the intervention instead of a physical therapist. Measures will be taken before, during and after the intervention.
10032009|NCT01773382|No Intervention|control|standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP <130/80 mmHg)
10032010|NCT01773382|Experimental|weight reduction|target weight reduction is 3-5% from baseline
10032011|NCT01773408|Experimental|Part 1: RO5503781|Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
10032012|NCT01773408|Experimental|Part 2: RO5503781 + Cytarabine|Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
10032013|NCT01773408|Experimental|Part3:RO5503781+Cytarabine+Anthracycline|Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
10032014|NCT01773408|Experimental|Part 4: Optimized RO5503781 + Cytarabine|Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
10032015|NCT01773434|Experimental|MORAb-004|
10032016|NCT01773447|Active Comparator|Set-back suture|Wound to be close by set-back suture technique.
10032017|NCT01773447|Active Comparator|Vertical mattress suture technique|Wound to be closed by vertical mattress technique.
10032018|NCT01773460|Experimental|Everolimus|Everolimus is given beyond progress
10032019|NCT01773460|Placebo Comparator|Everolimus-placebo|Everolimus-placebo is given beyond progress
9470101|NCT03631823||Radio/ without chemotherapy group|The participants in this group receive the radiotherapy but without chemotrherapy
9470102|NCT03631823||Healthy volunteer group|The volunteers for control group
9470103|NCT03631797|Experimental|Microvascular reactivity evaluation|"Patients referred for a preoperative arterial palmar arches assessment before cardiac valvular or coronary surgery.~Intervention is measurement of microvascular reactivity with a laser speckle contrast imaging before surgery."
9470104|NCT03631758|Experimental|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
9470105|NCT03631758|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
10032020|NCT01773499||Patient with Cellulitis|Patients with uncomplicated cellulitis treated as outpatients
10032021|NCT01773512|Experimental|Rosuvastatin|All patients will be using rosuvastatin 40 mg
10032022|NCT01773538|Active Comparator|Anti cHE treatment arm|Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
10032023|NCT01773538|Placebo Comparator|Placebo arm|The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
10032024|NCT01773551||Optical Index of Breast Density|Breast Density
10032025|NCT01773564|Active Comparator|Available current hospital dressing|Control group: depending on the type of dressing available at the hospital, either 3M™ HP Dressing or Smith & Nephew IV3000 ™
10032026|NCT01773564|Experimental|3M™ IV Advanced Securement dressing|New generation transparent dressing
9470106|NCT03631758|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
9470107|NCT03631745|Experimental|NAMI Mental Health 101 and NAMI FaithNet|Mental Health 101 and FaithNet
9470108|NCT03631745|No Intervention|Wait-list Control|After the 12-month follow-up, wait-list control churches will be provided with the opportunity to receive Mental Health 101 and NAMI FaithNet interventions.
9470109|NCT03631693|Active Comparator|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
10032027|NCT01773577||Physician Pract. Employee and Off. Staff|The office staff and providers and physician practices enrolled in the RHIO
10032028|NCT01773590|Other|Asthmatics|Rhinovirus Infection
9470110|NCT03631693|Active Comparator|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
10032029|NCT01773590|Other|Healthy Volunteers|Rhinovirus Infection
10032030|NCT01773603|No Intervention|Conventional incubation|Five-day embryo culture in conventional incubators
10032031|NCT01773603|Active Comparator|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
9470111|NCT03631641|Experimental|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
9470112|NCT03631628|Experimental|MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + MT and 1 hour conventional training.
9470113|NCT03631628|Placebo Comparator|sham-MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + sham-MT and 1-hour conventional training.
9470114|NCT03631615|Experimental|Neoadjuvant therpy|neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
9470115|NCT03631602|Experimental|Arm 1|posaconazole oral suspension
9470116|NCT03631602|Active Comparator|Arm 2|itraconazole oral solution
9470117|NCT03631589|Experimental|MSCs treated|
9470118|NCT03631576|Experimental|Arm 1|CD123/CLL1 CAR-T Cells treat
9470119|NCT03631563|Experimental|Arm 1|ATG-F treated
9470120|NCT03631563|Active Comparator|Arm 2|ATG treated
9470121|NCT03631550|Active Comparator|Active|Relivion Active device
9470122|NCT03631550|Sham Comparator|Sham|Relivion Sham device
10032032|NCT01773616|Experimental|Rituximab|Rituximab, methyl prednisolone and mycophenolate mofetil
10032033|NCT01773616|Active Comparator|Oral prednisolone|Oral prednisolone, methyl prednisolone and mycophenolate mofetil
10032034|NCT01773629|Experimental|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
10032035|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
10032036|NCT01773642|Experimental|Cognitive-behavioral intervention|A cognitive-behavioural intervention aimed at supporting caregivers through paediatric HIV diagnosis disclosure to the child in their care.
10032037|NCT01773642|No Intervention|Standard of Care|
10032038|NCT01773655||tissue|This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM.
9470123|NCT03631537|Experimental|NST group|Nutrition support team gives the dietary supplement or other nutritional support during the period of chemotherapy
9470124|NCT03631537|No Intervention|routine group|clinicians decide whether to give and how to give the dietary supplement and other nutritional support
9470125|NCT03631524|No Intervention|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
9470126|NCT03631524|Experimental|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
9470127|NCT03631511|Experimental|RetroMTA|Direct pulp capping with RetroMTA (BioMTA, Daejeon, Korea)
9470128|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
9470129|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
9470130|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
9470131|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
9470132|NCT03631485||parents having children with cancer|No intervention.
9470133|NCT03631472|Experimental|RheOx Treatment|RheOx Treatment (i.e., Bronchial Rheoplasty)
9470134|NCT03631459||Kanglaite Injection/Capsules|Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
10032039|NCT01773668|Experimental|Integrated sensor and infusion set|
10032040|NCT01773694|Active Comparator|Early Water Exposure|The Intervention group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
10032041|NCT01773694|No Intervention|Standard Care|The Standard Care group will receive standard wound care instructions and verbal education by the staff to keep the dressing dry and intact for 48 hours.
10032042|NCT01773733||BMI ≥ 30|
10032043|NCT01773733||BMI ≥27 kg/m2 associated with DM2|
10032044|NCT01773746|Active Comparator|Room Air|Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
10032045|NCT01773746|Active Comparator|60% Group|Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
10032046|NCT01773759|Experimental|Intervention child care programs|Intervention child care programs will receive immunization outreach and education.
10032047|NCT01773759|No Intervention|Control child care programs|Control programs will receive no more than usual training regarding childhood immunization requirements.
10032048|NCT01773772|Experimental|Progesterone|Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those > or = 42 kg.
10032049|NCT01773772|Placebo Comparator|Placebo|Subjects will take placebo at 1600 h and again at 2000 h.
10032050|NCT01773798|Experimental|IDegAsp 15|
10032051|NCT01773798|Experimental|IDegAsp|
9470135|NCT03631420|Experimental|UMC119-01|UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product
9470136|NCT03631407|Experimental|Vicriviroc QD at Dose Level 1 + Pembrolizumab|Participants vicriviroc (dosed orally; once daily [QD]) at dose level 1 in combination with 200 mg pembrolizumab (intravenous [IV] infusion; every 3 weeks [Q3W]) for up to 35 cycles (cycle length: 3 weeks).
9470137|NCT03631407|Experimental|Vicriviroc QD at Dose Level 2 + Pembrolizumab|Participants receive vicriviroc (dosed orally; QD) at dose level 2 in combination with 200 mg pembrolizumab (IV infusion; Q3W) for up to 35 cycles (cycle length: 3 weeks).
10032052|NCT01773798|Experimental|IDeg|
10032053|NCT01773798|Active Comparator|IAsp|
9470138|NCT03631394|Experimental|beetroot and anthocyanin|A compound pharmacy will formulate capsules with nitrates extracted from beetroot and anthocyanins from tart cherries. A daily dose of the capsules will be taken for 7 days after the washout period. Each dose will comprise 500 mg of nitrates and 450 mg of anthocyanins. In a meta-review by Dominguez and colleagues, 6-8 mmol of nitrates from beetroot was associated with increased exercise performance. Another review by Kelley et al., showed that marathon runners and resistance trainers ingesting between 450-480 mg of anthocyanins had reduced muscle soreness and decreased oxidative stress. Subject will consume each supplement orally with only water 2 hours pre-prandial.
9470139|NCT03631394|Placebo Comparator|beetroot and placebo|The same compound pharmacy will formulate capsules with nitrate extracted from beetroot and a placebo element made of starch. This product will taste the same as the nitrate and anthocyanin supplementation. A daily dose of the capsules will be taken for 7 days after the washout period. Each supplementation will have 500 mg of nitrate and 450 mg of placebo. Subjects will consume each supplement orally with only water 2 hours pre-prandial.
10032054|NCT01773798|Experimental|IDeg + IAsp|
10032055|NCT01773811|No Intervention|Control|Individuals will write objectively about the events of their day.
10032056|NCT01773811|Experimental|Narrative Writing: Trauma-Assigned|Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
10032057|NCT01773811|Active Comparator|Narrative Writing: Trauma-Spontaneous|Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
10032058|NCT01773824|Other|No feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial).
10032059|NCT01773824|Experimental|Antibiotic prescription feedback|Physicians receive quarterly electronic feedback on their antibiotic prescriptions
9470140|NCT03631368|Experimental|Botox|
10037096|NCT01821716|Experimental|1|"Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
10037097|NCT01821742||Children requiring fluid bolus on PICU|
9470141|NCT03631342|Experimental|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
9470142|NCT03631342|Experimental|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
9470143|NCT03631342|Experimental|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
9470144|NCT03631342|Experimental|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
9470145|NCT03631342|Experimental|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
10032060|NCT01773837|Experimental|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
10032061|NCT01773837|Placebo Comparator|placebo|the same number of pills (p.o.) than methylphenidate for six days
10032062|NCT01773850||Patients|Patients with a breast lesion undergoing surgical biopsy. All patients will undergo stationary Carbon Nanotube x-ray digital breast tomosynthesis imaging in addition to routine conventional digital mammography.
10032063|NCT01773876|Active Comparator|Micafungin|MYCAMINE 100 mg intravenous an injection of 24 hours
10032064|NCT01773876|Placebo Comparator|PLACEBO|0.9% sodium chlorides 100ml infusion
10032065|NCT01773902|Experimental|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
9470146|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
9470147|NCT03631316|Experimental|Generic valganciclovir|Participants will receive generic formulation (Pisa) of valganciclovir, 450 mg tablets, total dosage 900 mg daily for 4 days.
9470148|NCT03631316|Active Comparator|Innovative valganciclovir|The same participant will receive innovative drug valcyte (roche), 450 mg tablets, total dosage 900 mg daily during 4 days.
9470149|NCT03631303||ICD patients with ATP/shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who received appropriate ICD therapy during follow-up.
9470150|NCT03631303||ICD patients without ATP/Shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who were free from appropriate ICD therapy during follow-up.
10032066|NCT01773902|Experimental|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
10032067|NCT01773902|Active Comparator|Standard protein supplementation|Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge
9470151|NCT03631303||Pacemaker-patients|10 2-chamber pacemaker-patients (LVEF >50%).
10032068|NCT01773915||AD patients|Subject fulfilling the McKhann criteria for clinical probable AD
10032069|NCT01773915||Healthy elder persons|Healthy controls with abscence of any cognitive disorder
9470152|NCT03631277|Experimental|photo-activated oral disinfection|photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
9470153|NCT03631277|Active Comparator|calcium hydroxide|Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
9470154|NCT03631264|Experimental|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
9470155|NCT03631264|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
10032070|NCT01773980||Patient and Clinic Intervention|"The patient intervention consists of a single 90-minute interactive in-person session.~The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff."
10032071|NCT01773980||Patient Intervention Only|The patient intervention consists of a single 90-minute interactive in-person session.
10032072|NCT01773980||Clinic Intervention Only|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
10032073|NCT01773980||Neither Clinic nor Patient Intervention|Consists of no intervention
9470156|NCT03631251|Experimental|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
9470157|NCT03631238||Apparently normal participants|Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment.
9470158|NCT03631212|No Intervention|Waitlist control|Wait-list control group
10032074|NCT01774006||Group culture|Embryos cultured in groups of 2-10
10032075|NCT01774006||Individual culture|Embryos cultured individually
10032076|NCT01774032|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.
10032077|NCT01774058|Experimental|Ilomedin, bloodflow volume, measurement,|Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
9470159|NCT03631212|Experimental|Flexiquit|Digital ACT-based intervention for smoking cessation
9470160|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
9480259|NCT03535402|Other|open label treatment|single arm with patients receiving 200 mg SC twice a week of sarilumab
9470161|NCT03631173|Active Comparator|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
10032078|NCT01774123||Healthy|Healthy controls
10032079|NCT01774123||MS-ON|Multiple sclerosis with optic neuritis
10032080|NCT01774123||MS-NON|Multiple sclerosis without optic neuritis
10032081|NCT01774136|Experimental|Enhanced HIV and MCH training for CHW|The intervention includes two components: (1) a 2-week HIV/C-IMCI training for CCGs and their associated facilitators and supervisors, and (2) continuous support and supervision following the continuous quality improvement (CQI) framework, a low-technology approach to management and supervision of health programs.
10032082|NCT01774136|No Intervention|Standard of Care|
10032083|NCT01774162|Active Comparator|FNA for cytology|Fine needle aspiration using conventional FNA for cytology
9470162|NCT03631173|No Intervention|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
10032084|NCT01774162|Experimental|FNB core biopsy for histology|Fine needle biopsy using ProCore needle for histology.
10032085|NCT01774175||Coolprep|A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
10032086|NCT01774175||Picolyte|Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
10032087|NCT01774188||Intraocular pressure, EECP, no glaucoma|To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
9470163|NCT03631160|Experimental|TAES treatment|"Patients in the treatment group receive Transcutaneous Acupoint Electrical Stimulation (TAES) at Zhongji ( CV3),Guanyuan ( CV4), bilaterally Sanyinjiao ( SP6) and bilaterally Ciliao ( BL32) points by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained until the end of treatment."
9470164|NCT03631160|Sham Comparator|Sham TAES treatment|"Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output."
9470165|NCT03631147|Experimental|Rifaximin treatment group|Rifaximin 400mg bid for 8 weeks
9470166|NCT03631147|No Intervention|The control group|
9470167|NCT03631134|Experimental|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
9470168|NCT03631121|Experimental|Basalin to Lantus|the patients who are using Basalin treatment will use isodose of Lantus instead
9470169|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
9470170|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
9470171|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
9470172|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
9470173|NCT03631082|Experimental|Slump stretching group|"Slump stretching will be performed with the patient in the long sitting position. The position will be held for 30 seconds. A total of 5 repetitions will be completed.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, and quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
10032088|NCT01774188||intraocular pressure, EECP, glaucoma|To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks.
10032089|NCT01774201|Experimental|Breathing exercises|Daily deep breathing exercises during two month
10032090|NCT01774201|No Intervention|Control|Control group
10032091|NCT01774214|Experimental|A|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm A, subjects will perform the Push-Pull Technique of manual fluid resuscitation first, followed by the Disconnect-Reconnect Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
10032092|NCT01774214|Experimental|B|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm B, subjects will perform the Disconnect-Reconnect Technique of manual fluid resuscitation first, followed by the Push-Pull Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
10032093|NCT01774227|Experimental|The pops-titration group|"The titration method uses power that is titrated according to the audible pop."
10032094|NCT01774227|Experimental|The slow-coagulation group|The slow-coagulation group utilize the low-energy using the Gaasterland's slow-coagulation technique
10032095|NCT01774240|No Intervention|before|no systematic approach
10032096|NCT01774240|Experimental|after|systematic screening and treatment of delirium
10032097|NCT01774266||Molina - Chile|Molina is one of the counties with the highest mortality rate of gastric cancer in Chile. Molina has a population of 40.000 hab mostly rural. Half of the population lives in Molina city and the other half in the suburbs. Molina is located near the Mountain Andes.
10032098|NCT01774279||anaplastic thyroid cancer|
10032099|NCT01774292|Active Comparator|Alkalized lidocaine|160 mg of 4% lidocaine (4 ml) in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
10032100|NCT01774292|Placebo Comparator|Sterile saline|4 mL of sterile saline in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
10032101|NCT01774318|Other|preterm cohort|preterm infants born at medical university of vienna and born at gestational age 23+0 - 28+6 weeks of gestation intervention: aEEG and conventional EEG measurements will be performed every two weeks untill 36 weeks of gestation
10032102|NCT01774331||Immunoglobulin Therapy|Immunoglobulin Therapy
10032103|NCT01774370||Pradaxa group|
10032104|NCT01774396|Other|group 2|The intervention will be the injection of Emervel® Volume Lidocaine alone in the dorsa of one hand and Emervel® Deep Lidocaine alone in the dorsa of the contralateral hand.
9470174|NCT03631082|Active Comparator|Lumbar mobilization group|"Maitland Grade 1 - 2 Posterior to anterior lumbar spine mobilization will be applied for 30 - 45 seconds for all segments through L1 to L5 at rate of 1 oscillation per 2 seconds.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
9470175|NCT03631069||Dementia|People with hospital episode statistics labels of dementia
10032105|NCT01774396|Experimental|group 1|EThe intervention will be the injection of mervel® Volume Lidocaine plus Emervel® Touch in the dorsa of one hand and Emervel® Deep Lidocaine plus Emervel® Touch in the dorsa of the contralateral hand
9470176|NCT03631069||Normal|
10032106|NCT01774422|Experimental|noninvasive ventilation alone|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
10032107|NCT01774422|Other|noninvasive ventilation associated with the DECAP CO2 device|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
10032108|NCT01774435|Experimental|EN3342|EN3342 (risperidone) subcutaneous implant
10032109|NCT01774448|No Intervention|Waitlist Control|Participants in the control group will undergo a non-intervention 8-week period while on the 'waitlist control' then will be crossed-over to the Mindfulness-Based Cognitive Therapy intervention.
10032110|NCT01774448|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy is an 8-week intervention, one session per week for 2 hours, where participants will learn and practice formal and informal mindfulness meditation, and participate in group discussion and inquiry.
10032111|NCT01774461|No Intervention|Sham RIC|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
10032112|NCT01774461|Active Comparator|Remote ischemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
10032113|NCT01774474|Active Comparator|Non diabetics: bromfenac|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
10032114|NCT01774474|Active Comparator|Non diabetics: dexamethasone|dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
10032115|NCT01774474|Active Comparator|Non diabetics: bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
10032116|NCT01774474|Active Comparator|Diabetics: eye drops|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
10032117|NCT01774474|Active Comparator|Diabetics: eye drops & TA|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)"
10032118|NCT01774474|Active Comparator|Diabetics: eye drops & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)"
10032119|NCT01774474|Active Comparator|Diabetics: eye drops, TA & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)~& a peroperative intravitreal injection of 1.25 mg bevacizumab"
9470177|NCT03631030|Other|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
9470178|NCT03631017|Experimental|[18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
10032120|NCT01774487|Experimental|Pentoxifylline|"All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes."
10032121|NCT01774513|Experimental|Procore Needle|
10032122|NCT01774539||Physeal Injury - Distal Radius|Patients who suffer a physeal fracture of the distal radius will be scanned and compared to their healthy contralateral limb.
10032123|NCT01774552||Port-wine stain|Photo Acoustic Microscopy and Optical Coherence tomography
10032124|NCT01774565|Experimental|Fully Automated Closed-Loop Insulin Delivery (phase 1-4)|The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose. In phase 3 and 4 faster-acting insulin aspart (Fiasp) is applied.
10032125|NCT01774565|Active Comparator|Usual care/ fully-automated closed-loop using Iasp|"Phase 1-3: During usual care (conventional therapy), subject's s.c. insulin dose and regimen on admission will be adjusted as necessary by the clinical team according to local centres' usual clinical practice. Subjects will have masked CGM sensors inserted during the study (CGM readings will be masked throughout the study).~Phase 4: subjects will receive fully-automated insulin delivery using standard insulin aspart (Iasp)"
10032126|NCT01774617||Patients with advanced liver disease|Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level >1.5 mg/dL), severe bleeding disorder (prothrombin activity test < 30% or platelets count <35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.
10032127|NCT01774630|Experimental|Nilotinib|300 mg/twice a day
10032128|NCT01774643||Pancreatic cancer with liver metastases|Tumor tissue biopsy, blood samples
10032129|NCT01774656|Experimental|HeartMate II plus Pharmacological Treat|"The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.~The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily."
10032130|NCT01774669|Experimental|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
10032131|NCT01774669|Active Comparator|Conventional therapy|Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
10032132|NCT01774682|Other|6-minute walk test|the 6-minute walk test is performed for each patient prior to the surgery and 6 months after by a specialist.
10032133|NCT01774695|Other|Control and intervention|In the first study half of the subjects first served as controls for 12 weeks and then they went through the intervention. The other half only went through the intervention.
10032134|NCT01774708||Bed Exit|"Participants will be up to 60 ambulatory Budd Terrace residents.~Inclusion/Exclusion:~Inclusion:~Ambulatory patient able to leave the bed.~Willingness to consent and participate in a 30-night study~Exclusion:~Lack of capacity to consent, without an identifiable surrogate.~Terminal Prognosis~Unstable health, as determined by the principal investigator, medical doctor, or registered nurse."
10032135|NCT01774734|Experimental|neck strength exerciser (NSE) group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based NSE training 20 minutes daily
10032136|NCT01774734|Placebo Comparator|Physical therapy group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based general neck exercise 20 minutes daily
10032137|NCT01774747|Experimental|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
10032138|NCT01774747|Placebo Comparator|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
10032139|NCT01774773|Experimental|Group A|E5501 5mg, then 20mg, then 40 mg, then 5mg
10032140|NCT01774773|Experimental|Group B|E5501 20mg, then 40mg, then 5 mg, then 5mg
10032141|NCT01774773|Experimental|Group C|E5501 40mg, then 5mg, then 20 mg, then 5mg
10032142|NCT01774812|Active Comparator|Vitamin D Sequence 1|6 weeks - alfacalcidol 0.25mcg + placebo 3x per week, 12 week washout, 6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days)
10032143|NCT01774812|Active Comparator|Vitamin D Treatment Sequence 2|6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days), 12 week washout, 6 weeks - alfacalcidol 0.25mcg + placebo 3x per week
10032144|NCT01774825|Active Comparator|IQP-CL-101|2 softgels twice a day
10032145|NCT01774825|Placebo Comparator|Placebo|2 softgels twice a day
10032146|NCT01774838|Experimental|Prasugrel|3 months treatment with 10 mg prasugrel
10032147|NCT01774838|Active Comparator|Clopidogrel|3 months treatment with clopidogrel 75 mg
10032148|NCT01774864|Experimental|DA-8159 dose 1|Udenafil
10032149|NCT01774864|Experimental|DA-8159 dose 2|Udenafil
10032150|NCT01774864|Placebo Comparator|Placebo|
10032151|NCT01774877|Experimental|Xinfeng capsule & placebo|"Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months~placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
10032152|NCT01774877|Active Comparator|leflunomide & placebo|"leflunomide :10mg each time, one time a day, by mouth,for 3 months~placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
10032153|NCT01774916|Other|patients|
10032154|NCT01774916|Other|volunter|
9470179|NCT03630991|Experimental|Cohort I (edetate calcium disodium, multivitamin)|During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
9470180|NCT03630991|Experimental|Cohort II (succimer, multivitamin)|During standard of care chemotherapy, patients receive succimer PO daily for 8 or 21 days of each cycle beginning day 1. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
9470181|NCT03630978||Liver resection|
9470182|NCT03630965|No Intervention|Group A|No CPR video
9470183|NCT03630965|Experimental|Group B|CPR video
10032155|NCT01774942|Experimental|Procedure/Surgery (Impants/Overdentures)|One-arm clinical intervention study: All teeth out, full dentures, dental implants, blood draw. The interventions are not experimental in nature, they are standard procedures, namely extraction of all natural teeth followed by suturing to hold soft tissue in place during initial healing; surgical insertion of commercially available dental implants; and fabrication and re-lining (filling in with acrylic the base of the denture as needed during healing and shrinking of underlying tissue) of full dentures, that is full plates in upper and lower jaw to replace all teeth.
10032156|NCT01774994|Experimental|stable isotopes|stable isotope infusion for measurement of metabolism
10032157|NCT01775007|Experimental|Normal Healthy Subjects|Brillouin Ocular Analyser
10032158|NCT01775020|Experimental|L-arginine|L-arginine
10032159|NCT01775033|Experimental|Multicomponent intervention|Hospitals in the experimental arm will receive a four-component intervention that integrates local education, community outreach, telemedicine and protocolized triage and transport
10032160|NCT01775033|No Intervention|Control|Hospitals in the control arm will receive usual care.
10032161|NCT01775059|Experimental|Integrated sensor and infusion set.|
10032162|NCT01775098|Experimental|Allopurinol|treatment with allopurinol
9470184|NCT03630952|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
10032163|NCT01775098|Placebo Comparator|placebo|placebo comparator
9470185|NCT03630952|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
9470186|NCT03630952|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
9470187|NCT03630939|Experimental|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
9470188|NCT03630939|Experimental|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
9470189|NCT03630939|Placebo Comparator|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
9470190|NCT03630926||Prostate Cancer (PCa)|Comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy.
9470191|NCT03630926||Benign Prostatic Hypertrophy (BPH)|comprosed of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP).
9470192|NCT03630926||Bladder/kidney stone|Comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
9470193|NCT03630900|Experimental|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
9470194|NCT03630900|No Intervention|5% O2 culture|
9470195|NCT03630887|No Intervention|Control|Non-active prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
9470196|NCT03630887|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
9470197|NCT03630887|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
9480260|NCT03535389|Experimental|Pathologic group|Patients addressed to our imaging department for the realization of a knee scanner as part of routine care and presenting clinical PFI syndrome (Patellofemoral instability diagnosis based on physical examination, history and Kujala score)
10032164|NCT01775111|Sham Comparator|Cognitive Training|Cognitive Training (riddles, skill games, ...) is performed twice a week in small groups
10032165|NCT01775111|Experimental|Strength Training|Progressive strength training is applied, meaning that the intensity is adjusted continuously in order to obtain a sufficient training stimulus. Exercises are chosen to involve the major muscle groups and are performed by using the own body weight or elastic bands.
10032166|NCT01775111|Experimental|Strength Training and Supplement|In addition to strength training as described above, participants receive a water-soluble dietary supplement 9x/week (FortiFit, Nutricia) consisting of 20.7 g of protein (56 En%, 19.7 g whey protein, 3 g leucine,> 10 g essential amino acids), 9.3 g carbohydrates (25 En%, 0.8 BE), 3.0 g fat (18 En%), 1.2 g fiber (2 En%), 800 IU (20μg) of vitamin D, 250mg calcium, vitamins B6 and B12, folic acid and magnesium.
10032167|NCT01775150|Experimental|health education|health education via text messaging
10032168|NCT01775150|No Intervention|no health education|no health education via text messaging
10032169|NCT01775163||Self Directed Exercise|Participants randomized to the self-directed group will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss. Participants will not be given a specific exercise recommendation in terms of weekly energy expenditure.
10032170|NCT01775163||Low Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 8 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
10032171|NCT01775163||High Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 20 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
10032172|NCT01775176||Polycystic Ovary Syndrome|Overweight women with polycystic ovary syndrome. 20 - 40 years, inclusiveBody mass index ≥ 25kg/m2History of irregular menstrual cycles (fewer than 8 regular cycles in the past year)Clinical and/or biochemical androgen excess (Free androgen index>3.85 and/or hirsuitism rating ≥8)Anovulatory menstrual cycles (determined during screening)
9470198|NCT03630887|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
9470199|NCT03630874|Experimental|Experimental arm|
10032173|NCT01775215||A - Symptomatic severe AS|Patients with symptomatic severe aortic stenosis (AS) as per ESC guidelines, requiring aortic valve replacement.
10032174|NCT01775215||B - Asymptomatic moderate to severe AS|Asymptomatic patients with moderate to severe aortic stenosis (AS) as per ESC guidelines ,with Left Ventricular ejection fraction >50%, not yet requiring aortic valve replacement.
10032175|NCT01775228|No Intervention|Regular follow up care|No intervention group - received routine follow up care following discharge from hospital after cardiac surgery (no peer support intervention).
10032176|NCT01775228|Active Comparator|Peer Support intervention|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
9470200|NCT03630874|No Intervention|Control arm|"Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the right prescription of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided."
9470201|NCT03630861||GBM|Primary glioblastoma (GBM)
9470202|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
10032177|NCT01775254||Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancers followed by adjuvant chemotherapy.
10032178|NCT01775254||No Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancer and who do not receive chemotherapy.
10032179|NCT01775267|Experimental|ALPPS|Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
9470203|NCT03630861||Brain metastases|Brain metastases (BM)
9470204|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
9470205|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
9470206|NCT03630848|Experimental|10 mg/ml protein concentration in Embryo Culture Media|
9470207|NCT03630848|No Intervention|5 mg/ml protein concentration in Embryo Culture Media|
9470208|NCT03630796|Active Comparator|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
9470209|NCT03630796|Other|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
9480261|NCT03535389|Active Comparator|Control group|"Patients addressed to our imaging department for osteo-articular pathologies other than patellofemoral instability (non-fracture trauma, vascular pathologies, degenerative or soft tissues).~Does not have any clinical PFI syndrome~Matched (1: 1 ratio) to PFI patients by age (+/- 40 years) and sex"
10032180|NCT01775267|Active Comparator|PVO|Patient undergo portal vein embolization or ligation
10032181|NCT01775280|Experimental|Radioembolization|Radioembolization using Yttrium-90 microspheres using a transarterial approach
10032182|NCT01775293|Experimental|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
10032183|NCT01775319|Active Comparator|Biofortified wheat|Biofortified wheat
9470210|NCT03630783|Experimental|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
9470211|NCT03630783|Placebo Comparator|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
9470212|NCT03630770|No Intervention|Control|This group receives no feeding supplement.
9470213|NCT03630770|Experimental|MCT Oil|This group is supplemented with MCT oil
9470214|NCT03630757|Experimental|Treatment|While holding the patient's head with the therapist's hands,the cervical spinous processes with the fingertips palpitate to the occipital condyle towards the proximal.Then the fingers of both hands applied pressure to the axis in the space between the occipital condyle and the spinous process
9470215|NCT03630757|Placebo Comparator|Group 2|reaching to the feet while sitting together with warming and cooling periods
10032184|NCT01775319|Placebo Comparator|Control wheat|Control wheat with low level of Zn
9470216|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
9470217|NCT03630718|No Intervention|Control Group (CG)|Patients assigned to no intervention
9470218|NCT03630718|Active Comparator|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
10032185|NCT01775319|Active Comparator|Fortified wheat|Wheat fortified before consumption
10032186|NCT01775332|Experimental|Educational Intervention|Educational Intervention - Access to educational materials provided (i.e. website, videos, brochure)
9470219|NCT03630718|Active Comparator|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
9470220|NCT03630692||observance of oral drug treatment|Study of observant or nonobservant patient behavior for their oral drug treatment
9803093|NCT04553822|Experimental|Assisted autogenous drainage group (DAA)|The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes.
9470222|NCT03630627|Experimental|SB26 for Part 1|SB26: various single doses, administered to various cohorts
9470223|NCT03630627|Experimental|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
9470224|NCT03630627|Placebo Comparator|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
9470225|NCT03630627|Placebo Comparator|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
9470226|NCT03630614|Experimental|Electronic cigarette condition|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
9470227|NCT03630614|Active Comparator|Varenicline condition|Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
9470228|NCT03630614|Placebo Comparator|Placebo condition|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
9470229|NCT03630575|Experimental|Newborns exposed in-utero to psychoactive substances|
9470230|NCT03630549|Active Comparator|Standard of Care|"Offer of home-based same-day ART initiation~Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~No SMS intervention"
10032187|NCT01775332|No Intervention|No Intervention/Use of Own Resources|No educational materials are provided to participants, but they can use their own resources
9803094|NCT04553822|Experimental|Group prolonged slow expiration (ELPr)|This technique is applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume.
9803095|NCT04553822|Active Comparator|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer.
10032188|NCT01775345|Experimental|Isotonic exercises + ST|"This group will realize 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a maximum repetition (MR)(MR is the maximum resistance that a muscle can conquer).~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
10032189|NCT01775345|Experimental|Isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
9470231|NCT03630549|Experimental|Village-based ART refill|"Offer of home-based same-day ART initiation~Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)~Offer of Individually customized SMS~Monthly reminder SMS: to pick up ART~SMS communicating VL result"
10032190|NCT01775345|Experimental|Isotonic and isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
10032191|NCT01775358|Experimental|ALRN-5281 0.015 mg/kg|Dosage-0.015 mg/kg
9470232|NCT03630523|Other|Vaccination|Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
9470233|NCT03630510|Experimental|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
9470234|NCT03630510|No Intervention|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
9470235|NCT03630497|Experimental|Period 1 Single Dose SD1 (first dose)|"Period 1 Group SD1 a single IV infusion of first single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470236|NCT03630497|Experimental|Period 1 Single Dose SD2 (second dose)|"Period 1 Group SD2 a single IV infusion of second single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470237|NCT03630497|Experimental|Period 1 Single Dose SD3 (third dose)|"Period 1 Group SD3 a single IV infusion of third single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470238|NCT03630497|Experimental|Period 1 Single Dose SD4 (fourth dose)|"Period 1 Group SD4 a single IV infusion of fourth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470239|NCT03630497|Experimental|Period 2 Single Dose SD1 (fifth dose)|"Period 2 Group SD1 a single IV infusion of fifth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470240|NCT03630497|Experimental|Period 2 Single Dose SD2 (sixth dose)|"Period 2 Group SD2 a single IV infusion of sixth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470241|NCT03630497|Experimental|Period 2 Single Dose SD3 (seventh dose)|"Period 2 Group SD3 a single IV infusion of seventh single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470242|NCT03630497|Experimental|Period 2 Single Dose SD4 (Optional)|"(Optional) Period 2 Group SD4 a single IV infusion of eighth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
9470243|NCT03630497|Experimental|Multiple Dose MD1|"MD1 once daily IV infusions of first multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
9470244|NCT03630497|Experimental|Multiple Dose MD2|"MD2 once daily IV infusions of second multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
9470245|NCT03630484|Active Comparator|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
9470246|NCT03630484|Active Comparator|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
10032192|NCT01775358|Experimental|ALRN-5281 0.05 mg/kg|Dosage- 0.05 mg/kg
9470247|NCT03630471|Active Comparator|Control|Enhanced usual care (problem-solving booklets only).
9470248|NCT03630471|Experimental|Intervention|PRIDE 'Step 1' problem-solving intervention.
9470249|NCT03630458|Experimental|Pearl millet couscous - made in Senegal|Steamed pearl millet couscous - commercially produced in Senegal
10032193|NCT01775358|Experimental|ALRN-5281 0.15 mg/kg|Dosage- 0.15 mg/kg
10032194|NCT01775358|Placebo Comparator|Placebo 0.015 mg/kg|Dosage- 0.015 mg/kg
10032195|NCT01775358|Placebo Comparator|Placebo 0.05 mg/kg|Dosage- 0.05 mg/kg
10032196|NCT01775358|Placebo Comparator|Placebo 0.15 mg/kg|Dosage - 0.15 mg/kg
10032197|NCT01775384|Experimental|Nutrasorb|Soy protein powder sorbed with polyphenols from blueberries and green tea extract
10032198|NCT01775384|Placebo Comparator|Placebo|Soy protein isolate powder without polyphenols (with food coloring)
10032199|NCT01775397|Experimental|Fidaxomicin|Fidaxomicin with alternating matching placebo
10032200|NCT01775397|Active Comparator|Vancomycin|Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period
9470250|NCT03630458|Experimental|Pearl millet couscous - made in USA|Steamed pearl millet couscous - pearl millet obtained from Senegal but processed and prepared in USA
9470251|NCT03630458|Experimental|Pearl millet thick porridge|Thick porridge prepared according to traditional West African methods with pearl millet obtained from Senegal but processed and prepared in USA
9470252|NCT03630458|Experimental|Wheat couscous|Steamed wheat couscous - wheat flour processed and prepared in USA
9470253|NCT03630458|Active Comparator|White rice|White rice - medium-grain prepared using a rice cooker
10032201|NCT01775436|Active Comparator|Healthy Living Control|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
10032202|NCT01775436|Experimental|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
9470254|NCT03630445|Experimental|Isomaltooligosaccharides (IMOs)|"Isomaltooligosaccharides (IMOs) incorporated into a yogurt test meal.~IMOs are a mixture of short-chain carbohydrates with a purported slow digestion property."
10032203|NCT01775449|Experimental|polyamines depleted diet|• in the group with a polyamines depleted diet : 2-4 cans per day of Polydol® (oral alimentation without polyamines), associated to predefined menus low in polyamines, according to the chemotherapy cycle and for 107 days
10032204|NCT01775449|Other|normal polyamines containing diet|• in the control group with a normal polyamines containing diet: 1 can per day of Polydol® associated with predefined menus with normal average in polyamines and for 107 days.
9470255|NCT03630445|Experimental|Xtend® sucromalt|"Xtend® sucromalt incorporated into a yogurt test meal.~Sucromalt is derived from a combination of sucrose (cane or beet sugar) and maltose (corn sugar), yet it has been found to be slowly digested."
10032205|NCT01775462|Experimental|EDI200, 3mg/kg|Five doses of EDI200 given at 3 mg/kg twice weekly
10032206|NCT01775462|Experimental|EDI200, 10 mg/kg|Five doses of EDI200 given at 10 mg/kg twice weekly
10032207|NCT01775475|Active Comparator|Arm I (CHOP)|Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10032208|NCT01775475|Experimental|Arm II (oral chemotherapy)|Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9470256|NCT03630445|Experimental|Combination of IMOs and Xtend® sucromalt|Combination of IMOs and Xtend® sucromalt incorporated into a yogurt test meal.
9470257|NCT03630445|Experimental|Raw corn starch|"Raw corn starch incorporated into a yogurt test meal.~Raw corn starch is uncooked starch from corn. Because it is not cooked, it has a slow digestion property."
9470258|NCT03630445|Experimental|Maltodextrin|"Maltodextrin incorporated into a yogurt test meal.~Maltodextrin is a type of starchy carbohydrate (polysaccharide) composed of units of D-glucose (simple sugars). The maltodextrin used for this study had a fast digestion property."
9470259|NCT03630432|Active Comparator|Group A|Immediate 8 week course of pulmonary rehabilitation
9470260|NCT03630432|Placebo Comparator|Group B|Initial 8 weeks of usual care
9470261|NCT03630419|Experimental|Mito-Food Plan and Cellular Repair|Mito-Food Plan with adjunctive Cellular Repair Therapy
9470262|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
9470263|NCT03630380||Single Arm|All children under five years of age with clinical suspicion of pneumonia (fever or respiratory complaints) who have a chest radiograph ordered will be consented. Clinical history, physical exam findings (temperature, respiratory rate, oxygen saturation, and lung auscultation findings), laboratory findings (white blood cell count, differential, and CRP) will be recorded. Lung ultrasound will be performed on all patients.
9480262|NCT03535298|Experimental|EHT: Early Highly-effective|"Participants randomized to the EHT: Early Highly-effective arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab, Kesimpta) as their initial disease modifying treatment.~Interventions: one of the highly effective MS therapies~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
9480263|NCT03535298|Experimental|ESC: Escalation|"Participants randomized to the ESC: Escalation arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment.~Interventions: one of the MS therapies NOT in the highly effective group~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
9480264|NCT03535298|No Intervention|OBS: Observational|"Participants will not be restricted to a group of MS therapies.~Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm."
9480265|NCT03535285|Experimental|Surgical modification side|Periodontal ligament distraction without the oblique cuts but with apical horizontal cut
9480266|NCT03535285|Active Comparator|Conventional surgery|Periodontal ligament distraction
9480267|NCT03535259|Experimental|Sorafenib and IMRT|Concurrent sorafenib and IMRT, followed sorafenib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
9480268|NCT03535246|Experimental|Single arm|EIE cells to treat cancer.
9480269|NCT03535233|Active Comparator|Intralesional group|intralesional triamcinolone acetonide 5 mg/ml monthly
9480270|NCT03535233|Active Comparator|Topical therapy group|Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night
9470264|NCT03630367|Experimental|study group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
9470265|NCT03630367|Active Comparator|control group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous
9470266|NCT03630341|Experimental|study group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
9470267|NCT03630341|Active Comparator|control group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
9470268|NCT03630315|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of OTX-TKI
9470269|NCT03630315|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of OTX-TKI.
10032209|NCT01775488|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
9470270|NCT03630315|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of OTX-TKI.
9470271|NCT03630315|Experimental|Cohort 3 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
9470272|NCT03630315|Experimental|Cohort 4 (High Dose)|Subjects will receive a high dose of OTX-TKI.
9470273|NCT03630315|Experimental|Cohort 4 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
9470274|NCT03630276|Other|Neutrophil/lymphocyte ratio|
10032210|NCT01775514||Participants With Cancer|Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
10032211|NCT01775527|Other|blood test|
10032212|NCT01775540|Experimental|Systane Ultra|Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
10032213|NCT01775540|Placebo Comparator|Saline solution|Saline solution Eyedrop, 1 drop used QID for 4 weeks
10032214|NCT01775540|Active Comparator|Maxidex|Steroid eyedrop, 1 drop QID for 4 weeks
10032215|NCT01775566||Eperisone SR tablet 75mg, Myonal 50mg|Eperisone SR tablet 75mg Myonal 50mg
10032216|NCT01775579|Experimental|Crestor tablet 20 mg|Crestor tablet 20 mg single--->wash out---->Glucophage SR tablet 750 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
10032217|NCT01775579|Experimental|Glucophage SR tablet 750 mg and Crestor tablet 20 mg both|Glucophage SR tablet 750 mg, Crestor tablet 20 mg both--->wash out---->Glucophage SR tablet 750 mg single------>washout--->Crestor tablet 20 mg single
9470275|NCT03630276|Other|Platelet/lymphocyte ratio|
10032218|NCT01775579|Experimental|Glucophage SR tablet 750 mg|Glucophage SR tablet 750 mg single --->wash out---->Crestor tablet 20 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
9470276|NCT03630276|Other|CRP|
9470277|NCT03630263|Experimental|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
9470278|NCT03630263|Placebo Comparator|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
9470279|NCT03630250|Experimental|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
10032219|NCT01775592|Other|Arterakin|"Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - < 8 years: 1.0, 1.0, 1.0, 1.0 8 - < 15 years:1.5, 1.5, 1.5, 1.5~≥ 15 years:2.0, 2.0, 2.0, 2.0"
10032220|NCT01775605|Active Comparator|Synera|Synera Pain Patch
10032221|NCT01775605|No Intervention|No patch control|No intervention group
10032222|NCT01775605|Sham Comparator|Control|Sham
10032223|NCT01775618|Experimental|Main study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
10032224|NCT01775618|Experimental|Part 2 (Expansion group)|Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
10037600|NCT01826552|Active Comparator|Resolute Integrity|The Patient group who are treated with ② Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
9470280|NCT03630250|No Intervention|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
9470281|NCT03630250|Experimental|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
9480271|NCT03535220||Observational/ Interventional|Hematologic Disease
9803096|NCT04552795|Experimental|Open-Label 3TC|12 subjects will receive 3TC, 300-mg, daily for 24 weeks.
10032225|NCT01775618|Experimental|Extension study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.
10032226|NCT01775631|Experimental|Arm -1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
10032227|NCT01775631|Experimental|Arm 1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
10037098|NCT01821755|Experimental|Behavioral: Foster parent intervention|Foster parents receive a foster parent intervention consisting of 10 individual home visits and three group sessions. Duration of the intervention is four months
10037099|NCT01821755|No Intervention|Control|waiting-list control group who receive care-as-usual
9470282|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac & neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
9470283|NCT03630172|Experimental|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
10037100|NCT01821768|No Intervention|Arm 1: No sentinal lymph node biopsy|Patients will receive no additional axillary surgery which is experimental.
10037101|NCT01821768|Active Comparator|Arm 2: Sentinel lymph node biopsy|Patients will receive standard of care sentinel lymph node biopsy
10037102|NCT01821820|Experimental|Pistachios|Pistachio treatment (3 oz/d) for two weeks; 3 oz pistachio nuts and water (1.5 oz. before, and 1.5 oz during) cycling 75 km.
10037103|NCT01821820|No Intervention|No pistachios|No pistachios for two weeks, or before and during 75 km cycling.
10037104|NCT01821846||Liraglutide|
10037105|NCT01821872|Active Comparator|Sampling at approx 15 minutes|Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol
9470284|NCT03630172|Sham Comparator|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
9470285|NCT03630146|Experimental|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 5-12 weeks.
9470286|NCT03630146|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iPeer2Peer program.
9470287|NCT03630133|Experimental|Intracept System Ablation|Single Arm
9470288|NCT03630107|Experimental|WO 5101 Shampoo for Scalp and Hair|WO 5101 is used in subjects with chronically itchy scalp
9470289|NCT03630094|Experimental|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
9470290|NCT03630081|Experimental|FEP-TAZ 4 g|FEP-TAZ Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
9470291|NCT03630081|Active Comparator|Meropenem|Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min
9470292|NCT03630068||Patients with hepatocellular carcinoma treated with microwave|
9470293|NCT03630042|Experimental|Pembrolizumab and Rituximab|
10037106|NCT01821872|Active Comparator|Sampling at approx 30 minutes|Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol
10037107|NCT01821872|Active Comparator|Sampling at approx 120minutes|Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol
10037108|NCT01821885|Experimental|Spirometry and a brief advice to quit smoking|"Intervention group:~The intervention consists of completing a questionnaire and undergo spirometry with bronchodilator test by a trained nurse. Later, the patients receives a brief advice to quit smoking and a report of the spirometry results by their family doctor."
10037109|NCT01821885|Active Comparator|Brief advice to quit smoking|"Control group:~Patients in the control group complete a questionnaire by a nurse and then receive a brief advice to quit smoking by their family doctor."
10037110|NCT01821911|Experimental|Zagreb2-1-1|Injection on day 0、7、21
10037111|NCT01821911|Active Comparator|Essen|Injection on day 0、3、7、14、28
10037112|NCT01821950|No Intervention|Physical education as usual|Physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
10037113|NCT01821950|Experimental|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
10037114|NCT01821976|Active Comparator|Ertl Procedure|Patients randomized to the Ertl Procedure Arm will receive an amputation very similar to the Burgess Procedure, except the surgeon will perform an additional step to make the cut end of the tibia bone heal to the cut end of the fibula bone with a bone bridge. This bone bridge connects the two bones together.
10037601|NCT01826565|No Intervention|Control|i-gel will be inserted without rotation
9470294|NCT03630029|Other|Administer a dose 12mgFeS/9mg SnPP|12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.
9470295|NCT03630029|Other|Administer a dose 60mgFeS/45 mg SnPP|12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Stannous Protoporphyrin and followed for seven days.
9470296|NCT03630029|Other|Administer a dose 120mgFeS/90mg SnPP|12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Stannous Protoporphyrin and followed for seven days.
9470297|NCT03630029|Other|Administer a dose 180mgFeS/135mg SnPP|12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Stannous Protoporphyrin and followed for seven days.
9470298|NCT03630029|Other|Administer a dose of FeS/SnPP CKD Arm|12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Stannous Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.
9470299|NCT03629964|Experimental|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
9470300|NCT03629912|Experimental|Exercise + Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises AND health information on fall risks + diet/nutrition.
9470301|NCT03629912|Active Comparator|Exercise + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises ONLY.
9470302|NCT03629912|Active Comparator|Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating health information on fall risks + diet/nutrition ONLY.
9470303|NCT03629912|No Intervention|Bingo Only|Participants use the Bingocize app to play bingo only.
9470304|NCT03629899|Experimental|RETINA IMPLANT Alpha AMS|"After implantation surgery, every single sub-test will be performed with randomized implant activation (ON or OFF). During every trial of each sub-test there will be a study coordinator and a technician. The study coordinator will have a set randomization examination schedule while the technician will record patient response without knowledge of the randomization examination schedule. The patient, technician and investigator will all be masked to the testing conditions."
9470305|NCT03629860|Active Comparator|ascending ramus group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures.~after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
9470306|NCT03629860|Active Comparator|Chin Group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from chin to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures~after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
9470307|NCT03629847|Experimental|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
9470308|NCT03629821|Experimental|Ballet|Subjects who will receive the experimental protocol.
9470309|NCT03629821|No Intervention|Control|Subjects who will not receive the experimental protocol, only will be on a wait list.
9470310|NCT03629808||Group1: 4-6cm|4-6cm from starting point of gastrectomy to pylorus
9470311|NCT03629808||Group2: 2-4cm|2-4cm from starting point of gastrectomy to pylorus
9470312|NCT03629769|Experimental|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
9470313|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
9470314|NCT03629717|Experimental|Denosumab|An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.
9470315|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
9470316|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
9470317|NCT03629665|Active Comparator|rTMS and naming combined with ILAT|Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
9470318|NCT03629665|Sham Comparator|sham rTMS and naming combined with ILAT|Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
9470319|NCT03629639|Experimental|Metformin|the distributed subjects will be orally administered Metformin 500mg bid lasting for 12 weeks.
9470320|NCT03629639|Placebo Comparator|Placebo|the distributed subjects will be orally administered Metformin-like placebo 500mg bid lasting for 12 weeks.
9470321|NCT03629626|No Intervention|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
9470322|NCT03629626|Experimental|ERAS protocol|preoperative / intraoperative/ postoperative management
9470323|NCT03629613|Sham Comparator|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~During baseline testing, no supplement or placebo intake will be used."
9470324|NCT03629613|Experimental|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
10032228|NCT01775657|Experimental|Air leak present - Analogue|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, air leak present.
9470325|NCT03629600|Experimental|Aggressive Hydration|Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) [COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
10032229|NCT01775657|Active Comparator|Air leak absent - Analogue (Pleur Evac)|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, no air leak present
9470326|NCT03629600|Active Comparator|Rectal Indomethacin|Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin [Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA] just after the completion of ERCP procedure.
9470327|NCT03629587||Patients presented H pylori positive|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
9470328|NCT03629587||Patients with H pylori negative|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
9470329|NCT03629574|Experimental|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
9470330|NCT03629574|No Intervention|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
9470331|NCT03629548|Active Comparator|early amniotomy plus dinoprostone|10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
9470332|NCT03629548|Experimental|foley balloon catheter plus dinoprostone|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix
9470333|NCT03629522|Active Comparator|ondansetron group|Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
9470334|NCT03629522|Placebo Comparator|control group|administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
9470335|NCT03629509|Other|Pre-Intervention|"The BEFORE decision aid will be available for use on the RUBY communication portals (Twitter, Facebook and study portal)~Data will be collected 6 weeks before the implementation of the BEFORE decision aid in RUBY sites to establish a baseline"
9470336|NCT03629509|Experimental|BEFORE Decision Aid Intervention|"Evaluate more intensive strategies to promote use of the BEFORE decision aid through:~We will advertise the availability of the BEFORE decision aid with posters placed in clinic areas at each RUBY site, and will have small handouts available to be distributed in clinic.~We will conduct an educational intervention describing and promoting the use of the BEFORE decision aid and general oncofertility information to nurses and support staff at each RUBY site. This will include an optional 1hr informational webinar, direct outreach and training of nurses/support staff on the use of the tool."
9470337|NCT03629509|Other|Post-Intervention|Data will be collected after the BEFORE decision aid has been implemented in each RUBY site regarding the recommendation of fertility resources, most useful/least useful tool, and use of the BEFORE decision aid.
9470338|NCT03629496|Experimental|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
9470339|NCT03629496|No Intervention|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
10032230|NCT01775657|Experimental|Air leak present - Digital (Thopaz)|Patients with an air leak present, randomized to Thopaz (digital drainage) monitoring system.
10032231|NCT01775657|Active Comparator|Air leak absent - Digital (Thopaz)|Patients randomized to digital system, no air leak present.
9470342|NCT03629457|Experimental|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2 hours. Participants must practice at home for 15 minutes a day
10032232|NCT01775683||Group A - chronically homeless|Men and women, greater than or equal to age 18 years, English-speaking, who are currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months.
10032233|NCT01775683||Group B - control/formerly homeless|Men and women, greater than or equal to 18 years, English-speaking who are not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month
9470343|NCT03629457|Experimental|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2 hours. Participants must practice at home for 30 minutes a day
10032234|NCT01775696||sporadic AD|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate dementia)
10032235|NCT01775696||familial forms of AD|15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations
10032236|NCT01775696||asymptomatic relatives|30 asymptomatic relatives to familial AD patients
10032237|NCT01775696||controls|40 controls
10032238|NCT01775696||genetic FTD|5 genetic forms of FTD
10032239|NCT01775709|Experimental|PE tube with Duckbill Valve|PE tube with Duckbill Valve
10032240|NCT01775748|Other|Active First|Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day
9470344|NCT03629457|No Intervention|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
9470345|NCT03629431|Active Comparator|postoperative standard care|Standard care after surgery in postoperative unit
9470346|NCT03629431|Experimental|Prophylactic non-invasive ventilation|Prophylactic noninvasive ventilation in postoperative and intensive care unit
9470347|NCT03629418|Experimental|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
9470348|NCT03629418|Active Comparator|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
9470349|NCT03629405|No Intervention|A - Negative control (untreated) for product C|On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C
9470350|NCT03629405|No Intervention|B - Negative control (untreated) for product D|On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D
9470351|NCT03629405|Experimental|C - Cosmetic Product WO 3741 with pH 4|On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.
9470352|NCT03629405|Experimental|D - Cosmetic Product WO 4081-1 with pH 5.8|On the forearms four test areas were located, which were labeled from A-D.
9470353|NCT03629392|Experimental|Low met/cys diet|Dietary intervention
9470354|NCT03629392|Experimental|Moderate met/cys diet|Dietary intervention
9470355|NCT03629392|Active Comparator|High met/cys diet|Dietary intervention
9470356|NCT03629379|Active Comparator|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
9470357|NCT03629379|Active Comparator|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
9470358|NCT03629366|Experimental|Supported Employment (SE)|Follow-up with Supported Employment (SE), provided by a job specialist trained in the eight evidence-based principles of Individual Placement and Support (IPS). The SE intervention is provided in addition to the mandatory introduction program for refugees in Norway (treatment as usual).
9470359|NCT03629366|Active Comparator|Treatment as usual (TAU)|Follow-up with treatment as usual, which involves participation in the mandatory introduction program provided for all refugees in Norway. The program includes training in Norwegian language and culture, as well as the various traditional employment schemes offered by the Norwegian labor and welfare Administration.
9470360|NCT03629353|Experimental|intubation group|The enrolled patients will be oxygenated by endotracheal tube during operation.
9803097|NCT04552171|Experimental|Access to Game Plan app and 24-hour helpline|Participants in this condition will be provided access to the Game Plan app and encouraged to use it after they complete their baseline assessments and STI testing has been completed. These participants will also be provided with access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not.
10032241|NCT01775748|Other|Placebo First|Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day
10032242|NCT01775761|Experimental|Period 1: 960 mg tafamidis (Vyndaqel)|
9470361|NCT03629353|Experimental|THRIVE group|The enrolled patients will be oxygenated by intubationless high flow nasal cannula during operation.
9470362|NCT03629301|Experimental|ID-DPP group|Internet-delivered intervention based on the DPP
9470363|NCT03629301|Other|Wait-list Group|
10032243|NCT01775761|Experimental|Period 2: 400 mg moxifloxacin|400 mg moxifloxacin
10032244|NCT01775761|Experimental|Period 3: Placebo|
9470364|NCT03629288|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and one tablet containing lactose once a day for three days immediately after the scaling and root planning.
9470365|NCT03629288|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500 milligrams (mg) of Azithromycin once a day for three days immediately after the scaling and root planning.
9470366|NCT03629275|Experimental|CTX0E03 Drug Product and delivery device|20 million neural stem cells
9470367|NCT03629275|Sham Comparator|Placebo|Sham Surgery
9470368|NCT03629262|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
9470369|NCT03629262|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
9803098|NCT04552171|No Intervention|Access to a 24-hour helpline|"Participants in this condition will be provided access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not. Use of this comparison condition is intended to provide a real-world test of the added benefit of using Game Plan, above and beyond the current standard of care for HIV/STI self-testing, which involves providing users with access to a 24-hour helpline."
10032245|NCT01775826|Other|All Purposes|All participants.
10032246|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(oral)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
10032247|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(IV)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
10032248|NCT01775878|No Intervention|Usual Care|This arm received usual care from the diabetes care managers
9470370|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
9470371|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
9470372|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
9470373|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
9470374|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
9470375|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
9470376|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
9470377|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
9470378|NCT03629210|Experimental|Combination Treatment|Combination treatment: Participants will receive intravitreal Eylea (AFL, 2.0 mg) injection and OZURDEX implant (0.7 mg) injection within 0 to 8 days of each other.
9470379|NCT03629210|Active Comparator|Monotherapy|Monotherapy treatment: Participants will receive OZURDEX implant (0.7 mg) injection.
9470380|NCT03629197|Experimental|Communication skills training|Intervention clinicians will receive 2 standardized patient visits. The first visit will consist of an 8 minute video on the development of 5 key communication skills, a 10-12 minute role-play session to practice using these skills, and 8-10 minutes of constructive feedback. The 2nd visit will include only the role-play and feedback components. Clinicians will also get a printed pocket card and pamphlet explaining the targeted communication skills in more detail.
9470381|NCT03629197|Active Comparator|Control|Control clinicians will receive a written summary of the 2016 CDC opioid prescribing guidelines, which include recommendations for best practices for use of opioids to treat chronic non-cancer pain. CDC guidelines will serve as an attention control.
9470382|NCT03629158|Experimental|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
9470383|NCT03629158|No Intervention|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
9470384|NCT03629145|Experimental|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
9470385|NCT03629145|Placebo Comparator|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
9470386|NCT03629132|Experimental|PRP|Platelet-rich plasma
9470387|NCT03629132|Sham Comparator|Gel|Self-crosslinking sodium hyaluronate gel
9470388|NCT03629106|Experimental|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
9470389|NCT03629106|Experimental|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
9470390|NCT03629093||Long-time anesthesia exposure|Infants receive general anesthetics longer than 3 hours in total.
9470391|NCT03629093||Short-time anesthesia exposure|Infants receive general anesthetics shorter than 3 hours in total.
9470392|NCT03629067|Experimental|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)~There will be a 14 washout of days between the each period."
9470393|NCT03629067|Experimental|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
9470394|NCT03629067|Experimental|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
10032249|NCT01775878|Experimental|Telemonitoring Device|Patients in this arm received a telemonitoring device installed in their homes
10037602|NCT01826565|Experimental|Rotation|Rotational technique applied
10032250|NCT01775891|Active Comparator|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
9470395|NCT03629015|Experimental|Stemchymal®|Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
9470396|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
9470397|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
9470398|NCT03628989|Experimental|Cardiac Cathertization Patients|Participants will use technology based distraction during procedure.
9470399|NCT03628989|Experimental|Allergy Patients|Participants will use technology based distraction during procedure
9470400|NCT03628989|No Intervention|Procedure-Only Patients|
9470401|NCT03628976|Sham Comparator|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
9470402|NCT03628976|Active Comparator|tVNS to tragus|tVNS will be applied to the tragus.
9470403|NCT03628963|Experimental|Concerto+ (Intervention group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will use Concerto+ application during 6 months.
9470404|NCT03628963|No Intervention|Usual care (Control group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will not use the application Concerto+ but receive usual care from FMG.
9470405|NCT03628937|Experimental|Intervention group|"Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks.~Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks"
9470406|NCT03628937|Placebo Comparator|Control group|The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
9470407|NCT03628872|Active Comparator|Scaling and Root Planing with Hand Instruments|Patients will undergo scaling and root planing with hand instruments (half of their mouth, following a split-mouth design)
9470408|NCT03628872|Experimental|Er:YAG Laser Scaling|Patients will undergo scaling and root planing with Er:YAG Laser in the untreated half of their mouth.
9470409|NCT03628833|Experimental|Incontinence Management system|
9470410|NCT03628820|Experimental|Therapy Dog|"This group is exposed to the therapy dog and handler. On a convenience sample of shifts, a dog will be available. Participants will not know when dogs will be present and will not be informed of whether or not they will see a dog on any given shift. The dog and handler will be kept out of site of other providers. Participants who agree to participate will be approached by study personnel between 3 and 7 hours into his or her shift and asked would now be a good time to see a therapy dog? If the physician answers yes, then the physician will be escorted to a separate private, quiet room away from the usual work area to interact with a therapy dog and handler. We will ask the physician to spend approximately 5 minutes with the therapy dog, but will not specify or mandate any time. Study personnel will record the time spent. Only the handler and dog will be present in the room."
9470411|NCT03628820|Experimental|Mandala Coloring|This group is not exposed to the therapy dog or handler. At 3-7 hours into the shift, study personnel will encourage providers to take a 5 min period of mindfulness, achieved by coloring mandalas. Participants will be escorted out of the work area to the same private, quiet room where the interaction occurs with the dog and handler in the therapy dog group. Participants will have their choice of one of three mandalas to color and will be provided a full palette of colored pencils. When the provider's time is up, study personnel will notify them of the five minute period. Study personnel will not be present in the room but will photograph the work when the participant is done with the session and record the image in REDcap. The original art work will be returned to the provider.
9470412|NCT03628820|No Intervention|No Intervention|This group is not exposed to the therapy dog or handler.
10032251|NCT01775891|Placebo Comparator|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
10032252|NCT01775969|No Intervention|Standard of Care|Written discharge instructions only
9470413|NCT03628807||Retrospective 1|Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.
9470414|NCT03628807||Retrospective 2|Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.
9470415|NCT03628807||Prospective|Prospective cohort that received TIPS from 01/01/2013 onwards
9470416|NCT03628794|Other|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
9470417|NCT03628794|Other|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
9470418|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
9470419|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
9470420|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
10032253|NCT01775969|Experimental|Text Message|Written discharge instructions plus a text message with antibiotic prescription instructions
9470421|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
10032254|NCT01775969|Experimental|Voicemail|Written discharge instructions plus a voicemail with antibiotic prescription instructions
10032255|NCT01775982||Study population|"See inclusion and exclusion criteria.~Intervention: Psychiatric evaluation Intervention: Geriatric evaluation~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
10032256|NCT01776021|Active Comparator|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
10032257|NCT01776021|Placebo Comparator|Placebo|placebo beverage at a dose of one 8 oz. beverage per day for six months
9470422|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
9470423|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
9470424|NCT03628755|Active Comparator|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
9470425|NCT03628755|Active Comparator|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
9470426|NCT03628755|Experimental|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
9470427|NCT03628729|Experimental|Embrace™ WetBond™ Pit & Fissure Sealant.|pits and fissures will be sealed with bioactive pits-and-fissure sealant
9470428|NCT03628729|Active Comparator|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Pits and fissures will be sealed by fluoride releasing resin based pits and fissures sealant
9470430|NCT03628703|Experimental|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
9470431|NCT03628690|Experimental|BandGrip|Topical skin closure device
9470432|NCT03628690|Active Comparator|Standard Suture|Standard sutures will be used for wound closure
9470433|NCT03628664|Active Comparator|CT planned total knee arthroplasty|Surgeon will follow the CT plan
9470434|NCT03628664|No Intervention|Non CT planned total knee arthroplasty|Surgeon will not follow the CT plan
9470435|NCT03628651||HCC Surveillance|Approximately 1400 HCC surveillance subjects (controls) will be enrolled.
9470436|NCT03628651||HCC|Approximately 700 subjects with untreated clinically diagnosed HCC will be enrolled.
9470437|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
9470438|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
9470439|NCT03628625|Experimental|Study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
9470440|NCT03628625|Placebo Comparator|Control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
9470441|NCT03628573|Other|Intermittent Theta burst stimulation.|Procedure: repetitive transcranial magnetic stimulation (iTBS) to the left Dorsolateral Prefrontal Cortex; 3 sessions per day, for 20 days.
9470442|NCT03628547||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur soccer players and10 professional soccer players.
9470443|NCT03628547||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur basketball players and10 professional basketball players.
9470444|NCT03628547||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur volleyball players and10 professional volleyball players.
9470445|NCT03628547||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur runners and 10 professional runners.
9470446|NCT03628547||table tennis athlete|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur table tennis athlete and 10 professional table tennis athlete.
9470447|NCT03628547||field tennis athlete|10 amateur field tennis athlete 10 professional field tennis athlete
9470448|NCT03628547||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur kickboxers and 10 professional kickboxers.
9470449|NCT03628547||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur archers and 10 professional archers.
9470450|NCT03628521|Other|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
9803099|NCT04544618|Experimental|Active intervention group|Participants will be exposed to a virtual reality simulation of the operating room environment for a minimum of ten minutes.
9470451|NCT03628521|Other|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
9470452|NCT03628521|Other|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
9470453|NCT03628495|Experimental|SSCP + SPMS|
9470454|NCT03628495|Active Comparator|PG|
9470455|NCT03628482|Active Comparator|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
9470456|NCT03628482|Experimental|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
9803100|NCT04544618|Placebo Comparator|Control intervention group|Participants will explore a non-surgery related virtual reality simulation, pre-programmed to the virtual reality headset for a minimum of ten minutes.
9470457|NCT03628469|Experimental|Proactive Health Support|The purpose of the intervention is to enhance patients' self-management strategies and thereby enable patients to cope with illness at home and prevent the development of those conditions, that are sensitive to preventive efforts.The intervention includes active listening, coaching and counselling and elements from case management such as assessing the need for healthcare services. Emphasis is on supporting and empowering the patient to make the necessary contacts to healthcare professionals.
9470458|NCT03628469|No Intervention|Usual care|Usual care
9470459|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
9470460|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
9470461|NCT03628430|Placebo Comparator|Group C|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 0.9% NaCl"
9470462|NCT03628430|Active Comparator|Group A|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 4.2 % sodium bicarbonate"
9470463|NCT03628391|Active Comparator|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
9803101|NCT04544618|No Intervention|Treatment as usual group|Participants will receive standard of care with no additional intervention aside from information received at their surgical oncology appointment and optional preoperative education classes (available to all patients).
9803102|NCT04540497|Experimental|VIB0551|Inebilizumab administered as an IV infusion.
9803103|NCT04540497|Placebo Comparator|Placebo|Placebo administered as an IV infusion.
9803104|NCT04539665|Experimental|Intervention Arm|Prospective study arm involving an extended mesenteric ileocolic excision.
9803105|NCT04539665|No Intervention|Control Arm|Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.
10032258|NCT01776047|Active Comparator|Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)|Exforge® 10/160
10032259|NCT01776047|Experimental|G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)|G-0081
10032260|NCT01776073|Experimental|Patient navigation|In addition to receiving the standard of care, these patients will be connected with a patient navigator who will provide personalized assistance with regard to completion of the pre-waitlisting process
10032261|NCT01776073|No Intervention|Standard of Care|These patients will receive the standard of care, which includes assistance from the current Emory Transplant Center team of social workers, physicians, and other support staff with regard to completion of the pre-waitlisting process
10032262|NCT01776086|Other|Normal patients|for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task
10032263|NCT01776099|Active Comparator|pure galactose|5 grams of galactose, three times a day with the main meals, duration: 4 weeks
10032264|NCT01776099|Placebo Comparator|pure palatinose|5 grams of palatinose, three times a day with the main meals, duration: 4 weeks
10032265|NCT01776099|Placebo Comparator|soluble non-fermentable fibers|5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks
10032266|NCT01776099|Active Comparator|non-soluble non-fermentable fibers|5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks
10032267|NCT01776112|Experimental|SZ-Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
10032268|NCT01776112|Placebo Comparator|SZ-TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
10032269|NCT01776112|Experimental|HC-Exercise|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
10032270|NCT01776125||Dystrophic Scolisis and NF1|Patients with NF1 diagnosed with dystrophic scoliosis that have been clinically treated will be asked for a cheek swab for genetic testing
10032271|NCT01776125||Non-dystrophic scoliosis and NF1|NF1 patients with non-dystrophic scoliosis that have been treated clinically. will be asked for a cheek swab for genetic testing
10032272|NCT01776138||Bladder Cancer Patients|Patients diagnoses with bladder cancer who are eligible to undergo treatment.
10032273|NCT01776177||Continue Therapy Group|Patients who continued to recieve Omalizumab therapy beyond 6 month period
10032274|NCT01776177||Discontinued Therapy group|Patients who discontinued Omalizumab therapy prior to 6 month period from the start of therapy
10032275|NCT01776203|Active Comparator|medroxyprogesterone acetate|
10032276|NCT01776203|No Intervention|control|
10032277|NCT01776216|Experimental|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy into their everyday diet.
10032278|NCT01776216|Placebo Comparator|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products into their everyday diet.
10032279|NCT01776229|Experimental|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
9470464|NCT03628391|Placebo Comparator|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
9480272|NCT03535207|Experimental|high dose chemoradiotherapy|all eligible patients receive intensity-modulated radiotherapy 50 Gy in 25 fractions over 5 weeks and concurrent paclitaxel and cisplatin once weekly for 5 weeks，followed by hyperfractionated intensity-modulated radiotherapy boost to gross tumor volume concurrent with the same chemotherapy
9480273|NCT03535168|Experimental|Dose 1 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.
10032280|NCT01776229|No Intervention|Waitlist Control|All potential participants will be evaluated and some will be randomly placed in the control group, following the five-week treatment phase, participants in the control group will be re-evaluated and offered the treatment
10032281|NCT01776255|Experimental|Healthy Children, Strong Families (first)|Healthy Children, Strong Families intervention (first). This is a series of monthly educational tool kits mailed to primary caregivers for use with the participating child. This arm crosses over to receive the Child Safety in Year 2.
10032282|NCT01776255|Active Comparator|Child Safety (first)|A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
10032283|NCT01776281|Experimental|Kangaroo Mother Care|Other than routine clinical care per hospital policy. Infants will receive skin-to-skin contact for minimum one hour daily during hospital stay and at home till one month.
10032284|NCT01776281|Active Comparator|Standard Care|Routine incubator or cot care with breastfeeding support from nurses as per policy.
10032285|NCT01776294||prehypertensives|students will be classified as prehypertensives as per the JNC-7 (Joint National Commission) guidelines based on their Blood Pressure measurement
10032286|NCT01776294||normotensives|students will be classed as normotensives based on their BP measurement as per JNC-7 guidelines (systolic <120 AND diastolic <80)
10032287|NCT01776320|Experimental|VITAROS|VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks
10032288|NCT01776333|No Intervention|usual care|
10032289|NCT01776333|Experimental|video arm|video decision aid intervention
10032290|NCT01776346||Barrett's Esophagus/Esophageal Adenocarcinoma|Patients who have Barrett's esophagus or esophageal adenocarcinoma.
10032291|NCT01776346||Healthy control|
10032292|NCT01776359|Active Comparator|High Protein|High Protein
10032293|NCT01776359|Placebo Comparator|Low Protein|Low Protein
10032294|NCT01776372|Active Comparator|Digital thoracic drainage system|Medela Thopaz Thoracic Drainage System
10032295|NCT01776372|Active Comparator|Non-digital thoracic drainage system|Atrium Express Dry Seal Chest Drain
9480274|NCT03535168|Experimental|Dose 2 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.
10032296|NCT01776385|Experimental|Group patients|Patients with Malignant Pleural Mesothelioma (all stages)
10032297|NCT01776385|Placebo Comparator|Control group|Patients with pneumothorax or of benign tumor of the thyroid
10032298|NCT01776411|Experimental|Single Arm|Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
10032299|NCT01776437|Experimental|Treatment A|Period 1: fasted control → Period 2: fed control
9480275|NCT03535168|Experimental|Dose 3 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.
9480276|NCT03535168|Experimental|Matching placebo|Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.
9480277|NCT03535168|Experimental|BAY1902607+Matching Placebo|"Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo"
9480278|NCT03535168|Experimental|Matching Placebo+BAY1902607|"Part 2:~Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607"
9480279|NCT03535103|Experimental|ARM A|Gonal-F®
9480280|NCT03535103|Experimental|ARM B|LM001
9480281|NCT03535090||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
9480282|NCT03535077||Suspicious Nevi undergoing biopsy|Subject with suspicious Nevi undergoing biopsy per SOC
9803106|NCT04537416||Women with recurrent pregnancy loss|consecutive women at least 18 years old but not greater than 40 years old with a chief complaint of recurrent pregnancy loss
10032300|NCT01776437|Experimental|Treatment B|Period 1: fed control → Period 2: fasted control
10032301|NCT01776463|Experimental|Z-360|1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))
9470465|NCT03628378|No Intervention|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
9470466|NCT03628378|Experimental|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
9470467|NCT03628365|Active Comparator|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
10032302|NCT01776463|Placebo Comparator|Placebo|1)Single dose study, 2)Multiple doses study
10032303|NCT01776489||food allergic|positive reaction during DBPCFC
10032304|NCT01776489||Non-food allergic|no reaction during DBPCFC
10032305|NCT01776502||Patients with Hyperparathyroidism|The cohort of patients is made of patients with primary mild hyperparathyroidism and who have received a surgery at Nantes, Angers, Limoges or Marseille University Hospitals
10032306|NCT01776515|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|
9470468|NCT03628365|Placebo Comparator|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
9470469|NCT03628352|Experimental|Tricaprilin|Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
9470470|NCT03628339|Experimental|Midazolam, then tepotinib followed by midazolam + tepotinib|Participants will receive a single oral dose of midazolam on Day 1 of treatment period 1 followed by daily single oral dose of tepotinib from Day 1 to Day 10 of treatment period 2 and then co-administration of tepotinib and midazolam on Day 11 of treatment period 2.
9470471|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
9470472|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
9470473|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
9470474|NCT03628300||piperacillin serum measurement|patient that underwent at least one piperacillin serum concentration monitoring
9470475|NCT03628300||included for analysis|patient that have been included for analysis according to previously described criteria
9470476|NCT03628287|Active Comparator|Original Care Coordination Program|Specific intervention components include: 1) outreach for initial case finding and after any missed appointment; 2) case management, including social services and benefits assessments; 3) multidisciplinary care team communication and decision-making via case conferences; 4) patient navigation, including appointment reminders, assistance with scheduling appointments, transportation resources, and accompaniment to primary care visits; 5) antiretroviral treatment adherence support, including directly observed therapy for individuals with greatest need; and 6) structured health promotion, for which clients are assigned to program tracks (determining their frequency of health promotion visits: weekly, monthly or quarterly), depending on their level of assessed need.
9803107|NCT04537234|Experimental|Group 1: High-Dose Quadrivalent Influenza Vaccine (QIV-HD)|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
9803108|NCT04537234|Active Comparator|Group 2: Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD)|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
10032307|NCT01776515|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|
10032308|NCT01776528|Experimental|Cohort 1 SAD|NGM282 Dose 1 vs Placebo
10032309|NCT01776528|Experimental|Cohort 2 SAD|NGM282 Dose 2 vs Placebo
10032310|NCT01776528|Experimental|Cohort 3 SAD|NGM282 Dose 3 vs Placebo
10032311|NCT01776528|Experimental|Cohort 4 SAD|NGM282 Dose 4 vs Placebo
10032312|NCT01776528|Experimental|Cohort 5 SAD|NGM282 Dose 5 vs Placebo
10032313|NCT01776528|Experimental|Cohort 6 SAD|NGM282 Dose 6 vs Placebo
10032314|NCT01776528|Experimental|Cohort 7 MAD|NGM282 Dose 1 vs Placebo
10032315|NCT01776528|Experimental|Cohort 8 MAD|NGM282 Dose 2 vs Placebo
10032316|NCT01776528|Experimental|Cohort 9 MAD|NGM282 Dose 3 vs Placebo
10032317|NCT01776528|Experimental|Cohort 10 MAD|NGM282 Dose 4 vs Placebo
10032318|NCT01776528|Experimental|Cohort 11 MAD|NGM282 Dose 5 vs Placebo
10032319|NCT01776528|Experimental|Cohort 12 MAD|NGM282 Dose 6 vs Placebo
10032320|NCT01776567|Active Comparator|Cobalt Chromium Everolimus-eluting stent (Xience Prime)|Cobalt Chromium Everolimus-eluting stent (Xience Prime)
10032321|NCT01776567|Active Comparator|Platinum Chromium Everolimus-eluting stent (Promus Element)|Platinum Chromium Everolimus-eluting stent (Promus Element)
10032322|NCT01776580||Lower urinary tract symptoms|Women with lower urinary tract symptoms
10032323|NCT01776593||Lower urinary tract symptoms|
10032324|NCT01776619|Experimental|Multiple Dose: Cohort 1|
10032325|NCT01776619|Experimental|Multiple Dose: Cohort 2|
10032326|NCT01776619|Experimental|Multiple Dose: Cohort 3|
10032327|NCT01776619|Experimental|Multiple Dose: Cohort 4|
10032328|NCT01776619|Experimental|Relative Bioavilability: Cohort 1|
10032329|NCT01776658|Experimental|SYL1001 eye drops dose A|Ocular topical administration of SYL1001 eye drops dose A
10032330|NCT01776658|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
10032331|NCT01776671|Other|Gralise|Efficacy of Gralise
10032332|NCT01776684|Experimental|EGFR positive arm|Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
10032333|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fasting|
10032334|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fed|
10032335|NCT01776697|Experimental|pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD|
10037115|NCT01821976|Active Comparator|Burgess Procedure|Patients randomized to the Burgess Procedure Arm will receive a below the knee amputation where the bone is cut and skin and muscle from the back of the leg are rotated to cover the cut end of your bone. This provides good soft tissue padding to the bone and a good shape to the leg for later fitting of your prosthesis.
10037116|NCT01821989|Active Comparator|Low Dose|Lactoferrin,dose of 100 mg/day.
10032336|NCT01776710|Experimental|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
10032337|NCT01776710|No Intervention|Standard care control|Standard care will consist of general advice to increase walking and an information sheet on peripheral arterial disease, plus a consultation with a Consultant Vascular Surgeon.
9470477|NCT03628287|Experimental|Revised Care Coordination Program|"The revised model includes the original intervention components without program track assignments or the three-month induction period of weekly visits. Program additions include a set of tools for assessment and counseling around client HIV self-management capacity; allowance of video chat for delivery of some services; and optional iART (immediate ART: ensuring the client has a filled prescription within 4 days of enrollment or diagnosis). Other changes include greater guidance on recruiting individuals with unsuppressed VL and a switch from per-member-per-day reimbursement to fee-for-service reimbursement that accounts for resource demands, such as staff travel to clients' homes, and offers higher rates for meeting performance standards."
9470478|NCT03628274|Experimental|Magnetic Resonance Imaging (RMI) 7 Tesla|
10032338|NCT01776736|Experimental|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
9470479|NCT03628261|Other|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
10032339|NCT01776749|No Intervention|no SubQ|No subcutaneous leads due to adequate low back stimulation by only SCS. Patient not randomised
10032340|NCT01776749|Active Comparator|SubQ ON|Subcutaneous stimulation on
10032341|NCT01776749|Sham Comparator|SubQ OFF|subcutaneous leads implanted, but no stimulation
10032342|NCT01776762|Experimental|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
10032343|NCT01776762|No Intervention|Standard Follow-home programme|Standard Follow-home programme without individual nutritional therapy
9470480|NCT03628261|Other|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
9470481|NCT03628248|Experimental|embolization|
9470482|NCT03628248|Other|No embolization|
9470483|NCT03628222|Experimental|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
9470484|NCT03628222|Active Comparator|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
9470485|NCT03628196||Quality Improvement Program Basic and Enhanced Phase|Patients that meet the eligibility criteria and participate in the QIP.
9470486|NCT03628196||Retrospective Group|Patients seen a year prior to the QIP period at the clinic but that did not participate in the QIP.
10032344|NCT01776775|Active Comparator|abdominal binder|use of postoperative abdominal binder 30 days after the hernia repair
10032345|NCT01776775|No Intervention|No abdominal binder|No intervention
10032346|NCT01776788|Experimental|insulin lispro injection, exenatide injection|
10032347|NCT01776788|Active Comparator|insulin lispro injection|
10032348|NCT01776801|Experimental|Hydrocephalus|Patients suffering of hydrocephalus (cognitive impairment, gait disturbance, urinary incontinence and enlargement of the ventricles) require for clinical purpose infusion studies i.e. injection of mock cerebrospinal fluid (CSF) in the sub arachnoid space to artificially increase ICP. We aim at using infusion studies as a indirect tool to assess whether a moderate increase in ICP has any influence on haemodynamics.
10032349|NCT01776853|Placebo Comparator|Glucose|40g glucose in 500ml water flavoured with lime juice
10032350|NCT01776853|Experimental|Fructose|40g fructose in 500ml water flavoured with lime juice
10032351|NCT01776853|Experimental|Fructans|40g fructans in 500ml water flavoured with lime juice
10037117|NCT01821989|Experimental|High Dose|Lactoferrin, dose of 150 mg/kg/ twice daily.
10037118|NCT01821989|Placebo Comparator|Control|Receive placebo in form of distilled water.
10037603|NCT01826578|Experimental|single port arm|
9470487|NCT03628196||Concurrent Group|Patients seen during the QIP period at the clinic but that did not participate in the QIP.
9470488|NCT03628183|Active Comparator|Hydrolysate Infant Formula 1|Ready to feed infant formula in can
9470489|NCT03628183|Experimental|Hydrolysate Infant Formula 2|Ready to feed infant formula in bottle
9470490|NCT03628170|Experimental|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
9470491|NCT03628170|Active Comparator|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
9470492|NCT03628157|Experimental|intervention|using a bio-oss bovine bone alone
9470493|NCT03628157|Active Comparator|control|using a bio-oss bovine bone with autogenous bone ratio 1:1
9470494|NCT03628144|Experimental|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
9470495|NCT03628144|Active Comparator|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
10032352|NCT01776866|Other|Coronary Angiography|"Patient first undergo standard coronary angiography(SA) of either left or right coronary system followed by dual-axis rotational coronary angiography(DARCA). The SA protocol consist of six different projections (right anterior oblique (RAO)-caudal, RAO-cranial (CRA), left anterior oblique (LAO)-CRA, LAO-caudal (CAU), antero-posterior (AP)-CRA and AP-CAU) for left coronary artery (LCA) and two projections (LAO and AP-cranial) for right coronary artery (RCA).~The DARCA protocol consist of two coronary acquisitions specified by the protocol: one for LCA (Swing LCA CRA 35 5.8s), another for RCA (Swing RCA AP 4.0s)."
10032353|NCT01776879||early & advanced PD 1st degree relatives|no intervention is performed in the study
10032354|NCT01776879||recording speech and voice|no intervention(s) will be administered
10032355|NCT01776879||speech intelligibility|no intervention(s) will be administered
10032356|NCT01776892|Experimental|Collagenase and needle aponeurotomy|"Participants in this arm of the study will be treated once with needle aponeurotomy and up to 3 times at 4 week intervals with collagenase injection.~Affected Dupuytren's cords will be treated with 1-3 collagenase clostridium histolyticum injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained."
10032357|NCT01776892|Active Comparator|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained. Participant feedback is obtained throughout the procedure to prevent digital nerve or flexor tendon injury. Participants are asked to report Tinel's sign which indicates that the needle is in close proximity to the digital nerve and to report pain with needle advancement which indicates proximity to the flexor tendon.
10037119|NCT01822002|Active Comparator|Canalith repositionig maneuver; Epley maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver.
9470496|NCT03628131|Experimental|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
9470497|NCT03628118||open radical hysterectomy|"The patients who would undergo open radical hysterectomy procedure."
9470498|NCT03628105|Experimental|CR Before Exposure|Participants in this arm will receive 15 minutes of CR (preparation) before engaging in exposure and will complete the 15-minute questionnaire filler task after exposure.
9470499|NCT03628105|Experimental|CR After Exposure|Participants in this arm will complete the 15-minute questionnaire filler task before exposure and receive 15 minutes of CR (consolidation) after engaging in exposure.
9470500|NCT03628092|Active Comparator|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
9470501|NCT03628092|Placebo Comparator|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
9470502|NCT03628079|Experimental|Single arm study|"ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole."
9470503|NCT03628053|Experimental|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
9470504|NCT03628053|Active Comparator|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
9470505|NCT03628040|Sham Comparator|Sham Block|Patient will receive a single shot of normal saline 20 mL injected at the erector spinae plane
9470506|NCT03628040|Active Comparator|Erector Spinae Block|Patient will receive a single shot of Ropivacaine Injection [Naropin] 0.5% 20 mL injected at the erector spinae plane
9470507|NCT03628027|Experimental|Treatment Algorithm|The treatment algorithm arm will be the experimental arm in which GPs use the computerised decision support tool to guide their prescribing of antidepressants.
9470508|NCT03628027|No Intervention|Treatment-as-usual|The treatment-as-usual arm will comprise GPs prescribing antidepressants and providing care as they typically would.
9470509|NCT03628014|Other|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
9470510|NCT03628001|Other|A|ERCP with (Group A) ES before biliary SEMS placement
9470511|NCT03628001|Other|B|ERCP without (Group B) ES before biliary SEMS placement
9470512|NCT03627975|No Intervention|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
9470513|NCT03627975|Experimental|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
9470514|NCT03627975|Experimental|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
9470515|NCT03627962|Experimental|gaze-directed oculomotor training|device: Tobii PCEye Treatment group went through the oculomotor training with a gaze-pointer interface (Tobii PC Eye) in reading in Chinese.
9470516|NCT03627962|No Intervention|control|No intervention: participants in control read ordinary Chinese textbooks.
9470517|NCT03627949|Experimental|Intervention group 1|Students in the intervention group 1 received first 4-week treatment on physical activity followed by 4-week treatment on healthy dietary behaviour.
9803109|NCT04535128||COVID-19 Positive|Patients with positive COVID-19 PCR
10037120|NCT01822002|Active Comparator|Canalith repositioning maneuver : Semont maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver group.
9470518|NCT03627949|Experimental|Intervention group 2|Students in the intervention group 2 received first 4-week treatment on healthy dietary behaviour followed by 4-week treatment on physical activity.
9470519|NCT03627949|No Intervention|Control group|Students in the control group were not provided with any supportive treatments on physical activity or healthy dietary behaviour.
9470520|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
9470521|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
9470522|NCT03627910|Experimental|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
9470523|NCT03627910|Active Comparator|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
9470524|NCT03627884|Active Comparator|Normal Saline Catheter Lock Solution Group|Patients receiving normal saline catheter locking solution
9470525|NCT03627884|Active Comparator|Sodium Bicarbonate Catheter Lock Solution|Patients receiving sodium bicarbonate catheter locking solution
9470526|NCT03627871|Experimental|Trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population and are told this norm has been increasing recently.
9470527|NCT03627871|Experimental|Non-trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population but are not told about recent trends.
9470528|NCT03627871|Experimental|Trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population and are told this norm has been increasing recently
9470529|NCT03627871|Experimental|Non-trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population but are not told about recent trends.
9470530|NCT03627871|Experimental|Control|Participants receive information about exercise unrelated to social norms or recent trends.
9470531|NCT03627845|Experimental|Experimental|PHP-303, single oral dose, up to 6 ascending dose cohorts
9470532|NCT03627845|Placebo Comparator|Placebo|Placebo, single oral dose, up to 6 ascending dose cohorts
9470533|NCT03627819|Active Comparator|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
9470534|NCT03627819|Active Comparator|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
9470535|NCT03627819|Placebo Comparator|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
9470536|NCT03627793|Active Comparator|High load non-frail|Non-frail participants who will receive resistance training at 70% of their maximal strength
9470537|NCT03627793|Active Comparator|low load non-frail|Non-frail participants who will receive resistance training at 30% of their maximal strength
9470538|NCT03627793|Experimental|high load frail|Frail participants who will receive resistance training at 70% of their maximal strength
9470539|NCT03627793|Experimental|low load frail|Frail participants who will receive resistance training at 30% of their maximal strength
9470540|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
9470541|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
9470542|NCT03627754|Experimental|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
9470543|NCT03627754|Experimental|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
9470544|NCT03627754|Experimental|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
9470545|NCT03627741|Experimental|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
9470546|NCT03627728|Experimental|regorafenib|Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease
9470547|NCT03627728|Placebo Comparator|placebo|Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease
9470548|NCT03627715|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
10037604|NCT01826578|No Intervention|Conventional arm|Using 3-4 port for laparosocpic surgery
9470549|NCT03627715|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
9470550|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
9470551|NCT03627689|Experimental|Active air purifier arm|Active portable air purifier for 1 month at bedside
10037605|NCT01826591|Experimental|Experimental: Low-Carbohydrate Diet|Healthy, Low-Carbohydrate Diet
9470552|NCT03627689|Sham Comparator|Sham air purifier arm|Placebo portable air purifier for 1 month at bedside
9470553|NCT03627676|Experimental|Intervention|
10032358|NCT01776892|Active Comparator|Collagenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
10032359|NCT01776918||Metabolic Disease- Phenylketonuria|
9470554|NCT03627663|Experimental|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
9470555|NCT03627650|Experimental|1 group of 15 patients|procedure/surgery: fat grafting injection of scar
9470556|NCT03627650|Experimental|Same group of 15 patients|procedure/surgery: placebo injection of scar
9470557|NCT03627637|Experimental|Experimental: Soy nuts|
9470558|NCT03627637|No Intervention|Control - no soy nuts|
9470559|NCT03627611|Active Comparator|T4|
9470560|NCT03627611|Experimental|T3|
9470561|NCT03627598|Active Comparator|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
9470562|NCT03627598|Experimental|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
9470563|NCT03627585|No Intervention|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
9470564|NCT03627585|Active Comparator|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
9470565|NCT03627572||Active cohort (N=1000)|Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
9470566|NCT03627572||Passive cohort (N=9000)|Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
9470567|NCT03627559||Pancreaticoduodenectomy patients|All patients undergoing pancreaticoduodenectomy receive a microdialysis catheter before skin closure and will be monitored postoperatively for lactate, pyruvate, glucose and glycerol in the microdialysate at certain timepoints
10032360|NCT01776918||Mitochondrial disorder|
10032361|NCT01776931|Experimental|Lysine intake|Dietary supplement:lysine intake
10032362|NCT01776944||Obese children|
10032363|NCT01776957||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
10032364|NCT01776970|Experimental|Sativex|Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml)
10032365|NCT01776970|Placebo Comparator|Placebo|Placebo oromucosal spray
10032366|NCT01777009|Experimental|Patellar Eversion|Patients randomized to the Patellar Eversion arm of the study were surgically exposed by everting the patella during their Primary Total Knee Replacement Surgery.
10032367|NCT01777009|Active Comparator|Patellar Lateral Retraction|Patients randomized to the Patellar Lateral Retraction arm of the study were surgically exposed by laterally retracting the patella during their Primary Total Knee Replacement Surgery.
10032368|NCT01777022|No Intervention|Current treatment|Current education and management protocols will be followed
10032369|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
10032370|NCT01777048|Experimental|Omega-3 Fatty Acids|1g of Omega-3 per day [400mg DHA & 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
10032371|NCT01777048|Placebo Comparator|Omega-3 Placebo|1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
10032372|NCT01777074||Generalist physicians Cohort|
10032373|NCT01777074||Paediatricians Cohort|
10032374|NCT01777087|Experimental|Healthy normal volunteers|Healthy normal volunteers
10032375|NCT01777100|Experimental|sufentanil|Anesthetic induction with IV sufentanil at 0.5 mcg.kg-1 and analgesic maintenance with IV remifentanil at 0.1 to 0.3 mcg.kg-1.min-1 on demand target-controlled infusion
10032376|NCT01777100|No Intervention|remifentanil|Anesthetic induction with target-controlled infusion IV remifentanil at 0.5 mcg.kg-1.min-1 in 5 minutes followed by analgesic maintenance on demand of IV target-controlled infusion remifentanil at 0.1 to 0.3 mcg.kg-1.min-1.
10032377|NCT01777113|Experimental|High Intensity Aerobic training|The subjects will perform a high intensity treadmill training
10032378|NCT01777113|Experimental|High Intensity Strength Training|The subjects will perform and high intensity training on the same leg horizontal press.
10032379|NCT01777113|Active Comparator|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises.
10032380|NCT01777178|Experimental|Low bicarbonate dialysis|
10032381|NCT01777204||Tacrolimus|Influence of tacrolimus on gastrointestinal transit and motility in renal transplant recipients.
10032382|NCT01777204||Cyclosporine|Influence of cyclosporine on gastrointestinal transit and motility in renal transplant recipients.
10032383|NCT01777204||Mycophenolate mofetil|Influence of mycophenolate mofetil on gastrointestinal transit and motility in renal transplant recipients.
10032384|NCT01777204||Mycophenolate sodium|Influence of mycophenolate sodium on gastrointestinal transit and motility in renal transplant recipients.
10032385|NCT01777204||Everolimus|Influence of everolimus on gastrointestinal transit and motility in renal transplant recipients.
10032386|NCT01777204||Sirolimus|influence of sirolimus on gastrointestinal transit and motility in renal transplant recipients.
10032387|NCT01777204||Without immunosuppression|Gastrointestinal transit and motility in healthy volunteers.
9470568|NCT03627546|Experimental|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
9470569|NCT03627546|No Intervention|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
9803110|NCT04534387|Experimental|Experimental Group|This group will receive the Spanish-Language Hearing Loss Toolkit materials.
10032388|NCT01777230||All patients|Alle subjects included retain in one cohort.
10032389|NCT01777243|Experimental|Part A Arm|Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
10032390|NCT01777243|Experimental|Part B Arm|The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
10032391|NCT01777256|Experimental|GSK2586184 50 mg Arm|Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal
10032392|NCT01777256|Experimental|GSK2586184 100 mg Arm|Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
10032393|NCT01777256|Experimental|GSK2586184 200 mg Arm|Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
10032394|NCT01777256|Experimental|GSK2586184 400 mg Arm|Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
10032395|NCT01777256|Placebo Comparator|Placebo|Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.
10032396|NCT01777295|Experimental|HBsAg/AS Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 2 doses of HBsAg/AS, at Day 0 and Day 30.
10032397|NCT01777295|Active Comparator|Engerix-B Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 3 doses of Engerix-B at Day 0, Day 30 and Day 180.
10032398|NCT01777347|Experimental|3% Saline|Nebulized 3% Saline
10032399|NCT01777347|Placebo Comparator|0.9% Normal Saline|Nebulized 0.9% normal saline
10032400|NCT01777360|Experimental|THERMOPLASTY|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
10032401|NCT01777373||Idiopathic pulmonary fibrosis (IPF)|Idiopathic pulmonary fibrosis (IPF)
10032402|NCT01777373||Control|Control
10032403|NCT01777373||Non-IPF interstitial lung disease (ILD)|Non-IPF interstitial lung disease (ILD)
10032404|NCT01777373||Uncharacterized ILD|Uncharacterized ILD
10032405|NCT01777386|Active Comparator|preexpanded flap|Fourteen patients were treated with fifteen '' preexpanded perforator flap surgery '' interventions. The last six cases were evaluated in terms of perforator artery diameter before and after expansion process. The preexpanded flap donor sites' perforator artery diameters were also compared with their anatomic equivalents located in the symmetric side of the body.
10032406|NCT01777386|No Intervention|control side|In six of the 14 patients, perforator artery diameter of the nonexpanded symmetric anatomical side of the body (equivalent to the expanded site)were measured.
10032407|NCT01777451||Neurofibromatosis 1|"All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )~GROUP 2:~No suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
10032408|NCT01777464|Experimental|patients|patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
10032409|NCT01777464|Sham Comparator|healthy controls|healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
10032410|NCT01777477|Experimental|Chloroquin in addition to Gemcitabine|Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle.
10032411|NCT01777503|Experimental|prasugrel|prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
10032412|NCT01777503|Active Comparator|clopidogrel|Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
10032413|NCT01777516||healthy volunteers|1 group with no treatment : They provide the blank plasma to be used at in vitro study.
10032414|NCT01777529|Experimental|Multidose|Multidose from MMR Vaccine produced by Bio-Manguinhos/Fiocruz
10032415|NCT01777529|Active Comparator|Singledose|Singledose from MMR (GSK-TV), produced by GlaxoSmithKline
10032416|NCT01777607|Experimental|Intervention|
9470570|NCT03627533|Experimental|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on MA-IC3 endocrine (ear points), GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
9470571|NCT03627533|Sham Comparator|Sham electroacupuncture|Sham electroacupuncture are done at same electroacupuncture point location but puncture are not done, also electro stimulator are turned off.
9470572|NCT03627520|Other|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
10032417|NCT01777633|Experimental|re-irradiation|re-irradiation for progressive DIPG in children
10032418|NCT01777646|Experimental|MSC-NTF|
9470573|NCT03627481|Experimental|AERD patients|Patients managed with Endoscopic sinus surgery for treatment of AERD.
10032419|NCT01777659|Experimental|TENS CABG|Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
10032420|NCT01777659|Placebo Comparator|P-TENS CABG|Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
10032421|NCT01777672|Active Comparator|Dietary and oral hygiene recommendations|Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.
10032422|NCT01777672|Experimental|oral TRPV1 agonist|Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.
10032423|NCT01777672|Experimental|pharyngeal electrical stimulation|Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.
10032424|NCT01777672|Experimental|transcutaneous electrical stimulation|Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
10032425|NCT01777685|Other|sulpiride 50 mg|
10032426|NCT01777711|Active Comparator|Couple condition|Couples randomized to the couple condition will undergo the experimental manipulations and both partners will complete all study measures. Both members of the couple will be given body mass index (BMI) based on measurements taken during the intervention. Both will complete three surveys on paper and do some prompted planning and goal-setting together regarding weight loss through healthier eating and physical activity.
10032427|NCT01777711|Active Comparator|Individual Condition|Couples randomized to the individual condition will be stratified on gender and one partner, chosen at random, will undergo the experimental manipulations and complete all study surveys while the other will not (heretofore called the active partner vs. the passive partner). The active partner will receive BMI feedback based on measurements taken during the intervention appointment, complete three surveys, and verbally state some goals and plans for weight loss to the passive partner. The passive partner will not complete any study materials or participate in the intervention during the session.
10032428|NCT01777724|Experimental|Intervention|The intervention is a combination of Triple P Discussion Groups and Stress Control
10032429|NCT01777724|No Intervention|Control|Waitlist control. Participants allocated to the waitlist control will be able to access the intervention after post-intervention equivalent measures have been completed.
10032430|NCT01777737|Experimental|Cotrimoxazole|Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
9470574|NCT03627468|Experimental|Gel, 5%|Sofpironium Bromide Gel, 5%, q.d. for 48 weeks
9470575|NCT03627468|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 48 weeks
9470576|NCT03627455||Male, with DM|
9470577|NCT03627455||Male, without DM|
9470578|NCT03627455||Female, with DM|
9470579|NCT03627455||Female, without DM|
9470580|NCT03627442|Active Comparator|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
9470581|NCT03627442|Active Comparator|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
9470582|NCT03627403|Experimental|Selinexor, all patients|Single Arm Study, all patients will get selinexor
10032431|NCT01777737|Placebo Comparator|Placebo|Identical capsules to cotrimoxazole
9470583|NCT03627390|Experimental|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
9470584|NCT03627390|Experimental|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
9470585|NCT03627377|No Intervention|Control Phase|3-month initial control phase (no intervention, month 1-3)
9470586|NCT03627377|Experimental|Intervention Phase|6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
9470587|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
10032432|NCT01777750|Active Comparator|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
10032433|NCT01777750|No Intervention|Standard treatment|Standard treatment
10032434|NCT01777815|Experimental|Implanting ePTFE sutures|Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
10032435|NCT01777828||Transcatheter Aortic Valve Implantation|FRANCE TAVI registry aims to identify all patients with a change of valves implanted catheter meets the selection criteria of the technical accepting the scheduled evaluations in the context of this disease and who have agreed to participate in the study .
10032436|NCT01777841|Other|Electronic Care plan delivery|
10032437|NCT01777867||Healthy Volunteers|Subjects in this arm were healthy volunteers. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
10032438|NCT01777867||Non-erosive reflux disease with reflux|Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
10032439|NCT01777867||Non-erosive reflux disease without reflux|Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn). Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
10032440|NCT01777893|Experimental|HP-HI|High protein/ high intensity physical activity
10032441|NCT01777893|Experimental|HP-MI|High protein/ moderate intensity physical activity
10032442|NCT01777893|Experimental|MP-HI|Moderate protein/ high intensity physical activity
10032443|NCT01777893|Experimental|MP-MI|Moderate protein/ moderate intensity physical activity
10032444|NCT01777906||Fluticasone|Fluticasone nasal spray will be given 2 sprays twice a day for 6 weeks.
9470588|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
9470589|NCT03627338||Norfloxacin|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
9470590|NCT03627338||Non-selective beta blockers|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
9470591|NCT03627338||diuretics|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
9470592|NCT03627312|Experimental|Omega-3|this group receives a fruit juice drink containing omega-3
9470593|NCT03627312|Placebo Comparator|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
9470594|NCT03627312|Other|Treatment as Usual|this group do not receive a fruit juice drink
9470595|NCT03627273|Experimental|walker|'6 minutes walking test' with a walker
9470596|NCT03627273|Active Comparator|no walker|'6 minutes walking test' without walker
9470597|NCT03627247|Experimental|Cognitive Behavioral Stress Management|Women randomized to CBSM participated in an eight-week prenatal course called SMART Moms (Stress Management and Relaxation Training for Moms) aimed at teaching coping and relaxation skills that address stressors and daily challenges experienced during pregnancy and motherhood.
9470598|NCT03627247|No Intervention|Attention Control Group|"Women randomized to the AC group participated in an eight-week program where they received printed materials (offered in Spanish and English) by mail once per week, on common prenatal health information topics (e.g., common discomforts of pregnancy, labor and delivery) chosen from the March of Dimes Foundation's Becoming a Mom handouts (March of Dimes, 2011). Women in this group were contacted once per week by phone by a research staff member to make sure that they received their mailed prenatal health information and to see if they had any questions."
9470599|NCT03627234|Experimental|Same Day Discharge|Same day discharge after hysterectomy is the standard of care at George Washington University Hospital.
10032445|NCT01777906||Dexamethasone sodium phosphate 0.032%|Dexamethasone 0.032% nasal spray will be given at a dose of 2 sprays twice a day for 6 weeks.
10032446|NCT01777919|Experimental|Temozolomide+Disulfiram/copper|"Disulfiram/copper combination will be started on the 5th postoperative day and before the initiation of the standard radiochemotherapy (fractionated irradiation with a total dose of 60 Gy with concomitant 75 mg/m2 body surface temozolomide each day, including weekends, during irradiation). After completion of the radiation therapy patients will receive maintenance temozolomide 150-200 mg/m2 body surface on Days 1-5 every 28 days for 6 months. Daily administration of disulfiram and copper will take place for the whole study period.~NOTE: Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
10032447|NCT01777958||Cohort|
10032448|NCT01777971||Patients with cirrhosis|Male and female subjects who have cirrhosis of the liver and diuretic-resistant ascites (based on International Ascites Clib criteria) and have been evaluated and approved to have a large-volume paracentesis as part of standard of care treatment.
10032449|NCT01778036||Neck pain patients following physiotherapy treatment|Neck pain patients will follow physiotherapy treatment in primary health care.
10032450|NCT01778075|Experimental|Treatment sequence AB|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
10032451|NCT01778075|Experimental|Treatment sequence BA|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
9470600|NCT03627234|Experimental|Overnight stay|Overnight stay is not the standard of care at George Washington University Hospital. It is being used as an experimental condition.
9470601|NCT03627221|Experimental|music listening and social network|The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
9470602|NCT03627221|No Intervention|Control group|The control group will not receive music listening at sleep time and will not be invited to join a social network for 12 weeks. But their sleep quality, sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
9470603|NCT03627182|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
9470604|NCT03627182|Placebo Comparator|Placebo|Placebo
9470605|NCT03627169||MATRx plus/PSG group|Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
9470606|NCT03627156|Experimental|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
9470607|NCT03627156|No Intervention|Control|Control Arm is an arm to which the intervention will not be implemented.
9470608|NCT03627143|Other|Local implementation of AAFF guidelines|The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
9470609|NCT03627130|Active Comparator|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
9470610|NCT03627130|Placebo Comparator|Potassium Chloride|Potassium Chloride
9470611|NCT03627117|Experimental|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
9470612|NCT03627117|Experimental|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
10032452|NCT01778088|Other|Single Group|I-131-CLR1404 Injection
10032453|NCT01778101|Experimental|lansoprazole|lansoprazole 1mg/kg twice a day for 14days
10032454|NCT01778114|Placebo Comparator|Placebo + orange juice without vitamin D|Placebo + orange juice without vitamin D
9470613|NCT03627104|Other|Normoprotein diet with animal protein|The patient will intake the diet assigned for a month
9470614|NCT03627104|Other|Normoprotein diet with vegetable protein|The patient will intake the diet assigned for a month
9470615|NCT03627104|Other|High-protein diet with animal protein|The patient will intake the diet assigned for a month
9470616|NCT03627104|Other|High-protein diet with vegetable protein|The patient will intake the diet assigned for a month
9470617|NCT03627078|Experimental|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
10032455|NCT01778114|Experimental|Placebo + 1000 IU vitamin D3 in OJ|Vitamin D3 in orange juice
10032456|NCT01778114|Experimental|Placebo + 1000 IU vitamin D2 in OJ|Vitamin D2 in orange juice
10032457|NCT01778114|Active Comparator|1000 IU vitamin D3 + placebo OJ|1000 IU vitamin D3 + placebo OJ
10032458|NCT01778114|Active Comparator|1000 IU vitamin D2 + placebo OJ|1000 IU vitamin D2 + placebo OJ
10032459|NCT01778140|Experimental|Patient-specific reminder|Intervention: Patient-specific computerized reminder. The physicians assigned to this arm will use the patient-specific CDSS on CPOE. The patient-specific reminder is designed as a real-time CDSS implemented on CPOE to monitor physician's contrast-enhanced image study orders. Computerized pop-up reminders provide the patient-specific CIN risk profile and optimal decision options which are generated when patients with high risk or with unknown risk of CIN are encountered.
10032460|NCT01778140|Active Comparator|Non-patient-specific reminder|Intervention: Non-patient-specific Computerized reminder. The physicians assigned to this arm will use the Non-patient-specific reminders through CPOE. Non-patient-specific reminders always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
10032461|NCT01778140|No Intervention|Control Arm|The physicians assigned to this arm will not use and any computerized reminder.
10032462|NCT01778153|Experimental|Equinox Personal Coaching|Participants assigned the Coached group will receive up to 36 sessions about three times a week, consisting of both strength and aerobic exercises, through a program designed by Equinox Fitness Centers.
10032463|NCT01778153|No Intervention|Self-directed exercise training|Participants in the Self-directed group will receive general exercise training advice as any member of the fitness club would, and will record the details of their exercise in log sheets. They will be asked to continue their usual exercise routine.
10032464|NCT01778166|Active Comparator|Standard early enteral nutrition|There would be 100 patients in this group
10032465|NCT01778166|Experimental|Immuno-enhanced early enteral nutrition|There would 100 patients in this group
10032466|NCT01778192|Active Comparator|Same day PEG|group 1 (same day PEG, N=50) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
10032467|NCT01778192|Active Comparator|split PEG|group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
10032468|NCT01778192|Active Comparator|SPMC 2|group 3 (SPMC 2, N=50) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
10032469|NCT01778192|Active Comparator|SPMC 3|group 4 (SPMC 3, N=50) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
10032470|NCT01778205||Pregnant women|Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks
10032471|NCT01778218|Experimental|99mTc-EC-DG|99mTc-EC-DG injection followed by SPECT imaging during a cardiac rest study (Visit 1) and an exercise/regadenoson study (Visit 2)
10032472|NCT01778231|Experimental|Vitamin Supplement|1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
10032473|NCT01778231|Placebo Comparator|Inert oil capsule|1 capsule daily for 16 weeks
10032474|NCT01778244|Experimental|metformin|metformin
10032475|NCT01778244|Placebo Comparator|placebo|placebo
9470618|NCT03627078|Sham Comparator|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
9470619|NCT03627052|Experimental|Itacitinib|
10032476|NCT01778257|Experimental|Mate extracts group|Mate extract(3150 mg/day)for 12 weeks
9470620|NCT03627052|Placebo Comparator|Placebo|
9470621|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
10032477|NCT01778257|Placebo Comparator|Placebo group|Placebo (3150 mg/day) for 12 weeks
9470623|NCT03627013|Experimental|Kidney Custodiol-N|
9470624|NCT03627013|Active Comparator|Kidney Custodiol|
9470625|NCT03627013|Experimental|Liver Custodiol-N|
9470626|NCT03627013|Active Comparator|Liver Custodiol|
9470627|NCT03627013|Experimental|Kidney/Pancreas Custodiol-N|
9470628|NCT03627013|Active Comparator|Kidney/Pancreas Custodiol|
9470629|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
9470630|NCT03626987||Bacterial identification|Describe the MALDI-TOF spectrum to identify peaks that may be associated with epidemiological and clinical characteristics of bacterial strains
9470631|NCT03626974|Experimental|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
9470632|NCT03626974|Placebo Comparator|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
9470633|NCT03626961||discharge|patients discharged from icu
9470634|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
9470635|NCT03626948|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
9470636|NCT03626935|Experimental|3D-printed customized guide plate|3D-printed customized guide plate will be used to guide the Kirschner wires in ankle arthrodesis.
9470637|NCT03626896|Experimental|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
9470638|NCT03626844|Experimental|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
9470639|NCT03626844|Active Comparator|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
9470640|NCT03626831|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe (1x SC 420 mg evolocumab).
9470641|NCT03626831|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of Placebos (1x SC Placebo).
9470642|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS> 2 or intracranial tumor progression.
9470643|NCT03626805||Migraine patients|Migraine patients attending the Danish Headache Centre
9470644|NCT03626805||Healthy Controls|Age and sex matched
9480283|NCT03535064|Experimental|Schools received hand hygiene workshop|Schoolgirls of randomly assigned schools attended one-hour Arabic handwashing workshop conducted by the principal investigator one week after submitting all baseline questionnaires. Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
9480284|NCT03535064|No Intervention|Schools with did not receive hand hygiene workshop|Schoolgirls in control group followed their usual hand washing procedure. When the study ended, schoolgirls of control school were exposed to the same intervention by the same investigator.
9480285|NCT03535051|Experimental|Treatment A|Combination treatment of fractional carbon dioxide laser monthly sessions and topical tacrolimus 0.03% daily application (Tacrolimus Oint 0.03%)
10037121|NCT01822015|Experimental|Treatment (sirolimus, idarubicin, cytarabine)|Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
10037606|NCT01826591|Experimental|Experimental: Low-Fat Diet|Healthy, Low-Fat Diet
9480286|NCT03535051|Active Comparator|Treatment B|Monotherapy with only topical tacrolimus 0.03% daily intervention: Tacrolimus Oint 0.03%
9480287|NCT03535038|Experimental|Inferior vena cava (IVC) diameter|subjects underwent IVC diameter measurement after VPW measurement
9480288|NCT03535038|Active Comparator|Vascular pedicle width (VPW)|Supine chest x ray was done and the VPW is assessed by radiologists.
9803111|NCT04534387|Active Comparator|Active Control Group|This group will receive standard of care Spanish language information from the American Speech-Language-Hearing Association (ASHA) Audiology Series
10032478|NCT01778270|Other|non invasive sensor pleural drainage|feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor in Ohm before and after pleura drainage, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume before and after pleura drainage. Additionally heart sound analysis via electronic stethoscope will be compared to standard methods.
9470645|NCT03626779|Other|immediate placment and loading with prf|Immediat placment and loading with prf
9470646|NCT03626779|No Intervention|immediate implant placment and loading|Immediate implant placment and loading without prf
10032479|NCT01778270|Other|non invasive sensor healthy control|"the same measurements as in arm 1: feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor before and after pleura drainage in Ohm, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume once in 25 healthy controls.~Additionally heart sound analysis via electronic stethoscope will be compared to standard methods."
10032480|NCT01778283|Experimental|Acetate-free solution first|Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
10032481|NCT01778283|Active Comparator|Acetate-based solution first|Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
10032482|NCT01778309|Experimental|n-acetylcysteine/placebo supplementation|n-acetylcysteine supplementation, orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise placebo, orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder.
10032483|NCT01778322||Index Embolization Cohort|WEB Aneurysm Embolization System
10032484|NCT01778335|No Intervention|Control|Control arm subjects will receive best medical care.
9470647|NCT03626766|Active Comparator|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
10032485|NCT01778335|Experimental|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
10032486|NCT01778348|Experimental|Overnight closed-loop combined with CGM|Glucose level is controlled by the automated closed loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system overnight at home for a total duration of 12 weeks.
9470648|NCT03626766|Active Comparator|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
9470649|NCT03626766|Active Comparator|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
9470650|NCT03626766|No Intervention|No Photo|No patient photographs displayed in the electronic health record.
9470651|NCT03626753|Active Comparator|Oral Group|"received in post operative period oral analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
9470652|NCT03626753|Active Comparator|Intravenous group|"received in post operative period intravenous analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
9470653|NCT03626740|Experimental|TheraCal|Indirect pulp capping with TheraCal
9470654|NCT03626740|Active Comparator|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
9470655|NCT03626727|Experimental|Sodium Oxybate Oral Solution (Xyrem®)|4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
9470656|NCT03626675|Other|study group|"They will be subjected to:~Preoperative A-complete ophthalmic examination will be done for every patient; B- Biometric parameters measured with the AS-OCT C- Medical fitness for all patients D- Informed consent will be obtained from all patients after through explanation of operation and its potential benefits and risks.~Surgery combined Phaco trabeculectomy~Post operative:~-Follow-up examinations will be performed for every patient at 1day, 1 week, 1 and 3 months postoperatively.~and biometric parameters measured with the AS-OCT before and after the surgery will be used to collect the data.~-The data will be managed and analysed with confidentiality by scientifically qualified persons"
9470657|NCT03626649|Experimental|DiamondTemp Cardiac Ablation System|Cardiac ablation procedure
9470658|NCT03626636|Active Comparator|Active Group|Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
9470659|NCT03626636|Placebo Comparator|Placebo Group|Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
9470660|NCT03626610|Experimental|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
9470661|NCT03626610|No Intervention|Non-interventional|Patients will have standard care.
9480289|NCT03535012||Reconstruction using an implant|Immediate 2 stage implant based breast reconstruction after mastectomy. All expanders are placed in the subpectoralis muscle using ADM as a sling. After expansion of the tissue expander change to the permanent implant is performed.
9803112|NCT04534283|Experimental|Abemaciclib + LY3214996|Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
9803113|NCT04533659|Active Comparator|Control group|This group will receive 4-week diabetes nutrition education with digital self-monitoring for diet and blood glucose.
9470662|NCT03626597|Active Comparator|CHV-provided post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
10032487|NCT01778348|Active Comparator|Real-time CGM alone|The subjects will use the study CGM alone at home for the period of 12 weeks. Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
9470663|NCT03626597|Active Comparator|Phone-based post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
9470664|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
9470665|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
9470666|NCT03626571||Native valve infective endocarditis|Patients with infective endocarditis of native valves of the heart with no contraindications to MRI scanning.
9470667|NCT03626571||Prosthetic endocarditis|Patients with endocarditis of prosthetic heart valves or device-related infections.
10032488|NCT01778361||HIV positive|
9470668|NCT03626571||Non-infective post-operative|Patients who have recently undergone valve or device implantation with no evidence of post-operative infection.
9470669|NCT03626558|Experimental|Distroke patients|"For every patient include in the study, ultrasound measures at the admission/discharge of hospitalization will be realized.~All the patients will see each other suggested participating in a new collection of remote ultrasound measures of the stroke (around 2-3 months). These measures will be made during the usual consultation proposed by the department of neurology. This medical consultation is a part of the follow-up post--stroke recommended by the High Authority of Health. These measures will allow us to highlight the kinetics of recovery of the diaphragmatic function except any intervention of reeducation of muscles inspirers."
9470670|NCT03626532|Experimental|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
9470671|NCT03626532|Active Comparator|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
9470672|NCT03626519|Experimental|Test with Menthol|Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
9470673|NCT03626519|Placebo Comparator|Test with placebo|Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
9470674|NCT03626506|Experimental|spironolactone|Subjects will take spironolactone 20~40mg once daily on top of amlodipine 5~10mg once daily.
10032489|NCT01778361||HIV negative|
9470675|NCT03626506|Active Comparator|indapamide|Subjects will take indapamide 1.5~3.0mg once daily on top of amlodipine 5~10mg once daily.
9470676|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
9470677|NCT03626467|Experimental|Arm 1|Men infected by HIV who have sex with men
9470678|NCT03626454|Active Comparator|group B|'Norepinephrine bolus' of 6 µg plus Normal Saline 0.9% Infusion Solution
9470679|NCT03626454|Active Comparator|group I|'Norepinephrine infusion' 6 µg/kg/h plus 'Normal Saline Flush, 0.9% Injectable Solution
9470680|NCT03626441|Placebo Comparator|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
9470681|NCT03626441|Experimental|Ginger|Two coloured capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
10032490|NCT01778374|Experimental|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
10032491|NCT01778374|Experimental|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
10032492|NCT01778387|Active Comparator|Laparoscopic ventral hernia repair|Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
10032493|NCT01778387|Placebo Comparator|Open ventral hernia repair|Open repair: Incision was made over hernia defect, reducing herniary contents by opening sac if it is necessary. We made 4 cm soft tissue flaps around edge of defect depending on available healthy fascial tissue. Chevrel technique with fascial closure using anterior rectus sheath with continuous and absorbable suture and placement of polypropylene mesh (Parietene standart polypropylene mesh, Covidien, Norwalk, CT) in an onlay position fixed with polypropylene suture.
10032494|NCT01778400|Experimental|Radiofrequency ablation|Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
9470682|NCT03626402|Experimental|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
9470683|NCT03626402|No Intervention|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
9470684|NCT03626363|Experimental|Mindfulness-Based Stress Reduction|
9470685|NCT03626363|Active Comparator|Stress Management Education|
9470686|NCT03626324|Experimental|C2P Study|Clinical Evaluation of Connected Catheter 2P Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
9470687|NCT03626298|Placebo Comparator|Adapalene and placebo (ADAP)|
9470688|NCT03626298|Experimental|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
9470689|NCT03626272|Active Comparator|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
9470690|NCT03626272|Active Comparator|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
9470691|NCT03626272|Active Comparator|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
9470692|NCT03626259|Other|losartan and amlodipine|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
9470693|NCT03626259|Active Comparator|Losartan|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
9470694|NCT03626246||Kidney disease|Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
9470695|NCT03626233||Vascular group|Pregnant women with vascular pathology
9470696|NCT03626233||Control group|"Pregnancy without any vascular complication~Delivery before or after 37 weeks of gestation (GW)~In case of delivery after 37GW: birth by cesarean delivery"
9470697|NCT03626220||acupuncture group|acupuncture with de-chi sensation
9470698|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
9470699|NCT03626207||Retinitis pigmentosa|Retinitis pigmentosa patients with severe visual impairment
9470700|NCT03626181|Experimental|Active TBS-DLPFC|There is only one arm. All participants will receive Theta Burst Stimulation (transcranial magnetic stimulation) of the dorsolateral prefrontal cortex.
9470701|NCT03626168|Active Comparator|Consumption of 100% watermelon juice|Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
9470702|NCT03626168|Placebo Comparator|Consumption of a placebo beverage|Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
9470703|NCT03626155|Experimental|Seated Control|
10032495|NCT01778400|Active Comparator|Ethanol|Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
10032496|NCT01778413|Experimental|ATRIPLA three times a week.|Atripla (600 mg/200 mg/245 mg) three times a week.
9470704|NCT03626155|Experimental|Morning Exercise (walking)|
9470705|NCT03626155|Experimental|Afternoon Exercise (walking)|
10032497|NCT01778413|Active Comparator|ATRIPLA one time a day.|Atripla (600 mg/200 mg/245 mg) one time a day.
10032498|NCT01778439|Experimental|OMP-52M51|
10032499|NCT01778452|Active Comparator|Natural cycle|Natural cycle endometrial biopsy, lh+7
10032500|NCT01778452|Experimental|Antagonist cycle + endometrial priming.|Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5
10032501|NCT01778452|Experimental|Agonist cycle + endometrial priming.|Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
10032502|NCT01778621|Experimental|Acupuncture (Hwato®)|30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up.
10032503|NCT01778621|No Intervention|No acupuncture|No intervention was done for this group of patients.
10032504|NCT01778647|Experimental|Stimulants plus Lovaza|Usual dose of stimulant plus Lovaza (prescription Omega-3 fatty acids) at a dose of 1800 mg daily.
10032505|NCT01778647|Placebo Comparator|Stimulants plus placebo|Usual dose of stimulants plus placebo(corn oil), which will be given to the patients by MMC's pharmacy.
10032506|NCT01778660|Active Comparator|Standard Counselling|Patients in this arm are randomised to standard counselling.
10032507|NCT01778660|Experimental|Mnemonic Counselling|Patients in this arm are randomised to counselling with the aid of a mnemonic.
10032508|NCT01778673||Distal radius fractures Sundsvall Hospital|
10032509|NCT01778673||Distal radius fractures Östersund Hospital.|
10032510|NCT01778686|Experimental|Citalopram and Pindolol|"Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.~Pindolol peroral administration starting 3 days before scanning:~Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon."
10032511|NCT01778686|Placebo Comparator|Placebo|"Placebo for pindolol: sugar tablets that resembles pindolol~Placebo for ATD: amino acid drink balanced formula (containing tryptophan)~Placebo for Seropram: NaCl infusion"
10032512|NCT01778686|Experimental|Acute tryptophan depletion|Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.
10032513|NCT01778699|Experimental|Lozenges with Lactobacillus brevis CD2|During the treatment phases subjects will use 2 lozenges a day.
10032514|NCT01778699|Placebo Comparator|Lozenges|During the treatment phases subjects will use 2 lozenges a day.
10032515|NCT01778712|Experimental|Intervention|Multi-level intervention
10032516|NCT01778738|Experimental|Sleeve gastrectomy|Sleeve gastrectomy.
10032517|NCT01778738|Experimental|Gastric bypass|Gastric bypass surgery.
10032518|NCT01778738|No Intervention|Control group|This is an extra control group without diabetes. All subjects are morbidly obese patients recruited from the Morbid Obesity Centre.
10032519|NCT01778777|Experimental|UniverseReverse|Cohort get an universe reverse prosthesis
10032520|NCT01778790|Sham Comparator|Sham Stimulation for 8 weeks|Implantation of internal pulse generator (IPG), Sham Stimulation
9470706|NCT03626155|Experimental|Evening Exercise (walking)|
9470707|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
9470708|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
9470709|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
9470710|NCT03626129|No Intervention|Traditional rapid deflation|"Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered (Initial inflated air volume). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding)."
9470711|NCT03626129|Experimental|Oximetry guided deflation|"Group B: Initial step with sheath removal as in group A. Before departure from the cath.lab. a Patent hemostasis test (see description in Interventions below) is performed. Further action as described in Interventions below."
9470712|NCT03626103|Experimental|+ Brief ED Intervention (BI), + Text|Participants receive both the Brief ED Intervention component (a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant) and the Text Message Intervention component (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills).
9470713|NCT03626103|Experimental|+ Brief ED Intervention (BI), no Text|Participants receive the Brief ED Intervention component only (which is a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant).
9470714|NCT03626103|Experimental|No Brief ED Intervention (BI), + Text|Participants receive the Text Message Intervention component only (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills). Participants receive a brochure containing online and community resources for violence and depression prevention instead of the Brief ED Intervention component.
9470715|NCT03626103|No Intervention|No Brief ED Intervention (BI), no Text|Participants receive neither the Brief ED Intervention component, nor the Text Message Intervention component. Participants receive a brochure containing online and community resources for violence and depression prevention, instead of the Brief ED Intervention component.
9470716|NCT03626090|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
9470717|NCT03626077|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
9470718|NCT03626077|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
9470719|NCT03626077|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
9470720|NCT03626064|Other|PROMPT Participants|80 participants who are homeless or at-risk for homelessness, smoke tobacco, and identify as People Who Use Drugs in Ottawa.
9470721|NCT03626051|Active Comparator|rigid tape group|
9470722|NCT03626051|Experimental|fibular tape group|
9470723|NCT03626025|No Intervention|Mass Learning Group|Participants underwent an eight-hour microsurgery training course in a single session under the mass-learning format.
9470724|NCT03626025|Other|Spaced Learning Group|Participants underwent two-hour microsurgery training sessions every week for a total of 4 sessions under the spaced learning format.
9470725|NCT03625999|Experimental|Training Group|Parents and children selected for the Training group will be lent a laptop for the duration of the at-home training, and assisted in opening the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on the laptop) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
10032521|NCT01778790|Active Comparator|Stimulation for 8 weeks|Implantation of IPG and active stimulation
10032522|NCT01778803|Experimental|defactinib (VS-6063) plus paclitaxel|Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
10032523|NCT01778829|Active Comparator|CPAP ventilation mode|Once the patient is extubated, CPAP ventilation mode is inmediately administered in order to prevent reintubation
10032524|NCT01778829|Experimental|NIPPV ventilation mode|NIPPV: Non Invasive Ventilation mode is administered inmediately after extubation to prevent reintubation
10032525|NCT01778842|Experimental|Prasugrel low dose|Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
10032526|NCT01778842|Experimental|Clopidogrel standard dose|Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.
10032527|NCT01778868||Overweight and obese individuals|
10032528|NCT01778868||Normal weight individuals|
10032529|NCT01778881|Experimental|Massage + Exercise|Massage and stretching exercises
10032530|NCT01778881|Experimental|Relaxation +Imagination|Relaxation and Imagination therapies
10032531|NCT01778881|Experimental|Dental treatment|Reconstruction with composite resin
10032532|NCT01778881|Experimental|Massage + Exercise + Relaxation + Imagination|Massage, stretching exercises, relaxation and imagination
10032533|NCT01778894||Healthy Control|Healthy controls with no history of heart disease or heart failure. Subjects will undergo a medical history review and 1 echocardiograph procedure.
10032534|NCT01778894||>Grade 2 Diastolic Dysfunction|Diastolic Heart Failure, > Grade II (NYHA functional class) and/or > Grade II Diastolic Dysfunction as evaluated by echocardiography
10032535|NCT01778907|No Intervention|Normal genotype- control (NG-C)|In the external control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice. Allocation to this arm is not based on randomization.
10032536|NCT01778907|No Intervention|Deviating genotype -control (DG-C)|In the internal control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice
10032537|NCT01778907|Experimental|Deviating genotype (DG-I)|In the intervention group, genotype information accompanied by a drug dosing advice will be given to the treating physician. Blood level of the drug will be communicated by a dedicated research team to the treating physician according to daily practice.
10032538|NCT01778920|Experimental|IV Injection of EC17|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
10032539|NCT01778933|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
9470726|NCT03625999|No Intervention|Wait-List Control|The families assigned to the wait-list control group will not receive access to the game until after 4 weeks and completion of the secondary round of testing at the lab. After the second lab visit and completion of the testing, families will be given access to the video game training exercise (on a loaned laptop), walked through the game's operation and controls, and encouraged to use it as often as they or their child like. If the child plays the game for a minimum of 20 minutes, 3 times per week, for 4 weeks, the family will be invited back to CARE for post-testing.
9803114|NCT04533659|Experimental|Intervention group|This group will receive 4-week personalized behavioral nutrition intervention with digital self-monitoring for diet and blood glucose and diabetes nutrition education. Participants will discuss the personalized nutrition change goals and recommendations based on metabolic profiling for assessing dietary patterns.
9803115|NCT04526665|Experimental|Elafibranor 80mg|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
10032540|NCT01778946|Experimental|Nicotine|"Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)~All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).~Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.~All participants will apply a new patch daily for a total of 28 days (1 month)"
10032541|NCT01778959|Active Comparator|standard OVD|
9470730|NCT03625960|Experimental|Cantharidine group|Application of cantharidine to perenial warts
10032542|NCT01778959|Active Comparator|Iris hooks|
10032543|NCT01778959|Active Comparator|Malyugin Ring|
10032544|NCT01778959|Active Comparator|OVD|
10032545|NCT01778972|Experimental|Otago home training programme|"Otago home exercise programme was designed specifically to prevent fall. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
9470731|NCT03625960|Active Comparator|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
9470732|NCT03625947||Hemoptysis patients|Hemoptysis patients caused by endobronchial malignancies
9470733|NCT03625934|Experimental|VVX001 (20 micrograms)|Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
9470734|NCT03625934|Placebo Comparator|Placebo|Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
10032546|NCT01778972|Experimental|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
10032547|NCT01778972|No Intervention|Control grop|Participants are instructed to live their ordinary lives.
10032548|NCT01778998|Active Comparator|MICS-group|
10032549|NCT01778998|Active Comparator|SICS-group|
10032550|NCT01778998|Active Comparator|SICS pre-cut|
9470737|NCT03625908|Active Comparator|OCT-guided PCI|Patients will receive PCI under OCT-guidance.
9470738|NCT03625908|Active Comparator|Angiography-guided PCI|Patients will receive PCI under Angiography-guidance.
9470739|NCT03625895||Agrylin|Participants who received treatment with Agrylin will be evaluated for this study.
9470740|NCT03625856|Experimental|Intervention|1500 mg Chlorella Vulgaris capsule
9470741|NCT03625856|Placebo Comparator|Control|1500 mg placebo (starch)
10032551|NCT01778998|Active Comparator|SICS stab-incision|
10032552|NCT01779011||A cohort post amputation|Those patients undergoing either traumatic amputation or surgical amputation of limb
10032553|NCT01779011||A cohort post limb conserving surgery|Patients whose surgical management involved conservation of their injured limb
10032554|NCT01779037||Inpatient Rehabilitation Patients|
10032555|NCT01779063|Experimental|web based multimedia intervention|interactive,web based multimedia intervention
10032556|NCT01779063|Active Comparator|education booklet|printed educational booklet
10032557|NCT01779076|Experimental|100% oxygen during extubation|In this arm the intervention will consist of 100 % oxygen.
10032558|NCT01779076|Experimental|30% oxygen during extubation|In this arm the intervention will consist of 30 % oxygen.
10032559|NCT01779089|Experimental|Minocycline|Minocycline 100 mg po bid for 6 months
10032560|NCT01779089|Placebo Comparator|Placebo|Placebo one tablet po bid
10032561|NCT01779102|Experimental|0.1 µg C-Tb|The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
9470742|NCT03625843|Experimental|Mindfullness exercises|Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
9470743|NCT03625843|No Intervention|Control|Sitting quietly in a room alone.
10032562|NCT01779102|Active Comparator|2 T.U Tuberculin PPD RT 23 SSI|The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
10032563|NCT01779102|Experimental|0.1 µg C-Tb / 2 T.U Tuberculin PPD|The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme
10032564|NCT01779128|Experimental|Experimental Arm|PET/CT Scan MR-PET Scan
9470744|NCT03625830|Experimental|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
9470745|NCT03625830|Active Comparator|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
9470746|NCT03625817|No Intervention|Urban setting|The participants will be staying in their permanent house in an urban area in Cyprus for at least 7 days. On the 7th day, they will be wearing 2 temperature sensors, for skin and air temperature. They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
9470747|NCT03625817|Experimental|Mountainous setting|The intervention is the short stay in the mountainous area of Troodos for atleast 7 consecutive days. The participants will be staying in their holiday house in the mountainous-rural area of Troodos, Cyprus for at least 7 days. On the 7th day, they will wear 2 temperature sensors, for skin and personal air temperature monitoring (every minute data points). They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
9470748|NCT03625804|Experimental|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
10032565|NCT01779154||eosinophilic gastrointestinal disorders|Individuals with a diagnosis of EGID including: eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis
10032566|NCT01779193|Experimental|latic acid bacteria and cranberry|oral latic acid bacteria and cranberry capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
10032567|NCT01779193|Active Comparator|cranberry|oral cranberry capsule without lactic acid bacteria, one pill daily
10032568|NCT01779193|Placebo Comparator|placebo|placebo without lactic acid bacteria and cranberry, one pill daily
9470749|NCT03625804|Experimental|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
9470750|NCT03625804|Placebo Comparator|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
10032569|NCT01779206|Active Comparator|Anthracycline - Taxane|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
10032570|NCT01779206|Experimental|Taxane - Anthracycline|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
9470751|NCT03625791||radiation-induced sarcomas|
9470752|NCT03625791||radiotherapy for at least 5 years and without sarcomas|
10032571|NCT01779232|Placebo Comparator|control|patients treated with placebo for at least 4 months before IVF attempt
9470753|NCT03625791||primary sarcomas|
9470754|NCT03625778|Placebo Comparator|Placebo Cohort 1|Participants will receive subcutaneous (SC) placebo matched to MEDI0382 Cohort 1 once daily for 9 weeks.
9470755|NCT03625778|Experimental|MEDI0382 Cohort 1|Participants will receive SC MEDI0382 titrated doses of Dose 1 to 7 once daily (7-step titration/ 1 week per dose) from Weeks 1 to 7 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 7 to 9.
9470756|NCT03625778|Placebo Comparator|Placebo Cohort 2|Participants will receive SC placebo matched to MEDI0382 Cohort 2 once daily for 14 weeks.
9470757|NCT03625778|Experimental|MEDI0382 Cohort 2|Participants will receive SC MEDI0382 titrated doses of Doses 1, 2, 3, 5, and 7 once daily (5-step titration/ 2 week per dose) from Weeks 1 to 10 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 11 to 14.
9470758|NCT03625778|Placebo Comparator|Placebo Cohort 3|Participants will receive SC placebo matched to MEDI0382 Cohort 3 once daily for 18 weeks.
10032572|NCT01779232|Active Comparator|danazol|patients treated with danazol (100mg/day)for at least 4 months before IVF attempt
9470759|NCT03625778|Experimental|MEDI0382 Cohort 3|Participants will receive SC MEDI0382 titrated doses of Doses 1, 8, 4, and 7 once daily (4-step titration/ 4 week per dose) from Weeks 1 to 16 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 17 to 18.
9470760|NCT03625726|Experimental|patients with cirrhosis|pathophysiology study, blood sample
9470761|NCT03625726|Placebo Comparator|healthy volunteers|pathophysiology study, blood sample
9470762|NCT03625726|Placebo Comparator|patients with hepatocellular carcinoma|pathophysiology study, blood sample
10032573|NCT01779245|Placebo Comparator|Control|A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
10032574|NCT01779245|Experimental|High-Calcium|A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
10032575|NCT01779258|Other|Group 2|Active control arm, Locatop@, Locapred@
10032576|NCT01779258|Other|Group 3|Absence of emollient treatment, Locatop@, Locapred@
10032577|NCT01779258|Experimental|Group 1|"glycerol, paraffin (liquid and white soft), Locatop@~, Locapred@"
9470763|NCT03625700||Hypoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation <94 % irrespective of supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation <88% irrespective of supplemental oxygen"
9470764|NCT03625700||Normoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.~Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen."
9803116|NCT04526665|Placebo Comparator|Placebo|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
10032578|NCT01779271|Experimental|Pelubiprofen|
10032579|NCT01779271|Active Comparator|Loxoprofen|
10032580|NCT01779284|Active Comparator|Travoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
10032581|NCT01779284|Active Comparator|Latanoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
10032582|NCT01779310||Alzheimer's disease|Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
10032583|NCT01779323||Pre and Post Sling Pelvic MRI|Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI.
10037122|NCT01822028|Placebo Comparator|Treatment A|"Treatment A: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
10037123|NCT01822028|Experimental|Treatment B|"Treatment B: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
10037124|NCT01822041|Active Comparator|Part A - 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509
10037125|NCT01822041|Active Comparator|Part B: 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509
9470765|NCT03625700||Hyperoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation >98% in combination with supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation >92% in combination with supplemental oxygen"
9470766|NCT03625687|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)
9470767|NCT03625674|Other|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
9470768|NCT03625674|Other|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
9470769|NCT03625674|Other|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
9470770|NCT03625674|Other|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
9470771|NCT03625661|Experimental|Arm with Ferinject|Ferinject will be administered once at inclusion
9470772|NCT03625635|Experimental|Nutrition diagnosis and intervention|At baseline and 6-mo after, a nutrition diagnosis will be done by measuring body composition components with DXA and basic anthropometric measurements. Based on the results, an individualized food-based intervention will be prescribed for each patient according to her diagnosis, food preferences, cultural and socioeconomic status. Follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed and initial measurements are repeated.
9470773|NCT03625622|Placebo Comparator|Placebo|Placebo, orally administered once daily for 26 weeks.
9470774|NCT03625622|Active Comparator|AR1001 - 10 mg|Active, AR1001 - 10 mg, orally administered once daily for 26 weeks.
9470775|NCT03625622|Active Comparator|AR1001 - 30 mg|Active, AR1001 - 30 mg, orally administered once daily for 26 weeks.
9470776|NCT03625596|Active Comparator|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
9470777|NCT03625596|Experimental|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
9470778|NCT03625596|Experimental|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
9470779|NCT03625596|Experimental|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
9470780|NCT03625596|Placebo Comparator|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
9470781|NCT03625583||chronic myeloid leukaemia|chronic myeloid leukaemia diagnosed from 2007 - 2017
9470782|NCT03625570|Experimental|PT³|Power Training combined with interval treadmill training
9470783|NCT03625570|Active Comparator|Traditional training|Strength training combined with traditional treadmill training
9470784|NCT03625544|Experimental|MagnetOs™ Granules|MagnetOs™ Granules
9470785|NCT03625544|Active Comparator|Autograft|Autologous bone graft
9470786|NCT03625531|Experimental|Personalized acupuncture|Two sets of acupoints will be selected for the two types. The basic acupoint-prescription includes CV 4, CV 6, CV 12 and SP 6 bilaterally, ST 25 bilaterally, EX-CA 1 bilaterally, ST 40 bilaterally and SP 9 bilaterally. Additional point ST 36 bilaterally and moxibustion as adjuvant therapy will be added for the type of yang deficiency of spleen and kidney, while additional points K 13, LR 3 for the type of yin deficiency of liver and kidney. Besides, flexible modifications of 2-3 acupoints will be performed according to patients special symptoms.
9470787|NCT03625531|Experimental|Fixed acupuncture|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.
10037126|NCT01822054||Normal weight|
10037127|NCT01822054||Obese|
10032584|NCT01779336|Experimental|PL225B|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
10032585|NCT01779349|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
10032586|NCT01779362|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.
9470788|NCT03625531|Active Comparator|Letrozole|Women in the letrozole group will be given letrozole (Femara, Novartis Pharmaceuticals, Basel, Switzerland) from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
9470789|NCT03625531|Placebo Comparator|Placebo letrozole|Women will receive placebo letrozole with no acupuncture from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. Placebo letrozole will be given in the same way as letrozole.
10032587|NCT01779362|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.
10032588|NCT01779362|Placebo Comparator|Placebo|Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.
9470790|NCT03625518|Active Comparator|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
9470791|NCT03625518|Active Comparator|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
9470792|NCT03625505|Experimental|Dose Escalation Venetoclax + Gilteritinib|Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
9470793|NCT03625505|Experimental|Dose Expansion Venetoclax + Gilteritinib|Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.
9470794|NCT03625492|Experimental|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
9470795|NCT03625492|Active Comparator|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
9470796|NCT03625453|Experimental|ABX-1431|Oral use of hard capsule (10 milligrams), maximum dose per day: 40 milligrams
10032589|NCT01779362|Active Comparator|Liraglutide + Metformin|Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
10032590|NCT01779401|Active Comparator|Clopidogrel + Aspirit|A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
10032591|NCT01779401|Active Comparator|Clopidogrel + Aspirin|B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
10032592|NCT01779401|Active Comparator|Clopidogrel + Aspirin + Cilostazol|C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd
9470797|NCT03625453|Placebo Comparator|Placebo|Oral use of hard capsule
9470798|NCT03625440|Other|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.~The Digit span test and PASAT with waterpipe smoking"
9470799|NCT03625440|Other|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.~The Digit span test and PASAT without waterpipe smoking"
9470800|NCT03625427|Placebo Comparator|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
9470801|NCT03625427|Experimental|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
9470802|NCT03625427|Experimental|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
9470803|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
9803117|NCT04525716||COVID-19|Patients with confirmed COVID-19 infection
10032593|NCT01779414|No Intervention|Enhanced Usual Care|Participants in this arm of the study will receive a standard, usual care psychological risk assessment by a social worker and then recommended to a mental health referral.
10037128|NCT01822067||Normal weight- Non Maternal obesity|Full-term neonates at 2 weeks of age born to normal weight mothers
10037129|NCT01822067||Obese- Obese Mothers|Full-term neonates at two weeks of age born of obese mothers
9470804|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
9470805|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
9803118|NCT04525716||Non-COVID-19|Patients without confirmed COVID-19 infection
9803119|NCT04525365|Experimental|Pleural aspiration|Pleural aspiration under sedation
9803120|NCT04525365|Active Comparator|Closed Thoracostomy|Actual management
9803121|NCT04522908|Experimental|Cabozantinib - Single Arm|Single Arm with Cabozantinib starting dose 40 mg for 4 weeks and dose escalation to 60 mg afterwards.
10032594|NCT01779414|Experimental|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
10032595|NCT01779427|Experimental|AIM Intervention|
9470806|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
9470807|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
10032596|NCT01779427|Experimental|Wait List Control|Participants are in the Wait List Control group for 10 weeks and then they will participate in the AIM Intervention
9470808|NCT03625401|Experimental|AD-35 60 mg|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
10032597|NCT01779466|Experimental|Experimental A|
10032598|NCT01779466|Experimental|Experimental B|
10032599|NCT01779466|Placebo Comparator|Placebo|
9470809|NCT03625401|Placebo Comparator|Placebo of AD-35 30 mg|Placebo group: 3 placebo tablets
9470810|NCT03625375|Experimental|Treatment Group|Individuals will perform exercises 3 times a week.
10032600|NCT01779479|Experimental|Cabacitaxel|
9470811|NCT03625375|No Intervention|Control Group|Individuals will not perform exercises
9470812|NCT03625362|Experimental|Hydrogen|1 L of hydrogen-rich water
10032601|NCT01779479|Active Comparator|Paclitaxel|
9470813|NCT03625362|Placebo Comparator|Placebo|1 L of tap water
9470814|NCT03625336||Prostate Calcifications|Men with prostate calcifications
10032602|NCT01779492|Experimental|GL2907|Oxycodone HCl 20mg
9470815|NCT03625310|Active Comparator|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
9470816|NCT03625310|Experimental|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
9470817|NCT03625310|Experimental|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
9470818|NCT03625310|Experimental|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
10032603|NCT01779492|Active Comparator|Oxycontine CR 10mg|Oxycodone HCl 10mg
10032604|NCT01779505|Experimental|GS-4774 at 10 yeast units (YU)|10 YU of GS-4774 given either weekly or monthly
10032605|NCT01779505|Experimental|GS-4774 at 40 YU|40 YU of GS-4774 given either weekly or monthly
10032606|NCT01779505|Experimental|GS-4774 at 80YU|80 YU of GS-4774 given either weekly or monthly
10032607|NCT01779531||pCR，XT|
10032608|NCT01779544|Active Comparator|Brief intervention only|Brief intervention, an educational model, consists of information
10032609|NCT01779544|Active Comparator|Exercise group|Brief educational intervention combined with exercise therapy
10032610|NCT01779570|Experimental|Macrolide treatment|Azithromycin 500 mg daily for 5 days
10032611|NCT01779570|No Intervention|No macrolide treatment|No azithromycin
10032612|NCT01779583||Advanced gastric cancer patients|Treatment näive advanced gastric cancer patients candidates to first-line chemotherapy
10032613|NCT01779583||Control group|Healthy adult volunteers without a cancer diagnosis
10032614|NCT01779596|Experimental|Bosentan|Single dose of Bosentan (125 mg)
10032615|NCT01779596|Placebo Comparator|Placebo|Single dose of placebo (125 mg)
9470819|NCT03625297|No Intervention|Shelter cat adoption control group|Families of children with autism will complete a control period with no intervention, then adopt a shelter cat after completion of the control period
9470820|NCT03625297|Experimental|shelter cat adoption|Families of children with autism will adopt a shelter cat
9470821|NCT03625284|Experimental|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
9470822|NCT03625284|Placebo Comparator|Placebo|capsules of an edible oil
9470823|NCT03625271|No Intervention|Control|All subjects will undergo same study procedures. Subjects in the Control Arm will receive treatment as usual by the prescribing clinician/investigator. The prescribing clinician/investigator will not receive the PEER Report of probable medication response for a control arm subject.
9470824|NCT03625271|Experimental|Experimental|All subjects will undergo same study procedures. Subjects in the Experimental Arm will receive treatment as usual by the prescribing clinician/investigator. However, the prescribing clinician/investigator will receive the PEER Report of probable medication response for an experimental arm subject. The report will provide additional data/information regarding probable medication response for an experimental arm subject to the prescriber .
9470825|NCT03625219|Active Comparator|Prednisone|Cohort B only: Subjects will take 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
9470826|NCT03625219|Placebo Comparator|Placebo|Cohort B only: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
9470827|NCT03625206|Experimental|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
9470828|NCT03625206|Placebo Comparator|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
9803122|NCT04515810|Experimental|Arm I (PACT)|Participants use PACT mHealth app.
10032616|NCT01779609|Experimental|Bosentan + Exercise|2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise
10032617|NCT01779609|Placebo Comparator|Placebo + Exercise|2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise
10032618|NCT01779609|Other|Exercise|3x/week supervised exercise for 8 weeks
10032619|NCT01779622|Experimental|1|Healthy volunteers are ingesting a mixed meal either rapidly or slowly
10032620|NCT01779635|Active Comparator|oXiris as first filter|Start off the first CRRT circuit with oXiris, then cross-over to M150, then oXiris, then back to M150
10032621|NCT01779635|Other|M150 as first filter|Patients in M150 arm will start off with M150 as first filter for CRRT, then cross-over to oXiris after the former clots, then back to M150, then to oXiris.
10032622|NCT01779661|Active Comparator|Infant Aquatics|
10032623|NCT01779661|Active Comparator|Infant Massage|Infant Massage
10032624|NCT01779687|Active Comparator|raltegravir alone|Raltegravir 400 mg BID for 7 days
10032625|NCT01779687|Active Comparator|Atorvastatin alone|Atorvastatin 20 mg QD for 7 days
10032626|NCT01779687|Experimental|Raltegravir + atorvastatin|Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days
10032627|NCT01779713||Vasospastic patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) and developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
10032628|NCT01779713||Control patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) not developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
10032629|NCT01779726|Experimental|CT scan before chest physician|CT scan before chest physician
10032630|NCT01779726|Active Comparator|Usual diagnostic workup|Usual diagnostic workup
10032631|NCT01779739|No Intervention|No perineorrhaphy|Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair
10032632|NCT01779739|Active Comparator|Perineorrhaphy|Subjects will have a perineorrhaphy added to the vaginal repair of prolapse
10032633|NCT01779765|Experimental|PHGG|2.5gr per day for the first week and then 5gr per day for 11 weeks.
10032634|NCT01779765|Placebo Comparator|Maltodextrin|2.5gr per day for the first week and then 5gr per day for 11 weeks.
10032635|NCT01779791|Experimental|PCI-32765 (Ibrutinib)|
10032636|NCT01779804||Patients with foot and ankle injury|After baseline data is obtained a cohort of patients with acute foot and ankle injuries will have OFAR applied
10032637|NCT01779817|Other|child born to hyperthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
10032638|NCT01779817|Other|child born to euthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
10032639|NCT01779830|Experimental|0.3 mg LY2624803|Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
10032640|NCT01779830|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
10032641|NCT01779830|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
10032642|NCT01779830|Active Comparator|10 mg Zolpidem|Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
10032643|NCT01779830|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods.
10032644|NCT01779843|Experimental|Treatment|"Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)"
10032645|NCT01779882|Active Comparator|BU-CY|Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
10032646|NCT01779882|Experimental|CY-BU|Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
10032647|NCT01779895|Active Comparator|NCC2461|probiotic blended in maltodextrin powder to be taken daily
10032648|NCT01779895|Placebo Comparator|Placebo|maltodextrin
10032649|NCT01779908|Experimental|Vitamin D supplementation|5000 IU of vitamin D3 for 6 months
10032650|NCT01779908|Placebo Comparator|Placebo|Placebo pill for 6 months
10032651|NCT01779921||FVII|
10032652|NCT01779960||Londrina|20 patients with moderate-severe COPD from State University of Londrina, Brazi
10032653|NCT01779960||Leuven|20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium
10032654|NCT01779973|Experimental|Remote Observed Dosing|Compliance with dosage observations of suboxone doses using remote observed dosing 4 days per week and 1 weekly in-office visit.
10032655|NCT01779999||PICC-carrying patients|All patients carrying a peripherally inserted central catheter in our service
10032656|NCT01780012|Experimental|Intervention|Osteoporosis prevention program: Women will receive oral and written information and advices on osteoporosis, a letter and a leaflet on osteoporosis management to give to their family physician, and phone call reminders.
10032657|NCT01780012|No Intervention|Control|Control women will receive usual post-fracture care without information
10032658|NCT01780025||Mixed hearing loss|
10032659|NCT01780038|Experimental|Receipt of Genetic Results|Receipt of Genetic Results indicates that participants have received the results of genotyping for RS1051730
10032660|NCT01780038|Active Comparator|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
10032661|NCT01780051|Experimental|Sequence A|
10032662|NCT01780051|Experimental|Sequence B|
10032663|NCT01780064|Placebo Comparator|Standard group|routine monitoring with questionnaires
10032664|NCT01780064|Active Comparator|Interviews with psychologist|Patients have interviews with a psychologist (at cure one of chemotherapy treatment,at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy) and questionnaires
10032665|NCT01780077|Experimental|RXI-109|
10032666|NCT01780077|Placebo Comparator|Placebo|
10032667|NCT01780090|Experimental|iPad software|Student participants will use specialized, iPad software under the direction of the SLP, 1 time a week over the course of 2 months.
9470829|NCT03625193||Ambulatory patients with SCI|"Age at least 18 years~Body mass index (BMI) between 18.5 - 29.9 kg/m2~Having an incomplete SCI from traumatic or non-traumatic causes~Ability of independent standing up from a chair with or without hand support~Ability of independent walking with or without walking device over at least 10 meters continuously.~Ability to follow commands used in the studies"
9470830|NCT03625180||Treatment|NAMIC technique
9470831|NCT03625167|Experimental|Treatment with petrolatum|In each healthy volunteer, one of the two forearms is randomly assigned to the intervention. This forearm is treated with petrolatum for 4 respectively 8 weeks.
9470832|NCT03625167|No Intervention|Control|The control forearm will remain untreated throughout the study.
9470833|NCT03625154|Active Comparator|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
9470834|NCT03625154|Active Comparator|non operative experimental group|Patients with positive gravity stress (medial clear space > 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to <4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
9470835|NCT03625154|Active Comparator|operative observational group|Patients with positive gravity stress (medial clear space > 4 mm) who undergo a reduction with closing of the medial clear space to <4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
10032668|NCT01780116|Experimental|Medicaiton adherence therapy|"Adherence therapy, consisting of six, 2-hour sessions over 3 months, in three phases:~Engaging patients: assessing needs and concerns in medication adherence;~Reviewing strengths and barriers and developing coping strategies; and~Rationalizing beliefs and concerns and preventing relapse."
10032669|NCT01780116|No Intervention|Routine community care|Routine Community psychiatric nursing services provided by the Community Psychiatric Nurses in the practice field
10032670|NCT01780129|Experimental|Polydatin Injectable (HW6)|10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
10032671|NCT01780129|Placebo Comparator|HW6 blank dummy (0.9%NaCl)|10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
10032672|NCT01780155||1|Parents and premature newborns with a birth weight less than or equal to1250 g from member institutions of the hospital network will be invited to participate in this study.
10032673|NCT01780181||TCM plus chemotherapy|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang, four packages,twice a day, three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
9470836|NCT03625128|Experimental|F-18 PMPBB3|F-18 PMPBB3 imaging
9480290|NCT03535012||Reconstruction using abdominal tissue|immediate free DIEP flap breast reconstruction after mastectomy. DIEP(deep inferior epigastric perforator) free flap was prepared and transferred to the breast pocket. Microanastomosis was done under the microscopic magnification. On sitting position, free flap was inset into breast pocket with confirming of satisfactory inflammatory fold.
9480291|NCT03534999|Experimental|TENS|This is intervention Group. Patients in this group received Transcutaneous Electrical Nerve Stimulation (TENS). The VAS and Oxford hip score was administered prior to the treatment to ascertain their pain intensity and hip disability level. The site of intervention (5cm away from incision site) was cleaned properly with cotton wool soaked in methylated spirit in an outward motion. Before the self-adhesive, pre gelled electrodes was placed on the cleansed sites.The TENS unit was switched on and the parameters was adjusted to the required level. For this study, parameters used are: 100µs pulse duration, 100Hz frequency and an intensity comfortable for the patient for a duration of 15 minutes.
9480292|NCT03534999|No Intervention|Control|This was the group with no intervention. Subjects were on their normal analgesic and antibiotic medication for the period of research. The VAS and Oxford hip score were administered on the first day to ascertain pain intensity and hip disability level. The subject continued on the normal analgesics only till the third day and VAS and Oxford hip score was re-administered to assess any change in the pain intensity and hip disability level.
9480293|NCT03534973|Active Comparator|Caffeine intake|Caffeine is given orally prior to cataract surgery
9480294|NCT03534973|Sham Comparator|No caffeine intake|Caffeine is not given orally prior to cataract surgery
9480295|NCT03534960|Other|High Flow Nasal Oxygen Therapy|Patients are randomized to the high flow nasal oxygen therapy group
9480296|NCT03534960|Other|Nasal CPAP|Patients are randomized to the nasal continuous positive airway pressure treatment group
10037130|NCT01822080|Experimental|Dienogest|50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
9480297|NCT03534947|Experimental|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
9803123|NCT04515810|Active Comparator|Arm II (standard care)|Participants engage in standard care with no modifications.
10032674|NCT01780181||Placebo plus chemotherapy|TCM Placebo: oral granules,YangYinFang orYiQiFang or YiQiYangYinFang, 10% of the original dose,four packages,twice a day ,three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
10032675|NCT01780194||Lumbar fusion group|
10032676|NCT01780194||Conservative treatment group|
10032677|NCT01780207|No Intervention|OSA without PFO|
10032678|NCT01780207|Other|OSA with PFO|PFO closure
10032679|NCT01780233|Experimental|Fentanyl 400 µg sublingual spray + naltrexone 50 mg|Patients received a single administration of 400 µg of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally.
10032680|NCT01780233|Active Comparator|Actiq® 400 µg transmucosally + naltrexone 50 mg|Patients received a single administration of 400 µg of Actiq® transmucosally + naltrexone hydrochloride 50 mg orally.
10032681|NCT01780233|Active Comparator|Fentanyl citrate injection 100 µg iv + naltrexone 50 mg|Patients received a single administration of 100 µg of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally.
10032682|NCT01780246|Experimental|nusinersen|
10032683|NCT01780259|Experimental|Cohort 1: Treatment A|Participants will receive 1 spray of esketamine solution in each nostril once (total dose: 28 mg).
10032684|NCT01780259|Experimental|Cohort 1: Treatment B|Participants will receive 1 spray of esketamine solution in each nostril twice, with 5 minutes interval (total dose: 56 mg).
10032685|NCT01780259|Experimental|Cohort 1: Treatment C|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 5 minutes interval between each repeated sprays (total dose 84 mg).
10032686|NCT01780259|Experimental|Cohort 1: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
10032687|NCT01780259|Experimental|Cohort 2: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
10032688|NCT01780259|Experimental|Cohort 3: Treatment E|Participants will receive 1 spray of esketamine solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution.
10032689|NCT01780259|Experimental|Cohort 3: Treatment F|Participants will receive 1 spray of placebo solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution.
10032690|NCT01780272|Other|Normoglycaemia followed by hypoglycaemia|
10032691|NCT01780272|Other|Hypoglycaemia followed by normoglycaemia|
10032692|NCT01780285|Active Comparator|Nitinol-framed PTFE mesh hiatal repair|Nitinol-framed lightweight PTFE mesh for hiatal repair
10032693|NCT01780285|Active Comparator|Lightweight mesh hiatal repair|Partially absorbable lightweight mesh for hiatal repair
9470837|NCT03625115|No Intervention|Usual Care (Control)|Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
9470838|NCT03625115|Experimental|Family Navigator (Intervention)|Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.
9470839|NCT03625089|Active Comparator|Group 1 - FRS arm|Both group will participate in the nurse-led programme on CV risk screening and carotid ultrasound for carotid plaque assessment. Subjects in group 1 will initiate Atorvastatin treatment (20mg daily per oral) if their Framingham Risk Score >10%
9470840|NCT03625089|Experimental|Group 2 USG arm|Subjects in group 2 will initiate Atorvastatin treatment (20mg daily per oral) if they had carotid plaque upon carotid ultrasound findings..
9470841|NCT03625076|Experimental|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
9470842|NCT03625076|Active Comparator|Procedural Sedation|Intravenous etomidate or propofol
9470843|NCT03625063|Active Comparator|Exercise training group|Inspiratory muscle, upper extremity aerobic exercise and progressive resistance trainings
9470844|NCT03625063|Sham Comparator|Control training group|Upper extremity aerobic exercise and progressive resistance trainings
9470845|NCT03625050|Experimental|Chuna + Usual care|
9470846|NCT03625050|Active Comparator|Usual care|
9470847|NCT03625037|Experimental|Epcoritamab (GEN3013, DuoBody®-CD3xCD20)|Open label, single arm trial where Epcoritamab will be administered.
9470848|NCT03625011|Placebo Comparator|Placebo Group|Participants will be randomized to either Control Group or Gabapentin Group
9470849|NCT03625011|Active Comparator|Gabapentin Group|Participants will be randomized to either Control Group or Gabapentin Group
9470850|NCT03624998|Experimental|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
9470851|NCT03624985|Experimental|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
9470852|NCT03624985|Placebo Comparator|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
9470853|NCT03624959|Experimental|Treatment Group A - Ozanimod 0.46mg|A single dose of ozanimod 0.46 mg on Day 1
9470854|NCT03624959|Experimental|Treatment Group B - Ozanimod plus Gemfibrozil|Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
9470855|NCT03624959|Experimental|Treatment Group C - Ozanimod 0.92mg|A single dose of ozanimod 0.92 mg on Day 1.
10032694|NCT01780298||Group 1: COPD GOLD Stage 1-2|Sixty subjects with a clinical diagnosis of COPD, according to the GOLD guidelines (Stages 1-2), who are current smokers with at least a 10 pack-year smoking history.
10032695|NCT01780298||Group 2: Current Cigarette Smokers|Sixty subjects who are current smokers with at least a 10 pack-year smoking history and matched to the COPD cases by ethnicity, gender and age (within 5 years).
10032696|NCT01780298||Group 3: Ex-Smokers|Sixty subjects who are ex-smokers with at least a 10 pack-year smoking history who have not smoked for at least one year and matched to the COPD cases by ethnicity, gender and age (within 5 years).
10032697|NCT01780298||Group 4: Never Smokers|Sixty subjects who have never smoked (non-smokers) and matched to the COPD cases by ethnicity, gender and age (within 5 years).
10032698|NCT01780311|Active Comparator|Antiarrhythmic drugs|Flecainide or Propafenone or Sotalol (oral, standard dosage)
10032699|NCT01780311|Experimental|ABLATION|Catheter Ablation
10032700|NCT01780363||controls|frequency of mevalonate kinase gene frequency
10032701|NCT01780363||Behçet patients|frequency of mevalonate kinase gene mutations
10032702|NCT01780376|Experimental|WBV group|whole-body vibration (WBV) group
10032703|NCT01780402|Experimental|Hand feeding intervention delivery|Trained Research Feeding Assistants (TRFA), blind to the study outcomes, will assist enrolled PWDs with all three meals for two days using a pre-specified hand feeding technique. Videotaping will occur for two enrolled PWD during the six day time frame to promote efficiency. Coding of the video will be done by a trained Data Technician after meals have been recorded to determine frequency of aversive feeding behaviors, calculate meal intake, and time spent assisting with the meal.
10032704|NCT01780415||Bastovit|all the patients that have supernumerary embryos to vitrify at blastocyst stage
10032705|NCT01780441||Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex
10032706|NCT01780467|Experimental|patients with and without treatment by L dopa)|to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
10032707|NCT01780467|Other|healthy paired control|to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
10032708|NCT01780480|Experimental|Dynamic Chinese herbal granule formula|Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
10032709|NCT01780480|Placebo Comparator|Placebo|The process is the same as the experimental arm, except that the matched placebo granules should be in turn of Chinese herbal granules.
10032710|NCT01780493|Other|Direct Nipple Ureteroneocystostomy|
10032711|NCT01780519|Other|L/VL APOE e3/e4 carrier|long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
10032712|NCT01780519|Other|L/S APOE e3/e4 carrier|long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
10032713|NCT01780519|Other|S/VL APOE e3/e3 carrier|short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
9470856|NCT03624959|Experimental|Treatment Group D - Ozanimod plus Itraconazole|Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
9470857|NCT03624959|Experimental|Treatment Group E - Ozanimod plus Rifampin|Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
9470858|NCT03624933|Experimental|28-Day Cannabis Abstinence|The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
9470859|NCT03624907|Other|Consecutive Daily Treatment|Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
9470860|NCT03624907|Other|Non-Consecutive Daily Treatment|Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days
9470861|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
9470862|NCT03624881|Experimental|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
9470863|NCT03624868|Experimental|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
9470864|NCT03624868|Active Comparator|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
9803124|NCT04514653|Active Comparator|Ranibizumab control|Control treatment arm
10032714|NCT01780519|Other|VL/VL APOE e3/e3 carrier|Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
9470865|NCT03624855||Description of BJI due to Pseudomonas aeruginosa|patients having bone and joint infection on implant due to Pseudomonas aeruginosa
10032715|NCT01780519|Other|S/S APOE e3/e3 carrier|short poly - T variants of TOMM40 and APOE e3/e3 carrier
9470866|NCT03624829||Exp: Patients of GPs with shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are randomized to shared care before the 12 months.
9470867|NCT03624829||Con: Patients of GPs without shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are not randomized to shared care before the 12 months, and all patients 16-65 years old who during 12 months have been in contact with a GP in any of the six GP center before the randomization and implementation of shared care.
10032716|NCT01780532|Experimental|Photo Acoustic Imaging|An exploratory, single armed, pilot study designed to evaluate the feasibility of Photo Acoustic Imaging (PAI) in a clinical setting.
9470868|NCT03624764|Experimental|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
9470869|NCT03624764|Active Comparator|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
9470870|NCT03624738|Active Comparator|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
9470871|NCT03624738|Active Comparator|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
9470872|NCT03624725|Active Comparator|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
9470873|NCT03624725|No Intervention|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
9470874|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
9470875|NCT03624699|Experimental|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
9470876|NCT03624686||healthy volunteer|
9470877|NCT03624686||luekemia patient|
9470878|NCT03624673|Experimental|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
9470879|NCT03624673|Active Comparator|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
9470880|NCT03624647|Experimental|Power toothbrush|
9470881|NCT03624647|Placebo Comparator|Manual toothbrush|
10032717|NCT01780558|Other|group NC-A|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the natural cycles.
10032718|NCT01780558|Other|group HRT-B|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospitalwill be recruited , who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
10032719|NCT01780571|No Intervention|Control group|Neutral pressure breathing after 2 min preoxygenation
10032720|NCT01780571|Active Comparator|Active group|CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation
10032721|NCT01780597||Organ Donors (declared Brainstem-Dead)|This group of subjects is defined as those who have previously expressed their future wish to organ donation and who have suffered events leading to declaration of brainstem-death. Furthermore these subjects will have had their hearts declined for heart transplantation on the basis of poor function.
9470882|NCT03624621|Experimental|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
9470883|NCT03624621|Placebo Comparator|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
9470884|NCT03624621|No Intervention|Treatment as usual|Usual intervention supervised by their psychiatrist
9803125|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
10032722|NCT01780610|Other|group OI-A|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited , who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the Letrozole and human chorionic gonadotrophin ovulation induced cycles.
10032723|NCT01780610|Other|group HRT-B|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
10032724|NCT01780623|Experimental|Bright White Light|Bright white light exposure every morning for 30 minutes for 28 consecutive days
10032725|NCT01780623|Active Comparator|Dim Red Light|Dim red light exposure every morning for 30 minutes for 28 consecutive days
10032726|NCT01780649|Experimental|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)
10032727|NCT01780649|Active Comparator|ICSI|Intracytoplasmic sperm injection (ICSI)
9470885|NCT03624608|Experimental|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
10032728|NCT01780688|Active Comparator|smoking conventional cigarettes (CC)|After a 1-day nicotine deprivation, subjects are smoking one single cigarette (usual own brand) on one day and then smoking ad libitum on the subsequent day
10032729|NCT01780688|Experimental|using the Tobacco Heating System 2.1 (THS 2.1)|After a 1-day nicotine deprivation, subjects are puffing one single tobacco stick using the THS 2.1 on one day and then puffing ad libitum on the subsequent day
9470886|NCT03624595|Experimental|Dexmedetomidine group|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
9470887|NCT03624595|Placebo Comparator|Placebo group|Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
10032730|NCT01780701||High risk prostate cancer patients|Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
10032731|NCT01780701||Low risk prostate cancer patients|Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
10032732|NCT01780714|Active Comparator|Conventional cigarettes (CC)|Smokers are continuing to smoke exclusively their usual own brand of CC, for 5 days, ad libitum, under highly controlled conditions
10032733|NCT01780714|Experimental|Tobacco Heating System 2.1 (THS 2.1)|Smokers are switching to the exclusive and ad-libitum use of THS 2.1 for 5 days, under highly controlled conditions
9470888|NCT03624569|Sham Comparator|Bagel diet|Bagel consumed daily for 2 weeks
9470889|NCT03624569|Experimental|Potato diet|Potato consumed daily for 2 weeks
9470890|NCT03624556|Experimental|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
9470891|NCT03624556|Placebo Comparator|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
9470892|NCT03624530|Experimental|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
10032734|NCT01780727|No Intervention|Standard Hemodynamic Management (SHEM)|use of standard hemodynamic management
9470893|NCT03624530|No Intervention|No TKI therapy|Prophylactic TKI will not be given.
10032735|NCT01780727|Experimental|EGHEM|use of echocardiography guided hemodynamic management to control fluid and drug therapy.
10032736|NCT01780740|Experimental|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
9470894|NCT03624478|Experimental|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
9470895|NCT03624465|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System use of surgical tool
9470896|NCT03624452|Experimental|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
9470897|NCT03624452|Experimental|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
9470898|NCT03624439|Experimental|Normal airway|normal airway. the language has not been inflated. the instructor assessed the difficulty of intubation based on the Cormack - Lehane scale to the first degree
9470899|NCT03624439|Experimental|Difficult airway|dofficult airway. Difficult airways were obtained by means of language inflation using a simulator control panel, so as to obtain the degree of intubation difficulty assessed by an independent anesthesiologist to the third degree according to the Cormack-Lehane scale
9470900|NCT03624426|Experimental|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. The possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction. The actual intervention will depend on the possible mechanism of nerve injury and treated accordingly.
9470901|NCT03624426|No Intervention|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
9470902|NCT03624413|Experimental|Social Media Intervention|Adolescent HIV-positive participants receiving the social media intervention.
9470903|NCT03624413|Active Comparator|Standard of Care|Adolescent HIV-positive participants receiving the standard of care.
9470904|NCT03624400|Experimental|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
9470905|NCT03624400|Active Comparator|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
10032737|NCT01780740|Placebo Comparator|Sugar pill|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included.
9470906|NCT03624387|No Intervention|Control Group( No Painting Sessions)|No Geriatric Inclusive Art session.
9470907|NCT03624387|Experimental|Intervention Group( Painting Session)|Painting sessions for participants
9470908|NCT03624361|Experimental|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
9470909|NCT03624348|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
9470910|NCT03624348|No Intervention|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
9470911|NCT03624335|Experimental|Group 1: ECC|"In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.~Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping"
9470912|NCT03624335|Experimental|Group 2: DCC|In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping
9470913|NCT03624322|Active Comparator|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
9470914|NCT03624322|Experimental|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
9470915|NCT03624309|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
9470916|NCT03624309|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
9470917|NCT03624296|Experimental|patient with multiple sclerosis (MS)|
9470918|NCT03624283|Experimental|Group A|Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;
9470919|NCT03624283|Experimental|Group B|Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;
9470920|NCT03624283|Experimental|Group C|Group C will receive an combination of Exercise-based VR plus Betahistine.
9470921|NCT03624270|Experimental|Frontline oral arsenic trioxide, ATRA and ascorbic acid (AAA)|"Induction:~Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days~Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis < 10 x 10^9/L; or age ≥ 65 years; or cardiac function impairment)~Hydroxyurea 2-4g per day if WBC > 5 x 10^9/L during the first 7 days of induction.~Consolidation (for all patients):~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles~Maintenance (for all patients):~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
9470922|NCT03624257|Experimental|Scaling and root planning + Laser treatment|
9470923|NCT03624257|Active Comparator|Mucosal flap surgery|
9470924|NCT03624244|Experimental|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
9470925|NCT03624244|Other|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
9470926|NCT03624231|Experimental|Arm 1|"Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy.~Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1)."
9470927|NCT03624231|Experimental|Arm 2|"Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14.~Overall patients will receive treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total)."
9470928|NCT03624218|No Intervention|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
9470929|NCT03624218|Experimental|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
9470930|NCT03624179||Rheumatoid arthritis patients|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
9470931|NCT03624179||healthy control|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
9470932|NCT03624166|Active Comparator|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
9470933|NCT03624166|Placebo Comparator|isotonic saline|isotonic saline 3 ml volume will be given
9470934|NCT03624153|Experimental|Robotic-assisted intervention|70 minutes Robotic-assisted intervention.
9470935|NCT03624153|Active Comparator|Conventional intervention|70 minutes conventional rehabilitation.
10032738|NCT01780753|Experimental|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
10032739|NCT01780766||Indolent myeloma patient|
10032740|NCT01780766||Symptomatic Myeloma patient|
9470936|NCT03624140|Experimental|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
9470937|NCT03624088|Experimental|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
9470938|NCT03624075|No Intervention|control group|The control group had a protocol of a health education / self-gestation session lasting 60 minutes. This session should include topics such as definition of knee OA, guidance on knee anatomy and physiology, prayer over articulation, rehabilitation and practice of exercises, and as volunteer to receive an educational and self explanatory primer with all the content that is exposed during a lesson .
9470939|NCT03624075|Placebo Comparator|Placebo group|The placebo group will simultaneously receive two techniques of applying tensionless KT. The first technique that will be applied is inverted 'Y' on the rectus femoris. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
9470940|NCT03624075|Experimental|intervention group|The intervention group will receive the same protocol as the placebo group, differing only in relation to the tension of the bandage. According to Kase et al (2003), the techniques recommend the relief of pain and edema and performance. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
9470941|NCT03624062|Other|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
9470942|NCT03624062|Other|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
9470943|NCT03624062|Other|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
9470944|NCT03624062|Other|TBD ug IBC in 0.5 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the maximum safe IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.5 mL MAS-1 emulsion
9470945|NCT03624049|Other|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
9470946|NCT03624023|Experimental|TWB-103|(Mixture of TWB-102 cell and TWB-103 hydrogel)
9470947|NCT03624010|Experimental|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
9470948|NCT03623997||Stable isotope labeled iron II sulfate|All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.
9470949|NCT03623984|Experimental|Gallium Dotatate|All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
9470950|NCT03623971|Experimental|Artificial Intelligence|A universal diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of cataract.
9470951|NCT03623958|Experimental|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
9470952|NCT03623958|Active Comparator|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
9470953|NCT03623932|Active Comparator|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
9470954|NCT03623932|Experimental|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
9470955|NCT03623919|Experimental|Exercise group|"Group games, including two teams of seniors aged 50 years or older. The FallSensing games software include 3 mini-games to be played by two teams with up to 3 players each will compete against each other alternately.~The players will perform an initial evaluation with FallSensing screening tool, 16 sessions of group games (2 times a week/8weeks) with FallSensing multiplayer games and a final evaluation also with FallSensing screening tool.~Both initial and final evaluation include six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for Exercise."
9470956|NCT03623906|Experimental|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
9470957|NCT03623906|Active Comparator|Air insufflation colonoscopy|Room air insufflation colonoscopy
9470958|NCT03623880|Experimental|Unified Protocol|This is a type of CBT for emotional distress.
9470959|NCT03623880|Active Comparator|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
9470960|NCT03623867|Experimental|Secukinumab|Subject will received secukinumab 150mg at week 0-4, and once monthly till week 48
9470961|NCT03623867|Placebo Comparator|Placebo|Subject will received placebo 150mg at week 0-4, and once monthly till week 48
9470963|NCT03623841|Experimental|Dual-task training group|Participants in dual-task training group will execute dual-task training via exer-game which combined with treadmill, 3 times per week, least 8 weeks.
9470964|NCT03623841|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training only, 3 times per week, least 8 weeks.
9470965|NCT03623815|Other|Sham tDCS followed by active tDCS|Within subjects design. This group received sham (placebo) transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received 2mA of active tDCS for 20 minutes in session two.
9470966|NCT03623815|Other|Active tDCS followed by sham tDCS|Within subjects design. This group received 2mA of active transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received sham (placebo) tDCS for 20 minutes in session two.
10032741|NCT01780779||Osteosarcoma|"All patients with Osteosarcoma), proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURAMOS protocol)~An MRI will be performed before, during and post-treatment"
10032742|NCT01780779||Ewing Sarcoma|"All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURO-EWING protocol)~An MRI will be performed in all included patients before, during and after the chemotherapy"
10032743|NCT01780792|Experimental|Dance Dance Revolution game play|Dance Dance Revolution video game play
9470967|NCT03623802|Experimental|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
9470968|NCT03623802|Experimental|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
9470969|NCT03623789|Active Comparator|Group I|Primary total hip replacement with application of Floseal hemostatic matrix on potential bleeding sites after prosthesis implantation, and intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
9470970|NCT03623789|Active Comparator|Group II|Primary total hip replacement with intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
9470971|NCT03623789|Placebo Comparator|Group III|Control group, neither TXA nor Floseal® will be used. Equivalent volume of normal saline injection pre- and post-operatively
9470972|NCT03623776|Experimental|JS001 alone|Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
9470973|NCT03623776|Experimental|JS001+chemotherapy|Subjects receive JS001 240 mg, pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
9470974|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
9470975|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
9470976|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
9470977|NCT03623750|Experimental|EGFR-TK Inhibitor plus EGF-PTI|Elegile patients will receive a single pre-treatment low dose of intravenous cyclophosphamide 200mg/m2 before experimental treatment starts. Daily oral therapy with afatinib according to the SmPC of the product in nominal treatment cycles of 21 days followed by immunisation with EGF-PTI.
9470978|NCT03623737|Experimental|paclitaxel plus cisplatin|A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
9470979|NCT03623737|Active Comparator|cisplatin plus 5-fluorouracil|A. P: Cisplatin 75 mg/m2, 2 h IVF, on day 1 of week 1 and week 5 during CRT. B. F: 5-FU 1,000 mg/m2, 24 h IVF, on day 1, 2, 3, 4 of week 1 and week 5 during CRT.
9470980|NCT03623724|Experimental|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
9470981|NCT03623724|Active Comparator|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
9803126|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
9803127|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 3)|RGX-314 Dose 3
10032744|NCT01780792|No Intervention|control|individuals continue usual care for 8 weeks
10032745|NCT01780805||Young adult alcohol drinkers|Young adults between the ages of 21-25 who regularly drink alcohol
10032746|NCT01780818|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
10037131|NCT01822080|Placebo Comparator|Placebo|50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
9470982|NCT03623711|Experimental|Escitalopram group|including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.
9470983|NCT03623711|Experimental|Duloxetine group|including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.
9470984|NCT03623711|Experimental|Bupropion group|including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.
10032747|NCT01780818|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
9470985|NCT03623711|Placebo Comparator|Healthy control|50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.
10032748|NCT01780818|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
9470986|NCT03623685|Experimental|voluson 8|
9470987|NCT03623659|Active Comparator|AH group|Subjects whose vitrified/warmed blastocysts will be subjected to the treatment of laser assisted hatching
9470988|NCT03623659|No Intervention|Control group|Subjects whose vitrified/warmed blastocysts will be subjected to the same procedures except for the treatment of laser assisted hatching
9470991|NCT03623633|Active Comparator|Denosumab and Raloxifene|denosumab and raloxifene
9470992|NCT03623633|Active Comparator|Denosumab and Alendronate|denosumab and alendronate
9470993|NCT03623620|Experimental|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
9470994|NCT03623620|No Intervention|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
9470995|NCT03623581|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
9470996|NCT03623568|Experimental|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
9470997|NCT03623555||E-IPV|"Women who have been exposed to intimate partner violence. Half of this group will also have a history of childhood maltreatment.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
9470998|NCT03623555||NE-IPV|"Women who have never been exposed to intimate partner violence. Half of this group will also present a diagnosis of Major Depressive Disorder.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
9470999|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
9480298|NCT03534947|Experimental|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
9480299|NCT03534947|Other|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
9480300|NCT03534921||People with severe mental illness (SMI)|In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged >=18 years with a record of severe mental illness so that at least one event occurs in the study period.
9480301|NCT03534921||People with SMI and type 2 diabetes|Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.
9480302|NCT03534921||People with diabetes (matched controls)|This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.
9480303|NCT03534908||NAFLD group|those with NAFLD
9480304|NCT03534908||Control group|those without NAFLD
9480305|NCT03534895|Placebo Comparator|PC1|5mL normal saline intravenous, single-administration, as pre-medication
9480306|NCT03534895|Experimental|PC2|midazolam 0.02mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
9480307|NCT03534895|Experimental|PC3|midazolam 0.06mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
10032749|NCT01780857||PPP patients|Patients with palmoplantar pustulosis who have had blood and tissue samples taken.
10032750|NCT01780857||Healthy controls|Patients without palmoplantar pustulosis or any inflammatory skin condition who have had blood and tissue samples taken.
9471000|NCT03623529|Experimental|Active Comparator: LJPC-501|LJPC-501 Angiotensin II Solution for infusion
9471001|NCT03623529|Placebo Comparator|Placebo Comparator: Placebo|0.9% sodium chloride solution
9471002|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
9471003|NCT03623503||first group|Observational study of 25 newborn with a likely EOS
9471004|NCT03623503||second group|Observational study of v33 newborn with a possible EOS
9471005|NCT03623490|Experimental|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
9471006|NCT03623490|No Intervention|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
9471007|NCT03623477|Active Comparator|Cognitive Remediation (CRT)|Participants assigned to CRT alone will complete 24 hours of neurocognitive training activities and 12 hours of control computer activities.
9471008|NCT03623477|Experimental|CRT+ Social Cognition Training|Participants assigned to the combination of CRT and SCT will complete 24 hours of computerized neurocognitive training in memory, attention, and processing speed, and 12 hours of computerized social cognition training focused on improving emotion recognition, social perspective taking, and mentalizing abilities.
9471009|NCT03623464|Active Comparator|Mobile app and Fitbit + Standard of care|Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
9471010|NCT03623464|Other|Standard of care|Participants will receive standard of care
9471011|NCT03623451|Experimental|Chinese Medicine Formula|All 100 patients were treated with Chinese Medicine Formula(CMF) for three menstrual cycles.
9471012|NCT03623438|Experimental|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
9471013|NCT03623438|Active Comparator|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
10032751|NCT01780883|Placebo Comparator|Placebo|5 tablets of placebo once a day, an hour before falling asleep, for 6 weeks.
10032752|NCT01780883|Experimental|2 mg melatonin|1 tablet of 2mg melatonin and 4 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
9471014|NCT03623425|Experimental|68Ga-PSMA-11 PET before 18F-FCH PET|Crossover design
9471015|NCT03623425|Experimental|18F-FCH PET before 68Ga-PSMA-11 PET|Crossover design
9471016|NCT03623412|Experimental|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
9471017|NCT03623412|Active Comparator|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
9471018|NCT03623399|No Intervention|15 mmhg-15mmhg|Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 15 mmhg.
9471019|NCT03623399|Other|15 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
9471020|NCT03623399|Other|12 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 12 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
9471021|NCT03623386|Experimental|Patients with PD neurofeedback training|Patients will receive neurofeedback training.
9471022|NCT03623386|Active Comparator|Patients with PD control|Patients will not receive neurofeedback training.
10032753|NCT01780883|Experimental|4 mg melatonin|2 tablets of 2mg melatonin and 3 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
10032754|NCT01780883|Experimental|10 mg melatonin|5 tablets of 2mg melatonin once a day, an hour before falling asleep, for 6 weeks.
10032755|NCT01780896||Study Group|
10037132|NCT01822093|Experimental|Cytovir-ADV|Adenovirus-specific T-cells
9471023|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
9471024|NCT03623308|Experimental|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
9471025|NCT03623308|Experimental|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
9471026|NCT03623295||Cohort study population|For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.
9471027|NCT03623295||Sub study population|A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.
9471028|NCT03623282|Experimental|Synatura® 15 mL|Synatura syrup single arm
9471029|NCT03623256|Active Comparator|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
9471030|NCT03623256|Active Comparator|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
9471031|NCT03623256|Active Comparator|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
9471032|NCT03623256|Experimental|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
9471033|NCT03623230|Sham Comparator|GCont|Only dressing will be applied to patients without actually nerve block performed
9471034|NCT03623230|Active Comparator|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
9471035|NCT03623230|Active Comparator|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
9471036|NCT03623217||Kidney transplant participants receiving tacrolimus|Transplant participants who have received tacrolimus twice daily for a minimum of 6 months to a maximum of 12 months after the surgery, and who are within 1 month of switching to the once daily regimen of modified release tacrolimus.
9471037|NCT03623204||Patients with bariatric surgery for obesity|
9471038|NCT03623191||Patients with erosive pustular dermatosis of the leg|
9471039|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.~or (2) difficulties to attend their health care appointments, during the last 3 months."
9471040|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
9471041|NCT03623165||Arm|Cordella™ Heart Failure System
10032756|NCT01780909|Experimental|Paromomycin Sulfate Fasted State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
10032757|NCT01780909|Experimental|Paromomycin Sulfate Fed State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state. Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed. 20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
10032758|NCT01780909|Experimental|Paromomycin Sulfate w/ Domperidone|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
10032759|NCT01780909|Experimental|Paromomycin Sulfate w/ Loperamide HCl|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
10032760|NCT01780948|Placebo Comparator|everolimus|Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL
10032761|NCT01780948|Experimental|everolimus with atorvastatin 20 mg|"Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.~Atorvastatin 20 mg/day (fixed dose)"
10032762|NCT01781000|Experimental|Auditiory verbal discrimination training|Brain Fitness & Brain Training- Posit Science
10032763|NCT01781000|Experimental|Facial affect discrimination training|Behavioral: Facial Affect Training- FAT
10032764|NCT01781000|Active Comparator|Treatment as usual|standard treatment/rehabilitation protocol of schizophrenia ward
10032765|NCT01781013|Experimental|Technology-supported care|This arm consists of Clinic Resource Management (CRM) clinics and serves as our intervention arm where the tested technology is implemented. Our overarching aim in these comparisons is to assess the potential effects of technology-facilitated depression symptom monitoring, relapse prevention, and medication adjustments and to examine depression care receipt and symptom improvement, patient/provider acceptance, and cost.
10032766|NCT01781013|No Intervention|Supported-Care|This arm consists of CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
10032767|NCT01781013|No Intervention|Usual Care|This arm consists of non-CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
10037133|NCT01822106|Active Comparator|Omeprazole|Omeprazole at a rate of 20mg once per day
10037134|NCT01822106|Experimental|Wu-Chu-Yu Tang|Wu-Chu-Yu Tang at a rate of 3.0 g three times per day
10037135|NCT01822145||ICD recipients|ICD recipients with documented cardiac arrest or ventricular arrhythmias
9471042|NCT03623100|Experimental|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
9471043|NCT03623100|Experimental|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
9471044|NCT03623087|Experimental|SIMPLE|cisplatin, gemcitabine, ifosfamide, etoposide (VP-16), L-asparaginase, dexamethasone
9471045|NCT03623074|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
10032768|NCT01781039||low HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
10037607|NCT01826617||Prostate Cancer- Indolent type|Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
9471046|NCT03623074|Experimental|Test Arm 2|Single vision, impact-resistant spectacle lenses
10037608|NCT01826617||Prostate cancer- aggressive type|Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
9471047|NCT03623074|Other|Test Arm 3|Single vision, impact-resistant spectacle lenses
9471048|NCT03623061||Low Fibrinogen Level|Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations). Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
9471049|NCT03623061||Normal Fibrinogen Level|Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
9471050|NCT03623061||High Fibrinogen Level|Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
9471051|NCT03623048|Experimental|Propolis extract|intervention
9471052|NCT03623048|Experimental|Pomegranate extract|intervention
9471053|NCT03623048|Active Comparator|Chlorhexidine|comparator
9471054|NCT03623048|Placebo Comparator|Saline|comparator
9471055|NCT03623022|Experimental|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
9471056|NCT03623022|Experimental|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
9471057|NCT03623009|Experimental|Intervention|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
9471058|NCT03623009|Sham Comparator|Control|The control arm will receive a neutral article prior to completing the assessment.
9471059|NCT03622983||Collection of sample and data|Collection of biological samples and clinical data
9471060|NCT03622970|Experimental|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
9471061|NCT03622970|Active Comparator|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
9803128|NCT04514393|Experimental|methotrexate, ibrutinib, and temozolomide (MIT regimen)|Methotrexate will be given on day 1 of each 28-day cycle；Ibrutinib will be given day 1-28 of each 28-day cycle; Temozolomide will be given day 1-5 of each 28-day cycle. Methotrexate and Temozolomide are given for up to 4 cycles; Ibrutinib is continued until disease progression, intolerable toxicity, or death.
9803129|NCT04513964||Control|Patient not suffering from COVID-19
9803130|NCT04513964||COVID-19|Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology
9803131|NCT04513678|Experimental|ImmunOncoTool Condition|The ImmunOncoTool condition includes access to the web-based platform, routine monitoring of irAEs every week for twelve weeks and then bi-weekly for an additional eight weeks, and messages to healthcare providers and patients if a reported irAE is deemed severe enough that it warrants provider attention.
9803132|NCT04513678|No Intervention|Control|Participants in the control condition are not assigned an intervention. They receive standard of care.
9803133|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Video-chat psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
9471062|NCT03622957||Type 2 diabetes subjects|Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic
9471063|NCT03622944|Active Comparator|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
9471064|NCT03622944|Active Comparator|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
10032769|NCT01781039||high HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
10032770|NCT01781039||Hearing Aid fitting: MAD|Microphone adaptive directionality (MAD) feature will be activated, the WDC set to linear, and the DNR minimized
9471065|NCT03622944|Active Comparator|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
9471066|NCT03622931|Experimental|the experimental arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
9471067|NCT03622931|Placebo Comparator|the placebo arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + placebo once per week for up to 4 cycles
9471068|NCT03622918|Sham Comparator|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
9471069|NCT03622918|Experimental|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
9471070|NCT03622866|Active Comparator|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
9471071|NCT03622866|Active Comparator|Traditional pulse width|Traditional pulse width stimulation using the Algovita System
9471072|NCT03622853|Experimental|intraarticular steroid injection|intraarticular steroid hydrodilatation (shincort 40mg )
9471073|NCT03622840|Other|Parkinson's disease patients with cognitive impairment|Online cognitive remediation program.
9471074|NCT03622827|Experimental|Chemoradiotherapy + Endostar|"Chemoradiotherapy with Endostar：~Chemoradiotherapy: pelvic radiotherapy with concurrent chemotherapy that consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day,civ, day 1-4) for 2 cycles every 3 weeks.~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the chemotherapy every 3 weeks, total of two cycles during chemoradiotherapy course."
9471075|NCT03622814|Experimental|Treatment - Partners at Meals (PAM)|People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
10032771|NCT01781039||Hearing Aid fitting: WDC|Wide dynamic compression (WDC) feature will be set to target levels, the MAD feature set to omnidirectional, and the DNR minimized.
10032772|NCT01781039||Hearing Aid fitting: DNR|Digital noise reduction (DNR) set to maximum, MAD set to omnidirectional, and WDC set to linear
10032773|NCT01781039||Hearing Aid fitting: Positive control|All hearing aid features enables
10032774|NCT01781039||Hearing Aid fitting: Negative control|All hearing aid features disabled
10032775|NCT01781052||Group 1|
10032776|NCT01781065|Experimental|transcranial direct current stimulation|Anodal stimulation on motor cortex
10032777|NCT01781065|Sham Comparator|Sham transcranial direct current stimulation|Turn off after 10 s of stimulation
10037609|NCT01826617||Acute Prostatitis|Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
10037610|NCT01826617||Chronic Prostatitis|Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
9471076|NCT03622814|Placebo Comparator|Enhanced Usual Condition (EUC)|In the non-treatment respite care centers, an Enhanced Usual Condition will be delivered to caregivers of People with Dementia (PWD). This program consists of enhanced training in caregiving using components from a module of the evidence-based Savvy Caregiver program (K. Hepburn) given in a group setting with opportunity for a question and answer period; the program is given for new enrollees and every 6 months. The PI (EJA), the nutritionist (KM) or the Program Manager (MCP) will lead these groups. Weight of the PWD is measured initially and monthly (x5); amount of food consumed will be measured using the Samsung tablets, also initially and monthly (x5).
9471077|NCT03622801||Intra-arterial administration|Patients with intra-arterial administration of Iopromide
9471078|NCT03622801||Intravenous administration|Patients with intravenous administration of Iopromide
9471079|NCT03622762|Experimental|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
9471080|NCT03622762|Placebo Comparator|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
9471081|NCT03622749|Active Comparator|Patients|Individuals with Bipolar 1 Disorder
9471082|NCT03622749|No Intervention|Controls|Healthy controls
9471083|NCT03622710|Experimental|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
9471084|NCT03622710|Active Comparator|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
9471085|NCT03622684|Experimental|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
9471086|NCT03622671|Active Comparator|Skeletonized LIMA|In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.
9471087|NCT03622671|Active Comparator|Pedicled LIMA|In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.
9471088|NCT03622645|Experimental|Range of motion in hand|Assessment of Wrist flexion/extension, radial/ulnar deviation, supination/pronation, 1.-5. DIP, PIP and MCP flexion/extension ROM measurements of the fingers with universal goniometer and Leap motion sensor
10032778|NCT01781091|Experimental|FULLY CLOSED-LOOP VENTILATION|IntelliVent-ASV automatic mode
10032779|NCT01781091|Active Comparator|Conventional modes ventilation|Conventional modes
10032780|NCT01781117|Experimental|HoLEP group|Holmium Laser Enucleation of the Prostate (HoLEP)
10032781|NCT01781130|Placebo Comparator|Percutaneous release alone|The patients who perform percutaneous release of trigger finger only
10032782|NCT01781130|Experimental|Percutaneous release + Steroid injection|Steroid local injection after percutaneous release of trigger finger
10032783|NCT01781143|Experimental|Perform echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
10032784|NCT01781195||Advagraf-based immunosuppression|50 patients after liver transplantation (25 with a MELD-score ≤20 and 25 patients with a MELD-score >20) under CNI-based immunosuppression with Advagraf
10032785|NCT01781221|Active Comparator|Alpha-Bio's GRAFT Natural Bovine Bone|two different bone substitutes commonly used in dental procedures.
10032786|NCT01781221|Active Comparator|Bio-Oss xenograft|two different bone substitutes commonly used in dental procedures.
10032787|NCT01781247|Experimental|Intervention group|Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
10032788|NCT01781247|Active Comparator|Control group|Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.
10032789|NCT01781260||Young. Fit. Minor neurosurgical operation. Prone position.|18-65 year old patients, without serious medical co-morbidities (assessed as ASA I/II status) who are having minor to moderate severity neurosurgical operations in the prone position.
10032790|NCT01781273|Placebo Comparator|Cranberry juice alone|500 mL of cranberry juice
10032791|NCT01781273|Experimental|BAC 0.5 g/L|Cranberry juice with ethanol to rise BAC to 0.5 g/L
10032792|NCT01781273|Experimental|BAC 0.65 g/L|Cranberry juice with ethanol to rise BAC to 0.65 g/L
10032793|NCT01781273|Experimental|BAC 0.8 g/L|Cranberry juice with ethanol to rise BAC to 0.8 g/L
10032794|NCT01781312|Experimental|ProTectis|
10032795|NCT01781312|Experimental|Gastrus|
10032796|NCT01781325|Active Comparator|IBEHR|IBEHR
10032797|NCT01781325|No Intervention|Standard therapy|written instructions
10032798|NCT01781338|Experimental|Induction Therapy|The kind of induction therapy is dependent on the respective sub-protocol.
10032799|NCT01781351|Experimental|taping the ankle|
10032800|NCT01781364|Experimental|Cognitive Training|Brain Fitness Training, Posit Science SF
10032801|NCT01781377|Experimental|PROPOFOL|PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION
10032802|NCT01781377|Experimental|METOCLOPRAMIDE|METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
10032803|NCT01781377|Experimental|PROPOFOL & METOCLOPRAMIDE|PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
10032804|NCT01781377|Placebo Comparator|PLACEBO|SALINE INFUSION
10032805|NCT01781416||1|
10032806|NCT01781442||Patient Arm- temsirolimus|
10032807|NCT01781494|Active Comparator|Immobilization|Immobilization followed by protected range of motion
10032808|NCT01781494|Experimental|Immediate range of motion|Immediate motion after anterior submuscular ulnar nerve transposition
10032809|NCT01781507|Experimental|Cetirizine|Cetirizine 10 mg orally once a day
10032810|NCT01781507|Placebo Comparator|Sugar pill|This will be the placebo arm
9471089|NCT03622606|Experimental|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
10032811|NCT01781520|Experimental|S-1 plus DC-CIK|"Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles."
9471090|NCT03622567|Other|Push Notifications|Push notification number (0, 1, 3, 5) will be counter balanced within-subjects.
9471091|NCT03622554|No Intervention|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
9471092|NCT03622554|Experimental|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
9471093|NCT03622541|Experimental|sorafenib|
9471094|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
9471095|NCT03622502|Experimental|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
10032812|NCT01781520|Active Comparator|DC-CIK alone|DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.
10032813|NCT01781520|Active Comparator|S-1 alone|Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
9471096|NCT03622502|Active Comparator|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
10032814|NCT01781520|Active Comparator|Best supportive care|
10032815|NCT01781533|Experimental|algorithm|
10032816|NCT01781546|Experimental|drug-eluting balloon (DEB)|Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (>30% in main branch and >50% side-branch), Includes both stable CAD and ACS patients.
10032817|NCT01781546|Active Comparator|bare-metal stent (BMS)|Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.
10032818|NCT01781559|Experimental|phenolic acid + maltodextrin|phenolic acid + maltodextrin;
10032819|NCT01781559|Placebo Comparator|Maltodextrin|Maltodextrin
10032820|NCT01781559|Active Comparator|flavanol + maltodextrin|flavanol + maltodextrin
10032821|NCT01781585||sustained low-efficiency dialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
10032822|NCT01781585||continuous veno-venous hemofiltration|Patients were randomized to receive CVVH or SLED and the next day on the other.
10032823|NCT01781598||Patients treated with Patient specific instruments in TKA|
10032824|NCT01781624|Experimental|Study Oral Nutritional Supplement|2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend.
10032825|NCT01781650|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
10032826|NCT01781650|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
10037611|NCT01826617||Benign Prostatic Nodular Hyperplasia|Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
10037612|NCT01826630|Active Comparator|CLn BodyWash|CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
9471097|NCT03622489|Experimental|Tab ibuprofen + IV acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and IV Acetaminophen 1 gr 14:00 hr, IV Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, IV Acetaminophen 1 gr~-Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
9471098|NCT03622489|Experimental|Tab Ibuprofen + Tab acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and PO Acetaminophen 1 gr 14:00 hr, PO Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, PO Acetaminophen 1 gr~- Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
10037613|NCT01826630|Active Comparator|Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis
9471099|NCT03622489|Experimental|"On demand analgesia"|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Mternity ward:~Will not receive scheduled pain medication, but offered some only upon patients' request according to VNS score:~Tab. Acetaminophen 1 gr, for VNS 1-3, up to 4 times a day, at east 6 hours between doses.~PO drops Dipyrone 1 gr, for VNS 4-7, or if pain persists for 1 hour after receiving Acetaminophen, up to 4 times a day, at least 6 hours between doses.~Tab Ibuprofen 400 mg, for VNS 8-10, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 8 hours between doses."
9471100|NCT03622476|Experimental|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
9471101|NCT03622463|Experimental|Antroquinonol 100 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
9471102|NCT03622463|Experimental|Antroquinonol 50 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
9471103|NCT03622463|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, once a day
9471104|NCT03622450|Experimental|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
9471105|NCT03622450|Active Comparator|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
9471106|NCT03622437|Experimental|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
9471107|NCT03622437|Active Comparator|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
9471108|NCT03622411|Experimental|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
9471109|NCT03622411|Active Comparator|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
10037614|NCT01826656|Other|post-menopausal osteoporotic women|Subjects of test group will follow a tooth extraction and they will perform a CBCT scan within 10 days from the extraction and after 3 months (+/-15 days)
9471110|NCT03622411|Active Comparator|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
9471111|NCT03622398|Experimental|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
9471112|NCT03622398|Active Comparator|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
9471113|NCT03622372|Experimental|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
9471114|NCT03622372|Active Comparator|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
9471115|NCT03622333|Experimental|Familial Carcinoid Tumors|All patients with proven Familial Carcinoid Tumors
9471116|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
9471117|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
9471118|NCT03622307|Experimental|S-ICD therapy combined with VT Ablation|To evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients
9471119|NCT03622294|Experimental|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
9471120|NCT03622281|Experimental|Colonoscopists who received quality intervention|
9471121|NCT03622281|No Intervention|Colonoscopists who did not received quality intervention|
9471122|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
9471123|NCT03622255|Other|MINST|Minimally invasive non-surgical technique (MINST): Root instrumentation under local anesthesia using specific hand instruments (micro- curettes) and delicate piezon ultrasonic instruments in the area of intraosseous defect.
9471124|NCT03622255|Active Comparator|MINST with EMD|Minimally invasive non-surgical technique (MINST) with application of Enamel Matrix Derivative (EMD): Root instrumentation under local anesthesia using micro- curettes and delicate piezon ultrasonic instruments in the area of intraosseous defect. Experimental intervention by application of EDTA gel for 2 minutes on the root surface of the involved tooth, followed by rinsing with saline, drying and application of Enamel Matrix Derivative gel, to fill the defect.
9471125|NCT03622242|Experimental|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
9803134|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Video-chat psychotherapy (VCP)|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
10037615|NCT01826656|Active Comparator|non-osteoporotic post-menopausal women|Subjects of the control group will follow a tooth extraction and will perform a CBCT scan within 2 days from the extraction and after 3 months (+/- 2 days)
9471126|NCT03622242|Active Comparator|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
9471127|NCT03622229|Active Comparator|EUS-FNB with side-fenestrated needle|"Before randomization, the endosonographer chooses the needle gauge to perform biopsy preferring the 25 gauge caliber for difficult lesions. The needle advances inside the lesion and the operator will perform some needle movements back and forth into the lesion while slowly withdrawn the stylet (slow-pull technique). If possible the direction of the needle inside the lesion will be changed during the movements (fanning technique) to sample different areas of the lesion. Three needle passes will be performed and the material acquired at each pass will be placed directly in formalin in a single vial.~Diagnostic Test: Histologic evaluation"
9471128|NCT03622229|Active Comparator|EUS-FNB with fork-tip needle|"Intervention: like above.~Diagnostic Test: Histologic evaluation."
9471129|NCT03622216|Experimental|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
9471130|NCT03622216|Placebo Comparator|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
9471131|NCT03622203||Real life patients|Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)
9471132|NCT03622203||Difficult coronary lesions|Patients with bifurcation and multivessel disease, that is those with an increased risk of ST
9471133|NCT03622203||STEMI|Patients with STEMI
9471134|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
9471135|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
9471136|NCT03622177||HIV+|
9471137|NCT03622177||HIV- STI+|
9471138|NCT03622177||HIV- STI-|
9471139|NCT03622164|Active Comparator|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
9471140|NCT03622164|Experimental|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
9471141|NCT03622151|Experimental|Intervention group|Primer la Llar Program (housing first model): to live in permanent and individual housing and receiving weekly visits from a multidisciplinary team.
9471142|NCT03622151|No Intervention|Control group|"Treatment as usual:~attention from the resources of the homeless network in Barcelona."
9471143|NCT03622138|Experimental|Naive EBP Providers|Naive Providers (providers with no prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
9471144|NCT03622138|Experimental|Experienced EBP Providers|Experienced EBP Providers (providers with prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
9471145|NCT03622125||1|Patients who apply anti-scorpion venom serum Birmex at the discretion of the attending physician were given vital signs.
9471146|NCT03622125||2|Patients who apply anti-scorpion venom serum Alacramyn at the discretion of the attending physician were given vital signs.
9471147|NCT03622099||The study group|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
9471148|NCT03622086|Experimental|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
9471149|NCT03622086|Experimental|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
9471150|NCT03622060|Active Comparator|Nitroglycerin|500 microgram intraarterial Nitroglycerin
9471151|NCT03622060|Placebo Comparator|Nicardipine|200 microgram intraraterial Nicardipine
9471152|NCT03622047|Experimental|dexmedetomidine ropivacaine|Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
9471153|NCT03622047|Experimental|sufentanil ropivacaine|compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.
9471154|NCT03622047|Experimental|No analgesia labor|Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
10032827|NCT01781650|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
10032828|NCT01781663|Experimental|KAM2904 Face Cream and KAM3008 Body Lotion|A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
10032829|NCT01781663|Sham Comparator|petrolatum-based moisturizer|control group
10032830|NCT01781689|Experimental|Functional Electric Stimulation|perform arm cranking with functional electrical stimulation
10032831|NCT01781689|Sham Comparator|traditional rehabilitation program|Receive traditional rehabilitation programs
9471155|NCT03622021|Experimental|AK111 30mg|Single dose of 30mg AK111 or placebo is administered subcutaneously to healthy subjects
9471156|NCT03622021|Experimental|AK111 75mg|Single dose of 75mg AK111 or placebo is administered subcutaneously to healthy subjects
9471157|NCT03622021|Experimental|AK111 150mg|Single dose of 150mg AK111 or placebo is administered subcutaneously to healthy subjects
9471158|NCT03622021|Experimental|AK111 300mg|Single dose of 300mg AK111 or placebo is administered subcutaneously to healthy subjects
10032832|NCT01781689|No Intervention|Health|with no motor function impairment
10032833|NCT01781702|Experimental|Pelubiprofen 30 mg|Pelubiprofen 30 mg, tid
10032834|NCT01781702|Active Comparator|Celebrex 200 mg|Celebrex 200 mg, tid
10032835|NCT01781715|Experimental|Multivessel stenting|This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
9471159|NCT03622021|Experimental|AK111 450mg|Single dose of 450mg AK111 or placebo is administered subcutaneously to healthy subjects
9471160|NCT03622021|Experimental|AK111 600mg|Single dose of 600mg AK111 or placebo is administered subcutaneously to healthy subjects
10032836|NCT01781715|Active Comparator|Staged revascularization|This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
10032837|NCT01781741|Experimental|Treatment (TEMLA and SBRT)|Patients undergo TEMLA to remove the mediastinal lymph nodes followed by a single fraction of SBRT to the primary tumor (unless VATS procedure done) and mediastinal lymph node beds (if positive on TEMLA), with or without minimally invasive surgery.
10032838|NCT01781754||Diabetic patients|Un balanced diabetic patients
9471161|NCT03622008|Experimental|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
10032839|NCT01781780|Active Comparator|General Nutrition Recommendations|Participants will be provided with a free USDA nutrition pamphlet describing general good nutrition habits. They will also receive an instruction handout to emphasize some of the points in the dietary guidelines in the handout. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the suggestions as best they can into their daily life.
9471162|NCT03622008|Placebo Comparator|Placebo|placebo IV
9471163|NCT03621995||Obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
9471164|NCT03621995||Non obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
9471165|NCT03621995||Negative group|Malondialdehyde and Catalase level measurement without cryopreservation
9471166|NCT03621969|Experimental|Group 1|"Group 1 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment."
9471167|NCT03621969|Experimental|Group 2|"Group 2 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy daily at home (they will take the RePlay devices and tablets home) (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."
9471168|NCT03621943|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
9471169|NCT03621943|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
9480308|NCT03534882|Experimental|Washout|Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
9480309|NCT03534882|No Intervention|Control|Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.
9480310|NCT03534869|Experimental|Ear Acupuncture and Oral Analgesics|"The acupuncture treatment consisted of three acupuncture needles on the dominant ear according to French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point that is used to increase the anaesthetic effect according to both French and Chinese traditions.~Additional oral analgesics (NSAID) could be supplied at any time upon patients request during hospitalization. Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy."
9471170|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
10032840|NCT01781780|Experimental|Breakfast Recommendation|Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
9471171|NCT03621891||healthy individuals|Orally and systemically healthy individuals who has no hypo-functional teeth, hyper-occlusion or occlusal trauma
9471172|NCT03621891||periodontitis patients|Systemically healthy individuals who has chronic periodontitis but no hypo-functional teeth, hyper-occlusion or occlusal trauma
9471173|NCT03621891||healthy-occlusal trauma|Orally and systemically healthy individuals who has occlusal trauma caused by bruxism
9471174|NCT03621891||periodontitis-occlusal trauma|Systemically healthy individuals who has both chronic periodontitis and occlusal trauma caused by bruxism
9471175|NCT03621865|Experimental|subject sequence 1|subject allocation sequence 1. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471176|NCT03621865|Experimental|subject sequence 2|subject allocation sequence 2. IIntervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471177|NCT03621865|Experimental|subject sequence 3|subject allocation sequence 3. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471178|NCT03621865|Experimental|subject sequence 4|subject allocation sequence 4. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471179|NCT03621865|Experimental|subject sequence 5|subject allocation sequence 5. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471180|NCT03621865|Experimental|subject sequence 6|subject allocation sequence 6. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471181|NCT03621865|Experimental|subject sequence 7|subject allocation sequence 7. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471182|NCT03621865|Experimental|subject sequence 8|subject allocation sequence 8. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471183|NCT03621865|Experimental|subject sequence 9|subject allocation sequence 9. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471184|NCT03621865|Experimental|subject sequence 10|subject allocation sequence 10. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
9471185|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
9471186|NCT03621826||Children with Sickle Cell Anemia|Data from patients with sickle cell anemia will be entered into a retrospective database for evaluation of implementation rates of TCD (stroke) screening). A small number of these children/parents/stakeholders will be selected by convenience sampling to participate in a survey and/or interview to assess barriers and enablers to stroke prevention therapy.
9471187|NCT03621800|Experimental|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
9471188|NCT03621800|No Intervention|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
9471189|NCT03621722|Experimental|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
9471190|NCT03621722|Experimental|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
9471191|NCT03621722|No Intervention|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
9471192|NCT03621722|No Intervention|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
9471193|NCT03621709||CoreValve™ Evolut R™ 34mm|All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.
9471194|NCT03621683|Experimental|ovarian bio-stimulation|"Intervention:~ovarian bio-stimulation: blood rich plasma platelets"
9471195|NCT03621683|Active Comparator|Antioxidant therapy|"Intervention:~antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3"
9471196|NCT03621631|Experimental|optimized Tai Chi intervention|
9471197|NCT03621631|Active Comparator|traditional Tai Chi intervention|
9471198|NCT03621618|Other|dobutamine|Cardiac failure
9471199|NCT03621618|Other|norepinephrine|Sepsis
9471200|NCT03621605|Experimental|VIB9600|"Single dose of VIB9600 administered by IV infusion or SC injection.~Multiple dose VIB9600 administered by IV infusion every 2 weeks for 4 weeks."
9471201|NCT03621605|Placebo Comparator|Placebo|Placebo comparator administered by slow IV infusion or SC injection.
10032841|NCT01781780|Experimental|No Breakfast Recommendation|Participants randomized to the no breakfast group will receive a detailed handout with instructions to not consume any calories before 11:00 a.m. every day. Only water or 0 calorie beverages may be consumed from the time of waking until 11:00 a.m. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
10032842|NCT01781793|Placebo Comparator|Fibrotic ILD Patients, Room Air|Fibrotic ILD patients will breathe room air (21% oxygen) during a constant work rate exercise test
10032843|NCT01781793|Active Comparator|Fibrotic ILD Patients, Hyperoxia|Fibrotic ILD patients will breathe hyperoxia (60% oxygen) during a constant work rate exercise test
10032844|NCT01781819|Experimental|ARFI SVI ultrasound imaging|Acoustic Radiation Force Impulse (ARFI) Shear Wave Velocity Imaging (SVI) ultrasound imaging
10032845|NCT01781845|Experimental|ARFI-SVI Ultrasound|Ultrasound scan using acoustic radiation force impulse-shear wave velocity imaging in the characterization of pediatric hydronephrosis. This is a non-invasive scan that uses sound waves to create the images.
10032846|NCT01781858||pulmonary embolism|Consecutive outpatients and inpatients with first episode of acute pulmonary embolism
10032847|NCT01781871|Experimental|Prevenar13|68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured
9471202|NCT03621579|Other|the RNFLT and CMT|the retinal nerve fiber layer (RNFLT) and macular thickness (CMT)
9471203|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events > 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
9471204|NCT03621553|Experimental|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
9471205|NCT03621553|Placebo Comparator|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
9471206|NCT03621553|Other|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
9471207|NCT03621527|Active Comparator|Standard group|"For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
9471208|NCT03621527|Experimental|Epidural group|"Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air.~According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
9471209|NCT03621514|Other|painless indwelling catheter|This group of patients underwent catheterization after anesthesia. At the end of the operation, the patient was removed from the catheter before anesthesia was awakened.
9471210|NCT03621514|Other|indwelling catheter|This group of patients underwent catheterization after anesthesia,and the catheter was indwelled. The patient was routinely removed for 24 to 72 hours after surgery.
9471211|NCT03621501|Placebo Comparator|Staged complete revascularization|• Culprit only + staged (within six weeks after index procedure) complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Control arm)
9471212|NCT03621501|Active Comparator|Immediate complete revascularization|• Immediate complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Experimental arm)
9471213|NCT03621462|Experimental|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
9471214|NCT03621436|Experimental|TRVD Therapy|
9471215|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
9471216|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
9471217|NCT03621371|Experimental|Metacognitive therapy|
9471218|NCT03621371|Experimental|Intolerance of uncertainty therapy|
9471219|NCT03621345|Active Comparator|ESP block group|"The bilateral erector spine plane (ESP) block will be performed with ultrasound guided, preoperatively. Following antiseptic preparation of block site with povidone iodine, ultrasound probe will be placed 3 cm lateral to spine at T5 level. After identifying the erector spinae muscle and transverse process, the overlying skin will be infiltrated with local anesthetics and 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL 1% lidocaine) will be injected deep to the erector spinae muscle. The same procedure will be performed on the other side. Also, patients will receive intravenous patient controlled analgesia with morphine, and 1 g acetaminophen for supplemental analgesia if pain score raises over 5/10 on NRS and 50 mg meperidine for rescue analgesic for persistent pain.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
9471220|NCT03621345|Sham Comparator|sham block|"A sham block will be performed while looking for intended location for ESP block placement. Skin will be infiltrated with local anesthetics but ESP block will not be performed, instead of ESP block 2 mL subcutaneous saline injection will be applied.~Intervention: Sham block Other: Standard Pain Followup and Monitorization"
9471221|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
9471222|NCT03621319|Active Comparator|Hybrid argon plasma ablation (HAPC)|Eligible participants will be randomized to receive ablation of dysplasia with Hybrid argon plasma coagulation (HAPC) after EMR of visible lesions (if present) has been performed as per standard of care.
9471223|NCT03621319|Active Comparator|Radiofrequency ablation (RFA)|Eligible participants will be randomized to receive treatment of dysplasia with RFA after EMR of visible lesions (if present) has been performed as per standard of care.
9471224|NCT03621306||Men and women aged 18+|Men and women over the age of 18
9471225|NCT03621293|Active Comparator|Liberal Oxygenation (LO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
9471226|NCT03621293|Experimental|Conservative Oxygenation (CO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
9471227|NCT03621280|Experimental|Levoketoconazole|Levoketoconazole taken twice daily up to 1200 mg daily
10032848|NCT01781871|Active Comparator|Pneumovax|68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group
9471228|NCT03621267|Experimental|Interactive Stepping Exercise|"Interactive Stepping Exercise (1 hour, 3 times/week, 12 weeks)~The 1-hour training program will start with10 minutes warm-up session, after that 40 minutes of ISE, and ended with 10 minutes of cool down session.~Interactive Stepping Exercise (ISE) will perform on a thin mat that was partitioned into 24 squares. The ISE program included forward, backward, lateral and oblique steps, and step patterns were progressively made more complicated."
9471229|NCT03621267|Active Comparator|Home exercise program|60 minutes, 3 times/week, 12 weeks of home exercise
9471230|NCT03621228|Experimental|MindfulGarden|Standard care + exposure to an interactive digital device
9471231|NCT03621228|No Intervention|Control|Standard care only
9471232|NCT03621215|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK) diluted with 220 mL of water once per day (250 mL total volume per day). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries per day.
9471233|NCT03621215|Placebo Comparator|Fruit-flavoured placebo drink|"Matched for sensory characteristics and energy (with the addition of glucose).~once per day (250 mL total volume per day)"
9803135|NCT04513080|Experimental|Phase 1, Level 2: MBP with weekly VCP|Phase 1 participants who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm), monthly VCP with unlimited MBP (switch/minimal augmentation arm).
9803136|NCT04513080|Experimental|Phase 1 Level 2: MBP with monthly VCP|Phase 1 participants randomized to VCP who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm) or monthly VCP with unlimited MBP (switch/minimal augmentation arm).
9471234|NCT03621176|Experimental|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
9471235|NCT03621163|Experimental|bleaching agent|intervention : bleaching agent ( Boost 40%)
9471236|NCT03621163|Active Comparator|laminate veneers|laminate veneers ( monolithic lithium - silicate)
9471237|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
9471238|NCT03621111|Experimental|Adherence plan|At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
9471239|NCT03621111|No Intervention|Control group|All the patients discharged from the cardiological ward between September 2017 and February 2018 with a primary diagnosis of acute myocardial infarction has been enrolled in the control arm. These patients have been discharged with the current standard therapy and without any adherence plan performed by the community pharmacists. The investigators will collect the data from the administrative pharmaceutical databases throughout 12 months from the hospital discharge.
9471240|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
9803137|NCT04513080|Experimental|Phase 2 Level 1: Message-Based Psychotherapy (MBP)|Phase 2 participants who respond to MBP after 6 weeks of care will continue in this condition for another 6 weeks. Participants who do not respond by week 6 will be randomized to one of two augmentation arms, MBP plus monthly video chat (Premium Plan: PP) or MBP plus weekly video chat (Ultimate Plan: UP) for another 6 weeks of care.
10032849|NCT01781871|Experimental|liver Prevenar13|30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.
9803138|NCT04513080|Experimental|Phase 2, Level 1: Video-Chat Psychotherapy (VCP)|Phase 2: Weekly psychotherapy appointments that last between 30-45 minutes. Participants who do not respond to this model will be randomized to switch (PP) or augment (UP) VCP.
9803139|NCT04513080|Experimental|Phase 2, Level 2: MBP with monthly VCP|"Phase 2: This intervention will serve as the switch arm for participants who do not respond to VCP by week 6, and one of two augmentation arms for participants who do not respond to MBP. The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist."
10032850|NCT01781871|Active Comparator|liver Pneumovax|30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.
9471241|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
9471242|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
9471243|NCT03621072|Other|Reference|Fluconazole 150mg Capsule Originator
9471244|NCT03621072|Experimental|Experimental|Fluconazole 150mg Capsule Localized Originator
9471245|NCT03621059|Experimental|Behavioral Therapy with TS|habit reversal training (HRT)
9471246|NCT03621059|No Intervention|observational|observational and usual care Pyridoxine(50mg)
9471247|NCT03621046|Experimental|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
9471248|NCT03621046|Placebo Comparator|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
9471249|NCT03621033|Other|non-transparent cap-assisted endoscopic intubation|we do not use transparent cap-assisted endoscopic intubation.
9471250|NCT03621033|Other|transparent cap-assisted endoscopic intubation|we use transparent cap-assisted endoscopic intubation in the second insertion.
9471251|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
9471252|NCT03621020||Aspirin monotherapy|Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
9471253|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
9471254|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
9471255|NCT03621020||Dual antiplatelet therapy (DAPT)|Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
9471256|NCT03621007||POMC deficiency obesity|
9471257|NCT03621007||LEPR deficiency obesity|
9471258|NCT03621007||PCSK1 deficiency obesity|
9471259|NCT03620994||Irritable Bowel Syndrome|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University, Xijing Hospital ,Tangdu Hospital or affiliated hospital of Northwest University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
9471260|NCT03620955||Risk stratification|Risk stratification based on cytogenetic and molecular and MRD level after three courses of chemo therapy.
9471261|NCT03620929|Experimental|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
9471262|NCT03620929|No Intervention|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
9471263|NCT03620916|Experimental|Intrathecal morphine|Intrathecal morphine (0,4 mg) immediately before operation
9471264|NCT03620916|Active Comparator|Intravenous morphine|Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
9471265|NCT03620877|Experimental|personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
9471266|NCT03620864|Active Comparator|Motor control exercise|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
10032851|NCT01781884|Active Comparator|Gamma Aminobutyric Acid (GABA)|GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
10032852|NCT01781884|Active Comparator|Gamma Aminobutyric Acid GABA)|GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
10032853|NCT01781884|Placebo Comparator|placebo|placebo will be given thrice daily for 52 weeks
10032854|NCT01781897|Active Comparator|mosapride|mosapride
9471267|NCT03620864|Experimental|Motor control exercise plus neurodynamic intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
9471268|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (< 70 yo)
9471269|NCT03620838||Group 1|Patients with endometrioma who had at least one endometrioma >3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed
9471270|NCT03620838||Group 2|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with OCP during the study period
9471271|NCT03620838||Group 3|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with oral progesterone during the study period
9471272|NCT03620838||Group 4|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with surgery short after recruitment
9471273|NCT03620838||Group 5|The control group, who do not have endometrioma and any gynecological disorder
9471274|NCT03620825|Experimental|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
9471275|NCT03620825|Active Comparator|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
9471276|NCT03620825|No Intervention|Negative control|No intervention is performed
9471277|NCT03620812|Experimental|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
9471278|NCT03620812|Active Comparator|soy protein|
9471279|NCT03620812|Placebo Comparator|no protein|
9471280|NCT03620799|Experimental|Intervention group|10 participants will be assigned to the intervention group in order to the inclusion criteria for the study. Experimental group. Manual therapy intervention
9471281|NCT03620799|No Intervention|Control group|10 participants will be assigned to the control group in order to the inclusion criteria for the study. Control group
9471282|NCT03620786||HIFU Study Participants|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
9471283|NCT03620760|Experimental|Lower dose ticagrelor|Subjects will be treated with ticagrelor 45 mg twice daily in combination with aspirin 100mg once daily.
9471284|NCT03620760|Active Comparator|Standard dose ticagrelor|Subjects will be treated with ticagrelor 90 mg twice daily in combination with aspirin 100mg once daily.
9471285|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
9471286|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
9471287|NCT03620721|Experimental|M-Body|mindfulness group intervention
9471288|NCT03620721|No Intervention|Usual Care|treatment as usual
9471289|NCT03620682|Experimental|Mobile mental health intervention|Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
9471290|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
10032855|NCT01781897|Experimental|Electro-acupuncture|Electro-acupuncture
10032856|NCT01781897|Sham Comparator|mosapride + sham acupuncture|mosapride + sham acupuncture
10032857|NCT01781910|Experimental|Branch Chain Amino Acid supplement|A drink supplement containing 1.22 grams of branched chain amino acids, plus glucose.
10032858|NCT01781910|Placebo Comparator|Placebo supplement|The placebo was formulated to match both the taste and color of the test supplement. Crystal Light Lemonade powder (Kraft Foods, Northfield, IL, USA) was mixed with 5.6g of powdered dextrose (Now Foods, Bloomingdale, IL, USA) to match the amount of dextrose present in the BCAA supplement.
10032859|NCT01781923|Experimental|Cognitive Remediation|"12 week computer-based cognitive remediation program aimed to improve working memory, processing speed, and verbal learning/memory.~40 week small group social skills training sessions aimed to improve social skills and cognition."
10032860|NCT01781923|No Intervention|Control|No intervention
9471291|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
9471292|NCT03620630|No Intervention|Usual Care|Patients allocated to usual care will continue with their current NHS management in line with national and local guidelines.
9471293|NCT03620630|Active Comparator|myCOPD|Patients allocated to the myCOPD arm will receive access to a web based application called myCOPD
9471294|NCT03620617|Experimental|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
9471295|NCT03620617|No Intervention|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
9471296|NCT03620604||Stress urinary incontinence surgery|This is a single observational study were all patients had stress urinary incontinence. All of them underwent surgery performing a single incision sling type ALTIS
9471297|NCT03620591|Active Comparator|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
9471298|NCT03620591|Placebo Comparator|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
9471299|NCT03620565||Laparoscopic sacrocolpopexy(LSC)|Patients who prefer to accept laparoscopic sacrocolpopexy after hysterectomy. For patients who has desire of uterine-preservation,laparoscopic sacrocervicopexy or sacrohysteropexy is carried.
9471300|NCT03620565||Reconstruction with transvaginal mesh(TVM)|Patients who undertake pelvic reconstruction with tran-vaginal mesh(commercial mesh kits or self-cut synthesized mesh).
9471301|NCT03620565||Reconstruction with native tissue(NT)|Patients who prefer to accept reconstruction with native tissue,mainly including high uterosacral ligament suspension, sacrospinous ligament fixation,ischial spinous fascia fixation,the Lefort operation.
9471302|NCT03620565||Tension-free vaginal tape surgery(TVT)|Patients who undertake anti-incontinence surgeries(tension-free vaginal tape procedure).
9471303|NCT03620552|Experimental|18F-S16 injection and PET/CT scan|The subjects were intravenously injected with 370MBq 18F-S16 and underwent PET/CT scan immediately after the injection.
9471304|NCT03620526|Experimental|Iloprost|patients received inhaled iloprost 10 mcg/mL x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
9471305|NCT03620526|Placebo Comparator|Placebo|patients received inhaled normal saline with the same amount x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
9471306|NCT03620513|Placebo Comparator|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
9471307|NCT03620513|Experimental|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
9471308|NCT03620513|Experimental|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
9471309|NCT03620513|Experimental|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
9471310|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
9471311|NCT03620448|Experimental|bCPAP Arm.|"Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components:~(i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya."
9471312|NCT03620448|Other|Oxygen Arm|Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
9471313|NCT03620435|Experimental|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
9471314|NCT03620422|Other|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
9480311|NCT03534869|Active Comparator|Oral Analgesics Only|Postoperative standard oral analgesic therapy (NSAID) supplied at any time upon patients request during hospitalization. Oral ibuprofen would be given as first line therapy, while oral paracetamol would be given as second line therapy.
10032861|NCT01781936|Experimental|Low dose FA-i (Fluocinolone Acetonide insert)|Each FA-i contains 180 µg FA (Fluocinolone Acetonide) designed to be released over 15 - 30 months.
9471315|NCT03620422|Placebo Comparator|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
9471316|NCT03620422|Active Comparator|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
9471317|NCT03620396|Experimental|Experimental: Interventional|Group A patients consists of Gingivitis patients whose serum is collected at base line and treated with Scaling and root planing and after three months serum is collected for assessment of Trefoil factor 3.
9471318|NCT03620396|Experimental|Experimental Interventional|Group B patients consists of Periodontitis patients whose serum is collected at base line and treated with Scaling and Root Planing and after three months serum is collected for assessment of Trefoil factor 3.
9471319|NCT03620370|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
9471320|NCT03620370|No Intervention|Control group|The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
9471321|NCT03620357|Experimental|Continuous Glucose Monitor (CGM) Group|
9471322|NCT03620357|Active Comparator|SMBG Group|
9471323|NCT03620344|Experimental|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
9471324|NCT03620344|Sham Comparator|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
9471325|NCT03620331|Active Comparator|Non Surgical + Surgical|Non surgical approach (NS) followed by surgical treatment (S) of peri-implantitis
9471326|NCT03620331|Experimental|Immediate Surgery|Direct surgical approach (S), without a previous non surgical approach
9471327|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
9471328|NCT03620292|Experimental|Intraoperative NIR fluorescence imaging|"A non-randomized, non-blinded, prospective, single center pilot dose escalation study with bevacizumab-800CW for NIR fluorescence image guided surgery in hilar cholangiocarcinoma~IV-administration of 10, 25 or 50 mg of the fluorescent tracer bevacizumab-800CW to a total of 15 patients with resectable hilar cholangiocarcinoma 3 days prior to surgery.~Peroperative open air NIR fluorescence imaging~Ex vivo endoscopic and histopathological NIR fluorescence imaging"
9471329|NCT03620279|Experimental|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
9471330|NCT03620266|Experimental|Bilberry|Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
9471331|NCT03620266|Placebo Comparator|Reference/Placebo|Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
9471332|NCT03620266|Experimental|Bioprocessed oat bran|Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
9471333|NCT03620266|Experimental|Combination of oat and bilberry|Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
9471334|NCT03620253|Experimental|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
9471335|NCT03620253|Placebo Comparator|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
9471336|NCT03620240|Experimental|Sleep Education|Half of the participants are randomly assigned to the Sleep Education group. These participants will undergo 4 weekly class-based lesson, during which they are educated about sleep.
9471337|NCT03620240|No Intervention|Control|Half of the participants are randomly assigned to the Control group. These participants undergo 4 weekly class-based lessons, during which they are educated about health-related topics, but not about sleep.
9471338|NCT03620227|Experimental|Beetroot juice|ingestion of beetroot juice before an exercise session.
9471339|NCT03620227|Placebo Comparator|Placebo|ingestion of placebo before an exercise session.
9471340|NCT03620214||healthy children|Healthy children consulting at the odontology department of Reims CHU for carious screening or orthodontic diagnosis; excluding research
9471341|NCT03620175|Active Comparator|5 Percent TolaSure Topical Gel|
9471342|NCT03620175|Active Comparator|1.5 Percent TolaSure Topical Gel|
9471343|NCT03620175|Active Comparator|0.5 Percent TolaSure Topical Gel|
9471344|NCT03620175|Placebo Comparator|Topical Vehicle Gel|
9471345|NCT03620149|Experimental|Denosumab|denosumab at reduced dose
10032862|NCT01781949|Other|A: Nontargeted rapid HIV screening|Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
9471346|NCT03620136|Experimental|locoregional analgesia by a block on the adductor channel|
9471347|NCT03620136|Experimental|locoregional analgesia by periarticular local infiltrations|
9471348|NCT03620097|Experimental|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
9471349|NCT03620097|Placebo Comparator|Control Arm|30 children will take a placebo with similar lipid characteristics
9471350|NCT03620084|Experimental|Expiratory Muscle Strength Training (EMST)|Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
9471351|NCT03620071|Experimental|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
9471352|NCT03620071|Experimental|Control|Standard Care
9471353|NCT03620045|Experimental|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
10032863|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
9471354|NCT03620045|No Intervention|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
9480312|NCT03534856|Experimental|Mindfulness meditation|Two weeks of short, daily guided mindfulness meditations were provided.
9480313|NCT03534843||Surgical treatment|Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
9480314|NCT03534843||Non-surgical treatment|Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
9480315|NCT03534830||eLASV > 38.5|exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI.
9480316|NCT03534830||eLASV < 38.5|non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs
10032864|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions related to HIV risk using a traditional behavioral risk screening tool to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
10032865|NCT01781988|Experimental|A.individual therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
10032866|NCT01781988|Experimental|B. non-individualized therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
9480317|NCT03534791|Experimental|Reminders|Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
9480318|NCT03534791|No Intervention|Control group|Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
9480319|NCT03534778||patients undergoing neck dissection|all patients undergoing neck dissection
9480320|NCT03534765||Retrospective arm|Retrospective multicentre cohort with 1 year outcomes available following emergency surgery for NELA eligible gastrointestinal pathology. Please refer to WP1 inclusion and exclusion criteria for eligibility.
9480321|NCT03534765||Prospective, multicentre arm|10 centre prospective observational arm. Please refer to WP2 inclusion and exclusion criteria for eligibility.
9480322|NCT03534739|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
9480323|NCT03534739|Active Comparator|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
10032867|NCT01782001|Experimental|Vitamin A and zinc|combination of vitamin A and zinc supplements
10032868|NCT01782001|Active Comparator|Vitamin A and placebo|vitamin A with placebo
10032869|NCT01782014|Experimental|Water Insufflation|Colonoscopy using water insufflation
10032870|NCT01782014|Active Comparator|Carbon dioxide insufflation|Colonoscopy using carbon dioxide insufflation
9480324|NCT03534739|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
9480325|NCT03534726||Patients|Patients with cardiomyopathy
9480326|NCT03534726||Normal subjects|No prior history of heart disease.
9480327|NCT03534713|Experimental|Neoadjuvant chemotherapy+standard therapy|neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
9480328|NCT03534713|Active Comparator|standard therapy alone|standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
9480329|NCT03534700|Active Comparator|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
9480330|NCT03534700|Experimental|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
10032871|NCT01782014|Active Comparator|Air insufflation|Colonoscopy using air insufflation
10032872|NCT01782027|Experimental|3H-cholesterol|
10032873|NCT01782040|No Intervention|Control Group|Control Group didn't receive any treatment and it was evaluated at the same time and the same way of interventions group
9471355|NCT03620032|Other|Standard treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
9471356|NCT03620032|Experimental|Experimental treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
9471357|NCT03620019|Experimental|Single Arm: Denosumab+ PD-1 Inhibitor|Subjects in this trial will be given denosumab every 4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Subjects who started Pembrolizumab (initiated 21 days after the first dose of denosumab is given) will continue to have it administered intravenously (IV) every 3 weeks. New subjects will receive Nivolumab administered intravenously (IV) every 4 weeks (initiated 21 days after the first dose of denosumab is given). Combination therapy will continue as long as subjects benefit from therapy for up to 1 year.
9471358|NCT03619993|Experimental|Arm A: Start with On-body injector|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)
9471359|NCT03619993|Experimental|Arm B: Start with pre-filled syringe|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)
9471360|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
9471361|NCT03619967|Experimental|Multispectral imaging device|Bio-inspired multispectral imaging device will be used to record fluorescence signals emited by dyes (Indocyanine green and methylene blue) routinely used for visual identification of sentinel lymph nodes per current standard of care worldwide.
9471362|NCT03619954|Experimental|NK cells infusion|
9471363|NCT03619941|Placebo Comparator|Placebo|
9471364|NCT03619941|Experimental|Montmorency Tart Cherry Juice|
9471365|NCT03619928|Experimental|Dry needling|Procedure in which a thin needle is used to penetrate the skin, subcutaneous tissues and muscle with the intention of mechanically stimulating the tissue without the use of an anesthetic. The physiological mechanism supporting the effects of dry needling remains to be clarified. It has been suggested that the needle works according to the pain gate control theory, indicating that one type of sensory input could be inhibited in the Central nervous system by another input
9471366|NCT03619928|Active Comparator|Massotherapy|Among the therapeutic approaches for DOMS is massage therapy. Several authors have examined the effects of DOMS massage and indirect markers of muscle damage, such as impaired muscle function, edema and muscle changes in blood proteins.
9471367|NCT03619915||Greater dependence|
9471368|NCT03619915||Less dependence|
9471369|NCT03619915||Independent|
9471370|NCT03619876|Active Comparator|Non-TNF inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
9471371|NCT03619876|Active Comparator|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
9471372|NCT03619850|Experimental|Ferumoxytol|
9471373|NCT03619850|Active Comparator|Iron sucrose|
9480333|NCT03534674|Experimental|Intervention|Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.
10032874|NCT01782040|Experimental|Auriculotherapy group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.It was used 6 points: Kidney, Liver, Stomach, Brain Stem, Ovary and Uterus point with semi-permanent needles one time per week for 8 sessions
10032875|NCT01782053|Experimental|Control condition|Current packaging with warning on side replaced with one of 9 mandated warning statements
10032876|NCT01782053|Experimental|Text plus picture|Revised packaging with half of front and back of pack showing FDA proposed warning including image.
10032877|NCT01782053|Experimental|Picture plus additional warning text|Same as text plus picture but containing additional text elaborating on the basis for the warning.
10032878|NCT01782066|Experimental|Menveo, dose escalating|
10032879|NCT01782066|Experimental|Nimenrix, dose escalating|
10032880|NCT01782079|Experimental|L. brevis|
10032881|NCT01782092||Chiropractic & Diabetes|All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.
10032882|NCT01782105|Active Comparator|Control group|In addition to the usual monitoring of pregnancy, this group will receive information about the recommended weight gain during pregnancy and an evaluation about of their nutritional and physical activity habits.
10032883|NCT01782105|Experimental|Intervention group|"This group will receive a regular monitoring by health professionals (nutritionist and kinesiologist) who will ensure nutritional changes and physical activity necessary to secure the adoption of a healthy lifestyle and could participate to a physical activity group session once a week until week 36 of gestation.~The intervention include:~A nutritional counseling every 2 weeks by a nutritionist until week 36 of gestation; a physical activity group session once a week lead by a kinesiologist until week 36 of gestation; 2 sessions of physical activity counseling (weeks 12 and 24)."
10032884|NCT01782118|Experimental|Lactobacillus GG|Lactobacillus GG given for six weeks two times per day.
9471374|NCT03619824|Experimental|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
10032885|NCT01782118|Placebo Comparator|Placebo|Placebo two times per day for six weeks
10032886|NCT01782144|Active Comparator|NutriSystem|weekly behavior group weight loss education
10032887|NCT01782144|Placebo Comparator|Education|monthly behavior group weight loss education
10032888|NCT01782157||Prompt intervention|The prompt intervention group will receive context-aware text, audio, and video prompts to initiate specified activities of daily living.
10032889|NCT01782157||No prompt intervention|The no prompt intervention will not receive any prompts to initiate activities of daily living.
10032890|NCT01782170|Active Comparator|Iocide Oral Rinse|Iocide Oral Rinse once daily 30 second rinse for 24 weeks
9471375|NCT03619785|Experimental|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
9471376|NCT03619785|Active Comparator|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
10032891|NCT01782170|Placebo Comparator|Placebo Control|Once daily 30 second rinse for 24 weeks
10032892|NCT01782183|Experimental|Thermal camera by Flir HM series|all patients in both study and control groups will undergo thermal camera photo of the tonsils by Flir HM series
10032893|NCT01782196|Experimental|Type A Pouch followed by Type B pouch|Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
10032894|NCT01782196|Experimental|Type B Pouch followed by Type A pouch|Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3
9471377|NCT03619772|Experimental|Bilateral|Participants will control game using EMG from both upper limbs.
10032895|NCT01782235|Experimental|Tocilizumab arm|Tocilizumab arm will receive tocilizumab.
10032896|NCT01782235|Placebo Comparator|Placebo arm|Placebo arm will receive placebo.
9471378|NCT03619772|Active Comparator|Unilateral|Participants will control game using the more impaired upper limb.
9471379|NCT03619759||Sugammadex|Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
10032897|NCT01782248|Other|Alzheimer disease|Patients with Alzheimer disease
10032898|NCT01782248|Other|Fronto-temporal lobar dementia|Patients with Fronto-temporal lobar dementia
10032899|NCT01782248|Other|Control|Control group
10032900|NCT01782261|Experimental|Liraglutide|Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.
10032901|NCT01782261|Active Comparator|Saxagliptin|Saxagliptin 5mg tablet by mouth every day for 4 weeks
10032902|NCT01782274|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
10032903|NCT01782274|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
9471380|NCT03619759||Non-sugammadex|Patients who didn't use sugammadex Pyridostigmine 15~20mg intravenous, at the end of surgery, before extubation
9471381|NCT03619746|No Intervention|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
9471382|NCT03619746|Experimental|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
9471383|NCT03619720|Experimental|Participants|
9471384|NCT03619642|Other|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
9471385|NCT03619642|Other|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
9471386|NCT03619642|Other|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
9471387|NCT03619629|Experimental|Kinesio-taping|Kinesiotape will be applied both ankles.
9471388|NCT03619629|Experimental|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied both ankles.
9471389|NCT03619629|Sham Comparator|Sham Kinesio-taping|Sham kinesio-taping technique will be applied both ankles.
9471390|NCT03619629|Sham Comparator|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement will be applied both ankles.
9471391|NCT03619616|Experimental|ZSP1603 (single dose)-7.5 mg (Cohort 1)|Subject adminsitered at a dose of ZSP1603 7.5 mg on day 1 under fasted condition.
9471392|NCT03619616|Experimental|ZSP1603 (single dose)-12.5mg (Cohort 2)|"Subject adminsitered at a dose of ZSP1603 12.5 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
9471393|NCT03619616|Experimental|ZSP1603 (single dose)-25 mg (Cohort 3)|"Subject adminsitered at a dose of ZSP1603 25 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
9471394|NCT03619616|Experimental|ZSP1603 (single dose)-50 mg (Cohort 4)|"Subject adminsitered at a dose of ZSP1603 50 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
9471395|NCT03619577|Experimental|Sequential training-high frequency|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
9471396|NCT03619577|Experimental|Sequential training-low frequency|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
9471397|NCT03619564||No protein restriction|No protein restriction
9471398|NCT03619564||Low protein diet (LPD)|LPD: < 0.8 g/kg bodyweight
9471399|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
9471400|NCT03619538|Placebo Comparator|control group|
9471401|NCT03619538|Experimental|Nefopam group|
9471402|NCT03619525|Active Comparator|recruitment group|will receive intermittent lung recruitment during CPB
9471403|NCT03619525|No Intervention|control group|will recieve no intervention
9471404|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
9471405|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
9471406|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
9471407|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
9471408|NCT03619499|Experimental|non invasive|infants who fulfill criteria of severe bronchiolitis will be connected to non invasive ventilation
9471409|NCT03619499|No Intervention|invasive|infants who were connected to invasive mechanical ventilation
9471410|NCT03619486|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
9471411|NCT03619486|Experimental|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
9471412|NCT03619473|Experimental|intervention|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~underwent the educational session under helmet initiative program~received one standard motorcycle child safety helmet per family~assessed for proper helmet usage (type, chinstrap, standard helmet usage) 3 months after educational session and after received standard motorcycle child safety helmet~evaluated for the behavioral of helmet usage 3 months after educational session and after received standard motorcycle child safety helmet"
9471413|NCT03619473|No Intervention|control|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~assessed for proper helmet usage after 3 months 4 evaluated for the behavioral of helmet usage after 3 months~do not receive any educational session or standard motorcycle child safety helmet"
9480334|NCT03534674|No Intervention|Control|Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).
9480335|NCT03534661|Placebo Comparator|Teduglutide + Normal Saline|Teguglutide + (L-NMMA control)
10032904|NCT01782287|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
10032905|NCT01782287|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
10032906|NCT01782300|Experimental|TV003 Vaccine|Participants will receive an injection of the TV003 vaccine at study entry and Day 360.
10032907|NCT01782300|Placebo Comparator|Placebo Vaccine|Participants will receive an injection of the placebo vaccine at study entry and Day 360.
10032908|NCT01782339|Experimental|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
10032909|NCT01782352|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
10032910|NCT01782352|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
10032911|NCT01782352|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
10032912|NCT01782352|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
9471414|NCT03619460|Experimental|piezoelectric extraction|The flap will be raised using a Piezoelectric elevator, the eventual bone around the third molar crown will be removed with the same piezoelectric lever used for luxation and root extraction. The eventual rizectomy will be performed using a piezoelectric saw.
9471415|NCT03619460|Active Comparator|conventional extraction|The flap will be raised using a manual elevator and the eventual bone around the third molar crown will be removed with a bone bur with a straight handpiece while the eventual rizectomy will be performed using a bone bur. Manual levers will be used for luxation and tooth extraction
9471416|NCT03619447|Active Comparator|ESP block group|Under general anaesthesia, Ultrasound guided ESP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
9471417|NCT03619447|Active Comparator|serratus block group|Under general anaesthesia, Ultrasound guided SAP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
9471418|NCT03619434|Active Comparator|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
9471419|NCT03619434|Experimental|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
9471420|NCT03619421|Experimental|Supplement with food|Zinc supplement to be taken at time of breakfast consumption
9471421|NCT03619421|Experimental|supplement prior to food|Zinc supplement to be taken 30-min before breakfast consumption
9803140|NCT04513080|Experimental|Phase 2, Level 2: MBP with weekly VCP|Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.
9803141|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
9471422|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index <3% on pH-metry. Antacid therapy will be discontinued.
9471423|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index > 3% on pH-metry.~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
9471424|NCT03619382||Healthy|Subjects identified to have a healthy foot/ankle
10032913|NCT01782365|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
10032914|NCT01782365|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of SWS
10032915|NCT01782391|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
10032916|NCT01782391|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
10032917|NCT01782404|Experimental|Chlorhexidine|
10032918|NCT01782417|Other|Patient and provider intervention|participants will receive a patient and provider intervention
10032919|NCT01782430|Experimental|Standard oxygenation|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
10032920|NCT01782430|Experimental|High flow nasal oxygen therapy|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
9471425|NCT03619369|Active Comparator|Early Circumcision|
9471426|NCT03619369|Placebo Comparator|Routine Circumcision|
9471427|NCT03619369|Active Comparator|Delayed Circumcision|
9471428|NCT03619343|Experimental|No ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography.
9471429|NCT03619343|Active Comparator|ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
9471430|NCT03619330|Active Comparator|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
9471431|NCT03619330|Active Comparator|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
9471432|NCT03619317||Cancer esophagus and gastroesophageal junction|EGEJ cancer patients referred to combined therapy of chemoRT and surgery can be included.
9471433|NCT03619304|Experimental|no coffee|oral squamous cell carcinoma cell line without intervention
9471434|NCT03619304|Active Comparator|green coffee|oral squamous cell carcinoma cell line with application of green coffee
9471435|NCT03619304|Active Comparator|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
9471436|NCT03619304|Active Comparator|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
9471437|NCT03619291|Experimental|High-intensity functional training|all-out exercise
9471438|NCT03619291|Active Comparator|Aerobic exercise|walking
9471439|NCT03619291|Sham Comparator|control|sitting
9471440|NCT03619278|Experimental|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 dose of 10-1074 antibodies and 3 doses of romidepsin
9471441|NCT03619278|Placebo Comparator|Placebo|Participants will receive 5 doses of placebo, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
9471442|NCT03619265|Experimental|Prickly pear juice|Prickly pear juice, 3 oz daily for 8 weeks.
9471443|NCT03619265|Placebo Comparator|Pear-flavored juice|Pear-flavored juice, 3 oz daily for 8 weeks.
9471444|NCT03619252|Experimental|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
9471445|NCT03619252|Active Comparator|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
9471446|NCT03619239|Experimental|Cohort 1|Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.
9471447|NCT03619239|Experimental|Cohort 2|Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.
9471448|NCT03619239|Experimental|Cohort 3|Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.
10032921|NCT01782430|Other|invasive ventilation (VNI)|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
10032922|NCT01782443|Experimental|Experimental Treatment Arm|Ziv-aflibercept IV every 2 weeks, 4 mg/kg
9471449|NCT03619239|Experimental|Cohort 4|Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.
9471450|NCT03619239|Experimental|Cohort 5(Dose-expansion)|Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)
9471451|NCT03619226|Experimental|test patch|two adhesive patches are applied to the abdominal area
9471452|NCT03619200||Fallers|"Participants who reported at least one fall in the 12-months follow-up period were categorized as fallers."
9471453|NCT03619200||Non-Fallers|"Participants who did not report any fall in the 12-months follow-up period were categorized as non-fallers."
9471454|NCT03619187|Experimental|Single Arm|Study Product
9471455|NCT03619174|Active Comparator|Active Treatment|Treatment dose
9471456|NCT03619174|Placebo Comparator|Sham Treatment|Sub-therapeutic dose
9471457|NCT03619161|No Intervention|No cleaning (control)|Patients will have a bacterial culture taken from their bathtub and then continue regular care. We will offer to clean their bathrooms after the 4 week intervention period ends.
9471458|NCT03619161|Experimental|Bubbles|Patients will have a bacterial culture taken from their bathtub and have their bathrooms cleaned by the investigators
9471459|NCT03619161|Active Comparator|Bleach and Bubbles|Patients will have a bacterial culture taken from their bathtub, have their bathrooms cleaned by the investigators, and be given instructions to perform bleach baths twice weekly.
9471460|NCT03619148|Other|High-Flow Humidified Nasal Oxygen - TOE participants|High-Flow Humidified Nasal Oxygen - standard care
9471461|NCT03619148|Active Comparator|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen - staff volunteers
10032923|NCT01782456|Experimental|Study Oral Nutritional Supplement|2 servings per day of a complete and balanced, ready-to-drink oral nutritional supplement with a new protein blend.
10032924|NCT01782508|Experimental|imatinib|Participants will take 400mg tablets once daily for one year
10032925|NCT01782508|Active Comparator|inteferon|Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
10032926|NCT01782521|No Intervention|Primer|Metal brackets bonded with primer
9471462|NCT03619122|Experimental|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
10032927|NCT01782521|Experimental|No primer|Metal brackets bonded without primer
9471463|NCT03619122|No Intervention|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
9471464|NCT03619109||Healthy Volunteers|No real intervention since samples from volunteers are not tested on Nanōmix eLab™ System near any volunteers. Leftover samples are stored at Sponsor for potential future analysis/ projects.
9471465|NCT03619096|Active Comparator|Test Group (tunnel technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a tunnel Technique
9471466|NCT03619096|Placebo Comparator|Control Group (extended flap technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a extended flap technique
9471467|NCT03619083||Breast cancer patients treated with chemotherapy|
9471468|NCT03619083||patients not exposed to chemotherapy|
9471469|NCT03619083||healthy controls|
9471470|NCT03619070|Experimental|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
9471471|NCT03619070|Experimental|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
9471472|NCT03619070|Experimental|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
9471473|NCT03619070|Other|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
9471474|NCT03619057||> 18 years|
9471475|NCT03619057||10 to 18 years|
9471476|NCT03619031|Experimental|LONG LEAVENING|Acute test meal
9471477|NCT03619031|Experimental|SHORT LEAVENING|Acute test meal
9471478|NCT03619031|Active Comparator|TRADITIONAL|Acute test meal
10032928|NCT01782534||aortic dissection|aortic dissection
9471479|NCT03619005|Placebo Comparator|Placebo|
9471480|NCT03619005|Active Comparator|Prasterone|
9480336|NCT03534661|Active Comparator|Teduglutide + L-NMMA|Tedulgutide + L-NMMA
9480337|NCT03534661|Placebo Comparator|Placebo + L-NMMA|(Teduglutide control) + L-NMMA
10032929|NCT01782547|Experimental|Telehealth Intervention|Telehealth intervention - 6 months
10032930|NCT01782547|Active Comparator|Usual care|Usual care control with comparable frequency of contact
10032931|NCT01782560|Placebo Comparator|Placebo|Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications.
9480338|NCT03534648|Experimental|Effect of PF-05221304 on PF-06865571 PK|
9480339|NCT03534648|Experimental|Effect of PF-06865571 on PF-05221304 PK|
10032932|NCT01782560|Active Comparator|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
10032933|NCT01782573|Active Comparator|Chlorhexidine gluconate ( CHG )|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
9471481|NCT03618992|Active Comparator|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
9471482|NCT03618992|No Intervention|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
9471483|NCT03618992|No Intervention|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
9471484|NCT03618966|Experimental|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
9471485|NCT03618966|Active Comparator|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
9471486|NCT03618953|Experimental|Arm 1 (Intravenous dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
9471487|NCT03618953|Experimental|Arm 2 (Intravenous and Intra-tumoral injection dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 & 29.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
9471488|NCT03618940|Experimental|School-based educational intervention|"assessed for knowledge and attitude on burn injury prevention~underwent the School-based educational intervention~impact evaluation~Output evaluation 3 months after School-based educational intervention"
9471489|NCT03618927|Experimental|Daily physical activity intervention|The intervention consisted of a DPA program designed by a national organization with expertise in school-based physical activity programming and delivered in school by teachers. The program was offered to students in grades 4 through 8 and consisted of 20 minutes of structured DPA in school for 20 consecutive weeks. The DPA activities included jumping jacks, squats, running and other body weight exercises.
9471490|NCT03618927|No Intervention|Control - treatment as usual|Participants in control classes completed regular school activities as per the Ontario curriculum.
10032934|NCT01782573|Active Comparator|0.9% Sodium Chloride ( N/S )|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
9471491|NCT03618914||Non-anemic women|
9471492|NCT03618914||anemic women|anemia due to iron deficiency
9471493|NCT03618901|Experimental|Rock Steady Boxing|Non-contact boxing program.
9471494|NCT03618901|Active Comparator|PD SAFEx|Sensory attention focused exercise.
9471495|NCT03618888|Active Comparator|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
9471496|NCT03618888|Experimental|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
9471497|NCT03618875|Active Comparator|ice|Patients were randomly assigned to receive an ice 5 minutes prior the IViT
10032935|NCT01782599|Experimental|Dual nicotine patch and electronic cigarette|Nicotine patch and the electronic cigarette will be administered.
10032936|NCT01782612|Active Comparator|General Ansethesia|Subjects undergoing Total uni-Hip Replacement will receive standard General Anesthesia with Laryngeal Mask Airway and Multimodal analgesic techniques
10032937|NCT01782612|Experimental|Peripheral Nerve Blocks|Subjects undergoing Total uni-Hip Replacement will receive Lumbar plexus block and Sciatic nerve block with 0.4% Ropivacaine and Multimodal analgesic techniques
10032938|NCT01782625|Experimental|dive to 122 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with no exercise at depth
10032939|NCT01782625|Experimental|dive to 158 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with no exercise at depth
10032940|NCT01782625|Experimental|dive to 122 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with exercise at depth
10032941|NCT01782625|Experimental|dive to 158 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with exercise at depth.
10032942|NCT01782638|Experimental|deep brain stimulation with high frequency|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
10032943|NCT01782638|Other|low frequency on gait of patients|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
10032944|NCT01782651||HER2+ metastatic breast cancer patients treated with lapatinib|HER2+ metastatic breast cancer patients treated with lapatinib plus capecitabine
10032945|NCT01782677|Experimental|Bilateral Surgical Resection of Carotid Bodies|Patients undergoing Bilateral Surgical Resection of Carotid Bodies.
10032946|NCT01782716||ASA|
10032947|NCT01782716||ASA+Euroscore|
10032948|NCT01782755|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of Lactobacillus rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in sterile water, administered through a nasogastric, nasoduodenal, percutaneous gastrostomy or percutaneous jejunal tube twice daily while patients are mechanically ventilated until 24 hours of spontaneous breathing. The first dose will be within 48 hours of intubation.
10032949|NCT01782755|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in sterile water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population
10032950|NCT01782768|Experimental|Effect of different NPPV mode on NRD|13 hypercapnic recovering AECOPD patients were placed on different mode of noninvasive positive pressure ventilation(NPPV,such as the PAV or PSV mode) randomly.For each mode, three levels (PA-, PA, PA+or PS-, PS, PS+), ) of support were applied.PS and PA are set for the patient's comfort . On the basis of these two levels, 25% increase and reduction assisted level of pressure were set both for PS and PA (PA-, PA+or PS-, PS+). At each level, the patients were ventilated at least 20 minutes until the breathing was stable.
10032951|NCT01782781|Placebo Comparator|Group P|"Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.~In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv."
10032952|NCT01782781|Active Comparator|Group A|"Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.~Drug: ropivacaine, ketorelac and epinephrine~In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv."
10032953|NCT01782794||Cohort A|Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
10032954|NCT01782794||Cohort B|Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
9471498|NCT03618875|Placebo Comparator|placebo|Patients were randomly assigned to a room temperature patch (placebo) 5 minutes prior the IViT
9471499|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
9471500|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
9471501|NCT03618810||PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
9471502|NCT03618810||PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
10032955|NCT01782807|No Intervention|Hysterectomy|Hysterectomy without oophorectomy or salpingectomy
10032956|NCT01782807|Experimental|Hysterctomy with salpingectomy or fimbriectomy|Salpingectomy or Fimbriectomy
10032957|NCT01782820||dexamethasone late|dexamethasone during induction of anesthesia
10032958|NCT01782820||no dexamethasone|no dexamethasone during measurements
10032959|NCT01782820||dexamethasone early|dexamethasone before induction of anesthesia
10037136|NCT01822158|Other|vaginal delivery debrief checklist|Utilization of a Vaginal Delivery Debrief Checklist after vaginal deliveries for a period of three months, by team members who have consented to be a part of this study and who are present at vaginal deliveries. The Vaginal Delivery Debrief checklist consists of 2 levels. The first level includes a list of 6 key elements, such as APGAR scores,estimated blood loss, perineal repair, etc. The second level,or extended debrief, occurs whenever unanticipated outcomes, such as low APGAR scores, postpartum hemorrhage or a difficult delivery occurs. Team members complete the checklist after each delivery they attend.
9471503|NCT03618797|Experimental|HL-PIF cap.160/2mg + Placebo|"Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~once a day"
9471504|NCT03618797|Active Comparator|Livalo tab. 2mg + Placebo|"Pitavastatin ca 2mg~once a day"
9471505|NCT03618784|Experimental|FURESTEM-RA Inj.|
9471506|NCT03618784|Placebo Comparator|Placebo Comparator: Placebo|
9471507|NCT03618758|Experimental|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
9480340|NCT03534622|Experimental|Delafloxacin|"Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a~1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses."
10032960|NCT01782846|Active Comparator|Ixprim®|2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)
10032961|NCT01782846|Active Comparator|Dafalgan Codeine®|Two capsules of Dafalgan Codeine® given orally (1000 mg Paracetamol + 46.8 mg Codeine)
9471508|NCT03618732|Experimental|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
9471509|NCT03618732|Other|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
10032962|NCT01782911|Experimental|Resveratrol|Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.
9471510|NCT03618719||Obstructive sleep apnea|Patients with treatment-naive obstructive sleep apnea (OSA) who need continuous positive airway pressure (CPAP) therapy on clinical basis
9471511|NCT03618719||Control|Healthy controls without OSA
10032963|NCT01782911|Placebo Comparator|Control|Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.
10032964|NCT01782924|Experimental|KHK4827 140mg SC|
10032965|NCT01782924|Experimental|KHK4827 210mg SC|
10032966|NCT01782937|Experimental|KHK4827|
10032967|NCT01782950|Other|anti-tuberculosis drugs|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months
10032968|NCT01782976|Experimental|Cilengitide + Bevacizumab|Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
10032969|NCT01782989|Experimental|ORACEA®|40mg doxycycline
10032970|NCT01782989|Placebo Comparator|Placebo|
9471512|NCT03618706|Experimental|involved-field RT + standard salvage treatment|Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
9471513|NCT03618667|Experimental|single group|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.
9471514|NCT03618654|Experimental|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
9471515|NCT03618654|Experimental|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
9471516|NCT03618602|Experimental|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
9471517|NCT03618602|Experimental|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
9471518|NCT03618602|Experimental|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
9471519|NCT03618602|Experimental|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
10032971|NCT01783002|Experimental|Primary hyperparathyroidism|Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
10032972|NCT01783028|Experimental|Community Health Worker support|home visits from community health workers providing education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers
10032973|NCT01783028|No Intervention|the usual care control group|Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support asthma self-management (such as classes and support groups) and educational pamphlets
10032974|NCT01783067|Experimental|Iron and zinc biofortified pearl millet|Participants in the experimental arm consume pearl millet which has been biofortified with iron and zinc.
10032975|NCT01783067|Active Comparator|Pearl millet|Participants in the control arm consume non-biofortified pearl millet.
10032976|NCT01783093||Sickle cell and pulmonary hypertension|
10032977|NCT01783106|Active Comparator|budesonide|Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks
10032978|NCT01783106|Experimental|Ciprofloxacine, doxycycline and hydroxychloroquine|Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds
10032979|NCT01783119|Experimental|Aloe Vera|Consume 200 ml of aloe vera gel per day over a period of three months
10032980|NCT01783119|Placebo Comparator|water|Consume 200 ml of placebo per day over a period of three months
10032981|NCT01783132|Other|Budesonide|Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
10032982|NCT01783132|No Intervention|Standard of care|Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.
10032983|NCT01783145||Patients|Patients with disseminated TC who have finished their chemotherapy, if needed followed by surgery, and who are in complete remission and currently in active follow-up.
9471520|NCT03618589|Placebo Comparator|opioid only|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
9471521|NCT03618589|Experimental|pregabalin add-on|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
9471522|NCT03618576|Experimental|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
9471523|NCT03618524|Experimental|Experimental|Lower limb hot water immersion
10032984|NCT01783158||Diagnostic group|A total of 132 patients with HNSCC were enrolled in this study. The patients underwent esophagoscopy and chromoendoscopy. The most frequent primary tumors were oropharyngeal (49/132), tumors of the oral cavity (36/132) and larynx (35/132). The majority of subjects (107/132 patients, 81.1%) had advanced HNSCC carcinomas (stages III and IV). Multiple LVLs were discovered in 24 subjects (18.2%), and no LVLs in 108 (81.8%) subjects. Fifty-five LVL biopsy specimens were obtained and assessed. Squamous cell carcinomas were detected in two patients, peptic esophagitis in 11 patients, gastric heterotopic mucosa in two patients, hyperplasia in two patients, and low- and high-grade dysplasia in three patients.
10032985|NCT01783171|Experimental|Arm A (dinaciclib, Akt inhibitor MK2206)|"Patients receive dinaciclib IV over 2 hours on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9471524|NCT03618511|Experimental|Financial Incentive Group|
9471525|NCT03618511|Experimental|Reminders Group|
9471526|NCT03618511|Experimental|Financial Incentive and Reminders Group|
9471527|NCT03618511|No Intervention|Control Group|
9471528|NCT03618511|Experimental|Information Group|
9471529|NCT03618511|Experimental|Stigma-relieving Group|
9471530|NCT03618511|Experimental|Information and Stigma-relieving Group|
9471531|NCT03618498|Other|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
9471532|NCT03618472|Experimental|metformin|The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
9471533|NCT03618472|Placebo Comparator|placebo|The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
10032986|NCT01783171|Experimental|Arm B (Akt inhibitor MK2206, dinaciclib)|"Patients receive Akt inhibitor MK2206 PO on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9471534|NCT03618459||Breast-surgery patients|A consecutive cohort of adult patients undergoing breast surgery with a combined anesthesia technique, employing a thoracic single-shot paravertebral block performed before surgery. Operations performed were in all cases unilateral tumor resections, lumpectomies and mastectomies without axillary lymphadenectomy.
9471535|NCT03618433|Experimental|Study group|"Standart exercise protocol and KİNECT® video based physiotherapy~The treatment protocol of the study group will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises.In total, a 25-minute Kincet® video game program will be applied in addition to the 15-minute basic and standart exercise program."
9471536|NCT03618433|Active Comparator|Control group|"Standart exercise protocol and Upper extremity rehabilitation~The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol"
9471537|NCT03618407||Oral oseltamivir group|Patients with influenza virus positive and early oral oseltamivir capsules
9471538|NCT03618407||Oral Lotus Capsules group|Patients with positive influenza virus and early oral administration of lotus extract capsules
9471539|NCT03618407||other group|Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early
9471540|NCT03618394||Smoflipid|premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion
9471541|NCT03618394||Intralipid|premature neonates receiving Soybean Based lipid emulsion
9480341|NCT03534609|Experimental|Genius System Neck Treatment|Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
9480342|NCT03534583|Active Comparator|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 3 consecutive days for 1.5-3 hours. There will then be a a gap of 4 days where participants will practice what they have learned, followed by 3 consecutive days of 1.5-3 hours of instruction. Starting the following week participants will attend once weekly follow up sessions (60-90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes, HEP will be delivered by a trained social worker (or equivalent).
10032987|NCT01783197|Experimental|Paclitaxel and carboplain plus selumetinib|"Cohort 1: Standard Chemotherapy (paclitaxel and carboplatin) plus selumetinib~If you are registered to Cohort 1, you will receive two commonly-used chemotherapy drugs called paclitaxel and carboplatin, plus you will be given the experimental drug selumetinib."
10032988|NCT01783197|Experimental|pemetrexed and cisplain plus selumetinib|"Cohort 2: Standard Chemotherapy (pemetrexed and cisplatin) plus selumetinib (cohort closed)~If you are registered to Cohort 2, you will receive two commonly-used chemotherapy drugs called pemetrexed and cisplatin, plus you will be given the experimental drug selumetinib."
10032989|NCT01783197|Experimental|pemetrexed plus selumetinib|"Cohort 3: Standard Chemotherapy (pemetrexed) plus selumetinib (cohort closed)~If you are registered to Cohort 3, you will receive one commonly-used chemotherapy drug called pemetrexed, plus you will be given the experimental drug selumetinib."
10032990|NCT01783210|Experimental|TLC(Therapeutic Lifestyle Changes) group|"Intervention: Specific Therapeutic Lifestyle Changes program in pregnancy. TLC Program includes a diet (with a specific amount of calories and macronutrients) and a mild physical activity."
10032991|NCT01783210|Other|Control group|"Intervention: Dietary and behavioral counselling in pregnancy. The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake."
10032992|NCT01783223||Intoxicated patients|patients in the Emergency Department who appear to be intoxicated with ethanol.
10032993|NCT01783249|No Intervention|Control|Usual care monitoring
10032994|NCT01783249|Other|Exercise using stationary cycling|Stationary cycling exercise program
10032995|NCT01783262|Active Comparator|Extracorporeal shock wave therapy|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
9471542|NCT03618381|Experimental|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
9471543|NCT03618381|Experimental|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
9471544|NCT03618368|Experimental|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.
9471545|NCT03618368|Placebo Comparator|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).
9471546|NCT03618368|Experimental|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.
9471547|NCT03618368|Placebo Comparator|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).
9471548|NCT03618355|Experimental|Cohort 1: 0.5 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg every week."
9471549|NCT03618355|Experimental|Cohort 2: 1 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg every week."
9471550|NCT03618355|Experimental|Cohort 3: 0.5 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg daily."
9471551|NCT03618355|Experimental|Cohort 4: 1 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg daily."
10032996|NCT01783262|Placebo Comparator|sham extracorporeal shock wave therapy|The second grouop of patients received 0.04 mJ/mm2, 2400 pulses once a week for 4 weeks.
10032997|NCT01783275|Experimental|Aerobic Exercise|12 weeks of aerobic exercise
10032998|NCT01783275|No Intervention|Control|12 weeks with no change in diet or exercise habits (weight maintenance).
10032999|NCT01783301|Active Comparator|Antral follicle count|"Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide~AFC < 6 on both ovary: 375 IU FSH~6<AFC <=15 on both ovary: 225 IU FSH~AFC> 15 on both ovary: 150 IU FSH"
10033000|NCT01783301|Active Comparator|Anti-Mullerian Hormone|"Start dose of FSH based on AMH guide~AMH < 5 pmol/L or < 0.7ng/ml: 375 IU FSH~AMH 5 to < 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH~AMH ≥ 15 pmol/L or > 2.1ng/ml: 150 IU FSH"
10033001|NCT01783314|Active Comparator|Normal liver function|Control group. Subjects will obtain MRI of liver.
10033002|NCT01783314|Experimental|Hepatitis C|Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
9471552|NCT03618342||PCOS|PCOS women
10033003|NCT01783327|Experimental|Teens-Connect|The Teens-Connect Program is an internet-based program that combines Managing Diabetes and TEENCOPE.
10033004|NCT01783327|Active Comparator|Planet D|Planet D is an internet program developed by the American Diabetes Association for children and adolescents with diabetes.
10033005|NCT01783340|Active Comparator|CQ and falciparum immunization|"This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Placebo capsules daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
10033006|NCT01783340|Experimental|CQ/AZM and falciparum immunization|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).~Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
10033007|NCT01783340|Placebo Comparator|CQ and AZM control|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
9471553|NCT03618342||Healthy controls|Healthy control women
10033008|NCT01783353|Placebo Comparator|Corn starch pill|Two (2) corn starch pills will be taken three (3) times a day for 60 days.
10033009|NCT01783353|Experimental|Zinc gluconate|Two (2) zinc gluconate 50 mg capsules will be taken three (3) times a day for 60 days.
9471554|NCT03618329|Active Comparator|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
10033010|NCT01783366|No Intervention|CONTROL|In the control group (Group A) inserting the lubricated NG tube through the nostril, at that time head maintained in the neutral position.
10033011|NCT01783366|Active Comparator|tube-exchanger|The tube-exchanger group (Group B) made use of tube-exchanger G36402 (CAEC, [cook medical, Bloomington, IN]) as a stylet that was lubricated and inserted within 20-F NGT until the tip of the tube-exchanger was at the tip of the NGT
9471555|NCT03618329|No Intervention|No Prehabilitation|Not: exercise, nutrition and anxiety reduction in the preoperative period
9471556|NCT03618316|Experimental|Open-label imeglimin + cimetidine|Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine
10033012|NCT01783379||ICU patient on micafungin|ICU patients with an invasive fungal infection on micafungin treatment
10033013|NCT01783392|Active Comparator|Unilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.
10033014|NCT01783392|Active Comparator|Bilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.
10033015|NCT01783392|Active Comparator|Shoulder stimulation|Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.
9471557|NCT03618303|Experimental|Interventional|All patients will undergo the same intervention of having a PET-MRI scan and optical coherence tomography.
9471558|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
9471559|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
9471560|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI) defined as intracranial hemorrhage or contusion.
9471561|NCT03618277|Other|Intra individual|Before and after being treated by a product (outside the study)
9471562|NCT03618264|Experimental|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
9471563|NCT03618264|Active Comparator|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
10033016|NCT01783405||Cases|FH heterozygous
10033017|NCT01783405||Controls|Parents of FH heterozygotes with FH
10037137|NCT01822171|Experimental|Discharge counseling and MTM follow-up|"At the time of hospital discharge the subject will receive:~Discharge medication counseling from a pharmacist~Home medication if needed~Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic."
9471564|NCT03618251||ischemic stroke|all patients with a suspicion of ischemic stroke
9471565|NCT03618238|Experimental|Anlotinib|patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.
9471566|NCT03618212||Myeloma patients|
9471567|NCT03618173|Experimental|dexamethasone|IV dexamethasone group : dexamethasone administrated at the induction of general anesthesia, at the dose of 0,2mg/kg (= 0,2mL/kg of a syringe with a 1mg/mL concentration) maximum 8mg (=8mL).
9471568|NCT03618173|Placebo Comparator|Placebos|IV placebo group : saline serum is administrated at the induction of general anesthesia, at the dose of 0,2mL/kg, maximum 8mL.
9471569|NCT03618160|Experimental|Part 1: SAD (Cohort 1 to 3)|Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
9471570|NCT03618160|Experimental|Part 2: MAD (Cohort 4 to 6)|Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
9471571|NCT03618160|Experimental|Part 3: Single Dose (Cohort 7)|Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
9471572|NCT03618121|Experimental|Biofeedback plus gaming (Nevermind)|1) Group A is a biofeedback plus gaming group. Participants in this group play a horror videogame called Nevermind, while also wearing a chest strap heart rate monitor. The object of the videogame is to assist a patient by entering his/her mind and helping him/her work through some trauma memories. The way the game works is that the more anxious players are, the faster their heart beats, and the faster the heart beats, the harder and scarier the game gets. Thus, in order for one to do well in the game, he or she has to learn how to control the heartbeat and stress through relaxation. A therapist will help people in this group to learn relaxation techniques to help calm their body and finish the game.
9471573|NCT03618121|Active Comparator|Gaming only|2) Group B is a gaming only group. Like Group A, participants in this group play a Nevermind, but this time they do not wear a heart rate monitor. A therapist will still be present to help people in this group to learn relaxation techniques to help calm themselves during game play, but in this case the game does not change based on heart rate.
9471574|NCT03618121|Active Comparator|Biofeedback only (The Pip)|3) Group C is a biofeedback only group. In Group C, participants use a device called The Pip that measures Galvanic Skin Response. The Pip interacts with a few basic apps used in this study to teach relaxation. In one app, players control flying dragons. The more relaxed players are (as measured by GSR), the higher and faster their dragon flies. In another app, players control the changing of seasons. The more relaxed players are, the faster they can make seasons change from winter to spring. In another app, players can watch a simple graph of their stress over a period of time. Participants can learn to decrease stress by learning to make the line on the graph go down. In Group C, a therapist will also be present with participants to help them learn techniques to reduce stress.
10033018|NCT01783431|Experimental|Leukapheresis and Poly-ICLC|Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
9471575|NCT03618121|Active Comparator|Relaxation training only|4) Group D is a relaxation training only group. In Group D, participants receive relaxation training from a trained therapist. Participants in this group learn and practice with their therapist different techniques to help them relax and reduce stress.
9471576|NCT03618108|Active Comparator|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
9471577|NCT03618108|Placebo Comparator|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
9471578|NCT03618095|Experimental|Main Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
9471579|NCT03618095|Experimental|Roll-In Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
9471580|NCT03618095|Experimental|Bicuspid Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
9471581|NCT03618082|Active Comparator|usual practice|control group (usual practice): patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance. The dosage of the anesthetic agent, as well as the prophylactic administration of morphine at the end of the intervention, will be decided by the anesthesiologist.
9471582|NCT03618082|Experimental|targeted analgesia to ANI|"experimental group: patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance, as well as the prophylactic administration of morphine at the end of the intervention, will be administered according to the ANI.~- In addition, desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC)."
9471583|NCT03618069|No Intervention|routine investigation|
9471584|NCT03618069|Active Comparator|study protocol CCI (CTA, cardiac CT) and MRI scans|
9471585|NCT03618043|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
9471586|NCT03618004|Experimental|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
9471587|NCT03618004|Active Comparator|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
9471588|NCT03617991|Experimental|Exercise Group|Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
9471589|NCT03617991|No Intervention|Control Group|The control group will be contacted weekly to check on health status.
9471590|NCT03617978|Experimental|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
10033019|NCT01783457|Experimental|Individual psychoeducation|Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
10033020|NCT01783457|Active Comparator|Control|Usual treatment
10033021|NCT01783587|Experimental|High Risk Group|Dose escalation of afatinib + docetaxel + radiation therapy
10033022|NCT01783587|Experimental|Intermediate Risk Group|Dose escalation of afatinib + radiation therapy
10033023|NCT01783600|Other|NanoCross .014 balloon catheter|NanoCross .014 balloon catheter
10033024|NCT01783613|Experimental|Docosahexaenoic acid administration|50 patients will receive docosahexaenoic acid
10033025|NCT01783613|Placebo Comparator|placebo|50 patients will receive placebo
10033026|NCT01783626|Sham Comparator|Evodial|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
10037138|NCT01822184||No treatment|Observational non-treatment study
9471591|NCT03617978|Experimental|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
10033027|NCT01783626|Experimental|Evodial+ Condition B1|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
10033028|NCT01783626|Experimental|Evodial+ Condition B2|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
9471592|NCT03617978|Experimental|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
9471593|NCT03617978|Experimental|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
9471594|NCT03617965||Mild thrombocytopenia|Patients with a platelet count of 100 × 10e9 to 149 × 10e9/L.
9471595|NCT03617965||Moderate thrombocytopenia|Patients with a platelet count of 50 × 10e9 to 99 × 10e9/L
9471596|NCT03617965||Severe thrombocytopenia|Patients with a platelet count<50 × 10e9/L
9471597|NCT03617965||Control group|Patients with normal platelet count (i.e.150 × 10e9 to 399 × 10e9/L)
9471598|NCT03617952|Experimental|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.~The P3 Bio Intervention is implemented in this group."
9471599|NCT03617952|Experimental|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.~The P3 Bio Intervention is implemented in this group."
10033029|NCT01783626|Experimental|Evodial+ Condition C|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
9471601|NCT03617926|Experimental|Test product|Water-based lotion (internal code (X92001666)
9471602|NCT03617926|Active Comparator|Reference|Commercial, pyrethrin-based shampoo (RID shampoo)
9471603|NCT03617900|Placebo Comparator|Placebo|
9471604|NCT03617900|Experimental|Ginger|
9471605|NCT03617900|Active Comparator|Paracetamol|
9471606|NCT03617887|Experimental|Experimental group|Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus:
9471607|NCT03617887|Experimental|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise
9471608|NCT03617835|Experimental|Spesolimab|
9471609|NCT03617809||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
9471610|NCT03617809||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
9471611|NCT03617757|Experimental|All recruited patients|Blood taking procedure, oral glucose tolerance test and questionnaire will be included.
9471612|NCT03617744|Experimental|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
9471613|NCT03617744|No Intervention|No Surgical Intervention|Liver transplantation will proceed as per routine practice
10033030|NCT01783652|Experimental|Intervention group|Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.
10033031|NCT01783652|No Intervention|Control group|Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.
10033032|NCT01783665|Experimental|Aerobic Exercise|3x/week supervised moderate intensity aerobic exercise on recumbent stepper
10033033|NCT01783665|Active Comparator|Home exercise program|Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic
10033034|NCT01783691|Experimental|NKTT120|
10033035|NCT01783717|Experimental|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
10033036|NCT01783756|Experimental|Treatment (lapatinib ditosylate, everolimus, capecitabine)|Patients receive lapatinib ditosylate PO QD and everolimus PO QD on days 1-21, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
10033037|NCT01783769|No Intervention|Normal O.R. Traffic|"This Normal O.R. Traffic protocol follows the national standards of care."
10033038|NCT01783769|Active Comparator|"Low O.R. Traffic"|"This protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
10033039|NCT01783782|Experimental|DIET|Group A followed the standard regime consisting of a clear liquid diet for 12 hours on the day before CE, followed by an overnight fast.
10033040|NCT01783782|Experimental|HIGH PEG|Group B received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed always by an overnight fast.
10037139|NCT01822210|Experimental|Botox|Injection of Botox in the tumor and surrounding stomach wall.
10033041|NCT01783782|Experimental|LOW PEG|Group C, defined as a low volume regime, received 25 mL/Kg (up to 1Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed by an overnight fast.
10033042|NCT01783782|Experimental|SIMETHICONE|Group D received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion.
10033043|NCT01783782|Experimental|SIMETH+PEG|Group E received 25 mL/Kg (up to 1 Lt/die) of polyethylene glycol 4000 solution with simethicon solution followed by an overnight fast plus 20mL oral simethicone and 200mL water 30 minutes before capsule ingestion.
10033044|NCT01783795|Other|Genetic Analysis|Genetic Analysis
10033045|NCT01783808|Experimental|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
10033046|NCT01783808|No Intervention|Control group|The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.
10033047|NCT01783834|Active Comparator|pemetrexed|pemetrexed
9471614|NCT03617705|Active Comparator|HIV+ drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
9471615|NCT03617705|Active Comparator|HIV- drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
9471616|NCT03617692||Oral Cannabis|This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
9471617|NCT03617679|Active Comparator|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
9471618|NCT03617679|Placebo Comparator|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
9471619|NCT03617666|Experimental|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
9471620|NCT03617653|Other|Group A - Intervention|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis, Exercise intervention from Visit 2 to Visit 13, End of 3 month assessment.
9471621|NCT03617653|Other|Group B- Control|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis & End of 3 month assessment.
9471622|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
9471623|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
9471624|NCT03617627|Experimental|Experimental group|Patients will be included in a self-management intervention.
9471625|NCT03617627|No Intervention|Control group|Patients will receive a booklet with information.
9471626|NCT03617614||Collaborative Care Model|Participants who received care from the Medical Psychiatry Alliance Seniors Outpatient Collaborative Care Program at Trillium Health Partners.
9471627|NCT03617614||Mood Consult|Participants who received a one time mood consultation at the Centre for Addiction and Mental Health.
9471628|NCT03617601||> 4 MET|Patients with functional capacity over 4 MET
9471629|NCT03617601||< 4 MET|Patients with functional capacity under 4 MET
9471630|NCT03617575|Placebo Comparator|apo-Lactoferrin|unsaturated (= no iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal A1
9471631|NCT03617575|Placebo Comparator|holo-Lactoferrin|saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal B1
9471632|NCT03617575|Placebo Comparator|FeSO4|Ferrous sulfate = FeSO4 acting as the reference Test Meal C1
9471633|NCT03617575|Placebo Comparator|1. FeSO4|Ferrous sulfate = FeSO4 Test Meal A2
9471634|NCT03617575|Placebo Comparator|FeSO4 after 1 day break|Ferrous sulfate = FeSO4 Test Meal B2
9471635|NCT03617575|Placebo Comparator|FeSO4 after 2 day break|Ferrous sulfate = FeSO4 Test Meal C2
9471636|NCT03617549||All Participants|Mothers of singleton moderate preterm appropriate for Gestational Age (AGA) infants (29-32+6 weeks gestation in the neonatal intensive care unit at the Golisano Children's Hospital
9471637|NCT03617510|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
9471638|NCT03617510|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
9471639|NCT03617510|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
10033048|NCT01783834|Active Comparator|gefitinib|gefitinib
10033049|NCT01783873|Placebo Comparator|Placebo|
10033050|NCT01783873|Active Comparator|flour allergen extract or quaternary ammonium compound|
10033051|NCT01783899|Experimental|Hemospray Group|"Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.~In addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
10033052|NCT01783925||Group 1|
9471640|NCT03617510|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
9471641|NCT03617497|Active Comparator|Healthy control participants|Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography
9471642|NCT03617497|Active Comparator|Alzheimer disease|Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography
9471643|NCT03617497|Experimental|Alzheimer disease with high seizure risk|Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography
9471644|NCT03617484|Experimental|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle."
9471645|NCT03617471|Experimental|Paracetamol oral tablets 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
9471646|NCT03617471|Experimental|Paracetamol oral granules 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
9471647|NCT03617458|Active Comparator|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg po three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
9471648|NCT03617458|Placebo Comparator|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
9471649|NCT03617458|Active Comparator|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
9471650|NCT03617458|Placebo Comparator|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
9471651|NCT03617432|Experimental|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
9471652|NCT03617432|Experimental|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
9471653|NCT03617406|Other|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
9471654|NCT03617393||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection.
9471655|NCT03617393||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
9471656|NCT03617393||DM group|Patients without pulmonary infection while the fasting blood-glucose > 8 mmol/L.
9471657|NCT03617393||Control group: normal people|Patients without pulmonary infection while the fasting blood-glucose in the normal range.
9471658|NCT03617380|Experimental|PHARMD-TOC i|PharmD Follow-Up Post Discharge
9471659|NCT03617380|Active Comparator|USUAL CARE|Usual Post Discharge Procedures
9471660|NCT03617354||Trainee Gynaecologists|"RANZCOG accredited O&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;~Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).~Will be able to attend each of the 10 training days."
9471661|NCT03617341||Brain MRI|Regular brain MRI can detect early brain metastases in metastatic Breast cancer with high risk subgroups, such as HER2-positive and triple negative.
10033053|NCT01783951|Experimental|DC-CIK plus S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
10033054|NCT01783951|Active Comparator|S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
10033055|NCT01783964|Experimental|[14C]-Elacytarabine Microdose|intravenous (IV) administration of one dose of elacytarabine
10033056|NCT01783977|Experimental|Part A: Group 1: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
10033057|NCT01783977|Experimental|Part B: Group 2: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
10037140|NCT01822236|Experimental|Craniosacral Therapy Program|A program of 10 craniosacral therapy techniques
10037141|NCT01822236|Active Comparator|One technique of craniosacral therapy|Decompression L5-S1.
10037142|NCT01822249|Active Comparator|EPI-743 15 mg/kg|Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily
10033058|NCT01783977|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
10033059|NCT01783977|Experimental|Part B: Group 3: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
9471664|NCT03617315|Experimental|Hyaluronic Acid|One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days
9471665|NCT03617315|Experimental|CrossLinked Hyalurnic Acid|One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days
9471666|NCT03617302|Experimental|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
9471667|NCT03617302|Placebo Comparator|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
9471668|NCT03617289|Experimental|Treatment|Receiving Magnesium Sulfate
9471669|NCT03617289|Placebo Comparator|Placebo|Receiving D5W
9471670|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
9471671|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
9471672|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
9471673|NCT03617224|Experimental|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
9471674|NCT03617224|Experimental|Radiation: TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
9471675|NCT03617146|Experimental|Intervention Arm|"Participants in the intervention arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education.~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.~Month 3: Follow up distress-specific education.~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement."
9471676|NCT03617146|Active Comparator|Control Arm|"Participants in the control arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).~Month 3: Follow up distress-specific education (same as for the intervention arm)."
9517190|NCT03308552|Active Comparator|SIB-IMRT combined chemotherapy followed by chemotherapy|"SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.~Concurrent chemotherapy: Paclitaxel and platinum based drug are administered once a week for at least 5 weeks during radiotherapy treatment days."
10033060|NCT01783977|Placebo Comparator|Part B: Group 3: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
10033061|NCT01783977|Experimental|Part B: Group 4: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 140.
10033062|NCT01783977|Placebo Comparator|Part B: Group 4: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 140.
10033063|NCT01784003||Non-amputee|People without an amputation will be recruited to participate in the study.
10033064|NCT01784003||Below the knee amputee|People with a unilateral transtibial amputation will be recruited to participate in the study.
10033065|NCT01784016|Experimental|Healthy Smokers|Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.
10033066|NCT01784016|Experimental|Healthy Nonsmokers|Healthy nonsmoking controls aged 18-50 reporting consumption of <100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of < 9 ppm at screening.
10033067|NCT01784042|Placebo Comparator|No dietary energy restriction plus Placebo|No dietary energy restriction plus Placebo
10033068|NCT01784042|Placebo Comparator|Dietary energy restriction plus placebo|Dietary energy restriction plus placebo
10033069|NCT01784042|Experimental|Lovaza|Lovaza only
10033070|NCT01784042|Experimental|Dietary energy restriction plus Lovaza|Dietary energy restriction plus Lovaza
10033071|NCT01784081||palliative care with iPC3|Palliative care with decision aids will be administered at each palliative care visit.
10033072|NCT01784094||Low back pain subjects|Subjects with chronic or recurrent low back pain
10033073|NCT01784094||No low back pain subjects|Subjects who are generally healthy with no low back pain
10033074|NCT01784107|Experimental|Belotecan and Ifosfamide|
10033075|NCT01784120|Experimental|doxotubicin/Genexol-PM|
9471677|NCT03617120|Experimental|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
9471678|NCT03617094|Experimental|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
9471679|NCT03617094|Active Comparator|Standard Conservative treatment (CT)|Thoracolumbar corset.
9471680|NCT03617081|Experimental|NNC0113-2023|Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose.
9471681|NCT03617081|Placebo Comparator|Placebo|Participants will receive placebo (NNC0113-2023)
9471682|NCT03617068|Active Comparator|Coconut Oil Cream|This group consist of batik traditional workers who use coconut oil cream for 2 weeks.
9471683|NCT03617068|Placebo Comparator|Placebo Cream|This group consist of batik traditional workers who use placebo cream which contained the vehiculum of the cream; using for 2 weeks.
9471684|NCT03617029|Experimental|Microcoil|Needle localization for deep-seated lung nodules with microcoil placement
9471685|NCT03617029|Active Comparator|Contrast|Needle localization for deep-seated lung nodules with contrast injection
9471686|NCT03617016|Experimental|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
9471687|NCT03617016|Placebo Comparator|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
9803142|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
9471689|NCT03616938|Experimental|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
9471690|NCT03616938|Experimental|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
9471691|NCT03616938|Experimental|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
9471692|NCT03616925|Experimental|Platelet rich fibrin matrix|surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites
9471693|NCT03616925|Active Comparator|surgical open flap debridement|only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites
9471694|NCT03616873||Adults aged 60 or older|
9471695|NCT03616847|Experimental|Standard care|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will remain inflated until the wound is closed.
9471696|NCT03616847|Experimental|Tourniquet release|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will be removed. There will be a five minute delay before the wound is closed.
9471697|NCT03616834|Experimental|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
9471698|NCT03616808|No Intervention|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
10033076|NCT01784146|Placebo Comparator|Oxygen|
10033077|NCT01784146|Experimental|PEEP + Heliox|
10033078|NCT01784146|Experimental|Oxygen + PEEP|
10033079|NCT01784146|Active Comparator|Heliox|
10033080|NCT01784172|Experimental|electroacupuncture group|"Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50～60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
10033081|NCT01784172|Experimental|sham electroacupuncture group|"Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
10033082|NCT01784185|Experimental|virtual bronchoscopy guided transbronchial needle aspiration|virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
10033083|NCT01784198|Experimental|Protein Intake|Dietary supplement:Protein intake
10033084|NCT01784224|Experimental|Speaking Valves|"All participants will either have a Blom tracheotomy tube in place or have their current tracheotomy tube changed to a Blom tracheotomy tube to allow for use of both the Blom low profile voice inner cannula and the Passy-Muir one-way speaking valves.~The Blom low profile voice inner cannula and Passy-Muir speaking valves will be provided to participants in a random order. All valves will be placed by the PI. Duration of data collection trials will range from 10 to 30 minutes."
10033085|NCT01784237|Experimental|Anterior meatuscopy|All patients in the study group receive anterior meatoscopy whereas patients in the control group perform a sniff test to select the most patent nostril for nasal anesthesia and transnasal endoscopic insertion.
10033086|NCT01784237|Active Comparator|Nasal sniff test|A sniff test for nasal patency is a common method before ultrathin transnasal esophago-gastro-duodenoscopy (UT-EGD) to select the right or left nostril for insertion.
10033087|NCT01784250|Experimental|Propanolol|Propranolol 40mg tablets, one tablet administered 1 hour before surgery
9471699|NCT03616808|Active Comparator|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
9471700|NCT03616795|Experimental|LY3154207 and [14C]-LY3154207|A single dose of LY3154207 and [14C]-LY3154207administered orally.
9471701|NCT03616769||quantiles of serum uric acid level|quantiles according to the patient's serum uric acid level
9471702|NCT03616756|Experimental|Intervention group|
9471703|NCT03616756|Active Comparator|Control group|
9471704|NCT03616743|Experimental|Brief pain and smoking arm|The experimental arm incorporated a novel psychoeducational component that addressed associations between cigarette smoking and chronic pain
9471705|NCT03616743|Active Comparator|Brief smoking control arm|"The brief smoking control arm was comprised of the 5A's of smoking cessation."
9471706|NCT03616691|Experimental|Atezolizumab|The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
9471707|NCT03616691|Experimental|Atezolimab+Bevacizumab|Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy (stage 2). Both of drugs are administered via intravenous infusion every 3 weeks.
9471708|NCT03616678|Experimental|VenTouch System Implant|"The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have moderately severe or severe mitral regurgitation (grade 3 or 4 MR)."
9471709|NCT03616665|Other|CBASPersonalized|Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient.
9471710|NCT03616652|Experimental|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
9471711|NCT03616652|Placebo Comparator|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
9471712|NCT03616639|Experimental|Oxycodone|Continuous subcutaneous infusion (CSCI) of oxycodone.
9471713|NCT03616639|Active Comparator|Morphine|Continuous subcutaneous infusion (CSCI) of morphine.
9471714|NCT03616626|Active Comparator|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
9471715|NCT03616626|Experimental|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
9471716|NCT03616626|Experimental|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
9471717|NCT03616613||Men|Men born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
9471718|NCT03616613||Women|Aleatory sample of women born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
9471719|NCT03616561||Apremilast|The cohort will be recruited in Hospital General de Granollers and Hospital Moises Broggi
9471720|NCT03616548|Other|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
9471721|NCT03616509|Experimental|Placebo and Growth Hormone|2 months on placebo followed by 12 months on GH
9480935|NCT05168891|Experimental|Control group (CG)|Patients will receive professional supragingival teeth/implant prophylaxis, oral hygiene instructions, and implant-supported prosthesis corrections if needed. After 1 week, peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed. After one month, the regenerative surgical therapy will be performed as it follows: the intrabony component of the defect will be filled with a xenograft and covered with a collagen membrane allowing a non-submerged healing. Finally, the patients will be enrolled in a PIMT program every 3 months.
10033088|NCT01784250|Placebo Comparator|Placebo|Placebo tablets, one tablet administered 1 hour before surgery
10033089|NCT01784250|Experimental|Clonidine|clonidine 150mcg tablets, one tablet administered 1 hour before surgery
10033090|NCT01784263|Experimental|Individual Cognitive Behavioral Therapy|
9471722|NCT03616457||All Study Participants|All study participants will undergo the same study procedures, including Automated Breast Ultrasound (ABUS).
10033091|NCT01784263|Active Comparator|Standard Community Treatment|
10033092|NCT01784276|No Intervention|Control|Children assigned to Group A (control group) received usual care and therefore had no intervention before or during the return visit.
10033093|NCT01784276|Experimental|Video peer modeling|Video peer modeling (at home, the child watched a DVD recording of a typically developing child undergoing a dental visit);
10033094|NCT01784276|Experimental|Video goggles or portable DVD only|Video goggles/DVD (during the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player);
10033095|NCT01784276|Experimental|Video peer modeling plus video goggles|Video peer modeling plus video goggles/DVD. At home, the child watched a DVD recording of a typically developing child undergoing a dental visit; During the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player.
9471723|NCT03616444|Experimental|TCM-Xiaoai Jiedu Decoction|Xiaoai Jiedu Decoction：Oldenlandia 20g,kuh-seng 9g,Codonopsis pilosula 15g,bighead atractylodes rhizome 12g,smoked plum 9g,the rhizome of Chinese goldthread 3g,RHIZOMA ZINGIBERIS PREPARATA 6g,Semen Coicis 20g. Take one pack a day, divided into twice one day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year， last two years.
9471724|NCT03616444|Placebo Comparator|TCM-Xiaoai Jiedu Decoction Placebo|The control group took placebo twice a day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year，last two years.
9471725|NCT03616405|Experimental|14-day modified sequential therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.~Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 10mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the firs 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
10033096|NCT01784289||normal|Patients with no overweight and no type 2 diabetes
10033097|NCT01784289||lipodystrophy|patients with a lipodystrophy, most are diabetics
9471726|NCT03616392|Experimental|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
9471727|NCT03616392|Experimental|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
9471728|NCT03616392|Experimental|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
9471729|NCT03616392|Experimental|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
9471730|NCT03616379|Placebo Comparator|Psychoeducational Control|
9471731|NCT03616379|Experimental|Affect Regulation Condition|
9471732|NCT03616379|Experimental|Affect Labelling Condition|
9471733|NCT03616353|Experimental|Group 1: Corticosteroid Injection|Patients in this group will undergo an injection of corticosteroid into the carpal tunnel as per current treatment practices.
9471734|NCT03616353|Experimental|Group 2: Perineural Hydrodissection|Patients in this group will undergo a perineural hydrodissection plus an injection of corticosteroid into the carpal tunnel, as a novel technique.
9471735|NCT03616340|Experimental|Ketorolac|
9471736|NCT03616340|Experimental|Kenalog|
9471737|NCT03616327|Other|MATRx in-lab or MATRx plus test|Participants will undergo the MATRx in-lab or MATRx plus home test to determine adequacy for mandibular repositioning oral appliance therapy. The tests only differ in their setting (i.e., in the sleep lab or at home). All participants will receive the same treatment protocol preceding and following the MATRx/MATRx plus test.
9471738|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
9471739|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
9471740|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
9471741|NCT03616301|Experimental|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
10033098|NCT01784289||obese non diabetics|Patients with obesity (BMI <30kg/m2), without diabetes
10033099|NCT01784289||obese diabetics|Patients with obesity (BMI <30 kg/m2), with diabetes
10033100|NCT01784302|Active Comparator|Maalox Plus extra|Subjects will receive doses of raltegravir 400 mg and maalox plus extra
10033101|NCT01784302|Active Comparator|Multivitamin|Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet
10033102|NCT01784302|Active Comparator|Sodium bicarbonate|Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate
10033103|NCT01784315||Chloroquine, primaquine and ACT|"Standard dose of Chloroquine( 10mg/kg on day 0 and 5mg/kg on day1 and day2) and Primaquine(0.25mg/kg for 14 days).~Artemisinin combination therapies (ACT) of 4 tablets on 0,8,24,36,48 and 60 hours will be used for Chloroquine resistant P.vivax infection"
9471742|NCT03616301|Active Comparator|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
9471743|NCT03616288|Placebo Comparator|Negative Control|placebo; 0 mg thiamine
10033104|NCT01784328|Other|Use of a bowel irrigation system|Open label. No placebo use in this study. All volunteers will trial the bowel irrigation system. Eligible volunteers will be those patients who have failed conventional supportive bowel care.
10033105|NCT01784354|Placebo Comparator|Education|target education toward Raynaud's
9471744|NCT03616288|Experimental|EAR Group|1.2 mg thiamine as thiamine hydrochloride
9471745|NCT03616288|Experimental|Double EAR Group|2.4 mg thiamine as thiamine hydrochloride
9471746|NCT03616288|Experimental|Positive Control|10 mg thiamine as thiamine hydrochloride
9471747|NCT03616275|Experimental|HRV biofeedback group|8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education
9471748|NCT03616275|No Intervention|control group|1 session of healthy lifestyle education
9471749|NCT03616262|Active Comparator|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
9471750|NCT03616262|Active Comparator|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
9471751|NCT03616249|Experimental|Sleep quality|To compare if elderly sartcopics present sleep losses at higher levels than non-sarcopenic elderly
9471752|NCT03616249|Experimental|sleep-wake cycle.|To compare if elderly sarcopenics present sleep-wake cycle. disorders at higher levels than non-sarcopenic elderly
9471753|NCT03616249|Active Comparator|Exercise And Sleep quality|Comparing resistance training in the sarcopenician elderly showed improvements in sleep patterns.
9471754|NCT03616249|Active Comparator|Exercise And sleep-wake cycle.|Comparing resistance training in the elderly with sarcopenia presents better sleep-wake cycle.
9471755|NCT03616236|Active Comparator|TAU|Participants will receive a referral to buprenorphine treatment in the community.
9471756|NCT03616236|Experimental|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
9471757|NCT03616210|Experimental|Protective ventilation|Protective ventilation strategy (tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O)
9471758|NCT03616210|No Intervention|Conventional ventilation|Conventional mechanical ventilation (tidal volume between 9 to 10 ml.kg-1 of predicted body weight and PEEP between 3 and 5 cmH2O)
9471759|NCT03616197|Active Comparator|Group 1|"Thin Biotype group has described as Group 1. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thin biotype, the patient was assigned to the thin biotype group."
9471760|NCT03616197|Active Comparator|Group 2|"Thick biotype group has described as Group 2. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thick biotype, the patient was assigned to the thick biotype group."
9471761|NCT03616184|Experimental|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
9471762|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
9471763|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
9471764|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
9471765|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
9480937|NCT05167656|Experimental|Intraoral Manual Therapy plus exercise and education.|Six sessions of intraoral manual therapy plus exercise and counselling.
9480938|NCT05167656|Experimental|Extraoral Manual Therapy plus exercise and education.|Six sessions of extraoral manual therapy plus exercise and counselling.
9471766|NCT03616145|Experimental|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
10033106|NCT01784354|Active Comparator|Acupressure|acupressure- dilatation
9471767|NCT03616145|Sham Comparator|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
9471768|NCT03616145|No Intervention|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
9471769|NCT03616132|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions.
10033107|NCT01784354|Active Comparator|Acupressure relaxation|acupressure relaxation protocol
9471770|NCT03616093|Experimental|Test Beet shot|Active supplement containing 6.2 mmol nitrate
10033108|NCT01784367|Experimental|ECLA-group|Treatment with a pump driven, venovenous extracorporeal lung assist
10033109|NCT01784380||the case group|
10033110|NCT01784380||the control group|
9471771|NCT03616093|Placebo Comparator|Placebo beverage|Placebo supplement containing negligible nitrate
9471772|NCT03616080|Experimental|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
9471773|NCT03616080|No Intervention|control|children without soccer paly program usual activity and therapy
9471774|NCT03616067|Experimental|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
9471775|NCT03616067|Active Comparator|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
9471776|NCT03616015|Experimental|Patient|"For all patients included in the study, the following interventions will be performed :~several blood samples (quantity collected requiring classification of this study as interventional according to French law)~several fecal samples~anxiety tests~stress tests"
9471777|NCT03616002|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
9471778|NCT03615989|Placebo Comparator|Exercise and Carbohydrate (CHO)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, 50g of carbohydrate (maltodextrin) + water was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 50g of carbohydrate was consumed with water 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
9480939|NCT05167656|Active Comparator|Exercise and education.|Exercise and counselling alone without any manual therapy treatment.
9803143|NCT04507711|Experimental|0 ng/ml|Blood specimen which was added of 0 ul of palonosetron
9803144|NCT04507711|Experimental|25 ng/ml|Blood specimen which was added of 1 ul of palonosetron
10033111|NCT01784380||the treatment group|Patients of the treatment group recieved drugs,then we observed drugs' treatment effect.
10033112|NCT01784406|Experimental|Autonomy-supportive counselling|"2-4 autonomy-supportive conversations with an experienced nurse, educated both theoretically and practically in the method Guided Self-Determination that includes specific reflection sheets and use of advanced communication; in addition to standard care."
10033113|NCT01784406|No Intervention|Control|Standard of care.
10033114|NCT01784432|Active Comparator|Low-level laser therapy and training|Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
10033115|NCT01784432|Active Comparator|Training without low-level laser therapy|Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
10033116|NCT01784445|Experimental|Ceftazidime plus placebo|Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo
10033117|NCT01784445|Active Comparator|Diclophenac sodium plus placebo|Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo
9471779|NCT03615989|Experimental|Exercise and Milk (Milk)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, ~500 ml of skim milk was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 500 ml of skim milk was consumed 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
9471780|NCT03615963||normal|patient complains of anginal chest pain but coronary angiography is normal
9471781|NCT03615963||coronary artery disease|patient complains of chest pain with coronary angiography showing atherosclerotic plaques causing luminal obstruction
9471782|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
9471783|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
9471784|NCT03615937|Experimental|Comprehensive Intervention|"This is a holistic package of interventions, including:~Child interactive intervention (dialogic reading and play intervention)~Family Empowerment (positive parenting and grandparenting)~Access to Community Hub and its services~Enhancement to the kindergartens~Health education, screening, and support"
10033118|NCT01784458||intra-abdominal hypertension(IAH)|IAH group : patients developing IAH non-IAH group : patients without IAH
10033119|NCT01784471|Experimental|Magic foot shoe|Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
10033120|NCT01784484||patients with abnormal liver enzymnes|
10033121|NCT01784497||Recipients of Living Donor Liver Transplantation|Patients who will undergo Living Donor Liver Transplantation (LDLT) In Ain Shams Center For Organ Transplantation (ASCOT) .
10033122|NCT01784510|Active Comparator|2 cm|
10033123|NCT01784510|Experimental|6 cm|
10033124|NCT01784536|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
10033125|NCT01784549|Active Comparator|Cisplatin Docetaxel|- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles
10033126|NCT01784549|Experimental|Gefitinib Pemetrexed Vinorelbine Gemcitabine|"Gefitinib day for 8 wks;~Pemetrexed day 1 q 21 days for 3 cycles;~Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;~Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;~Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;~Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;"
10033127|NCT01784575|Experimental|Patient Navigator Intervention|The Patient Navigator Intervention arm will have two 20 minute interactive sessions with a patient navigator in which they will learn about quality measures and view scores on the Massachusetts Health Quality Partner's website.
10033128|NCT01784575|Active Comparator|Control|The control arm will receive an information pamphlet about health care quality.
10033129|NCT01784601||Control Group|We will be including all patients undergoing shoulder surgery not scheduled for a nerve block.
10033130|NCT01784601||Study Group|We will be including all patients undergoing shoulder surgery scheduled for a nerve block.
10033131|NCT01784627|No Intervention|Treatment at Usual|Participants in this group will receive treatment as usual (TAU) from their provider, which may or may not include screening and brief advice regarding alcohol use.
10033132|NCT01784627|Experimental|c-ASBI|Participants in this group will receive the computerized alcohol screening and brief intervention (c-ASBI).
10033133|NCT01784640|Experimental|Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)|Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
10033134|NCT01784653|No Intervention|Treatment as Usual|Patients will receive the usual care from the treatment program
10033135|NCT01784653|Experimental|iMET|Participants will complete a self-guided computerized Motivational Enhancement Therapy
10033136|NCT01784653|Experimental|MET|Clinician-delivered Motivational Enhancement Therapy
10033137|NCT01784679||Natural History Prospective Observational Group|
10033138|NCT01784679||Online Registry Patient Reported Group|
10033139|NCT01784692|Placebo Comparator|Placebo|10 participants will be randomized to take 1 capsule of placebo daily.
10033140|NCT01784692|Experimental|Immulina 200 mg/day|10 participants will be randomized to take 200 mg/day of Immulina.
10033141|NCT01784692|Experimental|Immulina 400 mg/day|10 participants will be randomized to take 400 mg/day of Immulina.
10033142|NCT01784692|Experimental|Immulina 800 mg/day|10 participants will be randomized to take 800 mg/day of Immulina.
10033143|NCT01784705|Experimental|Transcranial bright light therapy|
10033144|NCT01784705|Placebo Comparator|Transcranial placebo treatment|
10037143|NCT01822249|Placebo Comparator|Placebo|Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight
10037144|NCT01822262|Experimental|gallbladder reservation|Patients in trial group all took minimally invasive cholecystolithotomy with gallbladder reservation
10037145|NCT01822262|Experimental|laparoscopiccholecystectomy|Patients in control group all received LC.
10037146|NCT01822275|Other|Low Dose WBRT|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
10037147|NCT01822314|Active Comparator|Paclitaxel|"Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
10037148|NCT01822314|Experimental|Abraxane|"Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
10037149|NCT01822327|Experimental|Contingent Vouchers Unmatched|CRA therapy plus Voucher incentives contingent on cocaine abstinence with monetary values set at usual monetary values across all patients.
9471785|NCT03615937|Active Comparator|Health Support|"This is a control arm with only health components.~1. Health education, screening, and support"
10037150|NCT01822327|Experimental|Contingent Vouchers, Matched|CRA therapy plus Vouchers contingent on cocaine abstinence, with more severe patients receiving twice the usual voucher monetary values.
9471786|NCT03615885|Placebo Comparator|Placebo Drink|Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.
9471787|NCT03615885|Experimental|Montmorency Tart Cherry Capsules|10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.
9471788|NCT03615885|Experimental|Montmorency Tart Cherry Juice|Single-bolus of Montmorency tart cherry juice (130 mL)
9471789|NCT03615859||Healthy volunteers|Healthy volunteers whose data represents a negative control
9471790|NCT03615859||Prednisolone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of prednisolone
9471791|NCT03615859||Hydrocortisone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of hydrocortisone
10033145|NCT01784731||Patients|
10033146|NCT01784744||ASD Control|Patients aged 5 to 17 diagnosed with ASD.
10033147|NCT01784744||ASD Case|Patients diagnosed with ASD aged 5 to 17 with a history of amelioration of symptoms during febrile episodes.
10033148|NCT01784757|Experimental|ODM-201 Tablet A|ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
10033149|NCT01784757|Experimental|ODM-201 Tablet B|ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
10033150|NCT01784783|Experimental|HOPE Intervention|"Pregnant women and their male partners will receive home-based couple HIV testing and counseling and partner education 1-2 weeks after enrollment. The intervention will include educational messages concerning socio-behavioral, condom-based, and treatment-oriented approaches to prevention of horizontal and vertical HIV transmission, based on the status of each of the partners. The couple will also be educated about the importance of facility delivery, exclusive breastfeeding, family planning, and post-partum contraception.~During the HOPE Intervention, the purpose and design of the study will be explained to male partners. Men will be asked to provide written informed consent for study participation. Provided they consent, men will complete a questionnaire asking for sociodemographic characteristics, medical and sexual history, behavioral data and information on prior HIV testing and counseling."
10033151|NCT01784783|Experimental|INVITE Intervention|Pregnant women will be tested and encouraged to bring their male partners to the antenatal clinic for testing. Women will receive a clinic invitation to give to their male partners to attend the next visit for couple HIV counseling and testing. The couples will also be offered the relevant components of the intervention at the final study visit, 6 months postpartum.
10033152|NCT01784809|Experimental|Multimedia HIV/STI prevention|Multimedia WORTH is a 4-session group based gender specific HIV and drug abuse prevention intervention.
10033153|NCT01784809|Active Comparator|Traditional HIV/STI prevention|Traditional WORTH is a 4-session group-based HIV/STI and drug abuse prevention intervention that covers the same content as Multimedia WORTH without the use of interactive videos, computerized assessments, and other audiovisual tools.
10033154|NCT01784809|Placebo Comparator|Wellness Promotion|Wellness Promotion is a 4-session group based intervention that aims to improve diet, physical fitness and well-being which is designed as an attentional control condition.
10033155|NCT01784822||Zenapro™ Hybrid Hernia Repair Device|Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias.
9471792|NCT03615859||New adrenal insufficiency group|Participants who have recently been given a new diagnosis of adrenal insufficiency
9471793|NCT03615859||High dose steroids groups|Participants who are treated with high dose steroids for management of any medical condition to serve as a positive control
9471794|NCT03615846||Dual Anti-Platelet Therapy (DAPT)|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
9471795|NCT03615846||One Anti Platelet Medication Only|"Whole blood from patients who are currently receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
9471796|NCT03615846||naive|No medication with anti-platelet effects There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care.
9471797|NCT03615833|Experimental|Patients with Vitamin D deficiency|Patients with Vitamin D deficiency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
9803145|NCT04507711|Experimental|250 ng/ml|Blood specimen which was added of 10 ul of palonosetron
10033156|NCT01784835|Other|control|patients under standard medical care
10033157|NCT01784835|Experimental|OMT|patients under usual medical care plus osteopathic treatment
10033158|NCT01784887|Active Comparator|Bioelectric Dressing|SOC + Bioelectric Dressing
10033159|NCT01784887|No Intervention|SOC|Standard of Care
10033160|NCT01784900|Experimental|Schema B (140µg)|"D0 : 20 μg of catumaxomab~D2 : 40 μg~D4 : 80 μg"
10033161|NCT01784900|Experimental|Schema A (100µg)|"D0 : 10 μg of catumaxomab~D2 : 30 μg~D4 : 60 μg"
10033162|NCT01784913|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.
10033163|NCT01784939||HEPFER cohort|"male, aged 18 and over, hereditary hemochromatosis C282Y homozygous diagnosed and followed in the service of Liver Diseases, University Hospital of Rennes~- Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the basis of at least four previous plasma ferritin < 50μg / L"
10033164|NCT01784952|Experimental|Whole grains and lequmes|
10033165|NCT01784952|Placebo Comparator|refined rice|
10037151|NCT01822327|Active Comparator|Non-Contingent Vouchers control|CRA therapy plus Vouchers earned independent of drug use
10037152|NCT01822340|Experimental|Cohort 1|Once weekly HM10560A
9471798|NCT03615820|Experimental|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films
9471799|NCT03615820|Placebo Comparator|Oromucoadhesive film|Oromucoadhesive film that has no niosomal PPE in its content
9471800|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
9471801|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
9471802|NCT03615781|Experimental|Two week's arm - surgery|The investigators perform a surgical drainage and removal of the infected orthopedic implant.
10033166|NCT01784978|Experimental|Rotational arm|Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
10033167|NCT01784978|Active Comparator|Sequential arm|The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.
10033168|NCT01785004|Active Comparator|Vitamin D + fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
10033169|NCT01785004|Active Comparator|Vitamin D + fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
9471803|NCT03615781|Active Comparator|Four week's arm - surgery|The investigators surgically remove the infected implant.
9471804|NCT03615781|Experimental|Two week's arm - drugs|The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
9471805|NCT03615781|Active Comparator|Four week's arm - drugs|The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).
9471806|NCT03615768|Experimental|Adapalene-Clindamycin Combination Gel|
9471807|NCT03615768|Active Comparator|Adapalene Gel|
9471808|NCT03615768|Active Comparator|Clindamycin Gel|
9471809|NCT03615755|No Intervention|Standard Therapy|Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)
9471810|NCT03615755|Active Comparator|Combination Therapy|Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)
9471811|NCT03615729||Rheumatoid arthritis patients|A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
9471812|NCT03615729||controls|A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers
9471813|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
9471814|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
9471815|NCT03615677|Experimental|LXI-15028 50mg group (n=130)|
9471816|NCT03615677|Active Comparator|Esomeprazole 40mg group (n=130)|
9471817|NCT03615651|Placebo Comparator|Placebo|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
9471818|NCT03615651|Experimental|Probiotic|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
9471819|NCT03615638|Experimental|Fall prevention group|Fall prevention program
9471820|NCT03615638|No Intervention|Usual care group|Usual postoperative care
10033170|NCT01785004|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
9471821|NCT03615638|No Intervention|Asymptomatic control|No intervention
9471822|NCT03615625|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 40 min
9471823|NCT03615625|Experimental|Power Training Session|The power training session lasted 40 min, in which the participants performed a resistance exercise session using high velocity contractions during the exercises characterizing a power training session
9471824|NCT03615612|Other|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
9471825|NCT03615612|Other|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
9471826|NCT03615586|Active Comparator|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone. The intervention consists of the presence of a female chaperone.
9471827|NCT03615586|Active Comparator|Without Chaperone|Female patients examined by male physicians without a chaperone. The intervention is the absence of a female chaperone.
9471828|NCT03615560||Preeclampsia (mild)|
9471829|NCT03615560||Preeclampsia (severe)|
9471830|NCT03615560||Gestational hypertension|
9471831|NCT03615560||Control group|
9471832|NCT03615547|Experimental|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
9471833|NCT03615547|Experimental|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
10033171|NCT01785004|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
10033172|NCT01785017||Chidren with critical asthma|Pre- and post-SCAMP
10033173|NCT01785030|Experimental|50% Nitrous oxide|
10033174|NCT01785043|Experimental|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day. The starting dose will be 0.6 mg. After one week, the dose will be increased to 1.2 mg, and then it will be increased to 1.8 mg one week later to achieve better control of blood glucose. When Liraglutide is added to existing treatment containing metformin, as it is our scenario, the dose of metformin does not have to be changed.
10033175|NCT01785043|Active Comparator|Sitagliptin|"Sitagliptin will be administered once daily at a 100 mg dose. When Sitagliptin is used in combination with metformin, as it is our scenario, the dose of metformin should be maintained. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.~Sitagliptin will be used daily during the study period of 12 weeks."
10033176|NCT01785056|Experimental|Privigen|Privigen is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Subjects will be given 2 g/kg/month of IVIGfor 6 months. Each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
10033177|NCT01785056|Placebo Comparator|Placebo (Albuminar-5)|Albuminar-5 is a sterile solution of albumin obtained from large pools of adult human venous plasma and used as the placebo in this study. Albuminar-5 will be administered by the intravenous route and each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
10033178|NCT01785082|Experimental|LiMAx-group|Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of >150 µg/kg/h would correspond to a general ward indication.
9471834|NCT03615495||Flourish device|The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients.
9471835|NCT03615469|Active Comparator|Neuromusclar electrical stimulation|"NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time."
9471836|NCT03615469|Sham Comparator|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation
9471837|NCT03615456|Active Comparator|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
9471838|NCT03615456|Active Comparator|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
9471839|NCT03615443||Treatment-naive metastatic non-squamous NSCLC|
9471840|NCT03615430|Placebo Comparator|Control group|saline control group, 15 mL of the saline was administered to superficial and deep surface of serratus anterior in Control group via ultrasound before the surgery
9471841|NCT03615430|Experimental|SPB group|Serratus plane block group, 15ml of 0.25% ropivacaine, a widely used local anesthetic for peripheral nerve block, was administered to superficial and deep surface of serratus anterior in SPB group via ultrasound before the surgery
9471842|NCT03615417|Experimental|HFNC - High Flow Nasal Cannula|Participants are preoxygenated by High Flow Nasal Cannula (HFNC) OptiFlow.
9471843|NCT03615417|Active Comparator|FM - FaceMask|Participants are preoxygenated by standard anesthesia FaceMask.
9471844|NCT03615378|Placebo Comparator|Placebo|
9471845|NCT03615378|Active Comparator|Vitamin D 1000 IU D3 daily|
9471846|NCT03615378|Active Comparator|Vitamin D 5000 IU D3 daily|
9471847|NCT03615365||Patients with moderate-to-severe COPD.|"Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria.~Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry."
9471848|NCT03615352|Experimental|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
9471849|NCT03615352|Experimental|ovarian cyst aspiration and coagulation|laparoscopic ovarian endometrioma aspiration and coagulation
9471850|NCT03615339|Experimental|Molkosan|"Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning & evening).~Total duration was 6 weeks."
10033179|NCT01785082|No Intervention|control group|Control group without intervention. Post-surgical management as defined prior to surgery following well-established clinical standards.
10033180|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450~Ibuprofen, 400 mg/day, from Day 1 to Day 90"
10037153|NCT01822340|Experimental|Cohort 2|Once weekly HM10560A
10037154|NCT01822340|Experimental|Cohort 3|Once weekly HM10560A
9471851|NCT03615326|Experimental|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
9471852|NCT03615326|Active Comparator|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
9517191|NCT03308552|Placebo Comparator|SIB-IMRT Alone followed by chemotherapy|SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
10033181|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg and Vitamin D|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
9471853|NCT03615313|Experimental|PD-1 antibody expressing mesoCAR-T cells|Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (±3days).
9471854|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
9471855|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
10033182|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D|"GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
9471856|NCT03615287||Group A|40 subjects undergoing Medical Treatment
9471857|NCT03615287||Group B|40 subjects undergoing Surgical Treatment
9471858|NCT03615287||Group C|40 control subjects
10033183|NCT01785108|Placebo Comparator|Placebo|
10033184|NCT01785121|Active Comparator|Control Group|Patients who are randomized to the MSO group will get a protocoled exercise advice from a member of the HF team (nurse, cardiologist or physiotherapist). During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their current activity.
10033185|NCT01785121|Experimental|Wii Group|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
10033186|NCT01785147|Experimental|BP1.4979 3mg|BP1.4979 3mg during 3 months
10033187|NCT01785147|Experimental|BP1.4979 10mg|BP1.4979 10mg during 3 months
10033188|NCT01785147|Experimental|BP1.4979 15mg|BP1.4979 15mg during 3 months
10033189|NCT01785147|Placebo Comparator|Placebo|Placebo during 3 months
10033190|NCT01785173|Experimental|Endoscopic-guided gauze pledgetting|All patients in the study group receive endoscopic-guided gauze pledgetting (EGGP) nasal anesthesia. Each patient will receive an anterior rhinoscopy to select the most patent meatus for gauze pledegetting by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up the acute angle between the shorter leg and hypotenuse of a right-angled gauze strip (already soaked with anesthesia/decongestant) and retract back just into the biopsy channel. When the transnasal endoscope tip is set in the nasal vestibule, the preloaded biopsy forceps is protruded slowly into the desired meatus under endoscope monitoring. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
9471859|NCT03615274|Experimental|Experimental|Children in the training group must complete home-based executive function training by iPad. At the same time, they are asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
9471860|NCT03615274|Active Comparator|Placebo non-adaptive training|Children in the control group must complete cognitive control tasks. They are also asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
9471861|NCT03615261|Experimental|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
9471862|NCT03615209|Active Comparator|Transauricular vagus nerve stimulation|Non invasive vagus nerve stimulation will be conducted with Cerbomed NEMOS via the left ear.
9471863|NCT03615209|Sham Comparator|Transauricular sham stimulation|Non invasive sham stimulation will be conducted with Cerbomed NEMOS via the left ear lobe.
9471864|NCT03615196|Experimental|USB005 0.03%|USB005 (aclerastide) Ophthalmic Solution 0.03%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
9471865|NCT03615196|Experimental|USB005 0.1%|USB005 (aclerastide) Ophthalmic Solution 0.1%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
9471866|NCT03615196|Experimental|USB005 0.3%|USB005 (aclerastide) Ophthalmic Solution 0.3%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
9471867|NCT03615196|Experimental|USB005 0.45%|USB005 (aclerastide) Ophthalmic Solution 0.45%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
9471868|NCT03615196|Placebo Comparator|USB005 Placebo|USB005 Ophthalmic Solution Placebo; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
10033191|NCT01785173|Active Comparator|Cotton-tipped applicator pledgetting|"Another randomized group of patients will receive cotton-tipped applicator gauze pledgetting (CTGP) method of nasal anesthesia. Two cotton-tippled applicators help determine the following: (a) right or left side, (b) inferior or middle nasal meatus (INM or MNM) and (c) the need of local epinephrine. The investigators apply gently in parallel two sterile 3 x 1/10, double-ended, plastic shaft cotton-tipped applicators, pretreated with minimal amount of 2% viscous lidocaine plus 4% liquid lidocaine, to lubricate and anesthetize the more patent meatus One cotton-tipped applicator is re-used to deliver a triangular gauze strip to the selected meatus during the gauze pledgetting procedure."
10033192|NCT01785199|Placebo Comparator|normal (AHI < 5)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
10033193|NCT01785199|Active Comparator|mild OSA (AHI between 5 and 15)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
10033194|NCT01785199|Active Comparator|moderate OSA (AHI between 15 and 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
10033195|NCT01785199|Active Comparator|severe OSA (AHI > 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
10033196|NCT01785212|Other|Stapler-hepatectomy|The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
9471869|NCT03615157|Experimental|Home-based exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with walking at 60-70% of heart rate reserve monitored by a heart rate monitor (30 minutes/session for 5 days/week) and peripheral muscle training including upper and lower limbs (50% of the 1-maximum repetition test)
9471870|NCT03615157|Active Comparator|Supervised exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with sessions (3 days/week) supervised by a physiotherapist, including cycling at 60-70% of heart rate reserve and peripheral muscle training of upper and lower limbs (50% of the 1-maximum repetition test)
9471871|NCT03615131||MRI-TRUS fusion prostate biopsy|Single Arm Study, MRI and Prostate-Biopsy on same patient, individual patient acts as own control for intervention
9471872|NCT03615118|Experimental|Intervention|Patients randomized to the intervention group will receive the AniMóvil intervention, including: the Sentirse Mejor manual that patients can refer to for information about CBT and skill practice, weekly IVR depression symptom assessments and psychoeducational messages, daily SMS mood monitoring and CBT reinforcement messages, and CHW telephone CBT sessions in the event of elevated PHQ-9 scores during the study. CHWs will use information from patients' IVR/SMS monitoring to support intervention-group patients' depression self-management under close supervision from their mental health specialist supervisor. Intervention patients will be part of a 'stepped' intervention based on the severity of their depression upon entry into the program and assessment throughout the intervention.
9471873|NCT03615118|Active Comparator|Enhanced Usual Care|Enhanced usual care patients will receive usual care, including the Sentirse Mejor manual developed by the research team in conjunction with local Ministries of Mental Health and tailored by the study team, emphasizing CBT principles, and daily SMS messages asking participants to report their mood on a 1 to 9 scale. Enhanced usual care group patients who report mood scores of 1 or 2 (worst scores) for at least 3 days per week and 3 consecutive weeks will be called by the Community health worker and referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression. Enhanced usual care patients will be part of a 'stepped' program based on the severity of their depression upon entry into the program and assessment throughout the intervention.
9471874|NCT03615092|Active Comparator|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
9471875|NCT03615092|Placebo Comparator|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
9471876|NCT03615053|Other|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
9471877|NCT03615040|Experimental|Anti-ST2|Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
9471878|NCT03615040|Placebo Comparator|Placebo|Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
9471879|NCT03615027|Experimental|Intervention|see detailed description
9471880|NCT03615014|Other|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
9471881|NCT03614988|Active Comparator|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
9471882|NCT03614988|Experimental|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
9471883|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
9471884|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:~occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein~tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery~abutment or encasement of the celiac axis~involvement of lymph nodes outside the area of resection"
9471885|NCT03614897|Experimental|Education|Providers participating in education related to guidelines for treating patients at risk of falling
9471886|NCT03614884|Experimental|Gambling and Smoking Treatment|Participants in this arm will be given access to the online integrated treatment for gambling and smoking.
10033197|NCT01785212|Other|CUSA-hepatectomy|The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
10033198|NCT01785225|Experimental|modified commercial drape Tegaderm (R)|
10033199|NCT01785238|Experimental|cases with neonatal acute renal failure in preterm|
10033200|NCT01785238|Other|controls without neonatal acute renal failure in preterm|
10033201|NCT01785251|Experimental|NMES|Application of neuromuscular electrical stimulation to the calf muscles of the patient in order to elicit contraction of the calf muscle pump and thus, eject venous blood proximally.
10037155|NCT01822340|Experimental|Cohort 4|Biweekly HM10560A
10037156|NCT01822340|Active Comparator|Cohort 5|Once daily Genotropin
9471887|NCT03614884|Active Comparator|Gambling Only Treatment|Participants in this arm will be given access to the online gambling only treatment.
9471888|NCT03614871||No arms|There are no interventions
9471889|NCT03614858|Experimental|Cohort 1|Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
9471890|NCT03614845|Active Comparator|VCV-Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography. after induction of anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode.
9471891|NCT03614845|Active Comparator|PCV-VG- Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography.after induction of anesthesia patients will be supported by mechanical ventilation on pressure controlled volume guaranteed mode
9471892|NCT03614832|Experimental|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
9471893|NCT03614832|Active Comparator|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
9471894|NCT03614819|Experimental|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
9471895|NCT03614819|Active Comparator|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
9471896|NCT03614806|Experimental|Patients tested for hyperventilation|Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
9471897|NCT03614793|Active Comparator|Cooled Radiofrequency Ablation Procedure|
9471898|NCT03614793|Active Comparator|Facet Joint Inject Procedure|
9471899|NCT03614780|Experimental|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
9471900|NCT03614767||Successes|Patients with >50% improvement during test procedure of sacral neuromodulation.
9471901|NCT03614767||Failures|Patients with <50% improvement during test procedure of sacral neuromodulation.
9471902|NCT03614754||Successes|Patients with reduction of symptoms >50% during the test procedure for sacral neuromodulation.
9471903|NCT03614754||Failures|Patients with reduction of symptoms <50% during the test procedure for sacral neuromodulation.
9471904|NCT03614741|Active Comparator|Control group|Bolus of 4500 IU tinzaparin
9471905|NCT03614741|Active Comparator|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
9471906|NCT03614715|Experimental|CinnaGen interferon beta-1a|CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
9471907|NCT03614715|Active Comparator|Biogen interferon beta-1a|Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
9480940|NCT05165459|Experimental|Cytori Celution System in Chronic Non-Healing venous Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
10033202|NCT01785264|Active Comparator|Open surgery|Treatment is divided into three arms, and patients between 18 and 60 years of age sustaining first time achilles tendon ruptures will be invited to participate. All three groups will have identical rehabilitation protocol. Open surgical repair is done through a 10 cm longitudinal incision, through the fascia curries and the paratenon. After necessary revision of the injure site, the tendons ends is sutured with a double layer, three knot, Krakow whip suture technique. 5 to 10 degrees of overcorrection compared to the uninjured side is endeavored. The paratenon is sewn as much as possible back over the injure site and suture material. The fascia is sutured and then continuous lying mattress skin suture.
10033203|NCT01785264|Active Comparator|Non-operative treatment|Non-operative treatment starts with casting the ankle in equinus position. The rest of the treatment from there on will be identical to the two other arms: Minimal invasive and open surgery. Casting lasts for 2 weeks for all three arms.
10033204|NCT01785264|Active Comparator|Mini-invasive surgery|Patients allocated to mini-invasive treatment will (as patients treated with open surgery) be operated within 7 days from injury with the technique developed by Dr Amlang and Prof Zwipp in Dresden. Patients in all three arms will have an active, early weight bearing rehabilitation protocol.
10033205|NCT01785277||SCIM scores for patients with SCI|All patients with SCI included in the study
10033206|NCT01785290|Experimental|Haloperidol 1mg/q8h|Prophylactic haloperidol of 1 mg/q8h i.v.
9471908|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
9471909|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
9471910|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
9471911|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
9471912|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
9471913|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
9471914|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
9471915|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
10033207|NCT01785290|Experimental|Haloperidol 2mg/q8h|Prophylactic haloperidol 2mg/q8h i.v.
10033208|NCT01785290|Placebo Comparator|Sodium chloride 0.9%|Placebo (Sodium chloride 0.9%) three times a day
10033209|NCT01785303|Active Comparator|Model A|Model A consists of a 4 session CBT-I in phase I and CPAP for OSA in Phase II.
9471916|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
9471917|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
10033210|NCT01785303|Active Comparator|Model B|Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
9471918|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
10033211|NCT01785303|Other|Model C|Model C consists of 4 weeks of monitoring with sleep diaries in Phase I. Phase II consists of CPAP for OSA.
10033212|NCT01785316|Experimental|IHP|Isolated Hepatic Perfusion
10033213|NCT01785316|No Intervention|BAC|Best alternative care
9471919|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
10033214|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose A|"alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.~alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
10033215|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose B|alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.
9471920|NCT03614676|Other|Pregnant Women/Mothers Group|Subjects, 18 to 45 years of age and with pre-pregnancy body mass index (BMI) ≥18.5 and ≤ 39.9 kg/m2 enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract illness (LRTI) associated with respiratory syncytial virus (RSV). Collection of maternal blood samples and cord blood samples at delivery are planned for determination of antibody titers.
9471921|NCT03614676|Other|Neonates/Infants Group|Infants born to mothers aged 18-40 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization
10033216|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose C|alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.
10033217|NCT01785355||Dental treatment|Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
10033218|NCT01785368|Other|Before guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period BEFORE the implementation of the referral guidelines.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Baseline observation"
9471922|NCT03614663|Experimental|ZYN002 - CBD transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg CBD Q12H or placebo.~Patients weighing greater than 35 kg will be randomized to receive 250 mg CBD Q12H or placebo."
9471923|NCT03614663|Placebo Comparator|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
10033219|NCT01785368|Other|After guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period AFTER the implementation of the referral guideline.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Implementation of guidelines"
10033220|NCT01785381|No Intervention|usual care|usual care
10033221|NCT01785381|Other|Added value of coordinator|Added value of coordinator
10033222|NCT01785394|Active Comparator|5 grass allergen extract|30 patients will receive the active component 5 grass allergen extract daily during the active pollen season (February-July)
9471924|NCT03614650|Experimental|EIE cells to treat cancer|EIE cells to treat cancer
9471925|NCT03614637||Cannabis User Group|Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
10033223|NCT01785394|Placebo Comparator|Placebo|30 patients will receive placebo
10033224|NCT01785407|Active Comparator|80 mg FeSO4|
10033225|NCT01785407|Active Comparator|40 mg FeSO4|40 mg FeSO4
9471926|NCT03614637||Non-Cannabis User Group|Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
9471927|NCT03614624|Experimental|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
9471928|NCT03614598|Active Comparator|LMA-UNIQUE™|
9471929|NCT03614598|Active Comparator|LMA-SUPREME™|
10033226|NCT01785407|Active Comparator|160 mg FeSO4|
10033227|NCT01785407|Active Comparator|240 mg FeSO4|
10033228|NCT01785446|Active Comparator|P 1|"In this group patients were aged from 20 to 45. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
10033229|NCT01785446|Active Comparator|P 2|"In this group patients were aged from 46 to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
9471930|NCT03614598|Active Comparator|I-GEL®|
10033230|NCT01785446|Active Comparator|P 3|"In this group patients were aged from 66 to 85. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
10033231|NCT01785446|Active Comparator|D|"In this group patients were aged from 46to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Dexmedetomidine infusion is started at induction,a bolus dose of 0.5 µg/kg is given over the first hour which is followed by infusion of 0.4 µg/kg/hr.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
10033232|NCT01785485||Primary care patients|Primary care patients who are members of UAIHC.
9803146|NCT04507711|Experimental|2500 ng/ml|Blood specimen which was added of 100 ul of palonosetron
10033233|NCT01785498|No Intervention|Control Group|Receive standard clinical care and supports.
10033234|NCT01785498|Experimental|Supplementary resources|Receive standard care and supports plus supplementary resources developed for the intervention.
10033235|NCT01785511|Sham Comparator|Sham UVA|sham exposure will be provided by covering the UVA lamps with space blanket.
9471931|NCT03614585|Experimental|High-intensity interval training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The protocol will involve 10 60-second intervals of high intensity interspersed with 9 60-second low-intensity intervals. The initial high intensity intervals will start at 80% of the HRR (RPE=14-17) and progress by 10% every 4 weeks. Low intensity intervals will be performed at 30% of HRR (RPE=9-11). Three-minute warm-up and 2-minute cool-down periods will be performed at 30% of HRR. Total HIIT time including warm-up and cool-down is 24 minutes.
9471932|NCT03614585|Experimental|Moderate-intensity continuous training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The MICT protocol will be increased using a progression schedule previously used (initial intensity at 40% HRR (RPE=9-11), and progressed by 10% HRR every 4 weeks up to 60% HRR (RPE=13-14) will be maintained until the end of the intervention). A 3-minute warm-up and 2-minute cool-down will be performed at 30% HRR (RPE=9-11). The total duration of MICT, including warm-up and cool-down, will be 35 minutes.
9471933|NCT03614559||CTO PCI group and non CTO PCI group|CTO PCI group： Succession of CTO revascularization non CTO PCI group： Failure or not tried to revascularization
9471934|NCT03614559||Initially attempted and re-attempted|PCI initially attempted group： First time to try to revascularization PCI re-attempted group: Second or more time to try to revascularization
9471935|NCT03614559||PCI during China Club or not|PCI during Chronic Total Occlusion Club， China Club : CAG in 2016.11.04 Another group: CAG in other time
10033236|NCT01785511|Experimental|UVA Radiation|Patients will be exposed to UVA radiation for 20 minutes
10033237|NCT01785537||E-cigarettes only|Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes
10033238|NCT01785537||Traditional cigarettes only|Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers.
10033239|NCT01785537||Mixed group|Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up
10033240|NCT01785550||Control Group|No intervention to be performed.
9471936|NCT03614559||Morning，Afternoon，Night|Morning group:（8:00-12:59） Afternoon group：（13:00-17:59） Night group：（after 18:00）
9471937|NCT03614546|Other|A（surgery） group|Hepatectomy
9471938|NCT03614546|Experimental|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
9471939|NCT03614546|Experimental|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
9471940|NCT03614546|Experimental|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
9471941|NCT03614546|Experimental|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
9471942|NCT03614546|Experimental|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
9471943|NCT03614546|Experimental|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
9471944|NCT03614533|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
9471945|NCT03614533|Active Comparator|Inactivated Poliovirus Vaccine (IPV)|Children will receive a single 0.5-ml dose of Inactivated Poliovirus Vaccine (IPV) by the intramuscular route.
9471946|NCT03614520|Experimental|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
9471947|NCT03614520|Experimental|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
9471948|NCT03614507|Experimental|FreeO2 group|Automatic oxygen flow titration
9471949|NCT03614507|Active Comparator|Manual group|Manual oxygen flow titration
10033241|NCT01785550||Ultrasound Group|All will receive nerve and muscle ultrasound.
10033242|NCT01785563|Experimental|Nasal NIV-NAVA|Infants will be transitioned from their current mode of ventilation to nasal NIV-NAVA. If patients are currently on nasal NIV-NAVA an increase in the NAVA level will be utilized for the intervention.
9471950|NCT03614494|Active Comparator|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
9471951|NCT03614494|Placebo Comparator|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
9517192|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
10033243|NCT01785576|Experimental|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
10033244|NCT01785576|No Intervention|Treatment as Usual|The treatment as usual group will complete all assessements and will not receive the psychosocial couple based intervention.
10037157|NCT01822379|Experimental|Cell transplantation|All patients will undergo transplantation of two distinct vitiligo lesions. One lesion will receive cells prepared with trypsin. The other lesion will receive cells prepared with dispase.
10037158|NCT01822392|Active Comparator|Online treatment, High therapist contact|Participants receive online Parent Management Training (interactive).
9471952|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
9471953|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
9471954|NCT03614468|Experimental|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age.
9471955|NCT03614468|Active Comparator|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
9471956|NCT03614455|Experimental|Milademetan alone (A)|During Period 1, participants receive a single 100 mg milademetan oral dose on Study Day 1, with PK sampling to 168 hours post-dose (during the following 7-day washout period)
9471957|NCT03614455|Other|Milademetan with itraconazole (AB)|During Period 2, participants receive itraconazole, 200 mg twice daily (BID) on Study day 8 and 200 mg once daily (QD) on Study Days 9 through 20, along with a single 100 mg milademetan dose on Day 14
9471958|NCT03614455|Other|Milademetan with posaconazole (AC)|During Period 2, participants receive 200 mg posaconazole three times daily (TID) on Study Days 8 through 20, along with a single 100 mg milademetan dose on Day 14
9471959|NCT03614442|Experimental|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
9471960|NCT03614442|Active Comparator|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
9471961|NCT03614429|No Intervention|Control|"Group 1: control group, n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
9471962|NCT03614429|Experimental|Ch group|"Group 2: Chlorhexidine group (Ch group), n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
9471963|NCT03614403|Experimental|Vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
9471964|NCT03614403|No Intervention|control|Control patients will not be received any intervention
9471965|NCT03614390|Other|MBCT group|"There is only 1 arm in the study.~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
9471966|NCT03614377||Patients with low burden of sleep-disordered breathing|
9471967|NCT03614377||Patients with high burden of sleep-disordered breathing|
10033245|NCT01785589|Other|coronary angiography-FFR-CZT|Patients who were referred to our cardiology department for stress-rest CZT SPECT for known or suspected CAD and submitted for a clinical reason to invasive coronary angiography within 2 month of the SPECT studies. for these patients, A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
10033246|NCT01785641|Experimental|ceftazidime+ciprofloxacin|2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
10033247|NCT01785641|Active Comparator|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
10033248|NCT01785641|Experimental|cefazolin+gentamicin|cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
10033249|NCT01785641|Active Comparator|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
10033250|NCT01785654||reventilation collapse|
9471968|NCT03614351|Experimental|Physical Therapy plus Protein Supplement|Participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
9471969|NCT03614351|Active Comparator|Physical Therapy Control|Participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
9471970|NCT03614338|Experimental|Core Participants Weight Loss Program|Small changes weight loss program
9471971|NCT03614325|Experimental|Virtual Reality Immersive Relaxation|"Patients in the experimental group will wear a headset and be immersed in a virtual reality environment during their surgery. There are various short videos and environments such as sitting on a beach that are designed to promote relaxation and calmness.~Throughout their surgery patients will be monitored according to current anesthesia standards. The relaxation programming will run for the duration of the operative procedure. At the end of the procedure the headset will be removed and standard postoperative care will commence."
9471972|NCT03614325|No Intervention|Usual Anesthesia Care|Patients in the usual care arm will undergo the current standard of care for hand/wrist surgery and postoperative recovery. They will be asked to refrain from using a virtual reality headset during their surgery.
9471973|NCT03614312||BMI 18-25 Pregnant Women|BMI 18-25 less than 36 weeks pregnant
9471974|NCT03614299||pSS cohort|Patients with pSS included in the study
9471975|NCT03614273|Active Comparator|Group 1 (HS)|Nebulized with 4 ml of 3% hypertonic saline for a duration of 20 minutes
9471976|NCT03614273|Active Comparator|Group 2 (Adr)|Nebulized with 0.1 mg/kg of adrenaline (non-racemic solution, 1:1000 concentration), which was diluted in normal saline to make it a 4 ml solution, for a duration of 20 minutes
9471977|NCT03614247|Active Comparator|RIRS|Patients underwent retrograde intrarenal surgery for lower calyceal stone between 1cm and 2cm in size
9471978|NCT03614247|Active Comparator|Micro-PNL|Patients underwent micro percutaneous nephrolithotomy (tract size <10 F) for lower calyceal stone between 1cm and 2cm in size
9471979|NCT03614247|Active Comparator|Ultramini-PNL|Patients underwent ultra-mini percutaneous nephrolithotomy (tract size <15 F) for lower calyceal stone between 1cm and 2cm in size
9471980|NCT03614247|Active Comparator|Mini-PNL|Patients underwent mini percutaneous nephrolithotomy (tract size <20 F) for lower calyceal stone between 1cm and 2cm in size
9471981|NCT03614247|Active Comparator|Standard PNL|Patients underwent standard percutaneous nephrolithotomy (tract size >25 F) for lower calyceal stone between 1cm and 2cm in size
9471982|NCT03614221|Experimental|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
9480941|NCT05164978|Experimental|DEP combine with PD-1 antibody|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 1.5mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; sintilimab injection 200mg day 4. This regimen was repeated after 2 weeks.
10033251|NCT01785667||Young Danish adults with type 1 diabetes|This is an observational study with no interventions.
10033252|NCT01785693|Other|NaC1|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
10033253|NCT01785693|Other|Levobupivacaine + clonidine|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
10033254|NCT01785719|Experimental|Overweight Women|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
10033255|NCT01785732|Active Comparator|Renal denervation|Patients are randomized to renal denervation
10033256|NCT01785732|No Intervention|Optimization of medical therapy|Antihypertensive treatment is optimized
10033257|NCT01785745|Active Comparator|Traditional therapeutic exercise|The traditional exercise protocol contains mainly strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance.
10033258|NCT01785745|Experimental|Neurocognitive therapeutic exercise|The neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture).
10033259|NCT01785758|Experimental|Renal Group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
10033260|NCT01785758|Active Comparator|Control group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
10033261|NCT01785784|Experimental|burn patients|
10033262|NCT01785797|No Intervention|Control: burr hole drainage only|Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
10033263|NCT01785797|Experimental|Intervention: silicon subdural drain|Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.
10033264|NCT01785823|Experimental|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr
10033265|NCT01785823|Active Comparator|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the decremental rates of 6.0 ml/hr (D6-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
9471983|NCT03614221|Active Comparator|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
9471984|NCT03614208|Experimental|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
10033266|NCT01785823|Active Comparator|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at at the decremental rates of 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
10033267|NCT01785836|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
10033268|NCT01785836|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
9471985|NCT03614208|No Intervention|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
9471986|NCT03614195|Experimental|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
9471987|NCT03614195|Active Comparator|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
9471988|NCT03614195|Active Comparator|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
10033269|NCT01785836|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
10033270|NCT01785836|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
9471989|NCT03614182|Experimental|physical training concurrent with cognitive training|The physical training concurrent with cognitive training group (the P+C group) will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
9471990|NCT03614182|Active Comparator|physical training followed by cognitive training|The physical training followed by cognitive training will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
9471991|NCT03614182|Active Comparator|physical training without cognitive training|The physical training without cognitive training group will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
9471992|NCT03614169|Experimental|Direct HIS-pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS or it is not possible to correct the LBBB, a left ventricular (LV) lead is implanted instead.
9471993|NCT03614169|Active Comparator|Biventricular pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold)
9471994|NCT03614117|Active Comparator|L.salivarius PS7 6-months|Lactobacillus salivarius PS7 during 6-months; approximately 1*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
9471995|NCT03614117|Active Comparator|L. salivarius PS7 + placebo (3+3)|Lactobacillus salivarius PS7 during 3 months; approximately 1*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
9471996|NCT03614117|Placebo Comparator|Control group|Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
9471997|NCT03614104|Active Comparator|mobile health technology|Health education with mobile health technology
9471998|NCT03614104|Sham Comparator|Without mobile health technology|Health education without mobile health technology
9471999|NCT03614091|Active Comparator|Paravertebral plane block group|The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
10033271|NCT01785862|Experimental|Drug|V0498, Ibuprofen 25 mg
10033272|NCT01785862|Placebo Comparator|Placebo|Placebo
10033273|NCT01785888||Locally advanced/metastatic NSCLC pts.|Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
9472000|NCT03614091|Active Comparator|Erector spinae plane block group|the transducer will be placed in a transverse orientation to identify the spinous process, lamina,and transverse process.The tip of the transverse process will be centered on the ultrasound screen, and the transducer will be rotated 90 degrees into a longitudinal orientation to obtain a parasagittal view. Depending on the level imaged, 2 or 3 hypoechoic muscle layers were identiﬁed overlying the tip of the transverse processes. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superfacial to the transverse processes. An 8cm 22-gauge block needle will be Inserted in-plane to the ultrasound beam in a cephalad-to-caudad Direction to place the needle tip between the posterior fascia of Erector spinae and the tip of the targeted transverse process.following which a total of 20 mL of 0.5%bupivacaine will be injected.
10033274|NCT01785901||Target subject population 1500|Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China
10033275|NCT01785914||1|
10033276|NCT01785927|Other|ABCD|ABCD A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
10033277|NCT01785927|Other|BCDA|BCDA A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
9472001|NCT03614065|Placebo Comparator|arm a|This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
9472002|NCT03614065|Experimental|arm b|This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
10033278|NCT01785927|Other|CDAB|CDAB A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
10033279|NCT01785927|Other|DABC|DABC A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
9472003|NCT03614052|Experimental|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
9472004|NCT03614052|Placebo Comparator|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
9472005|NCT03614039|Active Comparator|probiotic-smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
9472006|NCT03614039|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
9472007|NCT03614026|Experimental|Teachers and Parents as Partners Intervention|Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
9472008|NCT03614026|No Intervention|Business as usual control|In the business-as-usual control condition, participants will have access to any services that a school would routinely provide (e.g., develop and implement a behavior support plan) as well as services families can access in the community (e.g., mental health support).
9472009|NCT03614013||Immunotherapy responders/non-responders|paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
9472010|NCT03614000|Experimental|positive screenings|
9472011|NCT03613987|No Intervention|NIPPV|non synchronized non invasive positive pressure ventilation
9472012|NCT03613987|Experimental|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
9480942|NCT05163665|Active Comparator|Through-the-Scope clip group|Standard-of-Care clipping equipment and technique performed in closure of GI defect area after polyp removal.
9480943|NCT05163665|Experimental|X-Tack suturing group|Use of Endoscopic Helix Tacking System (X-Tack) by Apollo Endosurgery for the closure of GI defect after polyp removal.
10033280|NCT01785940|Experimental|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
10033281|NCT01785953||1|
10033282|NCT01785966|Experimental|Daily checklist and clinician prompting|Checklist during multidisciplinary daily visits + clinician prompting + audit & feedback
10033283|NCT01785966|No Intervention|Usual care|Usual care
10033284|NCT01785979|Experimental|Prednisone induction - chloroquine|0.5 mg/Kg daily of prednisone for 4 weeks after randomization, 0.25 mg daily for weeks 5-6, 0.15 mg daily for week 7 and 2.5 mg daily for week 8 and chloroquine at a fixed dose (300 mg base per week) for months 1-12
10033285|NCT01785979|Active Comparator|chloroquine|chloroquine at a fixed dose (300 mg base per week) for months 1-12
10033286|NCT01785992|Other|Irosustat (Single arm study)|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or the development of unacceptable toxicities.
10033287|NCT01786005|Sham Comparator|Sham|Imitation of stimulation.
10033288|NCT01786005|Experimental|High-frequency stimulation|High-frequency stimulation
10033289|NCT01786005|Experimental|TBS Theta burst stimulation|TBS Theta burst stimulation
10033290|NCT01786005|Experimental|Low-frequency stimulation|Low-frequency stimulation
10033291|NCT01786018|Experimental|1|"Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)~Busulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)~Fludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
10033292|NCT01786031|Experimental|experimental|metastasis biopsy
10033293|NCT01786044|Experimental|MasterMed|MasterMed, an online interactive educational program
10033294|NCT01786044|Placebo Comparator|Usual care|Access to an online patient portal
10033295|NCT01786057|Active Comparator|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
9472013|NCT03613974|Experimental|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
9472014|NCT03613935|Placebo Comparator|Product 1|Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
10033296|NCT01786057|Placebo Comparator|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
10033297|NCT01786070|Active Comparator|Budesonide|Budesonide : 1 mg/4ml every 12 hrs for 48 hrs
10033298|NCT01786070|Placebo Comparator|Placebo|Normal saline at an equivalent volume (4 ml every 12 hrs for 48 hrs)
9472015|NCT03613935|Active Comparator|Product 2|Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
9472016|NCT03613935|Active Comparator|Product 3|Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
9472017|NCT03613935|Active Comparator|Product 4|Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
10033299|NCT01786083|Experimental|Lifestyle counseling|Application of Problem Solving Technique
10033300|NCT01786083|No Intervention|No counseling|Usual care by caregiver
10033301|NCT01786096|Experimental|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
9472018|NCT03613922|Experimental|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
9472019|NCT03613922|Active Comparator|Routine Physiotherapy Group|Only routine physiotherapy program was applied
10033302|NCT01786122|Experimental|Exercise group|supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
10033303|NCT01786122|No Intervention|control group|Pharmacological treatment and selfcare encouragement.
9472020|NCT03613909|Experimental|CP950|CP950 Off The Ear (OTE) sound processor
9472021|NCT03613909|Active Comparator|BTE|Behind the Ear (BTE) sound processor (either a CP810 or CP900 series)
10033304|NCT01786135|Experimental|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
10033305|NCT01786200|Active Comparator|Aspirin|20 patients randomised to aspirin 75mg PO once daily
10033306|NCT01786200|Active Comparator|Ibuprofen|20 patients randomised to ibuprofen 400mg PO three times daily
10033307|NCT01786200|No Intervention|Control|20 patients randomised to receive no treatment
10033308|NCT01786213||Colonoscopist A|
10033309|NCT01786213||Colonoscopist B|
10033310|NCT01786213||Colonoscopist C|
9472022|NCT03613896|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
10033311|NCT01786213||Colonoscopist D|
10033312|NCT01786213||Colonoscopist E|
10033313|NCT01786213||Colonoscopist F|
10033314|NCT01786213||Colonoscopist G|
10033315|NCT01786213||Colonoscopist H|
10033316|NCT01786213||Colonoscopist I|
10033317|NCT01786213||Colonoscopist J|
10033318|NCT01786226|Experimental|Mifepristone 2.5 mg daily for three months|Experimental: 1
10033319|NCT01786226|Experimental|Mifepristone 5 mg daily for three months|Experimental: 2
10033320|NCT01786278|Experimental|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
10033321|NCT01786278|Other|Endoscopic Stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
10033322|NCT01786291||CPAP compliant|CPAP (continuous positive airway pressure) compliant patients
10033323|NCT01786291||CPAP non-compliant|patients who did not use CPAP therapy
10033324|NCT01786304||Fecal incontinence|Patient with fecal incontinence and referred for a treatment with sacral nerve stimulation
10033325|NCT01786317||Fecal incontience|Patient with fecal incotinence who will be explored using high resoltuion manometry
10033326|NCT01786317||Healthy controls|Healthy volunteers who will be explored using high resoltuion manometry
10033327|NCT01786356|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
10033328|NCT01786356|Other|B&L MI60|eyes with implanted intraocular lens B&L MI60
10037159|NCT01822392|Experimental|Online treatment, Low therapist contact|Participants receive online Parent Management Training (recorded).
10037160|NCT01822405|Active Comparator|Pentoxifylline + Tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
10037161|NCT01822405|Experimental|pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy|
9472023|NCT03613896|Active Comparator|3D printed dentures|a complete denture made through 3d printing
9472024|NCT03613883|Experimental|Primary Study Arm|The intervention is done to those patients that are managed by endovascular stent that is inserted in the parent artery to induce slowness in the blood flow thus initiate thrombosis in the aneurysmal sac.
9472025|NCT03613883|Experimental|Expanded Selection Arm|The intervention is done to the expanded selection arm and is managed by embolic materials (coils / glue) that occlude the aneurysm by proximal occlusion, proximal and distal occlusion or sac packing
9472026|NCT03613870|Active Comparator|PermeaDerm|Participants receive PermeaDerm dressing for wound treatment until wounds have healed completely
10033329|NCT01786369||Admitted Patients with Acute Psychosis|Patients 18 years of age or older with a documented diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder who are admitted to an inpatient psychiatric unit at Zucker Hillside Hospital for a psychotic compensations. Patients must have been in the outpatient setting for at least one month prior to admission on a regimen including risperidone, olanzapine, quetiapine, paliperidone or aripiprazole.
10033330|NCT01786382|Experimental|midazolam|potential effects of PPI-668 on midazolam pharmacokinetics
10033331|NCT01786382|Experimental|omeprazole|potential effects of PPI-668 on omeprazole pharmacokinetics
10033332|NCT01786382|Experimental|telaprevir|potential effects of PPI-668 on telaprevir pharmacokinetics
10033333|NCT01786395|Experimental|- UF-021|UF-021 is experimental code for isopropyl unoprostone
10033334|NCT01786395|Placebo Comparator|- Placebo|
9472027|NCT03613870|Active Comparator|Mepilex Ag|Participants receive Mepilex Ag dressing for wound treatment until wounds have healed completely
9472028|NCT03613857||Clopidogrel group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose 600 mg oral clopidogrel (plavix) tablets before the procedure.
9472029|NCT03613857||Ticagrelor group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose180 mg oral ticagrelor (brilique) tablets before the procedure.
9472030|NCT03613844|Experimental|DHA|oral DHA supplementation at 2 grams per day
9472031|NCT03613844|Placebo Comparator|Placebo|Placebo for DHA
9472032|NCT03613805|Active Comparator|Dexcom G5 - Eversense|Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
9472033|NCT03613805|Experimental|Eversense- Dexcom G5|Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
9472034|NCT03613792|Active Comparator|Remifentanil and Ketamine Group|Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
9472035|NCT03613792|Active Comparator|Fentanyl and Midazolam|The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
9472036|NCT03613779|Experimental|LUS-guided therapy group|"LUS-guided therapy group. Patients randomly allocated to this arm will receive standard of care + LUS examination accessible to treating physician in every visit. Depending on the results of LUS examination, a low dose or high dose of diuretics will be administered.~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
9472037|NCT03613779|Active Comparator|Control group.|"Control group. Patients randomly allocated to this arm will receive standard of care + LUS examination blinded to the treating physician in every visit. Diuretic titration will be based on standard practice (physical examination, symptoms and lab results).~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
9472038|NCT03613766|Experimental|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
9472039|NCT03613766|No Intervention|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
9472040|NCT03613753|Experimental|Arm A|Chemotherapy:irinotecan plus lobaplatin
9472041|NCT03613753|Active Comparator|Arm B|Chemotherapy:irinotecan
9472042|NCT03613714|Active Comparator|Intervention Group|At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
9472043|NCT03613714|No Intervention|Usual Care|Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
9472044|NCT03613701||Moyamoya disease patients|Moyamoya disease patients/Healthy volunteers
9472045|NCT03613688|Experimental|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
9472046|NCT03613688|Experimental|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
10033335|NCT01786408|Experimental|TAP20-C|Single Use Integrated Capillary Blood Collection System
10033336|NCT01786408|Active Comparator|SAFE-T-FILL CAPILLARY SYSTEM|Single Use Capillary Blood Collection System
10033337|NCT01786421||General population|Healthy volunteers,patients with hyperlipidemia,a known medical history of cardiovascular diseases or type 2 diabetes mellitus.
10033338|NCT01786447||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
10033339|NCT01786447||Orthopedic Control|Patients who present to the health care facility with isolated extracranial orthopedic injury within 4 hours of injury
10033340|NCT01786460||Healthy Volunteers|
10033341|NCT01786473|Experimental|Testogel 1% 5g QD|
9472047|NCT03613688|Experimental|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
9472048|NCT03613688|Experimental|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
9472049|NCT03613675|Experimental|Video games|All participants will be asked to play 4 video games.
9472050|NCT03613636||CAP cohort|"Children of age 3 to 16 years;~In- and outpatients;~Clinically diagnosed community-acquired pneumonia (CAP)."
10033342|NCT01786473|Placebo Comparator|Placebo gel 5g QD|
10033343|NCT01786486||Delivery system entry|
9472051|NCT03613636||Healthy control cohort|"Healthy asymptomatic children of age 3 to 16 years;~undergoing an elective surgical procedure."
9472052|NCT03613636||Family control cohort|- Family members of index CAP patients.
9472053|NCT03613623||Patients|Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
9472054|NCT03613623||Physicians|Physicians for those treating the patients enrolled in the study.
9472055|NCT03613610|Active Comparator|Three needles group|
9472056|NCT03613610|Active Comparator|Single needle group|
9472057|NCT03613597|Experimental|Etoposide plus Lobaplatin group|Chemotherapy:etoposide plus lobaplatin (EL)
9472058|NCT03613597|Active Comparator|Etoposide plus Cisplatin group|Chemotherapy:etoposide plus cisplatin (EP)
9472059|NCT03613584|Active Comparator|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
9472060|NCT03613584|Placebo Comparator|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
9472061|NCT03613571|Experimental|ILB|ILB treatment
9472062|NCT03613558|Experimental|Dexmedetomidine Sedation|This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery.
9472063|NCT03613558|Placebo Comparator|Placebo|This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine.
9472064|NCT03613545|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
9472065|NCT03613545|Sham Comparator|placebo fecal microbiota transplantation|Infusion of sham
9472066|NCT03613545|Sham Comparator|Traditional treatments|Traditional treatments according to associated guidelines such as probiotics, antibiotics or antidepressants
9472067|NCT03613519|Placebo Comparator|Usual care (sleep hygiene)|A web-based program that presents ways to improve behaviors and environments that can affect sleep.
9472068|NCT03613519|Active Comparator|SHUTi (Sleep Healthy Using the Internet)|SHUTi is web-based cognitive-behavioral therapy instrument for insomnia (CBT-I)
9472069|NCT03613519|Active Comparator|modified SHUTi (SHUTi modified for Black women)|The CBT-I instrument tailored for Black women.
9472070|NCT03613480|Experimental|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
9472071|NCT03613480|No Intervention|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
9472072|NCT03613467||VATS lobectomy|Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
9472073|NCT03613467||Thoracotomy lobectomy|Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
9472074|NCT03613441|Experimental|Mindful Awareness Practices (MAPs)|Mindful Awareness Practices is a mindfulness-based intervention developed at UCLA's Mindful Awareness Research Center. It is a weekly 2-hour, 6-session, group-based course in mindfulness meditation that is available in-person or online.
9472075|NCT03613441|No Intervention|Control|Waitlist control (intervention will be available to this group at the end of the study period)
9472076|NCT03613428|Experimental|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
9472077|NCT03613415|Experimental|Expansion by Densah bur|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of Densah bur under copious irrigation.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
9480944|NCT05163652|Experimental|3 months after two doses|group 1：the third does was given 3 months after two doses CoronaVac group 2：the third does was given 3 months after two doses BBIBP-CorV group 3：the third does was given 3 months after one does CoronaVac and one does BBIBP-CorV
10033344|NCT01786499|Other|Relaxation Response Training|
10033345|NCT01786525|Experimental|House Calls only|60-minute educational intervention in patient's home which will be delivered by a health educator.
10033346|NCT01786525|Active Comparator|House Calls + Web-Based Decision Support|Home based intervention plus web-based patient-centered decision support program that will be offered to participants following the home based intervention.
10033347|NCT01786525|No Intervention|Control|100 patients on the Organ Transplant Tracking Record who are not receiving the study intervention
9472078|NCT03613415|Active Comparator|Expander|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of screw expanders.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
9472079|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
9472080|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
9472081|NCT03613389|Experimental|oral topical vitamin E|
10033348|NCT01786538|Experimental|Regorafenib/FOLFOX|
9472082|NCT03613389|No Intervention|voriconazole and levofloxacin|
10033349|NCT01786538|Active Comparator|Placebo/FOLFOX|
10033350|NCT01786577||Surgery|80 patients will undergo total knee replacement surgery; two Magnetic Resonance Imaging scans; cognitive assessment testing.
10033351|NCT01786577||Non-Surgery|80 non-surgery participants will be included as part of the control group; two Magnetic Resonance Imaging scans; cognitive assessment testing.
10033352|NCT01786590|Experimental|EBUS-TBNA|
10033353|NCT01786616||Formoterol|12 mcg BID for four weeks
10033354|NCT01786642||conscious|bronchoscopy without sedative drugs
10033355|NCT01786642||conscious sedation|bronchoscopy under midazolam
10033356|NCT01786655|Experimental|Neosaxitoxin in saline|Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
10033357|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2%|Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
10033358|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml|Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
10033359|NCT01786655|Placebo Comparator|Saline placebo|Subjects receive one injection of saline on the back of one calf (test side).
10033360|NCT01786681|Experimental|Positive pressure before surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour before bariatric surgery.
10033361|NCT01786681|Experimental|Positive pressure during the surgery|Individuals treated with 10 cm H2O of PEEP (Positive End Expiratory Pressure) during the surgical procedure.
10033362|NCT01786681|Experimental|Positive pressure after surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour after bariatric surgery.
10033363|NCT01786681|No Intervention|Control|Individuals treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
10033364|NCT01786694|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
10033365|NCT01786720||Prior Triple Therapy|Patients prescribed triple therapy prior to initial date of COPD diagnosis
10033366|NCT01786720||Triple therapy at COPD diagnosis|Patients prescribed triple therapy on date of initial COPD diagnosis
10033367|NCT01786720||Triple therapy after COPD diagnosis|Patients prescribed triple therapy after initial date of COPD diagnosis
10033368|NCT01786733|Experimental|Behavioral Activation|Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.
10033369|NCT01786733|Active Comparator|Supportive Therapy|Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
9472083|NCT03613376|No Intervention|No Compression|Patients in this group will not receive any compression after treatment
9472084|NCT03613376|Active Comparator|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
9472085|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
9472086|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
9480945|NCT05163652|Experimental|4 months after two doses|group 1：the third does was given 4 months after two doses CoronaVac group 2：the third does was given 4 months after two doses BBIBP-CorV group 3：the third does was given 4 months after one does CoronaVac and one does BBIBP-CorV
9517193|NCT03308500|Experimental|High-intensity intermittent games HIIG|High-intensity intermittent games (HIIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 75% ≤ - RPE 6-8.
10033370|NCT01786746|Experimental|Psychotherapy|Psychotherapy arm that consists of a randomization into 12 session manualized cognitive behavioral therapy or culturally adapted cognitive behavioral therapy for Chinese Americans.
10033371|NCT01786759|Active Comparator|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
10033372|NCT01786759|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
10033373|NCT01786772|Experimental|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
9472087|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
9472088|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
9472089|NCT03613337||current smokers|Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
10033374|NCT01786772|Active Comparator|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
10033375|NCT01786785||Stroke Patients|Subjects between 2 and 17 years of age with a confirmed arterial ischemic stroke.
10033376|NCT01786785||Controls|Age and Gender Matched Controls
10033377|NCT01786798|Other|Transvaginal sonography|
10033378|NCT01786811|Experimental|Trained Clinicians|Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
9472090|NCT03613337||nonsmokers|Nonsmokers are those who never smoked in their lifetime.
9472091|NCT03613337||former smokers|Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
9472092|NCT03613324||Bladder outlet obstruction (BOO)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was <12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
9472093|NCT03613324||Detrusor underactivity (DU)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was <12 mL/s and PdetQmax was <10 cmH2O during voiding cystometry.
9472094|NCT03613324||ND BOO/DU|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
9472095|NCT03613311||Evident urodynamic stress incontinence(USI)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction.
9472096|NCT03613311||Occult USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction after prolapse reduction by vaginal gauze.
9472097|NCT03613311||ND USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
9472098|NCT03613298|Experimental|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:~Evaluate its ability to locate and assess the volume of the endometriosic lesion~Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
9472099|NCT03613285|Active Comparator|conventional brackets|Conventional brackets with Mac Laughin bennette Trevisi (MBT) prescription
9472100|NCT03613285|Active Comparator|Smart clip passive self ligating brackets|Smart clip passive self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
10033379|NCT01786811|No Intervention|Non-trained Clinicians|Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
10033380|NCT01786811|No Intervention|Non-volunteer Clinicians|These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.
10033381|NCT01786824|Experimental|Bicarbonate|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.~Intervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
10037162|NCT01822418|Experimental|Treatment|Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).
10033382|NCT01786824|Active Comparator|Saline|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.~Intervention: Hydration strategy using saline Intervention: Coronarography"
10033383|NCT01786824|Experimental|Bicar + L-Carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
10033384|NCT01786824|Experimental|Saline + L-carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
10033385|NCT01786837|Experimental|Treatment|FMS will be administered for 5 weeks
10033386|NCT01786837|Sham Comparator|Sham|FMS at 5% intensity for 5 weeks
10033387|NCT01786863||Neuromuscular blockade|
10033388|NCT01786889|Experimental|Patient with angiosarcoma of the liver|Blood and urine collections, questionnaire and telephone interview
10033389|NCT01786915|Experimental|Bendavia 10mg|Bendavia capsule, 10mg, once daily for 7 days
10033390|NCT01786915|Placebo Comparator|Placebo|Placebo (matching), once daily for 7 days
9472101|NCT03613285|Active Comparator|Empower active self ligating brackets|Empower active self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
9472102|NCT03613272|Experimental|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
10033391|NCT01786915|Experimental|Bendavia 50mg|Bendavia capsule, 50mg, once daily for 7 days
10033392|NCT01786928|Experimental|resistance training|resistance training of the upper and lower limbs, two series of 80% of repetition maximum test
10033393|NCT01786928|No Intervention|Control|Traditional Respiratory Therapy for bronchial hygiene
10033394|NCT01786941|No Intervention|Lean Group|Healthy Controls - no intervention
9472103|NCT03613272|Experimental|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
9472104|NCT03613259|Experimental|Diagnostic (fluorothymidine F-18 PET)|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.
9472105|NCT03613233|Active Comparator|traditional glaucoma surgery|glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy
9472106|NCT03613233|Active Comparator|microinvasive glaucoma surgery (MIGS)|glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device
9472107|NCT03613207|Experimental|Dermal pharmacokinetic measurement|"Measurement of dermal pharmacokinetic (PK) parameters (AUC, Cmax) within each subject.~For dermal PK measurement cutaneous interstitial fluid will be sampled using dermal open flow microperfusion (dOFM). Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine/prilocaine.~Each subject will have 9 test sites in total which are treated with:~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~test sites: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~2 test sites: untreated test site"
10033395|NCT01786941|Other|Pre-Diabetes Group|Pre-Diabetes Group will undergo a 6-mo Aerobic and Resistance combined exercise training intervention
10033396|NCT01786941|Other|Gastric Bypass Group|Non-diabetic patients intending to undergo Gastric Bypass surgery
10033397|NCT01786980||liver cancer, Radical hepatic resection|
10033398|NCT01787019|Experimental|30 weeks|initiation of oral feedings at 30 weeks
9517194|NCT03308500|Active Comparator|Moderate-intensity games (MIG)|Moderate intensity games (MIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 60-74% ≤ - RPE 4-5.
10033399|NCT01787019|Active Comparator|33 weeks|initiation of oral feedings at 33 weeks
10033400|NCT01787045|Experimental|Intervention Group|"Early and Active Physical Therapy will be performed by physiotherapist twice a day. During first week patients will be positioned in chair or bed and performed cycle-ergometer exercise during 30 min.~Our physiotherapy protocol will be continued until Intensive Care Unit (ICU) discharge."
10033401|NCT01787045|Other|Control Group|Routinary Passive Range of Motion will be performed by physiotherapist 20 min and twice a day until ICU discharge.
10033402|NCT01787058||Dubai Cares beneficiary|Pupils who attend a school that has benefitted from a water, sanitation and hygiene intervention as part of the Dubai Cares program.
10033403|NCT01787058||Control|Pupils who attend a school of the same size and location as a school that benefitted from a water, sanitation and hygiene (WASH) intervention through the Dubai Cares program, but which has not benefitted from that program or any other WASH program since 2009.
10033404|NCT01787071||one group|Patients receiving fluid challebnge
10033405|NCT01787084||Inoperable Patients Alternative Access|Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
10037163|NCT01822431||Patients with type 1 diabetes mellitus|Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring
10037164|NCT01822431||Healthy controls|Autonomic function tests, Pupillometry, Holter monitoring
9472108|NCT03613194|Other|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
9803147|NCT04507360|Experimental|Engagement Strategy - 1|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
9803148|NCT04507360|Experimental|Engagement Strategy - 2|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
9803149|NCT04504123|Experimental|Doxycycline|Participants received doxycycline hyclate 50 mg capsule orally once a day for 6 months
9803150|NCT04504123|Placebo Comparator|Placebo|Participants received placebo (inactive) capsule orally once a day for 6 months
9803151|NCT04502706|Experimental|GS-0189 (Monotherapy Dose Escalation, MDE)|Relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) participants will receive GS-0189 doses of 10, 30, or 100 mg every 2 weeks.
10033406|NCT01787110|No Intervention|No oxygen|"For patients randomised to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
10033407|NCT01787110|Active Comparator|Oxygen|"For patients randomised to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
10033408|NCT01787123|Placebo Comparator|Control: standard management|Standard management for patient suffering from aneurysmal subarachnoid haemorrhage
10033409|NCT01787123|Active Comparator|Intervention: standard management AND Cerebrolysin|Standard management for aneurysmal subarachnoid hemorrhage and a 14-day administration of intravenous Cerebrolysin
10033410|NCT01787149|Placebo Comparator|Placebo|DMARDs alone
9803152|NCT04502706|Experimental|GS-0189 + Rituximab (Combination Dose Escalation, CDE)|R/R NHL participants will receive GS-0189 doses of 100, 300, 1000, 2000, and 3000 mg in combination with rituximab at 375 mg/m^2.
10033411|NCT01787149|Experimental|ENIA11|ENIA11 25 mg
10033412|NCT01787162||myeloproliferative disorders|Echocardiography, spiroergometry, cardiac catheterization
9803153|NCT04502706|Experimental|GS-0189 + Rituximab (Pharmacokinetic (PK) Evaluation)|R/R NHL participants will receive GS-0189 dose of up to 30 mg followed by the highest designated safe dose from the Combination Dose Escalation cohort (CDE) in combination with rituximab at 375 mg/m^2.
9803154|NCT04502706|Experimental|GS-0189 + Rituximab (Alternate Schedule Evaluation, ASE)|R/R NHL participants will receive GS-0189 every 4 weeks in combination with rituximab 375 mg/m^2. The GS-0189 dose will be determined based on the totality of safety, PK, and pharmacodynamic (PD) data from the preceding cohorts.
9803155|NCT04502706|Experimental|GS-0189 + Rituximab (DLBCL Expansion)|Diffuse large B-cell lymphoma (DLBCL) participants will receive GS-0189 in combination with rituximab 375 mg/m^2. The GS-0189 dose will be determined based on the totality of safety, PK, and PD data from the preceding cohorts.
10033413|NCT01787214|Active Comparator|Full dose|full dose of walnuts (20% energy needs)
10033414|NCT01787214|Active Comparator|Half-dose|Half dose of walnuts (10% of energy needs)
10033415|NCT01787214|Other|Control|Walnut free meals
10033416|NCT01787227||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
10033417|NCT01787227||Blinded, Prospective Arm|Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.
10033418|NCT01787253||Irritable bowel syndrome (IBS)|
10033419|NCT01787253||Healthy controls|
10033420|NCT01787253||Microscopic Colitis (MC)|
9472109|NCT03613168|Experimental|Trastuzumab plus Gem/Cis|Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg
9472110|NCT03613142|Experimental|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
9472111|NCT03613142|Active Comparator|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
9472112|NCT03613103|Active Comparator|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
9472113|NCT03613103|Experimental|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
9472114|NCT03613090|Experimental|Collagen-hydroxyapatite Scaffold (Syn-Oss)|Placement of a collagen-hydroxyapatite scaffold (Syn-Oss), placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material).
9480946|NCT05163652|Experimental|5 months after two doses|group 1：the third does was given 5 months after two doses CoronaVac group 2：the third does was given 5 months after two doses BBIBP-CorV group 3：the third does was given 5 months after one does CoronaVac and one does BBIBP-CorV
9803156|NCT04499274|Experimental|0 ng/ml|Blood specimen which was added 0 ul of ondansetron
10033421|NCT01787253||Irritable bowel disease (IBD)|
9472115|NCT03613090|Active Comparator|Collagen Scaffold (Colla-Plug)|Placement of a collagen scaffold (Colla-Plug) over a blood clot, placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material). The Colla-Plug material is placed adjacent to the blood clot that has formed inside the root canal space. It act as a matrix for the subsequent placement of the mineral trioxide aggregate material. It has been used as the standard of care in regenerative endodontics since 2004.
9472116|NCT03613064|Experimental|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
9472117|NCT03613064|Experimental|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
9480343|NCT03534583|Experimental|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (6-8 participants). During the first week participants will attend three 2.5-3 hour sessions on three consecutive days. There will then be a gap of 4 days where participants can apply the tools provided, followed by three more consecutive days of 1.5-3 hours of instruction. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency.
9480344|NCT03534557||COPD|FEV1/FVC and FEV1/FEV6 will be compared within the same cohort of COPD patients
9480345|NCT03534518|Active Comparator|SCI-patients receiving overground training|
9480346|NCT03534518|Active Comparator|SCI-patients receiving treadmill training|
9480347|NCT03534505|Experimental|Ketorolac injections|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
9480348|NCT03534505|Active Comparator|bupivacaine|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
9480349|NCT03534492|Experimental|Durvalumab plus Olaparib|Durvalumab 1500 mg every 4 weeks for up to a maximum of 2 months (up to 2 doses/cycles) plus Olaparib 300 mg b.i.d. up to 56 days (2 cycles of 28 days each cycle).
9480350|NCT03534479|Experimental|CVID-IVIgG, polyclonal IgG i.v. infusion|The patients of the CVID-IVIgG, polyclonal IgG infusion, group are studied five weeks from their last therapeutic polyclonal IgG i.v. infusion (IVIgG). On the mornings of day 0, vascular reactivity of the brachial artery, assessed as Flow mediated dilation (FMD), is measured and blood collected for biochemistry (baseline). Immediately after the FMD measurements and the blood collection, the 24 patients receive half dose of IVIgG necessary to treat their disease (400 mg/kg body weight in 10% solution). Twenty-four hours later, before infusing the second half of the dose of the IVIgG, vascular reactivity is again measured and blood collected. Vascular reactivity is again measured 1, 2, and 3 weeks after the first IVIgG infusion.
9480351|NCT03534414||Intervention|A Portfolio Dietary Pattern involving a combination of 4 cholesterol lowering foods, namely: plant sterols, viscous fibre, plant protein, and nuts.
9480352|NCT03534414||Control|A National Cholesterol Education Program (NCEP) based diet, a diet low in saturated fat and cholesterol.
9480353|NCT03534401|No Intervention|Standard Family Planning Counseling|Clients receive standard FP counseling services.
9480354|NCT03534401|Experimental|ARCHES Kenya Intervention in FP Counseling|Clients receive the ARCHES Kenya intervention in addition to standard FP counseling services.
9480355|NCT03534388|Other|Prospective Subjects|
9517195|NCT03308487|Active Comparator|vitamin D3 (1000 IU)|group 1
9517196|NCT03308487|Active Comparator|vitamin D3 (2000 IU)|group 2
10033422|NCT01787266||1|pregnant women
10033423|NCT01787318|Experimental|ePID closed loop system using Insupatch|Insupatch activated at mealtimes
10033424|NCT01787318|Active Comparator|ePID closed loop system without InsuPatch|InsuPatch will not be activated at mealtimes
10033425|NCT01787344|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A (Botulax®)
10033426|NCT01787344|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
10033427|NCT01787357|Experimental|Sequence 1 (ADBC)|Each volunteer will receive Treatment A on Day 1 of Treatment Period 1, followed by Treatment D on Day 1 of Treatment Period 2, followed by Teatment B on Day 1 of Treatment Period 3, and followed by Treatment C on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
10033428|NCT01787357|Experimental|Sequence 2 (BACD)|Each volunteer will receive Treatment B on Day 1 of Treatment Period 1, followed by Treatment A on Day 1 of Treatment Period 2, followed by Treatment C on Day 1 of Treatment Period 3, and followed by Treatment D on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
10033429|NCT01787357|Experimental|Sequence 3 (CBDA)|Each volunteer will receive Treatment C on Day 1 of Treatment Period 1, followed by Treatment B on Day 1 of Treatment Period 2, followed by Treatment D on Day 1 of Treatment Period 3, and followed by Treatment A on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
10033430|NCT01787357|Experimental|Sequence 4 (DCAB)|Each volunteer will receive Treatment D on Day 1 of Treatment Period 1, followed by Treatment C on Day 1 of Treatment Period 2, followed by Treatment A on Day 1 of Treatment Period 3, and followed by Treatment B on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
10033431|NCT01787370||Patients undergoing coronary angiography|Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
10033432|NCT01787396|Experimental|Arm1|Gemigliptin 50mg + Metformin Once daily with dinner
10033433|NCT01787396|Experimental|Arm 2|Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner
10033434|NCT01787396|Experimental|Arm3|Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner
10033435|NCT01787422|Experimental|Telemedicine Visit|Patients who are seen by use of an off-site telemedicine physician.
10033436|NCT01787422|Active Comparator|Traditional Visit|Patients who are seen in followup with a traditional in-office visit.
10033437|NCT01787435||All women exposed to PPI at any time during pregnancy|Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
10033438|NCT01787435||All women exposed to H2RA at any time during pregnancy|Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
10033439|NCT01787435||Pregnant women with no recorded use of acid suppressing drugs|Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
10033440|NCT01787448|Experimental|Ibuprofen 5% topical gel|
9472118|NCT03613051||age band one|age band one ( from 3 to 6 years ) we test manual dexterity by posting coins with prefered hand and non prefered hand test balance by jumping on mats
9472119|NCT03613051||age band two|age band two ( from 7 to 10 years ) test manual dexterity by threading lace
9472120|NCT03613051||age band three|age band three ( from 11 to 18 years ) test manual dexterity by turning pegs test balance by zigzag hopping
9472121|NCT03613025|Other|Case : confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
9472122|NCT03613025|Other|Control : non confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
9472123|NCT03613012||Pain index|Pain index will be extracted from the EEG of chronic pain patients before and after pain treatments
9472124|NCT03612999|Experimental|CGM and Activity Tracker|Subjects receive a continuous glucose monitor (CGM) and activity tracker and are instructed to record daily activities and psychological data.
9472125|NCT03612986|Active Comparator|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)~1 tablet/day, oral administration"
9472126|NCT03612986|Placebo Comparator|B: Placebo|"Placebo~1 tablet/day, oral administration"
9472127|NCT03612947|Active Comparator|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4.
10033441|NCT01787448|Experimental|Topical gel vehicle|
10033442|NCT01787448|Active Comparator|Sodium lauryl sulfate 0.1%|
10033443|NCT01787448|Sham Comparator|Sodium chloride solution 0.9% (saline)|
10033444|NCT01787474|Experimental|Treatment (NK cells)|Patients receive filgrastim-sndz SC QD beginning on day -7 and continuing until ANC are equal or over 1000. Patients also receive fludarabine phosphate IV over 30 minutes and approximately 4 hours later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine, patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).
10033445|NCT01787487|Experimental|Arm I (MF patients)|Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
10033446|NCT01787487|Experimental|Arm II (MDS/MPN patients)|Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
10033447|NCT01787513|Experimental|CBM Version A + iCBT|CBM Version A is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
9472128|NCT03612947|Placebo Comparator|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
9472129|NCT03612934||patients under the age of 65 years|patients under the age of 65 years
9472130|NCT03612934||patients at the age of 65 years and over|patients at the age of 65 years and over
9472131|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
9472132|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
9472133|NCT03612895|Experimental|Internal Care Coordination|The smoker will be connected to a Tobacco Care Coordinator who is based centrally within the health care system but has ready access via EHR, email, and telephone with staff in each primary care practice.
9472134|NCT03612895|Experimental|External Community Referral|"This intervention will connect the smoker directly via warm transfer to a the Massachusetts Smokers Helpline operated by National Jewish Health, which will provide its standard services to smokers."
9472135|NCT03612895|Other|Usual Care|Passive referral to quitline and referral to primary care physician.
9472136|NCT03612882||Western University Students|Online questionnaire
10033448|NCT01787513|Placebo Comparator|CBM Version B (Control) + iCBT|CBM Version B (Control) is an Internet-based intervention taking place over 1 week (identical to CBM Version A without the putative active components) followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
10033449|NCT01787526|Active Comparator|Oral Iron|oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
10033450|NCT01787526|Experimental|Intravenous high dose iron|high dose intravenous iron (ferric carboxymaltose, 1000mg)
9472137|NCT03612869|Experimental|AAV SGSH gene therapy (LYS-SAF302)|One-time intracerebral administration of adeno-associated viral vector serotype rh10 containing the human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA.
9472138|NCT03612843||Dry needle|Dry needling is provided as a part of a comprehensive treatment program by a physical therapist. The patient and the therapist will record any adverse events that occur.
9472139|NCT03612830|Experimental|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
10033451|NCT01787539|Experimental|Complete Perioperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery with the same regimen as in the preoperative part."
9472140|NCT03612830|Experimental|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
9472141|NCT03612817|Active Comparator|Tafluprost/timolol with PM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
9472142|NCT03612817|Active Comparator|Tafluprost/timolol with AM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)
9472143|NCT03612778|Experimental|Plant-based diet|Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, <15% from fat, and 70-75% from carbohydrates. Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
9472144|NCT03612778|Active Comparator|Mediterranean diet|Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
9472145|NCT03612765|Experimental|Intervention group|Participants in the intervention group will receive face-to-face intervention sessions that include interviews, discussions and didactic teaching.
9472146|NCT03612765|No Intervention|Control group|Participants in the control group will receive usual care that normally includes three monthly outpatient doctor consultations and when necessary, heart failure nurse referral.
9472147|NCT03612752|Experimental|Active arm|CMI-168
9472148|NCT03612752|Placebo Comparator|Placebo arm|Placebo
9472149|NCT03612739|Experimental|Cohort 1|5-azacytidine + 1x10^8 NKR-2 CAR-T Cells
9472150|NCT03612739|Experimental|Cohort 2|5-azacytidine + 3x10^8 NKR-2 CAR-T Cells
9472151|NCT03612739|Experimental|Cohort 3|5-azacytidine + 1x10^9 NKR-2 CAR-T Cells
9472152|NCT03612700|Experimental|CPFA-rich diet|Free living diet controlled in CPFA intake
10033452|NCT01787539|No Intervention|Preoperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Patients with tumor regression grade 0, 1, 2 randomized to preoperative chemotherapy will not undergo postoperative chemotherapy and will be followed-up."
10033453|NCT01787552|Experimental|LDE225 + INC424|LDE225 and INC424 in combination
10033454|NCT01787565||painPREMIER cohort|
10033455|NCT01787565||Control cohort|
10033456|NCT01787578|Experimental|Sobetirome|Subjects will receive oral doses of sobetirome. All subjects will start with a 50 mcg dose, once-daily for 14 days. If this dose proves safe and well tolerated, subjects will receive a 100 mcg dose once-daily for an additional 14 days.
10033457|NCT01787617|Placebo Comparator|Control Group|We will randomly assign 52 individuals to a no exercise healthy living group.
10033458|NCT01787617|Experimental|Aerobic Plus Resistance Training Group|We will randomly assign 52 individuals to an aerobic plus resistance training group.
10033459|NCT01787630|Experimental|Hyaluronic acid|Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.
10033460|NCT01787669|Active Comparator|Avastin (bevacizumab)|Intravitreal Avastin loading doses followed by as prn for remainder of 6 months according to defined retreatment criteria
10033461|NCT01787669|Active Comparator|Ozurdex (dexamethasone)|single dose at baseline and repeat dose when required according to defined re-treatment criteria
10033462|NCT01787695|No Intervention|No treatment (covered)|
10033463|NCT01787695|Active Comparator|UVA1|
10033464|NCT01787708|Active Comparator|Low intensity red laser|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
10037165|NCT01822444||Intent-to-treat population with aCRC or mCRC|Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria
10037166|NCT01822483|Experimental|Mycophenolate sodium|Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone
9472157|NCT03612674|Active Comparator|Standard colonoscopy (S)|A standard colonoscopy will be performed.
9472158|NCT03612674|Experimental|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
9472159|NCT03612661|Experimental|Intuitive Eating Group Intervention|Intuitive eating intervention delivered in a group format with 8-10 women, led by 2 facilitators.
10033465|NCT01787708|Active Comparator|High intensity red light|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
9472160|NCT03612661|Experimental|Intuitive Eating Guided Self-Help|Participants in this condition engage in 8 weeks of self-study of the intuitive eating intervention have ~20 minute weekly phone call with a study interventionist.
9472161|NCT03612622|Active Comparator|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for two weeks
9472162|NCT03612622|Placebo Comparator|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for two weeks
9472163|NCT03612609|Other|blood, urine and semen sample|15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines
9472164|NCT03612583|Experimental|Lower PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be set at 8 cm H2O
9472165|NCT03612583|Experimental|Higher PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be titrated to achieve end-expiratory PL = 2-3 cm H20 and at least 5 cm H2O greater than the level applied in the lower PEEP arm
9472166|NCT03612570|Experimental|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
9472167|NCT03612557|Experimental|active treatment arm|penicillin G benzathine treatment
9472168|NCT03612531|Experimental|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
9472169|NCT03612518|Experimental|Text and Voice Messages|Participants will receive text messages and voice messages
9472170|NCT03612518|Experimental|Interactive Phone Call|Participants will receive interactive phone calls
9472171|NCT03612518|No Intervention|Control|Participants in this arm will not be exposed to any intervention.
9472172|NCT03612505|Active Comparator|Intervention|
9472173|NCT03612505|No Intervention|Control|
9472174|NCT03612492|Active Comparator|Esmolol Group|Patients will receive esmolol during induction of anesthesia
9472175|NCT03612492|Active Comparator|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
9472176|NCT03612479|Experimental|KIDFIT Healthy|
9472177|NCT03612479|Active Comparator|KIDFIT Safe|
9472178|NCT03612440|Experimental|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
9472179|NCT03612440|Placebo Comparator|Group C|40 patients receive matching placebo (normal saline)
9472180|NCT03612427||Breastfed infants|Infants depending on breastfeeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
9472181|NCT03612427||Formula-fed infants|Infants have formula feeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
9472182|NCT03612414|Experimental|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
9472183|NCT03612414|Placebo Comparator|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
9472184|NCT03612401|Other|Neurogenic Bladder|Spinal Cord Injury patients with known neurogenic bladder on treatment with Anticholinergic Agents at baseline switched to mirabegron as the study intervention
9472185|NCT03612388||cardioplegia with MPS® (Myocardial protection system)|cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
9472186|NCT03612388||cardioplegia with Cardioplexol ®|cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)
9472187|NCT03612362|Experimental|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
9472188|NCT03612362|No Intervention|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
10033466|NCT01787708|No Intervention|No treatment1 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
10037167|NCT01822483|Active Comparator|Mycophenolate mofetil|Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
10037168|NCT01822509|Experimental|Treatment (ipilimumab, nivolumab)|See Detailed Description.
9472189|NCT03612349|Other|Condition 1: All Products|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, all tobacco products are available in menthol and non-menthol flavors.
9472190|NCT03612349|Other|Condition 2: No menthol LCCs|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, the online tobacco marketplace does not include menthol flavored little cigars and cigarillos.
9472191|NCT03612323|Experimental|Intra-ligamentary Piroxicam|Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.
9472192|NCT03612323|Active Comparator|Intra-ligamentary Articaine|Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine
10033467|NCT01787708|No Intervention|No treatment2 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
10033468|NCT01787721|Experimental|Ankle manipulation|Treatment will consist of manipulation of the tibiotalar joint intended to produce anterior to posterior glide of the tibia on the talus
9472193|NCT03612297||ATOUTBIO|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
9472194|NCT03612297||EVOLAB|Complete reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
9472195|NCT03612284|Experimental|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
9472196|NCT03612232|Experimental|Cabozantinib|oral cabozantinib as tablets continuously (60 mg single dose, tablets)
9472197|NCT03612219|Experimental|IMRT with CC+Adjuvant Apatinib|Treat with Apatinib mesylate tablet for adjuvant treatment(the dose was 250 mg,orally,qd,28 days for an observation period,Six cycles)of local advanced nasopharyngeal carcinoma after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
9472198|NCT03612219|Active Comparator|IMRT with CC|Only obeservation after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
9472199|NCT03612193||Study A: Chronic >1 year|
9472200|NCT03612193||Study A: Acute <1 year|
9472201|NCT03612193||Study A: Household Control|
9472202|NCT03612193||Study B: Newly Diagnosed <6 months|
9472203|NCT03612193||Study B: Household Controls|
9472204|NCT03612167|Experimental|multi-modal cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
9472205|NCT03612167|Active Comparator|nutritional group|A quasi-experimental design with nonequivalent control was adopted in a senior center. The intervention for control group was a 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
9472206|NCT03612128|Other|control group|Children continued their traditional physiotherapy
9472207|NCT03612128|Active Comparator|intervention group|We applied mirror therapy in addition to traditional physiotherapy
9472208|NCT03612115|Experimental|Neuromuscular electrical stimulation intervention|Neuromuscular electrical stimulation treatment
9472209|NCT03612115|No Intervention|Control|No additional intervention
9472210|NCT03612102|Active Comparator|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
9472211|NCT03612102|No Intervention|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
9472212|NCT03612089||Low back pain group|Individuals with non-specific chronic low back pain
9472213|NCT03612089||Healthy control group|Healthy individuals without low back pain
9472214|NCT03612076||Global cost of management of PJI|
9472215|NCT03612063|Experimental|Fitbit Iconic HR and Garmin Vivosmart HR|
9472216|NCT03612063|Experimental|Fitbit Iconic HR and TomTom Spark 3|
10033469|NCT01787721|Sham Comparator|Sham manipulation|Sham manipulative procedure of the tibiotalar joint.
10033470|NCT01787747|Experimental|Cohorts A and C|Single dose (D1) followed by twice daily dosing for 7 days
10033471|NCT01787747|Experimental|Cohorts B and D|Single dose (D1) followed by twice daily dosing for 7 days
9472217|NCT03612063|Experimental|Garmin Vivosmart HR and TomTom Spark 3|
9472218|NCT03612063|Experimental|Fitbit Iconic HR and Apple Watch III|
9472219|NCT03612063|Experimental|Apple Watch III and Garmin Vivosmart HR|
9472220|NCT03612063|Experimental|Apple Watch III and TomTom Spark 3|
9472221|NCT03612050|Placebo Comparator|Enhanced Usual Care|facilitate any clinical interventions
9472222|NCT03612050|Experimental|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
9472223|NCT03612037|Placebo Comparator|Control Phase|cellulose (600 mg)
9472224|NCT03612037|Experimental|Experimental Phase|alpha lipoic acid (600 mg)
9472225|NCT03612024||request for organ donation approved|
9472226|NCT03612024||request for organ donation rejected|
9472227|NCT03612011|Experimental|Onco-Repair|Onco-Repair tube of 150 ml
9472228|NCT03612011|Placebo Comparator|Placebo|Placebo tube of 150 ml
9472229|NCT03611998|Experimental|Survivors of Sex Trafficking|Survivors of sex trafficking (SST) who were living in a residential facility participated in this project by receiving occupation-based programming to address limitations in executive function skills over the course of the 8-month project. Sessions were held twice-monthly for an hour duration at each session.
9472230|NCT03611985|Experimental|Epidiferphane + taxane chemotherapy|
9472231|NCT03611933|No Intervention|Control group (CG)|Patients in the CG were provided with routine nursing care, as practiced in the clinic, including restricted bed rest. For this purpose, patients were given supine position in which the HOB was elevated 15° for 6-10 h; the patient's leg on the of the side of intervention was kept straight.
9472232|NCT03611933|Experimental|Experimental group (EG)|Patients in the EG were applied position changes between the first minute and sixth hour. During the initial six hours a supportive, thin pillow, 4 x 40 x 100 cm in size, was placed between the patient's shoulders and gluteals; this reduced the pressure on local tissues and muscle groups.
9803157|NCT04499274|Experimental|200 ng/ml|Blood specimen which was added 0.20 ul of ondansetron
9472233|NCT03611920||Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
9472234|NCT03611920||Dexamethasone|Teeth were soaked in dexamethasone (60μ ml-1) for 20 minutes before replantation
10033472|NCT01787747|Experimental|Cohorts E and F|Single dose (D1) followed by twice daily dosing for 7 days
10033473|NCT01787747|Experimental|Cohorts G and I|Single dose (D1) followed by twice daily dosing for 7 days
9472235|NCT03611907|Active Comparator|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
10033474|NCT01787747|Experimental|Cohorts H and J|Single dose (D1) followed by twice daily dosing for 7 days
10033475|NCT01787773|Experimental|Veniti Inferior Vena Cava Filter|
10033476|NCT01787786||Irritable Bowel Disease|Infliximab administered according to current FDA and EMS approved doses and intervals.
10033477|NCT01787851|Active Comparator|Triheptanoin oil|The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
10033478|NCT01787851|Placebo Comparator|Simple sugar|0.25mg/kg of sugar syrup will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake four-times per day before meals.
10033479|NCT01787864||Cross-Sectional Post-Ablation|"The cross-sectional arm will consist of patients who have undergone ablative therapy for Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence of Barrett's Esophagus (BE) since their first ablation.~Cross-sectional participants will receive one-time study biopsies during a routine care follow-up endoscopy."
10033480|NCT01787864||Prospective Longitudinal Pre-Ablation|"Concurrently enrolled will be a prospective longitudinal arm which will consist of patients prior to their first ablation procedure. The prospective cohort will be followed for 12 months or longer if Barrett's Esophagus (BE) is not yet clear 6 months after the initial treatment.~Prospective longitudinal participants will receive biopsies prior to ablation therapy and 6 and 12 months after the initial treatment. If Barrett's Esophagus (BE) is not yet clear at 6 months, biopsies will be taken at the first endoscopy after Barrett's Esophagus (BE) clearance and again at the next clinically scheduled follow-up visit."
9472236|NCT03611907|Active Comparator|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
9472237|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
9472238|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
9472239|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
9472240|NCT03611855|Experimental|BCI Rehabilitation|Patients trained on use of BCI-controlled orthotic device are given a device for home use. Patients are asked to use the device an hour per day, 5 days per week, for 12 weeks. During device use, patients are instructed via pre-programmed instructions on a tablet paired with the device to either rest or vividly imagine moving their affected hand. The device receives signals from a scalp electrodes within a headset the patient dons prior to use. The device interprets these signals and closes the patient's hand during a successful rest trial, and opens the patient's hand during a successful move trial.
9472241|NCT03611855|Active Comparator|Range of Motion Therapy|Active and Passive Range-of-Motion (AROM, PROM) therapy strategies are commonly prescribed by physical therapists for at-home post-stroke motor deficit rehabilitation that can be performed independently. Patients practice movement with joints and limbs affected by the stroke, either by using the unaffected limb (or the assistance of a caretaker) to stretch the affected limb (PROM) or by actively moving the affected limb (AROM). Patients are asked to perform this therapy one hour per day, 5 days per week, for 12 weeks.
9472242|NCT03611842||Healthy eardrum|OME (otitis media with effusion)with normal tympanic membrane
9472243|NCT03611842||Atrophic eardrum|OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket
9472244|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
9472245|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
9472246|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
9472247|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
9472248|NCT03611816||Group 3|Patient with cryptogenic stroke history before the age of 50.
9472249|NCT03611803|Experimental|Ekso Group|
9472250|NCT03611803|Active Comparator|Control|
10033481|NCT01787877||Stroke patients reporting to the ER|
9472251|NCT03611790|Experimental|Intervention|NeVa VS
9472252|NCT03611764|Experimental|Arm 1: Body Scan|"The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes~Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.~Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den"
9472253|NCT03611725|Active Comparator|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
9472254|NCT03611725|Placebo Comparator|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
9472255|NCT03611712|Experimental|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
10033482|NCT01787903|Active Comparator|Real-time continuous glucose monitor|16 weeks use of a real-time continuous glucose monitor
10033483|NCT01787903|Placebo Comparator|Continuous glucose monitor|16 weeks use of a (blinded, retrospective) continuous glucose monitor
10033484|NCT01787929|Other|Cemented hemiarthroplasty|hemiarthroplasty surgery with cement for displaced femoral neck fractures
10033485|NCT01787929|Other|Uncemented hemiarthroplasty|hemiarthroplasty surgery without cement is a surgery for displaced femoral neck fractures
10033486|NCT01787942|Active Comparator|Blepharoplasty|"Participants under this group will undergo blepharoplasty from the oculoplastic clinic. These patients will form the case group of the cross-sectional study, and will be on follow-up for the prospective study."
10033487|NCT01787942|Placebo Comparator|Control|"Participants under this group will be recruited from the general ophthalmology clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the control group of the cross-sectional study."
9472256|NCT03611712|No Intervention|CCRT alone arm|
9472257|NCT03611699|Active Comparator|Umeclidinium bromide/vilanterol|Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that acts to reduce the amount of air trapped in the lungs at the end of of expiration.
9472258|NCT03611699|Placebo Comparator|Placebo|A placebo inhaler will be administered to serve as a control comparator to the umeclidinium bromide/vilanterol inhaler.
9472259|NCT03611686||patient followed for metastatic prostate adenocarcinoma|patient wil be followed for metastatic prostate adenocarcinoma during 3 years
9472260|NCT03611673|Experimental|Group A: 15 Scents|Participants will be asked to inhale 15 different scents two times a day.
9472261|NCT03611673|Active Comparator|Group B: 4 Scents|Participants will be asked to inhale 4 different scents two times a day.
9472262|NCT03611660|Active Comparator|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
9472263|NCT03611660|Experimental|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
9472264|NCT03611647|Active Comparator|Probiotic|
9472265|NCT03611647|Placebo Comparator|Placebo|
9472266|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
9472267|NCT03611608|Experimental|LY3316531 Dose 1|LY3316531 administered IV
9472268|NCT03611608|Experimental|LY3316531 Dose 2|LY3316531 administered IV
9472269|NCT03611608|Placebo Comparator|Placebo|Placebo administered IV
9472270|NCT03611595|Experimental|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
9472271|NCT03611543||Screening Patients|100 Patients. Each patient who agrees to participate and is consented and is undergoing a routine screening mammogram will receive her normal 4 view 2D plus 3D combination imaging (Left Cranial Caudal (LCC), Left Mediolateral-Oblique (LMO), Right Cranial Caudal (RCC), Right Mediolateral-Oblique (RMLO)) mammogram, with the current standard paddle. In addition she will also receive a CC and a MLO in one of her breasts as determined by a randomization scheme with the new investigational curved paddle. The amount of compression applied to both mammograms will be that to achieve tautness.
9472272|NCT03611543||Diagnostic Patients|400 Patients. Patients who agree to participate, are consented and are undergoing a diagnostic exam will have her prescribed diagnostic 2D plus 3D combination imaging as well as a CC or MLO with both the standard paddle and the new investigational curved paddle compressed to tautness on the breast of interest. The order of the paddles will be randomized and the view (CC or MLO) will be based in the visibility of the area of interest for which the diagnostic imaging was ordered. (It is possible that one of the views is superior to assess the area of interest).
9472273|NCT03611530|Experimental|CoQun®|Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
9472274|NCT03611530|Placebo Comparator|Placebo|Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.
9472275|NCT03611517|Experimental|Sexual rehabilitation programme|The intervention exists of a nurse-led sexual rehabilitation programme, which is provided in addition to the care as usual. The intervention consists of four one-hour sessions at 1 month, 3, 6, and 12 months after RT. Women treated with RTBT will receive an additional appointment with the nurse (2 months after RTBT). Furthermore, the latter group receives a vaginal dilator set.
9472276|NCT03611517|No Intervention|Care as usual|The control group receives the optimal care as usual, according to each participating hospital's guidelines. Additionally, all patients receive an information booklet including information concerning sexuality after RT for GC. Patients who underwent RTBT also receive a vaginal dilator set.
10033488|NCT01787955|Experimental|Braun anastomosis group|
10033489|NCT01787955|Active Comparator|conventional group|conventional Pylorus preserving pancreaticoduodenectomy
10033490|NCT01787968||TcI, TcII|TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping
10037169|NCT01822600|Experimental|Normal albumin group|"Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L.~Patients in this group receive intravenous omeprazole treatment."
10037170|NCT01822600|Experimental|Intervention group|"Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin < 30 g/L.~Patients in this group receive both Human albumin and intravenous omeprazole."
10033491|NCT01787994|Experimental|Cohort 1|"Cohort 1: HIV-1-positive women and men ≥18 years with a CD4 count > 350 cells/mm3, HIV-1-RNA levels undetectable by ultrasensitive HIV PCR Abbott assay. Subjects with HIV-1 RNA < 400 copies/mL are also eligible; however, the HIV-1 RNA must be < 50 copies/mL within 60 days prior to study entry based on the Abbott assay. Subjects with intermittent isolated episodes of detectable low level viremia (> 50 but <1,000 copies RNA/mL; blips) will be eligible.~There should be at least 2 documented HIV-1 RNA assays, one drawn >3 months before study entry, one drawn <3 months before study entry. Subjects should be on HAART (no changes to treatment within 4 weeks of study entry) for at least 3 months.~Cohort 1 subjects will receive a single dose of MazF-T cells."
10033492|NCT01787994|Experimental|Cohort 2|"Cohort 2: HIV-1-positive men and women ≥18 years with a CD4 count > 450 cells/mm3, having well controlled HIV replication on HAART. The subjects should have a CD4 nadir ≥200 cells/mm3. Subjects in Cohort 2 will participate in a 16 week analytical treatment interruption beginning 2 weeks after T cell infusion.~Cohort 2 subjects will receive a single dose of MazF-T cells."
10033493|NCT01788007|Experimental|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
10033494|NCT01788007|Placebo Comparator|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
10033495|NCT01788007|Active Comparator|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
10033496|NCT01788020|Experimental|DRC+Bortezomib|"Induction experimental arm (Arm B):~Cycle 1:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5~Cycle 2-6:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
10033497|NCT01788020|Active Comparator|DRC|"Induction standard arm (Arm A)~Cycle 1:~Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5;~Cycle 2-6:~Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
10033498|NCT01788033|Active Comparator|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
9472277|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
9472278|NCT03611491|Experimental|Princess® FILLER Lidocaine|Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point
9472279|NCT03611478|Experimental|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
9472280|NCT03611478|Placebo Comparator|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
9472281|NCT03611465|Other|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
9472282|NCT03611465|Experimental|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients scheduled for a cardiac defibrillator implantation in primary prevention.
9472283|NCT03611465|Experimental|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
9472284|NCT03611452|Experimental|Simple continuous|the sutures will be taken continuously by simple method
9472285|NCT03611452|Active Comparator|subcuticular|the sutures will be taken subcuticular
9472286|NCT03611452|Active Comparator|interrupted|the sutures will be taken interrupted method
9472287|NCT03611439|Active Comparator|ReBuilder Actives|Subjects take one 650 mg capsule by mouth twice a day for 12 months.
9472288|NCT03611439|Placebo Comparator|ReBuilder Placebo|Subjects take one placebo capsule by mouth twice a day for 12 months.
9472289|NCT03611426|Experimental|rhThrombin ( Topical )|Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
9472290|NCT03611426|Placebo Comparator|placebo|Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy;
9472291|NCT03611413||ERAS programme|Patients who have been treated under an ERAS programm
9472292|NCT03611413||conventional care|Patients who have been treated under an conventional care
9472293|NCT03611400|Experimental|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
9472294|NCT03611400|Placebo Comparator|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
9472295|NCT03611387||Normal|Patients without any type of glaucoma
9472296|NCT03611387||Primary angle closure glaucoma|Patients with primary angle closure glaucoma
9472297|NCT03611387||Primary open-angle glaucoma|Patients with primary open-angle glaucoma
9472298|NCT03611374|Experimental|Erector Spinae Plane Block|All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
9480356|NCT03534336|No Intervention|Control|"Participants are enrolled in a 12-week, self-administered online weight loss program. The program is delivered through 12 weekly sessions; each includes educational videos and a health literacy quiz. Each quiz contains 10 questions, and a quiz is considered passed when at least 7 questions are answered correctly. All participants are encouraged to follow the program, take the quizzes, and lose 5% of their baseline body weight by the end of the program.~No financial incentives are given for losing weight or passing quizzes."
9480357|NCT03534336|Experimental|Incentive for Education|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Education for passing at least nine quizzes by the end of the program."
9472299|NCT03611348|Active Comparator|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
10033499|NCT01788033|Placebo Comparator|Placebo|0.3 mg/kg placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
10033500|NCT01788059|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.
10033501|NCT01788072|Active Comparator|Intranasal Oxytocin|
10033502|NCT01788072|Placebo Comparator|Placebo|
10033503|NCT01788085|Experimental|pH monitoring procedure|Bravo pH monitoring procedure
10033504|NCT01788098||Rheumatoid Arthritis|Patients with rheumatoid arthritis
10033505|NCT01788098||Healthy controls|Healthy control subjects
9472300|NCT03611348|Active Comparator|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
9472301|NCT03611335||Site 1 H+H|Lincoln Medical and Mental Health Center
9472302|NCT03611335||Site 2 H+H|Bellevue Hospital
10033506|NCT01788111|Experimental|Low back exercises 1|Specific low back extensor exercises in special training bench
10033507|NCT01788111|Active Comparator|Low back exercise 2|Traditional low back exercises.
10033508|NCT01788124||Metal Speculum|exam with metal speculum
10033509|NCT01788124||Plastic Speculum|exam with plastic speculum
10033510|NCT01788137|Active Comparator|CHOP|CHOP regimen Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles.
10033511|NCT01788137|Active Comparator|c-ATT regimen|c-ATT regimen Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
10033512|NCT01788176|Placebo Comparator|Saline|One single intravenous infusion of 100ml of saline (placebo control group).
10033513|NCT01788176|Active Comparator|Zoledronic acid|one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
10033514|NCT01788189|Experimental|Lenalidomide|"The LeMLAR protocol:~Lenalidomide 25 mg p.o., days 1 - 21; Methotrexate 30 - 60 - 90 - 120 - 150 mg/m² i.v. bolus, days 1, 8, 15; Leucovorin 4 x 45 mg p.o. (every 6 hrs), days 2, 9, 16; Cytarabine (Ara-C) 75 - 150 - 225 - 300 - 375 mg/m² i.v. bolus, days 1, 8, 15; Rituximab 375 mg/m² i.v. infusion, day 1.~28-day cycles, maximum 6 cycles, definition of dose-limiting toxicity in cycles 1 and 2, intra-patient dose escalation after cycles 2 and 4 in case of absence of dose-limiting toxicity in previous cycles"
10033515|NCT01788241||CAG and CT group|CAG group = patients included based on coronary angiography screening; CT group = patients included based on computed tomography screening
10033516|NCT01788254|Experimental|Drug cocktail|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
9472303|NCT03611335||Site 3 H+H|Metropolitan Hospital
9472304|NCT03611335||Site 4 H+H|Elmhurst Hospital Center
9472305|NCT03611335||Site 5 H+H|Coney Island Hospital
9472306|NCT03611335||Site 6 H+H|Woodhull Medical and Mental Health Center
9472307|NCT03611322|Experimental|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
9472308|NCT03611322|Active Comparator|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
9472309|NCT03611309|Experimental|Surgeon-palliative care team co-management|In the Surgeon-palliative care team co-management arm, all patients receive the surgical care of surgeon alone management, which includes surgeon and the surgical team. In addition to this surgeon alone care, palliative care will also be provided by a specialist team. For patients in this arm, patients and/or family members will be seen by the palliative care team: (1) in an outpatient setting prior to surgery, (2) in the hospital within 72 hours of their initial surgery and as needed afterwards, and (3) via phone on in-clinic (per patient preference) on an at least monthly basis and/or as needed for 12 weeks following surgery.
9472310|NCT03611309|Other|Surgeon alone management|The surgeon and surgical team will manage symptoms, psychosocial support, and prognostic related communication. The surgeon and surgical team care for the patient and their family both prior to and following surgery. The surgeon team is given guidelines published by the National Cancer Coalition Network as to when palliative care specialist consultation is recommended
9472311|NCT03611283|Experimental|Test group|"Patients had to use:~Mouthwash treatment (250 ml): Aqua, Betaine, Glycerin, PEG-40, Hydrogenated Castor Oil, Propylene Glycol, Xylitol, Aroma, Potassium Phosphate, Diazolidinyl Urea, Allantoin, Olea Europaea Fruit Oil, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Panthenol, Tocopheryl Acetate, Sucralose, Carum Petroselinum Seed Oil, Limonene.~Toothpaste treatment (50 ml): Glycerin, Aqua, Hydrated Silica, Xylitol, Betine, Tetrapotassium Pyrophosphate, Olea Europaea Fruti Oil, Xanthan Gum, Titanium Dioxide, Potassium Phosphate, Aroma, Sodium Fluoride, Diazolidinyl Urea, Papain, Carum Petroselinum Seed Oil, Panthenol, Tocopheryl Acetate, Limonene"
9472312|NCT03611283|Placebo Comparator|Placebo group|"Patients had to use:~Mouthwash placebo(250 ml): Aqua, Glycerin, PEG-40 Hydrogenated Castor Oil, Propylene Glycol, flavoring, Potassium Phospate, Diazolidinyl Urea, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Tocopheryl Acetate, Sucralose, LImonene.~Toothpaste placebo (50 ml): Aqua, Sorbitol, Hydrated Silica, Glycerin, Tetrapotassium Pyrophosphate, Xanthan Gum Titanium Dioxide, Sodium Lauryl Sulphate, Potassium Phosphate, flavoring, Sodium Fluoride, Diazolidinyl Urea, Sucralose, Limonene"
9472313|NCT03611257|Experimental|dRAST|"Hematologic patients with bacteremia will receive antibiotics based on dRAST results."
9472314|NCT03611257|Active Comparator|Current standard method|Hematologic patients with bacteremia will receive antibiotics based on current standard method results.
10033517|NCT01788267|Experimental|Healthy volunteers|Volunteers realize a HR-pQCT scanner
9472315|NCT03611244|Experimental|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
9472316|NCT03611244|No Intervention|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
9472317|NCT03611231|Experimental|Experimental|chidamide
9472318|NCT03611218|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.
9472319|NCT03611205|Experimental|Diagnostic (dPET/CT)|Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.
9472320|NCT03611192|Experimental|Multicomponent exercise group|
10033518|NCT01788267|Experimental|Cystic Fibrosis patient|Patients realize a HR-pQCT scanner
10033519|NCT01788280|Experimental|All participants|All enrolled participants
10033520|NCT01788293|Active Comparator|Intervention group|Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
10033521|NCT01788293|No Intervention|Control group|Control group will receive fluid at the discretion of the anesthetist
10033522|NCT01788319|Experimental|lasertrabeculoplasty|
9472321|NCT03611192|Active Comparator|Home-program exercise group|
9472322|NCT03611179|Experimental|advanced ovarian cancer cases|patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 & Carboplatin AUC 5 every 21 days)
9472323|NCT03611140|Experimental|Dietary portfolio (DP)|The dietary portfolio was given daily at the breakfast and dinner for 2 months. The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein, oat, and inulin) that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
9472324|NCT03611140|Placebo Comparator|placebo (P)|The placebo (P) was given daily at the breakfast and dinner for 2 months. The placebo intervention consisted of a mixture of calcium caseinate, maltodextrins, sweetener and of artificial flavoring that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
9472325|NCT03611127|Experimental|early pulmonary rehabilitation (EPR)|early pulmonary rehabilitation started shortly after hospital discharge for COPD exacerbation.
9472326|NCT03611127|No Intervention|Usual care (UC)|No pulmonary rehabilitation for this group
9472327|NCT03611114|Experimental|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
10033523|NCT01788332|Active Comparator|Olaparib|3 100mg tablets to be administered twice a day with approximately 240ml of water.
9472328|NCT03611114|Placebo Comparator|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
9472329|NCT03611088|Experimental|Newborns submitted to Kangaroo Position.|
9472330|NCT03611088|No Intervention|Newborns not submitted to Kangaroo Position.|
9472331|NCT03611049|Placebo Comparator|Low dose Vitamin D intervention|intervention includes 800 IU Vitamin D3 replacement
9472332|NCT03611049|Active Comparator|High dose Vitamin D intervention|Intervention includes 5000 IU Vitamin D3 replacement
9472333|NCT03611036|Experimental|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
9472334|NCT03611036|Active Comparator|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
9472335|NCT03610984||Intensive structured education group|Regular outpatient visit in every 3 months to these patients. The glucose control and diabetes complication screening will be evaluated in visit. Patients will also be evaluated by specialized psychologists, dietitians and therapists. Diabetes self-management education will be regularly exposed to patients
9472336|NCT03610984||Conventional education group|Outpatients visit to endocrinologists when necessary in a conventional way.
9472337|NCT03610958|Experimental|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
10033524|NCT01788332|Placebo Comparator|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water.
10033525|NCT01788345|Experimental|non-invasive ventilation|
10033526|NCT01788371|No Intervention|No antiviral arm|provide standard of care to mothers and standard immunoprophylaxis to their infants
10033527|NCT01788371|Experimental|Lamivudine|lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
9472338|NCT03610945|Experimental|EDP-305 and fluconazole interaction (Part 1)|
9472339|NCT03610945|Experimental|EDP-305 and quinidine interaction (Part 2)|
9472340|NCT03610932|Experimental|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
9472341|NCT03610932|Active Comparator|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
10033528|NCT01788371|Experimental|Telbivudine|Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
10033529|NCT01788384|Active Comparator|Acanya|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
10033530|NCT01788384|Experimental|Clindamycin Phosphate / Benzoyl Peroxide|Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
10033531|NCT01788384|Placebo Comparator|Vehicle Gel|Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
10033532|NCT01788397|Experimental|Physical activity|Physical activity 2-4 times pr. day
10033533|NCT01788397|No Intervention|Control group|No intervention in the control group
10033534|NCT01788410||Cryoablation under image guidance|Patients with facet joint disease, or compressed or damaged nerve roots causing pain in the head, neck or spine. Procedures performed with MRI Seednet Cryotherapy System (Galil Medical).
10033535|NCT01788436|Experimental|Group 1: Patients with schizophrenia|
10033536|NCT01788436|Active Comparator|Group 2: Young healthy volunteers|
10033537|NCT01788436|Experimental|Group 3: Elderly healthy volunteers|
10033538|NCT01788462||HIV and Lipodystrophy|The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).
10033539|NCT01788488|No Intervention|Standard Therapy|
10033540|NCT01788488|Experimental|Procalcitonin-guided therapy|Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
9472342|NCT03610919|Experimental|Oxytocin nasal spray(5 doses)|Oxytocin nasal spray for 5 days, 24 IU per day
9472343|NCT03610919|Experimental|Oxytocin nasal spray(3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day.
9472344|NCT03610919|Placebo Comparator|Placebo nasal spray(control group)|Placebo nasal spray for 5 days,24 IU per day.
9472345|NCT03610893|Active Comparator|Perineural dexamethasone|addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
9472346|NCT03610893|Active Comparator|Perineural dexmedetomidine|addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
9472347|NCT03610880|Experimental|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
9472348|NCT03610880|Experimental|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
9803158|NCT04499274|Experimental|2000 ng/ml|Blood specimen which was added 2 ul of ondansetron
10033541|NCT01788501|Experimental|Tacrolimus/Methotrexate|"Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
10033542|NCT01788501|Active Comparator|Cyclosporine/Methotrexate|"Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
10033543|NCT01788514|Other|Videogame|Subject will play educational videogame
10033544|NCT01788527|Experimental|CGM|Continuous Glucose Monitoring
10033545|NCT01788527|No Intervention|HGM|Standard of care, Home Glucose Monitoring
10033546|NCT01788540|Experimental|Intralipid|"IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.~the intralipid infusion is then repeated within the one week of positive pregnancy test and every 2 weeks till end of first trimester"
10033547|NCT01788540|No Intervention|Control|No intervention
10033548|NCT01788553||patients with generalized anxiety disorder|
10033549|NCT01788579|Experimental|Multimedia WINGS|A one-hour session of a self-paced multimedia IPV screening, brief intervention and referral service delivered on a computer.
10033550|NCT01788579|Active Comparator|Caseworker Delivered WINGS|A one-hour session of IPV screening, brief intervention and referral service delivered by a case manager.
10033551|NCT01788605|Experimental|ramosetron|
10033552|NCT01788618|Other|Experimental group|Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
10033553|NCT01788618|Other|The control group 1 (Homework)|Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
10033554|NCT01788618|Other|Control group 2 ( telephone follow)|Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
10033555|NCT01788644||No treatment (observational study)|
10033556|NCT01788657|Experimental|Standard internet-based cognitive behavior therapy|Standard internet-based cognitive behavior therapy for depression with a written treatment material consisting of 60000 words (textmaterial only).
9472349|NCT03610867|Experimental|Furaprevir capsule (SAD)|single ascending oral dose (100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
9472350|NCT03610867|Placebo Comparator|Placebo (SAD)|"Single ascending oral dose of Furaprevir similar capsule.~."
9472351|NCT03610867|Experimental|Furaprevir capsule (MAD)|multiple ascending oral doses (200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
9472352|NCT03610867|Placebo Comparator|Placebo (MAD)|Multiple ascending oral doses of Furaprevir similar capsule
9472353|NCT03610854|Experimental|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
9472354|NCT03610841||preterm labor|Workgroup consists of patients which diagnosed with preterm labor between the age of 21 and 34
9472355|NCT03610841||healthy|24-36 6/7 weeks of pregnant between the age of 21 and 34
9472356|NCT03610789||REDAPT Revision Femoral System|REDAPT Revision Femoral System Monolithic Sleeveless Stems, monolithic sleeved stems and/or Acetabular Components or modular shells and/or augments
9472357|NCT03610776|Experimental|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
9472358|NCT03610776|Active Comparator|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
9472359|NCT03610763|Active Comparator|Transplantation/Replantation Patients|Can plateaued hand function in hand transplantation patients/hand replantation patients in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
9803159|NCT04499274|Experimental|20000 ng/ml|Blood specimen which was added 20 ul of ondansetron
9472360|NCT03610763|Active Comparator|Nerve Injury Patients active|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
9472361|NCT03610763|No Intervention|Actigraphy Testing|We will acquire a set of actigraphy data from a group of hand transplant/replant patients and unilateral, adult amputees in order to evaluate typical patterns of limb use prior to hand transplantation and to investigate prosthesis utilization.
9472362|NCT03610711|Experimental|Arm A Nivolumab Only|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
9472363|NCT03610711|Experimental|Arm B Nivolumab + Relatlimab|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks and Relatlimab (anti-LAG3) every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
9472364|NCT03610698|Experimental|Facilitated Intervention|Intervention arm facilitated by a trained team member, delivering the 8 positive emotion skills over 5 weeks.
9472365|NCT03610698|Experimental|Self-Guided Intervention|Intervention arm that is self-guided on an online platform, delivering the 8 positive emotion skills over 5 weeks.
9472366|NCT03610698|Active Comparator|Emotion Reporting Control|Participants in the emotion reporting control condition will be reporting their emotions daily for the same length as the intervention.
9472367|NCT03610685|Placebo Comparator|Placebo|Participants will be given 2 weeks of placebo treatment. The placebo capsules will be taken once a day orally. The daily dose of placebo treatment will match the Prednisone dose for each participant.
9472368|NCT03610685|Active Comparator|Prednisolone|Participants will be given 2 weeks of prednisolone treatment. This is administered orally once a day. The daily dose is calculated according to 0.5mg/kg with a maximum dose of 40mg per day.
9472369|NCT03610672|Active Comparator|OD prevention/response training|Immediately following the baseline assessment, trained research staff will conduct a brief (20 min.) OD training with each participant. Participants will be asked to view the NYC Department of Health and Mental Hygiene's 13-minute OD prevention and response training video (available online free-of-charge). Following the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to execute this assembly procedure. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
9472370|NCT03610672|Experimental|OD training + mobile PI intervention|Participants will complete the same baseline assessment and OD training (plus naloxone) as those in the first condition. Participants also will receive mobile phones pre-loaded with the PI App and will be sent daily prompts. As part of the PI App, participants will be asked to share information about avoiding problems associated with opioid use with peers in their social network, and to encourage their peers to download the PI App for their own use.
9472371|NCT03610620|Experimental|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
9472372|NCT03610607|Active Comparator|intense education of periodontal health maintenance|
10033557|NCT01788657|Experimental|Condensed internet-based cognitive behavior therapy|Condensed internet-based cognitive behavior therapy for depression with a written treatment material consisting of 30000 words (available as text or audio).
10033558|NCT01788670|Placebo Comparator|Water|Lemon-flavoured water (150 ml)
10033559|NCT01788670|Active Comparator|Ethanol high dose|The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
10033560|NCT01788670|Active Comparator|Ethanol low dose|The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
10033561|NCT01788696|Active Comparator|Group A - Early Imaging|Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52.
10033562|NCT01788696|Active Comparator|Group B - Delayed Imaging|Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment). Scan will take place at week 26 and week 52.
10033563|NCT01788709|Active Comparator|A|Fortrans (split dose) + Mentholyptus drops
10033564|NCT01788709|Active Comparator|B|MoviPrep (split dose)
10033565|NCT01788722||Group 1|
10033566|NCT01788748|Active Comparator|bipolar radiofrequency and infrared|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
10033567|NCT01788748|Active Comparator|fractional bipolar radiofrequency|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
9472373|NCT03610607|Placebo Comparator|No intense education of periodontal health maintenance|
9472374|NCT03610594|Experimental|kalaripayattu|The experimental groups will treated with kalaripayattu exercises for the period of 12 weeks
10033568|NCT01788748|Active Comparator|combined treatment|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
10033569|NCT01788761|Experimental|Probiotic Supplemented Group|500,000,0000 cells of Lactobacillus GG (utilizing either Culturelle for Kids or Kids Culturelle preparation) and 500,000,000 cells of Bifidobacterium Infantis (utilizing Align capsule) diluted in 3 ml breastmilk/formula and administered enterally from first day of enteral feeds until term gestation/discharge/transfer/death (whichever occurs first) every day infant is receives enteral feedings
9472375|NCT03610594|No Intervention|Wait list control|Control group will not be given any intervention. After the treatment period is over, all the subjects will be given Kalaripayattu training.
9472376|NCT03610568|Experimental|Growing up GREAT! Intervention|
9472377|NCT03610568|No Intervention|Control|
10033570|NCT01788761|Sham Comparator|Control Group|3 ml enteral feeding of breastmilk/formula administered once daily in addition to regularly prescribed enteral feedings from day of first feeding until term gestation/discharge/transfer/death (which ever occurs first) and administered every day that infant receives enteral feedings
10033571|NCT01788774|Other|Risperidone ISM 50mg|Three different single doses will be evaluated
9472378|NCT03610555||Current website|Show patient one of the website
9472379|NCT03610555||New patient centered website|Show patient another (different) of the website
9472380|NCT03610542|Experimental|Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting.
9472381|NCT03610542|Experimental|Cognitive Behaviour Therapy with 2 Booster Sessions|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting. 2 booster sessions (forty-five minutes each) will be provided at three and nine months. Each session will recap the content of the initial 6 sessions.
9472382|NCT03610542|No Intervention|Control|This is a no intervention control arm
9472383|NCT03610529|Experimental|ECG monitoring system CardioSenseSystem group|
9472384|NCT03610529|Active Comparator|ECG monitoring system Philips Intellivue|
9472385|NCT03610503|Experimental|Music|Patients listen to music during EMG test
10033572|NCT01788774|Other|Risperidone ISM 75mg|Three different single doses will be evaluated
10033573|NCT01788774|Other|Risperidone ISM 100mg|Three different single doses will be evaluated
10033574|NCT01788787||Texas Quitline|Patients interested in smoking cessation treatment by calling the Texas Quitline.
10033575|NCT01788787||Training Providers|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians).
10033576|NCT01788800|Experimental|Exercise training|"Cognitive Behavioural Therapy (CBT)~+ Exercise training 3 times/week, 30 minutes on a treadmill, 70% maximal oxygen uptake (VO2max), 8 weeks"
10033577|NCT01788800|Active Comparator|Movements|"Cognitive Behavioural Therapy (CBT)~+ Low intensity physical activity without cardiovascular activation, 3 times/week, 30 minutes, 8 weeks"
9472386|NCT03610503|No Intervention|Control (Standard Care)|Patients do not listen to music during EMG test (ie. Standard of care)
9472387|NCT03610477|Active Comparator|Medium Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.
9472388|NCT03610477|Placebo Comparator|Long Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.
9472389|NCT03610425||Post-op evidence based bundle w/ Pre-op education|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the post-operative evidence based bundle/standard pre-operative education.
9472390|NCT03610425||Standard pre-operative education alone|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the standard pre-operative education alone.
9472391|NCT03610412|Active Comparator|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
9472392|NCT03610412|Placebo Comparator|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
9472393|NCT03610373|Experimental|Shared Decision Making|In this arm, parents and children will participate in a shared decision-making protocol with the clinician to plan their treatment. The treatment options available are established, evidence-based treatment techniques. The shared decision-making protocol was developed for this research project.
9472394|NCT03610373|Active Comparator|Clinician Guided|In this arm, the clinician will plan the treatment in consultation with their supervisor, and share the treatment plan with the parent and child. The parent and child will have the opportunity to ask questions about the treatment plan (and, if they do not agree, reject the treatment plan), but they are not actively involved in making each decision. This is more typical of usual care.
9472395|NCT03610360|Active Comparator|Arm A|Arm A will receive the study drug MesoPher plus best supportive care
9472396|NCT03610360|No Intervention|Arm B|Arm B will follow best supportive care as deemed appropriate by the investigator.
9472397|NCT03610347|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
9472398|NCT03610347|Active Comparator|Drug-Eluting Stent (DES)|Sirolimus Eluting Stent (Orsiro®)
9472399|NCT03610321|Active Comparator|Statin group|Receiving statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) only for 1 month.
9472400|NCT03610321|Experimental|Gefarnate group|Combined treatment with statins (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) and gefarnate (100 mg, three times daily, oral) for 1 month.
9472401|NCT03610295|Experimental|PPI group|cataract extraction surgery with prophylactic peripheral iridectomy
9472402|NCT03610295|Active Comparator|historical control group|cataract extraction surgery
9472403|NCT03610282|Experimental|EEG Dynamics|EEG data will be collected on patients receiving propofol and IV methylphenidate together.
9472404|NCT03610282|Placebo Comparator|Propofol EEG Dynamics|EEG data will be collected on patients receiving propofol and a saline placebo.
9480358|NCT03534336|Experimental|Incentive for Weight Loss|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Weight Loss for losing 5% of their baseline body weight."
9480359|NCT03534310|Active Comparator|Lifestyle modification|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive
10033578|NCT01788813|Experimental|GSK2245035 Arm|Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).
9472405|NCT03610243|Experimental|Self-administered acupressure|"The proposed self-administered acupressure intervention is patient-centered comprising four pre-selected acupoints that should be applied pressure on by all patients and a list of additional acupoints from which patients can choose two for self-administration according to the personalized recommendations of trainers. In this way, each patient will receive an individualized protocol (four pre-selected and two self-selected acupoints).~The intervention consists of: individual participant training (Two 2-hour one-on-one training sessions in week 1), self-practice (15 minutes of self-administered acupressure twice a day), and follow-up visits (a 1-hour follow-up visit at weeks 2, 3, and 4)."
10033579|NCT01788813|Placebo Comparator|Placebo Arm|Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)
10033580|NCT01788826|Experimental|Prophylactic Mesh|Use of a prefascial polypropylene mesh when closing midline laparotomy
10033581|NCT01788826|Experimental|No prophylactic mesh closure|In this arm the laparotomy of the patients are closed with a running absorbable suture without a mesh
10033582|NCT01788852||Perinatally HIV-infected adolescents|Perinatally HIV-infected adolescents
10033583|NCT01788852||behaviorally HIV-infected adolescents|behaviorally HIV-infected adolescents
10033584|NCT01788852||HIV negative adolescents|HIV negative adolescents
10033585|NCT01788865|Experimental|cSEMS|Patients with malignant ureteral obstruction have cSEMS(Covered self-expandable dual-layered metal stent) implant
10033586|NCT01788878|Experimental|Questionnaires|completion of questionnaires
10033587|NCT01788891||second-line pediatric cohort|Asian HIV-positive children <18 years old who are receiving HIV care at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD) sites that have been identified for TASER-P participation will be monitored for treatment failure of second-line ART
9472406|NCT03610243|No Intervention|Wait-list control|The wait-list control group will be contacted in the third week to attend a health talk unrelated to symptom management.
10033588|NCT01788904||Patients with acute mesenteric ischemia|Patients with acute mesenteric ischemia meeting the in-/exclusion criteria
10033589|NCT01788917|Active Comparator|linseed oil|
10033590|NCT01788930|Active Comparator|CPAP|"This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.~Other Name: positive airway pressure"
9472407|NCT03610230|Experimental|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
9472408|NCT03610230|Active Comparator|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
9472409|NCT03610217|Experimental|Interstitial lung disease induction|
9472410|NCT03610217|Experimental|Pulmonary arterial hypertension|
9472411|NCT03610217|Experimental|Raynaud's phenomenon|
9472412|NCT03610217|Experimental|Digital ulcers|
9472413|NCT03610217|Experimental|Inflammatory arthritis|
9472414|NCT03610217|Experimental|Gastroesophageal reflux|
9472415|NCT03610217|Experimental|Bacterial overgrowth|
9472416|NCT03610217|Experimental|Constipation|
9472417|NCT03610217|Experimental|Skin involvement|
9472418|NCT03610217|Experimental|Pain|
9472419|NCT03610204|Experimental|Deep massage (DM) group|"The therapist performs the deep massage with buffalo horn technique. A small rod with a cone-like end was used in the technique. By pressuring the rod end with a higher force against the body surface of the participant, it produces higher pressure that may release the deep-layer fascia of muscles. Thus this technique features a deep massage."
9472420|NCT03610204|Active Comparator|Superficial massage (SM) group|"The therapist performs the superficial massage with buffalo horn technique. By pressuring the rod end with a lower force against the body surface of the participant, it produces lower pressure. Thus this intervention features a superficial massage."
9472421|NCT03610191||Surgery|Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin.
9472422|NCT03610191||non-surgical control|Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients.
9472423|NCT03610178|Active Comparator|very tight glycemic targets|
10033591|NCT01788930|Placebo Comparator|Sham-CPAP|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
10033592|NCT01788956||ICU Patients|80 subjects (male and female)
9472424|NCT03610178|Active Comparator|tight-moderate glycemic targets|
9472425|NCT03610178|No Intervention|Control group|Only observation in women with normal glucose tolerance
9472426|NCT03610152|No Intervention|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
9472427|NCT03610152|Experimental|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
9472428|NCT03610139|Active Comparator|low dose vitamin D3 supplementation|Patients in this group will take 800 IU daily dose of vitamin D supplementation. They will be kept on 800 IU for 6 months. If they still had low vitamin D at 3 months, they will be asked about their adherence to the supplement, the investigators will remind them to take it as prescribed, and the investigators will keep the 800 IU vitamin D supplement dose for another 3 months. If they were still deficient at 6 months, the investigators will switch them to 10,000 IU weekly dose.
9480360|NCT03534310|Experimental|Lifestyle modification plus Liraglutide 3 mg|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive. The patients will also receive Liraglutide 3 mg daily sc.
10033593|NCT01788969|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training 4 weeks (3 X week) with Lexapro (10mg SSRI), wash out period of 1 week, gait training, for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
10033594|NCT01788969|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
10033595|NCT01788982|Experimental|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
10033596|NCT01788982|Placebo Comparator|Placebo|Placebo should be administered orally at a dose of 200 mg twice daily. Cross-over to nintedanib is allowed after progression.
10033597|NCT01788995||Cohort|
10033598|NCT01789008|Other|Transient elastography|evaluation of fibrosis stage by transient elastography
10033599|NCT01789008|Active Comparator|liver biopsie|evaluation of fibrosis stage by liver biopsie
10033600|NCT01789060||p-AKT|p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
9472429|NCT03610139|Experimental|high dose vitamin D3 supplementation|"Patients in this group will take 50,000 IU weekly dose of vitamin D supplementation. Patients who will reach normal serum vitamin D level, between 40-80 ng/ml, at 3 or 6 months will be asked to decrease their Vitamin D3 supplementation as follows: Those who will reach levels between 40-60ng/ml will be switched to 10,000 IU three times per week, and those who reach levels between 60-80 ng/ml will be switched to 10,000 IU once weekly.~If they did not have any improvement in their levels of vitamin D at 3 or 6 months, they will be asked about their adherence to the supplement and the investigators will remind them to take it as prescribed and the investigators will keep them at the 50,000 IU weekly dose."
9472430|NCT03610126||volume controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
10033601|NCT01789073|Experimental|Oral Impact, Nestlé Health Science|Oral Impact-arm receives the intervention the last 7 days prior to surgery
10033602|NCT01789073|No Intervention|Control|The control-arm receives no intervention but is treated according to the standard procedures
10033603|NCT01789086|Experimental|Liraglutide|
9472431|NCT03610126||pressure controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode
9472432|NCT03610113|No Intervention|CONSERVATIVE TREATMENT|Conservative treatment is conceived to the use of sling for three weeks, followed by rehabilitation protocol
9472433|NCT03610113|Experimental|REVERSE ARTHROPLASTY TREATMENT|"This group receives a surgical intervention by the use of reverse shoulder arthroplasty through deltopectoral approach and tuberosities reattachment.~It is followed by the same rehabilitation protocol than conservative treatment"
9472434|NCT03610100|Experimental|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
9472435|NCT03610100|Active Comparator|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
9472436|NCT03610087|Other|Low Intensity Intervention|The comparison group (low intensity) receives access to the e-platform and given an educational package with information about nutrition, physical activity, and smoking based on the NAVIGATE program (Mueser et al., 2015); i.e., a comprehensive program for implementing coordinated speciality care) with weekly e-mail reminders for 12 weeks. Participants receive access to online resources and free online webinars about these healthy behaviours.
9472437|NCT03610087|Experimental|High Intensity Intervention|The intervention group (high intensity) receives a technology-enabled CCM intervention. Participants receive access to an online platform and infographic modules to learn more about nutrition, physical activity, and smoking cessation. Also, they are assigned a personal health coach who collaboratively schedules weekly virtual sessions via the platform to discuss the educational materials, goal setting and motivation, and provide support in the 12-week program. The participant's health coach reviews the participant's concerns and goals weekly with a virtual care team (VCT; including a psychiatrist, addictions specialist, nutrition specialist, peer mentor, and recreational therapist), who provides individualized recommendations to include in the participant's treatment plan. Participants have access to online resources and online webinars about nutrition, physical activity and smoking.
9472438|NCT03610074|Experimental|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
9472439|NCT03610035|Experimental|Experimental|NPT189
9472440|NCT03610035|Placebo Comparator|Placebo Comparator|Placebo
9472441|NCT03610022|Experimental|Patients with BCC and annexial carcinoma|Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib
10033604|NCT01789086|Placebo Comparator|Placebo|
10033605|NCT01789099|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
10033606|NCT01789112|Experimental|CCM aggregate|Taking of 10 blood samples
10033607|NCT01789125|Active Comparator|Smoking Termination and Anxiety Reduction Treatment|Cognitive-behavioral treatment program that blends smoking cessation and anxiety reduction treatment strategies
10033608|NCT01789125|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
10033609|NCT01789164||Healthy group|Healthy group with no history of TBI or concussion. Gender matched non-TBI volunteers
10033610|NCT01789164||TBI group|Males and females between 18 and 60 years who have a diagnosis of TBI and are symptomatic with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched non-TBI volunteers
9472442|NCT03610009|Active Comparator|2D ultrasound|Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
9472443|NCT03610009|Active Comparator|SonoAVC|SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
9472444|NCT03609996||PDR treated with Laser|
9472445|NCT03609996||PDR treated with Lucentis|
9472446|NCT03609983|Experimental|Daily Weighing|Participants will weigh themselves daily and receive feedback daily.
9472447|NCT03609983|Experimental|Weekly Weighing|Participants will weigh themselves weekly and receive feedback weekly.
9472448|NCT03609983|No Intervention|No Weighing|Participants will refrain from weighing themselves.
9472449|NCT03609970|No Intervention|Control|No intervention
9472450|NCT03609970|Experimental|UVR (Solar simulated radiation)|Twice weekly 1.25 SED (sub-erythemal) (4 weeks)
10033611|NCT01789177|Experimental|Modified incentive spirometry|Patients will be given a disposable incentive spirometer postoperatively and instructed to use the spirometer every hour while awake.
9472451|NCT03609970|Experimental|Vitamin D3 supplementation|4X 1000IU cholecalciferol tablets daily (28 days)
9472452|NCT03609957|Experimental|Aerobic Exercise Training|Moderate intensity (75% heart rate reserve) cycling exercise for 32 minutes, 3 days per week for 5 weeks
10033612|NCT01789177|Active Comparator|Postoperative chest physiotherapy|Patients will be given standard postoperative chest physiotherapy, according to hospital protocol, but will not receive incentive spirometers.
9472453|NCT03609957|Experimental|Interval Training|High intensity (95% heart rate reserve) cycling exercise for 20 minutes, 3 days per week for 5 weeks
9472454|NCT03609957|No Intervention|Control|Control (no exercise intervention) group
10033613|NCT01789190||Group S (sedentary)|Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
10033614|NCT01789190||Group A (active)|The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly
10033615|NCT01789216|Placebo Comparator|Placebo|"Standard pain management + perioperative intravenous placebo & oral placebo.~Control group will receive an oral dose of placebo up to two hours prior to surgery and twice daily for up to 48 hours following any surgery, in addition to an intravenous dose of placebo up to two hours prior to surgery and every 6 hours for up to 48 hours following surgery. All study medications will be in addition to standard of care pain medication.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
10033616|NCT01789216|Active Comparator|NSAID|"Standard pain management + perioperative intravenous ketorolac & oral placebo.~The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an oral dose of placebo up to two hours prior to the procedure and every 12 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
10033617|NCT01789216|Active Comparator|Gabapentinoid|"Standard pain management + perioperative intravenous placebo & oral pregabalin.~The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an IV dose of placebo up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
10033618|NCT01789229||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions."
10033619|NCT01789229||Benign controls|Patients with a benign tumor or an inflammatory disease - to be matched by age.
9472455|NCT03609931||Mitral Valve repair|Patients undergoing mitral valve repair
9472456|NCT03609905|Experimental|Intervention group|interventions: The MSCs of 5×10*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week，a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
9472457|NCT03609905|Other|Control group|interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
9472458|NCT03609892|Experimental|berberine plus amoxicillin quadruple therapy|Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
9472459|NCT03609892|Active Comparator|tetracycline plus furazolidone quadruple therapy|Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
9472460|NCT03609879|No Intervention|without cervical collar|baseline - without cervical collar
9472461|NCT03609879|Experimental|with cervical collar|scenarios with cervical collars
9472462|NCT03609866|Active Comparator|control|will be performed metatarsophalangeal joint passive mobilization
9472463|NCT03609866|Experimental|experimental|rapid thoracic compression technique will be applied
9472464|NCT03609827||Pediatric patients undergoing Hematopoietic Stem Cell Transplant|Children undergoing allogeneic hematopoietic stem cell transplant (alloHCT) at University of California, San Francisco Benioff Children's Hospital.
9472465|NCT03609814||Pediatric Bone Marrow Transplantation Recipients|Children undergoing alloHCT at UCSF Benioff Children's Hospital.
9472466|NCT03609775|Experimental|Treatment A (ethanol + ACT-541468)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
9472467|NCT03609775|Experimental|Treatment B (ethanol placebo + ACT-541468)|5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
9472468|NCT03609775|Experimental|Treatment C (ethanol + ACT-541468 placebo)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
9472469|NCT03609775|Experimental|Treatment D (ethanol placebo + ACT-541468 placebo)|5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
9472470|NCT03609762|Experimental|Intervention group|EQ-5D-5L HRQOL results be available to the attending doctor
9472471|NCT03609762|No Intervention|Control group|usual care. All subjects attending the control clinics will not need to complete the electronic EQ-5D-5L before seeing the doctor during their follow-up visits. The doctor will manage the patient as usual, based on the usual clinical information. The doctor will complete the clinician-reported follow-up clinical data form (CRF) for each subject at the end of the consultation.
9472472|NCT03609749|Experimental|Mindfulness Training for Primary Care|"Experimental: Mindfulness Training for Primary Care For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3). For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, the investigators acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional fMRI study."
9472473|NCT03609723||MPS® in patients with CABG|Patients undergoing coronary artery bypass grafting with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC)
10033620|NCT01789229||Healthy controls|People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
10033621|NCT01789242|Experimental|Carfilzomib|All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
10033622|NCT01789294|Experimental|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects
9472474|NCT03609723||OPCABG in patients with CABG|Patients undergoing coronary artery bypass grafting without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
9472475|NCT03609710|Experimental|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
9472476|NCT03609710|Active Comparator|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
9472477|NCT03609684|Experimental|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
9472478|NCT03609684|Experimental|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
9472479|NCT03609684|Active Comparator|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
9472480|NCT03609671|Experimental|Standard of Care + Intervention (Individualized Therapy)|Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.
9472481|NCT03609671|Other|Control Group: Standard of Care|Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.
9472482|NCT03609645|Active Comparator|Fascia iliaca block (FIB)|Group will receive Fascia iliaca block (FIB) with local anesthetic and femoral articular branch block (FAB) with normal saline (Placebo).
9472483|NCT03609645|Experimental|Femoral articular branches block(FAB)|Group will receive Fascia iliaca block (FIB) with normal saline (Placebo) and Femoral AON articular branch block (FAB) with local anesthetic.
9472484|NCT03609632|Experimental|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
9472485|NCT03609606|Experimental|Part A, Sequence1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D013 on Day22~Day28"
9472486|NCT03609606|Experimental|Part A, Sequence 2|"Period 1: Treatment of D013 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
9472487|NCT03609606|Experimental|Part B, Sequence 1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D326 and D337 on Day22~Day28"
9472488|NCT03609606|Experimental|Part B, Sequence 2|"Period 1: Treatment of D326 and D337 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
9480361|NCT03534310|Active Comparator|Sleeve Gastrectomy|The patients will undergo laparoscopic sleeve gastrectomy
9480362|NCT03534297|Experimental|dapansutrile capsules|"A total of 8 patients in each cohort will receive dapansutrile capsules:~Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days~Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days~Cohort 3 will receive 5x 100 mg dapansutrile capsules QID for 14 days"
10033623|NCT01789294|No Intervention|Observation|A close clinical observation without therapy was taken in control patients, whom parents were alerted to refer immediately if symptoms persisted or get worse.
9480363|NCT03534297|Placebo Comparator|Placebo Capsules|"A total of 2 patients in each cohort will receive placebo capsules:~Cohort 1 will receive 5 placebo capsules QD for 14 days~Cohort 2 will receive 5 placebo capsules BID for 14 days~Cohort 3 will receive 5 placebo capsules QID for 14 days"
9480364|NCT03534219|Experimental|Intervention Arm: EarPopper|"All patients in this arm will receive the EarPopper device.~Length of administration: 1 year Dose: Dosing of the EP device will be twice per day, once in the morning and once before bedtime. This is consistent with previous dosing which showed no adverse events and an excellent safety profile. 5, 6~Administration:~Hold nosepiece firmly against nostril opening creating a good, tight seal is crucial. Plug the other nostril closed.~Push button to start the airflow and swallow while the device is running.~Repeat on other nostril. After 5 minutes, repeat steps 1 - 3. This will complete one treatment.~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
9480365|NCT03534219|No Intervention|Control|"All patients in this arm will not receive any intervention. EarPopper device will be given to this group at the end of follow-up period (1 year)~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
9480366|NCT03534193|Other|Group 1|Participants randomized to Group 1 will receive Standard Diabetic Education with Registered Nurse and Molly Center Diabetes Care Guide (paper-based)
10033624|NCT01789294|Experimental|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists
10033625|NCT01789307|Active Comparator|corn syrup solids|corn syrup solids oral ingestion
9472489|NCT03609593|Experimental|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
10033626|NCT01789307|Experimental|sucrose|sucrose oral ingestion
10033627|NCT01789333|Experimental|9 mw/cm2 at 10 minutes group|30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
9472490|NCT03609567|Experimental|Aromatherapy|Aromatherapy using essential oils
9472491|NCT03609567|Placebo Comparator|Placebo|Aromatherapy using odorless placebo
9472492|NCT03609554|Experimental|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
9472493|NCT03609554|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
10033628|NCT01789346|Other|532nm KTP laser|Cutera ExcelV 532nm KTP laser
10033629|NCT01789346|Active Comparator|595nm PDL|Cynosure Cynergy 595nm pulsed-dye laser
10033630|NCT01789359|Other|anthocyanin-free diet|Maintain anthocyanin-free diet throughout study. Day 1 to day 30, consume daily 250 ml single strength blueberry juice containing 229 mg anthocyanins, taken either as 1 morning dose or 1/3 dose morning, 1/3 mid-day and 1/3 evening. At d 31-38 continue anthocyanin-free diet. On d 39 consume daily dose.
10033631|NCT01789385|Other|dexmedetomidine|Precedex 200 mcg 2ml
10033632|NCT01789398|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
10033633|NCT01789398|Placebo Comparator|placebo|Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
9472494|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
9472495|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
9472496|NCT03609528|Experimental|CamPROBE biopsy method|To be completed
9472497|NCT03609515|Experimental|Patients with contract about patient-controlled admissions|Patients have a contract about short self-referred inpatient admissions in mental health services without approval by clinicians, for a maximum of 5 days and with a minimum of three weeks between such stays
9472498|NCT03609502|Experimental|behavioral|Adults with and without language impairment will be given three different types of behavioral training, and assessments of learning through those trainings, at two time points.
9472499|NCT03609502|Experimental|neuroimaging|Following speech sound behavioral training, adults with and without language impairment will undergo post-training perceptual assessments in an MRI scanner before and after post-training sleep.
9472500|NCT03609489|Experimental|Test Group|Apatinib combined with Capetabine
9472501|NCT03609489|Active Comparator|Control Group|Capecitabine
9472502|NCT03609476|Active Comparator|Standard of care group|No saline instillation
9472503|NCT03609476|Active Comparator|Room temperature saline group|room temperature saline instillation
9472504|NCT03609476|Active Comparator|Warmed saline group|warmed saline instillation
9472505|NCT03609463|Experimental|Well-being and small change|Participants will be randomized to receive 4 individual 1-hour weekly sessions of the well-being intervention before starting the 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
9472506|NCT03609463|Active Comparator|Small change|Participants will be randomized to receive 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
9472507|NCT03609450|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
9472508|NCT03609450|Other|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
9472509|NCT03609437||ESUS patients|Acute ischemic stroke patients satisfying embolic stroke of undetermined source (ESUS) diagnostic criteria.
9472510|NCT03609437||Controls|Healthy volunteers (colleagues, friends, relatives and others).
9472511|NCT03609424|Experimental|PDR001 plus Imatinib|
9472512|NCT03609411||Splenectomy|Patients undergoing liver transplantation with simultaneous splenectomy
10033634|NCT01789411||ATHEROREMO-IVUS cohort|Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
10033635|NCT01789437|Active Comparator|Dexamethasone Intravitreal Implant|
9472513|NCT03609411||Liver transplantation|Patients undergoing liver transplantation only
9472514|NCT03609398|Experimental|RVF Vaccine|1.0 mL dose given SQ in upper arm
10033636|NCT01789450|Experimental|Section of Periareolar Dermis|Section of Periareolar Dermis
10033637|NCT01789463|Active Comparator|Self rehabilitation|Self rehabilitation
10033638|NCT01789463|Experimental|Self rehabilitation plus physiotherapy|Self rehabilitation plus physiotherapy
10033639|NCT01789489|Active Comparator|3 dimensional sonohysterography|3 dimensional sonohysterography
10033640|NCT01789489|Active Comparator|Standard hysteroscopy|Standard hysteroscopy
10033641|NCT01789502|Active Comparator|Plastic stents|Plastic stents are inserted by ERCP
10033642|NCT01789502|Experimental|Fully covered metal stents|Fully covered metal stents are inserted by ERCP
10033643|NCT01789515||rectal cancer|Low Anterior Resection for Rectal Cancer
10033644|NCT01789528|Experimental|CAZ-AVI or CXL|"Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours~Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam)"
10033645|NCT01789541||Atrial fibrillation|Patients with atrial fibrillation undergoing ablation
10033646|NCT01789541||AV-nodal reentry tachycardia|Patients with AV-Nodal Reentry Tachycardia undergoing ablation
10033647|NCT01789554|Experimental|MLS dispatch for bystander CPR|When an alarm call of a suspected OHCA suspected is received by the EMS dispatch operator a Mobile positioning system (MPS) is activated. The MPS uses the mobile phone network to geographically locate all lay volunteers connected to a tailored mobile phone service called mobile life saver (MLS). The MPS then locates all lay volunteers within a pre defined radius from the suspected OHACA an alerts them with a computer generated voice call and an sms containing data about were about were the suspected OHCA is located. A map is also sent in order to make route finding easy.
10033648|NCT01789554|No Intervention|NO MLS dispatch for bystander CPR|No activation of mobile positioning system to locate and recruit lay responders to nearby OHCAs
10033649|NCT01789580|No Intervention|Control group|The participants play on their preferred online gambling site (experimental gambling session) without gambling moderator.
10033650|NCT01789580|Experimental|Bonus group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : bonus (with different modalities of the moderator).
10033651|NCT01789580|Experimental|Auto-exclusion group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto-exclusion.
10033652|NCT01789580|Experimental|Auto- limitation group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto- limitation(with different modalities of the moderator).
10033653|NCT01789580|Experimental|Information group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : information (with different modalities of the moderator).
10033654|NCT01789593|Other|Hypoglycaemia / euglycaemia clamp|
10033655|NCT01789593|Other|Euglycaemia clamp / hypoglycaemia|
10033656|NCT01789619||Extended release tacrolimus (Advagraf®)|
10033657|NCT01789645|Experimental|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
10033658|NCT01789645|Active Comparator|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
10033659|NCT01789658|Experimental|Cryotherapy|Cryotherapy during conditioning treatment with chemotherapy prior to HSCT
10033660|NCT01789658|No Intervention|Control|Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT
10033661|NCT01789671|Experimental|Peer Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by parents who previously received this treatment (PEER). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
10033662|NCT01789671|Active Comparator|Professional Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by behavioral specialists(PROFESSIONAL). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
10033663|NCT01789684|Experimental|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve 1) appropriate referral of breast cancer patients at risk for HBOC to genetic counseling in the community cancer center setting and 2) pre-surgical referral among newly diagnosed patients. They will also receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
10033664|NCT01789684|No Intervention|Passive Provider Intervention|Participating Sites assigned to the passive intervention cluster will only receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
10033665|NCT01789697|Experimental|Receives text messages/emails|Will receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
10033666|NCT01789697|No Intervention|Does not receive text messages/emails|Will not receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
10033667|NCT01789710|Experimental|Active Contingency Management|All participants are assigned to a single arm, active contingency management. In this arm, participants are provided monetary rewards for remaining abstinent from smoking.
10033668|NCT01789723|Experimental|Cohort 1: Fusilev - 10 doses|"Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
10033669|NCT01789723|Experimental|Cohort 2: Fusilev - 6 doses|"Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
10033670|NCT01789723|Experimental|Cohort 3: Fusilev - 4 doses|"5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
10033671|NCT01789723|Experimental|Cohort 4: Fusilev - 2 doses|"5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
10033672|NCT01789723|Experimental|Cohort 5: Fusilev - 1 dose|"Fusilev: 5 mg/m2 once on Day 2.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
10033673|NCT01789749|Active Comparator|No Coagulation Arm|Patients do not receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
10033674|NCT01789749|Experimental|Coagulation Arm|Patients to receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
10033675|NCT01789762|Active Comparator|Historical control arm|Patients transfused with platelet concentrates re-suspended in autologous plasma
10033676|NCT01789762|Active Comparator|Control arm|Patients transfused with platelets prepared in additive solution
10033677|NCT01789762|Experimental|Experimental arm|Patients transfused with platelets treated by pathogen reduction process
10033678|NCT01789788|Placebo Comparator|Placebo|
9472515|NCT03609372|Experimental|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
9472516|NCT03609359|Experimental|Lenvatinib + Pembrolizumab|Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
9472517|NCT03609346||STEMI|Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
9472518|NCT03609333|Experimental|Internal arm|
9472519|NCT03609320|Experimental|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
9472520|NCT03609307|Active Comparator|injection Combined Intravitreal bevacizumab and propranolol|patients receive two injections at each session Bavacizumab
9472521|NCT03609307|Active Comparator|injection Intravitreal bevacizumab|patients receive only Bevacizumab
9472522|NCT03609294|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 35 days between the each period."
9472523|NCT03609294|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
9472524|NCT03609294|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
9472525|NCT03609281||Scheduled cesaren group|Patient delivered by elective cesarean section without labour pains
9472526|NCT03609281||Emergency cesarean group|Patients delivered by cesarean section due to an emergency
9472527|NCT03609268|Active Comparator|MWA|Patients receive microwave ablation (MWA)
9472528|NCT03609268|Experimental|SBRT|Patients receive stereotactic body radiotherapy (SBRT)
9472529|NCT03609255|Active Comparator|Control group (C)|
9472530|NCT03609255|Experimental|Sedentary behavior group (SB)|
9472531|NCT03609255|Experimental|Stress management group (SR)|
9472532|NCT03609242|Experimental|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
9472533|NCT03609242|No Intervention|Control|Arm 2 will receive standard of care
9472534|NCT03609229|Experimental|Study group|Abdominal Sacrocolpopexy with burch technique
9472535|NCT03609229|Active Comparator|control group|Abdominal Sacrocolpopexy without burch technique
9472536|NCT03609190|Experimental|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
9472537|NCT03609190|Placebo Comparator|Placebo|i.v. infusion of NaCl over 40 min
10033679|NCT01789788|Experimental|RO6811135|
10033680|NCT01789801|Active Comparator|Palpation only|"Patients randomized to this arm will have radial artery puncture via palpation of arteries.~Intervention: RAP palpation only"
10033681|NCT01789801|Experimental|Ultrasound guidance|"Patients randomized to this arm will have radial artery puncture with ultrasound guidance for artery localisation.~Intervention: RAP with ultrasound guidance"
10033682|NCT01789827|Experimental|Cohort I (scintigraphy prior to immunotherapy and 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.
10033683|NCT01789827|Experimental|Cohort II (scintograpy prior to immunotherapy, 3-4, 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.
9472538|NCT03609164|Experimental|Suture-spanning augmentation of single-row repair|
9472539|NCT03609164|Active Comparator|single-row repair|
9472540|NCT03609151|Active Comparator|group A|laparoscopic hepatectomy (surgery)
9472541|NCT03609151|Experimental|group B|stereotactic body radiotherapy (SBRT)
9472542|NCT03609138||Study Cohort|
9472543|NCT03609125|Experimental|CBS eyedrop|The product is prepared from cord blood serum (CBS) analyzed in advance with regard to the content of specific neurotrophic growth factors.
9472544|NCT03609112||Patients treated for a brain tumor|As part of their usual follow-up, these patients have neuropsychological evaluations following their treatment. A complete neuropsychological evaluation will therefore be performed as part of their usual follow-up during the inclusion period of this study and only the data from this evaluation will be taken into account for the statistical analysis of this study.
9472545|NCT03609112||Patients treated for a non-cerebral tumor|A single neuropsychological assessment will be proposed to these patients after the end of treatment and during the inclusion period of this study. This evaluation will be carried out during a visit to Gustave Roussy as part of their usual follow-up. If on the occasion of this evaluation, cognitive disorders or psychological disorders were highlighted, a neuropsychological and / or psychological follow-up would be proposed.
9472546|NCT03609112||Patients who received Methotrexate|"Methotrexate is used in the treatment of certain brain tumors as in that of non-cerebral tumors. Some of these patients, particularly those who have had neurological complications with methotrexate, will already have longitudinal neuropsychological follow-up as part of their usual follow-up. For these patients, only one complete neuropsychological assessment will be performed during the inclusion period and will be considered for statistical analysis.~For patients in the course of treatment with methotrexate, during the period of inclusion of this study, a longitudinal follow-up will be carried out with neuropsychological evaluations close and successive at the time of their coming to Gustave Roussy within the usual framework of their care."
9472547|NCT03609099|Active Comparator|Moxifloxacin|Active treatment to patients treated during the 5 previous days.
9472548|NCT03609099|Experimental|Placebo|Placebo treatment to patients treated during the 5 previous days.
9480367|NCT03534193|Experimental|Group 2|Participants randomized to Group 2 will receive Molly Center Standard Diabetes Education plus access to Tablet based interactive diabetes education modules
9480368|NCT03534141|Experimental|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
9480369|NCT03534141|Active Comparator|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
9472549|NCT03609060|Experimental|DEXAML|"Induction therapy:~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.~Post remission therapy:~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
9472550|NCT03609008|Active Comparator|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
9472551|NCT03609008|Placebo Comparator|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
9472552|NCT03608995|Experimental|Premaquick©|
9472553|NCT03608995|Other|Quikcheck|
9472554|NCT03608982|Experimental|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions & answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
9472555|NCT03608982|Active Comparator|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
9472556|NCT03608969||Study Group|Children with cerebral palsy aged 3-16 years will be evaluated in terms of the orofacial function using the Nordic Orofacial test- screening (NOT-S). Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) level and Communication Function Scale (CFS) of child will be recorded. Oral health related quality of life will be assessed using the Parental- Caregiver Perceptions Questionnaire. Caries experience will be measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft)
9472557|NCT03608943||Adrenal insufficiency|"Individuals who are in the process of changing their treatment from:~hydrocortisone to prednisolone or;~prednisolone to hydrocortisone"
9480370|NCT03534128|Experimental|Spatial navigation evaluation|
9480371|NCT03534115|Placebo Comparator|Placebo|Placebo was prepared by using the same solution containing buffers that were used in the preparation of NAC solution, except it did not contain NAC
9480372|NCT03534115|Experimental|Experimental Arm|solution containing NAC with buffers
10033684|NCT01789853|Experimental|Intensive Walking|High intensity walking training in variable context for 8 weeks
10033685|NCT01789853|Active Comparator|Conventional Physical Therapy|Regular physical therapy for 8 weeks
10033686|NCT01789879|Active Comparator|Control group (no current ART)|Levonorgestrel subdermal implant in subjects not yet receiving ART (control group)
10033687|NCT01789879|Active Comparator|NVP-based ART group|Levonorgestrel subdermal implant in subjects receiving nevirapine-based ART
10033688|NCT01789879|Active Comparator|EFV-based ART group|Levonorgestrel subdermal implant in subjects receiving efavirenz-based ART
10033689|NCT01789892|Experimental|Diagnostic (methylprednisolone and FDG PET/CT scan)|Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.
10033690|NCT01789918|Experimental|Percutaneous renal denervation|PARADISE percutaneous renal denervation
10033691|NCT01789931|Experimental|Research arm|"The participants will undergo an examination day in which they will complete VO2max test to evaluate their aerobic fitness. Afterwards they'll undergo 3 heat tolerance test (HTT) days: without CB protective clothing, with CB protective clothing, and with work clothes. During the tests, a Lifebeam sensor will be attached to their skin."
10033692|NCT01789944|Experimental|Provide Treatment|Peers provide treatment to 2nd generation following receipt of the intervention.
10033693|NCT01789944|Experimental|Treatment Only|Peers receive treatment and return for a 6-month follow-up
10033694|NCT01789957|Experimental|Open-label AC2993|
10033695|NCT01789996|Active Comparator|Alternative six minute walk test|"Subjects will be given the following instructions~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
10033696|NCT01789996|Placebo Comparator|Standard six minute walk test|"Subjects will be given the following instruction~1. walk as far as they can in 6 minutes"
10033697|NCT01790009|Active Comparator|Flavanol Rich drink|Flavanol-rich drink containing 800 mg/75 Kg of Body Weight (BW)
10033698|NCT01790009|Active Comparator|Flavanol rich drink|Flavanol Intervention drink 400 mg/75 Kg BW
10033699|NCT01790009|Active Comparator|Acetaminophen|2 tabletsx500 mg
10033700|NCT01790022|Experimental|Methylprednisolone 500 mg|Methylprednisolone 500 mg administered intravenously at baseline
10033701|NCT01790061|Experimental|Standardized FMT|endoscopy Tubing Once or repeat
10033702|NCT01790061|Experimental|Traditional treatments|Oral Tubing
10037171|NCT01822600|Experimental|Cohort control group|"The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level < 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group.~Patients in this group receive intravenous omeprazole treatment."
10037172|NCT01822613|Experimental|LJM716-BYL719 arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
10037173|NCT01822613|Active Comparator|Paclitaxel, Docetaxel or Irinotecan arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
10037174|NCT01822626|Experimental|motivational counseling|
10037175|NCT01822626|No Intervention|Usual Care|
10033703|NCT01790074|Experimental|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
9472558|NCT03608930|Experimental|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
9472559|NCT03608930|No Intervention|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
10033704|NCT01790074|Placebo Comparator|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
10033705|NCT01790087|Experimental|ANX-188 Therapeutic dose level|IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours
10033706|NCT01790087|Experimental|ANX-188 Supratherapeutic dose|IV administration. 300 mg/kg for one hour followed by 200 mg/kg/hr for five hours
10033707|NCT01790087|Placebo Comparator|Saline|IV administration. Six hour infusion.
9472560|NCT03608917|Experimental|Treatment group|"Drug:Total Glucosides of Paeony (TGP)~Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally."
10033708|NCT01790087|Active Comparator|Moxifloxacin|Oral tablet. 400 mg.
10033709|NCT01790139|No Intervention|Control|Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
10033710|NCT01790139|Experimental|Intervention-Oral Simethicone|Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
10033711|NCT01790165|Experimental|TDT067|Active treatment
10033712|NCT01790165|Placebo Comparator|Placebo|Placebo
10033713|NCT01790191|Experimental|RE group|Repeated consumption of artichoke purée. This group was exposed to basic artichoke puree from Exposure 1 to 10 (E1 to E10)
9472561|NCT03608917|Placebo Comparator|Control group|"Drug:Total Glucosides of Paeony (TGP) analogue~Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally."
9472562|NCT03608904|Experimental|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
9472563|NCT03608904|Placebo Comparator|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
9472564|NCT03608891|Active Comparator|Control Arm|Conventional titanium miniplates
9472565|NCT03608891|Experimental|Intervention arm|Patient specific 3D plates
9472566|NCT03608878|Active Comparator|TACE alone arm|TACE (Transarterial Chemoembolization)
9472567|NCT03608878|Experimental|adagloxad simolenin arm|TACE plus adagloxad simolenin/OBI-821 adjuvant therapy
9472568|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
9472569|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
9472570|NCT03608826|Experimental|Single Arm Study|Invesigational RAMware will be downloaded onto the LINQ device.
9472571|NCT03608813||Controls|Healthy subjects
9472572|NCT03608813||Case|PCOS affected subjects
9472573|NCT03608800|Experimental|Intermittent fasting|two nonconsecutive days of 75% diet energy restriction per week for 8 weeks
10033714|NCT01790191|Active Comparator|FFL group|Repeated consumption of artichoke purée. This group (Flavor-flavor learning group) was exposed to sweet artichoke puree from Exposure 1 to 10 (E1 to E10).
10033715|NCT01790191|Active Comparator|FNL group|Repeated consumption of artichoke purée. This group (Flavor-nutrient learning group) was exposed to fat, energy-dense artichoke puree from Exposure 1 to 10 (E1 to E10).
9472574|NCT03608800|No Intervention|Control diet|maintain the energy intake as usual
9472575|NCT03608787|Experimental|Cohort 1-Early Intervention|Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
9517197|NCT03308461|Experimental|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
10033716|NCT01790204|Experimental|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
9472576|NCT03608787|Experimental|Cohort 2-Delayed Intervention|Following baseline, participating outlets in this arm will receive receive Pseudo-Intoxicated Mystery Shops (P-I/MS) with no feedback. After 3 months they will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback.
10033717|NCT01790217||Cohort|
10033718|NCT01790230|No Intervention|Standard of Care|Standard of Care Arm - subjects treated by routine manner
9472577|NCT03608761|Experimental|Rebamipide 2%|"- wash-out: 2 weeks~- rebamipide 2% four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- autologous serum for 3 months"
9472578|NCT03608761|Experimental|Autologous serum|"- wash-out: 2 weeks~- autologous serum four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- rebamipe 2% for 3 months"
9472579|NCT03608761|Experimental|autologous serum and rebamipide 2%|rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed
9472580|NCT03608722|Experimental|BrainCheck vs Pen and paper tests|Compare patient performance on BrainCheck neurocognitive test vs pen and paper dementia tests (SLUMS, MMSE, MoCA), as well as an exploratory analysis comparing BrainCheck performance to aid in identifying patients with MCI and dementia vs physician diagnosis
9472581|NCT03608722|Experimental|BrainCheck performance in ESRD patients|Assess BrainCheck test performance in patients with ESRD and how undergoing hemodialysis treatment can impact cognitive performance.
10033719|NCT01790230|Experimental|LifeSeal™ Kit|LifeSeal™ Kit Arm - subjects treated with the LifeSeal™ Kit device + Standard of Care treatment
9472583|NCT03608618|Experimental|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
9472584|NCT03608618|Experimental|Cohort 2 and 2i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)
9472585|NCT03608618|Experimental|Cohort 3 and 3i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)
9472586|NCT03608618|Experimental|Cohort 4 and 4i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)
9472587|NCT03608592|Experimental|UCMSCs group|Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min.
9472588|NCT03608553|Experimental|ExAblate|ExAblate MR Guided Focused Ultrasound
9472589|NCT03608527|Experimental|Active motor treatment (AMT) group|15 people with multiple sclerosis performing a 8 week rehabilitative treatment based on task-oriented voluntary exercises (3 sessions/week).
9472590|NCT03608527|Active Comparator|Passive motor treatment (PMT) group|15 people with multiple sclerosis performing a 8 week passive mobilization delivered by a physical therapist (3 sessions/week).
9472591|NCT03608514|Active Comparator|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. & can be titrated every 15-30 minutes up to 2µg/Kg/min.~The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
9472592|NCT03608514|Other|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
9472593|NCT03608501|Experimental|Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.
9480373|NCT03534102|No Intervention|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
9517198|NCT03308422||Parents of 2-6-years-old children|Parents of preschool children in Nancy agglomeration
10033720|NCT01790269||fingolimod treated patients|Indication for on-label treatment with fingolimod (Gilenya®) according to the current approval
10033721|NCT01790282|Experimental|estradiole - progesterone arm|Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
10033722|NCT01790282|Active Comparator|Progesterone only arm|Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
10033723|NCT01790308|Active Comparator|CSII|continuous subcutaneous insulin infusion for 2-4 weeks
10033724|NCT01790308|Active Comparator|Liraglutide|continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks
10033725|NCT01790321|No Intervention|Pump water|Untreated pump water (pump water recognised as improved water source by WHO)
10033726|NCT01790321|Placebo Comparator|Filtered water|Pump water purified by the LSF-filtering device
10033727|NCT01790321|Experimental|Zinc water|Pump water purified and zinc-fortified by the LSF-filtering device
9472594|NCT03608475|Active Comparator|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
9472595|NCT03608475|Experimental|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
9472596|NCT03608462|Sham Comparator|rTMS targeting the right DLPFC|60 patients will be randomly allocated into this group,half of them will receive iTBS on the right DLPFC,while the other half will receive sham stimulation.
9472597|NCT03608462|Sham Comparator|rTMS targeting the left LPC|60 patients will be randomly allocated into this group,half of them will receive iTBS on left LPC,while the other half will receive sham stimulation.
9472598|NCT03608462|No Intervention|Observation group|To investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
10033728|NCT01790334||Spontenous Ventilation (Group S)|ultrasonography of Right internal jugular vein
10033729|NCT01790334||Pressure control Ventilation (Group P)|ultrasonography of Right internal jugular vein
10033730|NCT01790334||Volume control ventilation (Group V)|ultrasonography of Right internal jugular vein
9472599|NCT03608449|Active Comparator|study group|after monitoring treatment outcomes for 4 weeks, treatment plan or psychotherpist will be changed according to scoring by the director of department.
9472600|NCT03608449|Placebo Comparator|control group|treatment as usual. treatment counitunes as usual without depending on monitoring treatment outcomes.
10033731|NCT01790347|Experimental|Exercise group|
10033732|NCT01790347|No Intervention|Control group|Sedentary pregnant women
10033733|NCT01790386||Surgical Patients Group|Patients undergoing cardiovascular surgery and cardiology procedures
10033734|NCT01790386||Reference Ranges Group|Healthy volunteer subjects for determination of normal hemostasis parameter results
10033735|NCT01790399|Experimental|Identification of sentinel node(s)|
10033736|NCT01790412|Experimental|Exercise group|"Three sessions per week:~Supervised exercise program"
10033737|NCT01790412|No Intervention|Control|Sedentary pregnant women
10033738|NCT01790425|Experimental|water colonoscopy|The water (study) method: Warm water (body temperature) will be infused into colon to open the lumen for water infusion colonoscopy. Higher rate of complete colonoscopy will be achieved.
10033739|NCT01790425|Active Comparator|Air Colonoscopy|The air (conventional) method: Air is pumped gently (insufflation) into the colon will be used to open the inside space of the colon and aid in colonoscope insertion
10033740|NCT01790451|Active Comparator|peripheral ablation|an ablation of the peripheral area of the prostate
10033741|NCT01790451|Active Comparator|More central ablation|an ablation, more centrally, in proximity of the urethra
10033742|NCT01790464|Placebo Comparator|NS gauze|Standard airway anesthesia with 20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked in normal saline (Control Group)
10033743|NCT01790464|Active Comparator|Lidocaine gauze|20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
10033744|NCT01790477|Experimental|Auricular Acupuncture|Use of auricular acupuncture in bilateral ears
10033745|NCT01790477|No Intervention|Control|
10033746|NCT01790529|Experimental|Early Prophylaxis|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
9472601|NCT03608410|Experimental|PRO intervention|Weekly PRO questionnaires Quality of life every 2 months
9472602|NCT03608410|No Intervention|Standard of care|Quality of life every 2 months
9472603|NCT03608358|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
9472604|NCT03608358|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
9472605|NCT03608358|Placebo Comparator|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
9472606|NCT03608332|No Intervention|Group S|"weaning readiness will be evaluated with the standard criteria :- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13"
10033747|NCT01790529|Active Comparator|Late Prophylaxis|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
10033748|NCT01790542|Other|A|Iron fortified cereal
10033749|NCT01790542|Other|B|Iron fortified cereal with fruit
10033750|NCT01790542|Other|C|Meat
10033751|NCT01790555|Experimental|Namisol|The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).
10033752|NCT01790555|Other|Diazepam/Placebo|"The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).~Before surgery, diazepam is used as an active comparator, to aid in blinding. After surgery, an inactive placebo is used as an inactive comparator."
10033753|NCT01790607|Experimental|Subjects with moderate chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
10033754|NCT01790607|Experimental|Healthy subjects matched to moderate hepatic impaired subjects|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
10033755|NCT01790607|Experimental|Subjects with mild chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
10033756|NCT01790607|Experimental|Healthy subjects matched to mild hepatic impaired subjects|Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
10033757|NCT01790607|Experimental|Subjects with severe chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
10033758|NCT01790620|Experimental|CVVHD-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
9472607|NCT03608332|Experimental|Group SD|"weaning readiness will be evaluated with the following criteria:- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13~C) Ultrasound criteria:-~• Diaphragmatic excursion >11 mm"
10033759|NCT01790620|Active Comparator|CVVH-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
10033760|NCT01790646||patients undergoing general anesthesia|every elective patient undergoing general anesthesia for neurosurgical procedures with endotracheal intubation
10033761|NCT01790672|Placebo Comparator|Water|Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
10033762|NCT01790672|Active Comparator|Alcoholized wine|"Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.~Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol."
9472608|NCT03608319|Experimental|Single dose following overnight fast|
9472609|NCT03608319|Experimental|Single dose following high fat breakfast|
9472610|NCT03608319|Experimental|Single dose sprinkled on applesauce following overnight fast|
9472611|NCT03608306|Experimental|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
9472612|NCT03608306|Active Comparator|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
9472613|NCT03608293|Experimental|Smokers|Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
9472614|NCT03608293|Active Comparator|Non smokers|Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
9472615|NCT03608280|Active Comparator|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
9472616|NCT03608280|Experimental|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
9472617|NCT03608267|Experimental|Intervention|
9472618|NCT03608241|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single dose of an oral contraceptive during the first period of the study (period 1) and then continue to the second period (Period 2) of the study where they will receive PF-06651600 every day for 11 days and a single dose of an oral contraceptive towards the end of the period.
9472619|NCT03608241|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
9472620|NCT03608228||Parkinson's Disease|
9472621|NCT03608215|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
9472622|NCT03608215|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
10033763|NCT01790672|Placebo Comparator|De-alcoholized wine|Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
9472623|NCT03608189||ACL injury subjects|Subjects with anterior cruciate ligament injuries.
9472624|NCT03608176|Experimental|PASO diet group|
9472625|NCT03608176|Active Comparator|Low-fat diet group|
9472626|NCT03608176|Other|Waiting list group|
9472627|NCT03608150|Experimental|Therapeutic Group|Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
9472628|NCT03608150|Active Comparator|Control Group|Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
10033764|NCT01790672|Active Comparator|Ethanol|"Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.~Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.~Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water."
10033765|NCT01790711|Experimental|FMT by endoscopy|Once, fresh or frozen bacteria
10033766|NCT01790724|Experimental|Walking exercise|Participants will be instructed in safe walking exercise. They will participate in an eight week, tapered, on-site program. Participants will also attend group workshops where they will learn self-regulatory skills such as goal-setting, self-monitoring, barrier trouble-shooting, rewarding, and relapse prevention and recovery.
10033767|NCT01790724|Active Comparator|Metabolic health education|Participants will complete an eight-week online metabolic health education course. Topics will include glucose control, insulin, weight management, nutrition, physical activity, eye/kidney/foot health, stress reduction, and doctor-patient communication.
9472629|NCT03608111|Active Comparator|single task balance training|
9472630|NCT03608111|Active Comparator|dual task balance training|
9472631|NCT03608098|Active Comparator|Short Pulse Duration Group|A short pulse duration (300 μs or 350 μs) will be used in this group.
9472632|NCT03608098|Active Comparator|Long Pulse Duration Group|A long laser pulse duration (700 μs or 1500 μs) will be used in this group.
9472633|NCT03608085|Experimental|Pharmacist Heart failure MTM training|Community pharmacist who will receive heart failure medication therapy management training
9472634|NCT03608085|Experimental|Patient Heart failure MTM intervention|Independently living community dwelling subjects who are prescribed at least 1 cardiovascular medication for HF and 3 additional chronic medications after discharge from the Hospital for an MTM consultation by a pharmacist trained in heart failure medication therapy management.
9472635|NCT03608072|Experimental|Dose group 1|
9472636|NCT03608072|Experimental|Dose group 2|
9472637|NCT03608072|Experimental|Dose group 3|
9472638|NCT03608059|Experimental|ATG/PTCy|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +34 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
9472639|NCT03608059|Active Comparator|standard ATG|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -4 to -1 , cyclosporine A (CsA) initiating on day -5 and mycophenolate mofetil (MMF) initiating on day +1 . CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 2 times per day (maximum dose 2g per day) until day +30 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
9472640|NCT03608059|Active Comparator|standard PTCy|The GvHD prophylaxis consisted of cyclophosphamide (Cy) 50 mg/kg on day +3, +4,cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +5. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +35 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
9472641|NCT03608046|Experimental|Avelumab, Cetuximab, Irinotecan|"Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.~Irinotecan: administrated every 2 weeks (180 mg/m2)."
9472642|NCT03608033|Experimental|OMS721|Administration of OMS721
9472643|NCT03608033|Placebo Comparator|Placebo|Administration of Vehicle (D5W or Saline Solution)
9472644|NCT03608007|Experimental|X-396 Capsule|Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
9472645|NCT03607968||All women in this study|All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline [i.e., 100 * (postoperative pad weight - baseline pad weight)/baseline pad weight].
9472646|NCT03607955|Experimental|AVB-S6-500 + Paclitaxel + Carboplatin|"Paclitaxel will be given intravenously at a dose of 175 mg/m^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle~Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy~AVB-S6-500 will be given at doses based on the dose escalation schema~The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles)."
10033768|NCT01790737|Active Comparator|A|Cyclophosphamide plus filgrastim
10033769|NCT01790737|Active Comparator|B|Filgrastim
10033770|NCT01790763|Active Comparator|Keramatrix|Keramatrix
10033771|NCT01790763|Active Comparator|Mepilex|Mepilex
10033772|NCT01790776|Active Comparator|Conventional urethrography|Current golden standard.
10033773|NCT01790776|Experimental|Sono-urethrography|Experimental urethrography, which could be followed by conventional urethrography if the results are inconclusive.
9480374|NCT03534102|Experimental|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
10033774|NCT01790789|Experimental|Stress reduction program|
10033775|NCT01790789|Other|Attention control|
10033776|NCT01790802|Experimental|Active laser|Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
10033777|NCT01790802|Sham Comparator|Sham laser procedure|The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing.
9472647|NCT03607929|Experimental|optimal and hydration|Physiological Saline Solution 300 ml/h AND drink freely mineral water during labor
9472648|NCT03607929|Active Comparator|variability and hydration|Other Solutions >o < 300 ml/h AND uncontrolled drink during labor
10033778|NCT01790841||ICD system with DF4 connection|Iforia/Ilesto ICD with DF4 connection and Linox smart DF4 lead/ Protego
10033779|NCT01790841||ICD system with DF-1 connection|Ilesto/Iforia ICD with DF-1 connection
9472649|NCT03607916|Experimental|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472650|NCT03607916|Experimental|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472651|NCT03607916|Experimental|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472652|NCT03607916|Experimental|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472653|NCT03607916|Experimental|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472654|NCT03607916|Experimental|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472655|NCT03607916|Experimental|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472656|NCT03607916|Experimental|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472657|NCT03607916|Experimental|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472658|NCT03607916|Experimental|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
9472659|NCT03607903|Active Comparator|Subcutaneous adalimumab and placebo|adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)
10033780|NCT01790854|Experimental|Prasugrel dose 5 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
10033781|NCT01790854|Active Comparator|Prasugrel dose 10 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months
10033782|NCT01790880|Active Comparator|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system, for 90 minutes per day, 6 days per week for 6 weeks.
10033783|NCT01790880|Experimental|ORLA + Writing|"Practice on ORLA + writing computer program, 90 minutes per day, 6 days per week, for 6 weeks."
10033784|NCT01790893|Experimental|intravitreal aflibercept injection|"Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.~."
9472660|NCT03607903|Active Comparator|PLacebo and subcutaneous adalimumab|saline ID (0.9%, 0.4 mL) and adalimumab SC (40 mg in 0.4 mL)
9472661|NCT03607903|Experimental|Placebo and intradermal adalimumab|saline SC (0.9%, 0.4 mL) and adalimumab ID (40 mg in 0.4 mL)
9472662|NCT03607903|Experimental|Intradermal adalimumab and placebo|adalimumab ID (40 mg in 0.4 mL) and saline SC (0.9%, 0.4 mL)
9472663|NCT03607877|Active Comparator|pedometer walking (PW)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months.
9472664|NCT03607877|Active Comparator|pedometer walking with training (PWT)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down. Exercise intensity for the first four weeks was 50-55% heart rate reserve (HRR) with training for 3 months.
9472665|NCT03607877|Experimental|positive education and walking (PEPWT)|PEPWT: 15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months and six sessions of positive education.
10033785|NCT01790893|Experimental|intravitreal aflibercept|Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.
10037176|NCT01822639|Experimental|Sequence 1|Subjects in this arm will receive Treatment A in period 1 and Treatment B in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
10037177|NCT01822639|Experimental|Sequence 2|Subjects in this arm will receive Treatment B in period 1 and Treatment A in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
10037178|NCT01822704|Active Comparator|Control|This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
9472666|NCT03607864|Experimental|coral bone graft and xenograft|Extraction of upper anterior badly broken teeth with immediate implant placement with the use of coral bone and xenograft as grafting material between the implant and the labial socket bone
9472667|NCT03607851|Active Comparator|Conventional titration group|
9472668|NCT03607851|Experimental|Rapid titration group 1|
9472669|NCT03607851|Experimental|Rapid titration group 2|
9472672|NCT03607825|Experimental|Neurapheresis System|CSF filtration
9472673|NCT03607799|Experimental|Dietary Intervention|"A dietitian develops personalized diet advice for each intervention group participant. She sets 2-4 SMART goals according to the following principles: 1) Replace fried foods and meat with vegetable protein, raw and cooked vegetables; 2) Reduce refined carbohydrate intake; 3) Improve carbohydrate quality (replace high glycemic index, refined grain foods with lower glycemic index, whole-grain foods; 4) Reduce trans fats; 5) Schedule regular mealtimes, 3-4 hours apart; 6) Reduce high-carbohydrate snacks; 7) Reduce desserts and/or drinks high in starch and sugar. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
9472674|NCT03607799|Active Comparator|Control|"Control group participants will be provided with paper copies and website links to The Sensible Guide to a Healthy Pregnancy, which provides advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the SA community. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
9472675|NCT03607786|Active Comparator|RIVP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(28-30℃). The combination of selective antegrade cerebral perfusion and retrograde inferior vena caval perfusion is performed. The antegrade perfusion flow rate was is maintained at 6-12 mL/min/kg.Pump pressure of retrograde perfusion was is maintained at 20-30 mmHg, and blood flow was is maintained at 8-12 mL/min/kg.
9472676|NCT03607786|Active Comparator|ACP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(26-28℃). Only select antegrade cerebral perfusion is performed by maintaining the flow rate at 6-12 mL/min/kg.
9472677|NCT03607773|Active Comparator|Mindfulness Behavioural Intervention (MBI) group|10 one-hour mindfulness sessions
9472678|NCT03607773|No Intervention|Control group|Standard of care.
9472679|NCT03607760||ECMO|severe respiratory failure with ECMO
9472680|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
9472681|NCT03607734|Other|Group 1 - Interventional Treatment|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
9472682|NCT03607721|Experimental|DBS Patients Group|Body Motion Evaluation DARI
10037179|NCT01822704|Experimental|Low intensity vibration|This group will receive three 45-minute whole body vibration training sessions for 10 consecutive weeks. The vibration will be of low intensity (frequency: 20 Hertz, amplitude: 1mm).
9472683|NCT03607721|Active Comparator|Control Group|Body Motion Evaluation DARI
10037180|NCT01822704|Experimental|High intensity vibration|This group will receive three 45-minute whole body vibration training sessions per week for 10 consecutive weeks.The vibration will be of higher intensity than the low intensity vibration group (frequency: 30 Hertz, amplitude: 1mm).
10037181|NCT01822717|Experimental|Nonvisual foot inspection|Instruction for nonvisual foot inspection included in comprehensive diabetes self-management education
10037182|NCT01822717|Active Comparator|Usual Care for foot inspection|Usual instruction for foot care included in comprehensive diabetes self-management education
10037183|NCT01822730|Experimental|paliperidone|paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
10037184|NCT01822730|Active Comparator|.Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks
9472684|NCT03607708|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
9472685|NCT03607708|Active Comparator|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
9472686|NCT03607669||Healthy Controls|Healthy volunteers of similar age and gender
9472687|NCT03607669||Ischaemic Cardiomyopathy|Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
10033786|NCT01790906|Active Comparator|RSD+Conventional therapy|We will recruit 100 randomised CHF patients who meet the inclusion criteria.First undergo renal artery angiography procedure to confirm anatomy.If renal artery meet the inclusion criteria,give the renal sympathetic denervation.At the same time, we will use conventional therapy to protect cardiac function.then we will conduct a clinic follow-up and a telephone follow-up.
10033787|NCT01790906|Placebo Comparator|Conventional therapy|We also will recruit 100 randomised CHF patients who meet the inclusion criteria.there are no significant differences in age,gender,race,past medical history,personal history and so on between the two groups.In this group we will use therapy just like the RSD+Conventional therapy group.we will conduct a clinic and a telephone follow-up.
10033788|NCT01790919|Experimental|Cognitive Therapy plus Cognitive Support|Cognitive therapy for depression with cognitive support added
10033789|NCT01790919|Active Comparator|Cognitive therapy|Cognitive therapy for depression
10033790|NCT01790945||No treatment Study|Population of subjects will have been diagnosed with mild NPDR, Moderate NPDR, Severe NPDR, PDR and DME
10033791|NCT01790971|Active Comparator|Intrathecal morphine|100μg of morphine will be added to the intrathecal mixture.
10033792|NCT01790971|Active Comparator|No Intrathecal morphine|Morphine will not be added to the intrathecal mixture.
9472688|NCT03607669||Hypertrophic Cardiomyopathy|Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
9472689|NCT03607669||Dilated Cardiomyopathy|Patients with dilated cardiomyopathy and NYHA II-III heart failure
10033793|NCT01790997|Experimental|Treatment I|1 tablet of DLBS1033 490 mg thrice daily, after meal
10033794|NCT01790997|Active Comparator|Treatment II|1 tablet of aspirin 80 mg once daily, after meal
10033795|NCT01790997|Active Comparator|Treatment III|1 tablet of clopidogrel 75 mg once daily, after meal
10033796|NCT01791010|Experimental|Inspiratory muscle training|Inspiratory muscle training for 8 weeks using a device that provides a linear resistance in the inspiratory phase. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was at 40% of Maximal Inspiratory Pressure.
10033797|NCT01791010|Sham Comparator|Training sham|Training sham for 8 weeks using a device without provides resistance. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was canceled.
9472690|NCT03607656|Experimental|TCM combines CapOX/SOX/S-1+D/FLOT|"Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.~The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy."
9472691|NCT03607656|Active Comparator|CapOX/SOX/S-1+D/FLOT|The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.
9472692|NCT03607643|Placebo Comparator|Colon: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
10033798|NCT01791023|Experimental|Physical exercise|Physical exercise
10033799|NCT01791036|Experimental|Adductor Canal Block Group|Adductor Canal Block
10033800|NCT01791036|Active Comparator|Femoral Nerve Block Group|Femoral Nerve Block
10033801|NCT01791049|Experimental|Active|Single escalating doses of TD-1607, administered intravenously
10033802|NCT01791049|Placebo Comparator|Placebo|Placebo
10033803|NCT01791062|Experimental|HYTOP®|
10033804|NCT01791075|Active Comparator|Tan Endoglide|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
10033805|NCT01791075|Active Comparator|Endosaver/serter|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
10033806|NCT01791088|Experimental|Treatment (sirolimus)|Patients receive sirolimus PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10033807|NCT01791101|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
10033808|NCT01791114|Experimental|Cold water consumption|Subjects will participate in two trials as part of this protocol: a) cold water (4 °C) consumption and b) tepid (36 °C) water consumption
10033809|NCT01791114|Experimental|Meal consumption|Subjects will participate in two trials as part of this protocol: a) High calorie meal consumption and two weeks later b) no meal consumption.
10033810|NCT01791114|Experimental|Cold exposure|Participants will complete three studies: a) cold exposure study (above their individually determined shivering threshold ~ 16°C); b) Cold exposure plus 0.5mg/kg up to 40mg propranolol at the beginning of the metabolic study and again after 4-6 hrs; c) thermoneutral conditions (26 - 28°C).
9472693|NCT03607643|Experimental|Colon: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
9472694|NCT03607643|Placebo Comparator|Rectal: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
9472695|NCT03607643|Experimental|Rectal: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
9472696|NCT03607643|Placebo Comparator|Multiple myeloma: Chemo + Placebo|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
9472697|NCT03607643|Experimental|Multiple myeloma: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
9472698|NCT03607643|Placebo Comparator|Pancreatic: Chemo + Placebo|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
9472699|NCT03607643|Experimental|Pancreatic: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
10033811|NCT01791114|Experimental|Exercise|Subjects between 18 and 35 years old will be asked to participate in two trials: a) Exercise, i.e. four times for 10 min- at 85% VO2max (maximal oxygen consumption). with 15-min breaks between each bout b) and two weeks later rest.
10033812|NCT01791140||Cohort|
10033813|NCT01791166|Experimental|Pulmonary transplant|
9472700|NCT03607643|Placebo Comparator|GBM: Chemo + Placebo|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
9472701|NCT03607643|Experimental|GBM: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
9472702|NCT03607630|No Intervention|Waiting Pre-Intervention Control|Participant completes measures for 1-3 weeks (randomly chosen) before they complete the intervention. Participants act as their own controls
9472703|NCT03607630|Experimental|Imagery Rescripting|3 Sessions of Imagery Rescripting
9472704|NCT03607617||Wedge 1|Five randomized clinics will implement SDH tool.
9472705|NCT03607617||Wedge 2|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
9472706|NCT03607617||Wedge 3|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
9472707|NCT03607617||Wedge 4|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
9472708|NCT03607617||Wedge 5|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
9472709|NCT03607617||Wedge 6|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
9472710|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
9472711|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
9472712|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
10033814|NCT01791179|Experimental|Substance Abuse Treatment Group|
10033815|NCT01791192|Experimental|FTY720|Fingolimod
9472713|NCT03607591|Active Comparator|Active rTMS group|One daily session: active 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
10033816|NCT01791192|Active Comparator|Oral Corticosteroid|Oral Corticosteroid
10033817|NCT01791218|Experimental|CABG, AVR or CABG+AVR and PVI|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
10033818|NCT01791218|Active Comparator|CABG, AVR or CABG+AVR|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation
10033819|NCT01791231|Experimental|Radiolabeled 14C-canagliflozin|Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.
10033820|NCT01791257||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
10033821|NCT01791257||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
10033822|NCT01791257||Neurological healthy controls|12 patients (ASA 1) undergoing spinal anesthesia for orthopedic surgery have 2 ml of cerebrospinal fluid drawn preceding injection of local analgetic.
10033823|NCT01791270||OSA versus Control subjects.|sleep apnea-hypopnea syndrome and control
10033824|NCT01791270||OSA patients before and after treatment, CPAP|Continuous positive pressure CPAP
9472714|NCT03607591|Placebo Comparator|Placebo rTMS group|One daily session: inactive 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
10033825|NCT01791283||Healthy volunteers|Healthy volounteers with no previous medical history, age between 20-40. Both male and female. Subjects are provided extensive information about the study and the obligations and expectations included. All subjects sign a witnessed informed consent before inclusion.
10033826|NCT01791296|Experimental|Dexmedetomidine|Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
10033827|NCT01791296|Placebo Comparator|Placebo|Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
10033828|NCT01791309|Experimental|combination panitumumab and vemurafenib|This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
9472715|NCT03607578|Other|Control Group - Minimal Intervention|Minimal intervention
9472716|NCT03607578|Experimental|Protection Routine 1|
9472717|NCT03607578|Experimental|Protection Routine 2|
9472718|NCT03607578|Experimental|Protection Routine 1+2|
9472719|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(good perfusion)
9472720|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(middle perfusion)
9472721|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(poor perfusion)
9472722|NCT03607513|Experimental|Single Ascending Dose (SAD)|The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.
10033829|NCT01791335||COPD patients receiving NIV|
10033830|NCT01791348|Other|d2 test of attention|
10033831|NCT01791361||Round 1|50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
10033832|NCT01791361||Round 2|50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
10033833|NCT01791361||Round 3|50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
9472723|NCT03607513|Experimental|Multiple Ascending Dose (MAD)|The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.
9472724|NCT03607500|Experimental|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
9472725|NCT03607500|No Intervention|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
9472726|NCT03607474||Couple (Patients and caregivers)|"Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.~Questionnaires of life quality for patients Questionnaires of life quality for caregivers"
10033834|NCT01791374|Experimental|Rilotumumab Monotherapy|Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W
9472727|NCT03607461|Experimental|Smartphone App Users|Smartphone App Users will receive important information and prescriptive exercise via a smartphone app upon returning home from the hospital following total knee arthroplasty
9472728|NCT03607461|Active Comparator|Home Health Users|Home Health Users will have already undergone traditional home health physical therapy and/or skilled nursing for the purpose of comparing outcomes
9472729|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
9472730|NCT03607435|Experimental|Test Article Scanning|Spectroscopy for Analyte Quantification
9472731|NCT03607383|Experimental|Red rice yeast group|Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions
9472732|NCT03607383|Active Comparator|Statin group|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
9472733|NCT03607331|Experimental|Auricular vagus nerve stimulation|Auricular Concha Electro-acupuncture: twice a day at home as required, once in the morning and once in the evening, with 5 consecutive days per week for two months
9472734|NCT03607331|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
10033835|NCT01791374|Experimental|Rilotumumab plus CX|Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W
10033836|NCT01791387|Experimental|Dovitinib|Dovitinib 500 mg taken orally once daily 5 days on / 2 days off, until disease progression
10033837|NCT01791400|Other|sumatriptan|Patients who underwent 6 mg sumatriptan subcutaneous one time
10033838|NCT01791400|Other|Metoclopramide|Patients who underwent 20 mg Metoclopramide intravenous one time
9472735|NCT03607305|Active Comparator|BP limb 70cm|Patients underwent a RYGB with a biliopancreatic limb of 70cm
9472736|NCT03607305|Experimental|BP limb 120cm|Patients underwent a RYGB with a biliopancreatic limb of 120cm
9472737|NCT03607292|Experimental|Group A|Anterior sciatic nerve block
10033839|NCT01791426|Experimental|Artelac Rebalance|Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL.
10033840|NCT01791426|Active Comparator|Vismed|Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL.
10033841|NCT01791439|Experimental|Lidocaine|Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.
10033842|NCT01791439|Placebo Comparator|Saline|Application of saline to the glossopharyngeal nerve.
10033843|NCT01791452||NAFLD|
10033844|NCT01791504|Experimental|TissuGlu Surgical Adhesive|Standard wound closure techniques plus TissuGlu and no drains.
10033845|NCT01791504|No Intervention|Control - Standard of Care|Standard wound closure techniques with drains.
10033846|NCT01791530||MV>48h|10-20 consecutive admissions with a predictive duration of intubation and mechanical ventilation > 48h.
10033847|NCT01791543|Experimental|Intramural Needle Catheter Ablation|Ablation of Ventricular Tachycardia with Intramural Needle Ablation Catheter
10033848|NCT01791556|No Intervention|Standard of Care|clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
9472738|NCT03607292|Experimental|Group P|Posterior sciatic nerve block
9472739|NCT03607279||NGAL - retropubic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
9472740|NCT03607279||NGAL - robotic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
9472741|NCT03607266||Group I (Ibuprofen)|Ibuprofen Group will receive 800 mg iv ibuprofen in 100 cc of isotonic solution within 30 min before the procedure
9472742|NCT03607266||Group D (Dexketoprofen|Dexketoprofen Group will receive 50 mg iv dexketoprofen in addition to 100 cc of isotonic solution within 30 min before the procedure
9472743|NCT03607266||Placebo Group|will receive 100 cc of isotonic solution within 30 min before the procedure
9472744|NCT03607253|Other|Men|Healthy young men aged between 18-25 years
9472745|NCT03607253|Other|Women|Healthy young women aged between 18-25 years
9472746|NCT03607240|Experimental|LUS-guided alveolar recruitment|Lung ultrasound-guided alveolar recruitment maneuver will be performed
9472747|NCT03607240|Active Comparator|conventional alveolar recruitment|Alveolar recruitment maneuver will be provided with positive pressure of 30 cmH2O for 10 seconds.
9472748|NCT03607227|Active Comparator|Local anesthetic|Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
9472749|NCT03607227|Placebo Comparator|Saline|Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as in the active substance arm.
9472750|NCT03607214|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
9472751|NCT03607214|No Intervention|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
9472752|NCT03607201||Diabetic|History of diabetes prior to Acute Coronary Syndrome
9472753|NCT03607201||Non-diabetic|No documented history of diabetes prior to Acute Coronary Syndrome
9472754|NCT03607188|Experimental|ZG0418 200mg QD|ZG0418 200mg/day,oral
9472755|NCT03607188|Experimental|ZG0418 300mg QD|ZG0418 300mg/day,oral
9472756|NCT03607188|Experimental|ZG0418 400mg QD|ZG0418 400mg/day,oral
9472757|NCT03607188|Experimental|ZG0418 500mg QD|ZG0418 500mg/day,oral
9472758|NCT03607188|Experimental|ZG0418 600mg QD|ZG0418 600mg/day,oral
9472759|NCT03607175|Active Comparator|Steroid-eluting implant (Propel)|Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
9472760|NCT03607175|Experimental|Triamcinolone-impregnated CMC foam|Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
9472761|NCT03607149|Active Comparator|STANDARD ARM|Calculation of the dose of pemetrexed as a function of body surface area
9472762|NCT03607149|Experimental|EXPERIMENTAL ARM|Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)
9472763|NCT03607136|Experimental|exercise training|Participants in the exercise training group received a 12-week exercise training.
9472764|NCT03607136|No Intervention|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
9472765|NCT03607123||Baseline|After implantation of pacemaker, the pacing mode and the lower rate of pacemaker will be set as VDD and 50/45 bpm respectively, to get the baseline burden of atrial fibrillation without atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. Patients who can not tolerate will drop out. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group / stage (Atrial Pacing, Step1).
9472766|NCT03607123||Atrial Pacing (Step 1)|After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
9472767|NCT03607123||AAD (Step 2)|After Step 1, and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage. Anti-arrhythmic drugs including propafenone, amiodarone and dronedarone will be prescribed. After follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (RFCA, Step3).
9472768|NCT03607123||RFCA (Step 3)|After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
9472769|NCT03607123||SAFE PAF-SND II|After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
9472770|NCT03607110||ketamine|ketamine used
9472771|NCT03607110||fentanyl|fentanyl used
9472772|NCT03607097|Experimental|Secondary prevention of DRPs (medication code) (intervention)|The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence
9472773|NCT03607097|No Intervention|Usual care (control group)|The patient is reviewed according to the standard procedure, consisting only on the review of the medical prescription in the emergency department by the pharmacist assisting the unit
9472774|NCT03607084|Experimental|Intervention|The intervention group receives a school health program that has two components: the training of selected teachers to become school Health Workers and bi-annual health screenings of all students.
9472775|NCT03607084|No Intervention|Control|The control group receives regular school programming.
9472776|NCT03607071|Experimental|Prednisolone|The patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
9472777|NCT03607045|Placebo Comparator|control group|bouquet technique
9472778|NCT03607045|Active Comparator|test group|headless screw
9472779|NCT03607032|Experimental|RespinPad and usual treatment|
9472780|NCT03607032|Active Comparator|only usual treatment|
9472781|NCT03607006|Experimental|Patient specific PEEK sheets|Patient specific PEEK sheets will be fixed with titanium screws and act as containment system for the mixed autogenous/xenogenic bone graft that will fill the gap between the sheets and the ridge .
9472782|NCT03607006|Active Comparator|Autogenous bone shell technique|Bone shells will be fixed with titanium screws to the ridge and mixed autogenous/xenogenic bone graft will fill the gap between the shells and the ridge .
10033849|NCT01791556|Experimental|HIV-1 viral load testing|viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
10033850|NCT01791608|Active Comparator|Zinc sulphate|Preschool children healthy enrolled in FAN Foundation of Medellin, which will be supplied with zinc sulphate
10033851|NCT01791608|Experimental|Zinc Amino Acid Chelate|Preschool children healthy enrolled in FAN Foundation of Medellin , which will be supplied with zinc amino acid chelate
10033852|NCT01791608|Placebo Comparator|Milk without fortification|Milk without zinc
10033853|NCT01791621|Experimental|Elimination/Challenge Diet|Once non-IgE mediated food allergy testing has been administered, study participants will follow food choices according to a pre-specified elimination diet for three weeks (Elimination phase). After the Elimination phase, study participants will introduce one food every three days (Challenge phase)and monitor their symptoms. Eight different foods will be introduced in the Challenge phase of the study.
10033854|NCT01791634|Experimental|proximal open wedge osteotomy with LPS system|Proximal open wedge osteotomy with Low profile plate and screws
10033855|NCT01791634|Active Comparator|proximal wedge osteotomy|Proximal wedge osteotomy procedure
10033856|NCT01791647|Active Comparator|myo-inositol|1500 mg/day myoinositol
10033857|NCT01791647|Active Comparator|metformin|1500 mg/day of metformin
10033858|NCT01791660|Experimental|Zeltiq Coolsculpting System|non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
10033859|NCT01791673|Experimental|Ultrasound Glaucoma treatment|Cyclocoagulation using High Intensity Focused Ultrasound (HIFU)
9472783|NCT03606993|Experimental|Lucky Iron Fish™ (LIF)|For Mother-infant dyads enrolled into the LIF arm, mother receives a cooking supplement: one ~ 200g iron ingot.
10033860|NCT01791686|Experimental|Dense Deposit Disease|"► Induction Period~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.~► Maintenance Period~The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks."
9472784|NCT03606993|No Intervention|Enhanced standard of care (eSOC)|For mother-infant dyads in the eSOC arm, families are not provided iron supplementation (consistent with standard of care) but have additional visits and laboratory monitoring beyond well-child care (enhanced).
10033861|NCT01791699|Placebo Comparator|Control group|"The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
9472785|NCT03606954|Active Comparator|Combination topical corticosteroid|"The combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
9472786|NCT03606954|Active Comparator|Non-combination topical corticosteroid|"The non-combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
10033862|NCT01791699|Active Comparator|Moxonidine group|"Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
10033863|NCT01791712|Experimental|On-line hemodiafiltration|On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
10033864|NCT01791712|Active Comparator|High-flux hemodialysis (control)|The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
10033865|NCT01791738|Experimental|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
10033866|NCT01791738|No Intervention|Standard total hip arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
10033867|NCT01791751|Experimental|Clomifene Citrate|Clomifene Citrate 50 mg
10033868|NCT01791751|No Intervention|Control|No intervention
10033869|NCT01791777|Experimental|Purveyor|"The purveyor arm will include SafeCare Coaching that is conducted by a Training Specialists from the National SafeCare Training and Research Center (NSTRC), a GSU (Georgia State University)-Center that conducts training and research on the SafeCare model."
10033870|NCT01791777|Experimental|Local|"The the local are will receive SafeCare Coaching that is provided by a staff member who works for the local social service agency."
10033871|NCT01791790|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
10033872|NCT01791790|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
10033873|NCT01791829||Luminal A with other Clinical Criteria|BCS postulated to be at low risk for IBTR following Endocrine Therapy
10033874|NCT01791842|Experimental|Tocilizumab first, then placebo|one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months.
10033875|NCT01791842|Experimental|Placebo first, then Tocilizumab|one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months.
10037185|NCT01822769|Experimental|Cardiopulmonary rehabilitation|The subjects will attend 2 sessions each week for 12 weeks. Each session will be approximately 2 hours in duration, consisting of both exercise (aerobic and strength,~60 minutes) and education. In addition, subjects will be directed to participate in 3 weekly ~40 minute home exercise training sessions, personalized to their level of aerobic conditioning.
10037186|NCT01822769|Other|Standard of care|Subjects randomized to standard of care will not be enrolled in a rehabilitation program, but may receive any other clinically indicated exercise training or other intervention (e.g., an exercise prescription).
9472787|NCT03606928|Experimental|modified FLOT|modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours
10033876|NCT01791855|Experimental|Healthy Volunteers|
9472788|NCT03606915||no pain|pain evaluation for patients performed surgery without painful condition (bleeding or others)
10033877|NCT01791855|Experimental|Mild Renal Impairment|
10033878|NCT01791855|Experimental|Moderate renal impairment|
10033879|NCT01791855|Experimental|Severe renal impairment|
10033880|NCT01791868|Experimental|Intravenous sodium valproate|"Intravenous sodium valproate:~30 mg/kg during 15 min then 1 mg/kg/h during 12 h"
10033881|NCT01791868|Placebo Comparator|Intravenous Placebo|"Intravenous Placebo:~NaCl 0,9 % during 15 min at first then during 12 h."
9472789|NCT03606915||acute pain|pain evaluation for patients performed surgery with painful condition within several days
9472790|NCT03606915||chronic pain|pain evaluation for patients performed surgery with the painful condition for over months
9472791|NCT03606902|Active Comparator|(Group f):|"Intervention:~Procedure: Epidural catheter insertion~Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
9472792|NCT03606902|Active Comparator|(Group Lf):|"Intervention:~Procedure:Epidural catheter insertion~Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
9472793|NCT03606889|Experimental|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
9472794|NCT03606889|Experimental|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
9472795|NCT03606863|Experimental|Perioperative peripheral parenteral nutrition|Perioperative peripheral parenteral nutrition during 4 days
9472796|NCT03606863|No Intervention|Standard fluid therapy|Standard fluid therap
9472797|NCT03606850|Experimental|Treatment by citalopram|The patients will receive a treatment by citalopram at 20mg/day. If patients respond by at least 20% on the HAMD-21 scale at day 14 : continuation at 20 mg/day. If patients do not respond by at least 20% at day 14 : increase the dose at 40 mg/day. The patients who will not respond by at least 50% on the HAMD-21 scale at day 28 will be excluded of the study and will undergo a new treatment plan. The patients who will respond by at least 50% on HAMD-21 at day 28 will continue citalopram at the same dose and will be reappraised at day 60. The patients will be assessed for the markers of neuroexcitability at day 1, day 3, day 7, day 14, day 28 and day 60.
9472798|NCT03606824|Placebo Comparator|Pivastatin and placebo|After randomization, patients in Pivastatin + placebo group will receive pitavastatin and placebo.
9472799|NCT03606824|Experimental|Pivastatin and LT-4|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
9472800|NCT03606811|Active Comparator|fluroscopic guided block|
9472801|NCT03606811|Experimental|double modality guided block|
9472802|NCT03606785|Active Comparator|tranexamic acid group|
9472803|NCT03606785|Placebo Comparator|placebo group|
9472804|NCT03606772||supracervical hysterectomy|Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
9472805|NCT03606746|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.
9472806|NCT03606733|Experimental|A custom made Suprachoroidal needle for macular diseases|A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana
9472807|NCT03606720|Experimental|group(A) low level laser therapy|composed of 30 patients who received pelvic stabilization exercises and low level laser therapy For 12 sessions over six week's period by 2 sessions per week.
9472808|NCT03606720|Active Comparator|group(B) pelvic stabilization exercises only|composed of 30 patients who pelvic stabilization exercises only For 12 sessions over six week's period by 2 sessions per week.
9472809|NCT03606720|Active Comparator|group (C) low level laser therapy only|composed of 30 patients who low level laser therapy only For 12 sessions over six week's period by 2 sessions per week.
9472810|NCT03606707|Experimental|corticosteroid|steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
9472811|NCT03606707|No Intervention|oral steroid|systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day.
9472812|NCT03606694|Experimental|Dihydromyricetin|Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
9472813|NCT03606694|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
9472814|NCT03606681|Active Comparator|Calcium Hydroxide (Dycal)|Indirect pulp capping treatment with Calcium Hydroxide
10033882|NCT01791881|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
10033883|NCT01791881|Experimental|Botulinum toxin type A(Hugeltox)|Botulinum toxin type A(Hugeltox)
10033884|NCT01791907|Experimental|Structured education in carbohydrate counting|A structured education in carbohydrate counting, a course inspired by the DAFNE program (Dose Adjustment For Normal Eating)
10033885|NCT01791907|Experimental|Structured education in healthy food choices and low GI|"A new, structured education for heart healthy food choices and low glycemic index in type 1 diabetes. The education is called My Wellness-LADDER (Lifelong Adult Diet & Diabetes Education Resource) and it is specifically designed to provide high long-term adherence through improved empowerment and transformative life style change."
10033886|NCT01791907|No Intervention|Regular routine|
10033887|NCT01791933||CAM treatment|
10033888|NCT01791946|Experimental|Treatment Group A (Post-Surgery)|Subjects enrolled in this arm will first have eye alignment corrective surgery and then complete six weeks of the investigational binocular treatment training.
10033889|NCT01791946|Experimental|Treatment Group B (Pre-Surgery)|Subjects enrolled in this arm will first complete six weeks of the investigational binocular treatment training and then have eye alignment corrective surgery.
9472815|NCT03606681|Experimental|Mineral Trioxide Aggregate (ProRoot MTA)|Indirect pulp capping treatment with Mineral Trioxide Aggregate
9472816|NCT03606681|Experimental|Theracal LC|Indirect pulp capping treatment with Theracal LC
9472817|NCT03606655|Experimental|Kava|This is a single-arm pre- and post- Phase 0/1 study with one primary goal to explore the feasibility of recruitment of participants, adherence rate, acceptability of treatment and completion rate with 14 day dietary supplement kava treatment in head and neck cancer patients who continue to smoke. The other primary goal is to evaluate distribution of change in nicotine and NNK metabolism after 14 day kava treatment..
9472818|NCT03606629||Endoprosthesis implantation|Device implantation
10033890|NCT01791946|Sham Comparator|Sham Treatment|Subjects enrolled in this arm will first complete six weeks of the sham binocular treatment and then undergo eye alignment corrective surgery.
10033891|NCT01791959|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
10033892|NCT01791959|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
9472819|NCT03606616||ACOSOG Z0011 no further ALND arm|patients meeting the criteria for ACOSOG Z0011 trial inclusion：histologically confirmed invasive breast cancer;clinical T1/T2;breast conserving surgery；1 or 2 positive sentinel lymph nodes; Whole-breast RT planned; no preoperative chemotherapy
9472820|NCT03606603||Surgical patients|Adult patients after elective major abdominal gastrointestinal surgery with pre-existing malnutrition or who are at significant risk for malnutrition or nutrition-related complications, with indications for nutritional support
9472821|NCT03606590|Experimental|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
9472822|NCT03606577|Experimental|Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone|
9472823|NCT03606564||paediatric patients undergoing day care surgery|
9472824|NCT03606551||New Orthodontic Patients|"New patient subjects who are just initiating full orthodontic treatment will have their premolars, canines, and incisors bonded with the EXD-959 Bracket System, using the related EXD-961 instruments, according to the manufacturer's IFU.~Their remaining teeth will be bonded with the brackets of the orthodontist's choice. Three of the 5 new patients recruited may be patients that the orthodontist will choose to initiate treatment with the EXD-959 study brackets being applied to the upper teeth only. Having this option will allow the investigators to recruit subjects with deeper over-bites where their standard of care would be to apply esthetic brackets on the upper teeth and metal brackets on the lower teeth."
9472825|NCT03606551||Intercept Orthodontic Patients-Progress|This group will include a minimum of three, and up to 5 patients at each study site who have moved into rectangular wires; and in whom, the orthodontist- investigator believes they will be able to evaluate rotation corrections using the EXD-959 Bracket System. For example, rotation correction of the upper central incisor which will test the width of the bracket's holding points in situations that have wide teeth and greater inter-bracket distance.
9472826|NCT03606551||Intercept Orthodontic Patients-Finishing|This group will include a minimum of three, and up to 5 patients per study site who are estimated to be within 4 months of completing their orthodontic treatment; and in whom, the orthodontist-investigator believes they will be able to evaluate both torque control and debonding experiences using the EXD-959 Bracket System.
9472827|NCT03606473|Experimental|Prenatal cocaine exposed subjects|[C-11]NPA PET at baseline and post d-amphetamine
9472828|NCT03606473|Experimental|Comparison subjects|[C-11]NPA PET at baseline and post d-amphetamine
9472829|NCT03606447|Experimental|Single IV administration of [14C]-Uproleselan|
9472830|NCT03606434|Experimental|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
9472831|NCT03606421||Arm A|Patients in Arm A will be treated with stereotactic radiosurgery (SRS) which is a modern method of treating brain lesions that delivers a high amount of radiation to a small volume of the brain affected by a tumour; and is the standard of care for patients with a limited number of brain metastases.
9472832|NCT03606421||Arm B.|Patients in Arm B will be treated with whole brain radiotherapy, due to the number of lesions in their brain.
9472833|NCT03606408|Other|osilodrostat|open label, with patients receiving same dose as provided in the parent study
9472834|NCT03606395|Experimental|Single ascending dose_healthy subjects|"NV-5138:~Single dose of 150, 300, 600, 1000, 1600 or 2400 mg single dose of placebo"
10033893|NCT01791985|Experimental|Single arm study|"NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off."
10033894|NCT01791998|Experimental|Treatment (MR-thermal image guided LITT)|Patients undergo MR-thermal image guided LITT over 1 hour.
10033895|NCT01792011|Experimental|PVI|A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management.
10033896|NCT01792037|Active Comparator|Etomidate|After taking of the blood samples, patients in Group I will be intubated with 0.3 mg/kg etomidate iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
9472835|NCT03606395|Experimental|Single dose in subjects with TRD|NV-5138 oral solution single dose (dose to be determined from Part A) single dose of placebo
9472836|NCT03606369|Experimental|Palonosetron|"Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4."
10037187|NCT01822782||Cases|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Cases are classified as those with a vaginal lesion due to delivery."
10033897|NCT01792037|Active Comparator|etomidate, steroid|After taking of the blood samples, patients in Group II will be intubated with 0.3 mg/kg etomidate iv following a 2mg/kg methylprednisolone iv Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
10033898|NCT01792037|Active Comparator|midazolam|"After taking of the blood samples, patients in Group III will be intubated with 0.01 mg/kg midazolam iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.~Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired."
10033899|NCT01792063|Active Comparator|Sevoflurane A|Generic sevoflurane
10033900|NCT01792063|Active Comparator|Sevoflurane B|Orginal sevoflurane
10033901|NCT01792089||non-obese healthy subjects|subjects with BMI<25 and no known disease
10033902|NCT01792089||post-gastric bypass|post-obese subjects 12-48 months after Roux-en-Y gastric bypass
10033903|NCT01792089||matched control subjects|Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
10037188|NCT01822782||Controls|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Controls are classified as those without a vaginal lesion due to delivery."
9472837|NCT03606369|Active Comparator|Ondansetron|"Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs."
9472838|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
9472839|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
9472840|NCT03606304|Experimental|Problem-solving therapy|The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.
9472841|NCT03606291|Experimental|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
9472842|NCT03606278|Experimental|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
9472843|NCT03606278|Active Comparator|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
9480375|NCT03534102|Experimental|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
9480376|NCT03534089|Placebo Comparator|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with standard infant formula (without lactoferrin supplementation)
9480377|NCT03534089|Experimental|Low level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with low level of lactoferrin (38mg/100g). Lactoferrin:38mg/100g
9480378|NCT03534089|Experimental|High level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with high level of lactoferrin (76mg/100g)
9480379|NCT03534063|Active Comparator|genotype-guided opioid therapy|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
9480380|NCT03534063|No Intervention|usual care|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
9480381|NCT03534050|Experimental|postoperative adjuvant RT|In this prospective observational study, all potentially eligible patients are clinically indicated for receiving postoperative adjuvant RT. Namely, partial cranial irradiation will be initiated within one month approximately after enrollment. Prescription dose will be 5000 - 6000 cGy in 25 - 30 fraction during 5 - 7 weeks.
9480382|NCT03534037|Experimental|Febuxostat 40mg|Febuxostat 40mg orally per day
9480383|NCT03534037|Active Comparator|Benzbromarone 50mg|Benzbromarone 50mg orally per day
9480384|NCT03534037|Other|Control|Dietary control only
9480385|NCT03534024|Active Comparator|nanomicielle curcumin|
9480386|NCT03534024|Placebo Comparator|plecebo|
9480387|NCT03533972|Experimental|Test group|subjects will be provided with Ashwagandha capsules 500 mg twice daily, after meals with plain water for 1 month
9480388|NCT03533972|Placebo Comparator|Control group|subjects will be provided with placebo capsules.
9480389|NCT03533959||alirocumab therapy group|patients with 10mg daily rosuvastatin and alirocumab at least 75mg every 2 weaks
9480390|NCT03533959||standard statin therapy group|patient with 10mg daily rosuvastatin and never use alirocumab or other PCSK-9 inhibitor
9480391|NCT03533933|Active Comparator|Autologous connective tissue graft|Soft tissue harvesting from patient palate
9480392|NCT03533933|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
9480393|NCT03533920|Experimental|UNI-DEB|
10033904|NCT01792102|Experimental|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
10033905|NCT01792167|Experimental|Second Step|Second Step Curriculum
9472844|NCT03606265|Experimental|App+Web|Treatment as usual + app Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
9472845|NCT03606265|Active Comparator|Treatment as usual|Treatment as usual (waiting list) Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
9472846|NCT03606239|Experimental|isotoxic hypofractionated group|"Hypofractionated radiation:~1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 69Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 69 Gy. The lowest radiation dose: 45Gy.~Chemotherapy:~Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.~The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy."
10033906|NCT01792167|No Intervention|Stories of Us|Stories of Us was provided to schools
10033907|NCT01792180|No Intervention|Control group|No intervention besides weekly telephone calls from the computerized falls telephone system
10033908|NCT01792180|Experimental|Intervention group|Weekly use of the mobility feedback device, use of instruction book with every day exercises, use of activity diary in intervention group.
10033909|NCT01792193||Parkinson's disease|Patients with Parkinson's disease
10033910|NCT01792193||Control|Healthy controls
10033911|NCT01792206|Active Comparator|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
10033912|NCT01792206|Placebo Comparator|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
9472847|NCT03606174|Experimental|Cohort 1|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
10033913|NCT01792219|Experimental|interprofessioal education module|an interprofessional education module will be given to learn to collaborate interprofessionally.
10033914|NCT01792232|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific allergen placed in lung
10033915|NCT01792232|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific allergen placed in lung
10033916|NCT01792232|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by subject saline placed in lung
10033917|NCT01792232|Active Comparator|Diesel exhaust control|Exposure for 2 hours to diesel exhaust followed by saline placed in lung
10033918|NCT01792245|Active Comparator|NB-UVB|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
10033919|NCT01792245|Active Comparator|Topical PUVA|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
10033920|NCT01792258||critical ill patients|The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU
10033921|NCT01792271|Placebo Comparator|AB: 7% HS home tx, then 0.12% NaCl|"Inhaled Inhaled 7% HS (hypertonic saline) home treatment' , then 0.12% sodium chloride solution home treatment.~The intervention consists of the subject receiving both concentrations of inhaled sodium chloride solution, each during a different home treatment periods. Subjects randomized to order AB will receive inhaled 7% NaCl (sodium chloride solution) mist during the first home treatment period, then 0.12% NaCL during the second home treatment period."
10033922|NCT01792271|Placebo Comparator|BA: 0.12% NaCl home tx, then 7% HS|Subjects randomized to order BA will receive inhaled 0.12% NaCl mist during the first home treatment period, then Inhaled 7% HS home treatment during the second home treatment period.
10033923|NCT01792297|Experimental|Bovine Colostrum|60 g/d bovine colostrum in powder form to be mixed with drinks. The dose will be spread out 3 times per day (20 g per dose)
9472848|NCT03606174|Experimental|Cohort 2|Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
9472849|NCT03606174|Experimental|Cohort 3|Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
9472850|NCT03606174|Experimental|Cohort 4|Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
9472851|NCT03606174|Experimental|Cohort 5|Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
9472852|NCT03606174|Experimental|Cohort 6|Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
10033924|NCT01792297|Active Comparator|Whey protein|60 g/d whey protein powder mixed into drinks. It is to be divided into 3 daily doses (20 g per dose)
10033925|NCT01792310|Experimental|Dose Cohort 1|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.
10033926|NCT01792310|Experimental|Dose Cohort 2|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 500 mg twice daily
10033927|NCT01792310|Experimental|Dose Cohort 3|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 1g twice daily
9472853|NCT03606174|Experimental|Cohort 7|Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
9472854|NCT03606174|Experimental|Cohort 8|Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
9472855|NCT03606174|Experimental|Cohort 9|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
9472856|NCT03606148||SurePathTM|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In SurePathTM group, subjects who underwent SurePathTM liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
9472857|NCT03606148||Conventional|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePathTM liquid cell test with the second obtained sample."
9472858|NCT03606135||The Pneumonia Group|Subjects with chest images (x-ray or CT scan) indicating pneumonia.
9472859|NCT03606135||The Control Group|Healthy subjects
9472860|NCT03606122|Experimental|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
9472861|NCT03606109|Active Comparator|TTO + IV TXA|
9472862|NCT03606109|No Intervention|TTO, no IV TXA|
9472863|NCT03606070|Other|Patients with NSCLC|"Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.~Patients will realize:~a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
9472864|NCT03606057|Experimental|Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo|Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.
9472865|NCT03606057|Active Comparator|Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin|Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
9472866|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
9472867|NCT03606018|Experimental|Insulin Lispro Mix 25|Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
9472868|NCT03606018|Active Comparator|Humalog® Mix 25|Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
9472869|NCT03606005||Group 1: Allogeneic-HSCT recipients|Dyspnea [Modified Medical Research Council dyspnea scale (MMRC)], submaximal exercise capacity [6-minute walk test (6-MWT)], physical activity level [metabolic holter], quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] and pulmonary functions [spirometry] were evaluated in allogeneic-HSCT recipients (.Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
9472870|NCT03606005||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
10033928|NCT01792310|Experimental|2-OHOA Dose Cohort 4|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 2g twice daily
10033929|NCT01792310|Experimental|2-OHOA Dose Cohort 5|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g twice daily
10033930|NCT01792310|Experimental|2-OHOA Dose Cohort 6|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g three times daily
10033931|NCT01792310|Experimental|2-OHOA Dose Cohort 7|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 8g twice daily
9472871|NCT03605992|Experimental|Home-based Rehabilitation|Home-based cardiac rehabilitation that includes the components of education and physical exercises mainly unsupervised and oriented by telephone.
9472872|NCT03605992|Active Comparator|CentreRehabilitation|Traditional cardiac rehabilitation offered at the outpatient centre including components of education and physical exercises mainly supervised.
9472873|NCT03605979||diabetes group|Patient with hypoglycemia unawareness
9472874|NCT03605940|Experimental|Experimental group|corticosteroids + ECP
9472875|NCT03605940|Active Comparator|Contrôl group|corticosteroids alone
9472876|NCT03605901|Active Comparator|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
9472877|NCT03605901|Experimental|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 4 breaths/min, induction of general anesthesia and intubation will proceed.
9472878|NCT03605888|Experimental|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
9472879|NCT03605888|No Intervention|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
9472880|NCT03605888|Other|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
9472881|NCT03605875|Experimental|Web-App|A customized web-app tool to be used by patients to communicate concerns to their nephrologist
9472882|NCT03605875|Active Comparator|Paper|A customized paper tool to be used by patients to communicate concerns to their nephrologist
9472883|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
10033932|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.
10033933|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Non-glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.
10033934|NCT01792323|Experimental|1 bolus of insulin lispro with short bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds
10033935|NCT01792323|Experimental|1 bolus of insulin lispro with long bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes
10033936|NCT01792349|Experimental|STARFISH intervention|STARFISH is a smartphone-based programme designed as a behavioural intervention to encourage the user to become more physically active
10033937|NCT01792349|No Intervention|Control group|A smartphone application will record levels of physical activity, but subjects will not have access to daily step count or to the STARFISH application.
9472884|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
9472885|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
9472886|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
9472887|NCT03605797||No intervention|To study the indication and results of fixing the sacral fracture by tension band plating
9472888|NCT03605758|Active Comparator|Ivermectin on Days 1 and 2|Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
10033938|NCT01792362|Experimental|AMH|obese PCOS patients who underwent weight loss diet
10033939|NCT01792375|Active Comparator|Concurrent membrane sweeping with Dinoprostone|
10033940|NCT01792375|Active Comparator|Dinoprostone|
10033941|NCT01792388|Placebo Comparator|Soya Bean oil|
10033942|NCT01792388|Active Comparator|Vitamin D|
10033943|NCT01792401|Placebo Comparator|Placebo|Patients on enteral feeding in intensive care units are administered a placebo
10033944|NCT01792401|Active Comparator|Probiotics|Patients on enteral feeding in intensive care unit are given a probiotic
10033945|NCT01792414|Active Comparator|Active TES|Active TES
10033946|NCT01792414|Sham Comparator|Sham TES|Sham TES
10033947|NCT01792440||non-cystic fibrosis bronchiectasis|patients with non-cystic fibrosis bronchiectasis will be evaluated cross-sectionally
10033948|NCT01792440||healthy control subjects|healthy control subjects will be evaluated cross-sectionally
10033949|NCT01792453|Experimental|240 mL water drink|Volunteers will be asked to drink 240 mL water drink
10033950|NCT01792466|Experimental|Transpacnreatic sphincterotomy|In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
10033951|NCT01792466|No Intervention|Double wire without sphincterotomy|In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation
10033952|NCT01792479|Experimental|Arm A: BIND-014 every 3 weeks|
10033953|NCT01792479|Experimental|Arm B: BIND-014 weekly|
10033954|NCT01792505|Experimental|Biological/Vaccine|
10033955|NCT01792544|Experimental|Statement|A statement is added to the echocardiography report describing if and when a follow-up echocardiogram is recommended. The statement may be positive (e.g. follow-up recommended in 6 months) or negative (e.g. no follow-up recommended).
10033956|NCT01792544|Experimental|No Statement|No statement is added to the echocardiography report
10033957|NCT01792557|Active Comparator|Phenol|Crystallized Phenol Group
10033958|NCT01792557|Active Comparator|Limberg|Limberg Flap Group
10033959|NCT01792557|Active Comparator|Modified Limberg|Modified Limberg Flap Group
10033960|NCT01792557|Active Comparator|Karydakis|Karydakis Flap Group
10033961|NCT01792570|Experimental|RPV + DRV/r|switch to RPV + DRV/r
10033962|NCT01792570|Active Comparator|continue the PI/r-containing HAART.|continue the PI/r-containing HAART
10033963|NCT01792596|Other|pasta|1. Plain pasta
10033964|NCT01792596|Other|pasta with protein|Pasta with protein
9472889|NCT03605758|Active Comparator|Ivermectin on Days 1 and 14|Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
10033965|NCT01792596|Other|pasta with fiber|Pasta with Fiber
9472890|NCT03605732|Experimental|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
9472891|NCT03605732|Active Comparator|Patient education|Patients will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
9472892|NCT03605654|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
9472893|NCT03605654|Active Comparator|Active Control Arm|Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study
9472894|NCT03605654|Experimental|Non-Randomized Exploratory Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
9472895|NCT03605641|Experimental|JUUL electronic cigarette|JUUL electronic cigarette. Virginia Tobacco 5% tobacco-derived nicotine.
9472896|NCT03605641|Active Comparator|VUSE Solo electronic cigarette|Reynolds American International VUSE Solo electronic cigarette. Original flavor 4.8% tobacco-derived nicotine.
9472897|NCT03605641|Active Comparator|Conventional cigarette|Canadian purchased, store bought (not hand-rolled) conventional full-flavored cigarettes of subjects' preference.
9472898|NCT03605628|Other|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
9472899|NCT03605615|No Intervention|CONTROL|In this group parturients will be attended in standardized manner, which in our hospital means a humanized approach with choice of position in socond stage and without routine episiotomy.
9472900|NCT03605615|Experimental|VOCALIZATION|In this group parturients will besides being be attended with our standar care, will receive training to vocalize during second stage.
9472901|NCT03605589|Experimental|Blinatumomab and Pembrolizumab|"Blinatumomab and Pembrolizumab will be given for 2 cycles (each cycle lasts 35 days).~Blinatumomab administered as a continuous IV infusion. Patient Weight Greater Than or Equal to 45 kg (Fixed dose) Patient Weight Less Than 45 kg (BSA-based dose)~Cycle 1 (Days 1-7):~Patient Weight Greater Than or Equal to 45 kg: 9 mcg/day Patient Weight Less Than 45 kg: 5 mcg/m2/day~Cycle 1(Days 8-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Cycle 2 (Days 1-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Pembrolizumab: 2 mg/kg (max dose 200 mg) administered as a 30 minute IV infusion on day 12 of cycle 1 and day 5 of cycle 2."
9472902|NCT03605576|Experimental|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9472903|NCT03605576|Active Comparator|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9472904|NCT03605563|Experimental|FSN: Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9472905|NCT03605563|Active Comparator|TENS: Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
9472906|NCT03605537|Experimental|Stent|"Subjects will undergo repair of the choanal atresia in the operating room with a drug eluting stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. At this time in the operating room the intervention arm will have the stent removed. Following removal of the stent, photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
9472907|NCT03605537|No Intervention|No Stent|"Subjects will undergo repair of the choanal atresia in the operating room with no stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. Photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
9472908|NCT03605524|Other|Sensory training|"Sensory (Olfactory or visual) training will be done at home for 12 weeks.~The effect of the training will be evaluated using an experimental protocol includes (i) clinical and psychometric evaluations, (ii) the study of olfactory perception using Sniffin' Sticks Test and (iii) the study of the emotional perception using the subjective Sense'n Feel method and the objective measurement of the spontaneous pupillary dilatation."
9472909|NCT03605485|Experimental|Trial Continuous Positive Airway Pressure (CPAP) mask|Trial nasal pillows CPAP mask
10033966|NCT01792609|Active Comparator|Maximum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
10037189|NCT01822795|Experimental|Lung volume reduction coïl treatment|Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention
10033967|NCT01792609|Active Comparator|Minimum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
9472910|NCT03605472|Experimental|Patients|
10033968|NCT01792622||Phase I Patient Interviews|Indepth interviews will be completed with approximately 15 patients.
10033969|NCT01792622||Phase II Patient Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
10033970|NCT01792648|Active Comparator|Standard Reference Diet|
9472911|NCT03605459|Experimental|Device use|"Only one treatment arm; the Comfort Plug™ is a device designed to control urinary incontinence in male subjects by being placed in the urethra to stop urine leakage."
9472912|NCT03605446|Experimental|Animal 12%|Animal based protein biscuit containing 12% of total energy as protein
9472913|NCT03605446|Experimental|Animal 20%|Animal based protein biscuit containing 20% of total energy as protein
9472914|NCT03605446|Experimental|Plant 12%|Plant based protein biscuit containing 12% of total energy as protein
9472915|NCT03605446|Experimental|Plant 20%|Plant based protein biscuit containing 20% of total energy as protein
9472916|NCT03605446|Placebo Comparator|Wheat biscuit|
9472917|NCT03605433|Experimental|Oral Anticoagulation+Antiplatelet|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.
9472918|NCT03605433|Experimental|Oral Anticoagulation|Rivaroxaban 20 mg once daily
9472919|NCT03605433|Active Comparator|Antiplatet|Aspirin 100 mg once daily
9472920|NCT03605420|Experimental|Experimental group|Receiving one family visit prior to hospital admission
9472921|NCT03605420|No Intervention|Control group|Without receiving one family visit prior to hospital admission
9472922|NCT03605407|Experimental|Experimental group|Patient receiving one visit prior to hospital admission
9472923|NCT03605407|No Intervention|Control group|Patient without receiving one visit prior to hospital admission
9472924|NCT03605329|Other|Type 1 diabetic patients with OSAS|to explore the severity of NAC in case of OSAS
9472925|NCT03605290|Active Comparator|Mechanically aligned TKR|patients were operated using the standard mechanically aligned technique
9472926|NCT03605290|Experimental|Kinematically aligned TKR|patients were operated using the newer mechanically aligned technique
9472927|NCT03605251|Experimental|TAS5315 low dose group|TAS5315 low dose and Methotrexate as specified
9472928|NCT03605251|Experimental|TAS5315 high dose group|TAS5315 high dose and Methotrexate as specified
9472929|NCT03605251|Placebo Comparator|Placebo group|Placebo and Methotrexate as specified
9472930|NCT03605238|Experimental|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone to reduce acute inflammation, then infuse anti-CD19/20-CAR retroviral vector-transduced autologous derived T cells only once.
9472931|NCT03605225|Experimental|Cellphone application|Train of Four (TOF) ratio displayed by the Cellphone Application
9472932|NCT03605225|Active Comparator|Draeger TOF Scan|Train of Four (TOF) ratio displayed by the Draeger TOF Scan
10033971|NCT01792648|Experimental|Almond Supplemented Diet|
10033972|NCT01792648|Active Comparator|Low Carbohydrate Reference Diet|
10037190|NCT01822795|Other|Regular Medical Treatment|No intervention, just a follow up under usual medical treatment
9472933|NCT03605199|Experimental|Denosumab active treatment|Denosumab active treatment
9472934|NCT03605186|Experimental|Chamomile oral cryotherapy|"The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
9472935|NCT03605186|Active Comparator|Oral cryotherapy|"The plain icecubes will be prepared in the clinic with 400 mL of distilled water.~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
9472936|NCT03605173|Experimental|free vitamin d|free vitamin is directly measured from blood serum using an ELISA kit
9472937|NCT03605173|Experimental|total vitamin d|Total vitamin d is measured routinely from blood serum
9472938|NCT03605160|Active Comparator|traditional group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents. All operations are videotaped during the whole operation. The total polish time is recorded as the time of all polish procedures.
9472939|NCT03605160|Experimental|fluid-jet group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule. All operations are videotaped during the whole operation. The total time of all jet procedures recorded in the videotape is the total time of jet.
9480394|NCT03533907||treated|The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day
10033973|NCT01792661|Active Comparator|MyChart|The control group receives standard Cleveland Clinic care and has access to MyChart which is the standard Cleveland Clinic electronic PHR.
10033974|NCT01792661|Active Comparator|Enhanced MyChart|The enhanced PHR functionality adds the ability to securely receive and review CKD-education related messages to the existing features available to all PHR users. The CKD-educational related messages can be automatically delivered at pre-defined intervals and customized for each individual patient at their discretion and convenience.
10033975|NCT01792661|Active Comparator|Patient Navigator|A tracking log is kept by the Patient Navigator of each interaction regarding type of encounter, length of encounter, barriers addressed, and actions that occurred, adapting what is in use for the NIH-funded Patient Navigator program.
10033976|NCT01792661|Active Comparator|Patient Navigator and Enhanced MyChart|Combines patient self empowerment, regarding their CKD, with the Enhanced MyChart along with the aid and direction of a Patient Navigator.
10033977|NCT01792674|Experimental|In situ simulation|'In situ simulation' which is training in the actual patient care unit, in this situation the labour suite and operation theatre
10033978|NCT01792674|Active Comparator|Off site simulation|The control group will receive the same training 'off site simulation', i.e., in training rooms away from the actual patient care unit.
10033979|NCT01792700|Active Comparator|MEA|MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.)
10033980|NCT01792700|Active Comparator|EBMT|EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d)
9472940|NCT03605147|Experimental|CaHMB|CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
9472941|NCT03605147|Active Comparator|Control|Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
9472942|NCT03605134||study group|level of cardiac troponin and diastolic function assessment by means of transthoracic echocardiography
9472943|NCT03605108|Active Comparator|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
9472944|NCT03605108|Placebo Comparator|Placebo|Rice flour only
9472945|NCT03605095|Active Comparator|8 mg/ml nitroglycerin|Higher concentration of NO donor (Nitromint) vs dilution
9472946|NCT03605095|Active Comparator|1 mg/ml nitroglycerin|Lower concentration of NO donor (Nitropohl) vs physiological saline
9472947|NCT03605082|Experimental|UCB0107|Subjects will be randomized to receive a predefined dosage of UCB0107 in order to maintain the blinding.
9472948|NCT03605082|Placebo Comparator|Placebo|Subjects will be randomized and receive a placebo in order to maintain the blinding.
9472949|NCT03605069|Other|First TWA (A)|"In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.~In the first arm; randomization of the first selected TWA to active treatment or placebo"
9472950|NCT03605069|Other|Second TWA (B)|In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.
9472951|NCT03605056|Experimental|CRD regimen|CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
9472952|NCT03605043||Overall cohort|All Persons Living with HIV who enlisted in any one of three high-volume HIV clinics in Tororo District of Eastern Uganda between 2014 and 2017.
9472953|NCT03605030|Active Comparator|Novel Lead Based Armboard|
9472954|NCT03605030|Placebo Comparator|Standard Armboard|
9472955|NCT03605004||Negative|Adult patients with undiagnosed conditions who have received an uninformative negative result from exome sequence.
9472956|NCT03605004||VUS|Adult patients with undiagnosed conditions who have received one or more variants ofuncertain significance from exome sequence.
9472957|NCT03604965|Experimental|GP+CCRT|GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
9472958|NCT03604965|Active Comparator|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
9472959|NCT03604926||chemo-naive patients|
9472960|NCT03604926||pre-treated patients with systemic chemotherapy +/- a targeted|
9472961|NCT03604887||study group|All pregnant women who will attend the labor unit during the study period will be invited to participate in the study.
9472962|NCT03604874|Active Comparator|low dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.
10033981|NCT01792713|Active Comparator|Sertaconazole 2% cream|2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up
10033982|NCT01792713|Placebo Comparator|Placebo Arm|2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up
9472963|NCT03604874|Experimental|high dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions
9472964|NCT03604848|Experimental|NGS-guided regimen: Regimen A|Regimen A: 9-month regimen for simple MDR-TB patients 4 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 5months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
9472965|NCT03604848|Experimental|NGS-guided regimen: Regimen B|Regimen B: 12-month simple MDR-TB regimen for simple MDR-TB patients 6 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 6 months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
9480395|NCT03533881|Active Comparator|Arom Digest Slim and nutritional changes|Subjects take collagen and follow minimal nutritional changes.
9480396|NCT03533881|Active Comparator|Nutritional changes|Subjects only follow minimal nutritional changes
10033983|NCT01792726|Experimental|TARGIT|The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
10033984|NCT01792726|Active Comparator|External beam radiotherapy boost|The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
10033985|NCT01792739|Experimental|Kadit B|Probiotic Lactobacillus casei variety rhamnosus granules
9472966|NCT03604848|Experimental|NGS-guided regimen: Regimen C|"Regimen C : for complicated MDR-TB patients In regimen C, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol based on the drug susceptibility test results. The duration of treatment in the complicated MDR-TB group is consistent with control group, with 6 months of intensive phase and 18 months of consolidation phase."
9472967|NCT03604848|Active Comparator|WHO-approved MDR-TB regimen|6 months of pyrazinamide, amikacin,moxifloxacin, prothionamide , and cycloserine , followed by 18 months of pyrazinamide, moxifloxacin, prothionamide , and cycloserine
10033986|NCT01792739|Placebo Comparator|Kadit A|Placebo
10033987|NCT01792765|No Intervention|Control Arm|This arm will undergo ureteroscopy using conventional fluoroscopy to guide the procedure and visualize scope position, safety wire status, etc.
10033988|NCT01792765|Experimental|Ultrasound guidance|This arm will have intraoperative ultrasound guidance to determine safety wire position and for scope guidance.
10033989|NCT01792778|Active Comparator|ViaValve Safety IV Catheter|Catheter insertion using the ViaValve Safety IV Catheter.
10033990|NCT01792778|Active Comparator|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|Catheter insertion using the Insyte Autoguard BC Shielded IV Catheter
10033991|NCT01792791||Single Arm|
10033992|NCT01792804|Experimental|Orally administered antibiotic|First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
9472968|NCT03604822|Experimental|Music therapy protocol|Each participant received 12 home-based music therapy treatment sessions over 6-week time period.
9472969|NCT03604809|Experimental|OT Guided Cognitive Interventions|Occupational Therapy interventions will be adjusted according to the patient's Richmond Agitation and Sedation Scale (RASS).
9472970|NCT03604809|No Intervention|Usual Care|This will be the standard of care currently provided for delirium prevention within the Department of Critical Care Medicine in Calgary using the ABCDEF bundled approach.
9472971|NCT03604796|Active Comparator|Continuous IV Acetaminophen|Intravenous Infusion
9472972|NCT03604796|Active Comparator|Rectal Acetaminophen|Rectal Solution
9472973|NCT03604770||Women seeking fertility treatment|Women aged 18-45 who are seeking fertility treatment at Bethesda Fertility Center will be provided a survey and food diary to complete.
9472974|NCT03604757|Experimental|PET/CT Imaging|
9472975|NCT03604744|Experimental|LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
9472976|NCT03604744|Placebo Comparator|LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
9472977|NCT03604744|Placebo Comparator|Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
9472978|NCT03604744|Placebo Comparator|Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
10033993|NCT01792804|Experimental|Intravenously administered antibiotic|First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
10033994|NCT01792843||Parkinson's disease|Patients with Parkinson's disease according to international criteria
10033995|NCT01792856|Experimental|intervention group|Subjects are scheduled to receive a 6-month group-based recovery-oriented coaching program. This is a structured, manualised treatment program based on life coaching principles with cognitive-behavioural and solution-focused elements incorporated. It guides subjects to undergo an active, yet stepwise change process by stimulating motivation, setting achievable goals, generation of action plans via collaborative exploration, fostering self-regulatory capacity, and provision of autonomy-supportive treatment environment and peer support. Subjects' perceived competence, sense of control, self-management skills and hence functioning will be improved via successful experiences and positive feelings generated after attainment of self-initiated goals. Cognitive-behavioural techniques such as self-monitoring, activity scheduling and behavioural modification will be employed.
9472979|NCT03604744|Placebo Comparator|Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
9472980|NCT03604731||Uncomplicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures
9472981|NCT03604731||Complicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures complicated by multiorgan failure
9472982|NCT03604679|Experimental|SyB C-0501|"SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD"
9472983|NCT03604666||Health care process with Nurse Navigator|"A Nurse Navigator will:~Be present at the announcement consultation~Give information on the outpatient circuit~Offer assistance for patients over 75 years~Complete onco-geriatric orientation questionnaires~Take care of patients on the ambulatory circuit"
9472984|NCT03604666||Health care process|Health care process
9472985|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
9472986|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
10033996|NCT01792856|Experimental|control group|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
10033997|NCT01792895|Active Comparator|Manipulation group|This Technique will be applied over four sessions, during two weeks
9472987|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
9472988|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
9472989|NCT03604627|Other|Patients treated for cancer during childhood or adolescence|Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg / m²)
9472990|NCT03604614|Experimental|HIPEC and chemotherapy|Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）
9472991|NCT03604614|Sham Comparator|Without HIPEC|Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）
9472992|NCT03604588|Other|Patients with oropharyngeal cancer|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
9472993|NCT03604575|Experimental|Insulin Lispro|Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg
9472994|NCT03604575|Active Comparator|Humalog®|Single subcutaneous administration of Humalog® in dose 0.3 IU / kg
9472995|NCT03604549|Placebo Comparator|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
9472996|NCT03604549|Experimental|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
9472997|NCT03604510|Experimental|Electroencephalographic recordings|Electroencephalographic recordings
9472998|NCT03604484|Active Comparator|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
9472999|NCT03604484|No Intervention|No Tricuspid annuloplasty|Control patients
9480397|NCT03533868|No Intervention|Standard of Care (SOC)|Patients in this arm will have their viral load monitored using the standard of care method, using the Roche Cobas TaqMan HIV-1® v2 (Roche) assay.
9480398|NCT03533868|Experimental|Point-of-care (POC)|Patients in this arm will have their follow-up viral loads (after baseline) monitored using a Point-of-care viral load monitoring test, the Cepheid Xpert HIV-1 Viral Load assay.
9480399|NCT03533803|Active Comparator|Group A (Indomethacin)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
9480400|NCT03533803|Placebo Comparator|Group B (Control)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
9480401|NCT03533790|Experimental|DEP-Ru|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2 mg/kg days 1 to 5,then gradually reduce; ruxolitinib 0.3mg/kg/d。This regimen was repeated after 2 weeks.
9480947|NCT05163652|Experimental|6 months after two doses|group 1：the third does was given 6 months after two doses CoronaVac group 2：the third does was given 6 months after two doses BBIBP-CorV group 3：the third does was given 6 months after one does CoronaVac and one does BBIBP-CorV
9480948|NCT05162976|Experimental|Treatment (CC-486, nivolumab)|Patients receive azacitidine PO QD on days 1-7 and nivolumab IV over 30 minutes on day 8. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
9480949|NCT05161806|Experimental|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
9480950|NCT05156476|Active Comparator|Genicular nerve block-iPACK group|"Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Genicular nerve block will be performed on the the superomedial, the superolateral, the inferomedial and inferolateral genicular nerve.~Drug: a total of 30 ml of ropivacaine 0.5% (150 mg) will be used for this treatment arm."
9480951|NCT05156476|Active Comparator|Femoral triangle block-iPACK group|Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0.5% (150 mg) will be used for this treatment arm
9480952|NCT05156476|Active Comparator|Local Infiltration Analgesia (LIA)|LIA (performed by surgeon) Method: Blind injection Drug: a total of 200 ml of 0.2% ropivacaine will be used (400 mg). Of this, 150 ml of ropivacaine 0.2% will be mixed with 1 mg of adrenaline.
9480953|NCT05155410|Experimental|Experimental|"Participants will consume 15 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~All meals will be provided throughout the supplementation period Participants will wear a continuous glucose monitor for the first 10 consecutive days during the supplementation period."
9480954|NCT05155410|Placebo Comparator|Placebo|Participants will consume a flavor-matched placebo drink and undergo the same procedures described in the Experimental Arm
9480955|NCT05154578|Experimental|Group 1: 4 week dose interval; 2 doses|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
9803160|NCT04490824|Active Comparator|Treated Then Control Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale KELEA Excellerated Water for 2 days followed by inhaling water without an elevated level of KELEA for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
9473000|NCT03604471|Other|Atorvastatin|All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).
9473001|NCT03604419|Experimental|PB-119 100 μg|PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)
9473002|NCT03604419|Experimental|PB-119 150 μg|PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
9473003|NCT03604419|Experimental|PB-119 200 μg|PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
9473004|NCT03604419|Placebo Comparator|PB-119 Placebo|PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
9473005|NCT03604380|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
9473006|NCT03604380|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
9473007|NCT03604367||GAITRite assessment|Subjects will undergo the GAITRite assessment of functional walking and then complete the Functional MRI Bipedal paradigm followed by questionnaires and assessments regarding the virtual environment.
9473008|NCT03604354|Active Comparator|Pregabalin|Pregabalin 150mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
9473009|NCT03604354|Experimental|Tapentadol|tapentadol 100mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
9473010|NCT03604328|Experimental|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
9473011|NCT03604315|Experimental|Treatment (FDG PET/CT, [18F]FTT PET/CT)|Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo [18F]FTT PET/CT over 1 hour.
9473012|NCT03604250|Experimental|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
9473013|NCT03604237|Experimental|Targeted forceps biopsy|In this group, an endoscopist takes a forceps biopsy at depressed mucosa or large nodular area of large colorectal tumors after meticulous surface evaluation.
9473014|NCT03604237|No Intervention|Conventional forceps biopsy|In this group, an endoscopist takes a forceps biopsy at the most convenient area of large colorectal tumors.
9473015|NCT03604224||Canagliflozin Containing Treatment Regimens|No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.
9473016|NCT03604146||control group|Doctors and nurses were trained to treat chronic obstructive pulmonary disease according to the GOLD guidelines.Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
9473017|NCT03604146||Intervention group|Doctors and nurses will not receive any training from research team. Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
9473018|NCT03604133||Patients receiving ICD devices|
9473019|NCT03604120|Experimental|Preoxygenation with high flow therapy by nasal cannula|High flow oxygen therapy by nasal cannula.
9473020|NCT03604120|Active Comparator|Preoxygenation by standard Facial mask|"Patients randomized in STANDARD FACIAL MASK group will receive a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction or Fiber-optic intubation under spontaneous ventilation."
10033998|NCT01792895|Active Comparator|Mobilisation|This treatment will be applied on cervical spine during four sessions, over two weeks
9473021|NCT03604094||Group I|0-1 month old newborns
9473022|NCT03604094||Group II|1 month-2 year-old pediatric patients
9473023|NCT03604081|Experimental|Intervention Group|One hour of intense massed practice of lower extremity either in the form of shaping or task practice
9473024|NCT03604081|Placebo Comparator|Control Group|Conventional physical therapy for 1 hour as per current standard of care that follows stroke clinical practice guideline.
9473025|NCT03604068|Active Comparator|Active Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.
9473026|NCT03604068|Sham Comparator|Control Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.
9473027|NCT03604055|Other|Endobronchial hamartomas treatment|After removal of endobronchial lesions, cryotherapy is applied to the area of origin. Recurrences are followed. Recurrences are recorded as poor results, compared with good results.
9473028|NCT03604042|Active Comparator|Weight-driven protein fortification|Individualized protein fortification based on weight gain
9473029|NCT03604042|Experimental|BUN-driven protein fortification|Individualized protein fortification based on BUN concentrations
9473030|NCT03604029||Qualifying Subjects|Qualifying subjects who are high risk for ACS.
9473031|NCT03604029||Qualifying Subjects with ACS|Qualifying subjects who are diagnosed with ACS
9473032|NCT03604016|Experimental|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
9473033|NCT03604016|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
9473034|NCT03604003|Experimental|bedtime dosing ARB for hypertension|bedtime administration of potassium losartan has benefit for the isolated nocturnal hypertension
9473035|NCT03604003|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
9473036|NCT03603990|Experimental|Vitrectomy|"Patient with standard pars plana vitrectomy~During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
9473037|NCT03603990|Active Comparator|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
9473038|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
10033999|NCT01792895|Active Comparator|Mobilization with movement|This Technique will be applied over four sessions, during two weeks
10034000|NCT01792908|Experimental|KT group|The KT group received ankle KT on the lateral ligament in the non-dominant leg and a recommendation guide. The Kinesio tape procedure was carried out by the same certified athletic therapist to ensure consistency throughout the study.
10034001|NCT01792908|No Intervention|Control group|Any intervention has been applied. Using another kind of tape or a different KT application for control group may increase cutaneous information, undermining our goal.
10034002|NCT01792921||control waitlist|
10034003|NCT01792934|Active Comparator|XELOX or FOLFOX regimen|XELOX or FOLFOX regimen
10034004|NCT01792934|Experimental|XELOX or FOLFOX regimen and maximal tumor debulking|XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).
10034005|NCT01792947|Active Comparator|Diet|Diet 1200 Kcal during 3 months
10034006|NCT01792947|Experimental|PENS associated to diet|Percutaneous electroneurostimulation of dermatome T6 associated to diet 1200 Kcal
10034007|NCT01792960||familial hypertrophic cardiomyopathy|familial hypertrophic cardiomyopathy patients and their relatives
10034008|NCT01792999|No Intervention|Non-contrast KBCT|About 187 subjects, who had diagnostic imaging of the breast including mammography and were categorized as Breast Imaging-Reporting and Data System(BIRADS) scores 1, 2, 3, 4, or 5, received KBCT imaging without contrast injection.
10034009|NCT01792999|Experimental|Contrast-enhanced KBCT|About 231 subjects, who had diagnostic imaging of the breast including mammography and were scheduled for biopsy or surgery, received contrast-enhanced KBCT imaging of the affected breast before biopsy or surgery.
10034010|NCT01793012||critically ill intensive care patients|Treatment with one or more of the following antibiotics: piperacillin/tazobactam, cefepime, meropenem, ciprofloxacin, linezolid, colistin
10034011|NCT01793025|Experimental|ATAC Therapy|
10034012|NCT01793038|Active Comparator|CC-plus uFSH|clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12
10034013|NCT01793038|Experimental|Aromataze inhibitor plus uFSH|Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12
10034014|NCT01793064|Experimental|Adaptive Intervention Group (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
10034015|NCT01793064|Active Comparator|Static Intervention group (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
10034016|NCT01793077||Prostate Cancer patients|
10034017|NCT01793090|Active Comparator|EPI-743|"EPI- 743 in capsule or formulation comprised of USP/NF (United States Pharmacopeia and The National Formulary)Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.~Dose: 100mg or 200 mg tid for 12 months, to be continued if clinically effective"
10034018|NCT01793090|Placebo Comparator|Placebo supplementation|placebo in the same formulation as the active comparator will be administered to patients, assigned to this arm in a randomized design
10034019|NCT01793155|Experimental|Inspiratory muscle training|Inspiratory muscle training for two weeks following surgery
10034020|NCT01793155|Placebo Comparator|Standard physiotherapy|Breathing exercises, cough/hugh, advice on early and active mobilization
10034021|NCT01793181||CRVO patients|Patients with a newly diagnosed CRVO. Maximum duration 3 months.
10034022|NCT01793181||Control patients|Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
10034023|NCT01793194|No Intervention|No Stocking Use|For pregnant women randomized to the no stocking use group, no compression stockings will be worn.
10034024|NCT01793194|Experimental|Compression Stocking Use|Patients who are randomized to the stocking use group (Treatment Subgroup A) will be formally measured for their stockings by a certified stocking fitter, given (at no charge) two pair of 20-30mmg Hg maternity pantyhose compression stockings, and will undergo a brief tutorial regarding how to put the stockings on. Each patient will be instructed to wear the stockings on a daily basis, during the day.
10034025|NCT01793207||Normal|Subjects who had a normal colonoscopic examination (No polyps, masses or any evidence of colorectal neoplasia)
10034026|NCT01793207||colorectal cancer|Patients with endoscopic and histopathological evidence of colorectal cancer
10034027|NCT01793207||Adenoma|Patients with colorectal adenomas only detected on colonoscopy
10034028|NCT01793207||Hyperplastic polyps|Patients with hyperplastic polyps detected on colonoscopy.
10034029|NCT01793220|Experimental|SMS Reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
10034030|NCT01793220|No Intervention|No SMS Reminders|The service user will not be sent text message reminders prior to each appointment at their Psychosis Community Service
10034031|NCT01793233||Ancillary-Correlative (menstrual diary, biomarker analysis)|Patients complete a menstrual diary to document vaginal bleeding and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment.
9473039|NCT03603938|Experimental|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
9473040|NCT03603938|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
9473041|NCT03603899|Experimental|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
9473042|NCT03603886|Experimental|Telemedicine Pain Management|
9473043|NCT03603886|Other|Waitlist Control|Treatment as usual comparator
9473044|NCT03603873||Patients|
9473045|NCT03603834|Experimental|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
9473046|NCT03603821||LUTS male|Clinical assesment of males older than 50 years with lower urinary tract symptoms presumably related to benign prostate enlargement
9473047|NCT03603795|Experimental|A|"55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1.~200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
10034032|NCT01793246||pCLE for Discrete lung lesions|Patients undergoing bronchoscopy for the diagnosis of a lesion with probe based laser endomicroscopy (pCLE) imaging before biopsy
10034033|NCT01793246||pCLE for acute lung transplant rejection|Patients undergoing bronchoscopy for the detection of acute rejection of lung transplant with probe based laser endomicroscopy (pCLE) imaging before biopsy
10034034|NCT01793259|Other|prefilled pen then prefilled syringe|weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
10034035|NCT01793259|Other|prefilled syringe then prefilled pen|weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks
10034036|NCT01793272|Other|Pentoxifylline|effect of pentoxifylline on ICSI outcome
10034037|NCT01793298|Experimental|Healthy Subjects - ASM-024 Single Administration|Single administration of ascending doses of ASM-024
10034038|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo|Single administration of placebo
10034039|NCT01793298|Experimental|Healthy Subjects - ASM-024 Repeat Administration|Repeat administration of ascending doses of ASM-024
10034040|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo Repeat Administration|Repeat administration of ascending doses of placebo
10034041|NCT01793298|Experimental|Subjects with Asthma|Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion
10034042|NCT01793311|Sham Comparator|Group1: Decaffeinated coffee|contains 0.5-2 mg of caffeine
10034043|NCT01793311|Active Comparator|Group2: regular dose coffee|contains 91.8 mg of caffeine
10034044|NCT01793311|Active Comparator|Group3: high dose coffee|contains 144 mg of caffeine
10034045|NCT01793324||GER|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012
10034046|NCT01793324||UK|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012
10034047|NCT01793337|Other|Cold first|temperature is measured in cold (-20°C) environment first, and warm (23°C) environment afterwards
10034048|NCT01793337|Other|Warm first|temperature is measured in warm (23°C) environment first, and cold (-20°C) environment afterwards
10034049|NCT01793350|Active Comparator|BC-DN-01 topically applied cream, DPN|4g topically applied BC-DN-01 cream applied twice daily to each leg and foot, for 12 weeks
10034050|NCT01793350|Placebo Comparator|Placebo topically applied cream, DPN|4g topically applied cream applied twice daily to each leg and foot, for 12 weeks
10034051|NCT01793363|Experimental|tracheotomized patients|
10034052|NCT01793389|Active Comparator|Subepithelial connective tissue graft|Soft tissue harvested from palatum of the subjects.
10034053|NCT01793389|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
10034054|NCT01793402||Preterm infants born at or less than 32 weeks gestation|
10034055|NCT01793415|Active Comparator|IodoCarb (r)|3 g iodinated activated charcoal, IodoCarb(r), daily for 28 +-2 days.
10034056|NCT01793415|Placebo Comparator|Placebo|3 g of non-iodinated activated charcoal daily for 28+-2 days.
9480402|NCT03533777|Active Comparator|Antegrade Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in standard antegrade fashion (with the tip pointed towards the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
10034057|NCT01793428||Injured patient admitted in vital emergency unit|
10034058|NCT01793441|Placebo Comparator|Placebo|Participants will receive placebo matching to RG7314 in each stage (Stage I, II, III and IV) for 12 weeks.
10034059|NCT01793441|Experimental|RG7314|Participants will receive RG7314 orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
10034060|NCT01793454|Active Comparator|40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the surgery.
10034061|NCT01793454|Active Comparator|80% oxygen|Patients in this group will be ventilated with a fraction of inspired oxygen 80% during the surgery.
10037191|NCT01822808|Active Comparator|Hydralazine|24 week course of Hydralazine 25mg 3 times daily for 4 weeks, thereafter uptitrating to 50mg hydralazine 3 times daily up to week 24. Those assigned to the Hydralazine control arm will receive the same number of identical placebo tablets.
10034062|NCT01793480|Experimental|patient-controlled dose of methadone|The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
10034063|NCT01793480|Experimental|fixed-dose of methadone|The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
9473048|NCT03603795|Placebo Comparator|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1."
9473049|NCT03603782|Experimental|1|
9473050|NCT03603782|Experimental|2|
9473051|NCT03603782|Experimental|3|
9473052|NCT03603782|Experimental|4|
9473053|NCT03603769|Experimental|Group A: Food Supplement (Salmon Polar Lipids) Intervention|"Experimental: After fasting overnight, subjects will come to our metabolic unit where in a randomized and double blinded way they will be provided several versions of the food supplement either of stomach resistant (intestine release) or stomach non-resistant (stomach release) each containing either 0.25 (Low Dose) or 0.50 g (High Dose) of Salmon Polar Lipids (SPL)~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the SPL-food supplement intervention. Aggregation of platelets will be assessed in these samples as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
9473054|NCT03603769|Placebo Comparator|Group B: Consumption of Placebo Comparator|"Experimental: After fasting overnight subjects will come to the metabolic unit in UL at 08.00 am where in a randomized and double blinded way they will be provided a placebo capsule containing only glycerin.~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the placebo administration. Aggregation of their platelets will be assessed as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
9473055|NCT03603756|Experimental|Cohort 1|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.
9473056|NCT03603756|Experimental|Cohort 2|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.
9473057|NCT03603743|Experimental|high intensity interval training|high intensity interval training: two sets of 8-min intervals at 100% of peak power output (PPO). Each interval set was composed of repeated bouts of 30 s at 100% of PPO interspersed by 30 s of passive recovery in the seated position. Four minutes of passive recovery were allowed between the two sets.
9473058|NCT03603743|Active Comparator|moderate intensity and continuous exercise|moderate intensity and continuous exercise: 30 minutes at 60% of PPO.
9473059|NCT03603704|Experimental|LY3209590|"Insulin naïve participants with Type 2 Diabetes Mellitus received 5 mg and 10 mg LY3209590 administered subcutaneously (SC) in Cohort 1 and 2 respectively.~Participants with T2DM received 20 mg LY3209590 administered subcutaneously in Cohort 3."
10034064|NCT01793493|Experimental|Cognitive stimulation|
10034065|NCT01793493|Active Comparator|Sanitary education|
10034066|NCT01793506||PID|Any subject having testing done to evaluate the immune system is eligible for this study. This will include patients with known PIDs as well as patients evaluated for a suspected immunodeficiency.
10034067|NCT01793519|Active Comparator|Anti-tumor necrosis factor agent|Anti-TNF agent - etanercept, infliximab, adalimumab - administered parentally at standard dosage and frequencies
10034068|NCT01793519|Placebo Comparator|Placebo|Administered appropriately to active comparator
10034069|NCT01793545||Endometrial Cancer Cohort|Women with abnormal bleeding or other conditions associated with increased risk ofendometrial cancer.
10034070|NCT01793558|No Intervention|Control; passive insulation|The mothers will receive passive temperature insulation by a cotton blanket (standard procedure) after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the cotton blanket (also passive insulation without active warming) for 20 min after birth (bonding period).
10034071|NCT01793558|Experimental|Active Warming|The mothers will receive active warming by a forced-air warming blanket after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the warming blanket for 20 min after birth (bonding period).
10034072|NCT01793571|Experimental|TAP block|20 ml Levobupivacaine 0,5%
10034073|NCT01793571|Active Comparator|Local wound infiltration|20 ml levobupivacaine 0,5%
10034074|NCT01793584|Active Comparator|Laparoscopic hysterectomy|Total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy
10034075|NCT01793584|Active Comparator|Abdominal hysterectomy|Total Abdominal Hysterectomy
10034076|NCT01793597||clopidogrel|previous treatment with clopidogrel
10034077|NCT01793597||ticagrelor|previous treatment with ticagrelor
10034078|NCT01793636|Experimental|AZD2014|AZD2014- tablets, starting dose 50mg BD everyday, until disease progression or untolerable toxicity
10034079|NCT01793636|Active Comparator|Everolimus|Everolimus- tablets, starting dose 10mg OD everyday until disease progression or untolerable toxicity
10034080|NCT01793649|Experimental|Cross-Over Sequence 1|85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)
10034081|NCT01793649|Experimental|Cross-Over Sequence 2|2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)
10034082|NCT01793675||haploidentical transplant|transplant with haploidentical donor
9473060|NCT03603704|Active Comparator|Placebo|Participants from Cohort 1 and 2 received Placebo administered SC.
9473061|NCT03603691|Active Comparator|Modified Manual Muscle Test|The MMMT will be tested in a test-retest design
10034083|NCT01793727|Experimental|Glidescope intubation|Comparison of direct laryngoscopy and Glidescope videolaryngoscopy
10034084|NCT01793740|Experimental|Cogmed|These children are enrolled in the Cogmed intervention.
10034085|NCT01793740|No Intervention|Waitlist|These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
10034086|NCT01793753||Propofol|Chronically constipated children ages 2-6 years who will receive anesthesia for anorectal manometry including propofol per standard of care
9473062|NCT03603691|Active Comparator|Neurostatus BMRC|The Neurostatus BMRC measures Strength and will be used in a test-retest design
9473063|NCT03603691|Active Comparator|MicroFET2|The MicroFET2 is a hand held dynamometer to measure strength
9473064|NCT03603678|Experimental|Part A single dose BAY2253651|Single dose BAY2253651
9473065|NCT03603678|Placebo Comparator|Part A single dose Placebo|Single dose matching placebo
9473066|NCT03603678|Experimental|Part B multiple dose BAY2253651|Multiple dose BAY2253651 on 5 consecutive nights
10034087|NCT01793766|Experimental|Brain modulation|10 sessions of brain modulation with Eldith/Neuroconn transcranial Direct Current Stimulation device
10034088|NCT01793766|Placebo Comparator|Placebo (sham modulation)|10 placebo sessions where no brain modulation takes place
9473067|NCT03603665|Experimental|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
9473068|NCT03603665|Experimental|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
9473069|NCT03603665|Experimental|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
9473070|NCT03603626|Experimental|Preemptive pregabalin|
9473071|NCT03603626|Placebo Comparator|Placebo|
9473072|NCT03603613|Experimental|EPP: Entrepreneurship Programme|EPP: Entrepreneurship Programme: Youth randomized into the EPP-only arm will receive GIZ's employment programming within two weeks after the completion of the baseline assessments. The GIZ-supported EPP program includes six training modules. The modules include skills related to entrepreneurship, financial literacy, and skills building.
9473073|NCT03603613|Experimental|EPP+YRI|EPP+YRI: Youth randomized into the EPP+YRI arm will begin the Entrepreneurship programme within two weeks of baseline assessments. The entrepreneurship modules will occur for 15 days for 5 hours each day, 5 days per week. Immediately following the EPP, youth will begin receiving the YRI. The YRI curriculum (12 modules), will be delivered twice weekly over the course of 6 weeks. Each session lasts approximately 90-minutes, with additional time taken as needed. These sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention quantitative assessment.
9473074|NCT03603613|No Intervention|Control|Control: Youth randomized into the control arm will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline and post-intervention). Due to access to funding and feasibility, youth in the control arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. The list of youth from the control group will be provided to GIZ so they can participate in the future phases. Youth will also be compensated for their participation in our quantitative assessments.
9473075|NCT03603587|Experimental|Patients who will benefit from the removal of a scalp tumour|"Patients who will benefit from the removal of a scalp tumour in the alopecic zone will be recruited in the dermatology department of the St-Etienne University Hospital.~They will have biopsy, blood sample, examination of the scalp, questionnaire on sun exposure, Norwood scale, scinexa score, questionnaire of clinicals signs and questionnaire of the history of the hair loss."
9473076|NCT03603574|Experimental|EWA through the needle|EWA through the needle group, 5 mL of normal saline are injected through the epidural needle after the occurrence of LOR. The needle is subsequently connected to the pressure transducer (leveled with the heart) via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
10034089|NCT01793779|Placebo Comparator|Control|Placebo supplement given prior to exercise and two times per day following exercise
10034090|NCT01793779|Experimental|cold water immersion|Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
10034091|NCT01793779|Experimental|HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
10034092|NCT01793779|Experimental|cold water immersion group + HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
10034093|NCT01793818|Placebo Comparator|Group 1 Phase I/II|Three injections with no active principle
10034094|NCT01793818|Active Comparator|Group 2 Phase I/II|Three injections of Tat Oyi vaccine containing 11 µg of active principle
10034095|NCT01793818|Active Comparator|Group 3 Phase I/II|Three injections Tat Oyi vaccine containing 33 µg of active principle
10034096|NCT01793818|Active Comparator|Group 4 Phase I/II|Three injections Tat Oyi vaccine containing 99 µg of active principle
10034097|NCT01793831|Experimental|Fecal microbiota transplantation|Standard fecal microbiota transplantation, once.
10034098|NCT01793844||A (R-CHOP21)|"CHOP combined with Rituximab regimen（R-CHOP21）~Treatment Arm A(R-CHOP21): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P) 60mg/m2 orally on days 2 to 6. The therapy was repeated every 21 days for a total of 6 cycles."
10037192|NCT01822808|Active Comparator|Isosorbide dinitrate|24 week course of Isosorbide dinitrate 10mg 3 times daily for 4 weeks, thereafter uptitrating to 20mg isosorbide dinitrate 3 times daily up to week 24. Those assigned to the Isosorbide dinitrate control arm will receive the same number of identical placebo tablets.
10034099|NCT01793844||B (CHOP14)|Biweekly CHOP regimen （CHOP14） Treatment Arm B (CHOP14): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50mg/m2 for injection on day1; and Vincristine(O), 1.4 mg/m2 for injection on day1, prednisone(P) 60mg/m2 orally on days 1 to 5. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 6 for a total use of 6-8 days.
10034100|NCT01793844||C （R-CHOP14)|Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
10034101|NCT01793857||Study Group|Approximately 1300 primary caregivers of at least one child aged 6 months to less than 30 months who were interviewed during a clinic visit in Panama.
10034102|NCT01793870|Experimental|Treatment A (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 milligram [mg]) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
9473077|NCT03603574|Experimental|EWA through the catheter|EWA through the catheter group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
9473078|NCT03603561|Active Comparator|Active cTBS|
9473079|NCT03603561|Sham Comparator|Sham cTBS|
9473080|NCT03603548|Active Comparator|Advagraf|
9473081|NCT03603548|Experimental|Envarsus|
9473082|NCT03603522|Experimental|BioGaia-DSM17938 then Placebo Comparator|28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.
9473083|NCT03603522|Placebo Comparator|Placebo Comparator then BioGaia DSM17938|28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.
9473084|NCT03603496|Experimental|Personalized Tobacco Care Management|PTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call +/- text messaging +/- email. At each contact the patient is offered a return call from the hospital-based tobacco coach forcounseling, medication advice, and coordination of care with the patient's outpatient health care team.
9473085|NCT03603496|Active Comparator|eReferral to State Tobacco Quitline|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the quitline will be included in the patient's medical chart.
9473086|NCT03603483|Active Comparator|Patients with sever aortic stenosis 1|Procedure: the patients will undergo aortic valve replacement with aortic root enlargement.
9473087|NCT03603483|Active Comparator|Patients with sever aortic stenosis 2|Procedure: the patients will undergo conventional aortic valve replacement
9473088|NCT03603470|Other|Patients with previous prothesis instability|
9473089|NCT03603470|Other|Patients without prothesis instability|
9473090|NCT03603444||First study group: patients with PHPT|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
9473091|NCT03603444||Second study group: patients with HypoP|"Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
9473092|NCT03603444||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
9473093|NCT03603431|Experimental|Single Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
9473094|NCT03603431|Placebo Comparator|Single Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
10034103|NCT01793870|Experimental|Treatment B (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
10037193|NCT01822847||catheterization|patients undergoing elective heart catheterization
10034104|NCT01793870|Experimental|Treatment C (33.75 mg total maximum dose)|Single oral dose of carvedilol (31.25 mg) as a 1 x 25 mg immediate release tablet, a 1 x 6.25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
10034105|NCT01793870|Experimental|Treatment D (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg x immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fed conditions.
10034106|NCT01793896|Sham Comparator|control period|control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
9473095|NCT03603431|Experimental|Multiple Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
9473096|NCT03603431|Placebo Comparator|Multiple Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
9473097|NCT03603418|Experimental|Group D (Study group-Dexamethasone group)|Forty patients undergoing induction of labor will receive 8 mg (2ml) of the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product from Epico-Egypt, and labor induction will be performed according to the American College of Obstetricians and Gynecologists protocol, i.e, starting by 25 mcg of PGE1 vaginally, in the form of Vagiprost, every 3-6 hours according to patient response, Dexamethasone will be given one hour before the first dose of Vagiprost, when bishop score reaches 6 to 8, oxytocin will be added by 5 drops/minute of 500 cc saline + 5 units of oxytocin with the dose increasing by 5-10 drops / minute every 30 minute till optimal contractions are reached which are three uterine contractions in 10 minutes and each lasting for 40-50 seconds
9473098|NCT03603418|Placebo Comparator|Group C (Control group)|Forty patients undergoing induction of labor will receive 2ml of distilled water intramuscular one hour before the initiation of labor induction, and labor induction will be performed by the same protocol as above.
9473099|NCT03603405|Experimental|Experimental: ADV/HSV-tk (gene therapy)|"Experimental: ADV/HSV-tk (gene therapy)~The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 30 sessions (over 6 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent with the radiotherapy dependent on patient status based on best clinical judgment following the Stupp protocol.~Patient can receive second treatment of HSV-tk after 6 months."
9473100|NCT03603392|Experimental|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
9473101|NCT03603379|Experimental|C225-ILs-dox i.v.|C225-ILs-dox administered intravenously
9473102|NCT03603366||Primary prevention|"Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD~Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD"
9473103|NCT03603366||Secondary prevention|"Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin for secondary prevention of CVD~Patients eligible for and not using low-dose aspirin for secondary prevention of CVD"
9473104|NCT03603366||Physicians|Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.
9473105|NCT03603327|Other|Treatment|All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
9473106|NCT03603262|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
9473107|NCT03603249|Experimental|Clopidogrel and Trimetazidine Arm|Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.
9473108|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
9473109|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
9473110|NCT03603210||Patients treated with DCB angioplasty|"Patient cohort is comprised of all patients who received drug coated balloon angioplasty at NNUH during the above period. Within this cohort there will be two main groups which are drug coated balloon (DCB) angioplasty for de novo coronary artery disease (CAD) and DCB angioplasty for ISR/ST. Graft cases will be reported as a small third group.~Outcomes will also be reported for three sub groups of de novo disease group, namely, dcb-only angioplasty for de novo disease, dcb-only angioplasty as primary percutaneous coronary intervention (PPCI) and dcb-only angioplasty group using a DCB with a diameter of 3mm or more in de novo disease."
9473111|NCT03603197|Experimental|BP-C1|Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
10034107|NCT01793896|Experimental|Diet group|Mediterranean diet prescription during 3 months
10034108|NCT01793896|Experimental|Exercise group|Subjects will be trained 3 times a week during 3 months
10034109|NCT01793896|Experimental|Diet + Exercise|Both a dietary prescription plus exercise training during 3 months
10034110|NCT01793922|Active Comparator|PD|pneumodilation
10034111|NCT01793922|Active Comparator|POEM|peroral endoscopic myotomy
10034112|NCT01793948|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
10034113|NCT01793948|Placebo Comparator|Arm II (placebo)|Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
10034114|NCT01793961|Other|"Cannabis Arm"|patient addicted to cannabis
10034115|NCT01793961|Other|"Tobacco Arm"|patient addicted to tobacco
10034116|NCT01793961|Other|"Healthy volunteers"|no smokers
10034117|NCT01793974||Latent Autoimmune Diabetes in Adult|Individuals who meet criteria for Latent Autoimmune Diabetes in Adult
10034118|NCT01793974||Without Latent Autoimmune Diabetes in Adult|Individuals who do not meet criteria for Latent Autoimmune Diabetes in Adult
9473112|NCT03603197|Placebo Comparator|Placebo|Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
9473113|NCT03603171||DM2 group|Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.
9473114|NCT03603171||Healthy controls group|A group of gender and age-matched healthy controls.
10034119|NCT01793987|No Intervention|control: shaver|
10034120|NCT01793987|Experimental|Coblation polypectomy|
9473115|NCT03603145|Experimental|Immediate insertion|Randomized to insertion within 48 hours of medical abortion
9473116|NCT03603145|No Intervention|Standard Insertion|Insertion at 2-4 weeks post medical abortion
9473117|NCT03603132|Active Comparator|Hetrombopag Olamine A|health subjects received 7.5 mg Hetrombopag Olamine while fasting.
9473118|NCT03603132|Active Comparator|Hetrombopag Olamine B|health subjects received a high-fat meal one hour after taking7.5 mg Hetrombopag Olamine
9473119|NCT03603132|Active Comparator|Hetrombopag Olamine C|health subjects received a high-fat meal two hours after taking7.5 mg Hetrombopag Olamine
9473120|NCT03603119|Active Comparator|Group A|Dexamethasone-ondansetron
9473121|NCT03603119|Experimental|Group B|Midazolam
9473122|NCT03603080|Experimental|Medication arm|
9473123|NCT03603080|No Intervention|No medication arm|
9473124|NCT03603067||monophthalmic group|The BCVA of the worse eye is less than 0.05 or CFOV is less than 5°. The better eye need to receive ocular surgery.
9473125|NCT03603067||Normal group|The BCVA of the worse eye is more than 0.3 and CFOV is more than 10°. One of two eyes need to receive ocular surgery.
9473126|NCT03603054|Active Comparator|Active neck mobilization|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
9473127|NCT03603054|Experimental|Active Mobilization of the Sciatic nerve|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
9473128|NCT03603041|No Intervention|Control|These participants will maintain their daily food and exercise routine and will receive no intervention.
9473129|NCT03603041|Experimental|Whey Protein Supplementation|Participants will receive protein supplementation daily for 16 weeks.
9473130|NCT03603041|Experimental|Omega-3 Fatty Acids (O3FA)|Participants will receive O3FA supplementation daily for 16 weeks.
9473131|NCT03603041|Experimental|Whey Protein and O3FA|Participants will receive protein and O3FA supplementation daily for 16 weeks.
10034121|NCT01794013|Active Comparator|Parent trianing|The parent training group will learn about DIR/ Floortime™ model approach through one on one coaching for 1 hour at the beginning of the study, the end of 1st and 3th month and through 2 hours DVD lecture and a pocket book.
10034122|NCT01794013|Active Comparator|Routine care|The children in the control group will continue their standard routine care.
10034123|NCT01794026|Experimental|diffusion MRI|histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
9473132|NCT03603041|Placebo Comparator|Whey Protein and Placebo Fat Source|Participants will receive protein and placebo fat source supplementation daily for 16 weeks.
9473133|NCT03603015|Other|Pilot group: urodynamics and cuff test|Single-arm study with all participants undergoing cystometrogram, then cystometrogram with simultaneous penile cuff test, then penile cuff test alone
9473134|NCT03602976|No Intervention|Observation|
9473135|NCT03602976|Experimental|UDCA at Month 6|
9473136|NCT03602963||Dexcom G5 mobile CGM system|Children (6 to 18 years) with type 1 diabetes mellitus treated with insulin injections and wearing a FreeStyle Libre Flash glucose sensor that will switch to the Dexcom G5 mobile glucose monitoring system.
9473137|NCT03602950|No Intervention|Control group|50 diabetic ladies at full term will undergo elective CS and will receive the usual surgical care routinely done at our hospital
9473138|NCT03602950|Active Comparator|study group|50 diabetic ladies will undergo elective CS at full term and autologous PRP will be injected subcutaneously before skin closure.
9473139|NCT03602937|Experimental|Renastep|All participants to incorporate Renastep into their usual dietary regime.
9473140|NCT03602911|Other|Proof of Concept|The isotope 68Ga, available as NETSPOT and 18F-FDG-PET/CT per established protocol will both be administered
9473141|NCT03602898|Experimental|Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
9473142|NCT03602898|Experimental|Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
10034124|NCT01794052|Experimental|DSS enabled health care delivery model|Evidence based, DSS enabled, health care delivery model
10034125|NCT01794065||Cypher|100 patients who have received a Cypher stent during their coronary intervention
10034126|NCT01794065||Taxus Express|100 patients who have received a Taxus Express stent during their coronary intervention
10034127|NCT01794065||Endeavor|100 patients who have received an Endeavor stent during their coronary intervention
10034128|NCT01794065||Promus/Xience V|100 patients who have received a Promus/Xience V stent during their coronary intervention
9473143|NCT03602898|Experimental|Arm 3 (tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
9473144|NCT03602872|Experimental|Group 1|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
9473145|NCT03602872|Experimental|Group 2|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
9473146|NCT03602872|Experimental|Group 3|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
9473147|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
9473148|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
9473149|NCT03602807|Experimental|Active treatment|
9473150|NCT03602794|Active Comparator|PECs Block|"Total local anaesthetic dose: 30ml ropivacaine 0.5%~•Pecs block will be performed by anaesthetist using ultrasound guidance in plane approach: 10ml ropivacaine 0.5% will be delivered at the plane between pectoralis major and pectoralis minor, another 20ml ropivacaine 0.5% will be delivered in the plane between the pectoralis minor and serratus anterior muscles at the level of the third and fourth ribs"
9473151|NCT03602794|Placebo Comparator|Local Infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
9473152|NCT03602781|Placebo Comparator|Cohort 1: Placebo 99.999% Nitrogen|"Randomized Withdrawal Treatment Period Week 1-8:~Placebo at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
9473153|NCT03602781|Active Comparator|Cohort 2: iNO 75 mcg/kg IBW/hr|"Randomized Withdrawal Treatment Period Week 1-8:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
9473154|NCT03602768|Experimental|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
9473155|NCT03602768|Experimental|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
9473156|NCT03602768|Placebo Comparator|Cambridge Brain Sciences Training|This is a commercial and research brain training platform, composed of 7 games that are online adaptations of the standard measures of cognition including working memory and spacial planning.
10034129|NCT01794065||Promus Element|100 patients who have received a Taxus Element stent during their coronary intervention
10034130|NCT01794078|Placebo Comparator|Control|Oral placebo, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
10034131|NCT01794078|Experimental|Aminophylline 400 mg|Oral aminophylline 400 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
10034132|NCT01794078|Experimental|ambrisentan 5 mg|Oral ambrisentan 5 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
9473157|NCT03602768|No Intervention|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
9473158|NCT03602755||Patients with newly diagnosed transplant-ineligible MM|Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.
9473159|NCT03602742|Other|24-hour Holter and 14-day EZYPRO®|This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.
9473160|NCT03602729|No Intervention|Group 1|No study related education given
9473161|NCT03602729|Experimental|Group 2|Written BF education
9473162|NCT03602729|Experimental|Group 3|Verbal BF education
10034133|NCT01794078|Experimental|Combined aminophylline 400 mg and ambrisentan 5 mg|Oral combined aminophylline 400 mg and ambrisentan 5 mg, administered as single doses during simulated altitude episodes Cycle 1 and Cycle 2
10034134|NCT01794091|Experimental|Eplerenone|In a subgroup of 50 patients, 25 will be randomized to eplerenone to assess effects on fibrotic index pre- and post-6 months of therapy.
9473163|NCT03602729|Experimental|Group 4|Video BF education
9473164|NCT03602716|Experimental|HD-tDCS group|This HD-tDCS group will be stimulated by active HD-tDCS.
9473165|NCT03602716|Sham Comparator|Sham HD-tDCS group|This sham HD-tDCS group will have a sham stimulation with HD-tDCS.
9473166|NCT03602703||chronic HCV|chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
10034135|NCT01794091|Placebo Comparator|Sugar pill|
10034136|NCT01794104|Experimental|1|Open-label Phase I trial evaluating weekly administration of LMP400, on days 1, 8, and 15, in 28-day cycles.
10037194|NCT01822860|Placebo Comparator|Placebo|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
9473167|NCT03602703||Liver cirrhosis without HCC|Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
9473168|NCT03602703||Liver cirrhosis with HCC|Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
9473169|NCT03602703||Control group|Healthy subjects
9473170|NCT03602690|Experimental|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
9473171|NCT03602664||Thoracic surgery|Patients undergoing thoracic surgery
9473172|NCT03602651||MAGZEN®|All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)
9480403|NCT03533777|Experimental|Retrograde Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in a retrograde fashion (with the tip pointed away from the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
9480404|NCT03533751|Placebo Comparator|Placebo|Placebo
9480405|NCT03533751|Experimental|Group 1|etokimab (ANB020)
9480406|NCT03533751|Experimental|Group 2|etokimab (ANB020)
9480407|NCT03533751|Experimental|Group 3|etokimab (ANB020)
9480408|NCT03533751|Experimental|Group 4|etokimab (ANB020)
9480409|NCT03533738|Experimental|Food selection 1|To consume vegetables followed by meat & rice together
9480410|NCT03533738|Experimental|Food selection 2|To consume meat followed by vegetables & rice together
9480411|NCT03533738|Experimental|Food selection 3|To consume as follows: vegetables, meat, rice
9480412|NCT03533738|Experimental|Food selection 4|To consume vegetables followed by meat and rice together
9480413|NCT03533738|Experimental|Food selection 5|To consume rice followed by vegetables & meat together
9480414|NCT03533725|Experimental|Intervention group|Breastfeeding counseling and education services using mHealth tools
9480415|NCT03533725|No Intervention|Comparative control group|No intervention, only standard of care
9480416|NCT03533699|Active Comparator|Propranolol|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
9480417|NCT03533699|Placebo Comparator|placebo|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
9480418|NCT03533686|Experimental|Single-Sided Deafness Adult (Aim1) Group|Adult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
9480419|NCT03533686|Experimental|Conductive Hearing Loss Adult (Aim 2) Group|Adult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
9480420|NCT03533686|Experimental|Adhear followed by BAHA (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
9480421|NCT03533686|Experimental|BAHA followed by Adhear (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
9480422|NCT03533686|Experimental|Pediatric Unilateral Conductive Hearing Loss (Aim 3a) Group|Pediatric participants (aged 2-17 years) with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
9480423|NCT03533686|Experimental|Pediatric Bilateral Conductive Hearing Loss (Aim 3b) Group|Pediatric participants (aged 2-17 years) with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
9480424|NCT03533673|Experimental|Cohort 1|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 1)
9480425|NCT03533673|Experimental|Cohort 2|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 2)
9480426|NCT03533673|Experimental|Cohort 3|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 3)
9480427|NCT03533647||entire cohort (observational)|none (observational study)
9480428|NCT03533634|Experimental|superior group|this group with midshaft clavicle fracture were treated with superior reconstruction plate
9480429|NCT03533634|Experimental|anteroinferior group|this group with midshaft clavicle fracture were treated with anteroinferior reconstruction plate
9480430|NCT03533621|Experimental|Probiotic|1 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
9480431|NCT03533621|Placebo Comparator|Placebo|1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
9480432|NCT03533595|No Intervention|Standard Suture|Standard suture for thoracolumbar fusion will be used per standard of care.
9480433|NCT03533595|Active Comparator|Stratafix Barbed Suture|Stratafix Barbed Suture for thoracolumbar fusion will be used.
10034137|NCT01794156|Active Comparator|Cognitive behavior therapy|"The cognitive-behavioral model is presented and individualized.~Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs~Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.~Combined phase: continues ERP while making explicit links to the cognitive targets.~Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues."
10034138|NCT01794156|Active Comparator|Mindfulness-based stress reduction (MBSR)|The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience.
9473173|NCT03602638|Experimental|Sitagliptin|
9473174|NCT03602638|Active Comparator|CONTROL|Acarbose
9473175|NCT03602625||Preterm group|All the live-born infants with gestational age less than 37weeks and more than 20weeks born in the cooperative hospital every day or every two or three days.
9473176|NCT03602625||Term group|The one next-live-born infants with gestational age at 37weeks or more than 37weeks.
9473177|NCT03602586|Experimental|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9473178|NCT03602573||pre-menopause|
9473179|NCT03602573||post-menopause|
9473180|NCT03602560|Experimental|Seladelpar 5-10 mg|
9473181|NCT03602560|Experimental|Seladelpar 10 mg|
9473182|NCT03602560|Placebo Comparator|Placebo|
9473183|NCT03602547|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
9473184|NCT03602534||cases with variable acne severity scores|"group will include 50 females~Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)~Assessment of body mass index (BMI)~blood serum samples will be collected from all patients to do thyroid function test"
9473185|NCT03602534||healthy controls|"group will include 29 females~Assessment of body mass index (BMI)~blood serum samples will be collected from all healthy controls to do thyroid function test"
10037195|NCT01822860|Experimental|Chlorthalidone 12.5 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
9473186|NCT03602508||mirabegron|Patients on mirabegron as prescribed by a physician in routine clinical practice.
9473187|NCT03602508||antimuscarinics|Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.
9473188|NCT03602469|Experimental|Bupivacaine|Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia
9473189|NCT03602469|Active Comparator|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia
9473190|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
9473191|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
9480434|NCT03533569||Osteoarthritis|Participants with an established diagnosis of knee osteoarthritis
9473192|NCT03602443|Experimental|Experimental|This group will receive the LSVT(R)BIG Intervention first (4 weeks) and then cross over to the Waitlist Control (no intervention for 4 weeks).
9473193|NCT03602443|Other|Waitlist Control|This group will receive the Waitlist Control (4 weeks) and then cross over to receive the LSVT(R)BIG Intervention (4 weeks).
9473194|NCT03602430|Experimental|Drug Group|twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period
9473195|NCT03602430|Placebo Comparator|Placebo Group|twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.
9473196|NCT03602417|Experimental|Flare type stent|Flare type stent (Taewoong medical) has a wide diameter at proximal end to prevent stent migration.
10034139|NCT01794156|Experimental|Inference-based therapy|"The inference-based therapy will be delivered in 10-step~The client will:~learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt~learn why this doubt is 100% irrelevant here and now~learn the inferential confusion process~have to recognize that the doubt originates from him/her~have to identify/describe the narrative leading him/her to the doubt~have to identify the cross-over point when he/she leaves reality~learn to be aware of the reasoning devices~learn how personal themes dictate the idiosyncratic nature of the person's obsession~explore and reinforced an alternative self-view~be trained to use properly his/her senses in the face of obsessional triggers situations"
10034140|NCT01794169|Experimental|Azacitidine|Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
10034141|NCT01794169|Active Comparator|DA|"Two courses of DA in accordance with the Swedish National treatment program (reduced doses):~In case one induction course was given:~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~In case two induction courses were given:~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5."
9473197|NCT03602417|Active Comparator|Conventional D-type stent|Conventional D-type (Taewoong medical) stent has a same diameter at both ends.
9473198|NCT03602404||St. Petersburg: School aged children|Generally healthy 9 to 12 years old children
10034142|NCT01794182|Placebo Comparator|Matching Placebo|Participants received a bolus dose of matching placebo over 2 minutes, followed by a continuous matching placebo infusion for 72 hours.
9473199|NCT03602404||St. Petersburg: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
9473200|NCT03602404||Marrakesh: School aged children|Generally healthy 9 to 12 years old children
9473201|NCT03602404||Marrakesh: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
9473202|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
9473203|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
9473204|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
9473205|NCT03602365|Experimental|OXYGEN CONSUMPTION SINGLE ARM|Single arm Study Volunteer will h lie in supine posture for 20 min and oxygen consumption(VO2) will be measured in duplicate. Gentle Jogger (GJ) will be started in supine posture for 20 min and VO2 measured again in duplicate. The subject will be asked to sit in a chair for 20 min and VO2 will be measured in duplicate. Gentle Jogger (GJ) will be started in seated posture for 20 min and VO2 measured again in duplicate.
9473206|NCT03602326|Experimental|Neurodevelopmental Therapy-Bobath group|Bobath Approach Principles and exercises will be performed 5 days a week with physical therapists and everyday with caregivers. Physiotherapy will be initiated as early as possible according to the principles of the method by experienced NDT-B therapists. Exercises will be implemented according to the patients' status and will be used to maintain and improve muscle strength and endurance. Both the unaffected and affected side will be included in rehabilitation. The exercises given are designed to be simple, understandable, task-oriented and repetitive, in accordance with the Bobath approach and the functional state of the patient at that time. In order to prevent motor amnesia and neglect of the affected side, correct positioning and sensory input will be provided since the first session.
9473207|NCT03602326|Active Comparator|Standart Rehabilitation Group (SR group)|Patients will be included in standard rehabilitation sessions, 5 days per week. The rehabilitation sessions will be performed by standard clinical physiotherapists according to the hospital routine. The rehabilitation program will consist of in-bed joint range of motion exercises and bedside mobilization applications. The patients will be included in the rehabilitation program as early as possible and the program will continue until the patients are discharged
9473208|NCT03602313|Active Comparator|Traditional Gait Training|The Traditional Gait Training group will receive gait training as presently performed without additional modalities.
9473209|NCT03602313|Experimental|Body Weight Support Training|The Body Weight Support group will received body weight support gait training in lieu of traditional gait training.
9473210|NCT03602300|Active Comparator|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
9473211|NCT03602300|Experimental|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
9473212|NCT03602287|Active Comparator|2% lignocaine|In the Lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril, which would act as a control.
10034143|NCT01794182|Experimental|Glyburide for Injection|Participants received a 0.13 mg bolus dose of glyburide over 2 minutes, followed by a 0.16 mg/hr continuous infusion for 6 hours and than a 0.11 mg/hr for 66 hours for a total dosing period of 72 hours.
9473213|NCT03602287|Placebo Comparator|Normal saline|In the Normal saline group, 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril.
9473214|NCT03602274||orthopedic and visceral surgery patients|patient having been subjected to an intervention from the orthopedic or visceral surgery department being prescribed 4 g paracetamol / day
9473215|NCT03602274||Overdosed patients|Patent admitted to hospital with paracetamol overdoses
9473216|NCT03602261|Active Comparator|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
9473217|NCT03602261|Active Comparator|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
9473218|NCT03602261|Active Comparator|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
9473219|NCT03602261|Placebo Comparator|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
9473220|NCT03602248|Experimental|Speed endurance training protocol A|"Performance of two different speed endurance training protocols:~Speed endurance training protocol A will consist of 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)."
9473221|NCT03602248|Experimental|Speed endurance training protocol B|Speed endurance training protocol B will consist of 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
9473222|NCT03602248|No Intervention|Control condition|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
9473223|NCT03602222|Active Comparator|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
9473224|NCT03602222|Experimental|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
9473225|NCT03602209|Experimental|4 weeks of treatment|
9473226|NCT03602209|Active Comparator|6 weeks of treatment|
9473227|NCT03602196|Experimental|pregnant women|"pregnant women with one visit per trimester of pregnancy (14-18 weeks, 24-28 weeks and 34-38 weeks)~For the ancillary study: non-pregnant nulliparous women"
9473228|NCT03602183|Experimental|Normal airway scenario|intubation in normal airway scenario
9473229|NCT03602183|Experimental|Tongue edema scenario|intubation in the tongue edema scenario. Tongue edema was obtain using simulator indicators
9473230|NCT03602183|Experimental|Spinal immobilization with normal airway scenario|intubation in spinal immobilization with normal airway scenario
9473231|NCT03602183|Experimental|Spinal immobilization with tongue edema scenario|endotracheal intubation with immobilized cervical spine and tongue edema scenario
9473232|NCT03602170|Experimental|High-Intensity Interval Training|8 weeks of high-intensity interval training. Three sessions per week will be performed (24 total sessions).
9473233|NCT03602170|Active Comparator|Moderate-Intensity Continuous Training|8 weeks of moderate-intensity continuous training. Three sessions per week will be performed (24 total sessions).
9473234|NCT03602144|Active Comparator|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
9473235|NCT03602144|Experimental|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
9473236|NCT03602131|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
9473237|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 20 mg|Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
9473238|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 40 mg|Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes. ministered intravenously over the course of 30 minutes.
9473239|NCT03602105|Active Comparator|Intervention group|Exercise interventions for 6-12 weeks. Adherence is monitored with day journals
9473240|NCT03602105|No Intervention|Control group|Care as usual
9473241|NCT03602040|Experimental|PISICC group|Psychoeducational intervention
9473242|NCT03602027|Experimental|Anlotinib Plus Gefitinib|"This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day and Gefitinib. middle-dose groups: Anlotinib 10mg per day and Gefitinib. high-dose groups: Anlotinib 12mg per day and Gefitinib.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any dose group, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any dose group, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
9473243|NCT03602014|Experimental|Study 1: Dose Optimization of Northera|Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
10034144|NCT01794195|Experimental|apathetic patients with Parkinson's disease|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
10034145|NCT01794195|Experimental|non apathetic paired patients|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
10034146|NCT01794195|Experimental|healthy paired control|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
10034147|NCT01794208|Experimental|treatment 1|Follitropin Epsilon 52.5 IU quaque die (QD) s.c.
10034148|NCT01794208|Experimental|treatment 2|Follitropin Epsilon 75 IU QD s.c.
9473244|NCT03602014|Placebo Comparator|Study 2: Blinded Placebo & Northera|Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
10034149|NCT01794208|Experimental|treatment 3|Follitropin Epsilon 112.5 IU QD s.c.
10034150|NCT01794208|Experimental|treatment 4|Follitropin Epsilon 150 IU QD s.c.
10034151|NCT01794208|Experimental|treatment 5|Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.
9473245|NCT03602001|Experimental|attentive eating smartphone app group|Participant's received the intervention 'Attentive eating smartphone application'. This is a smartphone application that encourages a more attentive eating style. Participants also received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
9473246|NCT03602001|Active Comparator|control group|Participants received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
9473247|NCT03601988|Active Comparator|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
9473248|NCT03601988|Experimental|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
9473249|NCT03601975|Experimental|anlotinib plus Gemcitabine/Cisplatin|patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
9473250|NCT03601975|Placebo Comparator|placebo plus Gemcitabine/Cisplatin|patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
9473251|NCT03601962|Experimental|Aqualief® tablets|oral mucoadesive tablets
9473252|NCT03601962|Placebo Comparator|Placebo tablets|oral mucoadesive tablets
9473253|NCT03601936|Other|Infants less than 6 months of age|The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.
9473254|NCT03601910|Experimental|A group|"Period 1: D308 10mg Tab. 1T~Period 2: CKD-380 10mg Tab. 1T"
9473255|NCT03601910|Experimental|B group|"Period 1: CKD-380 10mg Tab. 1T~Period 2: D308 10mg Tab. 1T"
9473256|NCT03601897|Experimental|Part 1 - Completed|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.
9473257|NCT03601897|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with paclitaxel~Triple-negative and Stage IV inflammatory breast cancer~Ovarian cancer~Endometrial cancer~Gynecological Carcinosarcoma"
9473258|NCT03601884|Experimental|OHP and Treatment as usual (TAU)|"Optimal Health Program (OHP) A self-management program that promotes patients to be actively involved in their own healthcare and overall well-being through enhancing self-efficacy.~Treatment is delivered by a trained facilitator in OHP. The OHP is delivered in groups of 8 to 10 participants It consists of 5 weekly, 1.5 hour sessions and an additional booster session post-program at 3 months a The group facilitator will contact the participants by phone at 8 weeks and 16 weeks.~Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
9473259|NCT03601884|Other|TAU Alone|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
9473260|NCT03601871|Active Comparator|Control group|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
9473261|NCT03601871|Experimental|Thalidomide group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
10034152|NCT01794208|Active Comparator|treatment 6|Follitropin alfa 150 IU QD s.c.
10034153|NCT01794221|Active Comparator|Stitches only|Stitches only closing circumcision wound
10034154|NCT01794221|Experimental|Stitches and skin adhesive|application of 2-octyl cyanoacrylate skin adhesive.
10034155|NCT01794234||Cohort|
10034156|NCT01794247|Experimental|Intrathecal magnesium|Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
10034157|NCT01794247|Active Comparator|Intrathecal fentanyl|Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant
10034158|NCT01794260|Placebo Comparator|Placebo cream|Placebo cream
10034159|NCT01794260|Experimental|Plai cream|Cream from Zingiber cassumunar Roxb. extract
9473262|NCT03601845|Other|MRE-IA (no stimuli)|Additional sequencing only
9473263|NCT03601845|Active Comparator|MRE-IA with stimuli|Visual stimulation while using additional sequencing
9473264|NCT03601832|Experimental|4-D navigated stereotactic radiosurgical ablation|The patients enroled to this arm of the study will undergo 4-D navigated stereotactic radiosurgical ablation.
9473265|NCT03601819|Experimental|Pacritinib|200 mg twice daily (with possible dose reduction to 100 mg twice daily)
9473266|NCT03601806|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9473267|NCT03601793|Experimental|Internet intervention with assistance|This arm is given access to the internet intervention Alcohol Help Center with email assistance from a health educator during the first two weeks after randomization.
9473268|NCT03601793|Active Comparator|Internet intervention without assistance|This arm is given access to the internet intervention Alcohol Help Center without any assistance from a health educator.
9473269|NCT03601780|Active Comparator|Local wound infiltration|local wound infiltration plus usual care
9473270|NCT03601780|Placebo Comparator|Control|usual care only
9473271|NCT03601754|Experimental|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
9473272|NCT03601741|Active Comparator|Antimicrobial Stethoscope Diaphragm Covers|
9473273|NCT03601741|Active Comparator|Uncovered Stethoscopes|
9473274|NCT03601676|Active Comparator|Intervention|
9473275|NCT03601676|No Intervention|Control|
9473276|NCT03601663|Experimental|Group 1|Participants in the main experimental group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, a wearable activity tracker to support self-monitoring, and autonomy-support delivered through weekly emails to help enhance motivation for physical activity.
9473277|NCT03601663|Active Comparator|Group 2|Participants in this comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, and a wearable activity tracker to support self-monitoring. They will not receive any specific support to enhance motivation for physical activity.
9473278|NCT03601663|Active Comparator|Group 3|Participants in this information-only comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity.
9473279|NCT03601650|Experimental|Mindful eating|Participants will be encouraged to focus on the sensory properties of their food every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to focus on the sensory properties of their food every time they eat.
9473280|NCT03601650|Active Comparator|Eating without distractions|Participants will be encouraged to eat their food without distractions every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to eat their food without distractions every time they eat.
9473281|NCT03601650|No Intervention|No strategy control|Participants will simply complete the measures
9473282|NCT03601624|Experimental|Experimental|"Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
10034160|NCT01794273|Experimental|ephedrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
10034161|NCT01794273|Experimental|phenylephrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
10034162|NCT01794286|Active Comparator|Control Group|Trigger alerts only
10034163|NCT01794286|Experimental|Intervention Group|Trigger alerts + provider bulletins
9473283|NCT03601611|Experimental|Experimental|Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).
9473284|NCT03601598|Experimental|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
9473285|NCT03601585|Experimental|Rolly Brush|Chew for 1 minute
9473286|NCT03601585|Experimental|Chewing gum|Chew for 1 minute
9473287|NCT03601585|Experimental|Apple|Chew for 1 minute
9473288|NCT03601585|Active Comparator|Brush|brush for 1 minute
9473289|NCT03601559|Active Comparator|Lactobacillus paracasei Lpc-37|Probiotic
9473290|NCT03601559|Placebo Comparator|Placebo|Inert placebo
9473291|NCT03601546||Patients with HCV infection|
9473292|NCT03601533|Other|Phenol|Patients will undergo neurolysis of genicular nerves with 1,5 mL of 7% phenol in each of the genicular nerves (superior, medial and lateral).
10034164|NCT01794325|Active Comparator|Trans-radial access|Coronary angiography performed through trans-radial access
10034165|NCT01794325|Active Comparator|Trans-femoral access|Coronary angiography performed through trans-femoral access
9473293|NCT03601494|Active Comparator|Intervention|peri-neural platelet rich plasma injection under ultrasound guidance in addition to medical treatment.
9473294|NCT03601494|Placebo Comparator|Control|medical treatment only
9473295|NCT03601429|Experimental|Lactogyn|1 capsule of Lactogyn 2 times daily for the first 7 days then 1 time daily for 4 months
9473296|NCT03601429|Placebo Comparator|Placebo|1 capsule of Placebo Comparator 2 times daily for the first 7 days then 1 time daily for 4 months
9473297|NCT03601416|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.
9473298|NCT03601416|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia.
9473299|NCT03601403|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
9473300|NCT03601403|Experimental|Inhaler technique|The intervention group received the standard medical and pharmacological care provided by the hospital. In addition, a tablet-assisted training on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program.
9473301|NCT03601390||PET/CT and EBV DNA|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT protocol 12 weeks after the end of IMRT (primary endpoint).Plasma EBV DNA test will be performed 4, 12, 24 weeks after the end of IMRT. In patients with negative PET/CT results, 2 follow-up visits are required to complement nasopharyngoscope examination and plasma EBV DNA test in the frist year. All patients will undergo annual PET/CT or traditional follow-up examination and plasma EBV DNA test 1 year after completing chemoradiation unless recurrent/residual disease is histopathologically-confirmed.
9473302|NCT03601377|Experimental|Training away from threat|"Experiment 1 and 2: In the intervention group -training away from threat-, in all angry-neutral faces presentation the probe is presented only after neutral face. Probe type (< or >) is not factorially counterbalanced but there is equal possibility of presentation for each of the following: angry-face location, probe location, or actor.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
9473303|NCT03601377|Experimental|Training towards threat|"Only for Experiment 2: The second ABMT condition -training towards threat- is identical to the first one with the exception that in all angry-neutral face presentations the symbol is presented only after threat face. In addition, at the beginning of every session participants will be informed that a random number of participants will have to repeat their speech. They will also be informed that this instruction will be given right after the dot probe task completion. This will be done in order for the participants to maintain their state anxiety but repetition of the speech task will not actually happen at this stage.~Experiment 2: received 4 times (2 times for 2 weeks)"
9473304|NCT03601377|Placebo Comparator|Placebo|"Experiment 1 and 2: In the placebo group, angry-face location, probe location and actor are fully counterbalanced with regards to their presentation.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
9473305|NCT03601364||Group 1|1.Mechanical ventilator closed group (Mechanical ventilator off)
9473306|NCT03601364||Group 2|"Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
9473307|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,~Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
9473308|NCT03601351||TT|Tumor Tissue. Colon or rectum neoplasia stage II and III tumor tissue.
10034166|NCT01794338|Experimental|Bio-A Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected."
10037196|NCT01822860|Active Comparator|Hydrochlorothiazide 25 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
9473309|NCT03601351||NTT|Nontumorous Tissue. Colon or rectum neoplasia stage II and III adjacent nontumorous tissue.
9473310|NCT03601338|Active Comparator|Bemiparin group|"Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery~Other Name: Hibor; Laboratories Rovi pharmaceuticals"
9473311|NCT03601338|Placebo Comparator|control group|Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
9473312|NCT03601312|Active Comparator|Treatment-As-Usual|Individuals receiving treatment as usual will be receiving exposure and response prevention (ERP), the standard of care for pediatric OCD.
9473313|NCT03601312|Experimental|OC-Go|Individuals in the OC-Go group will be receiving exposure and response prevention (ERP) augmented by the OC-Go application.
9473314|NCT03601299|Experimental|Traditional food arm|Traditional food-focused menu
9473315|NCT03601299|No Intervention|Non-intervention arm|Standard RurAL CAP menu
9473316|NCT03601260|Other|Gout Patients|Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
9473317|NCT03601247|Other|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
9473318|NCT03601234|Experimental|laparoscopic surgery|This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.
9480435|NCT03533569||Rheumatoid arthritis|Participants with an established diagnosis of rheumatoid arthritis
10037197|NCT01822873||Normal|
10037198|NCT01822873||Age-related macular degeneration|
9473319|NCT03601234|Experimental|laparoscopic and endoscopic combined surgery|LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy.
9473320|NCT03601208|Experimental|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
10034167|NCT01794338|Active Comparator|Strattice Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.."
9473321|NCT03601195||Subjects|Chinese women carrying multiple pregnancies
9473322|NCT03601169|Experimental|Low Dose MMFS-205-SR|Low dose, oral MMFS-205-SR twice daily (1,000 or 1,500 mg/day total, depending on lean body mass: ~22mg/kg LBM/day) for 6 weeks
9473323|NCT03601169|Experimental|High Dose MMFS-205-SR|High dose, oral MMFS-205-SR twice daily (1,500 or 2,000 mg/day total, depending on lean body mass: ~33mg/kg LBM/day) for 6 weeks
9473324|NCT03601169|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 6 weeks
9473325|NCT03601156|Experimental|NATACE-RT|Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
10034168|NCT01794351|Experimental|Placebo then resveratrol|Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
10034169|NCT01794351|Experimental|Resveratrol then placebo|Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
10034170|NCT01794364|Experimental|Experimental: Cohort A|Each subjects in Cohort A will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
10034171|NCT01794377|Active Comparator|40 of an endurance training|Endurance training at 50% of VO2 peak measured by indirect calorimetry. Dietary Supplement: supplementation in fruits and vegetables.
9473326|NCT03601156|Active Comparator|NACT-RT|Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
9473327|NCT03601130|Other|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
9473328|NCT03601130|Active Comparator|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
9473329|NCT03601104|Active Comparator|HIET (n = 15)|High intensity eccentric training: A high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
9473330|NCT03601104|Experimental|HIET-BFR (n= 15)|High intensity eccentric training with blood flow restriction (BFR): A high intensity eccentric (80% isometric peak) training of the knee extensors in isokinetic will be performed, associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) for 6 weeks, 3 times a week.
9473331|NCT03601104|Experimental|LIET-BFR (n = 15)|Low intensity eccentric training with blood flow restriction (BFR): A low intensity eccentric (40% isometric peak) training of the knee extensors in isokinetic will be performed associated with a pressure cuff placed in the proximal thigh (40% absolute occlusion pressure) for 6 weeks, 3 times a week.
9473332|NCT03601104|Active Comparator|LIET (n= 15)|Low intensity eccentric training: A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
9473333|NCT03601091|Active Comparator|PR|PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
9473334|NCT03601091|Active Comparator|DO|DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
9473335|NCT03601078|Experimental|bb2121 in relapsed and refractory multiple myeloma patients|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
9473336|NCT03601065||Routine colonoscopy Cohort|
9473337|NCT03601039|Experimental|Absnow Absorbable ASD Closure System|All subjects are implanted with Absnow Absorbable ASD Occluder
9480436|NCT03533569||Spondyloarthritis or psoriatic arthritis|Participants with an established diagnosis of spondyloarthritis or psoriatic arthritis
9480437|NCT03533569||Case controls|Participants with no arthritis or knee pain as controls
9480438|NCT03533530|Active Comparator|No electrical source imaging (ESI)|In all patients, the multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, except for ESI.
9480439|NCT03533530|Experimental|Low-density ESI (LD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using LD EEG recordings.
9480440|NCT03533530|Experimental|High-density ESI (HD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using HD EEG recordings.
9480441|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
10034172|NCT01794377|Experimental|30 minutes of a high intensity training|"This arm consist of an interval strength training for 30 min on bicycle ergometer (which include strengthening exercises in an high intensity interval training).~Dietary Supplement: supplementation in fruits and vegetables."
9473338|NCT03601026|Experimental|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
9473339|NCT03601026|No Intervention|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
10034173|NCT01794390||Turbuhaler and MDI patients (Arm 1)|Patients (Diskus naive) will be randomised to receive training on the PulmoJet© device followed by Diskus, or vice versa
10034174|NCT01794390||Diskus patients (Arm 2)|Patients (Turbuhaler naive) will be randomised to receive training on the PulmoJet© device followed by Turbohaler, or vice versa
10034175|NCT01794416|Active Comparator|Thoracoscopic epicardial ablation|"Patients were treated with video-assisted thoracoscopy under general anesthesia. PVI was performed from the epicardial side with a bipolar RF ablation clamp (AtriCure). At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. An additional application was made in the interatrial Waterston groove in the right side to isolate the ganglionic plexi from the atria. On the left side, the ligament of Marshal was cut, but no additional ablation of ganglionic plexi was pursued.~The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
10037199|NCT01822912|Active Comparator|Heart Failure Disease Management Program|Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
10037200|NCT01822912|Placebo Comparator|Heart Failure Usual Care|SNF patients with HF will receive usual care
9473340|NCT03601000|Experimental|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
9473341|NCT03601000|Placebo Comparator|Placebo|Placebo given three times every day for 16 weeks.
9473342|NCT03600987|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
9473343|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
9473344|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
9473345|NCT03600974||Acid-A(+)|Subjects with DeMeester scores>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
9473346|NCT03600974||Acid-A(-)|Subjects with DeMeester scores<14.72
9473347|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number > 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
9473348|NCT03600974||impedance-I（-）|Subjects with total reflux number < 80 in 24h pH-impedance monitoring.
9473349|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
9473350|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
9473351|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
9473352|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
9473353|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
9473354|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I~II
9473355|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
9473356|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
9473357|NCT03600935|Experimental|Vancouver Clinical Pathway|The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
9473358|NCT03600922|Experimental|Intervention group|
9473359|NCT03600896|Experimental|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
9473360|NCT03600896|Experimental|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
9473361|NCT03600870|Experimental|Open Label|All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
9473362|NCT03600857|Experimental|Home administration|Home administration of 0.8 mg misoprostol pv
10034176|NCT01794416|Active Comparator|Endocardial catheter ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster). The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
10034177|NCT01794429|Placebo Comparator|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
9473363|NCT03600857|No Intervention|Hospital administration|Hospital administration of 0.8 mg misoprostol pv
9473364|NCT03600831|Experimental|concurrent chemoradiotherapy group|All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
9473365|NCT03600831|Active Comparator|radiotherapy group|All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).
9473366|NCT03600818|Experimental|Group 1|Sarilumab once every 2 weeks plus prednisone taper regimen of 14 weeks
9473367|NCT03600818|Placebo Comparator|Group 2|Placebo matching sarilumab once every 2 weeks plus prednisone taper regimen of 52 weeks
9473368|NCT03600779|Experimental|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
9473369|NCT03600779|Active Comparator|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
9473370|NCT03600779|Experimental|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
9473371|NCT03600779|Active Comparator|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
9473372|NCT03600766|Active Comparator|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks
9473373|NCT03600766|Active Comparator|Placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
9473374|NCT03600753|Experimental|symptomatic patients|symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
9473375|NCT03600753|Active Comparator|asymptomatic patients|"symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus.~A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed"
9473376|NCT03600753|Other|healthy subjects|Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
9473377|NCT03600727|Experimental|Propofol group|Patients in this arm will be sedated by propofol.
9473378|NCT03600727|Experimental|Dexmedetomidine group|Patients in this arm will be sedated by dexmedetomidine.
9473379|NCT03600675||South Asian Indians|No intervention will be applied for any group
9473380|NCT03600675||Caucasians|No intervention will be applied for any group
9473381|NCT03600662|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
9473382|NCT03600662|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
9473383|NCT03600636|Other|Control|
9473384|NCT03600636|Other|antiphospholipid syndrome patients|
9473385|NCT03600623|Experimental|Folfirinox + SBRT|Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
9473386|NCT03600623|Experimental|Gemcitabine-nab Paclitaxel + SBRT|Gemcitabine-nab Paclitaxel comprises the following: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 every 4 weeks; nab Paclitaxel 125 mg/m2 on Days 1, 8, and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
9473387|NCT03600610|Experimental|patient group|malnourished patients with anorexia nervosa gadolinium-enhanced cardiac MRI will be performed
10034178|NCT01794429|Active Comparator|exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
9473388|NCT03600610|Active Comparator|control group|age- and sex- matched, normal weight, healthy volunteers gadolinium-enhanced cardiac MRI will be performed
9473389|NCT03600584|Experimental|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
9473390|NCT03600584|Active Comparator|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
9473391|NCT03600571|Experimental|AM groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
9473392|NCT03600571|Experimental|MMP groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
9473393|NCT03600571|Experimental|AM groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
10034179|NCT01794442||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
9473394|NCT03600571|Experimental|MMP groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
9473395|NCT03600545|Experimental|Active|4 weeks daily practice of the brain exercises
9473396|NCT03600545|No Intervention|control|no brain exercises
9473397|NCT03600532|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
9473398|NCT03600532|No Intervention|Treatment as Usual (TAU)|Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
9473399|NCT03600532|No Intervention|Community Control Group (CCG)|Patients will engage in a rest period before completing the post-assessment.
9473400|NCT03600519||AMD Patients|OCT scan
9473401|NCT03600506|Active Comparator|Dexmedetomidine|Intervention drug of the study
9473402|NCT03600506|Placebo Comparator|Placebo|Normal Saline (Placebo)
9473403|NCT03600493|Active Comparator|Dexemetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
9473404|NCT03600493|Active Comparator|Lidocaine|Lidocaine prepared in a syringe with the same volume of Dexmedetomidine to assure blinding given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
9473405|NCT03600467|Experimental|Adrogen Postive Solid Tumours|
9473406|NCT03600454|Experimental|Hip surgery: spinal anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive spinal anesthesia in combination with monitored anesthesia care (MAC).
9473407|NCT03600454|Experimental|Hip surgery: general anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive general anesthesia
9473408|NCT03600454|Experimental|Colectomy: general anesthesia and epidural analgesia|Patients scheduled to undergo elective laparoscopic hemicolectomy will receive general anesthesia combined with epidural analgesia (EA).
9473409|NCT03600454|Experimental|Colectomy: general anesthesia|Patients will receive general anesthesia.
9473410|NCT03600441|Experimental|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
9473411|NCT03600415|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
9473412|NCT03600415|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
9473413|NCT03600402|Experimental|Experimental Group|
9473414|NCT03600402|Other|Control Group|
9473415|NCT03600389|Experimental|Intervention Arm (Implementing Patient Priorities Care)|Aligning healthcare recommendations to achieve patients' specific health outcome goals within the context of what patients are willing and able to do.
10034180|NCT01794442||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
9473416|NCT03600389|No Intervention|Control Arm (Not Implementing Patient Priorities Care)|Routine Care
9473417|NCT03600363|Experimental|metformin arm|
9473418|NCT03600363|Placebo Comparator|control arm|
9473419|NCT03600337|Experimental|Experimental Condition|Working to Optimize Wellness in Teens with PCOS
9473420|NCT03600337|No Intervention|Control Condition|Participants in this arm will receive treatment as usual and will be given the intervention after 1 month assessments are completed for the intervention group
9473421|NCT03600324|Experimental|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
9473422|NCT03600324|Experimental|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
9473423|NCT03600324|Experimental|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
9473424|NCT03600324|Experimental|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
9473425|NCT03600311|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
9473426|NCT03600311|Active Comparator|Caloric Restriction and CHO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
9473427|NCT03600311|Experimental|Caloric Restriction and PRO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of whey protein following exercise.
9480442|NCT03533491|Experimental|App Evaluation|All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.
9480443|NCT03533478|Experimental|Group I|32 patients with mild or moderate diabetic macular edema.
9480444|NCT03533478|Placebo Comparator|Group II|32 patients with mild or moderate diabetic macular edema
9473428|NCT03600298|Other|Pediatric intensive care unit-nurses|"Phase I: During the month leading up to the simulation two trained observers / raters will observe the rate of Closed-Loop Communication in the pediatric intensive care unit (PICU) among study participants.~Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.~Phase II + III: During the follow up phase, trained raters will again observe the study-participating PICU staff relative to their communication behaviour in the month following simulation training (Phase II) and again three months later (Phase III)."
9473429|NCT03600285|Experimental|TB1-K|TB1-K preservation arm
10034181|NCT01794442||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
10034182|NCT01794468|Experimental|study group-Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor
9473430|NCT03600272|Experimental|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
9473431|NCT03600272|Other|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
9473432|NCT03600259||Acute Myocardial Infarction|
9473433|NCT03600233|Experimental|CVM-1118|CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
9473434|NCT03600220|No Intervention|drug use|routine drug use, each patient was using 1-3 antihypertensive drug of a heterogeneous pharmacological group ranging from ACE inhibitors, diuretics, and beta blockers
9473435|NCT03600220|Experimental|drug combine acupuncture|routine drug use combine acupuncture twice a week for 3 months
9473436|NCT03600207|Active Comparator|Control group -complex training|complex training
9473437|NCT03600207|Active Comparator|Experimental group -diaphragm training|diaphragm training
9473438|NCT03600181||orotracheal intubation|Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
9473439|NCT03600155|Experimental|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9473440|NCT03600155|Experimental|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9473441|NCT03600155|Experimental|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9473442|NCT03600129|Experimental|QLB with 0,375% ropivacaine|
9473443|NCT03600129|Placebo Comparator|QLB with 0,9% NaCl|
9473444|NCT03600064|Other|Misoprostol group|
9473445|NCT03600064|No Intervention|NO intervention|
9473446|NCT03600038|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
9473447|NCT03600038|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
9473448|NCT03600025|Other|non-randomized|Responses will be compared before and after vaccination
10034183|NCT01794481|No Intervention|Usual Care|Participants allocated to usual care will receive their usual treatment program which will include dietician counseling as needed. As part of standardized care, participants will not be encouraged to begin a new exercise program(patients needing physical therapy at time of enrollment will be excluded.
9473449|NCT03600012|Experimental|intervention group|"intervention group: Cycling Functional Electrical Stimulation & Physiotherapy~Children in intervention group were taken in a therapy program withRT 300 SLSA FES system for cycling functional electrical stimulation training additionly to physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 sessions in a week and 45 min per session."
9473450|NCT03600012|Active Comparator|control group|"control group: Physiotherapy~Children with cp in control group were taken physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 times in a week, 45 min per session."
10037201|NCT01822938|Experimental|effects of a incentive program for physical activity|The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke
10037202|NCT01822938|No Intervention|control group|No intervention
10037203|NCT01822951|Experimental|Cerebrolysin Verum|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.~Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
9473451|NCT03599973|Other|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
9473452|NCT03599960|Experimental|Chemotherapy|
9473453|NCT03599921||Family-based Treatment|Participants will receive family-based treatment.
9473454|NCT03599921||Enhanced Cognitive behavioral therapy|Participants will receive enhance cognitive behavioral therapy.
9473455|NCT03599921||Family-based Treatment for ARFID|Participants will receive family-based treatment modified for Avoidant/Restrictive Food Intake Disorder (ARFID).
9473456|NCT03599921||FBT + UP for ARFID|Participants will receive family-based treatment with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents, named FBT + UP for ARFID.
10034184|NCT01794481|Experimental|Resistance Exercise Training|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
10034185|NCT01794494||Open surgical group|Bypass surgery for critical limb ischemia
10034186|NCT01794494||Endovascular treatment|Endovascular recanalization for critical limb ischemia
10034187|NCT01794507|Experimental|ABT-199 + BTZ/Dex Dose Escalation Cohorts|Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.
10034188|NCT01794507|Experimental|ABT-199 + BTZ/Dex Safety Expansion Cohort|Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.
10034189|NCT01794533|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
10034190|NCT01794533|Active Comparator|Lidocaine with Epinephrine + fentanyl|
9473457|NCT03599895|Experimental|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
9473458|NCT03599895|Experimental|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
9473459|NCT03599856|No Intervention|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
9473460|NCT03599856|Experimental|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
9473461|NCT03599843|Experimental|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
9473462|NCT03599830|Other|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
9473463|NCT03599817|Experimental|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
9473464|NCT03599778|Experimental|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
9473465|NCT03599778|Active Comparator|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
9473466|NCT03599765|Experimental|Arm I (LCT, routine therapy)|Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.
9473467|NCT03599765|Experimental|Arm II (routine therapy)|Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.
9473468|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
9473469|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
9473470|NCT03599726|Experimental|Active study drug: Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
9473471|NCT03599726|Placebo Comparator|Placebo study drug: Placebo|Placebo 5 mg per day for week 1-2 or 5-6
10034191|NCT01794546|Experimental|Immediate Telehealth|"The immediate intervention group will receive the telehealth intervention during the first 6 months of the study timeline."
9473472|NCT03599700||myeloproliferative neoplasms|"history taking~physical examination~laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
9473473|NCT03599674|Experimental|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
9473474|NCT03599609|Experimental|Treatment|Treatment: Simvastatin 40mg/day
9473475|NCT03599596|Active Comparator|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
9473476|NCT03599596|Active Comparator|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
9473477|NCT03599570|Experimental|Intervention|Arm 1 will receive the STOP-HPV performance feedback intervention
9473478|NCT03599570|No Intervention|Control|Arm 2 will receive standard of care
9473479|NCT03599557|Experimental|Intervention|Arm 1 will receive the STOP-HPV communication intervention
9473480|NCT03599557|No Intervention|Control|Arm 2 will receive standard of care
9473481|NCT03599544|Active Comparator|Robot-Assisted Therapy (RT)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
9473482|NCT03599544|Experimental|Robot + Active Learning Program(RT-ALPS)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
9473483|NCT03599518|Experimental|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 250 mg oral dose of gefitinib
9473484|NCT03599492||Cirrhosis Patients|10 Patients with body mass index (BMI) etiology of cirrhosis
9473485|NCT03599479|Experimental|Virtual reality group|"After experiencing the VR machine in the transfer bed for 5 minutes, the subject moves to the operating room.~After the subject moves to the surgical bed, he/she takes the appropriate position for the fluoroscopic pain intervention, and wears the virtual reality device (headset, headphone, smartphone).~After the subject starts the VR program, the practitioner starts the fluoroscopic pain intervention.~Lidocaine skin infiltration and description of the practitioner during the intervention are performed with the intervention when necessary."
9473486|NCT03599479|No Intervention|Conventional group|The fluoroscopic pain intervention is performed using only local anesthetics and description of the practitioner during the intervention as in the conventional cases.
9473487|NCT03599466|Experimental|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
9473488|NCT03599466|Active Comparator|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
9473489|NCT03599453|Experimental|Treatment (chemokine modulation therapy)|Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo additional biopsy. Following biopsy and chemokine modulation therapy, participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
9473490|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
9473491|NCT03599427|Active Comparator|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
9473492|NCT03599427|Placebo Comparator|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
9473493|NCT03599401|Active Comparator|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
9473494|NCT03599401|Active Comparator|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
10034192|NCT01794546|Active Comparator|Wait List Control|"The wait list control group will receive the telehealth intervention during months 6 through 12 of the study timeline."
10034193|NCT01794559|Experimental|Informed by PEER Interactive Report|"The PEER Interactive Report -This study is prospective in nature. For subjects in the experimental group, the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication.~The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days.~The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health."
9473495|NCT03599401|Placebo Comparator|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
9473496|NCT03599388|Experimental|SASI|"Sleep Diaries (daily)~Fitbit 24/7~Phone/videoconference (weekly with study team)~Epworth Sleepiness Scale (weekly)~PROMIS fatigue scale-morning (weekly)~PROMIS fatigue scale-evening (weekly)"
9473497|NCT03599375|Experimental|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
10034194|NCT01794559|No Intervention|No Report|This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health.
10037204|NCT01822951|Active Comparator|Donepezil Verum|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly)."
9473498|NCT03599336|Other|Nonoperative Treatment|Subjects will have nonoperative treatment to treat proximal humerus fracture that is broken into 3 or 4 parts.
9473499|NCT03599336|Other|Operative Course for rTSA|Subjects will have shoulder replacement surgery to treat proximal humerus fracture that is broken into 3 or 4 parts.
9473500|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
9473501|NCT03599310|Experimental|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
9473502|NCT03599310|Placebo Comparator|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
9473503|NCT03599284|Experimental|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
9473504|NCT03599284|Experimental|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
9473505|NCT03599284|Experimental|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
9473506|NCT03599284|Active Comparator|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
9473507|NCT03599258|Other|Arm 1|Skylife device
9473508|NCT03599258|Active Comparator|Arm 2|Standard therapy
9473509|NCT03599232|Active Comparator|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).~assessed at end of the module(7 weeks) through summative OSCE"
9473510|NCT03599232|No Intervention|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
9473511|NCT03599219|Other|case|donors with an hemorrhagic score >2 and / or hematoma (more than 4 cm) that occurred during blood donation
9473512|NCT03599219|Other|control|donors with an hemorrhagic score <2.
9473513|NCT03599206|Experimental|Ozone|
9473514|NCT03599206|Placebo Comparator|Filtered Air|
9473515|NCT03599180||Knee Osteoarthritis group|KOA patients without accept treat in the past month
9473516|NCT03599180||Control group|Heathly volunteers
9473517|NCT03599128|Placebo Comparator|Placebo|Placebo
9473518|NCT03599128|Experimental|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
10034195|NCT01794572|Experimental|Total BM irradiation dose|"Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication."
10034196|NCT01794585|Experimental|Virtual Reality Based Exercise|
9473519|NCT03599128|Experimental|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
9473520|NCT03599128|Experimental|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
9473521|NCT03599115|Experimental|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
9473522|NCT03599115|Active Comparator|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
9473523|NCT03599102|Experimental|LOVED intervention|Intervention group receives the LOVED program, an 8-week program where participants receive video education modules, and weekly video chat sessions with other end-stage renal disease patients and a prior living kidney African American recipient. The program aims to increase knowledge and skills on how to promote individual strategies on how to ask for a kidney from others.
9473524|NCT03599102|No Intervention|Standard Care|Standard interaction with transplant center and physician care.
10034197|NCT01794585|Active Comparator|Standard Exercise|
10034198|NCT01794598|Experimental|Educational materials|Receiving educational materials of depression care
10034199|NCT01794598|Sham Comparator|No educational materials|Receiving an envelope but no inclusion of educational materials of depression care
10034200|NCT01794611|Experimental|Laryngoscopy|Patients will be intubated by an experienced anesthesiologists. Anesthesiologist first uses Macintosh laryngoscope then KingsVision videolaryngoscope and lastly C-MAC videolaryngoscope to intubate patients. Cormack-Lehane scores, the time from the start of laryngoscopy to visualization of the vocal cords and the time from the visualization of the vocals from the successful intubation will be recorded. The success of the intubation will be assessed with bilateral chest auscultation. If visualization of the vocal cords or placing of the endotracheal tube was not successful after 60 seconds with a particular laryngoscope, it will be left out and patient will be ventilated for 1 minutes and then pass to other laryngoscopes.
9473525|NCT03599076||Manifest HD|
9473526|NCT03599076||Premanifest HD|
9473527|NCT03599076||Control|
9473528|NCT03599063|Experimental|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
9473529|NCT03599063|Experimental|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
9473530|NCT03599063|Experimental|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
9473531|NCT03599063|Experimental|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
9473532|NCT03599063|Experimental|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
9473533|NCT03599063|Experimental|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
9473534|NCT03599063|Experimental|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
9473535|NCT03599063|Experimental|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
9473536|NCT03599037|Experimental|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
9473537|NCT03599037|No Intervention|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
9473538|NCT03599024|Experimental|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
9473539|NCT03599024|Active Comparator|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
9473540|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
9473541|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
9473542|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
10034201|NCT01794624|Active Comparator|Cognitive Therapy|Cognitive Therapy for Catastrophizing
10034202|NCT01794624|Active Comparator|Behavioral Therapy|Behavioral Therapy for Sleep Continuity Disturbance
10034203|NCT01794624|No Intervention|TMJD Education|6-sessions of TMJD disease education/support control
10034204|NCT01794637||the end-stage liver disease patients|the end-stage liver disease scheduled for liver transplantation
10034205|NCT01794650|Other|Meal composition|Changing the glycaemic index of the meals consumed after exercise and before sleep. (High GI - High GI, Low GI - Low GI, High GI - Low GI, Low GI - High GI).
10034206|NCT01794676||Family 1|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
9473543|NCT03598998|Experimental|Treatment (pralatrexate and pembrolizumab)|Patients receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
9473544|NCT03598985||Patients with CAI|"Patients referred with a confirmed diagnosis of CAI, with a Cumberland Ankle Instability tool score lower than 27 points. Patients should have had a recurrent sprain within the previous year.~Patients will have their balance assessed using the Myankle smartphone application simultaneously with Biodex balance system assessment."
9473545|NCT03598985||Healthy participants|"Healthy participants who are not complaining of pain and have not be exposed to trauma, injury or undergone surgery for the lower quadrant of the body.~Participants will have their balance assessed using the MyAnkle smartphone application simultaneously with Biodex balance system assessment."
9473546|NCT03598972||control|teeth of children of non vitamin taking mother
9473547|NCT03598972||intervention|children teeth of vitamin taking mother
9473548|NCT03598959|Experimental|Treatment|Treated with tofacitinib and chidamide for 4 cycles.
9473549|NCT03598946|Experimental|Human Papilloma Virus Test urinary|Urinary Test by a kit which is send to the woman's house
10034207|NCT01794676||Family 2|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
10034208|NCT01794676||Family 3|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
10034209|NCT01794728||Elderly inpatients with heart failure|A single cohort group of elderly patients hospitalized for heart failure.
9473550|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
9473551|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
9473552|NCT03598907||Standard management of coagulopathy|"The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy."
9473553|NCT03598907||POC management of coagulopathy|"group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss."
9473554|NCT03598881|Experimental|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
9473555|NCT03598881|Active Comparator|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
9473556|NCT03598868|Experimental|Vortioxetine|Vortioxetine 5-20 mg
9473557|NCT03598868|Placebo Comparator|Placebo|Placebo augmentation
9473558|NCT03598855|Experimental|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
9473559|NCT03598855|No Intervention|Control|
9473560|NCT03598842|Experimental|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.
9473561|NCT03598842|Experimental|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
9473562|NCT03598842|Active Comparator|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
9473563|NCT03598842|No Intervention|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
9473564|NCT03598816|Experimental|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles~The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab~The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
9473565|NCT03598816|Experimental|Arm 2: Durvalumab + Tremelimumab|"All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
9473566|NCT03598764|Other|Classic head extraction group|
9473567|NCT03598764|Other|External Pop out group|
9473568|NCT03598751|Experimental|BCD-085|"Blinded period:~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
9473569|NCT03598751|Placebo Comparator|Placebo|"Blinded period:~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14~patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22~patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
9473570|NCT03598738|Active Comparator|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
9473571|NCT03598738|No Intervention|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
9473572|NCT03598725|Experimental|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
9480445|NCT03533452|Active Comparator|PRE-GA|10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter
9480446|NCT03533452|Sham Comparator|POST-GA|10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter
10034210|NCT01794754|Other|Control|Care as usual
10034211|NCT01794754|Experimental|Occupational therapy|Occupational therapy
9473573|NCT03598712|Experimental|Compression by chest bandage urgo K2®|"After the second puncture, the local compression by thoracic bandage will be put in place.~The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.~During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.~The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation."
10034212|NCT01794767|Active Comparator|0,9% NaCl flush|for children enrolled in this group, the nurse will perform the flushing of peripheral venous catheter using flush-solution as a bolus with saline 0.9% NaCl in the amount (ml) needed to fill the entire circuit of the catheter. The flushing will be performed routinely at the end of each fleboclisis
10034213|NCT01794767|Experimental|Heparin 50U/ml|for children enrolled in this group, the nurse will perform the washing of peripheral venous catheter using flush-solution as a bolus with heparin 50U/ml in the amount (ml) needed to fill the entire circuit of the catheter. The washing will be performed routinely at the end of each fleboclis
10034214|NCT01794793|Experimental|Pasireotide subcutaneous|0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
10034215|NCT01794793|Experimental|Pasireotide Long Acting Release (LAR)|10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
10034216|NCT01794819|Experimental|C-reactive protein test|"The C-reactive protein test was performed in the intervention group at both the first and second consultations.~The Afinion test system (Axis Shield) was used, which provides results within 5 minutes and before treatment was determined. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L."
10034217|NCT01794832||Elderly with severe aortic stenosis|Patients with severe symptomatic aortic stenosis referred for consideration of surgical aortic valve replacement
10034218|NCT01794858|Experimental|Therapeutic Hypothermia|"Primary - Organ specific outcome at 28 days Logistic Organ Dysfunction Score (LOD) will be compared before and after TH. Change in LOD will reflect LOD day 4 minus LOD day 1 (Ehrmann, Can J Anesth 2006).~Secondary~Lab values: D-Dimer, IL-6, CRP~APACHE II Scores Day 1 and after TH (day 4)~Length of stay in the ICU and hospital~Prevalence of infections~28-day mortality~Hypothermia-related side effects: cardiac arrhythmia, electrolyte balance, hyperglycemia, bleeding, acute pancreatitis"
10034219|NCT01794884|Experimental|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg)(volume ratio=1:5).Intravenous injection twice (24 hours、1 hour before operation).
9473574|NCT03598712|Active Comparator|punctures|"After the second puncture, the patient will be seen at the same frequency as in the experimental arm.~The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical."
9473575|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
9473576|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
9473577|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
9473578|NCT03598699|Placebo Comparator|AXR-159 Ophthalmic Solution Vehicle|Control Group
9473579|NCT03598686|No Intervention|HOSENG Control|"Standard of care during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~For absent household members or household members who refuse testing: They are encouraged to get tested by the Village Health Worker (VHW) or the nearby health facility"
9473580|NCT03598686|Experimental|HOSENG Intervention|"HOSENG Intervention during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~a) If any absent person in the household: One of the present household members is tested and trained using the oral HIVST (OraQuick©)~For absent household members or household members who refuse testing: One oral HIVST (OraQuick©) is left behind and has to be brought back to the VHW after usage. Otherwise it will be collected by the VHW after two weeks."
9473581|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
9473582|NCT03598660||Breast cancer patients|"The present study will be carried on 50 breast cancer patients before surgery.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA)."
9473583|NCT03598660||Healthy controls|"The present study will be carried on 15 age and sex matched controls.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
9473584|NCT03598660||Benign breast diseases|"The present study will be carried on 15 patients with benign breast diseases.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
9473585|NCT03598634|Active Comparator|Epi-on cross-linking|Intervention: Drug: Riboflavin 0.15 in 20% dextran solution
9473586|NCT03598634|Active Comparator|Epi-off cross-linking|intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid
9473587|NCT03598621|Experimental|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
10034220|NCT01794884|Placebo Comparator|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation).
9473588|NCT03598621|Experimental|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
9473589|NCT03598621|Experimental|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
10034221|NCT01794897|Experimental|Valacyclovir treatment|Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
9473590|NCT03598595|Experimental|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9473591|NCT03598582|Other|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
9473592|NCT03598569||lung cancer|
9473593|NCT03598569||other lung diseases|
9473594|NCT03598556|Experimental|Vitamin D3 Supplementation Arm|This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
9473595|NCT03598556|Placebo Comparator|Placebo Arm|This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
9473596|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
9473597|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
9473598|NCT03598517|Experimental|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
9473599|NCT03598504|Active Comparator|Healthy Controls Group|1. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
9473600|NCT03598504|Active Comparator|Spinal Cord Injury Group|"1a. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).~1b. In the lab, we will trigger spasms in paralyzed leg muscles in one of two common postures (seated, reclined), detect the contractions using electromyography (EMG), and condition alternate spasms with vibration using our custom device. We will examine the vibration parameters that reduce muscle spasms best.~2. Participants will complete 1 or 2 multi-day experiments. EMG (24-hour) data will be collected at baseline (day 1), during the vibration intervention (day 2), and post intervention (day 3) to examine the acute effects of vibration on muscle spasms"
9473601|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
9473602|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
9473603|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
9473604|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
9473605|NCT03598452|Experimental|High dose of ganciclovir group|IVG was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
9473606|NCT03598426|Active Comparator|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
9473607|NCT03598426|Active Comparator|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
9473608|NCT03598426|Active Comparator|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
9473609|NCT03598413|No Intervention|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
9473610|NCT03598413|Experimental|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
9473611|NCT03598400|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
9473612|NCT03598400|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
9473613|NCT03598400|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
9480956|NCT05154578|Experimental|Group 2: early intervention; 4 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA
10034222|NCT01794897|Placebo Comparator|Placebo|Placebo comparator: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
10034223|NCT01794910|Experimental|Plevic floor muscle therapy|The pelvic floor muscle therapy to women with vaginal or cesarean deliveries involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions.
9473614|NCT03598374|Experimental|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
9473615|NCT03598374|Placebo Comparator|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
9473616|NCT03598348|Experimental|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
10034224|NCT01794910|No Intervention|Controll group|Women with vaginal or cesarean deliveries did not did not undergo muscle training
10034225|NCT01794962|Experimental|Manual therapy and exercises|Manual therapy treatment: spinal manipulation, Soft tissue treatment, muscle energy techniques. Exercises: stabilisation exercises, Mckenzie exercises and general muscle exercises.
9473617|NCT03598348|No Intervention|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
9473618|NCT03598348|Experimental|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
9473619|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
9473620|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
9473621|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
9473622|NCT03598322|Active Comparator|Dextrose 1mL|Dextrose injection, Dextrose 1mL, active comparator
9473623|NCT03598322|Experimental|Dextrose 2mL|Dextrose injection, Dextrose 2mL
9473624|NCT03598322|Experimental|Dextrose 4mL|'Dextrose injection, Dextrose 4mL
10034226|NCT01794962|Experimental|Cognitive Functional Therapy|An in depth interview, including investigating the patients beliefs on back pain, fear towards movement, anxiety and distress, using reflecting questions. The physical part consists of specific and functional exercises related to the patients functional complaints.And general physical activity for 30 mins 3-4 times weekly.
10034227|NCT01794975|Active Comparator|Ketamine|Ketamine will be administered intravenously using a pseudo steady state infusion approach with a target plasma concentration of 300 ng/ml starting 15 minutes before the PET scan and continued throughout the scan.
9473625|NCT03598296|Experimental|Group A:Group Tube|Patients are inserted the large size tube (28F).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
9473626|NCT03598296|Experimental|Group B:Group Ball|Patients are inserted the small size tube connects with a negative pressure ball(drainage ball).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
9473627|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
9473628|NCT03598218|Experimental|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
9473629|NCT03598218|Experimental|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
9473630|NCT03598205|Experimental|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
9473631|NCT03598205|No Intervention|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
9473632|NCT03598192|Experimental|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.~Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
9473633|NCT03598192|Experimental|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
9473634|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
9473635|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
9473636|NCT03598101|Experimental|Test group|
9480957|NCT05154578|Experimental|Group 3: early intervention; 8 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of placebo at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
9473637|NCT03598088|Other|Healthy Sexually Active Women|Healthy, sexually active women who are not at risk for pregnancy due to previous female tubal sterilization will receive both Ovaprene and the Caya diaphragm throughout the course of the trial. The purpose of the Caya PCT cycle is to ensure that in this study population and at these sites, results that are expected to be observed in a PCT cycle with an approved vaginal barrier can be replicated.
9473638|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide intravenous infusion 120 micrograms over 20 minutes
9473639|NCT03598075|Other|CGRP|CGRP intravenous infusion 30 micrograms over 20 minutes
9473640|NCT03598049|Experimental|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
9473641|NCT03598049|Active Comparator|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
9473642|NCT03598023|Active Comparator|Group 1|Cytal® Burn Matrix
9473643|NCT03598023|Active Comparator|Group 2|EZ-Derm® Porcine Xenograft
9473644|NCT03598010|Experimental|Lenodiar Pediatric in Acute/Prolonged Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
9473645|NCT03598010|Experimental|Lenodiar Pediatric in Chronic Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
9473646|NCT03597997|Experimental|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
10034228|NCT01794975|Active Comparator|Atomoxetine and the cold pressor test|An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
9473647|NCT03597997|Sham Comparator|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
9473648|NCT03597984|No Intervention|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
9473649|NCT03597984|Experimental|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
9473650|NCT03597971|Experimental|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
9473651|NCT03597971|Placebo Comparator|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
9473652|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
9473653|NCT03597945|Placebo Comparator|Group Placebo|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of normal saline as adjuvant."
9473654|NCT03597945|Active Comparator|Group Magnesium|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of Magnesium sulfate 15% (450 mg) as adjuvant."
9473655|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
9473656|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
9473657|NCT03597919|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
9473658|NCT03597919|Experimental|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
9473659|NCT03597906|Experimental|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
10034229|NCT01794975|Placebo Comparator|Placebo|Placebo capsules are given to mimic the atomoxetine treatment at each treatment visit except the atomoxetine visit. A baseline PET scan with [11C]ORM-13070 will be performed for all subjects with the placebo treatment only.
10034230|NCT01794988|Experimental|Group Cognitive Behavioral Therapy|Participants will undergo 11 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
10034231|NCT01794988|Active Comparator|Pain Education|Participants will receive 11 weeks of pain education and a pre- and post-intervention MRI brain scan.
9473660|NCT03597906|Experimental|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
9473661|NCT03597906|Experimental|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
9473662|NCT03597893|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
9473663|NCT03597893|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
9473664|NCT03597880|Other|obese patient|BMI>30 kg/m2 and underwent bariatric surgery
9473665|NCT03597867|Placebo Comparator|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
9473666|NCT03597867|Experimental|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
9473667|NCT03597867|Experimental|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
9473668|NCT03597867|Experimental|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
9473669|NCT03597867|Experimental|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
9473670|NCT03597841||Patients with CRKp BSI:Combination therapy|
9473671|NCT03597841||Patients with CRKp BSI: Monotherapy|
9473672|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
9473673|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
9473674|NCT03597815||DME positive, OSA positive|Visit 1: Baseline DME Treatment. Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injection is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 6-month visit post DME initial treatment Visit 5: 2-3 month follow up - titration study (at sleep lab) Visit 6: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group Visit 7: 12-month sleep apnea follow up
9473675|NCT03597815||DME positive, OSA negative|Visit 1: Baseline DME Treatment Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injections is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 6-month visit post DME initial treatment Visit 4: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group
9473676|NCT03597815||DME negative (NPDR positive), OSA positive|no injections needed. Visit 1: Baseline NPDR diagnosis Sleep lab visits Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 2-3 month follow up - titration study Visit 5: 12-month sleep apnea follow up
9473677|NCT03597815||DME negative (NPDR positive), OSA negative|no injections needed. Visit 1: Baseline NPDR diagnosis Visit 2: Diagnosis of OSA - Overnight sleep study
9473678|NCT03597802|No Intervention|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
9473679|NCT03597802|Active Comparator|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
9473680|NCT03597802|Active Comparator|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
9473681|NCT03597776|Experimental|Lidocaine Group|Bolus of intravenous lidocaine of 2mg/kg over 5 mins will be given before skin incision.
9473682|NCT03597776|Placebo Comparator|Placebo Group|Normal Saline of 2mg/kg over 5 mins will be given as bolus before skin incision
9473683|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
9473684|NCT03597750|Experimental|Static air support devices (Repose®)|"Alternating-pressure devices will be replaced by static air support devices (Repose®) during 14 days:~Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors~The frequency of repositioning remains unchanged."
9473685|NCT03597750|No Intervention|Alternating-pressure devices|"Instead of replacing the alternating-pressure devices by static air support devices (Repose®), the residents remain on their alternating-pressure devices.~The frequency of repositioning remains unchanged."
9473686|NCT03597737|Experimental|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
9473687|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
9473688|NCT03597711|Active Comparator|IVCannulation 24G non-safety cannula|Peripheral Intravenous cannulation using 24G non-safety cannula
9473689|NCT03597711|Active Comparator|IVCannulation 26G safety cannula|Peripheral Intravenous cannulation using 26G safety cannula
9473690|NCT03597711|Active Comparator|IVCannulation 24G safety cannula|Peripheral Intravenous cannulation using 24G safety cannula
9480447|NCT03533426|Active Comparator|Pump based patient controlled analgesia|"Analgesia is maintained using disposable silicon ballon pump Accufuser containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg & the pump is sufficient for about 60 hours according to patient response."
9480448|NCT03533426|Active Comparator|serratus anterior plane catheter block|"Linear ultrasound transducer (superficial) 6-12 MHz is utilized to count the ribs up to 4th or 5 th rib in the mid-axillary line. Musculature of thoracic wall is identified sonographically,an echogenic needle 14-16 G, 100 mm is inserted in plane with the U/S probe towards the plane deep to the serratus anterior muscle. Under real - time U/S, single shot of 20ml contrast medium iohexol = omnipaque 150 mg I2 / ml is injected to check the plane and level (T3-T8/9) of SAPB.A reinforced radiopaque catheter is threaded through the needle and its final position underneath the plane of serratus anterior muscle is confirmed fluoroscopically. 20ml 0.25% levobupivacaine (Chirocaine).Analgesia is maintained using 0.125% levobupivacaine infusion at a rate of 7-12 ml/h according to patient response."
9480449|NCT03533413|Active Comparator|Interventional:Combined CT-fluroscopy|Combined CT-fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
9480450|NCT03533413|Active Comparator|Interventional: standard fluroscopy|Fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
9480451|NCT03533400|Active Comparator|Group 1|Group 1 (control group) will be given the standard Jamboxx musical device. They will be trained to use the device during two 20 minute training session with a respiratory therapist, and will be instructed to play the device for a minimum of 30 minutes, 3 times a week. The Jamboxx musical device is a hands-free breath controlled musical device designed for people with quadriplegia. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key.
9480452|NCT03533400|Experimental|Group 2|Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
9480453|NCT03533387|Experimental|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
9480454|NCT03533387|Experimental|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
9480455|NCT03533387|Active Comparator|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
9480456|NCT03533348||Fasting arm|Patients will need at least 4 hours of fasting prior to contrast-enhanced CT scans.
10034232|NCT01794988|Experimental|Therapeutic Interactive Voice Response|Four months of therapeutic interactive voice response (TIVR).
10034233|NCT01794988|Active Comparator|No TIVR|Control - no intervention
10034234|NCT01795001||late-onset FECD|tissue samples from patients with late-onset Fuchs' endothelial corneal dystrophy (FECD)
9480457|NCT03533348||No fasting|Patients are allowed to eat and drink freely prior to contrast-enhanced CT scans.
9480458|NCT03533335|Active Comparator|Chlorhexidine spray|0.2% chlorhexidine oral spray, once daily
9480459|NCT03533335|Experimental|Chlorine Dioxide spray|0.1% pH-balanced chlorine dioxide oral spray, once daily
9480460|NCT03533335|Placebo Comparator|Sterile water spray|Placebo
9480461|NCT03533309|Experimental|computer guided|"Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.~."
9480462|NCT03533309|Active Comparator|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
9480463|NCT03533296|Experimental|Children|Children who receive elective surgery under general anesthesia and are supported by mechanical ventilation
9480464|NCT03533270||Urethroplasty|Patients with traumatic urethral injury associated with pelvic fractures who underwent urethroplasty
9480465|NCT03533231|Active Comparator|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
9480466|NCT03533231|Experimental|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
9480467|NCT03533231|Active Comparator|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
10034235|NCT01795001||normal control|tissue samples from patients with normal corneas
10034236|NCT01795001||non-FECD edematous control|tissue samples from patients with corneal edema but without FECD
10034237|NCT01795014||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an IOP above 21 mmHg that could suggest possible glaucoma suspects.
10034238|NCT01795014||Primary open-angle Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
10034239|NCT01795014||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
10034240|NCT01795027|Experimental|S-1 plus Oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
10034241|NCT01795027|Active Comparator|S-1 single|S-1 40~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection
10034242|NCT01795040|Experimental|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
10034243|NCT01795040|Placebo Comparator|placebo without PUFAs|Placebo without PUFAs
10034244|NCT01795053|Experimental|playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and intensity and thereby reduce ADHD symptoms
10034245|NCT01795053|Placebo Comparator|open play session|the open play sessions are conducted in the same rooms, by the same staff and in the same time frame as the experimental sessions. The therapist plays with the child without structuring the sitauation through behavioral tecniques. The play situation is designed to be ineresting and comfortable for the child.
10034246|NCT01795066|Experimental|EUS-FNB with 25-gauge|
10034247|NCT01795092|No Intervention|Control|Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider. We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
10034248|NCT01795092|Experimental|Dermatology consultation|Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition. Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
10034249|NCT01795131|Active Comparator|Vitamin B12|Supplementation group (N=60) that will receive 250 µg of vitamin B12 in addition to 60 mg of Fe and 400µg of folate.
10034250|NCT01795131|Placebo Comparator|Placebo|Placebo group (N=60) that will receive placebo tablets and 60 mg of Fe and 400µg of folate daily.
10034251|NCT01795144|Active Comparator|Healthy controls|"Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
10034252|NCT01795144|Experimental|Monogenic diabetes|"Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
10034253|NCT01795157|Experimental|CCADSS|questionnaire completed using i-Pad
10034254|NCT01795157|Active Comparator|pen-paper|Questionnaire completed using pen and paper
10034255|NCT01795170||Test Group|Patients receiving a lysine restricted diet adjunct to pyridoxine therapy will be considered as participants in the 'exposure'/test group
10034256|NCT01795170||Control Group|Patients on pyridoxine mono-therapy will be participants in the 'control' group
10037205|NCT01822964|Active Comparator|targeted brain cooling|In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
9473691|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I & II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
9473692|NCT03597646|Experimental|Kinesio Taping|Kinesio Taping group consisted of 19 patients. Kinesio Tape was applied 2 times a week for a period of 4 weeks. Kinesio Taping was applied for musculus diaphragmaticus, musculus externus obliquus abdominis and internus obliquus abdominis.
9473693|NCT03597646|Active Comparator|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
9473694|NCT03597646|No Intervention|Control|Control group also consisted of 19 CHF patients. No interventions were applied for them. Pharmacological treatment of control group continued and they were advised for using their medication properly.
9473695|NCT03597620|Experimental|Patients with plaque psoriasis 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions.
9473696|NCT03597620|Experimental|Patients with stable dose of biologic treatment & 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
9473697|NCT03597620|Experimental|Patients with Scalp Psoriasis|For the subgroup for scalp psoriasis, patient will use the shampoo Head & Shoulders formula with 1% Pyrithione Zinc as the active ingredient
10034257|NCT01795183|Experimental|Amisulpride|Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week
10034258|NCT01795209|Experimental|Ranibizumab group|Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
9473701|NCT03597594|Active Comparator|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 2 - RAG1, RAG2 (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
9473702|NCT03597594|Experimental|Donor Lymphocyte Infusions|"Phase I:~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose >0.3 to ≤0.56; Dose level 2, Dose >0.56 to ≤1.8; Dose level 3, Dose >1.80 to ≤3.0~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.~Phase II:~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.~Cells for infusion are prepared using the CliniMACS System."
9473703|NCT03597555|Experimental|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
9473704|NCT03597555|Placebo Comparator|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
9473705|NCT03597542|Experimental|Maltodextrin|Participants will consume 56g of maltodextrin dissolved in 500mL of water.
9473706|NCT03597542|Experimental|Egg|Participants will consume 36g of spray-dried egg powder (equivalent to 3 eggs) dissolved in 500mL of water.
9473707|NCT03597516|Experimental|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
9473708|NCT03597516|Placebo Comparator|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
9473709|NCT03597503|Experimental|Flexible dose of SPN-810|Subjects will be treated with flexible dose of SPN-810
9473710|NCT03597503|Placebo Comparator|Placebo|Subjects will be treated with Placebo
9473711|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
9473712|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
9473713|NCT03597477||Control|Patients with no developmental diagnoses
9473714|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
9473715|NCT03597451||Control|Healthy individuals of similar age and sex to patients
9473716|NCT03597412|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
9473717|NCT03597412|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
10034259|NCT01795209|Sham Comparator|Standard of care group|Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.
9473718|NCT03597386||All Participants|
9473719|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
9473720|NCT03597373||not reintubation|Favourable respiratory function
9473721|NCT03597334||critical ill patients|critical ill patients who admit to ICU
9473722|NCT03597321|Experimental|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
9473723|NCT03597321|No Intervention|Arm B- No intervention|
9473724|NCT03597308|Active Comparator|Opioid Group|
9473725|NCT03597308|Active Comparator|NSAID group|
9473726|NCT03597308|Active Comparator|Acetaminophen|
9473727|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
9473728|NCT03597282|Experimental|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
9473729|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
9473730|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
9473731|NCT03597282|Experimental|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
10034260|NCT01795222|Active Comparator|Oral Midazolam|Midazolam oral syrup 1mg/Kg twenty minutes before starting the procedure
9473732|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
9473733|NCT03597282|Experimental|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
9473734|NCT03597256|Experimental|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
9473735|NCT03597256|No Intervention|Control Group|No treatment
9473736|NCT03597243|Experimental|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
9473737|NCT03597243|No Intervention|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
9473738|NCT03597230|Experimental|patients operated on for pancreatic resection|All consecutive patients operated on for pancreatic resection
9473739|NCT03597217|Experimental|Cohort A_Active|3 single doses treatment of PF-05221304
9473740|NCT03597217|Experimental|Cohort B_Active|Repeated doses of PF-05221304
9473741|NCT03597217|Placebo Comparator|Cohort B_Placebo|Repeated doses of placebo
9473742|NCT03597204|Other|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
9473743|NCT03597191|Experimental|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
10034261|NCT01795222|Placebo Comparator|placebo|placebo oral syrup twenty minutes before starting the procedure
9473744|NCT03597191|Placebo Comparator|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
9473745|NCT03597152|Experimental|Treatment|WelTract
9473746|NCT03597152|Placebo Comparator|Control|Inert Placebo
9473747|NCT03597100|Experimental|Cala TWO|Two 40-minute stimulation sessions daily, separated by at least two hours
9473748|NCT03597087|Experimental|General anesthesia|Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol
9473749|NCT03597087|Experimental|Spinal anesthesia|Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine
9473750|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
9473751|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
9473752|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
9473753|NCT03597048|Experimental|Curriculum|Participants received only the curriculum intervention
9473754|NCT03597048|Active Comparator|Contact|Participants received only the contact intervention
9473755|NCT03597048|Active Comparator|Materials|Participants received only the materials intervention
9473756|NCT03597048|Experimental|Curriculum and Contact|Participants received both curriculum and contact interventions
9473757|NCT03597048|Experimental|Curriculum and Materials|Participants received curriculum and materials interventions
9473758|NCT03597048|Active Comparator|Contact and Materials|Participants received contact and materials intervention
9473759|NCT03597048|Active Comparator|Curriculum, Contact and Materials|Participants received curriculum, contact and materials interventions
9473760|NCT03597048|No Intervention|No intervention|Participants received no intervention
9473761|NCT03597035|Experimental|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
9473762|NCT03596996|Experimental|Ferrous Sulfate|Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.
9473763|NCT03596996|Placebo Comparator|Placebo|
9473764|NCT03596983|Experimental|Short Sleep Patients|
9473765|NCT03596970|Experimental|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
9473766|NCT03596970|Active Comparator|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
9473767|NCT03596957|Active Comparator|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
9473768|NCT03596957|No Intervention|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
9473769|NCT03596944||Statin|History of statin use for primary prevention
9473770|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
9473771|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
9473772|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
9473773|NCT03596918|Experimental|Supportive care (vincristine sulfate, bleomycin sulfate)|Patients receive vincristine sulfate IV over 1-2 minutes and bleomycin sulfate IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9473774|NCT03596892|Experimental|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
9473775|NCT03596892|Active Comparator|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
9473776|NCT03596879|Experimental|dCBTI|Online access to the digital CBTI program Sleepio.
9473777|NCT03596879|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations.
9473778|NCT03596853|Experimental|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
9473779|NCT03596853|Sham Comparator|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
9473780|NCT03596827|Active Comparator|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
9473781|NCT03596827|Experimental|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
9473782|NCT03596827|Experimental|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
9473783|NCT03596827|Experimental|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
9473784|NCT03596827|Experimental|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
9473785|NCT03596788|Experimental|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
9473786|NCT03596788|Placebo Comparator|Placebo Beverage|An artificially-sweetened beverage containing aspartame
9473787|NCT03596775|Experimental|Dexmedetomidine group|the children received 0.5 μg/kg of intravenous dexmedetomidine over 10 minutes after induction of anesthesia
9473788|NCT03596775|Placebo Comparator|Control Comparator group|the children received 10ml saline over 10 minutes after induction of anesthesia
9473789|NCT03596749|Experimental|Sevelamer Carbonate|Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals
9473790|NCT03596749|No Intervention|Control|blank-control
9473791|NCT03596736|Experimental|Elbow Hemiarthroplasty|
9473792|NCT03596736|Active Comparator|Total Elbow Arthroplasty|
9473793|NCT03596710|Experimental|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
9473794|NCT03596658|Experimental|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
9473795|NCT03596632|Experimental|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
9473796|NCT03596619|Experimental|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).
9473797|NCT03596619|No Intervention|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
9473798|NCT03596606|Experimental|Myofunctional Motor Control Exercises|"Both groups will be treated with Osteopathic treatment and in one of them the myofunctional motor control treatment will be added as intervention. The experimental group will be the one that will receive the combined treatment.~The patient will receive five sessions, one session every week."
9473799|NCT03596606|Active Comparator|Osteopathic Treatment|The control group will receive only osteopathic treatment (TO). The patient will receive five sessions, one session every week.
9473800|NCT03596593|Experimental|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
9473801|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
9473802|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity < 296 mOsm/L
9473803|NCT03596567|Experimental|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
9473804|NCT03596567|Experimental|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
9473805|NCT03596567|Experimental|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
9473806|NCT03596541|Experimental|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
9473807|NCT03596541|Active Comparator|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
9473808|NCT03596528|Other|Lung biopsy|Lung biopsy
9473809|NCT03596515|Experimental|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
9473810|NCT03596515|No Intervention|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
9473811|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
9473812|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
9473813|NCT03596476|Experimental|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
9473814|NCT03596463||Group A|Patients treated according to suggestions of tumor board
9473815|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
9473816|NCT03596437|Experimental|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
9473817|NCT03596437|Experimental|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
9473818|NCT03596424|Active Comparator|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
9473819|NCT03596424|Active Comparator|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
9473820|NCT03596424|Active Comparator|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
9473821|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
9473822|NCT03596372|Experimental|Patients with Solid tumors|Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme.
9473823|NCT03596372|Experimental|Patients with Gastric cancer|"Expansion with patients having gastric and/or gastroesophageal adenocarcinoma:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
9473824|NCT03596372|Experimental|Patients with Colorectal cancer|"Expansion with patients having colorectal cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
9473825|NCT03596372|Experimental|Patients with Non-small-cell-lung cancer|"Expansion with patients having adeno Non-small-cell-lung cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
9473826|NCT03596372|Experimental|Low-dose expansion|Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD).
9473827|NCT03596359|Experimental|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
10034262|NCT01795235|Other|Saline s.c. injection and placebo tablet|Saline s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
10034263|NCT01795235|Other|glucagon s.c. injection and placebo tablet|1 mg glucagon s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
10034264|NCT01795235|Other|Saline s.c. injection and atenolol tablet|Saline s.c. injection and 100 mg atenolol tablet
10034265|NCT01795235|Other|glucagon s.c. injection and atenolol tablet|1 mg glucagon s.c. injection and 100 mg atenolol tablet
9473828|NCT03596359|Active Comparator|Control group|The control group received routine treatment
10034266|NCT01795248|Experimental|Liraglutide|1.8 mg liraglutide, subcutaneous, once-daily for five years
10034267|NCT01795248|Placebo Comparator|Placebo|Placebo, subcutaneous, once-daily for one year
10034268|NCT01795248|No Intervention|Control|Control without previous GDM.
9473829|NCT03596346|Active Comparator|Test group|20 g of rapeseed ingredient (RI) daily
9473830|NCT03596346|Placebo Comparator|Control group|0 g of rapeseed ingredient (RI) daily
9473831|NCT03596307|Experimental|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
9473832|NCT03596307|Placebo Comparator|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
9473833|NCT03596294|Experimental|Treatment sequence AB|"Period A:~Saline + clazosentan~Period B:~Rifampicin + clazosentan"
9473834|NCT03596294|Experimental|Treatment sequence BA|"Period B:~Rifampicin + clazosentan~Period A:~Saline + clazosentan"
9473835|NCT03596281|Experimental|Cohort A|
9473836|NCT03596281|Experimental|Cohort B|
9473837|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
9473838|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
9473839|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
9473840|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
9473841|NCT03596216|Experimental|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
9473842|NCT03596216|Experimental|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
9473843|NCT03596190|Other|Assessment arm|
9473844|NCT03596125|Experimental|N-acetylcysteine (NAC)|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
9473845|NCT03596125|Placebo Comparator|Placebo|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
9473846|NCT03596112|Experimental|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
9473847|NCT03596112|Active Comparator|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
9473848|NCT03596099|Experimental|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
9473849|NCT03596099|Placebo Comparator|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
9473850|NCT03596086|Experimental|ADV/HSV-tk (gene therapy)|"The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.~Patient can receive second treatment of HSV-tk after 6 months"
9473851|NCT03596060|Active Comparator|General anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will be randomly assigned to undertake surgery under general anesthesia in the first 48 hours. Anesthetics to be used are propofol, fentanyl and rocuronium. Maintenance will be achieved with remifentanyl and propofol (TIVA) and the depth of anesthesia will be monitored by BIS. Morphine will be administered bolus IV immediately postoperatively.
9473852|NCT03596060|Active Comparator|Regional anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
9473853|NCT03596047|Experimental|Standard treatment + Radial wave therapy|Sildenafil according to the degree of patient involvement + 6 sessions of radial waves.
9473854|NCT03596047|Placebo Comparator|Standard treatment + Placebo therapy|Sildenafil according to the patient's degree of affectation + 6 sessions of placebo therapy.
9473855|NCT03596034|Experimental|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
9473856|NCT03596008|Experimental|Active1|freeze-dried strawberry powder (25 g) in active drink
9473857|NCT03596008|Placebo Comparator|Placebo|Placebo drink
10034269|NCT01795261||Lifestyle counseling|Prevention of mother to child transmission of HIV
9473858|NCT03595982|Experimental|Procardia XL 30 mg|Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
9473859|NCT03595982|Active Comparator|Procardia XL 60 mg|Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.
9473860|NCT03595969||acute leukemia group|150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
9473861|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
10034270|NCT01795261||Lifestyle counseling Male|male partners and PMTCT completion rate among HIV-infected pregnant women.
10034271|NCT01795274|Experimental|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
10034272|NCT01795287|Active Comparator|Spinal anesthesia|Spinal anesthesia
10034273|NCT01795287|Active Comparator|General anesthesia|General anesthesia with fentanyl, propofol and rocuronium and sevoflurane
9480468|NCT03533231|Experimental|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
9480469|NCT03533192|Experimental|Receipt of It's Your Game...Keep it Real|It's Your Game...Keep it Real is an HIV, STI, and teen pregnancy prevention program
9480470|NCT03533192|No Intervention|Usual care|Students received their regular health education.
9480471|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 placebo (A)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0."
9480472|NCT03533179|Experimental|Esmolol+glucagon 1 placebo (B)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0."
9480473|NCT03533179|Experimental|Esmolol+glucagon 1 (C)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
9480474|NCT03533179|Experimental|Esmolol-placebo+glucagon 2 (D)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)"
9480475|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 (E)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
9480476|NCT03533166|Experimental|Chlorhexidine|Mechanical treatment + 0.03% chlorhexidine + 0.05% CPC mouthrinse
9480477|NCT03533166|Placebo Comparator|Placebo|Mechanical treatment + Placebo mouth rinse
9480478|NCT03533153|Experimental|WJ-MSC cells implantation group|"MSC cells (allogeneic transplantation from WJ-MSC primary cells); the frequency: for one time within12h after emergency coronary artery revascularization; dose levels: 1X10^8; method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
9480479|NCT03533153|Placebo Comparator|CTSTMD PBS without WJ-MSC group|"Saline only was injected in the control group. The frequency: for one time 2-12h after emergency coronary artery revascularization. Dose levels: the same dosage given to MSC group. Method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
9480480|NCT03533140|Active Comparator|DUCEST Neurostimulator V Group A|
9480481|NCT03533140|Sham Comparator|DUCEST Neurostimulator V Group B|
9480482|NCT03533127|Experimental|LY01008+Carboplatin/Paclitaxel|Drug: LY01008 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
9480483|NCT03533127|Experimental|Bevacizumab + Carboplatin/Paclitaxel|Drug: Bevacizumab Bevacizumab 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
9480484|NCT03533101|Experimental|Tocilizumab 4 mg/kg|Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
9480485|NCT03533101|Active Comparator|Tocilizumab 8 mg/kg|Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation
10034274|NCT01795300|Experimental|Carbon Ion Radiotherapy|Treatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
10034275|NCT01795300|Experimental|Proton Therapy|Treatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
10034276|NCT01795300|Experimental|Hypofractionated Photon Therapy|Treatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
9473862|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
9473863|NCT03595943|Experimental|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
9473864|NCT03595943|Active Comparator|Regular hospital diet|Moderate glycemic index diet based on hospital menus
9473865|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
9473866|NCT03595891||Adult with acute PE before the introduction of apixaban|
10034277|NCT01795300|Active Comparator|Conventional Photon Radiotherapy|Treatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
10034278|NCT01795313|Experimental|HLA-A2 restricted tumor antigen vaccine|This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod
10034279|NCT01795326||Germany|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
10034280|NCT01795326||United Kingdom|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
10034281|NCT01795326||Spain|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
10034282|NCT01795326||Hungary|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
10034283|NCT01795326||Netherlands|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
10034284|NCT01795326||Sweden|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
10034285|NCT01795326||Romania|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
9473867|NCT03595891||Adult with acute PE after the introduction of apixaban|
9473868|NCT03595865|Experimental|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
9473869|NCT03595865|Experimental|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
9473870|NCT03595852|Experimental|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
9473871|NCT03595852|Placebo Comparator|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
9473872|NCT03595839|Active Comparator|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
9473873|NCT03595839|Active Comparator|Fistulotomy without Marsupialization|lay open of the fistula track
9473874|NCT03595826|Experimental|1. Neurostimulant pharmaceutical drugs..|1.Participants receiving medicinal drugs, such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.
9473875|NCT03595826|Experimental|2. Exercise Intervention|Participants receiving a minimum of 8 sessions of exercise intervention, for the duration of an hour each session. Exercises will be to build muscle tone, improve core stability, enhance balance, improve fine and gross motor skills and visual motor integration.
9473876|NCT03595826|Experimental|3. Neurostimulants + Exercise intervention|See Arms 1 and 2 above. Both interventions administered together: Pharmaceutical drugs plus exercise intervention
9473877|NCT03595826|Experimental|4. Control Group|Participants will not receive any intervention during the research process. They will be given an intervention after the research is completed.
9473878|NCT03595813|Experimental|Patients treated with Immune Checkpoint Blockade|
10034286|NCT01795326||Italy|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
10034287|NCT01795339|Experimental|AZD3293|Part 1: Up to 6 sequential cohorts of healthy elderly subjects are planned, with multiple ascending doses, starting with 5 mg (subject to confirmation by the Safety Review Committee) Part 2: Up to 16 mild-to-moderate AD patients administered one to up to 3 dosage levels of AZD3293
10034288|NCT01795339|Placebo Comparator|Placebo|Part 1: Placebo given (2 subjects in each cohort) Part 2: Placebo given (up to 4 subjects)
10034289|NCT01795365|Active Comparator|Epstein + (group I)|"Epstein + (Group I) PSA <10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion <50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0"
10034290|NCT01795365|Experimental|Epstein - (group II)|"Epstein - (Group II) PSA <15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion <50% and ≤8mm; mp MRI positive; T1-T2c N0 M0"
10034291|NCT01795391||Tegaderm HP|Patients whose intravasculare devices dressings are made exclusevely with Tegaderm HP dressings.
10034292|NCT01795391||Advanced|Patients whose intravasculare devices dressings are made exclusevely with Advanced dressings
10034293|NCT01795404|Experimental|Inquiry Based Stress Reduction (IBSR) Program|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts. Through the use of self-inquiry practices participants are taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants take an active role in investigating their stressful thoughts, and by this regulating their stress and managing symptoms and emotions, thus enabling them to cope better with the distress related to the possibility of cancer.
10034294|NCT01795404|No Intervention|Control group|Waited-list control
10034295|NCT01795417|Experimental|XP200 device RF treatments|Every subject in the study will undergo 4 treatments and will be followed up for 6 months with photoraphic 3 evaluations: before treatment, 3 and 6 months follow-up. Photographs will be scored on a Fitzpatrick scale by 3 blinded evaluators.
10034296|NCT01795430|Experimental|Treatment (radiation therapy/chemotherapy, stem cell infusion)|"BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.~BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
10034297|NCT01795443|Active Comparator|Healthy volunteers 1|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
9473879|NCT03595800|Experimental|haploidentical related donors|
9473880|NCT03595800|Active Comparator|Matched unrelated donor|
9473881|NCT03595787|Experimental|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
9473882|NCT03595735|Experimental|Treatment Group|Receives treatment with the Zenflow Spring System
9473883|NCT03595722|Experimental|Early rectal cancer|Patients with early rectal cancer undergoing a treat and resect pathway - patients will be treated with high intensity focused ultrasound 7-10 days prior to the surgical resection of their rectal cancer
9473884|NCT03595722|Experimental|Late pelvic cancer|Patients with late pelvic (rectal, endometrial, cervical) cancer will undergo a treat and observe pathway - patients will be treated with high intensity focused ultrasound and their response will be observed
9473885|NCT03595709|Experimental|combined tablet (EFV 400,TDF 300, 3TC 300)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
9473886|NCT03595696|Experimental|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes for Core Muscle Strength training and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
10034298|NCT01795443|Active Comparator|Healthy volunteers 2|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
10034299|NCT01795443|Active Comparator|Healthy volunteers 3|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
10037206|NCT01822964|Placebo Comparator|no use of targeted brain cooling|In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
9473887|NCT03595696|Active Comparator|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks (Core Muscle Strength Training).
9473888|NCT03595683|Experimental|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
9473889|NCT03595683|Experimental|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
9473890|NCT03595670||experimental group|"• Patients diagnosed bipolar in mania, depression or euthymic phases according DSM-IV critiera by psychiatrist~standardized questionnaires and interview will be performed"
10034300|NCT01795443|Active Comparator|Healthy volunteers 4|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
10034301|NCT01795443|Active Comparator|Healthy volunteers 5|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
10034302|NCT01795443|Active Comparator|Healthy volunteers 6|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
10034303|NCT01795443|Experimental|Back pain patients 1|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
10034304|NCT01795443|Experimental|Back pain patients 2|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
9473891|NCT03595644|Experimental|SBRT plus TKI group|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
9473892|NCT03595644|Active Comparator|TKI treatment group|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
9473893|NCT03595631|Active Comparator|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
9473894|NCT03595631|Experimental|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
9473895|NCT03595605|Experimental|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
9473896|NCT03595605|Active Comparator|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
9473897|NCT03595540|Experimental|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
9473898|NCT03595527|Experimental|Patients consulting in the emergency room|Patients consulting in the emergency room.
9473899|NCT03595514|Active Comparator|Single Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
9473900|NCT03595514|Experimental|Double Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
9473901|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
9473902|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
9473903|NCT03595488|Experimental|Treatment arm|"Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.~300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection"
9473904|NCT03595475||Psychiatric RBD cases|"Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~The onset of mental symptoms preceded the onset of RBD:~Onset of RBD symptom was younger than 50 years old (as most patients with pRBD tended to be younger at mid-40s with an earlier age onset than typical iRBD)."
9473905|NCT03595475||Psychiatric cases|"Age- and sex- matched with pRBD proband;~Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG;~Free of neurodegenerative diseases."
9473906|NCT03595475||Age- & sex-matched health control|"Age- and sex- matched with pRBD proband;~Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on RBDQ-HK and v-PSG;~Free of neurodegenerative diseases."
10034305|NCT01795443|Experimental|Back pain patients 3|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
9473907|NCT03595462|Experimental|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to ~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
9473908|NCT03595462|Placebo Comparator|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
9473909|NCT03595436|Experimental|Pea Protein Breakfast Preload|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preloads will be standardized to ~325 kcal. The preloads will include the same fat content but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
9473910|NCT03595436|Placebo Comparator|Carbohydrate Control Breakfast Preload|The study participants will be provided with a control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
9473911|NCT03595436|Active Comparator|Whey Protein|The study participants will be provided with an active control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein amount and type and carbohydrate amount. All ingredients are GRAS listed and approved.
9473912|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
9473913|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
9473914|NCT03595410||Recurrence laryngeal cancer|
9473915|NCT03595410||No recurrence laryngeal cancer|
9473916|NCT03595397|Active Comparator|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
9473917|NCT03595397|Active Comparator|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
9473918|NCT03595397|Active Comparator|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
9473919|NCT03595384|Experimental|Soccer-based adaptation to the DPP|Participants taking part in a 24 week soccer program as part of diabetes prevention.
9473920|NCT03595371|Experimental|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
9473921|NCT03595358|Experimental|Arm|"Ellume Home Flu Test and ellume.lab Flu A+B Test~Upper respiratory tract samples from participants will be tested with:~Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture."
9473922|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
9473923|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
9473924|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
9473925|NCT03595332|Experimental|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
9473926|NCT03595332|Experimental|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
9473927|NCT03595319|Experimental|Young patients|Patients between 19 and 40 years-old
9473928|NCT03595319|Experimental|Elder patients|Older than 65
9473929|NCT03595306|Experimental|Prebiotic A|
9473930|NCT03595306|Experimental|Prebiotic B|
9473931|NCT03595306|Experimental|Prebiotic C|
9473932|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
9473933|NCT03595254|Experimental|Thrive Intervention|Online cognitive behavior therapy program
9473934|NCT03595254|No Intervention|Waitlist Control|Wait 8 weeks before receiving program access
9473935|NCT03595241|Experimental|Group A - active treatment|
9473936|NCT03595241|No Intervention|Group B - conservative management|
9473937|NCT03595202|Other|Step1:4㎎ TID|TS-143 12mg total dose/day or Placebo
9473938|NCT03595202|Other|Step2:11㎎ TID|TS-143 33mg total dose/day or Placebo
9473939|NCT03595189|Experimental|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
9473940|NCT03595189|Experimental|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
9473941|NCT03595189|Experimental|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
9473942|NCT03595189|Placebo Comparator|Placebo|Saline solution for infusion
9473943|NCT03595163|Experimental|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
9473944|NCT03595163|Active Comparator|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
9473945|NCT03595137|Experimental|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
9473946|NCT03595137|Placebo Comparator|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
9473947|NCT03595111|Experimental|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
9473948|NCT03595085|Experimental|catheter directed interventions|Those patients will undergo catheter directed fragmentation followed by local thrombolysis using streptokinase
9473949|NCT03595085|Active Comparator|systemic thrombolysis|Those patients will receive systemic streptokinase
9473950|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
9473951|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
9473952|NCT03595046|Experimental|erector spinae plane block group (group E)|ultrasound-guided erector spinae plane block
9473953|NCT03595046|Active Comparator|thoracic paravertebral block group (group P)|ultrasound-guided thoracic paravertebral block
9473954|NCT03595033|Experimental|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
9473955|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
9473956|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
9473957|NCT03595007||Phase 1|
9473958|NCT03595007||Phase 2|
9473959|NCT03595007||Phase 3|
9473960|NCT03594994|No Intervention|Control|Normal sleep habits < 6h
9473961|NCT03594994|Experimental|Sleep Extension|Extend time-in-bed to 8 hours
9473962|NCT03594981|Experimental|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
9473963|NCT03594968||polycystic ovary syndrome (PCOS)|"Presence of ≥2 of the following:~oligomenorrhea and/or anovulation~Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism."
9473964|NCT03594968||healthy|healthy patients who had no polycystic ovary
9473965|NCT03594929|Active Comparator|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
9473966|NCT03594929|Sham Comparator|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
9473967|NCT03594916|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
9473968|NCT03594916|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
9473969|NCT03594903|Experimental|Expectation violation (positive outcome of therapy)|Experimental: patients' report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
9473970|NCT03594903|Other|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
9473971|NCT03594890|Experimental|OVX836 (Intramuscular)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
9473972|NCT03594890|Placebo Comparator|Placebo (Intramuscular)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
9473973|NCT03594890|Experimental|OVX836 (Intranasal)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
9473974|NCT03594890|Placebo Comparator|Placebo (Intranasal)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
9473975|NCT03594877|Experimental|Psoriasis patients|Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
9473976|NCT03594877|No Intervention|Healthy volunteers|Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
9473977|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
9473978|NCT03594851|Experimental|Administration of individualized advice|"Administration of individualized advice to improve the quality of older people's sleep, based on the following interventions :~Pittsburgh Sleep Quality Index, Sleep diary, Mini Mental State Examination, Autonomy assessment (Katz Index of Independence in Activities of Daily Living~& Lawton Instrumental Activities of Daily Living), Neuropsychiatric Inventory (Cummings) for the caregiver, if applicable, Mini Zarit Caregiver Burden Scale, for the caregiver, if applicable, Cornell Scale for Depression in Dementia, Quality of Life in Alzheimer's Disease, Neuropsychiatric Inventory"
9473979|NCT03594838|Experimental|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
9473980|NCT03594838|Experimental|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
9473981|NCT03594838|No Intervention|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
9473982|NCT03594825|Experimental|nighttime group|patients with nocturnal hypertension taking valsartan at nighttime
9473983|NCT03594825|Active Comparator|daytime group|patients with nocturnal hypertension taking valsartan at daytime
9473984|NCT03594812|Experimental|Experimental group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region.
10034306|NCT01795443|Experimental|Back pain patients 4|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
9473985|NCT03594812|Placebo Comparator|Placebo group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region but the radiofrequency device was switched off- Radiofrequency without power.
9473986|NCT03594799|Experimental|Bed Rest Control Group|60 days of strict head-down tilt bed rest
9473987|NCT03594799|Experimental|Cocktail intervention|60 days of strict head-down tilt bed rest along with a Cocktail supplementation composed of natural antioxidants XXS-2A-BR2 comprising vitamin E, Selenium and coupled with omega-3
9473988|NCT03594786|Experimental|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
9473989|NCT03594760|Experimental|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
9473990|NCT03594734|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
9473991|NCT03594734|Active Comparator|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
10034307|NCT01795443|Experimental|Back pain patients 5|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
10034308|NCT01795443|Experimental|Back pain patients 6|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
10034309|NCT01795469|Experimental|Abdominal and LE compression|Zoex compression garment during tilt testing (all straps)
10034310|NCT01795469|Experimental|abdominal compression only|Zoex compression garment use during tilt table testing (straps 4 and 5 fastened around thighs and abdomen)
10034311|NCT01795469|Experimental|Lower extremity compression only|Zoex compression garment use during tilt table testing (straps 1-4, lower extremity and thighs, fastened)
10034312|NCT01795482|Experimental|Group 2, Prewarming only before general anaesthesia|Active forced-air warming for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
10034313|NCT01795482|Experimental|Group 3, Prewarming before epidural and general anaesthesia|Active forced-air warming for 15 min before start of epidural anaesthesia and for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
9473992|NCT03594721|Experimental|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
9473993|NCT03594721|Experimental|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
9473994|NCT03594708|Placebo Comparator|Placebo|placebo consisting of rice starch, light olive oil, and vegetable oil
9473995|NCT03594708|Active Comparator|Supplement|active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc
9473996|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
9473997|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
9473998|NCT03594682|Experimental|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
10034314|NCT01795482|No Intervention|Group 1, control group|No active warming before start of epidural or general anaesthesia, active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
9473999|NCT03594682|Active Comparator|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
9474000|NCT03594669|Experimental|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
9474001|NCT03594656|Experimental|Early-start Group|Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
10034315|NCT01795521|Experimental|Stereotactic Body Radiotherapy (SBRT)|All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
9474002|NCT03594656|Placebo Comparator|Delayed-start Group|Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
9474003|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
9474004|NCT03594643||control|patient not smoking nor using electronic cigarette
9474005|NCT03594617|Experimental|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
9474006|NCT03594617|No Intervention|Control institutions|The control institutions do not receive any intervention.
9474007|NCT03594604|Experimental|Norethindrone|Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.
9474008|NCT03594604|Active Comparator|Oral Contraceptive Pills|Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.
9474009|NCT03594578|Experimental|Episodic future thinking|"Participants will complete a guided interview designed to elicit a number of personalized events that are likely to occur during various future time frames (e.g., 1 day, 1 week, 3 months, 1 year, etc.), as well as text cues designed to prompt episodic future thinking (e.g., In 3 months, I will be at my daughter's wedding). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
9474010|NCT03594578|Sham Comparator|Episodic recent thinking (control)|"Participants will complete a guided interview designed to elicit a number of personalized events that occurred in the recent past (e.g., earlier today, yesterday), as well as text cues designed to prompt episodic thinking (e.g., Earlier today, I was playing tennis with my wife.). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
9474011|NCT03594565|Experimental|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.~Dosage: 2 puffs."
9474012|NCT03594539|No Intervention|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
9474013|NCT03594539|Placebo Comparator|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
9480486|NCT03533088|Experimental|Hospitalized rehabilitation|Patients in this group will recieve rehabilitation program twice in a week at our clinic after the surgical procedure until post-operative 12 weeks.
10034316|NCT01795599|Experimental|mifepristone/misoprostol|
10034317|NCT01795599|Active Comparator|misoprostol|
10034318|NCT01795599|Active Comparator|mifepristone|
10034319|NCT01795612|Other|Arm A|6-month ETP, during adjuvant or neoadjuvant therapy
10034320|NCT01795612|Other|Arm B|6-month ETP, after adjuvant or neoadjuvant therapy
10034321|NCT01795612|Other|Arm C|12-monthETP, during and after adjuvant or neoadjuvant treatment
10034322|NCT01795651||Take-Home message|
10034323|NCT01795664|Active Comparator|Seretide Evohaler|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
10034324|NCT01795664|Experimental|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
9474014|NCT03594526|Experimental|Maternal support to become mother|"Maternal support to become mother: is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of:~Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~Four Educational sessions and support sessions for maternal empowerment in each home visit.~Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
9474015|NCT03594526|Active Comparator|Control group: usual Care|The participants will receive the usual education about the care of the mother during the puerperium, the care of the newborn, including breastfeeding.
9474016|NCT03594513|Active Comparator|MCAF+PR+CTG|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive the connective tissue graft harvested from the palate on the recessed area before the sutures.Then, the flap will be coronally positioned and sutured to completely cover the graft.
9474017|NCT03594513|Experimental|MCAF+PR+XMD(Mucoderm®)|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive a porcine acellular dermal matrix on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
10034325|NCT01795677|Experimental|RUXOLOTINIB|Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone
10034326|NCT01795703|Experimental|Abiraterone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
10034327|NCT01795729|Experimental|1: Coronary stent+optimal medical therapy|Coronary stent on top of optimal medical therapy
9474020|NCT03594461|Experimental|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
10034328|NCT01795729|Active Comparator|2: Optimal medical therapy|Optimal medical therapy
10034329|NCT01795742|Active Comparator|Electric Nebulizer|Pulmo-Aide Model 5650D
10034330|NCT01795742|Experimental|Human-Powered Nebulizer|Human-Powered
10034331|NCT01795755|Experimental|Treat as usual + Horse assisted therapy ( HAT)|Treatment as usual means mentalization based inpatient treatment. Horse assisted therapy(HAT) is a structured program of 12 X 90 minute sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists.
10034332|NCT01795755|Active Comparator|Treatment as usual|Treatment as usual means mentalization based inpatient treatment.
10034333|NCT01795768|Experimental|Single Treatment Arm|16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.
10034334|NCT01795781||Patients receiving a new anticoagulant|Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively
10034335|NCT01795794|Experimental|LOSEC|"LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the control group of herself."
10034336|NCT01795820|Other|Group 1 (no loading)|Patients allocated to this group will not receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start), while ticagrelor 90 mg bis in die will be administered from the day of the pharmacological shift on.
10034337|NCT01795820|Other|Group 2 (loading)|Patients allocated to this group will receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start). On the very day of the pharmacological shift, patients allocated in Group 2 will receive Ticagrelor 180 mg (loading dose) on the morning and Ticagrelor 90 mg on the evening, while ticagrelor 90 mg bis in die will be administered from the day after the pharmacological shift on.
10034338|NCT01795846||monosensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites
10034339|NCT01795846||polysensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.
10034340|NCT01795872|Other|Several diagnostic procedures|
10034341|NCT01795885|Experimental|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the show 16 and Pregnant once a week for 4 weeks."
10034342|NCT01795924|Experimental|PD-616 plus low-dose Cytarabine|Patients will receive low-dose cytarabine (20 mg/m2) subcutaneously (SC) once daily (QD), followed by a 1-hour intravenous (IV) infusion of PD-616 for 5 consecutive days during Week 1 (D1 to D5) and Week 2 (D8 to D12) of a 28-day treatment cycle. Cytarabine is to be administered approximately 30 minutes before PD-616. In Phase 1 part, the starting dose of PD-616 is 0.0875 mg/m2, with sequential increments of 0.0375 mg/m2, to 0.125, and 0.1625 mg/m2. The dose of PD-616 to be administered in Phase 2 part will be the maximum tolerated dose (MTD)determined from Phase 1 part of the study.
10034343|NCT01795950|Experimental|0.5 M PLX-PAD|0.5 million (M) PLX-PAD cells per kg body weight
9474021|NCT03594461|Experimental|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
9474022|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
9474023|NCT03594435|Experimental|Ibudilast|10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
9474024|NCT03594435|Placebo Comparator|Placebo Oral Capsule|matched to experimental drug
9474025|NCT03594396|Experimental|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
9474026|NCT03594370||control|Limbal image by OCT in normal subjects.
9474027|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
9474028|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
9474029|NCT03594357||Multiple sclerosis|MS patients (EDSS: 0-5,5)
9474030|NCT03594357||Control|Healthy individuals without chronic disease
9474031|NCT03594344|Experimental|Hyperbaric oxygen therapy|30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.
9474032|NCT03594344|No Intervention|Control group|Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.
10034344|NCT01795950|Experimental|1 M PLX-PAD|1.0 million (M) PLX-PAD cells per kg body weight
10034345|NCT01795950|Experimental|2 M PLX-PAD|2.0 million (M) PLX-PAD cells per kg body weight
10034346|NCT01795963|Placebo Comparator|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
10034347|NCT01795963|Active Comparator|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress.
10034348|NCT01795976|Experimental|NY-ESO-1 T cells|"NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype A serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg.."
10034349|NCT01795989||Healthy Volunteers|Research only musculoskeletal (MSK) MRI for healthy volunteers.
10034350|NCT01795989||Clinical Efficacy|Clinically indicated musculoskeletal (MSK) MRI with sequences obtained using this pediatric elbow coil.
10034351|NCT01796002|Experimental|Experimental: Romidepsin plus CHOP|"Patients in experimental arm receive romidepsin plus CHOP (Ro-CHOP) administered in 3 week cycles for 6 cycles.~Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks."
10034352|NCT01796002|Active Comparator|Standard: CHOP|Patients in control Arm receive cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
10034353|NCT01796015|Other|For the 97 patients|"day 0: ultrasound of ONSD (= 4 measurements: 1 transverse and 1 sagittal for each eye) + transcranial Doppler at T-15 (15 minutes before ICP measurement), within 1h following ICP measurement, and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~day 1: ONSD ultrasound + transcranial Doppler in the morning and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~days 2 and 3 : same as day 1~when leaving the intensive care unit: Pediatric Overall Performance Category (POPC) scale"
10034354|NCT01796015|Other|For the control group|one single ONSD in addition to their usual care (4 measurements: 1 transverse and 1 sagittal for each eye) in the morning in absence of painful sensation
10034355|NCT01796015|Other|For the learning curve|minimum 15 ONSD ultrasounds will be performed by each of the 15 intensive care doctor or interns expected. One ONSD ultrasound corresponds to 2 measurements: 1 transverse and 1 sagittal. Each volunteer will have maximum 30 ONSD ultrasound measures over a 1 month period.
9474033|NCT03594331|Experimental|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
9480958|NCT05154578|Experimental|Group 4: single dose|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA, and one injection of placebo at 30 (±1) weeks GA.
10034356|NCT01796028|Placebo Comparator|Arm A : TAXOTERE® + Metformin placebo|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
10034357|NCT01796028|Experimental|Arm B : TAXOTERE® + Metformin|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
10034358|NCT01796041|Experimental|IV Injection of ICG|
10034359|NCT01796054|Experimental|Stress Free Now with group support|Randomized participants have access to online stress reduction program, Stress Free Now. Participants will log in to online program, read daily lessons and practice therapeutic exercises. They will also attend weekly group support session during 6-week program
10034360|NCT01796054|Experimental|Stress Free Now|Randomized participants have access to online stress reduction program, Stress Free Now, for 6 weeks. Participants will log into online program, read daily lessons and practice therapeutic exercises.
9474034|NCT03594331|Experimental|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
9474035|NCT03594331|Experimental|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
9474036|NCT03594292|Experimental|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
10034361|NCT01796054|No Intervention|Control|Randomized participants do not have access to online stress reduction program, Stress Free Now, nor do they attend weekly group support sessions.
9474037|NCT03594292|Active Comparator|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
9474038|NCT03594279|Experimental|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
9474039|NCT03594279|Experimental|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
9474040|NCT03594279|No Intervention|Control|This arm will receive the routine standard of care.
9474041|NCT03594253|Experimental|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman & Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
9474042|NCT03594253|No Intervention|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
9480487|NCT03533088|Experimental|Home-based rehabilitation|Patients in his groups will performed home-based rehabilitation in the early stages of the post-op period. They will com to our clinic once in a two weeks and the recieve the exercise program to perform at home until the 6. weeks of the post-operative period. After the 6. week they will come to our clinic once in a week until the post-operative 12. week.
10034362|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Interv.|Participants are randomized to motivational and family weight loss program plus the online intervention.
10034363|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Control|Participants are randomized to motivational and family weight loss intervention and then the online control program.
10034364|NCT01796067|Experimental|Basic Health Educ. & Online Interv.|Participants are randomized to the basic health education program and then the online intervention program.
10034365|NCT01796067|Active Comparator|Basic Health Educ. & Online Control|Participants are randomized to the basic health education program and then to the online control program.
10034366|NCT01796080|Active Comparator|Mueller manoeuvre|Mueller manoeuvre lasting for 20 seconds
10034367|NCT01796080|Active Comparator|Inspiratory threshold|One continuous inspiration through an inspiratory threshold load for 20 seconds
10034368|NCT01796080|Active Comparator|Expiratory apnoea|Expiratory apnoea (without respiratory effort) lasting for 20 seconds
10034369|NCT01796080|Sham Comparator|Steady state normal breathing|Steady state normal breathing for 20 seconds
10034370|NCT01796093||Digoxin cross-over ivabradine|Digoxin 0,125 mg once a day 5 days per week during 3 months. Ivabradine, 7,5 mg b.id. during 3 months.
10034371|NCT01796106|Experimental|Icon|The study clinician will provide Icon treatment to all study participants randomized to study arm 1 after the radiograph and visual exam.
9474043|NCT03594240|Active Comparator|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
9474044|NCT03594240|Placebo Comparator|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
9474045|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
10034372|NCT01796106|Active Comparator|control|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish) to all study participants randomized to study arm 2 after the radiograph and visual exam.
10034373|NCT01796119|Experimental|Ridge Splitting|"Dental implants placed using ridge splitting technique. To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
10034374|NCT01796119|Active Comparator|Implants placed using drilling technique|"Dental implants placed in the ridge with sufficient thickness using drilling technique.~To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
10034375|NCT01796132|No Intervention|Control|Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
9474046|NCT03594201||group1|A+B grade sperm count after treatment=0
10034376|NCT01796132|Experimental|SSRI/SNRI exposure|Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
10034377|NCT01796158|Experimental|cASBI+cMET|Participants will complete the computerized alcohol screening and brief intervention (cASBI)protocol at the time of an office visit and also complete the 2-session computerized Motivational Enhancement Therapy intervention (cMET).
9474047|NCT03594201||group2|0<A+B grade sperm count after treatment≤10^6
9474048|NCT03594201||group3|10^6<A+B grade sperm count after treatment<2*10^6
9474049|NCT03594201||group4|A+B grade sperm count after treatment≥2*10^6
9474050|NCT03594188|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
9474051|NCT03594188|Active Comparator|local anesthesia|Patients in this group will have RF ablation for treatment of HCC under local anesthesia.
9474052|NCT03594149|Experimental|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
9474053|NCT03594149|No Intervention|control|No levofloxacin will be given.
9474054|NCT03594136|Experimental|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
9474055|NCT03594097|Experimental|Treatment cookies|
9474056|NCT03594097|Active Comparator|Control cookies|
9474057|NCT03594019|Placebo Comparator|Control Group|Patients in the control group will follow the conventional treatment protocol combined with connective tissue graft. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Then, connective tissue graft will be harvest from palatal and fixed between bucall mocosa and bucall bone. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
9474058|NCT03594019|Experimental|Test Group|Patients in the test group will receive conventional immediate implant placement combined with socket shield technique. Briefly, the hopeless teeth will be splited from mesial and distal, the buccal part will be preseved and the palatal part will extracted. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. After 4 months, implant impression and crown delivery will be finished.
9474059|NCT03594006|Other|Cancer patients on active therapy|
9474060|NCT03593980|Experimental|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
9474061|NCT03593967|Experimental|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
9474062|NCT03593967|Experimental|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
9474063|NCT03593954|Experimental|JNJ-61393215 2 mg + Ritonavir 100 mg|Participants will receive suspension of JNJ-61393215 2 mg (Day 1 and 5) orally and tablet of Ritonavir 100 mg twice a Day (Day 4-14) orally.
9474064|NCT03593941||Alzheimer's dementia and challenging behaviour symptoms|Care home residents >65y No interventions as this is a pilot project
9474065|NCT03593941||Alzheimer's dementia and no challenging behavioural symptoms|Care home residents >65y No interventions as this is a pilot project
9474066|NCT03593941||Older adults without dementia|Care home residents >65y No interventions as this is a pilot project
9480959|NCT05154578|Placebo Comparator|Group 5: placebo|Participants will receive one injection of placebo at 22, 26 and 30 weeks (±1) GA
10034378|NCT01796158|Active Comparator|cASBI|Participants will complete the computerized screening and brief intervention protocol at the time of a primary care office visit.
10034379|NCT01796171|Experimental|Part A, Arm 1: with lilotomab pre-dosing|"Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.~COMPLETED enrolment into this arm"
9474067|NCT03593889|Experimental|Intervention group|The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.
9474068|NCT03593889|Other|Control group|The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units.
9474069|NCT03593863|No Intervention|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
9474070|NCT03593863|Experimental|Intervention Group|Physical Education (PE) Programme
10034380|NCT01796171|Experimental|Part A, Arm 2: without pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.~COMPLETED enrolment into this arm"
10034381|NCT01796171|Experimental|Part A, Arm 3: with rituximab pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.~COMPLETED enrolment into this arm"
10034382|NCT01796171|Experimental|Part A, Arm 4: with higher dose lilotomab pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.~COMPLETED enrolment into this arm"
9474071|NCT03593850|Experimental|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
9480960|NCT05151484|Active Comparator|Group 1 Low Turnover|Teriparatide (anabolic) For 1 Year
9480961|NCT05151484|Active Comparator|Group 2 Low Turnover|"Standard of Care - Control:~Treated with Alendronate (antiresorber) For 1 Year"
9480962|NCT05151484|Active Comparator|Group 3 Normal-High Turnover|Standard of Care Treatment with Alendronate (antiresorber) For 1 Year
10034383|NCT01796171|Experimental|Part A, Arm 5: with intermediate dose lilotomab pre-dosing|"Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.~COMPLETED enrolment into this arm"
10034384|NCT01796171|Experimental|Part B|"Available dosing arm - '40/15'~Open to Enrolment"
10034385|NCT01796223|Experimental|Feedback|Feedback system included in psychotherapy
10034386|NCT01796223|Active Comparator|control|Psychotherapy as usual
10034387|NCT01796262|Placebo Comparator|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
10034388|NCT01796262|Active Comparator|docosahexaenoic acid|DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
10034389|NCT01796275|Experimental|Group A|Subjects will have a core session intervention and booster intervention; questionnaire evaluation is conducted at baseline, post-session, pre-booster and 3 month after core session.
10034390|NCT01796275|Experimental|Group B|Subjects will only have a core session intervention; Questionnaire evaluation are conducted at baseline (T1-baseline), post-session (T2), 4 weeks after core session (T3) and 3 month after core session (T4).
10034391|NCT01796275|Other|Group C|Group C is a waiting list control, only questionnaire evaluations can be conducted at T1-baseline, T3- tea gathering and T4- 3 month after baseline evaluation; when finish T4 evaluation, the core session and booster can be optionally conducted subsequently.
10034392|NCT01796288|Experimental|Erlotinib & simultaneous radiotherapy|patients started simultaneously radiotherapy for all gross tumors
10034393|NCT01796288|Other|Erlotinib & no radiotherapy|patients received no radiotherapy for all gross tumors
10034394|NCT01796314|Experimental|Group A : intervention|"85 dyads patient/caregiver in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver"
10034395|NCT01796314|No Intervention|Group B : Control|There si no associated intervention
10034396|NCT01796327|Experimental|Treatment|Dacomitinib will be administered as a single oral dose and as an intravenous infusion
10034397|NCT01796340|Experimental|Food cue exposure|
10034398|NCT01796340|Active Comparator|Psycho-education|
10034399|NCT01796353|Experimental|sexual rehabilitation|exercise plus psycho-education
10034400|NCT01796353|Active Comparator|usual care|usual care
10034401|NCT01796366|Experimental|Insulin 338 + placebo|
10034402|NCT01796366|Active Comparator|Insulin glargine + placebo|
10034403|NCT01796379|Experimental|High Intensity Interval Training|
10034404|NCT01796379|Other|Moderate Training|Regular exercise training offered as usual care to all heart transplant recipients.
10034405|NCT01796405|Experimental|Low-Risk|Multifocal or Low-Risk Multi System Clofarabine, Low Dose, Two Cycles
10034406|NCT01796405|Experimental|High-Risk|High-risk Multi System Clofarabine, Standard Dose, Two Cycles
10034407|NCT01796418|Experimental|Beraprost sodium|Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks
10034408|NCT01796418|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 12 weeks
10034409|NCT01796431|Experimental|Eviplera®|Participants will take Eviplera every day for 14 days. Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in order to understand how long these drugs persist in the blood.
10034410|NCT01796444|Active Comparator|Axillary Lymph Node Dissection|After sentinel lymph node biopsy, surgery for standard axillary lymph node dissection. Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
10034411|NCT01796444|Experimental|Non-Axillary Lymph Node Dissection|After sentinel lymph node biopsy, no surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial). Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
10034412|NCT01796483|Active Comparator|healthy Volunteers|
9474072|NCT03593850|Active Comparator|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
10034413|NCT01796483|Experimental|Patients|
10034414|NCT01796496|Experimental|Manipulative Therapy Techniques|Manipulative Therapy Techniques involve three techniques on lumbar and sacral areas. This protocol will be administered one a week for 3 weeks.
10034415|NCT01796496|Active Comparator|Functional Technique|Manipulative Therapy Technique involves one technique on lumbar area. This protocol will be administered one a week for 3 weeks.
10034416|NCT01796522|Active Comparator|Nifedipine (60 mg / day orally)|The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
10034417|NCT01796522|Active Comparator|Progesterone 200 mg / day vaginally|The name of this arm is Progesterone. Soft gelatin capsule vaginal use, used in clinical practice as maintenance tocolytic therapy after episode of threatened preterm labor. The 200mg capsule administered once daily to week 34 of gestation. The patients assigned to this arm will begin treatment while the patient assigned to the arm of nifedipine.
10034418|NCT01796535||PerX360º System™|Patients treated with PerX360º System™
10034419|NCT01796561|Active Comparator|Olive leaf extract liquid|20ml of polyphenol-rich olive leaf extract liquid to be consumed daily for 6 weeks
10034420|NCT01796561|Placebo Comparator|Placebo liquid|20ml of polyphenol-free placebo liquid (containing water, glycerin, flavours, colours and aromas) to be consumed daily for 6 weeks
10034421|NCT01796574|Experimental|Ketogenic diet|Patients will receive the ketogenic diet as a formula delivered via feeding tube. Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet.
10034422|NCT01796587||LoFric Origo|
10034423|NCT01796600|Experimental|Conventional and a cone-beam scanner 5G|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
10034424|NCT01796613|Active Comparator|Vaginal Ring - intermittent regimen|3 weeks ring use followed by one week of no ring use to allow menstruation
10034425|NCT01796613|Active Comparator|Vaginal Ring - continuous regimen|3 weeks of ring use with no off period. The next ring is immediately inserted after the previous one
10034426|NCT01796626|Experimental|Wrinkle treatment|Wrinkle treatment with ResurFX 1565nm module
10034427|NCT01796626|Experimental|Striae treatment|Striae treatment with the REsurFX 1565nm module
10034428|NCT01796639||kidney transplantation patients with living-donor grafts|
9474073|NCT03593837|Experimental|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
9474074|NCT03593837|Placebo Comparator|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
9474075|NCT03593824|Experimental|dense cataract group|
9474076|NCT03593824|Experimental|non-dense nuclear cataract group|
9474077|NCT03593785|Experimental|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
9474078|NCT03593785|Experimental|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
9474079|NCT03593785|Experimental|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
9474080|NCT03593785|Experimental|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
9474081|NCT03593785|Experimental|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
9474082|NCT03593746|Experimental|HIIT and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with high intensity interval training (HIIT)
9474083|NCT03593746|Sham Comparator|High intensity interval training (HIIT)|Light-Emitting Diode (LED) therapy simulation followed by physical training with high intensity interval training (HIIT)
9474084|NCT03593746|Experimental|Combined training and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with combined training
9474085|NCT03593746|Sham Comparator|Combined training|Light-Emitting Diode (LED) therapy simulation followed by physical training with combined training.
9474086|NCT03593733|Experimental|Cold Water Immersion|Cold Water Immersion
9474087|NCT03593733|Experimental|Photobiomodulation Therapy|Photobiomodulation Therapy
9474088|NCT03593720||Hypospadias|Patients with hypospadias
9474089|NCT03593720||Control|Patients without hypospadias
9474090|NCT03593707|Experimental|Metformin Alone|Metformin alone
9474091|NCT03593707|Experimental|Metformin + PF-06865571|Co-administer metformin and PF-06865571
9474092|NCT03593694|Other|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
9474093|NCT03593694|Active Comparator|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
9474094|NCT03593694|Experimental|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
9474095|NCT03593668|Active Comparator|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
9474096|NCT03593668|Active Comparator|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
9474097|NCT03593642|Placebo Comparator|Control Group|Erector spinae bilateral catheters with continuous infusion iso saline during 48h after surgery Day 0 to day 2
9474098|NCT03593642|Experimental|Regional analgesia group|Erector spinae bilateral catheters with continuous infusion Ropivacaine 0.1 or 0.2%, depending on age, infusion during 48h after surgeryDay 0 to day 2
9474099|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
9474100|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
9474101|NCT03593564|Experimental|KINDER Participant|The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
9474102|NCT03593551|Experimental|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
9474103|NCT03593512|Experimental|PPN DBS|All patients will undergo bilateral PPN DBS
9474104|NCT03593486|Experimental|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
9474105|NCT03593486|Sham Comparator|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
9474106|NCT03593473|Experimental|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
9474107|NCT03593473|Placebo Comparator|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
10034429|NCT01796652||Home and hospital treatment groups|Patients were randomized into either home or hospital groups after a brief hospitalization(≤24 hours. Hospital patients were followed 5 days in hospital.Home patients were visited on 2nd,3rd and 5th days by a staff nurse and the vital signs, symptoms, and general condition were recorded and transmitted back to the attending physician. On the 7th, 14th and 30th days, the home and hospital group patients were requested to return for a follow-up clinic visit at Bezmialem, at which time an assessment of their symptoms, physical examination, and laboratory evaluation was conducted.
10034430|NCT01796678|Experimental|Arginine|100 mg/kg T.I.D 3x a day IV or PO
9474108|NCT03593460|Experimental|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
10034431|NCT01796678|Placebo Comparator|Placebo|Saline or sugar pill
9474109|NCT03593460|Experimental|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
9474110|NCT03593460|Experimental|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
9474111|NCT03593460|Experimental|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
9474112|NCT03593460|Experimental|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
9474113|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
9474114|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
9474115|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
9474116|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
9474117|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
9474118|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
9474119|NCT03593421|Experimental|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
9474120|NCT03593421|Experimental|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
9474121|NCT03593421|Experimental|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
10034432|NCT01796691||Standard therapy|Antiplatelet therapy following coronary stenting without platelet function testing
10034433|NCT01796691||Optimized antiplatelet therapy|"Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.~Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)"
10034434|NCT01796704||healthy and mild heart failure|diversity of patients
10034435|NCT01796717|Active Comparator|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
9474122|NCT03593421|Experimental|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
9474123|NCT03593421|Experimental|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
9474124|NCT03593408||Pediatric Patients on ECMO Support|
9474125|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
9474126|NCT03593369|Experimental|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
9474127|NCT03593369|Experimental|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
9474128|NCT03593369|Active Comparator|Standard of Care|SOC only (5 patients)
9474129|NCT03593356|Experimental|Monthly cash gift payments of $333|These subjects receive $333 each month for 52 months via debit card.
9474130|NCT03593356|Active Comparator|Monthly cash gift payments of $20|These subjects receive $20 each month for 52 months via debit card.
9474131|NCT03593343|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
9474132|NCT03593343|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
9474133|NCT03593330|Experimental|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
9474134|NCT03593330|No Intervention|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
9474135|NCT03593317|Experimental|Spironolactone group|
9474136|NCT03593317|Placebo Comparator|Placebo group|
10034436|NCT01796717|Experimental|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
9474137|NCT03593304|Active Comparator|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
9474138|NCT03593304|Placebo Comparator|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
9474139|NCT03593278|Experimental|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
9474140|NCT03593265|Experimental|Healthy group|healthy subjects MUNIX will be performed
9474141|NCT03593239|Experimental|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
9474142|NCT03593239|Experimental|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
9474143|NCT03593239|Experimental|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
9474144|NCT03593239|Experimental|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
9474145|NCT03593239|Experimental|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
9474146|NCT03593239|Experimental|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
9474147|NCT03593239|Experimental|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
9474148|NCT03593239|Experimental|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
9474149|NCT03593239|Experimental|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
9474150|NCT03593239|Experimental|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
9474151|NCT03593226|Experimental|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
9474152|NCT03593187|Experimental|Cal-1( LVsh5/C46) drug product|
9474153|NCT03593174|Experimental|Ossur Rigid Dressing|Use of ORD, which is a type of Removable Rigid Dressing (RRD), as a post tibial amputation dressing modality.
9474154|NCT03593174|Active Comparator|Elastic bandage|Use of the elastic bandage as a post amputation dressing modality.
9474155|NCT03593161|Experimental|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
9474156|NCT03593161|No Intervention|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
10034437|NCT01796730|Experimental|sequence I|10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)
10034438|NCT01796730|Experimental|sequence II|bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)
10034439|NCT01796730|Experimental|sequence III|placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout (7 days) - bambuterol 5mg (21 days)
10034440|NCT01796743||Controls|Age and gender matched controls ('control' group) with acute MI with similar degree of troponin elevation who are managed based solely on the basis of clinical or angiographic data alone.
10034441|NCT01796743||Cardiac MRI|Hospitalized patients with acute MI with a clinically-indicated CMR ordered will be enrolled. Data for T2 mapping will be added to the clinically prescribed cardiac MRI scan.
9474157|NCT03593148|Other|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
9474158|NCT03593135|Experimental|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
9474159|NCT03593135|Placebo Comparator|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
10034442|NCT01796756|Experimental|Handover program|Standardized handover program Dedicated place and time Template Face-to-face communication Evidence-based education session Feedback and audit
10034443|NCT01796756|No Intervention|Usual handover practice|
9474160|NCT03593122|Experimental|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
9474161|NCT03593096|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
9474162|NCT03593096|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
9474163|NCT03593083|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
9474164|NCT03593083|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
9474165|NCT03593070|Experimental|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
9474166|NCT03593070|No Intervention|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
9474167|NCT03593057|Experimental|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, one every 15 days.
9474168|NCT03593057|Active Comparator|Control group.|Advice on self-care and body awareness.
9474169|NCT03593044|Experimental|One Week Atropine|0.01% concentration atropine drops
9474170|NCT03593031|Active Comparator|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
9474171|NCT03593031|Sham Comparator|CI Sham therapy|CI Sham therapy
9474172|NCT03593031|Active Comparator|Controls OBVAT|Control receive active therapy
9474173|NCT03593031|Sham Comparator|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
9474174|NCT03593005|Experimental|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
9474175|NCT03593005|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
9474176|NCT03592992|Experimental|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
9474177|NCT03592992|Active Comparator|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
10037207|NCT01822977|No Intervention|Proton pump inhibitor|"We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.~A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment)."
10037208|NCT01822990||Atherosclerotic patients|Male patients with intermittent claudication.
10037209|NCT01822990||Control subjects|healthy male subjects with normal results on vascular examination and no cardiovascular risk factors, who are not in receipt of any pharmacological treatment, matched by age within two years with peripheral arterial disease patients
10037210|NCT01823003|Experimental|A. 34 Gy in a single fraction|34 Gy by single fraction Risk-adapted radiation dose.
10037211|NCT01823003|Experimental|B. 54Gy (18Gy/fr. x 3 fractions)|54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose
10037212|NCT01823003|Experimental|C. 50Gy (12 x 5 fr.s)|54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose
10037213|NCT01823003|Experimental|D. 60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose
10037214|NCT01823029|Experimental|erythropoietin,injection of iron and enteral nutrition|The patients receive treatment of erythropoietin,injection of iron and enteral nutrition.
10037215|NCT01823029|Experimental|erythropoietin and enteral nutrition.|The patients receive treatment of erythropoietin and enteral nutrition.
10037216|NCT01823042|Experimental|enteral nutrition+azathioprine|Patients is fasting and receive enteral nutrition and azathioprine treatment.
10037217|NCT01823042|Experimental|azathioprine|Patients have regular diet and receive only azathioprine treatment.
10037218|NCT01823055|Experimental|Surgery|Transvaginal suture capturing mesh device
10037219|NCT01823068|Experimental|Vandetanib treatment arm|Vandetanib 300 mg once daily orally
10037220|NCT01823081|Active Comparator|Intravitreal bevacizumab (Avastin)|Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks
10034444|NCT01796769|Experimental|Conventional|
10034445|NCT01796769|Active Comparator|Telemedicine|
9474178|NCT03592979|Experimental|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
9474179|NCT03592979|Experimental|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
9474180|NCT03592966|Placebo Comparator|Placebo|Freeze-dried placebo powder
9474181|NCT03592966|Active Comparator|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
9474182|NCT03592953|Experimental|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
9474183|NCT03592953|Experimental|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
9474184|NCT03592953|No Intervention|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
9474185|NCT03592927|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
9474186|NCT03592927|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
9474187|NCT03592914||subjects with respiratory disease|This study is a comparative, single-center study. This is a minimal risk study using a non-significant risk device. A minimum of 60 and maximum of 70 subjects will be enrolled in the study. Subject participation will last approximately 1 hour(s).
9474188|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
9474189|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
9474190|NCT03592862|Experimental|HTL0018318 high dose|oral capsule, once daily
9474191|NCT03592862|Experimental|HTL0018318 mid dose|oral capsule, once daily
9474192|NCT03592862|Experimental|HTL0018318 low dose|oral capsule, once daily
9474193|NCT03592862|Placebo Comparator|Placebo|oral capsule, once daily
9474194|NCT03592849|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
9474195|NCT03592836|Active Comparator|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
9474196|NCT03592836|Active Comparator|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
9474197|NCT03592823|No Intervention|control|receiving radiofrequency ablation and anticoagulant therapy
9474198|NCT03592823|Experimental|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
9474199|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
9474200|NCT03592797|Experimental|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
9474201|NCT03592797|Sham Comparator|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
9474202|NCT03592784|Experimental|Food Order Therapy + Medical Nutrition Therapy|
9474203|NCT03592784|Active Comparator|Medical Nutrition Therapy Alone|
9474204|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
9474205|NCT03592732||A|Patients with atrial fibrillation
9474206|NCT03592732||B|Patients without atrial fibrillation
10034446|NCT01796782|Active Comparator|Xeloda|Subjects will receive Xeloda until progression
9474207|NCT03592719|Experimental|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
9474208|NCT03592719|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
9474209|NCT03592706|Experimental|IKC and TACE|IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)
9474210|NCT03592706|Active Comparator|TACE|TACE (Transcatheter Arterial Chemoembolization)
9474211|NCT03592680|Active Comparator|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
9474212|NCT03592680|Placebo Comparator|Placebo|Placebo as an alternative for Vitamin C tablets
10034447|NCT01796782|Experimental|QYHJ Granules|patients will receive QYHJ Granules until progression
10034448|NCT01796795|Placebo Comparator|vehicle gel|The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
10034449|NCT01796795|Active Comparator|SR-T100 gel with 1.0% of SM|SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
9474213|NCT03592667|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
9474214|NCT03592667|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
9474215|NCT03592654|Experimental|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
9474216|NCT03592628|Placebo Comparator|Standard Instructions|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care.
9474217|NCT03592628|Experimental|Enhanced Instruction|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care AND they received an additional printed visual diagram.
9474218|NCT03592615|Experimental|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
9474219|NCT03592615|Experimental|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
9474220|NCT03592602|Experimental|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
9474221|NCT03592589|No Intervention|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
9474222|NCT03592589|Experimental|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
9474223|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
9474224|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:~family history (first degree relative) one or more neurological and/or psychiatric conditions;~examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
9474225|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
9474226|NCT03592550||Group A|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
9474227|NCT03592550||Group B|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
9474228|NCT03592537|Active Comparator|fentanyl|Group F: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + (5ug) of fentanyl intrathecally
9474229|NCT03592537|Active Comparator|midazolam|Group M: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + 0.5 mg of midazolam intrathecally
10034450|NCT01796795|Active Comparator|SR-T100 gel with 2.3% of SM|SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
10034451|NCT01796808|Other|Pathway A|"Screening visit followed by pedal fat grafting procedure with local anesthetic and visits at:~1 week~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month)~Crossover to standard podiatry visits~Study visit 6 (18 months)~Study visit 7 (24 months)"
10034452|NCT01796808|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6months)~Study Visit 2 (12 months)~Crossover to Pathway A~pedal fat grafting procedure and local anesthetic and visits at:~1 week~Post op study visit 2 (1 month post procedure)~Post op study visit 3 (2 month post procedure)~Post op study visit 4 (6 month post procedure)~Post op study visit 5 (12 month post procedure)"
10034453|NCT01796821|Placebo Comparator|Vehicle gel|vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
10034454|NCT01796821|Active Comparator|SR-T100 gel with 1.0 % SM|SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
10034455|NCT01796821|Active Comparator|SR-T100 gel with 2.3% SM|SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
10034456|NCT01796834|Experimental|Mindfulness-Based Stress Reduction|Subjects attend a community based Mindfulness-Based Stress Reduction course.
10034457|NCT01796847||PTEN, hyperglycemia|
9474230|NCT03592537|Placebo Comparator|Bupivacaine|Group B:intrathecal 0.5% bupivacaine (0.3 mg/kg)
9480488|NCT03533075|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
9480489|NCT03533075|No Intervention|Care as Usual|Usual care at Veterans Affairs Medical Centers (VAMC) for Veterans who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization.
9480963|NCT05146609|Experimental|HR-HOSPITAL|Patients assigned to the strategy HR-HOSPITAL, who are high risk population (HR), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
9474231|NCT03592511|Experimental|Intervention|WGPF-burger group
9474232|NCT03592511|Placebo Comparator|Control|Control-burger group
9474233|NCT03592498|Active Comparator|Sulfadiazine, Silver|Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
10034458|NCT01796886|Experimental|patient's neurological status|
10034459|NCT01796899|Other|Brivaracetam 10 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 10 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
10034460|NCT01796899|Other|Brivaracetam 50 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 50 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
10034461|NCT01796899|Other|Brivaracetam 75 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 75 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
10034462|NCT01796899|Other|Brivaracetam 100 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
10037221|NCT01823081|Active Comparator|Combined intravitreal fasudil and bevacizumab (Avastin)|Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks
9474234|NCT03592498|Experimental|Skin of Nile tilapia|"Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.~Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered)."
9474235|NCT03592485|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
9474236|NCT03592485|Experimental|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
9474237|NCT03592472|Experimental|Pazopanib plus abexinostat|Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
9474238|NCT03592472|Placebo Comparator|Pazopanib plus placebo|Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
9474239|NCT03592459|Experimental|Device feasibility (Macy catheter, opioids)|Patients undergo placement of rectal catheter and receive opioids through the Macy catheter.
9474240|NCT03592446|Experimental|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
9474241|NCT03592446|Sham Comparator|Sham-raVNS|Sham vagus nerve stimulation at ear.
9474242|NCT03592433|Experimental|I Can PIC|The I Can PIC website will be provided to participants randomized to the experimental/intervention group.
9474243|NCT03592433|No Intervention|Attention Control|Participants randomized to the attention control group will be provided a link to a website developed by the American Cancer Society Cancer Action Network.
9474244|NCT03592420|Experimental|Interdisciplinary interventions|"Multicomponent interventions~On-site supervised group exercise program (11 weeks)~Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)~Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards~Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
9474245|NCT03592420|Active Comparator|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
9474246|NCT03592394|Active Comparator|Somatic IVR (s-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
9474247|NCT03592394|Active Comparator|Distractive IVR (d-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
9474248|NCT03592381|Experimental|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
9474249|NCT03592381|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
9474250|NCT03592355|Experimental|Intervention|"If enrolled in the intervention arm, the following steps will occur:~The Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
10034463|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg (10 mg/mL)~Form: Intravenous bolus injection~Frequency: Once daily~Duration: 1 day"
9474251|NCT03592355|No Intervention|Control|"If enrolled in the control arm, the following steps will occur:~Three months from the time of the follow-up email, the Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
9474252|NCT03592342|Placebo Comparator|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
9474253|NCT03592342|Experimental|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
10034464|NCT01796925|Experimental|aura6000 THN Therapy|The aura6000 THN system will be implanted and activated for nightly therapy during sleep.
10034465|NCT01796938|Experimental|Group 1: Healthy subjects|Single dose of 100 mg Lacosamide
10034466|NCT01796938|Experimental|Group 2: Subjects with mild renal insufficiency|Single dose of 100 mg Lacosamide
10034467|NCT01796938|Experimental|Group 3: Subjects with moderate renal insufficiency|Single dose of 100 mg Lacosamide
10034468|NCT01796938|Experimental|Group 4: Subjects with severe renal insufficiency|Single dose of 100 mg Lacosamide
10034469|NCT01796938|Experimental|Group 5: Subjects with end stage renal insufficiency|Single dose of 100 mg Lacosamide
10034470|NCT01796951|Experimental|Celecoxib, aspirin, followed by aspirin/celecoxib|Celecoxib 200 mg twice daily x3 days, aspirin 325 mg daily x10 days, celecoxib 200 mb twice daily + aspirin 325 mg daily x 3 days
10034471|NCT01796990|Active Comparator|REF group|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
10034472|NCT01796990|Other|ACT group|"The ACT group gets the same procedure as the REF group. In addition, they will participate the ACT based program. The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
10034473|NCT01797003|Active Comparator|Opening wedge HTO|Opening wedge high tibial osteotomy using Puddu plate
10034474|NCT01797003|Active Comparator|Closing wedge HTO|Closing wedge high tibial osteotomy using cramp fixation
10034475|NCT01797042|Active Comparator|Fructose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
9474254|NCT03592342|Experimental|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
9474255|NCT03592342|Experimental|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
9474256|NCT03592316|Experimental|Lower Extremity Amputation Pathway|Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.
10034476|NCT01797042|Active Comparator|Glucose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
9474257|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
9474258|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
9474259|NCT03592277|Experimental|Intervention Arm|Patients in this arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
9474260|NCT03592277|No Intervention|Control Arm|Patients in the control arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
9474261|NCT03592251|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
9474262|NCT03592251|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
10034477|NCT01797042|Active Comparator|High fructose corn syrup 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
9474263|NCT03592251|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
9474264|NCT03592238|Experimental|Aerobic Exercise Intervention|Participants will exercise on a motor-driven treadmill at a constant speed during the 23-min period.
9474265|NCT03592238|Active Comparator|Trier Social Stress Test for Children|The Trier Social Stress Test for Children consists of a speech task in which children must finish a story and a mental arithmetic task, completed in front of a camera and two neutral observers.
9474266|NCT03592238|Placebo Comparator|Seated Rest|Participants will sit in a comfortable chair, placed in the same room as the motor-driven treadmill, for a period of 25-min.
9474267|NCT03592225|Other|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
9474268|NCT03592225|No Intervention|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
9474269|NCT03592199|Experimental|1st Line Sunitinib and 2nd Line Axitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
9474270|NCT03592173|Experimental|SAS20|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 20ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
9474271|NCT03592173|Active Comparator|SAS0|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 0ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
9474272|NCT03592173|Active Comparator|SAS50|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 50ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
9474273|NCT03592160|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
9474274|NCT03592160|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
9474275|NCT03592147|Other|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
9474276|NCT03592134||Clinical settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by clinical practice (nocturnal gas exchange, apneas, bradycardia, oxygen desaturation)
9474277|NCT03592134||Physiological settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by the measurement of work of breathing
9474278|NCT03592108|Experimental|CSR remote monitoring|The remote monitoring of CPAP treatment will be modified in order to detect the presence of CSR as soon as any significant increase of the apnea-hypopnea index occurs.
9474279|NCT03592095|Experimental|DN group|The intervention group will receive real dry needling (DN) (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
9474280|NCT03592095|Placebo Comparator|Placebo needle|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
9474281|NCT03592082|Active Comparator|Standard care alone|Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
9474282|NCT03592082|Experimental|Standard care with Bismuth subsalicylate (BSS)|Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
9474283|NCT03592069|Active Comparator|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
9474284|NCT03592069|Active Comparator|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
9474285|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
9474286|NCT03592017|Experimental|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
9474287|NCT03592017|Experimental|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
9474288|NCT03592004||Guangdong General Hospital|
9474289|NCT03592004||Cancer Hospital Chinese Academy Of Medical Sciences|
9474290|NCT03592004||Beijing Friendship Hospital|
9474291|NCT03592004||Yunnan Cancer Hospital|
9474292|NCT03592004||Liaoning Cancer Hospital|
9474293|NCT03592004||The First Hospital Of China Medical University|
9474294|NCT03592004||Affiliated Hospital Of Hebei University|
9474295|NCT03591991|Active Comparator|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
9474296|NCT03591991|Placebo Comparator|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
9474297|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
9474298|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of <10 pack-years
9474299|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least >10 pack-years
9474300|NCT03591965|Experimental|ATG-008|To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.
9474301|NCT03591939||1|cases of Diabetic type two nephropathy
9474302|NCT03591939||2|controls of normal subjects
9474303|NCT03591926|Experimental|"BAL Arm"|Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure at baseline and after two weeks of treatment.
9474304|NCT03591926|Experimental|"Non-BAL Arm"|Subjects in this arm will not undergo any BAL procedures.
9474305|NCT03591913|Experimental|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
9474306|NCT03591913|Active Comparator|control group|will receive sublingual misoprostol immediately after skin closure
9474307|NCT03591900|Active Comparator|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
9474308|NCT03591900|Active Comparator|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
9474309|NCT03591874|Experimental|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
9474310|NCT03591874|Placebo Comparator|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
9474311|NCT03591861|Experimental|Ketogenic Diet|"Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)~Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months~Laboratory studies prior to hospital admission and then at each follow-up visit~Hospital admission (3-5 day) to start the ketogenic diet~Standard of care chemotherapy with BCNU for up to 2 years~Ketogenic diet can continue for up to 2 years"
9474312|NCT03591848|Experimental|DECISIF|Exposed to an online support decision tool, in addition of the standard oral information
9474313|NCT03591848|Active Comparator|IRIS|Exposed to a standard oral information
9474314|NCT03591835|Active Comparator|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
9474315|NCT03591835|Active Comparator|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
9474316|NCT03591809|Experimental|combined exercise training group|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
9474317|NCT03591809|No Intervention|Control group|The patients in the control group will not apply an exercise training.
10034478|NCT01797042|Active Comparator|Sucrose 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
9474318|NCT03591796|Experimental|HFOV|Ventilated infants were randomized to HFOV.
9474319|NCT03591796|Active Comparator|CMV|Ventilated infants were randomized to CMV.
9474320|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
9474321|NCT03591757|Experimental|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
9480490|NCT03533062|Active Comparator|trigonal sparing botox injection|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area excluding trigone in other arm Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).•then after 6 months postoperative anticholinergics administration .
10034479|NCT01797068|Experimental|Patient Navigator|Patients in the experimental group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH).
9474322|NCT03591744|Experimental|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
9474323|NCT03591718|Experimental|BI 456906|
9474324|NCT03591718|Experimental|Placebo|
9474325|NCT03591705|Experimental|TACE-HAIC|hepatic artery chemo-lipiodolization with EADM, followed by FOLFOX-based chemotherapy artery infusion
9474326|NCT03591705|Active Comparator|HAIC|FOLFOX-based chemotherapy hepatic artery infusion
9474327|NCT03591692|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
9474328|NCT03591692|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
9474329|NCT03591679|Experimental|study group|patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
9474330|NCT03591679|Active Comparator|control group|patients at risk of uterine atony undergoing cesarean section received oxytocin only.
9474331|NCT03591666|Experimental|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9474332|NCT03591653|Experimental|LXI-15028 50mg group|
9474333|NCT03591653|Placebo Comparator|Placebo group|
9474334|NCT03591640|Active Comparator|Pregnant with hemoglobinopathy|Standard of care with blood test before active labor
9474335|NCT03591640|Active Comparator|Pregnant without known hemoglobinopathy|Standard of care with blood test before active labor
9474336|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
9474337|NCT03591601|Active Comparator|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
9474338|NCT03591601|Experimental|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
9474339|NCT03591601|Placebo Comparator|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
9474340|NCT03591588|Active Comparator|high-saturated fat diet|Diet high in saturated fat (~50% calorie from fat, ~25% from saturated fat)
9474341|NCT03591588|Active Comparator|low-fat diet|Diet with low fat (~25% calorie from fat)
9474342|NCT03591575|Experimental|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
9474343|NCT03591575|Placebo Comparator|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
9474344|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
9474345|NCT03591549|Experimental|fulvestrant arm|patients will receive fulvestrant + zoladex intramuscular monthly with an assessment every three months to assess the response and progression
9474346|NCT03591536|Other|pentoxifylline oral|50 adult patient underwent elective CABG intervention to be administered will be receiving main drug (pentoxifylline )oral 400 mg' every 8 hours from three days before surgery and on the day of surgery effect of intervention regarding antioxidant
9474347|NCT03591536|Placebo Comparator|placebo|50 adult patient underwent elective CABG received oral placebo pill resembling completely to pentoxifylline 400 mg, every 8 hours from three days before surgery and on the day of surgery
9474348|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
9474349|NCT03591497|Experimental|Intervention Group|"Instrument to be used:~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.~Programme schedule:~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
9474350|NCT03591497|No Intervention|Control Group|Virtual reality sessions were not provided.
9474351|NCT03591484|Experimental|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
9474352|NCT03591484|Experimental|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
9474353|NCT03591484|Active Comparator|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
9474354|NCT03591484|Active Comparator|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
9474355|NCT03591471|Experimental|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
10034480|NCT01797068|Active Comparator|Standard of Care|Patients in the active comparator group will experience the usual intake process in the ED setting.
10034481|NCT01797107|Experimental|Treatment eye|Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
9474356|NCT03591471|Active Comparator|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
9474357|NCT03591445|Experimental|Experimental：Bronchoscopy|Patients with ground glass opacity featured lung cancer who are candidates for surgeyr received the bronchoscopy examination before surgery.
9474358|NCT03591432|Experimental|THRIVE|Using transnasal humidified rapid insufflation ventilatory exchange (THRIVE) oxygenation technique in elderly patients undergoing induction of anesthesia.
9474359|NCT03591432|Active Comparator|Facemask|Using facemask technique in elderly patients undergoing induction of anesthesia.
9474360|NCT03591419|Experimental|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
9474361|NCT03591419|Active Comparator|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
9474362|NCT03591393|Experimental|Pregnant women|"questionnaire at 1st and 3rd trimester, 10-12 weeks postpartum and 12 months postpartum~pelvic floor ultrasound at 1st trimester and at 3rd trimester"
9474363|NCT03591367|Other|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
9474364|NCT03591354|Experimental|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is participants who had 6 months of SAP in the primary trial (DCLP3 Pivotal Trial)~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
9474365|NCT03591354|Active Comparator|Predictive-Low Glucose Suspend (PLGS)|"Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ & Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is not applicable to objective 2~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
9474366|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
9474367|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
9474368|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
10034482|NCT01797107|Placebo Comparator|Durasite|Vehicle of Azasite used as placebo
10034483|NCT01797133|Active Comparator|Fellow arm|Patients in this arm will receive the ID fellow-based antibiotic pre-authorization intervention.
10034484|NCT01797133|Active Comparator|Pharmacist arm|Patients in this arm will receive the pharmacist-based antibiotic pre-authorization intervention.
10034485|NCT01797146|Active Comparator|CARE|All patients in the intervention wards will receive the Catheter Reminder and Evaluation (CARE) intervention.
10034486|NCT01797146|No Intervention|Control|All patients in the control wards will receive usual care without the CARE intervention.
9474369|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
9474370|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes >1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
9474371|NCT03591302|Experimental|Immune tolerance, Kidney transplantation|Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
9474372|NCT03591289|Active Comparator|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
9474373|NCT03591289|Active Comparator|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
9474374|NCT03591276|Experimental|Pembrolizumab and PLD|"Cohort S1: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 every 3 weeks.~Reduced Dose Cohort (R1)*: IV pembrolizumab 200 mg flat dose with IV PLD 24 mg/m2 every 3 weeks.~*Subjects will be recruited into the R1 cohort only if DLT is reported in 2 or more subjects during the first 2 cycles of treatment in the first 6 patients of the S1 cohort."
9474375|NCT03591237|Experimental|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
9474376|NCT03591224|Active Comparator|Intervention|Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
9474377|NCT03591224|Placebo Comparator|Control|Pharmacist optimizing antidepressant therapy based on standard of care
9474378|NCT03591211|Experimental|Qigong Training|
9474379|NCT03591211|Active Comparator|Cognitive Training|
9474380|NCT03591198|Experimental|Qigong Training|
9474381|NCT03591198|Active Comparator|Cognitive Training|
9474382|NCT03591185|Experimental|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
9474383|NCT03591172|Experimental|propolis|natural antibacterial, anti-inflammatory irrigation solution
9474384|NCT03591172|Experimental|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
9474385|NCT03591172|Active Comparator|saline|sodium chloride irrigation solution
9474386|NCT03591159|Active Comparator|Membrane Sweeping Group|
9474387|NCT03591159|No Intervention|Control Group|
9474388|NCT03591133|Other|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
9474389|NCT03591133|Other|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
9474390|NCT03591133|Other|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
9474391|NCT03591133|Other|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
9474392|NCT03591133|Other|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
9474393|NCT03591133|Other|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
9474394|NCT03591107|Experimental|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
9474395|NCT03591107|Active Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
9474396|NCT03591081|Other|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
9474397|NCT03591055|Experimental|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
9474398|NCT03591055|No Intervention|Control group|Participants in the control group will receive the usual standard care and regular referrals.
9474399|NCT03591042|Experimental|cervical length screening|cervical length screening
9474400|NCT03591042|No Intervention|no screening|no screening
9474401|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
9474402|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
9474403|NCT03590977|Experimental|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
9474404|NCT03590977|Placebo Comparator|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
9474405|NCT03590964|Active Comparator|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
9474406|NCT03590964|Experimental|Sinus lift using bone ring containing the implant|Patients with atrophied posterior maxilla will undergo sinus lift using bone ring containing the implant.
9474407|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
9474408|NCT03590912|No Intervention|Wait and watch (Group D)|Wait and watch for 1 month
9474409|NCT03590912|Experimental|Mometasone spray (Group B)|Standard dose of mometasone furoate nasal spray (one spray in each nostril once daily) for one month will be given
9474410|NCT03590912|Experimental|antibiotic + histaminic + oxymetazoline drops (Group A)|This group will receive oral cefpodoxime (10 mg/kg/day in two divided dose for a week) plus oral histaminics and oxymetazoline drops. Standard dose of oral histaminics (levocetirizine, 1.25 mg for age below six years, 2.5 mg for older age) for a month plus oxymetazoline nasal drops (Nasivion 0.025%) for two weeks will be given
9474411|NCT03590912|Experimental|Oral steroid (Group C)|Patients in this group will receive one mg/kg/day of oral prednisolone (Oral steroid) in two divided dose for a week followed by half mg/kg/day in two divided dose for next one week
9480491|NCT03533062|Active Comparator|trigonal involved|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area including the trigone .Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).then after 6 months postoperative anticholinergics administration .
9480964|NCT05146609|Experimental|HR-DDP|Patients assigned to the strategy HR-DDP, who are high risk population, will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the drug dependence center (DDP) the participants used to attend.
10034487|NCT01797172|Experimental|Percutaneous Cervical Nucleoplasty|Percutaneous Cervical Nucleoplasty
10034488|NCT01797172|Active Comparator|Pulsed Radio Frequency|Pulsed Radio Frequency treatment
9474412|NCT03590899||Healthy patients|
9474413|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
9474414|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
9474415|NCT03590873|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
9474416|NCT03590873|Experimental|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
9474417|NCT03590860|Experimental|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
9474418|NCT03590860|Placebo Comparator|Placebo (Part A)|Placebo matching LY3322207 administered SC
9474419|NCT03590860|Experimental|LY3322207 (Part B)|LY3322207 administered SC once weekly
9474420|NCT03590860|Placebo Comparator|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
9474421|NCT03590860|Experimental|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
9474422|NCT03590847|Experimental|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
9474423|NCT03590834|Experimental|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
9474424|NCT03590834|Experimental|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
9474425|NCT03590834|Active Comparator|Active Control|Active comparison group
9474426|NCT03590808|Experimental|Immune checkpoint inhibitor|"Solid cancer patients who receiving immune checkpoint inhibitor patients~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
9474427|NCT03590808|Active Comparator|Cytotoxic chemotherapy|"Solid cancer patients who receiving conventional cytotoxic chemotherapy~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
9474428|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
9474429|NCT03590769|Experimental|PET/MR using FDG-18 radiotracer|Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.
9474430|NCT03590756|Experimental|High mango group|250g (1.5 cup) of mango intake per day, 4 days a week for 16 weeks
9474431|NCT03590756|Other|Low mango group|85g (0.5 cup) of mango intake per day, 4 days a week for 16 weeks
9474432|NCT03590717|Other|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
9474433|NCT03590717|Experimental|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
9474434|NCT03590717|Experimental|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
9474435|NCT03590704|Experimental|Intervention Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region. The bandage will not be applied on the scar. If there are any complications such as itching, redness, discomfort and / or others, the patients will remove the material at home and communicate on return to the institution. They will remain four days approximately for revaluation and intervention suspension.
9474436|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
9474437|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
9474438|NCT03590665|Other|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
10034489|NCT01797198|Experimental|gemfibrozil + ASP3652|Multiple doses of gemfibrozil and single dose of ASP3652
9474439|NCT03590665|Other|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
9474440|NCT03590626|Experimental|Dulaglutide group|receive dulaglutide 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks plus standard treatment for type 2 diabetes
9474441|NCT03590626|No Intervention|Control group|receive standard treatment for type 2 diabetes and up titration of treatment will be done by anti-diabetic medicines other than the GLP-1 receptor agonist
9474442|NCT03590600|Experimental|Cohort 1: 125 mg BTZ-043 fasting|N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
9474443|NCT03590600|Placebo Comparator|Cohort 1: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
9474444|NCT03590600|Experimental|Cohort 2: 250 mg BTZ-043 fasting|N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
9474445|NCT03590600|Placebo Comparator|Cohort 2: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
9474446|NCT03590600|Experimental|Cohort 3: 500 mg BTZ-043 fasting|N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
9474447|NCT03590600|Placebo Comparator|Cohort 3: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
9474448|NCT03590600|Experimental|Cohort 4: 1000 mg BTZ-043 fasting|N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
9474449|NCT03590600|Placebo Comparator|Cohort 4: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
9474450|NCT03590600|Experimental|Cohort 5: 2000mg BTZ-043 fasting|N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
9474451|NCT03590600|Placebo Comparator|Cohort 5: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
9474452|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
9474453|NCT03590561|Experimental|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
9474454|NCT03590561|No Intervention|Control diet|Participants will eat regular diet.
9474455|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
9474456|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
9474457|NCT03590522||Group I:|Thirty heart failure patients
10034490|NCT01797198|Experimental|ASP3652 + repaglinide|Multiple doses of ASP3652 and the single dose of repaglinide
10034491|NCT01797211|Experimental|diet group A|Mediterranean diet+olive oil
10034492|NCT01797211|Experimental|Diet Group B|Mediterranean diet+not-fried fish
10034493|NCT01797211|Experimental|Diet Group C|Mediterranean diet+nuts
10034494|NCT01797224||Cohort 1 - Exposed Cohort|Pregnant women with a current diagnosis of an approved indication who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception.
10034495|NCT01797224||Cohort 2 - Diseased Comparison Cohort|Pregnant women with a current diagnosis of a Cimzia approved indication who have not used Cimzia (certolizumab pegol) during the current pregnancy.
10034496|NCT01797224||Cohort 3 - Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
10034497|NCT01797224||Group 4 -Cimzia Registry, Not Qualified for the Cohort Study|Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
10034498|NCT01797237|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
10034499|NCT01797237|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
10034500|NCT01797289|Experimental|First episode of loss of consciousness|
10034501|NCT01797315|Active Comparator|Sirolimus|Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
10034502|NCT01797315|No Intervention|Standard therapy|Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.
10034503|NCT01797341|Experimental|Prograf arm|"patients will self-administer tacrolimus in the form of Prograf (twice daily administration.~Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day."
10034504|NCT01797341|Experimental|Advagraf Arm|patients will self-administer tacrolimus in the form of Advagraf (once daily dosing) Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
10034505|NCT01797354|Experimental|Cognitive-behavioral therapy and hypnosis group|Patients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
10034506|NCT01797354|Active Comparator|Support group|Patients will receive (in groups of 6) fifteen 120-min support group session.
10034507|NCT01797393|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
9474458|NCT03590522||Group II:|Twenty healthy controls
10034508|NCT01797393|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .The mucosa was observed by inflating the bowel with air while withdrawing the colonoscope.All the patients were examined without sedation during the whole procedure.
10034509|NCT01797393|Experimental|" Air assisted water colonoscopy"|" Air assisted water injection colonoscopy: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.All the patients were examined without sedation during the whole procedure."
10037222|NCT01823094||Variability of measurements|variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates
9474459|NCT03590509|Experimental|Telemedicine Program*|"Integrated Telemedicine-Home Visitation* Program.~*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
9474460|NCT03590509|Active Comparator|Control|Usual Comprehensive Care
9474461|NCT03590496|Active Comparator|Arm 1|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.
9474462|NCT03590496|Placebo Comparator|Arm 2|31 patients will be treated with placebo capsules (twice a day) for 8 weeks.
9474463|NCT03590470|Experimental|Experimental_INTERCARE intervention|Implementation of a nurse-led model of care adapted to the Swiss context, comprising a geriatric nurse expert with specific training in multidimensional clinical assessment and quality improvement tools.
9474464|NCT03590470|No Intervention|Control|The design used for the INTERCARE intervention is a non-randomized stepped wedge design, therefore all nursing homes will receive the intervention but at different time points. All nursing homes will be in a control phase before receiving the intervention, and switch to the intervention phase, once the intervention is implemented.
9474465|NCT03590457|Other|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
9474466|NCT03590444|Active Comparator|Prompt laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on the same day [Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
9474467|NCT03590444|Active Comparator|Deferred laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment [Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
9474468|NCT03590431|Other|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
9474469|NCT03590431|Other|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
9474470|NCT03590431|Other|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
9474471|NCT03590418||Intestinal stoma output|No interventions.
9474472|NCT03590418||Colonic feaces|No interventions.
9803161|NCT04490824|Placebo Comparator|Control Than Treated Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale water without an elevated level of KELEA for 2 days followed by inhaling KELEA Excellerated water for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
9803162|NCT04484025|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 7 days, with 30-day follow-up
9803163|NCT04484025|Experimental|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 7 days, with 30-day follow-up
9803164|NCT04484025|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 7 days, with 30-day follow-up
9803165|NCT04483973|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 14 days, with 30-day follow-up
9803166|NCT04483973|Experimental|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 14 days, with 30-day follow-up
9803167|NCT04483973|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 14 days, with 30-day follow-up
9803168|NCT04479787|Active Comparator|Spinal Cord Stimulation (SCS)|An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
9803169|NCT04479787|Active Comparator|Comprehensive Medical Management (CMM)|CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
9803170|NCT04474834||PRS|Providing polygenic risk score (PRS)
9803171|NCT04471714|Experimental|Control|Control participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
9803172|NCT04471714|Experimental|Spinal Cord Injury|Participants with a spinal cord injury will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
9803173|NCT04467749|Experimental|Suspension Wheel|Participants will be given a set of in-wheel suspension wheels to use in their normal daily routine for three months.
9474473|NCT03590418||Healthy Control|No interventions.
9474474|NCT03590392|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10^9 vp through intramuscular route.
9474475|NCT03590392|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10^10 vp through intramuscular route.
9474476|NCT03590392|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10^10 vp through intramuscular route.
9474477|NCT03590379|Experimental|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
9803174|NCT04465188|Experimental|Experimental arm|Surgical procedure to prevent retinal detachment in the unaffected eye
9803175|NCT04465188|No Intervention|Control arm|Standard procedure of clinical practice without any surgical procedure for the unaffected fellow eye.
9803176|NCT04463446|Experimental|The app arm|Use of CHD app
9803177|NCT04463446|Active Comparator|Nurse-led intervention arm|Nurse-led intervention
9803178|NCT04454567|Experimental|ABI-H0731 + SOC NrtI|Participants with chronic hepatitis B virus (HBV) infection with partial virologic suppression on NrtI alone will receive ABI-H0731 300 mg once daily plus standard of care (SOC) NrtI for 96 weeks, followed by SOC NrtI alone for an additional 24 weeks (120 weeks total).
9803179|NCT04454567|Placebo Comparator|Placebo + SOC NrtI|Participants with chronic HBV infection with partial virologic suppression on NrtI alone will receive placebo to ABI-H0731 once daily plus SOC NrtI for 48 weeks, followed by ABI-H0731 300 mg once daily plus SOC NrtI for Weeks 48 to 96, followed by SOC NrtI alone for Weeks 96 to 120.
9803180|NCT04448301|Experimental|PointCheck Cohort|
9803181|NCT04445792|Experimental|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
9474478|NCT03590379|Active Comparator|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
9474479|NCT03590379|Active Comparator|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
9474480|NCT03590353|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
9474481|NCT03590353|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
9474482|NCT03590340|Experimental|Group 1a (PfSPZ Vaccine)|"Group 1a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 113.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
9474483|NCT03590340|Experimental|Group 2a (PfSPZ Vaccine)|"Group 2a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last prime dose by DVI injection."
9474484|NCT03590340|Experimental|Group 3a (PfSPZ Vaccine)|"Group 3a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
9474485|NCT03590340|Experimental|Group 4a (PfSPZ Vaccine)|"Group 4a: subjects (n=21) will receive two doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1 and 8 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
9474486|NCT03590340|Placebo Comparator|Group 1b (NS)|"Group 1b: subjects (n=5) will receive normal saline (NS) placebo on Days 1, 3, 5, 7, and 113.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
9474487|NCT03590340|Placebo Comparator|Group 2b (NS)|"Group 2b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, and 7.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
9474488|NCT03590340|Placebo Comparator|Group 3b (NS)|"Group 3b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, 7, and 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
9474489|NCT03590340|Placebo Comparator|Group 4b (NS)|"Group 4b: subjects (n=5) will receive NS placebo on Days 1 and 8.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
9474490|NCT03590327|No Intervention|Apathy +, rTMS -|This arm will be followed without intervention
9474491|NCT03590327|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
9474492|NCT03590327|Sham Comparator|Sham|This group will be randomized to receive sham treatment
9474493|NCT03590314|Experimental|Experimental group|The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland).
9474494|NCT03590314|Active Comparator|Control group|The control group was treated using a conventional training, without end effector robot.
10034510|NCT01797406|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
10034511|NCT01797406|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
9474495|NCT03590301|Experimental|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
9474496|NCT03590301|Active Comparator|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
9474497|NCT03590288||TIPS group|Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.
10034512|NCT01797419|Experimental|GS-5806|Single dose, oral liquid, .5 mL/kg
10034513|NCT01797419|Placebo Comparator|Placebo|Single dose, oral liquid, .5 mL/kg
10034514|NCT01797497|Experimental|Care plan and coaching group|In the intervention group, parents complete a referral care plan with their children's physicians and receive a brief coaching session about how to exchange information with specialists. Outcome data are collected from parents before and after the specialist visit.
10034515|NCT01797497|No Intervention|Preintervention group|In the preintervention group, no care plan is used and no coaching takes place. Outcome data are collected from parents before and after the specialist visit.
10034516|NCT01797510|Experimental|Coaching|Interventional web based coaching study
10034517|NCT01797510|No Intervention|Usual Care|
10034518|NCT01797549||History of having sustained TBI|Males and females between 18 and 60 years who have a diagnosis of TBI
9474498|NCT03590262|Experimental|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
9474499|NCT03590249|Experimental|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
9474500|NCT03590249|No Intervention|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
10034519|NCT01797549||Control group|Control group with no history of TBI or concussion. Gender and age matched non-TBI volunteers
10034520|NCT01797588|Active Comparator|adductor-canal block and periarticular infiltration|Adductor-canal block,performed prior to surgery using ultra sound guidance by an anesthetist, with a total of 30mL of 0.33% ropivacaine injected into the area surrounding the saphenous nerve. Periarticular infiltration, performed intra-operatively by the surgeon, involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee.
10034521|NCT01797588|Active Comparator|adductor-canal block|The adductor-canal block only group will receive an adductor-canal block prior to surgery in the block room using ultra sound guidance by an anesthetist. After the adductor-canal is located a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve. Participants will also receive 110mL of normal saline administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
10034522|NCT01797588|Active Comparator|periarticular infusion group|Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
10034523|NCT01797601|Active Comparator|Human Insulin|Nasal spray
10034524|NCT01797601|Placebo Comparator|Placebo solution|Nasal spray
10034525|NCT01797653|Placebo Comparator|Placebo CPAP|patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks.
10034526|NCT01797653|Active Comparator|therapeutic CPAP|patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
9474501|NCT03590236|Experimental|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
9474502|NCT03590236|Active Comparator|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
10037223|NCT01823094||Treatment induced effects|The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment
9474503|NCT03590236|No Intervention|Control group|Waiting list patients
9474504|NCT03590210|Experimental|Group A - L-sarcoma|Patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
9474505|NCT03590210|Experimental|Group B - non-L-sarcoma|Patients with unresectable or metastatic soft tissue sarcoma other than liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (GIST excluded) will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
9474506|NCT03590197|Placebo Comparator|Control Arm|The patients in Control Arm will receive placebo with valproate (20 mg/kg).
9474507|NCT03590197|Experimental|Melatonin Arm|The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.
9474508|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
9474509|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
9474510|NCT03590171|No Intervention|Arm HR-A|Induction: Backbone ALL R3
9474511|NCT03590171|Experimental|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
9474512|NCT03590158|Experimental|TRF|Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
9474513|NCT03590132|Experimental|SAAF|participants in this arm receive the SAAF intervention at age 11-12.
9474514|NCT03590132|Experimental|SAAF-T|participants in this arm receive the SAAF-Teen intervention at age 14-15.
9474515|NCT03590132|Experimental|SAAF SAAF-T|participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15
9474516|NCT03590132|No Intervention|Control|These participants receive no interventions.
9474517|NCT03590119|Experimental|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
9474518|NCT03590119|Active Comparator|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
9474519|NCT03590106|Experimental|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:~Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.~Demonstrate negative drug screens done randomly during their hospitalization.~Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).~Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.~Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
9474520|NCT03590093|Experimental|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
9474521|NCT03590093|Active Comparator|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
9474522|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
9474523|NCT03590067||Heamodialysis group|
9474524|NCT03590067||Kidney transplantation group|
9474525|NCT03590054|Experimental|Treatment (abexinostat, pembrolizumab)|Participants receive abexinostat PO BID on days 1-21 and pembrolizumab IV on over 30 minutes day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9474526|NCT03590028|Experimental|Early Nephrology Consult (ENC)|The ENC will be a structured consultative note that will provide detailed recommendations around issues such as Differential Diagnosis, Drug Dosing and Volume Status. The research ENC will have a daily follow-up with documented recommendations.
9474527|NCT03590028|Active Comparator|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
9474528|NCT03590015|Other|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
9474529|NCT03590015|Other|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
9474530|NCT03589963|No Intervention|Pre-intervention|regular CPNP programming
9474531|NCT03589963|Experimental|Post-intervention|regular CPNP programming plus access to postnatal lactation support
9474532|NCT03589950|Experimental|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
9474533|NCT03589950|Active Comparator|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
9474534|NCT03589924|Experimental|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
9474535|NCT03589924|Active Comparator|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
9474536|NCT03589898|Experimental|Gabapentin|Single dose of gabapentin 900 mg will be given and neuroimaging markers will be measured before and after administration of gabapentin
9474537|NCT03589872||Study Group|patients with parkinson disease
9474538|NCT03589833|Placebo Comparator|MTX|Treated with oral methotrexate and two placebos.
9474539|NCT03589833|Placebo Comparator|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
9474540|NCT03589833|Active Comparator|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
9474541|NCT03589833|Experimental|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
9474542|NCT03589820|Active Comparator|Artificial liver support system group|30 patients will receive treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine.
10034527|NCT01797679|Other|Strength Training|"The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.~Intervention: Other: Strength training"
10034528|NCT01797679|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 85% of maximal heart rate.
10034529|NCT01797679|No Intervention|Control Group|The control group will do as usual.
10034530|NCT01797692|Other|geriatric assessment|geriatric assessment
10034531|NCT01797718|Active Comparator|Testosterone|~1mg/kg every 4 weeks for 6 months
10034532|NCT01797718|Active Comparator|Letrozole|2.5mg daily for 6 months
10034533|NCT01797744|Experimental|Vestibular rehabiliation|Vestibular rehabiliation
10034534|NCT01797744|No Intervention|Control group|Usual rehabilitation whitout additional vestibular exercises
10034535|NCT01797757|Active Comparator|Fish oil enriched with EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
9474543|NCT03589820|No Intervention|Control group|30 patients will receive treatment of internal medicine.
10034536|NCT01797757|Active Comparator|MAG-EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
10034537|NCT01797757|Active Comparator|MAG-EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
10034538|NCT01797757|Active Comparator|Fish oil enriched with EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
10034539|NCT01797770||Mechanical bowel preperation|mechanical bowel preparation with polyethylene glycol one day prior to surgery
10034540|NCT01797796|Experimental|PF-06305591|
9474544|NCT03589781|Experimental|Mikei Red Reishi Essence EX|There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).
9474545|NCT03589781|Placebo Comparator|Placebo|Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.
9474546|NCT03589755|Active Comparator|mindful meditation|Behavioral intervention, providing meditation
9474547|NCT03589755|No Intervention|Waiting list|Patient on a waiting list
9474548|NCT03589742|Experimental|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
9474549|NCT03589716|Other|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
9474550|NCT03589716|Other|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
9474551|NCT03589690|Experimental|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
9474552|NCT03589690|Placebo Comparator|Placebo|Starch-filled capsules (600 mg/day)
9474553|NCT03589677||Myotonic dystrophy type 1|"Subjects of both sexes with a diagnosis of Steinert's disease (DM1), de novo or with the previous diagnosis that shows significant worsening detectable during the follow-up foreseen by the normal cure procedure with clinical presentation indicating a CNS compromise will be evaluated for:~quality of life evaluation~exam of neuroimaging~study of myomiRNAs before and after rehabilitation"
9474554|NCT03589664||Non-Sternotomy Group|Subjects who have no prior sternotomy
9474555|NCT03589664||Sternotomy Group|Subjects who previously underwent a sternotomy procedure.
9474556|NCT03589638|Active Comparator|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
9474557|NCT03589638|Active Comparator|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
9474558|NCT03589638|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
9474559|NCT03589625|Experimental|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
9474560|NCT03589625|Experimental|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
9474561|NCT03589599|Experimental|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
9474562|NCT03589599|Experimental|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
9474563|NCT03589586|Experimental|DermACELL AWM + Conventional Care|DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.
9474564|NCT03589586|No Intervention|Conventional Care|Conventional wound care will include advanced wound dressings and multilayer compression.
9474565|NCT03589560|Experimental|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
9474566|NCT03589560|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
9474567|NCT03589547|Experimental|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
9474568|NCT03589534|Other|pregnancy test|pregnancy tests
9480965|NCT05146609|Experimental|GP-HOSPITAL|Patients assigned to the strategy GP-HOSPITAL, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
10034541|NCT01797796|Placebo Comparator|Placebo|
10034542|NCT01797809||Group 1|
10034543|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Placebo|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 48 weeks~Ribavirin 200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 48 weeks~Placebo 0 mg Tablets, by mouth, Once daily, 24 weeks"
10034544|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Daclatasvir|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response~Ribavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response~Daclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks"
10034545|NCT01797861|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose PDT will be performed (Treatment Visit 2)."
9474569|NCT03589521|Experimental|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
9474570|NCT03589508|Experimental|In-Person Sessions: ABCP_P|In-person therapy sessions: 6 Weekly Prevention Session conducted in person (half of participants will attend alone, half of participants will attend with a significant other)
9474571|NCT03589508|Experimental|Video conference sessions: ABCP_T|Video conference therapy sessions: 6 Weekly Prevention Session conducted using videoconference (half of participants will attend alone, half of participants will attend with a significant other)
9474572|NCT03589495|Active Comparator|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
10037224|NCT01823120|No Intervention|No text messages|Patients in the non-intervention group will not receive any text messages. However, they will also receive the routine outpatient follow-up arrangements associated with attendance at an ED with self-harm including the provision of a contact phone number for the Samaritans.
9803182|NCT04445792|Other|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
9474573|NCT03589495|Placebo Comparator|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
9474574|NCT03589482|Experimental|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
9474575|NCT03589482|Active Comparator|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
9474576|NCT03589443|Experimental|Multiplexed heptapeptides|QRH & KSP sprayed onto area of interest and imaged before and after application
9474577|NCT03589430||1 child A|child A liver cirrhosis
9474578|NCT03589430||2 child B|child B liver cirrhosis
9474579|NCT03589430||3 child C|child C liver cirrhosis
9474580|NCT03589404|Experimental|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
9474581|NCT03589391|Experimental|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
9474582|NCT03589391|No Intervention|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
9474583|NCT03589378|Experimental|PEAF|Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
9474584|NCT03589378|No Intervention|Control group|HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.
9474585|NCT03589365|Other|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
9474586|NCT03589365|Other|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
9474587|NCT03589313|Experimental|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
9474588|NCT03589287|Experimental|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
9474589|NCT03589287|Experimental|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
9474590|NCT03589287|Experimental|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
9474591|NCT03589274|Experimental|I-FS-CBT|In I-FS-CBT each participant saw a therapist weekly. The first session was 90 minutes long, and subsequent sessions were 60 minutes long. The I-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care.
9474592|NCT03589274|Experimental|G-FS-CBT|The G-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care. The session organization was modified for a closed group format. The group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence.
9474593|NCT03589261|Other|MRI (magnetic resonance imaging)|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
9474594|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
9474595|NCT03589248||US score|assess the AGI by ultrasonography(US) score
9480492|NCT03533049|Experimental|myFAMI intervention|"All participants will receive the standard discharge education from their transplant and inpatient care team.~Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge."
9480493|NCT03533049|Active Comparator|Control|Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.
9480494|NCT03533023|Experimental|TRE + SOC|Time Restricted Eating + Standard of Care
9480495|NCT03533023|Other|SOC|Standard of Care
9480496|NCT03532997|Experimental|Intervention|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel app called ELOS (stands for extra layer of support) in a prospective cohort study. The investigators will compare participant acceptance of this new electronic tool to industry standards and follow ultimate referrals to outpatient palliative care compared to historical, matched controls."
9480497|NCT03532984||adults aged 20-29|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
9480498|NCT03532984||adults aged 30-39|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
9480499|NCT03532984||adults aged 40-49|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
9480500|NCT03532984||adults aged 50-59|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
9480501|NCT03532984||adults aged 60-69|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
9480502|NCT03532984||adults aged 70-79|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
9480503|NCT03532984||adults aged 80+|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
9480504|NCT03532984||geriatric patients|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
9803183|NCT04445792|Experimental|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
9803184|NCT04445792|Other|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
10034546|NCT01797861|Active Comparator|Micropulse laser (ML) treatment|"ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiography. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein angiogram.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first ML treatment), a second ML treatment will be performed (Treatment Visit 2)."
10034547|NCT01797874|Experimental|Pazopanib|pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
9474596|NCT03589235|Experimental|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be used in both donor and receiving sites after a free gingival graft.
10034548|NCT01797874|Placebo Comparator|placebo|placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
10034549|NCT01797887|Experimental|Ayurveda|Ayurveda Diet and Lifestyle Counseling
10034550|NCT01797887|Active Comparator|Conventional|Standard Conventional Diet and Lifestyle Counseling
10034551|NCT01797900|Experimental|Inductive + concurrent chemotherapy|Inductive chemotherapy :paclitaxel 175mg/m2 d1+ cisplatin 80mg/m2d1, every 21 days for two cycles concurrent chemotherapy:cisplatin 80mg/m2 on week 1, 4, 7 radiotherapy: IMRT
9474597|NCT03589235|Experimental|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be used in both donor and receiving sites after a free gingival graft.
9474598|NCT03589222|Experimental|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
9474599|NCT03589196|Active Comparator|Photoselective Vaporization|
9474600|NCT03589196|Active Comparator|Plasma Kinetic Vaporization|
9474601|NCT03589196|Active Comparator|Transurethral Resection Of The Prostate|
9474602|NCT03589170||People over 60 years of age|People over 60 years of age without previous known atrial fibrillation
9474603|NCT03589157|Experimental|Drug-coated balloon group|
9474604|NCT03589157|Active Comparator|second-generation drug-eluting stent group|
9474605|NCT03589131|Active Comparator|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
9474606|NCT03589131|Active Comparator|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
9474607|NCT03589118|Experimental|Qi Gong|Qi gong sessions added to usual well defined medical and psychological support
9474608|NCT03589118|No Intervention|Control|Usual well defined medical and psychological support
9474609|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
9474610|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
9474611|NCT03589079||Monogenic Disorder|Participants exhibiting clinical phenotypes suggestive of an underlying novel monogenic disorder, with/without the presence of familial recurrence of the phenotype and/or parental consanguinity will be included. Sanger and/or Next generation Sequencing (NGS) - Panel/WES/WGS approaches will be used to facilitate identification of de novo/inherited variants in the child/proband.
9474612|NCT03589066|Experimental|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
9474613|NCT03589066|Experimental|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
10034552|NCT01797900|Active Comparator|concurrent + adjuvant chemotherapy|concurrent chemotherapy: cisplatin 80 mg/m2, on week 1, 4, 7 adjuvant chemotherapy: paclitaxel 175mg/m2 + cisplatin 75mg/m2, every 21 days for 4 cycles radiotherapy: IMRT
10034553|NCT01797913|Experimental|gemcitabine|
9474614|NCT03589053|Experimental|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
10034554|NCT01797926|Experimental|Group 1 (5 mg amlodipine and 50 mg losartan)|Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design
10034555|NCT01797926|Experimental|Group 2 (5 mg amlodipine and 100 mg losartan)|Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design
10034556|NCT01797939||Erosive reflux disease (ERD)|
9474615|NCT03589053|Sham Comparator|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
9474616|NCT03589040|Other|Ripivirine arm|All subjects will be administered oral ripilvirine 25mg once daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
10034557|NCT01797939||Non-erovise reflux disease (NERD)|
9474617|NCT03589040|Other|Darunavir arm|All subjects will be administered oral DRV/r 600/100mg twice daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
9474618|NCT03589027|Experimental|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
10034558|NCT01797939||Functional heartburn (FH)|
10034559|NCT01797952|Active Comparator|Lactobacillus CD 2 lozenges|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
9474619|NCT03589027|Experimental|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
9474620|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
9474621|NCT03588988|Experimental|Dexmedetomidine group|
9474622|NCT03588988|Placebo Comparator|Control group|
9474623|NCT03588962|Experimental|Metal allergy driven restenosis|Patients with angiographically proven in-stent restenosis developed after technically correct implantation. Patch tests for the metals used in stent production will be applicated. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
9474624|NCT03588962|Placebo Comparator|Looking for allergic restenosis|Patients with (technically correctly) implanted stent. Patch tests will be applicated to identify cases with contact allergy. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards.The patients will then be monitored for a 12 months follow-up period in purpose of evaluating the dependance between in-stent restenosis and contact allergy. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
9474625|NCT03588949|Experimental|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
9474626|NCT03588949|Placebo Comparator|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
9474627|NCT03588936|Experimental|Nivolumab (0.25 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
9474628|NCT03588936|Experimental|Nivolumab (0.5 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
9474629|NCT03588923|Active Comparator|Cohort 1|SH229 (400 mg) or matching placebo, once daily
9474630|NCT03588923|Active Comparator|Cohort 2|SH229 (600 mg) or matching placebo, once daily
9474631|NCT03588923|Active Comparator|Cohort 3|SH229 (800 mg) or matching placebo, once daily
9474632|NCT03588897|No Intervention|Normal Diet|Elderly patients receiving normal diet
9474633|NCT03588897|Experimental|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
9474634|NCT03588871|Experimental|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
9474635|NCT03588871|Experimental|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
9474636|NCT03588871|Experimental|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
9474637|NCT03588845|Other|Protocol Treatment|"If a score on the GSS is > 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
9474638|NCT03588845|Other|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
9474639|NCT03588819|Experimental|2-fraction SABR|
9474640|NCT03588767|Experimental|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
9474641|NCT03588767|Active Comparator|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
9474642|NCT03588728|Experimental|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
9474643|NCT03588728|Sham Comparator|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
9474644|NCT03588728|Sham Comparator|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
10034560|NCT01797952|Placebo Comparator|Placebo lozenges|The placebo is a mix of sugars and salts used as excipients in the active formulation
10034561|NCT01797978|Experimental|Intravenous methylene blue administration|2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs
10034562|NCT01797978|Placebo Comparator|Placebo|Normal saline administration instead of methylene blue
10034563|NCT01797991|Active Comparator|Group A (dexamethasone per os)|"Dexamethasone 20 mg per os 12 hours and 6 hours before paclitaxel (form: opaque white capsules)~Matching placebo for dexamethasone IV (NaCl 0,9%) 30 minutes before paclitaxel"
9474645|NCT03588728|No Intervention|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
9474646|NCT03588715|Experimental|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
9474647|NCT03588715|Experimental|bNAb only|bNAb (3BNC117 + 10-10-74) only
10034564|NCT01797991|Experimental|Group B (dexamethasone IV)|"Dexamethasone 20 mg IV 30 minutes before paclitaxel~Matching placebo for dexamethasone per os (lactose capsule) 12 hours and 6 hours before paclitaxel (form: opaque white capsules)"
9474649|NCT03588689|No Intervention|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
9474650|NCT03588689|Experimental|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
9474651|NCT03588676|No Intervention|Normoxia|Participants will sleep in room air and receive no melatonin.
9474652|NCT03588676|Placebo Comparator|Hypoxia and Placebo|5mg placebo before sleep study
9474653|NCT03588676|Experimental|Hypoxia and Melatonin|5mg melatonin before sleep study
10034565|NCT01798017|Experimental|Mifepristone-misoprostol|Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol
10034566|NCT01798030||Vitamin D|Specimen analysis
9474654|NCT03588663|Experimental|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
9474655|NCT03588663|Active Comparator|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
9474656|NCT03588650|Experimental|HLX20, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 1, 3, 10 and 20 mg/kg, starting from 1 mg/kg.
9474657|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
9474658|NCT03588624|Experimental|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
9474659|NCT03588611|Experimental|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
9474660|NCT03588611|Active Comparator|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
9474661|NCT03588611|Active Comparator|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
9474662|NCT03588611|Experimental|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
9474663|NCT03588598|Experimental|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
9474664|NCT03588585|Active Comparator|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
9474665|NCT03588585|Active Comparator|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
9474666|NCT03588559|Experimental|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
9474667|NCT03588533|Experimental|Herzuma-capecitabine/cisplatin(XP)|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks~Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks~Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks"
9474668|NCT03588507|No Intervention|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
9480505|NCT03532958|Placebo Comparator|Placebo|Normal saline
9480506|NCT03532958|Experimental|Low Dose BNZ-1|0.5 mg/kg QW
9480507|NCT03532958|Experimental|Moderate Dose BNZ-1|2 mg/kg QW
9480508|NCT03532945|Experimental|Bioactive Glass-Ceramic Spacer|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with Novomax, which is the bioactive glass ceramic intervertebral spacer.
9480509|NCT03532945|Active Comparator|Titanium cage|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with titanium cage.
10034567|NCT01798043|Experimental|Septal RV lead with >50% pacing (B1)|Cardiac MRI with pacemaker stimulation
10034568|NCT01798043|Experimental|Septal RV lead with <50% pacing (B2)|Cardiac MRI with and without pacemaker stimulation
10034569|NCT01798043|Experimental|Apical RV lead with >50% pacing (A1)|Cardiac MRI with pacemaker stimulation
10034570|NCT01798043|Experimental|Apical RV lead with <50% pacing (A2)|Cardiac MRI with and without pacemaker stimulation
9474669|NCT03588507|Active Comparator|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
9474670|NCT03588494|Active Comparator|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
9474671|NCT03588494|Experimental|W1-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
9474672|NCT03588494|Experimental|W2-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
9474673|NCT03588481||Coronary stenosis|
9474674|NCT03588468|Sham Comparator|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
9474675|NCT03588468|Active Comparator|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
9474676|NCT03588468|Experimental|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
9474677|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
9474678|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
9474679|NCT03588429|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
9474680|NCT03588429|Experimental|Isoflurane|Anesthesia was maintained with isoflurane.
9474681|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
10034571|NCT01798069|Experimental|Behavioral intervention|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
10034572|NCT01798069|Active Comparator|behavoral intervention|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading medical publication workshops. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
10034573|NCT01798082|No Intervention|Standard counseling|
10034574|NCT01798082|Experimental|Standard counseling, pelvic organ prolapse decision aid|In addition to standard counseling at the time of the initial new patient visit, the patients randomized to the experimental arm will recieve a pelvic organ prolapse decision aid prior to their initial visit.
10034575|NCT01798095|Experimental|Aplisol|To confirm the response of PPD materials
10034576|NCT01798095|Active Comparator|PPD Standard|Determine equivalent specificity for new material compared to standard material.
10034577|NCT01798108|Experimental|Radium-223 dichloride|The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
10034578|NCT01798121|Experimental|Aplisol|To compare new PPD to reference standard material
10034579|NCT01798121|Placebo Comparator|Reference standard|Response of standard material
10034580|NCT01798147|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
10034581|NCT01798147|Experimental|SIRT|Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)
10034582|NCT01798160|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
10034583|NCT01798160|Experimental|SIRT|Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)
10034584|NCT01798199|Experimental|Alzheimer disease|
9474682|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
10034585|NCT01798212|Other|full thickness gastroplication|
10034586|NCT01798238|Placebo Comparator|Placebo group|
10034587|NCT01798238|Experimental|MP-513 group|
9474683|NCT03588390|Experimental|Dose Group 1|
9474684|NCT03588390|Experimental|Dose Group 2|
10034588|NCT01798251|Experimental|XELOX-X|"XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.~X Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
9474685|NCT03588390|Experimental|Dose Group 3|
9474686|NCT03588390|Experimental|Dose Group 4|
10034589|NCT01798251|Active Comparator|XELOX|XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance.
9474687|NCT03588390|Experimental|Dose Group 5|
9474688|NCT03588390|Experimental|Dose Group 6|
10034590|NCT01798277|Active Comparator|Catheter Ablation|Radiofrequency ablation procedure
10034591|NCT01798277|Active Comparator|Medical therapy|Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.
9474689|NCT03588390|Experimental|Dose Group 7|
10034592|NCT01798290|Experimental|Behavioral: narrative medicine: reading workshop|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading patients' diaries or nurses'diaries. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
9474690|NCT03588390|Experimental|Dose Group 8|
9474691|NCT03588364|Experimental|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
9474692|NCT03588364|No Intervention|Waitlist Control|Six-week waiting period.
9474693|NCT03588351|Active Comparator|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
9474694|NCT03588351|Experimental|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
9474695|NCT03588351|Experimental|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
9474696|NCT03588338|Active Comparator|Perfalgan|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
9474697|NCT03588338|Other|Control|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
10034593|NCT01798290|Active Comparator|Behavioral: critical reading|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading literature. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
10034594|NCT01798329|Active Comparator|Probiotic|Probiotic VSL#3 for 15 weeks, dosage variations according to the weight
9474698|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
9474699|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
9474700|NCT03588273|Other|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
10034595|NCT01798329|Placebo Comparator|Placebo|subjects treated with placebo for 15 weeks
10034596|NCT01798342|Active Comparator|Maltodextrin|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin
10034597|NCT01798342|Experimental|Glutamine|The same volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of glutamine
10034598|NCT01798355|Experimental|Cognitive Behavioral Therapy|
9474701|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
9474702|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
9474703|NCT03588221|Other|Six-step hand hygiene technique with application time of 30|
9474704|NCT03588221|Other|Six-step hand hygiene technique with application time of 15|
9474705|NCT03588221|Other|Three-step hand hygiene technique with application time of 3|
9474706|NCT03588221|Other|Three-step hand hygiene technique with application time of 1|
9474707|NCT03588208|Experimental|Intervention Group|
9474708|NCT03588208|Active Comparator|Control Group|
9474709|NCT03588195|Experimental|Education Group|
9474710|NCT03588195|Active Comparator|Control Group|
9474711|NCT03588182|Experimental|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
9480510|NCT03532906|Active Comparator|TAP block|Patients receive the injection of local anaesthetic into the right abdominal wall (TAP block) together with the injection of local anaesthetic into the surgical wounds.
9480511|NCT03532906|Other|Control|Patients receive the injection of local anaesthetic into the surgical wounds only.
10034599|NCT01798355|Active Comparator|Treatment as usual|
10034600|NCT01798368|Experimental|PBASE system 2.0|
10034601|NCT01798381|Active Comparator|Essential fatty acids|Omega-3
10034602|NCT01798381|Placebo Comparator|Placebo|Placebo tablet
9474712|NCT03588182|No Intervention|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
9474713|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
9474714|NCT03588156|Experimental|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
9474715|NCT03588156|Placebo Comparator|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
9803185|NCT04445792|Experimental|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
10034603|NCT01798407|Experimental|Activa Tremor Control Sys (DBS Implant)|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase.
9803186|NCT04445792|Other|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
9474716|NCT03588143|Active Comparator|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
9803187|NCT04442646|Experimental|ASG= Asthma School Group, with educational intervention|"experimental asthma school group (ASG) will attend control visits as Control Group every three months. In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day"
9803188|NCT04442646|No Intervention|CG= Control Group, With no educational intervention|Control group will attend control visits every three months.
10034604|NCT01798407|Experimental|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
10034605|NCT01798420||Corticosteroid|
9474717|NCT03588143|Experimental|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
9474718|NCT03588143|Placebo Comparator|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
10034606|NCT01798420||non-corticosteroid group|
9474719|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
9474720|NCT03588104|Experimental|POWER2DM support group|Participants in this group will receive access to the POWER2DM system as an adjunct to usual care. The participants have three intervention visits in which they will use the Shared Decision Making Dashboard to set self-management goals and will use the Self-Management Support system for trying to reach those goals in the periods after the intervention visits.
9803189|NCT04431999|Experimental|Whole blood group|Damage control resuscitation for trauma care using whole blood.
9803190|NCT04431999|Active Comparator|Fractionated blood products group|Damage control resuscitation for trauma care using component therapy.
9803191|NCT04430582||Hypoglycemia after upper gastrointestinal (GI) surgery|Participants with hypoglycemia after upper GI surgery, recruited from the Joslin Hypoglycemia Clinic and from other hypoglycemia studies at Joslin.
9474721|NCT03588104|Active Comparator|Usual care group|Participants in this group will follow their usual diabetes care with their own diabetes care team.
9803192|NCT04430582||Asymptomatic post-bariatric participants|Participants with a history of bariatric surgery, but without a diagnosis of hypoglycemia, or symptoms of hypoglycemia. They will be recruited by advertisement flyers at postoperative surgical clinics at local hospitals (e.g. Brigham and Women's and Beth Israel Deaconess Hospitals) and from other hypoglycemia studies at Joslin.
10034607|NCT01798433|Experimental|One stent technique alone|One stent technique alone for non-true LM bifurcation
10034608|NCT01798433|Experimental|One stent technique + Elective FKB|One stent technique + Elective FKB for non-true LM bifurcation
10034609|NCT01798433|Experimental|Provisional approach|Provisional approach for true LM bifurcation
10034610|NCT01798433|Experimental|Elective 2-stent|Elective 2-stent for true LM bifurcation
10034611|NCT01798446|Experimental|Axitinib|This is a single arm study. Axitinib arm is the only arm who receive axitinib.
10034612|NCT01798459|Active Comparator|Methylphenidate|Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.
10034613|NCT01798459|Placebo Comparator|Placebo|Placebo is given before performing a continuous performance test.
9474722|NCT03588091|Experimental|arm1|Pyrotinib Plus trastuzumab and docetaxel
9474723|NCT03588091|Placebo Comparator|arm2|placebo plus trastuzumab and docetaxel
10034614|NCT01798472|Experimental|uncemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an uncemented hemiarthroplasty
10034615|NCT01798472|Experimental|reverse hybrid total hip arthroplasty|Patients aged between 65 and 79 years treated with an reverse hybrid arthroplasty.
10034616|NCT01798472|Active Comparator|cemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an cemented hemiarthroplasty
9474724|NCT03588078|Experimental|combination of APR246 and azacitidine|Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
9474725|NCT03588065|Experimental|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
9474726|NCT03588065|Active Comparator|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
9474727|NCT03588065|Sham Comparator|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
9474728|NCT03588052|Experimental|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
9474729|NCT03588052|Active Comparator|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
9474730|NCT03588039|Experimental|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474731|NCT03588039|Experimental|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474732|NCT03588039|Experimental|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474733|NCT03588039|Experimental|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474734|NCT03588039|Experimental|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474735|NCT03588039|Experimental|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474736|NCT03588039|Experimental|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474737|NCT03588039|Experimental|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474738|NCT03588039|Experimental|Dose expansion-Urothelial cancer|The dose expansion period will enroll subjects with advanced/metastatic urothelial to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
9474739|NCT03588026|Experimental|Arm 1 - 9 months of treatment (rVA576 plus SOC)|6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).
9474740|NCT03588026|Experimental|Arm 2 - 6 months on SOC|6 months on SOC only. Followed by 3 months (SOC plus rVA576).
10034617|NCT01798472|Active Comparator|cemented total hip arthroplasty|Patients aged between 65 and 79 years treated with an cemented total hip arthroplasty.
10034618|NCT01798498|Experimental|Princess® VOLUME|"Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.~A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.~The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds"
10034619|NCT01798511|Experimental|Nasogastric Tube Feeding|Patients who are to have NTF will receive enteral nutrition within 6 hours after randomisation via a nasogastric tube placed into the stomach. A commercially available low fat semi-elemental feed (Peptisorb®, Nutricia Clinical NZ) will be used. The caloric target will be 2000 kcal per day. Enteral tube feeding will be commenced at a rate of 30 mL/h and increased gradually until 100 mL/h over 24-48 h.
9474741|NCT03588013|Experimental|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) < -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ < -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
9474742|NCT03588013|Active Comparator|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ > 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
10034620|NCT01798511|Active Comparator|Conventional Nutritional Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case enteral tube feeding will be introduced) or the signs of AP mitigate,in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced.
10034621|NCT01798524||Kidney allograft recipients|
10034622|NCT01798537|Experimental|Neomycin Colistin Nystatin Vancomycin|"All participating study arm patients will receive SDD from admission to discharge according to the following plan:~ENTERAL MEDICATION (via feeding tube) x 4 times daily:~375 mg Neomycin 100 mg Colistin Sulphate~1 million units Nystatin * 250 mg Vancomycin *~Nystatin will be prescribed only if there is a positive sputum or urine culture for yeast or candida Vancomycin will be prescribed only in case of a positive screen or culture for MRSA"
9474743|NCT03588013|No Intervention|US children with celiac disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
9474744|NCT03588013|No Intervention|US children with Crohn's disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
9474745|NCT03588013|No Intervention|Healthy age-matched US children|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children < 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
9474746|NCT03588000|Experimental|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
9474747|NCT03588000|No Intervention|Control group|Voluntary self-monitoring of blood glucose
9474748|NCT03587987|Active Comparator|Neopuff|neopuff
9474749|NCT03587987|Experimental|r PAP|rPap device
9474750|NCT03587961|Experimental|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
9474751|NCT03587961|Experimental|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
9474752|NCT03587961|Experimental|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
10034623|NCT01798537|No Intervention|Control|No SDD given for 1 year Screening performed as in intervention arm
10034624|NCT01798563||Tremor Dominant PD|Volunteers with predominantly tremor-related motor symptoms of PD
10034625|NCT01798563||Postural Instability & Gait Difficulty PD|Volunteers with primarily walking & balance-related motor symptoms of PD.
9474753|NCT03587948||Case group|Children and adolescents with diabetes mellitus
9474754|NCT03587948||Control group|Children and adolescents without diabetes mellitus
9803193|NCT04430582||Hypoglycemia no upper GI surgery & no diabetes (DM) or pre-DM|Participants with hypoglycemia and no history of upper gastrointestinal surgery, and NO current diagnosis of diabetes or pre-diabetes, recruited from the Joslin Hypoglycemia Clinic, or from other hypoglycemia studies at Joslin.
10034626|NCT01798563||Healthy Controls|Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD.
9474755|NCT03587922|Experimental|Treatment Arm|Single arm study with treatment of Fantom scaffold
9474756|NCT03587909|Active Comparator|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
9803194|NCT04430582||Controls, no hypoglycemia or history of upper GI surgery|Participants without hypoglycemia or upper gastrointestinal surgery (controls), recruited by local advertisement. Some participants may be recruited from other hypoglycemia studies at Joslin.
10034627|NCT01798576||Pegylated interferon alfa-2a|Participants with chronic hepatitis C with previous treatment failure received combination therapy with pegylated interferon alfa-2a plus ribavirin or treatment regimens containing direct-acting anti-viral (DAAs)
10034628|NCT01798602|Experimental|Rosuvastatin|"Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug~Both are crushed for administration"
10034629|NCT01798602|Placebo Comparator|Placebo|Identical drug vehicle with no active agent
10034630|NCT01798628|Experimental|Sequence ABC|
10034631|NCT01798628|Experimental|Sequence ACB|
10034632|NCT01798628|Experimental|Sequence BAC|
10034633|NCT01798628|Experimental|Sequence BCA|
10034634|NCT01798628|Experimental|Sequence CAB|
9474757|NCT03587909|Active Comparator|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
9474758|NCT03587896|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
9474759|NCT03587896|No Intervention|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
9474760|NCT03587883|Experimental|Cocoa Flavanol intervention|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II.
9474761|NCT03587883|Placebo Comparator|Control intervention|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II.
9474762|NCT03587870|Experimental|Bolus enteral nutrition with Fresubin Intensive|Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
9474763|NCT03587870|Active Comparator|Continuous enteral nutrition with Fresubin Intensive|Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
9474764|NCT03587857|Experimental|Arm 1: Intervention|All YLWH who choose to enroll in the study will receive access to WYZ, the mobile health application. The participants will be asked to use the app for 6 months, during which the investigators will assess the feasibility and acceptability of WYZ. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
9474765|NCT03587831|Experimental|VSG + LSM|"Procedure/Surgery: Vertical Sleeve Gastrectomy will be performed using five laparoscopic ports. The short gastric and epiploic vessels will be taken down With a 40 French Bougie in place, the greater curvature will be excised starting 6 cm proximal to the pylorus.~Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention will align with methods listed in the LSM arm description. However, participants assigned to the VSG will not have calorie ceilings during the first 6 months of rapid weight loss, and they will receive additional instruction regarding food volume and adequate protein intake."
9474766|NCT03587831|Active Comparator|LSM|Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention is modeled after the LookAHEAD trial, with modules modified for participants undergoing surgery, and designed to produce maximum achievable weight loss. Both groups will increase their level of moderate-intensity physical activity (such as walking) to a total of 325 minutes per week. All lifestyle-medical management participants will be given calorie intake targets of 1200, 1500, or 1800 kilocalories per day, depending on body weight, with the goal of producing a weight loss of 1 to 2 pounds per week. There will be 24 weekly counseling meetings during the first 6 months, bi-weekly meetings between months 7 and 9, and monthly meetings between months 10 and 12.
9474767|NCT03587818|No Intervention|Control group|"Conventional care. Patients were receiving several written patient education materials (PEMs), mostly related to specific parts or procedures related to the surgery and the recovery.~Communication between patients and professionals during consultations occurred according to conventional care practice."
9480966|NCT05146609|Experimental|GP-PCC|Patients assigned to the strategy GP-PCC, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the primary care center (PCC) to be performed by the general practitioner.
10034635|NCT01798628|Experimental|Sequence CBA|
10037225|NCT01823120|Experimental|Supportive and interactive text messages|We will deliver daily supportive and informative text messages for one month followed by one supportive and informative text message every other day the second month and then one weekly text message the third month to patients in the intervention group after they have been discharged from the ED following an episode of self-harm. Supportive text messages will mainly target relieving the patients of mood symptoms and providing them with strategies for dealing with suicidal thoughts while the informative ones will provide patients with a dedicated mobile phone number through which they can receive interactive support from the Samaritans. The text messages will encourage participants to text the Samaritans in times of crisis. Please see appendix I for examples of the relevant text messages.
10037226|NCT01823133|Experimental|gemigliptin only|Multiple administrations of gemigliptin
10037227|NCT01823133|Experimental|rosuvastatin only|Multiple administrations of rosuvastatin
10037228|NCT01823133|Experimental|gemigliptin and rosuvastatin|Multiple administrations of gemigliptin and rosuvastatin
10037229|NCT01823159|Active Comparator|Retigabine|Administration of a single dose of 400 mg retigabine, two hours before the measures
10037230|NCT01823159|Placebo Comparator|placebo|Randomized administration of a single dose of placebo, two hours before the measures.
10037231|NCT01823172|Experimental|Methylene Blue|1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node
10037232|NCT01823185|Active Comparator|Clopidogrel|CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
10037233|NCT01823185|Experimental|Ticagrelor or prasugrel|Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
10037234|NCT01823198|Experimental|Treatment (NK cells, PBSC transplant)|Patients receive fludarabine phosphate IV over 1 hour and busulfan IV over 3 hours on days -13 to -10. Patients then receive allogeneic CD56-positive CD3-negative natural killer cells IV over 1 hour on day -8. Patients also receive aldesleukin SC QD on days -8 to -4. Patients then undergo allogeneic PBSC transplant on day 0.
10037235|NCT01823211||ischaemic cardiomyopathy|EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation
10037236|NCT01823211||non-ischaemic cardiomyopathy|EP study,magnetic resonance imaging with LGE, ICD implantation
10034636|NCT01798654||Antithrombotic agents|
10034637|NCT01798667|Placebo Comparator|Placebo|PO administration
10034638|NCT01798667|Experimental|DA-8031 dose 1|PO administration
9474768|NCT03587818|Experimental|Intervention group|"I. Written interactive PEM structured into chapters/phases of the care process. Designed to serve three purposes:~generic information of the surgery and recovery process on a group level to promote high readability, suitability and comprehensibility~arena of dialogues between patient and professionals; voicing concerns, share perspectives~for the patient to personally reflect on generic information.~II. Person-centred communication in dialogues using the PEM as a supportive tool, facilitated by four communication strategies:~professionals guiding the patient through the care process~communicating an introduction, agenda and closing~being sensitive to the patient's questions, beliefs, experiences and resources~dialogue based on story, posing open-ended questions, and following up."
9474769|NCT03587779|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
10034639|NCT01798667|Experimental|DA-8031 dose 2|PO administration
10034640|NCT01798667|Experimental|DA-8031 dose 3|PO administration
10034641|NCT01798680|Experimental|Vitamin D3 (cholecalciferol)|
10034642|NCT01798680|Placebo Comparator|Placebo|
9474770|NCT03587779|Experimental|Desflurane|Anesthesia is maintained with desflurane.
10034643|NCT01798693|Placebo Comparator|Placebo (maltodextrin)|Maltodextrin
9474771|NCT03587766|Experimental|Group A|Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
9474772|NCT03587766|Experimental|Group B|Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
9474773|NCT03587766|Experimental|Group C|Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
9474774|NCT03587753|Active Comparator|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
9474775|NCT03587753|Active Comparator|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
9474776|NCT03587701|Experimental|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
9474777|NCT03587701|Experimental|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
9474778|NCT03587701|Experimental|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
10034644|NCT01798693|Active Comparator|Multi-Nutrient Blend|Blend of vitamins, minerals, and amino acids, given twice daily
10034645|NCT01798719|Placebo Comparator|Diet: Dietary Advice|Some general dietary advice about healthy dietary components, servings size and frequency of servings
10034646|NCT01798719|Experimental|Low glycemic index Mediterranean Diet|Low glycemic index Mediterranean Diet prescription with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
10034647|NCT01798732|Experimental|Selective laser trabeculoplasty (Tango Laser, Ellex)|Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
10034648|NCT01798745|Experimental|Cohort A: JNJ-54452840 20 mg|Each patient will receive 20 mg of JNJ-54452840 as a single dose.
9474779|NCT03587662|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|"INDUCTION: Patients receive ixazomib PO, gemcitabine IV over 90 minutes, and doxorubicin IV over 15-30 minutes on day 1. Treatment repeats every 14 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ixazomib PO and gemcitabine IV over 90 minutes. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
9474780|NCT03587649|Experimental|[18F]MNI-1126|To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
9474781|NCT03587610|Active Comparator|Intervention arm|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
9474782|NCT03587610|No Intervention|Standard care|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
9480967|NCT05145751||COVID-19 infection|Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection
9480968|NCT05144503|Experimental|SpherePVI™ Catheter|Subjects treated with the SpherePVI™ Catheter
9480969|NCT05143931|Active Comparator|WW Only|WW is commercially-available weight management program focusing on diet, physical activity and mindset skills.
10034649|NCT01798745|Experimental|Cohort A: JNJ-54452840 80 mg|Each patient will receive 80 mg of JNJ-54452840 as a single dose.
10034650|NCT01798745|Experimental|Cohort A: JNJ-54452840 160 mg|Each patient will receive 160 mg of JNJ-54452840 as a single dose.
10034651|NCT01798745|Placebo Comparator|Cohort A: Placebo|Each patient will receive matching placebo as a single dose.
10034652|NCT01798745|Experimental|Cohort B: JNJ-54452840 <= 240 mg|Each patient will receive JNJ-54452840 at a dose of less than or equal to 240 mg as a single dose (dose determined by the Data Monitoring Committee).
9474783|NCT03587597|Experimental|socket shield technique|socket shield technique with immediate temporization
9474784|NCT03587597|Active Comparator|conventional immediate implant|conventional implant placement with immediate temporization
9474785|NCT03587571|Active Comparator|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
9474786|NCT03587571|No Intervention|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
9474787|NCT03587558|Experimental|Carvedilol group|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
9474788|NCT03587558|Active Comparator|Flecainide group|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
9474789|NCT03587545|Experimental|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
9474790|NCT03587545|Experimental|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
9474791|NCT03587545|Placebo Comparator|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.~Placebo nasal spray."
9474792|NCT03587545|Experimental|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
9474793|NCT03587545|Experimental|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
9474794|NCT03587545|Placebo Comparator|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
9474795|NCT03587532|Experimental|Indocyanine Green Angiography|ICG based angiography after creation of the stomach graft and after thoracic pull-up of the graft. Dynamic digital images will be obtained starting immediately after intravenous bolus administration of 0.5 mg/kg of ICG.
9474796|NCT03587506||Patients: group|Group I (n=10) included patients who did not develop any major or minor seizure during the follow-up period and their follow up EEG was free of any epileptiform discharge
9474797|NCT03587506||Patients: group II|Group II (n=11) included patients who developed only minor seizures and their follow up EEG showed epileptiform discharge
9474798|NCT03587506||Patients: group III|Group III (n=9) were patients who developed one or more major seizures during the follow-up period whatever their EEG findings.
10034653|NCT01798745|Placebo Comparator|Cohort B: Placebo|Each patient will receive matching placebo as a single dose.
10034654|NCT01798745|Experimental|Cohort C: JNJ-54452840 for 3 days|Each patient will receive JNJ-54452840 once daily for 3 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
10034655|NCT01798745|Placebo Comparator|Cohort C: Placebo|Each patient will receive matching placebo once daily for 3 days.
10034656|NCT01798745|Experimental|Cohort D: JNJ-54452840 for 5 days|Each patient will receive JNJ-54452840 once daily for 5 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
10034657|NCT01798745|Placebo Comparator|Cohort D: Placebo|Each patient will receive matching placebo once daily for 5 days.
10034658|NCT01798745|Experimental|Cohort E: JNJ-54452840 weekly|Each patient will receive JNJ-54452840 once weekly on Days 1, 8, 15, and 22 at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
10034659|NCT01798745|Placebo Comparator|Cohort E: Placebo|Each patient will receive matching placebo once weekly on Days 1, 8, 15, and 22.
10034660|NCT01798745|Experimental|Cohort F: JNJ-54452840 multiple dose|Each patient will receive JNJ-54452840 once daily (for 3 or 5 days) or once weekly (up to Day 22) as determined by the Data Monitoring Committee and as explored in Cohorts C, D, and E (daily dose not exceeding 240 mg).
10034661|NCT01798745|Placebo Comparator|Cohort F: Placebo|Each patient will receive matching placebo once daily (for 3 or 5 days) or once weekly (up to Day 22).
10034662|NCT01798771|Other|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
10034663|NCT01798771|Other|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
10034664|NCT01798784|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive an electronic pill container and are provided with daily reminders to take their medication but are not enrolled in the sweepstakes.
10034665|NCT01798784|Experimental|Sweepstakes Incentive 1|Arm 2 will be a sweepstakes incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
10034666|NCT01798784|Experimental|Sweepstake Incentive 2|Arm 3 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which monetary prizes may be awarded if participants take their medication prior to receiving a reminder.
10034667|NCT01798784|Experimental|Sweepstake Incentive 3|Arm 4 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which each participant maintains an account that will accumulate money based on their medication adherence throughout the study.
10034668|NCT01798797||no treatment|non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months
10034669|NCT01798823||EIB+A+|"children with EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
10034670|NCT01798823||EIB+A-|"children with EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
10034671|NCT01798823||EIB-A+|"children without EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
10034672|NCT01798823||EIB-A-|"children without EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
9474799|NCT03587506||Controls|healthy volunteers (n=30) who were not related to the patients and had no family history of epilepsy.
9474800|NCT03587480|Other|TME+LLND group|Total Mesorectal Excision plus Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.
9474801|NCT03587480|Other|TME+nCRT group|Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.
9474802|NCT03587467||health|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~smooth and soft stool like sausage or snake~Voluntary participate in this study"
9474803|NCT03587467||chronic hepatitis b carrier|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
9474804|NCT03587467||chronic hepatitis b|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
9474805|NCT03587467||decompensated cirrhosis|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
9474806|NCT03587454|Experimental|Tele-Glaucoma arm|Subjects enrolled in tele-glaucoma arm for remote assessment
9474807|NCT03587441|Active Comparator|The Intervention Group (N)|Neostigmine Methylsulfate intervention : A one milliliter syringe will contain 20 µg of Neostigmine methyl sulfate. 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 µg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
9474808|NCT03587441|Placebo Comparator|The Control Group (P)|Dextrose 5% in water intervention : an equal volume (0.2 ml) of dextrose 5% will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
9474809|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
9474810|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
9474811|NCT03587402|Experimental|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
9474812|NCT03587402|Active Comparator|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
9474813|NCT03587389|Experimental|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
9474814|NCT03587376|Experimental|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
9474815|NCT03587376|Active Comparator|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
9474816|NCT03587363|Experimental|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
9474817|NCT03587363|Experimental|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
9474818|NCT03587363|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
9474819|NCT03587363|Experimental|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.
9474820|NCT03587350|Active Comparator|Interventional Treatment|
9474821|NCT03587350|No Intervention|Usual care|
9474822|NCT03587337||Prophylaxis|
10034673|NCT01798836|Experimental|Oestradiol and ultrashort GnRH agonist/antagonist protocol|Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
9474823|NCT03587337||Antibiotic tp|
9474824|NCT03587324|Experimental|Experimental: aspirin, clopidogrel|Perioperative measurement of ASA and clopidogrel resistance in patients undergoing vascular treatment
9474825|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
9474826|NCT03587298||Group 2|Control group: matched age; no NAFKL
9474827|NCT03587285|Experimental|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
9474828|NCT03587285|Experimental|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
9474829|NCT03587259|Active Comparator|2D mammography|45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
10034674|NCT01798836|Active Comparator|GnRH agonist or antagonist protocol.|Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF
9474830|NCT03587259|Experimental|Tomosynthesis|45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
9474831|NCT03587246||Pregnant women|
9474832|NCT03587246||non-pregnant women|
9474833|NCT03587233|Active Comparator|Women with higher professional status|"Women with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
9474834|NCT03587233|Active Comparator|Women with lower professional status|"Women with lower professional status in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
9480970|NCT05143931|Experimental|WW + Home modification and grocery delivery (AVOID)|WW + modification of home food environment + online grocery shopping and delivery
9480971|NCT05143931|Experimental|WW + Inhibitory control training (RESIST)|WW + daily gamified inhibitory control training
10034675|NCT01798862|Experimental|Endometrial injury by hysteroscopy or pipelle sapling|Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
10034676|NCT01798862|Active Comparator|COH for IVF without hysteroscopy or pipelle sampling|Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
10034677|NCT01798875|Active Comparator|Metformin|oral metformin at a dose of 850mg twice daily
9480972|NCT05143931|Experimental|WW + Home food modification and grocery delivery (AVOID) + Inhibitory control training (RESIST)|WW + modification of home food environment + online grocery shopping and delivery + daily gamified inhibitory control training
10034678|NCT01798875|Active Comparator|Oral contraceptive|oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)
10034679|NCT01798901|Experimental|Treatment (HDAC inhibitor AR-42, decitabine)|"INDUCTION THERAPY: Patients receive HDAC inhibitor AR-42 PO daily on days 1, 3, and 5 or 1, 3, 4, 5 and decitabine IV over 1 hour on days 6-15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving CR or CRi receive HDAC inhibitor AR-42 as in Induction Therapy and decitabine IV over 1 hour on days 6-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
10034680|NCT01798953||UC/PSC with IPAA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileal pouch-anal anastomosis
10034681|NCT01798953||UC with IPAA|Patients with ulcerative colitis reconstructed with ileal pouch-anal anastomosis.
10034682|NCT01798953||UC/PSC with IRA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileorectal anastomosis.
10034683|NCT01798953||UC with IRA|Patients with ulcerative colitis reconstructed with ileorectal anastomosis.
10034684|NCT01798979|Experimental|Midazolam and GLPG0634|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8) and multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
10034685|NCT01799005|Active Comparator|flavanol rich intervention|Ingestion of 410mg flavanols twice a day for 30 days
10034686|NCT01799005|Placebo Comparator|flavanol free intervention|Ingestion of a macro and micro nutrients matched flavanol free drink
10034687|NCT01799018||SAH Patients|Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
9474835|NCT03587233|Active Comparator|Men with higher professional status|"Men with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
9474836|NCT03587233|Active Comparator|Men with lower professional status|"Men with lower professional status working in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form' and the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
9474837|NCT03587220|Experimental|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
10034688|NCT01799018||Control Patients|Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.
9474838|NCT03587220|Experimental|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
9474839|NCT03587194|Experimental|Otezla|Otezla BID
9474840|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
9474841|NCT03587168||Healthy Controls|Healthy People
9474842|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
9474843|NCT03587155||Control|Embryo or infant without ASNS mutation.
9474844|NCT03587129|Experimental|apatinib|1 times a day, atapinib, 500 mg, is taken orally
9474845|NCT03587103|Experimental|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
9474846|NCT03587103|Experimental|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
10034689|NCT01799031|Experimental|Arm I (WISE)|Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
10034690|NCT01799031|Active Comparator|Arm II (control)|Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
10034691|NCT01799044|Experimental|Irreversible electroporation|Single arm study: Irreversible electroporation of colorectal liver metastasis
10034692|NCT01799057|Experimental|Metformin|Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e. maximum of 2000mg per day).
10034693|NCT01799057|Placebo Comparator|Placebo|Matching placebo twice daily for 16-18 weeks.
10034694|NCT01799070||CHS|
10034695|NCT01799083|Experimental|Decitabine|A continuous 5-day treatment of lower dose decitabine within 4-6 weeks is regarded as a treatment cycle, transfusion of auto-CIK cells or chemotherapy regimen may be used for patients.
10034696|NCT01799096|Experimental|Sucrose|Receives sucrose
10034697|NCT01799096|Placebo Comparator|Aspartame|Receives Aspartame sweetened drinks
10034698|NCT01799109|Experimental|nebulization ms and albuterol|magnesium sulfate 150mg & albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
10034699|NCT01799109|Active Comparator|nebulized albuterol|albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
10034700|NCT01799109|Experimental|nebulized ms|magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
10034701|NCT01799122|Active Comparator|Precise sling vs TVT-O sling|
10034702|NCT01799148||Particulate air pollutants|Cohort of consecutive patients admitted with diagnosis of acute coronary syndrome in the cardiology unit of a tertiary hospital, which will quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to admission.
10034703|NCT01799161|Active Comparator|DS-1|6 week course of gp96 Vaccine: >= 4 x 10^7 cells twice monthly on Day 1. Up to 3 courses, 9 vaccinations.
10034704|NCT01799161|Active Comparator|DS-2|6 week course of gp96 Vaccine: >= 2 x 10^7 cells weekly on Day 1. Up to 3 courses, 18 vaccinations.
10034705|NCT01799161|Active Comparator|DS-3|6 week course of gp96 Vaccine: >= 1 x 10^7 cells twice weekly on Days 1 and 4. Up to 3 courses, 36 vaccinations.
10034706|NCT01799174|Active Comparator|UVA-1 Phototherapy|Receive medium dose UVA-1 (70 J/cm2) 3x/week for 10 weeks
10034707|NCT01799174|Sham Comparator|Placebo|"Receive sham UVA1 phototherapy (0 J/cm2) 3x/week for 10 weeks"
10034708|NCT01799187|Experimental|revascularization|revascularization is is an alternative new treatment of immature permanent teeth with necrotic pulp. The use of triple antibiotic paste is followed by Induction of bleeding from the apical root during this intervention.
10034709|NCT01799187|Active Comparator|apexification|apexification is a traditional therapy of immature permanent teeth with necrotic pulp.calcium hydroxide is served as medication to induce the developing of root .
10034710|NCT01799252||Doxy|Women who are prescribed a seven-day regimen of doxycycline following medical abortion
10034711|NCT01799252||No Doxy|Women who are not prescribed antibiotics following medical abortion
10034712|NCT01799291|Other|Treatment: Decision Making Tutorial|A brief presentation on mood disorders (i.e., Control condition) combined with the intervention (i.e., Treatment condition): a 20-minute training on decision-making errors and cognitive de-biasing strategies.
10034713|NCT01799291|No Intervention|Control|A brief presentation about mood disorders.
10034714|NCT01799304|Experimental|no distractor control group|postural control and locomotion of CP children without attentional distractor and without additional cognitive task (control condition)
9474847|NCT03587103|Experimental|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
9474848|NCT03587077|Experimental|study group|Women will receive vaginally one tablet misoprostol 200 mcg(Misotac; Sigma Pharma, SAE, EGYPT) plus one tablet isosorbide mononitrate 40 mg(Effox 40 mg; Minapharm). A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
10034715|NCT01799304|Experimental|visual and sound attentional distractors|postural control and locomotion of CP children with visual and sound attentional distractors (video film).
9474849|NCT03587077|Placebo Comparator|control group|Women will receive vaginally one tablet misoprostol 200 mcg Plus one tablet placebo.A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
9474850|NCT03587064|Active Comparator|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
10034716|NCT01799304|Experimental|sound attentional distractor alone|postural control and locomotion of CP children with sound attentional distractor alone (sound track of the video film).
10034717|NCT01799304|Experimental|additional cognitive task|postural control and locomotion of CP children with an additional cognitive task (adapted Stroop task with animals)
10034718|NCT01799317|Active Comparator|Treatment with vitamin D2|Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
10034719|NCT01799317|No Intervention|Standard of Care|Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
10034720|NCT01799330|Experimental|Group 1:Active TCEMS|Transcutaneous Electrical Muscle Stimulation (TCEMS): Group 1 will undergo TCEMS using an Omnistim FX-2 with two surface patch electrodes (8 x 6 cm) applied to each quadriceps, hamstring and calf muscles. The knee angle will remain at 90 degrees during simultaneous muscle stimulation to prevent joint movement. Electrical stimulation will be performed for 20 minutes on each limb, 3 days/week for 8 continuous weeks on an outpatient basis. The stimulator will be set to generate brief bursts of electrical impulses at 50Hz lasting 200 ms every 1500 ms. Muscles will be stimulated with an asymmetrical square wave pulse with an initial intensity set to create a visible contraction ranging from 55 mA to 120 mA.
10034721|NCT01799330|Placebo Comparator|Group 2: Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response.
10034722|NCT01799343|Experimental|Immersion into water|Normal healthy singleton pregnant women. The case serves as its own control. Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion (Baseline), during immersion (Immersion) and after immersion (Post-immersion).
10034723|NCT01799356|Active Comparator|moxifloxacin Group|Treatment at uPID with moxifloxacin
10034724|NCT01799356|Placebo Comparator|Ofloxacin Group|Treatment at uPID with Ofloxacin plus metronidazole
10034725|NCT01799369|No Intervention|Control|Routine post-operative care
10034726|NCT01799369|Experimental|Intervention|Post-operative care influenced by the Surgical Apgar Score
10034727|NCT01799382|Experimental|EBUS-TBNA + Rapid on-site evaluation|Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA
10034728|NCT01799382|Active Comparator|EBUS-TBNA|Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation
10034729|NCT01799395||Lung Cancer|All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied.
10034730|NCT01799408||betamethasone|Patients who had intra-articular injection of betamethasone
10034731|NCT01799408||Hyaluronic acid|Patients who had intra-articular injection of hyaluronic acid
10034732|NCT01799421||Non-haematologic cancer|
10034733|NCT01799434|Experimental|Exercise|All participants had to run 20min on their individual anaerobic threshold
10034734|NCT01799447|Other|Early intervention|Early intervention. Quasiexperimental study. Inclusion of 150 first times families in intervention and matched with 150 families from control group.
10034735|NCT01799460||CR/CTR group|The complete remission group treated by the Comprehensive Treatment Regimen
10034736|NCT01799460||NR/CTR group|The non-remission group treated by the Comprehensive Treatment Regimen
10034737|NCT01799460||CR/IA group|The complete remission group treated by Immunosuppressive Agents
10034738|NCT01799460||NR/IA group|The non-remission group treated by Immunosuppressive Agents.
10034739|NCT01799486|Experimental|Telbivudine|Telbivudine,600mg/d,oral,100patients,2 years.
10034740|NCT01799486|Experimental|Adefovir|Adefovir,10mg/d,oral,100 patients,2years.
10034741|NCT01799486|Experimental|Enecavir|Enecavir,0.5mg/d,oral,100 patients,2 year
10034742|NCT01799499|Experimental|Group A: 20 mg MMC mixed with 60cc TC-3|Group A: 20 mg MMC mixed with 60cc TC-3 hydrogel. (n=8)
10034743|NCT01799499|Experimental|• Group B: 40 mg MMC mixed with 60cc TC-3|• Group B: 40 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
10034744|NCT01799499|Experimental|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
9480973|NCT05142631|Experimental|Fruquintinib in soft tissue sarcoma|Fruquintinib : 5mg, once a day (QD), oral on an empty stomach or after a meal, taken with 100 ~ 200ml drinking water for 3 weeks and stopped for 1 week.
10034745|NCT01799512|Experimental|real-time continuous glucose monitoring|"real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range.~The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol).~When glycaemic changes of >25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol."
10034746|NCT01799512|Active Comparator|blinded continuous glucose monitoring|"In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively.~IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol."
10034747|NCT01799525|Experimental|Hypercapnia|Intervention: SAH patients are subjected to gradual hypercapnia by reduction of respiratory volume in one trial session every day. PaCO2 is raised from normocapnia to 50 mmHg for 10 - 15 minutes and 60 mmHg for 10 - 15 minutes.
9474851|NCT03587064|Experimental|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
9474852|NCT03587051|Experimental|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
9474853|NCT03587051|Active Comparator|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
9474854|NCT03587038|Experimental|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
9474855|NCT03587038|Experimental|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
9474856|NCT03587025|Active Comparator|Amitryptyline|Patients who will be take amitryptyline, 75mg, only use, 30min before surgery.
9474857|NCT03587025|Placebo Comparator|Placebo|Patients who will be take placebo 30min before surgery.
9474858|NCT03587012|Experimental|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
9474859|NCT03587012|Experimental|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD combined with simultaneous transcranial alternating current stimulation (tACS)
9474860|NCT03586986||FDR with abnormal brain MRI|First degree relatives fulfilling lesions disseminated in space on MRI
9474861|NCT03586986||FDR with normal brain MRI|First degree relatives not fulfilling lesions disseminated in space on MRI
9474862|NCT03586986||Non-FDR|Age and sex-matched controls to FDRs noted above
9474863|NCT03586973|Experimental|Cohort A: Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state. Participants received first/second line anticancer therapy with sorafenib before this study were assigned to Cohort A.
9474864|NCT03586973|Experimental|Cohort B: Cabozantinib 60 mg|Cabozantinib 60 mg, tablet orally, once daily in the fasted state. Participants who did not receive first/second line anticancer therapy with sorafenib before this study were assigned to Cohort B.
9474865|NCT03586960|Experimental|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
9474866|NCT03586947|Experimental|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
9474867|NCT03586947|No Intervention|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
9474868|NCT03586934|Other|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
9474869|NCT03586934|Experimental|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
9474870|NCT03586921|Experimental|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
9474871|NCT03586921|Active Comparator|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
9474872|NCT03586908|Experimental|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
9474873|NCT03586882|Experimental|Spinal Cord Stimulation Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
9474874|NCT03586882|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
9474875|NCT03586869|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
10034748|NCT01799551|Active Comparator|Ca CBT|Experimental arm will receive brief version of Culturally adapted CBT for depression. This is based on our previous work in which we adapted CBT for depression in Pakistan
10034749|NCT01799551|No Intervention|Treatment As Usual|Patients in this arm will get only Treatment As Usual, which normally includes regular follow up and medicines.
9474876|NCT03586856|Active Comparator|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
9474877|NCT03586856|Active Comparator|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
9474878|NCT03586843|Experimental|Part A: Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous [SC] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
9474879|NCT03586843|Experimental|Part A: Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
9474880|NCT03586843|Experimental|Part A: Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
9474881|NCT03586843|Experimental|Part A: Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
9474882|NCT03586843|Experimental|Part A: Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
9474883|NCT03586843|Experimental|Part A: Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
9474884|NCT03586843|Experimental|Part B: JNJ-64565111|Participants will receive a single SC ascending doses of JNJ-64565111 on Days 1, 8, 15, 22, 29 and 36.
9474885|NCT03586817|Active Comparator|Palonosetrona|Palonosetron 75 mcg during the anesthesia
9474886|NCT03586817|Active Comparator|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
9474887|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
9474888|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
9474889|NCT03586791|Experimental|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
9474890|NCT03586791|Active Comparator|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
10034750|NCT01799564|Experimental|Micropulse|Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions
9474891|NCT03586791|Sham Comparator|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
10034751|NCT01799564|No Intervention|Control|The fellow eye does not receive any treatment
10034752|NCT01799577||Gynecologist|Gynecologist can use laparoscopic surgery.
10034753|NCT01799603|Experimental|TMC435 in fasted then fed condition|Participants under fasting condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fed condition of second treatment period (after washout period of 9 days, between the two treatment periods).
9474892|NCT03586778|Experimental|MTEX-DN|dry needling, manual therapy, and therapeutic exercise
9474893|NCT03586778|Active Comparator|MTEX|manual therapy and therapeutic exercise
9474894|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
9474895|NCT03586752|Experimental|On-line group|On-line program course
10034754|NCT01799603|Experimental|TMC435 in fed then fasted condition|Participants under fed condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fasting condition of second treatment period (after washout period of 9 days, between the two treatment periods).
9474896|NCT03586752|Active Comparator|Standard group|Standard program course
10034755|NCT01799616|Experimental|Pamidronate|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
9474897|NCT03586739|Experimental|"Covered stents strategy"|
9474898|NCT03586739|Active Comparator|"Bare metal stents strategy"|
9474899|NCT03586713|Other|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
9474900|NCT03586700|Experimental|Xiao zhong fang granules|Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
9474901|NCT03586700|Placebo Comparator|Placebo Xiao zhong fang granules|Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
9474902|NCT03586674|Active Comparator|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
9474903|NCT03586674|Experimental|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
9474904|NCT03586661|Experimental|Treatment (niraparib, copanlisib)|Patients receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9474905|NCT03586622|Experimental|Low FODMAP diet|Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
9474906|NCT03586622|Experimental|VSL#3®|Each IBS patient randomized to the probiotic VSL#3 arm (n=52) will at randomization be given VSL#3 for 4 weeks (56 sachets) together with a leaflet on VSL#3 - holding information on the product from the manufacture regarding storage, nutritional information etc. If the patients have any questions regarding the treatment, they can ask the project investigator handing out the VSL#3 to them. They will be instructed in taking their VSL#3 (2 sachets a day) as described by the manufacturer
9474907|NCT03586570|Experimental|Aprocitentan|
9474908|NCT03586570|Placebo Comparator|Placebo|
9474909|NCT03586557|Experimental|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
9474910|NCT03586557|Active Comparator|Corticosteroid|1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
9474911|NCT03586518||Haemodialysis patients|"The plans for patient recruitment were developed in partnership with our local haemodialysis patient participation and involvement group. Patients will be identified from the supportive care register established for haemodialysis patients in Leicester in 2008.~Inclusion:~Prevalent haemodialysis patient (more than 3 months)~Active on the supportive care register with anticipated death in the subsequent 12 months~Able to give informed consent~Consent to donation of heart for research following death~Able to understand written and verbal explanations in English~Exclusion:~Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)~Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)~Unable to give informed consent~Unable to understand written and verbal explanations in English"
9474912|NCT03586505|Experimental|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.~The patients switch off the light when the discomfort is too elevated"
9474913|NCT03586492|Other|Patient with myocardial ischemia|
10034756|NCT01799616|Other|Placebo|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
10034757|NCT01799642||Cystic Fibrosis Patients|Participants with Cystic Fibrosis
10034758|NCT01799642||Healthy Controls|Participants who do not have cystic fibrosis and are otherwise healthy.
9474914|NCT03586466|Experimental|BupreCare|The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
9474915|NCT03586466|Active Comparator|Treatment as Usual|This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
9474916|NCT03586466|Active Comparator|Treatment as Usual with MEMS|This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.
9474917|NCT03586453|Experimental|Osimertinib|Osimertinib: Oral, once a day, dosage determined per protocol
9474918|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
9474919|NCT03586440||forward head rounded shoulder posture|"craniovertebral angle (CVA) ≤ 50 degree~distance between on table and acromion ≥ 2.5 cm"
9474920|NCT03586440||normal posture group|"Craniovertebral angle> 50 degree~distance between on table and acromion < 2.5 cm"
9474921|NCT03586414|Experimental|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
9474922|NCT03586414|Experimental|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
9474923|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
9474924|NCT03586388|Experimental|Oral immunotherapy protocol|Eligible children receive the oral food challenge (OCD) protocol
9474925|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
9474926|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
9474927|NCT03586336|Experimental|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
9474928|NCT03586336|Sham Comparator|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
9474929|NCT03586323|Experimental|L-SLNB|performed a superior laryngeal nerve block with lidocaine
9474930|NCT03586323|Placebo Comparator|S-SLNB|performed a superior laryngeal nerve block with saline
9474931|NCT03586310|Other|4 nights with PSG|For all subjects: 4 nights with polysomnography and ear-EEG
9474932|NCT03586310|Other|12 nights with ear-EEG|"For a subset of the subjects in arm the '4 nights with PSG', a second phase follows in which each subject sleeps 12 nights with only ear-EEG.~If a night's recording is unsuccessful, for whatever reason, up to 6 additional nights may be attempted."
9474933|NCT03586271||trifocal lens|trifocal lens implantation(AT Lisa tri 839MP)
10034759|NCT01799681|Experimental|EXPERIMENTAL|a 4-week indoor and 4-week outdoor balance training with stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
10034760|NCT01799681|Active Comparator|CONTROL|an eight-week training on upper limb stretching and strengthening, hand agility exercise, knot tying and Chinese calligraphy
9474934|NCT03586271||bifocal lens 1|bifocal lens implantation(Diff-aay)
9474935|NCT03586271||bifocal lens 2|bifocal lens implantation(ReSTOR +3.0D)
9474936|NCT03586271||bifocal lens 3|bifocal lens implantation(ReSTOR +2.5D)
9474937|NCT03586245|Active Comparator|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.~57FePP (95.8%) 3.49 mg~Aspergillus oryzae (unenriched) 0.025 mg~FePP natural abundance 0.685 mg.~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
9474938|NCT03586245|Experimental|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.~ASP-p (8% Fe; natural abundance) 3.516 mg~58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg~4.2 total mg of Fe"
9474939|NCT03586245|Other|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .~Aspergillus oryzae (unenriched) 0.027 mg~57FeSO4 (95.4%) 3.18 mg~4.2 total mg of Fe"
9474940|NCT03586232|Placebo Comparator|Control|Participants will take two placebo pills q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
9474941|NCT03586232|Experimental|Arnica Montana|Participants will take Arnica Montana, 30C oral, pill and a placebo pill q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
9480974|NCT05140148|Placebo Comparator|Placebo|placebo pill, twice daily
9474942|NCT03586232|Experimental|Arnica Montana and Bromelain|Participants will take Bromelain, 500mg oral pill + Arnica Montana, 30C oral, q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
9474943|NCT03586219|No Intervention|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
10034761|NCT01799694|Experimental|Autologous Expanded Stem Cells|Inject of Autologous Adipose-derived expanded stem cells
9474944|NCT03586219|Experimental|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
9474945|NCT03586206||Mild-moderate C.difficile infection|
9474946|NCT03586206||severe C.difficile infection|
9474947|NCT03586206||severe complicated/fulminant C.difficile infection|
9474948|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
9474949|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
9474950|NCT03586180||Dr. Clowns|they will perform shows for children and parents
9474951|NCT03586154|Other|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
9474952|NCT03586154|Active Comparator|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
9474953|NCT03586141|Other|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
9474954|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
9474955|NCT03586089|Experimental|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
9474956|NCT03586089|Placebo Comparator|Placebo|Patients will receive an inactive placebo (IV).
9474957|NCT03586076|Experimental|JHL1922|
9474958|NCT03586076|Active Comparator|Pulmozyme|
9474959|NCT03586037|Experimental|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
9474960|NCT03586037|Experimental|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
9474961|NCT03586037|Experimental|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
9474962|NCT03586037|Experimental|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
9474963|NCT03586037|Experimental|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
9474964|NCT03586037|Experimental|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
9474965|NCT03586024|Experimental|Cohort 1|cohort 1: NK/T-cell lymphoma;
9474966|NCT03586024|Experimental|Cohort 2|EBV-associated diffuse large B cell lymphomas
9474967|NCT03585998|Experimental|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide/Cisplatin) with durvalumab, and followed by consolidation durvalumab
9474968|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
9474969|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
9474970|NCT03585972|Experimental|Frailty Prevention Program|4 face-to-face sessions, with a licensed and registered occupational therapist over 4 months
9474971|NCT03585972|No Intervention|Educational materials|Participants receive publicly available educational materials
9474972|NCT03585946||Cyclosporine|
9474973|NCT03585946||Intravenous Immunoglobulin|
9474974|NCT03585946||Etanercept|
9474975|NCT03585946||Steroids|
9474976|NCT03585920|Active Comparator|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
9474977|NCT03585920|Experimental|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (<8 g oil per 40 g snack)
9474978|NCT03585920|Experimental|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (<8 g oil, matched sensory signals)
9474979|NCT03585907|Experimental|Modified Atkins Diet (MAD)|A diet that can produce ketones
9474980|NCT03585907|Active Comparator|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
9480512|NCT03532867|Experimental|Healthy volunteers|"After an ophthalmic consultation, the healthy volunteers are summoned to perform the exercise test in the form of an aerobic exercise on an ergometric bicycle with 3 different intensity levels calculated on the theoretical maximum aerobic power.~The OCT examination in the EDI mode, centered on the macular and peri-papillary region, as well as the systolic and diastolic blood pressure and the heart rate.~In healthy patients performing aerobic physical exercise in the Department of Sports Medicine , the investigators will perform the following Intervention :~Examination of pressures before stopping the exercise~Examination of pressure during the exercise~Examination of pressures after stopping the exercise"
9480513|NCT03532854|Experimental|Sequence A|Ezetimibe/Rosuvastatin -> Valsartan -> Valsartan and Ezetimibe/Rosuvastatin
9480514|NCT03532854|Experimental|Sequence B|Valsartan -> Valsartan and Ezetimibe/Rosuvastatin-> Ezetimibe/Rosuvastatin
9480515|NCT03532854|Experimental|Sequence C|Valsartan and Ezetimibe/Rosuvastatin -> Ezetimibe/Rosuvastatin -> Valsartan
9480516|NCT03532854|Experimental|Sequence D|Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin-> Valsartan
9480517|NCT03532854|Experimental|Sequence E|Valsartan -> Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin
9474981|NCT03585894|Other|Sumatriptan|Sumatriptan 4 mg/mL I.V will be administrated over 10 min
9474982|NCT03585894|Active Comparator|Ketorolac|Ketorolac 30 mg/mL I.V will be administrated over 10 min
9474983|NCT03585881|Experimental|window bracket positioning tray|
9474984|NCT03585881|No Intervention|conventional indirect boning tray|
9474985|NCT03585868|Placebo Comparator|Placebo|Beverage without flavonoids
9474986|NCT03585868|Sham Comparator|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
9474987|NCT03585868|Experimental|Flavonoids|Beverage with a flavonoid rich mixture
9474988|NCT03585855|No Intervention|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
9474989|NCT03585855|Experimental|MSC transplantation|patients with ABMR treated with MSC transplantation
9474990|NCT03585842||Pre-test group|Patients from CMP B coming for consultation or day hospital
9474991|NCT03585842||Test group|Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
9474992|NCT03585829|Active Comparator|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
9474993|NCT03585829|Active Comparator|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
9474994|NCT03585803|Other|KMRC011 5μg or Placebo|Cohort 1
9474995|NCT03585803|Other|KMRC011 10μg or Placebo|Cohort 2
9474996|NCT03585803|Other|KMRC011 15μg or Placebo|Cohort 3
9474997|NCT03585803|Other|KMRC011 20μg or Placebo|Cohort 4
9474998|NCT03585803|Other|KMRC011 25μg or Placebo|Cohort 5
9474999|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
9475000|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
9475001|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
9475002|NCT03585751|Active Comparator|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
9475003|NCT03585751|Experimental|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
9475004|NCT03585751|Experimental|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
9475005|NCT03585738|Experimental|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
9475006|NCT03585738|Placebo Comparator|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
9475007|NCT03585725|Experimental|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
9475008|NCT03585699|Active Comparator|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
9475009|NCT03585699|Active Comparator|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
9475010|NCT03585686|Experimental|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
9475011|NCT03585673|Experimental|Docetaxel-PM+Oxaliplatin|"Docetaxel-PM 35mg/m2 D1, 8 I.V.~Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
9475012|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
9475013|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
9475014|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
9475015|NCT03585634|Other|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
9475016|NCT03585621|Experimental|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
9475017|NCT03585582||PARDS survivors|"Children <18 years~diagnosed with PARDS, as defined by PALICC~admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
9475018|NCT03585556|Experimental|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
10034762|NCT01799707|Active Comparator|vision restoration training|Vision restoration training (VRT): visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
9475019|NCT03585530|Experimental|treatment group|
9475020|NCT03585517|Experimental|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
9475021|NCT03585491|Experimental|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
9475022|NCT03585491|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
9475023|NCT03585465|Experimental|A: Cyclophosphamide Vinblastine Nivolumab|This arm was applicable to first stage, and is closed
9475024|NCT03585465|Experimental|B: Capecitabine Nivolumab|This arm was applicable to first stage, and is closed
9475025|NCT03585465|Experimental|C: Cyclophosphamide Vinblastine Capecitabine|This arm was applicable to first stage, and is closed
9475026|NCT03585465|Experimental|"Metronomic CT "|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine)~This arm is applicable to second stage, and 43 patients are expected"
9475027|NCT03585465|Experimental|"Metronomic CT + Nivolumab"|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine) + Nivolumab~This arm is applicable to second stage, and 43 patients are expected"
9475028|NCT03585452||Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
9475029|NCT03585452||Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
9475030|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
9475031|NCT03585426|Experimental|Vancomycin 1g q12h|
9475032|NCT03585426|Experimental|Vancomycin 1g q8h|
9475033|NCT03585413|Active Comparator|Specific Micronutrient-probiotic-combination|"Intake of one micronutrient capsule three times daily and probiotic powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient capsules consist of vitamins, minerals, phytochemicals and bioactive substances. The probiotic supplement is a powder of 10 different species of probiotic bacteria."
9475034|NCT03585413|Placebo Comparator|Micronutrient-placebo-combination|"Intake of one micronutrient capsule three times daily and placebo powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient-control-combination consists of a micronutrient capsule (vitamins and minerals) but without phytochemicals and bioactive substances, and a placebo powder manufactured to mimic the probiotic powder."
9475035|NCT03585400||Observational Study|Observational Study: Not Applicable for Observational Studies
9475036|NCT03585387||Main|Each subject in this group will be its own control for the two navigation methods.
9475037|NCT03585374|Experimental|A_test drug_Methoxyflurane (Penthrox®)|Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
9475038|NCT03585374|Active Comparator|B_comparator_Morphine/Paracetamol/Ketoprofen|"The comparator to be administered will vary according to pain intensity and local clinical practice.~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .~Maximum time of infusion 10 minutes."
9480518|NCT03532854|Experimental|Sequence F|Valsartan and Ezetimibe/Rosuvastatin -> Valsartan -> Ezetimibe/Rosuvastatin
9480519|NCT03532841|Experimental|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
9475039|NCT03585361|Experimental|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
9475040|NCT03585361|Active Comparator|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
9475041|NCT03585348||Study cohort|The estimated cohort consists of 317.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (205.000) as well as Massachusetts General Hospital (112.000) and received treatment by anesthesia and surgical providers who have completed at least 50 anesthesias and surgeries at their respective institution, respectively.
9475042|NCT03585309|Experimental|Laparascopy comper with coagulation and without coagulation|
9475043|NCT03585283|Experimental|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
9475044|NCT03585283|Sham Comparator|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
9475045|NCT03585231|Experimental|Experimental|This is the experimental arm of the study. This includes receiving immediate access to the novel/experimental smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
9475046|NCT03585231|Active Comparator|Control|This is the control arm of the study. This includes receiving receiving immediate access to the standard of care smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
9475047|NCT03585231|Active Comparator|Delayed Control|This is the second control arm of the study. This includes receiving the novel/experimental smoking cessation messaging program after completing the 3-month follow-up survey. Therapy description withheld to protect the integrity of the study.
9475048|NCT03585218|Experimental|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
9475049|NCT03585218|No Intervention|Control Group|The control group is not subject to intervention.
9475050|NCT03585205|Experimental|Stress and cognitive load Induction|Participants will engage in a computerized task which induces cognitive load. Each participant will perform the task once under a stress condition and once under a neutral (non-stress) condition.
9475051|NCT03585192|Experimental|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
9475052|NCT03585192|Active Comparator|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
9475053|NCT03585179|Experimental|Oral tranexamic acid|250 mg of tranexamic acid bid orally
9475054|NCT03585179|Experimental|Topical tranexamic acid|5% topical tranexamic acid bid
9475055|NCT03585179|Active Comparator|Topical hydroquinone|4% hydroquinone once daily at night
9475056|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
9475057|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
9475058|NCT03585140|Active Comparator|Normal Diet|Participants will receive a normal diet according to their metabolic status.
9475059|NCT03585140|Experimental|Low glycemic diet|Participants will receive a low-glycemic index and load diet according to their metabolic status. Milk and vitamin supplements will be eliminated from the diet.
9475060|NCT03585127|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
9475061|NCT03585127|Experimental|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
9475062|NCT03585114|Experimental|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive [F-18] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
9475063|NCT03585101|Experimental|All participants|Intervention: Elbasvir/grazoprevir
9475064|NCT03585088|Other|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
9475065|NCT03585062|Experimental|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40~60mg bid, day 1~14 (S-1: BSA <1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
9475066|NCT03585036|Active Comparator|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
9475067|NCT03585036|Active Comparator|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure~."
9475068|NCT03585036|Placebo Comparator|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
9475069|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
9475070|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
9475071|NCT03585010|Experimental|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
9475072|NCT03585010|Active Comparator|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
9475073|NCT03584997|Experimental|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
9475074|NCT03584997|Active Comparator|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
9475075|NCT03584984|Experimental|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|socket preservation with a mixture of autogenous bone graft acquired at the time of extraction mixed with a 50:50 ratio of Anorganic bovine bone
9475076|NCT03584984|Active Comparator|Anorganic bovine bone graft (ABB)|filling the extraction socket with ABB graft
9475077|NCT03584984|Active Comparator|Absorbable gelatin Sponge|Filling the socket with an absorbable gelatin sponge
9475078|NCT03584971||female patients|women in fertility treatment according to Long GnRH Agonist Protocol
9475079|NCT03584971||control group|random sample of male students
9475080|NCT03584919|Active Comparator|EM doxycycline|patients with EM who received doxycycline
9475081|NCT03584919|Active Comparator|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
9475082|NCT03584919|Placebo Comparator|controls|control subjects without history of Lyme disease
9475083|NCT03584906|Experimental|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
9475084|NCT03584906|Experimental|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
9475085|NCT03584906|Experimental|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
9475086|NCT03584906|Experimental|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
9475087|NCT03584893||Epidemiologic observational study cohort|All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.
9475088|NCT03584880|Experimental|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
9475089|NCT03584880|Placebo Comparator|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
9475090|NCT03584867|Experimental|study Group|refresher CPR
9475091|NCT03584867|No Intervention|control|NO refresher
9475092|NCT03584854|Active Comparator|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
9475093|NCT03584854|Active Comparator|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
9475094|NCT03584841|Experimental|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
9475095|NCT03584841|Experimental|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
9475096|NCT03584841|Active Comparator|Healthy volunteers|
9475097|NCT03584828|Experimental|Tele-Rehabilitation - intervention|Following the standard rehabilitation intake process the subjects in the Tele-rehaab arm will receive physiologic consultation based on clinical stress tests and clinical data passed from the physician. The Tele-rehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
9475098|NCT03584828|No Intervention|Usual care|The usual care arm will receive general recommendations for a healthy and active lifestyle and community cardiologist and primary care physician according to local guidelines.
9475099|NCT03584802|Experimental|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
9475100|NCT03584802|Active Comparator|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
9475101|NCT03584789|No Intervention|Standard Practice|
9475102|NCT03584789|Experimental|Clinical Decision Support|
9475103|NCT03584789|Experimental|Clinical Decision Support + Education|
9475104|NCT03584776|Experimental|Virtual Reality Post Spinal Fusion|Patients randomized to the VR group will have the opportunity to utilize VR during the post operative period, and will also experience VR during research visits each day following surgery.
9475105|NCT03584776|No Intervention|Standard of Care|Patients randomized to the non-VR condition will experience the usual standard of care following spinal fusion surgery. This will include 15-30 minutes of movie viewing during research visits.
9475106|NCT03584750|Active Comparator|Intervention group|Floating
9475107|NCT03584750|Placebo Comparator|Control group|Placebo floating
9475108|NCT03584750|No Intervention|No-treatment group|Waiting list
9475109|NCT03584698|Experimental|study group|Misoprostol + Evening primrose oil group
9475110|NCT03584698|Active Comparator|control group|Misoprostol only group
9475111|NCT03584685|Experimental|With Mask|Use of the surgical mask in one routine wound treatment appointment.
9475112|NCT03584685|Active Comparator|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
9475113|NCT03584672||Patients with Multiple Sclerosis|Patients with Multiple Sclerosis (Expanded Disability Status Scale (EDSS) score < 7)
9475114|NCT03584672||Healthy Controls|Healthy people
9475115|NCT03584659|No Intervention|Standard of care|This arm will continue standard procedure regarding side effect registration and handling
9475116|NCT03584659|Experimental|PRO|This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.
9475117|NCT03584633|Other|Lymphedema|The subjects with lymphedema will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with Indocyanine Green Lymphography.
9475118|NCT03584620|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
9475119|NCT03584620|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
9475120|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
9475121|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
9475122|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
9475123|NCT03584581|Experimental|Olive polyphenols|
9475124|NCT03584581|Placebo Comparator|Control|
9475125|NCT03584568|Experimental|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
9475126|NCT03584568|Other|Basic Skill Building|This arm focuses on basic skill building only.
9475127|NCT03584555|Active Comparator|120 μm group|The subjects underwent SMILE using 120 μm cap.
9475128|NCT03584555|Active Comparator|140 μm group|The subjects underwent SMILE using 140 μm cap.
9475129|NCT03584529|Experimental|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
9475130|NCT03584529|No Intervention|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
9475131|NCT03584529|Experimental|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
9475132|NCT03584529|No Intervention|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
9475133|NCT03584503|Active Comparator|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
9475134|NCT03584503|No Intervention|Group C|Group C intubated with classic endotracheal tube
9475135|NCT03584451|Active Comparator|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
9475136|NCT03584451|No Intervention|without rehabilitation sport|no further rehabilitation program after THA
9475137|NCT03584438|Experimental|Hanlon Real iTBS Protocol 1|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 3600 pulses are delivered over 19 minutes.
9475138|NCT03584438|Experimental|Hanlon Real iTBS Protocol 2|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 1800 pulses are delivered over 9 minutes and 30 seconds.
9475139|NCT03584438|Experimental|Huang Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 190 seconds (a total of 600 TMS pulses).
9475140|NCT03584438|Experimental|Gamboa Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 380 seconds (a total of 1200 TMS pulses).
9475141|NCT03584438|Sham Comparator|Sham iTBS protocol|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin over the left motor cortex (C3) and beneath the coil.
9475142|NCT03584425|Experimental|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
9475143|NCT03584425|Experimental|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
9475144|NCT03584412|Experimental|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
9475145|NCT03584412|Other|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
10034763|NCT01799707|Placebo Comparator|Discrimination training|Discrimination training. Here, the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
9475146|NCT03584386|Experimental|V-CAMS (aka Jaspr)|"In Phase I (formative), participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.~Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants in the Telehealth RCT will be randomly assigned to receive the V-CAMS/Jaspr companion mobile app JAH in addition to their usual outpatient care. Study assessments will be administered remotely at three time points: baseline, 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as completing setup of JAH on their personal mobile phone."
9475147|NCT03584386|No Intervention|Care As Usual|"Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants enrolled in the Telehealth RCT will be randomly assigned to CAU in addition to receiving crisis safety planning. Study assessments will be administered remotely at baseline and at 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as setting up the control condition crisis stability plan."
9475148|NCT03584373|Experimental|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).~Acetaminophen - Oral; patient directed as needed. Not prescribed.~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
9475149|NCT03584373|Active Comparator|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
9475150|NCT03584360|Experimental|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
9475151|NCT03584360|Experimental|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
9475152|NCT03584360|Experimental|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
9475153|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
9475154|NCT03584308|Experimental|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
9475155|NCT03584308|Placebo Comparator|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
9475156|NCT03584282|No Intervention|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
9475157|NCT03584282|Active Comparator|Text Messaging|Participants in this group will receive the text messaging intervention.
9475158|NCT03584282|Active Comparator|Peer Navigation|Participants in this group will receive the peer navigator intervention.
9475159|NCT03584282|Active Comparator|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
9475160|NCT03584269|Experimental|NIV Device + LTOT|administration of ventilary support, without using an invasive artificial airway
9475161|NCT03584269|Active Comparator|LTOT|standard treatment, without NIV
9475162|NCT03584256||gymnasts|Female gymnasts, older than 13 years, with status of ineternational or national level,
9475163|NCT03584256||swimmers|Female swimmers, older than 12 years, with status of ineternational or national level,
9475164|NCT03584243|Experimental|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.~The intervention administrated is a cross-linking with oxygen treatment"
9475165|NCT03584230|Experimental|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to positive group"
9480520|NCT03532841|Placebo Comparator|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
9480521|NCT03532815|Active Comparator|Lifestyle Modification group|
9480522|NCT03532815|No Intervention|Control group|
10034764|NCT01799759|Experimental|Online intervention for parent and child|Children complete 8 online modules of Project FUN Parents complete 6 modules of Project FUN for Parents
10034765|NCT01799759|Other|Instruments only|The waiting list control group only completes instruments and body composition, fitness measures
9475166|NCT03584230|Experimental|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to negative group"
9475167|NCT03584230|No Intervention|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
9475168|NCT03584191||People with Obesity|General population - potential participants will be recruited using various and numerous general population as appropriate in each country.
9475169|NCT03584191||Health Care Professionals|Health Care Professionals include primary care physicians and specialists who treat patients with obesity.
9480523|NCT03532802|Active Comparator|Metoprolol Succinate|Metoprololsuccinat
9480524|NCT03532802|Placebo Comparator|Placebo oral capsule|Placebo
9480525|NCT03532789|Experimental|herbal patch group|using herbal patch as an intervention
9480526|NCT03532789|Placebo Comparator|placebo patch group|using placebo patch as an intervention
9480527|NCT03532763|Experimental|Tocotrienol-rich fraction|
9480528|NCT03532763|Placebo Comparator|Placebo|
9480529|NCT03532737|Experimental|Investigational Arm|"All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor CHEMOTHERAPY: Cisplatin: 100 mg/m2 Q21d D1, D22, D43. OR Cetuximab Loading dose 400 mg/m², one week before radiation then maintenance dose 250 mg/m² weekly, D8, D15, D22, D29, D36, D43.~PD-1 inhibitor: Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks 21 days prior to radiation, then Day 1 of radiation and then every 21 days for total 6 doses~Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66-70 Gy/ 30-35 Fr over 6-7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB)."
9480530|NCT03532711||Chemotherapy|FOLFOX/XELOX/FOLFIRI
9480531|NCT03532698||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
9480532|NCT03532698||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
9480533|NCT03532685|Active Comparator|Severe Asthma Obese Patients Surgery|Bariatric surgery
9480534|NCT03532685|No Intervention|Severe Asthma Obese Patients|usual care
9480535|NCT03532685|No Intervention|Severe Obese Patients|usual care
9480536|NCT03532672|Experimental|Acute Fasting|Eutrophic and obese women will fast 10 hours during daily activities after a standardized breakfast.
10037237|NCT01823250|Experimental|CIFFTA|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)involves four months of intervention. Adolescents and families receive one family therapy session per week and an additional session which is either a psycho-educational session for the adolescent and/or parents, or an individual therapy session with the adolescent. There is a total of 2 sessions per week.
9480537|NCT05263674|No Intervention|"Non-sedative medical treatment"|"The patient is treated with an additional high-dose intravenous antiepileptic drug, which is selected by the treating neurologist. If NCSE continues to be detected at cEEG or clinically> 3 hours after starting treatment, the patient should receive standard treatment (i.e. sedation in the intensive care unit or addition of additional intravenous antiepileptic drugs) in accordance with local guidelines and the assessment of the treating neurologist. The following preparations are permitted as additional treatment:~Levetiracetam (60 mg / kg as saturation dose followed by maintenance dose of 2-4 g / day), valproate (60 mg / kg as saturation dose followed by maintenance dose of 20 mg / kg / day), phosphenytoin (20 PE as saturation dose followed by maintenance dose 5 mg PE / kg / day), lacosamide (400 mg as a saturation dose followed by a maintenance dose of 200-400 mg / day), topiramate (200-400 mg per probe as a saturation dose followed by a maintenance dose of 200-400 mg / day)."
9480538|NCT05263674|Experimental|Fast sedation|Within a maximum of 60 minutes after the diagnosis of NCSE (EEG or clinical), the patient must be sedated with high-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone. After 20 hours, the sedation should be completely phased out within 3 hours.
9480539|NCT05263661|Experimental|LIFT|ligation of interesphincteric fistula tract
9480540|NCT05263661|Active Comparator|FLAP|Rectal advancement flap
9480541|NCT05263648|Other|Virtual Reality Sessions|Patients will undergo at least two VR sessions. One prior to and one during the course of radiation treatment.
9480542|NCT05263609|Experimental|Arm A|"Arm A (CR/oPR on pembrolizumab monotherapy):~Patients will continue pembrolizumab monotherapy if CR/oPR on initial treatment with pembrolizumab monotherapy. If CR/oPR persists at 8 cycles (24 weeks) after assignment on arm A, pembrolizumab break will commence. Patients will be monitored for disease progression with imaging every 9 weeks (+/- 1 week). If patients develop progression, pembrolizumab will be resumed and continued until subsequent PD. At that point, axitinib may be added to pembrolizumab as part of the study or patients may discontinue study treatment per the treating investigator's discretion."
9480975|NCT05140148|Active Comparator|Amantadine|100 mg amantadine twice daily, or if 65 years or older once daily
9475170|NCT03584178|Experimental|Mucosal Atomization Device|Budesonide via MAD Device
9475171|NCT03584178|Experimental|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
9475172|NCT03584152|Active Comparator|DRUG ARM A|Norco 5Mg-325Mg Tablet, administered orally every 4 hours for 5 days total
9475173|NCT03584152|Active Comparator|DRUG ARM B|Tylenol 325Mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
9475174|NCT03584139|Experimental|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
9475175|NCT03584139|Active Comparator|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
9475176|NCT03584126||Patients with AF|Patients with atrial fibrillation visiting the outpatient clinic; examined by general examination, electrocardiography, ecocardiography and MRI.
9475177|NCT03584126||Control|Healthy adult volunteers; examined by the study physicians by general examination, electrocardiography, ecocardiography and MRI.
9475178|NCT03584113|Active Comparator|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
9475179|NCT03584113|Active Comparator|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
9475180|NCT03584087|Placebo Comparator|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
9475181|NCT03584087|Active Comparator|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
9475182|NCT03584087|Active Comparator|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
9475183|NCT03584074|Experimental|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
9475184|NCT03584074|Active Comparator|COX-2 inhibitor|Celecoxib 200mg qd
9475185|NCT03584061|Experimental|Fat grafting/fat transplant.|Each patient receives fat grafting to the site of dermal pain. Fat is to be harvested for either the abdomen or the thigh.
9475186|NCT03584035|Experimental|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
9475187|NCT03584035|Active Comparator|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
9475188|NCT03583996|Experimental|Open Label|All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
9475189|NCT03583983|Other|Personalized Health Recommendations|
9475190|NCT03583983|Other|No Health Recommendations|
9475191|NCT03583957|Experimental|Entire Study|Each patient is eligible for all interventions in the study.
9475192|NCT03583944|Experimental|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
9475193|NCT03583918|Experimental|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
9475194|NCT03583905|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
9475195|NCT03583905|Placebo Comparator|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
9475196|NCT03583905|Placebo Comparator|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
9475197|NCT03583892||Group A|In the Group A, a single-dose of 600mg gabapentin was used as part of a multimodal analgesic technique.
9475198|NCT03583892||Group B|In the group B gabapentin was not administered.
9475199|NCT03583879|Experimental|Exoskeleton exercise|8-week exercise program using the exoskeleton
9475200|NCT03583879|Active Comparator|Standard exercise|8-week exercise program not using the exoskeleton
9475201|NCT03583879|Placebo Comparator|No exercise|8-weeks of no treatment (wait-list control)
9475202|NCT03583866|Experimental|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
9475203|NCT03583866|Placebo Comparator|Placebo|Endothelial function will be determined following a seven day treatment of placebo
9475204|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
9475205|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
9475206|NCT03583840|No Intervention|Control group|Participants who will not be directed to the ScreenMen website
9475207|NCT03583840|Experimental|Intervention group|Participants who will be directed to the ScreenMen website
9475208|NCT03583827|Experimental|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
9475209|NCT03583827|Active Comparator|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
9475210|NCT03583801|Experimental|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :~sweet orange (Citrus sinensis L. Persoon)~fine lavender (Lavandula angustifolia P. Miller)~little seed from the mandarin tree (Citrus reticulata blanco)"
9475211|NCT03583801|Placebo Comparator|without aromatherapy|
9480976|NCT05138887|Placebo Comparator|placebo group|The placebo group was administered a vitamin tablet (Centrum) orally, once a day
9475212|NCT03583788|Experimental|Hypnotherapy group|The intervention consisted of individual hypnotherapy of 5 hourly sessions (60 minutes) over 5 weeks, a total of five hours. The hypnotherapy treatment method was Erickson's (permissive) hypnosis (17). It began with a conversation about patient's past life events, present situation, alcohol problem and his or her thoughts about it. The hypnotherapy Group did not receive any treatment of motivational interviewing.
9475213|NCT03583788|Active Comparator|Motivational interviewing group|The comparator patient group received individual therapy as motivational interviewing (MI) for 5 hourly sessions over 5 weeks, a total of five hours. The patients in the experimental group did not receive this.
9475214|NCT03583762|Experimental|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
9475215|NCT03583762|Experimental|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
9475216|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
9475217|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
9475218|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
9475219|NCT03583736|Active Comparator|Rapid first contact virtual visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
9475220|NCT03583736|Placebo Comparator|First contact in person office visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
9475221|NCT03583723|Experimental|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
9475222|NCT03583710|Experimental|Arm A (mitotane)|Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
9475223|NCT03583710|Experimental|Arm B (mitotane, etoposide, cisplatin)|Patients receive mitotane as in Arm A. Patients also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
10037238|NCT01823250|Active Comparator|Traditional Family Therapy (TFT)|The Traditional Family Therapy condition consists of once per week family therapy based on Structural Family Theory and a didactic group intervention once per week in which HIV/STI risk is discussed.
9475226|NCT03583645|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
9475227|NCT03583645|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
9475228|NCT03583619|Experimental|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
9475229|NCT03583619|Active Comparator|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
9475230|NCT03583593|Experimental|DIAMEL|Study group that receives the active product.
9475231|NCT03583593|Placebo Comparator|Placebo|Control group receiving double-blind placebo.
9475232|NCT03583567|Placebo Comparator|0.9% Normal Saline|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
9475233|NCT03583567|Experimental|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
9475234|NCT03583515|Experimental|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
9475235|NCT03583515|Placebo Comparator|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
9475236|NCT03583502|Experimental|Supplemented|krill oil and fish oil supplement
9475237|NCT03583502|No Intervention|Controls|The control group did not receive any supplementation.
9475238|NCT03583489|Placebo Comparator|Placebo|
9475239|NCT03583489|Experimental|APD421|
9475240|NCT03583489|Experimental|APD421 + ondansetron|
9475241|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
9475242|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
9475243|NCT03583476||Concomitant therapy|Patients with concomitant therapy
9475244|NCT03583476||Sequential therapy|Patients with sequential therapy
9475245|NCT03583437|Experimental|Healthy male volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
9475246|NCT03583437|Experimental|Healthy female volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
9475247|NCT03583424|Experimental|Treatment (venetoclax, BEAM)|Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
9475248|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
9475249|NCT03583398||TAVI TAo|
9475250|NCT03583398||TAVI TF|
9475251|NCT03583398||AVR|
9475252|NCT03583346|Experimental|M6495|
9475253|NCT03583346|Placebo Comparator|Placebo|
9475254|NCT03583320|Experimental|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
9475255|NCT03583320|No Intervention|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. >50% stenosis in the left main (LM) coronary artery, and/or >50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
9475256|NCT03583294|Experimental|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
9475257|NCT03583294|Experimental|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
9475258|NCT03583294|Experimental|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
9475259|NCT03583294|Experimental|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
9475260|NCT03583281|Active Comparator|Flax oil|Participants will consume capsules containing flax oil (4 grams alpha-linolenic acid [ALA] per day) for 4 weeks
9475261|NCT03583281|Active Comparator|Fish oil|Participants will consume capsules containing DHA-enriched fish oil (4 grams DHA per day + 0.8 grams EPA per day) for 4 weeks
9475262|NCT03583268|Active Comparator|Moderate Intensity Exercise Alone|45 minutes of moderate intensity exercise at 45-55% of maximum aerobic capacity (active participants) or heart rate reserve (sedentary participants) used as a control condition. Participants will consume a glucerna bar at 10pm following this session.
9475263|NCT03583268|Experimental|70% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 70% heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
9475264|NCT03583268|Experimental|80% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 80% of heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
9475265|NCT03583268|Experimental|90% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 90% of maximum aerobic capacity (active participants every two minutes) or heart rate reserve (sedentary participants every 4 minutes). Participants will consume a glucerna bar at 10pm following this session.
9475266|NCT03583242||DME treat with antiangiogenic|"3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.~1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
9475267|NCT03583229|Other|Aspirin - single arm|1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
9475268|NCT03583229|Experimental|Extracorporeal photopheresis|All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
9475269|NCT03583229|No Intervention|Control group|The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.
9475270|NCT03583216||Diabetic pregnancy|Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
9475271|NCT03583216||Non-diabetic pregnancy|Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
9480543|NCT05263609|Experimental|Arm B|"Arm B (sPR/SD/PD):~Patients with sPR, SD or PD after 6 cycles of pembrolizumab monotherapy will be started on axitinib in addition to continuing pembrolizumab. If patients develop subsequent PD, treatment will be discontinued. If the subsequent scans show SD/PR/CR, the combination treatment will be continued until PD or unacceptable toxicity."
9475272|NCT03583203|Experimental|Experimental Group|This group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
9475273|NCT03583203|No Intervention|Control Group|The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask, Advice, Assess, Assist and Arrange).
9475274|NCT03583190|Experimental|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
9475275|NCT03583190|Active Comparator|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
9475276|NCT03583177||healthy volunteers|
9475277|NCT03583177||cancer patients|
9475278|NCT03583177||undergoing chronic hemodialysis patients|
9475279|NCT03583164|Experimental|F901318|open-label single-arm of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi which are susceptible to F901318 in patients with limited treatment options.
9475280|NCT03583151|Active Comparator|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
9475281|NCT03583151|Experimental|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
9475282|NCT03583138||Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
9475283|NCT03583138||No buprenorphine|No buprenorphine
9475284|NCT03583125|Experimental|EOC 317|"Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.~Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21."
9475285|NCT03583112|Active Comparator|Dapoxetine|In this group, patients received one dapoxetine hydrochloride tablet before MRI scan.
9475286|NCT03583112|Placebo Comparator|Placebo|In this group, patients received placebo tablet before MRI scan.
9475287|NCT03583086|Experimental|Treatment (vorolanib, nivolumab)|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
9475288|NCT03583073|Active Comparator|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
9475289|NCT03583073|Experimental|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
9475290|NCT03583060|Experimental|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
9475291|NCT03583060|No Intervention|Control|
9475292|NCT03583021|Experimental|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
9475293|NCT03583021|Placebo Comparator|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
9475294|NCT03583008|Experimental|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
9475295|NCT03583008|No Intervention|Control|Providers in this arm will not receive any intervention.
9475296|NCT03582995|Active Comparator|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
9475297|NCT03582995|Experimental|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
9475298|NCT03582982|Experimental|Eccentric overload exercise|
9475299|NCT03582969|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
9475300|NCT03582969|Placebo Comparator|Placebo|Placebo capsules
9475301|NCT03582917|Experimental|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
9475302|NCT03582917|No Intervention|No treatment|
9475303|NCT03582904|Experimental|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over < 30 minutes.
9475304|NCT03582904|Sham Comparator|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over 2 minutes.
9475305|NCT03582891|Other|Parkinson's Disease STN Target|Parkinson's disease patients implanted in STN
9475306|NCT03582891|Other|Parkinson's disease patients GP Target|Parkinson's disease patients implanted in Globus Pallidus
9475307|NCT03582891|Other|Dystonia patients|Isolated dystonia patients
9475308|NCT03582878|Active Comparator|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
9475309|NCT03582878|Experimental|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
9475310|NCT03582865||responding|patients who received Tamoxifen 20 mg daily for at least 3 years with good response (no relapse) to tamoxifen. Both genotyping assessment and TDM of tamoxifen and its metabolites will be performed and correlated with the records. Follow up for these patients for further assessment of tamoxifen effectiveness will be carried out for 1- 2 years.
9475311|NCT03582865||relapse|patients who received Tamoxifen 20 mg daily for at least 3 years who were good responder to the drug but then the response has been diminished (relapse) and they have been shifted to another therapy. They will be exposed to genotyping study of CYP 2D6 to recognize the phenotyping style of that patient that may explain diminishing of response to tamoxifen therapy.
9475312|NCT03582865||tamoxifen resistant|patients who received Tamoxifen 20 mg daily for not more than 1 year with poor response to tamoxifen (early relapse) and clinically will be shifted to use another medication as they were diagnosed as tamoxifen resistant. Like the second group, they will be exposed to genotyping study of CYP2D6 with the same concept.
9475313|NCT03582852|Active Comparator|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
9475314|NCT03582852|Active Comparator|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
9475315|NCT03582839|Experimental|PROTECT+|The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
9475316|NCT03582787|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
10034766|NCT01799772|Experimental|Comprehensive behavioral intervention|"It will involve regular contacts over 6 month period. It will include 2 weekly contacts for weeks 1-6, weekly contacts for weeks 7-8, bi-weekly contact for months 3-4, and monthly contact for months 5-6. There is a combination of 20 individual and group-based sessions.~It is a combination of 4 components: a) Evidence-based exercise program, b) Physical activity promotion, c) Healthy nutrition guidance, and d) Self-management."
9475317|NCT03582787|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
9475318|NCT03582761|Experimental|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
9475319|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
9475320|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
9475321|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
9475322|NCT03582735|Experimental|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
9475323|NCT03582735|No Intervention|Control|No intervention according to current practice.
9475324|NCT03582696|Other|No Arms|Participants are not assigned to randomized study arms or groups.
9475325|NCT03582683|Experimental|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
9475326|NCT03582683|Active Comparator|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
9475327|NCT03582670|Experimental|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
9475328|NCT03582670|Active Comparator|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
9475329|NCT03582670|Other|Control Group|Study participants do not attend any strategy training sessions.
9475330|NCT03582644|Experimental|CRYOTHERAPY INTERVENTION|Patients with end stage knee osteoarthritis, both sexes, 60 years or higher
10037239|NCT01823263|Experimental|Partial sleep deprivation|Partial sleep deprivation: participants will have a 4-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed by repeated blood sampling and an 'Intake task'.
9475331|NCT03582605|Placebo Comparator|Control Group|All participants will be weighed. This group will receive a placebo (glucose) 1 hour prior to insertion of mini-screw implants.
9475332|NCT03582605|Experimental|Experimental Group|All participants will be weighed so that appropriate dosing can be ensured and will receive 2 grams of Amoxicillin 1 hour prior to mini-screw insertion. Patients weighing less than 40 kg will be given 50mg/kg of Amoxicillin.
9475333|NCT03582592|Experimental|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
9480544|NCT05263583|Experimental|Cohort 1|Cohort 1 will receive a dose of 3.6 mg/m2/day of sepantronium bromide
9480545|NCT05263583|Experimental|Cohort 2|Cohort 1 will receive a dose of 4.8 mg/m2/day of sepantronium bromide
9475334|NCT03582592|No Intervention|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
9475335|NCT03582579|Experimental|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
9475336|NCT03582579|Experimental|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
9475337|NCT03582579|Experimental|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
9475338|NCT03582579|Experimental|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
9475339|NCT03582540|Active Comparator|early double-guidewire technique (DGT)|First arm: early double-guidewire technique The early arm attempts biliary cannulation using the DGT immediately once the guidewire is inserted in the pancreatic duct in cases of difficult biliary cannulation.
9475340|NCT03582540|Active Comparator|delayed double-guidewire technique (DGT)|In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
9475341|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
9475342|NCT03582501|Experimental|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
9475343|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
9475344|NCT03582423|Experimental|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
9475345|NCT03582423|Placebo Comparator|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
9475346|NCT03582410|Active Comparator|Absorbable suture|laparoscopic sacral colpopexy with absorbable suture
9475347|NCT03582410|Active Comparator|Non absorbable suture|laparoscopic sacral colpopexy with non absorbable suture
9475348|NCT03582397|Experimental|Experimental|Subjects to receive virtual reality mirror therapy via WiseMind Software (Realiteer) 3x/week for 4 weeks.
9475349|NCT03582384|Experimental|Treatment|
9475350|NCT03582358||Verrine|Patients served verrines
9475351|NCT03582358||CNO|Patients served wrapped supplements
9480546|NCT05263583|Experimental|Recommended Phase 2 Dose - Cohort 3|The recommended Phase 2 dose will be established based on the safety, pharmacokinetic and pharmacodynamic data from Cohort 1 and Cohort 2
9480547|NCT05263570||Stage II-III HR+/HER2+ Early Breast Cancer|Stage II-III HR+/HER2+ Early Breast Cancer
10034767|NCT01799772|Active Comparator|Standard of Care Exercise Program (SCE)|The SCE will be delivered by a physical therapist. It represents the typical rehabilitation after TKA surgery. It is expected to provide small and short-lived functional improvement. Subjects will participate in 12 supervised sessions (2 x/week, for 6 weeks). The SCE consists of: a) lower extremity range of motion and stretching exercises, b) lower extremity strengthening exercises of moderate intensity, and d) endurance exercises using treadmill.
10034768|NCT01799785|Experimental|Aerobic exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
9480550|NCT05263544||Patients with displaced IUD|
9480551|NCT05263544||Patients without displaced IUD|
9480552|NCT05263531|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
9480553|NCT05263531|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIPC treatment with pressure set at 60 mmHg
9480554|NCT05263505|Experimental|Baricitinib|4mg daily
9480555|NCT05263505|Active Comparator|Antiproliferative|methotrexate, azathioprine, or mycophenolate
9480556|NCT05263479|Experimental|HS-20089 (Phase Ia：Dose escalation )|HS-20089 for IV infusion of various dose strengths administered in 21 day dosing cycles.
9480557|NCT05263479|Experimental|HS-20089 (Phase Ib: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
9480558|NCT05263466|Experimental|Brain tumour patients|Patients will be those undergoing routine care of primary brain tumours. Study group patients will undergo additional PET-MRI examination and biopsies in addition to the standard of care.
9480559|NCT05263427|Experimental|TOCONAUTE and gold standard : cardiotocograph|
9480560|NCT05263414|Active Comparator|Active tVNS|In the active tVNS session, tVNS will be delivered via a programmable stimulation unit connected to two titan ear electrodes mounted on a gel frame. Active tVNS will be delivered over the cymba conchae of the left ear for a 70 minutes session. Stimulation intensity will be set at an intensity corresponding to individual sensitivity threshold. The intensity of the stimulation will be gradually increased in order to reach the intensity of stimulation with a ramping-up phase of 30 secs. During the stimulation, participants will perform the tasks. At the end of the stimulation session participants will be asked to report possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales.
9480977|NCT05138887|Experimental|experimental group 1|The experimental group 1 was administered BH4 orally, with a dose of 2mg/kg.d (If the drug dose is within the range of 51-150mg, the drug dose will be 100mg), once per day
10034769|NCT01799785|Placebo Comparator|Usual care group|These patients will continue with their normal daily activity and will not be provided with supervised aerobic exercise training during the study period.
10034770|NCT01799798|Experimental|Denosumab subcutaneously|
10034771|NCT01799811||CLI patient's needing open bypass|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.
10034772|NCT01799837|Other|Healthy Controls|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
10034773|NCT01799837|Other|Veterans with PTSD|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
10034774|NCT01799850|Active Comparator|Actos|Actos 30 mg daily
9475352|NCT03582345|Experimental|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for > 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
9475353|NCT03582332|Active Comparator|Group A in phase 1|Indomethacin 75 mg, extended release capsule twice daily
9475354|NCT03582332|Active Comparator|Group B in phase 1|Indomethacin 25 mg capsule, 2 capsule twice daily
9475355|NCT03582332|Active Comparator|Group A in phase 2|Etoricoxib 90 mg once daily
9475356|NCT03582332|Active Comparator|Group B in phase 2|Etoricoxib 60 mg once daily
9475357|NCT03582319|Experimental|Biodentine|Regenerative material for pulp therapy
9475358|NCT03582319|Active Comparator|Formocresol|Fixative agent for pulp therapy
9475359|NCT03582306|Experimental|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
9475360|NCT03582306|Experimental|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
9475361|NCT03582280|Experimental|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:~Amor powder, each eppendorf contains 200mg Calcium~Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
9475362|NCT03582267|Experimental|Dietary Supplement|Docosahexaenoic Acid (DHA)
9475363|NCT03582267|No Intervention|No Intervention|No Docosahexaenoic Acid supplementation
9475364|NCT03582254|Experimental|[18F]-FDG PET/MR|[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital
9475365|NCT03582228|Experimental|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
9475366|NCT03582202|Active Comparator|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
9475367|NCT03582202|Placebo Comparator|standard care|Nutritional handling by nurses supported by a dietician if needed
9475368|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
10034775|NCT01799850|Placebo Comparator|placebo|double blind placebo controlled
10034776|NCT01799863|Experimental|Ketorolac trometamol 0.45%|Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.
10034777|NCT01799863|Placebo Comparator|Artificial tears|Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.
10034778|NCT01799876|Experimental|Autologous Cell|Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.
10034779|NCT01799876|Sham Comparator|Control|Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).
10034780|NCT01799902||Male subjects with LUT predominant storage symptoms (OAB)|male subjects with Overactive Bladder Syndrome (OAB) being treated with solifenacin in monotherapy or combination
10034781|NCT01799954|Other|NYVAC Prime / NYVAC + AIDSVAX® B/E Boost vs. Placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a NYVAC vaccine prime and NYVAC + AIDSVAX® B/E boost. Twenty participants will get vaccines and 4 will get only placebos.
9475369|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
9475370|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
9475371|NCT03582150|Experimental|Receiving Soberlink Device|
9475372|NCT03582124|Experimental|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
9475373|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
9475374|NCT03582098||Idelalisib and Rituximab|Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
9475375|NCT03582072|Experimental|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by > 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
10034782|NCT01799954|Other|NYVAC + AIDSVAX® B/E Prime / Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of priming and boosting with the vaccines NYVAC + AIDSVAX® B/E. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 1 to see if the priming makes a difference in the body's immune response.
10034783|NCT01799954|Other|DNA prime + NYVAC + AIDSVAX® B/E Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 4 to see if the priming makes a difference in the body's immune response.
10034784|NCT01799954|Other|DNA+AIDSVAX® B/E prime / NYVAC+AIDSVAX® B/E boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine + AIDSVAX® B/E priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 3 to see if the priming makes a difference in the body's immune response.
9475376|NCT03582072|No Intervention|control|practice outside of the top 20% of prescribers whose prescribing increase by >4%, GPs were not sent a letter
9475377|NCT03582059|Other|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
9475378|NCT03582059|Other|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
9475379|NCT03582046|No Intervention|Monitoring Group|Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
9475380|NCT03582046|Active Comparator|Mean Arterial Pressure (MAP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
9475381|NCT03582046|Experimental|Abdominal Perfusion Pressure (APP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
9475382|NCT03582020|Placebo Comparator|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
10034785|NCT01799980||Cervical mediastinoscopy|This group will undergo cervical mediastinoscopy before surgery to stage their lung cancer (procedure decided by the surgeon).
10034786|NCT01799980||Endo-bronchial ultrasound|This group will undergo endobronchial ultrasound before surgery to stage their lung cancer (procedure decided by the surgeon).
10034787|NCT01800006||Group 1|
10034788|NCT01800019|Active Comparator|NRT arm|"Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.~Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day."
10034789|NCT01800019|Active Comparator|NRT and HIV Tailored Quit Smoking Counseling|"Drug: Nicotine Replacement Therapy (Nico-Derm®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
10034790|NCT01800019|Active Comparator|Varenicline (VR) Arm|"Drug: Varenicline (Champix®)~Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)"
10034791|NCT01800019|Active Comparator|Varenicline (VR) and HIV Tailored Quit Smoking Counseling|"Drug: Varenicline (Champix®)~0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)~Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
10034792|NCT01800032||Plexiform Neurofibroma|NF1 associated plexiform neurofibroma
9475383|NCT03582020|Active Comparator|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
9475384|NCT03582020|Active Comparator|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
9475385|NCT03582020|Active Comparator|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
9475386|NCT03582007|Experimental|Murepavadin|Murepavadin + ertapenem
9475387|NCT03582007|Active Comparator|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
9475388|NCT03581994|No Intervention|Standard Practice|Not receiving any intervention/educational materials on drug-drug interaction testing
9475389|NCT03581994|Experimental|Compulsory DDI Testing|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
9475390|NCT03581994|Experimental|Optional DDI Testing|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
9475391|NCT03581968|Experimental|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
9475392|NCT03581968|Experimental|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
9475393|NCT03581955|Experimental|Banana Cavendish|240g of fruit plus 150ml of Fresubin ® 2kcal fiber neutral flavor
9475394|NCT03581955|Experimental|Control drink|250ml of Fresubin ® 2kcal fiber neutral flavor
9475395|NCT03581955|Experimental|Tomato|300g of tomato plus of Fresubin ® 2kcal fiber neutral flavor plus 12g of refined sunflower oil.
9475396|NCT03581929|Experimental|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
9475397|NCT03581929|Placebo Comparator|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
9475398|NCT03581916|Experimental|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
9475399|NCT03581903|Experimental|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
10034793|NCT01800032||Optic Glioma|NF1 associated optic glioma
10034794|NCT01800045|Experimental|Pitolisant|Pitolisant at 5, 10, 20 or 40mg
10034795|NCT01800045|Placebo Comparator|Placebo|Capsules of placebo containing lactose
10034796|NCT01800084|Experimental|Patients undergoing SPECT-CT|"The patients in this study are scheduled for a SPECT-CT at the Nîmes University Hospital as part of their normal care regimen.~Intervention: Device: Asir Image Acquisition"
10034797|NCT01800097|Placebo Comparator|placebo|placebo
10034798|NCT01800097|Active Comparator|Modafinil|Modafinil
10034799|NCT01800110|Experimental|2|label I- 200 cc pomegranate juice once daily for 6 weeks post partum. label II- control group, no placebo is givening.
10034800|NCT01800123||Acute poisoning|Consecutive acute drug self poisoned patients admitted in the ED.
10034801|NCT01800136|Experimental|rTMS; tDCS|
10034802|NCT01800149|Active Comparator|BBM+collagen|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with BioOss Collagen and covered with Bio-Gide
9475400|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
9475401|NCT03581877|Experimental|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
9475402|NCT03581877|Active Comparator|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
9475403|NCT03581864||Group of 14 patients with post-traumatic complete anirirdia|14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions.
9475404|NCT03581851|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
10034803|NCT01800149|Active Comparator|BBM granules|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with Bio-Oss Granules, 0-25-1 mm, and covered with Bio-Gide
9475405|NCT03581851|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
9475406|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
9475407|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
9475408|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
9475409|NCT03581812|Active Comparator|Intervention snack 1|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
9475410|NCT03581812|Active Comparator|Intervention snack 2|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
9475411|NCT03581812|Placebo Comparator|Control snack|Control snack food reflecting the macro-nutrient profile of a typical UK snack.
9475412|NCT03581799|Other|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
9475413|NCT03581773|Active Comparator|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
9475414|NCT03581773|Placebo Comparator|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
9475415|NCT03581760|Experimental|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
9475416|NCT03581760|Active Comparator|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
9475417|NCT03581747||Subjects with atopic dermatitis|
9475418|NCT03581747||Controls|
9475419|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
9475420|NCT03581695||Pulmonary Hypertension and Congenital Heart Disease|Pulmonary Hypertension and Congenital Heart Disease
9475421|NCT03581695||Congenital Heart Disease|Congenital Heart Disease
9475422|NCT03581695||Healthy Controls|Healthy Controls
9475423|NCT03581682|Experimental|Tele-Visit Using Parental Home Echo|All parents will have hands-on echo training. We will test if a tele-visit using parental home echo is clinically reliable compared to an on-site clinic visit, costs less, and improves parental sense of empowerment.
9475424|NCT03581669||THA + cerclage acetabulum|
9475425|NCT03581656|Experimental|Arm|The ChordArt System is intended for chordal replacement in patients with mitral valve insufficiency due to leaflet prolapse or flail delivered through a catheter based technology for mitral chordal replacement via a small incision in the thorax.
9475426|NCT03581630|Experimental|Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet|
9475427|NCT03581630|Experimental|Breast cancer subjects-Mediterranean Diet|
9475428|NCT03581630|Active Comparator|Healthy subjects-naltrexone/bupropion+Mediterranean Diet|
9475429|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
9475430|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
10034804|NCT01800175|Experimental|Formulation C|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
9803195|NCT04428905|Experimental|Arm I (personalized care plan, telehealth sessions)|Patients receive a personalized care plan/resource manual. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) about self-management skills building, then 3 maintenance telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) for additional self-management skills building support. A copy of patient's care plan is also sent to their PCP.
9475433|NCT03581591|Experimental|Primary; open label|Injection of Burosumab every two to three weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
9475434|NCT03581565|Active Comparator|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
9475435|NCT03581565|Active Comparator|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
9475436|NCT03581565|Active Comparator|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
9475437|NCT03581539|Active Comparator|Group #1|Transverses Abdominis Plane (TAP) block
9475438|NCT03581539|Active Comparator|Group #2|Quadratus Lumborum (QL) block
9475439|NCT03581539|Active Comparator|Group #3|Surgeon Infiltration using Exparel
9475440|NCT03581500|Experimental|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
10034805|NCT01800175|Experimental|Formulation D|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
10034806|NCT01800188||Dialysis|Patients with dialysis dependent ESRD and normal fasting glucose will undergo a meal test during a hemodialysis and hemodiafiltration session. A meal test without dialysis is optional.
9475441|NCT03581461|Experimental|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
9475442|NCT03581448|Experimental|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.~The intervention Sensory Restoration During Prosthesis Control will be used."
9475443|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
9475444|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
9475445|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
9475446|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
10034807|NCT01800214||Alzheimer's disease (AD)|
10034808|NCT01800214||Vascular Cognitive Disorders (VCD)|
10034809|NCT01800214||Lewy Body Disease (LBD)|
9475449|NCT03581370|Active Comparator|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
9475450|NCT03581370|Experimental|4 hours infusion|"The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.~."
9475451|NCT03581357|Active Comparator|Control/Waitlist (Anxiety Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
9475452|NCT03581357|Active Comparator|Mindfulness App (Anxiety Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
9475453|NCT03581357|Active Comparator|Control/Waitlist (Neuropathy Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
10034810|NCT01800214||Frontotemporal Dementia (FTD)|Behavioral-variant Frontotemporal Dementia (bvFTD) Language-variant Frontoemporal Dementia including Semantic dementia (SD) and Progressive non-fluent aphasia (PNFA) Corticobasal degeneration (CBD) Progressive supranuclear palsy (PSP)
10034811|NCT01800214||Mild Cognitive Impairment (MCI)|
9480978|NCT05138887|Experimental|experimental group 2|The experimental group 2 was administered BH4 orally, with a dose of 5 mg/kg.d (If the drug dose is within the range of 151-250mg, the drug dose will be 200mg, two times a day; If the drug dose is within the range of 251-350mg, the drug dose will be 300mg, three times a day)
10034812|NCT01800214||Cognitively Normal (CN)|
10034813|NCT01800214||Small Vessel Disease -Neurodegenerative (SVD)|
10034814|NCT01800214||Subjective Cognitive Complaints (SCC)|
10034815|NCT01800253|Experimental|Total sleep deprivation|Participants will be required to stay up for the entire night before 'Blood Samples' and 'Tissue samples' will be taken and the 'Portion Size Task' and 'Inhibitory task' will be performed. This will then be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
10034816|NCT01800253|Experimental|Sleep|Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
10034817|NCT01800266|Experimental|Symptom and Fidelity Monitoring (SFM)|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
10034818|NCT01800266|Experimental|SFM + Behavioral Rehearsal|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
10034819|NCT01800279|Active Comparator|Deontology Therapy|The patients in the control group will port a deprogramming occlusal splint to sleep every night, an average of 8 hours per day, for 12 weeks of the treatment.
10034820|NCT01800279|Experimental|Physiotherapy Protocol|The physiotherapy protocol involves the application of kinesitherapy techniques and a myofascial therapy protocol. This protocol will be administered twice a week for 12 weeks.
9475454|NCT03581357|Active Comparator|Mindfulness App (Neuropathy Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
9475455|NCT03581331|Experimental|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
9475456|NCT03581266|Experimental|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
9475457|NCT03581266|Experimental|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
9475458|NCT03581253|Experimental|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
9475459|NCT03581214|Active Comparator|Room air|Room air (no mask)
9475460|NCT03581214|Placebo Comparator|Oxygen|10L/min Oxygen by facemask
9475461|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
9475462|NCT03581201||No contraception|Healthy females without any contraception at all.
9475463|NCT03581188|Experimental|Self-examination of the skin|Participants will perform self-surveillance of the skin using a dermatoscope device. They will receive guidance from the ASICA skin checker and receive reminders every 2 months to perform self-examination. They will receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
9475464|NCT03581188|No Intervention|Control|Participants will receive an educational booklet 'Your guide to early melanoma'and scheduled visits to their clinician as required.
9475465|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
9475466|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
9475467|NCT03581162||Patients|Patients with diagnosis of Juvenile Mixed Connective Tissue Disease
9475468|NCT03581162||Controls|Healthy, age-and sex-matched controls
9475469|NCT03581149|Active Comparator|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
9475470|NCT03581149|Active Comparator|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
9475471|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
9475472|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
9475473|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
9475474|NCT03581071|Experimental|Step1:1mg in non-dialysis subject|
9475475|NCT03581071|Experimental|Step2-1:1mg in hemodialysis subjects|
9475476|NCT03581071|Experimental|Step2-2:6mg in non-dialysis subject|
9475477|NCT03581071|Experimental|Step3-1:11㎎ in hemodialysis subjects|
10034821|NCT01800292|Experimental|sildenafil therapy|Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.
10034822|NCT01800305|Experimental|Pegylated rhEPO|Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg，3.2mcg/kg, 4.2mcg/kg, 5.5 mcg/kg, 7.2 mcg/kg, 9.3 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe.started with the second 3.2mcg/kg dose,Every subject takes Niferex 150mg every day, from day 1 to day 20. ) of the test drug (Pegylated rhEPO)
9475478|NCT03581071|Experimental|Step3-2:11㎎ in non-dialysis subject|
9475479|NCT03581058|Experimental|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
9475480|NCT03581058|Experimental|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
9475481|NCT03581058|No Intervention|Sober|All participants will complete same tasks sober.
9475482|NCT03581032||A-Active reprogram follwed by sham|This arm will be randomized to have PACING device reprogramming followed by sham reprogramming
9475483|NCT03581032||B-Sham followed by active reprogram|This arm will be randomized to have sham reprogramming followed by active pacing reprogramming
9475484|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
9475485|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
9475486|NCT03580980|Active Comparator|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
9475487|NCT03580980|Active Comparator|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
9475488|NCT03580980|Active Comparator|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
9475489|NCT03580967|Other|Drug: Vortioxetine|
9475490|NCT03580954|Experimental|Repetitive TMS (estimulation)|
9475491|NCT03580954|Active Comparator|Repetitive TMS (inhibition)|
9475492|NCT03580915|Experimental|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
10034823|NCT01800305|Active Comparator|EPIAO®|Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, of the comparator drug(EPIAO®) at day 1, 3, 5, 8, 10, 12.
9475493|NCT03580915|Active Comparator|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
9475494|NCT03580902|Active Comparator|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
9475495|NCT03580902|Experimental|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
9475496|NCT03580889|Active Comparator|Atropine sulphate|Atropine 5 mcg/kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blood pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly
9475497|NCT03580889|Active Comparator|Glycopyrrolate|Glycopyrrolate 2.5 mcg / kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
9475498|NCT03580889|Active Comparator|Normal Saline|Normal saline 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
9475499|NCT03580876|Other|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
9475500|NCT03580876|Other|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR~Loss of response under Adalimumab: 40mg EW SC Randomization to:~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
9475501|NCT03580811|Active Comparator|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
9475502|NCT03580811|Experimental|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
9475503|NCT03580798|Experimental|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
9475504|NCT03580798|Active Comparator|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
9475505|NCT03580772||Persona TKR|Patients will have undergone a medial congruent Persona total knee replacement
9475506|NCT03580772||Attune TKR|Patients will have undergone a Attune total knee replacement
9475507|NCT03580772||Control participants|Patients will not have recieved a primary TKR
10037240|NCT01823263|Experimental|Normal sleep|Normal sleep: participants will have an 8-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed with repeated blood sampling and an 'Intake task'.
10037241|NCT01823276|Active Comparator|Tyrosine-Containing Bar|150 mg/kg dose of tyrosine per administration, administered twice
10037242|NCT01823276|Placebo Comparator|Placebo Bar|0 mg/kg dose of tyrosine per administration, administered twice
10037243|NCT01823302|Other|nutritional counseling|nutritional counseling
9475508|NCT03580759|Experimental|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
9475509|NCT03580759|No Intervention|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
9475510|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
9475511|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
9475512|NCT03580733|Placebo Comparator|placebo|placebo
9475513|NCT03580733|Experimental|antifungal therapy|caspofungin
9475514|NCT03580720|Experimental|Intervention|Intervention group, receiving Inspiratory threshold loading protocol.
9475515|NCT03580707|Active Comparator|Part 1|Compare rapidity of CNS effects of levetiracetam (LEV) & brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
9475516|NCT03580707|Active Comparator|Part 2|Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose & BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.
9475517|NCT03580694|Experimental|Cemiplimab Monotherapy|In a single dose escalation cohort, participants will receive cemiplimab alone.
9475518|NCT03580694|Experimental|Combination Therapy|"Dose Escalation cohorts:~In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination.~In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination.~Dose Expansion cohorts:~In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab."
9475519|NCT03580681|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
9475520|NCT03580681|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
9475521|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
9475522|NCT03580642|Experimental|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
9475523|NCT03580642|No Intervention|Control|Habitual treatment.
9475524|NCT03580629|Experimental|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
9475525|NCT03580603|Experimental|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
9475526|NCT03580603|No Intervention|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
9480561|NCT05263414|Sham Comparator|Sham tVNS|In the sham tVNS session tVNS will be delivered via a programmable stimulation unit connected to two titan ear electrodes mounted on a gel frame. Sham tVNS will be delivered over the left lobe auricle area, which is free from cutaneous vagal innervation. It will last 70 minutes. Stimulation intensity will be set at the intensity corresponding to the individual sensitivity threshold, as it will be defined on the left ear lobe. The intensity of the stimulation will be gradually increased to reach the intensity of the stimulation with a ramping up phase of 30 secs. During the sham stimulation, the tasks will be performed. At the end of the stimulation session participants will be asked to report possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales.
9480562|NCT05263336|Active Comparator|Intervention|Intraoperative verdye green iv administration to visualize blood supply to the anastomosis
9480563|NCT05263336|No Intervention|Control|No administration of verdye green intraoperatively
9480564|NCT05263323|Experimental|Experimental Group - Education Group|"Stage 1; In the intervention group, at the first stage, the data were filled with the data collection tools of the intervention group.~Stage 2; It was made two weeks after the first visit in stage 1. Patient education according to Neuman Systems Theory was given to the patients who participated in the study, who received hemodialysis treatment in the center determined as the intervention group. This training was applied in the form of one-on-one training by going to the homes of the patients on the day they did not go to dialysis, within the topics determined according to the theory.~Stage 3. It was done one month after the 2nd stage. Patient education according to Neuman Systems Theory was repeated to the patients, and a pre-prepared education guide called Let's Learn Hemodialysis was distributed and a question-answer evaluation was made.~Stage 4; It was done one month after the 3rd stage. The data of the intervention group were collected again with data collection tools."
10034824|NCT01800331|Experimental|Text2bHealthy|The intervention arm receives the Text2bHealthy program on a PDA
10034825|NCT01800331|No Intervention|Control group|The control group will complete a paper dairy to keep track of their lifestyle behaviours
10037244|NCT01823302|Other|nutritional counseling and milk-based supplement|nutritional counseling plus oral milk-based nutrition supplement
10034826|NCT01800344|Active Comparator|The laryngeal mask airway-ClassicTM (LMA)|The LMA is a large foreign body that exerts pressure on the pharyngeal mucosa. High LMA intracuff pressures may reduce pharyngeal mucosal perfusion and lead to throat discomfort.
9475527|NCT03580590|Experimental|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
9475528|NCT03580590|Experimental|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
9475529|NCT03580590|Placebo Comparator|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
9475530|NCT03580577||Cirrhotic with venous thromboembolism|"cirrhotic patients with a venous thromboembolic event (including deep venous thrombosis, pulmonary embolism, acute non-malignant portal vein thrombosis, splenic vein, inferior vena cava thrombosis or mesenteric vascular occlusion).~Each patient will subjected to through history taking and careful examination to detect and risk factors also laboratory work to detect thrombocytopenia, disease severity, coagulation status thrombelastography before starting anticoagulants.~Patients will start treatment with anticoagulants therapy after liaise with the specialized physician.~Protein C, protein S and antithrombin III level will be assessed 3 months after the acute thrombotic event and 1 month of vitamin K antagonist (VKA) withdrawal."
9475531|NCT03580577||Cirrhotic without venous thromboembolism|"cirrhotic patients without any thrombotic events Each patient will subjected to through history taking and careful examination to detect and risk factors.~- Protein C, protein S and antithrombin III level will be assessed at baseline."
9475532|NCT03580564|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
9475533|NCT03580551|Experimental|Intervention Group|Ten participants from each racial group (Black/White) will be assigned to the Intervention, which will receive the home-based DVD Chair Exercise Program. This is the group that will receive the chair exercise intervention upon enrollment.
9475534|NCT03580551|Active Comparator|Waitlist Control Group|Ten participants from each racial group (Black/White) will be assigned to the Waitlist Control Group, which will receive the home-based DVD Chair Exercise Program at the end of 8 weeks.
9475535|NCT03580538|Experimental|elastic tube group|
9803196|NCT04428905|Active Comparator|Arm II (ASCO care plan, telehealth sessions)|Patients receive an ASCO care plan. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) to answer questions on a handbook about life after cancer treatment, then 3 monthly telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) to answer questions about the handbook. A copy of the ASCO care plan is also sent to their PCP.
9803197|NCT04428866||Participants with post-bariatric hypoglycemia|Individuals with history of Roux-en-Y gastric bypass surgery, who have a history of hypoglycemia will be recruited from the Joslin Hypoglycemia Clinic.
9803198|NCT04428866||Asymptomatic participants with Roux-en-Y gastric bypass (RYGB)|Individuals with history of RYGB, without a history of or symptoms of hypoglycemia will be recruited from local postoperative surgical clinics and from the community.
9475539|NCT03580499|Experimental|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
9475540|NCT03580486||Patients with Parkinson's Disease|Parkinson's Disease (Hoehn and Yahr stage 1-4)
9475541|NCT03580486||Healthy controls|Healthy people
9475542|NCT03580460|No Intervention|Waitlist control|After 8 weeks, individuals randomized to this arm receives the computer-delivered smoking cessation counseling intervention
9475543|NCT03580460|Experimental|Computer Delivered Intervention|Individuals receive a 15-20 minute computer delivered smoking cessation counseling intervention
9475544|NCT03580447|Experimental|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
9475545|NCT03580447|Placebo Comparator|Placebo|During this period participants receive daily maltodextrin supplements for four week
9475546|NCT03580434|Experimental|V-STRUT|V-STRUT implantation
9475547|NCT03580408|Experimental|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)~Consolidation treatment:~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :~For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.~Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)~In case of progressive disease , patients will be considered in treatment failure."
9475548|NCT03580395|Experimental|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
9475549|NCT03580395|Sham Comparator|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
9803199|NCT04428866||Control group|Individuals without a history of bariatric surgery will be recruited by local advertisement.
9803200|NCT04428723||Hypoglycemia, no upper gastrointestinal (GI) surgery|Males or females with hypoglycemia with neuroglycopenia, but no history of upper GI surgery, diabetes or prediabetes
9475550|NCT03580330|Experimental|Intervention Group|
9475551|NCT03580330|No Intervention|Control Group|
9475552|NCT03580304|Experimental|industrial-physical-cognitive|
9475553|NCT03580304|Experimental|industrial- cognitive-physical|
9475554|NCT03580304|Experimental|physical- industrial- cognitive|
9475555|NCT03580304|Experimental|physical-cognitive- industrial|
9475556|NCT03580304|Experimental|cognitive- industrial-physical|
9475557|NCT03580304|Experimental|cognitive-physical-industrial|
9475558|NCT03580291|Experimental|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.~Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.~A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
9475559|NCT03580291|Active Comparator|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
9475560|NCT03580265|Experimental|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
9475561|NCT03580265|Sham Comparator|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
9475562|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants <37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants <37weeks at birth over a 1-year stating from march 2018.~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
9475563|NCT03580239|Experimental|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
9475564|NCT03580239|Placebo Comparator|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
9475565|NCT03580226||Good glycemic control|Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
9475566|NCT03580226||Poor glycemic control|Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c >= 7.0.
9475567|NCT03580200|Experimental|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
9475568|NCT03580200|No Intervention|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
9475569|NCT03580187|Other|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.~morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-)"
9475570|NCT03580174|Active Comparator|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed physiotherapy
9475571|NCT03580174|Active Comparator|Routine physiotherapy group|Ten children with CP will receive conventional, traditional physiotherapy
9475572|NCT03580148|Active Comparator|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
9475573|NCT03580148|Active Comparator|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
9475574|NCT03580135|Experimental|Propolis powder|"resin (50%),~vegetable Balsam, wax~essential aromatic oils (30%)~salivary secretions (10%)~pollen(5%)~other substances (5%) including amino acids~,ethanol vitamin A, B complex, and E, minerals, steroids~ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.~Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
9475575|NCT03580135|Active Comparator|Mineral Tri Oxide|"Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.~A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
9475576|NCT03580122|Experimental|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
9475577|NCT03580109|Active Comparator|Immediate spa treatment|Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts
9475578|NCT03580109|Sham Comparator|Late spa treatment|Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization
9475579|NCT03580096|Experimental|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
9475580|NCT03580096|Active Comparator|Control group|Standard intervention consisting of exercises aimed at improving balance.
9475585|NCT03580018|Experimental|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
9475586|NCT03580018|Placebo Comparator|Control Group|The control group patients only received ACLRs without TXA injections.
9475587|NCT03580005|Active Comparator|Quillichew ERCT|Quillichew ERCT
9475588|NCT03580005|Placebo Comparator|Placebo to match Quillichew ERCT|Placebo to match Quillichew ERCT
9475589|NCT03579992|Experimental|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
9475590|NCT03579992|Experimental|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
9475591|NCT03579992|Experimental|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
9517199|NCT03308409|Active Comparator|Protocol 1|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
9475592|NCT03579979|Experimental|Self control|"During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points."
9475593|NCT03579953|Experimental|Real cTBS to MPFC|One session of real cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
9475594|NCT03579953|Sham Comparator|Sham cTBS to MPFC|One session of sham cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
9475595|NCT03579927|Experimental|Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)|Participants receive rituximab IV over 3 hours on days -14 and -8, carmustine IV over 2 hours on day -13, etoposide IV over 3 hours BID on days -12 to -9, cytarabine IV over 1 hour BID on days -12 to -9, melphalan IV over 30 minutes on day -8, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5. Participants undergo ASCT on day 0. Beginning day 0, participants receive filgrastim SC QD until evidence of an ANC of 0.5 x 10^9/L per 3 consecutive days.
9475596|NCT03579888|Experimental|Treatment (fludarabine, cyclophosphamide, CD19 T cell)|"CHEMOTHERAPY: Patients receive fludarabine IV over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.~T-CELL INFUSION: Patients receive autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells IV over 15-30 minutes on day 0."
9475597|NCT03579875|Experimental|Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP|"Given to:~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia"
9475598|NCT03579875|Experimental|Treatment Plan 2: CY, FLU and MP|"Given to:~• HLA-identical sibling donor recipients with aplastic anemia"
9475599|NCT03579875|Experimental|Treatment Plan 3: BU, Cy, FLU, MP and Rituximab|"Given to:~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia who cannot tolerate TBI~Per treating physician preference"
9475600|NCT03579862||Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|
9475601|NCT03579862||Pulmonary Embolism (PE)|
9475602|NCT03579862||Pulmonary Arterial Hypertension (PAH)|
9475603|NCT03579849|Experimental|Perfusion SPECT|"Included patients with a diagnosis of acute PE on CTPA and who had a subtraction iodine mapping CT will undergo a SPECT/CT within 24 hours.~Each lung subtraction iodine mapping CT will be interpreted blindly by 3 radiologists. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.~Each perfusion SPECT will be interpreted blindly by 3 nuclear medicine physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused."
9475604|NCT03579836|Experimental|Phase I-1 (#4 Cohort)|BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
9475605|NCT03579836|Experimental|Phase I-2 (#3 Cohort)|BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
9475606|NCT03579836|Experimental|Phase II (#1 Cohort)|BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
9475607|NCT03579823|Experimental|AVT02 100 MG/ML|Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
9475608|NCT03579823|Active Comparator|Adalimumab 100 MG/ML [HUMIRA]|Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) [HUMIRA]
9475609|NCT03579810|Experimental|Investigational|"An education intervention was implemented in 5 schools including 516 children, 360 parents and 240 teachers.~The Pedagogical Intervention last two and a half years. In children, the intervention included class activities (1/week) and the use of educational materials for the development of pedagogical activities (posters and educative guide).~In parents included 3 workshops/year (2 hours each) about the areas of the intervention; sending healthy notes (1/month) and celebration of healthy family day (1/year).~In teachers included 3 workshops/year (2 hours each) about the areas of the intervention; planning and realization of pedagogical activities to develop with the students (1/week) and follow-up visits to school (1/month)."
9475610|NCT03579810|Active Comparator|Control|"The control group consisted of 4 schools including 354 children, 305 parents and 110 teachers.~The activities in control group last two and a half years. Children received the standard curriculum in health and physical activity of the national Ministry of Education.~In parents and teachers included 3 workshops/year (2 hours each) about the first aid and accident prevention."
9475611|NCT03579784|Experimental|Durvalumab+Olaparib+Paclitaxel|"st cycle : Paclitaxel+Olaparib~Olaparib 150mg bid on D1-28~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15~nd cycle and thereafter: Durvalumab+Olaparib+Paclitaxel :~Olaparib 150mg bid on D1-28~Durvalumab 1.5 g iv on D1~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks~During first 4 weeks, palictaxel/olaparib dual combination will be used. Since 2nd cycle, palictaxel/olaparib/Durvalumab combination will be used."
9475612|NCT03579771|Experimental|Gemcitabine, cisplatin, nab-paclitaxel|Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
9475613|NCT03579758|Active Comparator|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
9475614|NCT03579758|Experimental|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
9475615|NCT03579745|Active Comparator|Conventional lingual mechanics|
9475616|NCT03579745|Experimental|Lever arm lingual mechanics|
9475617|NCT03579732||Long-term users|Adults using low-dose aspirin for > 3 years
9475618|NCT03579732||Episodic users|Adults using low-dose aspirin inconsistently, or consistently but < 3 years
9475619|NCT03579732||Former users|Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
9475620|NCT03579732||Non-consumers|Adults who did not use low-dose aspirin
9475621|NCT03579706|Experimental|Intervention|The intervention condition will involve participants completing baseline measures, the Cognitive Anxiety Sensitivity Treatment, post measures, and a 4 month follow up assessment.
9475622|NCT03579706|Placebo Comparator|Control|The control condition will involve participants completing baseline measures, the Physical Health Education Training, post measures, and a 4 month follow up assessment.
9475623|NCT03579654|Experimental|Arm 1 - Proscavax vaccine treatment|In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.
9475624|NCT03579654|No Intervention|Arm 2 - Active Surveillance|In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.
9475625|NCT03579589|Active Comparator|Sugammadex|"If spontaneous recovery has reached second twitch after TOF: 2 mg/kg~If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg~When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg"
9475626|NCT03579589|Active Comparator|Neostigmine|50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.
9475627|NCT03579576||HCV infected patients|All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
9475628|NCT03579550|Active Comparator|Intervention arm: Hysterocopy group|Office hyteroscopic metroplasty will be performed. After oparetion 9 months spontaneous conception Intervention arm for hysteroscopy group
9475629|NCT03579550|No Intervention|Spontaneous cycles plus COH/IUI|Six months spontaneous coitus cycles plus 3 cycles of Clomiphene citrate and intrauterine insemination (COH/IUI)
9475630|NCT03579537|Experimental|Hemodyalisis patients|group of patients in hemodialysis who performs the exercise program
9475631|NCT03579524|Active Comparator|ESPB group|Erector Spinae Plane Block administered group
9475632|NCT03579524|Active Comparator|SAPB group|Serratus Anterior Plane Block administered group
9475633|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
9475634|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
9475635|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
9475636|NCT03579472|Experimental|Treatment (bintrafusp alfa, eribulin mesylate)|Patients receive bintrafusp alfa IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
9475637|NCT03579420|Experimental|Brief lifestyle program|3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach
9475638|NCT03579420|Active Comparator|Traditional lifestyle longer program|6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods
9475639|NCT03579407|Active Comparator|Traditional Open Ended Trocar|Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
9475640|NCT03579407|Experimental|Fenestrated Blunt Trocar|Patients will undergo bone marrow aspiration using the Marrow Cellution bone marrow aspiration needle. This needle has several fenestrations along the trocar through which the bone marrow is aspirated. Approximately 8-10 mL of high concentrate bone marrow will be collected, which will not be concentrated.
9475641|NCT03579381||Immune Controllers|Patients with very low or undetectable levels of viremia without treatment
9475642|NCT03579381||Acute Infection|Early infection, i.e. within 2 weeks of infection
9475643|NCT03579368|Other|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
9517200|NCT03308409|Experimental|Protocol 2|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
9475644|NCT03579355|Experimental|DFND Program|"Dentist Fighting Nicotine Dependence, (DFND) intervention program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills. DFND was administered over 5 weeks, at a rate of 2 sessions per week. Each session lasts an hour. Fourteen classrooms in four schools represented the experimental arm and received DFND."
9475645|NCT03579355|No Intervention|Informational Booklet|Fourteen classrooms in four schools represented the No Intervention arm (control). They received only an informational booklet about tobacco adverse health effects.
9475646|NCT03579342|Experimental|App technology and coaching|Participants in the intervention group with app technology and coaching participate in a first meeting with the coach and will thereafter receive active support from the coach every 4 weeks for the duration of the intervention.
9475647|NCT03579342|Experimental|App technology only|Participants in the intervention group with only app technology participate in a first meeting with the coach but do not get any additional support during follow-up.
9475648|NCT03579342|No Intervention|Control group|Participants in the control group participate in baseline assessments. The control group will get access to the app and will have a meeting with a coach after 12 weeks of follow-up.
9475649|NCT03579303|Active Comparator|Homoeopathic remedies in PCOS|Homoeopathic treatment for menstrual disorders in females with PCOS
9475650|NCT03579303|Active Comparator|Homoeopathic remedies and yoga in PCOS|Homoeopathic treatment integrated with yoga therapy for menstrual disorders in females with PCOS
9475651|NCT03579277|Active Comparator|Radial forearm free flap|Subjects in this arm will receive a radial forearm free flap.
9475652|NCT03579277|Active Comparator|Ulnar forearm free flap|Subjects in this arm will receive an ulnar forearm free flap.
9475653|NCT03579264|No Intervention|Standard Arm|No use of My Viva Plan.
9475654|NCT03579264|Experimental|Intervention Arm|Use of My Viva Plan.
9475655|NCT03579251|Other|Pilot test|12 weeks of behavioral intervention (Black Men's Care), including an in-person session and two-way SMS, with a three-month follow-up period post-intervention.
9475656|NCT03579238|No Intervention|Distant|The clinician sits quietly 3 feet away from participant who is lying on a soft table at rest.This position is held for 5 minutes without moving.
9475657|NCT03579238|No Intervention|close|The clinician sits at the head of the table with his arms on the table alongside the participant's head but not touching the resting patient who is lying at rest on the table. This position is held for 5 minutes without moving.
9475658|NCT03579238|Sham Comparator|touching|"The clinician lifts the patient's head passively off the table in order to place his hands underneath the participant's head, palms facing upwards and in contact with the back of the head of the participant. The participant's head is gently lowered to rest upon the clinician's hands. No external force is provided by the clinician upon the participant's head as the head rests in the clinician's palms on the table. This position is held for 5 minutes without moving. This is called a touching intervention and is meant to be a sham. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
9475659|NCT03579238|Experimental|Occipital motion inhibition|"The clinician gently inhibits motion of the participant's occiput into flexion phase of the primary respiratory mechanism, and allows extension phase only. Upon sensing a still point, where no further flexion motion is palpated, the clinician will state to the research assistant now to indicate he feels a still point. This position is held for 5 minutes without moving. This is called a CV4 or modified CV4 intervention. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
9475660|NCT03579225||MATRx plus test|
9475661|NCT03579199|Experimental|exploration of abdominal cavity using a NIR/ICG camera|
9475662|NCT03579186|Experimental|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
9475663|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
9475664|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
9475665|NCT03579173||Passive Tidal Breathing and Infant PFT|To delineate the relationship between passive tidal breathing lung function testing in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
9475666|NCT03579147|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
9475667|NCT03579134|Experimental|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
9475668|NCT03579134|Active Comparator|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
9475669|NCT03579095|Experimental|American ginseng|200mg Cereboost and Maltodextrin
9475670|NCT03579095|Placebo Comparator|Placebo|Placebo
9475671|NCT03579082|Experimental|Arm A|"R±DHAP + decitabine:~decitabine:10mg/d,ivgtt,d(-5)-(-1);R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle."
9475672|NCT03579082|No Intervention|Arm B|R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.
9475673|NCT03579069||Ductus venosus Doppler realized|Ductus venosus Doppler realized
9475674|NCT03579069||Ductus venosus Doppler unrealized|Ductus venosus Doppler unrealized
9475675|NCT03579043|Experimental|Nutritive Sweetener|Participants will consume 36 ounces of Coke daily for three consecutive days.
9475676|NCT03579043|Experimental|Non-Nutritive Sweetener|Participants will consume 36 ounces of Diet Coke daily for three consecutive days.
9475677|NCT03579043|Experimental|Carbonated Water|Participants will consume 36 ounces of carbonated water daily for three consecutive days.
9475678|NCT03579030|Experimental|Single Dose of RTA 1701 or Placebo|"RTA 1701 capsules or placebo taken orally in a single dose.~Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo"
9475679|NCT03579030|Experimental|Multiple Dose of RTA 1701 or Placebo|"RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks.~Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo"
9475680|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
9475681|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
9475682|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
9475683|NCT03579004|Experimental|Trimodality approach|"2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).~4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy."
9475684|NCT03578991|No Intervention|Arm 1|"Control group - Treatment as usual:~Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist."
9475685|NCT03578991|Experimental|Arm 2|"Intervention - Smart pillbox:~Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox."
9475686|NCT03578991|Experimental|Arm 3|"Intervention - Smart pillbox & Interactive digital platform:~Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform."
9475687|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
9475688|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
9475689|NCT03578952|Experimental|Pure AR|Patients with symptomatic severe aortic valve regurgitation without severe aortic stenosis requiring aortic valve replacement.
9475690|NCT03578913|Active Comparator|porcelain fused to metal crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
9475691|NCT03578913|Experimental|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading
9475692|NCT03578900|Experimental|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
9475693|NCT03578900|Active Comparator|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
9475694|NCT03578900|Experimental|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
9475695|NCT03578900|Experimental|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
9803201|NCT04428723||Hypoglycemia, with history of upper GI surgery|Males or females with hypoglycemia with neuroglycopenia, with history of upper GI surgery
9475696|NCT03578900|Experimental|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
9475697|NCT03578887|Active Comparator|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
9475698|NCT03578887|Active Comparator|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
9803202|NCT04428723||Controls, without hypoglycemia or upper GI surgery|Males or females with no history of upper gastrointestinal surgery, hypoglycemia, or diabetes.
10034827|NCT01800344|Active Comparator|The AES Ultra CPVTM LMA (Ultra)|Ultra is a new supraglottic airway with anatomical features and insertion technique virtually identical to the LMA-ClassicTM. The cuff and the shaft are made of silicone with a built-in CPV pilot balloon valve which provides continuous monitoring of the intracuff pressure. The CPV cuff pressure indicator has 3 zones indicated by color: yellow corresponds to pressure < 50 cm H2O; green 60 cm H2O; and red >70 cm H2O
9475699|NCT03578887|No Intervention|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
9475700|NCT03578874|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
9475701|NCT03578861|Experimental|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
10034828|NCT01800357|Experimental|mildronate|infusion of mildronate
9475702|NCT03578848|Active Comparator|uAOBP & Home BP|On the scheduled visits, the uAOBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
9475703|NCT03578848|Experimental|CBP & Home BP|On the scheduled visits, the CBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
9475704|NCT03578835||Multi-center BSI cohort|Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
9475705|NCT03578822|Experimental|Group A|Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent
9475706|NCT03578822|Other|Group B|rhPro-UK simulation agent and Aspirn
9475707|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
9480565|NCT05263323|Active Comparator|Control Group|"Data collection for individuals in the control group included two stages, one at the beginning and one at the end of the study.~The first stage was applied to the experimental group during the first stage. The data of the control group were collected with data collection tools.~The second stage was given to the experimental group during the fourth stage. In this visit, The data of the control group were collected again with data collection tools."
9480566|NCT05263310|Experimental|Educational Video and Action Plan handout|"Patients in the intervention arm will be given access to an educational video (Prepare for Your Diabetes Care) and will be supported in viewing the video and the Action Plan handout.~This program will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps with the participant's primary care provider."
9480567|NCT05263310|Active Comparator|Usual Care|Patients in the control arm will continue with usual care and also complete baseline, 6-month, and 12-month surveys
9480568|NCT05263297|Other|video group|During the bloodletting process, children in the video game group will be played with audio and visual video games that they can play with one hand. Thus, children will be provided with both visual and auditory stimuli. It will be preferred that children play the video game that they have knowledge about and know how to play the game. For this reason, children in the video game group will be given the chance to choose video games suitable for their age and development level on their parents' smartphones. These video games within the scope of the research will not be named and will not be promoted/advertised.
9480569|NCT05263297|Other|kaleidoscope group|In this study, a kaleidoscope with colorful patterns that can be used by children with one hand will be used. In the research, the kaleidoscope will be introduced to children and how to use it will be explained. After the procedure, the kaleidoscope will be disinfected using appropriate disinfectant materials.
9480570|NCT05263284|Experimental|Treatment (8-chloroadenosine, venetoclax)|Patients receive 8-Cl-Ado IV over 4 hours daily on days 1-5 and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
9480571|NCT05263271|Experimental|Experimental cohort|Gentulizumab administered IV once a week and a dosing cycle is 4 weeks
9480572|NCT05263245|No Intervention|Standard regimen|Patients will continue to use cabozantinib in fasted state, as part of standard of care, in the recommended dose as prior to enrollment in the study.
9480573|NCT05263245|Experimental|Experimental regimen|In phase A of the study, patients will take the prior recommended dose cabozantinib with a continental breakfast. In phase B of the study, patients will take 60 mg tablets with a continental breakfast, the frequency depending on their original dose in the standard regimen.
9803203|NCT04425239|Active Comparator|CONTINUOUS ARM:|Patients will receive Panitumumab plus FOLFIRI until progressive disease, unacceptable toxicity or informed consent withdrawal.
10034829|NCT01800357|Placebo Comparator|placebo|infusion of placebo mildronate
9475708|NCT03578783|Experimental|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
9475709|NCT03578783|Placebo Comparator|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
9475710|NCT03578757|Experimental|intervention group|stress management program and the same usual practice (restrictive diet, physical activity and thermal spa treatment)
9475711|NCT03578757|Active Comparator|usual practice group|Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders
9475712|NCT03578744|Experimental|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
9475713|NCT03578744|Experimental|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
9475714|NCT03578692||Surgery group|The protocol for patients assigned to surgery group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed bad response to medicine (glucocorticoid for 5 days and rescue therapy for 3 days) were recommended and classified in the surgery group. Their baseline manifestations were collected and compared with the medical group, to exploit the baseline indicators with great sensitive and specificity predicting the high risk for surgery.
9475715|NCT03578692||Medical group|The protocol for patients assigned to medical group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed response to medicine (glucocorticoid for 5 days or rescue therapy for 3 days) were classified in the medical group. Their baseline manifestations were collected and compared with the surgery group.
9475716|NCT03578679|Experimental|HEGOR/AZICUR shampoo solution|At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
9475717|NCT03578666|Experimental|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
9475718|NCT03578666|Experimental|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
9475719|NCT03578666|No Intervention|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
9475720|NCT03578653|Experimental|Merging Yoga and Occupational Therapy for Parkinson disease|The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
9475721|NCT03578640|Experimental|Treatment arm|Elbasvir, Grazoprevir 50-100Mg Oral Tablet
9475722|NCT03578627|No Intervention|Assessment-only|
9475723|NCT03578627|Experimental|Intervention|
9475724|NCT03578614|No Intervention|Control Group|There is no intervention for Control Group
9475725|NCT03578614|Experimental|Intervention Group|Intervention Group will be submitted to three physical activity sessions (two supervised and one nonsupervised) conducted over 6 months
9475726|NCT03578601||Thyroid surgery|Patient undergoing thyroid surgery
9475727|NCT03578588|Experimental|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
9475728|NCT03578588|Experimental|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
9475729|NCT03578588|Experimental|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
9475730|NCT03578588|Experimental|Banapenem C1group|250mg Once daily for 7 consecutive days
9475731|NCT03578588|Experimental|Banapenem C2group|500mg Once daily for 7 consecutive days
9475732|NCT03578575|Experimental|Danggui Buxue Tang group|Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
10034830|NCT01800370|Experimental|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
9475733|NCT03578575|Placebo Comparator|Placebo group|Use Placebo 5g/time, 3 times a day, for 12 weeks.
9475734|NCT03578562|Experimental|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
9475735|NCT03578536|Experimental|CIT with Recovery Rapids|"This project will develop a therapeutic model that promotes use of the impaired arm and hand. Researchers often call this type of therapy constraint induced therapy. In this study, participants focus on using the impaired limb rather than the unaffected limb. Study participants will only be able to play the game using the impaired limb.~A small group of patients will participate in a question and answer session about preferences for activities which make up transfer tasks. Patients will also receive automated reminders to use the impaired arm throughout the day. Twelve (12) Veterans will be recruited annually from the inpatient Stroke Specialty Program. Six (6) patients will be assigned to the Treatment group and receive the intervention. The remaining six (6) will receive the current standard of care. Outcome measures will include motor function tests that evaluate upper extremity function."
9480576|NCT05263219|Experimental|Transarterial chemoembolization with drug-eluting beads plus hepatic arterial infusion chemotherapy|Patients will receive the combination treatment of DEB-TACE and HAIC.
9475736|NCT03578536|No Intervention|Standard of Care|As part of standard care, participants will receive a minimum of daily OT, PT and Speech for a total of three hours. Current occupational therapy intervention options for inpatient stroke rehab patients with UE neuromotor impairments include active assisted range of motion exercise, morning bedside ADL sessions, high-repetition task-specific training, mirror therapy, Digi-flex, theraputty, theraband, free weights, weighted therapy bars for strengthening exercises in clinic and use with home exercise programs (HEP). Additional tools used as determined by therapist include FES modalities to assist with upper extremity neuromotor re-education, unweighted reaching tasks via the ArmeoSpring, and functional work task training/strengthening. They also participate in recreation therapy as appropriate.
9475737|NCT03578523||Chronic Kidney Disease|"CKD stage 3-4 eGFR 59-20mls/min/1.73 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
9475738|NCT03578523||Acute Kidney Injury|"AKI stage 2-3 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
9475739|NCT03578510|Active Comparator|SHD|Standard hemodialysis
9475740|NCT03578510|Experimental|HHD|Hemocontrol hemodialysis
9475741|NCT03578497|Experimental|IL-1 receptor antagonist Anakinra 100 mg|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
9475742|NCT03578484||Volunteer female subjects|Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
9475743|NCT03578471|Active Comparator|Hearing Aid without NR and BF|Hearing Aid without Noise Reduction (NR) or beam forming (BF) enabled serves as reference condition.
9475744|NCT03578471|Experimental|Hearing Aid with NR|Hearing Aid with Noise Reduction (NR) enabled.
9475745|NCT03578471|Experimental|Hearing Aid with BF|Hearing Aid with beam forming (BF) enabled.
9475746|NCT03578458|Other|US Healthy diet|Subjects will install a mobile app for use and will be randomly assigned to a healthy diet.
9475747|NCT03578458|Other|Vegetarian diet|Subjects will install a mobile app for use and will be randomly assigned to a vegetarian diet.
9475748|NCT03578458|Other|Mediterranean diet|Subjects will install a mobile app for use and will be randomly assigned to a Mediterranean diet.
9475749|NCT03578445|Experimental|Patients with a pancreatic cystic lesion|
9475750|NCT03578432|Experimental|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
9475751|NCT03578419|Active Comparator|Control Period|Standard-Volume Blood Collection Tubes
9475752|NCT03578419|Experimental|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
9475753|NCT03578406|Experimental|HPV TCR-T|HPV E6-specific TCR-T cell
9475754|NCT03578406|Experimental|HPV TCR-T with anti-PD1|HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element
9475755|NCT03578380|Experimental|Surgery|Lymphovenous anastomosis
9475756|NCT03578380|Active Comparator|Compression|Conservative treatment with physiotherapy and compression
9475757|NCT03578354|Experimental|4-AP|15 mg 4-aminopyridine twice daily
9475758|NCT03578354|Experimental|Atenolol|25 mg atenolol twice daily
9475759|NCT03578354|Placebo Comparator|Placebo|Masked placebo twice daily
9475760|NCT03578341|Experimental|Colostrum|Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.
9475761|NCT03578341|Placebo Comparator|Placebo|Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.
9475762|NCT03578328||Cardiac arrest with targeted temperature management|
9475763|NCT03578315|Experimental|Solar lentigo|25 Patients with Solar lentigo
9475764|NCT03578315|Experimental|Nevus zygomaticus|25 Patients with Nevus zygomaticus
9475765|NCT03578289|Experimental|Experimental Group (telemental health_|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
9475766|NCT03578289|Experimental|Waiting Control Group (usual care)|Participants randomly assigned to the control group will receive routine care for three months followed by the 8-week CBT intervention
9475767|NCT03578276|Active Comparator|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
9803204|NCT04425239|Experimental|INTERMITTENT ARM:|Patients will have a treatment free interval until progressive disease (PD), when they will receive up to 8 cycles of Panitumumab plus FOLFIRI. In the presence of complete or partial response, or stable disease, non-progressing patients will undergo again to treatment free interval until PD, when they will restart treatment. Treatment cycling will continue till any PD on treatment.
9480577|NCT05263219|Active Comparator|Hepatic arterial infusion chemotherapy|Patients will receive HAIC treatment alone.
10034831|NCT01800370|Placebo Comparator|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
9475768|NCT03578276|Active Comparator|Standard of Care|"Gatifoxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
9475769|NCT03578263|Experimental|carbetocin arm|carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby
9475770|NCT03578263|Active Comparator|oxytocin and ergometrine arm|oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist plus intramuscular ergometrine 0.2 mg after the birth of the baby
9475771|NCT03578250|Experimental|Study Group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will apply error augmentation force-field to perturbate the arm of the participant away from the straight trajectory line."
9475772|NCT03578250|Experimental|Control group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will not apply any perturbations on the participant's arm."
9475773|NCT03578211|Experimental|DAs group|Shared decision making using decision aids
9475774|NCT03578211|No Intervention|Control group|Standard oral explanation guided with booklets
9475775|NCT03578159||Arsha Vidya Chhatralaya|Chhatralaya is residential setting for children 8 to 16 years old. It provides residence,food and education opportunities along with regular practice of Yoga, Spiritual sessions and vedic practices to learn and follow.
9475776|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
9475777|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
9475778|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
9475779|NCT03578055|Active Comparator|BDD with UDCA|Postoperative BDD with UDCA treatment
9475780|NCT03578055|Placebo Comparator|Placebo|Placebo
9475781|NCT03578042|Active Comparator|LosanetAMplus|Patients taking the fixed triple combination
9475782|NCT03578042|Other|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
9475783|NCT03578029|Experimental|RGN-137|It is formulated as a gel for topical administration.
9475784|NCT03578029|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
9475785|NCT03578016|Experimental|Circle of Security-Parenting|10 weekly, manualized group sessions at the clinic
9475786|NCT03578016|Other|Treatment as Usual (TAU)|TAU consists of clinical assessment and treatment.
9475787|NCT03578003|Experimental|Morning Bright Light Therapy|Subjects who engage in morning bight light therapy
9475788|NCT03578003|No Intervention|Control|Subjects who do not engage in morning bright light therapy
9475789|NCT03577977||Patients treated with Betaferon|Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.
9475790|NCT03577951|Experimental|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
9475791|NCT03577951|Experimental|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
9475792|NCT03577925||HSIL|the patients with HSIL
9475793|NCT03577925||stage IA1 cervical squamous cancer|the patients with stage IA1 cervical squamous cancer
9475794|NCT03577912|Active Comparator|TAP block administered by Surgery|transversus abdominis (TAP) plane block is performed by the surgeon at the conclusion of the surgery, still under general anesthesia, prior to removing the trocars a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under direct surgeon observed laparoscopic visualization. (Split dose 30cc/side)
9475795|NCT03577912|Active Comparator|TAP block administered by Anesthesia|transversus abdominis (TAP) plane block is performed by the anesthesiologist at the conclusion of the surgery after incisions are closed and dressing are on, prior to emergence from general anesthesia, a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under by the anesthesiologist using ultrasound visualization. (Split dose 30cc/side)
9475796|NCT03577899|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
9475797|NCT03577899|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
9475798|NCT03577899|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
9475799|NCT03577886|Experimental|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
9475800|NCT03577886|Placebo Comparator|Placebo|Phosphate Buffer Diluent solution
9803205|NCT04423939|Experimental|Hematopoietic Stem Cell Transplantation (HCT) Patients|20 HCT patients at Duke
9475801|NCT03577873|Placebo Comparator|gallbladder preserved|Patients with stones in their bile ducts and gallbladders will keep gallbladders in stay after clearance of bile duct stones with ERCP.
9475802|NCT03577873|Experimental|cholecystectomy|Patients with stones in their bile ducts and gallbladders will undergo cholecystectomy after clearance of bile duct stones with ERCP.
9475803|NCT03577860|Active Comparator|Bupivacaine 4ml|The interscalene brachial plexus block is performed with 4ml at level of C5-6 roots
9475804|NCT03577860|Active Comparator|Bupivacaine 15ml|The interscalene brachial plexus block is performed with 15ml at level of C5-6
9475805|NCT03577847||1|Intervention group: Stroke patients investigated with rural CT scanning at HSS, Ål. Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
9475806|NCT03577847||2|Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT scanning. Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
9475807|NCT03577834|Experimental|Liquid vinegar|Participants in this arm were instructed to drink 2 tablespoons of red wine vinegar (provided) mixed with water twice each day for weeks 1 to 8 of the trial.
9475808|NCT03577834|Placebo Comparator|Vinegar pill|Participants in the control group were instructed to take one vinegar pill (provided) each day for weeks 1-8 of the trial.
9475809|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
9475810|NCT03577782|Experimental|Single group|HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
9475811|NCT03577756||Infants with cystic fibrosis|Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
9475812|NCT03577756||Healthy infants|Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
9475813|NCT03577743|Experimental|experimental arm|bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
9475814|NCT03577717|Experimental|computerized cognitive training|"participants will be trained by the Cookies for the brainy day, including memory, attention, calculation, executive functions, and language training."
9475815|NCT03577717|Active Comparator|occupational therapy|participants will receive craft activities of occupational therapy, such as weaving, origami etc.
9475816|NCT03577691|Experimental|Training for use of web based Decision Aid|Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
9475817|NCT03577691|Placebo Comparator|No training for use of web based Decision Aid|Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
9475818|NCT03577678|Experimental|observational|orthopaedic Surgery to fix lateral half prosthesis for clavicle
9475819|NCT03577665|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
9475820|NCT03577652|Experimental|Ticagrelor, 90mg, 12h|
9475821|NCT03577652|Experimental|Ticagrelor, 90mg, 24h|
9475822|NCT03577652|Experimental|Ticagrelor, 180mg, 24h|
9475823|NCT03577626|Experimental|Hemay005 Fast|
9475824|NCT03577626|Experimental|Hemay005 Fed|
9475825|NCT03577613||Early stage Cervical Cancer- Open Radical Hysterectomy(RH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a open RH at our institution as primary treatment were included in the study
9475826|NCT03577613||Early stage Cervical Cancer- Laparoscopic Radical Hysterectomy|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a laparoscopic RH at our institution as primary treatment were included in the study
9475827|NCT03577613||Early stage Cervical Cancer- Robotic radical Hysterectomy(RRH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a robotically assisted RH at our institution as primary treatment were included in the study
9475828|NCT03577600|Experimental|QMRT using the Cytotron®|Experimental: QMRT using the Cytotron® Intervention: 28 days of treatment with QMRT with the Cytotron®. Patients diagnosed with terminal brain tumors between 3 and 16 years of age whose parents agree to participate in the study and have signed informed consent and informed consent in patients with age or mental age over 8 years.
9475829|NCT03577574|Active Comparator|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
9475830|NCT03577574|Active Comparator|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
9475831|NCT03577574|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
9803206|NCT04423939|Experimental|Caregivers|20 HCT patients caregivers at Duke
9475832|NCT03577561|No Intervention|Control group A|Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving proficiency based progression training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.
9475833|NCT03577561|Active Comparator|Control Group B|Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
9475834|NCT03577561|Active Comparator|Interventional Group|"The blood sampling error rate of doctors in training provided with the intervention i.e. improved proficiency based progression training programme will be analysed from July 10th 2018 until the study ends.~The proficiency based progression training will consist of an online eLearning module to teach the doctors the correct process to take blood in the hospital. The doctors will then have to attend a face to face training day on a simulation ward where they will be asked to take blood according to a metric of 77 steps with less than 13 errors and no critical errors. Finally, the doctors will be observed taking blood on the ward and again must take it to a proficient standard."
9475835|NCT03577535|Experimental|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
9475836|NCT03577535|No Intervention|No Oncoxin Treatment®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
9475837|NCT03577509|Experimental|ABCD|Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg
9475838|NCT03577496|Experimental|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
9475839|NCT03577483|Other|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to criteria
9475840|NCT03577483|Other|Multiple system atrophy|Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
9475841|NCT03577483|Other|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
9475842|NCT03577470||Group 1|Participants will not receive any intervention as a part of this study. This group will include participants in treatment with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), who were always being treated with boosted-darunavir (DRV)-based regimen. The primary data source will be the medical records of each participant participating in this study.
9475843|NCT03577470||Group 2|Participants will not receive any intervention as a part of this study. This group will include participants who started their antiretroviral (ARV) treatment with any combination excluding DRV before starting D/C/F/TAF treatments, who were always being treated with ARV treatment with any combination excluding DRV before starting D/C/F/TAF treatments. The primary data source will be the medical records of each participant participating in this study.
9475844|NCT03577470||Group 3|Participants will not receive any intervention as a part of this study. This group will include participants started with D/C/F/TAF as naive. The primary data source will be the medical records of each participant participating in this study.
9475845|NCT03577457|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
9475846|NCT03577457|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
9475847|NCT03577457|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
9475848|NCT03577457|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
9475849|NCT03577444||Dysphagia patients|Patients who had been diagnosed with neurogenic dysphagia related to either stroke or traumatic brain injury at two university affiliated hospitals
9475850|NCT03577392|Experimental|XELOX chemotherapy with recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
9475851|NCT03577392|Active Comparator|XELOX chemotherapy without recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
9475852|NCT03577379|No Intervention|Control|Patients in the control arm will receive standard of care for their rotator cuff tear, and will not receive the additional whole blood fibrin clot.
9475853|NCT03577379|Experimental|Treatment|Patients in the control arm will receive standard of care for their rotator cuff tear, in addition to, the whole blood fibrin clot.
9475854|NCT03577353|Experimental|experimental-DTW|The intervention of the experimental group was based on dual-task treadmill walking while using the Virtual Reality (VR) tool.
9475855|NCT03577353|Active Comparator|Control- TMW|The intervention of the control group was based on single-task treadmill walking.
9475856|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
9475857|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
9475858|NCT03577314||miscarriage|Patients were aged from 18 to 35 years, 50 females who have history of at least two unexplained recurrent miscarriage below 20th week of pregnancy
9475859|NCT03577314||healthy|50 systemically healthy females with at least two normal births and no poor obstetric history such as preeclampsia and premature birth
9475860|NCT03577262|Experimental|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
9480578|NCT05263180|Experimental|Expenrimental: EMB-09|Participants enrolled at different time will receive EMB-09 once a week (IV) at different ascending dose levels.
9475861|NCT03577262|Experimental|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
9475862|NCT03577249|Experimental|Single arm|
9475863|NCT03577236|Experimental|Zenflow Spring System|Receives treatment with the investigational device
9475864|NCT03577223|Experimental|Whole Eggs|
9475865|NCT03577223|Active Comparator|Egg White-Based Egg Substitute|
9475866|NCT03577210|Other|computer-guided augmentation genioplasty|patient-specific PEEK implant
9480579|NCT05263128||Boston carpal tunnel syndrome questionnaire|
9480580|NCT05263128||Hand-20 questionnaire|
9480581|NCT05263115|Active Comparator|Resistance exercise|12-week progressive power-oriented resistance exercise program on leg press machine
9480582|NCT05263115|Experimental|Functional stair and stepping-based exercise|12-week progressive functional weight-bearing stair and stepping-based exercise program
9480583|NCT05263024||left atrial appendage clip|Cardiac valvular patients complicated with atrial fibrillation need cardiac valvular surgery, according to the patient's wishes, cardiac auricular clamp at the same time
9480584|NCT05263024||Left atrial appendage treated with conventional methods|Valvular heart disease with atrial fibrillation requires valvular heart surgery and left atrial ligation
9480585|NCT05263011|Experimental|Avocado snack|1 avocado
9480586|NCT05263011|Placebo Comparator|control snack + fiber supplement + vegetable oil|high fat, high fiber control
9480587|NCT05263011|Other|control snack|Low-fiber, low-fat
9480588|NCT05262985|Other|Treatment with Durvalumab+|Comparison of standard treatment verses the addition of Durvalomab to the standard protocol.
9480589|NCT05262972|Experimental|Group I|The subject will obtain a conservative treatment for this type of pathology consisting of the development of a personalized plantar orthosis
9480590|NCT05262972|Experimental|Group II|The subjects belonging to this group, in addition to providing their corresponding personalized plantar orthosis, will receive a complementary treatment consisting of the application of ultrasound-guided percutaneous electrolysis
9480591|NCT05262946|Active Comparator|control|control arm: usual care and foot care education.
9480592|NCT05262946|Experimental|experimental|experimental arm: sensorimotor training, foot care education and usual care
9480593|NCT05262920|Experimental|The BSM Intervention|"Guided by the Individual and Family Self-Management Theory, the Lucas team developed the Breastfeeding and BNP Self-Management (BSM) intervention. The BSM intervention uses a cloud-based platform, links to educational modules, and daily journaling, to provide women uniform best practice knowledge and skills for BF and BNP self-management.~Strategies include guided imagery, therapeutic breathing, mindfulness, relaxation, non-pharmacological interventions that are integrated within the self-management process such as goal-setting, self-monitoring, problem-solving, and social support through texting."
9480594|NCT05262920|Active Comparator|Attention Control|Attention control participants will receive equivalent attention as the BSM group. The fourth-trimester care based on the CDC HEAR HER campaign and infant health information modules will be provided through the REDCap link.
9480595|NCT05262907|Experimental|Ventripoint 3D Echocardiogram|Ventripoint 3D Echo performed on subject to validate technology for use in single ventricle patients.
9480596|NCT05262907|Active Comparator|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
9480979|NCT05138757|Experimental|Treatment Group|Subjects who meet inclusion criteria will be randomized 1:1. The treatment group will receive prebiotic therapy for 30 days, then subjects will start peanut oral immunotherapy (POIT) in addition to the prebiotic. Subjects will continue through a prescribed course of POIT for approximately 180 days. After completion of POIT up-dosing, subjects will continue on maintenance POIT plus prebiotic therapy for an additional 180 days at which time they will undergo a DBPCFC. Subjects will then stop prebiotic therapy and continue on maintenance POIT in extended observation for approximately 4 years.
9480980|NCT05138757|Placebo Comparator|Control Group|Subjects who meet inclusion criteria will be randomized 1:1. The control group will receive placebo therapy for 30 days, then subjects will start peanut oral immunotherapy (POIT) in addition to the placebo. Subjects will continue through a prescribed course of POIT for approximately 180 days. After completion of POIT up-dosing, subjects will continue on maintenance POIT plus placebo for an additional 180 days at which time they will undergo a DBPCFC. Subjects will then stop placebo and continue on maintenance POIT in extended observation for approximately 4 years.
9480981|NCT05136794||Opioid free anaesthesia|patient anesthtesized with lidocaine
9480982|NCT05136794||Opioid anaesthesia|patients anesthetized with sufentanil
9480983|NCT05132517||Stroke Patients|Ischemic-/hemorragic stroke patients, who admitted on the stroke unit.
9517201|NCT03308409|Experimental|Protocol 3|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
10034832|NCT01800370|Experimental|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.~Includes blood draws and fasting requirements."
10034833|NCT01800383||Control|No Axis I psychiatric disorder and no trauma exposure
10034834|NCT01800383||Trauma-Exposed Normal Control|History of trauma exposure and subthreshold PTSD symptoms.
10034835|NCT01800383||PTSD|Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised
10034836|NCT01800396|Placebo Comparator|Milk protein|Milk powder, twice daily at breakfast and dinner.
10034837|NCT01800396|Experimental|Milk protein rich in phospholipids|Milk powder, twice daily at breakfast and dinner.
10034838|NCT01800409|Experimental|AFES training|Participants will take part in AFES training sessions five times per week (Mon-Fri) for a total of 8 weeks During these sessions participants will receive AFES for 40 minutes. Training sessions are designed to strengthen the participants abdominal muscles in order to improve respiratory function
9475867|NCT03577158|Experimental|Closed-loop controller with exercise mitigation module|"Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with mitigation module.~Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP with mitigation module) based on blood glucose estimations from CGM."
9475868|NCT03577158|Experimental|Closed-loop controller without exercise mitigation module|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP without mitigation module) based on blood glucose estimations from CGM.
9475869|NCT03577158|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous subcutaneous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
9475870|NCT03577145|Experimental|Tomato, onion & lovage soup with inulin|One dose of tomato (300g), onion (100g) & lovage (20g) with 10g inulin will be given to subjects in the form of a soup
9475871|NCT03577145|Experimental|Tomato, onion & lovage soup|One dose of tomato (300g), onion (100g) & lovage (20g) will be given to subjects in the form of a soup
9475872|NCT03577145|Experimental|Inulin|One dose of 10g inulin will be given to subjects in the form of a drink
9475873|NCT03577132|Experimental|Luminal type|Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)
9475874|NCT03577132|Experimental|Basal typr|Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)
9475875|NCT03577119|Experimental|Full-fat yogurt|Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).
9475876|NCT03577119|Experimental|Non-fat yogurt (Control)|Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).
9475877|NCT03577093||ischemic stroke|acute ischemic stroke patients within 6h after stroke onset
9475878|NCT03577093||control|healthy controls
9475879|NCT03577080|Active Comparator|ET+RT+ NMES|neuromuscular electrical training NMES
9475880|NCT03577080|Placebo Comparator|ET+RT|placebo neuromuscular electrical training NMES
9475881|NCT03577067||Patients submitted to liver resection|Patients underwent liver resection for primary and secondary disease
9475882|NCT03577054|Experimental|HBB Prompt|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~Providers at this hospital will have access to the most updated version of HBB Prompt (beta) after HBB training.~Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training). The recommended frequency to use the app will be once per shift."
9475883|NCT03577054|Placebo Comparator|Control|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~The control group will not have exposure to the HBB Prompt app post training. Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training)."
9475884|NCT03577028|Experimental|Experimental: HPN424-1001|"In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion with dose escalation until an estimated therapeutic dose level has been reached.~In Part 2 (Dose Expansion), patients will receive HPN424 at the recommended phase 2 dose(s) established in Part 1 of the study. Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added."
9475885|NCT03577015||critically ill patients at risk for DIC|patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis
9475886|NCT03577002|Active Comparator|Clinician SICP|Advance care planning between primary care clinician and the patient/family using the Serious Illness Care Program (SICP)
9475887|NCT03577002|Active Comparator|Team SICP|Advance care planning between team members and the patient/family using the Serious Illness Care Program (SICP)
9475888|NCT03576963|Experimental|Treatment (guadecitabine, nivolumab)|This study consists of an initial dose escalation followed by an expansion cohort. Dose escalation of guadecitabine starts from 30 mg/m^2 given SC on days 1-5 every 28 days in combination with fixed dose of nivolumab at 240 mg given IV on days 8 and 22 every 28 days. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
9475889|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
9475890|NCT03576937||Cohort 1|Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
9480597|NCT05262894|Experimental|Breathing in the snow|Breathing in the snow using a specially designed apparatus and measuring the respiratory gases distribution in snow.
10034839|NCT01800409|No Intervention|Control period|Four week control period. The order of the control and training periods will be randomised for each participant.
9475891|NCT03576937||Cohort 2|Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
9475892|NCT03576924|Active Comparator|Imposed-MICT|Continuous exercise for 30 minutes per session at 60-65% of heart rate max for five times per week, consistent with physical activity guidelines that advocate 150 minutes per week of moderate activity.
9475893|NCT03576924|Active Comparator|Imposed-HIIT|Five repeated vigorous intervals of 1-min duration at 85-90% of heart rate max with 1-min recovery periods, with 3-min warm-up and 2-min cool-down, making the total session duration 15 min for five times/week, equated to match the guidelines of 75 min of vigorous exercise per week.
9475894|NCT03576924|Experimental|CHOICE|Participants will always self-select the exercise type that they will do, either the IM-HIIT or the IM-MICT protocols, which will be matched to the parallel imposed conditions.
9475895|NCT03576911|Experimental|Coenzyme Q10|100mg CoQ10 capsule taken orally three times per day for 6 months
9475896|NCT03576911|Placebo Comparator|Placebo|Placebo capsule taken orally three times per day for 6 months
9475897|NCT03576872|Experimental|Psychoeducational intervention|"Psychoeducational will be conducted prior to chemotherapy.~Teach session will occur prior and during administration of chemo~A small quiz will be conducted to asses understanding of the educational binder"
9475898|NCT03576859|Other|cirrhotic patients with chronic liver failure|
9475899|NCT03576859|Other|cirrhotic patients without chronic liver failure|
9475900|NCT03576846|Experimental|Intervention|Stretching and Spinal Manipulative Therapy
9475901|NCT03576846|Active Comparator|Comparator|Stretching
9475902|NCT03576833|Experimental|Balloon|
9475903|NCT03576820|Experimental|Lidocaine|Subjects will receive a one time dose of 20mg of 2% lidocaine (1 mL) via nasal mucosal atomizer
9475904|NCT03576820|Placebo Comparator|Placebo|Subjects will receive a one time dose of 1 mL of 0.9% sodium chloride solution via nasal mucosal atomizer.
9475905|NCT03576807|Experimental|CD20 CAR-T cells|Experimental: CD20 CAR-T cells
9475906|NCT03576794|Active Comparator|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
9475907|NCT03576794|Placebo Comparator|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
9475908|NCT03576781|Experimental|Real iTBS to the DLPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
9475909|NCT03576781|Sham Comparator|Sham iTBS to the DLPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
9475910|NCT03576781|Experimental|Real cTBS to the MPFC|One session of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
9475911|NCT03576781|Sham Comparator|Sham cTBS to the MPFC|One session of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
9475912|NCT03576755|Experimental|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 6 or 12 months
9475913|NCT03576755|Placebo Comparator|placebo|matching placebo capsule administered orally once daily for 6 or 12 months
9475914|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
9475915|NCT03576729||Hurler syndrome participants|Participants who have MPS IH, also called Hurler syndrome
9475916|NCT03576729||Hurler-Scheie/Scheie participants|Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.
9475917|NCT03576729||Healthy Controls|Age-matched healthy controls
9475918|NCT03576703|Experimental|EX+H2O|Exercise and diet that did not include SSB
9475919|NCT03576703|Experimental|EX+SSB|Exercise and diet that includes SSB
9475920|NCT03576703|No Intervention|CONTROL|No exercise and diet that did not include SSB
9475921|NCT03576677|Active Comparator|Levosimendan|Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.
9475922|NCT03576677|Placebo Comparator|Placebo|Study participants in this arm will receive a 6 hours infusion of placebo (sterile isotonic sodium chloride + 5% dextrose + vitamin B)
9475923|NCT03576664|Experimental|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
9475924|NCT03576664|Experimental|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
9475925|NCT03576651|Experimental|JHL1149|
9475926|NCT03576651|Active Comparator|US-sourced-Avastin™|
9475927|NCT03576651|Active Comparator|EU-sourced Avastin™|
9475928|NCT03576638|Active Comparator|Sinemet|Controlled Release 25/100
9475929|NCT03576638|Experimental|AP CD/LD|
9475930|NCT03576625|Placebo Comparator|High oleic sunflower oil (HOSO)|30 ml HOSO emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
9475931|NCT03576625|Experimental|Buglossoides oil emulsion|30 ml Buglossoides oil emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
9475932|NCT03576599|Active Comparator|Zoledronic Acid Injectable Product|Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
9475933|NCT03576599|Placebo Comparator|Placebo|Patients randomized to Placebo infusion (saline), repeated after 3 months
9475934|NCT03576573||Primary Total Hip Arthroplasty|Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components
9475935|NCT03576547|Experimental|Treatment (ponatinib, venetoclax, dexamethasone, rituximab)|See Detailed Description
9475936|NCT03576521|Experimental|Ocoxin-Viusid®|The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
9475937|NCT03576521|Placebo Comparator|Placebo|The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.
9475938|NCT03576508|Experimental|CNTX-4975-05 Intra-Articular (IA) Injection|Receives IA injection into the most painful OA knee.
9475939|NCT03576508|Active Comparator|Topical 8% Capsaicin Patch|Receives Capsaicin Patch on posterior rib cage.
9475940|NCT03576495|Experimental|Early Intervention / Retention Group|"The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention/Retention Group).~Follow-up testing will be conducted after one year to evaluate learner retention.~Further, the investigators will test post-exposure effect retention in the Early Intervention Group at the end of year 2."
9475941|NCT03576495|Active Comparator|Delayed Intervention Group|"The investigators will conduct baseline testing prior to the standard residency curriculum, and administer the PACTS curriculum the following year.~Both between- and within-group differences will be examined based on curriculum exposure in intervention year 1 as well as within-group differences for the Delayed Intervention Group at the end of year 2."
9475942|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
9475943|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
9475944|NCT03576469|Experimental|C1-esterase inhibitor [recombinant] (C1-INH-R)|"Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects on IVIG therapy who experience ADRs. The study will have 2 periods:~6 - 8 weeks - subjects will receive 2 infusions of IVIG~9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion"
9475945|NCT03576456|Active Comparator|Alprazolam|Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
9475946|NCT03576456|Placebo Comparator|Placebo Oral Tablet|Patients receive placebo 1 hour prior to coronary angiography.
9475947|NCT03576430|Active Comparator|active|active stress handling
9475948|NCT03576430|No Intervention|control|no stress handling
9475949|NCT03576404|Experimental|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
9475950|NCT03576391|Experimental|Control condition|Control condition to assess whether the repetition of a RAM task without fatiguing task in between 2 repetitions affects trunk motor control and cortical movement preparation.
9475951|NCT03576391|Experimental|Physical Fatigue condition|Fatigue condition to assess whether a physical fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
9475952|NCT03576391|Experimental|Cognitive Fatigue condition|Fatigue condition to assess whether a cognitive fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
10034840|NCT01800422|Experimental|Arm I (telapristone acetate)|Patients receive telapristone acetate orally once daily for 2-10 weeks and then undergo surgical resection.
10034841|NCT01800422|Placebo Comparator|Arm II (placebo)|Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.
9475953|NCT03576378|Experimental|Experimental: Brentuximab vedotin plus EPEM|Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)
9475954|NCT03576352|Experimental|Pediatric anesthesiologist|10 rapid sequence tracheostomy (RST) on rabbit cadaver
9475955|NCT03576352|Experimental|Pediatric intensivists|10 rapid sequence tracheostomy (RST) on rabbit cadaver
9475956|NCT03576352|Experimental|Pediatric surgeons|10 rapid sequence tracheostomy (RST) on rabbit cadaver
9475957|NCT03576352|Experimental|Pediatric emergency physicians|10 rapid sequence tracheostomy (RST) on rabbit cadaver
9480598|NCT05262868|Active Comparator|Active|Magnetic stimulus intensity of 80% of the motor threshold applied at the frequency of 20 Hz over the left DLPFC with a total number of pulses of 1200 / treatment session for a total of 5 sessions /week for 3 consecutive weeks
10034842|NCT01800435|Active Comparator|aPCC, aPCC + TXA|aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
10034843|NCT01800435|Active Comparator|rFVIIa, rFVIIa + TXA|rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
10034844|NCT01800461|Experimental|OPC-Stroke, Usual care|OPC-Stroke - 10 weekly sessions of goal setting followed by problem solving process
10034845|NCT01800461|Other|Usual care|Usual care - Follow-up by physician and possible receipt of home care services
10034846|NCT01800487|Active Comparator|silymarin|Silymarin 140 mg three times a day for 4 weeks
10034847|NCT01800487|Placebo Comparator|placebo|"Placeo~1 tab three times a day for 4 weeks"
9475958|NCT03576339|Sham Comparator|Sham Group - Free Gingival Graft + Sham Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the SHAW Group will receive the simulation of the electrical stimulation process, thus non current will be applied.
9475959|NCT03576339|Experimental|Test Group - Free Gingival Graft + Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Conductive electrodes for electrical current application will be applied to the palatal donor area on each side of the wound at a distance of 3 mm from the wound edge. An alternating current of 100 microamperes (μA) at 9 kilohertz (kHz), will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, five consecutive days.
9475960|NCT03576326|Experimental|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
9475961|NCT03576326|No Intervention|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
9475962|NCT03576300||control|subjects without dry eye and diabetes
9475963|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
9475964|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
9475965|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
9475966|NCT03576287|Experimental|apremilast|apremilast standard doses
9475967|NCT03576274|Experimental|Technology Enhanced Home Exercise only|Participants in TEHE group will receive a combined technology and home exercise program. Participants will schedule an online meeting with the research team for exercise goal setting and preference. Participants will receive a daily symptoms survey. They will receive, reminder, motivation message and physical performance feedback though the mobile phone application.
9475968|NCT03576274|Experimental|Technology Enhanced Home Exercise plus|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
9475969|NCT03576274|Experimental|Technology Enhanced Home Exercise-Mindfulness intervention|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
9475970|NCT03576274|No Intervention|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
9475971|NCT03576274|Active Comparator|Auricular Point Acupressure only|"Participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
9475972|NCT03576248|Experimental|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
9475973|NCT03576248|Sham Comparator|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
10034848|NCT01800500|Experimental|Arm I (fixed rate ST product prices)|Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks
10034849|NCT01800500|Experimental|Arm II (escalating ST product prices)|Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.
9475974|NCT03576248|Experimental|2 mA left prefrontal tDCS|2000 μA anodal transcranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraorbital return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
9475975|NCT03576248|Sham Comparator|Sham left prefrontal tDCS|The same stimulation as active transcranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
9475976|NCT03576235|Experimental|a treatment group|PG102P 1.5 g/day
9475977|NCT03576235|Placebo Comparator|a control group|placebo
9475978|NCT03576222|Active Comparator|patients with preventive PICO|PICO dressing is used in patients with incisional hernia intraoperatively
9475979|NCT03576222|Placebo Comparator|patients with preventive MEPORE|MEPORE dressing is used in patients with incisional hernia intraoperatively
9475980|NCT03576209|Active Comparator|Intervention Group|12 week intervention
9475981|NCT03576209|No Intervention|Control Group|No walking program
9475982|NCT03576196|Experimental|Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
9475983|NCT03576196|Other|Usual Care|"Patients in the control group received usual care, which consists of an educational session prior to surgery, based on medical, anatomical and pathological aspects of the syndrome.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
9475984|NCT03576170|Active Comparator|aromatherapy-scent|
9475985|NCT03576170|Active Comparator|aromatherapy-touch|
9475986|NCT03576170|No Intervention|wait-list control|
9475987|NCT03576157|Experimental|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
9475988|NCT03576157|No Intervention|Comparison|Existing standard of care; no new health messages
9475989|NCT03576105|Experimental|experimental group|G1 - 32 patients Photodynamic therapy with convention methylene blue as photosesintizer irrigation /sterile saline Conventional methylene blue as photosensitizer -Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Photodynamic therapy -Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
9475990|NCT03576105|Active Comparator|positive control group|G2 - 32 patients Photodynamic therapy with oral formula of methylene blue as photosesintizer, treatment identical to G1, however methylene blue will be delivered in a new formulation for oral use (patent aplicattion INPI BR1020170253902) irrigation /sterile saline Photodynamic therapy -Methylene blue for oral use as photosensitizer-Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
9475991|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
9475992|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
9475993|NCT03576079|Experimental|Laser therapy|12 laser sessions over 3 months
9475994|NCT03576079|Active Comparator|anterior re-positioning splint therapy|anterior re-positioning splint worn for 8 hours during night time for 3 months
9475995|NCT03576079|Placebo Comparator|inactive laser therapy|placebo laser for 12 sessions over 3 months
9475996|NCT03576053|Experimental|Histamine+cowhage+heat|
9475997|NCT03576053|Experimental|Histamine+cowhage+serotonin+pre-heating|
9475998|NCT03576053|Placebo Comparator|lidocaine and saline+heat|
9475999|NCT03576027|Experimental|Hyperbaric oxygen therapy|
9476000|NCT03576014|Experimental|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
9476001|NCT03576001|Experimental|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus Testosterone undecanoate
9476002|NCT03576001|Placebo Comparator|Placebo group|Hybrid exercise plus placebo medication
9476003|NCT03575988||Diabetes group|
9476004|NCT03575988||Control group|
9476005|NCT03575949|Experimental|Diagnostic (FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard CRT completion.
9476006|NCT03575923||Intervention site 1|2 planted trees; bulb planting
9476007|NCT03575923||Comparison site 1A|
9476008|NCT03575923||Comparison site 1B|
9476009|NCT03575923||Intervention site 2|12 planted trees; bulb planting; artificial tree decorations (string lights)
9476010|NCT03575923||Comparison site 2A|
9476011|NCT03575923||Comparison site 2B|
9476012|NCT03575923||Intervention site 3|3 planted trees; artificial tree decorations (string lights, tree socks)
9476013|NCT03575923||Comparison site 3A|
9476014|NCT03575923||Comparison site 3B|
9476015|NCT03575923||Intervention site 4|8 planted trees; bulb planting; artificial tree decorations (string lights, tree socks)
10034850|NCT01800513|Experimental|Endometrial Biopsy|Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.
9476016|NCT03575923||Comparison site 4A|
10034851|NCT01800513|Sham Comparator|Control|Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.
9476017|NCT03575923||Comparison site 4B|
9476018|NCT03575884|Experimental|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
9476019|NCT03575884|No Intervention|Control|Students will be taught the standard preschool curriculum.
9476020|NCT03575858|Experimental|Barrel shaped interdental brushes|test group
9476021|NCT03575858|Active Comparator|Tapered interdental brushes|control group
9476022|NCT03575845|Experimental|Occupational therapy informed yoga|Occupational therapists adapted postures to meet the abilities and rehabilitation needs of individual breast cancer survivors engaging in group-delivered yoga sessions
9476023|NCT03575819|Experimental|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
9476024|NCT03575819|Experimental|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
9476025|NCT03575780|Experimental|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
9476026|NCT03575741||Patients|After suffering from a concussion patients will be investigated 48 h, 72 h, 120 h, 360 h and 720 h after sustaining the injury. Postural control will be measured using 7 different easy balance tests.
9476027|NCT03575741||Control|Healthy children will be measured in the very same way to collect data of possible matched controls.
9476028|NCT03575728|Other|Mood disorder|Participants who screen positive for a history of mood disorders
9476029|NCT03575728|Other|Other|Participants who do not screen positive for a history of mood disorders
9476030|NCT03575715|Experimental|EBUS group|EBUS and guide sheath (GS) are inserted into bronchi in the assistance of navigation bronchoscopy. The EBUS probe and GS are confirmed to reach the lesion by EBUS images, cytologic and pathologic specimens are obtained with or without fluoroscopic guidance.
9476031|NCT03575689|Experimental|Splint|A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
9476032|NCT03575689|No Intervention|No Splint|B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same.
9476033|NCT03575676|Experimental|Group A|Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks and placebo BID for 6 weeks.
9476034|NCT03575676|Experimental|Group B|Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks and SOM3355 100mg BID for 6 weeks.
9476035|NCT03575650||Cardiac imaging modalities|Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.
9476036|NCT03575637|Experimental|Olanzapine intervention group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
9476037|NCT03575637|No Intervention|Control group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen.
9476038|NCT03575624|Experimental|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
9476039|NCT03575611|Experimental|Treatment (SBRT)|Patients undergo SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist.
9476040|NCT03575598|Experimental|Sitravatinib and Nivolumab|"Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.~Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study."
9476041|NCT03575585|Experimental|Comparator: No Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
9476042|NCT03575585|Experimental|Active1: Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, and received a personalized feedback report.
9476043|NCT03575585|Experimental|Active2: No feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
9476044|NCT03575585|Experimental|Active3: Feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, and received a personalized feedback report.
9476045|NCT03575572|Experimental|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
9476046|NCT03575559|Experimental|Individual planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form up to three own individual plans. They are not allowed to speak to each other. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Individual planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, individual distraction task.
9476047|NCT03575559|Experimental|Collaborative planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms together, referring to their joint physical activity. The friendship dyad forms up to three joint plans about engaging in PA together. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Collaborative planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, collaborative distraction task.
9476048|NCT03575559|Active Comparator|Individual distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies. Several questions will be asked about characteristics of the two super heroes in the movie and whether these heroes are comparable. Each participant watches the movie alone and answers all questions by him/herself. Both members of the dyad are not allowed to speak to each other.
9476049|NCT03575559|Active Comparator|Collaborative distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies together. Several questions ask about the characteristics of the two super heroes in the movie and whether these heroes are comparable. Both members of the dyad watch the movie together and answer the questions conjointly.
9476050|NCT03575520|Experimental|Peg group|
9476051|NCT03575507|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
9476052|NCT03575494||female infertility|Women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months
9476053|NCT03575494||healthy|healthy patients who had minimum two normal pregnancies
9476054|NCT03575481||Post stroke patients|
9476055|NCT03575468|Experimental|Enhanced E-cigarette Coaching (EEC)|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
9476056|NCT03575468|Active Comparator|Quitline treatment as usual (TAU)|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
9480599|NCT05262868|Placebo Comparator|Sham|"Sham procedure implies the use of a sham coil of exactly the same dimension and appearance as the one used for the effective treatment. This sham coil is made for research purposes by the producing company and used in accordance with the instructions for use, which explicitly mention it (cf. instruction manual page 34: Stimulation Coil DuoMAG 70BFP (70BFP1, 70BFP2), typical use for blinded studies)."
9480600|NCT05262855|Experimental|68Ga-FAPI-46 PET/CT|Patients receive [68Ga]FAPI-46 intravenously followed by PET/CT 15-25 minutes later
9480601|NCT05262829|Experimental|MSCs local treatment group/combined treatment group|In the local treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day. In the combined treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day; on the second day, 1 million cells/kg of body weight were administered intravenously.
9480602|NCT05262816|Experimental|sanyinjiao group|Perpendicular insertion about 0.8-1.2cun at bilateral sanyinjiao(SP6) acupoint.Then,bilateral SP6 were connected with Electronic Acupuncture Treatment Instrument (KWD-808-I,Yingdi, China). The frequency of the pulse was 20 Hz with a pulse duration of 200 us.Intensity of stimulus was depending on patient's tolerance.
9480603|NCT05262816|Active Comparator|guanyuan group|Perpendicular insertion about 0.8-1.2cun at bilateral Guanyuan(CV4), Zhongji (CV3) acupoints.Then,the two acupoints were connected with Electronic Acupuncture Treatment Instrument (KWD-808-I,Yingdi, China). The frequency of the pulse was 20 Hz with a pulse duration of 200 us.Intensity of stimulus was depending on patient's tolerance.
9480604|NCT05262790||PNS group|The patients with prominently negative symptoms (PNS) had a greater score on the negative than on the positive subscale of the PANSS, a negative symptoms score > 20, and at least one of items from PANSS negative symptoms scale ≥ 4 points
9476057|NCT03575455|Experimental|Exercise|"Concussed participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax.~Healthy participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax."
9476058|NCT03575455|No Intervention|Seated Control|"Concussed participants will participate in a single 20' treatment session of seated rest.~Healthy participants will participate in a single 20' treatment session of seated rest."
9476059|NCT03575442|Other|"3 session program of art therapy"|Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
9476060|NCT03575429|Active Comparator|Engagement Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates motivational interviewing (MI) and problem-solving education (PSE). The family navigator will meet with parents for up to 6 individual MI+PSE sessions for each 3-month stage of intervention.
9476061|NCT03575429|Active Comparator|Engagement + Coaching Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates MI+PSE. Family navigators will also coach families to embed intervention strategies for toddlers with ASD in everyday activities using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. The family navigator will meet with parents for 12 weekly home visits for each 3-month stage of intervention.
9476062|NCT03575377|Experimental|Deterra Bag|These families will receive a Deterra® bag (a drug Disposal Aid) and instructions on its use by a research team member.
9476063|NCT03575377|No Intervention|Control|These families will receive routine postoperative instructions only.
9476064|NCT03575338|Active Comparator|Open Scarf Osteotomy|This group of patients will undergo surgery performing an open scarf osteotomy
9476065|NCT03575338|Experimental|Minimally invasive scarf Osteotomy|This group of patients will undergo surgery performing a Minimally invasive scarf osteotomy
9476066|NCT03575325|Experimental|CPX-351 Treatment|"Participants will receive induction with CPX-351 at a dose of 100 u/m^2 administered intravenously over 90 minutes on days 1, 3 and 5 of a 28 day cycle.~This may be followed by consolidation with CPX-351 at a dose of 65 u/m^2 administered intravenously over 90 minutes on days 1 and 3 of a 28 day cycle (up to 3 cycles)."
9476067|NCT03575312|Experimental|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
9476068|NCT03575299|Experimental|Study group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.
9476069|NCT03575299|Placebo Comparator|Control Group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.
9476070|NCT03575286||Pregnant female|Patient has been determined pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
9476071|NCT03575286||Non-pregnant female|Patient has been determined not pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
9476072|NCT03575273|Experimental|Opioid dependence receiving methadone|Patients with a history of opioid dependence receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
9476073|NCT03575273|Experimental|Opioid dependence not on methadone|Patients with a history of opioid dependence not current receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
9476074|NCT03575273|Active Comparator|Healthy controls|Healthy controls without history of opioid use will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
9476075|NCT03575260||Fulvestrant|Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter
9476076|NCT03575260||Exemestane|Exemestane 25mg per day
9476077|NCT03575234|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2, surgery)|Participants receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, participants undergo surgery.
9476078|NCT03575195|Experimental|Intervention|Rifaximin
9476079|NCT03575195|Placebo Comparator|Placebo|Matching placebo
9476080|NCT03575182|Experimental|Gait retraining program|
9476081|NCT03575182|No Intervention|Physical therapy standard care|
9476082|NCT03575169||Patients with TBI|Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
9476083|NCT03575130|Experimental|Glanatec|
9476084|NCT03575130|Placebo Comparator|Placebo|
9476085|NCT03575117|Experimental|NCI HYT--GA + CSM--Be Well|"Participants who view the Common Sense Model (CSM) Be Well text and image communication will be invited to receive two sets of daily text messages: (1) one text message and one image per day and (2) National Cancer Institute (NCI) HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view a slide presentation with imagery and text related to colorectal cancer risk and sedentary lifestyle. The same messages will be delivered as a drip campaign alongside the NCI HYT-GA text messaging program."
9480605|NCT05262790||PPS group|The patients with predominantly positive symptoms (PPS) had a greater score on the positive than on the negative subscale of the PANSS
9476086|NCT03575117|Other|NCI HYT--GA + ACS usual messages|Adapted American Cancer Society (ACS) informational messages about colorectal cancer risk and lifestyle will be invited to receive one set of daily text messages, NCI HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view an informational slide presentation that is based on adapted language from American Cancer Guidelines related to cancer prevention and physical activity (https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html).
9476087|NCT03575091|No Intervention|control group|The infants will receive the standard care at the ward.
9476088|NCT03575091|Experimental|Non-individualized|The parents will be guided manually by the nursing staff and receive written information about how to change body positions of their child regularly throughout the hospital stay.
9476089|NCT03575091|Experimental|Individualized|The infant will receive frequent changes of body positions, stimulation to physical activity, and stimulation to deep breathing while bouncing on a large ball in the arms of an adult. Additional light chest compressions and inhalations may be given. A physiotherapist will perform the intervention at least once daily, and the parents will be manually guided and receive written information about how to change body positions of their child regularly in a similar way throughout the hospital stay.
9476090|NCT03575078|Experimental|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
9476091|NCT03575065|Experimental|Cohort 1: Triple-negative breast cancer (TNBC)|Locally advanced or metastatic TNBC
9476092|NCT03575065|Experimental|Cohort 2: HR(+)/HER2(-) breast cancer|Locally advanced or metastatic HR(+)/HER2(-) breast cancer
9476093|NCT03575039|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted the VitaFlow II Transcatheter Aortic Valve System.
9476094|NCT03575026|Experimental|Intervention|Subjects will receive 12-week music-with-movement intervention at home by their trained caregivers for 12 weeks, at least 3 sessions per week and 30 minutes for each session.
9476095|NCT03575026|Placebo Comparator|Wait-list control|Subjects will receive 12-week usual care (social activity) at home. Dose is similar to intervention arm. After the completion of 12-week usual care, subjects will receive the same music intervention as intervention arm.
9476096|NCT03575013|Experimental|Avelumab and Docetaxel|"Induction phase:~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles~Maintenance phase:~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
9476097|NCT03575000|Experimental|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
9480606|NCT05262790||Control|Healthy control
9480607|NCT05262738|Experimental|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects in this arm will be randomized to the 50 micrograms of vaginal misoprostol (intervention) group, they will be admitted to labor and delivery and undergo placement of 50 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
9480608|NCT05262738|Active Comparator|25 Micrograms Vaginal Misoprostol (Control)|Subjects in this arm will be randomized to the 25 micrograms of vaginal misoprostol (control) group, they will be admitted to labor and delivery and undergo placement of 25 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
9480609|NCT05262712|Experimental|Stimulation|During motor training participants in the stimulation arm receive vitro-tactile feedback applied to the feet when touching an object as measured by force-sensing resistors mounted to the sole of the feet.
9480610|NCT05262712|Placebo Comparator|Control|The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the feet but receives no stimulation.
9480611|NCT05262699|Experimental|Stimulation|During motor training participants in the stimulation arm receive vibro-tactile feedback applied to their fingers when touching an object as measured by force-sensing resistors mounted to the fingertips.
9480612|NCT05262699|Placebo Comparator|Control|The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the hands but receives no stimulation.
9480613|NCT05262660||SAAE group|Patients who were diagnosed with primary aldosteronism choice SAAE at our institution
9480614|NCT05262660||MRA group|Patients who were diagnosed with primary aldosteronism choice medical treatment(mineralocorticoid receptor antagonists, MRA)) at our institution
9480615|NCT05262634||study group: iron deficiency|Pregnant women with a documented iron deficiency in the first trimester
9480616|NCT05262634||control group: normal iron status|Pregnant women with normal hematological parameters and iron status in the first trimester
9480617|NCT05262621|Experimental|Music intervention combined with progressive muscle relaxation|Music intervention combined with progressive muscle relaxation
9480618|NCT05262621|No Intervention|Control group|no music therapy will be done.
9480619|NCT05262608|Experimental|Intervention/Treatment|Subjects will receive a regimen of Olaparib tablets 300 mg twice daily until radiographic disease progression (assessed by the investigator according to RECIST1.1 and PCWG 3) or intolerable adverse events (assessed by the investigator according to the actual clinical situation).
9480620|NCT05262595|Experimental|Arm 1|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
9480621|NCT05262595|Experimental|Arm 2|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
9480622|NCT05262595|Experimental|Arm 3|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
9476098|NCT03574987|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
9476099|NCT03574987|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
9476100|NCT03574987|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
9476101|NCT03574974|Experimental|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
9476102|NCT03574974|Placebo Comparator|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
9476103|NCT03574961|Experimental|e-Support Group|Participants in this arm will receive the treatment, 12 weeks of 1-hr weekly moderated e-Support sessions.
9476104|NCT03574961|Placebo Comparator|e-Journaling Placebo|Participants in this arm will complete 12 weeks of 1-hr weekly online journaling activities.
9476105|NCT03574948|Experimental|5-HTP|8 weeks active substance 5-HTP (2 x 100 mg per day)
9476106|NCT03574948|Placebo Comparator|placebo oral capsule|8 weeks placebo (2 x 1 capsule per day)
9476107|NCT03574935|Experimental|External Chinese medicine|"External Chinese medicine include 3 kinds of formula，including:~Qin, Hua and Bu will be applied to cover the participants' lesions in wet dressing form. Dosage form:5g/ml; frequency:qd; duration:2months."
9476108|NCT03574935|Active Comparator|External Western medicine|Ethacridine Lactate Solution, 1% Sulfadiazine Silver Cream and rb-bFGF will be applied to cover the participants' lesions. Dosage form:3g/ml; frequency:qd; duration: 2months.
9476109|NCT03574922|Active Comparator|Balance Exercises|Balance Exercises
9476110|NCT03574922|Active Comparator|Core Stabilization Exercises|Balance and core stabilization exercises
9476111|NCT03574922|No Intervention|Control|Assessments only
9476112|NCT03574909|Experimental|Treatment Arm|"Treatment Arms: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda Pharma SL (Reg 59.210).~There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
9476113|NCT03574909|Placebo Comparator|Control Arm|"Placebos to be used are hard gelatin capsules (Sanitatis®) for patients randomized to the placebo arm. These capsules are externally identical to Tromalyt capsule. The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate (Sanitatis®) Placebo: There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
9476114|NCT03574883|Experimental|In-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference between the two stimulation sites will be 0°.
9476115|NCT03574883|Active Comparator|Anti-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference will be 180°,
9476116|NCT03574883|Sham Comparator|Sham tACS|The stimulation (anti-phase) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
9476117|NCT03574883|Experimental|Active tDCS|1000 μA tDCS stimulation will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator
9476118|NCT03574883|Sham Comparator|Sham tDCS|The stimulation will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
9476119|NCT03574870|Experimental|Chemoraditherapy|"Patients with head and neck cancer require chemo and radiation therapy (Cohort A):~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment"
9476120|NCT03574870|Experimental|Primary surgery w/o radiotherapy|"Patients with head and neck cancer require primary surgery alone (Cohort B-SA)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery~Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment ."
9476121|NCT03574857|Active Comparator|Metolazone|Metolazone 5 mg by mouth once daily for 2 days
9476122|NCT03574857|Active Comparator|Chlorothiazide|Chlorothiazide 500 mg IV once daily for 2 days
9476123|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
9476124|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
9476125|NCT03574844|Placebo Comparator|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
9476126|NCT03574831||Stretta|Radio Frequency Ablation (RFA) using a Stretta device.
9476127|NCT03574805|Active Comparator|PRS-060|PRS-060 or Placebo
9476128|NCT03574805|Placebo Comparator|Placebo|PRS-060 or Placebo
9476129|NCT03574766|Experimental|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
9476130|NCT03574766|No Intervention|Control Group|Routine lactation support.
9528741|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:~patients with osteoarthritis of the hip or knee and rehabilitated in the institute~patients with primary and secondary tumors of the skeleton~patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
9528742|NCT03208426|Experimental|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
9528743|NCT03208426|Active Comparator|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
9528744|NCT03208101|Experimental|Test group|DTP-HepB-IPV-Hib vaccine
9528745|NCT03208101|Active Comparator|Control group|DTP-HepB-Hib vaccine & IPV
9528785|NCT03207711|Active Comparator|Diet Education|All participants will receive instruction in the carbohydrate-restricted diet (CR).The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat. Foods that are encouraged include green leafy and other non-starchy vegetables, nuts, seeds, oils (especially olive oil), fish, poultry, tofu, and avocados. Other foods consistent with the diet include berries (in modest amounts), meats, eggs, and cheese. Key foods to minimize include any sugar-sweetened foods or beverages, bread, pasta, potatoes, highly processed packaged foods, and other starchy foods.
9528786|NCT03207711|Experimental|Diet Education + Mindfulness|In addition to the carbohydrate-restricted diet described above, the Ed+MBI group will receive mindfulness training consisting of two integrated components: 1) use of a mindful eating app at home to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based meetings to discuss and troubleshoot how the mindfulness practices are working. Key mindfulness content includes helping people improve their relationship with food and control food cravings and using mindful eating approaches including paying attention, noticing habit loops, understanding brain science and food/sugar addiction, disrupting emotional and stress eating, cultivating acceptance and curiosity, lovingkindness, detaching from thoughts, using healthy restraint, and maintaining motivation.
9528787|NCT03208023|Active Comparator|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
9528788|NCT03208023|Experimental|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
9528789|NCT03207932||ultrasound|CVC insertion using ultrasound
9528790|NCT03207932||landmark technique|CVC insertion using landmark technique
9528791|NCT03207633|Active Comparator|First group|First group (20 patients) receive for 10 sessions of low frequency rTMS targeting right DLPFC by means of a Butterfly coil using the following parameters: 120% RMT, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
9528792|NCT03207633|Active Comparator|Second group|The second group (20 patients) will receive 10 sessions of low-frequency rTMS over the right orbitofrontal cortex (OFC) by means of a Butterfly coil using the following parameters: 120% motor threshold, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
9528793|NCT03207633|Sham Comparator|Third group|The third group (the sham condition) (20 patients) will receive sham stimulations of rTMS with the same pulse delivery as the other groups but with the coil placed perpendicular to the scalp.
9528794|NCT03207581|Experimental|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
9528795|NCT03207581|Active Comparator|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
9528796|NCT03207607|Experimental|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
9528797|NCT03207607|Experimental|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
9528798|NCT03207607|Experimental|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
9528799|NCT03207607|Experimental|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
9528800|NCT03207607|Experimental|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
9528801|NCT03207607|Experimental|Snack skipping|Participants received snack skipping
9528802|NCT03207568|Experimental|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
9528803|NCT03207308|Experimental|Vitamin A supplementation|55 children will receive a Mega-dose of preformed Vitamin A as recommended by the Senegalese Ministry of Health
9528804|NCT03207178|Experimental|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
9528805|NCT03207373|Experimental|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
9528806|NCT03207464|Experimental|Multiple Sclerosis|Subjects meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 6.5.
9528807|NCT03207464|Experimental|Healthy Control|This group will serve as non disease population.
9528808|NCT03207217|Experimental|Phase I Knowledge Assessment|
9528849|NCT03207516|Active Comparator|Sourdough --> Brewer's Yeast|"Sourdough --> Brewer's Yeast~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
9528850|NCT03207516|Active Comparator|Brewer's Yeast --> Sourdough|"Brewer's Yeast --> Sourdough~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
9528851|NCT03206983|Experimental|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
9528852|NCT03207113|Experimental|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
9528853|NCT03206996|Experimental|Child Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
9528854|NCT03206996|Experimental|Parental Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
9528855|NCT03207087|Experimental|WEB Aneurysm Embolization Device|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. Subjects will be screened for study eligibility after giving informed consent.
9528856|NCT03207126|Other|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
9528857|NCT03207048|Experimental|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
9528858|NCT03207048|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation
9528859|NCT03207100|Experimental|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
9528860|NCT03207100|Active Comparator|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
9528861|NCT03206957|Other|Study group|Down Syndrome children
9528862|NCT03206957|Other|Control group n°1|Down Syndrome children's mothers
9528863|NCT03206957|Other|Control group n°2|Age and sex matched healthy children
9528864|NCT03206957|Other|Control group n°3|Down syndrome children's healthy siblings
9528865|NCT03206944|Experimental|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
9528866|NCT03206944|Experimental|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
9528867|NCT03206892|Experimental|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
9528868|NCT03206892|Active Comparator|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
9528869|NCT03206697||Aneuploid mitochondria|Mitochondrial DNA content and metabolic parameters
9528870|NCT03206801|Experimental|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
9528871|NCT03206801|No Intervention|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
10058237|NCT02016729|Experimental|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
10058238|NCT02016742|Experimental|RDC5 dose level 1|Single dose of RDC5
9528872|NCT03206710||smokers who received Vitamin C|
9528873|NCT03206710||smokers who received placebo|
9528874|NCT03206710||control group non-smokers|
9528875|NCT03206840|Experimental|Group 1|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
9615445|NCT02545179|No Intervention|control|Previous therapy
9528876|NCT03206840|Experimental|Group 2|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
9528877|NCT03206827|Active Comparator|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
9528878|NCT03206827|Experimental|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
9528879|NCT03206827|Experimental|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
9528880|NCT03206736|Experimental|Loop DS Patients|Patients who receive a Loop DS procedure
9528881|NCT03206632|Experimental|BI 690517 dose group 1|
9528882|NCT03206632|Experimental|BI 690517 dose group 2|
9528883|NCT03206632|Experimental|BI 690517 dose group 3|
9528884|NCT03206632|Placebo Comparator|Placebo|Matching placebo for each dose group
9528885|NCT03206671|Experimental|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
9528886|NCT03206671|Experimental|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
9528887|NCT03206671|Other|R2 stage III standard arm|Standard chemotherapy
9528888|NCT03206671|Experimental|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
9528889|NCT03206671|Experimental|R3/R4 standard arm|Rituximab window + standard chemotherapy
9528890|NCT03206684|Experimental|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
9528891|NCT03206684|Active Comparator|rhG-CSF|rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
9528892|NCT03206580|Experimental|Concentric training|Concentric training
9528893|NCT03206580|Experimental|Concentric-eccentric training|Concentric-eccentric training
9528894|NCT03206775||Healthy controls (Phase 1)|Participants will participate in Cognitive Assessments (Phase 1) developed by Posit Science
9528895|NCT03206775||Healthy Controls, Battery A (Phase 2)|Participants will complete the Cognitive Battery A (Phase 2) developed by Posit Science while at the Minnesota State Fair.
10058239|NCT02016742|Experimental|RDC5 dose level 2|Single dose of RDC5
9528896|NCT03206775||Healthy Controls, Battery B (Phase 2)|Participants will complete the Cognitive Battery B (Phase 2) developed by Posit Science while at the Minnesota State Fair.
9528897|NCT03206775||Healthy Controls, Battery C (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
9528898|NCT03206775||Healthy Controls (Phase 3)|Participants will complete the full Posit Science cognitive assessment battery and self-report questionnaires for credit in the Research Experience Program at the University of Minnesota.
9528899|NCT03206775||Healthy Controls, Battery D (Phase 2)|Participants will complete the Cognitive Battery E (Phase 2) developed by Posit Science while at the Minnesota State Fair.
9528900|NCT03206775||Healthy Controls, Battery E (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
9528901|NCT03206775||Adolescents with anxiety diagnosis (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
9528902|NCT03206775||Adolescents, healthy controls (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
9528903|NCT03206723|Active Comparator|Group 1|1. Standard care
9528904|NCT03206723|Active Comparator|Group 2|"Standard care~Bandage contact lens"
9528905|NCT03206658|Placebo Comparator|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
10058240|NCT02016742|Experimental|RDC5 dose level 3|Single dose of RDC5
10058241|NCT02016742|Experimental|RDC5 dose level 4|Single dose of RDC5
9528906|NCT03206658|Experimental|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
9528907|NCT03206762|Experimental|Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
9528908|NCT03206762|Active Comparator|POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT)
9528909|NCT03206619||Social, Local and Mobile|Patients having smoking cessation standard care (behavioral and pharmacological therapy) and using the SoLoMo mobile app that sends them motivational messages.
9528910|NCT03206606||Control Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University.
9528911|NCT03206606||Experimental Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University that will use the mobile application SPIRO(c) for a period of four months.
9528912|NCT03206853|Experimental|Hybrid operation group|Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion.
9528913|NCT03206853|Other|Traditional therapy group|The aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.
9528914|NCT03206567|Active Comparator|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
9528915|NCT03206567|Placebo Comparator|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
9528916|NCT03206554|Active Comparator|LIA|Local infiltration analgesia
9528917|NCT03206554|Sham Comparator|sham LIA|Saline injections
9528918|NCT03206866||patients with HCC|
9528919|NCT03206866||patients with hepatitis C Ab positive|
10037628|NCT01826760||acute-on-chronic hepatitis B liver failure, training group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
9528920|NCT03206866||patients with hepatitis C Ab negative|
9528921|NCT03206541||Cases|The cases are defined as individuals that present with new onset of a neurological syndrome of unknown etiology, including but not limited to encephalitis, myelitis, meningitis, polyneuropathy/Guillain-Barre syndrome and cranial nerve involvement.
9528922|NCT03206541||Controls|"There are two age-matched control groups:~Household controls that have lived with the case for at least three months before the onset of neurological symptoms.~Controls with a febrile syndrome of unknown etiology that do not present neurological involvement and is recruited in the same center as the case."
9528923|NCT03206528||VSMS with ear unit|application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
9528924|NCT03206528||VSMS without ear unit|application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
9528925|NCT03206515|Other|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
9528926|NCT03206515|Other|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
9528927|NCT03206489|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
9528928|NCT03206489|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
9528929|NCT03206346|Experimental|Ingavirin|Broad spectrum antiviral drug
9528930|NCT03206346|Placebo Comparator|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
9528931|NCT03206164|Experimental|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
9528932|NCT03206164|Active Comparator|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
9528933|NCT03206502|Experimental|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
9528934|NCT03206125||Controls|Controls
9528935|NCT03206125||ESCC Cases|ESCC Cases
9528936|NCT03206138|Experimental|GX-188E, GX-I7|GX-188E + GX-I7
9528937|NCT03206138|Experimental|GX-188E, Imiquimod|GX-188E + Imiquimod
9528938|NCT03206385||CK Boost pelvis|
10037629|NCT01826760||acute-on-chronic hepatitis B liver failure, testing group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
10058242|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
9528939|NCT03206177|Experimental|Paclitaxel/Carboplatin + Galunisertib|
9528940|NCT03206190|Experimental|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
9528941|NCT03206190|Experimental|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
9528942|NCT03206190|Experimental|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
9528943|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
9528944|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
9528945|NCT03206255||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
9528946|NCT03206255||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
9528947|NCT03206255||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
9528948|NCT03206229|Experimental|TPI-120 (PEG-rhG-CSF)|PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
9528949|NCT03206229|Active Comparator|Neulasta (PEG-rhG-CSF)|Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
9528950|NCT03206398|Other|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
9528951|NCT03206294|Other|pharmacist assessment intervention group|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
9528952|NCT03206307||Group 1|Group 1 will be questioned 36 months (in 2017) after their medical rehabilitation which was in 2013/2014.
9528953|NCT03206307||Group 2|Group 2 has the medical rehabilitation in 2017 and will be questioned at the end of the medical rehabilitation and 6, 12 and 18 months after that
9528954|NCT03206203|Experimental|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9528955|NCT03206203|Experimental|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
9528956|NCT03206372||Case group|The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.
9528957|NCT03206372||Control group|The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure
9528958|NCT03206242||initial|0 month begin physiotherapy
9528959|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
9528960|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
9528961|NCT03206359||Patients|Patients with SLE
9528962|NCT03206359||Healthy subjects|
9528963|NCT03206333||Breast cancer patients treated with radiotherapy|
9528964|NCT03206320|No Intervention|Control|
9528965|NCT03206320|Active Comparator|Reference|
9528966|NCT03206320|Experimental|New|
9528967|NCT03206268||healthy eyes|
9528968|NCT03206268||uveitis eyes|
9528969|NCT03206034|Experimental|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
9528970|NCT03206034|Placebo Comparator|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
9528971|NCT03206112||Focal Dystonia|Subjects diagnosed with Focal Dystonia
9528972|NCT03206112||Healthy Volunteers|Healthy Volunteers
9528973|NCT03206437|Experimental|Mindfulness-Based Stress Reduction|This group will take the 8 week MBSR course within 4 weeks of their first testing visit. When the course is finished they will come in for their second testing visit. The course meets once a week in person for 2.5 hours and participants are expected to do practices at home.
9528974|NCT03206437|Other|Waitlist|The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
9528975|NCT03206021|Experimental|Phase I Dose-escalation|5'azacytidine will be administered on Days 1-7 at a dose of 75mg/m2/day, followed by escalating doses of Carboplatin on Day 14 in a rolling 6 design. Carboplatin will be dosed initially at AUC 4. Dose level -1 will reduce 5'azacytidine to 50mg/m2/day.
9528976|NCT03206021|Experimental|Posterior Fossa Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 20 patients with recurrent/refractory posterior fossa ependymoma.
9528977|NCT03206021|Experimental|Recurrent Brain and Solid Tumour Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation up to 12 patients with recurrent/refractory brain and solid tumour.
9528978|NCT03206008|Placebo Comparator|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
9528979|NCT03206008|Active Comparator|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
9528980|NCT03205878|Active Comparator|Control group|Patients will receive standard care, being CPAP treatment
9528981|NCT03205878|Experimental|Intervention group|Patients will receive CPAP and telecoaching
9528982|NCT03205995|Experimental|OMS721|Administration of OMS721
9528983|NCT03205800|Active Comparator|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
9528984|NCT03205800|No Intervention|No treatment|The other extraction socket site will be untreated.
9528985|NCT03205930|Experimental|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
9528986|NCT03205579|Experimental|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
9528987|NCT03205579|Active Comparator|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
9528988|NCT03205917|Experimental|Group 1A HIV-Uninfected|PGDM1400 low dose
9528989|NCT03205917|Experimental|Group 1B HIV-Uninfected|PGDM1400 mid dose
9528990|NCT03205917|Experimental|Group 1C HIV-Uninfected|PGDM1400 high dose
9528991|NCT03205917|Experimental|Group 2A HIV-Uninfected|PGDM1400 + PGT121 low dose
9528992|NCT03205917|Experimental|Group 2B HIV-Uninfected|PGDM1400 + PGT121 mid dose
9528993|NCT03205917|Experimental|Group 2C HIV-Uninfected|PGDM1400 + PGT121 high dose
9528994|NCT03205917|Experimental|Group 3A HIV-infected off ART|PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
9528995|NCT03205917|Experimental|Group 3B HIV-infected off ART|PGDM1400 + PGT121 at high dose; HIV + without ART
9528996|NCT03205670|Experimental|Urethroplasty with a tissue-engineered construct|The investigators will take a sample of the buccal mucosa to isolate epithelial cells. Autologous cells will be seeded on a hybrid matrix. Urethroplasty with this tissue-engineered construct will be performed. This is a single arm study with no control. All patients will undergo the surgical operation.
9528997|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
9528998|NCT03205683|Experimental|Intraneural facilitation therapy|The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
9528999|NCT03205683|Sham Comparator|Sham therapy|"Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).~Missing > 4 sessions will invalidate subject outcomes."
9529000|NCT03205891|Experimental|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.~Each cycle is 21 days.~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
9529001|NCT03205969|Experimental|Functional mobile game|Functional mobile game for chemotherapy side effect education
9529002|NCT03205839|Experimental|Acceptance-based self-help|"Participants in this group will receive the self-help booklet.~Surviving to Thriving: ACT self-help for living well with a visible difference in appearance"
9529003|NCT03205839|No Intervention|Waitlist control group|Participants in this group will be placed onto a waitlist for the four-week intervention period.
9529004|NCT03205774|Sham Comparator|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
9529005|NCT03205774|Sham Comparator|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
9529006|NCT03205774|Sham Comparator|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
9529007|NCT03205774|Sham Comparator|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
9529008|NCT03205735||normal DPD result group|patients group with a normal DPD result
9529009|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
9529010|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
9529011|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
9529012|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
9529013|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
9529014|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
9529015|NCT03205631|Sham Comparator|Sham Natural Frequency Patch|
9529016|NCT03205631|Active Comparator|Active Natural Frequency Patch|
9529017|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
9529018|NCT03205982|Sham Comparator|Control|WiseApp that delivers fitness reminders
9529019|NCT03205982|Experimental|Intervention|WiseApp that delivers medication adherence reminders
9529020|NCT03205787|Experimental|Trifolium pratense|Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
9529021|NCT03205904|Active Comparator|Intervention group|Group that will be receive the diet
9529022|NCT03205904|No Intervention|control|Group that will not receive the diet
9529023|NCT03205540|Experimental|Epidural analgesia|Lumbar continuous epidural block
9529024|NCT03205540|Experimental|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
9529025|NCT03205527|Experimental|Slip training for chronic stroke|Chronic stroke subjects in this training group will receive bilateral overground, slip perturbation training.
9529026|NCT03205527|No Intervention|Control for chronic stroke|Chronic stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
9529027|NCT03205527|Experimental|Slip training for sub-acute stroke|Sub-acute stroke survivors in this training group will receive bilateral overground, slip perturbation training.
9529028|NCT03205527|No Intervention|Control for sub-acute stroke|Sub-acute stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
9529029|NCT03205514||NSTE-ACS with intermediate stenosis and negative FFR|Patients hospitalized because of an acute coronary syndrome without ST segment elevation and with intermediate culprit lesion with negative fractional flow reserve evaluation (>0.80).
9529030|NCT03205501|Experimental|IV-tracer EMI-137|"IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.~Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
9529031|NCT03205189|Other|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
10058243|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
9529032|NCT03205189|Other|Postoperative prescription group|This group will receive the postoperative prescription.
9529033|NCT03205202|Active Comparator|Cocoa extract + multivitamin|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin"
9529034|NCT03205202|Active Comparator|Cocoa extract + multivitamin placebo|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin placebo"
9529035|NCT03205202|Active Comparator|Cocoa extract placebo + multivitamin|"Dietary Supplement: Multivitamin~Dietary Supplement: Cocoa extract placebo"
9529036|NCT03205202|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|"Dietary Supplement: Cocoa extract placebo~Dietary Supplement: Multivitamin placebo"
9529037|NCT03205228|Experimental|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
9529038|NCT03205228|Active Comparator|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
9529039|NCT03205228|Active Comparator|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
9529040|NCT03205176|Experimental|AZD5153 Monotherapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
9529041|NCT03205176|Experimental|AZD5153 + Olaparib Combination Therapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
9529042|NCT03205124|Experimental|Pre-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Once the stimulation is complete, the stimulator is detached and the patient is informed of the surgical date. The wires are taken out at the conclusion of the pre-operative appointment. These patients will have fine gauge wires for post-operative sham stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. However, the voltage will only be increased to a level they are able to sense.
9529043|NCT03205124|Sham Comparator|Sham stimulation|These patients will have the stimulator attached to their wires 3 days prior to scheduled surgical date and postoperatively as were in the previous groups. However, the voltage will only be increased to a level they are able to sense. The stimulator was then be turned off without the patients' knowledge. All connections are left in place for anhour duration. These patients will similarly have their wires removed after the conclusion of their pre-operative appointment and at the first post-operative follow-up within 1 week of surgery.
9529044|NCT03205124|Experimental|Pre and Post-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
9529045|NCT03205254|Active Comparator|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
9529046|NCT03205254|Active Comparator|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
9529047|NCT03205436|Experimental|Graft|Affinity human amniotic membrane
9529048|NCT03205332|Experimental|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
9529049|NCT03205332|No Intervention|Control|Assessment only.
9529050|NCT03205215|Experimental|Immediate Treatment|This arm will receive hyperbaric oxygen therapy once consented.
9529051|NCT03205215|Experimental|Waitlist - to be treated|This arm will receive a hyperbaric oxygen therapy after waiting two months.
9529052|NCT03205410|Experimental|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
9529053|NCT03205410|Sham Comparator|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
9529054|NCT03205397|Experimental|Accompanying and information procedure|Preparation for anesthesia (explanations, film, booklet), the presence of a relative in the operating room and the awakening of the child.
9529055|NCT03205397|Other|Usual care|Consultation of anesthesia and the care of the child without parental presence
9529056|NCT03205462|Experimental|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
9529057|NCT03205462|Experimental|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
9529058|NCT03205462|Experimental|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
9529059|NCT03205319|Experimental|Intervention arm / e-learning|Patients will receive e-learning instead of upper GI endoscopy.
9529060|NCT03205319|No Intervention|Control arm / upper GI endoscopy|Patients will receive the upper GI endoscopy, i.e. standard of care
9529061|NCT03205293|Experimental|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
9529062|NCT03205293|No Intervention|Control Group|Regular school curriculum
9529063|NCT03205267|Experimental|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
9529064|NCT03205241|Experimental|n-3 PUFA|Omega-3 polyunsaturated fatty acid - 5.7g/ day for 4 weeks
9529065|NCT03205241|Placebo Comparator|Placebo|Olive Oil - 6g/ day for 4 weeks
9529066|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
9529067|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
9529068|NCT03205345|Active Comparator|Emricasan (25 mg)|Emricasan 25 mg
9529069|NCT03205345|Active Comparator|Emricasan (5 mg)|Emricasan 5mg
9529070|NCT03205345|Placebo Comparator|Placebo|Matching placebo
9529071|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
9529072|NCT03205449|Experimental|MaPa Programme|Masayang Pamilya Parenting Program: A 12-session, a group-based parenting programme focused on reducing violence against children and improving child wellbeing in low-income families with young children
9529073|NCT03205449|Active Comparator|Treatment-as-usual|Parenting Effectiveness Service programme: A family strengthening programme delivered by trained service providers on a monthly basis.
9529074|NCT03205085|Experimental|CTEPH PATIENTS|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
9529075|NCT03205085|Experimental|PAH PATIENTS|patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation
9529076|NCT03205020||women with preterm labor|
9529077|NCT03205020||women delivered at full term|
9529078|NCT03204994|Experimental|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
9529079|NCT03204955|Experimental|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
9529080|NCT03204955|Active Comparator|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
9529081|NCT03204968|No Intervention|control|
9529082|NCT03204968|Active Comparator|Treated|
9529083|NCT03204812|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles for tremelimumab and up to 13 cycles for durvalumab in the absence of disease progression or unacceptable toxicity.
9529084|NCT03204929|Experimental|Cu(II)ATSM|Cu(II)ATSM dosed once daily
9529085|NCT03204786|Experimental|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
9529086|NCT03204786|Experimental|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
9529087|NCT03204786|Placebo Comparator|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
9529088|NCT03204890|Experimental|TPTNS|Transcutaneous Posterior Tibial Nerve Stimulation
9529089|NCT03204825|Experimental|Active TENS|Participants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
9529090|NCT03204825|Placebo Comparator|Placebo TENS|Placebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
9615446|NCT02545231|Active Comparator|Low dose 1mg pitavastatin|pitavastatin 1mg which is considered low dose statin will be administered for 36 months
9615447|NCT02545231|Active Comparator|High dose 4mg pitavastatin|pitavastatin 4mg which is considered high dose statin will be administered for 36 months
9529091|NCT03204825|Experimental|Patient-Centred Education|Patient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
9529092|NCT03204825|Experimental|Patient-Centred Education + Active TENS|Combination of Patient-Centred Education arm and Active TENS arm.
9529093|NCT03205059|Experimental|LST MS curriculum+ Bullying/Cyberbullying serious game|
9529094|NCT03205059|Active Comparator|LST MS curriculum|
9529095|NCT03205033|Active Comparator|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
9529096|NCT03205033|Placebo Comparator|Placebo|Placebo Oral Capsules, once a day at bedtime
9529097|NCT03204903|Experimental|Laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using laser acupuncture during 3 sessions per week for 12 weeks.
9529098|NCT03204903|Sham Comparator|Sham laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using sham laser acupuncture (without laser output) during 3 sessions per week for 12 weeks.
9529099|NCT03204734|Experimental|Capecitabine|Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.
9529100|NCT03204734|Experimental|endocrine therapy|endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.
9529101|NCT03204851|Active Comparator|Venous Stasis Ulcer|Venous Stasis Ulcer
9529102|NCT03204851|Active Comparator|Pressure Ulcers|Pressure Ulcers
9529103|NCT03204851|Active Comparator|Diabetic Foot Ulcers|Diabetic Foot Ulcers
9529104|NCT03204851|Active Comparator|Wounds from a variety of etiologies|Wounds from a variety of etiologies
9529105|NCT03205007|Experimental|Health promotion nutrition program|Health promotion nutrition program
9529106|NCT03204773||HSP patients|Patients with hereditary spastic paraplegia regardless of their genetic mutation
9529107|NCT03204773||Healthy controls|healthy controls (spouses, relatives, or other healthy controls)
9529108|NCT03204864|Active Comparator|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
9529109|NCT03204864|Experimental|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
9529110|NCT03204760|Experimental|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
9529111|NCT03204760|Experimental|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
9529112|NCT03204877|Active Comparator|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
9529113|NCT03204877|Placebo Comparator|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
9529114|NCT03204708|Active Comparator|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
9529115|NCT03204708|Active Comparator|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
9529116|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
9529117|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
9529118|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
9529119|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
9529120|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
9529121|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
9529122|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
9529123|NCT03204747||Patients enrolled|"Patient with multiple sclerosis and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes.~A first record of gait will be at strong desire to void. A second record will be after void Gait records consist on : 3 10meter walk test and 1 Timed up and Go test."
9529124|NCT03204682|Experimental|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
9615448|NCT02545192|Experimental|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
9615449|NCT02545192|Sham Comparator|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
9615450|NCT02545218|Active Comparator|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
9615451|NCT02545218|Active Comparator|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
10037630|NCT01826773|Experimental|Stress only CardioPET™|"Group I will consist of 15-20 patients and will have CardioPET™ imaging performed with a repeat identical stress component at ≥ 48 hours and ≤ 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.~The analysis of the acquired imaging data will determine if CardioPET™ is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET™ imaging group is to measure blood flow at near maximal stress."
10037631|NCT01826773|Experimental|Rest only CardioPET™|"Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating ≥2 segments of ischemia. These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.~CardioPET™ imaging in these subjects must be performed ≥ 48 hours and ≤ 10 days from the initial stress (stress MPI or echocardiography) at rest only. An angiography must be scheduled to be performed within 30 days."
9529125|NCT03204604|Experimental|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
9529126|NCT03204604|Experimental|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
9529127|NCT03204370||MPS4A patients|
9529128|NCT03204630|Active Comparator|Bifido|Infant formula containing Bifidobacterium breve CECT7263
9529129|NCT03204630|Active Comparator|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
9529130|NCT03204630|Placebo Comparator|Control|Standard infant formula
9529131|NCT03204461||PCOS-NIH|
9529132|NCT03204461||PCOS-Rotterdam|
9529133|NCT03204461||Controls|
9529134|NCT03204331|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
9529135|NCT03204331|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
9529136|NCT03204331|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
9529137|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
9529138|NCT03204305|Active Comparator|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
9529139|NCT03204305|Active Comparator|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
9529140|NCT03204487|Experimental|Patients with glaucoma or ocular hypertension|
9529141|NCT03204591||LC with SALI|cirrhosis patients with severe acute liver injury
9529142|NCT03204344|Experimental|Intervention group|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking."
9529143|NCT03204344|Sham Comparator|Control group|"For all patients, routine fasting (drinking water allowed) begins from 22:00 on the day before surgery， water fasting begins from 6:00 on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided from 6:00. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, magnesium sulfate) are added when becessary."
10037632|NCT01826786|Experimental|JNJ-42165279 (100 mg)|
10037633|NCT01826786|Placebo Comparator|Placebo|
9529144|NCT03204578|Experimental|AB (Midazolam OD/Dormicum)|Subjects with sequence AB will first receive the Intervention OD formulation (Period A, 30 µg Midazolam) and at the second visit the oral solution (Period B, 30 µg Dormicum ).
9529145|NCT03204578|Experimental|BA (Dormicum/midazolam OD)|Subjects with sequence BA will first receive the Intervention oral solution (Period B, 30 µg Dormicum) and at the second visit the OD disintegrating formulation (Period A, 30 µg Midazolam).
9529146|NCT03204500|Experimental|Active treatment with dual therapy|This group is composed by 20 ALS subjects under 600mg valproate and 600 mg of litium carbonate per day, during 21 months. The tablets are given orally with meals.
9529147|NCT03204500|Placebo Comparator|placebos|This group is composed by 20 ALS subjects under placebo. Blue tablets ( placebo of VPA) and white tablets (placebo of Li) are administered under the same conditions.
9529148|NCT03204617|Experimental|DDDMM + CCM|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20. At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
9529149|NCT03204617|Placebo Comparator|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since fifth placebo administration, administration of 0.9% sterile normal saline solution at weeks 0, 12 and 24.
9529150|NCT03204474|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
9615452|NCT02545244|Experimental|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
9529151|NCT03204474|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each])
9529152|NCT03204409||Symptomatic adults|adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h)
9529153|NCT03204565|Experimental|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
9529154|NCT03204565|Active Comparator|CAF (control)|coronally advanced flap alone
10037634|NCT01826799||adult ICU patients|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to understand Dutch are eligible.
10037635|NCT01826864|Experimental|Arm I (sargramostim and sentinel lymph node biopsy)|Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.
10037636|NCT01826864|Active Comparator|Arm II (hypertonic saline and sentinel lymph node biopsy)|Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.
9529155|NCT03204318|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
9529156|NCT03204318|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
9529157|NCT03204318|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
9529158|NCT03204435|Other|Traditional therapy|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented by stages.
9529159|NCT03204435|Experimental|Hybrid operation|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented in one-stage in hybrid operating theater.
9529160|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
9529161|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
9529162|NCT03204513|Experimental|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
9529163|NCT03204513|Active Comparator|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
9529164|NCT03204253|Experimental|rFSH + r-LH in combination|treatment group
9529165|NCT03204253|Active Comparator|rFSH alone|control group
9529166|NCT03204175|Experimental|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
9529167|NCT03204175|Active Comparator|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
9529168|NCT03204097|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
9529169|NCT03204097|Active Comparator|group 2|SRP followed by 1% Alendronate (ALN) gel
9529170|NCT03204097|Active Comparator|group 3|SRP followed by Aloevera (AV) gel
9529171|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
10037637|NCT01826877|Experimental|Treatment (autologous dendritic cells)|Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
10037638|NCT01826890|Experimental|NAVA technology|Following randomisation, a NAVA catheter will be introduced. The Electrical Activity of the Diaphragm (EAdi) will be viewed primarily to ensure a minimum level of diaphragm activation during the weaning phase. NAVA mode suitability/safety assessments will be conducted in all patients prior to the first initiation of the NAVA mode. The NAVA preview function on the Maquet Servo-i ventilators will be used to transfer from the previous mode to the NAVA mode, and the assessment will last for a maximum of 30 minutes. We are recommending the use of the NAVA ventilation mode during the weaning period. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
9529172|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
10058244|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
9615453|NCT02545244|Active Comparator|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
9529173|NCT03203967|Experimental|Epidural morphine|"Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
9529174|NCT03203967|Placebo Comparator|Epidural placebo|"Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
9529175|NCT03204006|Active Comparator|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
9529176|NCT03204006|Placebo Comparator|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
9529177|NCT03204032|Experimental|Tegafur and Temozolomide|
9529178|NCT03204032|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|
9529179|NCT03204227|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
9529180|NCT03204227|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
9529181|NCT03203889|Experimental|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
9529182|NCT03203889|Active Comparator|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
9529183|NCT03203902|Active Comparator|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
9529184|NCT03203902|Placebo Comparator|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
9529185|NCT03203902|No Intervention|Control|No intervention
9529186|NCT03204149|Experimental|Treatment group|"The treatment group will be treated with the MC-8XL laser device, emitting 808 nm laser beam with a green laser beam.~Intervention: MC-8XL low level laser device and Standard wound care"
9529187|NCT03204149|Sham Comparator|Control group|"The control group will receive treatment with a sham laser device, emitting a low power green light with inactive Infrared (IR) laser for indication only.~Intervention: Sham laser device and Standard wound care"
9529188|NCT03204045|Active Comparator|fentanyl|fentanyl 1 ㎍/kg
9529189|NCT03204045|Active Comparator|oxycodone|oxycodone 0.08 mg/kg
9529190|NCT03204045|Placebo Comparator|control|isotonic saline
9529191|NCT03204162|No Intervention|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
9529192|NCT03204162|Experimental|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
9529193|NCT03204058|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
9529194|NCT03204058|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
9529195|NCT03204058|Active Comparator|group 3|SRP followed by 1% Metformin ( MF) gel
9529196|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
9529197|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
9529198|NCT03204071|Placebo Comparator|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
9529199|NCT03204071|Active Comparator|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
9529200|NCT03204071|Active Comparator|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
9529201|NCT03203954|Active Comparator|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
9615454|NCT02545244|Active Comparator|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
9529202|NCT03203954|Experimental|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
9529203|NCT03203954|Experimental|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
9529204|NCT03203915|Experimental|Group 1|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo"
9529205|NCT03203915|Experimental|Group 2|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose"
9529206|NCT03203915|Experimental|Group 3|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose"
9529207|NCT03203915|Experimental|Group 4|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo"
9529208|NCT03203915|Experimental|Group 5|"Order of treatments:~C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose"
9529209|NCT03203915|Experimental|Group 6|"Order of treatments:~C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose"
9529210|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
9529211|NCT03204201|Experimental|Urethral instillation of ICG|Urethral instillation of indocyanine green (ICG)
9529212|NCT03203824|Experimental|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
9529213|NCT03203824|Active Comparator|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
9529214|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
9529215|NCT03203811|Experimental|Low Dose|2mg, HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
9529216|NCT03203811|Experimental|Middle Dose|3.75mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
9529217|NCT03203811|Experimental|High Dose|5mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
9529218|NCT03203798|Active Comparator|Training of pelvic floor muscles|
9529219|NCT03203798|Experimental|Hipopressive abdominal gymnastics|
9529220|NCT03203928|Experimental|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
9529221|NCT03203928|No Intervention|Control|No treatment provided.
9529222|NCT03203785|Experimental|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
9529223|NCT03203785|Placebo Comparator|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
9529224|NCT03203577|Active Comparator|Hospital initiation|Initiation of mechanical ventilation in hospital initiation of Home Mechanical ventilation takes place in a hospital; this makes this arm the standard care.
9529225|NCT03203577|Experimental|Home initiation|Initiation of mechanical ventilation at home Initiation of mechanical ventilation in a patient's home setting with telemonitoring
9529226|NCT03203538|Experimental|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
9529227|NCT03203538|Active Comparator|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
9529228|NCT03203538|Experimental|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
9529229|NCT03203538|Active Comparator|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
9529230|NCT03203538|Experimental|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
9529231|NCT03203538|Active Comparator|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
9529232|NCT03203512|Active Comparator|Intervention|Fish oil capsules
9529233|NCT03203512|Placebo Comparator|Placebo|High-oleic safflower oil capsules
9529234|NCT03203707|Experimental|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
9529235|NCT03203707|No Intervention|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
9529236|NCT03203759|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
9529237|NCT03203759|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
9529238|NCT03203772|Experimental|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
9529239|NCT03203694|Experimental|Walking intervention|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
9529240|NCT03203694|No Intervention|Control|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
10037639|NCT01826890|No Intervention|Standard Care|A NAVA catheter will be inserted following randomisation. The NAVA capabilities of the ventilator will be disabled. Patients will be ventilated according to local weaning protocol as per current standard care with either Pressure Support, Synchronised Intermittent Mandatory Ventilation, Volume Controlled Ventilation, Pressure Controlled Ventilation or Pressure Regulated Volume Controlled Ventilation. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
10037640|NCT01826903||depressed mother/child dyad - intervention|
9529241|NCT03203694|Experimental|Lower body heating|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
9529242|NCT03204019|Experimental|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9529243|NCT03204019|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
9529244|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
9529245|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
9529246|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
9529247|NCT03203746|Experimental|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
9529248|NCT03203746|Active Comparator|Group II: SRP only|Scaling and root planing only without lycopene
9529249|NCT03203746|No Intervention|Group III: healthy subjects|No intervention
9529250|NCT03203668|Other|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
9529251|NCT03203525|Experimental|Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])|Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9529252|NCT03203525|Experimental|Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])|Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9529253|NCT03203720|No Intervention|Standard Care (SC)|Standard Care (SC) in a specialty mood disorders clinic for youth with mood disorders.
9529254|NCT03203720|Experimental|SC + Brief Motivational Intervention|Standard Care (SC) in a specialty mood disorders clinic plus a Brief Motivational Intervention (BMI) targeting medication adherence.
9529255|NCT03203733|Experimental|'Cooral™'|oral cooling with use of cooling device
9529256|NCT03203733|Active Comparator|cryotherapy|Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.
10037641|NCT01826903||depressed mother/child dyad - no intervention|
10037642|NCT01826903||non-depressed mother/child dyad|
9529257|NCT03203434||Esophageal anastomotic leakage|
9529258|NCT03203434||Esophageal uncomplicated controls|
9529259|NCT03203434||Pancreatic anastomotic leakage|
9529260|NCT03203434||Pancreatic uncomplicated controls|
9529261|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
9529262|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
10037643|NCT01826916|Experimental|5mg/m2 DX-88 IV|5mg/m2 DX-88 (ecallantide)administered intravenously
10037644|NCT01826916|Experimental|10mg/m2 DX-88 IV|10mg/m2 DX-88(ecallantide)administered intravenously
10037645|NCT01826916|Experimental|20mg/m2 DX-88 IV|20mg/m2 DX-88 (ecallantide) administered intravenously
10037646|NCT01826916|Experimental|30 mg DX-88 SC|30mg DX-88(ecallantide)administered subcutaneously
10037647|NCT01826929|Experimental|Therapeutic education|Organized intervention strategy:Informed active patient, shared decision making, appointment planning, primary care doctor-nurse teamwork, actions based on scientific evidence.
9529263|NCT03203304|Experimental|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
9529264|NCT03203304|Experimental|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
9529265|NCT03203590|Active Comparator|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
9529266|NCT03203590|Experimental|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
9529267|NCT03203278|Experimental|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
9529268|NCT03203278|No Intervention|Control group|Usual care
10037648|NCT01826929|No Intervention|Usual care model|
9529269|NCT03203551|Placebo Comparator|C; Control; Saline solution|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
9529270|NCT03203551|Experimental|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
9529271|NCT03203551|Experimental|RC10%; 10% Ricinus communis|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
9529272|NCT03203551|Experimental|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
9529273|NCT03203239|Experimental|Red Light treatment|This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
9529274|NCT03203616|Experimental|Kadcyla (T-DM1)|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
9529275|NCT03203408|Experimental|OSTENIL PLUS|A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
9529276|NCT03203408|Active Comparator|SYNVISC-ONE|A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
9529277|NCT03203265|Other|A:Offline HIV testing and counseling|Participants in Group A will be invited to come to the Thai Red Cross Anonymous Clinic, RSAT or SWING drop-in centers in Bangkok, or SWING or Sisters drop-in centers in Pattaya. After registration, they will receive standard HIV Testing and Counseling (HTC) services.
9529278|NCT03203265|Other|B1:Offline|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only.
9529279|NCT03203265|Other|B2: Online|participants will be mailed a rapid HIV test kit. A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit, obtaining blood through finger prick, performing the testing steps, and reading the test result.
9529280|NCT03203486|Experimental|Meditteranean Diet|NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
9529281|NCT03203395|Experimental|Heart patients|Screening and counselling
9529282|NCT03203213|Experimental|Interventional arm|"Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient~Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)~A urine sample is taken if possible."
9529283|NCT03203369|Experimental|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
9529284|NCT03203369|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
9529285|NCT03203317|Experimental|Insulin-stimulation|2 h insulin-clamp
9529286|NCT03203317|Experimental|Exercise|10 min of maximal exercise
9529287|NCT03203655|Experimental|Intervention Group|The intervention group will be enrolled in the CareMessage™ Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
9529288|NCT03203655|Other|Control Group|The control group will receive the control condition. They will hear an initial talk about weight loss but will not be enrolled in any program or intervention.
10037649|NCT01826942|Experimental|Thin skin|Single fractional CO2 treatment at surgical area closure procedure on thin skin
10037650|NCT01826942|Experimental|Thick skin|Single fractional CO2 treatment at surgical area closure procedure on thick skin
10037651|NCT01826955||Open gastrectomy|patient who undergoing open gastrectomy
10037652|NCT01826955||laparoscopic gastrectomy|patient who undergoing laparoscopic gastrectomy
10058245|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
10037653|NCT01826968|Experimental|Recruitment Group|The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
10037654|NCT01826968|No Intervention|Control Group|We did not used alveolar recruitment maneuver
9529289|NCT03203473|Experimental|Overall cohort: Initial Primary Treatment with Nivolumab (induction phase)|"Therapy with nivolumab IV every 2 weeks~Serial imaging assessments every 8 weeks~After confirmatory scans, patients are assigned to Arm A or Arm B."
9529290|NCT03203473|Experimental|Arm A: Observation Arm (for patients with persistent response to induction nivolumab)|"Patients with persistent response (complete or partial response) to induction nivolumab are assigned to Arm A (Observation Arm).~Patients discontinued nivolumab after allocation to Arm A.~Serial imaging assessments every 8 weeks.~If scans persistently show PR/CR, patients remained on observation.~If progressive disease develops, therapy with nivolumab (480 mg IV every 4 weeks) will be resumed.~If there is subsequent progression on nivolumab monotherapy, ipilimumab (1 mg/kg IV every 3 weeks x 2 doses) is added.~If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
9529291|NCT03203473|Experimental|Arm B: Nivolumab+Ipilimumab then nivolumab alone (for patients with SD/PD to induction nivolumab)|"Patients with confirmed SD/PD to induction nivolumab are allocated to Arm B (Combination Therapy Arm).~In combination therapy, patients received nivolumab 3 mg/kg and ipilimumab 1 mg/kg intravenously every 3 weeks for two doses.~After then nivolumab will be continued at 480 mg IV every 4 weeks until disease progression.~Arm B patients undergo imaging at 12 weeks and then every 8 weeks."
9529292|NCT03203499|Experimental|ANS-6637|Single ascending doses of ANS-6637 administered orally
9529293|NCT03203499|Placebo Comparator|Placebo|Placebo administered orally
9529294|NCT03203226|Experimental|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
9529295|NCT03203226|No Intervention|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
9529296|NCT03203343|Active Comparator|PIRS group|Patients operated laparoscopically - PIRS technique
9529297|NCT03203343|Active Comparator|Marcy group|Patients operated by open modified Marcy technique
9529298|NCT03203187|Placebo Comparator|No mango intake|No mango intake for two weeks
9529299|NCT03203187|Experimental|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
9529300|NCT03203421|Active Comparator|Low Dose (Group 1)|One low dose of ChAdOx1 LS2 (5 x 10^9 vp) on day 0.
9529301|NCT03203421|Active Comparator|Prime-Boost (Group 2)|One high dose of ChAdOx1 LS2 (2.5 x 10^10 vp) on day 0 and one dose of MVA LS2 (2 x 10^8 pfu) on day 56.
9529302|NCT03203421|No Intervention|Control Group A|No vaccinations will be administered.
9529303|NCT03203421|No Intervention|Control Group B|No vaccinations will be administered.
9529304|NCT03203174|Experimental|Split-hand Microneedle Botulinum Toxin A|One palm with microneedle pretreatment prior to application of topical botulinum toxin A
9529305|NCT03203174|Sham Comparator|Split-hand Sham Microneedle Botulinum Toxin A|Contralateral palm with sham microneedle pretreatment prior to application of topical botulinum toxin A
9529306|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
9529307|NCT03202836|Experimental|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
9529308|NCT03202836|Other|no medication|only tocolysis plus corticosteroid for 48 hours
9529309|NCT03202979|Experimental|Group 1|Trazodone 20 mg
9529310|NCT03202979|Experimental|Group 2|Trazodone 10 mg
9529311|NCT03202979|Placebo Comparator|Group 3|Placebo
9529312|NCT03202849|Experimental|Vitamin D and A Supplementation|Participants receive a single dose of vitamin D and a single dose of vitamin A prior to HSCT.
9529313|NCT03202849|Active Comparator|Vitamin D Supplementation with Placebo|Participants receive a single dose of vitamin D and a single dose of placebo prior to HSCT.
9529314|NCT03202966|Experimental|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
9529315|NCT03203122|Experimental|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
9529316|NCT03203122|Sham Comparator|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
9529317|NCT03202927|Experimental|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
9529318|NCT03202927|Active Comparator|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
10037655|NCT01826994|Other|patients|heart type fatty acid binding protein testing
10037656|NCT01827007|Experimental|Study arm, elevation of PEEP|
9529319|NCT03203031||Neonates with abdominal surgery and quadratus lumborum block|0-6 months children with abdominal surgery. After standard induction of general anesthesia, patients will receive 0.5 ml/kg of ropivacaine (2 mg/ml) in a quadratus lumborum block. Ultrasonography will be used to guide the injection. In the postoperative period, pain scores and analgesics consumption will be recorded until the 48th hour post surgery.
9529320|NCT03203070|Active Comparator|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
9529321|NCT03203070|Experimental|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
9529322|NCT03202875|Experimental|Test (T)|SAR341402: single dose injection
9529323|NCT03202875|Active Comparator|Reference 1 (R1)|NovoRapid®: single dose injection
9529324|NCT03202875|Active Comparator|Reference 2 (R2)|NovoLog®: single dose injection
9529325|NCT03203135|Experimental|Intervention Group|
9529326|NCT03203135|No Intervention|Control Group|
10037657|NCT01827020|Active Comparator|Group L (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.
9529327|NCT03202914|Active Comparator|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
9529328|NCT03202914|Active Comparator|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
9529329|NCT03202914|Experimental|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
9529330|NCT03203018|Experimental|Women participating in HL intervention|Groups of women from disadvantaged communities will participate in a three session health literacy workshop
9529331|NCT03202797||Patients|
9529332|NCT03202888|Experimental|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
9529333|NCT03203005|Experimental|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
10037658|NCT01827020|Active Comparator|Group K (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg plus lidocaine 2% 1 mg/kg of the intranasal cavity.
9529334|NCT03203044|No Intervention|Regular Diet Arm|Maintains a regular diet for the duration of the study.
9529335|NCT03203044|Experimental|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
9529336|NCT03202862|Experimental|ESR1 mutated|ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase inhibitor therapy
9529337|NCT03202823||Diabetics|
9529338|NCT03202823||Non-diabetics|
9529339|NCT03202940|Experimental|Cobimetinib + Alectinib|Alectinib administered twice daily at pre-determined dosage orally Cobimetinib administered daily at pre-determined dosage orally
9529340|NCT03202992|Experimental|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
9529341|NCT03202992|Experimental|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
9529342|NCT03202992|Experimental|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
10037659|NCT01827020|Placebo Comparator|Group S (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.
9529343|NCT03202992|Experimental|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
9529344|NCT03202992|Experimental|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
9529345|NCT03202992|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
9529346|NCT03202992|Experimental|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
9529347|NCT03202992|Experimental|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
9529348|NCT03202992|Experimental|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
9529349|NCT03202992|Experimental|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
9529350|NCT03203096|Placebo Comparator|Placebo|identically tasting and looking Placebo
9529351|NCT03203096|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium Citrate / Magnesium Oxide once daily
9529352|NCT03202953|Experimental|1:1 I:E ratio VCV (Group I)|volume controlled ventilation with 1:1 inspiratory to expiratory ratio After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
9529353|NCT03202953|Active Comparator|autoflow VCV (Group A)|autoflow volume-controlled ventilation After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
10037660|NCT01827033|Other|meditation training|
10037661|NCT01827059|Active Comparator|Bosentan|Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets
10037662|NCT01827059|Placebo Comparator|Placebo|Placebo tablet
9529354|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
9529355|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
9529356|NCT03203057||control group|10 individuals get randomised to control group.
9529357|NCT03203057||short ischemic time|10 individuals get randomised to a controlled coronary occlusion for 30 seconds
9529358|NCT03203057||intermediate ischemic time|10 individuals get randomised to a controlled coronary occlusion for 60 seconds
9529359|NCT03203057||long ischemic time|10 individuals get randomised to a controlled coronary occlusion for 90 seconds
9529360|NCT03202784|Experimental|BCX7353 API in capsule|fasted administration of BCX7353 API in capsule
9529361|NCT03202784|Experimental|BCX7353 blend in capsule|fasted administration of BCX7353 blend in capsule
9529362|NCT03202784|Experimental|BCX7353 blend in capsule with food|administration of BCX7353 blend in capsule following high-fat meal
9529363|NCT03202771|Experimental|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
9529364|NCT03202771|Active Comparator|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
9529365|NCT03202758|Other|Durvalumab + Tremelimumab + FOLFOX|"Durvalumab for 12 months~Tremelimumab for up to 4 doses/cycles~FOLFOX"
9529366|NCT03202745|No Intervention|Control|The control arm will not receive any communications as a result of this study.
9529367|NCT03202745|Experimental|Patient Consequences|The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
9529368|NCT03202745|Experimental|Prescriber Consequences|The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
9529369|NCT03202576|No Intervention|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
9529370|NCT03202576|Experimental|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
9529371|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
9529372|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
9529373|NCT03202563|Experimental|Gemigliptin 50mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
9529374|NCT03202563|Active Comparator|Dapagliflozin 10mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
9529375|NCT03202615|Experimental|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
9529376|NCT03202615|Active Comparator|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
9529377|NCT03202654|Experimental|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
9529378|NCT03202654|Active Comparator|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
9529379|NCT03202459|Active Comparator|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
9529380|NCT03202459|Active Comparator|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
9529381|NCT03202459|Placebo Comparator|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
9529382|NCT03202485|Active Comparator|Toric Implantable Collamer Lens|Subjects in this group will implant Toric Implantable Collamer Lens for high myopic astigmatism
9529383|NCT03202485|Experimental|ICL+ Astigmatic keratotomy|Subjects in this group will implant Implantable Collamer Lens and combined with astigmatic keratotomy for high myopic astigmatism
9529384|NCT03202628|Experimental|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9529385|NCT03202641|Experimental|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).~Interventions:~PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).~PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
9529386|NCT03202693|Experimental|PA-824|[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
10037663|NCT01827072|Experimental|NPB-01|Intravenous immunoglobulin
9529387|NCT03202732|Other|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
9529388|NCT03202732|No Intervention|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
9529389|NCT03202719|Active Comparator|IPV at ages 14 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
9529390|NCT03202719|Active Comparator|IPV at ages 14 weeks, 18 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
9529391|NCT03202719|Active Comparator|IPV at ages 14 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
9529392|NCT03202719|Active Comparator|IPV at ages 6 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
9529393|NCT03202719|Active Comparator|IPV at ages 6 and 14 weeks|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
9529394|NCT03202407|Placebo Comparator|calcium group|"will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
9529395|NCT03202407|Experimental|sevelamer group|"will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
9529396|NCT03202680|Active Comparator|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
9529397|NCT03202680|Experimental|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
9529398|NCT03202446|Experimental|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
9529399|NCT03202446|Experimental|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
9529400|NCT03202446|Active Comparator|Arm 3: Control Arm|Patients will receive the standard of care.
9529401|NCT03202433|Experimental|Virtual Reality Distractor|The objective is to apply a technique, using virtual reality lenses, with relaxing audio-visual contents of no more than ten minutes, to reduce stress before and during the blood donation process and to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle
9529402|NCT03202433|No Intervention|Traditional Blood Donation Process|The objective is to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle, without virtual reality support
9529403|NCT03202420|Experimental|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
9529404|NCT03202355|Experimental|Group 1 (Control)|Subjects assigned to this group receive fixed appliance orthodontic treatment only
9529405|NCT03202355|Experimental|Group 2 (OP1)|Subjects assigned to this group receive fixed appliance orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
9529406|NCT03202524|Active Comparator|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
9529407|NCT03202524|Experimental|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
9529408|NCT03202329|Other|standard care|responsible surgeon has actively to ask for cardiology support (he decides whether a heart failure specialist should see the patient post-operatively)
9529409|NCT03202329|Other|nurse-based care|heart failure nurses visit postoperatively every (working-) day to check fluid balance, medication, rhythm and general condition
10037664|NCT01827085||Macintosh laryngoscope|Patients will be intubated with a conventional Machintosh laryngoscope
10037665|NCT01827085||Videolaryngoscope|Intubation with Stortz video laryngoscope
10037666|NCT01827124|Experimental|carbetocin and placebo|100microgram carbetocin IV and 1cc normal saline(placebo)infusion
10037667|NCT01827124|Experimental|oxytocin and placebo|20Interntional unit oxytocin infusion and 1cc normal saline IV
10037668|NCT01827137|Experimental|vaccine|Galinpepimut-S (GPS) inoculations are started 12-22 d following autologous stem cell transplantation (ASCT). GPS (1.0 ml of emulsion) is given s.c. on weeks 0, 2, 4, 6, 8, & 10 (i.e., x 6). Injection sites are pre-stimulated with Sargramostim (GM-CSF; 70 μg) s.c. on d -2 (± 1 d ) & d 0 of each GPS inoculation. N.B.: during each GPS inoculation, the Sargramostim & GPS are administered to the same anatomical site. Subjects are observed for >/= 30 minutes after vaccination. Non-progressing subjects who are clinically stable (no active infection with fevers & no cardiovascular/respiratory compromise) may receive up to 6 more vaccinations q-month. The use of post-ASCT maintenance therapy with either lenalidomide or bortezomib is allowed starting >/= 3 months after ASCT.
10037669|NCT01827150|Experimental|Redbull, optic nerve|"15 subjects will each be drinking a can of Redbull (250 ml) and an equal amount of water (250 ml) in two different sessions. The order in which they will do so, is determined by randomization.~Intervention: Drug: Redbull, energy drink"
10037670|NCT01827176||Recurrent Acute Rhinosinusitis|Recurrent Acute Rhinosinusitis is defined as acute rhinosinusitis more than 3 times/6 months or more than 4 times/year
10037671|NCT01827189||Comprehensive primary care practices|Comprehensive primary care practices are the intervention group.
9529410|NCT03202498|Experimental|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
9529411|NCT03202498|Placebo Comparator|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
9529412|NCT03202498|Experimental|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
9529413|NCT03202498|Placebo Comparator|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
9529414|NCT03202290|Other|Gambling disorder|patients suffering from gambling disorder
9529415|NCT03202290|Other|Controls|healthy controls
9529416|NCT03202706||Patients|
9529417|NCT03202381|Experimental|Degarelix|
9529418|NCT03202277|Experimental|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
9529419|NCT03202277|Active Comparator|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
9529420|NCT03202342|Experimental|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
9529421|NCT03202342|Experimental|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
9529422|NCT03202342|Experimental|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
9529423|NCT03202342|Experimental|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
9529424|NCT03202342|Experimental|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
9529425|NCT03202342|Experimental|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
9529426|NCT03202342|Experimental|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
9529427|NCT03202342|Experimental|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
9529428|NCT03202342|Experimental|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
9529429|NCT03202342|Experimental|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
9529430|NCT03202173|Active Comparator|normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
10037672|NCT01827189||Comparison practices|Comparison practices are the case-control group--the matched set of practices in a comparison area--whose patients' outcomes will be compared to those of intervention practices.
10037673|NCT01827202|Active Comparator|Aliskiren|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
10037674|NCT01827202|Active Comparator|Candesartan|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
9529431|NCT03202173|Experimental|lymphoid hyperplasia|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of nasopharyngeal mucosa after intravenous injecting 10% fluorescein..
9529432|NCT03202173|Experimental|nasopharyngeal carcinoma|pCLE images of nasopharyngeal carcinoma, which was associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
9529433|NCT03202186|Placebo Comparator|Placebo|oral administration of Placebo capsule
10037675|NCT01827215|Experimental|Intervention (Virtual Patient Advocate)|The Intervention Virtual Patient Advocate (VPA) Group participants will be given a username and secure password to log on to the Gabby site for the 12 months of the intervention. They will be encouraged to log on every two weeks or twice a month, but using the system is voluntary. They will be given the contact information of the Program Manager in the event that they have any issues or questions about the system. The research team will call each intervention participant after 6 and 12 months to conduct a follow-up phone call to collect outcome data. At the end of the intervention period, intervention participants will be invited to participate a focus group session.
9529434|NCT03202186|Experimental|Progesterone 200 mg|oral administration of progesterone 200 mg
9529435|NCT03202186|Experimental|Progesterone 300 mg|oral administration of progesterone 300 mg
9529436|NCT03202186|Experimental|Progesterone 400 mg|oral administration of progesterone 400 mg
10037676|NCT01827215|No Intervention|Control (Letter)|The control group will receive a letter listing the preconception risks identified in the risk assessment and they will be encouraged to see their clinician to discuss them.
10037677|NCT01827228|Experimental|Primary Recent infection network tracing|"Subjects: LAg+ recent HIV infection testees & referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues. We'll network trace direct contacts of Index Cases & network/venue members of contacts; and maybe 3rd ring as exploratory part of project. We'll test network/venue members for recent & acute HIV. If they have recent/acute HIV infection, their network/venue contacts will be traced. We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management. We will distribute community alerts to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected."
9529437|NCT03202238|Active Comparator|Conventional|Venepuncture without the use of any venepuncture assistive device
9529438|NCT03202238|Active Comparator|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
9529439|NCT03202238|Experimental|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
9529440|NCT03202368|Experimental|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
9529441|NCT03202199|Experimental|PET/MRI|PET/MRI examination
9529442|NCT03202394|Active Comparator|Active intervention|Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
9529443|NCT03202394|Placebo Comparator|Placebo intervention|Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
9529444|NCT03202316|Experimental|Cohort I (atezolizumab, cobimetinib, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off for 4 weeks of the safety lead-in course. Patients then receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-4. Cycles 1-4 repeat every 21 days and subsequent cycles with atezolizumab and cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9529445|NCT03202316|Experimental|Cohort II (atezolizumab, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 3 weeks for cycles 1-6 and every 4 weeks for subsequent cycles, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-6. Cycles 1-6 repeat every 21 days and subsequent cycles with atezolizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9529446|NCT03202212|Experimental|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
9529447|NCT03202212|Active Comparator|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
10058246|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \ prominent symptom/sign[n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
9529448|NCT03202004|Experimental|GSK2894512 1% cream group|Subjects will apply a thin layer of GSK2894512 1% (10 milligrams per gram [mg/g]) topical cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
9529449|NCT03202004|Placebo Comparator|Vehicle cream group|Subjects will apply a thin layer of vehicle cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
9529450|NCT03202056|Experimental|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
9529451|NCT03202056|Sham Comparator|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
9529452|NCT03202056|No Intervention|Control|Control group. No intervention.
9529453|NCT03202030|Experimental|IDR|Immediate dentoalveolar restoration conducted with bone removed from the tuber
9529454|NCT03202030|Active Comparator|Bio-oss|Bovine demineralized bone (Bio-oss Collagen) applied on the buccal resorption of the immediate implant
9529455|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
9529456|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
9529457|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
9529458|NCT03202108|Experimental|Consumption of Krio|Incorporation of Krio into the daily diet.
9529459|NCT03202095|Experimental|Open Label Treatment with Creatine|5 grams daily of oral creatine monohydrate powde
9529460|NCT03201783|Other|immediate group|the intervention: immediate frozen-thawed embryo transfer (FET) which means FET will be performed in the first cycle following the stimulated IVF cycle
9529461|NCT03201783|Other|delayed group|the intervention: delayed frozen-thawed embryo transfer (FET) which means FET will be performed at least in the second cycle following the stimulated IVF cycle
9529462|NCT03201822|Experimental|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
9529463|NCT03201822|Experimental|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
9529464|NCT03201822|Experimental|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
9529465|NCT03201822|Experimental|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
9529466|NCT03201861|Experimental|paclitaxel and cisplatin|Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.
9529467|NCT03201861|Active Comparator|epirubicin and cyclophosphamide|"Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel~Investigators will declare one of the following regimens:~Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.~Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles."
9529468|NCT03202147|Active Comparator|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
9529469|NCT03202147|Placebo Comparator|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
9529470|NCT03201887|Experimental|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
9529471|NCT03201887|Experimental|Sub-optimal effort Chronic pain|Sub-optimal effort
9529472|NCT03201887|No Intervention|Traumatic Brain Injury|optimal effort
9529473|NCT03201887|No Intervention|Chronic pain|optimal effort
9529474|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
9529475|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
9529476|NCT03201926|Experimental|mealworms|mealworms
9529477|NCT03201926|Placebo Comparator|grain powder|grain powder
9529478|NCT03201913|Experimental|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
9529479|NCT03202082|Experimental|Neuropsychological testing|Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
9529480|NCT03202082|No Intervention|Treatment as usual|Participants from this group will be administered the initial and follow-up survey.
9529481|NCT03201692|Active Comparator|Treadmill Training|40' treadmill training walking holding the handrail
9529482|NCT03201692|Experimental|Virtual Reality Treadmill Training|40' treadmill training walking with virtual visual and auditory cues
9529483|NCT03201744|Experimental|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
9529484|NCT03201744|Experimental|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
9529485|NCT03201991|Other|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
9529486|NCT03201575|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
9529487|NCT03201575|Other|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
9529488|NCT03201978|Experimental|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
9622021|NCT02519283|Active Comparator|GUIDED-HF|GWTG:HF has been successfully implemented across multiple inpatient populations and health systems over the last decade and has been shown to improve HF disparities.
9529489|NCT03201978|Placebo Comparator|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
9529490|NCT03201796|Experimental|Group 1|Prulifloxacin 600 mg
9529491|NCT03201796|Active Comparator|Group 2|Levofloxacin 500 mg
9529492|NCT03201653|Active Comparator|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
9529493|NCT03201653|Experimental|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
9529494|NCT03201770|Experimental|Pyramax|Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)
9529495|NCT03201510||Observational|Observational study
9529496|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
9804140|NCT01733329|Experimental|Misoprostol|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
10037678|NCT01827228|Active Comparator|Contact tracing of long-term HIV+ people|We will start with 50 subjects in each city who test HIV+ but LAg negative-and who report they have just learned they are HIV+. We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm. HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
10037679|NCT01827228|Active Comparator|HIV negative comparison arm|This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
9529497|NCT03201679||Patients without preoperative sepsis|
9529498|NCT03201627|Experimental|treatment|
9529499|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
9529500|NCT03201614|Experimental|A-CP HA|Patients randomized in this group will be treated with a combination of platelet-rich plasma plus hyaluronic acid prepared with A-CP HA Kit.
9529501|NCT03201614|Active Comparator|ArthroVisc 40|Patients randomized in this group will be treated with hyaluronic acid only (ArthroVisc 40); hyaluronic acid is the same as the one contained in the A-CP HA Kit.
9529502|NCT03201614|Placebo Comparator|Placebo|Patients randomized in this group will be treated with a saline solution.
9529503|NCT03201549|Experimental|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
9529504|NCT03201536|Active Comparator|sutures|zipLine3 device verses conventional sutures
9529505|NCT03201536|Active Comparator|Zip3 Device|
9529506|NCT03201588|Experimental|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
9529507|NCT03201588|No Intervention|Clinoleic|"Sterile fat emulsion [containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
9529508|NCT03201835|Experimental|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
9529509|NCT03201835|Experimental|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
9529510|NCT03201835|Experimental|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
9529511|NCT03201835|Experimental|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
9529512|NCT03201835|Active Comparator|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
9529513|NCT03201952|Active Comparator|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
9529514|NCT03201952|Active Comparator|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
9529515|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
9615455|NCT02545413|Experimental|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
9529516|NCT03201705|Experimental|Refractory neuropathic leg and low back pain|Patients with refractory neuropathic leg and low back pain as result of FBSS will be enrolled in the study and receive electrocatheter implant. Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
9529517|NCT03201393|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
9529518|NCT03201393|Placebo Comparator|Placebo|
9615456|NCT02545413|Placebo Comparator|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
9615457|NCT02545205|Experimental|Hybrid Assistive Limb (HAL)|
9615458|NCT02545205|Active Comparator|Conventional gait training|
10037680|NCT01827241||Colonoscopy Outcomes|Data collected from endoscopy reports to complete a descriptive analysis of demographics, colonoscopy procedure performance, and assess type of benign colon polyps detected during screening and surveillance from 02/01/2009 - 12/31/2020.
9615459|NCT02545361|Experimental|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
9615460|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
9615461|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
9615462|NCT02545166||Dynamic controls|10 aortic aneurysm repair patients, 10 critical leg ischaemia patients, 10 endovascular aneurysm repair patients, 10 kidney transplant patients, and 10 free flap surgery patients.
9615463|NCT02545166||Local sampling patients|10 Patients undergoing revascularisation, 10 patients undergoing lower limb surgery with a tourniquet and 5 patients diagnosed with acute compartment syndrome.
9615464|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
9615465|NCT02545010|Experimental|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
9615466|NCT02545036|Experimental|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
9615467|NCT02545036|No Intervention|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
9615468|NCT02544958|Experimental|Er:YAG laser|4 treatments of 1 month interval
9615469|NCT02544971|Experimental|NF-N group|Neurofeedback in a neutral context
9615470|NCT02544971|Active Comparator|NF-T group|Neurofeedback in a trauma-related context
9615471|NCT02544971|Active Comparator|Control group|Treatment as usual
10037681|NCT01827280|Experimental|Metformin|Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
9615472|NCT02544919|No Intervention|Control group|No Intervention group: Patients do not receive any lipid emulsion of any type during the study period
10037682|NCT01827280|Experimental|Vildagliptina|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
9615473|NCT02544919|Active Comparator|SMOF Group|Intervention Group: Patients receive 1 gm.kg.day-1 SMOFlipid for 48 hours before the operation and 5 days post-operatively.
9615474|NCT02544906|No Intervention|Control|No drugs will be given. the emergence agitation will be monitored and recorded
9615475|NCT02544906|Experimental|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
9615476|NCT02544906|Experimental|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
9615477|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase I)|The first 6 participants will be enrolled in the open label Phase I portion of the study and will receive Tadalafil, Anti-mucin 1 (MUC1) Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
9662923|NCT04599868|Active Comparator|High dose of magnesium sulfate group|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 2g/h
9529519|NCT03201432|Other|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
9529520|NCT03201432|Experimental|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
9529521|NCT03201471|Experimental|treatment group|In this group, the patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1; CTX 750mg/m2, ivgtt,d2; EPI 70mg/m2, ivgtt,d2; VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2, PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18; one cycle every 21 days； abbreviation： CTX： cyclophosphamide；EPI：etoposide；VCR： vincristine；Pred：prednisone； R-CHOP：the chemo-therapy regimen composed of Rituximab, cyclophosphoamide; etoposide, vincristine and prednisone.
9529522|NCT03201224||Group without image transmission|"Before Group"
9529523|NCT03201224||Group with image transmission|"After Group"
9529524|NCT03201289||Cardiac surgery|
9529525|NCT03201185|Experimental|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
9529526|NCT03201185|No Intervention|No intervention|Conventional treatment after transcatheter aortic valve implantation
9529527|NCT03201874|Active Comparator|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
9529528|NCT03201874|Experimental|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
9529529|NCT03201601|Experimental|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
9529530|NCT03201601|Active Comparator|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
9529531|NCT03201250|Experimental|Treatment|"Combination of cabozantinib, carfilzomib and dexamethasone~Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.~Carfilzomib: carfilzomib will be administered intravenously over 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.~Dexamethasone: dexamethasone will be administered at 40 mg orally or intravenously on days 1, 8,15 and 22 of each 28-day cycle (for patient age ≥ 75, acceptable to be given as 20 mg orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, 23)"
9529532|NCT03201302|Experimental|School physical education class|Children who participated only in their school physical activity classes only for the entire school year.
9529533|NCT03201302|Experimental|Taekwondo|Children who participated in organized Taekwondo training for the entire school year.
9529534|NCT03201302|Experimental|Martial arts|Children who participated in organized Martial arts training for the entire school year.
9529535|NCT03201302|Experimental|Climbing|Children who participated in organized climbing training for the entire school year.
9529536|NCT03201302|Experimental|Volleyball|Children who participated in organized volleyball training for the entire school year.
9529537|NCT03201302|Experimental|Artistic gymnastics|Children who participated in organized artistic gymnastics training for the entire school year.
9529538|NCT03201302|Experimental|Swimming|Children who participated in organized swimming training for the entire school year.
9529539|NCT03201302|Experimental|Dance|Children who participated in organized dance training for the entire school year.
9529540|NCT03201302|Experimental|Basketball|Children who participated in organized basketball training for the entire school year.
9529541|NCT03201302|Experimental|Wrestling|Children who participated in organized wrestling training for the entire school year.
9529542|NCT03201302|Experimental|Football (soccer)|Children who participated in organized football (soccer) training for the entire school year.
9529543|NCT03201302|Experimental|Rhythmic gymnastics|Children who participated in organized rhythmic gymnastics training for the entire school year.
9529544|NCT03201302|Experimental|Track and field|Children who participated in organized track and field training for the entire school year.
9529545|NCT03201302|Experimental|Tennis|Children who participated in organized tennis training for the entire school year.
9529546|NCT03201302|Experimental|Combination of activities 1|Children who participated in two different weight-bearing activities for the entire school year.
9529547|NCT03201302|Experimental|Combination of activities 2|Children who participated in one weight-bearing and in one non weight-bearing activity for the entire school year.
9529548|NCT03201263|Active Comparator|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
9529549|NCT03201263|Experimental|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
9529550|NCT03201276||Drug group|patients taking glucosamine
9529551|NCT03201354|Active Comparator|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
9529552|NCT03201354|Active Comparator|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
9529553|NCT03201237|Experimental|30 min AOT|
9529554|NCT03201237|Placebo Comparator|60 min AOT|
9529555|NCT03201328|Active Comparator|healthy subjects|
9529556|NCT03201328|Experimental|patients with unilateral cochlear implants|
9529557|NCT03201328|Experimental|patients with bilateral cochlear implants|
10037683|NCT01827293|Active Comparator|Promethazine|IV promethazine (25 mg)
9529558|NCT03201341|Other|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
9529559|NCT03201341|Other|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
9529560|NCT03201341|Other|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
9529561|NCT03201341|Other|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
9529562|NCT03201341|Other|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
9529563|NCT03201068|Experimental|Probiotic supplement|Renew Life Formulas, Inc
9529564|NCT03201068|Placebo Comparator|Placebo|Placebo capsule
9529565|NCT03201081|Experimental|training group|The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
9529566|NCT03201081|No Intervention|control group|The control group, did not participate in the motivational resistance-training program.
9529567|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
9529568|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
9529569|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
9529570|NCT03201159|Experimental|VLX103 150mg|In the first group, 150 mg dosing cohort, one VLX103 tablet will be administered daily for 14 days.
9529571|NCT03201159|Experimental|VLX103 300mg|In the second group, 300 mg dosing cohort, two VLX103 tablets will be administered daily for 14 days.
9529572|NCT03201159|Experimental|VLX103 450mg|In the third group, 450 mg dosing cohort, three VLX103 tablets will be administered daily for 14 days.
9529573|NCT03201094|No Intervention|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
9529574|NCT03201094|Experimental|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
9529575|NCT03201094|Experimental|NMES only|Patients will undergo two 30 minute NMES sessions per day during study period.
9529576|NCT03201094|Experimental|HPRO only|Patients will receive HPRO three times daily during study period
9529577|NCT03201146|Experimental|Apatinib 750mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
9529578|NCT03201146|Experimental|Apatinib 500mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
9529579|NCT03201146|Experimental|Apatinib 250mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
9529580|NCT03201146|Experimental|Apatinib|Phase 2 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
9529581|NCT03201146|Active Comparator|AP or AC|Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum-based doublet chemotherapy, as the control group in the phase 2 study.
9662953|NCT04455828||Non-hospitalized Heart Failure subjects|Subjects who have not been hospitalized in the past 1 year, but have a diagnosis of heart failure, will be enrolled during routine outpatient care to wear the WHOOP device for 90 days.
10037684|NCT01827293|Active Comparator|lorazepam|IV lorazepam (2 mg)
10037685|NCT01827345|Experimental|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
10037686|NCT01827384|Experimental|Regimen I (veliparib, temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9529582|NCT03201120|Experimental|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
9529583|NCT03201120|Experimental|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
9529584|NCT03201172||Univation® X|
9529585|NCT03201172||iUni®|
9529586|NCT03201107|Experimental|Pilates group|This group receives physical training based on pilates exercises
9529587|NCT03201107|No Intervention|No intervention group|This group does not receive any treatment
10037687|NCT01827384|Experimental|Regimen II (adavosertib, carboplatin)|Patients receive adavosertib PO BID for 5 doses starting on day 1 and carboplatin IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
10037688|NCT01827384|Experimental|Regimen III (everolimus)|Patients receive everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10037689|NCT01827384|Experimental|Regimen IV (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9529588|NCT03201055|Experimental|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
9529589|NCT03201367|Active Comparator|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban"
9529590|NCT03201367|Placebo Comparator|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
9529591|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
9529592|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
9529593|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
9529594|NCT03200938|Experimental|PBS CIMMO|Intervention: PBS CIMMO cement
9529595|NCT03200938|Active Comparator|Zinc oxide|Intervention: Formocresol and zinc oxide
9529596|NCT03200821|Experimental|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
9529597|NCT03200821|Active Comparator|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
9529598|NCT03200743||Hpertension|
9529599|NCT03200743||Health|
9529600|NCT03200782|Placebo Comparator|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
9529601|NCT03200782|Active Comparator|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
9529602|NCT03200782|Active Comparator|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
9529603|NCT03200990|Experimental|iVAC2L pVAD|Clinically indicated ventricular support for high-risk PCI with Pulsecath iVAC2L.
10037690|NCT01827397|Experimental|EN41-UGR7C HIV vaccine|Group 1: IM injection of 210 µg UGR7-C in 560 µg of Alum at month 0, 1 and 4
9529604|NCT03200873|Active Comparator|high impulsivity|participants with high impulsivity (BIS >62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
9529605|NCT03200873|Active Comparator|low impulsivity|participants with low impulsivity (BIS between 52 to 62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
9529606|NCT03200847|Experimental|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
9529607|NCT03200951|Experimental|Bolus group|
9529608|NCT03200951|Active Comparator|Infusion group|
9529609|NCT03200652|Experimental|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
9662954|NCT04451798|Experimental|Intervention|Impella implantation and hemodynamic measurement
9804200|NCT01735214||Patients with POAG or OHT|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
10037691|NCT01827397|Placebo Comparator|NaCl|Group 2: IM injection of 700 µL of 0.9% sodium chloride (NaCl) at month 0, 1 and 4
9529610|NCT03200899|Experimental|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
9529611|NCT03200899|Active Comparator|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
9529612|NCT03200769|No Intervention|Group I|AHI/h < 15
9529613|NCT03200769|Experimental|Group IIa|15 < AHI/h < 30. Randomization group. Intervention : CPAP active
9529614|NCT03200769|Experimental|Group IIb|15 < AHI/h < 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
9529615|NCT03200769|Active Comparator|Group III|AHI/h > 30. Intervention : CPAP active
9529616|NCT03200665|Experimental|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
9529617|NCT03200665|No Intervention|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
9529618|NCT03200756|Experimental|Sedentary Group|The experimental group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
9529619|NCT03200756|Active Comparator|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
9529620|NCT03200808|Experimental|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
9529621|NCT03200795|Experimental|Rebound exercise group|Participants randomized to this group will be instructed on the proper techniques of the desired movements (hopping) on the rebounder.
9529622|NCT03200795|Experimental|Circuit training group|The circuit training for the participants in this group will be designed for each participant. Training will take place 3 times a week for 8 weeks. The participants will undergo 10 minutes warm up before and 10 minutes cool down after the training. Resistance exercises will be performed on weight machines. Throughout the resistance training program, participants will be alternating between the bench press, seated row, lateral pull down, biceps forward, front thigh, back thigh, leg press and rowing.
9529623|NCT03200730|Experimental|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
9529624|NCT03200730|No Intervention|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
9529625|NCT03200691|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.~SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.~After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
9529626|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
9529627|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
9529628|NCT03200626||Cytokine alone or JIT plerixafor based mobilization|
9529629|NCT03200626||Routine plerixafor based mobilization|
9529630|NCT03200626||Chemomobilization|
9529631|NCT03200639|Active Comparator|Physical training, CT|Combined Trained with no cancer (CT): Post menopausal women with no cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
9529632|NCT03200639|Active Comparator|Physical training, HIITBW|High intensity interval training with body weight with no cancer (HIITBW): Post menopausal women with no cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
9529633|NCT03200639|Experimental|Physical training, CTc|Combined Trained with gynecological and/or breast cancer (CTc): Post menopausal women with with gynecological and/or breast cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
9529634|NCT03200639|Experimental|Physical training, HIITBWc|High intensity interval training with body weight with gynecological and/or breast cancer (HIITBWc): Post menopausal women with gynecological and/or breast cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
9529635|NCT03200834|Active Comparator|D2 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D2 lymph node dissection
9529636|NCT03200834|Experimental|D3 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D3 lymph node dissection
9529637|NCT03200548|Experimental|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
9529638|NCT03200548|Experimental|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
9529639|NCT03200548|Sham Comparator|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
9529640|NCT03200548|Placebo Comparator|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
9529641|NCT03200600|Experimental|Dexamethasone and flurbiprofen axetil|"Dexamethasone 10 mg is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
9529642|NCT03200600|Experimental|Dexamethasone and lipid microsphere|"Dexamethasone 10 mg is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
9529643|NCT03200600|Experimental|Normal saline and flurbiprofen axetil|"Normal saline 2 ml is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
9529644|NCT03200600|Experimental|Normal saline and lipid microsphere|"Normal saline 2 ml is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
9529645|NCT03200444|Experimental|Testing of 6 adhesive strips|"Each subject tests six adhesive strips on pre-striped skin.~Standard adhesive 1~standard adhesive 2~Standard adhesive 3~P-4~P-15~P-16~The six strips are applied on abdominal skin. The order to which the adhesive strips are located on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of the adhesive strips will be measured at 5 visits."
9529646|NCT03200561|Active Comparator|S group|IVIG (2g/Kg in 12 hours)+oral prednisolone (2mg/Kg/day for 5 days)
9529647|NCT03200561|Placebo Comparator|I group|IVIG (2g/Kg in 12 hours)
9529648|NCT03200574|Other|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
9529649|NCT03200613|Experimental|Apixaban|Apixaban 2.5 mg orally twice daily
9529650|NCT03200613|Active Comparator|Low Molecular Weight Heparin|Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily
9529651|NCT03200405|Experimental|DynaMeshVisible|the umbilical hernia will be fixed with a mesh, which is incorporated with Fe3O4 particles to become visible in MRI
9529652|NCT03200405|Active Comparator|DynaMeshCICAT|the umbilical hernia will be fixed with a Non-MRI-visible PVDF Mesh
9529653|NCT03200418|Experimental|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.~The difference between the four patches is that they consist of different adhesives.~One patch is made of a standard hydrocolloid adhesive~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
9529654|NCT03200470||Suspected PJI|
9529655|NCT03200496|Experimental|TALION®|
9529656|NCT03200496|Experimental|DA-5206(Fasting)|
9529657|NCT03200496|Experimental|DA-5206(Fed)|
9529658|NCT03200509|Experimental|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
9529659|NCT03200509|Sham Comparator|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
9529660|NCT03200522|Active Comparator|Prudent diet then Western diet|Participants randomized to this arm will received 6 days of meals consistent with a Prudent diet, followed by a washout period, and then 6 days of meals consistent with a Western diet.
9804201|NCT01735279|Placebo Comparator|Placebo|The placebo group will receive 3g per day of mineral oil during 90 days treatment
9529661|NCT03200522|Active Comparator|Western diet then Prudent diet|Participants randomized to this arm will received 6 days of meals consistent with a Western diet, followed by a washout period, and then 6 days of meals consistent with a Prudent diet.
9529662|NCT03200392|Experimental|L-DGG/LRB|laser root surface conditioning & laser DGG harvesting
9529663|NCT03200392|Experimental|B-DGG/LRB|laser root surface conditioning & blade DGG harvesting
9529664|NCT03200392|Active Comparator|B-DGG|blade DGG harvesting
9529665|NCT03200041|Other|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
9529666|NCT03200041|Other|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
9529667|NCT03200093|Experimental|Oral vancomycin|"Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days."
9529668|NCT03200093|Placebo Comparator|Placebo arm|"Ora-Sweet 5 mL~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days."
9529669|NCT03200301|Experimental|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
9529670|NCT03200301|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
9529671|NCT03200171||Group I|HCC patients who received DAAs for chronic HCV previously (either responders or not)
9529672|NCT03200171||Group II|HCC patients who are naive to DAAs.
9529673|NCT03200145||Control|The control group is made by persons living in nursing homes under usual care
9529674|NCT03200197|Experimental|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
9529675|NCT03200197|Active Comparator|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
9529676|NCT03200249|Experimental|Treatment|"- Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)~Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy~Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); boost with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.~- TME surgery (8 weeks after the end of treatment)"
9529677|NCT03200210|Experimental|Treatment with Febuxostat|Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
9529678|NCT03200210|Placebo Comparator|Treatment with placebo|Same dose and dose adjustment as the intervention arm.
9529679|NCT03200028|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 30 minutes per session.
9529680|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
9529681|NCT03200158|Other|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
9529682|NCT03200483|Experimental|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
9529683|NCT03200483|Experimental|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
9529684|NCT03200483|Experimental|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
9529685|NCT03200431|Experimental|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
9529686|NCT03200080|Placebo Comparator|Treatment A|Placebo oral tablet and Placebo oral capsule
9529687|NCT03200080|Experimental|Treatment B|Tozadenant 120 mg
9529688|NCT03200080|Experimental|Treatment C|Tozadenant 240 mg
9529689|NCT03200080|Experimental|Treatment D|Tozadenant 480 mg
9529690|NCT03200080|Active Comparator|Treatment E|d-amphetamine 20 mg
9529691|NCT03200080|Active Comparator|Treatment F|d-amphetamine 40 mg
9529692|NCT03200236|Experimental|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
9529693|NCT03200236|Active Comparator|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
9529694|NCT03200119|Experimental|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
9529695|NCT03200119|No Intervention|Control group|Conventional lifestyle modification
9529696|NCT03200015|Experimental|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
9529697|NCT03200184|Experimental|Treatment|Subjects will receive sofosbuvir and daclatasvir
9529698|NCT03200067|Experimental|Personalized rehabilitation service group|Breast cancer patients who use mobile healthcare service application and receive personal feedback from clinician
9529699|NCT03200067|No Intervention|Conventional group|Breast cancer patients with conventional care
9529700|NCT03200223|Experimental|Personalized lifestyle intervention group|Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician
9529701|NCT03200223|No Intervention|Conventional group|Patients with conventional care
9529702|NCT03200054|No Intervention|Clinic-based Care|Clinic-based care is the current standard of care and is defined as referral of women on antiretroviral therapy (ART) to general primary care adult ART services.
9529703|NCT03200054|Experimental|Adherence Club Care|Adherence club care involves referral of women on ART to community-based ART services in the form of adherence clubs, which are led by community health workers and supported by ART clinic nurses.
9529704|NCT03199989|Active Comparator|adjuvant chemotherapy group|patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy[CapeOX（Capecitabine+Oxaliplatin）] by the current guidelines
9529705|NCT03199989|Experimental|observation group|patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
9529706|NCT03200002|Experimental|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
9529707|NCT03200002|Experimental|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
9529708|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
9529709|NCT03199976|Experimental|Tiotropium Bromide & Salbutamol|Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
9529710|NCT03199976|Active Comparator|Fluticasone Propionate & Salbutamol|Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
9529711|NCT03199976|Active Comparator|Salbutamol|Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
9529712|NCT03199807|Experimental|NRT + radiotherapy|HCC received NRT and radiotherapy
9529713|NCT03199898||34-32 GA|premature infants born <34,6-32,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
9529714|NCT03199898||32-28 GA|premature infants born <32-28,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
9529715|NCT03199898||28-23 GA|premature infants born <28-23,0 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
9529716|NCT03199651|Active Comparator|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
9529717|NCT03199651|Experimental|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
9529718|NCT03199833|Experimental|Arms|RETRAINER-S2 & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S2 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
9529719|NCT03199833|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
9804141|NCT01733329|Placebo Comparator|Folic Acid|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
9529720|NCT03199716|Experimental|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
9529721|NCT03199716|No Intervention|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
9529722|NCT03199937|Experimental|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
9529723|NCT03199937|Active Comparator|Waitlist control group|Current standard of care
9529724|NCT03199664|Active Comparator|Group A (NB-UVB)|Intervention: patients will be treated with Narrow band ultra violet rays alone for 6 months
9529725|NCT03199664|Active Comparator|Group B ( combined NB-UVB & Tacrolimus)|Intervention: patients will be treated with NB-UVB & Tacrolimus 0.03 % ointment for 6 months
9529726|NCT03199703|Active Comparator|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
9529727|NCT03199703|Active Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
9529728|NCT03199690|Experimental|Single arm|"Single arm trial design based on the dosing regimen below:~Day 1 - 7~- Dolutegravir 50 mg once daily with food~Day 8 - 14 - Dolutegravir 100 mg once daily with food~Day 15 - 28~- Rifampicin 600 mg once daily~Day 29 - 35 - Rifampicin 600 mg once daily & Dolutegravir 50 mg once daily~Day 36 - 42~- Rifampicin 600 mg once daily & Dolutegravir 100 mg once daily"
9529729|NCT03199742|Active Comparator|PTSD Coach with no Coaching|Participants will receive the PTSD coach mobile app.
9529730|NCT03199742|Experimental|PTSD Coach with Peer Coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a Veteran peer.
9529731|NCT03199742|Experimental|PTSD Coach with Clinician coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a clinical psychologist.
9529732|NCT03199742|Experimental|PTSD Coach with Automated Coaching|Participants will receive the PTSD Coach + mobile app which will provide automated, personalized coaching for 8 weeks.
9529733|NCT03199950|Experimental|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am & 10.00pm)
9529734|NCT03199950|Placebo Comparator|No treatment|Patients will receive oral placebo 2dd (08.00am & 10.00pm)
10037692|NCT01827410||patients with a ventral hernia repair|All patients with a ventral hernia repair performed in Region Zealand and registered in The Danish Ventral Hernia Database during October 1st 2010 to October 1st 2011
10037693|NCT01827423|Experimental|Surgical removal of sinonasal papiloma|The study group consisted of patients following a surgical removal of sinonasal papiloma, in which the SCCA blood levels were assessed in pre-defined intervals.
9529735|NCT03199781|Experimental|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
9529736|NCT03199677|Experimental|apatinib with 500mg qd po|Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
9529737|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
9529738|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
9529739|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
9529740|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
9529741|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
10037694|NCT01827436|Active Comparator|Conventional physical therapy|Includes traditional physical treatment, such as gait and balance training and muscle strengthening.
9529742|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
10037695|NCT01827436|Active Comparator|Asymmetrical gait training|Includes walking on a split-belt treadmill with the belts moving at different speeds under each leg, alternated with overground walking training.
10037696|NCT01827501|Experimental|Group GDT|Goal-directed Management according to pulse contour analysis (PulsioflexTM Monitoring)
10037697|NCT01827501|No Intervention|Group Co|Conventional fluid management
9529743|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
9529744|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
9529745|NCT03199729|Experimental|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
9529746|NCT03199729|Experimental|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
9529747|NCT03199729|No Intervention|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
9529748|NCT03199729|Experimental|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
9529749|NCT03199625|Experimental|Cognitive Therapy group|treatment with Cognitive Therapy
9529750|NCT03199625|Experimental|Behavior Therapy group|treatment with Behavior Therapy
9529751|NCT03199625|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
9529752|NCT03199586|Experimental|NP-G2-044|capsule
9529753|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
9529754|NCT03199508|Experimental|the 3-day voiding diary group|The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
9529755|NCT03199508|Active Comparator|the 7-day voiding diary group|The 7-day voiding diary group is as the control group in which several centers use the 7-day voiding diary by cluster randomization. The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights. The 3-day voiding diary group is the experimental group in which several centers use the 3-day voiding diary by cluster randomization.
9529756|NCT03199820|Active Comparator|Cook Cervical balloon|Cook cervical double balloon catheter
9529757|NCT03199820|Active Comparator|Prostin E2 Vaginal suppository|Prostaglandin E2 sustained release vaginal insert
9529758|NCT03199638|Experimental|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
9529759|NCT03199638|Experimental|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
9529760|NCT03199638|No Intervention|control group|"in which we will use historic data from previous study (Statins in children with type 1 diabetes: effects on metabolism, inflammation and endothelial function) by choosing 12 children between 13-19 years with type 1 diabetes and meeting the very same inclusion/ exclusion criteria. We have readily available data for their HbA1C, CGM downloads, all labs and anthropometry for 3 months. We will select age, gender, and HbA1c-matched adolescents as these data were prospectively collected."
9529761|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
9529762|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
9529763|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
9529764|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
9529765|NCT03199339|Active Comparator|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
9529766|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
9529767|NCT03199339|Active Comparator|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
9529768|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
9529769|NCT03199339|Active Comparator|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
9529770|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
9529771|NCT03199339|Active Comparator|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
9529772|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
9529773|NCT03199339|Active Comparator|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
9529774|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
9529775|NCT03199339|Active Comparator|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
9529776|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
9529777|NCT03199339|Active Comparator|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
9529778|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
9529779|NCT03199339|Active Comparator|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
9529780|NCT03199365|Experimental|Prevention (TSSC intervention)|Participants undergo two TSSC intervention sessions delivered at participants' homes by trained CHWs over 1.5 hours.
9529781|NCT03199456|Experimental|Zip Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
9804142|NCT01733407|Placebo Comparator|Sugar pill|Placebo arm
9529782|NCT03199456|Active Comparator|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
9529783|NCT03199469|Experimental|Lower Dose|"1.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~1.3 x10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time."
10037698|NCT01827514||People with diagnosed cancer|People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
9529784|NCT03199469|Experimental|Higher Dose|"3.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~3.5 x 10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time"
9529785|NCT03199469|No Intervention|Delayed-Treatment Control|Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. After the follow up period, eligible delayed-treatment control subjects will be dosed with AT132 and initiate the same post-dose procedures as subjects who received AT132.
9529786|NCT03199261|Experimental|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
9529787|NCT03199261|Active Comparator|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
9529788|NCT03199443||Overactive bladder patients|
9529789|NCT03199443||Non Obstructive Urinary Retention patients|
9529790|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
9529791|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
9529792|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
9529793|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
9529794|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
9529795|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
9529796|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
9529797|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
9529798|NCT03199417|Experimental|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
9529799|NCT03199417|Placebo Comparator|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
9529800|NCT03199560|Active Comparator|Tilmanocept|Tc 99m tilmanocept
9529801|NCT03199560|Active Comparator|Sulfur Colloid|Tc 99m filtered sulfur colloid
9529802|NCT03199482|Active Comparator|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
9529803|NCT03199482|Placebo Comparator|Placebo|Placebo will be administrated to patients before stating of root canal treatment
9529804|NCT03199430|Placebo Comparator|Placebo|1450mg Corn flour
9529805|NCT03199430|Active Comparator|Epigallocatechin gallate|1450mg Epigallocatechin gallate
9529806|NCT03199495|Experimental|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
9529807|NCT03199495|Sham Comparator|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
9529808|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
9529809|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
9529810|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
10037699|NCT01827540|Experimental|Cenicriviroc + Midazolam, and CVC + DTG|Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 & w/ CVC 150mg on Day 9.
9529811|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
9529812|NCT03199313|Active Comparator|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
9529813|NCT03199313|Placebo Comparator|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
9529814|NCT03199313|Active Comparator|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
9529815|NCT03199313|Placebo Comparator|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
9529816|NCT03199313|Active Comparator|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
9529817|NCT03199313|Placebo Comparator|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
9529818|NCT03199534|Experimental|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
9529819|NCT03199534|Experimental|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
9529820|NCT03199534|Experimental|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
9529821|NCT03199352||RYGB: Hand-sewn|This group would receive a Roux-en-y gastric bypass with the anastomosis hand-sewn using a minimally-invasive robotic surgical approach
9529822|NCT03199352||RYGB: linear-staple|This group would receive a Roux-en-y gastric bypass with the anastomosis sewn with a linear stapler using a laparoscopic surgical approach
9529823|NCT03199521||Atrial Fibrillation newly diagnosed, starting apixaban|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays before and after stabilisation(4 weeks) of their anticoagulation. This will allow to compare the effect of apixaban on endogenous fibrinolysis before and after treatment.
9529824|NCT03199521||Atrial fibrillation on stable warfarin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against warfarin on endogenous fibrinolysis on stable treatment.
10037700|NCT01827540|Experimental|Dolutegravir , and DTG + CVC|Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.
9529825|NCT03199521||Atrial Fibrillation on stable aspirin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against aspirin on endogenous fibrinolysis on stable treatment.
9529826|NCT03199378||Caucasian|English speaking Caucasian individuals
9529827|NCT03199378||African American|English speaking African American individuals
9529828|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
9529829|NCT03199222|Experimental|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
9529830|NCT03199222|No Intervention|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
9529831|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
9529832|NCT03199248||the participant accepted aspiration for DMC only|
9529833|NCT03199235|Experimental|LIF + Citrus|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
9529834|NCT03199235|Active Comparator|enhanced standard of care|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
9529835|NCT03199209|Experimental|Group I (home visit, information about healthy lifestyles)|Participants and their family member meet with a community health worker in their home over 90 minutes to learn about physical activity, healthy eating, and to set goals, once a month for 6 months. Participants also receive 2-5 text messages per week that contain health tips related to healthy lifestyles and information about local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
9529836|NCT03199209|Experimental|Group II (home visit, information about healthy homes)|Participants and their family member meet with a community health worker in their home over 90 minutes to receive information on how to be safe and healthy at home and information about indoor air quality, home safety, CPR/first aid, how to prepare for emergencies, and keeping pests away, once a month for 6 months. Participants also receive 2-5 text messages per week that contain information about healthy homes and local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
9529837|NCT03199326|Experimental|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
9529838|NCT03199326|No Intervention|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
9529839|NCT03199144|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy delivering 30 Gy in 5 fractions over 9 days
9529840|NCT03199131|Experimental|CTEPH|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
9529841|NCT03199131|Other|Control group|Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
9529842|NCT03199170|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
9529843|NCT03199170|Experimental|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
9529844|NCT03199170|Experimental|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
9529845|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
9529846|NCT03199196|Experimental|Group 1 - Intervention|"Participants given an activity tracker at the given an accelerometer at each visit. Participants instructed in use of a smartphone application at the baseline visit.~Participant emailed electronic newsletters to read that may help participant be more physically active.~Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
9529847|NCT03199196|Other|Group 2 - Control|"Participants sent electronic newsletters throughout the study that may help participant be more physically active.~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
10037701|NCT01827553|Experimental|Induction CT, chemoradiotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;
9529848|NCT03199066||All NHL subtypes|no interventions
9529849|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
9529850|NCT03199066||FL|only patients with follicular lymphoma
9529851|NCT03199066||MCL|only patients with mantle cell lymphoma
9529852|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
9529853|NCT03199066||MZL|only patients with marginal zone lymphoma
9529854|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
9529855|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
9529856|NCT03199157|Active Comparator|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
9529857|NCT03199157|No Intervention|Control group|
9529858|NCT03199105|Experimental|preoperative education and tetracaine|
9529859|NCT03199105|Experimental|tetracaine|
9529860|NCT03199092|Experimental|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
9529861|NCT03199092|Experimental|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
9529862|NCT03198936|Experimental|Cognizin® SynapsaTM|Dose - 2 capsules twice a day with meals
9529863|NCT03198936|Placebo Comparator|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
9529864|NCT03199014|Experimental|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
9529865|NCT03199014|Active Comparator|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
9529866|NCT03199027|No Intervention|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
9529867|NCT03199027|Experimental|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
9529868|NCT03198975||Preoperative imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo preoperative Gd-EOB-DTPA enhanced magnetic resonance image.
9529869|NCT03198637|Experimental|Monitoring|Neuromuscular Blockade's monitoring
9529870|NCT03198637|Active Comparator|Clinical assessment|No active monitoring of cisatracurium
9529871|NCT03198780|Experimental|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
9529872|NCT03198845|Active Comparator|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
9529873|NCT03198845|Sham Comparator|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
9529874|NCT03198910||Pulmonary arterial hypertension|
9529875|NCT03198910||Chronic thromboembolic pulmonary hypertension|
9529876|NCT03198624|Active Comparator|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
9529877|NCT03198624|Active Comparator|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
9529878|NCT03198624|Active Comparator|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
9529879|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
9804143|NCT01733407|Active Comparator|L-serine|amino acid supplementation with L-serine
10037702|NCT01827553|Active Comparator|Induction CT, chemotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
10037703|NCT01827566|Active Comparator|gluten|10 grams of gluten in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
10037704|NCT01827566|Placebo Comparator|gluten free flour|10 grams of gluten free flour in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
10037705|NCT01827579|Experimental|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
9529880|NCT03198624|Active Comparator|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
9529881|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
9529882|NCT03198858|Other|Ablation with Carto® 3 System|Ablation with Carto® 3 System
9529883|NCT03198858|Other|Ablation CartoUnivu™|Ablation CartoUnivu™
9529884|NCT03198832|Sham Comparator|Type 2 diabetes mellitus and periodontitis|periodontal debridement in a single session.
9529885|NCT03198832|No Intervention|Type 2 diabetes mellitus and without periodontitis|maintained every three months.
9529886|NCT03198741|Active Comparator|Aspirin+clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
9529887|NCT03198741|Experimental|Aspirin|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
9529888|NCT03198741|Experimental|Clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
9529889|NCT03198819||Rifampisin group|"Researchers will administer topical Rifampicin and intravenous cefotaxime~For Rifampicin; 10 mg/kg/day, 24 h infusion on defect area during 3 days~For cefotaxime; 50 mg/kg/day, twice a day, intravenous during 5 days."
9529890|NCT03198819||Control group|"Researchers will only administer intravenous cefotaxime~1) Doses; 50 mg/kg/day, twice a day, intravenous during 5 days."
9529891|NCT03198702|Experimental|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
9529892|NCT03198702|Sham Comparator|Sham group|The babies receive a simulated injection procedure at the age of 12 months
9529893|NCT03198663|Experimental|POSSE Intervention|
9529894|NCT03198663|Other|Control|Delayed intervention
9529895|NCT03198923|Experimental|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
9529896|NCT03198676|Active Comparator|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
9529897|NCT03198676|Active Comparator|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
9529898|NCT03198676|Active Comparator|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
9529899|NCT03198676|Placebo Comparator|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
9529900|NCT03198455|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
9529901|NCT03198455|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
9529902|NCT03198585|Active Comparator|Empagliflozin 10 mg|
9529903|NCT03198585|Placebo Comparator|Placebo|
9529904|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
9529905|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction < 50%
9529906|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:~Mitral lateral annulus e' in tissue Doppler < 10 cm/s~American society of echocardiography (ASE) criteria 2009~ASE criteria 2016"
9529907|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion < 17 cm
9529908|NCT03198481|Active Comparator|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
9529909|NCT03198481|Active Comparator|Physician Counseling Video Group|MUS video by a physician.
9529910|NCT03198546|Other|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 and TGFβ targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
9529911|NCT03198403|Experimental|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS > 3) will have a popliteal plexus block
9529912|NCT03198403|No Intervention|No intervention|Patients with postoperative pain NRS < or = 3
9529913|NCT03198390||Subjects with chronic skin conditions|Subjects with chronic skin conditions including but not limited to atopic dermatitis, contact dermatitis, hidradenitis suppurativa, and psoriasis
9529914|NCT03198390||Healthy subjects|
9529915|NCT03198533|Active Comparator|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
9615478|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
9529916|NCT03198533|Active Comparator|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
9529917|NCT03198806|Active Comparator|Control group in supine position|"Intervention:~- Only treadmill aerobic exercise with 60 min recovery in supine position"
9529918|NCT03198806|Experimental|Hydration group in supine position|"Interventions:~Treadmill aerobic exercise with 60 min recovery in supine position~Water intake"
9529919|NCT03198806|Active Comparator|Control group in orthostatic position|"Intervention:~- Only treadmill aerobic exercise with 10 min recovery in orthostatic position"
9529920|NCT03198806|Experimental|Hydration group in orthostatic position|"Interventions:~Treadmill aerobic exercise with 10 min recovery in orthostatic position~Water intake"
9529921|NCT03198442|Experimental|Breast PET|PET imaging of breast with patient in prone position.
9529922|NCT03198572|Experimental|Berberine|Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
9529923|NCT03198572|Placebo Comparator|Placebo|Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
9529924|NCT03198793|Experimental|QGC001|Capsules of QGC001 250 mg
9529925|NCT03198377|Experimental|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
9529926|NCT03198377|Experimental|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
9529927|NCT03198377|Experimental|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
9529928|NCT03198377|Sham Comparator|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
9529929|NCT03198429|Experimental|Embedded fathering intervention|"This condition focuses on workers' practice with fathers who have been identified as perpetrators in cases of child exposure to domestic violence. Workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the need to engage fathers as part of intervention in cases of child exposure to DV~access to a practice leader and consultant to respond to question and concerns about working with father perpetrators of DV~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases being assigned to ongoing service workers will be flagged by intake at the time they are opened to ongoing services as being a potentially appropriate referral to the Caring Dads program~clients who are then referred to CD as part of clinical service will be given access to this program at the earliest possible opportunity."
9529930|NCT03198429|Experimental|Embedding mother-child intervention|"Workers in the MIM condition will receive additional training and facilitated referral to MIM for eligible clients. Specifically, workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the impact of DV on mothers, mothering, and child development~access to a practice leader and consultant to respond to question and concerns about working with women victims of DV on parenting issues~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases judged by intake workers as being appropriate referrals to the MIM program (see Methods) and being assigned to these workers for ongoing service will be flagged at the time of transfer as being potentially appropriate referrals to the Mothers in Mind program~clients who are then referred to MIM as part of clinical service will be given access to this program at the earliest possible opportunity."
9529931|NCT03198429|Experimental|Combined intervention|A final group of workers will be randomly assigned to receive all the training, support, and referral opportunities associated with both the Embedded Mothers in Mind condition and the Embedded Caring Dads condition.
9529932|NCT03198429|No Intervention|Treatment as usual|Workers in the service as usual condition will continue to provide in-home support to children and families in accordance with current practice. Workers will receive regular supervision from their supervisors. A review of practice reveals that, in general, workers make referrals to intervention programs in only a small minority of cases. Such referrals will continue under this study protocol - service will proceed as usual. This condition is not a placebo, families are continuing to receive the full child protection service that they would normally have received if this trail were not being run.
9529933|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
9529934|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
9804144|NCT01733472|Placebo Comparator|RA-arm|RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
9804202|NCT01735279|Experimental|Omega3|The omega 3 group will receive 3g per day of fish oil during 90 days treatment
9529935|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
9529936|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
9529937|NCT03198897||Observation|Patients with a Homozygous familial Hypercholesterolemia or high-grade suspicion for Homozygous familial Hypercholesterolemia
9529938|NCT03198949|Experimental|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
9529939|NCT03198949|Placebo Comparator|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
9529940|NCT03198364|Experimental|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
9529941|NCT03198364|Active Comparator|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
9529942|NCT03198273|Experimental|Clinical pilates exercises|Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
9529943|NCT03198273|Experimental|Physiotherapy Program|Standard physiotherapy program consisting of conservative treatment is applied to both groups. The conservative treatment schedule to be applied to planned as 10 sessions, 3 times a week.
9529944|NCT03198208||Reference group|No fentanyl dose administered during surgery
10037706|NCT01827579|No Intervention|Control (normal HSCT)|Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
9529945|NCT03198208||Comparative group|Fentanyl dose administered during surgery
9529946|NCT03198325|Experimental|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
9529947|NCT03198286|Experimental|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
9529948|NCT03198182|Experimental|Module A|BMS-986036 Arm
9529949|NCT03198182|Placebo Comparator|Module B|Placebo Arm
9529950|NCT03198338|Experimental|TAP group|Drug: 0.25% Bupivacaine, 0.5mL/kg
9529951|NCT03198338|Sham Comparator|Placebo group|Drug: 0.9% Normal Saline, 0.5mL/kg
9529952|NCT03198312|Experimental|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
9529953|NCT03198312|Active Comparator|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
9529954|NCT03198247|Active Comparator|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
9529955|NCT03198247|Experimental|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
9529956|NCT03198117|Experimental|Huaier Granule|Huaier Granule
9529957|NCT03198117|Placebo Comparator|placebo|placebo
9529958|NCT03198117|No Intervention|No-treatment Control|patients refused any treatment
9529959|NCT03198260|Experimental|Fascial Manipulation|fascial manipulation is a manual therapy technique were to apply deep frictional massage to the deep fascial structure or point to increase its pliability
9529960|NCT03198260|Active Comparator|Running kinematics|the change in a range of joint angles during different phases of running
9615479|NCT02544880|Experimental|Tadalafil plus Vaccine Placebo Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, placebo for the Anti-MUC1 Vaccine and placebo for the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
10037707|NCT01827618|Experimental|Rapamycin|Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy
10037708|NCT01827618|No Intervention|Control|
10037709|NCT01827631|Experimental|GSK1605786 500 mg once daily|GSK1605786 500 mg is given once daily in the morning
10037710|NCT01827631|Experimental|GSK1605786 500 mg twice daily|GSK1605786 500 mg is given twice daily in the morning and in the evening
9529961|NCT03198299|Active Comparator|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
9529962|NCT03198299|No Intervention|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
9529963|NCT03198130|Experimental|REGN2810|REGN2810 administered IV over a 30 minute infusion
9529964|NCT03198169|Experimental|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
9529965|NCT03198169|Experimental|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
9529966|NCT03198169|Experimental|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
9529967|NCT03198169|Experimental|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
9529968|NCT03198091|Experimental|Dun Ye Guan Xin Ning mono-therapy|
9529969|NCT03197961|Experimental|DMPA with tenofovir/emtricitabine PrEP|the drug combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg which is known as Truvada® will be taken orally once daily for 14 days by all participants. Drug concentrations will be measured (blood sampling) and one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection after the first course of tenofovir disoproxil fumarate/emtricitabine is completed. Then, a second round of the combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg (Truvada®) will be taken orally once daily for 14 days by all participants.
9529970|NCT03198104||Liver disease|Paediatric patients (50-60 pts.) with liver disease who are scheduled for an ultrasound-guided liver biopsy as part of their standard care - these patients will be scanned using MRI and fibroscan, then will proceed through standard care pathway to receive blood tests and a liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to the MRI data to determine it's accuracy in detecting and distinguishing different types of liver disease.
9529971|NCT03198104||Autoimmune Hepatitis Group (AIH)|Paediatric patients who have been diagnosed with autoimmune hepatitis and are about to initiate pharmacological treatment (15-30 pts.) will be scanned using MRI and fibroscan, then proceed through the standard care pathway to receive repeated blood tests and liver biopsies throughout treatment. MRI and fibroscan will be repeated before each liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to MRI data to determine it's accuracy in monitoring liver disease.
9529972|NCT03198104||Healthy Volunteers|Healthy volunteers (20-30 children) will be scanned using MRI and fibroscan and used as healthy controls.
9529973|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
9529974|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
9529975|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
9529976|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
9529977|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
9529978|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
9529979|NCT03198143|Experimental|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
9529980|NCT03198143|Placebo Comparator|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
9529981|NCT03198143|Experimental|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
9529982|NCT03198143|Placebo Comparator|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
9529983|NCT03197974|Other|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
9804145|NCT01733472|Experimental|GA-arm, remifentanil|GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
10037711|NCT01827644|Experimental|Sequence 1|Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
9529984|NCT03197974|Other|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
9529985|NCT03197779|Experimental|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
10037712|NCT01827644|Experimental|Sequence 2|Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
9529986|NCT03197779|Experimental|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
9529987|NCT03197779|Experimental|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
10058247|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
9529988|NCT03197779|Placebo Comparator|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
9529989|NCT03197779|Placebo Comparator|Placebo|Placebo intravenous administration
9529990|NCT03198065|Experimental|Hand-made glove setting|The patients receive Hand-made glove setting
9529991|NCT03198065|Experimental|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
9529992|NCT03197818|Experimental|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
9529993|NCT03197818|Active Comparator|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
9529994|NCT03197896|Experimental|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
9529995|NCT03197896|Active Comparator|Group II (general health information)|The educator reviews topics about health promotion actions.
9529996|NCT03197987|Experimental|Endocuff colonoscopy|Endocuff-assisted colonoscopy
9529997|NCT03197987|Active Comparator|Cap colonoscopy|Cap-assisted colonoscopy
9529998|NCT03197792|Experimental|Pulmonary endarterectomy patients|All patients
9529999|NCT03197948||Health Services Research (electronic patient reported outcome)|Patients complete questionnaires over 15 minutes once a week over 3 months via a smartphone application. Patients rate urinary function, bowel habits, sexual function, hormonal function, and overall satisfaction. Patients with advanced disease also answer questions related to pain, fatigue/lack of energy, weight loss, and worry domains.
9530000|NCT03198026|Experimental|Treatment (ibrutinib, obinutuzumab)|"Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2 months after cycle 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.~After completion of study treatment, patients are followed up monthly for 1 year, every 3-6 months for 4 years, and then annually for up to 2 years."
9530001|NCT03197636||Malignant melanoma patients|40 patients with metastatic melanoma are included. Patients are admitted to Department of Oncology, Aarhus University Hospital (AUH). The patients are recruited to the study from the outpatient clinic of the Department of Oncology when they are about to begin treatment with pembrolizumab.
9530002|NCT03197636||Healthy controls|20 Healthy volunteers (HV) are included, matched by age and gender.
9530003|NCT03197623|Experimental|LLP2A-ALENDRONATE|50, 150, 400, 750 or 1200 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
9530004|NCT03197623|Placebo Comparator|Placebo|Placebo given as a one time intravenous administration over 120 minutes.
9530005|NCT03197571|Experimental|Nant Urothelial Cancer Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
9530006|NCT03197805|Experimental|Use of PAM 50 test in Her2 equivocal breast cancer patient|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test).
9530007|NCT03197753|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion
9530008|NCT03197753|Active Comparator|Nasotracheal intubation|Nasotracheal tube insertion
9530009|NCT03197727|Other|GC Saliva-Check BUFFER|Saliva test pH Buffering capacity Flow rate
9530010|NCT03198013|Experimental|Module A|Single Ascending Dose
9530011|NCT03198013|Experimental|Module B|Multiple Ascending Dose
9530012|NCT03197714|Experimental|OPB-111077|Level 1: 200 mg daily Level 2: 250 mg daily
9530013|NCT03197584|Experimental|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
9530014|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
9530015|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
9481001|NCT05099055|Experimental|Test group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with dexmedetomidine 3 mcg (0.75 mL) previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
9481002|NCT05099055|Active Comparator|Control group|Monitoring will be installed upon arrival.Metoclopramide 10 mg IV and Dexamethasone 4 mg will be given for nausea-prophylaxis. Patients may be given ondansetron 4 mg as rescue. Cefazoline 2G or clindamycin 900 mg will be given.A sterile spinal technique will be performed with a 25G Whitacre. Bupivacaine 12 mg (1.6 ml) will be drawn and given, along with morphine 100 mcg, fentanyl 15 mcg and normal saline 0.25 ml previously blindly prepared for a total of 2.35 ml.Adequate blood pressure will be maintained with phenylephrine infusion or ephedrine IV. Glycopyrrolate 0.2 mg may be given for bradycardia.Once an adequate sensory block is obtained, the obstetrics team can perform the surgery.The patient will receive a dose of ketorolac 30 mg IV before leaving the PACU and then Naproxen 500 mg PO every 12 hours.She will receive acetaminophen 975 mg PO every 6 hours and hydromorphone 2-4 mg PO every 3 hours prn. Patients will also have access to a protocol for treatment of nausea and pruritus.
9481003|NCT05098522|Experimental|Arm 1: IRL201104|IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
9481004|NCT05098522|Placebo Comparator|Arm 2: Placebo|Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
9481005|NCT05097040|Experimental|Acceptance and commitment therapy (ACT) group|A total of 7 ACT sessions individually guided by a trained coach through Zoom videoconferencing
9481006|NCT05097040|No Intervention|Control group|Care as usual
9481007|NCT05095298|No Intervention|Control Group|Participants volunteered not to receive the third dose of vaccine, and agreed to be followed-up for 1 year
9481008|NCT05095298|Experimental|Inactivated Vaccine Group|Participants volunteered to receive the third dose of inactivated vaccine
9481009|NCT05095298|Experimental|Recombinant subunit protein vaccine|Participants volunteered to receive the third dose of subunit protein vaccine
9481010|NCT05095298|Experimental|mRNA vaccine Group|Participants volunteered to receive the third dose of mRNA vaccine ( To be enrolled, the vaccine has not been approved in China)
9481011|NCT05092841|Experimental|PXT3003|Liquid oral solution, 10 mL twice a day, morning and evening with food
9481012|NCT05092841|Placebo Comparator|PXT3003 Placebo|Liquid oral solution, 10 mL twice a day, morning and evening with food
9481013|NCT05090358|Experimental|Ketogenic Diet|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will partake in a ketogenic diet in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
9481014|NCT05090358|Experimental|Low Carbohydrate Diet|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will be assigned to Low Carbohydrate Diet/LCD therapy each in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
9481015|NCT05090358|Experimental|SGLT2i Therapy|Postmenopausal women and men with histologically-confirmed, HR-positive, HER2-negative, PIK3CA mutant MBC who have received no more than 1 line of endocrine-based therapy in the metastatic setting will be eligible. Participants on this arm will be assigned to SGLT2i therapy each in combination with SOC endocrine therapy (fulvestrant) and PI3K inhibition (alpelisib)
9481016|NCT05090046||Christchurch Health and Development Study (CHDS)|The Christchurch Health and Development Study (CHDS) is a birth cohort study comprising 1265 people born in Christchurch in 1977. Participants have been followed to age 40, with 75-80% retention at data collection points.
9481017|NCT05089071|Experimental|CADe group|Endoscopists perform colonoscopy with CADe system
9481018|NCT05089071|No Intervention|Control|Endoscopists perform colonoscopy without CADe system
9481019|NCT05088421|Experimental|BWC0977|"SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hour. Planned doses to be studied are: 120, 240, 480 and 720. Dose for a planned 5th cohort will be determined based on the safety and tolerability data of preceding SAD Cohorts.~MAD Cohorts: Subjects will receive multiple doses of BWC0977 via IV infusion over 2 hour for 10 consecutive days. Up to three dose groups will be studied. Planned doses and frequencies will be confirmed based on the safety, tolerability and PK data of BWC0977 obtained in SAD Cohorts"
9481020|NCT05088421|Placebo Comparator|Placebo|"Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hour.~MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hour for 10 consecutive days. Frequency of infusions will be determined based on safety, tolerability and PK data obtained for BWC0977 in SAD Cohorts."
9481021|NCT05084963|Experimental|Arm 1: IRL201104 Dose A|IRL201104 IV on Days 0, 7, and 14
9481022|NCT05084963|Experimental|Arm 2: IRL201104 Dose B|IRL201104 IV on Days 0, 7, and 14
9481023|NCT05084963|Placebo Comparator|Arm 3: Placebo|Placebo IV on Days 0, 7, and 14
9481024|NCT05084638|Experimental|Ofatumumab|Ofatumumab will be provided in an autoinjector for subcutaneous administration. Dosing regimen for this study is an initial dose of 20mg at Baseline/Week 0, followed by Week 1, 2 and every month thereafter, beginning at Week 4 (Month 1) until Month 18. There will be an optional extension of dosing through month 30.
9481025|NCT05084638|No Intervention|Healthy Control|Healthy Control arm will be age- and sex-matched subjects (to the ofatumumab treated arm) and will not receive a study treatment.
10037713|NCT01827644|Experimental|Sequence 3|Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
10037714|NCT01827644|Experimental|Sequence 4|Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
10037715|NCT01827644|Experimental|Sequence 5|Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
9481026|NCT05082051|Active Comparator|CDX-7108|CDX-7108, an oral recombinant lipase. It is a modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovans (btLIP) and produced by fermentation of recombinant Escherichia coli.7
9481027|NCT05082051|Placebo Comparator|Placebo|Excipients only
9481028|NCT05080777|Experimental|Tele-Savvy Group|The participants will be enrolled into the Tele-Savvy group. Software analytics monitor caregivers' use of asynchronous material each week.
9481029|NCT05080777|Active Comparator|Attention Control Group|The participants will be enrolled in the Caregiving During Crisis program. Software analytics monitor caregivers' use of asynchronous material each week.
9481030|NCT05079451|Experimental|Study Participants|Participants will receive an infusion of both study drugs (3BNC117-LS and 10-1074-LS) and will then discontinue antiretroviral therapy two days later. Participants will receive a second dose of study drug (3BNC117-LS only) at week 12 if viral suppression (when the amount of HIV in the body is kept to a very low level, which keeps the immune system working and prevents illness), is maintained and participants remain off antiretroviral therapy.
9481031|NCT05079217|Experimental|Experimental Group|600 participants will receive one dose of booster vaccination with high-dosage inactivated SARS-CoV-2 vaccine .
9481032|NCT05079217|Active Comparator|Control Group|600 participants will receive one dose of booster vaccination with medium-dosage inactivated SARS-CoV-2 vaccine .
9481033|NCT05078047|Experimental|Experimental arm|"Reduced dose intensity of IO:~IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision"
9481034|NCT05078047|No Intervention|Control arm|"Standard IO:~Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice."
9481035|NCT05073016|Active Comparator|Finger Taping Task + iTBS intermittent group|Finger Taping Task + iTBS Daily application group: the group receives these applications every other day for 5 sessions.
9481036|NCT05073016|Active Comparator|Finger Taping Task intermittent Group|Finger Taping Task intermittent application group: the group receives the application every other day for 5 sessions.
9481037|NCT05057195|Experimental|Interstitial radiation therapy|Duration: 11 days
9481038|NCT05057195|Active Comparator|Postoperative external beam therapy, on the bed of the removed tumor|Duration: 4 weeks
9481039|NCT05057143|Experimental|Replacement of a defect in the chest wall with an individual implant|A patient with a tumor lesion of the chest wall undergoes СT scan with a step width of less than 1 mm, then engineers design an individual model to replace the defect. Using a 3D printer, a model is made based on the patient's anthropometric data.
9481040|NCT05057143|Active Comparator|Replacement of a defect in the chest wall with titanium plates|The use of standard titanium plates to replace the chest defect. These plates must be modeled and modified using special equipment intraoperatively, based on the characteristics of the defect after resection.
9481041|NCT05057130|Experimental|Three-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. Methotrexate 12 g / m2 at 28 and 35 days IV with leucovorin 60 mg / m2 in the first 5 days after each administration of methotrexate. The interval between cycles is 42 days
9481042|NCT05057130|Active Comparator|Two-component chemotherapy|Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration. G-CSF support from 4 to 13 days. The interval between cycles is 28 days
9481043|NCT05057117|Active Comparator|Botulinum toxin A|One treatment with standard dosage (50-100 units) of botulinum toxin A in one axilla
9481044|NCT05057117|Active Comparator|Microwave thermolysis|One standard treatment (energy level 5) with microwave thermolysis in one axilla
9481045|NCT05056298|Experimental|Insole and Exercise group|will contain 17 patients, they will receive the custom made arch support insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
9530016|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
10037716|NCT01827644|Experimental|Sequence 6|Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
10037717|NCT01827657|Experimental|Part 1 Cohort 1 - Mild hepatic impairment|Subjects with mild hepatic impairment will be enrolled in Cohort 1 and will receive a single dose of 60 mg GSK2336805
10037718|NCT01827657|Experimental|Part 1 Cohort 2 - Moderate hepatic impairment|Subjects with moderate hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805
10037719|NCT01827657|Experimental|Part 1 Cohort 3 - Matched healthy volunteers to Cohort 2|Control subjects will be matched for gender, age (+/- 10 years), body mass index (BMI) (+/- 20%), and smoking status to the subjects in the moderate hepatic impairment arm. These healthy volunteers will receive a single dose of 60 mg GSK2336805
10037720|NCT01827657|Experimental|Part 2 Cohort 4 - Severe hepatic impairment|Subjects with severe hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805. The decision to move forward into Part 2 (severe hepatic impairment) will be based on a review of the preliminary safety and pharmacokinetic data from subjects with moderate hepatic impairment
10037721|NCT01827657|Experimental|Part 2 Cohort 5 - Matched healthy volunteers to Cohort 4|Based on emerging data from Part 1, the sponsor may decide to enroll matched controls to the severe hepatic group (i.e. in case of a change in dose or the demographics of the severe hepatic group are not well matched with the moderate control data). The subjects in this optional control cohort will be matched for gender, age (+/- 10 years), BMI (+/- 20%), and smoking status to the subjects in the severe hepatic impairment category
10037722|NCT01827683|Active Comparator|Hyperbaric oxygen therapy group|hyperbaric oxygen therapy during the first 2 months
10037723|NCT01827683|Other|Crossed group|no active intervention during the first 2 months.After 2 months will be crossed to HBOT
10037724|NCT01827696|Experimental|Treatment|American Ginseng ingestion
10037725|NCT01827696|Placebo Comparator|Placeobo|non-active ingredient
10037726|NCT01827722|Experimental|Ozurdex Arm|Ozurdex intravitreal injection (combination with monthly sham injection) administered at a 16 week interval beginning on Day 1 and ending at Week 16.
9530017|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
10037727|NCT01827722|Experimental|Ranibizumab Arm|Ranibizumab injection (combination with sham injections beginning on Day 1 and Week 16) administered at monthly intervals beginning Day 1 and ending at Week 20.
10037728|NCT01827722|Experimental|Combination Ozurdex with Ranibizumab PRN|"Ozurdex intravitreal injection administered at 16 week intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered at Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly (in combination with sham if reinjection parameters are not met).~Reinjection Parameters:~10 letter drop from best corrected visual acuity or a 100 µm increase in central retinal thickness according to optical coherence tomography (Spectralis HRA + OCT)."
10037729|NCT01827748|Experimental|Intraoperative Autorefractor IAR-1|This is a auto refractor mounted on an operating microscope.
10037730|NCT01827748|Active Comparator|Hartmann-Shack Auto Refractor|The Hartmann-Shack type auto refractor used with the subject sitting upright in front of the instrument.
10037731|NCT01827774|Experimental|Surgisis® Soft Tissue Graft|
10037732|NCT01827800|Experimental|eHealth weight loss intervention|The 12-month eHealth behavioral intervention includes interactive self-monitoring and feedback, tailored skills training materials, telephone counseling calls from a study coach, and primary care provider counseling.
10037733|NCT01827800|No Intervention|Usual care|Participants in the usual care arm will receive the usual primary care services offered by their community health center primary care providers.
10037734|NCT01827813|Active Comparator|Saturation biopsy|Saturation biopsy was performed in left lateral decubitus position after application of sedo-analgesia by the anesthesiologists on an outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen. As a total,24,26 or 28 biopsies were taken depending on prostate volume.
10037735|NCT01827813|Active Comparator|10-12 core biopsy|10-12 core biopsy was performed in left lateral decubitus position without sedo-analgesia on an outpatient basis. After preparation of the probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. As a total 10 or 12 core biopsies were taken depending on prostate volume. The biopsies were taken form right base, right mid, right apex, right far-lateral base, right far-lateral mid and left base, left apex, left far-lateral base, and left far-lateral mid in 10 core biopsy, also two additional transitional zone biopsies were taken in 12 core biopsies.
10058248|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) [n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
10058249|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign [n=30]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
9530018|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
9530019|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
9530020|NCT03197493|Experimental|High Dose|carbidopa-levodopa 25-100 mg 2 tablets TID
9530021|NCT03197493|Experimental|Intermediate Dose|carbidopa-levodopa 25-100 mg 1 tablet TID
9530022|NCT03197519|Experimental|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
10037736|NCT01827826|Active Comparator|Intervention|Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks. Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks. After 24 weeks, the investigators randomly divided the intervention group in half. The first group did not receive any more phone calls from the interventionist. The second group continued to receive monthly 20-minute phone calls from the interventionist. At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
9530023|NCT03197519|Other|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
10037737|NCT01827826|No Intervention|Control|Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
9530024|NCT03197506|Experimental|Group 1 (pembrolizumab, surgery, temozolomide, radiation)|"NEOADJUVANT (CYCLE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.~SURGERY (CYCLE 2): Patients undergo standard of care surgery within days 4-7.~CONCURRENT (CYCLE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
10037738|NCT01827852||Cohort|
9530025|NCT03197506|Experimental|Group 2 (pembrolizumab, temozolomide, radiation therapy )|"CONCURRENT (CYCLE 1): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLES 2-6): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 of cycles 2-5 and 1 and 22 of cycle 6 (up to a total of 17 doses). Patients also receive temozolomide PO daily on days 1-5, 29-33, and 57-61 of cycles 2 and 6, days 22-26 and 50-54 of cycle 3, days 15-19 and 43-47 of cycle 4, days 8-12 and 36-40 of cycle 5. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
9530026|NCT03197480|Other|DME treatment group|"All patients will received 4 intravitreal injections of aflibercept.~Based on the OCT outcome they will be classified into 2 groups for assessment of biomarkers:~Less than 20% reduction in CRT on OCT or <5 letter improvement of VA (if VA<6/6 and CRT>=340) Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT"
9530027|NCT03197610|Experimental|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
9530028|NCT03197610|Experimental|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
9530029|NCT03197272|Experimental|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
9530030|NCT03197272|Active Comparator|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
10037739|NCT01827865|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
10037740|NCT01827865|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
10037741|NCT01827878|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
10037742|NCT01827878|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
10037743|NCT01827891|Placebo Comparator|control group|Control participants did not experience the procedure of transient upper-limb ischemia.
10037744|NCT01827891|Active Comparator|remote ischemic preconditioning (RIPC) group|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
10037745|NCT01827917|Experimental|rabies vaccine|When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die
10037746|NCT01827956||Blood sample|Blood sample for identifying the polymorphism
10037747|NCT01827969|Experimental|ablathermy focused ultrasound|ablathermy focused ultrasound
10037748|NCT01827982|Experimental|Part 1 - Cohort 1: JNJ-54861911 1 mg|Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.
10037749|NCT01827982|Experimental|Part 1 - Cohort 2: JNJ-54861911 3 mg|
10037750|NCT01827982|Experimental|Part 1 - Cohort 3: JNJ-54861911 9 mg|
9530031|NCT03197246|Experimental|IVECG and chest X-ray|The patients in this group will be examined with perioperative IVECG for PICC tip placement, as well as standard postoperative chest X-ray.
9530032|NCT03197246|Active Comparator|Standard|Standard method, PICC tip placement confirmed by postoperative chest X-ray .
10037751|NCT01827982|Experimental|Part 2 - Cohort 4: JNJ-54861911 9 mg|
10037752|NCT01827982|Experimental|Part 2 - Cohort 5: JNJ-54861911 27 mg|
10037753|NCT01827982|Experimental|Part 2 - Cohort 6: JNJ-54861911 81 mg|
10037754|NCT01827982|Experimental|Part 2 - Cohort 7: JNJ-54861911 160 mg|
10037755|NCT01827982|Experimental|Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])|
10037756|NCT01827982|Placebo Comparator|Parts 1 through 3 - Placebo|Participants in each cohort will receive matching placebo.
10037757|NCT01827995|Other|Duo test|Self assessment
10037758|NCT01827995|Other|Routine follow up|Follow up in the clinic
10037759|NCT01828047||Elective colorectal surgeries|Patients undergoing elective colorectal procedures with an Enhanced Recovery Program. Orthogonal polarization spectral (OPS) imaging will be used to measure sublingual microcirculation
10037760|NCT01828060|Experimental|Jobelyn™|Dietary supplement Jobelyn™, 500mg daily for 8 weeks Jobelyn is a sorghum bicolor extract marketed as dietary supplement Other Name: Sorghum bicolor extract
10037761|NCT01828060|Placebo Comparator|Placebo|Placebo capsules
10037762|NCT01828086|Experimental|CJM112|CJM112 in different doses; single ascending and multiple ascending
10037763|NCT01828086|Placebo Comparator|Placebo|Placebo to match
10037764|NCT01828086|Active Comparator|Secukinumab|Active investigational drug.
9530033|NCT03197402|Active Comparator|Comparator group|Milk protein gel delivery system supplementation
10058250|NCT02016820|Experimental|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
10058251|NCT02016820|Other|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
10058252|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
10058253|NCT02016846|Placebo Comparator|Placebo|
10058254|NCT02016846|Active Comparator|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
10058255|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
10058256|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
10058257|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
10058258|NCT02016911|Experimental|Subjects with hepatic impairment|
10058259|NCT02016911|Active Comparator|Subjects with normal hepatic function|
10058260|NCT02016937||group g|general anesthesia, n: 21
10058261|NCT02016937||group S|spinal anesthesia, n: 21
10058262|NCT02016937||group E|epidural anesthesia, n: 21
10058263|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
10058264|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
10058265|NCT02016976|Active Comparator|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
10058266|NCT02016976|Active Comparator|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
10058267|NCT02016989|Other|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
9530034|NCT03197402|Experimental|Leucine-enriched protein group|Leucine-enriched protein gel delivery system supplementation
9530035|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
10058268|NCT02016989|Experimental|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
10058269|NCT02017002|Active Comparator|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
10058270|NCT02017002|Placebo Comparator|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
10058271|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
10058272|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
10058273|NCT02017067|No Intervention|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
10058274|NCT02017067|Experimental|hydraulic resistance circuit training|12 weeks resistance training
10058275|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
9530036|NCT03197454|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
9530037|NCT03197454|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
10037765|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
9530038|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
9530039|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
9530040|NCT03197220|Experimental|fish|
9530041|NCT03197220|Experimental|walnut|
9530042|NCT03197220|Experimental|fish-walnut|
9530043|NCT03197649|No Intervention|Control|No laser phototherapy treatment
9530044|NCT03197649|Experimental|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
9530045|NCT03197285|Active Comparator|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
9530046|NCT03197285|Experimental|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
9530047|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
9530048|NCT03197415|Experimental|PRP group|Intradisc injection of autologous platelet-rich plasma gel
9530049|NCT03197350|Active Comparator|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next 4 years. Eligible patients include those with age ≥50 years, LVEF ≥45%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
9530050|NCT03197350|Active Comparator|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.~Intervention: cMR"
9530051|NCT03197441|Experimental|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
9530052|NCT03197688||Notapplicable|Not applicable as non-interventional study
9530053|NCT03197207|Experimental|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
9530054|NCT03197207|Experimental|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
9530055|NCT03197740|Active Comparator|aricept Tab 5mg|
9530056|NCT03197740|Experimental|donepezil patch 25cm2|
9530057|NCT03197740|Active Comparator|aricept Tab 10mg|
9530058|NCT03197740|Experimental|donepezil patch 50cm2|
9530059|NCT03197857|Experimental|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
10037766|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
9530060|NCT03197857|Experimental|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
9530061|NCT03197857|Experimental|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
9530062|NCT03197857|Experimental|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
9530063|NCT03197857|Experimental|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
9530064|NCT03197857|Experimental|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
9530065|NCT03197428|Experimental|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
9530066|NCT03197428|Placebo Comparator|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
9530067|NCT03197311|Experimental|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
9530068|NCT03197311|No Intervention|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
9530069|NCT03197337|Experimental|Control manipulation first|Patients in this group will first undergo the control manipulation while the study manipulation will follow.
9530070|NCT03197337|Experimental|Study manipulation First|Patients in this group will first undergo the study manipulation while the control manipulation will follow.
9530071|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Lombardia Region
9530072|NCT03197116|Active Comparator|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
9530073|NCT03197116|Placebo Comparator|No reminder|No additional reminder will be offered
9530074|NCT03197077|Experimental|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
9530075|NCT03197077|Active Comparator|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
9530076|NCT03197181|Experimental|anodal transcranial direct current stimulation|anodal transcranial direct current stimulation (current strength: 1 mA, duration: 20 min) over the frontopolar cortex
9530077|NCT03197181|Sham Comparator|sham transcranial direct current stimulation|sham transcranial direct current stimulation (current strength: 1 mA, duration: 0.5 min) over the frontopolar cortex
9530078|NCT03196908|Experimental|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
9530079|NCT03196908|Experimental|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
9530080|NCT03196908|Placebo Comparator|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
9530081|NCT03197168|Experimental|Intervention|Intervention to reduce self-stigma among people with mental illness + Usual care
9530082|NCT03197168|Placebo Comparator|Control|Usual care
9530083|NCT03196869|Experimental|Chrono-chemotherapy group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group
9530084|NCT03196869|Other|Routine intravenous drip|control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
9530085|NCT03196921|Experimental|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
9530086|NCT03196921|Experimental|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
9530087|NCT03196986|Experimental|MIL60|MIL60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
9530088|NCT03196986|Active Comparator|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
9530089|NCT03197012|Experimental|Main Study: 90Y-DOTA-TOC|90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
9530090|NCT03197012|Experimental|Sub-study: 90Y and 68Ga-DOTA-TOC|"90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.~Patients enrolled in the correlative sub-study will also receive 111-259 MBq (3-7 mCi) of 68Ga-DOTA-TOC concurrent with 90Y-DOTA-TOC"
9530091|NCT03196830|Experimental|Treatment group|the group of patients who received CAR-T treatment
9530092|NCT03196895|Active Comparator|WR|Weight reduction training
9530093|NCT03196895|Active Comparator|GE|PPG training
9530094|NCT03196895|Experimental|GEM|PPG training + discrete BG feedback
10058276|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
9530095|NCT03196895|Experimental|GEM+CGM|PPG training + continuous BG feedback
9530096|NCT03196999|Active Comparator|Personalized Attention Bias Training|Personalized version of ABM Training.
9530097|NCT03196999|Placebo Comparator|Neutral Attention Training Condition|Non-active version of ABM training.
9530098|NCT03196999|Active Comparator|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
9530099|NCT03196856|Experimental|Yogurt Group|Group will be consuming 200g of Greek Yogurt (Plain, 0%) 3 times daily for 12 weeks
9530100|NCT03196856|Placebo Comparator|Study Designed Supplement Group|Group will consume an isoenergetic, protein void, maltodextrin-based placebo supplement during the same time points for 12 weeks as well. The Placebo contain maltodextrin and pudding powder to mimic the consistency of Greek yogurt.
10037767|NCT01828138|Other|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement."
9530101|NCT03197103|Experimental|N-Acetylcysteine (NAC)|Breast enlargement with autologous fat graft obtained by liposuction with Pietruski solution (tumescent solution with NAC).
9530102|NCT03197103|No Intervention|Control|Contralateral breast enlargement with autologous fat graft obtained by liposuction with standard tumescent solution.
9530103|NCT03196947|Experimental|Single arm, APO010 Dose escalation|
9530104|NCT03196817|Active Comparator|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
9530105|NCT03196817|Active Comparator|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
9530106|NCT03196752|Experimental|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
9530107|NCT03196882|Active Comparator|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
9530108|NCT03196882|Experimental|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
9530109|NCT03196882|Active Comparator|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
9530110|NCT03196882|Experimental|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
9530111|NCT03196804|Experimental|LC28-0126|LC28-0126(IV)
9530112|NCT03196804|Placebo Comparator|Placebo|Placebo of LC28-0126
9530113|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
10037768|NCT01828138|Other|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
9530114|NCT03197051||Q2|Q2 means a group of lower 25~50% of serum syndecan-1 concentration.
9530115|NCT03197051||Q3|Q3 means a group of higher 50~75% of serum syndecan-1 concentration.
9530116|NCT03197051||Q4|Q4 means a group of highest 75~100% of serum syndecan-1 concentration.
9530117|NCT03196843|Experimental|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
9530118|NCT03196843|Active Comparator|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
9530119|NCT03196739|Experimental|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
9530120|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
9530121|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
9530122|NCT03196648|Experimental|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
9530123|NCT03196648|Experimental|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
9530124|NCT03196648|Active Comparator|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
9530125|NCT03196583|Experimental|Single-arm study|Velo-Lingual Bite (BVL)
9530126|NCT03196609|Experimental|Cohorte|"This cohort will consist of patients as described below:~15 patients with non-small cell lung cancer (NSCLC)~10 patients with hepatocellular cancer:~10 patients with colorectal cancer~10 patients with breast cancer~10 patients with prostate cancer~10 patients with glioblastoma"
9530127|NCT03196726|Experimental|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
9530128|NCT03196726|Placebo Comparator|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
9530129|NCT03196713|Other|Tailored supervision|
9530130|NCT03196713|Other|Regular supervision|
9530131|NCT03196622|Experimental|Older people|A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.
9530132|NCT03196674|Active Comparator|manipulated feedback|
9530133|NCT03196674|Active Comparator|non-manipulated feedback|
9530134|NCT03196700|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered
9530135|NCT03196453|Active Comparator|Probiotic|Lactobacillus rhamnosus GG
9530136|NCT03196453|Active Comparator|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
9530137|NCT03196453|Placebo Comparator|Placebo|Placebo
9530138|NCT03196544|Experimental|Social Approach Training (5 sessions)|
9530139|NCT03196544|Experimental|Social Approach Training (10 sessions)|
9530140|NCT03196544|No Intervention|Delayed Treatment (Waitlist)|
9530141|NCT03196466||antiepileptics titration|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
9530142|NCT03196466||antiepileptics titration and available blood samples|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
9530143|NCT03196557|Experimental|Arm A|Specified dose on specified days
9530144|NCT03196557|Placebo Comparator|Arm B|Specified dose on specified days
9530145|NCT03196401|Experimental|Durvalumab Plus Radiation Therapy|Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.
9615480|NCT02544880|Experimental|Tadalafil Placebo plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive placebo for Tadalafil, the Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
9615481|NCT02544880|Other|Control Group|For eligible participants who opt out of receiving study intervention. Participants in this group will receive SOC treatment only.
9615482|NCT02544893|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
9615483|NCT02544893|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
9615484|NCT02544893|Active Comparator|serum phsyologic|0,9% 21 ml serum physiologic
9615485|NCT02544945|Active Comparator|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
9615486|NCT02544945|Experimental|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
9615487|NCT02545062|Experimental|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
9615488|NCT02545062|Experimental|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
9615489|NCT02545153|Active Comparator|Fibrin sealant|Tisseel, Baxter (Aprotinin and Fibrinogen)
9615490|NCT02545153|Placebo Comparator|Control|Suturing the incision without fibrin glue
9615491|NCT02544815|Active Comparator|Digoxin|Oral digoxin 0.25 mg: one pill per day for three consecutive days.
9615492|NCT02544815|Placebo Comparator|Placebo|Oral placebo for three days.
9615493|NCT02545088|Experimental|Study group Hybrid Assistive Limb (HAL)|
9615494|NCT02545088|Active Comparator|1st control group|
9615495|NCT02545088|Active Comparator|2nd control group|
9615496|NCT02544932|Experimental|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
9615497|NCT02544932|Experimental|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
9615498|NCT02544932|Active Comparator|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
9615499|NCT02544997|Experimental|Poziotinib|12mg P.O. for 2wks q21days
9615500|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
9615501|NCT02544867|Experimental|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
9622022|NCT02519335|Other|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
9622023|NCT02519166|Other|Patients with chronic wounds|
10037769|NCT01828138|Other|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
9530146|NCT03196570|Experimental|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
9530147|NCT03196570|Active Comparator|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
9530148|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
9530149|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
9530150|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
9530151|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
9530152|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:6|K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
9530153|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:4|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
9530154|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
9530155|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
9530156|NCT03196414|Experimental|CART-138/BCMA/19/more|
9530157|NCT03196531|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
9530158|NCT03196531|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
9530159|NCT03196531|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
9530160|NCT03196531|Experimental|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
9530161|NCT03196362|Active Comparator|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
9530162|NCT03196362|Placebo Comparator|placebo|one tablet of placebo will be given twice daily
9530163|NCT03196206|Experimental|Group A|Normal Renal Function
9530164|NCT03196206|Experimental|Group B|Moderate Renal Impairment
9530165|NCT03196206|Experimental|Group C|Severe Renal Impairment
9530166|NCT03196128|Active Comparator|Digital|
10037770|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
10037771|NCT01828177|Experimental|PDI-320|Foam, twice daily for up to 12 weeks
9530167|NCT03196128|Active Comparator|Non Digital|
9530168|NCT03196336|Other|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
9530169|NCT03196336|Other|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
9530170|NCT03196141|Active Comparator|Healthy volunteers|"Part#1: 15 healthy volunteers; 2 assessment sessions. Session 1: StO2 vs. EndoPAT Method comparison analysis; both StO2 and EndoPAT will be applied simultaneously & pulse oximeter probes placed bilaterally on fingers. Baseline readings will be taken for 5 minutes. The blood pressure cuff will be inflated to suprasystolic pressure and StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Session 2: This session will occur within 1 week of session 1. This session is to determine the consistency of the response.~All probes will be applied as in session 1 and cycles of 10 minutes for 3 sessions will be done. All the measurements in session 1 will be captured in session 2.~This will determine inter-day variability. (total time is 53 min)."
9530171|NCT03196141|Active Comparator|Pregnant women with normal BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness."
9530172|NCT03196141|Active Comparator|Pregnant women with high BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness.~Participants with hypertension will be followed in conjunction with routine clinical follow-up at 2, 6 and 12 weeks post-partum."
9530173|NCT03196115||Observation|Patients with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
9530174|NCT03196323||Initial Cohort|"In Aim 1, the investigators will evaluate psychometrically RettBe 1.0 following, in part, previous studies including our examination of anxiety instruments and adaptation of the Anxiety, Depression and Mood Scale (ADAMS) for RTT, and their adaptations of the Aberrant Behavior Checklist-Community (ABC-C) for fragile X syndrome and Down syndrome. In Aim 1, the investigators will also refine RettBe 1.0 by adding new missing items based on parental input or clinician (PIs of sites involved) feedback. The resulting instrument, RettBe 2.0 will be tested in Aim 2."
9530175|NCT03196323||Validation Cohort|Testing of RettBe 2.0 will be carried out with a new (naïve) validation cohort of 300 subjects and two raters (preferentially both parents/caregivers, alternatively one teacher or therapist), to determine inter-rater reliability. One rater, preferentially a parent, will be asked to also complete three other behavioral measures (RSBQ, ADAMS, ABC-C) for comparisons. Scores for RettBe 2.0 will be analyzed in terms of psychometric properties, as performed for RettBe 1.0. However, in addition to structure (construct validity) and content validity, the investigators will also examine convergent and discriminant validity by correlating domain RettBe 2.0 scores with those of comparable and non-comparable domain scores of the RSBQ, ADAMS, and ABC-C, respectively.
9530176|NCT03196375|Experimental|Experimental|
9530177|NCT03196375|Placebo Comparator|Placebo Comparator|
9530178|NCT03196388|Experimental|Enzalutamide with External|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
10037772|NCT01828177|Experimental|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
10037773|NCT01828177|Experimental|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
10037774|NCT01828177|Placebo Comparator|Vehicle|Foam, twice daily for up to 12 weeks
10037775|NCT01828190|Experimental|Hyperbaric oxygen|hyperbaric oxygen therapy will be given for 2 months. TNF alpha blocker therapy will remain the treatment received before recruitment.
10037776|NCT01828203|Experimental|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
10037777|NCT01828203|Placebo Comparator|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
10037778|NCT01828229|Experimental|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
10037779|NCT01828229|Experimental|inactivity|Inactivity for two weeks
10037780|NCT01828229|Experimental|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
10037781|NCT01828229|Experimental|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
9530179|NCT03196258|Experimental|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
9530180|NCT03196258|No Intervention|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
9530181|NCT03196102|Experimental|BTI + Cigarette smoking military tailored pamphlet|BTI + Cigarette smoking military tailored pamphlet
9530182|NCT03196102|Active Comparator|Cigarette smoking military tailored pamphlet|Cigarette smoking military tailored pamphlet
9530183|NCT03196102|Active Comparator|Standard smoking cessation pamphlet|Standard smoking cessation pamphlet
9530184|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
9530185|NCT03196271|Other|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
9530186|NCT03196310|Experimental|PRP|Intra-articular injection of platelet rich plasma.
9530187|NCT03196310|Active Comparator|Corticosteroid|Intra-articular injection of kenalog.
9530188|NCT03196310|Placebo Comparator|Normal Saline|Intra-articular injection of normal saline
9530189|NCT03196154||Metformin|Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
9530190|NCT03196154||Metformin + Gliclazide|Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
9530191|NCT03196089|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
9530192|NCT03196089|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
9530193|NCT03196063|Active Comparator|Eccentric|"Patients allocated in this group will perform three sets of 15 unipodal squats with the affected limb on an inclined plane. The patient will be instructed to perform only the eccentric phase of the exercise, keeping the torso erect and flexing the knee up to 90 degrees. The return to the initial position will be performed with the unaffected leg. To increase exercise load, the patient will carry a bag with washers. This protocol will last eight weeks, with 24 face-to-face sessions.~Both groups will also receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
9530194|NCT03196063|Experimental|Modified protocol|"Patients allocated in this group will receive treatment based on a protocol published in a clinical practice guide, with modifications to make the protocol more pragmatic. Thus, the use of mechanotherapy devices will be replaced by free weight exercises, so that the protocol can be performed in environments that do not offer this type of machinery. This protocol is composed of four exercise stages, being the first three stages performed in the presence of the physiotherapist, and will last eight weeks with approximately 24 face-to-face sessions.~Both groups will receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
9530195|NCT03196050|Experimental|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
9530196|NCT03195907||PPT group|Those participated in pulmonary rehabilitation program
9530197|NCT03195907||Control group|Those served as control group
9530198|NCT03196037|Experimental|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
9530199|NCT03195790|Active Comparator|Medical center treatment arm|Family-based pediatric obesity treatment delivered at an urban medical center.
9530200|NCT03195790|Experimental|Home treatment arm|Family-based pediatric obesity treatment delivered in the family's home.
9530201|NCT03195751||Manual Goniometer measurements|Measurements of shoulder range of motion using manual goniometer
10037782|NCT01828229|Active Comparator|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
10037783|NCT01828242|Experimental|Empowerment model to Diabetes|Empowerment model to improve dietary intake
10037784|NCT01828242|Active Comparator|Control group following conventional approach|Control group following conventional approach
10037785|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
9530202|NCT03195751||Software development kit measurements|Measurements of shoulder range of motion using a proprietary SDK
9530203|NCT03195920|Experimental|Enhanced Lithotripsy System|Treatment for urinary stones with the Enhanced Lithotripsy System
9530204|NCT03195985|Experimental|Mindfulness-based Intervention|Mindfulness intervention of 4 weeks
9530205|NCT03195985|Active Comparator|"Age Well psycho-education course"|4-week active control condition
9530206|NCT03195647|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
9530207|NCT03195647|Active Comparator|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
9530208|NCT03195634||HVPG group|"When HVPG > 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day.~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or>20% from baseline."
10037786|NCT01828294|Other|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
10037787|NCT01828307|Active Comparator|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
10037788|NCT01828307|Experimental|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
10037789|NCT01828320|Experimental|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
10037790|NCT01828320|Active Comparator|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
9481046|NCT05056298|Active Comparator|Exercise group|will contain 17 patients, they will receive the standard insole in addition to the strengthening of foot muscles both intrinsic and extrinsic muscles.
9481047|NCT05055713|Experimental|Secondary prevention-1|Endoscopic therapy+ beta blockers
9481048|NCT05055713|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
9481049|NCT05055713|Experimental|Primary prevention-1|Endoscopic therapy
9481050|NCT05055713|Experimental|Primary prevention-2|Endoscopic therapy+ PSE
9481051|NCT05055713|Experimental|Acute bleeding-1|Endoscopic therapy+somatostatin
9481052|NCT05055713|Experimental|Acute bleeding-2|Endoscopic therapy+PSE+somatostatin
9481053|NCT05054309|Active Comparator|Probiotic|Bifidobacterium longum [BL NCC3001]
9481054|NCT05054309|Placebo Comparator|Placebo|Maltodextrin
9481055|NCT05053087|Experimental|Ropivacaine group with bolus infusions|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in pulsed intermittent bolus.
9481056|NCT05053087|Experimental|Ropivacaine group with continuous infusions|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in a continuous infusion.
9481057|NCT05053087|Placebo Comparator|Single shot adductor canal block group|Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with saline.
9481060|NCT05049720|Experimental|Experimental|Patients will be implanted with an Extravascular ICD and undergo requisite electrical testing.
9481061|NCT05049655||Study Formula|New infant formula fed ad lib
9481062|NCT05049655||Comparator Formula|Commercially available infant formula fed ad lib
9481063|NCT05049655||Human Milk Reference Group|Human milk
9481064|NCT05049031|Experimental|Breast cancer treated with hormone therapy|Adult patients with T1-T3, N0-N2, M0 breast cancer and referred to the Menopause Center of Toulouse Hospital for their breast cancer
9481065|NCT05047523|Experimental|ALXN1840|ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.
9481066|NCT05047523|Active Comparator|Standard of Care|Participants will receive their current therapy or initiate Standard of Care therapy.
9481067|NCT05044715|Experimental|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) as an intervention.
9481068|NCT05044715|Experimental|Compassion-Focused Therapy|Participants in this arm will be enrolled in a CFT group intervention.
9481069|NCT05042791|Experimental|SRT combined with pyrotinib and capecitabine|"SRT: SRT needs to be comprehensively considered based on the size, number, and location of the lesion, and SRS and FSRT are performed according to clinical needs.~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
9481070|NCT05042791|Active Comparator|WBRT combined with pyrotinib and capecitabine|"WBRT: WBRT need to be considered based on the size, number, and location of the lesion.~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
9481071|NCT05041062|Experimental|All Participants in Study Who Have Mesothelioma|Individuals in this group will receive a combination of two immunotherapy drugs (nivolumab and ipilimumab) before and after surgery to remove their cancer. There will also be a follow up period to determine how well the drugs and surgery worked to get rid of your cancer. Your overall participation in this study (including drug treatment, surgery and follow up visits) will last for roughly one and a half years. All eligible participant who enroll in the study will participate in this group.
9481074|NCT05026775|Experimental|Initial Medication Adherence (IMA) intervention|General practitioners (GP) will apply the IMA intervention to all patients receiving a new prescription for treatment of cardiovascular disease or diabetes. Following the IMA intervention, nurses and community pharmacists will offer information support in line with the information provided by the GP.
9481075|NCT05026775|Active Comparator|Usual care|Patients will receive the usual care when being prescribed a new prescription for treatment of cardiovascular disease or diabetes. Nurses and community pharmacists will be asked to also provide usual care to those patients.
9481076|NCT05022693|Experimental|BIO89-100 30 mg, Open Lable, Single Dose|
9481077|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 200×10^6 anti-CD19 chimeric antigen receptor (CD19-CAR+) viable natural killer (NK) cells, single-dose, intravenously, once on Day 0.
9481078|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0.
9481079|NCT05020015|Experimental|Part 1: Dose Expansion: LBCL: TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0 to determine RP2D.
9530209|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure >25mmHg and a pulmonary arterial wedge pressure <15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
9530210|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP <20mmHg)).
9530211|NCT03195816|Experimental|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
9530212|NCT03195816|No Intervention|MCI control group|The control group will receive a usual standard care without engagement in intervention
9530213|NCT03195998||Group A|Gestational Age 23 0/7 - 28 6/7 weeks
9530214|NCT03195998||Group B|Gestational Age 29 0/7 weeks - 34 6/7 weeks
9530215|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
9530216|NCT03195855|Experimental|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.~Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).~Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
9530217|NCT03195855|No Intervention|Control group of usual care including podiatry|"Control group (n=29):~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
9530218|NCT03195582|Experimental|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
9530219|NCT03195582|No Intervention|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
9530220|NCT03195868|Experimental|Photobiomodulation|All patients will be treated similarly in this study
9530221|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
9530222|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
9530223|NCT03195608|Experimental|Intervention|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
9530224|NCT03195608|Active Comparator|Control|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, participants will drive the scenario and receive feedback from a trained evaluator regarding their live performance. No lane change assistance system will be utilized. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world.
9530225|NCT03195946|Experimental|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
9530226|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
9530227|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
9804203|NCT01735396|Experimental|Abiraterone Acetate|Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.
9530228|NCT03195738|Experimental|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
9530229|NCT03195673|Experimental|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.~Procedure: Carotid Artery Stenting"
9530230|NCT03195673|Other|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
9530231|NCT03195842|No Intervention|Usual discharge care|Standard discharge instructions, meaning conversation with physician, usually via interpreter, along with written instructions compiled by the nurse. Written instructions include pre-translated handouts for common languages, and untranslated (English) patient-specific instructions.
9530232|NCT03195842|Experimental|Recordable card|Usual care, as above, plus patient-specific and standard instructions recorded in the patient's preferred language for care and given to them on a card to take home.
9530233|NCT03195803|Experimental|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
9530234|NCT03195803|Active Comparator|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
9530235|NCT03195933|Experimental|Cortisol first, Placebo second|Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during first functional magnetic resonance imaging (fMRI) session; Identically appearing placebo capsule during second fMRI session.
9530236|NCT03195933|Experimental|Placebo first, Cortisol second|Placebo capsule during first fMRI session; Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during second fMRI session.
9530237|NCT03195621|Experimental|Interventional therapy group|
9530238|NCT03195621|No Intervention|Conservative treatment group|
9530239|NCT03195543||Patients with PAH|Diagnostic tests will be performed on patients with Pulmonary Artery Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
9530240|NCT03195543||Patients with CTEPH|Diagnostic tests will be performed on patients with Chronic Thromboembolic Pulmonary Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
9530241|NCT03195764|Experimental|T-1101 (Tosylate)|
9530242|NCT03195530||Elderly patients|Patients over 65 years, scheduled to general surgery, requiring general anesthesia
9530243|NCT03195452|Experimental|Raltegravir|antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
9530244|NCT03195491|Experimental|Monotherapy|Nivolumab administered every two weeks
9530245|NCT03195504|Experimental|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
9530246|NCT03195504|Active Comparator|CON (control)|Standard flow oxygen during induction of anesthesia
9530247|NCT03195361|Experimental|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
9530248|NCT03195413|Experimental|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
9530249|NCT03195413|No Intervention|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
9530250|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
9530251|NCT03195348|Experimental|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
9530252|NCT03195205|Other|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
9530253|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
9530254|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
9530255|NCT03195257|Placebo Comparator|Hypoglycemia-saline|
9530256|NCT03195257|Experimental|Hypoglycemia-GIP|
9530257|NCT03195257|Active Comparator|Hypoglycemia-GLP-1|
9530258|NCT03195257|Experimental|Hyperglycemia-GIP|
9530259|NCT03195257|Placebo Comparator|Hyperglycemia-Saline|
9530260|NCT03195829|Experimental|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
9530261|NCT03195829|Active Comparator|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
9530262|NCT03195556|Experimental|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
10058277|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
9530263|NCT03195556|Experimental|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
9530264|NCT03195088|Experimental|Active Treatment|Single rising doses of BI drug
10058278|NCT02017106|Experimental|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
9530265|NCT03195088|Placebo Comparator|Placebo|Matching volumes of drug-free solution
9530266|NCT03195036|No Intervention|Control|The control group of women/children dyads who consent and are patients at the control clinics will not have any exposure to ECD programming.
9530267|NCT03195036|Experimental|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation.
9530268|NCT03195049|Experimental|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
9530269|NCT03195049|Experimental|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
9530270|NCT03195439|Experimental|patients in ICU|
9530271|NCT03195153|Experimental|statin only|30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
9530272|NCT03195153|Experimental|allopurinol only|30 DAYS OF ALLOPURINOL (300 MG)
9530273|NCT03195153|Experimental|statin and allopurinol|30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
9530274|NCT03195101|Experimental|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
9530275|NCT03195270|Experimental|Single Arm|[18F]FDG PET/MRI
9530276|NCT03195296||Graves' Orbitopathy|Patients with Graves' Orbitopathy subjected to orbital decompression
9530277|NCT03195075|Active Comparator|Group 1|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography guided biliary drainage
9530278|NCT03195075|Active Comparator|Group 2|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to percutaneous trans-hepatic biliary drainage.
9530279|NCT03194984|Other|Young Patient|With 18-25 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
9530280|NCT03194984|Other|Adult Patient|With 40-65 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
9530281|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
9530282|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
9530283|NCT03195309|Active Comparator|Group A|Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl
9530284|NCT03195309|Active Comparator|Group B|Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl
9530285|NCT03195309|Active Comparator|Group C|Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl
9530286|NCT03195166|Experimental|hemodynamic profile|FloTrac sensor/Vigileo
9530287|NCT03195231|Experimental|Wuling Powder Group|Take Wuling Powder 3 times a day，3 pills each time for 12 weeks
9530288|NCT03195231|Placebo Comparator|Placebo Group|Take placebo drug which cannot be distinguished from the experimental drug 3 times a day，3 pills each time for 12 weeks
9530289|NCT03195387|Experimental|D-1/120 mg MMV390048|Treatment of cohort 1: subjects receive a single oral dose of MMV390048 on Day -1, prior to PfSPZ challenge on Day 0.
9530290|NCT03195387|Experimental|D-7/120 mg MMV390048|Treatment of cohort 2: subjects receive a single oral dose of MMV390048 on Day -7, prior to PfSPZ challenge on Day 0.
9530291|NCT03195387|Experimental|D-X/YY mg MMV390048|Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
9530292|NCT03195387|Placebo Comparator|Placebo|MMV390048 placebo
9530293|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
9530294|NCT03195218|Experimental|HRME examination|HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
9530295|NCT03194958|No Intervention|Standard Quitline|Participants will receive standard Missouri quitline services
9530296|NCT03194958|Experimental|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
9530297|NCT03194958|Experimental|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
9530298|NCT03194958|Experimental|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
10058279|NCT02017106|Active Comparator|Sequential Phlebectomies|Endovenous laser ablation only
10058280|NCT02017119|Experimental|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
9530299|NCT03195192|Other|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
9530300|NCT03195062|Experimental|Test meal|The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
10037791|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
10037792|NCT01828346|Experimental|Treatment|5-Azacitidine plus birinapant
9530301|NCT03194997|Experimental|Dance|The group randomized to Dance intervention will receive a 3-week intervention with belly dance classes. The classes will be divided in: Warm up and stretching (10 minutes), Main part with belly dance steps and movements (40 minutes) and relaxation (10 minutes).
9530302|NCT03194997|Experimental|Pilates|The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
9530303|NCT03194997|No Intervention|Control|The group randomized to Control group will be invited to maintain routine activities and be contacted by phone every two months and will receive an explanatory booklet on the benefits of physical activity after diagnosis of breast cancer as well as instructions on lymphedema prevention. Also, this group will be invited to three meeting during the 16 weeks of intervention, the first meeting will focus on stretching exercise to develop at home, a second meeting will be about self-esteem and the last meeting will be about prevented of lymphedema. The women in this group will not receive a dance or pilates intervention.
9530304|NCT03195426|Experimental|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
9530305|NCT03195140|Experimental|Intervention Arm|"The intervention arm (use of PLGS feature) will utilize Tandem Diabetes Care's ambulatory insulin infusion pump with integrated Dexcom G5 CGM and predictive low glucose suspend function. This pump is called the t:slim X2 with Basal-IQ Technology and is referred to in the protocol as the Tandem PLGS pump."
10037793|NCT01828359|Experimental|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
9530306|NCT03195140|No Intervention|Control Arm|The control arm (SAP only) will utilize an identical pump in functionality as the Tandem PLGS pump except for the lack of the PLGS feature and the associated user interface. This pump is called the t:slim X2 Dexcom G5 Mobile CGM Enabled pump, and is referred to in the protocol as the Tandem SAP pump.
10037794|NCT01828359|Active Comparator|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
9530307|NCT03194945|Active Comparator|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
9530308|NCT03194945|Active Comparator|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
9530309|NCT03194945|Active Comparator|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
9530310|NCT03194945|Active Comparator|Lifestyle alone|No OHA is given after CSII
9530311|NCT03195023|Active Comparator|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
9530312|NCT03195023|Active Comparator|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
9530313|NCT03194906|Active Comparator|Memantine|Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
9530314|NCT03194906|Placebo Comparator|Placebo|Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.
9530315|NCT03194919|Experimental|Negotiating quit date|Endre: a digital smoking cessation counsellor
9530316|NCT03194919|Active Comparator|Preset quit date|Endre: a digital smoking cessation counsellor
9530317|NCT03194828|Active Comparator|Monitoring only|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
9530318|NCT03194828|Experimental|Monitoring and reminder|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system
9530319|NCT03194750|Experimental|Share Data|
9530320|NCT03194750|Active Comparator|Do Not Share Data|
9530321|NCT03194815|Active Comparator|Intravenous immunoglobulin and Rituximab|One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
9530322|NCT03194815|Placebo Comparator|Placebo|One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
9530323|NCT03194620|Placebo Comparator|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
9530324|NCT03194620|Experimental|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
9530325|NCT03194620|Experimental|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
9530326|NCT03194620|Experimental|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin-3-O-gallate (EGCG)
10037795|NCT01828372|Other|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
10037796|NCT01828385|Experimental|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
9530327|NCT03194620|Experimental|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin-3-O-gallate (ECG)
9530328|NCT03194620|Active Comparator|(-)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin (EC)
9530329|NCT03194620|Experimental|(-)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin (EGC)
9530330|NCT03194620|Experimental|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
9530331|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
9615502|NCT02544867|Experimental|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26-28]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
9615503|NCT02544841|Experimental|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is the treatment condition. SSI is an in-person, individual-level, clinic-based intervention that aims to reduce risky sexual behaviors among sexually active adolescent females.
9615504|NCT02544841|Active Comparator|Female Sexual Health|Female Sexual Health is the control counterfactual condition. It is an individual-level, information-only sex education program that aims to increase participants' knowledge on various topics related to STIs.
9615505|NCT02544828|Experimental|Experimental group|Iron Sucrose 200mg
9615506|NCT02544828|Placebo Comparator|Control Group|placebo
9615507|NCT02544854|Experimental|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
9615508|NCT02544854|Experimental|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
9615509|NCT02544854|Experimental|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
9615510|NCT02545114|Other|Tolvaptan|Intervention arm. Open label, no control group
9615511|NCT02544776|Experimental|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
9615512|NCT02544776|Active Comparator|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
9615513|NCT02544802|Experimental|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection
9615514|NCT02544750|Experimental|GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
9615515|NCT02544659|Experimental|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
9615516|NCT02544646|Other|trabeculectomy|
9615517|NCT02544685|Active Comparator|Synbiotics group|"Interventions: administration of Probio-Fix Inum + Beneo Synergy 1~Start of prophylaxis: 5 days before or 2 days after starting chemotherapy~Prophylaxis duration: 3 months"
9615518|NCT02544685|Placebo Comparator|Placebo group|"Interventions: administration of placebo~Start: 5 days before or 2 days after starting chemotherapy~Duration: 3 months"
10037797|NCT01828385|Active Comparator|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
9615519|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
9615520|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
9615521|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
9615522|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
9615523|NCT02544672|Experimental|Myoelectric Elbow-Wrist-Hand Orthosis|
9615524|NCT02544789|Experimental|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
9615525|NCT02544737|Experimental|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
9615526|NCT02544711|Experimental|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
9615527|NCT02544711|Other|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
9615528|NCT02544620||Total Hip arthroplasty|"Unselected primary THA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
9615529|NCT02544620||Total Knee arthroplasty|"Unselected primary TKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
9615530|NCT02544620||unicompartmental knee arthroplasty|"Unselected primary UKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
9530332|NCT03194841|Experimental|Heart Failure Application|A mobile application that allowed for input of physiologic data, qualitative questions about symptoms and education
9530333|NCT03194685|Experimental|Cohort 1: 10 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530334|NCT03194685|Experimental|Cohort 2: 20 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530335|NCT03194685|Experimental|Cohort 3: 35 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530336|NCT03194685|Experimental|Cohort 4: 50 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530337|NCT03194685|Experimental|Cohort 5: 75 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530338|NCT03194685|Experimental|Cohort 6: 100 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530339|NCT03194685|Experimental|Cohort 7: 150 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530340|NCT03194685|Experimental|Cohort 8: 225 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530341|NCT03194685|Experimental|Cohort 20: 50 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530342|NCT03194685|Experimental|Cohort 21: 75 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530343|NCT03194685|Experimental|Cohort 22: 100 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
9530344|NCT03194711||Patients with stable CAD|
9530345|NCT03194529|Experimental|FMT in children with disease remission|All children (with Crohn's disease in remission) will receive the equivalent of 50 g of stools from a healthy donor (FMT) into the jejunum through upper endoscopy.
9530346|NCT03194724||High Vitamin A exposure|There was no intervention
9530347|NCT03194724||Low vitamin A exposure|No intervention
9530348|NCT03194802|Experimental|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
9530349|NCT03194802|Active Comparator|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
9530350|NCT03194607||Patients|
9530351|NCT03194607||Controls|
9530352|NCT03194425|Experimental|OAB|Patients with overactive bladder on sacral neuromodulation.
9530353|NCT03194425|Experimental|NOUR|Patients with non-obstructive urinary retention on sacral neuromodulation.
9530354|NCT03194633||Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.
9530355|NCT03194399|Experimental|Breast cancer patients|
9530356|NCT03194659|No Intervention|Placebo|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, no additional choline chloride will be added to the cocktail.
9530357|NCT03194659|Experimental|Supplemental Choline|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the experimental arm of the trial, supplemental choline chloride will be added to the cocktail.
9530358|NCT03194438|Experimental|UZIT arm|Multi-modal components integrative therapy intervention program, Urban Zen Integrative Therapy.
9530359|NCT03194594|Active Comparator|Group K (n = 31)|will receive a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
9530360|NCT03194594|Active Comparator|Group D (n = 31)|will receive dexamethasone 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
9530361|NCT03194594|Experimental|Group KD (n = 31)|will receive ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v., at 5 minutes after the induction of anesthesia
9530362|NCT03194555|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
9530363|NCT03194555|Placebo Comparator|Placebo|
9530364|NCT03194386|No Intervention|Control|usual care
9530365|NCT03194386|Active Comparator|Reassurance|15 minutes psychologist visit
9530366|NCT03194386|Experimental|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
9530367|NCT03194412|Experimental|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
9530368|NCT03194412|Experimental|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
9530369|NCT03194412|Experimental|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
9530370|NCT03194412|Experimental|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
9530371|NCT03194412|No Intervention|Control group|Without intervention
9530372|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
9530373|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
9530374|NCT03194191|Experimental|Regular acupuncture needles|"Real acupuncture procedure The real acupuncture will be performed by means of standard stainless-steel needles (0.30-mm diameter, 30-mm length/Gauge 8 x 1.2), located bilaterally in 5 real acupoints."
9530375|NCT03194191|Sham Comparator|Sham acupuncture needles|Sham acupuncture with a no penetrating sham needle (blunt and telescopic), giving the impression of insertion but without penetrating the skin will be placed bilaterally in 5 false acupoints
9530376|NCT03194360||delirium group|
9530377|NCT03194360||nondelirium group|
9804204|NCT01735617|Experimental|Hydrocortisone Modified Release Capsules|Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
9530378|NCT03194295|Experimental|Community Support Intervention|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
9530379|NCT03194295|Active Comparator|Standard Care|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
10037798|NCT01828398|Sham Comparator|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
9530380|NCT03194230|No Intervention|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
9530381|NCT03194230|Experimental|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
10037799|NCT01828398|Experimental|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
10037800|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
10037801|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
10037802|NCT01828437|Experimental|Pyridoxine plus prednisolone|allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
10037803|NCT01828437|Active Comparator|Prednisolone|allocated patients receive prednisolone alone
10037804|NCT01828463|No Intervention|no treatment|comparrator
9530382|NCT03194282|Experimental|chronic stroke patient with insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
9530383|NCT03194282|Sham Comparator|chronic stroke patient without insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
9530384|NCT03194100||Diabetes Mellitus|
9530385|NCT03194100||Prediabetes|
9530386|NCT03194100||Normal glucose tolerance|
9530387|NCT03194152|Experimental|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
9530388|NCT03194152|Experimental|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
9530389|NCT03194139|Experimental|Sentinel Cohort|
9530390|NCT03194139|Experimental|Crossover Design|
9530391|NCT03194204|Active Comparator|RA patients treated with methotrexate|"Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
9530392|NCT03194204|Active Comparator|RA patients treated with methotrexate plus doxycycline|"Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.~Cardiac assessment :~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
9530393|NCT03194126|Experimental|Mifepristone + Misoprostol OR oxytocine + laminaria|
9530394|NCT03194126|Other|Mifepristone + Misoprostol OR oxytocine|
9530395|NCT03194113|Active Comparator|Trauma-Focused Treatment|Weekly sessions of prolonged exposure
9530396|NCT03194113|Active Comparator|Emotion Regulation Treatment|weekly sessions of emotion regulation and skills training.
9530397|NCT03194113|Active Comparator|Intensive Trauma-Focused Treatment|prolonged exposure, 3 sessions per week
10037805|NCT01828463|Experimental|Nitisinone 1mg|interventional
9530398|NCT03193983|Experimental|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
9530399|NCT03193983|Experimental|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
9530400|NCT03194061|Experimental|Hypofractionated chemoradiation|20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
9530401|NCT03194074|Experimental|propofol group|Propofol/remifentanil-based general anesthesia.
9530402|NCT03194074|Experimental|desflurane group|Desflurane/remifentanil-based general anesthesia.
10037806|NCT01828463|Experimental|Nitisinone 2mg|interventional
10037807|NCT01828463|Experimental|Nitisinone 4mg|interventional
10037808|NCT01828463|Experimental|Nitisinone 8mg|interventional
10037809|NCT01828489|Active Comparator|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
10037810|NCT01828489|Experimental|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
10037811|NCT01828489|Experimental|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
10037812|NCT01828489|Experimental|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
10037813|NCT01828502|Experimental|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
10037814|NCT01828502|Other|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
9530403|NCT03194048|Experimental|Functional Chewing Training|Children with CP and have tongue thrust included this group.
9530404|NCT03194048|Active Comparator|Control|Children with CP and have tongue thrust included this group.
9530405|NCT03193827|Experimental|study group|In this group in-line filters (Pall, Dreieich, Germany) are connected to peripheral vascular access and used during anaesthesia and the following 96 postoperative hours.
9530406|NCT03193827|Active Comparator|control group|Patients randomised to standard care are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient.
9530407|NCT03193775|Active Comparator|chronic HBV with persistent HBsAg|"inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA."
9530408|NCT03193775|No Intervention|control group|A control group (n=100) did not receive HBV vaccine
9530409|NCT03193749|Experimental|Amiodarone Hydrochloride|Oral treatment for at least 6 months
9530410|NCT03193749|Placebo Comparator|Placebo|Oral treatment for at least 6 months
9530411|NCT03193684|Experimental|Treatment|dapagliflozin 10 mg per day
9530412|NCT03193684|Placebo Comparator|control|matching placebo 1 pill per day
9530413|NCT03193879||COPD group|COPD patients
9530414|NCT03193879||Asthma group|Asthma patients
9530415|NCT03193879||Health group|Healthy volunteers
9530416|NCT03193840|Experimental|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
9530417|NCT03193671||Benign|Benign tumors, pre-and postmenopausal
9530418|NCT03193671||Malignant|Malignant tumors, pre-and postmenopausal
9530419|NCT03193671||Borderline|Borderline tumors, pre-and postmenopausal
9530420|NCT03193671||Malignant+borderline|Malignant+borderline tumors, pre-and postmenopausal
9530421|NCT03193905|Other|Cotton blanket|30 hypothermia patients undergo the standard procedure with a cotton blanket during major spinal surgery
9530422|NCT03193905|Other|Bairhugger Full Access Underbody blanket|30 hypothermia patients undergo the Bairhugger Full Access Underbody blanket procedure during major spinal surgery (new procedure)
9530423|NCT03193944|Active Comparator|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
9530424|NCT03193944|Placebo Comparator|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
9530425|NCT03193957|Experimental|SB4|SB4 (etanercept) 50 mg/mL
9530426|NCT03193814|Experimental|Chemotherapy + Apatinib|chemotherapy regimens include: Folfox (Oxaplatin 85 mg/m2 IV over 2 hours, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks) or Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks)； apatinib 500mg po qd
9530427|NCT03193645||Degarelix|
9530428|NCT03193788|Experimental|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
10037815|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
10037816|NCT01828541|Other|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
10037817|NCT01828541|Experimental|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
10037818|NCT01828580|Experimental|AutoLap|
9530429|NCT03193788|No Intervention|observation|observation group will be observed with best supportive care until progressive disease
9530430|NCT03193658|Active Comparator|Group T|Will receive bilateral US guided Thoracolumbar Interfascial Plane (TLIP) block at the proposed level of surgery before the start of the surgery
9530431|NCT03193658|Active Comparator|Group O|Will not receive the block and postoperative pain control will be managed by I.V drug based multi-modal approach (Opioid & acetaminophen) only.
9530432|NCT03193853|Experimental|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
9530433|NCT03193970||Bladder Cancer Patients Undergoing Radical Cystectomy|Prospective registry of bladder cancer patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating centers.
9530434|NCT03193723|Active Comparator|Group A|US guided five step field block will be performed
9530435|NCT03193723|Active Comparator|Group B|Spinal anesthesia will be administered in sitting position
9530436|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
9804205|NCT01735630|Experimental|ELND005|ELND005 film coated tablets, BID for 12 weeks
9530437|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
9530438|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
9530439|NCT03193801|Experimental|Failing mitral transcatheter valve|Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
9530440|NCT03193697|Experimental|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
9530441|NCT03193697|Experimental|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
9530442|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
9530443|NCT03193918|Experimental|Crenolanib combined with ramucirumab/paclitaxel|
9530444|NCT03194009|Active Comparator|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
9530445|NCT03194009|Active Comparator|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
9530446|NCT03193268|Experimental|High intensity agility group|Exercise therapy
9530447|NCT03193268|Experimental|Non-agility cycling group|Parkinson's Bicycle Group, which takes 1 hour of exercise every day for 5 weeks
9530448|NCT03193268|No Intervention|No-exercise control group|Control Parkinson's disease control group thad will not receive exercise treatment
9530449|NCT03193229|Experimental|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
9530450|NCT03193229|Active Comparator|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
9530451|NCT03193411|Other|microkeratome group|30 eyes were treated by microkeratome
9530452|NCT03193411|Other|femtosecond group|30 eyes were treated by femtosecond laser
9530453|NCT03193242|Experimental|Intervention|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
9530454|NCT03193242|No Intervention|Control|"Electronic Asthma Management System: eAMS - Control~At control sites, eligible clinicians will be offered access to the web-based clinician-oriented asthma action plan (AAP) educational module produced by the Lung Association, copies of the Canadian Asthma Guidelines, and standard fillable paper-based AAPs (the eAMS will be offered after study end)."
9530455|NCT03193489|Experimental|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
10037819|NCT01828606|Experimental|Coban 2 system|The two layer system is more stiff and the material is different designed
9530456|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
9530457|NCT03193385||Closed reduction|
9530458|NCT03193255|Active Comparator|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
9530459|NCT03193255|Active Comparator|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
9530460|NCT03193255|Active Comparator|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
9530461|NCT03193255|Active Comparator|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
9530462|NCT03193502|Experimental|Portal Vein thrombosis|rivaroxaban
9530463|NCT03193580|Experimental|Anodal Conventional tDCS|The intervention will be anodal conventional tDCS. Anodal tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0 milliamp. Anode positioned over the right primary motor cortex, and the cathode over the contralateral supraorbital area.
9530464|NCT03193580|Experimental|Anodal High Definition tDCS|The intervention will be anodal high definition-tDCS. Anodal HD-tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0milliamp. Anode entered over the right primary motor cortex, and four cathodes placed in a ring formation surrounding the anode.
9530465|NCT03193580|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same anodal conventional tDCS protocol as outlined above. This includes the initial stimulation sequence of ramp up of 30 seconds, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist after 120 seconds of stimulation to automatically ramp down to 0milliamp over 30 seconds.
9804206|NCT01735630|Placebo Comparator|Placebo|Matched placebo BID for 12 weeks
10058281|NCT02017119|Experimental|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
10037820|NCT01828606|Experimental|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
9530466|NCT03193294|Active Comparator|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
9530467|NCT03193294|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
9530468|NCT03193320|Active Comparator|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
9530469|NCT03193320|Active Comparator|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
9530470|NCT03193320|Experimental|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
9530471|NCT03193424|Experimental|Apatinib|
9530472|NCT03193424|Active Comparator|docetaxel|
9530473|NCT03193359|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections to head/neck areas at Day 0 and Week 12.
9530474|NCT03193346|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.
9530475|NCT03193346|Placebo Comparator|Placebo|Placebo matching BOTOX® [Sodium chloride 0.9 milligrams (mg)] IM injections in head/neck areas at Day 0 and Week 12.
9530476|NCT03193307|Experimental|All subjects|Microgynon alone (run in period) then Microgynon & BI 409306 treatment period
9530477|NCT03193450|Experimental|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
9530478|NCT03193450|Active Comparator|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
9530479|NCT03193463|Experimental|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
9530480|NCT03193463|Experimental|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
9530481|NCT03193463|Experimental|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
9530482|NCT03193437|Experimental|Selinexor|Open Label Selinexor 40 mg
9615531|NCT02544555|Experimental|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
10037821|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
10058282|NCT02017132|Active Comparator|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
9530483|NCT03193281|Other|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
9530484|NCT03193606|Experimental|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
9530485|NCT03193606|No Intervention|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
9530486|NCT03193177||the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
10037822|NCT01828632|Experimental|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
9530487|NCT03193203|Experimental|Sequence 1|SB4 (etanercept) 50 mg/mL PFS and AI
9530488|NCT03193203|Experimental|Sequence 2|SB4 (etanercept) 50 mg/mL AI and PFS
9530489|NCT03192917|Experimental|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
9530490|NCT03192917|Placebo Comparator|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
9530491|NCT03192878||Naive patients|Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
9530492|NCT03192878||Switch patients|Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
9530493|NCT03193125|Experimental|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
9530494|NCT03193125|Placebo Comparator|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
9530495|NCT03192839|Experimental|Low dose PUFA|
9530496|NCT03192839|Experimental|High dose PUFA|
9530497|NCT03192839|Placebo Comparator|Placebo|
9530498|NCT03192852|Experimental|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
9530499|NCT03192852|Experimental|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
9530500|NCT03192852|Experimental|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
9530501|NCT03192852|Experimental|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
9530502|NCT03192982|Experimental|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
9530503|NCT03192982|Active Comparator|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
9530504|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
9530505|NCT03193073|Active Comparator|CKD patients with different stages|"Full clinical history and through clinical examination.~Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.~Iron study at time of diagnosis and 3 months after treatment .~Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
9530506|NCT03193073|Active Comparator|Newly renal transplanted patients .|"Full clinical history and through clinical examination.~Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.~Pre-transplant full blood count serial measures every / 3 months for 2 years.~Pre transplant serum Iron study and annually for 2 years.~24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~Post-transplant serum FGF-23 (as independent risk factor) at 6months.~Different immunosuppressive protocols.~Pre-transplant panel reactive antibody,donor-specific antibody"
9615532|NCT02544555|Active Comparator|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
9615533|NCT02544724|Experimental|NM-IL-12|NM-IL-12 will be administered subcutaneously
9804207|NCT01735877|Experimental|Mirror therapy|All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
9530507|NCT03192943|Experimental|Dose Escalation|monotherapy and combination therapy
9530508|NCT03193034|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty.
9530509|NCT03193112||Study group|The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
9530510|NCT03193099|Other|Premanifest HTT mutation carriers|
9530511|NCT03193099|Other|non HTT mutation carriers|
9530512|NCT03192969|Experimental|Abatacept Combination Therapy|Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
9530513|NCT03192969|Placebo Comparator|Placebo Monotherapy- 28 Weeks|Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
9530514|NCT03192969|Placebo Comparator|Placebo Monotherapy- 52 Weeks|Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
9530515|NCT03192865||diaphragmatic paralysis/paresis group|"Diaphragmatic paralysis can be associated with regional anesthesia procedure in arthroscopic shoulder surgery as phrenic nerve is close to the brachial plexus.~Diaphragmatic paralysis will be defined using ultrasounds."
9530516|NCT03192865||No diaphragmatic paralysis/paresis group|Some strategies of peripheral nerve block are able to spare diaphragmatic paralysis.
9530517|NCT03192813||Symetis ACURATE neo™ transfemoral TAVI system|Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.
9530518|NCT03192813||Medtronic CoreValve Evolut R TAVI System|Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.
9530519|NCT03192592|Experimental|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
9530520|NCT03192566|Experimental|Tylenol Dosing|"Dosing of Tylenol for postoperative pain relief will include:~children < 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children > or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours)."
9530521|NCT03192631|Experimental|with financial incentive|Patients randomized to this arm will start with receiving the financial incentive. Cross-over after 9 months to treatment as usual.
9530522|NCT03192631|No Intervention|treatment as usual|Patients randomized to this arm will start with receiving treatment as usual, cross-over after 9 months to incentive arm.
9530523|NCT03192618|Experimental|treatment group|
9530524|NCT03192618|No Intervention|control group|
9530525|NCT03192514|Experimental|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
9530526|NCT03192514|No Intervention|Usual Care|Usual care By GP´s
9530527|NCT03192423||Expert|The physicians in the Expert-group will perform a LP following local standard procedure protocol.
9530528|NCT03192423||Intermediate|The physicians in the Intermediate-group will perform a LP following local standard procedure protocol.
9530529|NCT03192423||Novice|The physicians in the novice-group will perform a LP following local standard procedure protocol.
9530530|NCT03192722|Experimental|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
9530531|NCT03192722|Other|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
9530532|NCT03192722|Other|Immediate exposure to LuxIQ/2|Participants are examined with LuxIQ/2 to determine preferred lighting as determined by device followed by examination with OttLite Cobra
9530533|NCT03192722|Other|Immediate exposure to OttLite Cobra|Participants are examined with OttLite Cobra to determine preferred lighting followed by LuxIQ/2
9530534|NCT03192501||Study group (A group)|In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
9530535|NCT03192501||Control group (B group)|In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
9530536|NCT03192761|Active Comparator|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
9530537|NCT03192761|Active Comparator|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
9530538|NCT03192761|Active Comparator|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
9530539|NCT03192553|Experimental|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
9530540|NCT03192553|Experimental|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
9530541|NCT03192553|Experimental|One-Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
9530542|NCT03192553|Other|CDC Procedure (Control)|Participants will doff PPE following the CDC procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
9530543|NCT03192605|Experimental|Blueberry|150 grams wild blueberries
9530544|NCT03192605|Placebo Comparator|Placebo|Placebo control
9530545|NCT03192579|Experimental|Standard lipid lowering therapy|Start with only rosuvastatin 2.5mg and up to 20mg/day
9530546|NCT03192579|Active Comparator|Intensive lipid lowering therapy|Start EPA and rosuvastatin 10mg/day and up to 20mg/day
9804208|NCT01735877|Sham Comparator|Control group|Group 2 will be given sham mirror therapy
9530547|NCT03192657|Experimental|Basiliximab group|"Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.~Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
9530548|NCT03192657|Active Comparator|control group|"Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
9530549|NCT03192644|Experimental|Group A (TAI)|
9530550|NCT03192644|Active Comparator|Group B (TACE)|
10037823|NCT01828632|No Intervention|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
10037824|NCT01828645|No Intervention|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
10037825|NCT01828645|Experimental|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
10037826|NCT01828658|No Intervention|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
10037827|NCT01828658|Active Comparator|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
10037828|NCT01828671|Active Comparator|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
9530551|NCT03192683|Active Comparator|Regular sling|
9530552|NCT03192683|Experimental|Cast-sling|
9530553|NCT03192527|Experimental|Arm A|KN015, Triptorelin
10037829|NCT01828671|Active Comparator|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
9530554|NCT03192527|Placebo Comparator|Arm B|placebo, Triptorelin
9530555|NCT03192696|Experimental|Treatment Cohort|Atherectomy of in-stent restenosis
9530556|NCT03192709|Experimental|A|Sildenafil vaginal suppositories users
9530557|NCT03192709|Placebo Comparator|B|Daily vaginal placebo users with HMG administration
9530558|NCT03192709|Placebo Comparator|C|Daily vaginal placebo users with HMG administration day until the day of oocyte retrieval.
9530559|NCT03192670|Sham Comparator|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
9530560|NCT03192670|Experimental|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
9530561|NCT03192670|Experimental|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
9530562|NCT03192670|Experimental|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
9530563|NCT03192449|Experimental|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
9530564|NCT03192735|Experimental|Apatinib Combined With SOX|In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
10058283|NCT02017132|Placebo Comparator|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
9530565|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
9530566|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
9530567|NCT03192202|Experimental|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
9530568|NCT03192202|Experimental|Cohort 2|1.5 mg/kg of AFM13 three times per week for weeks 1-8.
9530569|NCT03192202|Experimental|Cohort 3|0.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
9530570|NCT03192202|Experimental|Cohort 4|1.5 mg/kg in of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
9530571|NCT03192202|Experimental|Cohort 5|7.0 mg/kg of AFM13 once weekly for weeks 1-8.
9530572|NCT03192202|Experimental|Cohort 6|4.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
9530573|NCT03192371|Experimental|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
9530574|NCT03192371|Experimental|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
9530575|NCT03192111|Experimental|Mild Renal Impairment|Subjects with mild renal impairment
9530576|NCT03192111|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment
10037830|NCT01828671|Active Comparator|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
9530577|NCT03192111|Experimental|Severe Renal Impairment|Subjects with severe renal impairment
9530578|NCT03192111|Experimental|Healthy Subjects|Healthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
9530579|NCT03192085|Other|SITA FAST then SITA STANDARD|SITA FAST and SITA STANDARD
9530580|NCT03192085|Active Comparator|SITA STANDARD then SITA FAST|SITA FAST and SITA STANDARD
9530581|NCT03192280|Experimental|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.~Images of the treated area will be captured using multiple medical devices."
9530582|NCT03193164|Experimental|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
9530583|NCT03193164|Sham Comparator|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
9530584|NCT03192319|Experimental|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
9530585|NCT03192319|Active Comparator|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
9530586|NCT03192319|Active Comparator|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
9530587|NCT03192319|Active Comparator|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
9530588|NCT03192163||ResearchMatch Group|
9530589|NCT03192163||Northwestern Center for Ethnic Skin Group|
9530590|NCT03192293|Experimental|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:~Metformin: 850mg (one tablet) twice a day~Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
9530591|NCT03192332|Experimental|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
9530592|NCT03192332|Active Comparator|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
9530593|NCT03192254|Active Comparator|Self-Monitoring Control|Daily tracking of fruit and vegetable consumption
9530594|NCT03192254|Experimental|Daily Incentives|Incentives for fruit and vegetable consumption delivered daily
9530595|NCT03192254|Experimental|Delayed Lump Sum Incentives|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
9530596|NCT03192072||Subjects with Acute Respiratory Illness|Patients with acute respiratory illness identified in the Emergency Department
9530597|NCT03192267||No treatment|No treatment
9530598|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
9530599|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
9530600|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
9530601|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
9530602|NCT03192059|Experimental|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
9530603|NCT03191994|Experimental|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
9530604|NCT03191994|No Intervention|MDD control group|This group will receive usual care with no exercise
9530605|NCT03191994|Experimental|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
9530606|NCT03191994|No Intervention|Healthy control|This group will not perform exercise
9530607|NCT03192020|Active Comparator|Percutaneous needle fasciotomy|
9530608|NCT03192020|Active Comparator|Collagenase clostridium histolyticum|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times.
9530609|NCT03192020|Active Comparator|Limited fasciectomy|
9530610|NCT03192033|Other|Arterial closure device used is Proglide® (Abbott)|
9530611|NCT03192033|Other|Arterial closure device used is Femoseal® (Terumo)|
9530612|NCT03192241|Experimental|Pump|Mothers provided with a manual breast pump
9530613|NCT03192241|Active Comparator|book|Mothers provided with a children's book
10037831|NCT01828671|Active Comparator|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
10058284|NCT02017145|No Intervention|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
9530614|NCT03192098|Experimental|Progressive|Patients will be dilated > 3mm and can be dilated up to 6mm in diameter
9530615|NCT03192098|Active Comparator|Conservative (rule-of-3)|Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)
9530616|NCT03191929|Experimental|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
9530617|NCT03191929|Active Comparator|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
9530618|NCT03191955||Cancer|Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery
9530619|NCT03191955||Non-cancer|Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions
9530620|NCT03191981|Experimental|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
9530621|NCT03191903|Experimental|Cingal|Cingal is a combination product consisting of 88 milligrams of cross-linked HA (hyaluronic acid) with 18 milligrams of TH (triamcinolone hexacetonide) in a 4 milliliter (mL) intra-articular injection.
9530622|NCT03191903|Active Comparator|Monovisc|Monovisc is a device that consists of 88 milligrams of cross-linked HA (hyaluronic acid) in a 4 milliliter (mL) intra-articular injection.
9530623|NCT03191903|Active Comparator|Triamcinolone Hexacetonide (TH)|Triamcinolone hexacetonide (TH) is a corticosteroid supplied in a 20 milligram per 1 milliliter (20 mg/mL) intra-articular injection.
9530624|NCT03191851|Active Comparator|Standard Device|Standard device
9530625|NCT03191851|Experimental|Melody Device|Melody device without Pump
9530626|NCT03191851|Experimental|Melody Device with pump|Melody Catheter device with Andromeda Pump
9530627|NCT03191877|Experimental|COFFEE|they will start to drink coffee 6 hours postoperative for maximum 3 doses (100ml), 8 hours apart, diet will start after 1st audible bowel sound.
9530628|NCT03191877|Active Comparator|oral fluid|"they will drink plain fluid (water) 6 hours postoperative. Diet will start after 1st audible bowel sound.~Women in this group will not receive either coffee."
9530629|NCT03191877|No Intervention|control|the control group and they will be NPO for 24 hours on IV fluid (3 LITRES/24 HOURS). Diet will start after 1st audible bowel sound
9530630|NCT03191825|Active Comparator|Standard web-application|Endre: a digital smoking cessation counsellor
9530631|NCT03191825|Experimental|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
9530632|NCT03191825|Experimental|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
9530633|NCT03191942|Experimental|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
9530634|NCT03191942|Active Comparator|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
9530635|NCT03191968|Experimental|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
9530636|NCT03191968|Active Comparator|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
9530637|NCT03191838|Experimental|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
9530638|NCT03191838|No Intervention|Controls|The control group will not be given distraction equipment.
9530639|NCT03191773|Experimental|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
9615534|NCT02544542|Experimental|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
9615535|NCT02544542|Active Comparator|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
9804209|NCT01735916|Active Comparator|CRT-P ON|CRT-P Implant CRT-P ON
9804210|NCT01735916|Placebo Comparator|CRT-P OFF|CRT-P Implant CRT-P OFF
9530640|NCT03191760|Experimental|Behavioral Activation and Social Engagement|Participants will attend 6 in-person therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
9530641|NCT03191422|Experimental|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
9530642|NCT03191448|Experimental|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
9530643|NCT03191734|Experimental|AQUABEAM System|AQUABEAM System
9530644|NCT03191435|Experimental|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
9530645|NCT03191435|Placebo Comparator|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
9530646|NCT03191591|Experimental|First 1,000 Days Program|
9530647|NCT03191721|Experimental|Test: Triclosan toothpaste|"To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
9530648|NCT03191721|Placebo Comparator|Control: Fluoride toothpaste|"To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
9530649|NCT03191682|Experimental|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
9530650|NCT03191474|No Intervention|Standard of Care Arm|Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.
9530651|NCT03191474|Experimental|T-POWr Intervention Arm|Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.
9530652|NCT03191539|Experimental|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
9530653|NCT03191409||Control Group|Health adults with no evidence of brain lesions on conventional magnetic resonance imaging(MRI) and no neural developmental disorders.
9530654|NCT03191409||Patients Group|ESRD patients pre-hemodialysis will be collected.The following exclusion criteria were applied in this study: (a)history of drug or alcohol abuse, (b) brain lesions such as a tumor or stroke assessed on the basis of medical history, (c) history of or current psychiatric disorders, and (d) head motion more than 1.0 mm or 1.0°during magnetic resonance imaging. All patients completed laboratory tests to evaluate renal function,serum creatinine, and urea levels within the 12 hours before magnetic resonance imaging.
9530655|NCT03191500|Experimental|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
9530656|NCT03191513|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
9530657|NCT03191513|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
9530658|NCT03191513|Active Comparator|Control|Rapeseed oil. 50g fat.
9530659|NCT03191643||differentiated thyroid cancer|Patients with locally recurrent thyroid cancer, treated with radical radiotherapy after total thyroidectomy +/- central compartment and/or laterocervical lymphadenectomy, previously treated with one or more cycles of 131 Iodine-ablation (RAI) and TSH suppression.
9530660|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
9530661|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
9530662|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
9530663|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
9530664|NCT03191617|Experimental|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
9530665|NCT03191617|Active Comparator|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
9530666|NCT03191487|Experimental|ChimioPal|Systematic collection of clinical and laboratory toxicities.
9530667|NCT03191487|Active Comparator|Standard|The usual management and logistic pathways will be respected.
9530668|NCT03191383|Experimental|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
9530669|NCT03191383|Experimental|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
9530670|NCT03191383|Experimental|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
9530671|NCT03191383|Placebo Comparator|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
9530672|NCT03191383|No Intervention|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
9530673|NCT03191383|No Intervention|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
9530674|NCT03191383|No Intervention|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
9530675|NCT03191383|No Intervention|Control infant Group|Infants born to mothers who received a single placebo injection
9530676|NCT03191565|Experimental|App-Condition|In this condition the intervention is that participants enter their skills-use and mood on a smartphone. They can follow their progress on graphs on the smartphone, get reminders to train skills, get psychoeducation about what the different emotion regulation coping skills can do, and how to do the skills. therapists can watch patient progress online, and review skill use together with the patients while in psychotherapy. The intervention is using a smartphone as an adjunct to the treatment.
9530677|NCT03191565|Active Comparator|Paperdiary-condition|Patients are, weekly, given a paper diary sheet to fill out on a daily basis at home No prompting, no accumulative overview of progress. Patients are supposed to bring this paper to the weekly therapysession
9530678|NCT03191370|Active Comparator|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
9530679|NCT03191370|Experimental|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
9530680|NCT03191370|No Intervention|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
9530681|NCT03191370|Experimental|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
9530682|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.~no intervention/Observational"
9530683|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.~no intervention/Observational"
9530684|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.~no intervention/Observational"
9530685|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).~no intervention/Observational"
9530686|NCT03191071|Experimental|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
9530687|NCT03191071|Experimental|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
9530688|NCT03191071|Active Comparator|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
9615536|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
9804211|NCT01735981|Experimental|video game exercise|Video game exercise using Dance Dance Revolution
9804212|NCT01735981|Other|control|hand-held video game control
9530689|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
9530690|NCT03191162|Active Comparator|B300/60|Benznidazole 300mg/day p.o. divided in two doses for 60 days
9530691|NCT03191162|Experimental|B150/60|Benznidazole 150mg/day p.o. divided in two doses for 60 days
9530692|NCT03191162|Experimental|B400/15|Benznidazole 400mg/day p.o. divided in two doses for 15 days
9530693|NCT03191110||Colorectal cancer patients|
9530694|NCT03191331|Experimental|Intervention group|Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
9530695|NCT03191331|No Intervention|Control group|The control group will receive written material on healthy diet during pregnancy, otherwise basic care and guidance at maternity care clinics.
9530696|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
9530697|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
10058285|NCT02017145|Experimental|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
9530698|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
9530699|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
9530700|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
9530701|NCT03191175||HIV patients|
9530702|NCT03191175||Control patients|
9530703|NCT03191305|Active Comparator|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
9530704|NCT03191305|Active Comparator|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
9530705|NCT03191214||No Warming|Patients undergoing brief surgical procedures of >15 minutes for whom no warming devices are being employed.
9530706|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
9530707|NCT03190980|Experimental|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
9530708|NCT03190980|Experimental|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
9530709|NCT03190980|Placebo Comparator|Placebo|neonates will receive 2 ml of sterile water before heel prick
9530710|NCT03191318|Active Comparator|ERAS pathway|Laparoscopic sleeve gastrectomy with ERAS pathway
9530711|NCT03191318|Active Comparator|Standard pathway|Laparoscopic sleeve gastrectomy with standard pathway
9530712|NCT03191123|Active Comparator|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
9530713|NCT03191123|Experimental|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
9530714|NCT03191201|Active Comparator|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
9530715|NCT03191201|Placebo Comparator|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
9530716|NCT03190850|Experimental|Intervention|"Intervention: Exercises wih load Device: Powerbreathe"
9530717|NCT03190850|Placebo Comparator|Control|Control: Exercises without load
9530718|NCT03191097|Experimental|Ingavirin|
9530719|NCT03191097|Placebo Comparator|Placebo oral capsule|
9530720|NCT03191188|Experimental|Levothyroxine|
9530721|NCT03191188|Placebo Comparator|Placebo|
9530722|NCT03191032|Experimental|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
9530723|NCT03191032|No Intervention|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
9530724|NCT03191006|Active Comparator|study group: MEI BIN insoles|Participants in the study group will be prescribed with a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
9530725|NCT03191006|No Intervention|control group: without MEI BIN insoles|Participants in this control group will not receive a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
9530726|NCT03190928||1|Patients with grades 1-2 or 3a follicular lymphoma (FL)
9530727|NCT03190863|Experimental|Motor imagery combined with neurofeedback (MINF)|
9530728|NCT03190863|Active Comparator|Motor imagery (MI)|
9530729|NCT03190863|Sham Comparator|Control (C)|
9530730|NCT03190902|Experimental|specific computer training (ST) - POMS|
9530731|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - POMS|
9530732|NCT03190902|Experimental|specific computer training (ST) - ADHD|
9530733|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - ADHD|
9530734|NCT03191136|Experimental|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
9530735|NCT03191136|Experimental|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
9530736|NCT03190876|No Intervention|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
10037832|NCT01828671|Active Comparator|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
10037833|NCT01828684|Experimental|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
9530737|NCT03190876|Active Comparator|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
9530738|NCT03190876|Active Comparator|No drain|Conventional body contouring procedure, no application of drains
9530739|NCT03190889|No Intervention|STAN|Patients in the STAN group will participate in twelve sessions of supervised physical therapy over a six week period. Patients will participate in agility and plyometric drills, and continue strength exercises from the previous treatment phase. The clinic program will be performed in conjunction with a home running program. Patients in this group will not receive feedback from the therapist regarding movement quality during activities.
9530740|NCT03190889|Other|HOME|HOME Program is distinguished by patients participating in a home only intervention that consists of running and strengthening exercises performed twice a week for six weeks. No plyometric or agility drills are performed in this study arm. This represents the minimal intervention to prepare for a return to sports. No neuromuscular training or movement training beyond the sagittal plane will be performed.
9530741|NCT03190889|Experimental|TNMT|Patients who are enrolled in the TNMT group will participate in 12 sessions of supervised outpatient physical therapy over a six week period. The TNMT protocol is distinguished by performance of exercises designed to enhance core and hip strength, performance of neuromuscular training exercise that are designed to correct movement flaws associated with second ACL injury25, providing verbal and visual feedback and performance of single leg drills on both legs.
9530742|NCT03190746||No SNP|Subjects have two copies of the wild type gene
9530743|NCT03190746||SNP present|Subjects have one or two copies of the SNP
9530744|NCT03190720|Experimental|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
9530745|NCT03190720|Experimental|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
9530746|NCT03190798|Active Comparator|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
9530747|NCT03190798|Placebo Comparator|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
9530748|NCT03190681|Experimental|methylphenidate|
9530749|NCT03190681|Placebo Comparator|inactive pill|
9530750|NCT03190707|Experimental|Intervention|The intervention consists of three key components aiming at promoting a better attachment between child and mother/parents and through that giving the child the best possible beginning of life. The three components aim at: 1) detecting ill-being in vulnerable pregnant woman and initiation of potential treatment, 2) strengthening knowledge sharing and organizing the course for the families across the sectors, 3) strengthening parenting skills.
9530751|NCT03190707|No Intervention|Control|The existing practice for psychosocial vulnerable pregnant women on Gentofte-Herlev Hospital, Denmark, will be offered for women allocated to the control group. The control group will be measured at the same follow-up periods as the intervention group.
9530752|NCT03190811|Experimental|Anti-PD-1 plus DC-CIK|
9530753|NCT03190811|Active Comparator|Anti-PD-1 alone|
9530754|NCT03190772|Experimental|Positive placebo group|Participants receive a placebo nasal spray. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
9530755|NCT03190772|Placebo Comparator|Placebo control group|Participants receive a placebo nasal spray and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
9530756|NCT03190772|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
9530757|NCT03190733|Experimental|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
9530758|NCT03190733|Active Comparator|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
10037834|NCT01828684|Sham Comparator|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
9530759|NCT03190785|Experimental|Benzoic acid washout and exposure|All subjects will be in this arm which employs a pre-post exposure design. Subjects will undergo a 2 week washout period where they avoid consumption of benzoate containing beverages. Then there is a 1 week exposure period comprising daily consumption of benzoate containing beverages to result in up to 5 mg/kg per day benzoic acid intake.
9530760|NCT03190824|Experimental|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
9530761|NCT03190694|Experimental|Dapagliflozin 10mg Tablet|10 mg Green, plain, diamond shaped, film coated tablet (orally)
9530762|NCT03190694|Placebo Comparator|Placebo Matching Dapagliflozin Tablet|Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient
9530763|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
9530764|NCT03190395|Experimental|CPVI Group|CPVI Group: Pure Circumferential pulmonary vein isolation(CPVI)
9530765|NCT03190395|Active Comparator|CPVI+LARA Group|CPVI+LARA Group: Circumferential pulmonary vein isolation combine with Left Atrium Roofline Ablation
9804213|NCT01735994|Experimental|Healthy Weight Intervention|Eating Disorder Prevention Program
10037835|NCT01828697|Active Comparator|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:~Fixed low dose nadroparin, or;~Fixed low dose enoxaparin, or;~Fixed low dose dalteparin, or;~Fixed low dose tinzaparin."
10037836|NCT01828697|Active Comparator|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.~Intermediate dose nadroparin, or;~Intermediate dose enoxaparin, or;~Intermediate dose dalteparin, or;~Intermediate dose tinzaparin."
9530766|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
9530767|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
9530768|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
9530769|NCT03190408||Shock|
9530770|NCT03190603|Experimental|Celecoxib arm|Axial Spondyloarthritis patients who takes celecoxib 400mg for day
9530771|NCT03190421|Experimental|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
9530772|NCT03190421|Active Comparator|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
9530773|NCT03190512|Active Comparator|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
9530774|NCT03190512|Placebo Comparator|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.~Intervention: The Psychological questionnaires were filled."
9530775|NCT03190577|Experimental|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
9530776|NCT03190642|Active Comparator|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
9530777|NCT03190642|Active Comparator|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
9530778|NCT03190616|Experimental|drug,apatinib|apatinib 500mg/qd, 28d/cycle
9530779|NCT03190551|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
9530780|NCT03190551|Active Comparator|costoclavicular approach|Patients in this group will be randomized to receive an costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
9530781|NCT03190629|Active Comparator|High-flux hemodialysis|3 times per week
9530782|NCT03190629|Experimental|On line-hemodiafiltration|3 times per week
9530783|NCT03190486|Experimental|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
9530784|NCT03190486|Experimental|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
10037837|NCT01828710|Sham Comparator|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
10037838|NCT01828710|Active Comparator|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
10037839|NCT01828710|Placebo Comparator|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
10037840|NCT01828723|Experimental|SVF-Enriched Lipoinjection|
10037841|NCT01828736|Active Comparator|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
10037842|NCT01828736|Experimental|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
9530785|NCT03190486|Experimental|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
9530786|NCT03190486|Experimental|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
9530787|NCT03190668|Active Comparator|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
9530788|NCT03190668|Active Comparator|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
9530789|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
9530790|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
9530791|NCT03190317||Providers and staff of HIV-infected veteran|This groups represents the population of providers and staff who utilize the MHV portal to deliver care for HIV-infected veterans.
9530792|NCT03190473|Experimental|Svelte|
9530793|NCT03190473|Active Comparator|Control|
9530794|NCT03190655|Experimental|Aluminaid|Treatment group: Aluminaid wound dressing
9530795|NCT03190655|Active Comparator|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
9530796|NCT03190447|Active Comparator|Conventional dressing|The conventional dressing (sterile gauzes) will be applied
9530797|NCT03190447|Experimental|Aquacel Surgical®|Postoperative sterile dressing composed by non-woven inner pad (in contact with wound) Technology Hydrofiber® formed from sodium carboxymethylcellulose
9804214|NCT01735994|Other|Brochure wait list|Brochure wait list control group
9530798|NCT03190447|Experimental|Mepilex Border post-op®|Flexible absorbent all-in-one post-op dressing, super-absorbent fibres for high and fast absorption with optimised retention.
9530799|NCT03190447|Experimental|Opsite post-op visible®|Adhesive dressing with absorbent foam in the form of a grid to visualize the wound without lifting the dressing
9530800|NCT03190447|Experimental|Urgotul ABSORB border silicona®|A soft-adherent TLC (Technology Lipido-Colloid) layer (polymers and hydrocolloid particles) combined with an absorbent polyurethane foam pad and a highly absorbent layer. A vapour permeable waterproof outer film with silicone adhesive on the edges.
9530801|NCT03190525||Multiple Myeloma patients|
9530802|NCT03190304|Active Comparator|Enalapril|Enalapril at a dose of 10 mg twice daily for 6 months
9530803|NCT03190304|Experimental|Neprilysin (LCZ696)|LCZ696 at a dose of 200 mg twice daily for 6 months
9530804|NCT03190278|Experimental|Part 1: Dose Escalation|"Several tested doses of UCART123v1.2 with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART123v1.2 administered at the selected dose determined from the dose escalation phase"
9530805|NCT03190148|Other|Pregnant women with RYGB-operation|Pregnant women with a history of RYGB-Operation were investigated.
9530806|NCT03190148|Other|Normal weight pregnant women|Normal weight pregnant women were investigated.
9530807|NCT03190148|Other|Obese Pregnant women|Obese pregnant women were investigated.
9530808|NCT03189992|Experimental|CC-GSYXZ|Colon cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection
9530809|NCT03189992|Placebo Comparator|CC-WZ|Colon cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
9530810|NCT03189992|Experimental|HCC-GSYXZ|Hepatoma cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection.
9530811|NCT03189992|Placebo Comparator|HCC-WZ|Hepatoma cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
9530812|NCT03189979|Experimental|Club Fit|Intervention includes exposure to physical activity and healthy eating intervention policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
9530813|NCT03190187|Active Comparator|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
9530814|NCT03190187|Sham Comparator|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
9530815|NCT03189940|Active Comparator|App user group|
9530816|NCT03189940|Sham Comparator|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
9530817|NCT03189966|Experimental|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(0.8 ml/kg) after general anesthesia
9530818|NCT03189966|Experimental|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(0.8 ml/kg).after general anesthesia.
9530819|NCT03189966|No Intervention|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
9530820|NCT03189953|Experimental|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
9530821|NCT03190057||Consecutive percutaneous coronary intervention|
9530822|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
9530823|NCT03190018|Experimental|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
9530824|NCT03190070|Experimental|Study group|All study participants are in the same group and will have their kidney function measured twice, before and after ingestion of protein, 1 g/(kg body weight). The protein will be given in the form of the protein drink Liquacel (Global Health Products, Rochester, NY).
9530825|NCT03190239|Experimental|Apatinib|Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd
9530826|NCT03190135|Experimental|BOKS: 2 day per week|
9530827|NCT03190135|Experimental|BOKS: 3 day per week|
9530828|NCT03190135|No Intervention|Non-BOKS|
9530829|NCT03190031|Experimental|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
9530830|NCT03190031|Active Comparator|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
9530831|NCT03190044|Experimental|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
9530832|NCT03190044|Placebo Comparator|Migranineurs (placebo)|One pill per day of placebo: Cellulose
9530833|NCT03190122|Active Comparator|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
9530834|NCT03190122|Experimental|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
9530835|NCT03189914|Experimental|RX-3117 + Abraxane|"RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle.~Abraxane: 75 - 125 mg/m^2, infused once per week for 3 weeks. 1 washout week/ cycle."
9530836|NCT03189836|Experimental|ACTR707 in combination with rituximab|
9804215|NCT01736085|No Intervention|Material Group|Subjects will receive self-help materials
10037843|NCT01828762|Experimental|DC-TC+GM-CSF|
9530837|NCT03189810|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
9530838|NCT03189810|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
9530839|NCT03189888|Other|apheresis|leukapheresis in ulcerative colitis
9530840|NCT03190226|Experimental|L-PRF membranes|"Intra-oral split thickness preparation - apically repositioned to the periosteum.~L-PRF membranes will be used to cover the site. Free Gingival Grafts will be used to cover the site."
9530841|NCT03189797|Experimental|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:~In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions."
9530842|NCT03189797|No Intervention|control group|In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
9530843|NCT03189784|Experimental|mobilization group|this group will receive mobilization with movement techniques.
9530844|NCT03189784|No Intervention|Control group|The control group will receive no intervention
9530845|NCT03189771|Experimental|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
9530846|NCT03189771|Placebo Comparator|no occlusal surface reduction|No occlusal surface reduction after single visit root canal treatment
9530847|NCT03189927|Experimental|BD-Covered stent|Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae
9530848|NCT03189901|No Intervention|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
9530849|NCT03189901|Experimental|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
9530850|NCT03190161|Experimental|Schizophrenia Patients|Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
9530851|NCT03189615|Experimental|Patients with mild hepatic impairment (Group1)|
9530852|NCT03189615|Experimental|Patients with moderate hepatic impairment (Group 2)|
9530853|NCT03189615|Experimental|Healthy subjects (Group 3)|
9530854|NCT03189576|Other|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
9530855|NCT03189628|Experimental|stromal vascular fraction|Transplantation of resuspended SVF
9530856|NCT03189628|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
9530857|NCT03189563|Placebo Comparator|Placebo|placebo, tid
9530858|NCT03189563|Experimental|DA-9805 low|DA-9805 45mg
9530859|NCT03189563|Experimental|DA-9805 high|DA-9805 90mg
9615537|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
9615538|NCT02544594|Active Comparator|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
9615539|NCT02544594|No Intervention|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
9615540|NCT02544516|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
9615541|NCT02544516|Active Comparator|control group|healthy patients who will perform cognitive tasks
9615542|NCT02544529|Experimental|Echothiophate Iodide|Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
9615543|NCT02544529|Placebo Comparator|Carboxymethylcellulose Sodium (0.5%)|Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
9615544|NCT02544568|Experimental|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
9615545|NCT02544568|Experimental|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
9615546|NCT02544568|Experimental|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
9615547|NCT02544568|Experimental|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
9615548|NCT02544438|Experimental|Astarabine|Astarabine
9615549|NCT02544464|Experimental|Experimental group|ferric carboxymaltose 1000 mg
9615550|NCT02544464|Placebo Comparator|Control group|placebo
9615551|NCT02544425|Experimental|VIDL+ASCT|"VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase~Peripheral blood stem cell mobilization:Etoposide~Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
10037844|NCT01828775|Experimental|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
10037845|NCT01828775|Experimental|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
10037846|NCT01828788|Experimental|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
9530860|NCT03189667|Experimental|Drug coated balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with Drug-coated balloon"
9530861|NCT03189667|Active Comparator|Plain balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with additional Plain balloon angioplasty:"
9530862|NCT03189498|Experimental|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter per minute [mL/min]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
9530863|NCT03189498|Experimental|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR >=60 to less than [<] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
9530864|NCT03189498|Experimental|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR >=30 to <60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
9530865|NCT03189498|Experimental|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR >= 15 to <30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
9530866|NCT03189498|Experimental|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR <15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
9530867|NCT03189680|Experimental|Exercise therapy|Parkinson's disease group that receive 3 weeks of intensive exercise therapy in a rehabilitation center.
9530868|NCT03189680|No Intervention|Control|Parkinson's disease control group that will not receive exercise treatment.
9530869|NCT03189680|No Intervention|Healthy|A healthy group whose results will be compared with Parkinson's disease groups.
9530870|NCT03189459|Active Comparator|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~Completion of Home Visit Program intervention."
9530871|NCT03189459|Active Comparator|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
9530872|NCT03189459|No Intervention|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
9530873|NCT03189459|Active Comparator|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.~Completion of Caregiver Mentorship Program intervention."
9530874|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
9530875|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
10058286|NCT02017158|Experimental|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
9530876|NCT03189472|Experimental|active tDCS|
9530877|NCT03189472|Sham Comparator|sham tDCS|
9530878|NCT03189511|Experimental|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
9530879|NCT03189485||Normal Controls and MCI|All subjects will receive 18F-AV-1451 PET scan.
9530880|NCT03189537|Experimental|Ingavirin|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
9530881|NCT03189537|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 7 days
9530882|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
9530883|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
9481080|NCT05020015|Experimental|Part 1: Dose Expansion: iNHL: TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Indolent Non-Hodgkin Lymphoma (iNHL) will receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells, single-dose, intravenously, once on Day 0 to determine RP2D.
9481081|NCT05020015|Experimental|Part 2: Cohort 1- LBCL|Participants with LBCL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 at RP2D, intravenously, once on Day 0.
9481082|NCT05020015|Experimental|Part 2: Cohort 2- iNHL|Participants with iNHL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously followed by TAK-007 at RP2D, intravenously, once on Day 0.
9481083|NCT05016258||KONTACT MB|Adult patients needed one or multiple implant-supported fixed restoration(s)
9481084|NCT05013983|Experimental|Low-dose vaccine (6-11 years)|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
9481085|NCT05013983|Experimental|Medium-dose vaccine (6-11 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
9481086|NCT05013983|Experimental|Medium-dose vaccine (12-17 years)|three doses of medium-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
9481087|NCT05013983|Experimental|High-dose vaccine (12-17 years)|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21，42.
9481088|NCT05013983|Placebo Comparator|Low-dose placebo (6-11 years)|three doses of low-dose placebo at the schedule of day 0, 21，42.
9481089|NCT05013983|Placebo Comparator|Medium-dose placebo (6-11 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
9481090|NCT05013983|Placebo Comparator|Medium-dose placebo (12-17 years)|three doses of medium-dose placebo at the schedule of day 0, 21，42.
9481091|NCT05013983|Placebo Comparator|High-dose placebo (12-17 years)|three doses of high-dose placebo at the schedule of day 0, 21，42.
9481092|NCT05013307|Experimental|CASE|In this prospective study the investigators aim to quantify participants' responses to physical activity and cognitive testing. Participants will be asked to undergo cognitive testing prior to engaging in physical activity, to identify any provocation of symptoms in adolescents ranging from ages 10 to 22 years. Responses to physical activity will be measured through metabolic testing (heart rate reserve and relative VO2 max) and physiologic markers (e.g., blood pressure, heart rate, oxygen saturation, rate of perceived exertion, dyspnea). Additionally, participants will be monitored for any changes in symptoms that occur during or after physical activity as measured by the modified PCSS symptom inventory.
9481093|NCT05005078|Placebo Comparator|Placebo|WST-057 Matching placebo
9481094|NCT05005078|Experimental|WST-057 active|WST-057 topical solution
9804216|NCT01736085|Active Comparator|Materials plus Voucher|Subjects will receive self-help materials and a voucher for 2 week's worth of nicotine patches
9481095|NCT05003362|No Intervention|usual care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician.
9481096|NCT05003362|Active Comparator|ACT|An 8-week mindfulness-based group therapy.
9481097|NCT05002946|Experimental|A: SP-104 Fasting|Oral administration of SP-104 under fasting conditions
9481098|NCT05002946|Experimental|B: SP-104 Under Fed Conditions|Oral administration of SP-104 under fed conditions
9481099|NCT05002946|Active Comparator|Naltrexone Hydrochloride Tablets Fasting|Oral administration of Naltrexone Hydrochloride Tablets, 50 mg USP under fasting
9481100|NCT05001516|Experimental|LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 0.2mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=1;"
9481101|NCT05001516|Experimental|LM302 Dose Escalation Level 2, 0.4 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 0.4mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=3;"
9481102|NCT05001516|Experimental|LM302 Dose Escalation Level 3, 0.8 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 0.8mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
9481103|NCT05001516|Experimental|LM302 Dose Escalation Level 4, 1.6mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
9481104|NCT05001516|Experimental|LM302 Dose Escalation Level 5, 2.4mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=9;"
9481105|NCT05001516|Experimental|LM302 Dose Escalation Level 6, 2.8mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=12;"
9481106|NCT04997109|Experimental|APPLES-tele first, then PCA|Participants receiving the APPLES-tele intervention for 6 weeks followed by the PCA intervention for 6 weeks.
9481107|NCT04997109|Experimental|PCA first, then APPLES-tele|Participants receiving the PCA intervention for 6 weeks followed by the APPLES-tele intervention for 6 weeks.
9481108|NCT04997109|Active Comparator|Standard of Care Control Arm|Participants receiving the standard of care for 6 weeks.
9481109|NCT04996030|Experimental|Single-Dose PK Module: Sequence 1|Participants will receive ATO as IV infusion in fasted state on Day 1, SY-2101 administered orally in fed state on Day 8, and SY-2101 administered orally in fasted state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle
9481110|NCT04996030|Experimental|Single-Dose PK Module: Sequence 2|Participants will receive ATO as IV infusion in fasted state on Day 1, SY-2101 administered orally in fasted state on Day 8, and SY-2101 administered orally in fed state on Day 15 during Weeks 6, 7, and 8 of any consolidation cycle being received as part of SOC treatment consolidation cycle.
9481111|NCT04996030|Experimental|Multiple-Dose IV Module|Participants will receive IV infusion of ATO, once daily (QD), 5 days/week for 28 days as a part of at least 1 cycle (Weeks 1 through 4) of SOC treatment consolidation.
9530884|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
9530885|NCT03189407|Other|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
9530886|NCT03189758|Experimental|Intervention|Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
9530887|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
9530888|NCT03189654||Control group|Oxygen Administration via nasal tube
9530889|NCT03189732|Experimental|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
9530890|NCT03189732|Active Comparator|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
9530891|NCT03189732|Active Comparator|No metformin + exercise|60min physical exercise without pretreatment of metformin
9530892|NCT03189394|Experimental|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
9530893|NCT03189394|Experimental|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
9530894|NCT03189394|Active Comparator|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
9530895|NCT03189043|Experimental|Test|Use of antimicrobial surface
9530896|NCT03189043|No Intervention|Control|No antimicrobial surface
9530897|NCT03189355|Experimental|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
9530898|NCT03189056||Single cohort|"single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography~If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure."
9530899|NCT03189017|Experimental|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
9530900|NCT03189017|Placebo Comparator|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
9530901|NCT03189238|Placebo Comparator|Placebo|
9530902|NCT03189238|Active Comparator|PRP|
9530903|NCT03189368||Heart failure patients eligible for CRT|"Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.~Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired."
9530904|NCT03189290|Active Comparator|ropivacaine|"Active Comparator: ropivacaine group~- Before general anaesthesia, ultrasound guided Quadratus Lumborum Block (QLB) will be performed with 30 mL 0.33% Ropivacaine"
9530905|NCT03189290|Placebo Comparator|placebo|"Sham Comparator: saline group~- Before general anaesthesia, ultrasound guided Sham Quadratus Lumborum Block (QLB) will be performed with 30 mL saline."
9530906|NCT03189095|Experimental|Intervention|
9530907|NCT03189095|No Intervention|Wait-List Control|
9530908|NCT03189212|Active Comparator|Usual Care Visit|
9530909|NCT03189212|Experimental|Telemedicine Visit|
9530910|NCT03189082|Experimental|Intervention group|
9530911|NCT03189264|Active Comparator|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
9530912|NCT03189264|Placebo Comparator|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
9530913|NCT03189225|Other|Capillary And Venous Accuracy|All subjects provided blood sample(s) to be tested on three Blood Glucose Monitoring Systems ( OneTouch Ultra 2, OneTouch Verio (Rice), OneTouch SelectPlus), LifeScan reference instrument ( YSI 2300) and hospitals own biochemistry analysers.
10037847|NCT01828788|Placebo Comparator|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
10037848|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
9481112|NCT04996030|Experimental|Multiple-Dose Oral Module|Participants will receive SY-2101, orally, QD, 5 days/week for 28 days as a part of 1 cycle (Cycle 4; Weeks 1 through 4) of SOC treatment consolidation.
9481113|NCT04995536|Experimental|Treatment (radiation therapy, CAS3/SS3)|Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node, and receive CAS3/SS3 intratumorally on days 2, 4, 16, and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9, 11, 23, and 25.
9481114|NCT04985604|Experimental|Arm #1|DAY101 monotherapy
9481115|NCT04985604|Experimental|Arm #2|DAY101 plus pimasertib
9481116|NCT04983589|Experimental|AGN-190584|One drop bilaterally twice daily for 14 days.
9481117|NCT04983589|Placebo Comparator|Vehicle|One drop bilaterally twice daily for 14 days.
9481118|NCT04978415|Experimental|subtenon's block|we use the subtenon cannula to inject the local anesthetic mixture
9481119|NCT04978415|Experimental|peribulbar block|we use the usual 25G sharp needle to inject the local anesthetic mixture
9481120|NCT04974086|Experimental|CDS Tool Evaluation|All participants will receive intervention and feasibility, acceptability, and usability of intervention will be assessed from each participant cohort group.
9481121|NCT04968743|Experimental|Participants With Unilateral Stroke|"Participants with self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics and MRI scan, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the unilateral stroke will be confirmed. In participants with stroke, TMS will be applied over the motor cortex on the affected and non-affected hemisphere at the intensity of up to 120% resting motor threshold."
9481122|NCT04968743|Experimental|Participants Without Unilateral Stroke|"Participants without self-reported unilateral stroke will take part in two experimental sessions:~First, for assessment of stroke characteristics, and second, the main transcranial magnetic stimulation experiment. During the first experimental session, the lack of unilateral stroke will be confirmed. In participants without stroke, TMS will be applied targeting at the intensity of up to 120% resting motor threshold both left and right hemisphere."
9481125|NCT04961619||dabrafenib and trametinib|patients on adjuvant treatment with dabrafenib + trametinib
9481126|NCT04956900|Experimental|Aurase wound gel X0|Cohort 1: Aurase wound gel x0 dose concentration
9481127|NCT04956900|Experimental|Aurase wound gel X1|Cohort 2: Aurase wound gel x1 dose concentration
9481128|NCT04956900|Experimental|Aurase wound gel X1.8|Cohort 3: Aurase wound gel X1.8 dose concentration
9481129|NCT04956900|Experimental|Aurase wound gel X5|Cohort 4: Aurase wound gel X5 dose concentration
9481130|NCT04956900|Experimental|Aurase wound gel X9|Cohort 5: Aurase wound gel X9 dose concentration
9481131|NCT04952909|Experimental|ShortCut™|
9481132|NCT04949568||Cohort|Adul Haitian immigrants.
9481133|NCT04947007|Active Comparator|Group 1|In this group, US guided suprascapulary and axillary nerve block will be performed with 15cc+15c local anesthetic.
9481134|NCT04947007|Active Comparator|Group 2|In this group, US guided suprascapulary and axillary nerve block will be performed with 10cc+10c local anesthetic.
9481135|NCT04947007|Active Comparator|Group 3|In this group, US guided suprascapulary and axillary nerve block will be performed with 5cc+5c local anesthetic.
9481136|NCT04947007|Active Comparator|Group 4|In this group, US guided suprascapulary and axillary nerve block will be performed with serum physiologic.
9481137|NCT04943445|Experimental|Treatment: Single Arm|"Induction chemo-immunotherapy:~Carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.~Concurrent radio-immunotherapy:~Radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.~Consolidation immunotherapy:~Pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses."
9481138|NCT04940533||Participants receiving CFTR modulator therapy - Trikafta|This is a single arm study. Participants in this study are receiving CFTR modulator therapy.
9481139|NCT04937972|Experimental|SHR-1701 Combined With fluzoparib|
9481140|NCT04937270|Experimental|High frequency application time is 5 minutes|The group which treats for 5 minutes by using the high-frequency therapy device
9481141|NCT04937270|Experimental|High frequency application time is 7 minutes|The group which treats for 7 minutes by using the high-frequency therapy device
9615552|NCT02544477|Experimental|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
9481142|NCT04937270|Experimental|High frequency application time is 9 minutes|The group which treats for 9 minutes by using the high-frequency therapy device
9481143|NCT04937270|Active Comparator|Superficial heat therapy|Group treated with superficial heat therapy for 20 minutes
9481144|NCT04937010|Active Comparator|Industry standard stimulation|Standard sub threshold stimulation parameters
9481145|NCT04937010|Sham Comparator|Experimental stimulation|Sham stimulation
9481146|NCT04935775|Experimental|Untrained Touch Provided|
9481147|NCT04935775|No Intervention|Standard of Care|
9481148|NCT04933370|Active Comparator|Industry standard stimulation|Industry standard stimulation settings
9481149|NCT04933370|Sham Comparator|Experimental stimulation|Experimental stimulation settings
9804217|NCT01736085|Active Comparator|Materials plus Patches|Subjects will receive self-help materials and a 2 week's worth of nicotine patches
9804146|NCT01733628||Bevacizumab + Chemotherapy|Patients who received the addition of Bevacizumab (BV) every 2-3 weeks to Chemotherapy (CT) with either oxaliplatin or irinotecan plus fluoropyrimidines in patients with Metastatic Colorectal Cancer (MCRC), either paclitaxel or capecitabine in patients with Metastatic Breast Cancer (MBC), as first-line therapy.
9530914|NCT03189186|Experimental|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
9530915|NCT03189069||Patients prescribed apixaban|
9530916|NCT03189069||Patients prescribed dabigatran|
9530917|NCT03189069||Patients prescribed rivaroxaban|
9530918|NCT03189069||Patients prescribed warfarin|
9530919|NCT03189147|Experimental|Biceps Tenodesis|Patients in this group will received biceps tenodesis intervention to address their labral lesion
9530920|NCT03189147|Active Comparator|Debridement|Patients in this group will received debridement intervention to address their labral lesion
9530921|NCT03189030|Experimental|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10^9 CFU
9530922|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
9530923|NCT03189316|Other|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
9530924|NCT03189316|Other|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
9530925|NCT03189160|Experimental|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
9530926|NCT03189160|Experimental|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
9530927|NCT03189160|No Intervention|Non-treatment control group|
9530928|NCT03189329|Active Comparator|Group L|Patients undergoing block with 2% lidocaine hydrochloride
9530929|NCT03189329|Active Comparator|Group LB|Patients undergoing block with 0.5% levobupivacaine
9530930|NCT03189342|Experimental|Single Task Training|Performed balance and gait exercises
9530931|NCT03189342|Experimental|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
9530932|NCT03189342|Experimental|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
9530933|NCT03188978|Experimental|Treatment|Atorvastatin 40mg once daily orally for 8 weeks starting 2 weeks before AVF creation
9530934|NCT03188978|Placebo Comparator|Placebo|1 tablet once daily orally for 8 weeks starting 2 weeks before AVF creation
9530935|NCT03188939|Active Comparator|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
10037849|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
9530936|NCT03188939|Active Comparator|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
9530937|NCT03188939|Active Comparator|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
9530938|NCT03188692|Experimental|BK1310|
9530939|NCT03188731||Pregnant Women|
9530940|NCT03188835|Other|Isocaloric Diet|Two weeks of isocaloric diet
9530941|NCT03188835|Other|Fructose diet|Two weeks of hypercaloric diet supplemented with fructose
9530942|NCT03188835|Other|Glucose diet|Two weeks of hypercaloric diet supplemented with glucose
9530943|NCT03188809|Active Comparator|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
9530944|NCT03188809|Active Comparator|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
9530945|NCT03188757|Experimental|hyperglycaemic clamp|
9530946|NCT03188601||Rambam|Approximately 40 patients in total.No intervention planned.
9530947|NCT03188601||Soroka|Approximately 10 patients in total.No intervention planned.
9530948|NCT03188601||Tel Aviv Souraski|Approximately 40 patients in total.No intervention planned.
9530949|NCT03188601||Jerusalem Hadassah|Approximately 50 patients in total. No intervention planned.
9530950|NCT03188848|Experimental|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
9530951|NCT03188848|Placebo Comparator|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
9530952|NCT03188887|Active Comparator|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade.
9530953|NCT03188887|Experimental|EXPERIMENTAL|Corticotherapy + RAS blockade treatment. Drug injection (intravenous) + tablets
9530954|NCT03188653|Active Comparator|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
9530955|NCT03188653|Active Comparator|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
9530956|NCT03188653|Active Comparator|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
9530957|NCT03188653|Active Comparator|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
9530958|NCT03188653|Active Comparator|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
9530959|NCT03188653|Active Comparator|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
9530960|NCT03188653|Active Comparator|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free & Clear Liquid Cleanser
9530961|NCT03188783|Experimental|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
9530962|NCT03188783|Experimental|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
10037850|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
9530963|NCT03188783|Experimental|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
9530964|NCT03188783|Experimental|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
9530965|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
9530966|NCT03188900||preeclampsia|pregnancy with preeclampsia
9530967|NCT03188900||control|pregnancy without preeclampsia
9530968|NCT03188640|Other|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
9530969|NCT03188744||Group 1|Patients with CC with PFMD.
9530970|NCT03188744||Group 2|Patients with CC without PFMD.
9530971|NCT03188744||Group 3|Patients without CC with PFMD.
9530972|NCT03188744||Group 4|Patients without CC without PFMD.
9530973|NCT03188679|Other|mRNA sequencing|amniotic fluid for patients with CMV seroconversion during pregnancy will undergo mRNA sequencing
9530974|NCT03188952|Active Comparator|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
9530975|NCT03188952|Experimental|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
9530976|NCT03188614|Placebo Comparator|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
9530977|NCT03188614|Experimental|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
9530978|NCT03188497|Experimental|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
9530979|NCT03188497|Experimental|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
9530980|NCT03188497|Experimental|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
10037851|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
10058287|NCT02017158|No Intervention|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
9530981|NCT03188497|Experimental|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
9530982|NCT03188497|Experimental|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
9530983|NCT03188497|Experimental|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
9530984|NCT03188627|Experimental|Bronchial basal cells|Transplantation of autologous bronchial basal cells
9530985|NCT03188627|No Intervention|Control|Conventional treatment
9530986|NCT03188562|Experimental|EBUS-TBNA, EUS-NA|"PET/CT~Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
9530987|NCT03188562|Experimental|TEMLA|"PET/CT~Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
9530988|NCT03188575|Experimental|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
9530989|NCT03188575|Active Comparator|Waiting List|Waiting list control
9530990|NCT03188315|Experimental|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
9530991|NCT03188315|Active Comparator|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
9530992|NCT03188445|Experimental|IV administration|Iron isomaltoside (Monofer) Administered iv
9530993|NCT03188445|Active Comparator|Oral administration|Ferrous fumarate with ascorbic acid Administered oral
9530994|NCT03188341||vascular surgery patients|"clinically concealed repolarization disturbances during vascular surgery procedure~clinically disclosed cardiac complications during and after vascular surgery procedure"
9530995|NCT03188471|Experimental|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
9530996|NCT03188471|Active Comparator|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
9530997|NCT03188328|Experimental|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
9530998|NCT03188549|Active Comparator|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
9530999|NCT03188549|Active Comparator|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
9531000|NCT03188549|Active Comparator|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
9531001|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
9531002|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
9531003|NCT03188458|Other|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
9531004|NCT03188510|Experimental|LY3074828 Reference|LY3074828 administered subcutaneously (SC) as 3 injections
9531005|NCT03188510|Experimental|LY3074828 Test 1|LY3074828 administered as SC injections in two prefilled syringes
9531006|NCT03188510|Experimental|LY3074828 Test 2|LY3074828 administered as SC injections in four prefilled syringes
9531007|NCT03188198|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy.Cyclophosphamide 750 mg/m^2 IV on Day 1.Doxorubicin 50 mg/m^2 IV on Day 1.Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1.Prednisone 40 mg/m^2/day PO on Days 1-5.filgrastim or pegfilgrastim as defined in the protocol Required ancillary medications is administered during all cycles as defined in the protocol. Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.~Interventions:-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: filgrastim-Drug: pegfilgrastim"
9531008|NCT03188198|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment: Cycle 1 Doses:Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy. Doxorubicin 10 mg/m^2/day CIVI on Days 1-4.Etoposide 50 mg/m^2/day CIVI on Days 1-4. Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours). Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions). Prednisone 60 mg/m^2 PO BID on Days 1-5 Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.~Interventions:~-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: etoposide-Drug: filgrastim"
9531009|NCT03188289|Placebo Comparator|Placebo gel|The placebo gel is used by all patients on one side of the mouth and serves as a control group.
9531010|NCT03188289|Active Comparator|Clorhexidine gel|Chlorhexidine gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
9531011|NCT03188289|Active Comparator|Clorhexidine-Chitosan gel|Clorhexidine-chitosan gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
9531012|NCT03188289|Active Comparator|Hyaluronic acid gel|Hialuronic acid gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
9531013|NCT03188302|Other|Specimen collection|Collection of stool samples
9531014|NCT03188276|Active Comparator|CHC patients|32 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.
9531015|NCT03188276|No Intervention|Healthy controls|20 Healthy controls without any treatment
9531016|NCT03188159|Experimental|IV Vinorelbine|IV Vinorelbine 25mg/m2
9531017|NCT03188172|Experimental|Trial Treatment|"Induction:~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11~ASCT stem cell harvest:~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly~Consolidation part 1:~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22~Consolidation part 2:~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1~Maintenance:~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
9531018|NCT03188250|Experimental|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
9531019|NCT03188250|No Intervention|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
9531020|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
9531021|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
9531022|NCT03188094||South Asians with Prediabetes|
9615553|NCT02544477|Active Comparator|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
10037852|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
10037853|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
9531023|NCT03188211|Other|Intervention|Clinicians allocated to intervention arm will receive an e-learning educational program based on simulation-based technologies (Dr Sim). Dr Sim provides a powerful editing system that allows to create clinical cases according to the educational need and purposes. It will be distributed on an e-learning platform, allowing the user to act in a highly interactive learning environment. Management of the virtual patients is carried out interactively and each diagnostic and or therapeutic choice will be supported by any scientific data, guidelines recommendations, drug descriptions and literature references useful to address the best choice for that specific patient as it should be in real practice.
9531024|NCT03188211|Other|Control|Clinicians allocated to control arm will not receive the e-learning educational program based on simulation-based technologies (Dr Sim).
9531025|NCT03188237|Experimental|AfyaJamii facility|Facilities using AfyaJamii
9531026|NCT03188237|No Intervention|Referent facility|Facilities using Focused Antenatal Care Individual Model
9531027|NCT03188367|Active Comparator|1A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531028|NCT03188367|Active Comparator|1B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531029|NCT03188367|Active Comparator|1C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531030|NCT03188367|Placebo Comparator|2C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531031|NCT03188367|Placebo Comparator|2B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 10 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531032|NCT03188367|Placebo Comparator|2A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531033|NCT03188367|Active Comparator|1A - HV|Seventy healthy volunteers will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9615554|NCT02544412|Experimental|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, & Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
10037854|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
9531034|NCT03188367|Active Comparator|1B - HV|Seventy healthy volunteers will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531035|NCT03188367|Active Comparator|1C - HV|Seventy healthy volunteers will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531036|NCT03188367|Placebo Comparator|2C- HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531037|NCT03188367|Placebo Comparator|2B - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531038|NCT03188367|Placebo Comparator|2A - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
9531039|NCT03188406||Gastric cancer|Patients with clinical or histological diagnosis of stomach cancer
9531040|NCT03188406||Gastric intestinal metaplasia|Patients classified as OLGIM >0
9531041|NCT03188406||Non-atrophic gastritis|Patients classified as OLGA 0
9531042|NCT03188029|Experimental|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
9531043|NCT03188016|Experimental|Intensive Interaction with music|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
9531044|NCT03188016|Active Comparator|Standard Intensive Interaction|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker
9531045|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
9531046|NCT03187951|Experimental|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
9531047|NCT03187951|Experimental|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
9531048|NCT03188133|Experimental|VH|schizophrenia patients with visual hallucinations
9531049|NCT03188133|Active Comparator|AH/NH|schizophrenia patients with auditory hallucinations or no hallucinations
9531050|NCT03188133|Active Comparator|C|healthy controls
9615555|NCT02544412|No Intervention|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
9531051|NCT03188003|Experimental|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
9531052|NCT03188003|Experimental|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
9531053|NCT03187964|No Intervention|PLHIV Centralised Xpert Ultra|Patient sputum specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised Xpert Ultra TB testing at the National Health Laboratory Services (NHLS) facility in Greenpoint, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
9531054|NCT03187964|Active Comparator|PLHIV Point of Care Xpert Ultra|Patient sputum specimen collected at KCHC and Xpert Ultra TB testing done on site at point of care (POC).
9531055|NCT03187964|No Intervention|PLHIV Centralised Xpert VL|Patient blood specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised viral load testing at the NHLS facility in Tygerberg Hospital, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
9531056|NCT03187964|Active Comparator|PLHIV Point of Care Xpert VL|Patient blood specimen collected at KCHC and Xpert HIV-1 viral load testing done on site at point of care (POC).
9531057|NCT03187990|Experimental|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional [68Ga]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
9531058|NCT03187990|Experimental|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional [68Ga]PSMA-11 PET/MRI scan with [68Ga]PSMA.
9531059|NCT03187912|Active Comparator|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
9531060|NCT03187912|Active Comparator|Riboflavin with HPMC|Riboflavin drops with HPMC
9531061|NCT03188146||PBC patients with liver biopsy|Ursodeoxycholic acid will be given compliance to the treatment guideline.
9615556|NCT02544347|Other|diabetes mellitus group|gingival crevicular fluid was collected
9615557|NCT02544347|Other|Control group|gingival crevicular fluid was collected
9615558|NCT02544347|Other|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
9615559|NCT02544347|Other|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
9615560|NCT02544282|Active Comparator|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
9615561|NCT02544282|Placebo Comparator|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
9615562|NCT02544373|Active Comparator|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
9615563|NCT02544373|Other|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
9615564|NCT02544360|Experimental|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
9615565|NCT02544360|No Intervention|Control|The control group consists of schools participating in the survey but not receiving the intervention.
9615566|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
9615567|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
9615568|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
9615569|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
9615570|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
9615571|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
9615572|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
9615573|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
10037855|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
9531062|NCT03188419||1|Retrospective chart review of patients with inherited immunodeficiency diseases requiring allogeneic hematopoietic stem cell transplant (allo HSCT)
9531063|NCT03188224|Experimental|Intervention|MyTransition app
9531064|NCT03188224|No Intervention|Control|Usual care
9531065|NCT03187899|Sham Comparator|"Interscalene block plus sham"|"Patients in this group will receive a traditional interscalene block and a sham superficial plexus block with ropivacaine and 5-10cc of normal saline. N = 20"
9531066|NCT03187899|Active Comparator|Interscalene plus superficial plexus block|Patients in this group will receive a traditional interscalene block and a superficial plexus block with ropivacaine . N = 20
9531067|NCT03187795|Experimental|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
9531068|NCT03187795|Experimental|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
9531069|NCT03187704|Active Comparator|filtration|Air filtration in homes
9531070|NCT03187704|Sham Comparator|no filtration|Sham air filtration
9531071|NCT03187821|Active Comparator|Superior|Laser peripheral iridotomy done at superior part of iris.
9531072|NCT03187821|Active Comparator|Nasal/temporal|Laser peripheral iridotomy done at temporal/nasal part of iris.
9531073|NCT03187743|Experimental|Pharmacokinetics/dynamics|Blood samples at 3 visits
9531074|NCT03187808|Experimental|Group A|Group A is a group of performing single thoracic manipulation at zygapophyseal joint of T6-T7.
9531075|NCT03187808|Experimental|Group B|Group B is a group of performing single thoracic manipulation combined with special massage technique (RT technique).
9531076|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
9531077|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
9531078|NCT03187691|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
10037856|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
9531079|NCT03187691|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
9531080|NCT03187691|Experimental|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
9531081|NCT03187600|Active Comparator|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
10037857|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
9531082|NCT03187600|Experimental|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
9531083|NCT03187626|Experimental|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
9804218|NCT01736085|Active Comparator|Counseling|Subjects will receive up to 5 sessions of telephone counseling
10037858|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
10037859|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
10037860|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
10037861|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
9531084|NCT03187626|Active Comparator|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
10037862|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
9531085|NCT03187548|Experimental|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
9531086|NCT03187639|Experimental|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
10037863|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
9531087|NCT03187639|Active Comparator|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
9531088|NCT03187587|Experimental|imILT treatment|Immunostimulating Interstitial Laser Thermotherapy (imILT)
9531089|NCT03187587|Active Comparator|Standard chemotherapy treatment|This study arm recieves chemotherapy treatment as standard care at the clinical study site.
9531090|NCT03187574||Group A|group received Elevate Ant™ single-incision mesh
9531091|NCT03187574||Group B|group received Perigee™ transvaginal mesh
9531092|NCT03187561|Experimental|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
9531093|NCT03187561|Experimental|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
9531094|NCT03187561|Other|Control|Participants in this arm will not receive either intervention.
9531095|NCT03187665||1-6 years|12 subjects in the age range of 1-6 years old.
9531096|NCT03187665||6-10 years|12 subjects in the age range of 6-10 years old.
9531097|NCT03187665||11-17 years|12 subjects in the age range of 11-17 years old.
9531098|NCT03187873|Experimental|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
9531099|NCT03187873|No Intervention|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
9531100|NCT03187522|Experimental|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
9531101|NCT03187405|No Intervention|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
9531102|NCT03187405|Experimental|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
9531103|NCT03187431|Experimental|IPF patients|autologous bone marrow mesenchymal stem cells
9531104|NCT03187275|Experimental|Swedish Massage Therapy|Participants in this arm will receive Swedish massage, which is the most commonly offered and best-known type of massage.
9531105|NCT03187275|Active Comparator|Light Touch Intervention|Participants in this arm will receive light touch only.
9531106|NCT03187483|Active Comparator|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
9531107|NCT03187483|Active Comparator|Control|Orthodontic treatment with conventional adhesive-coated brackets
9531108|NCT03187444|Experimental|Patients with chronic inflammatory rheumatism|All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
9531109|NCT03187457|Other|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
10037864|NCT01828827|Experimental|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
10037865|NCT01828827|Experimental|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
10037866|NCT01828866|Active Comparator|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
10037867|NCT01828866|Experimental|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
10037868|NCT01828879|Experimental|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
10037869|NCT01828892|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
9531110|NCT03187457|Other|Control group|Healthy women without Bacterial Vaginosis and without treatment
9531111|NCT03187093|Active Comparator|Vortioxetine|
9531112|NCT03187093|Active Comparator|Escitalopram|
9531113|NCT03187223|Active Comparator|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
9531114|NCT03187223|Experimental|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
9531115|NCT03187340|Active Comparator|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
10037870|NCT01828892|Sham Comparator|Control|Patients in this group only received standard of care when their fistula output < 200ml/24h.
10037871|NCT01828892|Experimental|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
9481150|NCT04930653|Experimental|Treatment (ECP, mogamulizumab)|Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CR)/PR after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
9481151|NCT04929808|Active Comparator|Control group|Will receive the standard institutional skin care for acute radiodermatitis
9481152|NCT04929808|Experimental|Experimental group|Will receive the novel, self-prepared skin care product
9481153|NCT04927195|Experimental|Cohort 1|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 7.5 x 10^11 cells, capsules, once daily, 14 days total
9481154|NCT04927195|Experimental|Cohort 2|12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 1.5 x 10^12 cells, capsules, once daily, 14 days total
9481155|NCT04927195|Experimental|Cohort 3|24 subjects with moderate atopic dermatitis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
9481156|NCT04927195|Experimental|Cohort 4|24 subjects with moderate psoriasis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
9481157|NCT04927195|Experimental|Cohort 5|24 subjects with mild asthma; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10^11 cells, capsules, once daily, 56 days
9481158|NCT04914663|Experimental|All-extremity exercise|
9481159|NCT04914663|Active Comparator|Treadmill exercise|
9481160|NCT04914663|No Intervention|Usual Care|
9481161|NCT04912531|No Intervention|Usual Care Arm|No intervention will be given to patients in the usual care arm.
9481162|NCT04912531|Experimental|Virtual Reality and Olfactory Stimuli Arm|Patients will undergo a virtual reality and olfactory stimuli therapy session at their appointment where they receive their pulmonary function test, 90 minutes before surgery, and each morning and evening they recovery in the hospital. In addition, patients will receive nighttime olfactory stimulation using a bedside olfaction device.
9481163|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 1 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
9481164|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
9481165|NCT04910100|Experimental|Timolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
9481166|NCT04910100|Active Comparator|Timolol Ophthalmic Solution 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
9804147|NCT01733680|Active Comparator|Amiloride|"Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.~Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI."
9481168|NCT04908241|Experimental|TRAIL|TRAIL is a 4-week progressive exercise and self-management intervention for lower extremity recovery delivered by a trained registered physical therapist, in a 2:1 participant-to-therapist ratio. Each participant grouping will receive two telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours).
9481169|NCT04908241|Active Comparator|EDUCATION|"The EDUCATION control arm is a 4-week education program focusing on stroke knowledge and risk factors. It will be delivered by health professionals who have experience working with individuals with stroke, knowledge of chronic disease self-management (e.g. physical or occupational therapists, nurses, kinesiologists), and who have completed study-specific training on the EDUCATION program~Participants will receive video conferencing sessions with the same schedule and 2:1 participant-to-coach ratio as TRAIL. Each participant grouping will receive two educational telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours)."
9481170|NCT04907214|Experimental|Empagliflozin|Individuals receive empagliflozin 25mg/day orally for 12 weeks
9481171|NCT04907071|Experimental|Malperfusion Primary Cohort|"Patients presenting to hospital with AAD meeting criteria for malperfusion syndrome preoperatively which includes both components:~Imaging findings indicating reduced flow to the Celiac Trunk, Superior mesenteric artery, either renal artery or either iliac artery~Clinical stigmata of end organ ischemia (abdominal pain, distended abdomen, oliguria/anuria, reduced pulses, signs of limb ischemia) OR Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte abnormalities)"
9481172|NCT04907071|Experimental|Malperfusion Secondary Cohort:|"Patients who develop new clinical signs or laboratory results indicating distal malperfusion after proximal repair of the AAD is complete and proximal blood flow is redirected into the true lumen.~New Clinical signs include: Loss of femoral pulses, distended abdomen, reduced urine output, dusky extremities~New Laboratory signs include: Rising lactate (>50% above baseline), Rising Creatinine, Metabolic Acidosis, Rising LFTs"
9481173|NCT04907071|Experimental|No Malperfusion Cohort|Patients presenting with AAD with no evidence of malperfusion syndrome preoperatively and postoperatively.
9481174|NCT04903522|Experimental|Depressive patients|Patients suffering from major depressive disorder with anxiety symptoms
9481175|NCT04901221|Experimental|Extrusion arch|"Hand made stainless steel extrusion arch wire (0.016x0.22)"
9481176|NCT04896775|Experimental|NiteCAPP CARES|Cognitive Behavioral Treatment-Insomnia. 4 online treatment sessions focusing on behavior and cognitions related to sleep.
9481177|NCT04896775|Experimental|NiteCAPP SHARES|Sleep Hygiene and Related Education. 4 online treatment sessions focusing on sleep hygiene and related education.
9481178|NCT04881877|Experimental|Synthetic nitrite Condom|Participants will be randomized to condom use order. Participants will be provided with 5 synthetic nitrite condoms at the first visit and switched to 5 of either the latex graphene condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study
10037872|NCT01828905|Experimental|Cerament|"CERAMENT™|BONE VOID FILLER as bone graft substitute"
9804148|NCT01733680|Placebo Comparator|Placebo|Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI
10037873|NCT01828905|Active Comparator|Bone graft|Autologous cancellous bone graft (iliac crest)
10037874|NCT01828918|Other|early recurrence|find the postoperative early relapse out
10037875|NCT01828931|Active Comparator|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
10037876|NCT01828931|Experimental|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
10037877|NCT01828944|Active Comparator|Extra virgin olive oil|Extra virgin olive oil
10037878|NCT01828944|Experimental|Enriched extra virgin olive oil|Enriched extra virgin olive oil
10037879|NCT01828944|Placebo Comparator|refined olive oil|refined olive oil
9481179|NCT04881877|Experimental|Latex and graphene Condom|Participants will be randomized to condom use order. Participants will be provided with 5 latex graphene condoms at the first visit and switched to 5 of either the synthetic nitrite condom or latex condom at visit 2 and 3. All couples will use each of the 3 condom types during the study.
9481180|NCT04881877|Experimental|Standard latex condom:|Participants will be randomized to condom use order. Participants will be provided with 5 latex condom at the first visit and switched to 5 of either the latex graphene condom or synthetic nitrite condoms at visit 2 and 3. All couples will use each of the 3 condom types during the study.
9481181|NCT04873583|Experimental|Steroids + Standard of care|Standard of care (including aspirin) and intravenous steroids, followed by oral tapering.
9481182|NCT04873583|No Intervention|Standard of care|Standard of care (including aspirin)
9481183|NCT04872777|No Intervention|Standard of care|"Standard of care (SOC) control condition: Following study group assignment, the following procedures will be completed for SOC control:~Digital scale provision (subjects may keep the scale)~Reinforcement of need to comply with SOC treatment as directed by their NASH clinician~Capture of available clinical information over preceding 28-days."
9481184|NCT04872777|Experimental|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~Noom application set-up and troubleshooting on smartphone (license provided)~Digital scale provision (subjects may keep the scale)~Capture of available clinical information over preceding 28-days."
9481185|NCT04869514|Active Comparator|either lumbar manipulation (LMANIP)|LMANIP will consist of high velocity low amplitude (HVLA) SMT at the L4/L5 motion segment. LMANIP consists of two HVLA impulses, applied in side-posture on the right and left side (order pseudorandomized).
9481186|NCT04869514|Active Comparator|thoracic manipulation (TMANIP)|TMANIP will consist of high velocity low amplitude (HVLA) SMT at the T4/5 motion segment. TMANIP consists of supine SMT to the right and left (order pseudorandomized) using a thenar contact at facet joint level T4/5
9481187|NCT04869514|Sham Comparator|lumbar mobilisation (LMOB)|LMOB will be applied with the same positioning as in the LMANIP procedure, but instead of a thrust, a slow, a slow, passive mobilization without impulse will be applied
9481188|NCT04869514|No Intervention|No intervention|A natural history arm will serve to further control for potential specific and non-specific effects of TMANIP and LMOB. Subject will rest in side-lying position for the same duration as during the active interventions.
10037880|NCT01828957|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
10037881|NCT01828957|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
9481191|NCT04866433|Experimental|Binaural group|Play realtime binaural sound applied music through headphones
9481192|NCT04866433|Active Comparator|Audio group|Play music through headphones.
9481193|NCT04866433|Sham Comparator|Control group|Wear headphones that do not produce sound.
10037882|NCT01828970|Experimental|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
10037883|NCT01828996|Active Comparator|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
10037884|NCT01828996|Placebo Comparator|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
10037885|NCT01829009|No Intervention|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
9497572|NCT03473834|Experimental|Modified exercise programme|Modified exercise program is the intervention for the exercise group that they will be received this programm over 1 month.
9497573|NCT03473834|Active Comparator|Parkinson's disease Medication|Medication is the standard treatment for individuals with Parkinson's disease. Therefore, the control group will be received the medication only.
9497576|NCT03473717|Active Comparator|classic method group|IUD/IUS insertion will be done using the conventional method
9497577|NCT03473717|Active Comparator|direct method group|IUD/IUS insertion will be done using the direct method
10037886|NCT01829009|Experimental|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
10037887|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
9531116|NCT03187340|Experimental|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
10037888|NCT01829035|No Intervention|Arm S|sorafenib 400mg bid daily po until progression
9531117|NCT03187392|Active Comparator|lidocaine injection|
9531118|NCT03187392|Experimental|lidocaine-prilocaine cream|
9531119|NCT03187366|No Intervention|Status quo|Status quo pesticide use
9531120|NCT03187366|Active Comparator|Low risk|Villages shifted to low risk pesticides that don't kill prawns
9531121|NCT03187366|Experimental|No agrochemicals|Villages that eliminate agrochemicals
9531122|NCT03187054|Active Comparator|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
9531123|NCT03187054|Experimental|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
9531124|NCT03187106|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for a total of 6 doses; 500 mg metronidazole per oral every 8 hours for a total of 6 doses
9531125|NCT03187106|Placebo Comparator|Placebo / standard of care|Placebo pills per oral every 8 hours for a total of 6 doses
9531126|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
9531127|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
9531128|NCT03186989|Experimental|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
9531129|NCT03186989|Placebo Comparator|Placebo|Artificial CSF
9531130|NCT03187249|Experimental|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
9531131|NCT03187249|Experimental|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
9531132|NCT03187249|Experimental|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
9531133|NCT03187249|No Intervention|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
9531134|NCT03187184|Experimental|OneOme RightMed® Test|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
9531135|NCT03187041|Experimental|Skin surface pressures under tourniquets and sensation|"Phase 1: Each phlebotomist will apply the tourniquet 10 separate times to the right arm of each subject. The tourniquet will remain on the arm for approximately ten seconds, to be able to allot enough time to collect an accurate pressure measurement. All 10 tourniquet skin pressure measurements will take place on the same day for a subject.~Phase 2: 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 1 hour. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use."
9531136|NCT03187496|Experimental|Single Arm|
9531137|NCT03187145||diabetic patients|
9531138|NCT03187145||healthy control|
9531139|NCT03187171|Active Comparator|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
9531140|NCT03187171|Active Comparator|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
9531141|NCT03187314|Experimental|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
9531142|NCT03187015|Other|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
9531143|NCT03187067||Mozambique, cases|
9531144|NCT03187067||Mozambique, controls|
9531145|NCT03187067||Pakistan, cases|
10037889|NCT01829035|Experimental|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
9531146|NCT03187067||Pakistan, controls|
9531147|NCT03187080|Experimental|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
9531148|NCT03187080|Sham Comparator|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
9531149|NCT03187080|Experimental|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
9531150|NCT03187080|Sham Comparator|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
9531151|NCT03187080|Experimental|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
10037890|NCT01829061||No Treatment|
10037891|NCT01829087|Experimental|Botox injection|
10037892|NCT01829087|Placebo Comparator|Control|
9531152|NCT03187080|No Intervention|Group 3 Arm B|Breast reduction, standard perioperative management.
10037893|NCT01829100|Experimental|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
10037894|NCT01829100|No Intervention|waitlist|15-week waitlist
9481194|NCT04863846||Clinical standard (first study phase)|Current clinical standard, non-algorithm-based decision-making (prior to implementation of the algorithm)
9481195|NCT04863846||Algorithm-based allocation (second study phase)|New algorithm-based allocation to an intubation technique (after implementation of the algorithm)
9481197|NCT04851912||General|Participants with or without psychiatric disorders
9481198|NCT04847583|Experimental|Telacebec (Q203) with COVID-19 standard of care (SoC)|
9481199|NCT04847583|Active Comparator|COVID-19 Standard of care (SoC)|
10037895|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
10037896|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
10037897|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
10037898|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
10037899|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
10037900|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
10037901|NCT01829152|No Intervention|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
10037902|NCT01829152|Experimental|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
10037903|NCT01829178|Placebo Comparator|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]
10037904|NCT01829178|Active Comparator|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
10037905|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
10037906|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
10037907|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
10037908|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
9497578|NCT03473704|Experimental|Treatment group (TG)|The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
9497579|NCT03473704|Placebo Comparator|Control group (CG)|The control group (CG) will be evaluated in the same phases as the TG.
9497580|NCT03473691|Experimental|Glembatumumab vedotin (GV)|
10037909|NCT01829256|Experimental|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
10037910|NCT01829256|No Intervention|Education Control|Will receive educational material about management of kidney disease
10037911|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
10037912|NCT01829282|Experimental|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:~Provide HIV and STI test results~First Interview~Attend 8 sessions - 1 session per week~Second interview occurs immediately following the 8th session with HIV and STI tests~Third interview occurs 3 months after the 8th session with HIV and STI tests"
10037913|NCT01829282|Active Comparator|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.~Provide HIV and STI test results~First Interview~No sessions for 8 weeks~Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled~Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.~Attend 8 sessions - 1 session per week~Fourth interview occurs immediately after the 8th session with HIV and STI tests~Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
10037914|NCT01829308|Experimental|Specialist|The brief interventions are delivered by behavioral health counselors.
10037915|NCT01829308|Active Comparator|Generalist|The brief interventions are delivered by the primary care provider.
10037916|NCT01829321|Experimental|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
10037917|NCT01829321|Placebo Comparator|Placebo|1 capsule placebo twice daily
10037918|NCT01829334|Active Comparator|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
10037919|NCT01829334|Experimental|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
10037920|NCT01829334|Experimental|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
10037921|NCT01829334|Experimental|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
10037922|NCT01829373|Experimental|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
10058288|NCT02017184|Experimental|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
10058289|NCT02017197|Other|Sequence A|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2"
10058290|NCT02017197|Other|Sequence B|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2"
9531153|NCT03187080|Experimental|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
9531154|NCT03187080|No Intervention|Group 4 Arm B|Breast augmentation, standard perioperative management.
9531155|NCT03186963|Experimental|No immobilization|Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
9531156|NCT03186963|Active Comparator|Volar splint|Patients receive a volar plaster splint with inelastic bandage after the surgery, and are instructed not to remove the immobilization for 2 weeks. After this period, the immobilization is removed and patients begin rehabilitation with physiotherapy.
9531157|NCT03186950|Active Comparator|Restoration with Stainless Steel Crowns|Restoration of the tooth after endodontic treatment using stainless steel crown.
9531158|NCT03186950|Experimental|Restoration using BulkFill CR|Restoration of the tooth after endodontic treatment using bulkfill composite resin
9531159|NCT03186976|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
9531160|NCT03186976|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
9531161|NCT03186937|Experimental|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
9531162|NCT03186859|Active Comparator|Roux-en-Y Gastric Bypass (RYGB) surgery|
9531163|NCT03186859|Active Comparator|Sleeve Gastrectomy (SG) surgery|
9531164|NCT03186924|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
9531165|NCT03186924|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
9531166|NCT03186885|Experimental|In-Person Family Intervention|Healthy Frio In-Person Family-focused Intervention; In-person group setting at a community center
9531167|NCT03186885|Experimental|Remote Technology Family Intervention|Healthy Frio Remote Technology Family-focused Intervention; Home-based delivered remotely with technology
9531168|NCT03186885|Active Comparator|Control|Control; Participants will receive standard health education materials, a community resource guide, and encouragement to follow up with their primary care provider for office-based counseling.
9531169|NCT03186573|No Intervention|Control Group|The athletes will not receive any drink and will do the simulations of the fight.
9531170|NCT03186573|Active Comparator|Intervention group|(Intervention, grape juice) - athletes will receive 400 ml per day of grape juice (containing 66g of carbohydrates) for 14 days and will do the fight simulations.
9531171|NCT03186573|Placebo Comparator|Placebo Group|(Placebo, grape-flavored maltodextrin carbohydrate) - athletes will receive400ml of drink daily with 66g of maltodextrin for 14 days and will do the fight simulations; The amount of maltodextrin is equal to the amount of carbohydrate present in grape juice.
9531172|NCT03186768|Experimental|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
9531173|NCT03186768|No Intervention|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
9531174|NCT03186599|No Intervention|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
9531175|NCT03186599|No Intervention|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
9531176|NCT03186599|Experimental|low adherence intervention group|"Patient with the WALKON mobile application.~Patient with monthly feedback call~Patients on continuous MEMS monitoring."
10058291|NCT02017197|Other|Sequence C|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®"
9531177|NCT03186651|Experimental|Trans Vagina Support|Tension Free Vaginal Support (TVS):The subjects in the TVS Group used pads during week 1 (Baseline), fitted, trained and selected device size week 2 and used the selected device size during week 3 (treatment week).
9531178|NCT03186651|No Intervention|Standard Care|Standard of care (SoC): The subjects in the SoC group continued with conventional treatment i.e. using pads during week 1, 2 and 3. They were offered to use the TVS device for two weeks after completion of week 3.
9531179|NCT03186729|Experimental|Antithrombotic treatment|For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
9531180|NCT03186729|No Intervention|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
9531181|NCT03186755|Experimental|Hylo-Dual|Hyaluronic acid 0.05% & Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
9531182|NCT03186755|Active Comparator|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
9804149|NCT01733732|Experimental|Systane Balance|SYSTANE® BALANCE Lubricant Eye Drops, 1 drop in each eye 4 times a day for 30 days
10058292|NCT02017197|Other|Sequence D|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1"
10037923|NCT01829412|Experimental|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:~Patients at first-line treatment for MM:~Within 15 days before the start of the treatment~Within one month after the end of the first-line treatment~Six (6) months after the end of the first-line treatment~Patients at relapse after disease response (CR or PR) lasting at least 6 months~At relapse~Within 15 days after the end of the treatment of relapse~Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
10037924|NCT01829438|No Intervention|Without music|6MWT without music
10037925|NCT01829438|Experimental|With fast music|6MWT with a fast music
9531183|NCT03186833||Group A|males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).
9531184|NCT03186833||Group B|males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
9531185|NCT03186833||Group C|male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
9531186|NCT03186833||Group D|male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
9531187|NCT03186833||Group E|male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)
9531188|NCT03186898|Experimental|Proton Therapy (Radiation Therapy)|Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.
9531189|NCT03186898|Experimental|Photon Therapy (Radiation Therapy)|Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.
9531190|NCT03186742|Experimental|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
9531191|NCT03186742|No Intervention|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
9531192|NCT03186690|Experimental|Biodentine|This includes teeth that were treated with Biodntine cement
9531193|NCT03186690|Experimental|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
9531194|NCT03186872|No Intervention|Care as usual|Participants randomized to this group will continue to see the IBD medical home team as usual
9531195|NCT03186872|Experimental|Digital behavioral program app|Participants randomized to this group will see the IBD medical home team and will utilize the cognitive behavioral app as the intervention.
9531196|NCT03186560|Active Comparator|Group A: Arterial Leg Ulcer|Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
9531197|NCT03186560|Active Comparator|Group B: Mixed Leg Ulcer|only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6
9531198|NCT03186560|Active Comparator|Group C: Diabetic Foot Ulcer - neuropathic|On clinical inspection present as neuropathic
9531199|NCT03186560|Active Comparator|Group D: Diabetic Foot Ulcer - neuroischemic|On clinical inspection present as neuroischemic
9531200|NCT03186664|Experimental|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
9531201|NCT03186664|Active Comparator|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
9531202|NCT03186846|Active Comparator|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
9531203|NCT03186846|Active Comparator|placebo|No multimodal monitoring will be applied in control group.
9531204|NCT03186586|Experimental|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
9531205|NCT03186586|Placebo Comparator|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
10037926|NCT01829438|Experimental|With slow music|6MWT with a slow music
10037927|NCT01829438|Experimental|With preferred music|6MWT with the preferred music of the child
10037928|NCT01829451|Experimental|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
10037929|NCT01829451|Placebo Comparator|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
10037930|NCT01829490|Experimental|Starter Group|The first six volunteers will receive one dose of 5x10^9vp of ChAdOx1 85A intramuscular injection.
10037931|NCT01829490|Experimental|Group A|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A intramuscular injection.
10037932|NCT01829490|Experimental|Group B|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection 56 days later.
9531206|NCT03186794|Experimental|SLE Exercise|We propose to enroll 20 sedentary, adult, women with negligible to mild SLE disease activity (SELENA-SLEDAI less than or equal to 4) in this pilot study. Subjects must also have a Fatigue Severity Scale (FSS) composite score less than or equal to 4.0. We will restrict our recruitment to women with SLE as this is a small pilot study and would like to eliminate possible gender-biased confounders of physical activity (approximately 90% of patients with SLE are women).
10037933|NCT01829490|Experimental|Group C|12 subjects will receive two doses of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection at day 119.
9531207|NCT03186547|Experimental|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
9531208|NCT03186547|Experimental|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
9531209|NCT03186911|Other|E-liquid Group|Participants will sample two different e-liquids.
9531210|NCT03186807||low risk pregnancy|"Inclusion criteria - Women aged 18-45 years old ,Pregnant women between 14+0 and 34+0 weeks.speaking Hebrew language and eligible for obtaining informed consent.~Gestation who had a singleton fetus in cephalic presentation, with well documented gestational age by first trimester US scan CRL.~Biometric measurement within 10th to 90th percentile.and low risk for fetal brain developmental disorders."
9531211|NCT03186716|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
9531212|NCT03186716|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
9531213|NCT03186820|Experimental|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
9531214|NCT03186625|Experimental|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
9531215|NCT03186625|Placebo Comparator|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
9531216|NCT03186612|Active Comparator|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
9531217|NCT03186612|Experimental|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
9531218|NCT03186703|Experimental|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
9531219|NCT03186703|No Intervention|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
9531220|NCT03186534|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
9531221|NCT03186534|Active Comparator|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
10037934|NCT01829529|Experimental|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
10037935|NCT01829542|Active Comparator|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
9531224|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
9531225|NCT03186274|No Intervention|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
10037936|NCT01829542|Active Comparator|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
10037937|NCT01829542|Active Comparator|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
10037938|NCT01829542|Active Comparator|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
10037939|NCT01829542|Active Comparator|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
10037940|NCT01829542|Placebo Comparator|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
10037941|NCT01829555|Experimental|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
10037942|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
10037943|NCT01829594|Experimental|Case Management|
10037944|NCT01829607|Active Comparator|Functional electrical stimulation|Functional electrical stimulation of lower limbs
9531226|NCT03186274|Experimental|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
9531227|NCT03186274|Experimental|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
10037945|NCT01829607|Placebo Comparator|Placebo|
9531228|NCT03186495|Experimental|Normal renal function|Subjects with normal renal function
9531229|NCT03186495|Experimental|Mild renal impairment|Subjects with mild renal impairment
9531230|NCT03186495|Experimental|Moderate renal impairment|Subjects with moderate renal impairment
9531231|NCT03186495|Experimental|Severe renal impairment|Subjects with severe renal impairment
10037946|NCT01829620|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
10037947|NCT01829620|Experimental|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
9531232|NCT03186495|Experimental|Requiring haemodialysis treatment|Subjects requiring haemodialysis treatment
9531233|NCT03186430|Experimental|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
9531234|NCT03186430|No Intervention|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
9531235|NCT03186417|Experimental|Cohort 1|2 million human MSC (hMSC)/kg infusion versus placebo infusion
9531236|NCT03186417|Experimental|Cohort 2|4 million hMSC/kg infusion versus placebo infusion
9531237|NCT03186417|Experimental|Cohort 3|6 million hMSC/kg infusion versus placebo infusion
9531238|NCT03186482|Active Comparator|Descovy® (TAF/FTC)|"ATC Code J05AR17. Pharmaceutical form (use standard terms): Film-Coated Tablet Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol: 56 days.~Maximum dose allowed 200mg/25mg per day. Total dose 200/25mg. Oral Use."
9531239|NCT03186482|Active Comparator|Viread® (TDF)|"ATC Code J05AF07. Pharmaceutical form (use standard terms): Film-Coated Tablet. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 245mg per day. Total dose: 245mg. Oral Use."
9531240|NCT03186482|Active Comparator|Rifadin® (Rifampicin)|"ATC Code J0AB02 Pharmaceutical form (use standard terms): Capsule, Hard. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 600mg per day. Total dose: 600mg. Oral Use."
9531241|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
9531242|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
9531243|NCT03186469|Other|Behavioral: Standard of Care Control|Standard of care.
9531244|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
9531245|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
9531246|NCT03186105|Experimental|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days.
9531247|NCT03186092|Active Comparator|Intervention Group|inspiratory muscle training with load
9531248|NCT03186092|Sham Comparator|Control Group|unloaded inspiratory muscle training
9531249|NCT03186313|Experimental|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
10037948|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
10037949|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
10037950|NCT01829672|Experimental|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
10037951|NCT01829685|Active Comparator|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
10037952|NCT01829685|Active Comparator|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
9531250|NCT03186313|Active Comparator|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
9531251|NCT03186313|Experimental|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
9531252|NCT03186313|Active Comparator|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks.
9531253|NCT03186248|Experimental|Short myotomy|Per oral endoscopic myotomy extending from 3 cm cephalad to 3 cm distal to EGJ
9531254|NCT03186248|Active Comparator|Long myotomy|Per oral endoscopic myotomy extending from 6-8cm cephalad to and 3 cm distal to EGJ.
9531255|NCT03186196|Experimental|Group 1|Diet with 191 mcg/day of Folate
9531256|NCT03186196|Active Comparator|Group 2|Diet containing 90 mcg / day of Folate
9615574|NCT02544295|Experimental|Clinical interview-Virtual reality task:1|Healthy controls will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
9531257|NCT03186300|Other|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
9531258|NCT03186183|Experimental|GPS program|"The individual GPS motivational interviewing counseling program has 4-6 sessions.~Week 1: information on sexually transmitted infections and HIV disclosure laws is reviewed. Participants are introduced to the sex diary, stress exercise, and stages of change model.~Week 2: a decisional balance exercise about the participant's current sexual behavior is completed and a behavioral goal is chosen.~Week 3: participants explore their greatest fears and hopes about the goal, and the importance of and their confidence in achieving it.~Week 4: the facilitator and participant identify triggers, automatic thoughts, counters, strategies, supports, and rewards pertaining to the pursuit of the goal and role play the new goal.~1-2 supplemental sessions may be added as needed."
9531259|NCT03186079|Active Comparator|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
9531260|NCT03186079|Placebo Comparator|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
9531261|NCT03186053|Experimental|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
9531262|NCT03186053|Placebo Comparator|Control|The control group was treated with saline in the same manner.
9531263|NCT03186352|Experimental|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
9531264|NCT03186339||TAVI patients|patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
9531265|NCT03186339||SAVR patients|patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
9531266|NCT03186339||MM patients|patients in whom the aortic stenosis is medically managed
9531267|NCT03186066|Active Comparator|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
9531268|NCT03186066|Experimental|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
9531269|NCT03186326|Active Comparator|Arm A Chemotherapy (standard treatment)|FOLFOX or FOLFIRI +/- targeted therapy
9531270|NCT03186326|Experimental|Arm B - Immunotherapy (experimental arm)|Avelumab
9531271|NCT03186170|Experimental|SSA|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSA versus traditional technique of swin up) as well as embryo development.~In this arm, the sperm selection for IVF will be performed by the new proposed technique of Sperm Selection Assay which consist to expose spermatozoa a progesterone quemoatractant Sperm selection via SSA technique"
9531272|NCT03186170|Active Comparator|control|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up for sperm selection) as well as embryo development.~In this arm, the sperm selection for IVF will be the traditional swin up technique with different Percoll gradient Sperm selection via traditional swin-up"
10037953|NCT01829698|Experimental|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
10037954|NCT01829698|Active Comparator|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
9531273|NCT03186365|Experimental|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
9531274|NCT03186365|Active Comparator|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
9531275|NCT03186443|Active Comparator|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
9531276|NCT03186443|Experimental|gabapentin|compared to pregabalin effect on herpetic neuralgia
9531277|NCT03186144|Experimental|No arm : descriptive study|
9531278|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
9531279|NCT03186235||Group I : 18 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
9531280|NCT03186235||group II : 16 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
9531281|NCT03186235||group III:18 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
9804150|NCT01733732|Active Comparator|Systane Gel|SYSTANE® Gel, 1 drop in each eye 4 times a day for 30 days
10037955|NCT01829711|Experimental|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
9531282|NCT03186235||group IV: 18 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
9531283|NCT03186235||Group V:18 patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
9531284|NCT03186027|Active Comparator|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.~Active supplement based on Coenzyme Q10 plus NADH"
9531285|NCT03186027|Placebo Comparator|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.~Placebo: phosphoserine plus vitamin C"
9531286|NCT03186131|Active Comparator|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
9531287|NCT03186131|Active Comparator|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
9531288|NCT03186040|Other|Lacosamide|
9531289|NCT03186287|Experimental|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
9531290|NCT03186287|Experimental|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
9531291|NCT03186287|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
9531292|NCT03186001|Experimental|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
9531293|NCT03186001|Experimental|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
10037956|NCT01829763|Experimental|botox|
9531294|NCT03186001|Experimental|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
9531295|NCT03186014|Experimental|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
9531296|NCT03185871|Experimental|Celecoxib|"The participants will be scheduled for the two quantitative breast MRI exams. Following the first MRI exam, participants will start taking celecoxib 200mg twice a day with food. Subjects will take a minimum of 26 doses and no more than 32 doses of celecoxib during the study.~Participants will intake 200mg of celecoxib two times a day (400mg/day total) for 2 weeks after biopsy. Histologic tissue samples will be obtained for evaluation at time of biopsy of the tumor and at time of surgery removal of the tumor."
9531297|NCT03185962||Successful extubation|extubated successfully
9531298|NCT03185962||Extubation failure|reintubated within 48 hours
9531299|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
9531300|NCT03185910|Experimental|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
9531301|NCT03185910|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
9531302|NCT03185949|Sham Comparator|Sedation and subcutaneous lidocaine|Lidocaine injected at the femoral artery site. This patients will undergo behavioral therapy for 6 months and will crossover and will receive bariatric embolization.
10037957|NCT01829776|Experimental|education|Educational intervention
10037958|NCT01829789|Experimental|G-CRT|Group Community Reinforcement Training for parents
9531303|NCT03185949|Experimental|interventional: bariatric embolization|• In patients randomized to intervention bariatric embolization will be performed using Endobar Infusion Catheter System. After procedure patients will undergo behavioral therapy
9531304|NCT03185858|Experimental|SINEMA intervention group|The intervention arm will implement the SINEMA model for one year, which consists of a provider-facing intervention aiming to strengthen the capacity of village doctors in delivering stroke secondary prevention, and a stroke survivor-facing intervention aiming to promote medication adherence and physical activity.
10037959|NCT01829789|Active Comparator|I-CRT|Individual Community Reinforcement Training for parents
10037960|NCT01829802|Experimental|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
10058293|NCT02017197|Other|Sequence E|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1"
10037961|NCT01829802|Active Comparator|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
9497581|NCT03473678|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 10 days
9497582|NCT03473678|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 10 days
9497583|NCT03473652|Other|Adapted walking platform|
9497584|NCT03473639|Experimental|Entinostat and Capecitabine|"Dose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery.~The dose combinations include:~Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine~If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment."
10037962|NCT01829815|Experimental|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
10037963|NCT01829815|Other|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
9497585|NCT03473626|Experimental|Alicaforsen tablets|Regimen A - Alicaforsen tablets with food
9497586|NCT03473626|Experimental|alicaforsen tablets|Regimen B - Alicaforsen tablets without food
9497587|NCT03473613|Active Comparator|Calcium infusion|10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days
9497588|NCT03473613|Active Comparator|Oral Cabergoline|Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily
9497589|NCT03473600|Experimental|study group|•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
9497590|NCT03473600|Active Comparator|control group|•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
9497591|NCT03473587|Experimental|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
9497592|NCT03473587|Active Comparator|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
9497593|NCT03473548|Experimental|Portable Sleep Monitor|Type III portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
9497594|NCT03473535|Active Comparator|PST Alone|Participants will receive six sessions of face-to-face PST.
9497595|NCT03473535|Experimental|Blended-Therapy|Participants with receive six sessions of face-to-face PST supplemented by the BEACON platform.
9497596|NCT03473522|Experimental|anodal tDCS +Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs. Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
9497597|NCT03473522|Sham Comparator|Sham tDCS+ Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
9497598|NCT03473509|Experimental|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP >140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
9497599|NCT03473509|No Intervention|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
9497600|NCT03473496|Experimental|CART therapy in multiple myeloma|In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
9497601|NCT03473470|No Intervention|not warmed|Not warming system
9497602|NCT03473470|Active Comparator|warmed group 1|forced air warming and warmed intravenous fluids
9497603|NCT03473470|Active Comparator|warmed group 2|warmed intravenous fluids
10037964|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
10037965|NCT01829841|Experimental|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
10037966|NCT01829841|Active Comparator|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
10058294|NCT02017197|Other|Sequence F|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®"
10058295|NCT02017236|Experimental|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
10058296|NCT02017236|Experimental|Volitinib,after general diet|B:single oral Volitinib, after general diet
10058297|NCT02017249|Experimental|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
10058298|NCT02017249|Placebo Comparator|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
10058299|NCT02017262|Experimental|Self-management group|8 weekly sessions of group self-management
10058300|NCT02017262|Active Comparator|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
10058301|NCT02017275|Experimental|BuMA group|Implant BuMA stent only
9615575|NCT02544295|Experimental|Clinical interview-Virtual reality task:2|Patients will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
10058302|NCT02017275|Active Comparator|EXCEL group|Implant EXCEL stent
10058303|NCT02017288||Cancer|Participants diagnosed with incident oral cancer
10058304|NCT02017288||Control|Participants without oral lesions or cancers matched to oral cancer/precursor participants on age, gender, smoking/betel nut habits
10058305|NCT02017288||Precursor|Participants clinically diagnosed with oral lesions
10058306|NCT02017314|Active Comparator|Group 5|Patients with BMI > 50
10058307|NCT02017314|Active Comparator|Group IV|Patients with BMI between 40 and 49.9
10058308|NCT02017314|Active Comparator|Group III|Patients with BMI between 35 and 39.9
10058309|NCT02017314|Active Comparator|Group II|patients with BMI between 30 and 34.9
10058310|NCT02017314|Active Comparator|Group I|Patients with BMI <30
10058311|NCT02017340|Placebo Comparator|Placebo|250 patients will receive the placebo
10058312|NCT02017340|Active Comparator|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
10058313|NCT02017353|Experimental|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
10058314|NCT02017366|No Intervention|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
10058315|NCT02017366|Active Comparator|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
10058316|NCT02017392|Experimental|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
10058317|NCT02017392|No Intervention|blank control|No intervention.
10037967|NCT01829867|Experimental|sNN0031|
10037968|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
10037969|NCT01829893|Active Comparator|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
10037970|NCT01829893|Experimental|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
10037971|NCT01829906|Experimental|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
10037972|NCT01829906|Experimental|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
10037973|NCT01829932|Active Comparator|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
10037974|NCT01829932|Active Comparator|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
10037975|NCT01829971|Experimental|MRX34|Single agent MRX34
10037976|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
10037977|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
10037978|NCT01830010|Experimental|Study Part 1: KRP203|All patients to receive KRP203 for 111days
10037979|NCT01830010|Experimental|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
10037980|NCT01830010|Experimental|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
10037981|NCT01830023||cardiac ultrasound examination|
10037982|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
10037983|NCT01830049||Group I|Older males with ED
9615576|NCT02544256|Experimental|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
10037984|NCT01830049||Group II|Older males with normal erectile function
10037985|NCT01830049||Gourp III|Young males with normal rectile function
10037986|NCT01830062|Experimental|CACS and NIRS|All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
10037987|NCT01830075|No Intervention|Control group|The control group receives care as usual.
10037988|NCT01830075|Experimental|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
10037989|NCT01830088|Experimental|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
10037990|NCT01830088|Active Comparator|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
10037991|NCT01830101|Experimental|TMZ plus concurrent re-irradiation|TMZ plus concurrent re-irradiation
10037992|NCT01830101|Experimental|TMZ alone|TMZ alone
10037993|NCT01830114|Experimental|Web app evaluation group|
10037994|NCT01830153|Experimental|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
10037995|NCT01830166|Experimental|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
10037996|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
10037997|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
10037998|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
10037999|NCT01830231|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
10038000|NCT01830231|Active Comparator|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation~280 mg/m2 in patients aged >75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
9481244|NCT04841291|Experimental|Virtual Simulation-Based Arm|Access virtual simulation-based diabetes foot care education once for 30 minutes plus the standard care.
9481245|NCT04841291|No Intervention|Standard Care Arm|Participants will continue utilizing the usual follow-up diabetes care which occurs every month.
9481246|NCT04840875|Experimental|chimeric antigen receptor T cell treatment|
9481247|NCT04832802|Experimental|ACCESS-Vets Intervention Group|This group will receive ACCESS-Vets, a customized employment intervention adapted for use in VA healthcare.
9481248|NCT04832802|Active Comparator|IPS (Usual Care) Group|This group will receive IPS (Individual Placement and Support), the usual evidence-based supported employment program in VA.
9481249|NCT04832607|Experimental|Multivirus (CMV, EBV, AdV)-specific T cells|"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus~Max dose:~HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW~HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW~Min. dose:~- 10 T cells/kg recipient BW"
9481250|NCT04832607|Placebo Comparator|Sodium chloride|Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA
9481251|NCT04831619|Experimental|PET scanner in addition to MRI|
9481252|NCT04827212|No Intervention|Control|Control group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks
9481253|NCT04827212|Experimental|Treatment|Treatment group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks. In addition, the Companion will be deployed in the treatment group only.
9481254|NCT04826926|Experimental|Non-surgical periodontal treatment NSPT|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
9481255|NCT04823221||Rezūm system|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
9481256|NCT04822389|Experimental|Home-based telerehabilitation exercise|Exercise training is conducted in the patient's home conditions using modern technology to transfer medical data remotely - the participants receive a heart rate monitor and sensor. To know what to do and how to exercise, the first (1-2) exercise training sessions will be controlled by the physiotherapist in a rehabilitation clinic in the hospital, who creates individual exercise training for each patient. The patient's training data will be downloaded and updated regularly via the internet platform and clinicians will evaluate these results and provide patients with telephone feedback.
9481257|NCT04822194|Experimental|Distancing|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).
9481258|NCT04822194|Active Comparator|Reinterpretation|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).
9481259|NCT04815590|Experimental|Sublocade|This consists of 2 once-monthly 300 mg followed by 4 once-monthly 100 mg subcutaneous injections.
9481260|NCT04815031||COMIRNATY|COVID-19 mRNA vaccine (nucleoside-modified)
9481261|NCT04812964|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
9481262|NCT04812964|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
9481263|NCT04812483|Other|Standard Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1:~No planed further treatment. = standard therapy (without eltrombopag)"
9481264|NCT04812483|Experimental|Study Arm|"HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2:~The subjects in the experimental arm will be treated with eltrombopag:~Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows."
9481265|NCT04809519|Experimental|UHTINuM|UHTINuM is an acronym that defines multimodal interventions consisting of three components. These interventions are as follows: (1) Structured yoga program including meditation and breathing techniques (2) Hypertensive Treatment Compliance Training (3) Teaching blood pressure measurement and monitoring at home.
9481266|NCT04809519|Active Comparator|Control group|Control group will be receive information notes and standard brochures related to physical activity, healthy lifestyle behaviors advice, stop smoking etc. and will be referred to a specialist physician.
9481267|NCT04806386|Experimental|Psyllium fiber supplement treatment|All patients will receive psyllium fiber in the form of edible bars, 7g, twice a day to total 14g per day.
9481268|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
9481269|NCT04787211|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
9481270|NCT04787211|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
9481271|NCT04786028|Experimental|Isatuximab with CyBorD and Lenalidomide Maintenance|This is a single arm study of Isatuximab administered intravenously in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD), and Lenalidomide maintenance treatment
9481272|NCT04779866|Experimental|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
9481273|NCT04779866|Active Comparator|White Noise Hypnosis Control|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
9481274|NCT04779554|Experimental|Flat Dose Mitomycin C|Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
9481275|NCT04779554|Experimental|Weight-Based Mitomycin C|Participants in this group will receive weight-based dosing of mitomycin C intra-operatively: 1) 9 mg/m2 at minute 0 and 2) 3.5 mg/m2 at minute 60 for total dose of 12.5 mg/m2. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
9481276|NCT04778774|Experimental|Adductor canal block group|Adductor canal block group
9481277|NCT04778774|Experimental|Femoral nerve block group|Femoral nerve block group
9481278|NCT04777175||KRAS mutation|patients carry with KRAS mutation
9481279|NCT04777175||ALK fusion|patients carry with ALK fusion
9481280|NCT04777175||ERBB2 mutation|patients carry with ERBB2 mutation
9481281|NCT04777175||MET skipping/amplication|patients carry with MET skipping/amplication
9481282|NCT04777175||RET fusion|patients carry with RET fusion
9481283|NCT04777175||BRAF mutation|patients carry with BRAF mutation
9481284|NCT04772482||All Participants|All participants will undergo path testing to determine skin sensitivity to certain compounds.
9481285|NCT04772248||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
9481286|NCT04772248||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
9481287|NCT04771364||Standard care|"Patients aged >65 years old scheduled for hip fracture between January 1st 2019 and December 31th 2019.~Standard anesthesiology cares were performed, as usual in our hospital institution."
9481288|NCT04771364||ASAP cohort|"Patients aged >65 years old scheduled for hip fracture between January 1st 2020 and December 31th 2020.~Standard anesthesiology cares were performed, as usual in our hospital institution, but the investigator focused the attention on these cares' adaptation: early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic therapy."
9481289|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
9481290|NCT04770467|Placebo Comparator|Placebo in adult subjects with severe COVID-19|
9481291|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
9481292|NCT04770467|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
9481293|NCT04768010|Experimental|Misoprostol|Participants will receive 100-200 micrograms of oral misoprostol twice daily.
9481294|NCT04765696||Persons 55 years or older considering relocation|No intervention is administered.
9481295|NCT04764591|Active Comparator|Lateral sagittal approach|Patients in this group will be randomized to receive a lateral sagittal approach for Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
9481296|NCT04764591|Active Comparator|Costoclavicular approach|Patients in this group will be randomized to receive a costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
9481297|NCT04763915|Experimental|GeneSHARE|Access to GeneSHARE, a web-based toolkit including interactive and narrative components to enhance FC of genetic test results.
9481298|NCT04763915|Experimental|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
9481299|NCT04763915|Active Comparator|Standard-of-care|Receive standard-of-care from their treating healthcare provider.
9481300|NCT04759950|Experimental|Physical exercise & cognitive training group|The Physical exercise & cognitive training group receives a multicomponent physical exercise program combined with computer-based cognitive training.
9481301|NCT04759950|Experimental|Mindfulness & cognitive training group|The Mindfulness & cognitive training group receives mindfulness-based stress reduction therapy combined with computer-based cognitive training.
9481302|NCT04759950|Active Comparator|Cognitive training group|The Cognitive training group, as an active control group, receives only computer-based cognitive training.
9481303|NCT04759326|Active Comparator|Hippotherapy treated group|The hippotherapy protocol will comprise three cycles. The first one consists of one session per day for 2 weeks allowing (i) to evaluate the patient and his neuro-functional skills, and (ii) to determine and carry out the treatment taking into account the silent barriers that may exist (PSTD, fatigue, pain, fear...) and strongly interfere with functional outcome (developing ways to overcome them). After a 9-week 'wash out' period (during which the patient consolidates the new patterns, translates them into daily activities and identifies new needs) where the patient continues his or her outpatient neurorehabilitation care, a further intermediate 1-week daily capacity building hippotherapy cycle follows. Then, after a second 9-week 'wash out' period (where the patient once again consolidates the new patterns, translates them into daily activities and identifies new needs), a final 1-week daily capacity building hippotherapy cycle will be carried out. Protocol will last 22 weeks.
9497604|NCT03473457|Experimental|CART therapy in Acute myeloid leukemia|In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
9497605|NCT03473431|Experimental|ketamine|single infusion of 0.5 mg / kg ketamine
9497606|NCT03473431|Sham Comparator|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
9481304|NCT04759326|Placebo Comparator|Conventional neurorehabilitation treated group|Patients in the control group will receive standard outpatient rehabilitation treatment consisting of a program of physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support per week corresponding to the four weeks in which the treated group will be in hippotherapy. For the remaining 18 weeks, the treatment options for each patient, regardless of the group, will also include physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support.
9481305|NCT04756037|Experimental|Relugolix/E2/NETA|Participants will receive relugolix combination therapy for 1 year (13 consecutive 28-day treatment cycles).
9481306|NCT04749368|Experimental|Cohort A|Participants will receive BRII-835 (VIR-2218) for 32 weeks
9481307|NCT04749368|Experimental|Cohort B|Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40
9481308|NCT04749368|Experimental|Cohort C|Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40
9481309|NCT04749290|Experimental|Study Formula|a Cow's Milk Based Infant Formula Containing Both OPO and CPP for term infants (JunLeBao ZhiZhen)
9481310|NCT04749290|Active Comparator|Comparator Formula|Commercially available infant formula without OPO for term infants (JunLeBao LeChun)
9481311|NCT04749290|No Intervention|Human Milk Reference Group|Human milk
9481312|NCT04747886|Active Comparator|WW Only|Participants will receive 3-month access to the WW digital program.
9481313|NCT04747886|Experimental|WW + PolyRules!|Participants will receive 3-month access to the WW digital program and the PolyRules! app.
9481314|NCT04747548|Active Comparator|Kurbo Only|Participants will receive 1-month access to the Kurbo digital program.
9481315|NCT04747548|Experimental|Kurbo + PolyRules!|Participants will receive 1-month access to the Kurbo digital program and the PolyRules! app.
9481316|NCT04747236|Experimental|AZA and ROMI|Oral Azacytidine (AZA) (300 mg daily on days 1-14) plus Romidepsin (ROMI) (14 mg/m2 as an intravenous infusion over 4 hours on days 8, 15 and 22 of a 35-day cycle.
9481317|NCT04747236|Active Comparator|Investigator's Choice|Investigator's choice to include: ROMI, 14 mg/m2 IV infusion on days 1, 8, and 15 of a 28 day cycle, belinostat,1000 mg/m2 IV infusion on days 1-5 every 21 days, pralatrexate, 30 mg/m2 IV push once weekly for 6 weeks of a 7-week treatment cycle, or gemcitabine, 1000 mg/m2 IV infusion on days 1, 8, and 15 of a 28-day cycle.
9481318|NCT04743778|Experimental|Virtual Diabetes Self-Management Education and Support|Participants randomized into the virtual empowerment-based DSME/S group will receive one hour of DSME/S delivered by a Certified Diabetes Care and Education Specialist (CDCES) per week for 10 weeks delivered via the Zoom for Health at U-M service may be used for Protected Health Information (PHI, regulated by HIPAA). To ensure treatment fidelity, three DSME/S sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
9481319|NCT04743778|Active Comparator|Control Group|Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
9481320|NCT04740580|Experimental|Glycine plus N-acetylcysteine|Glycine and cysteine are amino-acid (protein) precursors of glutathione. Cysteine is provided as N-acetylcysteine
9481321|NCT04740580|Placebo Comparator|Alanine|Alanine is an amino-acid (protein), and not a precursor of glutathione synthesis
9481322|NCT04728906|Experimental|Heart patch + cardiomyocytes - hAESC|Patients who undergo bypass (CABG) surgery are given heart patch in areas where grafting (bypass) is not feasible
9481323|NCT04719520|No Intervention|traditional method|radio and telephone to notify the patient's family to the operating room
9481324|NCT04719520|Experimental|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
9481325|NCT04717128|Experimental|Baby doll with user remote controlled jaw|In this arm, standardized patients will use the Newborn Oral Assessment and Latch Simulator (NORALSim) to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
9481326|NCT04717128|Active Comparator|Baby doll with hand controlled jaw|In this arm, standardized patients will use a cloth baby doll with a puppet-style mouth to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
9481327|NCT04711525|Experimental|Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be exposed to interactive classroom instruction, and their parents will be exposed to the Web-based program. In the experimental group, apart from the standard preschool health education curriculum, the preschool children will also be exposed to the interactive activities and quizzes using Web 2.0 tools, educational videos of a healthy lifestyle, sensory-based food education activities, cooking demonstrations, fun, and active games, and exercises. Whereas the parents will be exposed to Web-based healthy lifestyle educational materials, videos, and pictures sharing, quizzes, and communication through the WhatsApp and closed Facebook groups. Besides, a total of 3 messages per week will be delivered to the parents in the experimental group. The messages will be included announcing the release of a new topic, a reminder to log in to the website and read the health information, and a reminder to participate in the online activities.
9481328|NCT04711525|Active Comparator|Standard health education|The children in the control group do not have exposed to the i-MaCHeL interactive classroom instruction, and their parents do not have access to the i-MaCHeL website materials. Thus, the children will be continued with standard health education only in the preschool setting, and their parents will be received Web-based health newsletters. The Web-based newsletters consist of general health information that are relevant to the preschool life stage. In ensuring that the experimental and control groups appear the same, the topics in the Web-based newsletters will have a look and feel similar nature to the experimental group condition. But still, the topics will not be included the interactive components such as videos and pictures sharing activities, quizzes, individualized feedback, and communication through WhatsApp and closed Facebook groups. Only one message (announcement of the release of a new topic) per week will be delivered to parents of the control group.
10038001|NCT01830244|Experimental|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
10038002|NCT01830257|Experimental|sending message|The investigators would send the tip to the children's guardian
10038003|NCT01830270|Experimental|PET regimen|
10038004|NCT01830283|Active Comparator|1 dose varicella vaccine|The providers would get the 2nd dose since they had one dose varicella vaccine
9531305|NCT03185858|No Intervention|Control group|Villages in the control arm continue their usual practice without the introduction of any of the SINEMA activities described above. People who have hypertension or who are at high-risk of hypertension may receive follow-up visits four times per year as part of the basic public health services required by the government.
9531306|NCT03185728|Experimental|iLookOut|Online, interactive learning program developed by study team.
9531307|NCT03185728|Active Comparator|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
9531308|NCT03185728|No Intervention|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
9531309|NCT03185975|Placebo Comparator|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
9531310|NCT03185975|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
9531311|NCT03185988|Experimental|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|HER2 positive GI tumor beyond CRC, ESCC, BTC,GC&GEJA
9531312|NCT03185988|Experimental|Esophageal squamous cell carcinoma|HER2 positive Esophageal squamous cell carcinoma
9531313|NCT03185988|Experimental|Biliary tract cancer|HER2 positive Biliary tract cancer
9531314|NCT03185988|Experimental|Colorectal cancer|HER2 positive and RAS/BRAF wild type colorectal cancer
9531315|NCT03185923|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
9531316|NCT03185923|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
9531317|NCT03185715|Other|Counseling policy embryo transfer|All recipients completed a validated self-report questionnaire on the preference on the number of embryos to be transferred and the relevance for the decision-making process attributed to certain factors. The questionnaire also included questions on sociodemographic characteristics, medical-reproductive background and cycle's results and risks perception. All recipients received oral and written counselling. After counselling, during the treatment, the recipients completed a second questionnaire in order to check if their decision had changed.
9531318|NCT03185650|Other|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
9531319|NCT03185650|Other|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
9531320|NCT03185806|Experimental|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
9531321|NCT03185806|No Intervention|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
9531322|NCT03185741|Experimental|UMS Strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record.~Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with important medication-related information following health literacy best practices."
9531323|NCT03185741|Experimental|UMS Strategy + SMS Text Messaging|In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.
9531324|NCT03185741|No Intervention|Usual Care|Patients of providers randomized to the usual care arm will receive their standard care
9531325|NCT03185780|Experimental|Treatment|Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
9531326|NCT03185845|Experimental|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
9531327|NCT03185845|No Intervention|Regular anticoagulation|stop anticoagulation after regular treatment
9531328|NCT03185936|Experimental|Optic disc pit maculopathy|pars plana vitrectomy with internal limiting membrane (ILM) peeling, endolaser
9531329|NCT03185767|Other|SLE group|
9531330|NCT03185767|Other|control group|
9531331|NCT03185884|Active Comparator|Control|- 237 ml beverage; consumed once per test visit
9531332|NCT03185884|Experimental|Experimental|- 237 ml beverage; consumed once per test visit
9531333|NCT03185494|Experimental|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
9531334|NCT03185689|Experimental|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
9531335|NCT03185689|No Intervention|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
9615577|NCT02544256|No Intervention|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
9531336|NCT03185611|Experimental|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
9531337|NCT03185611|Active Comparator|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
9531338|NCT03185442|Experimental|PRF-fMRI|
9531339|NCT03185624|Experimental|Rifaximin|Prescribed Rifaximin (600mg, twice daily) for 3 months after surgery
9531340|NCT03185624|No Intervention|Blank control|No intervention after surgery
9531341|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
9531342|NCT03185559|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
9531343|NCT03185559|Sham Comparator|Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
9531344|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
9531345|NCT03185598||non-MACE|no MACE occurred
9531346|NCT03185598||MACE|MACE occurred
9531347|NCT03185754|Experimental|early phase lung cancer|sublobar resection and lobectomy
9531348|NCT03185702||Patients with Turner Syndrome|Chromosomal diagnosis and typical features
9531349|NCT03185702||Unaffected controls|Normal females and unaffected family members
9531350|NCT03185416|No Intervention|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
9531351|NCT03185416|Experimental|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
9531352|NCT03185676|Experimental|Billberry|A bilberry-based probiotic beverage
9531353|NCT03185676|Active Comparator|Control|A control beverage without bilberries or probiotics
9531354|NCT03185429|Experimental|Experimental|"Drug:Cyclophosphamide~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
9531355|NCT03185507|Experimental|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
9531356|NCT03185507|No Intervention|Control|Participants sat quietly for 20 minutes
9531357|NCT03185364|Experimental|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
9531358|NCT03185364|Placebo Comparator|Control group|placebo oral tablet, 12 weeks
9531359|NCT03185403|Active Comparator|continous paravertebral block|"echoguided thoracic continous paravertebral block was placed before the surgery.~A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required."
9531360|NCT03185403|Active Comparator|continous Thoracic epidural block|thoracic epidural catheter was inserted before the surgery. A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required.
9531361|NCT03185793|Placebo Comparator|Placebo|placebo for 5 weeks
9531362|NCT03185793|Experimental|2.5mg SHR4640|SHR4640 for 5 weeks
9531363|NCT03185793|Experimental|5mg SHR4640|SHR4640 for 5 weeks
9531364|NCT03185793|Experimental|10mg SHR4640|SHR4640 for 5 weeks
9531365|NCT03185793|Active Comparator|50mg benzbromarone|Benzbromarone for 5 weeks
9531366|NCT03185390|Other|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
9531367|NCT03185637||Gastroschisis|All patients presenting primarily to the institution with gastroschisis during the data collection period will be included in the study.
9531368|NCT03185637||Anorectal malformation|All patients presenting primarily to the institution with anorectal malformation during the data collection period will be included in the study.
9531369|NCT03185637||Appendicitis|All patients under 16-years of age presenting primarily to the institution with appendicitis during the data collection period will be included in the study.
9531370|NCT03185637||Intussusception|All patients under 16-years of age presenting primarily to the institution with intussusception during the data collection period will be included in the study.
9531371|NCT03185637||Inguinal hernia|All patients under 16-years of age undergoing surgery for an inguinal hernia at the institution during the data collection period will be included in the study.
9531372|NCT03185468|Experimental|4SCAR-PSMA|4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.
9531373|NCT03185468|Experimental|4SCAR-FRa|4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.
9615578|NCT02544308|Active Comparator|No further treatment|No further treatment
9531374|NCT03185351|Active Comparator|BUPIVACAINE|"patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.~."
9531375|NCT03185351|Active Comparator|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
9531376|NCT03185351|Active Comparator|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
9531377|NCT03185286|Experimental|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
9531378|NCT03185338|Experimental|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
9531379|NCT03185338|Experimental|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
9531380|NCT03185338|Experimental|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
9531381|NCT03185338|Experimental|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
9531382|NCT03185338|Experimental|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
9531383|NCT03185338|No Intervention|Control school|Control school will be evaluate but will not receive any intervention
9531384|NCT03185091|Other|rapid ventricular pacing|Safety of rapid ventricular pacing during neurosurgical procedures
9531385|NCT03185221|Experimental|Cordimax|Rapamycin Eluting Coronary Stent
9531386|NCT03185221|Active Comparator|XIENCE V|Everolimus Eluting Coronary Stent
9531387|NCT03185247|Experimental|Group Intervention|10-week parent-child multi-family group
9531388|NCT03184948|Active Comparator|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
9531389|NCT03184948|Active Comparator|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
9531390|NCT03184948|No Intervention|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.~*No individual participants are recruited for this study."
9531391|NCT03185234|Active Comparator|Real tDCS|Anodal tDCS at an intensity of 2 mA is applied for 10 minutes at a time on 5 consecutive days. The anodal electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere, the cathodal electrode is located supraorbital on the right side. Motor tasks are performed before and after the stimulation.
9531392|NCT03185234|Sham Comparator|Sham tDCS|Sham stimulation is applied for 10 minutes at a time on 5 consecutive days. One electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere and a second electrode supraorbital on the right side. Motor tasks are performed before and after the stimulation.
9531393|NCT03185104|Experimental|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
9531394|NCT03185104|Placebo Comparator|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
9531395|NCT03185156|Experimental|propofol group|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
9531396|NCT03185156|Placebo Comparator|control group|first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump
10038005|NCT01830283|Experimental|2 dose varicella vaccine|The provider never get the varicella vaccine
9531397|NCT03184909|Experimental|Tulsi active|
9531398|NCT03184909|Placebo Comparator|Tulsi placebo|
9615579|NCT02544308|Experimental|Lenalidomide + Dexamethasone|Lenalidomide 25mg orally daily on days 1-21 Dexamethasone 20mg orally on days 1, 8, 15 & 22 Up to 9 cycles
10038006|NCT01830296|Active Comparator|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
9531399|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
9531400|NCT03185325||Non hodgkin lymphoma patients|bone marrow puncture and venous blood samples
9531401|NCT03185325||healthy voulnteers|venous blood samples
9531402|NCT03184896||Hip Fracture|
10038007|NCT01830296|Active Comparator|IV morphine PCA|IV remifentanil+morphine PCA
9531403|NCT03184844|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
9531404|NCT03184961|Experimental|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.~Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%."
9531405|NCT03185208|Experimental|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
10038008|NCT01830309|Experimental|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
10038009|NCT01830309|Experimental|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
9531406|NCT03185208|Placebo Comparator|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
9531407|NCT03185312||patients with acne vulgaris|Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
9531408|NCT03185312||patients with vitiligo|Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..
9531409|NCT03185312||control|"Skin biopsies will be taken from skin of controls.~. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3."
9531410|NCT03185143|Experimental|Naltrexone and Acetaminophen Combination|
9531411|NCT03185143|Active Comparator|Sumatriptan 100 mg|
9531412|NCT03185143|Placebo Comparator|Placebo|
9531413|NCT03184883|Experimental|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
10038010|NCT01830322|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
10038011|NCT01830322|Active Comparator|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
9531414|NCT03184883|Active Comparator|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
9531415|NCT03184857|Active Comparator|two stage sinus lifting using bovine bone particles|Open maxillary sinus lifting will be done with sinus augmentation using bovine bone particles
9531416|NCT03184857|Experimental|two sage sinus lifting using Nano HA bone particles|Open maxillary sinus lifting will be done with sinus augmentation using Nano HA bone particles
9531417|NCT03185169|Other|Replens and coconut oil|Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
9531418|NCT03185195|Experimental|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
9531419|NCT03185195|Experimental|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
9531420|NCT03185195|Experimental|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
9531421|NCT03185039|Experimental|kidney cancer|Localized, oligometastatic or metastatic
9531422|NCT03184870|Experimental|Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI|FOLFIRI: FOL (folinic acid [leucovorin]) F (fluorouracil [5-fluorouracil]) IRI (irinotecan [CAMPTOSAR])
9531423|NCT03184870|Experimental|Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel|
9531424|NCT03184870|Experimental|Part 1 Arm C [2L Pancreatic & 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab|2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable
9531425|NCT03184870|Experimental|Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI|
9531426|NCT03184870|Experimental|Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI|
9531427|NCT03184870|Experimental|Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI|
9531428|NCT03184870|Experimental|Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel|
9531429|NCT03184870|Experimental|Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel|
9531430|NCT03184870|Experimental|Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel|
9531431|NCT03184870|Experimental|Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab|
9531432|NCT03184870|Experimental|Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab|
9531433|NCT03184870|Experimental|Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy|
9531434|NCT03184870|Experimental|Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy|
9531435|NCT03184831|Active Comparator|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
9531436|NCT03184831|Experimental|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
9531437|NCT03184922|Active Comparator|Fixed suspensory loop|Non-adjustable femoral cortical fixation device to be used
10038012|NCT01830322|Experimental|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
10038013|NCT01830322|Experimental|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
9531438|NCT03184922|Experimental|Adjustable suspensory loop|Adjustable femoral cortical fixation device to be used
9531439|NCT03185130|Active Comparator|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
9531440|NCT03185130|Experimental|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
9531441|NCT03185299|Experimental|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
9531442|NCT03185299|Experimental|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
9531443|NCT03185000|Experimental|Immediate ATIMP (AP)|Patients randomised to AP will receive Treg immunotherapy (TR004) infusion at Week 0 and Placebo infusion at Week 8.
9531444|NCT03185000|Experimental|Delayed ATIMP (PA)|Patients randomised to PA will receive Placebo infusion at Week 0 and Treg immunotherapy (TR004) infusion at Week 8.
9531445|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
9531446|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
9531447|NCT03184805|Active Comparator|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
9531448|NCT03184805|Experimental|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
9531449|NCT03185078|Experimental|Active Comparator: Low density ESWT Application|ESWT application will be done at energy density of 0.12 mJ/mm2.
10038014|NCT01830335|Experimental|Drug|Indomethacin 1.2 mg kg 1 dose
10038015|NCT01830335|Placebo Comparator|Placebo|flour capsule
9531450|NCT03185078|Experimental|Active Comparator: High density ESWT Application|ESWT application will be done at an energy density of 0.3 mJ/mm2.
9531451|NCT03185078|Sham Comparator|Control|The ESWT application will be executed when the ESWT application is in the off position. During application, pre-recorded sound beats will be played to the treatment group.
9531452|NCT03184740|Experimental|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
9531453|NCT03184740|Sham Comparator|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
9531454|NCT03184714|No Intervention|Control|
9531455|NCT03184714|Experimental|Interventional group|NIPPV as treatment of OS
9615580|NCT02544191|Experimental|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
9615581|NCT02544165|Experimental|Caffeine intake|100mg of Caffeine intake
9615582|NCT02544165|Experimental|Cigarette smoking|smoking of one cigarette
9615583|NCT02544165|Experimental|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
9615584|NCT02544165|No Intervention|Control group|no intervention group
9615585|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
9531456|NCT03184649|Experimental|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
10038016|NCT01830348|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
10038017|NCT01830348|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
9531457|NCT03184649|Experimental|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
10038018|NCT01830361|Experimental|midostaurin (PKC412), capsules|midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.
10038019|NCT01830374||Women with bulimia nervosa|This is not a treatment study. All participants will go through the same steps.
10038020|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
10038021|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
10038022|NCT01830400||Eslicarbazepine Acetate tablets|
10038023|NCT01830413||Stenting|cerebral artery stenting for systematic Intracranial artery stenosis
9531458|NCT03184649|Placebo Comparator|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
10038024|NCT01830439|Experimental|Fed PA-824 200mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
10038025|NCT01830439|Experimental|Fasted PA-824 200 mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
10038026|NCT01830439|Experimental|Fed PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
10038027|NCT01830439|Experimental|Fasted PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
10038028|NCT01830452|Experimental|Parietex Progrip mesh|Ventral hernioplasty using a (self gripping / self adhering / self fixating) Progrip mesh not needing fixation devices
9531459|NCT03184597|Experimental|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A*24:02 and HLA-B*15:02 in a patient, aromatic AEDs were not administrated for this patient.
9531460|NCT03184597|Experimental|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.~When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:01 or HLA-A*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
9531461|NCT03184597|Experimental|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B*15:11, HLA-A*02:01and HLA-DRB1*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
9531462|NCT03184597|Experimental|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
9531463|NCT03184779|Experimental|Intervention|The intervention group will receive an educational video containing safety messages and an injury prevention component with the intent of reducing behaviours and actions on the hill than can potentially lead to injury.
10038029|NCT01830452|Active Comparator|Parietex Mesh|Ventral hernioplasty using a polyester mesh fixed with non absorbable sutures as described by Lichtenstein/Amid
10038030|NCT01830465|Experimental|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
10038031|NCT01830478|Experimental|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
10038032|NCT01830491|Experimental|Clopidogrel napadisilate|aspirin 100mg
10038033|NCT01830491|Active Comparator|clopidogrel bisulfate|aspirin 100mg
10038034|NCT01830504|Experimental|NVP-BKM120 (BKM120) PI3K inhibitor|
10038035|NCT01830517|Experimental|amlodipine camsylate|amlodipine camsylate 5mg
10038036|NCT01830517|Active Comparator|losartan potassium|losartan potassium 50mg
10038037|NCT01830530|Experimental|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
10038038|NCT01830530|Placebo Comparator|Placebo|Two tablets containing placebo daily in the morning
10038039|NCT01830556|Active Comparator|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
9531464|NCT03184779|No Intervention|Control|The control group will receive the usual procedures associated with school outings where students have the opportunity to watch the standard welcome video (~8 minutes) with information on how their day will go and how to use and put on safety equipment. The information given in the control procedure emphasizes preparation and how to use and put on equipment rather than safety messages oriented towards preventing injury and collisions. Students in the control group will watch the video prior to participating in the ski area school program.
9531465|NCT03184467|Placebo Comparator|Control group|Normal saline 0.9%
9531466|NCT03184467|Experimental|Study group 1|GV1001 0.56 mg
9531467|NCT03184467|Experimental|Study group 2|GV1001 1.12 mg
9531468|NCT03184532||D|diabetic patients
9531469|NCT03184532||ND|non-diabetic patients
9531470|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
9531471|NCT03184753|Experimental|Single arm|OC-IgT cells to treat ovarian cancer.
9531472|NCT03184545|Experimental|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
9531473|NCT03184545|Active Comparator|Only PT|Group 2: Only Physical therapy (PT).
9531474|NCT03184675|Experimental|Functional action observation training|
9531475|NCT03184675|Other|General action observation training group|
9531476|NCT03184415|Experimental|DWC20155/DWC20156 Combination Therapy|
9531477|NCT03184415|Active Comparator|DWC20155 Monotherapy|
9531478|NCT03184415|Active Comparator|DWC20156 Monotherapy|
9531479|NCT03184350|Other|Adjuvant pelvic proton radiation|
9531480|NCT03184402|Experimental|DWJ1252|
9531481|NCT03184402|Active Comparator|Gasmotin|
9531482|NCT03184688|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
9531483|NCT03184688|Placebo Comparator|Normal saline|Normal saline for hydrodissection
9531484|NCT03184493|Experimental|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
9531485|NCT03184493|Experimental|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
9531486|NCT03184493|Active Comparator|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
9531487|NCT03184493|No Intervention|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
9531488|NCT03184363|Experimental|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
9531489|NCT03184584|Experimental|PBI-4050|
9531490|NCT03184610||OCT-scanning|Patients with Keratoconus are scanned with an OCT-Prototype
9531491|NCT03184610||OCT-scanning for volunteers|Volunteers with healthy eyes are scanned with an OCT-Prototype
9531492|NCT03184766|Experimental|1|Treatment Order: Test, Comparator 1, Comparator 2
9531493|NCT03184766|Experimental|2|Treatment Order: Test, Comparator 2, Comparator 1
9531494|NCT03184766|Experimental|3|Treatment Order: Comparator 1, Test, Comparator 2
9531495|NCT03184766|Experimental|4|Treatment Order: Comparator 1, Comparator 2, Test
9531496|NCT03184766|Experimental|5|Treatment Order: Comparator 2, Test, Comparator 1
9531497|NCT03184766|Experimental|6|Treatment Order: Comparator 2, Comparator 1, Test
9531498|NCT03184662|Experimental|HIPA group|"Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.~The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study."
9531499|NCT03184662|Active Comparator|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
9531500|NCT03184376|Experimental|Prebiotic|Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.
9531501|NCT03184376|Placebo Comparator|Placebo|Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.
9531502|NCT03184389|Other|Within-participant micro-randomization|Each minute when participant is available is randomly assigned to either intervention (to practice a stress management exercise) vs. no intervention prompt. When intervention occurs, participant's smartphone vibrates and relaxation app opens, prompting performance of a relaxation exercise.
9531503|NCT03184506|Sham Comparator|control group|
9531504|NCT03184506|Active Comparator|pre-warming group|
9531505|NCT03184337|Active Comparator|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
9531506|NCT03184337|Experimental|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
9531507|NCT03184272|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
9531508|NCT03183973|Experimental|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
9531509|NCT03183973|Experimental|placebo group|
9531510|NCT03184298|Other|Group|Participants receive three interventions: Surveys, Interviews, and Group Workshops
9531511|NCT03184168|Experimental|treatment|[14C]lorlatinib
9531512|NCT03184038|Other|Assessment of neurocognitive function|Patients undergo assessment of neurocognitive function at baseline and at 2, 4, 6, and 12 months after undergoing standard of care Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT)
9531513|NCT03184324|Experimental|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily
9531514|NCT03184324|Experimental|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily
9531515|NCT03184324|Experimental|DWP14012 80mg|DWP14012 40mg*2, tablet, orally, once daily
9531516|NCT03184324|Active Comparator|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
9531517|NCT03184142|Experimental|Simulation|During a suturing class at the simulation center, the students enter a classroom. Although the students are not aware of this, among them is an actor playing the role of a student. One of the two professors is also an actor. As the activity progresses, the professor targets the student played by an actor. The intimidation intensifies until the end. At the end of the activity, there is a debriefing explaining to the students that the bullying professor and the victim were actors.
9531518|NCT03184142|Experimental|Video|During a suturing class at the simulation center, after 55 minutes of suturing, the students will be exposed to a 15-minute video on workplace and hospital intimidation and how to manage it.
9531519|NCT03184142|Placebo Comparator|Control|During a suturing class at the simulation center, the students suture for the entire 70-minute duration of the activity. They are not exposed to intimidation (control group).
9531520|NCT03183986|Active Comparator|Phototherapy 478 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 478 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
9531521|NCT03183986|Active Comparator|Phototherapy 459 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 459 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
9531522|NCT03184025|Other|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
9531523|NCT03184220|Experimental|EXPERIMENTAL GROUP|"Patients who are pregnant, have pacemaker and those surgically operated cervical spine patients who have been treated with myofascial therapy a month earlier.~Multimodal physical therapy program includes:~Myofascial syndrome cervical therapy treatment."
9531524|NCT03184220|Experimental|CONTROL GROUP|"Multimodal physical therapy program includes:~ultrasound therapy (US),~transcutaneous electric nerve stimulation (TENS)~massage."
9531525|NCT03183947|Experimental|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
9531526|NCT03183947|Experimental|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
9531527|NCT03183999|Experimental|GINST group|Experimental group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Fermented ginseng (GINST) was supplied.
9531528|NCT03183999|Placebo Comparator|Control group|Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
9531529|NCT03184311|Experimental|High-intensity interval training (HIT)|A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
9531530|NCT03184311|Placebo Comparator|Moderate-intensity continuous training (MCT)|A 12-week MCT will be performed 3 times per week on a bicycle ergometer. All sessions will consist of moderate continuous training (MCT) at 60-70% of peak heart rate (HRpeak) for 47 minutes.
9531531|NCT03184012|Experimental|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
9531532|NCT03184012|Experimental|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
9531533|NCT03184090|Experimental|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
9531534|NCT03184246|Experimental|GlideScope|intubation with GlideScope
9531535|NCT03184246|Active Comparator|Direct laryngoscopy|intubation with laryngoscope
9531536|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
9531537|NCT03184116|Experimental|Individual intervention|Individual intervention using cognitive-behavioral principles
9531538|NCT03184116|No Intervention|Control|No additional intervention
9531539|NCT03184064|Experimental|Treatment arm 1|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
9531540|NCT03184064|Experimental|Treatment arm 2|Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
9615586|NCT02544243|Experimental|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
9531541|NCT03184064|Experimental|Treatment arm 3|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
9531542|NCT03184064|Experimental|Treatment arm 4|Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
9531543|NCT03184129|Experimental|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
9531544|NCT03184129|Experimental|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
10038040|NCT01830556|Experimental|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
9531545|NCT03184259|Experimental|Robotic ankle system|Subjects will wear the Ankle Robot during 20-session gait training, power assistance will be provided from the motor to the ankle joint.
9531546|NCT03184259|Experimental|Robotic knee system|Subjects will wear the Knee Robot during 20-session gait training, power assistance will be provided from the motor to the knee joint.
9531547|NCT03184259|Placebo Comparator|Ankle Sham group|Subjects will wear the Ankle Robot during 20-session gait training, but no power assistance will be provided from the motor to the ankle joint.
9531548|NCT03184259|Placebo Comparator|Knee Sham group|Subjects will wear the Knee Robot during 20-session gait training, but no power assistance will be provided from the motor to the knee joint.
9531549|NCT03184259|No Intervention|Health Control|Healthy subjects will wear the Ankle Robot and/or Knee Robot during walking tasks (with or without power assistance), to collect control data for investigating if there are any effects of the robotic assistance on normal gait pattern.
9531550|NCT03184285|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
9531551|NCT03184194|Experimental|Nivolumab-daratumumab|daratumumab 16 mg/kg: 8 times once weekly, then 8 times every 2 weeks; then every 4 weeks; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks
9531552|NCT03184194|Experimental|Nivolumab-daratumumab with cylclophosphamide|daratumumab 16 mg/kg: weekly for 8 weeks, then Q2W for 16 weeks, ten Q4W thereafter; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks; low-dose cyclophosphamide 50mg daily on days 1-28 of each 28-day cycle;
9531553|NCT03183960|Experimental|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
9531554|NCT03183960|Active Comparator|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
9531555|NCT03183921||Cases|All ICU patients with nosocomial lower respiratory tract infection
9531556|NCT03183882|Experimental|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
9531557|NCT03183882|Active Comparator|Control Feedback|One-time summary report of their individual history of opioid prescribing
9531558|NCT03183817|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
9531559|NCT03183817|No Intervention|Usual Care|Evidence-based care
9531560|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
9531561|NCT03183739|Experimental|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
9531562|NCT03183739|Experimental|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
9531563|NCT03183739|Experimental|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
9531564|NCT03183739|Placebo Comparator|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
9531565|NCT03183700|Other|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
9531566|NCT03183700|Experimental|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
9615587|NCT02544243|Experimental|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
10038041|NCT01830569|Experimental|EBMeDS group|The regular Evidence Linker and the EBMeDS system will be available in this group.
10038042|NCT01830569|Other|Control group|The regular Evidence Linker will be available in this group.
9531567|NCT03183700|Experimental|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
9531568|NCT03183765|Experimental|MMR vaccine|Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
9531569|NCT03183765|Active Comparator|Cryotherapy|patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
9531570|NCT03183830|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
9531571|NCT03183830|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
9531572|NCT03183752|Experimental|Metformin|patients randomized to Metformin group
9531573|NCT03183752|Placebo Comparator|Placebo|patients randomized to placebo group
9531574|NCT03183843|Active Comparator|Dabigatran|Dabigatran etexilate 150 mg by mouth every 12 hours for a year
9531575|NCT03183843|Active Comparator|Warfarin|Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
9531576|NCT03183674|Experimental|oxytocin spray|oxytocin nose spray dose 0,4IU/kg, once unique dose
9531577|NCT03183674|Placebo Comparator|placebo|saline nose spray, 0,9 %, once unique dose
9531578|NCT03183856|Experimental|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
9531579|NCT03183856|Active Comparator|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
9531580|NCT03183791|Experimental|RELAX group|
9531581|NCT03183791|Active Comparator|Monitored Usual Care (MUC) group|
9531582|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
9531583|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
9531584|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
9531585|NCT03183596|Active Comparator|Deep Serratus Anterior Block|"Patients in the deep Serratus Anterior Block (DSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone deposited deep to the serratus. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
9531586|NCT03183596|Active Comparator|Superficial Serratus Anterior Block|"Patients in the superficial Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
9531587|NCT03183635|Experimental|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
9531588|NCT03183635|Placebo Comparator|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
9531589|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
9531590|NCT03183557|Active Comparator|ZA alone|
9531591|NCT03183557|Active Comparator|ZA plus VD|
9531592|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers|"Arm1: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the lungs in the FOV is followed by two vertex-to-thigh PET/CT scans.~NOTE: If the patient cannot tolerate lying down for an extended period of time at the time of imaging, the patient may be switched to scanning protocol Option B, which does not include an initial 60-minute dynamic PET/CT scan.~IPF Patients will have a repeat [18F]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan (within 12-24 months post initial scan for previously scanned IPF patients if they are willing to be re-consented)."
9531593|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in PSC Patients|"Arm 2: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the liver in the FOV is followed by two vertex-to-thigh PET/CT scans.~A repeat [18F]FP-R01-MG-F2 PET/CT scan will be performed within 3-8 weeks post initial scan if a signal is present in the first scan."
9531594|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients|Arm 3: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
9531595|NCT03183466|Experimental|Patients included in inclusion criteria|
9531596|NCT03183479|Experimental|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
9531597|NCT03183479|Placebo Comparator|Control group|The patients in control group will be administered with normal saline solution as placebo.
9531598|NCT03183336|Experimental|Interpositional block graft|ridge split interpositional block graft
9531599|NCT03183336|Active Comparator|Onlay block graft|decortication onlay block graft
9531600|NCT03183349|Experimental|platelet rich fibrin|immediate implant grafting
9531601|NCT03183349|Active Comparator|deprotienized bovine bone (tutogen)|immediate implant grafting
9531602|NCT03183362|Experimental|Barbed suture ( STRATAFIX™ )|Cesarean section incision is closed using barbed sutures
9531603|NCT03183362|Active Comparator|Conventional suture (VICRYL™)|Cesarean section incision is closed using conventional sutures
9531604|NCT03183375|Experimental|Hydroxyurea arm|This arm will be given investigational drug that is Hydroxyurea .This intervention will be given along with the standard treatment that is blood transfusion and iron chelation.
9531605|NCT03183375|No Intervention|Standard arm|this arm will only receive the standard treatment which is blood transfusion and iron chelation
9531606|NCT03183271|Experimental|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
9531607|NCT03183297|Experimental|JMI-001|JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two).
9531608|NCT03183297|Active Comparator|Naproxen|Naproxen 220mg or 440mg
9531609|NCT03183297|Active Comparator|Fexofenadine|fexofenadine 60mg or 120mg
9531610|NCT03183297|Placebo Comparator|Placebo|
9531611|NCT03183193|Placebo Comparator|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
9531612|NCT03183193|Experimental|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
9531613|NCT03183258|Experimental|Sentinel Skin Flap|
9531614|NCT03183544|Experimental|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
9531615|NCT03183232|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
9531616|NCT03183232|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
9531617|NCT03183232|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
9531618|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
9531619|NCT03183427||Control group|Group of subjects without pineal cyst
9531620|NCT03183440|Experimental|PREBIOTICS|188 pregnant women
9531621|NCT03183440|Placebo Comparator|PLACEBO|188 pregnant women
9531622|NCT03183310|Active Comparator|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
9531623|NCT03183310|Placebo Comparator|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
9531624|NCT03183492|Experimental|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
9531625|NCT03183089|Experimental|Active|
9531626|NCT03183089|Active Comparator|Active Comparator|
9531627|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient>40mmHg and/or aortic valve area <1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
9531628|NCT03183219|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
9531629|NCT03183219|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
9531630|NCT03183219|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
9531631|NCT03183206|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor
9531632|NCT03183206|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
9531633|NCT03183206|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery
9615588|NCT02544269|Experimental|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
9615589|NCT02544269|Active Comparator|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
9615590|NCT02544204|Active Comparator|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
9615591|NCT02544204|Placebo Comparator|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
9615592|NCT02544204|Active Comparator|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
9615593|NCT02544204|Placebo Comparator|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
9615594|NCT02544061|Experimental|NM-IL-12 plus Standard of Care (SOC)|"Single 12 µg unit subcutaneous dose of NM-IL-12 plus SOC.~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
9615595|NCT02544061|Placebo Comparator|Placebo plus SOC|"Single subcutaneous dose of placebo plus SOC~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
9615596|NCT02544126|Experimental|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
9615597|NCT02544126|Active Comparator|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
9481329|NCT04707573|Experimental|CKD, Stage 3|Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate [eGFR] 30 - 59 milliliters [mL]/minute) received a single 500 milligram (mg) oral dose of vadadustat after fasting for at least 4 hours.
9481330|NCT04707573|Experimental|CKD, Stage 4|Participants with Stage 4 CKD (eGFR <30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of vadadustat after fasting for at least 4 hours.
9481331|NCT04702997|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline urine albumin to creatinine ratio (UACR) less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
9481332|NCT04702997|Experimental|Maximum bardoxolone methyl dose of 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline urine albumin to creatinine ratio (UACR) greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4, and 30 mg at Week 6.~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
9481333|NCT04702997|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
9481334|NCT04691180|Experimental|Cohort 1|BRII-196 and BRII-198 dose level 1 or placebo
9481335|NCT04691180|Experimental|Cohort 2|BRII-196 and BRII-198 dose level 2 or placebo
9481336|NCT04685304|Experimental|PGx-guided care|Pharmacogenetic results (e.g., CYP2D6, CYP2C9) and a pharmacist consultation will be provided to their primary care provider. This consultation note (PharmD consult) will aid primary care providers in the interpretation and application of PGx results in prescribing decisions. The ultimate prescribing decision is at the discretion of the primary care provider and patient.
9481337|NCT04685304|Active Comparator|Standard care|"Care for study subjects will occur without PGx results at the discretion of the study subject, their primary care provider.~After the active participation ends (i.e. after the three month follow up is complete), PGx results and a PharmD consult will be provided similar to the PGx-guided arm."
9481338|NCT04682470||All patients|
9481339|NCT04676555||Ocrelizumab|Ocrelizumab is administered intravenously (IV) under the guidance of a specialized physician and followed by one-hour observation after the infusion. It requires a corticosteroid pre-medication and some antipyretics may also be administered.
9481340|NCT04676555||Ofatumumab|Ofatumumab is administered through a subcutaneous injection and allows self-administration after training.
9481341|NCT04674683|Experimental|Test Arm|HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days
9481342|NCT04674683|Placebo Comparator|Control Arm|Placebo oral BIW + nivolumab IV at specific doses on specific days
9481343|NCT04673851|Experimental|FEP Clients|Approximately 90 first episode psychosis (FEP) clients recruited from First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in the online platform Horyzons for 3 months (cohort 1) or 6 months (cohort 2) as a part of their care plan. Participants will be encouraged to use both the therapeutic content and the moderated online community throughout their time in the study.
9481344|NCT04673851|Other|FEP Clinicians|Approximately 40 providers (clinicians and peer support specialists) affiliated with First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in a focus group discussing the implementation and integration of Horyzons into their care routine with clients who participated in the study.
9481345|NCT04671797|Experimental|Early Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at an early dinner time (DLMO-3h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
9481346|NCT04671797|Experimental|Late Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
9481347|NCT04671797|Experimental|Late Dinner + Late Sleep first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by delayed bedtime (DLMO+6h). This arm will cross-over to the other 2 arms in random order.
9481348|NCT04671342|Experimental|Validation Arm|Participants will wear the DreamKit device (test device) while instrumented with polysomnography sensors (gold standard).
9481349|NCT04670263|Experimental|Dry Eye Disease|Subjects who will be diagnosed at baseline with Dry Eye Disease according to standard diagnosis
9481350|NCT04670263|Active Comparator|Healthy|Subjects who will be diagnosed at baseline with no Dry Eye Disease according to standard diagnosis
9481351|NCT04662099|Experimental|Conditioning chemotherapy plus CAR T cells infusion|
9481353|NCT04659161|Experimental|KarXT|
9481354|NCT04659161|Placebo Comparator|Placebo|
9531634|NCT03183037|Experimental|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
9531635|NCT03183037|Placebo Comparator|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
9531636|NCT03183037|Active Comparator|Usual Care Group|Twelve weeks of usual care.
9531637|NCT03183505|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
9531638|NCT03183505|Placebo Comparator|Placebo|Placebo,oral, twice per day
9531639|NCT03183115|Experimental|RFA group|Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD
9531640|NCT03183115|No Intervention|Control group|No intervention; surveillance endoscopy alone
9531641|NCT03183076|Active Comparator|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
9531642|NCT03183076|Active Comparator|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
9531643|NCT03183453|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
9531644|NCT03183453|No Intervention|Non-confabulators control group|Non-confabulators (brain injured patients but without confabulations) in this control group only performed the pre- and post-measurements without treatment.
9531645|NCT03183453|No Intervention|Healthy control group|Healthy participants in this control group only performed the pre- and post-measurements without treatment.
9531646|NCT03182894|Experimental|Epacadostat + Pembrolizumab + Azacitidine|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
9531647|NCT03182972|Experimental|Intervention arm|"Seminar presentation will be done using the followings:~Power point presentation on the following topics as it relates to medication reconciliation:~Communication skill (with patients and also with other members of the healthcare team)~Documentation of pharmaceutical care activities~Medication history taking~Drug therapy problems~Medication reconciliation practice~Case studies on medication reconciliation~Role plays on medication reconciliation"
9531648|NCT03182972|No Intervention|Control arm|Control group
9531649|NCT03182985|Experimental|Time Restricted Feeding|Patients will reduce daily oral intake to 10 hours per day
10038043|NCT01830582|Experimental|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
9531650|NCT03183050|Experimental|Question Prompt List|This is a single-arm study. Therefore, all participants will receive the prompt list.
9531651|NCT03182699|Experimental|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
9531652|NCT03182699|Active Comparator|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
9531653|NCT03182712|Experimental|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
9531654|NCT03182712|Placebo Comparator|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
9531655|NCT03182803|Experimental|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
9531656|NCT03183024|Placebo Comparator|placebo|placebo for benralizumab sc given during run-in phase
9531657|NCT03183024|Experimental|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
9531658|NCT03183011|Other|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
9531659|NCT03182816|Experimental|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
9615598|NCT02544087|No Intervention|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
9615599|NCT02544087|Other|Clearing heat|Treat with KDZ injection on the basis of basic treatment
9615600|NCT02544087|Other|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
9615601|NCT02544087|Experimental|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
10038044|NCT01830582|Experimental|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
10038045|NCT01830582|Experimental|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
9481355|NCT04658303||Pimonidazole|Single dose of 0.5 gm/m^2 of pimonidazole (approximately 13 mg/kg)
9481356|NCT04656873||ICI treatment|Adult cancer patients starting ICI monotherapy or combination therapy at UNC Chapel Hill per clinical standard of care and willing to allow specimens from surplus tissue to be banked for research purposes (in the case of resections) AND willing to have additional specimens taken for research purposes (in the case of biopsies). Patients will be followed for samples and clinical data from medical records from before starting ICI therapy until 2 years after the end of ICI treatment.
9481357|NCT04649112|Experimental|Dose Level 1|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
9481358|NCT04649112|Experimental|Dose Level 2|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
9481359|NCT04649112|Experimental|Dose Level 3|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
9481360|NCT04646395|Experimental|Tafasitamab and Acalabrutinib|"Acalabrutinib will be administered continuously at the dose of 100 mg BID (equivalent to a total daily dose of 200 mg), from day 1 to day 28 of each cycle for 24 cycles.~Tafasitamab will be administered 12 mg/kg iv on days 1, 8, 15 and 22 for the first 3 cycles. Then patients will continue treatment until cycle 24 with tafasitamab 12mg/kg iv on day 1"
9481361|NCT04641858|Active Comparator|BCG-Denmark|Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the right upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
9481362|NCT04641858|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color and appearance as the resuspended BCG vaccine.
9481363|NCT04641559|Experimental|Personalized nutrition group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue during four months.
9481364|NCT04641559|Experimental|Personalized Plan group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue and behavioural change program during four months.
9481365|NCT04641559|Placebo Comparator|Control group|General recommendations but not personalization nor behavioural change advice will be implemented during four months.
9481366|NCT04634799|Active Comparator|TM5614|TM5614 30 mg tablets. 6 tablets (180 mg) taken by mouth, once daily for up to 7 days
9481367|NCT04634799|Placebo Comparator|Placebo|Placebo tablets. 6 tablets taken by mouth, once daily for up to 7 days
9481368|NCT04627896|Experimental|Katty focal therapy|Patients fulfilling inclusion criteria undergo focal treatment with Trinity-guided Katty device
9481369|NCT04624776|Active Comparator|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
9481370|NCT04624776|Placebo Comparator|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
9481371|NCT04623242|Experimental|Gantenerumab|
9481372|NCT04623242|Experimental|Solanezumab|
9481373|NCT04623242|Placebo Comparator|Matching placebo (Gantenerumab)|
9481374|NCT04623242|Placebo Comparator|Matching Placebo (Solanezumab)|
9481375|NCT04621838|Experimental|Assigned intervention.|"Silicone Foam Dressing. Silicone Foam Lite.~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silicone Foam dressing and Silicone Foam Lite Dressing."
9481376|NCT04621825|Experimental|Assigned intervention|"ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam.~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam."
9481377|NCT04611750|Experimental|Active Medication (AD036)|Participants will take AD036 QHS for 14 days.
9481378|NCT04611750|Placebo Comparator|Placebo Medication|Participants will take placebo QHS for 14 days.
9481379|NCT04610346|Other|Immediate|Participants in this group will begin the training protocol immediately (within 1 week) after baseline pre-training evaluation is completed.
9481380|NCT04610346|Other|Delayed|Participants in the delayed arm will participate in two pre-training evaluations, one immediately upon enrollment and one at the end of the delay period immediately before beginning training
9481381|NCT04600128|Active Comparator|Dairy-based Greek yogurt|Plain dairy-based Greek yogurt
9481382|NCT04600128|Active Comparator|Dairy-based cheddar cheese|Mild dairy-based cheddar cheese
9481383|NCT04600128|Active Comparator|Plant-based Greek yogurt|Plain plant-based Greek yogurt
9481384|NCT04600128|Active Comparator|Plant-based cheese|Medium cheddar plant-based cheese
9481385|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV
9481386|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV
9481387|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV
9531660|NCT03182959|Experimental|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
9531661|NCT03182959|Experimental|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
9531662|NCT03182777|Active Comparator|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
9531663|NCT03182777|Active Comparator|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
9531664|NCT03182842|Experimental|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
9531665|NCT03182842|Active Comparator|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
9531666|NCT03182673|Experimental|SHR7390, SHR-1210 and SHR3162|"Total 60-100 subjects with advanced solid tumors~In the two-drug combination therapy,subjects were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose.~In the second study part, subjects accepted three drug combination therapy, SHR7390 is administered orally for 21 days and discontinued for 7 days in a 28-day treatment cycle,SHR3162 was administered orally twice a day for 28 days at a fixed dose of 100 mg. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose"
9531667|NCT03182881|Experimental|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
9531668|NCT03182881|Active Comparator|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
9531669|NCT03182790|Experimental|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
9531670|NCT03182790|Experimental|Group B|COSH booklet + general brief advices +Placebo Messages
9531671|NCT03183102|No Intervention|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
9531672|NCT03183102|Experimental|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
9531673|NCT03182647||Non surgery|Patients were not treated with surgery initially
9531674|NCT03182647||Surgery|Patients had an initial surgical treatment
9531675|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
9531676|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
9531677|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
9531678|NCT03182855|Active Comparator|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
9531679|NCT03182855|Active Comparator|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
9531680|NCT03182634|Experimental|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
9531681|NCT03182634|Experimental|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
9531682|NCT03182634|Experimental|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
9531683|NCT03182634|Experimental|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
9615602|NCT02543827|Experimental|MV140 I|The subjects will receive daily dose of MV140 during 6 months
10038046|NCT01830582|Experimental|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
10038047|NCT01830608||300 patients with AMD|
9481388|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV
9481389|NCT04589767||children admitted in PICU|children enrolled will be evaluated by two nurses using CAPD Italian version. One nurse will repeat the evaluation two minutes later.
9481390|NCT04586712|Experimental|Active CBD-extract high dose|High Dose (1000mg/30mL hemp extract = 62.5mg/day)
9481391|NCT04586712|Experimental|Active CBD low dose|Low Dose (500mg/30mL hemp-extract = 25mg/day)
9481392|NCT04586712|Placebo Comparator|Vehicle-Control (Placebo)|(0mg/30mL hemp extract = no hemp extract)
9481393|NCT04582344|Experimental|SARS-COV-2 Vaccine|600 SU of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 14 days apart.
9481394|NCT04582344|Placebo Comparator|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, intramuscular injection, two doses given 14 days apart.
9481395|NCT04581473|Experimental|CT041 autologous CAR T-cell injection|Two stages: Phase 1b: dose escalation and dose expansion; Phase 2: verify CT041 efficacy and safety
9481396|NCT04581473|Active Comparator|Physician's Choice|Participants will receive physician's choice of treatment in Phase II
9481397|NCT04580537|Experimental|Laser-assisted Enstilar delivery|Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
9481398|NCT04580537|Active Comparator|Enstilar|Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
9481399|NCT04579393|Active Comparator|Intervention|fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19
9481400|NCT04579393|Placebo Comparator|Intervention - Placebo|Placebo in combination with standard of care (SOC) for the treatment of COVID-19
9481401|NCT04577482||Participants treated with Glecaprevir/Pibrentasvir|Participants will receive glecaprevir/pibrentasvir (GLE/PIB) as prescribed by physician in accordance with local clinical practice.
9481402|NCT04575883|Experimental|MedBIKE HIIT|MedBIKE HIIT Exercise Program
9481403|NCT04575285|Experimental|Electroencephalogram (EEG)|All participants will undergo EEG recording at baseline and end of treatment for a duration of 10-20 minutes per session.
9481404|NCT04571645|Experimental|Dociparstat sodium (DSTAT)|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Dociparstat 4 mg/kg IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.
9481405|NCT04571645|Placebo Comparator|Placebo|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Placebo IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Placebo via continuous IV infusion 24 hours daily for 5 or 7 days.
9481406|NCT04569747|Experimental|PERTUZUMAB + TRASTUZUMAB + ADJUVANT ENDOCRINE THERAPY|"Study treatment will be administered in 21-day (3- week, +/- 3 days) cycles for one year (18 cycles).~Trastuzumab + Pertuzumab SC fixed dose combination~Hormonal therapy- oral, daily per cycle (may add LHRH agonist per investigator discretion)"
10038048|NCT01830634|Experimental|Theraband with strengthening and stretching exercise|All subjects were received theraband exercises (strengthening and stretching), and then compare the measured outcomes between groups.
10038049|NCT01830647||Cohort|
9481409|NCT04563637||Computer Based Vision|A 15 second long video will be obtained at the research site using a smart phone or tablet. Then subjects will undergo a whole body dual energy x-ray absorptiometry scan . Then the subject will go home and take a second 15 second long video. The videos will then be analyzed by computer based vision application and the body fat percentage measured by dual energy x-ray absorptiometry scan will be compared.
9481410|NCT04555590|No Intervention|Pre H-HOPE Cohort|The Pre-H-HOPE Comparison Cohort will not receive the H-HOPE intervention, and represents the prior standard (non-HOPE).
9481411|NCT04555590|Experimental|H-HOPE Cohort|The H-HOPE Cohort will receive the H-HOPE intervention.
9481412|NCT04554693|Experimental|Metronidazole|Metronidazole
9481413|NCT04554693|Placebo Comparator|Placebo|Halal and Kosher certified gelatin placebo capsules
9481414|NCT04550013|Active Comparator|Heavy-Slow Resistance training|Heavy-Slow Resistance training. Three times weekly for 12 weeks.
9481415|NCT04550013|Experimental|Low-Load Blood Flow Restriction training|Low-Load Blood Flow Restriction training. Three times weekly for 12 weeks
9497607|NCT03473418|Experimental|Ketoconazole gel|use of Ketoconazole in situ gel for treatment of vaginal candidiasis
9497608|NCT03473418|Active Comparator|terconazole cream|use of terconazole 0.8 cream for treatment of vaginal candidiasis
9497609|NCT03473405|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
9497610|NCT03473405|Experimental|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
9497611|NCT03473379||Phase 1: concept elicitation and coding|The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.
9615603|NCT02543827|Experimental|MV140 II|The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
10038050|NCT01830660|Experimental|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
10038051|NCT01830660|Placebo Comparator|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
9531684|NCT03182634|Experimental|Cohort E - olaparib and AZD6738|AZD6738 160mg to be administered once daily on Days 1-7 of each cycle and olaparib 300mg to be administered twice daily on a continuous schedule starting on Cycle 1 Day 1.
9531685|NCT03182608|Experimental|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
9531686|NCT03182608|Experimental|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
9531687|NCT03182517||chronic kidney diseases|patients with chronic renal failure on dialysis since 3-5 years
9531688|NCT03182556|Placebo Comparator|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
9531689|NCT03182556|Experimental|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
9531690|NCT03182556|Experimental|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
9531691|NCT03182530|Active Comparator|ULTRA method group|
9531692|NCT03182530|Active Comparator|standard patent hemostasis group|
9531693|NCT03182530|Experimental|control group|
9531694|NCT03182621|Experimental|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
9531695|NCT03182621|Active Comparator|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
9531696|NCT03182569|Experimental|flexible catheter|The flexible Subcutaneous catheter for insulin administration
9531697|NCT03182569|Active Comparator|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
9531698|NCT03182543|Experimental|AM1|Mango pulp beverage
9531699|NCT03182543|Experimental|AM2|Mango pulp and peel beverage
9531700|NCT03182543|Placebo Comparator|Control|Control beverage
9531701|NCT03182595|Experimental|open---label|An open---label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13---week period.
9531702|NCT03182478|Active Comparator|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
9531703|NCT03182478|Active Comparator|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
9531704|NCT03182439|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
9531705|NCT03182439|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
9531706|NCT03182439|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
9531707|NCT03182439|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
9531708|NCT03182413|Placebo Comparator|PBO|Placebo
9531709|NCT03182413|Active Comparator|MOD|Modafinil 100mg
9531710|NCT03182413|Experimental|THN102 100/1|modafinil 100 mg + 1 mg flecainide
9531711|NCT03182413|Experimental|THN102 100/3|modafinil 100 mg + 3 mg flecainide
9531712|NCT03182413|Experimental|THN102 100/9|modafinil 100 mg + 9 mg flecainide
9531713|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
9531714|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
9531715|NCT03182400|Experimental|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
9531716|NCT03182504|Experimental|Nacubactam Plus Meropenem|Participants will receive a single dose of nacubactam co-administered with meropenem.
9531717|NCT03182491||Anaphylaxis|
9531718|NCT03182491||Febrile transfusion reactions|
9531719|NCT03182491||Mild allergic reactions|
9531720|NCT03182491||Healthy controls|
9531721|NCT03182465|Other|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
9531722|NCT03182296|Experimental|Gestational diabetes|Women with a history of gestational diabetes
9531723|NCT03182296|Active Comparator|Control|Women without a history of gestational diabetes
9615604|NCT02543827|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 6 month
9615605|NCT02543866|Experimental|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
9804219|NCT01736085|Active Comparator|Counseling plus Voucher|Subjects will receive up to 5 sessions of telephone counseling plus a voucher for 2 week's worth of nicotine patches.
10038052|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
9804220|NCT01736085|Active Comparator|Counseling plus Patches|Subjects will receive up to 5 sessions of telephone counseling plus 2 week's worth of nicotine patches.
10038053|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
10038054|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
10038055|NCT01830686|Experimental|Sugarcane bagasse|10 subjects will consume food (brownies and cookies) made with 13 g of sugarcane bagasse everyday for 4 weeks
10038056|NCT01830686|Active Comparator|Non-caloric, non-fermentable fiber|10 subjects will consume food (brownies and cookies) made with 13 g of non caloric, non-fermentable fiber everyday for 4 weeks
10038057|NCT01830686|Placebo Comparator|Minimal fiber|10 subjects will consume food (brownies and cookies) made with 4 g of dietary fiber everyday for 4 weeks
10038058|NCT01830712||Chart review|
10038059|NCT01830725||Gout/Hyperuricemia|Subjects with a diagnosis of hyperuricemia (defined as a uric acid of > 7.2 mg/dl) and/or gout.
10038060|NCT01830725||Control|Approximate age and gender matched controls without hyperuricemia or gout
10038061|NCT01830738|Experimental|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.~Intervention: Single-port, peri-umbilical hysterectomy"
10038062|NCT01830738|Active Comparator|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.~Intervention: Multi-port hysterectomy"
10038063|NCT01830751|Experimental|Limit trunk flexion upon rising|Immediately upon rising particpants perform the Restrained Sitting Treatment intervention for one hour.
10038064|NCT01830751|Sham Comparator|Limit trunk flexion before going to bed|Immediately prior to going to bed, particpants perform the Restrained Sitting Treatment intervention for one hour.
10038065|NCT01830764|Other|Red light dose (PDT) 75 J/cm2|Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2
10038066|NCT01830764|Other|Red Light (PDT) 150 J/cm2|Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2
9481416|NCT04549116|Experimental|Investigational|Progesterone-IBSA 25mg, twice daily (BID) subcutaneous (SC) injection every 12 hours and Crinone Placebo, once daily (QD) intravaginally.
10038067|NCT01830777|Experimental|Experimental Arm|Brentuximab Vedotin + MEC
9481417|NCT04549116|Active Comparator|Comparator|Crinone 8%, 90 mg, QD intravaginally and Progesterone-IBSA Placebo, BID SC Injection every 12 hours
9481418|NCT04548869|Experimental|CDX-0159|20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159
9481419|NCT04546841|Experimental|Vaccination|"A single vaccination with the IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides, XS15 emulsified in Montanide ISA 51 VG) (500 µl) will be applied subcutaneously (s.c.) to the abdominal skin.~Part I: Age 18-55 at the time of screening, n=12~Part II: Age 56-74 years at the time of screening, n=12~Part III: Age ≥ 75 years at the time of screening, n=12"
9481420|NCT04543877|Experimental|Inulin and Ty21a Vaccine|Participants will consume 12 grams/day of inulin for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
9481421|NCT04543877|Placebo Comparator|Maltodextrin and Ty21a Vaccine|Participants will consume 12 grams/day of maltodextrin (control) for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
9481422|NCT04542408|Experimental|Intensive anticoagulation strategy|In-hospital (ICU & normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC
9481423|NCT04542408|Other|Moderate anticoagulation strategy|In-hospital (ICU & normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban
9481424|NCT04541082|Experimental|ONC206|
9481425|NCT04540484||ALGH Physicians|Attending physicians on the medical staff, fellow physicians, and resident physicians that work at Advocate Lutheran General Hospital (ALGH) from March 1st, 2020 and forward.
10038068|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
10038069|NCT01830829|Experimental|Jaylyn|Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
10038070|NCT01830829|Placebo Comparator|Placebo|Placebo
10038071|NCT01830868||Zonisamide tablets|
10038072|NCT01830894|Experimental|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
10038073|NCT01830894|Experimental|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
10038074|NCT01830894|Experimental|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
10038075|NCT01830907|Active Comparator|Enteral|Enteral nutrition composed of carbohydrates and vitamins
10038076|NCT01830907|Active Comparator|Parenteral|
9481426|NCT04540484||Household Members|Household members above age 18 who lived in household of ALGH physician who tested positive for COVID-19 IgG antibodies, and who lived with that physician for at least 2 consecutive weeks.
9481427|NCT04530383|Experimental|Metformin dose regimen A|Participants with CFRD on elexacaftor/tezacaftor/ivacaftor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures through week 14. They will then undergo a two week washout period. For the second half of the study metformin will be resumed and, if tolerated, dose will be increased by 500mg on weeks 17 and 18 to a final dose of 1000 mg twice daily through end of study (week 30).
10038077|NCT01830946|Experimental|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
10038078|NCT01830946|Placebo Comparator|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
9531724|NCT03182348||Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
9531725|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
10038079|NCT01830946|Experimental|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
10038080|NCT01830959|Experimental|Roflumilast|Roflumilast
9531726|NCT03182257|Experimental|ONO-7579 Part A|Single Ascending doses of ONO-7579
9531727|NCT03182257|Experimental|ONO-7579 Part B|Expansion phase of ONO-7579
10038081|NCT01830959|Placebo Comparator|Placebo|Placebo
9531728|NCT03182374|Active Comparator|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
9531729|NCT03182374|Active Comparator|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
9531730|NCT03182361|Experimental|Study group|Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
9531731|NCT03182322|Experimental|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
9531732|NCT03182322|Placebo Comparator|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
9531733|NCT03182231|Experimental|RYGB patients|Patients who will receive a RYGB surgery
9531734|NCT03182075|Experimental|Active Training|OCD participants will receive active emotional reactivity training (14 sessions) via computer.
9531735|NCT03182075|Sham Comparator|Passive Training|OCD participants will receive passive computerized training (14 sessions) via computer.
9531736|NCT03182062|Active Comparator|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
9531737|NCT03182062|Active Comparator|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.~Postoperatively, standard oxygen therapy."
9531738|NCT03181919|Experimental|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
9531739|NCT03181919|No Intervention|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
9531740|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
9531741|NCT03182036|Experimental|Study group|Portable pulsed oxygen
9531742|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
9531743|NCT03181997||TAVI patients without cancer|Patients with no active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
9804221|NCT01736124|Experimental|Computerized Cognitive Training (CCT)|Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
10038082|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
10038083|NCT01830998||control, MCI|control and MCI group.Glycaemic control
10038084|NCT01830998||control and MCI|treatment and without treatment
10038085|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
10038086|NCT01831011|Experimental|mildronate|infusion of mildronate
10038087|NCT01831011|Active Comparator|cinepazide maleate|infusion of cinepazide maleate
10038088|NCT01831024|Experimental|Treatment Group|Dignicap System
10038089|NCT01831024|No Intervention|Control Group|Concurrent age and chemotherapy matched control
10038090|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
10038091|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
9531744|NCT03182088|Experimental|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
9531745|NCT03182088|Experimental|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
9531746|NCT03182088|Experimental|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
9531747|NCT03181945|Active Comparator|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
9531748|NCT03181945|Active Comparator|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
9531749|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
9531750|NCT03182192|Experimental|Hypoglycemia|Patients with hypoglycemia after gastric bypass
9531751|NCT03182192|Active Comparator|Control|Patients without hypoglycemia after gastric bypass
9531752|NCT03182101|Experimental|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
9531753|NCT03181880|Active Comparator|Aclidinium/formoterol|Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
9531754|NCT03181880|Active Comparator|Bronchodilators|The comparator arm consists of SOC.
9531755|NCT03182114|Placebo Comparator|supine position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in supine position
9531756|NCT03182114|Experimental|Left lateral tilted position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in left lateral tilted position
9531757|NCT03182127|Other|one Group|Magnetic resonance imaging and ultrasound will be done for all patient
9531758|NCT03182283|No Intervention|Pre-intervention|All patients at the psychosis wards receive care as usual before staff goes through educational intervention.
9531759|NCT03182283|Other|Post-intervention|After staff attended educational intervention and implemented Person-centered psychosis care in the wards all patients admitted will receive person-centered care.
9531760|NCT03182010|Experimental|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
9531761|NCT03182010|Active Comparator|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
9531762|NCT03182270|Experimental|pancreatic cysts|
9531763|NCT03181906|Experimental|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
9531764|NCT03181906|No Intervention|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
9531765|NCT03181854|Experimental|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
9531766|NCT03181854|No Intervention|Control Group|Usual palliative care can be provided if desired.
9531767|NCT03181672|Active Comparator|Stellate ganglion block|Stellate ganglion block
9531768|NCT03181672|Placebo Comparator|control group|Deltoid muscle injection
10038092|NCT01831050|Experimental|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
10038093|NCT01831050|Experimental|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
9531769|NCT03181763|Experimental|MDMA|Participants receive 100 mg MDMA
9531770|NCT03181763|Placebo Comparator|Placebo|Participants receive inactive placebo
9531771|NCT03181776|Experimental|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
9531772|NCT03181568|Other|Control|This arm group (control) will receive standard wound care of chronic wounds
9531773|NCT03181568|Other|Treatment|The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
9531774|NCT03181581|Experimental|High grade gliomas stage 1 ACF|In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
9531775|NCT03181581|Experimental|Low-high grade gliomas stage 2 ACF|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
9531776|NCT03181581|Active Comparator|High grade gliomas stage 1 control|In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
9531777|NCT03181581|Active Comparator|Low-high grade gliomas stage 2 control|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma
9531778|NCT03181841|Experimental|Active dose 1|Single dose of PF-06412562 in low dosage strength
9531779|NCT03181841|Experimental|Active dose 2|Single dose of PF-06412562 in medium dosage strength
9531780|NCT03181841|Experimental|Active dose 3|Single dose of PF-06412562 in higher dosage strength
9531781|NCT03181841|Placebo Comparator|Placebo|Single dose of placebo
10038094|NCT01831050|Experimental|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
9531782|NCT03181737|Experimental|Covivio|"Covivio is an internet intervention for people with diabetes mellitus type 2. Content is continuously adapted to patients´ concerns and needs. Techniques to promote the disease self-management (i.e. nutrition, exercise), the motivation for health behavior (i.e. discussing pros and cons) conveying goal setting, mediating knowledge about diabetes (i.e. basics, symptoms & complications, diagnosis, therapy) , and reducing depressive symptoms (i.e. increasing activation, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets.~Patients are also prompted complete brief adherence self-monitoring questionnaires (adherence index) regularly. Optional text messages with motivational content accompany the program daily. The program can be accessed for 56 days after registration."
9531783|NCT03181737|Active Comparator|Relaxio|Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
9531784|NCT03181737|No Intervention|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Covivio six months post-baseline (i.e., wait list with respect to Covivio access).
9531785|NCT03182205|Experimental|Inspiratory muscle exercise (IME)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure.
9531786|NCT03182205|Sham Comparator|Sham IME|Participants will be submitted to inspiratory muscle exercise with the same equipment as the intervention group, but without a load generating resistance.
9531787|NCT03182049||GPA (Wegener's granulomatosis) patients|
9531788|NCT03181646|No Intervention|control group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive only supportive care
9531789|NCT03181646|Experimental|study group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive citicoline along with supportive care
9531790|NCT03181659|Experimental|Group 1: patients with NSCLBP who do not seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
9531791|NCT03181659|Experimental|Group 2: patients with NSCLBP who do not seek care|Therapeutic Education, Therapeutic Exercice
9531792|NCT03181659|Experimental|Group 3: patients with NSCLBP who seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
9531793|NCT03181659|Experimental|Group 4: patients with NSCLBP who seek care|Therapeutic Education, Therapeutic Exercice
9531794|NCT03181555|Other|Pregnant Obese African American Women|Exploratory
9531795|NCT03181685|Active Comparator|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
9531796|NCT03181685|Active Comparator|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
9531797|NCT03181464|Experimental|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
9531798|NCT03181464|Placebo Comparator|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
9531799|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
9531800|NCT03181438|Experimental|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of 0.375% ropivacaine"
9531801|NCT03181438|Sham Comparator|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of Saline"
9531802|NCT03181698||first group|patients with more than one episodes of mania
10038095|NCT01831050|Experimental|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
10038096|NCT01831050|Experimental|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
10038097|NCT01831050|Experimental|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
10038098|NCT01831050|Experimental|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
9481428|NCT04530383|Experimental|Metformin dose regimen B|Participants with CFRD on elexacaftor/tezacaftor/ivafactor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures. If tolerated, dose will be increased by 500mg on weeks 1 and 2 to a final dose of 1000 mg twice daily through week 14.They will then undergo a two week washout period. For the second half of the study metformin will be resumed at a dose of 500 mg twice daily through the end of study (week 30).
9481429|NCT04528563|Experimental|Ketorolac Tromethamine|IV ketorolac tromethamine, 0.5 mg/kg to a maximum of 30 mg plus IV morphine placebo;
9481430|NCT04528563|Active Comparator|Morphine Sulfate|IV morphine 0.1 mg/kg to a maximum of 5 mg plus IV ketorolac placebo
9481431|NCT04521335|Experimental|Treatment: all patients|disulfiram and copper gluconate in combination
9481432|NCT04520061|Experimental|Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
9481433|NCT04520061|No Intervention|Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
9481434|NCT04516278|Experimental|Biological: bevacizumab|ONS-5010
10038099|NCT01831050|Experimental|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
10038100|NCT01831050|Experimental|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
10038101|NCT01831063|No Intervention|1|This group received the traditional seizure teaching. This consisted of verbal instruction from health care professionals on acute seizure management and administration of the rescue medication.
9481435|NCT04511130|Experimental|MT-401 following HSCT|Treatment with MT-401 at 90 days following HSCT
9481436|NCT04511130|No Intervention|Standard of Care following HSCT|Standard of Care
9481437|NCT04511130|Experimental|MT-401 following relapse|Treatment with MT-401 following relapse after first HSCT
9481440|NCT04507178|No Intervention|prophylactic dose LMWH|Patients assigned to the control group will receive standard care according to current protocol with a prophylactic dose of LMWH (nadroparin once daily 2850 AxaIE subcutaneously) starting within 24 hours after coiling, continued until discharge or when mobilized for at least six hours a day.
9481441|NCT04507178|Active Comparator|therapeutic dose LMWH|In the intervention group, the standard prophylactic dose will be replaced by a higher dose of LMWH (nadroparin; twice daily 5700 IE) starting within 24 hours after coiling and continued for 21 days after initial SAH. After this, patients will continue with standard care (prophylactic dose until discharge or when mobilized for more than six hours per day).
9481442|NCT04503811||Frail Older People|The first phase of the data collection process will include one to one interviews with up to twenty (20) frail older people. The pre-selected inclusion criteria for this category of participants include; older people (aged 65 years and over); individuals diagnosed with frailty and receiving (part of their) care services at the Day Hospital; the capacity to give free and fully informed consent; ability to use the English language, as well as judgement by the clinical staff and/or nominated manager that the potential participant can take part in an in-depth interview.
9481443|NCT04503811||Day Hospital Staff|The second phase of the data collection process will entail one to one interviews with up to ten (10) Staff at the Day Hospital. The study will include staff that routinely work with frail older people at the Day Hospital including nurses (registered and unregistered), doctors, physiotherapists, occupational therapists and therapy assistants that can give free and fully informed consent. Furthermore, the study will include both part-time and full-time staff with a minimum of six months of work experience with frail older people.
9481444|NCT04500899|Experimental|Mydfrin|Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection.
9481445|NCT04486313|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
9481446|NCT04486313|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
9481447|NCT04481373|Experimental|THRIVE|Acceptance and Commitment Therapy plus Education about HIV A master's level mental health professional will provide the 4-5 hour intervention for out-of-care PWH during a hospitalization. There are two important components to the intervention: Acceptance and Commitment Therapy (ACT) content, targeting avoidance with acceptance-based coping and active engagement in values-based living, and HIV education.
9481448|NCT04481373|Other|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
9481449|NCT04480840|Placebo Comparator|Placebo|
9481450|NCT04480840|Experimental|PLN-74809 Dose Level 1|Dose: 40 mg;
9481451|NCT04480840|Experimental|PLN-74809 Dose Level 2|Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
9481452|NCT04480840|Experimental|PLN-74809 Dose Level 3|Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2
9481453|NCT04480723|Other|Participants with Low or Intermediate Probability of PH|Participants who underwent a work-up for the suspicion of PH that includes transthoracic echocardiography (TTE) and who were considered to have a low or intermediate probability of PH according to TTE (local interpretation) will be enrolled. Blood samples will be taken and a cardiac magnetic resonance imaging (MRI) will be performed to evaluate the presence of Pulmonary Hypertension (PH). The TTEs that were performed by local standards will be collected and undergo central interpretation using European society of Cardiology / European respiratory society (ESC/ERS) guidelines to confirm the local interpretation.
9481454|NCT04479644|Experimental|Cohort 1|BRII-198 dose level 1 or placebo
9481455|NCT04479644|Experimental|Cohort 2|BRII-198 dose level 2 or placebo
9531803|NCT03181698||second group|sex-matched and age- matched healthy controls
9531804|NCT03181295|No Intervention|Usual care|Standard periodic health review (PHR) appointment. [As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.]
9531805|NCT03181295|Experimental|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
9531806|NCT03181321|Experimental|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
9531807|NCT03181321|No Intervention|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
9531808|NCT03181425||Imaging assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
9531809|NCT03181334|Active Comparator|Branch I|"Condition 1: (Standard Intervention)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation letter to complete free colorectal cancer (CRC) screening."
9531810|NCT03181334|Experimental|Branch II and Branch III|"Condition 2: (Time Guideline)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal cancer (CRC) screening within a specified time frame:~Branch II - Brief Time (1-week)~Branch III - Extended Time (3-weeks)"
9531811|NCT03181334|Experimental|Branch IV and Branch V|"Condition 3: (Time Guideline + Incentive)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal (CRC) screening within a specified time frame with a monetary incentive:~Branch IV - High Incentive~Branch V - Low Incentive"
9531812|NCT03181347|Experimental|Roux-en-Y Gastric Bypass (RYGB)|Severely obese patients scheduled for Roux-en-Y Gastric Bypass surgery
9531813|NCT03181347|Experimental|Sleeve Gastrectomy (SG)|Severely obese patients scheduled for Sleeve Gastrectomy surgery
9531814|NCT03181347|Active Comparator|Non-surgical|Severely obese controls with dietary and activity modifications and excludes meal replacement or pharmacologic interventions
10038102|NCT01831063|Experimental|2|This group received the traditional seizure teaching as well as the supplemental simulation based seizure management teaching. The simulation based seizure teaching consisted of numerous opportunities to manage a simulated seizure with instructor guidance and feedback. This session was deemed complete when caregivers verbalized confidence with seizure management.
10038103|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
9531815|NCT03181399|Experimental|Triheptanoin|This is a single arm study.
9531816|NCT03181269|Experimental|Intervention education|Participants will receive the intervention education and data recording package.
9531817|NCT03181269|Placebo Comparator|Placebo education|Participants will receive the placebo educational and data recording package.
9615606|NCT02543879|Experimental|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
9615607|NCT02543879|Experimental|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
9615608|NCT02543879|Experimental|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
9615609|NCT02543879|Experimental|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
9615610|NCT02543853|Active Comparator|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
9615611|NCT02543853|Active Comparator|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
9615612|NCT02543931|Placebo Comparator|Placebo|Participants will take 4 placebo capsules twice a day for one month
9615613|NCT02543931|Experimental|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
9615614|NCT02543931|Experimental|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
9615615|NCT05227859|Experimental|Piezocision therapy|In this group of patients, the canine will be retracted in association with piezocision.
9615616|NCT05227859|Experimental|Low-level laser therapy|In this group of patients, the canine will be retracted in association with LLLT.
9615617|NCT05227859|Active Comparator|Conventional treatment|In this group of patients, the canine will be retracted conventionally without any acceleration intervention.
9615618|NCT05227846|Experimental|Human Umbilical Cord-derived Mesenchymal Stem Cells|Standard of care (SOC) plus a dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 5, 10 and 15 ×10E7 cells. Proceed from lower dose to next higher dose if no safety concerns for each cohort.
9615619|NCT05227807|Active Comparator|Control group|the control group received routine care.
9615620|NCT05227807|Experimental|Intervention group|Intervention develop from the theoretical framework of social cognition theory
9615621|NCT05227781|Experimental|L-Citrulline|L-Citrulline: 10 grams/day
9615622|NCT05227781|Placebo Comparator|Placebo|Maltodextrin: 10 grams/day
9615623|NCT05227768|Experimental|VV116|Subjects will receive VV116 orally for single dose.
9615624|NCT05227768|Experimental|Placebo|Subjects will receive placebo orally for single dose.
10038104|NCT01831102||Mexican American|Mexican American ancestry
10038105|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
9531818|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
9531819|NCT03181243|Experimental|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
9531820|NCT03181243|Experimental|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
9531821|NCT03181282|Experimental|Physical Therapy|Participants assigned to Physical Therapy (PT) will attend a 1-hour visit with a physical therapist twice weekly for 8 weeks. The PT intervention, which will mirror traditional PT for those with PD, will include exercises designed to improve balance and gait.
9531822|NCT03181282|No Intervention|Control|Participants in the control group will receive the current standard of care following STN-DBS. As such, STN-DBS settings and anti-PD medications will be optimized according to the determination of their neurologist in the same fashion as they will be in the experimental group. Those in the control group will not receive prescribed exercise from a physical therapist.
9531823|NCT03181620|No Intervention|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
9531824|NCT03181620|Experimental|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
9531825|NCT03181360|Active Comparator|Tenecteplase|Tenecteplase + Best standard treatment
9531826|NCT03181360|Other|Control|No tenecteplase + Best standard treatment
9531827|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
9531828|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
9531829|NCT03181815|Experimental|treatment arm|The patients in this arm will receive C-CAG regimen for salvage treatment,detailed as following: Cladribine 5mg/㎡，d1-5；G-CSF 300ug,d0-9; aclarubicin 10mg,d3-6;cytarabine 10mg/㎡ q12h, SC, d3-9;4 weeks a cycle
9531830|NCT03181802|Experimental|botulinum toxin A|
9531831|NCT03181802|Placebo Comparator|Placebo|
9531832|NCT03181386|Experimental|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
9531833|NCT03181386|Experimental|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
9531834|NCT03181386|Active Comparator|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
9531835|NCT03181217|Experimental|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
10038106|NCT01831128||Control|No ASV treatment
10038107|NCT01831167|Experimental|dynamic light|dynamic light
10038108|NCT01831167|No Intervention|reference|normal light
10038109|NCT01831180||Premenopausal women 19-25 yrs|
10038110|NCT01831180||Postmenopausal 60 yrs +|
10038111|NCT01831193|Active Comparator|Diabetic|
10038112|NCT01831193|Active Comparator|Non-diabetic|
10038113|NCT01831206|Experimental|Collagen cross-linking|Collagen cross-linking with standard treatment
10038114|NCT01831206|No Intervention|standard treatment|Standard treatment alone
10038115|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
10038116|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
10038117|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
10038118|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
10038119|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
10038120|NCT01831297||syncope|
10038121|NCT01831310|Active Comparator|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
10038122|NCT01831310|Experimental|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
10038123|NCT01831310|Experimental|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
10038124|NCT01831310|Experimental|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
9481456|NCT04479644|Experimental|Cohort 3|BRII-198 dose level 3 or placebo
10038125|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
9481457|NCT04479631|Experimental|Cohort 1|BRII-196 dose level 1 or placebo
9481458|NCT04479631|Experimental|Cohort 2|BRII-196 dose level 2 or placebo
9481459|NCT04479631|Experimental|Cohort 3|BRII-196 dose level 3 or placebo
9481460|NCT04467697|Experimental|SOV2012-F1-treated|Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 600 mg SOV2012-F1 per day (300 mg in the morning and 300 mg in the evening) based on plasma T after 14 and 42 days of treatment.
9481461|NCT04466345|Experimental|Semaglutide|Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
9481462|NCT04466345|Placebo Comparator|Placebo|Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).
9481463|NCT04465760|Experimental|Supportive Care (xisomab 3G3)|Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT.
9481464|NCT04464538|Placebo Comparator|Health information|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
9481465|NCT04464538|Experimental|Group education session and individualised coaching (online)|Participants assigned to the WALC-R intervention will attend a virtual baseline educational group session which will include a maximum of five people. The aim of the sessions will be to introduce the basics of the benefits of walking for exercise and why exercise is beneficial, as well as to give information, support and motivation to help participants to independently walk more in their daily routines.The group session will also include goal setting, in which participants will be encouraged to set their own daily walking targets to increase their habitual levels of walking. All participants will be given a pedometer to self-monitor how far they walk and a diary to record activity context throughout the intervention daily. Participants will meet briefly (20-30 minutes) via the internet with an assigned coach every 2 weeks.
9481466|NCT04461275|Experimental|ERAS 2.0 group|Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol.
9481467|NCT04459286|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
9481468|NCT04459286|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus study intervention composed of orally administered nitazoxanide and atazanavir/ritonavir tablets
9481469|NCT04459221|Experimental|Facilitating access to HPV vaccination|
9481470|NCT04459221|No Intervention|promotion of HPV vaccination|
9481471|NCT04455152|Experimental|Self-control|two-week period of practicing self-control (attempting to avoid eating sweet foods) and self-monitoring success in doing so
9481472|NCT04455152|No Intervention|wait list|waiting 2 weeks after baseline assessment before gaining access to web-based self-help
9481473|NCT04453852|Experimental|Group A|Spike antigen (25ug) + 15 mg Advax-2 adjuvant
9481474|NCT04453852|Placebo Comparator|Group B|Saline
9481475|NCT04453202|Experimental|Cohort 1 Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an Ad26-based RSV vaccine on Day 1.
9481476|NCT04453202|Experimental|Cohort 1 Group 2: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 1) on Day 1.
9481477|NCT04453202|Experimental|Cohort 1 Group 3: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 2) on Day 1.
9481478|NCT04453202|Experimental|Cohort 1 Group 4: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 3) on Day 1.
9481479|NCT04453202|Placebo Comparator|Cohort 1 Group 5: Placebo|Participants will receive IM injection of placebo on Day 1.
9481480|NCT04453202|Experimental|Cohort 2 Group 6: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
9481481|NCT04453202|Experimental|Cohort 2 Group 7: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 1) on Day 1.
9481482|NCT04453202|Placebo Comparator|Cohort 2 Group 8: Placebo|Participants will receive IM injection of placebo on Day 1.
9481483|NCT04453202|Experimental|Cohort 3 Group 9: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
9481484|NCT04453202|Experimental|Cohort 3 Group 10: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 2) on Day 1.
9481485|NCT04453202|Experimental|Cohort 3 Group 11: Placebo|Participants will receive IM injection of placebo on Day 1.
9481486|NCT04448834|Experimental|Treatment|A single cycle of blinatumomab which includes 4 weeks of CIVI of blinatumomab followed by a 2 week treatment free interval
9481487|NCT04447820|Experimental|K-877-ER Dose A|K-877-ER dose A administered once daily
9481488|NCT04447820|Experimental|K-877-ER Dose B|K-877-ER dose B administered once daily
9481489|NCT04447820|Experimental|K-877-IR|K-877-IR administered twice daily.
9481490|NCT04445688|Experimental|AD036|AD036 oral capsule administered before sleep
9481491|NCT04445688|Active Comparator|Atomoxetine|Atomoxetine oral capsule administered before sleep
9481492|NCT04445688|Placebo Comparator|Placebo|Placebo oral capsule administered before sleep
10038126|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
10038127|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
10038128|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
10038129|NCT01831336||Orsiro DES|
10038130|NCT01831362|Experimental|Focused Attention (FA)|This 8 week program consists solely of focused attention practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
9531836|NCT03181217|Experimental|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
9531837|NCT03181217|Experimental|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
9531838|NCT03181217|Experimental|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
9531839|NCT03181191|Active Comparator|Totally pancreatectomised patients|Oral glucose tolerance test and biopsies
9531840|NCT03181191|Active Comparator|Type 2 diabetes patients|Oral glucose tolerance test and biopsies
9531841|NCT03181191|Active Comparator|Healthy control subjects|Oral glucose tolerance test and biopsies
9531842|NCT03181178|Active Comparator|KokoPlus and Nutrition Education|Macro-micronutrient complementary food supplement and Nutrition Education
9531843|NCT03181178|Active Comparator|Micronutrient and Nutrition Education|A micronutrient powder and Nutrition Education
9531844|NCT03181178|Active Comparator|Nutrition Education Only|Nutrition Education
9531845|NCT03181178|No Intervention|Growth Monitoring Only|Growth monitoring
9531846|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
9531847|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
9531848|NCT03181113||peginterferon alfa 2b|
9531849|NCT03181113||peginterferon alfa 2a|
9531850|NCT03181165|Experimental|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
9531851|NCT03181165|No Intervention|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
9531852|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
9531853|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
9531854|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
9531855|NCT03181100|Experimental|Cohort I (vemurafenib, cobimetinib, atezolizumab)|Patients receive vemurafenib PO BID on days 1-21, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
9531856|NCT03181100|Experimental|Cohort II (atezolizumab, cobimetinib)|Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
9531857|NCT03181100|Experimental|Cohort III (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 60-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
9531858|NCT03181100|Experimental|Cohort IV (nab-paclitaxel, atezolizumab, paclitaxel,)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
10038131|NCT01831362|Experimental|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
9531859|NCT03180827|Experimental|ovarian tissue cryopreservation|
9531860|NCT03181087|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
9531861|NCT03180814|Active Comparator|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
9531862|NCT03180814|Experimental|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
9531863|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
9531864|NCT03180788|Active Comparator|Traditional ESD|The patients in this Group will undergo traditional ESD.
9531865|NCT03180788|Experimental|Traction assisted ESD|The patients in this Group will undergo traction assisted ESD
9531866|NCT03180918|Experimental|testicular tissue cryopreservation|
9531867|NCT03180866|No Intervention|Non-treatment Control|Control arm will not have any intervention
9531868|NCT03180866|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
9531869|NCT03180957|Experimental|Anti-TNF|adalimumab
9531870|NCT03180957|Placebo Comparator|Placebo|saline
9531871|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
9615625|NCT05227729||Patients undergoing abdominal surgery|Inclusion criteria: > 18 years old, American Society of Anesthesiologists physical status 1-3, abdominal surgery of > 1,5 hrs estimated duration, no contraindications to the use of oesophageal ultrasound.
9531872|NCT03181022|No Intervention|Phase 1a|To develop a measure of MI fidelity to ensure methodological rigor, acceptability and feasibility of administration, and clinical usefulness (Phase 1a). Ratings of 200 recordings of full patient-provider interactions with ratings of thin slices (recording 1 minute every 5 minutes) will be compared.
9531873|NCT03181022|No Intervention|Phase 1b|To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
9531874|NCT03181022|No Intervention|Phase 2|To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
9531875|NCT03181022|Experimental|Phase 3|To pilot test the implementation intervention and process/outcome evaluation protocols at two ATN sites in preparation for a full-scale trial.
9531876|NCT03180970|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
9531877|NCT03180970|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
9531878|NCT03180970|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
9531879|NCT03180970|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
9531880|NCT03180970|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
9531881|NCT03180879|Experimental|1|Treatment Order: Test, Reference, Comparator
9531882|NCT03180879|Experimental|2|Treatment Order: Test, Comparator, Reference
9531883|NCT03180879|Experimental|3|Treatment Order: Reference, Test, Comparator
9531884|NCT03180879|Experimental|4|Treatment Order: Reference, Comparator, Test
9531885|NCT03180879|Experimental|5|Treatment Order: Comparator, Test, Reference
9531886|NCT03180879|Experimental|6|Treatment Order: Comparator, Reference, Test
9531887|NCT03180983|Other|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
9531888|NCT03180983|No Intervention|CONTROL GROUP|No intervention
9531889|NCT03180944|Experimental|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
9531890|NCT03180944|Experimental|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
9531891|NCT03180944|Experimental|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
9531892|NCT03180944|Experimental|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
9531893|NCT03180944|Experimental|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.
9531894|NCT03181048|Experimental|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
9531895|NCT03181048|Active Comparator|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
9531896|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
9531897|NCT03180775|Sham Comparator|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
9531898|NCT03180775|Experimental|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
9531899|NCT03180775|Experimental|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
9531900|NCT03180775|Experimental|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
9531901|NCT03180775|Experimental|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
9531902|NCT03180775|Experimental|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
9531903|NCT03180775|Experimental|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
9531904|NCT03180775|Experimental|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
9531905|NCT03180775|Experimental|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
9531906|NCT03180775|Experimental|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
9531907|NCT03180775|Experimental|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
9531908|NCT03180762|Experimental|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
9531909|NCT03180762|Experimental|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
9531910|NCT03180762|Experimental|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
9531911|NCT03180762|Experimental|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
9531912|NCT03180762|Experimental|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
9531913|NCT03180762|Experimental|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
10038132|NCT01831362|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused attention and open- monitoring practices
10038133|NCT01831375|Experimental|Speak Up|Participants will learn how to speak up to their medical doctors for improving their medical care.
9531914|NCT03180762|Experimental|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics [PK] of preceding dose levels; no more than 50 percent (%) of the highest dose tested [though as high as possible within this restriction] and considered well tolerated in Part 1) under fed conditions on Day 1.
9531915|NCT03180762|Experimental|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
9531916|NCT03180723|Experimental|study group|Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)
9531917|NCT03180723|Active Comparator|control group|Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.
9531918|NCT03180736|Experimental|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
9531919|NCT03180736|Active Comparator|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
9531920|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.6 U/kg|Single subcutaneous injection of 0.6 U/kg
9531921|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
9531922|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 1.0 U/kg|Single subcutaneous dose of 1.0 U/kg
9531923|NCT03180710|Active Comparator|Humalog® Mix25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
9531924|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
9531925|NCT03180658|Experimental|experimental|GTR+CGF+bone graft, CGF
9531926|NCT03180658|Active Comparator|controlled|CGF+bone graft
9531927|NCT03180476|Experimental|apatinib|apatinib,500mg,qd，28 day/cycle until the emergence of PD, death, intolerable toxicity
9531928|NCT03180632|Active Comparator|Group A|Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
9531929|NCT03180632|Placebo Comparator|Group B|Patient will receive a placebo similar in color, form and size.
9531930|NCT03180632|No Intervention|Group 3|Patient will receive no intervention.
9531931|NCT03180567|Experimental|Warfarin resistant patients|Genetic Mutations
9531932|NCT03180567|Placebo Comparator|Control|Genetic Mutations
9531933|NCT03180541|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
9531934|NCT03180541|No Intervention|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:~live in areas where no DBT intervention is currently available OR~were offered a place on the DBT programme but decided not to partake at that time"
9531935|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
9531936|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
9531937|NCT03180671|No Intervention|Group 1 Control|Counselling with explanation of preventive procedures.
9531938|NCT03180671|Active Comparator|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
9531939|NCT03180671|Active Comparator|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
9531940|NCT03180671|Active Comparator|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
10038134|NCT01831375|Other|Get Connected|Attention control group
10038135|NCT01831388|Experimental|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
9531941|NCT03180593|Active Comparator|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
9531942|NCT03180593|Active Comparator|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
9531943|NCT03180437|Active Comparator|Group A|In this group, the patients will receive IRE surgery to control the local tumor under CT .
9531944|NCT03180437|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
9531945|NCT03180398|Experimental|Multi-parametric MRI for Prostate Cancer|MRI will be acquired for prostate cancer patients undergoing radiation treatment.
9531946|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
9531947|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
9531948|NCT03180424|Active Comparator|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
9531949|NCT03180424|Experimental|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
9531950|NCT03180424|Placebo Comparator|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
9531951|NCT03180229|Active Comparator|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
9531952|NCT03180229|No Intervention|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
9531953|NCT03180320|Experimental|BESMILE-HF group|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.
9531954|NCT03180320|Other|Control|Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.
9531955|NCT03180346|Active Comparator|Single-Use Negative Pressure Wound Therapy|
9531956|NCT03180346|Active Comparator|Standard of Care|
9531957|NCT03180359|Experimental|Patient already transplanted or waiting for a transplantation|
9531958|NCT03180151|No Intervention|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
9531959|NCT03180151|Experimental|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
9531960|NCT03180333|Experimental|PNA 1|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
9531961|NCT03180333|Placebo Comparator|PNA placebo|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
9531962|NCT03180333|Experimental|PNA 2|Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
9531963|NCT03180333|Experimental|PNA 3|Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
9531964|NCT03180333|Experimental|PNA 4|The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
9531965|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
9531966|NCT03180112||control group|Healthy children of matching age and sex.
9531967|NCT03180125|Experimental|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
9531968|NCT03180125|Placebo Comparator|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
9531969|NCT03180164|Other|chronic lung diseases|bronchiectasis , bronchial asthma and chronic obstructive pulmonary disease assess anxiety and depression by hospital anxiety and depression scale
9531970|NCT03180372|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
9531971|NCT03180242|Experimental|EG12014|EG12014
9531972|NCT03180242|Active Comparator|EU-sourced Herceptin|EU-sourced Herceptin
9531973|NCT03180242|Active Comparator|US-sourced Herceptin|US-sourced Herceptin
9531974|NCT03180203|Experimental|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
9531975|NCT03180203|Active Comparator|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
9531976|NCT03180281|Experimental|DPP4 group|DPP4 inhibitor,1 pill qd
9531977|NCT03180281|Experimental|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
9531978|NCT03180281|Placebo Comparator|SU group|SU,Glimepiride，1-2mg qd
9531979|NCT03180255|Experimental|EGP-437|40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
9531980|NCT03180255|Placebo Comparator|Placebo|100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
9531981|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
9531982|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
9531983|NCT03180099|Active Comparator|Thoracolumbar Interfascial Plane Block|Bilateral ultrasound guided thoracolumbar interfascial plane block
9531984|NCT03180099|Active Comparator|Epidural Block|Epidural Block
9531985|NCT03180177|Experimental|Experimental group|"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
9531986|NCT03180177|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
9531987|NCT03180086|Experimental|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
9531988|NCT03179995|Experimental|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
9531989|NCT03179995|Placebo Comparator|Placebo Arm|Normal saline will be administered post-operatively until day 5
9531990|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
9531991|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
9531992|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
9531993|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
9531994|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
9531995|NCT03180008|Active Comparator|Fit and Strong!|
9531996|NCT03180008|Experimental|Fit and Strong! Plus|
9531997|NCT03179709||Intervention|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the active treatment arm of ROSE.
9531998|NCT03179709||Control|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the control treatment arm of ROSE.
9531999|NCT03179709||Refusal|The investigators will interview physicians who have refused to allow their patients to be enrolled in ROSE.
9532000|NCT03179839|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
9532001|NCT03179839|Placebo Comparator|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
9532002|NCT03179839|Active Comparator|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
9532003|NCT03179774|Experimental|Clinical registry-ER and OMT|In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
9532004|NCT03179774|No Intervention|Clinical registry-OMT|In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
9532005|NCT03179774|Experimental|RCT-ER and OMT|In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.
9532006|NCT03179774|No Intervention|RCT-OMT|In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.
9532007|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
9532008|NCT03179878|Experimental|SYNB1020|SYNB1020
9532009|NCT03179878|Placebo Comparator|Placebo|100 mL masking solution
9532010|NCT03179982|Experimental|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
10038136|NCT01831401|Experimental|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) & standard straight acetabular component introducer without alignment guide.
9481493|NCT04443192|Active Comparator|Part A Cohort 1 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 1
9481494|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Single Dose|Single oral dose of placebo by mouth in the fasted state
9481495|NCT04443192|Active Comparator|Part A Cohort 2 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 2
9481496|NCT04443192|Active Comparator|Part A Cohort 3 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 3
9481497|NCT04443192|Active Comparator|Part A Cohort 4 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 4
9481498|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Two Doses|Two doses of placebo (12 h apart) by mouth in the fasted state
9532011|NCT03179982|No Intervention|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
10038137|NCT01831401|Experimental|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) & modified 35° acetabular component introducer.
10038138|NCT01831401|Experimental|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) & standard straight acetabular component introducer without alignment guide.
10038139|NCT01831401|Experimental|7° Head Down & Standard Introducer.|Operating table position 7° head down & standard straight acetabular component introducer without alignment guide.
10038140|NCT01831401|Experimental|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down & modified 35° acetabular component introducer.
10038141|NCT01831401|Experimental|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down & inclinometer-assisted acetabular component introducer.
10038142|NCT01831401|Experimental|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & standard straight acetabular component introducer without alignment guide.
10038143|NCT01831401|Experimental|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & modified 35°acetabular component introducer.
9532012|NCT03179904|Experimental|Cohort A (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
9532013|NCT03179904|Experimental|Cohort B (TVB-2640, trastuzumab, endocrine therapy)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28 and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Patients also continue endocrine therapy of either anastrozole PO QD, exemestane PO QD, fulvestrant IM on days 1 and 14 of cycle 1 and day 1 of subsequent cycles, or letrozole PO QD. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
9532014|NCT03179722|Experimental|Intervention group: Frenchspeaking patients|Intervention: Medication review
9532015|NCT03179722|Experimental|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
9532016|NCT03179813|Experimental|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
9532017|NCT03179813|Placebo Comparator|Control Group|Intraoperative irrigation with saline solution.
9532018|NCT03179800|Experimental|MobiusHD Implantation|MobiusHD Implantation
9532019|NCT03179800|Sham Comparator|Sham Implantation|Sham Implantation
9532020|NCT03180021||Patients with Lupus Nephritis|
9532021|NCT03180021||Patients with IgA Neuropathy|
9532022|NCT03179735|Experimental|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
9532023|NCT03179735|Experimental|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
9532024|NCT03179735|Placebo Comparator|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
9532025|NCT03179683|Active Comparator|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
9532026|NCT03179683|No Intervention|No application|no treatment were aplied
9532027|NCT03179696|Experimental|Mobile-assisted CBT|Psychosocial intervention combining in-person and smartphone-based cognitive-behavioral therapy (CBT) for experiential negative symptoms in schizophrenia called, Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
9532028|NCT03179956|Experimental|Ribociclib|
9532029|NCT03179358|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
9532030|NCT03179501|Experimental|NP001|NP001
9532031|NCT03179501|Placebo Comparator|Placebo|Normal saline
10038144|NCT01831401|Experimental|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & inclinometer-assisted acetabular component introducer.
9532032|NCT03179371||1|Mothers whose fetus has CDH
10038145|NCT01831414|Experimental|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
10038146|NCT01831414|Experimental|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
10038147|NCT01831440|Other|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
10038148|NCT01831440|Other|medicine (SSRI antidepressants)|clinical routine antidepressant treatment--Selective serotonin reuptake inhibitors（SSRIs）.
10038149|NCT01831453|Placebo Comparator|isopropylmyristate oil|placebo Soft gelatinous capsules filled with isopropylmyristate oil
10038150|NCT01831453|Active Comparator|experimental|omega-3 1 gram three times daily for 6 months
10038151|NCT01831479|Experimental|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
10038152|NCT01831492|Active Comparator|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
9532033|NCT03179488|Experimental|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
9532034|NCT03179488|Sham Comparator|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
9615626|NCT05227651|Experimental|AK104|Patients will be treated with 1-2 cycles of neoadjuvant AK104. 4-6 weeks after the first cycle of neoadjuvant treatment, patients will undergo radical surgery.
9615627|NCT05227625|Experimental|Body dissatisfaction management group|ACT-inspired group for the management of body dissatisfaction
9615628|NCT05227625|Active Comparator|relaxation group|standardized relaxation program
9615629|NCT05227599|Other|Daily Diary Method Cohort|"Participants will be asked to complete a self-report questionnaire that has been validated to assess daily affect. There are 5 items assessing positive affect (joyful, cheerful, happy, lively, proud) and 5 items assessing negative affect (miserable, mad, afraid, scared sad). The respondent is asked to rate these 10 different feelings on a 5-point Likert scale from 1, not much or not at all to 5, a lot."
9615630|NCT05227586||LA + RA ablation|Patients with persistent atrial fibrillation and right atrial enlargement received adjunctive right atrial ablation when left atrial ablation did not terminate atrial fibrillation.
9615631|NCT05227586||LA ablation only|Patients with persistent atrial fibrillation and right atrial enlargement received left atrial ablation only
9615632|NCT05227560|Experimental|Emotional Freedom Technique group|"Personal characteristics questionnaire, State Anxiety Scale (SQS) and Stress Coping Styles Scale (SST) were applied to the intervention group at the pre-test stage. Subjective discomfort level scale (ERDS) was also applied to the intervention group before EFT was applied. After four sessions of EFT, DKO, SBO, ORDS were applied to the intervention group again in the post-test phase."
9615633|NCT05227560|No Intervention|Control|Participants in the control group received no intervention throughout the study.
9615634|NCT05227521|Experimental|AH-GRASP feedback intervention group|All study participants will receive the AH-GRASP feedback intervention.
9615635|NCT05227508|Experimental|brizo SC012|a capsule containing 400 mg. SC012 (unique soy extract) TWICE A DAY : MORNING , EVENING.
9615636|NCT05227508|Placebo Comparator|PLACEBO|a capsule containing 400 mg OF PLACEBO, TWICE A DAY: MORNING , EVENING.
9615637|NCT05227495|Experimental|VR group|
10038153|NCT01831492|Placebo Comparator|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
10038154|NCT01831505|Experimental|Multiple drug microinjection|Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them
10038155|NCT01831518|Experimental|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
9615638|NCT05227495|Active Comparator|control group|
9615639|NCT05227482|Active Comparator|Standard dosimetric approach for 90Y activity calculation|The radionuclide activity to be injected is calculated with standard dosimetric approach such as body surface area (BSA) method or Medical Internal Radiation Dose (MIRD) monocompartmental method.
9615640|NCT05227482|Experimental|Personalized voxel-based dosimetric method for 90Y activity calculation|The radionuclide activity to be injected is calculated with voxel-based approach based on pre-treatment simulation with the injection of 99mTc-MAA and the acquisition of SPECT/CT images.
9615641|NCT05227469|Experimental|Skeletal class II twinblock + myofunctional therapy|Myofunctional exercises will be prescribed in addition to the standart twin block therapy. Movements will be taught to this group, for which we have prescribed the exercises. It will be ensured that the exercises are done more properly and regularly by taking video recordings every other day from the group that does the exercises twice a day. Incorrect exercises will be corrected by providing feedback.
9615642|NCT05227469|No Intervention|Control|Standard twin block therapy will be used for Class II patients. Patients will be informed that they are involved in a study that follows growth and development, and they will receive feedback on whether they use their devices properly, but no myofunctional exercise.
9615643|NCT05227430|Experimental|Surgical trainees|Surgical trainees that would be given educational video tutorials before entering gynecological laparoscopic surgeries
9615644|NCT05227430|No Intervention|Control|Surgical trainees that would not be given educational video tutorials before entering gynecological laparoscopic surgeries
9615645|NCT05227417|Experimental|Intervention|SMS-based intervention delivered with a web-based system, which will include weekly health check-ins, appointment reminders all delivered via SMS (text messages).
9615646|NCT05227417|No Intervention|Control|Standard of care: Those who test positive in both tests receive post-test counseling, including emotional support, and are linked to a facility for antiretroviral (ART) initiation, ideally within one week. During the 1st medical appointment after diagnosis, lab tests are requested including CD4 and viral load. In most cases, ART initiation occurs at the second medical appointment when safety lab results are available. Currently, it is not mandatory to have CD4/VL results available to start ART. It is recommended that patients have CD4 counts and viral load assessed twice during the first year. A one-month supply of ART is provided initially. If clients are adherent, ART is dispensed every 3 months by nurses who also assess adherence. Standard follow-up is performed by nurses when clients visit the center for their appointments.
9615647|NCT05227378|Experimental|neoantigen tumor vaccine|neoantigen tumor vaccine with or without PD-1/L1
9615648|NCT05227326|Experimental|Treatment (PCNA inhibitor AOH1996)|Patients receive PCNA inhibitor AOH1996 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10058318|NCT02017405|Other|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
10038156|NCT01831531|Experimental|S-1|"Patients will receive chemoradiation with S-1.~Interventions:~Drug: S-1 Radiation: Radiation therapy"
10038157|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
10038158|NCT01831583|Experimental|Measurement of PPG waveforms|Collection of photoplethysmograph(PPG)waveform data from patients with obstructive sleep apnea for 4-8 hours
10038159|NCT01831583|Experimental|Measurement of Pulse Arrival Time (PAT)|Collection of PAT waveform data from patients with obstructive sleep apnea for 4-8 hours
9481499|NCT04443192|Active Comparator|Part A Cohort 5 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 5
9481500|NCT04443192|Active Comparator|Part A Cohort 6 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 6
9481501|NCT04443192|Active Comparator|Part A Cohort 7 - ZF874 - Single Dose|Single oral dose of ZF874 by mouth after consuming a high-fat breakfast. Dose Level 3
9481502|NCT04443192|Active Comparator|Part B Cohort 1 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
9481503|NCT04443192|Placebo Comparator|Part B Cohort 1 - Placebo to ZF874|Two doses of placebo (12 h apart) by mouth daily for 28 days.
9481504|NCT04443192|Active Comparator|Part B Cohort 2 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
9481505|NCT04443192|Active Comparator|Part B Cohort 3 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
9481506|NCT04443192|Active Comparator|Part B Cohort 4 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
9481507|NCT04441996|Experimental|Therapeutic plasma exchange (TPE)|Participants with COVID-19-associated hyperviscosity randomized to receive therapeutic plasma exchange (TPE).
9481508|NCT04441996|Active Comparator|Standard of care|Participants with COVID-19-associated hyperviscosity randomized to receive standard of care treatment.
9481509|NCT04440943|Experimental|CDX-527|"Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance.~Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase."
9481510|NCT04440163|Experimental|1-Immuno Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
9481511|NCT04440163|Experimental|2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
9481512|NCT04440163|Experimental|3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
9481513|NCT04440163|Experimental|4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
9481514|NCT04440163|Experimental|5-Safety Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
9481515|NCT04440163|Experimental|6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
9481516|NCT04440163|Experimental|7-Safety Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
9481517|NCT04440163|Experimental|8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
9481518|NCT04437563|No Intervention|Control|('Standard' care). No intervention offered.
9481519|NCT04437563|Experimental|Intervention|('Standard' care +) The 'Herlev Hospital Empowerment of Relatives through More and Earlier information Supply' (HERMES) intervention.
9481520|NCT04429178||women in the 1st trimester of pregnancy.|
9481521|NCT04429178||women in the 2nd trimester of pregnancy.|
9481522|NCT04429178||women in the 3rd trimester of pregnancy.|
9481523|NCT04429178||non-pregnant women|
9481524|NCT04427202|Other|Referral to harm reduction services|Participants will be taken through the study survey and interview, blood and urine toxicology testing and given a referral to a harm reduction organization.
9481525|NCT04426656|No Intervention|Part 2 Standard of Care|Participants will receive written HIV prevention materials including basic facts of PrEP, recommendations for HIV/STI(sexually transmitted infections) testing and referrals to local HIV/STI testing sites and prevention services.
9481526|NCT04426656|Experimental|Part 2 mini-app|In addition to the standard of care, participants in the mini-app arm will have access to the mini-app (i.e. the intervention) during the whole study period.
9481527|NCT04424641|Experimental|Treatment|Open Label, single arm where GEN1044 will be administered
9481528|NCT04420754|Experimental|Cohort -1|AIC100 Cell Dose Level -1 (Flat Dose): 1 x 10e6 CAR T cells
9481529|NCT04420754|Experimental|Cohort 1|AIC100 Cell Dose Level 1 (Flat Dose): 1 x 10e7 CAR T cells
9481530|NCT04420754|Experimental|Cohort 2|AIC100 Cell Dose Level 2 (Flat Dose): 1 x 10e8 CAR T cells
9481531|NCT04420754|Experimental|Cohort 3|AIC100 Cell Dose Level 3 (Flat Dose): 5 x 10e8 CAR Tcells
9481535|NCT04415684|Experimental|Test Arm|
9481536|NCT04411914|Experimental|Clavulanic Acid|9 Participants will receive 500 mg of CLAV at baseline. Subjects who can tolerate 500 mg/day for 3 days (or matched placebo) will have a dose escalation to 750 mg/day for 3 days. Subjects who can tolerate 750mg/day for three days will have a dose escalation to 1000mg for 4 days.
9481537|NCT04411914|Placebo Comparator|Placebo|"3 participants will receive placebo and serve as a control group. They will be blinded to their condition and will have a dose escalation at the same time as the experimental group, and be given additional placebo pills to match the number given to the experimental group."
9481538|NCT04411082|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
9481539|NCT04411082|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
9481540|NCT04411082|Placebo Comparator|Placebo|Oral administration of once daily placebo
9481541|NCT04409561||Interventions|This patient pool shall be representative of the US population in term of the relative proportion of race/ethnicities. In addition, the population shall be enriched with patients above 60 year old as the target population of the PSP test is mostly the elderly.
10038160|NCT01831622|Experimental|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.*~Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*~Day 2:~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.*~CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
10038161|NCT01831622|Experimental|fMRI-arm|"Asterisk applies only for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.*~CRF 2, Adult ASRS and WAIS subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.*~Day 2 (after 14 - 40 days):~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).*~CRF 3, ASRS and EHI.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
10038162|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.~Exclusion Criteria~younger than 18 years old.~where the clinician/General Practitioner (GP) does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate."
10038163|NCT01831635||General Practice Control|"For each MPN case one GP control will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.~The following patient groups will be excluded. Those:~younger than 18 years old.~where the clinician/GP does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate. The WHO performance evaluation scale will be used at the stage of participant identification. Only those scoring 0-3 will be considered eligible for inclusion in the study. Those scoring 3 are described as Symptomatic >50% in bed but not bedbound."
10038164|NCT01831635||Non-blood relative or family control|Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.
10038165|NCT01831648|Experimental|Volonteers|Blood sample
9481542|NCT04407611|No Intervention|Conventional modality|Control arm. Conventional modality entails telephone disclosure of genetic results by a licensed genetic counselor.
9481543|NCT04407611|Experimental|Online modality|Online self-guided modality entails return of genetic results directly to participants, with optional genetic counselor follow-up via telephone.
10038166|NCT01831661|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA
10038167|NCT01831661|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
9481544|NCT04407546||Families with Children|Families containing an immunocompromised individual that have children in the family setting.
9481545|NCT04407546||Famlies without children|Families containing an immunocompromised individual that do not have children in the family setting.
9481546|NCT04399460|Experimental|Low Dairy Energy Restrictive Diet|Low-dairy (<1 serving/day) and 500kcal/deficit per day energy restrictive diet
9481547|NCT04399460|Experimental|3 Servings of Full-Fat Dairy with Energy Restrictive diet|Energy-restrictive diet (500 kcal/deficit per day) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
9481548|NCT04399460|Experimental|3 Servings of Full-Fat Dairy but no energy restriction|Normal diet (no energy restriction) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
9481549|NCT04391335||Group 1|Participants who meet the screening criteria for the development of bronchiolitis obliterans syndrome (BOS) according to the NIH criteria
9481550|NCT04391335||Group 2|Participants who may or may not have abnormal spirometry; however they do not fulfill the NIH criteria for the development of BOS
9481551|NCT04388020|Experimental|Test Arm|
9481552|NCT04379518|Experimental|Arm I (rintatolimod, recombinant interferon alfa-2b)|Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on day 3 (or 4) in the absence of disease progression or unacceptable toxicity.
9481553|NCT04379518|Active Comparator|Arm II/IV (standard of care)|Patients receive standard of care.
9481554|NCT04379518|Experimental|Arm III (rintatolimod)|Patients receive rintatolimod IV over 2.5-3 hours once.
10038168|NCT01831674|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
9481555|NCT04378569|Active Comparator|ARQ-252 cream 0.3% QD (once daily)|Active Comparator
9481556|NCT04378569|Active Comparator|ARQ-252 cream 0.3% BID (twice daily)|Active Comparator
9481557|NCT04378569|Active Comparator|ARQ-252 cream 0.1% QD (once daily)|Active Comparator
9481558|NCT04378569|Placebo Comparator|Vehicle cream BID (twice daily)|Placebo Comparator
9481559|NCT04378569|Placebo Comparator|Vehicle cream QD (once daily)|Placebo Comparator
9481560|NCT04378114|Experimental|Subjects with diabetes wearing Guardian™ Sensor (3). C algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one frequent sample test (FST). C sensor algorithm applied retrospectively to raw sensor data.
9481561|NCT04378114|Experimental|Subjects with diabetes wearing Guardian™ Sensor (3). Zeus algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one FST. Zeus sensor algorithm applied retrospectively to raw sensor data.
9481562|NCT04359030||Freestyle group|Patients treated with a Freestyle aortic valve bioprosthesis
9481563|NCT04359030||Perimount group|Patients treated with a Perimount aortic valve bioprosthesis
9481564|NCT04353960||anticholinergic|Patients who receive anticholinergic medication before strabismus surgery
9532035|NCT03179644|Experimental|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
9532036|NCT03179618|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
9532037|NCT03179618|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
9532038|NCT03179423|Experimental|GNbAC1|Monthly IV repeated dose
9532039|NCT03179423|Placebo Comparator|Placebo|Monthly IV repeated dose
9532040|NCT03179540|Experimental|non-operative management|Patients with low rectal cancer who have achieved a complete clinical response following chemoradiotherapy will undergo active follow-up with regular clinical visits, physical exam, endoscopy and imaging assessments at regular intervals for 2 years to assess for tumour re-growth or spread to the liver and lungs
9532041|NCT03179449|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
9532042|NCT03179332|Experimental|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
9532043|NCT03179332|Active Comparator|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
9532044|NCT03179332|Active Comparator|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
9532045|NCT03179592||Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
9532046|NCT03179579|Experimental|Experimental group|"HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
9532047|NCT03179579|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
9532048|NCT03179527|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
9532049|NCT03179527|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
9532050|NCT03179605|Experimental|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
9532051|NCT03179514|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
9532052|NCT03179514|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
9532053|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
9532054|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
10038169|NCT01831674|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
10038170|NCT01831687|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
10038171|NCT01831687|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
10038172|NCT01831700|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
9532055|NCT03179384|Experimental|ceftriaxone treatment|
9532056|NCT03179566|No Intervention|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
9532057|NCT03179566|Active Comparator|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
9532058|NCT03179566|Active Comparator|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
9532059|NCT03179306||Samples|de-identified images and clinical data from NCI studies.
9532060|NCT03179202|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 4 Leads placed in their low back, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
10038173|NCT01831700|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
10038174|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
9532061|NCT03179293|Active Comparator|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
9532062|NCT03179293|Placebo Comparator|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
9532063|NCT03179150||Oncological patients with extra-thoracic cancer|Patients enrolled into the study performed CT either for staging, restaging or follow-up of extrathoracic malignancies.
9532064|NCT03179228|Experimental|Prostate Embolization|Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
9532065|NCT03179280|Active Comparator|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
9532066|NCT03179280|No Intervention|Healthy adolescents|3 standard meals with varying composition were consumed
9532067|NCT03178994|Experimental|2% ketoconazole cream|2% ketoconazole cream apply on face twice daily for 10 weeks.
9532068|NCT03178994|Placebo Comparator|Placebo|Hydrophilic cream (in-house preparation) apply on face twice daily for 10 weeks.
9532069|NCT03179007|Experimental|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
9532070|NCT03179254|Experimental|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
9532071|NCT03179254|Active Comparator|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
9532072|NCT03179059|Experimental|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
9532073|NCT03179059|Experimental|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
9532074|NCT03179059|No Intervention|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
9532075|NCT03179085|Active Comparator|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
9532076|NCT03179085|Experimental|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
9532077|NCT03179267|Experimental|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
9532078|NCT03178916||Low risk pregnant women|evaluation of the efficacy of breastfeeding Low risk pregnant women
9532079|NCT03178916||high risk pregnant women|evaluation of the efficacy of breastfeeding high risk pregnant women
9532080|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
9532081|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
9532082|NCT03178903|Active Comparator|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
9532083|NCT03178903|Sham Comparator|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
9532084|NCT03179098|Active Comparator|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
9532085|NCT03179098|Active Comparator|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
9532086|NCT03179176|Experimental|HFUD utilisation|
9532087|NCT03178981|Active Comparator|Conventional cigarette|Commercially-available combustible cigarette
10038175|NCT01831739||Multi-organ|Non-acute presentation, any Scadding stage, evidence of 5 or more organ systems involved, chronic or uncertain clinical course.
9532088|NCT03178981|Experimental|Second-generation e-cigarette A|Prototype second-generation (closed-tank) e-cigarette
9532089|NCT03178981|Experimental|Second-generation e-cigarette B|Prototype second-generation (closed-tank) e-cigarette
10038176|NCT01831739||Non-acute, Stage I, untreated|Non-acute presentation, Scadding stage I, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
10038177|NCT01831739||Stage II-III, treated|Non-acute presentation, Scadding stages II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treated for at least 3 months.
10038178|NCT01831739||Stage II-III, untreated|Non-acute presentation, Scadding stage II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
9481565|NCT04353960||non-anticholinergic|Patients who do not received anticholinergic medication before strabismus surgery
9481566|NCT04350840|Experimental|Feedback|Participating endoscopists will make high confidence diagnosis according to their judgment time
9481567|NCT04349124|Other|Treatment Group|The treatment group will provided with month supply of 30mg tablets of nifedipine extended release prior to discharge from the delivery admission. Dose increases in clinic will be at the discretion of providers, however a treatment algorithm will be provided for guidance.Treatment group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
9481568|NCT04349124|Placebo Comparator|Control Group|The control group will not receive any medications at discharge. Providers will be instructed to only prescribe new blood pressure medication at subsequent postpartum visits if the blood pressure is in the sever range (>/=160/110). The control group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
9481569|NCT04345211|Active Comparator|Group1 (G1): walking group|"All walks will be done immediately after the MT and TB intervention, as this has been shown to improve the synergistic effect of combining the two interventions. The walking sessions will be organized twice a week. The walking sessions will begin with a 10-minute warm-up. After warming up, you will take a continuous walk for 10-20 min, at a target intensity of 13 (somewhat difficult) on the Borg scale. Using the Borg scale, which ranges from 6 to 20, participants will be asked to walk at an intensity of 13 (perception of somewhat difficult activity). Each session will be completed with a 10 minute cool down period. The objectives of Walinking will be individualized according to the level of physical condition of each participant. The walking group will include a weekly walking goal of 75 minutes."
9481570|NCT04345211|Active Comparator|Group 2 (G2): walking plus manual therapy|"Walking as previously described plus a self-administered manual chest therapy:~- Neurolymphatic points pressure: Participants will be placed in a neutral position and their arms next to their bodies. They are asked to take a conscious breath. The physical therapist will apply firm, direct rotary pressure through the thumb or fingertip for 1 minute from the T1 transverse processes to the T12 transverse processes. Suboccipital decompression / mobilization, slippage of the cervical vertebral joints (anterior / posterior), myofascial release of sternocleidomastoid and trapezius, slippage of the sternoclavicular joint (anterior / posterior direction), myofascial release of intercostal muscles and paravertebral muscles (anterior rib mobilization, posterior, lateral), mobilization of the scapulothoracic joint, diaphragmatic release."
9481571|NCT04345211|Active Comparator|Group 3 (G3): walking plus thorax exercises with Theraband.|Walking as previously described plus a self-administered exercises with elastic-band. The exercises will include chest and arms exercises in sitting position.
9481572|NCT04345211|No Intervention|Group 4 (G4): control group|Control group will do usual life and assessments as the rest of the groups.
9481573|NCT04340323|Experimental|Group A-intensive exercise group|"Dosage of intensive exercise group - 12 weeks, five times a week for 30 minutes per day; five times with education by a physiotherapist, followed by continuation at home.~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.~Educating probands about anatomy, physiology and pelvic floor muscle function.~Training of pelvic floor muscles in different positions.~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
9481574|NCT04340323|Active Comparator|Group B-low-intensity exercise group|"Dosage of low-intensity exercise group - 12 weeks, twice a week for 15 minutes per day; five times with physiotherapist education, followed by continuation at home.~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.~Educating probands about anatomy, physiology and pelvic floor muscle function.~Training of pelvic floor muscles in different positions.~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
9481575|NCT04333160|Experimental|JTA-004|single knee intra-articular injection of JTA-004 solution (2ml)
9481576|NCT04333160|Placebo Comparator|placebo|single knee intra-articular injection of saline solution (2ml)
9481577|NCT04333160|Active Comparator|Hylan G-F 20|single knee intra-articular injection of Hylan G-F 20 (6ml)
9497612|NCT03473379||Phase 2: Item generation and analysis|The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.
10038179|NCT01831739||Stage IV treated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treatment current and for at least 3 months.
10038180|NCT01831739||Stage IV untreated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
10038181|NCT01831739||Acute Sarcoidosis, untreated|Acute presentation, Scadding stages I, II, or III, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
10038182|NCT01831739||Remitting, untreated|Remitting clinical course, no treatment for at least 3 months.
9481578|NCT04330391|No Intervention|Usual Care|Individuals randomized to the usual care group will receive standard care. This may include a physical therapist and/or nutritionist referral. Brigham and Women's Hospital offers several programs for patients interested in losing weight, including the Nutrition Wellness Service (NWS) and Program for Weight Management (PWM). Insurance coverage for these programs varies by patient insurance.
9532090|NCT03178981|Experimental|Second-generation e-cigarette C|Prototype second-generation (closed-tank) e-cigarette
9481579|NCT04330391|Experimental|Intervention|Intervention subjects will use the Nutrimedy mobile app and be connected at enrollment with a registered dietitian who will contact intervention participants weekly or bi-weekly via video calls and unlimited in-app text messaging for up to three months. The first week will include either one 55-minute video session or two 25-minute sessions. Weeks 2-4 will have weekly 25-minute video calls, and weeks 5-12 will have biweekly 25-minute sessions for a total of 8-9 sessions over 12 weeks. Together, participants and dietitians will come up with goals for the 12 weeks, and dietitians will check on progress toward these goals using in-app tools such as food logs and messaging between video calls. All patients will be encouraged to lose at least 20 pounds with a goal BMI<40 kg/m2 after 12 weeks. The intervention group will also receive all aspects of the usual care arm including the opportunity to have a physical therapist and/or nutritionist referral.
9481580|NCT04326283|Experimental|Trametinib (0.5 mg)|One tablet of trametinib 0.5 mg per day
9481581|NCT04326283|Experimental|Trametinib (1 mg)|Two tablets of trametinib 0.5 mg per day
9481582|NCT04326283|Active Comparator|Riluzole (100 mg)|One tablet of riluzole 50 mg taken twice per day
9481583|NCT04325906|Active Comparator|high flow nasal cannula only|Receive high flow nasal cannula only
9481584|NCT04325906|Experimental|HFNC plus prone positioning|Receive high flow nasal cannula plus prone positioning
9481585|NCT04324359|Experimental|SURF-201|0.2% topical corticosteroid solution
9481586|NCT04324359|Placebo Comparator|Vehicle|Placebo
9481587|NCT04319653|Experimental|Dynamic pelvic MRI|
9481588|NCT04319445|Experimental|Migraine Patients/Providers/Faculty/Staff/Other|
9481589|NCT04316832|Experimental|Intervention/treatment|The mindfulness based cognitive training will be delivered in one session and will include short mindfulness exercises.
9481590|NCT04316832|Placebo Comparator|No intervention|Control exercise, participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
9481591|NCT04315233|Experimental|Treatment: all patients|Ribociclib and belinostat will be given at escalating doses and on multiple administration schedules throughout the dose escalation component of the study. The MTD identified in the dose escalation component will be used to define the dose and administration schedule used in the dose expansion.
9481592|NCT04314414|Experimental|Intervention group|Participants in the intervention group will receive a semi-scripted brief motivational interview from the peer recovery coach (PRC) in addition to the standard of care at Boston Medical Center (BMC) for HIV, HCV, and opioid use disorder.
9481593|NCT04305275|Experimental|SAGE-324 60 mg|Participants will receive SAGE-324 60 mg dose (tablets) orally in the morning for 28 days.
9481594|NCT04305275|Placebo Comparator|SAGE-324 Matched Placebo|Participants will receive SAGE-324 matched placebo, oral tablets for 28 days.
9481595|NCT04300296|Experimental|Cutaneous lichen planus secukinumab 300mg Q4W|Secukinumab 300 mg every 4 weeks provided in 1ml PFS in cutaneous lichen planus patients
9481596|NCT04300296|Placebo Comparator|Cutaneous lichen planus placebo|Placebo in 1ml PFS in cutaneous lichen patients
9481597|NCT04300296|Experimental|Mucosal lichen planus secukinumab 300 mg Q4W|Secukinumab 300 mg every 4 weeks provided in 1 ml PFS in mucosal lichen planus patients
9481598|NCT04300296|Placebo Comparator|Mucosal lichen planus placebo|Placebo 1 ml PFS in mucosal lichen planus patients
9481599|NCT04300296|Experimental|Lichen planopilaris secukinumab 300 mg Q4W|Secukinumab 300 mg every 4weeks provided in 1ml PFS in lichen planopilaris patients
9481600|NCT04300296|Placebo Comparator|Lichen planopilaris placebo|Placebo in 1ml PFS in lichen planopilaris patients
9481601|NCT04295928|Experimental|Intervention|Implementation of a personalized pharmaceutical plan with a view to increasing the patient's therapeutic education in the hospital and in the community (entrance and discharge reconciliation, 3 pharmaceutical interviews in the hospital, strengthening of the community-hospital link , 3 outpatient pharmaceutical consultations)
9481602|NCT04295928|No Intervention|Usual care period|No changes to usual center practices
9481603|NCT04285671|Experimental|Treatment (necitumumab, trastuzumab, osimertinib)|Patients receive necitumumab IV over 60 minutes and trastuzumab IV over 30-90 minutes on days 1 and 15. Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9481605|NCT04279561|Experimental|Diagnostic (68GA-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
9481606|NCT04270630|No Intervention|Standard of care|Patients in the control arm of the study will undergo standard of care treatment, discussing catheterization with their treating physicians.
9481607|NCT04270630|Experimental|Shared decision aid|Patients in the interventional arm of the study will discuss catheterization with their treating physicians, in addition to having access to the shared decision aid tool and a shared decision conversation with a co-investigator clinician.
9481608|NCT04270526|Active Comparator|Active treatment|50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
9481609|NCT04270526|Placebo Comparator|Placebo treatment|50 mL 1% lidocaine + 50ml of 0.9% normal saline
9481610|NCT04269993|Placebo Comparator|Vaporized cannabis: placebo|Vaporized cannabis: placebo dose
9481611|NCT04269993|Experimental|Vaporized cannabis: medium THC/medium CBD|Vaporized cannabis: medium THC/medium CBD dose
9532091|NCT03178981|Experimental|Second-generation e-cigarette D|Prototype second-generation (closed-tank) e-cigarette
9532092|NCT03178981|Active Comparator|Second-generation e-cigarette E|Commercially-available second-generation (closed-tank) e-cigarette
9532093|NCT03179111|Experimental|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
9532094|NCT03179111|Experimental|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
9532095|NCT03178708|Active Comparator|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
9532096|NCT03178708|Placebo Comparator|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
9532097|NCT03179020|Experimental|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
9532098|NCT03179020|Active Comparator|Usual Care ICUs|Management of the potential donor according usual care.
9532099|NCT03178864|Experimental|Rivaroxaban|Rivaroxaban
9532100|NCT03178864|Active Comparator|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
10038183|NCT01831739||Cardiac defining therapy|Chronic or uncertain clinical course, no multi-organ involvement, cardiac manifestations defining need for systemic corticosteroid and/or immunomodulatory therapy.
9532101|NCT03178968|Experimental|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
9532102|NCT03178968|Experimental|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
9532103|NCT03178968|Experimental|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
9532104|NCT03178929|Experimental|S-Adenosyl Methionine Treatment|"Patients will be treated with S-Adenosyl Methionine treatment after radical treatment.~2000mg, po"
9532105|NCT03178929|No Intervention|control group|Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
10038184|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
10038185|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
10038186|NCT01831830|No Intervention|control condition|The control group receives two attention-control calls.
9532106|NCT03178825|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
9532107|NCT03178656|Active Comparator|PVTT WITH SORAFENIB|"AASLD recommend therapy:~sorafenib tablet, 400mg, bid."
9532108|NCT03178656|Experimental|PVTT WITH OPERATION|patients suitable for surgery
9532109|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
9532110|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
9532111|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
9532112|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
10038187|NCT01831830|Experimental|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
10038188|NCT01831843|Placebo Comparator|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
9532113|NCT03178734|Other|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
9532114|NCT03178734|Other|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
9532115|NCT03178695|Experimental|Treatment Group|PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
9532116|NCT03178695|No Intervention|Comparison Group|Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
9532117|NCT03178812|Active Comparator|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
10038189|NCT01831843|Experimental|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
10038190|NCT01831843|Experimental|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
9481612|NCT04269408|Experimental|NicaPlant®|"10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.~In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines."
10038191|NCT01831869|Active Comparator|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
9481613|NCT04269408|Other|Control|Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.
9481614|NCT04259086|Experimental|DAXI|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL) & Lateral Canthal Lines (LCL)
9481615|NCT04249687|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Mode of administration: intramuscular injection
9481616|NCT04249687|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
9481617|NCT04249583|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
9481618|NCT04249583|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
9481619|NCT04247425|Experimental|Supportive Care (resistance training, exercise counseling)|Patients complete a series of progressive resistance training exercises at home twice weekly over 1 hour and receive instructional guidance from an exercise physiologist via videoconferencing once per week during one of these sessions for up to 12 weeks.
9497613|NCT03473379||Phase 3: Instrument refinement and internal validation|The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire
9497614|NCT03473379||Phase 4: External validation|In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments
9497615|NCT03473314|Experimental|Nitric Oxide gas at 160ppm|Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days
9497616|NCT03473288|Active Comparator|Moderate Intensity Treadmill Exercise|Moderate intensity treadmill exercise three times per week for 10-12 weeks
9497617|NCT03473288|Placebo Comparator|Sedentary Controls|Serve as a sedentary (little exercise) control for 10-12 weeks
9497618|NCT03473275||1: control|"Healthy normotensive participants. Cold pressor test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.~PinPrick test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
9497619|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
9497620|NCT03473275||3. resistant hypertensive|"Patients with proven resistant hypertension and not renal denervated or for whom a renal denervation is planned according to the criteria of the CHUV.~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
9497621|NCT03473275||4. renal denervation|Patients with a renal denervation. Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
9497622|NCT03473262||EMPA|Empagliflozin 25 mg/day
9497623|NCT03473262||INS|Insulin Glargine dose-titrated
9497624|NCT03473210|Active Comparator|Amniopatch group|in which women were subjected to active treatment included prophylactic antibiotics and antenatal corticosteroids with an effort to seal the ruptured membranes using the amniopatch technique.
9497625|NCT03473210|Active Comparator|control group|in which women were subjected to conservative management with prophylactic antibiotics and antenatal corticosteroids
9497626|NCT03473158|Active Comparator|Mechanical|fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle
9497627|NCT03473158|Active Comparator|Chemical|fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle
9497628|NCT03473145|Active Comparator|Health Living Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention. This group will receive one in-person health coaching sessions and 6 phone counseling sessions.
9497629|NCT03473145|Experimental|Reduce Sitting|Participants in the Reduce Sitting condition will receive an intervention aimed at reducing daily sitting time. This group will receive five in-person health coaching sessions and two phone counseling sessions.
9497630|NCT03473145|Experimental|Sit-to-Stand Transition|Participants in the Sit-to-Stand Transition condition will receive an intervention aimed at increasing the daily number of brief sit-to-stand transitions. This group will receive five in-person health coaching sessions and two phone counseling sessions.
9497631|NCT03473132|Experimental|Treatment|Based on starting international normalized ratio (INR) and target INR, the dose of four factor prothrombin complex concentrate will be calculated and infused. Coagulation factor levels will be assessed over 48-72 hours.
9497632|NCT03473119||Control|Healthy individuals
9497633|NCT03473119||Asthma|Asthma acute exacerbations
9497634|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
9497635|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
9497636|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
9497637|NCT03473119||CAP|Community-acquired pneumonia
9497638|NCT03473106|Experimental|Surgical Side|Surgical side requiring the use of a pneumatic tourniquet.
9497639|NCT03473106|No Intervention|Non Surgical Side|Contralateral side (Control Thigh).
9497640|NCT03473093|Active Comparator|morphine|This group will receive only morphine infusion (20microgram/kg/h)
9497641|NCT03473093|Active Comparator|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
10038192|NCT01831869|No Intervention|blank|no intervention
10038193|NCT01831882||Major Depressive Disorder|
10038194|NCT01831882||Healthy Control|
10038195|NCT01831908|Sham Comparator|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
10038196|NCT01831908|No Intervention|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
10038197|NCT01831947|Experimental|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
10038198|NCT01831947|Experimental|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
10038199|NCT01831973|Experimental|Lipotecan, injection for chemotherapy|Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
10038200|NCT01831986|Experimental|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
9532118|NCT03178812|Active Comparator|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
9532119|NCT03178890|Experimental|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
9532120|NCT03178643|Active Comparator|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
9532121|NCT03178643|Active Comparator|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
9532122|NCT03178643|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
9532123|NCT03178799||FLS|Fracture Liaison Service (Care managers based coordination service for fragility fracture patients with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years.)
9532124|NCT03178799||UC|usual care (Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years. )
9532125|NCT03178747|Active Comparator|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
9532126|NCT03178747|Sham Comparator|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
9532127|NCT03178604|Active Comparator|Classic massage|Classic massage (CM) treatment based on petrissage. It applies: 1 minute of mild effleurage, 5 minutes of deep effleurage with the thumbs, 5 minutes of firm kneading and 1 minute of tapotement (20 minutes in total). This procedure was repeated for each muscle group.
9532128|NCT03178604|Active Comparator|Sham massage|Sham massage (SM). 20 minutes in total soft effleurage was performed. This procedure was repeated for each muscle group.
9532129|NCT03178591|Active Comparator|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
9532130|NCT03178591|Active Comparator|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
9532131|NCT03178383|Experimental|Integrated Approach|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
10038201|NCT01831986|Placebo Comparator|Sugar caps.|Placebo (4 caps/day)
9532132|NCT03178383|Active Comparator|Standard Comparison|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
10038202|NCT01831999|Experimental|RecoveryTrack - Extended Care (RT-E)|Counselors will conduct monitoring and feedback sessions using the RecoveryTrack-Extended Care (RT-E) web-based monitoring system for clients newly admitted to Intensive Outpatient (IOP) treatment. Counselors will be instructed to document their reminders, contact attempts, and scheduling of RT-E appointments within a Contact Log incorporated into RT-E. All RT-E sessions will be audio recorded.
9532133|NCT03178435|No Intervention|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
9532134|NCT03178435|Active Comparator|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
9532135|NCT03178318|Other|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
9532136|NCT03178292|Active Comparator|Levofloxacin|Levofloxacin 500 mg daily for 5 days
9532137|NCT03178292|Placebo Comparator|Placebo|Placebo tab daily for 5 days
9532138|NCT03178422|Experimental|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
9615649|NCT05227274||MFM-Play|Neuromuscular disease patients completed MFM using MFM-Play
10058319|NCT02017405|Other|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
10038203|NCT01831999|No Intervention|Treatment as Usual (TAU)|Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
10038204|NCT01832012|Active Comparator|Video refresher|Group 3, received 7 minute video refresher prior to examination.
10038205|NCT01832012|Experimental|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
9481620|NCT04247074|Experimental|QM1114-DP in the LCL + Placebo in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
9481621|NCT04247074|Placebo Comparator|Placebo in the LCL and GL|"A buffered solution; Mode of administration:~intramuscular injection"
9481622|NCT04247074|Experimental|Placebo in the LCL + QM1114-DP in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
10038206|NCT01832012|No Intervention|No intervention|Group 2
10038207|NCT01832025|Active Comparator|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
10038208|NCT01832025|Active Comparator|External|external maxillary sinus floor elevation technique with simultaneous implant placement
10038209|NCT01832051|Experimental|HER2-PET|Injection of 89Zr-trastuzumab followed by PET scan
10038210|NCT01832064|Experimental|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
10038211|NCT01832077||rural doctor|examine patient's fundus by 90D fundus pre-set lens
10038212|NCT01832077||grader|grade fundus pictures in ZOC
10038213|NCT01832103|Experimental|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
10038214|NCT01832116|Experimental|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
9481623|NCT04247074|Experimental|QM1114-DP in the LCL + GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
9481624|NCT04245683||Operative Group|Patients who select operative treatment and follow up after successful neoadjuvant treatment.
9481625|NCT04245683||Non-operative Group|Patients who select non-operative follow up after successful neoadjuvant treatment
9481626|NCT04243486|Experimental|UHE-105 Shampoo|UHE-105 Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
9481627|NCT04243486|Placebo Comparator|Vehicle Shampoo|Vehicle Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
10038215|NCT01832129|Active Comparator|i.m. injection of Vitamin B12|Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.
10038216|NCT01832129|Experimental|Oral administration of vitamin B12|High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.
10038217|NCT01832168|Other|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
10038218|NCT01832168|Experimental|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
9481628|NCT04241315|Experimental|Near-Infrared Imaging group|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
9481629|NCT04241315|Other|No Imaging Group|All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.
9481630|NCT04229368|Active Comparator|Low Vitamin D3 Supplementation|Subjects enrolled into Group 1 (low-dose Vitamin D3 supplementation) will receive 800 IU of oral Vitamin D3 (Cholecalciferol) daily for 4 weeks prior to surgery, followed by 800 IU of oral Vitamin D3 daily for 3 months after surgery. Vitamin D3 supplementation will be given for a total of 4 months. Supplementing Vitamin D-deficient patients with a minimum of 800 IU of Vitamin D3 daily is supported by the IOM.
9481631|NCT04229368|Active Comparator|High Vitamin D3 Supplementation|Subjects enrolled into Group 2 (high-dose Vitamin D3 supplementation) will receive 50,000 IU of oral Vitamin D3 (Cholecalciferol) twice per week for 1 weeks followed by 50,000 IU once per week for 3 weeks prior to surgery. After surgery they will receive 50,000 IU of oral Vitamin D3 once per week for 4 weeks followed by 800 IU daily for 8 weeks. Vitamin D3 supplementation will be given for a total of 4 months.
9481632|NCT04229368|No Intervention|No supplementation|Subjects with serum 25(OH)D level ≥30ng/mL will not receive any Vitamin D supplementation both pre- and postoperatively, as these are considered sufficient. These control patients will be asked to take any supplements containing Vitamin D for the duration of their participation in the trial. All patients in group 3 will have their serum 25(OH)D checked at 3 months after the surgery.
9481633|NCT04225533|Experimental|SP16|Patients will receive a single dose of SP16 0.2 mg/kg by subcutaneous injection
9481634|NCT04225273|Experimental|Investigational Arm in pivotal study- 43USSA1705|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection
9481635|NCT04225260|Experimental|QM1114-DP in the LCL and the GL areas|"The investigational product (QM1114-DP) is a BoNT Type A.~At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines."
9481636|NCT04222712|Experimental|TRS01 low dose|
9481637|NCT04222712|Experimental|TRS01 high dose|
9481638|NCT04214639|Experimental|IDP-126 Gel|
9481639|NCT04214639|Placebo Comparator|IDP-126 Vehicle Gel|
9481640|NCT04211389|Active Comparator|ARQ-151 cream 0.3%|Active comparator
9481641|NCT04211389|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
9481642|NCT04211363|Active Comparator|ARQ-151 cream 0.3%|Active comparator
9481643|NCT04211363|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
9481644|NCT04209296||Major Depressive Disorder (MDD)|DSM-5 Diagnosis of MDD
9481645|NCT04209296||Bipolar Disorder|DSM-5 Diagnosis of Bipolar Disorder
9481646|NCT04209296||Obsessive Compulsive Disorder (OCD)|DSM-5 Diagnosis of OCD
9481647|NCT04209296||Post-traumatic Stress Disorder (PTSD)|DSM-5 Diagnosis of PTSD
9532139|NCT03178422|Active Comparator|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
9532140|NCT03178396|Experimental|Young, intervention|patients ages 18-45, taking melatonin
9532141|NCT03178396|No Intervention|Young, control|patients ages 18-45, usual care
9532142|NCT03178396|Experimental|Older, intervention|patients ages 60 and older, taking melatonin
9532143|NCT03178396|No Intervention|Older, control|patients ages 60 and older, usual care
9532144|NCT03178565|Experimental|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
9532145|NCT03178565|Active Comparator|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
9532146|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
9532147|NCT03178409||HCC|Patients affected by classical HCC
9532148|NCT03178409||MFCCC|Patients affected by classical MFCCC
9532149|NCT03178539|Active Comparator|diclofenac|patients will receive intra-operative diclofenac sodium at dose of 0.3 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
9532150|NCT03178539|Active Comparator|ketorolac|patients will receive intra-operative ketorolac tromethamine at dose of 0.5 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
9532151|NCT03178305|Experimental|Intervention|"Besides the behavior change programme (Do Something Different)~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
9532152|NCT03178305|No Intervention|Care as usual|Patients in this arm will receive care as usual with no restrictions.
10038219|NCT01832194|Experimental|Botox|"Botox:~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
9532153|NCT03178357|Other|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
9532154|NCT03178357|Other|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
9532155|NCT03178461|No Intervention|Room temperature parenteral fluids|"This group will receive IV room temperature fluids, which is the standard of care.~The composition of the fluids given will be normal saline with 5% dextrose."
9532156|NCT03178461|Experimental|Body temperature parenteral fluids|"This group will receive IV warmed fluids, body temperature, which is the experimental intervention.~The composition of the fluids given will be normal saline with 5% dextrose."
9532157|NCT03178513|Experimental|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
9532158|NCT03178513|No Intervention|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
9532159|NCT03178253||3|
9532160|NCT03178500|Experimental|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
9532161|NCT03178500|Experimental|Stair step protocol|If there is no response (no follicle >10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
9532162|NCT03178526|Active Comparator|levostatin gel|levostatin gel 1.2% topical gel was put into teh periodontal pocket using an insulin syringe
9532163|NCT03178526|Placebo Comparator|placebo gel|placebo gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
9532164|NCT03178474|Active Comparator|Breast-Fed Group|The infants will be fed with human breast milk by their mother
9532165|NCT03178474|Experimental|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
9532166|NCT03178474|Experimental|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
9532167|NCT03178279|Experimental|Use of the Physical Health Plan|Use of the Physical Health Plan
9532168|NCT03178240|Experimental|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
9532169|NCT03178240|No Intervention|Control|The control croup takes part in the survey but does not receive an intervention.
9532170|NCT03178227|Experimental|Intervention|The intervention is a school-based intervention involving photoaging of the students selfies which takes 45 minutes total.
9532171|NCT03178227|No Intervention|Control|No intervention.
9532172|NCT03178175|Experimental|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
9532173|NCT03178175|Sham Comparator|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
10038220|NCT01832207|Active Comparator|MTS|Motor threshold of stimulation
9532174|NCT03178214|Experimental|Infacort - Yoghurt|One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes. This will be taken with 240mL of water.
9532175|NCT03178214|Experimental|Infacort - Soft Food|One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes. This will be taken with 240mL of water.
9532176|NCT03178214|Active Comparator|Infacort - Dry Granules|One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed. This will be taken with 240mL of water.
9532177|NCT03178188|Experimental|laser treated DLE lesions|DLE which received the pulsed-dye laser
9532178|NCT03178188|Sham Comparator|sham treated DLE lesions|DLE which received the sham
9532179|NCT03178110|Experimental|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week.
9532180|NCT03178123|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
9532181|NCT03178123|Active Comparator|high-dose recombinant interferon a-2B|Patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
9532182|NCT03178136||case group|There is no intervention in case group.
9532183|NCT03178136||control group|The control group as the contrast for case group.
9532184|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
9532185|NCT03178019||Prediabetes group|Subjects with prediabetes
9532186|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
9532187|NCT03177993|Experimental|IDA 1|"ivermectin, diethylcarbamazine and albendazole Day 0,~permethrin Day 0 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
9532188|NCT03177993|Experimental|IDA 2|"ivermectin, diethylcarbamazine and albendazole Day 0, ivermectin Day 8~permethrin Day 0 and Day 8 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
9532189|NCT03177993|Active Comparator|DA|"diethylcarbamazine and albendazole Day 0~permethrin Day 8 if scabies present in participant or household member~Details of dosing:~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash off after 4hrs when less than 2 months; apply to whole body and wash o after 8hrs when 2 months and older."
9532190|NCT03177967|Experimental|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
9532191|NCT03177967|Experimental|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
9532192|NCT03177967|Active Comparator|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia~Interventions: Psychoeducative advice to improve sleep"
10038221|NCT01832207|Active Comparator|STS|Sensorial threshold of stimulation
10038222|NCT01832207|Sham Comparator|Placebo|
10038223|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
10038224|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
10038225|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
10038226|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
10038227|NCT01832233|Experimental|Renal Denervation|Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
10038228|NCT01832272|Experimental|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
10038229|NCT01832272|No Intervention|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
10038230|NCT01832285|Experimental|Fluvoxamine|Tablets of Fluvoxamine in dosage 100mg/day will be added to the treatment regimen and continued for 6 weeks
10038231|NCT01832298|Experimental|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
9532193|NCT03177889|Sham Comparator|Usual treatment|oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]
9532194|NCT03177889|Active Comparator|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
9532195|NCT03177928|Active Comparator|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
9532196|NCT03177928|Active Comparator|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
9532197|NCT03177928|Active Comparator|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
9532198|NCT03177876|Experimental|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles [Nanostreams] with simultaneous implant placement
9532199|NCT03177876|Active Comparator|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
9532200|NCT03178084|Experimental|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
9532201|NCT03178084|Active Comparator|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
9532202|NCT03178084|Experimental|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
9615650|NCT05227183|Experimental|Patients with suicidal recurrence during VigilanS monitoring (Reattempters)|Patients with at least a past experience of suicidal attempt (SA), included after their last SA in the 6 months VigilanS monitoring protocol and who have presented a recurrence of SA during this monitoring
9615651|NCT05227183|Experimental|Patients without suicidal recurrence during VigilanS monitoring (No reattempters)|Patients with at least a past experience of suicidal attempt (SA), included after their last SA in the 6 months VigilanS monitoring protocol and who have not presented a recurrence of SA during this monitoring
9615652|NCT05227144|Experimental|Dose Escalation|ORIC-533 dosed orally, once per day of each consecutive 28-day cycle.
9615653|NCT05227144|Experimental|Dose Expansion|RP2D dose
9615654|NCT05227105|Active Comparator|Physical Activity intervention|Five physical activity coaching calls with MoveLine and weekly physical activity. Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.
9615655|NCT05227105|Placebo Comparator|Delayed intervention|Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.
9615656|NCT05227066|Experimental|traditional physical therapy group|received traditional physical therapy protocol
9615657|NCT05227066|Experimental|lower extremity weights group|received the same traditional physical therapy in addition to lower extremity weights
9615658|NCT05227001|Experimental|PF-07852352 Influenza saRNA, low dose|
9615659|NCT05227001|Experimental|PF-07852352 Influenza saRNA, mid dose|
9615660|NCT05227001|Experimental|PF-07852352 Influenza saRNA, high dose|
9615661|NCT05227001|Experimental|PF-07836391 Influenza saRNA, low dose|
9615662|NCT05227001|Experimental|PF-07836391 Influenza saRNA, mid dose|
9615663|NCT05227001|Experimental|PF-07836391 Influenza saRNA, high dose|
9615664|NCT05227001|Experimental|PF-07836394 Influenza saRNA, low dose|
9615665|NCT05227001|Experimental|PF-07836394 Influenza saRNA, mid dose|
9615666|NCT05227001|Experimental|PF-07836394 Influenza saRNA, high dose|
9615667|NCT05227001|Experimental|PF-07836395 Influenza saRNA, low dose|
9615668|NCT05227001|Experimental|PF-07836395 Influenza saRNA, mid dose|
9615669|NCT05227001|Experimental|PF-07836395 Influenza saRNA, high dose|
9615670|NCT05227001|Experimental|PF-07836396 Influenza saRNA, low dose|
9615671|NCT05227001|Experimental|PF-07836396 Influenza saRNA, mid dose|
9615672|NCT05227001|Experimental|PF-07836396 Influenza saRNA, high dose|
9615673|NCT05227001|Experimental|PF-07867246 Influenza saRNA, mid dose|
9615674|NCT05227001|Experimental|PF-07867246 Influenza saRNA, low dose|
9615675|NCT05227001|Experimental|PF-07867246 Influenza saRNA, high dose|
9615676|NCT05227001|Placebo Comparator|Placebo|
9615677|NCT05227001|Active Comparator|Quadrivalent influenza vaccine (QIV)|
9615678|NCT05226962|Active Comparator|Ketone|An acute bout of exercise performed after the ingestion of a commercial ketone monoester supplement.
9615679|NCT05226962|Placebo Comparator|Control|An acute bout of exercise performed after the ingestion of a taste-matched placebo supplement.
9615680|NCT05226949||Cases|"60 newborns with neonatal HSV infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
9615681|NCT05226949||Controls|"60 newborns without infection.~Interventions:~Diagnostic test and disease pathogenesis: Host RNA expression profiling by RNA sequencing and proteomic analyses. Controls will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA and proteomic profiles)."
9615682|NCT05226923|Experimental|KSP-1007 single ascending dose|Single, ascending intravenous dose of KSP-1007
9615683|NCT05226923|Placebo Comparator|Placebo single dose|Single dose of placebo (0.9% normal saline)
9615684|NCT05226923|Experimental|KSP-1007 multiple ascending dose|Multiple, ascending, intravenous doses of KSP-1007
9615685|NCT05226923|Placebo Comparator|Placebo multiple dose|Multiple doses of placebo (0.9% saline)
9615686|NCT05226923|Experimental|KSP-1007 multiple ascending dose + Meropenem multiple dose|Multiple, ascending intravenous doses of KSP-1007 and multiple doses of meropenem (fixed dose)
9615687|NCT05226923|Placebo Comparator|Placebo + Meropenem multiple dose|Multiple doses of placebo (0.9% normal saline) plus multiple doses of meropenem (fixed dose)
9532203|NCT03177941|Experimental|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
9532204|NCT03177941|Active Comparator|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.~Assigned Interventions~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
9532205|NCT03177954|Experimental|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
9532206|NCT03178058||Parturients for CS|"Parturients presenting for Cesarean section will be enrolled preoperatively. Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
9532207|NCT03178032|Experimental|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
9532208|NCT03177824|Experimental|S|Sildenafil citrate (25mg)
9532209|NCT03177824|Placebo Comparator|P|placebo oral tablet
9532210|NCT03177837|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
9532211|NCT03177837|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
9532212|NCT03177863|Experimental|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
9532213|NCT03177655|Experimental|Guided Imagery|Guided Imagery meditation
9532214|NCT03177655|Active Comparator|Journaling|Keeping a journal
9532215|NCT03177811|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
9532216|NCT03177811|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
9532217|NCT03177616|No Intervention|Usual Care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.
9532218|NCT03177616|Experimental|Chiropractic Treatment + Usual Care|Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
9532219|NCT03177785|Experimental|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
9532220|NCT03177785|No Intervention|Control|Wait-list control
9532221|NCT03177980||Fentanyl|All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
9532222|NCT03177980||Fentanyl and Clonidine|Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
9532223|NCT03177707|Experimental|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
9532224|NCT03177707|Other|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
9532225|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
9532226|NCT03178006||obese|BMI 30-40kg/m2
9532227|NCT03178006||control|BMI 20-27,5kg/m2
9532228|NCT03177850|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
9532229|NCT03177850|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
9532230|NCT03177720|Active Comparator|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
9532231|NCT03177720|Active Comparator|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
9532232|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
9532233|NCT03177668|Experimental|YS110|"Phase 1 part: Administration of 3 different dose cohort~Phase 2 part: Administration of recommended dose determined from result of Phase 1 part"
9532234|NCT03177902||Observational group|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy
9532235|NCT03177902||Control group|Healthy Volunteers
9532236|NCT03177915|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
9532237|NCT03177915|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
9532238|NCT03177629|Experimental|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
9532239|NCT03177629|No Intervention|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
9532240|NCT03177629|Active Comparator|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
9532241|NCT03177590|Experimental|Recordings of facial and vocal emotional|Recordings of facial and vocal emotional productions during Children are performing three tasks
9532242|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
9532243|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
9532244|NCT03177564|Active Comparator|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
9532245|NCT03177564|Active Comparator|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
9532246|NCT03177564|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
9532247|NCT03177577|Placebo Comparator|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
9532248|NCT03177577|Active Comparator|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
9532249|NCT03177538|Active Comparator|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
9532250|NCT03177538|Active Comparator|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
9532251|NCT03177434|Active Comparator|Dicopeg Junior|"Polyethylene glycols (PEG) - 3350 Dosage form: oral solution sachets Frequency: 2 doses~Dosage:~weight up to 8 kg - 1 sachet per day~weight 8 - 12 kg - 2 sachets a day~weight 12 - 20 kg - 3 sachets a day~weight> 20 kg - 4 sachets per day, Duration: 12 weeks vs Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks"
9532252|NCT03177434|Active Comparator|Lactulose|Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks
9532253|NCT03177499|Experimental|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.~Intervention: Procedure: Invasive PPG"
9532254|NCT03177174|Active Comparator|Docetaxel|
9532255|NCT03177174|Active Comparator|Cisplatin|
9532256|NCT03177174|Active Comparator|DocetaxelCisplatin|Cisplatin combined with Docetaxel
9532257|NCT03177252|Experimental|Scalp block with lidocaine and bupivacaine|"Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
9532258|NCT03177252|Placebo Comparator|Scalp block with saline|"Scalp block with saline~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
9532259|NCT03177382|Experimental|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
9532260|NCT03177382|Active Comparator|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
9532261|NCT03177317|Experimental|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
9532262|NCT03177304|Experimental|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
9532263|NCT03177239|Experimental|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
9532264|NCT03177213||pemphigus vulgaris patients|20 pemphigus vulgaris patients will be included in the study, either newly diagnosed or recurrent. Patients will be recruited on admission from Dermatology department and Outpatient Clinic, Assiut University Hospitals
9532265|NCT03177213||Healthy controls|10 healthy age and sex matched subjects will be included as controls.
9532266|NCT03177148|Active Comparator|Usual Care|"1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar~NO active enrollment of parents~Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
9615688|NCT05226910|Experimental|tDCS and intensive therapies|Cathodal tDCS and constraint induce movement therapy
9615689|NCT05226910|Sham Comparator|Sham and intensive therapies|Sham tDCS and constraint induce movement therapy
9615690|NCT05226897|Experimental|Test|Take YYC405-T and Metformin≥1000mg, Dapagliflozin 10mg
10038232|NCT01832311|Experimental|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
10038233|NCT01832311|Experimental|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
9532267|NCT03177148|Experimental|Intervention by Clinicians|"Clinicians complete surveys during enrollment and end of the intervention~1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.~Enroll 35 eligible parents per practice~Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.~Dietitians will provide up to 6 telephone counseling sessions.~•Parents will complete surveys after enrollment and at the end of intervention"
9532268|NCT03177278|Experimental|Arm 1|
10038234|NCT01832311|No Intervention|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
10038235|NCT01832311|No Intervention|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
9532269|NCT03177226|Experimental|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
9532270|NCT03177226|Sham Comparator|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
9532271|NCT03177161|Experimental|Postal Questionnaire|
9532272|NCT03177161|Experimental|Online Questionnaire|
9532273|NCT03177161|Experimental|Face-to-face Questionnaire|
9532274|NCT03177161|Experimental|Telephone Questionnaire|
9532275|NCT03177356|Experimental|extraction,implant placement,PRF|Extraction of Mandibular first molar and Implant placement followed by Placement of placement of Platelet rich fibrin as space filling material
9532276|NCT03177356|Active Comparator|Exctraction,Implant placement,Bone graft|Extraction of mandibular first molar followed by implant placement and xenogenic bone graft as space filling material
9532277|NCT03177447|Other|Summative evaluation trial of ENABLE CHF-PC|Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.
9532278|NCT03177135|Experimental|AmnioSense diagnostic pantyliner|AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods
9532279|NCT03177057|Experimental|Arm I (self-monitoring)|ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.
9532280|NCT03177057|Experimental|Arm II (text messages)|ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.
9532281|NCT03177057|Experimental|Arm III (self-monitoring, text messages)|ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.
9532282|NCT03177057|Sham Comparator|Arm IV (questionnaire administration)|ARM IV (CONTROL GROUP): Patients complete study assessments.
9532283|NCT03176797|Experimental|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
9532284|NCT03176901|Experimental|Mindfulness-Based Stress Reduction|8 week manualized, standardized mindfulness-based stress reduction program taught by a certified Mindfulness-Based Stress Reduction instructor
9532285|NCT03176901|Active Comparator|Health Enhancement Program|8 week manualized, standardized health enhancement program, taught by a certified health education specialist
9532286|NCT03176849|Experimental|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient will be classified as sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation according to current Endocrine Society Guidelines.
9532287|NCT03176849|Active Comparator|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with standard of care per Endocrine Society Guidelines. This supplementation is based on a patient's initial vitamin D level.
9532288|NCT03176914|Experimental|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
10038236|NCT01832337|Experimental|precondition|
10038237|NCT01832350|Experimental|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
10038238|NCT01832363|Experimental|HXe MRI guided treatment sequence for BT|Patients in this arm will undergo bronchial thermoplasty treatment where the first session of the procedure will target the six most problematic airways as determined with HXe imaging. Patients will have the remaining of the airways treated in the two subsequent sessions.
9532289|NCT03176914|Active Comparator|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
9532290|NCT03177109|Active Comparator|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
9532291|NCT03177109|Active Comparator|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
9532292|NCT03177109|Active Comparator|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
10038239|NCT01832363|Active Comparator|Standard treatment sequence for BT (control)|Patients in this arm will undergo standard treatment sequence of bronchial thermoplasty. To preserve the blind of the procedure to the subjects, the same timeline and clinical measures will be followed as for HXe guided patients.
10038240|NCT01832376|Experimental|Ultrasound guided needle lavage|Ultrasound guided needle lavage
9532293|NCT03176966|Active Comparator|Vitamin E then Ropinirole|Patients will be provided with vitamin E, 400 international units (IU), at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to Ropinirole. Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
9532294|NCT03176966|Active Comparator|Ropinirole then Vitamin E|Patients will be prescribed ropinirole at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to vitamin E, 400 international units (IU). Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
9532295|NCT03176992|Active Comparator|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
9532296|NCT03176992|No Intervention|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
9532297|NCT03176992|No Intervention|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
9532298|NCT03176745||healthy controls|"no history of pulmonary disease~absence of symptoms, smoking history < 10 pack years~normal lung function testing"
10038241|NCT01832389|Active Comparator|Group P|PiCCO-controlled group
10038242|NCT01832389|No Intervention|Group C|control group
10038243|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
10038244|NCT01832428|Other|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
10038245|NCT01832441|Other|Transfer of autologous MNC intrathecally|single arm Intra thecal transplantation of autologous MNC
10038246|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
10058320|NCT02017405|Other|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
10058321|NCT02017405|Other|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
9532299|NCT03176745||chronic obstructive pulmonary disease|"clinical history and/or specialist diagnosis of COPD and risk factor(s)~persistent bronchial obstruction and/or hyperinflation and/or radiological sign of emphysema, each without alternative explanation~dyspnea, cough and/or sputum production"
9532300|NCT03176745||bronchial asthma|"clinical history and/or specialist diagnosis of bronchial asthma~respiratory symptoms compatible with asthma varying over time~variable and/or reversible obstructive ventilation disorder and/or airway hyperresponsiveness~exclusion of alternative explanation"
9532301|NCT03176745||sarcoidosis|"clinical history and/or specialist diagnosis of sarcoidosis~lymphocytic alveolitis and CD4/CD8 > 3.5 in bronchoalveolar lavage and/or noncaseating epithelioid granuloma~exclusion of alternative explanation"
9532302|NCT03176680|Experimental|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
9532303|NCT03176680|No Intervention|Fluid therapy normalization|No fluid loading after induction.
9532304|NCT03176667|Experimental|ESP for VATS|Erector Spinae plane (ESP) block
9532305|NCT03176667|Active Comparator|ICB for VATS|Intercostal block (ICB)
9532306|NCT03177018|Experimental|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
9532307|NCT03176823|Sham Comparator|Control Arm|"Control-arm patients will be treated with standard Best Practice management of traumatic brain injury, with the addition of sham-RIC. The sham intervention will use a purpose-built device which will visually and audibly mimic a functional RIC device, with the key distinction being non-inflation of the arm cuff with resultant non-occlusion and no induced ischemia. To mask patient enrollment, all patients in both study arms will have the arm and RIC device draped in an opaque sheet so that the extremity distal to the RIC device are not visible to medical staff during the period of intervention."
9532308|NCT03176823|Experimental|RIC Arm|The RIC treatment will be applied with a purpose-built commercial RIC device which will aid in standardizing dose and delivery. Therapeutic RIC will be provided by the CellAegis Technologies autoRIC device on an upper extremity. As with the control cohort, this cohort will undergo complete extremity draping.
9532309|NCT03177044|Experimental|Behavioural treatment|2 to 6 sessions of bowel behavioural training with a pelvic floor physiotherapist
9532310|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
9532311|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
9532312|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
9532315|NCT03176940|Experimental|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
9532316|NCT03176940|Experimental|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
9532317|NCT03176940|Experimental|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
9532318|NCT03176940|Experimental|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
9532319|NCT03176940|Experimental|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
9532320|NCT03176940|Experimental|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
9532321|NCT03176875|Experimental|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
9532322|NCT03176875|Active Comparator|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
9532323|NCT03176888|Experimental|Exercise|Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints. Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy. The duration of the intervention will be the weeks between enrolling in the study and surgery (~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
9532324|NCT03176888|No Intervention|Standard care|Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study. They will however undergo the same testing sessions as patients in the Exercise group.
9532325|NCT03177031|Active Comparator|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
9532326|NCT03177031|Experimental|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
9532327|NCT03176810|Active Comparator|OCT-guided PCI|PCI is performed by OCT guidance.
9532328|NCT03176810|Active Comparator|Angiography-guided PCI|PCI is performed by angiography guidance alone.
9532329|NCT03177083|Active Comparator|peginterferon beta-1a|
9532330|NCT03177083|Active Comparator|Current Therapy|
9532331|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
9532332|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
9532333|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
9532334|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
9532335|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
9532336|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
9532337|NCT03176706||Russian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Russia.
9532338|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
9532339|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
9532340|NCT03176771|Experimental|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
9532341|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
9532342|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
9532343|NCT03177096|Experimental|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
9532344|NCT03176758|Active Comparator|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
9615691|NCT05226897|Placebo Comparator|Placebo control|Take YYC405-T Placebo and Metformin≥1000mg, Dapagliflozin 10mg
9615692|NCT05226871|Other|Arm 1|Cetuximab
9615693|NCT05226871|Experimental|Arm 2|Palbociclib plus Cetuximab
10038247|NCT01832467|Experimental|cetuximab-containing chemotherapy|"Cetuximab may be given at either one of the following schedules at the investigator's discretion:~2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.~Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.~Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.~Regimens to be combined with biweekly cetuximab:~Irinotecan at 2-weekly schedule.~FOLFIRI (as inpatient or via ambulatory pump).~FOLFOX (as inpatient or via ambulatory pump)."
9532345|NCT03176758|Active Comparator|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
9532346|NCT03176693|Active Comparator|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
10038248|NCT01832519||CF group|Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
10038249|NCT01832519||Non-CF Control|1 chest MRI with contrast and blood for proteomics and metabolomics
10038250|NCT01832545|Active Comparator|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
9532347|NCT03176693|Experimental|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
10038251|NCT01832545|Experimental|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
10038252|NCT01832558|Experimental|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
10038253|NCT01832558|Placebo Comparator|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
10038254|NCT01832571|Experimental|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
10038255|NCT01832584|Experimental|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
9532348|NCT03177070|Experimental|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
9532349|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
9532350|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
9532351|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
9532352|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
9532353|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
9532354|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
9532355|NCT03176641|Active Comparator|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
9532356|NCT03176641|Placebo Comparator|Control group|30 patients will receive meniscus repair surgery only.
9532357|NCT03176576|Experimental|Patient Navigator (PN)|Patient Navigator (PN) Intervention Group. In addition to the Baseline Questionnaire and the Follow-up Questionnaire, PN intervention participants will complete a brief Patient Navigator Satisfaction Survey.
9532358|NCT03176576|Other|Usual Care (UC)|Usual Care (UC) Control Group. Control sample of patients not receiving PN intervention will complete a Baseline Questionnaire and the six-week Follow-up Questionnaire. Participants under UC will have access to all services typically provided to Moffitt Cancer Center (MCC) patients. Any baseline distress score greater than three will be reported to the patient's primary oncologist and clinic nurse.
9532359|NCT03176628|Experimental|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
10038256|NCT01832584|Experimental|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
10038257|NCT01832584|Placebo Comparator|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
10038258|NCT01832623|Experimental|Exploration of Vitamin D roles|Various exams will be performed during two visits (the same day or within three months) in order to answer the objectives of the study.
10038259|NCT01832636|Active Comparator|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
10038260|NCT01832636|Active Comparator|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
10038261|NCT01832636|Active Comparator|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
10038262|NCT01832636|Placebo Comparator|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
9532360|NCT03176628|Placebo Comparator|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
9532361|NCT03176524|Experimental|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
9532362|NCT03176524|Experimental|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
9532363|NCT03176524|Active Comparator|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
9532364|NCT03176394|Experimental|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
9532365|NCT03176394|Placebo Comparator|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
9532366|NCT03176342|Experimental|patch test arm|Patch test by selected allergens and drawing blood for ELIspot and LTT
9532367|NCT03176264|Experimental|PDR001|
9532368|NCT03176420|Experimental|Symptomayic chronically occluded cervical ICA|
9532369|NCT03176355|Other|Chronic dacryocystitis patients|
9532370|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
9532371|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
9532372|NCT03176485|Experimental|ArmA: With Solar Simulated Light Exposure|
9532373|NCT03176485|Experimental|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
9532374|NCT03176485|No Intervention|ArmC: Without Solar Simulated Light Exposure|
9532375|NCT03176589|Sham Comparator|sham PEP|3 cycles of 10 deep inspiration and expiration in a sham tube without expiratory resistance
9532376|NCT03176589|Active Comparator|PEP|3 cycles of 10 deep inspiration followed by expiration with positive expiratory pressure (PEP) device or PEP bottle of 10-15 cm of water pressure
9532377|NCT03176589|Experimental|deep breathing maneuvers|3 cycled of 10 deep breathing maneuvers without PEP or sham PEP
9532378|NCT03176251|Active Comparator|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
9532379|NCT03176251|Experimental|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
9532380|NCT03176316|Experimental|Naloxone|1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours
9532381|NCT03176329|Other|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
9532382|NCT03176329|Other|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
9532383|NCT03176472|Experimental|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
9532384|NCT03176472|Placebo Comparator|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
9615694|NCT05226871|Other|Arm 3|Palbociclib plus Fulvestrant
9615695|NCT05226871|Other|Arm 4|Palbociclib plus Letrozole
9615696|NCT05226845|Experimental|exercise to improve the neck strength in neck pain chosen by the therapist|
9615697|NCT05226845|Experimental|exercise to improve the neck strength in neck pain chosen by the patient|
9615698|NCT05226832|Experimental|Injection Group|
10038263|NCT01832649|Experimental|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
10038264|NCT01832649|Active Comparator|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
10038265|NCT01832662|Experimental|Coffee|4 cups/day of 2.5g of coffee each
10038266|NCT01832662|Active Comparator|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
10038267|NCT01832662|Placebo Comparator|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
10058322|NCT02017418|Experimental|zeaxanthin|placebo zeaxanthin
10058323|NCT02017418|Active Comparator|combinatory supplement|placebo combinatory supplement
9532385|NCT03176368|Experimental|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
9532386|NCT03176446|Active Comparator|Control Group|The children anesthesia will be traditional technique
9532387|NCT03176446|Active Comparator|Computerized Group|The children anesthesia will be computerized technique
9532388|NCT03176446|Active Comparator|DentalVibe Group|The children anesthesia will be DentalVibe technique
9532389|NCT03176511|Experimental|MOB+DTBC Group|A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
9532390|NCT03176511|Active Comparator|MOB Group|A Matter of Balance Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of social time each class. Each class is 2 hours 15 minutes.
10038268|NCT01832675|Active Comparator|Bupivacaine lozenge|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
10038269|NCT01832675|Active Comparator|Xylocain, cutaneous spray, solution|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
9532391|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
9532392|NCT03176537|Placebo Comparator|Placebo|Gel, daily
9532393|NCT03176537|Experimental|TRT|Testosterone Replacement Therapy
9532394|NCT03176212|Active Comparator|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
9532395|NCT03176212|Placebo Comparator|Control|In this arm, subjects consumed a beverage with identical macronutrients
9532396|NCT03176121|Experimental|Oxycodone treatment|"Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.~After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks)."
9532397|NCT03176199|Experimental|Control-released oxycodone|Control-released oxycodone Q12H, initial daily dose is 20 mg + immediate-released oxycodone for PRN
9532398|NCT03176199|Active Comparator|Immediate-released oxycodone|Immediate-released oxycodone Q6H, initial daily dose is 20mg + immediate-released oxycodone for PRN
9532399|NCT03176186|No Intervention|TH/TTM|Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
9532400|NCT03176186|Active Comparator|TH/TTM plus Xenon|50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
9532401|NCT03176225|Experimental|Test Arm|In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch
9532402|NCT03176225|Active Comparator|Control Arm|In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch
9532403|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
9532404|NCT03175978|Experimental|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
9532405|NCT03175952||PCI|
9532406|NCT03176082|Experimental|Intervention Group|"Intervention group will receive:~A reminder letter indicating need for screening~A FIT kit with completion instructions~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)~A pre-paid return mailer for FIT Kit"
9532407|NCT03176082|Active Comparator|Comparison Group|"Comparison group will receive:~A reminder letter indicating need for screening~Instructions for obtaining a FIT kit~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
9532408|NCT03176108|Experimental|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
9532409|NCT03176108|Sham Comparator|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
9532410|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
10038270|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
10038271|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
10038272|NCT01832701|Experimental|coffee|4 cups of soluble coffee per day (2.5g per cup)
10038273|NCT01832701|Placebo Comparator|Maltodextrine with caffeine|4 cups per day containing 2.5 g of product each
10038274|NCT01832714||mTBI|Subjects who undergo an mTBI event
10038275|NCT01832714||Control|Subjects who do not undergo an mTBI
9532411|NCT03176069|Active Comparator|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
9532412|NCT03176069|Active Comparator|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
9532413|NCT03175939|Experimental|CCRT alone|External beam radiotherapy > 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
9532414|NCT03176043|Experimental|Thirst Driven infusion|Subjects who are self administering fluid will be instructed when (at any point in the experiment) they are experiencing thirst to request a fluid bolus with an electronic trigger. In response to this trigger the researcher will then deliver a 200ml bolus of IV fluid. After delivery of the fluid bolus, a lockout period is set for 15mins within which the researcher will not deliver another bolus in response to the trigger.
9532415|NCT03176043|Active Comparator|NICE infusion|Subjects receiving standard fluid maintenance will receive a baseline infusion rate of 30 mL/kg/24hr (1.25 mL/kg/hr). In addition to this a 500 mL bolus will be delivered if any of the following clinical signs, indicating hypovolaemia, are observed on regular examination: low peripheral perfusion, heart rate >90 /min, systolic BP <100 mmHg, respiratory rate >20, peripheral capillary refill >2sec. A maximum of 2000 mL of fluid will be delivered by additional boluses.
9532416|NCT03176173|Experimental|Arm I (image guided radiation therapy)|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while undergoing standard of care immunotherapy.
9532417|NCT03176173|Active Comparator|Arm II (standard of care immunotherapy)|Patients who decline to undergo radiation therapy receive standard of care immunotherapy.
9532418|NCT03176017|Active Comparator|Ejaculatory sparing TUIP|Ejaculatory sparing TUIP
9532419|NCT03176017|Placebo Comparator|Conventional TUIP|regular non ejaculatory sparing TUIP
9532420|NCT03176056|Experimental|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate <=90g/day
9532421|NCT03176056|Active Comparator|Calori restricted diet|Traditional diabetic diet
9532422|NCT03175926|Experimental|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
9532423|NCT03175926|Experimental|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
9532424|NCT03175926|Experimental|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
9532425|NCT03175887|Experimental|Intervention Arm|Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.
9532426|NCT03175887|Other|Treatment Arm|"After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.~If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment."
9532427|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
9532428|NCT03175900|Experimental|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
9532429|NCT03175900|Placebo Comparator|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
9532430|NCT03176030||Fortified foods|Fortified foods will be delivered to this group for 3 consecutive days mainly on a mid-meal trolley three times a day (between breakfast and lunch around 10am, between lunch and dinner around 3 pm, and in the evening). However, fortified foods will be available 24 hours and patients will be encouraged to order as many as they like anytime during the day.
9532431|NCT03176030||Baseline|Prior to implementing the intervention, dietary intake among eligible patients offered the standard hospital menu will be measured on the study wards for 24 hours during three days in each of the study wards to estimate the energy and protein intake.
10038276|NCT01832740|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
10038277|NCT01832740|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
10038278|NCT01832779||Achalasia subjects|Information about teh subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after the subject's medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
10038279|NCT01832792|Experimental|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
10038280|NCT01832792|Other|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
10038281|NCT01832805|Experimental|Theta burst stimulation|Specific developed sham coil.
10038282|NCT01832831||Continent Men|
10038283|NCT01832831||Incontinent Men|
10038284|NCT01832844|Active Comparator|"Group  with scan prior to infiltration "|
10038285|NCT01832844|Placebo Comparator|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
9532432|NCT03175679|Experimental|Autologous iNKT Cells + Tegafur +Interleukin-2(IL-2)|Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.
9532433|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
9532434|NCT03175666|Experimental|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
9532435|NCT03175757|Experimental|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
9532436|NCT03175757|Placebo Comparator|Placebo|Placebo
9532437|NCT03175705|Experimental|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
9532438|NCT03175835|Experimental|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
9532439|NCT03175783|Experimental|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
10038286|NCT01832857|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
9532440|NCT03175783|Sham Comparator|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
9532441|NCT03175614|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
10038287|NCT01832870|Experimental|Treatment|Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
10038288|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
10038289|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
9532442|NCT03175614|Experimental|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
9532445|NCT03175653|Experimental|Arm A - Oxycodone Pill A|Participants in this study arm will receive a prescription for a lower number oxycodone (oxycodone A) pills for post-cesarean pain control.
9532446|NCT03175653|Active Comparator|Arm B - Oxycodone Pill B|Participants in this study arm will receive a prescription for a higher number of oxycodone (oxycodone B) pills for post-cesarean pain control.
9532447|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
9532448|NCT03175822|Experimental|Visual Arts Training|Visual Arts Training
9532449|NCT03175822|No Intervention|Waitlist Control|Waitlist Control
9532450|NCT03175536||HDHP with PDL|Enrollees switched from a high-deductible health plan (HDHP) to a HDHP with a preventive drug list (PDL)
9532451|NCT03175536||HDHP without PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) without a preventive drug list (PDL). Enrollees who stayed in a HDHP without a PDL will also serve as controls for the study group who switch from HDHPs without PDLs to HDHPs with PDLs.
9532452|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible < $500
9532453|NCT03175848|Experimental|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
9532454|NCT03175393||postprandial dyslipidemia|
9532455|NCT03175640|Experimental|Implementation intervention|
9532456|NCT03175497|Experimental|Telatinib mesylate treatment arm|"Open label, single arm trial. For the 1st phase: three cohorts, and each with 3-6 solid tumor patients who will be treated with telatinib at predetermined dose: 600 mg bid, 900 mg bid, or 1200 mg bid, respectively.~For the 2nd phase, one cohort with 12 GC patients who will be treated with telatinib at 900 mg bid"
9532457|NCT03175354|Experimental|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
9532458|NCT03175354|Experimental|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
9622027|NCT02519322|Experimental|Arm A (nivolumab, surgery)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
9532459|NCT03175341|Experimental|Vitamin C Supplement|"Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.~Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1"
9532460|NCT03175341|Active Comparator|Placebo|"Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.~Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician."
9532461|NCT03175874|Other|osteoporosis and alzheimer|patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.
9532462|NCT03175874|Other|osteoporosis without alzheimer|Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.
9532463|NCT03175874|Other|Patient with arthrosis without alzheimer|Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.
9532464|NCT03175913|Experimental|Vapocoolant spray group|vapocoolant spray was applied for 10 second
9532465|NCT03175913|Active Comparator|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
9532466|NCT03175627|Active Comparator|Filtek One|Bulk fill composite material used for posterior tooth fillings.
9532467|NCT03175627|Active Comparator|Filtek Z250|Composite material used for incremental filling of posterior teeth.
9532468|NCT03175809|Active Comparator|PFM training|4 sessions (40 minutes approximately), Twice a week for 2 weeks of pelvic floor training with electromyographic biofeedback.
9532469|NCT03175809|Experimental|PFM training plus dry needling|PFM training associated with the use of dry needling over abdominal, gluteal and lombar miofascial trigger points.
9532470|NCT03175523|Active Comparator|Imaging guided Bioresorbable scaffold|
9532471|NCT03175523|Experimental|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
9532472|NCT03175484||Observation TLX|surgical specialty ( including anesthesia) residents and nurses undergoing High Fidelity Simulation scenarios.
9532473|NCT03175549|Active Comparator|Otezla (apremilast)|100 mg (50 mg/bid) taken orally for 5 days after a 9 day titration to recommended dose
9532474|NCT03175549|Placebo Comparator|Placebo|Placebo pill taken orally for 14 days
9532475|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
9532476|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
9532477|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
9532478|NCT03175380|Experimental|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
9532479|NCT03175315|Experimental|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
9532480|NCT03175315|No Intervention|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
9532481|NCT03175289|Active Comparator|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
10038290|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
9532482|NCT03175289|Experimental|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
9532483|NCT03175211|Experimental|BI 456906|
9532484|NCT03175211|Placebo Comparator|Placebo|
9532485|NCT03175107|Experimental|PD_patients|Patients with Parkinson disease or Parkinsonism (characteristic symptoms such as rigidity, extrapyramidal symptoms), with functional disorders in upper extremities and minor problems at daily activities, with the level 2-3 in the Hoehn and Yahr Scale. They will perform exergaming at home for up to 4 weeks.
9804151|NCT01733745|Experimental|SYSTANE® Family|SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
9532486|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
9532487|NCT03175081|Experimental|Test group|Patients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
9532488|NCT03175081|Experimental|Control group|Patients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure.
9532489|NCT03175146|Experimental|Experimental|Stereotactic Body Radiation Therapy
9532490|NCT03175055|Experimental|Phoenix|Phoenix
9532491|NCT03175185||Parents of children with ADHD|100 parents of 50 children who were diagnosed with ADHD and
9532492|NCT03175185||Parent of children without ADHD|100 parents of 50 children who are ADHD free as a control group
9532493|NCT03174977|Experimental|18F-Raltegravir|
9532494|NCT03174912|Active Comparator|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
9532495|NCT03174912|No Intervention|Group 2|Patients not treated with BCG
9532496|NCT03174912|Active Comparator|Group 3|Patients treated with BCG
9532497|NCT03175016|Experimental|DEBIRI|Transcatheter arterial chemoembolization(TACE) with Irinotecan eluting-bead(DEBIRI)
9532498|NCT03174899|Experimental|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
9532499|NCT03174899|Experimental|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
9532500|NCT03174899|Experimental|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
9532501|NCT03174899|Experimental|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
9532502|NCT03174899|Experimental|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
9532503|NCT03175029|Experimental|TAC-302|
9532504|NCT03175029|Placebo Comparator|Placebo|
9804222|NCT01736124|Active Comparator|Active control|Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
9532505|NCT03175133|Experimental|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
9532506|NCT03175250|Active Comparator|Health Education|This condition included live health education followed by health education videos on HIV risks, testing, and condom use. The videos were presented over laptop.
9532507|NCT03175250|Active Comparator|Action Plan|This condition included live health education followed by computerized procedures focusing on action plans for HIV testing and condom use and some of the same health education videos in the Health Education condition.
9532508|NCT03175250|Experimental|Memory Practice|This condition included live health education followed by computerized action plan procedures (as in the Action Plan condition), followed by several memory practice procedures also delivered over laptop. The memory practice procedures were designed to help participants more readily retrieve and use action plans in critical situations.
9532509|NCT03174938|Other|COHORT A: Cognitively healthy younger individuals (40-65 y)|"We will recruit 300 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline.~An auxiliary cohort (termed Cohort A2) of 40 healthy individuals aged 20-40 years of age will also be included."
9532510|NCT03174938|Other|COHORT B: Cognitively healthy elderly individuals (66-100 y)|"We will recruit 300 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline."
9532511|NCT03174938|Other|COHORT C: SCD and MCI|"550 patients with either subjective cognitive decline or mild cognitive impairment will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, all cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio) will be included.~FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done every 2 years. Amyloid PET will be performed at baseline and after 4 years.~A auxiliary cohort (Cohort C2) 150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y."
9532512|NCT03174938|Other|COHORT D: Dementia due to Alzheimer's disease|"300 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include 50 cases aged 40-65 years of age, 200 cases aged 66-79 years of age and 50 cases aged 80-100 years of age.~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
9532513|NCT03174938|Other|COHORT E: Other dementias|"Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited:~160 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD), Progressive nonfluent aphasia (PNFA), semantic dementia (SD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD).~50 cases with subcortical Vascular dementia (VaD).~200 cases with either Parkinson's disease (PD), Parkinson's disease with dementia (PDD), Dementia with Lewy Bodies (DLB), Multiple system atrophy (MSA).~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
9532514|NCT03175003|Active Comparator|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
9532515|NCT03175003|Active Comparator|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
9532516|NCT03175003|Experimental|Food Product 3|Experimental 1
9532517|NCT03175003|Experimental|Food Product 4|Experimental 2
9532518|NCT03175263||Patients with chronic migraine|Patients with chronic migraine refractory to conventional treatments
9532519|NCT03175588|Experimental|virtual rehabilitation|video based exercise
9532520|NCT03175588|No Intervention|physical Activity|different type of physical Activity
9532521|NCT03175510||patients group|Patients with low back pain (18-65 years)
9532522|NCT03174886|Experimental|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
10058324|NCT02017431|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
9532523|NCT03174886|Experimental|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
9532524|NCT03175237|Experimental|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
10038291|NCT01832896|Experimental|Ecallantide|"Study Medication, Dose, and Mode of Administration:~Single dose of ecallantide subcutaneous dosing:~Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.~Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
10038292|NCT01832909|Experimental|Walnut Diet first, then Control Diet|Controlled diet with 1.5 oz/d of walnuts, followed by controlled diet without walnuts.
10038293|NCT01832909|Experimental|Control Diet first, then Walnut Diet|Controlled diet without almonds first (control), then controlled diet with 1.5 oz/d of almonds.
9532525|NCT03175237|Experimental|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
10038294|NCT01832922|Experimental|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
9532526|NCT03174873|Other|Laparoscopy for unexplained infertile couples|
10038295|NCT01832922|Active Comparator|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
10038296|NCT01832935|Active Comparator|insulin glargine|patients receiving variable doses of Insulin glargine.start with 0.2 to 0.6unit per kg
9532527|NCT03174951|Experimental|Treatment group|IVIg group
9532528|NCT03174951|No Intervention|control group|Patients who do not receive any treatment despite a history of Recurrent Pregnancy Loss problem as controls
9532529|NCT03174964|Experimental|Treatment group|IVIg group
9532530|NCT03174964|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
9532531|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
9532532|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
9532533|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
9532534|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
9532535|NCT03175094|Experimental|Holistic Health Recovery Program for HIV+ Intervention|
9532536|NCT03175094|No Intervention|Control|
9532537|NCT03175458|Experimental|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
9532538|NCT03175458|Active Comparator|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
9532539|NCT03174860|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.
9532540|NCT03174860|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
9532541|NCT03174834|Other|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
9532542|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
9532543|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
9532544|NCT03174808|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
9532545|NCT03174821|Experimental|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
9532546|NCT03174821|No Intervention|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
9532547|NCT03174795|Experimental|RO7079901 and Meropenem|Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.
9615699|NCT05226806||Healthy adults|"Inclusion criteria: both, mals and female, age 45 years and older. Exclusion criteria: Medical contraindications for a maximum stress test and endurance test by the attending physician~Pathologies in the context of the preliminary examinations:~Acute and chronic cardiovascular diseases except arterial hypertension (systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg in untreated and drug-treated participants) and minor valve insufficiency~Acute and chronic lung diseases~Liver and kidney diseases~diabetes mellitus~Alcohol (> 30g / day) or drug abuse~Obesity from grade 2 (body mass index> 35 kg / m²)~Orthopedic diseases with reduced physical performance~Existing pregnancy"
9615700|NCT05226780|Experimental|NBI-921352|106 week treatment Period
9532548|NCT03174548|Experimental|Fed Tablet period (Test, T)|Sotagliflozin oral in fed conditions
9532549|NCT03174548|Experimental|Fasted Tablet period (Reference, R)|Sotagliflozin oral in fasting conditions
9532550|NCT03174548|Experimental|Oral Solution period (S)|Sotagliflozin oral solution in fasting conditions
9532551|NCT03174496||Children aged 4-7 years|
9532552|NCT03174496||Children and adolescents aged 8-16 years|
9532553|NCT03174470|Experimental|TENS stimulator|Single day Transcutaneous electrical nerve stimulations utilizing a commercial TENS stimulator (TensMed S82 ENRAF-NONIUS)
9532554|NCT03174522|Experimental|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
9532555|NCT03174522|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
9532556|NCT03174587|Experimental|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
9532557|NCT03174561|Other|Inuline, Choline and Silymarin + Diet|"Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions together with a dietary supplement.~Intervention: Dietary Supplement, a combination of Inuline, Silymarin and Choline The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days"
9532558|NCT03174561|Other|Diet restriction|Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
9532559|NCT03174730|Experimental|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
9532560|NCT03174730|Other|Control|Participants will get SmartQuit, but not the growth mindset intervention.
9532561|NCT03174509|Active Comparator|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
9532562|NCT03174509|Active Comparator|Traditional Extubation|Traditional extubation is used for patients in this group.
9532563|NCT03174639|Experimental|Inverted and free ILM insertion|Both inverted and free ILM flaps were inserted into the macular hole
9532564|NCT03174626|Experimental|WLSCC Intervention|Williams LifeSkills framework on stress management and cancer care
9532565|NCT03174626|Other|Usual Care|No intervention is provided
9532566|NCT03174782|Active Comparator|Treatment|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
9532567|NCT03174782|Placebo Comparator|Control|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
9532568|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
9532569|NCT03174717|Experimental|Music intervention|LTC residents will participate in an individualized music performance with a musician
9532570|NCT03174756|Experimental|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
9532571|NCT03174756|Experimental|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
9532572|NCT03174756|Active Comparator|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
9532573|NCT03174756|Active Comparator|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
9532574|NCT03174756|Placebo Comparator|Placebo|15 ml of Sterile water
9532575|NCT03174483|Experimental|hypertonic saline|nasal spray will be used twice daily
9532576|NCT03174483|Active Comparator|fluticasone|nasal spray will be used once daily
9532577|NCT03174769|Active Comparator|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk"
9532578|NCT03174769|Experimental|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk"
9532579|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
9532580|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
9532581|NCT03174691|Experimental|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
9532582|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
9532583|NCT03174743|Placebo Comparator|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
9532584|NCT03174743|Placebo Comparator|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
9532585|NCT03174743|Active Comparator|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
9532586|NCT03174743|Active Comparator|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
9532587|NCT03174678|Experimental|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
9532588|NCT03174678|Other|Control|Apple juice
9532589|NCT03174613|Experimental|LC51-0255|tablets, PO
9532590|NCT03174613|Placebo Comparator|Placebo|tablets, PO
9532591|NCT03174431|Active Comparator|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
9532592|NCT03174431|Active Comparator|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
9532593|NCT03174444|Experimental|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
9532594|NCT03174444|No Intervention|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
9532595|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
9532596|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
9532597|NCT03174145|Active Comparator|Active group|
9532598|NCT03174145|Sham Comparator|Control group|
9532599|NCT03174340|Experimental|Exercise + diet|"Exercise intervention:~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.~Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.~The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.~This is in addition to the diet (see below, control group)"
9532600|NCT03174340|No Intervention|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
9532601|NCT03174106|Experimental|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
9532602|NCT03174106|No Intervention|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
9532603|NCT03174119|Active Comparator|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
9532604|NCT03174119|Placebo Comparator|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
9532605|NCT03174171|Experimental|Intervention|Everolimus 0.75 mg b.i.d. orally for 14 days.
9532606|NCT03174236|Experimental|Ceftriaxone|Arm 1 IV Ceftriaxone: Participants in this group receive 80mg/kg IV ceftriaxone once a day for a minimum of 48 hours and a usual maximum of seven days.
9532607|NCT03174236|Active Comparator|Benzyl penicillin plus gentamicin|Arm 2 IV Benzyl penicillin plus gentamicin (usual care): Participants in this group receive 50 000 U/kg IV benzyl penicillin every six hours for a minimum of two days and a maximum of seven days.
9532608|NCT03174236|Experimental|Metronidazole|Arm 1 Metronidazole: Participants receive 10 to 16 mg/kg oral metronidazole twice a day for seven days.
9532609|NCT03174236|Placebo Comparator|Placebo|Arm 2 Placebo: Participants receive an oral placebo dose to match that for Metronidazole twice a day for seven days.
10038297|NCT01832935|Active Comparator|Insulin NPH|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
10038298|NCT01832948|Experimental|Treatment|Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h
10038299|NCT01832974|Other|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
10038300|NCT01832974|Other|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
10038301|NCT01832974|Other|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
10038302|NCT01832974|Experimental|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
10038303|NCT01832987|Experimental|co-trimoxazole|On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.
10038304|NCT01833000|Other|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
9481648|NCT04209283|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Experimental: Intervention phase ('B'):~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).~Intervention: Behavioral: Brief cognitive intervention"
9481649|NCT04208087|Experimental|SI-722|
9481650|NCT04208087|Placebo Comparator|Placebo|
9481651|NCT04207736|Active Comparator|Reproxalap Ophthalmic Solution (0.25%)|
9481652|NCT04207736|Placebo Comparator|Vehicle Ophthalmic Solution|
9481653|NCT04205656|Experimental|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
9481654|NCT04205656|Experimental|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
10038305|NCT01833013|Other|endometriosis cohort|females suffer from endometriosis
10038306|NCT01833052|Other|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
10038307|NCT01833052|Other|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
9481655|NCT04205656|Placebo Comparator|Control|Patients randomized in the placebo arm will undergo their standard of care treatment and will not receive LP-PRP or BMC.
10038308|NCT01833091|Experimental|intervention|creat light period 12 hours with cover on incubator
9481656|NCT04205019|Experimental|Neuro-Cell group|Patient receives treatment once at start of study and followed up for safety.
9481657|NCT04204655||Cohort|rehabilitants of the phase B, C and D during neurological rehabilitation
9481658|NCT04203667|Other|EndoRotor Resection Arm|All participants enrolled in this study will undergo treatment with the EndoRotor during colonoscopy for endoscopic mucosal resection in the colon to resect and remove tissue, not intended for biopsy, of the gastrointestinal system including post-endoscopic endoscopic mucosal resection of tissue persistence with a scarred base and residual tissue from peripheral margins following endoscopic mucosal resection.
10038309|NCT01833091|No Intervention|control|
10038310|NCT01833104|Experimental|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
10038311|NCT01833104|Experimental|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
10038312|NCT01833104|No Intervention|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
9481663|NCT04202965|Experimental|PTG-300|PTG-300 Subcutaneous
9481664|NCT04196530|Experimental|Dose Escalation of BDB001 with atezolizumab|"This part of the study will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of BDB001 with atezolizumab is reached."
9481665|NCT04196530|Experimental|Dose Expansion of BDB001 with atezolizumab|"At the end of the dose escalation part of the study, the BDB001 dose to be used in combination with atezolizumab in the expansion part of the study will be established after thorough review of all available safety, preliminary efficacy, PK and PD data.~A biologically active dose will be selected that is either the MTD, if one was established in the escalation part, or an RP2D if no MTD was established. Approximately 20 additional subjects will initially be enrolled in the dose expansion part."
10038313|NCT01833104|Active Comparator|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
9481667|NCT04189133|Experimental|Study group|The study group will receive the daily administration sc of Luveris with increasing dosages two weeks (Treatment phase) as follows: Rec-LH 75 IU daily for 2 weeks; Rec-LH 150 IU daily for 2 weeks; Rec-LH 300 IU daily for 2 weeks; Rec-LH 600 IU daily for 2 weeks.
9481668|NCT04189133|Active Comparator|Control group|"The control group will receive the administration im of Gonasi HP as follows:~hCG 500 IU two times weekly, for 2 weeks; hCG 1000 IU two times weekly, for 2 weeks; hCG 1500 IU two times weekly, for 2 weeks; hCG 2000 IU two times weekly, for 2 weeks."
9497642|NCT03473080|Other|Internet CBT|Participants and their parents receive 16 weeks of internet-delivered cognitive behavior therapy (CBT) with psychologist support.
10038314|NCT01833104|No Intervention|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
10038315|NCT01833156|Experimental|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
10038316|NCT01833182|Placebo Comparator|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
9532610|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
9532611|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at > 0 twitches train of four
9532612|NCT03174210|Experimental|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
9532613|NCT03174210|Experimental|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
9532614|NCT03174288|Experimental|Exercise alone|24 weeks of exercise treatment
9532615|NCT03174288|Experimental|spironolactone alone|24 weeks of Spironolactone treatment
9532616|NCT03174288|Experimental|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
9532617|NCT03174262|Experimental|Ergonomic Computer Workstation Training|
9532618|NCT03174262|No Intervention|Control Group|
9532619|NCT03174249|Experimental|Exposure therapy|Graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.
9532620|NCT03174392|Experimental|Resistance based training study:|Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
9532621|NCT03174392|Active Comparator|Speed based training study:|Each training session will begin by determining the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
9532624|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
9532625|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
10058325|NCT02017431|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
9532626|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
9532627|NCT03174353|Experimental|Lanreotide arm|Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
9532628|NCT03174067|Experimental|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
9532629|NCT03174067|Active Comparator|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
9532630|NCT03174041|Experimental|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
9532631|NCT03174041|Experimental|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
9532632|NCT03174041|Experimental|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
9532633|NCT03174041|Experimental|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
9532634|NCT03174093|Experimental|MATCh AFib|Participants assigned to the intervention group will have the support of the MATCh AFib application during the consultations with their physician and receive individual text messaging targeting knowledge about atrial fibrillation, medication adherence and monitoring during months 1-3.
9532635|NCT03174093|No Intervention|Standard Care|Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment, INR monitoring and consultations with their physician without mHealth support)
9532636|NCT03174028|Active Comparator|laparoscopic group|laparoscopic pull-through
9532637|NCT03174028|Sham Comparator|posterior sagittal group|posterior sagittal anorectoplasty
10058326|NCT02017431|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
9532638|NCT03174327|Other|Hepatic Transplantation|
9532639|NCT03174015|Experimental|Intervention|"Landlords on selected plots will receive the Bauleni Secret intervention. Landlords and selected tenants will be surveyed in baseline/end-line data collection."
10038317|NCT01833182|Experimental|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
9532640|NCT03174015|No Intervention|Control|Landlords and selected tenants will be surveyed in baseline/end-line data collection only.
9532641|NCT03173820|Placebo Comparator|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
9532642|NCT03173820|Active Comparator|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
9532643|NCT03173716|Active Comparator|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
9532644|NCT03173716|No Intervention|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
9532645|NCT03173742|Experimental|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
9532646|NCT03173742|Experimental|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
9532647|NCT03173742|Experimental|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
9532648|NCT03173742|Experimental|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
9532649|NCT03173742|Experimental|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
9532650|NCT03173742|Experimental|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
9532651|NCT03173885|Experimental|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
9532652|NCT03173885|No Intervention|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
9532653|NCT03173872|Experimental|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
9532654|NCT03173989|Experimental|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
9532655|NCT03173989|Active Comparator|Orientation|Patients received orientation for home.
9532656|NCT03173755||People with normal weight|
9532657|NCT03173755||people with overweight and obesity|
9532658|NCT03173859|Experimental|Rotational|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days
9532659|NCT03173859|Active Comparator|Sequential|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
9532660|NCT03173833|No Intervention|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
9532661|NCT03173833|Experimental|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.~And they will be able to discuss their care needs with their health care practitioners."
9532662|NCT03173898|Experimental|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
9532663|NCT03173898|Active Comparator|local infiltration|PDL anesthesia versus local infiltration
9532664|NCT03173781|Experimental|droxidopa|"Droxidopa will be supplied in 100 and 200 mg pill sizes. The subject should administer the three doses 4 hours apart with the last dose prior to 4:00 pm (example: 8:00 am, 12:00 pm, and 4:00 pm). The proposed dosing is 100mg TID at baseline, then titrate slowly up to 600 mg TID. During titration, droxidopa or placebo, initiated at 100 mg TID was titrated upward in 100-mg TID increments every 48 hours until the subject:~Reaches the maximum permitted dosage of 600 mg TID;~Has a systolic blood pressure≥160mmHg or diastolic blood pressure ≥100mmHg after 10 minutes supine on 3 consecutive measurements; or~Experiences intolerable adverse events (AEs)."
9532665|NCT03173781|Placebo Comparator|placebo|sugar pill
9532666|NCT03173911|Active Comparator|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
9622028|NCT02519322|Experimental|Arm B (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV over 1 hour and ipilimumab IV over 90 minutes on days 1, 22, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
9532667|NCT03173911|Active Comparator|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
9532668|NCT03173911|Active Comparator|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
9532669|NCT03173911|Active Comparator|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
9532670|NCT03173768|No Intervention|pre-intervention period|The charts of patients who were prescribed intravenous antibiotics at hospital discharge were reviewed. Appropriateness of intravenous antibiotics was assessed by ID specialists.
9532671|NCT03173768|Experimental|post-intervention period|The intervention is the charts of patients who were prescribed intravenous antibiotics at hospital discharge by the primary team were prospectively reviewed and intervened by ID team (ID specialist approval)
9532672|NCT03173846||Adult children of AD patients|
9532673|NCT03173703|Experimental|Test Arm|Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
9532674|NCT03173703|Active Comparator|Control Arm|Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
9532675|NCT03173807|Active Comparator|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
9532676|NCT03173807|Active Comparator|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
9532677|NCT03173963|Active Comparator|Drug|Empagliflozin 10mg once a day
9532678|NCT03173963|Placebo Comparator|Placebo|1 placebo tablet a day
9532679|NCT03173677|Active Comparator|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
9532680|NCT03173677|Active Comparator|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
9532681|NCT03173677|Active Comparator|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
9532682|NCT03173690|Experimental|Intervention group|Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward
9532683|NCT03173690|Other|Control group|No intervention at the ICU, medication reconciliation at the ward
9532684|NCT03173651|Experimental|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
9532685|NCT03173651|Experimental|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
9532686|NCT03173651|Experimental|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
9532687|NCT03173794|No Intervention|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
10038318|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
9532688|NCT03173794|Experimental|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
9532689|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
9532690|NCT03173625|Experimental|AC-076 sc administration - single ascending dose|On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
9532691|NCT03173625|Placebo Comparator|Placebo|For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition
9532692|NCT03173612|Experimental|AML-CAMS-2016 trial|AML-CAMS-2016 regimen includes risk-stratified therapy and the use of Dasatinib in CBF-AML.The induction regimen includes MAE (etoposide 150mg/㎡/d d1-5, cytarabine 200mg/㎡/d d6-12 , mitoxantrone 5 mg/㎡/d d6-10), CAG (aclacinomycin 6mg/㎡/d d1-8, Ara-C 10mg/㎡ q12h d1-14 , G-CSF 200ug/㎡/d d1-14),IAE (idarubicin 8 mg/㎡/d d1-3, Ara-C 500mg/㎡/d d1-3 d8-10, VP-16 200mg/㎡/d d8-10).Consolidation regimen includes IA (Ara-C 1g/㎡ q12h d1-4, IDA 10mg/㎡/d d1), MA (Ara-C 1g/㎡ q12h d1-4, MTZ 5mg/㎡/d d1-3), IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5), MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6). Dasatinib (60-80mg/㎡) is used in CBF-AML as a part of consolidation therapy.
9532693|NCT03173599|Experimental|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
9532694|NCT03173599|Experimental|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
9532695|NCT03173599|Experimental|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
9532696|NCT03173599|Experimental|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
9532697|NCT03173599|Experimental|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
9532698|NCT03173599|Experimental|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 480mg."
9532699|NCT03173599|Placebo Comparator|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
9532700|NCT03173417|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
9532701|NCT03173287|Experimental|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
9532702|NCT03173274|Experimental|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO < 6 ppm).
9532703|NCT03173274|Active Comparator|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
9532704|NCT03173404|Experimental|Group I|Patients underwent hysteroscopy examination before IVF cycle.
9532705|NCT03173404|No Intervention|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
9532706|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
9532707|NCT03173573|Experimental|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
9532708|NCT03173573|Placebo Comparator|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
9532709|NCT03173573|Experimental|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
9532710|NCT03173573|Experimental|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
9532711|NCT03173573|Experimental|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
9532712|NCT03173573|Placebo Comparator|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
9532713|NCT03173573|Experimental|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
9532714|NCT03173573|Placebo Comparator|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
9532715|NCT03173573|Experimental|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
9532716|NCT03173378||Narcoleptic Patients|Type 1 and Type 2 narcoleptic adult patients usually followed at the Lyon Sleep Medicine and Respiratory Disease center
9532717|NCT03173378||Control|Adult age-matched family members of the patients
9532718|NCT03173235||Infertile women|Women which desire to have children but are probable infertile between 18 and 45 year old
9532719|NCT03173235||healthy women|Healthy women without systemic diseases in the age of 18 to 45 years
9532720|NCT03173365|Experimental|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
9532721|NCT03173638|Experimental|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
9532722|NCT03173443|Experimental|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
9532723|NCT03173443|Experimental|double lumen tube|fiberoptic intubation with double lumen tube.
9532724|NCT03173495|Experimental|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
9532725|NCT03173495|Placebo Comparator|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
9532726|NCT03173495|Active Comparator|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
9532727|NCT03173391|Experimental|HMS5552|75mg BID
9532728|NCT03173391|Placebo Comparator|Placebo|BID
9532729|NCT03173339|Active Comparator|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
9532730|NCT03173339|Experimental|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
9532731|NCT03173261|Other|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
9532732|NCT03173326|Experimental|Subarachnoid block|
9532733|NCT03173326|Active Comparator|General anesthesia|
9532734|NCT03173508|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
9532735|NCT03173508|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
9532736|NCT03173430|Experimental|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
9532737|NCT03173222|Active Comparator|EA1|
9532738|NCT03173222|Active Comparator|EA2|
9532739|NCT03173222|No Intervention|Control|
9532740|NCT03173209|Other|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
9532741|NCT03173183|Experimental|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
9532742|NCT03173183|Active Comparator|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
9532743|NCT03173183|Placebo Comparator|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
9532744|NCT03172962|Experimental|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
9532745|NCT03172962|Active Comparator|Usual care (control)|Will receive the usual care at the hospital
9532746|NCT03172923|Active Comparator|sliding hip screw|fixation of fracture with a sliding hip screw
9532747|NCT03172923|Experimental|intramedullary nail|fixation of the fracture with an intramedullary nail
9615701|NCT05226767|Active Comparator|Active Arm|Patients who receive treatment with the NLC-V research product depending on the weight of the patients, as follows - Patients weighing less than 70 kg will receive 2 capsules, 4 times a day (80 mg in total per day) Patients weighing between 70 kg and 100 Kg will receive 3 capsules, 4 times a day (a total of 120 mg per day). Patients weighing over 100 kg will receive 4 capsules, 4 times a day (a total of 160 mg per day). NLC-V capsules Will be taken during days 1-10 for the patient's hospitalization NLC-V capsules will be taken during days 1-10 for the patient's hospitalization
9615702|NCT05226767|Placebo Comparator|Placebo|Patients who receive placebo in addition to the usual treatment for COVID-19. The placebo consists of the same solvent, but without the active ingredients of NLC-V. Placebo will be given to patients in the same manner and with the same frequency as NLC-V
9615703|NCT05226754|Active Comparator|GROUP A|diacerein 50 mg (capsules) every 12 hours for 10 days
9615704|NCT05226754|Placebo Comparator|GROUP B|placebo capsules (lactose and magnesium stearate)
9615705|NCT05226741|Experimental|Head protection|Participants are given a form of head protection
9615706|NCT05226728|Experimental|pharmacokinetic-guided pembrolizumab cohort|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression.
9497643|NCT03473067|Experimental|Social Norms Marketing|This arm includes a social norms marketing campaign tailored to the school.
9497644|NCT03473067|Active Comparator|Capacity Building|This arm includes a series of teacher training, and parent engagement meetings, with the goal of building capacity to address violence in the school.
9497645|NCT03473054||Web-based Mindfulness Course|Participants will complete a 2 week baseline phase, followed by the four week web-based mindfulness course intervention phase, and a four week follow-up period.
9497646|NCT03473041|Active Comparator|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
9497647|NCT03473041|Active Comparator|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
9497648|NCT03473028|Active Comparator|transabdominal ultrasound|400 obese female undergo transabdominal ultrasound guided embryo transfer
9497649|NCT03473028|Active Comparator|transvaginal group|400 obese female undergo transvaginal ultrasound guided embryo transfer
9497650|NCT03473015|Experimental|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
9497651|NCT03473015|No Intervention|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
9497652|NCT03473002|Placebo Comparator|Placebo|One dose of placebo (0.9% Sodium Chloride) intranasally, n=4
9497653|NCT03473002|Experimental|SeVRSV|1 x 10^7 EID50 (one dose) of SeVRSV vaccine intranasally, n=16
9497654|NCT03472976|Experimental|Group 1|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Imiquimod (Aldara) cream topically (deltoid) on Day 1 and Day 22. N=25
9497655|NCT03472976|Experimental|Group 2|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Aqueous Cream B.P. (Control Cream) topically (deltoid) on Day 1 and Day 22. N=25
9497656|NCT03472963|No Intervention|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
9497657|NCT03472963|Experimental|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
9497658|NCT03472963|Experimental|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
9497659|NCT03472963|Experimental|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
9497660|NCT03472963|Experimental|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
9497661|NCT03472963|Experimental|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
9497662|NCT03472963|Experimental|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
9497663|NCT03472963|Experimental|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
9497664|NCT03472950|Experimental|Ranolazine 500mg|Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
9497665|NCT03472950|Experimental|Ranolazine 1000mg|Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
9497666|NCT03472937|Active Comparator|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
9497667|NCT03472937|Active Comparator|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
9497668|NCT03472924|Experimental|Kinesio Tape|Kinesiotaping of the peroneus longus according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016) followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs.
9497669|NCT03472924|No Intervention|Control|Baseline measures followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs, but no use of kinesiotape.
9532748|NCT03173157|Experimental|Value Feedback Arm|A weekly email will be sent to all inpatient, resident-staffed cardiology teams outlining best use practices from AHA/ACC statements on trans-thoracic echoacardiography and data feedback on in-hospital charges, running 13 week average usage and previous week usage of full and limited trans thoracic echocardiograms
9532749|NCT03172858|Experimental|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
9532750|NCT03172858|Active Comparator|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
9532751|NCT03172936|Experimental|Dosing Schedule A|Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
9532752|NCT03172936|Experimental|Dosing Schedule B|Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
9532753|NCT03173040|Experimental|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
9532754|NCT03173040|Placebo Comparator|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
9532755|NCT03172871|Experimental|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
9532756|NCT03172871|Active Comparator|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
9532757|NCT03172988|Experimental|Dexamethasone and flurbiprofen axetil|Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
9532758|NCT03172988|Experimental|Dexamethasone and lipid microsphere|Dexamethasone 10 mg is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
9532759|NCT03172988|Experimental|Normal saline and flurbiprofen axetil|Normal saline 2 ml is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
9532760|NCT03172988|Placebo Comparator|Normal saline and lipid microsphere|Normal saline 2 ml is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
10038319|NCT01833208|Experimental|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
10038320|NCT01833221|Experimental|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
9532763|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
9532764|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
9532765|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
9532766|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
9532767|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
9532768|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
9532769|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
9532770|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
10038321|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
9481669|NCT04185246|Experimental|Single arm|"Subjects will be enrolled with sequential allocation to 1 of 3 cohorts with the following intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg.~Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day"
9481670|NCT04184037|Experimental|Auditory neurofeedback (NFB)|Participants in this arm will meditate with the help of a custom version of the Muse app, which guides users in meditation while providing auditory neurofeedback on their state of mindfulness. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app. The neurofeedback consists of changing weather sounds that are heard against a background soundscape (e.g., a beach or rainforest sound). When a user is in a focused state, the weather in the soundscape is good (e.g., it is quiet or a light breeze can be heard). When a user starts mind-wandering, the weather sounds change for the worse: it begins to rain, the wind gets louder, and there may be thunder. When the user returns to a calm state, the weather sounds quiet down again and only the background soundscape is heard. Participants are asked to pay attention to the weather sounds and to use this feedback to train their mind to remain focused on the present moment.
9481671|NCT04184037|Active Comparator|No neurofeedback (no-NFB)|Participants in this arm will meditate using a custom version of the Muse app that is identical in all respects to the mobile app used by the NFB group, expect that the auditory neurofeedback is not active. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app, but the soundscape during the sessions will only contain the background sounds (e.g., the breach or rainforest scene), without any changes to the weather.
9481672|NCT04174612|Active Comparator|Standard clinical treatment|"Patients will complete 3+7 + Midostaurin induction course."
9481673|NCT04174612|Experimental|Experimental treatment|"The experimental arm will provide 2 main modifications compared to standard:~i) immediate switch to intensified induction with high-doses Cytarabine (on days 5, 6 and 7 of induction) ii) early allocation to high-risk disease category to be refined according to ELN stratification and post induction MRD status"
9481674|NCT04164888|Experimental|CIVI 007, Dose A|Subcutaneous (SC) injection of a PCSK9 inhibitor- low dose given twice
9481675|NCT04164888|Experimental|CIVI 007, Dose B|SC injection of PCSK9 inhibitor- dose titration
9481676|NCT04164888|Experimental|CIVI 007, Dose C|SC injection of PCSK9 inhibitor- high dose given twice
9481677|NCT04164888|Placebo Comparator|Placebo|Placebo SC injection matching PCSK9 inhibitor given twice
9481678|NCT04163432|Experimental|Arm A: Chemo-Immuno|ArmA receives chemotherapy on D1 and immunotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
9481679|NCT04163432|Experimental|Arm B: Immuno-Chemo|ArmB receives immunotherapy on D1 and chemotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
9481680|NCT04163185|Experimental|AXS-07|Taken once upon migraine
9481681|NCT04163185|Placebo Comparator|Placebo|Taken once upon migraine
9481682|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod Dose A|
9481683|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod Dose B|
9481684|NCT04162769|Placebo Comparator|12-Week Double-Blind Treatment Period: Placebo|
9481685|NCT04162769|Experimental|52-Week Open-Label Extension Period: Etrasimod Dose B|
9481686|NCT04161456|Experimental|Apremilast|Apremilast twice daily 30 mg
9481687|NCT04158687|Experimental|1 g CTP-692|Powder for oral solution, taken once daily
9481688|NCT04158687|Experimental|2 g CTP-692|Powder for oral solution, taken once daily
9481689|NCT04158687|Experimental|4 g CTP-692|Powder for oral solution, taken once daily
9481690|NCT04158687|Placebo Comparator|Placebo|Powder for oral solution, taken once daily
9481691|NCT04156633||conventional identification methods (controls)|Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.
9481692|NCT04156633||new identification method (cases)Biofire FilmArray© BCID panel|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
9481693|NCT04156633||new identification method (cases) WGS approaches|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.
10038322|NCT01833260|Experimental|With music|Pulmonary rehabilitation with music in the room
10038323|NCT01833260|No Intervention|Without music|
10038324|NCT01833273|Experimental|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
9532771|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
9532772|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
9532773|NCT03173053|Active Comparator|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
9532774|NCT03173053|Active Comparator|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
9532775|NCT03173066|Experimental|Single Arm|Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
9532776|NCT03173027|Experimental|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
9532777|NCT03173027|Placebo Comparator|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
9532778|NCT03173092|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs for up to 3 years.
9532779|NCT03173118|Other|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
9532780|NCT03173118|Other|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
9532781|NCT03173131|Experimental|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
9532782|NCT03173131|No Intervention|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
9532783|NCT03173105|Active Comparator|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
9532784|NCT03173105|Sham Comparator|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
9532785|NCT03173105|Active Comparator|Group 3 (G3)|active tDCS + static proprioceptive exercises
9532786|NCT03173105|Sham Comparator|Group 4 (4)|sham tDCS + static proprioceptive exercises
9532787|NCT03172832|Active Comparator|Percutaneous Transhepatic Drainage|Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
9532788|NCT03172832|Active Comparator|Endoscopic Retrograde Cholangiography|Subjects randomized to this arm will undergo ERC as the first drainage intervention.
9532789|NCT03172845|Experimental|Vulnerable plaque|Thin-cap fibro atheroma (TCFA) was defined as a lipid-rich plaque with the thinnest fibrous cap thickness<65um. Plaque rupture was identified by the presence of fibrous cap discontinuity with a clear cavity formation inside the plaque. Plaque erosion is characterized by luminal thrombus and absence of the endothelium or without evidence of fibrous cap disruption. Fibro calcific plaque contains OCT evidence of fibrous tissue along with calcium that appears as a signal-poor or heterogeneous region with a sharply delineated border which is applied to larger calcifications. Calcified nodule is characterized as a signal or multiple regions of calcium protruding into the lumen, superficial calcification accompanied by substantive calcium proximal and or distal to the lesion. Thrombus is defined as a mass attached to luminal surface or floating within the lumen. It is seen as a protrusion inside the lumen of the artery with signal attenuation.
9532790|NCT03172845|Active Comparator|Without any vulnerable plaqueStable plaque|patient with bifurcation lesion undergoing baseline coronary angiography and baseline OCT.
9532791|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
9532792|NCT03172819|Experimental|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
9532793|NCT03172676|No Intervention|Helicobacter pylori negative patients|chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.
9532794|NCT03172676|Active Comparator|Helicobacter pylori positive patients with intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).
9532795|NCT03172676|No Intervention|Helicobacter pylori positive patients without intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study
9532796|NCT03172715|Active Comparator|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
9532797|NCT03172715|Experimental|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
10038325|NCT01833286|Experimental|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
10038326|NCT01833286|Active Comparator|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
10038327|NCT01833299|Active Comparator|TACE group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
10038328|NCT01833299|Experimental|TACE+sorafinib|TACE+sorafinib
10038329|NCT01833312|Experimental|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
9532798|NCT03172663|Experimental|group 1|
9532799|NCT03172663|Active Comparator|group 2|
10038330|NCT01833312|No Intervention|Control|Best medical treatment
10038331|NCT01833325|Experimental|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
10058327|NCT02017431|Experimental|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
10058328|NCT02017457|Experimental|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
9803722|NCT03494621|Experimental|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
9803723|NCT03494530|Other|Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
9532800|NCT03172689|Other|CardioQ|CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor
9532801|NCT03172650||study group|non alcoholic fatty liver disease patients
9532802|NCT03172650||Control group|fatty liver patients
9532803|NCT03172572||Indication for surgery|Solid neoplasms
9532804|NCT03172767||Preterm Preschoolers|Preterm children who haven't attend school.
9532805|NCT03172767||Term Preschoolers|Term children who haven't attend school.
9803724|NCT03494530|Other|Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
9803725|NCT03489278||Affected|Affected with ALS or a related disorder.
9804152|NCT01733745|Active Comparator|Standard of Care|Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
9532806|NCT03172793|Experimental|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
9532807|NCT03172793|Experimental|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
9532808|NCT03172793|Experimental|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
9532809|NCT03172741|Placebo Comparator|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
10038332|NCT01833338|Other|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
10038333|NCT01833351|Experimental|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
9481696|NCT04145297|Experimental|Treatment: all patients|"Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily.~Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level. Both medications will be administered in 28-day cycles"
9481697|NCT04144582|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Metastatic or Non-driver Gene Mutation Non-small Cell Lung Cancer
9481698|NCT04144569|Experimental|PD-1 Combined With Pyrotinib|PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
9481699|NCT04141215|Experimental|BIOBank bone paste (PPT322)|Allogeneic bone paste derived from human living donor femoral heads
9481700|NCT04141215|Active Comparator|BIOBank cortico-cancellous bone powder (PPT6)|Allogeneic bone powder derived from human living donor femoral heads (used in current practice)
9481701|NCT04141059|Experimental|Oligopin|Intervention group that will intake 100 mg of Oligopin® for 6 weeks
9481702|NCT04141059|Placebo Comparator|Placebo|Placebo group that will intake 250 mg of Maltodextrin
9481703|NCT04139122|Experimental|Cohort 1-4: SJP-0132|Each cohort will receive a single dose of 1 of 4 strengths of SJP-0132
10038334|NCT01833351|Experimental|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
10038335|NCT01833364|Experimental|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
10038336|NCT01833377|Experimental|caraway sample|caraway sample
9481704|NCT04139122|Placebo Comparator|Cohort 1-4: Placebo|Single dose of placebo
9481705|NCT04139122|Experimental|Cohort 5-6: SJP-0132|Cohort 5 SJP-0132 will receive the second maximum acceptable dose from Cohorts 1-4 for 4 weeks. Cohort 6 SJP-0132 will receive the maximum acceptable dose from Cohorts 1-4 for 4 weeks
9481706|NCT04139122|Placebo Comparator|Cohort 5-6: Placebo|Multiple dose placebo for 4 weeks
9481707|NCT04138056|Experimental|XRSV formulation 3_dTpa Group|Subjects randomized to the XRSV formulation 3_dTpa group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481708|NCT04138056|Placebo Comparator|XPlacebo_RSV formulation 3 Group|Subjects randomized to the XPlacebo_RSV formulation 3 group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of Placebo in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481709|NCT04138056|Experimental|XRSV formulation 2_dTpa Group|Subjects randomized to the XRSV formulation 2_dTpa group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481710|NCT04138056|Placebo Comparator|XPlacebo_RSV formulation 2 Group|Subjects randomized to the XPlacebo_RSV formulation 2 group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of Placebo in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a second dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481711|NCT04138056|Placebo Comparator|XPlacebo_dTpa Group|Subjects randomized to the XPlacebo_dTpa group receive a single dose of Placebo in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481712|NCT04138056|Experimental|URSV formulation 3_dTpa Group|Subjects randomized to the URSV formulation 3_dTpa group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9532810|NCT03172741|Experimental|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
10038337|NCT01833377|Active Comparator|Placebo|
10038338|NCT01833390|Experimental|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
10038339|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
9803726|NCT03485820|Experimental|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
10038340|NCT01833442|Active Comparator|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
10038341|NCT01833442|Active Comparator|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
10038342|NCT01833507|Active Comparator|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
9481713|NCT04138056|Placebo Comparator|UPlacebo_RSV formulation 3 Group|Subjects randomized to the UPlacebo_RSV formulation 3 group receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of Placebo in the right arm during the vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481714|NCT04138056|Experimental|URSV formulation 2_dTpa Group|Subjects randomized to the URSV formulation 2_dTpa group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of dTpa vaccine in the right arm during vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481715|NCT04138056|Placebo Comparator|UPlacebo_RSV formulation 2 Group|Subjects randomized to the UPlacebo_RSV formulation 2 group receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of Placebo in the right arm during vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 vaccine (12 to 18 months post 1st vaccination) in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481716|NCT04138056|Placebo Comparator|UPlacebo_dTpa Group|Subjects randomized to the UPlacebo_dTpa group receive a single dose of Placebo in the left arm, a single dose of dTpa vaccine in the right arm during vaccination 1 phase and are followed up until Day 181. The subjects that agree to participate in the study extension receive a single dose of RSVPreF3 formulation 3 (12 to 18 months post 1st vaccination) vaccine in the non-dominant arm during the vaccination 2 phase and are followed up until the study end.
9481717|NCT04134910|Experimental|Physical therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
9481718|NCT04134442|Experimental|Bupivacaine Liposome|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist).~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
9481719|NCT04134442|Active Comparator|Standard therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist).~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
9481720|NCT04133519|Active Comparator|Arm 1|Arm 1 is an active behavioral treatment for IBS (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD).
9481721|NCT04133519|Active Comparator|Arm 2|Arm 2 is a behavioral treatment (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)
9481722|NCT04132466|Experimental|Enrolled Subjects|Adult subjects who met eligibility criteria and provided written informed consent to participate
9481723|NCT04130919|Experimental|Tilpisertib 300 mg|Participants will receive blinded tilpisertib 300 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
9481724|NCT04130919|Experimental|Tilpisertib 100 mg|Participants will receive blinded tilpisertib 100 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
9481725|NCT04130919|Placebo Comparator|Placebo|Participants will receive blinded tilpisertib matching placebo for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
9481726|NCT04130919|Experimental|Open-label Treatment Phase|Based on the efficacy assessment results at Week 10, participants who do not achieve MCS response will have the option to receive open-label tilpisertib 300 mg for up to 50 weeks.
9481727|NCT04129086|Experimental|Ketamine plus Usual care|
9481728|NCT04129086|Active Comparator|Usual care|
9481729|NCT04128007|Experimental|ARQ-154 foam 0.3%|active
9481730|NCT04128007|Placebo Comparator|ARQ foam VehicleRQ-154 foam Vehicle|placebo
9481731|NCT04127786|Experimental|Group 1: VRVg-2|VRVg-2, 3 injections at Day 0, Day 7, and Day 28
9481732|NCT04127786|Active Comparator|Group 2: Verorab|Verorab, 3 injections at Day 0, Day 7, and Day 28
9481733|NCT04127786|Active Comparator|Group 3: Imovax Rabies|Imovax Rabies, 3 injections at Day 0, Day 7, and Day 28
10038343|NCT01833507|Placebo Comparator|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
9532811|NCT03172741|Experimental|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
9532812|NCT03172741|Experimental|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
9532813|NCT03172728|Experimental|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
9532814|NCT03172728|No Intervention|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
9532815|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
9532816|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
9532817|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
9532818|NCT03172442|Experimental|orthodontic removable traction appliance|"Patients in this group will be treated using the orthodontic removable traction appliance (vacuum plate with two hooks between lateral incisor and canine in each side). An rapid maxillary expander will be applied to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.~Class III elastic traction from upper first molar to the hook in both side. This appliance will be used full-time with Class III elastics (6- to 8-ounce) traction."
9532819|NCT03172442|No Intervention|Control group|without intervention
9532820|NCT03172611|Experimental|Plant-based diet|A defined, plant-based diet was prescribed for 4 weeks.
9532821|NCT03172637||Group A|50 female end stage renal disease patients
9532822|NCT03172637||Group B|50 normal female patients
9532823|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
9532824|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
9532825|NCT03172624|Experimental|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
9532826|NCT03172624|Experimental|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
9532827|NCT03172559|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
9532828|NCT03172559|No Intervention|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
9532829|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
9532830|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
9532831|NCT03172598|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.
9532832|NCT03172598|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.
9532833|NCT03172598|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.
10038344|NCT01833559|Other|Incidence of GDM|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
10038345|NCT01833559|Other|Gestational outcomes|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
9532834|NCT03172598|Experimental|MT-8554, then placebo|The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase
10038346|NCT01833559|Other|Metabolic disorder|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
9532835|NCT03172598|Experimental|Placebo, then MT-8554|The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase
9532836|NCT03172377|Experimental|Intervention group|Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.
9532837|NCT03172377|No Intervention|Control group|Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.
9532838|NCT03172390|Experimental|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
9532839|NCT03172585|Other|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
9532840|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
9532841|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
9532842|NCT03172416|Other|Oxaliplatin|"3+3 dose escalation of oxaliplatin~This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin.~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3),120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level.~Oxaliplatin every 6 weeks with IV nivolumab every 2 weeks~PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks"
9532843|NCT03172286|Active Comparator|Patient treated with fake radiofrequencer|
9532844|NCT03172286|Experimental|Patient treated with radiofrequencer|
9532845|NCT03172299|Active Comparator|Injection of anti-VEGF|
9532846|NCT03172299|Placebo Comparator|false injection of anti-VEGF|
9532847|NCT03172273|Experimental|TIPS with PTFE|Transjugular Intrahepatic portosystemic shunt with PTFE covered stents
9532848|NCT03172273|Active Comparator|paracentesis|Paracentesis with albumine invision
9532849|NCT03172533|Active Comparator|verum group|approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks
9532850|NCT03172533|Placebo Comparator|placebo group|placebo
9532851|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
9532852|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
9532853|NCT03172351|Experimental|EDoF1|
9532854|NCT03172351|Active Comparator|Monofocal|
9532855|NCT03172351|Active Comparator|EDoF2|
9532856|NCT03172208|Experimental|Group 1: Japanese - Caplacizumab Dose 1 iv (SD)|Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants
9532857|NCT03172208|Placebo Comparator|Group 1: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
9532858|NCT03172208|Experimental|Group 2: Japanese - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants
9532859|NCT03172208|Experimental|Group 2: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
9532860|NCT03172208|Experimental|Group 2: White - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants
9532861|NCT03172208|Placebo Comparator|Group 2: White - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to White participants
9532862|NCT03172208|Experimental|Group 3: Japanese - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
9532863|NCT03172208|Placebo Comparator|Group 3: Japanese - Placebo sc (SD)|Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants
9532864|NCT03172208|Experimental|Group 3: White - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants
9532865|NCT03172208|Placebo Comparator|Group 3: White - Placebo sc (SD)|Single dose (SD) Placebo administered subcutaneously (sc) to White participants
9532866|NCT03172208|Experimental|Group 4: Japanese - Caplacizumab Dose 2 sc (MD)|Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
9532867|NCT03172208|Placebo Comparator|Group 4: Japanese - Placebo sc (MD)|Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants
9532868|NCT03172182|Experimental|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
9532869|NCT03172182|No Intervention|Control Group|Conventional verbal education of preoperative proceudres
9532870|NCT03172234|Active Comparator|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
10038347|NCT01833572|Experimental|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
10038348|NCT01833585|Experimental|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
10038349|NCT01833598|Active Comparator|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
10038350|NCT01833598|Active Comparator|PNT alone|percutaneous needle tenotomy alone
10038351|NCT01833611|Experimental|ETV group|Entecavir 0.5mg at first year; then open with entecavir 0.5mg qd for 2nd, 3rd year
10038352|NCT01833611|Placebo Comparator|Placebo group|Placebo at first year, then opne with entecavir 0.5mg qd for 2nd, 3rd year
10038353|NCT01833624|Active Comparator|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
10038354|NCT01833624|Experimental|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
9481739|NCT04124692|No Intervention|No-treatment control group|
9481740|NCT04124692|Experimental|Treatment group|
9481741|NCT04121949|No Intervention|Control group|The control group will receive standard-of-care treatment recommended by current ESC guidelines for patients with low to intermediate likelihood of stable CAD using the Diamond-Forrester (DF) score only: Rule-out if DF-score <15%; NIT if DF-score 15-85%.
9481742|NCT04121949|Experimental|Intervention group|The intervention group will undergo a modified diagnostic pathway where a CAD-score <30 rules out stable CAD in the group of patients having a DF-score <15% and a CAD-score ≤20 rules out stable CAD in the group of patients having a DF-score in the range 15-85%, and thus not tested with NIT. Otherwise NIT is performed.
9481743|NCT04120116|Experimental|FX-322 Single Dose, Placebo Three Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Single Dose, Placebo Three Doses.
9481744|NCT04120116|Experimental|FX-322 Two Doses, Placebo Two Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Two Doses, Placebo Two Doses.
9481745|NCT04120116|Experimental|FX-322 Four Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Four Doses.
9481746|NCT04120116|Placebo Comparator|Placebo Four Doses|Four intratympanic injections of a hydrogel formulation, Placebo Four Doses.
9481747|NCT04115098|Experimental|Drug order 1|
9481748|NCT04115098|Experimental|Drug order 2|
9481749|NCT04115098|Experimental|Drug order 3|
9481750|NCT04115098|Experimental|Drug order 4|
9481751|NCT04115098|Experimental|Drug order 5|
9481752|NCT04115098|Experimental|Drug order 6|
9481753|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Metformin|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)~Metformin - 500 mg by mouth twice daily"
9481754|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Rosiglitazone|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)~Rosiglitazone - 4 mg by mouth once daily"
9481755|NCT04114136|Active Comparator|Anti-PD-1 mAb (nivolumab or pembrozilumab)|nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
9481756|NCT04110054|Experimental|S-600918 50 mg|Participants will receive 50 mg S-600918 orally once a day for 28 days.
9481757|NCT04110054|Experimental|S-600918 150 mg|Participants will receive 150 mg S-600918 orally once a day for 28 days.
9481758|NCT04110054|Experimental|S-600918 300 mg|Participants will receive 300 mg S-600918 orally once a day for 28 days.
9481759|NCT04110054|Placebo Comparator|Placebo|Participants will receive placebo to S-600918 orally once a day for 28 days.
9481760|NCT04109976|Experimental|Bimekizumab-SS|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
9481761|NCT04109976|Experimental|Bimekizumab-AI|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).
9481762|NCT04104685|Experimental|FCD105 Foam|FCD105 Foam
9481763|NCT04104685|Active Comparator|3% Minocycline Foam|3% Minocycline Foam
9481764|NCT04104685|Active Comparator|0.3% Adapalene Foam|0.3% Adapalene Foam
9481765|NCT04104685|Placebo Comparator|Vehicle Foam|Vehicle Foam
9481766|NCT04101071|Experimental|Modular ketogenic enteral feed|Ketogenic enteral feed to be administered continuously for 10 days.
9481767|NCT04101071|Active Comparator|Standard enteral feed|Standard enteral feed to be administered continuously for 10 days.
9481768|NCT04098848|Experimental|Intradialytic exercise|Cycling exercise 30 minutes a time, three times a week during hemodialysis
9481769|NCT04098848|No Intervention|Control group|not participate in cycling exercise during hemodialysis
9481770|NCT04096326|Experimental|AGN-151586|
9481771|NCT04096326|Placebo Comparator|Placebo|
9481772|NCT04093765|Experimental|Sustained high incidence villages|Villages classified as high incidence, low probability of elimination (P. falciparum cumulative incidence >84 cases/1000/year, in spite of >1 year of functioning malaria post) will be eligible to be included in group 1. Villages in this group will be addressed by MSAT waves of 10-15 villages. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
9481773|NCT04093765|Experimental|Seasonal focal transmission villages/locations|"This group will follow the NMCP case/and foci investigation guidelines, but use URDT instead of standard RDT for screening. MSAT group 2 locations will be cluster of houses, villages or clusters of villages selected based on the results of case or foci/outbreak investigation. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.~Village inclusion after case investigation~Village inclusion after outbreak investigation"
9481774|NCT04091646|Active Comparator|ARQ-154 foam 0.3%|active
9532871|NCT03172234|Active Comparator|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
9532872|NCT03172234|Placebo Comparator|control group (group C)|the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.
9532873|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
9532874|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
9532875|NCT03172117|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
9532876|NCT03172169||Healthy control group|no intervention
9532877|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was >48 hours and the first SBT failure
9532878|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
9532879|NCT03172104||Very preterm group|"Preterm infants <30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born <30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
9532880|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born >36 completed weeks' GA and weighing >2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
9532881|NCT03171974|Experimental|treatment group|The treatment group will be injected with dexamethasone instracapsular under US according to our built protocol.
9532882|NCT03171935|Experimental|High-Flow Nasal Cannula Oxygenation|
9532883|NCT03171935|Experimental|Noninvasive Positive Pressure Ventilation|
9532884|NCT03171935|Active Comparator|Conventional Weaning|
9532885|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
9532886|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
9532887|NCT03172013||Healthy volunteers|Healthy individuals
9532888|NCT03171896|Experimental|Intervention|Medical clown
9532889|NCT03171896|Sham Comparator|No Intervention|No clown in the room
9532890|NCT03171987|Experimental|Lidocaine patch|Lidocaine patch local application 1 piece per day for 28 days at back pain area.
9532891|NCT03171987|Active Comparator|Flurbiprofen patch|Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.
9532892|NCT03172052|Experimental|streptokinase instillation|Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred and if drained fluid through the tube was <100 cc in 24 h provided that tube is patent and properly positioned.
9532893|NCT03172052|Experimental|instillation of MESNA|Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
9532894|NCT03172052|Experimental|Medical thoracoscopy procedure|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope
9532895|NCT03172052|Experimental|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
9532896|NCT03171870|Other|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
9532897|NCT03172000|Active Comparator|Colonoscopy and biopsy|IBD patients
9532898|NCT03172000|No Intervention|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
9532899|NCT03171922|Experimental|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
9532900|NCT03171922|Experimental|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
9532901|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
9532902|NCT03172065|Other|control group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml saline
9532903|NCT03172065|Other|Dexmedetomidine group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml dexmedetomidine (0.5 mic)
9532904|NCT03172143|Active Comparator|Mesenteric sparing ileocolic resection|Ileocolic resection without removal of the lymph nodes in the mesentery.
9532905|NCT03172143|Active Comparator|High ligation ileocolic resection|Ileocolic resection with removal of lymph nodes in the mesentery
9532906|NCT03172091|Experimental|Acute rejection|Pulmonary transplant patients with acute rejection
9532907|NCT03172091|Other|Control group|Pulmonary transplant patients without acute rejection
9532908|NCT03171844|Experimental|Skin to skin|Implement of skin to skin
9532909|NCT03171818|Experimental|Darbepoetin|Darbepoetin alfa (Aranesp, Amgen)
9532910|NCT03171818|Placebo Comparator|Placebo|Saline
9532911|NCT03171961|Experimental|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
9532912|NCT03171961|Experimental|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
9532913|NCT03171961|Experimental|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
9532914|NCT03171948|Experimental|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
9532915|NCT03171948|Experimental|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
9532916|NCT03172078|Active Comparator|Target-control infusion without bispectral index monitoring|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
9532917|NCT03172078|Active Comparator|Target-control infusion with bispectral index monitoring|Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
9532918|NCT03171831|Experimental|Haploidentical HSCT|"Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).~Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）~GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）"
9532919|NCT03171714|Experimental|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
9532920|NCT03171714|Active Comparator|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
9532921|NCT03171662|Experimental|group study|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
9532922|NCT03171753|Experimental|Music therapy|Listening prerecorded music through an individual headset for 30 min in before the induction of anesthesia
9532923|NCT03171753|Active Comparator|Control|patients wear headphones for 30 minuts without any sound
9532924|NCT03171701||maturation of arteriovenous fistula|
9532925|NCT03171727|Experimental|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
9532926|NCT03171727|No Intervention|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
9532927|NCT03171467|Experimental|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
9532928|NCT03171779||Usual practice|
9532929|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
9532930|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
9532931|NCT03171623|Experimental|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
9532932|NCT03171623|Placebo Comparator|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
9532933|NCT03171623|Placebo Comparator|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
9532934|NCT03171623|Placebo Comparator|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
9532935|NCT03171623|Placebo Comparator|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
9532936|NCT03171402||Low fruit and vegetable consumers|Participants with low F&V consumption, as defined by 24-hr dietary recall
9532937|NCT03171402||High fruit and vegetable consumers|Participants with high F&V consumption, as defined by 24-hr dietary recall
9615707|NCT05226689|Other|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert.
9615708|NCT05226663|Experimental|Treatment ([18F]FTT PET/CT)|Patients receive [18F]FTT IV over a few seconds to a minute and then undergo PET/CT scan over 20-30 minutes at baseline and another optional scan 1 week later. During the [18F]FTT PET/CT scan patients.
9615709|NCT05226650|Experimental|Regular meal pattern|Participants will follow a regular meal pattern for a week
9615710|NCT05226650|Experimental|Irregular meal pattern|Participants will follow an irregular meal pattern for a week
9615711|NCT05226624|Experimental|Rooming-in care|Rooming-in care
9615712|NCT05226624|Active Comparator|Base line|Base line prior to implementation
9615713|NCT05226611|Experimental|Tender point treatment with Counterstrain|A tender point was located in the upper trapezius region of the test subject and treated with counterstrain. The side with the highest initial pain level was used as the treatment side. Pain level was measured before and after treatment. The MyotonPRO was also used to measure physiologic parameters of the muscle before and after treatment.
9615714|NCT05226546|Other|control group|Patient underwent simple olfactive training for one month.
9615715|NCT05226546|Experimental|PRP injected group|Patient had one injection in each olfactory cleft.
9615716|NCT05226533|Experimental|Niclosamide 432mg|Niclosamide 432mg (intramuscular injection) + Remdesivir
9615717|NCT05226533|Experimental|Niclosamide 960mg|Niclosamide 960mg (intramuscular injection) + Remdesivir
9615718|NCT05226533|Placebo Comparator|Placebo|Placebo (intramuscular injection) + Remdesivir
9615719|NCT05226520|Experimental|Probiotic NCC3001|Sachets of NCC3001 and excipient (maltodextrin) to be administered orally every day for 6 weeks
9615720|NCT05226520|Placebo Comparator|Matched Placebo Comparator|Sachets of matching placebo containing maltodextrin, yeast extract, cystein HCl and pea flour to be administered orally every day for 6 weeks
9615721|NCT05226507|Experimental|Dose Escalation|Seven dose levels are planned, with a starting dose level of 50 mg once per day, up to a maximum planned dose of 150 mg twice per day (300 mg per day).
9615722|NCT05226481||TF-CBT|Trauma-focused cognitive-behavioral therapy (TF-CBT), an evidence-based method for the treatment of posttraumatic stress among youth, was provided to children and adolescents referred to CAMHS.
9615723|NCT05226429|Experimental|UNAIR Inactivated COVID-19 Vaccine 3 microgram|
9615724|NCT05226429|Experimental|UNAIR Inactivated COVID-19 Vaccine 5 microgram|
9615725|NCT05226429|Active Comparator|CoronaVac Biofarma COVID-19 Vaccine|
9615726|NCT05226351|Active Comparator|Dronabinol PTSD|Donabinol before cognitve testing - PTSD patients
9532938|NCT03171740|Active Comparator|Dexmedetomidine|Children will receive 1mcg/kg intranasal dexmedetomidine and oral saline, 30 minutes before going to operation theater.
9532939|NCT03171740|Active Comparator|Midazolam oral solution|Children will receive 0,5mg/kg oral midazolam and intranasal saline, 30 minutes before going to operation theater.
9532940|NCT03171350|Experimental|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test
9532941|NCT03171532|Active Comparator|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
9532942|NCT03171532|Active Comparator|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
9532943|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
9532944|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
9532945|NCT03171519|Active Comparator|Exercise|
9532946|NCT03171519|Experimental|Exercise + acupuncture|
9532947|NCT03171584|Experimental|Terbinafine group|Arm (1) will receive Terbinafine (250mg/day for 6 weeks).
9532948|NCT03171584|Experimental|Fluconazole group|Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).
9532949|NCT03171584|Experimental|Itraconazole group|Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)
9532950|NCT03171506|Experimental|Usual care plus ketogenic diet|
9532951|NCT03171506|Placebo Comparator|Usual care plus AND diet|
9532952|NCT03171493|Experimental|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
9532953|NCT03171649|Experimental|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
9532954|NCT03171649|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
9532955|NCT03171675||Preterm/Chronic Periodontitis|Included ten female patients who underwent spontaneous preterm birth and were diagnosed with chronic periodontitis upon clinical examination
9532956|NCT03171675||Preterm/Healthy Periodontium|Included ten female patients who underwent spontaneous preterm birth and who had a healthy periodontium upon clinical examination
9532957|NCT03171675||Term/Chronic Periodontitis|Included ten female patients who underwent spontaneous normal term birth and were diagnosed with chronic periodontitis upon clinical examination
9532958|NCT03171675||Term/Healthy Periodontium|Included ten female patients who underwent spontaneous normal term birth and who had a healthy periodontium upon clinical examination (Armitage1999)
9532959|NCT03171610|Experimental|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
9532960|NCT03171610|Active Comparator|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
9532961|NCT03171558|Experimental|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
9532962|NCT03171558|Active Comparator|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
9532963|NCT03171571|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
9532964|NCT03171597|Other|conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
9532965|NCT03171597|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
9532966|NCT03171597|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
9532967|NCT03171597|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
9615727|NCT05226351|Active Comparator|Dronabinol healthy controls|Donabinol before cognitve testing - healthy controls
10038355|NCT01833637|No Intervention|Arm A: Control Group|Patients randomized to the control group will be asked to fill out a patient symptom questionnaire using an iPad at the time of registration and then every 24 hours until released from the hospital. It should take about 10 minutes to complete the questions each time. The survey will not interfere with the care the healthcare team will be providing. Patients will be asked to fill our a Patient Satisfaction Questionnaire at the time of discharge.
10058329|NCT02017470|Experimental|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
10058330|NCT02017470|No Intervention|Conventional general cardiology outpatient programme|
10038356|NCT01833637|Active Comparator|Arm B: APN Intervention Group|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
10038357|NCT01833650|No Intervention|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
9481775|NCT04091646|Placebo Comparator|ARQ-154 foam Vehicle|placebo
9481776|NCT04089735|Experimental|APP13007 0.05% twice daily (BID)|1 drop 0.05% APP13007 twice daily for 21 days to the operated eye
9481777|NCT04089735|Experimental|APP13007 0.05% Placebo twice daily (BID)|1 drop matching vehicle placebo for 0.05% APP13007 twice daily for 21 days to the operated eye
9481778|NCT04089735|Experimental|APP13007 0.05% twice daily (BID) and once daily (QD)|1 drop 0.05% APP13007 twice daily followed by 1 drop once daily to the operated eye
9481779|NCT04089735|Experimental|APP13007 0.05% Placebo twice daily (BID) and once daily (QD)|1 drop matching vehicle placebo for 0.05% APP13007 twice daily followed by 1 drop once daily to the operated eye
9481780|NCT04089735|Experimental|APP13007 0.1% twice daily (BID) and once daily (QD)|1 drop 0.1% APP13007 twice daily followed by 1 drop once daily to the operated eye
9481781|NCT04089735|Experimental|APP13007 0.1% Placebo twice daily (BID) and once daily (QD)|1 drop matching vehicle placebo for 0.1% APP13007 twice daily followed by 1 drop once daily to the operated eye
9481782|NCT04088357|Active Comparator|5 Percent TolaSure Topical Gel|5%(w/w) TolaSure Gel
9481783|NCT04088357|Placebo Comparator|Topical Vehicle Gel|Vehicle Gel
9481784|NCT04084483|Experimental|Group 1|K-161 Ophthalmic Solution Dose A.
9481785|NCT04084483|Experimental|Group 2|K-161 Ophthalmic Solution Dose B.
9481786|NCT04084483|Experimental|Group 3|K-161 Ophthalmic Solution Dose C.
9481787|NCT04084483|Placebo Comparator|Group 4|Vehicle Solution Dose.
9481788|NCT04081363|Experimental|Intervention|Single oral dose (50 mg) capsule of extended-release centanafadine
9481789|NCT04077424|Active Comparator|Fluzone-High Dose|FDA approved high dose inactivated influenza vaccine (HD-Fluzone)
9481790|NCT04077424|Active Comparator|Fluad|Adjuvanted (MF59) inactivated influenza vaccine (Fluad)
9481791|NCT04077424|Active Comparator|Recombinant Hemagglutinin vaccine (Flublok)|Recombinant hemagglutinin vaccine
9481792|NCT04070170|Experimental|Low-level laser therapy and no orthodontic force|No orthodontic force. Laser is applied on the first day and the premolars is extracted after 24 hours
9481793|NCT04070170|Experimental|Low-level laser therapy and application of orthodontic force|Orthodontic force and Laser is applied on the first day and the premolars is extracted after 24 hours
9481794|NCT04070170|Active Comparator|Orthodontic force only|Orthodontic force is applied and the premolars is extracted after 24 hours, with no laser therapy
9481795|NCT04070170|Experimental|Low-level laser therapy and orthodontic force|Orthodontic force and Laser is applied and the orthodontic tooth movement is evaluated
9481796|NCT04070170|Active Comparator|Orthodontic force with no laser therapy|Orthodontic force is applied and the orthodontic tooth movement is evaluated, with no laser therapy
9481797|NCT04068051|Experimental|AXS-07|
9481798|NCT04067661|Experimental|Intervention|Participants and their partners will complete four couples counseling sessions focused on developing and enhancing relationship skills to decrease HIV risk behaviors.
9481799|NCT04067661|Active Comparator|Control|Participants and their partners will receive information and referrals on HIV risk and prevention strategies.
9481800|NCT04066634|Experimental|Assist in Diagnosis|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
9481801|NCT04064684|Experimental|Budesonide administered by nebulizer|
9481802|NCT04064684|Placebo Comparator|Placebo administered by nebulizer|
9481803|NCT04060784|Experimental|Immediate implant placement and provisionalization|On the control group, Implant will be placed immediately after tooth extraction. The gap between the implant and buccal bone will be filled with bone graft. Temporary crown will be attached to implant fixture.
9481804|NCT04060784|Experimental|Socket shield technique|On the test group, Implant will be placed immediately after tooth extraction. A piece of root shield will be retained intentionally at facial side. Temporary crown will attached to implant fixture.
9481805|NCT04060446||Observational (smoke cigarettes)|Patients smoke 5 cigarettes separated by 30 minute washout periods. Between 48 hours and 1 week later, patients smoke another 5 cigarettes separated by 30 minute washout period with CReSSMicro topography measurement device and BioRadio device for recording inhalation patterns.
9481806|NCT04059640|Experimental|LiquiBand FIX8® OHMF Device|Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.
9481807|NCT04054921|Experimental|Interventions|PTG-300
9481808|NCT04053387|Experimental|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
9481809|NCT04051957|Experimental|Isosorbide Mononitrate|
9481810|NCT04051957|Placebo Comparator|Placebo|
9481811|NCT04049864|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
9481812|NCT04047563|Active Comparator|Normal Saline + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
9481813|NCT04047563|Experimental|PMZ-1620 (sovateltide) + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
9481814|NCT04046484|Active Comparator|Normal Saline (Dose: Equal volume) + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
9481815|NCT04046484|Experimental|PMZ-1620 + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
9481816|NCT04043923|Experimental|Norketotifen|Norketotifen oral capsules, once daily for 5 days
9481817|NCT04043923|Placebo Comparator|Placebo|Placebo oral capsules, once daily for 5 days
9481818|NCT04041102||Infantile (Type 1) or Juvenile (Type 2) GM1 Gangliosidosis|This study observes one cohort: up to 40 Infantile GM1 (Type 1) or Juvenile GM1 (Type 2) subjects.
9481819|NCT04039022|Experimental|AXS-05 (dextromethorphan and bupropion)|
9481820|NCT04035200|Experimental|V117957 1 mg|V117957 tablets taken orally at bedtime
9481821|NCT04035200|Experimental|V117957 2 mg|V117957 tablets taken orally at bedtime
9481822|NCT04035200|Placebo Comparator|Placebo|Placebo to match V117957 tablets taken orally at bedtime
9481823|NCT04033081|Experimental|CivaSheet Treatment|Implanted with CivaSheet during tumor removal
9481824|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1A|Administration of AGN-242428 ophthalmic solution
9481825|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1B|Administration of AGN-242428 ophthalmic solution
9481826|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1C|Administration of AGN-242428 ophthalmic solution
9481827|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1A|Administration of AGN-231868 ophthalmic solution
9481828|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1B|Administration of AGN-231868 ophthalmic solution
9481829|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1C|Administration of AGN-231868 ophthalmic solution
9481830|NCT04030962|Placebo Comparator|Stage 1: AGN-242428 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
9481831|NCT04030962|Placebo Comparator|Stage 1: AGN-231868 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
9481832|NCT04030962|Experimental|Stage 2: AGN-242428 Group 1|Administration of AGN-242428 ophthalmic solution
9481833|NCT04030962|Experimental|Stage 2: AGN-242428 Vehicle Group 2|Administration of matching placebo (vehicle) ophthalmic solution
9481834|NCT04030962|Experimental|Stage 2: AGN-231868 Group 3|Administration of AGN-231868 ophthalmic solution
9481835|NCT04030962|Experimental|Stage 2: AGN-231868 Vehicle Group 4|Administration of matching placebo (vehicle) ophthalmic solution
9481836|NCT04030962|Active Comparator|Comparator Ophthalmic Solution|Administration of comparator ophthalmic solution
9481837|NCT04030143|Experimental|Aripiprazole 2M LAI|"2 Months (2M) Long-acting injection (LAI).~Participants will receive a total of 4 injections of aripiprazole 2M LAI, administered every 56 days (+/- 2 days) from Day 1.~Participants will continue to take their current oral antipsychotic or be given 10 to 20 mg oral aripiprazole for 7 days after the first administration."
9481838|NCT04030143|Active Comparator|Aripiprazole 1M depot injection|"1 Month (1M) depot injection.~Participants will receive a total of 8 injections of aripiprazole 1M depot, administered every 28 days (+/- 2 days) from Day 1.~Participants will continue to take their current oral antipsychotic or be given 10 to 20 mg oral aripiprazole for 14 days after the first administration."
9481839|NCT04030026|Active Comparator|Arm 1a: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 1
9481840|NCT04030026|Placebo Comparator|Arm 2a: Placebo|Placebo twice a day for Treatment Period 1
9481841|NCT04030026|Placebo Comparator|Arm 1b: Placebo|Placebo twice a day for Treatment Period 1
9481842|NCT04030026|Active Comparator|Arm 2b: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 2
9481843|NCT04029610|Active Comparator|Local anesthesia of lidocaine and arterial blockage on the arm|Local anesthesia of lidocaine and arterial blockage on the arm
9481844|NCT04029610|Experimental|Local anesthesia with lidocaine and adrenalin|Local anesthesia with lidocaine and adrenalin
9481845|NCT04029181|Experimental|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval.
9481846|NCT04029181|Experimental|Feasibility cohort|The purpose of part B of the study is to analyze the PK of the anti-CD8 imaging agent in patients before and during treatment with checkpoint inhibitors.
9481847|NCT04028700|Experimental|G6PD Deficient Red Blood Cell Transfusion, then Non-G6PD deficient Red Blood Cell Transfusion|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity.
9481848|NCT04028700|Active Comparator|Non-G6PD deficient Red Blood Cell Transfusion, then G6PD Deficient Red Blood Cell Transfusion,|Transfusion of a red blood cell unit that has been identified by local laboratory procedures to not be deficient in G6PD enzyme activity followed after 4 months by transfusion of a red blood cell unit that has been identified by local laboratory procedures to be deficient in G6PD enzyme activity
9481849|NCT04026997|Experimental|Cohort 1|CIN-102 tablets by mouth twice daily for 14 days
9481850|NCT04026997|Placebo Comparator|Cohort 1 - Placebo|Placebo tablets by mouth twice daily for 14 days
9481851|NCT04026997|Experimental|Cohort 2|CIN-102 tablets by mouth twice daily for 14 days
9481852|NCT04026997|Placebo Comparator|Cohort 2- Placebo|Placebo tablets by mouth twice daily for 14 days
9481853|NCT04026997|Experimental|Cohort 3|CIN-102 tablets by mouth twice daily for 14 days
9481854|NCT04026997|Active Comparator|Cohort 3- Placebo|Placebo tablets by mouth twice daily for 14 days
9532968|NCT03171376|Active Comparator|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
9532969|NCT03171376|Active Comparator|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
9532970|NCT03171376|Active Comparator|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
9532971|NCT03171324|Experimental|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
9532972|NCT03171324|Experimental|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
9532973|NCT03171324|Experimental|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
9532974|NCT03171324|Experimental|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
9532975|NCT03171363|Experimental|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
9532976|NCT03171298|Experimental|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
9532977|NCT03171454|Experimental|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
9532978|NCT03171454|Experimental|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
9532979|NCT03171389|Experimental|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
9532980|NCT03171389|Experimental|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
9532981|NCT03171389|Experimental|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
9532982|NCT03171285||Less than 35 years old|Clinical and laboratory evaluations
9532983|NCT03171285||Greater than or equal to 35 years|Clinical and laboratory evaluations
9532984|NCT03171311|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
9532985|NCT03171311|Experimental|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
9532986|NCT03171441||Controls|eutrophic children
9532987|NCT03171441||Overweight|Overweight children
9532988|NCT03171441||Obese|Obese children
9532989|NCT03171428||TAA|Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach
9532990|NCT03171428||AA|Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)
9532991|NCT03171337|Experimental|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
9532992|NCT03171337|Active Comparator|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
9532993|NCT03171337|Sham Comparator|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
9532994|NCT03171272|Experimental|Experimental Group|
9532995|NCT03171272|Sham Comparator|Control Group|
9532996|NCT03171012|Experimental|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
9532997|NCT03171012|Active Comparator|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
9532998|NCT03171012|Experimental|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
9532999|NCT03171012|Active Comparator|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
9533000|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
9533001|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
9533002|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
9533003|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
9533004|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
9533005|NCT03171142|Active Comparator|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
9533006|NCT03171142|Active Comparator|Air group|receive oxygen 21%via nasal cannula 2L/min
9615728|NCT05226351|Placebo Comparator|Placebo PTSD|Placebo before cognitve testing - PTSD patients
9615729|NCT05226351|Placebo Comparator|Placebo healthy controls|Placebo before cognitve testing - healthy controls
10038358|NCT01833650|Experimental|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
10038359|NCT01833650|Experimental|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
9533007|NCT03171077|Active Comparator|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
9533008|NCT03171077|Experimental|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
9533009|NCT03171077|Active Comparator|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
9533010|NCT03171168|Active Comparator|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
9533011|NCT03171168|Experimental|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
9533012|NCT03171181|Experimental|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
9533013|NCT03171181|No Intervention|control group|Control group, to obtain reference values.
9533014|NCT03171181|No Intervention|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
9533015|NCT03171090|Active Comparator|sphenopalatine block using local anasthetic|
9533016|NCT03171090|Placebo Comparator|sphenopalatine block using saline|
9533017|NCT03171246|Experimental|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for up to 12 weeks."
9533018|NCT03171064|Experimental|Experimental intervention arm (EX)|The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
9533019|NCT03171064|No Intervention|Wait list - control group (UC)|Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.
9533020|NCT03171194|Experimental|Drug: Low Dose Mesenchymal Stem Cells ( MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
9533021|NCT03171233|Active Comparator|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
9533022|NCT03171233|Active Comparator|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
9533023|NCT03170973|Experimental|Comparison of fatty acids before and after exercise|
9533024|NCT03170973|No Intervention|Comparison of fatty acids at baseline and 24 hours after|
9533025|NCT03170947|Experimental|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
9533026|NCT03170947|Active Comparator|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
9533027|NCT03170986|Experimental|Multisectoral Agriculture and Microfinance Arm|
9533028|NCT03170986|No Intervention|Control Arm|
9533029|NCT03171038|Experimental|Telemonitoring group|6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
9533030|NCT03171038|No Intervention|Usual care group|Usual care from t0 up until the common stopping date (t2).
9533031|NCT03171116||CKD-CT|subjects with CKD stages II-V under conservative treatment
9533032|NCT03171116||CKD-HD|subjects with CKD stage V on hemodialysis
9533033|NCT03171116||RTx renal transplant|renal transplant recipients
9533034|NCT03171116||Controls|control subjects
9533035|NCT03170895|Experimental|sorafenib and Omacetaxine Mepesuccinate|"The starting dose of sorafenib will be 400 mg twice daily. Sorafenib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~OM will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with sorafenib) in 28-day cycle.~Sorafenib and OM will be continued until leukemia progression or allogeneic HSCT. Thereafter, patients will be followed up and information about disease status and survival will be collected."
9533036|NCT03170843|Experimental|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
9533037|NCT03170843|No Intervention|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
9533038|NCT03171155|Experimental|XPro System|Implantation of XPro System during percutaneous vascular closure
9533039|NCT03170791|Experimental|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
9533040|NCT03170921|Experimental|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
9533041|NCT03170921|Experimental|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
9533042|NCT03170921|Experimental|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
9533043|NCT03171220|Experimental|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
9533044|NCT03170856|Experimental|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
9533045|NCT03170856|No Intervention|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
9533046|NCT03171207|Experimental|Start with Lite Run Gait Trainer|Patients start therapy with the Lite Run Gait Trainer device, followed by a Current Harness System in an ABAB design.
9533047|NCT03171207|Experimental|Start with Current Harness System|Patients start therapy with a Current Harness System, followed by the Lite Run Gait Trainer in an ABAB design.
9533048|NCT03170765|Experimental|GROUP A|measles vaccine at 6 months and 9 months of age
9533049|NCT03170765|Experimental|GROUP B|measles vaccine at 7.5 months and 9 months of age
9533050|NCT03170765|Active Comparator|GROUP C|measles vaccine at 9 months of age (current practice)
9533051|NCT03170713|Active Comparator|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
9533052|NCT03170713|Active Comparator|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
9533053|NCT03170713|Placebo Comparator|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
9533054|NCT03170830|Experimental|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
9533055|NCT03170830|Experimental|unstable angina disease control group|Age:>18 years.Unstable angina patients meet the diagnostic criteria.
9533056|NCT03170830|Experimental|acute myocardial infarction group|Age:>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
9533057|NCT03170674|Experimental|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
9533058|NCT03170674|Experimental|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
9533059|NCT03170674|Experimental|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
9533060|NCT03170674|No Intervention|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
9533061|NCT03170700|No Intervention|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
9533062|NCT03170700|Experimental|In-person|Nutrition program with in-person parental feeding content.
9533063|NCT03170700|Experimental|Online|Nutrition program with online parental feeding content.
9615730|NCT05226338|Experimental|Sequence 1|3 period, 3 dose level
9615731|NCT05226338|Experimental|Sequence 2|3 period, 3 dose level
9481855|NCT04021862|Experimental|Treatment Arm 1 (bermekimab every week)|"Loading Dose: 400 mg subcutaneous (SC) injection of bermekimab and a SC injection of placebo at week 0 (Baseline)~Treatment Dose: 400 mg subcutaneous injection of bermekimab administered weekly (qw) from week 1 to week 15."
9481856|NCT04021862|Experimental|Treatment Arm 2 (bermekimab every other week)|"Loading Dose: Two 400 mg SC injections of bermekimab at week 0 (Baseline)~Treatment Dose: 400 mg SC injection of bermekimab administered every other week (q2w) alternating with placebo q2w from week 1 to week 15"
9481857|NCT04021862|Placebo Comparator|Placebo|"Loading Dose: Two SC injections of placebo at week 0 (Baseline)~Treatment Dose: Subcutaneous injection of placebo administered once weekly (qw) from week 1 to week 15."
9481858|NCT04021797|Sham Comparator|Sham|For the sham condition, the electrodes will be attached to an ear location that has not been shown to engage the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the active tVNS condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
9481859|NCT04021797|Experimental|Active|For the active condition, the electrodes will be attached to the ear at a place previously demonstrated to stimulate the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the sham condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
9497670|NCT03472872|Experimental|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
9497671|NCT03472872|Experimental|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
9497672|NCT03472859|Experimental|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
9497673|NCT03472859|Experimental|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
9497674|NCT03472846|Active Comparator|Group 1 - DMAB|postmenopausal women without type 2 diabetes mellitus treated with denosumab
9497675|NCT03472846|Active Comparator|Group 2 - TPTD|postmenopausal women with type 2 Diabetes mellitus treated with teriparatide
9497676|NCT03472846|Active Comparator|Group 3 - DMAB|postmenopausal women with type 2 diabetes mellitus treated with denosumab
9497677|NCT03472846|Active Comparator|Group 4 - TPTD|postmenopausal women without type 2 diabetes mellitus treated with teriparatid
9497678|NCT03472820|Experimental|Intervention Group|The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.
9497679|NCT03472820|No Intervention|Control Group|The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.
9497680|NCT03472807|Other|Cancer patient|"Collection of blood sample or saliva~Collection of a tumor sample taken before the participation of the patient in study~Collection of blood sample if tumor sample is not available"
9497681|NCT03472807|Other|Parent of cancer patient|-Collection of blood sample or saliva
9497682|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
9497683|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
9497684|NCT03472755|Other|Direct anterior techniques.|. In the direct anterior technique, patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached.
9497685|NCT03472729|Experimental|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
9497686|NCT03472729|No Intervention|Wait-list control|Wait-list control group to be offered workshops after the study is complete
9497687|NCT03472703|Other|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
9497688|NCT03472703|Other|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
9497689|NCT03472690|Experimental|Active|0.1 mL, self-administered subcutaneous injection, every second day
9497690|NCT03472690|Placebo Comparator|Placebo|0.1 mL, self-administered subcutaneous injection, every second day
9497691|NCT03472677|Experimental|Cohort 1|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
9497692|NCT03472677|Experimental|Cohort 2|Controlled cooling wrap versus ice pack cooling.
9497693|NCT03472677|Experimental|Cohort 3|Controlled cooling parameters will be determined after evaluation of data from prior cohorts.
9497694|NCT03472677|Experimental|Cohort 4|Controlled cooling with knee device versus no cooling (determined after evaluation of data from previous cohorts).
9497695|NCT03472664|Experimental|Modified Mediterranean Ketogenic Diet|"The MMKD is a low carbohydrate/high fat diet aimed at inducing ketosis, as the experimental diet in the proposed study. Participants on the MMKD will keep their daily carbohydrate consumption below 20 grams per day throughout the 4 month intervention.The MMKD group will be supplied with extra virgin olive oil during their in person visits to use as a source of fat in their diet, and will be encouraged to eat plentiful fish, lean meats, and nutrient rich foods that meet the requirement of <20 grams total carbohydrates per day.~Participants will receive a daily multivitamin (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet."
9481860|NCT04019704|Experimental|AXS-05|AXS-05 (bupropion and dextromethorphan) oral tablets
9481861|NCT04019704|Placebo Comparator|Placebo|Placebo oral tablets to match AXS-05
9481862|NCT04019041|Experimental|bermekimab ew|2 800 mg bermekimab loading dose subcutaneous injections, followed by weekly 400 mg bermekimab injections
9481863|NCT04019041|Experimental|bermekimab eow|2 800 mg loading dose subcutaneous injections, followed by alternating weekly 400 mg bermekimab injections with matching placebo injections
9481864|NCT04019041|Placebo Comparator|placebo ew|2 800 mg placebo loading dose subcutaneous injections, followed by weekly placebo subcutaneous injections
9481865|NCT04016974|Experimental|Oral semaglutide|
9481866|NCT04016974|Placebo Comparator|Placebo|
9481867|NCT04015518|Experimental|Dose group 1|
9481868|NCT04015518|Experimental|Dose group 2|
9481869|NCT04015518|Experimental|Dose group 3|
9481870|NCT04015518|Experimental|Dose group 4|
9481871|NCT04015518|Placebo Comparator|Placebo only|
9481872|NCT04007367|Experimental|SAGE-217|
9481873|NCT04007367|Placebo Comparator|Placebo|
9481874|NCT04003974|Experimental|Treatment|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
9481875|NCT04003974|Placebo Comparator|Placebo|FSHD1 patients with genetic confirmation will receive a Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
9481876|NCT04003155|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
9481877|NCT04003155|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
9481878|NCT04003155|Placebo Comparator|placebo|Participants will receive placebo for 12 weeks, after 12 weeks participants will be re-assigned to either low dose or high dose fezolinetant for 40 weeks.
9481879|NCT04003142|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
9481880|NCT04003142|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
9481881|NCT04003142|Placebo Comparator|placebo|Participants will receive placebo for 12 weeks, after 12 weeks participants will be re-assigned to either low dose or high dose fezolinetant for 40 weeks.
9481882|NCT03997838|Experimental|VVZ-149 Injections|
9481883|NCT03997838|Placebo Comparator|Placebo|
9481884|NCT03997812|Experimental|VVZ-149 Injections|
9481885|NCT03997812|Placebo Comparator|Placebo|
9481886|NCT03996447|Other|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI
9481887|NCT03996447|Other|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI
9481888|NCT03993223|Experimental|MTrP group|Healthy overhead athletes with upper trapezius myofascial trigger point
9481889|NCT03993223|Sham Comparator|Control group|Healthy overhead athletes without upper trapezius myofascial trigger point
9481890|NCT03992872|Experimental|Prior Alpha|All study participants will receive the same Investigational Product according to the same schedule. Subjects are prior recipients of experimental alphavirus vaccines.
9481891|NCT03992872|Active Comparator|Control: Naïve Alpha|All study participants will receive the same Investigational Product according to the same schedule. The alphavirus vaccine naïve subjects will serve as controls for determining the effect of pre-existing alphavirus immunity on vaccine safety and immunogenicity.
9481892|NCT03989947|Experimental|Active BMN 111|Age-appropriate daily subcutaneous injections of BMN 111 as determined by the 111-206 study
9481893|NCT03986138|Experimental|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
9481894|NCT03986138|Experimental|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI
9481895|NCT03983980|Experimental|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
9481896|NCT03983980|Placebo Comparator|Vehicle Cream Group|Vehicle cream applied once daily
9481897|NCT03979313|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
9481898|NCT03979313|Placebo Comparator|Placebo|Commercially available 0.9% (w/v) saline
9481899|NCT03974100|Experimental|GP2411|60 mg /mL subcutaneous injection every 6 months
9481900|NCT03974100|Active Comparator|EU authorized Prolia|60 mg /mL subcutaneous injection every 6 months
9481901|NCT03972943|Active Comparator|Cohort I (observation)|Patients not diagnosed with OSA undergo observation for 6 months.
9481902|NCT03972943|Experimental|Cohort II: (CPAP treatment)|Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.
9481903|NCT03970720|Experimental|T1DM - Unaware: Metoclopramide|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg metoclopramide four times a day during the four-week intervention period.
9481904|NCT03970720|Placebo Comparator|T1DM - Unaware: Placebo|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
9533064|NCT03170596|Experimental|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
9533065|NCT03170596|Active Comparator|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
9533066|NCT03170752|Experimental|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:~Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);~Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);~Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
9533067|NCT03170752|No Intervention|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
10038360|NCT01833650|Experimental|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
10038361|NCT01833663|Experimental|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
10038362|NCT01833663|Active Comparator|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
10038363|NCT01833676|Active Comparator|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
10038364|NCT01833676|Active Comparator|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
9533068|NCT03170687|Experimental|foot cast|
9533069|NCT03170687|Active Comparator|short leg cast|
9533070|NCT03170726|Active Comparator|arveles|Ibuprofen 800 mg in normal saline 150 cc and dexketoprofen (50 mg) before operation will be given in 30 minutes
9533071|NCT03170726|Active Comparator|intrafen|intrafen 800 mg in normal saline 150 cc before operation will be given in 30 minutes
9533072|NCT03170726|Placebo Comparator|plasebos|150 cc normal saline will be given in 30 minutes during preoperative period
9533073|NCT03170570|Experimental|treatment|retreatment using intensity-modulated radiotherapy for cervical cancer patients with in-field recurrence
9533074|NCT03170739|Experimental|Dexmedetomidine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery.
9533075|NCT03170739|Experimental|Dopamine|Dopamine 3ug/kg/min ivpump at the beginning of surgery.
9533076|NCT03170739|Experimental|Dexmedetomidine+dopamine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery.
9533077|NCT03170739|No Intervention|Control group|No intervention
9533078|NCT03170622||IBD|Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
9533079|NCT03170505||Acellular Dermal Matrix|
9533080|NCT03170505||Conchal Cartilage|
9533081|NCT03170310|Experimental|Apatinib|
9533082|NCT03170635|Other|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
9533083|NCT03170531||Custom MR spine coil|
9533084|NCT03170401|No Intervention|no protein supplementation|trauma subjects receiving enteral nutrition without any protein supplementation
9533085|NCT03170401|Active Comparator|protein supplementation|trauma subjects receiving enteral nutrition with additional protein supplementation
9533086|NCT03170427|Sham Comparator|8 mg (2 mL) levobupivacaine|8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
9533087|NCT03170427|Active Comparator|6 mg (1.6 mL) levobupivacaine|6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
10038365|NCT01833689|Placebo Comparator|food consumption: control|The control product will be 50g glucose powder dissolved in 250ml of water
10038366|NCT01833689|Active Comparator|food consumption: product|The test food will provide 50g of available carbohydrate
10038367|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
10038368|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
10038369|NCT01833715|Active Comparator|Morphine|morphine group 0.08 mg / kg, to start surgery
10038370|NCT01833715|Experimental|Methadone|methadone group 0.08 mg / kg, to start surgery
10038371|NCT01833728|Experimental|nefopam-propacetamol combination group|
9533088|NCT03170414||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
9533089|NCT03170466|Experimental|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
9533090|NCT03170466|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
10038372|NCT01833728|Active Comparator|propacetamol alone group|
10038373|NCT01833767|Experimental|Cyclophosphamide and Interleukin-2|Cytoxan IV on day 1, IL2 IV on days 1-5
10038374|NCT01833780||GBS carriage status|
10038375|NCT01833780||GBS status during labor|
10038376|NCT01833793||Group 1|
10038377|NCT01833819|Other|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
10038378|NCT01833819|Other|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
10038379|NCT01833858|Placebo Comparator|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
10038380|NCT01833858|Active Comparator|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
10038381|NCT01833871|Experimental|myometrial fibroid/adenomyoma|Patients scheduled for myomectomy or hysterectomy with preoperative diagnosis of uterine myoma, adenomyosis or both by ultrasound .Trans-vaginal 3D power Doppler and uterine artery doppler will be done for all participants prior to surgery.
10038382|NCT01833884|Other|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
10038383|NCT01833910|Experimental|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
10038384|NCT01833910|Experimental|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
10038385|NCT01833910|Experimental|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
10038386|NCT01833910|Experimental|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
10038387|NCT01833923|Experimental|anlotinib|dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week
10038388|NCT01833949|Active Comparator|ULOD arm (N=49)|"Unilateral laparoscopic drilling~In the ULOD group, we treated the right ovary.The thermal dose of 60 J applied per one cubic centimeter of ovarian volume was calculated from the mean total energy applied on a 10 cm3 ovary (627 J) from three earlier ULOD reports. Ovarian volume had been measured by ultrasound at baseline to determine the total thermal dose to apply on the right ovary. The number of punctures (Np) was also calculated for each patient according to the following formula:~Np = 627 J / 30 W / 4 s Therefore, patients in the ULOD group differed in the number of punctures and energy received by the right ovary, depending on its volume."
10038389|NCT01833949|Active Comparator|BLOD arm (N=47)|"Bilateral laparoscopic drilling~In the comparator, BLOD group, all patients received 600 J per ovary (totaling 1200 J) through five punctures at 30 W for 4 s each (5 punctures x 4 s x 30 W = 600 J).~The ovaries in both groups were cooled after the drilling by irrigating the abdominal cavity with 200-300 mL of physiological saline."
10038390|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
10038391|NCT01833975|Other|stem cell [ MNCs ]|transplantation of autologous stem cell [MNCs ]
10038392|NCT01834014|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
10038393|NCT01834014|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
10038394|NCT01834040|Other|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
10038395|NCT01834053|Other|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
10038396|NCT01834066|Other|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
10038397|NCT01834079|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
10038398|NCT01834092|Active Comparator|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
10038399|NCT01834092|Experimental|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
9481905|NCT03970720|Placebo Comparator|T1DM - Aware: Placebo|T1DM participants with hypoglycemia awareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
9481906|NCT03966586|Experimental|Enhanced Care|Usual clinical care + intervention components
9481907|NCT03966586|Active Comparator|Usual Care|Usual clinical care and counseling
9481909|NCT03960606|Experimental|10 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
9481910|NCT03960606|Experimental|20 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
9481911|NCT03960606|Experimental|35 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
10038400|NCT01834105|Experimental|Liuwei Dihuang Pills|
10038401|NCT01834131|No Intervention|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
10038402|NCT01834131|Experimental|Comprehensive Intervention|"Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.~Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.~Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
10038403|NCT01834157||methotrexate|methotrexate with or without low-dose corticosteroids
10038404|NCT01834157||other DMARDs|other DMARDs (leflunomide, azathioprine, mycophenolate mofetil) with or without low-dose corticosteroids
9481912|NCT03960606|Placebo Comparator|Placebo|Placebo
9533091|NCT03170648|Experimental|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
9533092|NCT03170323|Experimental|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
9533093|NCT03170323|Active Comparator|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
9533094|NCT03170336|Experimental|amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks
9533095|NCT03170336|Active Comparator|hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
9533096|NCT03170440|Experimental|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
9533097|NCT03170440|Active Comparator|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
9533098|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
9533099|NCT03170245||B thalassemia group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
9533100|NCT03170245||Control group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
9533101|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
9533102|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
9533103|NCT03170102|Other|Building capacity through education|Building capacity process through education - Occupational therapy students participate in online webinars and discussions following completion of readings.
9533104|NCT03170089|Active Comparator|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
9533105|NCT03170089|No Intervention|Control|NO program or scaling done
9533106|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
10038405|NCT01834157||low-dose corticosteroids|low-dose corticosteroids without DMARDs
9533107|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
9533108|NCT03170128|Active Comparator|Outpatient Physical Therapy|
9533109|NCT03170128|Active Comparator|Home Exercises|
9533110|NCT03169946|Active Comparator|Test Group|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
9533111|NCT03169946|Active Comparator|Positive Control Group :|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
9533112|NCT03170050|Experimental|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
9533113|NCT03170050|Active Comparator|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
9533114|NCT03170115|Experimental|Aspirin|Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
9533115|NCT03170115|Placebo Comparator|Placebo Oral Tablet|Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy
9533116|NCT03169959|Experimental|Cohort 1: Sequence 1 (ABC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
9533117|NCT03169959|Experimental|Cohort 1: Sequence 2 (ACB)|"Subjects were randomized to treatment sequence 1 ACB:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
9533118|NCT03169959|Experimental|Cohort 1: Sequence 3 (BAC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
9533119|NCT03169959|Experimental|Cohort 1: Sequence 4 (BCA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
9615732|NCT05226338|Experimental|Sequence 3|3 period, 3 dose level
9533120|NCT03169959|Experimental|Cohort 1: Sequence 5 (CAB)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
9533121|NCT03169959|Experimental|Cohort 1: Sequence 6 (CBA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5mg saxagliptin / 5mg dapagliflozin / 1000 mg metformin XR without food."
9533122|NCT03169959|Experimental|Cohort 2: Sequence 1 (DEF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
9533123|NCT03169959|Experimental|Cohort 2: Sequence 2 (DFE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
9533124|NCT03169959|Experimental|Cohort 2: Sequence 3 (EDF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
9533125|NCT03169959|Experimental|Cohort 2: Sequence 4 (EFD)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
9533126|NCT03169959|Experimental|Cohort 2: Sequence 5 (FDE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
9533127|NCT03169959|Experimental|COhort 2: Sequence 6 (FED)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
9533128|NCT03170011|Experimental|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
9533129|NCT03169907|Experimental|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
9533130|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
9533131|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
9533132|NCT03169764|Experimental|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
9533133|NCT03169829|Experimental|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
9533134|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
9533135|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
9533136|NCT03169842|Experimental|Cyst fluid glucose|Single arm- cyst fluid glucose will be measured from pancreatic cyst fluid aspirate
9533137|NCT03169803|Experimental|Single arm, NeuroTronik CANS Therapy System|
9533138|NCT03169868|Experimental|Enhanced Medication reconciliation|Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
9533139|NCT03169868|No Intervention|Standard Medication reconciliation|Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only
9533140|NCT03169738|Experimental|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
9533141|NCT03169725|Experimental|Test group 1|Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
9533142|NCT03169725|Experimental|Test group 2|Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
9533143|NCT03169725|Experimental|Test group 3|High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
9533144|NCT03169725|Active Comparator|Comparator|Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
9533145|NCT03170492|Experimental|Computerized Cognitive Training|RehaCom for 480 minutes over 12 weeks.
9533146|NCT03170492|Active Comparator|Pencil-and-Paper Cognitive Training|Table-top based activities for 480 minutes over 12 weeks.
9533147|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
9533148|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
9533149|NCT03169712|Active Comparator|CBT for PTSD|15 sessions of trauma-focused CBT
9533150|NCT03169712|Experimental|Imagery Rehearsal Therapy + CBT for PTSD|5 sessions of IRT + 15 sessions of trauma-focused CBT
9533151|NCT03170479|Experimental|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
9533152|NCT03170479|Placebo Comparator|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
9533153|NCT03169933|Other|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
9533154|NCT03170180|Experimental|sunitinib|
9533155|NCT03170180|Experimental|gefitinib|
9533156|NCT03170180|Experimental|imatinib|
9533157|NCT03169920|Active Comparator|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
9533158|NCT03169920|Active Comparator|Control Group|Modified-Minimally Invasive Surgical Technique alone.
9533159|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
9533160|NCT03169790|Experimental|Nant NHL Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, oxaliplatin, rituximab, stereotactic body radiation therapy, ALT-803,ETBX-061, and haNK.
9533161|NCT03169660|Experimental|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
9533162|NCT03169777|Experimental|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
9533163|NCT03169582|Active Comparator|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
9533164|NCT03169582|Active Comparator|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
9533165|NCT03169647|Experimental|Intervention|listening-based protocol (type A)
9533166|NCT03169647|Placebo Comparator|Control|listening-based protocol (type B)
9533167|NCT03169348|Experimental|study group|Hepatitis- C virus with thrombocytopenia
9533168|NCT03169400||Theranova treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
9533169|NCT03169400||Standard treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
9533170|NCT03169465|Experimental|open group|patients with posterior calcaneal deformity
9533171|NCT03169465|Active Comparator|endoscopic group|patients with posterior calcaneal deformity
9533172|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
9533173|NCT03169478|No Intervention|multiple myoma control group|The control group will not have any balloon therapy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
9533174|NCT03169478|Experimental|multiple myoma IUB dilatation group|The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
9533175|NCT03169504|Experimental|Acupuncture|Patients in this arm will receive acupuncture.
9615733|NCT05226338|Experimental|Sequence 4|3 period, 3 dose level
9615734|NCT05226338|Experimental|Sequence 5|3 period, 3 dose level
9615735|NCT05226338|Experimental|Sequence 6|3 period, 3 dose level
9615736|NCT05226312|Experimental|Local Warm Compress|They are gauze covers brought to a certain temperature (temperature varies between 26-34°C or 79-93°F in warm applications) as a compress material, or wraps and covers that can be reheated.
9533176|NCT03169504|Experimental|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
9533177|NCT03169504|Experimental|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
9533178|NCT03169322|Active Comparator|Test Group|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing (SRP)
9533179|NCT03169322|Active Comparator|Control Group|Nose breathers having chronic periodontitis will receive scaling and root planing (SRP)
9533180|NCT03169491|Experimental|Therapeutic|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
9533181|NCT03169491|Sham Comparator|Suboptimal|Continuous positive airway pressure (CPAP) every night for two weeks at fixed pressure of 4 cmH2O, via oronasal interface.
9533182|NCT03169491|Other|Severe OSAS|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
9533183|NCT03169426|Experimental|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.~Intervention: taking beta-blocker"
9533184|NCT03169426|No Intervention|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
9533185|NCT03169543|Experimental|Sleep deprivation|36-hours of total sleep deprivation
9533186|NCT03169556|Experimental|video-laryngoscope guided lightwand|
9533187|NCT03169556|Active Comparator|lightwand|
9533188|NCT03169569|Experimental|Hemostatic powder group (Endo-clot™ group)|Patients who will undergo ESD with Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) after hemostasis on the post-resection ulcer using conventional method and removal of specimen.
9533189|NCT03169569|Active Comparator|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|For patients in the control group, hemostasis with conventional method (electrical coagulation and/or clip, Coagrasper®, Olympus, Japan) will be done.
9533190|NCT03170037|Active Comparator|Standard V-E ventilation technique|After induction of anesthesia subject will be ventilated using the standard V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
9533191|NCT03170037|Experimental|Reversal V-E ventilation technique|After induction of anesthesia subject will be ventilated using the reversal V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
9533192|NCT03169413||cases|Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
9533193|NCT03169413||control one|Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
9533194|NCT03169413||control two|Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
9533195|NCT03169439|Other|hepatic focal lesions and pancreatic masses|
9533196|NCT03169335|Experimental|Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
9533197|NCT03169335|Active Comparator|Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
9533198|NCT03169374|Experimental|Virtual Reality Technology|Virtual Reality Therapy
9533199|NCT03169309|Experimental|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
9533200|NCT03169179|Experimental|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
9533201|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
9533202|NCT03169218|Experimental|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
10038406|NCT01834157||No DMARD or corticosteroids|No DMARD or corticosteroid treatment
9533203|NCT03169218|Placebo Comparator|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
9533204|NCT03169205||preexisting Diabetes mellitus type 1|
9533205|NCT03169205||preexisting Diabetes mellitus type 2|
9533206|NCT03169205||Gestational Diabetes mellitus|
9533207|NCT03168997|Other|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
9533208|NCT03168997|Other|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
9533209|NCT03168997|Other|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
9533210|NCT03169114|Active Comparator|Amikacin injection|Antibiotic Non-Operative Management Strategy
9533211|NCT03169114|Active Comparator|Appendicectomy|Surgery Management Strategy
9533212|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
9533213|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
9533214|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
9533215|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
9533216|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
9533217|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
9533218|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
9533219|NCT03169010||Pulmonary Takaysu Arteritis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
9533220|NCT03169387|Experimental|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
9533221|NCT03169387|Active Comparator|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
9533222|NCT03169270|Experimental|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
9533223|NCT03169270|Active Comparator|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
9533224|NCT03168984|Experimental|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
9533225|NCT03168984|Placebo Comparator|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
9533226|NCT03169049|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
9533227|NCT03169049|Sham Comparator|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
9533228|NCT03169088|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one-year follow-up, plus connected coaching.
9533229|NCT03169127|Experimental|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
9533230|NCT03169023|Experimental|Arm 1: ScaleDown (only first 16 patients)|"Baseline quality of life and image surveys~Weigh themselves every day on the provided Wi-Fi Scale~Personalized feedback with text message comes as soon as participants step on the scale~At the 6 month time period, quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~Only 16 participants were in this arm because ScaleDown went out of business~At 12 month follow-up weight will be abstracted from medical record"
9533231|NCT03169023|Active Comparator|Arm 2: Enhanced Usual Care|"Baseline quality of life and image surveys~Brief in-person counseling session by a research assistant using the Enhanced Usual Care Handouts from the American Cancer Society website which provides guidelines on healthy eating and exercise~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At 12 month follow-up weight will be abstracted from medical record"
9615737|NCT05226312|No Intervention|Not Local Warm Compress|No warm wet application will be made to this group. It will be tracked for only 3 days.
9804153|NCT01733758|Experimental|Albiglutide 30 mg weekly|Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
9804154|NCT01733758|Experimental|Albiglutide 50 mg weekly|Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
10038407|NCT01834157||CPH/CSA - Exploratory cohort|cyclophosphamide or cyclosporine-A with or without other DMARDs or low-dose corticosteroids
10038408|NCT01834157||Biologics - Exploratory cohort|Biologic therapy with or without other DMARDs or low-dose corticosteroids
10038409|NCT01834157||Combinations - Exploratory cohort|Combination of two or more DMARDs with or without low-dose corticosteroids
9533232|NCT03169023|Experimental|Arm 3: iOTA|"Baseline quality of life and image surveys~Weigh themselves everyday using the provided Balance High Accuracy Digital Body Fat Scale~Health coach will meet one-on-one with each participant (in-person or phone) to review health risk assessment and to choose 3 behavior goals related to healthy eating and physical activity at enrollment, 3 months, and 6 months~Self-monitoring via SMS text messaging. Weekly check-ins by text providing data about weight and goals~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~At 12 month follow-up weight will be abstracted from medical record"
9533233|NCT03169257|Experimental|OB|Obese subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years. OB subjects will undergo for 12 months an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes.
9533234|NCT03169257|No Intervention|NW|Normal weight subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years and age, sex and pubertal status matched with the OB group
9533235|NCT03169283|Experimental|Cereal 1|A cereal high in viscous dietary fiber B glucan
9533236|NCT03169283|Active Comparator|Cereal 2|A cereal without B glucan
9533237|NCT03168958|Active Comparator|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
9533238|NCT03168958|Sham Comparator|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
9533239|NCT03169140|Active Comparator|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
9533240|NCT03169140|Active Comparator|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
9533241|NCT03169140|Active Comparator|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
9533242|NCT03169140|Active Comparator|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
9533243|NCT03168776|Experimental|BuMA Supreme Coronary Stent System|
9533244|NCT03168776|Active Comparator|Xience or Promus Everolimus Stent System|
9533245|NCT03168737|Experimental|Group A (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.
9533246|NCT03168737|Experimental|Group B (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans >= 24 hours later up to 10 days.
9533247|NCT03168763|Experimental|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
9533248|NCT03168763|Experimental|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
9533249|NCT03168763|Experimental|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
9533250|NCT03168763|Experimental|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
9533251|NCT03168945|Active Comparator|Novel diagnostics arm|The intervention is to screen a sputum specimen collected on a participant with suspected TB in the community at the point-of-contact in a mobile van using an on-site GeneXpert MTB/RIF machine
9533252|NCT03168945|Placebo Comparator|Routine screening arm|The control arm is to send a sputum specimen collected on a participant with suspected TB at the mobile van for routine smear microscopy at a laboratory
9533253|NCT03168815|Experimental|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
9533254|NCT03168815|Active Comparator|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
9533255|NCT03168724|Experimental|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
10038410|NCT01834170|Experimental|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
10038411|NCT01834183|Experimental|Tivozanib/Gemcitabine|Segment 1: Tivozanib, taken orally days 1-21 of each 28 day cycle. Segment 2: Tivozanib, taken orally days 1-21 of each 28 day cycle. Gemcitabine, taken intravenously, Days 1 and 8 of each 28 day cycle.
9533256|NCT03168724|No Intervention|Control|Group not getting the intervention
9533257|NCT03168646|Active Comparator|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
9533258|NCT03168646|Active Comparator|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
9533259|NCT03168659|Other|Treatment|Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
9533260|NCT03168828|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
10038412|NCT01834196|Other|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
9533261|NCT03168620|Active Comparator|ITR group|In ITR group after partial caries removal(PCR), interim therapeutic restoration of glass ionomer cement (GIC) Ketac molar was placed for one month before definitive adhesive restoration
9533262|NCT03168620|Active Comparator|Non ITR group|In NON-ITR group, cavity preparation was similar to ITR group, but definitive restoration was done in the same visit
10038413|NCT01834235|Active Comparator|Abraxane, gemcitabine|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
9533265|NCT03168789|Experimental|Tension Tamer (TT)|Breathing Awareness Mediation delivered by smartphone app.
9533266|NCT03168789|Active Comparator|Lifestyle education program (SPCTL)|Healthy lifestyle education provided by text messages and links to media. Runkeeper app to log physical activity.
9533267|NCT03168802|Experimental|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
9533268|NCT03168802|Active Comparator|Radiofrequency ablation facet treatment|Radiofrequency ablation for facet joint pain once at Lumbar spine
9533269|NCT03168854|Experimental|GAP Arm 1|10 subjects will receive 5 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 0, 4, 8, 12, and 20 for a maximum cumulative dose of 1000 GAP3KO bites per subject
9533270|NCT03168854|Experimental|GAP Arm 2|6 subjects will receive 3 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 8, 12, and 20 for a maximum cumulative dose of 600 GAP3KO bites per subject
9533271|NCT03168854|Active Comparator|Malaria-naive Infectivity Control Arm|6 healthy volunteers will receive challenge with wild type Plasmodium falciparum NF54 sporozoites through the bites of five infectious A. stephensi moquitoes using standard CHMI procedures
9533272|NCT03168893|Experimental|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
9533273|NCT03168893|Experimental|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
9533274|NCT03168867|No Intervention|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
9533275|NCT03168867|Experimental|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
9533276|NCT03168698|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
9533277|NCT03168698|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
9533278|NCT03168698|Active Comparator|Oxytocin 0.5IU|Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
9533279|NCT03168698|Active Comparator|Oxytocin 5IU|Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
9533280|NCT03168685|Experimental|Experimental|"Multiple device intervention~SureSource Engage mobile application~ActiGraph Link~weight scale"
9533281|NCT03168633|Experimental|patients receiving emails|"Diagnosed DM2 patients who meet inclusion criteria. the patients will receive emails containing information about DM2 as a method of reminding patients of the importance of adjusting post diagnosis life-style changes.~web-based DM2 information pages"
9533282|NCT03168607|Experimental|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
9533283|NCT03168594|Experimental|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
9533284|NCT03168594|Experimental|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
9533285|NCT03168581|Experimental|CN-105|All eligible subjects will receive study drug, CN-105
9533286|NCT03168568|Experimental|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
9533287|NCT03168568|Active Comparator|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
9533288|NCT03168360|Experimental|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
9533289|NCT03168360|Active Comparator|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
9533290|NCT03168204|Experimental|Risk of being frail experimental group|
9533291|NCT03168204|No Intervention|Risk of being frail control group|
9533292|NCT03168204|No Intervention|No/low risk of being frail|
9533293|NCT03168204|No Intervention|Risk of being frail care avoiders|
9533294|NCT03168373|Experimental|Intensive group|language rehabilitation therapy by language therapist for 1 hours on every working day for 4 weeks
9533295|NCT03168373|Active Comparator|Conventional group|language rehabilitation therapy by language therapist for 30 minutes on every working day for 4 weeks
9533296|NCT03168516|Experimental|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
10038414|NCT01834235|Experimental|Abraxane, gemcitabine, NPC-1C|"Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.~Patients on arm B will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 4-week cycle. This will be administered 30minutes after completion of the gemcitabine infusion."
10038415|NCT01834248|Experimental|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10038416|NCT01834287|Experimental|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
10038417|NCT01834287|Active Comparator|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
10038418|NCT01834300|Experimental|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
10058331|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
9481913|NCT03959592|Active Comparator|Lutein, zeaxanthin and mesozeaxanthin|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
9481914|NCT03959592|Placebo Comparator|Placebo|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).
9481915|NCT03957590|Experimental|Tislelizumab + chemoradiotherapy|Tislelizumab once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
9481916|NCT03957590|Placebo Comparator|Placebo combined + chemoradiotherapy|Placebo once every 3-week cycle (Q3W) + paclitaxel on Day 1 of every cycle, for a total of 2 cycles + cisplatin on Day 1 to 3 of every cycle (3 weeks), for a total of 2 cycles + Radiotherapy
9481917|NCT03956355|Experimental|Tapinarof (DMVT-505)|Tapinarof (DMVT-505) Cream Group
9481918|NCT03956355|Placebo Comparator|Vehicle Cream|Vehicle Cream Group
9481919|NCT03955783|Experimental|Treatment (venetoclax, selinexor)|Patients receive venetoclax PO QD on days 1-28. Patients with DLBCL receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Venetoclax naïve AML patients receive selinexor on days 8, 15, and 22 of cycle 1, followed by days 1, 8, 15, and 22 of subsequent cycles. Venetoclax refractory AML patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9481920|NCT03951077|Experimental|Various doses of Elagolix plus matching placebo|Various dosing regimens for Elagolix taken orally plus matching placebo taken orally depending on arm assignment.
9481921|NCT03951077|Placebo Comparator|Placebo|Placebo taken orally twice a day (BID)
9481922|NCT03950752|Experimental|Bagels with optimized composition in fatty acids|Participants will consume three bagels with an optimized composition in fatty acids and without oil palm in only one day.
9481923|NCT03950752|Active Comparator|Bagels with conventional composition in fatty acids|Participants will consume three bagels with a conventional composition in fatty acids in only one day.
9481924|NCT03949673|Other|Knee or Hip Joint Arthroplasty|Patients with OA of the knee or hip who are participating in an ongoing fasinumab phase 3 parent study
9481925|NCT03948646|Experimental|Active|Sofpironium bromide, 15% gel, once per day
9481926|NCT03948646|Placebo Comparator|Vehicle|Vehicle gel, once per day
9481927|NCT03947957|Other|collection of expectoration, stools and blood|
9481928|NCT03943680|Experimental|PRGF|Post-extraction socket grafted with PRGF-Endoret
9481929|NCT03943680|Active Comparator|ABB|Post-extraction socket grafted with anorganic bovine bone (ABB)
9481930|NCT03943147|Experimental|BMS-986165 Dose 1|Specified Dose on Specified Days
9481931|NCT03943147|Experimental|BMS-986165 Dose 2|Specified Dose on Specified Days
9481932|NCT03943147|Placebo Comparator|Placebo for BMS-986165|Specified Dose on Specified Days
9481933|NCT03943147|Experimental|Mycophenolate Mofetil (MMF)|Specified Dose on Specified Days
9481934|NCT03941548|Experimental|CTP-543 QD Dose Regimen|Oral tablet for 24 Weeks
9481935|NCT03941548|Experimental|CTP-543 BID Dose Regimen|Oral tablet for 24 Weeks
9481936|NCT03941301|Experimental|Bright treatment light|
9481937|NCT03941301|Placebo Comparator|Red light|
9481938|NCT03941262|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once a week for five weeks.
9481939|NCT03941262|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered once a week for five weeks.
9481940|NCT03941262|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered once a week for five weeks.
9481941|NCT03941262|Experimental|Cohort 4 - SNK01 with avelumab|SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.
9481942|NCT03941262|Experimental|Cohort 4 - SNK01 with pembrolizumab|SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.
9481943|NCT03938038|Active Comparator|Serial ultrasound assessments for GDT|
9481944|NCT03938038|Active Comparator|Usual care|
9481945|NCT03937882|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Thymosin beta 4
9481946|NCT03937882|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
9533297|NCT03168516|No Intervention|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
9481947|NCT03936894|Experimental|Treatment|Canakinumab treatment
9481948|NCT03935958|Experimental|Curcumin Arm (Arm 1)|20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.
9481949|NCT03935958|Placebo Comparator|Placebo Arm (Arm 2)|20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood samples and questionnaires.
9481950|NCT03935724|Experimental|1A Intervention group 8 patients|Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident). N=8
9481951|NCT03935724|Placebo Comparator|1B Placebo group 8 patients|Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=8
9481952|NCT03935724|Experimental|2A Intervention group 27 patients|Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident) N=27
9481953|NCT03935724|Placebo Comparator|2B Placebo group 27 patients|Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=27
9481954|NCT03934099|Experimental|LC350189 50mg|LC350189 50mg, Once a day (QD)
9481955|NCT03934099|Experimental|LC350189 100mg|LC350189 100mg, QD
9481956|NCT03934099|Experimental|LC350189 200mg|LC350189 200mg, QD
9481957|NCT03934099|Placebo Comparator|Placebo|Placebo, QD
9481958|NCT03933410|Experimental|KB195|KB195 is a novel glycan
9481959|NCT03933020|Experimental|Exercise Group|
9481960|NCT03933020|Active Comparator|Control Group|
9481961|NCT03928184|Experimental|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
9481962|NCT03928184|Placebo Comparator|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
9481963|NCT03926195|Experimental|Double-Blind Phase: Filgotinib|Filgotinib up to Week 13
9481964|NCT03926195|Placebo Comparator|Double-Blind Phase: Placebo|Placebo up to Week 13
9481965|NCT03926195|Experimental|Extension Phase: Open-Label Filgotinib|Participants who received double-blind filgotinib and did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) and were arthritis responders at Week 13 will enter the Extension Phase and receive open-label filgotinib up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
9481966|NCT03926195|Other|Extension Phase: Standard of Care|Participants who received double-blind placebo and participants who received double-blind filgotinib and were arthritis non-responders who did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) at Week 13 will enter the Extension Phase and receive standard of care up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
9481967|NCT03926195|Other|Monitoring Phase: Standard of Care|Participants with a prespecified decrease in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) anytime at/after Week 13 will receive standard-of-care therapy as per investigator discretion in the Monitoring Phase for up to 52 weeks or until reversibility in semen parameters is met, whichever occurs first.
9481968|NCT03926169|Experimental|Risankizumab: Dose A|Participants randomized to receive risankizumab dose A in treatment period A and placebo followed by risankizumab dose B in treatment period B
9481969|NCT03926169|Experimental|Risankizumab: Dose B|Participants randomized to receive risankizumab dose B in treatment period A and placebo followed by risankizumab dose B in treatment period B
9481970|NCT03926169|Placebo Comparator|Placebo|Participants randomized to receive Placebo in treatment period A and risankizumab dose B in treatment period B
9481971|NCT03926117|Placebo Comparator|Placebo|Matching placebo
9481972|NCT03926117|Experimental|Ziltivekimab 7.5 mg|
9481973|NCT03926117|Experimental|Ziltivekimab 15 mg|
9481974|NCT03926117|Experimental|Ziltivekimab 30 mg|
9481975|NCT03926026|Experimental|NCX 4251 QD|NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
9481976|NCT03926026|Placebo Comparator|Placebo QD|Placebo once daily for 14 days
9481977|NCT03926026|Experimental|NCX 4251 BID|NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
9481978|NCT03926026|Placebo Comparator|Placebo BID|Placebo twice daily for 14 days
9481979|NCT03925480|Experimental|Azithromycin|A single 2g dose of Azithromycin
9481980|NCT03925480|Placebo Comparator|Placebo|Matching Placebo
9481981|NCT03924180|Experimental|GMP - Dietary Supplement for PKU patients|Glycomacropeptides -GMP Glytactin
9481982|NCT03924180|Active Comparator|Control -Amino acids mixtures|Mixtures of conventional amino acids.
9481983|NCT03922165||DS peds eligible for Adenotonsillectomy|Dyads of caregivers and children with DS aged 3-13 years diagnosed with SDB and referred for treatment with adenotonsillectomy.
9481984|NCT03921411|Experimental|Nemolizumab|Nemolizumab
9481985|NCT03917511|Experimental|Robotic training with mirror therapy|20 minutes mirror therapy followed by 40 minutes robotic-assisted training
9481986|NCT03917511|Sham Comparator|Robotic-assisted training|20 minutes sham mirror therapy followed by 40 minutes robotic-assisted training
9481987|NCT03916731|Experimental|STARgraft AV|Participants will be implanted with 6mm diameter STARgraft AV grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
9481988|NCT03916731|Active Comparator|Control (ePTFE)|Participants will be implanted in the same upper arm location with standard 6mm diameter ePTFE dialysis access grafts. All other aspects of this study arm are identical to the Experimental one.
9481989|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention|AQ: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). The participant may or may not stay solely on AQ throughout the study.
9533298|NCT03168386|Experimental|Intensive motor rehabilitation group|
9533299|NCT03168477|Experimental|dry needling and spinal manipulation|
9533300|NCT03168477|Active Comparator|mobilization, exercise, modalities|
9533301|NCT03168464|Experimental|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
9533302|NCT03168191|Experimental|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
9533303|NCT03168191|Experimental|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
9533304|NCT03168191|Placebo Comparator|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
9533305|NCT03168451|Experimental|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
9533306|NCT03168451|No Intervention|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
9533307|NCT03168529|Active Comparator|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
9533308|NCT03168529|Placebo Comparator|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
9533309|NCT03168165|No Intervention|Usual Care|Usual care, no intervention
9533310|NCT03168165|Experimental|Pain Neuroscience Education Training|The region of clinics randomized to this arm will receive PNE education, which consists of 6 weeks online training followed by an on-site training day.
9533311|NCT03168243|Experimental|High Energy High Protein Tube Feed|As study is a single arm design, all patients will be in the intervention group. The will act as their own control by means of a 3 day baseline period. All patients in the study will receive the same intervention, the high energy high protein tube feed, in quantities specified by their dietitian based on their nutritional requirements.
9533312|NCT03168178|Active Comparator|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
9533313|NCT03168178|Experimental|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
9615738|NCT05226299|Experimental|Experimental: Supra-threshold capsaicin|Arm: Experimental: Supra-threshold capsaicin Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
9615739|NCT05226299|Placebo Comparator|Arm: Placebo Comparator: Saline|Participants will be exposed repeatedly to aerosolized saline through a nebulizer during treatment.
9615740|NCT05226260|Experimental|Intervention|Intervention clinics receiving fully functional Epic order panel with set default [short] duration by diagnosis: for cellulitis and drained abscess, 5 days. For impetigo and undrained abscess, 7 days.
9615741|NCT05226260|No Intervention|Control|Control clinics receiving basic Epic order panel with antibiotic doses by diagnosis but duration free text (must be entered manually by clinician prescriber).
9615742|NCT05226247|Other|high-risk of weaning-induced pulmonary edema|Critically-ill patients under mechanical ventilation for more than 48h, who are at high-risk of weaning-induced pulmonary edema and in whom the attending physician decided to perform a spontaneous breathing trial.
9615743|NCT05226234||Experimental group|
9615744|NCT05226169|Experimental|Active treatment arm : IV FCM|Intravenous ferric carboxymaltose
9615745|NCT05226169|Active Comparator|Control treatment arm: Conservative management|"Conservative management~Absolute IDA: oral ferrous sulfate~Functional IDA: no treatment or oral ferrous sulfate according to the physician's choice~Other IV iron or PRC transfusion or ESA therapy is not allowed"
9615746|NCT05226091|Experimental|Intervention arm|GP practices randomised to the intervention will receive a mail and email about the result of the PLEASANT study and advising them to implement the study findings.
9615747|NCT05226091|No Intervention|Usual care arm|GP practices randomised to control will not receive either mail or email and they will continue with usual care.
9615748|NCT05226078|Experimental|Four Sessions of CBT-I|
9615749|NCT05226078|Experimental|Eight Sessions of CBT-I|
9615750|NCT05226078|Experimental|Ten Sessions of CBT-I|
9615751|NCT05226078|Experimental|Twelve Sessions of CBT-I|
9615752|NCT05226052|Experimental|S. boulardii|treatment arm group (3 capsules of Floratil 200mg®/day)
9615753|NCT05226052|Placebo Comparator|Placebo|control group (3 capsules of placebo/day)
9615754|NCT05226013|Experimental|PEGylated Urate Oxidase for Injection|PEGylated Urate Oxidase for Injection，specification:5mg，Single dose ascending.Healthy subjects were divided into three dose groups (0.5mg, 1mg, 2mg), and hyperuricemia patients were divided into four dose groups (2mg, 4mg, 8mg, 12 mg), with increasing dose design.Each group will receive the experimental drug in 6 subjects.
9615755|NCT05226013|Placebo Comparator|Placebo|Placebo , specification: 5mg,Single dose. Groups received the placebo in 2 patients per group.
9615756|NCT05226000|Experimental|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
9615757|NCT05225974|Experimental|Liraglutide injection|
9615758|NCT05225974|Active Comparator|Liraglutide injection(Victoza®)|
10038419|NCT01834300|Experimental|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
10038420|NCT01834352|Active Comparator|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
10038421|NCT01834352|Placebo Comparator|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
10038422|NCT01834365|Experimental|Structured education & checklist|Formatted education and checklist every month for 3 months
9481990|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention + NSC|AQ+NSC: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). NSC sessions are scheduled approximately every other week (frequency) and last approximately 30 minutes per session (dose). The participant may or may not stay on AQ+NSC throughout the study.
9481991|NCT03916484|Experimental|AQ followed by AQ+NSC|At 3 months, those who were initially randomized to AQ who meet protocol defined definition for intervention non-responsiveness, are reassigned to AQ+NSC to complete months 4 - 6 of the trial.
9481992|NCT03916484|Experimental|AQ+NSC followed by AQ|At 3 months, those who were initially randomized to AQ+NSC who meet protocol defined definition for intervention responsiveness, may get re-randomized to AQ alone to complete months 4 - 6 of the trial.
9481993|NCT03916081|Active Comparator|ARQ-151 cream 0.05%|
9481994|NCT03916081|Active Comparator|ARQ-151 cream 0.15%|
9481995|NCT03916081|Placebo Comparator|ARQ-151 cream Vehicle|
9481996|NCT03916042|Experimental|Reproxalap (0.25% Novel Formulation) QID to BID|
9481997|NCT03916042|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
9481998|NCT03915067|Active Comparator|BOTOX High Dose|BOTOX High Dose will be injected into the platysma muscle on Day 1.
9481999|NCT03915067|Active Comparator|BOTOX Low Dose|BOTOX Low Dose will be injected into the platysma muscle on Day 1.
9533314|NCT03168555|Experimental|Intervention|chenodeoxycholic acid 1250mg po.
10038423|NCT01834365|Active Comparator|Structured education|Formatted education every month for 3 months
9482000|NCT03915067|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1.
9482001|NCT03912233|Experimental|Part 1: F/MF genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive multiple dose levels of VX-121 in TC with TEZ/VX-561.
9482002|NCT03912233|Placebo Comparator|Part 1: Placebo|
9482003|NCT03912233|Experimental|Part 2: F/F genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive VX-121 in TC with TEZ/VX-561
9482004|NCT03912233|Active Comparator|Part 2: Placebo + TEZ/IVA|
9482005|NCT03911102|Experimental|Cohort 1: DaxibotulinumtoxinA Dose A|Subjects will receive Dose A of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
9482006|NCT03911102|Experimental|Cohort 2: DaxibotulinumtoxinA Dose B|Subjects will receive Dose B of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
9482007|NCT03911102|Experimental|Cohort 3: DaxibotulinumtoxinA Dose C|Subjects will receive Dose C of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
9482008|NCT03911102|Experimental|Cohort 4: DaxibotulinumtoxinA Dose D|Subjects will receive Dose D of DaxibotulinumtoxinA for injection for the treatment of moderate to severe Lateral Canthal Lines (LCL)
9482010|NCT03899259|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9482011|NCT03899259|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9482012|NCT03899259|Placebo Comparator|Placebo|Placebo administered orally.
9482013|NCT03898323|Experimental|AABM Training|Alcohol Approach Bias Modification (AABM) training is a computer training program that participants interact with by pushing and pulling a joystick. Participants are asked to respond to the format of a presented picture, irrespective of the pictures' content. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. AABM training consists of 3 sessions per week over 2 weeks, for a total of 6 sessions.
9482014|NCT03897257|Experimental|UHE-103A1 cream|Topical cream applied twice daily for 2 weeks.
9482015|NCT03897257|Experimental|UHE-103A2 cream|Topical cream applied twice daily for 2 weeks.
9482016|NCT03897257|Experimental|UHE-103B cream|Topical cream applied twice daily for 2 weeks.
9482017|NCT03897257|Experimental|UHE-103A1B cream|Topical cream applied twice daily for 2 weeks.
9482018|NCT03897257|Experimental|UHE-103A2B cream|Topical cream applied twice daily for 2 weeks.
9482019|NCT03896009|Experimental|AXS-07|Taken once upon a qualifying migraine
9482020|NCT03896009|Active Comparator|Meloxicam|Taken once upon a qualifying migraine
9482021|NCT03896009|Active Comparator|Rizatriptan|Taken once upon a qualifying migraine
9482022|NCT03896009|Placebo Comparator|Placebo|Taken once upon a qualifying migraine
9482023|NCT03892772|Experimental|SAS0421a, SAS0421b and SAS0421c|Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.
9482024|NCT03892772|Active Comparator|SAS0421a and SAS0421b|Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.
9482025|NCT03892772|Active Comparator|SAS0421c|Participants will take SAS0421c for 3 days. Half doses will be given on the first night.
9482026|NCT03892772|Placebo Comparator|Placebo|Participants will take placebos for 3 days.
9482027|NCT03889405|Experimental|Study group|Healthy 32 weeks or more pregnant women, at an early stage of labor.
10038424|NCT01834365|Active Comparator|Without Structured Education with checklist|No structured education with checklist
9533315|NCT03168152|Experimental|MWA|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
9533316|NCT03168152|Experimental|SBRT|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
9533317|NCT03168490|Active Comparator|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
9533318|NCT03168490|Active Comparator|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
9533319|NCT03168490|Active Comparator|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
9533320|NCT03168490|Placebo Comparator|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
9533321|NCT03168490|Placebo Comparator|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
9533322|NCT03168503|Experimental|LGG+Promitor™|LGG:10^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
9533323|NCT03168503|Experimental|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
9533324|NCT03168503|Experimental|LGG-PB12+Promitor™|LGG-PB12:10^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
9533325|NCT03168503|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
10038425|NCT01834378|No Intervention|No intervention|
10038426|NCT01834378|Experimental|Low intensity intervention|
9533326|NCT03168412|Experimental|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
9533327|NCT03168412|Active Comparator|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
9533328|NCT03168399|Experimental|Consumption of PKU Explore|Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
9533329|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Peanut skin prick test wheal ≥ 8 mm."
9533330|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative skin prick test (wheal < 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
9533331|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
9533332|NCT03168230||PVE|Patients who required PVE prior to the attempt of liver resection.
9533333|NCT03168230||No-PVE|Patients who received upfront surgery (no PVE prior to the intervention)
9533334|NCT03168139|Experimental|Olaptesed pegol + Pembrolizumab|
9533335|NCT03168074|Experimental|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).
9533336|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
10038427|NCT01834378|Experimental|High intensity intervention|
10038428|NCT01834391||Geriatric Traumatic Injury|Geriatric trauma pateints being admitted to Saint Marys Hosptial.
10058332|NCT02017548|Experimental|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
9533337|NCT03168048|Experimental|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
9533338|NCT03168087||0% dilution|Blood specimen which was diluted with 0% level using a plasmalyte-148 solution
9533339|NCT03168087||20% dilution|Blood specimen which was diluted with 20% level using a plasmalyte-148 solution
9533340|NCT03168087||40% dilution|Blood specimen which was diluted with 40% level using a plasmalyte-148 solution
9533341|NCT03168087||60% dilution|Blood specimen which was diluted with 60% level using a plasmalyte-148 solution
9533342|NCT03168061|Experimental|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
9533343|NCT03168035|Experimental|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
9533344|NCT03168009|Experimental|Bariatric Surgery|Patients will undergo either Omega Loop Gastric Bypass or Sleeve Gastrectomy. The decision which type of surgery will be performed, will by made by the surgeon and the patient based on clinical considerations and the patient's wishes.
9533345|NCT03168100|Experimental|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
9533346|NCT03167983||dementia|patients with dementia
9533347|NCT03167983||control|healthy control
9533348|NCT03167762|Experimental|Study group|
9533349|NCT03167723|Experimental|28 French chest tube for hemothorax|28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
9533350|NCT03167723|Experimental|14 French chest tube for hemothorax|14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
9533351|NCT03167736|Experimental|Electric dry needling, manipulation|
9533352|NCT03167736|Active Comparator|conventional physical therapy|
9533353|NCT03167827|Experimental|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
9533354|NCT03167827|Placebo Comparator|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
9533355|NCT03167775|Experimental|Elemene + the best supportive treatment|the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .
9533356|NCT03167658|Experimental|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
9533357|NCT03167658|No Intervention|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
9533358|NCT03167658|No Intervention|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
9533359|NCT03167840|Experimental|Physical training alone (PT)|Physical Training (flexibility, endurance, strengthening, and balance training) for 60-90 minutes 3x/week over 12 weeks of moderate intensity.
9533360|NCT03167840|Experimental|Cognitive training alone (CT)|Cognitive training with a focus on orientation, memory, attention and executive functioning for 60-90 minutes per session, once per week for 12 weeks.
9533361|NCT03167840|Experimental|Physical and cognitive training (PACT)|Integrated cognitive training in physical exercise for 60-90 minutes per session, 3x/week over 12 weeks.
9533362|NCT03167840|No Intervention|Wait-list group (WG)|The control group on wait-list. They will be instructed to go on with their usual activities and will receive the intervention, combined physical and cognitive training, at a later date.
9533363|NCT03167918|Experimental|Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO
9533364|NCT03167918|Experimental|Xuefuzhuyu Decoction|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po
9533365|NCT03167918|Experimental|Xuefuzhuyu Decoction &Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)& Xuefuzhuyu Decoction（100 ml bid，po)
9533366|NCT03167905|Experimental|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
9533367|NCT03167905|Active Comparator|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
9533368|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
9533369|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
9533370|NCT03167710|Experimental|dry needling, manipulation stretching|
9533371|NCT03167710|Active Comparator|manual therapy, exercise, ultrasound|
9533372|NCT03167866|Placebo Comparator|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
9533373|NCT03167866|Experimental|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
9533374|NCT03167996|Experimental|Group B/ HealthPals|"Group B have access to HealthPals app where they will coordinate with a trained health coach Group B patients will only come into SSATHI clinic to see their doctor for an initial visit and 6 month follow up, and they will have a telephone visit with their doctor at 3 months instead of an in-clinic visit~Lab testing is the same for both Group A/ control and Group B patients"
9804155|NCT01733758|Placebo Comparator|Placebo|Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
9533375|NCT03167996|No Intervention|Group A/ Control|"Group B will not have access to HealthPals app~Group A patients will come into SSATHI clinic to see their doctor for an initial visit, a 3 month follow up, and a 6 month follow up~Lab testing is the same for both Group A/ control and Group B patients"
9533376|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
9533377|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
9533378|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
9533379|NCT03167645|Experimental|Human albumin|Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
9533380|NCT03167645|No Intervention|Control|Standard clinical care
9533381|NCT03167957|Experimental|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
9533382|NCT03167957|Experimental|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
9533383|NCT03167697|Experimental|Synergy|This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
9533384|NCT03167697|Active Comparator|Routine|This group will continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.
9533385|NCT03167853|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg per 2 weeks until disease progresses or unacceptable tolerability occurs.
9533386|NCT03167788|Experimental|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period.
9533387|NCT03167788|Active Comparator|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
9533388|NCT03167944|Experimental|Conventional electrocautery|
9533389|NCT03167944|Experimental|Low thermal electrosurgery system|
9533390|NCT03167931|Experimental|18-49 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
9533391|NCT03167931|Experimental|50-85 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
9533392|NCT03167684|Experimental|Oral appliance therapy|Oral appliance (SomnoMed) worn nightly
9533393|NCT03167684|No Intervention|Control|Sham oral appliance device
9533394|NCT03167814|Active Comparator|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
9533395|NCT03167814|No Intervention|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
9533396|NCT03167632||dental patients|
9533397|NCT03167619|Experimental|A - olaparib alone|Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
9533398|NCT03167619|Experimental|B - olaparib plus durvalumab|Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
9533399|NCT03167879|Experimental|SCC1--high intensity supervision|Integration of safer conception counseling into family planning services, with intensive training and supervision
9533400|NCT03167879|Experimental|SCC2-- low intensity supervision|Integration of safer conception counseling into family planning services, with less intensive training and supervision that mimics Ministry of Health approach
9533401|NCT03167879|No Intervention|Usual care family planning services|Family planning services that are currently available as part of usual care, which focus almost solely on contraception and pregnancy prevention
9533402|NCT03167593|Placebo Comparator|Control|Capsules containing 300 mg of maltodextrin.
9533403|NCT03167593|Experimental|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
9533404|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
9533405|NCT03167333|Experimental|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
9533406|NCT03167333|Active Comparator|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
9533407|NCT03167450||Adults|Adults have sickle cell disease
9533408|NCT03167450||Parents|Parents with children/adults who have sickle cell disease
9533409|NCT03167450||Physicians|Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
9804156|NCT01733758|Active Comparator|Liraglutide 0.9 mg daily|Subjects will be randomly assigned to open-label liraglutide for 52 weeks
9804157|NCT01733953|Experimental|Atorvastatin|6-Months Atorvastatin Therapy; 40mg oral, once daily
9482028|NCT03888378|Active Comparator|0.3% Topical Minocycline Ointment|Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
9482029|NCT03888378|Active Comparator|1% Topical Minocycline Ointment|Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
9482030|NCT03888378|Placebo Comparator|Topical Vehicle Ointment|Topical administration of Topical Vehicle Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
9482031|NCT03887052|Experimental|Study Arm|Adult cardiac patients at risk for sudden cardiac arrest otherwise protected with an Implantable Cardioverter Defibrillator (ICD)
9482032|NCT03887026|Experimental|NKT Low Dose|NKT single dose - Low
9482033|NCT03887026|Experimental|NKT High Dose|NKT single dose - High
9482034|NCT03887026|Placebo Comparator|Placebo|Placebo single dose
9482035|NCT03886610||Healthy controls|Individuals without spinal cord injury
9482036|NCT03886610||Subacute SCI patients|Subacute patients with spinal cord injury (duration >2 weeks)
9482037|NCT03886610||Chronic SCI patients|Patients with chronic spinal cord injury (duration ≥24 months)
9482038|NCT03885011|Experimental|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
9482039|NCT03885011|Active Comparator|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
9482040|NCT03885011|Active Comparator|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
9482041|NCT03884543|Experimental|Individualized high PEEP strategy|Recruitment maneuver (performed after induction of anesthesia, after any disconnection from the mechanical ventilator, and before extubation) followed by the decremental PEEP trial to determine the highest level of PEEP resulting in the lowest driving pressure. This is again followed by a recruitment maneuver, after which PEEP is set at the level indicated by the decremental PEEP trial.
9482042|NCT03884543|No Intervention|Standard low PEEP strategy|PEEP at maximum 5cm H2O. No recruitment maneuvers. Patients are randomized and intraoperatively ventilated with conventional strategy. (PEEP at maximum 5cm H2O without recruitment maneuvers)
9482043|NCT03881852|Experimental|AXS-12 (reboxetine)|
9482044|NCT03881852|Placebo Comparator|Placebo|
9482045|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID|
9482046|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID|
9482047|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID to BID|
9482048|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
9482049|NCT03879408|Experimental|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
9482050|NCT03879408|Experimental|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
9482051|NCT03879408|Active Comparator|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
9482052|NCT03879408|Active Comparator|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
9482053|NCT03879408|Placebo Comparator|Placebo tablet|Single dose of four placebo tablets
9482054|NCT03877289|Experimental|Oxybutynin|Children aged 4 - 6 years: Oxybutynin 2.5 mg (2.5ml) po TID Children aged 7 - 16 years: Oxybutynin 5 mg (5ml) po TID
9482055|NCT03877289|Placebo Comparator|Placebo|Orasweet liquid placebo
9482056|NCT03875716|Experimental|Low Risk|"Observation without adjuvant therapy~Pathologic T0-2, N0-1~Minimum of 15 lymph nodes retrieved on neck dissection per dissected side of the neck~-≤2 positive lymph nodes confined to level II and/or level III~No extranodal extension~Clear margins"
9482057|NCT03875716|Experimental|Intermediate Risk|"Reduced-dose radiation (46Gy)~Pathologic T0-2N0-2 and any one of the following features:~->2 positive lymph nodes~<15 lymph nodes retrieved on neck dissection for each side of the neck~Positive lymph nodes in level IB, IV, or V~-≤1mm extranodal extension~Positive lymph node(s) contralateral to the primary tumor~Close margins"
9482058|NCT03875716|Experimental|High Risk|"Postoperative radiation (60Gy) without chemotherapy~Pathologic T0-4N0-2 and any one of the following features:~->1mm extranodal extension~Microscopic positive margins"
9482059|NCT03872453|Active Comparator|Arm 1 - BHV-3500 (zavegepant) 5 mg|One dose of 5 mg
9482060|NCT03872453|Active Comparator|Arm 2 - BHV-3500 (zavegepant) 10mg|One dose of 10 mg
9482061|NCT03872453|Active Comparator|Arm 3 - BHV-3500 (zavegepant) 20mg|One dose of 20mg
9482062|NCT03872453|Placebo Comparator|Arm 4 - Matching BHV-3500 (zavegepant) Placebo|One dose of placebo
9482063|NCT03866200|Experimental|resveratrol|
9482064|NCT03866200|Placebo Comparator|Placebo|
9482065|NCT03863080|Experimental|Regimen A|RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
9804158|NCT01733953|Placebo Comparator|Sugar Pill (Placebo)|6-Months Placebo (sugar pill); oral, once daily
9482066|NCT03863080|Experimental|Regimen B|RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
9482067|NCT03863080|Placebo Comparator|Placebo|Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
9482068|NCT03861091|Experimental|Risedronate|Risedronate 150 mg given once 7-21 days prior to initiation of SBRT
9482069|NCT03861091|Placebo Comparator|Matching Placebo|Matching placebo, dose not applicable given once 7-21 days prior to initiation of SBRT
9482070|NCT03857659|Experimental|Point of care ultrasound (POC-US)|Point of care ultrasound (POC-US) to measure abdominal circumference and amniotic fluid every 4 weeks from 28-36 weeks
9482071|NCT03857659|Active Comparator|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
9482072|NCT03857646|Other|Intralipid|
9482073|NCT03857646|Other|SMOF lipid|
9482074|NCT03856749|Experimental|Treatment|The wheelchair user and caregiver will be trained together on wheelchair skills using remote technology (Zoom for healthcare and/or Facetime).
9482075|NCT03856749|No Intervention|Control|The wheelchair user and caregiver will receive the same self-study materials provided to the Treatment arm. Usual care, which may include wheelchair skills training for both wheelchair users and caregivers( but which often does not do so to an adequate extent) by wheelchair user's clinical therapist.
9482076|NCT03856047|Experimental|NNC0174-0833, 4.5 mg|Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
9482077|NCT03856047|Experimental|NNC0174-0833, 2.4 mg|Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
9482078|NCT03856047|Experimental|NNC0174-0833, 1.2 mg|Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
9482079|NCT03856047|Experimental|NNC0174-0833, 0.6 mg|Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
9482080|NCT03856047|Experimental|NNC0174-0833 0.3 mg|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
9482081|NCT03856047|Placebo Comparator|Placebo 2.4 mg (NNC0174-0833)|Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
9482082|NCT03856047|Placebo Comparator|Placebo 4.5 mg (NNC0174-0833)|Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
9482083|NCT03856047|Placebo Comparator|Placebo 1.2 mg (NNC0174-0833)|Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
9482084|NCT03856047|Placebo Comparator|Placebo 0.6 mg (NNC0174-0833)|Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
9482085|NCT03856047|Placebo Comparator|Placebo 0.3 mg (NNC0174-0833)|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
9482086|NCT03856047|Active Comparator|Liraglutide 3.0 mg|Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
9482087|NCT03856047|Placebo Comparator|Placebo 3.0 mg (Liraglutide)|Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.
9482088|NCT03853837||Prospective Fontan patients|Fontan patients to be enrolled and complete study tests/procedures
9482089|NCT03853837||Retrospective Fontan patients|Fontan patients to be retrospectively reviewed and used as control subjects
9482090|NCT03853343|Placebo Comparator|Placebo|3 capsules per day (1 before each meal) of cellulose
9482091|NCT03853343|Active Comparator|Seaweed extract|3 capsules per day (1 before each meal) of seaweed extract
9482092|NCT03852719|Experimental|Delayed Treatment|Participants will receive delayed treatment with bulevirtide 10 mg/day subcutaneously (SC) for 96 weeks after an observational period of 48 weeks.
9482093|NCT03852719|Experimental|Bulevirtide 2 mg/day|Participants will receive bulevirtide 2 mg/day SC for 144 weeks.
9482094|NCT03852719|Experimental|Bulevirtide 10 mg/day|Participants will receive bulevirtide 10 mg/day SC for 144 weeks.
9482095|NCT03851705|Experimental|Part 1 - Inclisiran|Participants will receive a dose of 300 milligram (mg) Inclisiran sodium administered by SC injection on Day 1 and Day 90.
9482096|NCT03851705|Placebo Comparator|Part 1 - Placebo|Participants will receive a dose of placebo administered by SC injection on Day 1 and Day 90.
9482097|NCT03851705|Experimental|Part 2 - Inclisiran|All participants will receive a dose of 300 mg inclisiran sodium administered by SC injection on Days 270, 450 and 630. (Participants who were on placebo in Part 1, will receive the first dose of inclisiran on Day 180.)
9482098|NCT03850574|Experimental|HM43239|This phase 1/2 study consists of dose escalation and expansion. Dose escalation cohort is planned up to 10 dose levels. If subject in the dose escalation cohort at any dose level achieves clinical response then the dose level will continue to enroll.
9482099|NCT03849456|Experimental|GWP42006|Oral solution taken twice daily with food for 52 weeks.
9482100|NCT03845829|Experimental|Patients with TBAD treated with TEVAR|In situ laser assisted fenestration for the left subclavian artery during the TEVAR procedure for TBAD.
9482101|NCT03845023|Placebo Comparator|Placebo|Placebo
9482102|NCT03845023|Active Comparator|Dose 1|AD036 Dose 1
9482103|NCT03845023|Active Comparator|Dose 2|AD036 Dose 2
9482104|NCT03845023|Active Comparator|Dose 3|AD036 Dose 3
9482105|NCT03844074|Experimental|bevacizumab|ONS-5010
9482106|NCT03844074|Active Comparator|ranibizumab|
9482107|NCT03840837|No Intervention|Arm 1: baseline only (cross-sectional)|At baseline, all participants will undergo instrumented gait/balance testing, using a wearable sensor (Dynaport MT), and cognitive testing, using a computerized cognitive test battery (NeuroTrax Mild Cognitive Impairment & Early Dementia Battery by MindStreams). In other words, all participants will be part of arm 1.
9482108|NCT03840837|Experimental|Arm 2: rivastigmine (longitudinal)|As study intervention, a subgroup of participants will then be treated with transdermal rivastigmine patch for 12 weeks, with dose increases every 4 weeks and titration up to 13.3 mg/24h, if tolerated. For the arm 2 subgroup of participants, the same assessment that was performed at baseline (quantitative gait testing and NeuroTrax computerized cognitive test battery) will be repeated after 12 weeks, with the patient on a stable dose of transdermal rivastigmine.
9482109|NCT03837743|Experimental|DUR-928 Topical Solution|DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
9482110|NCT03837743|Placebo Comparator|Vehicle Topical Solution|Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
9482111|NCT03836287|Experimental|Active|Sofpironium bromide, 15% gel, once per day
9482112|NCT03836287|Placebo Comparator|Vehicle|Vehicle gel, once per day
9497696|NCT03472664|Experimental|American Heart Association Diet|The American Heart Association Diet (AHAD), is a low fat/high carbohydrate diet (<40 grams/day) will be used as the control diet. Participants on the AHAD will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Participants will receive the same daily multivitamin supplement (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet.
9497697|NCT03472651|Experimental|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
9497698|NCT03472651|Experimental|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
9497699|NCT03472638|Experimental|Active -> Sham|15 days of active, followed by 15 days of sham rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
9497700|NCT03472638|Experimental|Sham -> Active|15 days of sham, followed by 15 days of active rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
9497701|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
9497702|NCT03472560|Experimental|Avelumab in combination with axitinib|Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
9497703|NCT03472508|Sham Comparator|0 mg folic acid|Enalapril Maleate (10mg) with 0 mg folic acid
9497704|NCT03472508|Active Comparator|0.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg)
9497705|NCT03472508|Active Comparator|0.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg) with 0.2 mg folic acid
9497706|NCT03472508|Active Comparator|0.8mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg)
9497707|NCT03472508|Active Comparator|1.2mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.4 mg folic acid
9497708|NCT03472508|Active Comparator|1.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.8 mg folic acid
9497709|NCT03472508|Active Comparator|2.0mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.2 mg folic acid
9497710|NCT03472508|Active Comparator|2.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.6 mg folic acid
9497713|NCT03472482||Ab+ cognitively intact volunteers|"amyloid-positive cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
9497714|NCT03472482||Ab- cognitively intact volunteers|"amyloid-negative cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
9497715|NCT03472482||amyloid-positive MCI patients|"amyloid-positive patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
9497716|NCT03472482||amyloid-negative MCI patients|"amyloid-negative patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
9497717|NCT03472482||AD patients|"patients in the dementia stage of Alzheimer's Disease~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
9497718|NCT03472482||LBD patients|"patients with Lewy Body Dementia~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
9497719|NCT03472456||Articaïne|
9497720|NCT03472456||Eugénol|
9497721|NCT03472443|Experimental|Sinew Acupuncture|
9497722|NCT03472443|No Intervention|Waitlist|
9497723|NCT03472430|Active Comparator|Treatment group|Transcutaneous electrical nerve stimulation machine, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
9497724|NCT03472430|Sham Comparator|Placebo group|TENS machine with electrodes not emitting any impulses, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
9497725|NCT03472417|Active Comparator|Active partial rebreathing device|
9497726|NCT03472417|Sham Comparator|Dummy partial rebreathing device|
9500334|NCT05321524|Experimental|SD (1.5mg adult-equivalent dose of OCA) + MD Medium dose (5mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Low Dose Cohort, 8 (±1) eligible subjects will be assigned to the Medium Dose Cohort and will receive a 5 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart."
9482113|NCT03834753|Experimental|bevacizumab|ONS-5010
9482114|NCT03834753|Active Comparator|ranibizumab|
9482115|NCT03832569|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
9482116|NCT03832179|Active Comparator|Anti-vascular endothelial growth factor|Intravitreal Bevacizumab, Ranibizumab, or Aflibercept
9482117|NCT03832179|Experimental|Ozurdex|Intravitreal Ozurdex
9482118|NCT03829241|Experimental|Arm 1: BHV-4157- Experimental|
9482119|NCT03829241|Placebo Comparator|Arm 2: Placebo Comparator Drug|
9482120|NCT03827018|Active Comparator|mavrilimumab|Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
9482121|NCT03827018|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
9482122|NCT03826186|Active Comparator|Traditional epidural group|The traditional approach to placing thoracic epidurals by loss-of-resistance technique using a ground glass syringe will be used in this group.
9482123|NCT03826186|Experimental|CompuFlo epidural group|This device (CompuFlo) will aid in correct placement of the epidural by electronically sensing pressure in real time and by providing a numerical value on a read out screen to determine a loss of resistance. There is also an audio signal that signals a loss of resistance.
9482124|NCT03825315|Experimental|DAXI for Injection: LOW Dose|LOW Dose Group
9482125|NCT03825315|Experimental|DAXI for Injection: HIGH Dose|HIGH Dose Group
9482126|NCT03825315|Placebo Comparator|Placebo|Placebo Group.
9482127|NCT03824587|Experimental|Tenapanor 30 mg BID|"During the Double-Blind Treatment Period, subjects will receive tenapanor starting at a dose of 30 mg bid (three 10 mg tablets each time).~Investigators may decrease or increase the dose of study medication based on s-P levels and/or gastrointestinal (GI) tolerability in 10 mg increments to a minimum of 10 mg bid or a maximum of 30 mg bid at any time during the Double-Blind Treatment Period."
9482128|NCT03824587|Placebo Comparator|Placebo|same size, weight and appearance of experimental drug
9482129|NCT03823300|Experimental|Arm A: Faricimab|
9482130|NCT03823300|Active Comparator|Arm B: Aflibercept|
9482131|NCT03823287|Experimental|Faricimab|
9482132|NCT03823287|Active Comparator|Aflibercept|
9482133|NCT03822832|Experimental|Spesolimab|i.v.
9482134|NCT03822832|Placebo Comparator|Placebo|i.v.
9482135|NCT03821402|Experimental|DAXI for injection dose LOW DOSE|LOW dose group
9482136|NCT03821402|Experimental|DAXI for injection dose MEDIUM DOSE|MEDIUM dose group
9482137|NCT03821402|Experimental|DAXI for injection Dose HIGH DOSE|HIGH dose group
9482138|NCT03821402|Placebo Comparator|Placebo|Placebo group
9482139|NCT03820323|Other|Standard of Care|Participants in the Standard-of-Care control arm will receive laboratory based VL testing based on the existing Kenyan national guidelines by routine clinical staff (not study staff). DRM testing is usually done if there is a failing 2nd line ART regimen based on the current Kenyan guideline.
9482140|NCT03820323|Experimental|Intervention|POC VL and targeted DRM testing.
9482141|NCT03818828|Experimental|TTAX01|TTAX01 will be applied directly to the wound surface and fixed with sterile adhesive strips, plus a secondary foam dressing held in place by multi-layer compression bandaging. A single layer of the test article should cover the entire open surface of the wound. TTAX01 may overlap onto adjacent healthy tissue and must be fenestrated prior to or after fixture. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case product will be withheld; or, if the test article has been accidentally dislodged within 1-week post application, it may be replaced at the subsequent treatment visit.
9482142|NCT03811912|Experimental|CTP-543 QD Dose Regimen|Oral tablet for 24 Weeks
9482143|NCT03811912|Experimental|CTP-543 BID Dose Regimen|Oral tablet for 24 Weeks
9482144|NCT03806933|Experimental|NT 201 Dose group 1|Stage 1 and 2. Intramuscular injection into the glabellar area.
9482145|NCT03806933|Experimental|NT 201 Dose group 2|Stage 1. Intramuscular injection into the glabellar area.
9482146|NCT03806933|Experimental|NT 201 Dose group 3|Stage 1. Intramuscular injection into the glabellar area.
9482147|NCT03806933|Experimental|NT 201 Dose group 4|Stage 2. Intramuscular injection into the glabellar area.
9482148|NCT03806933|Experimental|NT 201 Dose group 5|Open Label Extension Period. Intramuscular injection into the glabellar area.
9482149|NCT03806296|Experimental|Manipulation|"For ~2 weeks, participants will be asked to adhere to the following:~Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration)~Decrease evening blue light exposure via blue blocker goggles (2 h before bed)~Increase morning bright light exposure via bright light goggles (30 m after rise)~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
9482150|NCT03806296|Active Comparator|Control|"For ~2 weeks, participants will asked to adhere to the following:~- Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
9482151|NCT03806179|Experimental|Betalutin with rituximab treatment|Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
9482152|NCT03805711|Experimental|Aortic Valve Replacement with HLT® Transcatheter System|Replacement of aortic valve using the HLT® Transcatheter System (HLT System) comprised of The Meridian® II Valve with TriVent™ Anticalcification Treatment and The Pathfinder® II Delivery System
9482153|NCT03804853|Experimental|Immediate Active Shoulder Rehabilitation|
9482154|NCT03804853|Active Comparator|Traditional Should Rehabilitation|
9804159|NCT01734161|Active Comparator|Dexamethasone|One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
10058333|NCT02017548|Experimental|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
9804160|NCT01734161|Placebo Comparator|Placebo|One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
9497727|NCT03472404|Experimental|Intervention Group|Internal Brace augmented ankle Ligament reconstruction
9497728|NCT03472404|Active Comparator|Control Group|Brostrom-Gould ankle Ligament reconstruction
9497729|NCT03472391|Active Comparator|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
9497730|NCT03472391|No Intervention|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
9497731|NCT03472378|Experimental|Active Treatment Group|DFN-15
9497732|NCT03472378|Placebo Comparator|Placebo Group|
9497733|NCT03472365|Experimental|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd.
9497734|NCT03472365|Experimental|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continous oral. Study treatment will be started on Day 1 of each 3-week cycle.
9497735|NCT03472352|Experimental|Single Arm|The subjects will be given an anticancer medication (A01) and immune cells (IC01).
9497736|NCT03472339|Experimental|Group A|diclofenac sodium75 mg, intravenously, once
9497737|NCT03472339|Active Comparator|Group B|diclofenac sodium 100 mg, orally, once
9497738|NCT03472313|Experimental|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-958.
9497739|NCT03472300||Frederiksberg Citizens|All citizen in the Frederiksberg Community aged 60-69
9497740|NCT03472261|Experimental|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
9497741|NCT03472261|Active Comparator|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
9497742|NCT03472248|Experimental|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
9497743|NCT03472235|Active Comparator|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
9497744|NCT03472235|Active Comparator|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
9497745|NCT03472222|Experimental|Arsha Vidya Program|Arsha Vidya outreach community program was conducted with children. An unique well-planned teaching program developed to educate Indian cultural values & heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays.
9497746|NCT03472209||Group A|ETCO2=26-35 mmHg
9497747|NCT03472209||Group B|ETCO2=36-45 mmHg
9497748|NCT03472196|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
9497749|NCT03472183|Other|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
9497750|NCT03472183|Other|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
9497751|NCT03472183|Other|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
9497752|NCT03472170|Experimental|Experimental Arm|"The nutritional supplement used will be bovine lactoferrin, a product marketed according to the regulations of the European Union, and approved by the European Food Safety Agency (EFSA) in 2012, and by the American Agency for Food and Drug Administration ( FDA) in 2013. It will be acquired after purchase from Dicofarm® (Rome, Italy).~The Hospital Pharmacy Service will provide the established dose of lactoferrin, according to the administration schedule of 150 mg / kg / day (maximum 300 mg / day).~The treatments will be administered in liquid form, in the least amount possible. The administration of lactoferrin will be carried out enterally, orally or by nasogastric tube.~The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
9497753|NCT03472170|Placebo Comparator|Control Arm|"Placebo with similar visual and taste characteristics to the nutritional supplement of bovine lactoferrin.~It will be administered in liquid form, in the least amount possible. The administration of placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
9533410|NCT03167372|Experimental|Bright white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of bright white light and dim red light; alternating bright white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 bright white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
9533411|NCT03167372|Active Comparator|Dim white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of dim white light and dim red light; alternating dim white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 dim white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
9533412|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
9533413|NCT03167385|Experimental|Experitmental|Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.
9533414|NCT03167398|Experimental|CRE carriers|Fecal Microbiota Transplantation
9533415|NCT03167580|Experimental|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
9533416|NCT03167580|Active Comparator|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 cm H2O) after intubation and during all mechanical ventilation.
9533417|NCT03167268|Experimental|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
9533418|NCT03167268|Placebo Comparator|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
9533419|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
9533420|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
9533421|NCT03167294|Other|Single Arm|AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH
9533422|NCT03167528|Experimental|Lung transplant|"Patients who must undergo a lung transplant at the FOCH hospital.~Before and after transplantation, patients benefits of learning and realization sessions of complementary techniques:~Relaxation,~Hypnosis,~Holistic gymnastics,~Transcutaneous electrical nerve stimulation (TENS),~Sophrology."
9533423|NCT03167567|Experimental|intervention|These women will have a medical clown present in the room during their labor
9533424|NCT03167567|No Intervention|Control|These women will not have a medical clown in the room during their labor
9533425|NCT03167502|Active Comparator|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
9533426|NCT03167502|Experimental|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
9533427|NCT03167515|Experimental|074-6751 Lotion|
9533428|NCT03167307|Experimental|Omega-3 fatty acid oil|A daily dose of 500mg EPA/ 250mg DHA in the 8 to <13 year olds, and 1000mg EPA / 500mg DHA in the 13 to <18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
9533429|NCT03167307|Placebo Comparator|Placebo oil|Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
9533430|NCT03167606|Experimental|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile for the next three months.
9533431|NCT03167606|Experimental|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile and will be asked to complete their surveys every 3 months and return to the study site in 9 months for a follow-up visit (at which time they will receive the MyPEEPS Mobile intervention).
9533432|NCT03167463|Experimental|choanoplasty with flap|flap surgery
9533433|NCT03167216|Experimental|Treatment arm|Treated arm with cromolyn sodium and cetirizine hydrochloride
9533434|NCT03167190|Other|Control|Traditional landmark-based lumbar puncture technique by palpation
9533435|NCT03167190|Experimental|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
9533436|NCT03167008||idiopathic male infertility|"total of 30 male patients with idiopathic male infertility.~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
9533437|NCT03167008||fertile male group|"total of 30 fertile male (as control)~Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
9533438|NCT03166969|Experimental|Patients taken care in neurovascular unit|
9533439|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
9533440|NCT03166956|Experimental|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
9533441|NCT03166956|Placebo Comparator|Control (C) group|"Placebo:~Subjects in the C group received isocaloric maltodextrin as placebo."
9533442|NCT03167125|Active Comparator|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
9533443|NCT03167125|Active Comparator|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
9533444|NCT03167125|No Intervention|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
9533445|NCT03167164|Experimental|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
9533446|NCT03167086|Experimental|Single Session Skills-Based Pain Psychology Class|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention for chronic pain."
9533447|NCT03167086|Active Comparator|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
9533448|NCT03167086|Active Comparator|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (ER) on 4 important factors: duration, structure, format and site.
9533449|NCT03166943|Experimental|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
9533450|NCT03166943|Active Comparator|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
9533451|NCT03166891|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
9533452|NCT03167112|Experimental|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
9533453|NCT03167034|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
9533454|NCT03167034|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
9533455|NCT03167177|Experimental|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
9533456|NCT03167047|Active Comparator|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).~Patients will also receive standardised pain relief of paracetamol and fentanyl"
9533457|NCT03167047|Active Comparator|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.~Patients will also receive standardised pain relief of paracetamol and fentanyl"
9533458|NCT03166995|Experimental|Experimental group 1|Low impact aerobic exercise group. 1hour, twice a week
9533459|NCT03166995|Experimental|Experimental group 2|Postural exercises group. 1hour, twice a week
9533460|NCT03166995|No Intervention|Control propriocepcion|No exercise, just proprioceptive control.
9533461|NCT03166709|Active Comparator|Treatment As Usual|Intensive Outpatient Program (IOP) addiction treatment
9533462|NCT03166709|Experimental|Experimental|Secondary Prevention Intervention (PARS) plus Treatment as Usual
9533463|NCT03166904|Experimental|AZD2014|Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle
9533464|NCT03166917|Experimental|3D printing implant|3D printing implant in bone defect
9533465|NCT03166917|Placebo Comparator|Autogenous bone grafting|autogenous bone grafting in bone defect
9533466|NCT03167060|Active Comparator|Active Rhinochill|Intranasal cooling device , using nasal cannula
9533467|NCT03167060|Sham Comparator|Control Rhinochill|Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)
9533468|NCT03166878|Experimental|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
9533469|NCT03167099|Experimental|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
9533470|NCT03167099|No Intervention|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
9533471|NCT03166683|Experimental|Hemopatch|Use of hemopatch like a control of bile leakage/sealant during liver resection surgery.
9533472|NCT03166683|Active Comparator|Standard of care|Application of standards of care, may include other sealant / hemostatic devices as patches or liquid/gels, during liver resection surgery.
9533473|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
9533474|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
9533475|NCT03166852|Experimental|Home-training group|High-intensity training at home 3 times/week for 5 weeks
9533476|NCT03166644|Experimental|Control Group|Patients with major abdominal surgery
9533477|NCT03166644|Experimental|Intervention Group|Patients with standard practice
9533478|NCT03166748|Active Comparator|MTA pulpotomy|mineral trioxide aggregates (MTA) is accepted as an optimum material for use in vital pulp therapy of permanent teeth
9804161|NCT01734239|Experimental|Pneumovax™ 23: Participants Between 2 and 49 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
10038429|NCT01834430|Experimental|EN group|The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 ~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 ~ 80 ml/h. On the third day, tube feeding utilized 1500 ~ 2000 ml with the speed of 100 ~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
9533479|NCT03166748|Experimental|Potassium Nitrate in Polycarboxylate cement|Potassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol [ZOE]) It reduced pain following full crown preparation.
9533480|NCT03166670||study group|children with acute secretory diarrhea
9533481|NCT03166670||Control group|normal healthy children
10038430|NCT01834430|No Intervention|parenteral nutrient group|
10038431|NCT01834443|Experimental|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
10038432|NCT01834443|Experimental|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
9533482|NCT03166839||Region 1: Africa|Women living in and experiencing PPH in countries located in Africa.
9533483|NCT03166839||Region 2: Asia|Women living in and experiencing PPH in countries located in Africa.
9533484|NCT03166839||Region 3: Europe, NA, SA, Aus|Women living in and experiencing PPH in countries located in Africa.
9533485|NCT03166865|Experimental|Intervention group|Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
9533486|NCT03166865|Other|Control group|Intraarticular injection of hyaluronic acid
9533487|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
9533488|NCT03166982|Experimental|laparoscopy|the tubo-ovarian abscess should be drained by interventional radiology, preferably by transvaginal or laparoscopic
9533489|NCT03166982|Experimental|ultrasound-guided puncture|The transvaginal echo guided puncture to replace the first laparoscopy because of its less invasive nature, this is a simple act, fast, possible under mild sedation, the cost is still lower than laparoscopy
9533490|NCT03166813|Experimental|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
9533491|NCT03166813|Placebo Comparator|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
9615759|NCT05225961|Experimental|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 10 ml (500 micrograms) of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters).
9615760|NCT05225961|Active Comparator|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. One vial of ASPIRINA ® in not more than 250 ml in 0.9% sodium chloride solution, 5% and 10% glucose solution, Ringer's solution or lactated Ringer's. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial.
9615761|NCT05225948|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
9615762|NCT05225948|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization. Besides, the patients will be treated with standard medical treatment according to consensus on diagnosis and treatment of cerebral small vessel disease in China 2015, including antiplatelet aggregation and lipid-stabilizing drugs as well as neurotrophic and circulation improving treatment.
9615763|NCT05225922|Experimental|Experimental|Communication Partner Training:The group will receive usual care in addition to a CPT program, which will consist of face-to-face education and counselling sessions, a manual and telephone support.
9615764|NCT05225922|Active Comparator|Comparison Group|This group will receive usual speech therapy sessions.
9615765|NCT05225909||Patients who Undergo ERCP procedure with aScope|This will be patients who undergo ERCP procedure using aScope.
9615766|NCT05225896||DNER ataxia|Patients with well-characterized DNER antibodies.
9615767|NCT05225883||Autoimmune encephalitis and paraneoplastic neurological syndromes|Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens
9804162|NCT01734239|Experimental|Pneumovax™ 23: Participants >=50 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
10038433|NCT01834443|Sham Comparator|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
10058334|NCT02017548|No Intervention|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
10058335|NCT02017561|Active Comparator|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
9533492|NCT03167138|Experimental|Autologous micro-fragmented adipose tissue|Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems® system.
9533493|NCT03166787|Experimental|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
9533494|NCT03166787|Experimental|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
9533495|NCT03166787|Experimental|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
9533496|NCT03166800|Placebo Comparator|Placebo|20 subjects will receive placebo.
9533497|NCT03166800|Active Comparator|20mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
9533498|NCT03166800|Active Comparator|40mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
9533499|NCT03166241|Experimental|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
9533500|NCT03166241|Placebo Comparator|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
9533501|NCT03166254|Experimental|Cohort A: Stage IV squamous NSCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
9533502|NCT03166254|Experimental|Cohort B: Extensive stage SCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
9533503|NCT03166306|Experimental|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with [89Zr]-bevacizumab.
9533504|NCT03166306|Experimental|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with [89Zr]-bevacizumab.
9533505|NCT03166306|Active Comparator|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with [89Zr]-bevacizumab.
9533506|NCT03166228|Active Comparator|normal saline0.9%|0.9% saline distension media is used as long as diathermy is not in use
9533507|NCT03166228|Placebo Comparator|1.5% GLYCINE|1.5% GLYCINE DURING OPERATIVE HYSTEROSCOPY as long as diathermy is in use
9533508|NCT03166566|Other|laminar drainage implant surgery|patients included and operated
9533509|NCT03166462|No Intervention|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
9533510|NCT03166462|Experimental|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
9533511|NCT03166293|Experimental|Immediate Group|Children will participate in intensive leg training with a physical therapist 1 hour/day, 4 days/week for 12 weeks. Children will continue to receive standard physical therapy care. Children will be followed for one year from the time of enrollment in the study.
9533512|NCT03166293|Experimental|Delay Group|Children will be monitored for 3 months with no intervention. Children will participate in intensive leg training with a physical therapist after the 3 month delay period. Training will be 1 hour/day, 4 days/week for 12 weeks. They will continue to receive standard care throughout. Children will be followed for one year from the time of enrollment in the study.
9533513|NCT03166540|Experimental|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
9533514|NCT03166540|Experimental|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
9533515|NCT03166540|Experimental|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
9533516|NCT03166605|No Intervention|Control|"First group: Control~Follow the current standard protocol used at Albany Medical Center that includes:~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period"
9533517|NCT03166605|Sham Comparator|Sham|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
9533518|NCT03166605|Experimental|Experiment|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing.~Receive 3 ml simethicone 1 hours after capsule swallowing~Receive 1.5 ml simethicone 2 hours after capsule swallowing~Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
10038434|NCT01834456|Experimental|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
9533519|NCT03166384|Active Comparator|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.~interventions: 'conventional suture and tie'"
9533520|NCT03166384|Experimental|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.~interventions: electrosurgical bipolar sealing devices"
9533521|NCT03166553|Experimental|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
9533522|NCT03166553|No Intervention|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
9533523|NCT03166280||hepatitisC-pre-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis before receiving their treatment
9533524|NCT03166280||hepatitis C-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis- 12 weeks after stoppage their treatment of sofosbuvir 400 mg/day plus Daclatasvir 60 mg/day for 12 weeks.
9533525|NCT03166397|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
9533526|NCT03166423|Experimental|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
9533527|NCT03166423|Experimental|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
9533528|NCT03166527|Other|Open Label study|open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
9533529|NCT03166514|Experimental|Commercially Available Food Bar|62 g. Fitjoy Bar
9533530|NCT03166514|Placebo Comparator|Placebo|25 g. Dextrose
9533531|NCT03166501|Experimental|Treatment|Lanicemine 100mg Intravenous
9533532|NCT03166501|Placebo Comparator|Placebo|Normal saline Intravenous
9533533|NCT03166579|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
9533534|NCT03166449|Experimental|Neomune|18 patients with traumatic brain injury were given Neomune as enteral nutrition.
9533535|NCT03166449|Active Comparator|Fresubin® HP energy|18 patients with traumatic brain injury were given Fresubin® HP energy as enteral nutrition.
9533536|NCT03166436|Experimental|RFA plus stenting|Endoluminal radiofrequency ablation followed by biliary stenting
9533537|NCT03166436|Active Comparator|Stenting alone|Biliary stenting alone
9533538|NCT03166358|Experimental|hatha yoga intervention|Participants randomized to the intervention are asked to attend 8 hatha yoga classes delivered in a group format.
9533539|NCT03166358|No Intervention|waitlist control|Participants randomized to the waitlist control condition complete assessments while the intervention group completes the yoga intervention. They are given the option to complete 8 hatha yoga classes delivered in group format once the waitlist period is finished.
9533540|NCT03166410|Experimental|Cell Treatment|
9533541|NCT03166488|Experimental|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
9533542|NCT03166345|Experimental|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
9533543|NCT03166345|Experimental|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
9533544|NCT03166345|No Intervention|No intervention|The control arm.
9533545|NCT03166475|Experimental|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury & Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
9533546|NCT03166475|Experimental|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
9533547|NCT03166475|Experimental|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
9533548|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
9533549|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
9533550|NCT03166189|Experimental|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
9533551|NCT03166189|Active Comparator|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
9533552|NCT03165838|Experimental|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
9533553|NCT03165838|Experimental|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
9533554|NCT03165864|Experimental|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
9533555|NCT03165864|Placebo Comparator|Placebo|Saline .9%
9533556|NCT03166111|Experimental|lidocaine group|lidocaine in-situ gel inserted vaginally
9533557|NCT03166111|Placebo Comparator|placebo group|placebo gel inserted vaginally
9533558|NCT03166137|Experimental|Carbon dioxide laser group|(group A): thirty patients will be treated by application of carbon dioxide laser.
9533559|NCT03166137|Active Comparator|Cryotherapy group|(group B): thirty patients will be treated by cryotherapy application.
9533560|NCT03166059|Experimental|Single arm|CaveoVasc® Thrombolysis Protection System
9533561|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
9533562|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome [Ph1]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
9533563|NCT03165812|Experimental|SADJB-SG group|Patients in this group will undergo bariatric surgery. There are two parts to this procedure. One is the restrictive type of weight loss surgery, which reduces the stomach size. The other type prevents the body from absorbing fats and sugar properly, as the small intestine will be attached to the small stomach, bypassing most of the stomach and upper part of the small intestine. This surgery will be performed using a minimally invasive technique known as laparoscopic keyhole surgery.
9533564|NCT03165812|Experimental|IMT group|Patients in this group will be subjected to strict adherence to diet, optimisation of diabetic medications and close monitoring of blood glucose and HbA1c.
9533565|NCT03165877|Experimental|Low-glycemic index|Low-glycemic index lunches and dinners (<55%)
9533566|NCT03165877|Active Comparator|Control|Medium/high glycemic index lunches and dinners (>60%)
9533567|NCT03165890|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
9533568|NCT03165890|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
9804163|NCT01734317|Experimental|Dressing|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
9533569|NCT03166007|Experimental|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
9533570|NCT03166007|Active Comparator|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
9533571|NCT03165942|Experimental|Alcoholic Beverage|Participants will complete an MRI and oral alcohol session.
9533572|NCT03165942|Placebo Comparator|Non-Alcoholic Beverage|Participants will complete an MRI and oral non-alcoholic session.
9533573|NCT03166163|Experimental|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
9533574|NCT03166163|Active Comparator|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
9533575|NCT03166020|Experimental|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
9533576|NCT03166020|Active Comparator|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
9533577|NCT03166072|Active Comparator|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
9533578|NCT03166072|Placebo Comparator|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
9533579|NCT03166150|Experimental|Multi-modal rehabilitation program|12 weeks of various exercises
9533580|NCT03166150|Active Comparator|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
9533581|NCT03166046|Active Comparator|Study Group|Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
9533582|NCT03166046|Placebo Comparator|Control Group|Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
9533583|NCT03165929|Active Comparator|flurbiprofen-free gingival graft|
9533584|NCT03165929|Placebo Comparator|placebo-free gingival graft|
9533585|NCT03165929|Active Comparator|flurbiprofen-connective tissue graft|
9533586|NCT03165929|Placebo Comparator|placebo-connective tissue graft|
9533587|NCT03165799|Experimental|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
9533588|NCT03165799|No Intervention|No Intervention|Participants did not receive mindfulness education.
9533589|NCT03165903|Experimental|Cue and Implementation-Intention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption.
9533590|NCT03165903|Other|Control Arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message.
9533591|NCT03165825|Experimental|Tranforaminal|will receive cervical epidural injection via a transforaminal route with dexamethasone steroid
9533592|NCT03165825|Active Comparator|Interlaminar|will receive cervical epidural injection via an interlaminar route with betamethasone steroid
9533593|NCT03165786|Experimental|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
9533594|NCT03165786|No Intervention|Control Group|Real-time continuous glucose monitoring
9533595|NCT03165773|Experimental|Oatmeal|87 grams oatmeal
9533596|NCT03165773|Active Comparator|Corn grits|67 grams corn grits
9533597|NCT03165643||NGT-normal birth weight|
9533598|NCT03165643||NGT-macrosomia|
9533599|NCT03165643||GDM-normal birth weight|
9533600|NCT03165643||GDM-macrosomia|
9533601|NCT03165630|No Intervention|Group 1|Education or Control group.
9533602|NCT03165630|Experimental|Group 2|Transportation incentives
9533603|NCT03165630|Experimental|Group 3|Transportation and rehabilitation services incentives
9533604|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
9533605|NCT03165695|Experimental|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
9533606|NCT03165695|Placebo Comparator|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
9533607|NCT03165760|No Intervention|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
9482160|NCT03802201|Experimental|PTG-300 Active|Drug: PTG-300 Subcutaneous
9482161|NCT03799627|Experimental|Vadadustat|The initial dose of vadadustat (300, 450, or 600 milligrams [mg]) will be based upon the dose of epoetin alfa dose participants had received prior to vadadustat treatment
9482162|NCT03799627|Experimental|Vadadustat TIW|Participants randomized to vadadustat (Main and erythropoiesis-stimulating agent [ESA] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing
9482163|NCT03799627|Active Comparator|Epoetin alfa|Epoetin alfa
9482164|NCT03798743|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
9482165|NCT03797963|Active Comparator|PBM+ACB|Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone
9482166|NCT03797963|Experimental|ABB+ACB|Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone
9482167|NCT03797521|Experimental|SXC-2023 50mg QD|SXC-2023 50mg dosed once daily for 6 weeks
9482168|NCT03797521|Experimental|SXC-2023 200mg QD|SXC-2023 200mg dosed once daily for 6 weeks
9482169|NCT03797521|Experimental|SXC-2023 800mg QD|SXC-2023 800mg dosed once daily for 6 weeks
9482170|NCT03797521|Placebo Comparator|Matching Placebo QD|Matching Placebo dosed once daily for 6 weeks
9482171|NCT03796637|Experimental|nmDMD Participants|Participants who have been receiving ataluren, will be dosed daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for >=9 months from ongoing PTC-sponsored nmDMD clinical trials.
9482172|NCT03795922|Experimental|MT10109L|MT10109L will be injected into the GL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
9482173|NCT03795922|Placebo Comparator|Placebo|Placebo will be injected into the GL: initial double-blind treatment on Day 1.
9482174|NCT03794882|Experimental|QLB + Medical Management|Subjects will undergo Intervention: Procedure/Surgery: Quadratus Lumborum Block and receive Intervention: Procedure: Standard Medical Management as needed.
9482175|NCT03794882|Active Comparator|Standard Medical Management|Subjects will receive Intervention: Procedure: Standard Medical Management as needed.
9482176|NCT03793478|Experimental|All Participants|All participants will receive re-induction therapy that includes fludarabine and cytarabine in combination with experimental drug quizartinib. For prophylaxis, IT chemotherapy with cytarabine, methotrexate and prednisolone/hydrocortisone will be given prior to or between re-induction cycles. After completing re-induction therapy, eligible participants may also receive optional consolidation chemotherapy which includes cytarabine, etoposide and quizartinib, if HSCT is not available immediately. After completing re-induction or HSCT successfully, eligible participants can go on to receive continuation therapy with quizartinib.
9482177|NCT03792555|Experimental|Paltusotine|
9482178|NCT03792555|Placebo Comparator|Placebo|
9482179|NCT03789656|Experimental|Paltusotine|
9482180|NCT03788967|Experimental|TBPM-PI-HBr 300 mg film-coated tablets|TBPM-PI-HBr 600 mg administered orally three times per day for 7 to 10 days.
9482181|NCT03788967|Active Comparator|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 10 days.
9482182|NCT03786770|Experimental|Cohort 1: Dose A|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
9482183|NCT03786770|Experimental|Cohort 2: Dose B|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
9482184|NCT03786770|Experimental|Cohort 3: Dose C|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
9482185|NCT03786770|Experimental|Cohort 4: Dose D|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
9482186|NCT03785743|Experimental|TLPD|Total laparoscopic pancreaticoduodenectomy for pancreatic cancer
9482187|NCT03785743|Experimental|OPD|Open pancreaticoduodenectomy for pancreatic cancer
9482188|NCT03785145|Experimental|MT10109L|MT10109L will be injected into the LCL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
9482189|NCT03785145|Placebo Comparator|Placebo|Placebo will be injected into the LCL: initial double-blind treatment on Day 1.
9482190|NCT03783923|Experimental|Deflazacort|Participants will receive deflazacort 0.6 milligrams per kilograms per day (mg/kg/day) orally. The dose could be reduced in case of tolerability issues. Any participant assigned to placebo prior to the Version 4.0 amendment (prior to or after 01 February 2020) will have the option to be consented under Version 4.0 and will be switched to deflazacort for 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (prior to 01 February 2020) will have the option to re-consent under Protocol Version 4.0 and continue for an additional 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (after 01 February 2020) will have the option to re-consent under Protocol Version 4.0 at their Week 13 Visit and continue treatment until Week 26. Any new participant enrolled until 31 May 2020 will receive deflazacort for 26 weeks.
9482191|NCT03782103|Experimental|Zurex Prep (70% IPA)|Isopropyl alcohol (IPA) 70%
9482192|NCT03782103|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
9482193|NCT03782103|Placebo Comparator|Zurex Prep Vehicle|Zurex Prep without IPA
9482194|NCT03780244|Experimental|Investigational Study Product|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection (SWFI)
9482195|NCT03780244|Active Comparator|Reference Product|Injection with Sculptra Aesthetic reconstituted with 5ml SWFI
9533608|NCT03165760|Experimental|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
9533609|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
9533610|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
9533611|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
9533612|NCT03165344|Experimental|hydrocortisone group|
9533613|NCT03165344|Placebo Comparator|prednisone grope|
9533614|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
9533615|NCT03165357|Experimental|Sodium bicarbonate|"Group taking oral NaHCO3 supplementation in a progressive-dose regimen.~Interventions:~The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
9533616|NCT03165357|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin).~Interventions:~The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
9533617|NCT03165435|Experimental|CV-MG01|The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
9533618|NCT03165435|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
9533619|NCT03165383|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
9533620|NCT03165383|Placebo Comparator|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
9533621|NCT03165331|Other|Intervention group|The intervention group will go through the intervention programme (Ung Face IT) after T1 and randomisation. Programme takes 7 weeks to complete + Treatment as usual (local health care services). Questionnaires after the 7 weeks (T2) and after three months (T3) and 6 months (T4).
9533622|NCT03165331|Other|Control group|Treatment as usual for three months after T1 and randomisation, with local health care support if needed. Questionnaires at T2 and T3 before participants are given access to the intervention (Ung Face IT) after three months. Questionnaire at T4 (post-intervention).
9533623|NCT03165474|Active Comparator|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
9533624|NCT03165474|Experimental|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
9533625|NCT03165578|Experimental|Neurofeedback|Neurofeedback training.
9533626|NCT03165578|Sham Comparator|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
9533627|NCT03165565|Experimental|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
9533628|NCT03165565|Active Comparator|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
9533629|NCT03165591|Experimental|Experimental|Daily tablet of V3-P given orally for 2 months
9533630|NCT03165500|Active Comparator|Diazepam|Sedation of the anxious patient with diazepam 5 mg for measuring vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
9533631|NCT03165500|Active Comparator|Midazolam|Sedation of the anxious patient with midazolam 7.5 mg for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
10058336|NCT02017561|Experimental|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
9533632|NCT03165500|Active Comparator|Nitrous Oxide + Oxygen Gas|Inhaled sedation of the mixture of 40% of nitrous oxide and 60% of oxygen gas for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
9533633|NCT03165396|Experimental|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining
9533634|NCT03165396|Experimental|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
9533635|NCT03165396|Experimental|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
9533636|NCT03165396|Experimental|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
9533637|NCT03165656||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
10038435|NCT01834456|No Intervention|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~The control group will continue to receive usual care as they did before they enrolled in this study"
10038436|NCT01834469|Other|ICG NIR imaging|see Summary and description iv injection of ICG
9533638|NCT03165656||High altitude control|Healthy highlanders living above 2500 m.
9533639|NCT03165656||Low altitude control|Healthy lowlanders living below 1000 m.
9533640|NCT03165253|Active Comparator|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
9533641|NCT03165253|Other|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
9533642|NCT03165669|Experimental|Cervical pillow|"The cervical pillow is known as the Viscospring PostuRite - medium model, made by SOFF-ART S.r.l. - Via Maestri del Lavoro 49 - 05100 Terni, Italy. The Viscospring PostuRite pillow is externally made of viscoelastic polyurethane and internally 60 independent, individually coated harmonic phosphate-coated steel springs, are thought to promote correct posture of the cervical spine, due to the adaptation of the pillow to the shape and movements of the head.~Each intervention will be supported by a 30-minutes informative session delivered by a physical therapist, and will be completed by the delivery of an informative brochure."
9533643|NCT03165669|Active Comparator|Education|The educational intervention will be conducted by a physical therapist and will consist of a advice on positions, movements and activities recommended or not recommended for people with chronic neck pain, both in the workplace and in leisure time, including nighttime postures. Each educational intervention will be carried out individually, will last half an hour and will be supported by the delivery of an informative brochure.
9533644|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
9533645|NCT03165487||Triple Negative Breast Cancer|triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
9533646|NCT03165513|Experimental|Experimental arm|mhGAP-IG psychosocial intervention
9533647|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
9533648|NCT03165123|Placebo Comparator|placebo group|The patients will receive oral placebo tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
9533649|NCT03165123|Active Comparator|Azithromycin group|The patients will receive 250 mg oral Azithromycin tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
9533650|NCT03165604|Active Comparator|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
9533651|NCT03165604|Active Comparator|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
9533652|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
9533653|NCT03165214|Active Comparator|coil group|micro coils
9533654|NCT03165214|Experimental|glue group|hystoacryl mixed with lipidol
9533655|NCT03165162|Experimental|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
9533656|NCT03165422||Adult patients with melanoma|Adult patients with melanoma at participating centers in Japan
9533657|NCT03165552|Experimental|Educational Arm|This group will receive an acute kidney injury educational intervention
9533658|NCT03165032||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
9533659|NCT03165032||High altitude control|Healthy highlanders living above 2500 m.
9533660|NCT03165032||Low altitude control|Healthy lowlanders living below 1000 m.
9533661|NCT03165149|Active Comparator|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
9533662|NCT03165149|Active Comparator|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
10038437|NCT01834482|Active Comparator|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
9533663|NCT03165149|Active Comparator|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
9533664|NCT03165227|Experimental|BI 685509 Dose 1|
9533665|NCT03165227|Experimental|BI 685509 Dose 2|
9533666|NCT03165227|Experimental|BI 685509 Dose 3|
9533667|NCT03165227|Placebo Comparator|Placebo|
9533668|NCT03165240|Experimental|BI 690517 Dose 1|
9533669|NCT03165240|Experimental|BI 690517 Dose 2|
9533670|NCT03165240|Experimental|BI 690517 Dose 3|
9533671|NCT03165240|Experimental|Eplerenone|
9533672|NCT03165240|Placebo Comparator|Placebo|
9533673|NCT03165071|Experimental|ACT-132577 (50 mg)|8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast
9533674|NCT03165097|Experimental|ACT-709478|"40 subjects will receive multiple doses of ACT-709478 at the planned dose levels of 30, 60, 100, and 200 mg.~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
9533675|NCT03165097|Placebo Comparator|Placebo|Matched placebo administered accordingly
9533676|NCT03165097|Other|Midazolam|4 mg taken by mouth on Day 1 of the corresponding cohort
9533677|NCT03165097|Experimental|ACT-709478 combined with Midazolam|On Day 22 and Day 30, midazolam (4 mg) and ACT-709478 (60 mg or 100 mg) to be co-administered.
9533678|NCT03165084|Experimental|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
9533679|NCT03165084|Other|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
9533680|NCT03165084|Other|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
9533681|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
9533682|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
9533683|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
9615768|NCT05225870|Other|patients with colorectal carcinoma|patients with colorectal carcinoma will undergo colectomy. their colectomy specimens will be sectioned, tissue blocks will be prepared from tumor and adjacent normal mucosa. sections will be stained immunohistochemically by antibody against cortactin.
9615769|NCT05225844|Experimental|Camrelizumab Plus Apatinib mesylate|for advanced gastric cancer with previous standard treatment failure
9615770|NCT05225844|Experimental|Camrelizumab and Apatinib mesylate|for advanced colorectal cancer with previous standard treatment failure
9615771|NCT05225831|Experimental|SL19+22 CAR-T|Eligible patients will be treated with SL19+22 CAR-T.
9615772|NCT05225792|Experimental|Injured Service Members|
9615773|NCT05225779|Active Comparator|sevoflurane|General Anesthesia procedure with sevoflurane
9615774|NCT05225779|Active Comparator|desflurane|General Anesthesia procedure with desflurane
9615775|NCT05225766|Active Comparator|Group ESPB|Erector spinae plane block
9615776|NCT05225766|Active Comparator|Group RSB|Rectus sheath block
9615777|NCT05225753||patients treated with Affixus Zimmer-Biomet|
9615778|NCT05225753||patients treated with EBA2 Citieffe|
9615779|NCT05225753||patients treated with Proximal Femoral Nail Antirotation Synthes|
9615780|NCT05224908|Experimental|pregnant women with a breech fetus|pregnant women with a breech fetus performing standing and sitting EOS pelvimetry
10038438|NCT01834482|Active Comparator|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
9615781|NCT05224492|Experimental|Sulforaphane Group|
9615782|NCT05224492|Placebo Comparator|Placebo Group|
9615783|NCT05213897||30 subjects testing positive for Covid-19|30 subjects testing positive for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay
9615784|NCT05213897||30 subjects testing negative for Covid-19|30 subjects testing negative for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay
9615785|NCT05213637|Experimental|EAL Treatment Group|The patients with primary HCC will receive 12~20 doses of EAL infusion (1×10^9~2×10^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.
9615786|NCT05213637|Active Comparator|Control Group|The patients with primary HCC will receive a single TACE after radical resection.
9615787|NCT05205213||lateral retromuscular preperitoneal group|All patients undergoing open lateral retromuscular preperitoneal repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
9615788|NCT05205213||Reverse TAR group|All patients undergoing open reverse TAR repair through the previous lateral incision for L3-L4 IHs between February 2012 and January 2020
10038439|NCT01834495|Experimental|Balloon expandable stent|study design is 1:1 randomization design. Patients will be randomized in a 1:1 manner according to different two (balloon expandable versus Self expandable)stents. Randomization procedure will be performed using a web-based program
9615789|NCT05205057||Pre-menopausal|Pre-menopausal women
9615790|NCT05205057||Post-menopausal women|post-menopausal women
9621682|NCT02522182|Experimental|Intensive Secondary Prevention Programme|The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
9621683|NCT02522182|Active Comparator|Usual Treatment|The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
9622029|NCT02519322|Experimental|Arm C (nivolumab, relatlimab, surgery)|Patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour on days 1 and 29. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour every 4 weeks for 10 doses in the absence of disease progression or unacceptable toxicity.
9622030|NCT02519257|Experimental|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
9533684|NCT03165292|Experimental|Arm A: High administered activity 131I-mIBG radiolabelled with iodine-131 and Topotecan|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
9533685|NCT03165292|Experimental|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
9533686|NCT03165318|Active Comparator|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
9533687|NCT03165318|Sham Comparator|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
9533688|NCT03165305|Experimental|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
9533689|NCT03165305|No Intervention|No Intervention group|Includes routine neonatal care in the delivery room
9533690|NCT03165006||Screened women with breast cancer|
9533691|NCT03164837|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
9533692|NCT03164876|Experimental|Dose AUT00206 800 mg BD|AUT00206 800mg twice daily for 28 days
9533693|NCT03164876|Placebo Comparator|Placebo|Placebo to match AUT00206 twice daily for 28 days
9533694|NCT03164902|Experimental|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
10038440|NCT01834495|Active Comparator|Self expandable stent|same to Balloon expandable stent
10038441|NCT01834508|Other|Treatment group|
9533695|NCT03164915|Experimental|LIV-GAMMA SN Inj.|
9533696|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
9533697|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
9533698|NCT03164967|Other|Active Drug|All subjects will receive Bivigam based on their prior dosing to be adjusted as clinically necessary.
9533699|NCT03164694|Experimental|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
9533700|NCT03164694|Active Comparator|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
9533701|NCT03164733||<40|patients younger than 40 years
9533702|NCT03164733||40-60|patients younger than 60 years and not older than 40 years
9533703|NCT03164733||60-80|patients younger than 80 years and not older than 80 years
9533704|NCT03164733||>80|patients older than 80 years
9533705|NCT03164746|Active Comparator|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
9533706|NCT03164746|Experimental|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
9533707|NCT03164811|Experimental|GDFT group|The GDFT group will receive 400 ml of 12.5% carbohydrate drink after 6 pm until the bed time in the day before surgery and 200 ml in the morning of the surgery day. Acetate ringer solution will be start at 7:00. After induction PPV will be measure and fluid bolus 200 ml in 10 minutes will be given if PPV >13 before prone position. During the operation, the patient in GDFT group will receipt fluid therapy according to acceptable PPV
9533708|NCT03164811|Other|controlled group|The carbohydrate drink will not be given. Fluid, blood and blood product administration will be under attending anesthesiologist order.
9533709|NCT03164785|Experimental|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
9533710|NCT03164785|No Intervention|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
9533711|NCT03164642|Experimental|LENA with Feedback|Mothers who will run the LENA system with their young children, AND who will receive feedback from their service providers on how to enhance the language the home language environment.
9533712|NCT03164642|Placebo Comparator|LENA no feedback|Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.
9533713|NCT03164590|Active Comparator|ketamine|
10058337|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
10058338|NCT02017600|Experimental|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
9533714|NCT03164590|Active Comparator|dexmedetomidine|
9533715|NCT03164590|Placebo Comparator|bupivacaine|
9533716|NCT03164577|Active Comparator|DARTNA|DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
9533717|NCT03164577|Placebo Comparator|Usual care plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
9533718|NCT03164499|Active Comparator|Control group|Individual counselling on lifestyles.
9533719|NCT03164499|Experimental|Intervention group|Individual counselling on lifestyles and additional group counselling on lifestyles.
9533720|NCT03164603|Experimental|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
9533721|NCT03164668|Other|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
9533722|NCT03164668|Other|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
9533723|NCT03164668|Other|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
9533724|NCT03164668|Other|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
9533725|NCT03164512|Placebo Comparator|Placebo|Placebo oral and vapor
9533726|NCT03164512|Experimental|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
9533727|NCT03164512|Experimental|Vaporized Cannabidiol|100mg cannabidiol in vapor
9533728|NCT03164512|Experimental|Oral Cannabidiol|100mg oral cannabidiol
9533729|NCT03164460|Experimental|Group I (SBRT)|Patients undergo SBRT every other day for a total of 5 treatments.
9533730|NCT03164460|Experimental|Group II (IMRT/IMPT)|Patients undergo IMRT/IMPT once daily (Monday-Friday) for up to 30-35 treatments.
9533731|NCT03164330|No Intervention|Control|The control group takes a baseline survey, and thereafter has minimal interaction with the project, until a follow-up biometric screening is conducted during the one-year follow-up.
9533732|NCT03164330|Experimental|A25|"Group A25 is offered no compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - low compensation"
9533733|NCT03164330|Experimental|A75|"Group A75 is offered no compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - high compensation"
9533734|NCT03164330|Experimental|B25|"Group B25 is offered moderate compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
9533735|NCT03164330|Experimental|B75|"Group B75 is offered moderate compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
9533736|NCT03164330|Experimental|C25|"Group C25 is offered high compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation, Wellness Activities - high compensation"
9533737|NCT03164330|Experimental|C75|"Group C75 is offered high compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation Wellness Activities - high compensation"
9533738|NCT03164421|Experimental|N-Acetylcysteine|N-Acetylcysteine used by clomiphene resistant pcos women
9533739|NCT03164421|Active Comparator|L-carnitine|L-carnitine used by clomiphene resistant pcos women
9533740|NCT03164343|Experimental|Pain Neuroscience Education for children|All participants within this study will receive Pain Neuroscience Education
9533741|NCT03164304|Active Comparator|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
9533742|NCT03164304|Experimental|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
9533743|NCT03164200|Experimental|High fat breakfast|45% fat 35% Carbohydrate 20% protein
9533744|NCT03164200|Experimental|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
9533745|NCT03164213|Experimental|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
9533746|NCT03164213|Sham Comparator|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
9533747|NCT03164187||Diabeton MR 60|
9533748|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
9533749|NCT03164070||Control group|Control group of healthy persons
9533750|NCT03164317|Active Comparator|Intervention|Trained NCC together with electronic decision support system
9533751|NCT03164317|Other|Control|No trained NCC and electronic decision support system
9533752|NCT03164447|Experimental|Multi-Drug Resistant|
10058339|NCT02017613|Experimental|Single arm|RP6530 administered orally
10038442|NCT01834521|Experimental|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
10038443|NCT01834521|No Intervention|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
10038444|NCT01834534|Experimental|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
10038445|NCT01834534|No Intervention|Usual care|Usual medical care.
10038446|NCT01834547|Experimental|Methylphenidate|Methylphenidate
10038447|NCT01834547|Experimental|modafinil|modafinil
9533753|NCT03164382|Experimental|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
9533754|NCT03164382|Active Comparator|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
10038448|NCT01834547|Experimental|caffeine|caffeine
10038449|NCT01834547|Placebo Comparator|placebo|placebo
10038450|NCT01834573|Active Comparator|Intervention|Patients of the intervention arm receive a 10 week exercise program
10038451|NCT01834573|No Intervention|Control|Patients of the control arm do not participate in exercise
10038452|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
9533755|NCT03164148|Experimental|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
9533756|NCT03164122|Experimental|Intra-articular injection|
9533757|NCT03164239|Experimental|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
9533758|NCT03164239|No Intervention|Control group|The control group (CG) were encouraged to continue previous lifestyle.
9533759|NCT03164031|Experimental|Close-fitting orthotic shorts condition|Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
10038453|NCT01834612|Active Comparator|Blood draw|CM1500 with blood draw
10038454|NCT01834612|Sham Comparator|No blood draw|CM 1500 with no blood draw
10038455|NCT01834638|Experimental|ABT-126 low dose|ABT-126 low dose
9533760|NCT03164031|Active Comparator|Looser fitting shorts condition|Looser shorts will be made to measure for each participant, designed to look similar to the orthotic shorts but provide minimal support or compression. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
9533761|NCT03164291|Experimental|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
9533762|NCT03164005||Group 1|subjects without metabolic diseases
9533763|NCT03164005||Group 2|subjects with metabolic diseases
9533764|NCT03164252|Active Comparator|Grupo I- Lower laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 10 J / cm2 fluency, in the immediate period after surgical period of the third molar third molar extraction / impacted by the intraoral region
9533765|NCT03164252|Active Comparator|Grupo II- Greater laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 30J / cm2 fluency, in the immediate period after surgical of the third molar third molar extraction / impacted by the intraoral region
9533766|NCT03164252|Placebo Comparator|Grupo III- Laser sham|Application of laser sham, the handpiece of the device will be positioned intraorally and activated. However, the tip of the applicator will be covered by an opaque material that prevents radiation from passing through.
9533767|NCT03163953|Experimental|TPAG with long break|PA coaching based on TPAG and long break or break 15 minutes for every 2 hours (TPAG with LB)
9533768|NCT03163953|Experimental|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
10038456|NCT01834638|Experimental|ABT-126 middle dose|ABT-126 middle dose
10038457|NCT01834638|Experimental|ABT-126 high dose|ABT-126 high dose
10038458|NCT01834664|Other|STEM CELL|Transfer of autologous stem cell [MNCs ]intrathecally
10038459|NCT01834677||Healthy Human|
10038460|NCT01834677||Depressed Human|
10038461|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
10038462|NCT01834677||Human Diagnosed with Parkinson's Disease|
10038463|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (>=20 years at the date of surgery)
10038464|NCT01834703|Active Comparator|UAE treatment|After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
10038465|NCT01834703|Active Comparator|HIFU|After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
10038466|NCT01834742|Experimental|Part A, arm 1|Evening dose 1 plus fixed morning dose
10038467|NCT01834742|Experimental|Part A, arm 2|Evening dose 2 plus fixed morninf does
10038468|NCT01834742|Experimental|Part A, arm 3|Evening dose 3 plus fixed morning dose
10038469|NCT01834742|Active Comparator|Part A, arm 4|Moviprep
10038470|NCT01834742|Experimental|Part B, arm 1|Fixed evening dose plus morning dose 1
10038471|NCT01834742|Experimental|Part B, arm 2|Fixed evening dose plus morning dose 2
10038472|NCT01834742|Experimental|Part B, arm 3|Fixed evening dose plus morning dose 3
10038473|NCT01834742|Experimental|Part B, arm 4|Fixed evening dose plus alternative morning dose
10038474|NCT01834755|Other|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
10038475|NCT01834768|Experimental|A|Eplerenone
9482196|NCT03778554|Experimental|Beta blocker treatment|"Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice~Bisoprolol up to a total dose of 10 mg daily~Carvedilol up to a total dose of 50 mg daily~Metoprolol succinate up to a total dose of 200 mg daily~Nebivolol up to a total dose of 10 mg daily"
9482197|NCT03778554|No Intervention|No beta blocker treatment|Standard care without beta blocker treatment
9482198|NCT03777917|Experimental|Belotero Balance®|
9482199|NCT03777917|No Intervention|No treatment|
9482200|NCT03777176|Experimental|Standard of Care + dasiglucagon|8 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
9482201|NCT03777176|Other|Standard of Care|4 weeks of standard of care + 4 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
9482204|NCT03775421|Experimental|Open-label treatment period|oral administration of 10 mg macitentan once daily
9482205|NCT03772964|Experimental|500mg exposure|Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
9482206|NCT03772964|Experimental|1000mg exposure|Subjects will be exposed to 1000mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
9482207|NCT03772964|Experimental|1500mg exposure|Subjects will be exposed to 1500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
9482208|NCT03771664|Experimental|SAGE-217|
9482209|NCT03771664|Placebo Comparator|Placebo|
9482210|NCT03771040|Experimental|Masitinib (titration to 6.0 mg/kg/day)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
9482211|NCT03771040|Placebo Comparator|Placebo|Participants receive matched placebo
9482212|NCT03769116|Experimental|SRP-9001 in Part 1 Followed by Placebo in Part 2|Patient will receive SRP-9001 at Part 1 followed by matching Placebo at Part 2 followed by an open-label extension at Part 3.
9482213|NCT03769116|Experimental|Placebo in Part 1 Followed by SRP-9001 in Part 2|Patient will receive matching Placebo at Part 1 followed by SRP-9001 at Part 2 followed by an open-label extension at Part 3.
9482214|NCT03768089|Experimental|Part A: VX-121 in Healthy Subjects (HS)|Single dose escalation.
9482215|NCT03768089|Placebo Comparator|Part A: Placebo|
9482216|NCT03768089|Experimental|Part B: VX-121 in HS|Multiple-dose escalation.
9482217|NCT03768089|Placebo Comparator|Part B: Placebo|
9482218|NCT03768089|Experimental|Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-121 in TC with TEZ/IVA.
9482219|NCT03768089|Placebo Comparator|Part C: Placebo|
9482220|NCT03768089|Experimental|Part D: VX-121 in TC with TEZ/IVA in subjects with CF|VX-121 in TC with TEZ/IVA in subjects with CF.
9482221|NCT03768089|Placebo Comparator|Part D: Placebo|
9482222|NCT03766685|Experimental|Bimekizumab-SS|Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
9482223|NCT03766685|Experimental|Bimekizumab-AI|Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).
9482224|NCT03766295|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
9482225|NCT03766295|Active Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
9482226|NCT03764475|Other|Long-term Safety of ARQ-151|Open Label Long-term Safety of ARQ-151
9482227|NCT03761225|Experimental|Masitinib & docetaxel|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
9482228|NCT03761225|Placebo Comparator|Placebo & docetaxel|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
9482229|NCT03759795|Experimental|Intervention Group|Acceptance and Commitment Training (ACTr)
10038476|NCT01834781|Active Comparator|Pulsed electromagnetic fields|Pulsed electromagnetic fields is applied transcranially 30 minutes twice a day for 7 days a week over 6 consecutive weeks
9533769|NCT03163953|Other|Control|No intervention
9533770|NCT03164096|Experimental|intrathecal bupivacaine|intrathecal bupivacaine hydrochloride 0.5%,12.5mg
9533771|NCT03164109|Experimental|GC4419 IV|
9533772|NCT03164109|Placebo Comparator|Placebo|
9533773|NCT03164109|Active Comparator|Oral moxifloxacin|
9533774|NCT03164083|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
9533775|NCT03164083|Experimental|placebo|The patients who are in control group and underwent placebo injection
9533776|NCT03164135|Experimental|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
9533777|NCT03164395|Experimental|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
9533778|NCT03164395|Active Comparator|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
9533779|NCT03163901|Active Comparator|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
9533780|NCT03163901|Other|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
9533781|NCT03163901|No Intervention|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
9533782|NCT03163901|No Intervention|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
9533783|NCT03163914|Active Comparator|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
9533784|NCT03163914|Active Comparator|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
9533785|NCT03163914|Active Comparator|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
9533786|NCT03163914|Placebo Comparator|Control|Saline infusion will apply at equivalent volume till the surgical operation
9533787|NCT03163654|Active Comparator|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
9533788|NCT03163654|Active Comparator|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
9533789|NCT03163693|Experimental|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
9533790|NCT03163693|Placebo Comparator|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
9533791|NCT03163719||Patients with generalized convulsive seizure|All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.
9533792|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
9533793|NCT03163927|Experimental|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
9533794|NCT03163927|No Intervention|Control|Participants observe a procedure performed by a senior.
9533795|NCT03163823|Placebo Comparator|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
9533796|NCT03163823|Experimental|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
9533797|NCT03163784|Placebo Comparator|Arm A|Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.
9533798|NCT03163784|Experimental|Arm B|Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.
9533799|NCT03163784|Experimental|Arm C|Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.
10038477|NCT01834781|Placebo Comparator|Wearing the inactive device|The inactive device is worn on the head for 30 minutes twice a day for 7 days a week over 6 consecutive weeks
10038478|NCT01834794|Experimental|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
10038479|NCT01834807||Cohort|
10058340|NCT02017626|Experimental|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
10038480|NCT01834820|Experimental|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
9533800|NCT03163810|Experimental|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
9533801|NCT03163979|Active Comparator|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
10038481|NCT01834820|Experimental|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
9533802|NCT03163979|Active Comparator|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
9533803|NCT03163979|Active Comparator|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
9533804|NCT03163979|Sham Comparator|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
9533805|NCT03164161|Active Comparator|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
9533806|NCT03164161|Active Comparator|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
9533807|NCT03164161|Active Comparator|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
9533808|NCT03164161|No Intervention|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
9533809|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes >70 years old, left atrium (LA) diameter >7 cm, or preoperative left ventricle (LV) ejection fraction < 40% and patients falls in these criteria were excluded from this group.
9533810|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
9533811|NCT03163615|Experimental|Tibet Rhodiola Capsule|
9533812|NCT03163615|Placebo Comparator|Placebo oral capsule|
9533813|NCT03163602|Active Comparator|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
9533814|NCT03163602|Active Comparator|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
9533815|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
9533816|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
9533817|NCT03163641|Experimental|Treatment 1|Ocular Bandage Gel
9533818|NCT03163641|Experimental|Treatment 2|Ocular Bandage Gel
9533819|NCT03163641|Active Comparator|Control Group|Artificial tears with Acuvue Oasys
9533820|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
10038482|NCT01834820|Active Comparator|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
10038483|NCT01834833|No Intervention|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
10038484|NCT01834833|Experimental|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
10038485|NCT01834846|Experimental|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
9533821|NCT03163849|Placebo Comparator|control group|oral tablets
9533822|NCT03163849|Experimental|Study group|sofosbuvir , daclatasvir oral tablets
9533823|NCT03163862|Placebo Comparator|Placebo|Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
9533824|NCT03163862|Experimental|G-CSF group|"Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.~The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer"
9533825|NCT03163862|Sham Comparator|Comparative group|patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
9533826|NCT03163706|Experimental|Schizophrenia patients|Patients with DSM-5 criteria of schizophrenia
9533827|NCT03163706|Other|Control group|Control, no schizophrenia
9533828|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:~Full medical History and physical examination~Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration~Abdominal Ultrasound~Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
9533829|NCT03163628|Experimental|7 biomarkers combination|
9533830|NCT03163966|Experimental|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
9533831|NCT03163966|Experimental|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
9533832|NCT03163966|Experimental|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
9533833|NCT03163966|Experimental|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
9533834|NCT03163797||Oropharyngeal cancer|A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
9533835|NCT03163940|Experimental|Laughter Yoga (LY) Group|The LY session will be offered twice weekly, for 45 minutes each time. Each participant will be asked to attend a total of 8 groups (over 4 weeks).
9533836|NCT03163940|No Intervention|Treatment-as-usual (TAU)|The TAU will receive their usual routine community mental health care (including medications) and attend medical outpatient appointments as determined by their individual needs.
9533837|NCT03163589|Experimental|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
9533838|NCT03163589|Placebo Comparator|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
10038486|NCT01834846|Active Comparator|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
10038487|NCT01834859|Experimental|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
9533839|NCT03163524|Experimental|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
9533840|NCT03163524|Sham Comparator|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
9533841|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
9533842|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
9533843|NCT03163277|No Intervention|Standard of care|Continue current antiretroviral regimen
9533844|NCT03163277|Experimental|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
9533845|NCT03163238|Active Comparator|Group D|One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
9533846|NCT03163238|Placebo Comparator|Group S|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
9533847|NCT03163420|Placebo Comparator|Placebo|placebo
9533848|NCT03163420|Experimental|Diclofenac potassium|Diclofenac potassium 50 mg
9533849|NCT03163563||Easywarm|Self warming blanket to prevent perioperative hypothermia
9533850|NCT03163563||BairHugger|Forced-air warming blanket to prevent perioperative hypothermia
9533851|NCT03163290|Experimental|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
9533852|NCT03163290|Active Comparator|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
9615791|NCT05204654|Experimental|In-office fabricated appliance|A customized in-office fabricated appliance using the printed digital model of the subject will be used for AP correction. AP correction will be completed following CMA protocol (see model description)
9615792|NCT05204654|Active Comparator|Carriere Motion Appliance|The appropriate length appliance will be placed as directed in the CMA handbook on the maxillary first molar and canine. AP correction will be completed following CMA protocol (see model description)
9615793|NCT05204264|Experimental|Acceptance and Commitment Therapy (ACT)|Intervention based on Acceptance and Commitment Therapy that promotes the acceptance and defusion of unwanted internal experiences and commitment to values of the personal life project.
9615794|NCT05204264|Experimental|Mindfulness-based Emotional Regulation (MER)|Intervention inspired in the Mindfulness-Based Stress Reduction program that fosters the development of a behavioral pattern made up of conscious responses in order to decrease reactivity to stressors.
9615795|NCT05204082|No Intervention|Standard IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have standard IV insertion
9615796|NCT05204082|Other|SU-VEID assisted IV Insertion|Pediatric patients in surgical pre-op requiring an IV catheter for surgery will have IV insertion using SU-VEID device
9615797|NCT05203900|Experimental|Investigational formula|Infant formula with Human Milk Oligosaccharide
9615798|NCT05203900|Placebo Comparator|Control formula|Infant formula without Human Milk Oligosaccharide
9615799|NCT05203718|Experimental|Patients with Obesity|NYU Langone Health patients ≥18 to 80 years of age with a BMI ≥30.0 kg/m2
9615800|NCT05203601|Experimental|SIBP-03(Recombinant anti-HER3 humanized monoclonal antibody injection)|"Stage 1: dose escalation stage Injection, first dose 2mg/kg, then 5mg/kg until the dose are no longer met the requirements of continuing the trial or up to 40 mg/kg.~Stage 2: joint extension stage:~① Group of advanced head and neck squamous cell carcinoma ：SIBP-03 & Cetuximab 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW 10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW~② Group of breast cancer：SIBP-03 & Trastuzumab & Docetaxel 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w.~10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w."
9615801|NCT05203328|Experimental|High flow nasal cannula oxygen|High flow nasal cannula oxygen will be provided during the procedure using a Vapotherm device
9615802|NCT05203328|Active Comparator|Regular nasal cannula|Regular nasal cannula oxygen will be provided during the procedure
9615803|NCT05203224|Experimental|Intravenous Dornase alfa (DNase)|Patients will receive a single intravenous dose of dornase alfa (at either 0.125mg/kg, 0.25mg/kg, or 0.5mg/kg in escalating tiers), administered as a bolus over ~30 seconds.
9615804|NCT05202197||Experimental|Alzheimer´s patients
9615805|NCT05202080|Experimental|Opioid Counseling and PCS Video Group|This arm of the study will receive the opioid counseling and pain coping skills video 2 weeks prior to their surgery in addition to the conventional information provided to all patients undergoing total joint arthroplasty.
9615806|NCT05202080|No Intervention|Standard of Care Group|This arm of the study will the conventional information provided to all patients undergoing total joint arthroplasty.
9615807|NCT05201872||laparoscopic surgery|Different surgical methods for rectal cancer resection
9615808|NCT05201872||Transanal endoscopic surgery|Different surgical methods for rectal cancer resection
9615809|NCT05200754|Experimental|Convalescent/Vaccine-boosted Plasma|Infusion of plasma on day 1 and 2 (238 - 337 ml anti-SARS-Cov-2 CP/PVP each)
9615810|NCT05200754|No Intervention|Standard of Care|No intervention - standard therapy
9615811|NCT05200650|Experimental|TumoCure Treatment|Subjects will be treated with a single intra-tumor injection of TumoCure, containing the polymeric delivery system and the Cisplatin hemotherapy agent at a dose of 100mg.
9615812|NCT05199480|Experimental|E-cigarette liquid type 1|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
9615813|NCT05199480|Active Comparator|E-cigarettes liquid type 2|Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.
9615814|NCT05199480|No Intervention|No e-cigarettes|No e-cigarette use
9615815|NCT05198765|Experimental|BMI-CDS|Clinicians and their patients assigned to intervention clinics will receive shared decision support tools for weight loss management.
9615816|NCT05198765|No Intervention|Control|Clinicians and their patients assigned to control clinics will engage in the usual standard of care with no access to shared decision support tools.
9615817|NCT05195879|Experimental|XTR004|Single dose 6.0-8.0 mCi intravenous injection of XTR004 and investigation of XTR004 (MPI radiotracer).
9622031|NCT02519257|Experimental|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
10038488|NCT01834859|Experimental|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
10038489|NCT01834872|Experimental|Amigo|Ablation completed with Amigo
10038490|NCT01834872|Active Comparator|Manual|Ablation completed with manual catheter
10038491|NCT01834885|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
10058341|NCT02017626|Experimental|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
10038492|NCT01834885|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
10038493|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
9533853|NCT03163355|Active Comparator|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
9533854|NCT03163355|Placebo Comparator|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
9533855|NCT03163537||Kidney transplantation, postmortal, day|
9533856|NCT03163537||Kidney transplantation, postmortal, night|
9533857|NCT03163537||Kidney transplantation, living donor|
9533858|NCT03163407|Active Comparator|Norepinephrine group|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
9533859|NCT03163407|Active Comparator|Ephedrine group|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
9533860|NCT03163485|Experimental|Dialytrode|Multimodal neuro-monitoring by dialytrode (investigational medical device)
9533861|NCT03163485|Other|Standard treatment|Either EVD and/or micro-dialysis according to standard treatment
10038494|NCT01834911|Experimental|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
9533862|NCT03163316||Breast cancer patients|Patients will undergo unenhanced magnetic resonance imaging on both axillae.
9533863|NCT03163381|Experimental|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
10038495|NCT01834950|Experimental|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
10038496|NCT01834963|Experimental|Interferon Alfa、Fluorouracil|"Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
10038497|NCT01834963|Experimental|Cisplatin、Fluorouracil|"Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
10038498|NCT01834989|Active Comparator|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
9533864|NCT03163251|Experimental|READ-SG Cohort|Each post-graduate year (PGY) will receive the intervention of a monthly peer-facilitated small group sessions (READ-SG Sessions) based on topics that are common to residency training and based on themes regarding humanism in medicine.
9533865|NCT03163576|Experimental|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
9533866|NCT03163576|Active Comparator|control group|patients received usual phosphate binders .
9533867|NCT03163433|Experimental|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
9533868|NCT03163433|No Intervention|Control|Usual consultations
9533869|NCT03163459|Active Comparator|mechanical thrombectomy group|Conventional mechanical thrombectomy
9533870|NCT03163459|Experimental|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
9533871|NCT03163160|Experimental|Pelvic floor manual therapy group|Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
9533872|NCT03163160|Experimental|Pelvic floor electrolysis group|Pelvic floor electrolysis technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue. The therapeutic protocol will be applied for 4 weeks.
9533873|NCT03163329|Experimental|TAVR group|
9533874|NCT03163329|Active Comparator|SAVR group|
9533875|NCT03163550|Experimental|Cohort 1|Healthy volunteers
9533876|NCT03163550|Experimental|Cohort 2|Healthy volunteers
9533877|NCT03163550|Experimental|Cohort 3|Healthy volunteers
9533878|NCT03163550|Experimental|Cohort 4|Healthy volunteers
9533879|NCT03163550|Experimental|Cohort 5|Healthy volunteers
9533880|NCT03163173|Experimental|Single Arm - Treatment Group|30 mg (~100 μCi) dose of [14C]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
9533881|NCT03163212|Experimental|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
9533882|NCT03163212|Experimental|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
9533883|NCT03163212|Experimental|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
9533884|NCT03162926|Experimental|Single-group|Up to six (6) VC-02-20 implants
9533885|NCT03163108|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
10038499|NCT01834989|Placebo Comparator|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
10038500|NCT01835002|Experimental|OkuStim|Electrostimulation Standard Treatment with OkuStim
9622032|NCT02519400|Experimental|Amitriptyline|Single oral dose of amitriptyline, 25 mg
9533886|NCT03163108|Active Comparator|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
9533887|NCT03163108|Experimental|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
9533888|NCT03163121|Experimental|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
9533889|NCT03163121|Experimental|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
9533890|NCT03163121|Experimental|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
9533891|NCT03163121|Experimental|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
9533892|NCT03163121|Experimental|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
9533893|NCT03163121|Experimental|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
9533894|NCT03163121|Placebo Comparator|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
9533895|NCT03162848|Experimental|SystemCHANGE intervention|The SystemCHANGE™ intervention utilizes the Socioecological Model and Plan-Do-Check Act model as its framework and focuses on changing the individual's environment to change behavior using small experiments with feedback.
9533896|NCT03162848|No Intervention|Attention Control|The attention control group will receive education at baseline, 1 month, and 2 months following America Heart Association brochures.
9533897|NCT03162861|Experimental|the observation group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
9533898|NCT03162861|Experimental|the control group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
9533899|NCT03162874|Placebo Comparator|PLACEBO|
9533900|NCT03162874|Experimental|PXT002331 - 10mg|
9533901|NCT03162874|Experimental|PXT002331 - 30mg|
9533902|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
9533903|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
9622033|NCT02519101|Experimental|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
9533904|NCT03162887|Experimental|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
9533905|NCT03162757|Experimental|Subclavian vein access|
9533906|NCT03162757|Experimental|Internal jugular vein access|
9533907|NCT03162991|Experimental|12-Week Aerobic Exercise Intervention|
9533908|NCT03162991|No Intervention|12-Week Control Period|
9533909|NCT03162913|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry powder.
9533910|NCT03162913|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo powder.
9533911|NCT03162965|Active Comparator|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
9533912|NCT03162965|Active Comparator|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
9533913|NCT03163030|Experimental|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
9533914|NCT03163043|Experimental|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
9533915|NCT03163082|Active Comparator|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
9533916|NCT03163082|Active Comparator|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
9533917|NCT03163082|Active Comparator|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
9533918|NCT03163082|Active Comparator|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
9533919|NCT03163004|Experimental|Intervention group|Implementation of standing desks in the classroom
9533920|NCT03163004|No Intervention|Control group|
9533921|NCT03163056|Other|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
9533922|NCT03163056|Active Comparator|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
9533923|NCT03163056|Active Comparator|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
9533924|NCT03162822|Active Comparator|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
9533925|NCT03162822|Active Comparator|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
9533926|NCT03162822|Active Comparator|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
9533927|NCT03162822|Active Comparator|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
9533928|NCT03163069|Experimental|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
9533929|NCT03163069|Experimental|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
9533930|NCT03163069|Experimental|Regular dentifrice|in-office bleaching with the regular dentifrice
9533931|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
9533932|NCT03162770|Experimental|Intervention Group|This group will receive the Mindfulness meditation practice and after that patients will not receive any other intervention.
9533933|NCT03162770|No Intervention|No Control Group|Initially this control group will wait and after 12 weeks this group will receive the intervention
9615818|NCT05194722|Experimental|Orthopedic spine patients ≥ 65 years old Group|In addition to participating in semi-structured interviews and usability testing of the study interventions, participants in this arm will receive one month of access to Wysa. They will complete measures of clinical effectiveness and hypothesized behavioral targets at baseline and one-month follow-up.
9615819|NCT05193539|Experimental|Augmented reality and virtual reality rehabilitation|This group underwent augmented reality and virtual reality rehabilitation for 60 minutes per session, 5 days per week for 2 weeks.
10038501|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
10058342|NCT02017639|Experimental|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
9533934|NCT03162653|Active Comparator|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
9533935|NCT03162653|Placebo Comparator|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
9533936|NCT03162679|Experimental|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
9533937|NCT03162679|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
9533938|NCT03162731|Experimental|Treatment ( nivolumab, ipilimumab, radiation therapy)|Patients receive nivolumab IV over at least 30 minutes every 2 weeks and ipilimumab IV over at least 90 minutes every 6 weeks. Beginning week 3, patients undergo simultaneous integrated boost intensity modulated radiation therapy or volumetric modulated arc therapy for 5 days per week over 7 weeks. Patients continue nivolumab every 2 weeks for 12 doses and ipilimumab every 6 weeks for 4 doses. Courses repeat for up to 23 weeks in the absence of disease progression or unacceptable toxicity.
9533939|NCT03162640||P|for cannabis
9533940|NCT03162640||C|for the control group
9533941|NCT03162588|Experimental|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
9533942|NCT03162393||group 1|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve
9533943|NCT03162393||group 2|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve
9533944|NCT03162393||group 3|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
9533945|NCT03162393||group 4|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
9533946|NCT03162393||group 5|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and triceps branch
9533947|NCT03162393||group 6|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve and radial nerve; contralateral C7 nerve transfer to median nerve and triceps branch
9533948|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
9533949|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
9533950|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
9533951|NCT03162406|Experimental|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
9533952|NCT03162406|Placebo Comparator|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
9533953|NCT03162419|Active Comparator|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
9533954|NCT03162419|Experimental|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
9533955|NCT03162419|Experimental|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
9533956|NCT03162575|Experimental|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
9533957|NCT03162575|No Intervention|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
9622034|NCT02519101|No Intervention|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
9533958|NCT03162900|Experimental|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
10058343|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
9533959|NCT03162900|Experimental|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
9533960|NCT03162484|Experimental|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
9533961|NCT03162484|No Intervention|Control group|People in control group did not receive any physical activity program.
9533962|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
9533963|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
9533964|NCT03162432|Experimental|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
9533965|NCT03162562|Experimental|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
9533966|NCT03162718|Other|single arm|exercise
9533967|NCT03162315|No Intervention|Fresh embryo transfer|fresh embryo transfer (standard of care)
9533968|NCT03162315|Experimental|Freeze all|Vitrification of all embryos and replacement of a thawed embryo in a subsequent cycle
9533969|NCT03162367|Experimental|Autologous epidermal cell suspension group|
9533970|NCT03162367|Active Comparator|Silver sulfadiazine ointment group|
9533971|NCT03162237|Experimental|Porcine islets and autologous treg|Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10^6/Kg
9533972|NCT03162237|Active Comparator|AutologousTreg|Autologous Treg:2x10^6/Kg
9533973|NCT03162016|Experimental|Transplants of acellular matrix|
9533974|NCT03162016|Active Comparator|Transplants of connective tissue|
9533975|NCT03162224|Experimental|HPV associated recurrent/metastatic HNSCC|Approximately 50 patients with HPV associated recurrent/metastatic HNSCC
9533976|NCT03162185|Experimental|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
9533977|NCT03162185|Placebo Comparator|Control group|Half of the participants ( n= 30) will receive the placebo.
9533978|NCT03162276|Experimental|Intervention|Inquiry Based Stress Reduction
9533979|NCT03162276|Placebo Comparator|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
9533980|NCT03162289|Active Comparator|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
9533981|NCT03162289|Active Comparator|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
9533982|NCT03162133|Experimental|Exercise group|After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
9533983|NCT03162133|Experimental|Waiting list Control group|"Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise.~After their post-assessment they were able to attend the Baduanjin classes."
9533984|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
9533985|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences. Clinical patients may also elect to undergo a research only scan of approximately one hour.
9533986|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
9533987|NCT03162029||control group|CBCT imaging of medically-free participants
9533988|NCT03161990||Transgluteal approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a transgluteal approach.
9533989|NCT03161990||Posterior approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a posterior approach.
9533990|NCT03162120|Active Comparator|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
10058344|NCT02017678|Experimental|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
9533991|NCT03162120|Active Comparator|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
9533992|NCT03162159||cohort for model computing|patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
9533993|NCT03162159||cohort for model validation|patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
9533994|NCT03162198||Cirrhosis with HCC|
9533995|NCT03162198||Cirrhosis without HCC|
10038502|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
9533996|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
9533997|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
9533998|NCT03162263|Experimental|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
9533999|NCT03162263|Active Comparator|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
9534000|NCT03162081||Users|"Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
9534001|NCT03162081||Non-users|"Age and gender matched controls not using the above~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
9534002|NCT03162081||Screening group|"Patients over 65 admitted to hospital as in-patients~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity"
9534003|NCT03162068||Control group|Cases are recruited thanks to advertisement within CHU.
9534004|NCT03162068||Post menopausal women|Post-menopausal women are recruited within rheumatology service.
9534005|NCT03162068||Cushing' syndrome group|Cushing' syndrome patients are recruited during hospitalisation in endocrinology service
9534006|NCT03162094|Experimental|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
9534007|NCT03162094|Experimental|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
9534008|NCT03162094|Placebo Comparator|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
9534009|NCT03162003||Cohort 1|Patient with visceral disease and/or bone lesions (excluding patients who only have nodal disease), who have commenced or are about to commence ADT and whose disease has not shown any evidence of castration resistance.
9534010|NCT03162003||Cohort 2|Patient with castrate-resistant disease at time of treatment change
9534011|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
9534012|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
9534013|NCT03161951||Control group|Control group of healthy persons
9534014|NCT03162250|Experimental|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
9615820|NCT05193539|Active Comparator|Conventional occupational therapy|This group underwent conventional occutational therapy for 60 minutes per session, 5 days per week for 2 weeks.
9482230|NCT03759795|No Intervention|Wait-list control|No intervention during trial. Participants in this group will be offered the training once the study is complete.
9615821|NCT05190458|Other|Non-invasive mechanical ventilation (group A)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
9482231|NCT03759197|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
9482232|NCT03759197|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
9482233|NCT03754309|Experimental|KY1005 lower dose|Low dose KY1005
9482234|NCT03754309|Experimental|KY1005 higher dose|High dose KY1005
9482235|NCT03754309|Placebo Comparator|Placebo|Matched placebo
9482236|NCT03749252|Experimental|CNS Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing CNS contrast-enhanced MRI
9482237|NCT03749252|Experimental|CNS Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing CNS contrast-enhanced MRI
9482238|NCT03749252|Experimental|CNS Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing CNS contrast-enhanced MRI
9482239|NCT03749252|Experimental|Body Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
9482240|NCT03749252|Experimental|Body Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
9482241|NCT03749252|Experimental|Body Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
9482242|NCT03747575|Experimental|Treatment|Participants will receive MSTT1041A
9482243|NCT03747575|Placebo Comparator|Placebo|Participants will receive placebo matched to MSTT1041A
9482244|NCT03746015|Experimental|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in flavivirus-naïve participants (Group 1) and dengue-immune participants (Group 2). TDV comprised of 1 molecularly characterized, attenuated dengue virus strain and 3 chimeric dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) respectively.
9482245|NCT03742518|Experimental|Topical SM04554 0.15% solution|Topical SM04554 0.15% solution, once daily for up to 48 weeks
9482246|NCT03742518|Experimental|Topical SM04554 0.25% solution|Topical SM04554 0.25% solution, once daily for up to 48 weeks
9482247|NCT03742518|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for up to 48 weeks
9482248|NCT03740737|Experimental|Follitropin delta|
9482249|NCT03740737|Placebo Comparator|Placebo|
9482250|NCT03738618|Experimental|Follitropin delta|
9482251|NCT03738618|Placebo Comparator|Placebo|
9482252|NCT03738423|Experimental|Treatment 1|
9482253|NCT03738423|Experimental|Treatment 2|
9482254|NCT03738423|Experimental|Treatment 3|
9482255|NCT03738423|Experimental|Treatment 4|
9482256|NCT03738423|Experimental|Treatment 5|Matching placebo
9482257|NCT03737851|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
9482258|NCT03737851|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
9482259|NCT03737851|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
9482260|NCT03737812|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
9482261|NCT03737812|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
9482262|NCT03737812|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
9482263|NCT03737123|Experimental|Chemotherapy and Atezolizumab|Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
9482264|NCT03733054||Men|Men with lower limb amputation
9482265|NCT03733054||Women|Women with lower limb amputation
9482266|NCT03732833|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
9482267|NCT03732833|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
9482268|NCT03732833|Placebo Comparator|Placebo|Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
9482269|NCT03731052|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
9482270|NCT03731052|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
9482271|NCT03729596|Experimental|MGC018 Monotherapy|MGC018: Anti-B7-H3 antibody drug conjugate
9482272|NCT03729596|Experimental|MGC018 plus retifanlimab|MGC018: Anti-B7-H3 antibody drug conjugate; retifanlimab: Anti-PD-1 antibody
9482273|NCT03729362|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
9482274|NCT03729362|Active Comparator|alglucosidase alfa/placebo|Participants received alglucosidase alfa co-administered with placebo capsules.
9482275|NCT03727334|Experimental|Treatment|For the treatment arm, the participants will complete the intervention protocol following the first in-person study visit 7 months post-injury. The intervention involves 16 weeks of online, in-home spatial navigation training. During the 16 weeks, the participant will complete exercises for 1 hour/day, 5 days a week.
9534015|NCT03162250|Experimental|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
9534016|NCT03162250|Experimental|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
9534017|NCT03162250|Placebo Comparator|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
9534018|NCT03162146||Patient admitted to intensive care unit|All patients requiring intensive care unit stay
9534019|NCT03162211|Experimental|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
9534020|NCT03162211|No Intervention|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
9534021|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
9534022|NCT03161782|Experimental|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
9534023|NCT03161782|Experimental|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
9534024|NCT03161730|Experimental|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
9534025|NCT03161730|Experimental|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
9534026|NCT03161730|Active Comparator|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
9534027|NCT03161717|Experimental|Epidural electrical stimulation (EES)|n=20
9534028|NCT03161717|Active Comparator|Loss of resistance (LOR)|n=20
9534029|NCT03161691||Ischemic Stroke|Percutaneous neurovascular treatment of acute ischemic stroke patients.
9615822|NCT05190458|Other|High Velocity Nasal Insufflation (group B)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
9615823|NCT05181865|Experimental|Phase 1 - Cohort 1|
9615824|NCT05181865|Experimental|Phase 1 - Cohort 2|
9615825|NCT05181865|Experimental|Phase 1 - Cohort 3|
9615826|NCT05181865|Experimental|Phase 1 - Cohort 4|
9615827|NCT05181865|Experimental|Phase 1 - Cohort 5|
9615828|NCT05181865|Experimental|Phase 2a - Group 1|
9615829|NCT05181865|Experimental|Phase 2a - Group 2|
9615830|NCT05181865|Experimental|Phase 2a - Group 3|
9615831|NCT05178056|Active Comparator|Respiratory Training|Research subjects with no implanted stimulator undergoing RT intervention.
9615832|NCT05178056|Active Comparator|Spinal Cord Stimulation|Research subjects with implanted stimulator undergoing stimulation intervention.
9615833|NCT05178056|Experimental|Spinal Cord Stimulation and Respiratory Training|Research subjects with implanted stimulator undergoing stimulation intervention in combination with respiratory training.
9615834|NCT05175417||Case|Patients being considered for functional neurosurgical procedures, such as deep brain stimulation (DBS), radiofrequency ablation (RFA), gamma knife radiosurgery (GKR), or magnetic resonance-guided focused ultrasound (MRgFUS).
9615835|NCT05175417||Control|Healthy control volunteers.
9615836|NCT05172011||Extant, Clinical and De Novo Cohort -- INFECTED|SARS-CoV-2 infected children and young adults with and without current or prior PASC-like symptoms, including infected individuals with history of multisystem inflammatory syndrome in children (MIS-C), and infants born in the context of maternal SARS-CoV-2 infection during pregnancy
9615837|NCT05172011||Extant, Clinical and De Novo Cohort -- UNINFECTED|SARS-CoV-2 uninfected children and infants born to uninfected mothers
9615838|NCT05172011||Acute Cohort -- INFECTED|Newly SARS-CoV-2 infected individuals (≤4 weeks since onset of symptoms or positive laboratory testing)
9615839|NCT05172011||Acute Cohort -- UNINFECTED|Contemporaneous SARS-CoV-2 uninfected individuals selected from the same population as newly SARS-CoV-2 infected individuals
9615840|NCT05172011||Post-acute cohort -- INFECTED|Post-acute infected individuals (>4 weeks after initial symptoms or positive laboratory testing) in the extant, clinical and de novo cohorts, including infants born in the context of maternal SARS-CoV-2 infection during pregnancy, will be enrolled 1-24 months after initial SARS-CoV-2 infection.
9615841|NCT05172011||Post-acute cohort -- UNINFECTED|Uninfected individuals will be derived from a similar population with respect to age, sex, race and ethnicity, geographic origin, sociodemographics, and time of enrollment as the infected individuals.
9615842|NCT05172011||Post-COVID Vaccine Myocarditis|Individuals with history of myocarditis after receiving COVID-19 vaccine.
9615843|NCT05172011||Primary Caregivers|The primary caregiver of the child or young adult may optionally participate in the study.
9615844|NCT05172011||Biological Parent|If the primary caregiver is a biological parent, the other biological parent may optionally participate in the study
9534030|NCT03161769||Percutaneous neurovascular treatment|Procedure: Percutaneous neurovascular treatment of intracranial aneurysms
9534031|NCT03161886|Experimental|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
9534032|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
9534033|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
9534034|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
9534035|NCT03161873||avaBBT|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition, participants will measure their basal body temperature (BBT) daily.
9534036|NCT03161665|Experimental|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
9534037|NCT03161860|Experimental|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
9534038|NCT03161860|No Intervention|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
9534039|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
9534040|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
9534041|NCT03161639|No Intervention|Operator 1|Perform the pulpectomies except the working length measurement
9534042|NCT03161639|No Intervention|Operator 2|Perform the electronic length measurement of the pulpectomies
9534043|NCT03161639|Active Comparator|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
9534044|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
9534045|NCT03161652|Placebo Comparator|DME lactose pill|Patients with DME will be randomized to take a lactose pill (placebo).
9534046|NCT03161652|Experimental|DME levosulpiride|Patients with DME will be randomized to take levosulpiride.
9534047|NCT03161652|Placebo Comparator|DR lactose pill|Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)
9534048|NCT03161652|Experimental|DR levosulpiride|Patients with non-proliferative DR will be randomized to take levosulpiride
9534049|NCT03161652|Placebo Comparator|DR, vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).
9534050|NCT03161652|Experimental|DR, vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.
9534051|NCT03161652|Placebo Comparator|DME plus ranibizumab lactose pill|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)
9534052|NCT03161652|Experimental|DME plus ranibizumab levosulpiride|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride
9534053|NCT03161353|Experimental|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
9534054|NCT03161353|Experimental|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.~PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.~PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
9534055|NCT03161353|Experimental|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
9622035|NCT02519153|Placebo Comparator|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
9534056|NCT03161509|Experimental|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
9534057|NCT03161509|Experimental|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
9534058|NCT03161457|Experimental|JHL1101|Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.
9534059|NCT03161457|Active Comparator|MabThera|Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).
9534060|NCT03161366|Experimental|Single arm|Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
9534061|NCT03161314|Experimental|(Sub-project 1)PHP / (Sub-project 3)Strengthening|
9534062|NCT03161314|Active Comparator|(Sub-project 1)Normal healthy / (Sub-project 3)Stretching|(Sub-project 3) Conservative physical therapy treatment with stretching exercise
9534063|NCT03161522|Experimental|Group I (maintenance chemotherapy)|Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
9534064|NCT03161522|Experimental|Group II (local therapy)|Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
9534065|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
9534066|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
9534067|NCT03161470|Active Comparator|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
9534068|NCT03161470|Experimental|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
9534069|NCT03161470|Sham Comparator|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
9534070|NCT03161340|Experimental|Treatment group|Rapamycin group
9534071|NCT03161340|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
9534072|NCT03161301||Group 1|IL-37 genotype 1.1
9534073|NCT03161301||Group 2|IL-37 genotype 1.2
9534074|NCT03161301||Group 3|IL-37 genotype 2.2
9534075|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
9534076|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
9534077|NCT03161548|Experimental|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
9534078|NCT03161288|Experimental|Cohorts 1-3|Healthy volunteers will receive single rising doses of KY1005 or placebo
9534079|NCT03161288|Experimental|Cohorts 4-8|Healthy volunteers will receive multiple rising doses of KY1005 or placebo
9534080|NCT03161561|Other|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
9534081|NCT03161236|Experimental|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
9534082|NCT03161236|Active Comparator|non exercise group|• The non-exercise group will continue with their usual life style
9534083|NCT03161262|Experimental|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
9534084|NCT03161262|No Intervention|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
9622036|NCT02519153|Active Comparator|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
9622037|NCT02519114|Experimental|Bone MarrowTransplantation|KIR-mismatched haploidentical bone marrow transplantation
9534085|NCT03161418|Experimental|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
9534086|NCT03161418|Experimental|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
9534087|NCT03161210|Experimental|Dextrose Prolotherapy|
9534088|NCT03161210|Active Comparator|Local Anaesthetic|
9534089|NCT03161210|Placebo Comparator|Saline|
9534090|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
9534091|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
9534092|NCT03161574|Experimental|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
9534093|NCT03160976|No Intervention|Control Group|Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
9534094|NCT03160976|Active Comparator|Intervention Group|A single 50 minutes session of cold exposure with a cryolipolysis device. The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
9534095|NCT03160989|Experimental|Postmenopausal and hypertensive women|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
9534096|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
9534097|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
9534098|NCT03160937|Experimental|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
9534099|NCT03160937|Active Comparator|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
9534100|NCT03160950|Experimental|LuxaCrown|
9534101|NCT03161119|Experimental|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
9534102|NCT03161119|Active Comparator|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
9534103|NCT03160924|Active Comparator|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.~Preoperative counselling by surgeon, dietician and physiotherapist~Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)~Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics~Avoid use of drains~Early resumption of diet~Early mobilisation with physiotherapist~Dietary counselling by dietician~Early discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
9534104|NCT03160924|No Intervention|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.~No preoperative counselling~No Preoperative carbohydrate-loaded drink~Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.~Routine use of drains~Diet will be resumed when there is flatus clinically~Mobilisation as per patient's wish~Dietary counselling by dietician~Discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be seen in clinic on post-operative D14."
9534105|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
9534106|NCT03161197|Experimental|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
9534107|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
9534108|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
9534109|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
9534110|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
9534111|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
9534112|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
9534113|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
9534114|NCT03161080|Experimental|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
9534115|NCT03161080|Experimental|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
9534116|NCT03161080|Experimental|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
9534117|NCT03161015|Experimental|GBT440 Dose 1: Severe Renal Impairment|eGFR < 30 mL/min/1.73m2, not on dialysis
9534118|NCT03161015|Experimental|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or < eGFR < 60 mL/min/1.73m2
9534119|NCT03161015|Experimental|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or < eGFR < 90 mL/min/1.73m2
9534120|NCT03161015|Experimental|GBT440 Dose 1: Normal Renal function|eGFR > or = 90 mL/min/1.73m2
9534121|NCT03161132|Experimental|Olaparib 300mg|Olaparib bid orally at 300 mg (tablet formulation) continuously, combined with chemotherapy with Pegylated Liposomal Doxorubicin (up to 6 cycles), then, as monotherapy at the same dose and frequency (300mg bid orally) until progression of disease or unaccepted toxicity.
9534122|NCT03161132|Other|Pegylated Liposomal Doxorubicin (PLD)|PLD 40mg/m2 every 28 days intravenous for up to 6 cycles. This treatment will be combined with Olaparib (as described earlier).
9534123|NCT03161041|Experimental|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
9534124|NCT03160911|Experimental|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
9534125|NCT03160911|Active Comparator|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
9534126|NCT03161184|Active Comparator|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
9534127|NCT03161184|Experimental|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
9534128|NCT03161067|Experimental|Surgical implantation of BiCNS|
9534129|NCT03160833|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day
9534130|NCT03161145||Unresectable or metastatic renal cell carcinoma (mRCC)|Medical records will be reviewed for treatment patterns and outcomes
9534131|NCT03160820|Other|one dose of MMR|Subjects are vaccinated with MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 months old.
9534132|NCT03160820|Other|30 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 4 years old, sequentially.
9534133|NCT03160820|Other|42 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 5 years old, sequentially.
9534134|NCT03160820|Other|54 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 6 years old, sequentially.
9534135|NCT03160781|Experimental|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
9534136|NCT03160755||Qualitative Interviews|Adult outpatients with metabolic syndrome.
9534137|NCT03160664|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
9534138|NCT03160664|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
9534139|NCT03161106|Experimental|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
9534140|NCT03161106|Active Comparator|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
9534141|NCT03160807|Experimental|Levofloxacin 5 days|Levolet 500 mg given for 5 days
9534142|NCT03160807|Active Comparator|Levofloxacin 10 days|Levolet 500 mg given for 10 days
9534143|NCT03160729|Active Comparator|High dose|Dexamethasone 24 mg
9534144|NCT03160729|Active Comparator|Low dose|Dexamethasone 8 mg
9534145|NCT03160742||Non-invasive monitoring|In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.
9534146|NCT03160625|Active Comparator|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
9534147|NCT03160625|Active Comparator|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
9534148|NCT03160482||Papillary carcinoma, classical variant|
9534149|NCT03160482||Follicular carcinoma|
9534150|NCT03160482||Colloid nodule|
9534151|NCT03160482||Hyperplastic nodule|
9534152|NCT03160482||Adenomatoid nodule|
9534153|NCT03160482||Follicular adenoma|
9534154|NCT03160482||Papillary carcinoma, follicular variant|
9534155|NCT03160482||Medullary carcinoma|
9534156|NCT03160482||Lymphocytic thyroiditis|
9534157|NCT03160586|Active Comparator|Stutter|Children who stuttering
9534158|NCT03160586|Active Comparator|Control|Children who non stuttering
9534159|NCT03160391|Experimental|Music Training|Music Training
9534160|NCT03160391|Active Comparator|Dance Training|Dance Training
9534161|NCT03160391|No Intervention|Passive control group|Passive control group
9534162|NCT03160404|Experimental|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
9534163|NCT03160404|Active Comparator|ZOLPIDEM|10 mg/night during 6 weeks
9534164|NCT03160599|Experimental|Restricted Calorie Ketogenic Diet|"Calorie restriction: The basis of dietary design is 70-85% of individual's total calories. The total calorie is based on patient's activity level and their basal metabolism values, which is obtained from indirect calorimetry or harris-benedict formula.~Treatment will consist of ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard."
9534165|NCT03160677|Experimental|Intensive blood pressure management|
9534166|NCT03160677|Active Comparator|Standard blood pressure management|
9534167|NCT03160612|Other|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
9534168|NCT03160612|Other|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
9534169|NCT03160534|Experimental|Intervention|Preoperative exercise intervention
9534170|NCT03160534|No Intervention|Control|Only measurements
9534171|NCT03160651|Active Comparator|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
9534172|NCT03160651|Placebo Comparator|placebo|Patients will receive 28 days of matching placebo
9534173|NCT03160469|Experimental|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
9534174|NCT03160339|Experimental|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
9534175|NCT03160339|Active Comparator|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
9534176|NCT03160430|Experimental|Part A PK Arm|a single 100 mg dose of RVX000222 (apabetalone) on the day of dialysis, followed by a one (1) week washout period, and a second dose of RVX000222 (apabetalone) administered on a non-dialysis day (total of two (2) 100 mg RVX000222 doses)
9534177|NCT03160430|Placebo Comparator|Part B Sequence A|RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); Placebo b.i.d for 6 weeks
9534178|NCT03160430|Placebo Comparator|Part B Sequence B|Placebo b.i.d for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks
9534179|NCT03160248|Experimental|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
9534180|NCT03160248|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
9534181|NCT03160352|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
9534182|NCT03160313|Experimental|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
9534183|NCT03160313|Active Comparator|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
9534184|NCT03160300|Experimental|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
9534185|NCT03160300|Sham Comparator|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
9534186|NCT03160131|Active Comparator|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
9534187|NCT03160131|No Intervention|Control|All participants receive no NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
9534188|NCT03160144|Experimental|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
9534189|NCT03160144|No Intervention|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
9534190|NCT03160001|Placebo Comparator|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
9534191|NCT03160001|Experimental|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
9534192|NCT03160040||Minocycline IV|Participants who received 2 doses over 48 hours if given once daily or 4 doses over 48 hours if given twice daily of minocycline intravenous (IV) as monotherapy, with or without transition to oral minocycline.
9534193|NCT03160105|No Intervention|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
10038503|NCT01835054||Patients with mitral regurgitation|"At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.~At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.)."
9534194|NCT03160105|Experimental|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
9534195|NCT03160105|Experimental|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
9534196|NCT03160105|Experimental|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
9534197|NCT03160261|Experimental|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
9534198|NCT03160196|Experimental|Experimental practices|The decision support tool is a Web-based software program accessed via a GP computer desktop icon. Clicking the icon opens a single page of tick boxes asking for relevant aspects of the presenting illness. Most fields for relevant medical history and patient demographics are automatically populated from data in the electronic health record. Depending on diagnosis and risk estimation, the tool recommends a guideline-based management strategy. Override options exist but require a justification from the GP. The tool also provides relevant prescriptions, radiology access, and referral forms, and a variety of patient information leaflets. GPs in practices randomized to the intervention group will have to initiate the tool but will not have to follow the tool's advice.
9534199|NCT03160196|Active Comparator|Control practices|Control practices will be aware of the tool but will be unable to access it and managed patients by usual care, which could include care aligned with the Guidelines. Prior to randomization, GPs from all participating practices (control and intervention) will attend a 1-hour face-to-face didactic education session on diabetes mellitus 2 management and the Colombia diabetes mellitus 2 Guidelines. The intervention pertains to the cluster level.
9534200|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
9534201|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
9534202|NCT03159962|Active Comparator|Treated Group 1|Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
9534203|NCT03159962|Active Comparator|Treated Group 2|Patients treated with banded RME (Rapid Maxillary Expander) in the form of a butterfly palatal expander with a 13-mm screw cemented through bands on the second deciduous upper molars.
9534204|NCT03159962|No Intervention|Untreated Control Group|Matched untreated Class II control group prospectively evaluated after one year
9534205|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
9534206|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
9534207|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
9534208|NCT03159988|Experimental|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
9534209|NCT03160066|Active Comparator|Active|Capsules containing 1x10^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
10038504|NCT01835067|Sham Comparator|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
10038505|NCT01835067|Experimental|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
10038506|NCT01835067|Experimental|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
9534210|NCT03160066|Placebo Comparator|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
9534211|NCT03159975|Experimental|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
9534212|NCT03159975|Experimental|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
9534213|NCT03159975|Experimental|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
9534214|NCT03160014|Experimental|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
9534215|NCT03160014|Experimental|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
9534216|NCT03160014|Experimental|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
9534217|NCT03160014|Experimental|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
9615845|NCT05171972||Relapsing-remitting Multiple Sclerosis|Enrolled subjects in this group will have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria of the relapsing-remitting form with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and will be treated with Ofatumumab.
9615846|NCT05171972||Healthy Control Subjects|Enrolled subjects must not have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria, any other autoimmune disease, demyelinating co-morbidity, neurological disease or immune system altering disease.
9615847|NCT05168501|Experimental|Lead-In|Multiple rebreathing procedures using methodology developed by Duffin (referred to as Duffin's rebreathing procedure) will be conducted under hyperoxic and hypoxic conditions over the course of a day to confirm feasibility and gather reproducibility data using the procedure.
9615848|NCT05167864|Active Comparator|OnabotulinumtoxinA|Botox
9615849|NCT05167864|Active Comparator|AbobotulinumtoxinA|Dysport
9615850|NCT05167864|Active Comparator|IncobotulinumtoxinA|Xeomin
9615851|NCT05167864|Active Comparator|PrabotulinumtoxinA|Jeuveau
9615852|NCT05167539||Mechanical aortic valve replacement|simple procedure but need long term of anticoagulant
9615853|NCT05167539||Aortic root replacement|complicated procedure but without anticoagulant
9615854|NCT05162131|Experimental|1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)|PB2452 Infusion
9615855|NCT05162131|Experimental|1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)|PB2452 Infusion
9615856|NCT05162131|Experimental|1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
9615857|NCT05162131|Experimental|2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
9615858|NCT05162131|Experimental|3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
9615859|NCT05162131|Experimental|4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
9615860|NCT05162131|Experimental|5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
9615861|NCT05157945|Experimental|ALTO-300|ALTO-300 tablet PO; daily dosing 8 weeks
9615862|NCT05157646|Experimental|Exercise trackers|Fitbit physical activity trackers
9615863|NCT05157412|Experimental|Steroids + Doxycycline|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) along with Doxycycline (200 mg as a loading dose on the 1st day, followed by 100 mg once daily one hour before meal as a maintenance dose) for 3 weeks.
9615864|NCT05157412|Active Comparator|Steroids Only|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) for 3 weeks.
9615865|NCT05157282|Active Comparator|Active TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, active transcutaneous electrical spinal stimulation (TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
9615866|NCT05157282|Sham Comparator|Sham TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, sham transcutaneous electrical spinal stimulation (sham-TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
9615867|NCT05157282|Active Comparator|Active TESS + Training|Develop methodologies to promote recovery of reaching and grasping movements. To accomplish this goal, the investigators will combine TESS applied in a closed-loop manner with massed practice upper-limb training. Participants will be assigned to one of three groups in a randomized order for a controlled design: [1) Closed-loop TESS applied during grasping + training, 2) Closed-loop TESS applied during reaching + training, and 3) Closed-loop TESS applied during grasping & reaching + training.] TESS for 20-min will be followed by 60 min of massed practice exercise training (total=20 sessions).
9615868|NCT05156918|Experimental|Exercise Group|Exercise group participants will perform supervised high intensity exercise three times per week at the LLU department of physical therapy laboratory utilizing treadmills, stationary bicycles, and rowing machines.
9615869|NCT05156918|Active Comparator|Control Group|Control group participants will make no modifications to regular diet or exercise habits for 30 days.
9615870|NCT05155436|Experimental|Fixed-Dose Combination pill of Telmisartan and Amlodipine|Fixed-Dose Combination pill of Telmisartan 40 mg and Amlodipine 5 mg, once daily for 3 months
9615871|NCT05154513||Cohort 1|Children living with perinatally-acquired HIV who received early treatment in IMPAACT network studies or other research studies sponsored by the United States National Institutes of Health.
9615872|NCT05139511|Experimental|Study group|IPL + laser refractive surgery
9615873|NCT05139511|Placebo Comparator|Control group|Laser refractive surgery without IPL
9615874|NCT05136248|Experimental|intraarticular injection|intra-articular steroid injection with the ultrasound guidance technique,
9615875|NCT05136248|Active Comparator|peng block|Ultrasound guided drug injection between to iliopubic eminentia and psoas tendon
10038507|NCT01835067|Experimental|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
10038508|NCT01835093|Experimental|A single-arm study|
10038509|NCT01835106|Active Comparator|Epidural|Epidural catheter is used postoperatively
10038510|NCT01835106|Experimental|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
10038511|NCT01835119|Experimental|chewing gum|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at least 5 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
10038512|NCT01835119|No Intervention|control group|no gum
10038513|NCT01835184|Experimental|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10038514|NCT01835197|Experimental|SAD Cohorts 1-8 Experimental Arm|
10038515|NCT01835197|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
10038516|NCT01835197|Experimental|MAD Cohorts 3 through 5 Experimental Arm|
10038517|NCT01835197|Placebo Comparator|MAD Cohorts 3 through 5 Placebo Arm|
10038518|NCT01835197|Experimental|MAD Cohorts 6 and 7 Experimental Arm|
9534218|NCT03160053|Experimental|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
9534219|NCT03160053|No Intervention|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
9534220|NCT03160079|Experimental|Blinatumomab + Pembrolizumab|
9534221|NCT03160092|Experimental|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
9534222|NCT03159949|Experimental|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
9534223|NCT03159949|Experimental|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
9534224|NCT03159910|Experimental|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
9534225|NCT03159910|Active Comparator|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
9622038|NCT02519010|Experimental|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
9622039|NCT02519010|Active Comparator|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
10038519|NCT01835197|Placebo Comparator|MAD Cohorts 6 and 7 Placebo Arm|
10038520|NCT01835197|Experimental|MAD Cohort 8 Experimental Arm|
10038521|NCT01835197|Placebo Comparator|MAD Cohort 8 Placebo Arm|
10038522|NCT01835197|Experimental|MAD Cohort 9 Experimental Arm|
10038523|NCT01835197|Placebo Comparator|MAD Cohort 9 Placebo Arm|
10038524|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
10038525|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
10038526|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
10038527|NCT01835249|Experimental|Intensive BP Arm|"Participants randomized into the Intensive BP arm will have a goal of SBP <120mmHg. Drugs will be added and/or titrated at each visit (monthly) to achieve SBP <120 mmHg. At periodic milepost visits, addition of another drug will be required if not at goal."
10038528|NCT01835249|Active Comparator|Standard BP Arm|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mmHg @ 1 visit; ≥140 mmHg @ 2 consecutive visits; Down-titration if SBP <130 mmHg @ 1 visit; <135 mmHg @ 2 consecutive visits.
10038529|NCT01835275|Experimental|Music conditioning|Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia
10038530|NCT01835275|Active Comparator|Sound|Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia
10038531|NCT01835275|No Intervention|Calibration|Subjects are tested with music, sound, and silence, with no enhanced audio received
10038532|NCT01835288|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-2 hours daily for up to 45 days. Patients achieving complete remission, receive arsenic trioxide IV over 1-2 hours daily 5 days a week for 4 weeks. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
10038533|NCT01835301||DES|Patients who received a DES stent > 3 years ago.
10038534|NCT01835301||BMS|Patients who received BMS stents > 3 years ago.
10038535|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
10038536|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
10038537|NCT01835340|Experimental|propofol|Propofol Patients will receive propofol anesthesia on the study day
10038538|NCT01835353|Experimental|Prasugrel 100mg loading dose|Prasugrel 100mg loading dose
10038539|NCT01835353|Active Comparator|Prasugrel 60mg loading dose|
10038540|NCT01835392|Experimental|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
9534226|NCT03159884|Experimental|3+Q12W|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the additional medication criteria in 12 weeks during treatment, additional injection can be given;"
9534227|NCT03159884|Experimental|3+TAE|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the treatment-extended dosing criteria. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the extra dosing criteria."
10038541|NCT01835392|Sham Comparator|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
9534228|NCT03159741|Experimental|Inhibitor + GLP-2|
9534229|NCT03159741|Experimental|Placebo + GLP-2|
9534230|NCT03159741|Active Comparator|Placebo + GIP|
9534231|NCT03159741|Placebo Comparator|Placebo + Saline|
9534232|NCT03159715|Experimental|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
9534233|NCT03159715|Experimental|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
9534234|NCT03159715|Experimental|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
9534235|NCT03159650|Experimental|intravascular ultrasonography guided|
9534236|NCT03159650|Active Comparator|Angiography guided|
9534237|NCT03159845|Active Comparator|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
9534238|NCT03159845|Experimental|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
9534239|NCT03159728|Experimental|Educative intervention|"Who wish to participate in the program Caring for Caregivers will be the intervention group. The intervention or program Caring for Caregivers to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes four sessions or meetings with the caretaker, induction and three modules, the first is geared to strengthen the knowledge; the second, to strengthen the value and the third, to strengthen patience."
9534240|NCT03159728|No Intervention|Control group|"The control group will receive training about knowledge of chronic disease and care.~In addition, once it confirmed the effectiveness of the intervention participants in the control group will be contacted to contemplate the possibility of receiving the benefits of the intervention."
9534241|NCT03159494|Experimental|Intervention group|10 patients with type 2 diabetes enrolled to perform 8 times of High-Intensity Training. The subjects were tested before and after the training period.
9534242|NCT03159494|Experimental|Pilot study|6 patients with type 2 diabetes enrolled to perform 6 times of High-Intensity Training. The subjects were tested before and after the training period
9534243|NCT03159598|Active Comparator|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
9534244|NCT03159598|Experimental|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
9534245|NCT03159598|Active Comparator|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
10038542|NCT01835405|Active Comparator|LiquiBand Flex|LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations. It may be used in conjunction with, but not in place of deep dermal sutures.
10038543|NCT01835405|Active Comparator|Dermabond Advanced|Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.
10038544|NCT01835405|Active Comparator|Sutures (Prolene)|Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
10038545|NCT01835418|Experimental|Lisinopril|bedtime administration of lisinopril 20mg
10038546|NCT01835418|Experimental|Amlodipine|Bedtime administration of amlodipine 5mg
10038547|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
10038548|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
9534246|NCT03159507|Experimental|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
9534247|NCT03159754|Experimental|Early Appendectomy|
9534248|NCT03159754|Experimental|Interval Appendectomy|
9534249|NCT03159754|Experimental|No Appendectomy|
9534250|NCT03159702|Experimental|MEL/FLU and Total-Body Irradiation (TBI)|"For patients who are < 60 years.~Melphalan: 140 mg/m2/day IV on Day: -6~Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)~TBI: 200 cGy Day: -1.~For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of >3 (at the discretion of treating physician will have an option to receive):~Melphalan: 70 mg/m2/day IV on Day -6.~Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.~TBI: 200 cGy; Days -1."
9534251|NCT03159481|Experimental|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
9534252|NCT03159481|No Intervention|Usual Care Only|Usual glaucoma management only, no intervention.
9534253|NCT03159689|Experimental|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
9534254|NCT03159689|Active Comparator|Pretzels|a hypo caloric weight loss dietary plan with pretzels
9534255|NCT03159806||Outpatients|Attendees at the nephrology outpatient clinic at Hammersmith Hospital will be invited to take part in microdialysis sampling
9534256|NCT03159429|Experimental|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.~Intervention: Nasal breathing rehabilitation"
9534257|NCT03159429|Active Comparator|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.~Intervention: Standard rehabilitation"
9534258|NCT03159819|Experimental|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
9534259|NCT03159793|Active Comparator|Group A|Live Modelling
9534260|NCT03159793|Active Comparator|Group B|Filmed Modelling
9534261|NCT03159793|No Intervention|Group C|No Modelling
9534262|NCT03159585|Experimental|TAEST16001|Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.
9534263|NCT03159442|Experimental|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
9534264|NCT03159442|Experimental|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
9534265|NCT03159442|Experimental|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
9534266|NCT03159767|Experimental|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
9534267|NCT03159767|Experimental|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
9534268|NCT03159520|Active Comparator|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
9534269|NCT03159520|Active Comparator|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
9534270|NCT03159533|Active Comparator|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
9534271|NCT03159533|Placebo Comparator|Control Group|Wait-list
9534272|NCT03159832|Active Comparator|Normal renal function|All subjects were given SHR3824 20mg only one time.
9534273|NCT03159832|Active Comparator|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
9534274|NCT03159832|Active Comparator|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
9534275|NCT03159559|Experimental|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
9534276|NCT03159559|No Intervention|Control group|In the control group, patients received conventional therapy only.
9534277|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
9534278|NCT03159416|Experimental|Inclisiran (normal renal function)|Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
9534279|NCT03159416|Experimental|Inclisiran (mild renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
9534280|NCT03159416|Experimental|Inclisiran (moderate renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
9534281|NCT03159416|Experimental|Inclisiran (severe renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.
9534282|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
9534283|NCT03159325|No Intervention|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
9534284|NCT03159325|Experimental|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
9534285|NCT03159312|Experimental|Assigned Interventions|20 individuals undergoing bariatric surgery and post surgery normal indications with moderate exercise program
9534286|NCT03159312|No Intervention|Control group|Control group: 23 individuals undergoing bariatric surgery and post surgery normal indications without exercise program
9534287|NCT03159273|Experimental|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
9534288|NCT03159273|No Intervention|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
9534289|NCT03159286|Experimental|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
10038549|NCT01835457|Experimental|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
10038550|NCT01835457|Active Comparator|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
10038551|NCT01835509|Experimental|Intervention, Camp + Reunions|5 day , day camp plus 5 monthly reunions
10038552|NCT01835509|No Intervention|Control, Newsletters|
10038553|NCT01835535|Experimental|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
10038554|NCT01835561|Experimental|Part 1: Severe liver disease and healthy volunteer match|Subjects with severe liver disease (Group 2) and healthy volunteer subjects (Group 1) matched to the subjects with liver disease
10038555|NCT01835561|Experimental|Part 2: Mild and moderate Liver disease|Subjects with moderate (Group 3) and/or mild (Group 4) liver disease
10038556|NCT01835574|Other|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
10038557|NCT01835600|Active Comparator|with PEEP|10 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
10038558|NCT01835600|Placebo Comparator|without PEEP|0 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
10038559|NCT01835613|Other|Tocilizumab|"Biomarkers Measures~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
10038560|NCT01835639|Experimental|Vitamin D Supplementation|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
10038561|NCT01835652|Active Comparator|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
10038562|NCT01835652|Other|Passive Exercise|Passive Exercise (stretching and balance based exercise)
10038563|NCT01835665|Experimental|Nimodipine|
10038564|NCT01835678|Active Comparator|Linagliptin|Linagliptin
10038565|NCT01835678|Placebo Comparator|Placebo|Placebo
10038566|NCT01835691|Experimental|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
10038567|NCT01835691|Experimental|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
10038568|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
10038569|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
10038570|NCT01835717||Cognitively normal individuals|
10038571|NCT01835730|Experimental|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
10038572|NCT01835730|Placebo Comparator|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
10038573|NCT01835782|Active Comparator|2.5 grams BID|5 Patients will be evenly randomized into this group
10038574|NCT01835782|Active Comparator|.5 grams BID|5 Patients will be evenly randomized into this group
10038575|NCT01835782|Active Comparator|7.5 grams BID|5 Patients will be evenly randomized into this group
10038576|NCT01835782|Active Comparator|15 grams BID|5 Patients will be evenly randomized into this group
10038577|NCT01835795|Active Comparator|Radial Extracorporeal Shock Wave|Swiss DolorClast® CLASSIC applicator
10038578|NCT01835795|Placebo Comparator|Placebo|Swiss DolorClast® CLASSIC placebo applicator
10038579|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
10038580|NCT01835821|Experimental|prosthesis|"NobelProcera™ Crown shaded zirconia:~The device is an individual, ceramic core (figure a) made of shaded zirconium with an anatomic contour providing homogenous veneering material thickness and a minimum core thickness of 0.4 or 0.7mm. The core is veneered with dental porcelain (IPS e.max Ceram) at the dental laboratory"
9534290|NCT03159286|Experimental|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
10058345|NCT02017691|Experimental|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
9534291|NCT03159286|Experimental|Control|Participants view social networking site profiles with no alcohol content.
9534292|NCT03159390|Experimental|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
9534293|NCT03159338|Active Comparator|treatment group|One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation
9534294|NCT03159338|Placebo Comparator|Control group|In control site , placebo gel will be placed before rigid fixation
9534295|NCT03159364|Experimental|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
9534296|NCT03159013|Other|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
9534297|NCT03159013|Other|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
9534298|NCT03158948|Experimental|MOTREM 1|0.3 mg/kg/h
9534299|NCT03158948|Experimental|MOTREM 2|1.0 mg/kg/h
9534300|NCT03158948|Experimental|MOTREM 3|3.0 mg/kg/h
9534301|NCT03158948|Placebo Comparator|Placebo|
9534302|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
9534303|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
9534304|NCT03158974|Experimental|VIR007|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
9534305|NCT03159078|Other|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
9534306|NCT03159078|Experimental|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
9534307|NCT03159221|Experimental|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
9534308|NCT03159221|No Intervention|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
9534309|NCT03159065|Experimental|Bilberry|A bilberry-based beverage with fermented oatmeal
9534310|NCT03159065|Experimental|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
9534311|NCT03159065|Experimental|Mango|A mango-based based beverage with fermented oatmeal
9534312|NCT03159065|Experimental|Beetroot|A beetroot-based based beverage with fermented oatmeal
9534313|NCT03159065|Experimental|Rose hip|A rose hip-based based beverage with fermented oatmeal
9534314|NCT03159065|Active Comparator|Glucose drink|A reference glucose drink
9534315|NCT03159871|Experimental|Stratafix suture|
9534316|NCT03159871|Active Comparator|Vicryl suture|
9534317|NCT03159117|Experimental|PF 06688992|This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
9534318|NCT03159156|No Intervention|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
9534319|NCT03159156|Experimental|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
9534320|NCT03159156|Experimental|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
9534321|NCT03159156|Experimental|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
9534322|NCT03159182|Experimental|Pressure garment and silicone insert|Custom measured pressure garment with a textile bonded silicone insert in either the distal or proximal portion of the pressure garment, to be worn 23 hours per day.
9534323|NCT03159182|Active Comparator|Pressure Garment|Custom measured pressure garment, to be worn 23 hours per day.
9534324|NCT03159351|Experimental|active rTMS treatment|received active rTMS treatment 20 times for 20 days
9534325|NCT03159351|Sham Comparator|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
9534326|NCT03159104|Experimental|Tenoten for children|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
9534327|NCT03159104|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
9534328|NCT03159247|Experimental|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
9534329|NCT03158870||Pheochromocytoma|Patient who underwent surgical procedure for pheochromocytoma
9534330|NCT03159169|Experimental|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
9534331|NCT03159234|Other|Diabetic pregnant women|
9534332|NCT03159039|Experimental|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
9534333|NCT03159039|Active Comparator|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
10058346|NCT02017691|Other|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
9534334|NCT03158909|Experimental|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
9534335|NCT03158909|Active Comparator|Orientation about space and time|This group will receive orientations about space and time olny, every night.
9534336|NCT03159052|Experimental|SHR3824 Placebo|once daily, 24 weeks
9534337|NCT03159052|Experimental|SHR3824 5 mg|once daily, 52 weeks
9534338|NCT03159052|Experimental|SHR3824 10 mg|once daily, 52 weeks
9534339|NCT03158935|Experimental|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
9534340|NCT03158935|Experimental|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
9534341|NCT03158896|Experimental|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
9534342|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
9534343|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
9534344|NCT03158961|Experimental|TOETVA|a new approach in surgery which can treat the thyroid disease
9534345|NCT03158532|Placebo Comparator|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
9534346|NCT03158532|Experimental|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
9534347|NCT03158532|Active Comparator|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
9534348|NCT03158532|Experimental|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
9534349|NCT03158584|Active Comparator|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
9534350|NCT03158584|Active Comparator|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
9534351|NCT03158584|Active Comparator|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
9534352|NCT03158623|Experimental|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
9534353|NCT03158623|Experimental|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
9534354|NCT03158467||Phase 1|
9534355|NCT03158467||Phase 2|
9534356|NCT03158506|Experimental|[C14]-labelled HMS5552|
9534357|NCT03158805|Active Comparator|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
9534358|NCT03158805|Placebo Comparator|Placebo|Placebo (no active drug)
9534359|NCT03158597||AMI|
9534360|NCT03158597||Control|
9534361|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
9534362|NCT03158519|Experimental|iMETX intervention|Individualized exercise recommendation
9534363|NCT03158740|Active Comparator|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
9534364|NCT03158740|Active Comparator|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
9534365|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
9534366|NCT03158545|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
9534367|NCT03158545|Active Comparator|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
9534368|NCT03158545|Active Comparator|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
9534369|NCT03158610|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
9534370|NCT03158610|Active Comparator|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
9534371|NCT03158649|Experimental|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
9534372|NCT03158649|No Intervention|Waiting List condition|Waiting List control condition
9534373|NCT03158675|Experimental|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.~Intervention:~-Procedure: Fractional carbon dioxide laser.~-Drug: Topical corticosteroid.~-Radiation: Ultraviolet B narrow band."
9534374|NCT03158558|Experimental|AM-CBCT for PTSD|Accelerated, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy delivered in a single weekend retreat
9534375|NCT03158779|Experimental|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.~The SBRT schedule will be [6 x 9 Gy = 54 Gy] delivered in consecutive days."
9534376|NCT03158792|Active Comparator|Enoxaparin 20 mg|
9534377|NCT03158792|Active Comparator|Enoxaparin 30 mg|
9534378|NCT03158480|Experimental|DC-CIK+interferon Group|dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
9534379|NCT03158480|Placebo Comparator|Placebo+interferon Group|saline as placebo plus interferon intervention
9534380|NCT03158454|Other|Capsula Closure|
9534381|NCT03158454|Other|Non-Capsula Closure|
9534382|NCT03158415|Experimental|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
9534383|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
9534384|NCT03158441||control|same patients , dynamic scan
9615876|NCT05127876|Experimental|Group E|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group E: were administered intravenous ephedrine 10 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
9615877|NCT05127876|Experimental|Group OL|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OL: were administered intravenous ondansetron 4 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
9615878|NCT05127876|Experimental|Group OH|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OH: were administered intravenous ondansetron 8 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
9615879|NCT05127876|Placebo Comparator|Group P|"Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group P: was a control group who received 0.9% saline 10 mL over 1 minute as a placebo.~Then under aseptic precautions, spinal anesthesia was administered."
9615880|NCT05127720||patients with severe sleep apnea|defined by a pacemaker-derived mean RDI ≥ 20/h in the first 12 months after enrollment
9615881|NCT05127720||patients with autonomic imbalance|defined by PRD ≥ 5.75deg2 assessed within the first 12 months of enrollment
9615882|NCT05127720||patients with a sedentary lifestyle|defined by a pacemaker-derived mean daily physical activity level < 2h in the first 12 months after enrollment
9615883|NCT05127538|Active Comparator|Individuals diagnosed with neuropathic pain due to type 2 diabetes|"Individuals between the ages of 40-65~Individuals who take 4 points or more from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points or more from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
9615884|NCT05127538|Active Comparator|Individuals with type 2 diabetes but no neuropathic pain|"Individuals between the ages of 40-65~Individuals who take 4 points from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
9615885|NCT05127538|Active Comparator|Healthy control group|"Individuals between the ages of 40-65~Individuals who have no pain (Taking 1 point or less according to the Visual Pain Scale)"
9615886|NCT05124288||Acute Myeloid Leukemia relapsed patients|Adult patients (< 18 years old), with Acute Myeloid Leukemia, who relapse after allogeneic transplantation from either family or unrelated donors, regardless of the cellular source of the transplant (bone marrow, mobilized peripheral stem cells or cord blood).
9615887|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
9615888|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
9534385|NCT03158363|Experimental|"LPS, 36 hour immobilization and fast"|"Interventions:~Test subjects undergo 48 hour exercise restriction and overnight fast.~Study day 1:~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.~Study day 2:~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.~Study day 3:~- Blood sample."
9534386|NCT03158363|No Intervention|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
9534387|NCT03158350|Experimental|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
9534388|NCT03158350|No Intervention|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
9534389|NCT03158402|Sham Comparator|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
9534390|NCT03158402|Experimental|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
9534391|NCT03158337|Experimental|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
9534392|NCT03158428|Experimental|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
9534393|NCT03158428|Experimental|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
9534394|NCT03158389|Experimental|Subtrial A: APG101|"weekly application of 800 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
9534395|NCT03158389|Experimental|Subtrial B: Alectinib|"600 mg orally twice daily (bid) for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
9534396|NCT03158389|Experimental|Subtrial C: Idasanutlin|"at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
9534397|NCT03158389|Experimental|Subtrial D: Atezolizumab|"application of 1200 mg i.v. every three weeks for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
9534398|NCT03158389|Experimental|Subtrial E: Vismodegib|"daily application of 150 mg orally for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
9534399|NCT03158389|Experimental|Subtrial F: Palbociclib|"75/100/125 mg orally once daily on 21/28 days~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks~followed by a 4 weeks break (after last dose of 2nd cycle)~and with maintenance therapy with palbociclib at 125 mg daily for 6 months or until progression"
9534400|NCT03158389|Experimental|Subtrial G: Temsirolimus|"weekly application of 25 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
9534401|NCT03158376|Experimental|gabapentin group|"the day before surgery : gabapentin 400 mg orally~preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution~postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
9534402|NCT03158376|Placebo Comparator|placebo group|"The day before surgery: 1 placebo capsule orally~preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine~postoperative day 1 to 10: 1 placebo capsule x 3"
9534403|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
9534404|NCT03158324|Experimental|Advanced refractory solid tumors|Patients with advanced refractory solid tumors will be enrolled.
9534405|NCT03157986|Active Comparator|Whole Body Vibration training|Balance Training on a Vibration platform
9534406|NCT03157986|Active Comparator|Conventional Balance training|Balance Training on a Balance board
9534407|NCT03158142|Experimental|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
9534408|NCT03158168|Experimental|study group|"The first group will receive Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by insulin syringe in the largest wart at the first visit.( Only those patients who showed a positive response to the Candida test antigen).I njections will be repeated for all patients into the same lesion every 3 weeks for three treatment sessions. Follow up for next six months for any recurrences.~Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c."
9534409|NCT03158168|Active Comparator|control group|"The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis [19]. Injections will be repeated for all patients into the same lesion every 2 weeks for three treatment sessions.Follow up for next six months for any recurrences.~Preparation of 2% zinc sulfate: A measure of 2g. of zinc sulfate powder is to be dissolved in 100 ml of sterile distilled water and autoclaved at 95c for 20 min(20)."
9534410|NCT03158259|Experimental|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
9534411|NCT03158259|Active Comparator|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
9534412|NCT03158129|Experimental|Arm A (nivolumab)|Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
9534413|NCT03158129|Experimental|Arm B (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.
9534414|NCT03158129|Experimental|Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)|Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
9534415|NCT03158129|Experimental|Arm D (ipilimumab, nivolumab, chemotherapy)|Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
9534416|NCT03158103|Experimental|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
9534417|NCT03158207|Experimental|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
9534418|NCT03158207|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
9534419|NCT03158194|Experimental|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
9534420|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
9534421|NCT03157973|Experimental|Education intervention|
9534422|NCT03157973|No Intervention|Standard of Care|
9534423|NCT03158246|Experimental|Yigu Group|"a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
9534424|NCT03158246|Active Comparator|Aclasta Group|"a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
9534425|NCT03158025|Experimental|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant [LEM] tablets; 3 × placebo zolpidem [ZOL] tablets; 2 × placebo suvorexant [SUV], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
9534426|NCT03158025|Experimental|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
9615889|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
9615890|NCT05124275|Placebo Comparator|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
9534427|NCT03158025|Experimental|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
9534428|NCT03158025|Experimental|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
9534429|NCT03158025|Experimental|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
9534430|NCT03158025|Experimental|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
9534431|NCT03157999|Experimental|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
9534432|NCT03157999|No Intervention|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
10038581|NCT01835834|Experimental|zirconia bridge restoration|"The device is a ceramic core made of shaded zirconium with an anatomic contour core with a minimum of 0.6 mm** thickness and minimal connector size of 4.0 x 3.0 / 9.4 (height x width [mm] / area [mm2])** of high strength zirconia framework providing homogenous veneering material thickness as an external coating with 1.0 - 2.0 mm* wall thickness. The core is veneered with dental porcelain at the dental laboratory.~Intended use and indications:~NobelProceraTM Bridge Shaded Zirconia consists of an individualized, supporting substructure in a ceramic bridge construction for tooth/teeth replacement.~NobelProceraTM Bridge Zirconia is intended for patients in need of prosthetic oral reconstruction in order to restore chewing function. Zirconia bridges for natural tooth restorations are customized, designed, and milled from pre-sintered blanks of zirconia. The multi-unit restorations can be placed in all positions in the mouth."
10038582|NCT01835847|Experimental|A single-arm study|
10038583|NCT01835860|Other|Embolization|Prostate artery embolization
10038584|NCT01835873|Active Comparator|Lactated Ringer's|Crystalloid solution - 1000 ml preload
10038585|NCT01835873|Active Comparator|HES 130/0.42|Hydroxyethyl starch (HES 130/0.42) - 500 ml preload
10038586|NCT01835886|Experimental|Performs stair-climbing|Performs stair climbing
10038587|NCT01835925||Tissue specmien|
10038588|NCT01835938|Experimental|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:~Dose level (DL) 1 = 50 mg / day,~Dose level (DL) 2 = 100 mg / day, and~Dose level (DL) 3 = 150 mg / day .~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
10038589|NCT01835938|Placebo Comparator|placebo|
10038590|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
10038591|NCT01835951|Other|Grouped Debriefing|Grouped debriefing consists in the analysis of the management of the anaesthesia crisis simulated in the presence of all the subject included in the Grouped Debriefing group.
10038592|NCT01835964|Experimental|Glucose Variability Observation|The study procedures will start after CGM device training & practice using the blinded CGM for 2 days and will continue over the course of ~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
9534433|NCT03157869|Experimental|Transcranial Direct Current Stimulation|"Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
9534434|NCT03157869|Sham Comparator|Control|"Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
9534435|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
10038593|NCT01835977|Active Comparator|Focal ablation|Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE
9534436|NCT03157947|Experimental|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
9534437|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
9534438|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
9534439|NCT03157856||Experimental: fluorescence assessment|Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.
9534440|NCT03157895|Experimental|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
9534441|NCT03157895|No Intervention|Comparison group|This group receives Children's Administration services as usual.
9534442|NCT03157609|Experimental|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
9534443|NCT03157609|Active Comparator|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
9534444|NCT03157570|Experimental|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
9534445|NCT03157570|No Intervention|Control group|The control group have no intervention and receives only standard care.
9534446|NCT03157596|Experimental|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration & followed by an interactive discussion .~the same evaluation was carried out again 3 months after the intervention."
9534447|NCT03157596|No Intervention|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
9534448|NCT03157804|Experimental|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
9534449|NCT03157726|Active Comparator|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
9534450|NCT03157726|Active Comparator|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
10038594|NCT01835977|Active Comparator|Extended ablation|Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE
10038595|NCT01835990|Experimental|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
10038596|NCT01835990|Active Comparator|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
9534451|NCT03157934||Primary CSC admission|Patients with primary admission to endovascular-ready hospital (comprehensive stroke center)
9534452|NCT03157934||Primary non-CSC SU admission|Patients with primary admission to non-endovascular-ready hospital with (regional/local) stroke unit
9534453|NCT03157934||Non-acute stroke hospital admission|Patients with primary admission to non-acute stroke-ready hospital
9534454|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
9534455|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
9534456|NCT03157791|Experimental|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
9534457|NCT03157791|No Intervention|Control|Group B will receive no simethicone tablets.
9534458|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between~01-Jan-2013 and 30-Sep-2016."
9534459|NCT03157778|Experimental|Obese men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.
9534460|NCT03157778|Active Comparator|Normal-weight men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.
9534461|NCT03157505|Active Comparator|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
9534462|NCT03157505|Placebo Comparator|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
9534463|NCT03157622|Active Comparator|Exposure in vivo|In the Exposure in vivo (EXP) condition, patients are given a careful explanation of the fear-avoidance model. Patients are encouraged to adopt the model to their individual situation. Factors for the maintenance of chronic pain (such as pain cognitions and pain-related fear) are discussed. Especially, negative consequences of avoidance behavior are highlighted. In preparation of the exposure sessions, patients develop an individual fear hierarchy using the Photo Series of Daily Actives. Subsequently, patients are encouraged to test their fear-avoidance beliefs during behavioral experiments and to reduce avoidance behaviors during individually tailored exposure exercises.
9534464|NCT03157622|Active Comparator|Cognitive Behavioral Psychotherapy|In the Cognitive Behavioral Psychotherapy (CBT) condition, patients are introduced to several strategies to improve their pain management. The principle of graded activity encourages patients to re-engage in former activities by dividing these activities into smaller steps. Predetermined resting periods are offered as a form to prevent patients from phases of excessive demands followed by long terms of recovery. Progressive muscle relaxation is introduced as a technique to improve the experience of pain. The strategy of attention shifting is presented to change their perception of pain. Maladaptive pain-related cognitions are identified and challenged by cognitive interventions.
9534465|NCT03157700|Experimental|REAL media|Participants in this group will be assigned to use the REAL media curriculum.
9534466|NCT03157700|No Intervention|Programming as usual|Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
9534467|NCT03157739|Experimental|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
9534468|NCT03157713|Experimental|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
9534469|NCT03157713|Experimental|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
9534470|NCT03157713|Other|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
9534471|NCT03157479|Experimental|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
9534472|NCT03157479|Active Comparator|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
9615891|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
10038597|NCT01836003|Experimental|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
9534473|NCT03157544|Experimental|Pain Relief Kit|Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.
9534474|NCT03157557|Experimental|Lifestyle treatment|Lifestyle treatment
9534475|NCT03157557|No Intervention|Treatment as Usual|Treatment as Usual
9534476|NCT03157518|Experimental|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
9534477|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.~Inclusion Criteria:~Patients included in the study will be:~> 18 years of age~Non-cardiac patients~Non-obstetric patients~Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
9534478|NCT03157765|Experimental|EMB intervention|These patients receive and endometrial biopsy
9534479|NCT03157765|No Intervention|Routine care|These patient receive routine care
9534480|NCT03157908|Experimental|Smartphone app|All participants in this pilot study will install the smartphone app for testing
9534481|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
9534482|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
9534483|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
9534484|NCT03157427|Experimental|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
9534485|NCT03157427|No Intervention|Control|The non randomized hand is not teated.
9534486|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
9534487|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
9534488|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
9534489|NCT03157375|Other|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
9534490|NCT03157375|Other|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
9534491|NCT03157375|Other|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
9534492|NCT03157375|Other|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
9534493|NCT03157271|No Intervention|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
9534494|NCT03157271|Experimental|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
9534495|NCT03157154||First group|Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis
9534496|NCT03157154||Control group|Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).
9534497|NCT03157284|Placebo Comparator|Placebo|Placebo Group will receive 7gr Maltodextrin
9534498|NCT03157284|Experimental|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
9534499|NCT03157297|Experimental|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
9534500|NCT03157310|Experimental|Gefitinib|Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
9534501|NCT03157167|Experimental|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
9534502|NCT03157167|Experimental|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
9534503|NCT03157167|Experimental|200 mcg/5 mCi Tc99m-Tilmanocept|Up to six subjects will receive a single subcutaneous injection and a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
9534504|NCT03157336|Experimental|Peer-led Intervention|Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
9534505|NCT03157336|Experimental|Specialist-led Intervention|Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
9534506|NCT03157349|Experimental|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
9534507|NCT03157349|Sham Comparator|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
9534508|NCT03157245||participant|
10038598|NCT01836003|No Intervention|Usual Care|Has not yet received Tokafatso combination programmatic intervention
10038599|NCT01836016|Experimental|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
9534509|NCT03157414|Active Comparator|Empagliflozin|10 mg once daily for 24 weeks
9534510|NCT03157414|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
9534511|NCT03157102|Experimental|HFNC group|
9534512|NCT03157102|Other|Standard Oxygen Therapy group (STO group)|
9534513|NCT03157076|Active Comparator|Pacing mode with CLS|
9534514|NCT03157076|Active Comparator|Intrinsic mode|
10038600|NCT01836016|Experimental|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
10038601|NCT01836016|Experimental|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
9534517|NCT03157193|Experimental|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
10038602|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
10038603|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
10038604|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
10038605|NCT01836081|Experimental|fluid responsiveness|
10038606|NCT01836094|Experimental|Methylene Blue|Methylene Blue, 280mg, oral, one time
10038607|NCT01836094|Placebo Comparator|Placebo|FD&C Blue No. 2 (food dye), oral, one time
10038608|NCT01836120|Experimental|Raltitrexed plus Docetaxel|
10038609|NCT01836120|Active Comparator|Docetaxel|
10038610|NCT01836146|Experimental|Renal Artery Ablation|
10038611|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
10038612|NCT01836159|Experimental|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
10038613|NCT01836172|Placebo Comparator|Placebo t.i.d.|Placebo t.i.d.
10038614|NCT01836172|Placebo Comparator|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
10038615|NCT01836172|Placebo Comparator|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
10038616|NCT01836172|Placebo Comparator|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
10038617|NCT01836211|Experimental|Fast strategy|High sensitivity cardiac troponin T followed by computed coronary tomography angiography
10038618|NCT01836211|Active Comparator|Standard of care strategy|Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
10038619|NCT01836224|Active Comparator|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
10038620|NCT01836224|Experimental|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
10038621|NCT01836237|Experimental|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
10038622|NCT01836237|No Intervention|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
9534518|NCT03157193|Sham Comparator|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
9534519|NCT03157193|No Intervention|Control 2 Group|No gel application, only standard perimplantitis treatment.
9534520|NCT03157388|Experimental|Intervention|Combined Vancomycin and Gentamycin and Meropenem
9534521|NCT03156972|Active Comparator|Group a|
9534522|NCT03156972|Active Comparator|Group b|
9534523|NCT03156855|Experimental|sequential therapy for 14 days (S14)|14 day sequential therapy
9534524|NCT03156855|Active Comparator|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
9534525|NCT03156946|Experimental|Breastfeeding support program|
9534526|NCT03156946|Other|Usual or routine care|
9534527|NCT03157011|Experimental|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
9534528|NCT03157024|Experimental|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
9534529|NCT03157024|Active Comparator|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
9615892|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
9615893|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
10038623|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
10038624|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
9482276|NCT03727334|No Intervention|Control|The control arm participants will receive their typical standard of care; they will not complete the intervention but will complete all of the in-person visits at the same post-injury time-points as the treatment group.
9482277|NCT03727022|Experimental|0.07 mg SM04690|Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle
9482278|NCT03727022|Placebo Comparator|Vehicle|Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
10038625|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
10038626|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
9482279|NCT03726957|Experimental|Intervention group|The intervention arm included households which received improved cookstoves
9482280|NCT03726957|No Intervention|Control group|The control group included households, which did not receive improved cookstoves, and cooked in their usual traditional cookstoves.
9482281|NCT03726346|Experimental|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
9482282|NCT03724825||obese men|Adult obese men (BMI ≥ 30 kg/m2)
9482283|NCT03724825||normal men|normal weight men (18.5 ≤ BMI < 25 kg/m2 )
9482284|NCT03721965|Experimental|Itacitinib + Corticosteroids|
9482285|NCT03721016|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
9482286|NCT03721016|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
9482287|NCT03721016|Placebo Comparator|Placebo|Placebo will be injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
9482288|NCT03720613||Naldemedine|Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.
9482289|NCT03720613||Lubiprostone|Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.
10038627|NCT01836289|Experimental|High-dose Cyclophosphamide|High-dose Cyclophosphamide
9482290|NCT03720613||Naloxegol|Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.
9482291|NCT03718728|Active Comparator|Standard group|A personalized diet and physical exercise recommendations.
9482292|NCT03718728|Experimental|Mind&Life (standard + intervention) group|A personalized diet and physical exercise recommendations plus the acceptance and mindfulness-based group intervention program.
9482293|NCT03714776|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRx injected subcutaneously once-weekly
9482294|NCT03714776|Placebo Comparator|Placebo|Placebo matching solution injected subcutaneously once-weekly
9482295|NCT03713632|Active Comparator|Secukinumab 1|Secukinumab 300mg every 2 weeks
9482296|NCT03713632|Active Comparator|Secukinumab 2|Secukinumab 300mg every 4 weeks
9482297|NCT03713632|Placebo Comparator|Placebo 1|Placebo group to secukinumab 300mg every 2 weeks
9482298|NCT03713632|Placebo Comparator|Placebo 2|Placebo group to secukinumab 300mg every 4 weeks
9482299|NCT03713619|Active Comparator|secukinumab 1|Secukinumab 300mg every 2 weeks
9482300|NCT03713619|Active Comparator|secukinumab 2|Secukinumab 300mg every 4 weeks
9482301|NCT03713619|Placebo Comparator|placebo 1|Placebo group to secukinumab 300mg every 2 weeks
9482302|NCT03713619|Placebo Comparator|placebo 2|Placebo group to secukinumab 300mg every 4 weeks
9482303|NCT03713021|Experimental|TraceIT Tissue Marker|"Following successful tumor resection, TraceIT Tissue Marker will be applied in 0.2 to 0.5 mL injections at 5 locations to mark the tumor bed: superiorly, inferiorly, laterally, medially, and center of resection. The marginal injections will be within 3 mm of the resection edge and within 5 mm deep. The center of the resection bed will be injected within 5 mm deep if possible.~Within 6 weeks after surgery, a CT simulation scan will be performed per normal protocol for patients receiving surgery followed by adjuvant therapy. This scan will be used to generate the intensity-modulated radiation therapy (IMRT) treatment plan~Two treatment plans will be performed per patient using the simulation CT scan. One will be the standard of care treatment plan and will be the basis of the actual radiation treatment they receive. The second treatment plan will be based on utilizing the TraceIT hydrogel markers as a guide for the resection bed."
9482304|NCT03712371|Experimental|Chitosan dose escalation|
9482305|NCT03712137|Experimental|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional maintenance treatment at Month 12.
9482306|NCT03712137|Experimental|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
9482307|NCT03710564|Experimental|Masked Arm 1|Brolucizumab 6 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
9482308|NCT03710564|Active Comparator|Masked Arm 2|Aflibercept 2 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
9482309|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
9482310|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
9482311|NCT03709121|Placebo Comparator|Vehicle Ophthalmic Solution|
9482312|NCT03706521|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
9482313|NCT03705832|Experimental|Active drug|Subjects assigned to the intervention will receive 2 grams daily of Ginger Extract for 56 days.
10038628|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
9482314|NCT03705832|Placebo Comparator|Placebo|Subjects assigned to the placebo group will receive a matching placebo for 56 days.
10038629|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
10038630|NCT01836315||Obese|Defined by a BMI >35 kg/M2
10038631|NCT01836315||Non-Obese|Defined by a BMI <35 kg/M2
10038632|NCT01836328|Active Comparator|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
10038633|NCT01836328|Experimental|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
10038634|NCT01836341|Experimental|Afatinib w Cisplatin Pemetrexed Chemoradiation|"induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation*~*afatinib dose levels: 20mg daily, 30mg daily & 40mg daily (3+3 design) Then adjuvant afatinib x 2 years"
10038635|NCT01836354|Active Comparator|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
10038636|NCT01836354|No Intervention|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
10038637|NCT01836367|Experimental|Ingenol Mebutate 0.015%|two cycles of ingenol mebutate 0.015%
10038638|NCT01836380|Experimental|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
9482315|NCT03705234|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.
9482316|NCT03705234|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.
9482317|NCT03704584|Active Comparator|Treatment Group (corticosteroid injection plus lidocaine)|Treatment Group (corticosteroid injection plus lidocaine) subjects will receive (Methylprednisolone acetate injectable suspension and Lidocaine HCl) for their upper extremity condition for their upper extremity condition
9482318|NCT03704584|Other|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (Methylprednisolone acetate injectable suspension) for their upper extremity condition
9482319|NCT03703102|Placebo Comparator|Arm A|Subcutaneous administration of placebo
9482320|NCT03703102|Experimental|Arm B|Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
9482321|NCT03703102|Experimental|Arm C|Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
9482322|NCT03703102|Experimental|Arm D|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
9482323|NCT03703102|Experimental|Arm E|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)
9482326|NCT03699475|Experimental|A: haplo-HSCT plus rivogenlecleucel|"αβ T-cell and CD19+ B-cell-depleted haploidentical stem cell transplantation plus rivogenlecleucel~Rimiducid will be administered to inactivate rivogenlecleucel in the event of GVHD not responsive to standard of care treatment"
9482327|NCT03699475|Active Comparator|B: haplo-HSCT followed by cyclophosphamide|haploidentical stem cell transplantation followed by cyclophosphamide post-transplant
9482328|NCT03694327|Experimental|Treatment A Mobile Application|Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.
9482329|NCT03694327|Active Comparator|Treatment B Mobile Application|Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.
9482330|NCT03691974|Experimental|Fasinumab|
9482331|NCT03691974|Placebo Comparator|Placebo|
9482332|NCT03690388|Experimental|Cabozantinib|cabozantinib (60 mg) once daily orally (qd)
9482333|NCT03690388|Placebo Comparator|Placebo|placebo once daily orally (qd)
9482334|NCT03688906||Cohort A|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
9482335|NCT03688906||Cohort B|"Blood and stool specimen collection.~Samples must be collected prior to performing bowel preparation for the colonoscopy."
9482336|NCT03688906||Cohort C|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
9482337|NCT03687632|Experimental|Single arm - active|ST266 eye drops given to the study eye for 28 days (112 doses total will be administered).
9615894|NCT05119920|Placebo Comparator|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
9534530|NCT03157024|Sham Comparator|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
9534531|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
9534532|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
9534533|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
9534534|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
9534535|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
9534536|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
9534537|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
9534538|NCT03156959|Experimental|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
9534539|NCT03156959|Active Comparator|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
9534540|NCT03157323|Other|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
9534541|NCT03156920|Active Comparator|Sumatriptan|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of sumatriptan 50 mg
9534542|NCT03156920|Placebo Comparator|Placebo|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of placebo
9534543|NCT03156738|Experimental|Dose 1|MT-2990 or Placebo
9534544|NCT03156738|Experimental|Dose 2|MT-2990 or Placebo
9534545|NCT03156738|Experimental|Dose 3|MT-2990 or Placebo
9534546|NCT03156738|Experimental|Dose 4|MT-2990 or Placebo
9534547|NCT03156738|Experimental|Dose 5|MT-2990 or Placebo
9534548|NCT03156803|Experimental|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
9534549|NCT03156803|No Intervention|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
9534550|NCT03156842|Experimental|Fimasartan/Amlodipine, Rosuvastatin|Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin
9534551|NCT03156842|Active Comparator|Fimasartan/Amlodipine|a fixed dose combination of Fimasartan/Amlodipine
9534552|NCT03156842|Active Comparator|Fimasartan, Rosuvastatin|Co-administration of Fimasartan and Rosuvastatin
9534553|NCT03156907|Experimental|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (HDB) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
9534554|NCT03156764||Qp/Qs ratio monitoring|Qp/Qs ratio monitoring
9534555|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
9534556|NCT03156790|Experimental|Spectrila®|recombinant L-Asparaginase
9615895|NCT05111782|Experimental|Treatment Group|The treatment group will consist of persons with low back pain. This group will be further divided into groups for each decade.
9615896|NCT05111782|No Intervention|Healthy Control Group|The control group will consist of healthy controls. This group will be further divided into groups for each decade.
9615897|NCT05104073|Experimental|Intervention|The intervention arm is characterized by calibrated formula feeding recommendations. The intervention group parents will be given written instructions on infant hunger and satiety cues as well as copies of videos with guidance on bottle feeding and how to soothe fussy infants without feeding. N=30 meeting inclusion/exclusion criteria
9615898|NCT05104073|No Intervention|Control|The control arm will have ad lib feeds as per usual care. N=30 meeting inclusion/exclusion criteria
9615899|NCT05102942|Experimental|Group A: a gamified AACTP smartphone application + treatment as usual (TAU)|
9615900|NCT05102942|Placebo Comparator|Group B: a gamified AACTP sham-control application + TAU|
9615901|NCT05102942|No Intervention|Group C: only TAU|
9534557|NCT03156829|Experimental|Splint alone|
9534558|NCT03156829|Experimental|Cortico-steroid alone|
9534559|NCT03156829|Experimental|Splint and cortico-steroid combined|
9534560|NCT03156881|Experimental|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
9534561|NCT03156881|No Intervention|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
9534562|NCT03156725|Experimental|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
9534563|NCT03156725|Experimental|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
9534564|NCT03156712|Experimental|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
9534565|NCT03156712|Experimental|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
9534566|NCT03156712|Experimental|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
9534567|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
9534568|NCT03156686|No Intervention|Control|Patients will be randomly assigned to conventional hospital care
9534569|NCT03156686|Experimental|Home care treatment|Patients will be randomly assigned to the HOME-based hospitalization and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home.
9534570|NCT03156673|Experimental|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
9534571|NCT03156478|No Intervention|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
9534572|NCT03156478|Experimental|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participant's health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
9534573|NCT03156478|Experimental|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
9534574|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
9534575|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
9534576|NCT03156465|Experimental|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
9534577|NCT03156439|Experimental|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
9534578|NCT03156387|Experimental|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
9534579|NCT03156387|Active Comparator|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
9615902|NCT05102344|Active Comparator|Psychosocial Treatment as Usual|Participants assigned to the active comparator arm will receive active non-pharmacological treatment utilizing behavioral social skills training strategies previously found to be effective in reducing symptoms of ADHD and improving social skills for children with ADHD
9534580|NCT03156556|Experimental|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.~Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.~Lesson 2 presents different strategies to generate helpful cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors and graded exposure.~Lesson 5 is about problem solving and relapse prevention.~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
9534581|NCT03156374|Experimental|Ovulation test use|Use of both ovulation tests and standardised care
9534582|NCT03156400|Active Comparator|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
9534583|NCT03156400|Active Comparator|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
9534584|NCT03156413|Experimental|F&P Nasal Mask|Trial nasal pillows CPAP mask
9534585|NCT03156530|Experimental|Auricular acupuncture|Stimulated with needles at three joint points of the lower limb, knee and ankle. Balance assessments will be performed prior to (initial) pacing, 20 minutes after the initiation of the pacing protocol (second evaluation) and after 5 minutes the final evaluation.
9534586|NCT03156530|Placebo Comparator|Control|Not receive stimulation.
9534587|NCT03156348|Experimental|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
9534588|NCT03156348|No Intervention|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.~Information will be collected that allows the characterization:~Sociodemographic~Morbid~Pharmaco-therapeutic~Functionality before (baseline), during and after hospitalization~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
9534589|NCT03156283|Experimental|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
9534590|NCT03156283|Other|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
9534591|NCT03156335|Experimental|Focused Ultrasound|
9534592|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
9534593|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
9534594|NCT03156452|Experimental|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
9622040|NCT02518906|Experimental|Adolescent Identity Treatment|Psychotherapeutic treatment performed routinely at the centres in Basel and Santiago de Chile
10038639|NCT01836380|Experimental|Cycling Training|The cycling training will be conducted in the newly-constructed Exercise Training Intervention Core-Laboratory in the Department of Kinesiology and Health Education on the University of Texas campus. In the first 2-3 weeks a cycling instructor will provide personalized skill feedback to the subjects in the cycle training group. Subjects will cycle 15-20 minutes/day at a relatively low intensity of exercise while they receive cycling skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
10038640|NCT01836393|Experimental|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
10038641|NCT01836406|Experimental|Keromin Group|
10038642|NCT01836406|Placebo Comparator|Placebo Group|
9534595|NCT03156452|Active Comparator|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
9534596|NCT03156517|Active Comparator|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
9534597|NCT03156517|Active Comparator|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
9534598|NCT03156660|Experimental|Weight gain prevention (Group 1)|Small Changes weight stability intervention
9534599|NCT03156660|Experimental|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
9534600|NCT03156660|Active Comparator|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
9534601|NCT03156361|Experimental|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
9534602|NCT03156361|Active Comparator|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
9534603|NCT03156634|Experimental|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
9534604|NCT03156634|Active Comparator|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
9534605|NCT03156296|Active Comparator|BUPIVACAINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
9534606|NCT03156296|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
9534607|NCT03156608|Experimental|Novii Device ECG/EMG System|These patients will have the Novii ECG/EMG system placed throughout labor and delivery, unless a provider or investigator determines that a different device (internal or external) is necessary for a better signal.
9534608|NCT03156608|Active Comparator|Standard of Care External Monitor|A standard external monitor will be placed throughout labor and delivery, unless a provider or investigator determines that an internal device is necessary for a better signal.
9534609|NCT03156647||idiopathic Parkinson disease|
10038643|NCT01836419|Experimental|young adult group|young adult patients undergoing minor urologic surgery or lower extremity surgery
9534610|NCT03156647||iatrogenic parkinsonian syndrome|
9534611|NCT03156647||healthy volunteers|
9534612|NCT03156322|Active Comparator|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
9534613|NCT03156322|Active Comparator|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
9534614|NCT03156322|Active Comparator|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
9534615|NCT03156075|Experimental|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
9534616|NCT03156075|No Intervention|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
9534617|NCT03156049|Active Comparator|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
9534618|NCT03156049|Active Comparator|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
9534619|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
9534620|NCT03156127|Experimental|BR-UPS 5 mg tablet|
10038644|NCT01836419|Active Comparator|elderly group|elderly patients undergoing minor urologic surgery or lower extremity surgery
9534621|NCT03156127|Active Comparator|Inisia 5 mg tablet|
9534622|NCT03156036|Experimental|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
9534623|NCT03156036|Active Comparator|MGMT hypermethylated Cohort B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
9534624|NCT03156036|Active Comparator|MGMT unmethylated Cohort A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
9534625|NCT03156036|Active Comparator|MGMT unmethylated Cohort B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.~(n=37)"
9534626|NCT03156140|Experimental|motion|Right hand performs three different motion types
9534627|NCT03156218|Experimental|Without ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
9534628|NCT03156218|Experimental|With mild to moderate ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 100 and < 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
9534629|NCT03156205|Experimental|Interactive Music Therapy|
9534630|NCT03156205|Other|passive music listening|
9534631|NCT03156205|Other|passive earphone-use|
9534632|NCT03156179||Girls with type 1 diabetes|
9534633|NCT03156101|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10^6/kg / 1x10^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
9622041|NCT02518906|Experimental|DBT-A|Psychotherapeutic treatment performed routinely at the centre in Heidelberg
9534634|NCT03156166|Experimental|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children <5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
9534635|NCT03156166|Experimental|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
9534636|NCT03156166|Experimental|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
9534637|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
9534638|NCT03156153|Experimental|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
9534639|NCT03156153|Placebo Comparator|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
9534640|NCT03156192|Experimental|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
9534641|NCT03156010|Other|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
9534642|NCT03156010|Other|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
9534643|NCT03156062|Experimental|study group|
9534644|NCT03156062|Active Comparator|control group|
9534645|NCT03155919|Experimental|TAUchoc|Treatment composed by taurine powder and chocolate milk
9534646|NCT03155919|Placebo Comparator|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
9534647|NCT03156231|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
9534648|NCT03156231|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
9534649|NCT03155906|Experimental|Integrated treatment|Patients randomised to receive integrated treatment will be counselled on treatment by physician working at MAR outpatient clinic where patient receive OST care, and will receive medication and follow-up at the same MAR outpatient clinic. Treatment medication will be given in line with national guidelines with a close and integrated follow-up.
9534650|NCT03155906|Active Comparator|Standard treatment|Those randomised to receive standard treatment will be offered referral for standard HCV treatment at a medical ward hospital clinic. Treatment medication will be given in line with national guidelines.
9534651|NCT03155971|Experimental|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
9534652|NCT03156023|Active Comparator|Active|Receive active investigational product (AMG 570).
9534653|NCT03156023|Placebo Comparator|Placebo|Receive placebo investigational product
9534654|NCT03155867|Active Comparator|Meal replacement A|
9534655|NCT03155867|Active Comparator|Meal replacement B|
9534656|NCT03155867|Active Comparator|Meal replacement C|
9534657|NCT03155867|Active Comparator|Meal replacement D|
9534658|NCT03155867|Active Comparator|Meal replacement E|
9534659|NCT03155867|Active Comparator|Meal replacement F|
9534660|NCT03155893|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 2 orally under fed conditions.
9534661|NCT03155893|Experimental|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 16 orally under fed conditions.
10038645|NCT01836484||Surgically staged endometrial and cervical carcinoma|
9534662|NCT03155893|Experimental|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1*25 mg tablet) and SMV 150 mg (2*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3*400 mg tablet) single dose on Day 15 orally under fed conditions.
9534663|NCT03155893|Placebo Comparator|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2; ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV [2*50 mg tablets] on Days 8 to 14, orally once daily under fed conditions.
10038646|NCT01836536|Other|BEVACIZUMAB|BEVACIZUMAB standard of care
10038647|NCT01836562|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
9534664|NCT03155893|Experimental|Panel 2: Treatment F|Participants will receive ODV 200 mg (4*50 mg tablets) on Days 1 and 2; ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
9534665|NCT03155854|Active Comparator|Pretendinous cord excision|Patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be excised
9534666|NCT03155854|Active Comparator|Division/manipulation of the cord|patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be incised.
9534667|NCT03155984||Anti-CD20 antibody|Patients with hematological malignancies receiving anti-CD20 antibody therapy
9534668|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
9534669|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
9534670|NCT03155841|Experimental|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
9534671|NCT03155841|Active Comparator|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
9534672|NCT03155516|Experimental|GPM Ward|Good Pain management ward
9534673|NCT03155516|Active Comparator|Control Ward|Current practice controlled ward
9534674|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.~Exclusion Criteria：~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI>30 ④With serious postoperative complications."
9534675|NCT03155490|Experimental|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
9534676|NCT03155490|No Intervention|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
9534677|NCT03155568|Active Comparator|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
9534678|NCT03155568|Active Comparator|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
9534679|NCT03155568|Active Comparator|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
9534680|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
9534681|NCT03155581|Other|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
9534682|NCT03155581|Other|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
9534683|NCT03155594|Experimental|Single arm|Patients in this trial will receive a FreeStyle Libre patch that continuously measures glucose in addition to their standard glucose monitoring.
9534684|NCT03155477|Experimental|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
9534685|NCT03155477|Placebo Comparator|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
9534686|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
9534687|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
9534688|NCT03155633|No Intervention|Rest Group|Rest during the 9 days after the race
9534689|NCT03155633|Experimental|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
9534690|NCT03155633|Experimental|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
9534691|NCT03155698|Experimental|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side~Intervention:~Combination Product: microneedling and Platelet rich plasma.~radiation : NB-UVB phototherapy"
9534692|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
9534693|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
9534694|NCT03155711|Experimental|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
9482338|NCT03686514|Experimental|H3N2 birth cohort|The H3N2 cohort consists of participants born between 1968-1977.
9482339|NCT03686514|Experimental|H1N1 birth cohort|The H1N1 cohort consist of participants born between 1948-1957.
9482340|NCT03684278|Active Comparator|Infusion of 5 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 5 mg of Infliximab, per kg of patient body weight.
9482341|NCT03684278|Active Comparator|Infusion of 10 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 10 mg of Infliximab, per kg of patient body weight.
9482342|NCT03684278|Placebo Comparator|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) 0.9% Sodium Chloride to be administered as a one time intravenous infusion over a period of 2 hours.
9482343|NCT03682770|Experimental|dupilumab + AR101|Participant randomization of a ratio of 2 active dupilumab arms
9482344|NCT03682770|Experimental|placebo matching dupilumab + AR101|Participant randomization of a ratio of 1 placebo arm
9482345|NCT03679884|Experimental|Daridorexant 10 mg|Film-coated tablets administered orally, once daily in the evening
9482346|NCT03679884|Experimental|Daridorexant 25 mg|Film-coated tablets administered orally, once daily in the evening
9482347|NCT03679884|Experimental|Daridorexant 50 mg|Film-coated tablets administered orally, once daily in the evening
9482348|NCT03679884|Placebo Comparator|Placebo|Film-coated tablets administered orally, once daily in the evening
9482349|NCT03679884|Experimental|Ex-Placebo Daridorexant 25 mg|Film-coated tablets administered orally, once daily in the evening
9482350|NCT03676751|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
9482351|NCT03676751|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
9482352|NCT03672175|Experimental|SAGE-217 (low dose)|
9482353|NCT03672175|Experimental|SAGE-217 (high dose)|
9482354|NCT03672175|Placebo Comparator|Placebo|
9482355|NCT03665038|Experimental|Brexanolone|
9482356|NCT03664921|Experimental|Omnitram|Oral Omnitram (10 mg tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet (10 mg) and 4 tablets (40 mg) to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
9482357|NCT03664921|Placebo Comparator|Placebo|Oral placebo (tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet and 4 tablets to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
9482358|NCT03664752|Experimental|IDP-120 Gel|Component A
9482359|NCT03664752|Placebo Comparator|IDP-120 vehicle gel|Vehicle
9482360|NCT03664739|Experimental|IDP-120 Gel|Component A
9482361|NCT03664739|Placebo Comparator|IDP-120 Vehicle Gel|Gel
9482362|NCT03662659|Experimental|BMS-986213 + investigator's choice chemotherapy|BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX
9482363|NCT03662659|Experimental|Nivolumab + investigator's choice chemotherapy|Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX
9482364|NCT03662542|Experimental|Combination Therapy|Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
9482365|NCT03662542|Experimental|Monotherapy: Guselkumab|Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
9482366|NCT03662542|Active Comparator|Monotherapy: Golimumab|Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
9482367|NCT03660943|Placebo Comparator|Placebo|Intra-articular Placebo Injection
9482368|NCT03660943|Experimental|CNTX-4975-05 (trans-capsaicin)|Intra-articular 1.0 mg CNTX-4975-05 Injection
9482369|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
9482370|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
9482371|NCT03660878|Placebo Comparator|Vehicle Ophthalmic Solution|
9482372|NCT03659929|Experimental|Arm 1: 20 mg/day|Amphetamine Sulfate
9482373|NCT03659929|Experimental|Arm 2: 40 mg/day|Amphetamine Sulfate
9482374|NCT03659929|Placebo Comparator|Arm 3: Placebo|Placebo, no active drug
9482375|NCT03658629|Experimental|Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-1 (Day 0) and Placebo (Day 28)
9482376|NCT03658629|Experimental|Quad-NIV Preformulated with Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-2 (Day 0) and Placebo (Day 28)
9482377|NCT03658629|Experimental|Quad-NIV Preformulated with Adjuvant Dose B|Alternating deltoid injections of 2018-2019 Quad-NIV-3 (Day 0) and Placebo (Day 28)
9482378|NCT03658629|Experimental|Quad-NIV Preformulated with Increased B HA Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-4 (Day 0) and Placebo (Day 28)
9482379|NCT03658629|Experimental|Quad-NIV without Adjuvant|Alternating deltoid injections of 2018-2019 Quad-NIV-5 (Day 0) and Licensed 2018-2019 Influenza vaccine (Day 28)
9482380|NCT03658629|Active Comparator|Licensed High-Dose Trivalent Influenza Vaccine|Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine (Day 0) and Placebo (Day 28)
9482381|NCT03658629|Active Comparator|Licensed Quadrivalent Influenza Vaccine|Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine (Day 0) and Placebo (Day 28)
9482382|NCT03657849|Experimental|Sampling with 19-gauge and 21-gauge|All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
9482383|NCT03657810|Experimental|CL-108 5 mg|Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet
9482384|NCT03657810|Active Comparator|Norco|hydrocodone 5 mg/APAP 325 mg
9482385|NCT03657810|Placebo Comparator|Placebo|Placebo 0 mg matching CL-108
9482386|NCT03657797|Experimental|NCX 470 0.021%|NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
9534695|NCT03155711|Active Comparator|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
9534696|NCT03155750|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx every day during the 8-week study period.
9534697|NCT03155750|Active Comparator|sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse.
9534698|NCT03155737|Experimental|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
9534699|NCT03155737|Active Comparator|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
10038648|NCT01836575|Experimental|Arm B|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle] + Antiemetic therapy at investigator's discretion.
10038649|NCT01836575|Active Comparator|Arm A:|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.
10038650|NCT01836588|Active Comparator|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
10038651|NCT01836588|Active Comparator|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
10038652|NCT01836601|No Intervention|Pre-nighttime communication intervention arm|This arm is the pre-intervention arm of parents, nurses, and residents before the nighttime communication bundle has been enacted.
10038653|NCT01836601|Experimental|Post-nighttime communication intervention arm|This arm is the post-intervention arm of parents, nurses, and residents after the nighttime communication bundle has been enacted.
10038654|NCT01836614|Active Comparator|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
9534700|NCT03155646|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
9534701|NCT03155646|Active Comparator|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
9534702|NCT03155646|Active Comparator|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
9534703|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
9534704|NCT03155659||CHNS|
9534705|NCT03155659||NHANES|
9534706|NCT03155789||Low Back Pain emanating from L4-5|"S TLIF at L4-5 (n=10)~MI TLIF at L4-5 (n=10)~XLIF at L4-5 (n=10)"
9534707|NCT03155789||Low Back Pain emanating from L5-S1|"S TLIF at L5-S1 (n=10)~MI TLIF at L5-S1 (n=10)~XLIF at L5-S1 (n=10)"
9534708|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"S TLIF at L4-5 and L5-S1 (n=10)~MI TLIF at L4-5 and L5-S1 (n=10)~XLIF at L4-5 and L5-S1 (n=10)"
9534709|NCT03155503|Active Comparator|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
9534710|NCT03155503|Active Comparator|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
9534711|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
9534712|NCT03155464|Other|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
9534713|NCT03155464|Other|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
9534714|NCT03155438||Low responder|"Low responder : women aged 25-49 years old with less than 5 oocytes (1-4 oocytes) retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
9534715|NCT03155438||Normal responder|"Normal responder women aged 25-49 years old with 5-15 oocytes retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
9534716|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
9534717|NCT03155373||A|Asymptomatic/mild symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction >60%)
9534718|NCT03155373||B|Symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction greater than or equal to 60%)
9534719|NCT03155373||C|Patients with impaired pre-operative left ventricular function (defined as left ventricular ejection fraction <60%)
9534720|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
9534721|NCT03155087||healthy subjects|the healthy subjects was not intervened
9534722|NCT03155295||Physical reality simulation (rehearsal)|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. Participants with patients assigned to preoperative rehearsal will undergo pre-operative simulation only once.
10038655|NCT01836614|Placebo Comparator|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
10038656|NCT01836627|Experimental|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
10038657|NCT01836627|No Intervention|Control|The control group will continue with their current daily care
9534723|NCT03155295||Virtual reality simulation|The DaVinci surgical skills simulator (DVSSS) uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. Participants with patients assigned to preoperative simulation will complete a refresher module on the Virtual reality simulator.
10038658|NCT01836653|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
9534724|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
9534725|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
9534726|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI <28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
9534727|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI <28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
9534728|NCT03155152|Experimental|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
9534729|NCT03155152|Active Comparator|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
9534730|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
9615903|NCT05102344|Experimental|Animal Assisted Intervention|Participants assigned to the experimental arm will receive active non-pharmacological treatment utilizing behavioral social skills training strategies previously found to be effective in reducing symptoms of ADHD and improving social skills for children with ADHD accompanied by live therapy dogs
9615904|NCT05100927||An MR pulse sequence developing on the MRIdian system|This a pilot study to assess and optimize an MR pulse sequence that we are developing on the MRIdian system. It is a single-center trial recruiting only normal volunteers. Volunteers may be grouped by anatomic region of assessment.
9615905|NCT05100095|Experimental|Radiation therapy|Patients receive radiation therapy in 10 daily fractions (M-F) over 2 weeks.
9615906|NCT05098613|Experimental|CD19x22 CAR T Cell Infusion|Lymphodepleting chemotherapy following by infusion of CD19x22 CAR T Cells
9615907|NCT05097456|Active Comparator|Laser treatment|carbon dioxide treatment
9615908|NCT05097456|Sham Comparator|Sham treatment|sham treatment
9615909|NCT05093868|Experimental|FIRMap™ (Abbott Laboratories, Abbott Park, IL)|A 64-pole basket mapping catheter (FIRMap™, Abbott Laboratories, Abbott Park, IL) will be used to passively acquire electrical signals
9615910|NCT05082727|Experimental|KOVIR (TD0068)|Standard dose, 5 capsules/time x 3 times/day x 14 days
9615911|NCT05082727|Placebo Comparator|Placebo|Placebo, 5 capsules/time x 3 times/day x 14 days
9615912|NCT05081648|Experimental|Intervention group: Multiple Single Cannulation Technique (MuST)|
9615913|NCT05081648|Other|Control group: Rope-ladder cannulation technique (RL)|
9615914|NCT05081271|Active Comparator|Homologous booster vaccine group|A single dose booster of the same type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
10038659|NCT01836653|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
10038660|NCT01836679|Experimental|Arm 1|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
10038661|NCT01836679|Placebo Comparator|Arm 2|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
10038662|NCT01836692|Experimental|Thoracic radiotherapy|Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
10038663|NCT01836705|Experimental|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
10038664|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
10038665|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
10038666|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
10038667|NCT01836731|Experimental|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
9534731|NCT03155165||Group A Retroview™ colonoscope|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy will be submitted to a Retroview™ colonoscope
10038668|NCT01836731|Experimental|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
10038669|NCT01836731|No Intervention|Control|"The control group is not enrolled in the CBEHPP.~Because of the government's commitment for the national roll out to the CBEHPP, the control population will receive the intervention as soon as possible following the conclusion of the trial phase. Nevertheless, we will continue to evaluate the sustained impact of the intervention for two additional years by monitoring various behavioural outcomes and indicators and their impact on exposure outcomes (drinking water, hand hygiene, consumption, schooling and labour market participation etc.). We will use data from the RCT phase and clinical records to estimate the effect of any sustained impact on health. Long term impacts can be inferred by using data from the trial as well as data on long term behavioural outcomes."
10038670|NCT01836744|Active Comparator|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
10038671|NCT01836744|Active Comparator|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
10058347|NCT02017704|Active Comparator|IMRT and Capecitabine (potentially randomized to this arm)|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
10058348|NCT02017704|Experimental|Endo-HDR (potentially randomized to this arm)|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
10058349|NCT02017730|Experimental|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of [11C]BMT-136088
10058350|NCT02017730|Experimental|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of [11C]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of [11C]BMT-136088
9534732|NCT03155165||Group B Retroview™ colonoscope|The rest of colonoscopies indicated will be submitted to a Retroview™ colonoscope
10058351|NCT02017730|Experimental|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of [11C]BMT-136088
10058352|NCT02017730|Experimental|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with [11C]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
10059460|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
10059461|NCT02027532|Active Comparator|Cefazolin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
10059462|NCT02027532|Active Comparator|Vancomycin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
10059463|NCT02027571|Experimental|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
10059464|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
10059465|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
10059466|NCT02027584||preterm infant|gestational age at birth < 37 weeks
10059467|NCT02027584||term infant|gestational age at birth >36 weeks
10038672|NCT01836757|Experimental|MSM group|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
10038673|NCT01836757|Placebo Comparator|Placebo Group|Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
9534733|NCT03155191|Experimental|Dose Level -1 to 2|"0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.~cohort -1: 3×10^5 cells/kg cohort 1: 1×10^6 cells/kg cohort 2: 3×10^6 cells/kg."
10038674|NCT01836770||Transforaminal Epidural Steroid Injection|Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.
9534734|NCT03155204|Experimental|Test Product 1|tiotropium pMDI 2 inhalations
9534735|NCT03155204|Experimental|Test Product 2|tiotropium pMDI 2 inhalations
9534736|NCT03155204|Experimental|Test Product 3|tiotropium pMDI 2 inhalations
9534737|NCT03155204|Experimental|Test Product 4|tiotropium pMDI 2 inhalations
9534738|NCT03155204|Active Comparator|Commercial Product|tiotropium Respimat 2 inhalations
9534739|NCT03155113|Other|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
9534740|NCT03155334|Other|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
10038675|NCT01836783|Experimental|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
9534741|NCT03155334|Other|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
9534742|NCT03155360||Infant with colics|"Infants with colics according to Wessel definition :~Recurrent episodes of irritability, fussing or crying from birth to 4 months of age~Episodes last for 3 hours per day ; on 3 days per week ; for 3 weeks~Episodes can not be attributed to another disorder"
9534743|NCT03155360||Infant without colics|
9534744|NCT03155386||Standard Angiomammography (SenoBright®)|
9534745|NCT03155386||Optimized angiomammography|
9534746|NCT03155256|Experimental|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
9534747|NCT03155256|Experimental|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
9534748|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
9534749|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
9534750|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
9534751|NCT03155074|Experimental|High-Intensity Training|
9534752|NCT03155074|No Intervention|Usual Care|
9534753|NCT03155048|Active Comparator|oral estradiol group|patients with the usage of 6 milligrams/day oral estradiol
9534754|NCT03155048|Active Comparator|estradiol transdermal patch group|patients with the usage of 3.9 milligrams estradiol transdermal patch
9534755|NCT03155126||Saline group|Patients resuscitated with saline
9534756|NCT03155126||Acetated Ringer's sodium group|Patients resuscitated with Acetated Ringer's sodium
9534757|NCT03155282||Cirrhotic group|30 patients with cirrhosis will be evaluated by EUS-E to measure liver and spleen stiffness. Different cirrhosis etiologies will be included like cirrhosis induces by alcohol, virus, autoimmune, nonalcoholic steatohepatitis (NASH), cryptogenic, primary sclerosing cholangitis and primary biliary cirrhosis. The cirrhotic status will be determinate by clinical, biochemical and/or imaging methods (abdominal ultrasound or CT scan).
9534758|NCT03155282||Control group|30 normal patients with no history of liver disease (negative hepatitis B virus and hepatitis C virus serology, insignificant alcohol intake, normal ultrasound and laboratory), in whom a EUS has to be performed to evaluate a esophageal or gastric subepithelial lesion, chronic pancreatitis, will be evaluated by EUS-E to measure liver and spleen stiffness.
9534759|NCT03154827|Experimental|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
9534760|NCT03154840|Experimental|Eutropin 4IU|
9534761|NCT03154840|Experimental|Eutropin AQ 12IU|
9534762|NCT03154840|Experimental|Eutropin Pen 36IU|
9534763|NCT03154892|Experimental|Intracameral injection|Intracameral injection of conbercept for the treatment of NVG
9534764|NCT03154892|Active Comparator|Intravitreal injection|Intravitreal injection of conbercept for the treatment of NVG
9534765|NCT03154736|Experimental|Interview|Individual interview an in a group interview. Socio-economic questionnaire
9534766|NCT03155035|Experimental|Intervention|Albendazole 200 mg 2 tablets single dose
10038676|NCT01836783|Active Comparator|Allograft|Atraumatic tooth extractions and allograft procedures
10038677|NCT01836796|Active Comparator|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
10038678|NCT01836796|Active Comparator|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
10038679|NCT01836796|Placebo Comparator|Placebo|
10058353|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
10058354|NCT02017769||Healthy controls|Healthy, gender and age matched controls
9534767|NCT03155035|Placebo Comparator|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
9534768|NCT03154853|No Intervention|normal foot|no intervention
9534769|NCT03154853|Experimental|functional flatfoot|Behavioral: short foot exercise
9534770|NCT03154762|Experimental|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
9534771|NCT03154762|Sham Comparator|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
9534772|NCT03154931|Active Comparator|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
9534773|NCT03154931|Experimental|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
9534774|NCT03154814|Experimental|ulinastatin treatment|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
9534775|NCT03154814|Placebo Comparator|control|conventional CPB was applied without ulinastatin treatment
10038680|NCT01836822|Experimental|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
9534776|NCT03154775|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
9534777|NCT03154970|Experimental|Obstructive sleep apnea group (G OSA)|The cervical stabilization will be performed with craniocervical flexion training aiming to strength the deep cervical flexors. For this purpose a pressure biofeedback device (stabilizer) that allows progressive levels of pressure during exercise(22-30 mmHg) will be used, which will be increased according to the capacity of the individuals (avoiding compensations or pain). The participant will be instructed to perform the craniocervical flexion in the supine position, the duration of the contraction will be 10 seconds followed by 10 seconds of rest (3 sets of 10 repetitions). The sessions will be held 2 times in weeks, for 6 weeks.
9534778|NCT03154970|No Intervention|Control group (GC)|The GC will be reassessed after six weeks and the same G OSA treatment will be offered after this period.
9534779|NCT03154866|Experimental|Lactobacillus kefiri LKF01 DSM32079|
9534780|NCT03154866|Placebo Comparator|Placebo|
9534781|NCT03154944|Experimental|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
9534782|NCT03154944|Experimental|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
9534783|NCT03154944|Experimental|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
9534784|NCT03154879||Comatose cardiac arrest survivors|
9534785|NCT03154723|Experimental|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
9534786|NCT03155009|Experimental|Alectinib|600 mg orally twice daily (BID) for up to 2 years
9534787|NCT03154918|Experimental|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
9534788|NCT03154905||Control|Healthy controls
9534789|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
10038681|NCT01836835||Hyperemesis gravidarum|Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
10038682|NCT01836835||Healthy pregnant women|Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
10038683|NCT01836848|Experimental|indocyanine green|in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy
9534790|NCT03154684|Active Comparator|STARK intervention|New care concept for hip fracture patients
9534791|NCT03154684|Other|Standard Care|Swiss standard of care for hip fracture patients
9534792|NCT03154983|Experimental|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
9534793|NCT03154671|Experimental|Intervention group|At study enrollment participants allocated to the intervention arm will complete a comprehensive geriatric assessment with the study intervention team (nurse and physician). Based on these findings a care plan tailored to the needs of the older adult with cancer will be developed and implemented. The study intervention nurse will call the participant at least monthly to follow up and evaluate the care (e.g. whether adjustments are required) and more if needed. All participants will receive a monthly healthy aging newsletter.
10038684|NCT01836861|Experimental|IPI-145 and [14C] IPI-145|
10038685|NCT01836874||Topiramate|
10038686|NCT01836887|Placebo Comparator|Intervention 1|Very low polyphenol fruit based drink (control)
10038687|NCT01836887|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - low
10038688|NCT01836887|Active Comparator|Invervention 3|Polyphenol-enriched fruit-based drink - high
10038689|NCT01836900|Active Comparator|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
9534794|NCT03154671|No Intervention|Control group|The participant will receive usual care from their treating oncology team. All participants will receive a monthly healthy aging newsletter.
9534795|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (neutral)|
9534796|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (marijuana)|
9534797|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (neutral)|
9534798|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (marijuana)|
9534799|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (neutral)|
9534800|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (marijuana)|
9534801|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
9534802|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
9534803|NCT03154632|Active Comparator|US Group|Ultrasound Therapy
9534804|NCT03154632|Active Comparator|DCD Group|Digital Capacitive Diathermy Therapy
9534805|NCT03154645|Active Comparator|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
9534806|NCT03154645|Active Comparator|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
9534807|NCT03154619|Active Comparator|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
9534808|NCT03154619|Placebo Comparator|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
10038690|NCT01836900|Experimental|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
10038691|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
9534809|NCT03154411|Experimental|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
9534810|NCT03154320|Active Comparator|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 9, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
9534811|NCT03154320|Experimental|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
9534812|NCT03154255|Experimental|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
9534813|NCT03154255|No Intervention|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
9534814|NCT03154385|Experimental|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
9534815|NCT03154450|Experimental|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
9534816|NCT03154450|Active Comparator|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
9534817|NCT03154424|Placebo Comparator|Bridging (control group)|External fixation in treatment the distal radius fracture
9534818|NCT03154424|Active Comparator|Nonbridging (tested group)|External fixation in treatment the distal radius fracture improve grip strength?
9534819|NCT03154216|Experimental|Exercise only|90 minutes of exercise
9534820|NCT03154216|Experimental|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
10038692|NCT01836926|Active Comparator|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
10058355|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
10058356|NCT02017782|Experimental|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3). with at least 2 weeks between each exposure session
9534821|NCT03154216|Experimental|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
9534822|NCT03154216|No Intervention|No exercise and no beverage|No exercise and no beverage
9534823|NCT03154489|Other|Acenocoumarol|
9534824|NCT03154489|Other|control group|
9534825|NCT03154307|Experimental|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
9534826|NCT03154307|Experimental|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
9534827|NCT03154307|Sham Comparator|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
10038693|NCT01836926|Active Comparator|laparoscopic intersphincteric resection .|"instruments used: 4 or 5 laparoscopic trocars (two or three (10-mm) trocar, Two 5-mm trocars and a 12-mm trocar with reducers),Three 5-mm fenestrated grasping forceps, Five-millimetre coagulating shears, a 5-mm straight grasping forceps, Harmonic scalpel, 5 or 10 mm, a 10-mm fenestrated forceps, a 10-mm dissector,5 mm Bipolar grasper, a 5-mm needle holder, Twelve-millimetre linear staplers~intervention:~Trocar Placement and Exposure~Rectosigmoid Mobilization and Control of Inferior Mesenteric Vessels~Taking Down the Splenic Flexure~rectal dissection till the levator ani muscle and resection of thye lateral ligaments~then the peranal phase as in the laparotomy approach."
10038694|NCT01836939|Active Comparator|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
9534828|NCT03154307|Experimental|Short-term protocol|LF-rTMS intervention daily for up to 5 days in medically refractory status epilepticus participants only
9534829|NCT03154398||1|case control
9534830|NCT03154463|Active Comparator|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
9534831|NCT03154463|Active Comparator|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
10038695|NCT01836939|Active Comparator|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
9534832|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
9534833|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
10038696|NCT01836952||Infants|Infant born via vaginal delivery
9534834|NCT03154515|Experimental|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
9534835|NCT03154515|Placebo Comparator|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
9534836|NCT03154346||General Population|An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
9534837|NCT03154541|Experimental|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
10038697|NCT01836965|Experimental|Social Skills Intervention|The intervention is a 12-week social skills training program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session (in the form of a photography class with typically developing peers) meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the photography class. During the group therapy session adolescents will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with a typically developing peer for the photography class.
10038698|NCT01836978|No Intervention|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
10038699|NCT01836978|Experimental|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
10038700|NCT01836991|Other|D2 surgery|D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)
10038701|NCT01836991|Experimental|D2+ surgery|D2+ surgery(D2+8p、12b、13、14v lymph node)
10038702|NCT01837004|Experimental|CORTEX|The CORTEX group will attend 10, 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
9534838|NCT03154541|Experimental|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
9534839|NCT03154372|Other|deliberate practice|expert supervised practice with validated metrics
9534840|NCT03154372|Other|self-guided practice|self guided practice with validated metrics
9534841|NCT03154229|Active Comparator|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
9534842|NCT03154229|Active Comparator|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
9534843|NCT03154294|Experimental|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
9534844|NCT03154294|Experimental|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
9534845|NCT03154294|Experimental|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
9534846|NCT03154294|Experimental|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
9534847|NCT03154294|Experimental|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
9534848|NCT03154606|Experimental|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
9534849|NCT03154606|Active Comparator|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
9534850|NCT03154281|Experimental|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
9534851|NCT03154281|Experimental|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
9534852|NCT03154281|Experimental|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
9534853|NCT03154281|Experimental|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
9534854|NCT03154177|No Intervention|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
9534855|NCT03154177|Other|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
9534856|NCT03154177|Experimental|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
9534857|NCT03154177|Experimental|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
9534858|NCT03154125|Experimental|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
9534859|NCT03154125|Experimental|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
9534860|NCT03154125|Experimental|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
9534861|NCT03154060|Experimental|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
9534862|NCT03154034||Severe mitral regurgitation|
9534863|NCT03153800|Experimental|Bronchial basal cells|
9534864|NCT03153839|Experimental|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
9534865|NCT03153839|No Intervention|Control group|71 infants who will not practice the programme. They only will be evaluated.
9534866|NCT03153722|Experimental|Pediatric discharge process intervention|All patients hospitalized on the pediatric ward under the pediatric hospitalist service will participate in pediatric discharge process interventions.
9534867|NCT03153735|Experimental|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
9534868|NCT03153735|Active Comparator|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
9534869|NCT03153761|Experimental|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
9534870|NCT03153761|Experimental|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
9534871|NCT03153774|Experimental|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
9534872|NCT03153774|Experimental|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
9534873|NCT03153891|Experimental|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
9534874|NCT03153891|Experimental|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
9534875|NCT03153891|No Intervention|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
9534876|NCT03153852|Experimental|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
9534877|NCT03153943|Experimental|Workbook support group|Printed educational workbook and pedometer.
9534878|NCT03153943|Experimental|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
9534879|NCT03154008|Experimental|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
9534880|NCT03153930|Placebo Comparator|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
9534881|NCT03153930|Experimental|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
9534882|NCT03153813|Experimental|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
9534883|NCT03153813|Placebo Comparator|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
9534884|NCT03153904|Experimental|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
9534885|NCT03153904|Active Comparator|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
9534886|NCT03153917|Experimental|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
9534887|NCT03153995|Experimental|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
9534888|NCT03153995|Active Comparator|periosteal releasing incision|periosteal releasing incision will be performed for Eight patients during ridge augmentation surgery .
9534889|NCT03154021|Experimental|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
9534890|NCT03154021|Placebo Comparator|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
9534891|NCT03154073|Experimental|Moderate Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
9534892|NCT03154073|Experimental|Vigorous Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
9534893|NCT03153982|Experimental|Head and neck squamous cell carcinoma|"Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery.~Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg)."
9534894|NCT03153657|Experimental|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
9534895|NCT03153657|Placebo Comparator|Placebo|Intervention: Drug Placebo
9534896|NCT03153644||Patients|Women with chronic medical conditions
9534897|NCT03153644||Primary Care Providers and Medical Staff|"Primary care providers can include doctors and advanced practice professionals, including midwives, nurse practitioners, and physician assistants.~Medical staff can include social workers, nurses, medical assistants, and administrative staff"
9534898|NCT03153644||Primary Practice|Primary care practices (family medicine, internal medicine, medicine-pediatric, or any combination of these) that at a practice-level already provide contraceptive counseling and services to reproductive-age women
9534899|NCT03153683||Acute Ischemic Stroke Patients|This is a registry. No above standard of care interventions will take place. Participants must have an acute thromboembolus within an intracranial artery in the anterior circulation (internal carotid, anterior cerebral, middle cerebral), which undergoes mechanical thrombectomy per standard of care.
9534900|NCT03153696|Experimental|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
9534901|NCT03153696|Other|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
9534902|NCT03153605|Experimental|SATISI_7|
9534903|NCT03153527|Placebo Comparator|Placebo arm (intervention arm)|Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
9534904|NCT03153527|Active Comparator|Verum group (control/standard arm)|If patient is on > 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
9534905|NCT03153332||MDCT group|The MDCT images of seven hepatic tumors were loaded on software to uniform study conditions, allowing both axial and coronal scans visualization.
9534906|NCT03153332||3D visualization system group|The 3D virtual reconstructions of seven hepatic tumors were loaded on the visualization software which enables the rotation of the virtual model.
9534907|NCT03153332||3D printing group|3D-printed models of seven hepatic tumors were created based on MDCT images, participants were allowed to freely handle them.
9534908|NCT03153267|Active Comparator|EM-7 days doxycycline|
9534909|NCT03153267|Active Comparator|EM-14 days doxycycline|
9534910|NCT03153267|Placebo Comparator|Controls|
9534911|NCT03153501|Other|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
9534912|NCT03153488|Experimental|Methylphenidate|Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
9534913|NCT03153488|Experimental|Amphetamine|Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
9534914|NCT03153540|Active Comparator|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
9534915|NCT03153540|Sham Comparator|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
9534916|NCT03153293|Experimental|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
9534917|NCT03153358|Experimental|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
9534918|NCT03153618|Experimental|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
9534919|NCT03153618|No Intervention|Control|Current standard of care will be followed
9534920|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
9534921|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
9534922|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
9534923|NCT03153592|Active Comparator|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O.
9534924|NCT03153592|Experimental|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
9534925|NCT03153397|Experimental|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
9534926|NCT03153397|Active Comparator|Osmolite|non-prebiotic fiber containing formula (Osmolite)
9534927|NCT03153423|Other|Basic intermittent exotropia patients|
9534928|NCT03153553|Active Comparator|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
9534929|NCT03153553|Sham Comparator|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
9534930|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
9534931|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
9534932|NCT03153228||Control|29 healthy volunteers.
9534933|NCT03153436|Active Comparator|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
9534934|NCT03153436|Active Comparator|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
9534935|NCT03153345|Experimental|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
9534936|NCT03153345|Active Comparator|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
9534937|NCT03152942|Experimental|Progesterone alone|Progesterone 400 mg once daily until 34 weeks.
9534938|NCT03152942|Active Comparator|Progesterone and aminophylline.|Progesterone 400 mg and aminophylline 225 mg once daily until 34 weeks.
9534939|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
9534940|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
9534941|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
9534942|NCT03153072|Other|A child with supraventricular tachycardia|
9534943|NCT03152981|Active Comparator|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
9534944|NCT03152981|Active Comparator|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
9534945|NCT03153306|Experimental|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
9534946|NCT03153306|Experimental|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
9534947|NCT03153254|Experimental|Healthy persons|Test upper limb robot assisted therapy device. During 1 session of 1/2 hour.
9534948|NCT03153254|Experimental|Stroke patients|Training with new upper limb robot assisted therapy device. During 2 to 5 sessions of 1/2 hour.
9534949|NCT03153098||Standard delivery|Participants will receive a behaviour change technique booklet, consultations (baseline, and optional at 3, 6, and 12 months), a booster phone call (week 2), motivational text messages (weeks 3, 6, and 12), and signposting to 12 weeks of exercise classes.
9534950|NCT03153098||Enhanced delivery|Participants will receive the same as intervention but the 12 weeks of exercise will be free and tailored to their needs, and there will be optional exercise 'buddies' available.
9534951|NCT03153163|Experimental|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
9534952|NCT03153124|Experimental|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
9534953|NCT03153124|No Intervention|Control|No intervention
9534954|NCT03153176|Experimental|intervention|Training program for Physical Education teacher. Individual level: moderate to vigorous physical activity. Organizational level: school health policy for healthy lifestyle
9534955|NCT03153176|No Intervention|no intervention|Physical Education and school curriculum as usual
9534956|NCT03153046|Experimental|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
9534957|NCT03153046|Placebo Comparator|Maltodextrin|12 week ingestion of maltodextrin
9534958|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
9534959|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
9534960|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
9534961|NCT03153085|Experimental|TBI-1401(HF10) + Ipilimumab|1x10^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
9534962|NCT03153137|Experimental|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
9534963|NCT03153137|Placebo Comparator|Placebo|film-coated tablet; oral use
9534964|NCT03153215|Active Comparator|Intervention group|women with severe IUGR
9534965|NCT03153215|Active Comparator|Control group|women with severe IUGR
10058357|NCT02017782|Active Comparator|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3) with at least 2 weeks between each exposure session.
9534966|NCT03153566|Experimental|study group|include (15) patients will be injected with Tuberculin vaccine 0.3 ml every 2 weeks, vaccine will be injected in the largest wart, 4 sessions will be done then patients will be followed for 2 months
9534967|NCT03153566|Active Comparator|control group|include (15) patients will be treated with cryotherapy every 2 weeks ,4 sessions will be done then patients will be followed for 2 months
9534968|NCT03153566|Experimental|combined group|include (15) patients will be treated with combined cryotherapy and Tuberculin vaccine , one week cryotherapy and the other week Tuberculin vaccine , then patients will be followed for 2 weeks
9534969|NCT03153202|Experimental|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
9534970|NCT03153202|Experimental|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
9534971|NCT03152955|Experimental|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
9534972|NCT03152955|Experimental|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
9534973|NCT03152955|Sham Comparator|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
9534974|NCT03152929|Active Comparator|Paravertebral Block|The Paravertebral Block is performed along the spine utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
9534975|NCT03152929|Active Comparator|Pectoral Nerve Block|The Pectoral Nerve Block is performed anteriorly, at the level of the axillary line, also utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
9534976|NCT03152864|Experimental|Full Package|
9534977|NCT03152864|No Intervention|Sensing Only|
9534978|NCT03152916|Experimental|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
9534979|NCT03152903|Experimental|VPM1002 (Recombinant BCG vaccine)|
9534980|NCT03152903|Placebo Comparator|Placebo|
9534981|NCT03152565|Experimental|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
9534982|NCT03152721|Placebo Comparator|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
10058358|NCT02017795|Experimental|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
10058359|NCT02017795|Active Comparator|regular-care group|written asthma action plan (WAAP) group
10058360|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
10058361|NCT02017808||OCT|Healthy controls
10058362|NCT02017821|Experimental|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
9534983|NCT03152721|Experimental|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
9534984|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.~The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.~Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
9534985|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.~Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.~Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
9534986|NCT03152890|Experimental|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
9534987|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
9534988|NCT03152747||B|"Group B with no/partial PVD~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
9534989|NCT03152799|Experimental|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
9534990|NCT03152799|Sham Comparator|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
9534991|NCT03152578|Active Comparator|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
9534992|NCT03152578|Active Comparator|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
9534993|NCT03152578|Placebo Comparator|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
9534994|NCT03152825||Viable myocardium Group|"At least ONE of the following:~Late gadolinium enhancement <75%.~Improvement in segmental function ≥1 grade during low dose dobutamine"
9534995|NCT03152825||Non-viable myocardium group|"At least ONE of the following:~Late gadolinium enhancement ≥75%.~No improvement in segmental function during low dose dobutamine"
10038703|NCT01837017|Experimental|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb & core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
10038704|NCT01837017|No Intervention|Control|Wait-list control.
10038705|NCT01837030|Other|Oral Iron|
9534996|NCT03152825||Inducible ischaemia group|"At least ONE of the following:~perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine~new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
9534997|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
10038706|NCT01837030|Other|Oral Iron and Capsule Endoscopy|
10058363|NCT02017821|No Intervention|care as usual|
9534998|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
9534999|NCT03152812||free skin flaps|
9535000|NCT03152812||free muscle flaps|
9535001|NCT03152851|Experimental|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior & posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
9535002|NCT03152851|No Intervention|Non-pressure stimulus group|No pressure stimulus would be given
10058364|NCT02017834|Experimental|harmonic scalpel|
9535003|NCT03152643|Experimental|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
9535004|NCT03152643|Experimental|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
9535005|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
9535006|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
9535007|NCT03152682|Experimental|Consume GoodIdea at Visit 2 and Placebo at Visit 3|
9535008|NCT03152682|Experimental|Consume Placebo at Visit 2 and GoodIdea at Visit 3|
9535009|NCT03152695|Experimental|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
9535010|NCT03152877|Experimental|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
9535011|NCT03152877|Active Comparator|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
9535012|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
9535013|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
9535014|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
9535015|NCT03152331|Experimental|Receptive Awareness Training|
9535016|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
9535017|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
9535018|NCT03152435|Experimental|anti-tumor response of CART-EGFR|
9535019|NCT03152396|Other|Patients with inflammatory arthritis|All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.
9535020|NCT03152383|Experimental|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
9535021|NCT03152383|Active Comparator|Typically developing|Children who are typically developing
9535022|NCT03152383|Active Comparator|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
9535023|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
9535024|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
9535025|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
9535026|NCT03152370|Experimental|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose [RP2D] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared [mg/m^2]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
10038707|NCT01837043|Experimental|Belatacept|Subjects will be converted from standard of care CNI therapy to Belatacept 10 mg/kg IV on post renal transplant Day 7 (+/- 3 days). As suggested in the package insert for de novo dosing, further dosing of belatacept will be given as 10 mg/kg IV at weeks 2, 4, 8 and 12 then 5 mg/kg at week 16 and then every 4 weeks (+/- 5 days) through week 52. CNI will be stopped during the first belatacept infusion.
10038708|NCT01837043|Active Comparator|Calcineurin Inhibitor|Patients randomized to this arm will remain on the current CNI as prescribed by post-transplant standard of care therapy.
9535027|NCT03152370|Experimental|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
9535028|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
9535029|NCT03152214|Experimental|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:~1 session of exercise counseling~3 weekly 25-minute sessions of vigorous intensity aerobic exercise~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
9535030|NCT03152214|Active Comparator|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
9535031|NCT03152214|No Intervention|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:~• 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
9535032|NCT03152409|Active Comparator|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
9535033|NCT03152409|Placebo Comparator|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
9535034|NCT03152240||Women patients|Women patients
9535035|NCT03152240||Men patients|Men patients
9535036|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
9535037|NCT03152500|Experimental|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
9535038|NCT03152500|Active Comparator|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
9535039|NCT03152487|Active Comparator|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
9535040|NCT03152487|Active Comparator|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
9535041|NCT03152474|Active Comparator|Solumedrol 20mg|Solumedrol injection will be given in the vein every 8 hrs. for 7 days.
9535042|NCT03152474|Active Comparator|Vitamin A 100,000 IU|Vitamin A injection will be given in the arm muscle for 7 days.
9535043|NCT03152474|Placebo Comparator|Placebo|Placebo will be given in the vein every 8 hrs. for 7 days or given in the arm muscle for 7 days.
10038709|NCT01837082|Active Comparator|Iron|ferric carboxymaltose
10038710|NCT01837082|Placebo Comparator|Placebo|Sodium chloride 0.9%
10038711|NCT01837095|Experimental|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
10038712|NCT01837108|Placebo Comparator|Placebo|fully mimicking placebo 50 mg bid during 8 days
10038713|NCT01837108|Experimental|eplerenone|eplerenone 50 mg bid during 8 days
10038714|NCT01837121|Other|the SMS group|the diabetic retinopathy patient in the SMS group will receive a SMS reminder message about the revisit time,address 1 week and 3 day before the appointment.
10038715|NCT01837121|No Intervention|the control group|the diabetic retinopathy patient in the control group won't get any reminder message before the appointment.
10058365|NCT02017834|Active Comparator|standard technique|
10058366|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
10058367|NCT02017873|Active Comparator|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
9482387|NCT03657797|Experimental|NCX 470 0.042%|NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
9482388|NCT03657797|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
9482389|NCT03657797|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks
9482390|NCT03655990||Treatment with the JUVORA™ Dental Disc|Subjects receive the device as per normal standard practice, there are no other treatment arms for this prospective study.
9482391|NCT03653715|Experimental|Test Device|Within this arm the Clerio Vision LIRIC-modified Bifocal Contact Lens is administered.
9482392|NCT03653715|Active Comparator|Control Devices|Within this arm the Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, and Clerio Vision Single Vision Contact Lens are administered.
9482393|NCT03653026|Experimental|Upadacitinib 45 mg|Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period.
9482394|NCT03653026|Placebo Comparator|Placebo|Participants received placebo matching to upadacitinib once daily for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period.
9482395|NCT03648827|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.
9482396|NCT03647592||Cohorts 1|patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
9482397|NCT03647111||Cohorts 1|
9482398|NCT03647098||Cohorts 1|Treatment plan
9482399|NCT03647098||Cohorts 2|brain metastases
9482400|NCT03647098||Cohorts 3|Concomitant KRAS mutation
9482401|NCT03646994||Cohorts 1|ROS1 fusion positive NSCLC patients who received crizotinib
9482402|NCT03646968|Experimental|Cohorts|Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
9482403|NCT03638466|Active Comparator|Single dose of SPN-810|Subjects will be treated with medium dose of SPN-810
9482404|NCT03638466|Placebo Comparator|Placebo|Subjects will be treated with a matching Placebo
9482405|NCT03638453|Experimental|PediCARE|"PediCARE Administered x6 mos~Resource Provision: Monthly Groceries (delivery via Instacart)~Resource Provision: Transport to/from home/hospital 8x per month (via RideHealth)"
9482406|NCT03638453|Active Comparator|Usual Care|The control group will receive usual supportive care
9482407|NCT03638258|Experimental|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% topically applied once daily
9482408|NCT03638258|Experimental|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% topically applied once daily
9482409|NCT03638258|Placebo Comparator|ARQ-151 Vehicle cream|Matching vehicle cream containing only excipients of ARQ-151 cream applied once daily
9482412|NCT03635996|Experimental|Etripamil NS 70 mg|The dose of etripamil to be evaluated in NODE-302 is 70 mg.
9482413|NCT03633643|Placebo Comparator|Group A|Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
9482414|NCT03633643|Active Comparator|Group B|3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
9482415|NCT03632993|Active Comparator|Treatment I: CCH Shallow Injection, 3 Aliquots|"In Treatment I, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 mL aliquots (for a total injection volume of 0.3 mL).~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
9482416|NCT03632993|Active Comparator|Treatment II: CCH Shallow Injection, 1 Aliquot|"In Treatment II, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
9482417|NCT03632993|Active Comparator|Treatment III: CCH Deep Injection, 1 Aliquot|"In Treatment III, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
9482418|NCT03632993|Active Comparator|Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
9535044|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
9535045|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
9535046|NCT03152227|Experimental|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
9535047|NCT03152227|Active Comparator|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
9535048|NCT03152227|No Intervention|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
9535049|NCT03152188|Experimental|FMT|Fecal Microbiota Transplantation (FMT) capsules
9535050|NCT03152188|Placebo Comparator|Placebo|Placebo capsules
9535051|NCT03152318|Experimental|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
9535052|NCT03152318|Experimental|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Cyclophosphamide one intravenous injection 2 days prior to procedure.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
9535053|NCT03152175|Experimental|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
9535054|NCT03152175|Placebo Comparator|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
9535055|NCT03152097|Placebo Comparator|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
9535056|NCT03152097|Experimental|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
9535057|NCT03152032|Experimental|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
9535058|NCT03152045|Experimental|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
9535059|NCT03152045|No Intervention|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
9535060|NCT03152058|Experimental|Certolizumab Pegol|"All participants are administered certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
9535061|NCT03152253|Experimental|Text Message for Smoking Cessation|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
9535062|NCT03152253|Placebo Comparator|Non-Interventional Text Messages|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
9615915|NCT05081271|Active Comparator|Heterologous booster vaccine group|A single dose booster of the opposite type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
9615916|NCT05079230|Experimental|Magrolimab + Venetoclax + Azacitidine|"Participants will receive~magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
9615917|NCT05079230|Placebo Comparator|Magrolimab Placebo + Venetoclax + Azacitidine|"Participants will receive~magrolimab placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
9615918|NCT05068856|Experimental|HRS2543|
10058368|NCT02017873|Experimental|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
10058369|NCT02017886|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
9615922|NCT05062993|Experimental|study group|Patients with chronic radicular pain will be included in this study. Ultrasound guided caudal epidural pulse radiofrequency technique will be applied to the study group.
9535063|NCT03152149|Active Comparator|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
9535064|NCT03152149|Active Comparator|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
9535065|NCT03152071|Experimental|Robot assisted thoracic surgery|RATS
9535066|NCT03152071|Active Comparator|Video assisted thoracic surgery|VATS
9535067|NCT03151980|Active Comparator|Hamam treated skin and sun exposure|
9535068|NCT03151980|Other|Untreated skin and sun exposure|
9535069|NCT03151759||No radiotherapy|Surgery only
9535070|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
9535071|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
9535072|NCT03152123|Experimental|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
9535073|NCT03152123|Experimental|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
9535074|NCT03152123|Active Comparator|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
9535075|NCT03152123|Placebo Comparator|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
9535076|NCT03151785|Active Comparator|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
9535077|NCT03151785|Active Comparator|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
9535078|NCT03151785|Active Comparator|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
10038716|NCT01837134|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
9535079|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
9535080|NCT03151863|Active Comparator|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
9535081|NCT03151863|Experimental|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
9535082|NCT03151837|Experimental|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
9535083|NCT03151837|Placebo Comparator|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
9535084|NCT03151993|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
9535085|NCT03151993|Active Comparator|Actilyse|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
9535086|NCT03151967|Active Comparator|applicator containing active drug|Vaginal applicator containing Lactobacillus crispatus CTV-05
9535087|NCT03151967|Placebo Comparator|placebo vaginal applicator|Inactive vaginal applicator without any drug
9535088|NCT03151772|Experimental|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
9535089|NCT03151772|Experimental|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
9535090|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam~vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System~Vaginal smear for evaluation with Gram's stain and Nuget's criteria~Vaginal swab for yeast culture~Vaginal swab for Trichomonas vaginalis NAAT~Vaginal swab for discrepant analysis testing"
9535091|NCT03151954|Experimental|nasal polyps|"Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.~Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.~Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;~Explore the regulation of hippo-YAP pathway in NESCs."
9535092|NCT03151954|Placebo Comparator|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
9535093|NCT03151876|Experimental|ChiCGB|"Experimental: ChiCGB~Chidamide administered orally on D-7, -4, 0,+3~Cladribine administered at 10mg on D-6 to D-2~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.~Interventions:~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
9535094|NCT03152006|No Intervention|Control|The control arm does not receive the ACT intervention.
10038717|NCT01837134|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
10038718|NCT01837134|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
9535095|NCT03152006|Experimental|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
9535096|NCT03151889|Experimental|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
9535097|NCT03151889|No Intervention|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
9535098|NCT03151733|Experimental|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
9535099|NCT03151733|Placebo Comparator|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
9535100|NCT03151720|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
9535101|NCT03151720|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
9535102|NCT03151720|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
9535103|NCT03151720|Experimental|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
9535104|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
9535105|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
9535106|NCT03151681|Experimental|Propranolol pill + mismatch memory reactivation|Prediction-error will be incorporated into each treatment sessions.
9535107|NCT03151681|Experimental|Propranolol pill + standard memory reactivation|
9535108|NCT03151681|No Intervention|Waitlist|
9535109|NCT03151707|Experimental|Nicotinamide riboside 2g/day|
9535110|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
9535111|NCT03151564|Experimental|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
9535112|NCT03151564|Experimental|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
9535113|NCT03151655|Experimental|MATTeRS Video|
9535114|NCT03151655|Active Comparator|Didactic Video|
9535115|NCT03151577|Other|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
9535116|NCT03151668|Experimental|Dexmedetomidin|
9535117|NCT03151668|No Intervention|Midazolam|
9535118|NCT03151525|Experimental|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
9535119|NCT03151525|Active Comparator|Infliximab|Infliximab 5 mg/kg every 8 weeks
9535120|NCT03151499|Experimental|All Subjects|Reference Treatment (BI 409306) given alone followed by Test Treatment (BI 409306 + Rifampicin)
9535121|NCT03151538|Experimental|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
9535122|NCT03151538|Other|Controlled Group|This group of patients received healthy children.
9535123|NCT03151447|Experimental|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
9535124|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
9535125|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
10038719|NCT01837147|Experimental|Web-based Tracking Group|Technology-Based Physical Activity Promotion
10038720|NCT01837147|Active Comparator|Pedometer Group|Participants assigned to this group will receive a pedometer.
10058370|NCT02017886|Placebo Comparator|Placebo|Placebo tablet twice daily for three weeks
10038721|NCT01837160||Healthy Volunteers|"10 patients with normal echocardiogram studies and no history of ischaemic heart disease.~Patients to recieve CT-PET with fluciclatide, cardiac MRI scan, CT-coronary angiogram and echocardiogram."
9482419|NCT03632993|Active Comparator|Treatment V: CCH Shallow Injections, 4 Aliquots|"In Treatment V, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2mL of CCH (4 aliquots of 0.3mL each). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
9482420|NCT03630588|Placebo Comparator|Placebo|
9482421|NCT03630588|Experimental|Surimi intervention|
9482422|NCT03626545|Experimental|Canakinumab|Blinded Canakinumab administered at the recommended Phase III regimen (defined in the safety run-in part). Canakinumab will be given in combination with docetaxel (standard of care)
9482423|NCT03626545|Placebo Comparator|Placebo|Matching placebo, administered at the recommended Phase III regimen (defined in the safety run-in part), in combination with docetaxel (standard of care)
9482424|NCT03624816|Experimental|Restylane Defyne|injection with Restylane Defyne
9482425|NCT03624816|No Intervention|Control|no-treatment control
9482426|NCT03624127|Experimental|BMS-986165|
9482427|NCT03624127|Placebo Comparator|Placebo|
9482428|NCT03624127|Active Comparator|Apremilast|
9482429|NCT03617783|Active Comparator|Prebiotin|
9482430|NCT03617783|Placebo Comparator|Placebo|
9482431|NCT03617536|Experimental|CR845 0.25 mg Oral Tablet|Oral CR845 0.25 mg to be taken orally once daily for 12 weeks
9482432|NCT03617536|Experimental|CR845 0.5 mg Oral Tablet|Oral CR845 0.5 mg to be taken orally once daily for 12 weeks
9482433|NCT03617536|Experimental|CR845 1 mg Oral Tablet|Oral CR845 1 mg to be taken orally once daily for 12 weeks
9482434|NCT03617536|Placebo Comparator|Placebo Oral Tablet|Oral Placebo to be taken orally once daily
9482435|NCT03617367|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
9482436|NCT03616223|Experimental|FX-322 Low Dose|Single intratympanic injection of a hydrogel formulation
9482437|NCT03616223|Experimental|FX-322 High Dose|Single intratympanic injection of a hydrogel formulation
9482438|NCT03616223|Placebo Comparator|Placebo|Single intratympanic injection of a hydrogel formulation
9482439|NCT03614234|Experimental|Experimental open label|Pegunigalsidase alfa
9482440|NCT03611881|Experimental|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
9482441|NCT03611881|Experimental|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
9482442|NCT03611881|Experimental|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
9482443|NCT03611881|Experimental|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
9482444|NCT03611881|Experimental|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
9482445|NCT03611881|Experimental|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
9482446|NCT03611881|Experimental|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
9482447|NCT03611881|Experimental|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
9482448|NCT03611751|Experimental|BMS-986165|BMS-986165 oral administration
9482449|NCT03611751|Placebo Comparator|Placebo|Placebo oral administration
9482450|NCT03611751|Active Comparator|Active comparator|Active comparator oral administration
9482451|NCT03611010|Experimental|10 mg oral atorvastatin|Subjects taking 10 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
9482452|NCT03611010|Experimental|20 mg oral atorvastatin|Subjects taking 20 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
9482453|NCT03611010|Experimental|40 mg oral atorvastatin|Subjects taking 40 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
9482454|NCT03611010|Experimental|80 mg oral atorvastatin|Subjects taking 80 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
9482455|NCT03608397|Experimental|DAXI for injection low dose|Low Dose Group
9482456|NCT03608397|Experimental|DAXI for injection high dose|High Dose Group
9482457|NCT03608397|Placebo Comparator|Placebo|Placebo Group
9482458|NCT03608371|Experimental|BTRX-246040 Cohort 1|BTRX-246040 will be administered orally 40 mg (1capsule) in Cohort 1
9482459|NCT03608371|Experimental|BTRX-246040 Cohort 2|BTRX-246040 will be administered orally 80 mg (2 capsules) in Cohort 2
9482460|NCT03608371|Experimental|BTRX-246040 Cohort 3|BTRX-246040 will be administered orally120 mg (3 capsules) in Cohort 3
9482461|NCT03608371|Placebo Comparator|Placebo Cohorts 1-3|Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
9482462|NCT03605667|Experimental|BHV-4157|troriluzole, 280 mg capsules, QD
9482463|NCT03605667|Placebo Comparator|Placebo|matching 280 mg placebo capsules, QD
9482464|NCT03603639|Experimental|Placebo, E2730 40 mg, E2730 120 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
10038722|NCT01837160||Moderate Aortic Stenosis (n=10)|"Patients with moderate aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
9535126|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of >=3
10038723|NCT01837160||Mild Aortic Stenosis (n=10)|"Patients with mild aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
10038724|NCT01837160||Severe aortic Stenosis (n=10)|"Patients with severe aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
10038725|NCT01837160||Severe Aortic Stenosis for AVR (n=10)|"Patients with severe aortic stenosis proceeding to aortic valve replacement. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo a repeat CT-PET scan 3 months after the operation.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 months after the operation."
10038726|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
9535127|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
9535128|NCT03151460|Experimental|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
9535129|NCT03151460|No Intervention|Normal Controls|Age and education comparable healthy subjects
9535130|NCT03151486|Experimental|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
9535131|NCT03151486|Experimental|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
9535132|NCT03151486|Experimental|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
9535133|NCT03151486|Experimental|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
9535134|NCT03151486|Experimental|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
9535135|NCT03151486|Experimental|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
9535136|NCT03151486|Experimental|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
9535137|NCT03151486|Experimental|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
9535138|NCT03151486|Experimental|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
9535139|NCT03151486|Experimental|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
9535140|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
9535141|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
9535142|NCT03151603|Experimental|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)~and~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
9535143|NCT03151603|Active Comparator|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),~and~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
9535144|NCT03151421|Experimental|Home air quality monitoring and feedback|Home air quality monitoring and feedback
9535145|NCT03151343|Experimental|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
9535146|NCT03151343|Placebo Comparator|Placebo|Placebo, coated tablets, once daily, for 13 weeks
10038727|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
10038728|NCT01837186||EFP|Empyema following pneumonectomy
10038729|NCT01837186||nEFP|No empyema following pneumonectomy
10038730|NCT01837199|Experimental|Smoking|Metronidazole plus Amoxicillin
10038731|NCT01837199|Experimental|Non-Smoking|Metronidazole plus Amoxicillin
10038732|NCT01837238|Experimental|beta-hydroxy beta-methylbutyrate|Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
10038733|NCT01837238|Placebo Comparator|Placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
10038734|NCT01837251|No Intervention|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
10038735|NCT01837251|Experimental|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
10038736|NCT01837264|Experimental|Bone Marrow Cell Concentrate|
9535147|NCT03151291|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
9535148|NCT03151291|Experimental|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
9535149|NCT03151291|Experimental|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
9535150|NCT03151291|Experimental|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
9535151|NCT03151291|Experimental|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
9535152|NCT03151291|Experimental|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
10038737|NCT01837290|Active Comparator|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
10038738|NCT01837290|Placebo Comparator|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
9535153|NCT03151291|Experimental|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
9535154|NCT03151291|Experimental|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
9535155|NCT03151369|Other|Morphine|patients with the visual analog scale over 3 will receive morphine
9535156|NCT03151213|Active Comparator|Pregabalin|Pregabalin 150 mg before intervention
9535157|NCT03151213|Placebo Comparator|Placebo|Placebo before intervention
9535158|NCT03151278|Experimental|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of Ensite NavX without fluoroscopy.
9535159|NCT03151278|Active Comparator|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of X-ray plus any tree dimensional mapping system.
9535160|NCT03151382|Experimental|Experimental group|
9535161|NCT03151382|Other|Control group|
9535162|NCT03151174|Experimental|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
9535163|NCT03151174|Experimental|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
9535164|NCT03151174|No Intervention|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
9535165|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:~San Rafael Petzal~San Sebastian Huehuetenango~San Gaspar Ixchil~Santa Bárbara~Colotenango~Aguacatán"
9535166|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:~Tamahú~San Miguel Tucurú~Panzós~Senahú~Telemán"
9535167|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:~San Idelfonso Ixtahuacán~La Democracia~San Juan Atitán~Tectitán~Santiago Chimaltenango"
9535168|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:~Lanquín~Santa María Cahabón~Chisec~Chahal~Raxruhá~Campur"
9535169|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:~Nenton~Jacaltenango~Todos Santos Cuchumatán~Santa Eulalia~San Mateo Ixtatán~San Juan Ixcoy"
9535170|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:~Santa Cruz Verapaz~Tactic~San Pedro Carchá~San Juan Chamelco"
9535171|NCT03151200|Active Comparator|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
10038739|NCT01837303||Liquid based cytology|All participants will undergo both manual and conventional automated liquid based cytology (pap smear, cervical cytology).
9535172|NCT03151200|Sham Comparator|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
9535173|NCT03151187|Experimental|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
9535174|NCT03151187|Active Comparator|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
9535175|NCT03151031|Experimental|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
9535176|NCT03151031|No Intervention|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
9535177|NCT03151044|Experimental|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
9615923|NCT05056233|Experimental|Systane Hydration|Systane Hydration lubricant eye drops dosed 4 times a day for 6 weeks (2 weeks prior to surgery and 4 weeks post surgery), with investigator defined post-operative standard of care
9535178|NCT03151044|Active Comparator|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
9535179|NCT03150979|Experimental|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
9535180|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
9535181|NCT03151161|Experimental|Experimental Group|"Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;~Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
9535182|NCT03151161|Active Comparator|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
9535183|NCT03151122|Experimental|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
9535184|NCT03151122|Active Comparator|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
9535185|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
9535186|NCT03151252|Other|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
9535187|NCT03151252|Other|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
9535188|NCT03151252|Other|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
9535189|NCT03151096|Experimental|treatment arm|5mg Riboflavin pills
9535190|NCT03151096|Placebo Comparator|Placebo arm|Placebo pills
9535191|NCT03150966|Experimental|Patients who received nanocurcumin|Patients who received nanocurcumin
9535192|NCT03150966|Placebo Comparator|Patients who received placebo|Patients who received placebo
9535193|NCT03151005|Experimental|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
9535194|NCT03151005|Active Comparator|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
9535195|NCT03150953|No Intervention|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
9535196|NCT03150953|Experimental|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
9535197|NCT03150953|Experimental|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
9535198|NCT03151239|Placebo Comparator|Placebo|
9535199|NCT03151239|Experimental|NMN supplementation|
9535200|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.~ECG: 12 lead electrocardiogram that visualizes cardiac activity~history and physical: background information about athlete's and their family history~ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
9535201|NCT03150927|Experimental|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
9535202|NCT03150927|Placebo Comparator|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
9615924|NCT05056233|No Intervention|No Treatment|Investigator defined post-operative standard of care
9615925|NCT05045820|Active Comparator|Treatment|
9615926|NCT05045820|Sham Comparator|Sham|
10038740|NCT01837316|Experimental|FF/VI|A single dose inhalation of FF/VI 100/25 mcg in the morning
10038741|NCT01837316|Placebo Comparator|Placebo|A single dose inhalation of matching placebo in the morning
9615927|NCT05041907|Active Comparator|Positive control (monoclonals)|
9615928|NCT05041907|Experimental|Favipiravir|
9615929|NCT05041907|Experimental|Ivermectin|
9615930|NCT05041907|Experimental|Remdesivir|
9615931|NCT05041907|Other|Negative control group|
9535203|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:~Expression of insulin-like growth factor 1 receptor (IGF-1R)~Adiponectin~Leptin~Resistin~Osteocalcin~Osteoprotegerin~Insulin, c-peptid~HOMA-IR"
9535204|NCT03150992|Experimental|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
9535205|NCT03150641|Other|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
9535206|NCT03150641|Experimental|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
9535207|NCT03150602|Experimental|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
9535208|NCT03150628|Experimental|Study population|
9535209|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
9535210|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
9535211|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
9535212|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
9535213|NCT03150823|Experimental|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
9535214|NCT03150823|Experimental|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
9535215|NCT03150823|Sham Comparator|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
9535216|NCT03150862|Experimental|Arm A (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
9535217|NCT03150862|Experimental|Arm B (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
9535218|NCT03150862|Experimental|Arm A (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
9535219|NCT03150862|Experimental|Arm B (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
9535220|NCT03150862|Experimental|Arm C (Dose Escalation)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
9535221|NCT03150862|Experimental|Arm C (Dose Expansion-Cohorts C1 and C2)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
9535222|NCT03150706|Experimental|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
10038742|NCT01837329|Experimental|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
9535223|NCT03150654|Experimental|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
10038743|NCT01837342|Other|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
9535224|NCT03150771|Experimental|Cohort 1|Aripiprazole; single; gluteal
9535225|NCT03150771|Experimental|Cohort 2|Aripiprazole; single; gluteal
9535226|NCT03150784|Experimental|Motor coordination difficulties|"Type: Experimental main~EPIC club: 60min session / 2 times weekly / 7 weeks"
9535227|NCT03150784|Other|Non motor coordination difficulties|"Type: Experimental comparator~EPIC club: 60min session / 2 times weekly / 7 weeks"
9535228|NCT03150745|Other|Colposcopic group|
9535229|NCT03150745|Other|office hysteroscopic group|
10038744|NCT01837342|Experimental|Control arm|laproscopic drainage and washing
9535230|NCT03150576|Active Comparator|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
9535231|NCT03150576|Experimental|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
9535232|NCT03150576|Experimental|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
9535233|NCT03150849||patient group|patient with chronic lymphocytic leukemia
9535234|NCT03150849||control group|healthy control group
9535235|NCT03150667|Active Comparator|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
10038745|NCT01837355|Placebo Comparator|Placebo|placebo once daily for 12 weeks
9535236|NCT03150667|Active Comparator|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
9535237|NCT03150615|Experimental|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
9535238|NCT03150615|Placebo Comparator|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
9535239|NCT03150615|Other|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
9535240|NCT03150888||Hospital based hypertension cohort|
9535241|NCT03150888||Community based hypertension cohort|
9535242|NCT03150836|Experimental|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
9535243|NCT03150836|Experimental|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
9535244|NCT03150836|Experimental|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
9535245|NCT03150836|Experimental|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
9535246|NCT03150836|Experimental|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
9535247|NCT03150836|Experimental|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
9535248|NCT03150563|No Intervention|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
9535249|NCT03150563|Experimental|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
9535250|NCT03150563|Experimental|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
9535251|NCT03150563|Experimental|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
9535252|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
9535253|NCT03150316|Experimental|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
9535254|NCT03150290|Other|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
9535255|NCT03150290|Other|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
9535256|NCT03150498|Experimental|BTD-001 (fed)|
9535257|NCT03150498|Experimental|BTD-001 (fasted)|
9535258|NCT03150381|Active Comparator|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight).
10038746|NCT01837355|Experimental|Lactobacillus rhamnosus|lactobacillus rhamnosus once daily for 12 weeks
10038747|NCT01837381|Other|Transarterial Ethanol Ablation (TEA)|Two treatment sessions at 2 months apart were given and started within 4 weeks after randomization.
10059468|NCT02027597|Experimental|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
9482465|NCT03603639|Experimental|E2730 40 mg, E2730 120 mg, Placebo|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
9482466|NCT03603639|Experimental|E2730 120 mg, Placebo, E2730 40 mg|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
9482467|NCT03603639|Experimental|Placebo, E2730 120 mg, E2730 40 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
9482468|NCT03603639|Experimental|E2730 40 mg, Placebo, E2730 120 mg|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
9482469|NCT03603639|Experimental|E2730 120 mg, E2730 40 mg, Placebo|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
9482470|NCT03603288|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)
9482471|NCT03597360|Experimental|CT scan subjects|Three participants with severe Alzheimer's dementia will be studied
9482472|NCT03596762|Experimental|160 mg BAY3427080|
9482473|NCT03596762|Experimental|120 mg BAY3427080|
9482474|NCT03596762|Experimental|80 mg BAY3427080|
9482475|NCT03596762|Experimental|40 mg BAY3427080|
9482476|NCT03596762|Placebo Comparator|Placebo|
9482477|NCT03594747|Experimental|Tislelizumab combined with carboplatin and paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
9482478|NCT03594747|Experimental|Tislelizumab combined with carboplatin and nab-paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Nab-paclitaxel 100 mg/m2, D1, D8, and D15 of each cycle, administered as an IV infusion over 30 minutes, for 4 to 6 cycles
9482479|NCT03594747|Active Comparator|Carboplatin and paclitaxel|Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
9482480|NCT03594266|Experimental|Therapy A Spinal Cord Stimulation Parameter Set|
9482481|NCT03594266|Experimental|Therapy B Spinal Cord Stimulation Parameter Set|
9482482|NCT03594058|Experimental|Solabegron modified release tablets low dose|
9482483|NCT03594058|Experimental|Solabegron modified release tablets high dose|
9482484|NCT03594058|Placebo Comparator|Placebo Comparator|
9482485|NCT03591094|Active Comparator|PTI-428 dose level 1|
9482486|NCT03591094|Active Comparator|PTI-428 dose level 2|
9482487|NCT03591094|Placebo Comparator|Placebo PTI-428|
9482488|NCT03590366|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
9482489|NCT03590366|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
9482490|NCT03589768|Experimental|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).~N=133"
9482491|NCT03589768|Active Comparator|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.~N=67"
9482492|NCT03588884|Active Comparator|CTAP101|CTAP101/Calcifediol Capsules 60 micrograms (mcg) once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
9482493|NCT03588884|Experimental|Immediate-release (IR) calcifediol|Immediate-release (IR) calcifediol/266 micrograms (mcg) capsule before breakfast on the mornings of Day 1 and Day 29
9482494|NCT03588884|Experimental|Cholecalciferol|Cholecalciferol/Capsules 300,000 International Units (IU) (high-dose) before breakfast on the mornings of Day 1 and Day 29
9482495|NCT03588884|Active Comparator|Paricalcitol|Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and29 when dosing will occur before breakfast
9482496|NCT03586427|Experimental|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
9482497|NCT03586427|Experimental|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
9482498|NCT03586427|Experimental|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
9482499|NCT03586427|Experimental|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
9482500|NCT03586427|Placebo Comparator|Placebo|Placebo administered as 1 tablet taken orally every day
9482501|NCT03585660|Experimental|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
9535259|NCT03150381|Experimental|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
9535260|NCT03150381|Active Comparator|Control|Educational materials and optional participation in community-wide cancer awareness activities.
9535261|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
9535262|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
9535263|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
9535264|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
9535265|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
9535266|NCT03150433|Experimental|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
9535267|NCT03150433|Other|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
9535268|NCT03150446|Experimental|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
9535269|NCT03150550|Experimental|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
9535270|NCT03150550|Experimental|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
9615932|NCT05038800|Experimental|MK-0482|Participants will receive MK-0482 monotherapy administered in escalating doses as an intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
10038748|NCT01837394|Active Comparator|Block arm|Ultrasound guided block of the SN and ONP with 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
10038749|NCT01837394|Placebo Comparator|Placebo arm|Ultrasound guided placebo block of the SN and ONP with 7.5 ml of isotonic saline solution injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
9615936|NCT05030298|Experimental|Cohort A (stereotactic biopsy, radiosurgery, surgery)|Patients undergo MRI-guided stereotactic biopsy. Patients then undergo radiosurgery over 1 fraction. Within 14 days, patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
9615937|NCT05030298|Active Comparator|Cohort B (surgery, radiation therapy, chemotherapy)|Patients undergo surgery. Within 4-6 weeks, patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist.
9615938|NCT05021393|Experimental|Intervention Group|The intervention group will receive the services from a clinical pharmacist and the existing standard care available in the medical oncology ward.
9615939|NCT05021393|No Intervention|Control Group|The standard care includes the current existing care provided to patients in the hospital. In addition, it includes all the available medical and non-medical services except the service provided by the clinical pharmacist.
9615940|NCT05011279|Experimental|Pilot Study|"Participants in the pilot study will participate as members of family-based dyads (n=10 dyads). One member of each dyad will be a breast cancer survivor and one will be a blood relative.~Study involves interviews, questionnaires, Use of Move Together app with Garmin activity tracker watch"
9615941|NCT04992845|Experimental|Intervention|Vertebral Body Tethering surgery
9615942|NCT04989699|Active Comparator|OTX-TKI|
9615943|NCT04989699|Active Comparator|Aflibercept|
9615944|NCT04987723|Other|AF + HFrEF cohort|"Left Ventricular Ejection Fraction (LVEF) < 50% by echocardiogram during routine screening or within 12 months prior to enrolment day. The echo must have been performed >3 weeks after optimisation of HF and rate control therapies, otherwise repeat imaging will be performed after this has been achieved~With~NYHA functional status II-III at the enrolment visit."
9615945|NCT04987723|Other|AF + symptoms cohort|"Left Ventricular Ejection Fraction (LVEF) > 50% by echocardiogram during routine screening or within 12 months prior to enrolment day~With~modified European Heart Rhythm Association symptom classification 2b-4."
9615946|NCT04975516|Experimental|Group I (SBRT, chemotherapy)|Patients undergo SBRT QD or every other day for 5 fractions, and receive chemotherapy per standard of care.
9615947|NCT04975516|Active Comparator|Group II (chemotherapy)|Patients receive chemotherapy per standard of care.
9615948|NCT04975399|Experimental|Administration of CC-92328|CC-92328 administered intravenously in 28-day cycles
9615949|NCT04965246|Experimental|Physical activity|the physical activity intervention will be structured to increase light-intensity aerobic physical activity, to achieve a total of 150 minutes per week. The intervention will also include weekly support calls from research staff to improve compliance to physical activity
9615950|NCT04965246|Other|Usual care|Participants randomized to the usual care control group will serve as the control group for 15 weeks, and receive no intervention during this time.
9535271|NCT03150472|Experimental|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.~This type of Graft Matrix will be administered as the intervention."
9535272|NCT03150472|Active Comparator|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.~This type of Graft Matrix will be administered as the intervention."
9535273|NCT03150394|Experimental|Treatment of quadruple eradication therapy with GASTRUS|
9535274|NCT03150394|Placebo Comparator|Treatment of quadruple eradication therapy with PLACEBO|
9535275|NCT03150459|Experimental|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
9535276|NCT03150459|Experimental|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
9535277|NCT03150459|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
9535278|NCT03150524|Active Comparator|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
9535279|NCT03150524|Active Comparator|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
9535280|NCT03150251|Experimental|Overnight Oats|40 g of overnight oats
9535281|NCT03150251|Placebo Comparator|Soaked Cream of Rice|28.8 cream of rice
9535282|NCT03150251|Placebo Comparator|Cooked Cream of Rice|28.8 cooked cream of rice
9535283|NCT03150277|Experimental|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
9535284|NCT03150277|Experimental|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
9535285|NCT03150225|Experimental|Exercise group + supplementation|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily."
9535286|NCT03150225|Active Comparator|Control group + supplementation|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
9535287|NCT03150225|Experimental|Exercise group + placebo|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive starch capsules to be taken daily."
9535288|NCT03150225|No Intervention|Control group + placebo|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive starch capsules to be taken daily.
9535289|NCT03150420|Experimental|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
9535290|NCT03150420|Placebo Comparator|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
9535291|NCT03150537|Active Comparator|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
9535292|NCT03150537|Active Comparator|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
9535293|NCT03150537|Active Comparator|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
9535294|NCT03150264|Experimental|PCV-VG+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
9535295|NCT03150264|Active Comparator|PCV+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
9535296|NCT03150212|Experimental|Saccharomyces cerevisiae CNCM I-3856|
9535297|NCT03150212|Placebo Comparator|Placebo|
9535298|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
9535299|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
9535300|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
9615951|NCT04959929|Experimental|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to ~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
10038750|NCT01837407|Other|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
9535301|NCT03150134|Experimental|early reduction|Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
9535302|NCT03150134|Placebo Comparator|routine reduction|Arm/Group Descriptions.Immunosuppressive drugs(cyclosporine) were routine reduced by 3 months and discontinued in the 5 months without GvHD in the CR group. We used the result of chimerism as the reference.
9535303|NCT03149952|Other|Patient hospitalized for allogeneic haematopoietic stem cells|
9535304|NCT03149900||Secukinumab|"Patients will be recruited in the Comprehensive Center for Inflammation Medicine. The study population will consist of 40 subjects (both male and female), aged 18 years and older, in whom treatment with Secukinumab is clinically indicated and according to the licensed product specifications. The study drug will be prescribed by a doctor who is independent of this study. Visit 1 will be carried out prior to the first injection of Secukinumab.~All patients will receive a number and the data will be recorded in a pseudo-anonymised form. No blinding is necessary for investigators or patients (open study), as all patients receive the same treatment (marketed product)."
9535305|NCT03149874|Active Comparator|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
9535306|NCT03149874|Active Comparator|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
9535307|NCT03149835|Experimental|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
9535308|NCT03149835|Experimental|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
9535309|NCT03149965|Active Comparator|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
9535310|NCT03149965|Experimental|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
9535311|NCT03149861|Experimental|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
9535312|NCT03149861|Experimental|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
9535313|NCT03150147|Experimental|Non-ischemic preservation.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
9535314|NCT03150147|Other|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
9535315|NCT03150017|Experimental|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
9535316|NCT03150017|No Intervention|Usual Care|Continue to manage pain using usual care.
9535317|NCT03150121|Experimental|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
9535318|NCT03150121|Active Comparator|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
9535319|NCT03150121|Experimental|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
9535320|NCT03149913|Experimental|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
9535321|NCT03149913|Active Comparator|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
9535322|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
9535323|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
9535324|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
9535325|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
9535326|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
9535327|NCT03150030||Healthy controls|Healthy control subjects
9535328|NCT03149783|Experimental|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
9535329|NCT03149783|Placebo Comparator|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
9535330|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.~Laboratory blood tests will be collected and analyzed"
9535331|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
9535332|NCT03149926||Patients with Borderline Personality Disorder|
9535333|NCT03149926||Healthy controls|
9535334|NCT03149653|Experimental|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
9535335|NCT03149653|Active Comparator|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
9535336|NCT03149653|No Intervention|Comparator3|Healthy Control
9535337|NCT03149692|Experimental|Penile allograft|Penile human allografts transplanted
9535338|NCT03149458|Experimental|Dance group|dance program for 8 one-hour sessions.
9535339|NCT03149458|Active Comparator|control group|upper limb rehabilitation for 8 one-hour sessions.
9535340|NCT03149432|Active Comparator|Reference analgesic|Gabapentin Rehabilitation Local care
9535341|NCT03149432|Experimental|reference analgesic and mirror therapy|Mirror Therapy Gabapentin Rehabilitation Local care
9535342|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
9535343|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
9535344|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
9535345|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score >=1.67
9535346|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI<1.67
10038751|NCT01837420|Other|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
9535347|NCT03149497|Active Comparator|improved anterior approach only in traumatic cervical spine|
9535348|NCT03149497|Active Comparator|failed anterior approach only in traumatic cervical spine|
9535349|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
9535350|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
9535351|NCT03149601||Healthy Weight|Participants with BMI < 95th percentile
9535352|NCT03149601||Obese|Participants with BMI > or = 95th percentile
9535353|NCT03149419|Active Comparator|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
9535354|NCT03149419|Placebo Comparator|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
9535355|NCT03149536|Active Comparator|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
9535356|NCT03149536|Active Comparator|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
9535357|NCT03149536|Active Comparator|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
9535358|NCT03149536|Active Comparator|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
9535359|NCT03149536|Active Comparator|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
9535360|NCT03149536|Active Comparator|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
9535361|NCT03149614|Active Comparator|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
9535362|NCT03149614|Experimental|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
9535363|NCT03149588|Experimental|propofol|
9535364|NCT03149588|Experimental|sevoflurane|
9535365|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Escalation|Dose escalation and determination
9535366|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Determination|Additional enrollment into previously cleared monotherapy dose levels
9535367|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Expansion|Dose expansion
9535368|NCT03149549|Experimental|CX-2009 Monotherapy: 14-Day Dosing Regimen-Expansion|Dose escalation and determination in selected tumor types
9535369|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
9535370|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
9535371|NCT03149627||Individuals from selected households|Individuals residing in selected households in Lusaka Province, Zambia.
9535372|NCT03149510|Experimental|Mobile Application|Participants will be using a mobile application, activity monitor and scale.
9535373|NCT03149510|No Intervention|Control Group|Participants will receive standard of care.
9535374|NCT03149718|Active Comparator|SMC (n=23)|Standard Medication Counseling.
9535375|NCT03149718|Experimental|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
9535376|NCT03149640|Experimental|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
9535377|NCT03149640|Placebo Comparator|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
9535378|NCT03149679|Experimental|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
9535379|NCT03149575|Experimental|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
9535380|NCT03149575|Active Comparator|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
9535381|NCT03149445|Experimental|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
9535382|NCT03149445|Placebo Comparator|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
9535383|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
9535384|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
9535385|NCT03149393|Experimental|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
9535386|NCT03149393|Active Comparator|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
9535387|NCT03149666||Evaluation of bitter taste|Participants will be evaluated as to the intensity of bitter taste when performing watery mouthwash with quinine.
9535388|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
9535389|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
9535390|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
9535391|NCT03149367|Experimental|Fixed suture|
9535392|NCT03149367|Experimental|Adjustable suture|
9535393|NCT03149315|Experimental|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
9535394|NCT03149302|Experimental|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
9535395|NCT03149302|Experimental|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
9535396|NCT03149302|Experimental|LNT plus balance exercises|Local neck treatment plus balance training program.
9535397|NCT03149302|Experimental|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
9535398|NCT03149354|Other|Patients with HIV|Patients with HIV
9535399|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
9535400|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
9535401|NCT03148938|Experimental|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
9535402|NCT03148938|Active Comparator|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
9535403|NCT03148990|Experimental|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
9535404|NCT03148990|Active Comparator|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
9535405|NCT03148964||Follow-up Arm|Blood sampling only
9535406|NCT03149133|Experimental|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
9535407|NCT03149133|Experimental|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
9535408|NCT03149185|Active Comparator|T-CBSM|Technology based cognitive behavioral stress management.
9535409|NCT03149185|Active Comparator|T-HP|Technology based health promotion (control condition)
9535410|NCT03149159|Experimental|Nivolumab + Ipilimumab + SRT|
9535411|NCT03149146|Experimental|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
9615952|NCT04947124|Experimental|1% QLS-101|dosed once a day for 14 days as either first or second dosing period per randomization
9535412|NCT03149146|Active Comparator|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
9535413|NCT03149120|Experimental|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
9535414|NCT03149120|Experimental|Nivolumab with Pazopanib|Pazopanib at a dose of 800mg by mouth daily.
9535415|NCT03149081|Experimental|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
9535416|NCT03148951||Group 1|Group 1: patients receiving general anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
9535417|NCT03148951||Group 2|Group 2: patients receiving general anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
9535418|NCT03148951||Group 3|Group 3: patients receiving regional (spinal) anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
9535419|NCT03148951||Group 4|Group 4: patients receiving spinal anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
9535420|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
9535421|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
9535422|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
9535423|NCT03149094|Experimental|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
9535424|NCT03149094|Active Comparator|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
10038752|NCT01837420|Experimental|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
10038753|NCT01837420|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
9535425|NCT03149107|Experimental|IPPI + NAC|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
9535426|NCT03149107|Experimental|PSM + NAC|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
9535427|NCT03149107|Experimental|IPPI + Placebo|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
9535428|NCT03149107|Active Comparator|PSM + Placebo|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
9535429|NCT03149198|Experimental|Interventional group|Mat pilates exercises
9535430|NCT03149198|Active Comparator|Control group|Aquatic aerobic exercises
9535431|NCT03149276||Limited English Proficiency Group|"LEP persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered limited English proficient when a non-English language was preferred. Interventions included professional interpreter services and occupational therapy."
9535432|NCT03149276||English Speaking Group|"English speaking persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered English speaking when the English language was preferred. Intervention included occupational therapy."
9535433|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
9535434|NCT03149016|Experimental|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
9535435|NCT03149016|No Intervention|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
9535436|NCT03148834|Experimental|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
9615953|NCT04947124|Experimental|2% QLS-101|dosed once a day for 14 as either first or second dosing period per randomization
10038754|NCT01837433|Experimental|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
9535437|NCT03148834|No Intervention|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
9535438|NCT03148886|Experimental|PA intervention|The intervention consisted in a home-based adapted PA program defined at the inclusion, according to patient's capacities.
9535439|NCT03148925|Experimental|SELA-070|
9535440|NCT03148925|Placebo Comparator|Saline|
9535441|NCT03148912|Experimental|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
9535442|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
9535443|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
9535444|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
9535445|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
9535446|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
9535447|NCT03148678|Experimental|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
9535448|NCT03148678|Sham Comparator|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
9535449|NCT03148678|Experimental|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
9535450|NCT03148678|Sham Comparator|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
9535451|NCT03148782|Experimental|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
9535452|NCT03148808|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
9535453|NCT03148730|No Intervention|manual group|This group will have a standard of care anesthesia. All the drugs, fluid and adjustement of ventilation settings will be done manually by the supervising anesthesiologist using the same drugs and fluids as the closed-loop group
9535454|NCT03148730|Experimental|automated closed-loop group|This group will have a fully automated anesthesia, analgesia , ventilation and fluid management using 3 indenpendent closed-loop systems same drugs used in both groups ( propofol and remifentanil, Plasmalyte and /or Voluven)
9535455|NCT03148717|Active Comparator|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
9535456|NCT03148717|Active Comparator|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
9535457|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
9535458|NCT03148665||Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
9535459|NCT03148665||Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
9615954|NCT04942964|Experimental|ASP0367: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
9615955|NCT04942964|Experimental|ASP0367: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
9615956|NCT04942964|Experimental|ASP0367: Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of ASP0367 under fasting conditions on day 1.
9615957|NCT04941157|Experimental|Prophylactic cerebrospinal fluid drain placement|Patients randomized to receive the experimental treatment will have a prophylactic cerebrospinal fluid drain placed prior to their endovascular aortic repair. All components of the endovascular aortic repair are standard of care treatments.
9622042|NCT02518841|Active Comparator|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
9535460|NCT03148652|Experimental|Enhanced Intervention (CBT+working memory training)|A standard, manualized cognitive behavioral therapy-based intervention for individuals interested in quitting smoking plus computerized working memory training
9535461|NCT03148652|Placebo Comparator|Control Intervention Condition|Participants will receive a manualized cognitive behavioral therapy-based intervention
9535462|NCT03148561|Other|Misoprostol group|The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
9535463|NCT03148561|No Intervention|Expectant group|Women did not receive any medication.
9535464|NCT03148587|Experimental|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
9535465|NCT03148587|Experimental|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
9535466|NCT03148639|Experimental|Avatar therapy|Immediate Avatar therapy.
9535467|NCT03148639|Other|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
9535468|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
9535469|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
9535470|NCT03148574|Experimental|misoprostol|intrauterine 400 microgram
9535471|NCT03148574|Active Comparator|oxytocin|intravenous infusion 10 units
9535472|NCT03148535|Experimental|lithium carbonate|recieve lithium carbonate
9535473|NCT03148535|Experimental|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
9535474|NCT03148600|Active Comparator|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
9535475|NCT03148600|Placebo Comparator|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
9535476|NCT03148626|Experimental|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
9535477|NCT03148626|Placebo Comparator|Control|Usual education.
9535478|NCT03148340||VIPS monitoring group|The study population will consist of adult patients presenting for evaluation of acute brain pathology,
9535479|NCT03148509|Experimental|bupropion|receive bupropion
9535480|NCT03148509|Experimental|risperidone|receive risperidone
9535481|NCT03148509|Experimental|aripiprazole|receive aripiprazole
9535482|NCT03148431|Experimental|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
9535483|NCT03148431|Placebo Comparator|Placebo|Placebo administered IV once in healthy participants
9535484|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
9535485|NCT03148522|Experimental|escitalopram|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
9535486|NCT03148522|Experimental|duloxetine|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
9535487|NCT03148522|Experimental|mirtazapine|Eligible patients were assigned to mirtazapine treatment based on investigators' clinical practice.
9535488|NCT03148444|Experimental|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
9535489|NCT03148444|No Intervention|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
9535490|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
9535491|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
9535492|NCT03148483|Experimental|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
9535493|NCT03148483|Experimental|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
9535494|NCT03148483|Experimental|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
9535495|NCT03148483|Placebo Comparator|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
9535496|NCT03148353|Experimental|Modified subacromial injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
9535497|NCT03148353|Placebo Comparator|Standardized subacromial injection|"Intervention procedure: corticoseroid injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
9535498|NCT03148366|Experimental|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
9535499|NCT03148366|Active Comparator|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
9535500|NCT03148119|Experimental|Topical QRH Heptapeptide Administration|
9535501|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
9535502|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
9535503|NCT03148249|Experimental|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
9535504|NCT03148249|Experimental|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
9535505|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
9535506|NCT03148028||PID IBD patients|patients with an immunodeficiency and inflammatory bowel disease phenotype
9535507|NCT03148210|Active Comparator|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
9535508|NCT03148210|Placebo Comparator|Standard of Care|Spirometry result sent to family MD
9535509|NCT03148223|Experimental|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
9535510|NCT03148223|Placebo Comparator|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
9535511|NCT03148132|Active Comparator|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
9535512|NCT03148132|Experimental|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
9535513|NCT03148145|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
9535514|NCT03148145|Experimental|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
9535515|NCT03148145|Experimental|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
9535516|NCT03148145|Experimental|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
9535517|NCT03148041|Active Comparator|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
9535518|NCT03148041|Placebo Comparator|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
9535519|NCT03148314|Other|hospital- based standard dose of vaginal misoprostol|
9535520|NCT03148314|Other|Home-based extended low dose of buccal/sublingual misoprostol|
9535521|NCT03148015||ADH/LCIS|Atypical Ductal Hyperplasia or Lobular carcinoma in situ with DCIS
9535522|NCT03148015||DCIS|Pure Ductal Carcinoma in Situ
9535523|NCT03148015||Invasive|invasive ductal carcinoma with DCIS
9535524|NCT03148171|No Intervention|Routine PrEP Care|Routine PrEP Care at each clinical site.
9535525|NCT03148171|Active Comparator|WERK Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
9535526|NCT03148288|Experimental|Vitamin D supplementation|4000IU Vitamin D qd
9535527|NCT03148288|Placebo Comparator|placebo|
9535528|NCT03147950|Active Comparator|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
9535529|NCT03147950|Active Comparator|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
9535530|NCT03148002|Active Comparator|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
9535531|NCT03148002|Active Comparator|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
9535532|NCT03147924|Experimental|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
9535533|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
9535534|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
9535535|NCT03147976|Experimental|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
9535536|NCT03147963|Experimental|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
9535537|NCT03147963|Active Comparator|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
9535538|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
9535539|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
10038755|NCT01837433|Active Comparator|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
10038756|NCT01837446|Experimental|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
10038757|NCT01837446|Active Comparator|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
10038758|NCT01837459||Obese-Normal|Obese with Apnea Hypopnea index (AHI) <1
10038759|NCT01837459||Obese-SDB|Obese and with AHI>1
10038760|NCT01837459||Lean-Normal|Non-obese with AHI<1
10038761|NCT01837459||Lean-SDB|Non-obese with AHI>1
10038762|NCT01837472|Experimental|Probiotic|
10038763|NCT01837472|Placebo Comparator|Placebo|
10038764|NCT01837485|Experimental|Lactol|
10038765|NCT01837485|Placebo Comparator|Placebo|
10038766|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
10038767|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
10038768|NCT01837511||Cancer Group|Patients with pathologically proven stage I, II and III NSCLC.
10038769|NCT01837576|Experimental|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
10038770|NCT01837589|Other|QCT and DXA|All the patients will have both QCT and DXA
10038771|NCT01837602|Experimental|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
10038772|NCT01837615|Experimental|Photopill treatment|
10038773|NCT01837628|Active Comparator|Lidocaine gel|Intraurethral Lidocaine gel 2%
10038774|NCT01837628|Experimental|Paraffin Oil|Intraurethral injection
10038775|NCT01837641|Experimental|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
10038776|NCT01837641|Experimental|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
10038777|NCT01837641|Experimental|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
10038778|NCT01837641|Experimental|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
9482502|NCT03584945|Experimental|Obsessive Compulsive Disorder|
9482503|NCT03584945|Other|Subclinical Obsessive-Compulsive symptoms (OCS)|
9482504|NCT03584945|No Intervention|Healthy Control|
9482505|NCT03583359|Experimental|Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
9482506|NCT03583359|Other|Delayed Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
9482507|NCT03580369|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
9482508|NCT03580369|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
9482509|NCT03580369|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
9482510|NCT03580369|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
9482511|NCT03580356|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
9482512|NCT03580356|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
9482513|NCT03580356|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
9482514|NCT03580356|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
9482515|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 1|
9482516|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 2|
9482517|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 3|
9482518|NCT03579459|Placebo Comparator|Placebo|Normal saline solution (0.9% sodium chloride)
9482519|NCT03578237|Experimental|Treatment (active cryoneurolysis)|Receiving active cryoneurolysis
9482520|NCT03578237|Sham Comparator|Sham|Receiving sham cryoneurolysis procedure
9482521|NCT03576534|No Intervention|Control|Standard of care
9482522|NCT03576534|Active Comparator|Study|PBUF used prior to Cardiopulmonary bypass
9482523|NCT03571568|Experimental|BI-1206|BI-1206 IV Standard 3+3 Dose-Escalation Design
9482524|NCT03570749|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind
9482525|NCT03570749|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
9482526|NCT03570749|Placebo Comparator|Placebo|Placebo administered orally.
9482527|NCT03568461|Experimental|CTL019|tisagenlecleucel infusion
9482531|NCT03558503|Experimental|UGN-102|75 mg Mitomycin C (MMC) in 56 mL admixture (1.33 mg MMC per 1 mL of admixture).
9482532|NCT03556956|Experimental|Masitinib plus FOLFIRI|"Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid).~Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal."
9535540|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
9535541|NCT03147638|Experimental|1 month|patient treated with Anti coagulation for one month
9535542|NCT03147638|Active Comparator|3 months|standard of care , treatment for 3 months
9535543|NCT03147781|No Intervention|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
9535544|NCT03147781|Sham Comparator|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
9535545|NCT03147781|Experimental|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
9535546|NCT03147703|Experimental|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
9535547|NCT03147703|Experimental|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
9535548|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
9535549|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
9535550|NCT03147625|Experimental|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
9535551|NCT03147625|No Intervention|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
9535552|NCT03147716|Active Comparator|Enrollment Flyer|Participants in this condition received one of the strategies in the Parent Engagement Package: an enrollment flyer that provided information about the Triple P Positive Parenting Program being offered at their child's school, including the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form. Parents who returned the enrollment form received automated text, email and/or phone reminders and a confirmation letter prior to each parenting program session.
9535553|NCT03147716|Experimental|Enrollment Flyer & Testimonial Booklet|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a two-page, testimonial booklet that included photos and quotes from parents and children describing benefits other parents reported after participating in the Triple P Positive Parenting Program and fun activities children reported about the childcare. The booklet also contained the location of meetings, free childcare, choice of days/times and English or Spanish groups, and an enrollment form.
9535554|NCT03147716|Experimental|Enrollment Flyer & Teacher Endorsement|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a teacher endorsement of the Triple P Positive Parenting Program. The teacher also gave the participant a colorful brochure that included information about the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form.
9535555|NCT03147716|Experimental|Enrollment Flyer & Engagement Call|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus an engagement call from a Triple P provider. Providers followed a manualized protocol for implementing the engagement call, which included strategies to increase parental motivation to participate in Triple P and reduce barriers to participation.
9535556|NCT03147716|Experimental|All Engagement Strategies|Participants in this condition received all engagement strategies in the Parent Engagement Package: enrollment flyer, testimonial booklet, teacher endorsement, and provider engagement call.
9535557|NCT03147794|Experimental|FES using MyndMove Technology|This is the only arm of the study. Participants will be provided with the FES intervention as part of the protocol.
9535558|NCT03147807|Experimental|betaLACTA® result given to physician|In the experimental group, betaLACTA® rapid diagnostic test guided de-escalation result will be given to physician at Day 0 and empirical carbapenems will be de-escalated to Cefepime or Ceftazidime +/- Amikacin since the second dose.
9535559|NCT03147807|No Intervention|betaLACTA® result NOT given to physician|In the control group, betaLACTA® result will not be given to physician and patients will receive empirical carbapenem during the time required to obtain final results of antibiotic susceptibility test
9535560|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
9535561|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
9535562|NCT03147729|Other|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
9535563|NCT03147833|Experimental|Sport beverages Protein|Intervention group ingesting PROTEIN
9535564|NCT03147833|Active Comparator|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
9535565|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
9535566|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
9535567|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
9535568|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
10038779|NCT01837641|Experimental|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
9535569|NCT03147872|No Intervention|5% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol).
9535570|NCT03147872|Experimental|2% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria).
9535571|NCT03147859|Experimental|Group A-150mg dose of vedolizumab per infusion followed by ATI - Low Dose|* Please note that the previous low dose arm was 75mg of vedolizumab per infusion, but no participant was ever given this dose. The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 150 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 doses as tolerated. ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20.
9535572|NCT03147859|Experimental|Group B-300mg dose of vedolizumab per infusion followed by ATI - Mid Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 300 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
9535573|NCT03147859|Experimental|Group C-600mg dose of vedolizumab per infusion followed by ATI - High Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 600 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
10038780|NCT01837641|Placebo Comparator|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
9535574|NCT03147846|Experimental|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.~Keep the room temperature at 23-25˚C and wrap the baby if possible"
9535575|NCT03147846|Active Comparator|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
9535576|NCT03147677|Experimental|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
9535577|NCT03147677|Active Comparator|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
9535578|NCT03147677|Active Comparator|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
9535579|NCT03147599|Active Comparator|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
10038781|NCT01837641|Experimental|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
10038782|NCT01837641|Experimental|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
9535580|NCT03147599|Placebo Comparator|Placebo|Placebo
9535581|NCT03147586|Active Comparator|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
9535582|NCT03147586|Placebo Comparator|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
9535583|NCT03147443|Experimental|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
9535584|NCT03147443|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
9622043|NCT02518841|Experimental|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
10038783|NCT01837667|Experimental|LB-100 for Injection and Docetaxel|Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
10038784|NCT01837693|No Intervention|one year follow up|A random sample of HPV positive women with negative cytology will be invited to repeat HPV DNA test and biomarkers after a year, as recommended by the current screening protocols based on HPV DNA
10038785|NCT01837693|Experimental|direct sending in colposcopy|Experimental: immediate colposcopy. A random sample of HPV positive women with negative cytology will be sent to immediate colposcopy
10038786|NCT01837706||Emergency Room Patients|
10038787|NCT01837732|Experimental|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
10038788|NCT01837732|Active Comparator|B: relational|Relational: 10 mn verbal patient's centered exchanges
10038789|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
10038790|NCT01837771|Active Comparator|Diaphragmatic stimulation|Diaphragmatic stimulation via electrode for 4 weeks
10038791|NCT01837771|No Intervention|No intervention|
10038792|NCT01837784||Elderly patients|
10038793|NCT01837784||Patients with diabetes mellitus|
9535585|NCT03147443|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
9535586|NCT03147456|Experimental|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
9535587|NCT03147456|Placebo Comparator|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
9535588|NCT03147573|Experimental|Blood pressure monitoring|
9535589|NCT03147469|No Intervention|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
9535590|NCT03147469|Experimental|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
9535591|NCT03147469|Experimental|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
9535592|NCT03147469|Experimental|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
9535593|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
9535594|NCT03147339|Experimental|AGEs restricted diet|Low calorie diet + AGEs restricted diet
9535595|NCT03147339|No Intervention|control|Low calorie diet
9535596|NCT03147547|Active Comparator|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
9535597|NCT03147547|Experimental|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
9535598|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
9535599|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
9535600|NCT03147521|Experimental|Accidental falls care bundle|Care Bundle Implementation Arm
9535601|NCT03147521|Active Comparator|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
9535602|NCT03147404|Experimental|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
9535603|NCT03147300|Active Comparator|Östergötland region - Control group|
9535604|NCT03147300|Experimental|Östergötland region - Intervention group|
9535605|NCT03147313|Sham Comparator|Sham|
9535606|NCT03147313|Active Comparator|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
9535607|NCT03147313|Active Comparator|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
10038794|NCT01837784||Patients with heart failure|
10038795|NCT01837784||Patients with resistant hypertension|
10038796|NCT01837810|Experimental|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
10038797|NCT01837810|Placebo Comparator|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
10038798|NCT01837836|Experimental|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
10038799|NCT01837875|No Intervention|Control|Mailed informational literature
10038800|NCT01837875|Active Comparator|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
10038801|NCT01837875|Experimental|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
10038802|NCT01837888|No Intervention|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
9535608|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
9535609|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
9535610|NCT03147326|Other|FDG-NaF-MRI|"All participants will undergo three project scans/the following interventions:~FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice."
9535611|NCT03147365|No Intervention|Control group|Twenty five children who will not receive any physical therapy treatment.
9535612|NCT03147365|Experimental|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
9535613|NCT03147365|Experimental|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
9535614|NCT03147560|Experimental|Group 1|The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
9535615|NCT03147560|Experimental|Group 2|The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
9535616|NCT03147560|Experimental|Group 3|The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.
9535617|NCT03147261|Experimental|lifestyle intervention|Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.
9535618|NCT03147261|No Intervention|No intervention|Healthy diet recommendations following the usual pediatric advice
9535619|NCT03147235|Experimental|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
9535620|NCT03147235|No Intervention|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
9535621|NCT03147534|Active Comparator|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
9535622|NCT03147534|Active Comparator|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
9535623|NCT03147534|Active Comparator|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
9535624|NCT03147274|Experimental|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
9535625|NCT03147274|No Intervention|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
9535626|NCT03147209|Experimental|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
9535627|NCT03147183||candidates for renal transplant|
10038803|NCT01837888|Experimental|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
10038804|NCT01837914|Experimental|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
10038805|NCT01837914|Active Comparator|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
10038806|NCT01837927|Experimental|NVA237|NVA237 inhaled via the Breezhaler® device once daily
10038807|NCT01837927|Active Comparator|Tiotropium|Tiotropium 5μg inhaled via the Respimat® device once daily
10038808|NCT01837940|Placebo Comparator|Placebo|
10038809|NCT01837940|Active Comparator|dietary supplement|Lactobacillus reuteri DSM 17938
10038810|NCT01837953|Other|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
10038811|NCT01837953|Experimental|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
10038812|NCT01837979||DBS screening test|cell-free fetal DNA for Dried blood spots samples in high risk pregnant women.
10038813|NCT01837979||maternal serum screening test|cell-free fetal DNA for maternal serum screening test samples in high risk pregnant women.
10038814|NCT01837992|Active Comparator|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
10038815|NCT01837992|Active Comparator|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
10038816|NCT01837992|Other|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
10038817|NCT01838005|No Intervention|Standard of Care|"Routine implementation of the national PMTCT guidelines which are an adaptation of the WHO's Option A"
10038818|NCT01838005|Experimental|Conditional Cash Transfer|Financial incentive to attend regular clinic visits and receive PMTCT care
10038819|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
10038820|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
10038821|NCT01838031|No Intervention|the control group|The serum will be stored and the measurements will be obtained after the delivery
10038822|NCT01838031|Active Comparator|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
10038823|NCT01838057||painPREMIER cohort|
10038824|NCT01838057||Control cohort|
10038825|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
9535628|NCT03146962|Experimental|All Subjects|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
9535629|NCT03147053|Experimental|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
9535630|NCT03147053|Placebo Comparator|Placebo|Patients in this group were administered the placebo .
9535631|NCT03147131|Active Comparator|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: Fitmore Short Stem"
9535632|NCT03147131|Active Comparator|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: CLS Straight Stem"
9535633|NCT03147014|Other|Maternal Hyperoxygenation|Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.
9535634|NCT03146975|No Intervention|Healthy|
9535635|NCT03146975|Experimental|Periodontitis without diabetes|
9535636|NCT03146975|Experimental|Periodontitis compensated diabetes|
9535637|NCT03146975|Experimental|Periodontitis decompensated diabetes|
9535638|NCT03146975|No Intervention|Compensated diabetes non periodontitis|
9535639|NCT03146975|No Intervention|Decompensated diabetes non periodontitis|
9535640|NCT03147105|Experimental|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
9535641|NCT03147105|Active Comparator|waiting group|training after 12 weeks.
9535642|NCT03147027||VT ablation group|
9535643|NCT03147027||medication group|
9535644|NCT03147066|Experimental|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
9535645|NCT03147066|Active Comparator|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
9535646|NCT03147092|Experimental|Hypertension group|Hypertensive patients will be counseled to initiate life style changes as weight loss, salt reduction, exercise, reduced alcohol consumption, smoking cessation and fresh fruits and vegetables in their diets. Drug treatment will be started for subjects that are not responding to nonpharmacological treatment. The anti-hypertensive medications will be Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet, atenolol and Losartan potassium 50 mg. All of these anti-hypertensive drugs are available in the PPP. If BP control is not yet obtained, other antihypertensive drugs will be requested: clonidine, spironolactone, hydralazine and amlodipine.
9615958|NCT04941157|No Intervention|Selective cerebrospinal fluid drain placement|Patients randomized to the control arm of the study will not receive a prophylactic cerebrospinal fluid drain prior to their endovascular aortic repair. Patients will receive a CSF drain post-operative as needed to treat any symptoms of spinal cord ischemia. This arm of the study is current standard of care.
9615959|NCT04938570||University-level and amateur rugby players|"University-level and amateur rugby players will be recruited and assessed (motor, visual and symptom assessment) over one season ( June 2021 to August 2022).~Participants will be stratified according to gender (males n≈100, and females n≈100). Although the number of SRC that will be observed during the season is not known, the investigators will compare a number of head injuries/SRC to the results from cohort baseline testing. Participants that do not sustain a concussion will also have follow up testing at the end of the season."
9615960|NCT04936386||Healthcare professionals|Healthcare professionals (medical specialists and general practitioners, medical residents, midwives, professional nurses, medical students).
9615961|NCT04925102||GMFCS level I|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level I will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
10038826|NCT01838083|Experimental|Insulin glargine new formulation (test T formulation)|Once daily for 6 days
9615962|NCT04925102||GMFCS level II|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level II will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
9615963|NCT04925102||GMFCS level III|Goal specific treatment protocol with respect to the problem enlisted in GMFCS level III will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
9615964|NCT04925102||GMFCS level IV|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level IV will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
9615965|NCT04925102||GMFCS level V|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level V will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
9615966|NCT04924764|Active Comparator|Follow-up on daily basis|Patient receiving treatments on daily basis (5 days a week)
9615967|NCT04924764|Active Comparator|Follow-up on alternate days|Patients receiving treatment on alternate days (3 days a week)
9615968|NCT04910048|Active Comparator|Standard of Care|The first arm consists of UAMS standard of care (SOC), including providing a brochure with information (contact information, brief educational information) for the patient to consult with a nutritionist to help with self-directed weight loss.
10038827|NCT01838083|Experimental|Insulin glargine new formulation (reference R formulation)|Once daily for 6 days
9535647|NCT03147079|Experimental|Intervention|Lifestyle intervention
9535648|NCT03147079|Experimental|Internal controls|
9535649|NCT03147079|Experimental|External controls|
9535650|NCT03147196|Experimental|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9535651|NCT03147196|Experimental|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9535652|NCT03147196|Experimental|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9535653|NCT03147196|Experimental|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9535654|NCT03146923|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
9535655|NCT03146923|Experimental|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
9535656|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
9535657|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
9535658|NCT03147001|Experimental|Protein ingestion|Subjects ingested protein drinks
9535659|NCT03147001|Placebo Comparator|Placebo|Subjects ingested a non-caloric placebo drink
9535660|NCT03146988|Experimental|RGB-02 6 mg SC (test product)|
9535661|NCT03146988|Active Comparator|Neulasta®|
9535662|NCT03146949|Active Comparator|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
9535663|NCT03146949|Active Comparator|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
9535664|NCT03146858|Experimental|Enoxaparin|The patients will receive a 3-6 hour infusion of enoxaparin. The effects of the infusion will be assess when used on patients will acute heart attacks and undergoing emergency treatment with PPCI.
9535665|NCT03146715|Active Comparator|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
9535666|NCT03146715|Placebo Comparator|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
9535667|NCT03146780|Placebo Comparator|Conventional|
9535668|NCT03146780|Active Comparator|Digital 1|
9535669|NCT03146780|Active Comparator|Digital 2|
9535670|NCT03146780|Active Comparator|Digital 3|
9535671|NCT03146845|Experimental|Allevyn Life Non-Bordered|Foam Dressing
9535672|NCT03146845|Other|Standard care|Standard care dressing
9535673|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
9535674|NCT03146728||able-bodied|age height and weight matched able bodied
9535675|NCT03147157|Experimental|research group,low MR group|tacrolimus regimen guided by HLA matching rate
9535676|NCT03147157|No Intervention|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
9535677|NCT03147157|Experimental|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
9535678|NCT03147157|No Intervention|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
9535679|NCT03147157|Experimental|research group,high MR group|tacrolimus regimen guided by HLA matching rate
9535680|NCT03147157|No Intervention|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
9535681|NCT03146767|Experimental|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
9535682|NCT03146767|No Intervention|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
9535683|NCT03146832|Experimental|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
10038828|NCT01838109|Experimental|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
9535684|NCT03146832|Experimental|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
9535685|NCT03146832|No Intervention|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
9535686|NCT03146871|Experimental|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
9535687|NCT03146897|Active Comparator|Super Cereal Plus with amylase|
9535688|NCT03146897|Active Comparator|Corn-soy Blend Plus and Vegetable Oil|
9535689|NCT03146897|Active Comparator|Corn-soy Whey Blend and Vegetable Oil|
9535690|NCT03146897|Active Comparator|Ready-to-Use-Supplementary Food|
9535691|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
9535692|NCT03146520||Polyps|subjects with adenoma or polyps
9535693|NCT03146520||Other cancers|subjects with other cancers
9535694|NCT03146520||Healthy|subjects with no evidence of CRC
9535695|NCT03146624|Experimental|attachment|attachment retained obturator
9535696|NCT03146624|Active Comparator|clasp|clasp retained obturator
9535697|NCT03146650|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
9535698|NCT03146533|Experimental|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
10038829|NCT01838109|No Intervention|Control group|no intervention total 87 patients
10038830|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
9535699|NCT03146689|Experimental|Topical NSAID and topical capsaicin|"Within each participant:~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
9535700|NCT03146351|Experimental|Early and moderate preterm group|Infants born before 34 weeks included in this group
9535701|NCT03146351|Experimental|Late preterm group|Infants born between 34 and 37 weeks included in this group
9535702|NCT03146416|Experimental|Cohort 1|Evinacumab SC or placebo SC
9535703|NCT03146416|Experimental|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
10038831|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
10038832|NCT01838135|No Intervention|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
10038833|NCT01838135|Experimental|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
10038834|NCT01838161|Active Comparator|Part I|Interview questions will focus on reticence to vaccinate children.
10038835|NCT01838161|Experimental|Part II|"We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents.~a pretest survey~the video vignette~and a post-test survey measuring intention to receive appropriate adolescent vaccines"
9535704|NCT03146416|Experimental|Cohort 3|High dose regimen: evinacumab IV or placebo IV
9535705|NCT03146416|Experimental|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
9535706|NCT03146416|Experimental|Cohort 5|Evinacumab or placebo SC x 1 dose
9622044|NCT02518802|Experimental|Synchronous therapy|'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen. Gefitinb, 250mg per day,take orally for 2 years. Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
9622045|NCT02518802|Active Comparator|Chemotherapy|Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
9535707|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of <0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. [9] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
9535708|NCT03146611||control|healthy sex and age matched group
9535709|NCT03146546||Septic Shock|Patients with septic shock as defined by the Sepsis-3 criteria(9)
9535710|NCT03146546||Septic Shock with AKI|Patients with septic shock as defined by the Sepsis-3 criteria(9) with concomitant AKI
9535711|NCT03146572|Experimental|Intervention|Parent of child to receive intervention, Sit Down and Play
9535712|NCT03146572|Active Comparator|Control|Parent will receive handout to promote positive behavior
9535713|NCT03146637|Experimental|Activated CIK armed with bispecific antibody treatment group|CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
9535714|NCT03146637|Active Comparator|Traditional CIK treatment group|CIK cells were not activated
9535715|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
9535716|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
9535717|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
9535718|NCT03146481|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
9535719|NCT03146481|Placebo Comparator|placebo|Placebo
9535720|NCT03146273|Experimental|A|The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.
9535721|NCT03146273|Experimental|B|The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs
9535722|NCT03146299|Active Comparator|Group A: TLH|
9535723|NCT03146299|Active Comparator|Group B: LAVH|
9535724|NCT03146364|Experimental|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
9535725|NCT03146364|Experimental|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
9535726|NCT03146260|Experimental|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
9535727|NCT03146260|Experimental|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
9535728|NCT03146234|Experimental|CAR-GPC3 T cells|"Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion."
9535729|NCT03146468|Experimental|Nivolumab treatment arm|Nivolumab injection 3mg/kg intravenously every 2 weeks
9535730|NCT03146377|Experimental|Xeloxiri|
9535731|NCT03146390|Active Comparator|Essential oils (Listerine Mentol)|"a single mouthwash with 20 ml of essential oils for 30 seconds~20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1)."
9535732|NCT03146390|Placebo Comparator|Water|"a single mouthwash with 20 ml of sterile water for 30 seconds~20 ml rinses for 30 seconds with sterile water/2 times daily (1/0/1)."
9535733|NCT03146390|Experimental|Alcohol free essential oils|"a single mouthwash with 20 ml of alcohol free essential oils for 30 seconds~20 ml rinses for 30 seconds with alcohol free essential oils/2 times daily (1/0/1)."
10038836|NCT01838161|Experimental|Part III|"enhanced video educational intervention (video vignettes + standard of care vaccine event)~standard of care vaccination event"
9535734|NCT03146559|Experimental|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.~5 days per week, for 3 weeks, 15 minutes per day."
9535735|NCT03146559|Active Comparator|TENS only|"Custom-built software & hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.~5 days per week, for 3 weeks, 15 minutes per day."
9535736|NCT03146494||STAAD|
9535737|NCT03146494||Normal|
9535738|NCT03146312|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
9535739|NCT03146312|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
9535740|NCT03146286|Placebo Comparator|Control|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
9535741|NCT03146286|Experimental|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.7 g/kg bodyweight palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
9535742|NCT03146286|Experimental|Fish Oil|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.45 g/kg bodyweight palm stearin and 0.25 g/kg bodyweight fish oil (n3PUFA). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
9535743|NCT03146221|Other|Person to be surgically treated for arteritis|
9535744|NCT03146247|Other|One arm|all patients receive same dose and dosing regimen with Apremilast
9535745|NCT03146039|Other|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
9535746|NCT03146026|No Intervention|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
9535747|NCT03146026|Experimental|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
9535748|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
9535749|NCT03146143|Experimental|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
9535750|NCT03146143|No Intervention|non ultrafiltration control group|no ultrafiltration will be applied in this group
9535751|NCT03146000|Experimental|lidocaine-prilocaine|women will receive 5 mg lidocaine-prilocaine cream topically on the episiotomy line
9535752|NCT03146000|Active Comparator|meloxicam|women will receive one 15 mg meloxicam rectal suppository
9535753|NCT03146130|Active Comparator|Patient treated with N-acetylcysteine|Patients randomise in the drug group
9535754|NCT03146130|Placebo Comparator|Patient treated with placebo|Patients randomise in the placebo group
9535755|NCT03145987|Experimental|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
9535756|NCT03145987|Placebo Comparator|Placebo|Placebo orally administered once a day for 12 weeks.
9535757|NCT03146065|Experimental|PF-06730512|Study Drug being used in the study
9535758|NCT03146065|Placebo Comparator|Placebo|Placebo for IV/SC administration
9535759|NCT03146325|Experimental|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
9535760|NCT03146325|Placebo Comparator|PLACEBO|MATCHING PLACEBOS
9535761|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
9535762|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
9535763|NCT03146455||Health adults|(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
9535764|NCT03146169|Experimental|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
9535765|NCT03146052|Experimental|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
9535766|NCT03146052|Active Comparator|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
9535767|NCT03146182|No Intervention|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
9535768|NCT03146182|Experimental|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
9535769|NCT03146182|Experimental|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
9535770|NCT03145883|No Intervention|Control group|Control group
9535771|NCT03145883|Experimental|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
9535772|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
9535773|NCT03145844||Direct Acting Agents|No Intervention
9535774|NCT03145740|Experimental|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
9622046|NCT02518945|Placebo Comparator|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
9622047|NCT02518945|Active Comparator|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
10038837|NCT01838239|Experimental|Fish oil|
9535775|NCT03145740|Placebo Comparator|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
9535776|NCT03145753|Experimental|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
9535777|NCT03145753|Active Comparator|HIV/HCV Education|In this arm only education should be provided
9535778|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
9535779|NCT03145649||Healthy|Healthy mother-infant dyads
9535780|NCT03145948|Experimental|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
9535781|NCT03145948|Experimental|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
9535782|NCT03145948|Experimental|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
10038838|NCT01838252|Experimental|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
10038839|NCT01838252|Sham Comparator|Saline|
10038840|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
9535783|NCT03145948|Experimental|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
10038841|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
9535784|NCT03145948|Experimental|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
9535785|NCT03145948|Experimental|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
9535786|NCT03145597|Experimental|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
9535787|NCT03145597|Experimental|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
9535788|NCT03145714|Experimental|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
9535789|NCT03145714|Active Comparator|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
9535790|NCT03145909|Experimental|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
10038842|NCT01838278|Experimental|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
10038843|NCT01838291||Patients on Ferriprox therapy <1 month|
10038844|NCT01838330|Experimental|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
10038845|NCT01838330|No Intervention|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
9535791|NCT03145909|Experimental|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
9535792|NCT03145610|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
9535793|NCT03145610|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
9535794|NCT03146091|Experimental|Outpatient nonantibiotic treatment|
9535795|NCT03146091|Active Comparator|Outpatient antibiotic treatment|
9535796|NCT03146104|Active Comparator|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
9535797|NCT03146104|Active Comparator|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
9535798|NCT03145662|Active Comparator|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
9535799|NCT03145662|Active Comparator|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
9535800|NCT03145961|No Intervention|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
9622048|NCT02518828|Active Comparator|High SpO2|In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
9535801|NCT03145961|Experimental|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
10038846|NCT01838343|No Intervention|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
9535802|NCT03145922||Sarcoidosis|
10038847|NCT01838343|Experimental|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
9535803|NCT03145922||Healthy Controls|
9535804|NCT03145896|Active Comparator|IBD patients with Vitamin D treatment|
9535805|NCT03145896|No Intervention|IBD patients with no Vitamin D treatment|
9535806|NCT03145857|Experimental|[68]Ga-HA-DOTATATE|All participants will be imaged with [68]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven [68]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.
9535807|NCT03145675|Experimental|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).
9535808|NCT03145675|Active Comparator|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).
9535809|NCT03145675|Experimental|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
9535810|NCT03145675|Active Comparator|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
9535811|NCT03145870|Other|Patient with multiple symptomatic myeloma|
9535812|NCT03145636|Other|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
10038848|NCT01838356||No treatment.|
10038849|NCT01838369|Experimental|BI-505|
10038850|NCT01838382|Experimental|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
9535813|NCT03145636|Other|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
9535814|NCT03145636|Other|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
9535815|NCT03145727|Placebo Comparator|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
9535816|NCT03145727|Experimental|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
9535817|NCT03145727|Experimental|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
9535818|NCT03145558|Experimental|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
9535819|NCT03145558|Active Comparator|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
9535820|NCT03145363|Experimental|Intervention|receive interactive text messages
9535821|NCT03145363|Active Comparator|Control|Receive informational text messages
9535822|NCT03145480|Experimental|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
9535823|NCT03145480|Experimental|Frail arm|ibrutinib and obinutuzumab
10058371|NCT02017925|Experimental|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
10058372|NCT02017925|Experimental|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
10058373|NCT02017938|No Intervention|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
10058374|NCT02017938|Experimental|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
10058375|NCT02017938|Experimental|Stage 2: Health group|Stage 2 controlled group
9535824|NCT03145688|No Intervention|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments & information about the benefits of physical activity.
9535825|NCT03145688|Experimental|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents & children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try & skill training content to help with goal setting & tracking of physical activity.
9622049|NCT02518828|Active Comparator|Low SpO2|In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
9622050|NCT02518776|Other|Neuropsychological tests|
10038851|NCT01838395|Experimental|BL-8040 + Ara-C|"Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (monotherapy period) over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy (combined period) over 5 days. During the combined period, BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days and will not be escalated."
10038852|NCT01838408|Experimental|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
9535826|NCT03145688|Experimental|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
9535827|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
9535828|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
9535829|NCT03145402|Experimental|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
9535830|NCT03145402|Placebo Comparator|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
9535831|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
9615969|NCT04910048|Experimental|Intervention (POPOP)|The second arm is a specified 2-month POPOP focused on weight loss administered by the external partner, 20Lighter. The program includes customized meal plans; vitamin, mineral and nutritional supplementation; and daily engagement via a smartphone app with a 20Lighter health care provider. Video conferencing appointments will occur approximately every 3 weeks. The program does not require any exercise or physical engagement but does necessitate that patients have a smartphone or tablet with Bluetooth capability, cell signal or WIFI connection. During the first 40 days the customized meal plans are adhered to, then from days 41-60 patients will transition back to a normal dietary lifestyle via a customized plan based on considerations including, food preferences, physical engagement and height.
9615970|NCT04893837||Standard care plus infrascans|"All participants will receive regular clinical neurological assessments as ordered by the clinical care team. In addition, a research team member will perform an infrascan. This process will be repeated hourly at the same timepoint as the clinical neurological assessments. If a patient's neurological status deteriorates at any time point, and the medical team orders an early (unplanned) CT scan, the neurological data collection will cease once the patient is sent to CT.~Infrascan results will not be shared with the clinical care team, and will not guide the participants' care in any way."
9615971|NCT04891484|Experimental|Ondansetron group|Group O :patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
9615972|NCT04891484|Placebo Comparator|Control group|Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
9615973|NCT04884113||Experimental: Motorized Spiral Enteroscopy|"Procedure: Motorized Spiral Enteroscopy:~PowerSpiral enteroscope will be inserted and advanced with the assistance of motorized spiral rotation, After reaching the point of maximum insertion, cecum or if no further advancement of the enteroscope can be achieved, the enteroscope will be withdrawn using motorized counter-clockwise spiral rotation. When no total enteroscopy is reached, submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde enteroscopy is then performed in the same session or at second session"
9615974|NCT04861298|Active Comparator|Standard of care (SOC)|This arm will receive the standard of care (SOC) for COVID-19 as per the hospital guidelines.
9615975|NCT04861298|Experimental|Quercetin|This arm will receive standard of care + oral Quercetin for two weeks
9615976|NCT04859946|Experimental|Supportive care (itacitinib)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, thiotepa IV on day -7, and fludarabine IV over 1 hour on days -6 to -3.~STEM CELL TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4. Patients also receive itacitinib PO QD on days 5-60 in the absence of disease progression or unacceptable toxicity. Beginning day 5 after stem cell transplant, patients also receive tacrolimus IV over 24 hours until able to tolerate oral tacrolimus, whereby patients then receive tacrolimus PO BID."
9615977|NCT04858971||Control|No source will be indicated on information provided for review
9615978|NCT04858971||Government source|A government logo will be shown on information provided for review
9615979|NCT04858971||Medical source|A medical logo will be shown on information provided for review
9615980|NCT04858971||Social media source|A social media logo will be shown on information provided for review
9615981|NCT04852874|Experimental|Ultrasound-guided Quadratus Lumborum Block|
9622051|NCT02518815|Experimental|Prewarming group|Prewarmed for 20 minutes prior to OR using 3M Bair Paws System, a forced air warming blanket. This warming blanket was then used intraoperatively throughout the case.
9622052|NCT02518815|No Intervention|Control group|Patients received standard care, which is no active prewarming prior to OR. A full body, forced air warming blanket (same as treatment group) was used intraoperatively throughout the case.
9622053|NCT02518763|Experimental|Vitamin D3, 100 000 IU weekly, 4 times|
10038853|NCT01838408|Active Comparator|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
10038854|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
10038855|NCT01838434|Active Comparator|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
10038856|NCT01838434|Experimental|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
10038857|NCT01838460|Experimental|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
9535832|NCT03145337|Active Comparator|Cohort A|FlexHD ADM
9535833|NCT03145337|Active Comparator|Cohort B|AlloDerm RTU ADM
10038858|NCT01838460|Active Comparator|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
9535834|NCT03145519|Experimental|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
9535835|NCT03145519|Active Comparator|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
9535836|NCT03145441|Experimental|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
9535837|NCT03145441|No Intervention|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
9535838|NCT03145454|Experimental|Pain detection|Electroencephalographical responses will be collected during surgical gesture by different intervention: electroencephalography helmet, dermal electrode, blood pressure sensors, pupillometry glasses and Holter.
9535839|NCT03145376||patients before and after TAVI/MitraClip|geriatric assessment of patients before and after TAVI/Mitraclip
9535840|NCT03145272|Experimental|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
9535841|NCT03145831|Experimental|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
9535842|NCT03145493|Experimental|Usage of suction drains|Usage of suction drains
9535843|NCT03145493|No Intervention|No usage of suction drains|No usage of suction drains
9535844|NCT03145246||tooth loss|regeneration treated teeth loss
9535845|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
9535846|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss < 2 mm
9535847|NCT03145311|Active Comparator|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
9535848|NCT03145311|Sham Comparator|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
9535849|NCT03145792|Experimental|Seeking Safety|Behavioral therapy for trauma and addiction.
9535850|NCT03145792|Active Comparator|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
9535851|NCT05255744|Experimental|Whitsundays nasal mask|Participants will be asked to take home the investigational mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
9535852|NCT05255744|Active Comparator|AirFit N30i Quiet mask|Participants will be asked to take home the comparator mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
9535853|NCT05255718|Placebo Comparator|Control|The placebo supplement will have no polyphenol content and will consist of 100 mL of the following mixture: black cherry Koolaid, blue and red food coloring, sucrose and sorbitol. This placebo will match the sugar content of the chokeberry juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
10038859|NCT01838460|Active Comparator|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
9535854|NCT05255718|Experimental|Aronia|100 mL of Aronia juice. Dose of 100 mL is consumed once daily for duration of 28-30 day supplementation period.
9535855|NCT05255705||Patients undergoing Revascularisation at Barts Heart Centre|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with coronary artery disease undergoing revascularisation.
9535856|NCT05255692|Experimental|Complete evaluation UDO and fMRI|Evaluation including both urodynamic evaluation and functional MRI testing
9535857|NCT05255679|Experimental|Early FES|Receives standard care plus FES cycling in Phase 1 (starting 14 to 21 days after injury and for 3 months) and Phase 2 (from month 3 to month 6 after enrollment).
9535858|NCT05255679|Experimental|Delayed FES|Receives standard care only in Phase 1 (considered Control group in Phase 1), and standard care plus FES cycling in Phase 2 (from month 3 to month 6 after enrollment).
9535859|NCT05255679|No Intervention|Control|Receives standard care only
9535860|NCT05255666|Experimental|Experimental Group|"400 mg of Pembrolizumab intravenously on Day 1 of each Cycle (Cycle is 42 days)~50 mg/m2 of Nal-IRI intravenously on Day 1, Day 15, and Day 29 of each Cycle (Cycle is 42 days)"
9535861|NCT05255627|Experimental|Control Group|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
9615982|NCT04849312||Training|A subset of patients that are used to train the machine learning algorithm.
9615983|NCT04849312||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
9615984|NCT04846231|Active Comparator|Rosuvastatin|5 mg once per day
10038860|NCT01838460|Active Comparator|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
10038861|NCT01838460|Active Comparator|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
9535862|NCT05255627|Experimental|Mobile application group (Experimental Group)|"A mobile application program was installed on their phones for the experimental group students to benefit from. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
9535863|NCT05255614|Active Comparator|First Group|the participants will start training on the pelvic trainer and assessment will be via assessment via a checklist. Then at a later time, they will be trained on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator.
9535864|NCT05255614|Active Comparator|Second Group|the participants will start training on VR simulator (Sim Surgery) and assessment will be via Electronic auto assessment via the Simulator. Then at a later time, they will be trained on the pelvic trainer and assessment will be via assessment via a checklist.
9535865|NCT05255601|Experimental|Relatlimab + Nivolumab|
9535866|NCT05255588||Cohort|Subjects who are at high-risk (Asia Pacific Colorectal Screening Score ≥4.0) of developing CRC aged ≥40
9535867|NCT05255575||ertapenem treatment|
9535868|NCT05255549|Experimental|Group I|
10038862|NCT01838473|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
9535869|NCT05255549|Sham Comparator|Group II|
9535870|NCT05255536|Active Comparator|Serratus Anterior Plan Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
9535871|NCT05255536|Active Comparator|Serratus Anterior Plan Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine will be injected into the area.
9535872|NCT05255523|Experimental|Arm 1|Pyrotinib：400mg qd po continuous medication Capecitabine: 1000 mg/m2 bid po for 14 consecutive days with 7 days off, every 21 days as a cycle.
9535873|NCT05255484|Experimental|LM-108 Dose Escalation|Drug: LM-108 Administered intravenously
9535874|NCT05255484|Experimental|LM-108 Dose Expansion|Drug: LM-108 Administered intravenously
9535875|NCT05255484|Experimental|LM-108 Combination Dose Escalation|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
9535876|NCT05255484|Experimental|LM-108 Combination Dose Expansion|Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously
9535877|NCT05255458|Experimental|AK102 regimen 1|
9535878|NCT05255458|Placebo Comparator|Placebo|
9535879|NCT05255406|Experimental|Furmonertinib|Furmonertinib (160mg)
9535880|NCT05255393||Standard lymphadenectomy(LND) with sentinel lymph node mapping (SLN)|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
9535881|NCT05255393||Standard lymphadenectomy(LND) alone|"Patients will receive up to two mailings or messages and two phone calls if they do not respond. Self-addressed, stamped envelopes will be provided for return of questionnaires.~No other interventions are planned."
9535882|NCT05255367|Experimental|Intake of (poly)phenol rich foods|Daily consumption of 100 ml of a commercial juice of berries and pomegranate, 20 g dark chocolate and 1 green tea, to test if the supplementation of the diet with (poly)phenol rich foods, during 2 months, reduce the cardiometabolic risk in post-post-menopausal women.
9535883|NCT05255302|Active Comparator|Arm A : control Arm|6 months treatment by chemotherapy + pembrolizumab followed by pembrolizumab ± pemetrexed for patients with non-squamous cell carcinoma (SCC) until 2 years max
9535884|NCT05255302|Experimental|Arm B : experimental arm|6 months treatment by chemotherapy + pembrolizumab followed by pemetrexed for patients with non-SCC or observation for patients with SCC
9535885|NCT05255289|Experimental|Before TOT|Data obtained before the operation
9535886|NCT05255289|Experimental|After TOT|Data obtained after the operation
9535887|NCT05255276|Active Comparator|Group 1 Treatment A|A single-dose administration of sitravatinib malate 50 mg on Day 1. Day 12, a single dose of sitravatinib malate 50 mg will be will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
9535888|NCT05255276|Active Comparator|Group 1 Treatment B|On Days 9 to 11, itraconazole 200 mg will be administered QD in the morning. On Day 12, a single dose of sitravatinib malate 50 mg will be coadministered with itraconazole. Itraconazole QD dosing will continue on Days 13 to 18 to maintain steady state during the PK sample collection period.
10038863|NCT01838473|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
9535889|NCT05255276|Active Comparator|Group 2 Treatment A|A single-dose administration of sitravatinib malate 100 mg on Day 1 will be followed by a 72-hour PK sample collection period. Subjects will be discharged from the CRU on Day 4 after collection of 72-hour postdose PK sample and completion of all required study procedures.
9535890|NCT05255276|Active Comparator|Group 2 Treatment B|On Days 9 to 15, rifampin 600 mg will be administered QD in the morning. On Day 16, a single dose of sitravatinib malate 100 mg will be coadministered with rifampin followed by a 72 hour PK sample collection period. Rifampin QD dosing will continue on Days 17 to 22 to maintain steady state during the PK sample collection period.
9535891|NCT05255263|Active Comparator|Programmed Intermittent Epidural Bolus|Intermittent epidural bolus as the first line labor epidural analgesia maintenance infusion
9535892|NCT05255263|Active Comparator|Continuous Epidural Infusion|Continuous epidural infusion as the first line labor epidural analgesia maintenance infusion
9535893|NCT05255237|Experimental|Jaktinib|Patients will administer the study product twice per day for 24 weeks, for the safty assessment.
9535894|NCT05255224||Retrospective|Patients admitted to Mass Brigham Hospitals for cardiac surgery from 1st January 1998 to 31st December 2020
9535895|NCT05255224||Prospective|Patients admitted to Barts Health and Liverpool Heart and Chest Hospital for cardiac surgery between 1st October 2021 to 31st July 2023
9535896|NCT05255211|Experimental|Remimazolam|IV Remimazolam tosilate 0.3mg/kg
9535897|NCT05255211|Active Comparator|propofol|IV propofol 1.2~2.5mg/kg
10038864|NCT01838473|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
10038865|NCT01838473|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
9535898|NCT05255211|Placebo Comparator|saline|IV saline solution 10ml
9535899|NCT05255198||Anterolateral approach|
9535900|NCT05255198||Direct anterior approach|
9535901|NCT05255185|Experimental|All the patients|domino therapy treat the infection around the prosthesis after the limb salvage surgery of bone tumor
9535902|NCT05255172|Experimental|Supervised exercise|The exercise intervention will include 2 supervised sessions of ergometer cycling with a warm up period of 10 minutes and 20 minutes of cycling at the aerobic intensity below the anaerobic threshold as determined from baseline results. Patients in the exercise arm will have 1 unsupervised exercise session where the participants walk or bicycle for 30 minutes at an intensity experienced as somewhat hard (Borg 13) according to the Borg Rating of Perceived Exertion Scale.
9535903|NCT05255172|No Intervention|Standard of Care|The control group will receive advise to continue to live as usual. After 4 and 8 weeks, participants in the control group will be contacted by telephone for inquiry of general wellbeing. No other interventions will be performed in the control group.
9535904|NCT05255159|Experimental|18F-DOPA PET/CT scan|4 MBq/kg (minimum 100 MBq, maximum 600 MBq) 18F-DOPA injected intravenously with 40 mg furosemide and subsequent whole body PET/CT scan
9535905|NCT05255133|Experimental|GEP-NET and lung-NET patients|Liquid biopsies and scans
9535906|NCT05255094|Experimental|AK102 regimen 1|
9535907|NCT05255094|Experimental|AK102 regimen 2|
9535908|NCT05255094|Placebo Comparator|Placebo 1|
9535909|NCT05255094|Placebo Comparator|Placebo 2|
9535910|NCT05255081|Experimental|Treatment Arm|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
10038866|NCT01838486|Experimental|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
10038867|NCT01838525||SIRS, SEPSIS|
9535911|NCT05255081|Placebo Comparator|Control Arm|Spray with saline would be applied to organs under incision
9535912|NCT05255042||Trial Participants|"Overall Description of Trial Participants: The liver organ samples included in this project will be from patients undergoing elective surgery for a lesion in the liver in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.~Inclusion Criteria: The samples included in this project will be from patients undergoing elective liver surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of liver segment samples from radical surgery are adult age and presence of hepatic tissue in the discarded material after hepato-pancreato-biliary surgery.~Exclusion Criteria: The main exclusion criterion is acute invasive infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
9535913|NCT05255029|Experimental|PODEYE Toric Intra Ocular Lens Implantation experimental|Implantation of PODEYE toric intraocular lenses.
9535914|NCT05254964|Experimental|Intensive cognitive rehabilitation group|Participants receive intensive cognitive rehabilitation for 20 hours for 4 weeks.
9535915|NCT05254951|Experimental|Patients enrolled in the protocol|Patients will receive a tidal volume challenge to assess fluid responsiveness and then a volume expansion bolus to classify them into responders and not responders
9535916|NCT05254925|Active Comparator|Phototoxicity evaluation of sunscreen oil with 6% BEMT (SU E 101413 85)|"Assessment of the phototoxicity potential of sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer a test material (formulation: SU E 101413 85).~The phototoxic response of the investigational product: SU E 101413 85 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
9535917|NCT05254925|Other|Phototoxicity evaluation of sunscreen oil vehicle (SU E 101413 91)|"Vehicle Control: Assessment of the phototoxicity potential of sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (formulation: SU E 101413 91).~The phototoxic response of the investigational product: SU E 101413 91 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
9535918|NCT05254925|Active Comparator|Phototoxicity evaluation of dispersion of 6% BEMT in petrolatum (SU E 101413 82)|"Assessment of the phototoxicity potential of a dispersion of 6% BEMT (PARSOL® Shield) in petrolatum (formulation: SU E 101413 82).~The phototoxic response of the investigational product: SU E 101413 82 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
9615985|NCT04846231|Placebo Comparator|Placebo|comparable to rosuvastatin 5 mg once per day
9615986|NCT04846231|Active Comparator|Fish Oil|Nature Made 2 soft gels per day
10038868|NCT01838525||sepsis, severe sepsis, septic shock|
10038869|NCT01838525||health, SIRS, Sepsis|
10038870|NCT01838538|Experimental|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
10058376|NCT02017938|Experimental|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
10038871|NCT01838538|Active Comparator|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
9535919|NCT05254925|Other|Phototoxicity evaluation of petrolatum vehicle (SU-E-101413-83)|"Vehicle Control: Assessment of the phototoxicity potential of petrolatum vehicle (SU-E-101413-83).~The phototoxic response of the investigational product: SU E 101413 83 will be assessed following the determination of each subject's Minimal Erythema Dose (MED). Approximately 0.15 g or 0.15 ml of the investigational product will be applied to the skin of human subjects which will then be exposed to UV radiation an a erythema and dermal response scoring system will be used to evaluate the phototoxic response of the irradiated area within the treated test site of each subject."
9535920|NCT05254899|Experimental|Inductive and concurrent anti-PD-1 antibody combined with chemo-radiotherapy|All the enrolled patients receive 3 cycles of anti-PD-1 antibody (Tislelizumab 200mg d1) + P-GEMOX (Pegaspargase 3000u d2, Gemcitabine 1g/m2 d2, Oxaliplatin 85mg/m2 d2) systemic treatment every 14 days, followed by involved-site radiotherapy with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
9535921|NCT05254886|No Intervention|Routine practice|Patients who benefit from the classic management of CD (i.e. clinical + biological ± radiological ± endoscopic follow-up ± therapeutic education program).
9535922|NCT05254886|Experimental|Routine practice + nurse-led program|Patients who receive, in addition to routine practice, a single nursing consultation dedicated to the identification and management of comorbidities and EIMs in CD at the inclusion visit.
9535923|NCT05254873||AD-TAR|AD subjects who took part to Facial Emotion Recognition rehabilitation (TAR) during EYE-TAR(MA) study
9535924|NCT05254873||AD-Cognitive Stim|AD subjects who took part to cognitive stimulation session (12 sessions during 4 weeks) during EYE-TAR(MA) study
9535925|NCT05254860|Experimental|Interrupted suture|
9535926|NCT05254860|Experimental|Continous suture|
9535927|NCT05254834||Cancer Group|Collect Subject Data Collect Blood Specimen
10038872|NCT01838564|Active Comparator|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
10038873|NCT01838564|Experimental|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
10038874|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
10038875|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.~Never smoker (<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
10038876|NCT01838603||Interventional pain management patients|Patients passed through interventional pain management program
10038877|NCT01838629||thyroid nodule|
10038878|NCT01838668|Placebo Comparator|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
10038879|NCT01838668|Experimental|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
10038880|NCT01838668|Experimental|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
10038881|NCT01838707|Active Comparator|Bupivacaine|0.125% Bupivacaine HCL @ 4-5 ml/h
10038882|NCT01838707|Active Comparator|Bupivacaine, Morphine|0.125% Bupivacaine HCL , Morphine sulphate 3 mg @ 3-5 ml/h
10038883|NCT01838707|Active Comparator|Bupivacaine, Fentanyl|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
10038884|NCT01838720|Experimental|zero ischemia laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
10038885|NCT01838720|Active Comparator|conventional laparoscopic partial nephrectomy|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
9535928|NCT05254834||Non-cancer Group|Collect Subject Data Collect Blood Specimen One Year Follow Up On Cancer Status
10038886|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
10038887|NCT01838746||PCI|Patients undergoing PCI
10038888|NCT01838746||CABG|Patients undergoing CABG
10038889|NCT01838759||Hypovolemic hyponatremia|"Negative values of Overhydration measured by Bioimpedance spectroscopy"
9535933|NCT05254717|Experimental|Interventional arm|Following baseline study, the interventional arm assigned to receive counselling intervention on complementary food flour soaking
9535934|NCT05254717|No Intervention|control arm|The control group will be monitored for presence of any other intervention that might have a potential to mask the effect of the current intervention.
9615987|NCT04846231|Active Comparator|Cinnamon|1200mg, 2 capsules per day
9615988|NCT04846231|Active Comparator|Garlique|Manufactured by Focus Consumer Health Marketgate,1 tablet per day
9615989|NCT04846231|Active Comparator|Turmeric|Bio Schwartz Turmeric Curcumin 1500 mg, 3 capsules per day
9535935|NCT05254704||Group - assessment of reproductibility of TEX-Q-F|"This groupe will fill in the questionnaire twice :~at first before the anesthesia consultation~then, 7 days after the consultation (without further information) This group will be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
9535936|NCT05254704||Group - assessment of the responsiveness of the questionnaire after information|"This group will also fill in the questionnaire twice :~at first before the anesthesia consultation~then, 7 days after the consultation and AFTER a phone interview (about 15 minutes) with an experienced practitioner to provide appropriate information concerning the anesthesia and the postoperative rehabilitation process.~This group will also be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
9535937|NCT05254691|No Intervention|Standard care|All children are put on a time-cycled, pressure limited ventilation mode (AVEA, CareFusion, Yorba Linda, CA, USA). Inspiratory pressures are set to deliver a expiratory tidal volume of 5-7 ml/kg ideal bodyweight. The frequency of the delivered machine-breaths is set in accordance with age and disease condition of the patient. Then the patient set rate of breaths per minute delivered by the ventilator is reduced with 25%, allowing for more spontaneous breaths.
10038890|NCT01838759||Hypervolemic hyponatremia|"Positive values of Overhydration measured by Bioimpedance spectroscopy"
10038891|NCT01838772|Other|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks*.~*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
10038892|NCT01838798||Study population|"See in inclusion/exclusion criteria.~Interventions: Baseline activities; Clinical interview with a psychologist; Telephone interview 2 months after ICU discharge; Clinical interview with a psychologist ."
9535938|NCT05254691|Experimental|Sprinting|The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing).
9535939|NCT05254665|Experimental|Docetaxel Polymeric Micelles for Injection|Docetaxel Polymeric Micelles for Injection
9535940|NCT05254652|Experimental|Experimental: Duloxetine and Pregabalin|Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of duloxetine 30 mg, one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
9535941|NCT05254652|Active Comparator|Active Comparator: Duloxetine|Active comparator group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes only one pill of duloxetine 30 mg after breakfast.
9535946|NCT05254613|Experimental|Cohort 1|Participants will receive a single SC dose of ALXN1830 or placebo (750 mg).
9535947|NCT05254613|Experimental|Cohort 2|Participants will receive a single SC dose of ALXN1830 or placebo (1500 mg).
9535948|NCT05254613|Experimental|Cohort 3|Participants will receive a single SC dose of ALXN1830 or placebo (2250 mg).
9535949|NCT05254613|Experimental|Cohort 4|Participants will receive multiple SC doses of ALXN1830 or placebo (300 mg twice weekly; 8 doses total).
9535950|NCT05254613|Experimental|Cohort 5|Participants will receive multiple SC doses of ALXN1830 or placebo (750 mg once weekly; 12 doses total).
9535951|NCT05254613|Experimental|Cohort 6|Participants will receive multiple SC doses of ALXN1830 or placebo (1500 mg once weekly; 4 doses total).
9535952|NCT05254613|Experimental|Cohort 7|Participants will receive multiple SC doses of ALXN1830 or placebo (2250 mg once weekly; 4 doses total).
10038893|NCT01838850|Experimental|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
10058377|NCT02017938|No Intervention|Stage 3: PD controlled group|Stage 3 controlled group
9535955|NCT05254587||Retrospective|
9535956|NCT05254587||Prospective|
9535957|NCT05254574|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
9535958|NCT05254574|Placebo Comparator|Placebo SAM Ultrasound Device and Diclofenac Patch|Patients receive placebo treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 0% diclofenac patch.
9535959|NCT05254574|Active Comparator|Over the Counter Arthritis Pain Gel|Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
9535960|NCT05254561|Active Comparator|purified protein derivative (PPD)|Group A
10058378|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
9535961|NCT05254561|Active Comparator|Candida antigen.|Group B
9535962|NCT05254561|Active Comparator|Measles, Mumps and Rubella vaccine (MMR).|Group C
9535963|NCT05254561|Active Comparator|Triple combination of PPD, Candida antigen and MMR|Group D
9535964|NCT05254483|Experimental|Intervention group (IG)|Receiving exercise program immediately
9535965|NCT05254483|Active Comparator|Waitlist Control Group (WCG)|Receiving exercise program after 12 week wait.
9535966|NCT05254470||Pre-Low Intensity Continuous Ultrasound Treatment|Routine care for pain alleviation, range of motion and ability to return to work with traditional therapies from rehabilitation.
9535967|NCT05254470||Post-Low Intensity Continuous Ultrasound Treatment|Routine care of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies.
9535968|NCT05254444|No Intervention|Group 1: Control|No activities will take place in group 1.
9535969|NCT05254444|Experimental|Group 2: Social Marketing|Households in this arm will receive a multi-tiered social marketing campaign focusing on sustainable fish nutrition, dietary diversity and food safety.
9535970|NCT05254444|Experimental|Group 3: Social Marketing + Gear Modification|Households in this arm will receive a bundled intervention of the social marketing campaign as well as modified fishing gear (basket traps with fish escape gaps) and training on proper utilization and management.
10038894|NCT01838850|Active Comparator|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
10038895|NCT01838889|Experimental|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
9535973|NCT05254405|Experimental|Open-Label Infusion of Brexanolone|This is a single arm pilot study of open label brexanolone delivered intravenously over a continuous 60-hour period. Infusions will be administered in a certified healthcare setting in accordance with the Zulresso™ dosing, administration and safety guidelines.
9535974|NCT05254366||Cohort 1|Painless gastroscopic sedation cohort
9535975|NCT05254366||Cohort 2|Painless colonoscopy sedation cohort
9535976|NCT05254353||Patients with EVD|
9535977|NCT05254340|Experimental|Healthy volunteers|Adults ages 18-75 years with no prior history of gastrointestinal diseases or symptoms.
9535978|NCT05254327|Experimental|Arm A|Short Chemo-Radiation Therapy (SCRT) + BMX-001
9535979|NCT05254327|No Intervention|Arm B|Short Chemo-Radiation Therapy (SCRT)
9535980|NCT05254327|Experimental|Arm C|Long Course Chemo-Radiation Therapy (LCCRT) + BMX-001
9535981|NCT05254327|No Intervention|Arm D|Long Course Chemo-Radiation Therapy (LCCRT)
9535982|NCT05254301|Experimental|Personalized multimodal treatment|A combination of biometric parameter oriented nutritional counseling and a tailored physical training program.
9535983|NCT05254301|Active Comparator|Standard care|Physiotherapy with standard care advice for gradual cardiorespiratory and resistance training. (In this standard care setting, nutritional screening nor counseling is included.)
9535984|NCT05254262||Elderly patients|Patients age 70 or older, who are admitted in hospital for surgical operation (elective or emergency surgery)
9535985|NCT05254249|Active Comparator|Treatment Group|In the treatment group, intervention was given in the form of standard therapy and probiotic Lactobacillus plantarum IS 10605 in the amount of 2x1010 CFU for 12 weeks.
9535986|NCT05254249|Placebo Comparator|Placebo Group|In the placebo group, intervention was given in the form of standard therapy and placebo 2x1 sachets for 12 weeks.
9535987|NCT05254249|No Intervention|Healty Control Group|Healthy control group was not given any treatment. Stool samples were taken to examine the gut microbiota profile.
9535988|NCT05254236|Experimental|Medium-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using medium-dose COVID-19 Vaccine (Vero Cell), Inactivated
9535989|NCT05254236|Experimental|High-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using high-dose COVID-19 Vaccine (Vero Cell), Inactivated
9535990|NCT05254223|Experimental|Control Diet (NDA)|No dietary advice (NDA)
9535991|NCT05254223|Experimental|Anti-inflammatory Diet (AIDA)|Anti-inflammatory Dietary advice (AIDA)
9535992|NCT05254210|Experimental|Treatment with RF Device|Subjects may receive up to 3 treatments with the RF device if they are willing to receive treatment for brow lifting and/or present with conditions such as, but not limited to; wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, loose skin on the face, neck and/or body
9535993|NCT05254197||Retrospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 1998, and who have had MR re-examination after first MR exam because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. It is practically impossible to obtain informed consent from patients of this retrospective cohort, and consent was waived by the Institutional Review Board. Target population of this retrospective cohort is 1,500 tumors.
9535994|NCT05254197||Prospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since February 2022, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. The cohort will consists of patients who agree to participate with written consent. Target population of this prospective cohort is 1,500 tumors.
9535996|NCT05254171|Experimental|Experimental Arm|SBP-101 + Nab-paclitaxel and Gemcitabine
9535997|NCT05254171|Placebo Comparator|Control Arm|Placebo + Nab-Paclitaxel and Gemcitabine
9535998|NCT05254145||Group A|This group will include participants without an arthritic knee. These participants will be recruited from the Orthopedic Sports Medicine consultation
10038896|NCT01838889|No Intervention|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
10038897|NCT01838902|Other|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
10038898|NCT01838902|Experimental|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
9535999|NCT05254145||Group B|This group will include participants undergoing primary knee arthroplasty (KA).
9536000|NCT05254145||Group C|This group will include participants undergoing a surgical procedure whose opposite knee has no history of arthritis
9536001|NCT05254145||Group D|This group will include participants undergoing knee revision surgery with no suspicion of infection (aseptic knee revision replacement)
9536002|NCT05254145||Group E|This group will include participants undergoing knee revision with a known infection (septic knee revision replacements)
9536003|NCT05254132||aRECIST|Treatment naive patients with metastatic NSCLC (stage four) with life expectancy of more than three months.
9536004|NCT05254132||rATLAS|Treatment naive patients diagnosed with NSCLC.
10038899|NCT01838902|Experimental|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
10038900|NCT01838902|Experimental|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
9536007|NCT05254093|No Intervention|group A|
9536008|NCT05254093|Active Comparator|group B|
9536009|NCT05254093|Active Comparator|group C|
9536010|NCT05254080|Experimental|Active taVNS then Sham taVNS|Participants will receive active then sham (placebo) ear stimulation.
9536011|NCT05254080|Experimental|Sham taVNS then Active taVNS|Participants will receive sham (placebo) then active ear stimulation.
9536012|NCT05254067||Device recipient|
9536013|NCT05254054|Experimental|Vibration group|Participants in Vibration group will receive an 8-week whole body vibration training in addition to conventional exercise training.
9536014|NCT05254054|Active Comparator|Control group|Participants in Vibration group will only receive conventional exercise training.
9536015|NCT05254015|Experimental|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|"Compensatory Cognitive Training (CCT) Modules (7 sessions). Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illnesses. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive impairments and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Exposure to Discarding and Acquiring Modules (19 sessions). Symptoms of acquiring and saving are themselves avoidance behaviors to avoid internal distress related to negative thoughts and emotions. ET utilizes in vivo exposure exercises taking place in the home to enhance generalization of their new skills. Fear hierarchies typically start with a space that has low clutter volume or there is less of an urge to save a particular type of item in that environment."
9536016|NCT05254015|Active Comparator|Case Management (CM)|Case Management (CM). CM consists of a set of well-established strategies commonly used in community service settings to address serious and complex problems in particularly vulnerable and often marginalized populations such as those with HD.
9615990|NCT04846231|Active Comparator|Plant Sterol|Nature Made CholestOff Plus, 2 soft gels twice a day
9615991|NCT04846231|Active Comparator|Red Yeast Rice|Arazo Nutrition 1200 mg, 2 capsules per day
9615992|NCT04844918|Experimental|Tirzepatide Regimen A|Tirzepatide Regimen A administered subcutaneously (SC)
9615993|NCT04844918|Experimental|Tirzepatide Regimen B|Tirzepatide Regimen B administered subcutaneously (SC)
9615994|NCT04844918|Placebo Comparator|Placebo|Placebo administered SC
9615995|NCT04842708|No Intervention|Healthy Volunteers that are not to be vaccinated against COVID19|Healthy Volunteers that are not eligible to be vaccinated against COVID19
9615996|NCT04842708|Experimental|Healthy Volunteers that are assigned to be vaccinated against COVID19|Healthy Volunteers that are eligible to be vaccinated against COVID19
9615997|NCT04842084||healthy volunteers|Healthy volunteers both sex aged between 18 and 50 without personal or family history of hemorrhage, thrombosis before 45 years old,
9615998|NCT04840628|Experimental|neural respiratory drive|neural respiratory drive assessed by EMGdi recorded from a multipair esophageal electrode
9615999|NCT04828746|No Intervention|Control|Patients who will undergo lumbar puncture without pre-procedural ultrasound-guided skin marking
9616000|NCT04828746|Experimental|Experimental|Patients who will undergo lumbar puncture after pre-procedural ultrasound-guided skin marking
9616001|NCT04812366|Active Comparator|Group 1a|LHRHa plus apalutamide.
9616002|NCT04812366|Active Comparator|Group 1b|LHRHa plus apalutamide plus abiraterone acetate plus prednisone.
9616003|NCT04812366|Active Comparator|Group 2a|LHRHa plus abiraterone acetate plus prednisone.
9616004|NCT04812366|Active Comparator|Group 2b|LHRHa plus abiraterone acetate plus prednisone plus docetaxel.
9616005|NCT04812366|Active Comparator|Group 3|LHRHa plus abiraterone acetate plus prednisone plus niraparib
9616006|NCT04812366|Active Comparator|Group 4|LHRHa plus apalutamide plus atezolizumab
9616007|NCT04806724|Experimental|Program #1|Participants attend 5 sessions (1.5 hours each) consisting of education and skills training to address cancer-related reproductive and sexual health concerns. Sessions occur via videoconference.
9616008|NCT04806724|Active Comparator|Program #2|Participants attend 4 sessions (1.5 hours each) consisting of education and skills training to address cancer-related concerns. Sessions occur via videoconference.
10038901|NCT01838915|Experimental|Dietary Supplement: Prebiotics+Glutamine|
10038902|NCT01838915|Placebo Comparator|Placebo|
10038903|NCT01838928|Experimental|Bupivacaine|
10038904|NCT01838954|Active Comparator|Short-wave diathermy|Short-wave diathermy device turned on
10038905|NCT01838954|Placebo Comparator|control|Short-wave diathermy device turned off
10038906|NCT01838967|Experimental|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
9536017|NCT05253989|No Intervention|Control|Regular assessments as outlined in the outcomes assessment section. No other change from standard of care.
9536018|NCT05253989|Active Comparator|VR Intervention Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions.
9536019|NCT05253989|Active Comparator|VR Intervention + FES Group|Regular assessments as outlined in the outcomes assessment section. Regular VR training sessions, with FES stimulation.
9536020|NCT05253976||Patients who received the NexGen TM Augmentation Patella|
9536021|NCT05253963|No Intervention|Control|During the first and second study nights, subjects will undergo baseline polysomnography.
9536022|NCT05253963|Experimental|Continuous Positive Airway Pressure|Baseline polysomnography will be perfomed during the first study night and CPAP titration polysomnography will be performed during the second study night.
9536023|NCT05253950||Observational Group|A sample of 120 people was collected from all over Greece, more specifically 7.6% belong to the region of Attica, 7.6% belong to the region of Western Greece, 0.8% belong to the region of Thessaly, 32.8% belong to the region of Central Macedonia and 51.3% belong to the region of Crete .
9536024|NCT05253924||Preterm children (PT)|gestational age at birth <37
9536025|NCT05253924||Full-term children (FT)|gestational age at birth ≥ 37 weeks
10038907|NCT01838967|Experimental|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
10038908|NCT01838967|Experimental|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
9536026|NCT05253885||Smartphone addiction group|
9536027|NCT05253859||Cystic fibrosis registry (UK or US)|People with cystic fibrosis of any genotype registered on either the UK or US CF registry
9536028|NCT05253833|Active Comparator|Group 1|Allopurinol once daily for 24 weeks
9536029|NCT05253833|Experimental|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 22 weeks
9536030|NCT05253833|Experimental|Group 3|AR882 Dose 1 + Allopurinol for 24 weeks
10038909|NCT01838967|Experimental|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
10038910|NCT01838967|Experimental|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
10038911|NCT01838967|Experimental|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
10038912|NCT01838993|Active Comparator|Lidocaine|Inhalation of lidocaine before intubation
10038913|NCT01838993|Placebo Comparator|Control|Normal saline inhalation before intubation
9536035|NCT05253781|Experimental|Intervention|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
9536036|NCT05253781|Placebo Comparator|Control|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
9536037|NCT05253768|Experimental|intervention|Patients who receive a fecal microbiota transplantation via a nasointestinal tube.
9536038|NCT05253768|Placebo Comparator|placebo|Patients who receive a placebo FMT via a nasointestinal tube.
9536039|NCT05253742||Pregnant women presenting for MRI|Alternative motion-robust MR imaging sequences and procedures for automatic positioning while be tested during fetal brain imaging
9536040|NCT05253729|Experimental|Focused Extracorporeal Shock Wave Therapy (F-ESWT)|Participants in the intervention group received low-intensity F-ESWT once a week for three sessions plus conservative treatment.
9536041|NCT05253729|Active Comparator|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
9536042|NCT05253716|Experimental|immune nutrition support|In the immune nutrition support group, in addition to diet, and patients will also consume two bottles per day of a high-calorie, high-protein ONS and three capsules of fish oil after discharge lasted for 6 months.
9536043|NCT05253716|No Intervention|control|In the control group, patients will receive nutrition counseling in addition to diet.
9536044|NCT05253703|Other|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 5 minutes each.
9536045|NCT05253677|Experimental|CT-guided PCI strategy|"QAngio CT Research Edition is a software suite providing several functionalities for the analysis of coronary computed tomography angiography (CCTA) scans to extract and present relevant information on the coronary vasculature for further clinical investigation.~Also, QAngio CT Research Edition allows to export this information for later viewing during x-ray angiography (XA) procedures to help physicians plan and guide the interventional procedure."
9536046|NCT05253677|Active Comparator|intravascular ultrasound (IVUS)-guided PCI strategy|Intravascular ultrasound (IVUS) is an invasive intravascular imaging technique able to visualize the coronary vessel. The use of IVUS-guided PCI has been endorsed an recommended by the European Society of Cardiology. The device is considered part of standard of clinical care.
9536047|NCT05253664|Experimental|Woman-Centered Care Group|Woman-centered care was given to the experimental group. At the time of the study, 6 women were discharged early, 4 women did not want to continue the study, and the babies of 1 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 109 women in the experimental group.
9616009|NCT04791787|Active Comparator|Standard Weight Maintenance|Standard weight maintenance diet will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
9536048|NCT05253664|No Intervention|Control Group|Standard care was given to the control group. At the time of the study, 2 women were discharged early, 7 women did not want to continue the study, and the babies of 2 women were admitted to the neonatal intensive care unit due to complications so these women were excluded from the study. The study was completed with 218 mothers, with 109 women in the control group.
9536049|NCT05253638|Experimental|study group|"Patients will be recruited from the Rheumatology, Rehabilitation Department from The in patient and out patient clinic of Assiut University Hospitals with an informed consent will be obtained from all patients.~Adult SLE patients >18 who fulfilled the 2012 systemic lupus international collaborating clinics (SLICC) criteria"
9536050|NCT05253612|Other|ISPOCD test battery|The participants will be randomized to start with ISPOCD test battery followed by Mindmore digitalized cognitive test battery with 2 weeks passing between the cognitive testing for both groups
9536051|NCT05253612|Other|Mindmore digitalized cognitive test battery|Strating with Mindmore digitalized cognitive test battery followed by ISPOCD test battery, with 2 weeks passing between the cognitive testing for both groups
9536052|NCT05253599|Experimental|Isokinetic training|In the IKT group before isokinetic training, the subjects were asked to perform five minutes' warm-up followed by slow stretching of back extensors and flexors. The subject was asked to be in an isokinetic dynamometer (Biodex Corporation, New York, USA) in a vertical standing position.
9536053|NCT05253599|Experimental|Virtual reality training|The VRT group received virtual reality training with (Pro-Kin system PK 252 N Techno body, Pelvic Module balance trunk MF, Italy) focusing on the balance of core stability muscles.
9536054|NCT05253599|Active Comparator|Control group|The Control group focused on conventional balance training for core muscles. The training includes active isotonic and isometric exercise for abdominal muscles (Internal oblique, external oblique, transverse abdominus and Rectus abdominus) deep abdominal muscles (Psoas major, Psoas minor, Illiacus and Quadratus Lumborum) and back muscles (Erector spinae, Transverses spinalis, inter spinalis and Inter transverse).
9536057|NCT05253573|Experimental|Automated Treatment|AT consists of all SC components plus a fully automated smartphone-based JITAI that involves proactive, interactive, and personalized messages, images, or videos in Lao.
9536058|NCT05253573|Active Comparator|Standard Care|"SC consists of brief advice to quit smoking delivered by research staff, self-help written materials (the WHO's A guide for tobacco users to quit that we have translated to and validated in Lao), and a 2-week supply of NRT (transdermal patches)."
9536059|NCT05253560||Carriers of Gaucher disease|Family of patients with Gaucher disease, sequenced for the GBA1 gene.
9536060|NCT05253560||Gaucher patients|Patients from the Gaucher clinic in Shaare Zedek Medical Center, Jerusalem, Israel
9536061|NCT05253560||Healthy controls|Family members of Gaucher patients who are not carriers of Gaucher disease
9536062|NCT05248074|Other|Fasting group|"Period 1 : Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast~Peroid 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)"
9536063|NCT05248074|Other|Fed group|"Peroid 1: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)~Period 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast"
9536064|NCT05246878|Experimental|EDP-235 SAD Cohorts|EDP-235 Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5, orally, once daily in one single administration
9536065|NCT05246878|Experimental|EDP-235 MAD Cohorts|EDP-235 Dose 1, Dose 2 and Dose 3 orally, once daily for 7 days
9536066|NCT05246878|Placebo Comparator|EDP-235 SAD Placebo Cohorts|Matching placebo, orally, once daily in one single administration
9536067|NCT05246878|Placebo Comparator|EDP-235 MAD Placebo Cohorts|Matching placebo, orally, once daily for 7 days
9536068|NCT05246566||Subjects covered for suspected or SE diagnosis|"Patients covered for suspected or SE diagnosis defined by one of the following:~a prolonged generalized tonic-clonic crisis lasting more than 5 minutes and accompanied by impaired consciousness or at least 2 generalized tonic-clonic crisis without return to normal consciousness between crisis.~a focal convulsive crisis (motor or not) with disturbances of consciousness which lasts beyond 10 minutes or crisis which are repeated (≥ 2) at short intervals without recovery of interictal consciousness.~a focal convulsive crisis (motor or not) without alteration of consciousness that lasts beyond 10 to 15 minutes.~an absence-type crisis that lasts longer than 10 to 15 minutes.~a myoclonic, clonic and tonic crisis that lasts longer than 10 to 15 minutes.~a coma with an epileptic cause diagnosed on an EEG."
9536069|NCT05238805|Other|Observational heart and kidney metabolism|Participants will have a PET scan with 11C-Acetate followed by a TEP Scan with 11C-Acetoacetate all in the same day.
9536070|NCT05233306||GTS patient group|Cohort of adult GTS patients, males and females, age range 18 to 50 years
9536071|NCT05233306||Control group|Cohort of healthy control subjects, males and females, age range 18 to 50 years
9616010|NCT04791787|Active Comparator|Isocaloric Diet|Isocaloric diet will be provided for 10 days for subjects who are currently treated with a T2DM medication included in the inclusion criteria
9616011|NCT04791787|Active Comparator|Isocaloric Diet with Beta-hydroxy butyrate|Isocaloric diet with Beta-hydroxy butyrate will be provided for 10 days for subjects who are not currently treated with a T2DM medication.
10038914|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
10038915|NCT01839019|Placebo Comparator|Placebo|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
10038916|NCT01839019|Experimental|ODM-102|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
9536072|NCT05231811|Experimental|experimental group|During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated.
9536073|NCT05231811|No Intervention|control group|no intervention will be made in the control group
9536074|NCT05230810|Experimental|Ib Safety Cohort /II Expansion Cohort|In phase Ib, the tolerability of tucatinib and alpelisib combination will be confirmed and maximum tolerated dose determined. Therapy will be administered in 28 day cycles of tucatinib 300 mg PO BID and alpelisib 250 mg PO daily (dose level 1). Treatment will continue until unacceptable toxicity, disease progression, withdrawal of consent, or study closure. Fulvestrant will also be administered in patients with HR+/HER2+ metastatic breast cancer. Once RP2D is determined, the study will be continued to phase II, and new patients will enroll at RP2D. All patients in phase IB part, who are remaining on study at the time of initiation of phase II, will be rolled over to phase II. At that time, their study drug doses will be modified as follows: (1) if a patient is on the drug doses lower than RP2D, doses will not be increased; (2) if a patient is on a higher doses compared to RP2D, doses of study drugs will be changed to RP2D.
9536075|NCT05229718|Active Comparator|Usual Care Model|Patients enrolled in this arm will receive diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center.
9536076|NCT05229718|Active Comparator|Diabetes Collaborative Care Model for Young Adults|Patients enrolled in this arm will receive diabetes care per the diabetes collaborative care model for young adults.
9536077|NCT05229393|Experimental|Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Cervical Manual Therapy plus Breathing Reeducation Exercises group.~Cervical manual therapy will be the same as for the Manual Control Group (20 minutes).~Diaphragmatic Manual Therapy (10 minutes) and Breathing Reeducation Exercises (10 minutes). The program will be carried out three times per week lasting four weeks in total. Each session will last about 40 minutes."
9536078|NCT05229393|Sham Comparator|Cervical Manual Therapy Group B|Sham Comparator: Sham Treatment group or Manual Control Group Patients included in this group will receive Cervical Manual Therapy (25 minutes) plus sham Diaphragmatic Manual techniques (15 minutes). The program will be carried out three times per week lasting four weeks in total. Each session will last about 40 minutes.
9536079|NCT05229393|Active Comparator|Conventional Physiotherapy Program Group C|"Active Comparator: Conventional Treatment group Patients included in this group will receive a conventional physiotherapy program with Transcutaneous Electrical Nerve Stimulation-TENS (15 minutes) plus Microwave pulsed Diathermy (10 minutes), and soft tissue techniques (15 minutes).~The program will be carried out three sessions per week during the four weeks. Each session will last about 40 minutes."
9536080|NCT05229367|Experimental|Eccentric isokinetic group|In this group, eccentric isokinetic training of hamstring muscle was performed.
9536081|NCT05229367|Active Comparator|Concentric isokinetic group|In this group, concentric isokinetic training of hamstring muscle was performed.
9536082|NCT05227937||Single Dose Amikacin|Patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
9536083|NCT05227703|Experimental|CVL-231 15 mg, once daily (QD)|Oral Dose
9536084|NCT05227703|Experimental|CVL-231 30 mg, once daily (QD)|Oral Dose
9536085|NCT05227703|Placebo Comparator|Placebo, once daily (QD)|Oral Dose
9536086|NCT05227690|Experimental|CVL-231 10 mg, once daily (QD)|Oral Dose
9536087|NCT05227690|Experimental|CVL-231 30 mg, once daily (QD)|Oral Dose
9536088|NCT05227690|Placebo Comparator|Placebo, once daily (QD)|Oral Dose
9536089|NCT05227677|Experimental|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals and the anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
9536090|NCT05227677|Active Comparator|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals，but investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
9536091|NCT05226702|Experimental|COVAC-2 10 µg group|20 healthy adults ≥18 years of age receive the vaccine on Day 0.
9536092|NCT05226702|Experimental|COVAC-2 25 µg group|20 healthy adults ≥18 years of age receive the vaccine on Day 0
9536093|NCT05226702|Placebo Comparator|Placebo Control|20 healthy adults ≥18 years of age receive a dose of normal saline (placebo) on Day 0.
9536094|NCT05226182|Experimental|patients|"Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale.~Post measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview."
9536095|NCT05226182|Experimental|healthcare professionals|"Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale.~Post measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview."
9536096|NCT05226026|Experimental|NiteCAPP HELPS|4 weeks of online CBT-I (1 session/week for 1 hour), followed by tapered withdrawal and motivational interviewing and check-ins.
9536097|NCT05226026|Other|Treatment as Usual|Continuation of standard treatment for sleep and pain for 4 weeks, followed by tapered withdrawal and motivational interviewing and check-ins.
9536098|NCT05178823|Active Comparator|Corsodyl|Chlorhexidine
9536099|NCT05178823|Experimental|Solumium Oral|Chlorine dioxide
9536100|NCT05178823|Experimental|Listerine Total Care|Essential oils, sodium fluoride, zinc chloride
9536101|NCT05178823|Experimental|BioGate Si*CLEAN|Microsilver
9616012|NCT04782401|Active Comparator|Genicular Nerve Block|
10038917|NCT01839032|Experimental|Vinorelbine cisplatin radiotherapy|Induction period + radio chemotherapy
10038918|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
10038919|NCT01839071|Other|biopsy of fat tissue|
10038920|NCT01839084|Experimental|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
9536106|NCT05172726|Experimental|Open Label|
9536107|NCT05166304|Placebo Comparator|placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
9536108|NCT05166304|Experimental|rebamipide|100 mg rebamipide taken orally daily plus Methotrexate 7.5 mg weekly
10038921|NCT01839084|Active Comparator|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
9536109|NCT05159349||Exposed group|
9536110|NCT05159349||Non-exposed group|
9536111|NCT05157321|Active Comparator|Study Group|The patients in this group will receive active repetitive transcranial magnetic stimulation sessions for 4 weeks.
9536112|NCT05157321|Sham Comparator|control group|The patients in this group will receive sham repetitive transcranial magnetic stimulation sessions for 4 weeks.
10038922|NCT01839097|Experimental|Dose Finding Phase|"This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.~Enrollment will begin with the enrollment of patients into Cohort 3.~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
9536113|NCT05154305|Experimental|Children 6 months post acute treatment|children and adolescents between 6 months and 8 years post acute cancer treatment
9536114|NCT05152927|Experimental|Parathyroid Eye (PTeye)|For patients assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
9536115|NCT05152927|No Intervention|Usual Standard of Care|The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
9536116|NCT05149638|Active Comparator|Healthy volunteers|Healthy volunteers are those 18 years or older without prior diagnosis of adrenal insufficiency. Study participation by healthy volunteers helps us understand what cortisol levels should be in a healthy population. This information also helps us figure out what levels might be in people with adrenal insufficiency.
9536117|NCT05149638|Active Comparator|Patients with known adrenal insufficiency|This group consists of patients 18 years or older with an established diagnosis of adrenal insufficiency. Study participation by patients with adrenal insufficiency helps us understand what cortisol levels should be, in the new assays, among those with adrenal insufficiency.
9536118|NCT05149638|Active Comparator|Patients suspected to have adrenal insufficiency|This groups consists of patients 18 years or older who are suspected to have adrenal insufficiency. Study participation by this group will help us understand if the cortisol values we get from the new assay accurately diagnose adrenal insufficiency.
9536119|NCT05145257|Other|Elix Cycle Balance|Elix Cycle Balance supplement
9536120|NCT05143970|Experimental|IPH5301 administration|"Part I- Dose escalation:~Escalating dose levels of IPH5301 will be evaluated.~Part II-Cohort Expansion:~IPH5301 will be administrated in combination with trastuzumab and paclitaxel"
9536121|NCT05141123||Preloaded Fenestrated Stent-graft Designs for Endovascular Aortic Procedures|Patients presenting with an acute (up to two weeks from the onset) and subacute (between 3 and 12 weeks from the onset) type B dissection with a proximal suitable non-dissected landing zone in the aortic arch or descending thoracic aorta (supra-aortic trunks debranching may be employed to obtain an adequate proximal landing zone)
9536122|NCT05140642|Active Comparator|Sonographer Annotation|Currently, sonographer technicians provide preliminary interpretations prior to validation and overreading by cardiologists. This staggered, stepwise evaluation allows for the introduction of AI decision support with minimal impact on patient care. Physicians are already used to adjusting the preliminary report given the variable training of sonographers and on the lookout for changes, variation, or adjustments that need to be made.
9536123|NCT05140642|Experimental|Artificial Intelligence Annotation|In preliminary work, a novel AI algorithm developed to assess LVEF was shown to be more precise than human interpretation in 10,030 echocardiograms done at Stanford University (Ouyang et al. Nature, 2020). With randomization, a proportion of the preliminary interpretations will be done by AI technology and the study team will assess how different this preliminary interpretation is from the final interpretation.
9536124|NCT05134675||Consumption|Patients consuming homemade beer
9536125|NCT05134675||Not consumption|Patients are not consuming homemade beer
9536126|NCT05133661||HPV positive women|"Women aged 25-49 years seeking offered HPV testing (either self-collection or clinician collection of samples) and treatment of precancerous lesions as part of service package in study facilities will be enrolled in the study and interviewed at different time points.~A subset of the women screened will be selected for in-depth interview to gather data on: ease of use of self-collection kits for cervical cancer screening, receipt of the test results, and treatment for precancer. Another subset of women will be selected after HPV screening to participate in client exit interview."
9536127|NCT05133414|Experimental|Participants will receive stimulation of the left subclavian ansae.|Participants as self-controlled cases for the study. Human cardiac haemodynamics and electrophysiological in response to left subclavian ansae stimulation will be studied.
10038923|NCT01839123|Active Comparator|Non-Vacuum Socket|Prosthetic suction or pin socket
10038924|NCT01839123|Experimental|Vacuum Socket|Prosthetic LimbLogic vacuum socket
10058379|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
10038925|NCT01839136|Experimental|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
9536131|NCT05131113|No Intervention|Control group|The control group will receive the usual care
9536132|NCT05131113|Experimental|Interventionist group|The interventional group will add an individualized physical exercise program to the usual care.
9536133|NCT05127525|Experimental|Test Drug|IRX-101 drops instilled prior to intravitreal injection
9536134|NCT05127525|Active Comparator|Control|Povidone-Iodine/Betadine drops instilled prior to intravitreal injection
9536136|NCT05114902||PCV13 Non-vaccinated Settting|Pneumococcal vaccine-naïve children at the PCMC
9536137|NCT05114902||PCV13 Vaccinated Setting|Pneumococcal vaccine-exposed children at the SPMC
9536138|NCT05112809|Experimental|Normal hearing subjects|Subjects with normal hearing will have a standard hearing test utilizing the cochlear stimulation system.
9536139|NCT05112809|Experimental|Bilateral hearing impaired|Subjects with bilateral hearing impairment will have a standard hearing test utilizing the cochlear stimulation system.
9536140|NCT05112809|Experimental|Asymmetrical hearing-impaired|Subjects with asymmetrical hearing-impairment will have a standard hearing test utilizing the cochlear stimulation system.
9536141|NCT05099510|Active Comparator|NatrunixTM|Each participant will receive one single subcutaneous injection of 200 mg (Cohort 1), 400 mg (Cohort 2), or 800 mg (Cohort 3) of NatrunixTM.
9536142|NCT05099510|Placebo Comparator|Placebo|Each participant will receive one single subcutaneous injection of placebo.
9536143|NCT05096442|Experimental|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
9536144|NCT05096442|Active Comparator|SeQuent® Please NEO|Paclitaxel Coated PTCA Balloon Catheter
9536145|NCT05095948||Supportive Care (questionnaire, clinic conversation)|Patients complete questionnaires over 15-20 minutes and undergo audio recording of clinic conversations between the oncology team or the specialist palliative care team. Patients' medical records are also reviewed.
9536146|NCT05093322|Experimental|Part 1- Dose escalation|Dose escalation study with sequential dose escalation of surufatinib in combination with gemcitabine. Patients with any recurrent or refractory solid tumors or lymphoma, who have a known or expected dysfunction of VEGFR-1, -2, and -3; FGFR-1; or CSF-1R pathways may be enrolled.
9536147|NCT05093322|Experimental|Part 2 - Dose expansion|Once the MTD/RP2D has been determined in the part 1 portion of the study, the part 2 disease specific cohorts for patients with refractory or recurrent osteosarcoma, Ewing Sarcoma, and RMS and non- RMS will open for enrollment.
9536148|NCT05086380|Experimental|FND Patients Experimental|Group of patients with functional neurological disorders
9536149|NCT05086380|Active Comparator|Organic controls|Group of patients with organic neurological disorders
9536150|NCT05086380|Active Comparator|Healthy controls|Group of healthy controls
9536151|NCT05086380|Active Comparator|FND Patients Comparator|Group of patients with functional neurological disorders
9536152|NCT05084586|Active Comparator|Continuous Intravesical Infusion of Epirubicin|Patients who received continuous epirubicin infusion into the bladder in the early postoperative period.
9536153|NCT05084586|Sham Comparator|Single-Dose Instillation of Epirubicin|Patients who received single-dose epirubicin into the bladder in the early postoperative period.
9536155|NCT05079256|Experimental|Laser therapy|595 nm Pulsed dye laser (PDL) therapy for psoriasis
9536156|NCT05079256|No Intervention|deferred treatment|Untreated lesion
9536157|NCT05074290|Experimental|Epidiferphane + taxane chemotherapy|
9536158|NCT05064709|Experimental|CCM Group (CCM ON)|CCM therapy will be turned on in 2/3 of the subjects for the entire duration of the study.
9536159|NCT05064709|Sham Comparator|Sham Group (CCM OFF)|CCM therapy will be turned off in 1/3 of the subjects for the first 18 months of the study. After 18 months, CCM therapy will be turned on for the rest of the study duration.
9536160|NCT05064410|Experimental|Educational Intervention and Referral for Fecal Immunochemical Test (FIT) Kit or Colonoscopy|The Community Health Educator (CHE) will provide online, phone or in-person colorectal cancer (CRC) early detection, prevention, and screening education to increase knowledge of CRC and the importance of screening. These sessions will be conducted in small in-person sessions, virtually within a group, virtually via a self-paced/self-directed online learning module, or one-on-one via phone. Additionally, the CHE will provide information regarding FIT kit and colonoscopy screening and the screening process for attendees. The CHE and research assistant will be prepared to provide access to screening resources and services through participants' existing coverage. Those participants who do not have a primary care provider will be provided information on obtaining FIT kits through the mechanisms of the Federally Qualified Health Center (FQHC) and/or a colonoscopy through the cancer center on a case by case basis.
9536161|NCT05062343|Active Comparator|Dilapan-S|After randomization, the patient will have Dilapan-S placed via sterile speculum exam with placement of 3-5 rods. The rods will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the rods will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
9616013|NCT04782401|Active Comparator|Physical Therapy|
9536162|NCT05062343|Active Comparator|Cook Catheter|After randomization, the patient will have the Cook catheter placed via sterile vaginal or speculum exam with the uterine component of the balloon inflated to maximum 60mL. The balloon will remain in place until expelled or up to 24 hours or until the scheduled return to labor and delivery. At presentation to labor and delivery, the Cook catheter will be confirmed expelled or will be removed and a blinded examiner will complete a sterile cervical exam. At that point the primary health care providers will manage further labor per their standard practice.
9536163|NCT05056753|Active Comparator|Investigational Device|The HWBV chair consists of a custom-made saddle-seat type of chair. The vibration actuators are embedded into the underside design of the chair. The base contains two vibrators, one for each side of the chair, and the chair is split in half vertically so that the vibrating actuators are able to send a harmonic vibration at alternating frequencies, upwards through each side of the chair. The HWBV system is considered a non-significant and non-substantial risk device.
9536164|NCT05056753|Sham Comparator|Control Device|The Control device is identical in construction to the Active device. The vibration mode, however, is a significantly different setting than that used by the Active version, so that the mechanoreceptors in the cervical spine are not effectively stimulated.
9536167|NCT05043428|Experimental|Intervention Group|Those randomized to the intervention group will be asked to attend 16 online sessions (2 session/week). Each session will last one hour (total time: 16 hours. The exercise portion will be approximately 30 minutes of each session and led by a certified kinesiologist. These exercises are based on activities related to your daily life. As well, they will take part in peer support sessions. The peer support session will be approximately 30 minutes and be moderated by a behaviour change specialist who will also provide strategies to be active. In this peer support group, particpants will share and learn from other individuals living with COPD to help you stay active during and after the intervention. The online sessions will be video recorded to make sure that the program is delivered as designed.
9536168|NCT05043428|Active Comparator|Control Group|Those randomized to the control group will be asked to participate in an 8-week exercise program based on the exercise component of a standard home-based pulmonary rehabilitation program. During week 1 of the program, participants will receive a videocall via Microsoft Teams from the certified kinesiologist who will prescribe an exercise program, supervise the first exercise session, and provide a copy of Living Well with COPD, a list of strength exercises, and a home exercise diary. In weeks 2-8, participant exercises will be performed offline, on their own. Participants will be encouraged to engage in two or more exercise sessions per week, targeting both aerobic capacity and muscular strength, and document their exercise using a home diary. They will also receive a phone call once a week from the certified kinesiologist to discuss their exercise progress.
9536169|NCT05038813|Experimental|Anlotinib combined with TQB2450|Anlotinib: 12mg, capsule, once a day. TQB2450: 1200mg, Injection, Once every three weeks.
9536170|NCT05038644|Experimental|Arm Z: Dose Level -1 for Group A (T-ALL, T-LBL)|0.1 mg intravenous (IV) Cycle (C) 1 Day (D) 1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
9536171|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) for Group A (T-ALL, T-LBL)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
9536172|NCT05038644|Experimental|Arm B: Dose Level 1 for Group A (T-ALL, T-LBL)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
9536173|NCT05038644|Experimental|Arm C: Dose Level 2 Group A (T-ALL, T-LBL)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
9536174|NCT05038644|Experimental|Arm D: Dose Level 3 Group A (T-ALL, T-LBL)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
9536175|NCT05038644|Experimental|Arm Z: Dose Level -1 Group B (AML)|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
9536176|NCT05038644|Experimental|Arm A: Dose Level 0 (Starting Dose) Group B (AML)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
9536177|NCT05038644|Experimental|Arm B: Dose Level 1 Group B (AML)|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
9536178|NCT05038644|Experimental|Arm C: Dose Level 2 Group B (AML)|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
9536179|NCT05038644|Experimental|Arm D: Dose Level 3 Group B (AML)|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
9536180|NCT05028764||18 to 30 years of age group|Consisting of at least 13 males and 13 females
9536181|NCT05028764||31 to 50 years of age group|Consisting of at least 13 males and 13 females
9536182|NCT05026983|Experimental|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on day 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9536183|NCT05022004|Experimental|BRIN-20-01|
9536184|NCT05022004|Active Comparator|Azopt®|
9536185|NCT05021237|Experimental|Safety Lead In|Six patients with will be enrolled as first dose of 8.5Gy. If 0 or 1 patient experiences dose-limiting toxicity (DLT) out of six patients, then study will move on to expansion phase. If two or more patients experience DLT out of six patients, 6 additional patients will be recruited to lower dose level of 8Gy
9616014|NCT04778397|Experimental|Magrolimab + Azacitidine|Participants will receive an escalating dose of magrolimab and a fixed dose of azacitidine.
9536186|NCT05021185|Experimental|Interactive Mobile Doctor (iMD) Intervention|Participants will receive up to a total of 3 iMD sessions prior to their completion of radiation therapy; each session will take about 10-15 minutes and includes: 1) computerized assessments that will be delivered on the screen via text with accompanying audio and participants will respond directly on the tablet 2) tailored videos that deliver messages specific to patient's responses to selected assessment questions and 3) a summary printout
9536187|NCT05021185|No Intervention|Control Group|Participants will complete questionnaires and receive a handout containing tobacco cessation resources.
9536188|NCT05020990|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (Test) toric lens for one week.
9536189|NCT05020990|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) toric lens for one week.
9536190|NCT05017610|Experimental|Treatment (methimazole, lomustine, liothyronine)|See Outline in Detailed Description.
9536191|NCT05013801|Experimental|Cosmetic Facial Serum Q69|Cosmetic facial serum. To be used twice daily on lesional areas of the face for 12 weeks.
9536192|NCT05013801|Other|2% Hydroquinone|2% hydroquinone cream to be used twice daily on lesional areas of the face as directed by the dermatologist for no longer than 8 weeks.
9536193|NCT05012865||Patients with metastatic renal cell carcinoma|Patients with metastatic renal cell carcinoma
9536194|NCT05006833|Experimental|Bundled clinician training and bundled text messages|Clinicians will receive bundled approach training and parents will receive bundled text messages.
9536195|NCT05006833|Experimental|Bundled clinician training and benefits text messages|Clinicians will receive bundled approach training and parents will receive benefits text messages.
9536196|NCT05006833|Experimental|Bundled clinician training and no text messages|Clinicians will receive bundled approach training and parents will not receive any intervention text messages.
9536197|NCT05006833|Experimental|Benefits clinician training and bundled text messages|Clinicians will receive benefits approach training and parents will receive bundled text messages.
9536198|NCT05006833|Experimental|Benefits clinician training and benefits text messages|Clinicians will receive benefits approach training and parents will receive benefits text messages.
9536199|NCT05006833|Experimental|Benefits clinician training and no text messages|Clinicians will receive benefits approach training and parents will not receive any intervention text messages.
9536200|NCT05006833|Experimental|Deferred-clinician training and bundled text messages|Clinicians will receive training after the study and parents will receive bundled text messages.
9536201|NCT05006833|Experimental|Deferred-clinician training and benefits text messages|Clinicians will receive training after the study and parents will receive benefits text messages.
9536202|NCT05006833|No Intervention|Deferred-clinician training and no text messages|Clinicians will receive training after the study and parents will not receive intervention text messages.
9536203|NCT05002595||Modified quadruple therapy|pantoprazole 40mg bid, amoxicillin 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 14 days
9536204|NCT05002595||Tailored eradication|pantoprazole 40mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid or pantoprazole 40mg bid, tetracycline 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 7 days
9536205|NCT04998669|Experimental|Loncastuximab tesirine + Rituximab|"During the 12-week Induction Phase (Cycles 1 to 4), participants will receive loncastuximab tesirine on days 1 of each 3-week cycle for Cycles 1 through 4; and rituximab on days 1, 8, 15 of Cycle 1 and day 1 of Cycle 2.~Maintenance Phase 1 (Cycle 5) is 8 weeks: Participants achieving complete response (CR) or partial response (PR) during the Induction Phase will receive loncastuximab tesirine once every 3-weeks; and rituximab once during week 7 or 8. Participants achieving a response of Stable Disease (SD) or Progressive Disease (PD) will be taken off treatment.~Maintenance Phase 2 (Cycles 6 and 7) is 16 weeks:~Participants achieving CR during Maintenance Phase 1 receive rituximab once during week 7 or 8 of Cycles 6 and 7.~Participants achieving PR during Maintenance Phase 1 receive loncastuximab tesirine once every 3-weeks over each 8 week cycle; and rituximab once during week 7 or 8 of Cycles 6 and 7.~Participants achieving SD or PD will be taken off treatment."
9536206|NCT04987177|Experimental|Workload conditions to be tested|The intervention is the external workload a participant propels against. Participants will propel against N=20 different external workloads.External workload will be controlled by the wheelchair ergometer.
9536207|NCT04985305|Experimental|Intervention Group|"Educational session for GPs~Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs~Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form~Instructed to complete a teaching session at the nursing home with a pre-defined teaching material~Instructed to contact the nursing home before the home visit to encourage participation of regular staff and relatives in the home visit or, alternatively, to obtain information from regular staff and relatives before the home visit~Dialogue tool"
9536208|NCT04985305|Active Comparator|Control Group|"Educational session for GPs~Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs~Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form"
9536209|NCT04983875|Experimental|BAC-enhanced group|944 participants will receive a post-mammography results letter which includes information on their BAC results.
9536210|NCT04983875|Other|Waitlist control group|944 participants will receive a post-mammography results letter without BAC information, which is the current standard of care. These patients will receive BAC information following study completion (approximately 6 months after mammography).
9536211|NCT04982653|Experimental|Arm I (hepatectomy using small bites fascial closure)|Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure.
9536212|NCT04982653|Active Comparator|Arm II (hepatectomy using conventional fascial method)|Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure.
9536213|NCT04979403|Active Comparator|Usual care in physiotherapy|The usual care group will receive interventions recommended by clinical guidelines: education on the nature of LBP, advice to stay active and to continue usual activities, specific exercise programs combined with orthopedic manual therapy.
9536214|NCT04979403|Experimental|Psychologically-informed physiotherapy intervention|The psychologically-informed physiotherapy group will receive the control intervention enhanced with specific interventions targeting psychosocial factors (e.g., positive reinforcement, mindfulness-based stress reduction, diaphragmatic breathing, graded exposure). Most of these techniques are efficient to mitigate the impact of psychological factors such as anxiety and fear of movement. To standardize the psychologically-informed physiotherapy approach, physiotherapists will receive a two-day training course by a physiotherapist expert with this approach in chronic pain conditions (Alain Gaumond).
9616015|NCT04778397|Active Comparator|Control Arm: Venetoclax + Azacitidine|Participants who are appropriate for non-intensive therapy will receive an escalating dose of venetoclax and a fixed dose of azacitidine.
9616016|NCT04778397|Active Comparator|Control Arm: 7+3 Chemotherapy|Participants who are appropriate for intensive therapy will receive 7+3 chemotherapy: 7 day treatment with cytarabine and 3 day treatment with daunorubicin or idarubicin during induction and high-dose cytarabine and steroidal eye drops during consolidation.
9616017|NCT04773288|Experimental|Live feedback provided on display during handwashing|
9616018|NCT04773288|No Intervention|No live feedback provided during handwashing|
9616019|NCT04772859|Experimental|Online Lifestyle Intervention|Online sessions of nutrition education, physical activity, and family participation.
9616020|NCT04772859|Other|Control Group|General nutrition recommendations
9616021|NCT04771130|Experimental|Parts 1 and 2: AML Cohorts|Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.
9616022|NCT04771130|Experimental|Experimental: Parts 1 and 2: MDS Cohorts|Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
9616023|NCT04771130|Experimental|Part 3: AML Cohort|Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle (or 10-day cycle as determined after Parts 1 and 2). A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
9616024|NCT04771130|Experimental|Part 3: MDS Cohort|Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.
9616025|NCT04765462|Experimental|Allogeneic γδ T cell Group|Enrolled patients will be administered allogeneic γδ T cells with or without the combination of traditional therapies, including chemotherapy, targeted therapy, radiotherapy, immune checkpoint inhibitors and others.
9616026|NCT04764669|Experimental|DLB Without Amyloid Copathology|Participants with DLB (without amyloid copathology) will receive E2027 50 milligram (mg) capsules, orally, once daily up to 12 weeks.
9616027|NCT04764669|Experimental|DLB With Amyloid Copathology|Participants with DLB (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
9616028|NCT04764669|Experimental|PDD Without Amyloid Copathology|Participants with PDD (without amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
9616029|NCT04764669|Experimental|PDD With Amyloid Copathology|Participants with PDD (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
9616030|NCT04757116|Experimental|iTind arm|The iTind is a minimally invasive temporary implant
9616031|NCT04757116|Experimental|TURP arm|Transurethral Resection of the Prostate
9616032|NCT04751916|Experimental|Proprietary Essential Amino Acid Protein Supplement|Essential amino acid protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
9616033|NCT04751916|Active Comparator|Commercially-available whey protein supplement - Beneprotein®|Beneprotein® whey protein supplement; 15 grams (one packet) dissolved in 8 ounces of water twice daily for 6 months.
9616034|NCT04748848|Experimental|CC-90011 in combination with Venetoclax and Azacitidine in Dose Escalation|CC-90011 in combination with venetoclax and azacitidine in dose escalation
9616035|NCT04748848|Experimental|Venetoclax and Azacitidine|Venetoclax and Azacitidine control arm in dose expansion. The participants will be randomized to the treatment arm or control arm at a 2:1 ratio.
9616036|NCT04748848|Experimental|CC-90011 in combination with Venetoclax and Azacitidine in Dose Expansion|CC-90011 in combination with venetoclax and azacitidine in dose expansion
10058380|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
9616037|NCT04742777|Experimental|Rapamycin|Rapamycin 1mg for 8 weeks
9616038|NCT04739683|Active Comparator|Foley bulb|16F latex or silicone Foley catheter inflated with 30-40 cc of sterile water. The catheter will be taped to the inner thigh with gentle traction.
9616039|NCT04739683|Active Comparator|DILAPAN-S®|Synthetic hydrogel cervical dilator consists of the dilating part, the polypropylene handle, and the marker string. The dilating part is manufactured from an anisotropic xerogel of AQUACRYL.
9616040|NCT04732208||Diabetic patients|
9616041|NCT04731779|Placebo Comparator|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
9616042|NCT04731779|Experimental|25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
9616043|NCT04731779|Experimental|50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
9616044|NCT04731779|Experimental|200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
9616045|NCT04728919||COVID-19 positive cases|Subjects with acute respiratory infection and positive COVID-19 test, who are well enough to be treated at home.
9616046|NCT04728919||COVID-19 negative controls|Subjects with acute respiratory infection and negative COVID-19 test, who are well enough to be treated at home.
9616047|NCT04726748||Urolift cohort|80 patients with prostatic urethral lift surgery will be included
9616048|NCT04726748||Transurethral Resection of the Prostate/laser cohort|80 patients with a transurethral resection of the prostate or laser surgery (enucleation or vaporisation) will be included.
9616049|NCT04726748||National healthcare insurance system database (SNDS) cohort|1200 patients with any transurethral surgery (TURP/laser) will be included and randomly matched to patients of the Urolift cohort with ratio 5:1.
9616050|NCT04718168|Experimental|Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial|
9536215|NCT04974554|Experimental|FIT Families|1. FIT Families is a 6 month comprehensive multicomponent family-based behavioral intervention delivered by Community Health Workers (CHWs). FIT Families integrates home-based service delivery, Motivational Interviewing (MI; intrinsic motivation), Cognitive Behavior Skills Treatment (CBST; skills acquisition), supervised physical activity (PA), and Contingency Management (CM; extrinsic motivation). Sessions occur twice weekly for the first three months, and weekly for the second three months.
9536216|NCT04974554|Active Comparator|Home-Based Family Support|2. Home-based Family Support (HBFS). Adolescents and their primary caregiver randomly assigned to HBFS will receive 6 months of weekly, home-based, client-centered, non-directive supportive family counseling.
9536217|NCT04974047|Experimental|Cohort A (Responder)|Participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% will receive 3 cycles of tislelizumab (200 milligrams [mg]/cycle) plus 2 cycles of chemotherapy doublet (cisplatin + paclitaxel)
9536218|NCT04974047|Experimental|Cohort B (Non-responder)|Participants with a decrease in PET SUVmax < 35% will receive 3 cycles of tislelizumab (200 mg/cycle) plus 2 cycles of investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) plus concurrent radiotherapy (40 grays/20 fractions).
9536219|NCT04970641|Experimental|3GT journaling group|Subjects will participate in the Three Good Things (3GT) Positive Psychology journaling activity daily for six weeks.
9536220|NCT04970641|No Intervention|Non-journaling group|Subjects will not participate in the evening journal activity.
9536221|NCT04970147|Other|there are not arm for this study.|there is not a control group for this study.
9536222|NCT04958161|Experimental|Exercise Therapy|Exercise therapy will be performed three times per week for 12 weeks.
9536223|NCT04958161|No Intervention|Wait List Control|Wait-list-control participants will be asked to continue their normal activities over the 12 week period.
10058381|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
10058382|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
9536226|NCT04948138|Experimental|MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome|Patients with MELAS syndrome that will receive oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations)
10058383|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
10058384|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
9536229|NCT04935476|Active Comparator|Treatment|"Participants will receive standard of care and Dapsone per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.~Dosage form: Dapsone oral tablet"
9536230|NCT04935476|Placebo Comparator|Control|"Participants will receive standard of care and placebo per os (PO) twice daily for 21 days. If a dose is missed, it should not be replaced.~Dosage form: Placebo oral tablet"
9536231|NCT04930107|Active Comparator|Recurrent Infection Cohort|
9536232|NCT04930107|Active Comparator|Assumed First-Time Infection Cohort|
9536233|NCT04930107|No Intervention|Asymptomatic Cohort|
9536234|NCT04919863|Experimental|NTP42:KVA4|
9536235|NCT04919863|Placebo Comparator|Placebo|
9536236|NCT04917848||Older adults with cancer|Participants will be 70 years old or older with a diagnosis of gastrointestinal or gynecological cancer. Participants will be receiving or about to receive medical cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy, biological agents)
9536237|NCT04917042|Experimental|tazemetostat|
9536238|NCT04909177|Experimental|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
9536239|NCT04909177|No Intervention|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
9536240|NCT04908930|Experimental|Unexposed practice group- Aim 1|Data from an unexposed sample (football players practicing as they would otherwise).
9536241|NCT04908930|Experimental|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
9536242|NCT04905212|Experimental|Telitacicept 160mg|Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses
9536243|NCT04905212|Experimental|Telitacicept 240mg|Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses
9536244|NCT04905212|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly, and a total of 24 doses
9536245|NCT04899999|Experimental|Financial reward graphic message|
9536246|NCT04899999|Experimental|Health reward graphic message|
9536247|NCT04899999|Experimental|Self-efficacy graphic message|
9536248|NCT04899999|Experimental|Social norms graphic message|
9536249|NCT04895956|Active Comparator|Intra-sheath injection|In patients randomized to the intra-sheath, corticosteroids will be injected directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
9536250|NCT04895956|Experimental|Extra-sheath injection|In patients randomized to the extra-sheath arm, corticosteroids will be injected surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
9536251|NCT04895293|Experimental|RBM-007 Injectable Solution - 2.0 mg|Single intravitreal injection in study eye
9616051|NCT04718168|Experimental|Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial|
9616052|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial|
9616053|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial|
10038926|NCT01839136|Active Comparator|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
10038927|NCT01839149|Experimental|TI-001 (intranasal oxytocin)|TI-001 is intranasal oxytocin
10038928|NCT01839149|Placebo Comparator|Placebo|Placebo for TI-001 is the same intranasal formulation without oxytocin
10038929|NCT01839162|Experimental|Pelvic drape|Pelvic shield drape over the patient
10038930|NCT01839162|Experimental|Arm drape|Right radial arm drape over the patient
9536252|NCT04893265|Active Comparator|Text Messaging Only|Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing over 12 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 testing related information. The messages will be responsive to the rapid evolving developments and changes related to COVID-19 testing guidelines. Some of the messages will include a link to allow participants to get to the entire message/information on the study website.
9536253|NCT04893265|Experimental|INFORMED|"Participants will receive a weekly SMS Text or instant message on a topic related to COVID-19 testing as described in the Text Messaging Only. In addition, participants will receive a Lay Health Worker (LHW) Educational Outreach Program, which includes 2 group sessions via video calls like Zoom or another video conferencing platform and 2 follow-up contacts via telephone, text or other media assignment."
9536254|NCT04891016|Experimental|experimental group|patients received FLOT regimen on day 1 and toripalimab on day 3.
9536255|NCT04891016|Other|control group|patients received FLOT regimen and toripalimab on day 1.
9536256|NCT04889547|Experimental|Dexamethasone|Patient will receive intraoperative dexamethasone during distal radius open reduction and internal fixation
9536257|NCT04889547|Placebo Comparator|No dexamethasone|Patient will not receive intraoperative dexamethasone during distal radius open reduction and internal fixation
9536258|NCT04880044|Experimental|EC/EG & EGD|"Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay~If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected)~If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent"
9536259|NCT04878419|Experimental|Virtual Educational Intervention|Virtual Educational Intervention
9536260|NCT04876378||Diagnostic (questionnaires, MRI)|Patients complete a series of questionnaires over 15 minutes about knee function and pain, as well as physical activity. Patients also undergo an MRI over 60 minutes.
9536261|NCT04875364|Experimental|Early PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will be set up with a loaner CPAP for 8 weeks to initiate therapy right away.
9536262|NCT04875364|Experimental|Usual PAP Start|After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will remain untreated until they are set up with their clinically prescribed CPAP (typically takes about 8 weeks).
9536263|NCT04873453|Active Comparator|Full-spectrum Cannabidiol|150mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.
9536264|NCT04873453|Experimental|Broad-spectrum Cannabidiol|150mg/day of broad-spectrum cannabidiol, containing 0%THC.
9536265|NCT04873453|Placebo Comparator|Placebo|150mg/day of hemp-seed oil with no cannabinoids present.
9536266|NCT04872842||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
9536267|NCT04872842||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
9536268|NCT04867122|Placebo Comparator|Attention Control|"Family caregivers in the attention control study arm will receive three sessions of attention-matched control in addition to the services and support provided as part of usual outpatient palliative care. Attention-matched control will consist of three friendly visits with a trained research staff person."
9536269|NCT04867122|Experimental|Problem Solving Therapy Intervention|Family caregivers in the intervention study arm will participate in three problem-solving therapy sessions with a trained interventionist in addition to receiving the services and support provided as part of usual outpatient palliative care.
9536270|NCT04867122|Other|In-Depth Interviews for non-FCG Stakeholders|Each year of the project, the investigators will recruit 6 key stakeholders to participate in individual interviews focused on potential barriers and facilitators to adoption of the PST intervention into clinical practice for a total of 30 unique stakeholders who will be interviewed over the duration of this 5-year study.
9536271|NCT04867096|Experimental|Physical activity intervention|"Arm A : standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months."
9536272|NCT04867096|No Intervention|Control|"Arm B : standard oncologic care."
9536273|NCT04862949||Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
9536274|NCT04861064|Experimental|Treatment Group|
10038931|NCT01839162|Experimental|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
10038932|NCT01839162|Sham Comparator|No drapes|Standard radioprotection devices
10038933|NCT01839175|Experimental|Group 1|
10038934|NCT01839175|Active Comparator|Group 2|
10038935|NCT01839201|Active Comparator|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
9536275|NCT04860635|Experimental|F14 (sustained release celecoxib)|Intra-articular F14 administration immediately following TKR surgery, and concurrent with multimodal standard of care analgesia
9536276|NCT04860453|Experimental|Affected participants with 5 or more discordant cancers - WES|"Affected individuals with a family history of 5 or more discordant cancers in unilateral descent with a 3-generation pedigree will receive SOC CLIA/CAP multicancer panel (DNA collected via blood draw or punch biopsy) to examine monogenic variant diagnostic yield. Eligible participants (families with no mutations and at least 2 affected and 1 non-affected family members) may move forward with WES.~Any identified monogenic variants of interest will be sent to an industry partner with CLIA/CAP certification for validation. A 6-month follow-up visit will take place during which variants will be discussed and participants who underwent gHFI variant counting (those who were not considered a gene candidate) will have results explained. Appropriate genetic counselling, recurrence risk, and additional clinical referrals will be made as necessary"
9536277|NCT04860453|Active Comparator|SOC genetic counseling (routine clinical care)|"Affected individuals (cancer) with a family history suggestive of a known hereditary syndrome or meeting NCCN criteria for germline testing will receive SOC CLIA/CAP multicancer panel in order to examine monogenic variant diagnostic yield (retrospective data)~This arm would also include prospective participants from the 5 or more discordant cancers group who DID have a variant identified and therefore did not move on to WES."
9536278|NCT04858568||Hodgkin lymphoma|"Diagnoses:~Hodgkin lymphoma (classical Hodgkin lymphoma)"
9536279|NCT04858568||Aggressive B-NHL|"Diagnoses:~Aggressive B-NHL (E.g. Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, Burkitt lymphoma, de novo transformed lymphoma, follicular lymphoma grade 3b)"
9536280|NCT04858568||Indolent B-NHL|"Diagnoses:~Indolent B-NHL (E.g.follicular lymphoma grades 1-3a, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, nodular lymphocyte predominant Hodgkin lymphoma)"
9536281|NCT04858568||Peripheral T/NK-cell|"Diagnoses:~Peripheral T/NK-cell lymphomas (any mature T/NK cell malignancy)"
9536282|NCT04858178|Experimental|Individuals with spinal cord injury|
9536283|NCT04858178|Experimental|Individuals without spinal cord injury|
10038936|NCT01839201|Active Comparator|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
9536285|NCT04852367|Active Comparator|Arm A (Doxorubicin)|a single intravenous dose of Doxorubicin, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered as per local practice.
9536286|NCT04852367|Experimental|Arm B (ThermoDox + Focused Ultrasound)|under general anaesthetic, patients receive FUS, which is moved through the target tumour volume to raise the bulk tumour temperature above the thermal release threshold. At presumed target temperature, a single intravenous dose of ThermoDox®, 50 mg/ m2 in 250 mL of normal saline or 5% dextrose over a 30-min infusion is delivered concurrently to FUS, in line with the pharmacy manual provided by the manufacturer. FUS will continue following infusion, for no longer than two hours from infusion commencing.
9536287|NCT04850495|Experimental|Treatment (zanubrutinib, R-CHOP)|Patients receive zanubrutinib PO on days 1-21, rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
9536288|NCT04844905|Experimental|Ivermectin Mass Drug Administration|Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
9536289|NCT04844905|Placebo Comparator|Placebo Mass Drug Administration|Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
9536290|NCT04825301||training cohort|data collection
9536291|NCT04825301||validation cohort|data collection
9536292|NCT04824274|Experimental|Transversus abdominis plane block and intrathecal fentanyl|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + fentanyl 10 mcg. Following the completion of surgery, ultrasound-guided bilateral transversus abdominis plane block will be done with 0.375% ropivacaine 15 ml per each side.
9536293|NCT04824274|Active Comparator|Intrathecal morphine|Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + morphine 75 mcg. Following the completion of surgery, sham block will be done using normal saline.
10038937|NCT01839201|Active Comparator|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
10038938|NCT01839214|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
10038939|NCT01839214|Placebo Comparator|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
10038940|NCT01839227|Experimental|regional cerebral oxygen saturation|
10038941|NCT01839240|Experimental|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
10038942|NCT01839253|Experimental|Atenolol|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
10038943|NCT01839253|Active Comparator|Enalapril|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
10038944|NCT01839253|Placebo Comparator|control|none of antihypertensive agents
10038945|NCT01839266||acute PE survivor, acute PE nonsurvivor|acute PE survivor, acute PE nonsurvivor (in-hospital death)
10038946|NCT01839292|Active Comparator|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
9536294|NCT04823676|Active Comparator|Probiotic composition|A capsule containing a mix of probiotic strains (1.5 x 10^9 CFU/capsule ) administered once daily for 4 months
9536295|NCT04823676|Placebo Comparator|Placebo|A capsule containing placebo administered once daily for 4 months
9536296|NCT04821726|Experimental|Drug eluting balloon (Vmoky)|A paclitaxel eluting balloon produced by Yinyi (Liaoning) Biotech Co., Ltd. Balloon length: 8-40 mm, diameter：1.25-5.00 mm.
9536297|NCT04821219|Experimental|Tumoroid generation|Single arm, including all the patients enrolled to generate tumor models
9536298|NCT04821154||1) Revision Splined CCK|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, constrained condylar knee (CCK) articular surface, Persona Revision femoral component, and splined femoral stem.
9536299|NCT04821154||2) Revision Cemented CCK|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
9536300|NCT04821154||3) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, posterior stabilized/constrained posterior stabilized (PS/CPS) articular surface, Persona Revision femoral component, and splined femoral stem.
9536301|NCT04821154||4) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
9536302|NCT04821154||5) Revision Splined PS/CPS|Patients who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
9536303|NCT04821154||6) Revision Cemented PS/CPS|Patients who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, PS/CPS articular surface, Persona primary PS femoral component, with no femoral stem.
9536304|NCT04821154||7) Revision Cemented CCK with 5 Degree Primary Tibia|Patients who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK articular surface, Persona Revision femoral component, and cemented femoral stem.
9536305|NCT04821154||8) Primary Splined CCK/CPS/PS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a splined tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and splined femoral stem.
9536306|NCT04821154||9) Primary Cemented CCK/PS/CPS with 0 Degree Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 0 degree Persona Revision tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
9536307|NCT04821154||10) Primary Cemented CCK/PS/CPS with 5 Degree Primary Tibia|Patients with a primary implant (non-revision case) who were implanted with a cemented tibial stem, 5 degree Persona primary tibial component, CCK/PS/CPS articular surface, Persona Revision femoral component, and cemented femoral stem.
9536308|NCT04816357||Endometriosis & Migraine|"Premenopausal women aged 18-55 years, at time of operation~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)~For the cases migraine needs to be confirmed during the interview according to the IHS criteria."
9536309|NCT04816357||Endometriosis|"Premenopausal women aged 18-55 years, at time of operation~Endometriosis confirmed with surgery and histologic staging (Report of the surgery available)"
9536310|NCT04811482|Experimental|Intervention Group|This study consists of one arm, an intervention group.
9536311|NCT04796506|Active Comparator|Exercise Group|PD participants randomized to progressive resistance training PRT) will have 12 weeks of supervised PRT 3 times per week. After the 1st 12 weeks, responders to PRT (increase in slow wave sleep) will continue PRT for an additional 12 weeks, non-responders to PRT will transition to endurance training (ET).
9536312|NCT04796506|Placebo Comparator|Delayed Exercise Group|PD participants randomized to the delayed exercise control group will not exercise for the 1st 12 weeks of the study. After the 1st 12 weeks, participants in the delayed exercise group will transition to PRT for the 2nd 12 weeks.
9536313|NCT04794621|No Intervention|Standard of Care Only|This will be group 1
9536314|NCT04794621|Experimental|SOC and PED-10 +Procellera|In group 2, in addition to SoC, the patients will apply the EDThi dressing (PED-10) on the wound(s) for the first 3 weeks following enrollment followed by Procellera® or EDTlo for additional 3 weeks. The use of dressings will be discontinued anytime if complete wound closure is achieved.
9536315|NCT04777721|Experimental|Group 1: 1 x 10^4 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^4 cfu aerosol inhaled BCG. All Group 1 volunteers will have a bronchoscopy 14 days post challenge.
9536316|NCT04777721|Experimental|Group 2: 1 x 10^5 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^5 cfu aerosol inhaled BCG. All Group 2 volunteers will have a bronchoscopy 14 days post challenge.
9536317|NCT04777721|Experimental|Group 3: 1 x 10^6 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^6 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
9536318|NCT04777721|Experimental|Group 4: 1 x 10^7 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
9536319|NCT04774991|Active Comparator|Azithro 1-59 fixed point|Azithromycin distribution to children 1-59 months of age using a fixed-point delivery approach via existing community health workers
9536320|NCT04774991|Active Comparator|Azithro 1-59 door-to-door|Azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
9536321|NCT04771923|Experimental|Tranexamic acid|
9536322|NCT04771923|Experimental|Adrenaline|
9536323|NCT04770870|Other|Treatment Arm|All subjects who meet eligibility, consented, and enrolled into the study will receive treatment.
9622054|NCT02518789|Experimental|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
9536324|NCT04766268|Experimental|PAE group|Patients with BPH with moderate lower urinary tract symptoms fulfilling the inclusion criteria and exclusion criteria will be enrolled in the trial to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
10038947|NCT01839292|Active Comparator|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
9536325|NCT04762602|Experimental|Part 1 Dose Escalation Cohorts|Patients from each cohort will be administered HMPL-306 orally QD
9536326|NCT04762602|Experimental|Part 2 Dose Expansion Cohorts|Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose
9536327|NCT04762459|Active Comparator|Almonertinib|Drug: Almonertinib 110 mg A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.
9536328|NCT04762459|Experimental|Almonertinib/Pemetrexed/Cisplatin|"Drug: Almonertinib 110 mg Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years."
9536329|NCT04762459|Active Comparator|Pemetrexed/Cisplatin|"Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.~A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. If disease progresses during the treatment period and conditions required for the cross-treatment are met according to the assessment process, the patient can start to receive the open cross-treatment of Almonertinib. The overall treatment last for 3 years."
9536330|NCT04762017|Experimental|Multidose ACT-01|Once daily IV infusions of ACT-01 (n=18) for 5 consecutive days
9536331|NCT04762017|Placebo Comparator|Placebo|Once daily IV infusions of Placebo (n=18) for 5 consecutive days
9536332|NCT04754230|Experimental|1,000mg IV Tranexamic acid|Participants in this arm will be given a 1,000mg dose of intravenous tranexamic acid via saline infusion 15 minutes prior to the completion of surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
9536333|NCT04754230|No Intervention|Normal saline|Participants in this arm will not be given any extra intervention over their routine anesthetic care. They will continue to receive their normal saline infusion during surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
9536334|NCT04753996||Primary Sclerosing Cholangitis (PSC)|Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
9536335|NCT04753996||Control (non-PSC)|Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
9536336|NCT04745949|Experimental|Treatment (brentuximab vedotin, nivolumab, R-CHP)|Patient will receive an immune lead-in of 2 cycles of Brentuximab vedotin and Nivolumab (A-O) (cycles 1 and 2), which has an appropriate futility rules in place to close early if efficacy targets are not met. At cycle 3 and 4, patients will receive A-O with R-CHP. Patients who will have achieved complete response (CR) at PET/CT before cycle 5 will receive 2 more cycles of A-O-R-CHP (cycle 5 and 6) and A-O only for cycle 7 and 8. If these patients still present CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. In case of stable disease or progressive disease at PET/CT after cycle 4, the patient will be taken off the trial. Patients who present further response but no CR, at PET/CT before cycle 5 will receive 4 more cycles A-O-R-CHP (cycles 5-8). If they reach CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. All patients will receive a total of 8 cycles of A-O. The cycle duration is 21 days.
9536337|NCT04742439|Sham Comparator|Sham stimulation|
9536338|NCT04742439|Experimental|Individualized stimulation|
9536339|NCT04742439|Experimental|2mA stimulation|
9536340|NCT04742439|Experimental|4mA stimulation|
9536341|NCT04735796|Experimental|LM102 Dose Escalation Level 1, 3mg/kg|LM102 Dose Escalation Level 1, 3mg/kg, enrolled CLDN 18.2 positive advanced solid tumors
9536342|NCT04735796|Experimental|LM102 Dose Escalation Level 2, 10mg/kg|LM102 Dose Escalation Level 2, 10mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
9536343|NCT04735796|Experimental|LM102 Dose Escalation Level 3, 20mg/kg|LM102 Dose Escalation Level 3, 20mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
9536344|NCT04735796|Experimental|LM102 Dose Escalation Level 4, 30mg/kg|LM102 Dose Escalation Level 4, 30mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
9536345|NCT04735796|Experimental|LM102 Dose Escalation Level 5, 40mg/kg|LM102 Dose Escalation Level 5, 40mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
9536346|NCT04734106|Experimental|Desert Harvest Super-Concentrated, Freeze-Dried Aloe Vera Capsules|Participants will self-administer Desert Harvest super-concentrated, freeze-dried aloe vera capsules orally over a sixteen week period. The dosing regimen includes administering 3 capsules twice daily for the first month, 3 capsules three times daily for the second month, and 4 capsules three times daily for the third month. During the fourth month, participants will administer 10 capsules per day the first week (4 in the morning, 2 in the afternoon, and 4 in the evening), 8 capsules per day the second week (4 in the morning, 4 in the evening), 6 capsules per day the third week (3 in the morning, 3 in the evening), and 4 capsules per day the fourth week (2 in the morning, 2 in the evening). A participant must stay on a minimum of 6 capsules per day for the first three months in order to remain in the study.
9536347|NCT04734106|Placebo Comparator|Placebo|Participants will self-administer placebo capsules orally, matching the dosing regimen of the experimental treatment, over a sixteen week period. Placebo capsules will be identical in appearance and packaging to the experimental capsules.
9536348|NCT04731922|Experimental|TAK-510: Part 1|TAK-510 at starting dose of 5 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part A (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12) will be used based on emerging safety, tolerability, and PK data from Cohort 1 as determined by dose escalation committee.
9536349|NCT04731922|Experimental|TAK-510: Part 2|TAK-510 to be decided (TBD) or placebo-matching solution, subcutaneously, once daily from Day 1 through Day 5. Dose of multiple rising dose (MRD) Cohorts (Cohorts 13-17) of Part 2 will be determined based on emerging safety, tolerability, and available PK data from Part 1 (SRD) determined by dose escalation committee.
9536350|NCT04731922|Experimental|TAK-510: Part 3|TAK-510 TBD or placebo-matching solution, subcutaneously, once daily from Day 1 through Day 14. Dose of dose titration and redosing Cohorts (Cohorts 18-20) of Part 3 will be based on emerging safety, tolerability, and available PK data from Part 1 single rising dose (SRD) and Part 2 (MRD) as determined by dose escalation committee. Single redosing will be performed on Day 14 after 7 days of washout period following the 7 days treatment period.
9536351|NCT04718415|Experimental|sintilimab + carboplatin + nab-paclitaxel|"Treatment with sintilimab, nab-paclitaxel and carboplatin for up to 2 - 4 cycles:~Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
9536352|NCT04718025|Experimental|Low-dose ticagrelor with aspirin (LDTA)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, and will receive the following antiplatelet therapy:~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until 12 months after ACS."
9536353|NCT04718025|Experimental|Low-dose ticagrelor with placebo (LDTP)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, followed by discontinuation of aspirin after 3 months post-ACS, and will receive the following antiplatelet therapy:~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until day 90 after ACS;~ticagrelor 2x60mg + placebo starting from day 91 until 12 months after ACS."
9536354|NCT04718025|Active Comparator|Standard-dose ticagrelor with aspirin (SDTA)|Patients with ACS in this arm will receive standard dual antiplatelet therapy including ticagrelor 2x90mg + aspirin 1x100mg during the whole 12 months after ACS.
9536355|NCT04713514|No Intervention|Arm A : Best Supportive Care|Observational arm (Standard of care)
9536356|NCT04713514|Experimental|Arm B : OSE2101|"OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.~OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion."
9536357|NCT04713514|Experimental|Arm C : OSE2101 + Pembrolizumab|OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
9536358|NCT04710628|Experimental|PEMBROLIZUMAB + LENVATINIB|"Pembrolizumab 200 mg will be administered to patients as 30-minute IV infusion every 3 weeks (a window of -5 minutes and +10 minutes is permitted).~Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab). Lenvatinib cannot be chewed"
9536359|NCT04708067|Experimental|Treatment (hypofractionated radiation, bintrafusp alfa)|Patients undergo hypofractionated radiation therapy QD on weekdays (Monday-Friday) for 15 fractions in the absence of disease progression or unacceptable toxicity. Beginning 1 week after completion of radiation therapy, patients receive bintrafusp alfa IV over 1 hour on day 1. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
9536360|NCT04704076|Experimental|Early, Small-Volume Supplementation (ESVS)|Breastfeeding with up to 59 mL formula daily until 30 days of age, followed by recommendation to breastfeed exclusively through 6 months of age
9536361|NCT04704076|Active Comparator|Exclusive Breastfeeding|Recommendation to breastfeed exclusively for 6 months without any other food or fluid except vitamins, minerals and medications
9536362|NCT04701177||Subjective cognitive decline (SCD)|subjective perception of cognitive decline in the absence of cognitive impairment in formal neuropsychological assessment.
9536363|NCT04701177||Mild cognitive impairment (MCI)|Single or multidomain cognitive deficits with preservation of activities of daily living.
9536364|NCT04701177||Prodromal Parkinson's Disease|Parkinson's disease (PD) has a prodromal phase during which nonmotor clinical features as well as physiological abnormalities may be present.
9536365|NCT04700891|Experimental|Patients scheduled for elective surgery aged 65 and +|
9536366|NCT04697173|No Intervention|Standard consent|This group will be consented for invasive procedures using standard Hospital policy. Informed consent will be obtained either in person or via telephone with a witness from the patient or his/her legal guardian for any/all procedures medically indicated at that time, at the discretion of the Attending Physician.
9536367|NCT04697173|Experimental|Bundled consent|"Upon admission, this group will received the document titled Common PICU Procedures Explained and encourage to read the document. They will then, within 24 hours of admission be consented using the Bundle Consent Document for the group of invasive procedures listed and explained in that document."
9536368|NCT04696263|Active Comparator|Extraperitoneal SinglePort (SP) Robotic Radical Prostatectomy (Da Vinci ® SP system)|"All participants will undergo SOC robotic radical prostatectomy.~The procedure for this arm uses the Da Vinci ® SP system. Access point consists of one 3.5 cm single infraumbilical incision for the SP-RARP"
9536369|NCT04696263|Active Comparator|Extraperitoneal MultiPort (MP) Robotic Radical Prostatectomy (Da Vinci ® Xi system)|"All participants will undergo SOC robotic radical prostatectomy.~The procedure for this arm uses the Da Vinci ® Xi system, where four 8mm trocars will be used along with a 12 mm assistant trocar (a surgical instrument) to create six small incisions during the surgery"
9536370|NCT04688203|Active Comparator|Magnesium sulfate infudsion|patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
9536371|NCT04688203|Active Comparator|Labetalol infusion|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
9536372|NCT04687501|Experimental|VR-group|"The participants randomised into this group can choose for an immersive guided relaxation VR experience or an interactive VR experience. The VR intervention is additional to the standard postoperative care management, the standard pain protocol is explained below.~The VR-intervention will be given using the Oculus Go Virtual Reality glasses with touchpad."
9536373|NCT04687501|No Intervention|Standard care-group|"The participants randomized into the standard care- group will receive the usual standard pre-and postoperative management.~Standard pain protocol:~Preoperative (arrival day-care unit) start with 1000mg paracetamol orally administered.~Postoperative Meloxicam 15mg orally administered, or when oral medication is not possible (due to nausea e.g.) than diclofenac supp 100mg or diclofenac i.v. 75mg.~On recovery ward, when necessary depending on pain score (NRS>4): dipidolor 2.5-5mg i.v. and 10-15mg i.m. after consulting the anesthesiologist.~Postoperative at home 4dd1000mg paracetamol will be continued, in combination with meloxicam 1dd15mg during 3 days. Also tramadol 50mg with a maximum of 4dd will be prescribed."
9536374|NCT04684485|Placebo Comparator|Placebo of SCD-044 product|Placebo tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
9536375|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 Tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
9536376|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 Tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
9536377|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 Tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
9536378|NCT04684121|Experimental|Granexin gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 200 μM will be applied daily over ten days. Granexin® will be applied to one of two selected target burns."
9536379|NCT04684121|Placebo Comparator|Vehicle Gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Vehicle gel will be applied daily over ten days. Vehicle will be applied to one of two selected target burns."
9536380|NCT04679233|Experimental|Arm 1: Intervention Arm|Arm 1 will receive the aerobic prescription exercise intervention. As this is a feasibility and safety study, there will not be a second arm.
9536381|NCT04674033||Consumer|Participants who self-report regular consumption of non-nutritive sweeteners (>/=5 servings/week) based on a pre-screening dietary survey.
9536382|NCT04674033||Non-Consumer|Participants who self-report no consumption of non-nutritive sweeteners (0 servings/week) based on a pre-screening dietary survey.
9536383|NCT04672395|Experimental|Group 1|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
9536384|NCT04672395|Placebo Comparator|Group 2|Placebo Comparator: Group 20.9% Saline
9536385|NCT04672395|Experimental|Booster dose of SCB-2019|Adult SCB-2019 recipients will receive 1 dose of SCB-2019 at least 4 months after the second dose
9536386|NCT04672395|Placebo Comparator|Vaccination of placebo recipients with SCB-2019|Placebo participants will be offered two doses of SCB-2019 vaccine
9536387|NCT04668235|Experimental|Arm AZVUDINE|"Experimental:~AZVUDINE 1mg tablet,~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment for up to 14 days"
9536388|NCT04668235|Placebo Comparator|Arm Placebo|"Control:~AZVUDINE placebo,~Interventions:~AZVUDINE placebo, 5 tablets QD + standard treatment for up to 14 days"
9536389|NCT04659538|Experimental|CAPTIS Embolic Protection|TAVR will be performed according to standard institutional practice under local or general anesthesia by the transfemoral approach. The investigational device will be advanced and deployed across the aortic arch covering the ostia of the 3 great vessels (innominate, left carotid, and left-subclavian arteries) at the initiation of the procedure and withdrawn at the completion of the TAVR procedure.
9536390|NCT04658433|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 8 weeks.
9536391|NCT04658433|No Intervention|Control group|
10038948|NCT01839305|Experimental|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
10038949|NCT01839344|Experimental|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
9536394|NCT04636437|Experimental|DOR 100 mg + TAF/FTC (or TAF/3TC, depending on location)|By mouth daily with or without food
9536395|NCT04636437|Experimental|DOR 100 mg + TDF/FTC (or TDF/3TC, depending on location)|By mouth daily with or without food
9536396|NCT04636437|Experimental|Continuation of entry INSTI+TAF/FTC (or TAF/3TC)|
9536397|NCT04636320|Experimental|Patient group COVID-19|120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization
9536398|NCT04636320|Active Comparator|Healthy volunteer group|120 healthy volunteers. Age- and sex-matched controls
9536399|NCT04630938|Active Comparator|G-M|Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative.
9536400|NCT04630938|Active Comparator|G-ML|Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative.
9536401|NCT04630938|Placebo Comparator|G-0|Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups.
10038950|NCT01839344|Active Comparator|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
10038951|NCT01839344|Placebo Comparator|Placebo|An oral single dose of a solid, colored empty capsule.
9536402|NCT04621019|Experimental|Non-invasive lipolysis and circumference reduction of the abdomen|The treatment administration phase consists of four (4) treatment visits, delivered at least 1 week apart. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
9536403|NCT04608045|Experimental|CPX-POM, 900 mg/m2 by 20 minute IV infusion|
9536404|NCT04605211|Experimental|Being Present (Supportive Care)|Patients and caregivers receive Being Present intervention consisting of online audio-based mindfulness meditation exercise over 15 minutes at least 5 times per week, daily meditation reminders, and online webinars over 30-60 minutes every week.
9536405|NCT04604912||Peanut-allergic patients' group|The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.
9536406|NCT04604912||Control group|The aim is to include 20 control participants, 10 peanut-tolerant and 10 fish-tolerant individuals. Those participants will undergo diagnostic food challenges (incremental or single doses) while blood will be samples before, during and after the testing. Same safety measures will be applied for food challenges of control individuals, as for the allergic patients.
9536407|NCT04604262|Experimental|Treatment Group|Waterpik® in addition to the manual toothbrush
9536408|NCT04604262|No Intervention|Control|Manual toothbrush
9536409|NCT04599972|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
9536410|NCT04599972|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
9536411|NCT04599933|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
9536412|NCT04599933|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
9536413|NCT04594746|Experimental|Oral Amiodarone|Amiodarone hydrochloride 2000 mg
9536414|NCT04594746|Placebo Comparator|Placebo|Oral placebo
9536415|NCT04592237|Experimental|Group I (niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9536416|NCT04592237|Experimental|Group II (cetrelimab, niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
9536417|NCT04581824|Experimental|Participants receiving dostarlimab plus chemotherapy|Participants will receive dostarlimab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
9536418|NCT04581824|Active Comparator|Participants receiving pembrolizumab plus chemotherapy|Participants will receive pembrolizumab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
9616054|NCT04717297|Experimental|Tailored Medication Management Remote Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered remotely.
9616055|NCT04717297|Sham Comparator|Waitlist Attention Control Arm|The attention control group will receive two, 75-minute attention visits with a trained research assistant. Upon completion of waitlist period, the participants in the waitlist group will be offered the intervention in person.
9616056|NCT04717297|Experimental|Tailored Medication Management In-Person Intervention Treatment Arm|Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered in-person.
9616057|NCT04712747||Cases - patients with stroke|Ophthalmological examinations : At the inclusion visit and 3 months after their stroke Blood pressure measurement at rest : At the inclusion visit
9616058|NCT04712747||Controls - Individuals with no history of stroke|Ophthalmological examinations : At the inclusion visit Blood pressure measurement at rest : At the inclusion visit
9616059|NCT04705324|Experimental|Operative Hysteroscopy|Hysteroscopic separation
9616060|NCT04705324|Active Comparator|Dilation and Curettage|Curettage separation
9616061|NCT04692532|Experimental|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
9616062|NCT04692532|Experimental|Calorie restriction|25% energy restriction every day
9616063|NCT04692532|No Intervention|Control|Usual diet
9616064|NCT04687436||Foley catheter group|mechanical cervical ripening
9616065|NCT04687436||Double-balloon group|mechanical cervical ripening
9616066|NCT04687436||Cook cervical ripening balloon|mechanical cervical ripening
9616067|NCT04681534|Active Comparator|conventional DBS|
9616068|NCT04681534|Experimental|adaptive DBS|
9616069|NCT04676308||AI arm|Standard colonoscopy with Artificial Intelligence-GI GeniusTM
9616070|NCT04676308||Cuff arm|Endo-cuff Vision aided colonoscopy with Artificial Intelligence -GI GeniusTM
10038952|NCT01839357|Experimental|Rivaroxaban|
10038953|NCT01839370|Experimental|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
9536419|NCT04566666|Placebo Comparator|Placebo of SCD-044 product|Placebo of SCD-044 study drug
9536420|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 tablets at Dose 1
9536421|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 tablets at Dose 2
9536422|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 tablets at Dose 3
9536423|NCT04564534||Study cohort|"Adult (>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up.~The MoCA will be administered by trained professionals with MoCA certification.~Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure."
9536424|NCT04552990|Experimental|Tumor Excision, No Illumination|The first four patients will not receive illumination but have their tumors excised after jet-injection (AirGent2.0) of ALA (Levulan Kerastick), and 3h incubation; this will be done to assess biodistribution of ALA through fluorescence microscopy.
9536425|NCT04552990|Experimental|PDT treatment with jet-injections|Patient 5-16 will receive PDT treatment with jet-injections of ALA followed by 3h incubation under occlusion and thereafter illumination with red light (total dose 75 J/cm2). In patient 5-16, the PDT treatment will be repeated after 2 weeks.
9536426|NCT04542681|Placebo Comparator|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo (0.9% normal saline) (n=10)
9536427|NCT04542681|Active Comparator|MANP - 1st Cycle|Subjects will receive a single SQ injection of 2.5 μg/kg MANP (n=10)
9536428|NCT04542681|Active Comparator|MANP - 2nd Cycle|Subjects will receive a single SQ injection of 5 μg/Kg MANP (n=10)
9536429|NCT04542135|Active Comparator|Sulindac|sulindac 150 mg
9536430|NCT04542135|Placebo Comparator|Placebo|placebo pill
9536431|NCT04539041|Experimental|Cohort A NIO752|4 injections of NIO752 at dose A
9536432|NCT04539041|Experimental|Cohort B NIO752|4 injections of NIO752 at dose B
9536433|NCT04539041|Placebo Comparator|Placebo|4 injections of placebo
9536434|NCT04539041|Experimental|Cohort C NIO752|4 injections of NIO752 at dose C
9536435|NCT04539041|Experimental|Cohort D NIO752|4 injections of NIO752 at dose D
9536436|NCT04539041|Experimental|Cohort E NIO752|4 injections of NIO752 at dose E
9536437|NCT04539041|Experimental|Cohort F NIO752|4 injections of NIO752 at dose F
9536438|NCT04538755|Placebo Comparator|Placebo|Placebo capsule 4 hours before sleep
9536439|NCT04538755|Active Comparator|DAW2020|DAW2020 capsule 4 hours before sleep
9536440|NCT04536025||Prosthetists|Up to 24 prosthetists who are actively providing prosthetic care to people with lower limb amputation will be recruited for participating in focus groups to describe their decisional needs for providing prostheses to people with lower limb amputation.
9536441|NCT04536025||People with lower limb amputation|An estimated 14 people within 1 year from lower limb amputation, receiving their first prosthesis will be recruited for individual semi-structured interviews to describe their decisional needs for provision of a prosthesis.
9536442|NCT04536025||Expert working group|The expert working group will consist of at least 5 and up to 12 people with LLA actively receiving prosthetic care, and at least 5 and up to 12 prosthetic care providers with greater than 5 years of experience. Individuals will be invited to join the expert working group based on expertise, and representation of key stakeholders relevant to the prosthetic design process.
9536443|NCT04509973|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
9536444|NCT04509973|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
9536445|NCT04496167|Experimental|EN3835|EN3835 up to 1.74mg.
9536446|NCT04496167|Placebo Comparator|Placebo|Placebo
10058385|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
9536448|NCT04492800|Other|Paxman Scalp Cooling Device|Patients will undergo scalp cooling via the Paxman Scalp Cooling device for the first 3 cycles of treatment. Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
9536449|NCT04491253|Experimental|Intervention|The intervention is defined as informational support (transmission of information for health care, knowledge of DM2, nutrition, physical activity), instrumental (physical care) and emotional (management of anxiety, empowerment and decision-making).
9536450|NCT04491253|No Intervention|Control|Control group will receive usual care treatment at the diabetes mellitus nursing consultation in primary care.
9536451|NCT04490902|Active Comparator|Single graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from single donors.
9536452|NCT04490902|Experimental|Dual graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from different donors.
9536453|NCT04488523|Experimental|Family-based Telehealth Treatment|A family-based telehealth intervention.
9536454|NCT04487860|Experimental|AS012 dose regimen I|Oral
9536455|NCT04487860|Experimental|AS012 dose regimen II|Oral
9536456|NCT04487860|Experimental|AS012 dose regimen III|Oral
9536457|NCT04487860|Experimental|AS012 dose regimen IV|Oral
9536458|NCT04487860|Placebo Comparator|Placebo|Oral
9536459|NCT04483271|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 2 months.
9536460|NCT04483271|No Intervention|Control group|No intervention was given
9536461|NCT04482621|Active Comparator|Decitabine + Standard of Care (SOC)|Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
9536462|NCT04482621|Placebo Comparator|Standard of Care (SOC) + Placebo|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
9536463|NCT04482062|Experimental|Edwards EVOQUE System & OMT|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation
9536464|NCT04482062|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
9536465|NCT04482062|Experimental|Single-Arm Registry|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
9536466|NCT04480931|Experimental|mHealth Intervention Group|This group will be provided with the mobile health app (including introductory videos on how to use its features).
9536467|NCT04480931|Sham Comparator|Control Group|This group will receive an educational brochure about physical activity during pregnancy.
9536468|NCT04480645|Experimental|Treatment|Radioactive bandage applied to surface of the body worn for approximately one week.
9536469|NCT04474106|Experimental|ESWT|The extracorporeal shockwave therapy is applied once at the level of lesion and 5 segments above and below; or below the occiput (in lesions higher than C6) and above the sacrum (in lesions lower than T12). In addition, the ESWT is applied to the soles of both feet on the medial side of the plantar surface. The ESWT is applied as soon as possible within 48 hours post-injury.
9536470|NCT04474106|Sham Comparator|Control|In the control group, the same procedure is performed, but without the device emitting extracorporeal shock waves using a dummy head.
9536471|NCT04469959|Experimental|L-Dopa First / Placebo Second|"STEP 1(3 weeks): Participants initially assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and placebo tablets at 1pm and 5pm. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, with placebo at 1pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets at 9am, 1pm, and 5pm over three weeks. Following post-trial assessments, participants then enter a 1-week taper period and study drug is withdrawn."
9536472|NCT04469959|Placebo Comparator|Placebo First / L-Dopa Second|"Step 1 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets at 9am, 1pm, and 5pm over three weeks. Following post-trial assessments, participants then enter a 1-week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and placebo tablets at 1pm and 5pm. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, with placebo at 1pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period and study drug will be discontinued."
9536473|NCT04461899|Other|sclerotherapy|a sclerotherapy will be done in patients
9536474|NCT04443569|Experimental|Lidocaine Patch Group|This group will be women who were randomized to receive a lidocaine patch for postoperative pain following cesarean delivery in addition to routine postoperative pain management.
9536475|NCT04443569|No Intervention|Control Group|This group will be women randomized to routine postoperative pain management following cesarean delivery.
9536476|NCT04440930|Experimental|White tea|
9536477|NCT04440930|Active Comparator|Salt water with soda|
9536478|NCT04434937|Experimental|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
9536479|NCT04432792||Clinical Records Review|We will receive clinical chart data from the telehealth providers on 3,000 patients (which could include the survey study participants, but we will not know their identities) which will include date of birth, zip code, and dates of service - but will otherwise be de-identified.
9536480|NCT04432792||Study Survey Participants|We aim to enroll at least 3,000 participants to complete the study surveys.
9536481|NCT04428788|Experimental|Administration of CC-94676|
9536482|NCT04426279||patient with chronic inflammatory rheumatism|
9536483|NCT04425577|Other|Transabdominal Ultrasound|All patients enrolled will undergo a transabdominal ultrasound at a specified time point as outlined in the protocol.
9536484|NCT04421703|Experimental|Distance Collaborative|For sites randomized to the distance arm, training will be delivered via web conference, and technical assistance and assessment and feedback will be delivered by phone.
10038954|NCT01839370|Placebo Comparator|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
10038955|NCT01839383|Active Comparator|DCa1.25|using dialysate calcium concentration 1.25 mmol/L(DCa1.25)
9536485|NCT04421703|Experimental|Blended in-person/distance collaborative|For the QI collaborative arm, training will be delivered in two in-person collaborative meetings; and the remainder of the strategies will be delivered via web-conferencing.
9536486|NCT04420676|Active Comparator|Probiotic|Group 1: receiving a probiotic mixture (Omni-Biotic® 10 AAD) twice a day
9536487|NCT04420676|Placebo Comparator|Placebo|Group 2: receiving a similar looking and tasting placebo without bacteria twice a day
9536488|NCT04406623|Experimental|SL-172154|Intravenous administration
9536489|NCT04406584|Placebo Comparator|Saline|Injection of 1cc saline into olfactory cleft x4
9536490|NCT04406584|Experimental|Platelet Rich Plasma|Injection of 1cc patient's own platelet rich plasma (PRP) into olfactory cleft x4
9536491|NCT04380987||Predicovid|
10038956|NCT01839383|Active Comparator|DCa1.5|using dialysate calcium concentration 1.5mmol/L
10038957|NCT01839383|Active Comparator|DCa1.75|using dialysate calcium concentration 1.75mmol/L
10038958|NCT01839409|No Intervention|control|Control without vestibular stimulation
10038959|NCT01839409|No Intervention|Bilateral areflexia|Patient with vestibular bilateral areflexia
10038960|NCT01839409|No Intervention|Areflexia controls|Controls for patients with vestibular bilateral areflexia, matched in sex and age
10038961|NCT01839409|Experimental|vestibular stimulation|Subjects submitted to vestibular stimulation in order to improve circadian rhythms
10038962|NCT01839422|Experimental|Controls|Memory assessment. Brain imaging examination MRI.
10038963|NCT01839422|Experimental|Beginner Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
9536494|NCT04371900|Experimental|Experimental Group|Mothers randomized to receive a voucher to be used at Planned Parenthood to cover the cost of contraceptives
9536495|NCT04371900|No Intervention|Control Group|Mothers randomized to NOT receive a voucher. Mothers in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
9536496|NCT04357795|Experimental|CequaTM (Cyclosporine 0.09%) ophthalmic solution|
9536497|NCT04356638|Active Comparator|The sedative pre-medication oral Midazolam|
9536498|NCT04356638|Active Comparator|The sedative pre-medication intranasal Dexmedetomidine|
9536499|NCT04356638|Placebo Comparator|Placebo|
9536500|NCT04356638|No Intervention|No Sedative Pre-medication|
9536501|NCT04352608|Experimental|Emergency schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the emergency schedule
9536502|NCT04352608|Experimental|Emergency schedule & Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the emergency schedule
9536503|NCT04352608|Placebo Comparator|Emergency schedule &Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the emergency vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the emergency schedule
9536504|NCT04352608|Experimental|Routine schedule & Two doses of medium dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the routine schedule
9536505|NCT04352608|Experimental|Routine schedule &Two doses of high dosage vaccine|24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the routine schedule
9536506|NCT04352608|Placebo Comparator|Routine schedule & Two doses of placebo|24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the routine vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the routine schedule
9536507|NCT04352608|Experimental|Emergency schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
9536508|NCT04352608|Experimental|Emergency schedule & Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
9536509|NCT04352608|Placebo Comparator|Emergency schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the emergency vaccination schedule
9536510|NCT04352608|Experimental|Routine schedule & Three doses of medium dosage vaccine|60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
9536511|NCT04352608|Experimental|Routine schedule &Three doses of high dosage vaccine|60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
9536512|NCT04352608|Placebo Comparator|Routine schedule &Three doses of placebo|30 participants in phase Ⅱ will receive three doses of placebo at the routine vaccination schedule
9536513|NCT04352231|Experimental|High to Low Fiber Diet Intervention|Participants receive the high fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the low fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
9536514|NCT04352231|Experimental|Low to High Fiber Diet Intervention|Participants receive the low fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the high fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
9536515|NCT04351984||Severe Mitral Regurgitation|
9536516|NCT04346108|Experimental|Epoch 1: Immune Globulin Intravenous (IGIV)|Participants will receive approximately 200 to 600 milligrams per kilogram (mg/kg) of Immunoglobulin Globulin Intravenous (IGIV) infusion for every 3 or 4 weeks for a total of 13 weeks.
9536517|NCT04346108|Experimental|Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive approximately 50 to 200 mg/kg of IGSC infusion, 20 percent (%) once a week for a total of 24 weeks.
9536518|NCT04346108|Experimental|Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive approximately 100 to 400 mg/kg of IGSC infusion, 20% once every two weeks in a sub-set of 7 participants for a total of 12 weeks.
9536519|NCT04333810||Active IBD patients|Patients with active IBD, based on colonoscopic evaluation and biopsy results.
10038964|NCT01839422|Experimental|Severe Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
10038965|NCT01839435|Experimental|outpatient patients|Outpatient surgery will be proposed to all patients
10038966|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.~Intervention: Post-partum oral glucose tolerance test"
10058386|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
10038967|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.~Intervention: Post-partum oral glucose tolerance test"
10038968|NCT01839474|Experimental|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
9536520|NCT04333810||IBD patients in remission|IBD patients in remission, with no recently colonoscopic evidence of disease, and only on maintenance therapy.
9536521|NCT04332653|Experimental|Phase 1b: NT-I7 Dose Escalation|"NT-I7 will be administered on Day 1 of alternate 21 day cycles (Cycle 1, 3, 5 etc.). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
9536522|NCT04332653|Experimental|Phase 2a: CPI Treated Triple Negative Breast Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory triple negative breast cancer (TNBC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
9536523|NCT04332653|Experimental|Phase 2a: CPI Treated Non-small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory non-small cell lung cancer (NSCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
9536524|NCT04332653|Experimental|Phase 2a: CPI Treated Small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory small cell lung cancer (SCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
9536525|NCT04332653|Experimental|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
9536526|NCT04332653|Experimental|Phase 2a: CPI Naïve Pancreatic Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
9536527|NCT04332653|Experimental|Biomarker Cohort: CPI Naïve Ovarian Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory ovarian cancer (OC). Participants will receive a starting dose of 960 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
9536528|NCT04327310|Experimental|Meplazumab|The vial of meplazumab will be reconstituted with 1 mL of water for injection. The required amount of drug solution will be withdrawn and added to 100 mL sterile normal saline (0.9%) for IV infusion. A single dose of meplazumab will be infused over 60 minutes at a constant rate using an infusion pump.
9536529|NCT04327310|Placebo Comparator|Placebo|100ml placebo will be infused over 60 minutes at a constant rate using an infusion pump, single time.
9536530|NCT04325282|Experimental|Children with BECTS|Children will receive sham and active rTMS on 2 separate study visits separated by at least 1 week.
9536531|NCT04308057||Aquatic Exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in swimming or other aquatic, primarily aerobic-based, training regimes for more than 2 times a week, for more than 6 months, at the time of the assessments.
9536532|NCT04308057||Land-based exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in land-based, primarily aerobic training regimes (e.g. aerobic exercise) for more than 2 times a week, for a period longer than 6 months, at the time of the assessments.
9536533|NCT04308057||Mixed exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in both land-based and aquatic, primarily aerobic, exercise regimes on an equal basis, for more than 6 months.
9536534|NCT04308057||Sedentary.|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants who are sedentary (e.g., defined as undertaking less than 60 min of structured/planned physical activity per week), for a period longer than 6 months.
9536535|NCT04305405|Experimental|Dose 1|Below 35 kilos
9536536|NCT04305405|Experimental|Dose 2|Greater than/equal to 35 kilos
9536537|NCT04289051|Experimental|HYDRAL Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
9536538|NCT04289051|Active Comparator|BIOTENE® Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
9536539|NCT04289051|Placebo Comparator|Placebo Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
9536540|NCT04281147||No Ra-223 received|Patients did not receive Ra-223
10038969|NCT01839474|No Intervention|Control|Children will receive standard medical therapy.
10038970|NCT01839500||Cohort I: HER2-Positive mGC Treated With Trastuzumab|HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
10038971|NCT01839500||Cohort II: HER2-Positive mGC not Treated With Trastuzumab|HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
10038972|NCT01839500||Cohort III: HER2-Positive non-mGC|HER2-positive non-mGC participants will be included in this cohort.
9536541|NCT04281147||Early Ra-223 (2nd line)|Patients received Ra-223 in 2nd line
9536542|NCT04281147||Late Ra-223 (3rd or later lines)|Patients received Ra-223 in 3rd or later lines
9622055|NCT02518789|Experimental|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
9536543|NCT04275297|Experimental|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
9536544|NCT04275297|Placebo Comparator|Attention Control|The attention control condition consists of 8 weekly telephone calls with a study interventionist. Sessions will occur via scheduled telephone calls and follow a structured procedure. Telephone calls are designed to monitor symptoms and overall wellness. Each week, participants will be asked about current symptoms, flare patterns, and physical and emotional wellbeing.
9536545|NCT04272034|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
9536546|NCT04272034|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
9536547|NCT04272034|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
9536548|NCT04259281|Experimental|GTX-102 Cohort 4|3.3 mg for 3-4 monthly doses followed by a quarterly maintenance regimen
9536549|NCT04259281|Experimental|GTX-102 Cohort 5|5 mg for 3-4 monthly doses followed by a quarterly maintenance regimen
9536550|NCT04259281|Experimental|GTX-102 Cohort 6|2 mg for 4 monthly doses followed by a quarterly maintenance regimen of 2 mg
9536551|NCT04237792|Experimental|dexmedetomidine low dose group|low dose of dexmedetomidine to be given
9536552|NCT04237792|Experimental|dexmedetomidine middle dose group|middle dose of dexmedetomidine to be given
9536553|NCT04237792|Experimental|dexmedetomidine high dose group|high dose of dexmedetomidine to be given
9536554|NCT04233749|Experimental|Treatment|All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.
9536555|NCT04229095|Active Comparator|Belsomra,(suvorexant)|20 mg single-dose administration given on an inpatient clinical research unit
9536556|NCT04229095|Placebo Comparator|Placebo|Placebo single-dose administration given on an inpatient clinical research unit
9536557|NCT04214717|Experimental|Combination of DC-CIK with chemotherapy group|Patients will receive DC-CIK treatments combined with Chemotherapy .
9536558|NCT04214717|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
9536559|NCT04212728|Experimental|AMSCs plus PRP group|Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
9536560|NCT04212728|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
9536561|NCT04210180|Experimental|Varenicline plus e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. The FDA approved starter kit of varenicline will be provided to participants at V3 (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) along with additional G6 cartomizers. After the first week of varenicline, participants will receive the FDA-approved standard dose of varenicline (1 mg twice daily) and will continue to receive enough G6 cartomizers for the next 11 weeks.
9536562|NCT04195984|Experimental|Treatment|Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system
9536563|NCT04191967|Experimental|Thermocoagulation|Thermal ablation of cervix for treatment of CIN2/3 among HIV-positive women
9536564|NCT04175886||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with an indication for tofacitinib: 5mgx2 per day
9536565|NCT04175886||Healthy subjects|Healthy subjects matched to cases (1:1) on age (±5 years), sex, and menopausal status for women and body mass index (BMI, ±3 kg/m²)
9536566|NCT04174625|Experimental|Omega3-FA group|Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
9536567|NCT04174625|Experimental|Control group|VD3 group 50,000 IU/week
9536568|NCT04169737|Active Comparator|Arm I (acalabrutinib, venetoclax, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 3, patients receive venetoclax PO BID on days 1-28. Patients who are BM MRD4-positive or in PR also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 15 and day 1 of cycles 16-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
9536569|NCT04169737|Experimental|Arm II (acalabrutinib, venetoclax, early obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 beginning cycle 2 and venetoclax PO BID on days 1-28 beginning cycle 3. Patients also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and day 1 of cycles 2-6. Patients who are BM MRD4-positive or in PR receive obinutuzumab IV over 4-6 hours on day 1 cycles 15-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
9536570|NCT04167540|Experimental|Earlier stage PD|
9536571|NCT04167540|Experimental|Later stage PD|
10038973|NCT01839500||Cohort IV: HER2-Negative mGC|HER2-negative mGC participants will be included in this cohort.
9536572|NCT04167514|Experimental|AAT|Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration
9536573|NCT04167514|Placebo Comparator|Placebo|Albumin solution administered intravenously
9536574|NCT04166149||University of Maryland|Pancreas and pancreas kidney patients enrolled at University of Maryland. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
10038974|NCT01839500||Cohort V: HER2-Negative non-mGC|HER2-negative non-mGC participants will be included in this cohort.
10038975|NCT01839526|Other|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
10058387|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
9536575|NCT04166149||University of Wisconsin|Pancreas and pancreas kidney patients enrolled at University of Wisconsin. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
9536576|NCT04166149||Georgetown University|Pancreas and pancreas kidney patients enrolled at Georgetown University. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
9536577|NCT04158752|Experimental|Open Label Galcanezumab|Participants will receive their 1st injectable dose during the Day 30 visit. Participants will then inject themselves at home on Day 60 and again on Day 90.
9536578|NCT04147052|Experimental|iSLEEPms|Participants randomized to iSLEEPms complete a 4-week online program with telephone support, based on CBT-I.
9536579|NCT04147052|No Intervention|Treatment As Usual|Participants randomized to TAU continue their usual care and are encouraged to avoid starting any new sleep treatment unless deemed necessary by a health care provider.
9536580|NCT04140279|Experimental|Latanoprostene Bunod|Participants will receive LBN ophthalmic solution 0.024% in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
9536581|NCT04140279|Placebo Comparator|Placebo|Participants will receive Renu MultiPlus Lubricating and Rewetting Drops (placebo) in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
9536582|NCT04125069||Patients aged from 18 to 85 years|Cardiac surgery patients aged from 18 to 85 years,programmed for Coronary artery bypass graft requiring ECC.
9536583|NCT04123574|Experimental|Single Arm|BXCL701 will be administered for one week at a dose of 0.2 mg, twice daily (BID). If BXCL701 is well-tolerated after the first week of treatment, the dose will be increased to 0.3mg BID for a total daily dose of 0.6mg to all patients for the second week of treatment.
9536584|NCT04103138|Experimental|EEG-Guided Anaesthesia|Patients will have Sedline EEG sensor placed and anaesthesia guided by the EEG characteristics, patient state index (PSI) and suppression ratio (SR), in addition to routine clinical parameters.
9536585|NCT04103138|Active Comparator|Routine Care|Patients will have Sedline EEG sensor placed but the monitor is concealed so the clinician is blinded to the EEG response. Anaesthesia is guided by routine clinical parameters.
9536586|NCT04097223||Subjects with Pulmonary Disease, Chronic Obstructive|
9536587|NCT04089202|Active Comparator|In-person visit arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to an in-person visit with an Endocrinologist. This is currently the standard of care for patients referred for diabetes specialty care.~Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.~Surveys will be administered to measure patient burden and self efficacy."
9536588|NCT04089202|Experimental|Freestyle Libre sensor arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to have the Freestyle Libre Pro continuous glucose monitor (CGM) placed at their primary care clinic. The data collected from the diagnostic CGM will be utilized in conjunction with diet, exercise and medication logs provided by the patient and information from the patient's electronic medical record to complete an eConsult with treatment recommendations. Implementation of these recommendations will be per the primary care provider's discretion in conjunction with conversation with the patient in follow up visits.~Surveys will be administered to measure patient burden and self efficacy."
9536589|NCT04086121|Experimental|All Subjects|
9536590|NCT04078698|Experimental|Treatment with the IgG immunoadsorbers GLOBAFFIN® or LIGASORB®|Treatment with the IgG immunoadsorbers GLOBAFFIN® or LIGASORB® in clinical routine according to their intended use.
9536591|NCT04069624|Active Comparator|Services as Usual (SAU)|Substance abuse program (SAP) managed by the Kentucky Department of Corrections, with the option to initiate MOUD prior to jail release.
9536592|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth|Telehealth connection to a community MOUD provider.
9536593|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth and Peer Navigator|Telehealth connection to a community MOUD provider, in addition to a peer navigator
9536594|NCT04050449||Group 1: Switch to TLD from NNRTI first-line regimen|Participants switching to TLD from a first-line regimen containing a NNRTI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 1a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 1b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
9536595|NCT04050449||Group 2: Switch to TLD from boosted PI second-line regimen|Participants switching to TLD from a second-line regimen containing a boosted PI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 2a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 2b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
9536596|NCT04050449||Group 3: Concomitant TLD and RIF-containing TB treatment|Participants initiating concomitant TLD and RIF-containing TB treatment, with an additional daily dose of dolutegravir (DTG) 50mg. For participants already on RIF-containing TB treatment when TLD treatment is started, TLD treatment must be started within 8 weeks (56 days) of the start of RIF-containing TB treatment. Group 1, 2, or 4 participants who start RIF-containing TB treatment after enrollment will have additional evaluations at the start and end of concomitant HIV and TB treatment but will not be co-enrolled in Group 3 (their additional evaluations will, however, be considered when analyzing data from Group 3).
9536597|NCT04050449||Group 4: ART-naive initiating TLD therapy|Antiretroviral therapy (ART)-naïve participants initiating therapy with TLD
9536598|NCT04044001|Experimental|Stage 1 - Cohort 1 (BTZ 250)|Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14
10058388|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
9536599|NCT04044001|Experimental|Stage 1 - Cohort 2 (BTZ 500)|Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14
9536600|NCT04044001|Experimental|Stage 1 - Cohort 3 (BTZ 750)|Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14
9536601|NCT04044001|Experimental|Stage 1 - Cohort 4 (BTZ 1000)|Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14
9536602|NCT04044001|Experimental|Stage 1 - Cohort 5 (BTZ 1250)|Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14
9536603|NCT04044001|Experimental|Stage 1 - Cohort 6 (BTZ 1500)|Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14
9536604|NCT04044001|Experimental|Stage 1 - Cohort 7 (BTZ 1750)|Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14
9536605|NCT04044001|Experimental|Stage 1 - Cohort 8 (BTZ 2000)|Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14
9536606|NCT04044001|Experimental|Stage 2 - Arm 1 (BTZ high)|Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
9536607|NCT04044001|Experimental|Stage 2 - Arm 2 (BTZ medium)|Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
9536608|NCT04044001|Experimental|Stage 2 - Arm 3 (BTZ low)|Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
9536609|NCT04044001|Active Comparator|Stage 2 - Arm 4 (control)|"Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.~The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening:~participants weighing 38 - 54 kg: 3 tablets~participants weighing 55 - 70 kg: 4 tablets~participants weighing >70 kg: 5 tablets"
9536610|NCT04035408||All subjects|All the enrolled subjects will be considered for the assessment of the primary and secondary outcomes.
9536611|NCT04031729|Experimental|Aspirin|Low-dose (81mg) aspirin tablets
9536612|NCT04031729|Placebo Comparator|Placebo|Placebo tablets
9536613|NCT04028167|Experimental|Sequential FLOT followed by chemoradiation|Sequential Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/Leucovorin followed by chemoradiation with concurrent carboplatin and paclitaxel
9536614|NCT04026126|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline hemodynamic assessments as well as VO2max measurements. Subjects will complete 10 heat therapy treatments over the course of 14 days. Hemodynamics will be assessed with the use of the Clearsight© fingertip blood pressure cuff. Within 24-48 hours after the last heat therapy experience, hemodynamic assessments and VO2max will be performed. Blood samples will be collected pre- and post intervention and analyzed for levels of nitric oxide mediators, heat shock protein levels and pro-anti-inflammatory markers.
9536615|NCT04024670|Active Comparator|HRO|brief description do not too much
9536616|NCT04024670|Active Comparator|BMT|
9536617|NCT04024670|No Intervention|HRO Standard of Care|SOC
9536618|NCT04024670|No Intervention|BMT Standard of Care|SOC
9536619|NCT04022213|Experimental|Group A|Participants with DSRCT who have undergone GTR of their abdominopelvic disease and who have no definitive radiological evidence of disease in liver or outside the abd/pelvis. Patients if deemed of likely benefit to the patient after completing IP RIT plus WAP-IMRT, or will be mandated if ANC is persistently <500/ul despite use of G-CSF for >1 week, or if patients experience life threatening febrile neutropenia.
9536620|NCT04022213|Experimental|Group B|DSRCT patients who have macroscopic residual disease OR who have previously experienced progression of disease while on treatment but have subsequently had a GTR
9536621|NCT04022213|Experimental|Group C|Participants with tumors other than DSRCT and will be enrolled onto an assessment arm to determine eligibility. Immunohistochemistry to assess B7H3 expression will be performed on frozen or paraffin embedded tissue using omburtamab (frozen tissue) or a commercially available anti-B7H3 antibody (if paraffin embedded).
9536622|NCT04016558|Experimental|StreamLine|Diabetes education, behavioral management
9536623|NCT04016558|Experimental|TunedIn|Diabetes distress reduction, emotion regulation techniques.
9536624|NCT04016558|Experimental|FixIt|Unified program combining diabetes education, behavioral management, diabetes distress reduction, and emotion regulation techniques.
9536625|NCT04003766|Active Comparator|Percutaneous Biopsy|"The subject would undergo the standard of care procedure for a percutaneous biopsy of the liver.~All percutaneous biopsies will be performed after administration of local anesthetic. No pre-procedure antibiotics will be administered. Subcostal or subxyphoid area will be cleaned and draped in the standard manner. 2% lidocaine solution will be injected subcutaneously using a 25-gauge needle and then administered into the subcutaneous tissue up to the liver capsule. A 16-gauge biopsy needle is inserted into the liver parenchyma under US or CT-guidance, with the location of needle placement left to the discretion of the performing radiologist. One or two core biopsy samples will be obtained. All procured specimens will be placed in a single specimen container of 10% formalin for tissue processing. When biopsy samples have been obtained, the patient will be taken to the recovery area for post-procedure monitoring."
9616071|NCT04675996|Experimental|Phase 1/1b|"Phase 1: dose escalation phase with a 'hybrid' 3+3 design in all-comers cancer patients. Approximately 30 patients will be included.~Phase 1b: dose expansion phase in selected tumor types at the recommended phase 2 dose. Approximately 50 patients will be included."
9536626|NCT04003766|Active Comparator|Endoscopic-guided Ultrasound Biopsy|"The subject would undergo the standard of care procedure for an endoscopic-guided biopsy of the liver.~The left lobe of the liver is identified from the gastric lumen, EUS-guided fine needle biopsy (FNB) will be performed using a 19-gauge FNB needle, with the choice of needle type at the discretion of the performing endoscopist. Stylet will only be used to puncture the liver at the time of the first pass and then subsequently removed. No suction will be used. Fanning technique will not be used. A total of 10 to-and-fro needle movements will be performed during each pass. A total of two passes will be performed.All tissue specimens procured will be placed in a single specimen container of 10% formalin for tissue processing. When two passes are complete under EUS-guidance, the echoendoscope will be withdrawn from the patient and the patient will be taken to the recovery area for post-procedure monitoring."
9536627|NCT03997617|Other|Personalized Functional Profiling|
9616072|NCT04669288|Active Comparator|Treatment - Active|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered the active drug per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
9616073|NCT04669288|Placebo Comparator|Treatment - Placebo|Eligible patients will be randomly assigned to one of two treatment groups (1:1) and one arm will be administered placebo per the randomization schedule. Study medication will be provided to parents/guardians, along with instructions, for home-based administration. The first dose of the study medication will be administered before discharge from the ED.
9616074|NCT04649203|Experimental|Group 1|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 10 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 75 days
9616075|NCT04649203|Placebo Comparator|Group 2|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 10 days + Placebo, 2 tablets 2 times a day, for 75 days
9616076|NCT04648904|Experimental|Post-Mastectomy Radiotherapy|Treatment will consist of PMRT delivered using external beam RT techniques to a dose of 26 Gy in 5 fractions of 5.2 Gy delivered on consecutive weekdays with an optional chest wall boost of 5.2 Gy for 1-2 fractions or an alternate boost schedule of 2.5 Gy for 1-4 fractions at the discretion of the treating physician.
9616077|NCT04638569|Active Comparator|Ultrasound-guided obturator nerve block group|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle.
9616078|NCT04638569|Active Comparator|obtutaror nerve block with anatomical landmarks|In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL.
9616079|NCT04638465||A - Surgery Only|"Participants with the following diagnosis will receive transoral robotic surgery with neck dissection:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN0 or N1 (single node)~Tonsil - Stage: cT1-3, cN0 or N1 (single node)~Unknown primary - Stage: cT0 N1 (single node)~Radiation also given if indicated by intermediate or high risk features following surgery."
9616080|NCT04638465||B - Surgery with Adjuvant Therapy|"Participants with the following diagnosis will receive surgery followed by 6 Cycles of Cisplatin 40 mg/m2:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN1 (2-4 nodes) or N2~Tonsil - Stage: cT1-3, N1 (2-4 nodes)~Radiation also given if indicated by intermediate or high risk features following surgery."
9616081|NCT04638465||C - Concurrent Chemo/Radiation Therapy - Dose Level 1|"Participants with the following diagnosis will receive 6 Cycles of Cisplatin 40 mg/m2 + 60 Gy Radiation:~Tonsil - Stage: cT1-3, N2~Unknown Primary - Stage: cT0, N2"
9616082|NCT04638465||D - Concurrent Chemo/Radiation Therapy - Dose Level 2|"Participants with the following diagnosis will receive 7 Cycles of Cisplatin 40 mg/m2 + 70 Gy Radiation:~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT3-4, any N~Base of Tongue/Non-Tonsil Oropharynx - Stage: cAny T, N3~Tonsil - Stage: cT1-3, N3~Tonsil - Stage: cT4, any N~Unknown Primary - Stage: cT0, N3"
9616083|NCT04634253|Experimental|LY3462817 Low Dose|LY3462817 given intravenously (IV).
9616084|NCT04634253|Experimental|LY3462817 High Dose|LY3462817 given IV.
9616085|NCT04634253|Placebo Comparator|Placebo|Placebo given IV.
9616086|NCT04634162|Experimental|Cangrelor|Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
9616087|NCT04634162|Placebo Comparator|Placebo|Ticagrelor loading dose followed after 1 hour by placebo infusion
9616088|NCT04633148|Experimental|UniCAR02-T-pPSMA|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the peptide TMpPSMA.
9616089|NCT04632576|Experimental|auricular acupuncture|"auricular acupuncture is one of the many forms of acupuncture, and is a distinctive part of Chinese medicine that has been practiced in China for thousands of years. It is employed by placing fine needles in specifically designated puncture points on the external ear."
9616090|NCT04632576|No Intervention|Control|No intervention is given.
9616091|NCT04627753|Experimental|Lenalidomide and Rituximab therapy|"The clinical trial drug is administered in one cycle for 28 days and is administered as follows.~Drug : Rituximab It will be administered 375 mg/m² IV infusion Day 1. (Rituximab: up to 6 cycles)~Drug : Lenalidomide It will be administred 20 mg PO day 1 -21.~The medication is taken for up to 2 years, and if there is no recurrence, it is stopped after 2 years~, Or stop when disease progression is confirmed during the administration period."
9616092|NCT04616625||Methamphetamine exposed|Infants born to mothers with prenatal history of MA use during current pregnancy and/or positive meconium toxicology positive for MA in infant.
9616093|NCT04616625||Methamphetamine non-exposed|Infants born to mothers without prenatal history of MA use during this pregnancy and negative meconium toxicology for MA in infant.
9622056|NCT02518789|Placebo Comparator|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
9536628|NCT03993665||affected|All patients with a histologically confirmed squamous cell carcinoma in the head and neck region
9536629|NCT03993665||control|Whartin tumour or pleomorphic adenoma of the parotid gland without malignant transformation
9536630|NCT03992729||Tildrakizumab-Exposed Cohort|Exposure to tildrakizumab for the treatment of an approved indication
9536631|NCT03992729||Disease-Matched Comparison Cohort|No exposure to tildrakizumab at any time in the current pregnancy
9536632|NCT03991533||affected|patients with a histologically confirmed head and neck tumour
9536633|NCT03991533||control|histologically confirmed Whartin tumour or pleomorphic adenoma of the parotid gland, without malignant transformation
9536634|NCT03985072|Experimental|Andes-1537|There will be 5 different cohorts each representing a different type of solid cancer (gallbladder and biliary tract cancer, cervical cancer, gastric cancer, pancreatic cancer, and colorectal cancer). All patients will receive a dose of 400 mg of Andes-1537 five days per week for continuous cycles of 4 weeks that will be repeated until the patients presents drug toxicity requiring treatment discontinuation or disease progression without any noted clinical benefit as assessed by the investigator.
9536635|NCT03983564||All patients|Patients in this group will serve to validate the cutoff of the combination of the DES-OSA and BOSTON scores derived in the retrospective group.
9536636|NCT03982030|Experimental|Dalbavancin|Participants with susceptible gram-positive infections requiring prolonged parenteral antibiotic therapy will be treated with dalbavancin.
9536637|NCT03977363||Anticoagulated patients|Patients receiving anticoagulation treatment
9536638|NCT03971110|Experimental|Zoladex and Casodex|Subjects who are diagnosed with advanced prostate cancer at clinical stage of T3 and T4 (N0 or N1, M0 or M1 with five or fewer extra-pelvic lesions) are the target population of this study. The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
9536639|NCT03942653|Experimental|Goserelin Acetate + Pembrolizumab|Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV
9536640|NCT03897075|Experimental|Arm A|
9536641|NCT03897075|Placebo Comparator|Arm B|
9536642|NCT03840642|Active Comparator|Mirror Me|Parents randomized to the Mirror Me condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then they will be told their condition and to continue to use the website and practice what they have learned with their children.
9536643|NCT03840642|Experimental|Mirror Me Plus Remote Coaching|Parents randomized to the Mirror Me plus remote coaching condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then all parents in this condition will be told about the opportunity to participate in remote video teleconferences once per week for 5 weeks. Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week. Sessions will be recorded for data collection and therapist coaching fidelity. Participants will have access to Mirror Me for the duration of the research study.
9536644|NCT03805789|Experimental|AAT (low dose)|Open label. Alpha-1 antitrypsin (AAT) is a lyophilized product for intravenous administration
9536645|NCT03805789|Experimental|AAT (medium dose)|Open label. AAT is a lyophilized product for intravenous administration
9536646|NCT03805789|Experimental|AAT (high dose)|Open label. AAT is a lyophilized product for intravenous administration
9536647|NCT03805789|Experimental|AAT (selected dose from open-label)|Double-blind. AAT is a lyophilized product for intravenous administration
9536648|NCT03805789|Placebo Comparator|Placebo|Albumin solution administered intravenously
9536649|NCT03786926|Experimental|Treatment|All patients take HMPL-689 taken daily
9536650|NCT03783546|Experimental|Immediate Acupuncture|"Will receive a standardized acupuncture protocol for a 10-week period~20 sessions: twice a week for 10 weeks~After the completion of the 10 weeks main study period, participants will cross over to the usual care as a follow-up without acupuncture for additional 10 weeks."
9536651|NCT03783546|Active Comparator|Delayed acupuncture|"Will receive standard usual care without acupuncture for 10 weeks~Participants will cross over to receive the same acupuncture protocol for 10 weeks --10 sessions: once a week for 10 weeks before exiting the study"
9536652|NCT03752827|Experimental|Adipose Derived Regenerative Cells|Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear
9536653|NCT03752827|Active Comparator|Corticosteroid|Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.
9536654|NCT03744468|Experimental|Phase 1 Dose Escalation|Dose escalation of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors
9536655|NCT03744468|Experimental|Phase 2 Dose Expansion|Further explore the safety and clinical activity of BGB-A425 in combination with tislelizumab in participants with NSCLC, HNSCC and RCC.
9536656|NCT03739372|Experimental|Newly diagnosed HGG (Stratum A)|Children and young adults with newly diagnosed HGG receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
9536657|NCT03739372|Experimental|Diffuse midline HGG (Stratum B)|Children and young adults with diffuse midline high grade gliomas receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
9536658|NCT03718299|Other|tildrakizumab 100 mg|
9536659|NCT03685591|Experimental|Dose Level 1 (Part 1A)|PF-06952229 at 20mg twice daily (BID)
9536660|NCT03685591|Experimental|Dose Level 2 (Part 1A)|PF-06952229 at 40 mg BID
9536661|NCT03685591|Experimental|Dose Level 3 (Part 1A)|PF-06952229 at 80 mg BID
9536662|NCT03685591|Experimental|Dose Level 4 (Part 1A)|PF-06952229 at 150 mg BID
9536663|NCT03685591|Experimental|Dose Level 5 (Part 1A)|PF-06952229 at 250 mg BID
9536664|NCT03685591|Experimental|Dose Level 6 (Part 1A)|PF-06952229 at 375 mg BID
10038976|NCT01839539|No Intervention|B|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
10038977|NCT01839539|Experimental|A|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
9536665|NCT03685591|Experimental|Dose Level 7 (Part 1A)|PF-06952229 at 500 mg BID
9536666|NCT03685591|Experimental|Dose Level 8 (Part 1A)|PF-06952229 at 625 mg BID
9536667|NCT03685591|Experimental|Dose Level 9 (Part 1A)|PF-06952229 at 750 mg BID
9536668|NCT03685591|Experimental|Prostate Cancer Dose Level 1 (Part 1B)|PF-06952229 at 375 mg BID in combination with enzalutamide
9536669|NCT03685591|Experimental|Prostate Cancer Dose Level 2 (Part 1B)|PF-06952229 at 500 mg BID in combination with enzalutamide
9536670|NCT03685591|Experimental|Prostate Cancer Dose Level 3 (Part 1B)|PF-06952229 at 625 mg BID in combination with enzalutamide
9536671|NCT03685591|Experimental|Prostate Cancer Dose Level 4 (Part 1B)|PF-06952229 at 750 mg BID in combination with enzalutamide
9536672|NCT03685591|Experimental|Prostate Cancer (Part 2A)|PF-06952229 at recommended Phase 2 Dose BID
9536673|NCT03685591|Experimental|Prostate Cancer (Part 2B)|PF-06952229 at recommended phase 2 dose BID in combination with enzalutamide
9536674|NCT03675308|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 208.
9536675|NCT03675308|Experimental|Risankizumab|Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 208.
9536676|NCT03651206|Experimental|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
9536677|NCT03651206|Experimental|Arm B - Niraparib + TSR-042 (Dostarlimab)|"Niraparib, 200 mg or 300 mg, daily dose~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
9536678|NCT03651206|Active Comparator|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
9536679|NCT03625765|Experimental|SmartGoggles|The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. Investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nanomolar (nM) concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with optical density (OD) 6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
9536680|NCT03575364||Primary Analytic|Patients with unilateral acute or subacute DVT of less than 6 weeks' duration.
9536681|NCT03575364||Registry|Patients with proximal lower extremity DVT.
9536682|NCT03573817|Experimental|Period 1: Revefenacin + Formoterol (Sequential)|Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
9536683|NCT03573817|Experimental|Period 2: Revefenacin + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
9536684|NCT03573817|Placebo Comparator|Period 1: Placebo + Formoterol (Sequential)|Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
9536685|NCT03573817|Placebo Comparator|Period 2: Placebo + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
9536686|NCT03552276|Experimental|SUNPG18_07 q4 weeks, high dose|
9536687|NCT03552276|Experimental|SUNPG18_07 q12 weeks, high dose|
9536688|NCT03552276|Experimental|SUNPG18_07 q12 weeks, low dose|
9536689|NCT03518359|Experimental|Mental Training for Residents|The intervention will be the modified form of Mindfulness-Based Stress Reduction (MBSR). For this study investigator named the experimental arm Enhanced Stress Resilience Training (ESRT).
9536690|NCT03518359|Active Comparator|Active Control|"Active control that emphasizes externalized attention via the shared reading and listening model."
9536691|NCT03446521||Test group|Patients undergoing liver transplantation, no intervention (study-specific) is planed
9536692|NCT03446521||Control Group|Respective organ donors of the included liver recipients, no intervention (study-specific) is planed
9536693|NCT03318861|Experimental|Dose Escalation: 3 x 10^7 KITE-585|Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 autologous anti-B-cell maturation antigen (BCMA) CAR T cells at a dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
9536694|NCT03318861|Experimental|Dose Escalation: 1 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
9536695|NCT03318861|Experimental|Dose Escalation: 3 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 3 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
9536696|NCT03318861|Experimental|Dose Escalation: 1 x 10^9 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^9 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
9536697|NCT03318861|Experimental|Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585|RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min [Grade 2 chronic kidney disease]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 24 mg/m^2/day IV infusion for 3 days followed by a single intravenous infusion of KITE-585 anti-autologous BCMA CAR T cells at a tolerable dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
9536698|NCT03170349|Experimental|Edwards PASCAL Transcatheter Mitral Valve Repair System|
9536699|NCT03119064|Experimental|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 1 50mg/m2 IV every 2 weeks"
9536700|NCT03119064|Experimental|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 2 70 mg/m2 IV every 2 weeks"
9536701|NCT03119064|Experimental|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 3 80mg/m2 IV every 2 weeks"
9536702|NCT03117933|Active Comparator|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
9536703|NCT03117933|Experimental|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
9536704|NCT03117933|Experimental|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
9536705|NCT03107871|Experimental|Arm A|Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months
9536706|NCT03107871|Placebo Comparator|Arm B|Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months
9536707|NCT03098511|Other|Neurological Diagnostic Evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.
9536708|NCT03097328|Experimental|TAK-228|"TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle~Dosage will be determined by the study team"
9536709|NCT03095456|Experimental|Revefenacin|Active Revefenacin and placebo (in place of Spiriva Handihaler®)
9536710|NCT03095456|Active Comparator|Spiriva Handihaler®|Active Spiriva Handihaler® and placebo (in place of Revefenacin)
9536711|NCT03093844|Experimental|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
9536712|NCT03087448|Experimental|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.~PHASE II Cohort A (ALKi Naïve): those who have had no prior ALK inhibitor therapy (prior chemotherapy or immunotherapy is allowed). Aim 20 evaluable patients.~Cohort B (Post-crizotinib PD): those who have received prior treatment with crizotinib and documented disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Aim 21 evaluable patients.~Cohort C (PD on 2nd generation ALKi): those who have received prior treatment with 2nd generation ALKi (e.g. ceritinib, alectinib, loratinib, or brigatinib) and documented disease progression by RECIST 1.1 criteria. Aim 10 evaluable patients.~The Phase II doses will be determined by Phase I dose escalation study"
9536713|NCT03084523|Experimental|1|60 patients with intracranial atherosclerosis
9536714|NCT03084523|Experimental|2|20 patients with intracranial aneurysm
9536715|NCT03070301|Experimental|LEE011 and everolimus|Subjects will receive LEE011 200 mg daily, in combination with everolimus 5 mg daily; in the setting of toxicity, everolimus dosing will be changed to 2.5 mg daily or 2.5 mg every other day. Subjects will continue treatment until meeting one of the criteria for removal from study.
9536716|NCT03067844|Experimental|Alirocumab|Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
9536717|NCT03067844|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
9536718|NCT03064113|Experimental|Sequence 1|Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
9536719|NCT03064113|Experimental|Sequence 2|Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
9536720|NCT03064113|Experimental|Sequence 3|Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
9536721|NCT03064113|Experimental|Sequence 4|Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo
9536722|NCT03053310||Primary (P) - group|"Patients with a primary diagnosis~Patients treated with curative intent (stage I-IVb)"
10038978|NCT01839552|Experimental|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
9536723|NCT03053310||Relapse (R) - group|"Patients with a recurrent (loco)regional tumour~Patients treated with curative intent (stage I-IVb)"
9536724|NCT03053037|Active Comparator|Group S|mesial canals in Group S will be instrumented to size 25
9536725|NCT03053037|Active Comparator|Group L|mesial canals in Group L will be instrumented to size 35
9536726|NCT03051477|Experimental|Helixor® M|Advanced solid tumors
9536727|NCT03049540|Active Comparator|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
9536728|NCT03049540|Placebo Comparator|Placebo|Placebo 20 MG, p.o., once per day for 3 years
9536729|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
9536730|NCT03019653|Active Comparator|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
9536731|NCT03019653|Active Comparator|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
9536732|NCT02949700|Experimental|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
9536733|NCT02940769|Experimental|light glasses|Study subjects will wear light glasses
9536734|NCT02940769|Sham Comparator|sham glasses (placebo)|Study subjects will wear sham glasses
9536735|NCT02938013|Experimental|Group A|Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
9536736|NCT02938013|Active Comparator|Group B|Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
9536737|NCT02938013|Active Comparator|Group C|HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
9536738|NCT02919683|Experimental|Nivolumab With Ipilimumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Ipilimumab to be delivered at a pre-determine dose for one week~Blood Sample Collected~Standard of Care Surgery"
9536739|NCT02919683|Experimental|Nivolumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Blood Sample Collected~Standard of Care Surgery"
9536740|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
9536741|NCT02901548|Experimental|Durvalumab Plus Cystoscopy|Durvalumab: Fixed dose level IV infusion every 4 weeks for 13 study treatment cycles/infusions over 12 months/1 year. Cystoscopy with biopsy will be performed every 3 months to monitor the treatment response during this one year of treatment phase. It will be performed every 6 months during year 2 of the surveillance phase.
9536742|NCT02899858|Experimental|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
9536743|NCT02890459|Active Comparator|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
9536744|NCT02890459|Experimental|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
9536745|NCT02890459|Experimental|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
9536746|NCT02890459|Active Comparator|Aim 2 - Standard Care|Standard care Travel voucher
9536747|NCT02890459|Experimental|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
9536748|NCT02890459|Experimental|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
9536749|NCT02890459|Experimental|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
9536750|NCT02890459|No Intervention|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
9536751|NCT02890459|Experimental|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
9536752|NCT02890459|Experimental|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
10038979|NCT01839565||Patients|Patients undergoing osteosynthesis of acetabular fractures by using the Quadrilateral Surface Plate
9536753|NCT02890459|No Intervention|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
9536754|NCT02883387|Experimental|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
9536755|NCT02883387|Active Comparator|No Imaging Preoperatively|No preoperative vessel mapping will be done
9622057|NCT02518880|Other|Plasma volume measurements|
10038980|NCT01839578|Experimental|RCA Group|SHF-CVVHD with regional citrate anticoagulation
10038981|NCT01839578|Experimental|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
10038982|NCT01839591|Experimental|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
9536756|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
9536757|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (~2010) to 2013
9536758|NCT02820311|Experimental|TD-4208 175 mcg|double-blind
9536759|NCT02820311|Experimental|TD-4208 700 mcg|double-blind
9536760|NCT02820311|Placebo Comparator|Placebo for TD-4208|double-blind
9536761|NCT02820311|Active Comparator|Moxifloxacin 400 mg|open-label
9536762|NCT02812667|Experimental|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
9536763|NCT02797275|Experimental|Albuterol & Placebo|Participants will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) after the completion of the baseline screening visit. They will use albuterol for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the placebo treatment for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
9536764|NCT02797275|Experimental|Placebo & Albuterol|Participants will be placed on the placebo treatment after the completion of the baseline screening visit. They will use placebo for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
9536765|NCT02797184|Experimental|Aim 1. KNO3 dose response|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
9536766|NCT02790138|Placebo Comparator|Placebo IV|Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
9536767|NCT02790138|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
9536768|NCT02783625|Experimental|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
9536769|NCT02783625|Experimental|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11* Bortezomib subcutaneous injection, days 1, 4, 8, 11** duvelisib by mouth twice daily, days 1-28
10038983|NCT01839617|Active Comparator|Early parenteral nutrition|Parenteral nutrition starts at 2nd postoperative day.
10038984|NCT01839617|Active Comparator|Late parenteral nutrition|Parenteral nutrition starts at 7th postoperative day.
10038985|NCT01839630||Group 1|
10038986|NCT01839643|Experimental|2.4 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
9622058|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
9622059|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
9622060|NCT02518867|Experimental|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
10038987|NCT01839643|Experimental|3.0 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
10038988|NCT01839669|Active Comparator|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
10038989|NCT01839669|Experimental|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
10038990|NCT01839669|Sham Comparator|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
10038991|NCT01839721|Active Comparator|Bifilact® probiotics standard dose|concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
10038992|NCT01839721|Active Comparator|Bifilact® probiotics high dose|containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
10038993|NCT01839721|Placebo Comparator|placebo|Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day
10038994|NCT01839734|Experimental|Arm A|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
10038995|NCT01839734|No Intervention|Arm B|No intervention
10038996|NCT01839747|Experimental|Imaging|PET-MRI PET-CT
10038997|NCT01839760||Inpatient cohort|Patients admitted to general wards
10038998|NCT01839760||ICU cohort|Patients admitted to ICU
10038999|NCT01839773|Experimental|DHP107 (oral paclitaxel)|DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
10039000|NCT01839773|Active Comparator|Taxol® (IV paclitaxel)|Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
10039001|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
10039002|NCT01839812|Other|cosyntropin stimulation test|All patients enrolled in the study are administered cosyntropin stimulation tests to assess their adrenal response.
10039003|NCT01839825|Experimental|QuietCare|QuieCare system installed
10039004|NCT01839825|No Intervention|control|no system installed
10039005|NCT01839838|Experimental|APBI with protons|
10039006|NCT01839851||Asthma|Treatment with any inhaled corticosteroid
10039007|NCT01839851||Allergic rhinitis|Treatment with any intranasal glucocorticoid
10039008|NCT01839851||Asthma and allergic rhinitis|Inhaled corticosteroid + intranasal glucocorticoid
10039009|NCT01839864|Experimental|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
10039010|NCT01839877|Experimental|HIA DEBIRI + systemic FOLFOX|Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX
10039011|NCT01839890|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
10039012|NCT01839890|Active Comparator|Bare metal Stent|Conventional Bare Stent
10039013|NCT01839903|Active Comparator|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
9536780|NCT02772159|Experimental|Study Population|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
9536781|NCT02744053|Experimental|Diagnostic (DCE-MRI, MBI)|Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
9536782|NCT02726997|Experimental|Treatment (durvalumab, carboplatin, paclitaxel, questionnaire)|"NEOADJUVANT CHEMOTHERAPY: Before debulking surgery, patients receive durvalumab and carboplatin IV over 1 hour on day 1, and paclitaxel IV over 3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo debulking surgery.~SURGERY: After 3 courses of chemotherapy, patients undergo debulking laparoscopic surgery.~ADJUVANT THERAPY: Beginning after debulking surgery, patients receive carboplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on days 1, 8, and 15, and durvalumab IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive durvalumab IV over 1 hour on day 1 and 15. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity."
9536783|NCT02723994|Experimental|Ruxolitinib in combination with chemotherapy|
9536784|NCT02677922|Experimental|AG-120 + Azacitidine|
9536785|NCT02677922|Experimental|AG-221 + Azacitidine|
9536786|NCT02677922|Experimental|Azacitidine|
9536787|NCT02669173|Experimental|Treatment: Capecitabine + Bevacizumab|Capecitabine, PO dose to be determined by phase 1 dose escalation, cycle length 28 days. Treated with Bevacizumab, IV, 10 mg/kg days 1, 15 every 28 days, until progression.
9536788|NCT02665338|Sham Comparator|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
9536789|NCT02665338|Active Comparator|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
9536790|NCT02663297|Experimental|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10^7 cells/m^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10^8/m^2) given in the same trial.~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
10039014|NCT01839903|Active Comparator|Care as usual|Care as usual in the ED will be tracked
10039015|NCT01839929|Experimental|Prograf/Advagraf|conversion from Prograf to Advagraf
10039016|NCT01839942||no gap closure|no hernia gap closure
10039017|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure~extracorporal suturing of gap"
10039018|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
10039019|NCT01839955|Experimental|Arm I (Dose Escalation Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.
10039020|NCT01839955|Experimental|Arm II (Extension Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
10039021|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
10039022|NCT01839981|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
10058389|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
10058390|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
10058391|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
10039023|NCT01839994|Experimental|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
10039024|NCT01839994|Active Comparator|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
10039025|NCT01840007|Experimental|Metformin|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
10039026|NCT01840020||Gastric bypass|patients recruited from Central Norway
10039027|NCT01840020||Gastric sleeve|patients recruited from Central Norway
10058392|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
9536793|NCT02642315|Other|open-label|"open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days."
9536794|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
9536795|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
9536796|NCT02633163|Experimental|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution
9536797|NCT02633163|Experimental|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution
9536798|NCT02633163|Placebo Comparator|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
9536799|NCT02631447|Experimental|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
9536800|NCT02631447|Experimental|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
9536801|NCT02631447|Experimental|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
9536802|NCT02591030|Placebo Comparator|GEMCIS|
9536803|NCT02591030|Experimental|mFOLFIRINOX|
9536804|NCT02586831|Experimental|Arm A|"Participants in this group will receive Thymoglobulin, Aldesleukin, Adalimumab, and Exenatide over a period of 52 weeks.~Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2~Adalimumab (Humira®) will be administered at a dose of 50 mg every month, for 1 year~Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®) will be administered 1 million IU/dose; 5 consecutive days (days 10-14), & then every 2 weeks, for 52 weeks~Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks."
9536805|NCT02586831|Placebo Comparator|Arm B|Participants in this group will receive the placebos for Thymoglobulin, Aldesleukin, Adalimumab, Exenatide, and Neulasta over a period of 52 weeks.
9536809|NCT02581592|Experimental|Hepatic Impairment|Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.
9536810|NCT02581592|Experimental|Normal Hepatic Function|Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.
9536811|NCT02578082|Experimental|Renal Impairment|Eight subjects with Severe Renal Impairment (eGFR <30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.
9536812|NCT02578082|Experimental|Normal Renal Function|"Eight healthy participants matched to participants with severe renal impairment.~Intervention is TD-4208, 175mcg, inhaled, single dose."
9536813|NCT02574910|Experimental|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
9536814|NCT02574910|Experimental|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
9622061|NCT02518867|Experimental|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
9622062|NCT02518867|Sham Comparator|sham iTBS|sham iTBS for 3 days.
9536815|NCT02574910|Experimental|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
9536816|NCT02573766|Experimental|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
9536817|NCT02573766|Sham Comparator|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
9536818|NCT02573766|Other|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
9536819|NCT02518139|Experimental|TD-4208-1|88 mcg
9536820|NCT02518139|Experimental|TD-4208-2|175 mcg
9536821|NCT02518139|Active Comparator|Tiotropium|18 mcg
9536822|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.2 μg/d)|
9536823|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.4 μg/d)|
9536824|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.8 μg/d)|
9536825|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (1.6 μg/d)|
9536826|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (3.2 μg/d)|
9536827|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (6.5 μg/d)|
9536828|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (13 μg/d)|
9536829|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (25 μg/d)|
9536830|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (50 μg/d)|
9536831|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (100 μg/d)|
9536832|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (200 μg/d)|
9536833|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (400 μg/d)|
9536834|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (800 μg/d)|
9536835|NCT02512510|Active Comparator|TD-4208-1|88 mcg
9536836|NCT02512510|Active Comparator|TD-4208-2|175 mcg
9536837|NCT02512510|Placebo Comparator|Placebo|Placebo
9536838|NCT02509520|No Intervention|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
9536839|NCT02509520|Active Comparator|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
9536840|NCT02459080|Active Comparator|TD-4208-1|88 mcg
9536841|NCT02459080|Active Comparator|TD-4208-2|175 mcg
9536842|NCT02459080|Placebo Comparator|Placebo|Placebo
9536843|NCT02419417|Experimental|Monotherapy Treatment|Patients treated at various doses and schedules
9536844|NCT02419417|Experimental|Combination Therapy|Patients treated at selected doses and schdules
9536845|NCT02383251|Experimental|Pazopanib/Paclitaxel association|"Arm 1 :~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Then:~Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
9536846|NCT02383251|Active Comparator|Paclitaxel alone|"Arm 2 :~Paclitaxel 80mg/m2 i.v. on days 1, 8, 15~every 28 days until progression of disease or toxicity"
9536847|NCT02248701|Experimental|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
9536848|NCT02248701|Placebo Comparator|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
9536849|NCT02245672|Experimental|MGR001|MGR001 administered two times per day by inhalation throughout the study
9536850|NCT02245672|Active Comparator|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
9536851|NCT02245672|Placebo Comparator|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
9536852|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
9536853|NCT02129751|Experimental|bupropion hydrobromide|study drug
9536854|NCT02129751|Placebo Comparator|placebo|placebo
9536855|NCT02109172|Experimental|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
9536856|NCT02109172|Placebo Comparator|Placebo|Placebo inhalation solution twice daily for 7 days
9536857|NCT02109172|Experimental|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
9616094|NCT04612946|Experimental|Intervention Arm|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit and asked for permission to be referred (name and phone number) to the LCS navigator at Penn Medicine to schedule a telemedicine visit. Patients will also be given the option to directly contact the LCS navigator.
9616095|NCT04612946|Active Comparator|Control Arm|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their primary care providers.
9616096|NCT04604275|Experimental|Sucrase intervention followed by placebo|Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.
9482533|NCT03556956|No Intervention|Best Supportive Care|Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
9482534|NCT03554356|Experimental|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
9482535|NCT03553498|Experimental|IV hydromorphone and IV acetaminophen|"1000 mg IV acetaminophen administered over 5-10 minutes~1 mg hydromorphone administered over 5-10 minutes"
9482536|NCT03553498|Placebo Comparator|IV hydromorphone and placebo|"100 ml IV normal saline administered over 5-10 minutes~1 mg hydromorphone administered over 5-10 minutes"
9482537|NCT03548116|Sham Comparator|Group 1|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
9482538|NCT03548116|Experimental|Group 2|Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
9482539|NCT03548116|Experimental|Group 3|Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
9482540|NCT03548116|Sham Comparator|Group 4|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
9482541|NCT03548116|Experimental|Group 5|Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
9482542|NCT03548116|Experimental|Group 6|Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
9482543|NCT03548116|Sham Comparator|Group 7|Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
9482544|NCT03546907|Experimental|SAR440340|Administration of SAR440340 monotherapy injection
9482545|NCT03546907|Placebo Comparator|Placebo|Administration of matching placebo for injection of SAR440340
9482546|NCT03545321|Experimental|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
9482547|NCT03543410|Experimental|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
9482548|NCT03543410|Experimental|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets)
9482549|NCT03543410|Placebo Comparator|Placebo|Placebo (supplied in two tablets/day
9482550|NCT03542669|Experimental|6B11-OCIK injection|
9482551|NCT03541655|Active Comparator|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
9482552|NCT03541655|Experimental|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
9482553|NCT03541200|Experimental|Open Label|MT-8554
9482554|NCT03533660|Active Comparator|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
9482555|NCT03533660|Active Comparator|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
9482556|NCT03530293|Experimental|Valbenazine|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
9482557|NCT03530293|Placebo Comparator|Placebo|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
9482558|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
9482559|NCT03522597||Obese|Obese (BMI) women and their infants
9482560|NCT03522597||Diabetic|Women with gestational diabetes and their infants
9482561|NCT03521934|Experimental|Sotagliflozin|Sotagliflozin dose 1, once daily with possible uptitration in the first 8 months to dose 2
9482562|NCT03521934|Placebo Comparator|Placebo|Placebo dose 1, once daily with possible uptitration in the first 8 months to dose 2
9482563|NCT03521687|Experimental|Apremilast|Patients with CCCA
9482564|NCT03520036|Experimental|MT-7117 low dose|
9482565|NCT03520036|Experimental|MT-7117 high dose|
9482566|NCT03520036|Placebo Comparator|Placebo|
9482567|NCT03519711|Experimental|Cohort 1: CNSA-001 2.5 mg/kg/day or 10 mg/kg/day|Participants will receive CNSA-001 suspension 2.5 milligrams (mg)/kilogram (kg)/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 10 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
9482568|NCT03519711|Experimental|Cohort 2: CNSA-001 5 mg/kg/day or 20 mg/kg/day|Participants will receive CNSA-001 suspension 5 mg/kg/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 20 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
9482569|NCT03518138|Experimental|Group 1, study drug|65 patients treated with Q-122, 100 mg BID
9482570|NCT03518138|Placebo Comparator|Group 2, placebo|65 patients treated with placebo
9482571|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^10 colony-forming units [CFU]) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9482572|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9536858|NCT02106598|Experimental|Phase 2 - Head and Neck Cancer|Patients with early oral cavity squamous cell carcinoma, and prior to standard of care wide local resection of the primary tumor and elective neck dissection, will receive a locally-administered, peritumoral injection of fluorescent cRGDY-PEG-Cy5.5-C dots (0.25 - 1 ml) around the primary lesion while under standard-of-care anesthesia for identification of optically-avid SLNs and to assess for metastatic disease. After completion of the neck dissection, nodal specimens will be examined ex vivo for fluorescence signal. Any fluorescent and non-fluorescent nodes will be compared to determine the true positive and false positive rates for cancer detection in this pilot study. No change in standard of care surgical practice will occur.
9536859|NCT02070705|Experimental|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
9536860|NCT02070705|Experimental|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
9536861|NCT02070705|Experimental|Arm III (Pancreatic cancer)|Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection
9536862|NCT02070705|Active Comparator|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
9536863|NCT02043158||Ovarian Cancer Survivors|Short-term and long-term ovarian cancer survivors
9536864|NCT02040792|Placebo Comparator|Placebo|Placebo
9536865|NCT02040792|Experimental|44 mcg|TD-4208
9536866|NCT02040792|Experimental|88 mcg|TD-4208
9536867|NCT02040792|Experimental|175 mcg|TD-4208
9536868|NCT02040792|Experimental|350 mcg|TD-4208
9536869|NCT01979536|Experimental|Arm BV (brentuximab vedotin, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.~COURSE B (CYCLES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5."
9536870|NCT01979536|Experimental|Arm CZ (crizotinib, combination chemotherapy)|"COURSE A (CYCLES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.~COURSE B (CYCLES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B."
9536871|NCT01979003|Experimental|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
9536872|NCT01959633|Experimental|Vemurafenib+Cobimetinib + Peg-interferon|Vemurafenib 960 mg b.i.d. + Cobimetinib 60 mg o.d.(21 days on followed by 7 days off) + Peg-interferon 1/2/3 micrograms/Kg once weekly
9536873|NCT01936688|Experimental|MK-3222 200 mg + Placebo to Etanercept|MK-3222 200 mg subcutaneously (SC) on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
9536874|NCT01936688|Experimental|MK-3222 100 mg + Placebo to Etanercept|MK-3222 100 mg SC on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
9536875|NCT01936688|Placebo Comparator|Placebo to MK-3222 + Placebo to Etanercept|Placebo to MK-3222 administered SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12, then once weekly up to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive MK-3222 high dose or MK-3222 low dose on Weeks 12, 16, and 28 and, optionally, every 12 weeks thereafter through Week 220.
9536876|NCT01936688|Active Comparator|Placebo to MK-3222 + Etanercept 50 mg|Matching placebo to MK-3222 SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and then once weekly through Week 28.
10039028|NCT01840033|Active Comparator|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
10039029|NCT01840033|Experimental|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
10058393|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
9536880|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
9536881|NCT01861496|Experimental|LiPlaCis|Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.
9616097|NCT04604275|Experimental|Placebo followed by sucrase intervention|Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.
9616098|NCT04602949|Experimental|COVID-19 patients|subjects who were found as COVID-19 positive patients by swab RT-PCR
9616099|NCT04602949|Other|Healthy controls|subjects who were found as COVID-19 Negative, by swab RT-PCR
9482573|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9482574|NCT03516487|Experimental|SAD HV SB: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1). On Day 1, subjects in this cohort receive a solid breakfast (SB) that contains approximately the same amount of calories and protein as the meal supplement shake given to subjects in the other SAD cohorts.
9482575|NCT03516487|Experimental|SAD HV: SYNB1618 (2 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (2 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9482576|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9482577|NCT03516487|Placebo Comparator|SAD HV: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9482578|NCT03516487|Experimental|SAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive a single oral dose of SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9482579|NCT03516487|Placebo Comparator|SAD PKU: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
9482580|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive oral SYNB1618 (1 x 10^10 CFU) in a chilled buffered solution 3 times per day (TID) for 7 days in the MAD study (Part 2).
9482581|NCT03516487|Experimental|MAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive oral SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
9482582|NCT03516487|Experimental|MAD HV: SYNB1618 (7 x 10^10 CFU)|HV subjects receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
9482583|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive oral SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
9482584|NCT03516487|Placebo Comparator|MAD HV: Placebo|HV subjects receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
9482585|NCT03516487|Experimental|MAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
9482586|NCT03516487|Placebo Comparator|MAD PKU: Placebo|Subjects with PKU receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
9482587|NCT03515044|Experimental|Cohort 1 40 mg Rifaximin SSD once daily|40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
9482588|NCT03515044|Experimental|Cohort 2 40 mg Rifaximin SSD twice daily|40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
9482589|NCT03515044|Experimental|Cohort 3 80 mg Rifaximin SSD once daily|80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
9482590|NCT03515044|Experimental|Cohort 4 80 mg Rifaximin SSD twice daiy|Cohort 4 80 mg Rifaximin SSD twice daily (BID) and lactulose
9482591|NCT03515044|Experimental|Cohort 5 Placebo twice daily|SSD placebo twice daily (BID) and lactulose
9482592|NCT03512964|Other|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
9482593|NCT03510988|Experimental|Women with newly diagnosed breast cancer|
9482594|NCT03510884|Experimental|Alirocumab|Alirocumab (one of 4 doses, depending on body weight and Q2W or Q4W dose regimens) will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
9482595|NCT03510884|Placebo Comparator|Placebo|Alirocumab Placebo will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose
9497754|NCT03472157|Experimental|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
9497755|NCT03472157|Active Comparator|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
9497756|NCT03472144|Experimental|CRSwNP - Subgrp 1(Momentasone - Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
9497757|NCT03472144|Experimental|CRSwNP-Subgrp 2(Levofloxacin - Right)|Patients undergoing balloon sinuplasty with receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
9497758|NCT03472144|Experimental|CRSwNP-Subgrp 3(Steroid/Antibotic Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
9497759|NCT03472144|Experimental|CRSsNP - Subgrp 1 (Momentasone Right)|Patients undergoing ballon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
9497760|NCT03472144|Experimental|CRSsNP - Subgrp 2 (Levofloxacin Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
9497761|NCT03472144|Experimental|CRSsNP-Subgrp 3(Steroid/Antibiotic Right|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
9616100|NCT04602884|Experimental|COVID-19 Positive patients|subjects who were found COVID-19 Positive according to swab test.
9616101|NCT04602884|Other|Healthy subjects|subjects who were found COVID-19 Negative according to swab test.
9616102|NCT04599504|Experimental|Lisdexamfetamine dimesylate|
9616103|NCT04599504|Placebo Comparator|Placebo|
10039030|NCT01840046|Experimental|Interleukin 2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5."
10039031|NCT01840059|Experimental|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
9482596|NCT03505957|Experimental|SafeBreak Vascular Intervention|Every study participant will have SafeBreak Vasculars installed in each of their IV lines.
9482597|NCT03505749|Experimental|TI-MBRP|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
9482598|NCT03505749|Active Comparator|Standard MBRP|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
9482599|NCT03503877|Other|SAGE Media|SAGE single-step MEDIA
9482600|NCT03503877|Other|GLOBAL Media|LIFE GLOBAL single-step MEDIA
9482601|NCT03503669|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
9482602|NCT03503669|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
9482603|NCT03500263|Active Comparator|Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
9482604|NCT03500263|Placebo Comparator|Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
9482605|NCT03500263|Active Comparator|Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
9536882|NCT01827761||Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
9536883|NCT01826838|Experimental|Dasatinib|Three dasatinib dose levels will be evaluated, 50 mg/day, 70 mg/day and 100 mg/day. Dasatinib will begin with day #1 of radiation and will be discontinued once radiation is completed.
9536884|NCT01776905||Healthy control subjects|Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.
9536885|NCT01776905||Advanced-Stage Melanoma|To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.
9536886|NCT01776905||Early-Stage Melanoma|To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.
9536887|NCT01767675|Experimental|Secondary Cytoreductive Surgery with HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
9536888|NCT01767675|Experimental|Secondary Cytoreductive Surgery without HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
9616104|NCT04599465|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
10039032|NCT01840059|No Intervention|Control|HF-PEF patients who will serve as control.
10039033|NCT01840085|Experimental|0.03% DSC127 topical gel|
10039034|NCT01840098|Active Comparator|control|Isocaloric carbohydrate drink
10039035|NCT01840098|Active Comparator|low leucine content drink|A soy protein drink
10039036|NCT01840098|Active Comparator|high content of leucine drink|A whey protein drink
10039037|NCT01840098|Active Comparator|low leucine content + HMB drink|Soy protein drink added HMB
10039038|NCT01840124|Experimental|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
9482606|NCT03500263|Placebo Comparator|Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
9482607|NCT03500263|Active Comparator|Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
9482608|NCT03500263|Placebo Comparator|Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
9482609|NCT03499899|Experimental|LAG525 + spartalizumab|"Patients in this arm were given LAG525 plus spartalizumab and approximately 20 patients were randomized to this arm.~The sponsor and the study steering committee decided to prematurely stop enrollment of subjects to Arm 1 after data review showed an increased treatment discontinuation rate due to progressive disease in Arm 1 as compared to Arms 2 and 3 (both containing Carboplatin)."
9482610|NCT03499899|Experimental|LAG525+spartalizumab+carboplatin|Patients in this arm will be given LAG525 plus spartalizumab plus carboplatin and approximately 32 patients will be randomized to this arm.
9482611|NCT03499899|Experimental|LAG525 + carboplatin|Patients in this arm will be given LAG525 plus carboplatin and approximately 32 patients will be randomized to this arm.
9482612|NCT03499821|Experimental|Study population|EDOF ICL implanted into both eyes of eligible subjects.
9482613|NCT03499795|Experimental|VGX-3100|Adult participants, who are HIV negative with histologically confirmed anal or anal/peri-anal HSIL associated with HPV-16 and/or 18, will receive VGX-3100 administered by IM injection followed immediately by EP using the CELLECTRA™ 5PSP device. Participants will receive at least 3 doses of VGX-3100 at Day 0, Week 4 and Week 12. For partial responders at Week 36, a fourth dose may be administered at Week 40. All participants are scheduled to be followed to Week 88.
9482614|NCT03496571|Placebo Comparator|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
9482615|NCT03496571|Experimental|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
9482616|NCT03496571|Experimental|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
9482617|NCT03496012|Experimental|BIIB111 High Dose|Participants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
9482618|NCT03496012|Experimental|BIIB111 Low Dose|Participants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
9482619|NCT03496012|No Intervention|Untreated Control Group|Participants will receive no sham surgery or study medication.
9482620|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
9482621|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
9482622|NCT03494504|Placebo Comparator|Vehicle Ophthalmic Solution|
9482623|NCT03493932|Experimental|1|Recurrent Glioblastoma patients
9482624|NCT03488563|Experimental|B244 Dose 1|B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
9482625|NCT03488563|Experimental|B244 Dose 2|B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
9482626|NCT03488563|Placebo Comparator|Vehicle|Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
9482627|NCT03487913|Experimental|High dose|Oral lixivaptan
9482628|NCT03487913|Experimental|Low dose|Oral lixivaptan
9482629|NCT03482245|Experimental|Pneumonia: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
9482630|NCT03482245|Experimental|Diverticulitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
9482631|NCT03482245|Experimental|Appendicitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
9482632|NCT03482245|No Intervention|Pneumonia: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
9482633|NCT03482245|No Intervention|Diverticulitis: Ambient Light|Standard ambient hospital lighting (~300 lux)for an initial 24 hour photoperiod after surgery for diverticulitis.
9482634|NCT03482245|No Intervention|Appendicitis: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod after surgery for diverticulitis.
9482635|NCT03475706|Experimental|Solabegron immediate release tablets low dose|
9482636|NCT03475706|Experimental|Solabegron immediate release tablets high dose|
9482637|NCT03475706|Placebo Comparator|Placebo Comparator|
9482638|NCT03474588|Active Comparator|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant"
9497762|NCT03472144|Active Comparator|CRSwNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on left side and placebo on right side
9497763|NCT03472144|Active Comparator|CRSwNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
9536889|NCT01764529||The BVMC FCCM cohort|"Aim 1: To investigate the relationship between lesion burden and outcomes in FCCM.~Aim 2: To investigate the role of the gut microbiome in FCCM disease severity. Aim 3: To establish blood markers predictive of disease severity and progression for medical treatment of CCM."
9536890|NCT01753089|Other|WDVAX|Treatment
9536891|NCT01748149|Experimental|Vemurafenib|"Vemurafenib should be swallowed whole with 8 oz (1 cup) of water. Pharmacokinetic studies will determine if vemurafenib can be crushed. If patients receiving crushed tablets are felt to receive adequate exposure, then they will be allowed to participate in the expansion cohort. [Patients approved to take crushed tablets should use a pill crusher and mix pill with 3-5 ml apple sauce]. If not, then only patients able to swallow whole pills will be eligible.~The patient will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
9536892|NCT01725165|Experimental|Arm I (immediate LCT)|Patients undergo ablation of all residual local and metastatic sites of disease by surgery and/or EBRT. After completion of LCT, patients undergo either surveillance or maintenance treatment at the discretion of the treating physician.
9536893|NCT01725165|Active Comparator|Arm II (delayed/no LCT)|Patients undergo standard maintenance therapy or clinical observation, based on physician choice. Patients may cross-over to Arm I due to RECIST progression or toxicity at the treating physician's discretion.
9536894|NCT01704404|Experimental|Dose 1 TD-4208|22 µg
9536895|NCT01704404|Experimental|Dose 2 TD-4208|44 µg
9536896|NCT01704404|Experimental|Dose 3 TD-4208|88 µg
9536897|NCT01704404|Experimental|Dose 4 TD-4208|175 µg
9536898|NCT01704404|Experimental|Dose 5 TD-4208|350 µg
9536899|NCT01704404|Experimental|Dose 6 TD-4208|700 µg
9536900|NCT01704404|Placebo Comparator|Placebo|Placebo
9536901|NCT01654133|Experimental|endovascular repair TAAA|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
9536902|NCT01542580||Vanguard SSK 360 with PS Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized (non-constrained) tibial bearing.
9536903|NCT01542580||Vanguard SSK 360 with PSC Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized Constrained tibial bearing.
9536904|NCT01542580||Vanguard DA 360|Patients enrolled using a Vanguard DA 360 component.
9536905|NCT01542580||Vanguard 360 TiNbN Femur with PS Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
9536906|NCT01542580||Vanguard 360 TiNbN Femur with PSC Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
10058394|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
9536908|NCT01502917|Experimental|Radioactive iodine-labeled monoclonal antibody omburtamab|This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma.
9536909|NCT01307813|Experimental|Endoscopic suturing device|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
9536910|NCT01247233|Active Comparator|Standard or Hypofractionated radiotherapy|"Whole breast RT, 50 Gy + boost 16 Gy. Whole breast hypofractionated RT without boost, either 40 Gy or 42.5 Gy"
9536911|NCT01247233|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed
9536912|NCT00970866|Active Comparator|Iron and Folic Acid (IFA)|
9536913|NCT00970866|Active Comparator|Multiple Micronutrient (MMN)|
9536914|NCT00970866|Active Comparator|Lipid-based Nutrient Supplements (LNS)|
9536915|NCT00799396|Experimental|Overall Study|Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
9536916|NCT00761618|Experimental|Arm 1 - Daily|Intrapleural Catheters (IPC) drained every day
9536917|NCT00761618|Experimental|Arm 2 - 3 Times a Week|IPC drained 3 times a week
9536918|NCT00069238|Experimental|Alemtuzumab Dose Escalation|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles. Three cohorts of 3 to 6 patients will be treated. Cohort 1 will receive 30mg of Alemtuzumab, cohort 2 will receive 60mg of Alemtuzumab, and cohort 3 will receive 90mg of Alemtuzumab. If 1 of 3 participants entered at a given dose level experiences dose limiting toxicity (DLT), up to 3 additional participants will be entered at that dose level. If 2 of 6 participants experience DLT at a particular dose level, the maximum tolerated dose (MTD) has been exceeded. The preceding dose level will be the MTD, provided 6 participants have been entered at this level and no more than 1 has experienced DLT.
9536919|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
9536920|NCT03145051|Experimental|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
9536921|NCT03145051|Active Comparator|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
9616105|NCT04589676|Active Comparator|Personal recruitment|Participants in this training condition will receive recruitment messages that appeal to their personal sense of identity (e.g., you could be a hero if you get trained with naloxone).
9536922|NCT03145077|Experimental|Cohort 1 (DCE-MRI)|Patients with newly diagnosed tumors undergo DCE-MRI within 4 weeks prior to the first radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation. Patients who were previously irradiated and are at various stages of oncologic follow-up undergo DCE-MRI for a total of 2-5 times at baseline and at 6, 12, 24, 36, and/or 48 months post radiation. Patients in the third or subsequent years post treatment may undergo subsequent yearly imaging studies.
9536923|NCT03145077|Experimental|Cohort 2 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to the first re-radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation.
9536924|NCT03145077|Experimental|Cohort 3 (DCE-MRI)|Patients undergo DCE-MRI before and at 2 and 6 months post ORN treatment. Patients may undergo DCE-MRI during the mid-ORN treatment.
9536925|NCT03145077|Experimental|Cohort 4 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to and at 5-10 weeks and 12 months post surgery.
9536926|NCT03145571|Other|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
9536927|NCT03145571|No Intervention|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
9536928|NCT03145350|Active Comparator|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
9536929|NCT03145350|Active Comparator|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
9536930|NCT03145467|Experimental|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
9536931|NCT03145467|Experimental|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
9536932|NCT03145584|Active Comparator|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
9536933|NCT03145584|Sham Comparator|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
9536934|NCT03145415|Experimental|Bilateral Pudendal block|0.25 cc per kg of 0.2% ropivacaine will be injected once for right pudendal N block and the same volume for the left pudendal N block before the start of the surgery
9536935|NCT03145415|Active Comparator|Caudal block|1 cc per kg of 0.2% ropivacaine in the caudal space given before the start of surgery
9536936|NCT03145168|Experimental|High Target Mean Arterial Pressure|
9536937|NCT03145168|Active Comparator|Low target Mean Arterial Pressure|
9536938|NCT03145194|Experimental|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
9536939|NCT03145194|Placebo Comparator|Placebo|Patients will receive Placebo (2 matching tablets)
9536940|NCT03145116|Experimental|509|
9536941|NCT03145103|Experimental|409M|CT ASPHINA 409M IOL
9536942|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
9536943|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
9536944|NCT03145285|Experimental|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.~Treatment with single agent Abiraterone Acetate (AA) until progression"
9536945|NCT03145285|Experimental|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
9536946|NCT03145220|Active Comparator|EA-230|Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
9536947|NCT03145220|Placebo Comparator|Placebo|Intravenous infusion of NaCl (equivalent osmolarity with active intervention EA-230). Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
9536948|NCT03144999|Experimental|Low Dose|AAVCAGsCD59
9536949|NCT03144999|Experimental|Mid Dose|AAVCAGsCD59
9536950|NCT03144999|Experimental|High Dose|AAVCAGsCD59
9536951|NCT03145233|Experimental|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
9536952|NCT03145233|Experimental|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
9616106|NCT04589676|Experimental|Online training|Participants in this training condition will receive recruitment messages that appeal to their communal sense of identity (e.g., your family and friends will thank you for getting trained with naloxone).
9536953|NCT03145155|Experimental|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
9536954|NCT03145155|Placebo Comparator|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
9536955|NCT03144960|Other|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
9536956|NCT03144947|Experimental|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~After surgery, study patients will receive trastuzumab IV x 14 cycles"
9536957|NCT03144947|Experimental|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
9536958|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
9536959|NCT03144739|Active Comparator|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
9536960|NCT03144739|Experimental|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
9536961|NCT03144895|Other|Arterial catheter|by anatomical placement alone
9536962|NCT03144895|Other|Placement|of an arterial catheter by ultrasound tracking
9536963|NCT03144596|Experimental|Alfuzosin Hydrochloride|Alfuzosin hydrochloride 10 mg tablet by mouth, every 24 hours for 3 months
9536964|NCT03144596|Active Comparator|Tamsulosin Hydrochloride|Tamsulosin hydrochloride 0.4 mg tablet by mouth, every 24 hours for 3 months
9536965|NCT03144726|Experimental|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
9536966|NCT03144726|Other|Standard dressing|Standard dressing will be applied to this arm
9536967|NCT03145012|Experimental|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
9536968|NCT03144661|Experimental|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
9536969|NCT03144661|Experimental|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
9536970|NCT03144661|Experimental|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
9536971|NCT03144661|Experimental|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
9536972|NCT03144778|Experimental|Cohort I (durvalumab)|Participants receive durvalumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
9536973|NCT03144778|Experimental|Cohort II (durvalumab, tremelimumab)|Participants receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
9536974|NCT03144843|Experimental|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
9536975|NCT03144843|Placebo Comparator|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
9536976|NCT03144713|Experimental|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
9536977|NCT03144713|Active Comparator|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
9536978|NCT03144713|Active Comparator|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
9536979|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in four large Latin American cities (Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
9536980|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
9536981|NCT03144830|Experimental|Overground walking program|Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
9536982|NCT03144856|Experimental|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
9536983|NCT03144817|No Intervention|Control Group|
9536984|NCT03144817|Experimental|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
9536985|NCT03144882|Active Comparator|intervention|the trial group (n =35 )
9536986|NCT03144882|Placebo Comparator|placebo|control group
9536987|NCT03144609|Active Comparator|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
9536988|NCT03144609|Experimental|PEEP 7 & ARM|Experimental ARM & Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
9536989|NCT03144609|Experimental|PEEP 10 & ARM|Experimental ARM & Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
9536990|NCT03144869|Experimental|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
9536991|NCT03144869|Experimental|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
9536992|NCT03144752||Cohort 1: Participants between 8 to 14 weeks gestation|Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
9536993|NCT03144752||Cohort 2: Participants between 15 to 36 weeks gestation|Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
9536994|NCT03144921|Experimental|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
9536995|NCT03144921|Active Comparator|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention) about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
9536996|NCT03144557|Experimental|Intervention|Education protocol to correct inhalation technique
9536997|NCT03144934|Experimental|Administraion of investigational product|"0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7~6 subjects per each cohort~twice administration with 4-week intervals"
9536998|NCT03144934|Placebo Comparator|Administraion of placebo|"GX-I7 vehicle (formulation buffer)~2 subjects per each cohort~twice administration with 4-week intervals"
9536999|NCT03144986|Experimental|Deep insula-coil rTMS|"Active treatment phase consists of deep rTMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase.~Maintaince treatment phase includes two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks."
9537000|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
9537001|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
9537002|NCT03144323|Experimental|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
9537003|NCT03144323|No Intervention|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
9537004|NCT03144375|Active Comparator|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
9537005|NCT03144375|Active Comparator|Surgical treatment|Surgical treatment up front
9537006|NCT03144271|Experimental|NNC 0113-0217|Dose-escalation trial
9537007|NCT03144271|Placebo Comparator|Placebo|Dose-escalation trial
9616107|NCT04572412|Experimental|Low Dose Radiotherapy|Low Dose Radiotherapy
9616108|NCT04565925|Experimental|Sildenafil 20mg TID then Placebo TID|Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.
10058395|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
10058396|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
9482639|NCT03474588|Experimental|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant PLUS~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
9482640|NCT03472885|Experimental|Group 1: 100 mg Danicopan TID + Eculizumab|Starting dose of 100 mg danicopan TID in combination with eculizumab.
9482641|NCT03472885|Experimental|Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab|Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
9482642|NCT03472885|Experimental|Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab|Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
9482643|NCT03472885|Experimental|Group 4: Optimal Dose of Danicopan TID + Eculizumab|Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.
9482644|NCT03471767|Experimental|AXS-05|Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
9482645|NCT03471767|Active Comparator|Bupropion SR|Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
9482646|NCT03467152|Experimental|E2027|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of E2027 for 12 weeks.
9482647|NCT03467152|Placebo Comparator|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of E2027-matched placebo for 12 weeks.
9482648|NCT03467113|Experimental|ZX008 0.2 to 0.8 mg/kg/day|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (flexible dosing 0.2 mg/kg/day to 0.8 mg/kg/day)
9482649|NCT03460756|Experimental|Ganaxolone|Oral
9482650|NCT03460756|Placebo Comparator|Placebo|Oral
9482651|NCT03458130|Active Comparator|AG10 Low Dose|Low dose group
9482652|NCT03458130|Active Comparator|AG10 High Dose|High dose group
9482653|NCT03458130|Placebo Comparator|Placebo|
9482654|NCT03455504|Experimental|Cohort 1|FLAI + V400 mg
9482655|NCT03455504|Experimental|Cohort 2|FLAI + V600 mg
9482656|NCT03453619|Experimental|APL-2|Open Label, Study Drug, APL-2
9482657|NCT03452228|Experimental|evinacumab|
9482658|NCT03452228|Experimental|Placebo|
9482659|NCT03449199|Experimental|TMX-049 dose 1|
9482660|NCT03449199|Experimental|TMX-049 dose 2|
9482661|NCT03449199|Placebo Comparator|TMX-049 Placebo|
9482662|NCT03448081|Active Comparator|SNA-120 + Calcipotriene|
9482663|NCT03448081|Placebo Comparator|Placebo + Calcipotriene|
9482664|NCT03447990|Other|Part 1/SAD and Part 2/MAD - drug|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
9482665|NCT03447990|Other|Part 1/SAD and Part 2/MAD - placebo|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
9482666|NCT03446807|Experimental|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
9482667|NCT03446807|Placebo Comparator|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
9482668|NCT03442985|Experimental|Palovarotene 2.5 mg daily regimen|
9482669|NCT03442985|Experimental|Palovarotene 5.0 mg daily regimen|
9482670|NCT03442985|Placebo Comparator|Placebo regimen|
9482671|NCT03442764|Experimental|Group 1|Active Treatment for participants with base target trough concentration
9482672|NCT03442764|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
9482673|NCT03442764|Placebo Comparator|Placebo|Placebo Group
9482674|NCT03442751|Active Comparator|Epithelium-on CXL Treatment Group|Study eye receives Paracel 1, Paracel 2 R0185 and irradiated using KXL High Power System (10 J)
9482675|NCT03442751|Sham Comparator|Sham Treatment/Control Group|Sham eye receives Paracel Placebo and irradiated using KXL High Power System (2 J)
9482676|NCT03436615|Experimental|SB206 4%|SB206 4% topically twice daily
9482677|NCT03436615|Experimental|SB206 8%|SB206 8% topically twice daily
9482678|NCT03436615|Experimental|SB206 12%|SB206 12% topically once or twice daily
9482679|NCT03436615|Placebo Comparator|Placebo (vehicle gel)|Vehicle Gel topically once or twice daily
9482680|NCT03432260|Experimental|DUR-928 30 mg|Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
9482681|NCT03432260|Experimental|DUR-928 90 mg|Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
9482682|NCT03432260|Experimental|DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
9482683|NCT03430843|Experimental|Tislelizumab|Tislelzumab on Day 1, given every 21 days
9537008|NCT03144466|Experimental|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
9537009|NCT03144466|Experimental|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
9537010|NCT03144466|Experimental|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
9537011|NCT03144284||dental interns|dental interns in pediatric dentistry department, faculty of dentistry, Cairo University.
9537012|NCT03144388|Experimental|Variable Stepping Training|High intensity stepping training in multiple environments, including overground, on a treadmill and on stairs.
9537013|NCT03144388|Active Comparator|Variable Non-specific Training|High intensity non-stepping training, including balance, strength, and cycling tasks
9537014|NCT03144453|Experimental|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
9537015|NCT03144453|Active Comparator|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
9537016|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
9537017|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
9537018|NCT03144531|Experimental|SKIP Intervention|
9537019|NCT03144336|Experimental|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
9537020|NCT03144336|Active Comparator|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
9537021|NCT03144414|Active Comparator|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
9537022|NCT03144414|Active Comparator|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
9537023|NCT03144401|Active Comparator|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
9537024|NCT03144401|Active Comparator|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
9537025|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
9537026|NCT03144362|Active Comparator|Bilateral Sliding Technique|
9537027|NCT03144362|Active Comparator|Unilateral Sliding Techniques|
9537028|NCT03144362|No Intervention|Standard care|
9616109|NCT04565925|Experimental|Placebo TID then Sildenafil 20mg TID|Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
9616110|NCT04565028|Experimental|Contingency Management (CM)|Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users. CM is an intensive behavioral therapy in which participants are paid to reduce substance use.
9616111|NCT04562714|Experimental|Intervention (FGM + DSME)|Study participants randomized to the intervention arm will be provided with a FreeStyle Libre flash glucose monitor (FGM) system to use for 16 weeks in Phase 1. Study participants will receive one training session on proper use of the FGM and encouraged to test at least 4 times per day: fasting and post-meals. Participants will also receive six diabetes self-management education (DSME) sessions, consisting of four individual in-clinic sessions and two telephone sessions.
9616112|NCT04562714|Other|Control (DSME alone)|Study participants in the control arm will receive six diabetes self-management education sessions matched to time and location of the intervention group. The sessions will consist of four individual in-clinic sessions and two telephone sessions over 16 weeks. Control participants will be encouraged to self-monitor blood glucose four times daily (fasting and post-meals) as per existing diabetes self-care guidelines
9616113|NCT04549324||Sleep Apnea (AHI ≥ 15 per hour)|Patients with moderate/severe sleep apnea (Apnea/hypopnea-index ≥ 15 per hour).
9616114|NCT04549324||Non-Sleep Apnea (AHI < 5 per hour)|Patients without sleep apnea (Apnea/hypopnea-index < 5 per hour).
9616115|NCT04545515|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
9616116|NCT04543695|Active Comparator|adjuvant chemotherapy group|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
9616117|NCT04543695|Experimental|consolidation chemotherapy group|concurrent chemoradiotherapy → consolidation chemotherapy → TME (experimental group)
9616118|NCT04543695|Experimental|induction chemotherapy group|induction chemotherapy → concurrent chemoradiotherapy →TME ( experimental group).
10058397|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
9537031|NCT03144505|No Intervention|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
9537032|NCT03144505|Experimental|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
9537033|NCT03144505|Experimental|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
9537034|NCT03144115|Experimental|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH>40 mIU/ml)
9537035|NCT03144115|Placebo Comparator|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH>40 mIU/ml)
9537036|NCT03144115|Experimental|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH<30 mIU/ml)
9537037|NCT03144115|Placebo Comparator|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH<30 mIU/ml)
9537038|NCT03144050||0|Control - no diabetes
9537039|NCT03144050||1|Diabetes
9537040|NCT03144050||2|Diabetes w/neuropathy
9537041|NCT03144050||3|Diabetes with vascular disease
9537042|NCT03144050||4|Diabetes w/healed ulcer
9537043|NCT03144050||5|Diabetes with current ulcer
9537044|NCT03144128|Placebo Comparator|Control (Ctl)|Standard of Care resistance exercise and timed protein supplementation with placebo capsule daily for 12 weeks
9537045|NCT03144128|Experimental|Vitamin D|Standard of Care resistance exercise and timed protein supplementation with 5,000IU vitamin D supplementation daily for 12 weeks
9537046|NCT03144245|Experimental|AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels
9537047|NCT03144245|Experimental|Combination AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels in combination with pembrolizumab
9537048|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
9537049|NCT03144193|Experimental|Experimental|Topical anti-aging cosmetic cream (active)
9537050|NCT03144193|Placebo Comparator|Placebo|Basic formulation without active ingredients (vehicle)
9537051|NCT03144024|Experimental|band|
9537052|NCT03144024|Active Comparator|Rigid ring|
9537053|NCT03144102|Experimental|VR-based motor rehabilitation with tDCS|
9537054|NCT03144102|Active Comparator|Occupational Therapy with tDCS|
9537055|NCT03144102|Sham Comparator|VR-based motor rehabilitation with sham tDCS|
9537056|NCT03144102|Sham Comparator|Occupational Therapy with sham tDCS|
9537057|NCT03144167|Other|Patients, aged 18-88, with glioblastoma|
9537058|NCT03144154|Experimental|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
9537059|NCT03144154|No Intervention|Control group : Usual care|Control group receiving usual care but not the intervention
9537060|NCT03144141|Other|Patients with the diagnosis of threat of uterine delivery|
9537061|NCT03143946|Experimental|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
9537062|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:~≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy~Clinician's diagnosis based on his/her assessment~Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
9537063|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
9537064|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
9537065|NCT03144076|Experimental|Group A|[Other: RSBY Health Insurance] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
9616119|NCT04539392||Infertile couple|
9616120|NCT04537195|Experimental|Intervention Group|ADSMP-C
9616121|NCT04537195|No Intervention|Control Group|Wait-list control group
9537066|NCT03144076|Experimental|Group B|[Other: RSBY Health Insurance] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
9537067|NCT03144076|Experimental|Group C|[Other: RSBY Health Insurance] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
9537068|NCT03144076|No Intervention|Group D|[No intervention] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
9537069|NCT03143803|Active Comparator|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
9537070|NCT03143803|Placebo Comparator|Placebo|Placebo will contain an inert substance
9537071|NCT03143920|Experimental|Hyperbaric Oxygen|Hyperbaric oxygen therapy-2.4 atmosphere absolute for 90 minutes with 2-five minute air breaks administered daily, 5 days per week for 8 weeks total treatment.
9537072|NCT03143933|Active Comparator|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
9537073|NCT03143933|Active Comparator|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
9537074|NCT03143998|Experimental|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
9537075|NCT03143998|Experimental|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
9537076|NCT03143998|Experimental|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
9537077|NCT03143998|Experimental|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
9537078|NCT03143647||Control|"Female~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1~Not pregnant"
9537079|NCT03143647||Case|"Female~Pregnant with possible pre-eclampsia~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1"
9537080|NCT03143673|Experimental|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
9537081|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
9537082|NCT03143972|Experimental|Dexmedetomidine only|"Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.~A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min)."
9537083|NCT03143972|Experimental|Remifentanil only|Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).
9537084|NCT03143972|Experimental|Dexmedetomidine-Remifentanil interaction|"A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).~Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes."
9537085|NCT03143699|Experimental|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
9537086|NCT03143699|No Intervention|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
9537087|NCT03143777|No Intervention|Baseline|Standard physiotherapy and mobilisation
9537088|NCT03143777|Experimental|Sara Combilizer group|Ongoing care with the sara combilizer available for use
9537089|NCT03143530|Active Comparator|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
9537090|NCT03143530|Placebo Comparator|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
9537091|NCT03143907|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
9537092|NCT03143907|Other|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
9537093|NCT03143582|Experimental|Running group|13 week, bi-weekly running group
9537094|NCT03143725|Experimental|Treatment A|GLPG1972 oral solution after overnight fast
9537095|NCT03143725|Experimental|Treatment B|GLPG1972 oral DC tablet after breakfast
9537096|NCT03143725|Experimental|Treatment C|GLPG1972 oral WG tablet after overnight fast
9537097|NCT03143725|Experimental|Treatment D|GLPG1972 oral WG tablet after breakfast
9537098|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
10058398|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
10058399|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
10058400|NCT02018029||cardiac resynchronisation therapy|
10058401|NCT02018055|Active Comparator|Aspirin+Ticagrelor|A Group treated with Aspirin+Ticagrelor
9537099|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
9537100|NCT03143881|Experimental|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
9537101|NCT03143881|No Intervention|Control|Control patients will receive ED standard of care.
9537102|NCT03143634|Experimental|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
9537103|NCT03143634|Placebo Comparator|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
9537104|NCT03143751|Experimental|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
9537105|NCT03143751|No Intervention|Control|Standard cares alone.
9537106|NCT03143868|Experimental|Aerobic Exercise|
9537107|NCT03143868|Experimental|Resistance Exercise|
9537108|NCT03143868|Placebo Comparator|No Exercise|
9537109|NCT03143478|Experimental|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
9537110|NCT03143712|Experimental|Treatment A|GLPG1690 oral capsules after breakfast
9537111|NCT03143712|Experimental|Treatment B|GLPG1690 oral tablets after breakfast
9537112|NCT03143712|Experimental|Treatment C|GLPG1690 oral tablets after overnight fast
9537113|NCT03143738|Experimental|continuous anesthesia of adductor canal|
9537114|NCT03143738|Experimental|continuous anesthesia of femoral nerve|
9537115|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
9537116|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
9537117|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
9537118|NCT03143790|Active Comparator|ESWT|500 shockwave 3 different points on penis bilateral
9537119|NCT03143790|Placebo Comparator|Placebo|500 shockwave 3 different points on penis bilateral
9537120|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
9537121|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
9537122|NCT03143387|Active Comparator|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
9537123|NCT03143387|Experimental|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
9537124|NCT03143452|Active Comparator|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
9537125|NCT03143452|Active Comparator|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
9537126|NCT03143465|Experimental|CGRP|
9537127|NCT03143465|Experimental|Sildenafil|
9537128|NCT03143465|Placebo Comparator|Placebo|
9537129|NCT03143491|Experimental|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
9537130|NCT03143491|Experimental|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
9537131|NCT03143491|Experimental|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
9537132|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
9537133|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
9537134|NCT03143426|Experimental|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualisation.
9537135|NCT03143426|No Intervention|2D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 2D visualisation, the standard viewing method used during all laparoscopic surgeries currently.
9537136|NCT03143231|Experimental|Normal saline|Sodium Chloride 0.9% will be provided
9537137|NCT03143231|Experimental|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
9537138|NCT03143335|Active Comparator|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
9537139|NCT03143335|Active Comparator|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
9537140|NCT03143543|Experimental|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
9537141|NCT03143543|Placebo Comparator|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
9537142|NCT03143543|Experimental|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
9537143|NCT03143543|Placebo Comparator|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
9537144|NCT03143257||Subjects|Diagnosed with CHL, SSD and mixed HL who currently have or have had the Sophono implant
9537145|NCT03143192|Experimental|Aflibercept with Micropulse Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Micropulse Laser at initial visit and reassessed every 12 weeks.
9537146|NCT03143192|Sham Comparator|Aflibercept with Sham Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Sham Laser at initial visit and reassessed every 12 weeks.
9537147|NCT03143348||Control/Nonsurgical|Infants with postnatally confirmed acyanotic congenital heart disease not expected to require surgery in the first six months of life.
9537148|NCT03143348||Surgery w/o bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery without cardiopulmonary bypass.
9537149|NCT03143348||Surgery w/ bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
9537150|NCT03143205|Experimental|AWARENESS for sexual minorities|Group receives new CBT-based intervention
9537151|NCT03143205|Active Comparator|Writing tasks|Group receives writing-based sessions
9537152|NCT03143400|Active Comparator|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
9537153|NCT03143400|Active Comparator|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
9537154|NCT03143244|Active Comparator|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
9537155|NCT03143244|Active Comparator|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
9537156|NCT03143244|Placebo Comparator|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
9537157|NCT03143296|Experimental|Current recipient of a Med-El cochlear implant|Participants who have received a MED-EL cochlear implant as a standard of care for treatment of hearing loss. Participants are tested at one time point with a simulated reverberant environment.
9537158|NCT03143296|Active Comparator|Future Med-El Recipient|Cochlear implant candidates not yet implanted and chose Med-El device as standard of care for treatment of hearing loss. Participants are tested at 3 time points over 6 months in a simulated reverberant environment.
9537159|NCT03143309|Experimental|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
9537160|NCT03143309|Active Comparator|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
9537161|NCT03143114|Experimental|Myomectomy|Women will be subjected to laparotomy to remove the myomas
9537162|NCT03143114|No Intervention|Conservative management|Women will not be subjected to surgery (conservative management)
9537163|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
9537164|NCT03143049|Experimental|Pomalidomide, Cyclophosphamide, Dex (PCD)|
9537165|NCT03143049|Active Comparator|Pomalidomide, Dex (PD)|
9537166|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
9537167|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
9537168|NCT03143140|Experimental|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
9537169|NCT03143140|Other|tumor ablation|ablation of tumor directly
9537170|NCT03143088||Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
9537171|NCT03143088||Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
9537172|NCT03143075|Active Comparator|Inflammation group|Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
9537173|NCT03143075|Active Comparator|Non-inflammation group|Subjects with CRP<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
9537174|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
9537175|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
9537176|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
9537177|NCT03143283|No Intervention|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
10058402|NCT02018055|Experimental|Aspirin+Clopidogrel|A Group treated with Aspirin+Clopidogrel
9537178|NCT03143283|Experimental|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
9537179|NCT03143036|Experimental|Daratumumab, thalidomide and dexamethasone|
9537180|NCT03143023|Experimental|arginine toothpaste|
9537181|NCT03143023|Active Comparator|fluoride toothpaste|
9537182|NCT03142945|Active Comparator|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
9537183|NCT03142945|Experimental|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
9537184|NCT03142672|Experimental|Experimental group|Pulpotomy and tooth filling
9537185|NCT03142672|Active Comparator|Control group|Tooth filling
9537186|NCT03142997||group S|anesthetized children on spontaneous ventilation.
9537187|NCT03142997||group C|anesthetized children on controlled ventilation.
9537188|NCT03142789|Active Comparator|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
9537189|NCT03142789|Active Comparator|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
9537190|NCT03142789|Active Comparator|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
9537191|NCT03143010|Placebo Comparator|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
9537192|NCT03143010|Experimental|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
10039039|NCT01840137|Experimental|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
10039040|NCT01840150|Experimental|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
9537193|NCT03143010|Experimental|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
9537194|NCT03143010|Experimental|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
9537195|NCT03142776|Placebo Comparator|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
10039041|NCT01840176|No Intervention|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
9537196|NCT03142776|Active Comparator|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
9537197|NCT03142776|Active Comparator|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
9537198|NCT03142776|Active Comparator|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
9537199|NCT03142698|Experimental|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
10039042|NCT01840176|Other|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
10039043|NCT01840189|Active Comparator|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
10039044|NCT01840189|Active Comparator|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
10039045|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
10039046|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
9537200|NCT03142880|Active Comparator|commonly hyperbaric ropivacaine group|This group will receive spinal anesthesia with commonly hyperbaric ropivacaine solution,which was made by adding 50% glucose to the plain ropivacaine commercially availablethe to make it's density is close to commonly hyperbaric bupivacaine.
9537201|NCT03142880|Experimental|marginally hyperbaric ropivacaine group|This group will receive spinal anesthesia with marginally hyperbaric ropivacaine,which was made by adding 5% glucose to the plain ropivacaine commercially availablethe to make it's density is slightly denser than cerebrospinal fluid but much less denser than commonly hyperbaric bupivacaine/ropivacaine.
10039047|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
9537202|NCT03142646|Experimental|IM19 CART|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.
9537203|NCT03142802|Experimental|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
9537204|NCT03142724|Experimental|[18F]MNI-968|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-968.
9537205|NCT03142828|Active Comparator|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
9537206|NCT03142828|Placebo Comparator|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
10039048|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
9537207|NCT03142685|Experimental|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
9537208|NCT03142685|No Intervention|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
10039049|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
10039050|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg.
10039051|NCT01840241|Experimental|BIVON group|
10039052|NCT01840241|Placebo Comparator|Placebo group|normal saline infusion
10039053|NCT01840254|Experimental|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
10039054|NCT01840254|Placebo Comparator|normal saline|normal saline as a placebo
10039055|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
10039056|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
10039057|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
9537209|NCT03142737|Experimental|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
10039058|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
9537210|NCT03142737|Experimental|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
9537211|NCT03142737|Experimental|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
9537212|NCT03142737|Experimental|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
9537213|NCT03142737|Experimental|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
9537214|NCT03142906|Experimental|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
9537215|NCT03142906|No Intervention|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
10039059|NCT01840332|Experimental|L-thyroxin|this is one arm study
9482684|NCT03430843|Active Comparator|Investigator chosen chemotherapy|"Paclitaxel will be administered on Day 1, given every 21 days or on a weekly schedule.~OR docetaxel will be administered on Day 1, given 21 days. OR irinotecan will be administered on Days 1, 8, given 21 days."
9482685|NCT03428932|Active Comparator|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
9482686|NCT03428932|Active Comparator|Closed-Loop|Subjects will transition from their current treatment (insulin pump or injections) onto the Medtronic 670G insulin pump (intervention arm as a comparator) and will have close contact with the study team. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
9482687|NCT03428217|Experimental|CB-Cabo|CB-839 orally twice daily + cabozantinib orally once daily
9482688|NCT03428217|Placebo Comparator|Pbo-Cabo|Placebo orally twice daily + cabozantinib orally once daily
9482689|NCT03427814|Experimental|Pamiparib|Approximately 64 participants to receive pamiparib orally.
9482690|NCT03427814|Placebo Comparator|Placebo|Approximately 64 participants to receive placebo orally.
9482691|NCT03427125|Experimental|Tenapanor 10 mg, 20 mg, 30 mg BID|During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
9482692|NCT03427125|Placebo Comparator|Placebo|Placebo
9482693|NCT03427125|Active Comparator|Sevelamer Carbonate|Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)
9482694|NCT03423147|Experimental|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
9482695|NCT03423147|Active Comparator|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
10039060|NCT01840358|Other|Patients starting pump therapy|
10039061|NCT01840371|Experimental|Propofol based group|
9482698|NCT03420222|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
9482699|NCT03420222|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
9482700|NCT03416530|Experimental|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
9482701|NCT03416530|Experimental|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
9482702|NCT03416530|Experimental|Midline Glioma Biopsy|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.
9482703|NCT03416530|Experimental|H3 K27M CSF Biopsy|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory), have completed at least one line of prior therapy, must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF), and must be scheduled to undergo sedated MRIs.
9482704|NCT03416530|Experimental|Liquid ONC201 in relapsed/refractory H3 K27M glioma|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
9482705|NCT03416530|Experimental|Dose Expansion Cohort in relapsed/refractory H3 K27M glioma|Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
9482706|NCT03416530|Experimental|ONC201 given on two consecutive days of each week|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.
9482707|NCT03412890|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 28 weeks.
9482708|NCT03406702|Experimental|CX-8998|T-type calcium channel blocker
9482709|NCT03404570|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
9482710|NCT03404570|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
9482711|NCT03404570|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
9482712|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
9482713|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.1%)|
9482714|NCT03404115|Placebo Comparator|Vehicle Ophthalmic Solution|
9482715|NCT03403205|Experimental|ALXN1840|"ALXN1840 was administered orally for 48 weeks at doses ranging from 15 milligrams (mg) every other day (QOD) up to a titrated dose of 60 mg daily.~Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period."
10039062|NCT01840371|Active Comparator|Fentanyl based group|
10039063|NCT01840384|Experimental|Multi-micronutrients|Multi-micronutrients
9482716|NCT03403205|Active Comparator|Standard of Care (SoC) Medication|SoC medication was administered for 48 weeks. Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.
9482717|NCT03400085|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
9482718|NCT03400085|Experimental|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
9482719|NCT03398200|Experimental|Hyperbaric Oxygen Therapy|Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
9482720|NCT03398200|Active Comparator|No Hyperbaric Oxygen Therapy|Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
9482721|NCT03397134|Experimental|Roluperidone 64 mg|Roluperidone 64 mg for entire study
9482722|NCT03397134|Experimental|Roluperidone 32 mg|Roluperidone mg for entire study
9482723|NCT03397134|Placebo Comparator|Placebo-1|Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
9482724|NCT03397134|Placebo Comparator|Placebo-2|Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
9482725|NCT03394781|Experimental|DUR-928 10 mg|10 mg oral suspension
9482726|NCT03394781|Experimental|DUR-928 50 mg|50 mg oral suspension
9482727|NCT03385330|Active Comparator|LOWER oxygen saturation target group|Oxygen saturation target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
9482728|NCT03385330|Active Comparator|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
9482729|NCT03385239|Placebo Comparator|Pooled Placebo|Participants in each cohort (A,B,C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
9482730|NCT03385239|Experimental|Cohort A: ISIS 678354: 10 mg Q4W|Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
9482731|NCT03385239|Experimental|Cohort C: ISIS 678354: 15 mg Q2W|Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
9482732|NCT03385239|Experimental|Cohort D: ISIS 678354: 10 mg QW|Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
9482733|NCT03385239|Placebo Comparator|Cohort B: ISIS 678354: 50 mg Q4W|Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
9482734|NCT03382639|Experimental|Double-blind: Luvadaxistat 50 mg|Luvadaxistat 50 milligram (mg), tablets, orally, once daily up to 14 weeks.
9482735|NCT03382639|Experimental|Double-blind: Luvadaxistat 125 mg|Luvadaxistat 125 mg, tablets, orally, once daily up to 14 weeks.
9482736|NCT03382639|Experimental|Double-blind: Luvadaxistat 500 mg|Luvadaxistat 500 mg, tablets, orally, once daily up to 14 weeks.
9482737|NCT03382639|Placebo Comparator|Double-blind: Placebo|Luvadaxistat placebo-matching tablets, orally, once daily up to 14 weeks.
9482738|NCT03379675|Experimental|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
9482739|NCT03379675|Experimental|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
9482740|NCT03379675|Placebo Comparator|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
9482741|NCT03375203|Placebo Comparator|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
9482742|NCT03375203|Experimental|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
9482743|NCT03375203|Experimental|JNJ-42847922 10 mg plus Placebo|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
9482744|NCT03375203|Experimental|JNJ-42847922 20 mg plus Placebo|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
9482745|NCT03375203|Experimental|Zolpidem plus Placebo|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
9482746|NCT03373461|Placebo Comparator|Placebo|Placebo to LNP023
9482747|NCT03373461|Experimental|LNP023 dose 1|Dose 1 of LNP023
9482748|NCT03373461|Experimental|LNP023 dose 2|Dose 2 of LNP023
9482749|NCT03373461|Experimental|LNP023 dose 3|Dose 3 of LNP023
9482750|NCT03373435|Experimental|Treatment Group 1|patients will receive two dose regimens of exendin 9-39 and one placebo
9482751|NCT03373435|Experimental|Treatment Group 2|patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
9482752|NCT03371082|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
9482753|NCT03371082|Active Comparator|Lantus®|Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
9482754|NCT03370913|Experimental|valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
9482755|NCT03365947|Active Comparator|ARO-HBV Injection|
9482756|NCT03365947|Placebo Comparator|Placebo|
9482757|NCT03361956|Experimental|Part A: Arm 1 (JNJ-56136379 or NA) (open label)|Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]), and enter the 24 week post treatment follow-up phase.
9482758|NCT03361956|Placebo Comparator|Part A: Arm 2 (Placebo+NA [ETV] or [TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482759|NCT03361956|Experimental|Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482760|NCT03361956|Placebo Comparator|Part A: Arm 4 (Placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482761|NCT03361956|Experimental|Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482762|NCT03361956|Experimental|Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.
9482763|NCT03361956|Placebo Comparator|Part B: Arm 7 (placebo + NA [ETV or TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482764|NCT03361956|Experimental|Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482765|NCT03361956|Placebo Comparator|Part B: Arm 9 (placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482766|NCT03361956|Experimental|Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
9482767|NCT03359785|Experimental|Luvadaxistat 500 mg + Luvadaxistat 50 mg|Luvadaxistat 500 milligrams (mg) or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by Luvadaxistat 50 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
9482768|NCT03359785|Experimental|Luvadaxistat 50 mg + Luvadaxistat 500 mg|Luvadaxistat 50 mg or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by Luvadaxistat 500 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
9482769|NCT03357029|Active Comparator|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
9482770|NCT03357029|Sham Comparator|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
9482771|NCT03352427|Experimental|Dasatinib+Everolimus|"Dasatinib = 60 mg/m2 orally twice daily~Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml~Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles."
9482772|NCT03350035|Experimental|IV Ganaxolone active|Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
9482773|NCT03350035|Placebo Comparator|IV Placebo, non-active|Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
9482774|NCT03349645|Experimental|Ampion|4 mL Ampion (<5 kilodatlon (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution
9482775|NCT03348163|Experimental|Switch ART|Switch from current antiretroviral therapy (ART) to B/FTC/TAF bfor 48 weeks
9482776|NCT03348163|Active Comparator|Continue Current ART|Continue current (ART) therapy (emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks
9482777|NCT03347110|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 2 years.
9482778|NCT03345082|Experimental|0.5 mg ranibizumab with 2.0 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
9482779|NCT03345082|Experimental|0.5 mg ranibizumab with 0.5 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
9482780|NCT03345082|Sham Comparator|0.5 mg ranibizumab with sham|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
9482781|NCT03340974|Experimental|Arm A: SBRT + Avasopasem (GC4419)|
9537216|NCT03142841|No Intervention|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
9537217|NCT03142841|Experimental|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
9537218|NCT03142763|Experimental|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
9537219|NCT03142763|Experimental|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
9537220|NCT03142854|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
9537221|NCT03142854|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
9537222|NCT03142971|Experimental|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
9537223|NCT03142971|Active Comparator|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
9537224|NCT03142919|Experimental|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
9537225|NCT03142919|Active Comparator|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
9537226|NCT03142919|Placebo Comparator|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
9537227|NCT03142919|Placebo Comparator|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
9537228|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study~Inclusion criteria:~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
9537229|NCT03142620|Active Comparator|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
9537230|NCT03142620|Active Comparator|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 10 days"
9537231|NCT03142620|Active Comparator|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 28 days"
9616122|NCT04519502||Randomly Selected Delivery Dates 2019|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2019.
9616123|NCT04519502||Randomly Selected Delivery Dates 2020|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2020
9616124|NCT04519502||Confirmed COVID-19 Infections|Women with confirmed COVID-19 infection between March 1, 2020 and December 31, 2020 and who delivered on or before December 31, 2020.
9616125|NCT04515615|Experimental|Camrelizumab and chemotherapy|Participants receive camrelizumab 200 mg intravenously (IV) on the first day (q3w), then oxaliplatin 130 mg/m^2, IV on the first day (q3w), and tegafur gimeracil oteracil potassium capsule 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Three weeks as a course of treatment, a total of 8 courses.
9616126|NCT04503863|Experimental|Experimental 1|Single administration of middle dose NPC-22
9616127|NCT04503863|Experimental|Experimental 2|Single administration of high dose NPC-22
9616128|NCT04503863|Placebo Comparator|Experimental 3|Single administration of placebo dose NPC-22
9616129|NCT04489628|Active Comparator|Vitamin D|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
9616130|NCT04489628|Placebo Comparator|Placebo|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
9616131|NCT04488822|Experimental|Pexidartinib|
9616132|NCT04483414|Experimental|Patients with suspected BCR or metastatic prostate cancer|Patients with suspected BCR or metastatic prostate cancer
10039064|NCT01840384|Placebo Comparator|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
10039065|NCT01840397||Spine surgery|Patients undergoing spine surgery
9537232|NCT03142607|Active Comparator|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
9537233|NCT03142607|Active Comparator|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
9537234|NCT03142607|Active Comparator|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
9537235|NCT03142516|Experimental|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI~Irinotecan: 150 mg/m2 as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle.~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
9537236|NCT03142529|No Intervention|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
9537237|NCT03142529|Experimental|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
9537238|NCT03142477|Other|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
9537239|NCT03142477|Placebo Comparator|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
9537240|NCT03142477|Experimental|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
9537241|NCT03142503|Placebo Comparator|Placebo|Soybean supplementation
9537242|NCT03142503|Active Comparator|Diet + placebo|Soybean supplementation and diet intervention
9537243|NCT03142503|Experimental|Diet + Supplementation|Omega 3 and diet intervention
9537244|NCT03142165|Experimental|BMS-986263|
9537245|NCT03142165|Placebo Comparator|Placebo|
9537246|NCT03142217|Other|Patient with Huntington's Disease|
9537247|NCT03142295|Experimental|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
9537248|NCT03142555|Experimental|Health talk plus intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 minutes);~Social media (intensive reminders);~Regular personalized what's app interaction ( up to 2 months duration)"
9537249|NCT03142555|Placebo Comparator|Health talk plus less intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 mintues);~Social media ( less intensive reminders)"
9537250|NCT03142269|Active Comparator|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
9537251|NCT03142269|Placebo Comparator|unpolished group|the opposite unpolished was used as the control
9537252|NCT03142126|Experimental|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
9537253|NCT03142321|Experimental|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
10039066|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
9537254|NCT03142490|Experimental|Treatment|In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
9537255|NCT03142490|Active Comparator|Control|In vitro fertilization patients not submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
9537256|NCT03142282|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
9537257|NCT03142282|Experimental|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
9537258|NCT03142230|Experimental|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
9537259|NCT03142230|Active Comparator|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
9537260|NCT03142256|Active Comparator|Incentivised - Conditional Cash Transfer|Cash incentive for good drug levels assed by Dried Blood Spot
9537261|NCT03142256|No Intervention|No incentive|Truvada 200Mg-300Mg Tablet
9537262|NCT03142399|Experimental|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
9537263|NCT03142399|Placebo Comparator|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
9537264|NCT03142373|Experimental|CV4 group|CV4 technique
9537265|NCT03142373|Experimental|RR group|Rib Raising technique
9537266|NCT03142373|Placebo Comparator|Placebo group|Light touch
9537267|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
9537268|NCT03142386|Experimental|OMT group|Osteopathic manipulative treatment
9537269|NCT03142386|Active Comparator|Control Group|Physiotherapy
9537270|NCT03142464|No Intervention|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
9537271|NCT03142464|Experimental|No IV fluids|No IV fluids after the termination of the operation. T
9537272|NCT03142360|Experimental|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
9537273|NCT03142360|No Intervention|Non-Treatment group|On the other hand, the control group does not take anything.
9537274|NCT03142347|Active Comparator|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
9537275|NCT03142347|Experimental|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
9537276|NCT03142178|Experimental|Experimental 3VM1001 2g X 3 daily|3VM1001 active cream administered 2g cream three times daily for seven days
10039067|NCT01840423|Experimental|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
10039068|NCT01840423|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
9537277|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 2g X 3 daily|3VM1001 placebo vehicle administered 2g cream three times daily for seven days
9537278|NCT03142178|Experimental|Experimental 3VM1001 3g X 3 daily|3VM1001 active cream administered 3g cream three times daily for seven days
9537279|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X3 daily|3VM1001 placebo vehicle administered 3g cream three times daily for seven day
9537280|NCT03142178|Experimental|Experimental 3VM1001 3g x 4 daily|3VM1001 active cream administered 3g cream four times daily for seven days
9537281|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X 4 daily|3VM1001 placebo vehicle administered 3g cream four times daily for seven days
9537282|NCT03142308||Surgeons|Young surgeons in all surgical specialities
9537283|NCT03142542|Experimental|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
9537284|NCT03142542|Placebo Comparator|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
9537285|NCT03142100||Hebrew speaking participants|Hebrew speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
9537286|NCT03142100||Arabic speaking participants|Arabic speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
9537287|NCT03142009|Experimental|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
9537288|NCT03142009|No Intervention|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
9537289|NCT03141827|Experimental|Insulin|Nasal spray, insulin 40 IU, single dose
9537290|NCT03141827|Placebo Comparator|Placebo|Nasal spray, placebo, single dose
9537291|NCT03141970|Experimental|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
9537292|NCT03141970|No Intervention|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
9537293|NCT03142022||SDB and lung transplantation|Polysomnography at 1 year after lung transplantation.
9537294|NCT03141853|Experimental|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
9537295|NCT03141853|Placebo Comparator|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
9537296|NCT03141996|Experimental|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
9537297|NCT03141996|Active Comparator|Standard of care|Regular occupational therapy session
9537298|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
9537299|NCT03142061|Experimental|ECT|
9537300|NCT03142035|Experimental|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
9537301|NCT03142035|Active Comparator|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
9537302|NCT03142035|Other|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
9537303|NCT03142087|Active Comparator|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
9537304|NCT03142087|Active Comparator|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
9537305|NCT03141840|Experimental|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
9537306|NCT03141840|Placebo Comparator|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
9537307|NCT03141814||asthma|20 patients with ongoing ashma
9537308|NCT03141814||complete asthma remission|20 subjects with complete asthma remission
9537309|NCT03141814||clinical asthma remission|20 subjects with clinical asthma remission
9537310|NCT03141814||non-asthmatic healthy controls|20 subjects without respiratory symptoms and normal lung function and no bronchial hyperresponsiveness to methacholine and/or AMP
9537311|NCT03141723|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
9537312|NCT03141723|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
9537313|NCT03141723|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
9537314|NCT03141723|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
9537315|NCT03141866|Experimental|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
9537316|NCT03141866|Experimental|Exercise Intervention 2: Machine-based resistance training|Specialised, chair-based resistance training equipment for older adults.
9537317|NCT03141892||Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
9537318|NCT03141879|Experimental|Physical Activity Intervention|HUR resistance training intervention
9537319|NCT03141879|No Intervention|Regular care|(Wait-list control)
9537320|NCT03142074||Ascending thoracic aortic aneurysm|"Biomechanical and microstructural analysis of ATAA~ECG-gated CT"
9537321|NCT03141658|Experimental|TS-134 20 mg|
9537322|NCT03141658|Experimental|TS-134 60 mg|
9537323|NCT03141658|Experimental|Placebo|
9537324|NCT03141645|Experimental|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
9537325|NCT03141645|Active Comparator|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
9537326|NCT03141645|No Intervention|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
9537327|NCT03141918|Experimental|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
9537328|NCT03141918|Placebo Comparator|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
9537329|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
9537330|NCT03141944||Apathetic patients|"De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
9537331|NCT03141944||Non-apathetic patients|"De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
9537332|NCT03141632|Active Comparator|Dulaglutide|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
9537333|NCT03141632|Placebo Comparator|Placebo|0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
9537334|NCT03141697|Experimental|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
9537335|NCT03141697|Placebo Comparator|Room Air|Colonoscopy with Insufflatioin of Room Air
9537336|NCT03142048|Experimental|Schools of Health for the Elderly|"Participants receiving the community intervention (explained in the section Intervention)"
9537337|NCT03142048|No Intervention|Comparison Group|Participants in the study that do not receive the intervention
9537338|NCT03141801|Experimental|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
9537339|NCT03141801|Experimental|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
9537340|NCT03141801|Active Comparator|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
9537341|NCT03141801|Active Comparator|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
9537342|NCT03141710|Experimental|12 type 2 diabetes patients|Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
9537343|NCT03141593|Active Comparator|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
9537344|NCT03141593|Active Comparator|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
9537345|NCT03141593|Active Comparator|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
9537346|NCT03141593|Active Comparator|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
9537347|NCT03141580|Experimental|Study group|Subjects with carotid stent who consented to undergo near-infrared spectroscopy and intravascular ultrasound imaging.
9537348|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
9537349|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
9537350|NCT03141463|Experimental|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
9537351|NCT03141398||High-Risk Group|The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2* MRI of the pancreas (T2* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.
9537352|NCT03141268||Healthy volunteers|Normal subjects aged 18-80 years. No chronic diseases.
9537353|NCT03141268||IBS patients, lactose intolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose intolerant. No concomitant diseases.
9537354|NCT03141268||IBS patients, lactose tolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose tolerant. No concomitant diseases.
10039069|NCT01840423|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
10039070|NCT01840436|Placebo Comparator|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
9537355|NCT03141294|Placebo Comparator|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
9537356|NCT03141294|Experimental|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
9537357|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
9537358|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
10039071|NCT01840436|Experimental|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
10039072|NCT01840436|Experimental|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
10039073|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
9537359|NCT03141515|Active Comparator|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
9537360|NCT03141515|Experimental|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
9537361|NCT03141385|Experimental|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
9537362|NCT03141385|Sham Comparator|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
9537363|NCT03141502|Experimental|Skin Stretching Device (SSD)|the wound is primarily closed by aid of the SSD after necessary surgical debridement.
9537364|NCT03141502|Active Comparator|Skin Grafting (SG)|the wound is primarily closed by the technique of skin grafting after necessary surgical debridement.
9537365|NCT03141476|Other|Cefuroxime 1,5g|BMI <30kg/m*m
9537366|NCT03141476|Other|Cefuroxime 3g|BMI 30-50kg/m*m
9537367|NCT03141476|Other|Cefuroxime 4,5g|BMI >50kg/m*m
9537368|NCT03141541|No Intervention|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
9537369|NCT03141541|Experimental|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
9537370|NCT03141489|Experimental|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
9537371|NCT03141489|Experimental|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
9537372|NCT03141554|Active Comparator|Treatment Sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm)."
9537373|NCT03141554|Active Comparator|Treatment Sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle"
9537374|NCT03141554|Active Comparator|Treatment Sequence Group 3|"Treatment Sequence Group 3 = C -> A -> B~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)"
9537375|NCT03141333|Experimental|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
9537376|NCT03141333|No Intervention|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
9537377|NCT03141216|Experimental|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
9537378|NCT03141216|Experimental|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
9537379|NCT03141255|No Intervention|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
9537380|NCT03141255|Experimental|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
9537381|NCT03141229|Experimental|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
9537382|NCT03141229|Other|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
10039074|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
10039075|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
9482782|NCT03340974|Placebo Comparator|Arm B: SBRT + Placebo|
10039076|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
9482783|NCT03337451|Experimental|OPN-305|
9482784|NCT03336619|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
9482785|NCT03336619|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
9482786|NCT03335371|Experimental|TTP399 400 mg|
9482787|NCT03335371|Placebo Comparator|Placebo|
9803727|NCT03485820|Sham Comparator|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
9803728|NCT03484182|Active Comparator|Standard Home Exercise Program|
9803729|NCT03484182|Experimental|Web-based Home Exercise Program|
9482791|NCT03328507|Experimental|BLI4900|BLI4900 Bowel Preparation
9482792|NCT03328507|Active Comparator|PEG Control|Polyethylene glycol-based bowel preparation
9482793|NCT03328273|Other|Arm A Part 1 and 2|DISCONTINUED (ceralasertib monotherapy)
9482794|NCT03328273|Experimental|Arm B Part 1 and 2|ceralasertib + acalabrutinib in combination
9482795|NCT03322137|Active Comparator|SNA-120 (0.05% )|Pegcantratinib Ointment
9482796|NCT03322137|Active Comparator|SNA-120 (0.5%)|Pegcantratinib Ointment
9482797|NCT03322137|Placebo Comparator|Vehicle|
9482798|NCT03321929|Experimental|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects undergo lumpectomy as standard of care and will have the study intervention, guidance by intraoperative imaging using the LUM Imaging Device
9482799|NCT03321526|Experimental|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
9482800|NCT03321526|Active Comparator|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
9482801|NCT03320434|Experimental|PRT-2761 0.5%|
9482802|NCT03320434|Experimental|PRT-2761 1%|
10039077|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
9482803|NCT03320434|Active Comparator|Patanol|
9482804|NCT03320434|Active Comparator|Pred-forte|
9482805|NCT03320434|Placebo Comparator|PRT-2761 0%|
9482806|NCT03318393|Active Comparator|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
9482807|NCT03318393|Experimental|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
9482808|NCT03315143|Experimental|Sotagliflozin|Sotagliflozin dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
9482809|NCT03315143|Placebo Comparator|Placebo|Placebo dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
9482810|NCT03315130|Experimental|0.1 mg/kg zilucoplan (RA101495)|
9482811|NCT03315130|Experimental|0.3 mg/kg zilucoplan (RA101495)|
9482812|NCT03315130|Placebo Comparator|Placebo|
9482813|NCT03313882||donor|donor: normal heart samples from donor
9482814|NCT03313882||ICM|ICM: heart samples with ischemic cardiomyopathy
9482815|NCT03313882||NICM|NICM: heart samples with non-ischemic cardiomyopathy
9803730|NCT03478956|Experimental|Etrolizumab Q4W|Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
9804164|NCT01734382|Experimental|Part 1: Tocilizumab (TCZ) Q2W|Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants < 30 kg; 8 mg/kg for participants >/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.
9497764|NCT03472144|Active Comparator|CRSwNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
9537383|NCT03141203|Experimental|Dose Level 1|"8mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
9537384|NCT03141203|Experimental|Dose Level 2 (starting dose)|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
9537385|NCT03141203|Experimental|Dose Level 3|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
9537386|NCT03141203|Experimental|Dose Level 4|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
10039078|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
10039079|NCT01840488|Experimental|Irosustat (BN83495)|Single oral administration of irosustat
9537387|NCT03141203|Experimental|Dose Level 5|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
9537388|NCT03141203|Experimental|Dose Level 6|"14mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
9537389|NCT03141164|Experimental|Training|Computerized vision training
9537390|NCT03141164|Sham Comparator|Control|Sham
9537391|NCT03141138|Experimental|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
9537392|NCT03141138|Experimental|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
9537393|NCT03141138|Experimental|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
9537394|NCT03141138|Experimental|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
9537395|NCT03141125|Experimental|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.~In addition, patients also received standard therapy for scleroderma."
9537396|NCT03141125|Placebo Comparator|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
9537397|NCT03140982|Active Comparator|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
9537398|NCT03140982|Active Comparator|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
9537399|NCT03140956|Experimental|Levodopa formulation D|Levodopa formulation D
9537400|NCT03140956|Experimental|Levodopa formulation E|Levodopa formulation E
9537401|NCT03140956|Experimental|Levodopa formulation F|Levodopa formulation F
9537402|NCT03140956|Active Comparator|Sinemet IR 100/25mg|Sinemet IR 100/25MG
9537403|NCT03140956|Active Comparator|Sinemet CR 100/25mg|Sinemet IR 100/25MG
9537404|NCT03140956|Experimental|ODM-104 100mg|ODM-104 100MG
10039080|NCT01840501|Experimental|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
10039081|NCT01840501|Experimental|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
10039082|NCT01840501|Experimental|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
10039083|NCT01840501|Experimental|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
9537405|NCT03140956|Active Comparator|Carbidopa 20mg|Carbidopa 20MG
9537406|NCT03140956|Active Comparator|Carbidopa 65mg|Carbidopa 65MG
9537407|NCT03141008||Ketogenic diet exposed group|"Fibroscan changes with different diets:~Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes."
9537408|NCT03141008||NAFLD diet exposed group|"Fibroscan changes with different diets:~Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes."
9537409|NCT03141112||early CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy up to 48 hours after reaching criteria of severe sepsis.
9537410|NCT03141112||late CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy after 48 hours after reaching criteria of severe sepsis.
10039084|NCT01840501|Experimental|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
10039085|NCT01840501|Experimental|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
10039086|NCT01840501|Experimental|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
10039087|NCT01840501|Experimental|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
10039088|NCT01840501|Experimental|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
10039089|NCT01840501|Experimental|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
10039090|NCT01840501|Placebo Comparator|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
10039091|NCT01840501|Experimental|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
10039092|NCT01840501|Experimental|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
10039093|NCT01840501|Experimental|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
10039094|NCT01840501|Experimental|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
10039095|NCT01840501|Experimental|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
10039096|NCT01840501|Experimental|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
10039097|NCT01840501|Placebo Comparator|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
10039098|NCT01840527||Group 1|Advanced Melanoma
10039099|NCT01840527||Group 2|Stage II/III Melanoma
10058403|NCT02018068|Experimental|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
9482822|NCT03311269|Active Comparator|ClariVein RES 1% Injection|Sodium Tetradecyl Sulfate 1% Injection single administration
9482823|NCT03311269|Active Comparator|ClariVein RES 3% Injection|Sodium Tetradecyl Sulfate 3% Injection single administration
9482824|NCT03307577|Experimental|UHE-101 cream, 1%|Cream is applied twice a day
9482825|NCT03307577|Placebo Comparator|Vehicle cream|Cream is applied twice a day
9482826|NCT03305848|Other|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
9482827|NCT03303625|Experimental|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (>=) 18 to lesser than or equal to (<=) 50 years will receive vector Ad26.RSV.preF at 1*10^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
9537411|NCT03141047|Experimental|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
9537412|NCT03141047|No Intervention|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
9537413|NCT03141073|Experimental|HMS5552|75mg BID
9482828|NCT03303625|Placebo Comparator|Cohort 0: Adults (Placebo)|Participants aged >= 18 to <= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
9482829|NCT03303625|Experimental|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged >=12 to <=24 months will receive Ad26.RSV.preF at 5*10^10 vp via IM route (Group 3) on Day 1 and 29.
9537414|NCT03141073|Placebo Comparator|Placebo|BID
9622063|NCT02518958|Experimental|RRx-001 + Nivolumab|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Nivolumab (3 mg/kg) will be administered on Day 2 or Day 3 as a single agent.
9622064|NCT02518932|Experimental|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
9622065|NCT02518932|Placebo Comparator|Placebo|To examine the effect of saline on glucose uptake
9622066|NCT02518737||GIP-receptor deficient|Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.
9622067|NCT02518737||Controls|Matched controls, with a normal functioning GIP-receptor.
9622068|NCT02518724|Active Comparator|RIPC intervention group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after RIPC intervention exposure at the beginning of every meeting."
9622069|NCT02518724|Placebo Comparator|false exopsure group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after placebo intervention exposure at the beginning of every meeting."
9622070|NCT02518711|Experimental|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
9537415|NCT03140995|Active Comparator|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
9537416|NCT03140995|No Intervention|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
9537417|NCT03140943|Experimental|Carfilzomib, Thalidomide and Dexamethasone|
9537418|NCT03140878|Experimental|LGG|Lactobacillus rhamnosous (LGG) 450 billion CFU dissolved in water
9537419|NCT03140878|Placebo Comparator|Placebo|The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics
9616133|NCT04474184|Experimental|Aim 1 (focus group)|Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
9616134|NCT04474184|Experimental|Aim 2 (vaginal kit)|Participants receive a tampon kit for collection of vaginal samples.
9616135|NCT04471935|Other|At home Speech Hero therapy|
9616136|NCT04469465|Experimental|Danicopan + C5 Inhibitor|Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
9616137|NCT04469465|Placebo Comparator|Placebo + C5 Inhibitor|Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).
9616138|NCT04469036|No Intervention|Telephone consultation|Telephone consultation to a pediatric trauma specialist
9616139|NCT04469036|Experimental|Virtual Pediatric Trauma Center|The Virtual Pediatric Trauma Center (VPTC), uses live video, or telehealth, to bring the expertise of a Level I pediatric trauma center virtually to patients at a hospital emergency department.
9616140|NCT04440202|Active Comparator|Conventional sea bream group|This arm will consume 2 portions (each 200 g cooked) of conventional fish (sea bream) fillet per week for a 1-month period.
9616141|NCT04440202|Experimental|Enriched sea bream group|This arm will consume 2 portions (each 200 g cooked) of fish fillet bred with bioactive lipids from olive oil by-products per week for a 1-month period.
9616142|NCT04439344|Experimental|Treatment (binimetinib)|Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9616143|NCT04439318|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9616144|NCT04439292|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9616145|NCT04439279|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9622071|NCT02518711|No Intervention|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
10039100|NCT01840540|Experimental|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
10039101|NCT01840553|Active Comparator|polyethylene glycol|4 Liters of PEG administered split in 2 doses
10039102|NCT01840553|Experimental|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
10039103|NCT01840592|Experimental|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
10039104|NCT01840618||Obese PCOS and sleep apnea|"BMI >95%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
10039105|NCT01840618||Obese PCOS without sleep apnea|BMI >95%ile AND Polysomnography with AHI <2.5
10039106|NCT01840618||Normal weight Controls|BMI <85%ile AND regular menses
10039107|NCT01840618||Lean PCOS and sleep apnea|"BMI <85%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
10039108|NCT01840618||Lean PCOS without sleep apnea|BMI <85%ile AND Polysomnography with AHI <2.5
10039109|NCT01840631|Active Comparator|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
10039110|NCT01840631|Active Comparator|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
10039111|NCT01840644||all participants|Walking on treadmill, different velocities and incline
10039112|NCT01840683|Experimental|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
10039113|NCT01840696|Experimental|Regadenoson|
10039114|NCT01840709|Experimental|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
10039115|NCT01840709|No Intervention|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
10039116|NCT01840735|Active Comparator|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
9482830|NCT03303625|Placebo Comparator|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged >= 12 to <= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
10039117|NCT01840735|Placebo Comparator|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
10039118|NCT01840748||no vasodilator|patients receiving no vasodilator
10039119|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
10039120|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
10039121|NCT01840761|Experimental|herbal drug|Traditional Chinese herbal drug
10039122|NCT01840761|Placebo Comparator|Placebo|
10039123|NCT01840774|Active Comparator|Low-dose pain medication|80min IV infusion of a low-dose pain medication
10039124|NCT01840774|Placebo Comparator|saline placebo|80min IV infusion of a saline placebo
9482831|NCT03303170|Experimental|Sebacia Microparticles|
9482832|NCT03303170|Active Comparator|Nd:Yag Laser|
10039125|NCT01840787|Experimental|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
10039126|NCT01840800|Active Comparator|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
9482833|NCT03301051|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
10039127|NCT01840800|Active Comparator|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
10039128|NCT01840800|Placebo Comparator|Placebo|Saline 9 mg/ml
10039129|NCT01840813|Active Comparator|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
10039130|NCT01840813|Placebo Comparator|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
10039131|NCT01840826|Experimental|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 & 5.
9482834|NCT03301051|Placebo Comparator|Placebo|Single dose - Placebo
9482835|NCT03299166|Experimental|BHV-4157|
9482836|NCT03299166|Placebo Comparator|Placebo|
9482837|NCT03295396|Experimental|Arm A|ONC201 in relapsed H3 K27M glioma
9482838|NCT03295396|Experimental|Arm B|"ONC201 in relapsed H3 K27M glioma, excluding:~Primary malignant lesion located in the pons or spinal cord.~Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).~Prior bevacizumab treatment of >4 doses of >7.5 mg/Kg~Tumors with known 1p/19q co-deletion."
9497765|NCT03472144|Active Comparator|CRSsNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only left side and placebo on right side
9497766|NCT03472144|Active Comparator|CRSsNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
9497767|NCT03472144|Active Comparator|CRSsNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
9497768|NCT03472131|Experimental|Septic spondylodiscitis|A unilateral posterolateral approach and debridement with titanium cage insertion supplemented by screw fixation for severe sick patients suffering from septic spondylodiscitis
9497769|NCT03472118|Experimental|High Flow Apneic Oxygenation|Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
9497770|NCT03472105|Other|Habitual diet|18 participants were on a habitual diet for 7 days
9497771|NCT03472105|Active Comparator|New Nordic Renal Diet|18 participants were given a New Nordic Renal Diet for 7 days
9497772|NCT03472066||a group of women who have been conized|Previous conization
9497773|NCT03472066||control group with asymptomatic patients|on routine second trim no previous conization
9497774|NCT03472053|Experimental|BIO-11006 plus standard of care|Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
9497775|NCT03472053|Experimental|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
9497776|NCT03472040|Experimental|BCX7353 150 mg once daily|
9497777|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 1|
9497778|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 2|
9497779|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 3|
9497780|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 4|
9497781|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 5|
9497782|NCT03472001|Experimental|Training group|2-hour training based on reflection and feedback
9497783|NCT03472001|Active Comparator|Lecture group|1-hour lecture
9497784|NCT03472001|No Intervention|Control group|The remaining students only attending dermatology electives
9537420|NCT03140904|Other|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
10039132|NCT01840826|No Intervention|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
10039133|NCT01840839|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
10039134|NCT01840839|Sham Comparator|no stimulation|Sham stimulation during periods of SWS
10039135|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
10039136|NCT01840865|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
10039137|NCT01840865|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
9482839|NCT03293498|Experimental|Group A|Low dose NanoFlu - Day 0; Fluzone HD - Day 21
9482840|NCT03293498|Experimental|Group B|High dose NanoFlu - Day 0; Fluzone HD - Day 21
9482841|NCT03293498|Active Comparator|Group C|Fluzone HD - Day 0; Saline - Day 21
9482842|NCT03290534|Experimental|CivaSheet Directional LDR Brachytherapy|FDA Cleared CivaSheet directional Pd-103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
9482843|NCT03290248|Placebo Comparator|Vehicle|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
9482844|NCT03290248|Active Comparator|B 244 1x (low dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
9482845|NCT03290248|Active Comparator|B244 4x (mid dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
9482846|NCT03290131|Active Comparator|AERT 40 mg|40 mg Arbaclofen Extended-Release Tablets
9482847|NCT03290131|Active Comparator|AERT 80 mg|80 mg Arbaclofen Extended-Release Tablets
9482848|NCT03290131|Placebo Comparator|Placebo|Placebo
9482849|NCT03288454|Experimental|Cohort 1|ciraparantag (60 mg)
9482850|NCT03288454|Experimental|Cohort 2|ciraparantag (120 mg)
9482851|NCT03288454|Experimental|Cohort 3|ciraparantag (30 mg)
9482852|NCT03288454|Placebo Comparator|Placebo|placebo (saline for injection)
9482853|NCT03287232|Placebo Comparator|Placebo|
9482854|NCT03287232|Experimental|Prasterone|
9482855|NCT03285178|Experimental|IW-1701 (Olinciguat) Low Dose|
9482856|NCT03285178|Experimental|IW-1701 (Olinciguat) Medium Dose|
9482857|NCT03285178|Experimental|IW-1701 (Olinciguat) High Dose|
9482858|NCT03285178|Experimental|IW-1701 (Olinciguat) Higher Dose|
9482859|NCT03285178|Placebo Comparator|Placebo|
9482860|NCT03284385|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9482861|NCT03281382|Experimental|Investigational Arm|Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
9482862|NCT03280056|Active Comparator|NurOwn® (MSC-NTF cells)|Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals
9482863|NCT03280056|Placebo Comparator|Placebo|Three Intrathecal administrations of Placebo at bi-monthly intervals
9482864|NCT03277690|Experimental|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
9482865|NCT03277690|Placebo Comparator|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
9482866|NCT03272763|Experimental|F&P Toffee mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
9482867|NCT03267147||antiCCP positive|"Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis~no intervention is given"
9482868|NCT03267147||antiCCP negative|Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
9482869|NCT03265249|Experimental|Group 1|BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
9482870|NCT03265249|No Intervention|Group 2|Subjects will receive the standard of care pain control analgesia
9482871|NCT03263273|Placebo Comparator|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
9482872|NCT03263273|Active Comparator|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
9482873|NCT03263273|Active Comparator|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
9482874|NCT03259568|Active Comparator|Active rTMS|
9482875|NCT03259568|Sham Comparator|Sham rTMS|
9482876|NCT03254485|Experimental|IW-1973 High Dose|
9482877|NCT03254485|Placebo Comparator|Placebo|Placebo to match experimental drug
9482878|NCT03250117|Experimental|Cohort 1|Requip; One Ropinirole Implant
9482879|NCT03250117|Experimental|Cohort 2|Requip; Two Ropinirole Implants
9482880|NCT03250117|Experimental|Cohort 3|Requip; Three Ropinirole Implants
9482881|NCT03250117|Experimental|Cohort 4|Requip; Four Ropinirole Implants
9482882|NCT03249376|Experimental|Lumateperone|Lumateperone (ITI-007 60 mg) administered once daily every evening for 6 weeks
10039138|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
9622072|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
10039139|NCT01840891|Experimental|Noro virus shedder|Lactose H2 breath test (LH2BT)
10039140|NCT01840891|Active Comparator|No norovirus shedding|Lactose H2 breath test (LH2BT)
10039141|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
9482883|NCT03249376|Placebo Comparator|Placebo|Placebo administered once daily every evening for 6 weeks
9482884|NCT03241459|Experimental|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
9482885|NCT03241459|Active Comparator|Medtronic IN.PACT Admiral DCB|
9482886|NCT03241173|Experimental|INCAGN01949 + Nivolumab|INCAGN01949 combined with nivolumab.
9482887|NCT03241173|Experimental|INCAGN01949 + Ipilimumab|INCAGN01949 combined with ipilimumab.
9482888|NCT03241173|Experimental|INCAGN01949 + Nivolumab + Ipilimumab|INCAGN01949 combined with nivolumab and ipilimumab.
9482889|NCT03235024|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
9482890|NCT03235024|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
9482891|NCT03234907|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase.
9482892|NCT03234907|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV, infusion, at Weeks 0, 2, and 6 in the induction phase.
9482893|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q8W + Placebo Q8W|Vedolizumab 300 mg, IV, infusion, every 8 Weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching IV, infusion Q8W at Weeks 18, 26, 34, 42, 50 and 58 in the maintenance phase in participants who receive vedolizumab in the induction phase and achieve clinical response at Week 10.
9482894|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q4W|Vedolizumab 300 mg, IV, infusion, every 4 weeks (Q4W), from Week 14 to Week 58 in the maintenance phase in participants who receive vedolizumab or placebo in the induction phase and do not achieve clinical response at Week 10.
9482895|NCT03234907|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching IV, infusion, every 4 weeks, Week 14 to Week 58 in the maintenance phase in participants who receive placebo in the induction phase and achieve clinical response at Week 10.
9482897|NCT03228394|Experimental|Ganaxolone|Intravenous
9482898|NCT03228394|Placebo Comparator|Placebo|Intravenous
9482899|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (CAD)|
9482900|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)|
9482901|NCT03224650||Surgical|Patients treated surgically for spinal metastases
9482902|NCT03224650||Non-operative|Patients treated non-operatively for spinal metastases
9482903|NCT03224650||Expectant|Patients receiving no treatment for spinal metastases
9482904|NCT03219307|Experimental|NOVOCART 3D|Matrix associated autologous chondrocyte implant
9482905|NCT03219164|Experimental|AZLI|AZLI for 28 days
9482906|NCT03219164|Experimental|AZLI + Placebo|AZLI for 14 days followed by placebo for 14 days
9482907|NCT03218917|Experimental|INS1007 10 mg Oral Tablet|Once per day for 24 weeks.
9482908|NCT03218917|Experimental|INS1007 25 mg Oral Tablet|Once per day for 24 weeks.
9482909|NCT03218917|Placebo Comparator|Placebo Oral Tablet|Once per day for 24 weeks.
9482910|NCT03217591|Experimental|IW-1973 Low Dose|Administered daily for 12 weeks
9482911|NCT03217591|Experimental|IW-1973 High Dose|Administered daily for 12 weeks
9482912|NCT03217591|Placebo Comparator|Placebo|Placebo to match experimental drug administered daily for 12 weeks
9482913|NCT03215277|Experimental|Bimekizumab|Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
9482914|NCT03215277|Experimental|Certolizumab pegol|Subjects will receive several certolizumab pegol administrations on pre-defined time points.
9482915|NCT03210740|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
9482916|NCT03210740|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles
9482917|NCT03208985|Experimental|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
9482918|NCT03206814|Active Comparator|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
9482919|NCT03206814|Experimental|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
9482920|NCT03204422||Children's group|no intervention. participants, whose age was 5 to 18 years, were enrolled in Children's group.
9482921|NCT03204422||Adults group|no intervention. participants, whose age was over 18 years, were enrolled in Adults group.
9482922|NCT03204396|Active Comparator|Intervention group|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via pen s.c. once weekly for 12 weeks.
9482923|NCT03204396|Placebo Comparator|Placebo group|0.5 ml normal saline (0.9% sodium chloride (NaCl)), injection s.c. via syringe once weekly for 12 weeks.
9482924|NCT03202901|Experimental|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
9482925|NCT03202901|Placebo Comparator|Placebo|"Yeast brew extract (200 mg)~Excipients:~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
9482926|NCT03202017|Active Comparator|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
10039142|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
9537421|NCT03140904|Other|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
9537422|NCT03140839|Experimental|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
9537423|NCT03140839|Active Comparator|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
9537424|NCT03140839|Placebo Comparator|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
9537425|NCT03140930|Experimental|Duodenal tastants, ileal placebo|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)
9537426|NCT03140930|Experimental|Duodenal placebo, ileal tastants|Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)
9537427|NCT03140930|Experimental|Duodenal tastants, ileal tastants|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)
9537428|NCT03140930|Placebo Comparator|Duodenal placebo, ileal placebo|Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)
9537429|NCT03140891|Experimental|NHFOV|NHFOV is used as the supporting mode after extubation
9537430|NCT03140891|Active Comparator|NCPAP|NCPAP is used as the supporting mode after extubation
9537431|NCT03140553|Experimental|TCH|docetaxel/carboplatin/trastuzumab
9537432|NCT03140553|Active Comparator|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
9537433|NCT03140566|Experimental|Clinical assessment plus IVC diameter|Decongesting treatment guided by clinical assessment and ultrasound evaluation of the inferior vena cava diameter
9537434|NCT03140566|Sham Comparator|Clinical assessment only|Decongesting treatment guided by clinical assessment alone
9537435|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
9537436|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
9537437|NCT03140748|Other|Patients with fungal peritonitis|
9537438|NCT03140748|Other|Patients with peritonitis without yeast|
9537439|NCT03140865||Cognitively Normal|This group will include 300 healthy volunteers with no apparent memory problems. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
9537440|NCT03140865||Mild Cognitive Impairment|This group will include 400 volunteers who have mild memory problems that are observed during cognitive testing. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
9537441|NCT03140865||Alzheimer's disease|This group will include 150 volunteers with mild stage Alzheimer's disease dementia. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend visits to complete study interviews.
10039143|NCT01840969||CAOD group|Single arm study group
10039144|NCT01840982|Experimental|Giant embryonic brown rice|
9537442|NCT03140813|Experimental|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
9537443|NCT03140813|Experimental|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
9537444|NCT03140813|Experimental|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
9537445|NCT03140813|Experimental|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
9537446|NCT03140813|Experimental|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
9537447|NCT03140813|Experimental|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
10039145|NCT01840982|Experimental|Giant embryonic rice|
10039146|NCT01840982|Active Comparator|White rice|
10039147|NCT01840982|Active Comparator|Glucose solution|
10039148|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
10039149|NCT01841008|Experimental|Tacrolimus ointment 0.1%|
10039150|NCT01841008|Placebo Comparator|Group Placebo|
10039151|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
10039152|NCT01841086|Active Comparator|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
10039153|NCT01841086|Experimental|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
9537448|NCT03140527|Active Comparator|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
9537449|NCT03140527|Placebo Comparator|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
9537450|NCT03140527|Active Comparator|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
9537451|NCT03140527|Placebo Comparator|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
9537452|NCT03140527|Active Comparator|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
10039154|NCT01841099|Experimental|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
10039155|NCT01841099|Placebo Comparator|Placebo granules|Placebo granules
10039156|NCT01841112|Placebo Comparator|Placebo (Multiple dose part)|Placebo tablet
10039157|NCT01841112|Experimental|Dose 2, EM, single dose|Extensive Metaboliser (EM), single dose part, medium dose
10039158|NCT01841112|Experimental|Dose 3, EM, single dose|Extensive Metaboliser (EM), single dose part, high dose
10039159|NCT01841112|Experimental|Dose 3, PM, single dose|Poor Metaboliser (PM), single dose part, high dose
10039160|NCT01841112|Experimental|Dose 3, PM, multiple dose|Poor Metaboliser (PM), multiple dose part, high dose
10039161|NCT01841112|Placebo Comparator|Placebo (Single dose part)|Placebo tablet
10039162|NCT01841112|Experimental|Dose 1, EM, single dose|Extensive Metaboliser (EM), single dose part, low dose
9537453|NCT03140527|Active Comparator|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
9537454|NCT03140527|Placebo Comparator|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
9537455|NCT03140527|Active Comparator|MAD Cohort 1-3 CF PTI-801 Active - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
9537456|NCT03140527|Placebo Comparator|MAD Cohort 1-3 CF PTI-801 Placebo - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
9537457|NCT03140527|Active Comparator|Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
9537458|NCT03140527|Placebo Comparator|Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
9537459|NCT03140527|Active Comparator|Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
9622073|NCT02518672|Active Comparator|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
10039163|NCT01841125|Experimental|escitalopram|escitalopram 15mg
10039164|NCT01841125|Placebo Comparator|Placebo|placebo 15mg
10039165|NCT01841151|Active Comparator|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
10039166|NCT01841151|Active Comparator|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
10039167|NCT01841151|Active Comparator|WM training|Working Memory training (WMt)
10039168|NCT01841151|No Intervention|Waiting-list|Treatment as usual only
10039169|NCT01841164|Experimental|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
9537460|NCT03140527|Placebo Comparator|Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
9537461|NCT03140527|Active Comparator|Cohort 6 CF PTI-801 Active|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
9537462|NCT03140527|Placebo Comparator|Cohort 6 CF PTI-801 Placebo|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
9537463|NCT03140787|Experimental|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
9537464|NCT03140787|Active Comparator|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
9537465|NCT03140384|Active Comparator|Administration of oral Misoprostol|
9537466|NCT03140384|Active Comparator|Administration of Misoprostol vaginally|
9537467|NCT03140384|Active Comparator|Administration of buccal Misoprostol|
9537468|NCT03140449|Experimental|Rapamycin|Rapamycin(0.1%)
9537469|NCT03140449|Experimental|Calcitriol|Calcitriol(3mcg/g)
9537470|NCT03140449|Experimental|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
9537471|NCT03140644|Experimental|Patients with thoracic sarcoidosis|Patients routinely followed-up for thoracic sarcoidosis with a CT scan indicated in the follow-up
9537472|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
9537473|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
9537474|NCT03140319|Experimental|Fibroblast|Injection of Fibroblast
9537475|NCT03140319|Placebo Comparator|Placebo|the patient receive placebo injection
9537476|NCT03140618|Experimental|LEPPIC|The light and environment project in psychiatric inpatient care
10039170|NCT01841164|Placebo Comparator|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
10039171|NCT01841190||PROCALCITONIN|
10039172|NCT01841190||DELTA SOFA|
9537477|NCT03140462||liver transplant patients and donors|To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
9537478|NCT03140488|No Intervention|Lean-Control|"1) Control group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
9537479|NCT03140488|Experimental|Lean-Intervention|"2) Intervention group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
9537480|NCT03140488|No Intervention|Obese-Control|"3) Control group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
9537481|NCT03140488|Experimental|Obese-Intervention|"4) Intervention group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
9537482|NCT03140657|Experimental|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months.
9537483|NCT03140657|Placebo Comparator|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months.
9616146|NCT04439266|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
10059469|NCT02027597|Active Comparator|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
9482927|NCT03202017|Active Comparator|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
9482928|NCT03200704|Experimental|IC2000/SPY-PHI|Per standard of care, each subject will receive an injection of Tc-99m radioactive colloid. Then the periareolar area of the breast(s) identified with breast cancer will be injected (intradermal) twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Following the injection lymph node mapping will occur based on intraoperative fluorescence visualization using IC2000 and SPY-PHI. Lymph nodes will be excised following identification with IC2000 and SPY-PHI. The Gamma Probe will then be used with Tc-99m for confirmation of the excised lymph nodes as well as in the area of LN excision to ensure all LNs have been identified and excised.
9482929|NCT03198728|Experimental|SOV2012-F1-treated|200 patients treated with SOV2012-F1, starting dose of 600 mg - (400 mg with morning meal and 200 mg with evening meal). Dose titrated up to a maximum of 600 mg TU in the morning and 400 mg in the evening or down to 200 mg TU in the morning based on plasma T at Days 14 and 42.
9482930|NCT03198728|Active Comparator|Andro-Gel treated|100 patients treated with AndroGel, starting dose of 40.5 mg QD. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 42.
9482931|NCT03197870|Experimental|AKB-9778 15mg BID|
9482932|NCT03197870|Experimental|AKB-9778 15mg QD|
9482933|NCT03197870|Placebo Comparator|Placebo BID|
9482934|NCT03197064|Other|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
9482935|NCT03196219|Other|Arm 1|Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.
9482936|NCT03196219|Placebo Comparator|Arm 2|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 & 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
9482937|NCT03196219|Other|Arm 3|If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.
9482938|NCT03192995|Active Comparator|Experimental|lorcaserin, extended release
9482939|NCT03192995|Placebo Comparator|Control|Placebo
9482940|NCT03191864|Experimental|APT-1011 1.5 mg HS|Placebo after breakfast, APT-1011 1.5 mg HS
9482941|NCT03191864|Experimental|APT-1011 1.5 mg BID|APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
9482942|NCT03191864|Experimental|APT-1011 3 mg HS|Placebo after breakfast, APT-1011 3 mg HS
9482943|NCT03191864|Experimental|APT-1011 3 mg BID|APT-1011 3 mg after breakfast, APT-1011 3 mg HS
9482944|NCT03191864|Placebo Comparator|Placebo BID|Placebo 30 minutes after breakfast and HS
9482945|NCT03189173|Experimental|All patients|"Patients will receive all four interventions in randomized order.~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:~Interventions: Oral appliance | Oral appliance plus oxygen | Oxygen | No treatment"
9482946|NCT03188666|Experimental|REGN2477|
9482947|NCT03188666|Experimental|Placebo|
9482948|NCT03187834|Active Comparator|Azithromycin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Azithromycin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm and treated for 5 days.~Children will receive treatment everyday, once a day as is:~Azithromycin: 10 mg/kg once daily on Day 1, then 5 mg/kg once daily Days 2-5"
9482949|NCT03187834|Active Comparator|Amoxicillin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Amoxicillin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, twice a day as is:~Amoxicillin: 25 mg/kg/day, divided into twice daily doses for Days 1-5"
9482950|NCT03187834|Active Comparator|Cotrimoxazole|"Comparison of nasopharyngeal and rectal microbiome in children receiving Cotri-moxazole versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, once a day as is:~Co-trimoxazole: 240 mg daily for Days 1-5"
9482951|NCT03187834|Placebo Comparator|Placebo|"Comparison of nasopharyngeal and rectal microbiome in children receiving placebo versus children receiving antibiotics Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive Placebo everyday, once a day."
9482952|NCT03185013|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
9482953|NCT03185013|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
9482954|NCT03183128|Experimental|SER-109|Received oral dose of SER-109
9482955|NCT03183128|Placebo Comparator|Placebo|Received matching placebo
9482956|NCT03182686|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
9482957|NCT03182686|Other|Saline|Saline, solution, 4 mL, single intra-articular injection
9482958|NCT03180684|Experimental|VGX-3100 + EP|Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.
9482959|NCT03180684|Experimental|VGX-3100 + EP + Imiquimod|IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
10039173|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
9482960|NCT03175432|Experimental|Arm I (atezolizumab, bevacizumab)|Participants receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9482961|NCT03175432|Experimental|Arm II (atezolizumab, bevacizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9482962|NCT03175367|Experimental|Group A: dosing regimen 1|SC Evinacumab QW for 16 weeks
9482963|NCT03175367|Experimental|Group A: dosing regimen 2|SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
9482964|NCT03175367|Experimental|Group A: dosing regimen 3|SC Evinacumab QW for 16 weeks
9482965|NCT03175367|Experimental|Group A: matching placebo|Placebo SC QW for 16 weeks
9482966|NCT03175367|Experimental|Group B: dosing regimen 1|Intravenous (IV) Evinacumab Q4W for 24 weeks
9482967|NCT03175367|Experimental|Group B: dosing regimen 2|IV Evinacumab Q4W for 24 weeks
9482968|NCT03175367|Experimental|Group B: matching placebo|Placebo IV Q4W for 24 weeks
9482969|NCT03175224|Experimental|Single-Arm|APL-101 Oral Capsules
9482970|NCT03175068|Active Comparator|CBT|The clinical psychologist will use a manualized CBT approach tailored to MDD or gSAD. Over a 12-week period sessions will include core CBT strategies -- psychoeducation, cognitive intervention (e.g., cognitive restructuring), behavioral changes (i.e., fear exposure, behavioral activation strategies) and relapse prevention.
9482971|NCT03175068|Placebo Comparator|ST|The clinical psychologist will use an ST approach that resembles client-centered therapy of Carl Rogers (1951) which has been used as a control psychotherapy. The manual is based on supportive psychotherapy principles. Over a 12-week period sessions will emphasize reflective listening and elicitation of affect. In contrast to CBT, therapists allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathetic comments. Therapists will refrain from delineating any CBT theoretical framework and avoided cognitive and behavioral techniques that might overlap with CBT.
9482972|NCT03172910|Experimental|Cohort 1|ciraparantag (60 mg)
9482973|NCT03172910|Experimental|Cohort 2|ciraparantag (120 mg)
9482974|NCT03172910|Experimental|Cohort 3|ciraparantag (180 mg)
9482975|NCT03172910|Experimental|Cohort 4|ciraparantag (30 mg)
9482976|NCT03172910|Placebo Comparator|Placebo|placebo (saline for injection)
9482977|NCT03163667|Active Comparator|CB-839 plus everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
9482978|NCT03163667|Placebo Comparator|Placebo plus everolimus|Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles.
9482979|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
9482980|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.1%)|
9482981|NCT03162783|Experimental|ADX-102 Ophthalmic Lipid Solution (0.5%)|
9482982|NCT03161093|Experimental|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
9482983|NCT03161093|Experimental|Fasinumab dosing regimen 2|Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral
9482984|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen|
9482985|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen-matching placebo|
10039174|NCT01841242|Active Comparator|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
10039175|NCT01841242|Experimental|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
10039176|NCT01841255|Sham Comparator|Tidal breathing using the facemask|Control
9482986|NCT03150797|Experimental|Melatonin 3mg|Melatonin 3mg
9482987|NCT03150797|Experimental|Melatonin 6mg|Melatonin 6mg
9482988|NCT03150797|Placebo Comparator|Placebo oral capsule|Placebo
9482989|NCT03148860|Active Comparator|Methotrexate naive - Ustekinumab and Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
9482990|NCT03148860|Placebo Comparator|Methotrexate naive - Ustekinumab and Placebo to Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
9482991|NCT03148860|Active Comparator|Methotrexate pre-treated subjects-Ustekinumab and Methotrexate|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
9482992|NCT03148860|Placebo Comparator|Methotrexate pre-treated subjects-Ustekinumab and PLC|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
9482993|NCT03143153|Experimental|Nivolumab + Ipilimumab|
9482994|NCT03143153|Experimental|Nivolumab + Cisplatin + Fluorouacil|
9482995|NCT03143153|Active Comparator|Cisplatin + Fluorouracil|
9482999|NCT03140969|Experimental|QR-110|Administered every 3 months
9483000|NCT03137407|Experimental|DaxibotulinumtoxinA 240 units|Botulinum Toxins, Type A Intramuscular Injection
9483001|NCT03137407|Placebo Comparator|Placebo|Placebo Intramuscular Injection
9483002|NCT03137381|Experimental|CTP-543, 4 mg|Oral tablet, dosed twice-daily
9483003|NCT03137381|Experimental|CTP-543, 8 mg|Oral tablet, dosed twice-daily
9483004|NCT03137381|Experimental|CTP-543, 12 mg|Oral tablet, dosed twice-daily
9483005|NCT03137381|Placebo Comparator|Placebo|Oral tablet, dosed twice daily
9483006|NCT03131154|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
9483007|NCT03131154|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Solution|
10039177|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
10039178|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
10039179|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
9483008|NCT03128853|Experimental|Test subjects|Each subject receives the Rad-67 and DCI Mini sensor that will measure hemoglobin repeatedly in order to compare those measurements against a blood sample reference.
9483009|NCT03128827|Experimental|Test Subjects|All test subjects were pediatric patients following general anesthesia who received the RAM sensor which measures respiration rate.
9483010|NCT03124862|Experimental|Test group|The subjects will be enrolled into the test group and will receive ARM sensor.
9483011|NCT03123783|Experimental|Phase 1b escalation|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M escalated from 0.03 to 0.1 to 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
9483012|NCT03123783|Experimental|Phase 2 expansion Cohort 1|"Immunotherapy naïve, metastatic or locally advanced NSCLC~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
9483013|NCT03123783|Experimental|Phase 2 expansion Cohort 2|"Metastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
9483014|NCT03123783|Experimental|Phase 2 expansion Cohort 3|"Metastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1:~Group A: best response of progressive disease or with stable disease < 16 weeks~Group B: tumor response or with stable disease ≥ 16 weeks~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
9483015|NCT03122405|Experimental|Test group|The subjects will be enrolled in the test group and will simultaneously receive both RAM sensors.
9483016|NCT03120702|Experimental|Neonatal Test Subjects|All test subjects in this group are neonatal patients who will receive a investigational Rainbow SpHb sensor.
9483017|NCT03118570|Experimental|Setrusumab 20 mg/kg (Blinded)|Setrusumab 20 mg/kg intravenous (IV) infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
9483018|NCT03118570|Experimental|Setrusumab 8 mg/kg (Blinded)|Setrusumab 8 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
9483019|NCT03118570|Experimental|Setrusumab 2 mg/kg (Blinded)|Setrusumab 2 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
9483020|NCT03118570|Experimental|Setrusumab 20 mg/kg (Open-Label)|Setrusumab 20 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
9483021|NCT03118570|Placebo Comparator|Placebo|Placebo IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
9483022|NCT03116399|Experimental|PRISM 2.0 Condition|Exposing participants to the PRISM 2.0 interface.
9483023|NCT03116399|Placebo Comparator|Tablet Condition|Exposing participants to the regular computer/tablet
9483024|NCT03116113|Experimental|Part 1: BIIB112 Dose 1|Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
9483025|NCT03116113|Experimental|Part 1: BIIB112 Dose 2|Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
9483026|NCT03116113|Experimental|Part 1: BIIB112 Dose 3|Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
9483027|NCT03116113|Experimental|Part 1: BIIB112 Dose 4|Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
9483028|NCT03116113|Experimental|Part 1: BIIB112 Dose 5|Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
9483029|NCT03116113|Experimental|Part 1: BIIB112 Dose 6|Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
9483030|NCT03116113|Experimental|Part 2: BIIB112 High Dose|Participants will receive a single high dose of BIIB112 by sub-retinal injection.
9483031|NCT03116113|Experimental|Part 2: BIIB112 Low Dose|Participants will receive a single low dose of BIIB112 by sub-retinal injection.
9483032|NCT03116113|No Intervention|Part 2: Untreated Group|Participants will receive no intervention to allow for a controlled comparison.
9483033|NCT03111914|Other|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
9483034|NCT03110575|Experimental|TNX-102 SL|2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
9483035|NCT03109041|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
9483036|NCT03106038|Experimental|Nerindocianine for Injection|One Arm: Nerindocianine for Injection (Initial dosing cohort: 0.06 mg/kg body weight); solution, intravenous, one time administration during surgery. the study has only one arm.
9483037|NCT03105128|Experimental|Risankizumab Dose 1 (Period 1)|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
9483038|NCT03105128|Experimental|Risankizumab Dose 2 (Period 1)|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
9483039|NCT03105128|Placebo Comparator|Placebo (Period 1)|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
9483040|NCT03105128|Experimental|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
9483041|NCT03105128|Experimental|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
9483042|NCT03105128|Experimental|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
10039180|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
10039181|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
9483043|NCT03104842|Experimental|Arm A Transplantation|Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Induction Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd), after intensification another 4 cycles of I-KRd as consolidation will be followed by IKR maintenance until PD or Toxicity
9483044|NCT03104842|Experimental|Arm B No-Transplantation|Patients > 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd) (6 Cycles Induction, 2 Cycles Intensification, 4 Cycles Consolidation),to be followed by I-KR maintenance util PD or Toxicity
9483045|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 1)|Participants randomized to receive risankizumab dose 1 in Induction Period 1.
9483046|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 1)|Participants randomized to receive risankizumab dose 2 in Induction Period 1.
9483047|NCT03104413|Placebo Comparator|Placebo (Induction Period 1)|Participants randomized to receive placebo for risankizumab in Induction Period 1.
9483048|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
9483049|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
9483050|NCT03104413|Experimental|Risankizumab Dose 3 (Induction period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
9483051|NCT03103581|Experimental|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
9483052|NCT03094416|Experimental|levothyroxine sodium capsules|levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months
9483053|NCT03090646|No Intervention|Standard of Care|Participants in the control arm will be instructed to attend required follow-up as is standard of care, but will not receive a financial incentive.
9483054|NCT03090646|Experimental|Financial Incentive|Up to three gift cards to a major online retailer will be mailed to participants assigned to the intervention arm after complete (i.e. all components addressed) and timely (i.e. within the policy-defined follow-up period) submission of follow-up data at each 6-month, 1-year, and 2-year follow-up visit.
9483055|NCT03089606|Other|C11-AMT PET|"Whole body FDG PET/CT scan with IV contrast will be performed at least 24 hours before C11-AMT PET scanning, as per standard of care.~C11-AMT PET will be performed at least 24 hours before pembrolizumab treatment and at least 24 hours after FDG PET/CT scan.~Pembrolizumab 200mg by IV flat dose will be administered over 30 minutes on Day 1; Pembrolizumab dosing will be repeated every 3 weeks until progression or subject withdrawal for other reasons.~Whole body FDG PET/CT scan with IV contrast at end of treatment."
9483056|NCT03088605|Experimental|Active|TOP1630 Ophthalmic Solution
9483057|NCT03088605|Placebo Comparator|Placebo|Placebo (Vehicle) Ophthalmic Solution
9483058|NCT03082014|Active Comparator|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
9483059|NCT03082014|Active Comparator|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
9483060|NCT03082014|Active Comparator|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
10039182|NCT01841294|Experimental|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
10039183|NCT01841294|Placebo Comparator|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
10039184|NCT01841307|Experimental|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
10039185|NCT01841320|Experimental|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
10039186|NCT01841320|No Intervention|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
10039187|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
9483063|NCT03075462|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
9483064|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
9483065|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Add-back|
9483066|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
9483067|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Add-back|
9483068|NCT03070951|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|
9483069|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
9483070|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Add-back|
9483071|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
9483072|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Add-back|
9483073|NCT03070899|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
9483074|NCT03065582|Experimental|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
9483075|NCT03065556|Experimental|188-0551 Solution|188-0551 Solution applied topically twice daily
9483076|NCT03065556|Placebo Comparator|Vehicle Solution|Vehicle Solution applied topically twice daily
9483077|NCT03062540|Experimental|TNX-102 SL Tablet, 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
9483078|NCT03062540|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
9483079|NCT03060980|Experimental|Experimental: Group 1|ITCA 650 20/60 mcg/day
9483080|NCT03060980|Experimental|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
9483081|NCT03060980|Experimental|Experimental: Group 3|Glimepiride 1-6 mg/day
9497785|NCT03471988|Experimental|AK1820|Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
9497786|NCT03471988|Active Comparator|Voriconazole|Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.
9497787|NCT03471949|Experimental|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
9497788|NCT03471936|Other|Acquisition of pressure-volume loops|
9497789|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
9497790|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
9497791|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
9497792|NCT03471910|Experimental|Diosmin|Diosmin 600mg, one tablet once daily
9497793|NCT03471910|Active Comparator|Diosmin + Hesperidin|Diosmin 900mg + Hesperidin 100mg, one tablet once daily
9497794|NCT03471897||RCC|Patients with pathologically confirmed diagnosis of RCC
9497795|NCT03471897||Controls|Subjects self-reported as healthy
9497796|NCT03471884|Experimental|Nonintubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
9497797|NCT03471884|Active Comparator|Intubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
9497798|NCT03471858|Active Comparator|Cervical Balloon|Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline [1]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.
9497799|NCT03471858|Active Comparator|Prostaglandin|Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.
9497800|NCT03471819||Patients withf Atopic Dermatitis|Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.
9497801|NCT03471819||healthy volunteers|Normal individuals not complaining of any dermatological diseases
9497802|NCT03471806|Experimental|Bulimia Nervosa patients|Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
9497803|NCT03471806|Experimental|Healthy controls|Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
9497804|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp >20mm
9616147|NCT04439253|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9483082|NCT03060772|Experimental|Alcohol use disorder - Pioglitazone Treatment|Participants with alcohol use disorder randomized to this group will receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy after taking the study medication for 2 to 4 weeks.
9483083|NCT03060772|No Intervention|Alcohol use disorder - No Pioglitazone|Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
9483084|NCT03060772|No Intervention|Healthy controls without alcohol use disorder|Healthy individuals who do not have alcohol use disorder will be enrolled will serve as a control group. Healthy controls will be a matched to participants receiving the treatment based on age, gender, and smoking status. This group will have a single bronchoscopy.
9483085|NCT03059329||Fycompa-treated epilepsy participants|Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
9483086|NCT03058783|Experimental|IDP-124 Lotion|Lotion
9483087|NCT03058783|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
9483088|NCT03057600|Experimental|Cohort 1 - African ancestry, 3rd line+|"Intervention = Pac-CB combination~Patients must self-identify as African ancestry (AA; includes African American).~At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
9483089|NCT03057600|Experimental|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination~Patients must self-identify as African ancestry (includes African American).~No prior systemic therapy for advanced or metastatic disease.~Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was > 12 mo."
9483090|NCT03057600|Experimental|Cohort 3 - Non-AA, 3rd line+|"Intervention = Pac-CB combination~Patients do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 1."
9483091|NCT03057600|Experimental|Cohort 4 - Non-AA, 1st line|"Intervention = Pac-CB combination~Patients do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 2."
9483092|NCT03056638|Experimental|Degarelix in conjunction with stereotactic body radiosurgery|Degarelix monthly for 6 months SBRT 8 Gy x 5
9483093|NCT03056638|Experimental|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
9483094|NCT03052842|Other|Arm 1|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
9483095|NCT03052842|Other|Arm 2|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
9483096|NCT03052842|Other|Arm 3|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
9483097|NCT03052127|Experimental|Single Low Dose Light-activated AU-011|Low dose Light-activated AU-011 followed by a single laser light application
9483098|NCT03052127|Experimental|Single Medium Dose Light-activated AU-011|Medium dose Light-activated AU-011 followed by a single laser light application
9483099|NCT03052127|Experimental|Single High Dose Light-activated AU-011|High dose Light-activated AU-011 followed by a single laser light application
9483100|NCT03052127|Experimental|2 Repeat Medium Dose Light-activated AU-011|2 repeat medium doses of Light-activated AU-011 each followed by a single laser light application
9483101|NCT03052127|Experimental|3 Repeat Medium Dose Light-activated AU-011|3 repeat medium doses of Light-activated AU-011 followed by a single laser light application
9483102|NCT03052127|Experimental|Single High Dose Light-activated AU-011 x 2 lasers|High dose Light-activated AU-011 followed by two laser light applications
9483103|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011|3 repeat high doses of Light-activated AU-011 each followed by a single laser light application
9483104|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011 x 2 lasers|3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
9483105|NCT03052127|Experimental|Expansion 3 Repeat High Dose Light-activated AU-011 x 2 lasers|Expansion of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications (up to 12 additional subjects)
9483106|NCT03052127|Experimental|Observation until Documented Growth of Tumor|Observation until documented growth of tumor and then treatment with 2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
9483107|NCT03052127|Experimental|2 Cycles of 3 Repeat High Dose Light-activated AU-011x2 lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
9483108|NCT03052127|Experimental|Exp: 2 Cycles 3 Repeat High Dose Light-activatedAU-011x2lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications in subjects with evidence of documented tumor growth prior to study entry
9483109|NCT03050060|Experimental|Treatment (nelfinavir, immunotherapy, radiation therapy)|Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab, nivolumab or atezolizumab. The study will exclude irradiation of liver metastases as an added precaution.
9483110|NCT03044314|Experimental|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
9483111|NCT03041311|Experimental|trilaciclib+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive trilaciclib 240 mg/m2 administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
9483112|NCT03041311|Experimental|placebo+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive placebo administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
9483113|NCT03040973|Experimental|INC280|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent INC280 protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
9483114|NCT03040973|Experimental|INC280/EGF816|Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
9483115|NCT03040973|Active Comparator|INC280/Gefitinib|The starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated.
9483116|NCT03038074|Experimental|Test Group|The subjects will be enrolled in the test group and will receive Pulse Oximeter with respiration rate sensor to examine the respiration rate.
9483117|NCT03031782|Experimental|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
9483118|NCT03031782|Placebo Comparator|Treatment Period 2 - placebo|Placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
9483119|NCT03031197|Experimental|Tailored realtime triggered reminder pkg|The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
9483120|NCT03031197|No Intervention|Control|Comparison subjects will receive usual care and an offer of counseling at monthly clinic visits.
9483121|NCT03024255|Experimental|BBI-4000 Concentration 1|Low Concentration
9483122|NCT03024255|Experimental|BBI-4000 Concentration 2|Medium Concentration
9483123|NCT03024255|Experimental|BBI-4000 Concentration 3|High Concentration
9483124|NCT03024255|Placebo Comparator|Vehicle|Vehicle (Placebo)
9483125|NCT03023085|Experimental|BLI4700|BLI4700 Bowel Preparation
9483126|NCT03022578|Experimental|Treatment (LITT, lomustine)|Patients undergo LITT at baseline and receive lomustine PO on day 1. Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.
9483127|NCT03015259|Experimental|Treatment 1|Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
9483128|NCT03015259|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
9483129|NCT03015259|Placebo Comparator|Treatment 3|Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
9483130|NCT03014635|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
9483131|NCT03014635|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
9483132|NCT03014622|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
9483133|NCT03014622|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
9483134|NCT03013517|Experimental|Viaskin Peanut 250µg|
9483135|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
9483136|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
9483137|NCT03012165|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops
9483138|NCT03011450|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator for 12 weeks
9483139|NCT03011450|Active Comparator|40 week extension|K-877 or fenofibrate comparator for 40 weeks
9483140|NCT03009019|Experimental|DFN-15 Active|DFN-15 Active
9483141|NCT03009019|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
9483142|NCT03007888|Other|Sequence 1|Treatment Period 1: ER CD-LD Capsules - 15 days; Washout Period 7-days; Treatment Period 2- IR CD-LD Tablet - 15 days
9483143|NCT03007888|Other|Sequence 2|Treatment Period 1- IR CD-LD Tablet - 15 days; Washout Period 7-days; Treatment Period 2- ER CD-LD Capsules - 15 days
9483144|NCT03006276|Experimental|DFN-15 Active|DFN-15 Active
9483145|NCT03006276|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
9483146|NCT03005964|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
9483147|NCT03005964|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles.
9483148|NCT03004976|Experimental|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
9483149|NCT03004976|Placebo Comparator|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
9483150|NCT03004365|Active Comparator|Study Arm 1|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
9483151|NCT03004365|Active Comparator|Study Arm 2|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
9483152|NCT03004365|Active Comparator|Study Arm 3|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
9483153|NCT03004248|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
9483154|NCT03004053||Volunteers will be identified by the Head and Neck Service|25 volunteers (Part I - 8 volunteers. Part II - 17 volunteers). during the course of 12 months. The volunteers will be imaged with the endoscope, and the images will be evaluated visually and with qualitative (descriptive) statistics.
9483155|NCT03003247|Experimental|IDP-120 Gel|IDP-120 Gel is a combination treatment
9483156|NCT03003247|Active Comparator|IDP-120 Component A Gel|IDP-120 Monad Gel of Component A
9483157|NCT03003247|Active Comparator|IDP-120 Component B Gel|IDP-120 Monad Gel of Component B
9483158|NCT03003247|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel
9483159|NCT03002571|Experimental|IDP-124 Lotion|Lotion
9483160|NCT03002571|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
9483161|NCT03001817|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator twice daily for 12 weeks
9483162|NCT03001817|Active Comparator|40 Week Extension|K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
9483163|NCT03001310|Experimental|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of range AAV - CNGB3
9483164|NCT03001310|Experimental|Biological-medium dose AAV - CNGB3|Subretinal administration of a single medium dose of range AAV - CNGB3
9483165|NCT03001310|Experimental|Biological-high dose AAV - CNGB3|Subretinal administration of a single high dose of range AAV - CNGB3
9483166|NCT02999984|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
9483167|NCT02999789|Active Comparator|Intervention group|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The intervention group will have SMS reminder and audiovisual reminder functions turned on. SMS reminders will be sent twice daily to child's caregiver's cell phone reminding them to administer daily asthma medication. SmartInhaler with reminder function turned on that is attached to Inhaler medication will remind child's caregiver twice daily to administer daily asthma medication.
9483168|NCT02999789|Placebo Comparator|Placebo|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The placebo group will have SMS reminder and audiovisual reminder functions turned off. The SmartInhaler will only function to measure daily adherence. Once intervention group has finished their 6 week period, this group will have intervention turned on.
9483169|NCT02998840|Active Comparator|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
9483170|NCT02998840|Sham Comparator|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
9483171|NCT02998840|Active Comparator|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
9483172|NCT02998840|Sham Comparator|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
9483173|NCT02997657|Experimental|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
9483174|NCT02997657|Active Comparator|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
9483175|NCT02997501|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
9483176|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes <37 weeks
10039188|NCT01841359|Other|Pramlintide (Symlin)|"Participants in this study will be asked to complete 4 study visits. Study visit 1 will be for screening. Eligible individuals who provide informed consent will be asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms. At study visit 2, a baseline mixed meal tolerance test will be performed. Glucose, hormonal responses, and satiety will be assessed. Glucose and symptom log will be reviewed. Pramlintide will be prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During treatment, the participants will keep a record of all hypoglycemic symptoms and blood glucose measurements at those times.~Study visit 3 will occur at week 4 of treatment and focus on evaluation of symptoms and side effects. Participants will again complete a food and glucose diary for 3 days. During study visit 4 (week 8 of treatment), participants will undergo a repeat mixed meal tolerance test."
9483181|NCT02992041|Experimental|Lower dose VVZ-149 Injections|
9483182|NCT02992041|Experimental|Higher dose VVZ-149 Injections|
9483183|NCT02992041|Placebo Comparator|Placebo|
9483184|NCT02990806|Experimental|NI-071|Proposed biosimilar
9483185|NCT02990806|Active Comparator|Infliximab|Reference product
9483186|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
9483187|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
9483188|NCT02989597|Experimental|Intra-operative Methadone Hydrochloride|Patient who will be given a single dose of intra-operative methadone, and having standard care otherwise
9483189|NCT02989597|Active Comparator|Control|Patients administered standard of care
9483190|NCT02986659|Active Comparator|Metformin then Placebo|Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets. Treatment with metformin will be initiated at a dose of 425 mg (half pill) taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night at a dose of 850 mg for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two 850 mg pills, one in the morning and one at night, for a total dose of 1700 mg which is within the range of the usual effective dose of 1500 to 2000 mg/day for the remainder of the 3 months. Will then cross over to 3 months on placebo.
9483191|NCT02986659|Placebo Comparator|Placebo then Metormin|Dietary Supplement: Placebo with Methylcellulose capsules. Treatment with placebo will be initiated at a dose of a half pill taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two pills, one in the morning and one at night for the remainder of the 3 months. After 3 months on placebo, participants will then cross over to 3 months of metformin as described in the other arm.
9483192|NCT02985619|Active Comparator|IVB randomised group II|"Randomised patients (IVB group II) with central foveal thickness >300µm on OCT were submitted to 6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata, or as needed), with monthly visits for central subfoveal thickness map more than 300µm by Optic Coherence Tomography."
9483193|NCT02985619|Active Comparator|IVT randomised group I|Randomised patients (IVT group I) with central foveal thickness >300µm on OCT were submitted to 6 months treatment with 0.03ml (1.20mg) intravitreous injection of triamcinolone each 3 months (prn, as needed) for central sufoveal thickness map more than 300µm by Optic Coherence Tomography.
9483194|NCT02985619|Other|IVB group III (not randomised)|Patients with central foveal thickness ≤300µm were allocated to group III (IVB)
9483195|NCT02985151|Active Comparator|High Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at either the Mid mode or the Deep mode of the laser at visits three months apart. Thereafter, individuals in this group will be offered a third optional treatment at one of these settings.
9483196|NCT02985151|Placebo Comparator|Low Energy Placebo Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at the Light mode of the laser at visits three months apart. The Light mode is a low energy setting that superficially cleanses the skin, and would not affect the scar, which is deeper in the skin. Individuals in this group will be offered two optional high energy treatments subsequent to receiving the two light energy treatments.
9483197|NCT02978456|Experimental|quantitative coronary angiography guided|
9483198|NCT02978456|Active Comparator|Intravascular ultrasound guided|
9483199|NCT02975271|Experimental|Serlopitant|Dose of experimental drug Serlopitant
9483200|NCT02975271|Placebo Comparator|Placebo|Matching dose of Placebo
9483201|NCT02973633|Active Comparator|Healthy Volunteers|DTI will be performed in healthy volunteers to characterize normal fiber architecture in the heart and provide a comparison group for the patients imaged in the other arms.
9483202|NCT02973633|Active Comparator|Patients with Recent Myocardial Infarction|Patients with recent ST elevation myocardial infarcts will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with remodeling of the left ventricle.
9483203|NCT02973633|Active Comparator|Patients with Left Ventricular Hypertrophy|Patients with left ventricular hypertrophy and a history of heart failure will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with the onset and progression of heart failure.
9483204|NCT02973269|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
9483205|NCT02973269|Placebo Comparator|Placebo|Placebo Intramuscular injection
9483206|NCT02971891|Experimental|CLS006 (Furosemide)|CLS006 (Furosemide) Topical Gel, 0.125%
9483207|NCT02971891|Placebo Comparator|Vehicle|Vehicle Topical Gel
9483208|NCT02969369|Experimental|SEP-363856|SEP-363856 (25, 50, or 75mg/day), once daily
9483209|NCT02969369|Placebo Comparator|Placebo Capsule|Placebo once daily
9616148|NCT04439227|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9483210|NCT02968940|Experimental|Avelumab and hypofractionated radiation therapy(HFRT)|"Avelumab 10 mg/kg intravenously (IV) every 2 weeks.~Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
9483211|NCT02964273|Active Comparator|Phase A Tolvaptan|Participants will be randomized to receive active tolvaptan for 12 months. Study medication will be administered orally as a split dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. The starting dose is based on weight.
9483212|NCT02964273|Placebo Comparator|Phase A Placebo|Participants receive matching-placebo spray dried, immediate release tablets orally as a split-dose, with first dose taken upon awakening and second dose taken approximately 8 hours later.
9483213|NCT02964273|Active Comparator|Phase B Tolvaptan|Participants will receive open-label tolvaptan for 24 months. Study medication will be administered orally as a split dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. The starting dose is weight based.
9483214|NCT02962895|Experimental|VAY736 dose 1|VAY736 low
9483215|NCT02962895|Experimental|VAY736 dose 2|VAY736 medium
9483216|NCT02962895|Experimental|VAY736 dose 3|VAY736 high
9483217|NCT02962895|Placebo Comparator|Placebo|Placebo control
9483218|NCT02958202|Experimental|BMN 044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
9483219|NCT02958202|Experimental|BMN 044 IV 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
9483220|NCT02958202|Experimental|BMN 044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
9483221|NCT02956265|Experimental|Patients - Suffering from carcinomatous or polymorphous skin|
9483222|NCT02950922|Experimental|RVT-501 0.2% ointment|RVT-501 0.2% ointment BID x 28 days (30 adults, 20 adolescents)
9483223|NCT02950922|Experimental|RVT-501 0.5% ointment|RVT-501 0.5% ointment BID x 28 days (30 adults, 20 adolescents)
9483224|NCT02950922|Placebo Comparator|Vehicle ointment|Vehicle ointment BID x 28 days (30 adults, 20 adolescents)
9483225|NCT02947048|Experimental|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
9483226|NCT02947048|Experimental|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
9483227|NCT02947048|Experimental|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
9483228|NCT02947048|Experimental|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
9483229|NCT02947048|Placebo Comparator|Placebo|placebo t.i.d.
9483230|NCT02946125|Experimental|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
9483231|NCT02946125|Active Comparator|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
9483232|NCT02946125|Active Comparator|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
9483233|NCT02945085|Experimental|Home Based Care Team|Primarily in-home treatment provided by team led by nurse practitioner with geriatrics and geriatric psychiatry expertise.
9483234|NCT02945085|Active Comparator|Telephone Based Care Team|Primarily telephone-based treatment provided by existing care management program offered by collaborating Medicare Advantage insurer.
9483235|NCT02941926|Experimental|Ribociclib + letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
9483236|NCT02933671|Experimental|Suprainguinal Fascia Iliaca (SIFI) block|A nerve block technique using a numbing medication called ropivacaine.
9483237|NCT02933671|Placebo Comparator|Sham group|The same nerve block technique as above, however using an inactive solution of salt water.
9483238|NCT02933606|Experimental|BNC210 600 mg b.i.d.|Suspension administered orally for 12 weeks.
9483239|NCT02933606|Experimental|BNC210 300 mg b.i.d.|Suspension administered orally for 12 weeks.
9483240|NCT02933606|Experimental|BNC210 150 mg b.i.d.|Suspension administered orally for 12 weeks.
9483241|NCT02933606|Placebo Comparator|Placebo b.i.d.|Suspension administered orally for 12 weeks.
9483242|NCT02930850|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter sensor for measurement of hemoglobin.
9483243|NCT02927184|Placebo Comparator|Placebo|Placebo capsule
9622074|NCT02518672|Placebo Comparator|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
9483244|NCT02927184|Experimental|VK2809 (5mg)|5mg VK2809 capsule
9483245|NCT02927184|Experimental|VK2809 (10mg)|10mg VK2809 capsule
9483246|NCT02927184|Experimental|VK2809 (10mg QOD)|10mg VK2809 capsule
9483247|NCT02925949|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
9483248|NCT02925949|Active Comparator|LifeSteps|A 3-session HIV medication adherence support program for individuals.
9483249|NCT02924389|Other|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
9483250|NCT02924389|Other|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
9483251|NCT02923531|Experimental|X4P-001 Plus Nivolumab|Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study treatment will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
9483252|NCT02920008|Experimental|guadecitabine|Guadecitabine will be given SC at a dose of 60 mg/m2 in 28-day cycles (delayed as necessary to allow blood count recovery).
9483253|NCT02920008|Active Comparator|Treatment Choice (TC)|"High intensity~Low intensity~Best supportive care (BSC)."
9483254|NCT02918019|Experimental|MSTT1041A 210 mg|Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
9537484|NCT03140475||Individuals with schizophrenia|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates)~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response)~Clinical variables:~Positive and Negative Syndrome Scale / Birchwood Insight Scale / Beck Cognitive Insight Scale / Personal and Social Performance Scale / Calgary Depression Scale / Chlorpromazine equivalents~Neuropsychological variables:~National Adult Reading Test (French) / Wechsler Adult Intelligence Scale version IV (WAIS-IV) subtests (matrix reasoning, vocabulary, letter-number sequencing)"
9537485|NCT03140475||Controls|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates) /~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response) /~Clinical variables:~Calgary Depression Scale~Neuropsychological variables:~National Adult Reading Test (French) / WAIS-IV subtests (matrix reasoning, vocabulary, letter-number sequencing)"
9537486|NCT03140540|Active Comparator|Group A (stroke volume variation) guided fluid|Stroke volume variation guided intraoperative intravenous fluid will be administered.
9537487|NCT03140540|Active Comparator|Group B(Study group) TEE guided fluid|Transesophageal echocardiography will be used to guide the fluid therapy.
9537488|NCT03140514|Experimental|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
9537489|NCT03140514|No Intervention|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
9537490|NCT03140410||Linezolid-resistant S. epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidermidis strains, tested resistant to linezolid
9537491|NCT03140410||Linezolid-susceptible S.epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidemridis strains, tested susceptible to linezolid
9537492|NCT03140436|Experimental|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
9537493|NCT03140436|Experimental|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
9537494|NCT03140358|Active Comparator|Premyopia atropine|On Atropine 0.01%
9537495|NCT03140358|Placebo Comparator|Premyopia placebo|On placebo
9537496|NCT03140358|Active Comparator|Low myopia atropine|On Atropine 0.01% daily or every other day
9537497|NCT03140358|Placebo Comparator|Low myopia placebo|On placebo
9537498|NCT03140501|Experimental|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
9537499|NCT03140501|Other|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
9537500|NCT03140774||Cohort 1: Phase 1 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo.
9537501|NCT03140774||Cohort 2: Received r-VSV-ZEBOV vaccine|Previously exposed to Ebola vaccine rVSV-EBOV.
9537502|NCT03140774||Cohort 3: Phase 2 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo
9537503|NCT03140293|Active Comparator|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
9537504|NCT03140293|Experimental|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
9537505|NCT03140735|Other|Control group of 150 heart disease-free individuals|
9537506|NCT03140735|Other|Patients with aortic sclerosis|
9537507|NCT03140735|Other|Patients with moderate aortic stenting (RA)|
9537508|NCT03140735|Other|Patients with Serious Aortic Retention|
9537509|NCT03140332|Other|Patient with CHC|
9537510|NCT03140397|Placebo Comparator|Placebo|Capsules filled with mannitol and silicon dioxide
9537511|NCT03140397|Experimental|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
9537512|NCT03140397|Experimental|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
9537513|NCT03140306|Experimental|Low dose CT abdomen and pelvis|Low dose computed tomography
9537514|NCT03140306|Experimental|Control dose CT abdomen and pelvis|Control dose CT abdomen and pelvis
9537515|NCT03140280|Experimental|Dietary Intervention|Freeze-dried black raspberry powder administration.
9537516|NCT03140267|Experimental|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
9537517|NCT03140059|Active Comparator|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
9537518|NCT03140059|Active Comparator|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
9537519|NCT03140124|Other|Group 1|First session: worry stone, second session: exercise peddler
9537520|NCT03140124|Other|Group 2|First session: exercise peddler, second session: worry stone
9537521|NCT03139968|Experimental|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
9537522|NCT03139968|Active Comparator|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
9537523|NCT03139968|No Intervention|Control goup|Only conventional protection measurements.
9537524|NCT03140007|Other|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
9537525|NCT03140007|Active Comparator|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
9537526|NCT03140046|Experimental|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
9537527|NCT03140111|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
9537528|NCT03140111|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
9537529|NCT03140228|Experimental|I-Gel group|I-gel will be used for maintenance of airway during general anaesthesia
9537530|NCT03140228|Active Comparator|LMA ambu auraonce group|LMA ambu auraonce will be used for maintenance of airway during general anaesthesia
9537531|NCT03140202|Experimental|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
9537532|NCT03140202|Experimental|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
9537533|NCT03140072|Experimental|AZD9898|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where AZD9898 will be administered. Eight subjects will participate in each cohort. Within each cohort, 6 (alternatively 8 or 10) subjects will be randomized to receive a single dose of AZD9898. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, 4 (alternatively 6 or 8) patients will be randomized to receive a single dose of AZD9898. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 6 (alternatively 8, 10 or 12) subjects will be randomized to receive AZD9898. The subjects taking part in one of the MAD cohorts under fasted conditions will also take part in Part 3B in order to explore the influence of food on the PK of AZD9898.
9537534|NCT03140072|Placebo Comparator|Placebo|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
9537535|NCT03140020||Clipping|Clipping of an aneurysm of the anterior communicating artery - A titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after microsurgical aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from microsurgical treatment.
9537536|NCT03140020||Coiling|Coiling of an aneurysm of the anterior communicating artery - Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after endovascular aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from endovascular treatment.
9537537|NCT03140020||Healthy Controls|Healthy controls will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after baseline examinations. Furthermore all subjects will undergo additional neuropsychological examinations 12 months after baseline examination.
9537538|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
9537539|NCT03139851|Other|Cyclophosphamide and Pembrolizumab|"The treatments received are:~cyclophosphamide (50 mg/day, daily, per os)~pembrolizumab (200 mg every 3 weeks, intravenously [IV]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
9537540|NCT03140085|Active Comparator|Anbiotica|
9537541|NCT03140085|Active Comparator|Bacteriophages|
9537542|NCT03140085|Placebo Comparator|Placebo|
9537543|NCT03140215|Active Comparator|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
9537544|NCT03140215|Active Comparator|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
9537545|NCT03139981|Experimental|ASN002 40 mg|40 mg ASN002
9537546|NCT03139981|Experimental|ASN002 80 mg|80 mg ASN002
9537547|NCT03139981|Experimental|ASN002 20 mg|20 mg ASN002
9537548|NCT03139981|Experimental|ASN002 120 mg|120 mg ASN002
9483255|NCT02918019|Experimental|MSTT1041A 490 mg|Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
9483256|NCT02918019|Experimental|MSTT1041A 70 mg|Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
9483257|NCT02918019|Placebo Comparator|Placebo|Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
9483258|NCT02918006|Experimental|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
9483259|NCT02918006|Active Comparator|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
9483260|NCT02918006|Placebo Comparator|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
9483261|NCT02917629|Experimental|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 10-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
9483262|NCT02917629|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD daily for 10-21 days.
9483263|NCT02917187|Experimental|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
9483264|NCT02917187|Experimental|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
9483265|NCT02916446|Experimental|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, daily administration
9483266|NCT02916446|Placebo Comparator|Placebo|Placebo patch, daily administration
9483267|NCT02913612|Experimental|0.25% Timolol Treatment|Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol.
9483268|NCT02913612|Experimental|0.5% Timolol Treatment|Subjects assigned to this arm will be randomized to 0.5% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin an alternative treatment.
9483269|NCT02913612|No Intervention|Non-Intervention Group|Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.
9483270|NCT02907359|Experimental|Guadecitabine|Guadecitabine 60 mg/m2 given subcutaneously daily on Days 1-5 in 28-day cycles. The total amount (in mg) of guadecitabine to be administered is determined by body surface area.
9483271|NCT02907359|Active Comparator|Treatment Choice|"Best Supportive Care.~Low dose cytarabine.~Standard Intensive Chemotherapy."
9483272|NCT02906488||Patients with Parkinson's Disease|
9483273|NCT02905903|Other|Trichloroacetic Acid|Intervention-Apply 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study. Comparisons will be made using Investigators Global Assessment scoring of hyperpigmentation and erythema, colorimetry, photography, and biopsies
9483274|NCT02905240|Experimental|nSTRIDE APS|Autologous Protein Solution prepared using the nSTRIDE APS Kit
9483275|NCT02905240|Other|Saline|Saline control
9483276|NCT02905188|Experimental|GLYCAR T cells + Fludarabine and Cytoxan|GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
9483277|NCT02903355|Placebo Comparator|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
9483278|NCT02903355|Experimental|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
9483279|NCT02892149|Experimental|Vadadustat|
9483280|NCT02892149|Active Comparator|darbepoetin alfa|
9483281|NCT02886156|Experimental|CPAP plus BSC|Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center.
9483282|NCT02886156|Active Comparator|BSC intervention|Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
9483283|NCT02884544|Experimental|HLD100 10mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)
9483284|NCT02884544|Experimental|HLD100 20mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)
9483285|NCT02884544|Experimental|HLD100 30mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)
9483286|NCT02884544|Experimental|HLD100 40mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)
9483287|NCT02880956|Experimental|Group 2|Dose 2 ABBV-8E12
9483288|NCT02880956|Experimental|Group 3|Dose 3 ABBV-8E12
9483289|NCT02880956|Experimental|Group 1|Dose 1 ABBV-8E12
9483290|NCT02880956|Placebo Comparator|Group 4|Placebo for ABBV-8E12
9483291|NCT02872701|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
9483292|NCT02872116|Experimental|Nivolumab + Ipilimumab|"Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy~Enrollment is closed for this arm"
9483293|NCT02872116|Active Comparator|XELOX (Oxaliplatin + Capecitabine)|
9483294|NCT02872116|Active Comparator|FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)|
9483295|NCT02872116|Experimental|Nivolumab + XELOX|
9483296|NCT02872116|Experimental|Nivolumab + FOLFOX|
9483297|NCT02866227|Experimental|BV and/or VVC infection - Gel Treatment|Randomized 1:1 to gel nightly for 7 days. N = 40
9483298|NCT02866227|Experimental|BV and/or VVC infection - Vaginal Insert Treatment|Randomized 1:1 to insert nightly for 7 days. N = 40
9483299|NCT02865850|Experimental|Vadadustat|
9483300|NCT02865850|Active Comparator|darbepoetin alfa|
9483301|NCT02863991|Experimental|ONC201|Single agent ONC201.
9483302|NCT02859519|Experimental|MOB015B|Subjects will treat all affected fingernails and/or toenails with MOB015B for 48 weeks once daily at bedtime.
9483303|NCT02859519|Placebo Comparator|MOB015B Vehicle|Subjects will treat all affected fingernails and/or toenails with MOB015B Vehicle for 48 weeks once daily at bedtime.
9483304|NCT02858908|Experimental|Cohort 1 - Tideglusib|1000 mg tideglusib, orally, once daily
9483305|NCT02858908|Experimental|Cohort 2 - Tideglusib|400 mg tideglusib, orally, once daily
9483306|NCT02858895|Experimental|MDNA55|"Single infusion of MDNA55 via convection enhanced delivery (CED).*~*Subjects may be eligible to receive a second administration of MDNA55."
9483307|NCT02858037|Experimental|HIV Open-label Prevention|"Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women~MTN-020:NCT01617096 MTN-025: NCT02858037"
9497805|NCT03471754|Experimental|Treatment Arm A|TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.
9497806|NCT03471741||MARA-2: IMRT with concomitant boost|A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
9497807|NCT03471741||CG: 3D-RT with sequential boost|The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
9497808|NCT03471702|Experimental|Single Arm Study|All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.
9497809|NCT03471689|Experimental|Mindfulness|
9497810|NCT03471689|Active Comparator|Positive reappraisal|
9497811|NCT03471637|Experimental|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
9497812|NCT03471585|Placebo Comparator|Placebo oral capsule|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the THC arm.
9497813|NCT03471585|Experimental|THC|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the placebo arm.
9497814|NCT03471572||1|Ovarian Cancer
9497815|NCT03471559|Active Comparator|Reference formulation|Cannabidiol capsule, 200 mg
9497816|NCT03471559|Experimental|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
9497817|NCT03471546|Experimental|Palliative care|Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma. Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment. In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
9497818|NCT03471533|Experimental|Ëxperimental|"Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules a day will be consumed thirty minutes before breakfast for 84 days."
9497819|NCT03471533|Placebo Comparator|Placebo|Consumption during 84 days of saccharose. Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
9497820|NCT03471507|Experimental|Bonipar|
9497821|NCT03471507|Active Comparator|Diclofenac topical solution 1.5%|
9497822|NCT03471494||Breast cancer|
9497823|NCT03471494||Gastric cancer|
9497824|NCT03471494||Colon cancer|
9497825|NCT03471468|Experimental|kinetics of microparticles under chemotherapy|kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
9497826|NCT03471455|Active Comparator|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
9497827|NCT03471455|Active Comparator|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
9497828|NCT03471455|Active Comparator|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
9497829|NCT03471455|Active Comparator|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
9483308|NCT02847598|Experimental|Part A: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with systemic lupus erythematosus [SLE] with active skin manifestations and joint involvement.
9483309|NCT02847598|Placebo Comparator|Part A: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with [SLE] with active skin manifestations and joint involvement.
9483310|NCT02847598|Experimental|Part B: BIIB059 50 mg|BIIB059 50 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active cutaneous lupus erythematosus [CLE] with or without systemic manifestations.
9483311|NCT02847598|Experimental|Part B: BIIB059 150 mg|BIIB059 150 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
9483312|NCT02847598|Experimental|Part B: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
9483313|NCT02847598|Placebo Comparator|Part B: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
9483314|NCT02846545|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).
9483315|NCT02846545|Placebo Comparator|Group 2: Placebo|Participants will receive a matching placebo to golimumab.
9483316|NCT02843945|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
9483317|NCT02843633|Experimental|BioFreedom™ Drug Coated Stent|
9483318|NCT02832063|Active Comparator|B244 arm|B244 dose administered in a 1:1 (active vs placebo) ratio
9483319|NCT02832063|Placebo Comparator|Placebo arm|Placebo dose administered in a 1:1 (active vs placebo) ratio
9483320|NCT02829814|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
9483321|NCT02829814|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
9483322|NCT02822508|Experimental|BLI801 Laxative (high dose)|BLI801 Laxative (high dose)
9483323|NCT02822508|Experimental|BLI801 Laxative (mid dose)|BLI801 Laxative (mid dose)
9483324|NCT02822508|Experimental|BLI801 Laxative (low dose)|BLI801 Laxative (low dose)
9483325|NCT02822508|Placebo Comparator|BLI801 Placebo|BLI801 Placebo
9483326|NCT02820714|Experimental|BLI801 Laxative|BLI801 oral laxative
9483327|NCT02819440|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
9483328|NCT02819440|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
9483329|NCT02818894|Active Comparator|Lidocaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
9483330|NCT02818894|Active Comparator|Bupivacaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
9483331|NCT02816255|Placebo Comparator|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
9483332|NCT02816255|Active Comparator|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
9483333|NCT02814019|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
9483334|NCT02814019|Placebo Comparator|placebo|matching placebo tablets
9483335|NCT02813447|Active Comparator|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
9483336|NCT02813447|Placebo Comparator|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
9483337|NCT02811939|Experimental|Active THC and Placebo Pregnenolone|
9483338|NCT02811939|Experimental|Active THC and Active Pregnenolone|
9537549|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
9537550|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
9537551|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.~This group will be asked to provide a fecal and blood sample at one time point."
9537552|NCT03140163|Experimental|Subjects suffering from pneumonia|CXR ULD-CT
9537553|NCT03139708|Experimental|Alphagan plus|Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
9537554|NCT03139708|Experimental|Tropicamide and Phenylephrine plus|Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
9537555|NCT03139708|Active Comparator|Tropicamide and Phenylephrine only|Tropicamide and Phenylephrine only arm is given one drop of each times one.
9537556|NCT03139942|Experimental|Imaging using OPTIC probe|Single arm study to test the feasibility of a new device - the OPTIC imaging probe. All participants enrolled in the study may be imaged using optical spectral reflectance and autofluorescence imaging during their endoscopy procedure.
9537557|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
9537558|NCT03140150|Experimental|Active Group|A single visit 1 to 3 months after implantation then followed by the attending cardiologist.
9537559|NCT03140150|Other|Control Group|A first visit 1 to 3 months after implantation and then every 6 months or every year according to the recommendations of pacemaker follow-up (ie 2 or 4 systematic visits during the follow-up of 2 years).
9537560|NCT03139734|Other|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
9537561|NCT03139799|Experimental|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
9537562|NCT03139799|Active Comparator|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
9537563|NCT03139669|Experimental|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
9537564|NCT03140033|Active Comparator|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
9537565|NCT03140033|Placebo Comparator|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
9537566|NCT03140241|Experimental|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
9537567|NCT03139773|Experimental|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
9537568|NCT03139773|Experimental|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
9537569|NCT03139890|Experimental|High-fat milkshake|
9537570|NCT03139890|Experimental|High-carbohydrate milkshake|
9537571|NCT03139890|Experimental|High-protein milkshake|
9537572|NCT03139825|Other|Adolescent with suicidal behavior and personality disorder|
9537573|NCT03139812|Other|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
9537574|NCT03139812|Other|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
9537575|NCT03139760|Experimental|POWERSforID|POWERSforID intervention group
9537576|NCT03139760|No Intervention|Control|Usual clinical care
9537577|NCT03139864|Experimental|type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
9537578|NCT03139864|Active Comparator|without type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
9537579|NCT03139643|Experimental|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
9616149|NCT04439201|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
9537580|NCT03139643|Experimental|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
9537581|NCT03139643|Placebo Comparator|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
9537582|NCT03139630||HIV-infected patients|HIV-infected adult male or female patients who are HIV treatment naive and initiate antiretroviral therapy including a protease inhibitor during the follow up period.
9537583|NCT03139630||HIV-uninfected patients|HIV-uninfected adult male or female patients.
9537584|NCT03139656|Experimental|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
9537585|NCT03139656|Experimental|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
9537586|NCT03139656|Experimental|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
9537587|NCT03139474|Active Comparator|agonist group|Triptorelin at a dose 1 milligram per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
9537588|NCT03139474|Active Comparator|antagonist group|•Multiple dose Gonadotrophin releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .
9537589|NCT03139487|Active Comparator|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
9537590|NCT03139487|Experimental|Direct oral anticoagulant|"Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks~Apixaban, 10 mg orally twice daily for 7days followed by 5mg twice daily for 21 weeks"
9537591|NCT03139461|Experimental|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
9537592|NCT03139461|No Intervention|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
9537593|NCT03139539|Active Comparator|Ioban|In this arm patients will be operated using Ioban as incisional drape.
9537594|NCT03139539|No Intervention|Control|In this arm patients will be operated using no incisional drape.
9537595|NCT03139253|Experimental|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
9537596|NCT03139253|Experimental|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
9537597|NCT03139253|Experimental|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
9537598|NCT03139253|Experimental|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
9537599|NCT03139253|Experimental|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
9537600|NCT03139292|Experimental|ProSeal Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for PLMA insertion
9616150|NCT04439175|Experimental|Treatment (taselisib)|Patients receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9537601|NCT03139292|Experimental|AmbuAuraGain Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for AmbuAuraGain Laryngeal Mask Airway insertion
9537602|NCT03139591|Active Comparator|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
9537603|NCT03139591|Active Comparator|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
9537604|NCT03139409|Active Comparator|conventonal adhesive|peak lc bond
9537605|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
9537606|NCT03139422|Active Comparator|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
9537607|NCT03139422|Experimental|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
9537608|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
9537609|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
9537610|NCT03139565|Experimental|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
9537611|NCT03139565|Active Comparator|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
9537612|NCT03139435|Experimental|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
9537613|NCT03139175|Experimental|temporomandibular disorder group|subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system
9537614|NCT03139175|Active Comparator|chronic low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
9537615|NCT03139175|Other|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
9616151|NCT04439136|Experimental|Treatment (afatinib dimaleate)|Patients receive afatinib dimaleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9616152|NCT04439123|Experimental|Treatment (capivasertib)|Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9616153|NCT04439110|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
9616154|NCT04434469|Experimental|Arm A Flat Dose Escalation: RO7297089|Participants in Arm A will receive the target dose of RO7297089 as a flat dose at each scheduled study drug administration visit
9616155|NCT04434469|Experimental|Arm B Split Dose Escalation: RO7297089|Participants in Arm B will receive the first target dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose will be administered at subsequent study drug administration visits.
9616156|NCT04434469|Experimental|Arm C Step Dose Escalation: RO7297089|Participants in Arm C will receive the first cycle of RO7297089 as a single-step dose escalation. The Cycle 1 Day 1 dose will be lower than the target dose. The full target dose will be administered at subsequent study drug administration visits.
9616157|NCT04434469|Experimental|Phase I Expansion Stage: RO7297089|After dose escalation has been completed, approximately 30 patients will be enrolled in the expansion stage. Participants will receive RO7297089 at the recommended phase 2 dose (at or below the maximum tolerated dose).
9616158|NCT04434196|Experimental|CC-99282 + obinutuzumab|Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.
9616159|NCT04413331||Vasculitis|Those with systemic vasculitis
9616160|NCT04413331||EGPA vasculitis|
9616161|NCT04413162|Other|measurement before and after capsular distention|
9616162|NCT04390581|Experimental|Juvéderm® VOLIFT with Lidocaine|All participants to be injected with Juvéderm® VOLIFT with Lidocaine in both hands no more than 6ml total per both hands. Optional touch-up will be done on Day 30 according to aesthetic results.
9616163|NCT04386759||Healthcare workers|"Up to protocol v2.0: Filling when including a first self-survey concerning the period of the last fifteen days. The following questionnaires will be completed online every week until the end of the study. For healthcare worker who have already presented a symptomatic infection at the time of inclusion, only the self-survey inclusion will be completed, it will relate to the period of fifteen days preceding the diagnosis.~From protocol v3.0: After performing a RT-PCR or an antigenic test for COVID diagnosis, the healthcare workers will complete a unique self-questionnaire about individual and contextual risks factors during the 15 days preceding the test."
9616164|NCT04379635|Experimental|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Tislelizumab|Tislelizumab + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
9616165|NCT04379635|Placebo Comparator|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Placebo|Placebo + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium
9622075|NCT02518399|Experimental|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
9483339|NCT02811939|Experimental|Placebo THC and Active Pregnenolone|
9483340|NCT02811939|Placebo Comparator|Placebo THC and Placebo Pregnenolone|
9483341|NCT02811861|Experimental|Lenvatinib 18 mg plus Everolimus 5 mg|Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily in each 21-day cycle.
9483342|NCT02811861|Experimental|Lenvatinib 20 mg plus Pembrolizumab 200 mg|Lenvatinib 20 mg administered orally, once daily, in each 21-day cycle plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks on Day 1 of each 21-day cycle.
9483343|NCT02811861|Active Comparator|Sunitinib 50 mg|Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment in each 21-day cycle.
9483344|NCT02811679|Experimental|Blinatumomab|Blinatumomab will be administered as a continuous IV infusion through a central venous catheter for a 42 day cycle. Blinatumomab will start with a 7 day infusion at 9mcg/d. If no dose limiting toxicity (table 6.1) after 7 days, the dose will be escalated to 28 mcg/d for 7 additional days. If no dose limiting toxicity (table 6.1) after 14 days, blinatumomab will be infused at a target dose of at 112mcg/d for 28 days. Subjects will be restaged after a 6 week treatment free period by PET CT. All subjects without disease progression will receive an additional 4 week cycle starting at the target dose of 112 mcg/d.
9483345|NCT02810444|Experimental|BT595|Subjects will receive BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.
9483346|NCT02808585|Experimental|PB1046 Injection, 0.2 mg/kg|Four weekly doses of PB1046 Injection, 0.2 mg/kg
9483347|NCT02808585|Experimental|PB1046 Injection, 0.4 mg/kg|Four weekly doses of PB1046 Injection, 0.4 mg/kg
9483348|NCT02808585|Experimental|PB1046 Injection, 0.6 mg/kg|Four weekly doses of PB1046 Injection, 0.6 mg/kg
9483349|NCT02808585|Experimental|PB1046 Injection, 1.2 mg/kg|Four weekly doses of PB1046 Injection, 1.2 mg/kg
9483350|NCT02808585|Placebo Comparator|Placebo Comparator|Four weekly doses of Placebo (0.9% NaCl) Injection
9483351|NCT02807428|Experimental|AYX1 Injection 660 mg/6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
9483352|NCT02807428|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
9483353|NCT02805257|Experimental|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
9483354|NCT02805257|Placebo Comparator|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
9483355|NCT02804282|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
9483356|NCT02804035|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
9483357|NCT02802813|Active Comparator|Intervention arm|Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
9483358|NCT02802813|Placebo Comparator|Control arm|Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.
9483359|NCT02801331|Experimental|Stochastic Vibrotactile Stimulation (SVS)|Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 48-hrs post birth. SVS will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed). Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
9483360|NCT02801331|No Intervention|Treatment as Usual (TAU)|Infants randomized to this arm will be enrolled within 48-hours post birth and receive treatment as usual (TAU)- standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed). Infants will not receive any SVS. Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
9483361|NCT02798120|Experimental|SB204 4%|SB204 4% once daily
9483362|NCT02796170|Active Comparator|Dapagliflozin|This arm will undergo 6 weeks of Dapagloflozin then 6 weeks of placebo
9483363|NCT02796170|Other|Sulfonylurea|This arm will be open label, participants will receive usual care for 6 weeks, then be provided a sulfonylurea medication for 6 weeks.
9483364|NCT02796170|Active Comparator|Placebo|This arm will undergo 6 weeks of placebo then 6 weeks of Dapagloflozin
9483365|NCT02784288|Experimental|Neck Dissection|Patients undergo up-front neck dissection of the cervical lymph nodes to determine stratification into one of three standard-of-care treatment groups: transoral surgery of the primary site, radiation or chemoradiation.
9483366|NCT02784002|Experimental|Ridinilazole (SMT19969)|200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days
9483367|NCT02784002|Active Comparator|Fidaxomicin|200 mg tablet of Fidaxomicin twice a day for 10 days
9483368|NCT02782806|Experimental|Test group|All subjects are enrolled into the test group and receive Masimo Rad-67 Pulse Oximeter for measurement of hemoglobin.
9483369|NCT02782117|Experimental|Treatment Regimen A|Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.
9483370|NCT02778399|Experimental|OBE2109 dose 1|
9483371|NCT02778399|Experimental|OBE2109 dose 2|
9483372|NCT02778399|Experimental|OBE2109 dose 3|
9483373|NCT02778399|Experimental|OBE2109 dose 4|
9483374|NCT02778399|Experimental|OBE2109 dose 5|
9483375|NCT02778399|Placebo Comparator|Placebo / OBE2109 dose 6|
9497830|NCT03471442|Active Comparator|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
9483376|NCT02775162|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
9483377|NCT02775162|Other|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
9483378|NCT02773849|Experimental|INSTILADRIN|Intravesical administration of INSTILADRIN into the bladder
9483379|NCT02771626|Experimental|CB-839 + Nivolumab Dose Escalation|Phase 1: CB-839 administered as oral capsules twice daily in combination with standard dose nivolumab in patients with advanced/metastatic ccRCC, MEL, and NSCLC to select the recommended Phase 2 dose (RP2D).
9483380|NCT02771626|Experimental|Clear Cell RCC Naïve to Checkpoint Inhibitors|Cohort 1: CB-839/nivolumab combination in patients with advanced/metastatic ccRCC who have previously received at least one tyrosine kinase inhibitors (TKI) but are treatment naive to checkpoint modulators programmed death-1/programmed death ligand-1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
9483381|NCT02771626|Experimental|Clear Cell RCC Recently Treated with Nivolumab|Cohort 2: CB-839/nivolumab combination in patients with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
9483382|NCT02771626|Experimental|Clear Cell RCC with Prior PD-1 Therapy|Phase 2 - Cohort 3: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
9483383|NCT02771626|Experimental|Melanoma with Prior PD-1 Therapy|Cohort 4: CB-839/ nivolumab combination in patients with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
9483384|NCT02771626|Experimental|NSCLC with Prior PD-1 Therapy|Cohort 5: CB-839/ nivolumab combination with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
9483385|NCT02770716|Experimental|Terlipressin|"Participants will receive terlipressin intravenously as a bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (+/- 30 minutes), followed by a saline flush.~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
9483386|NCT02770716|Placebo Comparator|Placebo|"Participants will receive 1 vial of matching placebo intravenously as a bolus injection of 1 vial over 2 minutes every 6 hours (+/- 30 minutes), followed by a saline flush.~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
9483387|NCT02770391|Experimental|Apalutamide + Leuprolide Acetate|All participating patients will receive a single dose of leuprolide 7.5 mg intramuscularly (IM) in addition to Apalutamide 240 mg orally daily for four weeks prior to radical prostatectomy (RP). Treatment will be started on day (-28) ± 3 from the scheduled RP date to minimize the variability of treatment duration. Apalutamide may be continued up to and including the day before
9483388|NCT02765802|Experimental|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
9483389|NCT02765802|Experimental|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
9483390|NCT02762929|Experimental|Part A Cohort A|200 mg of HTX-011A via closed wound infiltration
9483391|NCT02762929|Experimental|Part A Cohort B|200 mg of HTX 011A via open wound infiltration
9483392|NCT02762929|Experimental|Part A Cohort C|200 mg of HTX-011B via closed wound infiltration
9483393|NCT02762929|Experimental|Part A Cohort D|200 mg of HTX 011B via open wound infiltration
9483394|NCT02762929|Active Comparator|Part A Cohort E|50 mg 0.5% bupivacaine hydrochloride injection via a closed wound infiltration
9483395|NCT02762929|Placebo Comparator|Part A Cohort F|Saline Placebo via a closed wound infiltration
9483396|NCT02762929|Experimental|Part B Cohort A|200 mg HTX 002 via closed wound infiltration
9483397|NCT02762929|Experimental|Part B Cohort B|200 mg HTX 002 via open wound infiltration
9483398|NCT02762929|Placebo Comparator|Part B Cohort C|Saline placebo via a closed and open wound infiltration
9483399|NCT02762929|Experimental|Part C Cohort A|120 mg of HTX-011B via closed wound infiltration
9483400|NCT02762929|Experimental|Part C Cohort B|120 mg of HTX-011B via open wound infiltration
9483401|NCT02762929|Experimental|Part C Cohort C|120 mg of HTX-011B local administration via instillation
9483402|NCT02762929|Placebo Comparator|Part C Cohort D|Saline placebo via open wound infiltration
9483403|NCT02762929|Experimental|Part D Cohort A|60 mg of HTX-011B via closed wound infiltration
9483404|NCT02762929|Experimental|Part D Cohort B|60 mg of HTX-011B via open wound infiltration.
9483405|NCT02762929|Placebo Comparator|Part D Cohort C|Saline placebo via open wound infiltration
9483406|NCT02762929|Experimental|Part E Cohort A|120 mg HTX 002 via closed wound infiltration
9483407|NCT02762929|Experimental|Part E Cohort B|120mg HTX 002 via open wound infiltration
9483408|NCT02762929|Placebo Comparator|Part E Cohort C|Saline placebo via closed and open wound infiltration
9483409|NCT02762929|Experimental|Part F Cohort A|HTX 009 via closed wound infiltration
9483410|NCT02762929|Experimental|Part F Cohort B|HTX 009 via open wound infiltration
9483411|NCT02762929|Placebo Comparator|Part F Cohort C|Saline placebo via closed and open wound infiltration
9483412|NCT02762929|Experimental|Part G Cohort A|30 mg of HTX 011B via closed wound infiltration
9483413|NCT02762929|Placebo Comparator|Part G Cohort B|Saline placebo via closed wound infiltration
9483414|NCT02762929|Experimental|Part H Cohort A|120 mg of HTX-011-056
9483415|NCT02762929|Experimental|Part H Cohort B|60 mg of HTX-011-056
9483416|NCT02762929|Placebo Comparator|Part H Cohort C|4.1 mL of normal saline
9537616|NCT03139305|Active Comparator|Glucagon Low Dose|
10039189|NCT01841372|Active Comparator|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
10039190|NCT01841372|Experimental|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
9483419|NCT02755597|Placebo Comparator|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
9483420|NCT02755597|Experimental|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Venetoclax 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
9483421|NCT02749955|Experimental|PS-PrEP Intervention Group|
9483422|NCT02749955|Active Comparator|PrEPLine Control Group|
9483423|NCT02749955|No Intervention|CDPH Prevention Projects|
9483424|NCT02744833|Experimental|GMI-1271|
9483425|NCT02744833|Active Comparator|Enoxaparin Sodium (Lovenox®)|
9483426|NCT02741791|Experimental|AXS-05|
9483427|NCT02741791|Active Comparator|Bupropion|
9483428|NCT02738125||Subjects starting/ receiving adalimumab|Subjects starting/ receiving Adalimumab for UC
9483429|NCT02736968|Experimental|E. histolytica- Active|N=34, 6mg auranofin daily x 7 days
9483430|NCT02736968|Placebo Comparator|E. histolytica- Placebo|N=34, 6mg placebo daily x 7 days
9483431|NCT02736968|Experimental|Giardia- Active|N=34, 6mg auranofin daily x 5 days
9483432|NCT02736968|Placebo Comparator|Giardia- Placebo|N=34, 6mg placebo daily x 5 days
9483433|NCT02736149|Experimental|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
9483434|NCT02735122|Experimental|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
9483435|NCT02735122|Active Comparator|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
9483436|NCT02735122|Active Comparator|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
9483437|NCT02735122|Placebo Comparator|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
9483438|NCT02734667|Experimental|CGM at diagnosis of T1D|Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
9483439|NCT02734667|No Intervention|Usual Care|Participants receive usual care for T1D for 6 months post diagnosis.
9483440|NCT02733432|Experimental|Cohort 1|CD101 Vaginal Gel (3%) topically self-administered intravaginally as a single dose on days 1 and 2 and for symptomatic relief CD101 External Gel (1%)topically self-applied to external vulva up to twice per day over 72 hours.
9483441|NCT02733432|Experimental|Cohort 2|CD101 Vaginal Ointment (6%) topically self-administered intravaginally as a single dose on day 1 and for symptomatic relief CD101 External Ointment (1%) topically self-applied to external vulva up to twice per day over 72 hours.
9483442|NCT02733432|Active Comparator|Cohort 3|Oral fluconazole (150mg) administered on day 1.
9483443|NCT02732184|Experimental|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
9483444|NCT02728726|Experimental|Treatment group|study drug (sugammadex) administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and patient is extubated.
9483445|NCT02728726|Placebo Comparator|Control group|placebo administered intravenously after routine reversal of anesthesia is performed and patient is extubated.
9483446|NCT02726906|Experimental|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
9483447|NCT02726906|Placebo Comparator|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
9483448|NCT02723162|Experimental|VRN+ NAC|Titrated VRN up to 1mg BID with NAC at 1200mg BID for 28 days
9483449|NCT02723162|Active Comparator|NAC+ PBO|1200mg BID for 28 days plus VRN placebo for 28 days
9483450|NCT02723162|Active Comparator|VRN+ PBO|Titrated VRN up to 1mg BID with NAC placebo for 28 days
9483451|NCT02723162|Placebo Comparator|PBO+PBO|Double placebo taken for 28 days
9483452|NCT02720718|Experimental|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
9483453|NCT02720718|Active Comparator|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
9483454|NCT02715375|Experimental|Device: CREON2000A|Children with mild to moderate asthma maintains allergy medicines have an experimental ultra violet device installed in their homes.
9483455|NCT02715375|Sham Comparator|Device: Sham Comparator|Children with mild to moderate asthma maintains allergy medicines have a sham device using a shielded blue light sham lamp that otherwise resembles the experimental device installed in their homes.
9483456|NCT02715115|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
9483457|NCT02715115|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
9483460|NCT02709317|Active Comparator|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
9497831|NCT03471442|Experimental|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
9497832|NCT03471429||Dog|Patient sees therapy dog for 15 minutes, which is standard of care at this hospital.
9497833|NCT03471429||No Dog|Patient receives standard of care
10039191|NCT01841385|Experimental|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
10039192|NCT01841385|No Intervention|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
9537617|NCT03139305|Active Comparator|Glucagon High Dose|
9537618|NCT03139305|Placebo Comparator|Placebo|
9537619|NCT03139500|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
9537620|NCT03139500|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
9537621|NCT03139500|Experimental|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
9537622|NCT03139331|Experimental|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
9537623|NCT03139201|Experimental|OxyAqua|OxyAqua (olifilcon D) daily disposable
9537624|NCT03139201|Active Comparator|Si-Hy|Si-Hy (olifilcon B) daily disposable
9537625|NCT03139214|Experimental|Intervention|Parenting intervention, 7 weekly sessions, each session 2 hours in length.
9537626|NCT03139214|No Intervention|Control|3 mailings about child development and stress management.
9537627|NCT03139383|Placebo Comparator|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
9537628|NCT03139383|Active Comparator|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
9537629|NCT03139396|Active Comparator|inlay shaped inlay bridge design|The inlay shaped inlay bridge design preparation show three types of preparation, the inlay shaped, the tub shaped inlay bridge design and the proximal box shaped designs. Intracoronal preparation of the inlay retained prosthesis for the abutments (inlay shaped and tub shaped) should show the following criteria: The inlay shaped preparation should show an occlusal-proximal box preparation and to be designed with the line angles should be rounded, smooth and rounded corners, and rectangular flat floor with no beveling for the occlusal and gingival margins. The occlusal inlay preparation should have preparation depth allowed for a thickness of 2.0 mm for the material of the bridge. The occlusal reduction show 4 mm width with extension of 4 or 6 mm mesio distally for the posterior teeth.
9537630|NCT03139396|Experimental|tub shaped inlay bridge design|The tub-shaped reduction consist of an occlusal proximal inlay and prepared as the same geometry as the inlay shaped preparation, except that for the proximal box preparation which is not present in this preparation design.
9537631|NCT03139149|Active Comparator|Early surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 12 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast in 3 h after admission. In case of of clinical and radiologic signs of obstruction in 12 h after admission, surgery is performed. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
9537632|NCT03139149|Active Comparator|Late surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 48 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast 3 h after admission. In case of present of obstruction and absence of contrast in colon in 36 h after intake (48 h after admission) a surgery is perform. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
9537633|NCT03139617|Active Comparator|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
9537634|NCT03139617|Experimental|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
9537635|NCT03139136|Active Comparator|MBS2320|
9537636|NCT03139136|Placebo Comparator|Placebo|
9537637|NCT03139058|Other|prevalence of cirrhosis|Study the prevalence of cirrhosis in patients with VADS cancer
9537638|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
9537639|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
9537640|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
9537641|NCT03138902|Experimental|Glucose Tolerance Beverage|75 g. of a fruit punch flavored oral glucose solution
9537642|NCT03138980|Experimental|Mobile application|
9537643|NCT03139045|Active Comparator|Venous puncture using VVV at the beginning of the procedure|
9537644|NCT03139045|Active Comparator|Venous puncture without VVV|
9537645|NCT03138759|Experimental|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
9497834|NCT03471416||Children with ALL|Children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
9497835|NCT03471403||FAP|FAP patients with duodenal adenomas
9497836|NCT03471390|Experimental|ProQuaS 2- Intervention|
9497837|NCT03471351|Experimental|Tenalisib+Pembrolizumab|Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.
9497838|NCT03471325|Experimental|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
9497839|NCT03471325|Experimental|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
9497840|NCT03471325|Experimental|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
9497841|NCT03471325|Placebo Comparator|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
9497842|NCT03471312||treated with magnesium therapy|will receive magnesium sulphate 10 mg \kg \day as a single oral dose for one month duration
9497843|NCT03471312||treated with placebo drug|will receive placebo drug
9497844|NCT03471286|Experimental|Sub-Protocol A|Epacadostat
9497845|NCT03471273|Other|endoscopic management|
9497846|NCT03471273|Other|follow up|
9497847|NCT03471273|Other|surgery|
9497848|NCT03471260|Experimental|Treatment (venetoclax, ivosidenib, azacitidine)|Patients receive venetoclax PO daily on days 1-14. Patients also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9497849|NCT03471208|Experimental|Dynamic Navigation|Dental implant surgery via dynamic navigation assistance
9497850|NCT03471208|Active Comparator|Freehand|Dental implant surgery via conventional freehand
9497851|NCT03471195||CP|A total of 20 children with cerebral palsy and dental decay will undergothe following Collection of Saliva Total Salivary Cytokine Profile
9497852|NCT03471195||Control|A total of 20 verbal children without cerebral palsy matched for age and extent of dental decay will undergo the following Collection of Saliva Total Salivary Cytokine Profile
9497853|NCT03471182|Active Comparator|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
9497854|NCT03471182|Active Comparator|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
9497855|NCT03471182|Active Comparator|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
9497856|NCT03471182|Active Comparator|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
9497857|NCT03471169|Experimental|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
9497858|NCT03471169|Sham Comparator|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
9497859|NCT03471156||Post EMR|Patients are observed post EMR procedure for pain. Standard of care data is collected
9497860|NCT03471130|Experimental|Low dose MT-8554 or placebo to match|Low dose MT-8554
9497861|NCT03471130|Experimental|High dose MT-8554 or placebo to match|High dose MT-8554
9497862|NCT03471117|Active Comparator|Pioglitazone|The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg/day. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg/day. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.
9497863|NCT03471117|Placebo Comparator|Placebo|Placebo pills are made of avicel microcrystalline cellulose and magnesium stearate, which are inactive ingredients in the Pioglitazone pills. The placebo pills will be of similar color and appearance as the Pioglitazone pills
9497864|NCT03471104|Experimental|PAID in clinical diabetes consultations|Participants randomised to the intervention arm. Participants complete the Problem Area in Diabetes scale (PAID) and evaluation PROMs. Participants with specified PAID scores will be offered an empowerment-based follow-up by diabetes specialist nurses.
9497865|NCT03471104|No Intervention|Control group|Participants randomised to the control group. Participants complete PROMs but the results/answers will not be available in the electronic patient records until the trial is finished. The participants will receive standard care.
9497866|NCT03471091|Experimental|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
9497867|NCT03471091|No Intervention|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
9497868|NCT03471052|Experimental|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)
9497869|NCT03471052|No Intervention|Sham procedure|Endoscopy will be performed under conscious sedation and all BarrX RFA equipment will be set up in room. A sound recording of the BarrxTM RFA device will be played (a distinct bell sound that is emitted from the generator) during the procedure.
9497870|NCT03471039|Active Comparator|Active|PACAP-27
9483461|NCT02709317|Experimental|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
9483462|NCT02706795|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
9483463|NCT02706353|Experimental|APX005M + Pembrolizumab|"Dose Escalation Phase:~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.~Dose Expansion Phase:~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
9483464|NCT02705755|Experimental|TD-9855 Part A|Subjects will receive placebo and escalating single doses of TD-9855
9483465|NCT02705755|Experimental|TD-9855 Part B|Subjects will receive a single dose of TD-9855 or placebo.
9483466|NCT02705755|Experimental|TD-9855 Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
9483467|NCT02704429|Experimental|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 week follow up; Part B: Open-label PRN1008, 24 weeks;4 weeks follow up
9483468|NCT02704364|Experimental|NGM282 Dose 1|NGM282 Dose 1
9483469|NCT02704364|Experimental|NGM282 Dose 2|NGM282 Dose 2
9483470|NCT02704364|Active Comparator|Placebo|Placebo
9483471|NCT02700529|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
9483472|NCT02700529|Placebo Comparator|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
9483473|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
9483474|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
9483475|NCT02697136|Experimental|CER-001|CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
9483476|NCT02697136|Placebo Comparator|Placebo|Saline infusion; 9 weekly infusions followed by 20 biweekly infusions
9483477|NCT02696499|Experimental|PA101B|
9483478|NCT02696499|Placebo Comparator|Placebo|
9483479|NCT02689258|Experimental|Part A Cohort A|200 mg of HTX-011A by infiltration
9483480|NCT02689258|Placebo Comparator|Part A Cohort B|Saline Solution by infiltration
9483481|NCT02689258|Experimental|Part A Cohort C|200 mg of HTX-011B by infiltration
9483482|NCT02689258|Experimental|Part A Cohort D|400 mg of HTX-011B by infiltration
9483483|NCT02689258|Experimental|Part A Cohort E|600 mg of HTX-011B by infiltration
9483484|NCT02689258|Experimental|Part B Cohort A|Subjects will be enrolled in Part B following completion of enrollment in Part A to evaluate HTX-011 and HTX-002, with or without saline solution.
9483485|NCT02689258|Experimental|Part C Cohort A|Subjects will be enrolled in Part C following completion of Part B to evaluate 400 mg HTX-011B via instillation, bupivacaine HCl 100 mg via injection and saline placebo via injection
9483486|NCT02689258|Experimental|Part D Cohort A|Up to 300 mg of HTX-011B
9483487|NCT02689258|Placebo Comparator|Part D Cohort B|Saline Solution
9483488|NCT02683239|Experimental|Fasinumab dosing regimen 1|
9483489|NCT02683239|Experimental|Fasinumab dosing regimen 2|
9483490|NCT02683239|Experimental|Placebo|
9483491|NCT02682316|Active Comparator|usual standard dry gauze used for wound management|Patients who are randomized to the standard dry gauze arm will have the standard dry gauze placed at time of wound closure. Their dressing will be removed on post-operative day 2 as per routine departmental practice.
9483492|NCT02682316|Experimental|Prevena Negative Pressure Wound Therapy System (NPWT)|Patients who are randomized to the Prevena Therapy System arm will have the Prevena Incision Management System device placed at time of wound closure. The device will be removed on day of discharge from the hospital or post-operative day 7, whichever comes first.
9483493|NCT02682238|Experimental|BBI-4000, 15%|15% BBI-4000 (sofpironium bromide) topical gel
9483494|NCT02682238|Placebo Comparator|Vehicle|Vehicle (placebo) gel
9483495|NCT02681055|Experimental|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
9483496|NCT02680574|Experimental|vadadustat|
9483497|NCT02680574|Active Comparator|darbepoetin alfa|
9483498|NCT02678793|Other|Subjects who have completed Study 4975-MN-202 will be eligible|Subjects who have completed Study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 μg in Study 4975-MN-203 if they meet the inclusion/exclusion criteria.
9483499|NCT02677805|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
9497871|NCT03471039|Placebo Comparator|Placebo|Saline
9483500|NCT02677805|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
9483501|NCT02677545|Experimental|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
9483502|NCT02677545|Active Comparator|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
9483503|NCT02677298|Experimental|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
9483504|NCT02677298|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
9483505|NCT02677038|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9483506|NCT02675829|Experimental|Cohort 1: Lung cancers, HER2 mutant|
9483507|NCT02675829|Experimental|Cohort 2: Lung cancers, HER2 amplified|
9483508|NCT02675829|Experimental|Cohort 3: Colorectal cancers|
9483509|NCT02675829|Experimental|Cohort 4: Endometrial cancers|
9483510|NCT02675829|Experimental|Cohort 5: Salivary gland cancers|
9483511|NCT02675829|Experimental|Cohort 6: Other solid cancers|
9483512|NCT02673749|Experimental|RP-G28 Dose 1|
9483513|NCT02673749|Experimental|RP-G28 Dose 2|
9483514|NCT02673749|Placebo Comparator|Placebo|
9483515|NCT02673476|Placebo Comparator|Placebo|Identical Placebo Comparator
9483516|NCT02673476|Experimental|ALS-008176|ALS-008176 tablets
9483517|NCT02672332|Experimental|SB204 4%|SB204 4% topically once daily
9483518|NCT02672332|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
9483519|NCT02669511|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
9483520|NCT02667444|Experimental|SB204 4%|SB204 4% topically once daily
9483521|NCT02667444|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
9483522|NCT02665234|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
9483523|NCT02665234|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
9483524|NCT02664558|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
9483525|NCT02664558|Placebo Comparator|placebo|placebo capsules TID, administered orally for a total of 24 weeks
9483526|NCT02662062|Experimental|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
9483527|NCT02661282|Experimental|Arm I (temozolomide, CMV-specific T cells, surgery)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer IV over 1-5 minutes on day 22. Patients undergo surgery on day 30 of cycle 1. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-21. Treatment repeats every 42 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9483528|NCT02661282|Active Comparator|Arm II (temozolomide, CMV-specific T cells)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer intravenously IV over 1-5 minutes on day 22. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
9483529|NCT02660424|Experimental|VX-150, placebo|Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
9483530|NCT02660424|Experimental|placebo, VX-150|Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
9483531|NCT02659397|Experimental|ETC-1002 + Atorvastatin|ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
9483532|NCT02659397|Placebo Comparator|Placebo + Atorvastatin|Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
9483533|NCT02657356|Placebo Comparator|Placebo capsules|Placebo capsules will be administered orally once a day for 24 weeks.
9483534|NCT02657356|Experimental|Bardoxolone methyl capsules|Each patient will receive bardoxolone methyl capsules administered orally once a day for 24 weeks. Starting dosage for each patient is 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically.
9483535|NCT02654990|Experimental|Arm A - 20mg PAN TIW|20mg panobinostat three times a week, 2 weeks on/1week of in combination with s.c. bortezomib and p.o. dexamethasone
9483536|NCT02654990|Experimental|Arm B - 20mg PAN BIW|20mg panobinostat twice a week, 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
9483537|NCT02654990|Experimental|Arm C - 10mg PAN TIW|10mg panobinostat three times a week 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
9483538|NCT02654327|No Intervention|Standard Care|Standard care with conventional lung protective mechanical ventilation
9483539|NCT02654327|Experimental|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
9483540|NCT02653599|Experimental|TTP273 300 mg daily (150 mg BID)|Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks
9483541|NCT02653599|Experimental|TTP273 150 mg daily|Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks
9537646|NCT03138759|Experimental|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
9483542|NCT02653599|Placebo Comparator|Placebo|Two matching placebo tablets administered orally twice daily for 12 weeks
9483543|NCT02653443|Experimental|Day 6|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
9483544|NCT02653443|Experimental|Day 7|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
9483545|NCT02650804|Experimental|BPM31510 plus gemcitabine|"BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.~Cycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21."
9483546|NCT02649062|Experimental|NGM282 Dose 1|NGM282
9483547|NCT02649062|Experimental|NGM282 Dose 2|NGM282
9483548|NCT02649062|Placebo Comparator|Placebo|Placebo
9483549|NCT02648620|Experimental|SurVeil Drug Coated Balloon catheter|Paclitaxel Coated Balloon catheter for angioplasty
9483550|NCT02648347|Experimental|vadadustat|
9483551|NCT02648347|Active Comparator|darbepoetin alfa|
9483552|NCT02647359|Experimental|Ataluren|Participants will receive ataluren orally 3 times a day (TID) at a dose of 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 48 weeks in Stage 1 (double-masked period) and for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
9483553|NCT02647359|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren TID orally in the morning, at midday, and in the evening for 48 weeks in Stage 1 (double-masked period) and ataluren orally TID at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
9497872|NCT03471026||pCMS+|Children undergoing infratentorial craniotomy for brain tumour resection whom develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
9497873|NCT03471026||pCMS-|Children undergoing infratentorial craniotomy for brain tumour resection whom do not develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
9497874|NCT03471026||Controls|Healthy control children whom have never undergone intracranial surgery have had advanced MRI sequences acquired
9497875|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
9497876|NCT03471000|Experimental|Short implants Treatment|Group 2 (G2; n=15 patients) had short implants (OsseoSpeed ™ L6mm Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed without sinus lift and augmentation procedure.
9497877|NCT03471000|Active Comparator|Regular Implants Treatment|Group 1 (G1; n=15 patients) had conventional dental implants (OsseoSpeed ™ L11 Ø4 mm and L13 Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed, preceded by the sinus lift procedure from a lateral window approach with the application of the xenogeneic bone graft Geistlich Bio-Oss® [Geistlich AG, Wolhusen, Switzerland]. The lateral window approach sinus lift surgery was performed 6 weeks prior to the implant placement by the same surgeon.
9497878|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
9497879|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
9497880|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
9497881|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
9497882|NCT03470974|Experimental|Intervention Group|The intervention group receives self-titration strategy training and lifestyle education.
9497883|NCT03470974|No Intervention|Control Group|The control group receives usual care and lifestyle education.
9497884|NCT03470961|Experimental|Anti-Tlymphocyte Globulins|intravenous，2mg/kg/d，for 5 days
9497885|NCT03470961|Active Comparator|Anti-thymocyte Globulins|intravenous，1.5mg/kg/d，for 4 days
9497886|NCT03470909|Other|Skin-Sparing Mastectomy (SSM)|
9497887|NCT03470909|Other|Nipple-Sparing Mastectomy (NSM)|
9497888|NCT03470896|Active Comparator|Preanesthesia teleconsultation|Preanesthesia teleconsultation through video-conference, between an anesthesiologist of the surgical center Emile Galle, in a medical consulting room in the surgical center Emile Galle, and a patient at home or at work. The patient must be in a quiet area, which allows the confidential medical contact.
9497889|NCT03470896|Active Comparator|Preanesthesia traditional consultation|Preanesthesia traditional consultation between an anesthesiologist of the surgical center Emile Galle, and a patient, in a medical consulting room in the surgical center Emile Galle.
9497890|NCT03470896|Other|Bis traditional consultation|"If a patient, in the group  preanesthesia teleconsultation  cannot realized his teleconsultation because of technical problem, he will be assigned on the sub group  bis traditional preanesthesia consultation ."
9497891|NCT03470883||endoscopic resection of a colorectal lesion|Patient having undergone endoscopic resection of a colorectal lesion stage 4 or 5 of the modified Vienna classification during the last 5 years at the institute.
9497892|NCT03470870||Patients discharged before 2 days after surgery|patients discharged before 2 days of hospitalization following surgery
10039193|NCT01841398|Active Comparator|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits & physical activity
10039194|NCT01841398|Placebo Comparator|Usual Care|Includes usual advice and no regular health messaging.
10039195|NCT01841411|Experimental|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
9483554|NCT02646982|Experimental|Candesartan|Candesartan will be given orally once a day in a stepwise manner as follows: All participants will be initiated on 8 mg candesartan. The dose will be increased in 2 week increments to 16 mg and 32 mg as long as the systolic blood pressure (SBP) >100 mm Hg, diastolic blood pressure (DBP) >40 mm Hg and participant reports no symptoms of hypotension (dizziness or weakness). The highest achievable dose will be the Maximal Tolerated Dose (MTD) and the participant will receive this dose for the remaining duration of the study (participants will be treated for 1 year).
9483555|NCT02646982|Placebo Comparator|Placebo|Participants will receive a matched placebo once a day orally for 12 months.
9483556|NCT02641028|Experimental|CERC-501|Administered orally once daily, 15mg daily, 8 days.
9537647|NCT03138850|Experimental|Olympus standard bite block|Standard of care using standard bite block and nasal cannula
10039196|NCT01841411|Experimental|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
10039197|NCT01841411|Active Comparator|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
10039198|NCT01841424|No Intervention|Control|Subjects receive usual care for pregnancy and postpartum.
10039199|NCT01841424|Experimental|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
10039200|NCT01841437||iStent|
10039201|NCT01841450|Experimental|iStent|Implantation of one iStent in conjunction with cataract surgery
10039202|NCT01841450|Active Comparator|Cataract surgery|Cataract surgery alone
9483557|NCT02641028|Placebo Comparator|Placebo|Administered orally daily, 8 days.
9483558|NCT02640950|Experimental|Open-Label TMS|Active Transcranial Magnetic Stimulation
9483559|NCT02638805|Experimental|Group 1|ITCA 650 20/60 mcg/day
9483560|NCT02638805|Experimental|Group 2|ITCA 650 60 mcg/day
9483561|NCT02637960|Experimental|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
9483562|NCT02637960|Experimental|Placebo matched to fedovapagon|One daily dose of placebo (matched to fedovapagon) for 12 weeks
9483563|NCT02636582|Experimental|Arm I (nelipepimut-S plus GM-CSF vaccine)|Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
9483564|NCT02636582|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
9483565|NCT02634853|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
9483566|NCT02634853|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
9483567|NCT02627274|Experimental|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
9483568|NCT02627274|Experimental|Part B: RO6874281 in Combination with Trastuzumab|Dose Escalation: RO6874281 will be administered as an IV infusion. RO6874281 will be administered QW for the first 4 administrations, then Q2W. The standard dose for trastuzumab will be a loading dose of 6 milligrams per kilogram (mg/kg) followed by a maintenance dose of 4 mg/kg from Cycle 2 in a Q2W regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.
9483569|NCT02627274|Experimental|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW for the first 4 administrations, then Q2W. Cetuximab will be administered Q2W at 500 milligrams per square meter (mg/m^2). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.~Extension Phase: The MTD for RO6874281 was determined to be 10mg and therefore patients in the extension will be treated with 10mg RO6874281. Cetuximab and R06874281 will be administered weekly during induction phase (cycle 1 and cycle 2). Both IMPs will be administered Q2W starting in cycle 3."
9483570|NCT02626338|Experimental|Arm A|"Mitoxantrone~Cytarabine~Crenolanib"
9483571|NCT02626338|Experimental|Arm B|"Mitoxantrone~Etoposide~Cytarabine~Crenolanib"
9483572|NCT02626338|Experimental|Arm C|"Fludarabine~Cytarabine~G-CSF~Idarubicin~Crenolanib"
9483573|NCT02626130|Experimental|Arm A (tremelimumab)|Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
10039203|NCT01841463|Experimental|P1446A-05|"The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-~In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
10039204|NCT01841476|Experimental|POL6326|2-hour single intravenous infusion doses of POL6326
10039205|NCT01841489|Experimental|Sequence 1|
9483574|NCT02626130|Experimental|Arm B (tremelimumab and cryoablation)|Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
9483575|NCT02624947|Placebo Comparator|Treatment Group A|Formulation buffer (0.5mL injection)
9483576|NCT02624947|Active Comparator|Treatment Group|RSV F vaccine with adjuvant (0.5mL injection)
9483577|NCT02620553|Experimental|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
9483578|NCT02620553|Placebo Comparator|Placebo|Oral Placebo
9483583|NCT02615067|Experimental|99mTc-MIP-1404 Injection|20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
9483584|NCT02613949|Active Comparator|12-week RINCE mode 1|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 1
9483585|NCT02613949|Active Comparator|12-week RINCE mode 2|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 2
9483586|NCT02613949|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
9483587|NCT02612922|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
9483588|NCT02612922|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
9483589|NCT02612129|Experimental|arimoclomol|arimoclomol capsules for oral administration (3 times daily). Doses:150-600 mg/day (based on weight)
9483590|NCT02612129|Placebo Comparator|Placebo|Matching placebo capsules
9483591|NCT02611609|Experimental|Cohort 1|Low dose MultiStem
9483592|NCT02611609|Experimental|Cohort 2|High dose MultiStem
9483593|NCT02611609|Experimental|Cohort 3|Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo
9483594|NCT02610296|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
9483595|NCT02610296|Placebo Comparator|Placebo|isotonic saline
9483596|NCT02610283|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
9483597|NCT02610283|Placebo Comparator|Placebo|isotonic saline
9483598|NCT02609828|Experimental|Arm 1|Tanezumab 20 mg subcutaneously
9483599|NCT02609828|Placebo Comparator|Arm 2|Placebo matched to active treatment subcutaneously
9483600|NCT02609048|Placebo Comparator|Placebo Dose|Placebo Capsule Two Capsules Daily
9483601|NCT02609048|Experimental|Seladelpar / MBX-8025 50 mg Dose|MBX-8025 50 mg capsule One Capsule Daily
9483602|NCT02609048|Experimental|Seladelpar / MBX-8025 200 mg Dose|MBX-8025 100 mg capsules (2 taken once daily)
9483603|NCT02608697|Experimental|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
9483604|NCT02608697|Experimental|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
9483605|NCT02608697|Experimental|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
9483606|NCT02608697|Experimental|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
9483607|NCT02608502|Experimental|Treatment Group A|RSV-F Vaccine (0.5mL Injection)
9483608|NCT02608502|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
9483609|NCT02607930|Experimental|B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo administered without regard to food for at least 144 weeks.
9483610|NCT02607930|Active Comparator|ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo administered without regard to food for at least 144 weeks.
9483611|NCT02607930|Experimental|Open-label Phase B/F/TAF to B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
9483612|NCT02607930|Experimental|Open-label Phase ABC/DTG/3TC to B/F/TAF|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
9483613|NCT02607683|Experimental|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
9483614|NCT02607683|Experimental|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
9483615|NCT02607683|Placebo Comparator|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
9497893|NCT03470870||Patients discharged after 2 days after surgery|patients discharging after 2 days of hospitalization following surgery
9537648|NCT03138850|Experimental|YX Mandibular advancement bite block|Mandibular advancement bite block group
9537649|NCT03138850|Experimental|Optiflow High flow nasal cannula|High flow nasal cannula group
9537650|NCT03138746||HBO|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen
9537651|NCT03138746||Hyperbaric air|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air
9537652|NCT03138863|Experimental|Fetuses with Left CDH|Performance of fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
9537653|NCT03138772||Healthy Controls|No intervention. Only monitoring LCI
9537654|NCT03138772||Cystic Fibrosis Patients|No intervention. Only monitoring LCI
9537655|NCT03138915|Experimental|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
9537656|NCT03138694||Methotrexate injection|Patients with Ectopic pregnancy treated with Methotrexate injection.
9537657|NCT03138694||Self resolution|"Patients with Ectopic pregnancy that had signs of self resolution with our Watchful waiting protocol."
9537658|NCT03139019|Experimental|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
9537659|NCT03139019|Experimental|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
9537660|NCT03139019|Experimental|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
9537661|NCT03139019|No Intervention|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
9537662|NCT03138811|Experimental|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
9537663|NCT03138811|Placebo Comparator|Placebo|placebo comparator administered as once daily inhaled dose
9537664|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
9537665|NCT03138603|Experimental|Metoprolol|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg prior to extubation, and subsequently an oral doser 25mg metoprolol tartrate) in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
9537666|NCT03138603|Placebo Comparator|Placebo|Patients will receive up to 3 IV doses of placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
9537667|NCT03138681|Placebo Comparator|Placebo|
9537668|NCT03138681|Experimental|ATP|
9537669|NCT03138681|Experimental|phosphocreatine|
9537670|NCT03138824|Experimental|SPIES assisted TURBT|Storz Professional Image Enhancement System (SPIES) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
9537671|NCT03138824|Experimental|WLI assisted TURBT|White Light Imaging (WLI) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
9537672|NCT03138668|Experimental|Low dose Ropivacaine|Perineural injection of 8 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve
9537673|NCT03138668|Experimental|High dose Ropivacaine|Perineural injection of 16 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve.
9537674|NCT03138785|Experimental|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
9537675|NCT03138785|Active Comparator|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
9537676|NCT03138616|Experimental|vitamin D intervention group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
9537677|NCT03138616|No Intervention|control group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
9537678|NCT03138616|Experimental|vitamin D intervention group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
9537679|NCT03138616|No Intervention|control group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
9537680|NCT03138993|Active Comparator|Patient decision aid|
9537681|NCT03138993|Sham Comparator|General sleep education|
9537682|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
9537683|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
9537684|NCT03138642|Experimental|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
9537685|NCT03138499|Experimental|Module A|Nivolumab combined with Brentuximab
9537686|NCT03138499|Experimental|Module B|Brentuximab alone
9537687|NCT03138278|No Intervention|Usual care|ICU with ordinary care for elderly ICU survivors and their care-givers
9537688|NCT03138278|Active Comparator|Telephone support|ICU with day-time telephone support to care-givers
9537689|NCT03138408|Experimental|SC-004|
9537690|NCT03138408|Experimental|SC-004 and ABBV-181|
9622076|NCT02518399|Sham Comparator|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
9537691|NCT03138291|Experimental|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
9537692|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
9537693|NCT03138447|Experimental|Prospective Cohort|
9537694|NCT03138447|No Intervention|Retrospective Cohort|
9537695|NCT03138187|No Intervention|control|without physical exercise sessions
9537696|NCT03138187|Experimental|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
9537697|NCT03138187|Experimental|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
9537698|NCT03138551|Experimental|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.~A: Baseline - typical mealtimes in the home.~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
9537699|NCT03138200|Other|Blood transfusion based on central venous oxygen saturation|
9537700|NCT03138356|Experimental|Cohort 1 Treatment A|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
9537701|NCT03138356|Experimental|Cohort 1 Treatment B|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
9537702|NCT03138356|Active Comparator|Cohort 1 Treatment C (Reference product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
9537703|NCT03138356|Experimental|Cohort 2 Treatment D|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
9537704|NCT03138356|Experimental|Cohort 2 Treatment E|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
9537705|NCT03138356|Active Comparator|Cohort 2 Treatment F (Reference Product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
9537706|NCT03138356|Experimental|Cohort 3 Treatment G|"Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
9537707|NCT03138356|Experimental|Cohort 3 Treatment H|"Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
9537708|NCT03138356|Active Comparator|Cohort 3 Treatment I (Reference Product)|"Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
9537709|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
9537710|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
9537711|NCT03138213|Experimental|TLPD|Ttotal laparoscopic pancreaticoduodenectomy
9537712|NCT03138213|Experimental|OPD|Open pancreaticoduodenectomy
9537713|NCT03138421|Experimental|ABX-1431 HCl|
9537714|NCT03138421|Placebo Comparator|Placebo|
9537715|NCT03138070|Experimental|Arm 1|14 days of BYL719 treatment, open label
9537716|NCT03138317|Experimental|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
9537717|NCT03138317|Experimental|Plasma|Group 2: knee injection of Plasma
9537718|NCT03138317|Placebo Comparator|Placebo|Group 3: knee injection of placebo (saline solution)
9622077|NCT02518412|Experimental|Active tDCS|Participants receive active tDCS stimulation. Half of the participants receive active tDCS stimulation, i.e 30 minutes active stimulation of the temporal cortex.
9622078|NCT02518412|Placebo Comparator|Placebo tDCS|Participants receive placebo tDCS stimulation. Half of the participants receive placebo tDCS stimulation, i.e 30 minutes inactive stimulation of the temporal cortex.
9483616|NCT02606305|Experimental|Regimen A (Mirvetuximab soravtansine + Bevacizumab)|Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
9483617|NCT02606305|Experimental|Regimen B (Mirvetuximab soravtansine + Carboplatin)|Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.
9483618|NCT02606305|Experimental|Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)|Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.
9483619|NCT02606305|Experimental|Regimen D (Mirvetuximab soravtansine + Pembrolizumab)|Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
9483620|NCT02606305|Experimental|Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)|Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.
9483621|NCT02605044|Experimental|Masitinib + FOLFIRI|masitinib + FOLFIRI
9483622|NCT02605044|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
9483623|NCT02604680|Experimental|BLI1100-1|Topical gel
9483624|NCT02604680|Experimental|BLI1100-2|Topical gel
9483625|NCT02604680|Experimental|BLI1100-3|Topical gel
9483626|NCT02604680|Experimental|BLI1100-4|Topical gel
9483627|NCT02604680|Placebo Comparator|Placebo|Topical gel
9483628|NCT02603614|Experimental|Cenderitide-Placebo|"Infusion Period A: Cenderitide Infusion Period B: Placebo~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
9483629|NCT02603614|Experimental|Placebo-Cenderitide|"Infusion Period A: Placebo Infusion Period B: Cenderitide~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
9483630|NCT02602353|Experimental|Loxoprofen Pain Patch|One Active Pain Patch containing loxoprofen applied once daily for 3 days
9483631|NCT02602353|Placebo Comparator|Placebo Patch|One Placebo Patch applied once daily for 3 days
9483632|NCT02602353|Other|No Treatment|No Treatment for 3 days
9483633|NCT02600494|Experimental|40 mg ITI-007 (Lumateperone)|40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
9483634|NCT02600494|Experimental|60 mg ITI-007 (Lumateperone)|60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
9483635|NCT02600494|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
9483636|NCT02600429|Experimental|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
9483637|NCT02600429|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
9483638|NCT02598960|Experimental|BMS-986156: Dose Escalation|
9483639|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Escalation|
9483640|NCT02598960|Experimental|BMS-986156: Dose Expansion|
9483641|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Expansion|
9483642|NCT02598960|Experimental|BMS986156 + Nivo: Cohort Expansion|
9483643|NCT02598557|Experimental|Arm I (exemestane)|Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
9483644|NCT02598557|Experimental|Arm II (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
9483645|NCT02598557|Experimental|Arm III (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
9483646|NCT02597803|Experimental|High Dose RGN-259|High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
9483647|NCT02597803|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
9483648|NCT02597803|Experimental|Low Dose RGN-259|Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
9483649|NCT02597634|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
9483650|NCT02597634|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
9483651|NCT02597491|Active Comparator|4 wk assessment + TLC monthly|4 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
9483652|NCT02597491|Active Comparator|4 week assessment + TLC quarterly|4 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
9483653|NCT02597491|Active Comparator|4 week assessment +TLC + MTM|4 week assessment, 4 weeks counseling, NRT, medication management (nonresponders)
9483654|NCT02597491|Active Comparator|8 week assessment + TLC monthly|8 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
9483655|NCT02597491|Active Comparator|8 week assessment + TLC quarterly|8 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
9483656|NCT02597491|Active Comparator|8 week assessment + TLC + MTM|8 week assessment, 8 weeks counseling, NRT, medication management (nonresponders)
9537719|NCT03138304|Experimental|Adventure video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
9537720|NCT03138304|Active Comparator|Educational Program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
9537721|NCT03138174||Diabetes|One group consisting of diabetic subjects
9537722|NCT03138148||Severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is superior to the entire cohort's 75th percentile
9537723|NCT03138148||less severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is inferior to the entire cohort's 75th percentile
9537724|NCT03138252|Active Comparator|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
9537725|NCT03138252|Active Comparator|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
9537726|NCT03138434||Optimization phase|The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
9537727|NCT03138434||Study phase|"This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned."
9537728|NCT03138239|Experimental|16 patients diagnosed with HCC|"12 patients will be tested at the stage of diagnosis (staging)~4 patients who have tested at staging, will be tested again after treatment.~4 patients with treatment failure or recurrence."
9537729|NCT03138083|Experimental|Module 1 Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
9537730|NCT03138083|Experimental|Module 1 Monotherapy Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
9537731|NCT03138083|Experimental|Module 1 Monotherapy Expansion Cohort(s)|Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
9537732|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
9537733|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
9537734|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Expansion Cohort|Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)
9537735|NCT03138265|Experimental|High intensity exercise training|HIT training protocol.
9537736|NCT03138135|Experimental|Intervention|The Intervention group will receive the HOME Study intervention.
9537737|NCT03138135|Active Comparator|Control|The Control group will receive standard of care.
9537738|NCT03138044|Experimental|Combined Treatment|The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.
9537739|NCT03138161|Experimental|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
9537740|NCT03138018|Active Comparator|Standard instruction|
9537741|NCT03138018|Experimental|Reduced threat instruction|
9537742|NCT03138031|Experimental|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
9537743|NCT03137862|Placebo Comparator|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
9537744|NCT03137862|Experimental|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
9537745|NCT03137862|Experimental|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
9537746|NCT03137810|Experimental|placental cord drainage|In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
9537747|NCT03137810|Active Comparator|Non placental cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
9537748|NCT03137823|Other|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
9537749|NCT03137927|Experimental|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5*10*8 bacteria cells (CFU)
9537750|NCT03137927|Placebo Comparator|Group 1 placebo|3 individuals will get placebo
9537751|NCT03137927|Experimental|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10*9 bacteria cells(CFU)
9537752|NCT03137927|Placebo Comparator|Group 2 placebo|3 individuals will get placebo
9537753|NCT03137927|Experimental|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4*10*9 bacteria cells(CFU)
9537754|NCT03137927|Placebo Comparator|Group 3 placebo|3 individuals will get placebo
9537755|NCT03137836|Experimental|Intervention|Sit-to-stand desks (Ergotron LearnFit®) will replace standard desks. In addition, meeting with parents and teacher's training will be conducted in order to support behavior change.
9537756|NCT03137836|No Intervention|Control|Control classroom will maintain their routine in sitting desks.
9537757|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
9537758|NCT03137849|Active Comparator|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
9537759|NCT03137849|Active Comparator|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
9537760|NCT03137849|Active Comparator|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
9537761|NCT03137849|Active Comparator|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
9537762|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
9537763|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
9537764|NCT03137875||patient smear negative|patient with a negative TB microscopy result
9537765|NCT03137914|Experimental|autologous chondrocyte transplantation|Autologous transplant of chondrocytes diluted in hyaluronic acid after orthognathic surgery. The transplantation will be performed through an intra-articular injection into the TMJ (arthrocentesis). Hyaluronic acid is used only as a soluble medium to dilute the chondrocytes, so it is not considered as another experimental group, or as part of interest in this investigation.
9537766|NCT03138005|Active Comparator|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
9537767|NCT03138005|Experimental|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
9537768|NCT03137966|Active Comparator|Deferoxamine|Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
9537769|NCT03137966|Placebo Comparator|Placebo|Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
9537770|NCT03137979|Experimental|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
9537771|NCT03137979|Experimental|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
9537772|NCT03137979|Other|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
9537773|NCT03137940|Experimental|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
9537774|NCT03137940|Sham Comparator|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
9537775|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
9537776|NCT03137953|Experimental|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
9537777|NCT03137732|Active Comparator|Surgeon-inserted|Rectus sheath catheter will be inserted under direct vision / palpation of the space at the end of the operation.
9537778|NCT03137732|Active Comparator|Anaesthetist-inserted|Rectus sheath catheter will be inserted under ultrasound guidance by the anaethetist.
9537779|NCT03137589|No Intervention|Control|Patients of this group are routinely treated without telemedical support.
9537780|NCT03137589|Active Comparator|Telemedical support|Patients of this group are routinely treated with telemedical support.
9537781|NCT03137758|Experimental|Level 1 (50 mg) PCUR-101|Starting Dose, 3+3 Cohort Design
10039206|NCT01841489|Experimental|Sequence 2|
10039207|NCT01841489|Experimental|Sequence 3|
10039208|NCT01841489|Experimental|Sequence 4|
10039209|NCT01841502|Active Comparator|paroxetine alone|paroxetine 20 mg tablet once daily oral
10039210|NCT01841502|Experimental|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
10039211|NCT01841515|Experimental|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
10039212|NCT01841528|Experimental|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
10058404|NCT02018068|Active Comparator|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
9483657|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
9483658|NCT02594254|Experimental|Study Arm 1|Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.
9483659|NCT02594254|Experimental|Study Arm 2|Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
9483660|NCT02594254|Experimental|Study Arm 3|Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
9483661|NCT02594254|Experimental|Study Arm 4|Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
9483662|NCT02594254|Experimental|Study Arm 5|Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
9483663|NCT02594254|Experimental|Study Arm 6|If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
9483664|NCT02594254|Experimental|Study Arm 7|If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.
9483665|NCT02593071|Experimental|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
9483666|NCT02593071|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
9483667|NCT02591199|Experimental|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
9483668|NCT02591199|Placebo Comparator|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
9483669|NCT02591199|Experimental|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
9483670|NCT02591199|Experimental|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
9483671|NCT02589275|Experimental|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
9483672|NCT02588677|Experimental|Masitinib (3.0) & Riluzole|masitinib 3 mg/kg/day + riluzole
9483673|NCT02588677|Experimental|Masitinib (4.5) & Riluzole|masitinib 4.5 mg/kg/day (2) + riluzole
9483674|NCT02588677|Placebo Comparator|Placebo & Riluzole|Matched placebo
9483675|NCT02586792|Experimental|Group 2|N up to 10 in prior receipt of a placebo in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
9483676|NCT02586792|Experimental|Group 1|N up to 40 in prior receipt of a monovalent inactivated influenza A/H7N7 virus vaccine in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
9483677|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 1|ISIS-GCGRRx - Dose Level 1
9483678|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 2|ISIS-GCGRRx - Dose Level 2
9483679|NCT02583919|Placebo Comparator|Placebo|Placebo
9483680|NCT02582073|Placebo Comparator|Placebo (0.5ml)|Six 0.5ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
9483681|NCT02582073|Placebo Comparator|Placebo (1.0ml)|Six 1.0ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
9483682|NCT02582073|Experimental|Grass MATA MPL (0.5ml) 5100SU|Six 0.5 mL injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA with 50 µg/0.5 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
9483683|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 10200SU|Six 1.0 mL injections sequentially of placebo, placebo, 600, 1600, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 10200 SU).
9537782|NCT03137758|Experimental|Level 2 (100 mg) PCUR-101|
9537783|NCT03137758|Experimental|Level 3 (150 mg) PCUR-101|
9537784|NCT03137758|Experimental|Level 4 (200 mg) PCUR-101|
9537785|NCT03137758|Experimental|Level 5 (250 mg) PCUR-101|
9537786|NCT03137758|Experimental|Level 6 (300 mg) PCUR-101|
9616166|NCT04377061||NCWS retrospective and prospective patients|"The clinical charts of NCWS patients, diagnosed by DBPC gluten/wheat challenge, between January 2001 and December 2019, attending the Department of Internal Medicine at the University Hospital of Palermo, the Department of Internal Medicine of the Hospital of Sciacca, and the Department of Medical and Surgical Sciences of the University of Bologna, will be reviewed retrospectively. The investigators prospectively will also survey patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS by DBPC gluten/wheat challenge. The patients will be recruited between January 2019 and January 2022 at the same centers, and at the Internal Medicine Division of the Cervello-Villa Sofia Hospital of Palermo, Palermo."
9616167|NCT04377061||CD retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of a control group of CD patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of CD patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
9616168|NCT04377061||IBS retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of another control group of IBS patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of IBS patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
9621684|NCT02522169|Active Comparator|Conventional treatment|"The patients of the control group undergo Infliximab-maintenance according to the approved dosing scheme, initially with 5 mg/kg body weight Infliximab. Before each administration laboratory parameters will be controlled (Albumin, CrP, Calprotectin) and disease activity scores will be obtained (PCDAI / PUCAI). Infliximab trough levels will be assessed but not have any implication. In the presence of clinical signs of a disease exacerbation and after exclusion of other causes an adjustment of the dosage will follow for the next Infliximab-infusion:~A) interval shortening, or B) Dose increase to 10 mg / kg body weight. With a clinical stable course of the disease without signs of deterioration, the dosage and the eight-week interval will be maintained."
9621685|NCT02522169|Experimental|Intervention Group|Aiming to maintain the therapeutic window of Infliximab a de- or increase of the dose or infusion interval will be carried out for the following administration, provided the patient shows no signs of a clinical worsening. With good trough levels and clinically stable conditions the therapy will be continued without modification until next check-up. In the case of an eminent disease exacerbation Infliximab trough levels and the search for anti - Infliximab antibodies should guide further treatment decisions. With trough levels below the target range antibody testing should be performed.
9621686|NCT02522208|Experimental|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
9621687|NCT02522208|Active Comparator|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
9621688|NCT02522078|Active Comparator|Dry Misoprostol|400 µg of dry misoprostol
9621689|NCT02522078|Experimental|Wet misoprostol|400 µg of wet misoprostol
9621690|NCT02522143|Sham Comparator|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
9621691|NCT02522143|Experimental|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
9621692|NCT02522117|Active Comparator|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
9621693|NCT02522117|Placebo Comparator|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
9621694|NCT02522156|Experimental|Looming Vulnerability Induction|"Four audiotape-guided imagery exercises, each lasting about 3 minutes:~Conveyor Belt: Places the participants in a dimly-lit factory, in which they are being carried along faster and faster on a conveyor belt as they smoke. This conveyor belt is described as ultimately leading to the diagnosis of lung cancer.~Office Building: Places participants in an office all alone, watching calendar pages fly off the wall. As participants smoke and time progresses, participants are meant to feel their lungs withering away and their heart beat becoming weaker and weaker.~Train Tracks: Set in the open plains on top of a set of railroad tracks. As participants smoke, a train heading directly towards them gains speed.~Clock Ticking: In this timing exercise, participants are instructed to imagine terrible health consequences related to smoking coming closer and closer to them as they smoke. Participants are asked to keep track of time for a period of three minutes."
9621695|NCT02522156|Placebo Comparator|Control|"Four audiotape-guided imagery exercises, as follows:~Escalator (parallel to conveyor belt above): Takes place in an empty mall in the morning. The participants imagine they are slowly and steadily being carried by the escalator until they reach the top.~Metro (parallel to office building): Involves riding public transportation while reading a magazine, steadily flipping the pages.~Driving (parallel to Train Tracks): Involves driving a car. The car in this case moves steadily with no traffic hindrances that would cause a reduction of speed.~Human Clock (parallel to Clock Ticking): Another timing exercise. In this case, the participants receive instruction to pretend they are a human clock."
9621696|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
9621697|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
9621698|NCT02522052|Experimental|Blue mussel diet|5 meals a week including blue mussels
10039213|NCT01841528|Experimental|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
10039214|NCT01841541|Experimental|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
10039215|NCT01841541|No Intervention|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
10039216|NCT01841645|Other|CLA depletion-repletion|
9537787|NCT03137654|Active Comparator|Affective Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using emotionally-laden stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
9537788|NCT03137654|Active Comparator|Neutral Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
9537789|NCT03137654|No Intervention|Control (Non-active)|Subjects complete a baseline assessment and a secondary assessment approximately three weeks later. No active intervention is delivered. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
10039217|NCT01841658|Experimental|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
9537790|NCT03137667|No Intervention|Control|No school-located influenza vaccination clinic
10039218|NCT01841658|Experimental|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
9537791|NCT03137667|Experimental|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
9537792|NCT03137680|No Intervention|Control Arm|No specific exercise regime for the control group. Usual hospital SOP will be adhered to
9537793|NCT03137680|Experimental|Exercise Arm|The exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of 6 weeks. This will be performed at least 6 weeks prior to the creation of the AV fistula
9537794|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
9537795|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
9537796|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
9537797|NCT03137472|Experimental|Active Treatment|Participants will receive active TMS in the target area once daily for two days
9537798|NCT03137472|Sham Comparator|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
9537799|NCT03137485|Active Comparator|Conventional|Patients in this arm will have conventional open lumbar discectomy operation.
9537800|NCT03137485|Active Comparator|Endoscopic|Patients in this arm will have Percutaneous Endoscopic Translaminar lumbar discectomy operation using Easy Go system Endoscopy
9537801|NCT03137524|Experimental|Hand Held Fan Therapy|
9537802|NCT03137524|No Intervention|No Intervention|
9537803|NCT03137498|Experimental|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)
9537804|NCT03137498|Active Comparator|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)
10039219|NCT01841671|Experimental|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
9537805|NCT03137641||Nurses in contact with chemotherapies|"It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected:~first : between 0 to 3h before the beginning of the workday second : between 0 to 2h after the end of the workday third : between 7 to 10h after the end of the workday"
9537806|NCT03137576|Active Comparator|Paravertebral block (PVB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Paravertebral Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
9537807|NCT03137576|Experimental|Erector Spinae Plane Block (ESPB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Erector Spinae Plane Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
9616169|NCT04366115|Active Comparator|AVM0703 COVID-19 ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
9537808|NCT03137602|Other|ATOMIC mobile app|The proposed ATOMIC intervention consists of four primary components: (a) one-on-one chats with a PA coach, (b) informational posts, (c) PA self-monitoring through an activity tracker and (d) educational modules regarding different aspects of becoming PA delivered through our MS specific PA app.
9537809|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
9537810|NCT03137329|Other|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
10039220|NCT01841671|Active Comparator|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
9537811|NCT03137329|Other|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements[58] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
9537812|NCT03137160|Experimental|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangranosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
9537813|NCT03137433|Experimental|Meal-Replacements|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data).
9537814|NCT03137433|Experimental|Meal-Replacements Plus|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data). This group will be provided additional information to go along with meal-replacements.
9537815|NCT03137212|Experimental|A group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 3-6 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
9537816|NCT03137212|Experimental|B group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 6-24 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
9537817|NCT03137420||Severely injured patients and their relatives|Severely injured patients (ISS > 16) and their relatives. Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
9537818|NCT03137420||Monotrauma patients and theri relatives|Patients with isolated non-life threatening musculo-skeletal injuries and their relatives (control). Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
9537819|NCT03137134|Active Comparator|Treatment A|(reference) Crizotinib cMS 300 mg in fasted state
9537820|NCT03137134|Experimental|Treatment B|(test) Crizotinib cMS 300 mg in fed state
9537821|NCT03137134|Experimental|Treatment C|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg in fasted state
9537822|NCT03137134|Experimental|Treatment D|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with apple sauce.
9537823|NCT03137134|Experimental|Treatment E|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with orange juice
9537824|NCT03137368|Experimental|treatment group|Exemestane Tablets combined with ovarian function suppression/ablation
9537825|NCT03137368|Active Comparator|control group|Tamoxifen Tablets combined with ovarian function suppression/ablation
10039221|NCT01841671|Active Comparator|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
10039222|NCT01841684|Experimental|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
10039223|NCT01841684|Placebo Comparator|Placebo|Participants receive placebo orally once daily for 12 weeks.
10039224|NCT01841710||Women|
10039225|NCT01841749|Other|Surgery|sentinel node biopsy and mastectomy
10039226|NCT01841788|Experimental|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
10039227|NCT01841788|Active Comparator|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
10039228|NCT01841788|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
9537826|NCT03137511|Experimental|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~The MG collects relevant clinical information~The MG takes 2 photographs of the lesion with his smartphone.~The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information~The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.~The dermatologist proposes an appointment to the patient."
9537827|NCT03137511|No Intervention|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~General practitioners and dermatologists continue their practice in the usual way."
9537828|NCT03137264||T790M positive|Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.
9537829|NCT03137264||T790M negative|Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.
9537830|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
9537831|NCT03137290|Active Comparator|Neostigmine|1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10mls with Normal Saline 0.9% in a 10ml standard syringe.
9537832|NCT03137290|Experimental|Sugammadex sodium|100mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal Saline 0.9%.
9537833|NCT03137342|Experimental|Pepped on PrEP|"Using an efficient stepped care (adaptive) model, all participants will receive three sessions of PrEP-STEPS counseling for PrEP adherence delivered by a Masters-level or above therapist. Some individuals may require a more intensive approach. These participants will receive an additional seven counseling sessions of behavioral activation with integrated cognitive behavioral therapy (CBT) designed to reduce stimulant use and promote positive behaviors."
9537834|NCT03137342|No Intervention|Standard of Care|PrEP adherence counseling from the Miriam Hospital PrEP Clinic.
9537835|NCT03137251|Experimental|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
9537836|NCT03137251|Experimental|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
9537837|NCT03137251|Sham Comparator|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
9537838|NCT03137147|Other|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
9537839|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
9537840|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
9537841|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
9537842|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
9537843|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
9537844|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
9537845|NCT03137199|Experimental|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
9537846|NCT03137199|Experimental|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
9537847|NCT03137186|Active Comparator|Investigational arm|Metformin will be added to standard of care
9537848|NCT03137186|No Intervention|Control arm|Patients will treated according to Standard of care only
9537849|NCT03137446|No Intervention|Usual Care|Participants randomized to the usual care resuscitation strategy will receive an initial 30 ml/kg bolus and then IV fluids as needed and without limit as well as IV vasopressors to maintain a MAP>65, determined by the primary care team for the duration of the study.
9537850|NCT03137446|Experimental|Restrictive Care|Participants randomized to the restrictive fluid resuscitation strategy will be LIMITED to 60 ml/kg (up to 6000 ml) of IV fluids as initial resuscitation followed by administration of IV vasopressors to maintain a MAP>65 mm Hg for the first 72 hours of care. The intervention is defined as capping the total allowed IVF administered. After 72 hours the participants are eligible for IV fluids as determined by the primary care team.
9537851|NCT03137108|Experimental|Incomplete Spinal cord injury|
9537852|NCT03137030|Experimental|GRT7014 - 1 Tablet (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
9537853|NCT03137030|Experimental|GRT7014 - 10 Tablets (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
9537854|NCT03137030|Active Comparator|Norco - 1 Tablet (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
9537855|NCT03137030|Active Comparator|Norco - 10 Tablets (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
10039229|NCT01841801|Active Comparator|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
9537856|NCT03137030|Experimental|GRT7014 - 5 Tablets (Optional Part 2)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
9537857|NCT03137030|Active Comparator|Norco - 5 Tablets (Optional Part 2)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
9537858|NCT03137017|Experimental|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
9537859|NCT03137017|Experimental|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
9537860|NCT03137017|Active Comparator|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
9537861|NCT03137017|Active Comparator|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
9537862|NCT03137082|Experimental|Guanfacine XR 3mgs/daily|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
9537863|NCT03137082|Placebo Comparator|Placebo (for guanfacine)|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
9537864|NCT03137056|Active Comparator|Hemodialysis with Theranova|This arm is represented by the period during which the patients will undergo dialysis with the Theranova membrane.
9537865|NCT03137056|Active Comparator|Hemodialysis with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
9537866|NCT03137056|Active Comparator|Hemodiafiltration with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
9537867|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
9537868|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
9537869|NCT03136965|Experimental|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
9537870|NCT03136965|Placebo Comparator|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
9537871|NCT03136965|Sham Comparator|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
9537872|NCT03137004|Experimental|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
9537873|NCT03136978||Endometriosis|Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery.
9537874|NCT03136978||Ovarian functional cysts|Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery.
9537875|NCT03136666|Experimental|Nifedipine + Candesartan cilexetil|Coadministration of single doses of nifedipine and candesartan tablets
9537876|NCT03136939||type 1 diabetes|
9537877|NCT03136939||type 2 diabetes|
9537878|NCT03136939||healthy people|
9537879|NCT03136770|Experimental|A|CK-30 600 mg -> red ginseng extracts 2.94 g
9537880|NCT03136770|Experimental|B|red ginseng extracts 2.94 g -> CK-30 600 mg
9537881|NCT03136744|Experimental|Sit Less with MS|The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
9537882|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
10039230|NCT01841801|Experimental|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
9537883|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
9537884|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
9537885|NCT03136991|Active Comparator|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
9537886|NCT03136991|Active Comparator|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
9537887|NCT03136991|Active Comparator|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
9537888|NCT03136991|Active Comparator|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
9537889|NCT03136848|Experimental|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
9537890|NCT03136874||Donors who procreated|
9537891|NCT03136874||Donors who don't procreated|
9537892|NCT03136952||Pediatric children under 1 yrs old|Observation study of two measurement points of cerebral oxygenation
9537893|NCT03136601|Active Comparator|PTNS monthly|Patients return for PTNS maintenance monthly.
9537894|NCT03136601|Experimental|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
9537895|NCT03136835|Experimental|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
9537896|NCT03136783|Other|Patient with stage IV melanoma|
9537897|NCT03136653|Experimental|Single arm Study MP0250 plus BOR + DEX|Single arm study of MP0250 plus bortezomib + dexamethasone
10039231|NCT01841801|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
10039232|NCT01841814|Experimental|lymphoma|
9537898|NCT03136900|Experimental|Study Diet|Enteral diet made of Nutrilon without lactose® fortified by concentration
9537899|NCT03136900|Active Comparator|Control Diet|Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.
9537900|NCT03136822|Other|Control|Standard dressing
9537901|NCT03136822|Experimental|Treatment|Standard dressing + Wound dressing (DERMALIX)
9537902|NCT03136705|Active Comparator|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
9537903|NCT03136705|Active Comparator|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
9537904|NCT03136705|Active Comparator|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
9537905|NCT03136705|Placebo Comparator|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
9537906|NCT03136718||First-time hearing aid users|Individuals using hearing aids for the first-time (or if previous users, have not having worn hearing aids for more than 3 years) will have access to the mobile-enabled RLOs (mRLOs) intervention, which will be given to the participants shortly after their hearing aid is fitted.
9537907|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
9537908|NCT03136588|Experimental|ICT based monitoring group|Intervention: In the ICT-based centralized monitoring group, both subjects and medical staff receive feedbacks regarding a missed dose, misuse, and overuse of the medication in the form of text messages and pill box alarms.
9537909|NCT03136588|No Intervention|Control group|Use standard questionnaire to gather information for drug adherence
9537910|NCT03136614|Active Comparator|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
9537911|NCT03136614|Active Comparator|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
9537912|NCT03136614|Active Comparator|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
9537913|NCT03136510|Other|Newly diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients new diagnosis of NVAF (VKA treatment ≤1 week) initiated with apixaban 5 mg
9537914|NCT03136510|Other|Previously diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients previously treated by VKA for more than 3 months switched to apixaban 5 mg
9537915|NCT03136354|Active Comparator|ESD Group|Endoscopic Submucosal Dissection
9537916|NCT03136354|Active Comparator|LAG Group|Laparoscopic Assisted Gastrectomy
9537917|NCT03136276|Active Comparator|IPS Empress CAD|Leucite Based glass Ceramics which is etchable ceramics and proved to have good success rate if used for laminate veneers
9537918|NCT03136276|Experimental|polished Celtra Duo|Zirconia reinforced lithium silicate, it is a recent material with glass ceramics enriched with 10% zirconia that offers high strength properties
9537919|NCT03136211|Experimental|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
9537920|NCT03136211|No Intervention|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
10039233|NCT01841827|Active Comparator|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
9537921|NCT03136341|Active Comparator|Abobotulinum toxin A|
10039234|NCT01841827|Placebo Comparator|Placebo|A capsule of placebo containing starch are taken orally on each study day.
10039235|NCT01841840|No Intervention|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
9537922|NCT03136341|Placebo Comparator|Placebo|
9537923|NCT03136393|Active Comparator|Control|Community based antenatal counselling
9537924|NCT03136393|Experimental|Intervention|Community based dietary counselling
9537925|NCT03136445|Experimental|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
9537926|NCT03136445|Placebo Comparator|Control Arm|Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.
9537927|NCT03136315|Experimental|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
9616170|NCT04366115|Placebo Comparator|Placebo COVID-19 ARDS - placebo|Matching placebo
9616171|NCT04366115|Active Comparator|AVM0703 Influenza ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
9616172|NCT04366115|Placebo Comparator|AVM0703 Influenza ARDS - placebo|Matching placebo
9616173|NCT04362761|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
9537928|NCT03136224|Experimental|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
9537929|NCT03136224|Active Comparator|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
9537930|NCT03136224|Sham Comparator|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
9537931|NCT03136432||Children with cerebral palsy|Children with cerebral palsy, who can walking dependently and continuously for 6 minutes.
9537932|NCT03136458|Experimental|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
10039236|NCT01841840|Experimental|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
10039237|NCT01841840|Experimental|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
9537933|NCT03136458|Active Comparator|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
9537934|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
9537935|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
9537936|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
9537937|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.~Inclusion criteria: Patients with type 2 diabetes, whose age>=18 years old will be extracted from database of LaCDRN.~Exclusion criteria: Patients without type 2 diabetes or age<18 years old."
9537938|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
10039238|NCT01841853|Experimental|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
10039239|NCT01841853|No Intervention|Control group|The control group will receive conventional care on their own initiative.
10039240|NCT01841866|Active Comparator|deep anesthetic state|LMA removal
10039241|NCT01841866|Placebo Comparator|awake|LMA removal
10039242|NCT01841879|Experimental|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
10039243|NCT01841879|Other|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
10039244|NCT01841892|No Intervention|Usual Care Control|
10039245|NCT01841892|Experimental|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
10039246|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
10039247|NCT01841918|Experimental|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
10039248|NCT01841918|Placebo Comparator|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
10039249|NCT01841944|Active Comparator|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
10039250|NCT01841944|Placebo Comparator|Corn oil|3x capsules of corn oil pr day
10039251|NCT01841983|Experimental|Intervention|Be Well Work Well
10039252|NCT01841983|No Intervention|Control|No intervention
10039253|NCT01841996|Experimental|ME1111 solution|
10039254|NCT01841996|Placebo Comparator|Vehicle Solution|
9537939|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.~Inclusion criteria:~Diabetes patients who consent to participate the study.~Age 65+;~Diagnosis code for diabetes in the last 2 years;~Diagnosis code for at least one additional chronic condition in the last 2 years.~Exclusion criteria: age<65; patient with diabetes without other chronic conditions."
9537940|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
9537941|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or age<18 years old."
10039255|NCT01842009|Experimental|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
10039256|NCT01842022|Other|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
10039257|NCT01842022|Other|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
9537942|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age<18 years old"
9537943|NCT03136471||Telehealth Services using HCPCS/CPT for COVID-19 Patients|Study population with versus without telehealth services. Telehealth services using the HCPCS/CPT codes will be defined in the following categories: Medicare telehealth visits (CPT codes: 99201-99215; HCPCS codes: G0425-G0427, G0406-G0408), virtual check-in (HCPCS codes: G2010, G2012), and e-visits (CPT codes: 99421-99423, HCPCS codes: G2061-G2063). Propensity score-matching will be used to ensure comparison groups are comparable at baseline.
9537944|NCT03136549|Placebo Comparator|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
9537945|NCT03136549|Experimental|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
9537946|NCT03136575|Active Comparator|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
9537947|NCT03136575|Placebo Comparator|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
9537948|NCT03136172||Premature infant|premature infants with 32 weeks or less gestational age or 1,500 g or less birth weight, who born in the Inha university hospital and admit to the neonatal intensive care unit of the Inha university hospital
9537949|NCT03136562||Kidney transplanted patients|Kidney transplanted patients in prednisolone treatment. Adrenal function is assessed by a synacthen test.
9537950|NCT03136562||Control group|Patients in dialysis not in prednisolone treatment. Adrenal function is assessed by a synacthen test.
9537951|NCT03136250|Active Comparator|Group A (Control Group - Static Stretching)|(Control Group - Static Stretching + Standard Treatment)
9537952|NCT03136250|Experimental|Group B (Autogenic Inhibition MET)|(Autogenic Inhibition - PIR + Standard treatment)
9537953|NCT03136250|Experimental|Group C (Reciprocal Inhibition MET)|(Reciprocal Inhibition - RI + Standard treatment)
10039258|NCT01842022|Other|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
10039259|NCT01842022|Other|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
9537954|NCT03136237|Experimental|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
9537955|NCT03136237|Experimental|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
9537956|NCT03136237|Experimental|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
9537957|NCT03136419|Placebo Comparator|Control|Placebo capsules bis in die for 8 weeks
9537958|NCT03136419|Experimental|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
9537959|NCT03136406|Experimental|NANT Pancreatic Cancer Vaccine|"A combination of agents will be administered to subjects in this study:~cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011."
9616174|NCT04362189|Experimental|HB-adMSCs|Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.
9621699|NCT02522052|Active Comparator|Meat/control diet|5 meals a week including meat
10039260|NCT01842048|Experimental|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
9537960|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
9537961|NCT03136146|Experimental|Treatment (combination chemotherapy)|See detailed description
9537962|NCT03135964|Active Comparator|foam|PU foam dressing from KCI
9537963|NCT03135964|Active Comparator|gauze|Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)
9537964|NCT03135977|Experimental|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
9537965|NCT03136016|No Intervention|control|without any activity
9537966|NCT03136016|Experimental|educational activities|The students will receive educational activities in the classroom.
9537967|NCT03136016|Experimental|nudging|The students will receive changes in the school environment (nudge strategies);
9537968|NCT03136016|Experimental|nudging + educational activities|The students will receive educational activities and changes in the school environment.
9537969|NCT03136029|Experimental|Oral AOx|8 week oral antioxidant treatment
9537970|NCT03136029|Placebo Comparator|Oral AOx (placebo)|Placebo for arm 1
9537971|NCT03136029|Experimental|Oral BH4|8 week oral tetrahydrobiopterin treatment
9537972|NCT03136029|Placebo Comparator|Oral BH4 (placebo)|Placebo for arm 3
9537973|NCT03136029|Experimental|Ex training|8-week knee-extensor exercise training program
9537974|NCT03136029|Sham Comparator|Ex training (attn con)|Attention control for arm 5
9537975|NCT03136042|Experimental|physiotherapists maneuvers|physiotherapy techniques
9537976|NCT03136042|Active Comparator|hypertonic saline 3%|four nebulizations with 3% hypertonic saline.
9537977|NCT03136042|Active Comparator|saline + physiotherapy maneuvers|1 nebulizations + physiotherapy techniques
9537978|NCT03135925|Other|Intervention|Exercise program
9537979|NCT03135938|Active Comparator|Grading Inferior Oblique Anterior Transposition|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
9537980|NCT03135938|Active Comparator|Classic Inferior Oblique Anterior Transposition|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes
9616175|NCT04362189|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.
9616176|NCT04360811|Other|Unexposed group : COVID 19 negatif pregant woman|COVID-19 negative women (not immunize
9616177|NCT04360811|Other|Exposed group : COVID 19 positif pregant woman|Women positive for COVID-19 (symptomatic and asymptomatic) COVID-19 negative women with long-standing immunity
9616178|NCT04347161|Experimental|Intervention Arm|Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
9616179|NCT04347161|Active Comparator|Control Arm|Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
9616180|NCT04346134|Experimental|mini-PNL group|In which percutaneous nephrolithotomy will be performed using miniature nephroscope.
9616181|NCT04346134|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
9616182|NCT04343209||Individuals with confirmed or suspected cardiovascular disease|Individuals in this group will undergo myocardial perfusion imaging, utilizing Ammonia N-13 PET imaging agent. Each individual will receive two intravenous injections of Ammonia N-13 in accordance with site imaging protocol.
9616183|NCT04335201|Experimental|Arm Label|with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
9616184|NCT04329702|Experimental|coping skills training plus therapist input|Participants will receive a CST therapist call within 48 hours of randomization to discuss the study rationale, to conduct a relaxation exercise, and to review app and study logistics. Participants will use the Blueprint mobile app for 1 month.
9616185|NCT04329702|Experimental|coping skills training without therapist input|Participants will receive a call from a research coordinator to get them started with the trial. Participants will use the Blueprint mobile app for 1 month. No therapist calls will be provided. Chat room access in the app will be provided.
9616186|NCT04329702|No Intervention|usual care control|Control participants will receive the same safety oversight as intervention participants and will be provided with phone and email contacts for study staff.
9616187|NCT04327219|Experimental|CDED diet|The CDED will be divided into 3 stages: 0-6 weeks- induction phase (phase 1), weeks 7-12 step-down phase (phase 2), week 13 -24 maintenance phase (phase 3). During these weeks the diet is structured and contains a list of allowed/disallowed foods, and mandatory foods with specific daily/weekly amounts. Patients will be asked to progress with the diet if they respond to the diet clinically. Patients who do not improve, but show a clinicaly significant trend in symptoms, may be asked to prolong a dietary phase until reaching clinical reaction.
9616188|NCT04327219|No Intervention|standard diet|The control standard diet will be personally tailored for nutritional needs according to patient's daily recommended intake (DRI) for calories and protein intake (25kcal/kg and 0.8-1gr/kg per day respectivlly), and will follow the clinical guidelines for dietary therapy of patients with IBD.
9616189|NCT04318665|Experimental|CT Perfusion|Severe TBI patients will be undergoing CT perfusion test
9621700|NCT02522130|Active Comparator|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
9537981|NCT03135912|Experimental|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
9537982|NCT03135912|Placebo Comparator|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
9537983|NCT03135912|Active Comparator|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
9537984|NCT03136133|Active Comparator|Active protein drink|Active protein drink
9537985|NCT03136133|Placebo Comparator|Placebo drink|Placebo drink
9537986|NCT03135847|Experimental|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
10039261|NCT01842048|Active Comparator|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
9537987|NCT03135886|Experimental|HIV Testing Practice Coaching Intervention Group|The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.
9537988|NCT03135886|Experimental|HIV and HCV Testing Practice Coaching Intervention Group|The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.
9537989|NCT03135886|Other|Information Control Group|The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.
9537990|NCT03136003|Experimental|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise"
10039262|NCT01842074|Experimental|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
10039263|NCT01842087|Placebo Comparator|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
9537991|NCT03136003|Active Comparator|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
9537992|NCT03136003|Experimental|Arm C: Exercise alone|"Intervention #1: Exercise~Intervention #2: no further intervention (rest)"
9537993|NCT03136003|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
9537994|NCT03135951|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)~Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle after TC administration"
9537995|NCT03135795|Experimental|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
9537996|NCT03135860|Experimental|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
10039264|NCT01842087|Experimental|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
9537997|NCT03135782|Experimental|Health Services Research (Chart review, training, coaching)|"MEDICAL CHART REVIEW: Medical charts from patients with diagnoses of head and neck cancer, lung cancer, prostate cancer, or breast cancer are reviewed at months 1-12 to determine the frequency of tobacco assessments and documentation of discussions with patients regarding tobacco use and utilization of cessation resources as before and after the proposed training.~PROVIDER TRAINING: Providers undergo training to use patient coaching such as the 5A's (Ask, Advise, Assess, Assist, and Arrange), to conduct regular tobacco intake assessment using motivational interviewing techniques. Providers also undergo training to use public/community tobacco cessation resources for patients ready to quit within six weeks, and have access to pharmacy residents for ad-hoc prescribing questions.~PATIENT COACHING: Patients attend 4 phone or in-person motivational interviewing coaching sessions over 30-45 minutes for 6-8 weeks or longer as needed."
9537998|NCT03136120||Subjects with suspected fibrotic ILD|Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.
9537999|NCT03135769|Experimental|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
9538000|NCT03135821|Placebo Comparator|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g~- 2 packets of sachets once before breakfast and once before dinner."
9616190|NCT04313881|Experimental|Magrolimab + Azacitidine|"Participants will receive the following magrolimab and azacitidine dosing regimens:~Magrolimab:~Magrolimab Priming Dose:~1 mg/kg on Days 1 and 4~15 mg/kg on Day 8~30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50)~Magrolimab Maintenance Dose:~30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle"
10058405|NCT02018081|Experimental|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
10039265|NCT01842100|Active Comparator|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
10058406|NCT02018094|Active Comparator|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
9483684|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 18200SU|Six 1.0 mL injections sequentially of placebo, 600, 1600, 4000, 4000, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 18200 SU).
9483685|NCT02582073|Active Comparator|Grass MATA (0.5ml) 5100SU|Six 0.5ml injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
9483686|NCT02581657|Experimental|PE0139 Injection|PE0139 Subcutaneous Injection - 6 weekly doses
9483687|NCT02581657|Placebo Comparator|Placebo Injection|Placebo Subcutaneous Injection - 6 weekly doses
9483688|NCT02580708|Experimental|Rociletinib and Trametinib|
9483689|NCT02580370|Experimental|Dose A|Botulinum toxin type A
9483690|NCT02580370|Placebo Comparator|Dose B|Placebo comparator
9483691|NCT02580305|Active Comparator|Experimental: SUVN-502 Low dose (50 mg)|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
9483692|NCT02580305|Active Comparator|Experimental: SUVN-502 High dose (100 mg)|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
9483693|NCT02580305|Placebo Comparator|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
9483694|NCT02580058|Experimental|avelumab|Arm A: avelumab alone
9483695|NCT02580058|Experimental|avelumab plus pegylated liposomal doxorubicin (PLD)|Arm B: avelumab plus PLD
9483696|NCT02580058|Active Comparator|PLD|Arm C: PLD alone
9483697|NCT02578771|Experimental|ZuraPrep with 70% Isopropyl alcohol|Test Article ZuraPrep with 70% isopropyl alcohol (IPA) will be compared with reference positive control Chloraprep
9483698|NCT02578771|Experimental|ZuraPrep without 70% IPA|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline
9483699|NCT02578771|Active Comparator|ChloraPrep Teal Tint|Test Article ZuraPrep with 70% isopropyl alcohol will be compared with reference positive control ChloraPrep [Chlorhexidine gluconate(CHG)/IPA] Teal Tint
9483700|NCT02578771|Placebo Comparator|Normal Saline 0.85%|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline 0.85%
9483701|NCT02578680|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
9483702|NCT02578680|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. With Amendment 10 (effective date: 23-Dec-2019), all participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.
9483703|NCT02578095|Placebo Comparator|Placebo|Placebo QD
9483704|NCT02578095|Experimental|VK5211- 0.5mg|0.5mgQD
9483705|NCT02578095|Experimental|VK5211- 1.0mg|1.0mg QD
9483706|NCT02578095|Experimental|VK5211- 2.0mg|2.0mg QD
9483707|NCT02576860|Experimental|Treatment|CLS001 (Omignan) gel applied once daily
9483708|NCT02576860|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
9483709|NCT02576847|Experimental|Treatment|Omiganan gel applied once daily
9483710|NCT02571998|Experimental|Treatment|Omiganan (CLS001) Topical Gel applied once daily
9483711|NCT02571998|Placebo Comparator|Vehicle Gel|Vehicle Topical Gel applied once daily
9483712|NCT02571907|Experimental|Zenith® Branch Endovascular Graft-Iliac Bifurcation|Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the Atrium iCAST™ and the Zenith® Flex AAA Endovascular Graft
9483713|NCT02570490|Experimental|CEM-102 (Sodium fusidate)|1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
9483714|NCT02570490|Active Comparator|Linezolid|600 mg by mouth every 12 hours for 10 days
9483715|NCT02570282|Experimental|Sildenafil|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
9483716|NCT02570282|Placebo Comparator|Placebo|Placebo IP will be the same as SST-6007 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6007
9483717|NCT02568566|Experimental|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
9483718|NCT02565732|Experimental|Dose A|Botulinum toxin type A
9483719|NCT02565732|Experimental|Dose B|Botulinum toxin type A
9483720|NCT02565732|Placebo Comparator|Dose C|Placebo comparator
9483721|NCT02564744|Experimental|Debio 1562|Participants with a diagnosis of relapsed and/or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma (FL), Marginal Zone Lymphoma (MZL)/Mucosa-associated Lymphoid Tissue (MALT), Mantle Cell Lymphoma (MCL) or other Non-Hodgkin's Lymphoma (NHL) with the Sponsor's approval, will receive Debio 1562 and Rituximab in 3 different parts of study i.e., Safety run in, Part 2 and Expansion (Part 3). Participants in Part 2 will be enrolled in two parallel cohorts (Cohort A and Cohort B).
9483722|NCT02564588|Experimental|Dasotraline|Dasotraline 4, 6, 8 mg
9483723|NCT02564588|Placebo Comparator|Placebo|Placebo Comparator
9483724|NCT02561442|Active Comparator|IV ceftriaxone (0.5hr) 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered IV over 30 minutes via infusion pump (Open Label)
9483725|NCT02561442|Experimental|subcutaneous ceftriaxone, (2hr), 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered subcutaneous over 2 hours (Blinded).
10039266|NCT01842100|Active Comparator|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
10039267|NCT01842113|Active Comparator|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
10039268|NCT01842113|Active Comparator|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
10039269|NCT01842126|Experimental|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
9483726|NCT02561442|Experimental|subcutaneous ceftriaxone, (2 hr), 2 gm|ceftriaxone for injection, (total dose = 2.0 g) administered subcutaneous over 2 hours (Blinded).
9483727|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 1|3 patients dosed at 0.01 mg/kg until MTD determined
9483728|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 2|4 patients dosed at 0.02 mg/kg until MTD determined
9483729|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 3|4 patients dosed at 0.04 mg/kg until MTD determined
9483730|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 4|4 patients dosed at 0.08 mg/kg until MTD determined
9483731|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 5|3 patients dosed at 0.12 mg/kg until MTD determined
9483732|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 6|4 patients dosed at 0.18 mg/kg until MTD determined
9483733|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 7|5 patients dosed at 0.27 mg/kg until MTD determined
9483734|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 8|7 patients dosed at 0.40 mg/kg until MTD determined
9483735|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 9|7 patients dosed at 0.33 mg/kg until MTD determined MTD determined at 0.33 mg/kg
9483736|NCT02561234|Experimental|AEB1102 Expansion|Uveal: 11 patients dosed at 0.33 mg/kg Cutaneous Melanoma: 11 dosed at 0.33 mg/kg SCLC: 13 patients dosed at 0.33 mg/kg
9483737|NCT02558439|Placebo Comparator|Placebo|Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
9483738|NCT02558439|Experimental|0.5 mg CNTX-4975|Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
9483739|NCT02558439|Experimental|1.0 mg CNTX-4975|Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
9483740|NCT02556710|Experimental|4 mL AMPION™|AMPION™, 4 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
9483741|NCT02556710|Placebo Comparator|4 mL Saline Placebo|Saline placebo, 4 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride.
9483742|NCT02556372|Experimental|JKB-122|AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal
9483743|NCT02554396|Experimental|PRX-100|PRX-100 ophthalmic solution
9483744|NCT02554396|Placebo Comparator|Placebo|saline solution
9483745|NCT02553343|Experimental|QIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)
9483746|NCT02553343|Experimental|QIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)
9483747|NCT02553343|Active Comparator|TIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine
9483748|NCT02553343|Active Comparator|TIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine
9483749|NCT02551237|Active Comparator|Radiochemotherapy|"Patients who will be treated with~radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with~oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
9483750|NCT02551237|Experimental|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
9483751|NCT02547818|Active Comparator|Group I|ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.
9621701|NCT02522130|Active Comparator|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
9483752|NCT02547818|Active Comparator|Group II|ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.
9483753|NCT02547818|Active Comparator|Group III|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.
9483754|NCT02547818|Placebo Comparator|Group IV|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.
9483755|NCT02547441|Experimental|Treatment|CLS001 (Omiganan) gel applied once daily
9483756|NCT02547441|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
9497894|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
9497895|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
10039270|NCT01842126|Experimental|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
10039271|NCT01842126|Experimental|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
9538001|NCT03135821|Active Comparator|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.~TCM Drug A:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g~TCM Drug B:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g~TCM Drug C:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g~TCM Drug D:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
9538002|NCT03135665|Other|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
9538003|NCT03135639|Experimental|Sham Stim followed by Alpha Stim|"20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS."
9538004|NCT03135639|Experimental|Alpha Stim followed by Sham Stim|"20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham."
9538005|NCT03135704|Active Comparator|"Re Spine Mattress"|"Adults suffering low back pain will treat their low back pain using the Re Spine mattress"
9538006|NCT03135704|Active Comparator|Physiotherapy|Adults suffering low back pain will treat their low back pain using conventional physiotherapy protocols
9538007|NCT03135496||Surgery with CEC|
9538008|NCT03135496||Without CEC|
9538009|NCT03135418|Experimental|Intervention|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
9538010|NCT03135418|Sham Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift a will be used to create an immersive visual environment.Patient will be watching the premade scenarios without interaction. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire, Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
9538011|NCT03135613|Experimental|Normal|Participants of this group are as controls.
9538012|NCT03135613|Experimental|MF|Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.
9538013|NCT03135652|Experimental|chemoradiotherapy|radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
9538014|NCT03135652|Active Comparator|chemotherapy|chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
9538015|NCT03135405|No Intervention|Usual care|
9538016|NCT03135405|Experimental|Intervention|
9538017|NCT03135392|Active Comparator|Breast Reconstruction with Artificial Implant|Participants undergoing unilateral reconstruction: patient will serve as internal control with contralateral breast and reconstructed breast will be compared to all other reconstructed breasts. Participants undergoing bilateral reconstruction: reconstructed breasts will be compared to all other reconstructed breasts
10039272|NCT01842126|Experimental|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
10039273|NCT01842139|Experimental|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
10039274|NCT01842139|Experimental|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
10039275|NCT01842139|Experimental|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
10039276|NCT01842165|Other|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
10039277|NCT01842178|Experimental|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.~Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control"
10039278|NCT01842178|Placebo Comparator|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
9538018|NCT03135392|Active Comparator|Autologous Breast Reconstruction without Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which do not have their nerves reconstructed during surgery
9538019|NCT03135392|Experimental|Autologous Breast Reconstruction with Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which have a nerve connected (neurotized) during surgery.
9538020|NCT03135457|Other|Group A|Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min
9538021|NCT03135457|Other|Group B|Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min
9538022|NCT03135561|Experimental|pedometer-plus-email|
9538023|NCT03135561|Active Comparator|pedometer-only|
9538024|NCT03135756||Depression and anxiety symptoms|
9538025|NCT03135756||Healthy controls|
9538026|NCT03135626|Experimental|Biodentine|Biodentine pulpotomy agent
9538027|NCT03135626|Experimental|ProRoot MTA|ProRoot MTA pulpotomy agent
9538028|NCT03135626|Experimental|MTA Plus|MTA Plus pulpotomy agent
9538029|NCT03135626|Active Comparator|Ferric Sulfate 20% Dental Gel|Ferric Sulfate %20 Dental Gel pulpotomy agent
9538030|NCT03135587|Experimental|Weight 0|The participants will not carry any loading to walk on treadmill.
9538031|NCT03135587|Experimental|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
9538032|NCT03135587|Experimental|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
9538033|NCT03135587|Experimental|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
9538034|NCT03135587|Experimental|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
9538035|NCT03135587|Experimental|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
9538036|NCT03135366|Active Comparator|Standard of Care (Control)|
9538037|NCT03135366|Experimental|Keheala Intervention (Treatment)|The intervention consisted of a daily request for self-verification of medication adherence, access to a supporter via a chat client, and information about TB.
9538038|NCT03135600|Experimental|Normal|The participants from this group are healthy people.
9538039|NCT03135600|Experimental|ACLD|The participants from this group suffer from anterior cruciate ligament injury.
9538040|NCT03135509|Experimental|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
9538041|NCT03135509|Experimental|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
9538042|NCT03135353|Experimental|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
9538043|NCT03135353|Experimental|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
9538044|NCT03135340|Experimental|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
9538045|NCT03135340|Active Comparator|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
10039279|NCT01842191|Experimental|Fish oil|
10039280|NCT01842191|Placebo Comparator|Placebo|
10039281|NCT01842204|Experimental|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
10039282|NCT01842204|Placebo Comparator|non-active kit|Patient receives a non-active kit.
9538046|NCT03135314|Active Comparator|Hypoxia Cocoa flavanol|Exercise or cognitive test in (acute) hypoxic condition after 7 days of cocoa flavanol intake
9538047|NCT03135314|Placebo Comparator|Hypoxia Placebo|Exercise or cognitive test in (acute) hypoxic condition after 7 days of placebo intake
9538048|NCT03135314|Active Comparator|Normoxia Cocoa flavanol|Exercise or cognitive test in normoxic condition after 7 days of cocoa flavanol intake
9538049|NCT03135314|Placebo Comparator|normoxia placebo|Exercise or cognitive test in normoxic condition after 7 days of placebo intake
9538050|NCT03135444|Experimental|Provider Field Test|15 providers will be given an initial version of the PSA TOOL, over a 4 week period, they will be able to provide feedback on the tool. This will be used to revise the screening decision aid. Informal interviews with providers will also be conducted by a member of the study team to obtain feedback about ease of use and usefulness of the tool.
9538051|NCT03135444|Experimental|Patient test of revised PSA TOOL|150 patients will be asked to use the revised PSA TOOL. Pre- and Post-tests will be given to see if the tool changed the knowledge that patients have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Informal interviews with patients who are exposed to the tool will also be conducted by a member of the study team to obtain feedback on issues addressed by the survey questions.
9538052|NCT03135301|Experimental|letrozole plus metformin|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued
9538053|NCT03135301|Active Comparator|letrozole|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding
9538054|NCT03135470||Current practice group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
9538055|NCT03135470||Standard operating protocol group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
9483757|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 4)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V (4:4:4:4) or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
9483758|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
9483759|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
9483760|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
9483761|NCT02546960|Experimental|ExPEC4V (16 : 16 : 16 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
9483762|NCT02546960|Placebo Comparator|Placebo|Participants will be stratified according to their age in 2 groups >= 18 to <50 years and >=50 years. Part 1: Participants will receive matching placebo to ExPEC4V as an intramuscular injection into the deltoid muscle. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe and well tolerated based on the review of safety data through Day 8 by the IDMC.
9483763|NCT02543567|Experimental|Group 1|Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57
9483764|NCT02543567|Experimental|Group 2|Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U single dose IM injection on Day 57
9483765|NCT02543567|Experimental|Group 3|Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U. single dose IM injection on Day 57
9483766|NCT02543567|Experimental|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
9483767|NCT02543268|Experimental|Group 1|Ad26.ZEBOV -Batch #1, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
9483768|NCT02543268|Experimental|Group 2|Ad26.ZEBOV -Batch #2, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
9483769|NCT02543268|Experimental|Group 3|Ad26.ZEBOV -Batch #3, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
9483770|NCT02543268|Experimental|Group 4|Placebo (0.9% saline)- single dose IM injection on Day 1 and Day 57
9483771|NCT02542384|Active Comparator|CR845 IV 1 mcg/kg|CR845 IV solution will be supplied in 2 mL glass vials.Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
9483772|NCT02542384|Active Comparator|CR845 IV 0.5 mcg/kg|CR845 solution will be supplied in 2 mL glass vials. Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
9538056|NCT03135470||Mobile phone app group|All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication
9538057|NCT03135223|Experimental|Intervention group|Co-created, school-based intervention to promote physical activity
9538058|NCT03135223|No Intervention|Control group|
9538059|NCT03135171|Experimental|Trastuzumab, Pertuzumab and Tocilizumab|
9538060|NCT03135275|Active Comparator|Staged complete PCI|Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
9538061|NCT03135275|Experimental|Immediate complete PCI|Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
9538062|NCT03135119|Active Comparator|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
9538063|NCT03135119|Experimental|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
9538064|NCT03135093||Stroke subjects|
9538065|NCT03135093||Healthy subjects|
9538066|NCT03135158||Women in labor|All participants who have a vaginal delivery
9538067|NCT03135288|Experimental|Cell-phone assisted|will be advised that they are going to receive a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits. They will be also provided with a cell phone number working 7 days a week to answer any query or questions regarding her family planning program.
9538068|NCT03135288|No Intervention|control group|will receive the same above adequate counseling with referral card but without any phone assistance
9538069|NCT03135236|Experimental|Parent training|All registered participants will participate in a series of trainings (3 separate) on sexuality education.
9538070|NCT03135197||Migalastat|Migalastat administered according to SmPC
9538071|NCT03135067|Experimental|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
9538072|NCT03135067|No Intervention|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling & testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
9538073|NCT03135184|Experimental|HDL Therapeutics PDS-2™ System|Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
9538074|NCT03135080|Experimental|Long-term HEAD START Training|Fifteen surgeons will participate in long-term HEAD START practice once live surgical training is complete. Each week the participant will complete 2 surgeries on the HEAD START device and mark the surgery number on the cartridge. Monthly, the participant will send the accumulated cartridges to Addis for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his/her impression of the surgeries with the participant during a regular monthly call. He/she will also note the findings on a standardized form. Practice will continue for approximately 4-6 months, depending on the length of the rainy season and time of enrollment.
9538075|NCT03135080|Active Comparator|Standard of Care|Once live surgical training is complete, fifteen surgeons will commence live surgery without supervision until the rainy season begins. Then they will break for the rainy season, per the typical practice. The trainer will assess their skill levels on live surgery at the end of training and again at the start of the surgical season in the fall.
9538076|NCT03134924|Experimental|Experimental condition|The WASH (Women's and Sexual Health) intervention included the elements of the enhanced standard of care condition and in addition, a group-based, culturally-tailored intervention to enhance the uptake of the recommendations. Facilitators covered an intervention manual on risks associated with IVP, symptoms of vaginal infections, vaginal health, women's experience with alternative methods for vaginal care, and communication with partners about vaginal health and the risks associated with IVP.
9538077|NCT03134924|Other|Enhanced Standard of Care|"This study provided an enhanced standard of care (SOC+) comparison condition, consisting of a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV using the Nugent criteria and provision of medication (oral metronidazole) within 48 hours of the examination in women with Nugent score of 7-10, regardless of the presence of symptoms. In addition, at baseline, participants received an individual education session on the risk of engaging in IVP, advice to discontinue IVP, and tips for healthy vaginal hygiene, emphasizing avoiding IVP and suggesting replacing IVP by external vaginal cleansing."
9538078|NCT03134950|Experimental|ADAPT|Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions are in person with a trained psychologist and the following 2-4 sessions are web-based. Each web-based session is followed by phone support.
9538079|NCT03134950|No Intervention|Medical Treatment as Usual|Medical treatment as usual
10039283|NCT01842217|Other|Premenopausal women|healthy female subjects: premenopausal
10039284|NCT01842217|Other|Postmenopausal women|healthy female subjects: postmenopausal
9538080|NCT03134976||Salvage Larynx|The first group includes subjects with cancer of the voice box (laryngeal squamous cell carcinoma) that has already been treated by either chemotherapy or radiation. This group will be treated using the standard of care, which includes starting thyroid hormone replacement therapy (levothyroxine) after surgery.
9621702|NCT02522130|Active Comparator|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
10039285|NCT01842230|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
10039286|NCT01842230|Active Comparator|Telmisartan 80mg and S-amlodipine 5mg|
10039287|NCT01842243|Active Comparator|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
10039288|NCT01842243|Active Comparator|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
9483773|NCT02542384|Placebo Comparator|Placebo IV|Placebo will be supplied in matched vials containing the same volume of buffer but with no active drug. It will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
9621703|NCT02522130|Placebo Comparator|placebo group|group D will receive placebo tablets.
10039289|NCT01842256|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
10039290|NCT01842256|Active Comparator|Atorvastatin 40mg|
10039291|NCT01842269|Experimental|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
10039292|NCT01842269|Active Comparator|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
10039293|NCT01842295|No Intervention|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
10039294|NCT01842321|Experimental|Abiraterone Acetate|
10039295|NCT01842347|Experimental|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
10039296|NCT01842373|Experimental|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
10039297|NCT01842373|Active Comparator|BLT|3 g of BLT will be applied to half of face for 60 minutes
10039298|NCT01842412||claudication|
9483774|NCT02542215|Experimental|Cobiprostone 30 mcg four times daily|Cobiprostone oral spray, four times daily, in addition to standard care radiation and chemotherapy
9483775|NCT02542215|Placebo Comparator|Placebo 0 mcg four times daily|Matching placebo oral spray, four times daily, in addition to standard care radiation and chemotherapy
9483776|NCT02539537|Active Comparator|Arm A: Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes on D1 of each week for the 4 weeks of the first cycle (1 cycle = 4 weeks). For the following five cycles, gemcitabine infusion on D1, D8, and D15 of each cycle, followed by 1 week without injection (i.e. in total 4 cycles over 24 weeks; with 19 administrations of Gemcitabine).
9483777|NCT02539537|Experimental|Arm B: Folfirinox|"Administered once every 14 days for 24 weeks (12 cycles). A cycle equals 14 days with injection on D1 of each cycle. Treatment starts with oxaliplatin (85 mg/m²) administration; IV infusion over 2 hours, followed by the simultaneous administration (using a Y-tubing) of folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours and irinotecan 180 mg/m² IV infusion over 90 minutes. The irinotecan will begin 30 minutes after the start of the folinic acid infusion.~5-Fluoro-uracil (5-FU) IV 2,400 mg/m²/h will be administered over 46 hours after the end of the folinic acid infusion, i.e. 1200 mg/m²/day for the duration of 2 days.~Treatment will be continued for 24 weeks (12 cycles)."
9483778|NCT02536170|Experimental|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
9483779|NCT02536170|Experimental|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
9483780|NCT02536170|Placebo Comparator|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
9483781|NCT02528539|Experimental|ITP (Integrative Thearpy Program)|"This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase.~Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks.~Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits"
9483782|NCT02527707|Experimental|lonafarnib/ritonavir|Lonafarnib starting at 50 mg bid in combination with ritonavir 100 mg bid and escalating to lonafarnib 75 mg bid and then 100 mg bid as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
9483783|NCT02525562|Other|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
9483784|NCT02525562|Other|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
9483785|NCT02525562|Other|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
9483786|NCT02524197|Active Comparator|CR845 0.25 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
9483787|NCT02524197|Active Comparator|CR845 0.50 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
10039299|NCT01842412||healthy|
10039300|NCT01842477|Experimental|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
9483788|NCT02524197|Active Comparator|CR845 1 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
9483789|NCT02524197|Active Comparator|CR845 5 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
9483790|NCT02521285|Experimental|Arm A (aspirin)|Patients receive aspirin PO QD for 12 months.
9483791|NCT02521285|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD for 12 months.
9483792|NCT02519439|Experimental|ganaxolone|Up to a maximum of 1800 mg/day
9483793|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
9483794|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
9483795|NCT02515175|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
9483796|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan|All patients in Part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy, topotecan. Patients will have PK assessment completed on days 1 and 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
9483797|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan -PART 2|All patients in Part 2 will be randomized 2:1 to receive trilaciclib (G1T28) to be administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
9483798|NCT02514447|Experimental|Placebo + Topotecan -PART 2|All patients in Part 2 will be randomized 1:2 to receive placebo administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
9483799|NCT02513784|Experimental|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
9483800|NCT02513784|No Intervention|No intervention|Subjects will be randomized to no intervention for 21 days.
9483801|NCT02513485|Active Comparator|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
9483802|NCT02513485|Active Comparator|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
9483803|NCT02513303|Experimental|Treatment Group|AV fistula surgery Single administration of sirolimus-eluting Collagen implant
9483804|NCT02513303|Other|Control Group|AV fistula surgery
9483805|NCT02511886|Experimental|Arbaclofen Placarbil (AP)|Orally administered Arbaclofen Placarbil (AP) sustained release (SR) tablets
9483806|NCT02511886|Placebo Comparator|Placebo|Subjects remain on placebo for entire study
9483807|NCT02510599|Experimental|Solithromycin|Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
9483808|NCT02509845|Experimental|Adolescent Safety Only Cohort|Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
9483809|NCT02509845|Experimental|Study Arm 1|Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
9483810|NCT02509845|Experimental|Study Arm 2|Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
9483811|NCT02509598|Experimental|Tc99m tilmanocept and Vital Blue Dye (optional)|0.5 mCi, 50 ug of Tc99m tilmanocept single administration. Optionally, 1-3 mL of vital blue dye, single administration (per institution's standard of care).
9483812|NCT02509494|Experimental|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
9483813|NCT02509494|Experimental|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
9483814|NCT02509494|Experimental|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
9483815|NCT02509494|Active Comparator|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
9483816|NCT02509494|Active Comparator|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.
9483817|NCT02508337|Experimental|XG-102|sterile ophthalmic solution for sub-conjunctival injection
9483818|NCT02508337|Placebo Comparator|placebo|sterile ophthalmic solution for sub-conjunctival injection
9497896|NCT03470844||5-10 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
9497897|NCT03470844||2-5 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
9497898|NCT03470844||1-2 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
9497899|NCT03470844||Control|"Healthy age, gender, socioeconomic and educational level matched control.~Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
9497900|NCT03470818|Experimental|Intervention group|"Preparatory instructional videos (flipped classroom model)~32 participants~Application of a flipped classroom model~Prior to the simulation session, the intervention group will have received the study intervention. This consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
9497901|NCT03470818|Sham Comparator|Control group|"Sham videos~Participants in the control group will also be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility.~This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
9497902|NCT03470805|Experimental|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
9497903|NCT03470792|Experimental|Microcirculation-assisted|ECMO blood flow will be adjusted by conventional clinical conditions, hemodynamic parameters and microcirculation parameters
9497904|NCT03470792|Active Comparator|Control|ECMO blood flow will be adjusted by clinical conditions and conventional hemodynamic parameters
9497905|NCT03470779|Experimental|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
9497906|NCT03470779|No Intervention|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
9497907|NCT03470766|Active Comparator|Active Lead (AL)|One octad lead placed where contacts 4 and 5 span the T9-T10 disc space.
9497908|NCT03470766|Sham Comparator|Sham Lead (SL)|One octad lead implanted subcutaneously behind the IPG and will serve to dissipate the current from the battery
9497909|NCT03470753|Active Comparator|Exercise Amount|Phase 1: 2 or 4 exercises.
9497910|NCT03470753|Active Comparator|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
9497911|NCT03470753|Active Comparator|Delivery Type|Phase 2: Handout vs electronic delivery
9497912|NCT03470753|Experimental|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
10039301|NCT01842503|Active Comparator|GET 73|300 mg (3 capsules) tid for 3 days
10039302|NCT01842503|Placebo Comparator|inactive ingredients capsule|3 capsules tid for 3 days
9483819|NCT02508038|Experimental|TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate|Patients with high-risk leukemia (who are at least one year of age and who have not received TBI as conditioning for a previous HSCT) will receive myeloablative conditioning with ATG, Fludarabine, Thiotepa, and TBI. All other subjects will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotepa, and Melphalan prior to transplant with a KIR/KIR ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCR-αβ+ and CD19+ cells. Patients will receive 5 doses of zoledronate (at 28 day intervals) starting 28 days after stem cell transplant.
9483820|NCT02504580|Experimental|Part A Cohort A|200 mg of HTX-011 by injection
9483821|NCT02504580|Experimental|Part A Cohort B|400 mg of HTX-011 by injection
9483822|NCT02504580|Experimental|Part A Cohort C|200 mg of HTX-011 by instillation
9483823|NCT02504580|Experimental|Part A Cohort D|400 mg of HTX-011 by instillation
9483824|NCT02504580|Experimental|Part A Cohort E|200 mg HTX-011 injection and 200 mg instillation
9483825|NCT02504580|Placebo Comparator|Part A Cohort F|Saline solution by injection
9483826|NCT02504580|Experimental|Part B Cohort A|200 mg HTX-011A by injection
9483827|NCT02504580|Experimental|Part B Cohort B|400 mg HTX-011A by injection
9483828|NCT02504580|Experimental|Part B Cohort C|200 mg HTX-011B by injection
9483829|NCT02504580|Experimental|Part B Cohort D|400 mg HTX-011B by injection
9483830|NCT02504580|Placebo Comparator|Part B Cohort E|Saline solution by injection
9483831|NCT02504580|Experimental|Part C Cohort A|200 mg HTX-002 by infiltration
9483832|NCT02504580|Experimental|Part B Cohort F|400 mg HTX-002 by infiltration
9483833|NCT02504580|Experimental|Part C Cohort B|200 mg HTX-011B by instillation
9483834|NCT02504580|Experimental|Part B Cohort G|400 mg HTX-011B by instillation
9483835|NCT02504580|Placebo Comparator|Part C Cohort C|Saline Solution by instillation
9483836|NCT02504580|Active Comparator|Part C Cohort D|0.25% bupivacaine hydrochloride injection
9483837|NCT02504580|Experimental|Part D Cohort A|400 mg HTX-011B via a combination of injection and instillation
9483838|NCT02504580|Experimental|Part E Cohort A|HTX-009 by injection
9483839|NCT02504580|Experimental|Part E Cohort B|HTX-009 by instillation
9483840|NCT02504580|Experimental|Part F Cohort A|300 mg of HTX-011B
9483841|NCT02504580|Experimental|Part F Cohort B|75 mg of 0.25% Marcaine
9483842|NCT02504580|Placebo Comparator|Part F Cohort C|10.26 mL of normal saline
10039303|NCT01842516|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
10039304|NCT01842516|Experimental|LCB01-0371 1200mg|LCB01-0371 1200mg
10039305|NCT01842516|Placebo Comparator|Placebo|Placebo
10039306|NCT01842529|Active Comparator|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
9483843|NCT02503137|Experimental|Experimental Arm 1|Topical SM04554 0.15% solution, once daily for approximately 90 days
9483844|NCT02503137|Experimental|Experimental Arm 2|Topical SM04554 0.25% solution, once daily for approximately 90 days
9483845|NCT02503137|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for approximately 90 days
9483846|NCT02502669|Active Comparator|Finasteride 23.5 mg tablets group|Finasteride 23.5mg tablets and large placebo tablets once per week
9483847|NCT02502669|Active Comparator|Finasteride 33.5 mg tablets group|Finasteride 33.5 mg tablets and small placebo tablets once per week
9483848|NCT02502669|Placebo Comparator|Placebo group|Large and small placebo tablets once per week
9483849|NCT02501304|Experimental|ReVENT Sleep Apnea System|All patients will be implanted with the ReVENT Sleep Apnea System
9483850|NCT02490488|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
9483851|NCT02490488|Placebo Comparator|Placebo & gemcitabine|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
9483852|NCT02489526|Experimental|VVZ-149 Injections|
9483853|NCT02489526|Placebo Comparator|Placebo|
9483854|NCT02488408|Experimental|Part A|To identify the maximum tolerated dose (MTD) of bemcentinib (BGB324) in participants with relapsed or refractory AML following treatment with cytotoxic chemotherapy or a targeted or biologic agent, or in participants with high risk MDS (Norway only).- This Arm of the study has completed recruitment
9483855|NCT02488408|Experimental|Part B|"To identify the safety and tolerability of bemcentinib:~as a single agent in participants with AML who are unsuitable for intensive chemotherapy~in a combination with cytarabine in participants with AML who are unsuitable for intensive chemotherapy~in a combination with decitabine in participants with AML who are unsuitable for intensive chemotherapy~as a single agent in participants with previously treated MDS"
9483856|NCT02486042|Active Comparator|Standard of Care (Standard Nutrition)|Infants in this group will receive standard lipids (predominantly Omega-6 fatty acids).
9483857|NCT02486042|Experimental|Omegaven|Infants in this group will receive lipid supplementation with omega-3 fatty acids.
9497913|NCT03470727|Experimental|Citrate arm|Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free
10058407|NCT02018094|Active Comparator|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
9483858|NCT02485938|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
9483859|NCT02485938|No Intervention|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
9483860|NCT02484378|Experimental|CER-001|CER-001 infusion
9483861|NCT02484378|Placebo Comparator|Placebo|Placebo infusion
9483862|NCT02477124|Active Comparator|transvaginal digital colposcope (TVCD)|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
9483863|NCT02477124|Active Comparator|standard of care screening|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
9483864|NCT02476201|Experimental|MPP ON|To activate the Multipoint Pacing (MPP) feature to ON in all patients
9483865|NCT02476019|Experimental|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
9483866|NCT02476019|Placebo Comparator|Placebo|Placebo administered subcutaneously
9483867|NCT02472418|Experimental|DFN-15 120 mg (treatment A)|DFN-15 120 mg (treatment A)
9483868|NCT02472418|Experimental|DFN-15 240 mg (treatment B)|DFN-15 240 mg (treatment B)
9483869|NCT02472418|Placebo Comparator|Placebo (treatment C)|Placebo (treatment C)
9483870|NCT02471898|Experimental|HTX-011|Evaluate the analgesic efficacy of HTX-011
9483871|NCT02471898|Placebo Comparator|Placebo|Saline
9483872|NCT02471222|Experimental|ADS-5102 (amantadine HCl extended release)|
9483873|NCT02471222|Placebo Comparator|Placebo|
9483874|NCT02470039|Experimental|Oral insulin 338 and subcutaneous placebo|
10058408|NCT02018094|Active Comparator|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
10058409|NCT02018094|Active Comparator|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
9483875|NCT02470039|Active Comparator|Subcutaneous insulin glargine and oral placebo|
9483876|NCT02469155|Experimental|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
9483877|NCT02469155|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
9483878|NCT02469155|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
9483879|NCT02469155|Active Comparator|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
9483880|NCT02466867|Experimental|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
9483881|NCT02466867|Experimental|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
9483882|NCT02466243|Experimental|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
9483883|NCT02466243|Placebo Comparator|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
9483884|NCT02465606|Experimental|Group 1: Lebrikizumab Dose Level 1 Monotherapy|During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
9483885|NCT02465606|Active Comparator|Group 2: Topical Corticosteroid Creams Only|During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
9483886|NCT02464046|Experimental|JNJ-42847922 then Placebo|Participants receive 2*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
9483887|NCT02464046|Experimental|Placebo then JNJ-42847922|Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.
9483888|NCT02462850|Experimental|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
9483889|NCT02462811|Experimental|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
9483890|NCT02462811|Active Comparator|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
9483891|NCT02462811|Placebo Comparator|Placebo|CL-108 formulation without API
9483892|NCT02462603|Experimental|EPI-589 500 milligrams (mg) twice daily (bid)|All enrolled participants will receive treatment with EPI-589
9483893|NCT02462187|Experimental|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
9538081|NCT03134976||Non-Salvage Larynx|The second group of subjects will consist of patients who have head and neck cancer of sites other than the voice box (larynx) without prior exposure to radiation or chemotherapy who are undergoing flap reconstruction surgery. This group will not be treated with levothyroxine so long as the subject has normal thyroid function. If a subject is hypothyroid, then thyroid hormone replacement will be given as a part of routine clinical care.
9538082|NCT03135054|Experimental|Combination|"Quizartinib is a second generation FLT3 inhibitors.The starting dose of quizartinib will be 30 mg/day oral unless the patients are taking a strong CYP3A4 inhibitor in which case the dose will be 20 mg /day. Quizartinib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~Omacetaxine Mepesuccinate will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with quizartinib) in 28-day cycle."
9538083|NCT03134859|Experimental|0 to 30 min/day tummy time|Group tasked to engage in an accumulation of 0 to 30 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
9538084|NCT03134859|Experimental|31-60 min/day tummy time|Group tasked to engage in an accumulation of 31 to 60 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
9538085|NCT03134859|Experimental|>61 min/day tummy time|Group tasked to engage in an accumulation of 61 or more minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
9538086|NCT03135145|Active Comparator|Lite Run Gait Trainer|Participants will be using the Lite Run Gait Trainer to assist them in weightbearing and walking after SDR or SEMLS surgery.
9538087|NCT03135145|Placebo Comparator|Usual Treatments|Participants will be using current treatments used in clinical practice to assist them in weightbearing and walking after SDR or SEMLS surgery.
9538088|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
9538089|NCT03135106|Experimental|Treatment A: Erdafitinib alone|Participants will receive single 4 milligram (mg) oral dose of erdafitinib on Day 1 in a fasted state.
9538090|NCT03135106|Experimental|Treatment B: Erdafitinib + Fluconazole|Participants will receive 400 mg fluconazole once daily orally from Day 1 to Day 11 in a fasted state and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 400 mg fluconazole dose.
9538091|NCT03135106|Experimental|Treatment C: Erdafitinib + Itraconazole|Participants will receive 200 mg itraconazole once daily orally from Day 1 to Day 11 and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 200 mg itraconazole dose.
9538092|NCT03134872|Experimental|SHR-1210+Chemotherapy|Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
9538093|NCT03134872|Active Comparator|Chemotherapy|Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
9538094|NCT03134937|Other|Study Arm|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
9538095|NCT03134794|Experimental|Educational Intervention|"Education intervention using the TLS. The active group will received an educational intervention applying proven concepts in medical education (cognitive reflection/checklist, traffic light system (TLS). Previous research showed that TL food labels prompted individuals to consider their health and to make healthier choices. A color-coded system influences the valuation process in favor of healthier choices by interfering with automatic decisions and triggering the re-evaluation process (Ena, Krajbich et al Judgement and DM 2016).~The TLS is being implemented to facilitate the identification of patients at risk of developing a clinical and radiological progression that could result in escalation of therapy."
9538096|NCT03134794|No Intervention|Control|Usual Care. The control group will make therapeutic decisions without being exposed to the educational intervention as part of the current standard practice.
9538097|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
9538098|NCT03134677|Experimental|Bupivacaine|We were performed spinal anesthesia sitting position by midline. After confirming the free flow of cerebrospinal fluid, bupivacaine was administered without aspiration.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
9538099|NCT03134677|Experimental|Sevoflurane|We were performed general anesthesia with sevoflurane. Anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
9538100|NCT03134729|Experimental|Serratus Plane Loco-regional block|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours~plus~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
9538101|NCT03134729|No Intervention|Standard of Care|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
9538102|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
10058410|NCT02018120|Active Comparator|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
10058411|NCT02018120|Experimental|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
10058412|NCT02018133||Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
9483894|NCT02462187|Experimental|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
9483895|NCT02462187|Experimental|NVN1000 16% Once daily|NVN1000 16% Gel once daily
9483896|NCT02462187|Placebo Comparator|Vehicle Gel|Vehicle Gel at frequency to match active
9483897|NCT02462187|Experimental|NVN1000 24% once daily|NVN1000 24% once daily
9483898|NCT02459236|Experimental|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
9483899|NCT02459236|Experimental|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
9483900|NCT02459236|Placebo Comparator|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
9483901|NCT02456675|Experimental|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
9483902|NCT02456675|Experimental|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
9483903|NCT02456480|Experimental|CLS001 topical gel, 2.5%|
9483904|NCT02456480|Experimental|CLS001 topical gel 1%|
9483905|NCT02456480|Placebo Comparator|Vehicle gel|
9483906|NCT02454933|Experimental|MEDI4736 & AZD9291 Combination|10mg/kg q2w (IV) infusion & once daily tablet 80 mg
9483907|NCT02454933|Experimental|AZD9291 Monotherapy|Once daily tablet 80 mg
9483908|NCT02447276|Experimental|Group A|Group A will receive REGN475 dosing regimen 1
9483909|NCT02447276|Experimental|Group B|Group B will receive REGN475 dosing regimen 2
9483910|NCT02447276|Experimental|Group C|Group C will receive REGN475 dosing regimen 3
9483911|NCT02447276|Experimental|Group D|Group D will receive REGN475 dosing regimen 4
9483912|NCT02447276|Experimental|Group E|Group E will receive matching placebo
9483913|NCT02446028|Experimental|BIOD-531|BIOD-531 injected twice daily
9483914|NCT02446028|Active Comparator|Humalog® Mix 75/25|Humalog® Mix 75/25 injected twice daily
9483915|NCT02445040|Experimental|Babylog VN500 in HFOV mode|Subjects will be treated with HFOV provided by the Babylog VN500 - the investigational device - for up to 14 days.
9483916|NCT02444910|Experimental|KDT501|Experimental drug, KDT501, is administered at 600mg for 10 consecutive days. On days 11 and 21 (+/- 1 day), based on the KDT501 drug exposure level, the subject will be provided instructions on dose adjustment of KDT501. Dose adjustments will be administered at 800mg for 10 consecutive days, determined at day 11; followed by 1,000mg for 8 consecutive days if determined at day 21.
9483917|NCT02442778|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
9483918|NCT02442778|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
9483919|NCT02442778|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
9483920|NCT02442765|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
9483921|NCT02442765|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
9483922|NCT02442765|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
9483923|NCT02439216|Experimental|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
9483924|NCT02439216|Experimental|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
9483925|NCT02439216|Placebo Comparator|Placebo|Matching placebo
9483926|NCT02438358|Experimental|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
9483927|NCT02438007|Experimental|Galeterone|
9483928|NCT02438007|Active Comparator|Enzalutamide|
9483929|NCT02436824|Experimental|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
9483930|NCT02436824|Placebo Comparator|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
9483931|NCT02436096|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
9483932|NCT02436096|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
9483933|NCT02435212|Active Comparator|Arm 1|
9483934|NCT02435212|Experimental|Arm 2|
9483935|NCT02435121|Experimental|SAR125844|Given intravenously weekly at the dose of 570 mg/m^2 for at least 18 weeks
9483936|NCT02434744|Experimental|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
9483937|NCT02434744|Experimental|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
9483938|NCT02434744|Experimental|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
9483939|NCT02434744|Experimental|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
9483940|NCT02434744|Placebo Comparator|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
9483941|NCT02434744|Placebo Comparator|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
9483942|NCT02434744|Placebo Comparator|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
9483943|NCT02434744|Placebo Comparator|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
9483944|NCT02433158|Experimental|Cohort 1|Includes one adult stratum (>18 years old) and one pediatric stratum (12-17 years old). Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg.
9538103|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
9538104|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
9538105|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
10039307|NCT01842529|Active Comparator|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
9538106|NCT03134664|Experimental|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
9538107|NCT03134664|Experimental|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
9538108|NCT03134690|Experimental|delayed start antagonist|30 women with f poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
9538109|NCT03134690|Experimental|conventional antagonist|30 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
9538110|NCT03134651|Active Comparator|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
9538111|NCT03134651|Active Comparator|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
9538112|NCT03134638|Experimental|Dose Escalation|Dose escalation phase to explore maximum tolerated dose across two dosing schedules. SY-1365 will be administered intravenously weekly and twice-weekly for 3 weeks of each 4-week cycle
9538113|NCT03134638|Experimental|Advanced Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
9538114|NCT03134638|Experimental|Relapsed Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatin)
9538115|NCT03134638|Experimental|Clear Cell Ovarian Cancer|Patients with clear cell ovarian cancer previously treated with ≥ 1 prior line of therapy (SY-1365 single agent)
9538116|NCT03134638|Experimental|Advanced Solid Tumors|Biopsy cohort of approximately 20-30 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained (SY-1365 single agent)
9538117|NCT03134638|Experimental|HR+ breast cancer|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy (SY-1365 + fulvestrant)
9538118|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
9538119|NCT03134495||non-exposed children|all children with no prescription of PPI
9538120|NCT03134469|Experimental|Probiotics|Intake of a probiotic capsule once daily
9538121|NCT03134469|Placebo Comparator|Placebo|Intake of a placebo capsule once daily
9538122|NCT03134534|Other|VATS group|Surgical procedure: VATS lobectomy
9538123|NCT03134534|Other|RATS group|Surgical procedure: RATS lobectomy
9538124|NCT03134482|Experimental|In vitro maturation (IVM)|"hCG primed in vitro maturation (IVM) procedure Gonadotropin is not used in this patient group If the endometrial thickness in 6mm or more and the mean diameter of largest follicle is 11 mm or less on menstrual cycle day 9 to 12 on ultrasonography, oocyte retrieval is planned two days later.~Recombinant hCG injection (priming) is given 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization.~The biochemical pregnancy is confirmed by serum beta hCG 15 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
9538125|NCT03134482|Active Comparator|Minimal stimulation IVF|"minimal stimulation IVF procedure These patients are stimulated with 150 or less IU of recombinant Follicle-stimulating hormone (FSH) from menstrual cycle day 3 in GnRH antagonist protocol.~If the mean diameters of two or more follicles are 17mm or more, oocyte retrieval is planned two days later.~Recombinant hCG is triggered 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization if needed.~The biochemical pregnancy is confirmed by serum beta hCG 14 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
10058413|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
10039308|NCT01842542|Experimental|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
9483945|NCT02433158|Experimental|Cohort 2|Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
9483946|NCT02429167|Experimental|PoNS Device|Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
9483947|NCT02429167|Sham Comparator|Sham PoNS Device|The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
9483948|NCT02428088|Experimental|Dasotraline 2 mg|Dasotraline 2 mg
9483949|NCT02428088|Experimental|Dasotraline 4 mg|Dasotraline 4 mg
9483950|NCT02428088|Placebo Comparator|Placebo|Placebo
9483951|NCT02426684|Experimental|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
9483952|NCT02422979|Experimental|PART 1 - Cohort 1|3-6 patients
9483953|NCT02422979|Experimental|PART 1 - Cohort 2|3-6 patients
9483954|NCT02422979|Experimental|PART 1 - Cohort 3|3-6 patients
9483955|NCT02422979|Experimental|PART 2 - Cohort 1|Number of patients depend on Part 1
9483956|NCT02422979|Experimental|PART 2 - Cohort 2|Number of patients depend on Part 1
9483957|NCT02422979|Experimental|PART 3|Up to 30 patients
9483958|NCT02421679|Experimental|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
9483959|NCT02416076|Active Comparator|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at the default Energy Level [EL2].
9483960|NCT02416076|Active Comparator|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at the default Energy Level [EL2] .
9483961|NCT02416076|Active Comparator|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
9483962|NCT02416076|Active Comparator|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at a higher Energy Level [EL4] .
9483963|NCT02416076|Active Comparator|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers' and 7-3.0 'Ulthera System, standard transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
9483964|NCT02416076|Active Comparator|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers'and 7-3.0 standard transducer on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFTof the face at a higher Energy Level [EL4].
9483965|NCT02413827|Experimental|Phase l: varlilumab and ipilimumab|
9483966|NCT02413827|Experimental|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
9483967|NCT02410902|Experimental|CM-AT|Active substance in single unit dose powder
9483968|NCT02410902|Placebo Comparator|Placebo|Placebo powder of inactive substance
9483969|NCT02410356|Experimental|TV-1106|TV-1106 to be injected once weekly.
9483970|NCT02410356|Active Comparator|dGH|dGH to be given as daily injections.
9483971|NCT02406209|Experimental|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
9483972|NCT02406209|Experimental|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
9483973|NCT02406209|Active Comparator|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
9483974|NCT02405585|Experimental|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.~Post adjuvant therapy: 6 monthly immunizations with HAPa"
9483975|NCT02405260|Experimental|TTP399 400 mg|TTP399 once daily
9483976|NCT02405260|Experimental|TTP399 800 mg|TTP399 once daily
9483977|NCT02405260|Active Comparator|Sitagliptin 100 mg|Sitagliptin once daily
9483978|NCT02405260|Placebo Comparator|Placebo|Placebo once daily
9483979|NCT02402530|Placebo Comparator|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
9483980|NCT02402530|Experimental|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
9483981|NCT02402530|Experimental|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
9483982|NCT02402309|Experimental|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
9483983|NCT02402309|Placebo Comparator|Topical vehicle dermatologic|Vehicle placebo for dermal application
9483984|NCT02402270|Experimental|ECP-019 A (Group A)|
9483985|NCT02402270|Experimental|ECP-019 B (Group B)|
9538126|NCT03134391|Active Comparator|vapocoolant spray|Subjects received Vapocoolant spray before spinal anesthesia
9538127|NCT03134391|Active Comparator|EMLA|Subjects received EMLA before spinal anesthesia
9538128|NCT03134586|Other|trial participant|All participants undergoes the same diagnostic imaging
9538129|NCT03134560|Active Comparator|With vein display instrument|Vein cannulation was done after the vein display instrument displays the veins using infrared
9538130|NCT03134560|No Intervention|Without vein display instrument|vein cannulation was done without any vein display instrument
9538131|NCT03134547|Active Comparator|low volume volatile anesthetics|1.0 % sevoflurane sedation via face mask , low dose sevoflurane group
9538132|NCT03134547|Active Comparator|high volume volatile anesthetics|2.5 % sevoflurane sedation via face mask, high dose sevoflurane group
9538133|NCT03134508||pregnant IBD women treated|pregnant IBD women treated by antiTNFα
9538134|NCT03134508||pregnant IBD women not treated|pregnant IBD women not treated by antiTNFα
9538135|NCT03134443|Active Comparator|Experimental group|Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
9538136|NCT03134443|Placebo Comparator|control group|Xiyanping injection simulation(andrographolide sulfonate simulation) 10-20ml/d, The treatment method is the same as the experimental group.
9538137|NCT03134612|Active Comparator|Ondansetron|Ondansetron 8mg (2mg/cc) was given intravenously via a 20 G vein canula
9538138|NCT03134612|Active Comparator|Lidocain|Lidocain 40mg (20mg/cc + 2cc of normal saline) was given intravenously via a 20 G vein canula
9538139|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
9538140|NCT03134456|Experimental|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
9538141|NCT03134417|Experimental|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
9538142|NCT03134417|Active Comparator|Vitamin D|Daily oral vitamin D (1000 IU) supplement
9538143|NCT03134417|Placebo Comparator|Placebo|Daily oral placebo (cellulose)
9538144|NCT03134378|Experimental|14 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
9538145|NCT03134378|Placebo Comparator|10 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
9538146|NCT03134430|Placebo Comparator|Normal saline|equal volume of normal saline as treatment group
9538147|NCT03134430|Active Comparator|peripheral Nerve block|0.35% ropivacaine and 0.5% lidocaine in normal saline
9538148|NCT03135041|Experimental|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
9538149|NCT03135041|Placebo Comparator|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
9538150|NCT03134846|Experimental|Phase 1: 10mg Cetuximab-IRDye800CW|Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
9538151|NCT03134846|Experimental|Phase 1: 25mg Cetuximab-IRDye800CW|Patients will receive 25mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
9538152|NCT03134846|Experimental|Phase 1: 50 mg Cetuximab-IRDye800CW|Patients will receive 50mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
9538153|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 15 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 15 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
9538154|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 25 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 25 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
9538155|NCT03134846|Experimental|After having established the optimal cetuximab-IRDye800CW dose|After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients for this specific dose (as determined in phase 1).
10039309|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
9538156|NCT03135132|Placebo Comparator|Control group|Usual dietary intake group
9538157|NCT03135132|Experimental|LCD group|Low calorie diet (LCD) group (300kcal/day intake reduction)
9538158|NCT03134300|Active Comparator|Low SES|
9538159|NCT03134300|Placebo Comparator|Normal/high SES|
9538160|NCT03134261|Other|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
9538161|NCT03134261|Other|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
9538162|NCT03134261|Other|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
9616191|NCT04313881|Placebo Comparator|Control Arm (Placebo + Azacitidine)|"Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitadine:~Placebo Priming Dose:~1 mg/kg on Days 1 and 4~15 mg/kg on Day 8~30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50)~Placebo Maintenance Dose:~30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle"
9616192|NCT04313244|Experimental|Group 1|0.5 mL Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) intramuscular (IM) will be co-administered with 0.5 mL Dengue Tetravalent Vaccine (TDV) subcutaneous (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).
9616193|NCT04313244|Experimental|Group 2|0.5 mL 9vHPV vaccine IM will be administered once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).
9616194|NCT04296981|Experimental|video-based patient information|Viewing an explanatory video (8 minutes) to improve communication and understanding of stroke issues and stages of the continuum of care
9616195|NCT04294849|Experimental|Venous Thromboembolism Arm|This will be a cohort of patients age 8- ≤ 21 years old with objectively diagnosed DVT and/or PE.
9616196|NCT04294225|Experimental|Treatment (anastrozole, letrozole)|Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 >= 1.3 pg/ml and E2 >= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
9538163|NCT03134352|Experimental|ZL-3101(Fugan) bid group|Fugan AM + Fugan PM
9538164|NCT03134352|Experimental|ZL-3101(Fugan) qd group|Fugan AM + Placebo PM
9538165|NCT03134352|Placebo Comparator|placebo group|Placebo AM + Placebo PM
9538166|NCT03134365|Experimental|Mixed meal|
10039310|NCT01842659|Experimental|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
10039311|NCT01842672|Experimental|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.
10039312|NCT01842685|Experimental|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
10039313|NCT01842698|Experimental|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
10039314|NCT01842724|Active Comparator|Motec total wrist arthroplasty|
10039315|NCT01842724|Active Comparator|Remotion total wrist arthroplasty|
9538167|NCT03134365|Active Comparator|Combined meal|
9538168|NCT03134287|Active Comparator|two-finger method|Those who received nasogastric tube placement by two-finger method
9538169|NCT03134287|Active Comparator|reverse sellick's method|Those who received nasogastric tube placement by reverse sellick's method
9538170|NCT03134274|Experimental|Pregnant women|Pregnant women above the age of 18 years, undergoing routine pre-natal care, who own and are familiar with use of a smartphone receive a Dip HBDA kit for home use.
9538171|NCT03134157|Experimental|Simvastatin and vaginal placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.
9538172|NCT03134157|Experimental|Simvastatin and oral placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.
9538173|NCT03134157|Experimental|Vaginal placebo+ oral placebo|The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.
9538174|NCT03134170|No Intervention|No intervention|The no intervention group will serve as control group. This group will receive standard care and will be an active comparator. At the end of the study they may join the intervention group
9538175|NCT03134170|Other|Intervention group|The intervention group will be seen by a pharmacist iin addition to their normal provider. The pharmacist will provide medication therapy review of the patient's therapy. The pharmacist will make recommendations to make revisions in the patient's therapy.
9538176|NCT03134235|Experimental|Raw, plant-based diet|A raw, plant-based diet was prescribed for 4 weeks.
9538177|NCT03134339|Experimental|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
9538178|NCT03134339|Experimental|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
9538179|NCT03134339|Experimental|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
9538180|NCT03134339|Experimental|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
9538181|NCT03134118|Experimental|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
9538182|NCT03133962|Other|Patients applying for CAP or long-term central catheter|
9538183|NCT03133975|Experimental|Treatment|Single high dose IM VIT D
9538184|NCT03133975|Active Comparator|Control|Usual diet mix of carbohydrates - lipid - protein - minerals & vitamins
9538185|NCT03133832|Experimental|The cure rate between the two treatment|Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
9538186|NCT03133832|Experimental|The amount of eggs produced|Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
9538187|NCT03133832|Experimental|The economic benefit|Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
9538188|NCT03134014|No Intervention|Breakfast Skipping (BS)|The BS group will continue to skip breakfast.
9538189|NCT03134014|Active Comparator|Normal Protein Breakfast (NP)|The NP groups will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The NP breakfasts will be 11% protein (10 g protein), 63% CHO, and 26% fat
9538190|NCT03134014|Active Comparator|High Protein Breakfast (HP)|The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
9538191|NCT03133845|Active Comparator|General anesthesia|In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values. Discretionary use of intrathecal morphine may be used.
9538192|NCT03133845|Experimental|Spinal anesthesia with light sedation|In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 10-15 mg of bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS>60-70. Discretionary use of intrathecal morphine may be used.
9538193|NCT03133884|Experimental|Acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 20 seconds.
9538194|NCT03133884|Other|Superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
10039316|NCT01842737|Experimental|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
10039317|NCT01842737|Active Comparator|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
9483986|NCT02402270|Experimental|ECP-019 C (Group C)|
9483987|NCT02402270|Active Comparator|Group D|
9483988|NCT02402270|Active Comparator|Group E|
9483989|NCT02401815|Experimental|Part 1: PLX9486 250 mg QD|Participants will receive PLX9486 250 milligrams (mg) orally once daily (QD) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483990|NCT02401815|Experimental|Part 1: PLX9486 350 mg QD|Participants will receive PLX9486 350 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483991|NCT02401815|Experimental|Part 1: PLX9486 500 mg QD|Participants will receive PLX9486 500 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483992|NCT02401815|Experimental|Part 1: PLX9486 1000 mg QD|Participants will receive PLX9486 1000 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483993|NCT02401815|Experimental|Part 1: PLX9486 500 mg BID|Participants will receive PLX9486 500 mg orally twice daily (BID) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483994|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Fasting)|Participants in fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483995|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Non-Fasting)|Participants in non-fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483996|NCT02401815|Experimental|Part 2e: PLX9486 500 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 500 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483997|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483998|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 37.5 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 37.5 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
9483999|NCT02401750|Experimental|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
9484000|NCT02401750|Experimental|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
9484001|NCT02401750|Placebo Comparator|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
9484002|NCT02398500|Experimental|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
9484003|NCT02398500|Experimental|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
9484004|NCT02398500|Active Comparator|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
9484005|NCT02396823|Experimental|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
9484006|NCT02396823|No Intervention|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
9484007|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
9484008|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c >7.5% & <10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
9484009|NCT02393937|Experimental|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
9484010|NCT02393937|Active Comparator|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
9484011|NCT02393937|Placebo Comparator|Placebo|Placebo Gel once daily for 70 days.
9484012|NCT02392026|Experimental|Metronidazole Gel|Metronidazole Vaginal Gel
9484013|NCT02391571|Experimental|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
9484014|NCT02391571|Active Comparator|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
9484015|NCT02391571|Other|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
9484016|NCT02390960|Active Comparator|Sildenafil|Sildenafil (SST-6006) is a preserved, white to off-white, topical cream. The active ingredient is 5% sildenafil citrate by weight. During the SST-6006 dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
9484017|NCT02390960|Placebo Comparator|Placebo|Placebo cream will be the same as SST-6006 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6006 topical sildenafil cream. During the placebo cream dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
9484018|NCT02389985|Experimental|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
9484019|NCT02389777|No Intervention|Control UV burn|No treatment of the UV Light burn will be given
9484020|NCT02389777|Active Comparator|ST266 treated UV burn immediately|ST266 will be applied topically immediately by spray to the UV light burn wound
9484021|NCT02389777|Active Comparator|ST266 treated UV burn delayed|ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
9484022|NCT02387788|Experimental|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
9484023|NCT02387606|Experimental|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
9484024|NCT02387606|Experimental|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
9484025|NCT02387606|Experimental|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
9484026|NCT02385201|Experimental|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
9484027|NCT02383810|Active Comparator|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
9484028|NCT02383810|Active Comparator|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
9484029|NCT02383810|Active Comparator|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
9484030|NCT02383810|Placebo Comparator|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
9484031|NCT02383810|Active Comparator|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
9484032|NCT02383810|Active Comparator|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
9484033|NCT02383810|Active Comparator|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
9484034|NCT02383810|Placebo Comparator|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
9484035|NCT02382510|Experimental|TRN-157|
9484036|NCT02382510|Placebo Comparator|Placebo|
9484037|NCT02382510|Active Comparator|Tiotropium|
9484038|NCT02377895|Experimental|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
9484039|NCT02377895|Active Comparator|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
9484040|NCT02376465|Experimental|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
9484041|NCT02376465|Experimental|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
9484042|NCT02376465|Active Comparator|PEG based below preparation|Oral bowel preparation for colonoscopy
9484043|NCT02372578|Experimental|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
9484044|NCT02372578|Active Comparator|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
9484045|NCT02372578|Placebo Comparator|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
9497914|NCT03470714|Experimental|Kinesiotaping Group|The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
9497915|NCT03470714|Active Comparator|Control group|The group in which the participants only perform the the force irradiation experiment.
9497916|NCT03470701|No Intervention|Control - usual care|This arm will receive usual care.
9497917|NCT03470701|Experimental|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
9538195|NCT03134066||Treatment-resistant depression patients|Subjects with TRD who have been deemed appropriate for (and have decided to receive) clinical, non-research ketamine treatment at the ketamine clinic at Massachusetts General Hospital. As this is an assessment-only observational study, no treatment assignment or randomization procedures will be used.
9538196|NCT03133897|Active Comparator|Prednisone|Prednisone group: Children will receive four doses (days) of prednisone 1 mg/kg/dose once daily (maximum dose 50 mg) following the initial dose of corticosteroid received in the ED under the Nursing Medical Directive or Pre-Printed Order form.
9538197|NCT03133897|Experimental|Dexamethasone|"Dexamethasone group: Children will receive the approximate pharmacologic equivalent of two doses (days) of dexamethasone 0.6 mg/kg/dose (maximum dose 16 mg per dose) once daily as follows. The standard dose of prednisone/prednisolone provided in the emergency department is 2 mg/kg/dose (maximum dose 50 mg), which is approximately equivalent to 0.3 mg/kg/dose of dexamethasone. Therefore, patients who received prednisone/prednisolone in emergency department as per the current Nursing Medical Directive and Pre-Printed Order form will receive a top-up These patients will then receive a dose of dexamethasone 0.6 mg/kg (maximum dose 16 mg) 24 hours after the initial corticosteroid dose received in the Emergency Department of dexamethasone 0.3 mg/kg (maximum dose 8 mg) upon enrollment."
9538198|NCT03134105|Experimental|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
9538199|NCT03134105|Active Comparator|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
9538200|NCT03134053|Experimental|extracorporeal shock-wave|
9538201|NCT03134053|Sham Comparator|massage|
9538202|NCT03133806|Experimental|Ultrasept LAA Closure System|Interventional percutaneous transcatheter device.
9538203|NCT03133949||Patients with idiopathic inflammatory aortitis|
9538204|NCT03133949||a group of witnesses|
9538205|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), low|Biological/Vaccine: ≥3.0logCCID50/ml but <3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)[ ≥3.0logCCID50/ml but <3.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
9538206|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), high|Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
9538207|NCT03133923|Active Comparator|Measles and Mumps Combined Vaccine，Live|manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
9538208|NCT03134040|Experimental|Incentives (Rebate)|On a weekly basis, participants receive a small monetary incentive to exercise each time they attend the YMCA.
9538209|NCT03134040|Experimental|Incentives (Donation)|On a weekly basis, a small monetary incentive to exercise is provided in the form of a donation to a charity of the participant's choice for attendance at the YMCA.
9538210|NCT03134040|Active Comparator|Control|Participants receive feedback on their exercise attendance on a weekly basis.
9538211|NCT03134001|Experimental|Test Group|Patients receiving oral analgesics via the PCoA™ Acute device
9538212|NCT03134001|No Intervention|Control Group|Patients receiving oral analgesics by nurse, upon request
9538213|NCT03133819|Other|Q-Sense_QST (TSA II)|"QST measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.~Using the method of limits, a threshold will determine as the average of four successive stimuli for cold and warmth sensation and two for heat pain."
10039318|NCT01842750|Experimental|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
10039319|NCT01842802|Experimental|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
9538214|NCT03134079|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
9538215|NCT03134079|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
9538216|NCT03134079|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
9538217|NCT03133780|Active Comparator|Ketamine|Patients will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
9616197|NCT04292470|Experimental|Amitriptyline|Amitriptyline 10 mg daily
10039320|NCT01842802|Experimental|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
9538218|NCT03133780|Active Comparator|Midazolam|Patients will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
9538219|NCT03133728||Pre-Intervention Group|The Investigators will visit each of the selected 3 clusters (i.e. 6 primary health clinics) to construct a retrospective cohort of high-risk HIV-infected women who entered the national PMTCT program and received the SOC between June 1, 2017 and May 31, 2018. Using existing data through the electronic health record information (SmartCare and LIMS), the investigators will gather individual-level retrospective data on high-risk Mother-Infant Pairs (MIPs) from PMTCT enrolment through the child's ART enrolment, initiation, and retention rate at 3 months.
9538220|NCT03133728||Post-Intervention Group|Study Research Assistants (RA) will review routine patient files and registers, augmented by existing electronic health record information, to identify a new cohort of high-risk Mother-Infant Pairs (MIPs) at each study site between the dates of June 1, 2019 and May 31, 2020. The outreach team will include, at a minimum, the study RA, a study peer, and an HIV counselor from the health facility, who will carry the Alere™ q HIV-1/2 Detect with them. When the outreach team contacts a high-risk MIP at community level, the team will approach the MIP for study screening, consent, and enrolment procedures. Study staff will ask the parent/guardian if the parent/guardian would like the IYC to be tested at their home, at a community health post, or other private space in the community. The IYC will be tested using both the Alere™ q HIV-1/2 Detect platform and a reflex DBS PCR test to evaluate performance of the POC platform in a mobile setting against the gold standard.
9538221|NCT03133637||Ceftriaxone Arm|
9538222|NCT03133754|Experimental|DP-PEEP|recruitment maneuver + individualized PEEP
9538223|NCT03133754|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
9538224|NCT03133533|Active Comparator|laparoscopic|laparoscopic inguinal hernia repair
9538225|NCT03133533|Active Comparator|robot-assisted|robot-assisted inguinal hernia repair
9538226|NCT03133507|Experimental|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
9538227|NCT03133507|Experimental|Reassurance Condition|Children will receive empathic support from the experimenter.
9538228|NCT03133507|Experimental|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
9538229|NCT03133455|Other|Patient with Fibromyalgia|
9538230|NCT03133663|Active Comparator|Control group|Pulse oximeter and auscultation to determine heart rate during neonatal resuscitation. Pulse oximeter will be used to determine oxygen saturation.
9538231|NCT03133663|Experimental|Electrocardiogram group|Electrocardiogram to determine heart rate during neonatal resuscitation. Pulse oximeter will still be used per Neonatal Resuscitation Program guidelines for oxygen saturation.
9538232|NCT03133741|Placebo Comparator|Placebo|Saline
9538233|NCT03133741|Other|GIP-A|Infusion of GIP-A alone as study tool.
9538234|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
9538235|NCT03133741|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
9538236|NCT03133715|Active Comparator|laparoscopic ventral hernia|laparoscopic ventral hernia repair
9538237|NCT03133715|Active Comparator|robot-assisted ventral hernia|robot-assisted ventral hernia repair
9538238|NCT03133468|Experimental|Part 1: AJM347|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
9538239|NCT03133468|Placebo Comparator|Part 1: Placebo|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
9538240|NCT03133468|Experimental|Part 2: Low-dose AJM347|"Caucasian and Japanese participants will receive a low dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods."
9538241|NCT03133468|Experimental|Part 2: High-dose AJM347|"Caucasian and Japanese participants will receive a high dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups)."
9538242|NCT03133468|Experimental|Part 3: AJM347|Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
10039321|NCT01842828|Active Comparator|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
9538243|NCT03133468|Placebo Comparator|Part 3: Placebo|Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
9538244|NCT03133572|Experimental|Supraglottic airway|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
9538245|NCT03133572|Active Comparator|Face-mask|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
9538246|NCT03133689||EPIC-Norfolk|This cohort comprises 25,636 residents of a predefined English healthcare region (11,606 men and 14,030 women). Participants in this cohort study were originally recruited from 35 general practices in Norfolk, England as part of an investigation into diet and cancer, but the study's scope was subsequently widened to include additional outcomes including cardiovascular diseases.
9616198|NCT04280887|Experimental|Intervention|Participants will wear the device for the specified test period (3 months)
10039322|NCT01842828|Other|Standard care|Standard care for smoking cessation
9484046|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
9484047|NCT02367313|Placebo Comparator|Placebo|Placebo
9484048|NCT02367313|Active Comparator|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
9484049|NCT02367313|Active Comparator|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
9484050|NCT02365649|Active Comparator|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
9484051|NCT02365649|Active Comparator|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
9484052|NCT02365649|Placebo Comparator|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
9484053|NCT02365649|Active Comparator|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
9484054|NCT02365649|Active Comparator|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
9484055|NCT02365649|Active Comparator|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
9484056|NCT02365649|Active Comparator|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
9484057|NCT02365649|Active Comparator|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
9484058|NCT02365649|Active Comparator|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
9484059|NCT02364726|Experimental|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
9484060|NCT02363491|Experimental|OPN-305|OPN-305
9484061|NCT02361944|Experimental|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
9484062|NCT02361944|Active Comparator|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
9484063|NCT02359227|Experimental|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
9484064|NCT02358538|Experimental|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
9484065|NCT02349022|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
9484066|NCT02346526|Experimental|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.~Blood Tests~CT scan~Bone scan~FACBC PET/MRI in a subset of participants"
9484067|NCT02346422|Experimental|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
9484068|NCT02346422|Placebo Comparator|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
9484069|NCT02343445|Experimental|P-1037 in Hypertonic Saline (HS)|P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
9484070|NCT02343445|Experimental|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
9484071|NCT02343445|Placebo Comparator|Saline|Placebo (0.17% saline) BID
9484072|NCT02343445|Sham Comparator|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
9484073|NCT02342249|Placebo Comparator|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
9484074|NCT02342249|Active Comparator|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
9484075|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
9484076|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
9484077|NCT02341560|Active Comparator|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
9484078|NCT02341560|Active Comparator|single or multiple dose|QPI-1007 Injection - 3.0 mg
9484079|NCT02341560|Sham Comparator|Sham|Sham injection procedure
9484080|NCT02341287|Active Comparator|Warming hydrogel glove|"Patients will wear a warming hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.~Warming hydrogel device"
9484081|NCT02341287|Placebo Comparator|Non thermal hydrogel glove|"Patients will wear a hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.~Non thermal hydrogel device"
9484082|NCT02339129|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
9484083|NCT02339129|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
9484084|NCT02339064|Experimental|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
9484085|NCT02338648|Experimental|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
9484086|NCT02338648|Placebo Comparator|Placebo TDS|Placebo Patch for Blinding Purposes
9484087|NCT02337751|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
9484088|NCT02337725|Experimental|TVP-1012 1 mg|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
9484089|NCT02337725|Placebo Comparator|Placebo|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
9497918|NCT03470688||Originator|Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
9497919|NCT03470688||Biosimilar|Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
9497920|NCT03470662|Experimental|experimental group|Care bundle
9497921|NCT03470662|No Intervention|control group|routine care
9497922|NCT03470649|Experimental|Treatment|Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
9497923|NCT03470649|No Intervention|Control|Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.
9497924|NCT03470636|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
9497925|NCT03470623|Experimental|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
9497926|NCT03470623|Experimental|steel screws|hallux valgus treated with chevron osteotomy using steel screws
9497927|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
9497928|NCT03470584||Tzu Chi Vegetarian Study|12062 Tzu Chi volunteers of the Buddhist Tzu Chi Foundation recruited throughout communities in Taiwan in the year 2005. All participants filled out a self-administered questionnaire on basic information, medical history, lifestyle, and diet. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
9497929|NCT03470584||Tzu Chi Health Study|6002 participants who came for health examination at the Dalin Tzu Chi Hospital between the years 2007 to 2009. 77% were Tzu Chi volunteers. All participants were interviewed on a structured questionnaire including basic information, medical history, lifestyle, and diet, and received a comprehensive health examination. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
9497930|NCT03470532|Experimental|Group A|buccal infiltration of 4% Articaine with epinephrine
9497931|NCT03470532|Active Comparator|Group B|buccal infiltration of 2% Mepivacaine with epinephrine
9497932|NCT03470506||Ischemic stroke|Diagnosed with an ischemic stroke by a Neurologist
9497933|NCT03470480|Experimental|Treatment rTMS + meth pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
9497934|NCT03470480|Active Comparator|Treatment rTMS + neutral pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
9497935|NCT03470480|Sham Comparator|Sham rTMS + meth pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
9497936|NCT03470480|Sham Comparator|Sham rTMS + neutral pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).
9497937|NCT03470454||diabetics on linagelptin|Diabetic patients were given linagelptin for blood glucose control
9497938|NCT03470454||diabetics on other DPP4 inhibitors|Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
9497939|NCT03470428||Pediatric Fontan Patients|Participants ages 10 to 18 who have had Lateral Tunnel or Extracardiac Fontan procedures.
10039323|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
10039324|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
9484090|NCT02336698|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
9484091|NCT02336698|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
9484092|NCT02336698|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
9484093|NCT02336685|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
9484094|NCT02336685|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
9484095|NCT02336685|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
9484096|NCT02336503|Experimental|BBI-4000 Dose 1|Low concentration of BBI-4000
9484097|NCT02336503|Experimental|BBI-4000 Dose 2|Middle concentration of BBI-4000
9484098|NCT02336503|Experimental|BBI-4000 Dose 3|High concentration of BBI-4000
9484099|NCT02336503|Placebo Comparator|Vehicle|Vehicle (placebo)
9484100|NCT02335918|Experimental|Varlilumab and Nivolumab|
9484101|NCT02333643|Experimental|CLS003|Topical digoxin/furosemide
9484102|NCT02333643|Experimental|Digoxin topical formulation|
9484103|NCT02333643|Experimental|Furosemide topical formulation|
9484104|NCT02333643|Placebo Comparator|Vehicle topical formulation|
9484105|NCT02332759|Experimental|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
9484106|NCT02332655|Experimental|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
9484107|NCT02330653|Experimental|Fecal Microbiota Transplant (FMT)|Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
9484108|NCT02330653|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
9484109|NCT02330445|Experimental|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
9484110|NCT02330445|Experimental|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
9484111|NCT02329834|Experimental|Treatment Sequence 1|Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours followed by i.v. Furosemide Injection, USP (80 mg)by i.v. bolus in second period
9484112|NCT02329834|Experimental|Treatment Sequence 2|Furosemide Injection, USP (80 mg) by i.v. bolus, followed by Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours in second period.
9484113|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
9484114|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
9484115|NCT02326454|Placebo Comparator|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
9484116|NCT02326454|Placebo Comparator|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
9484117|NCT02324985|Active Comparator|Active Arm|S-Ibuprofen Topical Gel 5%
9484118|NCT02324985|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
9484119|NCT02324725|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
10039325|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
10039326|NCT01842893|Experimental|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
9484120|NCT02324309|Experimental|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
9484121|NCT02324309|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
9484122|NCT02324309|Active Comparator|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
9484123|NCT02324309|Experimental|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
9484124|NCT02320708|Experimental|Test Acetaminophen (ACE) (1000 mg) and placebo|
9484125|NCT02320708|Active Comparator|Commerical ACE (1000 mg) and placebo|
9484126|NCT02320708|Active Comparator|Commerical Ibuprofen (IBU) (400 mg) and placebo|
9484127|NCT02320708|Placebo Comparator|Placebo|
9484128|NCT02317705|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
9484129|NCT02314299|Experimental|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
9484130|NCT02314299|Experimental|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
9484131|NCT02312011|Experimental|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
9484132|NCT02312011|Placebo Comparator|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
9484133|NCT02311673|Active Comparator|RM-493 Once Daily Dose 1|Dose 1 once daily in the morning
9484134|NCT02311673|Active Comparator|RM-493 Once Daily Dose 2|Dose 2 once daily in the morning
9484135|NCT02311673|Placebo Comparator|Placebo|Placebo in the morning
9484138|NCT02310802|Experimental|OBE001 dose 1|
9484139|NCT02310802|Experimental|OBE001 dose 2|
9484140|NCT02310802|Experimental|OBE001 dose 3|
9484141|NCT02310802|Placebo Comparator|Placebo|
9484142|NCT02310412|Experimental|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
9484143|NCT02310412|Experimental|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
9484144|NCT02309671|Experimental|FE 999049 6 µg|
9484145|NCT02309671|Experimental|FE 999049 9 µg|
9484146|NCT02309671|Experimental|FE 999049 12 µg|
9484147|NCT02309671|Active Comparator|FOLLISTIM 150 IU|follitropin beta
9484148|NCT02307851|Experimental|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
9484149|NCT02307851|Experimental|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
9484150|NCT02307851|Experimental|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
9484151|NCT02307851|Active Comparator|Group D|Comparator TIV, intramuscular injection (0.5mL)
9484152|NCT02307279|Experimental|Gelesis100|Gelesis100 twice daily
9484153|NCT02307279|Placebo Comparator|Placebo|Matching placebo twice daily
9484154|NCT02306811|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
9484155|NCT02306811|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
9484156|NCT02306811|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
9484157|NCT02306811|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
9484158|NCT02306291|Experimental|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
9484159|NCT02306291|Experimental|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
9484160|NCT02306291|Experimental|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
9484161|NCT02302079|Experimental|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
9484162|NCT02302079|Experimental|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
9484163|NCT02302079|Active Comparator|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
10039327|NCT01842919|Other|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
10039328|NCT01842919|Other|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
9484164|NCT02301234|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
9484165|NCT02301234|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
9484166|NCT02301234|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
9484167|NCT02301156|Experimental|Ublituximab + ibrutinib|"Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions~Ibrutinib: Fixed oral daily dose"
9484168|NCT02301156|Active Comparator|Ibrutinib|- Ibrutinib: Fixed oral daily dose
9484169|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484170|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484171|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484172|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484173|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484174|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484175|NCT02296645|Experimental|ZuraPrep|Isopropyl alcohol (IPA) (70%)
9484176|NCT02296645|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
9484177|NCT02295865|Experimental|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
9484178|NCT02295865|Experimental|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
9484179|NCT02295865|Experimental|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
9484180|NCT02295865|Experimental|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
9484181|NCT02293941|Experimental|JKB-122 5mg|5mg, oral, once daily
9484182|NCT02293941|Experimental|JKB-122 15 mg|15mg, oral, once daily
9484183|NCT02293941|Experimental|JKB-122 35 mg|35mg, oral, once daily
9484184|NCT02293941|Placebo Comparator|placebo|comparable capsule, oral, once daily
9484185|NCT02289846|Placebo Comparator|Placebo BID|Placebo once in the morning and once in the evening.
9484186|NCT02289846|Experimental|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
9484187|NCT02289846|Experimental|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
9484188|NCT02289846|Experimental|IW-9179 BID|IW-9179 once in the morning and once in the evening
9484189|NCT02289716|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
9484190|NCT02289716|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
9484191|NCT02289716|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
9484192|NCT02288845|Experimental|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
9484193|NCT02286804|Experimental|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
10039329|NCT01842919|Other|Pilot subject|Healthy volunteers to set up the kinesthetic test
10039330|NCT01842932|Experimental|Phloroglucin & Placebo|Phloroglucin 20ml before examination & Placebo 1ml before examination
9484194|NCT02286765|Active Comparator|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
9484195|NCT02286765|Active Comparator|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
9484196|NCT02283957|Experimental|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
9484197|NCT02283957|Experimental|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
9484198|NCT02283957|Placebo Comparator|2 mL injection of placebo|Single dose, 2 mL
9484199|NCT02283957|Experimental|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
9484200|NCT02282761|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
9484201|NCT02282761|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
9484202|NCT02282761|Placebo Comparator|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
9484203|NCT02282215|Experimental|CLT-008 low dose with G-CSF|Dose escalation
9484204|NCT02282215|Experimental|CLT-008 high dose with G-CSF|Dose escalation
9484205|NCT02282215|Experimental|CLT-008 with G-CSF|Randomized
9484206|NCT02282215|Active Comparator|G-CSF|Randomized
9484207|NCT02279823|Experimental|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
9484208|NCT02279823|Active Comparator|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
9484209|NCT02279823|Placebo Comparator|Placebo solution|Topical solution applied twice daily for 26 weeks
9484210|NCT02279602|Experimental|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
9484211|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
9484212|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
9484213|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
9484214|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
9484215|NCT02278133|Experimental|WNT974, LGX818 and cetuximab combo|Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
9484216|NCT02277704|Placebo Comparator|Treatment A|"2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
9484217|NCT02277704|Active Comparator|Treatment B|"1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
9484218|NCT02277704|Active Comparator|Treatment C|"2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime."
9484219|NCT02277106|Experimental|SAGE-547|Intravenous
9484220|NCT02277106|Placebo Comparator|Placebo|Intravenous sterile saline
9484221|NCT02276209|Experimental|Dasotraline 4 mg|Dasotraline 4 mg once daily
9484222|NCT02276209|Experimental|Dasotraline 6 mg|Dasotraline 6 mg once daily
9484223|NCT02276209|Placebo Comparator|Placebo|Placebo once daily
9484224|NCT02275351|Experimental|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
9484225|NCT02275351|Experimental|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
9484226|NCT02275351|Placebo Comparator|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
9484227|NCT02271503|Other|Sequence 1|Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
9484228|NCT02271503|Other|Sequence 2|Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
9484229|NCT02271503|Other|Sequence 3|Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
9484230|NCT02271334|Experimental|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
9484231|NCT02271334|Experimental|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
9484232|NCT02271334|Active Comparator|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
9484233|NCT02271334|Active Comparator|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
9484234|NCT02270892|Active Comparator|Group A|Left side Ulthera treatment
9484235|NCT02270892|Active Comparator|Group B|Right side Ulthera treatment
9484236|NCT02267642|Experimental|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
9484237|NCT02267525|Experimental|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
9484238|NCT02267525|Experimental|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
9484239|NCT02267525|Experimental|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
9484240|NCT02267525|Placebo Comparator|Placebo|Placebo capsules QD x 12 weeks
9484241|NCT02266719|Experimental|Fenestrated CMD cohort|Patients enrolled in this arm will be implanted with the custom made fenestrated device. The device is aimed to treat complex abdominal aortic aneurysms including juxtarenal, suprarenal and type IV thoracoabdominal aneurysms.
9484242|NCT02266719|Experimental|Type I - III TAAA cohort|Patients enrolled in this arm will be implanted with the custom made/ off-the-shelfp branched devices. The device is aimed to treat type I-III TAAAs.
9484243|NCT02266719|Experimental|Arch cohort|Patients enrolled in this arm will be implanted with patient-specific stent-grafts with one to three inner branches or a scallop.
9484244|NCT02266628|Experimental|Treatmetn Group A|RSV-F vaccine (0.5mL Injection)
9484245|NCT02266628|Placebo Comparator|Treatment Group B|Saline Placebo (0.5mL Injection)
9484246|NCT02265393|Active Comparator|OTO-104|12 mg OTO-104 (dexamethasone)
9484247|NCT02265393|Placebo Comparator|Placebo|OTO-104 vehicle
9484248|NCT02260674|Experimental|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
9484249|NCT02260674|Experimental|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
9484250|NCT02260674|Placebo Comparator|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
9484251|NCT02260193|Experimental|AKB-6548, starting dose 1|
9484252|NCT02260193|Experimental|AKB-6548, starting dose 2|
9484253|NCT02260193|Experimental|AKB-6548, starting dose 3|
9484254|NCT02257983|Active Comparator|EPI-743|EPI-743 400 mg P.O. TID
9484255|NCT02257983|Placebo Comparator|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
9484256|NCT02257619|Experimental|Itacitinib plus docetaxel|
9538247|NCT03133689||GAZEL|This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
9538248|NCT03133689||NSHD|This dataset comes from the 1946 National Birth Cohort study, which comprises all persons born in England, Scotland and Wales in one week in March 1946. The cohort comprises 5,362 individuals (2,815 men and 2,547 women). Data have been collected from participants on a regular basis throughout their life, including information on lifestyle and, in combination with administrative datasets, on health outcomes.
9538249|NCT03133689||Twenty-07-1930s|This cohort comprises 1,551 Scottish participants (702 men and 849 women) born around 1932 who were recruited in 1986 as part of a study of health inequalities. The repeated nature of the data collection will enable identification of longitudinal alcohol intake patterns, while linkage to Scottish health system records will enable identification of coronary heart disease onset.
9538250|NCT03133689||Twenty-07-1950s|This cohort comprises 1,444 Scottish participants (656 men and 788 women) born around 1952 who were recruited in 1986, alongside the T-07-1930s' cohort, as part of a study of health inequalities. Participant health was tracked through linkage with national health records.
9538251|NCT03133689||Whitehall II|This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
9538252|NCT03133494|Active Comparator|Laparoscopic cholecystectomy in smokers|ABG analysis of patients with history of smoking posted for laparoscopic cholecystectomy was collected
9538253|NCT03133494|Placebo Comparator|Laparoscopic cholecystectomy nonsmokers|ABG analysis of patients without history of smoking posted for laparoscopic cholecystectomy was collected
9538254|NCT03133520|No Intervention|Standard oxygen group|This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.
9538255|NCT03133520|Experimental|High flow oxygen therapy group|This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
9538256|NCT03133442|No Intervention|Baseline Nights|No vestibular stimulation is applied. However, the sound of the moving bed will be played back to the participant at the right sound intensity level.
9538257|NCT03133442|Experimental|Movement Nights|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat V4 rocking bed. Stimulation is provided for the entire 7 hours of the night from lights off to lights on. The stimulation frequency is in the range of 0.1-0.3 Hz, with an amplitude in the range of 0.05 to 0.1m
9538258|NCT03133611|Other|Parkinson's disease|Speech assessment. Routine clinical assessment.
9538259|NCT03133611|Other|REM sleep behaviour disorder|Speech assessment. Routine clinical assessment.
9538260|NCT03133611|Other|Healthy controls|Speech assessment. Routine clinical assessment.
9538261|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
9538262|NCT03133650|Experimental|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
9538263|NCT03133429|Experimental|Patients with MER stent|Patients eligible for Carotid Artery Stenting
9538264|NCT03133416|Active Comparator|PRP preparation|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval.
9538265|NCT03133416|Active Comparator|Physiotherapy|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
9538266|NCT03133416|Active Comparator|PRP and physiotherapy|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval;Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
9538267|NCT03133234||EGFR T790M Patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
9538268|NCT03133364|Active Comparator|Sensory optimized meals|"Intervention group is receiving:~Popular dishes selected from hospital and meal service menus optimized by sensory experts. Optimization is done with respect to taste, texture and appereance and on nutritional composition of the meals with focus on protein content."
9538269|NCT03133364|Placebo Comparator|Control|"Control group is receiving:~Popular dishes selected from hospital and meal service menus, NOT optimized by sensory experts."
10039331|NCT01842932|Experimental|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination & Placebo 20ml before examination
10039332|NCT01842945|No Intervention|Wait-list control|
9538270|NCT03133546|Experimental|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
9538271|NCT03133546|Active Comparator|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
9538272|NCT03133325|Other|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
9538273|NCT03133117|Experimental|Cerebral Bases of Central and Peripheral Visual Integration|
9538274|NCT03133065|Active Comparator|Group 1: treatment after 6 months post transplantation|53 patients received Sofosbuvir+ribavirin standard of care for treatment of HCV post liver transplantation for 6 months
9538275|NCT03133065|Active Comparator|Group 2: early treatment afer 3 months post transplantation|36 patients received other DAAs regiment for treatment of HCV post liver transplantation for 3- 6 months
9538276|NCT03133104||antenatal corticosteroids|Women who received a rescue dose of steroids
9538277|NCT03133104||No antenatal corticosteroids|Women who did not received a rescue dose of steroids
9538278|NCT03133091|Active Comparator|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
9538279|NCT03133091|Active Comparator|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
9538280|NCT03133026|Active Comparator|Sludge group|If Single operator cholangioscopy reveals only sludge then sludge will be cleared using conventional technique during ERCP.
9538281|NCT03133026|Active Comparator|Ingrowth / Overgrowth|If Single operator cholangioscopy reveals tumour ingrowth or overgrowth then to evaluate the role of biliary RFA for occluded stent due to tumour ingrowth or overgrowth
9538282|NCT03133078|Experimental|Exercise: step-down test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
9538283|NCT03133078|Experimental|Exercise: side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
9538284|NCT03133312|Experimental|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
9538285|NCT03133312|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
9538286|NCT03133195|Experimental|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
9538287|NCT03133195|Placebo Comparator|Placebo|Placebo subcutaneous once daily for 12 weeks
9538288|NCT03133247|Experimental|SHR-1316 dose-escalation|SHR-1316 doses will be escalated sequentially in 5 cohorts.
9538289|NCT03133052|Active Comparator|training group|Intervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
9538290|NCT03133052|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
9538291|NCT03133143|Experimental|Cognifit|Participants are instructed to play CogniFit 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
9538292|NCT03133143|Active Comparator|SIMS 4 (Maxis, Inc)|Participants are instructed to play SIMS 4 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
9538293|NCT03133143|No Intervention|Treatment as usual|No specific intervention will be offered to those who receive treatment as usual according to their treatment schedule. The participants are encouraged not to play video games during the study period.
9538294|NCT03133169||on chelation|"patients with B-thalassemia major samples of which will be examined for renal and liver function, Erythrocyte Glutamine level, ferritin level and complete blood picture. Also Echo will be done for measuring the Tricuspid regurge velocity.~group 1: cases on chelation: deferasirox 500mg oral tablet with initial dose 20 mg/kg guided by ferritin level~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
9538295|NCT03133169||No chelation|"group 2: cases without chelation~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
9538296|NCT03133169||splenectomy|"group 3: cases with splenectomy~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
9538297|NCT03133169||no splenectomy|group 4: cases without splenectomy Diagnostic Test: blood sample Diagnostic Test: Tricuspid regurge velocity
9538298|NCT03133130|Experimental|BMT101|cp-lasiRNA
9538299|NCT03133130|Placebo Comparator|Placebo|Normal Saline
9538300|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
9538301|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
9538302|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
9538303|NCT03132974|Experimental|SGHH|Admission to Sogyeonghwalhyeol-tang granule
9538304|NCT03132974|Experimental|SGHH with manipulation therapy|Admission to Sogyeonghwalhyeol-tang granule and manipulation therapy
9538305|NCT03132974|Placebo Comparator|Placebo with manipulation therapy|
9538306|NCT03133013|Experimental|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
9538307|NCT03133013|Other|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
9538308|NCT03133039|Active Comparator|bioabsorbable screw|
9538309|NCT03133039|Active Comparator|titanium screw|
9538310|NCT03132987|Experimental|Progressive strengthening program|Subjects identified as having a clinically relevant strength deficit will be asked to participate in physical therapy sessions 3 times per week for 3 weeks. The strengthening program will consist of an individualized, progressive exercise program with an emphasis on increasing lower extremity strength, power, and biomechanics.
9538311|NCT03132662|Active Comparator|Very Low Calorie Diet|The first group will continue according to the standard bariatric preoperative protocol and will be assigned a VLCLD of 900 cal/day (Optifast ® 4 servings/day each containing: 225 cal + 0.35 g linolenic acid) for 2-3 weeks prior to surgery according to the surgeon's preferences.
9538312|NCT03132662|Experimental|Omega-3|The second group will be assigned to 3 gr. daily oral intake of Ω-3 PUFAs ((Oceano3 ® 1000 mg Krill Oil tabs (150 mg EPA + 90 mg DHA) 3 times a day) for 4 weeks with only regular dietary suggestions before surgery.
9538313|NCT03132662|No Intervention|No-treatment|The third group will not receive treatment for liver size reduction prior to surgery.
9538314|NCT03132818||Patients undergoing AMP with oocyte donation|
9538315|NCT03132818||Couples supported in AMP with sperm donation|
9538316|NCT03132818||Couples supported in AMP intra torque|
9538317|NCT03133299|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
9538318|NCT03133299|Experimental|Vitamin D plus Glucocorticoid group|Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
9538319|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
9538320|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
9538321|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
9538322|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
9538323|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
9538324|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
9538325|NCT03132922|Experimental|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
9538326|NCT03132922|Experimental|Radiation Sub-Study: Autologous genetically modified MAGE-A4c1|
9538327|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
9538328|NCT03133182||Polypharmacy|People taking >=5 unique prescription drugs in the 3 months prior to surgery
9538329|NCT03133182||No polypharmacy|People taking <5 unique prescription drugs in the 3 months prior to surgery
9538330|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
9538331|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
9538332|NCT03132779|Experimental|One armed|One group of patient will take Intralipid for all
9538333|NCT03132597|Experimental|Early Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the beginning of the first semester
9538334|NCT03132597|Experimental|Late Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the second half of the first semester
9538335|NCT03132597|No Intervention|Control (not exposed)|Students not exposed to the mindfulness mandatory course (not exposed to the intervention)
9538336|NCT03132623|Active Comparator|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
9538337|NCT03132623|Placebo Comparator|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
9538338|NCT03132714|Active Comparator|PD + (AMX + MET)|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg
9538339|NCT03132714|Active Comparator|PD + CLM|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg
9538340|NCT03132714|Active Comparator|PD + (AMX + MET) + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT
9538341|NCT03132714|Active Comparator|PD + CLM + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT
10039333|NCT01842945|Experimental|Treatment with therapist contact|
10039334|NCT01842945|Experimental|Treatment without therapist contact|
9484257|NCT02255409|Experimental|aQIV|Adjuvanted Quadrivalent Subunit Influenza
9484258|NCT02255409|Active Comparator|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
9484259|NCT02254993|Experimental|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
9484260|NCT02254993|Experimental|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
9484261|NCT02254993|Experimental|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
9484262|NCT02254993|Experimental|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
9484263|NCT02254993|Experimental|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
9484264|NCT02254993|Experimental|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
9484265|NCT02254993|Experimental|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
9484266|NCT02254993|Experimental|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
9484267|NCT02254993|Experimental|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
9484268|NCT02254993|Experimental|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
9484269|NCT02254993|Experimental|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
9484270|NCT02253745|Experimental|Placebo:V81444|Placebo followed by a 7 day washout then V81444
9484271|NCT02253745|Experimental|V81444:placebo|V81444 followed by a 7 day washout then Placebo
9484272|NCT02252835|Experimental|Arhalofenate with febuxostat (PK cohort)|
9484273|NCT02252835|Experimental|Arhalofenate with febuxostat (non-PK cohort)|
9484274|NCT02249429|Experimental|bimiralisib (PQR309)|
9484275|NCT02247726|Placebo Comparator|Treatment Group A|Saline Placebo (0.5mL injection)
9484276|NCT02247726|Experimental|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
9484277|NCT02244606|Experimental|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
9484278|NCT02244606|Experimental|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
9484279|NCT02244606|Active Comparator|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
9484280|NCT02242760|Experimental|SB204 2% Twice daily|Twice daily SB204 2%
9484281|NCT02242760|Experimental|SB204 4% daily|Once daily SB204 4%
9484282|NCT02242760|Placebo Comparator|Vehicle Gel Daily|Vehicle Gel Daily
9484283|NCT02242760|Placebo Comparator|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
9484284|NCT02242760|Experimental|SB204 4% Twice Daily|Twice daily SB204 4%
9484285|NCT02242435|Experimental|Ampion 4ml|4 mL intra-articular injection of Ampion
9484286|NCT02242435|Placebo Comparator|Placebo Solution|4 mL placebo intra-articular injection
9484287|NCT02236312|Experimental|Botulinum Toxin 30 units|I.M. injection
9484288|NCT02236312|Experimental|Botulinum Toxin 45 units|I.M. injection
9484289|NCT02236312|Experimental|Botulinum Toxin 60 units|I.M. injection
9484290|NCT02236312|Placebo Comparator|Placebo|I.M. injection
9484291|NCT02236195|Experimental|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
9484292|NCT02236156|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
9484293|NCT02236156|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
9484294|NCT02235272|Experimental|XG-102|
9484295|NCT02235272|Placebo Comparator|Placebo|
9484296|NCT02235259|Experimental|XG-104 low dose|
9484297|NCT02235259|Experimental|XG-104 intermediate dose|
9484298|NCT02235259|Experimental|XG-104 high dose|
9484299|NCT02235259|Placebo Comparator|Placebo|Placebo
9484300|NCT02230891|Active Comparator|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
9484301|NCT02230891|Active Comparator|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
9484302|NCT02230891|Other|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
9484303|NCT02229929|Placebo Comparator|Part A: Placebo|Intravenous matched placebo
9484304|NCT02229929|Experimental|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
9484305|NCT02229929|Experimental|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
9484306|NCT02229929|Experimental|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
9484307|NCT02229929|Placebo Comparator|Part B: Placebo|Intravenous matched placebo
10039335|NCT01842971|Experimental|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
10039336|NCT01842984|Experimental|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
10039337|NCT01842984|No Intervention|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
10039338|NCT01842997|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
10039339|NCT01843010|Active Comparator|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
10039340|NCT01843010|Placebo Comparator|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
9538342|NCT03132714|Active Comparator|PD + (AMX + MET) + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT
9538343|NCT03132714|Active Comparator|PD + CLM + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT
9538344|NCT03132896||Patients with moderate or severe ARDS|
9538345|NCT03132948|Experimental|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
9538346|NCT03132792|Experimental|Autologous genetically modified AFPᶜ³³²T cells|
9538347|NCT03132610|Active Comparator|Experimental group|Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
10039341|NCT01843036|Experimental|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
10039342|NCT01843036|No Intervention|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
10039343|NCT01843049|Experimental|radiotherapy+chemotherapy|"Radiotherapy:~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.~Chemotherapy:~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
10039344|NCT01843075|Experimental|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
10039345|NCT01843075|Placebo Comparator|Placebo|Daily administration of matched placebo by subcutaneous injection
10039346|NCT01843088|Experimental|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
10039347|NCT01843088|Placebo Comparator|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
10039348|NCT01843101|Other|Healthy volunteers|10 healthy volunteers
10039349|NCT01843101|Other|Corneal Neovascularisation|5 patients with corneal neovascularisation
10039350|NCT01843101|Other|Keratoconus|5 patients with keratoconus
10039351|NCT01843114|Other|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
10039352|NCT01843114|Other|Healthy subjects|24 healthy age-and sex- matched control subjects
10039353|NCT01843127|Active Comparator|Placebo, Ranolazine, Exenatide|
10039354|NCT01843127|Active Comparator|Ranolazine, Placebo, Exenatide|
10039355|NCT01843140||Young female cancer survivors|
10039356|NCT01843153|Other|intermittent|injection of ropivacaine on demand
10039357|NCT01843153|Other|continuous|continuous ropivacaine infusion
9538348|NCT03132610|Placebo Comparator|control group|Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
9616199|NCT04280783|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
9616200|NCT04280783|Other|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
9616201|NCT04270084|Other|Treatment|Participants will be asked use a mobile health (m-health) app for 2 months. The app is designed to provide weekly education and motivation about healthful diet and physical activity behaviors in adolescents and their parent/adult caretaker. Both adolescent and parent/adult caretaker participants will use the app to enter weekly self-report data, set healthy eating and exercise goals, and receive educational and motivational content. Participants will conduct a weekly self-assessment of waist circumference, diet, and physical activity during the 2 month trial.
9484308|NCT02229929|Experimental|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
9484311|NCT02227290|Experimental|Naftin Cream, 2%|Once Daily
9484312|NCT02227290|Placebo Comparator|Placebo Cream|Once Daily
9484313|NCT02224235|Experimental|Group 1- COBRA 1 week DAPT|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
9484314|NCT02224235|Active Comparator|Group 2 - DES 6 month DAPT|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
9484315|NCT02224235|Experimental|Group 3 - COBRA Aspirin|COBRA PzF coronary stent followed by aspirin alone
9484316|NCT02223182|Experimental|Viaskin Milk 150 mcg|
9484317|NCT02223182|Experimental|Viaskin Milk 300 mcg|
9484318|NCT02223182|Experimental|Viaskin Milk 500 mcg|
9484319|NCT02223182|Placebo Comparator|Viaskin Placebo|
9484320|NCT02223039|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
9484321|NCT02223039|Experimental|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
9484322|NCT02223039|Placebo Comparator|Placebo|Subject to receive placebo intravenously
9484323|NCT02222948|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
9484324|NCT02222948|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
9484325|NCT02222948|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
9484326|NCT02222948|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
9484327|NCT02222948|Placebo Comparator|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
9484328|NCT02221232|Experimental|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
9484329|NCT02221232|Experimental|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
9484330|NCT02221232|Placebo Comparator|ZuraPrep Vehicle|ZuraPrep without IPA
9484331|NCT02221232|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
9484332|NCT02217228|Experimental|Sebacia microparticles and laser|Gold microparticle suspension + laser treatment x 3 over the course of two weeks
9484333|NCT02217228|Experimental|Vehicle suspension and laser|Vehicle suspension + laser treatment x 3 over the course of two weeks
9484334|NCT02217228|Experimental|Sebacia microparticles without laser|Gold microparticle suspension treatment x 3 over the course of two weeks
9484335|NCT02214550|No Intervention|Pain Discovery Aim|"This arm will receive no treatments and will be used as reference to compare to the other groups.~255 Reproductive age women (18-45) will be identified and divided into 5 groups~Healthy Controls~Chronic Pain (Positive Controls)~Dysmenorrhea (D)~Dysmenorrhea with Cross Organ Sensitization (D+COS)~Painful bladder syndrome (PBS)/interstitial cystitis (IC)~After a screening, dysmenorrhea with COS and PBS participants will be compared with controls. Daily Diaries will be completed for 1-3 months. During the luteal phase of the participants' menstrual cycle or a predetermined time, participants will complete aim #1 testing consisting of a battery of questionnaires, bladder sensitivity testing, quantitative sensory testing (QST), a blood draw and EEG testing. All participants will also complete a yearly follow-up questionnaire for 5 years."
9484336|NCT02214550|No Intervention|D+COS-no OC|For Aim #2, ten participants in the Dysmenorrhea + COS group will not receive an OC intervention. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
9484337|NCT02214550|Active Comparator|D+COS-cyclic microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive cyclic OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
9484338|NCT02214550|Active Comparator|D+COS-continuous microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
9484339|NCT02214550|Active Comparator|PBS-continuous microgestin 1/20|For Aim #2, 26 participants in the Painful Bladder Syndrome group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
9484340|NCT02213354|Experimental|Group 2|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
9484341|NCT02213354|Experimental|Group 6|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
9484342|NCT02213354|Experimental|Group 5|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
9484343|NCT02213354|Experimental|Group 4|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
9484344|NCT02213354|Experimental|Group I|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant intramuscularly (IM) on Day 1, Day 29 and Day 169
9484345|NCT02213354|Experimental|Group 3|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
9484346|NCT02213003|Experimental|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
9484347|NCT02212951|Experimental|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
9484348|NCT02212951|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
9484349|NCT02212951|Active Comparator|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
9484350|NCT02212951|Experimental|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
9484351|NCT02211508|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
9484352|NCT02211508|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
9484353|NCT02210806|Active Comparator|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
9484354|NCT02210806|Active Comparator|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
9484355|NCT02210806|Placebo Comparator|Placebo|One inhalation of placebo DPI . Total 0 mcg
9484356|NCT02210806|Active Comparator|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
9484357|NCT02210806|Active Comparator|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
9484358|NCT02210273|Experimental|Treatment|Subjects undergoing treatment with the Solace Bladder Control (Vesair) Balloon on day 0
9484359|NCT02210273|Sham Comparator|Solace Sham Treatment|Subjects undergoing sham treatment on day 0, and treatment with the Solace Bladder Control (Vesair) Balloon at 3 months
9484360|NCT02207257|Experimental|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
9484361|NCT02207257|Experimental|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
9484362|NCT02207257|Experimental|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
9484363|NCT02207257|Experimental|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
9484364|NCT02207257|Experimental|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
9484365|NCT02206100|Experimental|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
9484366|NCT02206100|Experimental|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
9484367|NCT02206100|Experimental|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
9484368|NCT02206100|Experimental|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
9484369|NCT02206087|Experimental|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
9484370|NCT02206087|Experimental|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
9484371|NCT02206087|Experimental|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
9484372|NCT02206087|Experimental|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
9484373|NCT02206087|Experimental|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
9484374|NCT02206087|Experimental|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
9484375|NCT02205840|Experimental|SI-614|
9484376|NCT02205840|Placebo Comparator|Placebo Vehicle|
9484377|NCT02205528|Placebo Comparator|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
9484378|NCT02205528|Experimental|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
9484379|NCT02205528|Active Comparator|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
9497940|NCT03470428||Adult Fontan Patients|Participants ages 18 to 60 who have had Lateral Tunnel or Extracardiac Fontan procedures.
9497941|NCT03470415||Group A|Patients with type 2 diabetes milletus with normoalbuminuria.
9497942|NCT03470415||Group B|Patients with type 2 diabetes milletus with microalbuminuria.
9497943|NCT03470415||Group C|Patients with type 2 diabetes milletus with macroalbuminuria.
9497944|NCT03470402|Experimental|Intervention group|"Women who screen as eligible for BRCA genetic counseling will receive the education and decision support tool, RealRisks, along with standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).~The enrolled health care providers of these women will be given access to BNAV, which summarizes their enrolled patients' breast cancer risk profiles and provides educational resources on genetic testing and prevention options. Before their clinical encounter with an enrolled patient, these providers will also be sent the personalized breast cancer risk summary that is created by data the patient entered into RealRisks."
9497945|NCT03470402|Active Comparator|Control group|Women who screen as eligible for BRCA genetic counseling will receive standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
9497946|NCT03470389|Experimental|HVPG|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
9497947|NCT03470376|Experimental|Nutraceutical combination (NC)|Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months
10039358|NCT01843166|Active Comparator|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
10039359|NCT01843166|Placebo Comparator|Control group|These patients will utilize a pessary with an inactive placebo cream.
10039360|NCT01843179|Experimental|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
10039361|NCT01843218|Other|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
10039362|NCT01843231|Experimental|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
10039363|NCT01843231|Active Comparator|Diet and exercise Control Group|Diet and Exercise only control group
10039364|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
10039365|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
10039366|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
10039367|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
10039368|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
10039369|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
10039370|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
10039371|NCT01843270|Experimental|ideal body weight|LMA size based on ideal body weight
10039372|NCT01843270|Experimental|actual body weight|LMA size according to actual body weight
10058414|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
9484380|NCT02205099|Experimental|SKL15508 High Dose|SKL15508 High Dose
9484381|NCT02205099|Experimental|SKL15508 Medium Dose|SKL15508 Medium Dose
9484382|NCT02205099|Experimental|SKL15508 Low Dose|SKL15508 Low Dose
9484383|NCT02205099|Placebo Comparator|Placebo|Placebo
9484384|NCT02204345|Experimental|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve [AUC] of 6 mg/milliliter [mL]*minute) and paclitaxel 200 mg per square meter (mg/m^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
9484385|NCT02200380|Experimental|CDX-301|
9484386|NCT02200380|Experimental|CDX-301 and plerixafor|
9484387|NCT02193139|Experimental|WL8713, 6 mg|6 mg WL8713 administered daily
9484388|NCT02193139|Experimental|WL8713, 12 mg|12 mg WL8713 administered daily
9484389|NCT02193139|Experimental|WL8713, 18 mg|18 mg WL8713 administered daily
9484390|NCT02193139|Experimental|WL8713, 24 mg|24 mg WL8713 administered daily
9484391|NCT02193139|Placebo Comparator|Placebo|placebo administered daily
9484392|NCT02191878|Experimental|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.~Phase 2 - dose expansion at the MTD."
9484393|NCT02187302|Experimental|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:~CRLX101 15 mg/m^2 IV on days 1 and 15 of a 28-day cycle;~bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
9484394|NCT02187302|Active Comparator|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
9484395|NCT02187003|Experimental|Rivipansel Treatment Arm|
9484396|NCT02187003|Placebo Comparator|Placebo Treatment Arm|
9484397|NCT02184195|Experimental|Olaparib|Olaparib tablets po. 300 mg twice daily
9484398|NCT02184195|Placebo Comparator|Placebo|Placebo tablets twice daily
9484399|NCT02184156|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL intra-articular injection of Ampion
9484400|NCT02184156|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
9484401|NCT02179749|Active Comparator|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
9484402|NCT02179749|Placebo Comparator|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
9484403|NCT02179151|Placebo Comparator|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
9538349|NCT03132701|Active Comparator|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
9538350|NCT03132701|Placebo Comparator|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
9538351|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
9538352|NCT03132584|Experimental|Cyclophosphamide and Alemtuzumab|"After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Cyclophosphamide~Alemtuzumab"
9538353|NCT03132558||CTA|Patients with AIS only receieved cerebral CTA exam.
9538354|NCT03132558||CTA+DSA|Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).
9538355|NCT03132545||PCOS|
9538356|NCT03132545||controls|
9538357|NCT03132480|Experimental|hypovolemia|
9538358|NCT03132272|Experimental|Immunoadsorption with Globaffin for Alzheimer Dementia|Immunoadsorption with Globaffin
9538359|NCT03132519|Experimental|Sevo-2.0|This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
9538360|NCT03132519|Experimental|Sevo-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
9538361|NCT03132519|Experimental|Des-2.0|This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
9538362|NCT03132519|Experimental|Des-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
9538363|NCT03132519|Active Comparator|Sevo-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
9538364|NCT03132519|Active Comparator|Des-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
9538365|NCT03132441|Experimental|Cardiac Rehabilitation|"Strength Training for Frailty:~All patients enrolled will be enrolled in 6 weeks of cardiac rehabilitation for the pilot study."
9538366|NCT03132233|Active Comparator|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
9538367|NCT03132233|Placebo Comparator|Placebo|Receives a matched placebo powder to the IMP.
9538368|NCT03132428||P Neonates|Premature (P) neonates [at least 27 weeks but less than 34 weeks of gestational age]
9538369|NCT03132428||TNT Neonates|Term-Near-Term (TNT) neonates at least 34 weeks of gestational age
9538370|NCT03132142|Experimental|Capsaicin|Capsacin (8%) patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
9538371|NCT03132142|Experimental|Trans-cinnamaldehyde|Trans-cinnamaldehyde (10%, dissolved in 90% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
9538372|NCT03132142|Experimental|L-menthol|L-menthol (40%, dissolved in 96% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
9538373|NCT03132142|Placebo Comparator|Vehicle patch|Inert vehicle patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
10058415|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
9538374|NCT03132194|Experimental|DPSG 7.5%|"DPSG 7.5% (Taro Pharmaceuticals USA)~Topical, twice daily on the face for 84 days."
9538375|NCT03132194|Placebo Comparator|Vehicle Gel|"Placebo product (Taro Pharmaceuticals Inc.)~Topical, twice daily on the face for 84 days."
9538376|NCT03132194|Active Comparator|Aczone|"dapsone 7.5~Topical, twice daily on the face for 84 days."
9538377|NCT03132311|Experimental|HIV positive subjects|"300 HIV positive adults with CD4 > 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, >500 cells/mm3).~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
9538378|NCT03132311|Active Comparator|HIV negative subjects|"100 HIV negative adults.~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
9538379|NCT03132506||paper-based patient-reported-outcomes|
9538380|NCT03132506||on web-based patient-reported-outcomes|
9538381|NCT03132376|Experimental|Breakfast Preload Drink|"Participants were given isovolumetric drinks, to consume in the morning after an overnight fast, followed by questionnaires asking throughout the day asking participants of their perceived hunger, fullness, desire to eat, and prospective food consumption, and if they would like to eat again. Four hours following consumption, they were given an ad libitum pasta meal to consume.~The drinks consisted of the following:~Water Preload Drink, Whey Protein Isolate Drink, Micellar Casein Protein Drink, Egg White Isolate Protein Drink, and Egg White Concentrate Protein Drink"
9538382|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
9538383|NCT03132259|Experimental|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
9538384|NCT03132259|Experimental|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
9616202|NCT04268784|Experimental|DNL343|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
9616203|NCT04268784|Placebo Comparator|Placebo|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
10058416|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
9538385|NCT03132324|Experimental|INCB059872 0.5 mg|INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.
9538386|NCT03132324|Experimental|INCB059872 1 mg|INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
9538387|NCT03132324|Experimental|INCB059872 2 mg|INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
9538388|NCT03132207||Pregnant women|Pregnant women attending hospital during pregnancy monitoring and / or being hospitalized in one of the maternity wards associated with the project.
9538389|NCT03132207||Professional|health professionals in charge of the follow-up of these pregnant women and their childbirth.
9538390|NCT03132285|Other|PrePex Day 0 foreskin removal|Day 0 foreskin removal
9538391|NCT03132181|Experimental|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
10039373|NCT01843283|Experimental|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
10039374|NCT01843283|Active Comparator|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
9538392|NCT03132181|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
9538393|NCT03132103|Experimental|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
9538394|NCT03132103|Placebo Comparator|Placebo SSR|Placebo SSR
9538395|NCT03132103|Experimental|Oral Vitamin D3|Oral Vitamin D3
9538396|NCT03132103|Placebo Comparator|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
9538397|NCT03132116|Experimental|Gentamicin|intra-nodal injection of gentamicin
9538398|NCT03132116|Placebo Comparator|Placebo|intra-nodal injection of placebo
9538399|NCT03132168|Other|Subjects undergoing radical cystectomy|Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
9538400|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
9538401|NCT03132064||post total knee arthroplasty|The measurements will made for patients before and after total knee arthroplasty to explore the improvements and possible correlation with preoperative pain psychology and hypersensitivity
9538402|NCT03131804|Experimental|Interventional Participants|Patients will represent their own controls (pre and post intervention), in the HD unit of Al Qassimi Hospital, Sharjah, United Arab Emirates.
9538403|NCT03132025|Experimental|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
9538404|NCT03132025|Active Comparator|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
9538405|NCT03132051|Experimental|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
9538406|NCT03131856|Experimental|Nutritional intervention programme|An individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).
9538407|NCT03131856|No Intervention|Usual care|Usual care which means no individual dietary plan and no nutrition follow-up visits after discharge.
9538408|NCT03131908|Experimental|GSK2636771 + Pembrolizumab|"Phase I: Participants receive the lowest dose level of GSK2636771. Each new group receives a higher dose of GSK2636771 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of GSK2636771 is found. Participants receive the same dose level of Pembrolizumab.~Phase II: Participants receive GSK2636771 at the highest dose that was tolerated in Phase 1. Participants receive the same dose level of Pembrolizumab."
9538409|NCT03131752|Experimental|Intervention Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~The intervention will last 7 days for all the patients. Three phases will be performed: warm up, knee muscle strengthening with elastic bands and stretch/relax."
9538410|NCT03131752|No Intervention|Control Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~Patients will be not receive intervention."
9538411|NCT03131830||Staff of the University Clinic of Tuebingen|Online-based questionnaire
9538412|NCT03131830||Participants of the 9th German Urogynecological Congress|Online-based questionnaire
9538413|NCT03131830||All members of the German Society of Obsetrics and Gynecology|Online-based questionnaire
9538414|NCT03131830||Pregnant women from Tübingen and Heidelberg|Online-based questionnaire
10058417|NCT02018185|Active Comparator|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
10039375|NCT01843296|Active Comparator|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
9538415|NCT03131739||Community Level Assessment|65 communities will undergo assessment of community / structural variables through review of public records and 3-5 key community interviewees per community.
9538416|NCT03131739||Individual Level Assessment|A subset of 6 communities will be elected through a stratification process. Youth will complete a set of protective factors measures and outcomes. Adults will complete a section of the Neighborhood Matters survey.
9538417|NCT03132012|Experimental|Indoor tanning intervention|Web-based intervention modules to discourage tanning.
9538418|NCT03132012|Active Comparator|standard of care control|General information regarding UV protection measures through an online Qualtrics interface. Content will mirror information provided in brochures typically available in a dermatology office or through skin cancer prevention websites.
9538419|NCT03131700|Experimental|RPH-001|A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .
9538420|NCT03131700|Active Comparator|EU sourced Avastin®|A single dose of Avastin® will be administered (IV) 5 mg/kg dose .
10039376|NCT01843296|Active Comparator|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
10039377|NCT01843296|Active Comparator|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
9538421|NCT03131791|Experimental|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
9538422|NCT03131791|Experimental|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
9538423|NCT03131843|Experimental|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
9538424|NCT03131843|Placebo Comparator|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
9538425|NCT03131973|Experimental|Methotrexate|Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
9538426|NCT03131973|Experimental|Cytochrome P450 and Transporter Substrates|Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.
9538427|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
9538428|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score < 9)
9538429|NCT03131882|Experimental|Hyaluronic acid|Hyaluronic acid
9538430|NCT03131882|Active Comparator|Triamcinolone acetonide|10mg/ml Triamcinolone acetonide
9538431|NCT03131661||SpA with DMARDs|Participants with first diagnosis or confirmed diagnosis of Spondyloarthritis (SpA) and naïve to conventional, targeted or biological Disease modifying anti-rheumatic drugs (DMARDs) will be observed in order to describe SpA characteristics and pattern of clinical presentation.
9538432|NCT03131778|Active Comparator|Open Liver Resection|Conventional open liver resection trough subcostal incision
9538433|NCT03131778|Experimental|Laparoscopic Liver Resection|Pure laparoscopic liver resection without hand assistance
9538434|NCT03131674|Experimental|Direct treatment|
9538435|NCT03131674|Experimental|Delayed treatment|
9538436|NCT03131765|Experimental|YS-ON-001|"Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur.~Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer"
9538437|NCT03131635|Experimental|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
9538438|NCT03131635|No Intervention|Delayed Treatment Group (DTG)|
10039378|NCT01843309|Experimental|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
9538439|NCT03131622|Experimental|Digital Therapeutics|Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
9538440|NCT03131622|No Intervention|Control|
9538441|NCT03131284|No Intervention|Control|Families of newborns whose paediatrician is assigned to the control arm, receive usual education about nutrition and lifestyle, during their child's first two years of life.
9538442|NCT03131284|Experimental|Intensive education.|Families of newborns whose paediatrician is assigned to the intervention arm, receive standardized lifestyle counseling along with educational written material about their child's first two years of life, which corresponds to the experimental treatment.
9538443|NCT03131271|Experimental|Experimental Group|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter. Immediately after its removal, the responsible nurse removed the catheter. A neutral instruction set was used on each patient prior to application of the ice pack. Patients in the experimental group were told that they may or may not experience pain during the catheter removal. The patients were also told that the aim of the study was to measure the effect of ice bag application upon pain during catheter removal, and that ice pack application may or may not be effective in terms of their own pain.
9616204|NCT04266054|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care
9538444|NCT03131271|No Intervention|Control Group|The control group received the standard clinic procedure in that the catheter was removed by the assigned nurse without any cold application to the femoral region. Each control patient was informed that some patients may experience pain during catheter removal, and that they may or may not experience pain. Patients were also told that their pain levels would be measured during catheter removal.
9538445|NCT03131583|Experimental|Cohort 1|Colchicine 0.5 mg Oral Tablet Day-14~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3~Day8 qd.
9538446|NCT03131349||column heading in tables|history examinations investigation:serum zinc and iron
9538447|NCT03131349||row heading in tables|history examinations investigation:serum zinc and iron
9538448|NCT03131258|Other|Donor Nephrectomy|Donor Nephrectomy
9538449|NCT03131336|Experimental|PeproStat|PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
9538450|NCT03131336|Placebo Comparator|Saline|Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
9538451|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
9538452|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
9538453|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
9538454|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
9538455|NCT03131518|Other|E-bicycle|Access to an e-bicycle will be provided.
9538456|NCT03131518|Other|Longtail bicycle|Access to a longtail bicycle will be provided.
9538457|NCT03131518|Other|Traditional bicycle|Access to a traditional bicycle will be provided.
9538458|NCT03131440|Experimental|Experimental Condition #1|core, support calls
9538459|NCT03131440|Experimental|Experimental Condition #2|core, support calls, app+
9538460|NCT03131440|Experimental|Experimental Condition #3|core, support calls, buddy
9538461|NCT03131440|Experimental|Experimental Condition #4|core, support calls, online gym
9538462|NCT03131440|Experimental|Experimental Condition #5|core, support calls, app notifications
9538463|NCT03131440|Experimental|Experimental Condition #6|core, app+
9538464|NCT03131440|Experimental|Experimental Condition #7|core, app+, buddy
9538465|NCT03131440|Experimental|Experimental Condition #8|core, app+, online gym
9538466|NCT03131440|Experimental|Experimental Condition #9|core, app+, app notifications
9538467|NCT03131440|Experimental|Experimental Condition #10|core, buddy
9538468|NCT03131440|Experimental|Experimental Condition #11|core, buddy, online gym
9538469|NCT03131440|Experimental|Experimental Condition #12|core, buddy, app notifications
9538470|NCT03131440|Experimental|Experimental Condition #13|core, online gym
9538471|NCT03131440|Experimental|Experimental Condition #14|core, online gym, app notifications
9538472|NCT03131440|Experimental|Experimental Condition #15|core, app notifications
9538473|NCT03131440|Experimental|Experimental Condition #16|core, support calls, app+, buddy
9538474|NCT03131440|Experimental|Experimental Condition #17|core, support calls, app+, online gym
9538475|NCT03131440|Experimental|Experimental Condition #18|core, support calls, app+, app notifications
9538476|NCT03131440|Experimental|Experimental Condition #19|core, support calls, buddy, online gym
9538477|NCT03131440|Experimental|Experimental Condition #20|core, support calls, buddy, app notifications
9538478|NCT03131440|Experimental|Experimental Condition #21|core, support calls, online gym, app notifications
9538479|NCT03131440|Experimental|Experimental Condition #22|core, app+, buddy, online gym
9538480|NCT03131440|Experimental|Experimental Condition #23|core, app+, buddy, online gym, app notifications
9538481|NCT03131440|Experimental|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
9538482|NCT03131440|Experimental|Experimental Condition #25|core, buddy, online gym, app notifications
9538483|NCT03131440|Experimental|Experimental Condition #26|core, app+, online gym, app notifications
9538484|NCT03131440|Experimental|Experimental Condition #27|core, support calls, app+, buddy, online gym
9538485|NCT03131440|Experimental|Experimental Condition #28|core, support calls, app+, buddy, app notifications
9538486|NCT03131440|Experimental|Experimental Condition #29|core, support calls, app+, online gym, app notifications
9538487|NCT03131440|Experimental|Experimental Condition #30|core
9538488|NCT03131440|Experimental|Experimental Condition #31|core, app+, buddy, app notifications
9538489|NCT03131440|Experimental|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
9538490|NCT03131544|Experimental|FLA for BPH Active Treatment|
9538491|NCT03131557|Experimental|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
9538492|NCT03131557|Active Comparator|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
9538493|NCT03131297|Experimental|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
9538494|NCT03131375|Active Comparator|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
9616205|NCT04266054|No Intervention|Control|The comparison group will receive usual clinical care.
10039379|NCT01843309|Placebo Comparator|Placebo|Placebo twice a day orally
10039380|NCT01843309|Experimental|Spironolactone 100mg|Spironolactone 100mg once a day
10039381|NCT01843322|Experimental|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
10039382|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
10039383|NCT01843387|Experimental|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
10039384|NCT01843387|Experimental|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
10039385|NCT01843400||Group 1|
10039386|NCT01843426|Experimental|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
10039387|NCT01843439|Experimental|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.~popularize and educate the asthma action plan~run a emergency call system for acute exacerbation~educate the proper techniques using inhalers~correct the deficiency of magnesium (magnesium 500mg per day)"
10039388|NCT01843452|Experimental|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
10039389|NCT01843478|Experimental|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
10058418|NCT02018185|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation
9484404|NCT02179151|Experimental|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
9484405|NCT02179151|Experimental|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
9484406|NCT02178098|Experimental|ETC-1002|ETC-1002 180 mg/day
9484407|NCT02178098|Placebo Comparator|Placebo|Placebo control
9484408|NCT02172872|Active Comparator|standard combination chemotherapy|
9484409|NCT02172872|Experimental|decitabine|
9484410|NCT02163746|Active Comparator|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
9484411|NCT02163746|Active Comparator|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
9484412|NCT02161627|Experimental|Automatic Control|Automatic Control using Saluda Medical External Trial System
9484413|NCT02161627|Active Comparator|Manual Control|Manual Control using Saluda Medical External Trial System
9484414|NCT02161419|Active Comparator|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
9484415|NCT02161419|Placebo Comparator|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
9484416|NCT02160678|Active Comparator|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
9484417|NCT02160678|Other|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
9484418|NCT02160678|Placebo Comparator|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
9484419|NCT02160665|Placebo Comparator|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
9484420|NCT02160665|Other|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
9484421|NCT02160665|Active Comparator|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
9484422|NCT02160262|Experimental|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
9484423|NCT02154412|Experimental|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
9484424|NCT02154412|No Intervention|No respiratory training|Participants will not participate in the respiratory muscle training.
9484425|NCT02153502|Experimental|AVP-786|
9484426|NCT02153502|Placebo Comparator|Placebo|
9484427|NCT02151474|Experimental|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
9484428|NCT02151474|Experimental|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
9484429|NCT02151474|Experimental|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
9484430|NCT02151474|Experimental|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
9484431|NCT02145364|Experimental|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
9484432|NCT02144181|Active Comparator|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
10039390|NCT01843478|Placebo Comparator|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
9538495|NCT03131375|Placebo Comparator|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
9538496|NCT03131427||Wilson's Disease|Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.
9538497|NCT03131427||Hereditary Hemochromatosis|Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.
9538498|NCT03131427||Hereditary Hyperbilirubinemias|Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).
9538499|NCT03131427||Inherited Cholestatic Liver Disease|Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).
9538500|NCT03131427||Other genetic/metabolic liver diseases|Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.
9538501|NCT03130998|Active Comparator|Control - Group A|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
9538502|NCT03130998|Experimental|Intervention - Group B|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive individualized support through a remote knowledge broker (rKB) communicating via interactive technology. The rKB will be certified in tobacco cessation counseling through CAMH's TEACH program and will have completed a specialty course on tobacco addiction treatment in those with mental illness. The rKB will have access to the CAMH network of KBs (e.g. Evidence Exchange Network ) for guidance and support, as this has been shown to be important for KB success.
9538503|NCT03131011|Experimental|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
9538504|NCT03131011|No Intervention|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
9538505|NCT03131115|Active Comparator|Lateral Crural Strut Graft|Lateral crura strut graft is a well described and universally used technique involves strengthening lateral crus of lower lateral cartilage of the nose with piece of cartilage.
9538506|NCT03131115|Active Comparator|Bone-Anchored suspension|Bone- Anchored suspension is a well described surgical technique which involves anchoring the nasal sidewall to the bony rim below the eye.
9538507|NCT03131128|Experimental|Mindfulness-based Intervention|2 sessions of diet nutrition education and 6 sessions of Mindfulness-based intervention, 1.5 hours each session.
9538508|NCT03131128|Active Comparator|Health Education Intervention|2 sessions of diet nutrition education and 6 sessions of Health Education, 1.5 hours each session.
9538509|NCT03130920|No Intervention|Control|
9538510|NCT03130920|Active Comparator|Remote ischemic preconditioning|
9538511|NCT03130920|Active Comparator|Local ischemic preconditioning|
9538512|NCT03131102||Patients with epithelial ovarian cancer (EOC)|Patients undergoing cytoreductive surgery due to epithelial ovarian cancer
9538513|NCT03131102||Subgroup - Metabolomics in EOC patients without ascites|In a subgroup (n=10), patients without preoperative ascites will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
10039391|NCT01843491|Experimental|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
10039392|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
10039393|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
10039394|NCT01843530|Experimental|Group 1|Cortisone, Clemastin + BERINERT
10039395|NCT01843530|Placebo Comparator|Group 2|Cortinsone, Clemastin + NaCl
10039396|NCT01843543|Experimental|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
9538514|NCT03131102||Subgroup - Metabolomics in EOC patients with ascites >500ml|In a subgroup (n=10), patients with preoperative ascites >500ml will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
9538515|NCT03130933|Active Comparator|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
9538516|NCT03130933|Placebo Comparator|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
9538517|NCT03130933|Active Comparator|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
9538518|NCT03130933|Placebo Comparator|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
9538519|NCT03130894||Healthy control|A FPG concentration < 6.1 mmol/l, and a 2-h oral glucose tolerance test (OGTT) plasma glucose concentration < 7.8 mmol/l was considered normal glucose tolerance.
9538520|NCT03130894||Type 2 diabetes|Type 2 diabetes was diagnosed when fasting plasma glucose (FPG) ≥ 7.0 mmol/l, and/or 2-h post-glucose load ≥ 11.1 mmol/l.
9538521|NCT03131050|Experimental|High-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
9538522|NCT03131050|Experimental|Low-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) QD; placebo (1 ml saline, i.m.) QD; escitalopram （10 mg/d p.o.）QD
9538523|NCT03131050|Placebo Comparator|Placebo add-on therapy|Placebo (1 ml saline, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
9538524|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
9538525|NCT03131180|Experimental|RLHS dashboard|Patients randomized to RLHS website access are given instructions on how the RLHS dashboard works both by phone and by email and are given open access to the RLHS dashboard website immediately after enrollment and before meeting with the CCPR clinical team for their consultation. Each user has an access code, which allows them to track their access. They maintain access to the website throughout their care in the CCPR. Patients in the RLHS access group complete the System Usability Scale (SUS; a 10 item questionnaire to evaluate software, websites, and applications) after use of the RLHS at consultation. Those in the RLHS access group also complete a 7-item exit interview either via phone or on REDCap.
9538526|NCT03131180|No Intervention|Standard consultation alone|Those not randomized to RLHS access undergo standard consultation only.
9538527|NCT03131037|Experimental|Study Arm|AdV-tk (aglatimagene besadenovec) + valacyclovir
9538528|NCT03131141|Experimental|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
9538529|NCT03131141|Experimental|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
9538530|NCT03131193|No Intervention|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
9538531|NCT03131193|Experimental|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
9538532|NCT03131193|Experimental|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
9538533|NCT03131193|Experimental|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
9538534|NCT03131193|Experimental|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
9538535|NCT03131193|Experimental|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
9538536|NCT03131024|Experimental|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
9538537|NCT03131024|Experimental|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
9538538|NCT03131024|No Intervention|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
9538539|NCT03130907|Active Comparator|Stent|
9538540|NCT03130907|Experimental|No stent|
9538541|NCT03130946|Experimental|Cryo-assisted core needle biopsy|Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.
9538542|NCT03130946|Active Comparator|Fine needle aspiration alone|Patients undergo lymph node biopsy with FNA alone.
9538543|NCT03130881|Experimental|PLB1003|ALK-positive (ALK+) advanced NSCLC
9538544|NCT03130972||developmental delay|Children who visited tertiary rehabilitation clinic for delayed motor development were all included.
10039397|NCT01843543|No Intervention|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
9538545|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
9538546|NCT03130751|Experimental|Mobile application|
9538547|NCT03130855|Experimental|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
9538548|NCT03130855|Active Comparator|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
9538549|NCT03130803|No Intervention|Baseline|9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
9538550|NCT03130803|Experimental|Insufficient Sleep|2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
9538551|NCT03130842|Active Comparator|Sublingual alprazolam|
9538552|NCT03130842|Active Comparator|Oral midazolam|
9538553|NCT03130829|Experimental|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
9538554|NCT03130829|Placebo Comparator|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
9538555|NCT03130816|Experimental|allogeneic cord blood transplantation|"Intravenous(IV) infusion will be done by the following method A. After 4 hours of fasting, subjects will be sedated with chloral hydrate (Pocral®) syrup B. Intravenous infusion will be conducted in stem cell center, CHA Bundang Medical Center and the therapy will be performed by the Principal Investigator or a physician delegated from the Principal Investigator. The physician conducting the infusion will not participate in the efficacy and result analysis of this study.~C. Oxygen saturation will be monitored during therapy."
9538556|NCT03130764|Experimental|Durvalumab/Tremelimumab|Patients with resected stage IB-IIIA NSCLC who have completed standard adjuvant therapy (as recommended by the treating physician) to receive durvalumab-tremelimumab will be enrolled. Patients will receive durvalumab (20 mg/kg) intravenously every 4 weeks for 1 year and tremelimumab (1 mg/kg) intravenously every 4 weeks for 4 doses.
9538557|NCT03130725|Experimental|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
9538558|NCT03130725|Active Comparator|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
9538559|NCT03130712|Experimental|GPC3-CART cells|
9538560|NCT03130504|Active Comparator|17α hydroxy progesterone caproate group|
9538561|NCT03130504|No Intervention|No intervention group|
9538562|NCT03130491|Other|TAVR + Embolic protection|subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
9538563|NCT03130465||Aripiprazole Once Monthly (AOM)|Schizophrenia patients who initiated maintenance treatment with AOM during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
9538564|NCT03130465||Daily oral atypical AP|Schizophrenia patients who initiated maintenance treatment with any daily oral atypical AP during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
9538565|NCT03130634|Experimental|prescription of silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
9538566|NCT03130634|No Intervention|control|During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy
9538567|NCT03130569|No Intervention|Control Group|Will simply complete surveys at baseline and at the three-month follow-up.
9538568|NCT03130569|Experimental|Web-based Module Group|Participants will complete surveys at baseline. Participants in this arm will be provided with information to access and complete a web-based educational module (AKA the intervention), at the end of which will be given the opportunity to request and complete genetic testing for skin cancer. Participants who elect to complete the genetic testing will receive their genetic testing results along with a two-week follow-up call. All participants will also complete the survey at the three month follow-up.
9538569|NCT03130556|Experimental|Glasdegib BE and Food|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet after a high fat, high calorie meal.
9538570|NCT03130556|Experimental|Glasdegib BE and PPI Effect|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet in the fasted state after repeated daily dosing with rabeprazole.
9538571|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
9538572|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
9538573|NCT03130543|No Intervention|Standard Formula|This is the group of subjects randomized to receive their standard formula
9538574|NCT03130543|Experimental|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
9538575|NCT03130543|Experimental|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
9538576|NCT03130452|Active Comparator|concomitant group|lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.
9538577|NCT03130452|Experimental|tailored treatment group I|23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.
9538578|NCT03130452|Experimental|tailored treatment group II|23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.
9538579|NCT03130647|Experimental|Focused ultrasound|Repeated measures sham control
10039398|NCT01843556|Experimental|E2022 Tape Formulation|
10039399|NCT01843569|Experimental|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
9484433|NCT02144181|Active Comparator|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
9484434|NCT02144181|Active Comparator|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
9484435|NCT02144181|Active Comparator|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
9484436|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
9484437|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
9484438|NCT02142959|Placebo Comparator|Lotion vehicle/Placebo|Lotion vehicle/placebo will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
9484439|NCT02137343|Experimental|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
9484440|NCT02137343|Placebo Comparator|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
9484441|NCT02135536|Experimental|NGM282 Dose 1|NGM282 Dose 1
9484442|NCT02135536|Experimental|NGM282 Dose 2|NGM282 Dose 2
9484443|NCT02135536|Experimental|NGM282 Dose 3|NGM282 Dose 3
9484444|NCT02130687|Active Comparator|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
9484445|NCT02130687|Experimental|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
9484446|NCT02130687|Active Comparator|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
9484447|NCT02128113|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days
9484448|NCT02128113|Experimental|0.5% omaveloxolone (RTA 408) opthalmic suspension|0.5% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
9484449|NCT02128113|Experimental|1% omaveloxolone (RTA 408) opthalmic suspension|1% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
9484450|NCT02125266|Experimental|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
9484451|NCT02125266|Experimental|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
9484452|NCT02125253|Experimental|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
9484453|NCT02125253|Active Comparator|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
9484454|NCT02125253|Placebo Comparator|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
9484455|NCT02116998|Experimental|GEN-004 with Aluminum Hydroxide|
9484456|NCT02116998|Placebo Comparator|Placebo|
9484457|NCT02116244|Experimental|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
9484458|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484459|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484460|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484461|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484462|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484463|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
9484464|NCT02114060|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
9484465|NCT02110368|Active Comparator|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
9484466|NCT02110368|Experimental|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
9484467|NCT02110212|Active Comparator|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
9484468|NCT02110212|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
9484469|NCT02109406|Experimental|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
9484470|NCT02109406|Experimental|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
10039400|NCT01843595|Experimental|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
10039401|NCT01843595|No Intervention|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
10039402|NCT01843608|No Intervention|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.~They cannot change physical activity and nutritional habits."
10039403|NCT01843608|Experimental|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.~They have to present an attendance above or equal to 80%."
10039404|NCT01843647|Experimental|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
10039405|NCT01843647|Active Comparator|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
10039406|NCT01843686|Experimental|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
9484471|NCT02109406|Placebo Comparator|Placebo MDI|Placebo MDI administered as two inhalations BID
9484472|NCT02109016|Experimental|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
9484473|NCT02106546|Experimental|Veliparib + Carboplatin + Paclitaxel|Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
9484474|NCT02106546|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
9484475|NCT02104388|Experimental|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
9484476|NCT02104388|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
9484477|NCT02104336|Experimental|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
9484478|NCT02104245|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
9484479|NCT02104245|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
9484480|NCT02104076|Experimental|Evolution® Biliary Stent-Fully Covered|
9484481|NCT02104050|Placebo Comparator|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
9484482|NCT02104050|Experimental|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
9484483|NCT02103322|Experimental|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
9484484|NCT02103322|Active Comparator|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
9484485|NCT02101268|Experimental|Arm 1: Momelotinib|Participants will receive momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
9484486|NCT02101268|Active Comparator|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
9484487|NCT02100436|Experimental|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
9484488|NCT02100436|Experimental|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
9484489|NCT02100436|Experimental|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
9484490|NCT02100150|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
9484491|NCT02100150|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
9484492|NCT02098473|Experimental|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
9484493|NCT02098473|Experimental|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
9484494|NCT02098473|Placebo Comparator|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
9484495|NCT02098278|Experimental|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
9484496|NCT02096666|Experimental|Single arm|
9484497|NCT02093429|Experimental|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
9484498|NCT02093429|Experimental|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
9484499|NCT02093429|Experimental|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
9484500|NCT02092935|Experimental|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
9484501|NCT02092935|Active Comparator|Vancomycin|125 mg capsule four times a day for 10 days
9484502|NCT02092922|Experimental|Filanesib|
9484503|NCT02092454|Experimental|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
9484504|NCT02092454|Placebo Comparator|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
9484505|NCT02092077|Experimental|TV-1106 0.554 mg|
9484506|NCT02092077|Experimental|TV-1106 0.924 mg/kg|
9484507|NCT02092077|Experimental|TV-1106 1.20 mg/kg|
9484508|NCT02092077|Active Comparator|somatropin 0.033 mg/kg/day|Dosages may be adjusted according to findings and as necessary
9484509|NCT02089425|Placebo Comparator|Placebo|Placebo patch: 0% indomethacin
9484510|NCT02089425|Experimental|K-103-IP|K-103-IP: 0.5% indomethacin
9484511|NCT02083289|Experimental|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
9484512|NCT02083289|Active Comparator|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
9484513|NCT02081703|Experimental|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
9484514|NCT02081703|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
9484515|NCT02081703|Experimental|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
9484516|NCT02081703|Placebo Comparator|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
9484517|NCT02081300|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
9484518|NCT02081300|Other|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
9484519|NCT02081118|Experimental|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
9484520|NCT02081118|Experimental|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
9484521|NCT02081118|Experimental|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
9484522|NCT02081118|Placebo Comparator|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
9484523|NCT02078674|Experimental|Group A|Placebo
9484524|NCT02078674|Experimental|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
9484525|NCT02078674|Experimental|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
9484526|NCT02078674|Experimental|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
9484527|NCT02078674|Experimental|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
9484528|NCT02078674|Experimental|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
9484529|NCT02078674|Experimental|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
9484530|NCT02078674|Experimental|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
9484531|NCT02078310|Experimental|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
9484532|NCT02078310|Placebo Comparator|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
9484533|NCT02078310|Experimental|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
9484534|NCT02078310|Placebo Comparator|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
9484535|NCT02077881|Experimental|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.~Phase 2 portion:~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
9484536|NCT02075281|Experimental|HM11260C|HM11260C 4 mg weekly sc injection
9484537|NCT02075281|Placebo Comparator|Placebo|Placebo weekly sc injection
9484538|NCT02075281|Experimental|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
9484539|NCT02075281|Experimental|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
9484540|NCT02075281|Experimental|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
9484541|NCT02074579|Experimental|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
9484542|NCT02074579|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
9484543|NCT02074410|Experimental|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
9484544|NCT02074410|Experimental|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
9484545|NCT02074410|Experimental|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
9484546|NCT02074410|Placebo Comparator|Placebo|Orally administering placebo daily for 28 days
9484547|NCT02074007|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
9484548|NCT02074007|Placebo Comparator|Placebo Comparator|"Topical ear drops~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
9484549|NCT02073123|Experimental|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).~Patients will continue until they experience disease progression or limiting toxicity."
9484550|NCT02073123|Experimental|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
9484551|NCT02073123|Experimental|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.~Nivolumab administered intravenously at 240 mg every 2 weeks."
9484552|NCT02072954|Experimental|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
10039407|NCT01843686|Placebo Comparator|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
10039408|NCT01843699|Experimental|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
9484553|NCT02072954|Active Comparator|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
9484554|NCT02072863|Experimental|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
9484555|NCT02072161|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
9484556|NCT02072161|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
9484557|NCT02072161|Placebo Comparator|Placebo|Orally, once daily in morning
9484558|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
9484559|NCT02067793|Placebo Comparator|Placebo|Placebo
9484560|NCT02067793|Experimental|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
9484561|NCT02067793|Experimental|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
9484562|NCT02067793|Experimental|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
9484563|NCT02066545|Placebo Comparator|Vehicle Gel|
9484564|NCT02066545|Experimental|CLS001 topical gel 1%|Topical application once daily
9484565|NCT02066545|Experimental|CLS001 topical gel 1.75%|Topical application once daily
9484566|NCT02066545|Experimental|CLS001 topical gel 2.5%|Topical application once daily
9484567|NCT02065869|Experimental|BPX-501 T cells and rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).~Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
9484568|NCT02065375|Experimental|RTA 408 0.5% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 0.5% or Placebo) in the study eye for 14 days
9484569|NCT02065375|Experimental|RTA 408 1.0% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 1.0% or Placebo) in the study eye for 14 days
10039409|NCT01843699|Placebo Comparator|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
10039410|NCT01843725|Experimental|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
9484572|NCT02064426|Experimental|Molidustat (BAY85-3934)|
9484573|NCT02064426|Active Comparator|Epoetin alfa/beta|
10039411|NCT01843725|Experimental|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
10039412|NCT01843738|Experimental|All participants|
9484574|NCT02063997|Experimental|Arhalofenate 600 mg|
9484575|NCT02063997|Experimental|Arhalofenate 800 mg|
9484576|NCT02063997|Active Comparator|Allopurinol 300 mg; colchicine 0.6 mg|
9484577|NCT02063997|Active Comparator|Allopurinol 300 mg|
9484578|NCT02063997|Placebo Comparator|Placebo|
9484579|NCT02063295|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
9484580|NCT02063295|Experimental|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
9484581|NCT02062060|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
9484582|NCT02062060|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
9484583|NCT02061332|Experimental|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
9484584|NCT02061332|Experimental|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
9497948|NCT03470376|Active Comparator|No nutraceutical combination (noNC)|Patients on standardized diet regimen without taking any NC
9497949|NCT03470363|Active Comparator|Group Spinal anesthesia|"Knee surgery under spinal anesthesia~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
9538580|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
9538581|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
9538582|NCT03130608|Experimental|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
9538583|NCT03130608|No Intervention|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
9538584|NCT03130673||hip fracture|fracture of proximal femur
9538585|NCT03130660|Experimental|Short Axis Ultrasonography|one person does both ultrasound and line insertion
9538586|NCT03130660|Experimental|Long Axis Ultrasonography|one person does ultrasound and another inserts the central line
9538587|NCT03130426|Experimental|Intervention|Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise
9538588|NCT03130426|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
9538589|NCT03130582||Disease status at mobilization PR|
9538590|NCT03130582||Disease status at mobilization PD|
9538591|NCT03130517|Other|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
9538592|NCT03130517|Other|Control group|Control group will recieve phototherapy only
9538593|NCT03130413|Experimental|Ambu Aura Gain|Ambu Aura Gain supraglottic airway size 2 or 2.5 will be inserted once patients are paralyzed
9538594|NCT03130413|Active Comparator|Air-Q|Air-Q supraglottic airway size 1.5 and 2.0will be inserted once the patients are paralyzed
9538595|NCT03130400||Normal|This group is control group. Participants in this group do not have knee diseases or any other bad injuries in lower limbs.
9538596|NCT03130400||KOA|Participants in this group have knee osteoarthritis and have no other bad injuries in lower limbs.
9538597|NCT03130400||ACLD|Participants in this group have anterior cruciate ligament deficiency with or without meniscus deficiency and have no other bad injuries in lower limbs.
9538598|NCT03130400||MD|Participants in this group have meniscus deficiency and have no other bad injuries in lower limbs.
9538599|NCT03130400||Plica|Participants in this group have plica syndrome and have no other bad injuries in lower limbs.
9538600|NCT03130374|Experimental|Mesenchymal stem cell treated group|Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
9538601|NCT03130374|No Intervention|Control group|Patients treated according to current clinical protocols
9538602|NCT03130387|Other|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
9538603|NCT03130361|Experimental|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
9538604|NCT03130348|Experimental|Treatment (ibrutinib, bortezomib, dexamethasone)|Patients receive ibrutinib PO QD on days 1-28. After 3 courses, patients who achieve partial response repeat treatment every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve partial response after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4, patients who do not achieve partial response also receive bortezomib SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
9538605|NCT03130166|Experimental|Intracorporeal anastomosis|Patients undergo robotic right colectomy with intracorporeal anastomosis.
9538606|NCT03130166|Active Comparator|Extracorporeal anastomosis|Patients undergo robotic right colectomy with extracorporeal anastomosis.
9538607|NCT03130244|Active Comparator|Device Placement|The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
9538608|NCT03130244|No Intervention|Control|The patients in this arm will receive the best medical management.
9538609|NCT03130140|Active Comparator|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
9538610|NCT03130140|Sham Comparator|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
9538611|NCT03130179|Experimental|Nicorette Strongmint lozenge 4mg|A single dose of one nicotine 4 mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
9538612|NCT03130179|Active Comparator|Niquitin Minimint lozenge 4mg|A single dose of one nicotine 4mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
9538613|NCT03130010|Placebo Comparator|The control group|One hour before the end of the operation, the control group was received 20 ml of saline.
10039413|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
10039414|NCT01843790|Placebo Comparator|Placebo, saline|Saline, dosed weekly for 8 weeks
10039415|NCT01843790|Experimental|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
10039416|NCT01843790|Experimental|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
10039417|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
10039418|NCT01843829|Experimental|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions~then surgery.~All drugs will be sourced from local stock"
9538614|NCT03130010|Active Comparator|The Nefopam group|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.
9538615|NCT03130322|Experimental|NightPP|Participants of the NightPP will be subjected to one MRI session and two MEG recording sessions: the first one before a physical practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
9538616|NCT03130322|Experimental|NightMI|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
9538617|NCT03130322|Experimental|NightCtrl|Participants of the NightCtrl will be subjected to one MRI session and two MEG recording sessions: the first one before a mental rotation practice session, a second MEG session right after practice,and second MEG session right after practice.
10039419|NCT01843829|Experimental|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions*~then surgery.~All drugs will be sourced from local stock"
10039420|NCT01843855|Experimental|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
9538618|NCT03130322|Experimental|Day|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
9538619|NCT03130335|Experimental|Bone Marrow Aspirate (BMA) Injection|
9538620|NCT03130218|No Intervention|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
10039421|NCT01843855|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
10058419|NCT02018198||Acute Respiratory Infection|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.
10058420|NCT02018198||Asymptomatic Cohort|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.
9538621|NCT03130218|Experimental|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
9538622|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
9538623|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
9538624|NCT03130153|Experimental|hypertensives on Aspirin mouthwash|
9538625|NCT03130153|Active Comparator|non-hypertensives on Aspirin mouthwash|
9538626|NCT03130153|Active Comparator|hypertensives on Saline mouthwash|
9538627|NCT03130283|Active Comparator|Home Hospitalization|Visit every day at home
9538628|NCT03130283|Placebo Comparator|Conventional Hospitalization|Review Clinical History
9538629|NCT03130114|Placebo Comparator|Control|Placebo mixture, 0.25 ml / kg / day
9538630|NCT03130114|Experimental|Azithromycin|Azithromycin mixture (40 mg / ml), 0.25 ml / kg / day
9538631|NCT03130270|Experimental|Apatinib group|Apatinib mesylate tablet：the starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd).
9538632|NCT03130101|Other|80% basal insulin reduction|
9538633|NCT03130101|Other|50% basal insulin reduction|
9538634|NCT03130101|Other|100% basal insulin reduction|
9538635|NCT03130049|Experimental|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS >3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
9538636|NCT03130049|No Intervention|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
9538637|NCT03130023|Experimental|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
9538638|NCT03129997|Active Comparator|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
9538639|NCT03129997|Placebo Comparator|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
9538640|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
9538641|NCT03129971|Experimental|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
9538642|NCT03129971|Experimental|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
9538643|NCT03129919|Experimental|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
9538644|NCT03129919|Active Comparator|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
9538645|NCT03129841|Experimental|early dinner+Diet|
9538646|NCT03129841|Experimental|late dinner+Diet|
9538647|NCT03129854|Experimental|experimental group|Prostate cryotherapy plus ADT
9538648|NCT03129854|No Intervention|control group|standard of care ADT continually
9538649|NCT03129906|Active Comparator|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
9538650|NCT03129906|Placebo Comparator|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
9538651|NCT03129932|Active Comparator|gluten phase|volunteers will receive 2 corn muffins containing12g of gluten/muffin to be consumed daily for 4 weeks
9538652|NCT03129932|Placebo Comparator|Placebo phase|volunteers will receive 2 corn muffins without gluten/muffin to be consumed daily for 4 weeks
9538653|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
9538654|NCT03129607||Observation group|Patients without POPF will be included into observation group.
9538655|NCT03129646|Experimental|Arm 1 - MF/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
9538656|NCT03129646|Experimental|Arm 2 - MF 28d/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
9538657|NCT03129646|Active Comparator|Arm 3 - SSG/PM 17d|Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
9538658|NCT03129633|Experimental|Promotores Network|Promotores will engage participants using the materials A Page of My Life and the Success Plan. Promotores will ask participants to rank their satisfaction with each of the domains included in the A Page of My Life and ask them what domain they want to change. Using non-directive questions, promotores will guide the participant to draft a plan for success. The promotor/a will follow up with participants within a week of enrollment and at least monthly via phone/text during six months. During the intervention period, promotores will meet with participants (child and parent together, if applicable) at least three times in-person during which they will deliver the short (15-minutes) educational components of the intervention.
9538659|NCT03129633|No Intervention|Wait-list Control|The community liaison will deliver a short (15-minute) educational session on the benefits of a healthy lifestyle and preventive use of health care, and give participants a pamphlet with relevant local health care and social service resources.
9538660|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
9538661|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes selected as follows: ID 3.0 mm for birth (>3 kg body weight) to < 8 months; ID 3.5 mm for 8 to < 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
9538662|NCT03129737|Experimental|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
9538663|NCT03129737|Active Comparator|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
9538664|NCT03129685|Experimental|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
9538665|NCT03129711|Experimental|glazed Celtra Duo|zirconia reinforced lithium silicate glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic
9538666|NCT03129711|Active Comparator|Glazed IPS Empress CAD|glazed Leucite based glass ceramics ,Its a glass ceramic which is etchable and proved to have good esthetics if used for laminate veneers
9538667|NCT03129581|Active Comparator|Time Restricted|This group will receive dietary counseling.
9538668|NCT03129581|No Intervention|Time Unrestricted|This group will not receive dietary counseling.
9538669|NCT03129763|Experimental|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
9538670|NCT03129763|Experimental|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
9538671|NCT03129763|Experimental|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
9538672|NCT03129763|Experimental|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
9538673|NCT03129763|Experimental|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
9538674|NCT03129659|Experimental|CT-group|Coronary CT angiography
9538675|NCT03130062|Experimental|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
9538676|NCT03130062|No Intervention|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
9538677|NCT03129698|Other|Formerly Arm Label|Apatinib 250mg daily
9538678|NCT03129529|Experimental|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
9538679|NCT03129529|Experimental|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
10059470|NCT02027597|Experimental|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
9538680|NCT03129412|Experimental|Arm 1|4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.
9538681|NCT03129308||HIV infected patients|4.5 ml of blood will be collected during a routine medical check-up.
9538682|NCT03129308||HIV negative control patients|4.5 ml of blood will be collected during a routine medical check-up.
9538683|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
9538684|NCT03129347|Experimental|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
9538685|NCT03129347|Experimental|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
9538686|NCT03129347|Experimental|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
9538687|NCT03129347|Experimental|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
9538688|NCT03129425|Experimental|Intervention group|Sessions in groups
9538689|NCT03129425|Sham Comparator|Control group|Sessions in groups
9538690|NCT03129438|Experimental|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
9538691|NCT03129438|Active Comparator|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
9538692|NCT03129373|Experimental|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
9538693|NCT03129373|Active Comparator|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
9538694|NCT03129373|Active Comparator|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
9538695|NCT03129282|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
9538696|NCT03129282|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
9538697|NCT03129490|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9538698|NCT03129490|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9538699|NCT03129490|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9538700|NCT03129490|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9616206|NCT04262258|Experimental|Blueberry Enriched Diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
9616207|NCT04225897|Experimental|RV521|"sisunatovir is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. The RV521 dry powder blend will be supplied in capsules containing 10, 20, or 50 mg RV521. The Investigational Medicinal Product (IMP) will be dispersed in a defined volume of suspending diluent prior to oral administration on a mg/kg basis. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of suspending diluent prior to administration will be provided in the Pharmacy Manual.~The proposed dosing regimen for Part A is a single open label dose of RV521. Part B and C is RV521 or placebo administered BID, 12 hours apart, for a period of 5 consecutive days with a total of 10 doses. However, this is subject to the recommendation of the DSMC."
9538701|NCT03129555|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9538702|NCT03129555|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9538703|NCT03129555|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9538704|NCT03129555|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
9538705|NCT03129191|Active Comparator|AB arm|"Sequence:~Aided with non-invasive bone conduction hearing aid A~Aided with non-invasive bone conduction hearing aid B"
9538706|NCT03129191|Active Comparator|BA arm|"Sequence:~Aided with non-invasive bone conduction hearing aid B~Aided with non-invasive bone conduction hearing aid A"
9538707|NCT03129295|Experimental|MPC-SHRC|oral tablet four times a day for 3 days
9538708|NCT03129295|Placebo Comparator|Placebo|oral tablet four times a day for 3 days
9538709|NCT03129399|Experimental|King Vision video laryngoscope|
9538710|NCT03129399|Active Comparator|McGrath MAC video laryngoscope|
9538711|NCT03129217||Patients weaning from mechanical ventilation|
9538712|NCT03129477|Experimental|Telemonitoring in NonInvasiveVentilation|"Tele-monitoring in noninvasive ventilation with Lumis 150 and others Resmed equipments with AirView monitoring system, in COPD patients.~• Education and adaptation of the patient to NIV."
9538713|NCT03129477|No Intervention|2- conventional monitoring group|"Conventional monitoring group~• Education and adaptation of the patient to NIV."
9538714|NCT03129204|Experimental|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
9538715|NCT03129204|No Intervention|Control Group|The control group will not receive the SAF-T intervention.
9538716|NCT03129542|Active Comparator|Midodrine Hydrochloride 10 milligrams|Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
9538717|NCT03129542|Placebo Comparator|Placebo oral capsule|For participants randomized to the placebo arm, an identical appearing capsule containing only Lactose Monohydrate powder will be administered every 8 hours for a total of 3 doses.
9538718|NCT03129230|Experimental|Free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck.
9538719|NCT03129256|Experimental|Apatinib & S-1|Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
9538720|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
9538721|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
9538722|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
9538723|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
9538724|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
9538725|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
9538726|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
9538727|NCT03129334|Experimental|LST Middle School Online|Students will participate in a series of e-learning modules plus classroom sessions related to drug abuse prevention, including prescription drug abuse
9538728|NCT03129334|No Intervention|Treatment as Usual (Control)|Students will not participate in the e-learning modules. They will receive any standard classroom instruction on drug abuse/health education.
9538729|NCT03129074|Experimental|Varlitinib given in combination with capecitabine|"PO varlitinib 300 mg BID~PO capecitabine 1000 mg/m2 BID"
9538730|NCT03129269|Experimental|neuroimaging amyloid diagnosis by MRI and PET scan|"There is only one arm. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. MRI and PET Scan.~Visits will be scheduled at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.~In addition, at 6 and 18 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check.~PET-Scan will be scheduled in the 2 months following inclusion for amyloid measurements. The MRI will be proposed, depending on the clinical relevance~A blood sample for biobank will be taken at visit 2 and at the end of the study (visit 5)."
9538731|NCT03129165|Experimental|Screening and prevention of CVD|
9538732|NCT03129464|Experimental|Cold Therapy|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. Intervention will include the patient being asked to use a reusable cold gel pack to deliver cold therapy to their abdominal incisions every 6 hours for the first 72 hours.
9538733|NCT03129464|No Intervention|Control|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. They will not receive any additional intervention.
9538734|NCT03129022|Active Comparator|Successful epidural anaesthesia|It is defined as VAS score <5, 30 min after a loading dose, given after the last attempt.
9538735|NCT03129022|Active Comparator|Failed epidural anaesthesia|It is defined as VAS score ≥5, 30 min after a loading dose, given after the last attempt.
9538736|NCT03129009|Active Comparator|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
9538737|NCT03129009|Experimental|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
9538738|NCT03129087|Experimental|Vocal activity|The vocal activity arm will require the participant to remain in the clinic and read aloud continuously for a period of one hour after a botulinum toxin injection
9538739|NCT03129087|Experimental|Vocal rest|The vocal rest arm will require the participant to remain in the clinic and remain on complete vocal rest for a period of one hour after a botulinum toxin injection
9538740|NCT03128801|Experimental|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
9538741|NCT03128801|Active Comparator|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
9538742|NCT03128788|Active Comparator|Active Comparator: supine position|Active Comparator: supine position thoracic epidural catheterization with supine position
9538743|NCT03128788|Active Comparator|Active Comparator: flexed lateral position|Active Comparator: flexed lateral position thoracic epidural catheterization with flexed lateral position
9538744|NCT03128710||Survey Group|Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment.
9538745|NCT03128710||Focus Group|Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation.
9538746|NCT03129048|Experimental|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
9538747|NCT03129048|Experimental|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
9538748|NCT03129048|Other|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
9538749|NCT03128866|Experimental|Arm I (tranexamic acid)|Patients receive tranexamic acid IV over 15 minutes 30 minutes prior to surgery and continuously during hemipelvectomy procedure in the absence of disease progression or unacceptable toxicity.
9538750|NCT03128866|Experimental|Arm II (no tranexamic acid)|Patients undergo standard of care hemipelvectomy in the absence of disease progression or unacceptable toxicity.
9538751|NCT03128970|No Intervention|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
9538752|NCT03128970|Experimental|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
9538753|NCT03128749|Experimental|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.~These patients will be also attending to their regular psychiatric visits for medication control."
9538754|NCT03128749|Active Comparator|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
9538755|NCT03128775|Experimental|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
9538756|NCT03128775|Experimental|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
9538757|NCT03128775|Experimental|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
9538758|NCT03128775|No Intervention|Control|without any activity
9538759|NCT03128762||Cases|"Patients in this group are asthmatic (see inclusion/exclusion) criteria.~Intervention: ILC2 levels in blood"
9538760|NCT03128762||Controls|"Controls are non-asthmatic subjects that are age and gender matched to asthma cases.~Intervention: ILC2 levels in blood"
9538761|NCT03129035|Active Comparator|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
9538762|NCT03129035|Active Comparator|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
9538763|NCT03128697|Experimental|Satiating diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
9538764|NCT03128697|Experimental|Satiating diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
9538765|NCT03128697|Active Comparator|Control diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
9538766|NCT03128697|Active Comparator|Control diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
9538767|NCT03128736|Experimental|dexlansoprazole group|dexlansoprazole 60mg
9538768|NCT03128736|Experimental|esomeprazole group|esomeprazole 40mg
9538769|NCT03128684|Experimental|Small Green Lentil Muffin|
9538770|NCT03128684|Experimental|Split Red Lentil Muffin|
9538771|NCT03128684|Placebo Comparator|Wheat Muffin|
9538772|NCT03128684|Experimental|Small Green Lentil Chili|
9538773|NCT03128684|Experimental|Split Red Lentil Chili|
9538774|NCT03128684|Placebo Comparator|Rice Chili|
9538775|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
9538776|NCT03128814||Elite (pre)adolescent tennis players|
9538777|NCT03128814||Age- and gender-matched controls|
9538778|NCT03128879|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO QD and ibrutinib PO QD. Courses repeat every 4 weeks for up to 24 courses in the absence of disease progression or unaccepted toxicity.
9538779|NCT03128463||significantly effective group|visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
9538780|NCT03128463||effective group|visual improvement ≥5 letters and <15 letters in EDTRS table after intravitreal injection of conbercept
9538781|NCT03128463||invalid group|visual improvement <5 letters and visual reduction<5 letters in EDTRS table after intravitreal injection of Combercept
9538782|NCT03128463||deterioration group|visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
9538783|NCT03128450|Experimental|h-NSC arm|"human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel，produced by Shanghai Angecon Biotechology Cooperate.~One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time."
9538784|NCT03128437|Experimental|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
9538785|NCT03128437|No Intervention|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.~Assessments will take place at baseline, week 2, week 4, and week 8."
9538786|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
9538787|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
9538788|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
9538789|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
9538790|NCT03128606|Experimental|GLPG3067 single dose|Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
9538791|NCT03128606|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension.
9538792|NCT03128606|Experimental|GLPG3067 oral suspension fed 1|Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
9538793|NCT03128606|Experimental|GLPG3067 oral tablet fed 1|Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
9538794|NCT03128606|Experimental|GLPG3067 oral tablet fasted 1|Single dose 1 of GLPG3067 oral tablet after an overnight fast.
9538795|NCT03128606|Experimental|GLPG3067 oral tablet fed 2|Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
9538796|NCT03128606|Experimental|GLPG3067 oral tablet fed 2 high-fat high-calorie|Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
9538797|NCT03128606|Experimental|GLPG3067 multiple dose|Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
9538798|NCT03128606|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension.
9538799|NCT03128606|Experimental|GLPG3067/GLPG2222 multiple dose|Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
9538800|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
9538801|NCT03128606|Experimental|GLPG3067/GLPG2222/GLPG2737 multiple dose|Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
9538802|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
9538803|NCT03128541||Ultrasound Spine in sitting position|Participants will be assigned to a sitting decubitus position to identify the Tuffier's Line
9538804|NCT03128541||Ultrasound Spine in lateral position|Participants will be assigned to a lateral decubitus position to identify the Tuffier's Line
9538805|NCT03128515|Experimental|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
9538806|NCT03128515|Active Comparator|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
9538807|NCT03128528|Placebo Comparator|Placebo Oral Tablet|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
9538808|NCT03128528|Active Comparator|Empagliflozin|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
9538809|NCT03128554|Experimental|Intervention with Training and Materials|Clinics randomized to the intervention group will receive a one time, 2-hour Continuing Medical Education/Group Learning training session on the smoking reduction intervention model, along with provider and patient handouts.
9538810|NCT03128554|No Intervention|Usual Care|Clinics randomized to the control group will not be exposed to the intervention program.
9538811|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
9538812|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
9538813|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
9538814|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL >5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
9538815|NCT03128320|Experimental|BAY1193397/Placebo (sequence A-B-C)|Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
9538816|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-C-A)|Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
9538817|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-A-C)|Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
9538818|NCT03128593|Experimental|Experimental: JR-141|
9538819|NCT03128333|Experimental|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
9538820|NCT03128333|Other|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
9538821|NCT03128489|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
9538822|NCT03128476|Active Comparator|1 bottle|
9538823|NCT03128476|Active Comparator|2 bottles|
9538824|NCT03128476|Placebo Comparator|Placebo|
9538825|NCT03128242|Experimental|oxytocin group|oxytocin treatment
9538826|NCT03128242|Placebo Comparator|placebo group|placebo treatment
9538827|NCT03128294||long-term survivors of ovarian cancer|long-term survivors of ovarian cancer
9538828|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
9622079|NCT02518503||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (high doses of rosuvastatin, high doses of atorvastatin, and high doses of simvastatin) between 1 January 1997 and 31 March 2011, or 1 year after the beginning of data availability.
10059471|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
9538829|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
9538830|NCT03128112|No Intervention|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
9538831|NCT03128112|Active Comparator|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
9538832|NCT03128060|Experimental|Home-based Palliative Care|Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
9538833|NCT03128060|Active Comparator|Enhanced Usual Care|Enhanced usual care refers to: 1) usual primary care provided by a primary care physician who has been offered special training in the core elements of palliative care; 2) case management services; and 3) provider support through palliative care consultation.
10058421|NCT02018211|Experimental|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
9538834|NCT03128645||Group 1|Standard method group
9538835|NCT03128645||Group 2|Abdominal corset group
9538836|NCT03127982|Experimental|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
9538837|NCT03127982|Active Comparator|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
9538838|NCT03128177|Experimental|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
9538839|NCT03128177|Experimental|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
9538840|NCT03128216|Active Comparator|Blind Local Anesthetic Infiltration|
9538841|NCT03128216|Active Comparator|Transversals Fascia Block|
9538842|NCT03128216|Active Comparator|Spinal Anesthesia|
9538843|NCT03128125|Experimental|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
9538844|NCT03128125|Other|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
9538845|NCT03128281|Experimental|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
9538846|NCT03128281|Experimental|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
9538847|NCT03128281|Active Comparator|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
9538848|NCT03127995|Experimental|HYPOFRACTIONATED|"40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions"
9538849|NCT03127995|Other|NORMOFRACTIONATED|"50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions"
10058422|NCT02018224|Experimental|End-to-end suturation without augmentation|
10058423|NCT02018224|Experimental|End-to-end suturation with augmentation|
10039422|NCT01843868|Other|R-CHOP and standard anti-emetics|"This is a single arm study.~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:~5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.~Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.~Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.~Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
10039423|NCT01843881|Experimental|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
10039424|NCT01843881|Placebo Comparator|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
9538850|NCT03128190|No Intervention|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of >65 mmHg, a vasopressor drug was administered.
9538851|NCT03128190|Experimental|PPV group|intraoperative fluid management was titrated to maintain PPV< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
9538852|NCT03128346|Experimental|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
9538853|NCT03128346|Active Comparator|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
9538854|NCT03128047|Experimental|Recurrent high grade gliomas and ependymomas|"Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab."
9538855|NCT03128073|Experimental|Single group|The intervention is with the Carry Life system ultrafiltration (CLS UF) device, which administers a Glucose-salt solution intermittently to a volume of the intraperitoneal fluid in the device.
9538856|NCT03128164|Experimental|HMPL-689|HMPL-689, oral, BID, doses should be taken at ~12-hour intervals (eg, at ~8 AM and at ~8 PM)
9538857|NCT03128151||Study group|Intraoperative neuromuscular monitoring and pharmacological reversion according to data sheet
9538858|NCT03128151||Control group|Treated according to usual clinical practice
9538859|NCT03127969|Other|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
9538860|NCT03127969|Other|Joint protection and exercise|Patients who received joint protection and exercise
9538861|NCT03128203|Experimental|Oxytocin|
9538862|NCT03128203|Placebo Comparator|Placebo|
9538863|NCT03128424|Experimental|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
9538864|NCT03128268|Experimental|All Enrollees|"Intervention: Diagnostic test~All enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI"
9538865|NCT03127930|Experimental|Intervention|Intervention: Participants receive both usual care including a standard brochure on patient management provided by the Alzheimer's Association plus a tailored problem-solving intervention to improve caregiver's management of medications for their family or friend care recipient who has memory deficit.
10039425|NCT01843894|Placebo Comparator|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
10039426|NCT01843894|Experimental|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
10039427|NCT01843907|Other|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
10039428|NCT01843907|Other|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
10039429|NCT01843907|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
10059472|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
9538866|NCT03127930|No Intervention|Usual Care|No Intervention: Participants do not receive the problem solving intervention and are followed as a Usual Care condition including receiving a standard brochure on patient management provided by the Alzheimer's Association. .
9538867|NCT03127852|Experimental|Telemonitoring (Medly)|The telemonitoring technology will enable patients with complex chronic illnesses, to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the mobile phone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
9538868|NCT03127852|No Intervention|Control|Standard of care: Patients are followed in a specialty care clinic treating their primary conditions. Patients typically have scheduled appointments every six months.
9538869|NCT03127917|Experimental|CitrullinePlacebo|Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.
9538870|NCT03127917|Experimental|PlaceboCitrulline|Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.
9538871|NCT03127878|Active Comparator|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
9538872|NCT03127878|Experimental|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
9538873|NCT03127579|Experimental|Longer meal duration|Families eat longer as they usually do
9538874|NCT03127579|No Intervention|Usual meal duration|Families eat as long as they usually do
9538875|NCT03127839|Active Comparator|Eccentric Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
10039430|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.~* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes~Group 2:~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes~Group 3:~Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes~Group 4:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM~Group 5:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM~Group 6:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM~Group 7:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
9538876|NCT03127839|Active Comparator|Traditional Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing traditional rotator cuff strengthening exercises to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the traditional rotator cuff strengthening exercises daily at home.
9538877|NCT03127839|Active Comparator|Eccentric Exercise + pain education|"In addition to the treatment provided in the Eccentric Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
9538878|NCT03127839|Active Comparator|Traditional Exercise + pain education|"In addition to the treatment provided in the Traditional Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
9538879|NCT03127657|Experimental|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
9538880|NCT03127891|Experimental|pranayama yoga|yoga breathing exercise
9538881|NCT03127891|Placebo Comparator|control group|no intervention
9538882|NCT03127670|Experimental|Solanum melongena peel extract 0.05%|25 Patients Solanum melongena peel extract 0.05% Twice daily applied topically for 12 weeks
9538883|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
9538884|NCT03127813|Experimental|Treated glaucoma|POAG patients established on treatment
9538885|NCT03127813|Experimental|Untreated|Newly diagnosed treatment naïve POAG patients
9538886|NCT03127813|Active Comparator|Control|Control subjects without glaucoma
9538887|NCT03127800|Experimental|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
9538888|NCT03127475|Experimental|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
9538889|NCT03127475|Sham Comparator|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
9616208|NCT04225897|Placebo Comparator|Placebo|The placebo capsules administered in Part B and C will contain mannitol and microcrystalline cellulose (vehicle). The placebo dry powder will be dispersed in suspending diluent and given orally BID. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of suspending diluent prior to administration will be provided in the Pharmacy Manual.
9538890|NCT03127462|Experimental|Individualized Education|
9538891|NCT03127462|No Intervention|Control group|
9538892|NCT03127553|No Intervention|A - control|Free diet with standard bread
9538893|NCT03127553|Active Comparator|B - low-salt diet with normal bread|Low-sodium diet with standard bread
9538894|NCT03127553|Experimental|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
9538895|NCT03127371|Experimental|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
9538896|NCT03127371|Experimental|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
9538897|NCT03127241|Active Comparator|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
9538898|NCT03127241|Active Comparator|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
9538899|NCT03127735|Experimental|BAY1436032|"Dose escalation:~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.~Dose expansion:~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
9538900|NCT03127683|Experimental|AuraGain group|"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."
9538901|NCT03127449|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
9538902|NCT03127423|Experimental|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
9538903|NCT03127423|Active Comparator|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
9538904|NCT03127436||Acarovac Hausstaubmilbe|"This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients (children and adults) in routine medical care.~During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.~Data on tolerability are documented by the physicians."
9538905|NCT03127410|Experimental|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
9538906|NCT03127397|No Intervention|Standard of Care|
9538907|NCT03127397|Experimental|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
9538908|NCT03127254|Experimental|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
9538909|NCT03127631|Active Comparator|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label antiplatelet agents, statins, ACE-I, and other antihypertensive medications where appropriate.
9538910|NCT03127631|No Intervention|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
9538911|NCT03127202|Experimental|Cardiac Resynchronization Therapy-Defibrillator|Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator
9538912|NCT03127280|No Intervention|Conventional Foley Care|Following surgery, the patient's Foley catheter is removed on the morning of post-operative day one.
9538913|NCT03127280|Experimental|Fast Tract Foley care|Following surgery, the patient's Foley catheter is removed on post-operative day zero, four hours after the completion of surgery.
9538914|NCT03127137|Other|Control cohort Group|Control cohort group will receive medications not predetermined by the set protocol.
9538915|NCT03127137|Active Comparator|Experimental Group 1|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
9538916|NCT03127137|Placebo Comparator|Experimental Group 2|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
9538917|NCT03127306||CAM-ICU (+) Delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
9538918|NCT03127306||CAM-ICU (-) Non-delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
9538919|NCT03127319|Experimental|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
9538920|NCT03127319|Active Comparator|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
10039431|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
9538921|NCT03127345|Experimental|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
10039432|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
10039433|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
10039434|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
10039435|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
10039436|NCT01843998|Experimental|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
9538922|NCT03127345|Active Comparator|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
9538923|NCT03127293||Hyperemesis Gravidarum group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
10039437|NCT01844011|Experimental|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
10039438|NCT01844011|No Intervention|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
10039439|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
10039440|NCT01844024|No Intervention|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
10039441|NCT01844037|Other|Renal denervation|Patients will be treated with the OneShot ablation system
10039442|NCT01844050|Experimental|Chinese herbal medicine|Individualized Treatment with Chinese herbal
9538924|NCT03127293||control group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
10039443|NCT01844050|Placebo Comparator|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
10039444|NCT01844063|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
10039445|NCT01844063|Experimental|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
10039446|NCT01844063|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
9538925|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) [with different particle size distribution (PSD) as compared to Treatment A, D, C and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
9538926|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
9538927|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment B, C, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
9538928|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
10039447|NCT01844102|Experimental|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
10039448|NCT01844128||overweight women with infertility|
10039449|NCT01844141|Experimental|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
10039450|NCT01844141|Active Comparator|70% alcohol|Ingrown toenail irrigated using 70% alcohol
10039451|NCT01844167|Active Comparator|Physical therapy arm (PT)|"The TENS device used: FDA K071951~Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
10058424|NCT02018237|Active Comparator|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
9538929|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and D] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
9538930|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) and cognitive impairment.~Intervention: Genome sequencing of fecal samples"
9538931|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) without cognitive impairment.~Intervention: Genome sequencing of fecal samples"
9538932|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
9538933|NCT03127072|Experimental|Arm A|RFA plus chemotherapy ± target therapy
9538934|NCT03127072|Active Comparator|Arm B|chemotherapy ± target therapy
9538935|NCT03127124|Experimental|NANT-008 in combination with other agents|NANT-008 will be administered in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
9538936|NCT03127163|Other|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
9538937|NCT03127046|Experimental|Group 1|Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole
9538938|NCT03127046|Experimental|Group 2|Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole
9538939|NCT03127046|Experimental|Group 3|Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac
9538940|NCT03127046|Experimental|Group 4|Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac
9538941|NCT03127046|Experimental|Group 5|Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole
9538942|NCT03127046|Experimental|Group 6|Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole
9538943|NCT03127098|Experimental|ETBX-011 in combination with ALT-803|A combination of agents will be administered to subjects in this dose-escalation study
9538944|NCT03126903|Experimental|Single-Arm|KeraKlear Non-Penetrating Keratoprosthesis
9538945|NCT03126981|Experimental|Whole, natural almonds|1.5 oz of whole, natural almonds
9538946|NCT03126981|Placebo Comparator|Low-fat, high refined starches/sugars|Low-fat foods,high in refined starches and added sugars
9538947|NCT03126994|Experimental|PhysioWave Cardiovascular Analyzer|The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.
9538948|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
9538949|NCT03127150||CL group|Subjects who had CL after pancreatic operation will be observed.
9538950|NCT03127150||Observation group|Subjects without CL after pancreatic operation will be observed.
9538951|NCT03127020|Experimental|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
9538952|NCT03126877|Experimental|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
9538953|NCT03126877|Active Comparator|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
9538954|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
9538955|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
9538956|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
9538957|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
9538958|NCT03126669|Active Comparator|Treratment|100% oxygen at 2 ATA at the hyperbaric chamber
9538959|NCT03126669|Placebo Comparator|Placebo|normal air, in the hyperbaric chamber
9538960|NCT03126864|Experimental|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
9538961|NCT03126864|Experimental|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
9538962|NCT03126578|Experimental|All subjects|"Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12.~Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731."
9538963|NCT03126604||vaginal delivery|Women underwent non complicated non instumental normal vaginal delivery
9538964|NCT03126604||Cesarean section|Women underwent elective Cesarean section
9538965|NCT03126656|Experimental|Hypogonadic with chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II), and hypogonadism (plasma testosterone levels <11.4 nmol / L);
9538966|NCT03126656|Experimental|Hypogonadic|patients just with hypogonadism (testosterone <11.4 nmol / L) in the absence of documented cardiovascular disease
9538967|NCT03126656|No Intervention|chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II) with normal testosterone levels(plasma testosterone levels > 11.4 nmol / L), in optimized standard therapy for heart failure
9538968|NCT03126721|Experimental|oral midazolam alone|single dose of oral midazolam administered alone in period 1
9538969|NCT03126721|Experimental|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
9538970|NCT03126734|Experimental|Experimental Group|The parents of this group will receive 5 sessions of infant massage course (1 per week) between two measurements of the variables
9538971|NCT03126734|No Intervention|Control Group|The parents of this group will not receive infant massage course (1 per week) between two measurements of the variables. They will receive it after two measurements.
9538972|NCT03126916|Experimental|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
9538973|NCT03126916|Experimental|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
9538974|NCT03126916|Experimental|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description. Closed to accrual as of 12/17/20.
9538975|NCT03126916|Experimental|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
9538976|NCT03126916|Experimental|Arm E (crizotinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
9538977|NCT03126825|Other|Conventional CI|The conventional CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
9538978|NCT03126825|Other|Hybrid CI|The Hybrid CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
9538979|NCT03126565|Experimental|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
9538980|NCT03126565|No Intervention|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
9538981|NCT03126708|Experimental|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
9538982|NCT03126708|Active Comparator|chemotherapy (cisplatin plus paclitaxel)|
9538983|NCT03126838||diaphragmatic dysfunction|diaphragmatic displacement < 10 ml, and / OR diaphragmatic thickening fraction < 36 %.
9538984|NCT03126838||non diaphragmatic dysfunction|diaphragmatic displacement > 10 ml, and / OR diaphragmatic thickening fraction > 36 %.
9538985|NCT03126942|Experimental|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
9538986|NCT03126942|Active Comparator|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
9538987|NCT03126695|Experimental|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
10059473|NCT02027636|No Intervention|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
9538988|NCT03126695|Experimental|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
9538989|NCT03126695|Experimental|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
9538990|NCT03126695|Active Comparator|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
9538991|NCT03127059|Experimental|Breathing Exercises|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Three physiotherapist-sessions of Breathing Exercises (BrEX) with duration of 60 minutes (the initial) and 30 minutes (other sessions) at week 1, 4, and 9. The participant is expected to do 10 minutes of home exercise twice daily. The entire intervention combines elements of the Papworth method, and the Buteyko technique."
9538992|NCT03127059|Other|Usual care|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Besides the individual instruction described above, patients will receive only short information given initially at recruitment. They are allowed to receive instruction in positive expiratory pressure-treatment and physiotherapy targeting other problems than dysfunctional breathing (DB)."
9538993|NCT03126591|Experimental|Olaratumab Dose Level 1 + Pembrolizumab|Olaratumab given intravenously (IV) and pembrolizumab given IV.
9538994|NCT03126591|Experimental|Olaratumab Dose Level 2 + Pembrolizumab|Olaratumab given IV and pembrolizumab given IV.
9538995|NCT03126591|Experimental|Olaratumab + Pembrolizumab Expansion|Olaratumab given IV and pembrolizumab given IV.
9538996|NCT03126526|Experimental|Food specific inhibitory control training|The stimuli in this task will involve pictures of food.
9538997|NCT03126526|Active Comparator|General inhibitory control training|The stimuli in this task will not involve pictures of food, but pictures of stationary and household items.
9538998|NCT03126526|No Intervention|Baseline brain activation assessment (healthy controls)|This arm is included to assess brain activation using EEG among healthy controls at baseline in order to compare responses to participants with eating disorders.
9538999|NCT03126487|Experimental|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
9539000|NCT03126422|Experimental|Dexmedetomidine 0 μg/kg/min|
9539001|NCT03126422|Experimental|Dexmedetomidine 0.03 μg/kg/min|
9539002|NCT03126422|Experimental|Dexmedetomidine 0.06 μg/kg/min|
9539003|NCT03126422|Experimental|Dexmedetomidine 0.09 μg/kg/min|
9539004|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
9539005|NCT03126357|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539006|NCT03126357|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539007|NCT03126357|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539008|NCT03126357|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539009|NCT03126357|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539010|NCT03126357|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539011|NCT03126357|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539012|NCT03126357|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539013|NCT03126357|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539014|NCT03126357|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
9539015|NCT03126279||Preoperative Chronic Knee OA Patients|Patients will be recruited from orthopaedic preoperative clinics from those awaiting total knee replacement surgery.
9539016|NCT03126279||Healthy Volunteers|Healthy volunteers will be recruited that are aged match to our OA patient cohort so meaningful comparisons regarding brain activity and pain sensitisation characteristics can be assessed.
9539017|NCT03126409|Experimental|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
9539018|NCT03126409|Active Comparator|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
10059474|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
9539019|NCT03126500||Malnourished|malnourished, geriatrics patients at hospital discharge
9539020|NCT03126461|Experimental|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
9539021|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
9539022|NCT03126058|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally. B: Remove catheter early.~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation for right hemicolectomy, Miles rectectomy and Hartman rectectomy, simple cleansing enema for left hemicolectomy,sigmoidectomy and Dixon rectectomy; C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
9539023|NCT03126032||Patients with suspected sepsis|"Patients presenting in the Emergency Room (ER) with the clinical suspicion of infection/sepsis.~Evaluation of the glycocalyx damage with the use of GlycoCheck™-System, as well as blood sample at presentation, day 1 and day 7 of their hospital stay."
9539024|NCT03126032||Non-Sepsis Patients|"Patients presenting in the Emergency Room with other conditions apart from infection/sepsis.~Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation."
9539025|NCT03126032||Healthy Individuals|Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation.
9539026|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
9539027|NCT03126149|Experimental|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
9539028|NCT03126149|Placebo Comparator|Cohort 1_Period 1_Placebo|Single dose of placebo
9539029|NCT03126149|Experimental|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
9539030|NCT03126149|Placebo Comparator|Cohort 1_Period 2_Placebo|Single dose of placebo
9539031|NCT03126149|Experimental|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
9539032|NCT03126149|Placebo Comparator|Cohort 1_Period 3_Placebo|Single dose of placebo
9539033|NCT03126149|Experimental|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
9539034|NCT03126149|Placebo Comparator|Cohort 1_Period 4_Placebo|Single dose of placebo
9539035|NCT03126149|Experimental|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
9539036|NCT03126149|Placebo Comparator|Cohort 2_Period 1_Placebo|Single dose of placebo
9539037|NCT03126149|Experimental|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
9539038|NCT03126149|Placebo Comparator|Cohort 2_Period 2_Placebo|Single dose of placebo
9539039|NCT03126149|Experimental|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
9539040|NCT03126149|Placebo Comparator|Cohort 2_Period 3_Placebo|Single dose of placebo
9539041|NCT03126149|Experimental|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
9539042|NCT03126149|Placebo Comparator|Cohort 2_Period 4_Placebo|Single dose of placebo
9539043|NCT03126162|Experimental|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
9539044|NCT03126162|Placebo Comparator|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
9539045|NCT03126201||Study Group|Patients with biopsy-proven primary focal segmental glomerulosclerosis.
9539046|NCT03126188||Sertraline group|Mild and Moderate depressive episode without somatic syndrome who are treated with Sertraline. Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
9539047|NCT03126188||Dosulepin group|Mild and Moderate depressive episode with somatic syndrome who were treated with Dosulepin. Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks
9539048|NCT03126188||Venlafaxine group|Severe depressive episode without psychotic symptoms who were treated with Venlafaxine. Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
9539049|NCT03126318|Active Comparator|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
9539050|NCT03126318|Placebo Comparator|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
9539051|NCT03126123|Other|acetic acid test|Patients will receive surgical treatment for anal condylomatosis and acetic acid on the mucosa of the anal canal before the surgical procedure
9622080|NCT02518503||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 31 of March 2011, or 1 year after the beginning of data availability.
10059475|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
10059476|NCT02027662|Experimental|Osvaren Granules|Osvaren Granules
10039452|NCT01844167|Experimental|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:~The TENS device used: FDA K071951~TENS is calibrated to allow for maximum range in the specifications.~A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.~The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.~If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
10039453|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
10039454|NCT01844245|Experimental|Endobiliary RFA group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.~Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
10039455|NCT01844245|No Intervention|Control group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.~Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
10039456|NCT01844258|Experimental|Modified technique for I/A group|"In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.~The capsulorhexis will be located in the peripheral area of the lens instead of the central area.~A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.~One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
10059477|NCT02027662|Active Comparator|Osvaren film-coated tablets|Osvaren film-coated tablets
9484585|NCT02061332|Experimental|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
9484587|NCT02058420|No Intervention|Placebo group|No active dose of tocotrienols
9484588|NCT02058420|Active Comparator|Low tocotrienols group|Low dose of tocotrienols
9484589|NCT02058420|Active Comparator|High tocotrienols group|High dose of tocotrienol
9484590|NCT02057380|Experimental|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
9484591|NCT02057380|Experimental|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
9484592|NCT02057380|Experimental|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
9484593|NCT02057380|Experimental|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
9484594|NCT02057380|Experimental|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
9484595|NCT02057380|Experimental|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
9539052|NCT03126175|Active Comparator|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
9484596|NCT02057380|Experimental|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
9484597|NCT02057380|Experimental|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
9484598|NCT02057380|Experimental|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
9484599|NCT02057380|Experimental|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
9484600|NCT02057380|Experimental|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
9484601|NCT02057380|Experimental|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
9484602|NCT02057341|Experimental|ARRY-371797 (Dose 1)|
9484603|NCT02057341|Experimental|ARRY-371797 (Dose 2)|
9484604|NCT02057315|Experimental|ELS-M11|Topical 5% ELS-M11 (3 g)
9484605|NCT02057315|Placebo Comparator|Placebo|A matching formulation with no active ingredient
9484606|NCT02057172|Experimental|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
9484607|NCT02057172|Experimental|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
9484608|NCT02057172|Experimental|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
9484609|NCT02057172|Experimental|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
9484610|NCT02057172|Experimental|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
9539053|NCT03126175|Experimental|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
9539054|NCT03125993|Experimental|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
9539055|NCT03126084|Active Comparator|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
9539056|NCT03126084|Active Comparator|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
9539057|NCT03126084|Active Comparator|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
9539058|NCT03126396|Experimental|Urgo 310 3166 dressing|Urgo 310 3166 dressing
9539059|NCT03126214|Experimental|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
9539060|NCT03126214|Active Comparator|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
9539061|NCT03126006|Experimental|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
9539062|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
9539063|NCT03125967|Active Comparator|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
9539064|NCT03125967|Placebo Comparator|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
9539065|NCT03125980|Experimental|Perioperative chemotherapy with CapOX regimen|
9539066|NCT03125980|Active Comparator|Postoperative chemotherapy with CapOX regimen|
9539067|NCT03126097|Experimental|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 [COCP Lead-in Phase]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 [JNJ-64155806 + COCP Co-administration Phase].
9539068|NCT03126071|Experimental|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
9539069|NCT03126071|Experimental|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
9539070|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
9539071|NCT03125863|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
9539072|NCT03125850|Experimental|day-ward group|
9539073|NCT03125850|Active Comparator|inpatient group|
9539074|NCT03125889|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.
9539075|NCT03125681|Experimental|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
9539076|NCT03125681|Placebo Comparator|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
9539077|NCT03125577|Experimental|4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123|Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
9539078|NCT03125551|Active Comparator|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
9539079|NCT03125551|Active Comparator|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
9539080|NCT03125551|Active Comparator|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
9539081|NCT03125551|Active Comparator|Ginseng|Ginseng 400mg po dly for 14 days
9539082|NCT03125551|Placebo Comparator|Placebo|Placebo po dly for 14 days
9622081|NCT02518529|Experimental|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
9622082|NCT02518607|Experimental|Group 1, Session 1, Active|"Lowest dose of SAD:~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
9622083|NCT02518607|Experimental|Group 1, Session 2, Active|"Dose Escalation SAD:~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
9539083|NCT03125772|Experimental|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
9539084|NCT03125772|Active Comparator|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus [40-O-(2-hydroxyethyl)- rapamycin], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
9616209|NCT04219813|Other|Patients affected with Non-celiac Gluten/Wheat Sensitivity|The researchers will deliver to each patient 10 kits for the analysis of the GIP and they will ask them to use them two times per week, for 5 weeks. Furthermore, the patients will test urine GIP in the event of symptoms/signs that they attribute to the accidental intake of gluten, within the same 5 weeks. Both gastrointestinal and extra-intestinal symptoms which the patients will attribute to the accidental intake of gluten, will be considered.
9616210|NCT04209790|Other|Neoadjuvant chemoradiation and surgical resection|The experimental part of the study would be this selection of resectable patients and sequencing neoadjuvant chemoradiation prior to surgery.
9616211|NCT04205383||pregnancy|pregnant women with normal pregnancy
9616212|NCT04205383||pregnancy with complications|pregnant women with placental-mediated complications of pregnancy type complications
9616213|NCT04205383||healthy volunteer|healthy, non-pregnant women volunteers
9616214|NCT04183790|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
9616215|NCT04180540|Experimental|Percutaneous Closure|Participants randomized to undergo percutaneous closure with PerClose after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
9616216|NCT04180540|Active Comparator|Manual Compression|Participants randomized to undergo manual compression after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
9616217|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
9616218|NCT04179981|Active Comparator|PAP therapy arm|PAP Therapy will be provided to eligible patients with OVS. This is the active therapy arm.
9616219|NCT04179396|Experimental|Arm A: Oral rucaparib and enzalutamide|
9616220|NCT04179396|Experimental|Arm B: Oral rucaparib and abiraterone|
9616221|NCT04177108|Experimental|Cohort 1 Arm A|PD-L1 Non-Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1:1 ratio.
9616222|NCT04177108|Experimental|Cohort 1 Arm B|PD-L1 Non-Positive Participants receiving Paclitaxel, Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
9616223|NCT04177108|Active Comparator|Cohort 1 Arm C|PD-L1 Non-Positive Participants receiving Paclitaxel, Placebo for Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
9616224|NCT04177108|Experimental|Cohort 2 Arm A|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1 ratio.
9616225|NCT04177108|Active Comparator|Cohort 2 Arm B|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Placebo for Ipatasertib. Participants will be randomised in a 1:1 ratio.
9616226|NCT04176705|Experimental|Laser|
9616227|NCT04176705|Placebo Comparator|No laser|
9616228|NCT04175678|No Intervention|Normal/Active|No intervention
9616229|NCT04175678|No Intervention|Obese/Inactive|Observational clinic visits
9616230|NCT04175678|Experimental|Diet|low fat/low caloric diet
9616231|NCT04175678|Experimental|Exercise Training|≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
9616232|NCT04175678|Experimental|Diet and exercise training|low fat/low caloric diet and ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
9616233|NCT04149288|Active Comparator|High-polyphenol olive oil|Participants will consume 40 mL of high-polyphenol olive oil each day at home for 2 weeks.
9616234|NCT04149288|Active Comparator|Low-polyphenol olive oil|Participants will consume 40 mL of low-polyphenol olive oil each day at home for 2 weeks.
9616235|NCT04142294|Experimental|4 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 4 g/day.
9616236|NCT04142294|Experimental|8 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 8 g/day
9616237|NCT04142294|Experimental|12 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 12 g/day
9616238|NCT04142294|Experimental|16 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 16 g/day. The 16 g /day dose will be administered if no adverse effects are observed for doses 4-12 g/day
9622084|NCT02518607|Experimental|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
9622085|NCT02518607|Experimental|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
10039457|NCT01844258|Active Comparator|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
10039458|NCT01844271|Placebo Comparator|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
9539085|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
9539086|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
9539087|NCT03125694|Active Comparator|Sitagliptin|
9539088|NCT03125694|Active Comparator|Pioglitazone|
9539089|NCT03125759||Control|patients without any history of stroke
9539090|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
9539091|NCT03125746|Experimental|LXI-15029|
9539092|NCT03125746|Experimental|LXI-15029+Exemestane|
9539093|NCT03125668|Experimental|Intervention Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
9539094|NCT03125668|Active Comparator|Control Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
9539095|NCT03125733|Experimental|STESD|Submucosal tunneling endoscopic septum division
9539096|NCT03125616|Active Comparator|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
9539097|NCT03125616|Experimental|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
9539098|NCT03125876|Experimental|CT053PTSA|60mg-100mg
9539099|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
9539100|NCT03125512|Experimental|Night Shift positional device|Randomized to Night shift positional therapy first for 8 weeks, followed by CPAP for 8 weeks, with a 1 week washout period.
10039459|NCT01844271|Experimental|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
10039460|NCT01844271|Experimental|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
10039461|NCT01844271|Experimental|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
9539101|NCT03125512|Active Comparator|Continuous positive airway pressure|Randomized to CPAP first for 8 weeks, followed by positional therapy for 8 weeks, with a 1 week washout period.
9539102|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.~Consultation of the patient's medical files at the hospital."
9539103|NCT03125538|Experimental|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
9539104|NCT03125538|Active Comparator|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
9539105|NCT03125473|Experimental|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
9539106|NCT03125473|Experimental|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
9539107|NCT03125473|Experimental|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
9539108|NCT03125473|Experimental|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
9539109|NCT03125239|Experimental|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Merestinib~LY2874455"
9539110|NCT03125252|Experimental|Bundle|Specific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
9539111|NCT03125252|Other|Control|Standard paramedical and medical practices
9539112|NCT03125148|Other|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
9803731|NCT03478956|Experimental|Etrolizumab Q8W|Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
9803732|NCT03461991|Other|Patients scheduled for corneal transplantation|
9484611|NCT02057172|Placebo Comparator|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
9484612|NCT02057172|Active Comparator|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
9484613|NCT02053116|Experimental|PF-05175157|
9484614|NCT02053116|Placebo Comparator|Placebo|
9484615|NCT02053103|Experimental|PF-05175157|
9484616|NCT02053103|Placebo Comparator|Placebo|
9484617|NCT02052778|Experimental|Phase 1 Dose escalation|Phase 1 Dose escalation portion for once daily and thrice weekly dosing of futibatinib (TAS-120) in patients with solid tumors.
9484618|NCT02052778|Experimental|Phase 1 Dose expansion|Phase 1 Dose expansion portion for once daily dosing of futibatinib (TAS-120) in patients with tumors harboring FGF/FGFR aberrations
9484619|NCT02052778|Experimental|Phase 2|Phase 2 portion for once daily dosing of futibatinib (TAS-120) in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions).
9484620|NCT02052739|Experimental|active drug|SAGE-547
9484621|NCT02052648|Experimental|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.~Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
9484622|NCT02052648|Experimental|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
9484623|NCT02052648|Experimental|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
9484624|NCT02052648|Experimental|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
9484625|NCT02050828|Experimental|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
9484626|NCT02050828|Experimental|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
9484627|NCT02050828|Active Comparator|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
9484628|NCT02049164|Experimental|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
9484629|NCT02049164|Experimental|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
9484630|NCT02049164|Experimental|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
9484631|NCT02049164|Placebo Comparator|Placebo|Placebo QD oral dosing for 14 weeks
9484632|NCT02048059|Experimental|ANG1005|Participants received ANG1005 intravenously (IV) at a dose of 600 mg/m^2 on Day 1 of each 21-day cycle. ANG1005 will be administered for up to a maximum of one year, or until disease progression or adverse events (AE) that are not tolerated.
9484633|NCT02047214|Experimental|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
9484634|NCT02046395|Other|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at < 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
9484635|NCT02044341|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
9497950|NCT03470363|Active Comparator|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
9497951|NCT03470350|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer treated with galunisertib and capecitabine
9497952|NCT03470337|Experimental|Phlogenzym|Treatment with German licensed drug Phlogenzym (6 tablets/day)
9497953|NCT03470337|Placebo Comparator|Placebo|Placebo equates Phlogenzym but without active ingredients
9539113|NCT03125148|Other|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
9539114|NCT03125447|Experimental|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
9539115|NCT03125447|Active Comparator|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
9539116|NCT03125174||control|healthy individuals with no history of lung disease
9539117|NCT03125174||bronchiectasis patients|individuals with a diagnoses of bronchiectasis
9539118|NCT03125161|Experimental|Arm A|HAI plus chemotherapy ± target therapy
9539119|NCT03125161|Active Comparator|Arm B|chemotherapy ± target therapy
9539120|NCT03125434|Experimental|healthy volunteers|EOS full-spine, MRI, gait analysis
9803733|NCT03461978|Other|10 patients with meibomian gland dysfunction|
9539121|NCT03125135|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the MightySat RX Pulse Oximeter Sensor.
9539122|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
9539123|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
9539124|NCT03125317||The control group|no intervention
9539125|NCT03125187|Experimental|Sodium heparin UQ First|The participants will receive the Sodium heparin UQ intravenous drug administration at first period and the Sodium heparin FK intravenous drug administration at second period
9539126|NCT03125187|Experimental|Sodium Heparin FK First|The participants will receive the Sodium heparin FK intravenous drug administration at first period and the Sodium heparin UQ intravenous drug administration at second period
9539127|NCT03125408||chronic HCV Infected patients|chronic HCV patients who will undergo standard of care FDA approved antiviral therapy to treat genotype 1,2, or 3 infections and will have blood drawn at various time points and tested using the DxN HCV Assay. Study is observational and results will not be used to manage patient care.
9539128|NCT03125356|Experimental|Diet Soda|Subjects will be asked to consume a diet soda three times daily for eight weeks.
9539129|NCT03125291|No Intervention|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
9539130|NCT03125291|Experimental|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
9539131|NCT03125083|Experimental|skin-restricted lupus (SRL) patients|Role of inflammation in psychiatric disorders in patients with cutaneous lupus
9539132|NCT03125369|Experimental|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
9539133|NCT03125369|Active Comparator|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
9539134|NCT03125213|Active Comparator|Peg-IFN plus AL-3778|
9539135|NCT03125213|Placebo Comparator|Peg-IFN plus matching placebo|
9539136|NCT03125330|Experimental|One-to-One Coaching|"Participants randomized to One-to-One Coaching meet for an initial 2-hour coaching session, followed by seven 1-hour coaching sessions every 3-weeks. These eight sessions take place over the course of 6 months.~Additional requirements for One-to-One Coaching:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to One-to-One Coaching.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
9539137|NCT03125330|Active Comparator|Group Coaching|"Participants meet for 90-minutes each month for 6 months for facilitated professional coaching with a group of colleagues.~Additional requirements:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to Group Coaching.~Prior to your initial group coaching session, participate in a 75-minute private phone interview with the primary investigator to discuss the how you make decisions and make sense of the world.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
9539138|NCT03125330|No Intervention|Group Coaching Waitlist|"Participants are offered group coaching at the completion of the 12-month study period. Six 90-minute group coaching sessions will occur over the course of six months.~Additional requirements:~• Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment (b) and at 6-months after study enrollment."
9539139|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
9539140|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
9539141|NCT03125343|Experimental|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
9622086|NCT02518607|Experimental|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
9622087|NCT02518607|Experimental|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
9803734|NCT03461978|Other|10 patients with cataract|
9803735|NCT03461978|Other|10 patients after minimally invasive glaucoma surgery (MIGS)|
9803736|NCT03461978|Other|10 patients after partial corneal transplantation|
9803737|NCT03461978|Other|5 patients with demodicosis|
10039462|NCT01844271|Experimental|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
9484636|NCT02044341|Placebo Comparator|Glycerin ear drops|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
9497954|NCT03470324|Active Comparator|[standard STN] + swallowing therapy|standard stimulation on subthalamic (STN) contacts plus swallowing therapy
9497955|NCT03470324|Experimental|[STN+SNr] + swallowing therapy|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) plus swallowing therapy
9497956|NCT03470311|Active Comparator|Benralizumab|Benralizumab 30mg in 1mL subcutaneously
9497957|NCT03470311|Placebo Comparator|Placebo|Matched placebo (1mL) to active Benralizumab subcutaneously
9497958|NCT03470298|Active Comparator|Mid luteal Endometrial Scratching (MLES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 . At this arm scratching done at mid luteal phase (day21) of the cycle before induction for ICSI
9497959|NCT03470298|Active Comparator|Retrieval Endometrial Scratching (RES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 .Here scratching done at same day of ovum pick up of ICSI cycle the difference only between arm of MLES and RES only in the timing of scratching .
9497960|NCT03470285|Other|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
9497961|NCT03470272|Experimental|Active Device|"Active Device: The FB Professional LED red light therapy system~FB Professional is a treatment regime using the FB Professional device for fat removal using red light therapy.~Intervention device: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs."
9497962|NCT03470259|Experimental|EMI-137 0.09mg/kg administration|"Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
9497963|NCT03470259|Experimental|EMI-137 0.13mg/kg administration|"Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
9497964|NCT03470259|Experimental|EMI-137 0.18mg/kg administration|"Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
9497965|NCT03470259|Experimental|EMI-137 0.045mg/kg administration|"If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
9497966|NCT03470246|No Intervention|CABG control group|The group of coronary artery disease patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
9497967|NCT03470246|Experimental|PACO intervention for CABG patients|The group of coronary artery disease patients receiving the PACO intervention for CABG patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
9497968|NCT03470246|No Intervention|AVR control group|The group of aortic valve stenosis patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
9497969|NCT03470246|Experimental|PACO intervention for AVR patients|The group of aortic valve stenosis patients receiving the PACO intervention for AVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
9484637|NCT02044081|Other|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
9484638|NCT02044081|Other|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
9484639|NCT02044081|Other|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
9484640|NCT02044081|Other|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
9484641|NCT02042378|Experimental|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
9484642|NCT02041195|Active Comparator|RM-493 Once Daily|Once daily in the morning, equivalent PBO in evening.
9484643|NCT02041195|Active Comparator|RM-493 Split Dose|Split dose, one half in the morning and one half in the evening.
9484644|NCT02041195|Placebo Comparator|Placebo|Placebo in the morning, placebo in the evening.
9484645|NCT02039401|Experimental|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
9484646|NCT02032277|Active Comparator|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
9484647|NCT02032277|Placebo Comparator|Arm C|Placebo + placebo + paclitaxel followed by AC.
9484648|NCT02032277|Placebo Comparator|Arm B|Placebo + carboplatin + paclitaxel followed by AC
9484649|NCT02032004|Experimental|Allogeneic Mesenchymal Precursor Cells|Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
9484650|NCT02032004|Sham Comparator|Control Treatment|Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
9484651|NCT02030925|Experimental|IW-3718|Twice a day
9484652|NCT02030925|Placebo Comparator|Matching Placebo|Twice a day
9484653|NCT02030860|Experimental|Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
9484654|NCT02030860|Active Comparator|No Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
9484655|NCT02030756|Active Comparator|Vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
9484656|NCT02030756|Sham Comparator|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
9484657|NCT02028338|Experimental|Dapivirine ring|dapivirine vaginal ring (25 mg)
9484658|NCT02028338|Placebo Comparator|Placebo ring|silicone vaginal ring
9484659|NCT02026401|Experimental|NGM282 Dose 1|NGM282 Dose 1
9484660|NCT02026401|Experimental|NGM282 Dose 2|NGM282 Dose 2
9484661|NCT02026401|Placebo Comparator|Placebo|Placebo
9484662|NCT02026349|Active Comparator|favipiravir|
9484663|NCT02026349|Placebo Comparator|placebo|
9484664|NCT02024529|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL Intra-articular injection of Ampion
9484665|NCT02024529|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
9484666|NCT02021370|Experimental|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
9484667|NCT02021370|Experimental|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
9484668|NCT02021370|Experimental|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
9484669|NCT02021370|Experimental|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
9484670|NCT02021370|Experimental|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
9484671|NCT02021370|Placebo Comparator|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
9484672|NCT02019589|Active Comparator|Progesterone 225 mg/day|Progesterone + Placebo
9484673|NCT02019589|Active Comparator|Progesterone, 300 mg/ day|Progesterone + Placebo
9484674|NCT02019589|Placebo Comparator|Placebo|Placebo
9484675|NCT02018926|Experimental|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
9484676|NCT02017912|Active Comparator|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
9484677|NCT02017912|Placebo Comparator|Excipient|Combined intramuscular and intrathecal placebo administration
9484678|NCT02017717|Experimental|Arm N:Nivolumab|Cohort 1, 1c, 1d and 2: Nivolumab specified dose on specified days
9539142|NCT03125343|Active Comparator|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
10039463|NCT01844271|Experimental|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
9539143|NCT03125421|Other|control period|standard preventive methods of pressure sores in each center
9539144|NCT03125421|Experimental|experimental period|experimental multifaceted preventive methods of pressure sores
9539145|NCT03125382|Active Comparator|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
9539146|NCT03125382|Active Comparator|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
9539147|NCT03125382|Experimental|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
9539148|NCT03125382|Experimental|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
9539149|NCT03125278||Medication indication on the label|Patients discharged from Regions Hospital (St. Paul, MN) where we have implemented a standard process of printing the indication for all new medications on the prescription bottle.
9539150|NCT03125278||No medication indication given|Patients discharged from Brigham and Women's Hospital (Boston, MA) where there is no requirement for providing information on medication indications to patients at discharge.
9539151|NCT03125057|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
9539152|NCT03125057|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
9539153|NCT03124914|Active Comparator|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
9539154|NCT03124914|Active Comparator|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
9539155|NCT03124654||Education|
9539156|NCT03124680|Active Comparator|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
9539157|NCT03124680|Placebo Comparator|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
9539158|NCT03124641|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of Hypothermic machine perfusion (HOPE) for 1-2 hours
9539159|NCT03124641|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
9539160|NCT03124615|Experimental|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
9539161|NCT03124628|Experimental|Flywheel resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform flywheel leg press resistance exercise twice per week.
9539162|NCT03124628|Active Comparator|Weight-stack resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform conventional, weight-stack leg press resistance exercise twice per week.
9539163|NCT03124433|Experimental|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
9539164|NCT03124589|No Intervention|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
10039464|NCT01844297|Other|TDF+3TC+EFV|
10039465|NCT01844310|Active Comparator|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
10039466|NCT01844310|Active Comparator|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
10039467|NCT01844323|Active Comparator|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
9539165|NCT03124589|Experimental|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
9539166|NCT03124446|Experimental|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
9539167|NCT03124446|Active Comparator|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
9539168|NCT03124498|Experimental|CIK Cell|"Phase I - Three dose levels escalated according to 3+3 rule~Phase II - The recommended dose level according to the results from Phase I"
9539169|NCT03124576||control group|Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
9539170|NCT03124576||group B|Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
9539171|NCT03124576||group C|Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
9539172|NCT03124576||group D|Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
9539173|NCT03124290|Other|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
9539174|NCT03124290|Other|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
9539175|NCT03124316|No Intervention|Email #1: FULLY TURNED OFF|No behavioural change techniques (BCTs) 'turned on' in the email. The email would contain only standardized content.
9539176|NCT03124316|Experimental|Email #2: ANTICIPATED REGRET|Anticipated regret content + standardized content
9539177|NCT03124316|Experimental|Email #3: MATERIAL INCENTIVE|Material incentive content + standardized content
9539178|NCT03124316|Experimental|Email #4: PROBLEM SOLVING|Problem solving content + standardized content
9539179|NCT03124316|Experimental|Email #5: REGRET + INCENTIVE|Anticipated regret content + Material incentive content + standardized content
9539180|NCT03124316|Experimental|Email #6: REGRET + PROBLEM SOLVING|Anticipated regret content + Problem solving content + standardized content
9539181|NCT03124316|Experimental|Email #7: INCENTIVE + PROBLEM SOLVING|Material incentive content + Problem solving content + standardized content
9539182|NCT03124316|Experimental|Email #8: ALL BCTs|Anticipated regret content + Material incentive content + Problem solving content + standardized content
9539183|NCT03124394||CRS and intraoperative chemotherapy|Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
10039468|NCT01844323|Active Comparator|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
10039469|NCT01844323|Active Comparator|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
10039470|NCT01844323|Active Comparator|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
9539184|NCT03124485|Experimental|Endoscopic Sleeve Gastroplasty|A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
9539185|NCT03124485|Active Comparator|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
9539186|NCT03124667|Experimental|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
9539187|NCT03124667|Active Comparator|Video Condition|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
9539188|NCT03124329|Experimental|Coronally Advanced Flap|
9539189|NCT03124329|Experimental|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|
9539190|NCT03124329|Experimental|Intrasulcular tunneling|
9539191|NCT03124329|Experimental|VISTA + Leukocyte-Platelet Rich Fibrin|
9539192|NCT03124524|No Intervention|Control group|33 healthy controls
9539193|NCT03124524|Active Comparator|Qlarista Group|group who were administered estradiol valerate/dienogest
9539194|NCT03124524|Active Comparator|Yasmin Group|group who were administered ethinylestradiol and drospirenone
9539195|NCT03124277|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
10039471|NCT01844336|Experimental|PBASE system 1.1 + CT100 (active treatment)|
10039472|NCT01844336|Placebo Comparator|PBASE system 1.1 + CT100 (placebo treatment)|
10039473|NCT01844401|Experimental|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
10039474|NCT01844401|Experimental|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
10039475|NCT01844414|Experimental|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
9539196|NCT03124277|Other|Control group|Best local diet
9539197|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
9484679|NCT02017717|Experimental|Arm N + I:Nivolumab + Ipilimumab|"Cohort 1: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days~Cohort 1b: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days"
9484680|NCT02017717|Active Comparator|Arm B: Bevacizumab|Cohort 2: Bevacizumab specified dose on specified days
9484681|NCT02016534|Experimental|Single arm|AMG 337 Monotherapy
9484682|NCT02014649|Experimental|20mg Laninamivir Octanoate|Dry Powder plus placebo
9484683|NCT02014649|Experimental|40mg Laninamivir Octanoate|Dry Powder
9484684|NCT02014142|Experimental|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
9484685|NCT02014142|Experimental|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
9484686|NCT02013310|Experimental|HT-0712 (50mg)|HT-0712 capsules administered once daily.
9484687|NCT02013310|Placebo Comparator|Placebo|Placebo capsules administered once daily.
9484688|NCT02010333|Experimental|Ha44 Gel 0.74% w/w|Open label, one arm
9484689|NCT02009579|Active Comparator|Experimental arm|Nintedanib/vargatef
9484690|NCT02009579|Placebo Comparator|Comparator arm|Placebo
9484691|NCT02009423|Experimental|Masitinib|masitinib-treatment arm
9484692|NCT02009423|Placebo Comparator|Placebo|placebo-treatment arm
9484693|NCT02008344|Active Comparator|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
9484694|NCT02008344|Placebo Comparator|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
9484695|NCT02006030|Experimental|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
9484696|NCT02006030|Active Comparator|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
9484697|NCT02004691|Experimental|GZ402665|Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
9484698|NCT02004691|Placebo Comparator|Placebo|Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
9484699|NCT01999764|Placebo Comparator|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
9484700|NCT01999764|Experimental|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
9484701|NCT01999764|Experimental|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
10039476|NCT01844414|Experimental|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
9484702|NCT01999361|Experimental|Myfortic treatment|Treatment with Myfortic
9484703|NCT01998828|Experimental|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
9484704|NCT01998828|Experimental|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
9484705|NCT01998828|Experimental|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
9484706|NCT01998828|Experimental|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
9484707|NCT01998035|Experimental|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)
9484708|NCT01998035|Experimental|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
9484709|NCT01998035|Experimental|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
9484710|NCT01998035|Experimental|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
9484711|NCT01998035|Experimental|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
9484712|NCT01998035|Experimental|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
9484713|NCT01998035|Experimental|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
9484714|NCT01994382|Experimental|Phase 1 Cerdulatinib|During Phase 1, participants will receive oral cerdulatinib on Day 1 and then starting on Day 4 at doses of 15 mg up to 100 mg QD or oral cerdulatinib at doses of 15 mg up to 45 mg BID in 28-day cycles (except Cohort 1 will have a 21-day cycle starting on Day 1) for up to 10 cycles.
9484715|NCT01994382|Experimental|Phase 2a Cerdulatinib|During Phase 2a, participants in cohorts based on cancer type will receive oral cerdulatinib at starting doses of 35, 30, or 20 mg BID on Day 1 in 28-day cycles for up to 10 cycles. Doses of cerdulatinib can be reduced to a minimum dose of 15 mg BID or increased to a maximum dose of 30 mg BID at the discretion of the Investigator based upon clinical judgment and with Sponsor Medical Monitor approval.
9484716|NCT01994382|Experimental|Phase 2a Cerdulatinib plus Rituximab|During Phase 2a, participants in this cohort will receive oral cerdulatinib at their applicable dose and an IV injection of rituximab 375 mg/m^2 on Days 1, 8, 15, and 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, and 10.
9484717|NCT01993641|Experimental|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
9484718|NCT01991210|Experimental|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
9539198|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
10039477|NCT01844414|Active Comparator|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
9539199|NCT03124472|Active Comparator|uterine artery ligation|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
9539200|NCT03124472|Active Comparator|Traditional lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
9539201|NCT03124186|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
10039478|NCT01844427|Active Comparator|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
10039479|NCT01844427|Placebo Comparator|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
9539202|NCT03124186|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
9539203|NCT03124420|Active Comparator|Group A (Drug: 7-day triple therapy)|Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
9539204|NCT03124420|Sham Comparator|Group B (Drug: 14-day triple therapy)|Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).
9539205|NCT03124238|Experimental|Massage|Massage therapy of the lumbar muscles in a prone position during 30 minutes
9539206|NCT03124238|No Intervention|Control|Rest during 5 minutes in a prone position
9539207|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
9539208|NCT03124082|Active Comparator|opioid|remifentanil 0,15-0,25 mcg/kg/h
9539209|NCT03124082|Experimental|opioid free|ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg
9539210|NCT03124095|Experimental|Combined Exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
9539211|NCT03124095|No Intervention|Control Group|The control group will be advised not to change their health habits. After the intervention they will be invited to participate in a physical exercise program.
9539212|NCT03123900|Experimental|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
9539213|NCT03123900|Experimental|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
9539214|NCT03123900|Experimental|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
9539215|NCT03123900|No Intervention|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
9539216|NCT03124160|Experimental|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
9539217|NCT03124160|Active Comparator|ParaGard® CuT380A|ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.
9539218|NCT03124017|Experimental|Alert Group|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
9539219|NCT03124017|No Intervention|Control Group|No electronic alert and no Geneva Risk Score calculation tool issued in the electronic patient chart
9539220|NCT03124043|Experimental|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
9539221|NCT03124043|Experimental|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
10039480|NCT01844440|Experimental|HRM|
9539222|NCT03124173|Other|Behavioral Tasks|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
9484719|NCT01991210|Active Comparator|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
9484720|NCT01989429|Active Comparator|Daivonex|topical application
9484721|NCT01989429|Placebo Comparator|vehicle|topical application
9484722|NCT01989429|Experimental|M518101|topical application
9484723|NCT01989325|Experimental|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
9484724|NCT01989325|Experimental|Carfilzomib|"Single agent arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
9484725|NCT01989234|Placebo Comparator|Placebo Comparator|Placebo Comparator
9484726|NCT01989234|Experimental|YKP10811 High Dose|YKP10811 High Dose
9484727|NCT01989234|Experimental|YKP10811 Mid Dose|YKP10811 Mid Dose
9484728|NCT01989234|Experimental|YKP10811 Low Dose|YKP10811 Low Dose
9484729|NCT01988584|Active Comparator|Umbilical Cord Blood (UCB) Arm|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
9484730|NCT01988584|Active Comparator|Bone Marrow Stem Cells (BMMNC's)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
9484731|NCT01988584|Placebo Comparator|Placebo (inactive substance) Group|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
9484732|NCT01984788|Active Comparator|BCX4161|400 mg TID for 28 days
9484733|NCT01984788|Placebo Comparator|Placebo|TID for 28 days
9484734|NCT01983306|Experimental|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
9484735|NCT01983306|Experimental|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
9484736|NCT01983306|Experimental|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
9484737|NCT01983306|Placebo Comparator|Placebo|Placebo orally once daily for 4-week Treatment Period
9484738|NCT01981837|Experimental|ALN-TTRSC (revusiran)|
9484739|NCT01979939|Experimental|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
9484740|NCT01979939|Experimental|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
9484741|NCT01978366|Experimental|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
9484742|NCT01978366|Experimental|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
9484743|NCT01978366|Experimental|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
9484744|NCT01978366|Experimental|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
9484745|NCT01978366|Experimental|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
9484746|NCT01975818|Experimental|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
9484747|NCT01975818|Experimental|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
9484748|NCT01975818|Experimental|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
9484749|NCT01975818|Experimental|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
9484750|NCT01975818|Active Comparator|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
9484751|NCT01975610|Experimental|CC-292 375mg|Treatment
9484752|NCT01975610|Placebo Comparator|Placebo|Control
9484753|NCT01973049|Experimental|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
9484754|NCT01973049|Experimental|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200mg tablet orally twice a day for 12 weeks"
9539223|NCT03123913|Experimental|Combination therapy|Testosterone Enanthate and Somatropin
9622088|NCT02518607|Experimental|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
9539224|NCT03123991|Experimental|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
9539225|NCT03123991|Other|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
10039481|NCT01844453|Experimental|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
10039482|NCT01844453|Experimental|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
10039483|NCT01844453|No Intervention|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
10039484|NCT01844466|Experimental|stroke patients|
9539226|NCT03124030||Direct Oral Anticoagulants|assuming Pradaxa or Apixaban or Eliquis; undergo simple dental extraction
9539227|NCT03124030||Oral Anticoagulant therapy|assuming Coumadin or Sintrom; undergo simple dental extraction
9539228|NCT03124004||Direct Oral Anticoagulants|assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement
9539229|NCT03124004||oral anticoagulant therapy|assuming Coumadin or Sintrom; undergoing periodontal debridement
9539230|NCT03123822|Experimental|Single vision glasses|Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
9539231|NCT03123822|Experimental|Single vision glasses with anti-glare coating|Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
9539232|NCT03123822|Experimental|Eyezen|Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours
9539233|NCT03124134|Experimental|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
9539234|NCT03124134|Experimental|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
9539235|NCT03124134|Placebo Comparator|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
9539236|NCT03124134|Placebo Comparator|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
9539237|NCT03124134|Experimental|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
9539238|NCT03124134|Placebo Comparator|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
9539239|NCT03123835|Other|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
10039485|NCT01844492|Active Comparator|ICU Usual Care Control|described below
10039486|NCT01844492|Experimental|The PARTNER Intervention|described below
10039487|NCT01844544||patients after femur neck fracture|
10039488|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
10039489|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
10058425|NCT02018237|Active Comparator|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
9616239|NCT04141878|Active Comparator|Aerobic Exercise Group|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise will vary, but will primarily focus on in-class walking tutorials. Participants will work with a Personal Trainer to create their own physical activity program that will fit their needs and schedule. The Personal Trainer will supervise the participants directly for the first 6 weeks. Once participants are consistently and safely meeting their goals, their Personal Trainer will allow unsupervised exercise sessions.
9616240|NCT04141878|Active Comparator|Diet Skills Group|Participants will attend weekly classes focused on incorporating heart healthy foods (e.g., fruits and vegetables) into their existing dietary plan. We will ask them to limit the number of calories they take in and will show them how to use portion control with the goal of losing body weight. Participants will also learn hands-on skills for preparing healthy meals at home in cooking classes led by professional chefs.
9616241|NCT04140214|Experimental|Standard Care and HTS|Standard care and twice-daily nebulised HTS (MucoClear 6%, PARI Pharma). Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser and eTrack controller (PARI Pharma).
10039490|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
10039491|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
9484755|NCT01973049|Experimental|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
9484756|NCT01973049|Experimental|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If < 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
9484757|NCT01972854|Experimental|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
9484758|NCT01972854|Placebo Comparator|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
9484759|NCT01972178|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
9484760|NCT01972178|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
9484761|NCT01972139|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
9484762|NCT01972139|Other|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
9484763|NCT01970501|Experimental|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
9484764|NCT01970501|Active Comparator|metoprolol succinate|"metoprolol succinate (Toprol-XL)~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing."
9484765|NCT01969838|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
9484766|NCT01969838|Active Comparator|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
9484767|NCT01968733|Active Comparator|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
9484768|NCT01968733|Experimental|Solithromycin|Intravenous with potential step-down to oral solithromycin
9484769|NCT01968720|Experimental|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
9484770|NCT01968187|Experimental|FE 992097|
9484771|NCT01968187|Placebo Comparator|Placebo|
9484772|NCT01967810|Experimental|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM participants
9484773|NCT01967810|Experimental|Arm 2|ANG1005, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants
9484774|NCT01967810|Experimental|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma participants
9484775|NCT01966601|Experimental|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
9484776|NCT01966601|Experimental|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
9484777|NCT01966601|Experimental|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
9484778|NCT01966601|Placebo Comparator|Placebo|Placebo via continuous IV infusion
9484779|NCT01966549|Experimental|CNTO 6785|
9484780|NCT01966549|Placebo Comparator|Placebo|
9484781|NCT01965613|Experimental|open label-Xilonix|Open label-Xilonix
9484782|NCT01965106|Active Comparator|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
9484783|NCT01965106|Sham Comparator|Control|Placebo (Sham injection procedure)
9484784|NCT01964989|Experimental|aQIV|flu vaccine
9484785|NCT01964989|Active Comparator|non-adjuvanted comparator|flu vaccine
9484786|NCT01963598|Experimental|Group 1|Dosing regimen 1
9484787|NCT01963598|Experimental|Group 2|Dosing regimen 2
9484788|NCT01963598|Experimental|Group 3|Dosing regimen 3
9484789|NCT01963598|Experimental|Group 4|Dosing regimen 4
9484790|NCT01963208|Experimental|ganaxolone|active
9484791|NCT01963208|Placebo Comparator|Placebo|placebo, non-active
9484792|NCT01961778|Active Comparator|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
9484793|NCT01961778|Active Comparator|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
9484794|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
9484795|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
9484796|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
10039492|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
10039493|NCT01844596|No Intervention|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
10039494|NCT01844596|Experimental|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
10039495|NCT01844596|Experimental|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
9484797|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
9484798|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
10039496|NCT01844609|Experimental|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
10039497|NCT01844609|Experimental|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
10039498|NCT01844622|Other|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
10039499|NCT01844635|Experimental|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
9484799|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
9484800|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
9484801|NCT01960686|Placebo Comparator|Placebo|Day 0: Placebo Day 28: Placebo
9484802|NCT01960010|Active Comparator|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
9484803|NCT01960010|Placebo Comparator|Vehicle|Vehicle
9484804|NCT01959282|Placebo Comparator|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
9484805|NCT01959282|Experimental|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
9484806|NCT01959282|Experimental|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
9484807|NCT01959282|Experimental|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
9484808|NCT01959282|Experimental|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
9484809|NCT01958853|Experimental|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
9484810|NCT01957722|Experimental|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
9484811|NCT01957722|Active Comparator|Microfracture|considered a typical treatment for articular cartilage repair
9484812|NCT01956812|Experimental|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
9484813|NCT01956812|Active Comparator|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
9484814|NCT01955616|Active Comparator|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
9484815|NCT01955616|Placebo Comparator|Placebo|by subcutaneous injection daily in the morning
9484816|NCT01955109|Experimental|Viaskin Peanut 250 mcg|
9484817|NCT01954173|Experimental|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
10039500|NCT01844635|Active Comparator|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
10039501|NCT01844648|Experimental|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
9539240|NCT03123770|Experimental|DC Follow T|Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.
9539241|NCT03123770|Active Comparator|EC Follow T|Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.
9539242|NCT03123796||Only PPI|Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists.
9539243|NCT03123796||Only H2RA|Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors.
9539244|NCT03123796||PPI and H2RA|Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists.
9539245|NCT03123796||No Acid Suppressive Treatment|Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists.
9539246|NCT03124147|Active Comparator|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
9539247|NCT03124147|Active Comparator|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
9539248|NCT03124147|Active Comparator|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
9539249|NCT03124147|Sham Comparator|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
9539250|NCT03123666|Experimental|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
9539251|NCT03123666|Placebo Comparator|Placebo|Placebo will be given identical to the interventional
10039502|NCT01844648|Placebo Comparator|NH004 placebo|placebo thin film, twice daily for 7 days
10039503|NCT01844661|Experimental|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
10039504|NCT01844674|Experimental|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
10039505|NCT01844713|Experimental|Experimental: Workbook|Distribution of the sun protection educational workbook
10039506|NCT01844713|No Intervention|Control|Distribution of general skin care information
10039507|NCT01844739|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
10039508|NCT01844739|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
10039509|NCT01844752|Experimental|NVN1000 1% Gel|NVN1000 1% Gel twice daily
10039510|NCT01844752|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily
10039511|NCT01844752|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily
10039512|NCT01844791|Experimental|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
10039513|NCT01844804|Experimental|A = PF-06438179|
10039514|NCT01844804|Active Comparator|B = Infliximab-EU|
10039515|NCT01844804|Active Comparator|C = Infliximab-US|
10039516|NCT01844843|Experimental|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
10039517|NCT01844869|Experimental|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
10039518|NCT01844882||Chronic Kidney Disease|
10039519|NCT01844908|Experimental|Electroacupuncture|
10039520|NCT01844934|No Intervention|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
10039521|NCT01844934|Experimental|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
10039522|NCT01844947|Experimental|vinflunine + sorafenib|Single arm study.
10039523|NCT01844960|Active Comparator|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
10039524|NCT01844960|Experimental|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
10039525|NCT01844973|Placebo Comparator|Vehicle|
10039526|NCT01844973|Active Comparator|M518101|
10039527|NCT01844999|Other|Usual patient education + standard educational websites|
10039528|NCT01844999|Experimental|Usual patient education + P3P decision support website|
10039529|NCT01845012|Experimental|Daily hemodialysis at low dialysate flow|
10039530|NCT01845038|Experimental|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
10039531|NCT01845038|Experimental|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
10039532|NCT01845038|Active Comparator|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
10039533|NCT01845051||Migraine group|Patients diagnosed with migraine
9539252|NCT03123692|Experimental|Treatment|14 days treatment with NBMI 300 mg/day
9484818|NCT01952990|Experimental|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to <20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to <40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
9484819|NCT01952132|Experimental|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
9484820|NCT01952132|Experimental|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
9484821|NCT01952132|Placebo Comparator|Placebo|Orally administering placebo daily for 14 days
9484822|NCT01952132|Experimental|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
9484823|NCT01951742|Placebo Comparator|Vehicle|vehicle without ANT-1401
9484824|NCT01951742|Experimental|Dose 1|lowest dose
9484825|NCT01951742|Experimental|Dose 2|second lowest dose
9484826|NCT01951742|Experimental|Dose 3|mid-level dose
9484827|NCT01951742|Experimental|Dose 4|second highest dose
9484828|NCT01951742|Experimental|Dose 5|highest dose
9484829|NCT01951690|Experimental|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
9484830|NCT01951274|Experimental|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
9484831|NCT01951274|Experimental|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
9484832|NCT01951274|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
9484833|NCT01951274|Placebo Comparator|Placebo|placebo tablets to be taken daily by mouth for 42 days
9484834|NCT01951235|Experimental|Imeglimin (Dose 1)|
9484835|NCT01951235|Experimental|Imeglimin (Dose 2)|
9484836|NCT01951235|Experimental|Imeglimin (Dose 3)|
9484837|NCT01951235|Experimental|Imeglimin (Dose 4)|
9484838|NCT01951235|Placebo Comparator|Placebo|
9484839|NCT01949324|Experimental|NT-501 Implant procedure|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
9484840|NCT01949324|Sham Comparator|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
9484841|NCT01942265|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
9484842|NCT01942265|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
9484843|NCT01942265|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
9484844|NCT01942265|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
9484845|NCT01942265|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
9484846|NCT01942265|Experimental|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
9484847|NCT01942265|Experimental|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
9484848|NCT01942265|Experimental|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
9484849|NCT01942265|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
9484850|NCT01942265|Experimental|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
9484851|NCT01941836|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
9484852|NCT01941836|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
9484853|NCT01941836|Active Comparator|ezetimibe 10mg/day|Orally, once daily in morning as capsules
9484854|NCT01941836|Experimental|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
9484855|NCT01941836|Experimental|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
9484856|NCT01941563|Experimental|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
9484857|NCT01941563|Sham Comparator|Control|Sham injection
9484858|NCT01941043|Experimental|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
9484859|NCT01941043|Experimental|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
9484860|NCT01941043|Placebo Comparator|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
9484861|NCT01940991|Placebo Comparator|Dose B|Dose B: Placebo
9484862|NCT01940991|Experimental|Dose A|Dose A: Botulinum Toxin Type A
9484863|NCT01939184|Experimental|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
9484864|NCT01939184|Experimental|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
9484865|NCT01939184|Experimental|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
9484866|NCT01939184|Experimental|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
9484867|NCT01939184|Placebo Comparator|WC3055-07P|Placebo tablet once daily for 12 weeks
9484868|NCT01938742|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
9484869|NCT01938742|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
9484870|NCT01938742|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
9484871|NCT01938742|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
9484872|NCT01938742|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
9539253|NCT03123692|Placebo Comparator|Placebo|14 days treatment with Placebo
9803738|NCT03461978|Other|5 patients with conjunctival pathologies|
9803739|NCT03461978|Other|5 patients with Acanthamoeba keratitis|
9803740|NCT03461978|Other|5 patients with aniridia|
9803741|NCT03453489|Experimental|Treatment (AMT-PET, telotristat etiprate)|Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.
10039534|NCT01845051||Healthy group|Healthy subjects with no migraine as control
10039535|NCT01845064|Experimental|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
9484873|NCT01938742|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
9484874|NCT01938742|Experimental|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
9484875|NCT01938599|Experimental|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
9484876|NCT01938599|Placebo Comparator|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
9484877|NCT01932099|Experimental|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
9484878|NCT01930357|Experimental|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
9484879|NCT01930357|Active Comparator|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
9484880|NCT01930123|Experimental|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
9484881|NCT01930123|Active Comparator|Health controls|15 healthy controls for comparison with NAFLD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
9484882|NCT01928420|Experimental|NIC5-15|Subjects with Alzheimer's Disease Intervention: Drug: NIC5-15
9484883|NCT01928420|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Drug: Placebo
9484884|NCT01927198|Experimental|RDEA3170 5 mg qd|No titration.
9484885|NCT01927198|Experimental|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
9484886|NCT01927198|Experimental|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
9484887|NCT01927198|Placebo Comparator|Placebo|Placebo group
9484888|NCT01923727|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
9484889|NCT01922843|Experimental|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
9484890|NCT01922843|Placebo Comparator|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
9484891|NCT01918397|Active Comparator|Dose 1|Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
9484892|NCT01918397|Experimental|Dose 2|Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
9484893|NCT01918397|Experimental|Dose 3|Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
9484894|NCT01918397|Experimental|Dose 4|Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
9484895|NCT01917825|Experimental|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
9497970|NCT03470246|No Intervention|MVR control group|The group of mitral valve insufficiency patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
9497971|NCT03470246|Experimental|PACO intervention for MVR patients|The group of mitral valve insufficiency patients receiving the PACO intervention for MVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
9497972|NCT03470220||Ultrasound|All included patients will be examined with ultrasound
9497973|NCT03470207|No Intervention|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
9497974|NCT03470207|Experimental|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
9497975|NCT03470181||Participants with Diagnosed CVS|This cohort will consist of 15 current patients previously diagnosed with Cyclic Vomiting Syndrome.
9497976|NCT03470181||Healthy Volunteers|This cohort will consist of 15 healthy volunteers, with no history of Cyclic Vomiting.
9497977|NCT03470168|Experimental|Hyperbaric Oxygen Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
10039536|NCT01845064|Experimental|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
10039537|NCT01845064|Experimental|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
9497978|NCT03470168|Placebo Comparator|Placebo group|were also taken inside the Hyperbaric Chamber, but received only normobaric oxygen therapy for the same period of time at 1 ATA
9803742|NCT03450668|Active Comparator|standard incubator|routinely used standard incubator already used in the neonatal unit
9803743|NCT03450668|Experimental|mOm incubator|new test incubator
10039538|NCT01845064|Experimental|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
10039539|NCT01845064|Placebo Comparator|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
10039540|NCT01845064|Placebo Comparator|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
10039541|NCT01845064|Placebo Comparator|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
10039542|NCT01845064|Placebo Comparator|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
10039543|NCT01845090|Active Comparator|Lanthanum carbonate|Lanthanum carbonate 375mg~750 mg tid for 6 months
10039544|NCT01845090|Active Comparator|Calcium carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
10039545|NCT01845116|Other|Single Arm|Single Omegaven® Intervention Arm
10039546|NCT01845129|Experimental|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
10039547|NCT01845129|Sham Comparator|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
10039548|NCT01845142|Active Comparator|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
10039549|NCT01845142|Placebo Comparator|intramuscular placebo|intramuscular 0.9% sodium chloride
10039550|NCT01845142|Active Comparator|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
10039551|NCT01845142|Placebo Comparator|subcutaneous placebo|subcutaneous 0.9% sodium chloride
10039552|NCT01845168|Active Comparator|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
9484896|NCT01917383|Experimental|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
9484897|NCT01917383|Active Comparator|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
9484898|NCT01913158|Placebo Comparator|Placebo suppository|Hydrogenated palm kernel oil suppositories
9484899|NCT01913158|Active Comparator|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
9484900|NCT01912560|Experimental|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
9484901|NCT01912560|Experimental|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
9484902|NCT01912560|Experimental|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
9484903|NCT01912560|Experimental|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
9484904|NCT01911897|Experimental|MobiusHD|MobiusHD
9484905|NCT01910025|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
9484906|NCT01910012|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
9484907|NCT01909427|Placebo Comparator|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
9484908|NCT01909427|Experimental|CNTO 6785 200 mg+MTX|
9484909|NCT01909427|Experimental|CNTO 6785 100 mg+MTX|
9484910|NCT01909427|Experimental|CNTO 6785 50 mg+MTX|
9484911|NCT01909427|Experimental|CNTO 6785 15 mg+MTX|
9484912|NCT01909232|Experimental|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
9484913|NCT01909232|Sham Comparator|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
9484914|NCT01908738|Experimental|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
9484915|NCT01908738|Experimental|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
9484916|NCT01908738|Placebo Comparator|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
9484917|NCT01908595|Experimental|M518101|Proper quantity twice daily
9484918|NCT01906489|Experimental|AKB-6548|
9484919|NCT01906489|Placebo Comparator|Placebo|
9484920|NCT01904409|Placebo Comparator|Placebo|Placebo tablets once daily.
9484921|NCT01904409|Experimental|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
9484922|NCT01904409|Experimental|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
9484923|NCT01904409|Experimental|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
9484924|NCT01904409|Experimental|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
9484925|NCT01904409|Experimental|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
9484926|NCT01903954|Active Comparator|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
9484927|NCT01903954|Experimental|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
9484928|NCT01902381|Experimental|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
9484929|NCT01897480|Experimental|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
10039553|NCT01845168|No Intervention|controlgroup, normal procedures|The control-group: GP working in normal procedures
10039554|NCT01845181|Placebo Comparator|Dose Level I - Group A - Placebo|2 capsules of placebo
10039555|NCT01845181|Experimental|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
9484930|NCT01897480|Active Comparator|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
9484931|NCT01896830|Experimental|Vaccine Group|Participants will receive the candidate C. difficile toxoid vaccine
9484932|NCT01896830|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
9484933|NCT01896583|Experimental|ASP7147|ASP7147, 300 mg, tablet, twice per day for 4 weeks oral
9484934|NCT01896583|Placebo Comparator|Placebo|oral
9484935|NCT01896531|Experimental|Ipatasertib + mFOLFOX6|Participants will receive oral ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
9484936|NCT01896531|Placebo Comparator|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
9484937|NCT01896479|Experimental|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
9484938|NCT01896479|Experimental|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
9484939|NCT01894958|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
9484940|NCT01894958|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water
9484941|NCT01893515|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
9484942|NCT01893515|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
9484943|NCT01893190|Active Comparator|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
9484944|NCT01893190|Experimental|Nimodipine Microparticles|Single intraventricular injection
9484945|NCT01893138|Experimental|Roll-in: AMDC for USR|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
9484946|NCT01893138|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
9484947|NCT01893138|Experimental|AMDC for USR|AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
9484948|NCT01893138|Placebo Comparator|Roll in: Placebo|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
9484949|NCT01891760|Experimental|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
9484950|NCT01891760|Active Comparator|Reference Therapy|Profore - Four-layer compression bandaging therapy
9484951|NCT01890837|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
9484952|NCT01890837|Placebo Comparator|Placebo|Placebo TID
9484953|NCT01890161|Experimental|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
9484954|NCT01890161|Placebo Comparator|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
9484955|NCT01887886|Experimental|Onartuzumab + Erlotinib|
9484956|NCT01887886|Active Comparator|Placebo + Erlotinib|
9484957|NCT01887366|Experimental|TV-1380 150 mg|
9484958|NCT01887366|Experimental|TV-1380 300 mg|
9484959|NCT01887366|Placebo Comparator|Placebo|
9484960|NCT01887002|Experimental|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
9484961|NCT01887002|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
9484962|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
9484963|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
9484964|NCT01885260|Placebo Comparator|Placebo|Placebo
9484965|NCT01885156|Placebo Comparator|Placebo Cream|Topically applied once daily
9484966|NCT01885156|Experimental|Naftin 1% Cream|Topically applied once daily
9484967|NCT01882699|Experimental|Cereve sleep system|Cereve sleep system
9484968|NCT01878461|Placebo Comparator|Vehicle|Proper quantity twice a day
9484969|NCT01878461|Experimental|M518101|Proper quantity twice a day
9484970|NCT01877395|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
9484971|NCT01877395|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
9484972|NCT01876719|Experimental|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
9484973|NCT01876719|Experimental|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
9484974|NCT01876719|Experimental|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
9484975|NCT01876719|Placebo Comparator|Placebo|Placebo, QD for 7 weeks
9484976|NCT01874938|Experimental|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
9484977|NCT01874626|Active Comparator|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
9484978|NCT01874626|Placebo Comparator|Placebo|Placebo topical formulation (Reference product)
9484979|NCT01873703|Experimental|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
10039556|NCT01845181|Placebo Comparator|Dose Level II - Group B - Placebo|1 capsule of placebo
10039557|NCT01845181|Experimental|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
10039558|NCT01845181|Experimental|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
9484980|NCT01873703|Placebo Comparator|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
10039559|NCT01845181|Placebo Comparator|Dose Level III - Group C - Placebo|2 capsules of placebo
9484981|NCT01873677|Placebo Comparator|Vehicle|Proper quantity twice a day
9484982|NCT01873677|Experimental|M518101|Proper quantity twice a day
9484983|NCT01873534|Experimental|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
9484984|NCT01873534|Experimental|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
9484985|NCT01873534|Experimental|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
9484986|NCT01873404|Experimental|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
9484987|NCT01873404|Placebo Comparator|Placebo|Matched placebo IV injection 3 times per week for 1 week
9484988|NCT01872598|Experimental|Masitinib escalating dose|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
9484989|NCT01872598|Experimental|Masitinib fixed dose (4.5 mg/kg/day)|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
9484990|NCT01872598|Experimental|Masitinib fixed dose (3.0 mg/kg/day)|Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
9484991|NCT01872598|Placebo Comparator|Placebo (escalating dose)|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
9484992|NCT01872598|Placebo Comparator|Placebo (fixed dose)|Participants receive fixed dose placebo, given orally twice daily
9484993|NCT01871428|Experimental|Aleglitazar|
9484994|NCT01871428|Placebo Comparator|Placebo|
9484995|NCT01871415|Experimental|Aleglitazar + metformin|
9484996|NCT01871415|Active Comparator|Placebo + metformin|
9484997|NCT01870609|Active Comparator|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
9484998|NCT01870609|Placebo Comparator|Placebo|2 placebo tablets, administered orally, twice daily
9484999|NCT01870505|Experimental|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
9485000|NCT01870505|Experimental|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
9485001|NCT01870505|Experimental|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
9485002|NCT01870505|Experimental|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
9485003|NCT01868516|Placebo Comparator|Placebo|One tablet of placebo to be administered orally twice a day.
9485004|NCT01868516|Experimental|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
9485005|NCT01868516|Experimental|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
9485006|NCT01868516|Experimental|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
9485007|NCT01867762|Experimental|JNJ 49095397|
9485008|NCT01867762|Placebo Comparator|Placebo|
9485009|NCT01866930|Experimental|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
9485010|NCT01866930|Experimental|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing <75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
9485015|NCT01864603|Experimental|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions"
9539254|NCT03123744|Experimental|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
9539255|NCT03123757|Other|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
10039560|NCT01845181|Experimental|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
9539256|NCT03123549|Experimental|Simplify Disc|Simplify Disc at two levels of the cervical spine
9539257|NCT03123549|No Intervention|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=188) of a previously completed two level cervical disc trial.
10039561|NCT01845181|Placebo Comparator|Dose Level IV - Group D - Palcebo|3 capsules of placebo
9539258|NCT03123718|Other|Intrathecal Methotrexate|
9539259|NCT03123718|Active Comparator|High-dose Intravenous Methotrexate|
9539260|NCT03123536||Point-of-care ultrasound group|High risk patients received point-of-care ultrasound assessment perioperatively, treatment was oriented by the findings of point-of-care ultrasound.
9539261|NCT03123536||Control group|High risk patients received management by the experience of the clinical team.
9539262|NCT03123562|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
9539263|NCT03123510|Experimental|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
9539264|NCT03123510|Placebo Comparator|placebo|sugar pills
9539265|NCT03123731|Active Comparator|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
9539266|NCT03123731|Experimental|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
9539267|NCT03123731|Experimental|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
9539268|NCT03123653|Experimental|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.
9539269|NCT03123406|Experimental|Severe SHPT|Administer Cinacalcet HCL to subjects whose iPTH>900 pg/ml from 1st to 32nd week.
10039562|NCT01845194|Experimental|Drug application|"Two treatment periods:~Treatment period 1:~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application~Treatment period 2:~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
10039563|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
10039564|NCT01845233||Non invasive ventilation|
10039565|NCT01845246|No Intervention|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
10039566|NCT01845246|Experimental|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
10039567|NCT01845259|Experimental|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
10039568|NCT01845259|Placebo Comparator|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
9539270|NCT03123406|Experimental|Moderate SHPT|Administer Cinacalcet HCL to subjects whose 600≤iPTH<900 pg/ml from 1st to 32nd week.
9539271|NCT03123406|Experimental|Mild SHPT|Administer Cinacalcet HCL to subjects whose 300≤iPTH<600 pg/ml from 1st to 32nd week.
9539272|NCT03123523||Patients group|35 patients
9539273|NCT03123523||Healthy volunteers|20 healthy volunteers
9539274|NCT03123601|Experimental|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
9539275|NCT03123640|Experimental|Intervention group|Pharmacist conducts medication reconciliation and medication review while the patient is admitted to the emergency Department. The pharmacist present results from medication reconciliation to physicians at the emergency Department before the Medical history is obtained. Further the pharmacist will discuss drug related problems obtained during the medication review with the physicians to customize and optimize the medication treatment for each patient.
9539276|NCT03123640|No Intervention|Control group|Standard treatment without pharmacist intervention in the emergency department
9539277|NCT03123484|Experimental|β-elemene+EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
9539278|NCT03123484|Active Comparator|EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
9539279|NCT03123289|Experimental|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
9539280|NCT03123289|Experimental|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.~Note that same patients scanned with different radiotracers serve in both arms."
9539281|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
9539282|NCT03123419|Other|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
9539283|NCT03123302||Group 1|Epileptic patients who are sedated with a total dose of propofol 2 mg/kg and midazolam 0.1 mg/kg.
9539284|NCT03123302||Group 2|Epileptic patients who are sedated with a total dose of pentothal 4 mg/kg and midazolam 0.1 mg/kg.
10039569|NCT01845272|Experimental|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
10039570|NCT01845272|Experimental|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
10039571|NCT01845285||aortic valve disease|aortic valve replacement
10039572|NCT01845298|Experimental|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
10039573|NCT01845311|Experimental|ReZolve2 Treatment Group|
10039574|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
10039575|NCT01845337|Active Comparator|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
10039576|NCT01845337|Active Comparator|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
10039577|NCT01845337|Active Comparator|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA < 1.5 m2), 45 mg (BSA 1. 5 to < 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
10039578|NCT01845337|Active Comparator|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA < 1.5 m2), 40mg (BSA 1.5 to < 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA >1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
10039579|NCT01845350|Other|M2 macrophages|M2 macrophage introduction
10039580|NCT01845363|Other|Cefazolin|"Cefazolin used in antimicrobial prophylaxis~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
10039581|NCT01845376|Experimental|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
10058426|NCT02018250|Experimental|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
9485016|NCT01864603|Active Comparator|1st: baseline community testing; 2nd: None|Comparator arm first phase: baseline community-based HIV and multi-disease testing; ART by country standard of care
9485017|NCT01862224|Experimental|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
9485018|NCT01862224|Placebo Comparator|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
9485019|NCT01861847|Placebo Comparator|Placebo Group|Placebo Comparator
9485020|NCT01861847|Active Comparator|Drug group|7 Keto-DHEA
9485021|NCT01861249|Experimental|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
9485022|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
9485023|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
9485024|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
9485025|NCT01858883|Experimental|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
9485026|NCT01855880|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
9485027|NCT01855880|Experimental|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
9485028|NCT01855880|Placebo Comparator|Placebo AbGn-168H|Subject to receive placebo
9485029|NCT01854294|Experimental|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
9485030|NCT01854294|Placebo Comparator|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
9485031|NCT01853995|Experimental|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
9485032|NCT01853995|No Intervention|Untreated Class II Control Group|control group
9485033|NCT01853722|Experimental|DCN01|
9485034|NCT01853722|Placebo Comparator|Unisol|
9485035|NCT01851083|Experimental|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
9485036|NCT01851083|Placebo Comparator|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
9485037|NCT01850381|Experimental|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
9485038|NCT01850381|Placebo Comparator|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
9485039|NCT01847573|Experimental|Cohort 1: HT-100 tablet, Dose 1|"Single dose administration: Dose 1~Multiple dose administration: Dose 1"
9539285|NCT03123302||Group 3|Non-epileptic patients who are sedated with a total dose of propofol 1 mg/kg and ketamine 1 mg/kg.
9539286|NCT03123302||Group 4|Non-epileptic patients who are sedated with a total dose of midazolame 0.1 mg/kg and ketamine 1 mg/kg.
9539287|NCT03123627|Experimental|New profilaxis|Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
9539288|NCT03123627|Active Comparator|Profilaxis recommended by TTS|Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.
9539289|NCT03123432|Experimental|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
9539290|NCT03123432|Active Comparator|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
9539291|NCT03123445|Experimental|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
9539292|NCT03123445|Active Comparator|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
9539293|NCT03123315|Experimental|Cook Bush DL™ Ureteral Illuminating Catheter|As part of this study an additional tool will be used during the hysterectomy. This tool is called a Cook Bush DL™ Ureteral Illuminating Catheter, which is a lighted ureteral stent. This is a very thin tube that goes into the ureter. A urologist, who is an expert at placing these devices, will insert a stent into each ureter during surgery. The lighted stents will help effectively find the ureters and keep track of them during the surgery. This same procedure is already being done in many other forms of abdominal surgery to help find the ureter. The stents will be removed before the surgery is complete and treatment will not differ in any other way.
9539294|NCT03123250|Experimental|Aquablation procedure|
9539295|NCT03123367|Active Comparator|Group 1: Nella VuSleeve|Sleeve
9539296|NCT03123367|Active Comparator|Group 2: Nella NuSpec|Speculum
9539297|NCT03123367|Active Comparator|Group 3: NellaSpec|Speculum
9539298|NCT03123367|Active Comparator|Group 4: Nella Insert|Sleeve
9539299|NCT03123458|Experimental|Single arm, cfMSC to treat immune disorders|cfMSCs treatment
9539300|NCT03123224|Experimental|Combined Aerobic and Resistance Exercise|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry. Exercises will focus on increasing the heart rate to a point at which participants will breathe more heavily and may sweat.
9539301|NCT03123224|Active Comparator|Balance and Flexibility|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry.
9539302|NCT03123276|Experimental|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
9539303|NCT03123146|Experimental|Fb-Cognitive Behavioral Therapy|Functional Behavior-Based Cognitive Behavioral Therapy: Group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
9539304|NCT03123146|No Intervention|Treatment as Usual (TAU)|"Children assigned to this condition received usual care, meaning that they could continue with any services. This group acted as a control group whereby access to intervention was patient-directed."
9539305|NCT03123159||HBV Infected patients|chronic HBV patients who will undergo standard of care FDA approved antiviral therapy to treat HBV infections. Will have blood drawn to be tested using the DxN HBV Assay. Study is observational and results will not be used to manage patient care.
9539306|NCT03123016|Experimental|Vitiligo with Apremilast and NB-UVB phototherapy|Each participant will be compared with one side of the body to the other side
9539307|NCT03123185|Experimental|Single rising dose part|Groups of healthy volunteers receive rising single doses of BI 705564
9539308|NCT03123185|Experimental|Food effect part|Groups of healthy volunteers receive single doses of BI 705564 with and without food
9539309|NCT03123237|Placebo Comparator|Control|"control will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
9539310|NCT03123237|Active Comparator|Diabetic|"diabetic cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
9539311|NCT03123237|Active Comparator|Hypertensive|"hypertesive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
9539312|NCT03123237|Active Comparator|Diabetic & Hypertensive|"Diabetic & Hypertensive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
9539313|NCT03123094|Experimental|BI 655130 dose group 1 (Intravenous)|
9539314|NCT03123094|Experimental|BI 655130 dose group 2 (Intravenous)|
9539315|NCT03123094|Experimental|BI 655130 dose group 3 (Intravenous)|
9539316|NCT03123094|Experimental|BI 655130 dose group 4 (Subcutaneous)|
9539317|NCT03123094|Placebo Comparator|Matching placebo for each dose group (Intravenous)|
9539318|NCT03123094|Placebo Comparator|Matching placebo (Subcutaneous)|
9539319|NCT03122951|Other|ovulation test use|All voluteers will receive device for use according to instructions
9539320|NCT03123172|Other|co2 gap|arterial and central venous blood gases to measure Co2 gap
9539321|NCT03123003|Experimental|SonicBone Ultrasound|Assessment of bone age by SonicBone Ultrasound will compared to wrist X-ray assessment
9539322|NCT03123107|Experimental|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
9539323|NCT03123081|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involves milking 30 cm length of cord at birth, after initiation of ventilation.
9539324|NCT03123081|No Intervention|Immediate Umbilical Cord Clamping|Procedure: No Intervention: Immediate Umbilical Cord Clamping or Immediate Cord Clamping.
9539325|NCT03122990|Experimental|Full mouth scaling and root planing|FM-SRP No surgical periodontal treatment will be performed in all dentition within 24 hours
9539326|NCT03122990|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP No surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
9539327|NCT03122977|Experimental|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
9539328|NCT03122977|Active Comparator|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
9539329|NCT03122834||Cohort A|Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
9539330|NCT03122834||Cohort B|Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
9539331|NCT03122938|Experimental|Lactoferrin Group|lactoferrin-supplemented formula
9539332|NCT03122938|Placebo Comparator|Control Group|formula without lactoferrin supplementation
9539333|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
9539334|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
9539335|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
9539336|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
9539337|NCT03122821|Experimental|Group 1|Trans-cranial direct stimulation + Mental Imagery
9539338|NCT03122821|Active Comparator|Group 2|Trans-cranial direct stimulation only
9539339|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:~Moderate or severe neonatal encephalopathy~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
9539340|NCT03122808||Control|"The inclusion criteria will be:~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes~Admission to the neonatal unit~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
9539341|NCT03122795|Experimental|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
9539342|NCT03122912|Experimental|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
9539343|NCT03122912|Active Comparator|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
9539344|NCT03122782|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
9539345|NCT03122782|Placebo Comparator|Normal Saline (control group)|Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
9539346|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
9539347|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
9539348|NCT03122470|Experimental|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
9539349|NCT03122600||vascular surgery group|Elderly patients undergoing vascular surgery in the lower half of the body
9539350|NCT03122561|Other|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
9539351|NCT03122561|Other|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
9539352|NCT03122561|Other|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
9616242|NCT04140214|Experimental|Standard Care and Carbocisteine|Standard care and carbocisteine (750 mg three-times-per-day until visit 3, reducing to 750 mg two times per day) over 52 weeks.
9622089|NCT02518607|Experimental|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
9485040|NCT01847573|Experimental|Cohort 2: HT-100 tablet, Dose 2|"Single dose administration: Dose 2~Multiple dose administration: Dose 2"
9485041|NCT01847573|Experimental|Cohort 3: HT-100 tablet, Dose 3|"Single dose administration: Dose 3~Multiple dose administration: Dose 3"
9485042|NCT01847573|Experimental|Cohort 4a: HT-100 tablet, Dose 4|"Single dose administration: Dose 4~Multiple dose administration: Dose 4"
9485043|NCT01847573|Experimental|Cohort 4b: HT-100 tablet, Dose 5|* Multiple dose administration: Dose 5
9485044|NCT01847573|Experimental|Cohort 5: HT-100 tablet, Dose 6|* Multiple dose administration: Dose 5
9485045|NCT01846793|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
9485046|NCT01846481|Experimental|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
9485047|NCT01846481|Experimental|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
9485048|NCT01846481|Experimental|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
9485049|NCT01846481|Experimental|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
9485050|NCT01845987|Placebo Comparator|Placebo|
9485051|NCT01845987|Experimental|CNTO 1959|
9485052|NCT01845649|Active Comparator|Active|Estradiol Vaginal Gel (0.03 mg estradiol / g )
9485053|NCT01845649|Sham Comparator|Vehicle|Vehicle Vaginal Gel
9485054|NCT01844180|Experimental|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
9485055|NCT01844180|Experimental|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
9485056|NCT01844180|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
9485057|NCT01842451|Experimental|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
9485058|NCT01842451|Experimental|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
9485059|NCT01839331|Experimental|Low Dose Ampion|4 mL Ampion
9485060|NCT01839331|Placebo Comparator|Placebo|4 mL placebo
9485061|NCT01839331|Experimental|High Dose Ampion|10 mL Ampion
9485062|NCT01839331|Placebo Comparator|10 mL Placebo|10 ml Placebo
9485063|NCT01836432|Experimental|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
9485064|NCT01836432|Active Comparator|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue FOLFIRINOX~Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel"
9485065|NCT01836432|Experimental|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
9485066|NCT01836432|Active Comparator|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest~Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days"
9485067|NCT01834339|Active Comparator|AlloDerm|The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
9485068|NCT01834339|Experimental|EVPOME|An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.
9485069|NCT01830985|Experimental|Single Arm VX-509|
9485070|NCT01825980|Experimental|BZF961|
9485071|NCT01825980|Placebo Comparator|Placebo|
9485072|NCT01825954|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
9485073|NCT01825954|Active Comparator|8-week RINCE|RINCE - active RINCE therapy involving 16 total treatment applications from NeuroPoint device, followed by 8 sham applications from the NeuroPoint device
9485074|NCT01825954|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
9485075|NCT01823016|Placebo Comparator|Placebo|
9485076|NCT01823016|Experimental|JNJ-38518168|
9485077|NCT01819909|Experimental|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
9485078|NCT01819909|Experimental|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
9485079|NCT01818921|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.
9485080|NCT01818921|Experimental|1.2 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
9485081|NCT01818921|Experimental|1.8 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
9485082|NCT01818154|Experimental|Minimal Erythema Dose LED|A 2 x 2 cm section of skin will be exposed to LED light.
9485083|NCT01818154|Placebo Comparator|Minimal Erythema Dose narrow band UVB|A 2 x 2 cm section of skin will be exposed to narrow band UVB light.
9485084|NCT01818076|Experimental|Dose A|Dose A: Botulinum toxin type A
9485085|NCT01816139|Experimental|WC3011|Vaginal Cream, 0.015 mg estradiol/0.5 g vehicle administered daily for initial 14 days followed by twice weekly for 10 weeks
9485086|NCT01816139|Placebo Comparator|Vehicle|0.5 g Vehicle vaginal cream administered daily for initial 14 days followed by twice weekly for 10 weeks
9485087|NCT01815450|Experimental|BLI1100|BLI1100 topical cream
9485088|NCT01815450|Experimental|BLI1100 - modified formulation|BLI1100 topical cream
9485089|NCT01815450|Placebo Comparator|Placebo|Topical cream
9485090|NCT01811576|Active Comparator|recombinant human growth hormone|Daily subcutaneous dose
9485091|NCT01811576|Experimental|TV-1106|Titration dose levels of TV-1106
9485092|NCT01810575|Active Comparator|WC3036-11F/Alprostadil in Vehicle 2.5%|Treatment A
9485093|NCT01810575|Experimental|WC3036-12F/Alprostadil in Vehicle 0.5%|Treatment B
9485094|NCT01810575|Placebo Comparator|WC3036-13P/Vehicle Only 0.5%|Treatment C
9485095|NCT01810484|Active Comparator|Group 1|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment only; Treatment Area B will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area C will be treated with CO2 laser treatment only"
9485096|NCT01810484|Active Comparator|Group 2|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area B will be treated with CO2 laser treatment only; Treatment Area C will be treated with Ultherapy® treatment only"
9485097|NCT01810484|Active Comparator|Group 3|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with CO2 laser treatment only; Treatment Area B will be treated with Ultherapy® treatment only; Treatment Area C will be treated with Ultherapy® treatment and CO2 laser treatment"
9485098|NCT01809964|Experimental|Dose 1|ANT-1401
9485099|NCT01809964|Experimental|Dose 2|ANT-1401
9485100|NCT01809964|Placebo Comparator|Vehicle|Placebo Vehicle
9485101|NCT01807897|Experimental|CPAP|Nocturnal continuous positive airway pressure
9485102|NCT01807897|Experimental|NSO|Nocturnal supplemental oxygen
9485103|NCT01807897|Other|HLSE|Healthy lifestyle and sleep education control
9485104|NCT01807819||Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
9485105|NCT01807546|Experimental|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
9485106|NCT01805609|Experimental|Working with the Caregiving Family (WCF) training|This is a new training curriculum for inpatient oncology providers called Working with the Caregiving Family (WCF) training, a program designed to teach MSKCC inpatient staff to address family-level concerns during acute hospitalization. The WCF training will teach staff to recognize and inquire about areas of family distress that are likely to impact the caregiving process; to provide brief, supportive interventions, and/or to transition families to specialized support services when needed. We will provide staff with skills to address especially challenging family situations (e.g., noncompliance with medical care, conflict, poor communication) in collaborative and compassionate ways. We will teach clinicians to intervene and respond more effectively when problematic relationships develop within families or between families and larger systems (e.g., medical team, institutional programs).
9485107|NCT01804829|No Intervention|Observational Control|Subjects who attain HCV RNA <100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 34 week period.
9539353|NCT03122509|Experimental|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
9539354|NCT03122509|Experimental|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
9539355|NCT03122639|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
9539356|NCT03122639|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
9539357|NCT03122652|Experimental|Terifunomide|
9539358|NCT03122652|Placebo Comparator|Placebo|
9539359|NCT03122730|Experimental|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
9539360|NCT03122613|Active Comparator|Curcumin|Dietary supplements of Curcumin capsules
9539361|NCT03122613|Placebo Comparator|Curcumin Placebo|Identical looking placebo of the active arm
9539362|NCT03122756|Experimental|Group (D)|will include 50 women who will receive intravenous dexamethasone.
9539363|NCT03122756|Placebo Comparator|Group (C)|will include 50 women who will receive intravenous normal saline (0.9 %).
9539364|NCT03122678|Experimental|Thiamine Supplementation Group|Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
9539365|NCT03122678|Placebo Comparator|Placebo Group|Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
9539366|NCT03122626|Experimental|Experimental Group|The intervention is a group, task-oriented exercise program involving two 1-hour exercise classes per week for 12 weeks. The class involves a seated warm-up, repetitive, progressive practice of functional balance and mobility tasks, and a seated cool down. The warm-up consists of active range-of-motion exercises, aerobic exercise, leg loading, stretching, and sit-to-stand training. The cool-down involves exercises with an emphasis on stretching and relaxation. Tasks are organized in a 3-station circuit completed by participants grouped by overall ability: Superstation 1: walking, aerobic training, and wall work (standing and reaching, wall push-ups); Superstation 2: standing weight shifts, coordinated with stepping and lunging; and Superstation 3: tap-ups, step-ups, and heel/toe raises, hamstring curls, marching-on-the-spot, and mini-squats. Participants are instructed to be physically active by walking in their neighbourhood, practicing the program exercises, or using the stairs.
9539367|NCT03122626|No Intervention|Wait-listed Control Group|The control group will receive usual care which will be monitored and is expected to consist of provision of a home exercise program and information on community resources according to current best practices. At the end of the study period, participants in the control group will be offered to participate in the 3-month exercise program.
9539368|NCT03122691|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
9539369|NCT03122691|Experimental|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
9539370|NCT03122691|Experimental|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
9539371|NCT03122691|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
9539372|NCT03122691|Experimental|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
9539373|NCT03122691|Experimental|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
9539374|NCT03122704|Experimental|Group B Streptococcus (GBS) screening|Vaginal and anal swab of patients will be screened for GBS screening
9539375|NCT03122717|Experimental|Gefitinib + Osimertinib|"Gerfitinib will administered orally at a pre determine dose daily~Osimertinib will administered orally at a pre determine dose daily"
9539376|NCT03122665|Active Comparator|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
9539377|NCT03122665|Active Comparator|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
9539378|NCT03122444|Experimental|Imipramine|Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.
9539379|NCT03122418|Experimental|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
9539380|NCT03122574|Experimental|Treatment|Pure (100%) lavender aromatherapy
9539381|NCT03122574|Placebo Comparator|Placebo Control|Pure (100%) jojoba aromatherapy
9539382|NCT03122574|No Intervention|Standard of care Control|No aromatherapy control group
10039582|NCT01845376|Experimental|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
10039583|NCT01845376|Experimental|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
9539383|NCT03122769|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
9539384|NCT03122392|Experimental|AMS 800 Artificial Urinary Sphincter|"The AMS 800™ Urinary Control System is an implantable, fluid-filled, solid silicone elastomer prosthesis used to treat urinary incontinence due to reduced outlet resistance (intrinsic sphincter deficiency) following prostate surgery. The AMS 800 Urinary Control System simulates normal sphincter function by opening and closing the urethra, under patient control. When the cuff is closed, urine stays in the bladder.~When the patient wishes to void, he simply squeezes and releases the pump several times. This causes the fluid in the cuff to move into the pressure-regulating balloon . The cuff opens and urine passes through the urethra. The balloon then automatically re-pressurizes the cuff through the pump, within several minutes, the cuff again closes the urethra.~The control pump, which in implanted in the scrotum, is also designed to allow the clinician or patient to deactivate and activate the system without additional surgery."
9539385|NCT03122353|Experimental|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
10039584|NCT01845389|Experimental|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
10039585|NCT01845389|Active Comparator|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
10039586|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
10058427|NCT02018250|Placebo Comparator|Placebo|5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.
9539386|NCT03122353|Active Comparator|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
9539387|NCT03122353|Placebo Comparator|Placebo|Topical suspension without active ingredient
9539388|NCT03122197|Experimental|Letrozole|"The treatment starting dose will be 2.5mg administered orally once daily. Daily doses up to 10mg and single doses of 30mg have been shown to be safe in prior studies and therefore we expect that letrozole doses up to 20mg in this study will be safe.~The recommended phase II dose (RP2D) will be considered the dose that results in ≥ 2uM letrozole concentration in the tumor or the highest dose achieved (20mg daily for cohort level 7) with < 2/6 patients with DLTs. This dose will be planned for future phase II studies to determine potential efficacy."
10058428|NCT02018250|Experimental|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
10058429|NCT02018250|Experimental|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
10058430|NCT02018250|Experimental|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
10058431|NCT02018250|Experimental|2.0 mg/kg MMB4 DMS|2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
10058432|NCT02018250|Experimental|3.0 mg/kg MMB4 DMS|3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
10058433|NCT02018263|Active Comparator|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
10058434|NCT02018263|Active Comparator|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
9539389|NCT03122262|Active Comparator|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
9539390|NCT03122262|Active Comparator|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
9539391|NCT03122262|Active Comparator|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
9539392|NCT03122158|Active Comparator|Major depressive disorder|In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
9539393|NCT03122158|Active Comparator|Anxiety disorders|In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
10058435|NCT02018263|Active Comparator|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
10058436|NCT02018276|Experimental|The effect of perioperative lidocaine infusion|
9539394|NCT03122236|Active Comparator|Standard walking with tDCS dosage A|Neurorehabilitation of Standard Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
9539395|NCT03122236|Active Comparator|Complex walking with tDCS dosage A|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
9539396|NCT03122236|Active Comparator|Complex walking with tDCS dosage B|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage B
9539397|NCT03122106|Experimental|Personalized neoantigen DNA vaccine|"Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.~Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.~At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
9539398|NCT03122275|Experimental|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
9539399|NCT03122275|Active Comparator|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
9539400|NCT03122210|Other|Control group|In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
9539401|NCT03122210|Other|FreeO2 with SpO2 target = 92%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.
9539402|NCT03122210|Other|FreeO2 with SpO2 target =97%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.
9539403|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
9539404|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
9539405|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
9539406|NCT03122249|Other|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
9539407|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
9539408|NCT03122340|Placebo Comparator|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
9539409|NCT03122340|Experimental|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
9539410|NCT03121963|Experimental|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
9539411|NCT03121963|Active Comparator|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
10039587|NCT01845415|Active Comparator|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
10039588|NCT01845415|No Intervention|No treatment Control|two communities receive no intervention
10039589|NCT01845415|Active Comparator|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
9539412|NCT03122080|Active Comparator|Electroacupuncture group|electroacupuncture+standard care
9539413|NCT03122080|Placebo Comparator|Control A group|placebo acupuncture+standard care
9539414|NCT03122080|Other|Control B group|standard care
9539415|NCT03122015|Experimental|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
9539416|NCT03122015|No Intervention|Standard care|
9539417|NCT03122132||Spanish cohort with HCV treated with DAA|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks
10039590|NCT01845428|Other|pravastatin|All participants will receive pravastatin 20mg daily
10039591|NCT01845454|Active Comparator|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
9485108|NCT01804829|Experimental|Civacir® 10% at 200 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
9485109|NCT01804829|Experimental|Civacir® 10% at 300 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
9485110|NCT01804088|Experimental|Stent|
9485111|NCT01803412|Experimental|Alternate Intravenous Dosing Arm|Subjects will receive drisapersen as a regimen of 3 mg/kg over 1 hr IV weekly throughout the duration of participation.
9485112|NCT01803412|Experimental|Primary continuous Dosing Arm|Subjects will receive drisapersen 6 mg/kg as SC injection(s) once a week, continuously throughout their duration of participation.
9485113|NCT01803412|Experimental|Alternate Intermittent Dosing Arm|Subjects will receive drisapersen intermittently, as a regimen of 6 mg/kg as SC injection(s) once a week for 8 weeks followed by 4 weeks of no dosing, throughout their duration of participation.
9485114|NCT01802866|Experimental|ACU-4429 2.5 mg|2.5 mg tablet
9485115|NCT01802866|Experimental|ACU-4429 5 mg|5 mg tablet
9485116|NCT01802866|Experimental|ACU-4429 10 mg|10 mg tablet
9485117|NCT01802866|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
9485118|NCT01802723|Experimental|LIPO-202, Low|Drug: salmeterol xinafoate
9485119|NCT01802723|Experimental|LIPO-202, Mid|Drug: salmeterol xinafoate
9485120|NCT01802723|Experimental|LIPO-202, High|Drug: salmeterol xinafoate
9485121|NCT01802723|Experimental|LIPO-202, Placebo|Drug: Placebo
9485122|NCT01799824|Experimental|Active|ANT-1403
9485123|NCT01799824|Placebo Comparator|Vehicle|Vehicle
9485124|NCT01798303|Experimental|LY2940094|40 mg LY2940094 oral tablet, QD for 8 weeks
9485125|NCT01798303|Placebo Comparator|Placebo|Identically matched placebo oral tablet, QD for 8 weeks
9485126|NCT01795911|Experimental|Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir|"Pegylated Interferon Lambda 180 μg Solution, Subcutaneous Once weekly for 12 weeks;~Ribasphere 1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg oral tablets per day [subjects should take either 400 mg for subjects < 75 kg or 600 mg ≥ 75 kg in the morning with food and 600 mg in the evening with food] for 12 weeks;~Daclatasvir 60 mg oral tablet Once daily for 12 weeks"
9485127|NCT01794663|Experimental|OPN-305|
9485128|NCT01794663|Placebo Comparator|Matching placebo|
9485129|NCT01792050|Placebo Comparator|Arm 1A: Docetaxel + Placebo|Arm 1A: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus placebo PO BID (days 1-14 of 21 day cycle).
9485130|NCT01792050|Experimental|Arm 1B: Docetaxel + Indoximod|Arm 1B: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus Indoximod 1200 mg PO BID (days 1-14 of 21 day cycle).
9485131|NCT01792050|Placebo Comparator|Arm 2A: Paclitaxel + Placebo|Arm 2A: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus placebo PO BID (days 1-21 of 28 day cycle).
9485132|NCT01792050|Experimental|Arm 2B: Paclitaxel + Indoximod|Arm 2B: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus Indoximod 1200 mg PO BID (days 1-21 of 28 day cycle).
9497979|NCT03470142|Active Comparator|traditional laparoscopy-assisted surgery|The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
9497980|NCT03470142|Experimental|total laparoscopic surgery with no incision (NOSES)|The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice such as anal.
9497981|NCT03470129|Active Comparator|Helioseal F|fissure sealing with the conventional product
9497982|NCT03470129|Experimental|Helioseal F Plus|fissure sealing with the new product
9497983|NCT03470116|Experimental|MacGrath MAC video laryngoscopy|Patients will benefit MacGrath MAC video laryngoscopy for intubation after curarization
9497984|NCT03470116|Active Comparator|direct laryngoscopy|Patients will benefit direct laryngoscopy for intubation after curarization
9497985|NCT03470103||Treatment naïve wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
9497986|NCT03470103||Treatment naïve DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
9497987|NCT03470103||Previously treated wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
9497988|NCT03470103||Previously treated DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
9497989|NCT03470090|Experimental|Neuromuscular Exercises Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and neuromuscular exercises training
9497990|NCT03470090|Active Comparator|Conventional Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and conventional exercises.
9497991|NCT03470077|Experimental|Group A|40 randomly allocated Patients undergoing repair of rupture globe will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
9497992|NCT03470077|Experimental|Group B|40 randomly allocated Patients undergoing repair of rupture globe.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
9497993|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
10058437|NCT02018276|Active Comparator|The effect of perioperative magnesium infusion|
9485133|NCT01790256|Active Comparator|Cereve Sleep System at 14-16 degrees C.|Active
9485134|NCT01790256|Active Comparator|Cereve Sleep System at 30 degrees C|Active
9485135|NCT01790100|Experimental|VX-135 low dose in combination with ribavirin|12 weeks of VX-135 in combination with ribavirin
9485136|NCT01790100|Experimental|VX-135 high dose in combination with ribavirin|
9485137|NCT01789736|Experimental|PG286|PG286 Ophthalmic Solution q.d. O.U.
9485138|NCT01789736|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
9485139|NCT01789736|Active Comparator|Travoprost 0.004%|Travoprost 0.004% q.d. O.U.
9485140|NCT01789268||Full-Term Healthy Infants (> /=37 weeks gestational age)|130 male and female term infants born at a gestational age of 37 0/7 to 41 6/7 weeks (Healthy comparator) will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
9485141|NCT01789268||Preterm Infants (<36 weeks gestational age)|150 male and female preterm infants born at gestational age 23 0/7 to 35 6/7 weeks will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
9485142|NCT01788839||women with breast cancer|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
9485143|NCT01788839||women with lymphoma|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
9485144|NCT01785771|Experimental|ITCA 650|
9485145|NCT01785433|Experimental|Treatment ABCD|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day"
9485146|NCT01785433|Experimental|Treatment BDAC|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day"
9485147|NCT01785433|Experimental|Treatment CADB|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day"
9485148|NCT01785433|Experimental|Treatment DCBA|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day"
9485149|NCT01784874|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg) Serum Free
9485150|NCT01784874|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies
9485151|NCT01784133|Active Comparator|omiganan mid dose|omiganan mid dose once daily application for 12 weeks
9485152|NCT01784133|Active Comparator|omiganan high dose|omiganan high dose once daily application for 12 weeks
9485153|NCT01784133|Placebo Comparator|Vehicle group|Vehicle once daily application for 12 weeks
9485154|NCT01784133|Active Comparator|omiganan low dose|omiganan low dose once daily application for 12 weeks
9485155|NCT01782729|Experimental|Tacrolimus ointment (pediatric)|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
9485156|NCT01781104|Active Comparator|RM-131|
9485157|NCT01781104|Placebo Comparator|Placebo|
9485158|NCT01780844|Active Comparator|Standard of Care|Basiliximab induction + Tacrolimus + MMF + Corticosteroids
9485159|NCT01780844|Experimental|CNI avoidance|Basiliximab induction + ASKP1240 + MMF + Corticosteroids
9485160|NCT01780844|Experimental|CNI minimization-MMF avoidance|Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
9485161|NCT01780428|Experimental|CL-108|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg)
9485162|NCT01780428|Active Comparator|Norco|Commercial product containing hydrocodone 7.5 mg. acetaminophen 325 mg
9485163|NCT01780428|Placebo Comparator|Placebo|CL-108 formulation without API
9485164|NCT01779947|Experimental|Estradiol Vaginal Insert 10 mcg|Estradiol Vaginal Insert 10 mcg - Test Product
9485165|NCT01779947|Active Comparator|Vagifem Tablets 10 mcg|Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug
9485166|NCT01779947|Placebo Comparator|Placebo|Placebo for the test product Estradiol Vaginal Tablets 10 mcg
9485167|NCT01779453|Experimental|ETC-1002|ETC-1002 treatment group, oral once daily
9485168|NCT01779453|Placebo Comparator|Placebo|Placebo treatment group, oral once daily
9485169|NCT01777594|Experimental|G-202 (Mipsagargin)|G-202 (mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
9539418|NCT03122002||Patients With Ischemic Stroke|The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
9539419|NCT03122002||Healthy Control|The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.
9539420|NCT03122041|Experimental|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
9539421|NCT03122041|Experimental|CON|Controls (CON) Lifestyle intervention
9539422|NCT03122028|Experimental|LAmbre closure system|
9539423|NCT03121911|Experimental|Group 1 - Interval Training (IT)|"All participants will be submitted to several exams of cardiac and pulmonary functions. Then, group 1 (IT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure (accelerometer). At the end of this period all the tests will be repeated.~Each exercise session will last for 60 minutes and will be divided into three parts as follows: warm up (10 minutes); interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold found in CPET (70%, 80%, 100% and 110%); cooling down (10 minutes)."
9539424|NCT03121911|Experimental|Group 2 - IT + IMT|"All participants will be submitted to the same evaluations before and after training, and 6 months after discharge. Group 2 (IT + inspiratory muscle training (IMT)) will participate in a 12 week physical training program. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure.~The group 2 will perform the IMT session at the end of the warm-up exercises, prior to the beginning of the IT on a cycloergometer. IMT session consists of 2 series of 12 inspirations with a 60% of MIP. Participant will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minutes interval between series. All the others exercises will be identical between group 1 and 2."
9539425|NCT03121911|No Intervention|Group 3 - Absence of rehabilitation|Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
9539426|NCT03122119|Experimental|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
9539427|NCT03121924|Experimental|Immediately oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~The first arm is the immediately denudation and immediately ICSI of the oocytes, and in the second arm the oocyte are denuded and injected after 4 hours from the pick up ."
9539428|NCT03121924|Experimental|Delayed oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~In this arm, the oocyte are denuded and injected after 4 hours from the pick up ."
9539429|NCT03122054|Other|Group L (n:88)|patients treated surgically with laparoscopic cholecystectomy immediately
9539430|NCT03122054|Other|Group D (n:88)|patients first treated medically and than treated surgically with delayed (4-8 weeks later) laparoscopic cholecystectomy
9539431|NCT03121989|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|"The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.~After the injection research, MRI will be done and images evaluated."
9539432|NCT03121989|Placebo Comparator|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
9539433|NCT03121937|Experimental|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
9539434|NCT03121937|No Intervention|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
9539435|NCT03121846|Experimental|apatinib group|apatinib 500mg po qd, 28 days for a cycle.
9539436|NCT03121859|Active Comparator|Neck stabilization exercise|The patients who had only neck stabilization exercise
9539437|NCT03121859|Active Comparator|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
9539438|NCT03121859|Active Comparator|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
9616243|NCT04140214|Experimental|Standard Care and Combination of HTS and Carbocisteine|Standard care and combination of twice-daily nebulised HTS (MucoClear 6%, PARI Pharma) and carbocisteine. Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser eFlow rapid nebuliser and eTrack controller (PARI Pharma). They will also be given carbocisteine (750 mg of three times per day until visit 3, reducing to 750 mg twice per day) over 52 weeks.
10039592|NCT01845454|Active Comparator|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
10039593|NCT01845454|Active Comparator|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
10039594|NCT01845454|Active Comparator|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
9485170|NCT01777555|Experimental|CVT-301|CVT-301 at Dose Level 1 for 1st 14 days of treatment then increased to Dose level 2 for last 14 days of treatment.
9485171|NCT01777555|Placebo Comparator|Inhaled Placebo|Subjects randomized to receive placebo in a 1:1 randomization scheme
9485172|NCT01777165|Experimental|Arm 1 ABT-719 lower dose|
9485173|NCT01777165|Experimental|Arm 2 ABT-719 intermediate dose|
9485174|NCT01777165|Experimental|Arm 3 ABT-719 higher dose|
9485175|NCT01777165|Placebo Comparator|Arm 4 placebo|
9485176|NCT01776606|Active Comparator|Dose A|Dose A: Botulinum toxin type A
9485177|NCT01776606|Placebo Comparator|Dose B|Dose B: Placebo
9485178|NCT01774578|Active Comparator|Arm 1: Docetaxel|"Arm 1: Docetaxel 75 mg/m^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.~First Progression: Gemcitabine 1250 mg/m^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity."
9485179|NCT01774578|Experimental|Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)|"Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
9485180|NCT01774578|Experimental|Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)|"Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
9485181|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
9485182|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
9485183|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
9485184|NCT01773928|Active Comparator|VCIV manufactured with current process (18-49 Years Old)|Vero cell-derived trivalent influenza vaccine (VCIV)
9485185|NCT01773928|Active Comparator|Fluzone® (18-49 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
9485186|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
9485187|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
9485188|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
9485189|NCT01773928|Active Comparator|Fluzone® (≥50 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
9485190|NCT01773785|Experimental|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
9485191|NCT01768975|Experimental|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
9485192|NCT01768975|Placebo Comparator|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
9485195|NCT01758458|Experimental|Treatment (autologous T cells and aldesleukin)|"Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.~Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
9485196|NCT01756924|Experimental|CEM-102 plus Rifampin|
9485197|NCT01756924|Active Comparator|Standard of Care|
9485198|NCT01756482|Experimental|GS-5806|GS-5806, powder for oral solution
9485199|NCT01756482|Placebo Comparator|Sugar powder for oral solution in juice|Sugar powder for oral solution
9485200|NCT01756339|Experimental|Solithromycin|Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
9485201|NCT01756339|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg PO daily on Day 1 through Day 7
9485202|NCT01754935|Experimental|VX-509 100 mg qd Arm|
9485203|NCT01754935|Experimental|VX-509 200 mg qd Arm|
9485204|NCT01754935|Experimental|VX-509 300 mg qd Arm|
9485205|NCT01754935|Placebo Comparator|Placebo Arm|
9485206|NCT01753167|Experimental|MCMV5322A/MCMV3068A|Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).
9485207|NCT01753167|Placebo Comparator|Placebo|Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.
9485208|NCT01751152|Experimental|NNC0114-0006|
9485209|NCT01751152|Placebo Comparator|Placebo|
9485210|NCT01750957|Placebo Comparator|Placebo|
9485211|NCT01750957|Experimental|RO4917523 Dose A|
9485212|NCT01750957|Experimental|RO4917523 Dose B|
9485213|NCT01749137|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1mg/24hrs via subcutaneous infusion for 90 days.
10039595|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
10039596|NCT01845480|Experimental|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
10039597|NCT01845480|Active Comparator|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
10039598|NCT01845493|Active Comparator|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
10039599|NCT01845493|Placebo Comparator|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
10039600|NCT01845506|Experimental|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
10039601|NCT01845506|Active Comparator|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
10039602|NCT01845519|Experimental|Tailored Group|
10039603|NCT01845519|Active Comparator|Targeted Group|
10039604|NCT01845532|Experimental|TPI group|
10039605|NCT01845532|Active Comparator|ELMA group|
10039606|NCT01845532|No Intervention|None group|
10039607|NCT01845545|No Intervention|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
9803744|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
10039608|NCT01845545|Experimental|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
10039609|NCT01845558|Experimental|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
10039610|NCT01845558|Placebo Comparator|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
10039611|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
10039612|NCT01845584|Experimental|NPB-01|Intravenous immunoglobulin
10039613|NCT01845610|Experimental|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
9539439|NCT03121872|Experimental|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
9539440|NCT03121872|Active Comparator|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
9539441|NCT03122314|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
9539442|NCT03122314|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
9539443|NCT03122067|Experimental|oxytocin group|male participants with oxytocin treatment
9539444|NCT03122067|Placebo Comparator|placebo group|male participants with placebo treatment
9539445|NCT03121976|Experimental|Ultrasound|Femoral catheters inserted using ultrasound only
9803745|NCT03429335|Experimental|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
9803746|NCT03429335|Active Comparator|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
10039614|NCT01845610|Experimental|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
10039615|NCT01845610|No Intervention|Control group|The control group will receive a delayed intervention
10039616|NCT01845623|Experimental|Treatment A|
10039617|NCT01845623|Experimental|Treatment B|
10039618|NCT01845623|Placebo Comparator|Treatment C|
10058438|NCT02018289|Experimental|Triclosan|Suture of the abdominal wall with triclosan coated suture
10039619|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
9485214|NCT01749137|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 90 days.
9485215|NCT01746082|Experimental|Subjects 18 - 64 years|100 (up to 120) subjects 18 - 64 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
9485216|NCT01746082|Experimental|Subjects > /= 65 years|100 (up to 120) subjects greater than or equal to 65 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
9485217|NCT01745497|Experimental|Ferrous Sulfate|3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
9485218|NCT01745497|Placebo Comparator|Placebo|Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal
9485219|NCT01744223|Experimental|SCT, BPX-501 dose 1, Rimiducid if needed|"2x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
9485220|NCT01744223|Experimental|SCT, BPX-501 dose 2, Rimiducid if needed|"5x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
9485221|NCT01744223|Experimental|SCT, BPX-501 dose 3, Rimiducid if needed|"1x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
9485222|NCT01744223|Experimental|SCT, BPX-501 dose 4, Rimiducid if needed|"3x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant .~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
9485223|NCT01743625|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
9485224|NCT01743625|Placebo Comparator|Placebo|Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
9485225|NCT01741194|Experimental|AC-1204|Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
9485226|NCT01741194|Placebo Comparator|Placebo|Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
9485227|NCT01741155|Experimental|Single Arm Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until progression or intolerable toxicity.
9485228|NCT01741155|Experimental|Randomized Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m^2 of SPI-1620 intravenous (IV) followed by docetaxel 75 mg/m^2 IV administered in 3-week cycles until progression or intolerable toxicity.
9485229|NCT01741155|Active Comparator|Randomized Part: Docetaxel|Patients will receive 75 mg/m^2 docetaxel in 3-week cycles until progression or intolerable toxicity.
9485230|NCT01737905|Experimental|Arm T|Experimental arm utilizing Epinephrine HFA-MDI (E004)
9485231|NCT01737905|Placebo Comparator|Arm P|Placebo comparator arm utilizing Placebo-HFA
9485232|NCT01737892|Experimental|Arm T-Epinephrine Inhalation Aerosol HFA|Experimental arm utilizing Epinephrine HFA-MDI (E004)
9485233|NCT01737892|Active Comparator|Arm C-Epinephrine Inhalation Aerosol CFC|Active comparator arm utilizing Epinephrine CFC-MDI
9485234|NCT01731730|Placebo Comparator|Placebo (Vehicle) Injection|Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
9485235|NCT01731730|Experimental|AYX1 Injection 110 mg|Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
9485236|NCT01731730|Experimental|AYX1 Injection 330 mg|Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
9485237|NCT01730768|Experimental|AQW051 10 mg/day|Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84.
9485238|NCT01730768|Placebo Comparator|Placebo to AQW051|Matching placebo administered orally.
9485239|NCT01730027|Experimental|ADC3680|ADC3680 oral once daily
9485240|NCT01730027|Placebo Comparator|Placebo|Placebo oral once daily
9485241|NCT01730027|Active Comparator|montelukast|montelukast oral once daily
9485242|NCT01729884|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
9485243|NCT01729403|Experimental|Aleglitazar|
9485244|NCT01729403|Placebo Comparator|Placebo|
9485245|NCT01728753|Placebo Comparator|Placebo|Placebo
9803747|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
9539446|NCT03121976|Active Comparator|Ultrasound + Nerve Stimulation|Femoral catheters inserted using ultrasound with nerve stimulation
9539447|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
9539448|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
9539449|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI > 40 kg/m2 will receive ultrasound exam.
9539450|NCT03121833|Experimental|Endostar & AIM regimen / GT regimen|Endostar & AIM regimen / GT regimen; Endostar 15mg, into 500ml 0.9% sodium chloride intravenous infusion of 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; AIM regimen is Pirarubicin (THP) + Ifosfamide (IFO), the specific dose is IFO 8-12g / m2, given 4-5 days; THP 75mg / m2, given 1-2 days; 21-28 days for a cycle; GT regimen is Docetaxel (TXT) + Gemcitabine (GEM), specific dose of Gemcitabine 1000mg / m2 (D1, D8) and Docetaxel 75mg / m2 (D8); 21-28 days for a cycle; Preferred AIM regimen, AIM regimen chemotherapy failure or can not tolerate anthracycline chemotherapy in patients with GT regimen.
9539451|NCT03121833|Placebo Comparator|Placebo & AIM regimen / GT regimen|Placebo + AIM regimen / GT regimen; Placebo is 500ml 0.9% sodium chloride, Intravenous 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; The chemotherapy regimen is the same as the experimental group.
9539452|NCT03121781|Active Comparator|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
9539453|NCT03121781|Active Comparator|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
9539454|NCT03121807|Experimental|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
9539455|NCT03121755||Sangre Por Salud cohort members|Subjects entered in the Sangre Por Salud Biobank
9539456|NCT03121625|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
9539457|NCT03121521|Experimental|melatonin|Melatonin 10mg/d p.o.
9539458|NCT03121521|Placebo Comparator|placebo|placebo 10mg/d p.o.
9539459|NCT03121638|Active Comparator|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
9539460|NCT03121638|Active Comparator|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
9539461|NCT03121638|Experimental|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
9539462|NCT03121638|Experimental|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
10039620|NCT01845675|Experimental|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
9539463|NCT03121638|Experimental|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
9539464|NCT03121430|Experimental|Group A|subjects using the drug eluting peripheral vascular stent system
9539465|NCT03121430|Active Comparator|Group B|subjects using the Nitinol Stent System (Cordis Corporation)
9539466|NCT03121703|Experimental|lumbar stabilization exercises group|diverse lumbar stabilization exercises
9539467|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
9539468|NCT03121716|Experimental|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
9539469|NCT03121729|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
9539470|NCT03121443||Patient position|Perfusion index
9539471|NCT03121742|Placebo Comparator|Treatment as usual [TAU] plus assessment|Patients will receive standard care plus assessment.
9539472|NCT03121742|Experimental|Treatment as usual [TAU] plus intervention|Patients will receive standard care plus an ecological momentary intervention.
9539473|NCT03121651|Experimental|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).~Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications."
9539474|NCT03121664|Experimental|Cohort 1|
9539475|NCT03121495|Active Comparator|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
9539476|NCT03121495|No Intervention|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
9539477|NCT03121573|Other|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
9539478|NCT03121482|Active Comparator|HFNC alone|Control group
9539479|NCT03121482|Experimental|HFNC and NIV|
9539480|NCT03121417|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
9539481|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
9803748|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
10039621|NCT01845688|Experimental|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
9539482|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
9539483|NCT03121391|No Intervention|Control|The medical intensive care unit in four hospitals will comprise the clusters. All four clusters begin the study under the control condition. Ventilator withdrawal is conducted by the usual personnel in those units. Data is collected through observation of the process and the respiratory comfort of the enrolled patients. Each cluster is randomly selected to sequentially cross over to the intervention. The remaining clusters continue with usual care (control) until selected for crossover.
9539484|NCT03121391|Active Comparator|Intervention|Each cluster is randomly selected to sequentially crossover to the intervention. When crossed over to the intervention the assigned intensive care nurse conducts the ventilator withdrawal according to the algorithm. The algorithm is informed by an objective measure of patient respiratory comfort. Data is collected through observation of the process and the respiratory comfort of the enrolled patients.
9539485|NCT03121313|Experimental|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.~Dose of tegafur-uracil will be based on patient's body surface area (BSA):~BSA < 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)~BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
9539486|NCT03121352|Experimental|Carboplatin + Nab-paclitaxel + Pembrolizumab|Combination therapy of Carboplatin, Nab-paclitaxel, and Pembrolizumab
10039622|NCT01845688|Placebo Comparator|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
9539487|NCT03121560|Active Comparator|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
9539488|NCT03121560|Experimental|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
9539489|NCT03121599|Experimental|18F-FLT PET/CT|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
10039623|NCT01845701|Experimental|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
10039624|NCT01845701|Experimental|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
9803749|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
9803750|NCT03423758||Primary open-angle Glaucoma|Already diagnosed primary open-angle glaucoma with age more than 30 years
10039625|NCT01845701|Active Comparator|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
10039626|NCT01845714|Active Comparator|Cross Linking Group (CxL group)|Patients that received CXL
10039627|NCT01845714|Active Comparator|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
10039628|NCT01845727|Experimental|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
10039629|NCT01845727|Experimental|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
10039630|NCT01845740|Experimental|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
10039631|NCT01845740|Experimental|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
10039632|NCT01845740|Placebo Comparator|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
10039633|NCT01845753||All colorectal cancer patients|
9803751|NCT03406429|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
9803752|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
10039634|NCT01845766|Experimental|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
9539490|NCT03121690|Experimental|prednisone|prednisone 40 mg/day for 7 days
9803753|NCT03403153|Other|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
9803754|NCT03401879|Experimental|Patients with MS|Patients with Multiple Sclerosis
10039635|NCT01845766|No Intervention|control arm|
10039636|NCT01845779|Experimental|patients in complete response|
9803755|NCT03401879|Experimental|Healthy control subjects|Healthy age- and sex- matched control subjects
10039637|NCT01845805|Experimental|Arm A: CC-486|"CC-486 (oral azacitidine), 300 mg total (three 100mg tablets), taken daily on days 1-21 (of a 28 day cycle); indefinite cycles until visible tumor recurrence, then first line chemotherapy"
10039638|NCT01845805|Active Comparator|Arm B: observation|"Observation, indefinite until visible tumor recurrence, then first line chemotherapy"
9485246|NCT01728753|Experimental|T-705 A|Favipiravir regimen 1: 1200 mg 3x daily (TID) on Day 1, then 600 mg TID on Days 2-5
9485247|NCT01728753|Experimental|T-705 B|Favipiravir regimen 2: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
9485248|NCT01728753|Experimental|T-705 C|Favipiravir regimen 3: 1800 mg BID on Day 1, then 800 mg BID for Days 2-5
9485249|NCT01728220|Active Comparator|Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
9485250|NCT01728220|Active Comparator|Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
9485251|NCT01728220|Active Comparator|Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
9485252|NCT01728220|Placebo Comparator|Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)|Placebo using 99.999% N2 minicylinder
9485253|NCT01728220|Active Comparator|Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
9485254|NCT01728220|Active Comparator|Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
9485255|NCT01728220|Active Comparator|Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)|Placebo using 99.999% N2 minicylinder
9485256|NCT01728064|Placebo Comparator|Placebo|Placebo capsules three times daily
9485257|NCT01728064|Active Comparator|EPI-743 400 mg|EPI-743 at a dose of 400 mg three times daily
9485258|NCT01728064|Active Comparator|EPI-743 200 mg|EPI-743 at a dose of 200 mg three times daily
9485259|NCT01726946|Experimental|VX-135 High Dose with ribavirin|12 weeks of a high dose of VX-135 in combination with ribavirin
9485260|NCT01726946|Experimental|VX-135 Low Dose with ribavirin|12 weeks of a low dose of VX-135 in combination with ribavirin
9485261|NCT01726257|Experimental|Nellix System|Nellix Endovascular Aneurysm Sealing System is the only arm for this study. This is a single arm study.
9485262|NCT01725152|Experimental|Ganaxolone|3 mg/kg up to 12 mg/kg, with maximum of 1500 mg/day
9485263|NCT01725152|Placebo Comparator|Placebo|non active
9485264|NCT01724112|Experimental|LY2940094|40 mg administered orally as 1 capsule QD for 8 weeks.
9485265|NCT01724112|Placebo Comparator|Placebo|Administered orally as 1 capsule QD for 8 weeks.
9485266|NCT01722864|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 10 to 35 days.
9485267|NCT01721733|Placebo Comparator|Placebo|Each patient will receive a volume of placebo based on weight
9485268|NCT01721733|Active Comparator|EPI-743 15 mg/kg|Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
9485269|NCT01721733|Active Comparator|EPI-743 5 mg/kg|Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
9485270|NCT01720160|Experimental|Device|1) BAROSTIM NEO System and 2) standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
9485271|NCT01720160|Active Comparator|Medical Management|Standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
9485272|NCT01718938|Experimental|Sequence 1|3-way crossover of velusetrag or placebo
9485273|NCT01718938|Experimental|Sequence 2|3-way crossover of velusetrag or placebo
9485274|NCT01718938|Experimental|Sequence 3|3-way crossover of velusetrag or placebo
9485275|NCT01718938|Experimental|Sequence 4|3-way crossover of velusetrag or placebo
9485276|NCT01718158|Experimental|Peginterferon Lambda-1a + Ribavirin + Daclatasvir|"Peginterferon Lambda-1a 180 µg solution for subcutaneous injection, once a week for 24 Weeks~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 weeks~Daclatasvir 60 mg tablets by mouth, once a day for 12 weeks"
9803756|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
10039639|NCT01845844|Experimental|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
10039640|NCT01845844|Active Comparator|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
10039641|NCT01845857|Experimental|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
10039642|NCT01845870||urinary albumin >300mg/24h|none extra intervention was given by the investigator
9539491|NCT03121690|Experimental|placebo|5ml saline /day for 7 days
9539492|NCT03121547|Placebo Comparator|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
9539493|NCT03121547|Experimental|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
9539494|NCT03121547|Experimental|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
9539495|NCT03121508|Other|TODAY Project|All participants will attend individualized self-management sessions led by an occupational therapist. The classes will focus on promoting modifying daily activities, habits, roles, and routines to promote healthy lifestyles for individuals with type 2 diabetes.
9539496|NCT03121300||High Risk Lung Cancer Patients|
9539497|NCT03121274|Active Comparator|Early pushing during vaginal delivery|patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not
9539498|NCT03121274|Active Comparator|Delayed pushingduring vaginal delivery|patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible
9539499|NCT03121248|Experimental|WBI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed
9539500|NCT03121248|Active Comparator|WBI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed
9539501|NCT03121248|Experimental|WBI - observational - 5|WBI 5 fractions SIB 5 fractions if needed
9539502|NCT03121248|Active Comparator|WBI - observational - 15|WBI 15 fractions SIB 15 fractions if needed
9539503|NCT03121248|Experimental|WBI + LNI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
9539504|NCT03121248|Active Comparator|WBI + LNI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
9539505|NCT03121248|Experimental|WBI with LNI - observational - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
9539506|NCT03121248|Active Comparator|WBI with LNI - observational - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
9539507|NCT03121248|Experimental|thoracic wall irradiation (TWI) +/- LNI - observational - 5|TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions
9539508|NCT03121248|Active Comparator|TWI +/- LNI - observational - 15|TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions
9539509|NCT03121339|Active Comparator|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
9539510|NCT03121339|Active Comparator|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
9539511|NCT03121287||Lung or Esophageal Patients|Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test & 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
9539512|NCT03121157|Experimental|Intervention|The intervention group will receive two sessions of computer-delivered motivational interviewing via CIAS software programmed to target adherence to medications. The intervention group will also receive text messaged adherence reminders between sessions. Both the computer-delivered sessions and text messages will be tailored to the participant using ecological momentary assessment.
10039643|NCT01845870||urinary albumin <30mg/24h|none extra intervention was given by the investigator
10039644|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
9539513|NCT03121157|No Intervention|Control|Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
9539514|NCT03121261|Experimental|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
9539515|NCT03121261|Active Comparator|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
9539516|NCT03121131|Other|Accurate Clinical Exam Findings|Radiologists will be provided with accurate clinical exam data.
9539517|NCT03121131|Other|Inaccurate Clinical Exam Findings|Radiologists will be provided with purposefully incorrect clinical exam data
9539518|NCT03121131|Other|No Clinical Exam Findings|Radiologists will be not be provided with any clinical exam data
9539519|NCT03121170|Experimental|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
9539520|NCT03121170|Experimental|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
9539521|NCT03121170|Placebo Comparator|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
9539522|NCT03121183||Patients who have undergone an extraction of implantable pace|
9539523|NCT03121222|Placebo Comparator|Lactose|The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
9485277|NCT01718158|Experimental|Peginterferon Alfa-2a + Ribavirin + Telaprevir|"Peginterferon Alfa-2a 180 µg solution for subcutaneous injection, once a week for 24 to 48 weeks depending on response~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 to 48 weeks depending on response~Telaprevir 375 mg tablets [2250 mg total daily dose: subjects should take 750 mg (two 375 mg tablets) orally three times a day, approximately 7-9 hours apart) for 12 weeks"
9485278|NCT01718145|Experimental|Arm 1: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Naive cohort"
9485279|NCT01718145|Active Comparator|Arm 2: Telaprevir + pegIFNα-2b + Ribavirin|"Telaprevir 750 mg tablets by mouth three times daily, pegIFNα-2b 1.5 μg/kg solution by Subcutaneous weekly & Ribavirin 600- 1000 mg Capsules by mouth twice daily for 24 Weeks~- Naive cohort"
10039645|NCT01845883|Other|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
9485280|NCT01718145|Experimental|Arm 3: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Relapser cohort"
9485281|NCT01715012|Experimental|ST266|ST266 sprayed to the skin graft and donor site
9485282|NCT01715012|Placebo Comparator|Saline|Saline (placebo)sprayed to the skin graft and donor site
9485283|NCT01714739|Experimental|Part 1|Dose Escalation and Initial Signal Detection in Multiple Solid Tumors - Nivolumab with Lirilumab
9485284|NCT01714739|Experimental|Part 2 and 3: Cohort Expansion|In platinum-refractory recurrent or metastatic SCCHN - Nivolumab with or without Lirilumab
9485285|NCT01714739|Experimental|Part 4: Cohort Expansion|Additional Signal Detection in Solid Tumors - Nivolumab with Lirilumab (Study Part 4 Removed; No Subjects Enrolled)
9485286|NCT01714739|Experimental|Part 5 and 6|Safety Lead-In and Additional Signal Detection in Solid Tumors -- Nivolumab Plus Ipilimumab with Lirilumab (Study Part 6 Removed; No Subjects Enrolled)
9485287|NCT01712451|Experimental|LIPO-102, Low|
9485288|NCT01712451|Experimental|LIPO-102, Mid|
9485289|NCT01712451|Experimental|LIPO-102, High|
9485290|NCT01712451|Experimental|LIPO-102; Placebo|
9485291|NCT01712451|Experimental|salmeterol xinafoate|
9485292|NCT01712217|Experimental|AT13387 and Crizotinib|Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
9485293|NCT01712217|Active Comparator|Crizotinib versus crizotinib + AT13387|Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the MTD established in Part A. Part B will enroll 128 patients with NSCLC who have been treated with crizotinib for at least 8 weeks and are still tolerating treatment without evidence of disease progression.
9485294|NCT01712217|Active Comparator|AT13387 or AT13387 + crizotinib|Part C is an open-label, randomized, Phase 2, Simon's 2-stage design of AT13387 administered alone once weekly for 3 weeks (QW×3) or in combination with crizotinib at the MTD established in Part A.
9485295|NCT01711346|Experimental|S303 Red Blood Cells (RBCs)|Participants will be assigned to S303 Red Blood Cells (RBCs) and then to Conventional, Untreated Red Blood Cells (RBCs).
9485296|NCT01711346|Active Comparator|Conventional, Untreated Red Blood Cells (RBCs)|Participants will be assigned to Conventional, Untreated Red Blood Cells (RBCs) and then to S303 Red Blood Cells (RBCs).
9485297|NCT01710644|Experimental|Burlulipase|Burlulipase orally, per meal
9485298|NCT01710644|Placebo Comparator|Placebo (Caramel in sterile water)|Placebo orally, per meal
9485299|NCT01709214|Experimental|Cebranopadol (GRT6005) Low-Dose Range|Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, and once daily Placebo; oral administration for 15 weeks
9485300|NCT01709214|Experimental|Cebranopadol (GRT6005) High-Dose Range|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, and once daily Placebo; oral administration for 15 weeks
9485301|NCT01709214|Placebo Comparator|Placebo|Twice daily Placebo, oral administration for 15 weeks
9485302|NCT01709214|Active Comparator|Oxycodone CR|Twice daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams; oral administration for 15 weeks
9485303|NCT01708551|Active Comparator|Group A|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
9485304|NCT01708551|Active Comparator|Group B|Subjects who were non-responders to a prior Ultherapy™ treatment for hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
9485305|NCT01708551|Active Comparator|Group C|Subjects will receive one double-density Ulthera System treatment; dual depth treatment at 4.5mm and 3.0mm.
9485306|NCT01708551|Active Comparator|Group D|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and standard energy level.
9485307|NCT01708551|Active Comparator|Group E|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and adjusted energy level.
9485308|NCT01707264|Experimental|NEOD001|NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
10039646|NCT01845896|Experimental|Combined exercise|12 weeks combined exercise programme (supervised)
10039647|NCT01845896|Experimental|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
9485309|NCT01704365|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
9616244|NCT04140214|No Intervention|Standard Care Only|Standard care over 52 weeks. Patients in the standard care group will use airway clearance techniques in the management of their BE.
10039648|NCT01845896|No Intervention|Control|sedentary/habitual lifestyle
10039649|NCT01845909||young adults - Central region of Portugal|
10039650|NCT01845922|Experimental|Low sodium diet|Low sodium diet
10039651|NCT01845922|No Intervention|Control|Standard diet regime
10039652|NCT01845935|Experimental|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
10039653|NCT01845948|Placebo Comparator|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
9485310|NCT01704365|Experimental|Group B|Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
9485311|NCT01704365|Experimental|Group C|Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
9485312|NCT01704365|Experimental|Group D|Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
9485313|NCT01704365|Experimental|Group E|High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
9485314|NCT01704365|Experimental|Group F|High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
9485315|NCT01704365|Experimental|Group G|High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
9485316|NCT01704365|Experimental|Group H|High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
9485317|NCT01704365|Experimental|Group J|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 & Day 28)
9485318|NCT01704365|Placebo Comparator|Group K|Placebo (Day 0 and Day 28)
9485319|NCT01703923|Experimental|FP01 6mg or Placebo|FP01 6mg Oral
9485320|NCT01703923|Experimental|FP01 12mg or Placebo|FP01 12mg Oral
9485321|NCT01703533|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
9485322|NCT01703533|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
9485323|NCT01702441|Experimental|AKB-9778|Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.
9485324|NCT01699737|Experimental|JTT-851 Dose 1|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
9485325|NCT01699737|Experimental|JTT-851 Dose 2|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
9485326|NCT01699737|Experimental|JTT-851 Dose 3|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
9485327|NCT01699737|Active Comparator|Glimepiride Dose 1|Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
9485328|NCT01699737|Placebo Comparator|Placebo active & Placebo comparator|Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
9485329|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.7%|AR-12286 Ophthalmic Solution 0.7%, both eyes
9485330|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% both eyes
9485331|NCT01699464|Active Comparator|Timolol maleate ophthalmic solution 0.5%|Timolol maleate ophthalmic solution 0.5% both eyes
9485332|NCT01698281|Experimental|Arm A: AEZS-108|Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
9485333|NCT01698281|Active Comparator|Arm B: Standard (SCCC)|"commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
9485334|NCT01697072|Experimental|Rilotumumab|Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
9485335|NCT01697072|Placebo Comparator|Placebo|Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
9485336|NCT01696435|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
9485337|NCT01696435|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
9485338|NCT01696435|Active Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~Fish oil placebo"
9485339|NCT01696435|Active Comparator|Vitamin D + fish oil|"Vitamin D3 (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
9485340|NCT01694277|Experimental|Masitinib|Participants receive masitinib (12 mg/kg/day), given orally twice daily.
9485341|NCT01694277|Active Comparator|Sunitinib|Participants receive sunitinib, given at 50 mg/day for 4 consecutive weeks out of 6 weeks, orally
9485342|NCT01691846|Experimental|aleglitazar|
9485343|NCT01691846|Placebo Comparator|placebo|
9485344|NCT01691755|Placebo Comparator|Placebo|
9485345|NCT01691755|Experimental|aleglitazar|
9485346|NCT01689246|Experimental|TRx0237 250 mg/day|
9485347|NCT01689246|Placebo Comparator|Placebo|
9485348|NCT01689246|Experimental|TRx0237 150 mg/day|
9485349|NCT01689233|Experimental|TRx0237 200 mg/day|
9485350|NCT01689233|Placebo Comparator|Placebo|
9485351|NCT01687985|Experimental|BLI801 laxative - low dose|BLI801 laxative - oral solution
9485352|NCT01687985|Experimental|BLI801 laxative - high dose|BLI801 laxative - oral solution
9485353|NCT01686620|Experimental|BIOD-123|BIOD-123 used as prandial insulin
9485354|NCT01686620|Active Comparator|Lispro (Humalog)|Lispro (Humalog) used as prandial insulin
9485355|NCT01685268|Experimental|Part A, Regimen 1|AT13387 given as a 1-hr IV infusion at a starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
9539524|NCT03121222|Experimental|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
9539525|NCT03121196||deprived women|Two groups of women will be compared deprived women and non-deprived women
9539526|NCT03121196||non-deprived women|Two groups of women will be compared deprived women and non-deprived women
9539527|NCT03120988|Experimental|Lavage with Platelet Poor Plasma (PPP)|"Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect washing out the joint space."
9539528|NCT03120910|Experimental|Test Subjects|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensor, including nasal sensors, with the same or similar technology and materials as the Masimo FDA cleared devices and sensors.
9539529|NCT03120897|Experimental|Test group|The subjects will be enrolled into the test group and will receive RAM sensor.
9539530|NCT03121014|Experimental|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
9539531|NCT03120962|Experimental|oxycodone|Oxycodone 20mg/day, for 4 weeks and famciclovir 500mg three-times daily for 7 days.
9539532|NCT03120962|Active Comparator|standard treatment|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day (whichever is lower), for 4-12 weeks and famciclovir 500mg three-times daily for 7 days.
9539533|NCT03121040|Experimental|Subjects ingested VAAM® for 10 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 10 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
9539534|NCT03121040|Experimental|Subjects ingested VAAM® for 6 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 6 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
9539535|NCT03121040|No Intervention|Subjects ingested nothing|Ten young athletes before ingesting Vespa amino acid mixture (VAAM®) , divided into different meter race including 1500-, 800- and 400-meter races.
9539536|NCT03121053|Active Comparator|sodium bicarbonate|250ml 1.4% sodium bicarbonate 1 h before TAVR
9539537|NCT03121053|Active Comparator|hypotone saline|0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR
9539538|NCT03120936|Other|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
9539539|NCT03121092|No Intervention|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
9539540|NCT03121092|Active Comparator|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
9539541|NCT03121118||Scan opportunity|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
9539542|NCT03121118||Comparison group|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
9539543|NCT03121079|Experimental|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
9539544|NCT03120845|Experimental|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
9539545|NCT03120845|Experimental|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
9539546|NCT03121066|Active Comparator|Experimental group|Transcranial Magnetic Stimulation + Conventional intervention
9539547|NCT03121066|Sham Comparator|Sham control group|Sham Transcranial Magnetic Stimulation + Conventional intervention
9539548|NCT03121066|No Intervention|Non TMS Control group|Conventional intervention alone
9539549|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
9539550|NCT03120884|Experimental|IVF|embryos are cultured using conventional in vitro fertilization.A maximum of 2 embryos will be transferred for each treatment cycle.
9539551|NCT03120884|Experimental|ICSI|embryos are fertilized using ICSI.A maximum of 2 embryos will be transferred for each treatment cycle.
9539552|NCT03120819|Active Comparator|Oncologist Recommendation only|Medical providers in this study provide a standardized brief recommendation for exercise to a consenting patient during a clinical visit. Patients randomized to this arm receive a packet that contained a study information sheet and standard published exercise information materials. The standard materials consisted of publicly available exercise recommendations for cancer survivors from the American Cancer Society (ACS). The packet of exercise information intended to represent general information about exercise and cancer that would be readily available to patients through the internet, a medical clinic, or cancer support services.
9616245|NCT04136288|Experimental|Males with erectile dysfunction (ED)|Males diagnosed with erectile dysfunction (ED) for over a year, but less than 5 years, will receive shock wave therapy via MoreNova device
9616246|NCT04134572||Ollier Disease and Maffucci Syndrome patients|The group comprises all patients affected by Ollier Disease and Maffucci Syndrome.
9616247|NCT04133285||Multiple Osteochondromas patients|Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).
9616248|NCT04133272||Ehlers-Danlos Syndrome patients|The group comprises all patients affected by Ehlers-Danlos Syndrome, including prenatal and fetal diagnosis of Ehlers-Danlos Syndrome
9539553|NCT03120819|Experimental|Oncologist Recommendation + DVD|Participants in this arm receive the same oncologist's recommendation and written materials as the comparator group and also received an instructional yoga DVD. Inclusion of the video is intended to provide patients with a tool for following the oncologist's exercise recommendation. The instructional video contains a brief introduction from a breast cancer survivor, who was also featured in the exercise portion of the DVD, and safety information about lymphedema from a lymphedema therapist. The exercise program is a 30-minute, low intensity, restorative yoga program to improve whole body flexibility and to be safe for participants who were in active treatment for cancer and/or who had metastatic disease. Women are encouraged to use the DVD at least 3 times per week.
9539554|NCT03120923|Experimental|Lidocaine 3 cc & Triamcinolone Acetonide|
9539555|NCT03120923|Active Comparator|Lidocaine 9cc & Triamcinolone Acetonide|
9539556|NCT03120975|Experimental|Computerized decision support|
9539557|NCT03120975|Active Comparator|Standard antibiotic stewardship|
9539558|NCT03120728|Experimental|12-14mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 12-14mm on transvaginal ultrasound.
9539559|NCT03120728|Experimental|15-17mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 15-17mm on transvaginal ultrasound.
9539560|NCT03120728|Experimental|18mm or greater leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 18mm or greater on transvaginal ultrasound.
9539561|NCT03120429|Experimental|Fish group|subjects will have 3 x 150 g lean fish/ week at main meal
9539562|NCT03120429|Experimental|Control group|subjects will have no seafood.
9539563|NCT03120455|Experimental|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
9539564|NCT03120455|Active Comparator|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
9539565|NCT03120455|Placebo Comparator|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
9539566|NCT03120442|Experimental|Propofol-fentanyl|Fentanyl 0.5 mcg/kg Propofol Target-controlled infusion to achieve MOAA/S 3-4 as end point of sedation Bispectral index (BIS) monitoring
9539567|NCT03120442|Experimental|Dexmedetomidine|Fentanyl 0.5 mcg/kg Dexmedetomidine in incremental titrated dose for moderate sedation to achieve MOAA/S 3-4 as end-point of titration Bispectral index (BIS) monitoring
9539568|NCT03120442|Experimental|Fentanyl|Fentanyl 0.5 mcg/kg Supplemental dosage of fentanyl for intraoperative anxiolysis
9539569|NCT03120468|Experimental|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
9539570|NCT03120468|Experimental|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
9539571|NCT03120715|Placebo Comparator|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
9539572|NCT03120715|Experimental|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
9539573|NCT03120533|Experimental|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
9539574|NCT03120533|Placebo Comparator|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
9539575|NCT03120416|Experimental|Resistance exercise training program|Eight exercises will be used to include large upper and lower body muscle groups. The baseline 1 repetition maximum (RM) will be used to set initial training loads. All exercise sessions will be performed under the supervision of an exercise physiologist. Vital signs and body weight will be recorded before each session. The workload during training will be adjusted to reflect 80% of the most recent 1 RM (approximately 8-12 RM set). In addition, patients' workloads will be progressively increased if the patients can lift the weight more than 12 repetitions. Participants will perform three sets of 8-12 repetitions on each machine per session.
9539576|NCT03120416|No Intervention|Control|Participants randomized to the control group will be offered an educational brochure regarding exercise published by the NKF.
9539577|NCT03120585|Experimental|Fluid Management Intervention|Restricting IV fluids to infants with respiratory distress to mimic fluid intake of normal healthy breast fed infants (less fluid that current standard of care)
9539578|NCT03120585|No Intervention|Control Group|Infants with respiratory distress will receive standard of care fluid management.
9539579|NCT03120403|Active Comparator|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
9616249|NCT04127006||Vision Cohort 1|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter 10 degrees or more in every meridian of the central field
9539580|NCT03120403|Active Comparator|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
9539581|NCT03120403|Active Comparator|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
9539582|NCT03120494|Experimental|Subjects at risk of HIV|25 high risk MSM and 50 negative partners in a sero-discordant couple will be recruited and emtricitabine and tenofovir (Truvada) for PrEP will be provided, per guidelines, for one year
9539583|NCT03120598|Active Comparator|ATTC strategy|Behavioral: Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
9539584|NCT03120598|Experimental|ISF strategy|Behavioral: Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change) and Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
9539585|NCT03120767|Experimental|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
9539586|NCT03120767|Active Comparator|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
9539587|NCT03120767|No Intervention|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
9539588|NCT03120481||Normal control|
9539589|NCT03120325|Experimental|Vagal Nerve Stimulation|All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
9539590|NCT03120754|Experimental|Experimental Group|Placement of peritoneal drainage
9539591|NCT03120754|Active Comparator|Control group|No peritoneal drainage
9616250|NCT04127006||Vision Cohort 2|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 [approximate Snellen equivalent 20/100 - 20/400] or (visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter less than 10 degrees in any meridian of the central field)
9616251|NCT04127006||Vision Cohort 3|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 18 or less [approximate Snellen equivalent 20/500 or worse]
9616252|NCT04125186||Pilot Part|After providing consent, participants with nocturia will complete web-based baseline EpiNP survey followed by 3-day bladder diary and then a qualitative interview.
9616253|NCT04125186||Main Part|After providing consent, participants will complete web-based baseline EpiNP survey. All respondents who report greater than equal to (≥)2 voids/night, and a randomly selected cohort of respondents reporting 0 and 1 void/night will use the EpiNP 3-day web-based bladder diary.
9616254|NCT04124861|Experimental|Drug free|"Arm A: Drug free Glucocorticoid（GC）is tapered and stopped in 8 weeks(GCs at a dose of ≤ 2.5 mg of prednisone or equivalent for treatment of adrenal insufficiency) .~Immunosuppressant is also tapered and discontinues in 8 weeks."
9616255|NCT04124861|Experimental|IS monotherapy|Arm B: Immunosuppressant only Glucocorticoid（GC）is tapered and stopped in 8 weeks. The same type and dosage of immunosuppressive agent before admission, including Mycophenolate mate(<= 1g/d) or Leflunomide (<=20mg/d) or Methotrexate (<=15mg/w) or Azathioprine (<=100mg/d)
9616256|NCT04124861|Experimental|GC combined with IS|Arm C: GC+Immunosuppressant Both Glucocorticoid(GC) (no more than 7.5mg/d) and immunosuppressant are kept as maintaining dose.
9616257|NCT04115774||Osteogenesis Imperfecta patients|The group comprises all patients affected by Osteogenesis Imperfecta, including prenatal and fetal diagnosis of Osteogenesis Imperfecta
9616259|NCT04096443|Experimental|Intervention|Fecal microbial transplant capsules
9616260|NCT04094181||VPRIV Participants|Participants who has been transitioned from ERTs/SRTs to VPRIV, the data will be collected retrospectively from time of transition until the point at which participant begins in this study and then will be followed up prospectively for 12 months.
9616261|NCT04082520|Experimental|Treatment (gallium Ga 68-DOTATATE PET/MRI, Lutathera)|Patients receive gallium Ga 68-DOTATATE IV and undergo a PET/MRI before cycles 1 and 4. Patients then receive lutetium Lu 177 dotatate IV over 30-40 minutes. Cycles repeat every 8 for up to 6 months in the absence of disease progression or unacceptable toxicity.
9616262|NCT04079907|Experimental|Ketone|This arm will receive a supplement with 25g ketone ester. It is a commercially available supplement and will be provided as a standard dose.
9616263|NCT04079907|Placebo Comparator|Placebo|This arm will receive an isocaloric supplement.
9616264|NCT04067960||Ancillary-correlative (pharmacogenomics testing)|Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients also complete quality of life assessment at baseline and at 3 months after pharmacogenomics testing.
10058439|NCT02018289|Sham Comparator|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
10058440|NCT02018328|No Intervention|Triple therapy, helicobacter pylori|
10058441|NCT02018328|Experimental|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
9539592|NCT03120299|Experimental|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks~Other Names:~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
9539593|NCT03120299|Placebo Comparator|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
9539594|NCT03120650|Experimental|Scalp acupuncture|number:58 The needle will be maintained in place for 30 minutes. Patients in both groups will receive rehabilitation five times per week (Monday through Friday) for 8 consecutive weeks.
9539595|NCT03120650|Active Comparator|Conventional rehabilitation|number:58 Rehabilitation will be conducted for 1 hour five times per week (Monday through Friday) for 8 weeks.
9539596|NCT03120338|Experimental|The Development and Wellbeing Assessment|"The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.~The DAWBA will be administered in addition to care as usual."
9539597|NCT03120338|No Intervention|Care as Usual|Care as usual
9539598|NCT03120377|Active Comparator|Platform group|Group submitted to the whole body vibration training program
9539599|NCT03120377|Sham Comparator|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
9539600|NCT03120689|Active Comparator|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
9539601|NCT03120689|Active Comparator|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
9539602|NCT03120689|Active Comparator|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
9539603|NCT03120689|Active Comparator|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
9539604|NCT03120637|Experimental|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
9539605|NCT03120637|No Intervention|Standard Treatment|
9539606|NCT03120364|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
9539607|NCT03120364|Active Comparator|Zostavax|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
9539608|NCT03120611|Experimental|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
9539609|NCT03120611|Active Comparator|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
9539610|NCT03120559|No Intervention|Control|"The dental consultation was the same for all the groups.~- Examination and diagnosis (15 min).~- Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).~- Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
9539611|NCT03120559|Other|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
9539612|NCT03120559|Other|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).~New Floss Holder - Gum Chucks/SMS"
9539613|NCT03120390|Experimental|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
9539614|NCT03120390|Experimental|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
9539615|NCT03120390|Active Comparator|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
9539616|NCT03120273|Experimental|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd in dexlansoprazole treatment arm for 5 days
9539617|NCT03120273|Active Comparator|Lansoprazole Injection|30 mg q12h in lansoprazole treatment arm for 5 days.
9539618|NCT03120247|Active Comparator|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
9539619|NCT03120247|Active Comparator|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
9539620|NCT03120247|Active Comparator|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
9539621|NCT03120286||Overweight and obesity|Women with BMI >25
9539622|NCT03120286||Normal weight group|Women with BMI =18-24
9539623|NCT03120260|Experimental|Short Sleep|Diet+ have 5 hour sleep at night (SS)
9539624|NCT03120260|Experimental|Normal Sleep|Diet+ have 7-8 hour sleep at night (NS)
9539625|NCT03120546|Experimental|Group A|rigid video stylet intubation - video laryngoscope intubation
9539626|NCT03120546|Experimental|Group B|video laryngoscope intubation - rigid video stylet intubation
9539627|NCT03120221||First trimester pregnant women|
9539628|NCT03120208|Experimental|women in the nonexposed group without a hemorrhage|
9539629|NCT03120208|Experimental|women in the exposed group with a hemorrhage|
9539630|NCT03120208|Experimental|Partners|
9539631|NCT03120195|Experimental|EndoRotor® ablation|Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
9539632|NCT03120234|Experimental|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
9539633|NCT03120234|Experimental|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
9539634|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
9539635|NCT03119857|Active Comparator|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
9539636|NCT03119857|Experimental|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
9539637|NCT03120104|Active Comparator|Pre-intervention group|Pre-intervention group interventions:pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
9539638|NCT03120104|Active Comparator|Post-intervention group|Post-intervention group: pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) two weeks after the stoma closure
9539639|NCT03120130|Experimental|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
9539640|NCT03120130|Experimental|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
9539641|NCT03120130|Experimental|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
9539642|NCT03120130|Experimental|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
9539643|NCT03120130|Experimental|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
9539644|NCT03120130|Experimental|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
9539645|NCT03120169|Active Comparator|treadmill endurance training|
9539646|NCT03120169|Active Comparator|cycling endurance training|
9539647|NCT03119974|Other|Tpo-RA discontinuation|
9539648|NCT03119896|Experimental|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
9539649|NCT03119896|No Intervention|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
9539650|NCT03120182|Active Comparator|Aspirin Arm|The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
9539651|NCT03120182|Placebo Comparator|Placebo Arm|The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
9539652|NCT03119961|Experimental|SONOCLOUD®|BBB opening by ultrasound
9539653|NCT03119870|Experimental|1|Each subject will conduct 3 sessions, i.e. a training session, an anatomical MRI session and an EEG session. The first session will be to train the subject to carry out the different behavioral tasks that he will then have to perform during the session of EEG.
9622090|NCT02518607|Experimental|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
9539654|NCT03120117|Experimental|Cough Test following Sling Surgery|All subjects enrolled will undergo sling surgery for treatment of stress urinary incontinence and subsequently asked to do a standing cough test.
9539655|NCT03120156|Active Comparator|No insoles|Control group of people with poor postural control that won't use insoles
9539656|NCT03120156|Active Comparator|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
9539657|NCT03120156|Active Comparator|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
9539658|NCT03120065|Other|MEMS follow up|Approximately 25% of the enrolled study population will have their adherence to medicines monitored by research personnel through the use of electronic dose monitoring caps (MEMS) for a period of 3 months. The participant's ART medication regimen will be dispensed in a bottle with a cap that monitors the time and date in which the cap is opened. Each month, the participant will bring the bottle with them on their clinic day for three months and the research personnel will extract the timing information from the cap.
9539659|NCT03119844|Experimental|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
9539660|NCT03119844|Experimental|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
9539661|NCT03120143|Experimental|Team sport and high protein group|This group participated in team sport based small-sided ball games with supplementation of a drink with a high content of protein after the training sessions
9539662|NCT03120143|Experimental|Team sport and low protein group|This group participated in team sport based small-sided ball games with supplementation of a drink low in protein content after the training sessions
9539663|NCT03120143|No Intervention|Control group|This group continued their usual life style without intervention
9539664|NCT03119935|Experimental|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
9539665|NCT03119935|Experimental|Ambu bag ventilation|Ordinary method (ambu bag ventilation
10039654|NCT01845948|Experimental|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
10039655|NCT01846000|Experimental|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
10039656|NCT01846000|Experimental|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
10039657|NCT01846000|Placebo Comparator|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
10039658|NCT01846000|Experimental|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
10039659|NCT01846000|No Intervention|Withou TMD|This will be a follow up group, with volunteers without TMD.
10039660|NCT01846013|Experimental|Stand|
10039661|NCT01846013|Experimental|Move|
10039662|NCT01846013|Experimental|Stand and Move|
10039663|NCT01846013|No Intervention|General Wellness|
9539666|NCT03120026|Experimental|Experimental Product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
9539667|NCT03120026|Placebo Comparator|Isocaloric Placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
9539668|NCT03120039||Healthy adults|Healthy adults without any limitations in upper extremity movement or function.
9539669|NCT03120000|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
10039664|NCT01846026|Experimental|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule~1 capsule per week"
10039665|NCT01846026|Placebo Comparator|Placebo|capsule with peanut oil
9539670|NCT03119948|Placebo Comparator|Group 1|Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
9539671|NCT03119948|Active Comparator|Group 2|Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
9539672|NCT03119948|Active Comparator|Group 3|Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
10039666|NCT01846078|Experimental|Mean absolute errors, median absolute errors|
10039667|NCT01846117|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
10039668|NCT01846117|Placebo Comparator|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
9539673|NCT03119909|Other|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
9539674|NCT03119909|Other|Learning of action-event associations not linked to action|"This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.~30 subjects will participate in the behavioral study and 60 will participate in the fMRI study)"
9539675|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
9539676|NCT03119818|Experimental|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
9539677|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
9539678|NCT03119532|Experimental|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
9539679|NCT03119532|No Intervention|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
9539680|NCT03119545|Experimental|Beardslee family centered intervention|This Group will have the family centered program.
9539681|NCT03119545|No Intervention|Comparison group|This Group will have standard care
9539682|NCT03119597|Placebo Comparator|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
9539683|NCT03119597|Experimental|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
9539684|NCT03119558|Experimental|18F-Florbetaben (Neuraceq®) PET/MRI|Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F-Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45-60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.
9539685|NCT03119506||Long Recess Duration/Before Lunch|
9539686|NCT03119506||Short Recess Duration/Before Lunch|
9539687|NCT03119506||Long Recess Duration/After Lunch|
9539688|NCT03119506||Short Recess Duration/After Lunch|
9539689|NCT03119493|Experimental|Periodized aerobic interval training|The experimental groups will participate in a 16 week, three times a week based-program of periodized aerobic interval training that consist in warming [5 minutes of general stretching and 5 minutes of walking on treadmill with heart rate less than 20 percent of heart rate reserve (HHR)], followed by periodized aerobic interval training on treadmill, and cooling down [5 minutes of walk in treadmill with a heart rate less than 20 percent of HRR and 5 minutes of rest]
9539690|NCT03119493|No Intervention|Control group|Participants in the control group will be instructed not to take part in any regular exercise programs during the study period.
9539691|NCT03119623|Active Comparator|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
9539692|NCT03119623|Active Comparator|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
9539693|NCT03119480||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
9539694|NCT03119792|Experimental|Investigational|An education intervention will be implemented for 600 children from the original cohort (300) and comparable cohort (300) over a four month period at community centers. These sessions will occur twice a month on the weekends. The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles.
9539695|NCT03119792|Active Comparator|Control|The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
9539696|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
9539697|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
9539698|NCT03119675|Other|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
9539699|NCT03119766|Experimental|Kolofort|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
9539700|NCT03119766|Placebo Comparator|Placebo|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
9539701|NCT03119441|Experimental|Dental water jet|Dental water jet (Jetpik JP210)
9539702|NCT03119441|Active Comparator|Dental floss|Dental floss
9539703|NCT03119519|Experimental|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
9539704|NCT03119519|Active Comparator|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
9616266|NCT04046328|Experimental|"Low Dose ECC Regimen"|ECC at the 1.7 g daily dose, administered BID as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.
9616267|NCT04046328|Experimental|"High Dose ECC Regimen"|ECC at the 4.25 g daily dose, administered BID as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.
10039669|NCT01846130|No Intervention|Control|Control bed rest group
9539705|NCT03119779|Experimental|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
9539706|NCT03119779|Active Comparator|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
10039670|NCT01846130|Experimental|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
9539707|NCT03119636|Experimental|NPC transplantation|The patients will receive Levodopa combined with a regular neural precursor cell (NPC) transplantation
9539708|NCT03119636|Experimental|HLA-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-matched neural precursor cell (NPC) transplantation
10039671|NCT01846130|Experimental|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
10039672|NCT01846130|Experimental|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
10039673|NCT01846130|Experimental|Whey protein|22 g of whey isolate 3x a day (with meals)
9539709|NCT03119636|Experimental|HLA-non-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-non-matched neural precursor cell (NPC) transplantation
9539710|NCT03119714|Active Comparator|Pemirolast|Pemirolast 200mg bid 14-16 days
9539711|NCT03119714|Placebo Comparator|Placebo Oral Tablet|Matching placebo bid 14-16 days
9539712|NCT03119753|Experimental|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
9539713|NCT03119753|Active Comparator|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
9539714|NCT03119428|Experimental|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
9539715|NCT03119428|Experimental|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
9539716|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
9539717|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
9539718|NCT03119727|Other|Automated oxygen adjustment|All patient in this study have automatic oxygen titration and automatic oxygen weanning
9539719|NCT03119467|Experimental|Single arm|RP4010 to be administered
9539720|NCT03119415|Experimental|Cooperative Learning|Teachers in intervention schools are training in cooperative learning (CL).
9539721|NCT03119415|No Intervention|Business as Usual|Schools continue with business as usual.
9539722|NCT03119402|Experimental|RRT + active tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of active tDCS (1.5 mA, 5x5cm anodal electrode on left parieto-temporal regions and 5x5cm cathodal electrode on right parieto-temporal regions).
9539723|NCT03119402|Sham Comparator|RRT + sham tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of sham tDCS (with the same active tDCS setup, current applied for 30 seconds,
9539724|NCT03119376|No Intervention|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
9539725|NCT03119376|Experimental|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
9616268|NCT04041310|Experimental|Cohort A - Dose-escalation|"Phase I. Part 1. Dose escalation cohort. Subjects treated with low dose or with high dose of GAd20-209-FSP prime and MVA-209-FSP boosts to define the RP2D, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors."
9539726|NCT03119376|No Intervention|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
9539727|NCT03119311|Experimental|VOG group|Video-oculography
9539728|NCT03119311|Active Comparator|APCT group|alternative prism cover test
9539729|NCT03119337|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
9539730|NCT03119337|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
9539731|NCT03119012|Active Comparator|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
9539732|NCT03119012|Active Comparator|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
9539733|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
9539734|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
9539735|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
9539736|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
9539737|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
9539738|NCT03119077|Experimental|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
9539739|NCT03119077|Placebo Comparator|Placebo|Placebo Dose 1 to 6 of BAY 1161116
9539740|NCT03119259|Active Comparator|ABC Clinical Program Only and Usual Care|Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program and IUHP. The ABC Clinical Program is the standard of ADRD care at Eskenazi Health and Primary Care Visits at Indiana University Health is the usual care.
9539741|NCT03119259|Experimental|BCN Mobile App Plus ABC and BCN Mobile app only|Patients and caregivers randomized to the intervention group will continue to receive care in ABC clinical program and IUHP, and have the BCN software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the BCN software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.
9539742|NCT03119051|Experimental|online cognitive training|Patients will receive 3-4 times of 20-30 minutes' training game every week
9539743|NCT03119051|No Intervention|no training|Patients will not undergo preoperative cognitive training.
9539744|NCT03119051|Experimental|Cognitive training and physical exercise|Patients will receive 3-4 times of 20-30 minutes' training game every week and 2 times of 60 minutes' Tai Chi Training
9539745|NCT03119207|Experimental|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
9539746|NCT03119207|No Intervention|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
9539747|NCT03119207|No Intervention|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
9539748|NCT03119194|Experimental|Reguimen A - [14C]-BIA 9-1067|"100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.~Single dose administration on a single occasion."
9539749|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity
9539750|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity
9539751|NCT03119298||Control group|Healthy subjects matched for age and sex
9803757|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
9539752|NCT03119350|Other|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
9539753|NCT03119129|Experimental|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
9539754|NCT03119129|Experimental|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
9539755|NCT03119129|Experimental|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
9539756|NCT03119129|Experimental|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
9539757|NCT03119038|Active Comparator|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
9539758|NCT03119038|Active Comparator|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
9539759|NCT03119220|Other|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
9539760|NCT03119220|Other|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
9539761|NCT03119233|Experimental|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
9539762|NCT03119246|Experimental|HD patients|
9539763|NCT03119246|Experimental|Controls|
9539764|NCT03119103|Other|Intervention of Functional Bed Sheet|Interventions will be non-invasive where healthy adults (over the age of 17, 10 male and 10 female) sleeps on the functional bed sheet overnight.
9539765|NCT03118973|Experimental|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
9539766|NCT03118973|Experimental|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
9539767|NCT03118960|Active Comparator|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
9539768|NCT03118960|Active Comparator|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
9539769|NCT03119324|Experimental|B-Cure® diode laser|"Thirty patients receiving LLLT by the B-Cure® diode laser (Good Energies, Haifa, Israel) 808nm low power device at 5 Joules/min, 250 milliWatts 15 KiloHertz for 8', (40 Joules each) in contact mode directly over the painful area, twice a day for 7 consecutive days.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
9539770|NCT03119324|Placebo Comparator|B-Cure® diode laser sham device|"Thirty patients that follows the same protocol of the SG but receive a B-Cure laser® sham device, seemingly identical to the effective one but devoid of main diode source.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
9539771|NCT03119324|Active Comparator|Nimesulide Ratiopharm® and Flexiban®|"Thirty patients follows the conventional drug therapy protocol, of two non-consecutive cycles of 5 days of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® (100 mg a day), interspersed with one 5 days cycle of Myorelaxant, Flexiban® (10 mg a day).~From day 1 to 5, patients assumed 50mg of Nimesulide Ratiopharm®, twice a day; from 6th to 10th day they assumed 10mg of Flexiban® in single dose, from day 11 to 15 they assumed 50mg of Nimesulide Ratiopharm® twice a day.~Patients were instructed to assume the therapy always at the same time"
9539772|NCT03118830|Active Comparator|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
9539773|NCT03118830|Active Comparator|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
9539774|NCT03118791|Placebo Comparator|Placebo|Capsules containing maltodextrin
9539775|NCT03118791|Active Comparator|80 mg ACN|Capsules containing 80 mg anthocyanins
9539776|NCT03118791|Active Comparator|160 mg ACN|Capsules containing 160 mg anthocyanins
9539777|NCT03118791|Active Comparator|240 mg ACN|Capsules containing 240 mg anthocyanins
9539778|NCT03118791|Active Comparator|320 mg ACN|Capsules containing 320 mg anthocyanins
9539779|NCT03118791|Active Comparator|480 mg ACN|Capsules containing 480 mg anthocyanins
9539780|NCT03118817|Experimental|HM95573|Single arm
9539781|NCT03118882|Active Comparator|Diet Group|
9539782|NCT03118882|Active Comparator|Physical activity group|
9539783|NCT03118882|Active Comparator|Physical activity and diet group|
9539784|NCT03118882|No Intervention|Control group|
9616269|NCT04041310|Experimental|Cohort B - Expansion Cohort Phase I|"Phase I. Part 1. Expansion cohort at RP2D. Subjects treated with RP2D dose of GAd20-209-FSP prime and MVA-209-FSP boosts, in combination with pembrolizumab.~Phase I. Part 2 - Extended Follow-up from week 27 to week 110. Subjects with unresectable or metastatic dMMR or MSI-H CRC, gastric, or G-E junction tumors."
9616270|NCT04041310|Experimental|Cohort C - Expansion cohort Phase IIa|Phase IIa. Expansion cohort at RP2D. Subjects treated with RP2D of GAd20-209-FSP prime and MVA-209-FSP, in combination with pembrolizumab. Subjects with locally advanced unresectable or metastatic, microsatellite instability high (MSI-H) or dMMR CRC who eligible for anti-PD-1 1st line treatment.
9616271|NCT04034004|Experimental|Meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
9616272|NCT04034004|Experimental|meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
9616273|NCT04031144|Experimental|Ultrafiltration|Ultrafiltration is applied at the end of cardiopulmonary bypass. Maximal clot formation (MCF) of ROTEM-EXTEM tracing is reduced before applying the ultrafiltration.
9616274|NCT04024020||Individuals with insomnia|Men and women with chronic insomnia (>5 years duration)
9616275|NCT04024020||Good sleepers|Men and women with a longstanding pattern of good sleep
9616276|NCT04021706|Active Comparator|anamorelin|one 100 mg tablet daily, taken one hour before breakfast
10039674|NCT01846130|Experimental|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
10039675|NCT01846130|No Intervention|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
9616277|NCT04021706|Placebo Comparator|microcrystaline cellulose|one identical appearing tablet daily, taken one hour before breakfast
9616278|NCT04015622|Experimental|A: Biomarker directed Therapy (BT)|ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
9616279|NCT04015622|Active Comparator|B: Clinician's Choice (CC)|Enzalutamide or docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
9616280|NCT04015115|Experimental|Youth Opioid Recovery Support service model|The components of the Youth Opioid Recovery Support service model includes 1) home-delivery of standard-of-care medication and individual/family counseling services; 2) assertive outreach efforts by the treatment team; and 3) contingency management incentives upon receipt of medication treatment.
9616281|NCT04012138|Experimental|Salbutamol|Patients in this experimental group will receive : 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air);
9616282|NCT04012138|Active Comparator|Insuline + dextrose|Patients in the experimental group will receive : 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period
9616283|NCT04012138|Experimental|Insuline + Dextrose + Salbutamol|"Patients in the experimental group will receive either:~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
9616284|NCT03992469|Experimental|E-B-FAHF-2|Low dose EBFAHF-2 (29 mg/kg/d divided two times a day) for 2 weeks followed by a full dose (71mg/kg/d divided two times a day) for 6 weeks
9616285|NCT03992469|Placebo Comparator|Placebo|capsules are identical in appearance to EBFAHF-2 capsules
9616286|NCT03992456|Experimental|Arm A (panitumumab)|Patients receive panitumumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
9616287|NCT03992456|Active Comparator|Arm B (regorafenib, trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12, or regorafenib PO QD on days 1-21, at the discretion of the treating physician. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
9616288|NCT03975309||Previous DHS Participants|Observational
9622091|NCT02518607|Placebo Comparator|Group 1, Session 1, Placebo|"Lowest dose of SAD:~Placebo, 1 liquid filled enterically coated capsule, single dose"
9622092|NCT02518607|Placebo Comparator|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
10058442|NCT02018341|Experimental|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
9539785|NCT03118752|Experimental|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
9539786|NCT03118752|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
9539787|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
9539788|NCT03118908|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
9539789|NCT03118908|Placebo Comparator|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
9539790|NCT03118609|Experimental|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.~Up to 150 participants will complete the Understanding Needs survey"
9539791|NCT03118999|Experimental|OM3-FFA|Omega3 linked to free fatty acids
9539792|NCT03118999|Experimental|OM3 -MAG|Omega3 linked to Monoacylglycerol
9539793|NCT03118999|Experimental|OM3-EE|Omega3 linked to ethylester
9539794|NCT03118544||Patients undergoing CTO PCI|Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.
9539795|NCT03118856||HD-WLE|Intervention: Prediction of polyp histology with HD-WLE
9539796|NCT03118856||EC|Intervention: Prediction of polyp histology with EC
9539797|NCT03118583|Experimental|Dietary supplement with carrageenan|300 mg/day of dietary supplement containing carrageenan
9539798|NCT03118648||stroke|"Patients over 18 years old leaving the correctional institution with orientation back home~First stroke deficit with non-regressive clinical expression in 24 hours~Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities~Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)~No psychiatric history that led to hospitalization for more than six months~Written informed consent after reading the briefing note~Patient affiliated or beneficiary of a social security scheme."
9539799|NCT03118492|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
9539800|NCT03118674|Experimental|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA < 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
9539801|NCT03118713|Experimental|ipragliflozin and metformin|Subjects will receive daily dosage of ipragliflozin and metformin as single tablets
9539802|NCT03118713|Experimental|glimepiride and metformin|Subjects will receive daily dosage of glimepiride and metformin as single tablets
9539803|NCT03118895|Experimental|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
9539804|NCT03118700|No Intervention|Non-exercise Control|Subjects will come to the laboratory for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow. During this time, subjects will remain seated with their body posture maintained constant
9539805|NCT03118700|Experimental|Aerobic Interval Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
9539806|NCT03118700|Experimental|Continuous Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
9539807|NCT03118635|Experimental|Intervention|Daily, four-hour physical activity intervention
9539808|NCT03118635|No Intervention|Control|No treatment control
9539809|NCT03118661|Experimental|Maraviroc after allo-HCT|"Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1~Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is <50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
9539810|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
9539811|NCT03118557|Experimental|Pilates pelvic floor strengthening exercise|
9539812|NCT03118505|Experimental|Group 1|Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
10058443|NCT02018341|Placebo Comparator|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
9539813|NCT03118505|Experimental|Group 2|Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
9539814|NCT03118505|Experimental|Group 3|Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
9539815|NCT03118505|Active Comparator|Control|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.
9539816|NCT03118453|Experimental|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
9539817|NCT03118453|Active Comparator|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
9539818|NCT03118622||Pentax group|Intubation using Pentax
9539819|NCT03118622||Macintosh group|Intubation using Macintosh
9539820|NCT03118440|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
9539821|NCT03118440|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
9539822|NCT03118323||Patients in need of endodontic treatment|n = 200
9539823|NCT03118479|Experimental|Androgen only addback|Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
9539824|NCT03118479|Experimental|Combined sex steroid addback|Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
9539825|NCT03118401|Experimental|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
9539826|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
9539827|NCT03118414|Experimental|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
9539828|NCT03118414|Experimental|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
9539829|NCT03118414|Experimental|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
9539830|NCT03118414|No Intervention|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
9539831|NCT03118388|Experimental|36 SEI youth|36 homeless youth (ages 16-24) randomized to the SEI intervention
9539832|NCT03118388|Experimental|36 IPS youth|36 homeless youth (ages 16-24) randomized to the IPS intervention
9539833|NCT03118219|Experimental|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
9539834|NCT03118219|Other|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
10058444|NCT02018354|Active Comparator|ACL Reconstruction|Standard ACL reconstruction only.
10058445|NCT02018354|Experimental|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
9539835|NCT03118193|Experimental|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
9539836|NCT03118362|Experimental|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
9539837|NCT03118362|Experimental|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
9539838|NCT03118232|Active Comparator|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
9539839|NCT03118232|No Intervention|Routine Bathing|Routine bathing per facility protocol.
9539840|NCT03118310|Placebo Comparator|Placebo|Placebo diet
9539841|NCT03118310|Experimental|5:2|5:2 diet
9539842|NCT03118310|Experimental|LCHF|LCHF diet
9539843|NCT03118154||Manual Physical Therapy, retrospective|Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
9539844|NCT03118154||Control, prospective|Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.
9539845|NCT03118206|Active Comparator|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
9539846|NCT03118206|Active Comparator|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
9539847|NCT03118206|Active Comparator|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
9539848|NCT03118336|Placebo Comparator|placebo group|
9539849|NCT03118336|Experimental|empaglifozine group|
9539850|NCT03118349|Experimental|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation Initial to maximum tolerated dose
9539851|NCT03118349|Experimental|Expansion Cohort|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
9539852|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
9539853|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
9539854|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
9539855|NCT03118245|Experimental|AuraGain group|AuraGain is inserted for maintenance of general anesthesia. The size 1 is for children <5kg, size 2 for 5-10kg, size 2 for 10-20kg, and size 2.5 for 20-30kg.
9539856|NCT03118245|Experimental|I-gel group|I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
9539857|NCT03118271|Active Comparator|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
9539858|NCT03118271|Active Comparator|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
9616289|NCT03972306|Experimental|Group A: Cohorts A1-A4|"Participants (participants pretreated with ocrelizumab) will receive a single injection of subcutaneous (SC) ocrelizumab co-mixed with rHuPH20 in the abdomen. For every new dose level, recruitment will be staggered by enrolling 1 participant in each cohort followed by a 48-hour waiting period to review safety and tolerability data by the Safety Monitoring Committee (SMC) prior to enrolling subsequent participants in the same cohort. Currently, the planned dose escalation steps for patients who enroll in Group A are as follows:~Cohort A1: 40 mg of SC ocrelizumab~Cohort A2: 200 mg of SC ocrelizumab~Cohort A3: 600 mg of SC ocrelizumab~Cohort A4: 1200 mg of SC ocrelizumab"
9616290|NCT03972306|Experimental|Group A: Cohort A5|In the non-randomized subphase, participants will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.
9539859|NCT03118271|Active Comparator|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
9539860|NCT03118258|Experimental|Pap smear|'Pap smear' arm: women are invited to participate in a preventive consultation. This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
9539861|NCT03118258|Experimental|Self-collected vaginal swab for HPV testing + pap smear triage|"'Self-collected vaginal swab for HPV testing + pap smear triage' arm : women are invited to participate in a preventive consultation. This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
9539862|NCT03118427|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
9539863|NCT03118427|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
9539864|NCT03118167|Experimental|Tea polyphenols & Acrylamide|TP 0.05g, 0.1g, 0.2g (starches filled, up to 0.35g) capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
9539865|NCT03118167|Experimental|AOB-w & Acrylamide|AOB-w 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
10039676|NCT01846143|Experimental|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
10058446|NCT02018367|Experimental|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
9539866|NCT03118167|Active Comparator|Placebo & Acrylamide|Placebo (Starches) 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
9539867|NCT03118050|Experimental|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.
9539868|NCT03118050|Experimental|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
9539869|NCT03118050|Experimental|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
9539870|NCT03118050|Experimental|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
9539871|NCT03118050|Experimental|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
9539872|NCT03118050|Experimental|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
9539873|NCT03118050|Experimental|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
9539874|NCT03118180|Experimental|CART19 group|All patients were included for CART19 therapy
9539875|NCT03118115|Experimental|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
9539876|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
9539877|NCT03118063|Experimental|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
9539878|NCT03118063|Active Comparator|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
9539879|NCT03118063|Active Comparator|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
9539880|NCT03118011|Active Comparator|No smoking|The ward where the patients can not go out to smoke
9539881|NCT03118011|Placebo Comparator|Smoking|The ward where the patients can go out to smoke.
9539882|NCT03118076|Placebo Comparator|Group R|Nerve blocks were administered with 0.3% ropivacaine without dexmedetomidine.
9539883|NCT03118076|Experimental|Group RD|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
9539884|NCT03118141|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
9539885|NCT03118141|Active Comparator|IVF group|Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
9539886|NCT03118128|Active Comparator|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
9539887|NCT03118128|No Intervention|No metformin|
9539888|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
9539889|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
9539890|NCT03117829|Experimental|Improve Brain Blood Flow|12 week diet and exercise program to improve brain blood flow
9539891|NCT03117790|Experimental|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
9539892|NCT03117790|Placebo Comparator|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
9539893|NCT03117764|Active Comparator|Acute IV AB for exacerbation at hospital|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
9539894|NCT03117764|Experimental|Acute IV AB for exacerbation at home|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
9539895|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
9539896|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
9539897|NCT03117907||Infants with low infectious status|
9539898|NCT03117907||Infants with high infectious status|
9539899|NCT03117894|Active Comparator|GA with RA|Regional Anesthesia and General Anesthesia.
9539900|NCT03117894|Active Comparator|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
9539901|NCT03117959|Placebo Comparator|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
9539902|NCT03117959|Experimental|Stryker shape match|no longer RCT
9539903|NCT03117842|Experimental|Intervention Group|Participants in the intervention group will receive the 3 text or voice messages weekly. The messages will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support.
9539904|NCT03117842|No Intervention|Control Group|"Those in the control group will get one check-in text or voice message between baseline and midline and another between midline and endline."
9539905|NCT03117660|Experimental|Vitamin A|Subjects will receive 3-4weeks of vitamin A
9539906|NCT03117660|No Intervention|Control|Subjects will receive no treatment
9539907|NCT03117946|Experimental|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.~Tumor tissues will be collected if available."
9539908|NCT03118024|Active Comparator|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
9539909|NCT03118024|Active Comparator|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
9539910|NCT03117972|Experimental|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
9539911|NCT03117972|Active Comparator|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
9539912|NCT03117920|Experimental|Minnelide|0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
9539913|NCT03117855|Experimental|Treatment (capecitabine, yttrium Y-90 radioembolization)|Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine PO BID on days 1-14.
9539914|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
9539915|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
9539916|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
9539917|NCT03117686||healthy volunteers|10 healthy volunteers climbing Mount Kilimanjaro receiving lung ultrasound
9539918|NCT03117686||patients after lung transplantation|10 patients > 2years after lung transplantation climbing Mount Kilimanjaro receiving lung ultrasound
9539919|NCT03117998|Experimental|REMD-477 Treatment A|Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
9539920|NCT03117998|Experimental|REMD-477 Treatment B|Administered as a repeated SC doses in subjects with Type 1 Diabetes
9539921|NCT03117998|Placebo Comparator|Matching placebo|Administered as a repeated SC doses in subjects with Type 1 Diabetes
9539922|NCT03117595|Active Comparator|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
9539923|NCT03117595|Active Comparator|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
9539924|NCT03117608|Experimental|AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)|injection of aMAT obtained with Lipogems® technology.
9539925|NCT03117608|Active Comparator|platelet-rich plasma (PRP)|single injection of platelet-rich plasma
9539926|NCT03117335|Active Comparator|Vinorelbine plus Cisplatin With placebos|The control group
9539927|NCT03117335|Experimental|Vinorelbine plus Cisplatin With Sulijia|The treatment group
9539928|NCT03117283|Experimental|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
9539929|NCT03117283|Sham Comparator|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
9539930|NCT03117387||moderate neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
9539931|NCT03117387||deep neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
9539932|NCT03117387||moderate neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
9539933|NCT03117387||deep neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
9539934|NCT03117465|Experimental|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
9539935|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
9539936|NCT03117452|Experimental|visual training condition|Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes. Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
9539937|NCT03117452|No Intervention|control condition|Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
9539938|NCT03117374|Experimental|Team Nutriathlon intervention|Participants were invited to participate in the Team Nutriathlon for an 8-week period
9539939|NCT03117374|No Intervention|Control|Participants were invited to follow the regular school curricular for an 8-week period
9539940|NCT03117478|Other|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
9539941|NCT03117478|Other|2. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
9539942|NCT03117478|Other|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
9539943|NCT03117478|Other|4. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
9539944|NCT03117556|Experimental|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
9539945|NCT03117556|No Intervention|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
9539946|NCT03117413|Other|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
9539947|NCT03117413|Other|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
9539948|NCT03117270|Experimental|oral filgotinib tablets|
9539949|NCT03117270|Placebo Comparator|placebo tablets|
9539950|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
10058447|NCT02018367|No Intervention|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
9539951|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
9539952|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
10039677|NCT01846143|Experimental|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
10058448|NCT02018380|Experimental|Shock Absorbing Insoles vs. Athletic shoes|
10058449|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
9539953|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
9539954|NCT03117491|Active Comparator|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
9539955|NCT03117491|Active Comparator|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
9539956|NCT03117491|Active Comparator|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
9539957|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
9539958|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
9539959|NCT03117322|Experimental|Synbiotic|"Each participant will receive the next:~agave inulin (4 g) in powder~Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks."
9539960|NCT03117322|Experimental|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
9539961|NCT03117322|Experimental|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
9539962|NCT03117322|Placebo Comparator|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
9539963|NCT03117439|No Intervention|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
9539964|NCT03117439|Experimental|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
9539965|NCT03117530|Experimental|Minocycline|
9539966|NCT03117725|Experimental|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
9539967|NCT03117725|Placebo Comparator|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
9539968|NCT03117348|Experimental|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
9539969|NCT03117348|Experimental|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
9539970|NCT03117244|Experimental|Exercise Group|
9539971|NCT03117244|Active Comparator|Exercise and NMES Group|
9539972|NCT03117244|No Intervention|Control Group|
9616291|NCT03972306|Experimental|Group A: Cohort AA|Participants will receive a single 600-mg dose ocrelizumab by intravenous (IV) infusion
9616292|NCT03972306|Experimental|Group B: Cohorts B1-B4|"Ocrelizumab treatment- naive participants will receive a minimum of 3 patients in Cohort B will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.~Cohort B1: 40 mg of SC ocrelizumab~Cohort B2: 200 mg of SC ocrelizumab~Cohort B3: 600 mg of SC ocrelizumab~Cohort B4: 1200 mg of SC ocrelizumab"
9616293|NCT03957941|Experimental|FamilyLink Pumping|Pump three times while away from infant, while watching baby via FamilyLink.
9616294|NCT03957941|Active Comparator|Standard Pumping|Pump three times while away from infant, not watching baby via FamilyLink.
9616295|NCT03956706|Experimental|Dose Escalation (18Gy)|Receive additional dose of 18Gy to the subventricular zone
9539973|NCT03118089|Experimental|Biscuit style oral nutritional supplement treatment|Participants will take the biscuit style oral nutritional supplement at an intervention level equivalent to their current oral nutritional supplement prescription
9539974|NCT03118089|No Intervention|Standard Care|Participants will remain on their current oral nutritional supplement
9539975|NCT03117426|Experimental|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
9539976|NCT03117426|Active Comparator|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
9539977|NCT03117231|Experimental|Active tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
9539978|NCT03117231|Sham Comparator|Sham tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
9539979|NCT03117257|Experimental|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
9539980|NCT03117257|Active Comparator|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
9539981|NCT03117205|Experimental|Kinesio Taping® group|
9539982|NCT03117205|Placebo Comparator|placebo group|
9539983|NCT03117192|Experimental|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
9539984|NCT03117192|Placebo Comparator|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
9539985|NCT03117179|Other|Patient with an interview|
9539986|NCT03117179|Other|Patient without an interview|
9539987|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria~Subjects should have at least one of the following problems~Presence of hemophagocytosis in tissue or bone marrow~Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria~Age > 18 years~Written informed consents~Subjects receive steroids and etoposide"
10039678|NCT01846143|Experimental|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
9539988|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
9539989|NCT03116919|Other|Potato arm|One group will be fed an extra serving of boiled, baked or mashed potatoes daily for 1 week
9539990|NCT03116919|Other|Non-starchy vegetable|Then crossover to an extra serving of a non-starchy vegetable
9539991|NCT03116906|Experimental|BI 685509|multiple rising doses of BI 685509
9539992|NCT03116906|Placebo Comparator|Placebo|matching placebo
9539993|NCT03117166|Experimental|Lidocaine|treatment arm
10039679|NCT01846156|Experimental|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
9539994|NCT03117166|Placebo Comparator|Saline|placebo arm
9539995|NCT03116971|Experimental|M3814 PiC with Etoposide and Cisplatin|Participants received M3814 100 milligram (mg) powder in capsule (PiC) orally once daily in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 milligram per square meter (mg/m^2) over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until progressive disease (PD).
9539996|NCT03116971|Experimental|M3814 (HME Tablet + PiC) with Etoposide and Cisplatin|Participants received M3814 100 mg hot melt extrusion (HME) tablet orally 5 days prior to Day 1 and M3814 100 mg PiC, orally once daily from Day 1 in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 mg/m^2 over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until PD.
9539997|NCT03116945|Experimental|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
9539998|NCT03117153|Experimental|DA-5502 liquid toothpaste|"SMFP 760mg, CPC 50mg, tocopherol acetate 10mg, panthenol 100mg, Dipotassium glycyrrhizinate 20mg.~everyday 3 times for 6 weeks"
9539999|NCT03117153|Placebo Comparator|placebo|"no active ingredients~everyday 3 times for 6 weeks"
9540000|NCT03117023|Experimental|dexmedetomidine group|sufentanil + dexmedetomidine
9540001|NCT03117023|No Intervention|control group|sufentanil + saline
9540002|NCT03117062|Experimental|Occlusal Reduction|performing occlusal reduction on functional cusps until abscence of contact was confirmed
9540003|NCT03117062|No Intervention|non-occlusal reduction|occlusal surface left intact
9540004|NCT03116880||Image registration|
9540005|NCT03117114|Other|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
9540006|NCT03117114|Active Comparator|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
9540007|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
9540008|NCT03117075|Experimental|Experimental|"using device for scoring pain scale, named ANAPA®"
10039680|NCT01846156|Experimental|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
10039681|NCT01846156|Active Comparator|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
9540011|NCT03116893|Experimental|Reference Treatment|BI 685509 given alone, fasted
9540012|NCT03116893|Experimental|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
9540013|NCT03116893|Experimental|Treatment 2|BI 685509, given together with itraconazole, fasted
9540014|NCT03116893|Experimental|Treatment 3|BI 685509, given together with rifampicin, fasted
9540015|NCT03117101|Experimental|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
9540016|NCT03117127|Active Comparator|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
9540017|NCT03117127|Experimental|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
9540018|NCT03116958|Active Comparator|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events…)."
9540019|NCT03116958|Experimental|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
9540020|NCT03116984|Active Comparator|Transcatheter arterial chemoembolization|TACE group: The frequency of treatment is determined based on the disease condition for patients who are randomly assigned to group of TACE treatment.TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery, and micro-embolization superselective catheterization is preferred.Adriamycin(30 to 60mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.The dose of ultra fluid lipiodol was determined by diameter and blood supply type of HCC,generally 5-20ml, and no more than 30ml once.The boundary is considered whether there are large amounts of lipiodol to deposit in the tumor and tiny branches shadow of portal veins in paracarcinoma under fluoroscopic guidance. Embolizing agents(gelatin sponge particles 350um-560um) are added after lipiodol emulsion embolization.It has a possibility of observeation alone if tumor achieves a complete response after two times TACE.
9540021|NCT03116984|Experimental|External-beam radiotherapy|EBRT group: Patients who were randomized to the external- beam radiotherapy (EBRT) 3-5 weeks after the completion 2 times TACE.Radiotherapy equipment is based on the conditions of the cooperative units. 3-DCRT, IMRT or IGRT will be opted based on hospital. IGRT can also be used via helical tomotherapy, Rapid Arc or VMAT. The target volume should include the visible tumor.
9540022|NCT03116815|Other|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
9540023|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
9540024|NCT03117088|Active Comparator|Checklist ISBAR 3|online-based checklist for standardized handovers
9540025|NCT03117088|Placebo Comparator|Checklist VICUR|comparator Checklist
9540026|NCT03116776|Experimental|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
9540027|NCT03116776|Active Comparator|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
9616296|NCT03956706|Experimental|Dose Escalation (20Gy)|Receive additional dose of 20Gy to the subventricular zone
10039682|NCT01846169|Experimental|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
10039683|NCT01846195|Sham Comparator|no blood draw|CM 1500 with no blood draw
10039684|NCT01846195|Active Comparator|blood draw|CM 1500 with blood draw
10039685|NCT01846234||MS patients|MS patients
10039686|NCT01846247|Placebo Comparator|Standard Care|Standard stroke unit rehabilitation care
10039687|NCT01846247|Experimental|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
9540028|NCT03116724|Experimental|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
9540029|NCT03116802|Experimental|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
9540030|NCT03116802|Active Comparator|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
9540031|NCT03116737|Experimental|Benzocaine Otic Solution|
9540032|NCT03116737|Placebo Comparator|Placebo|
9540033|NCT03116789|Active Comparator|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
9540034|NCT03116789|Active Comparator|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
9540035|NCT03116620|Experimental|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
9540036|NCT03116607|No Intervention|Control|The control group will receive the usual hospital care. In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
9540037|NCT03116607|Experimental|Intervened|"The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge.~In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.~patient education/ recommendations to the health team"
9540038|NCT03116646|Experimental|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
9540039|NCT03116711|Active Comparator|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
9540040|NCT03116711|Active Comparator|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
9540041|NCT03116711|Active Comparator|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
9540042|NCT03116711|Active Comparator|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
9540043|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care & one blood draw (40ml)
9540044|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
9540045|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
9540046|NCT03116763|Experimental|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
9540047|NCT03116763|Active Comparator|Control Group|The control group will receive standard care but without the iPeer2Peer program.
9540048|NCT03116659|Experimental|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
9540049|NCT03116581|Other|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
9540050|NCT03116581|Other|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
9540051|NCT03116672|Experimental|ketorolac 10 mg|Administration of one dose Ketorolac 10 mg 15 minutes before treatment
9540052|NCT03116672|Experimental|Diclofenac|Administration of one dose Diclofenac 15 minutes before treatment
9540053|NCT03116672|Experimental|Placebo oral capsule|Administration of Placebo capsule 15 minutes before treatment
9540054|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
9540055|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
9540056|NCT03116386|Other|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of~reporting all the falls occurring during the night~tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night~and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
9540057|NCT03116386|Sham Comparator|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
9540058|NCT03116386|Experimental|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
9540059|NCT03116594|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
9540060|NCT03116594|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
9540061|NCT03116594|Active Comparator|Zostavax|Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm
9540062|NCT03116412|No Intervention|Routine follow up|Follow up according to national guidelines.
9540063|NCT03116412|Experimental|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
9540064|NCT03116542|Experimental|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
9540065|NCT03116347|Experimental|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
9540066|NCT03116347|Experimental|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer <160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer ≥160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
9540067|NCT03116347|Active Comparator|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
9540068|NCT03116555|Experimental|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
9540069|NCT03116243||MSHS children and families|"Cohort includes:~children (1272)~parents (1272)~teachers (159)~teaching assistants (159)~program and center directors (253)"
9540070|NCT03116451|Experimental|Foot Health Promoting Program|The experimental group will receive an electronic intervention (Foot Health Promotion Program, FHPP) for 8 weeks consisting of foot self-care guidance (skin and nail self-care), foot exercises, foot stretching and professional footwear guidance. Each topic includes lectures (delivered via Adobe Presenter) and self-directed learning where participant will go through a list of links to websites and watch videos about foot self-care. In addition, the learning will be evaluated using four individual tasks related to foot self-care.
9540071|NCT03116451|No Intervention|Comparison group|The comparison group will not receive any instructions or guidance for foot self-care but participant in the comparison group will complete the same measurement points than experimental group. After the study, the comparison group will also receive the same intervention than experimental group (if effective).
9540072|NCT03116204||Patients hospitalized in a FRC department|
9540073|NCT03116191|Experimental|SK-1404 high dose|
9540074|NCT03116191|Experimental|SK-1404 middle dose|
9540075|NCT03116191|Experimental|SK-1404 low dose|
9540076|NCT03116191|Placebo Comparator|Placebo|
9540077|NCT03116503|Experimental|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
9540078|NCT03116373|Active Comparator|maxilla fixing then mandible fixing|The tracheal tube is first fixed on the maxilla. After the measures of the outcomes, its site of fixation is changed for the mandible for the outcome measurement in the second site of fixation.
9540079|NCT03116373|Active Comparator|mandible fixing then maxilla fixing|The tracheal tube is first fixed on the mandible. After the measures of the outcomes, its site of fixation is changed for the maxilla for the outcome measurement in the second site of fixation.
9540080|NCT03116256|Other|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
9540081|NCT03116256|Active Comparator|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
9540082|NCT03116256|Active Comparator|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
9540083|NCT03116516|Other|ARM1|"In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22."
9540084|NCT03116516|Other|ARM2|"In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22."
9540085|NCT03116269|Experimental|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
9540086|NCT03116269|Active Comparator|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
9540087|NCT03116126|Active Comparator|Guanfacine|
9540088|NCT03116126|Placebo Comparator|Placebo|
9540089|NCT03116360|Experimental|Single Arm|All patients will undergo traditional xray screening as well as experimental screening with diagnostic ultrasound. All subjects will undergo confirmatory MRI.
9540090|NCT03116321|Experimental|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
9540091|NCT03116321|Experimental|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
9540092|NCT03116321|Active Comparator|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
9540093|NCT03116178|Active Comparator|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
9540094|NCT03116178|Active Comparator|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
9540095|NCT03116139|No Intervention|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
9540096|NCT03116139|Active Comparator|Randomized to V/Q|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
9540097|NCT03116139|Active Comparator|Randomized to CT|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
9540098|NCT03116087|Active Comparator|Testosterone patch|Testosterone patches
9540099|NCT03116087|Placebo Comparator|Placebo|Placebo patches
9540100|NCT03116308|Experimental|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
9540101|NCT03116165|Experimental|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
9540102|NCT03116165|Placebo Comparator|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
9540103|NCT03116061||Multimorbidity cohort|The study population included a random sample of multimorbid patients (according to the EGPRN definition of multimorbidity). Patients were selected by 19 FPs in their offices in the county of Finistere (in north-west France) from July 2014 to December 2014. Randomization was achieved by including the first four multimorbid patients (according to the inclusion criteria) encountered during their second working day of each week. As patients were booking their appointments with the practice without the FPs' clearance, the FPs were not able to select them
9540104|NCT03116282|Experimental|Intervention|Conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of therapy where participants are not required to show up at a clinic.
9540105|NCT03116282|No Intervention|Control|Treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic.
9540106|NCT03116074|No Intervention|Study 1: Pre-intervention 1|"Usual care.~Patients/caregivers do not have access to patient portal. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
9540107|NCT03116074|Experimental|Study 1: Post-intervention|"Patient-Centered Discharge Toolkit: patient portal and provider safety dashboard PLUS patient pre-discharge checklist, provider discharge preparation indicator, secure patient-provider messaging~Patients/caregivers have access to patient portal with discharge module (pre-discharge preparation checklist) and secure patient-provider messaging tools activated. Providers have access to discharge preparation indicator on safety dashboard and secure patient-provider messaging tools."
9540108|NCT03116074|No Intervention|Study 1: Pre-intervention 2|"Usual care PLUS patient portal and provider safety dashboard.~Patients/caregivers have access to patient portal but not discharge module or secure patient-provider messaging tools. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
9540109|NCT03116074|No Intervention|Study 2: Pre-intervention|"Usual care on three general medicine units.~Patients/caregivers do not have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
9540110|NCT03116074|Experimental|Study 2: Post-intervention|Patients/caregivers have access to the discharge preparation checklist. Providers have access to safety dashboard.
9540111|NCT03115944|Experimental|UltraSpeed Treatment|UltraSpeed ultrasound treatments
9540112|NCT03116295|Experimental|Group 1 - 25 mg OPC|In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of OPC [AF] or a single 25 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
9616297|NCT03956706|Experimental|Dose Escalation (22Gy)|Receive additional dose of 22Gy to the subventricular zone
9540113|NCT03116295|Experimental|Group 2 - 50 mg OPC|In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of OPC [AF], or a single 50 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
10039688|NCT01846273|Experimental|Ranibizumab + vPDT|Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
10039689|NCT01846273|Active Comparator|Ranibizumab monotherapy|Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
9540114|NCT03115957|Experimental|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
9540115|NCT03115957|Experimental|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
10039690|NCT01846286||Newly Diagnosed HNC|For AIM 2 and AIM3, Newly diagnosed and previously untreated patients with locoregional squamous cell carcinoma of the head and neck recruited at MD Anderson: Pain assessed at baseline, weekly during treatment, and during clinic visits (every 6-8 weeks) for a period of 3 months after treatment. Quantitative sensory testing performed at baseline and at 3 months from completion of treatment to determine nociceptive versus neuropathic component.
10039691|NCT01846312||All participants|
10039692|NCT01846325|Experimental|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
9540116|NCT03116022|Active Comparator|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
9540117|NCT03116022|Experimental|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
9540118|NCT03116022|Placebo Comparator|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
9540119|NCT03116009|Active Comparator|Screening for diabetes with 1-hour GCT and HbA1|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
9540120|NCT03116009|Experimental|Early screening with only HbA1C|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
9540121|NCT03115996|Experimental|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
9540122|NCT03115996|Experimental|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
10039693|NCT01846325|Active Comparator|VitaminE plus placebo|vitamin E 600 mg plus placebo
10039694|NCT01846325|Placebo Comparator|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
10039695|NCT01846325|Active Comparator|DHA plus placebo|460 mg DHA plus placebo
9540123|NCT03115996|Experimental|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
9540124|NCT03115996|Experimental|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
9540125|NCT03115892|Experimental|intervention arm|Green Tea With Aloe Vera mouthwash twice daily for one week
9540126|NCT03115892|Active Comparator|control arm|Chlorhexidine Mouthwash twice daily for one week
9540127|NCT03116048|Other|Pecs group (study group)|Chronic pain assessment with study questionnaire
9540128|NCT03116048|Other|Control group (placebo group)|Chronic pain assessment with study questionnaire
9540129|NCT03116035|Active Comparator|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
9540130|NCT03116035|Active Comparator|Standard websites|selected, high-quality standard web-sites
9540131|NCT03115879|Placebo Comparator|Placebo Group|Hip manipulation simulation
9540132|NCT03115879|Experimental|Manipulation Group|Hip manipulation
9540133|NCT03115983|Experimental|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
9540134|NCT03115983|Active Comparator|Fusion|Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
9540135|NCT03115697|Active Comparator|Lactulose with Rifaximin|
9540136|NCT03115697|Experimental|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
10039696|NCT01846338|Experimental|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
10039697|NCT01846338|Placebo Comparator|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
10039698|NCT01846364|Experimental|A|Subjects with proliferative thyroid disease
10039699|NCT01846377|Experimental|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
10039700|NCT01846377|No Intervention|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
10039701|NCT01846390|Experimental|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
10039702|NCT01846403|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
10039703|NCT01846429|Experimental|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
10039704|NCT01846468|Experimental|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
10039705|NCT01846468|Experimental|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
10039706|NCT01846468|Experimental|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
9540137|NCT03115658|Experimental|Exercise Intervention|"Participants met with a PhD level psychologist experienced with health behavior change, to set a personalized exercise goal and plan. Participants were told the studies' goal to engage in 150 minutes of moderate intensity or greater physical activity each week, based on the ACSM recommendations, but participants were allowed to set any personal goal. Participants were also instructed on how to self-monitor their physical activity.~After the initial meeting all other intervention components were sent through the mail. The intervention consists of three types of print material that were mailed: stage-matched manuals, tailored feedback report, and tip sheets."
9540138|NCT03115645|Experimental|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
9540139|NCT03115645|No Intervention|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
9540140|NCT03115866|Experimental|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
9540141|NCT03115866|Experimental|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
9540142|NCT03115866|Experimental|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
9540143|NCT03115736|Experimental|Switch|Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen
9540144|NCT03115463|Experimental|OX25|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 10th to 25th percentile saturations observed in healthy term newborns.
9540145|NCT03115463|No Intervention|OX50|Resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines
9540146|NCT03115463|Active Comparator|OX75|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 75th percentile saturations observed in healthy term newborns.
9540147|NCT03115671|Experimental|Intervention|Each child participant in the Intervention group will be taking 4 capsules of Vayarin per day for 3 months. Each capsule contains 167mg Lipirinen, providing 75mg Phosphatidylserine (PS), 21.5mg EPA and 8.5mg DHA. This gives a daily dosage of 300mg PS and 120mg EPA/DHA. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
9540148|NCT03115671|No Intervention|Control|Participants in the Control group will not be given Vayarin. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
9540149|NCT03115775|Active Comparator|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
9540150|NCT03115775|Active Comparator|Vitamin D|Vitamin D3 (2000 IU per day)
9540151|NCT03115775|Active Comparator|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
9540152|NCT03115775|Placebo Comparator|Placebo|Corn oil (4000 mg per day)
10039707|NCT01846468|Experimental|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
9616298|NCT03940547|Experimental|Experimental - provision of flour|This arm will receive infant and young child feeding education performed by community health workers and very-low aflatoxin (AF) pre-blended porridge flour, ratio 4:1 maize to groundnut. Provision of this pre-blended flour will be 50 grams/day for 6-8 month olds, 60/day grams for 9-11 months and 75 grams/day for 12-18 month olds (with 10-15 grams added per day to account for any loss). Participants will also receive 1 kg of low-AF groundnut flour each month for 6-18 month olds. Finally, participants will receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
9616299|NCT03940547|Active Comparator|Control - promotion of flour|This arm will receive infant and young child feeding education performed by community health workers and promotion of porridge made from maize and groundnut to match what is provided to the intervention arm. Participants will also receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
9616300|NCT03920098||Mother-infant dyads|Mother-infant dyads
9616301|NCT03912831|Experimental|KITE-439|"Phase 1A (Dose Escalation): Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-439.~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-439, at a dose selected based on Phase 1A."
9616302|NCT02543697|Experimental|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
9616303|NCT02543684|Experimental|ready to eat mixed meal 1|
9616304|NCT02543684|Experimental|ready to eat mixed meal 2|
9616305|NCT02543684|Experimental|ready to eat mixed meal 3|
9616306|NCT02543684|Experimental|oral glucose load|
10039708|NCT01846520|Experimental|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
10039709|NCT01846520|No Intervention|Arm II (usual care)|Participants receive usual care.
9622093|NCT02518607|Placebo Comparator|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
9622094|NCT02518607|Placebo Comparator|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
9540153|NCT03115372|Experimental|Group I (CRC education)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
9540154|NCT03115372|Active Comparator|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
9540155|NCT03115606|Active Comparator|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
9540156|NCT03115606|Active Comparator|Fastrach LMA|Patients intubated with Fastrach LMA
10039710|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
9540157|NCT03115437|Experimental|Hard cushioned running shoes|Running shoes with cushioned properties among the hardest of the market benchmark (Stiffness: +/- 90 N/mm)
9540158|NCT03115437|Experimental|Soft cushioned running shoes|Running shoes with cushioned properties among the softest of the market benchmark (Stiffness: +/- 57 N/mm)
9540159|NCT03115489|Placebo Comparator|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
9540160|NCT03115489|Active Comparator|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
9540161|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
9540162|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
9540163|NCT03115554|Active Comparator|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
9540164|NCT03115554|Active Comparator|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
9540165|NCT03115398|No Intervention|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
9540166|NCT03115398|Experimental|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
9540167|NCT03115762|Experimental|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
9540168|NCT03115762|Active Comparator|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
9540169|NCT03115762|Active Comparator|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
9540170|NCT03115307|Experimental|Gonapeptyl|In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
9540171|NCT03115307|No Intervention|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
9540172|NCT03115359|Experimental|Mindfulness Meditation|Mindfulness Meditation intervention, adjunctive to usual care for opioid-treated chronic low back pain.
9540173|NCT03115359|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
9540174|NCT03115320|Experimental|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
9540175|NCT03115320|Other|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
9540176|NCT03115515|Experimental|Adjustment in number of doses of thyroid hormone per week|"Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase by 3 doses/week~TSH 5.0-9.9mIU/L, increase by 2 doses/week~TSH 2.0-4.9mIU/L, increase by 1 dose/week~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease by 1 dose/week~TSH<0.1mIU/L, decrease by 2 doses/week~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
9616307|NCT02543944|Active Comparator|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
10039711|NCT01846559|Experimental|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily~E.coli Endotoxin Day 7 - 2 ng/kg"
9622095|NCT02518607|Placebo Comparator|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
9540177|NCT03115515|Experimental|Adjustment in micrograms per day of thyroid hormone|"Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg~TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg~TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day~TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
9540178|NCT03115593|Experimental|postmenopausal patients with metrorrhagia|"Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).~The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer."
9540179|NCT03115385|Placebo Comparator|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
9540180|NCT03115385|Active Comparator|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
9540181|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
9540182|NCT03115346|Experimental|decision aid|the experimental group will receive the decision aid
9540183|NCT03115346|No Intervention|control|the control group will only receive the survey
9540184|NCT03115970||Trauma patients|All patients having / suspected to have severe trauma injuries
9540185|NCT03115567|No Intervention|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
9540186|NCT03115567|Experimental|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
9540187|NCT03115268|Experimental|Immediate|Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
9540188|NCT03115268|Active Comparator|Wait list control|Participants allocated to the wait list control arm will receive 6 months of usual care after randomisation. They will be re-assessed in month 7, and will then receive 6 months of social support groups delivered in EVA Park, with reassessment in month 14.
9540189|NCT03115255|Experimental|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
9540190|NCT03115125|Other|Adult patients with severe sepsis|
9540191|NCT03115138|Other|Patients with glial tumor|
9540192|NCT03115242|Experimental|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
9540193|NCT03115216|Active Comparator|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
9540194|NCT03115216|Active Comparator|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
9540195|NCT03115229|No Intervention|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
9540196|NCT03115229|Experimental|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
9540197|NCT03114852||CKD patients|"'blood collection'~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
9540198|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
9540199|NCT03114865|Experimental|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
9540200|NCT03114930|Other|Standard output|
9540201|NCT03114930|Other|Non standard output|
9540202|NCT03115047|Experimental|dexmedetomidine|"Unique dose of dexmedetomidine injection:~intravenous injection~0.35 mcg/kg~in two minutes~if shivering 5 minutes after delivery"
9540203|NCT03115047|Active Comparator|meperidine|"Unique dose of meperidine injection:~intravenous injection~0.35 mg/kg~in two minutes~if shivering 5 minutes after delivery"
10039712|NCT01846559|Placebo Comparator|No antiplatelet medication & Endotoxin|"No antiplatelet medication~E.coli Endotoxin Day 7 - 2 ng/kg"
9540204|NCT03115086||Existing User|Patients who have been using Cholbam for at least 30 days
9540205|NCT03115086||New User|First-time initiators of Cholbam
9540206|NCT03115060|Experimental|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
9540207|NCT03115060|Experimental|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
9540208|NCT03115060|Experimental|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
9540209|NCT03114917|Experimental|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
9540210|NCT03114917|No Intervention|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
9540211|NCT03114943|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
9540212|NCT03114943|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
9540213|NCT03115034|Active Comparator|CEA with melatonin|Patients under CEA with melatonin taken during perioperative period.
9540214|NCT03115034|Placebo Comparator|CEA with placebo|Patients under CEA with placebo taken during perioperative period.
9540215|NCT03115034|Sham Comparator|CEA with blank control|Patients under CEA with nothing unnecessary taken during perioperative period.
9540216|NCT03115008|Experimental|Video-based terminal feedback|
9540217|NCT03115008|No Intervention|Conventional concurrent feedback|
9540218|NCT03115190|Other|General practitioner diagnosis with Heart score|Patients with chest pain who are reviewed by the general practitioner (GP) at the GP cooperation will be evaluated with the Heart score to support the GP with the diagnosis.
9540219|NCT03115190|No Intervention|Triage Nurse education|The general practitioner cooperation employs nurses for (telephone) triage. They are aided by a computer based triage system, the Netherlands triage system (NTS), a 6-level urgency triage system. With this study we aim to educate the nurses in the signs and symptoms of chest pain patients. The training program will aim to educate the triage nurses in acute coronary syndrome, including pathophysiology, symptoms and risk factors. The NTS will be incorporated within the training. The triage nurses will receive a training session by Cardiologists with information about acute coronary syndrome, the symptoms and the risks.
9540220|NCT03115190|No Intervention|Baseline registry as comparison|"All patients referred to the emergency department (ED) with suspected acute coronary syndrome (ACS) will be evaluated. They will receive a questionnaire to evaluate the accuracy of referral and the delays of ACS patients. This will be compared to the registry at baseline. Some patients will either have not contacted the general practitioner cooperation (GPC) at all, or will have been referred to the ED directly through the GPC nurse triage.~The 30 day, 6 months and one year follow-up of all patients will be via medical records, or in case of no or not enough information, by telephone."
9540221|NCT03114800|Experimental|E-Scale|Weight monitoring
9540222|NCT03114904|Other|"Usual weaning management"|
9540223|NCT03114904|Other|Introduction to H2 for the discontinuation of therapeutics|
9540224|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
9540225|NCT03114956|Experimental|Group A|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
9540226|NCT03114956|Experimental|Group B|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
9540227|NCT03114956|Experimental|Group C|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
9540228|NCT03114956|Experimental|Group D|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
9540229|NCT03115073|Experimental|0,2% Candiplus|Candiplus® 0.2%
9540230|NCT03115073|Experimental|0,3% Candiplus|Candiplus® 0.3%
9540231|NCT03115073|Experimental|0,4% Candiplus|Candiplus® 0.4%
9540232|NCT03115073|Active Comparator|Clotri mono|Clotrimazole mono
9540233|NCT03114982|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
9540234|NCT03114982|Experimental|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
9540235|NCT03114982|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
9540236|NCT03114982|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
9540237|NCT03115151|Experimental|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
9540238|NCT03115151|Sham Comparator|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
10039713|NCT01846559|Experimental|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily~E.coli Endotoxin Day 7 - 2 ng/kg"
10039714|NCT01846585|Other|ABTI|Arousal Based Therapy for Insomnia
10039715|NCT01846585|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
10039716|NCT01846637|Experimental|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
9540239|NCT03114891|Experimental|fMRI-guided target|This site of stimulation will be created from participants' individualized resting connectivity data to guide stimulation that we show is especially effective in influencing downstream brain areas of interest. We will focus on a target region of the lateral prefrontal cortex (LPFC) that our data suggest is particularly effective at influencing the sgACC. Theta-burst stimulation will be administered to this target.
9540240|NCT03114891|Active Comparator|Standard brain target|As an alternative brain target, we will also test the efficacy of the dorsolateral prefrontal cortex as a target given its precedence as an FDA-approved stimulation site for remediating depressive symptoms. Theta-burst stimulation will be administered to this target.
9540241|NCT03115099|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
9540242|NCT03115099|Experimental|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
9540243|NCT03115099|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
9540244|NCT03115099|Experimental|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
9540245|NCT03115099|Active Comparator|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
9540246|NCT03115099|Experimental|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
9540247|NCT03115203|Other|Facial paralysis|
9540248|NCT03115203|Other|Healthy subject|
9540249|NCT03114826||Renal cell carcinoma in renal transplant patients|
9540250|NCT03114813||Clinically indicated primary prophylaxis|"Approach all those who have had a portal pressure measurement (HVPG) as part of their routine clinical care.~At baseline participants will consent to have an additional MRI scan before undergoing clinical screening Endoscopy.~All participants found to have oesophgeal varices that require primary prophylaxis, will be started on Carvedilol 6.25mg.~After 1 week, participants will return for dose optimisation~After 4-12 weeks of treatment, participants will have:~repeat one hour MRI scan~repeat HVPG to evaluate treatment response"
9540251|NCT03114878|Active Comparator|TRT / EMDR|Tinnitus Retraining Therapy / Eye Movement Desensitization Reprocessing
9540252|NCT03114878|Active Comparator|TRT / CBT|Tinnitus Retraining Therapy / Cognitive Behavioral Therapy
9540253|NCT03114839|Experimental|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
9540254|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
9540255|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
9540256|NCT03114787|Other|Patient receiving respiratory physiotherapy|
9540257|NCT03114787|Other|Patient not receiving respiratory physiotherapy|
10039717|NCT01846637|Active Comparator|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
9540258|NCT03114696|Experimental|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
9540259|NCT03114696|Placebo Comparator|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
9540260|NCT03114475|Experimental|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
9540261|NCT03114475|Placebo Comparator|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
9540262|NCT03114670|Experimental|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
9540263|NCT03114761|Experimental|CTA-IH|
9540264|NCT03114605|Experimental|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
9540265|NCT03114605|No Intervention|Control|Waiting List
9540266|NCT03114748|Experimental|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
9540267|NCT03114748|Experimental|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
9540268|NCT03114332|Experimental|Study Group|Patients for whom a subcutaneous drain was used
9540269|NCT03114332|No Intervention|Control group|No drain group
9540270|NCT03114709|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
9540271|NCT03114709|Active Comparator|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
9540272|NCT03114501|Experimental|Yoga Program Group|"Participants take part in the partner-based yoga program.~Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later)."
9540273|NCT03114501|Experimental|Waitlist Control Group (WLC)|"Participants receive standard of care.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).~After the study has been completed, participant and caregiver/alternative caregiver offered the opportunity to take part in the partner-based yoga program."
9540274|NCT03114540|Experimental|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
10039718|NCT01846650|Experimental|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
9540275|NCT03114540|Experimental|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
9540276|NCT03114540|Experimental|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
9540277|NCT03114540|Experimental|GBT440 Dose 1:Normal hepatic function|Healthy subjects
9540278|NCT03114566||Consenting healthy donor|Transplant and healthy HLA typed donors
9540279|NCT03114579|Other|Measure of the cardiac output obtained by a reference methode|
9540280|NCT03114579|Other|Measurement of cardiac output obtained by NEXFIN HD.|
9540281|NCT03114527|Experimental|Dedifferentiated Liposarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
9622096|NCT02518607|Placebo Comparator|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
9540282|NCT03114527|Experimental|Leiomyosarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
9540283|NCT03114722|Active Comparator|heparin 10U/ml|Heparinised saline (10U/ml) lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
9540284|NCT03114722|Experimental|citrate 4%|4% citrate lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
9540285|NCT03114644|Other|Babies born prematurely between 27 and 37 SA|
9540286|NCT03114423|Experimental|Treatment As Usual + Treatment with EMDR|
9540287|NCT03114423|Sham Comparator|Treatment As Usual + Cognitive Training|
9540288|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
9540289|NCT03114631|Experimental|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
9540290|NCT03114631|No Intervention|Control group|Patients treated according to clinical protocols
9540291|NCT03114631|Experimental|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
9540292|NCT03114384|Experimental|Healthy volunteers|
9540293|NCT03114514|Experimental|PRP injection|A PRP-injection will be performed three times during the course of treatment
9540294|NCT03114449|Experimental|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
9540295|NCT03114449|Sham Comparator|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
9540296|NCT03114410|Experimental|Re:MIX|In the experimental arm, the Re:MIX curriculum was implemented. The Re:MIX curriculum is a comprehensive teen pregnancy prevention consisting of ten hour-long sessions, delivered approximately once per week. The Re:MIX curriculum is taught by a professional health educator, partnered with a young parent educator who is a young parent (aged 18-25).
9540297|NCT03114410|No Intervention|Comparison|"In the comparison arm, teachers were given the option of implementing the Healthy Youth, Healthy You curriculum (focusing on nutrition, mental health, and fitness) or proceed with business as usual (no curriculum)."
9540298|NCT03114358|Experimental|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
9540299|NCT03114358|No Intervention|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
9540300|NCT03114254|Experimental|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
9540301|NCT03114293|No Intervention|Waiting group|Waiting group
9540302|NCT03114293|Experimental|Smartphone intervention|Smartphone bases behavioural intervention
9540303|NCT03114371|Experimental|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
9540304|NCT03114371|Placebo Comparator|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
9540305|NCT03114241|Active Comparator|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
9540306|NCT03114241|No Intervention|Control|Usual care.
9540307|NCT03114397|Active Comparator|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
9540308|NCT03114397|Placebo Comparator|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
9540309|NCT03114280|Experimental|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
9540310|NCT03114137||sickle cell patients|"age: five-year-old or more~major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0~steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
9540311|NCT03114137||control patients|"volunteer parents or siblings of sickle cell patients~hospital staff or their children matched on country and age +/- 3 ans with the patients"
9540312|NCT03114111|Active Comparator|Application of ALA|The treatment will consist of split-face comparisons of no application of aminolevulinic acid (ALA) vs ALA application to either half of the face. Prior to ALA application, the face will be swabbed for microbiome analysis. After the ALA application, the subjects will incubate with the ALA on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
10039719|NCT01846650|Active Comparator|XELODA|Single oral XELODA 2000mg qd
10039720|NCT01846676|Active Comparator|Program counseling|Active branch, subject to the rehabilitation program
10039721|NCT01846676|Placebo Comparator|No counseling|Passive branch, which was control, with usual management (no intervention).
10039722|NCT01846689|Experimental|ESS|Prescription medical food erythropoietin stimulating system
10039723|NCT01846715|Experimental|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
10039724|NCT01846754||Hemodialysis patients|
10039725|NCT01846767|Experimental|Type 2 diabetes|Diabetic patients Oral glucose breath test
10039726|NCT01846767|Experimental|Healthy controls|non-diabetic Oral glucose breath test
10039727|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA & stenting (possibly with additional endophlebectomy and AV-fistula)
9622097|NCT02518607|Placebo Comparator|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
9622098|NCT02518607|Placebo Comparator|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
9485356|NCT01685268|Experimental|Part A, Regimen 2|At13387 administered as a 1-hr IV infusion at a starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
9485357|NCT01685255|Active Comparator|Epacadostat|Subjects randomized to Arm A (epacadostat) will take epacadostat tablets at a dose of 600 mg BID, beginning on Day 1.
9485358|NCT01685255|Active Comparator|Tamoxifen|Subjects randomized to Arm B (tamoxifen) will take tamoxifen tablets at a dose of 20 mg BID, beginning on Day 1.
9485359|NCT01684163|Placebo Comparator|Placebo injection|Normal saline
9485360|NCT01684163|Experimental|GLYX-13, 5 mg/kg|Low dose of GLYX-13
9485361|NCT01684163|Experimental|GLYX-13, 10 mg/kg|High dose of GLYX-13
9485362|NCT01683084|Active Comparator|Telmisartan|One 40mg telmisartan pill given once daily for 24 months
9485363|NCT01683084|Placebo Comparator|Placebo|One 40mg placebo pill given once daily for 24 months
9485364|NCT01679951|Placebo Comparator|Placebo|
9485365|NCT01679951|Experimental|JNJ-38518168 (3 mg/d)|
9485366|NCT01679951|Experimental|JNJ-38518168 (10 mg/d)|
9485367|NCT01679951|Experimental|JNJ-38518168 (30 mg/d)|
9485368|NCT01678755|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
9485369|NCT01678755|Experimental|ABT-126 High Dose|ABT-126 High Dose
9485370|NCT01678755|Placebo Comparator|Placebo|Placebo
9485371|NCT01677754|Placebo Comparator|Placebo|Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
9485372|NCT01677754|Experimental|RO4602522 1 milligram (mg)|Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
9485373|NCT01677754|Experimental|RO4602522 5 mg|Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
9485374|NCT01677338|Experimental|13C-uracil and 99mTc sulfur colloid|Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.
9485375|NCT01677338|Experimental|99mTc sulfur colloid|Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.
9485376|NCT01675609|Placebo Comparator|Placebo|
9485377|NCT01675609|Experimental|Brimonidine Tartrate 0.025%|
9485378|NCT01674361|Experimental|Bitopertin 30 mg|"Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
9485379|NCT01674361|Experimental|Bitopertin 10 mg|"Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
9485380|NCT01674361|Placebo Comparator|Placebo|Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.
9485381|NCT01673659|Experimental|Test product|Mometasone furoate 50 mcg/actuation Nasal Spray
9485382|NCT01673659|Active Comparator|Reference product|Nasonex Nasal Spray
9485383|NCT01673659|Placebo Comparator|Placebo Nasal Spray|vehicle of the test product
9485384|NCT01670981|Experimental|ixmyelocel-T|Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
9485385|NCT01670981|Placebo Comparator|Placebo|Placebo delivered by catheter-based intramyocardial injection procedure.
9485386|NCT01670032|Experimental|CD07223 1.5 % Topical Gel BID|Drug: 1.5% CD07223 Topical Gel applied BID for 7 days
9485387|NCT01670032|Experimental|CD07223 1.5% Topical Gel TID|Drug: 1.5% CD07223 Topical Gel applied TID for 7 days
9485388|NCT01670032|Placebo Comparator|CD07223 vehicle gel BID|Drug: CD07223 Vehicle Topical Gel applied BID for 7 days
9485389|NCT01670032|Placebo Comparator|CD07223 vehicle gel TID|Drug: CD07223 Vehicle Topical Gel applied TID for 7 days
9485390|NCT01669980|Experimental|Ceftaroline fosamil|
9485391|NCT01669980|Active Comparator|IV Ceftriaxone and Vancomycin|
9485392|NCT01667341|Experimental|Low Dose GEN-003 with Matrix M-2|10µg GEN-003, 50µg Matrix M-2 Adjuvant
9485393|NCT01667341|Experimental|Mid Dose GEN-003 with Matrix M-2|30µg GEN-003, 50µg Matrix M-2 Adjuvant
9485394|NCT01667341|Experimental|High Dose GEN-003 with Matrix M-2|100µg GEN-003, 50µg Matrix M-2 Adjuvant
9485395|NCT01667341|Experimental|Low Dose GEN-003 Only|10µg GEN-003
9485396|NCT01667341|Experimental|Mid Dose GEN-003 Only|30µg GEN-003
9485397|NCT01667341|Experimental|High Dose GEN-003 Only|100µg GEN-003
9485398|NCT01667341|Placebo Comparator|Placebo|0.5 mL phosphate buffered saline
9485399|NCT01666977|Experimental|Arm A|Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
9485400|NCT01666977|Experimental|Arm B|Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
9485401|NCT01666977|Experimental|Arm C|Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
9497994|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
9540313|NCT03114111|Placebo Comparator|No Application of ALA|For the placebo, Demo Levulan Kerastick, which contains no active ingredient and is enclosed in same cardboard sleeve and cap, will be applied to the other side of the face to mimic the surface of the ALA application stick. After the placebo application, the subjects will incubate with the placebo on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
9540314|NCT03114098|Experimental|CYP2D6 gene abnormalities|"A salivary sample (2 ml sample) which will allow the investigation of an anomaly of the metabolism of psychotropic drug.~Blood sampling will be performed to assess treatment tolerance (6 ml). A sample (4 ml) will be kept for possible future analyzes in relation to the objectives of this study for the recruiting center of Nice.~Electrocardiogram~Clinical exam~Clinical Global Impression Scale (CGI-S)~Children's Global Assessment Scale (CGAS)~Sheehan Disability Scale (SDS)~Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III )~Wechsler Intelligence Scale for Children - 4 (WISC-4)~Wechsler Adult Intelligence Scale 4 (WAIS 4)~Diagnostic and Statistical Manual of Mental Disorders (DSM)~Autism Diagnostic Interview (ADI)"
9540315|NCT03114592|No Intervention|Standard Care|"Complete a survey asking about kidney function and participant demographics.~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
9540316|NCT03114592|Experimental|mHealth Tool|"Complete a survey asking about kidney function and participant demographics.~Review a 15-20 minute educational tool on a tablet about kidney health~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
9540317|NCT03114306|Experimental|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
9540318|NCT03114306|Active Comparator|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
9540319|NCT03114267||Patient with chronic lymphocytic thyroiditis|
9540320|NCT03114267||Healthy subjects|
9540321|NCT03114085|Experimental|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
9540322|NCT03114085|Active Comparator|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
9540323|NCT03114462|Experimental|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
9540324|NCT03114072|Active Comparator|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
9540325|NCT03114072|Active Comparator|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
9540326|NCT03114202|Experimental|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
9540327|NCT03114202|Other|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
9540328|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
9540329|NCT03114150|Experimental|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
9540330|NCT03114150|Active Comparator|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
9616308|NCT02543944|Placebo Comparator|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
9622099|NCT02518607|Placebo Comparator|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
9622100|NCT02518568|Experimental|Drug|
9622101|NCT02518542|Active Comparator|Per oral endoscopic therapy A|Per oral endoscopic myotomy
9485402|NCT01665391|Experimental|fresolimumab 1 mg/kg total body weight|
9485403|NCT01665391|Experimental|fresolimumab 4 mg/kg total body weight|
9485404|NCT01665391|Placebo Comparator|Placebo|
9485405|NCT01665352|Experimental|TTP054 400 mg|
9485406|NCT01665352|Experimental|TTP054 200 mg|
9485407|NCT01665352|Experimental|TTP054 800 mg|
9485408|NCT01665352|Placebo Comparator|Placebo|
9485409|NCT01661634|Experimental|Ularitide|Ularitide, lyophilizate for i.v. infusion, 15 ng/kg BW/min, for 48 hours
9485410|NCT01661634|Placebo Comparator|Placebo|Placebo lyophilizate for i.v. infusion
9485411|NCT01661166|Experimental|Fesoterodine 4mg|Fesoterodine 4mg, Oral once daily for three months
9485412|NCT01661166|Placebo Comparator|Placebo|Placebo Oral once daily for three months
9485413|NCT01660633|Other|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|Subjects will receive only High-Dose Melphalan HCL for Injection (Propylene Glycol-free) at 200mg/m2 (100mg/m2/day for two days).
9485414|NCT01659138|Experimental|SAR339658|SAR339658 at Weeks 0, 2, 4, and 6
9485415|NCT01659138|Placebo Comparator|Placebo|Placebo at Weeks 0, 2, 4, and 6
9485416|NCT01658826|Experimental|AIC316|100 mg once daily for 28 days
9485417|NCT01658826|Active Comparator|Valacyclovir|500 mg once daily for 28 days
9485418|NCT01658501|Experimental|Diet and Exercise|Diet and exercise only.
9485419|NCT01658501|Experimental|Metformin|Metformin only
9485420|NCT01658501|Experimental|Sulfonylurea|Sulfonylurea only
9485421|NCT01658501|Experimental|Metformin and Sulfonylurea|Metformin and Sulfonylurea combination therapy
9485422|NCT01658501|Experimental|PB1023|PB1023 weekly SC injection
9485423|NCT01658501|Placebo Comparator|Placebo Comparator|Placebo (0.9% Sodium Chloride) weekly SC injection
9485424|NCT01658501|Active Comparator|Active Comparator|Active Comparator (Victoza) daily SC injection
9485425|NCT01656239|Experimental|fedovapagon 1 mg|Once daily oral dose of 1 mg fedovapagon for 12 weeks
9485426|NCT01656239|Experimental|fedovapagon 2 mg|Once daily oral dose of 2 mg fedovapagon for 12 weeks
9485427|NCT01656239|Experimental|fedovapagon 4 mg|Once daily oral dose of 4 mg fedovapagon for 12 weeks
9485428|NCT01656239|Placebo Comparator|sugar pill|Once daily oral dose of placebo for 12 weeks
9485429|NCT01655680|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
9485430|NCT01655680|Experimental|ABT-126 Middle Dose|ABT-126 Middle Dose
9485431|NCT01655680|Experimental|ABT-126 High Dose|ABT-126 High Dose
9485432|NCT01655680|Placebo Comparator|Placebo|Placebo
9485433|NCT01653379|Experimental|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
9485434|NCT01652482|Active Comparator|FOLFIRI + Cetuximab|
9485435|NCT01652482|Experimental|FOLFIRI + MEHD7945A|
9485436|NCT01651871|Experimental|Treatment Group 1|
9485437|NCT01651871|Experimental|Treatment Group 2|
9485438|NCT01651871|Experimental|Treatment Group 3|
9485439|NCT01651871|Active Comparator|Treatment Group 4|
9485440|NCT01651871|Placebo Comparator|Treatment Group 5|
9485441|NCT01651143|Experimental|SAR100842|"Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
9485442|NCT01651143|Placebo Comparator|Placebo|"Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
9485443|NCT01650051|Placebo Comparator|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|
9485444|NCT01650051|Experimental|Phenazopyridine Hydrochloride Tables, USP 200 mg|
9485445|NCT01649999|Experimental|ASP015K lowest dose|Oral
9485446|NCT01649999|Experimental|ASP015K low dose|Oral
9485447|NCT01649999|Experimental|ASP015K medium dose|Oral
9485448|NCT01649999|Experimental|ASP015K high dose|Oral
9485449|NCT01649999|Placebo Comparator|Placebo|Oral
9485450|NCT01647451|Experimental|Active|
9485451|NCT01647451|Placebo Comparator|Placebo|
9485452|NCT01647308|Active Comparator|ISIS-APOCIIIRX|
9485453|NCT01647308|Placebo Comparator|Placebo|
9485454|NCT01643330|Experimental|AAV1/SERCA2a (MYDICAR)|Intracoronary infusion
9485455|NCT01643330|Placebo Comparator|Placebo|Intracoronary infusion
9485456|NCT01643226|Experimental|riboflavin solution and KXL System|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
9485457|NCT01643226|Placebo Comparator|placebo solution and KXL System|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
9485458|NCT01642550|Active Comparator|RM-131|Active study drug - RM-131
9485459|NCT01642550|Placebo Comparator|Placebo|Placebo comparator
9485460|NCT01641848|Experimental|Arthritic and injured ankles|InBone TAA
9485461|NCT01640756|Experimental|AqueSys Microfistula Implant|
9485462|NCT01640080|Experimental|Esketamine (Group 1)|
9485463|NCT01640080|Experimental|Esketamine (Group 2)|
9485464|NCT01640080|Placebo Comparator|Placebo|
9485465|NCT01638533|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9485466|NCT01636843|Experimental|60 mg|
9485467|NCT01636843|Experimental|120 mg|
9485468|NCT01636843|Experimental|240 mg|
9485469|NCT01636843|Experimental|Placebo|
9485470|NCT01636817|Experimental|60 mg|
9485471|NCT01636817|Experimental|120 mg|
9485472|NCT01636817|Experimental|240 mg|
9485473|NCT01636817|Placebo Comparator|Placebo|
9485474|NCT01635907|Experimental|Dovitinib|
9485475|NCT01634087|Experimental|100 mg QD Itacitinib|
9485476|NCT01634087|Experimental|100 mg QD Placebo|
9485477|NCT01634087|Experimental|200 mg QD Itacitinib|
9485478|NCT01634087|Experimental|200 mg QD Placebo|
9485479|NCT01634087|Experimental|200 mg BID Itacitinib|
9485480|NCT01634087|Experimental|200 mg BID Placebo|
9485481|NCT01634087|Experimental|600 mg once a day Itacitinib|
9485482|NCT01634087|Experimental|600 mg once a day Placebo|
9485483|NCT01633372|Experimental|itacitinib 100 mg|itacitinib 100 mg twice a day
9485484|NCT01633372|Experimental|itacitinib 200 mg|itacitinib 200 mg twice a day
9485485|NCT01633372|Experimental|itacitinib 300 mg|itacitinib 300 mg once a day
9485486|NCT01633372|Experimental|itacitinib 400 mg|itacitinib 400 mg once a day
9485487|NCT01633372|Experimental|itacitinib 600 mg|itacitinib 600 mg once a day
9485488|NCT01632228|Experimental|Onartuzumab + Bevacizumab|All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
9485489|NCT01632228|Active Comparator|Placebo + Bevacizumab|All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
9485490|NCT01632137|Placebo Comparator|Placebo (vehicle)|
9485491|NCT01632137|Experimental|Rebamipide 2% ophthalmic suspension|
9485492|NCT01630434|Experimental|OCS Lung (Treatment Group)|The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
9485493|NCT01630434|Active Comparator|Cold flush and storage (Control Group)|Donor lungs will be preserved using cold flush and storage (control group)
9485494|NCT01628094|Experimental|A: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
9485495|NCT01628094|Experimental|B: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
9485496|NCT01628094|Experimental|C: GT1a 2DAA|including RO5466731, RO5190591, ritonavir and ribavirin [Copegus]
9485497|NCT01628094|Experimental|D: GT1b 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
9485498|NCT01628094|Experimental|E: GT1b 2DAA|including RO54664731, RO5190591, ritonavir and ribavirin [Copegus]
9485499|NCT01628094|Experimental|Part II|
9485500|NCT01627314|Experimental|ProHema-CB with MAC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with myeloablative conditioning regimen (MAC)
9485501|NCT01627314|Experimental|ProHema-CB with RIC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with reduced intensity conditioning regimen (RIC)
9485502|NCT01627314|Placebo Comparator|Control Arm with MAC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with myeloablative conditioning regimen
9485503|NCT01627314|Placebo Comparator|Control Arm with RIC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with reduced intensity conditioning regimen
9485504|NCT01626599|Other|Assess product useability|All subjects participate in the same arm. This arm completes the primary objective of product usability.
9485505|NCT01626573|Experimental|Itacitinib 400 mg twice a day|Itacitinib 400 mg twice a day
9485506|NCT01626573|Placebo Comparator|Itacitinib 400 mg placebo twice a day|Itacitinib 400 mg placebo twice a day
9485507|NCT01626573|Experimental|Itacitinib 100 mg twice a day|This dose group will be studied twice during the study.
9485508|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo twice a day|This dose group will be studied twice during the study.
9485509|NCT01626573|Experimental|Itacitinib 100mg once a day|Itacitinib 100mg once a day
9485510|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo once a day|Itacitinib 100 mg placebo once a day
9485511|NCT01626573|Experimental|Itacitinib 200 mg twice a day|Itacitinib 200 mg twice a day
9485512|NCT01626573|Placebo Comparator|Itacitinib 200 mg placebo twice a day|Itacitinib 200 mg placebo twice a day
9485513|NCT01626573|Experimental|Itacitinib 300 mg once a day|Itacitinib 300 mg once a day
9485514|NCT01626573|Placebo Comparator|Itacitinib 300 mg placebo once a day|Itacitinib 300 mg placebo once a day
9485515|NCT01626573|Experimental|Itacitinib 600 mg once a day|Itacitinib 600 mg once a day
9485516|NCT01626573|Placebo Comparator|Itacitinib 600 mg placebo once a day|Itacitinib 600 mg placebo once a day
9485517|NCT01626378|Experimental|TRx0237 200 mg/day group|
9485518|NCT01626378|Placebo Comparator|Placebo|
9485519|NCT01625390|Experimental|Arm 1|
9485520|NCT01625390|Active Comparator|Arm 2|
9485521|NCT01625390|Experimental|Arm 3|
9485522|NCT01625234|Experimental|Phase I: X-396 (ensartinib)|Dose escalation starting at 25 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops
9485523|NCT01625234|Experimental|Phase II: X-396 (ensartinib)|RP2D 225mg stratified based on prior treatment and CNS activity
9485524|NCT01624636|Placebo Comparator|Placebo|
9485525|NCT01624636|Experimental|LFG316: 10 mg/kg (2 doses in cohort 1)|
9485526|NCT01624636|Experimental|LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).|
9485527|NCT01621243|Placebo Comparator|nab-paclitaxel, gemcitabine, placebo|"Part A: Not applicable.~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
9485528|NCT01621243|Experimental|nab-paclitaxel, gemcitabine, necuparanib|"Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
9485529|NCT01620515|No Intervention|Active Surveillance|Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.
9485530|NCT01620515|Experimental|NX-1207 2.5 mg|
9485531|NCT01620515|Experimental|NX-1207 15 mg|
9485532|NCT01619332|Experimental|LEZ763|Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
9485533|NCT01619332|Placebo Comparator|Placebo|Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
9485534|NCT01619332|Active Comparator|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
9485535|NCT01617096|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25mg dapivirine
9485536|NCT01617096|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
9485537|NCT01616524|Experimental|Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir|
9485538|NCT01616524|Experimental|Arm 2: pegIFNλ + Ribavirin + Daclatasvir|
9485539|NCT01616524|Experimental|Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir|
9485540|NCT01616303|Active Comparator|carboplatin & paclitaxel|first-line chemotherapy for ovarian cancer
9485541|NCT01616303|Experimental|carboplatin & paclitaxel & oregovomab|first-line chemotherapy for ovarian cancer plus oregovomab
9485542|NCT01616199|Experimental|Phase 1 Dose Escalation of PX-866 + vemurafenib|PX-866 given with vemurafenib
9485543|NCT01616199|Experimental|Phase 2 Combination PX-866 + vemurafenib|PX-866 given with vemurafenib
9485544|NCT01616199|Active Comparator|Phase 2 Single-agent vemurafenib|vemurafenib given as a single agent
9485545|NCT01612039|Experimental|ASP3291|
9485546|NCT01612039|Placebo Comparator|Placebo|
9485547|NCT01610245|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets and one placebo capsule twice daily with food for 5 days
9485548|NCT01610245|Active Comparator|Oseltamivir|Two placebo tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
9485549|NCT01610245|Active Comparator|Nitazoxanide and Oseltamivir|Two nitazoxanide 300 mg tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
9485550|NCT01610245|Placebo Comparator|Placebo|Two placebo tablets and one placebo capsule with food twice daily for 5 days
9485551|NCT01607294|Experimental|ETC-1002|ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
9485552|NCT01607294|Placebo Comparator|Placebo|Placebo daily 4 weeks
9485553|NCT01606566|Experimental|Amphinex induced PCI of bleomycin|"Drug: Amphinex induced PCI of bleomycin~Intervention:Intravenous administration of Amphinex (day 0) followed by intravenous administration of bleomycin and laser light application (day 4). Laser light application could be both interstitial and/or superficial depending on the tumour location."
9485554|NCT01605708|Experimental|Cohort 1|
9485555|NCT01605162|Experimental|E7016 plus TMZ|
9485556|NCT01604889|Experimental|Epacadostat 300 mg|300 mg twice daily (BID) in combination with ipilimumab
9485557|NCT01604889|Placebo Comparator|Placebo in combination with ipilimumab|
9485558|NCT01604889|Experimental|Epacadostat 25 mg|25 mg BID in combination with ipilimumab
9485559|NCT01604889|Experimental|Epacadostat 50 mg|50 mg BID in combination with ipilimumab
9485560|NCT01604889|Experimental|Epacadostat 75 mg|75 mg once a day (QD) in combination with ipilimumab
9485561|NCT01603407|Experimental|Daily prednisone|daily prednisone (0.75 mg/kg/day)
9485562|NCT01603407|Experimental|Intermittent prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
9485563|NCT01603407|Experimental|Daily deflazacort|daily deflazacort (0.9 mg/kg/day
9485564|NCT01602393|Experimental|CHF 5074 1x|oral tablet, multidose
9485565|NCT01602393|Experimental|CHF 5074 2x|oral tablet, multidose
9485566|NCT01602393|Experimental|CHF 5074 3x|oral tablet, multidose
9485567|NCT01602367|Experimental|Arm 1: BMS-823778 (2mg)|
9485568|NCT01602367|Experimental|Arm2: BMS-823778 (6mg)|
9485569|NCT01602367|Experimental|Arm 3: BMS-823778 (15mg)|
9485570|NCT01602367|Experimental|Arm4: Placebo|
9485571|NCT01601600|Placebo Comparator|Placebo|
9485572|NCT01601600|Experimental|BYM338|BYM338 active drug
9485573|NCT01598103|Placebo Comparator|Placebo to SAF312|
9485574|NCT01598103|Experimental|SAF312|
9485575|NCT01597349|Experimental|FP01 High dose|
9485576|NCT01597349|Experimental|FP01 Low dose|
9485577|NCT01597349|Placebo Comparator|Placebo|
9485578|NCT01594983|Experimental|LCQ908 1|LCQ908 (Diacylglycerol acyltransferase inhibitor)once daily for 12 weeks
9485579|NCT01594983|Experimental|LCQ908 2|LCQ908 once daily for 12 weeks
9485580|NCT01594983|Experimental|LCQ908 3|LCQ908 once daily for 12 weeks
9485581|NCT01594983|Active Comparator|Fenofibrate|Intervention Type: Drug Intervention Name: Fenofibrate
9485582|NCT01594983|Active Comparator|Fish Oil|Fish oil once daily for 12 weeks
9485583|NCT01594983|Placebo Comparator|Arm Label: Placebo|Intervention Type: other Intervention Name: other
9485584|NCT01594723|Experimental|120 mg LY2784544|120 milligram (mg) administered orally once daily for 6 cycles (168 days)
9485585|NCT01594216|Experimental|First Stage|Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily
9485586|NCT01594216|Experimental|Second Stage|Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily
9485587|NCT01593228|Experimental|1|"Patients receiving iniparib alone or in combination with other anti-cancer agents as defined by the parental study. Interventions:~Drug: Iniparib monotherapy~Drug: Iniparib + gemcitabine + carboplatin~Drug: Iniparib + topotecan~Drug: Iniparib + irinotecan~Drug: Iniparib + paclitaxel~Drug: Iniparib + liposomal doxorubicin + carboplatin"
9540331|NCT03114176|Experimental|Divers group|Throughout each dive, subjects performed a 20-minute long mild exercise on an underwater bike. The depth of dive was set at 15 meters, where the subjects performed an activity guided by Borg CR-10 scale at intensity level 3 (25 rpm). The ascent rate was set at 10 m/min, with a decompression stop at 5 meters for 3 min, according to the US Navy Manual Diving Table. 48 h prior to the immersions, none of the participants consumed medications or dived or flew. In the first part of the experiment, all subjects performed a dive breathing Enriched Air Nitrox (EAN, 32% ppO2). Baseline clinical measurements were collected before and after this first dive in order to have a reference [CTRL] and to measure physiological modifications due to immersion [NTRX]. After twenty days of no diving activity, subjects were engaged in a KD for seven days. At the end of this period, subjects performed a single immersion breathing EAN. The measures were performed after this single dive [KETO-NTRX]
9616309|NCT02543775|Experimental|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
9616310|NCT02543736|Other|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
9616311|NCT02543749|Experimental|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
9616312|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
9616313|NCT02543710|Experimental|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
9616314|NCT02543710|Experimental|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
9616315|NCT02543788|Other|patients|patients with chronic optic neuropathy in multiple sclerosis
9616316|NCT02543788|Other|Controls|healthy volunteers
9616317|NCT02543671|Active Comparator|vitamin D3 enriched cheese|vitamin D3 enriched, reduced-fat yellow cheese
9616318|NCT02543671|Placebo Comparator|plain cheese|plain (non-fortified) reduced-fat yellow cheese
9616319|NCT02543645|Experimental|Varlilumab and Atezolizumab|
9616320|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
9616321|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
9616322|NCT02543619|Active Comparator|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
9616323|NCT02543619|Active Comparator|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
9616324|NCT02543450|Experimental|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
9616325|NCT02543450|Active Comparator|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
9616326|NCT02543424|Experimental|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
9616327|NCT02543424|Sham Comparator|Control group|Healthy adults and children.
9616328|NCT02543463|Other|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
9616329|NCT02543463|Other|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
9616330|NCT02543411|Experimental|Lidocaine group|Administration of lidocaine 1%
9616331|NCT02543411|Placebo Comparator|Control group|Administration of normal saline
9616332|NCT02543489|Other|Flex IM Rod|
9621704|NCT02521987|Active Comparator|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
9621705|NCT02521987|Experimental|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
9621706|NCT02522000||Patients with functional dyspepsia|
9540332|NCT03114215|Active Comparator|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
9540333|NCT03114215|Placebo Comparator|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
9540334|NCT03113799|Other|Single Arm study|Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
9540335|NCT03114046|Experimental|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
9540336|NCT03113825|Experimental|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
9540337|NCT03113877||Clinical Testing for Autonomic Dysfunction|COMPASS-31 Survey completion. Autonomic Reflex Screen. Thermoregulatory Swear Test.
9540338|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
9540339|NCT03113786|No Intervention|Standard of Care|Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
9540340|NCT03113786|Active Comparator|CLARIX™100|Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
9540341|NCT03113786|Active Comparator|CLARIX CORD 1K|Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
9540342|NCT03113890|Experimental|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
9540343|NCT03113890|Other|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
9540344|NCT03114020|Experimental|Hyaluronic Acid inhalation solution|3mL of 0.03% Hyaluronic Acid inhalation solution BID for 28 days
9540345|NCT03114020|Placebo Comparator|Placebo Inhalation Solution|3mL matching placebo inhalation solution BID for 28 days
9540346|NCT03113903|Experimental|scheduled surgery|
9540347|NCT03113903|Other|healthy volunteers|
9540348|NCT03114163||Cohort 1: Nivolumab|≥2nd line treatment for recurrent/ metastatic (R/M) Squamous cell carcinoma of the head and neck (SCCHN), prior platinum-based therapy was administered for locally advanced, metastatic or recurrent disease
9540349|NCT03114163||Cohort 2: Nivolumab|1st line treatment for R/M SCCHN, prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting
9540350|NCT03113864|Placebo Comparator|Placebo|Will be identical looking to treatment
9540351|NCT03113864|Experimental|Lutein|10 mg of FloraGLO Lutein
9540352|NCT03114007|Experimental|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
9540353|NCT03114007|Experimental|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
10039728|NCT01846806|Experimental|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
9540354|NCT03114007|No Intervention|Control|Treatment as usual
9540355|NCT03113851|Experimental|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
9540356|NCT03113812|Experimental|ABvac40|
9540357|NCT03113812|Placebo Comparator|Placebo|
9540358|NCT03114189|Active Comparator|Footbath, care of sleep|"Warm water (37°C) filled up to the level of the ankle. Water has to be heated up to 42°C and increased to the calf 's half height within 15 minutes.~Information about wrong and correct behaviour."
9540359|NCT03114189|Active Comparator|Care of sleep|Information about wrong and correct behaviour.
9540360|NCT03113747|Experimental|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
9616333|NCT02543541|Active Comparator|Standard Supportive Care|
9616334|NCT02543541|Experimental|Structured Supportive Care|
9616335|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
9621707|NCT02522000||Healthy controls|
10058450|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
10058451|NCT02018406|Experimental|Intervention|Intervention Group
9616336|NCT02543502|Experimental|periodontal treatment|Group will receive treatment: periodontal treatment
10058452|NCT02018406|Placebo Comparator|Control|Control Group
9485588|NCT01591473|Experimental|FluMist + Ampligen, Group 1|Nasal administration; dose group 1; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
9485589|NCT01591473|Experimental|FluMist + Ampligen, Group 2|Nasal administration; dose group 2; FluMist + Poly I:Poly C12U 200 ug; 3 doses separated by 28 days
9485590|NCT01591473|Experimental|FluMist + Ampligen, Group 3|Nasal administration; dose group 3; FluMist + Poly I:Poly C12U 500 ug; 3 doses separated by 28 days
9485591|NCT01591473|Experimental|FluMist + Ampligen, Group 4|Nasal administration; dose group 4; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
9485592|NCT01591473|Experimental|FluMist + Ampligen, Group 5|Nasal administration; dose group 5; FluMist + Poly I:Poly C12U 1250 ug; 3 doses separated by 28 days
9485593|NCT01591473|Experimental|FluMist + Placebo, Group 6|Nasal administration; dose group 6; FluMist + placebo; 3 doses separated by 28 days
9485594|NCT01591447|Experimental|Solithromycin (CEM-101)|A single oral dose of 1200 mg solithromycin
9485595|NCT01591447|Experimental|Solithromycin 1000 mg|A single oral dose of 1000 mg solithromycin
9485596|NCT01590719|Experimental|Onartuzumab (MetMAb) with mFOLFOX6|Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
9485597|NCT01590719|Placebo Comparator|Placebo with mFOLFOX6|Placebo in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
9485598|NCT01590459|Placebo Comparator|Placebo Arm|
9485599|NCT01590459|Experimental|VX-509 100 mg qd Arm|
9485600|NCT01590459|Experimental|VX-509 150 mg qd Arm|
9485601|NCT01590459|Experimental|VX-509 100 mg bid Arm|
9485602|NCT01590459|Experimental|VX-509 200 mg qd Arm|
9485603|NCT01588535|Active Comparator|benzocaine solution|ear drops
9485604|NCT01588535|Placebo Comparator|Placebo|ear drops
9485605|NCT01588015|Experimental|Arm I (vaccine therapy)|Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
9485606|NCT01588015|Active Comparator|Arm II (control)|Patients undergo immune monitoring only.
9485607|NCT01587144|Placebo Comparator|Placebo|Participants will receive a matching placebo as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
9485608|NCT01587144|Active Comparator|Lucanthone|Participants will receive Lucanthone as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
9485609|NCT01585688|Experimental|hLL1-DOX|
9485610|NCT01584531|Experimental|21-Day Regimen|560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle
9485611|NCT01582503|Experimental|MEMP1972A 150 mg|
9485612|NCT01582503|Experimental|MEMP1972A 300 mg|
9485613|NCT01582503|Experimental|MEMP1972A 450 mg|
9485614|NCT01582503|Placebo Comparator|Placebo|
9485615|NCT01582347|Experimental|RBP-6300|During the Double-Blind Transfer Period (Days 1-7), participants take RBP-6300 at a level (either 10, 20 or 30 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for Subutex®/Suboxone®. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
9485616|NCT01582347|Active Comparator|Subutex®/Suboxone®|During the Double-Blind Transfer Period (Days 1-7), participants take Subutex®/Suboxone® at a level (either 8, 16 or 240 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for RBP-6000. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
9485617|NCT01582269|Experimental|LY2157299 monohydrate plus lomustine|"300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.~First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2."
9485618|NCT01582269|Experimental|LY2157299 monohydrate|300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)
9485619|NCT01582269|Active Comparator|lomustine plus placebo|"First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.~LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle."
9485620|NCT01581203|Experimental|Arm 1: Null or Partial Responder to P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
9485621|NCT01581203|Experimental|Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
9485622|NCT01581203|Experimental|Arm 3: Treatment naive (ASV + DCV)|"[Subjects will receive ASV + DCV for 24 weeks] followed by ASV + DCV for 24 weeks in protocol AI444026]~Subjects meeting prespecified rescue criteria in the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg/1200 mg (total daily dose) tablet by mouth for 24 or 48 weeks"
9485623|NCT01581203|Experimental|Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week|"Subjects meeting prespecified rescue criteria in the null or partial responder cohort or active arm of the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg / 1200 mg (total daily dose) Tablet by mouth, for 24 or 48 weeks"
9540361|NCT03113747|No Intervention|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:~Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;~Systemic antibiotic therapy for preventing infectious complications;~Adequate analgesia and sedation;~Decompression necrotomy in the first 24 hours following the burn trauma;~Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;~Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
9540362|NCT03113773|Experimental|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
9540363|NCT03113773|Experimental|Part B|Proleukin/Placebo in patients with cute coronary syndromes
9540364|NCT03113760|Experimental|Tadekinig alfa|Patients that have completed the SAOL phase without a flare will receive Tadekinig alfa for addition 8 weeks.
9540365|NCT03113760|Placebo Comparator|0.9% sodium chloride|Patients that have completed the SAOL phase without a flare will receive placebo comparator for addition 8 weeks.
9540366|NCT03113448|Active Comparator|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
9540367|NCT03113448|Placebo Comparator|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
9540368|NCT03113500|Experimental|Treatment (CHEP-BV)|"INDUCTION: Patients receive cyclophosphamide IV and doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (or for up to 5 cycles for patients who received 1 cycle of CHOP-like or CHP-BV therapy prior to induction, per investigator's discretion) in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy, post-consolidative radiation therapy, or after completing induction cycle 6 (cycle 5 for patients who qualify for receiving 5 cycles of CHEP-BV instead of 6), patients with objective response (complete response or partial response) receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
9540369|NCT03113695|Experimental|obinutuzumab, lenalidomide, and HDMP|
9540370|NCT03113604||Patients with untreated CHC not sorafenib|
9540371|NCT03113604||Patients with non-sorafenib CHC|
9540372|NCT03113604||Patients with CHCs responding to sorafenib|
9540373|NCT03113591|Experimental|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
9540374|NCT03113591|Active Comparator|Control group|undergo common total hip arthroplasty surgery
9540375|NCT03113539|Experimental|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.~Each subjects will have the two CT-scans on the same day."
9540376|NCT03113526|Active Comparator|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
9540377|NCT03113526|Active Comparator|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
9540378|NCT03113630|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
9540379|NCT03113630|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
9540380|NCT03113630|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
9540381|NCT03113630|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
9540382|NCT03113630|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
9540383|NCT03113630|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
9540384|NCT03113396|Experimental|baclofen|Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
9540385|NCT03113396|Placebo Comparator|placebo|Patients will receive placebo for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is baclofen (10mg t.i.d) (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
9540386|NCT03113682|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
9540387|NCT03113669|Other|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
9616337|NCT02543502|No Intervention|Control Group.|Group will not receive treatment: periodontal treatment
9616338|NCT02543606|Experimental|Esomelone|powder for injection/ infusion Esomeprazole 40mg
9616339|NCT02543606|Active Comparator|Nexium|powder for injection/ infusion Esomeprazole 40mg
10059478|NCT02027675|Experimental|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
9540388|NCT03113357|Experimental|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
9540389|NCT03113357|Experimental|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
9540390|NCT03113435|No Intervention|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
9540391|NCT03113435|Active Comparator|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
9540392|NCT03113435|Experimental|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
9540393|NCT03113708|Sham Comparator|Heparinisation,actual body weight|In 'Heparinisation,actual body weight' group , heparin sodium; will be done according to actual body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
9540394|NCT03113708|Experimental|Heparinisation, lean body weight|In 'Heparinisation, lean body weight' group heparin sodium will be done according to lean body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
9540395|NCT03113474|Experimental|Palatable-neutral|Participants are exposed to palatable food in the first test session, and to the neutral food in the second test session.
9540396|NCT03113474|Experimental|Neutral-palatable|Participants are exposed to neutral food in the first test session, and to the palatable food in the second test session.
9540397|NCT03113617|Experimental|Diagnostic (68Ga-RM2 PET/CT)|Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.
9540398|NCT03113461|Experimental|CPAP adherent|Study participants in this arm are using the CPAP intervention consistently
9540399|NCT03113461|Active Comparator|CPAP non-adherent|Study participants in this arm are not using the CPAP intervention consistently
9540400|NCT03113461|No Intervention|No OSA|Study participants who do not have OSA
10058453|NCT02018419|Experimental|Dosing Schedule A|"the priming step with ID injection of AlloStim on Days 0, 7, and 14;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;~the activation step with an IV infusion of AlloStim on Day 28;~the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
9540401|NCT03113344||Children with the usage of anti-infective drugs|
9540402|NCT03113292|Experimental|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
9540403|NCT03113292|Active Comparator|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
9540404|NCT03113318|Experimental|Lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection and pulmonary metastasectomy from colorectal cancer
9540405|NCT03113318|Active Comparator|Pulmonary metastasectomy only|Only pulmonary metastasectomy from colorectal cancer
9540406|NCT03113370|Experimental|Fish Oil|4 grams of fish oil per day
9540407|NCT03113370|Placebo Comparator|Placebo|4 grams of olive oil capsules per day
9540408|NCT03113123|Other|PrEP with Truvada®|"On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later~Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours."
9616340|NCT02543593|Experimental|Intervention|Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
10039729|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.~Fatigue will be assessed with the FIS and 6 Minute Walk Test.~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
9540409|NCT03113084|Experimental|Group Sodium Heparin UQ First|The participants will receive the Sodium heparin UQ subcutaneous drug administration at first period and the Sodium heparin FK subcutaneous drug administration at second period
9540410|NCT03113084|Experimental|Group Sodium Heparin FK First|The participants will receive the Sodium heparin FK subcutaneous drug administration at first period and the Sodium heparin UQ subcutaneous drug administration at second period
9540411|NCT03112967|Experimental|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
9540412|NCT03112967|Active Comparator|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
9540413|NCT03113279||Obese older individuals|Obese older individuals
9540414|NCT03113279||Lean older individuals|Lean older individuals
9540415|NCT03113279||Young lean individuals|Young lean individuals
9540416|NCT03113188|Experimental|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
9540417|NCT03112980|Experimental|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.
9540418|NCT03112980|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.
9540419|NCT03112954|Experimental|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
9540420|NCT03112954|Experimental|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
9540421|NCT03113266|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
9540422|NCT03113240|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
9540423|NCT03113240|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
9540424|NCT03113175|Experimental|Collabri Flex|Collaborative care
9540425|NCT03113175|Experimental|Consultation-Liaison|Consultations with general practitioner
9540426|NCT03113045|Experimental|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
9540427|NCT03113032|Experimental|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
9540428|NCT03113032|Experimental|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
9540429|NCT03113032|Active Comparator|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
9540430|NCT03113019|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
9540431|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
9540432|NCT03113227|Active Comparator|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
9540433|NCT03113227|Active Comparator|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
9540434|NCT03113110|Other|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG [Jardiance]
9540435|NCT03113201|Experimental|Collabri Flex|Collaborative care
9540436|NCT03113201|Experimental|Consultation-Liaison|Consultations with general practitioner
9540437|NCT03113136|Active Comparator|Low wattage E cigarette device|
9540438|NCT03113136|Active Comparator|High wattage E cigarette device|
9540439|NCT03113136|Active Comparator|Usual brand cigarette|
9540440|NCT03113214|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
9540441|NCT03113214|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
9540442|NCT03113214|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
9540443|NCT03113214|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
9540444|NCT03113214|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
9540445|NCT03113214|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
9540446|NCT03113006|Active Comparator|Standard Panretinal Photocoagulation|Localized to all four retinal quadrants.
9485624|NCT01581177|Experimental|T1|Two inhalations, one of Albuterol DPI 25 mcg/inh and one of Placebo DPI; Total Albuterol dose of 25 mcg
9485625|NCT01581177|Experimental|T2|Two inhalations of Albuterol DPI 25 mcg/inh; Total Albuterol dose of 50 mcg
9485626|NCT01581177|Experimental|T3|Two inhalations, one of Albuterol DPI 90 mcg/inh and one of Placebo DPI; Total Albuterol dose of 90 mcg
9485627|NCT01581177|Experimental|T4|Two inhalations of Albuterol DPI 90 mcg/inh; Total Albuterol dose of 180 mcg
9485628|NCT01581177|Placebo Comparator|P|Two inhalations Placebo DPI; Total Albuterol dose of 0 mcg
9485629|NCT01581177|Active Comparator|R1|One inhalation of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 90 mcg
9485630|NCT01581177|Active Comparator|R2|Two inhalations of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 180 mcg
9485631|NCT01581138|Experimental|12 week treatment|
9485632|NCT01581138|Experimental|16 week treatment|
9485633|NCT01580696|Active Comparator|Non-vaccine clinically matched control group|HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.
9485634|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
9485635|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
9485636|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
9485637|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
9485638|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
9485639|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
9485640|NCT01578655|Experimental|Cabazitaxel plus Custirsen|cabazitaxel, prednisone, and custirsen sodium
9485641|NCT01578655|Active Comparator|Cabazitaxel|cabazitaxel and prednisone
9485642|NCT01577654|Experimental|Arm A: EC145 alone|EC145 alone
9485643|NCT01577654|Experimental|Arm B: EC145 + Docetaxel|EC145 + Docetaxel
9485644|NCT01577654|Active Comparator|Arm C: Docetaxel alone|Docetaxel alone
9485645|NCT01577173|Experimental|A: MEHD7945A|
9485646|NCT01577173|Active Comparator|B: Cetuximab|
9485647|NCT01575470|Experimental|bone marrow mononuclear cells|a bone marrow harvest will be performed within 36 hours of injury followed by a single intravenous infusion of autologous bone marrow mononuclear cells (BMMNCs)
9485648|NCT01573351|Experimental|QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin|"Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks"
9485649|NCT01571635|Experimental|Sotatercept dose level 0.1mg/kg|Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
9485650|NCT01571635|Experimental|Sotatercept dose level 0.3mg/ kg|Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
9485651|NCT01571635|Experimental|Sotatercept dose level 0.5mg/kg|Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
9485652|NCT01571635|Experimental|Sotatercept dose level 0.75mg/kg|Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
9485653|NCT01571635|Experimental|Sotatercept dose level 1.0mg/kg|Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
9485654|NCT01571635|Experimental|Sotatercept dose level 1.5mg/kg|Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
9485655|NCT01571297|Active Comparator|RM-131|
9485656|NCT01571297|Placebo Comparator|Placebo|
9485657|NCT01568229|Experimental|AMG 747 - Dose 1|
9485658|NCT01568229|Experimental|AMG 747 - Dose 2|
9485659|NCT01568229|Experimental|AMG 747 - Dose 3|
9485660|NCT01568229|Placebo Comparator|Placebo Comparator|
9485661|NCT01568216|Experimental|AMG 747 - Dose 1|
9485662|NCT01568216|Experimental|AMG 747 - Dose 2|
9485663|NCT01568216|Experimental|AMG 747 - Dose 3|
9485664|NCT01568216|Placebo Comparator|Placebo Comparator|
9485665|NCT01567904|Experimental|Age group from 12 to 18 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
9485666|NCT01567904|Experimental|Age group from 6 to 12 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
9485667|NCT01567904|Experimental|Age group from 2 to 6 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
9485668|NCT01567904|Experimental|Age group from 3 months to 2 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
9485669|NCT01567904|Experimental|Age group from birth to 3 (<) months|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
9540447|NCT03113006|Experimental|Individ. Panretinal Photocoagulation|Localized to only the affected quadrants.
9540448|NCT03113097|Active Comparator|Good-quality embryo transfer|Women who had only good-quality embryo transfer
9540449|NCT03113097|Active Comparator|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
9540450|NCT03112941|Experimental|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
9540451|NCT03112941|Experimental|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
9540452|NCT03113162|Experimental|Autologous Hematopoietic Stem Cell with BEAM Regimen|Autologous HSCT following Reduced-Intensity BEAM Regimen
10039730|NCT01846832|Experimental|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
9540453|NCT03113058|Experimental|study group|
9540454|NCT03112915|Active Comparator|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
9540455|NCT03112915|Active Comparator|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
9540456|NCT03112889|Experimental|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
9540457|NCT03112681|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
9540458|NCT03112681|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
9540459|NCT03112681|Placebo Comparator|Placebo|Placebo tablet Once daily for 16 weeks
9540460|NCT03112707|Experimental|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
9540461|NCT03112642|Active Comparator|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
9540462|NCT03112642|Experimental|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
9540463|NCT03112616||Left-brain damaged chronic patients|
9540464|NCT03112616||Right-brain damaged chronic patients|
9540465|NCT03112772|Experimental|Group I|Participants who are receiving socket preservation using allograft (Puros® Allograft, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, Zimmer dental, Zimmer, USA).
9540466|NCT03112772|Experimental|Group II|Participants who are receiving socket preservation cancellous particulate bovine bone xenograft (CopiOs® Cancellous Particulate, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, 15x20mm, Zimmer dental, Zimmer, USA).
9540467|NCT03112772|No Intervention|Group III|No grafting materials will be inserted, so it serves as a negative control group.
9540468|NCT03112577|Experimental|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
9540469|NCT03112577|Experimental|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
9540470|NCT03112577|Experimental|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
9540471|NCT03112577|Experimental|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
9540472|NCT03112577|Active Comparator|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
9540473|NCT03112538|Active Comparator|Insulin pump|Medtronic Minimed Paradigm Veo Insulin Pump utilising rapid acting insulin Glulisine or Aspart
9540474|NCT03112538|Active Comparator|Multiple daily injections of insulin|Multiple daily injections consisting of a single basal insulin injection(Glargine) and 3 bolus insulin injections (rapid acting insulin Glulisine or Aspart) before each meal
9540475|NCT03112525||Patient under Rivaroxaban|
9540476|NCT03112525||Patient under Apixaban|
9540477|NCT03112837|Experimental|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
9540478|NCT03112837|No Intervention|non-drug group|only receiving radiotherapy and chemotherapy
9540479|NCT03112837|No Intervention|healthy control group|
9540480|NCT03112746|Experimental|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
10039731|NCT01846845|Active Comparator|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
10039732|NCT01846845|Experimental|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
10039733|NCT01846858||CO2 Laser|
9540481|NCT03112551|Active Comparator|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
9540482|NCT03112551|Experimental|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
9540483|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
9622102|NCT02518542|Active Comparator|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
10039734|NCT01846858||Monopolar energy|
9540484|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
9540485|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
9540486|NCT03112720|Active Comparator|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
9540487|NCT03112720|Experimental|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
9540488|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
9540489|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
9540490|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
9540491|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
9540492|NCT03112668|Experimental|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
9540493|NCT03112564|Other|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
9540494|NCT03112655|Experimental|Human african trypanosomiasis patient|RNA, neopterin and 5-hydroxytryptophan detection
9540495|NCT03112850|Active Comparator|Group A|Participants who will be fitted with hearing aids for the first 3 months of 6 months auditory training program
9540496|NCT03112850|Active Comparator|Group B|Participants who will be fitted with hearing aids for the second 3 months of 6 months auditory training program
9540497|NCT03112811|Experimental|Intubated infant|
9540498|NCT03112811|Experimental|Extubated infant|
9540499|NCT03112499|Active Comparator|PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who percutaneous nephrolithotomy (PCNL) will be conducted
9540500|NCT03112499|Active Comparator|mini-PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who mini- percutaneous nephrolithotomy (mini-PCNL) will be conducted
9540501|NCT03112499|Active Comparator|RIRS Group|Patients with renal calculi 10-30mm in maximal diameter in who retrograde intrarenal surgery (RIRS) will be conducted
9540502|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
9540503|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
9540504|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
9540505|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
9540506|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
9540507|NCT03112512|Experimental|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
9540508|NCT03112512|Experimental|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
9540509|NCT03112304|Experimental|MATCH-ADTC Wave 1|Wave 1 clinicians received MATCH training at the beginning of the project and used MATCH to treat participating children from their clinic for two years, with weekly case consultation from MATCH experts who were part of the study team, and then received consultation from their own clinic supervisors who had been trained as MATCH Associate Consultants (ACs), supported by the TRAC system.
9540510|NCT03112304|Experimental|MATCH-ADTC Wave 2|Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.
9540511|NCT03112265|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
9540512|NCT03112265|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
9540513|NCT03112122|Active Comparator|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
9540514|NCT03112122|Experimental|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
9540515|NCT03112122|Experimental|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
9616341|NCT02543593|Sham Comparator|Placebo|Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
9616342|NCT02543580|Experimental|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
9616343|NCT02543580|Experimental|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
9616344|NCT02543580|Experimental|sham electroacupuncture|electrode attached but no stimulation
9616345|NCT02543385|Active Comparator|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
9616346|NCT02543385|Placebo Comparator|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
9616347|NCT02543372|Experimental|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
9616348|NCT02543372|Active Comparator|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
9616349|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
9616350|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
9616351|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
9616352|NCT02543359|Experimental|Clinicians and Supervisors|After randomization clinicians and supervisors from community behavioral health agencies receive training in one of three PCIT training models: Train the Trainer (TTT), Learning Collaborative (LC) or Web-Supported Self Study (SS).
9616353|NCT02543359|Experimental|Administrators|After randomization administrators from participating community behavioral health agencies receive one of three treatments for PCIT (1/3 Learning Collaborative, 1/3 other treatment - none, and 1/3 other treatment - none).
9616354|NCT02543359|Experimental|Parent-Child Dyads|Parent-child dyads receive Parent-Child Interaction Therapy (PCIT) treatment from trained clinicians/supervisors.
9616355|NCT02543138|Experimental|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
9616356|NCT02543164|Other|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
9616357|NCT02543164|Other|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
9616358|NCT02543034|Experimental|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
9616359|NCT02543034|Active Comparator|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
9616360|NCT02543034|Active Comparator|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
9616361|NCT02543177|Experimental|group A|direct coronary angiography
9616362|NCT02543177|Experimental|group B|direct coronary angiography plus ischemic precondition
9616363|NCT02543177|Experimental|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
9616364|NCT02543177|Experimental|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
10039735|NCT01846910|Active Comparator|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
9616365|NCT02543099|Experimental|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
9616366|NCT02543099|Placebo Comparator|placebo|Patients will receive placebo 20mg daily until the end of the trial;
9616367|NCT02543125|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O,R:30 per minute .
9616368|NCT02543125|Active Comparator|NHFOV|NHFOV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,MAP：6-14 cm H2O,Hertz(HZ):5-10 to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O.
9621708|NCT02522039|Experimental|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
9621709|NCT02522039|Experimental|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
9621710|NCT02522039|Experimental|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
9621711|NCT02522039|No Intervention|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
9485670|NCT01567059|Experimental|Arm I (tosedostat and cytarabine)|Patients receive tosedostat PO QD on days 1-35 and cytarabine IV on days 1-5.
9621712|NCT02522026||Healthy volunteers|
9485671|NCT01567059|Experimental|Arm II (tosedostat and decitabine)|Patients receive tosedostat PO QD on days 1-35 and decitabine IV on days 1-5.
9485672|NCT01565655|Experimental|ASP015K lowest dose|ASP015K lowest dose once daily
9485673|NCT01565655|Experimental|ASP015K low dose|ASP015K low dose once daily
9485674|NCT01565655|Experimental|ASP015K medium dose|ASP015K medium dose once daily
9485675|NCT01565655|Experimental|ASP015K high dose|ASP015K high dose once daily
9485676|NCT01565655|Placebo Comparator|Placebo|Matching placebo once daily
9485677|NCT01563302|Experimental|Group 1|IONIS-STAT3Rx
9485678|NCT01562899|Experimental|Dose escalation|Dose finding group chosen in order to establish a safe and tolerated dose of binimetinib in combination with ganitumab in patients with selected advanced solid tumors.
9485679|NCT01562899|Experimental|KRAS mutated colorectal adenocarcinoma|"Patients with KRAS mutant colorectal cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
9485680|NCT01562899|Experimental|Metastatic pancreatic adenocarcinoma|"Patients with metastatic pancreatic cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
9485681|NCT01562899|Experimental|BRAF mutated melanoma|"Patients with mutant BRAF V600 melanoma.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
9485682|NCT01561807|Experimental|787 low dose|VX-787 low dose capsule, taken orally for 5 days
9485683|NCT01561807|Experimental|787 high dose|VX-787 high dose capsule, taken orally for 5 days
9485684|NCT01561807|Experimental|Placebo low dose|Matching placebo low dose capsule, taken orally for 5 days
9485685|NCT01561807|Experimental|Placebo high dose|Matching placebo high dose capsule, taken orally for 5 days
9485686|NCT01561768|Experimental|Group 1|
9485687|NCT01561768|Experimental|Group 2|
9485688|NCT01561768|Experimental|Group 3|
9485689|NCT01561768|Experimental|Group 4|
9485690|NCT01561768|Experimental|Group 5|
9485691|NCT01561690|Experimental|ARRY-502|
9485692|NCT01561690|Placebo Comparator|Placebo|
9485693|NCT01561521|Experimental|AKF-1 0.025%|
9485694|NCT01561521|Experimental|AKF-1 0.035%|
9485695|NCT01561521|Placebo Comparator|AKF-1 0%|
9485696|NCT01560104|Experimental|veliparib and carboplatin and paclitaxel|Veliparib on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
9485697|NCT01560104|Placebo Comparator|placebo and carboplatin and paclitaxel|Placebo on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
9497995|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
9497996|NCT03470038|Experimental|NGF condition + Control condition|"All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
9497997|NCT03470038|Experimental|Control condition + NGF condition|"All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
9497998|NCT03470025|Experimental|Psychological Intervention|A weekly combined face to face & telephone-based PI (F-TPI); Psychological Intervention and medical therapy
9497999|NCT03470025|Experimental|A telephone-based PI (TPI)|Psychological Intervention - A telephone-based PI (TPI); Psychological Intervention and medical therapy
9498000|NCT03470025|No Intervention|Optimal medical therapy|Patients will receive optimal medical therapy
9498001|NCT03469947|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during medical transport
9498002|NCT03469947|No Intervention|Matched Controls|Retrospective matched controls
9498003|NCT03469934|Experimental|ANB020|ANB020, administration of ANB020
9498004|NCT03469934|Placebo Comparator|Placebo|Placebo, administration of Placebo
9498005|NCT03469921||15-17 years old|15-17 years old
9498006|NCT03469921||18-25 years old|18-25 years old
9498007|NCT03469921||26-30 years old|26-30 years old
9498008|NCT03469921||acute leukemia|acute leukemia
9498009|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
9498010|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
9498011|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
9498012|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
9498013|NCT03469921||patients included in clinical trials|patients included in clinical trials
9540516|NCT03112161|Experimental|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
9540517|NCT03112161|Experimental|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
9540518|NCT03112161|Experimental|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
9540519|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
9540520|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
9540521|NCT03112200|Active Comparator|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
9540522|NCT03112200|Sham Comparator|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:~Partial meniscectomy~Lavage~Debridement~Loose body removal~Synovectomy~Removal of osteophytes in the notch or locations other than those adjacent to BML(s)~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
9540523|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
9540524|NCT03112148|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fed state.
9540525|NCT03112148|Experimental|Treatment B:|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fed state.
9540526|NCT03112148|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fasted state.
9540527|NCT03112148|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fasted state.
9540528|NCT03112148|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR-MODERATE administered in the fasted state
9540529|NCT03112148|Experimental|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state
9540530|NCT03112369|Experimental|Narrative Exposure Therapy (NET)|Counseling program
9540531|NCT03112369|Experimental|Motivational Interviewing w/Skills Training (MIST)|Counseling program
9540532|NCT03112343|Active Comparator|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
9540533|NCT03112343|Placebo Comparator|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
9540534|NCT03112356|Experimental|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
9540535|NCT03112330|Experimental|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
9540536|NCT03112187|Experimental|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
9540537|NCT03112135|Active Comparator|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
9540538|NCT03112135|Active Comparator|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
9540539|NCT03112135|Active Comparator|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
9540540|NCT03112239|Active Comparator|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
9540541|NCT03112239|Placebo Comparator|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
9540542|NCT03112395|Experimental|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
9540543|NCT03112759|Experimental|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
9540544|NCT03112759|No Intervention|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
9540545|NCT03112278|Active Comparator|Ceramic restorations|Ceramic ultrathin occlusal veneers
9803758|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
9540546|NCT03112278|Active Comparator|Composite resin restorations|Composite resin ultrathin occlusal veneers
9540547|NCT03112382|Active Comparator|zinc supplement plus vitamin A and E|patients will be receiving zinc supplement plus vitamin A and E for 3 months.
9540548|NCT03112382|Active Comparator|vitamin A and E|patients will be receiving equivalent dose of vitamin A and E only for 3 months
9540549|NCT03112382|No Intervention|no vitamins|patients will be observed for 3 months
9540550|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
9540551|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
9540552|NCT03112447|Experimental|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
9540553|NCT03112447|Active Comparator|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
9803759|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
10059479|NCT02027675|Experimental|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.~Each arm corresponds to a different intervention order."
9540554|NCT03112460||all patients|all of patients who went through basic and advanced cardiopulmonary resuscitations would be analyzed
9540555|NCT03112291|Experimental|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
9540556|NCT03112226|Active Comparator|GnRHant + E2|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks
9540557|NCT03112226|Placebo Comparator|GnRHant + Placebo|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks
9540558|NCT03112109||Intervention Group|Patients receiving 'new care'
9540559|NCT03112109||Control group|Patients receiving 'old / usual care'
9540560|NCT03111927|No Intervention|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
9540561|NCT03111927|Experimental|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
9540562|NCT03111927|Active Comparator|Control|Infant formula: standard level of myelin-relevant nutrients
9540563|NCT03111979|Experimental|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
9540564|NCT03111979|Placebo Comparator|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
9540565|NCT03111966||Spanish cohort with HCV treated with DAA|
9540566|NCT03112031|Experimental|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
9540567|NCT03112031|Active Comparator|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
9540568|NCT03112018|Active Comparator|Standard care|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation"
9540569|NCT03112018|Experimental|Enhanced care (intervention)|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation~Health provider training (PRONTO)~Quality Improvement (QI) Cycles"
9540570|NCT03111823|Experimental|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
9540571|NCT03111836|Sham Comparator|Control group|The Control group received limited to general information on blood pressure management
9621713|NCT02522026||Healthy smokers|
9621714|NCT02522026||COPD GOLD1|
9621715|NCT02522026||COPD GOLD2|
9803760|NCT03395613|No Intervention|Standard management|Standard sterile gauze dressing on surgical groin wound.
9803761|NCT03395613|Experimental|NPWT management|Negative Pressure Wound Therapy dressing on surgical groin wound.
9803762|NCT03385707|Experimental|CGM and Microbiota|Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks. They will not be aware of sensor glucose values. A stool sample will be collected. The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
9803763|NCT03377647|Active Comparator|Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
9803764|NCT03377647|Active Comparator|Year three intervention|Both interventions will occur in the Chinle Agency during year three.
9540572|NCT03111836|Active Comparator|Expert-driven group|The intervention will consisted of pre-determined exercise and dietary goals (e.g. increase daily steps by 1000 steps, consuming 2-3 servings of fruit and vegetables per day).
9540573|NCT03111836|Active Comparator|User-driven group|The User-driven group received an intervention that enabled participants to select their areas of lifestyle change using text and video web links embedded in the email. The trans-theoretical model was used to inform the design of the User-driven program.
9540574|NCT03111849||hospitalized chronic obstructive patients|
9540575|NCT03112096|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
9540576|NCT03112096|Experimental|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
9540577|NCT03111901|Experimental|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
9540578|NCT03111901|Experimental|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
9540579|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
9540580|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
9540581|NCT03111953|Active Comparator|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
9540582|NCT03111953|Experimental|BPD|Subjects received Biliopancreatic Diversion Surgery
9540583|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
9540584|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
9540585|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
9540586|NCT03111888|Experimental|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
9540587|NCT03112044|Experimental|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
9540588|NCT03112083|Active Comparator|Krill oil|Krill powder capsules, 4 g
9540589|NCT03112083|Placebo Comparator|Placebo|Placebo capsules, maize strach, 4 g
9540590|NCT03111810|Active Comparator|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
9540591|NCT03111810|Placebo Comparator|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
9540592|NCT03112057|Experimental|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
9540593|NCT03112057|Experimental|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
9540594|NCT03112057|Experimental|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
9540595|NCT03112057|Experimental|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
9540596|NCT03112057|Experimental|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
9540597|NCT03112070|Experimental|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
10039736|NCT01846910|Experimental|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
10039737|NCT01846923|Experimental|PCV13|
9540598|NCT03112070|No Intervention|Control session (CONTROL)|A 45-min session with no exercise. During this session, participants will remain seated or standing as desired. They will read, talk, and drink water, but do nothing else.
9540599|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
9540600|NCT03111706||Intact scar|women with intact scar detected during cesarean section
9540601|NCT03111537|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
9540602|NCT03111537|Experimental|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
9540603|NCT03111537|Experimental|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
9621716|NCT02522026||COPD GOLD3/4|
10039738|NCT01846936|Experimental|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
9540604|NCT03111537|Experimental|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
9540605|NCT03111524|Active Comparator|Intervention school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
9540606|NCT03111524|Active Comparator|Intervention school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher.The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
9540607|NCT03111524|Active Comparator|Intervention school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
9540608|NCT03111524|Active Comparator|Intervention school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
9540609|NCT03111524|Active Comparator|Intervention school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
9540610|NCT03111524|Placebo Comparator|control school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
9540611|NCT03111524|Placebo Comparator|control school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
9540612|NCT03111524|Placebo Comparator|control school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
9540613|NCT03111524|Placebo Comparator|control school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
9540614|NCT03111524|Placebo Comparator|control school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
9540615|NCT03111498|Other|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
9540616|NCT03111498|Other|practice-based training|practice-based training programme (one-to-one teaching)
9540617|NCT03111511|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
9540618|NCT03111472|Experimental|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
9540619|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
9540620|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
9540621|NCT03111589|Experimental|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
9540622|NCT03111589|Experimental|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
9540623|NCT03111589|Experimental|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
9540624|NCT03111589|Active Comparator|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
9540625|NCT03111563|Other|warm saline|case group ,
9540626|NCT03111563|Other|room temperature|control group
9540627|NCT03111667|Experimental|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
9540628|NCT03111667|Other|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
9540629|NCT03111667|Experimental|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
9540630|NCT03111667|Active Comparator|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
9540631|NCT03111667|No Intervention|Administrator Participants: Environment|School Administrators will provide data about the school environment.
9540632|NCT03111667|No Intervention|School Staff Participants: Environment|Staff will provide data about the school environment
9540633|NCT03111251|Experimental|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
9540634|NCT03111251|Experimental|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
9540635|NCT03111238|Experimental|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
9540636|NCT03111238|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
9540637|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
9540638|NCT03111368|Active Comparator|EUS- FNA Slow-pull|Endoscopic ultrasound-guided fine needle aspiration using a stylet slow-pull technique of solid pancreatic mass
9540639|NCT03111368|Active Comparator|EUS-FNA Negative Pressure|Endoscopic ultrasound-guided fine needle aspiration using negative pressure technique of solid pancreatic mass
9540640|NCT03111654|Other|Patients with pericardial closure of the auricle|
9540641|NCT03111654|Other|Patients without closure of the auricle|
9540642|NCT03111485|Experimental|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
9540643|NCT03111485|Experimental|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
9540644|NCT03111342|Experimental|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
9540645|NCT03111342|Sham Comparator|Dry-needling|A placement of thin needle into the cervix without substance injection
9540646|NCT03111342|No Intervention|No intervention|No intervention for pain relief prior to LNG-IUS insertion
9540647|NCT03111355|Experimental|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
9540648|NCT03111459|Experimental|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
9540649|NCT03111459|Experimental|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
9540650|NCT03111420|Experimental|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
9540651|NCT03111420|Experimental|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
9540652|NCT03111420|Experimental|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
9540653|NCT03111680|Experimental|intervention|this arm received an environmental intervention to make healthy eating and activity easier for residents
9540654|NCT03111680|No Intervention|control|the control participants received no interventions
9540655|NCT03111433|Experimental|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
9540656|NCT03111433|Active Comparator|Group II|this group of patients will receive their standard insulin treatment only
9540657|NCT03111615|Experimental|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
9540658|NCT03111615|No Intervention|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
9540659|NCT03111615|Other|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
9540660|NCT03111615|Other|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
9540661|NCT03111641|Experimental|Lung ultrasonography|
9540662|NCT03111264|Experimental|CHAMP group|Childcare centers randomly assigned the CHAMP group will receive an intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
9540663|NCT03111264|Experimental|CHAMP+ group|These childcare centers, also randomly assigned, will have the same intervention as the CHAMP group in addition to a parenting intervention that promotes wellness and healthy behaviors within families.
9540664|NCT03111264|No Intervention|Control|This group will not receive theCHAMP intervention at the childcare center nor will this group receive the CHAMP+ parenting intervention.
9540665|NCT03111602|Experimental|interventional group|The interventional group was submitted to dietary orientation to restrict polyphenol-rich foods
9540666|NCT03111602|No Intervention|control group|healthy group as comparator
9540667|NCT03111199|Placebo Comparator|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
9540668|NCT03111199|Experimental|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
9540669|NCT03111199|Experimental|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
9540670|NCT03111199|Experimental|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
9540671|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
9540672|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
9540673|NCT03111446|Active Comparator|Spinal Anesthesia|Spinal anesthesia will be used to anesthetize patients in this group for caesarian section
9540674|NCT03111446|Active Comparator|General Anesthesia|Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section
9540675|NCT03111329|Experimental|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.~Intervention = NO aspiration of gastric residuals"
9540676|NCT03111329|No Intervention|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
9540677|NCT03111225|Experimental|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
9540678|NCT03111225|No Intervention|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
9540679|NCT03111186|Active Comparator|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
9540680|NCT03111186|Active Comparator|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
9540681|NCT03111160|Experimental|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
9540682|NCT03111160|Active Comparator|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
9540683|NCT03111134|No Intervention|Routine Abdominal Closure|
9540684|NCT03111134|Experimental|New Abdominal Closure|modified component separation technique is used to abdomen closing.
9540685|NCT03111121|Active Comparator|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
9540686|NCT03111121|Active Comparator|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
9540687|NCT03111095|Experimental|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
9540688|NCT03111095|No Intervention|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
9540689|NCT03111082||Lean|BMI less than or equal to 29.9
10039739|NCT01846936|Active Comparator|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
10039740|NCT01846936|Active Comparator|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
9540690|NCT03111082||Obese|BMI between 30.0 and 39.9
9540691|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
9540692|NCT03110952|Experimental|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
9540693|NCT03110952|Experimental|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
9540694|NCT03110952|Experimental|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
9540695|NCT03110952|Placebo Comparator|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
9540696|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
9540697|NCT03111004||Comparator Group|The comparator group receives usual care
9540698|NCT03110939|Experimental|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
9540699|NCT03110939|No Intervention|control group|standard surgery of advanced lung cancer/esophageal cancer
9540700|NCT03110874|Experimental|Experimental group (one-way education)|"Experimental group (one-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~video based education"
9621717|NCT02522013|Experimental|Aminophylline group|IV injection of aminophylline
9540701|NCT03110874|Active Comparator|Control group(two-way education)|"Control group(two-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~direct education"
9540702|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
9540703|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
9540704|NCT03111069|Experimental|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
9540705|NCT03111069|Experimental|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
9540706|NCT03111056|Experimental|Web-Based Intervention|In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
9540707|NCT03111056|No Intervention|Assessment Only Control|Participants will be asked to complete only the daily monitoring assessment each morning for 14 days.
9540708|NCT03110965|Experimental|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
9540709|NCT03110757|Experimental|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
9540710|NCT03110757|Experimental|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
9540711|NCT03110757|Experimental|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
9540712|NCT03110757|Experimental|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
9540713|NCT03110757|Experimental|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
9540714|NCT03110757|Experimental|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
9540715|NCT03110757|Active Comparator|Pooled Active Comparator Group|Euvax B Hepatitis B vaccine (n=12)
9540716|NCT03110991|Experimental|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
9540717|NCT03110991|Experimental|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
9540718|NCT03110991|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
9540719|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA<34 weeks) with severe thrombocytopenia
9540720|NCT03110913|Experimental|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
9540721|NCT03110848|Experimental|Statins|Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
9540722|NCT03110848|Active Comparator|No statins|Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
9540723|NCT03110783|No Intervention|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
9540724|NCT03110783|Experimental|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
9540725|NCT03111017|Experimental|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
9540726|NCT03111017|No Intervention|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
9540727|NCT03110796|Experimental|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
9540728|NCT03110796|Experimental|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
9540729|NCT03110796|Placebo Comparator|No LU3103209|Dressing without LU3103209
9540730|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
9540731|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
9540732|NCT03110718|Experimental|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
9540733|NCT03110718|Active Comparator|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
9540734|NCT03110731|Experimental|Intervention group|Physical training (2x / week) was performed for 12 weeks
9540735|NCT03110731|No Intervention|Control Group|no intervention
9540736|NCT03110419|Experimental|Intervention|The training group will perform a Physical Exercise as multicomponent training.
10059480|NCT02027688|Active Comparator|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
9540737|NCT03110419|No Intervention|Control|The control group will only be evaluated, without any intervention.
9540738|NCT03110653|Active Comparator|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
9540739|NCT03110653|Placebo Comparator|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
9540740|NCT03110445|Experimental|rVV-740CTA vaccine|
9540741|NCT03110627|Experimental|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
9540742|NCT03110627|Active Comparator|VVI ICD|VVI ICD - Single chamber ICD system - Control group
9540743|NCT03110640|Experimental|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
9540744|NCT03110549|Experimental|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
9540745|NCT03110549|Experimental|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
10059481|NCT02027688|Active Comparator|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
9540746|NCT03110549|Experimental|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
9540747|NCT03110549|Experimental|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
9540748|NCT03110549|Experimental|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
9540749|NCT03110549|Experimental|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
9540750|NCT03110549|Experimental|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
9540751|NCT03110497|Experimental|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions [1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
9540752|NCT03110393|Experimental|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
9540753|NCT03110393|Active Comparator|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
9540754|NCT03110588|Experimental|PACE with Cabazitaxel @ 15 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
9540755|NCT03110588|Experimental|PACE with Cabazitaxel @ 20 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
9540756|NCT03110354|Experimental|DS-3201b in AML or ALL|DS-3201b is administered orally to participants with AML or ALL at a starting dose of 100 mg once a day, and then possibly at higher doses depending on safety observations
9540757|NCT03110341|Experimental|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
9540758|NCT03110341|Placebo Comparator|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
9621718|NCT02522013|Placebo Comparator|isotonic saline group|IV injection of isotonic saline group
9540759|NCT03110679|Experimental|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
9540760|NCT03110679|Experimental|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
9540761|NCT03110536||2h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 2 hours.
9540762|NCT03110536||4h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 4 hours.
9540763|NCT03110536||6h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 6 hours.
9540764|NCT03110328|Experimental|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
9540765|NCT03110406|Experimental|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
9540766|NCT03110406|Sham Comparator|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
9540767|NCT03110510|Experimental|FOLFIRI|D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Until disease progression, patient's refusal or unacceptable toxicities
9540768|NCT03110289|Experimental|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
9540769|NCT03110289|Sham Comparator|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
9540770|NCT03110302|Active Comparator|Office-based telehealth (OBT)|Veterans come to a VA clinic and meet with a therapist via telehealth, using videoconferencing technology
9540771|NCT03110302|Active Comparator|Home-based telehealth (HBT)|Veterans stay at home and meet with the therapist via telehealth, using videoconferencing technology
9540772|NCT03110302|Experimental|In home, in person (IHIP)|Therapist goes to the Veterans' homes to provide the psychotherapy
9540773|NCT03110276|Experimental|EYP001a|
9540774|NCT03110276|Placebo Comparator|Placebo|
9540775|NCT03110081|Experimental|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
9540776|NCT03110081|Active Comparator|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
9540777|NCT03110484|Experimental|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
9540778|NCT03110263|Experimental|Multicomponent internet-based self-help|Multicomponent internet-based self-help
9540779|NCT03110263|Experimental|Internet-based sleep restriction|Internet-based sleep restriction
9540780|NCT03110263|No Intervention|Waiting control group|Access to internet-based intervention after 8-weeks
9540781|NCT03110094|Other|Rheumatoid arthritis - Adalimumab|
9540782|NCT03110094|Other|Healthy volunteer|
9540783|NCT03110211|Experimental|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
9540784|NCT03110211|Experimental|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
9540785|NCT03110367|Active Comparator|Pain Reframing Intervention|"Participants will be randomized into this group:~- Memory reframe with parent facilitated by researcher:~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
9540786|NCT03110367|Sham Comparator|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Attention control (watch video [Planet Earth] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
9621719|NCT02522091|Other|young healthy volunteers (18-44 years old)|young healthy volunteers (18-44 years old)
9621720|NCT02522091|Other|healthy volunteers (45-69 years old)|healthy volunteers (45-69 years old)
9621721|NCT02522091|Other|Mild Cognitive Impairment Patients|Mild Cognitive Impairment Patients
9621722|NCT02522091|Other|Alzheimer's Disease patient|Alzheimer's Disease patient
9540787|NCT03110367|No Intervention|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
9540788|NCT03110120|Active Comparator|serratus|Serratus plane block and local control
9540789|NCT03110120|Sham Comparator|local|serratus control and local anesthesia
9540790|NCT03110133|Experimental|CP101|Full Spectrum Microbiota Capsule
9540791|NCT03110133|Placebo Comparator|Placebo|Matching Placebo Capsule
9540792|NCT03109912|No Intervention|Control|At the baseline fitness assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. Throughout the study, these 30 participants will receive generic, non-personalized encouragement and recommendations (if requested by the participant) for PA at routine clinic visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.
9540793|NCT03109912|Experimental|Exercise Intervention|The baseline fitness assessment includes an additional 30-minutes for exercise prescriptions; participant FitBit daily step goal is set based on a collaborative review between the participant and PT and participants receive individualized exercise prescriptions based on their assessment. Throughout the study, these 30 participants will receive customized encouragement and personalized fitness recommendations for PA at routine visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, study team members meet again with the participant for an additional 30-45 minutes to reinforce exercise through exercise prescriptions and individualized encouragement, export FitBit data and review any missing data concerning for equipment failure or user error and address any specific exercise concerns. FitBit daily step goals may be adjusted based on collaborative review between the participant and PT.
9540794|NCT03109899|Experimental|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
9803765|NCT03377647|Active Comparator|Year four intervention|Both interventions will occur in the Fort Defiance during year four.
9803766|NCT03371485|Experimental|AST-VAC2|Patients with advanced NSCLC, to receive AST-VAC2.
10039741|NCT01846962|Experimental|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
9540795|NCT03109899|No Intervention|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
9540796|NCT03110016|Experimental|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
9540797|NCT03110172|Active Comparator|KSS scale|Knee Society Score with Duloxetine Hydrochloride
9540798|NCT03110172|Active Comparator|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
9540799|NCT03110172|Active Comparator|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
10039742|NCT01846962|Experimental|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
9540800|NCT03110172|Active Comparator|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
9540801|NCT03109886|Experimental|Milciclib maleate|milciclib maleate ,10, 50 and 100 mg hard gelatine capsules , 100 mg once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles)
10039743|NCT01846962|Experimental|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
10039744|NCT01846962|Experimental|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
10039745|NCT01846975|Experimental|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
10039746|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
10039747|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
9485698|NCT01559701|Experimental|PF-00345439 (oxycodone)|PF-00345439 (oxycodone)
9485699|NCT01559363|Experimental|Cohort 1|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
9485700|NCT01559363|Experimental|Cohort 2|Two 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
9485701|NCT01559363|Experimental|Cohort 3|Three 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
9485702|NCT01559363|Experimental|Phase 2a Monday, Wednesday, Friday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday, Wednesday and Friday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
9540802|NCT03110042||Observational Cohort|All patients will receive usual standard of care with the heart failure management including the routine supplemental oxygen therapy.
9540803|NCT03110198|Experimental|Mesalazine with hydrocortisone sodium succinate|Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema
9540804|NCT03110198|Active Comparator|Mesalazine|Mesalazine （4g）enema
9540805|NCT03110198|Active Comparator|Hydrocortisone sodium succinate|Hydrocortisone sodium succinate (100mg ) enema
9540806|NCT03110159|Experimental|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
9540807|NCT03109977|Experimental|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
9540808|NCT03109925|Experimental|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
9540809|NCT03110055|Experimental|HCV patients with un-resectable HCC|"HCV genotype 1 (a and b) cirrhotic patients (child pugh A compensated cirrhosis) with advanced and un-resectable HCC who are eligible for TACE . The patients will receive Grazoprevir/Elbasvir and Transarterial Chemoembolization.~Their outcomes will be compared to the medical records of patients who underwent Transarterial Chemoembolization only, in the past."
9540810|NCT03110068||Preoperative clinical/imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo contrast-enhanced computed tomography (CECT) and contrast-enhanced ultrasound (CEUS).
9540811|NCT03109990|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
9540812|NCT03109990|Placebo Comparator|saline|Same amount of saline will be administrated.
9540813|NCT03110237|Active Comparator|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
9540814|NCT03110237|Experimental|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
9540815|NCT03109847|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
9540816|NCT03109847|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
9540817|NCT03109834|Active Comparator|Meal replacement (MR) group|"Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1)~During weight stabilization phase (phase 2) MR counted to food choice option."
9540818|NCT03109834|Other|Control (C) group|"Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1)~During 3-month weight stabilization phase (phase 2) MR counted to food choice option."
9540819|NCT03109834|Active Comparator|Verum group|"Specific micronutrient composition with omega-3 fatty acids (capsules)~Duration: 6-month weight maintenance phase (phase 3)"
10039748|NCT01847053|Placebo Comparator|Oatmeal control|Oatmeal control, around 70g; without cinnamon
10039749|NCT01847053|Active Comparator|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (~70 g)
10039750|NCT01847053|Active Comparator|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (~70 g)
10039751|NCT01847053|Active Comparator|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (~70 g)
10039752|NCT01847066|Active Comparator|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
9540820|NCT03109834|Placebo Comparator|Placebo group|"Placebo capsules~Duration: 6-month weight maintenance phase (phase 3)"
9540821|NCT03109691|Active Comparator|group 1|30 patients will receive bupivacaine
9540822|NCT03109691|Active Comparator|group 2|30 patients will receive bupivacaine and Dexamethasone. .
9540823|NCT03109730|Experimental|Cohort B1|ABI-H0731 or Placebo in varying doses by mouth for 28 days
9540824|NCT03109730|Experimental|Cohort B2|ABI-H0731 or Placebo in varying doses by mouth for 28 days
9540825|NCT03109730|Experimental|Cohort B3|ABI-H0731 or Placebo in varying doses by mouth for 28 days
9540826|NCT03109730|Experimental|Cohort B4|ABI-H0731 or Placebo in varying doses by mouth for 28 days
9540827|NCT03109730|Experimental|Cohort B5|ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days
9540828|NCT03109730|Experimental|Cohort B6|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
9540829|NCT03109808|Experimental|e-health strategy|Assigned intervention: e-health strategy
9540830|NCT03109808|Active Comparator|Traditional Oral Hygiene Education|Assigned intervention: traditional oral hygiene education
10039753|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
10039754|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
10039755|NCT01847066|Active Comparator|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
10039756|NCT01847079|Other|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
10039757|NCT01847079|No Intervention|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
9540831|NCT03109743|Experimental|Sisters-GPS: Group Clinical Visits|Those randomized to the Sisters-GPS arm will be expected to attend a total of seven group clinical visits, once a week for ~1.5 hours. Groups visits will include education, self-management skills development, and a clinical assessment by a medical provider with a focus on HIV treatment and adherence. Additionally, Sisters-GPS participants will be encouraged to participate in a private social media site specifically designed for the study, where participants will be able communicate with one another and with research staff. Group size will be 8-10 participants.
9540832|NCT03109743|Active Comparator|Control: One-on-one Adherence Counseling|Those randomized to the control condition will receive an appointment with a HIV treatment adherence counselor and will be expected to attend a minimum of three adherence counseling visits. .
9540833|NCT03109522|Experimental|axillary reverse mapping|Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
9540834|NCT03109522|Active Comparator|standard axillary surgery|The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
9540835|NCT03109756|Experimental|Single-dose 5 mg OV101|
9540836|NCT03109821||THA patients|
9540837|NCT03109795|Experimental|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
9540838|NCT03109795|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
9540839|NCT03109574|Other|Standard of Care Device|Current standard of care polyurethane catheter used at the hospital
9540840|NCT03109574|Other|Study Device|BioFlo DuraMax Chronic Hemodialysis Catheter
9540841|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
9540842|NCT03109587|Active Comparator|Vivomixx (Visbiome)|2 packets of probiotics by mouth/day for 12 weeks
9540843|NCT03109587|Placebo Comparator|Placebo|identical in appearance, but without probiotics.
9540844|NCT03109665||Glaucoma within NICOLA|NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
9540845|NCT03109366|Other|Online self-management support|Access to online self-management support tool for six months
9540846|NCT03109626|Active Comparator|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
9540847|NCT03109626|Placebo Comparator|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
9540848|NCT03109509|Active Comparator|Fitbit-only Group|Participants randomized to the FB group were provided a Fitbit Zip activity monitor and were instructed on how to wear the monitor, how to pair the activity monitor to their smartphone, and asked to provide our team consent to access their Fitbit data through Fitbit's Application Programming Interface (API)
9540849|NCT03109509|Experimental|Fitbit + Pokémon Go Group|Participants randomized to the FB+P group received the same Fitbit Zip activity monitor and text message reminders as the FB group. This group was also shown how to download the Pokémon Go application to their smartphone and were provided brief instructions on how to play the game. Participants were instructed to simply explore the game and play it at their leisure. Participants were not provided any specific goals related to game play or physical activity in general.
9540850|NCT03109704|Experimental|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
9540851|NCT03109704|Experimental|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
9540852|NCT03109704|Sham Comparator|Sham manipulation|The sham manipulation will be performed two times.
9540853|NCT03109431|Experimental|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
9540854|NCT03109431|Experimental|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
9540855|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
9540856|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
9540857|NCT03109496||OME Patients|Suffer from chronic Otitis Media with Effusion (OME) for at least 3 months and undergo ventilation tube placement.
9540858|NCT03109496||Healthy Control|Undergo surgery that gives access to the middle ear space (e.g. cochlear implant surgery) or adenoids, in absence of upper respiratory tract infections.
9540859|NCT03109600|Experimental|Vi-DT (Bio Farma)|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
9540860|NCT03109600|Active Comparator|Vi polysaccharide vaccine|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine
9540861|NCT03109600|Experimental|Vi-DT (Bio Farma) ~ Children|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
9540862|NCT03109600|Active Comparator|Vi polysaccharide vaccine ~ Children|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine
9540863|NCT03109340|Active Comparator|Supervised treadmill group|a. Supervised treadmill group (Group I): The participants were instructed walking exercise at their target heart rate on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
9540864|NCT03109340|Experimental|ECE PEDO pedometer group|b. ECE PEDO® pedometer group (Group II): Participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from their target range of steps per minute.
9540865|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
9540866|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
9540867|NCT03109678|Experimental|Aura-i / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube
9540868|NCT03109678|Experimental|Aura-i / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube
9540869|NCT03109678|Experimental|Fastrach / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube
9540870|NCT03109678|Experimental|Fastrach / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube
9540871|NCT03109652|Active Comparator|IV TXA alone|One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
9540872|NCT03109652|Experimental|IV TXA and Oral TXA 5 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5."
9540873|NCT03109652|Experimental|IV TXA and Oral TXA 2 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2."
9540874|NCT03109639|Active Comparator|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
9540875|NCT03109639|Active Comparator|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
9540876|NCT03109171|Other|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
9540877|NCT03109171|Other|Non-expert rater|"Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.~Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
9540878|NCT03109613|Experimental|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
9540879|NCT03109535|Active Comparator|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
9540880|NCT03109535|Experimental|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
9540881|NCT03109132|Active Comparator|Model 1|Device - O2/CO2 Oral/Nasal cannula sample line - Oridion smart CapnoLine® H Plus with Wedge cannula
9540882|NCT03109132|Active Comparator|Model 2|Device -O2/CO2 Oral/Nasal cannula sample line- Oridion smart CapnoLine® Plus with Non-Wedge cannula
9540883|NCT03109132|Active Comparator|Model 3|Device - Experimental sample line Model 3
9540884|NCT03109132|Active Comparator|Model 4|Device - Experimental sample line Model 4
9540885|NCT03109132|Active Comparator|Model 5|Device - Experimental sample line Model 5
9540886|NCT03109132|Active Comparator|Model 6|Device - O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
9540887|NCT03109392|Experimental|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
9540888|NCT03109392|Experimental|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
9540889|NCT03109392|Active Comparator|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
9540890|NCT03109379|Experimental|TAR-302-5018 (42-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
9540891|NCT03109379|Experimental|TAR-302-5018 (84-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
9621723|NCT02522091|Other|old healthy volunteers (70+ years old)|old healthy volunteers (70+ years old)
10039758|NCT01847105|Experimental|RevitaLens|AMO's RevitaLens contact lens solution
9540892|NCT03109080|Experimental|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
9540893|NCT03109158|Experimental|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
9540894|NCT03109405|Experimental|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
9540895|NCT03109405|Other|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
9540896|NCT03109236|Experimental|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state.~5 dose GCSF will be administered 5 days consecutively before bone marrow harvesting.~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system.~Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
9540897|NCT03109236|Active Comparator|Control|"Non-Transplant Arm:~Patients will receive 5 doses of GCSF"
9540898|NCT03109145|Experimental|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
9540899|NCT03109145|No Intervention|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
9540900|NCT03109106|Experimental|PCT Arm|"oAntibiotic management includes use of a validated PCT algorithm in addition to clinical judgment, other laboratory values, and microbiological pathogen identification. Subjects will be enrolled and data collected prospectively in 2017.~Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge."
9540901|NCT03109106|No Intervention|Control Group|Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
9540902|NCT03109119|Active Comparator|Group S|These patients will be induced and maintained with sevoflurane during anaesthesia.
9540903|NCT03109119|Sham Comparator|Group P|These patients will be induced and maintained with propofol during anaesthesia.
9540904|NCT03109314|Active Comparator|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
9540905|NCT03109314|Active Comparator|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
9540906|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
9540907|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
9540908|NCT03109301|Experimental|Arm 1|Patients > 18 years of age
9540909|NCT03109301|Experimental|Arm 2|Patients < 18 years of age
9540910|NCT03109223|Active Comparator|Commercially availabel infant formula|
9540911|NCT03109223|Experimental|Test formula with 2-FL|
9540912|NCT03109223|Active Comparator|Breast Fed|
9540913|NCT03109067|Experimental|Standardized meal|"Standardized meal for :~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
9540914|NCT03109249|Experimental|SPARC1613|Intravenous administration of SPARC1613
9540915|NCT03109249|Active Comparator|Reference 1613|Intravenous administration of Reference1613
9616369|NCT02543307|Experimental|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients' processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients' and health care professionals' as well as institutional outcomes.
9622103|NCT02518542|Active Comparator|Per oral endoscopic therapy C|Dilatation
9622104|NCT02518542|Active Comparator|Laparoscopic surgery|Laparoscopic Heller myotomy
10039759|NCT01847118|Experimental|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
10039760|NCT01847144|Active Comparator|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
10039761|NCT01847144|Active Comparator|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
9540916|NCT03109054||Low Anxiety Level|The patients had low anxiety levels. Anxiety levels will determine with S-Anxiety TX-1 (State-Trait Anxiety Inventory Test:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
9540917|NCT03109054||High Anxiety Level|The patients had high anxiety levels. Anxiety levels will determine with S-Anxiety (State-Trait Anxiety Inventory Test: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
9540918|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
10039762|NCT01847157|Experimental|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
10039763|NCT01847157|Sham Comparator|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
9540919|NCT03108820|Experimental|TMH Intervention|The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.
9540920|NCT03108820|Active Comparator|Usual Care|Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.
9540921|NCT03108846|Experimental|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
9540922|NCT03108846|Placebo Comparator|Placebo|1-3 capsules each containing placebo only once per day in the morning
9540923|NCT03108781|Active Comparator|Lavender Oil|
9540924|NCT03108781|Placebo Comparator|sunflower oil|
9540925|NCT03108937|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
9540926|NCT03108937|Placebo Comparator|saline|Same amount of saline will be administrated.
10039764|NCT01847170|Experimental|Fecal Microbial Transplantation|
9540927|NCT03108768|Experimental|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
9540928|NCT03108768|Active Comparator|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
9540929|NCT03108833|Experimental|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
9540930|NCT03108833|Experimental|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
9540931|NCT03108833|Active Comparator|Active Comparator Controlled Group|Alteplase:100mg if weight>=65kg, 1.5mg/kg if weight<65kg
9540932|NCT03108911|Experimental|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
10039765|NCT01847183|Experimental|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
9540933|NCT03108911|Experimental|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
9540934|NCT03108976|Sham Comparator|Control group|Children with a typical development.
9540935|NCT03108976|Active Comparator|Case group|Children with Autism Spectrum Disorders.
10039766|NCT01847183|No Intervention|Usual Curriculum|Students receive their usual alcohol curriculum
10039767|NCT01847222|Experimental|SANGUINATE™|PEG-bHb-CO
10039768|NCT01847222|Placebo Comparator|Normal Saline Solution|Saline Solution
10039769|NCT01847235|Experimental|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
10039770|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
10039771|NCT01847248||Severe sepsis|Patients with severe sepsis
10039772|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
10039773|NCT01847248||Control|Healthy volunteers
10039774|NCT01847261|Experimental|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
10039775|NCT01847261|Active Comparator|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
10039776|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
10039777|NCT01847300|Experimental|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
10039778|NCT01847300|No Intervention|Treatment as Usual|Participants in this group will receive treatment as usual.
9498014|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
9498015|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
9498016|NCT03469882|Experimental|High protein and exercise (HPE) group|Begining within 48 hours of ICU admission participants will receive nutrition support with energy expenditure measured by indirect calorimetry, 2.0 to 2.2 g/kg/day of protein and in-bed cycle ergometry exercise.
9498017|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise
9498018|NCT03469869|Experimental|balanced and sustainable diet|The intervention group will receive menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the control group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
9498019|NCT03469869|Active Comparator|balanced diet|the intervention group receive get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
9498020|NCT03469856|Other|single arm|The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values. angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 60 mg and continued with prasugrel only (10 mg once a day) for three months. Aspirin and clopidogrel will be discontinued. At the 3-months follow-up visit, prasugrel (only) will be replaced by aspirin (only) or dual-antiplatelet therapy according to local standard of care.
9498021|NCT03469830|Experimental|SSCP & SPMS|"The smart scar care pad (SCCP):~The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.~The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
9498022|NCT03469830|Active Comparator|SPMS|"The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
9498023|NCT03469817|No Intervention|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
9498024|NCT03469817|Other|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
9498025|NCT03469804|Experimental|Pembrolizumab|Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
9498026|NCT03469791|Active Comparator|Micro-decompression alone|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
9498027|NCT03469791|Active Comparator|Decompression and instrumented fusion|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
9498028|NCT03469778|Experimental|Robotic Therapy|After consent, 10 participants will be included in a training program, as described below: 1º session will be robotic calibration and assessment; the following 18 sessions will be conducted the robotic therapy for upper limbs, three times a week. Each session will have a total duration of 55 minutes, including initial patient positioning and adjusting and after a sequence of game tasks.
9498029|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
9498030|NCT03469752|Experimental|Intervention group|8 weekly education sessions 2.5 hours
9498031|NCT03469752|No Intervention|Wait-list control group|No education sessions
9498032|NCT03469726|Other|Patients with (suspected) PDAC|"Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.~Suspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months."
9498033|NCT03469713|Experimental|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
9498034|NCT03469700|Experimental|GA+PVB|Patients will receive general anesthesia with paravertebral block
9540936|NCT03108963|Experimental|L-carnitine and Metformin|L-carnitine and Metformin in Obese PCOS Women trying induction of ovulation with clomiphene citrate.
9540937|NCT03108963|Active Comparator|placebo|placebo was given toObese PCOS Women trying induction of ovulation with clomiphene citrate.
9540938|NCT03108989|Experimental|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
9540939|NCT03108989|Active Comparator|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
9540940|NCT03108872||LAAO group|One-hundred consecutive patients who underwent left atrial appendage occlusion from October 2010 to March 2015 in 5 Korean tertiary cardiovascular centers will be retrospectively registered.
9540941|NCT03108872||NOAC group|Two-hundred age-, sex-, CHA2DS2-VASc score- and HAS-BLED score- matched control will be selected with a 1:2 ratio among all patients treated with new oral anticoagulants to prevent ischemic events from 5 centers during same periods
9540942|NCT03108742|Experimental|dermal stapler|
9540943|NCT03108742|Active Comparator|classic intradermal suture|
9540944|NCT03108560|Experimental|Sublobar group|Patients receive sublobar resection, including wedge resection and segmentectomy.
9540945|NCT03108560|Active Comparator|Lobectomy group|Patients receive lobectomy.
9540946|NCT03108586|Active Comparator|FDI|Diagnosis and dental treatment decision based on the criteria of the International Dental Federation (FDI).
9540947|NCT03108586|Experimental|CARS|Diagnosis and dental treatment decision according to CARS (Caries Associated with Restorations or Sealants) detection criteria.
9540948|NCT03108690|Experimental|TDM and CI.|Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.
9540949|NCT03108690|No Intervention|Control|Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.
9540950|NCT03108703|Experimental|SBRT|RCC patients
9540951|NCT03108716|Experimental|hamate hook removal|The patients were assigned to hamate hook removal(n=13).
9540952|NCT03108716|Experimental|microscrew internal fixation|The patients were assigned to the microscrew internal fixation after open reduction (n=11).
9540953|NCT03108716|Experimental|short-arm tube-type plaster fixation|The patients were assigned to the short-arm tube-type plaster fixation (conservative treatment) (n=4).
9540954|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
9540955|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
9540956|NCT03108599|Experimental|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
9540957|NCT03108599|No Intervention|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
9540958|NCT03108794||Immune tolerance phase|Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.
9540959|NCT03108794||HBeAg positive CHB|HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.
9540960|NCT03108794||HBeAg negative CHB|HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.
9540961|NCT03108794||Inactive HBsAg carriers|Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.
9540962|NCT03108794||Compensated cirrhosis|"Diagnosis of compensated cirrhosis can be made if one of the following criteria was met:~by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4.~endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension.~at least 2 features of cirrhosis:~irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness > 4.0cm or > 5 rib units) on ultrasound ,CT or MRI;~PLT<100×109/L without other causes;~Serum album in<35 g/L or INR>1.3 or PT prolongs>3s;~LSM>13 kpa (ALT<5×ULN)."
9540963|NCT03108794||Decompensated cirrhosis|Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.
9540964|NCT03108794||Hepatocellular carcinoma|Diagnosis of hepatocellular carcinoma（HCC）can be established when one of the following one of the following 2 criteria:（1）in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or（2）histological evidence of HCC.
9540965|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
9540966|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of < 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
9540967|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
9540968|NCT03108430||Inhalation pneumonia|
9540969|NCT03108430||Proven inhalations|
9540970|NCT03108430||Suspected inhalations (coma + anamnesis)|
9540971|NCT03108534|Experimental|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
9540972|NCT03108534|Active Comparator|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
9540973|NCT03108534|Placebo Comparator|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
9540974|NCT03108612|Experimental|Study group|Intervention: Análisis de carga de trabajo (ACT)
9540975|NCT03108729|Experimental|eslicarbazepine acetate|elicarbazepine acetate, once daily flexible dosing
10039779|NCT01847326|Experimental|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
9540976|NCT03108755|Experimental|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
9540977|NCT03108755|Placebo Comparator|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
9540978|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
9540979|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
9540980|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
9540981|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
9540982|NCT03108651|Active Comparator|Case|Motivational message will be administrated.
9540983|NCT03108651|No Intervention|Control|Motivational message will not be administrated.
9540984|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
9540985|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
9540986|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
9540987|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
9540988|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
9540989|NCT03108950|Experimental|Home-Based Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
9540990|NCT03108664|Experimental|11.25 mg/mL SYL1001 ophthalmic solution|1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d
9540991|NCT03108664|Experimental|Vehicle ophthalmic solution|1 drop of vehicle ophthalmic solution in the affected eye(s) q.d
9540992|NCT03108313|Experimental|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
9540993|NCT03108313|Active Comparator|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
9540994|NCT03108625|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
9540995|NCT03108508|Experimental|Prod1|G5 Siliplant
9540996|NCT03108508|Experimental|Prod2|Orgono Powder®
9540997|NCT03108508|Experimental|Prod3|G7 ALOE
9540998|NCT03108417|Experimental|cNEP|continuous negative external pressure will be used nightly by all participants
9540999|NCT03108300|Experimental|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
9541000|NCT03108196|Experimental|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
9541001|NCT03108196|Experimental|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
9541002|NCT03108326||Group 1a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with biologics is not allowed.
9541003|NCT03108326||Group 1b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with 1 biologics is allowed
9541004|NCT03108326||Group 2|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with ≥2 biologic is allowed.
9541005|NCT03108326||Group 3a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with biologic is not allowed.
9541006|NCT03108326||Group 3b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
9622105|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
9485703|NCT01559363|Experimental|Phase 2a Monday and Thursday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday and Thursday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
9485704|NCT01559363|Experimental|Phase 2a, 50mg|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
9485705|NCT01559363|Experimental|Phase 2a, 50mg (SILK Cohort)|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
9485706|NCT01558999|Experimental|High concentration SI-614|
9485707|NCT01558999|Experimental|Low concentration SI-614|
9485708|NCT01558999|Placebo Comparator|Vehicle|
9485709|NCT01557777|Experimental|Navitoclax, ABT-263|
9485710|NCT01555554|Experimental|Propranolol Hydrochloride|
9485711|NCT01555554|Placebo Comparator|Placebo Group|
9485712|NCT01554696|Experimental|ASP015K lowest dose|ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
9485713|NCT01554696|Experimental|ASP015K low dose|ASP015K low dose daily in addition to concomitant weekly oral methotrexate
9485714|NCT01554696|Experimental|ASP015K medium dose|ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
9485715|NCT01554696|Experimental|ASP015K high dose|ASP015K high dose daily in addition to concomitant weekly oral methotrexate
9485716|NCT01554696|Placebo Comparator|Placebo|Placebo daily in addition to concomitant weekly oral methotrexate
9485717|NCT01549834|Experimental|ABT-126 Low Dose|low dose
9485718|NCT01549834|Experimental|ABT-126 High Dose|high dose
9485719|NCT01549834|Placebo Comparator|sugar pill|Placebo
9485720|NCT01546532|Experimental|RLX030|RLX030 as intravenous infusion for 24 hours.
9485721|NCT01546532|Placebo Comparator|Placebo|Placebo as intravenous infusion for 24 hours.
9485722|NCT01545453|Experimental|lebrikizumab - highest dose|
9485723|NCT01545453|Experimental|lebrikizumab - lowest dose|
9485724|NCT01545453|Experimental|lebrikizumab - middle dose|
9485725|NCT01545453|Placebo Comparator|placebo|
9485726|NCT01543919|Experimental|PH-787904 (arm1)|
9485727|NCT01543919|Experimental|PH-787904 (arm2)|
9485728|NCT01543919|Experimental|PH-787904 (arm3)|
9485729|NCT01543919|Experimental|PH-787904 (arm4)|
9485730|NCT01543919|Experimental|PH-787904 (arm5)|
9485731|NCT01543919|Experimental|Placebo|
9485732|NCT01543451|Experimental|Elsiglutide|
9485733|NCT01543451|Placebo Comparator|Placebo|
9485734|NCT01540864|Experimental|HPP404 35 mg|
9485735|NCT01540864|Experimental|HPP404 50 mg|
9485736|NCT01540864|Placebo Comparator|Placebo|
9485737|NCT01540630|Experimental|CNV1014802|
9485738|NCT01540630|Placebo Comparator|Placebo|
9485739|NCT01539226|Placebo Comparator|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
9485740|NCT01539226|Experimental|Dapivirine Vaginal Ring|Vaginal Ring containing 25mg of Dapivirine
9485741|NCT01536041|Experimental|Experimental 200 mg dose|
9485742|NCT01536041|Experimental|Experimental 20 mg dose|
9485743|NCT01536041|Active Comparator|Active Comparator Montelukast|
9485744|NCT01536041|Placebo Comparator|Placebo Comparator|
9485745|NCT01535950|Experimental|LFG316|
9485746|NCT01535950|Sham Comparator|Sham|
9485747|NCT01535508|Experimental|Liquid Vitamin D|
9485748|NCT01534403|Experimental|Epratuzumab 4x600 mg every 12 weeks Group|
9485749|NCT01534104|Experimental|pts who have primary or secondary brain tumors|The study will prospectively enroll subjects who have primary or secondary brain tumors located near the motor pathway (corticospinal tract) or language pathway (arcuate fasciculus). This is a nonrandomized study in which each subject will receive the standard of care as per the treating neurosurgeon.
9485750|NCT01533714|Experimental|Olokizumab 120 mg|Olokizumab 120 mg : subcutaneous injections at q2w (every two weeks).
9485751|NCT01531699|Experimental|ALT005 Ophthalmic Prep Solution|
9485752|NCT01531699|Placebo Comparator|saline control|
9485753|NCT01531699|Experimental|Comparator Product|Betadine ophthalmic prep solution
9485754|NCT01529853|Experimental|SAR156597 dose 1|SAR156597 dose 1, subcutaneous injection once every week
9485755|NCT01529853|Experimental|SAR156597 dose 2|SAR156597 dose 2, subcutaneous injection once every week
9485756|NCT01529853|Experimental|SAR156597 dose 3|SAR156597 dose 3, subcutaneous injection once every week
9485757|NCT01529853|Placebo Comparator|Placebo|Placebo (for SAR156597), subcutaneous injection once every week
9485758|NCT01529424|Experimental|Group 1|Non-extensive PK/non post-prandial
9485759|NCT01529424|Experimental|Group 2a|Extensive PK
9485760|NCT01529424|Experimental|Group 2b|Post-prandial assessment
9485761|NCT01529424|Experimental|Group 3|Stable dose of fibrate
9485762|NCT01529424|Experimental|Group 4|Fredrickson Type 1 dyslipidemia
9485763|NCT01528111|Experimental|Low dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
9485764|NCT01528111|Experimental|High dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
9485765|NCT01528111|Placebo Comparator|LX7101 Vehicle|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
9485766|NCT01527916|Placebo Comparator|sugar pill|
9485767|NCT01527916|Active Comparator|donepezil|
9485768|NCT01527916|Experimental|ABT-126 Low Dose|low dose
9485769|NCT01527916|Experimental|ABT-126 Middle Dose|middle dose
9485770|NCT01527916|Experimental|ABT-126 high dose|high dose
9485771|NCT01523184|Placebo Comparator|Placebo Capsule|Placebo Capsules
9541007|NCT03108326||Group 4|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with ≥2 biologics is allowed.
9485772|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 10 mg|
9485773|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 20 mg|
9485774|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 30 mg|
9485775|NCT01523171|Experimental|SAR302503 400 mg|once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
9485776|NCT01522469|Experimental|Crenolanib Besylate|
9485777|NCT01522196|Active Comparator|Varespladib|48 hour continuous infusion delivered intravenously (IV)
9485778|NCT01522196|Placebo Comparator|Placebo|48 hour continuous infusion delivered intravenously (IV)
9485779|NCT01521663|Experimental|IPX159|IPX159 90 mg daily at week 1 with titration to 180 mg daily at week 2 with possible titration to 270 mg daily at week 3.
9485780|NCT01521663|Placebo Comparator|Sugar Pill|IPX159 90 mg matching placebo daily at week 1 with titration to 180 mg matching placebo daily at week 2.
9485781|NCT01521598|Experimental|SKL11197|This arm is the experimental drug (SKL11197) arm. Patients will be randomized to this arm.
9485782|NCT01521598|Placebo Comparator|Placebo|This arm is the placebo comparator arm. Patients will be randomized to this arm.
9485783|NCT01520545|Experimental|Gablofen 3 mg/mL (baclofen Injection)|3 mg/mL Gablofen (baclofen Injection)
9485784|NCT01519804|Experimental|MetMAb+paclitaxel+platinum|
9485785|NCT01519804|Active Comparator|Placebo+paclitaxel+platinum|
9485786|NCT01517880|Experimental|6,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
9485787|NCT01517880|Placebo Comparator|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).
9485788|NCT01517880|Experimental|3,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
9485789|NCT01517776|Experimental|Cilengitide and metronomic temozolomide|Cilengitide 1800 mg/m² i.v. twice weekly and Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
9485790|NCT01517698|Experimental|RO4917523 0.5 mg|
9485791|NCT01517698|Experimental|RO4917523 1.5 mg|
9485792|NCT01517698|Placebo Comparator|Placebo|
9485793|NCT01516918|Experimental|Quadruple Regimen|All subjects will receive active study drugs (quadruple regimen: VX-222, telaprevir,Peg-IFN, and RBV) for a fixed treatment duration of 24 weeks.
9485794|NCT01516541|Experimental|Dalcetrapib|Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.
9485795|NCT01516541|Placebo Comparator|Placebo|Placebo orally daily, on a background of contemporary, guidelines-based medical care.
9485796|NCT01516476|Experimental|Liraglutide Arm|
9485797|NCT01516476|Placebo Comparator|Placebo Arm|
9485798|NCT01516476|Experimental|RO6807952 Arm 1|
9485799|NCT01516476|Experimental|RO6807952 Arm 2|
9485800|NCT01516307|Experimental|OPT-822/OPT-821 (30 μg/100 μg) and Cyclophosphamide|Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).
9485801|NCT01516307|Placebo Comparator|Phosphate Buffer Saline (PBS) and Cyclophosphamide|Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).
9485802|NCT01516203|Experimental|Arm 1|AZD5847 500 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
9485803|NCT01516203|Experimental|Arm 2|AZD5847 500 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
9485804|NCT01516203|Experimental|Arm 3|AZD5847 1200 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
9485805|NCT01516203|Experimental|Arm 4|AZD5847 800 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
9485806|NCT01516203|Active Comparator|Arm 5|Rifafour e-275 mg tablets given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
9485807|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
9485808|NCT01516086|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
9485809|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
9485810|NCT01516086|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
9485811|NCT01516086|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
9485812|NCT01516086|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution
9485813|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
9485814|NCT01516073|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
9485815|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
9485816|NCT01516073|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
9485817|NCT01516073|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
9541008|NCT03108235|Experimental|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
10039780|NCT01847339|Experimental|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
10039781|NCT01847339|Placebo Comparator|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
10039782|NCT01847352|Other|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
9541009|NCT03108235|Experimental|Intervention group B|HOM-HEMP with the smartphone app.
9541010|NCT03108235|Active Comparator|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
9541011|NCT03108365|Experimental|Axiostat|"Size: 1 x 1 cm~Chitosan based haemostatic dressing"
9541012|NCT03108365|Active Comparator|Cotton Gauze|Size: 1 x 1 cm
9541013|NCT03108248||ISP-TACE group|During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
9541014|NCT03108248||TACE group|During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
9541015|NCT03108170|Active Comparator|3 programs group|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her duo date
9541016|NCT03108170|Active Comparator|one program group|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her duo date.
9541017|NCT03108287|Active Comparator|RAK therapy|rabeprazole+amoxicillin+clarithromycin
9541018|NCT03108287|Active Comparator|RBAK therapy|rabeprazole+amoxicillin+clarithromycin+bismuth subcitrate
9541019|NCT03108209|Experimental|single arm|Signle arm study. Every subjects apply Photoderm Max lait SPF50+ and Photoderm stick SPF50+
9541020|NCT03108495|Experimental|Cohort 1 LN-145 monotherapy|Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
9541021|NCT03108495|Experimental|Cohort 2 LN-145 monotherapy|Patients previously treated with an antiprogrammed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor: Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
9541022|NCT03108495|Experimental|Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only|Patients will be administered with pembrolizumab, followed by NMA lymphodepletion, then infused with their autologous TIL (LN-145) followed by pembrolizumab every 3 or 6 weeks post IL-2 administration up to 24 months.
9541023|NCT03108495|Experimental|Cohort 4 - Non-enrolling Cohort|Cohort includes patient population not meeting inclusion criteria in cohort 1 and 2. Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
9541024|NCT03108495|Experimental|Cohort 5 Retreatment Cohort|Patients who have been previously treated with LN-145 may be given a second treatment with TIL.
9541025|NCT03108391|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
9541026|NCT03108391|Active Comparator|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
9541027|NCT03108352|Experimental|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
9541028|NCT03108352|Sham Comparator|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
9541029|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
9541030|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
9541031|NCT03108144|No Intervention|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
9541032|NCT03108144|Experimental|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
9541033|NCT03108274|Experimental|Part 1: Danicopan and Midazolam|"Period 1: Participants received a single dose of midazolam.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of midazolam.~Scheduled pharmacokinetics (PK) blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
10039783|NCT01847352|Other|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
10039784|NCT01847365|Experimental|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
10039785|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
10039786|NCT01847391|Experimental|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
9541034|NCT03108274|Experimental|Part 2: Danicopan and Fexofenadine|"Period 1: Participants received a single dose of fexofenadine.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of fexofenadine.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
9541035|NCT03108274|Experimental|Part 3: Danicopan and MMF|"Period 1: Participants received a single dose of MMF.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of MMF.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
9541036|NCT03108105|Experimental|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
9541037|NCT03108092|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
9541038|NCT03108092|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
9541039|NCT03108118||Acute respiratory failure|We are enrolling patients who are intubated because of acute respiratory distress syndrome, pneumonia, septic shock, or severe acute brain injury (GCS ≤ 8 prior to intubation). This population is targeted for study because they are at relatively high risk of requiring prolonged mechanical ventilation.
9541040|NCT03108079|Other|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.~Interventions are listed in the Interventions Section."
9541041|NCT03108066|Experimental|PT2385 Tablets|Twenty-five patients will be enrolled in each stage of a two-stage design
9541042|NCT03107858|Active Comparator|Norepinephrine|
9541043|NCT03107858|Active Comparator|Dopamine|
9541044|NCT03108001||Lean mothers|Participants that were in Glowing born from Lean mothers.
9541045|NCT03108001||Overweight mothers|Participants that were in Glowing born from Overweight mothers.
9541046|NCT03108001||Obese mothers|Participants that were in Glowing born from Obese mothers.
9541047|NCT03108001||Exercise group mothers|Participants that were in Expecting born from mothers that were in the exercise group.
9541048|NCT03108001||Non Exercise group mothers|Participants that were in Expecting born from mothers that were in the non- exercise group.
9541049|NCT03107806|Other|Glucose monitoring by OptiScanner®|Glucose monitoring and intervention guided by OptiScanner®
9541050|NCT03107806|Other|Blinded continuous glucose monitoring|Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements
9541051|NCT03107910|Other|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
9541052|NCT03107910|Other|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
9541053|NCT03107728|Experimental|Advanced orthotic brace|
9541054|NCT03107728|Active Comparator|Conventional orthotic brace|
9541055|NCT03107962|Experimental|PD-1 Blocking Antibody|Pembrolizumab
9541056|NCT03107650||High risk patients|Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
9541057|NCT03107650||Low risk patients|Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
9541058|NCT03107884|Experimental|Metformin (Bed Rest)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). During bed rest, participants will be given 1 gram of metformin two times a day (morning and evening). This dosage and frequency will occur during four consecutive days of bed rest.
9541059|NCT03107884|Placebo Comparator|Placebo (Bed Rest)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
9541060|NCT03107884|Experimental|Metformin (2 week run-in only)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). These participants will not participate in the bed rest portion of the protocol.
9541061|NCT03107884|Placebo Comparator|Placebo (2 week run-in only)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. These participants will not participate in the bed rest portion of the protocol.
9541062|NCT03108053|Active Comparator|Guidewire used|Patients whose semirigid ureteroscopy procedure is conducted with the use of safety guidewire
9803767|NCT03370393|Experimental|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
9803768|NCT03370393|No Intervention|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
9803769|NCT03362931|Experimental|XEN45 Glaucoma Treatment System (hereafter referred to as XEN)|XEN45 unilaterally implanted in the study eye
10039787|NCT01847391|Experimental|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
9485818|NCT01516073|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution 2mL
9485819|NCT01515241|Other|Open label single arm study of CER-001|Open label single arm study of CER-001
9485820|NCT01515007|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
9485821|NCT01515007|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
9485822|NCT01510119|Experimental|Intervention - Dose Level 1|RAD001 given 10mg/daily by mouth and 400mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
9485823|NCT01510119|Experimental|Intervention - Dose Level 2 Phase 2|RAD001 given 10mg/daily by mouth and 600mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
9485824|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
9485825|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
9485826|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
9485827|NCT01508026|Experimental|Nebivolol Low Dose|Nebivolol Monotherapy 5 mg
9485828|NCT01508026|Experimental|Nebivolol High Dose|Nebivolol Monotherapy 20 mg
9485829|NCT01508026|Experimental|Valsartan Low Dose|Valsartan Monotherapy 80 mg
9485830|NCT01508026|Experimental|Valsartan High Dose|Valsartan Monotherapy 160 mg
9485831|NCT01508026|Placebo Comparator|Placebo|Dose Matched placebo
9485832|NCT01507545|Active Comparator|MORAb-004|
9485833|NCT01507545|Placebo Comparator|Placebo|
9485834|NCT01503944|Other|Dementia with Lewy Bodies|
9485835|NCT01503944|Other|Parkinson's disease|
9485836|NCT01503944|Other|Healthy Elderly Volunteers|
9485837|NCT01503944|Other|Alzheimer's Disease|
9485838|NCT01501513|Experimental|BLI800 approved preparation regimen|BLI800 approved preparation regimen
9485839|NCT01501513|Experimental|BLI800 investigational preparation regimen|BLI800 investigational preparation regimen
9485840|NCT01501513|Active Comparator|PEG-3350 based bowel preparation|PEG-3350 based bowel preparation
9485841|NCT01501383|Active Comparator|VX-765 Dose 1 Part A|
9485842|NCT01501383|Active Comparator|VX-765 Dose 2 Part A|
9485843|NCT01501383|Active Comparator|VX-765 Dose 3 Part A|
9485844|NCT01501383|Active Comparator|VX-765 Dose 4 Part A|
9485845|NCT01501383|Placebo Comparator|Placebo Dose Part A|Placebo
9485846|NCT01501383|Active Comparator|VX-765 Dose Part B|
9485847|NCT01499563|Experimental|ITI-007 Low Dose|
9485848|NCT01499563|Experimental|ITI-007 High Dose|
9485849|NCT01499563|Placebo Comparator|Placebo|
9485850|NCT01499563|Active Comparator|Risperidone|
9485851|NCT01499420|Experimental|CSL112|
9485852|NCT01499420|Placebo Comparator|Placebo|
9485853|NCT01498484|Experimental|EBV-specific T cells|Patients will each receive a course of three weekly infusions of EBV-specific T cells (EBV-CTLs). Each weekly dose will provide 2 x 10^6 T cells/kg recipient weight (+/- 3 days). After the third dose, patients will be observed for approximately 3 weeks.
9485854|NCT01498328|Experimental|Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.|About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
9485855|NCT01498328|Experimental|Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control|About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
9485856|NCT01498328|Experimental|Group 2 and 2C: Refractory to Bevacizumab|Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).
9485857|NCT01497834|Experimental|Daclatasvir + Asunaprevir|
9485858|NCT01497704|Experimental|YN968D1|Active therapy arm for safety evaluation
9485859|NCT01495247|Experimental|BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.
9485860|NCT01495247|Experimental|BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days
9485861|NCT01495013|Active Comparator|Glimepiride Atorvastatin fixed dose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
9485862|NCT01495013|Active Comparator|Glimepiride +Atrovastatin loose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.
9485863|NCT01494233|Experimental|Low dose|500 mg LX1033 two times daily
9485864|NCT01494233|Experimental|Mid dose|500 mg LX1033 three times daily
9485865|NCT01494233|Experimental|High dose|1000 mg LX1033 two times daily
9485866|NCT01494233|Placebo Comparator|Placebo|Matching placebo dosing
9485867|NCT01493505|Placebo Comparator|Placebo|Placebo Paclitaxel Carboplatin
9541063|NCT03108053|Experimental|No guide wire used|Patients whose semirigid ureteroscopy procedure is conducted without the use of safety guidewire
9541064|NCT03107832|Active Comparator|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
9541065|NCT03107832|Experimental|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
9541066|NCT03108014||Breast milk fed|Fed primarily breast fed as an infant
9541067|NCT03108014||Milk based formula fed|Fed primarily milk based formula as an infant
9541068|NCT03108014||Soy based formula fed|Fed primarily soy based formula as an infant
9541069|NCT03107741|No Intervention|Passive Control|Subjects in this group will not receive any intervention.
9541070|NCT03107741|Placebo Comparator|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
9541071|NCT03107741|Active Comparator|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
9541072|NCT03107975|Experimental|Cell Therapy|intrathecal injection of human amniotic epithelial cells
9541073|NCT03107819||Pediatric patients undergoing EGD|Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.
9541074|NCT03107845|Active Comparator|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
9541075|NCT03107845|Experimental|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
9541076|NCT03107845|Experimental|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
9541077|NCT03107936|Experimental|smokeSCREEN game play|Participants are instructed to access the web-based videogame intervention, smokeSCREEN, through a secured website and play the game using their unique User ID and password.
9541078|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
9541079|NCT03107949|Experimental|Lungpacer Diaphragm Pacing Therapy (DPTS)|The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.
9541080|NCT03107767|Active Comparator|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
9541081|NCT03107767|No Intervention|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
9541082|NCT03107702||Melatonin and bariatric surgery|the relationship between melatonin level and analgesia requirement.
9541083|NCT03107663|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
9541084|NCT03107676|Active Comparator|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
9541085|NCT03107676|Active Comparator|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
9541086|NCT03107676|Active Comparator|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
9541087|NCT03107676|No Intervention|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
9541088|NCT03107494|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS) / RheOx
9541089|NCT03107546|Other|Skin graft|full thickness skin graft
9541090|NCT03107546|Experimental|Hyalomatrix|skin graft substitute
9541091|NCT03107481|Active Comparator|Acetaminophen|
9541092|NCT03107481|Active Comparator|Hydromorphone|
9541093|NCT03107598|Experimental|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
9541094|NCT03107598|Placebo Comparator|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
9541095|NCT03107442|Experimental|Exercise|12-weeks aerobic exercise intervention
9541096|NCT03107442|No Intervention|Control|Usual care, with recommendations for a healthy lifestyle.
9541097|NCT03107429|Active Comparator|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
9541098|NCT03107429|Experimental|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
9541099|NCT03107468|Experimental|Mokhuri intensive treatment group|Patients in this arm will be treated with 35-week of Mokhuri intensive treatment program which compromise 10 sessions of acupuncture, Chuna and patient consultation during 5 weeks.
9622106|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
9541100|NCT03107468|Active Comparator|Non-surgical conventional treatment group|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment during 5 weeks.
9541101|NCT03107325|Other|F-18 FDG|Only patients scheduled for a whole body PET scan will be eligible. Subjects of all ages will be imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
9541102|NCT03107234||Patient with breast cancer requiring surgery to|
9541103|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
9541104|NCT03107221|Experimental|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
9541105|NCT03107221|No Intervention|Control|Usual treatment from a specialist eating disorder service
9541106|NCT03107351|Sham Comparator|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
9541107|NCT03107351|Experimental|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
9616370|NCT02543307|No Intervention|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
9616371|NCT02543216|Experimental|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
9616372|NCT02543216|Experimental|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
9616373|NCT02543021|Active Comparator|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
9616374|NCT02543021|Experimental|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
9616375|NCT02543151|Experimental|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
9616376|NCT02543047|Active Comparator|Right Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the right region of the heart
9616377|NCT02543047|Active Comparator|Left Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the left region of the heart
9616378|NCT02543086|Experimental|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A & Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (~15 days)."
9616379|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
9616380|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
9616381|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
9616382|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
9616383|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose [MTD] or highest dose tested in Part 1) in combination with Lucentis™
9616384|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
9616385|NCT02543060|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
9616386|NCT02543060|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
9616387|NCT02543242|Experimental|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
9616388|NCT02543190|Experimental|compliance surveillance|"Prospective audits by study personnel~Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
9616389|NCT02543190|No Intervention|Usual Care|educational session at the start of the study
10039788|NCT01847391|Experimental|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
9616390|NCT02543008|Experimental|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
9616391|NCT02543008|Active Comparator|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
9616392|NCT02543008|Placebo Comparator|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
9541108|NCT03107208|Experimental|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
9541109|NCT03107208|Other|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
9541110|NCT03107273||Diagnostic patient|
9541111|NCT03107273||Control|
9541112|NCT03107247|Other|Tc-99m MDP|Patients ages 1-16 years old will be included. Routine SPECT imaging will be collected 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ for 10-15 s per view using a 1282 matrix. Half of the subjects will also be imaged between 30 and 90 min, PA. The 2nd half will be at 4-6 h, PA. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
10039789|NCT01847404|Experimental|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
9541113|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
9541114|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
9541115|NCT03107286|Other|Tc-99m MAG3|Children ages 1-6 years old will be eligible to participate. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
9541116|NCT03107312||Known vaccination history|Single blood sample collection from subjects with verified records of vaccination or recent booster immunization against measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection
9541117|NCT03107312||Migrants|Single blood sample collection from recent migrants to Germany without verified vaccination records
9541118|NCT03107338|Active Comparator|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
9541119|NCT03107338|Placebo Comparator|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
9541120|NCT03107390|Other|Patients with CD or RCH|
9541121|NCT03107390|Other|The control population|
9541122|NCT03107260|Other|Occurrence of postoperative cognitive dysfunction|
9541123|NCT03107143|Experimental|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
9541124|NCT03107143|No Intervention|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
9541125|NCT03107299|Other|Control|
9541126|NCT03107299|Other|Send sms to patients|
9541127|NCT03107299|Other|pharmaceutical maintenance following medical consultation|
9541128|NCT03107117|Experimental|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
9541129|NCT03107117|Active Comparator|Standard care|Standard care is typically referral to counseling for substance use
9541130|NCT03107507|Active Comparator|Levetiracetam|"Levetiracetam given in oral form via oro-gastric tube, first a bolus dose 40-50mg/kg then maintenance dose 10-30 mg/kg/day divided every 12 hours.~Duration: until seizure free"
9541131|NCT03107507|Active Comparator|Phenobarbital|"Phenobarbital given in IV form, loading dose 20mg/kg that can be repeated after a 20 minute interval not to exceed 40mg/kg then maintenance dose 2-4 mg/kg/day divided every 12 hours.~Duration: until seizure free"
9541132|NCT03107065|Experimental|single treatment|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands
9541133|NCT03107078|Experimental|Group Ia|"I:The increase of fat volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
9541134|NCT03107078|Experimental|Group Ib|"I:The increase of fat volume dominates. b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
9541135|NCT03107078|Experimental|Group IIa|"II:The increase of extraocular muscles volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
9541136|NCT03107078|Experimental|Group IIb|"II:The increase of extraocular muscles volume dominates . b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
9541137|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
9541138|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
9541139|NCT03106896||healthy control (CON group)|healthy population
9541140|NCT03106948|Placebo Comparator|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
9616393|NCT02542969|Other|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
10039790|NCT01847417|Experimental|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
9541141|NCT03106948|Active Comparator|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
9541142|NCT03106948|Active Comparator|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
10039791|NCT01847456|Experimental|insulin nasal spray|160 Units of human insulin as nasal spray
10039792|NCT01847456|Placebo Comparator|Placebo nasal spray|Nasalspray containing placebo solution
9541143|NCT03106935|Active Comparator|Obstet Gynecol,SecondSoochowU|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
9541144|NCT03106935|No Intervention|reproductive center,SecondSoochowU|For the control group ,women with subclinical hypothyroidism are not given any drugs .
9541145|NCT03106922|Experimental|PMF104|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6~500 ml in 1-1.5 hours <= to 18 kg~625 ml in 1-1.5 hours >18 kg 6<=Age<12:~750 ml in 1-2 hours <=25 kg~1000 ml in 1-2 hours 25-35 kg~1250 ml in 1-2 hours >35 kg 12>=Age<18 :~1500 ml in 2-3 hours <= 45 kg~1750 ml in 2-3 hours>45 kg.~Rescue dose (if no clear watery stools 3 hours after the entire solution):~250 ml 2 Age <=6;~500 ml 6 <=Age<12; up to a cumulative maximum volume of 2000 ml 12<=Age<18."
9541146|NCT03106922|Active Comparator|Klean- prep|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6:~90 ml/kg in 1-1.5 hours 2<=Age<6~80 ml/kg in 1-1.5 hours 5<=Age<6~2<=Age<6:~80 ml/kg in 1-2 hours 6<=Age<10~70 ml/kg in 1-2 hours 10<=Age<12~12<=Age<18:~70 ml/kg in 2-3 hours. Rescue dose (if no clear watery stools 3 hours after the entire Klean-Prep solution): 50% of the initial dose."
9541147|NCT03106805|Experimental|insertion by the end of the 4th week postpartum|
9541148|NCT03106805|Active Comparator|insertion by the end of the 6th week postpartum|
9541149|NCT03106857|Placebo Comparator|Group A|Physical activity, a low caloric diet, and the routine standard care for constipation
9541150|NCT03106857|No Intervention|Group B|No intervention
9541151|NCT03107039|Experimental|Exercise|This arm will use a resistance exercise curriculum.
9541152|NCT03107039|Active Comparator|Health Education|This arm will use health education curriculum.
9541153|NCT03106974|Active Comparator|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
9541154|NCT03106974|Active Comparator|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
9541155|NCT03107195|Other|Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 4-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
9541156|NCT03107169|Active Comparator|Vancomycin|Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days
9541157|NCT03107169|Experimental|FMT-FURM|Patients in this arm receive FMT-FURM
9541158|NCT03106883|Experimental|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions~Five five-minute blocks separate by 90-second rest periods"
9541159|NCT03106883|Sham Comparator|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)~Five five-minute blocks separate by 90-second rest periods"
9541160|NCT03107585|Experimental|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
10039793|NCT01847482|Experimental|Therapeutic Hypothermia|
10039794|NCT01847495|Experimental|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
10039795|NCT01847508|Active Comparator|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
10039796|NCT01847508|Active Comparator|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
10039797|NCT01847521|Experimental|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
9541161|NCT03107585|Placebo Comparator|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
9541162|NCT03107013|Experimental|[14C]-BTD-001|
9541163|NCT03106792|Experimental|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
10039798|NCT01847534|Other|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
10039799|NCT01847534|Experimental|Supplemental PN|"Supplemental PN to complete inadequate EN provision~Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.~EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.~The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
10039800|NCT01847586|Experimental|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
10039801|NCT01847586|Placebo Comparator|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
10039802|NCT01847586|Other|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
10039803|NCT01847599|Other|capecitabine|patients treated by capecitabine alone (n=100)
10039804|NCT01847599|Other|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
9485868|NCT01493505|Active Comparator|AMG 386|AMG 386 Paclitaxel Carboplatin
9485869|NCT01493271|Placebo Comparator|Placebo|
9485870|NCT01493271|Experimental|RO5093151|
9485871|NCT01491971|Experimental|Degarelix - Cohort 1|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
9485872|NCT01491971|Experimental|Degarelix - Cohort 2|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
9485873|NCT01491971|Experimental|Degarelix - Cohort 3|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
9485874|NCT01491932|Experimental|AFQ056|Patients entering the study will be titrated to target dose of AFQ056 twice daily or the highest tolerated dose at weekly intervals.
9485875|NCT01491568|Experimental|Investigational|
9485876|NCT01491529|Experimental|AFQ056 150 mg|Patients randomized to the AFQ056 150 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 150 mg twice daily.
9485877|NCT01491529|Experimental|AFQ056 200 mg|"Patients randomized to the AFQ056 200 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 200 mg twice daily.~Patients will be randomized in two groups by amantadine status.~Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
9485878|NCT01491529|Placebo Comparator|Placebo|Patients randomized to the Placebo arm will receive oral AFQ056 Placebo twice daily
9485879|NCT01491516|Experimental|Investigational|
9485880|NCT01489046|Experimental|Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine|
9485881|NCT01489046|Experimental|Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine|
9485882|NCT01489046|Experimental|Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine|
9485883|NCT01489046|Experimental|Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine|
9485884|NCT01488929|Experimental|5 mg TC-5619|One tablet of 5 mg TC-5619 will be administered orally once a day.
9485885|NCT01488929|Experimental|50 mg TC-5619|One tablet of 50 mg TC-5619 will be administered orally once a day.
9485886|NCT01488929|Placebo Comparator|Placebo|One tablet of placebo will be administered orally once a day.
9485887|NCT01487174|Experimental|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
9485888|NCT01487174|Active Comparator|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
9485889|NCT01487109|Placebo Comparator|Placebo|matching placebo tablets
9485890|NCT01487109|Active Comparator|CTP-499|600 mg tablet
9485891|NCT01487083|Experimental|Pomaglumetad methionil|Pomaglumetad methionil will be administered orally. Participants entering the study will be flexibly dosed between 20 mg, 40 mg, and 80 mg twice daily.
9485892|NCT01486849|Experimental|Dose Titration of CK-2017357 (Group 1)|Dose titration of active drug as add-on therapy to riluzole
9485893|NCT01486849|Placebo Comparator|Matching Placebo (Group 2)|Placebo as add-on therapy to riluzole
9485894|NCT01486277|Experimental|Quisinostat|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
9485895|NCT01484119|Active Comparator|Investigational Drug|ACT-129968
9485896|NCT01484119|Placebo Comparator|Comparative Drug|matching placebo tablets and capsules
9485897|NCT01484119|Active Comparator|Reference Drug|Cetirizine
9485898|NCT01483898|Experimental|ixmyelocel-T|
9485899|NCT01483898|Placebo Comparator|Placebo|
9485900|NCT01483742|Experimental|Combination without RO5024048|Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients
9485901|NCT01483742|Experimental|Combination with RO5024048|RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys [peginterferon alfa-2a] and ribavirin) in prior null responder patients
9485902|NCT01482403|Experimental|Treatment Arm A|24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
9498035|NCT03469700|Active Comparator|GA+placebo PVB|Patients will receive general anesthesia with placebo block
9541164|NCT03106792|Experimental|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
9541165|NCT03106792|Experimental|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
9541166|NCT03106792|Placebo Comparator|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
9541167|NCT03106766|Experimental|Acne cream 1x|Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
9541168|NCT03106766|Experimental|Acne cream 2x|Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
9541169|NCT03106831|Experimental|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
9541170|NCT03106831|Experimental|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
9541171|NCT03107000|Active Comparator|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
9541172|NCT03107000|Active Comparator|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
9541173|NCT03106675|Experimental|HIFU-treatment|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
9541174|NCT03106675|Active Comparator|Radiation therapy|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Varian Truebeam Radiotherapy System)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
9541175|NCT03106740|Experimental|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
9541176|NCT03106740|Placebo Comparator|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
9541177|NCT03106727|Active Comparator|Zalewa|Household Model Intervention introduced first - March 2017
9541178|NCT03106727|Active Comparator|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
9541179|NCT03106727|Active Comparator|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
9541180|NCT03106727|Active Comparator|Matope|Household Model Intervention to be introduced in December 2017
9541181|NCT03106727|Active Comparator|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
9541182|NCT03106727|Active Comparator|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
9541183|NCT03106558|Active Comparator|Manual instrument total knee replacement|
9541184|NCT03106558|Active Comparator|Robitic arm total knee replacement|
9541185|NCT03106597|Experimental|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1~2 week run-in period
9541186|NCT03106597|Active Comparator|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1~2 week run-in period
9541187|NCT03106818|Active Comparator|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
9541188|NCT03106818|Active Comparator|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
9541189|NCT03106818|Active Comparator|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
9541190|NCT03106662|Experimental|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
9541191|NCT03106649|Experimental|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
9541192|NCT03106649|No Intervention|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
9541193|NCT03106623|Experimental|ONO-8577 Arm|Oral administration of ONO-8577 once a daily for 4 weeks
9541194|NCT03106623|Active Comparator|Active Comparator Arm|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
9541195|NCT03106623|Placebo Comparator|Placebo Arm|Oral administration of Placebo once a daily for 4 weeks
9541196|NCT03106506|Experimental|Test-implant with graft|Patients who received a connective tissue graft around implants
9541197|NCT03106506|Active Comparator|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
9541198|NCT03106493||Primary|Singletons and 1 twin of each pair
9541199|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
9541200|NCT03106493||Tertiary|Higher order multiples and siblings
9541201|NCT03106584|Active Comparator|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
9541202|NCT03106584|Experimental|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
9541203|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
9616394|NCT02543073|Experimental|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
9541204|NCT03106610|Experimental|Nivolumab|"Participants receive Nivolumab by vein over about 60 minutes on Day 1 of Cycles 1-3 before scheduled surgery. Each study cycle is 14 days (2 weeks).~Questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery."
9541205|NCT03106571|Experimental|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
9541206|NCT03106571|Experimental|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
9541207|NCT03106571|Experimental|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
9541208|NCT03106571|Placebo Comparator|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
9541209|NCT03106532|Experimental|PHP-201 0.25% ophthalmic solution|PHP-201 0.25% ophthalmic solution, TID
9541210|NCT03106532|Experimental|PHP-201 0.5% ophthalmic solution|PHP-201 0.5% ophthalmic solution, TID
9541211|NCT03106532|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic solution, TID
9541212|NCT03106545|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves
9541213|NCT03106545|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves
9541214|NCT03106545|Sham Comparator|General anesthesia|General anesthesia
9541215|NCT03106454|Active Comparator|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
9541216|NCT03106454|Experimental|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
9541217|NCT03106467|Experimental|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy is performed through single-port which is installed in umbilicus.
9541218|NCT03106467|Active Comparator|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy is performed using conventional three-port technique which needs two additional ports outside umbilicus in addition to trans-umbilical port
9541219|NCT03106441|Experimental|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
9541220|NCT03106441|Active Comparator|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
9541221|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
9541222|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
9541223|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
9541224|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
9541225|NCT03106246||T2DM|Patients with established type II diabetes.
9541226|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
9541227|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
9541228|NCT03106363|Active Comparator|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
9541229|NCT03106363|Active Comparator|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
9541230|NCT03106363|Active Comparator|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
9541231|NCT03106363|Placebo Comparator|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
9541232|NCT03106519|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
9541233|NCT03106519|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
9541234|NCT03106428|Experimental|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
9541235|NCT03106428|Experimental|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
9541236|NCT03106428|Experimental|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
9541237|NCT03106285|Experimental|Lactobacillus reuteri DSM17938|Oil drops
9541238|NCT03106285|Placebo Comparator|Placebo|Oils drops
9541239|NCT03106376|Experimental|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
9541240|NCT03106389|Active Comparator|Misoprostol|This group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours.
9541241|NCT03106389|Experimental|Misoprostol/Transcervical catheter|This group will receive the same regimen, but will have in addition a transcervical balloon (Foleys') catheter that is inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix
9541242|NCT03106311|Active Comparator|Rupture of membranes group|Pregnant women with definite rupture of membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
9541243|NCT03106311|Active Comparator|Intact membranes group|Pregnant women with intact membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
9541244|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
9541245|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
9541246|NCT03106181|Active Comparator|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
9541247|NCT03106181|Experimental|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
9541248|NCT03106168|Experimental|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
9541249|NCT03106168|Experimental|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
9541250|NCT03106298||Iron Sucrose Treatment|All patients with iron deficiency anemia (those without CKD or HF, those with CKD only, those with HF only, and those with CKD/HF) will be given 5 weekly doses of 200 mg of intravenous iron sucrose.
9541251|NCT03106233||LTP flap breast reconstruction|All consecutive patients who underwent LTP flap breast reconstructions (unilateral, bilateral or stacked unilateral) between September 2012 and November 2016 at three centers in Maastricht, the Netherlands, and New York and New Orleans, the United States, were included. Autologous breast reconstruction was performed by using the upper lateral thigh region as a donor site.
9541252|NCT03106220|Active Comparator|home exercise|participate in home exercise program
9541253|NCT03106220|Placebo Comparator|standard care|encouraged to join physical therapy and walking goals
9541254|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
9541255|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
9541256|NCT03106194|Other|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.~Case management"
9541257|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
9541258|NCT03106064|Placebo Comparator|Usual Care Group|Intervention: Usual care
9541259|NCT03106064|Experimental|Intervention Group|Intervention:Promoting independence in self-care
9541260|NCT03106090|No Intervention|No SCP Control|Patients returning for early follow-up who did not receive SCP.
9541261|NCT03106090|No Intervention|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
9541262|NCT03106090|Experimental|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
9541263|NCT03106142|Other|Academic detailing visit arm|The GPs will receive an academic detailing visit by a medical visitor. GPs will receive information on the conservative evidence-based management of knee osteoarthritis with physiotherapy. The information will be summarized on a flyer for the GPs.
9541264|NCT03106142|No Intervention|control group|The two case vignettes will also be presented to GP who did not received the intervention.
9541265|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
9541266|NCT03106207|Other|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
9541267|NCT03105908|Other|Treatment|Internet delivered Acceptance and Commitment therapy, supported by a psychologist/psychology student under supervision.
9541268|NCT03105908|Other|Waiting list control condition|Participants receive no treatment for ten weeks, i.e. waiting list condition. Following post-assessment, the control condition receive unguided iACT (i.e. the same content and structure as iACT but without systematic therapist communication).
9541269|NCT03105830|Experimental|intervention and data collection|pain management by iv paracetamol
9541270|NCT03105986|Experimental|Treatment sequence AB|Participants will receive Treatment A (1000 milligram (mg) oral dose of JNJ-64041575 on Day 1) in Period 1, followed by Treatment B (1000 mg oral dose of JNJ-64041575 on Day 22 along with probenecid 500 mg on Day 21 to Day 28) in Period 2. A washout Period of 21 days will be maintained between each Period.
9541271|NCT03105986|Experimental|Treatment sequence BA|Participants will receive Treatment B (1000 mg oral dose of JNJ-64041575 on Day 1 along with probenecid 500 mg on Day -1 to Day 7) in Period 1, followed by Treatment A (1000 mg oral dose of JNJ-64041575 on Day 22) in Period 2. A washout Period of 21 days will be maintained between each Period.
9616395|NCT02543073|Active Comparator|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
9616396|NCT02542995|No Intervention|Non-intervention|Usual clinical conditions
9541272|NCT03106025|Experimental|Patients Receiving Ultrasound|Enrolled participants will receive a bedside ocular ultrasound of the affected eye and the ultrasound will be compared with the ophthalmologist diagnosis. The participant's medical record will also be reviewed for information regarding demographics, complications, and outcomes.
9541273|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
9541274|NCT03106116|Experimental|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
9541275|NCT03106116|Active Comparator|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
9541276|NCT03105856|Active Comparator|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
9541277|NCT03105856|Active Comparator|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
9541278|NCT03105856|No Intervention|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
9541279|NCT03105934|Experimental|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
9541280|NCT03105882|Experimental|Neuro-Spinal Scaffold|
9541281|NCT03105739|Experimental|Anesthetised|LMA removal once the halogenated anesthetic turned off
9541282|NCT03105739|Active Comparator|Awake|LMA removal once the patient fully regained consciousness
9541283|NCT03105752|Experimental|Research participants|"Each participant of a clinical trial completed the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) about its understanding of the information received. This questionnaire was retrieved immediately on the day of consent, with no possibility of referring to the content of information letter."
9541284|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
9541285|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
9541286|NCT03105960|Experimental|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
9541287|NCT03105960|Active Comparator|chlorhexidine mouthwash|"chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash~."
9541288|NCT03105661|Active Comparator|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
9541289|NCT03105661|No Intervention|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
9541290|NCT03105804|Experimental|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
9541291|NCT03105804|Experimental|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
9541292|NCT03105804|Experimental|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
9541293|NCT03105804|Experimental|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
9616397|NCT02542995|Other|Intevention|"QI interventions and got to see their own survey data - examples include:~Workflow redesign:~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms~Communication improvement:~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders~Chronic disease QI projects:~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
9616398|NCT02542982|Experimental|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
9616399|NCT02542982|Sham Comparator|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
9616400|NCT02542930|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
9616401|NCT02542917||All patients|IBDoc home test for faecal calprotectin
9616402|NCT02542904|Active Comparator|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
9616403|NCT02542904|Active Comparator|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
9616404|NCT02542878|Experimental|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.~A brief explanation of this self-application will be showed prior the intervention."
9616405|NCT02542878|Placebo Comparator|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
9616406|NCT02542852|Experimental|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
9541294|NCT03105791|No Intervention|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
10039805|NCT01847612|Experimental|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
10039806|NCT01847612|Active Comparator|methylene blue|injection of methylene blue during the surgery
10039807|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
9541295|NCT03105791|Active Comparator|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
9541296|NCT03105947|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
9541297|NCT03105947|Active Comparator|Butter|50g butter to be consumed daily for four weeks
9541298|NCT03105947|Active Comparator|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
9541299|NCT03106155|Experimental|vistusertib (AZD2014)|vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours
9541300|NCT03106012|Experimental|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
9541301|NCT03105674|Active Comparator|Standard Therapy|Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics) as a part of their peri-anal block prior to the surgery.
9541302|NCT03105674|Experimental|Multi-drug local anaesthetics|"Patients will receive a combination [Multi-drug local anesthetics (Combination)] of following drugs as a part of their peri-anal block prior to the surgery (multi-drug local anesthetics)~Ropivacaine 0.5% - 30 ml~Ketorolac 30mg/ml - 1 ml~Kenalog 10 mg/ml - 5 ml~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
9541303|NCT03105869|Experimental|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
9541304|NCT03105687|No Intervention|Control|"Participants in the Control group will receive standard Pharmaceutical Care according to the principles of Good Pharmaceutical Practice and national Slovak legislation requirements only.~Participants in the control group will also receive a welcome SMS one day after enrollment and an end-of-trial SMS three months after the enrollment. Additionally, prior to their scheduled follow-up visit (Visit 2), three months following the enrollment, trial pharmacists will call the participants to remind them of their follow-up visit."
9541305|NCT03105687|Experimental|Intervention|Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
9541306|NCT03105648||thyroid cancer|
9541307|NCT03105648||benign thyroid nodules|
9541308|NCT03105635|Other|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
9541309|NCT03105635|Other|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
9541310|NCT03105765|Active Comparator|Ketamine|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours."
9541311|NCT03105765|Placebo Comparator|Placebo|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Placebo (normal Saline) for 24 hours."
9541312|NCT03105973|Experimental|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
9541313|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
10039808|NCT01847651|Active Comparator|LOLA|"Other Names:~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
10039809|NCT01847651|Placebo Comparator|Placebo|
9541314|NCT03105544|Experimental|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
9541315|NCT03105544|No Intervention|Control|No intervention.
9621724|NCT02521922|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
9622107|NCT02518594|Active Comparator|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
10039810|NCT01847664|Experimental|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
10039811|NCT01847664|Experimental|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
10039812|NCT01847664|Placebo Comparator|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
9541316|NCT03105609||Naive wet age-related macular degeneration|Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.
9541317|NCT03105622|Experimental|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
9541318|NCT03105622|Experimental|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
9541319|NCT03105622|Experimental|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
9541320|NCT03105492||Pregnant women|Women who are pregnant
9541321|NCT03105570|Experimental|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
9541322|NCT03105505|Active Comparator|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
9541323|NCT03105505|Active Comparator|Synthomycine 5%,|Contains chloramphenicol 5%.
9541324|NCT03105505|Active Comparator|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
9541325|NCT03105596|Experimental|Chidamide plus DICE regimen|Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) regimen
9541326|NCT03105193|Experimental|Intraperitoneal Lignocaine|IP Lignocaine
9541327|NCT03105193|Experimental|Intravenous lignocaine|IV lignocaine
9541328|NCT03105440|Experimental|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
9541329|NCT03105440|Experimental|Virtual reality|"The software used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation Together with Federal University of Uberlândia. This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
9541330|NCT03105440|Experimental|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
9541331|NCT03105440|Experimental|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
9541332|NCT03105440|Experimental|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
9541333|NCT03105440|Experimental|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
9541334|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
9541335|NCT03105232||Group B|Buprenorfin
9541336|NCT03105232||Group C|Fentanyl
9541337|NCT03105232||Group D|Opioid rotation
9541338|NCT03105167|Experimental|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
9541339|NCT03105167|Experimental|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
9541340|NCT03105310|Active Comparator|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
9541341|NCT03105310|Experimental|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
9541342|NCT03105583||Pregnant women visiting the obstetrics department|
9541343|NCT03105219|Experimental|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
9541344|NCT03105219|Sham Comparator|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
9622108|NCT02518594|Placebo Comparator|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
9622109|NCT02518594|Active Comparator|Arabin Pessary|placement management from randomization to < 35 wks
9622110|NCT02518451|Experimental|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
9622111|NCT02518451|Active Comparator|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
9541345|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
9541346|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
9541347|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
9541348|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
9541349|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
9541350|NCT03105089|Active Comparator|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
9541351|NCT03105089|No Intervention|control|no intervention will be done
9541352|NCT03105284|Active Comparator|Liposuction of fat|The intervention examined is the extraction method by liposuction.
9541353|NCT03105284|No Intervention|Excision of fat|Control group
9541354|NCT03105141|Experimental|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
9541355|NCT03105141|Experimental|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
9541356|NCT03105141|Experimental|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
9541357|NCT03105141|Experimental|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
9541358|NCT03105115|Active Comparator|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
9541359|NCT03105115|Experimental|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
9541360|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
9541361|NCT03105349|Experimental|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
9541362|NCT03105245|Active Comparator|Short time interval + Normal ventilation|
9541363|NCT03105245|Active Comparator|Short time interval + Hyperventilation|
9541364|NCT03105245|Active Comparator|Long time interval + Normal ventilation|
9541365|NCT03105245|Active Comparator|Long time interval + Hyperventilation|
9541366|NCT03105336|Experimental|axicabtagene ciloleucel|
9541367|NCT03105375|Experimental|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
9541368|NCT03105375|Experimental|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
9541369|NCT03105375|Active Comparator|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
9541370|NCT03105466|Experimental|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
9541371|NCT03105102|Placebo Comparator|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
9541372|NCT03105102|Experimental|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
9541373|NCT03105102|Experimental|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
9541374|NCT03105102|Experimental|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants will receive double-blind subcutaneous (SC)risankizumab dose 1 and intravenous placebo at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
9541375|NCT03105102|Experimental|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants will receive double-blind subcutaneous placebo and intravenous risankizumab dose 3 at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
9541376|NCT03105102|Experimental|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or other AbbVie risankizumab Crohn's disease study or M16-006 or M15-991 without endoscopy will receive open-label risankizumab dose 1 or dose 2 depending on their preceding study beginning at Week 56.
9541377|NCT03105102|Experimental|Risankizumab On-Body Injector and Open Label (Sub-Study 4)|Participants in Sub-study 3 who meet eligible criteria for Sub-study 4 will receive risankizumab dose 1 or dose 2 via on-body injectors on Weeks 0,8 and 16. Beginning Week 24, participants will receive risankizumab dose 1 or dose 2 via pre-filled syringes Q8W.
9541378|NCT03105154|Experimental|Prevena Dressing|Groin dressed with Prevena
9541379|NCT03105154|Active Comparator|Conventional Dressing|Groin dressed with conventional bandage
9541380|NCT03105076|Experimental|DAs group|Shared decision making using decision aids
9541381|NCT03105076|No Intervention|Control group|Standard oral explanation guided with booklets
9541382|NCT03105206||Low Pole Renal Calculus|patients with low pole renal calculus who are suitable to treat by flexible ureteroscopy
9541383|NCT03105063|Experimental|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
9541384|NCT03105050||Countries in Europe|All 51 countries will fill out their unique data on access to bariatric surgery in Europe
9541385|NCT03105037||Study group|CTM assessed with supraglottic airway in situ and without
9541386|NCT03105024|Experimental|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
9541387|NCT03105024|Active Comparator|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
9541388|NCT03105024|No Intervention|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
9541389|NCT03104881|Experimental|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
9541390|NCT03104881|Experimental|2D end-effector type robot|2 dimension end-effector type upper extremity robot
9541391|NCT03104946||Bronchopulmonary Dysplasia|
9541392|NCT03104946||Retinopathy|
9541393|NCT03104946||Severe Retinopathy|
9541394|NCT03104946||Neonatal Necrotizing Enterocolitis|
9541395|NCT03104946||Brain injury|
9541396|NCT03104946||sepsis|
9541397|NCT03104946||Patent Ductus Arteriosus|
9541398|NCT03104946||Respiratory Distress Syndrome|
9541399|NCT03104933||Patients with septic shock|patients in septic shock admitted to the ICU
10039813|NCT01847677|Active Comparator|Paclitaxel & Carboplatin|"Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Surgery~Post-Operative treatment~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Bevacizumab 15 mg/Kg i.v. first day1~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
9541400|NCT03104920|Experimental|ERAS program|We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.
9541401|NCT03104920|Active Comparator|Traditional treatment|We give routine clinic practices for the treatment of HCC.
9541402|NCT03104777|No Intervention|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
9541403|NCT03104777|Experimental|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
9541404|NCT03104972|Experimental|tDCS - placebo|tDCS-placebo (sham) group to receive either transcranial direct stimulation (tDCS) or matching placebo (sham( during 5 following days (one session each day). After a one week break, there will be a crossover between the control group and the sham group: those we received tDCS in the 1st week will get sham, while those who received sham in the 1st week will received tDCS at the 3rd week.
9541405|NCT03104972|Experimental|tRNS - placebo|trans cranial random stimulation (tRNS)-sham group, who will receive the same type of intervention with the same intervals as above but with tRNS instead of tDCS.
9541406|NCT03104972|Experimental|tDCS-tRNS|tDCS-tRNS group. Here the same intervention as above will be provided with the same intervals, but real tDCS and real tRNS will be provided in a counterbalanced fashion. This would allow to compare the different treatment in a within-subject design, as well as to compare the effect of those to sham stimulation in the first two groups in a between-subject design.
9541407|NCT03105011|Experimental|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
9541408|NCT03104959|Placebo Comparator|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
9541409|NCT03104959|Experimental|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
9541410|NCT03104998|Other|coenzyme Q10|Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
9541411|NCT03104660|Experimental|CE certified mitral valve repair systems|CE certified transcatheter mitral valve repair systems
9541412|NCT03104790|Experimental|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
9541413|NCT03104790|Experimental|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
9541414|NCT03104764|Active Comparator|Scalpel|Frenotomy performed with conventional scalpel
9541415|NCT03104764|Experimental|Er:YAG laser|Frenotomy performed with Er:YAG laser
9541416|NCT03104803|Experimental|Long-term PAS|The intervention is given to one hand only
9541417|NCT03104803|No Intervention|No intervention|Contralateral hand of the same patient
9541418|NCT03104829|Active Comparator|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
9541419|NCT03104829|Experimental|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
9541420|NCT03104855|Experimental|Single pharmacokinetics arm|
9541421|NCT03104621|Experimental|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
9622112|NCT02518373|Experimental|G17DT & Omeprazole|"A 14-day washout period~An Omeprazole Treatment Period 1 (Day -15 to Day -1)~A G17DT treatment period (Day 0 to Day 85)~An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
9541422|NCT03104621|Experimental|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
9541423|NCT03104582|Experimental|Biliary drainage 1|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage
9541424|NCT03104582|Active Comparator|Biliary drainage 2|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage
9541425|NCT03104634|Experimental|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
9541426|NCT03104634|Placebo Comparator|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
9541427|NCT03104686|Active Comparator|Bread|Bread (50g available carbohydrate, 109 g) eaten with 500 mL of water
9541428|NCT03104686|Experimental|Short pasta (dry)|Cooked penne (142 g; 71 g uncooked) eaten with 500 mL of water
9541429|NCT03104686|Experimental|Long pasta (dry)|Cooked spaghetti (142 g; 71 g uncooked) eaten with 500 mL of water
10039814|NCT01847677|Experimental|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.~c) Postoperative treatment~Both arms:~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
10039815|NCT01847690|Placebo Comparator|Placebo|Treatment B is placebo (2 placebo tablets).
9541430|NCT03104686|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
9541431|NCT03104491|Experimental|Inotuzumab Ozogamicin|"Phase I:~A maximum of 12 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for ALL participants is 0.1-0.6mg/m^2 and for NHL participants 0.2-0.8mg/m^2~Dosing in the NHL cohort will start at Dose Level 0 (0.3mg/m^2) or one dose level below the ALL cohort maximum tolerated dose (MTD), whichever is higher.~Phase II:~ALL and NHL participants: Will be enrolled until all Phase I ALL/NHL participants (respectively) have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. Repeat cycles every 28 days for up to 12 cycles"
10039816|NCT01847690|Active Comparator|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
10039817|NCT01847703|Experimental|Robotic surgery|Experimental method, to be compared with standard care
10039818|NCT01847703|Active Comparator|Abdominal surgery|Conventional open surgery (laparotomy)
10039819|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
10039820|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
10039821|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
10039822|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
10039823|NCT01847742|Experimental|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
9541432|NCT03104608|Active Comparator|Automatic Self Transcending Meditation|Participants in the ASTM group will undergo training in groups of 10 by certified teachers. Further, the following self-rated scales will be administered by a trained rater at the fourth ASTM session (week 0) as well as at weeks 4, 8, 12, and 24: Time Trade-off (TTO), Visual Function Questionnaire (VFQ-25), the Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder (GAD-7).
9541433|NCT03104608|Placebo Comparator|Treatment as Usual|Participants will continue to receive their treatment as usual. The following self-rated scales will be administered by a trained rater at weeks 0, 4, 8, 12 and 24: TTO, VFQ-25, PHQ-9, and GAD-7.
9541434|NCT03104452||Pregnant Smokers|Participants are pregnant women who smoked in the six months prior to their pregnancy.
9541435|NCT03104387|Experimental|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
9541436|NCT03104387|Sham Comparator|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
9541437|NCT03104426|Active Comparator|Darbepoetin alfa group|Group treated with darbepoetin alfa (Aranesp) 10microg/kg once a week for a period of 8 weeks.
9541438|NCT03104426|No Intervention|Control group|"Standard care which involves close monitoring of hemoglobin levels and if necessary, top-up red cell transfusion."
9541439|NCT03104439|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously 3 times per cycle~Ipilimumab will be administered intravenously once per cycle~Radiation Therapy will be administered per hospital standard"
9541440|NCT03104595|Experimental|Cohort 1|EC-18 500 mg
10039824|NCT01847742|No Intervention|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
9541441|NCT03104595|Experimental|Cohort 2|EC-18 1000 mg
9541442|NCT03104595|Experimental|Cohort 3|EC-18 1500 mg
9541443|NCT03104595|Experimental|Cohort 4|EC-18 2000 mg
9541444|NCT03104348|Other|COPD screening|
10039825|NCT01847768|Experimental|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
10039826|NCT01847768|Active Comparator|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
10039827|NCT01847781|Active Comparator|IgG-deficient patients|Prevenar13
9541445|NCT03104894|Experimental|Study Group|The study group will receive meibomian glands massage and artificial drops PRN
9541446|NCT03104894|Sham Comparator|Control Group|The control group will receive sham meibomian glands massage and artificial drops PRN.
9541447|NCT03104504|No Intervention|No Intervention|Baseline Retrospective Chart Reviews that are conducted on subjects for the one year period prior to the implementation of the study will serve as the control.
9541448|NCT03104504|Other|Intervention|"The intervention targets will be the following suicide-related clinician behaviors.~suicide risk screening~safety planning~means restriction counseling~Post-acute care follow-up calls A Lean Implementation Strategy: The Implementation of the intervention targets guided by Lean; is expected to increase suicide-related clinician behaviors"
9541449|NCT03104712|Other|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
9541450|NCT03104712|Active Comparator|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
9541451|NCT03104712|Active Comparator|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
9541452|NCT03104712|Active Comparator|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
9541453|NCT03104712|Active Comparator|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
9541454|NCT03104712|Active Comparator|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
10039828|NCT01847781|Active Comparator|Healthy controls|Prevenar13
10039829|NCT01847794|Experimental|chemotheropy|
10039830|NCT01847807|Active Comparator|High-dose Astragalus group|treatment with 10 gram astragalus
9541455|NCT03104712|Active Comparator|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
9541456|NCT03104712|Other|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
9541457|NCT03104712|Other|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
9541458|NCT03104465|Experimental|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
9541459|NCT03104361|Experimental|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
9541460|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
9541461|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
9541462|NCT03104231|Experimental|study group|All the patients will be shown three-dimensional (3D) movie.
9541463|NCT03104335|Experimental|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
9541464|NCT03104907|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
9541465|NCT03104530||Brown crabmeat consumers|Those habitually consuming 40 grams or more of brown crab meat each week.
9541466|NCT03104530||Control|Those consuming less than 40 grams of brown crabmeat a year, or no brown crabmeat.
9541467|NCT03104309|Other|Levonorgestrel intrauterine system|
9541468|NCT03104140|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
9541469|NCT03104140|Active Comparator|Thiopental group|2 mg/Kg thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
10039831|NCT01847807|Active Comparator|Low-dose Astragalus group|treatment with 5 gram astragalus
10039832|NCT01847807|No Intervention|MS control|
9541470|NCT03104127|Experimental|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
9541471|NCT03104127|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
9541472|NCT03104127|No Intervention|Usual care|Have completed normal NHS therapy and no longer (> 6 months) receive active physiotherapy.
9541473|NCT03104179|Experimental|Treatment|CPB with Cytosorb
9541474|NCT03104179|No Intervention|Control|CPB without Cytosorb (Control)
9541475|NCT03104218|Experimental|tDCS group|tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training). The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles), contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
9541476|NCT03104218|Sham Comparator|Placebo group|"The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS."
9541477|NCT03104166|Experimental|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
9541478|NCT03104166|Active Comparator|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
9541479|NCT03104153|No Intervention|Output-based|
9541480|NCT03104153|Active Comparator|Early-removal|
9541481|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
9541482|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
9541483|NCT03104114|Placebo Comparator|Historical Control|Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
9541484|NCT03104114|Experimental|Pharmacist-intervention|In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
9616407|NCT02542891|Experimental|Blended CBT|"Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with smart phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 16 sessions (8 online and 8 face-to-face), once a week. The online platform is called Moodbuster.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
9616408|NCT02542891|Active Comparator|Treament as Usual (TAU)|"In order to increase the comparability between the two arms, we defined TAU as a traditional face to face CBT of 16 sessions. These sessions will be administered over a course of 16 weeks.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
9616409|NCT02542709|Active Comparator|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
9616410|NCT02542709|Sham Comparator|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
9616411|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
9616412|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
9616413|NCT02542670||control group|Genetic: Whole genome Sequencing
9616414|NCT02542722|Active Comparator|Control|General dietary and physical exercise recommendations
9616415|NCT02542722|Experimental|Intervention|Intensive intervention on dietary and physical exercise habits.
9616416|NCT02542735||Spanish di@bet.es cohort|Representative of Spanish population
9616417|NCT02542800|Experimental|Healthy participants|
9616418|NCT02542553|Experimental|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
9616419|NCT02542579||Subjects for pyrosequencing analysis|Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis
9616420|NCT02542748|Experimental|norepinephrine|norepinephrine is injected after spinal anesthesia
9616421|NCT02542748|Other|ephedrine|ephedrine is injected after spinal anesthesia
9616422|NCT02542566|Active Comparator|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
9616423|NCT02542566|Active Comparator|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
9616424|NCT02542787|Experimental|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
9541485|NCT03104088||SPG4 patients|
9541486|NCT03104088||Healthy controls|
10039833|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
9541487|NCT03104010|Experimental|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
9541488|NCT03104010|Experimental|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
9541489|NCT03103893|Experimental|Rapamycin|Rapamycin
9541490|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
9541491|NCT03104101|Active Comparator|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
9541492|NCT03104101|Active Comparator|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
9541493|NCT03103828|Active Comparator|Computer-tailored intervention|
9541494|NCT03103828|Active Comparator|Motivational Interviewing|
9541495|NCT03103828|Active Comparator|Motivational Enhancement Therapy|
9541496|NCT03103828|No Intervention|Control Group|
9541497|NCT03103997|Active Comparator|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
9541498|NCT03103997|Experimental|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
9541499|NCT03103997|Experimental|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
9541500|NCT03103984|Experimental|Control|The volunteers (overweight and obese) will receive nutritional counseling and a weight loss diet.
9541501|NCT03103984|Experimental|Immunosuppressed patients|The volunteers (liver transplantation) will receive nutritional counseling and a weight loss diet.
9541502|NCT03103802|Experimental|Intra-oral scanning|
9541503|NCT03103802|Experimental|extra-oral scanning of the plaster model obtained via alginate|
9541504|NCT03103802|Experimental|extra-oral scanning of plaster model obtained via rubber base|
9541505|NCT03103802|Experimental|extra-oral scanning of the rubber base impression|
9541506|NCT03103802|Experimental|extra-oral scanning of the alginate impression|
9541507|NCT03103854|Active Comparator|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
9541508|NCT03103854|Experimental|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
9541509|NCT03103854|Experimental|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
9541510|NCT03103854|Experimental|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
9541511|NCT03104049|Active Comparator|the PD NMT Group|the NMT Group were treated with NMT
9541512|NCT03104049|No Intervention|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
9541513|NCT03103958|Active Comparator|probiotic|Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
10039834|NCT01847833||Patients with brain tumors|
9541514|NCT03103958|Placebo Comparator|Placebo|Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
9541515|NCT03103932|No Intervention|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
9541516|NCT03103932|Experimental|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
9541517|NCT03104036|Active Comparator|Mesalazine enema|Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.
9541518|NCT03104036|Experimental|Faecal bacterial transplantation enema|Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.
9541519|NCT03104062|Other|Ticagrelor|Patients will be randomized to have Ticagrelor 90mg BID
9541520|NCT03104062|Other|Clopidogrel|Patientes will be randomized to have Clopidogrel 75mg once a day
9541521|NCT03103880|Experimental|Medication Adherence and Pulmonary Function Tests|
9541522|NCT03103880|Experimental|Medication Adherence and Peak Flow Measurements|
9541523|NCT03103776|Other|Patients who have Graves disease|
9541524|NCT03103776|Other|Patients having a goiter|
9541525|NCT03103815|Experimental|experimental group|Experimental group will receive Amivita.
9616425|NCT02542787|Placebo Comparator|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
10039835|NCT01847846|Experimental|Prototype mask|Participants will be randomised to trial the new prototype mask for 4 and 8 weeks. The prototype mask will be used in conjunction with the participant's home CPAP machine. The participant's will be instructed to use the prototype mask every night until the completion of the trial. No changes will be made to the participant's prescribed CPAP settings.
9541526|NCT03103737|Experimental|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
9541527|NCT03103737|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
9541528|NCT03103789||GERD patients|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement and have been diagnosed with GERD will have mucosal impedance measured by single catheter and balloon assembly.
9541529|NCT03103789||control|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement will have mucosal impedance measured by single catheter and balloon assembly.
9541530|NCT03104023|Active Comparator|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
9541531|NCT03104023|Experimental|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
9541532|NCT03103867|Experimental|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
9541533|NCT03103867|Active Comparator|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
10039836|NCT01847872|Experimental|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
10039837|NCT01847872|Experimental|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
9541534|NCT03103672||Groupe I|Patients who will receive inhalation anesthesia
10039838|NCT01847872|Experimental|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
10039839|NCT01847872|Experimental|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
10039840|NCT01847872|Experimental|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
10039841|NCT01847872|Experimental|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
10039842|NCT01847872|Experimental|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
10039843|NCT01847872|Experimental|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
10039844|NCT01847898|Experimental|Vertebral Body Stenting (VBS)|
10039845|NCT01847898|Experimental|Balloon Kyphoplasty|
10039846|NCT01847911|Experimental|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
10039847|NCT01847911|Active Comparator|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
10039848|NCT01847924|Active Comparator|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
10039849|NCT01847924|Placebo Comparator|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
10039850|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
9541535|NCT03103672||Groupe 2|Patients who will receive total intravenous anesthesia
9541536|NCT03103594|Active Comparator|DMSO alone|Half of the patients will undergo DMSO instillation
9541537|NCT03103594|Experimental|DMSO with Botox|The other half will be randomized to DMSO mixed with 200U of botulinum toxin instillation
9616426|NCT02542618|Experimental|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
10039851|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
10039852|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
10039853|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
10039854|NCT01847937||Hereditary axonal neuropathic|
10039855|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
10039856|NCT01847950|Experimental|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
10039857|NCT01847950|Placebo Comparator|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
10039858|NCT01847963|Experimental|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
10039859|NCT01847963|Experimental|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
10039860|NCT01847963|Experimental|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
10039861|NCT01847976|Experimental|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
10039862|NCT01847989|Experimental|rFXIII|
10039863|NCT01847989|Placebo Comparator|Placebo|
10039864|NCT01848002|Experimental|rFXIII|
10039865|NCT01848002|Placebo Comparator|Placebo|
10039866|NCT01848015||CTCs positive|
9541538|NCT03103711|Experimental|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
9541539|NCT03103711|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
9541540|NCT03103698|Other|Monitoring of perioperative analgesia by the ANI device|
9541541|NCT03103698|Other|conventional monitoring based on hemodynamic variations.|
9541542|NCT03103685|Placebo Comparator|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
9541543|NCT03103685|Experimental|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
9541544|NCT03103724|Experimental|Enzalutamide|All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
9541545|NCT03103659|Experimental|Elderly patient with cancer living in a nursing home|
9541546|NCT03103529|Experimental|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
9541547|NCT03103529|Active Comparator|late rehab|Children will begin active rehabilitation 4 weeks post-injury
9541548|NCT03103464|Experimental|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
9541549|NCT03103464|Active Comparator|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
9541550|NCT03103516|Experimental|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
9541551|NCT03103516|Experimental|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
9541552|NCT03103555|Experimental|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
9541553|NCT03103412|Experimental|TD-3504 Low-Dose|6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
9541554|NCT03103412|Experimental|TD-3504 Mid-Dose|6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
10039867|NCT01848028||Fumaric acid ester|Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed
10039868|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
10039869|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
10039870|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
10039871|NCT01848028||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
10039872|NCT01848028||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
10039873|NCT01848028||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
10039874|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
10039875|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
10039876|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
10039877|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
10039878|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
10039879|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
10039880|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
10039881|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
10039882|NCT01848080|Experimental|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
10039883|NCT01848080|Active Comparator|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
10039884|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation~sputum collection"
10039885|NCT01848106|Active Comparator|Bivalirudin|Bivalirudin bolus and infusion
10039886|NCT01848106|Experimental|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
10039887|NCT01848119|Active Comparator|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
10039888|NCT01848119|Placebo Comparator|Placebo|lactose capsules
10039889|NCT01848132|Active Comparator|R-CHOP|"6 cycles every 21 days.~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Vincristine: intravenous, 1,4 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
9541555|NCT03103412|Experimental|TD-3504 High-Dose|6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
9541556|NCT03103412|Placebo Comparator|Placebo|6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.
9541557|NCT03103568|Experimental|Arm A - CYP substrates|"In Arm A of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances tolbutamide, metoprolol and chlorzoxazone will be investigated. These substances are metabolized by CYP2C9, CYP2D6 and CYP2E, respectively.~A cocktail of the substances tolbutamide, metoprolol and chlorzoxazone will be given as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic serum concentrations level is reached. Serum and urine concentrations of nitisinone will then be investigated for 24 hours, followed by giving the substances tolbutamide, metoprolol and chlorzoxazone as a single dose together with nitisinone to investigate the PK during interaction."
9541558|NCT03103568|Experimental|Arm B - OAT substrates|"In Arm B of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances furosemide in the blood, which is transported by the transporter proteins OAT 1 and OAT 3, will be investigated.~Furosemide will be given intravenously as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic dose is reached. Furosemide will then be given as a single dose together with nitisinone to investigate the PK during interaction."
9541559|NCT03103451|Experimental|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
9541560|NCT03103451|Experimental|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
9541561|NCT03103451|Experimental|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
9541562|NCT03103451|Experimental|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
9541563|NCT03103451|Experimental|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
9541564|NCT03103451|Experimental|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
9541565|NCT03103451|Experimental|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
9541566|NCT03103646|Experimental|Lu AF35700|Day 1: Single dose of Lu AF35700. Extensive metabolisers (EMs): 10mg. Poor metabolisers (PMs): 5 mg
9541567|NCT03103646|Experimental|Lu AF35700 AND itraconazole|Days 29 to 31: once-daily dosage of 200 mg itraconazole. Day 32: Single dose of Lu AF35700 (EMs: 10 mg, PMs: 5 mg) and 300 mg itraconazole Days 33 to 42: once-daily dosage of 200 mg itraconazole
9541568|NCT03103633|Experimental|Individualized Goal-Directed Therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.
9541569|NCT03103633|Sham Comparator|Controlled|no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
9541570|NCT03103295|Experimental|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
9541571|NCT03103269|Experimental|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
9541572|NCT03103269|Experimental|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
9541573|NCT03103269|Experimental|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.~This group does not receive the Challenge! Small Group Intervention.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
9541574|NCT03103269|No Intervention|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
9541575|NCT03103204|Experimental|Normal weight full-mouth disinfection|"Normal weight (body mass index 18.5 - 24.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
10039890|NCT01848132|Experimental|B-R-CAP|"6 cycles every 21 days~Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
9541576|NCT03103204|Experimental|Overweight full-mouth disinfection|"Overweight (body mass index 25.0 - 29.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
9541577|NCT03103204|Experimental|Obesity I full-mouth disinfection|"Obesity I (body mass index 30.0 - 34.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
10039891|NCT01848171|Active Comparator|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
10039892|NCT01848171|No Intervention|blank|No intervention
10039893|NCT01848197|Experimental|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
10039894|NCT01848197|Active Comparator|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
10039895|NCT01848223||late menopause|
10039896|NCT01848236|Experimental|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
9616427|NCT02542618|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
10039897|NCT01848236|Experimental|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
10039898|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
10039899|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
10039900|NCT01848262|Active Comparator|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
10039901|NCT01848262|Experimental|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
10039902|NCT01848275|Active Comparator|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
10039903|NCT01848275|Experimental|Group 2|group 2 received ablation at proximal of bilateral renal arteries
10039904|NCT01848301|Experimental|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
10039905|NCT01848314|Experimental|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
10039906|NCT01848327|Experimental|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
10039907|NCT01848327|Placebo Comparator|Placebo|Placebo (40 gram packet orally once a day for 90 days)
10039908|NCT01848340|Experimental|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
10039909|NCT01848340|Experimental|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
10039910|NCT01848340|Placebo Comparator|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
10039911|NCT01848379|Experimental|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises~FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
10039912|NCT01848379|Active Comparator|Full Mouth Deconatamination(FD)|"FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
10039913|NCT01848379|No Intervention|No Treatment|Healthy individuals to be monitored cross-sectional
10039914|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
10039915|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
10039916|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
9541578|NCT03103204|Experimental|Obesity II full-mouth disinfection|"Obesity II (body mass index 35.0 - 39.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
9541579|NCT03103204|Experimental|Obesity III full-mouth disinfection|"Obesity III (body mass index ≥ 40.0 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
9541580|NCT03103399|Experimental|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
9541581|NCT03103399|Experimental|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
9541582|NCT03103399|Experimental|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
9541583|NCT03103399|Active Comparator|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
9541584|NCT03103399|Placebo Comparator|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
9541585|NCT03103217|Experimental|Brief CBT intervention|
9541586|NCT03103334|Experimental|Experimental A|Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh
9541587|NCT03103334|Experimental|Experimental B|Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh
9541588|NCT03103334|Experimental|Experimental C|Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen
9541589|NCT03103334|Experimental|Experimental D|Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen
9541590|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
9541591|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
9541592|NCT03103191||Case|"50 subjects with fibrosing interstitial lung disease.~50 subjects with pulmonary fibrosis secondary to collagen diseases."
9541593|NCT03103191||Control|"75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.~75 subjects with collagen disease without pulmonary fibrosis."
9541594|NCT03103230|Experimental|Motor Evoked Potentials|Patients with aphasia after a stroke
9541595|NCT03103152|Experimental|High dose Aspirin & Vitamin D|Aspirin high dose (300mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
9541596|NCT03103152|Experimental|High dose Aspirin, Vitamin D placebo|high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
10039917|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
10039918|NCT01848470|Experimental|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
10039919|NCT01848470|Experimental|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
10039920|NCT01848470|Experimental|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
10039921|NCT01848470|Experimental|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
10039922|NCT01848470|Placebo Comparator|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
10039923|NCT01848470|Placebo Comparator|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
10039924|NCT01848470|Placebo Comparator|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
10039925|NCT01848470|Placebo Comparator|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
10039926|NCT01848496|Experimental|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
10039927|NCT01848496|Active Comparator|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
10039928|NCT01848509|No Intervention|Without telemonitoring|Without teletransmission of alerts
10039929|NCT01848509|Experimental|With telemonitoring|With teletransmission of alerts
10039930|NCT01848535|Placebo Comparator|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
9541597|NCT03103152|Experimental|Low dose Aspirin , Vitamin D|Low dose aspirin (100mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
9541598|NCT03103152|Placebo Comparator|Low dose Aspirin, Vitamin D placebo|Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
9541599|NCT03103152|Experimental|Aspirin Placebo, Vitamin D|Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil
9541600|NCT03103152|Experimental|Aspirin placebo, Vitamin D placebo|Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil
9541601|NCT03103373|Active Comparator|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
9541602|NCT03103373|Active Comparator|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
9541603|NCT03103074|Experimental|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
9541604|NCT03103074|Placebo Comparator|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
9541605|NCT03103308|Experimental|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
10039931|NCT01848535|Placebo Comparator|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
9541606|NCT03103308|Experimental|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
9541607|NCT03103035|Experimental|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
9541608|NCT03103035|No Intervention|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
9541609|NCT03103386|Experimental|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
9541610|NCT03103386|Placebo Comparator|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
9541611|NCT03103243|Other|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
9541612|NCT03103126|No Intervention|Control|Standard care.
9541613|NCT03103126|Experimental|Combined resistance exercise and walking|Combined resistance exercise and walking.
9541614|NCT03103256|Experimental|YHP1701|PO, Once daily (QD), 8 weeks
9541615|NCT03103256|Active Comparator|YHR1703|PO, Once daily (QD), 8 weeks
9541616|NCT03103256|Active Comparator|YHR1704|PO, Once daily (QD), 8 weeks
9541617|NCT03102892|Active Comparator|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
9541618|NCT03102892|Experimental|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
9541619|NCT03103009|Experimental|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
9541620|NCT03103022|Experimental|Interventional Group|Preterm infants who met the eligibility criteria will receive both oral acetaminophen and ibuprofen. Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses and oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
10039932|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
9541621|NCT03103048|Active Comparator|Group 1|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages (start); 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage.
9541622|NCT03103048|Placebo Comparator|Group 2|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo (start); 3 - With bandage; 4 - With tensioned bandage.
9541623|NCT03103048|Active Comparator|Group 3|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage (start); 4 - With tensioned bandage.
10039933|NCT01848574|No Intervention|Usual procedure|Investigators will give medical information to their patients as usual.
10039934|NCT01848574|Experimental|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.~Deliver the following information in the orde of the items below:~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection~Briefly additional tests:~Radio show~Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
10039935|NCT01848587|Experimental|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
10039936|NCT01848587|Active Comparator|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
9541624|NCT03103048|Active Comparator|Group 4|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage (start).
9541625|NCT03102983|Experimental|Healthy Volonteers|
10039937|NCT01848600|Experimental|abstract without limitation section|the experimental arm is abstract without the limitation section
9541626|NCT03102944||healthy volunteers|no intervention, extra blood tube taken with blood donation at bloodbank and blood is tested on IVD away from patient.
9541627|NCT03102931|Experimental|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
9541628|NCT03102853|Active Comparator|Nordic diet|
10039938|NCT01848600|Other|abstract with limitation section|the control arm is abstract with the original limitation section
10039939|NCT01848613|Experimental|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
10039940|NCT01848613|Experimental|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
10039941|NCT01848639|Active Comparator|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
10039942|NCT01848639|Placebo Comparator|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
10039943|NCT01848652|Experimental|MYOCET|
10039944|NCT01848665|Experimental|Drug|Indomethacin, 1.2 mg kg 1 dose
10039945|NCT01848665|Placebo Comparator|Placebo|generic flour placebo capsule
10039946|NCT01848691|Experimental|Sickle Cell|This arm will include 20 children with sickle cell anemia
10039947|NCT01848691|Active Comparator|Control|This arm will include 20 children without sickle cell anemia
10039948|NCT01848704|Active Comparator|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
10039949|NCT01848704|Experimental|abstract without spin|The abstracts with spin were systematically rewritten without spin
9541629|NCT03102853|Other|Control diet|
10039950|NCT01848717|Experimental|Lift thread|
9541630|NCT03102866|Active Comparator|Arm I (usual care)|Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
9541631|NCT03102866|Experimental|Arm II (aerobic and strength training exercise)|Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
9541632|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 6-48 months who have previously received PCV13
10039951|NCT01848730|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
10039952|NCT01848730|Placebo Comparator|Placebo|Placebo tid 21 days
10039953|NCT01848743|Active Comparator|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
10039954|NCT01848743|Placebo Comparator|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
10039955|NCT01848769|Experimental|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
10039956|NCT01848769|Active Comparator|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
10039957|NCT01848782|Experimental|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
10039958|NCT01848782|Active Comparator|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
9541633|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
10039959|NCT01848795|Experimental|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
10039960|NCT01848795|Active Comparator|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
10039961|NCT01848808|Experimental|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
10039962|NCT01848808|Placebo Comparator|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
9541634|NCT03102957|Experimental|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
9541635|NCT03102957|Other|Healthy volunteers|1 functional MRI with memory and language tasks
10039963|NCT01848860|Sham Comparator|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
10039964|NCT01848860|Experimental|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
10039965|NCT01848873|Experimental|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
9541636|NCT03102827|Active Comparator|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
9541637|NCT03102827|Placebo Comparator|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
9541638|NCT03102515|Other|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
9541639|NCT03102515|Other|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
9541640|NCT03102788|Active Comparator|Control|Patients in the control group will receive their first consultation in specialist health care by a rheumatologist. Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid. The rheumatologist may also refer participants to occupational therapy if needed.
9541641|NCT03102788|Experimental|Intervention|Patients in the intervention group will receive their first consultation in specialist health care by an occupational therapy specialist. Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
9541642|NCT03102814|Active Comparator|Current rehabilitation program|The control group will receive the rehabilitation program currently provided at each participating centre at the start of the study.
9541643|NCT03102814|Experimental|BRIDGE rehabilitation program|In intervention phase, the BRIDGE program will be added to the current program.
9541644|NCT03102567|Experimental|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
9541645|NCT03102567|Placebo Comparator|placebo|oral hard gelatin capsules containing placebo for q.d. administration
9541646|NCT03102567|Experimental|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
9541647|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
9541648|NCT03102632|No Intervention|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
9541649|NCT03102632|Experimental|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
9541650|NCT03102502|Experimental|Enhanced External Counterpulsation|Patients receive a total of 35-36 hours of EECP treatment on top of guideline- driven standard medical therapy for coronary heart disease, 1-hour sessions every day over a 7-week period.
9541651|NCT03102502|Active Comparator|Control|Patients receive guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention.
9541652|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
9541653|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
9541654|NCT03102749||Normal weight|Included patients with a BMI < 25 will be part of this group.
9541655|NCT03102749||Overweight|Included patients with a BMI >= 25 and <30 will be part of this group.
9541656|NCT03102749||Obese|Included patients with a BMI >= 30 will be part of this group.
9541657|NCT03102606|Active Comparator|Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin|
9541658|NCT03102606|Experimental|Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim|
9541659|NCT03102658|Experimental|Obese subjects 100mg|8 subjects with a BMI>40kg/m2 will receive 100mg Micafungin
9541660|NCT03102658|Active Comparator|Obese subjects 200mg|8 subjects with a BMI>40kg/m2 will receive 200mg Micafungin
9541661|NCT03102658|Active Comparator|non-obese subjects|8 non obese subjects with a BMI >18.5 and <25 kg/m2 will receive 100mg Micafungin
9541662|NCT03102684|No Intervention|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
10039966|NCT01848873|Experimental|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
10039967|NCT01848873|Active Comparator|amolodipine|5 mg amlodipine, once daily for 8 weeks.
10039968|NCT01848886|Other|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
10039969|NCT01848886|Other|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
10039970|NCT01848886|Other|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
9541663|NCT03102684|Experimental|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
9541664|NCT03102684|Experimental|High exposure|Secondhand exposure to e-cigarette aerosols (high)
9541665|NCT03102489|Experimental|BP101|Treatment with BP101
9541666|NCT03102489|Placebo Comparator|Placebo|Treatment with placebo
10039971|NCT01848886|Other|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
10039972|NCT01848912||Bone Marrow Transplant Patients|
9541669|NCT03102775|Experimental|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
9541670|NCT03102775|Active Comparator|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
9541671|NCT03102671|Experimental|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
9541672|NCT03102671|Experimental|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
9541673|NCT03102801|Active Comparator|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
9541674|NCT03102801|Active Comparator|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
9541675|NCT03102476|Other|Patients with Type 1 Diabetes|Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
9541676|NCT03102593|Experimental|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
9541677|NCT03102593|Experimental|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
9541678|NCT03102593|Placebo Comparator|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
9541679|NCT03102463|Sham Comparator|Water Control|
9541680|NCT03102463|Active Comparator|Milk derived hydrolysate|
9541681|NCT03102463|Active Comparator|Parent Protein|
9541682|NCT03102385|Experimental|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
9541683|NCT03102385|Placebo Comparator|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
9616428|NCT02542839|Experimental|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
9616429|NCT02542839|Sham Comparator|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
9616430|NCT02542592|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
9616431|NCT02542592|Placebo Comparator|Placebo|Preoperative single dose of isotonic Sodium Chloride
9616432|NCT02542826|Experimental|Pulmonary Rehabilitation|
9616433|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)|Subjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
9616434|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50)|Subjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
9616435|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
9616436|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
9616437|NCT02542540|Experimental|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
9616438|NCT02542540|No Intervention|Children with OI without training|No training
9616439|NCT02542527|Experimental|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
9616440|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool, an Epworth sleepiness scale and have overnight oximetry recorded.
9616441|NCT02542202|Experimental|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
9616442|NCT02542319|Experimental|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
9485903|NCT01482403|Experimental|Treatment Arm B|24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
9485904|NCT01482403|Active Comparator|Treatment Arm C (Control)|4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
9485905|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
9485906|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
9485907|NCT01482390|Experimental|TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
9485908|NCT01482390|Active Comparator|TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
9485909|NCT01481571|Experimental|Vitrification media and device|Vitrification medium oocyte, warming medium oocyte and Rapid-i
9485910|NCT01481077|Experimental|Treatment A|
9485911|NCT01481077|Experimental|Treatment B|
9485912|NCT01481077|Experimental|Treatment C|
9485913|NCT01480583|Experimental|GRN1005|GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
9485914|NCT01480583|Experimental|GRN1005 with trastuzumab|GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
9485915|NCT01480479|Experimental|Rindopepimut/GM-CSF plus Temozolomide|
9485916|NCT01480479|Active Comparator|KLH plus Temozolomide|
9485917|NCT01478178|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
9485918|NCT01476904|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals
9485919|NCT01476904|Placebo Comparator|Arm P|Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals
9485920|NCT01476904|Active Comparator|Arm A|Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals
9485921|NCT01475786|Active Comparator|Low Dose 16mg VM202 and Placebo|intramuscular injections in each calf for a total of 16mg VM202: Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
9485922|NCT01475786|Active Comparator|High Dose 32mg VM202|Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202
9485923|NCT01475786|Placebo Comparator|Control - Placebo (normal saline)|32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14
9485924|NCT01475058|Experimental|Treatment (T cell therapy)|Patients undergo one IV infusion of donor-derived CD8+ central memory-derived CMV/CD19 or EBV/CD19 bi-specific T cells, at least 30 days after HCT.
9485925|NCT01474798|Experimental|RA-18C3|
9485926|NCT01474421|Experimental|AQW051 High Dose|AQW051 high dose daily given orally for 28 days.
9485927|NCT01474421|Experimental|AQW051 Low Dose|AQW051 low dose daily given orally for 28 days.
9485928|NCT01474421|Placebo Comparator|Placebo|Placebo daily given orally for 28 days.
9485929|NCT01474135|Experimental|0.25% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.25% AR-12286 and 0.004% travoprost
9485930|NCT01474135|Experimental|0.5% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.5% AR-12286/ 0.004% travoprost
9485931|NCT01474135|Active Comparator|0.004%Travoprost|Travatan(R) Z(travoprost ophthalmic solution)
9485932|NCT01474083|Experimental|GK1-399, low dose|
9485933|NCT01474083|Experimental|GK1-399, high dose, once per day|
9485934|NCT01474083|Experimental|GK1-399, high dose, twice per day|
9485935|NCT01474083|Placebo Comparator|Placebo|
9485936|NCT01472991|Experimental|TC-5619-238 (25mg)|TC-5619-238 25 mg will be provided as hard gelatin capsules
9485937|NCT01472991|Placebo Comparator|Placebo|Placebo will be provided as hard gelatin capsules similar to TC-5619-238
9485938|NCT01472991|Experimental|TC-5619-238 (5 mg)|TC-5619-238 5 mg will be provided as hard gelatin capsules.
9485939|NCT01472887|Experimental|SAR3419|All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation
9485940|NCT01472198|Experimental|Simtuzumab (open-label)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
9485941|NCT01472198|Experimental|Simtuzumab 200 mg (randomized)|Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years.
9485942|NCT01472198|Experimental|Simtuzumab 700 mg (randomized)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
9485943|NCT01472198|Placebo Comparator|Placebo (randomized)|Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years.
9485944|NCT01470664|Experimental|FST-100|
9485945|NCT01470664|Experimental|FST-100 (Component #1)|
9485946|NCT01470664|Placebo Comparator|FST-100 Vehicle|
9485947|NCT01470131|Experimental|Masitinib|Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone
9541684|NCT03102229|Experimental|Activity Monitoring|"Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks~Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
9541685|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
9541686|NCT03102255|Active Comparator|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
9541687|NCT03102255|Experimental|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
9541688|NCT03102359|Experimental|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
9541689|NCT03102359|Experimental|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
9541690|NCT03102359|Experimental|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
9541691|NCT03102359|No Intervention|Control|No intervention in this group
9541692|NCT03102346|Experimental|Home-based Cardiac Rehabilitation group|remote instructed exercise training at home
9541693|NCT03102346|No Intervention|routine group|no instructed exercise training
9541694|NCT03102333|Active Comparator|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
9541695|NCT03102333|Active Comparator|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
9541696|NCT03102164||cardiac rehabilitation|patients undergoing cardiologic rehabilitation according to the protocol used routinely at the Military Hospital in Wroclaw.The protocol of rehabilitation, adjusted to clinical status, individual needs and physical capability of the patient, includes gradually increasing level of physical exercise. Upon achieving relative stabilization of clinical status and excluding absolute contraindications to physical exercise, usually on the 2nd or 3rd day of hospitalization, the cardiologic rehabilitation is ordered by a physician in charge. The rehabilitation protocol comprises respiratory, assisted, active dynamic,and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase;they are conducted in a lying, sitting, or standing position.
9541697|NCT03102164||Controls|patients treated using standard pharmacotherapy within Center for Heart Disease, Military Clinical Hospital in Wroclaw.
9541698|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
9541699|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
9541700|NCT03102372|Experimental|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
9541701|NCT03102372|Placebo Comparator|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
9541702|NCT03102216|No Intervention|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
9541703|NCT03102216|Experimental|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
9541704|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
9541705|NCT03102216|Experimental|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
9541706|NCT03102216|Experimental|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
9541707|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
9541708|NCT03102216|Experimental|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
9541709|NCT03102216|Experimental|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
9541710|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
9541711|NCT03102216|Experimental|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
9541712|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
9541713|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
9541714|NCT03102060|Experimental|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
10039973|NCT01848925|Experimental|SANGUINATE™|PEG-bHb-CO
9541715|NCT03102177|Experimental|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
9541716|NCT03102112||Patients with glioma|Consecutive patients with privious MRI scans or symptoms that suggested a cerebral mass, not yet receive treatment.
9541717|NCT03102073||Radner test|reading speed evaluation
9541718|NCT03102398|Experimental|Single-arm and Open-label Study|
9541719|NCT03102268||cholangiocarcinoma patients|cholangiocarcinoma patients without any anti-cancer therapy
9541720|NCT03102268||benign biliary stricture patients|benign biliary stricture patients without any therapy targeting the stricture
9541721|NCT03101995|Experimental|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
9541722|NCT03102242|Experimental|Treatment|"Induction immunotherapy: atezolizumab 1200 mg IV q 21 days x 4 cycles. Restaging after cycle 2 and cycle 4 induction: patients with progression of disease (PD) at the post-cycle 2 assessment will stop atezolizumab and go immediately to chemoradiotherapy if still stage III and eligible for curative intent therapy.~Chemoradiotherapy: carboplatin AUC = 2 + paclitaxel 50 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 60 Gy given in 2 Gy fractions daily M-F x 30 fractions~Consolidation chemotherapy: Carboplatin AUC = 6 + paclitaxel 200 mg/m2 IV q 21 days x 2 cycles beginning 3-5 weeks after completion of radiation.~Adjuvant immunotherapy: atezolizumab 1200 mg IV q 21 days to complete one year of therapy (from start of induction)."
9541723|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
9541724|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
9541725|NCT03102450|Experimental|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
9541726|NCT03102320|Experimental|Cholangiocarcinoma|"Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin. Please note the study is no longer recruiting for the cholangiocarcinoma safety lead-in phase.~During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin. Please note the main study phase for cholangiocarcinoma will no longer be going ahead."
9541727|NCT03102320|Experimental|Adenocarcinoma of the pancreas|Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine
9541728|NCT03102320|Experimental|Other solid tumors|(Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors
9541729|NCT03102021|Active Comparator|1|erythropoeitin
9541730|NCT03102021|Placebo Comparator|2|saline placebo
9541731|NCT03102424|Experimental|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
9541732|NCT03102424|Placebo Comparator|Sham DW1330 device|The 20 weeks of treatment of the Sham DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
9541733|NCT03102008|No Intervention|2 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
9541734|NCT03102008|No Intervention|3 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
9541735|NCT03102008|No Intervention|4 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
9541736|NCT03102008|Experimental|16 Sessions of Therapeutic Intervention|Participants receive 50 minute sessions weekly of therapeutic intervention (Unified Protocol for the Treatment of Emotional Disorders in Adolescents). Symptom change assessed weekly on the internet or before each session (via self- and parent-report questionnaires). At the end of treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
9541737|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
9541738|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
9541739|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
10039974|NCT01848925|Active Comparator|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
9541740|NCT03101956|Experimental|L/S Manipulation Study Group|
9541741|NCT03101956|Active Comparator|Control Group|
9541742|NCT03102294|Active Comparator|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with ~50% of maximum inspiratory pressure
9541743|NCT03102294|Placebo Comparator|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
9541744|NCT03101839|Experimental|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
9616443|NCT02542319|Placebo Comparator|Placebo|Matching placebo tablets twice daily for 12 months.
9616444|NCT02542345|Experimental|magnetic resonance imaging|
9541745|NCT03101943|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
9541746|NCT03101943|Other|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
9541747|NCT03101865|Experimental|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
9541748|NCT03101865|Active Comparator|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
9541749|NCT03101930|Experimental|liraglutide|Subjects in the liraglutide group will receive subcutaneous liraglutide (0.6 mg/d for one week, 1.2 mg/d for one week, and then 1.8 mg/d for 12 weeks) and oral placebo.
9541750|NCT03101930|Active Comparator|sitagliptin|Subjects in the sitagliptin group will receive subcutaneous placebo daily and sitagliptin 100 mg/d orally for 14 weeks.
9541751|NCT03101930|Active Comparator|hypocaloric diet|Subjects in the hypocaloric diet group will be given a caloric goal designed to achieve a weight loss similar to that expected in the liraglutide treatment arm based on his or her resting energy expenditure. Subjects will be provided counseling and written instructions on how to achieve their daily caloric goal, including use of their own mobile phone applications to monitor caloric intake. To assure compliance with the prescribed caloric goal, subjects will meet with the study dietitian every other week for problem solving and review of diet intake logs.
9541752|NCT03101800|Experimental|Azathioprine and Allopurinol|
9541753|NCT03101800|Active Comparator|Azathioprine|
9541754|NCT03101904|Experimental|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
9541755|NCT03101904|Placebo Comparator|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
9541756|NCT03101878|Experimental|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
9541757|NCT03101878|Placebo Comparator|Placebo|Saline .9%
9541758|NCT03101774|Experimental|threshold-IMT group|Using inspiratory muscle training using threshold load device for 8 weeks
9541759|NCT03101774|Experimental|resisive-IMT group|Using inspiratory muscle training using resistive device for 8 weeks
9541760|NCT03101774|Sham Comparator|control group|not conduct inspiratory muscle training for 8 weeks
9541761|NCT03101852|Experimental|Nutritional therapy|Children included in the study with severe acute malnutrition receive Plumpy Nut: WHO recommends a Plumpy Nut® prescription of 75 to 100 kcal/kg/d in children aged 5 to 10 years and 60 to 90 kcal/kg/d above that age. The lowest value was used and maximum energy intake provided by RUF was limited to 2,000 kcal/d i.e. 4 sachets in order to preserve habitual diet and prevent appetite saturation
9541762|NCT03101852|Experimental|Nutritional supplementation|Children included in the study with moderate acute malnutrition receive Plumpy Sup: 60kcal/kg/day, limited to 4 doses/day.
9541763|NCT03101787|No Intervention|CCPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.~No special preparations for the trial are needed before the patient's arrival."
9541764|NCT03101787|Experimental|ECPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).~Time from arrest to start of cannulation is < 60 minutes."
9541765|NCT03101423|Active Comparator|interleukin-2|interleukin-2 treatment per month
9541766|NCT03101423|Active Comparator|DLI|donor lymphocyte infusion (DLI) treatment per month
9616445|NCT02542241|Experimental|Sodium Chloride [3%]|
9616446|NCT02542241|Active Comparator|Sodium Chloride [0.9%]|
9616447|NCT02542332|Active Comparator|With Data|Participants received statistical data about lung cancer screening
9616448|NCT02542332|No Intervention|Without Data|Participants had no statistical data on lung cancer screening
9485948|NCT01470131|Placebo Comparator|Placebo|Placebo in combination with Bortezomib and Dexamethasone
9485949|NCT01469832|Experimental|Subretinal injection of MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
9541767|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by > 10% increase in FVC (or at least > 200-ml change) or > 15% increase in single-breath DLCO (or at least > 3 ml/min/mm Hg)
9541768|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with > 10% decrease in FVC ( or > 200ml change) or > 15% decrease in DLCO (or at least > 3ml/min/mm Hg change).
9541769|NCT03101397||stable group|not included in improved group or deteriorated group
9541770|NCT03101410|Experimental|gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
9541771|NCT03101410|Experimental|gluten fee|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
9541772|NCT03101826|Experimental|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
9541773|NCT03101579|Experimental|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
9541774|NCT03101618||Allergic LAR|Laboratory animal researchers who experienced allergic symptom during exposure to laboratory or pet animals
9541775|NCT03101618||Non-allergic LAR|Laboratory animal researchers who did not experience allergic symptom during exposure to laboratory or pet animals
9541776|NCT03101618||Allergic PO|Pet owners who experienced allergic symptom during exposure to pet animals
9541777|NCT03101618||Non-allergic PO|Pet owners who did not experience allergic symptom during exposure to pet animals
9541778|NCT03101618||Allergic PIW|Allergic pet-related industry workers who experienced allergic symptom during exposure to pet animals
9541779|NCT03101618||Non-allergic PIW|Allergic pet-related industry workers who did not experience allergic symptom during exposure to pet animals
9541780|NCT03101709|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
9541781|NCT03101449|Experimental|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
9541782|NCT03101449|Experimental|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
9541783|NCT03101449|No Intervention|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
9541784|NCT03101683|Experimental|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
9541785|NCT03101631|Experimental|CASE ARM|"This is a three cohorts arm with intervention (CGA):~Nutritional Assessment: Mini Nutritional Assessment (MNA)~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~Psychological status: Geriatric Depression Scale (GDS)~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~Age~Haemoglobin~Creatinine Clearance (CrCl)~Presence of Geriatric Syndromes"
9541786|NCT03101631|No Intervention|CONTROL ARM|This is a three cohorts arm with no intervention
9541787|NCT03101475|Experimental|immunotherapy + local tumor ablation|Patients with unresectable colorectal liver metastases which show at least stable disease or partial remission after 4-6 months will receive treatment with durvalumab and tremelimumab plus local tumor ablation (Radiofrequency ablation RFA or Sterotactic body radiation therapy SBRT) of selected liver lesions, followed by maintenance treatment with durvalumab.
9541788|NCT03101670|Experimental|filgotinib|
9541789|NCT03101670|Placebo Comparator|placebo|
9541790|NCT03101436|Experimental|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
9541791|NCT03101436|Experimental|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
9616449|NCT02542371||HIV infected with known subclinical atherosclerosis|
9616450|NCT02542371||HIV infected without known subclinical atherosclerosis|
9616451|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
9616452|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
9616453|NCT02542176|Experimental|Freeze-dried Whole Grape Powder|
9616454|NCT02542176|Placebo Comparator|Grape Powder Placebo|
9541792|NCT03101553|Experimental|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
10039975|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed.Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain UNMCs standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
9541793|NCT03101553|Active Comparator|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
9541794|NCT03101384||Patient with a diagnostic error|"Defined by one of :~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm in the next 48h00 after the firts contact with a physician~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm by the first contacted physician but the diagnostic is done before 48h00 because the patient went at the emergency room on his own initiative.~More than one doctor consulted before the diagnostic of pulmonary embolism (excluding the emergency physician if the patient was referred by the 1st contact doctor)"
9541795|NCT03101384||Patient without a diagnostic error|Any patient that did not meet the criteria to define the diagnostic error
9541796|NCT03101319|Experimental|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a tablet containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
9541797|NCT03101319|Placebo Comparator|Antipsychotic and B Complex|Subjects randomised to the B Complex arm will receive a tablet of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
9541798|NCT03101345|Other|nutrition product|Peptamen® 1.5 Vanilla, orally administration
9541799|NCT03101332|Experimental|VR-CBT|Virtual Reality cognitive behavior therapy. 10-12 sessions of individual Cognitive Behavior Therapy with exposure tasks carried out through Virtual Reality.
9541800|NCT03101280|Experimental|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
9541801|NCT03101280|Experimental|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)].~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
9541802|NCT03101527|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
9541803|NCT03101644|Other|Darunavir|All patients treated with darunavir
9541804|NCT03101306|Experimental|MR scans|As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment. These will take place in the 1st, 2nd and 5th weeks of treatment.
9541805|NCT03101605|Experimental|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
9541806|NCT03101605|Other|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
9541807|NCT03101540|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
9541808|NCT03101059|Experimental|MKS pax|Munier-Kuhn Syndrome patients
9541809|NCT03101098|Experimental|Retroperitoneal hysterectomy|In subjects allocated to the experimental group, which the uterine vessels were ligated where it originates from the internal iliac artery,
9541810|NCT03101098|Active Comparator|Classical hysterectomy|The operative technique of classical total laparoscopic hysterectomy (TLH) performed in the control group was comparable to that of retroperitoneal TLH, except for one that coagulation and transection of uterine artery was achieved using an energy device alongside the cervix
9485950|NCT01466725|Experimental|Cohort 1|25 mg daily for 4 weeks (8 active/2 control)
9485951|NCT01466725|Experimental|Cohort 2|50 mg once daily for 4 weeks (8 active/2 control)
9485952|NCT01466725|Experimental|Cohort 3|100 mg daily for 6 weeks (8 active/2 control)
9485953|NCT01466725|Experimental|Cohort 4|100 mg twice daily for 6 weeks (8 active/2 control)
9485954|NCT01466374|Experimental|Cohort 1: Induction|Placebo
9485955|NCT01466374|Experimental|Cohort 2: Induction|Anti-IP-10 Antibody
9485956|NCT01466374|Experimental|Cohort 3: Induction|Anti-IP-10 Antibody
9485957|NCT01466374|Experimental|Cohort 1: Maintenance|Placebo
9485958|NCT01466374|Experimental|Cohort 2: Maintenance|Anti-IP-10 Antibody
9485959|NCT01466374|Experimental|Cohort 3: Maintenance|Anti-IP-10 Antibody
9485960|NCT01466374|Experimental|Cohort 1: Open Label|Anti-IP-10 Antibody
9485961|NCT01466088|Experimental|AZD3480|
9485962|NCT01466088|Active Comparator|Donepezil|Donepezil will be administered at 5 mg daily for 4 weeks and escalated to 10 mg daily for the remainder of the study.
9485963|NCT01464437|Active Comparator|AMG 151 - Arm 1|AMG 151 - Arm 1
9485964|NCT01464437|Active Comparator|AMG 151 - Arm 2|AMG 151 - Arm 2
9485965|NCT01464437|Active Comparator|AMG 151 - Arm 3|AMG 151 - Arm 3
9485966|NCT01464437|Active Comparator|AMG 151 - Arm 4|AMG 151 - Arm 4
9485967|NCT01464437|Active Comparator|AMG 151 - Arm 5|AMG 151 - Arm 5
9485968|NCT01464437|Active Comparator|AMG 151 - Arm 6|AMG 151 - Arm 6
9485969|NCT01464437|Placebo Comparator|Placebo Arm|AMG 151 Placebo Arm
9485970|NCT01463397|Experimental|SAR292833 dose level 1|Dose level 1 twice daily immediately after breakfast/dinner
9485971|NCT01463397|Experimental|SAR292833 dose level 2|Dose level 2 twice daily immediately after breakfast/dinner
9485972|NCT01463397|Placebo Comparator|Placebo|Placebo (for SAR292833) twice daily immediately after breakfast/dinner
9485973|NCT01463059|Placebo Comparator|Placebo every 2 weeks|Injections administered at week 0, 2, 4, 6, 8 and 10
9485974|NCT01463059|Experimental|Olokizumab 60 mg every 2 weeks|Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
9485975|NCT01463059|Experimental|Olokizumab 60 mg every 4 weeks|Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
9485976|NCT01463059|Experimental|Olokizumab 120 mg every 2 weeks|Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
9485977|NCT01463059|Experimental|Olokizumab 120 mg every 4 weeks|Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
9485978|NCT01463059|Experimental|Olokizumab 240 mg very 4 weeks|Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
9485979|NCT01461954|Experimental|FST-100|
9485980|NCT01461954|Placebo Comparator|FST-100 Vehicle|
9485981|NCT01461915|Experimental|Run-in|10 Subjects to be enrolled in the study to receive : gemcitabine + nab-paclitaxel + ODSH
9485982|NCT01461915|Experimental|Arm A|25 patients to be enrolled to receive gemcitabine + nab-paclitaxel + ODSH
9485983|NCT01461915|Active Comparator|Arm B|25 patients will be enrolled in the study to receive gemcitabine + nab-paclitaxel
9485984|NCT01461317|Experimental|Etrolizumab|Etrolizumab 100 milligrams (mg) subcutaneous (SC) administration every 4 weeks during the treatment period of up to 240 weeks.
9485985|NCT01460511|Placebo Comparator|P - Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
9485986|NCT01460511|Experimental|T - E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
9485987|NCT01459926|Experimental|Dose 1|
9485988|NCT01459926|Experimental|Dose 2|
9485989|NCT01459926|Experimental|Dose 3|
9485990|NCT01459926|Experimental|Placebo|
9485991|NCT01459679|Active Comparator|VibeX Treatment Group A|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
9485992|NCT01459679|Active Comparator|VibeX Treatment Group B|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
9485993|NCT01459679|Active Comparator|VibeX Treatment Group C|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
9485994|NCT01458405|Placebo Comparator|Placebo|
9485995|NCT01458405|Active Comparator|CAP-1002 Allogeneic Cardiosphere-Derived Cells|
9485996|NCT01457781|Active Comparator|0.025 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
9485997|NCT01457781|Active Comparator|0.075 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L [4880 ppm] NO mini-cylinder; change q 24 hours)
9485998|NCT01457781|Placebo Comparator|placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks* (99.999% Nitrogen [N2] mini-cylinder; change q 24 hours)
9485999|NCT01457677|Placebo Comparator|Placebo|
9486000|NCT01457677|Experimental|RO4995819 15 mg|
9486001|NCT01457677|Experimental|RO4995819 30 mg|
9486002|NCT01457677|Experimental|RO4995819 5 mg|
9486003|NCT01455896|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
9486004|NCT01455896|Other|ITCA placebo|
9486005|NCT01455870|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
9486006|NCT01455870|Active Comparator|sitagliptin|sitagliptin 100 mg/day
9486007|NCT01455857|Experimental|ITCA 650 40 mcg/day|
9486008|NCT01455857|Experimental|ITCA 650 60 mcg/day|
9486009|NCT01455857|Placebo Comparator|ITCA placebo|
9486010|NCT01455597|Experimental|Estradiol Vaginal Gel|WC3011 Estradiol Vaginal Gel, administered 3X weekly for 40 weeks
9541811|NCT03101072|Active Comparator|"Fixed long antibiotic course"|"Patients randomized to this group will receive a fixed long antibiotic course of 14 days."
9541812|NCT03101072|Experimental|"Fixed short antibiotic course"|"Patients randomized to this group will receive a fixed short antibiotic course of 7 days."
9541813|NCT03101072|Experimental|"Individualized antibiotic course"|"Individualized antibiotic course: starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75%"
9541814|NCT03100981|Experimental|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
9541815|NCT03100981|Other|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
10039976|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound.2.The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants ( subcostal position x2 and lateral position x2)
9541818|NCT03101215|Placebo Comparator|Placebo|glucose drink (100g) with placebo tablets
9541819|NCT03101215|Active Comparator|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
9541820|NCT03101202|Experimental|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
9541821|NCT03101202|No Intervention|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
9541822|NCT03100955|Active Comparator|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
9541823|NCT03100955|Experimental|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
9541824|NCT03101137|Active Comparator|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
9541825|NCT03101137|Active Comparator|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
9541826|NCT03101137|Placebo Comparator|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
9541827|NCT03101189|Experimental|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
9541828|NCT03101189|Experimental|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
9541829|NCT03101189|Placebo Comparator|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
9541830|NCT03101085|Experimental|S-equol|Participants will receive S-equol 50mg twice daily for one month
9541831|NCT03101085|Placebo Comparator|Placebo|Participants will receive matched placebo pill to take twice daily for one month
9541832|NCT03101124|Experimental|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
9541833|NCT03101124|Experimental|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
9541834|NCT03101124|Active Comparator|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
9486011|NCT01455493|Experimental|A|
9486012|NCT01455090|Experimental|Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
9486013|NCT01455090|Experimental|Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
9486014|NCT01455090|Experimental|Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
9486015|NCT01455090|Experimental|Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
10039977|NCT01848964|Experimental|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
10039978|NCT01849003|Experimental|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
9541835|NCT03101176|Experimental|Experimental: Single Arm|All consenting patients will undergo mpUS imaging prior to surgery with the ultrasound contrast agent Sonovue for the CEUS specific mode.
10039979|NCT01849003|Experimental|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
10039980|NCT01849003|Experimental|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
10039981|NCT01849003|Experimental|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
10039982|NCT01849003|Experimental|Cohort 5|"Participants will receive single doses of GS-6615 as follows:~Day 1: 20 mg (loading dose)~Day 2: 40 mg (loading dose)~Days 3-7: 6 mg (maintenance dose) once daily~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
9541836|NCT03101254|Experimental|LY3022855 + Vemurafenib + Cobimetinib|LY3022855 administered intravenously every week Vemurafenib administered by mouth twice daily Cobimetinib administered by mouth once daily on days 1-21of each cycle
9541837|NCT03100929|Experimental|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
9541838|NCT03100994|No Intervention|Group A|without nerve block
9541839|NCT03100994|Active Comparator|Group B|Ultrasound guided transmuscular quadratus lumborum block with 0.125% bupivacaine 30ml
9541840|NCT03100994|Active Comparator|Group C|Ultrasound guided quadratus lumborum type 2 block with 0.125% bupivacaine 30ml
9541841|NCT03101228|Experimental|Reduced sitting|Objectively measured daily inactive time will be reduced by one hour compared to the baseline.
9541842|NCT03101228|No Intervention|Control|Subjects will be guided to maintain their normal sedentary behaviour and physical activity habits.
9541843|NCT03100916|Experimental|Dose Ranging Arm|
9541844|NCT03100916|Experimental|Food Effect arm|
9541845|NCT03100903|Experimental|BI 655130|
9541846|NCT03100877|Experimental|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
9541847|NCT03100890|No Intervention|Control|Non-active comparator
9541848|NCT03100890|Active Comparator|Balance-Proprioception (Hospital)|Preoperative training (hospital)
9541849|NCT03100890|Experimental|Balance-Proprioception (Home)|Preoperative training (home)
9541850|NCT03100656|Other|Anorexia nervosa I|Anorexia nervosa with BMI <=17.5 kg/m² or BMI >17.5 kg/m² with regular binge-purge episodes
9541851|NCT03100656|Other|Anorexia nervosa II|Anorexia nervosa with BMI > 18.5 kg/m² for at least 12 months.
9541852|NCT03100656|Other|Controls|Healthy control women
9541853|NCT03100851|Experimental|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
9541854|NCT03100591|Experimental|14C-radiolabelled ACT-132577|On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state
9541855|NCT03100630|Active Comparator|Treatment A: RO7239361|RO7239361 subcutaneous injections on specified days; abdomen
9541856|NCT03100630|Active Comparator|Treatment B: RO7239361|RO7239361 subcutaneous injections on specified days; arm
9541857|NCT03100630|Active Comparator|Treatment C: RO7239361|RO7239361 subcutaneous injections on specified days; thigh
9541858|NCT03100695|No Intervention|Control|Patients will undergo operative procedure with no additional intervention.
9541859|NCT03100695|Experimental|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
9541860|NCT03100708||Patient with peritoneal carcinomatosis|Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.
9541861|NCT03100799|Other|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
9616455|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
9616456|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
9616457|NCT02542449|Active Comparator|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
10039983|NCT01849003|Experimental|Cohort 6|"Participants will receive single doses of GS-6615 as follows:~Day 1: 50 mg (loading dose)~Day 2-3: 10 mg once daily~Days 4-7: 20 mg once daily"
10039984|NCT01849016|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
10039985|NCT01849016|Placebo Comparator|Placebo|Placebo 1 oral tablet twice daily during 6 months
10039986|NCT01849029|Experimental|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
9541862|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
9541863|NCT03100721|Experimental|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
9541864|NCT03100721|Active Comparator|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
9541865|NCT03100604|Experimental|sevoflurane 2%, 1 MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
9541866|NCT03100604|Experimental|Desfluran 6-9% 1MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
9541867|NCT03100812|Experimental|Group A|
9541868|NCT03100812|Experimental|Group B|
9541869|NCT03100773|Experimental|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
9541870|NCT03100773|Experimental|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
9541871|NCT03100773|Experimental|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
9541872|NCT03100513|Active Comparator|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
9541873|NCT03100513|Active Comparator|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
9541874|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
9541875|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
9541876|NCT03100565|Placebo Comparator|colposcopic biopsy under local anesthetic sp|
9541877|NCT03100565|Placebo Comparator|Patients underwent colposcopic biopsy under forced coughing|
9541878|NCT03100461|Active Comparator|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
9541879|NCT03100461|Active Comparator|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
9541880|NCT03100461|Experimental|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
9541881|NCT03100461|Active Comparator|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
9541882|NCT03100526|Experimental|Intervention--PACT Intensive Management|The intervention is the PACT Intensive Management Program (PIM) which provides intensive interdisciplinary care planning, care coordination, patient self-management support, and tailored goal setting based on patient needs and preferences, and additional care management services.
9541883|NCT03100526|No Intervention|Usual care|High-Risk patients receiving care in PACT.
9541884|NCT03100552||Study population|Patients referred to a tertiary endoscopic resection practice found to have an SSP >= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
9541885|NCT03100448|Other|On1 Concept|On1 Concept & NobelActive implants
9541886|NCT03100188|Experimental|modified PD|Patients with residual renal kt/v were placed in intervention group
9541887|NCT03100435|Experimental|Er:YAG Laser|Er:YAG Laser only
9541888|NCT03100435|Active Comparator|Carbon Fiber Curette|Carbon fiber curette only
9541889|NCT03100435|Experimental|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
9541890|NCT03100435|No Intervention|No Treatment|No treatment (control)
9541891|NCT03100279|Experimental|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
9541892|NCT03100227|Active Comparator|PET [18F] FDG|Each subject will have a PET scan at [18F] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
9541893|NCT03100227|Sham Comparator|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
9541894|NCT03100162|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 3 months.
9541895|NCT03100162|Active Comparator|Probiotic 2g|Individuals receive 2 g of probiotic daily, for 3 months.
9541896|NCT03100162|Active Comparator|Probiotic 4g|Individuals receive 4 g of probiotic daily, for 3 months.
9541897|NCT03100253|Experimental|"Switching strategy"|Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
9541898|NCT03100253|Active Comparator|"Cycling strategy"|"Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR~Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
9541899|NCT03100409|Experimental|Dietary modification|Personalized dietary intervention, low residue diet
9541900|NCT03100409|No Intervention|Control|Dietary recommendations currently used in the INCan
9541901|NCT03100305||Extremely preterm infants|
9541902|NCT03100305||Very preterm infants|
9541903|NCT03100305||Moderately preterm infants|
9541904|NCT03100305||Late preterm infants|
9541905|NCT03100175|Experimental|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.~Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly~Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
9541906|NCT03100175|No Intervention|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
9541907|NCT03100097|Experimental|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
9541908|NCT03100097|No Intervention|Medical Management|Normal medical management
9541909|NCT03100136|Experimental|[11C]PF-06809247|A dose intravenous injection of [11C]PF-06809247 followed by PET scanning.
9541910|NCT03100292|Experimental|bariatric surgery|"This trial is a single-arm study and the enrolled patients are going to undergo sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).~If the patient has Barrett's esophagus on the preoperative endoscopy, SG is not permitted. Inflammatory bowel disease and Helicobacter pylori infection on a rapid urease test are contraindications of RYGB."
9541911|NCT03100318|Experimental|FYU-981|
9541912|NCT03100318|Active Comparator|Benzbromarone|
9541913|NCT03100201|Active Comparator|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
9541914|NCT03100201|Active Comparator|Control group|The control group will receive conventional occupational- and physiotherapy.
9541915|NCT03100214|Active Comparator|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions.
9541916|NCT03100214|Experimental|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
9541917|NCT03100422|Experimental|ARMin|Therapy with the arm therapy robot ARMin
9541918|NCT03100422|Active Comparator|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
9541919|NCT03100331|Experimental|Single Arm; all receive neuropsychological testing & follow-up|
9541920|NCT03100266|Experimental|probiotic|Lactobacillus rhamnosis GG
9541921|NCT03100266|Placebo Comparator|placebo|Inactive capsules
9541922|NCT03100084||I. Post Dates|"Pregnant women referred for clinical post term evaluation and/or labour induction.~Blood sampling."
9541923|NCT03100084||II. Induction of Labour|"Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).~Blood sampling."
9541924|NCT03100084||III. All Outpatients|"Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.~Blood sampling"
9541925|NCT03100084||IV. Diabetes in Pregnancy|Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.
9541926|NCT03100084||V. Reduced Fetal Movements|"Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.~Blood sampling."
9541927|NCT03100084||VI. Hypertensive Disorders in Pregnancy|"Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.~Blood sampling."
9541928|NCT03100084||VII. All Labour Admissions|All pregnant women ≥37+0 GW admitted for labour. Blood sampling.
9541929|NCT03099993|Other|A: Healthy volunteers|
9541930|NCT03099993|Other|B: Patient with heamiplegia|
9541931|NCT03099993|Other|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
9486016|NCT01455090|Experimental|Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
10039987|NCT01849029|Other|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
9541932|NCT03100019|Experimental|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
9541933|NCT03100019|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
9541934|NCT03100019|Experimental|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
9541935|NCT03100019|Placebo Comparator|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
9541936|NCT03100006|Experimental|Nivolumab and Oregovomab|
9541937|NCT03100032|Experimental|NVD-001|Autologous osteogenic cells in ECM with DBM
9486017|NCT01455090|Experimental|Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
10039988|NCT01849042|Other|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
9541938|NCT03100032|Active Comparator|Standard of Care|Best standard of care in surgical practice
9541939|NCT03099980|Experimental|Secukinumab|All participants will be assigned to receive secukinumab 300 mg (2 x 150 mg PFS subcutaneous injections) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 more weeks.
9541940|NCT03099941|Experimental|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
9541941|NCT03099941|Active Comparator|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
9541942|NCT03099928||Qualitative Interviews|
9541943|NCT03099902||Cases|Children with asthma/wheezing whose mothers were active smokers during pregnancy
10039989|NCT01849042|Active Comparator|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
9541944|NCT03099902||Controls|Children without asthma/wheezing whose mothers were active smokers during pregnancy
9541945|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
9541946|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
9541947|NCT03099889|Experimental|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
9541948|NCT03099889|No Intervention|Control arm|Receive general health mailings
9541949|NCT03099577|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
9541950|NCT03099577|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
9541951|NCT03099577|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
9541952|NCT03099577|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
9541953|NCT03099577|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
9541954|NCT03099577|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
9541955|NCT03099577|Experimental|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
9541956|NCT03099642|Experimental|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
9541957|NCT03099642|No Intervention|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
9541958|NCT03099629|Experimental|IMT|inspiratory muscle training
9541959|NCT03099720|Experimental|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
9541960|NCT03099720|Placebo Comparator|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
9541961|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
9541962|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
9541963|NCT03099759|Active Comparator|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
10039990|NCT01849081|Experimental|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
10039991|NCT01849081|Active Comparator|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
10039992|NCT01849094|Experimental|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
9541964|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (82mg)|
9541965|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (164mg)|
9541966|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (246mg)|
9541967|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-111 (175mg)|
9541968|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-112 (145mg)|
9541969|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-119 (233mg)|
9541970|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-125 (233mg)|
9541971|NCT03099837||Pregnant mothers|
9541972|NCT03099837||infants|
9541973|NCT03099837||children|
9541974|NCT03099785|Active Comparator|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
9541975|NCT03099785|Active Comparator|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
9541976|NCT03099785|Placebo Comparator|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
10039993|NCT01849094|Active Comparator|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
9541978|NCT03099603|Placebo Comparator|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
10039994|NCT01849094|Active Comparator|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
10039995|NCT01849107|Experimental|Plasma citrulline|
9541979|NCT03099603|Placebo Comparator|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
9541980|NCT03099603|Placebo Comparator|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
9541981|NCT03099603|Placebo Comparator|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
9541982|NCT03099590|Experimental|Active Treatment, Alkontrol-herbal|Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
9541983|NCT03099590|Placebo Comparator|Placebo Control|Matched dextran containing capsules will serve as placebo.
9541984|NCT03099499|Experimental|ONC201 treatment Arm|
9541985|NCT03099551|Active Comparator|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
9541986|NCT03099551|Active Comparator|Sonic Toothbrush users|Group using sonic toothbrush Edel White
9486018|NCT01455090|Experimental|Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
9486019|NCT01455090|Experimental|Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
9541987|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
9541988|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
9541989|NCT03099473|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
9541990|NCT03099473|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
9541991|NCT03099473|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
9541992|NCT03099460|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
9541993|NCT03099460|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
9541994|NCT03099460|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
9541995|NCT03099447|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
9541996|NCT03099447|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
9541997|NCT03099447|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
9541998|NCT03099850||Chronic Pancreatitis|
9541999|NCT03099772|Experimental|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
9542000|NCT03099512|Experimental|Ex+SFE Group|Individuals in this group who will perform exercises for knee and also short foot exercise
9542001|NCT03099512|Active Comparator|Ex Group|Individuals in this group who will perform exercises for knee only
9542002|NCT03099317|Experimental|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
9542003|NCT03099317|Sham Comparator|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
9542004|NCT03099616|Active Comparator|CLADS group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
9542005|NCT03099616|Active Comparator|Desflurane group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
9542006|NCT03099668|Experimental|OSAC|Single visit to a multidisciplinary clinic (the One Stop Arthritis Clinic, OSAC), followed by routine care
9542007|NCT03099668|No Intervention|Routine care|Routine care
9542008|NCT03099291|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants will receive a single dose of the RSV D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
9542009|NCT03099291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
9486020|NCT01455090|Experimental|Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
9486021|NCT01455090|Experimental|Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
9486022|NCT01455090|Experimental|Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
9486023|NCT01455090|Experimental|Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
9486024|NCT01455090|Experimental|Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablets orally twice daily 12 weeks~BMS-790052 30 mg tablets orally twice daily 12 weeks~BMS-791325 75 mg tablets orally twice daily 12 weeks~Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is < 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM]"
9486025|NCT01454089|Experimental|OGX-427 600 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)
9486026|NCT01454089|Experimental|OGX-427 1000 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)
9486027|NCT01454089|Active Comparator|Placebo|Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo
9486028|NCT01452516|Other|nanOss Bioactive Bone void filler|Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
9486029|NCT01452451|Placebo Comparator|Placebo|Placebo
9486030|NCT01452451|Active Comparator|HM11260C|HM11260C
9486031|NCT01452308|Experimental|Cohort 1|Participants will receive simtuzumab at a dose of 10 mg/kg by intravenous (IV) infusion every other week for a total of 3 infusions.
9486032|NCT01452308|Experimental|Cohort 2|Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg.
9486033|NCT01449591|Experimental|BFH772|
9486034|NCT01449591|Placebo Comparator|Vehicle|
9486035|NCT01449591|Active Comparator|Metronidazole|
9486036|NCT01449162|Experimental|Masitinib as add-on to oral corticosteroids|Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
9486037|NCT01449162|Placebo Comparator|Placebo as add-on to oral corticosteroids|Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
9486038|NCT01449071|Placebo Comparator|Placebo Group|
9486039|NCT01449071|Experimental|Epratuzumab 600 mg Group|
9486040|NCT01449071|Experimental|Epratuzumab 100 mg Group|
9486041|NCT01449071|Experimental|Epratuzumab 400 mg Group|
9486042|NCT01449071|Experimental|Epratuzumab 1200 mg Group|
9486043|NCT01445899|Experimental|PF-04523655 (Stratum II)|Stratum II, 6 monthly injections of PF-04523655 only
9486044|NCT01445899|Experimental|PF-04523655 and ranibizumab|Stratum II, 6 monthly injections of PF-0423655 and ranibizumab administered in combination
9486045|NCT01445899|Active Comparator|ranibizumab|Stratum II, 6 monthly IVT injections of ranibizumab only
9486046|NCT01445899|Experimental|PF-04523655 (Stratum I)|Stratum I
9486047|NCT01445795|Experimental|200 mg INX-08189 Fasted|Cohort 1: 200 mg INX-08189 QD fasted for seven days
9486048|NCT01445795|Placebo Comparator|Placebo QD Fasted|Cohort 1: Placebo QD fasted for seven days
9486049|NCT01445795|Experimental|100 mg INX-08189 with Ribavirin|Cohort 2: 100 mg INX-08189 100 mg dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID, the AM dose will be taken 4 hours after INX-08189 so it may be taken with food)
9486050|NCT01445795|Active Comparator|Placebo QD dosed with ribavirin|Cohort 2: Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
9486051|NCT01445795|Experimental|100 mg INX-08189 with a low-fat meal|Cohort 3: 100 mg INX-08189 with a low-fat meal QD x7 days
9486052|NCT01445795|Placebo Comparator|Placebo with low-fat meal|Cohort 3: Placebo administered with a low-fat meal QD for 7 days
9486053|NCT01445795|Experimental|100 mg INX-08189 Fasted|Cohort 4: 100 mg INX-08189 BID fasted x7 days
9486054|NCT01445795|Placebo Comparator|Placebo BID Fasted|Cohort 4: Placebo BID fasted x7 days
9486055|NCT01444365|Experimental|ABT-652 NSAID|ABT-652 capsules -2 ABT-652 capsules twice daily (add-on) NSAID - as prescribed
9486056|NCT01444365|Placebo Comparator|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID - as prescribed
9486057|NCT01443728|Experimental|Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
9486058|NCT01443728|Active Comparator|Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
9486059|NCT01442337|Experimental|ASP8597 low dose|
9486060|NCT01442337|Experimental|ASP8597 high dose|
9486061|NCT01442337|Experimental|ASP8597 highest dose|
9486062|NCT01442337|Placebo Comparator|Placebo|Placebo comparator used in Part 2 only
9486063|NCT01442090|Active Comparator|Everolimus|Participants will receive everolimus (10 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
9486064|NCT01442090|Experimental|GDC-0980|Participants will receive GDC-0980 (40 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
9486065|NCT01439919|Experimental|SSR411298 200 mg|SSR411298 200 mg, one tablet once daily for 4 weeks
9486066|NCT01439919|Placebo Comparator|Placebo|Placebo (for SSR411298), one tablet once daily for 4 weeks
9486067|NCT01438775|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
9486068|NCT01437787|Placebo Comparator|Placebo comparator|once daily X 28 days, orally, empty stomach, approximately same time each day
9486069|NCT01437787|Experimental|SAR302503 400 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
9486070|NCT01437787|Experimental|SAR302503 500 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
9486071|NCT01437735|Experimental|QAW039 po dose 1|
9486072|NCT01437735|Experimental|QAW039 po dose 2|
9486073|NCT01437735|Experimental|QAW039 po dose 3|
9486074|NCT01437735|Experimental|QAW039 po dose 4|
9486075|NCT01437735|Experimental|QAW039 po dose 5|
9486076|NCT01437735|Experimental|QAW039 po dose 6|
9486077|NCT01437735|Experimental|QAW039 po dose 7|
9486078|NCT01437735|Experimental|QAW039 po dose 8|
9486079|NCT01437735|Experimental|QAW039 po dose 9|
9486080|NCT01437735|Experimental|QAW039 po dose 10|
9486081|NCT01437735|Experimental|QAW039 po dose 11|
9486082|NCT01437735|Experimental|QAW039 po dose 12|
9486083|NCT01437735|Experimental|QAW039 po dose 13|
9486084|NCT01437735|Active Comparator|Montelukast po 10 mg|Comparator leukotriene receptor antagonist (LRTA)
9486085|NCT01437735|Placebo Comparator|Placebo|
9486086|NCT01437722|Experimental|1% SPL7013 Gel|
9486087|NCT01437722|Experimental|3% SPL7013 Gel|
9486088|NCT01437722|Placebo Comparator|placebo gel|
9486089|NCT01437657|Placebo Comparator|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
9486090|NCT01437657|Experimental|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
9486091|NCT01437657|Experimental|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
9486092|NCT01436487|Experimental|Cohort 1|Low dose MultiStem or Placebo
9486093|NCT01436487|Experimental|Cohort 2|High dose MultiStem or Placebo
9486094|NCT01436487|Experimental|Cohort 3|Highest, safe MultiStem dose (from Cohorts 1 and 2) or Placebo
9486095|NCT01436032|Experimental|N1539 15 mg|
9486096|NCT01436032|Experimental|N1539 30 mg|
9486097|NCT01436032|Active Comparator|Ketorolac|IV
9486098|NCT01436032|Placebo Comparator|Placebo|IV
9486099|NCT01436032|Experimental|N1539 7.5mg|
9486100|NCT01435369|Active Comparator|CT-011 at dose level 1 (1.5 mg/kg).|
9486101|NCT01435369|Active Comparator|CT-011 at dose level 2 (6 mg/kg).|
9486102|NCT01435226|Active Comparator|Arm 1|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV BID
9486103|NCT01435226|Active Comparator|Arm 2|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV placebo BID
9486104|NCT01435226|Active Comparator|Arm 3|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir placebo BID + RBV BID
9486105|NCT01435044|Experimental|SOF+RBV 12 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 12 weeks.
9486106|NCT01435044|Experimental|SOF+RBV 24 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 24 weeks.
9486107|NCT01435044|Experimental|GS-0938 Alone|Participants were randomized to receive GS-0938 plus placebo to match sofosbuvir for up to 24 weeks.
9486108|NCT01435044|Experimental|GS-0938+SOF|Participants were randomized to receive GS-0938 plus sofosbuvir for up to 24 weeks.
9486109|NCT01435044|Experimental|GS-0938+SOF+RBV|Participants were randomized to receive GS-0938 plus sofosbuvir plus RBV for up to 24 weeks.
9486110|NCT01435044|Experimental|Placebo|Deferred start group: Participants were randomized to receive placebo to match GS-0938 plus placebo to match sofosbuvir for 24 Weeks.
9486111|NCT01435044|Experimental|Retreatment Group - SOF+RBV 24 Weeks|After discontinuing a regimen containing GS-0938, participants received sofosbuvir plus RBV for up to 24 weeks.
9486112|NCT01434498|Active Comparator|Arm 1|GS-5885, GS-9451, tegobuvir (GS-9190), and Copegus® for 24 weeks
9486113|NCT01434498|Active Comparator|Arm 2|GS-5885, GS-9451, tegobuvir (GS-9190), and a placebo matching ribavirin for 24 weeks
9486114|NCT01434498|Active Comparator|Arm 3|GS-5885, GS-9451, a placebo matching tegobuvir, and Copegus® for 24 weeks
9486115|NCT01433497|Experimental|Experimental Arm A|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
9486116|NCT01433497|Experimental|Experimental Arm B|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
9486117|NCT01433497|Placebo Comparator|Placebo Comparator A|Participants receive placebo given orally twice daily.
9486118|NCT01433497|Placebo Comparator|Placebo Comparator B|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.
9486119|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 1|
9542010|NCT03099811|Experimental|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
9542011|NCT03099811|Other|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
9542012|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or > re-MI will be described.
9542013|NCT03099421|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
10039996|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
10039997|NCT01849133|Experimental|ELIOT|intraoperative radiotherapy
10039998|NCT01849133|Active Comparator|EXTERNAL RT|external fractionated radiotherapy
9542014|NCT03099382|Experimental|SHR-1210|
9542015|NCT03099382|Active Comparator|Investigator's Choice Standard Therapy|Docetaxel or Irinotecan
9542016|NCT03099330|Experimental|TQ-B3139|TQ-B3139 p.o. qd
9542017|NCT03099343|Experimental|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
9542018|NCT03099343|No Intervention|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
9542019|NCT03099226|Experimental|Group 1 - BIA 5-453 50 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
9542020|NCT03099226|Experimental|Group 2 - BIA 5-453 100 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
9542021|NCT03099226|Experimental|Group 3 - BIA 5-453 200 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
9542022|NCT03099278|Experimental|Ezetimibe|
9542023|NCT03099122|Experimental|Thymoglobuline|"A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice.~Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies."
9616458|NCT02542449|Placebo Comparator|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
10039999|NCT01849159|Active Comparator|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
10040000|NCT01849159|Placebo Comparator|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
10040001|NCT01849185|Active Comparator|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
10040002|NCT01849185|Placebo Comparator|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
10040003|NCT01849198|Other|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
9616459|NCT02542306|Experimental|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
10040004|NCT01849198|Other|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
10040005|NCT01849211|Other|neuromuscular block|
10040006|NCT01849224|Experimental|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
10040007|NCT01849224|No Intervention|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
10040008|NCT01849237|Active Comparator|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
9542024|NCT03099252||Enrolled|"Participating hospitals will offer the video to all parents on their MBU during the 6 month intervention period (using the preferred delivery methods of the hospital and the parents). The video will be available via multiple means to facilitate optimal parental exposure in diverse settings. This will ensure flexibility of the delivery of the intervention, based on preferences of the nominated nurse leaders and their HCP team, families and available resources.~All participating maternal/newborn centres will receive the following tools via the designated nurse unit leader of enrolled sites:~Parent-targeted BSweet2Babies video~Parent cards- Reminder for parents of video, with Quick Response (QR) code of the video~BSweet2Babies Poster-visual reminder for parents and HCP's on the enrolled units~Monthly support calls for the nursing leaders of the Mother Baby Units (MBU)~Bi-monthly community of practice teleconferences for the nursing leaders of the MBU"
9542025|NCT03099044|Active Comparator|Single Active Dose|Subjects are assigned to receive a single Active beverage and a single placebo beverage.
9542026|NCT03099044|Active Comparator|Double Active Dose|Subjects are assigned to receive 2 doses of Active beverage.
9542027|NCT03099044|Placebo Comparator|Placebo comparator|Subjects are assigned to receive 2 doses of a placebo beverage.
9542028|NCT03099408|Active Comparator|Metronidazole Oral|Metronidazole Oral
9542029|NCT03099408|Active Comparator|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
9542030|NCT03099265|Experimental|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
9542031|NCT03099070|No Intervention|Control, Not-Fasting|Participants will experience the control intervention and will not fast prior to the lab visit.
9542032|NCT03099070|Experimental|Control, Fasting|Participants will experience the control intervention and will fast prior to the lab visit.
9542033|NCT03099070|Experimental|Stress, Not-Fasting|Participants will experience the stress intervention and will not fast prior to the lab visit.
9542034|NCT03099070|Experimental|Stress, Fasting|Participants will experience the stress intervention and will fast prior to the lab visit.
9542035|NCT03099109|Experimental|LY3321367 Dose Escalation|LY3321367 given intravenously (IV).
9542036|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Escalation|LY3321367 and LY3300054 given IV.
9542037|NCT03099109|Experimental|LY3321367 Dose Expansion|LY3321367 given IV.
9542038|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Expansion|LY3321367 and LY3300054 given IV.
9542039|NCT03099109|Experimental|Japanese Arm D LY3321367|LY3321367 given IV.
9542040|NCT03099109|Experimental|Japanese Arm E LY3300054|LY3300054 given IV.
9542041|NCT03099109|Experimental|Japanese Arm F LY3321367 + LY3300054|LY3321367 and LY3300054 given IV.
9542042|NCT03098914||Beijing Haidian Hospital|
9542043|NCT03098914||Chinese PLA General Hospital|
9542044|NCT03098914||Beijing Tsinghua Chang gung Hospital|
9542045|NCT03099200||Cohort 1|Participants with early breast cancer currently undergoing treatment (either chemotherapy and targeted HER2 therapy OR targeted HER2 therapy alone) will be observed.
9542046|NCT03099200||Cohort 2|Participants with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving loco-regional treatment, chemotherapy or targeted HER2 therapy; participants may still be receiving hormone therapy) will be observed.
9542047|NCT03099200||Cohort 3|Participants receiving treatment for metastatic breast cancer will be observed.
9542048|NCT03099213|Experimental|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
9542049|NCT03099148|Experimental|LY3337641 (R-fasted)|A single dose of LY3337641 reference formulation (R) given orally with water after an overnight fast in one of four periods.
9542050|NCT03099148|Experimental|LY3337641 (T1-fasted)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
9542051|NCT03099148|Experimental|LY3337641 (T1-fed)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
9542052|NCT03099148|Experimental|LY3337641 (T2-fasted)|A single dose of LY3337641 test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
9542053|NCT03099239|Experimental|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
9542054|NCT03099239|Experimental|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
9542055|NCT03099239|Experimental|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
9542056|NCT03099135|Other|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
9542057|NCT03098849|Experimental|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
9542058|NCT03098849|No Intervention|Control Group|Standard care as usual
9542059|NCT03098992|Active Comparator|Fotona Dynamis Er:YAG Laser System|Active treatment with Fotona Dynamis Er:YAG Laser System
9542060|NCT03098992|Sham Comparator|Fotona Dynamis Er:YAG Laser System with Sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
9542061|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
9616460|NCT02542306|No Intervention|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
9616461|NCT02542254|Active Comparator|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
9616462|NCT02542254|Experimental|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
9486120|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 2|
9486121|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 1|
9486122|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 2|
9486123|NCT01428362|Experimental|Placebo/VI-1121|Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.
9486124|NCT01428362|Experimental|VI-1121/Placebo|Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.
9486125|NCT01425970|Experimental|25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 1
9486126|NCT01425970|Experimental|50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 2
9486127|NCT01425970|Experimental|100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 3
9486128|NCT01425970|Placebo Comparator|Placebo + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 4
9486129|NCT01425970|Experimental|100 mg INX-08189 + Ribavirin|PART B Arm 1
9486130|NCT01425970|Experimental|200 mg INX-08189 + Ribavirin|PART B Arm 2
9486131|NCT01425970|Experimental|Daclatasvir + INX-08189 100 mg|PART B Arm 3
9486132|NCT01425970|Experimental|Daclatasvir + INX-08189 200 mg|PART B Arm 4
9486133|NCT01425970|Experimental|Daclatasvir + INX-08189 50 mg + Ribavirin|PART B Arm 5
9486134|NCT01423149|Experimental|36 mg/m2 Combretastin A-4 Phosphate|
9486135|NCT01423149|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
9486136|NCT01423149|Experimental|27 mg/m2 Combretastatin A-4 Phosphate|
9486137|NCT01423110|Experimental|BYM338|
9486138|NCT01423110|Placebo Comparator|Placebo|
9486139|NCT01423058|Experimental|Momelotinib|
9486140|NCT01422148|Other|Amiodarone|oral amiodarone
9486141|NCT01422148|Experimental|minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
9486142|NCT01421056|Experimental|CHF 5074 1x|oral tablet, multidose
9486143|NCT01421056|Experimental|CHF 5074 2x|oral tablet, multidose
9486144|NCT01421056|Experimental|CHF 5074 3x|oral tablet, multidose
9486145|NCT01420783|Experimental|SAR302503 100 mg|once daily X 28 days
9486146|NCT01420783|Experimental|SAR302503 200 mg|once daily X 28 days
9486147|NCT01420783|Experimental|SAR302503 400 mg|once daily X 28 days
9486148|NCT01420783|Experimental|SAR302503 600 mg|once daily X 28 days
9486149|NCT01420770|Experimental|SAR02503 300 mg qd|daily X 28 days
9486150|NCT01420770|Experimental|SAR302503 400 mg qd|daily X 28 days
9486151|NCT01420770|Experimental|SAR302503 500 mg qd|daily X 28 days
9486152|NCT01418261|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
9486153|NCT01418261|Sham Comparator|Control group|Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications
9486154|NCT01418222|Experimental|A|
9486155|NCT01418222|Active Comparator|B|
9486156|NCT01418092|Placebo Comparator|Placebo|Capsules for oral administration
9486157|NCT01418092|Experimental|ALKS 37|Capsules for oral administration
9486158|NCT01417091|Experimental|Treatment group|
9486159|NCT01417091|No Intervention|Untreated reference group|
9486160|NCT01416428|Experimental|QDx2 Dosing Schedule|"QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
9486161|NCT01416428|Experimental|QDx5 Dosing Schedule|"QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
9486162|NCT01416402|Other|Arhalofenate with febuxostat and colchicine|
9486163|NCT01416064|Other|Molindone|Extension study, all subjects will be given Molindone at different (established) dosage levels based on the patient's weight, response and investigator discretion.
9486164|NCT01414920|Placebo Comparator|Placebo QD|
9486165|NCT01414920|Experimental|TAK-875 25 mg QD|
9486166|NCT01414920|Experimental|TAK-875 50 mg QD|
9486167|NCT01414920|Experimental|Sitagliptin 100 mg QD|
9486168|NCT01414920|Experimental|TAK-875 25 mg QD + Sitagliptin 100 mg QD|
9486169|NCT01414920|Experimental|TAK-875 50 mg QD + Sitagliptin 100 mg QD|
9486170|NCT01413932|Experimental|HT-2157|
9486171|NCT01413932|Placebo Comparator|Placebo|
9486172|NCT01412177|Experimental|OTO-104|
9486173|NCT01412177|Placebo Comparator|Placebo|
9486174|NCT01412034|Experimental|CER-001|Open label single arm study of CER-001
9486175|NCT01411163|Experimental|Creatine|
9486176|NCT01411150|Experimental|Creatine|
9486177|NCT01410695|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day, tablets, orally, twice a day
9486178|NCT01410695|Experimental|masitinib 6.0 mg|masitinib 6.0 mg/kg/day, tablets, orally, twice a day
9486179|NCT01410695|Active Comparator|methotrexate|methotrexate at the dose of 15 or 20 mg per week
9486180|NCT01410188|Experimental|OPA-6566 low dose|Treatment with OPA-6566 low dose
9486181|NCT01410188|Experimental|OPA-6566 medium dose|Treatment with OPA-6566 medium dose
9486182|NCT01410188|Experimental|OPA-6566 high dose|Treatment with OPA-6566 high dose
9486183|NCT01410188|Active Comparator|Latanoprost|Treatment with Latanoprost
9486184|NCT01410188|Placebo Comparator|Placebo|Placebo
9486185|NCT01410188|Experimental|OPA-6566 additional dose|Treatment with OPA-6566 additional dose
9486186|NCT01408082|Experimental|ISV-502|
9542062|NCT03098875|Active Comparator|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
9542063|NCT03098875|Active Comparator|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
9542064|NCT03098901|Other|no other arm|
9542065|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
9542066|NCT03098940|Experimental|Chewing gum|Chewing gum with various doses of dronabinol
9542067|NCT03098940|Active Comparator|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
9542068|NCT03098927|Active Comparator|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
9542069|NCT03098927|Active Comparator|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
9542070|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.~Intervention: Exposure to aircraft exhaust"
9542071|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.~Intervention: Non exposure to aircraft exhaust"
9542072|NCT03098953|Experimental|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
9542073|NCT03098771|Experimental|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
9542074|NCT03098771|Experimental|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
9542075|NCT03098823|Experimental|RAYOS®|
9542076|NCT03098823|Active Comparator|IR prednisone|
9542077|NCT03098810|Placebo Comparator|Normal children|Placebo
9542078|NCT03098810|Experimental|Malnourished children|Oral zinc sulphate syrup
9542079|NCT03098732|Experimental|Magnetically Enhanced Diffusion (MED)|The Experimental Treatment will receive the complete MED System Procedure consisting of MED MicroBeads and the MED Workstation magnet procedure for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
9542080|NCT03098732|Sham Comparator|MED Workstation Magnet Sham Control|The MED Workstation Magnet Sham Comparator will not receive MED MicroBeads while the MED Workstation Magnet will be activated as a Sham control for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
9542081|NCT03098628|Active Comparator|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
9542082|NCT03098628|Active Comparator|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
9542083|NCT03098628|Active Comparator|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
9542084|NCT03098628|Active Comparator|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
9542085|NCT03098628|Other|Z - Control|Control group. PCV vaccine given at end of study (24 months)
9542086|NCT03098667|Experimental|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
9542087|NCT03098667|Active Comparator|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
9542088|NCT03098680|Experimental|Group A (Placebo, Salbutamol, Nicardipine, Dobutamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)"
9542089|NCT03098680|Experimental|Group B (Placebo, Phenylephrine, Verapamil, Phentolamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)"
9542090|NCT03098719|Experimental|Intervention|
9542091|NCT03098719|No Intervention|Control|
9542092|NCT03098446|Experimental|Prolonged sitting with exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
9542093|NCT03098446|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
9616463|NCT02542254|Active Comparator|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
9542094|NCT03098706|Other|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
9542095|NCT03098706|Experimental|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
9542096|NCT03098537|Active Comparator|Enteral nutrion only|
9542097|NCT03098537|Other|Enteral nutrion + proton pump inhibitor|
9542098|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
9542099|NCT03098407|Other|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
9542100|NCT03098407|Other|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
9542101|NCT03098524|Experimental|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with 5 acts/minute, tidal volume = 3 ml/kg (ideal body weight) with positive end-expiratory pressure = 5 cmH2O
9542102|NCT03098524|Placebo Comparator|No ventilation (noV arm)|No mechanical ventilation during cardiopulmonary bypass.
9542103|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
9542104|NCT03098368|Active Comparator|Patient (active) group|"Rotigotine titration up to 16 mg/24 hr~Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose~Duration up to 12 weeks~The treatment was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
9542105|NCT03098368|Placebo Comparator|Control (placebo) group|"Placebo transdermal patch were titration with the same protocol as active group.~Duration up to 12 weeks~The treatment (placebo patch) was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
9542106|NCT03098355|Experimental|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
9542107|NCT03098316||POAG|Primary open angle glaucoma patients
9542108|NCT03098316||NTG|Normal/Low tension glaucoma patients
10040009|NCT01849237|Experimental|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
10040010|NCT01849302|Experimental|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
9542109|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
9542110|NCT03098342|Experimental|MB-PDT for Onychomycosis|
9542111|NCT03098342|Active Comparator|Amorolfine for Onychomycosis|
9542112|NCT03098212|Experimental|Aromatherapy|Receive essential oil diffuse by Aroma diffuser during labor. Pain score and dose of analgesics drug are recorded
9542113|NCT03098212|No Intervention|Non-aromatherapy|This group receive pain control by standard of care without essential oil (aromatherapy)
9542114|NCT03098225|Experimental|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
9542115|NCT03098225|Active Comparator|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
9542116|NCT03098160|Experimental|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
9542117|NCT03098095|Experimental|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
9542118|NCT03098095|Experimental|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
9542119|NCT03098498|Experimental|Two-Stage Subgingival Debridement|Initially soft subgingival bacterial biofilms are removed from periodontal lesions by an airpolishing device and erythritol cleaning powder. 6 weeks later subgingival calculus is mechanically removed in a second step by mechanical scaling and root planing
9542120|NCT03098498|Active Comparator|One-Stage Subgingival Debridement|Soft subgingival bacterial biofilms, as well as subgingival calculus are concomitantly removed from periodontal lesions by mechanical scaling and root planing
9542121|NCT03098238|Other|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
10040011|NCT01849302|Experimental|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
10040012|NCT01849302|Experimental|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
9542122|NCT03098238|Other|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
9542123|NCT03098238|Other|Patients with humoral rejection|Patients with humoral rejection
9542124|NCT03098199|Experimental|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
9542125|NCT03098199|Experimental|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
9542126|NCT03098199|Experimental|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
9542127|NCT03098199|Experimental|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
9542128|NCT03098251|Experimental|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
9542129|NCT03098251|Active Comparator|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
9542130|NCT03097978|Experimental|RIC arm system with pattern recognition|Subject will be fit with a custom socket and receive training on pattern recognition with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
9542131|NCT03097978|Experimental|RIC arm system with direct control|Subject will be fit with a custom socket and receive training on direct control with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
9542132|NCT03097978|Experimental|Commercial system with PR control|Subject will be fit with a custom socket and receive training on pattern recognition with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
9542133|NCT03097978|Experimental|Commercial system with Direct Control|Subject will be fit with a custom socket and receive training on direct control with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
9542134|NCT03098134|Experimental|VR-Video-Exposure|
9542135|NCT03098134|Active Comparator|Education-Video-|
9542136|NCT03098056|Experimental|PROG2|All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
9542137|NCT03098121|Experimental|Genotype 1 HCV and HIV co-infection|Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.
9542138|NCT03098264|Experimental|Simultaneous surgery|to perform surgery both on biliary stone and portal hypertension
9542139|NCT03098264|Active Comparator|Staged surgery|to perform surgery on biliary stone and portal hypertension by staged surgery
9542140|NCT03098004|Experimental|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
9542141|NCT03098004|Active Comparator|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
9542142|NCT03098290||Intermittent Claudication|Mild to severe claudication
9542143|NCT03098290||Ischaemic Rest Pain|
9542144|NCT03098290||Critical Limb Threatening Ischaemia|Ulcers, Necrosis, Gangrene
9542145|NCT03098017|Active Comparator|Couscous (dry)|Cooked couscous (50g available carbohydrate, 70g uncooked) eaten with 500 mL of water
9542146|NCT03098017|Experimental|Short pasta (dry)|Cooked penne (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
9542147|NCT03098017|Experimental|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
9542148|NCT03098017|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
9542149|NCT03097965|Active Comparator|DIET|"High Phyto-PRO food plan~Physical activity~Cognitive behavioral program"
9542150|NCT03097965|Experimental|PROGRAM|"High Phyto-PRO food plan~Physical activity~Cognitive Behavioral Program~Protein Shakes~Phytosterols supplement~Berberine supplement~Anti-oxidant supplement~Probiotic supplement~Fish Oil supplement~Multiple Vitamin/Multiple Mineral supplement"
9542151|NCT03098186|Active Comparator|Intervention SMS|"SMS aimed to improved adherence to medications used in secondary prevention of cardiovascular disease.~Control SMS: SMS to thanks for participation in the trial and reminders of trial appointments."
9542152|NCT03098186|Placebo Comparator|Control SMS|SMS to thanks for participation in the trial and reminders of trial appointments.
9542153|NCT03098108|Experimental|CCPT|
9542154|NCT03097991|Experimental|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
9542155|NCT03097991|No Intervention|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
9542156|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
9542157|NCT03097939|Experimental|Nivolumab and Ipilimumab|
9542158|NCT03097926|Active Comparator|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
10040013|NCT01849302|Experimental|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
9542159|NCT03097926|Experimental|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
9542160|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
9542161|NCT03097692|Active Comparator|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
10040014|NCT01849302|Experimental|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
10040015|NCT01849302|Experimental|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
9542162|NCT03097692|Active Comparator|Pharmacologic preconditioing|by sevoflurane anesthesia
9542163|NCT03097848|Experimental|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
9542164|NCT03097848|Active Comparator|RFA group|for eligible cases, RFA will be given only.
9542165|NCT03097900|Active Comparator|Treatment (Caffeine Citrate) group|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
9542166|NCT03097900|Placebo Comparator|Placebo (Water) group|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
9542167|NCT03097627|Experimental|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
9542168|NCT03097757|No Intervention|(standard of care fracture reduction|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray.
9542169|NCT03097757|Experimental|ultrasound guided fracture reduction|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
9542170|NCT03097835|Other|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
9542171|NCT03097835|Other|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
9542172|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
9542173|NCT03097887|Active Comparator|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
9542174|NCT03097887|Active Comparator|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
9542175|NCT03097770|Experimental|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on day 1 in the absence of disease progression or unacceptable toxicity.
9542176|NCT03097705|Other|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
9542177|NCT03097640|Experimental|CHAMP|Participants enrolled in CHAMP are followed by a team of a social worker and physician across the care continuum. CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
9542178|NCT03097640|No Intervention|Standard Care|Individuals in the standard care arm will receive care as they do normally when hospitalized, including medical and inpatient social work services, as well as outpatient care from their providers.
9542179|NCT03097718||Non-specific low back pain|Individuals with recurrent non-specific low back pain
9542180|NCT03097718||Healthy control subjects|Healthy individuals without low back pain
9542181|NCT03097679|Active Comparator|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
9542182|NCT03097679|Active Comparator|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
9542183|NCT03097562|Experimental|CT1|"FLACS- Initial Wound parameters (CT1)~Sample size calculation based on woundleak incidence estimated from preliminary results:~For CT1 vs MT, we will only need 10 per group to have 80% power assuming a 1:1 ratio of CT to MT and 5% type 1 error.~For CT1 vs CT2, we will need 22 per group to have 80% power (assuming 60% wound leakage in CT1 and 20% wound leakage in CT2, a 1:1 ratio, and a 5% type 1 error rate)~A total of 253 patients are eligible for this study, 101 with FLACS and 152 with Manual Cataract Surgery. We thus expect that our study population will allow adequate analysis of the main outcome parameters proposed herein."
10040016|NCT01849302|Experimental|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
10040017|NCT01849315|Placebo Comparator|Control|Sedentary intervention
10040018|NCT01849315|Active Comparator|AKIDS II|Physically active group
10040019|NCT01849328||Breast Cancer|
10040020|NCT01849328||Healthy|
10040021|NCT01849341|Experimental|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
10040022|NCT01849341|Active Comparator|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
9616464|NCT02542254|Experimental|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
10040023|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
10040024|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
10040025|NCT01849367|Experimental|Active tDCS (1)|
10040026|NCT01849367|Active Comparator|Active tDCS (2)|
10040027|NCT01849380|Experimental|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
10040028|NCT01849380|Active Comparator|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
10040029|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
10040030|NCT01849406|Active Comparator|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
10040031|NCT01849406|Placebo Comparator|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
10040032|NCT01849432||Control|Healthy Controls
9486187|NCT01408082|Active Comparator|AzaSite|
9486188|NCT01408082|Active Comparator|Dexamethasone|
9486189|NCT01408082|Placebo Comparator|Vehicle|
9486190|NCT01407874|Experimental|Placebo|Placebo + Allopurinol 200mg
9486191|NCT01407874|Experimental|Ulodesine (BCX4208) 5mg|BCX4208 5mg + Allopurinol 200 mg
9486192|NCT01407874|Experimental|Ulodesine (BCX4208) 10mg|BCX4208 10mg + Allopurinol 200mg
9486193|NCT01407003|Experimental|LIK066 in healthy subjects|
9486194|NCT01407003|Placebo Comparator|Matching placebo in healthy subjects|
9486195|NCT01407003|Experimental|LIK066 in patients with type 2 diabetes mellitus|
9486196|NCT01407003|Placebo Comparator|Matching placebo in patients with type 2 diabetes mellitus|
9486197|NCT01406561|Experimental|OMS103HP-S|OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
9616465|NCT02542254|Experimental|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
10040033|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
10040034|NCT01849432||Panic Disorder|Participants with Panic Disorder
10040035|NCT01849432||Specific Phobia|Participants who have specific phobias
10040036|NCT01849445|Active Comparator|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
10040037|NCT01849445|Active Comparator|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
10040038|NCT01849471||patients with prostate cancer|questionnaires
10040039|NCT01849484|Experimental|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
10040040|NCT01849484|Active Comparator|Control|Radiation according to indication without hippocampal sparing
10040041|NCT01849510|Experimental|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
10040042|NCT01849510|Active Comparator|standard|hypofractionated 10x3 Gy
9486198|NCT01406561|Placebo Comparator|Vehicle Irrigation Solution|Vehicle Irrigation Solution
9486199|NCT01404585|Placebo Comparator|Arm 1: Placebo|
9486200|NCT01404585|Experimental|Arm 2: BMS-817399 (200 mg)|
9486201|NCT01404585|Experimental|Arm 3: BMS-817399 (400 mg)|
9486202|NCT01403636|Experimental|mantle cell|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
9486203|NCT01403636|Experimental|follicular lymphoma|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
9486204|NCT01403636|Experimental|CLL/SLL|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
9486205|NCT01403636|Experimental|Diffuse large B cell lymphoma|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
9486206|NCT01402401|Experimental|AUY922 + Trastuzumab|
9486207|NCT01401985|Experimental|Cohort 1|5 mg TD-1211 once daily for 4 days followed by 10 mg for 14 days
9486208|NCT01401985|Experimental|Cohort 2|5 mg TD-1211 once daily for 4 days followed by 15 mg for 14 days
9486209|NCT01401985|Experimental|Cohort 3|5 mg TD-1211 once daily for 2 days followed by 10 mg for 14 days
9486210|NCT01401985|Experimental|Cohort 4|5 mg TD-1211 once daily for 2 days followed by 15 mg for 14 days
9486211|NCT01401985|Experimental|Cohort 5|2 mg TD-1211 once daily for 14 days
9486212|NCT01401985|Experimental|Cohort 6|2.5 mg TD-1211 every 6 hours for 14 days
9486213|NCT01400776|Experimental|Vaginal Gel Three Times Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 3X/week for 10 weeks
9486214|NCT01400776|Placebo Comparator|Vehicle Twice Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 2X/week for 10 weeks
9486215|NCT01400776|Experimental|Vaginal Gel Twice Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 2X/week for 10 weeks
9486216|NCT01400776|Placebo Comparator|Vehicle Three Times Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 3X/week for 10 weeks
9486217|NCT01400594|Experimental|HTU-520 Patch|Subjects will receive HTU-520 patch in a 1:1 ratio for 48 weeks applied to all toenails.
9486218|NCT01400594|Placebo Comparator|Placebo Patch|Subjects will receive placebo patch in a 1:1 ratio for 48 weeks applied to all toenails.
9616466|NCT02542254|Placebo Comparator|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
9616467|NCT02542475|Experimental|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
10040043|NCT01849523|Experimental|Web-based information and support|Web-based tailored information and support
9542184|NCT03097562|Experimental|CT2|"The revised profile CT2, consists of a wider anterior side cut angle (beveled corneal undercut) and a narrower posterior side cut angle compared to the initial CT1 profile. This new corneal incision profile is constructed to ensure a tigher wound closure and a better corneal wound reapposition.~The traditional manual wound performed with a standard keratome wil be used as a reference."
10040044|NCT01849523|No Intervention|Standard care|Standard care
10040045|NCT01849536|Experimental|SENSIMED Triggerfish®|SENSIMED Triggerfish®
10040046|NCT01849549|Experimental|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
9542185|NCT03097562|Active Comparator|MT control group|Standard manual technique (MT)
9542186|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
10040047|NCT01849549|Sham Comparator|healthy volunteers|healthy controls
9542188|NCT03097549|Experimental|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
9542189|NCT03097549|Other|Tät®II Information app|"Information only.~."
9542190|NCT03097536|Experimental|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
9542191|NCT03097536|No Intervention|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
9542192|NCT03097380|Experimental|AZD2115|
9542193|NCT03097380|Active Comparator|Spiriva (Tiotropium)|
9542194|NCT03097380|Experimental|[11C]AZ13754366|
9542195|NCT03097419|Experimental|Intervention|Remote post-ischemic conditioning
9542196|NCT03097419|No Intervention|Control|Standard medical care by the primary treatment team.
9542197|NCT03097354||Non-students|Ad-hoc sample of German adults, not currently enrolled at a university, lifetime alcohol users, no intervention/observational survey study design
9542198|NCT03097354||University students|Ad-hoc sample of German adults, currently enrolled at a university (most likely in Dresden, Germany), lifetime alcohol users, no intervention/observational survey study design
9542199|NCT03097445|Experimental|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
9542200|NCT03097445|No Intervention|Control|No intervention control group
9542201|NCT03097406||Osteoarthritis group|Patients with osteoarthritis (2017-2019) at Herlev Hospital treated with Global Unite total shoulder arthroplasty
9542202|NCT03097406||Osteoarthritis control group|Patients with osteoarthritis (2013-2016) at Herlev Hospital treated with a Global Advantage
9542203|NCT03097406||Fracture group|Patients with a fracture of the proximal humerus (2017-2019) at Køge and Herlev Hospital treated with Global Unite hemiarthroplasty
9542204|NCT03097406||Fracture control group|Patients with a fracture of the proximal humerus (2013-2016) at Køge and Herlev Hospital treated with Global FX hemiarthroplasty
9542205|NCT03097432||ORALVAC COMPACT BÄUME|This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.
9542206|NCT03097458|Experimental|Counselling|short-term counselling for families
9542207|NCT03097458|No Intervention|Wait-list control group|Wait-list control group
9542208|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
9542209|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
9542210|NCT03097523|Experimental|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:~Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed~Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)~Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
9616468|NCT02542423|Other|patients undergoing cardiac surgery|
9616469|NCT02542293|Experimental|Combination Therapy|Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
9616470|NCT02542293|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
10040048|NCT01849601|Experimental|PTA catheter|
10040049|NCT01849614||Patient group|Women with left-sided breast cancer
10040050|NCT01849640|Active Comparator|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
10040051|NCT01849640|Active Comparator|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
9542211|NCT03097510|Experimental|Transcendental Meditation|The TM technique is a simple, natural, effortless technique that allows the mind to experience finer levels of the thinking process until the mind transcends and experiences the source of thought, a state of deep, integrated relaxation. During the meditation session, the active mind settles down to a silent yet fully awake state of awareness. TM was taught to study participants by certified instructors, using standardized procedures for teaching.
9542212|NCT03097510|No Intervention|Wait list control|This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
9542213|NCT03097237|Experimental|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
9542214|NCT03097237|Active Comparator|Refined wheat|Refined wheat products with a low content of dietary fiber
9542215|NCT03097250||PKU Subjects|Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
9542216|NCT03097250||Controls|Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.
9542217|NCT03097263||Patients|Patients included for rehabilitation program
9542218|NCT03097120|Active Comparator|unopposed estrogen|0.625 mg of conjugated equine estrogen
9542219|NCT03097120|Active Comparator|estrogen-plus-medroxyprogesterone|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
9542220|NCT03097120|Placebo Comparator|placebo|placebo
9542221|NCT03097068|Experimental|0.3 mg Lucentis|Aqueous Humor sample post injection of 0.3 mg Lucentis
9542222|NCT03097224|Experimental|Prehabilitation group|Tele-supervised prehabilitation
10040052|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
9542223|NCT03097224|No Intervention|Control group|Usual care
9542224|NCT03097211|Experimental|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
9542225|NCT03097211|Experimental|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
9542226|NCT03097211|Experimental|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
9542227|NCT03097211|Experimental|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
9616471|NCT02542137|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
9616472|NCT02542124|Experimental|NM-IL-12 and TSEBT|TSEBT and subcutaneous doses of NM-IL-12
9616473|NCT02541929|Experimental|DHA|DHA (2grams/day) for 26 weeks
9616474|NCT02541929|Placebo Comparator|placebo|placebo (4 capsules per day) for 26 weeks
9616475|NCT02541955|Active Comparator|40 Units|40 units of Acthar per week
9616476|NCT02541955|Active Comparator|80 Units|80 units of Acthar twice per week
9616477|NCT02541916|Experimental|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
9616478|NCT02542033|Active Comparator|verum|500mL treated apple juice with low sugar content given on one experimental day
9616479|NCT02542033|Placebo Comparator|control|500mL un-treated apple juice with normal sugar content given on one experimental day
9616480|NCT02541994|Other|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
9616481|NCT02542085|Active Comparator|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
9616482|NCT02542085|Active Comparator|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
9616483|NCT02542111|Experimental|V-GDP|Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4
9616484|NCT02542007|Experimental|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
9616485|NCT02542007|Active Comparator|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
9616486|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
9486219|NCT01399684|Experimental|MEGF0444A + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A + mFOLFOX-6 (oxaliplatin, folinic acid, and 5-fluorouracil) regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles (Cycle = 14 days) and 5-fluorouracil, folinic acid, bevacizumab and MEGF0444A will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
9486220|NCT01399684|Placebo Comparator|Placebo + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A matching placebo + mFOLFOX-6 regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles and 5-fluorouracil, folinic acid, bevacizumab and placebo will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
10040053|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
9486221|NCT01399658|Experimental|Image-Guided Brachytherapy|Image-guided brachytherapy
9486222|NCT01399580|Placebo Comparator|Group A - Placebo QD|
9486223|NCT01399580|Active Comparator|Group B - Low dose Atrasentan QD|
9486224|NCT01399580|Active Comparator|Group C - High dose Atrasentan QD|
10040054|NCT01849666|Active Comparator|A: phenprocoumon single dose|
10040055|NCT01849666|Experimental|B: vemurafenib + phenprocoumon single dose|
10040056|NCT01849679||Post-Extubation Subjects|
10040057|NCT01849705||All subjects|No intervention
10040058|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
10040059|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.~10 x ½ an hour of individual psychotherapy."
9486225|NCT01397968|Experimental|YKP3089|
9486226|NCT01397968|Placebo Comparator|Placebo|
9486227|NCT01397578|Experimental|Part 1: Subcutaneous cohort exp|
9486228|NCT01397578|Experimental|Part 2: Intravenous cohort exp|
9486229|NCT01397578|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
9486230|NCT01397578|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous injection
9486231|NCT01397227|Experimental|Cohort 1 (Low Dose)|Ad35.CS.01/Ad26.CS.01 - 1 x 10^10 vp
9486232|NCT01397227|Experimental|Cohort 2 (High Dose)|Ad35.CS.01/Ad26.CS.01 - 5 x 10^10 vp
9486233|NCT01397227|Placebo Comparator|Cohort 1 - Placebo|
9486234|NCT01397227|Placebo Comparator|Cohort 2 - Placebo|
9486235|NCT01397201|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
9486236|NCT01397201|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
9486237|NCT01397201|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
9486238|NCT01397201|Active Comparator|Fluticasone propionate 220mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 220 mcg ICS plus placebo matching Respimat inhaler
9486239|NCT01397201|Placebo Comparator|Placebo|patient to receive placebo matching Respimat inhaler plus placebo matching HFA MDI inhaler
9486240|NCT01397162|Experimental|BI 54903 LD BID|BI 54903 low dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
9486241|NCT01397162|Experimental|BI 54903 MD BID|BI 54903 medium dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
9486242|NCT01397162|Experimental|BI 54903 HD BID|BI 54903 high dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
9486243|NCT01397162|Active Comparator|Fluticasone propionate 88 mcg BID|44 mcg Fluticasone propionate 2 puffs BID via HFA MDI plus placebo BI54903 via Respimat inhaler 2 puffs b.i.d.
9486244|NCT01397162|Placebo Comparator|Placebo|Placebo Respimat inhaler 2 puffs b.i.d. and placebo HFA MDI, 2 puffs b.i.d.
9486245|NCT01396811|Experimental|Active|Product 33525
9486246|NCT01396811|Placebo Comparator|Placebo|Product 33525 Placebo
9486247|NCT01396785|Experimental|Active|Product 33525
9486248|NCT01396785|Placebo Comparator|Placebo|Product 33525 Placebo
9486249|NCT01396278|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
9486250|NCT01396278|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
9486251|NCT01396278|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
9486252|NCT01396278|Active Comparator|Fluticasone propionate 440 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 440 mcg ICS plus placebo matching Respimat inhaler
9486253|NCT01396278|Active Comparator|Fluticasone propioante 88 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 88 mcg ICS plus placebo matching Respimat inhaler
9486254|NCT01396213|Experimental|Larazotide Acetate 0.5 mg|larazotide acetate 0.5 mg capsules TID
9486255|NCT01396213|Experimental|Larazotide Acetate 1 mg|larazotide acetate 1 mg capsules TID
9486256|NCT01396213|Experimental|Larazotide Acetate 2 mg|larazotide acetate 2 mg capsules TID
9486257|NCT01396213|Placebo Comparator|Placebo|placebo capsules TID
9486258|NCT01395004|Experimental|Active Drug - GSK2110183|This was an open-label study of oral GSK211083 administered at the maximum tolerated dose of 125 mg once daily.
9486259|NCT01393639|Experimental|PF-04171327 1 mg QD|
9486260|NCT01393639|Experimental|PF-04171327 5 mg QD|
9486261|NCT01393639|Experimental|PF-04171327 10 mg QD|
9542228|NCT03096964|Experimental|Nordic walking|Experimental: Nordic walking Training The total period of training was composed by 8-week of walking with poles, three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Nordic walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
9542229|NCT03096964|Experimental|Free Walking|Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
9542230|NCT03097198|Experimental|PbN-TED|Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
9542231|NCT03097198|Experimental|TED-PbN|Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
9542232|NCT03096860|Experimental|Alcohol consumption and hookah|
9542233|NCT03096860|Placebo Comparator|Placebo consumption and hookah|
9542234|NCT03096977|Experimental|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
9542235|NCT03096886|Experimental|Early CCBT|"Intervention: Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
9542236|NCT03096886|Experimental|Late CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to be waitlisted for up to 4 weeks and will receive CCBT within 4 weeks; imaging data will also be collected pre--treatment, following waitlist, and post-treatment of CCBT.~This arm will serve as the equivalent of a placebo comparator arm during the waitlist; and then as an experimental arm when receiving 8 weeks of CCBT treatment."
9542237|NCT03096886|No Intervention|Matched Comparison|"No Intervention: Matched Comparison~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
9542238|NCT03096951|Experimental|Prehabilitation group|Preoperative and postoperative telerehabilitation
9542239|NCT03096951|Active Comparator|Rehabilitation group|Postoperative telerehabilitation
9542240|NCT03097172||Group 1|"Stable elective patients Stenotic coronary artery 10 x LAD 10 x RCA 10 x Cx~30 patients total"
9542241|NCT03097172||Group 2|"Stable elective patients Chronic total occlusion of one artery~10 x LAD 10 x RCA~20 patients total"
9542242|NCT03096925|Experimental|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
9542243|NCT03096925|No Intervention|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
9542244|NCT03097094|Active Comparator|Male dog|Male dog extract used for skin prick test and conjunctival provocation
9542245|NCT03097094|Active Comparator|Female dog|Female dog extract used for skin prick test and conjunctival provocation
9542246|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
9542247|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
9542248|NCT03096938|Placebo Comparator|Normal screening group|patients receive the routine screening examination
9542249|NCT03096938|Experimental|methylation markers screening group|patients receive the methylation markers screening
9542250|NCT03097042|Active Comparator|Study group|The catheter will be pulled back slowly and without rotation
9542251|NCT03097042|Active Comparator|Control Group|The catheter will be pulled back by rotating 360 degrees round itself
9542252|NCT03096912|Experimental|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
9542253|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
9542254|NCT03097081|Experimental|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
9542255|NCT03097081|Active Comparator|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
9542256|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
9542257|NCT03097055|Experimental|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
9542258|NCT03097055|Sham Comparator|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
9542259|NCT03097016|Experimental|Single oral dose of 3 mg CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
9542260|NCT03096821||ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
9542261|NCT03096795|Placebo Comparator|Part 1: Placebo|Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.
9542262|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 1|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.
9542263|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 2|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.
10040060|NCT01849731|Experimental|Intervention A|Face-to face intervention
10040061|NCT01849731|Experimental|Intervention B|Face-to-face intervention plus telephone reinforcement
10040062|NCT01849731|No Intervention|Control Group|
10040063|NCT01849744|Experimental|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
10040064|NCT01849757|Active Comparator|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
10040065|NCT01849757|Active Comparator|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
10040066|NCT01849757|Placebo Comparator|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
9486262|NCT01393639|Experimental|PF-04171327 15 mg QD|
9486263|NCT01393639|Active Comparator|prednisone 5 mg QD|
9486264|NCT01393639|Active Comparator|prednisone 10 mg QD|
9486265|NCT01393639|Placebo Comparator|placebo|
9486266|NCT01390545|Active Comparator|Veltuzumab 80 mg|
9486267|NCT01390545|Active Comparator|Veltuzumab 160 mg|
9486268|NCT01390545|Active Comparator|Veltuzumab 320 mg|
9486269|NCT01390545|Placebo Comparator|Placebo|
9486270|NCT01389700|Experimental|SAR279356 dose 1|SAR279356 dose 1, single administration
9486271|NCT01389700|Experimental|SAR279356 dose 2|SAR279356 dose 2, single administration
9486272|NCT01389700|Placebo Comparator|Placebo|Matching placebo, single administration
9486273|NCT01388933|Experimental|TU-100|15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
9486274|NCT01388933|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 8 consecutive weeks
9486275|NCT01385592|Experimental|AFQ056 100 mg|
9486276|NCT01385592|Placebo Comparator|Placebo|
9498036|NCT03469687|Other|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
9498037|NCT03469674|Experimental|Molecular profile based treatment|Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile
9498038|NCT03469674|Active Comparator|Vaginal brachytherapy|Adjuvant vaginal brachytherapy (standard treatment)
9498039|NCT03469661||Immune Thrombocytopenia Diagnosis|
9498040|NCT03469661||Myelodysplastic Syndrome Diagnosis|
9498041|NCT03469622|Active Comparator|EndoRings|Colonoscopy is performed with the EndoRings attached
9498042|NCT03469622|Active Comparator|Standard Colonoscopy|Standard colonoscopy without any additional devices
9498043|NCT03469583|Experimental|EYP001 dose1|EYP001 capsules by mouth
9498044|NCT03469583|Active Comparator|Entecavir 1mg|2 tablets of 0.5mg, by mouth
9498045|NCT03469583|Experimental|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
9498046|NCT03469570|Experimental|Assisted Fluid Management|
9498047|NCT03469557|Experimental|Esophageal Squamous Cell Carcinoma (ESCC)|
9498048|NCT03469557|Experimental|Gastric (GC) and Gastroesophageal Junction (GEJ) Carcinoma|
9498049|NCT03469544||Group 1 (30)|"Patient with cancer thyroid proved by cytological analysis Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood ,Enzyme linked Immunosorbent Assay for serum midkine level"
9498050|NCT03469544||Group 2 (30)|"Patient with benign thyroid nodule Interventions;complete blood picture ,serum urea and creatinine,liver function test ,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
9498051|NCT03469544||Group 3 (30)|"Normal healthy subjects as control group Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
9498052|NCT03469531|Experimental|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
9498053|NCT03469531|Active Comparator|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
9498054|NCT03469518|Sham Comparator|β-Cx plus PS|Fruit and milk based beverage enriched with beta-cryptoxanthin and plant sterols
9498055|NCT03469518|Active Comparator|β-Cx plus PS plus GOS|Fruit and milk bases beverage enriched with beta-criptoxanthin, plant sterols and galactooligosaccharides
9498056|NCT03469505|Active Comparator|data from veterans using COPES|Data from veterans using COPES for chronic pain
9498057|NCT03469505|Active Comparator|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
9498058|NCT03469479|Experimental|Resection plus HAIC with FOLFOX|Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
9498059|NCT03469479|Active Comparator|Resection|Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
9498060|NCT03469466||untrained|Volunteers untrained in bedside ultrasound technique
9498061|NCT03469466||trained|Volunteers previously trained and experienced in bedside ultrasound technique
9498062|NCT03469466||healthy volunteer|Standardized patient who will undergo ultrasound study
10040067|NCT01849783|Experimental|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
10040068|NCT01849796|Active Comparator|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
10040069|NCT01849796|Sham Comparator|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
10040070|NCT01849809|Experimental|Gamma Ventral Capsulotomy|
10040071|NCT01849835|Experimental|trans-rectal|trans-rectal to perform the prostate biopsy
10040072|NCT01849835|Experimental|trans-perineal|trans-perineal to perform the prostate biopsy
10040073|NCT01849861|Experimental|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
10040074|NCT01849887|Active Comparator|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
9542264|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 3|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.
9542265|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 4|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.
9542266|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 5|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.
9542267|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.
9542268|NCT03096795|Experimental|Part 1: MEDI3506 IV Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.
9542269|NCT03096795|Placebo Comparator|Part 2: Placebo|Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
9542270|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 4|Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
9542271|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 5|Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
9542272|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 6|Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
9542273|NCT03096795|Placebo Comparator|Part 3: Placebo|Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.
9542274|NCT03096795|Experimental|Part 3: MEDI3506 IV Dose 6|Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.
9542275|NCT03096782|Experimental|Group I (chemotherapy, TBI, cord blood)|"Patients receive rituximab IV on day -11, ATG IV over 4 hours on days -9 and -8, fludarabine IV over 1 hour, clofarabine IV over 1 hour, busulfan IV over 3 hours on days -7 through -4, and TBI on day -3. Patients then receive a cord blood transfusion IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
9542276|NCT03096782|Experimental|Group II (chemotherapy, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -5 to -2, and melphalan IV over 30 minutes on day -2. Patients then receive a cord blood transplant IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
9542277|NCT03096782|Experimental|Group III (chemotherapy, TBI, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -3, cyclophosphamide IV over 1 hour on day -6, and one low-dose treatment of TBI on day -1. Patients then receive a cord blood transplant IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
9542278|NCT03096769|Other|Study Arm|
9542279|NCT03096756|Other|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
10040075|NCT01849887|Placebo Comparator|Placebo|Placebo
10040076|NCT01849900|Other|Healthy Lifestyle|60 women randomly assigned to the control group
10040077|NCT01849900|Other|Knowing your body|60 women randomly assigned to intervention group
10040078|NCT01849913|Experimental|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
10040079|NCT01849913|No Intervention|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
10040080|NCT01849926|Active Comparator|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
10040081|NCT01849926|Active Comparator|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
10040082|NCT01849939|Experimental|Fludarabin|
10040083|NCT01849965|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
10040084|NCT01849965|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
10040085|NCT01849965|Placebo Comparator|Standard of Care gel|Aquasite gel, as standard of care gel
9486277|NCT01384630|Other|Single group|
9486278|NCT01384383|Experimental|Arm 1|Response-Guided Therapy with GS-5885 30 mg plus GS-9451 200 mg, plus PEG and RBV for 6 or 12 weeks.
9486279|NCT01384383|Experimental|Arm 2|Response-Guided Therapy with PEG and RBV for 24 weeks.
9486280|NCT01382797|Placebo Comparator|Placebo|Capsules for oral administration
9486281|NCT01382797|Experimental|ALKS 37|Capsules for oral administration
9486282|NCT01382654|Experimental|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
9486283|NCT01382654|Experimental|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
9486284|NCT01382654|Experimental|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
9486285|NCT01382654|Experimental|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
9486286|NCT01382654|Active Comparator|azelastine 0.1%|nasal spray 2 sprays in each nostril for a total of 3 doses
9486287|NCT01381731|Experimental|Diquafosol tetrasodium ophthalmic solution 2%|topical ophthalmic solution
9486288|NCT01381731|Placebo Comparator|Placebo|saline ophthalmic solution
9486289|NCT01381666|Experimental|INS316|inhalation via nebulizer given for 2 doses for 60 minutes each
9486290|NCT01381666|Placebo Comparator|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
9486291|NCT01381107|Experimental|ALKS 5461 (ALKS 33 and buprenorphine)|
9486292|NCT01381107|Placebo Comparator|Placebo|
9486293|NCT01381094|Experimental|AKB-6548 240 mg|
9486294|NCT01381094|Experimental|AKB-6548 370 mg|
9486295|NCT01381094|Experimental|AKB-6548 500 mg|
9486296|NCT01381094|Experimental|AKB-6548 630 mg|
9486297|NCT01381094|Placebo Comparator|Placebo|
9486298|NCT01379209|Experimental|RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Dose escalation cohort 1 in part 1 of this study will include 2-6 patients"
9486299|NCT01379209|Experimental|RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 2 in part 1 of this study will include 2-6 patients"
9486300|NCT01379209|Experimental|RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 3 in part 1 of this study will include 2-6 patients"
9486301|NCT01379209|Experimental|RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 4 in part 1 of this study will include 2-6 patients"
9486302|NCT01379209|Experimental|RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 5 in part 1 of this study will include 2-6 patients"
9486303|NCT01379209|Experimental|RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 6 in part 1 of this study will include 2-6 patients"
9486304|NCT01379209|Experimental|RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 7 in part 1 of this study will include 2-6 patients (optional)"
9486305|NCT01379209|Experimental|RGI-2001 + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons."
9486306|NCT01378676|Placebo Comparator|Matching Placebo|
9486307|NCT01378676|Experimental|Active Drug Low Dose (CK-2017357 125 mg)|
9486308|NCT01378676|Experimental|Active Drug Mid Dose (CK-2017357 250 mg)|
9486309|NCT01378676|Experimental|Active Drug High Dose (CK-2017357 375 mg)|
9486310|NCT01377662|Placebo Comparator|Placebo|
9486311|NCT01377662|Experimental|OND-PR002 and MPh-IR|
9486312|NCT01373086|Experimental|LFF269 low dose|LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period
9486313|NCT01373086|Experimental|LFF269 high dose|LFF269 high dose + Matching Placebo to Eplerenone 50mg
9486314|NCT01373086|Active Comparator|Eplerenone|Eplerenone 50mg twice daily + matching placebo of LFF269
9486315|NCT01373086|Placebo Comparator|Placebo|Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg
9542280|NCT03096756|Experimental|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
9542281|NCT03096743|Experimental|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
9542282|NCT03096743|Experimental|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
9542283|NCT03096574||Pregnant women|"Over the age of 16~Under the care of staff working in: University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
9542284|NCT03096574||Maternity healthcare professionals|"Over the age of 18~Working in obstetrics or midwifery who regularly care for women in pregnancy at University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
9542285|NCT03096574||UK General Practitioners|"Fully-qualified general practitioners practicing in the UK~Able to read and write in English and give fully informed consent"
9542286|NCT03096561|Other|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
9542287|NCT03096587|Experimental|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
9542288|NCT03096587|Active Comparator|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
9542289|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
9542290|NCT03096704||slow transit time constipation|
9542291|NCT03096639|Active Comparator|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
9542292|NCT03096639|No Intervention|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
9542293|NCT03096470||anesthesia|The children were treated with closed reduction with anesthesia after prolonged traction
9542294|NCT03096470||No anesthesia|The children were treated with closed reduction with no anesthesia after prolonged traction
9542295|NCT03096652|Active Comparator|Midline approach|Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
9542296|NCT03096652|Active Comparator|Modified approach|Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
9542297|NCT03096691|Active Comparator|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
9542298|NCT03096691|Active Comparator|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
9542299|NCT03096535|Experimental|Cooling|Individualized cooling protocol.
9542300|NCT03096535|Experimental|Thermoneutral|Thermoneutral condition day.
9542301|NCT03096678||LBBB without LV dysfunction|LVEDD>55mm or LVEF<55%
9542302|NCT03096678||LBBB with LV dysfunction|LVEDD<55mm and LVEF>55%
9542303|NCT03096496||GIMEMA APL0406 patients|APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.
9542304|NCT03096301|Experimental|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
9542305|NCT03096301|Active Comparator|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
9542306|NCT03096301|Placebo Comparator|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
9542307|NCT03096548|Experimental|Sun Safety Ink! Program|A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
9542308|NCT03096548|Active Comparator|Attention Control|The attention control group will provide standard tattoo aftercare instructions to their clients.
9542309|NCT03096327|Experimental|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
9542310|NCT03096327|Placebo Comparator|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
10040086|NCT01849978|Active Comparator|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
9542311|NCT03096613|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
9542312|NCT03096613|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
9542313|NCT03096340|Experimental|IT-141|
9542314|NCT03096366|Experimental|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
9542315|NCT03096366|Active Comparator|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
9542316|NCT03096392|Experimental|HDV insulin lispro 100 UNT/mL|insulin lispro with 0.8 ml HDV added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
9542317|NCT03096392|Active Comparator|insulin lispro 100 UNT/ML|insulin lispro with 0.8 ml sterile water for injection added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
9542318|NCT03096522|Active Comparator|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
9542319|NCT03096522|Active Comparator|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
9542320|NCT03096431|Active Comparator|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
9542321|NCT03096431|Active Comparator|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
9542322|NCT03096431|Active Comparator|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
9542323|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
9542324|NCT03096262|Experimental|Stroke Patients|
9542325|NCT03096262|Active Comparator|Healthy Controls|
9542326|NCT03096457|Experimental|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
9542327|NCT03096457|Active Comparator|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
9542328|NCT03096457|Placebo Comparator|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
9542329|NCT03096249|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
9542330|NCT03096249|Placebo Comparator|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
9542331|NCT03096223|Experimental|KHK4083|
9542332|NCT03096210|Other|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
10040087|NCT01849978|Active Comparator|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
10040088|NCT01849991|Active Comparator|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10^8 cfu's orally once daily.)
10040089|NCT01849991|Placebo Comparator|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
10040090|NCT01850017|Experimental|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
9486316|NCT01372475|Active Comparator|Hymovis Viscoelastic Hydrogel|Intra-articular Injection
9486317|NCT01372475|Placebo Comparator|Placebo|Phosphate Buffered Saline Intra-articular Injection
9486318|NCT01371578|Experimental|Arm 2|"AM Dosing: One GS-5885 30 mg tablet, two GS-9451 100 mg tablets, orally with RBV and with food.~PM Dosing: RBV with food.~PEG, 180 µg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design). Pegasys® prefilled syringes (Hoffman-La Roche) will be supplied by Gilead Sciences."
9486319|NCT01370512|Experimental|droxidopa plus pyridostigmine|droxidopa 100mg by mouth three times a day plus pyridostigmine 60mg by mouth three times a day (one day)
9486320|NCT01370512|Active Comparator|droxidopa|droxidopa 100mg by mouth three times a day plus placebo (for pyridostigmine) by mouth three times a day (one day)
9486321|NCT01370512|Active Comparator|pyridostigmine|pyridostigmine 60mg by mouth three times a day plus placebo (for droxidopa) by mouth three times a day
9486322|NCT01370512|Placebo Comparator|placebo|placebo (for pyridostigmine) by mouth three times a day plus placebo (for droxidopa) by mouth three times a day
9486323|NCT01370421||Knee OA patients undergoing Total Knee Arthroplasty (TKA)|Participants will be 45 years or older, diagnosed with Osteoarthritis of the knee and be scheduled for a unilateral total knee replacement surgery.
9486324|NCT01369589|Experimental|P-552 on Day 1 and Placebo on Day 2|Randomly assigned subjects will receive a single dose of P-552 on Day 1 followed by a single dose of Placebo on Day 2
9486325|NCT01369589|Experimental|Placebo on Day 1 and P-552 on Day 2|Randomly assigned subjects will receive a single dose of Placebo on Day 1 followed by a single dose of P-52 on Day 2
9486326|NCT01369147|Experimental|Parenteral nutrition energy dose at 0.6x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 0.6 x resting energy expenditure (REE).
9486327|NCT01369147|Active Comparator|Parenteral nutrition energy dose at 1.0 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.0 x resting energy expenditure (REE).
9486328|NCT01369147|Experimental|Parenteral nutrition energy dose at 1.3 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.3 x resting energy expenditure (REE).
9486329|NCT01369095|Active Comparator|Arm 1: Duloxetine / Escitalopram + BMS-820836 placebo|
9486330|NCT01369095|Experimental|Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placebo|
9486331|NCT01369095|Experimental|Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placebo|
9486332|NCT01369095|Experimental|Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placebo|
9486333|NCT01369095|Experimental|Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placebo|
9486334|NCT01366820|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion of NNZ-2566 over 10 minutes followed by a continuous intravenous infusion of 6 mg/kg/h (n=133) intravenous infusion of NNZ-2566 for a total of 72 consecutive hours.
9486335|NCT01366820|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion of Sodium Chloride (0.9%) for Injection over 10 minutes followed by a continuous intravenous infusion of Sodium Chloride (0.9%) for Injection for a total of 72 consecutive hours.
9486336|NCT01366131|Experimental|A|
9486337|NCT01366131|Experimental|B|
9486338|NCT01366014|Experimental|ARRY-371797|
9486339|NCT01366014|Active Comparator|Oxycodone HCl ER|
9486340|NCT01366014|Placebo Comparator|Placebo|
9486341|NCT01365195|Placebo Comparator|Control|"Loading and Infusion:~Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate"
9486342|NCT01365195|Active Comparator|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
9486343|NCT01365195|Active Comparator|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
9486344|NCT01364662|Experimental|1|
9486345|NCT01364662|Experimental|2|
9486346|NCT01364662|Experimental|3|
9486347|NCT01364662|Experimental|4|
9486348|NCT01361802|Active Comparator|Ambroxol Spray 2.5mg|Ambroxol Spray Low Dose
9486349|NCT01361802|Active Comparator|Ambroxol Spray 5mg|Ambroxol Spray Medium Dose
9486350|NCT01361802|Active Comparator|Ambroxol Spray 10mg|Ambroxol Spray High dose
9486351|NCT01361802|Placebo Comparator|Placebo Spray|Placebo Spray
9486352|NCT01361555|Experimental|Arm 1: Placebo + BMS-820836 (0.5 mg/day)|
9486353|NCT01361555|Experimental|Arm 2: Placebo + BMS-820836 (1 mg/day)|
9486354|NCT01361555|Experimental|Arm 3: Placebo + BMS-820836 (2 mg/day)|
9486355|NCT01360853|Experimental|Arm A: Combination|Arm A: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle, + ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
9486356|NCT01360853|Active Comparator|Arm B: Gemcitabine only|Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
9486357|NCT01359969|Experimental|Recombinant Human C1 Inhibitor|Patients presented to the clinic within 5 hours of onset received rhC1INH 50 U/kg body weight up to a maximum of 4200 U.
9486358|NCT01359566|Active Comparator|Arbaclofen placarbil 15 mg BID|Arbaclofen placarbil (XP19986 SR4) 15 mg every morning and every evening
9616487|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
9486359|NCT01359566|Active Comparator|Arbaclofen placarbil 30 mg BID|Arbaclofen placarbil (XP19986 SR4) 30 mg every morning and every evening
9486360|NCT01359566|Active Comparator|Arbaclofen placarbil 45 mg BID|Arbaclofen placarbil (XP19986 SR4) 45 mg every morning and every evening
9486361|NCT01359566|Placebo Comparator|Placebo|Placebo every morning and every evening
9486362|NCT01358695|Placebo Comparator|Placebo Comparator|
9486363|NCT01358695|Experimental|Dose 1|Dose 1
9486364|NCT01358695|Experimental|Dose 2|Dose 2
9486365|NCT01358695|Experimental|Dose 3|Dose 3
9486366|NCT01358695|Experimental|Dose 4|Dose 4
9486367|NCT01358695|Experimental|Dose 5|Dose 5
9486368|NCT01357642|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of E004, QID, with 4-6 hr intervals
9486369|NCT01357642|Placebo Comparator|Arm P|Placebo comparator as 2×Placebo QID, with 4-6 hr intervals
9486370|NCT01357642|Active Comparator|Arm A|Active comparator, Primatene Mist, 2×220 mcg/inhalation, QID, with 4-6 hr intervals
9486371|NCT01357395|Experimental|Amuvatinib|Amuvatinib 300 mg PO TID + standard-of-care platinum-etoposide
9486372|NCT01356914|Experimental|Treatment A: BMS-914392|
9486373|NCT01356914|Experimental|Treatment B: BMS-914392|
9486374|NCT01356914|Experimental|Treatment C: BMS-914392|
9486375|NCT01356914|Placebo Comparator|Treatment D: Placebo|
9486376|NCT01356849|Placebo Comparator|Group A - Placebo QD|
9486377|NCT01356849|Active Comparator|Group B - Low dose Atrasentan QD|
9486378|NCT01356849|Active Comparator|Group C - High dose Atrasentan QD|
9486379|NCT01356160|Active Comparator|Arm 1|RGT with GS-5885 30 mg QD + GS-9451 200 mg QD + PEG/RBV
9486380|NCT01356160|Placebo Comparator|Arm 2|RGT with GS-5885 30 mg QD + GS-9451 placebo QD + PEG/RBV
9486381|NCT01355406|Other|PAD|This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at > 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
9486382|NCT01355393|Experimental|Stage I, Arm 1 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 1: HER2 peptide vaccine + 4 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
9486383|NCT01355393|Active Comparator|Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
9486384|NCT01355393|Experimental|Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
9486385|NCT01355393|Experimental|Stage I, Arm 2 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 2: HER2 peptide vaccine + 20 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
9486386|NCT01355393|Experimental|Stage I, Arm 3 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 3: HER2 peptide vaccine + 79 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
9486387|NCT01355393|Experimental|Stage I, Arm 4 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 4: HER2 peptide vaccine + 495 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
9486388|NCT01355393|Experimental|Stage I; Arm 5 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 5: HER2 peptide vaccine + 2000 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
9486389|NCT01354717|Active Comparator|Brand Carac|Treatment of actinic keratosis with active ingredient
9486390|NCT01354717|Active Comparator|Generic 0.5% 5-fluorouracil cream|Treatment of actinic keratosis with active ingredient
9486391|NCT01354717|Placebo Comparator|Placebo|treatment of actinic keratosis with placebo cream
9486392|NCT01353248|Active Comparator|Arm 1|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.
9486393|NCT01353248|Active Comparator|Arm 2|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 12 or 24 weeks.
9486394|NCT01351675|Placebo Comparator|Placebo|
9486395|NCT01351675|Experimental|Bardoxolone Methyl|
9486396|NCT01349998|Experimental|Safety Population|
9486397|NCT01349868|Experimental|PT005 MDI (Dose 1)|PT005 MDI (Dose 1)
9486398|NCT01349868|Experimental|PT005 MDI (Dose 2)|PT005 MDI (Dose 2)
9486399|NCT01349868|Experimental|PT005 MDI (Dose 3)|PT005 MDI (Dose 3)
9486400|NCT01349868|Placebo Comparator|Placebo MDI|Placebo MDI
9486401|NCT01349868|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
9486402|NCT01349868|Active Comparator|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 24 μg
9486403|NCT01348919|Experimental|CEP-18770 in Combination With Lenalidomide and Dexamethasone|
9486404|NCT01348152|Placebo Comparator|Placebo|Placebo TID
9486405|NCT01348152|Experimental|DAIKENCHUTO (TU-100) 15 g/day|TU-100 5g TID
9486406|NCT01345045|Experimental|ABT-639|ABT-639 twice daily for 6 weeks
9486407|NCT01345045|Active Comparator|pregabalin|pregabalin starting dose twice daily for week one then titrated up to maintenance dose twice daily for duration of the study
9486408|NCT01345045|Placebo Comparator|Placebo|Placebo twice daily for 6 weeks
9486409|NCT01345006|Experimental|MA09-hRPE|Patients will undergo subretinal injection of MA09-hRPE
9542333|NCT03096210|Other|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
9542334|NCT03096145|Experimental|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
9542335|NCT03096054|Experimental|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
9542336|NCT03096054|Experimental|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
9542337|NCT03096132|Active Comparator|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
9542338|NCT03096132|Experimental|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
9542339|NCT03096171|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
9542340|NCT03096171|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
9542341|NCT03096197|Experimental|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
9542342|NCT03096197|Experimental|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
9542343|NCT03095950|Active Comparator|News with Spin|News items reporting results of RCTs with spin
9542344|NCT03095950|Experimental|News without spin|News items reporting results of RCTs without spin
9542345|NCT03096015|Experimental|Intensive Treatment for Aphasia|
9542346|NCT03095872|Experimental|Bepanthen/Vaseline|One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
9542347|NCT03095911|Active Comparator|News with Spin|News items reporting results of RCTs with spin
9542348|NCT03095911|Experimental|News without spin|News items reporting results of RCTs without spin
9542349|NCT03095963|Active Comparator|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
9542350|NCT03095963|Active Comparator|Levothyroxine|The control group took levothyroxine only
9542351|NCT03096002||Lifestyle change (one-treatment group)|The lifestyle change program is a 3-week program that will introduce participants to a regular healthy lifestyle that includes exercising at least three times per week and the program will highlight simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 12 months after the program has concluded.
9542352|NCT03095898|Experimental|True Acupuncture|
9542353|NCT03095898|Sham Comparator|Sham Acupuncture|
9542354|NCT03095898|No Intervention|Control Group|
9542355|NCT03096080|Experimental|Cohort 1|Single 0.25 mg/kg dose of tesevatinib
9542356|NCT03096080|Experimental|Cohort 2|Single 0.50 mg/kg dose of tesevatinib
9542357|NCT03096080|Experimental|Cohort 3|Single 1.00 mg/kg dose of tesevatinib
9542358|NCT03095989|Experimental|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
9542359|NCT03095989|No Intervention|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
9542360|NCT03096184|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
9542361|NCT03095755|Experimental|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
9542362|NCT03095755|Sham Comparator|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
9616488|NCT02542098|Experimental|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
9542363|NCT03096028||PMNS cohort|The Pune Maternal Nutrition Study (PMNS) is a preconceptional birth cohort established in 1993 at Diabetes unit KEM hospital research center, Pune. 700 offsprings of the cohort are being followed every 6 years. Maternal vitamin B12 folate level during pregnancy were measured at 18 & 28 weeks.
9542364|NCT03096158|Experimental|Ventilatory Muscle Training (TREMVEN)|The enrolled participants will perform inspiratory muscle training (IMT) for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
9542365|NCT03096158|Experimental|Aerobic Training (AERO)|It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
9542366|NCT03096158|Experimental|Isometric Handgrip Training (ISO)|Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
9542367|NCT03095859|Active Comparator|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
9542368|NCT03095859|Experimental|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
9542369|NCT03095794|Experimental|neural mechanisms of decision making|Previous studies on how brain manages a value-based decision have been bounded to individual decisions. The current study will extend the understanding of social dimensions by answering four questions.
9542370|NCT03095924|Active Comparator|News with Spin|News items reporting results of RCTs with spin
9542371|NCT03095924|Experimental|News without spin|News items reporting results of RCTs without spin
9542372|NCT03095573|Experimental|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
9542373|NCT03095573|Active Comparator|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
9542374|NCT03095768|Experimental|Intervention|Lifestyle Education and Cooking Demonstration
9542375|NCT03095677|Experimental|Apnea Group (GApn)|Program of training with exercises including apneas
9542376|NCT03095677|Other|Control Group (GC)|Program of training with exercises without apnea
9542377|NCT03095586|Active Comparator|News with Spin|News items reporting results of RCTs with spin
9542378|NCT03095586|Experimental|News without spin|News items reporting results of RCTs without spin
9542379|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
9542380|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
9542381|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
9542382|NCT03095534|Experimental|3-Step Workout for Life|Participants will exercise at the moderate intensity three times a week for 10 weeks. The total of 30 workout sessions will consist of 18 sessions of group single-joint resistance exercise, 6 sessions of one-on-one multiple-joint resistance exercise, and 6 sessions of one-on-one activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice daily tasks around the home. The community fitness staff will modify the task demand to increase the physical challenge of the task to each participant, for example, increasing travel distance.
9542383|NCT03095690|Other|Idiopathic Parkinson's Disease patients|High resolution peripheral scanner (HRpQCT).
9542384|NCT03095716||elderly patients|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
9542385|NCT03095807|Experimental|NNC9204-1706 A|
9542386|NCT03095807|Placebo Comparator|Placebo|
9542387|NCT03095547|Experimental|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
9542388|NCT03095547|Experimental|F901318 & posaconazole|Interaction between posaconazole and F901318
9542389|NCT03095547|Experimental|F901318 & pantoprazole|Interaction between pantoprazole and F901318
9542390|NCT03095547|Experimental|F901318|F901318 alone
9542391|NCT03095833|Other|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
9542392|NCT03095833|Other|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
9542393|NCT03095846|Experimental|Winter Swimmers|Individualized cooling protocol
9542394|NCT03095846|Experimental|Not-winter Swimmers|Individualized cooling protocol
9542397|NCT03095495|Experimental|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
9542398|NCT03095495|Active Comparator|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
9542399|NCT03095703|Experimental|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
9542400|NCT03095560|Experimental|Semi-immersive virtual training with shadow (S-IVTS)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
9542401|NCT03095560|Experimental|Semi-immersive virtual training without shadow (S-IVT)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVT group the projector is located in front of the patient and the shadow is not visible.
9616489|NCT02541825|Experimental|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
9616490|NCT02541825|Other|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
9616491|NCT02541890|Experimental|Work place intervention|Work place intervention in addition to rehabilitation program.
9616492|NCT02541890|No Intervention|Rehabilitation program only|Rehabilitation program without intervention at the work place.
9616493|NCT02541877|Experimental|Down sizing valve in type-0 BAS|Down Sizing Transcatheter Self-expandable Valve in Type-0 BAS
9616494|NCT02541877|Active Comparator|Standard sizing valve in type-0 BAS|Standard Sizing Transcatheter Self-expandable Valve in Type-0 BAS
9616495|NCT02541877|Active Comparator|Standard sizing valve in TAS|Standard Sizing Transcatheter Self-expandable Valve in TAS
9616496|NCT02541734|Experimental|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
9616497|NCT02541734|Placebo Comparator|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
9616498|NCT02541747|Active Comparator|massage|massage for 30 min, once a week for 4 weeks
9616499|NCT02541747|No Intervention|control|Rest as control
9616500|NCT02541786|Active Comparator|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
9616501|NCT02541786|Experimental|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
9616502|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
9616503|NCT02541656|Experimental|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
9616504|NCT02541760|Experimental|Montelukast|4 ml monteleukast daily for one month
9616505|NCT02541760|Active Comparator|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
9616506|NCT02541760|No Intervention|Control|No intervention
9621725|NCT02521961|Experimental|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
9621726|NCT02521961|Active Comparator|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
9621727|NCT02521831|Active Comparator|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
9621728|NCT02521831|Active Comparator|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
9621729|NCT02521818|Experimental|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
9621730|NCT02521818|Active Comparator|NIA Diet for Seniors|Diet recommended by NIA for seniors
9621731|NCT02521896|Experimental|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
9621732|NCT02521857|Experimental|ALKS 5461|Sublingual tablet
9662955|NCT04449744|Active Comparator|MySafeRx Group A-(coaching + medication dispenser)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
9486410|NCT01344993|Experimental|MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
9486411|NCT01344187|Experimental|riboflavin solution and KXL System|Subjects will receive riboflavin solution followed by UVA irradiation for 4 minutes
9486412|NCT01344187|Placebo Comparator|placebo solution and KXL System|Subjects will receive placebo solution followed by UVA irradiation for 4 minutes
9486413|NCT01343966|Experimental|Part 1: Subcutaneous cohort exp|
9486414|NCT01343966|Experimental|Part 2: Intravenous cohort exp|
9486415|NCT01343966|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
9486416|NCT01343966|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous infusion
9486417|NCT01342315|Experimental|Active|Product 33525
9486418|NCT01342315|Experimental|Placebo|Product 33525 Placebo
9486419|NCT01339689|Experimental|Ganaxolone|active
9486420|NCT01339689|Placebo Comparator|Placebo|non-active
9486421|NCT01338883|Experimental|CVC 100 mg + Truvada|
9486422|NCT01338883|Experimental|CVC 200 mg + Truvada|
9486423|NCT01338883|Active Comparator|Sustiva + Truvada|
9486424|NCT01338805|Experimental|BGG492|hard gelatin capsule for oral administration at 50 mg TID, 100 mg TID or 150 mg TID
9486425|NCT01337752|Experimental|BHQ880 + bortezomib and dexamethasone|
9486426|NCT01337752|Placebo Comparator|BHQ880 Placebo + bortezomib and dexamethasone|
9486427|NCT01337349|Placebo Comparator|Sugar Pill|Placebo control Group with sugar pill three times daily for 6 months
9486428|NCT01337349|Experimental|Pentoxifylline|Pentoxifylline 400mg tablets to be taken three times daily for 6 months
9486429|NCT01337245|Experimental|Antivenom|For comparison with historical mortality rate, all patients prospectively enrolled will receive antivenom (Snake [Micrurus] North American immune F(ab')2 Equine) for treatment of coral snake bite.
9486430|NCT01336686|Experimental|Arhalofenate 400 mg|
9486431|NCT01336686|Experimental|Arhalofenate 600 mg|
9486432|NCT01336686|Placebo Comparator|Placebo|
9486433|NCT01336465|Experimental|rhuMAb Beta7|
9486434|NCT01336465|Placebo Comparator|placebo|
9486435|NCT01333540|Experimental|Active|Escalating Doses of TD-1211
9486436|NCT01333540|Placebo Comparator|Placebo|
9486437|NCT01332812|Experimental|Dexamethasone, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
9486438|NCT01332812|Sham Comparator|Control, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
9486439|NCT01332656|Experimental|Arm A|Ombrabulin, Paclitaxel and Carboplatin
9486440|NCT01332656|Placebo Comparator|Arm B|Placebo, Paclitaxel and Carboplatin
9486441|NCT01331850|Experimental|Previous null responders (Cohort B): Group 4|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
9486442|NCT01331850|Experimental|Previous null responders (Cohort B): Group 5|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 5 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
9486443|NCT01331850|Experimental|Previous null responders (Cohort B): Group 6|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.
9486444|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 1|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 1 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
9486445|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 2|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
9486446|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 3|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 3 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
9486447|NCT01328808|Experimental|group 2 Pain management|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks 15 mg/kg dose of APAP will be given every 12 hrs by an intravenous infusion over 30-minute"
9486448|NCT01328093|Experimental|LY2140023|Double Blind Phase: 40 mg administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg and a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
9616507|NCT02541591|Experimental|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
9616508|NCT02541591|Active Comparator|Control|MAP>65mmHg
10058454|NCT02018419|Experimental|Dosing Schedule B|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
9486449|NCT01328093|Active Comparator|Aripiprazole|Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
9486450|NCT01327183|Experimental|20 mg/kg RO4905417 before PCI|
9486451|NCT01327183|Experimental|5 mg/kg RO4905417 before PCI|
9486452|NCT01327183|Placebo Comparator|Placebo before PCI|
9486453|NCT01325688|Experimental|Group 1|PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days
9486454|NCT01325688|Experimental|Group 2|PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days
9486455|NCT01325688|Experimental|Group 3|PEP005 0.05% applied with no occlusion for up to three consecutive days
9486456|NCT01324466|Placebo Comparator|Vehicle|Vehicle
9486457|NCT01324466|Active Comparator|Active|Active NB-001(0.3%)
9486458|NCT01323205|Experimental|JNJ-40411813 (Part A)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
9486459|NCT01323205|Experimental|JNJ-40411813 (Part B)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks.
9486460|NCT01323205|Experimental|Placebo and JNJ-40411813 (Part B)|Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks.
9486461|NCT01322269|Experimental|HQK-1001 (30 mg/kg)|
9486462|NCT01322269|Experimental|HQK-1001 (40 mg/kg)|
9486463|NCT01322269|Experimental|HQK-1001 (50 mg/kg)|
9486464|NCT01321463|Experimental|PH-797804|
9486465|NCT01321463|Placebo Comparator|Placebo|
9486466|NCT01321359|Placebo Comparator|Vehicle|Vehicle
9486467|NCT01321359|Active Comparator|Active|Active NB-001(0.3%)
9486468|NCT01318642|Active Comparator|Placebo + Gemcitabine|Arm 2: AMG479-placebo IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle
9486469|NCT01318642|Experimental|AMG 479 20 mg/kg + Gemcitabine|ARM 1: AMG 479 20mg/kg IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle.
9486470|NCT01318434|Experimental|EB-1010 25 mg BID|Experimental Active
9486471|NCT01318434|Experimental|EB-1010 50 mg BID|Experimental Active
9486472|NCT01318434|Active Comparator|SSRI/SNRI|Active Comparator
9486473|NCT01318434|Placebo Comparator|EB-1010 0 mg BID|Placebo comparator
9486474|NCT01318252|Experimental|AL-54478|AL-54478 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
9486475|NCT01318252|Active Comparator|Latanoprost|Latanoprost 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
9486476|NCT01318252|Placebo Comparator|Vehicle|AL-54478 Vehicle, single dose, followed 7 days later with 14 days of once daily dosing
9486477|NCT01315210|Experimental|D-Ribose|
9486478|NCT01315210|Placebo Comparator|Placebo|
9486479|NCT01314222|Other|Arm 1: BMS-954561 40mg or 80mg|"BMS-954561 40mg or 80mg TID to Placebo OR Placebo to 40mg or 80mg TID~Active to Placebo or Placebo to Active (cross-over)"
9486480|NCT01314222|Other|Arm 2: BMS-954561 150mg or 300mg|"BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Active to Placebo or Placebo to Active (cross-over)"
9486481|NCT01314222|Other|Arm 3: Pregabalin 100mg|"Pregabalin 100mg TID to Placebo OR Placebo to 100mg TID~Active to Placebo or Placebo to Active (cross-over)"
9486482|NCT01313572|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson
9486483|NCT01313572|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with the active comparator: adenosine.
9486484|NCT01312454|Experimental|AL-59412C Concentration 1|AL-59412C injectable solution, single intravitreal injection
9486485|NCT01312454|Experimental|AL-59412C Concentration 2|AL-59412C injectable solution, single intravitreal injection
9486486|NCT01312454|Active Comparator|Travoprost|Travoprost injectable solution, single intravitreal injection
9486487|NCT01312454|Placebo Comparator|Vehicle|AL-59412C Vehicle, single intravitreal injection
9486488|NCT01311713|Experimental|(Part 1): CEP-9722|
9486489|NCT01311713|Experimental|(Part 2): CEP-9722|
9486490|NCT01310114|Experimental|Cohort 1|1 unit PDA001 [approximately 2 x 108 cells] in 240 mL per infusion on Day 1.
9486491|NCT01310114|Experimental|Cohort 2A - Experimental|1 unit PDA001 [approximately 2 x 108 cells] or placebo in 240 mL per infusion on Day 1
9486492|NCT01310114|Experimental|Cohort 2B - Experimental|4 units PDA001 [approximately 8 x 108 cells] or placebo in 240 mL per infusion on Day 1
9486493|NCT01309945|Active Comparator|Arm 1: Duloxetine 30mg|
9486494|NCT01309945|Placebo Comparator|Arm 2: BMS-820836 placebo|
9486495|NCT01309945|Experimental|Arm 3: BMS-820836 0.5-2.0 mg/day|
9486496|NCT01309945|Active Comparator|Arm 4: Duloxetine 30mg|
9486497|NCT01309945|Placebo Comparator|Arm 5: Duloxetine placebo|
9486498|NCT01309932|Experimental|A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin|Part A
9486499|NCT01309932|Experimental|A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin|Part A
9486500|NCT01309932|Active Comparator|A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV|Part A
9486501|NCT01309932|Experimental|A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)|Part B
9486502|NCT01309932|Experimental|A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)|Part B
9486503|NCT01309932|Experimental|A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)|Part B
9486504|NCT01309932|Experimental|A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)|Part B
9486505|NCT01307800|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks of treatment.
9486506|NCT01307800|Experimental|40 mg LY2140023|20 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
9486507|NCT01307800|Experimental|10 mg LY2140023|5 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
9486508|NCT01307800|Placebo Comparator|Placebo|Administered orally, BID for up to 7 weeks of treatment.
9486509|NCT01305824|Active Comparator|PRT 201 (10 micrograms)|
9486510|NCT01305824|Placebo Comparator|Placebo|
9486511|NCT01305824|Active Comparator|PRT-201 (30 micrograms)|
9486512|NCT01305538|Other|Arm 1 BMS-954561 40mg or 80mg|"Arm description: BMS-954561 40mg or 80mg three times daily (TID) to Placebo OR Placebo to 40mg or 80mg TID.~Arm type: Active to Placebo or Placebo to Active (cross-over)"
9486513|NCT01305538|Other|Arm 2 BMS-954561 150mg or 300mg|"Arm description: BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Arm type: Active to Placebo or Placebo to Active(cross-over)"
9486514|NCT01304862|Experimental|Self-management intervention|
9486515|NCT01304862|Active Comparator|Educational Videos about Healthy Living|
9486516|NCT01304524|Experimental|VGX 3100|
9486517|NCT01304524|Placebo Comparator|Placebo|
9486518|NCT01303783|Experimental|Nifedipine GITS 20 mg|Subjects received 20 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
9486519|NCT01303783|Experimental|Nifedipine GITS 30 mg|Subjects received 30 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
9486520|NCT01303783|Experimental|Nifedipine GITS 60 mg|Subjects received 60 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
9486521|NCT01303783|Experimental|Candesartan cilexetil 4 mg|Subjects received 4 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
9486522|NCT01303783|Experimental|Candesartan cilexetil 8 mg|Subjects received 8 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
9486523|NCT01303783|Experimental|Candesartan cilexetil 16 mg|Subjects received 16 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
9486524|NCT01303783|Experimental|Candesartan cilexetil 32 mg|Subjects received 32 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
9486525|NCT01303783|Experimental|Nifedipine/candesartan 20/4 mg|Subjects received the combination of 20 mg of nifedipine GITS/4 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486526|NCT01303783|Experimental|Nifedipine/candesartan 20/8 mg|Subjects received the combination of 20 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486527|NCT01303783|Experimental|Nifedipine/candesartan 20/16 mg|Subjects received the combination of 20 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486528|NCT01303783|Experimental|Nifedipine/candesartan 30/8 mg|Subjects received the combination of 30 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486529|NCT01303783|Experimental|Nifedipine/candesartan 30/16 mg|Subjects received the combination of 30 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486530|NCT01303783|Experimental|Nifedipine/candesartan 30/32 mg|Subjects received the combination of 30 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486531|NCT01303783|Experimental|Nifedipine/candesartan 60/16 mg|Subjects received the combination of 60 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486532|NCT01303783|Experimental|Nifedipine/candesartan 60/32 mg|Subjects received the combination of 60 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
9486533|NCT01303783|Placebo Comparator|Placebo|Subjects received placebo (3 tablets and 1 capsule) once daily for 8 weeks
9486534|NCT01302886|Experimental|BHQ880|
9486535|NCT01302249|Experimental|AR-12286|AR-12286 Ophthalmic Solution 0.5%
9486536|NCT01302249|Active Comparator|Timolol|Timolol maleate ophthalmic solution 0.5%
9486537|NCT01301781|Experimental|BLI801 laxative|BLI801 laxative - oral solution
9486538|NCT01301781|Placebo Comparator|Placebo|BLI801 placebo - oral solution
9486539|NCT01301157|Experimental|25ug M518101|
9486540|NCT01301157|Placebo Comparator|Vehicle|
9486541|NCT01301157|Active Comparator|Dovonex|
9486542|NCT01301157|Experimental|50ug M518101|
9486543|NCT01300858|Experimental|EGEN-001|
9486544|NCT01300208|Experimental|Cohort 1|CC-11050 (50 milligrams twice per day and Placebo)
9486545|NCT01300208|Experimental|Cohort 2|CC-11050 (100 milligrams twice per day and Placebo)
9486546|NCT01300208|Experimental|Cohort 3|CC-11050 (200 milligrams twice per day and Placebo)
9486547|NCT01300013|Experimental|Omecamtiv mecarbil|
9486548|NCT01300013|Placebo Comparator|Placebo|
9486549|NCT01298687|Experimental|Trav 0.00013%|Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
9486550|NCT01298687|Experimental|Trav 0.00033%|Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
9486551|NCT01298687|Experimental|Trav 0.001%|Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
9542402|NCT03095820|Active Comparator|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
9542403|NCT03095820|Experimental|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
9542404|NCT03095664|Experimental|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
9542405|NCT03095664|No Intervention|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
9542406|NCT03095482|Active Comparator|Active tDCS + In Vivo Exposure|Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 1.7 mA, followed by 30 minutes of in vivo exposure therapy.
9542407|NCT03095482|Sham Comparator|sham tDCS + In Vivo Exposure|Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
9542408|NCT03095443|Experimental|Personalized Music|Receives personalized playlist twice a day.
9542409|NCT03095443|Active Comparator|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
9542410|NCT03095443|Active Comparator|Attention Control|Receives audio-book twice a day.
9542411|NCT03095469|Experimental|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
9542412|NCT03095469|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
9542413|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
9542414|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
9542415|NCT03095404|Experimental|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
9542416|NCT03095404|Experimental|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
9542417|NCT03095391||Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
9542418|NCT03095391||Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
9542419|NCT03095391||Cohort 3|GFR: ≥ 30 and < 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
9542420|NCT03095391||Cohort 4|GFR: ≥ 15 and < 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
9542421|NCT03095417|Experimental|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
9542422|NCT03095417|Active Comparator|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
9542423|NCT03095417|Active Comparator|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
9616509|NCT02541539|Active Comparator|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
9542424|NCT03095417|Sham Comparator|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
9542425|NCT03095274|Experimental|Durvalumab|"Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) for 12 months in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: durvalumab 20 mg/kg."
9542426|NCT03095274|Experimental|Tremelimumab|"Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: tremelimumab 1 mg/kg Q4."
9542427|NCT03095170|Experimental|Computerized brain fitness training|"Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week."
9542428|NCT03095170|Experimental|Yoga|"Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week."
9542429|NCT03095170|Active Comparator|Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.
9542430|NCT03095144||Spinal anesthesia|Lumbar puncture was performed with a midline approach through either the fourth or fifth lumbar space using a 22 or 25 -gauge 4 cm disposable styletted needle. Spinal isobaric Bupivacaine 0.5%, 0.8-1 mg.kg-1 without epinephrine was injected using a 1ml tuberculin syringe.
9542431|NCT03095144||General anesthesia|The General anesthesia is preformed by intravenous Propofol (2-4 mg.kg-1) and Fentanyl (1-2 µg.kg-1) and Rocuronium bromide (0.5mg.kg-1) administration to facilitate endotracheal intubation, assisted by Sellick manoeuvre. Anaesthesia maintenance with Sevoflurane (2-3%) in an air/oxygen mixture, intravenous Fentanyl as required.
9542432|NCT03095365|Active Comparator|Dry needling|Received Dry needling in the neck muscles.
9542433|NCT03095365|Active Comparator|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
9542434|NCT03095365|Experimental|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
9542435|NCT03095352|Experimental|Arm A: Pembrolizumab + Carboplatin|Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
9542436|NCT03095352|Experimental|Arm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only|Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
9542437|NCT03095209||Standard of care concurrent chemo-radiation therapy|
9542438|NCT03095261|Experimental|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
9542439|NCT03095261|Active Comparator|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
9542440|NCT03095222|Active Comparator|Group 1: Daily|Daily ketamine infusions of 5 hours in length. Duration of participation will last 4 days.
9542441|NCT03095222|Active Comparator|Group 2: Continuous|Continuous ketamine infusions (24 hours/day). Duration of participation will last 4 days.
9542442|NCT03095378|Active Comparator|Control|Root treatment with scaling and root planing.
9542443|NCT03095378|Experimental|Citric acid plus tetracycline|Root treatment with 50% citric acid plus 10% tetracycline, pH1, passive application for 90s.
9616510|NCT02541539|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
9542444|NCT03095378|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy with toluidine blue O (100ug/ml - 60s pre-irradiation - pH4) and red laser (660nm, 30 milliwatts, 45 joules per square centimeter, sweeping mode, 90s)
9542445|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
9542446|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
9542447|NCT03095326|Experimental|Zinc Syrup 1.5 mg/kgbw/day|Patient were given zinc formula in the form of syrup with dosage of 1.5 mg/kg body weight/day with a maximum dose of 50 mg/day. The amount of syrup given is estimated to be enough for 4 weeks.
9542448|NCT03095326|Placebo Comparator|Sucrose syrup|Patient were given sucrose syrup as placebo. The syrup was made in the same flavor and consistency as the zinc syrup.
9542449|NCT03095235|Experimental|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
9542450|NCT03095092|Experimental|BIA 6-512 fed|BIA 6-512 400 mg following a standard meal
9542451|NCT03095092|Experimental|BIA 6-512 fasting|BIA 6-512 400 mg following at least 8 h of fasting
9542452|NCT03095183|Placebo Comparator|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
9542453|NCT03095183|Active Comparator|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
9542454|NCT03095339|Active Comparator|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
9542455|NCT03095339|No Intervention|Control|The control group did not receive any intervention
9542456|NCT03095105|Experimental|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
9542457|NCT03095105|Experimental|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
9542458|NCT03095079|Experimental|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1~14
9542459|NCT03095157|Placebo Comparator|Placebo|
9542460|NCT03095157|Experimental|Treatment|
9542461|NCT03095131|Experimental|12-lead ECG|
9542462|NCT03094988|Other|Control|The active attention control group will receive a binder with information about personal health including sleep hygiene, nutritional changes, and stress reduction. In addition, they will participate in a control version of the cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
9542463|NCT03094988|Experimental|Cognitive and physical prehabilitation|The intervention group will receive the prehabilitation program consisting of a guided progressive program of home-based aerobic and resistance training exercise, which will be adapted based on kinesiologist recommendation for each individual and the individual's perceived exertion. In addition, they will have access to the full cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
9542464|NCT03095040|Experimental|CM082 combined with everolimus|
9542465|NCT03095040|Experimental|CM082|
9542466|NCT03095040|Active Comparator|Everolimus|
9542467|NCT03094936|Other|Group A|This group own twenty patients who met all the inclusion criteria. These will be treated with APC.
9542468|NCT03094936|Active Comparator|Group B|This group own twenty patients who met all the inclusion criteria. These will be treated with APC plus Endoscopic Suture Technique (OverStitch TM).
9542469|NCT03095001|Experimental|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
9542470|NCT03095001|Active Comparator|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
9542471|NCT03094793|Experimental|abnormal EEGs|
9542475|NCT03094715|Active Comparator|Thrombectomy|Endovascular thrombectomy and best medical care
9542476|NCT03094715|Other|Best medical care|Best medical treatment
9803770|NCT03356860|Experimental|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
9486552|NCT01298687|Experimental|Trav 0.00267%|Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
9486553|NCT01298687|Active Comparator|TRAVATAN|Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)
9486554|NCT01298687|Placebo Comparator|Vehicle|Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
9486555|NCT01297543|Experimental|Consolidation Group A|Low dose CLT-008 (human myeloid progenitor cells)
9486556|NCT01297543|Experimental|Consolidation Group B|Intermediate dose CLT-008 (human myeloid progenitor cells)
9486557|NCT01297543|Experimental|Consolidation Group C|Intermediate dose CLT-008 (human myeloid progenitor cells), no G-CSF
9486558|NCT01297543|Experimental|Consolidation Group D|High dose CLT-008 (human myeloid progenitor cells)
9486559|NCT01297543|Active Comparator|Induction Group A1 (cytarabine 7+3)|G-CSF
9486560|NCT01297543|Experimental|Induction Group A2 (cytarabine 7+3)|Intermediate dose CLT-008 (human myeloid progenitor cells)
9486561|NCT01297543|Experimental|Induction Group A3 (cytarabine 7+3)|High dose CLT-008 (human myeloid progenitor cells)
9486562|NCT01297543|Active Comparator|Induction Group B1 (cytarabine HIDAC)|G-CSF
9486563|NCT01297543|Experimental|Induction Group B2 (cytarabine HIDAC)|Intermediate dose CLT-008 (human myeloid progenitor cells)
9486564|NCT01297543|Experimental|Induction Group B3 (cytarabine HIDAC)|High dose CLT-008 (human myeloid progenitor cells)
9486565|NCT01296087|Experimental|TC-6987|
9486566|NCT01296087|Placebo Comparator|Placebo|
9486567|NCT01295060|Experimental|Octreotide Implant|
9498063|NCT03469453|Experimental|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
9498064|NCT03469440|Active Comparator|Goal-directed therapy|Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
9498065|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy.
9498066|NCT03469414||Wheelchair Mobility and Speed|This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
9498067|NCT03469414||GPS Tracking|A GPS tracker will be placed on the wheelchairs of 25 individuals who consent to participate in this arm of the project. Using a GPS tracker will provide a direct measure of the community locations these participants go. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
9498068|NCT03469401||intervention|Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage
9498069|NCT03469388|Experimental|elective EVAR patients|Elective EVAR patients will be included in one arm only
9498070|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
9498071|NCT03469323|Experimental|Nonintubated VATS succinylcholine|Nonintubated VATS using mini-dose succinylcholine in the beginning of open pneumothorax
9498072|NCT03469323|Placebo Comparator|Nonintubated VATS placebo|Nonintubated VATS not using succinylcholine in the beginning of open pneumothorax
9498073|NCT03469310|Experimental|Acetaminophen|Tylenol (also known as acetaminophen) 1000mg every 6 hours for 3 days and tramadol 50 mg every 6 hours as needed for moderate to severe pain
9498074|NCT03469310|Active Comparator|Codeine Acetaminophen|Tylenol #3 (codeine-acetaminophen) 1 tab every 4 hours or 2 tabs every 6 hours as needed for pain
9498075|NCT03469284|Experimental|Group 1 (lower dose methylene blue, standard of care)|Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
9498076|NCT03469284|Experimental|Group 2 (medium dose methylene blue, standard of care)|Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
9498077|NCT03469284|Experimental|Group 3 (higher dose methylene blue, standard of care)|Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
9498078|NCT03469284|Active Comparator|Group 4 (standard of care)|Patients receive standard of care therapy.
9498079|NCT03469271|Other|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
9498080|NCT03469271|Other|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
9542477|NCT03095014|Experimental|Cesarean Myomectomy|Myomectomy plus Cesarean section
9803771|NCT03356860|Active Comparator|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
10040091|NCT01850017|No Intervention|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
9542478|NCT03095014|Active Comparator|Cesarean section|Cesarean section only
9542479|NCT03094962|Other|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
9542480|NCT03094767|Experimental|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
9542481|NCT03094767|Experimental|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
9542482|NCT03094663|Active Comparator|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.5% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~20cc 0.25% bupivacaine~2 mg IV dexamethasone."
9542483|NCT03094663|Experimental|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.25% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~a. 20cc 0.25% bupivacaine~Adductor canal block technique (supine position, post IV sedation)~a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone~IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
9542484|NCT03094741|Experimental|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
9542485|NCT03094897|Experimental|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
9542486|NCT03094780|Other|Quality of Life Counseling|
9542487|NCT03094689|No Intervention|Control group|
9542488|NCT03094689|Experimental|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
9542489|NCT03094689|Experimental|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
9542490|NCT03094910|Other|123I-MIBG|Only the group of participants with primary Raynaud's phenomenon (Raynaud's disease) is also scheduled for this intervention, the 123I-MIBG.
9542491|NCT03094910|Other|All participants|Examination of vibration perception threshold in fingertips, thermography, Ewing's test, tilt table test, blood samples.
9542492|NCT03094923|Experimental|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
9542493|NCT03094923|No Intervention|Control group|Control group will receive a supportive educational component in the preoperative period.
9542494|NCT03094858|Active Comparator|Comparison group|Equipment only comparison group will use Smartphone and Wristband to monitor sedentary behavior
9542495|NCT03094858|Experimental|Intervention group|Intervention group will receive prompts from Smartphone to reduce sedentary behavior using information from Wristband
9542496|NCT03094845|Placebo Comparator|Placebo|
9542497|NCT03094845|Experimental|hdmASIT+TM|
9542498|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
9542499|NCT03094949|Active Comparator|Partial Nephrectomy|a kind of operation for renal tumor
9542500|NCT03094949|Experimental|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
9542501|NCT03094676|No Intervention|Control|Only the HRV will be followed for two hours without intervention.
9542502|NCT03094676|Experimental|Only Massage|Only the massage, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
9542503|NCT03094676|Experimental|Only Exercise|Only the exercise, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
9542504|NCT03094676|Experimental|Exercise and Massage immediately|Performing the exercise and massage immediately after, will be accompanied by the HRV during the techniques and two hours after.
9542505|NCT03094676|Experimental|Exercise and Massage after recovery|Performing the exercise and massage will be applicated after recovery of HRV, will be accompanied by the HRV during the techniques and two hours afte
9542506|NCT03094572|No Intervention|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
9542507|NCT03094572|No Intervention|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
9542508|NCT03094572|No Intervention|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
9542509|NCT03094572|No Intervention|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
10040092|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
9542510|NCT03094572|No Intervention|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
9542511|NCT03094572|Experimental|visual motor tasks|fourth sub-study with hemiplegic patient
9542512|NCT03094572|No Intervention|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
9542513|NCT03094650|Experimental|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
9542514|NCT03094585|No Intervention|No information|The nurses in this group are offered no booklet or oral information
9486568|NCT01294202|Experimental|AT13387 and imatinib|AT13387 administered on days 1, 8 and 15, imatinib administered daily
9803772|NCT03353415|Experimental|CGM Use|Each participant will wear the DexCom continuous glucose monitor for four weeks. During the first two weeks, participants will not be able to read the sensor glucose levels. In the second two weeks, participants will be able to read the sensor glucose levels. Frequency of hypoglycemia will be compared between the two phases of the study.
9803773|NCT03348930|Experimental|Tolcapone|Each subject will have a 4 week treatment phase with Tolcapone
9486569|NCT01293669|Experimental|TC-6987|
9803774|NCT03348930|Placebo Comparator|Placebo|4 week placebo phase before or after Tolcapone phase depending on randomization.
9486570|NCT01293669|Placebo Comparator|Placebo|
9803775|NCT03336216|Active Comparator|Arm A|"Investigator choice of chemotherapy:~Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)"
9803776|NCT03336216|Experimental|Arm B|Cabiralizumab Q2W + Nivolumab Q4W
9486571|NCT01293552|Placebo Comparator|Control|blank vehicle formulation
9486572|NCT01293552|Experimental|Dose 1|Dose 1
9803777|NCT03336216|Experimental|Arm C|Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
10040093|NCT01850056|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
10040094|NCT01850056|Active Comparator|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
9486573|NCT01293552|Experimental|Dose 2|Dose 2
9486574|NCT01293552|Experimental|Dose 3|Dose 3
10040095|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
10040096|NCT01850095|Active Comparator|treatment 1|topical acid azelaic, used 2 times a day for 6 months
10040097|NCT01850095|Active Comparator|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
10040098|NCT01850095|No Intervention|control|control group ( only take biopsies and blood samples )
10040099|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
10040100|NCT01850134|Placebo Comparator|Control Study Product|1 serving of control beverage.
10040101|NCT01850134|Experimental|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
9486575|NCT01293552|Experimental|Dose 4|Dose 4
9486576|NCT01293461|Experimental|CBX129801|
9486577|NCT01293461|Placebo Comparator|Placebo|
9486578|NCT01291914|Experimental|FX005|
9486579|NCT01291914|Placebo Comparator|Placebo 1 (Carrier)|
9486580|NCT01291914|Placebo Comparator|Placebo 2 (Diluent)|
9486581|NCT01291901|Experimental|Active NP2|Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
9486582|NCT01291901|Placebo Comparator|Placebo|Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
9486583|NCT01287585|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol.
9486584|NCT01287585|Placebo Comparator|Placebo|an inert treatment with no therapeutic value.
9486585|NCT01284530|Experimental|Conversion-25|25 mg
10040102|NCT01850147|Experimental|Sunitinib|
10040103|NCT01850160|Experimental|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
10040104|NCT01850160|Experimental|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
9486586|NCT01284530|Experimental|Conversion-50|50 mg
9486587|NCT01284530|Experimental|Conversion-100|100 mg
9486588|NCT01284530|Experimental|Conversion-200|200 mg
9486589|NCT01284387|Experimental|3 μg ACC-001 / QS-21 50 μg IM dose 1|3 μg ACC-001 / QS-21 50 μg IM
9486590|NCT01284387|Experimental|10 μg ACC-001 / QS-21 50 μg IM dose 2|10 μg ACC-001 / QS-21 50 μg IM
9486591|NCT01284387|No Intervention|Placebo - Phosphate buffered saline (PBS) IM dose|Placebo - Phosphate buffered saline (PBS) IM
9486592|NCT01284348|Experimental|Sotatercept - 15 mg|Sotatercept 15 mg Subcutaneous (SC) Day 1 every 42 days
9486593|NCT01284348|Experimental|Sotatercept 30 mg|Sotatercept 30 mg SC Day 1 every 42 days
9486594|NCT01283594|Experimental|Tozadenant (SYN115) 60 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
9486595|NCT01283594|Experimental|Tozadenant (SYN115) 120 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
9486596|NCT01283594|Experimental|Tozadenant (SYN115) 180 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
9486597|NCT01283594|Experimental|Tozadenant (SYN115) 240 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
9486598|NCT01283594|Placebo Comparator|Sugar Pill|White-coated, modified-oval placebo tablets.
9486599|NCT01282606|Experimental|Drug I: SI-6603 (Low)|
9486600|NCT01282606|Experimental|Drug II: SI-6603 (Middle)|
9486601|NCT01282606|Experimental|Drug III: SI-6603 (High)|
9486602|NCT01282346|Experimental|SOLX Gold Shunt|
9486603|NCT01282255|Experimental|A|
9486604|NCT01282255|Placebo Comparator|B|
9486605|NCT01281631|Experimental|Low dose NP001|Low drug dose
9486606|NCT01281631|Experimental|High dose NP001|High drug dose
9486607|NCT01281631|Placebo Comparator|Placebo|normal saline
9486608|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q8h)|
9486609|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q12h)|
9486610|NCT01281462|Active Comparator|Doripenem|
9803778|NCT03336216|Experimental|Arm D|Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
10040105|NCT01850160|Experimental|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
9542515|NCT03094585|Experimental|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
9542516|NCT03094585|Experimental|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
9542517|NCT03094624|Experimental|Amusia|Since 2006, recruitment of amusia participants has been organized in the Lyon region, and some 20 participants (and their matched controls in terms of age, sex, laterality, musical practice, number of years of study) have already taken part various studies conducted at the CRNL. The recruitment of amusia participants and controls is continued in order to maintain a sufficient number of participants and compensate for the withdrawals within the cohort already constituted (lack of availability, geographical distance, etc.).
9542518|NCT03094624|Sham Comparator|Matched controls|Matched controls of age, sex, laterality, musical practice, number of years of studies.
9542519|NCT03094598|No Intervention|Control|No intervention
9542520|NCT03094598|Experimental|Leaflet|The leaflet is based on information and journalism theories, paying attention primarily to reader appeal and readability.
9542521|NCT03094598|Experimental|Brochure|The brochure is based on practical communication experience, focusing primarily on logical composition and presentation of condensed information.
9542522|NCT03094598|Experimental|Booklet|The booklet is also based on practical communication experience, but give more elaborate explanations.
9542523|NCT03094559|Experimental|FlowMet device|This is a feasibility study
9542524|NCT03094455|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
9542525|NCT03094455|Other|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
9542526|NCT03094377|Experimental|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
9542527|NCT03094377|Active Comparator|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
9542528|NCT03094364|Active Comparator|Immediate Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
9542529|NCT03094364|Active Comparator|Delayed Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
9542530|NCT03094286|Experimental|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
9542531|NCT03094520|Experimental|Anodal tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with anodal stimulation
9542532|NCT03094520|Sham Comparator|Sham tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with sham stimulation
9542533|NCT03094481|Active Comparator|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
9542534|NCT03094481|Active Comparator|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
9542535|NCT03094481|Active Comparator|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
9542536|NCT03094481|Active Comparator|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
9542537|NCT03094481|Active Comparator|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
9616511|NCT02541513|Experimental|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
9542538|NCT03094481|Active Comparator|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
9542539|NCT03094351|Experimental|Robot assisted esophagectomy|Robot-assisted esophagectomy with gastric conduit formation.
9542540|NCT03094351|Active Comparator|Thoracoscopic esophagectomy|Conventional thoracoscopic esophagectomy with gastric conduit formation.
9542541|NCT03094533|Active Comparator|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
9542542|NCT03094533|Active Comparator|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
9542543|NCT03094403|Experimental|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
9542544|NCT03094403|Active Comparator|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
9542545|NCT03094403|Placebo Comparator|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
9542546|NCT03094208|Experimental|study group|muscle strengthening, weight transfer, dual task balance exercises, dual task gait exercises.
9542547|NCT03094208|Active Comparator|control group|muscle strengthening, weight transfer, balance exercises, gait exercises.
9542548|NCT03094260|Experimental|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
9542549|NCT03094260|Placebo Comparator|Low intensity light therapy|Treatment with light therapy in low intensity (<500 lux)
9542550|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
9542551|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
9542552|NCT03094546|Experimental|Polyamine supplementation|Intervention: Dietary Supplement (Polyamine supplementation): 750 mg wheat germ extract
9542553|NCT03094546|Placebo Comparator|Placebo|Intervention: Dietary Supplement Placebo: 750 mg cellulose
9542554|NCT03094468|Experimental|P-3058|
9542555|NCT03094468|Placebo Comparator|Vehicle|
9542556|NCT03094507|Experimental|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
9542557|NCT03094507|Experimental|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
9542558|NCT03094182|Experimental|iron group|Patients in the iron group are given Intravenous iron isomaltoside during operation.
9542559|NCT03094182|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
9542560|NCT03094442|Active Comparator|Dexamethasone|"Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe.~We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug."
9542561|NCT03094442|Placebo Comparator|Saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
9542562|NCT03094247|Active Comparator|Conventional RUTF (S-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
9542563|NCT03094247|Experimental|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
9542564|NCT03094247|Experimental|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
9542565|NCT03094169|Experimental|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
9542566|NCT03094169|Experimental|Phase 2a Triple Negative Breast Cancer|Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
10040106|NCT01850173|Experimental|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
10040107|NCT01850173|No Intervention|Control group|general recommendations about physical activity and lifestyle
10040108|NCT01850186|Experimental|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
9542567|NCT03094169|Experimental|Phase 2a Head and Neck Carcinoma|Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
9542568|NCT03094169|Experimental|Phase 2a Non-Small Cell Lung Carcinoma|Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
9542569|NCT03094156|Experimental|Placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
9542570|NCT03094156|Experimental|BIA 6-512 25 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
9542571|NCT03094156|Experimental|BIA 6-512 50 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
9542572|NCT03094156|Experimental|BIA 6-512 75 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
9542573|NCT03094156|Experimental|BIA 6-512 100 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
9542574|NCT03094143|Experimental|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
9542575|NCT03094143|No Intervention|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
9542576|NCT03094143|No Intervention|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
9542577|NCT03094143|No Intervention|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
9542578|NCT03094130|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
9542579|NCT03094130|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
9542580|NCT03093974|Experimental|treatment|Inhaled colistimethate sodium twice daily
9542581|NCT03093974|Placebo Comparator|Saline solution|inhaled placebo twice daily
9542582|NCT03094039|Experimental|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
9542583|NCT03094039|Active Comparator|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
9542584|NCT03093831|Experimental|Ibrutinib|
9542585|NCT03093805|Experimental|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
9542588|NCT03093883|Experimental|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
9542589|NCT03093883|Active Comparator|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
9542590|NCT03093987|No Intervention|control group|usual care
9542591|NCT03093987|Experimental|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
9542592|NCT03093935|Experimental|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
9542593|NCT03093792|Placebo Comparator|Control|(no diet or exercise intervention)
9542594|NCT03093792|Experimental|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
9542595|NCT03093792|Active Comparator|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
9542596|NCT03093792|Active Comparator|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
9542597|NCT03094065|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin.
9542598|NCT03094065|Experimental|News without spin|News items reporting results of pre-clinical studies without spin.
9542599|NCT03093909|Experimental|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
9542600|NCT03093896|Placebo Comparator|snack mix|snack mix, 3 ounces: dried coconut, meat jerky, butter, cereal party mix
9542601|NCT03093896|Active Comparator|almonds, 1.5 ounces|almonds, 1.5 ounces/day
9542602|NCT03093896|Active Comparator|almonds, 3 ounces|almonds, 3 ounces/day
9542603|NCT03094078|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin
9542604|NCT03094078|Experimental|News without spin|News items reporting results of pre-clinical studies without spin
9616512|NCT02541721|Experimental|LabiaStick#01|Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.
9616513|NCT02541708|Experimental|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
9616514|NCT02541708|Active Comparator|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
9616515|NCT02541799|Experimental|Telemedicine|Participants allocated to this arm will be approached the using a telemedicine medium to discuss study participation. The consent form will be administered while the investigator is on a telemedicine link.
9616516|NCT02541799|Active Comparator|Standard Care|Participants allocated to this arm will be approached in standard fashion where the investigator approaches the patient face to face. The consent form will be administered while the investigator is in the participant's room.
9616517|NCT02541695|Active Comparator|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
9616518|NCT02541695|Experimental|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
9616519|NCT02541448|Active Comparator|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
9616520|NCT02541448|Active Comparator|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
9616521|NCT02541487||Nutritional/Physical Activity (NuPA) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
9616522|NCT02541487||Physical Activity only (PAo) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the exercise only arm that achieve pregnancy.
9616523|NCT02541487||Infertile, non-lifestyle intervention controls|Obese women (60) with unexplained infertility who meet the inclusion/exclusion criteria for FIT-PLESE but decline participation in the trial and who elect to undergo CC-IUI treatment and achieve pregnancy without prior diet and exercise interventions.
9616524|NCT02541526|Experimental|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
9616525|NCT02541526|Placebo Comparator|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
9616526|NCT02541552|Experimental|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
9616527|NCT02541500|Experimental|Minocycline|Patients in this arm will receive oral minocycline
9616528|NCT02541682|Other|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
9616529|NCT02541682|Other|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
9616530|NCT02541682|Other|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
9616531|NCT02541682|Other|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
9616532|NCT02541617|Active Comparator|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
9542605|NCT03094000|Experimental|Experimental group (CBTE-MIND)|Adding a mindfulness skills intervention to group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008)
9542606|NCT03094000|Active Comparator|Control group (CBTE)|Group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008), without a mindfulness skills intervention
9542607|NCT03094104|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
9542608|NCT03094104|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
9542609|NCT03093948|Experimental|Remote Ischemic post-conditioning|
9542610|NCT03093948|No Intervention|standard of care|
9542611|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
9542612|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
9542613|NCT03094429|Active Comparator|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
9542614|NCT03094429|Active Comparator|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
9542615|NCT03094429|Placebo Comparator|Placebo - 0 mg/day|The control treatment is placebo.
9542616|NCT03094091|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
9542617|NCT03094091|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
9542618|NCT03094117|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
9542619|NCT03094117|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
9542620|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
9542621|NCT03093753|Placebo Comparator|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
9542622|NCT03093753|Experimental|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
9542623|NCT03093753|Placebo Comparator|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
9542624|NCT03093753|Experimental|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
9542625|NCT03093753|Placebo Comparator|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
9542626|NCT03093753|Experimental|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
9542627|NCT03093753|Placebo Comparator|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
9542628|NCT03093753|Experimental|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
9542629|NCT03093753|Placebo Comparator|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
9542630|NCT03093753|Experimental|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
9542631|NCT03093753|Placebo Comparator|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
9542632|NCT03093753|Experimental|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
9542633|NCT03093753|Placebo Comparator|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
9542634|NCT03093753|Experimental|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
9542635|NCT03093467|Experimental|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
9542636|NCT03093467|Active Comparator|Control|Patients receive psychiatric treatment and psychotherapy as usual.
9542637|NCT03093740|Experimental|HCV treatment - no viral resistance|Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier
9542638|NCT03093740|Experimental|HCV treatment - viral resistance|Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir
9542639|NCT03093441|Experimental|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
9542640|NCT03093441|Active Comparator|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
9542641|NCT03093441|No Intervention|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
9542642|NCT03093428|Experimental|Radium-223|-Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
9486611|NCT01281254|Placebo Comparator|Placebo plus PLD|Arm B: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
9486612|NCT01281254|Experimental|AMG386 plus PLD|Arm A: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
9486613|NCT01280565|Experimental|Masitinib|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
9486614|NCT01280565|Active Comparator|Dacarbazine|Participants receive dacarbazine, given via IV bolus at 1,000 mg/m2 once every 3 weeks. Following a protocol amendment, the dacarbarzine treatment group has been closed
9486615|NCT01280344|Experimental|0.03 mg/kg BID|Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
9486616|NCT01280344|Experimental|0.06 mg/kg BID|Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
9486617|NCT01280344|Experimental|0.06 mg/kg TID|Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
9486618|NCT01280344|Placebo Comparator|Placebo|Matching placebo, TID (3 placebo infusions)
9486619|NCT01280331|Experimental|Q8003 12 mg/8 mg|Combination
9486620|NCT01280331|Active Comparator|Morphine sulfate 24 mg|Single component
9486621|NCT01280331|Active Comparator|Oxycodone HCl 16 mg|Single component
9486622|NCT01279590|Experimental|PPD10558|Dosing will be forced-titrated as follows: 40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks
9486623|NCT01279590|Active Comparator|Atorvastatin|Dosing will be forced titrated as 40 mg orally once daily for 4 weeks, and 80 mg orally once daily for 8 weeks
9486624|NCT01279590|Placebo Comparator|Placebo|Dosing will be 2 placebo capsules twice daily for 12 weeks
9486625|NCT01278134|Experimental|Arm B Extension|All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.
9486626|NCT01278134|Experimental|RO5024048 & ritonavir-boosted danoprevir without Ribavirin (B)|
9486627|NCT01278134|Experimental|RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A)|
9486628|NCT01276587|Experimental|Single arm|
9486629|NCT01275105|Other|Vehicle|
9486630|NCT01275105|Active Comparator|Brimonidine Tartrate 0.01%|
9486631|NCT01275105|Active Comparator|Oxymetazoline HCl 0.025%|
9486632|NCT01275105|Active Comparator|Brimonidine Tartrate 0.025%|
9486633|NCT01273389|Experimental|CNTO 136|CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.
9486634|NCT01273389|Placebo Comparator|Placebo|
9486635|NCT01272791|Experimental|Gemcitabine, bavituximab|Gemcitabine will be administered on Days 1, 8, 15 of each 28-day (4 weeks) cycle until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will receive 3 mg/kg weekly (in addition to gemcitabine) until disease progression or unacceptable toxicities
9486636|NCT01272791|Active Comparator|Gemcitabine|Patients randomized to Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities.
9486637|NCT01271920|Experimental|AUY922 + Trastuzumab|
9486638|NCT01271790|Active Comparator|Arm 1|GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
9486639|NCT01271790|Active Comparator|Arm 2|GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
9486640|NCT01271790|Placebo Comparator|Arm 3|Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
9486641|NCT01270945|Experimental|CV-18C3 and standard of care|CV-18C3 and standard of care
9486642|NCT01270945|Active Comparator|standard of care|Percutaneous revascularization
9486643|NCT01270347|Experimental|Aeroquin|Aeroquin, Inhaled Levofloxacin (MP-376)
9486644|NCT01270347|Active Comparator|TIS|Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals]
9486645|NCT01270282|Experimental|AM-101 0.81 mg/mL|Gel for injection; single or triple injection
9486646|NCT01270282|Placebo Comparator|Placebo|Gel for injection; single or triple injection
9486647|NCT01269658|Experimental|Azithromycin ophthalmic solution, 1%|
9486648|NCT01269658|Placebo Comparator|Vehicle|
9486649|NCT01268280|Experimental|Treatment Sequence 1|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 CK-2017357 500 mg
9486650|NCT01268280|Experimental|Treatment Sequence 2|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 CK-2017357 250 mg
9486651|NCT01268280|Experimental|Treatment Sequence 3|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 500 mg
9486652|NCT01268280|Experimental|Treatment Sequence 4|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 Placebo
9486653|NCT01268280|Experimental|Treatment Sequence 5|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 250 mg
9486654|NCT01268280|Experimental|Treatment Sequence 6|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 Placebo
9486655|NCT01266525|Experimental|SAR110894 - 0.5 mg|SAR110894, 0.5 mg once daily along with Donepezil.
9486656|NCT01266525|Experimental|SAR110894 - 2 mg|SAR110894, 2 mg once daily along with Donepezil.
9486657|NCT01266525|Experimental|SAR110894 - 5 mg|SAR110894, 5 mg once daily along with Donepezil.
9486658|NCT01266525|Placebo Comparator|Placebo|Placebo (for SAR110894) once daily along with Donepezil.
9486659|NCT01266135|Experimental|Arm 1: QAX576 10 mg/kg|
9542643|NCT03093428|Experimental|Pembrolizumab Plus Radium-223|"Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose~Pembrolizumab will be administered intravenously every 3 weeks at a pre-determined dose"
9542644|NCT03093545|Other|Normal BMI or underweight (< 24 Kg/m2)|
9542645|NCT03093545|Experimental|Obese (BMI > 30 Kg/m2)|
9542646|NCT03093558|Experimental|Intervention arm|Receive the ECA/Kardia for 30-day use.
9542647|NCT03093558|No Intervention|Usual care arm|Receive a journal for observation of adherence and symptoms.
9542648|NCT03093597|Active Comparator|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
9542649|NCT03093597|Active Comparator|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
9542650|NCT03093597|Active Comparator|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
9542651|NCT03093597|Active Comparator|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
9542652|NCT03093610|Active Comparator|Traditional|The chest tube in the traditional Group will be managed according to the current Guidelines of the investigators' department.
9542653|NCT03093610|Active Comparator|Test group|"The chest tube in the Test Group will constitute the experimental Group. The chest tube will be removed when the fluid production over 24h has reached a weight related threshold."
9542654|NCT03093623|Experimental|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
9542655|NCT03093623|No Intervention|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
9542656|NCT03093506|Active Comparator|Low-dose rhEpo|RhEpo 60IU/kg/week
9542657|NCT03093506|Active Comparator|Micro-dose rhEpo|RhEpo 20IU/kg/week
9542658|NCT03093506|Placebo Comparator|Placebo Control|Saline
9542659|NCT03093649|Experimental|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
9542660|NCT03093649|Active Comparator|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
9542661|NCT03093636|Experimental|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
9542662|NCT03093636|Placebo Comparator|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
9542663|NCT03093571|Experimental|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
9542664|NCT03093571|Experimental|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
9542665|NCT03093571|No Intervention|No intervention|No intervention, just monitoring of outcome parameters
9542666|NCT03093402|Experimental|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
9542667|NCT03093402|Experimental|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
9542668|NCT03093402|Experimental|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
9542669|NCT03093402|Placebo Comparator|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
9542670|NCT03093376|Experimental|Effortful Control Camp|"Children will participate in an interactive, child-friendly camp comprised of short, game-like exercises to teach inhibitory and attentional control, as well as visuospatial and working memory skills."
9542671|NCT03093519|Experimental|KHK6640|Intravenous administration
9542672|NCT03093519|Placebo Comparator|Placebo|Intravenous administration
9542673|NCT03093194|Active Comparator|Women going CS without vaginal preparation before surgery|Women going CS without vaginal preparation before surgery. No vaginal preparation before CS with Septal soap and septol.
9542674|NCT03093194|Placebo Comparator|Women going CS with vaginal preparation before surgery|Women going CS with vaginal preparation before surgery. vaginal preparation before CS with Septal soap and septol.
9542675|NCT03093532|No Intervention|Usual Care|The Usual Care group arm will received pre-printed discharge instructions and an outpatient referral. (This group represents standard of care.)
9542676|NCT03093532|Active Comparator|ED SBIRT-HTN|"The ED SBIRT-HTN (The Emergency Department Screening Brief Intervention and Referral for Treatment) arm consists of a series of risk assessment tools (surveys, video, and noninvasive bedside assessments) designed to be efficient, patient-centered and educational for participants in an emergency department setting. Through the intervention, participants will learn more about hypertension management and complications associated with uncontrolled BP. Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
9616533|NCT02541617|Experimental|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
9542677|NCT03093532|Active Comparator|E SBIRT-HTN + PACTH-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
9542678|NCT03093311|Experimental|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
9542679|NCT03093311|No Intervention|Arm B|Brain tissue oxygenation is not measured.
9542680|NCT03093220||community-acquired pneumonia|all adult patients (aged > 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
9542681|NCT03093363|Other|Intervention group|Asthmatic patients with the pharmacist's intervention
9542682|NCT03093363|Other|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
9542683|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
9542684|NCT03093298|Experimental|Obesity|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling
10040109|NCT01850186|Placebo Comparator|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
10040110|NCT01850199|Active Comparator|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
9542685|NCT03093233||VKA- and NOAC-related ICH|"Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)~Association of hematoma evacuation surgery with clinical outcomes~Associations of antithrombotic management with ischemic and hemorrhagic complications~Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
9542686|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
9542687|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
9542688|NCT03093714|Experimental|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
9542689|NCT03093714|Placebo Comparator|Placebo|Multiple dose placebo as repeat doses in CF subjects
9542690|NCT03093584|Active Comparator|Auricular stimulation|Auricular acupuncture with indwelling fixed auricular acupuncture needles
9542691|NCT03093584|Experimental|Expressive writing|Expressive writing - sharing the emotional expectations in front of forthcoming exam
9542692|NCT03093584|No Intervention|No intervention|No intervention, just observation and monitoring of outcome measures
9542693|NCT03093337|Experimental|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
9542694|NCT03093337|No Intervention|Control|No specific support.
9542695|NCT03093129|Active Comparator|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
9542696|NCT03093129|Placebo Comparator|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
9542697|NCT03093142|Experimental|tDCS & neurofeedback|30 minutes tDCS & 30 minutes neurofeedback
9542698|NCT03093142|Active Comparator|real neurofeedback|30 minutes real neurofeedback.
9542699|NCT03093142|Sham Comparator|sham neurofeedback|30 minutes sham neurofeedback.
9542700|NCT03093389|Experimental|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
9542701|NCT03093389|Experimental|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
9542702|NCT03093389|Experimental|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
9542703|NCT03093389|Experimental|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
10040111|NCT01850199|Experimental|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
10040112|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
9542706|NCT03093090|Active Comparator|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
9542707|NCT03093090|Active Comparator|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
9542708|NCT03093090|Active Comparator|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
10040113|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
9542709|NCT03093090|Active Comparator|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
9542710|NCT03093688|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
9542711|NCT03093168|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
9542712|NCT03093259|Experimental|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
9542713|NCT03093259|Placebo Comparator|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
9542714|NCT03093675|Experimental|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
9542715|NCT03093103|Active Comparator|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
10040114|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
10040115|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
10040116|NCT01850225|Experimental|Device implantation|Implantation of device
10040117|NCT01850238|Placebo Comparator|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
9486660|NCT01266135|Placebo Comparator|Arm 2: Placebo|
9486661|NCT01265901|Active Comparator|Sunitinib|Sunitib as Standard therapy per Label.
10040118|NCT01850238|Experimental|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
10040119|NCT01850251|Experimental|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
10040120|NCT01850251|Active Comparator|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
10040121|NCT01850264|Active Comparator|Quadripolar LV electrode|Application of a quadripolar LV electrode
10040122|NCT01850264|Active Comparator|Bipolar LV electrode|Application of a bipolar LV electrode
9486662|NCT01265901|Experimental|IMA901 plus GM-CSF added to sunitinib after single dose of cy|After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
9486663|NCT01265264|Experimental|ulodesine Placebo + Allopurinol 300mg|Oral dose administered daily for 84 days.
9486664|NCT01265264|Experimental|ulodesine 5mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
9486665|NCT01265264|Experimental|ulodesine 10mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
9486666|NCT01265264|Experimental|ulodesine 20mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
9486667|NCT01265264|Experimental|ulodesine 40mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
9486668|NCT01263886|Experimental|AVE8062 and combination|"Day 1: AVE8062~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
9486669|NCT01263886|Placebo Comparator|Placebo|"Day 1: placebo~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
9486670|NCT01262261|Experimental|Probuphine|patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
9486671|NCT01262235|Experimental|TKM-080301|
9486672|NCT01262001|Experimental|Cohort 1/1-EX|Subjects with moderate to severe idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
9486673|NCT01262001|Experimental|Cohort 2/2-EX|Subjects with mild to moderate idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
9486674|NCT01261403|Experimental|Group 1|1 Unit of PDA001 or 4 units Vehicle Control intravenous on Day 0 and Day 7
9486675|NCT01261403|Experimental|Group 2|4 Units PDA001 or 4 units Vehicle Control intravenous (Placebo) on Day 0 and Day 7
9486676|NCT01261403|Placebo Comparator|Vehicle control|Placebo - Vehicle Control Arm
9486677|NCT01261312|Experimental|Daily Regimen|"SGI-110 daily x5 dosing on a 28-day course~SGI-110 daily x10 dosing on a 28-day course"
9486678|NCT01261312|Experimental|Weekly Regimen|"SGI-110 weekly dosing for three weeks on a 28-day course~SGI-110 twice weekly dosing for three weeks on a 28-day course"
9486679|NCT01260870|Experimental|Cotavance|
9486680|NCT01260870|Active Comparator|Standard balloon angioplasty|POBA
9486681|NCT01258907|Experimental|A|
9486682|NCT01258907|Experimental|B|
9486683|NCT01258907|Placebo Comparator|C|
9486684|NCT01257607|Experimental|1% MIM-D3 Ophthalmic Solution|
9486685|NCT01257607|Experimental|5% MIM-D3 Ophthalmic Solution|
9486686|NCT01257607|Placebo Comparator|Placebo Ophthalmic Solution|
9486687|NCT01256762|Experimental|Imetelstat + Paclitaxel (with or without bevacizumab)|
9486688|NCT01256762|Experimental|Paclitaxel (with or without bevacizumab) alone|
9486689|NCT01255709|Experimental|Arm T1 Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
9486690|NCT01255709|Active Comparator|Arm C Primatene Mist|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
9486691|NCT01255709|Experimental|Arm T2 Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
9486692|NCT01255696|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
9486693|NCT01255696|Placebo Comparator|Placebo|Excipients for ALV003 absent the experimental compounds
9486694|NCT01254773|Experimental|Bapineuzumab SC Dose 1; 2 mg|
9486695|NCT01254773|Experimental|Bapineuzumab SC Dose 2; 7 mg|
9486696|NCT01254773|Experimental|Bapineuzumab SC Dose 3; 20 mg|
9486697|NCT01254773|Placebo Comparator|Placebo|
9486698|NCT01254370|Experimental|Catioprost|
9486699|NCT01254370|Active Comparator|Travatan Z|
9486700|NCT01254136|Experimental|Treatment A - INCB007839 300mg BID|This is a single arm, open label study in which all patients will receive a single dose of the investigational product INCB007839 in combination with a standard regimen of trastuzumab and vinorelbine.
9486701|NCT01253629|Experimental|25 mg bid AFQ056|1 capsule of 25 mg and 1 capsule of placebo per intake
9486702|NCT01253629|Experimental|50 mg bid AFQ056|2 capsules of 25 mg per intake
9486703|NCT01253629|Experimental|100 mg bid AFQ056|1 capsule of 100 mg and 1 capsule of placebo per intake
9486704|NCT01253629|Placebo Comparator|Placebo|2 capsules of placebo per intake
9486705|NCT01253603|Experimental|1|QAW039 capsules once daily for 28 days
9542716|NCT03093103|Placebo Comparator|Placebo|Placebo will be taken qd for 4 weeks.
10058455|NCT02018419|Experimental|Dosing Schedule C|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous infusion of AlloStim on days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
9486706|NCT01253603|Experimental|2|Placebo to QAW039 capsules once daily for 28 days
9486707|NCT01253603|Experimental|3|Fluticasone propionate inhaler twice daily for 28 days
10058456|NCT02018432|Experimental|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
9486708|NCT01252693|Experimental|Ozarelix|
9486709|NCT01252693|Active Comparator|Goserelin|
9486710|NCT01252641|Experimental|SB-728-T|Subjects will receive one intravenous infusion of SB-728-T
9486711|NCT01252628|Experimental|PX-866 (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
9486712|NCT01252628|Active Comparator|Cetuximab (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
9486713|NCT01252628|Experimental|PX-866 (CRC)|Phase 2 (Colorectal Carcinoma)
9486714|NCT01252628|Active Comparator|Cetuximab (CRC)|Phase 2 (Colorectal Carcinoma)
9486715|NCT01248975|Experimental|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
9486716|NCT01248975|Active Comparator|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
9486717|NCT01248975|Placebo Comparator|FP/SAL 250/50mcg BID plus placebo BID|P/SAL 250/50mcg BID plus placebo BID
9486718|NCT01245634|Experimental|A|
9486719|NCT01245634|Placebo Comparator|B|
9486720|NCT01243346|Experimental|Crenolanib (CP-868,596)|
9486721|NCT01243125|Experimental|NVC-422|
9486722|NCT01243125|Placebo Comparator|Saline|
9486723|NCT01243073|Experimental|imetelstat|Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.
9486724|NCT01242930|Experimental|Imetelstat (7.5 mg/kg)|Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
9486725|NCT01242930|Experimental|Imetelstat (9.4 mg/kg)|Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
9486726|NCT01242488|Experimental|CDP6038 60 mg sc every 2 weeks plus methotrexate|
9486727|NCT01242488|Experimental|CDP6038 60 mg sc every 4 weeks plus methotrexate|
9486728|NCT01242488|Experimental|CDP6038 120 mg sc every 2 weeks plus methotrexate|
9486729|NCT01242488|Experimental|CDP6038 120 mg sc every 4 weeks plus methotrexate|
9486730|NCT01242488|Experimental|CDP6038 240 mg sc every 2 weeks plus methotrexate|
9486731|NCT01242488|Experimental|CDP6038 240 mg sc every 4 weeks plus methotrexate|
9486732|NCT01242488|Active Comparator|Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate|
9486733|NCT01242488|Placebo Comparator|Placebo sc every 2 weeks plus methotrexate|
9486734|NCT01242488|Placebo Comparator|Placebo sc every 4 weeks plus methotrexate|
9486735|NCT01241331|Experimental|BLI1100|BLI1100 topical cream
9486736|NCT01241331|Placebo Comparator|Vehicle cream|Vehicle topical cream
9486737|NCT01241214|Experimental|Investigational drug - Dose 1|
9486738|NCT01241214|Experimental|Investigational drug - Dose 2|
9486739|NCT01241214|Experimental|Investigational drug - Dose 3|
9486740|NCT01241214|Experimental|Investigational Drug - Dose 4|
9486741|NCT01241214|Other|Active Matching Reference|
9486742|NCT01241214|Placebo Comparator|Matching Placebo|
9486743|NCT01240876|Experimental|CEP-37247|
9486744|NCT01240876|Placebo Comparator|Matching placebo|
9486745|NCT01240759|Experimental|S-707106 Dose A|One S-707106 A tablet + 3 Placebo A tablets
9486746|NCT01240759|Experimental|S-707106 Dose B|One S-707106 B tablet + 3 Placebo A tablets
9486747|NCT01240759|Experimental|S-707106 Dose C|S-707106 Dose C = Four S-707106 B tablets
9486748|NCT01240759|Active Comparator|Metformin|The standard of care dose of metformin for the individual patient + 3 Placebo A tablets
9486749|NCT01240694|Experimental|CEP-33457|200 mcg of CEP-33457
9486750|NCT01240512|Active Comparator|High Dose Arm|4000 IU/day Vitamin D3 (cholecalciferol) supplementation
9486751|NCT01240512|Active Comparator|Low Dose Arm|400 IU/day Vitamin D3 (cholecalciferol) supplementation
9486752|NCT01239758|Experimental|ACE-031 (Extension of cohort 1 from core study, A031-03)|
9486753|NCT01239758|Experimental|ACE-031 (Extension of cohort 2 from core study, A031-03)|
9486754|NCT01239758|Experimental|ACE-031 (Extension of cohort 3 from core study, A031-03)|
9486755|NCT01236638|Experimental|Momelotinib|
9486756|NCT01236404|Experimental|PB1023 Injection|Subcutaneous injection PB1023
9486757|NCT01236404|Placebo Comparator|Placebo (0.9% Sodium Chloride Injection)|Subcutaneous Injection Placebo
9486758|NCT01235936|Experimental|AKB-6548|
9486759|NCT01235754|Placebo Comparator|placebo gel|placebo transdermal gel
9486760|NCT01235754|Experimental|testosterone gel|transdermal testosterone gel
9486761|NCT01235585|Experimental|Bitopertin oral dose level 1|
9486762|NCT01235585|Experimental|Bitopertin oral dose level 2|
9486763|NCT01235585|Placebo Comparator|Placebo|
9486764|NCT01235559|Placebo Comparator|Placebo|
9486765|NCT01235559|Experimental|bitopertin [RO4917838] 1|
9486766|NCT01235559|Experimental|bitopertin [RO4917838] 2|
9486767|NCT01235039|Experimental|Formulation A|VIAject®25 for subcutaneous application
9486768|NCT01235039|Experimental|Formulation B|VIAject®7 for subcutaneous application
9486769|NCT01235039|Experimental|Formulation C|Insulin Lispro for subcutaneous application
9486770|NCT01234779|Experimental|A|
9486771|NCT01234779|Experimental|B|
9486772|NCT01234779|Active Comparator|C|
9486773|NCT01234779|Placebo Comparator|D|
9542717|NCT03092986|Active Comparator|chemotherapy with paclitaxel and carboplatin|Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
9542718|NCT03092986|Experimental|chemotherapy with cisplatin and vinblastine|Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
9542719|NCT03092999|Experimental|Healthy subjects|healthy subjects
9542720|NCT03092999|Experimental|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
9542721|NCT03092999|Experimental|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
9542722|NCT03093077|Experimental|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
9542723|NCT03093077|Active Comparator|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
9542724|NCT03092908|Placebo Comparator|Control group|Administer 5 ml placebo (purified water) three times a day.
9542725|NCT03092908|Experimental|Intervention group|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
10058457|NCT02018432|Experimental|Roflumilast conventional dosage|Roflumilast 500 μg qd
9542728|NCT03092869|Experimental|Experimental Group|Feet and Ankle Mobilization
9542729|NCT03092869|Active Comparator|Control Group|Proprioceptive Training
9542730|NCT03092973||Epistaxis Group|
9542731|NCT03092973||Control Group|
9542732|NCT03092882|Experimental|Intervention|Diabetes Self-Management Program
9542733|NCT03092882|No Intervention|Control|
9542734|NCT03092921|Experimental|F&P Mask Seal|Participants to use trial seal in-home for 1 week
9542735|NCT03092921|Experimental|F&P Mask|Participants to use trial mask in-home for 2 weeks
9542736|NCT03092817|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
9542737|NCT03092817|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
9542738|NCT03092856|Experimental|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9542739|NCT03092856|Active Comparator|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
9542740|NCT03092804||normal pressure hydrocephalus|"Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both~The NPH patients will undergo the CSF tap test and then receive the ventriculo-peritoneal shunting surgery. They will have the examination of brain constructure neuroimaging and functional MRI prior to and posterior to the shunting."
9542741|NCT03092804||normal control|Healthy volunteers will undergo the examination of brain constructure and functional MRI.
9542742|NCT03092830||1-arm, 500 participates|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
9542743|NCT03092648|Experimental|Bronchial basal cells|
9542744|NCT03092648|No Intervention|Control|
9542745|NCT03092778|Experimental|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
9542746|NCT03092765|Experimental|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542747|NCT03092765|Experimental|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542748|NCT03092765|Experimental|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542749|NCT03092765|Experimental|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542750|NCT03092765|Experimental|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542751|NCT03092765|Experimental|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542752|NCT03092765|Experimental|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542753|NCT03092765|Experimental|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
9542754|NCT03092596|Experimental|Patient-administered screening tool|Patients will complete a screener for alcohol and drug misuse.
9542755|NCT03092596|Experimental|Patient health navigator-administered screening tool|Patient health navigators will administer a screener for alcohol and drug misuse to patients.
9542756|NCT03092596|Experimental|Patient health navigator-assisted linkage to treatment|Patient health navigators will be trained in motivational interviewing to engage patients about linkage to substance abuse treatment.
9542757|NCT03092596|No Intervention|Treatment as usual|Patients will receive standard care.
9542758|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
9542759|NCT03092687||substance disorders|decedents with and without substance use disorders
9542760|NCT03092583|Experimental|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
9542761|NCT03092583|Other|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
9542762|NCT03092622|Experimental|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
9542763|NCT03092544|Active Comparator|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
9542764|NCT03092544|Active Comparator|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
9542765|NCT03092544|No Intervention|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
9542766|NCT03092544|No Intervention|Normal Control 1|10 normal controls (younger cohort, mean age 38)
9542767|NCT03092544|No Intervention|Normal Control 2|10 normal controls (younger cohort, mean age 58)
9542768|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
9542769|NCT03092557|Experimental|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
9542770|NCT03092570|Experimental|tDCS Post-CVA|The participants will get a 20min stimulation at a maximal intensity of 2mA
9542771|NCT03092570|Sham Comparator|Sham Post-CVA|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
9542772|NCT03092570|Experimental|tDCS Young Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
9542773|NCT03092570|Sham Comparator|Sham Young Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
9542774|NCT03092570|Experimental|tDCS Older Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
9542775|NCT03092570|Sham Comparator|Sham Older Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
9542776|NCT03092284|Active Comparator|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
9542777|NCT03092284|Placebo Comparator|Placebo|Saline
9542778|NCT03092310|Experimental|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
9542779|NCT03092193|Experimental|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
9542780|NCT03092193|Experimental|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
9542781|NCT03092180||Idiopathic inflammatory myopathies 1|Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset
9542782|NCT03092180||Idiopathic inflammatory myopathies 2|Intravenous infusion with methyprednisolone at disease onset
9542783|NCT03092245|Active Comparator|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
9542784|NCT03092245|Placebo Comparator|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
9542785|NCT03092206|Experimental|Group 1|F/TAF ; oral; Dose: 25/200 mg; Frequency: QD
9542786|NCT03092206|Experimental|Group 2|Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD
9542787|NCT03092206|Experimental|Group 3|Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD
9542788|NCT03092440||"Nursing students group"|nursing students
9542789|NCT03092440||"New nurses group"|Nurses with < 2 years experience
9542790|NCT03092440||"Expert nurses group"|Intensive nurses (with ≥ 4 years experience post graduate)
9542791|NCT03092414|Experimental|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
9542792|NCT03092414|Experimental|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
9542793|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
9542794|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
9803779|NCT03334851|Experimental|Part A, Cohort 1|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration
9542795|NCT03092167|Active Comparator|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
9542796|NCT03092167|No Intervention|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
9542797|NCT03092167|No Intervention|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
9542798|NCT03092466|Active Comparator|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
9542799|NCT03092466|Placebo Comparator|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
9542800|NCT03092154|Experimental|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
9542801|NCT03092154|No Intervention|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
9542802|NCT03092271|Active Comparator|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
9542803|NCT03092271|Experimental|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
9542804|NCT03092232|Experimental|Cohort 1_Active and Matching Placebo|
9542805|NCT03092232|Experimental|Cohort 2_Active and Matching Placebo|
9542806|NCT03092232|Experimental|Cohort 3_Active and Matching Placebo|
9542807|NCT03092141|Active Comparator|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
9542808|NCT03092141|Active Comparator|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
9542809|NCT03092388|Experimental|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
9542810|NCT03092388|Experimental|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.~Additionally, during daytime a special test with random parts of the study group basic is performed:~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
9542811|NCT03092336|Experimental|Electrical Stimulation|"The training with electrostimulation will be performed with the following intensity:~Medium frequency current: 2.500Hz Modulation frequency: up to 50Hz Time on / off: 1: 2 Average session time 10 to 15 min Being applied in the same muscle groups that will be trained in the group that will perform strength training."
9542812|NCT03092336|Experimental|Strength training|There will be 10 exercises: upper limbs: Supine with dumbbells; High pulley pull; Alternating thread with dumbbells; Triceps dumbbell test; Lower limbs: knee extensor, squatting with body weight, plantar flexion, knee flexion and plantar dorsiflexion. The session time will be from 45 minutes to one hour 2 times weekly totaling at the end of the 12 weeks, 24 strength training sessions.
9542813|NCT03092128||sensitive group; non-sensitive group|sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration. non-sensitive patients were defined as patients reached PD after first month administration and first three months administration.
9542814|NCT03092115|Experimental|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
9542815|NCT03091985|Experimental|Group A|"Drainage of the lactating breast using:~PersonalFit - Breast shield & Brownie - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
9542816|NCT03091985|Experimental|Group B|"Drainage of the lactating breast using:~Brownie - Breast shield & PersonalFit - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
9542817|NCT03091998|Active Comparator|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
9542818|NCT03091998|Placebo Comparator|Placebo (saline)|Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
9616534|NCT02541474|Other|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
9616535|NCT02541474|No Intervention|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
9616536|NCT02541370|Experimental|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
9616537|NCT02541396|Placebo Comparator|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
9616538|NCT02541396|Active Comparator|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
9616539|NCT02541396|Experimental|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
9616540|NCT02541396|Experimental|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
9616541|NCT02541396|Experimental|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
9542819|NCT03091972|Experimental|Contact force assisted linear ablation|Left atrial linear ablation performed using the contact force sensing catheter after pulmonary vein isolation
9542820|NCT03091972|Active Comparator|control|Left atrial linear ablation performed using the catheter without contact force sensing after pulmonary vein isolation
9542821|NCT03092037||All participants|All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.
9542822|NCT03092037||All participants (side-effects)|All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.
9542823|NCT03091907||Case|Children with a history of necrotizing enterocolitis
9542824|NCT03091907||control|Children with no history of necrotizing enterocolitis
9542825|NCT03091946|Placebo Comparator|Cooked cream of rice|Cream of rice with additional dried fruits, nuts and seeds cooked just prior to its consumption and served with skim milk as a beverage
9542826|NCT03091946|Experimental|Overnight oats|Oats with additional dried fruits, nuts and seeds soaked overnight in skim milk
9542827|NCT03092063|Experimental|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
9542828|NCT03092063|Experimental|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
9542829|NCT03092063|Experimental|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
9542830|NCT03092063|Experimental|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
9542831|NCT03092063|Experimental|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
9542832|NCT03092063|Experimental|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
9542833|NCT03092050|Active Comparator|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
9542834|NCT03092050|Experimental|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
9542835|NCT03092102|Experimental|A single dose HEC585（A1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542836|NCT03092102|Experimental|A single dose HEC585（A2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542837|NCT03092102|Experimental|A single dose HEC585/FE（A3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule~Treatment Period 1：No food prior to dosing；Treatment Period 2：High-fat meal prior to dosing"
9542838|NCT03092102|Experimental|A single dose HEC585（A4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542839|NCT03092102|Experimental|A single dose HEC585（A5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542840|NCT03092102|Experimental|A single dose HEC585（A6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542841|NCT03092102|Experimental|A single dose HEC585（A7）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542842|NCT03092102|Experimental|A single dose HEC585（A8）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542843|NCT03092102|Experimental|Multiple doses HEC585（B1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542844|NCT03092102|Experimental|Multiple doses HEC585（B2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542845|NCT03092102|Experimental|Multiple doses HEC585（B3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542846|NCT03092102|Experimental|Multiple doses HEC585（B4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542847|NCT03092102|Experimental|Multiple doses HEC585（B5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542848|NCT03092102|Experimental|Multiple doses HEC585（B6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
9542849|NCT03092076|Experimental|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
9542850|NCT03092076|Experimental|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
9616542|NCT02541396|Experimental|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
9542851|NCT03092076|No Intervention|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
9542852|NCT03091933|Experimental|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
9542853|NCT03091894|Active Comparator|propofol|patients will receive only propofol intravenous infusion for sedation
9542854|NCT03091894|Active Comparator|propofol-dex.|patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation
9542855|NCT03091790|Active Comparator|Synthetic Mesh|Synthetic mesh (mid-density polypropylene (generic) Bard soft mesh) will be used in open ventral hernia repair
9542856|NCT03091790|Active Comparator|Biologic Mesh|Biologic mesh (non cross linked porcine acellular dermal matrix: Strattice) will be used in open ventral hernia repair
9542857|NCT03091881|Active Comparator|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
9542858|NCT03091881|Placebo Comparator|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
9542859|NCT03091855||PLUG Dementia Trial|Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
9542860|NCT03091855||MRI PLUG Dementia Sub-Study|20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.
9542861|NCT03091868|Experimental|Group 1 (BIA 6-512 25 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
9542862|NCT03091868|Experimental|Group 2 (BIA 6-512 50 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
9542863|NCT03091868|Experimental|Group 3 (BIA 6-512 100 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
9542864|NCT03091868|Experimental|Group 4 (BIA 6-512 200 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
9542865|NCT03091803||Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
9542866|NCT03091803||Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
9542867|NCT03091842|Experimental|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
9542868|NCT03091842|Experimental|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
9542869|NCT03091842|Active Comparator|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
9542870|NCT03091712|Experimental|Paper Titration Tool and Glooko MIDS|"Glooko mobile insulin dosing system(MIDS), using the STEP WISE degludec titration algorithm.~The eligible subjects will be started on insulin degludec (Tresiba® U-200 FlexTouch®). Subjects will use MIDS for insulin degludec titration management. The clinician will configure MIDS Prescription Instruction Form(PIF) using pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program. The Clinician can alter this as appropriate based on medical judgment. Subjects will be started on MIDS and trained on use of Glooko MIDS mobile app. Subjects will get dose adjustment check up on the app and also alert to contact physician if subject experiences hyperglycemia or hypoglycemia."
9542871|NCT03091712|No Intervention|Paper Titration tool|"Usual care for insulin degludec (Tresiba® U-200 FlexTouch® pens) titration using the STEP WISE degludec titration algorithm.The eligible subjects will be started on insulin degludec(Tresiba® U-200 FlexTouch®).~Subjects in this group will be provided with a one-page description of the pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program and how to follow it. The Clinician can alter this as appropriate based on medical judgment. This document will also include instructions to contact the HCP if the subject experiences hyperglycemia or hypoglycemia."
9542872|NCT03091699|Experimental|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
10058458|NCT02018471|Experimental|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
9542873|NCT03091699|Active Comparator|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
9542874|NCT03091647|Experimental|acupressure intervention|Practice acupressure at home and complete daily logs
9542875|NCT03091647|Placebo Comparator|usual care|Receive usual care and complete daily logs
9542876|NCT03091543|Experimental|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
9542877|NCT03091543|Experimental|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
9542878|NCT03091543|Experimental|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
9542879|NCT03091543|Experimental|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
9542880|NCT03091543|Experimental|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
9542881|NCT03091634|Experimental|test group|the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.
9542882|NCT03091634|Placebo Comparator|control group|the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..
9542884|NCT03091491|Experimental|Nivolumab|
9542885|NCT03091491|Experimental|Nivolumab and Ipilimumab|
9542886|NCT03091517|Other|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
9803780|NCT03334851|Experimental|Part A, Cohort 2|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
9542887|NCT03091556||The individuals taking XLGB Pill|The overall individuals taking XLGB Pill with recommended dosage and achieving the inclusion criteria.
9542888|NCT03091530|Experimental|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
9542889|NCT03091530|Experimental|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
9542890|NCT03091374|Experimental|Growth Hormone|
9542891|NCT03091569|Active Comparator|Vitamin K|
9542892|NCT03091569|Placebo Comparator|Control|
9542893|NCT03091595|Experimental|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
9542894|NCT03091595|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
9542895|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
9542896|NCT03091582|Experimental|Cognitive behavioral therapy|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive factors and behavioral factors on affective distress.
9542897|NCT03091582|Experimental|Behavioral Activation|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
9542898|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
9542899|NCT03091686|Experimental|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)~HAPA SB Intervention Slideshow"
9542900|NCT03091686|Active Comparator|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)~HAPA MVPA Intervention Slideshow"
9542901|NCT03091686|No Intervention|Control Group|"Control (outcome questionnaire without any slideshow)~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
9542902|NCT03091426|Experimental|Omiganan 1%|
9542903|NCT03091426|Experimental|Omiganan 1.75%|
9542904|NCT03091426|Experimental|Omiganan 2.5%|
9542905|NCT03091426|Placebo Comparator|Vehicle|
9542906|NCT03091309|Experimental|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
9803781|NCT03334851|Experimental|Part A, Cohort 3|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
10040123|NCT01850277|Experimental|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
10040124|NCT01850277|Active Comparator|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
10040125|NCT01850290||Dopamine Imaging|
10040126|NCT01850303|Other|Surveillance|
10040127|NCT01850303|Experimental|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
10040128|NCT01850316|Experimental|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
10040129|NCT01850329|No Intervention|control|No computed-assisted information program will be administered.
10040130|NCT01850329|Experimental|intervention|computed-assisted information program will be administered.
10040131|NCT01850342|Experimental|Fat micrograft enhanced with ADRC|
10040132|NCT01850368|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
9542907|NCT03091309|Active Comparator|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
9542908|NCT03091322||SR-T group|single chamber pacemaker
9542909|NCT03091322||DR-T group|dual chamber pacemaker
9542910|NCT03091322||HF-T group|triple chamber pacemaker (IS-1 connector)
9542911|NCT03091322||HF-T QP group|triple chamber pacemaker (with IS4 connector) and a lead of the Sentus QP lead family
9542912|NCT03091504|Experimental|Albuterol via High flow nasal cannula|Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.
9542913|NCT03091335|Experimental|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
9542914|NCT03091335|No Intervention|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
9542915|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
9542916|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
9542917|NCT03091166|Active Comparator|Dexmedetomidine|
10040133|NCT01850407|No Intervention|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
9542918|NCT03091166|No Intervention|No Dexmedetomidine|
9542919|NCT03091023|Active Comparator|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
9542920|NCT03091023|Active Comparator|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
9542921|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
9542922|NCT03091101|Experimental|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
9542923|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
9542924|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
9542925|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
9542926|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
9542927|NCT03091075|Experimental|Treatment Group|receiving oral Oxandrolone 24 mg (12mg tablets) per day if male and 12 mg Oxandrolone per day if female, with dosing starting at time of surgery and continuing 12 weeks postoperative
9542928|NCT03091075|Placebo Comparator|Placebo Group|receiving placebo medication (Placebo Oral Tablet), oral tablet, with dosing beginning at time of surgery and continuing for 12 weeks postoperative
9542929|NCT03091062|Experimental|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
9542930|NCT03091088|Active Comparator|Control|walking at an intense pace
9542931|NCT03091088|Experimental|Experimental|osteoporosis specific-oriented training
9542932|NCT03091257|Experimental|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated~Treat cohort with Dabrafenib~Analysis~Treat cohort with Dabrafenib"
9542933|NCT03091257|Experimental|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated~Treat cohort with Dabrafenib and Trametinib~Analysis~Treat cohort with Dabrafenib and Trametinib"
9542934|NCT03091257|Experimental|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~KRAS or NRAS mutated~Treat cohort with Trametinib~Analysis~Treat cohort with Trametinib"
9542935|NCT03091270||BOLD-fMRI|Identifying the motor functional cortex in glioma patients with BOLD-fMRI.
9542936|NCT03091270||ZOOMit-fMRI|Identifying the motor functional cortex in glioma patients with ZOOMit-fMRI.
9542937|NCT03091036|Other|Proactive healthcare intervention|Participants who were included before (single-arm pre-post study), now a proactive and integrated intervention program for the health is performed of the complex chronic patient, based in an improvement of the care process.
9542938|NCT03091153|No Intervention|Control|Standard care. Annual medication review
9542939|NCT03091153|Experimental|Intervention|In depth medication review with a focus on deprescribing
9542940|NCT03091244||The individuals taking XLGB Capsule|The overall individuals taking XLGB Capsule with recommended dosage and achieving the inclusion criteria.
9542941|NCT03090984|Active Comparator|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
9542942|NCT03090984|Active Comparator|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
9542943|NCT03090984|Active Comparator|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
9542944|NCT03090893|Experimental|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
9542945|NCT03091010|Experimental|Fecal Microbiota Transplantation|
9542946|NCT03091010|Active Comparator|Steroid|
9542947|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
9803782|NCT03334851|Experimental|Part A, Cohort 4|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
10040134|NCT01850420|Experimental|IMC-1|Experimental intervention
10040135|NCT01850420|Placebo Comparator|Matching placebo|
9542948|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
9542949|NCT03090971|Experimental|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
9542950|NCT03090906|Experimental|Control group: SCTG from palate|Soft tissue augmentation palate
9542951|NCT03090906|Experimental|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
9542952|NCT03090919|Placebo Comparator|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
9542953|NCT03090919|Experimental|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (~250cc in volume).
9542954|NCT03090828|No Intervention|control|treatment as usual will be provided to patients
9542955|NCT03090828|Active Comparator|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
9542956|NCT03090828|Experimental|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
9542957|NCT03090802|Experimental|Intervention|The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
9542958|NCT03090802|No Intervention|Control|Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
9542959|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
9542960|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
9542961|NCT03090854||Alzheimer disease patients|
9542962|NCT03090685|Experimental|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
9542963|NCT03090685|Placebo Comparator|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
9542964|NCT03090672|Experimental|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
9542965|NCT03090672|Experimental|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
9542966|NCT03090672|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
9542967|NCT03090698|Active Comparator|Hylan|Intra-articular (knee) 6ml Hylan GF20 administration (single shot)
9542968|NCT03090698|Active Comparator|Hylan + Corticosteroid|Intra-articular (knee) 6ml Hylan GF20 and 1ml Triamcinolone 20mg/ml administration (single shot)
9542969|NCT03090698|Active Comparator|Corticosteroid|Intra-articular (knee) 1ml Triamcinolone administration (single shot)
9542970|NCT03090594|Other|Biopsy|Transbronchial biopsies with cryoprobe.
9542971|NCT03090607|Experimental|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
9542972|NCT03090607|Sham Comparator|Saline|Endoscopic injection of saline
9542973|NCT03090659|Experimental|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
9542974|NCT03090542|No Intervention|Control|
9542975|NCT03090542|Active Comparator|Product|
9542976|NCT03090529|Experimental|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
9542977|NCT03090529|No Intervention|Control group|The control group will receive usual medical care
9542978|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
9542979|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
9542980|NCT03090776|Other|unenriched|all eligible women for partial or total mastectomy intervention will be ketamine or placebo saline
9542981|NCT03090776|Other|enriched for PPMP risk|women at high risk for persistent pain after partial or total mastectomy intervention will be ketamine or placebo saline
9542982|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
9542983|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
9542984|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
9616543|NCT02541396|Experimental|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
9616544|NCT02541357|No Intervention|Usual care|Does not receive a specific study intervention
9616545|NCT02541357|Experimental|preoperative relaxation program|preoperative relaxation program
10040136|NCT01850433|Experimental|Internet CBT|
9542985|NCT03090724|Experimental|BIA 5-453 (Young)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
9542986|NCT03090724|Experimental|BIA 5-453 (Elderly)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
9542987|NCT03090711|Experimental|TMS|Real transcranial magnetic stimulation (TMS).
9542988|NCT03090711|Sham Comparator|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
9542989|NCT03090711|Experimental|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
9542990|NCT03090711|Sham Comparator|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
9542991|NCT03090568|Experimental|BIA 5-453 Fasting|BIA 5-453 200 mg in fasting conditions
9542992|NCT03090568|Experimental|BIA 5-453 Fed|BIA 5-453 200 mg in fed conditions
9542993|NCT03090555|Experimental|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
9542994|NCT03090555|Active Comparator|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
9542995|NCT03090880|No Intervention|Control|usual care,
9542996|NCT03090880|Experimental|Experimental|tinzaparin sodium
9542997|NCT03090633|Experimental|Fetoscopy|All participants will undergo fetoscopic repair of fetal spina bifida.
9542998|NCT03090867|Active Comparator|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
9542999|NCT03090867|Experimental|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~Each care is written down on a collecting sheet."
9543000|NCT03090581|Active Comparator|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
9543001|NCT03090581|Active Comparator|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
9543002|NCT03090581|Active Comparator|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
9543003|NCT03090503|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
9543004|NCT03090503|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
9543005|NCT03090490|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
9543006|NCT03090490|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
9543007|NCT03090516|Experimental|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
9543008|NCT03090516|Experimental|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
9543009|NCT03090516|Experimental|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
9543010|NCT03090477|Experimental|Pharmaceutical care and adherence aids|
9543011|NCT03090477|No Intervention|Control (dispensing of TKI & instruction about administration)|
9543012|NCT03090217|Experimental|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
9803783|NCT03334851|Experimental|Part A, Cohort 5|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
10040137|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
9543013|NCT03090217|Active Comparator|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
9616546|NCT02541357|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
10040138|NCT01850459||IQ-Matched Control Subjects|
10040139|NCT01850459||Age-Matched Neurotypical Controls|
9543014|NCT03090373|Sham Comparator|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
9543015|NCT03090373|Active Comparator|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
9543016|NCT03090204|Other|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
9616547|NCT02541357|Experimental|preop relaxation and surgery education|preoperative relaxation program AND single education unit
9616548|NCT02541383|Other|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
9616549|NCT02541383|Experimental|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
9616550|NCT02541383|No Intervention|Arm A Part 2|Observation
9616551|NCT02541383|Experimental|Arm B Part 2|daratumumab
9616552|NCT02541305|Active Comparator|Cotrol|No propioceptive program.
9616553|NCT02541305|Experimental|Experimental|Propioceptive program
9616554|NCT02541331|Experimental|ISMIGEN|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
9616555|NCT02541331|Placebo Comparator|PLACEBO|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
9616556|NCT02541344|Active Comparator|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
9616557|NCT02541344|Active Comparator|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
9616558|NCT02541344|Placebo Comparator|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
9616559|NCT02541318|Experimental|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
9616560|NCT02541318|Other|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
9616561|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
9616562|NCT02541279|Experimental|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
9616563|NCT02541279|Active Comparator|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
9616564|NCT02541461|Other|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI < 25 kg/m2
9616565|NCT02541461|Other|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
9616566|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
9616567|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
9616568|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
10040140|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
9616569|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
9616570|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
9616571|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
9616572|NCT02541071|Experimental|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
9616573|NCT02541071|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
9616574|NCT02541071|Experimental|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
9616575|NCT02541058||Confirmed 22q.11.2 deletion/duplication|
9616576|NCT02541058||Suspected 22q.11.2 deletion/duplication|
9616577|NCT02541045|Placebo Comparator|Group 1: Placebo|Placebo
9616578|NCT02541045|Experimental|Group 2: Metadoxine|therapy with metadoxine
9616579|NCT02541162|Experimental|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
9803784|NCT03334851|Experimental|Part A, Cohort 6|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
9543017|NCT03090451|Experimental|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
9543018|NCT03090451|Experimental|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
9543019|NCT03090464||Standard of Care (SOC)|Participants have standard of care with no access to digital disease management tool
10040141|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
9543020|NCT03090464||SOC + digital disease management|Participants have access to the digital disease management tool in addition to standard of care
9543021|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
9543022|NCT03090321|Active Comparator|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
9543023|NCT03090321|Active Comparator|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
9543024|NCT03090321|Active Comparator|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
9543025|NCT03090321|Placebo Comparator|Read AHA website|Daily reminder to read the American Heart Association (AHA) website.
10040142|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
10040143|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary [idiopathic] or secondary [symptomatic] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
10040144|NCT01850511|Experimental|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
9543026|NCT03090321|No Intervention|Baseline monitoring|No feedback is provided to the users. This is the control arm.
9543027|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
10040145|NCT01850537|Experimental|single arm study|treatment of degenerative disc disease using the PROW LIF
9543028|NCT03090334|Experimental|De-escalation|"In this group, investigators will manage the antifungal therapy according to the BG levels as follows:~antifungal therapy will be stopped immediately after the BG response in case of serum BG <80 pg/ml in presence of clinical stability (CS);~antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG <80 pg/ml in patients without CS. In these cases, if the following BG value is <80 pg/ml antifungal therapy will be stopped independently from the CS achievement.~antifungal therapy will be continued until day 10 for BG levels >200 pg/ml"
9543029|NCT03090334|No Intervention|Standard of care|"In this group antifungal treatment will be continued until clinician's decision.~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center."
9543030|NCT03090399|No Intervention|control group|patients in which standard fluid administration was applied
9543031|NCT03090399|Active Comparator|case group|patients in which fluids were administered according to FloTrac parameters
9543032|NCT03090178|Experimental|Patients|"Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
9543033|NCT03090178|Active Comparator|Healthy Volunteers|"Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
9543034|NCT03090113|Experimental|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
9543035|NCT03090113|Placebo Comparator|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
9543036|NCT03090438|Active Comparator|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
9543037|NCT03090438|No Intervention|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
9543038|NCT03090412|Experimental|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
10040146|NCT01850576|Experimental|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
10040147|NCT01850576|No Intervention|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
10040148|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
10040149|NCT01850654|Other|Probands|Participants with colorectal or endometrial cancer.
10040150|NCT01850654|Other|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
10040151|NCT01850654|Other|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
10040152|NCT01850667|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
10040153|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
10040154|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
10040155|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
9543039|NCT03090412|Experimental|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
9543040|NCT03090269|Experimental|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
9543041|NCT03090126||Alveolar hypoventilation|
9543042|NCT03090087|Experimental|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
9543043|NCT03090230|Experimental|Relay Pro Thoracic Stent-Graft System|The Relay Pro arm includes subjects who receive the device to treat traumatic injury of the descending thoracic aorta with the RelayPro Thoracic Stent-Graft System
9543044|NCT03090347|Experimental|High-sugar diet|Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).
9543045|NCT03090074|Active Comparator|Moderate carbohydrate restriction and traditional support|Moderate carbohydrate restriction and traditional support with group meetings
9543046|NCT03090074|Active Comparator|Extreme low carbohydrate diet and traditional support|Extreme carbohydrate restriction and traditional support with group meetings
9543047|NCT03090074|Active Comparator|Moderate carbohydrate restriction and ACT support|Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy
9543048|NCT03090074|Active Comparator|Extreme carbohydrate restriction and ACT support|Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy
9543049|NCT03090360|Placebo Comparator|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
9543050|NCT03090360|Experimental|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
9543051|NCT03090360|No Intervention|Breastfed reference group|Breastfed reference group
9543052|NCT03090152|Active Comparator|Periarticular Injection (PAI)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Peri-articular injection in the operating room~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
9543053|NCT03090152|Active Comparator|Epidural Patient-Controlled Analg (EPCA)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
9543054|NCT03090152|Experimental|PAI + EPCA|"Aspirin and nerve pain medications including duloxetine and clonidine~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~Anesthetic, Antiemetic and peri-articular injection in the operating room~A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
9543055|NCT03089814|Active Comparator|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
9543056|NCT03089814|Active Comparator|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
9543057|NCT03089840|Experimental|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
9543058|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
9543059|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
9543060|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
9543061|NCT03090061|Experimental|Light induced fluorescence intraoral camera|
9543062|NCT03090061|Active Comparator|Visual-tactile assessment method according to FDI criteria|
9543063|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
9543064|NCT03089957|Experimental|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
9543065|NCT03089957|Placebo Comparator|Control group|Control group will be in usual care without any intervention.
9543066|NCT03090048|Experimental|Vitamin A|retinyl palmitate USP
9543067|NCT03090048|Experimental|Azithromycin with Vitamin A|USP grade ingredients
9543068|NCT03090048|Active Comparator|Azithromycin|azithromycin monohydrate
9543069|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
9543070|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
9543071|NCT03090035|Experimental|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
9543072|NCT03089983|Active Comparator|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
9543073|NCT03089983|Active Comparator|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
9543074|NCT03089983|Experimental|Buprenorphine/Naloxone|Participants who choose buprenorphine/naloxone will receive an induction phase for 10 days and then move on to receiving it in the community for 6 months. Buprenorphine/naloxone has been authorized and is available for use in Malaysia.
9543075|NCT03089983|Active Comparator|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
9543076|NCT03089983|Experimental|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
9543077|NCT03089788|Other|Home-based test and skin test|
9543078|NCT03090009|Active Comparator|Flurbiprofen|Flurbiprofen 100 mg bid.
9543079|NCT03090009|Placebo Comparator|Placebo|Placebo taken bid
9543080|NCT03089723|Experimental|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
9543081|NCT03089723|Experimental|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
9543082|NCT03089671|Experimental|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
9543083|NCT03089671|Active Comparator|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
9543084|NCT03089632|Experimental|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
9543085|NCT03089710|Experimental|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.~Applied colloid: hydroxyethyl starch"
9543086|NCT03089775|Experimental|BBI-2000|Cohort A
9543087|NCT03089775|Placebo Comparator|Vehicle|Cohort A
9543088|NCT03089775|Other|Multiple treatments|Cohort B
9543089|NCT03089554|Experimental|Therapeutic Intervention|Therapeutic Intervention
9543090|NCT03089593|Experimental|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
9543091|NCT03089593|Placebo Comparator|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
9543092|NCT03089645|Experimental|Part 1|MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors
9543093|NCT03089645|Experimental|Part 2|Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.
9543094|NCT03089645|Experimental|Part 3|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC
9543095|NCT03089762|Experimental|SVF and PRP|
9543096|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
9543097|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
9543098|NCT03089567|No Intervention|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
9543099|NCT03089567|Active Comparator|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
9543100|NCT03089567|Experimental|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
9543101|NCT03089736|Experimental|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
9543102|NCT03089736|Other|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
9543103|NCT03089476|Other|High Risk Atopic Infants|Infants, who are at high risk of atopy, which will be determined by a validated questionnaire, will be enrolled. Infants will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), bacterial swabs, and parental questionnaires at each visit (3 visits total). At the latter 2 visits, infants will also undergo skin prick testing to evaluate for food sensitization.
9543104|NCT03089476|Other|Atopic Adults|Parents of infants enrolled in the study will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), and complete questionnaires at the first visit.
9543105|NCT03089463||Observation group|The entire participants in this study will be included in this group.
9543106|NCT03089398|Active Comparator|Hybrid Coronary Revascularization Group|HCR is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization, combined with percutaneous revascularization of at least one non-LAD target.
9543107|NCT03089398|Active Comparator|Percutaneous Coronary Intervention|PCI will be performed using standard techniques at the discretion of the operator. Only Food and Drug Administration (FDA) and Health Canada approved commercially available metallic drug-eluting stents may be used in this protocol.
9543108|NCT03089294|Active Comparator|Group A|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)
9543109|NCT03089294|Active Comparator|Group B|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)
9543110|NCT03089294|Active Comparator|Group C|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)
9543111|NCT03089294|Active Comparator|Group D|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)
9543112|NCT03089281|Other|SmartDelay™ algorithm|Subjects programmed with AV Delay and pacing chamber determined by SmartDelay
9543113|NCT03089281|Other|Fixed AV Delay with BiV pacing|Subjects programmed with a Fixed AV Delay of 120ms with BiV pacing
9543114|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
9543115|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients~Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.~Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
9543116|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)~Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.~Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
9543117|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.~Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.~Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
9543118|NCT03089502|Experimental|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
10040156|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
10040157|NCT01850680|Placebo Comparator|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
10040158|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
10040159|NCT01850719|Experimental|Arthroscopic Partial Meniscectomy|
9543119|NCT03089502|No Intervention|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
10040160|NCT01850719|Active Comparator|Physical Therapy|
9543120|NCT03089190|Active Comparator|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
9543121|NCT03089190|Active Comparator|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
9543122|NCT03089190|Active Comparator|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
9543123|NCT03089190|Placebo Comparator|Placebo|administration of inactive whey protein
9543124|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.~Polypectomy or biopsy will be performed if necessary (following current guidelines).~Specific molecular analysis of serrated lesions and CRC will be carried out."
9543125|NCT03089450|Experimental|CGBIO stent (DES)|The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
9543126|NCT03089450|Active Comparator|Biomatrix flex(DES)|The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
9543127|NCT03089528|Experimental|Videolaryngoscopy|the trachea will be intubated using a videolaringoscope
9543128|NCT03089528|Active Comparator|Direct laringoscopy|the trachea will be intubated using a laringoscope
9543129|NCT03089619|Active Comparator|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
9543130|NCT03089619|Active Comparator|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
9543131|NCT03089177|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
9543132|NCT03089177|No Intervention|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
9543133|NCT03089385|Experimental|Implementation group|This group will have the hypertension tool implemented on them.
9543134|NCT03089385|No Intervention|Control group|This group will not have the tool implemented.
9543135|NCT03089437|Experimental|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
9543136|NCT03089437|Experimental|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
9543137|NCT03089320|No Intervention|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
9543138|NCT03089320|Experimental|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth > 8 ng/ml will continue on to Step 2."
9543139|NCT03089424|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
9543140|NCT03089424|Active Comparator|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
9543141|NCT03089372|Active Comparator|Group A|Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
9543142|NCT03089372|Active Comparator|Group B|Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
9543143|NCT03089333|Experimental|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
9543144|NCT03089333|Active Comparator|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
9543145|NCT03089229|Experimental|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
9543146|NCT03089229|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
9543147|NCT03089346|Other|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
9543148|NCT03089307|Active Comparator|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
10040161|NCT01850732|Other|ultrasound of aorta|
10040162|NCT01850771|Active Comparator|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
10040163|NCT01850771|Active Comparator|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
9543149|NCT03089307|Active Comparator|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
9543150|NCT03089151|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
9543151|NCT03089151|No Intervention|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
9543152|NCT03089086|Active Comparator|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
9543153|NCT03089086|No Intervention|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
9543154|NCT03089138|Experimental|Regan Tangjiang，Simulation Shufengjiere Capsules|
9543155|NCT03089138|Active Comparator|Simulation Regan Tangjiang，Shufengjiere Capsules|
9543156|NCT03089138|Placebo Comparator|Simulation Regan Tangjiang and Shufengjiere Capsules|
9543157|NCT03089125|Active Comparator|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
9543158|NCT03089125|Experimental|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~Psychoeducation~Relaxation training for reducing physiological stress~Behavioral techniques for managing acute breathlessness"
9543159|NCT03088878|Experimental|Part 1|Cirmtuzumab followed by Cirmtuzumab plus ibrutinib
9543160|NCT03088878|Experimental|Part 2|Cirmtuzumab plus ibrutinib
9543161|NCT03088878|Experimental|Part 3 - Arm A|Cirmtuzumab plus ibrutinib
9543162|NCT03088878|Active Comparator|Part 3 - Arm B|Ibrutinib only
9543163|NCT03088878|Active Comparator|Part 4|Cirmtuzumab plus ibrutinib
9543164|NCT03088865|Experimental|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
9543165|NCT03088865|Active Comparator|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
9543166|NCT03088982||Lanmeur multimorbid patients|All multimorbid patients who met 12 FPs in the Lanmeur residential care home in the county of Finistere (in north-west France) from July 2014 to December 2014. These FPs were drawn from those physicians associated with the Lanmeur residential care home.
9543167|NCT03088904|Experimental|Group A: MZ twins (IIV4)|Group A: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
9543168|NCT03088904|Experimental|Group B: DZ twins (IIV4)|Group B: Up to 40 healthy dizygotic (DZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), and Day 6-8 and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
9543169|NCT03088904|Experimental|Group C: MZ twins (IIV4 or LAIV4)|"Group C: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).~This group was terminated in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability."
9543170|NCT03088969||patient with a chronic back pain|
9543171|NCT03089021|Experimental|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
9543172|NCT03089021|Experimental|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
9543173|NCT03088891|Experimental|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
9543174|NCT03088891|Placebo Comparator|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
9543175|NCT03088839||30 ALS patients|
9543176|NCT03088839||30 healthy controls|
9543177|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=37)
9543178|NCT03088956||Healthy|Healthy Participants (n=10)
9543179|NCT03089112|Experimental|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
9543180|NCT03089112|Experimental|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
9543181|NCT03089112|Experimental|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
9543182|NCT03089112|Experimental|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
9543183|NCT03089112|Experimental|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
9543184|NCT03089112|Experimental|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
9616580|NCT02541162|No Intervention|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
10040164|NCT01850784|Active Comparator|High energy formula|High energy formula (Similac)
9543185|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
9543186|NCT03088943|Other|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
9543187|NCT03088943|Other|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
9543188|NCT03088943|Other|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
9543189|NCT03088774|Experimental|New web-application|Information material developed in a participatory design together with patients.
9543190|NCT03088774|Experimental|Patient Handbook|Public available information.
9543191|NCT03088787||Patients for TAVR|Patients for TAVR
9543192|NCT03089060|Experimental|Silicone Finger Cap|Patients randomized to this arm will be treated with the novel silicone finger cap for the first two weeks of treatment.
9543193|NCT03089060|Active Comparator|Film dressing|Patients randomized to this arm will be treated with conventional film dressings for the first two weeks of treatment.
9616581|NCT02540967||BAY86-4875|Gadovist administration goup
9616582|NCT02541214|Experimental|Trial Nasal Mask|The participant will use the Saturn nasal mask for 2 weeks in home
9616583|NCT02541240|Experimental|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
9616584|NCT02541240|No Intervention|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
9616585|NCT02541175||All study participants|In order to cover a wide variety of common arrhythmias but keeping the number of subjects needed low (pilot study), the subjects are pre-selected according to following 4 categories: 1) 4 patients with intermitting or persisting atrial fibrillation. 2) 4 patients with atrial flutter 3) 6 patients with frequent atrial or ventricular extra-systoles. 4) 6 cardiac healthy subjects.
9616586|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
9616587|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
9616588|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
9616589|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
9616590|NCT02541123||Cohort E|Uninjured control group
9616591|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
9616592|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
9616593|NCT02541032|Active Comparator|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
9616594|NCT02541032|Active Comparator|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets >3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
9616595|NCT02541136|Experimental|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
9616596|NCT02541136|No Intervention|Control|Participants in the control group didn't change their sedentary habits.
9616597|NCT02541253|Experimental|GC3110A|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
9616598|NCT02541253|Active Comparator|GCFLU Pre-filled Syringe inj.|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
9616599|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
9616600|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
9616601|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
10040165|NCT01850784|Active Comparator|Standard formula|Standard formula
9543194|NCT03089008|Experimental|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
9543195|NCT03089008|Other|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
9543196|NCT03088735|Experimental|Blastocyst-stage embryo transfer strategy|
9543197|NCT03088735|Active Comparator|Cleavage-stage embryo transfer strategy|
9543198|NCT03088722|Experimental|Community health extension workers|Community health extension workers providing contraceptive implants
10040166|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
9543199|NCT03088722|No Intervention|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
10040167|NCT01850810|Experimental|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
10040168|NCT01850810|Placebo Comparator|Control Study Product|1 serving of control beverage.
10040169|NCT01850836|Active Comparator|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
10040170|NCT01850836|Sham Comparator|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
9543200|NCT03088592|Other|Deep Brain Stimulation|After informed consent is obtained, the patients will undergo routine DBS pre-operative evaluation and diagnostic testing. This includes a pre-operative 3T-MRI with and without gadolinium as well as pre-operative medical clearance by the patient's PCP or general practitioner and/or other medical specialist if necessary. They will also receive a baseline clinical evaluation including both motor function (Unified Parkinson's Disease Rating Scale on and off anti-parkinsonian medication) quality of life assessment (Parkinson's disease Questionnaire-39) and a full neuropsychological evaluation, if not already completed as part of the routine DBS candidacy evaluation within 2 months of surgery. Subjects will have medical clearance from their specialists and be be evaluated by an internal medicine physician prior to surgery and cleared to proceed.
9543201|NCT03088566|Experimental|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
9543202|NCT03088566|Active Comparator|Conventional foot screening|The patients are being foot screened according to conventional methods.
9543203|NCT03088631|Active Comparator|Metformin group|
9543204|NCT03088631|Placebo Comparator|Placebo group|
10040171|NCT01850849|Experimental|LEO 39652 cream|Active drug
9543205|NCT03088527|Experimental|RAD140 Part A and Part B|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
9543206|NCT03088670|Experimental|Gosogliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
9543207|NCT03088670|Active Comparator|Vildagliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
9543208|NCT03088709|Experimental|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
9543209|NCT03088644|Experimental|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
9543210|NCT03088644|Experimental|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
9616602|NCT02541019|Experimental|Palonosetron|Palonosetron (iv) one minute before anesthesic induction.
10040172|NCT01850849|Placebo Comparator|LEO 39652 cream vehicle|Placebo drug
10040173|NCT01850862|Experimental|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
10040174|NCT01850862|Active Comparator|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
10040175|NCT01850875|Experimental|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
10040176|NCT01850875|No Intervention|Treatment as usual (control group)|treatment as usual
10040177|NCT01850901|Experimental|Renal sympathetic denervation|Catheter-based renal nerve ablation
10040178|NCT01850901|No Intervention|Usual care|Antihypertensive treatment according to guidelines
10040179|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
10040180|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
9543211|NCT03088644|Experimental|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V[t]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
9543212|NCT03088644|Experimental|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram [mg]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
9543213|NCT03088683|Active Comparator|Nathanson Retractor|Nathanson retractor will be used
9543214|NCT03088683|Active Comparator|Reveel Retractor|Reveel retractor will be used
9543215|NCT03088696|Active Comparator|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
9543216|NCT03088696|Placebo Comparator|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
9543217|NCT03088514|Experimental|NITRATE-LVH intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months
9543218|NCT03088514|Placebo Comparator|NITRATE-LVH placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
9543219|NCT03088514|Experimental|NITRATE-CBP intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month
9543220|NCT03088514|Placebo Comparator|NITRATE-CBP placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
9543221|NCT03088501|Experimental|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
9543222|NCT03088501|Experimental|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.~Brief talk by health professionals.~Role-plays"
9543223|NCT03088501|No Intervention|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
9543224|NCT03088358|Experimental|TeaRx 50 mg|TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)
9543225|NCT03088358|Experimental|TeaRx 100 mg|TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
9543226|NCT03088358|Experimental|TeaRx 150 mg|TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
9543227|NCT03088358|Active Comparator|Enoxaparin|Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)
9543228|NCT03088397|Experimental|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
9543229|NCT03088397|Active Comparator|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
10040181|NCT01850927|Active Comparator|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
9543230|NCT03088397|Active Comparator|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
9543231|NCT03088254|Experimental|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
9543232|NCT03088254|Active Comparator|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
9543233|NCT03088254|Active Comparator|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
9543234|NCT03088371|Other|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
9543235|NCT03088371|Other|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
9543236|NCT03088410|Experimental|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
9803785|NCT03334851|Experimental|Part A, Cohort 7|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
9543237|NCT03088410|Active Comparator|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
9543238|NCT03088410|No Intervention|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
9543239|NCT03088488||Periodontally healthy subjects|
9543240|NCT03088488||Chronic periodontitis patients|
9543241|NCT03088462|Active Comparator|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
9543242|NCT03088462|Experimental|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
9543243|NCT03088540|Active Comparator|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
9543244|NCT03088540|Experimental|cemiplimab|cemiplimab regimen as monotherapy as per study protocol
9543245|NCT03088332|Experimental|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
9543246|NCT03088475|Experimental|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
9486774|NCT01234519|Experimental|Phase 1 - Cohort 1|"Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).~Patients will be enrolled in cohorts of 3 at a specified AEZS-108 dose beginning with 160mg/m^2. Enrollment will be suspended until all members of a cohort have been observed for dose limiting toxicities (DLT) for a period of 3 weeks (1 cycle of AEZS-108) from initial treatment with AEZS-108. Dose escalation will proceed within each cohort according to a specific scheme where DLT is defined."
9486775|NCT01234519|Experimental|Phase 1 - Cohort 2|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
9486776|NCT01234519|Experimental|Phase 1 - Cohort 3|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
10040182|NCT01850927|Sham Comparator|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
10040183|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
10040184|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
10040185|NCT01850953|Placebo Comparator|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
10040186|NCT01850953|Active Comparator|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
10040187|NCT01850966||Iguratimod|
10040188|NCT01850979|Active Comparator|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
9486777|NCT01234519|Experimental|Phase 1 - Cohort 4|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
9486778|NCT01234519|Experimental|Phase 2|AEZS-108 at MTD to determine efficacy in up to 40 patients.
9486779|NCT01234311|Placebo Comparator|placebo|Matching placebo
9486780|NCT01234311|Experimental|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
9486781|NCT01234038|Experimental|Part 1 Cohort 1|
9486782|NCT01234038|Experimental|Part 1 Cohort 2|
9486783|NCT01234038|Experimental|Part 2 Arm A|
9486784|NCT01234038|Experimental|Part 2 Arm B|
9486785|NCT01234025|Experimental|Part 1 Cohort 1|
9486786|NCT01234025|Experimental|Part 1 Cohort 2|
9486787|NCT01234025|Experimental|Part 2 Arm A|
9486788|NCT01234025|Experimental|Part 2 Arm B|
9486789|NCT01233960|Experimental|Prochymal|Infusions of Prochymal on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
9486790|NCT01233700|Experimental|Motivational Interviewing|Subjects will receive two, individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on assisting subjects to delineate their reasons for or against proceeding with living organ donation and assisting subjects to resolve any lingering concerns about their decisions regarding donation.
9486791|NCT01233700|Active Comparator|Enhanced Standard Care|Subjects will receive two individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on providing educational information to subjects regarding healthy lifestyle issues (healthy eating, diet, exercise, quitting smoking).
9486792|NCT01233700|No Intervention|Standard Care|Subjects will receive the standard care and education provided by the Living Donor Program at their medical center.
9486793|NCT01233375|Experimental|CO-1.01|
9486794|NCT01232595|Experimental|LFF571 (POC)|
9486795|NCT01232595|Active Comparator|Vancomycin (POC)|
9486796|NCT01232595|Experimental|LFF571 Dose level 1 (cohort 2)|
9486797|NCT01232595|Experimental|LFF571 Dose level 2 (cohort 2)|
9486798|NCT01232595|Experimental|LFF571 Dose level 3 (cohort 2)|
9486799|NCT01232595|Experimental|LFF571 Dose level 4 (cohort 2)|
9486800|NCT01232543|Experimental|Product 0405|Topical Active Investigational Product 0405
9486801|NCT01231347|Active Comparator|AMG 479 12 mg/kg dose + gemcitabine|Arm 2: AMG 479 12 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
9486802|NCT01231347|Placebo Comparator|Placebo + gemcitabine|Arm 1: AMG 479-placebo IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
9486803|NCT01231347|Active Comparator|AMG 479 20 mg/kg + gemcitabine|Arm 3: AMG 479 20 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
9486804|NCT01230957|Experimental|Group 1|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
9486805|NCT01230957|Experimental|Group 2|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
9486806|NCT01230957|Experimental|Group 3|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
9486807|NCT01230957|Experimental|Group 4|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
9486808|NCT01230957|Placebo Comparator|Group 5|Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
9486809|NCT01230957|Experimental|Group 6|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
9486810|NCT01230957|Experimental|Group 7|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
9486811|NCT01229982|Experimental|L-PPDS|
9486812|NCT01229644|Experimental|Cohort A|Adult newly diagnosed glioma (both low and high grade) patients, who are able to to take Crenolanib (CP-868,596) for at least 3 days prior to surgical resection.
9486813|NCT01229644|Experimental|Cohort B|Adult patients with recurrent high grade glioma, including patients treated with bevacizumab. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
9543247|NCT03088475|Active Comparator|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
9543248|NCT03088163|Experimental|DWI-MRI|
9543249|NCT03088280|Experimental|3mg/kg Group|Patients will received Thymoglobuline 3mg/Kg (reduced dose)
9543250|NCT03088280|Active Comparator|6mg/kg Group|Patients will received Thymoglobuline 6mg/Kg (standard dose)
9543251|NCT03088618|Experimental|Patients with septal deformity|To evaluate the safety and efficacy of surgical material for nasal septoplasty in septal deformity patients with nasal obstruction
9543252|NCT03088306|Active Comparator|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
9543253|NCT03088306|Active Comparator|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
9543254|NCT03088293|Experimental|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
9543255|NCT03088293|Experimental|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
9543256|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
9543257|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
9543258|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
9543259|NCT03088085|Experimental|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
9543260|NCT03088085|Active Comparator|Sleep Education|Education on sleep hygiene with tips for improving sleep.
9543261|NCT03087968|Experimental|GS-4997 + Prednisolone|"GS-4997 + Prednisolone for 28 days~HepQuant SHUNT Test"
9543262|NCT03087968|Placebo Comparator|Prednisolone + Placebo|"Placebo + Prednisolone for 28 days~HepQuant SHUNT Test"
9543263|NCT03088215|Experimental|A / Shock-waves|Will receive shock-waves
9543264|NCT03088215|No Intervention|B / Nothing|Will not receive shock-waves
9543265|NCT03087942|Experimental|Group 1|ESRD patients
9543266|NCT03087942|Experimental|Group 2|healthy volunteers
9543267|NCT03087942|Experimental|Group 3|severe and moderate renal impaired patients
9543268|NCT03087942|Experimental|Group 4|mild renal impaired patients
9543269|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
9543270|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
9543271|NCT03088189||Placebo|Mothers are receiving placebo
9543272|NCT03088046|Other|Micronized Progesterone|Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course
9543273|NCT03088098|Active Comparator|Treatment|Patient receiving LAAO
9543274|NCT03088098|No Intervention|Control|Patient undergoing medical therapy for stroke prevention
9803786|NCT03334851|Experimental|Part A, Cohort 8|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
9803787|NCT03334851|Experimental|Part B, Cohort 1|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous administration.
9543275|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
9543276|NCT03088124|No Intervention|active surveillance|Active surveillance without androgen deprivation
9543277|NCT03088124|Experimental|active surveillance with Apalutamide|Active surveillance during and after 6 months treatment with Apalutamide
9543278|NCT03088033|Experimental|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
9543279|NCT03088033|Sham Comparator|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
9543280|NCT03088228||healthy pregnants|
9543281|NCT03088228||mild preeclampsia|
9543282|NCT03088228||severe preeclampsia|
9543283|NCT03088176|Experimental|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
9543284|NCT03088072|Other|Edoxaban Arm|All patients enrolled in the study will receive 6 weeks of edoxaban therapy, at which time a TEE will be performed. If the result is acceptable, edoxaban will be discontinued, and the patient will be treated with dual antiplatelet therapy (aspirin and clopidogrel) until 6 month follow-up. If device thrombus is present at 6 week TEE, patient will be transitioned to aspirin and adjusted-dose warfarin and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference. Subjects will have a 6 month follow-up visit prior to study completion. After study completion, patients may be treated with aspirin monotherapy according to the FDA instructions for use for the WATCHMAN device, or according to operator discretion.
9616603|NCT02541019|Experimental|Ondansetron|ondansetron (iv) one minute before anesthesic induction and ondansetron regular three times a day for two days after the surgery.
10058459|NCT02018484|Experimental|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
10040189|NCT01850979|Placebo Comparator|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
10040190|NCT01850992|Active Comparator|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
10040191|NCT01850992|Placebo Comparator|Sham CPAP|This is placebo CPAP
9543285|NCT03087890|Active Comparator|Cotrimoxazole|Patients in the Cotrimoxazole study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme.
9543286|NCT03087890|Placebo Comparator|Placebo|Participants in the Placebo arm will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo
10040192|NCT01851005|Placebo Comparator|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
10040193|NCT01851005|Placebo Comparator|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
9543287|NCT03088150|Active Comparator|Surgical resection|Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.
9543288|NCT03088150|Experimental|Thermal ablation|Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.
9543289|NCT03087903|Experimental|150 mg of Grape Seed Extract (GSE)|150 mg of GSE twice daily in the form of 75 mg capsule of Leucoselect Phytosome preparation.
9543290|NCT03087877|Other|CGM Users|Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
9543291|NCT03087864|Experimental|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
9543292|NCT03087669|Experimental|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
9543293|NCT03087734|Active Comparator|Perpendicular stabilizer|Implantation of regular bar with perpendicular stabilizers
9543294|NCT03087734|Experimental|Oblique stabilizer|Implantation of new model of bar with oblique stabilizers
9543295|NCT03087838||delirium group|CAM-ICU is positive within the first 24 hours after operation
9543296|NCT03087838||non-delirium group|CAM-ICU is negative within the first 24 hours after operation
9543297|NCT03087565|Active Comparator|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
9543298|NCT03087565|Active Comparator|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
9543299|NCT03087578|Experimental|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
9543300|NCT03087578|Active Comparator|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
10040194|NCT01851005|Experimental|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
10040195|NCT01851005|Experimental|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
10040196|NCT01851018|Experimental|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
9543301|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
9543302|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
9543303|NCT03087825|Sham Comparator|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
9543304|NCT03087825|Active Comparator|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
9543305|NCT03087630|Experimental|Reasoned-Based Intervention|Receives reason-based intervention.
9543306|NCT03087630|Experimental|Social-Based Intervention|Receives social-based intervention.
9543307|NCT03087630|Experimental|Integrated Intervention|Receives integrated intervention.
9543308|NCT03087630|Experimental|Attention Control|Receives attention control feedback.
9543309|NCT03087526|Experimental|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
9543310|NCT03087721|Experimental|1x2 HIIT-LV, 3 times a week, 24 min|
9543311|NCT03087721|Active Comparator|CAE, moderate intensity, 3 times a week, 36 min|
9543312|NCT03087799|Experimental|Brief Behavioral Treatment for Sleep|
9543313|NCT03087799|No Intervention|Wait List Control|
9543314|NCT03087617|Active Comparator|Usual Care|Usual Care includes a lung cancer screening CT exam. Following the screen, a radiologist will analyze the CT scan image and send the results to the patient's Primary Care Physician (PCP). If the scan is read as a category 1 or 2 in the Lung Reporting and Data System (Lung-RADS), patients are provided a letter in the mail with their results. If the scan is read as a category 3, 4A, 4B, or 4X in Lung-RADS the patient will be contacted by their primary care physician's office and told to schedule a follow up appointment. Either in the letter or at the follow up appointment, patients will be given a Quitline number created specifically for this trial and maintained for the duration.
9543315|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report|In this arm, patients will receive the Usual Care described above and will additionally be provided with the Report. In this arm, the Report will provide the Quitline number.
9543316|NCT03087617|Active Comparator|Usual Care + Counseling|In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
9543317|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report + Counseling|In addition to the Usual Care and Counseling described above, patients in this arm will also receive the Report.
9543318|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
9543319|NCT03087539|Experimental|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
9543320|NCT03087539|Placebo Comparator|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
9543321|NCT03087500||Down Syndrome (DS)|120 clinically confirmed full trisomy 21, age 3-50 years of both sexes will be recruited as the target study population. Half of the individuals (n=60) will be children (3-17 years of age) while half (n=60) will be adults (18-50 years of age)
9543322|NCT03087500||Typically Developing Controls|60 typically developing individuals age 3-50, age and gender matched to at least one participant with DS. Half of the controls (n=30) will be age and gender match to children with DS and half (n=30) will be age and gender matched to adults with DS.
9543323|NCT03087708|Active Comparator|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
9543324|NCT03087708|Active Comparator|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
9543325|NCT03087708|Placebo Comparator|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
9543326|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
9543327|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
9543328|NCT03087240|Experimental|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
9543329|NCT03087240|Other|Control|Wait & Control Study Design: Dental Prophylaxis after 3 months (T2) only
9543330|NCT03087175|Experimental|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
9543331|NCT03087175|Active Comparator|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
9543332|NCT03087188||Utilization of inhalator|Film sequences will be shown to patients using incorrect application technique in order to improve technique. Learning success will be assessed subsequently and at a follow-up visit after 2-8 weeks
9543333|NCT03087266|Experimental|Full- Mouth Scaling and Root Planing|FM-SRP Non-surgical periodontal treatment will be performed in all dentition within 24 hours.
9543334|NCT03087266|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP Non-surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed with one week interval. In each appointment only a quadrant of the dentition will be instrumented."
9543335|NCT03087201|Experimental|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
9543336|NCT03087201|Placebo Comparator|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
9543337|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
9616604|NCT02540928|Experimental|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
9616605|NCT02540928|Placebo Comparator|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
9803788|NCT03334851|Experimental|Part B, Cohort 2|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
10058460|NCT02018510|Experimental|Group 1A|"HIV-uninfected individuals~1 mg/kg, single dose IV administration of 3BNC117"
9543338|NCT03087461|Experimental|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
9543339|NCT03087461|No Intervention|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
9543340|NCT03087318|Experimental|Rehabilitation medical center|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
9543341|NCT03087318|Experimental|Private sport club|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
9543342|NCT03087318|Experimental|Sport association|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
9543343|NCT03087279|Experimental|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
9543344|NCT03087279|Experimental|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
9543345|NCT03087279|No Intervention|Control|Regular, Sedentary academic lessons in math and language arts
9543346|NCT03087331|Experimental|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
9543347|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
9543348|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
9543349|NCT03087084|Experimental|Cardiac Pacing and Impedance Measurement system|
9543350|NCT03087032|Experimental|Liraglutide-bolus|'Liraglutide-bolus'(Liraglutide once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
9543351|NCT03087032|Active Comparator|Basal-bolus|'Basal-bolus' (insulin glargine once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
9543352|NCT03087006|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
9543353|NCT03087006|Placebo Comparator|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
9543354|NCT03087110|Experimental|Cord blood infusion|Matched sibling donor cord blood cell infusion
9543355|NCT03087097|Experimental|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
9543356|NCT03087097|No Intervention|Standard of Care|Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
9616606|NCT02541097|Active Comparator|Language therapy-Individual treatment|Participants will receive intervention for naming impairment based on either phonological or semantic cues.
9616607|NCT02541097|Active Comparator|Language therapy-Group treatment|Following the individual therapy, participants will be randomly assigned to either verbal or non-verbal group
9616608|NCT02541201|Experimental|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
9616609|NCT02541201|Placebo Comparator|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
9803789|NCT03334851|Experimental|Part B, Cohort 3|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
10040197|NCT01851018|Active Comparator|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
10040198|NCT01851031|Experimental|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
10040199|NCT01851031|Other|control group|24 patients (control group) were treated with the retromandibular approach
10040200|NCT01851044|Placebo Comparator|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
10040201|NCT01851044|Active Comparator|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
10058461|NCT02018510|Experimental|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
9543357|NCT03087292|Active Comparator|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
9543358|NCT03087292|No Intervention|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
9543359|NCT03087162|Experimental|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
9543360|NCT03087162|Active Comparator|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
9543361|NCT03087344|Experimental|Chronic liver disease|patient who will undergo liver biopsy will undergo liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
9543362|NCT03087149|Experimental|monitored group|The monitored group will received monitored vit D supplementation
9543363|NCT03087149|Active Comparator|standard group|The standard group will receive standard vit D supplementation
9543364|NCT03087227|Experimental|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
10040202|NCT01851044|Experimental|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
9543365|NCT03087227|No Intervention|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
10040203|NCT01851057|Active Comparator|Education Only|Education only arm (8 total sessions)
9543366|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
9543367|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
9543368|NCT03087422|Experimental|intervention|"The patients in this group will receive daily a text message (SMS) with some orientation about Homecare as an attempt to minimize the side effects of chemotherapy.~The text messages are based on oncology guidelines.The text messages contain information about water intake, emotional support, hygiene, immunity, nutrition, and physical activity. In addition, text messages about prevention and management of symptoms were also developed: nausea and vomiting, diarrhea, constipation, gas, changes in the skin and taste.~Also, the patients allocated in this group will receive the standard care."
9543369|NCT03087422|No Intervention|control|The patients allocated in this group will receive the standard care.
9543370|NCT03086941|Active Comparator|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
9543371|NCT03086941|Active Comparator|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
9543372|NCT03086967|Active Comparator|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
9543373|NCT03086967|Active Comparator|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
9543374|NCT03086954|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
9543375|NCT03087123|Active Comparator|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
9616610|NCT02541006|Experimental|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
10040204|NCT01851057|Experimental|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
10040205|NCT01851070|Placebo Comparator|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
10040206|NCT01851070|Active Comparator|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
10058462|NCT02018510|Experimental|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
10040207|NCT01851096|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
10040208|NCT01851109|No Intervention|Control|
10040209|NCT01851109|Experimental|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
10040210|NCT01851122|Placebo Comparator|Placebo|
10040211|NCT01851122|Experimental|l-theanine|
10040212|NCT01851135|Experimental|Patients with NF1|
10040213|NCT01851135|Other|Healthy controls|
10040214|NCT01851148|Sham Comparator|sham therapy|subtracting serial sevel (McPartland 2003)
10040215|NCT01851148|Other|usual care|triptans treatment only
10040216|NCT01851148|Experimental|OMT|8 sessions of osteopathic manipulative treatment
10040217|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
10040218|NCT01851187|Experimental|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
10040219|NCT01851187|Active Comparator|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
10040220|NCT01851200|Experimental|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
10040221|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
10040222|NCT01851226|Experimental|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
10040223|NCT01851226|Experimental|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
10040224|NCT01851226|Experimental|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
9543376|NCT03087123|Active Comparator|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
9543377|NCT03087123|Active Comparator|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
9543378|NCT03087071|Experimental|Cohort 1 (panitumumab)|Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
9543379|NCT03087071|Experimental|Cohort 2 (panitumumab, trametinib)|Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
10040225|NCT01851239||medical ICU inpatients|
10040226|NCT01851239||surgical ICU inpatients|
10040227|NCT01851252|Experimental|Methacetin (for BT) before / after Propanolol treatment.|The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.
10040228|NCT01851265|Other|Fasted|Olaparib capsules following no breakfast
10040229|NCT01851265|Other|Standard meal|Olaparib capsules after standard breakfast
10040230|NCT01851265|Other|High Fat|Olaparib capsules after high fat breakfast
10040231|NCT01851278|Active Comparator|high dose|intraarticular wrist injection of 40mg, 2ml
10040232|NCT01851278|Active Comparator|low dose|intraarticular wrist injection of 20mg, 1ml.
10040233|NCT01851304|Placebo Comparator|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
10040234|NCT01851304|Experimental|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
10040235|NCT01851304|Experimental|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
10040236|NCT01851304|Experimental|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
10040237|NCT01851304|Placebo Comparator|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
10040238|NCT01851304|Experimental|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
10040239|NCT01851304|Experimental|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
10040240|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
10040241|NCT01851343|Experimental|1|All patients will receive the same treatment
9543380|NCT03087071|Experimental|Cohort 3 (panitumumab)|Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
9543381|NCT03086980|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
9543382|NCT03086980|Placebo Comparator|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
9543383|NCT03086668|Experimental|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
9543384|NCT03086668|Experimental|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
9543385|NCT03086629|Other|PCI Group|Participants who are patients of consultants randomized to this group will use the PCI during clinics.
9543386|NCT03086629|Other|Non PCI Group|Participants who are patients of consultants randomized to this group will not use the PCI during clinics.
9543387|NCT03086720|Experimental|Sodium hypochlorite|Dentin pre-treatment with a experimental solution (sodium hupochlorite), after the dentin acid etching
9543388|NCT03086720|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching
9543389|NCT03086681|Experimental|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
9543390|NCT03086681|Active Comparator|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
9543391|NCT03086694||group surgery|using medications to maintain low stable blood pressure
9543392|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
9543393|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 < 80% predicted.
9543394|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 < 50% predicted.
9543395|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 < 30% predicted.
9543396|NCT03086902|Experimental|Cryo Ablation|PVCs will be mapped and ablated with a Cryo Ablation catheter
9543397|NCT03086902|Active Comparator|Radiofrequency Ablation|In this arm PVCs will be mapped and ablated with a Radiofrequency Ablation catheter
9543398|NCT03086759|Experimental|Platelet rich plasm group|
9543399|NCT03086759|Active Comparator|Triamcinolone Hexacetonide group|
9543400|NCT03086759|Placebo Comparator|Isotonic Saline Solution group|
9543401|NCT03086733|Experimental|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
9543402|NCT03086928|Experimental|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
10040242|NCT01851408|Experimental|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
10040243|NCT01851421||Double-Variant MC3R|Volunteers with homozygous polymorphisms causing protein changes to T6K and V81I.
10040244|NCT01851421||Wild Type MC3R|Volunteers with no polymorphisms in MC3R gene.
10040245|NCT01851460|Experimental|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
10040246|NCT01851486|Active Comparator|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
10040247|NCT01851486|Active Comparator|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
10040248|NCT01851486|Active Comparator|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
9543403|NCT03086928|Active Comparator|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
9543404|NCT03086798|Experimental|Magill forceps|experimental Magill forceps group: Magill forceps technique to facilitate nasotracheal tube advancement into trachea
9543405|NCT03086798|Experimental|cuff inflation|experimental cuff inflation group: cuff inflation technique to facilitate nasotracheal tube advancement into trachea
9543406|NCT03086824|Experimental|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
9616611|NCT02541006|Active Comparator|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
9616612|NCT02540902|Experimental|All-poly|Knee arthroplasty with all-polyethylene tibia
9616613|NCT02540889|Experimental|trial arm|100 hours of therapy.
9616614|NCT02540889|No Intervention|Normal therapy arm|12 weeks of normal therapy.
10040249|NCT01851486|Placebo Comparator|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
10040250|NCT01851499|Experimental|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
10040251|NCT01851499|Placebo Comparator|Microgranules|Same as Normast, without active component.
10040252|NCT01851512|Experimental|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
10040253|NCT01851512|Experimental|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
10058463|NCT02018510|Experimental|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
9543407|NCT03086811|Experimental|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
9543408|NCT03086811|No Intervention|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
10040254|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
9543409|NCT03086837|Experimental|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
9543410|NCT03086837|No Intervention|Control|No information
9543411|NCT03086785|Experimental|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
9543412|NCT03086512|Active Comparator|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
9543413|NCT03086512|Sham Comparator|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
9543414|NCT03086772|Experimental|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
9543415|NCT03086772|Active Comparator|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
9543416|NCT03086252|Experimental|Supportive care (patient-driven RBCT)|Patients undergo red blood cell transfusions (RBCT) based on their perception and/or the presence of anemia symptoms for up to 6 months.
9543417|NCT03086382|Experimental|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
9543418|NCT03086382|Experimental|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
9543419|NCT03086304|Experimental|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
9543420|NCT03086304|Experimental|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
9543421|NCT03086538|Experimental|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
9543422|NCT03086226|Experimental|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
9543423|NCT03086226|Experimental|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
9543424|NCT03086226|Active Comparator|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
9543425|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
9543426|NCT03086278|Experimental|Single Ascending Dose|
9543427|NCT03086291|Experimental|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
9543428|NCT03086434|Experimental|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
9543429|NCT03086434|Active Comparator|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
10040255|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
10040256|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
10040257|NCT01851551|Experimental|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
10040258|NCT01851564|Experimental|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
10040259|NCT01851564|Active Comparator|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
10040260|NCT01851564|Experimental|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
10040261|NCT01851564|Active Comparator|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
9803790|NCT03334851|Experimental|Part B, Cohort 4|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
9543430|NCT03086564|Experimental|ADCC & TACE|"The first course :~Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2*10^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.~The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
9543431|NCT03086564|Active Comparator|TACE|"Every course:~In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.~The 31th day is the same as the first day in the second course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
9543432|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
9543433|NCT03086395|Experimental|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
9543434|NCT03086863|Experimental|verum electroacupuncture|"Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle insertion by 10-15 mm and de qi sensation~Park sham guide tubes~Low frequency electronic stimulation (30 Hz)~Retention for 20 minutes."
9803791|NCT03334851|Experimental|Part B, Cohort 5|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
10040262|NCT01851577|Experimental|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
10040263|NCT01851577|Active Comparator|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
10040264|NCT01851603|Experimental|AVL-3288|Oral administration of AVL-3288
10040265|NCT01851603|Placebo Comparator|Sugar pill|Placebo
10040266|NCT01851616|Active Comparator|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
10040267|NCT01851616|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
10040268|NCT01851629|Experimental|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
10040269|NCT01851629|Active Comparator|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
10040270|NCT01851629|Other|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
10040271|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
10040272|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
10040273|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
10040274|NCT01851668||Preterm inter-hospital transfers|preterm infants <31 weeks gestation and <=day 3 of life
10040275|NCT01851668||Preterm infants inborn|Preterm infants <31 weeks gestation and <=3 days old born and remaining at same hospital.
10040276|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
10040277|NCT01851681|Active Comparator|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
10040278|NCT01851681|Active Comparator|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
10040279|NCT01851707|Experimental|IPI-145, low dose BID|
10040280|NCT01851707|Experimental|IPI-145, medium dose BID|
10040281|NCT01851707|Experimental|IPI-145, high dose BID|
10040282|NCT01851707|Placebo Comparator|Placebo BID|
10040283|NCT01851733|Experimental|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.~Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.~Biomarker blood draws will be drawn at different time points.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
10058464|NCT02018510|Experimental|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
9486814|NCT01229644|Experimental|Cohort C|Adult patients with biopsy proven low grade glioma who have residual measurable disease. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
9486815|NCT01229215|Experimental|FCFD4514S|
9486816|NCT01229215|Sham Comparator|sham|
9486817|NCT01228513|Active Comparator|0.01% ointment|Lowest concentration
9486818|NCT01228513|Active Comparator|0.03% ointment|Middle concentration
9486819|NCT01228513|Active Comparator|0.1% ointment|Highest concentration
9486820|NCT01228513|Placebo Comparator|Placebo (vehicle without active)|No active ingredient
9486821|NCT01228383|Experimental|CL184+PVRV|CL184 with rabies vaccine (PVRV)
9486822|NCT01228383|Active Comparator|HRIG+PVRV|HRIG with rabies vaccine
9486823|NCT01228383|Placebo Comparator|Placebo+PVRV|Placebo with rabies vaccine (PVRV)
9486824|NCT01228383|Experimental|CL184+HDCV|CL184 with rabies vaccine (HDCV)
9486825|NCT01228383|Placebo Comparator|Placebo+HDCV|Placebo with rabies vaccine (HDCV)
9486826|NCT01226628|Experimental|Cohort A|Phase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC)
9486827|NCT01226628|Experimental|Cohort B|Phase 1: 3 patients will receive 120,000 hUTC
9486828|NCT01226628|Experimental|Cohort C|Phase 1: 3 patients will receive 300,000 hUTC
9486829|NCT01226628|Experimental|Cohort D|Phase 1: 3 patients will receive 560,000 hUTC
9486830|NCT01226628|Experimental|Cohort E|Phase 1: 6 patients will receive 300,000 hUTC
9486831|NCT01226628|Experimental|Cohort F|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
9486832|NCT01226628|Experimental|Cohort G|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
9486833|NCT01226628|Experimental|Phase 2a|Up to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study
9486834|NCT01226563|Experimental|IK-5001|IK-5001 Sodium Alginate Calcium Gluconate intracoronary injection
9486835|NCT01226563|Placebo Comparator|Saline Solution|Saline Solution intracoronary injection
9486836|NCT01226290|Experimental|VizAblate treatment|VizAblate System: subject acts as her own control
9486837|NCT01225666|Experimental|Weekly low dose|MOD-4023
9486838|NCT01225666|Experimental|Weekly middle dose|MOD-4023
9486839|NCT01225666|Experimental|Weekly high dose|MOD-4023
9486840|NCT01225666|Experimental|Every-other week dose|MOD-4023
9486841|NCT01225640|Experimental|PNU-100480 600 mg BID|
9486842|NCT01225640|Experimental|PNU-100480 1200 mg QD|
9486843|NCT01225640|Active Comparator|RHZE|conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally
9498081|NCT03469271|Other|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
9498082|NCT03469271|Other|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
9498083|NCT03469245||abdominal aortic aneurysms treated by fenestrated endovascular|Patients have an abdominal aortic aneurysms treated by fenestrated endovascular anacondaTM of society Vascutek will be included. Predisurge society will perform numerical simulation.
9498084|NCT03469232|Experimental|Huanglian-Jiedu Decoction in acute pericoronitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
9498085|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent aphthous stomatitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
9498086|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent herpes simplex labialis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
9498087|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
9498088|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
9498089|NCT03469206|Sham Comparator|Direct MT|Direct mechanical thrombectomy (MT) with no intravenous thrombolysis
9498090|NCT03469206|Active Comparator|IVT combine with MT|Intravenous thrombolysis before mechanical thrombectomy
9498091|NCT03469180|Active Comparator|Control Group|Childrens in this group will receive treadmill training, three times a week for 8 weeks. Each season will be supervised and last 45 minutes.
9498092|NCT03469180|Experimental|Training Group|İn addition to treadmill training, childrens in this group (after a rest for 5 minutes) will also receive whole body vibration training for 15 minutes.
9498093|NCT03469167|Experimental|CEGP003|
9498094|NCT03469167|Active Comparator|Injection Tx|
9499824|NCT03454230|Experimental|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
10058465|NCT02018510|Experimental|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
10058466|NCT02018510|Experimental|Group 2A|"HIV-infected individuals on or off ART~1 mg/kg, single dose IV administration of 3BNC117"
9486844|NCT01225393|Experimental|A|
9486845|NCT01225393|Active Comparator|B|
9486846|NCT01225393|Placebo Comparator|C|
9486847|NCT01225380|Experimental|Arm 1|GS-9190 and GS-9256 in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
9486848|NCT01225380|Experimental|Arm 2|GS-9256 (active) and placebo matching GS-9190 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
9486849|NCT01225380|Placebo Comparator|Arm 3|Placebo matching GS-9190 and placebo matching GS-9256 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
9486850|NCT01225315|Experimental|Setipiprant - Dose 1|100 mg b.i.d.
9486851|NCT01225315|Experimental|Setipiprant - Dose 2|500 mg b.i.d.
9486852|NCT01225315|Experimental|Setipiprant - Dose 3|1,000 mg b.i.d
9486853|NCT01225315|Placebo Comparator|Matching Placebo|Oral placebo
9486854|NCT01225276|Experimental|Dosage Arm 1|NewGam 10% 0.4 g/kg
9486855|NCT01225276|Experimental|Dosage Arm 2|NewGam 10% 1.0 g/kg
9486856|NCT01225276|Experimental|Dosage Arm 3|NewGam 10% 2.0 g/kg
9486857|NCT01225276|Placebo Comparator|Dosage Arm 4|Placebo 0.9% Saline
9486858|NCT01224795|Experimental|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
9486859|NCT01224795|Placebo Comparator|Placebo|Placebo Peramivir, administered intravenously.
9486860|NCT01224262|Experimental|Fluzone + 0.45 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg)
9486861|NCT01224262|Experimental|Fluzone + 1.8 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg)
9486862|NCT01224262|Active Comparator|Fluzone|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
9486863|NCT01223911|Experimental|A|
9486864|NCT01223911|Placebo Comparator|B|
9486865|NCT01222702|Experimental|Cadazolid 250 mg|Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
9486866|NCT01222702|Experimental|Cadazolid 500 mg|Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
9486867|NCT01222702|Experimental|Cadazolid 1000 mg|Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
9486868|NCT01222702|Active Comparator|Vancomycin 125 mg|Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days
9486869|NCT01221246|Experimental|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
9486870|NCT01221246|Placebo Comparator|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.
9486871|NCT01221077|Experimental|Arm A: Erlotinib plus OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
9486872|NCT01221077|Placebo Comparator|Arm B: Erlotinib plus Placebo|As of 01 March 2013, the matching placebo is no longer being administered
9486873|NCT01220947|Experimental|Group A|Danoprevir 200 mg twice a day (BID) + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
9486874|NCT01220947|Experimental|Group B|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
9486875|NCT01220947|Experimental|Group C|Danoprevir 50 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
9486876|NCT01220947|Experimental|Group D|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 μg sc qw + Copegus 1000 mg or 1200 mg po daily for 12 weeks or 24 weeks
9486877|NCT01220947|Active Comparator|Group E|Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 48 weeks
9486878|NCT01220271|Experimental|Phase 1: 160 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
9486879|NCT01220271|Experimental|Phase 1: 300 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
9543435|NCT03086863|Sham Comparator|sham electroacupuncture|"Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle installation without penetration~Park sham guide tubes~Low frequency electronic stimulation (30 Hz) for a fake noise without conduction~Retention for 20 minutes."
9543436|NCT03086850|Experimental|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
9543437|NCT03086850|Active Comparator|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
9543438|NCT03086473|Other|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
9543439|NCT03086473|Other|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
9543440|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
9543441|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
9543442|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
9543443|NCT03086239|Experimental|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
9543444|NCT03086239|Experimental|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
9543445|NCT03086187|Other|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
9543446|NCT03086200|No Intervention|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
9543447|NCT03086200|Experimental|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
9543448|NCT03086174|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
9543449|NCT03085992|Experimental|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
9543450|NCT03086031|Experimental|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
9543451|NCT03086031|Active Comparator|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
9543452|NCT03085953|Experimental|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
9543453|NCT03085953|Other|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
9543454|NCT03086083|Experimental|EMDR standard protocol|Standard EMDR protocol, once.
9543455|NCT03086083|Active Comparator|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
9543456|NCT03085979|Experimental|Burch|Burch Colposuspension
9543457|NCT03085979|Experimental|Trans Obturator Tape|Trans Obturator Tape sling
9543458|NCT03085979|Experimental|Tension free vaginal tape|Tension free vaginal tape sling
9543459|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
9543460|NCT03086122|No Intervention|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
9543461|NCT03086122|No Intervention|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
9543462|NCT03086122|Experimental|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
9803792|NCT03334851|Experimental|Part B, cohort 6|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
9803793|NCT03328078|Experimental|Emavusertib (CA-4948) dose escalation|Part A1: Dose-level cohorts with up to 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for emavusertib .
9543463|NCT03086161|Active Comparator|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
9543464|NCT03086161|Experimental|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
9543465|NCT03085901|Active Comparator|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
9543466|NCT03085901|Active Comparator|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
9543467|NCT03085966|Experimental|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
9543468|NCT03086005|Experimental|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
9543469|NCT03086005|Placebo Comparator|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
9543470|NCT03086070|Experimental|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
9543471|NCT03086070|Placebo Comparator|Placebo arm|matching placebo capsules ones daily for 8 weeks
9543472|NCT03085940|Experimental|Hydroxychloroquine|
9543473|NCT03085940|Placebo Comparator|Placebo|
9543474|NCT03086148|Experimental|ketamine group|
9543475|NCT03086148|Placebo Comparator|normal saline group|
9543476|NCT03085654|Experimental|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
9543477|NCT03085654|Experimental|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
9543478|NCT03085654|Experimental|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
9543479|NCT03085654|Experimental|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
9543480|NCT03085654|Experimental|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
9543481|NCT03085654|Experimental|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
9543482|NCT03085641|Experimental|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~High flow rate: 40-50 L/min without additional oxygen~Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~High flow rate: 40-50 L/min with FiO2 of 28%"
9543483|NCT03085745|Experimental|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
9543484|NCT03085732|Active Comparator|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
9543485|NCT03085732|No Intervention|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
9543486|NCT03085628|Experimental|Oxytocin|Oxytoxin nasal spray
9543487|NCT03085628|Placebo Comparator|Placebo|Placebo nasal spray
10040284|NCT01851733|Experimental|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"Patients undergo MLA (MRI-guided laser heat ablation).~Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
9543488|NCT03085862||Lung ultrasound and EVLW|This prospective study involved 60 patients without known cardiac or pulmonary diseases admitted to the intensive care unit at our hospital after elective abdominal or vascular surgery. The inferior vena cava collapsibility index (IVCcl), PaO2/FiO2 ratio, and appearance of B-lines ≤7 mm were determined upon admission to the intensive care unit and at 6, 12, and 24 h later. Fluid overload was defined as IVCcl ≤ 40% and the presence of B-lines ≤7 mm. Tissue oxygenation impairment was defined as a PaO2/FiO2 ratio < 200.
9543489|NCT03085771|Active Comparator|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
9543490|NCT03085771|Placebo Comparator|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
9543491|NCT03085706|Experimental|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
9543492|NCT03085602|Experimental|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
9543493|NCT03085602|Active Comparator|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
9543494|NCT03085602|No Intervention|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
9543495|NCT03085615|Experimental|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
9543496|NCT03085615|Active Comparator|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
9543497|NCT03085784|Experimental|Loading Dose|"20 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, & 12. At week 12, patient will be followed & treated per treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
9543498|NCT03085784|Experimental|Treat and Extend|"20 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated & followed per the treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
9543499|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
9543500|NCT03085849|Experimental|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.~Dose escalation phase: 6-12 patients~MTD expansion cohort: 10 patients"
9543501|NCT03085550|No Intervention|Control|Conventional dressings management
9543502|NCT03085550|Experimental|Fat grafting only|Patients will undergo conventional fat harvesting as per Coleman technique and infiltration of fat into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
9543503|NCT03085550|Experimental|Fat grafting + Platelet rich plasma|Patients will undergo conventional fat harvesting as per Coleman technique. Fat will be mixed with autologous PRP and infiltrated into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
9543504|NCT03085563|Active Comparator|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
9543505|NCT03085563|Active Comparator|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
9543506|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
9543507|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
9543508|NCT03085472||benigh hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively benigh hematoma (less likely to expand and have a relatively good outcome).
9543509|NCT03085472||malignant hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively bad hematoma (more likely to expand and have a relatively poor outcome).
9543510|NCT03085446|Experimental|PDM nutritional intervention|
9543511|NCT03085446|Experimental|control|General information on nutrition and health
9543512|NCT03085303|Experimental|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
9543513|NCT03085303|Experimental|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
9543514|NCT03085303|Placebo Comparator|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
9543515|NCT03085251|Experimental|Blood glucose measurement|
9543516|NCT03085264|Experimental|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
9543517|NCT03085264|No Intervention|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
9543518|NCT03085225|Experimental|Combination of trabectedin with durvalumab|"Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level.~Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks."
9543519|NCT03085329|Experimental|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
9543520|NCT03085329|Experimental|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher & Paykel bubbler, which is the standard of care at Nationwide Children's.
9543521|NCT03085511|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
9543522|NCT03085511|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
9543523|NCT03085407|Active Comparator|early cholecystectomy|Early cholecystectomy was done within 48 after admission
9543524|NCT03085407|Sham Comparator|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
9662984|NCT04271540|Experimental|Subjects treated with Tildrakizumab|Informed consent will be obtained from study participants willing to participate in MiNIMA. Study participants will then undergo the baseline rest/stress cardiac PET scan along with echocardiography. The final PET scan and echocardiogram will occur at 6 months after the intervention.
9543525|NCT03085342|Experimental|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
9543526|NCT03085420|Experimental|≥30% TBSA burn injury|For patients in Group 1 with ≥30% TBSA, a baseline Echocardiogram (ECHO) will be obtained approximately one week from admission and monthly (+/- 1 week) or at an interval determined by cardiology during the acute inpatient stay. ECHO tests will be discontinued after 3 negative exams or when discontinued by cardiology, whichever comes first.
9543527|NCT03085420|No Intervention|<30% TBSA burn injury|For patients in Group 2 with <30% TBSA and presence of a cardiac abnormality standard clinical care appropriate for the type of arrhythmia will be followed.
9543528|NCT03085355|Active Comparator|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
9543529|NCT03085355|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
9543530|NCT03085381|Experimental|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
9543531|NCT03085381|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
9543532|NCT03085368|Experimental|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
9543533|NCT03085368|Experimental|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
9543534|NCT03085368|Active Comparator|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
9543535|NCT03085368|Active Comparator|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
9543536|NCT03085290|Experimental|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
9543537|NCT03085290|Experimental|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
9543538|NCT03085394|Active Comparator|Treatment arm|Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
9543539|NCT03085394|Placebo Comparator|Control Arm|Preoperative intravenous administration of 10ml normal saline.
9543540|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
9543541|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1~3 years
9543542|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3~5 years
9543543|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
9543544|NCT03085199|Other|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
9543545|NCT03084874|Experimental|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
9543546|NCT03084874|No Intervention|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
9543547|NCT03084887|Experimental|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
9543548|NCT03084887|No Intervention|controlled group|no intervention until secondary hospital
9543549|NCT03084952|Experimental|1 mg/day|
9543550|NCT03084952|Experimental|4 mg/day|
9543551|NCT03084952|Experimental|8 mg/day|
9543552|NCT03084952|Experimental|12 mg/day|
9543553|NCT03084952|Active Comparator|Glucantime|
9543554|NCT03084952|Experimental|Best dose 18-MC|
9543555|NCT03084952|Experimental|Minimum effective dose 18-MC|
9543556|NCT03085160|Experimental|Learning to Breathe|Six-week mindfulness-based group program for adolescents
9543557|NCT03085160|Active Comparator|Health Education|Six-week health education group program for adolescents
9543558|NCT03085121|Experimental|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
10040285|NCT01851759|Experimental|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
10040286|NCT01851759|Placebo Comparator|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
9543559|NCT03085121|Experimental|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
10040287|NCT01851785|No Intervention|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
10040288|NCT01851785|Experimental|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
10040289|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI => 5
10040290|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI < 5
10040291|NCT01851824|Experimental|Acenocoumarol + Vemurafenib|
9543560|NCT03085121|Active Comparator|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
9543561|NCT03085121|Active Comparator|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
9543562|NCT03085043|Experimental|Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)|Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
9543563|NCT03084861|Experimental|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
10040292|NCT01851837|Active Comparator|Group I|Study group I (57 participants) received the continuous training of exercise time.
10040293|NCT01851837|Active Comparator|Group II|Study group II (58 participants) received the interval training of exercise time.
10040294|NCT01851850|Experimental|Drug|
10040295|NCT01851889||CF-LVAD pump speed.|
10040296|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
10040297|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
10040298|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
10040299|NCT01851915|Active Comparator|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
10040300|NCT01851915|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
10040301|NCT01851941|Experimental|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
10040302|NCT01851954|Experimental|clarithromycin|Population PK
10040303|NCT01851967|Experimental|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
9543564|NCT03084861|Active Comparator|Conventional treatment|"Conventional treatment:~Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
10040304|NCT01851980|Experimental|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
10040305|NCT01851980|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
10040306|NCT01851980|Experimental|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
10040307|NCT01851993|Experimental|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
10040308|NCT01851993|Placebo Comparator|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
10040309|NCT01852006|Experimental|COPD AB ON|"Abdominal Binder ON"
10040310|NCT01852006|No Intervention|COPD AB OFF|"Abdominal Binder OFF (control)"
10040311|NCT01852097|Experimental|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
10040312|NCT01852097|No Intervention|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
10040313|NCT01852123|Other|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
10040314|NCT01852123|Other|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
10040315|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
9543565|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool [SIBAT], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure [S-STS CMCM] and the Columbia-Suicide Severity Rating Scale [C-SSRS] + Clinical Global Impression of Severity of Suicidality (Revised) [CGI SS-R]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
9543566|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
9543567|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
9543568|NCT03085069|Experimental|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
9543569|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
9543570|NCT03085069|Experimental|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
9543571|NCT03084913|Active Comparator|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
9543572|NCT03084913|Experimental|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
9543573|NCT03085134|Experimental|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
9543574|NCT03085134|Active Comparator|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
9543575|NCT03084822|Experimental|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
9543576|NCT03084978|Active Comparator|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
9543577|NCT03084978|Experimental|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
9543578|NCT03085030|Experimental|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
9543579|NCT03085030|Placebo Comparator|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
9543580|NCT03084848|Experimental|Active control|
9543581|NCT03084848|Experimental|Inhibitor control|
9543582|NCT03084835|Active Comparator|UC|Usual Care
9543583|NCT03084835|Active Comparator|WEB+TXT|Digital Intervention
9543584|NCT03084835|Active Comparator|WEB+TXT+TTS|Digital plus Counseling Intervention
9543585|NCT03084809|Experimental|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
9543586|NCT03084809|Experimental|FOLFOX4|"FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
9543587|NCT03084991||OCT group|1500 AMI patients with OCT imaging guidance during PCI
9543588|NCT03084991||CAG group|3000 AMI patients without OCT imaging guidance during PPCI
9543589|NCT03085082||skeletal class II subjects|patients with wits appraisal more than 3 mm measured on a cephalometric x ray obtained during diagnosis
9543590|NCT03085082||skeletal class III subjects|patients with wits appraisal less than -3 mm measured on a cephalometric x ray obtained during diagnosis
9543591|NCT03085082||skeletal class I patients|patients with Wits appraisal between -3 and +3 that is measured from a cephalometric x ray obtained during diagnosis of arch length discrepancy. this group will serve as control and obtained after recruitment of the other 2 groups in 1 to 1 fashion
9543592|NCT03084744|Experimental|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
10040316|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
9543593|NCT03084744|Placebo Comparator|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
9543594|NCT03084692|Experimental|Therapeutic Yoga and Resistance Exercise|The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
9543595|NCT03084705|Experimental|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
9543596|NCT03084705|Experimental|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
9543597|NCT03084679|No Intervention|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
9543598|NCT03084679|Other|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
9543599|NCT03084679|No Intervention|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
9543600|NCT03084679|Other|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
9543601|NCT03084588|Active Comparator|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
9543602|NCT03084588|Active Comparator|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
9543603|NCT03084575|Active Comparator|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
9543604|NCT03084575|Active Comparator|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
9543605|NCT03084666|Experimental|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
9543606|NCT03084666|Experimental|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
9543607|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
9543608|NCT03084783|Experimental|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
9543609|NCT03084783|No Intervention|Control group|Participants receive standard care and no dexamethasone.
9543610|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
9543611|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
9543612|NCT03084510|Experimental|Lotus Edge™ Valve System|The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
9543613|NCT03084497|Experimental|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
9543614|NCT03084497|No Intervention|Group without intervention|The subjects of this group won´t receive any intervention.
9543615|NCT03084341|Active Comparator|NMEE Group|Neuromuscular Electrical Elongation
9543616|NCT03084341|Active Comparator|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
9543617|NCT03084341|No Intervention|Control Group|No intervention
9543618|NCT03084276|Experimental|High-fat meal|
9543619|NCT03084276|Active Comparator|Low-fat meal|
9543620|NCT03084289|Experimental|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10^8 vp i.v.
9543621|NCT03084289|Experimental|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10^9 vp i.v.
9543622|NCT03084289|Experimental|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10^10 vp i.v.
9543623|NCT03084289|Experimental|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10^10 vp s.c.
9543624|NCT03084289|Experimental|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10^11 vp s.c.
9543625|NCT03084289|Experimental|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10^6 pfu i.v.
9543626|NCT03084289|Experimental|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10^7 pfu i.v.
9543627|NCT03084289|Experimental|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10^8 pfu i.v.
9543628|NCT03084250|Experimental|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
9543629|NCT03084250|Active Comparator|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
9543630|NCT03084484|Experimental|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
9543631|NCT03084484|Active Comparator|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the control group didi not receive any dietary advice."
9543632|NCT03084406|Experimental|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
10040317|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
10040318|NCT01852149|Experimental|MPAS Implant|MPAS Implant
10040319|NCT01852188|Other|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
10040320|NCT01852188|Other|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
9543633|NCT03084406|No Intervention|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
9543634|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit [apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
9543635|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
9543636|NCT03084419|Experimental|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
9543637|NCT03084458|No Intervention|Control|Once consented, recruited ICD patients will complete the baseline psychosocial and quality of life measures. At the first and final visit, a 6-minute walk test will be administered. Participants will be sent text messages to encourage physical activity. Participants will be re-assessed with psychosocial and quality of life measures at 30 and 90 days post enrollment. At the final (90 day) visit participants ICD will be interrogated to obtain accelerometer activity data.
9543638|NCT03084458|Experimental|Fitbit|Same as control condition. In addition, participants in the experimental group will receive a Fitbit device with full instructions and troubleshooting. These participants will be given daily step goals, which will be increased during the course of the study, and be able to monitor their progress using the Fitbit app.
9543639|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
9543640|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
9543641|NCT03084211|No Intervention|Control Group|The control group will be instructed to gradually return to activities.
9543642|NCT03084211|Experimental|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
9543643|NCT03084380|Experimental|anti-GPC3 CAR-T|Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion
9543644|NCT03084107|Experimental|Questionnaire|technology acceptance model (TAM) questionnaire
9543645|NCT03084393||study group|215 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week after surgery without safety issue. Patients will be divided into POCD and non-POCD groups according to the two times tests.
9543646|NCT03084393||non-surgical group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
9543647|NCT03084198|Active Comparator|Control group|Standard care for ALF
9543648|NCT03084198|Experimental|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
9543649|NCT03084367||iFR post angiographically successful PCI|
9543650|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
9543651|NCT03084094|Experimental|M1|Transcranial direct current Stimulation in primary motor cortex
9543652|NCT03084094|Experimental|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
9543653|NCT03084094|Sham Comparator|Sham|sham stimulation
9543654|NCT03084055|Experimental|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
9543655|NCT03084055|No Intervention|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
10040321|NCT01852240||erectile dysfunction|"Inclusion criteria:~male patients with ED defined by an IIEF-5 score of ≤ 21~age between 18-45a~Exclusion criteria:~systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)~pure psychogenic (non-organic) ED with good spontaneous / nightly erections~periodontal treatment within the last 3 months~antibiotic intake within the last 3 months"
10040322|NCT01852253|Active Comparator|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
9543656|NCT03084146|Experimental|Psoriasis|Psoriasis patients will be placed on an individualized 12-week elimination diet
9543657|NCT03084146|No Intervention|Healthy Control|Healthy Control patients will receive no intervention
9543658|NCT03084263|Experimental|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
10058467|NCT02018510|Experimental|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
9543659|NCT03084263|Active Comparator|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
9543660|NCT03084237|Experimental|HLX02+docetaxel|
9543661|NCT03084237|Active Comparator|Herceptin®+docetaxel|
9543662|NCT03084601|Active Comparator|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
9543663|NCT03084601|Experimental|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
9543664|NCT03084614||Controls|non exposed controls
9543665|NCT03084614||donors with naturally enriched antimicrobial blood samples and|Donors with naturally enriched antimicrobial blood samples an breast milk, Comparisons will be made with non exposed controls.
9543666|NCT03084133|Experimental|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.~Intervention 'Therapeutic Education Strategy'"
9543667|NCT03084133|No Intervention|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
9543668|NCT03084068|Experimental|Human umbilical cord allograft|Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
9543669|NCT03084068|Placebo Comparator|Placebo Control|Open Rotator Cuff Repair with standard suture repair
9543670|NCT03083964|Active Comparator|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
9543671|NCT03083964|Experimental|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
9543672|NCT03083938|Experimental|Omental Roll-up|
9543673|NCT03083938|No Intervention|No Omental Roll-up|
9543674|NCT03083951|Experimental|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
9543675|NCT03083951|Active Comparator|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
9543676|NCT03084003|Experimental|Almond group|2 oz. of almonds everyday for 8 weeks
9543677|NCT03084003|Active Comparator|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
9543678|NCT03084029|Experimental|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
9543679|NCT03084029|Experimental|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
9543680|NCT03084029|Placebo Comparator|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
9543681|NCT03084029|Placebo Comparator|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
9543682|NCT03084159|Experimental|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys (for feasibility and feedback prior to actual trial enrollment). Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
9543683|NCT03084159|Experimental|Intervention Only|This arm include new patients at the initial site that also received the intervention of using an education worksheet during their appointment and filled out post intervention surveys. Some of these providers/staff were not involved in the initial design of the intervention.
9543684|NCT03084159|No Intervention|Usual Care|A second site included usual care, which did not include the intervention. Participants were given post visit surveys similar to those in the two other study / intervention arms. This site served as a usual care comparison.
9543685|NCT03084120|Other|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
9543686|NCT03084120|Other|Reference group|"Pregnant women having a body mass index <25 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
9543687|NCT03084120|Other|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
9662985|NCT04267796|Experimental|Group I (lifestyle intervention)|Participants complete lifestyle intervention consisting of 1-3 sets of high-resistance circuit training sessions per week, up to 150 minutes of aerobic training per week, and diet recommendations from a health coach or registered dietitian twice per week for 16 weeks.
10058468|NCT02018510|Experimental|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
10040323|NCT01852253|Sham Comparator|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
10040324|NCT01852266|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
9543688|NCT03084120|Other|Obesity|"Pregnant women having a body mass index > 30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
9543689|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
9543690|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
9543691|NCT03084042||Healthy controls|Demographically matched healthy controls.
9543692|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
9543693|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
9543694|NCT03083912||Fortimel Complete|All of the residents included receive ONS
9543695|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
9543696|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
9543697|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
9543698|NCT03083899|Experimental|Diatast|Free patient-initiated use of out-patient services
9543699|NCT03083899|Placebo Comparator|Control|Scheduled diabetes control
9543700|NCT03083821|Experimental|Arm A|
9543701|NCT03083782|Active Comparator|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
9543702|NCT03083782|Experimental|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
9543703|NCT03083782|Experimental|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
9543704|NCT03083886|Active Comparator|Usual PCP led care|
9543705|NCT03083886|Experimental|Identify, Coordinated, Enhanced (ICE) Decision Making|
9543706|NCT03083886|Experimental|Individualized Postural Therapy (IPT)|
9543707|NCT03083730|Experimental|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
9543708|NCT03083834|Experimental|healthy subjects|low-dose cosyntropin stimulation test
9543709|NCT03083834|Experimental|hypoadrenal mitotane treated patients|low-dose cosyntropin stimulation test
9543710|NCT03083834|Experimental|hypoadrenal no-mitotane treated patients|low-dose cosyntropin stimulation test
9543711|NCT03083860|Other|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
9543712|NCT03083860|Other|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
9543713|NCT03083795|Experimental|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.~These participants will continue to receive BC Diabetes standard care."
9543714|NCT03083795|No Intervention|Control cohort|Patients in the control group will receive BC Diabetes standard care.
9543715|NCT03083873|Experimental|Cohort 1|Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL
10040325|NCT01852266|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
10040326|NCT01852279|Experimental|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
10040327|NCT01852279|Active Comparator|Passive muscle stimulation|FES will be delivered by therapist
10040328|NCT01852305|Experimental|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
10058469|NCT02018510|Experimental|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
9543716|NCT03083873|Experimental|Cohort 2|Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL
10040329|NCT01852305|Active Comparator|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
10040330|NCT01852318|Experimental|Pregabalin|pregabalin 75mg daily for 12 weeks
9543717|NCT03083873|Experimental|Cohort 3|Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL
9543718|NCT03083873|Experimental|Cohort 4|Treatment with LN-145-S1 cryopreserved TIL
9543719|NCT03083873|Experimental|Cohort 5|LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment
9543720|NCT03083743|Experimental|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
9543721|NCT03083743|Placebo Comparator|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
9543722|NCT03083587|Active Comparator|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
9543723|NCT03083587|Experimental|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
9543724|NCT03083626||Prescription opioid abusers|Patients 21-65 years old taking suboxone or methadone, currently experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
9543725|NCT03083626||Healthy control participants|Patients 21-65 years old not taking suboxone or methadone, not experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
9543726|NCT03083613|Experimental|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,~Eery 3 weeks"
9543727|NCT03083691|Other|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
9543728|NCT03083691|Other|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
9543729|NCT03083704|Experimental|Cohort 1|
9543730|NCT03083704|Experimental|Cohort 2|
9543731|NCT03083704|Experimental|Cohort 3|
9543732|NCT03083704|Experimental|Cohort 4|
9543733|NCT03083704|Experimental|Cohort 5|
9543734|NCT03083704|Experimental|Cohort 6|
9543735|NCT03083704|Experimental|Cohort 7|
10040331|NCT01852318|Active Comparator|fexofenadine|fexofenadine 60 mg daily for 12 weeks
10040332|NCT01852318|Placebo Comparator|Placebo|placebo 75 mg for 12 weeks
10040333|NCT01852331|Active Comparator|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
10058470|NCT02018510|Experimental|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
10058471|NCT02018510|Experimental|Group 3|HIV-infected individuals off ART, VL < 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
9543736|NCT03083704|Experimental|Cohort 8|
9543737|NCT03083704|Experimental|Cohort 9|
9543738|NCT03083704|Experimental|Cohort 10|
9543739|NCT03083704|Experimental|Cohort 11|
9543740|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 5g|plant-based protein hydrolysate 1 (5g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times per day for 12-weeks
9543741|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 10g|Plant-based protein hydrolysate 1 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
9543742|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 15 g|Plant-based 1 protein hydrolysate (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
9543743|NCT03083600|Placebo Comparator|Placebo|Cellulose Placebo stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks.
9543744|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 5g|Plant-based protein hydrolysate 2 (5 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
9543745|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 10g|Plant-based protein hydrolysate 2 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
9543746|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 15g|Plant-based protein hydrolysate 2 (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
10040334|NCT01852331|Placebo Comparator|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
10040335|NCT01852357|Sham Comparator|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
9543747|NCT03083652|Sham Comparator|Control|Conventional physiotherapy with NMEs device not activated
9543748|NCT03083652|Experimental|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
9543749|NCT03083717||Patients with compensated heart failure|
9543750|NCT03083717||Patients with decompensated heart failure|
10040336|NCT01852357|Experimental|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
10040337|NCT01852396|Experimental|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
9543751|NCT03083717||Healthy subjects|
10040338|NCT01852409|Experimental|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
9616615|NCT02540863|Experimental|myofascial release protocol and Rocabado exercise therapy|"Myofascial Release Protocol:~Suboccipital release.~Compression - decompression of temporomandibular joint.~Horizontal release of temporomandibular joint.~Deep fascia release in temporal region.~Masseter deep fascia release.~Pterygoiddeep fascia release.~Intraoral pterygoid deep fascia release."
10040339|NCT01852422||Pelvic prolapse|
10040340|NCT01852435|Active Comparator|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
10040341|NCT01852435|Experimental|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
9616616|NCT02540863|Active Comparator|exercise therapy|Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
9616617|NCT02540876|Experimental|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
9616618|NCT02540759|Placebo Comparator|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
10040342|NCT01852435|Experimental|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
10040343|NCT01852448||Patients with Cystic Fibrosis|Blood or Saliva Sample Collection and Glucose -potentiated arginine (GPA) stimulation tests will be completed for all enrolled patients.
10040344|NCT01852461|Active Comparator|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
10040345|NCT01852461|Active Comparator|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
10040346|NCT01852474|Experimental|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
9616619|NCT02540759|Experimental|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
10040347|NCT01852487|Active Comparator|Pumpkin Seed Oil|400mg/ day during 6 months
10040348|NCT01852487|Placebo Comparator|sweet potato starch|400mg/day during 6months
10040349|NCT01852500|Experimental|Sham OMT|patients under standard medical care plus sham OMT
9616620|NCT02540759|Experimental|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
9616621|NCT02540759|Experimental|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
9616622|NCT02540811|Experimental|dCELL® ACL Scaffold|
9616623|NCT02540824|Experimental|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
9616624|NCT02540837|Experimental|Bupivacaine|Obturator nerve block
9616625|NCT02540837|Placebo Comparator|Saline|Saline is injected as a placebo
9616626|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
9616627|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
9616628|NCT02540733||Diabetic stroke|
9616629|NCT02540733||Non-diabetic storke|
10040350|NCT01852500|Other|Control|patients under standard medical care plus only osteopathic evaluation
10058472|NCT02018510|Experimental|Group 4|HIV-infected individuals on ART, VL < 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
10058473|NCT02018510|Experimental|Group 5A|HIV-infected individuals on ART, VL < 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
10058474|NCT02018510|Experimental|Group 5B|HIV-infected individuals on ART, VL < 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
10058475|NCT02018523|Experimental|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
10058476|NCT02018536|Experimental|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
10058477|NCT02018536|Experimental|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
9616630|NCT02540785|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
9543752|NCT03083561|Experimental|LY3337641 Multiple Dose|Multiple doses of LY3337641 administered orally, with a two week follow-up period.
9543753|NCT03083561|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered orally, with a two week follow-up period.
9543754|NCT03083561|Experimental|LY3337641 Single Dose|Single dose of LY3337641 administered orally, with a two week follow-up period.
10040351|NCT01852526|Experimental|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
10040352|NCT01852526|Active Comparator|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
9543755|NCT03083561|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
9543756|NCT03083457|Experimental|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
10040353|NCT01852539|Experimental|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
9543757|NCT03083457|Experimental|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
10040354|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
9543758|NCT03083457|Experimental|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
9543759|NCT03083457|Experimental|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
9543760|NCT03083457|Experimental|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
10040355|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
10040356|NCT01852565|Experimental|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
9543761|NCT03083457|Experimental|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
9543762|NCT03083522|Experimental|OJS group|admission to Ojeok-san granule
9543763|NCT03083522|Placebo Comparator|Placebo Group|admission to placebo
9543764|NCT03083574|Experimental|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
10040357|NCT01852578|Experimental|1|
10040358|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
9543765|NCT03083496|Active Comparator|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
9543766|NCT03083496|Active Comparator|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
9543767|NCT03083509|Other|Group1 (Resistance trained individuals)|Resistance trained individuals (>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
9543768|NCT03083509|Other|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of <25 minutes and a training history of ≥5 hours per week for ≥2 years)
10040359|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
10040360|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
10058478|NCT02018536|Experimental|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
9543769|NCT03083509|Other|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
9543770|NCT03083405||Opipramol group|Patients diagnosed with SB and opipramol intervention.
9543771|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
9543772|NCT03083405||Healthy controls|Patients without diagnosed SB.
9543773|NCT03083431|Experimental|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg·d in 3-4 divided dosages) given for 4 10 weeks (depending on postmenstrual gestational age at birth)
9543774|NCT03083431|Placebo Comparator|Placebo|Placebo (same duration as oral propranolol solution)
9543775|NCT03083535|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
9543776|NCT03083535|Experimental|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
9543777|NCT03083535|Experimental|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
9543778|NCT03083392|Experimental|Treatment|treatment of chronic maxillary sinusitis using DIVA system
9543779|NCT03083418|Experimental|Control group|No EDP treatment.
9543780|NCT03083418|Experimental|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
9543781|NCT03083340|Experimental|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
9543782|NCT03083353|Experimental|isradipine|Participants will receive 15mg of immediate release isradipine.
9543783|NCT03083353|Placebo Comparator|placebo|Participants will receive a placebo pill identical in appearance to isradipine.
9543784|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
9543785|NCT03083327|Active Comparator|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
9543786|NCT03083327|Active Comparator|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
10040361|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
10040362|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
10040363|NCT01852604|Experimental|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
10040364|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
10040365|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
10040366|NCT01852617|Experimental|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
10040367|NCT01852617|No Intervention|No implementation of the intervention|Standard in-service activities
10040368|NCT01852630|Experimental|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
10040369|NCT01852630|Active Comparator|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
10040370|NCT01852643|Active Comparator|Spreader graft|
10040371|NCT01852643|Active Comparator|Lateral crural overlay|
10040372|NCT01852656|Active Comparator|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
10040373|NCT01852656|Active Comparator|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
10040374|NCT01852656|Active Comparator|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
10040375|NCT01852682|Experimental|PA21|
10040376|NCT01852695|Experimental|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
9543787|NCT03083145|Active Comparator|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
9543788|NCT03083145|Active Comparator|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
9543789|NCT03083119|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
9543790|NCT03083119|Placebo Comparator|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
9543791|NCT03083171|Placebo Comparator|Placebo|
9543792|NCT03083171|Active Comparator|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
9543793|NCT03083171|Active Comparator|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
10040377|NCT01852695|No Intervention|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
10040378|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
9543794|NCT03083171|Active Comparator|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
9543795|NCT03083158|Other|Group 1|Older adults, aged 61-80 years
9543796|NCT03083158|Other|Group 2|Younger adults, aged 40-60 years
9543797|NCT03083314|Experimental|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
10040379|NCT01852721|Experimental|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
9543798|NCT03083314|Active Comparator|COMPLETE AXILLARY DISSECTION (ALND)|
9543799|NCT03083210|Experimental|Lanreotide|Lanreotide, at a dose of 120mg will be administered without dose adjustment, by means of deep subcutaneous injection every 28 days.
9543800|NCT03082872|Experimental|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
9543801|NCT03082872|Experimental|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
9543802|NCT03082898|Experimental|AIS A or B using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) A or B (non- ambulatory) will receive regular dosing of exoskeleton walking.
9543803|NCT03082898|Experimental|AIS C or D using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) C or D (Poorly ambulatory) will receive regular dosing of exoskeleton walking.
9543804|NCT03082924|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
9543805|NCT03082924|Experimental|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
9543806|NCT03082924|Experimental|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
9543807|NCT03082924|Experimental|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
9543808|NCT03083015|Experimental|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
9543809|NCT03083015|Active Comparator|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
9543810|NCT03083184|Experimental|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
10040380|NCT01852721|Experimental|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
10040381|NCT01852734|Other|embolizations, uterine fibroid|embolization interventions with microspheres
9543811|NCT03083184|Other|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
9543812|NCT03082911|Experimental|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.~Each phone call will last approximately 5 minutes."
9543813|NCT03082911|Active Comparator|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
9543814|NCT03082937|Experimental|3 mg [14C]-A4250 capsule|
9543815|NCT03082859|Experimental|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
9543816|NCT03082859|Experimental|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
9543817|NCT03082859|Experimental|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
10040382|NCT01852747|Experimental|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
10040383|NCT01852747|No Intervention|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
10040384|NCT01852760||UC in Remission|Patients with UC in remission
9543818|NCT03082859|No Intervention|Sedentary (no exercise)|No exercise. Rest.
9543819|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 250mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
9543820|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 500mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
9543821|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 375mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
9543822|NCT03082833|Experimental|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
9543823|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
9543824|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
9543825|NCT03083054|Experimental|Patients|High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
9543826|NCT03083288|Experimental|Single Arm|
9543827|NCT03083106|Other|Elevoplasty treatment|Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective
9543828|NCT03083080|Experimental|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
9543829|NCT03082846|Experimental|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
9543830|NCT03082885|Experimental|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
9543831|NCT03082885|No Intervention|control group|Patients receive treatment based on standard Therapy
9543832|NCT03083223||lung disease|Patients with lung disease
9543833|NCT03083028|Active Comparator|Non Operative|"Non-Operative~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
9543834|NCT03083028|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
9543835|NCT03082963|Other|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
9543836|NCT03082820||Patients|Pain-related evoked potentials (PREP), Quantitative Sensory Testing (QST) and nerve conduction studies (NCS) were performed with patients with peripheral nerve injury.
9543837|NCT03082820||Controls|Pain-related evoked potentials (PREP) and Quantitative Sensory Testing (QST) were performed with healthy adults.
9543838|NCT03083275|Experimental|Resistance Training|
9543839|NCT03083275|No Intervention|Control|
9543840|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
9543841|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
9543842|NCT03082807|Experimental|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
9543843|NCT03082807|Experimental|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
9543844|NCT03082794|Experimental|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
9543845|NCT03082794|Experimental|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
9543846|NCT03082781|Experimental|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
9543847|NCT03082781|Experimental|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
10040385|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
9543848|NCT03082716|Active Comparator|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
9543849|NCT03082716|Experimental|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
9543850|NCT03082677|Experimental|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
9543851|NCT03082690|Experimental|DuoGel|IQP-0528 1% gel administered rectally one time
9543852|NCT03082703|Experimental|Text Messaging|
9543853|NCT03082703|No Intervention|Control|
9543854|NCT03082742|Active Comparator|Furosemide|Use of Furosemide, 40mg (1 tablet) per day, over 12 months
9543855|NCT03082742|Active Comparator|Hydrochlorothiazide|Use of Hydrochlorothiazide, 25mg (1 tablet) per day, over 12 months
9543856|NCT03082755|Experimental|Gabapentin Enacarbil (GEn)|1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
9543857|NCT03082755|Placebo Comparator|Placebo|1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
9543858|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (>=40mg/d)
9543859|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (>=40mg/d)
9543860|NCT03082638||Control|served in Gulf War during 1990 - 1991 and have no symptoms of Gulf War Illness based on criteria
9543861|NCT03082638||Case|Served in Gulf War during 1990 -1991 and have Gulf War Illness
9543862|NCT03082651|Active Comparator|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
9543863|NCT03082651|Experimental|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
9543864|NCT03082651|Experimental|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
9543865|NCT03082651|Experimental|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
9543866|NCT03082469|Active Comparator|CytoSorb|CytoSorb therapy for 48h
9543867|NCT03082469|No Intervention|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
9543868|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
9543869|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
9543870|NCT03082300|Experimental|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
9543871|NCT03082417|No Intervention|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
9543872|NCT03082417|Experimental|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
9543873|NCT03082417|No Intervention|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
9543874|NCT03082664|No Intervention|Standard dressing|Standard dressing will be applied after C-section.
9543875|NCT03082664|Experimental|PICO dressing|Device: PICO Single Use Negative Pressure Wound Therapy
9543876|NCT03082443|Experimental|Therapeutic group|
9543877|NCT03082443|No Intervention|Control group|
9543878|NCT03082313|Experimental|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time.
9543879|NCT03082495|Experimental|Exercise|Aerobic exercise
9543880|NCT03082495|No Intervention|Usual Care|Standard medical care
9543881|NCT03082625|Experimental|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
9543882|NCT03082625|Placebo Comparator|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
9543883|NCT03082612|Experimental|Intervention plus usual care|Participants (patients and their family caregivers) in this study arm will receive the Overcoming Psychological Distress through Hymns Intervention.
9543884|NCT03082612|Active Comparator|Usual care|Immediately after randomization and completion of baseline measures, participants in this study arm will receive usual care. Patients and their family caregivers will receive the Overcoming Psychological Distress through Hymns Intervention after the 3 week period of usual care.
9543885|NCT03082508|Experimental|Algisyl|Algisyl device (implants) administered during a surgical procedure.
9543886|NCT03082508|Active Comparator|Standard Medical Therapy|as per protocol
9543887|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
9543888|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
9543889|NCT03082534|Experimental|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
9543890|NCT03082534|Experimental|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
9543891|NCT03082534|Experimental|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
9543892|NCT03082534|Experimental|Cohort 4|"cutaneous HNSCC~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
9543893|NCT03082768|Experimental|[18F]MNI-968|To evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
9543894|NCT03082404|Experimental|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
9543895|NCT03082404|No Intervention|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
9543896|NCT03082573|Active Comparator|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
9543897|NCT03082573|Active Comparator|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
9543898|NCT03082430|Other|knee osteoarthritis patients.|therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
9543899|NCT03082456|Other|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
9543900|NCT03082352|Experimental|BF-Metoprolol Tablet 100mg|During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours
9543901|NCT03082352|Active Comparator|Betaloc Tablet 100mg|During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours
9543902|NCT03082391|Active Comparator|Heavyweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavyweight mesh.
9543903|NCT03082391|Active Comparator|Mediumweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a mediumweight mesh.
9543904|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
9543905|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
9543906|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
9543907|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
9543908|NCT03082365||pre-dialysis|
9543909|NCT03082365||end stage renal disease|
9543910|NCT03082274||Men age 40-85 years with an initial negative prostate biopsy|Men age 40 - 85 years of age Previous negative prostate biopsy within 30 months.
9543911|NCT03082248|Other|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
9543912|NCT03082248|Other|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
9543913|NCT03082235|Experimental|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
9543914|NCT03082235|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
9543915|NCT03082235|Experimental|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
9543916|NCT03082235|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
9543917|NCT03082235|Experimental|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
9543918|NCT03082235|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
9543919|NCT03082235|Experimental|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
9543920|NCT03082235|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
9543921|NCT03082235|Experimental|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
9543922|NCT03082235|Placebo Comparator|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
9543923|NCT03082235|Experimental|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
9543924|NCT03082235|Placebo Comparator|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
9543925|NCT03082235|Experimental|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
9543926|NCT03082235|Placebo Comparator|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
9543927|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
9543928|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
9543929|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
9543930|NCT03082144|Active Comparator|Group 1: RT-Intra-MTX|Intrathecal chemotherapy: MTX 15 mg, plus dexamethasone 5 mg, via lumbar puncture,once per week, 4 weeks in total.
10040386|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
10058479|NCT02018536|Experimental|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
9543931|NCT03082144|Experimental|Group2: RT-Intra-Ara-C|Intrathecal chemotherapy:Ara-C 50 mg, plus dexamethasone 5 mg, via lumbar puncture, once per week, 4 weeks in total.
9543932|NCT03082092|Experimental|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
9543933|NCT03082092|Placebo Comparator|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
9543934|NCT03082183|Experimental|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
9543935|NCT03082053|Experimental|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
9543936|NCT03082053|Experimental|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
9543937|NCT03081923|Experimental|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
9543938|NCT03081923|Experimental|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
9543939|NCT03082157|Experimental|Mighty Men Intervention|Mighty Men weight-loss intervention including health education and exercise during small group sessions
9543940|NCT03082157|No Intervention|Comparison|Exercise-only small group sessions
9543941|NCT03082105|Experimental|Winter snow|First test series breathing in dry snow in winter
9543942|NCT03082105|Experimental|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
9543943|NCT03082105|Experimental|Spring snow|Third test series breathing in very wet snow in spring
9543944|NCT03081975|Active Comparator|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
9543945|NCT03081975|Active Comparator|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
9543946|NCT03081845|Experimental|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
9543947|NCT03081845|Experimental|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
9616631|NCT02540785|Experimental|small-incision lenticule extraction|The patients in this group chose to receive the small-incision lenticule extraction surgery.
9616632|NCT02540746|Experimental|ERG Skills Training|ERG Skills Training for 12 weeks
9543948|NCT03082001|Active Comparator|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
9543949|NCT03082001|Experimental|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A & B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
9543950|NCT03081871|Experimental|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
9543951|NCT03081871|Active Comparator|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
9543952|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
9543953|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
9543954|NCT03082131|Experimental|Group 1|"Order of treatments:~A. Resistant Starch Wheat B. Regular Wheat"
9543955|NCT03082131|Experimental|Group 2|"Order of treatments:~A. Regular Wheat B. Resistant Starch Wheat"
9543956|NCT03082040|Experimental|intervention group|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks
9543957|NCT03082040|Other|waiting-list control group|Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period
9543958|NCT03082079|Experimental|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
9543959|NCT03082079|No Intervention|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
9543960|NCT03081819|Experimental|SH003|Participant will take SH003 for 3 weeks.
9543961|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
9543962|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
9543963|NCT03081949|Active Comparator|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
9543964|NCT03081949|No Intervention|Control|No treatment
9543965|NCT03082118|Experimental|Vesair Arm|Subjects treated with the Vesair Bladder Control System at enrollment.
9543966|NCT03081962|Experimental|Bundle application|The patients in this group will undergo an intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan impregnated sutures and application of Mupirocin ointment over the skin staples
9543967|NCT03081962|Active Comparator|Standard care|The patients in this group will follow a standard care, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
9543968|NCT03081936|Active Comparator|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
9543969|NCT03081936|Experimental|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
9543970|NCT03081936|Active Comparator|Breast feeding|Oral consumption of breast milk
9543971|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
9543972|NCT03082066||Adults|Even or older 18 years
9543973|NCT03081832|Experimental|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
9543974|NCT03081832|Experimental|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
9543975|NCT03081767|Other|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
9543976|NCT03081780|Experimental|FATE NK-100|
9543977|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
10040387|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
10040388|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
9499825|NCT03454230|No Intervention|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
9499826|NCT03454217|Active Comparator|Oxycodone|Postoperative pain treatment with oxycodone
9499827|NCT03454217|Active Comparator|Tramadol|Postoperative pain treatment with tramadol
9499828|NCT03454204||Pharmacokinetic|Establish a pharmacokinetic relationship between plasma concentration and the effect of norepinephrine in patients under concentration-target intravenous anesthesia by identifying significant covariates during general anesthesia.
9499829|NCT03454178||Hypertensive patients|150 Chinese patients with a diagnosis of essential hypertension from a primary care clinic
9499830|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
9499831|NCT03454139|Active Comparator|Subcostal TAP group|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,25 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia. After that, the patient is positioned to lithotomy position and the open-end catheter is inserted. After that the patient is turned to prone position and the percutaneous nephrolithotomy is performed. Tramadol 100 mg iv is administrated 20 minutes before the end of the surgery. Morphine patient controlled analgesia is planned for postoperative pain management.
9499832|NCT03454139|No Intervention|Non- TAP group|Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
9499833|NCT03454126|Experimental|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
9499834|NCT03454126|Experimental|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
9499835|NCT03454126|Experimental|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
9499836|NCT03454126|Experimental|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
9499837|NCT03454126|Experimental|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
9499838|NCT03454126|Experimental|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
9499839|NCT03454126|Experimental|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
9499840|NCT03454126|Experimental|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
9499841|NCT03454126|Experimental|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
9499842|NCT03454126|Experimental|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
9499843|NCT03454126|Experimental|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
9499844|NCT03454100|Experimental|multi-sectoral package of activities|Villages in the experimental arm received the full multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
10040389|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
10040390|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
9543978|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
9543979|NCT03082482|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
9543980|NCT03082482|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
9543981|NCT03082027||ultrasonography|diagnostic tool
9543982|NCT03082027||operative release|
9543983|NCT03081650|Experimental|Prospective Open label|"All of the patients that will be Selected to participate in the study will be given an AIRVO humidifier by the study sponsor. Patients will be connected to and instructed in the use of the AIRVO. The total flow will be set at 20-25 L/min, exact flow rate will be dependent on the patient's preference. Optiflow oxygen catheter will be used to ensure against unpleasant sensation due to high flow and to avoid push back in the system.~When acceptable flow rated has been established, it is recorded in the patient's folder. The patients is then instructed to use the AIRVO for a minimum eight (8) hour period, preferably at night. Using the humidifier for a longer period of time is allowed. The total number of hours the humidifier was operational will be recorded at the end of the study"
9543984|NCT03081572||Abacavir Group|HIV positive individuals currently taking an abacavir based regimen
9543985|NCT03081572||Tenofovir Group|HIV positive individuals currently taking a tenofovir based regime
9543986|NCT03081494|Experimental|spartalizumab (PDR001) + regorafenib|Subjects with metastatic MSS CRC received a combination of spartalizumab and regorafenib.
9543987|NCT03082170|Other|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
9543988|NCT03082170|Experimental|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
9543989|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
9543990|NCT03081624||Term Preschoolers|Term children who haven't attend school.
9543991|NCT03081559|Experimental|Intervention|Healthy Divas intervention
9543992|NCT03081559|No Intervention|Control|Treatment as usual
9543993|NCT03081702|Experimental|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
9543994|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
9543995|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
9543996|NCT03081533|Experimental|Circle Dance Program (CircleCare)|Caregivers (n=20) allocated to the experimental group will participate in 12-week CircleCare twice a week (24 sessions), for 60 min each session. The planning and conduction of the intervention will be the responsibility of the researcher, a Fitness Professional with training in Circle Dance, called focalizer.
9543997|NCT03081533|No Intervention|Control group|Caregivers (n=20) of this group will not receive the intervention, participating only in the assessment protocol. They will be instructed not to initiate any regular exercise program during the study period. At the end of the study, the same CircleCare applied to the experimental group will be offered to the interested of the control group.
9543998|NCT03081715|Experimental|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and reinfused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intravenously injected into the patient 30 min before cells infusion every time. Best supportive care was also provided for patients.~A total of 1 to 10 x 10^9 PD-1 Knockout T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent."
9543999|NCT03081728|Experimental|block|will be given block and continuous infusion with bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
9544000|NCT03081728|Experimental|control|IV analgesia only with diclofenac and paracetamol
9544001|NCT03081520|Experimental|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
9544002|NCT03081520|Experimental|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
10040391|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
10040392|NCT01852851|Active Comparator|Intervention Group|The intervention group will participate in the on-line eLearning program, an ergonomic assessment by an Occupational Therapist and job retention vocational counselling by a Vocational Rehabilitation Counsellor
9544003|NCT03081520|Experimental|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, >95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
9544004|NCT03081611|Experimental|Ram cannula|NIPPV VIA Ram cannula
9544005|NCT03081611|Active Comparator|Short nasal prongs|NIPPV VIA short nasal prongs
9544006|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
9544007|NCT03081689|Experimental|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
9544008|NCT03081481|Experimental|PRX302|intraprostatic administration
9544009|NCT03081676|Active Comparator|Glimepiride + GIP|Tablet Glimepiride + infusion of GIP
9544010|NCT03081676|Active Comparator|Placebo + GIP|Placebo tablet + infusion of GIP
9544011|NCT03081676|Active Comparator|Glimepiride + GLP-1|Glimepiride + infusion of GLP-1
9544012|NCT03081676|Active Comparator|Placebo + GLP-1|Placebo tablet + infusion of GLP-1
9544013|NCT03081676|Active Comparator|Glimepiride + Placebo|Glimepiride + infusion of placebo (saline)
9544014|NCT03081676|Placebo Comparator|Placebo + Placebo|Placebo tablet + infusion of placebo (saline)
9544015|NCT03081325|Experimental|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
9544016|NCT03081507|Experimental|LHW-led small media intervention arm (SM-LHW)|
9544017|NCT03081507|Experimental|LHW-led plus small media intervention arm (PN-LHW)|
9544018|NCT03081598|Placebo Comparator|Placebo|Daily dose of 6 capsules of placebo
9544019|NCT03081598|Active Comparator|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
9544020|NCT03081598|Active Comparator|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
9544021|NCT03081598|Active Comparator|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
9544022|NCT03081338||Study cohort|A mix of incident and prevalent patient cases will be included in order to capture patients at different stages of the disease trajectory.
9544023|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
9544024|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
9544025|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
9544026|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
9544027|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
9544028|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
9544029|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
9544030|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
9544031|NCT03081429||Perioperative covert stroke|
9544032|NCT03081429||Postoperative cognitive dysfunction|
9544033|NCT03081416|Experimental|Intranasal Ketamine arm|Intranasal ketamine administered to participant
9544034|NCT03081416|Active Comparator|Standard Therapy|Reglan 10 mg; Benadryl 25 mg administered to all participants Toradol 15-30 mg; dexamethasone 10 mg added at treating providers discretion.
9544035|NCT03081403|Other|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
9544036|NCT03081403|Other|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
9544037|NCT03081039|Active Comparator|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
9544038|NCT03081039|Active Comparator|Arm B|Gemcitabine alone for 6 cycles
9544039|NCT03081026||Ages less than 12|Those having ACL Reconstruction surgery during the desired dates at age 12 or less.
9544040|NCT03081026||Ages 12-13|Those having ACL Reconstruction surgery during the desired dates at ages 12 and 13.
9544041|NCT03081026||Ages 14 - 16|Those having ACL Reconstruction surgery during the desired dates at ages 14 - 16.
9544042|NCT03081286|Experimental|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
9616633|NCT02540746|Experimental|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
9544043|NCT03081286|Sham Comparator|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
10040393|NCT01852851|No Intervention|Control Group|"The control group will receive usual care and receive printed educational materials about work and arthritis."
10040394|NCT01852864|Experimental|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
10040395|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
10058480|NCT02018536|Experimental|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
9499845|NCT03454100|No Intervention|Control|Villages in the control arm did not receive teh multi-sectoral package of village level activities.
9499846|NCT03454087|Experimental|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
9499847|NCT03454087|Placebo Comparator|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
9499848|NCT03454074|Experimental|B-Fit intervention|Combines group education about brain health with individualized goal-setting and group problem-solving to help participants effectively integrate healthy behavioral changes into their everyday lives.
9499849|NCT03454074|Active Comparator|Education Only|Provide group education about healthy behavior changes without problem-solving component.
9499850|NCT03454074|No Intervention|Wait-list|No intervention administered. Will be offered intervention following a delay.
9499851|NCT03454061|Experimental|Intervention|Physical activity intervention
9499852|NCT03454061|No Intervention|Control|Keep usual activities in kindergarten
9499853|NCT03454022|Active Comparator|Usual care|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure."
9499854|NCT03454022|Experimental|DART|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure. They also receive a link to access the web-based decision-aid program, Decision-Aid for Renal Therapy (DART). Participants may access this program using a computer at home throughout the duration of the trial. Those who do not have a computer with web access at home are assisted in watching the program in the clinic."
9499855|NCT03454009|Experimental|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
9499856|NCT03454009|No Intervention|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
9499857|NCT03453996|Experimental|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
9499858|NCT03453996|Other|Control|Usual care.
9499859|NCT03453983|Experimental|Anodal tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
9499860|NCT03453983|Sham Comparator|Sham tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
9499861|NCT03453970|Experimental|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
9499862|NCT03453970|No Intervention|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
9499863|NCT03453957|Experimental|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
9499864|NCT03453957|No Intervention|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
9499865|NCT03453944|Experimental|VF03-K active stimulation|NMES applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
9544044|NCT03081195|Experimental|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
9544045|NCT03081195|Experimental|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
9544046|NCT03081195|No Intervention|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
9544047|NCT03081169|Active Comparator|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
9544048|NCT03081169|Active Comparator|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
9544049|NCT03081065|Experimental|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
9544050|NCT03081065|Experimental|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
9544051|NCT03081065|No Intervention|Control|Usual care
9544052|NCT03081078|Experimental|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
9544053|NCT03081078|Experimental|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
9544054|NCT03081078|No Intervention|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
9544055|NCT03081013|Active Comparator|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
9544056|NCT03081013|Experimental|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
9544057|NCT03080987|Experimental|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
9544058|NCT03080987|Experimental|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
9544059|NCT03080987|Experimental|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
9544060|NCT03080987|Experimental|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
9544061|NCT03080987|Experimental|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
9544062|NCT03080987|Experimental|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
9544063|NCT03081104|Active Comparator|hystroscopy|The procedure will be performed by a gynecological surgeon, under general anaesthesia with the patient in lithotomy position. Antibiotic prophylaxis may be administered, the cervix is grasped with pozzi forceps and dilated up to hegar 9 to facilitate insertion of the hysteroscopy. The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
9544064|NCT03081104|Active Comparator|ultrasound guided aspiration|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control. It was possible to keep the dilators and the suction cannula under constant view by slightly tilting the transducer as required. Advancement of any instrument was allowed only under direct ultrasound control.The completeness of the evacuation was confirmed by the scan in these cases.
9616634|NCT02540746|Experimental|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
9616635|NCT02540746|Experimental|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
10040396|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
10040397|NCT01852903|Experimental|calcium ascorbate|
9616636|NCT02540720|Experimental|group 1|Dexamethasone 0.5mg/kg.d i.v.
10040398|NCT01852903|Active Comparator|ascorbic acid|
10040399|NCT01852903|Placebo Comparator|placebo|
10040400|NCT01852916|Active Comparator|Nasal CPAP|Nasal CPAP using Infant flow
10040401|NCT01852916|Experimental|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
10040402|NCT01852929|Other|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
9544065|NCT03081104|Active Comparator|blind aspiration|The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
9544066|NCT03081351|Experimental|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
9544067|NCT03081351|Experimental|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
9544068|NCT03081260|Other|Patellar resurfacing|Patellar resurfacing during the total knee prosthesis Anatomic surgery
9544069|NCT03081260|Other|Patellar non-resurfacing|Patellar non-resurfacing during the total knee prosthesis Anatomic surgery
9544070|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
9544071|NCT03081442|Active Comparator|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
9544072|NCT03081442|Placebo Comparator|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
9544073|NCT03081390|Experimental|No migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
9544074|NCT03081390|Experimental|No migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
9544075|NCT03081390|Experimental|Migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
9544076|NCT03081390|Experimental|Migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
9544077|NCT03081208|Experimental|Nolasiban 900 mg|
9544078|NCT03081208|Placebo Comparator|Placebo|
9544079|NCT03081130||Intravenous laser irradiation treatment|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with intravenous laser irradiation of blood (ILIB) via an intravenous catheter for irradiation of the blood under a period of 60 minutes for 10 days.
9544080|NCT03081130||control|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with oral estradiol 8 mg per day and oestrogen gel 4 g per day for 14 days
9544081|NCT03081234|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
9544082|NCT03081234|Active Comparator|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
9544083|NCT03081091|Active Comparator|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
9544084|NCT03081091|Sham Comparator|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
9544085|NCT03081247|Experimental|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
9544086|NCT03081247|Experimental|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
10040403|NCT01852929|Other|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
10040404|NCT01852981|Experimental|Lifestyle counseling|Physical activity promotion using methods based on health education.
9544089|NCT03080909|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
9544090|NCT03080909|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
10040405|NCT01852981|Experimental|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
10040406|NCT01852981|No Intervention|Control|Control group.
10040407|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
9544091|NCT03080922|Experimental|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
9544092|NCT03080974|Experimental|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
9544093|NCT03080831|Active Comparator|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
9544094|NCT03080831|Active Comparator|Glucion 5%|
9544095|NCT03080818|Experimental|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
9544096|NCT03080818|Placebo Comparator|Control|Participants in this arm will receive placebo that look similar to probiotics
9544097|NCT03080857|Experimental|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
9544098|NCT03080662|Sham Comparator|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
9544099|NCT03080662|Experimental|Intervention|Inspiratory valve with increase resistance
9544100|NCT03080675|Experimental|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
9544101|NCT03080675|Placebo Comparator|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
9544102|NCT03080701|No Intervention|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
9544103|NCT03080701|Experimental|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
10040408|NCT01852994|Other|Testosterone replacement|Testosterone replacement will be done quarterly
9544104|NCT03080701|Experimental|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
9544105|NCT03080740|Active Comparator|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
9544106|NCT03080740|Active Comparator|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
9544107|NCT03080532||european population|
9544108|NCT03080766|Experimental|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.~The drug will then be administrated intravenously.~Dosage 20 mg/m2~28-day course, for each course, receive decitabine for 10 days"
9544109|NCT03080792|Experimental|Exercise|Exercise Intervention, moderate to high-intensity endurance and resistance exercise
9544110|NCT03080649|Active Comparator|Rotary bur|Device rotary bur
9544111|NCT03080649|Experimental|Er:YAG laser|Device Er:YAG laser
9544112|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
9544113|NCT03080584|Experimental|acupucture arm|all participants undergo 12 weeks of acupuncture
9616637|NCT02540720|Experimental|group 2|Dexamethasone & gamma globulin Dexamethasone 0.5mg/kg.d i.v. & gamma globulin i.v. qd*3d, and the total dose is 2g/kg
9616638|NCT02540720|Experimental|group 3|Dexamethasone & hemoperfusion Dexamethasone 0.5mg/kg.d i.v & hemoperfusion should be given at least three times in five days
9616639|NCT02540642|Active Comparator|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
10040409|NCT01852994|Other|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
10040410|NCT01853007|No Intervention|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
10058481|NCT02018536|Experimental|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
9544114|NCT03080870|Experimental|Intervention|"Art groups are held once a week, each with the duration of 60 minutes. They begin with a 45 minute art intervention and conclude with a 15 minute discussion. The art groups include music, dance and visual arts, which is psychologically, socially, and physically activating. Music has the main emphasis in art intervention. The preferences of the subjects are taken into consideration in art intervention. Art intervention is conducted by trained and experienced art pedagogues.~Art intervention aims to revive previously learned art-related skills, to learn and enhance new skills, and to improve and intensify physiological, emotional, social, motoric, and cognitive abilities."
9544115|NCT03080870|No Intervention|Control|Baseline and follow-up measurements.
9544116|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
9544117|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
9544118|NCT03080441|Experimental|Phase 1 Group 1|pressure stockings worn during dialysis treatment
9544119|NCT03080441|Experimental|Phase 1 Group 2|Midodrine before dialysis treatment
9544120|NCT03080441|Experimental|Phase 1 Group 3|pressure stocking and Midodrine
9544121|NCT03080805|Experimental|Pyrotinib Plus Capecitabine|
9544122|NCT03080805|Active Comparator|Lapatinib Plus Capecitabine|
9544123|NCT03080298|Experimental|Treatment with BP101|
9544124|NCT03080298|Placebo Comparator|Treatment with placebo|
9544125|NCT03080415|Experimental|Combined Therapy SOF and DCV|
9544126|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital~Consenting to participate in the study"
9544127|NCT03080363|Active Comparator|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
9544128|NCT03080363|No Intervention|Group Control|No intervention
9544129|NCT03080376|Experimental|Web-based intervention without support|3 months Web-based intervention without support
9544130|NCT03080376|Experimental|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
9544131|NCT03080376|Active Comparator|Traditional intervention|3 months of Printed-based intervention
9544132|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
9616640|NCT02540642|No Intervention|antidiabetics|Only regular antidiabetic drugs will be given
9616641|NCT02540486|Experimental|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
9616642|NCT02540486|Active Comparator|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
9616643|NCT02540707|Placebo Comparator|Solifenacin|Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
9616644|NCT02540707|Experimental|Mirabegron|Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
9616645|NCT02540694|Active Comparator|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
9616646|NCT02540694|Active Comparator|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
9616647|NCT02540694|Active Comparator|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
9616648|NCT02540694|Active Comparator|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
9616649|NCT02540551|Experimental|Sentinel node procedure.|Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.
9616650|NCT02540655|Experimental|Stemchymal®|Infusion of Stemchymal®
9616651|NCT02540655|Placebo Comparator|Vehicle|Infusion of excipients
9616652|NCT02540603|Experimental|Full Face Mask|F&P Jupiter Full Face Mask with Headgear
9616653|NCT02540499|Experimental|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
9616654|NCT02540421||Case|Recurrent lesions
9616655|NCT02540421||Control|Absence of lesions
9616656|NCT02540525|Experimental|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
9616657|NCT02540525|Active Comparator|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
9616658|NCT02540473|Experimental|Group therapy|12 week manualized group therapy (one hour per week)
9616659|NCT02540473|Other|Control Group|Participants get one hour of time away from patient care/duties to do as they wish.
9616660|NCT02540460|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
9616661|NCT02540460|Experimental|LCB01-0371 800mg BID|LCB01-0371 800mg BID
9616662|NCT02540460|Experimental|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
9616663|NCT02540460|Placebo Comparator|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
9616664|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
9616665|NCT02540512|Placebo Comparator|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
9662986|NCT04267796|Active Comparator|Group II (wait-list, lifestyle intervention)|Participants are placed on a wait-list and then complete lifestyle intervention after 4 months.
9544133|NCT03080506|Experimental|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
9544134|NCT03080506|No Intervention|No binder|The women will not be given a chance to wear abdominal binder or the likes.
9544135|NCT03080337|No Intervention|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
10040411|NCT01853007|Experimental|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
10040412|NCT01853033|Experimental|Group 1|Randomized 6 drug/2 placebo by group
9544136|NCT03080337|Experimental|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
9544137|NCT03080844|Experimental|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
9544138|NCT03080844|Active Comparator|No Practice|Participants will continue with their normal smoking behavior.
9544139|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
10040413|NCT01853033|Experimental|Group 2|Randomized 6 drug/2 placebo by group
10040414|NCT01853033|Experimental|Group 3|Randomized 6 drug/2 placebo by group
9544140|NCT03080324|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
9544141|NCT03080324|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
9544142|NCT03080402|Experimental|High KAM|Mechanically-driven neuromuscular training. 2 times per week for 6 weeks for a total of 12 sessions. Perturbation training
9544143|NCT03080402|No Intervention|Normal KAM|No intervention
10040415|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
10040416|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
10040417|NCT01853098|Experimental|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
10040418|NCT01853111|Experimental|Interleukin 2|Subjects who receive a tolerogenic drug protocol
10040419|NCT01853124|Experimental|Lacidofil|Lacidofil sachet containing active ingredients
10040420|NCT01853124|Placebo Comparator|Placebo|Placebo sachet containing inactive ingredients
10040421|NCT01853150|Experimental|rTMS Motor cortex|rTMS will be applied over the motor cortex
10040422|NCT01853150|Active Comparator|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
10040423|NCT01853163|Other|Gadolinium contrast agent|Patients who have received Gadolinium contrast agents in the past
10040424|NCT01853189|Other|OMT + Usual Care|
10040425|NCT01853189|Other|Usual Care|
10040426|NCT01853202|Experimental|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
10040427|NCT01853202|No Intervention|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
10040428|NCT01853241||Single balloon|Single Balloon Enteroscopy
10040429|NCT01853241||Spirus|Spirus Enteroscopy
10040430|NCT01853267|Active Comparator|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
10040431|NCT01853267|Experimental|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
10040432|NCT01853293|Active Comparator|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
10040433|NCT01853293|Placebo Comparator|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
10040434|NCT01853306|Experimental|Veliparib formulation A|veliparib formulation A
10040435|NCT01853306|Experimental|Veliparib formulation B|Veliparib formulation B
10040436|NCT01853306|Experimental|Veliparib formulation C|veliparib formulation C
10040437|NCT01853319|Experimental|Regorafenib|Regorafenib, 40 mg tablets
9544144|NCT03080545|Experimental|Open Label Enstilar|open label
9544145|NCT03080558|Experimental|endometriosis recto vaginal node|
9544146|NCT03080272||Spinal Surgery|No intervention will take place. Recruiting Autumn 2017 until spring 2018
9544147|NCT03080272||Gastric sleeve|No intervention will take place. Recruiting Autumn 2017 until spring 2018
9544148|NCT03080272||Total knee arthroplasty|No intervention will take place. Recruiting Spring 2018 until Summer 2018
9544149|NCT03080272||Shoulder arthroplasty|No intervention will take place. Recruiting Winter 2017 until Summer 2018
9544150|NCT03080272||Maxillofacial surgery|No intervention will take place. Recruiting 6 march 2017 until Autumn 2017
9544151|NCT03080636|Experimental|Men|11 men randomly underwent three experimental sessions in early morning prior to their work routine.
9544152|NCT03080636|Experimental|Women|9 women randomly underwent three experimental sessions in early morning prior to their work routine.
9544153|NCT03080597|Experimental|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
9544154|NCT03080480|Experimental|Pioglitazone|Treatment for chronic granulomatous disease patients with severe infection.
9544155|NCT03080519|Experimental|Endovascular Therapy|Renal artery revascularization
9544156|NCT03080311|Experimental|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
9544157|NCT03080350|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
9544158|NCT03080350|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
9544159|NCT03080428|Active Comparator|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
9544160|NCT03080428|Active Comparator|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
9544161|NCT03080428|Active Comparator|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
9544162|NCT03080428|Active Comparator|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
9544163|NCT03080467||Suture|Wound repair with suture
9544164|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
9544165|NCT03080246|Active Comparator|Strength Training Group|This group will begin coming to the Clinical Research Center (near the undergraduate campus of Wake Forest University) for exercise classes 2-3 days per week for about an hour each day. The investigators also have a site on High Point University's campus. The class will consist of a 10-minute warm-up, a 20-minute strength training period, 15-minutes of neuromuscular (balance/coordination) training, and a 15-minute cool down. These regular exercise classes at Wake Forest and High Point University will go on for 9 months, followed by another 9 months of option to continue at facility, plus follow-up via email and 2 group meetings/runs at Fleet Feet (at around months 12 and 15).
9544166|NCT03080246|No Intervention|Running Group|This group will be observed as they follow their usual run-training routine over the course of 18 months. Emails will be sent biweekly for 18 months to update the research team on injury/training status. The group will attend 5 group meetings/runs at Fleet Feet (at around months 1, 3, 6, 12, and 15). After the 18 months, the participants will be offered a free 8-week strength training program at the Clinical Research Center or High Point University.
9544167|NCT03080571|Experimental|Stem cell group|autologous BMMNC stem cells with standard care
9544168|NCT03080571|Active Comparator|Control|Patients randomised in this group received standard care only
9544169|NCT03080207|Experimental|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
9544170|NCT03080207|Experimental|Complex Decongestive Physiotherapy|
9544171|NCT03080207|Experimental|Low Level Laser|
9544172|NCT03080220|Experimental|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
10040438|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
9544173|NCT03080220|Experimental|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
9544174|NCT03080220|Placebo Comparator|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
10058482|NCT02018536|Experimental|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
9544175|NCT03080285|Active Comparator|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
9544176|NCT03080285|Experimental|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
9544177|NCT03080181|Experimental|pasireotide|Pasireotide was administered in a 12 months period
9544178|NCT03080194|Experimental|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
9544179|NCT03080194|Active Comparator|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
9544180|NCT03080168||Actigraph|"All participants will wear an Actigraph (monitoring device) for the duration of their inpatient stay.~NOTE: In clarification, for both this section and Section 4, this devices is an FDA-regulated monitoring device, but NOT an Intervention in this study."
9544181|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age >=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
9544182|NCT03079908|Experimental|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
9544183|NCT03079908|Active Comparator|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
9544184|NCT03079908|Placebo Comparator|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
9544185|NCT03080051|Experimental|[18F]MNI-952|To evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
9544186|NCT03079986|Experimental|Ignoring CL (group A)|Standard care irrespective of CL.
9544187|NCT03079986|Active Comparator|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
9544188|NCT03079817|Active Comparator|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
9544189|NCT03079817|Experimental|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
9544190|NCT03079843|Experimental|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
9544191|NCT03079843|Experimental|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
9544192|NCT03080025|Experimental|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva & Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.~It focuses on six essential key parts for the development of compassion:~Developing attentional stability and clarity of the mind (Mindfulness)~Cultivating insight into the nature of mental experience~Cultivating self-compassion~Developing impartiality~Developing appreciation and affection for others~Developing empathy and realizing engaged compassion"
9544193|NCT03080025|No Intervention|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression [S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin], but excluding current psychotherapy after probatory session."
9544194|NCT03079973|Experimental|P-3073|
9544195|NCT03079973|Placebo Comparator|Vehicle|
9544196|NCT03080038|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
9544197|NCT03080038|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
9544198|NCT03079830|Active Comparator|Ropivacaine continous infusion|Piritramid
9544199|NCT03079830|Sham Comparator|Saline continous|Piritramid
9544200|NCT03080064|Experimental|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
9544201|NCT03080155|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
9486880|NCT01220271|Experimental|Phase 2: Established dose LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
9486881|NCT01220271|Experimental|Phase 2: no LY2157299 (control)|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
9486882|NCT01208168|Experimental|Active drug|
9486883|NCT01208168|Placebo Comparator|Vehicle alone|
9486884|NCT01208129|Experimental|Active drug|
9486885|NCT01208129|Placebo Comparator|Vehicle alone|
9486886|NCT01207115|Experimental|ABT-652 high dose|ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
9486887|NCT01207115|Experimental|ABT-652 low dose|ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm
9486888|NCT01207115|Active Comparator|Naproxen|Naproxen capsules- twice daily for 8 weeks
9486889|NCT01207115|Placebo Comparator|Placebo|Placebo capsules- twice daily for 8 weeks
9486890|NCT01205334|Experimental|Autologous CMV-specific CTL|"The patient will receive one of the following doses:~1.5x10^7 cells/m2~4.5x10^7 cells/m2~1.5x10^8 cells/m2"
9486891|NCT01205061|Experimental|Emervel Deep Lidocaine|Emervel Deep Lidocaine injected into left nasolabial fold. Juvederm® Ultra Plus injected into right nasolabial fold.
9486892|NCT01205061|Active Comparator|Juvederm® Ultra Plus|Juvederm® Ultra Plus injected into left nasolabial fold. Emervel Deep Lidocaine injected into the right nasolabial fold.
9486893|NCT01205048|Experimental|Emervel Classic Lidocaine|Emervel Classic Lidocaine injected into left nasolabial fold. Juvederm® Ultra injected into right nasolabial fold.
9486894|NCT01205048|Active Comparator|Juvederm® Ultra|Juvederm® Ultra injected into left nasolabial fold. Emervel Classic Lidocaine injected into right nasolabial fold.
9486895|NCT01204762|Experimental|Part A Arm 1: pegIFN (180 μg)|
9486896|NCT01204762|Active Comparator|Part A Arm 2: pegIFNα-2a|
9486897|NCT01204762|Experimental|Part B: pegIFN lambda + Entecavir|
9486898|NCT01204749|Experimental|AMG 386|Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
9486899|NCT01204749|Placebo Comparator|AMG 386 Placebo|Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
9486900|NCT01204099|Active Comparator|Docetaxel (NSCLC)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
9486901|NCT01204099|Experimental|PX-866 (NSCLC)|Oral PX-866 administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
9486902|NCT01204099|Active Comparator|Docetaxel (SCCHN)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
9486903|NCT01204099|Experimental|PX-866 (SCCHN)|Oral PX-866, administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
9486904|NCT01203943|Experimental|Cohort 1|• Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
9486905|NCT01203943|Experimental|Cohort 2|• Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
9486906|NCT01203943|Experimental|Cohort 3|• Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
9486907|NCT01203943|Placebo Comparator|Placebo|Placebo
9486908|NCT01203631|Experimental|NNC 0142-0000-0002|
9486909|NCT01203631|Placebo Comparator|Placebo|
9486910|NCT01201837|Placebo Comparator|Placebo|
9486911|NCT01201837|Experimental|Low Dose|CER-001 Low Dose
9486912|NCT01201837|Experimental|Mid Dose|CER-001 Mid Dose
9486913|NCT01201837|Experimental|High Dose|CER-001 High Dose
9486914|NCT01198834|Placebo Comparator|Placebo Patch|Treatment with Placebo Patch
9486915|NCT01198834|Experimental|MRX-7EAT Patch|Treatment with MRX-7EAT Patch
9486916|NCT01198834|Experimental|Lidocaine Patch|Treatment with Lidocaine Patch
9486917|NCT01198834|Experimental|Etodolac Patch|Treatment with Etodolac Patch
9486918|NCT01198626|Experimental|JNJ-32729463|
9486919|NCT01198626|Active Comparator|moxifloxacin|
9486920|NCT01198626|Experimental|JNJ-32729463 Open-Label|subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
9486921|NCT01194960|Active Comparator|Docetaxel Alone|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
9486922|NCT01194960|Experimental|TroVax plus Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
9486923|NCT01194375|Experimental|Low Strength IDP-107|
9486924|NCT01194375|Experimental|High Strength IDP-107|
9486925|NCT01194375|Placebo Comparator|Placebo|
9486926|NCT01193361|Experimental|Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
9486927|NCT01193361|Experimental|Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
9486928|NCT01193361|Placebo Comparator|Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin|
9486929|NCT01193140|Experimental|Arm A|
9486930|NCT01192906|Experimental|1|
9486931|NCT01192906|Experimental|2|
9486932|NCT01192906|Placebo Comparator|3|
9544202|NCT03079804|Experimental|Experimental MWM|"Other names:~4 mobilizations - 10 seconds 20 seconds of rest"
9544203|NCT03079804|Active Comparator|Experimental Thrust|"Other names:~1 traction with caudal direction in high speed and low amplitude increasing dorsiflexion."
9544204|NCT03079804|Placebo Comparator|Placebo|"Other names:~It will accurately reproduce the positioning of the hand in the specific treatment condition (Thrust or MWM), however, without applying any movement or force. All interactions, procedures and deadlines will be identical."
9544205|NCT03079960|Experimental|Original patient group (PG-O)|"DBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study.~Cables and connectors of the macro electrodes will stay externalized for four days for cDBS adjustment procedures. During externalization, patients take part in test stimulation and recording sessions during which they perform short motor tasks.~The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure."
9544206|NCT03079960|No Intervention|Chronic patient group (PG-chronic)|"Patients in this group will take part in one recording session at any desired point in time after they have been implanted with a DBS system as part of their clinical routine treatment. During this session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~Recordings are performed while applying different DBS strategies. The different DBS strategies are selected as a set of safe configurations as they are used in clinical routine. The behavioral tests performed for PG-chronic are the same as conducted for PG-O."
9544207|NCT03079960|No Intervention|Preoperative patient group (PG-pre)|"Patients in this group will take part in one recording session that will take place one week prior to implantation surgery at the earliest, i.e. between day -7 and day 0. Decision for DBS treatment has been made prior to inclusion into this study.~During this recording session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~The behavioral tests performed for PG-pre are the same as conducted for PG-O."
9544208|NCT03080116|Experimental|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
9544209|NCT03080116|Active Comparator|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
9544210|NCT03080090|Experimental|High Intensity Exercise|Individuals in this condition will engage in aerobic exercise 3 times a week for 25 minutes each at 60% to 85% of age-predicted HRmax and smoking cessation intervention through a national quitline while using nicotine replacement patches.
9544211|NCT03080090|Active Comparator|Low Intensity Exercise|The intervention procedures for this group are identical to the Experimental Group group except that the target training intensity will be low intensity exercise, self-selected at 20% to 40% of age-predicted HRmax.
9544212|NCT03079934||Absorb-BVS|Bioresorbable vascular scaffold implantation
9544213|NCT03079856|Experimental|Brief Intervention|ED-based computer-guided intervention for substance use and HIV risk reduction utilizing Motivational Interviewing
9544214|NCT03079856|No Intervention|Enhanced Usual Care|Substance use and sexual health services information within a brochure provided to participants
9544215|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
9544216|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
9544217|NCT03080077|Active Comparator|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
9544218|NCT03080077|Experimental|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
9544219|NCT03079882||Living Donor Recipients|Recipients of renal transplants with the transplanted organ originating from living donors
9544220|NCT03079882||Deceased Donor Recipients|Recipients of renal transplants with the transplanted organ originating from deceased donors
9544221|NCT03079778|Active Comparator|TACE alone|Transarterial chemoembolization (TACE)
9544222|NCT03079778|Experimental|TACE plus RT|Combination of transarterial chemoembolization and radiation (TACERT)
9544223|NCT03079895|No Intervention|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
9662987|NCT04245865|Experimental|Arm A, standard treatment + tocotrienol|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + tocotrienol OR capecitabine + bevacizumab + tocotrienol
9544224|NCT03079895|Experimental|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
9544225|NCT03079765|Experimental|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
9544226|NCT03079765|Active Comparator|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
9544227|NCT03079752|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
9544228|NCT03079752|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
9544229|NCT03079752|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
9544230|NCT03079752|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
9544231|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
9544232|NCT03079479||Two Years Group|
9544233|NCT03079479||Five Years Group|
9544234|NCT03079479||Ten Years Group|
9544235|NCT03079479||Control Group|
9544236|NCT03079518|Active Comparator|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
9544237|NCT03079518|Active Comparator|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
9544238|NCT03079323|Experimental|PART-trial|External beam radiotherapy
9544239|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
9544240|NCT03079440|Experimental|TEMCAP|Temozolomide plus Capecitabine
9544241|NCT03079635|Active Comparator|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
9544242|NCT03079635|Active Comparator|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
9544243|NCT03079336|Experimental|State of the art (SOTA) check-in phase|The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
9544244|NCT03079336|Experimental|Prolonged focus on subtle changes|Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.
9544245|NCT03079557|Experimental|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
9544246|NCT03079466|Active Comparator|Treatment CPAP|A group treated with CPAP
9544247|NCT03079466|Sham Comparator|group without treatment|
9544248|NCT03079713|Experimental|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
9544249|NCT03079713|Sham Comparator|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
9544250|NCT03079713|Experimental|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
9544251|NCT03079583|Placebo Comparator|Control-group|Control Rice used for meal, normal zinc level
9544252|NCT03079583|Active Comparator|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
9544253|NCT03079453|Active Comparator|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
9544254|NCT03079453|No Intervention|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
9616666|NCT02540512|Experimental|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
9544255|NCT03079388|Experimental|Ready-to-use supplementary food + anti-infective bundle|The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
9544256|NCT03079388|Active Comparator|Corn-soy-blend|The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.
9544257|NCT03079505|Active Comparator|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
9544258|NCT03079505|Experimental|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
9544259|NCT03079726||Frail individuals (case)|Individuals classified as frail based on several clinical metrics
9544260|NCT03079726||Non-frail individuals|Individuals failing to meet criteria for frailty based on clinical metrics
9544261|NCT03079622|Active Comparator|Electric vacuum aspiration|Electric vacuum aspiration will be performed with Synevac® Vacuum Curettage System 10 (Richmond, CA, USA) with a rigid cannula.
9544262|NCT03079622|Active Comparator|Manual vacuum aspiration|Manual vacuum aspiration will be performed using the 60-mL double valve aspirator, manufactured by Ipas (Chapel Hill, NC, USA) with a flexible cannula.
9544263|NCT03079349|Active Comparator|Traditional Classroom|Medical Education
9544264|NCT03079349|Experimental|Online Synchronous Classroom|Medical Education
9544265|NCT03079648|Experimental|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
9544266|NCT03079648|Placebo Comparator|Placebo|Placebo for 12 weeks
9544267|NCT03079609|Experimental|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
9544268|NCT03079609|Active Comparator|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
9544269|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
9544270|NCT03079427|Active Comparator|Capecitabine|Adjuvant Capecitabine
9544271|NCT03079427|Experimental|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
9544272|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
9544273|NCT03079596|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
9544274|NCT03079596|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
9544275|NCT03079310|Experimental|Spinal cord stimulation|Boston Scientific SCS system
9544276|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
9544277|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
9544278|NCT03079219|Experimental|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
9544279|NCT03079219|Other|Standard|Aprepitant, Ondansetron, Dexamethasone
9544280|NCT03079245|Other|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
9544281|NCT03079245|Other|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
9544282|NCT03079245|Other|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
9544283|NCT03079245|No Intervention|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
9544284|NCT03079271|Other|open label|
9544285|NCT03078933|Active Comparator|Standard of Care|Standard of care for diabetic foot ulcer wound care
9544286|NCT03078933|Experimental|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
9544287|NCT03078933|Experimental|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
9544288|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
9544289|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
9544290|NCT03078985|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
9544291|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
9544292|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
9544293|NCT03079167|Experimental|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
9544294|NCT03079167|Placebo Comparator|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
9544295|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
9544296|NCT03079011|Experimental|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
9544297|NCT03079011|Experimental|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
9544298|NCT03079011|Experimental|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
9544299|NCT03079089|Other|Relapsed or refractory lymphoid hematological disorders|Patients in refractory or relapses with an indication of allo-HSC used the combination of an SET followed by the RIC with the PDLI
9544300|NCT03079258|Experimental|Exercise|Participants randomized to the exercise intervention group will be required to complete a 24-wk partially supervised exercise programme consisting of 3-4 sessions per week of 15 minutes progressing to 30 minutes over time.
9544301|NCT03079258|No Intervention|Control|Those randomized to the control group will continue with their standard care.
9544302|NCT03079128|Experimental|Intervention|Weight Watchers Intervention
9544303|NCT03079050|Experimental|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
9544304|NCT03079076|Active Comparator|thoracolumbar interfascial plane block|Bilateral ultrasound guided thoracolumbar interfascial plane block with 20 ml %0,25 bupivacaine
9544305|NCT03079076|Placebo Comparator|sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
9544306|NCT03079141|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
9544307|NCT03079141|Active Comparator|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
9616667|NCT02540512|Experimental|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
9616668|NCT02540304|Experimental|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
9616669|NCT02540304|No Intervention|Business as Usual|Business as usual
9616670|NCT02540239|Placebo Comparator|2L PEG|only used 2L PEG
9616671|NCT02540239|Experimental|Simethione+2L PEG|used 2L PEG+Simethione
9616672|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (< 30 days) >18 years old able to speak, read and write German, questionnaires
9616673|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (> 90 days) > 18 years old able to speak, read and write German, questionnaires
9616674|NCT02540343||test persons|no neck pain > 18 years old able to speak, read and write German, questionnaires
9616675|NCT02540395|Active Comparator|Group A: Standard of care|"Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines).~All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline"
9622113|NCT02518477|Experimental|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
9544308|NCT03079154|Experimental|Teacher-led MBCT course|Eight-session mindfulness-based cognitive therapy course, including an initial orientation session, led by a qualified mindfulness teacher working with the Sussex Mindfulness Centre, a part of the NHS Sussex Partnership Mental Health Trust.
9544309|NCT03079154|Active Comparator|Self-guided MBCT course|Mindfulness-based cognitive therapy course, after an initial information session, which is self-guided using the audiobook Mindfulness: A practical guide to finding peace in a frantic world by Mark Williams and Danny Penman (2011). It consists of eight substantive chapters that map on to the eight-session MBCT course taught by teachers to groups of students. Students will be asked to work through one chapter a week, thus matching the pace of the teacher-led intervention.
9544310|NCT03079154|No Intervention|Wait list control|Students in the wait list (control) arm do not receive any intervention for the same length of time as the experimental and active comparator arms of the intervention are taking place. Students are invited to complete the self-guided MBCT course after the end of the research project.
9544311|NCT03078998|Experimental|Juvenile idiopathic Arthritis|
9544312|NCT03078998|Experimental|Obstetric Brachial Plexus Palsy|
9544313|NCT03078998|Experimental|Cerebral Palsy|
9544314|NCT03079063|Experimental|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
9544315|NCT03079063|Active Comparator|Novoseven|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
9544316|NCT03079206|Experimental|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
9544317|NCT03079180|Experimental|Aged & strength training at 80% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~Training programs:~Frequency: 3 training sessions per week. Duration: 12 weeks. Intensity: 80% of one repetition maximum (1RM). The 1RM of the participants in each of the 3 exercises performed in the training program will be reviewed every 2 weeks during training. If 1RM increase, the training load will be adjusted accordingly.~Training exercises: A Warm-up will first be performed on a cycle ergometer during 10min. The training intervention will then consist in performing two sets on each one of the two exercises used for Patellar tendon stress: leg extension and leg press. To stress Achilles tendon, the subjects will perform four (4) sets using a calf raise machine. The subjects will perform 4 to 8 repetitions at 80% 1RM.~All training sessions will take place under appropriate supervision in UTC for the duration of the interventions according to the study design."
10040439|NCT01853358|Experimental|NK Cell infusion|"Cell collection~o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation~NK Cell selection~o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)~NK Cell ex-vivo activation~o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)~NK Cell infusion (60 to 90 days after transplantation)"
9544318|NCT03079180|Experimental|Aged & strength training at 55% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~The training program and training exercises in this group are the same as for the Aged & strength training at 80% 1RM arm except for the two following parameters.~Training intensity: Intensity of exercises will be 55% of one repetition maximum (1RM).~The subjects will perform 6 to 12 repetitions at 55% 1RM.~The two training programs (55% or 80% of 1RM) are designed to be equal in volume (resistance x repetitions x sets)."
10040440|NCT01853410|Experimental|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
9544319|NCT03079180|Experimental|Young & strength training at 55% 1RM|"Subjects: 20 subjects aged between 18 and 30 years~The training program and training exercises in this group are the same as for the Aged & strength training at 55% 1RM arm"
10040441|NCT01853423|Experimental|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
10040442|NCT01853436|Experimental|Single stage reconstructions|as defined for use in the Experimental arm
10040443|NCT01853436|Other|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
10040444|NCT01853449|Experimental|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
10040445|NCT01853449|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
10040446|NCT01853449|Active Comparator|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
10040447|NCT01853449|Placebo Comparator|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
10040448|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
9622114|NCT02518477|No Intervention|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
10040449|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
10040450|NCT01853501|Experimental|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
10040451|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
10040452|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
9544320|NCT03079232|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
9544321|NCT03079232|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
9544322|NCT03079037||Stimulation|Traditional deep brain stimulation
9544323|NCT03078920|Other|11 unilateral adult cochlear implant users|Speech Reception Threshold (SRT) measured with an adaptive test
9544324|NCT03079115|Active Comparator|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
9544325|NCT03079115|Other|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
9544326|NCT03078842|Active Comparator|Zinc-20|Zinc tablets, 20 mg per day
9544327|NCT03078842|Experimental|Zinc-10|Zinc tablets, 10 mg per day
9544328|NCT03078842|Experimental|Zinc-05|Zinc tablets, 5 mg per day
9544329|NCT03078712|Active Comparator|Peripheral Perfusion guided resuscitation|Resuscitation will be aimed at normalization of capillary refill time.
9544330|NCT03078712|Active Comparator|Lactate guided resuscitation|Resuscitation will be aimed at normalization or significant decrease in lactate levels.
9544331|NCT03078725|Active Comparator|Glyburide|hypoglycemic agent approved for treatment of GDMA2
9544332|NCT03078725|Active Comparator|Metformin|hypoglycemic agent approved for treatment of GDMA2
9544333|NCT03078803|Experimental|Fecal microbiota transplant|Transfer of healthy human gut bacteria
9544334|NCT03078803|Placebo Comparator|Placebo|Water
9544335|NCT03078738|Experimental|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 3 of OMT-28 (15, 30, 60 mg) Oral, healthy young male
9544336|NCT03078738|Experimental|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 3 of OMT-28 over 14 days (4, 12, 36 mg) Oral, healthy young male
9544337|NCT03078738|Experimental|OMT-28- Food Effect|Single dose of OMT-28 (4 mg) Oral, healthy young male
9544338|NCT03078738|Experimental|OMT-28-Gender|Single dose of OMT-28 (4 mg) Oral, healthy non-child bearing potential female
9544339|NCT03078738|Placebo Comparator|Placebo-SAD|Single dose levels 1 - 3 of matching placebo, Oral, healthy young male
9544340|NCT03078738|Placebo Comparator|Placebo MAD|Multiple dose levels 1 - 3 of matching placebo over 14 days Oral, healthy young male
9544341|NCT03078738|Placebo Comparator|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
9544342|NCT03078699|Experimental|stereotactic body radiation therapy|
9544343|NCT03078621|Experimental|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
9544344|NCT03078465|Experimental|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
9544345|NCT03078465|Active Comparator|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
9544346|NCT03078673|Experimental|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
9544347|NCT03078673|Experimental|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
9544348|NCT03078673|Experimental|Control group|Only regular training
9544349|NCT03078517|Active Comparator|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
9544350|NCT03078517|Experimental|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
9544351|NCT03078543|Other|ANTHEM™ PS Total Knee System implant|The ANTHEM™ PS Total Knee System will demonstrate non-inferiority of 10 year implant survivorship in patients undergoing total knee arthroplasty for osteoarthritis compared to reported literature
9544352|NCT03078530|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
9544353|NCT03078530|Experimental|Visbiome|Visbiome (probiotic mixture) is given to this group.
9544354|NCT03078530|Experimental|VSL #3|VSL #3 (probiotic mixture) is given to this group
9544355|NCT03078660|Experimental|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
9544356|NCT03078660|Active Comparator|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
9544357|NCT03078764|Experimental|Patient Arm using mHealth|Patients with uncontrolled type 2 diabetes
9544358|NCT03078764|Experimental|Community nurses|Nurses who receive mHealth report about patients in the patients' arm.
9544359|NCT03078452|Experimental|Arm I (biopsy using power drill)|Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
9544360|NCT03078452|Active Comparator|Arm II (biopsy using Jamshidi needle)|Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
9544361|NCT03078400|Experimental|Safety Phase|"Six to 12 subjects~Cohort 1 SPL-108 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles~Cohort 2 SPL-108 BID injection + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles"
9544362|NCT03078400|Experimental|Exploratory Expansion Phase|"Up to 12 subjects~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."
9544363|NCT03078777|Experimental|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
9544364|NCT03078777|Experimental|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
9544365|NCT03078374|Other|Reduced Anticoagulation|Reduced anticoagulation
9544366|NCT03078309|Experimental|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
10040453|NCT01853566|Experimental|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
10040454|NCT01853579|Experimental|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
9544367|NCT03078309|Experimental|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
9544368|NCT03078569|Experimental|testosterone gel|testosterone gel treatment group
9544369|NCT03078569|No Intervention|Control group|without testosterone treatment
9544370|NCT03078335|Experimental|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
9544371|NCT03078335|Active Comparator|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
9544372|NCT03078634|Active Comparator|Multi-Disciplinary clinic|
9544373|NCT03078634|Placebo Comparator|Standard Gastrointestinal clinic|
9544374|NCT03078257|Experimental|dual antiplatelet therapy|clopidogrel +aspirin
9544375|NCT03078257|Experimental|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
9544376|NCT03078257|Experimental|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
9544377|NCT03078257|Experimental|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
9544378|NCT03078257|Placebo Comparator|placebo|clopidogrel +aspirin +placebo
10040455|NCT01853579|Placebo Comparator|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
10040456|NCT01853657|Active Comparator|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
10040457|NCT01853657|No Intervention|Routine monitoring|Immunological and clinical monitoring
10040458|NCT01853670|Experimental|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:~These patients will have chemotherapy during the time of radiation treatment"
10040459|NCT01853670|Experimental|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:~These patients will have chemotherapy prior to other radiation treatment."
10040460|NCT01853683|Experimental|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
9544379|NCT03078686|Active Comparator|Control ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
9544380|NCT03078686|Experimental|Emulsification tSVF + PRP ARM 2|HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
9544381|NCT03078686|Experimental|Emulsification tSVF + PRP + cSVF ARM 3|tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
9544382|NCT03078686|Experimental|cSVF in Normal Saline IV ARM 4|cSVF + Normal Saline IV (500 cc) Infusion
9544383|NCT03078790|Experimental|meditation module|The patients in this arm will be offered the meditation/deep breathing module in the pre-operative area.
9544384|NCT03078322|Experimental|AV-101|L-4-chlorokynurenine 1440 mg daily for 14 days
9544385|NCT03078322|Placebo Comparator|Placebo|Placebo
9544386|NCT03078283|Experimental|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
9544387|NCT03078608|Experimental|Intervention arm|Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
9544388|NCT03078608|Active Comparator|Active control arm|Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
9544389|NCT03078608|Other|Wait list control arm|Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
9544390|NCT03078205|No Intervention|The control group|No Intervention
9544391|NCT03078205|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
9544392|NCT03078205|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
9544393|NCT03078296||Members of the AAGL|Physicians and other providers who are members of the AAGL.
9544394|NCT03078179|Experimental|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
9544395|NCT03078179|Placebo Comparator|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
9544396|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
9544397|NCT03078049||Sitagliptin|Patients take sitagliptin
9544398|NCT03078062|Active Comparator|Dexamethasone|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml. The study drug will be prepared by an independent assistant.
9544399|NCT03078062|Placebo Comparator|Normal Saline|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated. The infusion will be administered over 5 -10 minutes. The study drug will be prepared by an independent assistant.
9544400|NCT03077997|Experimental|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
9544401|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
9544402|NCT03078101|Experimental|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
9544403|NCT03078101|Placebo Comparator|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
9544404|NCT03078101|Experimental|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
9544405|NCT03078101|Placebo Comparator|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
9544406|NCT03078153|Experimental|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
9544407|NCT03078153|Experimental|Social Media Group|Provided social media support through a facebook group for 6 months
9544408|NCT03078153|No Intervention|Control|No intervention
9544409|NCT03078140|Active Comparator|Triferdine|Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery
9544410|NCT03078140|Active Comparator|Triferdine/Ferli-6|Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery
9544411|NCT03078114|Experimental|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
9544412|NCT03078114|Placebo Comparator|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
9544413|NCT03078088|Placebo Comparator|saline|normal saline
9544414|NCT03078088|Experimental|treatment|tham
9544415|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
9544416|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
9544417|NCT03077984|Experimental|the cohort of Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
9544418|NCT03077984|No Intervention|the cohort of western medicine treatment|The cohort of Western medicine treatment refers to the treatment of cerebrovascular disease prevention and cure guideline of China-related programmes, including anti-platelet aggregation, blood pressure,blood glucose,Blood Lipids lowering therapies.
9544419|NCT03077815|Other|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
9544420|NCT03077815|Other|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2~6) local press strength 50 mmHg at the upper arm
9544421|NCT03077945|Experimental|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
9544422|NCT03077945|Placebo Comparator|Control Condition|This group will complete control tasks, including viewing neutral videos.
9544423|NCT03077971|Experimental|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
9544424|NCT03077971|Experimental|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
9544425|NCT03077971|No Intervention|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
9544426|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
9662988|NCT04245865|Placebo Comparator|Arm B, standard treatment + placebo|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + placebo OR capecitabine + bevacizumab + placebo
9662989|NCT04244877|Experimental|Rifaximin|Rifaximin 550 mg by mouth twice daily for eight weeks.
9544427|NCT03077906||Existing gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who already had a disabling gastroœsophageal reflux resistant to medical treatment in pre-op, and lost it in post-op."
9544428|NCT03077906||De novo gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who developped gastroœsophageal reflux de novo."
9544429|NCT03077789|Experimental|TRABECULOTOMY|
9544430|NCT03077750|Experimental|VBP-245|VBP-245 Topical Gel Applied to Affected Area BID
9544431|NCT03077750|Placebo Comparator|Vehicle|Vehicle Gel Applied to Affected Area BID
9544432|NCT03077867|Experimental|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
9544433|NCT03077867|Experimental|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
9544434|NCT03077867|Experimental|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
9544435|NCT03077867|Active Comparator|control|anorganic bovine bone sinus floor augmentation with bone graft
9544436|NCT03077633|Active Comparator|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
9544437|NCT03077633|Placebo Comparator|Progesterone|Daily administration of vaginal progesterone (200mg tab)
9544438|NCT03077763|Active Comparator|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
9544439|NCT03077763|Active Comparator|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
9544440|NCT03077698|Experimental|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
9544441|NCT03077802|Experimental|Modified Seldinger technique, Experienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
9544442|NCT03077802|Active Comparator|Seldinger technique, Experienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
9544443|NCT03077802|Experimental|Modified Seldinger technique, Inexperienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
9544444|NCT03077802|Active Comparator|Seldinger technique, Inexperienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
9544445|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
9544446|NCT03077581|Active Comparator|Transevrsus abdominus plane block group|
9544447|NCT03077581|Active Comparator|Rectus sheath block group|
9544448|NCT03077581|Active Comparator|local infiltration group|
9544449|NCT03077854|Experimental|Functional Lung Avoidance-TRT|"Functional Lung Avoidance Thoracic Radiotherapy~The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable"
9544450|NCT03077854|Active Comparator|Standard-TRT|"Standard Thoracic Radiotherapy~The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging"
10040461|NCT01853683|Active Comparator|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
10040462|NCT01853709|Experimental|Multidisciplinary approach|"The multidisciplinary approach will include:~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
9544451|NCT03077828|Experimental|Treatment (pembrolizumab, etoposide, carboplatin, ifosfamide)|Patients receive pembrolizumab IV over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3.
9544452|NCT03077503|Experimental|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
9662990|NCT04215120|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
9544453|NCT03077503|Active Comparator|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
9544454|NCT03077529|Experimental|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
9544455|NCT03077529|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
9544456|NCT03077568|Experimental|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
9544457|NCT03077568|No Intervention|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
9544458|NCT03077516||Mobi-C|Prior recipient of Mobi-C Disc in IDE/Post Approval Study
9544459|NCT03077516||ACDF|Prior control subject in IDE/Post Approval Study
9544460|NCT03077477|Placebo Comparator|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);~SAD cohorts are defined as follows:~Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.~Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
9544461|NCT03077477|Placebo Comparator|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.~Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
9544462|NCT03077477|Active Comparator|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).~FE Crossover:~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
9544463|NCT03077555|Active Comparator|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
9544464|NCT03077555|Experimental|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
9544465|NCT03077464|Active Comparator|behavioral nutrition education|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory, for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included: 1) nutrition label literacy; 2) drinking water; 3) eating colors of the rainbow; 4) healthful snacks; 5) benefits of fruit and vegetable consumption; 6) moving more and sitting less; and 7) taking healthy habits home.
9544466|NCT03077464|Experimental|behavioral nutrition education plus skills|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included:1) nutrition label literacy;2) drinking water;3) eating colors of the rainbow;4) healthful snacks;5) benefits of fruit and vegetable consumption;6) moving more and sitting less;and 7) taking healthy habits home. Designed to differ from behavioral nutrition education condition by devoting at least 15 minutes of each session to an additional behavioral skills training component. The behavioral skills component was designed to bolster behavioral capability, healthy eating attitudes, self-efficacy, and proxy efficacy with activities such as snack preparation sessions, role-playing games, fruit and vegetable tasting, and playing games that promoted healthier dietary behaviors.
9544467|NCT03077451|Experimental|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
9544468|NCT03077399|Experimental|stroke|stroke patients, application of SCALA
9544469|NCT03077399|Experimental|control|patients without stroke, application of SCALA
9544470|NCT03077282|Experimental|group1|Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)
9544471|NCT03077282|Experimental|group2|Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)
9544472|NCT03077308||Rett Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 60 individuals with Rett syndrome.
9544473|NCT03077308||MECP2 Duplication Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with MECP2 Duplication syndrome.
9544474|NCT03077308||Rett-related disorders|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with CDKL5 syndrome and 14 individuals with FOXG1 syndrome.
9544475|NCT03077308||Controls|Auditory and Visual event-related potentials (ERP) and EEG in 60 Control individuals (30 males and 30 females).
9544476|NCT03077217|Active Comparator|the high-dose rifaximin|The high-dose rifaximin group was given rifaximin 1200 mg/day for 8 weeks.
9544477|NCT03077217|Active Comparator|the low-dose rifaximinl group|The low-dose rifaximin group was given rifaximin 800 mg/day for 8 weeks.
9544478|NCT03077217|Placebo Comparator|the control group|The control group didn't receive rifaximin treatment
9544479|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
9544480|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
9544481|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
9544482|NCT03077113|Other|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
9544483|NCT03077230|Experimental|Pre/Post Test of a Lung Cancer Screening Decision Aid|
9544484|NCT03077321|Active Comparator|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
9544485|NCT03077321|Experimental|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
9544486|NCT03077321|No Intervention|Control|Wait list control
9544487|NCT03077373|Experimental|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
9544488|NCT03077373|No Intervention|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
9544489|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
9544490|NCT03077386|Experimental|ENCOMPASS program|Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
9544491|NCT03077386|No Intervention|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
9544492|NCT03076957|Experimental|Treat Regimen|CKD-516(investigational Drug) Irinotecan
9544493|NCT03077360|Experimental|Weight loss only|
9544494|NCT03077360|Experimental|Exercise Only|
9544495|NCT03077360|No Intervention|Delayed Intervention Control|
9544496|NCT03077295|Experimental|High Fibre to High-Protein (HF-HP)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HF meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HP meals for 4 weeks"
9544497|NCT03077295|Experimental|High Protein to High-Fibre (HP-HF)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HP meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HF meals for 4 weeks"
9544498|NCT03077178|Experimental|Prospective cohort|Geriatric assessment
9616676|NCT02540395|Experimental|"Group B: Low Immunosuppression regimen"|"(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant).~In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline."
9616677|NCT02540278|Experimental|Treatment|Received the 11 lesson Positive Prevention Curriculum
9616678|NCT02540278|No Intervention|Control|Did not receive any sex-related instruction
9616679|NCT02540317|Experimental|Active treatment, Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
9616680|NCT02540317|No Intervention|Waiting list control|The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
9616681|NCT02540382|Experimental|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
9616682|NCT02540382|Other|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
9616683|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
9616684|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
9544499|NCT03077087|Experimental|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
9544500|NCT03077347|Experimental|Experimental Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
9544501|NCT03077347|Placebo Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
9544502|NCT03077139|Experimental|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
9544503|NCT03077126|Other|Pre-surgery Ultrasound|Aixplorer® ShearWave Elastography (SWE™) Ultrasound. Participants will undergo ultrasound prep with Fleet Enema and ultrasound procedure at their pre-op visit one to two weeks before their standard of care prostatectomy.
9544504|NCT03076944|Active Comparator|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
9544505|NCT03076944|Active Comparator|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
9544506|NCT03076944|Active Comparator|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
9544507|NCT03077035|Experimental|glass ionomer sealant|
9544508|NCT03077035|Active Comparator|resin-based sealant|
9544509|NCT03076931|Experimental|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
9544510|NCT03076931|Experimental|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
9544511|NCT03077074|Experimental|Low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
9544512|NCT03077009|Experimental|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
9544513|NCT03076918|Active Comparator|Conventional PDT|Aktilite® Galderma
9544514|NCT03076918|Experimental|FLEXITHERALIGHT PDT|Light Emitting Textile Device
9544515|NCT03076853||Patients with Pharmaceutical Record|
9544516|NCT03076905|Experimental|IV drug|AUC0-t of single intravenous dose of F901318
9544517|NCT03076892|Active Comparator|Conventional PDT|Aktilite® Galderma
9544518|NCT03076892|Experimental|PHOS ISTOS PDT|Light Emitting textile device
9544519|NCT03076671|No Intervention|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
9544520|NCT03076671|Experimental|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
9544521|NCT03076671|Experimental|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
9544522|NCT03077048|No Intervention|Low protein diet|Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
9544523|NCT03077048|Experimental|Supplemented low protein diet|Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
9544524|NCT03076879|Experimental|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
9544525|NCT03076879|No Intervention|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
9544526|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
9544527|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
9544528|NCT03076801|Experimental|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
9544529|NCT03076801|No Intervention|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
9544530|NCT03076645|Experimental|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
9544531|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
9544532|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
9544533|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
9544534|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
9544535|NCT03076658|Other|asymptomatic EOS Imaging|patients that qualify for study and EOS imaging to analyze spino-pelvic parameters
9544536|NCT03076580||cardiomyopathy|Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
9544537|NCT03076580||disease control|Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
9544538|NCT03076580||healthy control|Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
9544539|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
9544540|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
9544541|NCT03076762|Experimental|Intravesical suburothelial injection|Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
9544542|NCT03076762|Active Comparator|Intravesical trigonal injection|Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
9544543|NCT03076684|Experimental|low-fructose diet|Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
9544544|NCT03076684|Experimental|allopurinol treatment|Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
9544545|NCT03076684|No Intervention|control arm|After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
9544546|NCT03076840|Active Comparator|Kinesio tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip Y shape of (Kinesio Tex® Tape 5cm) insertion to origin technique to relieve the hamstring tightness while the muscle in stretched position for 15 second (hip flexion and knee extension and then application of the tape) with 25% stretch of the tape
9544547|NCT03076840|Sham Comparator|sham tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip I shape of (Kinesio Tex® Tape 5cm) with no stretch in the hamstring musculature and the tape applied perpendicular over the upper third of the hamstring muscle while the muscle in stretched position
9544548|NCT03076840|No Intervention|control group|The student in this group had no treatment in the same position of the previous groups (the hamstring muscle maintained in a stretching position for 15 second)
9544549|NCT03076567||case|Stomach cancer cases from two previously conducted studies in China
9544550|NCT03076567||control|Controls from two previously conducted studies in China
10040463|NCT01853709|Active Comparator|Conventional approach|"The conventional approach will include:~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
9544551|NCT03076827|Experimental|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
9544552|NCT03076827|Experimental|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
9544553|NCT03076632|Active Comparator|Non-disabled volunteers|"Volunteers without neurological injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
9544554|NCT03076632|Active Comparator|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
9544555|NCT03076632|Active Comparator|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
9544556|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
9544557|NCT03076736|Active Comparator|Resource pack|Aphasia resource pack
9544558|NCT03076736|Experimental|Singing group + resource pack|Singing group + Aphasia resource pack
9544559|NCT03076489|Experimental|high consumption habits|high consumption habits of fatty and sugary foods
9544560|NCT03076489|Experimental|low consumption habits|low consumption habits of fatty and sugary foods
9544561|NCT03076528|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive ankle & foot exercise program (game-based exercise) during hemo-dialysis, approximately 30 minutes, twice per week and for 4 weeks.
9544562|NCT03076528|Active Comparator|Non-technology foot and ankle exercise program|Subjects will be receiving non-technology foot and ankle exercise program during hemodialysis, approximately 30 minutes, twice per week and for 4 weeks.
9544563|NCT03076541||patients with restless legs syndrome|
9544564|NCT03076424||1|Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.
9544565|NCT03076424||2|Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.
9544566|NCT03076424||3|Normal weight lean controls without Type 2 Diabetes Mellitus.
9544567|NCT03076463|Experimental|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
9544568|NCT03076463|No Intervention|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
9544569|NCT03076151|Experimental|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
9544570|NCT03076450|Active Comparator|Maximum Oxygenation|Using PVC to set the initial peep, check ABG real-time, and according to PaO2+PaCO2≥400mmHg whether or not to adjust maintain PEEP.
9544571|NCT03076450|Experimental|Lung Ultrasound Re-aeration Score|Combine POC-LUS with PVC in set the initial peep, and then dynamic record LUS-RAS to feedback regulate PEEP.
9544572|NCT03076138|Experimental|Test group|Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)
9544573|NCT03076086|Experimental|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
9544574|NCT03076112|Experimental|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
9544575|NCT03076112|Active Comparator|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
9544576|NCT03076125|Experimental|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
9544577|NCT03076125|Sham Comparator|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
9544578|NCT03076034|Experimental|Post-menopausal women|We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
9544579|NCT03076034|Experimental|Males over 50 years|We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
9544580|NCT03076047||end tidal CO2 (ETCO2) monitoring|We will continuously record capnography data from the patients while they are in the post-anesthesia care unit (PACU). Study personnel will visit each patient while the patient is in the PACU to promote compliance with continuous CO2 monitoring.
9544581|NCT03076294|Experimental|MT after rTMS group|High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
9616685|NCT02540187||haemophilia A|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
10040464|NCT01853735||bowel injury, NPO|Patients with bowel injury who remain nil-per-os (fed nothing)
10040465|NCT01853735||bowel injury, EN|Patients with bowel injury who are fed by enteral nutrition (EN)
9544582|NCT03076294|Experimental|rTMS after MT group|Patients will be submitted to 45 minutes of manual therapy protocol. After that, high frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT).
9544583|NCT03076294|Sham Comparator|Control group|In this group, the order of interventions will be randomized. Therefore, the volunteer can start with manual therapy or sham TMS. In manual therapy, patients will be submitted to 45 minutes of a protocol. In addition, with regard to sham TMS, the same parameters will be used, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation.
9544584|NCT03076268|Experimental|Treatment Group|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings. This curriculum is delivered in Spanish.
9544585|NCT03076268|No Intervention|Control Group|The investigators will deliver a Nutrition Curriculum to 45Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.This curriculum is delivered in Spanish.
9544586|NCT03076203|Experimental|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
9544587|NCT03076255|Experimental|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
9544588|NCT03076177|Experimental|Kinesio taping group|Participants receiving kinesio taping application
9544589|NCT03076177|Sham Comparator|Non specific taping|Participants receiving non specific taping application
9544590|NCT03076320|Experimental|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency an duration: topically applied every 12 hours for 6 months."
9544591|NCT03076320|Active Comparator|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 month"
9544592|NCT03076216|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of Care chemotherapy either gemcitabine or gemcitabine + Abraxane
9544593|NCT03076281|Experimental|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
9544594|NCT03076281|Experimental|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
9544595|NCT03076281|Experimental|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
9544596|NCT03076372|Experimental|MM-310 monotherapy|MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
9544597|NCT03076021|Other|Adolescents|dextromethorphan pre- and post isotretinoin
9544598|NCT03076307|Experimental|Parkinson's disease|
9544599|NCT03076307|Active Comparator|Control group|
9544600|NCT03076060|Experimental|Migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of VLCKD by meal replacements poor in fats and carbohydrates."
9544601|NCT03076060|Sham Comparator|Sham diet migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of non-ketogenic VLCD by meal replacements poor in fats and proteins."
9544602|NCT03076229|Experimental|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
9544603|NCT03076229|Experimental|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
9544604|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
9544605|NCT03076073|No Intervention|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
9544606|NCT03076073|Active Comparator|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
9544607|NCT03076437|Experimental|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.~Interventions:~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
9544608|NCT03075943|Experimental|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
9544609|NCT03075943|Placebo Comparator|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
9544610|NCT03075748|Experimental|Primary study|Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
9544611|NCT03075748|Experimental|Expanded selection|Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
9544612|NCT03075787||patients with obstructive sleep apneas|
9544613|NCT03076099|Experimental|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
9544614|NCT03076099|Placebo Comparator|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
9544615|NCT03075657|Active Comparator|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
9544616|NCT03075657|Experimental|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
9544617|NCT03075657|Active Comparator|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
9544618|NCT03075657|Experimental|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
9544619|NCT03075683|Experimental|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
9544620|NCT03075683|Active Comparator|Applied relaxation|Internet-based applied relaxation
9544621|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
9544622|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
9544623|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
9544624|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
9544625|NCT03075813|Experimental|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
9544626|NCT03075813|No Intervention|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
9544627|NCT03075800|No Intervention|Assertive Community Treatment (ACT) - Only|ACT is a multidisciplinary, team-based approach to providing a range of treatment, rehabilitation, and support services to high-need, high-risk people with severe mental illness who tend not to use clinic-based services; most services are provided on an outreach basis (e.g., in the person's home) and services are available 24 /7(27).
9544628|NCT03075800|Experimental|Assertive Community Treatment+Illness Management and Recovery|IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
9544629|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
9544630|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
9544631|NCT03075995|Experimental|lapatinib administered with hight-fat breakfast|
9544632|NCT03075956|Experimental|5 mg E4 single-dose|Group A: a single 5 mg E4 dose will be administered under fasted conditions during period 1.
9544633|NCT03075956|Experimental|15 mg E4 single-dose|Group B: a single 15 mg E4 dose will be administered under fasted conditions during period 1.
9544634|NCT03075956|Experimental|45 mg E4 single-dose|Group C: a single 45 mg E4 dose will be administered under fasted conditions during Period 1.
9544635|NCT03075956|Experimental|15 mg E4 multiple-dose|15 mg E4 dose will be administered once daily for 14 consecutive days during Period 2.
9544636|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
9544637|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
9544638|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
9544639|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
9544640|NCT03075488|Active Comparator|Conventional landmark-guided technique|In this arm spinal anesthesia will be performed by using conventional cutaneous landmarks
9662991|NCT04215120|Experimental|Epoetin Injection|Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
9544641|NCT03075488|Experimental|Accuro device guided technique|In this arm spinal anesthesia will be performed only after having detected the intralaminar space, the mid-line, the depth and the orientation for spinal needle insertion with pre-procedural scan performed with Accuro device
9544642|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
9544643|NCT03075722|Experimental|Saturn nasal mask|Participants to use nasal mask in-home for 7 ± 3 days
9544644|NCT03075514|Active Comparator|Modified ketogenic diet (MKD)|MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day).
9544645|NCT03075514|Active Comparator|Medium chain triglyceride (MCT) diet|MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day).
9544646|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
9544647|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
9544648|NCT03075605||Subjects with previous attack|Subjects with previous attack
9544649|NCT03075605||Controls|Controls
9544650|NCT03075670|Experimental|N9-GP|
9544651|NCT03075670|Active Comparator|ALPROLIX®|
9544652|NCT03075540|Other|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
9544653|NCT03075358|Experimental|Lidocaine spray|
9544654|NCT03075358|Sham Comparator|Normal saline spray|
9544655|NCT03075358|No Intervention|No spray|
9544656|NCT03075397|Other|HIV-1 infected patients|Blood sample and sperm sample are collected
9544657|NCT03075319|Experimental|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
9544658|NCT03075319|Active Comparator|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
9544659|NCT03075332|Experimental|protocol with physical exercise|Both groups underwent a combined training intervention consisting of aerobic and resisted exercises in the same training session
9544660|NCT03075475|Experimental|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
9544661|NCT03075475|No Intervention|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
10040466|NCT01853735||no bowel injury, NPO|Patients without bowl injury who remain nil-per-os (fed nothing)
10040467|NCT01853735||no bowel injury, EN|Patient without bowl injury who are fed by enteral nutrition (EN)
10040468|NCT01853761|Experimental|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
10040469|NCT01853761|Experimental|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
10040470|NCT01853761|Experimental|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
9616686|NCT02540187||Haemophilia B|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
9616687|NCT02540135|Experimental|Arm A|Flourescein plus intraoperative MRI
9616688|NCT02540135|Active Comparator|Arm B|intraoperative MRI alone
10040471|NCT01853761|Experimental|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
10040472|NCT01853761|Placebo Comparator|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
9544662|NCT03075592||ERCP candidates|ERCP candidates
9544663|NCT03075371|Active Comparator|intragastric glucose administration|
9544664|NCT03075371|Placebo Comparator|intragastric water administration|
9544665|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
9544666|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
9544667|NCT03075306|No Intervention|usual care|usual care and materials on healthy weight
9544668|NCT03075306|Experimental|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
9544669|NCT03075345|Active Comparator|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
9544670|NCT03075345|Experimental|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
9544671|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
9544672|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
9544673|NCT03075280|Experimental|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
9544674|NCT03075280|No Intervention|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
9544675|NCT03075189|Experimental|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~Diet registration and testing at baseline, discharge and follow-up."
9544676|NCT03075189|No Intervention|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Diet registration and testing at baseline, discharge and follow-up."
9544677|NCT03075436|Experimental|Enhanced demand-side sanitation, hygiene|The intervention group will receive a package of enhanced, demand-side sanitation and hygiene interventions that are informed by formative research and facilitated by local government and Emory Ethiopia partners.
9544678|NCT03075436|Active Comparator|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
9544679|NCT03075124|Experimental|External Counter Pulsation group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
9544680|NCT03075124|No Intervention|Control group|Guideline-driven standard medical treatment
9544681|NCT03075098|Experimental|colposcopy of intraepithelial carcinoma|Digital colposcope will be used to detect the swede score of the lesion
9544682|NCT03075033|Active Comparator|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
9544683|NCT03075033|Active Comparator|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
9544684|NCT03075072|Active Comparator|Whole Brain Radiation|"MRI will be performed prior to radiation is administered~A hippocampal sparing approach will be used when possible~Dose will be 30 Gy in 10 fractions"
9544685|NCT03075072|Experimental|Stereotactic Radiation (SRS)|"MRI will be performed prior to radiation is administered~Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
9544686|NCT03075059|Experimental|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
9544687|NCT03075059|No Intervention|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
9544688|NCT03074942|Experimental|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
9544689|NCT03074968|Placebo Comparator|control|normal saline
9544690|NCT03074968|Active Comparator|benzydamine hydrochloride|Benzydamine Hydrochloride
9544691|NCT03075137|Experimental|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
9544692|NCT03075137|No Intervention|Control group|Guideline-driven standard medical treatment
9616689|NCT02540174|Experimental|Arm A|integrated addiction treatment program
10040473|NCT01853787|Experimental|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
9544693|NCT03074981|Experimental|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
9544694|NCT03075020|Active Comparator|Active carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration 22%
9544695|NCT03075020|Placebo Comparator|Air|
9544696|NCT03075176|Active Comparator|Wavefront optimized LASIK|
9544697|NCT03075176|Active Comparator|Wavefront optimized Photorefractive Keratectomy|
9544698|NCT03075176|Active Comparator|Topography-guided LASIK|
9544699|NCT03075176|Active Comparator|Topography-guided Photorefractive Keratectomy|
9544700|NCT03074994|Experimental|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
9544701|NCT03074994|Experimental|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
9544702|NCT03074994|No Intervention|Control group|Don't receive any route of TXA
9544703|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
10040474|NCT01853787|Active Comparator|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
9544704|NCT03074864|Experimental|EGFR-mutant IIIA/IIIB NSCLC|Erlotinib Hydrochloride 150mg daily intercalated with radiotherapy
9544705|NCT03074955|Active Comparator|Control|"leg wrapping without tension & maintain supine position~Apply elastic bandages to both legs without tension.~Maintain supine position after injecting propofol.~After 3 minutes from propofol injection, remove elastic bandages~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
9544706|NCT03074955|Experimental|Trendelenburg only|"leg wrapping without tension & apply Trendelenburg position~Apply elastic bandages to both legs without tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
9544707|NCT03074955|Experimental|Trendelenburg & leg wrapping|"leg wrapping with tension & apply Trendelenburg position~Apply elastic bandages to both legs with tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
9544708|NCT03074877|Experimental|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
9544709|NCT03074877|Experimental|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
9544710|NCT03074877|No Intervention|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
9544711|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
9544712|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
9544713|NCT03075241|Experimental|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
9544714|NCT03075241|Experimental|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
9544715|NCT03075241|Placebo Comparator|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
9544716|NCT03074916||DIP arthroplasty|
9544717|NCT03074916||DIP arthrodesis|
10040475|NCT01853800|Experimental|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
9616690|NCT02540174|Other|Arm B|standard of care
9499866|NCT03453944|Sham Comparator|VF03-K sham stimulation|Sham stimulation applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Sham stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
9499867|NCT03453918|Experimental|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
9499868|NCT03453918|Experimental|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
9499869|NCT03453905|Experimental|CTFEA|Decision on preventive surgery vs follow-up will be based on expert judgement, Mirels' score and CTFEA
9499870|NCT03453905|Other|Mirels|Decision on preventive surgery vs follow-up will be based on expert judgement and Mirels' score
9499871|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
9499872|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
9499873|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
9499874|NCT03453853|Experimental|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
9499875|NCT03453840|Active Comparator|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
9499876|NCT03453840|Experimental|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
9499877|NCT03453840|Active Comparator|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
9499878|NCT03453840|Experimental|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
9499879|NCT03453827||PEX|Patients after Cataract surgery with PES
9499880|NCT03453827||Control|Patients after Cataract surgery without PES
9499881|NCT03453814|Experimental|Interventional|Music therapy.
9499882|NCT03453814|No Intervention|Comparison|No music therapy.
9499883|NCT03453801|Experimental|MZ twins 2-5 yo|Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.
9499884|NCT03453801|Experimental|Non-twins 6 mo-10 yo|Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.
9499885|NCT03453801|Experimental|Non-twins 6-12 mo Flu/MMRV Naïve|Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
9499886|NCT03453788|Experimental|Intervention group|Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
10040476|NCT01853800|Experimental|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
9544718|NCT03074929|Experimental|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
9544719|NCT03074929|No Intervention|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
9544720|NCT03074851|Experimental|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
9544721|NCT03074851|Other|informational intervention|to give 1 month informational intervention
9544722|NCT03074695|Experimental|Dural Puncture Epidural (DPE)|Women who have analgesia initiated with a DPE technique
9544723|NCT03074695|Experimental|Standard Epidural (EPL)|Women who have analgesia initiated with an epidural technique
9544724|NCT03074721|Other|PCI with PCI Suite Software|
9544725|NCT03074721|Other|conventional PCI|
9544726|NCT03074825|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
9544727|NCT03074890|Experimental|Intervention (cases)|Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
9544728|NCT03074890|No Intervention|No Intervention (control))|all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply
9544729|NCT03074773|Active Comparator|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
9544730|NCT03074773|Active Comparator|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
9544731|NCT03074734|Other|Exposure to secondhand tobacco smoke|Exposure to secondhand tobacco smoke in outside smoking areas
9544732|NCT03074760||Contaminated acequias|
9544733|NCT03074760||Non-contaminated acequias|
9544734|NCT03074799|Active Comparator|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
9544735|NCT03074799|Experimental|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
9544736|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
9544737|NCT03074838|Experimental|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
9544738|NCT03074838|Active Comparator|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
9544739|NCT03074786|Experimental|Vaginal Matrix Ring|Dapivirine vaginal ring containing 25 mg of dapivirine to be replaced each month.
9544740|NCT03074786|Experimental|Oral Emtricitanbine/Tenofovir Disoproxil|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to be taken orally daily
9544741|NCT03074591|Active Comparator|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
9544742|NCT03074591|Placebo Comparator|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
9544743|NCT03074617|Experimental|LTE field|
9544744|NCT03074617|Sham Comparator|sham field|
9544745|NCT03074656|Experimental|Therapeutic drug monitoring|Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies
9544746|NCT03074656|Active Comparator|Standard care|Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies
9662992|NCT04175392|Active Comparator|Treatment Group: Probiotic|Probiotic 1 billion units Supplement Once Daily
9662993|NCT04175392|Placebo Comparator|Control Group: Placebo|Placebo Capsule Once Daily
10040477|NCT01853800|Experimental|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
9544747|NCT03074669|Experimental|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
9544748|NCT03074669|No Intervention|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
9544749|NCT03074552|Experimental|Probiotics|The probiotic preparation [ LactoLevure] will consist a combination of four probiotics.
9544750|NCT03074552|Placebo Comparator|Placebo|Placebo will consist of identical capsules of powdered glucose polymer, and they will be constructed by the same industry that manufactures the probiotics capsules.
9544751|NCT03074565|Experimental|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
9544752|NCT03074565|Active Comparator|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
9544753|NCT03074578|Experimental|Night-time desensitization|Watching a video containing verbal and visual violence in the evening, and again in the next morning
9544754|NCT03074578|Sham Comparator|Daytime desensitization|Watching a video containing verbal and visual non-violence in the morning, and then again the evening of the same day
9544755|NCT03074461|Experimental|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
9544756|NCT03074461|Active Comparator|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
9544757|NCT03074474|Other|OviTex Permanent 1S|All subjects included in this post-market study will have a ventral hernia repaired with OviTex Permanent 1S reinforced bioscaffold.
9544758|NCT03074396|Other|before and after use of program|one arm (10 patients and 4 physicians) before and after use of dialysisNet (for doctors) and Avatar Beans (for patients)
9544760|NCT03074383|Experimental|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
9544761|NCT03074383|Active Comparator|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
9544762|NCT03074422|Experimental|Hypsnosis|During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
9544763|NCT03074422|No Intervention|Control|Local anesthesia after clear and complete information of the procedure given the day prior to the surgery. In order to determine the pain perceived during the procedure, a VAS questionnaire will be used, directly after the frame disposal. The rest of the procédure is similar to the hypnosis group.
9544764|NCT03074448|Active Comparator|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
9544765|NCT03074448|Experimental|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
9544766|NCT03074435|No Intervention|Control|No intervention
9544767|NCT03074435|Experimental|insecticidal paint|The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
9544768|NCT03074435|Experimental|Larvicides|The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
9544769|NCT03074435|Experimental|Ivermectin|This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
9544770|NCT03074435|Experimental|Information, Education, Communication|After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
9544771|NCT03074604|Experimental|aortic no-touch OPCABG|aortic no-touch OPCABG
9544772|NCT03074604|Experimental|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
9544773|NCT03074604|Active Comparator|OPCABG with partial clamp|OPCABG with partial clamp
9662994|NCT04156126||Infertility - Frozen Embryo Transfer|Adult females undergoing a frozen embryo transfer
9544774|NCT03074305|Active Comparator|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.~Residual stenosis after lesion preparation : %DS <20%~Delivery time : < 30 seconds~Total inflation time : > at least 1 minute~Previous BVS : DEB diameter ratio : > 1.0:1~Maximum inflation pressure : at least above nominal pressure of DEB"
9544775|NCT03074305|Active Comparator|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
9544776|NCT03074344|Experimental|XLHA+CoQ10|XLHA+CoQ10 eye drop administered four times a day for 12 weeks (90 days).
9544777|NCT03074344|Active Comparator|Hyaluronic acid (HA)|Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days).
9544778|NCT03074292|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
9544779|NCT03074292|Active Comparator|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
9544780|NCT03074292|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
9544781|NCT03074526|Active Comparator|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
9544782|NCT03074526|Active Comparator|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
9544783|NCT03074526|Placebo Comparator|4mL Saline Placebo|Normal Saline
9544784|NCT03074266||Blood coagulation test 1|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct coagulation tests using GEM Hemochron 100 during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention in this study. The interventional procedure (described above) is standard of care and all results of blood coagulation testing using GEM Hemochron 100 performed in this study are not used to influence that care."
9544785|NCT03074266||Blood coagulation test 2|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct duplicate coagulation tests using Signature Elite during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention conducted in the course of this study. The interventional procedure (described above) is standard of care. The only difference in standard of care is that the blood coagulation test is run in duplicate."
9544786|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
9544787|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
9544788|NCT03074097|Active Comparator|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
9544789|NCT03074097|No Intervention|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
9499887|NCT03453788|No Intervention|Reference group|Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
9499888|NCT03453775|Active Comparator|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
9544790|NCT03074058|Experimental|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
9544791|NCT03074058|Active Comparator|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
9544792|NCT03074123|Experimental|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
9544793|NCT03074071|Active Comparator|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
9544794|NCT03074071|Active Comparator|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
9544795|NCT03073928|Active Comparator|Interscalene Block|"Receives interscalene block with 15mL of ropivacaine 0.5% at the level of C6. A total of 15mL will be injected with repeated aspirations to rule out intravascular placement of the needle tip. Once this is done, the needle tip will be moved to the lateral edge of sternocleidomastoid muscle and additional 3mL of 0.5% ropivacaine will be injected between the deep fascia of the sternocleidomastoid and deep investing fascia of the neck (superficial cervical plexus block SCP).~We will administer injection of saline similar to experimental group to blind the patient"
9544796|NCT03073928|Experimental|Paracoracoid SPB|Receives paracoracoid subscapularis plane block with the ultrasound. Using a 50mm 22G block needle 15ml of 0.5% Ropivacaine will be deposited anterior to the fascia of subscapularis muscle after eliciting a motor response with 0.6mA current delivered through the needle. Following this, superficial cervical plexus block will be done using 3mL of 0.5% ropivacaine similar to group 1.
9544797|NCT03073993|Active Comparator|Nasogastric|Feeding tube insertion in nasogastric group
9544798|NCT03073993|Active Comparator|Orogastric|Feeding tube insertion in orogastric group
9544799|NCT03074032|Experimental|ONC1-0013B 40 mg|ONC1-0013B 40 mg per os daily
9544800|NCT03074032|Experimental|ONC1-0013B 80 mg|ONC1-0013B 80 mg per os daily
9544801|NCT03074032|Experimental|ONC1-0013B 160 mg|ONC1-0013B 160 mg per os daily
9544802|NCT03074032|Experimental|ONC1-0013B 320 mg|ONC1-0013B 320 mg per os daily
9544803|NCT03074019|Experimental|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
9544804|NCT03074019|Experimental|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
9544805|NCT03074019|Placebo Comparator|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
9544806|NCT03074006|Experimental|low dose|
9544807|NCT03074006|Experimental|high dose|
9544808|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
9544809|NCT03074136|Experimental|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
9544810|NCT03074136|Experimental|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
9544811|NCT03074136|Experimental|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
9544812|NCT03074110|Active Comparator|Isocapnic hyperventilation|After end of surgery, hyperventilation and administration of a small, precalculated amount of CO2 into the breathing circuit will be performed.
9544813|NCT03074110|No Intervention|Standard procedure|After end of surgery, patients will be subdued to a standard weaning procedure.
9544814|NCT03073850|Experimental|Antiplatelet therapy|acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
9544815|NCT03073850|Experimental|Low-dose OAC therapy|Edoxaban of 30mg (Reduced dose of 15mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
9544816|NCT03073850|Active Comparator|Standard-dose OAC therapy|Edoxaban of 60mg (Reduced dose of 30mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
9544817|NCT03074201|Experimental|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
9544818|NCT03073863|Active Comparator|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
9544819|NCT03073863|Experimental|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
9544820|NCT03073889|Experimental|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
9544821|NCT03073889|Active Comparator|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
9544822|NCT03073889|No Intervention|Control|the control group has no treatment, n=15
9544823|NCT03074188||pre-dialysis patients|
9544824|NCT03074188||end stage renal disease|
9544825|NCT03073902||Observed group|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
9544826|NCT03073954|Active Comparator|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
9544827|NCT03073954|Sham Comparator|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
9544828|NCT03074175|Experimental|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
9544829|NCT03074175|Experimental|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
9544830|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
9544831|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
9544832|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
9544833|NCT03073772|No Intervention|Continued multimodal rehabilitation|No addition of extra training in this group. Only ordinary continued multimodal rehabilitation.
9544834|NCT03073772|Active Comparator|Computer-based cognitive training|This arm also consisted of continued multimodal rehabilitation.
9544835|NCT03073772|Active Comparator|Physical fitness training|This arm also consisted of continued multimodal rehabilitation.
10040478|NCT01853800|Experimental|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
9544836|NCT03073746|Experimental|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
9544837|NCT03073746|Experimental|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
9544838|NCT03073746|No Intervention|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
9544839|NCT03073512|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
9486933|NCT01192880|Experimental|Bitopertin 10 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 10 milligrams (mg) tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 10 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50 percent (%) of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
9486934|NCT01192880|Experimental|Bitopertin 20 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 20 mg tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 20 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50% of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 20 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
9486935|NCT01192880|Placebo Comparator|Placebo|Treatment Period 1: Participants will receive bitopertin matching placebo tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin matching placebo tablet orally once daily for 32 weeks (up to Study Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and will be switched to (in blinded manner) bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
9486936|NCT01192867|Experimental|RO4917838 20 milligrams (mg)|Participants, on stable antipsychotics, will receive RO4917838 orally at 20 mg once daily (QD) up to 56 weeks followed by an optional treatment extension for up to 3 years.
9486937|NCT01192867|Experimental|RO4917838 10 mg|Participants, on stable antipsychotics, will receive RO4917838 orally at 10 mg QD up to 56 weeks followed by an optional treatment extension for up to 3 years.
9486938|NCT01192867|Placebo Comparator|Placebo|Participants, on stable antipsychotics, will receive RO4917838 matching placebo orally QD up to 56 weeks.
9486939|NCT01192035|Active Comparator|NNRTI|
9486940|NCT01192035|Active Comparator|Protease inhibitor|
9486941|NCT01190644|Experimental|ACE 011 (Sotatercept)|35mg dose of ACE 011 will be given by subcutaneous injection on Day 1. Up to two additional doses of ACE 011 will be given every 42 days during the treatment period (Day 43 and Day 85)
9486942|NCT01189396|Experimental|T|Four doses of A006 taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
9486943|NCT01189396|Active Comparator|R|Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
9486944|NCT01189396|Placebo Comparator|P|Four doses of Placebo DPI taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 0 mcg.
9486945|NCT01188187|Experimental|Custirsen, Docetaxel, Prednisone|"Three doses of 640 mg custirsen administered intravenously (IV) as a loading dose between Days -9 to -1. Custirsen, 640 mg, given IV weekly on Days 1, 8, and 15 of each 21-day cycle. Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
9486946|NCT01188187|Active Comparator|Docetaxel, Prednisone|"Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
9486947|NCT01187836|Experimental|TRV120027|
9486948|NCT01187836|Placebo Comparator|Placebo|
9486949|NCT01186991|Experimental|Onartuzumab + Bevacizumab + Paclitaxel|Participants will receive treatment with onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable drug-related toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
9486950|NCT01186991|Experimental|Onartuzumab + Placebo + Paclitaxel|Participants will receive treatment with onartuzumab, placebo matching to bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
9486951|NCT01186991|Active Comparator|Placebo + Bevacizumab + Paclitaxel|Participants will receive treatment with placebo matching to onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
9486952|NCT01186861|Experimental|Arm A: OSI-906 plus erlotinib|OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1
9486953|NCT01186861|Placebo Comparator|Arm B: placebo plus erlotinib|placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1
9486954|NCT01183949|Experimental|Treatment|Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
9486955|NCT01183637|Experimental|Treatment|Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
9486956|NCT01183637|Active Comparator|Control|Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
9486957|NCT01181622|Experimental|denufosol tetrasodium Inhalation Solution|
9486958|NCT01181622|Placebo Comparator|Placebo|
9486959|NCT01180634|Experimental|1|Inhaled MP-376 (Aeroquin)
9486960|NCT01180634|Placebo Comparator|2|Placebo
9486961|NCT01180465|Experimental|LIPO-102 High|
9486962|NCT01180465|Experimental|LIPO-102, Low|
9486963|NCT01180465|Placebo Comparator|LIPO-102; Placebo|
9486964|NCT01177397|Experimental|CC-223|All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.
9486965|NCT01175785|Experimental|Treatment (chemo, radiation, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI twice daily on days -4 to -1. Patients undergo unmanipulated single- or double-unit umbilical cord blood transplantation on day 0 and receive ex vivo-expanded cord blood progenitor cells IV over 4 hours following the last unmanipulated cord blood infusion. Patients initially receive CSP IV over 1 hour beginning on day -3. CSP may be given PO when the patient can tolerate oral medications and has a normal gastrointestinal transit time. CSP is given until day 100, and may taper on day 101 if there is no graft versus host disease. Patients also receive MMF IV every 8 hours on days 0 to 7 and then may receive MMF PO beginning day 8 to 30. MMF is continued for a minimum of 30 days or until 7 days after blood counts recover whichever is later. If there is no evidence of acute GVHD and donor CD3 engraftment is at least 50% from one donor MMF may be tapered.
9486966|NCT01174732|Experimental|T1|A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation
9486967|NCT01174732|Experimental|T2|A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation
9486968|NCT01174732|Experimental|T3|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
9486969|NCT01174732|Experimental|T4|A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations
9486970|NCT01174732|Placebo Comparator|P|Placebo, 2 inhalations
9486971|NCT01174732|Active Comparator|R1|Proventil 90 mcg/inhalation, 2 inhalations
9486972|NCT01174732|Active Comparator|R2|Proventil 90 mcg/inhalation, 4 inhalations
9486973|NCT01173731|Experimental|AFQ056|
9486974|NCT01173497|Experimental|INIPARIB, irinotecan|
9486975|NCT01173341||Subgroup 2|Subgroup2 represents will undergo trastuzumab therapy only
9486976|NCT01173341||Subgroup 1|Subgroup 1 are anthracycline only treated patients.
9486977|NCT01173341||Subgroup 3|Subgroup 3 are patients that will undergo trastuzumab therapy with anthracyclines.
9486978|NCT01171313|Experimental|Treatment sequence 1|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
9486979|NCT01171313|Experimental|Treatment sequence 2|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
9486980|NCT01171313|Experimental|Treatment sequence 3|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
9486981|NCT01171313|Experimental|Treatment sequence 4|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
9486982|NCT01170650|Experimental|Arm A|EC145 + Pegylated Liposomal Doxorubicin (PLD)
9486983|NCT01170650|Active Comparator|Arm B|placebo + Pegylated Liposomal Doxorubicin (PLD)
9486984|NCT01169259|Active Comparator|Vitamin D + fish oil|
9486985|NCT01169259|Active Comparator|Vitamin D + fish oil placebo|
9486986|NCT01169259|Active Comparator|Vitamin D placebo + fish oil|
9486987|NCT01169259|Placebo Comparator|Vitamin D placebo + fish oil placebo|
9486988|NCT01168713|Active Comparator|Levofloxacin|
9486989|NCT01168713|Experimental|CEM-101|
9486990|NCT01168310|Experimental|1|
9486991|NCT01168310|Experimental|2|
9486992|NCT01168310|Experimental|3|
9486993|NCT01168310|Experimental|4|
9486994|NCT01168310|Experimental|5|
9486995|NCT01168310|Active Comparator|6|
9486996|NCT01168310|Placebo Comparator|7|
9486997|NCT01167244|Experimental|BMS-690514|
9486998|NCT01167166|Experimental|rigosertib|Patients will receive 2400 mg dose of rigosertib as a intravenous continuous infusion over 24 hours for 72 to 120 consecutive hours every 2 weeks for the first 4 weeks then will receive oral rigosertib at a 560 mg twice-daily dose as capsules taken continuously.
9486999|NCT01167114|Experimental|STA-9090|All subjects receive STA-9090
9487000|NCT01166412|Active Comparator|Dose level AG1000-6.5|
9487001|NCT01166412|Active Comparator|Dose level AG1000-12.5|
9487002|NCT01163227|Placebo Comparator|Placebo|
9487003|NCT01163227|Experimental|AQW051 Dose 1|
9487004|NCT01163227|Experimental|AQW051 Dose 2|
9487005|NCT01163227|Experimental|AQW051 Dose 3|
9487006|NCT01162681|Experimental|A-623 high dose weekly|
9487007|NCT01162681|Experimental|A-623 low dose weekly|
9487008|NCT01162681|Experimental|A-623 high dose every 4 weeks|
9487009|NCT01162681|Placebo Comparator|Placebo|
9487010|NCT01161615|Placebo Comparator|Placebo|Therapy with placebo
9487011|NCT01161615|Experimental|MRX-7EAT|Therapy with experimental drug
9487012|NCT01160601|Experimental|paclitaxel/carboplatin plus bavituximab|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles, in combination with 3 mg/kg bavituximab administered weekly.
9487013|NCT01160601|Active Comparator|paclitaxel/carboplatin|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
9487014|NCT01159249|Other|Open Met add-on vildagliptin|
9487015|NCT01159249|Other|Open TZD add-on vildagliptin|
9487016|NCT01159249|Other|Open α-GI add-on vildagliptin|
9487017|NCT01159249|Other|Glinides add-on vildagliptin|
9487018|NCT01156753|Experimental|CDX-011|
9487019|NCT01156753|Active Comparator|"Investigator's Choice chemotherapy"|
9487020|NCT01156415|Experimental|Agomelatine (AGO178) 0.5 mg|
9487021|NCT01156415|Experimental|Agomelatine (AGO178) 1 mg|
9487022|NCT01155362|Experimental|1 unit Human Placenta-Derived Cells PDA001|1 unit PDA001 in 240 millilters (mL) infused intravenously in one arm on Day 0 and Day 7.
10040479|NCT01853813|Other|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
10040480|NCT01853852|Experimental|50 mg|GR181413A/AT1001
9487023|NCT01155362|Experimental|4 units Human Placenta-Derived Cells PDA001|4 units PDA001 in 240 mL infused intravenously in one arm on Day 0 and Day 7.
9487024|NCT01155362|Placebo Comparator|vehicle control|4 units placebo in 240 mL infused intravenously in one arm on Day 0 and Day 7.
9487025|NCT01155362|Experimental|8 units Human Placenta-Derived Cells PDA001|4 units PDA-001 in 240 mL infused intravenously in each arm on Day 0 and Day 7 or 8 units PDA-001 in 240 mL infused intravenously in one arm on Day 0 and Day 7
9487026|NCT01154374|Experimental|MEBO Wound Ointment|Topical application twice daily
9487027|NCT01154374|Active Comparator|Standard of Care (sterile saline moistened gauze)|Topical application twice daily
9487028|NCT01152216|Experimental|Dimebon|
9487029|NCT01150695|Experimental|Group A (DVC-LVS)|Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
9487030|NCT01150695|Experimental|Group B (USAMRIID-LVS)|Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
9487031|NCT01148498|Experimental|Group 1|Older adults with mild Dementia Alzheimer's Type (DAT)
9487032|NCT01148498|Experimental|Group 2|Older adult controls with possible Alzheimer's Disease Pathology
9487033|NCT01148498|Experimental|Group 3|Older adult controls with no evidence of Alzheimer's Disease
9487034|NCT01148498|Experimental|Group 4|Younger subjects who are assumed to have no cognitive impairment
9487035|NCT01147939|Experimental|Elacytarabine|
9487036|NCT01147939|Active Comparator|Investigator's Choice|
9487037|NCT01147003|Experimental|BGG492 low dose|
9487038|NCT01147003|Placebo Comparator|Placebo|
9487039|NCT01147003|Experimental|BGG492 high dose|
9487040|NCT01146574|Experimental|0.1mg/kg Sotatercept|Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
9487041|NCT01146574|Experimental|0.3mg/kg Sotatercept|Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days
9487042|NCT01146574|Experimental|0.5mg/kg Sotatercept|Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days
9487043|NCT01146574|Experimental|0.7mg/kg Sotatercept|Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days
9487044|NCT01146574|Placebo Comparator|Placebo|The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.
9487045|NCT01146522|Experimental|LCQ908|
9487046|NCT01146522|Placebo Comparator|Placebo|
9487047|NCT01143246|Experimental|Terlipressin|intravenous terlipressin (1 mg) every 6 hours with concomitant albumin
9487048|NCT01143246|Placebo Comparator|Placebo|lyophilized mannitol
9487049|NCT01143064|Active Comparator|Progesterone|
9487050|NCT01143064|Placebo Comparator|Lipid emulsion without progestrone|
9487051|NCT01140217|Experimental|Active treatment|Norethindrone Acetate Transdermal Delivery System
9487052|NCT01139216|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
9487053|NCT01139216|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
9487054|NCT01139216|Placebo Comparator|Placebo|Placebo TID
9487055|NCT01138436|Experimental|MEBO Wound Ointment (MEBO)|Topical application once a day
9487056|NCT01138436|Active Comparator|Standard of Care|Application of Profore multilayer compression bandage system
9487057|NCT01138163|Experimental|Docetaxel plus bavituximab 1 mg/kg|
9487058|NCT01138163|Experimental|Docetaxel plus bavituximab 3 mg/kg|
9487059|NCT01138163|Placebo Comparator|Docetaxel plus placebo|
9487060|NCT01137968|Experimental|imetelstat plus standard of care|imetelstat plus standard of care (bevacizumab or observation)
9487061|NCT01137968|Other|Standard of care|Bevacizumab or observation
9487062|NCT01137526|Experimental|ABT-384 Dose 1|
9487063|NCT01137526|Experimental|ABT-384 Dose 2|
9487064|NCT01137526|Active Comparator|donepezil|
9487065|NCT01137526|Placebo Comparator|placebo|
9487066|NCT01135459|Experimental|CEP-33457|200 mcg of CEP-33457
9487067|NCT01135459|Placebo Comparator|Placebo|
9487068|NCT01133990|Active Comparator|FOLIRI|
9487069|NCT01133990|Experimental|E7820|FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820
9487070|NCT01133990|Experimental|FOLFIRI plus Bevacizumab|
9487071|NCT01131013|Experimental|Treatment Sequence 1|Dosing Period 1 - Placebo; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - 500 mg CK-2017357
9487072|NCT01131013|Experimental|Treatment Sequence 2|Dosing Period 1 - Placebo; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - 375 mg CK-2017357
9487073|NCT01131013|Experimental|Treatment Sequence 3|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 500 mg CK-2017357
9487074|NCT01131013|Experimental|Treatment Sequence 4|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - Placebo
9487075|NCT01131013|Experimental|Treatment Sequence 5|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 375 mg CK-2017357
9487076|NCT01131013|Experimental|Treatment Sequence 6|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - Placebo
9487077|NCT01130142|Active Comparator|Arm 1 (Phase 2)|IPI-926 in combination with gemcitabine
9487078|NCT01130142|Placebo Comparator|Arm 2 (Phase 2)|Placebo in combination with gemcitabine
9487079|NCT01130064|Experimental|QAX576|QAX576
9487080|NCT01130064|Placebo Comparator|Placebo|Placebo
10040481|NCT01853852|Experimental|150 mg|GR181413A/AT1001
10040482|NCT01853852|Experimental|450 mg|GR181413A/AT1001
10040483|NCT01853852|Placebo Comparator|Placebo|placebo
10040484|NCT01853865|No Intervention|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
9544840|NCT03073824|Experimental|vSculpt, model #VS1100|A novel intravaginal device for females
9544841|NCT03073629|Active Comparator|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
9544842|NCT03073629|No Intervention|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
9544843|NCT03073642|Active Comparator|Hydrotherapy|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk."
9544844|NCT03073642|Experimental|Hydrotherapy and Pain Education|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk.~During the 12 weeks of hydrotherapy treatment, volunteers will also receive 4 sessions of Pain Therapeutic Education, which is also known as Pain Neuroscience Education, which involves patient education on pain neurophysiology, pain chronification and amplification mechanisms, and chronic pain management. These sessions will be performed in specific dates scheduled according to the volunteers' availability, and with intervals that can last from one to two weeks."
9616691|NCT02540122|Active Comparator|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
9616692|NCT02540122|Active Comparator|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
9616693|NCT02540148|Experimental|Active Treatment|Patients will be fully consented before the start of the study. In the treatment group, subjects will undergo a treatment session to the enrolled eyes for three days during Week 1, followed by a single treatment session during Weeks 2, 14 and 26 with the Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.e.
9616694|NCT02540148|Sham Comparator|Non-active treatment|A second group of subjects will act as the control group. This group will undergo sham treatment to the enrolled eyes at the same intervals as the treatment group (Weeks 2, 14 and 26), but with a nonfunctional Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.
9616695|NCT02540109|Experimental|High-Definition tDCS (Active)|
9616696|NCT02540109|Experimental|High-Definition tDCS (Sham)|
9616697|NCT02540096|Experimental|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
9616698|NCT02540096|Placebo Comparator|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
9616699|NCT02540057|Active Comparator|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
9616700|NCT02540057|Active Comparator|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
9621733|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
9621734|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
9621735|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
10040485|NCT01853865|Experimental|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
10040486|NCT01853891|No Intervention|usual condition|sleep in usual room light condition for 5 nights
9487081|NCT01129674|Active Comparator|Standard of Care|
9487082|NCT01129674|Experimental|LY2140023|"20mg, 40mg or 80mg~After 104 weeks, patients have the option to continue on treatment until the end of the study"
9487083|NCT01129648|Placebo Comparator|BCX4208 placebo + Allopurinol placebo|Administered daily for 21 days.
9487084|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 100mg|Administered daily for 21 days.
9487085|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 200 mg|Administered daily for 21 days.
9487086|NCT01129648|Active Comparator|BCX4208 Placebo + Allopurinol 300 mg|Administered daily for 21 days.
9487087|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol Placebo|Administered daily for 21 days.
9487088|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 100 mg|Administered daily for 21 days.
9487089|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 200 mg|Administered daily for 21 days.
9487090|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 300 mg|Administered daily for 21 days.
9487091|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol placebo|Administered daily for 21 days.
9487092|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 100 mg|Administered daily for 21 days.
9487093|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 200 mg|Administered daily for 21 days.
9487094|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 300 mg|Administered daily for 21 days.
9487095|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol Placebo|Administered daily for 21 days.
9487096|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 100 mg|Administered daily for 21 days.
9487097|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 200 mg|Administered daily for 21 days.
9487098|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 300 mg|Administered daily for 21 days.
9487099|NCT01128530|Experimental|JNJ-32729463|JNJ-32729463 250 mg tablet and matching linezolid placebo twice daily
9487100|NCT01128530|Active Comparator|linezolid|linezolid 600 mg tablet and matching JNJ-32729463 placebo twice daily
9487101|NCT01128452|Placebo Comparator|Placebo|Placebo
9487102|NCT01128452|Experimental|EVT 101|EVT 101
9487103|NCT01128335|Active Comparator|Arm 1|MMF(1000mg bid) + tacrolimus + standard of care medications
9487104|NCT01128335|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
9487105|NCT01128335|Experimental|Arm 3|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
9487106|NCT01128335|Experimental|Arm 4|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
9487107|NCT01126970|Placebo Comparator|Placebos.|Velneperit Placebo q.d.+ Orlistat Placebo t.i.d.
9487108|NCT01126970|Experimental|Velneperit 400 mg|Velneperit 400 mg q.d.
9487109|NCT01126970|Active Comparator|Orlistat 120 mg|Orlistat 120 mg t.i.d.
9487110|NCT01126970|Experimental|Velneperit 400 mg + Orlistat 120 mg|Velneperit 400 mg q.d.and Orlistat 120 mg t.i.d
9487111|NCT01126190|Experimental|Neugranin|
9487112|NCT01126190|Active Comparator|Pegfilgrastim|
9487113|NCT01124708|Placebo Comparator|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
9487114|NCT01124708|Active Comparator|TC-5619|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, one capsule once daily p.o.
9487115|NCT01124565|Experimental|RT001|RT001 (Botulinum Toxin Type A) Topical Gel
9487116|NCT01124552|Experimental|RT001 Botulinum toxin Type A (Dose A)|RT001 (Botulinum toxin Type A)
9487117|NCT01124552|Experimental|RT001 Botulinum toxin type A (Dose B)|RT001 (Botulinum Toxin Type A)
9487118|NCT01124552|Other|Dose C|Vehicle Control
9487119|NCT01124552|Placebo Comparator|Dose D|Placebo
9487120|NCT01123785|Placebo Comparator|Control|Matched vehicle-control
9487121|NCT01123785|Experimental|INO-8875|Adenosine agonist eye drop
9498095|NCT03469154|Experimental|Dyad training|The participants in this arm will train in teams of two. Participants will be instructed in paediatric basic life support by instructional videos in a computer programme and train on children resuscitation manikins. Training involves recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management. The training involves series of short video clips and following exercises. Each participant performs the exercise and the other gives feedback. Afterwards roles are changed. The procedure is done for all exercises after a video clip. The duration of the training is maximum 50 minutes
9498096|NCT03469154|Active Comparator|Instructor led training|"Participants train in courses of up to 6 participants with an instructor. Training content is identical to dyad training content involving: recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management.~Skills are instructed by an instructor using af 4 step approach (1. show skills, 2. show with explanation, 3. participants instruct instructor, 4. participants performs the skills on resuscitation manikins). Training is maximum two hours but course duration is adjusted to number of participants two allow for similar hands-on time per participant as in the experimental arm."
9498097|NCT03469141|No Intervention|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
9498098|NCT03469141|Experimental|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
9498099|NCT03469128|Active Comparator|Cognitive processing therapy|Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT
9498100|NCT03469128|Active Comparator|Sertraline|Patients with co-occurrence PTSD & SUD disorders were treated by Sertraline.
9498101|NCT03469128|Placebo Comparator|Control group|Placebo Control group
9498102|NCT03469115|Active Comparator|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
9498103|NCT03469115|Active Comparator|BMI below 3%|Serum blood will be taken from slim youths
9498104|NCT03469089|Placebo Comparator|Placebo/placebo|Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)
10040487|NCT01853891|Experimental|dLAN|sleep with dim light at night for 5 nights
9544845|NCT03073551|No Intervention|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
10040488|NCT01853904|Other|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
10040489|NCT01853904|Other|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
10040490|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
10040491|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
10040492|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
10040493|NCT01853956|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
10040494|NCT01853956|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
10040495|NCT01853969||Patients who have carpal tunnel release surgery|
10040496|NCT01854008|Experimental|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
10040497|NCT01854008|Experimental|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
10040498|NCT01854021|Experimental|inhalational anesthesia|inhalational anesthesia
10040499|NCT01854021|Experimental|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
10040500|NCT01854021|Experimental|intravenous anesthesia|intravenous anesthesia
10040501|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
10040502|NCT01854073|Active Comparator|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
10040503|NCT01854073|Placebo Comparator|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
10040504|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
10040505|NCT01854099|Active Comparator|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
10040506|NCT01854099|Active Comparator|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
10040507|NCT01854099|Active Comparator|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
10040508|NCT01854112||T-cell lymphoma|
10040509|NCT01854125|Active Comparator|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
10040510|NCT01854125|Active Comparator|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
10040511|NCT01854125|Experimental|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
10040512|NCT01854151|No Intervention|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
9498105|NCT03469089|Experimental|Ketamine 0.58/placebo|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil
9498106|NCT03469089|Experimental|Ketamine 0.58/modafinil|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)
9498107|NCT03469089|Experimental|Ketamine 0.31/placebo|Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil
9498108|NCT03469076|Experimental|ACN Cream|Patients with mild to moderate acne using ACN Cream
9498109|NCT03469063|Experimental|AferBio|Daily oral AferBio (20 g/day, in sachets)
9498110|NCT03469063|Placebo Comparator|Placebo|Daily oral placebo (20 g/day, in sachets)
9498111|NCT03469037|Experimental|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
9498112|NCT03469037|Experimental|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
9498113|NCT03469024|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
9498114|NCT03469024|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
10040513|NCT01854151|Experimental|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
10040514|NCT01854164|Experimental|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
9544846|NCT03073551|Active Comparator|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
9544847|NCT03073577|Experimental|Treatment Group|PKX-001 will be supplemented to islet preservation CMRL-1066 medium at final concentration of 3 mg/mL during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays. Islets are maintained for minimal 6 hours up to 72 hours in supplemented CMRL1066-based media containing PKX-001 until the time of transplant. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally.
9544848|NCT03073616||Lung ultrasound|Every patient will receive a chest RX and lung US
9544849|NCT03073668|Experimental|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
9544850|NCT03073564|No Intervention|Incremental cardiopulmonary test|Incremental cardiopulmonary test for upper limbs will be performed only to identify patients who exhibit dynamic hyperinflation during upper limb exercise.
9544851|NCT03073564|Experimental|Endurance test|The endurance test for upper limbs will be performed in two conditions: In the first the patients perform the test in usual breathing, without the use of EPAP. In the second the test will be performed using the EPAP mask.
9544852|NCT03073564|Experimental|Functional test|The functional test for upper limbs will be performed from protocol already published for the 6-min pegboard and ring test (6PBRT). In this stage the patients will perform the 6PBRT in usual breathing and as the use of the EPAP mask.
9544853|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16
9544854|NCT03073655|Experimental|Group 1|it has been limited evidence of KT is effective
9544855|NCT03073655|Experimental|Group 2|it has been not known that KT is effective or not
9544856|NCT03073655|Experimental|Group 3|it has been known that KT has excellent result
9544857|NCT03073460|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 40 weeks gestation to assess the fetal ductus arteriosis.
9544858|NCT03073694|Active Comparator|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
9544859|NCT03073694|Experimental|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
9544860|NCT03073408|Active Comparator|1: Manual control group|The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
9544861|NCT03073408|Experimental|2: PI +Smith group|The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
9544862|NCT03073499|Experimental|Intervention|(Partial) Oncological Home Hospitalization
9544863|NCT03073499|No Intervention|Control|Standard oncological treatment at the hospital day care unit
9544864|NCT03073421|Other|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
9544865|NCT03073590|Experimental|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
9544866|NCT03073590|Active Comparator|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
9544867|NCT03073590|Experimental|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
9544868|NCT03073590|Active Comparator|Control without lunch|Control factory without lunch program A. Behavior change communications program
9544869|NCT03073317|Experimental|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
9544870|NCT03073317|No Intervention|CONTROL|Usual clinic control
9544871|NCT03073356|Experimental|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
9544872|NCT03073356|Experimental|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
9544873|NCT03073356|Experimental|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
9544874|NCT03073356|Experimental|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
9544875|NCT03073447|Other|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
9544876|NCT03073226|Experimental|Barrett's surveillance Olympus Spectrum|Barrett's surveillance with Olympus Spectrum.
9544877|NCT03073226|Experimental|Barrett's Surveillance Olympus Elite|Barrett's surveillance with Olympus ELITE.
9544878|NCT03073226|Experimental|Polyp Surveillance Olympus Spectrum|Colonic polyp surveillance/screening with Olympus Spectrum.
9487122|NCT01122784|Active Comparator|Group 1|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 182
9487123|NCT01122784|Active Comparator|Group 2|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 182
9487124|NCT01122784|Active Comparator|Group 3|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 121
9487125|NCT01122784|Active Comparator|Group 4|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 121
9487126|NCT01121107|Experimental|Left Atrial Pressure Monitoring System|Left Atrial Pressure (LAP) Monitoring System
9487127|NCT01121107|Active Comparator|Patient Advisor Module|Patient Advisory Module
9487128|NCT01120964|Experimental|Intravenous L-Citrulline|
9487129|NCT01120964|Placebo Comparator|Placebo of Intravenous L-Citrulline|
9487130|NCT01120470|Experimental|OGX-427 and Prednisone|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
9487131|NCT01120470|Active Comparator|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization"
9487132|NCT01119833|Experimental|GMI-1070|
9487133|NCT01119833|Placebo Comparator|Placebo|
9487134|NCT01117584|Experimental|ASP1941 lowest dose|oral tablet
9487135|NCT01117584|Experimental|ASP1941 low dose|oral tablet
9487136|NCT01117584|Experimental|ASP1941 high dose|oral tablet
9487137|NCT01117584|Experimental|ASP1941 highest dose|oral tablet
9487138|NCT01117584|Placebo Comparator|Placebo|oral tablet
9487139|NCT01116141|Active Comparator|Methotrexate (MTX) + Folic Acid|20 mg MTX weekly + 1 mg folic acid daily
9487140|NCT01116141|Experimental|0.3 mg CH-4051|0.3 mg CH-4051 daily
9487141|NCT01116141|Experimental|1.0 mg CH-4051|1.0 mg CH-4051 daily
9487142|NCT01116141|Experimental|3.0 mg CH-4051|3.0 mg CH-4051 daily
9487143|NCT01116141|Experimental|3.0 mg CH-4051 + folic acid|3.0 mg CH-4051 + 1.0 mg folic acid daily
9487144|NCT01114698|Experimental|JNJ26489112|
9487145|NCT01114698|Active Comparator|Venlafaxine XR|
9487146|NCT01114698|Placebo Comparator|Placebo|
9487147|NCT01114308|Experimental|Probuphine|Patients are first inducted on SL BPN then switched to 4 buprenorphine implants
9487148|NCT01114308|Placebo Comparator|placebo implant|patients are first inducted on SL BPN then switched to 4 placebo implants
9487149|NCT01114308|Active Comparator|sublingual buprenorphine|patients are inducted on SL BPN, then continue on SL BPN
9487150|NCT01113957|Experimental|Arm A|ABT-888 in combination with temozolomide
9487151|NCT01113957|Active Comparator|Arm B|pegylated liposomal doxorubicin alone
9487152|NCT01113593|Experimental|1|
9487153|NCT01113593|Experimental|2|
9487154|NCT01113593|Experimental|3|
9487155|NCT01113593|Experimental|4|
9487156|NCT01113593|Experimental|5|
9487157|NCT01112527|Experimental|Arm A|Patients with Glioblastoma that has returned or grown after chemotherapy or radiation treatment and who will be having a standard operation to remove the tumor.
9487158|NCT01112527|Experimental|Arm B|Participants with glioblastoma at first recurrence who are not surgical candidates and who have not had prior anti-VEGF therapy.
9487159|NCT01112527|Experimental|Arm C|Participants with glioblastoma who are not surgical candidates and who are at first recurrence from a therapeutic regimen containing bevacizumab.
9487160|NCT01112423|Experimental|BMS-823778 (2 mg)|
9487161|NCT01112423|Experimental|BMS-823778 (10 mg)|
9487162|NCT01112423|Experimental|BMS-823778 (20 mg)|
9487163|NCT01112423|Placebo Comparator|Placebo|
9487164|NCT01111955|Active Comparator|BMS-823778 (2 mg)|+ metformin
9487165|NCT01111955|Active Comparator|BMS-823778 (10 mg)|+ metformin
9487166|NCT01111955|Active Comparator|BMS-823778 (20 mg)|+ metformin
9487167|NCT01111955|Placebo Comparator|Placebo|+ metformin
9487168|NCT01111773|Experimental|Heated Lidocaine and Tetracaine Patch|
9487169|NCT01110902|Experimental|AGO178C 0.5 mg /day|
9487170|NCT01110902|Experimental|AGO178C 1 mg / day|
9487171|NCT01110902|Placebo Comparator|Placebo|
9487172|NCT01110889|Experimental|AGO178C 0.5 mg /day|
9487173|NCT01110889|Experimental|AGO178C 1 mg / day|
9487174|NCT01110889|Placebo Comparator|Placebo|
9487175|NCT01110746|Experimental|Formulation A|Single Injection
9487176|NCT01110746|Experimental|Formulation B|Single Injection
9487177|NCT01108705|Experimental|Brivanib|
9487178|NCT01108705|Placebo Comparator|Placebo|
9487179|NCT01107496|Experimental|SPN-812|viloxazine, oral, 300mg, tid, 6 weeks
9487180|NCT01107496|Placebo Comparator|Placebo|placebo, oral, tid, 6weeks
9487181|NCT01106989|Experimental|Heated lidocaine/tetracaine patch|Active
9487182|NCT01106807|Experimental|CD07223 1.5% gel|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
9487183|NCT01106807|Experimental|CD07223 0.5% gel|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
9487184|NCT01106807|Active Comparator|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces
9487185|NCT01105624|Experimental|azithromycin ophthalmic solution, 1%|
9487186|NCT01105624|Experimental|rewetting drops|
9544879|NCT03073226|Experimental|Polyp Surveillancewith Olympus ELITE.|Colonic polyp surveillance/screening with Olympus ELITE.
9544880|NCT03073239||ALS epidemiological characterization|epidemiological characterization
9544881|NCT03073239||Genetic findings in ALS patients|genética characterization
9544882|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
9544883|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
9544884|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
9544885|NCT03073395|Experimental|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug [68Ga]P16-093 in patients with a history of histologically confirmed cancer.
9544886|NCT03073395|Experimental|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug [68Ga]P16-093
9544887|NCT03073252|Experimental|Normal Protein|Consumption of normal protein (NP) meal
9544888|NCT03073252|Experimental|High Protein|Consumption of high protein (HP) meal
9544889|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep [10 from New York City (NYC); 10 from Rhode Island (RI)] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
9544890|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
9544891|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
9544892|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility.
9544893|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility in small groups.
9544894|NCT03073291|Experimental|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
9544895|NCT03073291|No Intervention|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
9544896|NCT03073135|Experimental|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
9544897|NCT03073135|Active Comparator|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
9544898|NCT03073343|Active Comparator|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
9544899|NCT03073343|Active Comparator|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
9544900|NCT03072992|Active Comparator|Group A: Paclitaxel & Curcumin|75 patients, treatment with Curcumin (CUC-01, yellow solution), 300mg i.v. plus i.v. Paclitaxel (colorless solution) 80 mg /m2 BS i.e., once weekly for 12 weeks.
9544901|NCT03072992|Placebo Comparator|Group B: Paclitaxel & Placebo|Group B, 75 patients, treatment with Paclitaxel (colorless solution) 80 mg /m2 BS, i.v. plus placebo i.v. solution (250 ml, yellow solution for masking/blinding), once weekly for 12 weeks.
9544902|NCT03073330|Experimental|One Step|The intervention is gestational diabetes screening with 2 hour GTT 75 g load.
9544903|NCT03073330|Active Comparator|Two Step|There is no intervention is this arm as patients will subjected to routine gestational diabetes screening with one hour glucola, 50 g load.
9544904|NCT03073096|Other|Intervention arm|LVA at time of nodal dissection
9544905|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
9544906|NCT03073304|Active Comparator|Control|Erythrocyte based prime solution
9544907|NCT03073304|Experimental|Intervention|Crystalloid based prime solution
9544908|NCT03072940||Patients with idiopathic RBD|
9544909|NCT03072940||Healthy volunteers|
9544910|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
9544911|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
9544912|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
9544913|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
9544914|NCT03073057|Active Comparator|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
9544915|NCT03073018|Experimental|Fosinopril + Pravastatin|Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years
9544916|NCT03073018|Active Comparator|Fosinopril + Placebo|Fosinopril (20 mg) + pravastatin placebo once daily for 4 years
9544917|NCT03073018|Active Comparator|Pravastatin + Placebo|Pravastatin (40 mg) + fosinopril placebo once daily for 4 years
9544918|NCT03073018|Placebo Comparator|Double Placebo|Fosinopril placebo and pravastatin placebo once daily for 4 years
9544919|NCT03073369|Active Comparator|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
9544920|NCT03073369|Placebo Comparator|Placebo|
9544921|NCT03072836|Experimental|CD alone|
9544922|NCT03072836|Experimental|SPA alone|
9544923|NCT03072836|Experimental|CD + SPA|
9544924|NCT03072966|Experimental|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
9544925|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
9544926|NCT03073083|Active Comparator|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
9544927|NCT03073083|Active Comparator|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
9544928|NCT03073083|Active Comparator|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
9544929|NCT03072914|No Intervention|The control group|The control group has a sphygmomanometer wound around the upper arm or lower extremity and applies the same pressure, but a 3-way stopcock is installed in the middle so that no pressure is applied.
9544930|NCT03072914|Active Comparator|RIPC with RIPostC group|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
9544931|NCT03072823|Active Comparator|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
9544932|NCT03072823|Placebo Comparator|placebo|olive oil ethyl esters
9544933|NCT03072888|Experimental|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
9544934|NCT03072888|Sham Comparator|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
9544935|NCT03072810|Experimental|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
9544936|NCT03072810|Other|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
9544937|NCT03072784|Active Comparator|group S|short time <90 m aortic cross clamping
9544938|NCT03072784|Active Comparator|group L|> 90 minutes aortic cross clamping
9544939|NCT03072758|Experimental|Men's Club Intervention Group|Participants randomized to this group will receive interventions from the study team.
9544940|NCT03072758|No Intervention|Men's Club Control Group|Male participants in the control group will receive only education pamphlets related to breastfeeding during the 3rd trimester of their female partner's pregnancy
9544941|NCT03072771|Experimental|ASCT + BEAM + Blinatumomab|"Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:~carmustine is typically given intravenously (IV) at a dose of 300 mg/m^2 on Day -7~etoposide is typically given IV at a dose of 100 mg/m^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)~cytarabine is typically given IV at a dose of 100 mg/m^2 BID on Days -6, -5, -4, and -3 (8 doses)~melphalan is typically given IV at a dose of 140 mg/m*2 on Day -2~Auto-SCT will take place on Day 0 as per institutional guidelines~Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks)."
9544942|NCT03072420|Experimental|Group no manual work or activity|Subject with an office or student job.
9544943|NCT03072420|Sham Comparator|Group manual work|Subject working in a manual or predominantly manual.
9544944|NCT03072472|Experimental|Endocuff-assisted Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope
9544945|NCT03072472|No Intervention|Standard Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope
9544946|NCT03072641|Experimental|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
9544947|NCT03072641|No Intervention|Control|
9544948|NCT03072433|Active Comparator|Standard of Care|Comparison group will receive the current standard of care. Nurses are instructed to tell mothers about nutrition and water, sanitation and hygiene at any point prior to discharge from hospital. In addition, nurses will tell primary caregivers to play with their children even while they are receiving treatment in a play area with toys available.
9544949|NCT03072433|Experimental|Counseling Intervention Package|Primary caregivers in the intervention group receive group education sessions involving psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene components during a total of four days.
9544950|NCT03072524||Stroke patients|Stroke patients who will undergo the FAST PLUS test within 12 hours from the stroke onset.
9544951|NCT03072693|Active Comparator|Group 1|Home-based remote heart failure management
9544952|NCT03072693|Placebo Comparator|Group 2|Home-based physiological parameter recording only
9544953|NCT03072485|Other|Sirolimus, metformin, diclofenac|First five enrolled participants
9544954|NCT03072485|Other|Metformin, diclofenac|Sixth to tenth enrolled participants
9544955|NCT03072680|Experimental|BPS PAST + BPS FUT|Participants practice BPS PAST the first week, then they switch fot BPS FUT.
9544956|NCT03072680|Experimental|BPS FUT|Participants practice BPS FUT during the two weeks.
9544957|NCT03072680|Active Comparator|CONTROL|Participants practice DAILY ACTIVITIES for the two weeks.
9544958|NCT03072589|Experimental|Regadenoson infusion|Dose escalation of Regadenoson infusion
9544959|NCT03072706|Active Comparator|Standard group|2D X-ray templating technology
9544960|NCT03072706|Experimental|Corin OPS™|Corin Optimised Positioning System (OPS) Dynamic Hip Analysis
9544961|NCT03072355|Active Comparator|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
9544962|NCT03072355|Active Comparator|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
9544963|NCT03072615||1|receiving TE before and 30 min after TIPS
9544964|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
9544965|NCT03072745|Experimental|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
9544966|NCT03072511|Experimental|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
9544967|NCT03072511|Active Comparator|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
9544968|NCT03072407|Placebo Comparator|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
9544969|NCT03072407|Experimental|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
9544970|NCT03072407|Experimental|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
9544971|NCT03072407|Experimental|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
9544972|NCT03072407|Experimental|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
10040515|NCT01854164|Placebo Comparator|Placebo|Placebo for 8 weeks
9544973|NCT03072368|Active Comparator|Blue eyes|50 babies born with blue eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
9544974|NCT03072368|Active Comparator|Brown eyes|50 babies born with brown eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
9544975|NCT03072368|Active Comparator|Green eyes|50 babies born with green eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
9544976|NCT03072368|Active Comparator|Hazel eyes|50 babies born with hazel eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
9544977|NCT03072381|Active Comparator|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
9544978|NCT03072381|Placebo Comparator|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
9544979|NCT03072342|Active Comparator|Intensive Periodontal Treatment (IPT)|
9544980|NCT03072342|Placebo Comparator|Control Periodontal Treatment (CPT)|
9544981|NCT03072277|Active Comparator|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
9544982|NCT03072277|Placebo Comparator|Placebo|Corn/Soy Oil
9544983|NCT03072264|Experimental|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
9544984|NCT03072264|Active Comparator|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
9544985|NCT03072264|Active Comparator|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
9544986|NCT03072446|Experimental|Gel-Beads arm|This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent
9544987|NCT03072394|Experimental|EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse.
9544988|NCT03072394|Active Comparator|Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
9544989|NCT03071939|Other|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
9544990|NCT03072004|Sham Comparator|Control|"Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the Low Level Laser Therapy (LLLT) group"
9544991|NCT03072004|Experimental|Low Level Laser Therapy|Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive intervention with low-intensity laser therapy (LLLT).
9544992|NCT03072030|Experimental|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
9544993|NCT03072030|Placebo Comparator|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
9544994|NCT03072329|Experimental|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
9544995|NCT03072017|Experimental|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
9544996|NCT03072082|Experimental|Danlou Tablet|Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
9544997|NCT03072082|Placebo Comparator|Danlou Tablet placebo|Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
9544998|NCT03072212||HIV infected with stroke|No intervention will be administered
9544999|NCT03072212||HIV uninfected with stroke|No intervention will be administered
9545000|NCT03072316||SSM immediate DIEP|Unilateral skin sparing mastectomy with immediate DIEP
9545001|NCT03072316||SSM immediate DIEP and PMRT|Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy
9545002|NCT03072316||mastectomy, PMRT, delayed DIEP|simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction
9545003|NCT03072316||SSM, temporizing implant, PMRT then DIEP|Unilateral SSM with temporizing implant, PMRT and subsequent
9545004|NCT03072056|Experimental|Extensive Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
9545005|NCT03072056|Experimental|Extensive Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
9545006|NCT03072056|Experimental|Extensive Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
9545007|NCT03072056|Experimental|Poor Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
9545008|NCT03072056|Experimental|Poor Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
9545009|NCT03072056|Experimental|Poor Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
9545010|NCT03072290|Experimental|low dose steroid|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
9545011|NCT03072290|Active Comparator|comparator|ultrasound-guided steroid injection using 1ml of 40 mg (40mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
9545012|NCT03072121|Experimental|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
9545013|NCT03072121|Placebo Comparator|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
9545014|NCT03072108|Experimental|Bonolive|
9545015|NCT03072108|Placebo Comparator|Placebo|
9545016|NCT03072173|Experimental|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
9545017|NCT03072173|Experimental|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
9545018|NCT03072199|Experimental|Rituximab|
9616701|NCT02540070|Active Comparator|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
9616702|NCT02540070|Experimental|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
9616703|NCT02540070|Experimental|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
9616704|NCT02540031|Experimental|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
9616705|NCT02540031|Active Comparator|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
9616706|NCT02539979|Active Comparator|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
9616707|NCT02539979|Placebo Comparator|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
9616708|NCT02540044|Experimental|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
9616709|NCT02540044|Active Comparator|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
9616710|NCT02540005||Aneurysmatic subarachnoid haemorrhage|Acute subarachnoid haemorrhage (confirmed by computed tomography, CT, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) AND confirmed origin either with computed angiography (CTA) or digital subtraction angiography (DSA)
9616711|NCT02540005||Control patients|Elective craniotomy due to non-ruptured intracranial aneurysm
9616712|NCT02539966|Experimental|Cohort A|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
9616713|NCT02539966|Experimental|Cohort B|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
9616714|NCT02539966|Experimental|Cohort C|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
9616715|NCT02540018|Active Comparator|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
9616716|NCT02540018|Active Comparator|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
9616717|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
9616718|NCT02539758|Experimental|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
9662995|NCT04156126||Spontaneous Conception|Adult females presenting with positive pregnancy test to the Obstetrics Department
10040516|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
10040517|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
10040518|NCT01854203|Experimental|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
10040519|NCT01854203|Experimental|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
10040520|NCT01854216|Experimental|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
10040521|NCT01854216|Experimental|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
10040522|NCT01854229|Active Comparator|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
10040523|NCT01854229|Active Comparator|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
10040524|NCT01854255|Experimental|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
10040525|NCT01854307|Experimental|Pneumoperitoneum and SVV/PPV|
10040526|NCT01854320|Experimental|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
10040527|NCT01854320|Active Comparator|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
10040528|NCT01854333|Other|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
9487187|NCT01103349|Experimental|BI671800|Patients receive BI671800 capsules twice daily
9487188|NCT01103349|Active Comparator|Montelukast|Patients receive Montelukast encapsulated tablets once daily
9487189|NCT01103349|Placebo Comparator|Placebo|Patients receive placebo capsules and/or encapsulated placebo tablets
9487190|NCT01103037|Experimental|QAV680|
9487191|NCT01103037|Placebo Comparator|QAV680 Placebo|
9487192|NCT01102660|Other|Treatment Sequence 1|
9487193|NCT01102660|Other|Treatment Sequence 2|
9487194|NCT01102660|Other|Treatment Sequence 3|
9487195|NCT01102660|Other|Treatment Sequence 4|
9487196|NCT01101906|Experimental|Arm A: OSI-906|150 mg BID
9487197|NCT01101906|Placebo Comparator|Arm B: Placebo|Placebo BID
9487198|NCT01101594|Experimental|hLL1-DOX|4 Different dose levels of hLL1-DOX will be studied in groups of 3-6 patients. Once an optimal dose has been found, up to additional 30 patients will be studied at that dose level.
9487199|NCT01100151|Experimental|RDC-1036 (ALKS 37)|Capsules for oral administration
9487200|NCT01100151|Placebo Comparator|Placebo|Capsules for oral administration
9487201|NCT01098435|Experimental|RDC-0313 (ALKS 33)|2-capsules taken orally
9487202|NCT01098435|Placebo Comparator|Placebo|2-capsules taken orally
9487203|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at middle dose|
9487204|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at low dose|
9487205|NCT01097096|Placebo Comparator|Placebo + Adjuvant 1 at middle dose|
9487206|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at middle dose|
9487207|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at low dose|
9487208|NCT01097096|Placebo Comparator|Placebo + Adjuvant 2 at middle dose|
9487209|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at middle dose|
9487210|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at low dose|
9487211|NCT01097096|Placebo Comparator|Placebo + either Adjuvant 1 or 2 at middle dose|
9487212|NCT01097018|Active Comparator|Perifosine + Capecitabine|Perifosine 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
9487213|NCT01097018|Placebo Comparator|Placebo + Capecitabine|Placebo 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
9487214|NCT01096979|Experimental|LIPO-102, High|LIPO-102, High
9487215|NCT01096979|Experimental|LIPO-102, Low|LIPO-102, Low
9487216|NCT01096979|Experimental|Placebo|Pbo
9487217|NCT01096966|Experimental|Bupivacaine TTS|
9487218|NCT01096966|Placebo Comparator|Placebo patch|
9487219|NCT01096862|Experimental|Group 1|lowest dose
9487220|NCT01096862|Experimental|Group 2|low dose
9487221|NCT01096862|Experimental|Group 3|high dose
9487222|NCT01096862|Experimental|Group 4|highest dose
9487223|NCT01096862|Experimental|Group 5|medium dose
9487224|NCT01096862|Placebo Comparator|Placebo|Matching placebo
9487225|NCT01095562|Experimental|ABT-126 Dose 1|
9487226|NCT01095562|Experimental|ABT-126 Dose 2|
9487227|NCT01095562|Placebo Comparator|Sugar Pill|
9487228|NCT01094496|Experimental|CDX-1307 Vaccine Regimen|Chemotherapy with CDX-1307 vaccine regimen (neoadjuvant phase), followed by bladder removal surgery (cystectomy). CDX-1307 vaccine regimen will continue to be given for up-to 1 year post-surgery (adjuvant/long-term follow-up phase).
9487229|NCT01094262|Experimental|JNJ-42160443 (lower dose)|
9487230|NCT01094262|Experimental|JNJ-42160443 (higher dose)|
9487231|NCT01094262|Active Comparator|Oxycodone CR (standard pain medication)|
9487232|NCT01094262|Placebo Comparator|Placebo|
9487233|NCT01094067|Experimental|1|Placebo at visit 1, tezosentan at visit 2
9487234|NCT01094067|Experimental|2|Tezosentan at visit 1, placebo at visit 2
9487235|NCT01092143|Experimental|BI671800 (low dose)|Patients receive BI671800 (low dose) capsules twice daily
9487236|NCT01092143|Active Comparator|Fluticasone|Patients inhale from Fluticasone MDI twice daily
9487237|NCT01092143|Placebo Comparator|placebo|Patients receive placebo capsules twice daily
9487238|NCT01092143|Experimental|BI671800 (medium dose)|Patients receive BI671800 (medium dose) capsules twice daily
9487239|NCT01092143|Experimental|BI671800 (high dose)|Patients receive BI671800 (high dose) capsules twice daily
9487240|NCT01092104|Experimental|TBR-652 25 mg QD|TBR 25 mg QD for 10 days
9487241|NCT01092104|Placebo Comparator|Placebo|Matching Placebo QD for 10 days
9487242|NCT01092104|Experimental|TBR-652 50 mg QD|TBR-652 50 mg QD for 10 days
9487243|NCT01092104|Experimental|TBR-652 75 mg QD|TBR-652 75 mg QD for 10 days
9487244|NCT01092104|Experimental|TBR-652 100 mg QD|TBR-652 100 mg QD for 10 days
9487245|NCT01092104|Experimental|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
9487246|NCT01092065|Experimental|AFQ056 100 mg (Bid)|
9487247|NCT01092065|Placebo Comparator|Placebo|
9487248|NCT01090024|Experimental|BI 671800 AM and PM|Patients receiving two capsules twice daily
9487249|NCT01090024|Experimental|BI 671800 AM|Patients receiving four capsules in the morning
9487250|NCT01090024|Experimental|BI 671800 PM|Patients receiving four capsules in the evening
9487251|NCT01090024|Placebo Comparator|Placebo|Patients receiving four capsules twice a day
9487252|NCT01089790|Experimental|1|
9487253|NCT01089790|Active Comparator|2|
9487254|NCT01089010|Experimental|Treatment Sequence 1|Treatment sequence 1 consisted of three dosing periods in which patients received single oral doses of placebo, 250 mg, and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
9487255|NCT01089010|Experimental|Treatment Sequence 2|Treatment sequence 2 consisted of three dosing periods in which patients received single oral doses of placebo, 500 mg, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
9487256|NCT01089010|Experimental|Treatment Sequence 3|Treatment sequence 3 consisted of three dosing periods in which patients received single oral doses of 250 mg, placebo and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
9487257|NCT01089010|Experimental|Treatment Sequence 4|Treatment sequence 4 consisted of three dosing periods in which patients received single oral doses of 250 mg, 500 mg and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
9487258|NCT01089010|Experimental|Treatment Sequence 5|Treatment sequence 5 consisted of three dosing periods in which patients received single oral doses of 500 mg, placebo, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
9487259|NCT01089010|Experimental|Treatment Sequence 6|Treatment sequence6 consisted of three dosing periods in which patients received single oral doses of 500 mg, 250 mg, and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
9487260|NCT01087151|Active Comparator|A|
9487261|NCT01087151|Experimental|B|
9487262|NCT01087151|Experimental|C|
9487263|NCT01086748|Experimental|160 mg LY2140023|80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
9487264|NCT01086748|Active Comparator|4 mg Risperidone|2 mg risperidone administered orally, BID for up to 7 weeks.
9487265|NCT01086748|Placebo Comparator|Placebo|Placebo administered orally, BID for up to 7 weeks.
9487266|NCT01086748|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, BID for up to 7 weeks.
9487267|NCT01086267|Experimental|BMS-908662 (A1)|Phase 1
9487268|NCT01086267|Experimental|Cetuximab (A1)|Phase 1
9487269|NCT01086267|Experimental|BMS-908662 (B1)|Phase 2
9487270|NCT01086267|Experimental|BMS-908662 + Cetuximab (B2)|Phase 2
9487271|NCT01085266|Experimental|Dimebon (latrepirdine)|Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
9487272|NCT01085084|Experimental|Laquinimod 0.5 mg arm|laquinimod 0.5 mg + placebo
9487273|NCT01085084|Experimental|Laquinimod 1 mg|laquinimod 1 mg
9487274|NCT01085084|Placebo Comparator|Placebo|placebo
9487275|NCT01084330|Experimental|AUY922|
9487276|NCT01084330|Active Comparator|Docetaxel or Irinotecan|
9487277|NCT01084161|Experimental|N1539 5 mg|
10040529|NCT01854346|Experimental|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
10040530|NCT01854346|No Intervention|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
10040531|NCT01854372|Experimental|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
10040532|NCT01854398|Experimental|CPAP group|
10040533|NCT01854398|Sham Comparator|sham-CPAP group|
10040534|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
9487278|NCT01084161|Experimental|N1539 7.5 mg|
9487279|NCT01084161|Experimental|N1539 15 mg|
9487280|NCT01084161|Experimental|N1539 30 mg|
9487281|NCT01084161|Experimental|N1539 60 mg|
9487282|NCT01084161|Placebo Comparator|Placebo|
9487283|NCT01084161|Active Comparator|morphine|
9487284|NCT01083615|Experimental|Custirsen|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of custirsen will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly custirsen infusions (640 mg total dose) on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
9487285|NCT01083615|Placebo Comparator|Placebo|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of placebo (isotonic, 0.9% sodium chloride) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly placebo infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
9487286|NCT01082549|Active Comparator|gemcitabine/carboplatin|
9487287|NCT01082549|Experimental|gemcitabine/carboplatin plus Iniparib|
9487288|NCT01082068|Experimental|Arm 1|XL147 (SAR245408) + letrozole
9487289|NCT01082068|Experimental|Arm 2|XL765 + letrozole
9487290|NCT01081782|Experimental|E1|
9487291|NCT01081782|Experimental|E2|
9487292|NCT01081782|Experimental|E3|
9487293|NCT01081782|Placebo Comparator|P|
9487294|NCT01080222|Experimental|Treatment Arm A|Treatment Arm A was discontinued as a result of patients meeting a pre-defined stopping rule related to viral breakthrough during the first four weeks of dosing.
9487295|NCT01080222|Experimental|Treatment Arm B|Treatment Arm B was discontinued as a result of patients meeting a pre-defined stopping rule relating to viral breakthrough.
9487296|NCT01080222|Experimental|Treatment Arm C|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
9487297|NCT01080222|Experimental|Treatment Arm D|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
9487298|NCT01080222|Experimental|Treatment Arm E|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
9487299|NCT01080222|Experimental|Treatment Arm F|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
9487300|NCT01079325|Experimental|SB-509|
9487301|NCT01079325|Placebo Comparator|Placebo|Saline
9487302|NCT01077700|Experimental|ABT-288 Dose 1|low dose of ABT-288
9487303|NCT01077700|Experimental|ABT-288 Dose 2|high dose of ABT-288
9487304|NCT01077700|Placebo Comparator|Sugar Pill|inactive substance
9487305|NCT01077297|Experimental|Tezosentan|
9487306|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.100 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban (0.080 mg/kg bolus followed by 0.100 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
9487307|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.140 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban 0.080 mg/kg bolus followed by 0.140 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
9487308|NCT01076764|Active Comparator|UFH + Eptifibatide|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Placebo (for Otamixaban)~Drug B: UFH (60 IU/kg bolus followed by 12 IU/kg/h infusion)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Eptifibatide (180 mcg/kg bolus followed by 2 mcg/kg/min infusion)"
9487309|NCT01074294|Placebo Comparator|Sugar pill|
9487310|NCT01074294|Experimental|OPC-34712|
9487311|NCT01073228|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 183 days
10040535|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
10040536|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
9545019|NCT03071978|Experimental|LV-fusion pacing|Left Ventricular pacing (without Right Ventricular pacing)
9545020|NCT03071978|Active Comparator|BV pacing|Bi-Ventricular pacing
9545021|NCT03072095|Experimental|Text-only|Text-only outreach
9545022|NCT03072095|Experimental|Text + Lottery|Text outreach + financial incentive
9545023|NCT03071991||Study group|Preincisional bupivacain will be used
9545024|NCT03071991||Control group|No preincisional anesthetic drug will be used
9545025|NCT03071874|Experimental|AZD2014|"AZD2014 will be administered orally at a pre-determine dose~Twice daily for two consecutive days out of every seven days~Cycles will last 28 days"
9545026|NCT03072225|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
9545027|NCT03072225|Placebo Comparator|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
9545028|NCT03071848||Bevacizumab|Participants with advanced cervical cancer (metastatic, recurrent or persistent) who have received treatment with bevacizumab from 01 January 2015 to 01 January 2016 (retrospective and independent from this study) combined with standard chemotherapy (cisplatin/carboplatin or topotecan and paclitaxel) will be observed.
9545029|NCT03071900|Experimental|SCCHN|squamous cell carcinoma of the head and neck
9545030|NCT03071900|Experimental|Control|health volunteers
9545031|NCT03071861|Experimental|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at <24 hours of age
9545032|NCT03071861|Placebo Comparator|Placebo|IV, Normal saline (placebo dose), one dose at <24 hours of age
9545033|NCT03071796|Experimental|multivitamin supplement|liquid multivitamin supplement for 12 weeks
9545034|NCT03071796|Placebo Comparator|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
9545035|NCT03071627|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
9545036|NCT03071627|Experimental|News without spin|News items reporting results of animal studies without spin.
9545037|NCT03071523|Experimental|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
9545038|NCT03071523|Active Comparator|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
9545039|NCT03071783|Experimental|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
9545040|NCT03071783|No Intervention|conventional|conventional handle
9545041|NCT03071614|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
9545042|NCT03071614|Experimental|News without spin|News items reporting results of animal studies without spin.
9545043|NCT03071679|Experimental|Omiganan|
9545044|NCT03071679|Experimental|Imiquimod|
9545045|NCT03071679|Experimental|Omiganan 1% and Imiquimod|
9545046|NCT03071679|Experimental|Omiganan 2.5% and Imiquimod|
9545047|NCT03071679|Placebo Comparator|Placebo|Vehicle
9545048|NCT03071666|Experimental|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
9545049|NCT03071666|Placebo Comparator|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
9545050|NCT03071653|Active Comparator|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
9545051|NCT03071653|Other|OMT only|Optimal Medical Therapy (OMT) only
9545052|NCT03071588|Active Comparator|Control|the conventional protocol in indirect pulp capping include the use of mechanical rotary burs for caries removal in teeth with reversible pulpitis.
9545053|NCT03071588|Experimental|Conservative|the conservative protocol of indirect pulp capping include the use of Carisolv gel for caries removal in teeth with reversible pulpitis.
9545054|NCT03071822|Experimental|PIGLETs|Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses
9545055|NCT03071731|Experimental|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
9545056|NCT03071731|Placebo Comparator|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
10040537|NCT01854437||placebo|placebo 1 tab TDS
10040538|NCT01854450|Experimental|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
10040539|NCT01854450|Other|control|usual obstetrical care
10040540|NCT01854463|Experimental|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
9545057|NCT03071536|Experimental|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.~Urine output will be recorded hourly for 6 hours."
9545058|NCT03071575|Active Comparator|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
9545059|NCT03071575|Active Comparator|Group B:|Group B will receive a measles-rubella dose at 9 months only
9545060|NCT03071692|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
9545061|NCT03071692|Placebo Comparator|Control Group|Matching K-877 placebo tablet twice daily.
9545062|NCT03071549|Active Comparator|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
9545063|NCT03071549|Active Comparator|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
9545064|NCT03071718|Experimental|Med-D|Subjects will follow a Mediterranean diet for two months
9545065|NCT03071718|Active Comparator|Cont-D|Subjects will follow a control diet for two months
9545066|NCT03071770|Experimental|ivosidenib (AG-120)|
9545067|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
9545068|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
9545069|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
9545070|NCT03071484|Experimental|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
9545071|NCT03071484|Placebo Comparator|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
9545072|NCT03071705|Experimental|Intervention|TKI plus Metformin
9545073|NCT03071705|Active Comparator|Control|TKI
9545074|NCT03071458||Patients with HCC|The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
9545075|NCT03071562|Experimental|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
10040541|NCT01854463|Placebo Comparator|placebo|administered elemental calcium 200mg daily for 24 weeks
10058483|NCT02018549|Experimental|Placebo|Inhalation through Chiesi NEXThaler DPI containing Placebo Dry Powder. Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
10058484|NCT02018575|Experimental|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
10058485|NCT02018588|Experimental|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
10058486|NCT02018601|Experimental|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
10058487|NCT02018601|Active Comparator|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
10058488|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
10058489|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
9545076|NCT03071562|No Intervention|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
9545077|NCT03071393|Active Comparator|Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen.
9545078|NCT03071393|Sham Comparator|Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo a sham placebo protocol with normal oxygen air (21% inspired oxygen).
9545079|NCT03071367|Experimental|Clinical Simulation|
9545080|NCT03071367|No Intervention|Classical Learning|
9545081|NCT03071354|Experimental|HMB Protein Supplementation Group|"Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
9616719|NCT02539849|Other|adalimumab + FOS|Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)
9545082|NCT03071354|Active Comparator|Control Group|"Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
9545083|NCT03071289|Active Comparator|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
9545084|NCT03071289|Experimental|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
9545085|NCT03071302|Active Comparator|keratoconus|"Evaluation of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes. Keratoconus with fellow eye without topographic and tomographic keratoconous pattern.Evaluation of tomographic datas. Sometimes we picked up the sample of corneal epithelium, and peripheral blood sample from corneal cross linking surgeries, in that case of keratoconus progression.~Group A Keratoconus/ like sound cornea. Group C Keratoconus / Keratoconus~Group C Keratoconus / Keratoconus"
9545086|NCT03071302|Placebo Comparator|sound cornea|"Evaluation of VSX1, SOD1, and TIMP3 genes. To analyze tomographic aspects, we evaluated the patients that underwent to LASIK (Lasei in situ Keratomileusis) with 2 year with follow up without any sign of ectasia To analyze the genes we picked up the sample of corneal epithelium, and peripheral blood sample from PRK (PhotoRefractive Keratectomy) surgeries. These patients showed topographic and tomographic normal pattern.~Group B Sound Cornea / Sound Cornea"
9545087|NCT03071432|Active Comparator|Non-diabetic patients|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
9545088|NCT03071432|Active Comparator|Diabetic patients with cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
9545089|NCT03071432|Active Comparator|Diabetic patients without cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
9545090|NCT03071341|Experimental|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
9545091|NCT03071380|Experimental|T test|Test drug (Repatoxaban) 1 tablet contains 10 mg rivaroxaban
9545092|NCT03071380|Active Comparator|B reference|Reference drug (Xarelto) 1 tablet contains 0 mg rivaroxaban
9616720|NCT02539836|Experimental|Obesity with dietary nutrition|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
10040542|NCT01854476|Experimental|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
10040543|NCT01854476|Placebo Comparator|Pad gauze|Pad gauze with no tranexamic acid
10040544|NCT01854489|Active Comparator|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
10040545|NCT01854489|Placebo Comparator|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
10040546|NCT01854489|Active Comparator|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
10040547|NCT01854502|Experimental|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
10040548|NCT01854502|No Intervention|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.~The child was given multi-faceted counseling for good oral health habits."
10040549|NCT01854502|Experimental|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
10040550|NCT01854515|Active Comparator|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
10040551|NCT01854515|Experimental|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
10040552|NCT01854541||Radiotherapy|All patients receiving radiotherapy
10040553|NCT01854554|Experimental|Intensity Modulated Proton Radiotherapy (IMPT)|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
9545093|NCT03071419|Experimental|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
9545094|NCT03071419|Active Comparator|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
10040554|NCT01854554|Experimental|Intensity Modulated Radiotherapy (IMRT)|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
10040555|NCT01854567|Experimental|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
9545095|NCT03070977|Experimental|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.
9545096|NCT03070977|No Intervention|Standard unit|Students in the control group receive training in standard psychiatric wards.
9545097|NCT03071029|Experimental|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
9545098|NCT03071029|No Intervention|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
9545099|NCT03071107|Active Comparator|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
9545100|NCT03071107|No Intervention|Control arm|Standard of care
10040556|NCT01854567|Active Comparator|Control|Infusion of two unexpanded cord blood units.
10040557|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
10040558|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
10040559|NCT01854606|Experimental|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
10040560|NCT01854619|Active Comparator|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
10040561|NCT01854619|Active Comparator|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
10040562|NCT01854619|Active Comparator|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
10040563|NCT01854671|No Intervention|standard care|
10040564|NCT01854671|Experimental|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
10040565|NCT01854684|Experimental|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
10040566|NCT01854723|Experimental|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
10040567|NCT01854723|Active Comparator|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
9616721|NCT02539836|Active Comparator|Liver fat of obese children|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
10040568|NCT01854736|Active Comparator|GRAZAX|Tablet 75.000SQ-T once daily
10040569|NCT01854736|Placebo Comparator|Placebo|Tablet with no active grass component
10040570|NCT01854749|Experimental|S1 combined with cisplatin|
10040571|NCT01854762|Experimental|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
10040572|NCT01854762|Active Comparator|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
10040573|NCT01854788|Active Comparator|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
10040574|NCT01854788|Active Comparator|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
10040575|NCT01854788|Active Comparator|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
10058490|NCT02018666|Experimental|spontaneous NAVA mode|
10058491|NCT02018666|Active Comparator|Inspiratory pressure support (IPS)|
10040576|NCT01854801|Experimental|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
10040577|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
10040578|NCT01854853|Experimental|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
10040579|NCT01854853|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
10040580|NCT01854866|Experimental|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
10040581|NCT01854892|Experimental|Manipulation|Spinal manipulation
10040582|NCT01854892|Experimental|Mobilization|Spinal mobilization
10040583|NCT01854892|Experimental|Laser Therapy|Cold laser therapy
10040584|NCT01854931|Other|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
9487312|NCT01073228|Active Comparator|EVP-6124 1 mg|one 1 mg capsule every day for 183 days
9487313|NCT01073228|Active Comparator|EVP-6124 2 mg|one 2 mg capsule every day for 183 days
9487314|NCT01073228|Placebo Comparator|Placebo|Placebo every day for 183 days
9487315|NCT01072981|Experimental|HyperAcute-Pancreas Immunotherapy + Standard of Care|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation + HyperAcute Immunotherapy
9487316|NCT01072981|Active Comparator|Standard of Care alone|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation Alone
9487317|NCT01071902|Experimental|Moxidex|Moxidex otic solution
9487318|NCT01071902|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
9487319|NCT01071902|Placebo Comparator|Vehicle|Vehicle
9487320|NCT01071850|Experimental|ASP1941 lowest dose|oral tablet
9487321|NCT01071850|Experimental|ASP1941 low dose|oral tablet
9487322|NCT01071850|Experimental|ASP1941 high dose|oral tablet
9487323|NCT01071850|Experimental|ASP1941 highest dose|oral tablet
9487324|NCT01071850|Active Comparator|Metformin|oral tablet
9487325|NCT01071850|Placebo Comparator|Placebo|oral tablet
9487326|NCT01071239|Experimental|Bone marrow processing|Bone Marrow processing using the CliniMACs device
9487327|NCT01071226|Experimental|Stratum 1|Patients receiving an unrelated donor or partially matched related donor.
9487328|NCT01071226|Experimental|Stratum 2|For the patient's whose donors are haploidentical or a 2 antigen mismatched where one of the mismatches includes DRB1
9487329|NCT01070433|Experimental|MEBO Wound Ointment (MEBO)|Topical application twice a day
9487330|NCT01070433|Active Comparator|Standard of Care|Topical application twice a day
9487331|NCT01069692|Placebo Comparator|Arm 1|Placebo
9487332|NCT01069692|Experimental|Arm 3|
9487333|NCT01069692|Experimental|Arm 2|
9487334|NCT01069692|Experimental|arm 4|SBR759A
9487335|NCT01069692|Experimental|arm 5|
9487336|NCT01068704|Active Comparator|BMS-690514 + Letrozole|
9487337|NCT01068704|Active Comparator|Lapatinib + Letrozole|
9487338|NCT01068613|Experimental|QAX028 high dose|
9487339|NCT01068613|Experimental|QAX028 low dose|
9487340|NCT01068613|Active Comparator|Tiotropium|
9487341|NCT01068613|Placebo Comparator|Placebo|
9487342|NCT01067859|Experimental|Arm 1|
9487343|NCT01067859|Experimental|Arm 2|
9487344|NCT01067859|Placebo Comparator|Arm 3|
9487345|NCT01065935|Active Comparator|ALN-RSV01|
9487346|NCT01065935|Placebo Comparator|Normal saline|
9487347|NCT01065077|Experimental|Arm 1|
9487348|NCT01065077|Experimental|Arm 2|
9487349|NCT01065077|Experimental|Arm 3|
9487350|NCT01065077|Placebo Comparator|Arm 4|
9487351|NCT01065012|Experimental|Udenafil 50 mg|50 mg Udenafil
9487352|NCT01065012|Experimental|Udenafil 100 mg|100 mg Udenafil
9487353|NCT01065012|Experimental|Udenafil 150 mg|150 mg Udenafil
9487354|NCT01065012|Placebo Comparator|Placebo|Placebo Tablets matching Udenafil tablets
9487355|NCT01064791|Experimental|Arm 1|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
9487356|NCT01064791|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
9487357|NCT01064791|Experimental|Arm 3|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
9487358|NCT01064791|Active Comparator|Arm 4|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
9487359|NCT01064518|Active Comparator|Dose A|RT001 Topical Gel
9487360|NCT01064518|Placebo Comparator|Dose B|Placebo Comparator
9487361|NCT01064440|Experimental|Low Dose VM202|Patients in this group will receive 8mg total of VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
9487362|NCT01064440|Experimental|High Dose VM202|Patients in this treatment group will receive a total of 16mg VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day42: 4mg of VM202 (16 injections of 0.5ml of VM202)
9487363|NCT01064440|Sham Comparator|Placebo|Patients in this group will receive a total of 8ml normal saline. Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
9487364|NCT01064037|Experimental|Arm 1|
9487365|NCT01064037|Experimental|Arm 2|
9487366|NCT01064037|Experimental|Arm 3|
9487367|NCT01064037|Placebo Comparator|Arm 4|
9545101|NCT03071185|Experimental|Group PCA+B|Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.
9545102|NCT03071185|No Intervention|Group PCA|Only intravenous patient controlled analgesia (PCA) was used postoperatively.
9545103|NCT03070990|Experimental|Arm A: Enfortumab vedotin 1.0 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
9545104|NCT03070990|Experimental|Arm B: Enfortumab vedotin 1.25 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
9545105|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
9545106|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
9545107|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photo-taken or video-recorded before its transection.
9545108|NCT03071198|Experimental|Preoperative neoadjuvant CT|Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
9545109|NCT03071198|Experimental|Preoperative neoadjuvant CT-RCT|Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
9545110|NCT03071198|Active Comparator|Concurrent chemo-radiotherapy|Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
9545111|NCT03071081|Experimental|TOP1288 200mg BID|1 day dosing
9545112|NCT03071081|Placebo Comparator|Placebo to TOP1288 200mg BID|1 day dosing
10040585|NCT01854957|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
10040586|NCT01854957|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
10040587|NCT01854970|Experimental|Patient|
10040588|NCT01854996|Experimental|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
9545113|NCT03071081|Experimental|TOP1288 1g BID|1 day dosing
9545114|NCT03071081|Placebo Comparator|Placebo to TOP1288 1g BID|1 day dosing
9545115|NCT03071081|Experimental|TOP1288 Xg (where X is <=1g) BID|7 days dosing
9545116|NCT03071081|Placebo Comparator|Placebo to TOP1288 Xg|7 days dosing
9545117|NCT03071055|Active Comparator|ranibizumab|ranibizumab 0.5mg in commercially available vial
9545118|NCT03071055|Experimental|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
9545119|NCT03071224|Experimental|[18F]MNI-946|To evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
9545120|NCT03071159|Other|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
9545121|NCT03071172|Experimental|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
9545122|NCT03071172|Active Comparator|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
9545123|NCT03071003|Experimental|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
10040589|NCT01854996|Experimental|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
10040590|NCT01854996|Experimental|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
10040591|NCT01855009|Active Comparator|MannaBears|Subjects will take 4 MannaBears daily
10040592|NCT01855009|Active Comparator|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
10040593|NCT01855009|Active Comparator|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
9545124|NCT03071003|Experimental|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
9545125|NCT03071003|Experimental|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
9545126|NCT03071042|Experimental|Apatinib plus Docetaxel|Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
9545127|NCT03071068|Experimental|THR-317 4mg|anti-PlGF recombinant monoclonal antibody, 4mg dose
9545128|NCT03071068|Experimental|THR-317 8mg|anti-PlGF recombinant monoclonal antibody, 8mg dose
9545129|NCT03071211|Experimental|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
9545130|NCT03071211|Active Comparator|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
9545131|NCT03071211|No Intervention|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
9545132|NCT03070873|Experimental|group A|accepted Perigee and Apogee mesh(PA)
9545133|NCT03070873|Experimental|group B|accepted Gynecare prolift mesh
9545134|NCT03070873|Placebo Comparator|group C|Traditional surgery without any mesh
9545135|NCT03070860|Experimental|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
9545136|NCT03071146||Bard® LifeStent® 5F Vascular Stent System|Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
9545137|NCT03070847|Experimental|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
9545138|NCT03070847|Active Comparator|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
9545139|NCT03070756|Other|treatment group (auto-CPAP)|"Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.~Interventions:~The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention)."
9545140|NCT03070665|Experimental|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
9545141|NCT03070665|No Intervention|Control group|Patients received normal ESD manipulation.
10040594|NCT01855022|Experimental|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
10040595|NCT01855022|No Intervention|Usual Care|Usual care that a patient would receive absent the intervention
9545142|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.
9545143|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.
9545144|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
9545145|NCT03070574|Experimental|2400 MG mesalamine (5-ASA) total|2400mg (1200mg mesalamine/1200mg) mesalamine once daily in the morning for the treatment phase of the study (24 months)
9545146|NCT03070574|Experimental|1200 MG mesalamine (5-ASA) total|placebo/1200mg mesalamine once daily in the morning for the treatment phase of the study (24 months)
9545147|NCT03070574|Placebo Comparator|Placebo|placebo/placebo once daily in the morning for the treatment phase of the study (24 months)
9545148|NCT03070600|Active Comparator|Universal PrEP Counselling|All enrolled women receiving antenatal care at facilities assigned to Universal PrEP arm will receive standardized HIV risk counseling and then self-select whether they want to use PrEP.
9545149|NCT03070600|Experimental|Targeted PrEP Clinics|All enrolled women receiving antenatal care at facilities assigned to the Targeted PrEP arm will be assessed for HIV-risk prior to receiving targeted PrEP counseling.
9545150|NCT03070795|Experimental|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
9545151|NCT03070795|Active Comparator|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
9545152|NCT03070834|Experimental|rIVCF|Randomized to receive insertion of retrievable inferior vena cava filter until chemical anticoagulation can be safely administered.
9545153|NCT03070834|No Intervention|Standard Care|Randomized to not receive insertion of retrievable inferior vena cava filter.
10040596|NCT01855035|Experimental|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
10040597|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
10059482|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
9545154|NCT03070639|No Intervention|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
9545155|NCT03070639|Active Comparator|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
9545156|NCT03070639|Experimental|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
9545157|NCT03070626|Experimental|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
9545158|NCT03070626|No Intervention|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
9545159|NCT03070587|Experimental|Positive Affect Training for SAD|The intervention will be conducted in groups with 68 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
9545160|NCT03070587|No Intervention|Wait list Control|These participants will not be given an intervention until after they have completed the study.
9545161|NCT03070704||Insulin degludec /liraglutide|
9545162|NCT03070561|Experimental|Sublingual film with peanut extract|
9545163|NCT03070652|Experimental|NBO, Newborn behavioral observation|In the intervention group new parents will receive the NBO delivered in connection with the examination of the newborn in a shared observation with the parents in the homevisit of the health visitor 3 weeks post partum
9545164|NCT03070652|Experimental|Practice as usual|In the comparison group new parents will receive practice as usual due to the examination of their newborn in the homevisit of the health visitor 3 weeks post partum
9545165|NCT03070678|Experimental|SAR439954 with or without mefenamic acid|Period 1: single oral dose of 400 mg sotagliflozin Period 2: initial loading dose of 500 mg in the morning of Day 1, followed by 250 mg from Day 1 H6 to Day 7 of mefenamic acid and a single oral dose of sotagliflozin on Day 2
9545166|NCT03070691|Active Comparator|LDE225 0.75% cream|
9545167|NCT03070691|Placebo Comparator|Vehicle|
9545168|NCT03070522|Active Comparator|Placebo|Placebo
9545169|NCT03070522|Active Comparator|Treatment|Prednisone
9545170|NCT03070444|Experimental|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
9545171|NCT03070444|Active Comparator|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
9545172|NCT03070535|Experimental|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of >70, and 20% protein.
9545173|NCT03070535|Experimental|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of <55), and 20% protein.
9545174|NCT03070457|Experimental|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
9545175|NCT03070457|Active Comparator|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
9545176|NCT03070613|Experimental|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
9545177|NCT03070821|Experimental|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
9545178|NCT03070821|Experimental|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
9545179|NCT03070821|Sham Comparator|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
9545180|NCT03070509|Experimental|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
9545181|NCT03070509|Experimental|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
9545182|NCT03070496|Experimental|STEMI cohort|"Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :~an additional blood sampling at 6 months~an additional electrocardiogram (ECG) at 6 months~Magnetic Resonance Imaging (MRI)~Quality of life questionnaire"
9545183|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
9545184|NCT03070314|Experimental|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
9545185|NCT03070379|Experimental|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
9545186|NCT03070379|No Intervention|Control group|No topical lidocaine pharyngeal anesthesia was performed.
9545187|NCT03070418|Experimental|Abdulhai|One show man technique, it is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision.
9545188|NCT03070405|Active Comparator|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
9545189|NCT03070405|Experimental|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
9545190|NCT03070288||Group 1|Red-green-blue measurements of nasal mucosa images of patients with allergic rhinitis
9545191|NCT03070288||Group 2|Red-green-blue measurements of nasal mucosa images of normal healthy individuals
9545192|NCT03070353|Experimental|Dextran 40|Dextran 40 infusion
9545193|NCT03070145|Experimental|Exercise Intervention|"12-weeks brisk walking and strength training~150 minute moderate aerobic activities, such as brisk walking~Strength training 3 days /week~One on one sessions with exercise physiologist~Optional group sessions"
9545194|NCT03070145|No Intervention|Usual Care|Usual Care provided
9545195|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
9545196|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
9545197|NCT03070262|Experimental|CA group|caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
9545198|NCT03070262|Placebo Comparator|placebo group|the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
9545199|NCT03070158|Experimental|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
9545200|NCT03070158|No Intervention|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
9545201|NCT03070275|Experimental|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
9545202|NCT03070275|Active Comparator|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
9545203|NCT03070223||Experimental: Pitavastatin|Participants who receive pitavastatin in the main study REPRIEVE (A5332).
9545204|NCT03070223||Placebo Comparator: Placebo|Participants who receive placebo for pitavastatin in the main study REPRIEVE (A5332).
9545205|NCT03070210|Other|EUS-celiac plexus block (EUS-CPB)|"This is the standard technique. In this approach, the needle is passed through the body of the stomach adjacent the celiac artery into the retroperitoneal space in 1 or 2 passes. The injectate (bupivacaine or alcohol) is injected and spreads through the retroperitoneal space, effectively bathing all the ganglia."
9545206|NCT03070210|Active Comparator|EUS-celiac ganglia block (EUS-CGB)|This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia <1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
9545207|NCT03070041|Experimental|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
9545208|NCT03070080|Active Comparator|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
9545209|NCT03070080|Active Comparator|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
9545210|NCT03070132|Experimental|BIIB074|Optimized oral dose three times daily (TID)
9545211|NCT03070132|Experimental|Placebo|Administered orally TID
9545212|NCT03070106|No Intervention|Usual Care|usual care delivered by an endocrinologist
10040598|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.~Side studies include:~pharmacogenetics~pharmacokinetics of SN-38~carboxylesterase activity in the index lesion~midazolam clearance test (only in Rotterdam patients)"
10040599|NCT01855100||Rivaroxaban|
9545213|NCT03070106|Active Comparator|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
9545214|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
9545215|NCT03070119|Experimental|BIIB067|Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
9545216|NCT03070015|Experimental|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
9545217|NCT03070015|Active Comparator|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
9545218|NCT03070028|Experimental|Phenol|crystallised phenol application
9545219|NCT03070028|Experimental|platelet rich plasma|PRP application
9545220|NCT03070054|No Intervention|Control|non-LIA group prior to surgery
10040600|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
10040601|NCT01855113||braces|those with braces for orthodontic correction.
10040602|NCT01855139||Rivaroxaban|
10040603|NCT01855152|Experimental|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
9545221|NCT03070054|Experimental|Treatment|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
9545222|NCT03070067||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
9545223|NCT03070067||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
9545224|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
9545225|NCT03069963|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
9545226|NCT03069963|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
9545227|NCT03069976|Experimental|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
9545228|NCT03069898|Experimental|TRUE Dads program track|In the TRUE Dads program, fathers and co-parents begin with a Core workshop meeting weekly for 6 weeks. After a check-in, a male-female group leader team focuses on a single topic that represents one of the three main goals of the project as a whole: Co-parenting relationships, Parenting, or Employment and financial stability. From 10 to 18 couples, seated at small tables in a large room, hear mini-lectures, watch videos, and engage in interactive exercises. Fathers then choose to attend one of three intensive workshops focused on couple relationships OR parenting OR economic self-sufficiency meeting 3 hours per week for the next 6 weeks. On an as-needed basis, fathers may be referred for employment programs and fathers and co-parents may be referred for mental health or other services.
9545229|NCT03069898|No Intervention|Control condition study track|Participants (fathers and co-parents) complete intake interview and fill out Baseline survey. They fill out follow-up survey one year later
9545230|NCT03069872|Experimental|Intervention|All GPs in Central Denmark Region, are planned to be enrolled in the study during the one year study period.
9545231|NCT03069794|Other|Use of stable force platform|Ennrollment of every patient programmed for spinal surgery in orthopaedic service
9545232|NCT03069950|Experimental|HAI FUDR/Dex in addition to Pmab plus FOLFIRI|Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
9545233|NCT03069950|Experimental|Pmab plus FOLFIRI alone|The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
9545234|NCT03069729||Control group|non-diabetic; no intervention
9545235|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
9545236|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
9545237|NCT03069833|Experimental|Computer-aided diagnosis|
9545238|NCT03069833|No Intervention|traditional diagnosis|
9545239|NCT03069781|Experimental|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
9545240|NCT03069781|Placebo Comparator|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
9545241|NCT03069820|Experimental|Study Population|Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
9545242|NCT03069768|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
9545243|NCT03069768|Active Comparator|Control|Smokers in this group will not be given the mSMART application.
9545244|NCT03069846|Experimental|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
9545245|NCT03069664|Active Comparator|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
9545246|NCT03069664|No Intervention|Control group|control group
9545247|NCT03069924|Active Comparator|No NRT - No Messaging|Brief counseling, but no NRT and no gain-framed messaging.
9545248|NCT03069924|Active Comparator|NRT - No Messaging|Brief counseling plus NRT but no gain-framed messaging.
9545249|NCT03069924|Active Comparator|No NRT - Messaging|Brief counseling plus gain-framed messaging but no NRT.
9545250|NCT03069924|Experimental|NRT plus Messaging|Brief counseling plus NRT and gain-framed messaging.
9545251|NCT03069651|Active Comparator|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
9545252|NCT03069651|Placebo Comparator|Routine Care|Usual clinical care.
9545253|NCT03069885|Active Comparator|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
9545254|NCT03069885|Experimental|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
9545255|NCT03069703|Active Comparator|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
9545256|NCT03069703|Experimental|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
9545257|NCT03069703|Experimental|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
9545258|NCT03069911|Experimental|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
9545259|NCT03069911|Placebo Comparator|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
9545260|NCT03069742|Experimental|Decision Aid|Women at high risk for developing breast cancer will use a decision support tool, RealRisks, that facilitates discussion of breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
9545261|NCT03069742|No Intervention|Control Group|Women at high risk for developing breast cancer will receive standard breast health education brochures.
9545262|NCT03069638|Experimental|Intranasal dexmedetomidine|Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
9545263|NCT03069638|Active Comparator|Nitrous oxide inhalation|Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
9545264|NCT03069625|Experimental|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
9545265|NCT03069625|Active Comparator|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
9545266|NCT03069391|Active Comparator|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
9545267|NCT03069391|Active Comparator|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
9545268|NCT03069443|Experimental|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
9545269|NCT03069443|No Intervention|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
9545270|NCT03069612|Experimental|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
9545271|NCT03069612|Sham Comparator|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
9545272|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
9545273|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
9545274|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
9545275|NCT03069456|Active Comparator|BIS group|Combined sigmoidal Emax models from the BIS data
9545276|NCT03069456|Experimental|ADMS group|Combined sigmoidal Emax models from the ADMS data
9545277|NCT03069508|Experimental|200 mg TID|200 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
9545278|NCT03069508|Experimental|300 mg TID|300 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
9545279|NCT03069508|Experimental|400 mg TID|400 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
9545280|NCT03069508|Experimental|500 mg TID|500 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
9545281|NCT03069586|Other|Low pressure pneumoperitoneum|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg).
9545282|NCT03069586|Active Comparator|low pressure peritoneum and pulmonary recruitment|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg) and at the end of surgery a manual pulmonary recruitment manoeuver (2 x 5sec max 40cmH2O) will be done
9545283|NCT03069560|Experimental|SMS|The patients will receive from the caregiver a first SMS 48 hours after their discharge from the hospital then a total of 4 messages : 48 hours, S1, S2, and S4.
9545284|NCT03069534|Experimental|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
9545285|NCT03069534|No Intervention|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
9487368|NCT01064024|Active Comparator|Phenazopyridine Hydrochloride Tablets, USP 200 mg|
9545286|NCT03069573||Eosinophilic Esophagitis - EoE|Diagnosis of pediatric EoE under current guidelines.
9487369|NCT01064024|Placebo Comparator|Placebo|Matching placebo to the phenazopyridine hydrochloride tablets
9487370|NCT01063803|Experimental|Arm 1: ATN-103_30mg|
9487371|NCT01063803|Experimental|Arm 2: ATN-103_80 mg|
9487372|NCT01060579|Experimental|AR-12286 0.5% ophthalmic solution|
9487373|NCT01060579|Experimental|AR-12286 0.25% Ophthalmic Solution|
9487374|NCT01060579|Experimental|Latanoprost 0.005% ophthalmic solution|
9487375|NCT01060254|Experimental|JNJ-42160443|
9487376|NCT01060254|Placebo Comparator|Placebo|
9487377|NCT01058434|Experimental|TKI258|
9487378|NCT01058018|Experimental|A - 100 mg per day RVX000222|Arm A: Treatment with RVX000222 at 50 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
9487379|NCT01058018|Experimental|B - 200 mg per day RVX000222|Arm B: Treatment with RVX000222 100 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
9487380|NCT01058018|Experimental|C - 300 mg per day RVX000222|Arm C: Treatment with RVX000222 150 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
9487381|NCT01058018|Placebo Comparator|D - Placebo|Arm D: Treatment with placebo for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
9487382|NCT01057667|Experimental|Arm A: With RO5024048|Patients in arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily).
9487383|NCT01057667|Active Comparator|Arm B: Standard treatment|Patients in arm B will receive standard treatment with Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
9487384|NCT01057147|Experimental|rebamipide 2% ophthalmic suspension|
9487385|NCT01057147|Placebo Comparator|placebo eye drops|
9487386|NCT01056393|Experimental|ibalizumab 800mg Q2Weeks|Subject will receive 800mg of ibalizumab every 2 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
9487387|NCT01056393|Experimental|ibalizumab 2000mg Q4Weeks|Subject will receive 2000mg of ibalizumab every 4 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
9487388|NCT01055912|Experimental|Lixivaptan|Capsule, 100mg Lixivaptan or matching placebo once daily.
9487389|NCT01055912|Placebo Comparator|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
9487390|NCT01055444|Experimental|Heated lidocaine/tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
9487391|NCT01055106|Active Comparator|1D|
9487392|NCT01055106|Active Comparator|3D|
9487393|NCT01055106|Active Comparator|5D|
9487394|NCT01055106|Active Comparator|Metronidazole|
9487395|NCT01055015|Experimental|1|Q8003, Flexible dose
9487396|NCT01055015|Experimental|2|Q8003, Low dose
9487397|NCT01054807|Other|GalyfilconHL/Galyfilcon8.7/Galyfilcon8.3|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)
9487398|NCT01054807|Other|Galyfilcon8.7/Galyfilcon8.3/GalyfilconHL|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
9487399|NCT01054807|Other|GalyfilconHL/Galyfilcon8.3/Galyfilcon8.7|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)
9487400|NCT01054807|Other|Galyfilcon 8.7/Galyfilcon HL/Galyfilcon 8.3|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator) /Galyfilcon A 8.3 BC (Experimental)
9487401|NCT01054807|Other|Galyfilcon8.3/GalyfilconHL/Galyfilcon8.7|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)
9487402|NCT01054807|Other|Galyfilcon8.3/Galyfilcon8.7/GalyfilconHL|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
9487403|NCT01053936|Experimental|Bardoxolone methyl: 5 mg|
9487404|NCT01053936|Experimental|Bardoxolone methyl: 10 mg|
9487405|NCT01053936|Experimental|Bardoxolone methyl: 15 mg|
9487406|NCT01053936|Experimental|Bardoxolone methyl: 30 mg|
9487407|NCT01053936|Experimental|Bardoxolone methyl: 2.5 mg|
10040604|NCT01855152|Experimental|Treatment as usual|Treatments delivered as usual
10040605|NCT01855165|Experimental|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
10040606|NCT01855165|No Intervention|General advice|
10040607|NCT01855191||Standard|
9487408|NCT01052194|Experimental|25 mg b.i.d. VX-509|
9487409|NCT01052194|Experimental|50 mg b.i.d. VX-509|
9487410|NCT01052194|Experimental|100 mg b.i.d. VX-509|
9487411|NCT01052194|Experimental|150 mg b.i.d. VX-509|
9487412|NCT01052194|Placebo Comparator|Placebo|
9487413|NCT01051414|Experimental|BMS-790052 + BMS-650032|
9487414|NCT01048255|Experimental|VX-765|
9498115|NCT03469011|Experimental|Imatinib oral100mg tablets|"A standard 3+3 trial design will be utilized for the imatinib dosing. In general, patients will be treated in cohorts of 3-6 with escalating doses of imatinib using oral 100mg tablets.~Dose Level -1=100mg, +1=200mg (starting dose for cohort 1), +2=300mg, +3=400mg, +4=600mg (if needed)."
9498116|NCT03468998|Active Comparator|Ridge Preservation with Small Particle Allograft|
9498117|NCT03468998|Active Comparator|Ridge Preservation with Large Particle Allograft|
9498118|NCT03468998|Active Comparator|Ridge Augmentation with Small Particle Allograft|
9498119|NCT03468998|Active Comparator|Ridge Augmentation with Large Particle Allograft|
9498120|NCT03468972|Experimental|Immunosuppression|corticosteroids or cyclophosphamide added on corticosteroids
9545287|NCT03069573||Gastroesophageal reflux disease - GERD|Diagnosis of pediatric GERD under current guidelines.
9545288|NCT03069573||Control|Exclusion diagnosis of EoE or GERD, with non specific gastrointestinal general complaints.
9545289|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
9545290|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
9545291|NCT03069599||10 resection only|patients undergoing surgical resection only
9545292|NCT03069339|Experimental|Carvedilol+EVL|
9545293|NCT03069339|Experimental|Carvedilol|
9545294|NCT03069339|Active Comparator|EVL|
9545295|NCT03069287|Experimental|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
9545296|NCT03068988|Experimental|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
9545297|NCT03068988|Placebo Comparator|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
9545298|NCT03069105||Family caregivers|The sample for this study will consist of caregivers of patients with cancer. Eligible subjects who agrees to participate in the research study and sign the consent form will participate by completing paper and pencil or electronic questionnaires.
9545299|NCT03069001|Active Comparator|Sofosbuvir-Simeprevir|"Sofosbuvir 400 mg orally once-daily.~Simeprevir 150 mg orally once-daily.~Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
9545300|NCT03069001|Active Comparator|Sofosbuvir-Ribavirin|"Sofosbuvir 400 mg orally once-daily.~Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).~Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
9545301|NCT03069092|Experimental|Aerobic exercise (AE)|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
9545302|NCT03069092|Experimental|Resistance exercise (RE)|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial.
9545303|NCT03069092|Experimental|Combined Resistance and Aerobic Exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
9545304|NCT03069092|No Intervention|No training control|Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
9545305|NCT03069170|Experimental|Stem Cells|Intravenous administration of purified autologous bone marrow-derived stem cells.
9545306|NCT03069170|Experimental|Stem Cell Transplantation|Intrathecal administration of purified autolgous bone-marrow derived stem cells.
9545307|NCT03069131|Experimental|Active rifaximin|
9545308|NCT03069131|Placebo Comparator|Rifaximin placebo|
9545309|NCT03069027|Placebo Comparator|Group I(control)|patients allocated for external nasal nerve block with saline adrenaline 1/200,000 (placebo)
9545310|NCT03069027|Active Comparator|Group II(block)|'External nasal nerve block by Xylocaine, adrenaline'
9545311|NCT03069183|Active Comparator|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
9545312|NCT03069183|Placebo Comparator|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
9545313|NCT03069157|No Intervention|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
9545314|NCT03069157|Active Comparator|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
9545315|NCT03069014|Active Comparator|400mg LM11A-31-BHS|400mg LM11A-31-BHS and 400mg Placebo per day
9545316|NCT03069014|Active Comparator|800mg LM11A-31-BHS|800mg LM11A-31-BHS
9545317|NCT03069014|Placebo Comparator|Placebos|800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day
9545318|NCT03069118|Experimental|Treatment|Three-month intervention on the online Workit Health platform
9545319|NCT03069118|Placebo Comparator|Control|A list of online resources/waitlist
9545320|NCT03069248|Experimental|treatment arm|"Salvage treatment with CHOP or DHAP followed by high dose therapy and stem cell support prior to consolidative immunotherapy with Rituximab and Alpha interferon.~."
9545321|NCT03069040|Experimental|nerve-sparing radical hysterectomy|The patient recived surgury of nerve-sparing radical hysterectomy.
9545322|NCT03069040|Active Comparator|radical hysterectomy|The patient recived surgury of radical hysterectomy.
9545323|NCT03069274|Other|Control|Only general nutritional recommendations were given.
9545324|NCT03069274|Experimental|Intervention|General nutritional recommendations, change their drinking habits.
9545325|NCT03069209|Experimental|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
10040608|NCT01855191||Standard + saliva collection|
10040609|NCT01855204|Active Comparator|Conventional|Computed tomographic urography was done with conventional protocols.
10040610|NCT01855204|Experimental|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
10040611|NCT01855217|Active Comparator|Sugammadex total body weight|1 mg/kg total body weight
10040612|NCT01855217|Active Comparator|Sugammadex ideal body weight|1 mg /kg ideal body weight
10040613|NCT01855217|Placebo Comparator|placebo|placebo 0,9% NaCl
10040614|NCT01855230|Experimental|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
10040615|NCT01855230|Placebo Comparator|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
10040616|NCT01855256|Experimental|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
9487421|NCT01046916|Experimental|TAK-700|
9487422|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment A)|
9487423|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment B)|
9487424|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment C)|
9487425|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment D)|
9487426|NCT01046422|Placebo Comparator|Placebo ± metformin (Treatment E)|
9487427|NCT01044381|Experimental|Luliconazole Solution, 10%|
9487428|NCT01043263|Experimental|EN3324 (axomadol)|
9487429|NCT01043263|Placebo Comparator|Placebo|
9487430|NCT01043029|Experimental|aleglitazar|
9487431|NCT01043029|Active Comparator|pioglitazone|
9487432|NCT01042925|Experimental|Arm 1|XL147 in combination with trastuzumab
9487433|NCT01042925|Experimental|Arm 2|XL147 in combination with trastuzumab and paclitaxel
9487434|NCT01042769|Experimental|Aleglitazar|
9487435|NCT01042769|Placebo Comparator|Placebo|
9487436|NCT01041677|Experimental|001|R256918 10 mg capsule twice daily
9487437|NCT01041677|Experimental|002|R256918 15 mg capsule twice daily
9487438|NCT01041677|Placebo Comparator|003|placebo placebo capsule twice daily
9487439|NCT01040637|Experimental|TD-1211 dose level 1|Ascending doses
9487440|NCT01040637|Experimental|TD-1211 dose level 2|Ascending doses
9487441|NCT01040637|Experimental|TD-1211 dose level 3|Ascending doses
9487442|NCT01040637|Experimental|TD-1211 dose level 4|Ascending doses
9487443|NCT01040637|Experimental|TD-1211 OIC dose level 1|Ascending doses
9487444|NCT01040637|Experimental|TD-1211 OIC dose level 2|Ascending doses
9487445|NCT01040637|Experimental|TD-1211 OIC dose level 3|Ascending doses
9487446|NCT01040637|Experimental|TD-1211 OIC dose level 4|Ascending doses
9487447|NCT01040637|Experimental|TD-1211 OIC dose level 5|Ascending doses
9487448|NCT01040637|Placebo Comparator|Placebo|Ascending doses
9487449|NCT01039805|Experimental|Cohort 1|Subjects randomized to either GSK962040 (50 mg) or placebo
9487450|NCT01039805|Experimental|Cohort 2|Subjects randomized to either GSK962040 (75 mg) or placebo
9487451|NCT01038843|Experimental|VA106483 1mg|
9487452|NCT01038843|Experimental|VA106483 2mg|
9487453|NCT01038843|Experimental|VA106483 4mg|
9487454|NCT01038843|Placebo Comparator|Sugar pill|
9487455|NCT01038804|Experimental|A. YM155 plus docetaxel|
9487456|NCT01038804|Active Comparator|B. docetaxel alone|
9487457|NCT01038739|Experimental|A|
9487458|NCT01038739|Experimental|B|
9487459|NCT01038739|Placebo Comparator|C|
9487460|NCT01037816|Active Comparator|FS-67 patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
9487461|NCT01037816|Placebo Comparator|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
9487462|NCT01037231|Experimental|Oxabact (tm)|
9487463|NCT01037231|Placebo Comparator|Placebo|
9487464|NCT01037179|Experimental|AL-4943A|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, 2 drops instilled in each eye twice daily for 10 weeks
9487465|NCT01037166|Experimental|Entecavir (0.5 mg)|
9487466|NCT01037166|Experimental|Entecavir (1mg)|
9487467|NCT01037062|Experimental|Entecavir|
9487468|NCT01037036|Experimental|Latanoprost Punctal Plug Delivery System followed by Xalatan|Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
9487469|NCT01035879|Experimental|MBX-2982 25 mg|
9487470|NCT01035879|Experimental|MBX-2982 100 mg|
9487471|NCT01035879|Experimental|MBX-2982 300 mg|
9487472|NCT01035879|Active Comparator|Sitagliptin 100 mg|
9487473|NCT01035879|Placebo Comparator|Placebo|
9487474|NCT01035502|Experimental|Elacytarabine plus idarubicin|
9487475|NCT01033357|Active Comparator|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
9487476|NCT01033357|Placebo Comparator|Graft|Lifespan® ePTFE Vascular Graft Only
9487477|NCT01033292|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
9487478|NCT01033123|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
9487479|NCT01030432|Experimental|Phase 2a: Arm 1|
9487480|NCT01030432|Placebo Comparator|Phase 2a: Arm 2|
9487481|NCT01030432|Experimental|Phase 2b: Arm 1|
9487482|NCT01030432|Placebo Comparator|Phase 2b: Arm 2|
9487483|NCT01029873|Experimental|ALT-801|
9487484|NCT01027013|Experimental|rebamipide 2% ophthalmic suspension|
9487485|NCT01027013|Placebo Comparator|Placebo eye drops|
9487486|NCT01025648|Experimental|T1 - E004 90 mcg/actuation|T1 - E004 (epinephrine inhalation aerosol) 90 mcg/actuation - treatment by 2 actuations of E004 at 90 mcg/actuation
9487487|NCT01025648|Experimental|T2 - E004 125 mcg/actuation|E004 (epinephrine inhalation aerosol), 125 mcg, 2 actuations
9545326|NCT03068975|Experimental|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
9545327|NCT03068975|Placebo Comparator|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
9545328|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
9545329|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
9545330|NCT03069066|Experimental|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
9545331|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
9545332|NCT03069222||Control|age and gender matched with patient enrolled
9545333|NCT03069235|Active Comparator|Standard of Care|group/individual counselling.
9545334|NCT03069235|Experimental|Family member / peer support|Structured family member / peer support.
9545335|NCT03069235|Experimental|Special infant feeding counselor support|Enhanced intervention with counselor support
9545336|NCT03068962|Experimental|beetroot juice|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of beetroot juice for 5 min,
9545337|NCT03068962|Experimental|low mineral water (Buxton water)|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of low nitrate mineral water in the mouth for 5 min or
9545338|NCT03068962|Experimental|antiseptic mouthwash then beetroot juice|Rinse with antiseptic mouthwash before holding 10 ml of beetroot juice in the mouth for 5 min
9545339|NCT03069079|Experimental|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
9545340|NCT03068936|Experimental|IMRT group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
9545341|NCT03068936|Other|IMRT plus cisplatin group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
9545342|NCT03068832|Experimental|Personalized peptide vaccine and poly-ICLC|"The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.~Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.~Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
9545343|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
9545344|NCT03068793||Patients with Major Depressive Disorder|Individuals who have been diagnosed with Major Depressive Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
9545345|NCT03068793||Patients with Gambling Disorder|Individuals who have been diagnosed with Gambling Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
9545346|NCT03068793||Patients with Post Traumatic Stress Disorder|Individuals who have been diagnosed with Post Traumatic Stress Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
9545347|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric, mood, or gambling disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric, mood, or gambling disorder.
9545348|NCT03068741|Active Comparator|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
9545349|NCT03068741|Placebo Comparator|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
9545350|NCT03068741|Experimental|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
9545351|NCT03068741|Active Comparator|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure <90mmHg, and will only continue the infusion until the systolic blood pressure is >=100mmHg.
9545352|NCT03068845|Experimental|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
9487488|NCT01025648|Experimental|T3 - 160 mcg/actuation|E004 (epinephrine inhalation aerosol), 160 mcg - E004 (epinephrine inhalation aerosol), 160 mcg/ actuation, 2 actuations
9487489|NCT01025648|Experimental|T4 - 220 mcg/actuation|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations
9487490|NCT01025648|Active Comparator|A - Active control|epinephrine inhalation aerosol, CFC propelled 220 mcg Epinephrine Inhalation Aerosol, CFC-MDI, 2 actuations
9487491|NCT01025648|Placebo Comparator|P, Placebo HFA|E004 placebo single treatment with 2 inhalations
9487492|NCT01024907|Experimental|Arm I|Patients undergo proton beam radiation therapy for 6 weeks in the absence of disease progression or unacceptable toxicity.
9487493|NCT01024101|Experimental|Paclitaxel|
9487494|NCT01024062|Experimental|Paclitaxel|
9487495|NCT01023880|Experimental|1|CEP-18770
9487496|NCT01023685|Experimental|CAD106|
9487497|NCT01023295|Placebo Comparator|Placebo|single dose
9487498|NCT01023295|Experimental|15 mg/m^2|15 mg/m^2 fosbretabulin, single dose
9487499|NCT01023295|Experimental|25 mg/m^2|25 mg/m^2 fosbretabulin, single dose
9487500|NCT01023295|Experimental|35 mg/m^2|35 mg/m^2 fosbretabulin, single dose
9487501|NCT01023295|Experimental|45 mg/m^2|45 mg/m^2 fosbretabulin, single dose
9487502|NCT01023204|Experimental|Paclitaxel|
9487503|NCT01022970|Placebo Comparator|Placebo|
9487504|NCT01022970|Active Comparator|QAX576|
9487505|NCT01022801|Experimental|Entecavir (0.01 mg)|
9487506|NCT01022801|Experimental|Entecavir (0.1 mg)|
9487507|NCT01022801|Experimental|Entecavir (0.5 mg)|
9487508|NCT01022346|Placebo Comparator|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
9487509|NCT01022346|Experimental|RO5217790|RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
9487510|NCT01020968|Experimental|Ixmyelocel-T|The treatment arm of the study will receive catheter-based injections of the study cellular product.
9487511|NCT01020968|Placebo Comparator|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control.
9487512|NCT01020565|Experimental|Entecavir (0.1 mg)|
9487513|NCT01020565|Experimental|Entecavir (0.5 mg)|
9487514|NCT01020097|Other|Arm I|Patients undergo fluorine F-18 EF5 positron emission tomography imaging. Scana are performed 180 minutes following injection.
9487515|NCT01019187|Placebo Comparator|Arm I|Patients receive oral placebo twice daily for 47 days.
9487516|NCT01019187|Experimental|Arm II|Patients receive oral armodafinil twice daily for 47 days.
9487517|NCT01019187|Experimental|Arm III|Patients receive oral placebo twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia comprising sleep restriction therapy, stimulus control instruction, sleep hygiene guidelines, and a session of cognitive therapy for 7 weeks.
9487518|NCT01019187|Experimental|Arm IV|Patients receive oral armodafinil twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia as in Arm III for 7 weeks.
9487519|NCT01018875|Experimental|Arm 1, Dose 1, ABT-288|Low Dose
9487520|NCT01018875|Experimental|Arm 2, Dose 2, ABT-288|High dose
9487521|NCT01018875|Active Comparator|donepezil|
9487522|NCT01018875|Placebo Comparator|sugar pill|
9487523|NCT01018550|Experimental|AMG 853|
9487524|NCT01018550|Placebo Comparator|Placebo|
9487525|NCT01018173|Placebo Comparator|placebo|
9487526|NCT01018173|Experimental|taspoglutide|
9487527|NCT01016808|Experimental|Q8003 12 mg/8 mg|Combination
9487528|NCT01016808|Active Comparator|Morphine sulfate 12 mg|Single component
9487529|NCT01016808|Active Comparator|Oxycodone HCl 8 mg|Single component
9487530|NCT01016782|Experimental|Test|Test product that contains active pharmaceutical ingredient
9487531|NCT01016782|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
9487532|NCT01016782|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
9487533|NCT01015430|Placebo Comparator|Placebo (for RO4917523 ascending doses)|
9487534|NCT01015430|Placebo Comparator|Placebo (for RO4917523 fixed dose)|
9487535|NCT01015430|Experimental|RO4917523 ascending doses|
9487536|NCT01015430|Experimental|RO4917523 fixed dose|
9487537|NCT01014806|Experimental|Low dose|
9487538|NCT01014806|Experimental|High dose|Investigational Influenza VLP Vaccine 60ug/strain
9487539|NCT01014806|Active Comparator|TIV|Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced
9487540|NCT01014572|Experimental|Aerobic Exercise Training + Placebo|
9487541|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Placebo|
9487542|NCT01014572|Experimental|Aerobic Exercise Training + Alagebrium|
9487543|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Alagebrium|
9487544|NCT01014078|Experimental|Azithromycin Ophthalmic Solution, 1%|
9487545|NCT01014078|Placebo Comparator|Placebo|
9487546|NCT01013324|Experimental|Single Arm|All subjects will receive single-agent XL147 dosed daily
9487547|NCT01012895|Experimental|Arm 1: Sentinel A|BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
9487548|NCT01012895|Experimental|Arm 2: Sentinel B|BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
9487549|NCT01012895|Experimental|Arm 3: Expansion A1|BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
9487550|NCT01012895|Experimental|Arm 4: Expansion A2|BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
9487551|NCT01012895|Experimental|Arm 5: Expansion B1|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
9487552|NCT01012895|Experimental|Arm 6: Expansion B2|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
9487553|NCT01012895|Experimental|Arm 7: Expansion B3|BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin
9487554|NCT01009775|Experimental|YM155 plus docetaxel|
9487555|NCT01009242|Experimental|0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV|Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.
9545353|NCT03068845|Active Comparator|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
9545354|NCT03068910|Experimental|Spironolactone|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
9545355|NCT03068910|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
9545356|NCT03068884|Sham Comparator|Tdcs sham|
9545357|NCT03068884|Placebo Comparator|Placebo|
9545358|NCT03068884|Experimental|Tdcs cathodal|
9545359|NCT03068884|Experimental|Tyrosine|
9545360|NCT03069144|Experimental|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
9545361|NCT03069144|Active Comparator|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
9545362|NCT03068858|Experimental|SYNTAX score category feedback group|A real-time SYNTAX score category feedback from angiographic core lab will be given to the cardiologists rightafter the angiographies.
9545363|NCT03068858|No Intervention|Controlled group|Cardiologists' subjective SYNTAX score category judgement will be recorded during the angiography.
9545364|NCT03068702||African Canadians|African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
9545365|NCT03068806||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
9545366|NCT03068806||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
9545367|NCT03068728|Other|All Study Participants|"Participants received hemostatic packing agent in one nasal cavity and no packing in the other.~Participants were randomized to one of three hemostatic packing agents (Arista, Nexfoam, Nasopore) through sealed envelope, chosen by surgeon prior to placement, with packing agent allocation and sidedness."
9545368|NCT03068871|Experimental|CET|CET - Coping Effectiveness Training group.
9545369|NCT03068871|Experimental|ACT|ACT - Acceptance and Commitment Therapy group
9545370|NCT03068689|Experimental|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
9545371|NCT03068689|Placebo Comparator|Placebo Control|Placebo prior to partial nephrectomy.
9545372|NCT03068676|Experimental|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
9545373|NCT03068676|Experimental|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
9545374|NCT03068598|Experimental|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
9545375|NCT03068637|Experimental|Care planning platform usage|This intervention will focus on the use of the Carevive care planning software for multiple myeloma patients age 65 and older who are at a treatment decision-making timepoint.
9545376|NCT03068624|Experimental|Treatment (cyclophosphamide, T-cells, aldesleukin, ipilimumab)|"PREPARATIVE REGIMEN: Patients receive cyclophosphamide IV over 30-60 minutes on day -2.~T-CELL INFUSION: Patients receive autologous CD8+ SLC45A2-specific T lymphocytes via hepatic arterial infusion via central catheter over 60 minutes on day 0. Within 6 hours of T-cell infusion, patients also receive aldesleukin BID SC for 14 days in the absence of disease progression or unacceptable toxicity.~POST T-CELL INFUSION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity."
9616722|NCT02539810|Experimental|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
9616723|NCT02539810|Active Comparator|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
9616724|NCT02539862|Experimental|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
9616725|NCT02539862|Other|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
9616726|NCT02539784|Experimental|Spinal Cord Stimulation|
9616727|NCT02539771|Other|Nocturnal VOC|
9616728|NCT02539771|Other|Diurnal VOC|
10040617|NCT01855256|Placebo Comparator|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
10040618|NCT01855269|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
10040619|NCT01855269|Active Comparator|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
9487556|NCT01009242|Experimental|1 mg/kg CDP6038 SC and Placebo SC|Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.
9487557|NCT01009242|Experimental|Optimized CDP6038 SC|Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.
9487558|NCT01008852|Experimental|Treatment Group 1|
9487559|NCT01008852|Experimental|Treatment Group 2|
9487560|NCT01008852|Experimental|Treatment Group 3|
9487561|NCT01008852|Experimental|Treatment Group 4|
9487562|NCT01008852|Placebo Comparator|Treatment Group 5|
9487563|NCT01007721|Experimental|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 25 mg plus 2 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
9487564|NCT01007721|Experimental|BI 671800 ED 400 mg|2 capsules of BI 671800 ED 100 mg plus 2 capsules of placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
9487565|NCT01007721|Active Comparator|Montelukast 10 mg|1 over-encapsulated montelukast 10 mg tablet (qd in the morning) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
9487566|NCT01007721|Active Comparator|Fluticasonepropionate nasal spray 200¿g|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 ¿g per nostril) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 overencapsulated montelukast placebo tablet (qd in the morning)
9487567|NCT01007721|Placebo Comparator|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening), plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
9487568|NCT01007721|Experimental|BI 671800 ED 800 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
9487569|NCT01007292|Experimental|YM155 plus rituximab|
9487570|NCT01007097|Experimental|TAK-875 6.25 mg QD|
9487571|NCT01007097|Experimental|TAK-875 25 mg QD|
9487572|NCT01007097|Experimental|TAK-875 50 mg QD|
9487573|NCT01007097|Experimental|TAK-875 100 mg QD|
9487574|NCT01007097|Experimental|TAK-875 200 mg QD|
9487575|NCT01007097|Active Comparator|Glimepiride 2 mg or 4mg QD|
9487576|NCT01007097|Placebo Comparator|Placebo QD|
9487577|NCT01005108|Experimental|placebo pill|
9487578|NCT01005108|Experimental|placebo accupuncture|
9487579|NCT01005108|Experimental|accupuncture|
9487580|NCT01005108|Experimental|gabapentin|
9487581|NCT01004081|Experimental|BIIB021 BID + exemestane|BIIB021 100 mg BID + exemestane 25 mg QD
9487582|NCT01004081|Experimental|BIIB021 TIW + exemestane|BIIB021 450 mg TIW + exemestane 25 mg QD
9487583|NCT01003379|Experimental|TC-5619|TC-5619 capsules will be administered once a day in a forced titration scheme at 1 mg for 4 weeks, 5 mg for 4 weeks and 25 mg for 4 weeks (12 weeks total).
9487584|NCT01003379|Placebo Comparator|Placebo|
9487585|NCT01002950|Experimental|ACU-4429 tablet|
9487586|NCT01002950|Placebo Comparator|Matching placebo tablet|
9487587|NCT01002924|Experimental|All Participants|All participants invited to enroll on study will receive EC145 (vintafolide) 2.5 mg by intravenous bolus on Monday, Wednesday, and Friday of Weeks 1 and 3 in each 4-week cycle.
9487588|NCT01002820|Experimental|participants|all subjects participating in 0602 are receiving ganaxolone for seizure control
9487589|NCT01002248|Experimental|Perifosine added to combination|"Perifosine added to the combination of Bortezomib and Dexamethasone. Perifosine is is supplied as a film-coated tablet containing 50 mg of active ingredient. Perifosine will be administered orally on an outpatient basis throughout the study. Daily administration will be one 50 mg tablet.~The first dose of perifosine should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1)."
9487590|NCT01002248|Placebo Comparator|Perifosine Placebo added to combination|Perifosine placebo added to the combination of Bortezomib and Dexamethasone. The placebo for perifosine is provided in 256 mg white to off-white, round, biconvex film-coated tablets to permit a blinded trial with perifosine 50 mg film coated tablets. Placebo will be administered orally on an outpatient basis throughout the study. Daily administration will be one perifosine placebo tablet. The first dose of placebo should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1).
9487591|NCT01002235|Experimental|Cohort 1|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 4 mg.
9487592|NCT01002235|Experimental|Cohort 2|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 8mg.
9487593|NCT01002235|Experimental|Cohort 3|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 16mg.
9487594|NCT01001923|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
9487595|NCT01001923|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
9487596|NCT01001715|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
9487597|NCT01001715|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
9487598|NCT01001351|Placebo Comparator|Placebo|
9487599|NCT01001351|Experimental|PRT-201|
9487600|NCT01001338|Experimental|RDEA594 200 mg qd|RDEA594 200 mg qd plus allopurinol qd
9487601|NCT01001338|Experimental|RDEA594 200 mg, 400 mg qd|"RDEA594 200 mg then 400 mg qd plus allopurinol qd.~Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
10040620|NCT01855269|Placebo Comparator|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
9545377|NCT03068585|Experimental|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
9545378|NCT03068585|No Intervention|Control|Control therapy
10040621|NCT01855282|Experimental|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
9545379|NCT03068494||Coronary Bifurcation Lesion|
9545380|NCT03068403|Other|Chemotherapy and Radiochemotherapy|
9545381|NCT03068403|Other|Radiochemotherapy|
9545382|NCT03068533|Active Comparator|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
9545383|NCT03068533|Experimental|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
10040622|NCT01855282|Active Comparator|Control|Control arm received no behavioral intervention
10040623|NCT01855295|Experimental|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
10040624|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
10040625|NCT01855321|Active Comparator|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
10040626|NCT01855321|Placebo Comparator|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
10040627|NCT01855334|Experimental|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
10040628|NCT01855334|Placebo Comparator|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
10040629|NCT01855334|Experimental|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
9545384|NCT03068325|Experimental|TF-EAT|
9545385|NCT03068377|Placebo Comparator|Placebo|Soft gel capsules without test material
9545386|NCT03068377|Experimental|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
10040630|NCT01855334|Experimental|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
10040631|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
9545387|NCT03068507|Experimental|Prehabilitation group|Trimodal prehabilitation management
9545388|NCT03068507|No Intervention|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
9545389|NCT03068572||NERD group|45 GERD patients without obviously abnormality were examined by conventional white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system GERD patients with the absence of mucosal breaks at conventional endoscopy,and those patients was given standard or double dose of oral proton pump inhibitor (PPI) for 2 weeks to determine the efficacy of anti-secretory therapy (the so-called PPI test).The response to PPI treatment comprised the NERD group.
9545390|NCT03068572||Control group|45 control patients were examined by white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system,those subjects who had undergone endoscopy solely for the purpose of a health check-up at the same time of the study period
9545391|NCT03068442|Experimental|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
10040632|NCT01855373|Other|Placebo|No active ingredient
10040633|NCT01855373|Active Comparator|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
10040634|NCT01855373|Active Comparator|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
10040635|NCT01855373|Active Comparator|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
10040636|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
10040637|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
10040638|NCT01855438|No Intervention|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
9545392|NCT03068520|Other|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
9545393|NCT03068520|Other|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.~will be followed with PET MRI"
9545394|NCT03068520|Other|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.~will be followed with PET MRI"
9545395|NCT03068429|Experimental|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
9545396|NCT03068351|Experimental|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
9545397|NCT03068351|Experimental|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
9545398|NCT03068338|Active Comparator|Conventional therapy|Intermittent pneumatic compression devices are used for prevention of DVT.
9545399|NCT03068338|Experimental|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
9545400|NCT03068481|Experimental|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
9545401|NCT03068481|Experimental|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
9545402|NCT03068481|Placebo Comparator|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
9545403|NCT03068481|Experimental|Patient part -Single dose|Single oral dose of KDT-3594
9545404|NCT03068481|Experimental|Patient part -Multiple dose|Multiple oral doses of KDT-3594
9545405|NCT03068299|Experimental|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
9545406|NCT03068299|Experimental|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
9545407|NCT03068559||Study population|"Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.~Patient has to be aged ≥ 18~Patient has to be able to complete questionnaire in French~Patient must benefit from health insurance~Patient must sign an informed consent form~Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
9545408|NCT03068286|Experimental|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
9545409|NCT03068286|Experimental|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
9545410|NCT03068286|Experimental|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
9545411|NCT03068546||Participants providing samples|NCI employees agreeing to provide samples for microbiome sample study
9545412|NCT03068247|Experimental|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
9545413|NCT03068247|Placebo Comparator|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
9545414|NCT03068065|Active Comparator|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
9545415|NCT03068065|Active Comparator|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
9545416|NCT03068065|Active Comparator|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
9545417|NCT03068234|Experimental|Pirfenidone group|The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
9545418|NCT03068234|Placebo Comparator|Control group|The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
10040639|NCT01855438|Experimental|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
9545419|NCT03068260|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml ropivacaine 0,375% single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
10040640|NCT01855438|Experimental|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
9545420|NCT03068260|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml saline single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
9545421|NCT03068208|Experimental|MB-PDT|
9545422|NCT03068208|No Intervention|Control|
9545423|NCT03068221|Active Comparator|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
9545424|NCT03068221|Active Comparator|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
9545425|NCT03068026|Experimental|Continuous exercise|Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.
9545426|NCT03068026|Experimental|Interval exercise|Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.
9545427|NCT03068013|Experimental|Managing Cancer Living Meaningfully|Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months. Sessions are reviewed to ensure treatment fidelity.
9545428|NCT03068013|Active Comparator|Supportive psycho-oncology intervention|Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
9545429|NCT03067974|Experimental|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
9545430|NCT03068078|No Intervention|Control-group|The control group will be eating a regular diabetes diet according to the Danish National Recommendations
9545431|NCT03068078|Experimental|Intervention-group|Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats
9545432|NCT03068182|Experimental|Arm crank Exercise|Sixty-five participated in an arm crank moderate intensity exercise for 40 minutes.
9545433|NCT03068182|Experimental|Treadmill Exercise|Sixty-five participated in a treadmill moderate intensity exercise for 40 minutes.
9545434|NCT03068117|Experimental|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
9545435|NCT03068117|No Intervention|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
9545436|NCT03068156|Experimental|excimer laser|
9545437|NCT03068156|No Intervention|Control|
9545438|NCT03068039|Active Comparator|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
9545439|NCT03068039|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
9545440|NCT03068000|Experimental|Judo training|Judo intervention will take place twice a week, lasting 50 minutes per session, for 3 months, divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
10040641|NCT01855451|Active Comparator|Radiation Therapy + Cetuximab|RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)
9545441|NCT03068000|Active Comparator|Ball games|The Ball Games will take place twice a week, with a duration of 50 minutes per session, for 3 months, divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
9545442|NCT03068195|Experimental|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
9545443|NCT03068195|Experimental|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
9545444|NCT03068195|Active Comparator|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
9545445|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
9545446|NCT03068052|Active Comparator|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
10040642|NCT01855451|Active Comparator|Radiation Therapy + Cisplatin|RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)
10040643|NCT01855477|Other|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
10040644|NCT01855490|Experimental|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
10040645|NCT01855503||Metastatic Breast Cancer|
10040646|NCT01855516|Active Comparator|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
10040647|NCT01855516|Active Comparator|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
10040648|NCT01855529|Experimental|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
10040649|NCT01855529|Placebo Comparator|NaCl arm|NaCl 0,9% 250ml 10 ml/h
9545447|NCT03068052|Experimental|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
9545448|NCT03067883|Experimental|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
9545449|NCT03067896|Active Comparator|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
9545450|NCT03067896|Active Comparator|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
9545451|NCT03067896|Active Comparator|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
10040650|NCT01855542|Experimental|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
9545452|NCT03067857|Experimental|Stem Cells|Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
10040651|NCT01855542|Active Comparator|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
10040652|NCT01855555||sedation group|Children requiring sedation for MRI/CT
10040653|NCT01855568|Experimental|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
10040654|NCT01855568|Experimental|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
10040655|NCT01855581||sedation group|Children requiring sedation for MRI/CT
10040656|NCT01855594|Experimental|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
10040657|NCT01855594|Placebo Comparator|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
10040658|NCT01855607|Experimental|topical menthol|topical menthol cream to hands and feet
9545453|NCT03067870|Experimental|Stem Cells|Autologous bone marrow-derived stem cell transplantation.
9545454|NCT03067740|Active Comparator|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
9545455|NCT03067740|Experimental|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
10040659|NCT01855607|Placebo Comparator|placebo cream|topical cream without menthol
10040660|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI <25.
10040661|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI > or = 25 and <30.
10040662|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI > or = 30.
10040663|NCT01855633|Experimental|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
10040664|NCT01855633|Active Comparator|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
9545456|NCT03067831|Experimental|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
9545457|NCT03067805|Experimental|Oxytocin|Oxytocin nasal spray
9545458|NCT03067805|Placebo Comparator|Placebo|Placebo nasal spray
9545459|NCT03067623|Experimental|PRP-infusion|PRP will be obtained from a fresh whole blood collected from a peripheral vein; the blood sample will be centrifuged at 1500g (RCF) for 10 minutes and the repeated reversal of the tube will allow obtaining the PRP at the concentration required. Then 0,5-1ml of PRP will be infused into the uterine cavity through a Tomcat catheter. The endometrial thickening will be evaluated by ultrasonography 24-48h after the instillation and, if the endometrial lining reaches 7mm the Embryo-transfer will be arranged.
9545460|NCT03067818|Experimental|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
9545461|NCT03067818|Experimental|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
9545462|NCT03067818|Active Comparator|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
9545463|NCT03067779|Other|Survey and mHealth Tool|"A survey has been designed that evaluates CRIC participants' computer and mobile phone usage, and perceived e-health literacy.~There is also a mobile health-based (mHealth) patient safety educational curriculum that evaluates CRIC participants' knowledge of patient safety hazards in CKD. The mHealth patient safety curriculum tool is also known as eCRIC."
9545464|NCT03067662|Experimental|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
9545465|NCT03067662|No Intervention|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
9545466|NCT03067701|Experimental|Carbon Monoxide Inhalation|In healthy young adults 18-39 years of age, The Investigator will determine if intermittent inhalation a 0.1% CO, from a 1-liter bag once every minute for 30-40 minutes, at a level that approaches the CO boost with hookah smoking, augments endothelial function, thus implicating CO as the major endothelial vasodilator substance in hookah smoke.
9545467|NCT03067649|Experimental|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
9545468|NCT03067649|Other|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
9545469|NCT03067753|Active Comparator|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
9545470|NCT03067753|Experimental|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
9545471|NCT03067558||Accuracy evaulation|Three age groups (young infants 0 to <2 months, children 2 to <12 months and 12 to 59 months) will participate in the accuracy evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
9545472|NCT03067558||Consistency evaluation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the consistency evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
9545473|NCT03067558||Respiratory rate fluctuation evaulation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
9616729|NCT02539771|Other|Slightly symptomatic|
10040665|NCT01855633|Sham Comparator|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
10040666|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
10040667|NCT01855672|Active Comparator|Perceivable Stimulation|Stimulation of the occipital nerves.
10040668|NCT01855672|Active Comparator|Non-Perceivable|Stimulation of the occipital nerves.
10040669|NCT01855685|Experimental|Open label|X vivo gene therapy
10040670|NCT01855698||All patients registered|
10040671|NCT01855711|Experimental|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
10040672|NCT01855724|Experimental|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
10040673|NCT01855737||Warfarin Using Group|
9487602|NCT01001338|Placebo Comparator|Matching Placebo|"RDEA594 matching placebo qd plus allopurinol qd, then allopurinol qd alone in open label period.~Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015."
9487603|NCT01001338|Experimental|RDEA594 600 mg qd|"RDEA594 200 mg then 400 mg then 600 mg plus allopurinol qd~Patients on lesinurad 600 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
9487604|NCT01001091|Experimental|AL-38583 0.01%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
9487605|NCT01001091|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
9487606|NCT01001091|Experimental|AL-38583 0.2%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
9487607|NCT01001091|Placebo Comparator|AL-38583 Vehicle|AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks
9487608|NCT01001091|Active Comparator|MAXIDEX|Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks
9487609|NCT01000922|Experimental|Regular Human Insulin|Single injection
9487610|NCT01000922|Experimental|Lispro|Single injection
9487611|NCT01000922|Experimental|VIAject|Single injection
9487612|NCT01000922|Experimental|VIAject 50%|Single injection
9487613|NCT01000922|Experimental|VIAject/Insulin glargine|Single injection
9487614|NCT01000922|Experimental|Insulin Glargine/VIAject|Single injection
9487615|NCT00997152|Experimental|Dose 1 JTT-654|
9487616|NCT00997152|Experimental|Dose 2 JTT-654|
9487617|NCT00997152|Placebo Comparator|Placebo|
9487618|NCT00994292|Experimental|1. YM150 Dose V, twice daily|
9487619|NCT00994292|Experimental|2. YM150 Dose W, once daily|
9487620|NCT00994292|Experimental|3. YM150 Dose X, twice daily|
9487621|NCT00994292|Experimental|4. YM150 Dose Y, once daily|
9487622|NCT00994292|Experimental|5. YM150 Dose Y, twice daily|
9487623|NCT00994292|Experimental|6. YM150 Dose Z, once daily|
9487624|NCT00994292|Placebo Comparator|7. Placebo|
9487625|NCT00993382|Experimental|Celivarone 50 mg|Celivarone, 50 mg once daily up to 10-15 days before the common study end date
9487626|NCT00993382|Experimental|Celivarone 100 mg|Celivarone, 100 mg once daily up to 10-15 days before the common study end date
9487627|NCT00993382|Experimental|Celivarone 300 mg|Celivarone, 300 mg once daily up to 10-15 days before the common study end date
9487628|NCT00993382|Active Comparator|Amiodarone|Amiodarone, 600 mg once daily for 10 days (loading dose) then 200 mg once daily up to 10-15 days before the common study end date
9487629|NCT00993382|Placebo Comparator|Placebo|Matching placebo once daily up to 10-15 days before the common study end date
9487630|NCT00993018|Experimental|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
9487631|NCT00993018|Experimental|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
9487632|NCT00993018|Experimental|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
9487633|NCT00993018|Placebo Comparator|Placebo|Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.
9487634|NCT00992732|Experimental|HQK-1004 + Valganciclovir|
9487635|NCT00992563|Experimental|AL-39324 Concentration Level A|AL-39324 ophthalmic suspension, single intravitreal injection
9487636|NCT00992563|Experimental|AL-39324 Concentration Level B|AL-39324 ophthalmic suspension, single intravitreal injection
9487637|NCT00992563|Experimental|AL-39324 Concentration Level C|AL-39324 ophthalmic suspension, single intravitreal injection
9487638|NCT00992563|Experimental|AL-39324 Concentration Level D|AL-39324 ophthalmic suspension, single intravitreal injection
9487639|NCT00992563|Experimental|AL-39324 Concentration Level E|AL-39324 ophthalmic suspension, single intravitreal injection
9487640|NCT00992563|Active Comparator|Lucentis|Ranibizumab 10 mg/mL solution, single intravitreal injection
9487641|NCT00991757|Experimental|001|carisbamate Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
9487642|NCT00991172|Placebo Comparator|placebo injection|
9487643|NCT00991172|Experimental|active|subcutaneous injection of REGN475
9487644|NCT00991172|Experimental|active 2|subcutaneous injection of REGN475
9487645|NCT00991068|Experimental|Synera|Synera topical patch
9487646|NCT00990912|Experimental|Carboplatin|
9487647|NCT00990912|Experimental|Irinotecan (12 (9) mg/m²/day)|
9487648|NCT00990912|Active Comparator|Irinotecan (10 (10) mg/m²/day|
9487649|NCT00990327|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
9487650|NCT00990327|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
9487651|NCT00989001|Experimental|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
9487652|NCT00989001|Placebo Comparator|Placebo|Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
9487653|NCT00988741|Experimental|ARQ 197|
9487654|NCT00988741|Placebo Comparator|placebo|
9487655|NCT00987545|Placebo Comparator|Placebo|
9487656|NCT00987545|Experimental|QAX576|
9487657|NCT00987272|Experimental|Pataday+Pataday Vehicle|Olopatadine Hydrochloride Ophthalmic Solution 0.2%, 1 drop in 1 eye and Olopatadine 0.2% Vehicle in the contralateral eye
9487658|NCT00987272|Active Comparator|Patanol+Patanol Vehicle|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, 1 drop in 1 eye and Olopatadine 0.1% Vehicle in the contralateral eye
9487659|NCT00986882|Experimental|SAF312A (2 doses in part B; 5 - 6 doses in part C)|
9487660|NCT00986882|Placebo Comparator|Placebo|
9487661|NCT00986882|Active Comparator|Ibuprofen|
9487662|NCT00985127|Experimental|40 mg|40 mg BCX4208
9487663|NCT00985127|Experimental|80 mg|BCX4208
9487664|NCT00985127|Experimental|120 mg|BCX4208
9487665|NCT00985127|Placebo Comparator|sugar pill|
9487666|NCT00985127|Experimental|160mg|BCX4208
9487667|NCT00985127|Experimental|240mg|BCX4208
9487668|NCT00985127|Experimental|320mg|BCX4208
9487669|NCT00983814|Experimental|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID)
9487670|NCT00983814|Placebo Comparator|Placebo|Placebo
9487671|NCT00983060|Experimental|NIM811|
9487672|NCT00983060|Placebo Comparator|Placebo|
9487673|NCT00982696|Experimental|Single Arm|Opioid Growth Factor (OGF)
9487674|NCT00982150|Experimental|Talampanel|Talampanel 50mg tid
9487675|NCT00981617|Experimental|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
9487676|NCT00981617|Experimental|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
9487677|NCT00981617|Experimental|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
9487678|NCT00981617|Placebo Comparator|Placebo|Matching placebo (capsules without active study drug) provided for daily oral administration
9487679|NCT00981357|Experimental|PF-04457845 followed by placebo|
9487680|NCT00981357|Experimental|Placebo followed by PF-04457845|
9487681|NCT00981357|Active Comparator|Naproxen followed by placebo|
9487682|NCT00981357|Active Comparator|Placebo followed by Naproxen|
9487683|NCT00979251|Experimental|ADS-8902|Amantadine and Ribavirin administered with Oseltamivir phosphate
9487684|NCT00979251|Active Comparator|Comparator|Oseltamivir Phosphate
9487685|NCT00979004|Experimental|ICA-105665|
9487686|NCT00978497|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
9487687|NCT00978497|Experimental|2|ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
9487688|NCT00978497|Experimental|3|ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
9498121|NCT03468972|Active Comparator|Intensive supportive care|intensive supportive care with RAS blockers, blood pressure control, and protein restriction diet
9498122|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
9498123|NCT03468946|Other|high caries risk|children with high caries -identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
9498124|NCT03468946|Other|medium caries risk|children with medium caries- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
9498125|NCT03468946|Other|low risk|no caries or low risk- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
9498126|NCT03468907|Experimental|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
9498127|NCT03468907|Experimental|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
9498128|NCT03468907|No Intervention|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
9498129|NCT03468894|No Intervention|Control|The control group will continue to work as usual at their regular workstations.
9498130|NCT03468894|Experimental|Intervention|A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
9498131|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
9498132|NCT03468842|Placebo Comparator|Placebo|Composition: excipients without probiotic: 2%w/v Guam guar and 6% w/v hydroxyethilcellulose Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
10040674|NCT01855763|Experimental|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
9487689|NCT00978016|Experimental|arbaclofen placarbil-Cohort 1|"arbaclofen placarbil 20 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
9487690|NCT00978016|Experimental|arbaclofen placarbil-Cohort 2|"arbaclofen placarbil 40 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
9487691|NCT00978016|Experimental|arbaclofen placarbil-Cohort 3|"arbaclofen placarbil 20 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
9487692|NCT00978016|Experimental|arbaclofen placarbil-Cohort 4|"arbaclofen placarbil 30 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
9487693|NCT00978016|Placebo Comparator|Placebo-Cohort 5|"Placebo dose with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
9487694|NCT00977522|Experimental|PF-03463275|
9487695|NCT00977522|Placebo Comparator|Placebo|
9487696|NCT00975091|Active Comparator|Entecavir 0.5|
9487697|NCT00975091|Active Comparator|Entecavir 1.0|
9487698|NCT00973817|Experimental|ELAD|Use of ELAD for up to 6 days to stabilize liver function plus standard of care treatment plus standard of care treatment. Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
9487699|NCT00973817|Other|Standard of care|Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
9487700|NCT00973284|Experimental|Norwalk VLP Vaccine 100 µg|Norwalk Virus-like Particle (VLP) Vaccine 100 µg, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 Reverse Transcription Polymerase Chain Reaction (RT-PCR) units, solution, orally, on Day 42 in the Challenge Stage.
9487701|NCT00973284|Placebo Comparator|Placebo|Norwalk VLP placebo-matching vaccine, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 RT-PCR units, solution, orally, on Day 42 in the Challenge Stage.
9487702|NCT00973141|Experimental|JNJ-42160443 1mg every 4 weeks|
9487703|NCT00973141|Experimental|JNJ-42160443 3mg every 4 weeks|
9487704|NCT00973141|Experimental|JNJ-42160443 3mg every 8 weeks|
9487705|NCT00973141|Experimental|JNJ-42160443 6mg every 8 weeks|
9487706|NCT00973141|Experimental|JNJ-42160443 10mg every 8 weeks|
9487707|NCT00973141|Placebo Comparator|Matching placebo every 4 or 8 weeks|
9487708|NCT00973024|Experimental|JNJ-42160443 1 mg|
9487709|NCT00973024|Experimental|JNJ-42160443 3 mg|
9487710|NCT00973024|Experimental|JNJ-42160443 6 mg/3mg|
9487711|NCT00973024|Experimental|JNJ-42160443 10 mg|
9487712|NCT00971035|Experimental|A|
9487713|NCT00971035|Experimental|B|
9487714|NCT00971035|Experimental|C|
9487715|NCT00971035|Placebo Comparator|D|
9487716|NCT00970424|Placebo Comparator|1|placebo, oral tablet administered once daily on background of pioglitazone
9487717|NCT00970424|Experimental|2|dutogliptin, oral tablet administered once daily on background of pioglitazone
9487718|NCT00969722|Experimental|ARM I|Intravenous MAb-3F8 plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
9487719|NCT00969722|Active Comparator|ARM II|Oral 13-cis-Retinoic Acid (RA) plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
9487720|NCT00968942|Active Comparator|Dose A|RT001
9487721|NCT00968942|Placebo Comparator|Dose B|Placebo
9487722|NCT00968851|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 84 days
9487723|NCT00968851|Active Comparator|EVP-6124 1.0 mg|one 1.0 mg capsule every day for 84 days.
9487724|NCT00968851|Placebo Comparator|Placebo|Placebo every day for 84 days
9487725|NCT00968825|Active Comparator|Dose D|RT001
9487726|NCT00968825|Placebo Comparator|Dose E|Placebo
9487727|NCT00967811|Experimental|1. Formulation E1|Formulation E1 of Latanoprost-PPDS
9487728|NCT00967811|Experimental|2. Formulation E2|Formulation E2 of Latanoprost-PPDS
9487729|NCT00966953|Placebo Comparator|Fluoride Toothpaste|fluoride control
9487730|NCT00966953|Active Comparator|Total/Whitening|positive control
9487731|NCT00966953|Experimental|antibacterial plant extract 1|Honokiol
9487732|NCT00966953|Experimental|antibacterial plant extract 2|magnolol
9487733|NCT00964990|Experimental|001|JNJ-42160443 SC injection (1 3 or 10 milligrams) once every 28 days
9487734|NCT00964990|Placebo Comparator|002|Placebo SC injection once every 28 days
9487735|NCT00963885|Placebo Comparator|Part 1: Placebo|Placebo in combination with standard doses of Pegasys and Copegus.
9487736|NCT00963885|Experimental|Part 1: RO5190591 300mg po|RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
9487737|NCT00963885|Experimental|Part 1: RO5190591 600mg po|RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
9545474|NCT03067792|Active Comparator|FOLFIRI|2nd palliative chemotherapy with FOLFIRI regimen,In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5- fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle. Response evaluation would be done after 3 cycle of chemotherapy in DP group
9487738|NCT00963885|Experimental|Part 1: RO5190591 900mg po|RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
9487739|NCT00963885|Placebo Comparator|Part 2: Placebo|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
9545475|NCT03067792|Active Comparator|DP|2nd palliative chemotherapy with Docetaxel/cisplatin regimen, In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle. Response evaluation would be done after 2 cycle of chemotherapy in DP group
9545476|NCT03067766|Experimental|Workshop A (10 weeks - comic art creation workshop)|Patients and a family member, caretaker, or friend participate in an artist-led comic art therapy workshop over 2 hours once a week for 10 weeks. Patients and participants receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop and midway through the workshop.
9545477|NCT03067766|Experimental|Workshop B and C (5 weeks - comic art creation workshop)|Patients participate in an artist-led comic art therapy workshop over 3 hours once a week for 5 weeks. Patients receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop.
9545478|NCT03067597|Experimental|Dinoprostone vaginal insert (DVI)|
9545479|NCT03067545|Experimental|step rate increase|increase in running stride rate by 10%
9545480|NCT03067688|Experimental|"Combination drug:Temisartan+Amlodipine+Rosuvastatin"|"60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks."
9545481|NCT03067688|Active Comparator|Temisartan+Amlodipine|"60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks."
9545482|NCT03067688|Active Comparator|Temisartan+Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks."
9545483|NCT03067727|Experimental|Dinoprostone vaginal insert|
9545484|NCT03067727|Placebo Comparator|Placebo|
9545485|NCT03067519|Experimental|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
9545486|NCT03067519|Active Comparator|Conventional management|usual postoperative care per surgeon
9545487|NCT03067480|Experimental|3-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
9545488|NCT03067480|Experimental|6-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
9545489|NCT03067532|Experimental|A|
9545490|NCT03067532|Active Comparator|B|
9545491|NCT03067454|Other|conservative group|Treatment with early mobilisation
9545492|NCT03067454|Other|operative group|Treatment with operation
9545493|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
9545494|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
9545495|NCT03067155|Experimental|Treatment group|The patients for which a suitable donor product can be obtained will be included in the treatment arm of the protocol. Treatment consists of the administration of CMV-specific T-cells, administered through intravenous transfusion. Depending on response in viral load and GVHD status, a second and/or third administration is possible.
9545496|NCT03067155|Active Comparator|Control group|Patients for which the investigator can't obtain a suitable donor product, will be included in the control group consisting of standard anti-viral treatment.
9545497|NCT03067103|Active Comparator|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
9545498|NCT03067103|Active Comparator|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
9545499|NCT03067103|Placebo Comparator|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
9545500|NCT03067285|Active Comparator|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
9487740|NCT00963885|Experimental|Part 2: RO5190591 300mg po|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
9487741|NCT00963053|Experimental|VA111913 100mg twice daily|
9487742|NCT00963053|Placebo Comparator|Starch pill|
9487743|NCT00962832|Placebo Comparator|Part 1 - Placebo intravenously|Participants received placebo intravenously every 4 weeks for 24 weeks.
9487744|NCT00962832|Experimental|Part 1 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 24 weeks.
9487745|NCT00962832|Placebo Comparator|Part 2 - Placebo subcutaneously|Participants received placebo subcutaneously every 2 weeks for 24 weeks.
9487746|NCT00962832|Experimental|Part 2 - Rontalizumab 300 mg subcutaneously|Participants received rontalizumab 300 mg subcutaneously every 2 weeks for 24 weeks.
9487747|NCT00962832|Experimental|Part 3 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 120 weeks.
9487748|NCT00961805|Experimental|Dance Group|Belly dance
9487749|NCT00961805|No Intervention|Control Group|Waiting list
9487750|NCT00961675|Active Comparator|FST201|
9487751|NCT00961675|Active Comparator|Ciprodex|
9487752|NCT00961090|Other|Single-Arm|Single-Arm All subjects received 20mg/kg of Aminolevulinic Acid diluted in 50cc of water, orally, approximately 3 hours prior to surgery.
9487753|NCT00959114|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
9487754|NCT00959114|Placebo Comparator|Placebo comparator|Excipients for ALV003 absent the experimental compounds
9487755|NCT00959036|Experimental|Treatment Group 1|ATN-103 10 mg every 4 weeks until week 12
9487756|NCT00959036|Experimental|Treatment Group 2|ATN-103 10 mg every 8 weeks until week 12
9487757|NCT00959036|Experimental|Treatment Group 3|ATN-103 30 mg every 4 weeks until week 12
9487758|NCT00959036|Experimental|Treatment Group 4|ATN-103 80 mg every 4 weeks until week 12
9487759|NCT00959036|Experimental|Treatment Group 5|ATN-103 80 mg every 8 weeks until week 12
9487760|NCT00959036|Placebo Comparator|Treatment Group 6|Placebo every 4 weeks
9487761|NCT00958971|Experimental|TKI258 - Positive|These are the participants who had a positive T(4;14) status
9487762|NCT00958971|Experimental|TKI258 - Negative|These are the participants who had a negative T(4;14) status
9487763|NCT00958971|Experimental|TKI258 Non-interpretable|These are the participants who had a non-interpretable T(4;14) status
9487764|NCT00957918|Experimental|Nicotine|Active drug is nicotine dihydrate bitartrate, provided as an oral capsule at escalating doses, 1 mg to 6 mg, once every 6 hours
9487765|NCT00957918|Placebo Comparator|placebo|Subjects in this arm receive placebo capsules orally
9487766|NCT00955981|Experimental|RDEA594 200 mg qd for 28 days|
9487767|NCT00955981|Experimental|RDEA594 200 mg, 400 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
9487768|NCT00955981|Experimental|RDEA594 200 mg, 400 mg and 600 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
9487769|NCT00955981|Placebo Comparator|Matching placebo|RDEA594 matching placebo qd for 28 days
9487770|NCT00955799|Experimental|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
9487771|NCT00955799|Placebo Comparator|Placebo|Placebo: identical placebo tablets
9487772|NCT00954590|Experimental|Dimebon (latrepirdine)|Dimebon, 20 mg orally three times daily
9487773|NCT00954590|Placebo Comparator|Placebo|Placebo orally three times daily
9487774|NCT00954057|Experimental|LIPO-102|Intraorbital Injection
9487775|NCT00954057|Placebo Comparator|Placebo|Intraorbital Injection
9487776|NCT00953420|Experimental|Chemotherapy and Immunotherapy|"Docetaxel 60 mg/m2 IV on Day 1~Carboplatin with target AUC of 5 (mg/ml x min) on Day 1~Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1~After cycle 1, subsequent cycles of chemotherapy may start once ANC > 1000 and platelets > 100,000 post nadir~Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles"
9487777|NCT00951405|Experimental|A|
9487778|NCT00951405|Experimental|B|
9487779|NCT00951405|Experimental|C|
9487780|NCT00950937||HIV Group|HIV infected persons
9487781|NCT00950937||Control Group|Non HIV-infected persons
9487782|NCT00950885|Placebo Comparator|Placebo|placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
9487783|NCT00950885|Experimental|Low dose melatonin|0.5 mg melatonin
9487784|NCT00950885|Experimental|High dose melatonin|3.0 mg melatonin
9487785|NCT00948909|Placebo Comparator|A. Sugar Pill|
9487786|NCT00948909|Experimental|B. ABT-126|
9487787|NCT00948909|Experimental|C. ABT-126|
9487788|NCT00948909|Active Comparator|D. donepezil|
9487789|NCT00948753|Experimental|Phase 1: 150mg Maraviroc|150mg twice daily
9487790|NCT00948753|Experimental|Phase 1: 300mg Maraviroc|300mg twice daily
9487791|NCT00948753|Experimental|Phase 2: 300mg Maraviroc|300mg twice daily
9487792|NCT00948142|Active Comparator|Linezolid|600 mg BID
9487793|NCT00948142|Experimental|CEM-102 Regimen A|
9487794|NCT00948142|Experimental|CEM-102 Regimen B|
9487795|NCT00947557|Active Comparator|Dutogliptin|Dutogliptin
9487796|NCT00947557|Placebo Comparator|Placebo|Placebo
9487797|NCT00947518|Experimental|Chlorhexidine skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
9487798|NCT00947518|Placebo Comparator|Saline skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing normal saline
9487799|NCT00947518|No Intervention|No skin cleansing|No skin application
9545501|NCT03067285|Experimental|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
9545502|NCT03067428|Active Comparator|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
9545503|NCT03067428|Placebo Comparator|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
9545504|NCT03067038|Active Comparator|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
9545505|NCT03067038|Sham Comparator|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
9545506|NCT03067142||Cohort 1 (Phase 1): PH1|Cross-Sectional/Observational
9545507|NCT03067142||Cohort 2 (Phase 1): Controls|Cross-Sectional/Observational
9545508|NCT03067142||Cohort 3 (Phase 2): PH1|Longitudinal/Observational
9545509|NCT03067168|Active Comparator|Bupivacaine Arm|The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
9545510|NCT03067168|Placebo Comparator|Placebo Arm|The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
9545511|NCT03067194|Active Comparator|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
9545512|NCT03067194|Active Comparator|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
9545513|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
9545514|NCT03067220|Experimental|Virtual out patient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
9545515|NCT03067233|Experimental|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
9545516|NCT03067207|Experimental|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
9545517|NCT03067207|Other|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
9545518|NCT03067246|Active Comparator|VBM Intubating Laryngeal Tube|Device: VBM Intubating Laryngeal Tube Intervention: VBM Intubating Laryngeal Tube insertion, seal pressure, endotracheal intubation
9545519|NCT03067246|Active Comparator|I-Gel|Device: I-Gel Intervention: I-Gel insertion, seal pressure, endotracheal intubation
9545520|NCT03067090|Experimental|Intra-articular Aquamid Reconstruction|Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
9545521|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
9545522|NCT03067363|Experimental|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
9545523|NCT03067363|Experimental|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
9545524|NCT03067363|Experimental|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
9545525|NCT03067363|Experimental|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
9545526|NCT03067363|Experimental|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
9545527|NCT03067363|Experimental|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
9545528|NCT03067363|Placebo Comparator|Part 1, Placebo|Placebo, single subcutaneous injection
9545529|NCT03067363|Experimental|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
9545530|NCT03067363|Experimental|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
9545531|NCT03067363|Experimental|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
9545532|NCT03067363|Placebo Comparator|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
9545533|NCT03067402|Other|Observation|Patient receives standard observation, i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years.
9545534|NCT03067402|Experimental|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
9545535|NCT03067376|Experimental|[14C]-CORT125134|Two capsules each containing 125 milligrams (mg) [14C]-CORT125134 administered to each participant on 1 occasion
9545536|NCT03067337|Experimental|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
9545537|NCT03067337|Experimental|Zirconia crowns (Group B)|Groups that received Zirconia crowns
9545538|NCT03067025||30 youth with MS|
9545539|NCT03067025||30 healthy control participants|
9545540|NCT03067051|Experimental|PDT and verteporfin dose finding|"Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.~The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.~The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).~The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer ."
9545541|NCT03067415|Experimental|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
9545542|NCT03067415|Active Comparator|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
9545543|NCT03067012|Experimental|Oncometabolic reconstruction|Patients undergoing oncometablic surgery
9545544|NCT03066908|Experimental|Single Arm|Sinopsys® Lacrimal Stent
9545545|NCT03066934||NIV Failure Group|NIV Failure Group consisted of children who failed their noninvasive ventilation session and required intubation or re-intubation
9545546|NCT03066934||NIV success group|Children who successfully managed their noninvasive ventilation therapy
9545547|NCT03066921|Placebo Comparator|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
9545548|NCT03066921|Experimental|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
9545549|NCT03066687|Experimental|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
9545550|NCT03066687|Experimental|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
9545551|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
9545552|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
9545553|NCT03066895|Experimental|Experimental|BabyGentleStick
9545554|NCT03066895|Active Comparator|Standard of Care|HMC Standard Lancing Device
9616730|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
9616731|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
9616732|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
9616733|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
9616734|NCT02539875|Experimental|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
9616735|NCT02539875|Experimental|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
9616736|NCT02539875|Active Comparator|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
9616737|NCT02539823|Placebo Comparator|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
9616738|NCT02539823|Experimental|CBD 400mg|Subjects will receive 400mg of cannabidiol
9616739|NCT02539823|Experimental|CBD 800mg|Subjects will receive 800 mg of cannabidiol
9616740|NCT02539914|Experimental|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
9487800|NCT00946569|Experimental|Treatment A (JNJ39758979)|Participants will receive JNJ39758979 300mg once daily for 12 weeks.
9487801|NCT00946569|Placebo Comparator|Treatment B (Placebo)|Participants will receive matching placebo once daily for 12 weeks.
9487802|NCT00945802|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
9487803|NCT00945802|Active Comparator|ciprofloxacin 0.3%, dexamethasone 0.1%|
9487804|NCT00945763|Placebo Comparator|placebo|
9487805|NCT00945763|Experimental|N1539 15 mg|
9487806|NCT00945763|Experimental|N1539 30 mg|
9487807|NCT00945763|Experimental|N1539 60 mg|
9487808|NCT00945763|Active Comparator|Motrin|
9487809|NCT00945672|Experimental|PF-04360365 10 mg/kg|
9487810|NCT00945672|Experimental|PF-04360365 7.5 mg/kg|
9487811|NCT00945672|Placebo Comparator|placebo|
9487812|NCT00945646|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
9487813|NCT00945646|Placebo Comparator|vehicle|
9487814|NCT00945490|Experimental|NX-1207|
9487815|NCT00945490|Placebo Comparator|Placebo|
9487816|NCT00945269|Experimental|Treatment (cellular adoptive immunotherapy)|Patients receive autologous T-cell IV over 30-60 minutes on days 0 and 28 and low-dose aldesleukin SC twice daily on days 0 to 13 and 28 to 41. Beginning 4-6 days before second T-cell infusion, patients receive denileukin diftitox IV over 30 minutes on days 1-3.
9487817|NCT00944970|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
9487818|NCT00944970|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
9487819|NCT00944970|Active Comparator|adenosine then adenosine|
9487820|NCT00944892|Experimental|Dose 1|
9487821|NCT00944892|Experimental|Dose 2|
9487822|NCT00944892|Experimental|Dose 3|
9487823|NCT00944892|Placebo Comparator|Placebo|
9487824|NCT00944294|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
9487825|NCT00944294|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
9487826|NCT00941486|Experimental|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%)
9487827|NCT00941486|Placebo Comparator|Vehicle|
9487828|NCT00940095|Experimental|Clazosentan 5 mg/h|Continuous intravenous infusion of clazosentan (5 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
9487829|NCT00940095|Experimental|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan (15 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
9487830|NCT00940095|Placebo Comparator|Placebo|Continuous intravenous infusion of placebo matching clazosentan started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
9487831|NCT00939276|Experimental|NEVANAC|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
9487832|NCT00939276|Placebo Comparator|Nepafenac Vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
9487833|NCT00939237|Experimental|Active Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
9487834|NCT00939237|Placebo Comparator|Placebo|placebo dietary supplement supplied as one capsule taken daily
9487835|NCT00938652|Active Comparator|Arm G/C|gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
9487836|NCT00938652|Experimental|Arm G/C/I|gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
9487837|NCT00938587|Experimental|PF-04171327 10 mg|
9487838|NCT00938587|Experimental|PF-04171327 25 mg|
9487839|NCT00938587|Active Comparator|Prednisone|
9487840|NCT00938587|Placebo Comparator|Placebo|
9487841|NCT00937352|Active Comparator|Bapineuzumab 0.5 mg/kg|0.5 mg/kg
9487842|NCT00937352|Active Comparator|Bapineuzumab 1.0 mg/kg|1.0 mg/kg
9487843|NCT00936871|Experimental|Part A|Lersivirine Tolerability
9487844|NCT00936871|Experimental|Part B|Thorough QTc
9487845|NCT00935987|Experimental|CYT387|
9487846|NCT00934921|Experimental|Ondansetron|Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
9487847|NCT00934921|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in second period
9487848|NCT00934180|Experimental|Ondansetron|Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
9487849|NCT00934180|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg OD Tablet (test) dosed in second period
9487850|NCT00932737|Active Comparator|HBB 20mg 1-5 tablets per episode|patient to receive 1-5 tablets containing 20mg HBB per APC episode
9487851|NCT00932737|Placebo Comparator|Placebo|patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode
9487852|NCT00931606|Experimental|1|ACE-011 Treatment Group (Dose Level 1)
9487853|NCT00931606|Experimental|2|ACE-011 Treatment Group (Dose Level 2)
9487854|NCT00931606|Experimental|3|ACE-011 Treatment Group (Dose Level 3)
9487855|NCT00931606|Placebo Comparator|4|Placebo
10040675|NCT01855763|Active Comparator|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
10040676|NCT01855776|Other|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
9487856|NCT00930163|Experimental|1|
9487857|NCT00930163|Placebo Comparator|2|
9487858|NCT00929968|Placebo Comparator|Placebo to VAK694|
9487859|NCT00929968|Experimental|VAK694|
9487860|NCT00929968|Active Comparator|Fluticasone propionate|
9487861|NCT00929539|Experimental|Dose 1 JTT-130|
9487862|NCT00929539|Experimental|Dose 2 JTT-130|
9487863|NCT00929539|Experimental|Dose 3 JTT-130|
9487864|NCT00929539|Placebo Comparator|Placebo|
9487865|NCT00929188|Experimental|001|JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
9487866|NCT00929188|Placebo Comparator|002|Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
9487867|NCT00928590|Experimental|DuoTrav APS|Travoprost/Timolol Maleate Fixed Combination solution, 1 drop in the study eye(s) once daily, at 9 AM, for 12 months
9487868|NCT00927914|Experimental|Ranirestat 80 mg|Two 80 mg Ranirestat tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
9487869|NCT00927914|Experimental|Ranirestat 40 mg|One 40 mg tablet of Ranirestat and a matching placebo, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
9487870|NCT00927914|Placebo Comparator|Placebo|Two placebo tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
9487871|NCT00927641|Active Comparator|Ketoprofen Patch (HKT-500)|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
9487872|NCT00927641|Placebo Comparator|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
9487873|NCT00925535|Active Comparator|Treatment A|Lersivirine
9487874|NCT00925535|Active Comparator|Treatment B|Rifabutin
9487875|NCT00925535|Experimental|Treatment C|Lersivirine and Rifabutin
9487876|NCT00924989|Experimental|Arm A: OSI-906|150 mg twice daily
9487877|NCT00924989|Placebo Comparator|Arm B: Placebo|Matching placebo twice daily
9487878|NCT00924833|Placebo Comparator|placebo|Placebo tablets. One tablet twice daily.
9487879|NCT00924833|Active Comparator|2: Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
9487880|NCT00924833|Active Comparator|3: Nebivolol|Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
9487881|NCT00922571|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the OptiMedica Catalys™ Precision Laser System (Catalys System)
9487882|NCT00920985|Experimental|Arm 1|
9487883|NCT00920985|Active Comparator|Arm 2|
9487884|NCT00920946|Placebo Comparator|Placebo|
9487885|NCT00920946|Experimental|Dimebon|
9487886|NCT00920764|Active Comparator|A|
9487887|NCT00920764|Active Comparator|B|
9487888|NCT00920764|Active Comparator|C|
9487889|NCT00920764|Placebo Comparator|D|
9487890|NCT00920582|Experimental|1|
9487891|NCT00920582|Experimental|2|
9487892|NCT00920582|Experimental|3|
9487893|NCT00920582|Placebo Comparator|4|
9487894|NCT00919893|Active Comparator|Cernilton|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
9487895|NCT00919893|Placebo Comparator|Placebo|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
9487896|NCT00918983|Experimental|NX-1207|
9487897|NCT00918983|Placebo Comparator|Placebo|
9487898|NCT00918814|Experimental|LIPO-102|LIPO-102
9487899|NCT00918814|Experimental|Placebo|Placebo
9487900|NCT00917826|Experimental|Arginine Butyrate + Ganciclovir/Valganciclovir|
9487901|NCT00917306|Experimental|PEP005 gel|PEP005 gel, 0.05% administered once daily for 2 consecutive days
9487902|NCT00917293|Experimental|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate, enteric-coated 2x 250mgs po bid.
9487903|NCT00917293|Placebo Comparator|Placebo|Placebo 2 pills, po bid.
9487904|NCT00917111|Experimental|CO2 Gas|
9487905|NCT00917111|Placebo Comparator|Inactive Placebo Gas|
9487906|NCT00917020|Experimental|Active: CO2 Gas|
9487907|NCT00917020|Placebo Comparator|Inactive Placebo Gas|
9487908|NCT00914602|Active Comparator|Treatment Period A|Treatment Period A: Sinemet® 25-100 treatment After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
9545555|NCT03066765|Experimental|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
9545556|NCT03066635|Experimental|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
9545557|NCT03066635|Experimental|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
9545558|NCT03066856|Experimental|Intervention|After baseline examinations, participants are randomized to an active dietary intervention group.The intervention group is invited to attend six full days of life-style intervention activities over the next six months. These activities include six cookery courses followed by lunch, six physical activity sessions (walking for 45 minutes) and six conferences. The intervention and control groups both complete questionnaires on adherence to the Mediterranean diet (MEDAS) at baseline and at the end of the study, and are asked for at least two 24-hour recalls of the previous day's food intake, and details of their physical exercise during the six-month intervention.
9545559|NCT03066856|No Intervention|Control|All participants receive general recommendations for the dietary prevention of cancer. After baseline examinations, women randomized in the control group carry on following the baseline recommendations.
9545560|NCT03066791|Active Comparator|Turmeric group|"Turmeric Tablets:~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.~Supplied by Sabinsa Corporation"
9545561|NCT03066791|Active Comparator|Curcumin Group|"Curcumin and Bioperine tablets:~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.~Supplied by Sabinsa corporation"
9545562|NCT03066791|Placebo Comparator|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 6 placebo tablets per day"
9545563|NCT03066869|Experimental|H.P. ACTHAR GEL|
9545564|NCT03066752||7 pediatric-onset multiple sclerosis|
9545565|NCT03066752||7 non-patient healthy volunteers|
9545566|NCT03066817|Placebo Comparator|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
9545567|NCT03066817|Experimental|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
9545568|NCT03066986|Experimental|25mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison).
9545569|NCT03066986|Experimental|25mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison, adjuvant comparison).
9545570|NCT03066986|Active Comparator|50mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 50mcg, ie. the current standard of care.
9545571|NCT03066986|Experimental|50mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 50mcg (adjuvant comparison).
9545572|NCT03066960|Active Comparator|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
9545573|NCT03066960|Sham Comparator|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
9545574|NCT03066596|Experimental|PRAGMATIC|Intervention practices will receive guideline information and assess children's asthma severity and control. For children with persistent/uncontrolled asthma, academic detailing and prompt in EHR following asthma guidelines will guide asthma management; outreach worker will follow up with patients referred to the by providers to receive care coordination to assure that provider management plan is followed by patient at home.
9545575|NCT03066713|Experimental|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
9545576|NCT03066713|Experimental|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
9545577|NCT03066713|Experimental|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
9545578|NCT03066713|Experimental|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
9545579|NCT03066674|Experimental|McKenzie group|This group will receive Hand-on technique on the lumbar spine.
9545580|NCT03066674|Experimental|Control group|The Group will not receive Hand-on technique on the lumbar spine.
9545581|NCT03066882|Experimental|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
9545582|NCT03066882|Experimental|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
9545583|NCT03066700||Hemospray application|The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
10040677|NCT01855776|Experimental|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
9545584|NCT03066973|Experimental|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
9545585|NCT03066973|No Intervention|Control group|control group that received standard care service.
9545586|NCT03066583|Placebo Comparator|trephination with placebo|meniscal repair with trephination and placebo
9545587|NCT03066583|Experimental|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
9545588|NCT03066570|Experimental|Single case study|Single case study using Graded exposure.
9545589|NCT03066557|Active Comparator|study group|TACE and Apatinib
9545590|NCT03066557|Experimental|control group|TACE alone
9545591|NCT03066544|Active Comparator|bupivacaine (Exparel)|subjects assigned by clinician's judgment - standard care choice A
9545592|NCT03066544|Active Comparator|naratriptan pill (Amerge)|subjects assigned by clinician's judgment - standard care choice B
9545593|NCT03066544|Active Comparator|dexamethasone tablet (Decadron)|subjects assigned by clinician's judgment - standard care choice C
9545594|NCT03066544|Active Comparator|ketorolac (Toradol)|subjects assigned by clinician's judgment - standard care choice D
9545595|NCT03066362|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
9545596|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
9545597|NCT03066349||Patients with PCOS undergoing IVM|
9545598|NCT03066219|Active Comparator|BRM421 Ophthalmic Solution|The active control with BRM421 solution
9545599|NCT03066219|Placebo Comparator|Placebo|The vehicle solution
9545600|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
9545601|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
9545602|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
9545603|NCT03066531|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
9545604|NCT03066531|Active Comparator|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.~Assigned Interventions: Behavioral: usual care (CBT)"
9545605|NCT03066336|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
9545606|NCT03066453|Experimental|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
9545607|NCT03066453|Experimental|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care
9545608|NCT03066271|Experimental|Exercise + usual care|"The supervised exercise training is carried out on a ergometer cycle as individual daily (mon-fri) training and each exercise training session consists of 20min.~The training comprised a warm-up phase followed by 3 exercise phases. Warm-up consisted of 5min light stationary cycling, adjusted to 50-60% of the patients peak power output determine at the incremental cycle test (iPPO). The first exercise phase comprised of 5min interval training consisting of 5x30 sec intervals at 80-95% of the patient's iPPO. Between each interval, there is a 30 sec pause. The 2nd exercise phase consisted of 5min continuous cycling at an intensity equaling 80% of the patient's iPPO. The 3rd exercise phase was similar to the first exercise phase. Intensities increased progressively from the first week to the last week (from 50%, 80% and 70% of iPPO according to the three different phases to 60%, 95% and 80 % of iPPO respectively."
9545609|NCT03066271|Experimental|Control - usual care|The patients randomized to the control group received no training but will be wearing the activity tracker during the intervention.
9545610|NCT03066466|Experimental|Arm A: Atorvastatin|The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant & continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
9545611|NCT03066466|Active Comparator|Arm B: Standard of Care|Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
9545612|NCT03066388|Experimental|Pulse pressure variations|Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.
9616741|NCT02539914|Active Comparator|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
9545613|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
9545614|NCT03066518|Placebo Comparator|Melatonin|Melatonin 5 mg, daily, eight weeks
9545615|NCT03066518|Placebo Comparator|placebo|Placebo, daily, eight weeks
9545616|NCT03066479|Experimental|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
9545617|NCT03066427|Experimental|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
9545618|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
9545619|NCT03066375|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
9545620|NCT03066505|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
9545621|NCT03066505|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
9545622|NCT03066180|Experimental|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
9545623|NCT03066180|Experimental|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
9545624|NCT03066258|Experimental|Dose 1|3E9 GC/eye of RGX-314
9545625|NCT03066258|Experimental|Dose 2|1E10 GC/eye of RGX-314
9545626|NCT03066258|Experimental|Dose 3|6E10 GC/eye of RGX-314
9545627|NCT03066258|Experimental|Dose 4|1.6E11 GC/eye of RGX-314
9545628|NCT03066258|Experimental|Dose 5|2.5E11 GC/eye of RGX-314
9545629|NCT03066245|Experimental|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
9545630|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
9545631|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
9545632|NCT03066323|Active Comparator|Tea extract|Rice with tea extract
9545633|NCT03066323|Placebo Comparator|No tea extract|Rice without tea extract
9545634|NCT03066492|Active Comparator|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
9545635|NCT03066492|Experimental|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
9545636|NCT03066089|Experimental|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
9545637|NCT03066089|No Intervention|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
9545638|NCT03066076|Active Comparator|Thyroidectomy|Total thyroidectomy
9545639|NCT03066076|Active Comparator|Antithyroid drug|Thiamazol, Propylthiouracil
9545640|NCT03066115|Experimental|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
9545641|NCT03066115|Experimental|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
9545642|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
9545643|NCT03066167||Controls|Healthy Controls with no known dysphagia
10040678|NCT01855776|Experimental|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:~$0 SGD for less than 50,000 steps during the week~$15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)~$30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
9545648|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
9616742|NCT02539719|Experimental|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
9545649|NCT03065907|Active Comparator|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
9545650|NCT03065907|Active Comparator|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
9545651|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
9545652|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
9545653|NCT03066154|Experimental|N15DOP|Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
9545654|NCT03065855|Experimental|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
9545655|NCT03065855|Active Comparator|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
9545656|NCT03065972|Active Comparator|Surgical fistula creation from patient's anatomy|Patients randomized to surgical arteriovenous fistula will have a fistula surgically created from their anatomy to be used for hemodialysis access.
9545657|NCT03065972|Active Comparator|Surgical graft implant|Patients randomized to surgical graft, will have a commercially available graft surgically implanted to be used for hemodialysis access.
9545658|NCT03065686|Experimental|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
9545659|NCT03065777|Experimental|ONE ENDO|Single file rotary system
9545660|NCT03065777|Experimental|F6 SKYTaper|Single file rotary system
9545661|NCT03065777|Active Comparator|ProTaper Universal|Muti-file rotary system
9545662|NCT03065881|Active Comparator|Dilated versus Natural pupil|
9545663|NCT03065881|Active Comparator|Normal retina versus abnormal retina|
9545664|NCT03065959|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
9545665|NCT03065959|Experimental|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
9545666|NCT03065946||Case series|Early wakening
9545667|NCT03065842|Experimental|Abortion- and contraceptive-use stigma reduction program|Four sessions (à 120 min), every week in 1 month.
9545668|NCT03065842|Active Comparator|Usual standards|Usual standards
9545669|NCT03065868|Experimental|eradictaion|H. pylori eradication group
9545670|NCT03065868|No Intervention|non-eradication|H. pylori non-eradication group
9545671|NCT03065894|Experimental|Stratified Care|"In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care)."
9545672|NCT03065894|Active Comparator|Current Care|"In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain."
9545673|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
9545674|NCT03066011||Voriconazole Group|Oral and Intravenous
9545675|NCT03066011||Posaconazole Group|Oral and Intravenous
9545676|NCT03065998|Active Comparator|Drug-A|opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
9545677|NCT03065998|Active Comparator|Drug-B|baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
9545678|NCT03065816|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
9545679|NCT03065816|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
9545680|NCT03065803|Active Comparator|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
9616743|NCT02539719|Experimental|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
9616744|NCT02539706|Experimental|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
9616745|NCT02539706|Active Comparator|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
10040679|NCT01855776|Experimental|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
9545681|NCT03065803|Other|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
9545682|NCT03065764|Other|Patients|For the first 3 patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to determine the optimal scan time point and to perform biodistribution measurements and dosimetry. All subsequent 7 patients receive only 1 PET scan post-injection (i.e. two PET scans).
9545683|NCT03065829|Experimental|ASSIST|The ASSIST intervention will deliver daily doses of MMT and vary dose intensity of all components each day based on the subject's biophysical data. Across a 30-day period, the ASSIST intervention will capture and analyze data to deliver on-demand MMT, guided practices to promote sleep hygiene and physical activity. Each day, subjects will receive at least one prompt to practice MMT (about 5 minutes at a time). However, based on the subject's biophysical sensor data, subjects could receive a maximum of 5 alerts or prompts per day from the device to enhance stress reduction, sleep hygiene, or physical activity.
9545684|NCT03065829|Experimental|Attention-Control|This intervention exposes subjects to the wearable technology without the self-management components to minimize novelty effects. Subjects assigned to this condition will wear the device for 30 days, which offers them an opportunity to experientially learn to self-monitor and employ self-regulatory skills by viewing the display biophysical data. Subjects in this condition will not receive any prompts from the device.
9545685|NCT03065699|No Intervention|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
9545686|NCT03065699|Active Comparator|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
9545687|NCT03066128|Experimental|Intervention|Participants in the Intervention Group will receive chronic ART management from a Professional Nurse and/or Enrolled Nurse every 2 months, and if stable after 6 months, community pharmacy ART collection through CCMDD. Viral load monitoring will be by a point-of-care viral load testing.
9545688|NCT03066128|Experimental|Standard of Care|Participants in the Standard-of-Care control arm will receive the standard-of-care for the clinic consisting of visits with a professional clinician (Physician or Professional Nurse) and once stable, community pharmacy ART collection through CCMDD.Viral load monitoring will be by lab-based viral load testing
9545689|NCT03065751|Active Comparator|TPE|
9545690|NCT03065751|No Intervention|Kontroll|
9545691|NCT03065595|Placebo Comparator|Intervention|Ophicephalus striatus extract
9545692|NCT03065595|Active Comparator|Control|Placebo drug
9545693|NCT03065738|Experimental|osteoarthritis knee ,severe varus deformity|reduction osteotomy in total knee replacement
9545694|NCT03065712|Experimental|FES PET/CT|"This is a single arm study that involves FES PET/CT.~Procedure: Computed Tomography~Drug: [F-18] fluoroestradiol: [F-18]FES~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
9545695|NCT03065439|Experimental|STarT Back Tool group 3|Patients scored as high risk patients by the STarT Back Tool
9545696|NCT03065439|Experimental|STarT Back Tool groups 1+2|Patients scored as low risk or medium risk patients by the STarT Back Tool
9545697|NCT03065608||Study Group|The study group included 36 patients with pain form of dysfunction.
9545698|NCT03065608||Control Group|The control group consisted of 36 patients with painless form of disorder.
9545699|NCT03065517|Experimental|VillageWhere App|Parent-youth dyads assigned to the VillageWhere condition will be asked to use the VillageWhere App that has been developed for this study. Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
9616746|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
9545700|NCT03065517|Placebo Comparator|Attention-Control Placebo App|Parent-youth dyads assigned to the control condition will be asked to use a free placebo control app that is well-liked by parents and youth but void of content already part of an existing evidence-based treatment for youth with conduct problems (e.g., geolocation tracking). Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial.
9545701|NCT03065504|Active Comparator|Turmeric group|"2,000 mg turmeric per day - supplied by Banyan® Botanicals )~o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg."
9545702|NCT03065504|Active Comparator|Turmeric-containing combination tablets|"• 2,000 mg Healthy Skin™ Tablets, contains:~Turmeric (Curcuma longa) - 50 mg/tablet~Hemidesmus Indicus root (Anantamul)~Indian Madder root~Neem leaf~Gotu Kola leaf~Indian TInospora stem~Amla fruit~Licorice root~Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets."
9545703|NCT03065504|Placebo Comparator|Placebo tablets group|"Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals~Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder~Dose: subjects in this group will take 2 tablets twice per day"
9545704|NCT03065426||Roux-en-Y Gastric Bypass|Patients planning to undergo Roux-en-Y Gastric Bypass will be invited to participate in this study.
9545705|NCT03065426||Sleeve Gastrectomy|Patients planning to undergo Sleeve Gastrectomy will be invited to participate in this study.
9545706|NCT03065673|Active Comparator|Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
9545707|NCT03065673|Placebo Comparator|Placebo gel|The patient will receive the application placebo gel on vestibular surface teeth, for 10 minutes.
9545708|NCT03065387|Experimental|Arm I (neratinib, everolimus)|Participants receive neratinib PO daily and everolimus PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9545709|NCT03065387|Experimental|Arm II (neratinib, palbociclib)|Participants receive Neratinib PO daily for 28 days and Palbociclib PO daily for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9545710|NCT03065387|Experimental|Arm III (neratinib, trametinib)|Participants receive neratinib PO daily and trametinib PO daily as directed. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
9545711|NCT03065452||Patients who underwent open decompression surgery|Observational study on patients who underwent open decompression surgery
9545712|NCT03065569|Active Comparator|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
9545713|NCT03065569|Experimental|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
9545714|NCT03065660|Active Comparator|Mifepristone|A single dose of oral mifepristone 200mg, followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later
9545715|NCT03065660|Placebo Comparator|Placebo|Oral placebo tablet followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later.
9545716|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
9545717|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
9545718|NCT03065634|Experimental|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
9545719|NCT03065634|Active Comparator|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
9545720|NCT03065491|Active Comparator|Active treatment|Combined nutraceutical
9545721|NCT03065491|Placebo Comparator|Placebo|Placebo
9545722|NCT03065621|Experimental|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
10040680|NCT01855841|Active Comparator|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
9545723|NCT03065374|Experimental|Treatment arm A|IMM-529, 1000 mg three times daily, orally
9545724|NCT03065374|Placebo Comparator|Treatment arm B|Matching Placebo, three times daily, orally
9616747|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
9616748|NCT02539927||Controlled|
9616749|NCT02539927||Not controlled|
9616750|NCT02539927||Control status yet to be clarified|
9616751|NCT02539615|Experimental|ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection|Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
10040681|NCT01855841|Placebo Comparator|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
10040682|NCT01855854|Experimental|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
9545725|NCT03065348|Experimental|Intervention|"Around 2 to 4 weeks before surgery:~Fried frailty score~CARE score assessment~NRS Kondrup assessment~Plasma albumin and CRP values~Start with daily oral whey protein administration until evening before surgery45~Around 5-7 days before surgery:~- Start with immunonutrition~Evening before surgery:~CARE score assessment~NRS Kondrup~CERAD cognition test assessment~Plasma albumin and CRP values, urine specific gravity~Carbohydrate loading~If urine specific gravity is >1.020 then additional tap water drinking will be encouraged~Day of surgery:~Carbohydrate loading~Start anesthesia with spinal anesthesia (continuous)~POD 7:~CARE assessment~CERAD assessment~Plasma albumin and CRP values~POD14:~CARE assessment~Plasma albumin and CRP value~POD 30:~CARE assessment~NRS Kondrup~CERAD assessment~Plasma albumin and CRP values~POD 90:~CARE assessment~NRS Kondrup~CERAD assessment"
9545726|NCT03065140|Experimental|Healthy Volunteers|"Healthy volunteers will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy Followed by a period of detraining.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
9545727|NCT03065140|Experimental|Diabetic Patients|"Diabetic patients will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy They will then undergo a supervised training period.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
9616752|NCT02539680|Experimental|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
9616753|NCT02539680|Experimental|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
9616754|NCT02539680|Experimental|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
9616755|NCT02539641|Other|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
9616756|NCT02539641|Other|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
9616757|NCT02539641|Other|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
9616758|NCT02539641|Other|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
9616759|NCT02539641|Other|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
9616760|NCT02539628|Experimental|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
9616761|NCT02539628|Active Comparator|Continuous infusion|ropivacaine 0.2%, 7ml/h
9616762|NCT02539602|Experimental|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
9616763|NCT02539602|No Intervention|Counterfactual|The counterfactual condition received no intervention.
9616764|NCT02539576|Experimental|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
9616765|NCT02539589|Experimental|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
9616766|NCT02539589|Active Comparator|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
9616767|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral~Pharmacokinetics"
9616768|NCT02539472|Experimental|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
9616769|NCT02539433|Experimental|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
9616770|NCT02539420|No Intervention|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
9616771|NCT02539420|Experimental|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
9616772|NCT02539420|Experimental|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
9616773|NCT02539355|Active Comparator|Diet A|Standard Healthy Diet (Diet A)
9616774|NCT02539355|Experimental|Diet B|Alternative Test Diet (Diet B)
9616775|NCT02539485|Other|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
9616776|NCT02539550|Placebo Comparator|Placebo|Placebo
9616777|NCT02539550|Experimental|PF-06266047|PF-06266047
9616778|NCT02539446|Other|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
10040683|NCT01855893|Experimental|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
9487909|NCT00914602|Experimental|Treatment Period B|Multiple-Dose XP21279 (with Lodosyn®) treatment. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
9545728|NCT03065270|Experimental|A group|
9545729|NCT03065270|Experimental|B group|
9545730|NCT03065361||Group A|"Group composed of 21 children and adolescents aged between 9 and 19 years old, treated by hemodialysis in two hospitals of Belo Horizonte. Just in case of some evidence of difference in the results within group A, because of the two types of dialysis (via fistula or catheter), this group can be subdivided in subgroups A1 (n=10) and A2 (n=11), respectively.~Group A was already on hemodialysis, the intervention was not performed by the researcher. Our goal was only to evaluate some characteristics of these individuals."
9545731|NCT03065361||Group B|Group composed of 21 children and adolescents matching age and gender for the Group A participants. The individuals were recruited in schools of Belo Horizonte.
9545732|NCT03065309|Experimental|Single Arm|Patients will receive bolus dose of remifentanil before intubation
9545733|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
9616779|NCT02539446|Other|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
9487910|NCT00914290|Other|IPX056-Baclofen IR-IPX056|Following 2 weeks of run-in period, subjects were randomized to IPX056 and Placebo IR for 2 weeks and then to Baclofen IR and Placebo IPX056 for 2 weeks.
9487911|NCT00914290|Active Comparator|IPX056-IPX056-Baclofen IR|Following 2 weeks of run-in period, subjects were randomized to Baclofen IR and Placebo IPX056 for 2 weeks and then to IPX056 and Placebo IR for 2 weeks.
9487912|NCT00913393|Placebo Comparator|1|Placebo IV
9487913|NCT00913393|Experimental|2|3 mg/kg FG-3019 IV
9487914|NCT00913393|Experimental|3|10 mg/kg FG-3019 IV
9487915|NCT00912691|Experimental|1|CM-AT
9487916|NCT00912158|Active Comparator|CPAP + ST|Continuous positive airway pressure (CPAP) and Standard medical therapy (ST)
9487917|NCT00912158|Active Comparator|BiPAP + ST|Bilevel positive airway pressure (BiPAP) and standard medical therapy (ST)
9487918|NCT00912158|Active Comparator|ST|Standard Medical therapy (ST)
9487919|NCT00911963|Experimental|Part A|This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.
9487920|NCT00911963|Experimental|Part B|VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks
9487921|NCT00911443|Experimental|Dacarbazine + Interferon alpha + thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
9487922|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
9487923|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
9487924|NCT00911443|Experimental|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
9487925|NCT00911443|Active Comparator|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
9487926|NCT00911274|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by CellCept® 250 mg Capsule dosed in second period.
9487927|NCT00911274|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
9487928|NCT00911248|Experimental|PTC299|PTC299 administered at 100 mg/dose twice per day
9487929|NCT00909766|Active Comparator|Panel A|
9487930|NCT00909766|Active Comparator|Panel B|
9487931|NCT00909766|Active Comparator|Panel C|
9487932|NCT00909766|Active Comparator|Panel D|
9487933|NCT00909766|Active Comparator|Panel E|
9487934|NCT00909766|Active Comparator|Panel F|Low Dose
9487935|NCT00909766|Active Comparator|Panel G|High Dose
9487936|NCT00909766|Placebo Comparator|Panel H|
9487937|NCT00909753|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg
9487938|NCT00909753|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg
9487939|NCT00909649|Active Comparator|1 fibrin glue|8 ml of fibrin glue was sprayed on the surgical area with Y canula ( doubleject application system).One milliliter of fibrin glue contains 70-100 mg. fibrinogen, 10-50 u factor 8 aprotinin 3000k iu/ml, 2-9 mg fibronectin,40-120 ug plasminogen ,4 Iu/ml thrombin, 40 mmol cocl2/L (immuno AG/austrial)
9487940|NCT00909649|No Intervention|2 non fibrin glue|after good haemostasis the same sized drain was applied in axillary and breast area and incision was closed. Followed by external compression for 10 minutes in both groups. Drains were left in places until the drainage for the preceding 24 h was less than 20 ml.
9487941|NCT00909610|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg dosed in second period.
9487942|NCT00909610|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.
9487943|NCT00909597|Active Comparator|pioglitazone|
9487944|NCT00909597|Experimental|taspoglutide 10mg|taspoglutide 10mg sc weekly
9487945|NCT00909597|Experimental|taspoglutide 10mg/20mg|taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly
9487946|NCT00909298|Experimental|1|TTP889 300 mg
9487947|NCT00909298|Placebo Comparator|2|TTP889 Placebo
9487948|NCT00908752|Active Comparator|Brivanib|Adjuvant treatment with TACE Therapy
9487949|NCT00908752|Placebo Comparator|Brivanib Placebo|Placebo adjuvant treatment with TACE Therapy
9487950|NCT00908648|No Intervention|1|standard white light
9487951|NCT00908648|Experimental|2|Narrow Band Imaging
9487952|NCT00908128|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
9487953|NCT00908128|Active Comparator|CellCept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
9487954|NCT00907907|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
9487955|NCT00907907|Active Comparator|Cellcept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
9487956|NCT00907387|Active Comparator|Dose A|Dose A RT001
9487957|NCT00907387|Active Comparator|Dose B|Dose B RT001
9487958|NCT00907387|Placebo Comparator|Dose C|Dose C Placebo
9487959|NCT00906334|Experimental|800 mg/m^2 ON 01910.Na|800 mg/m^2 ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 48 hours (i.e. 2 consecutive 24-hour infusions) every week for the first 3 weeks of 4-week cycle.
9487960|NCT00906334|Experimental|1800 mg ON 01910.Na|1800 mg ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 72 hours (i.e., 3 consecutive 24-hour infusions) every 2 weeks for the first four 2-week cycles and every 4 weeks afterwards.
9487961|NCT00905606|Experimental|1|Topiramate Tablets, 25 mg
9487962|NCT00905606|Active Comparator|2|Topamax® Tablets, 25 mg
9487963|NCT00905567|Experimental|Test First|Topiramate 2 x 25 mg Tablet
9487964|NCT00905567|Active Comparator|Reference First|Topamax® Tablet 2 x 25 mg
9487965|NCT00905385|Experimental|Low Dose: 3,200 CFU|5 subjects inoculated with 3,200 colony forming units (CFU).
9487966|NCT00905385|Experimental|High Dose: 32,000 CFU|5 subjects inoculated with 32,000 colony forming units (CFU).
9487967|NCT00905372|Experimental|LY2062430|
9487968|NCT00905372|Placebo Comparator|Placebo|
9487969|NCT00905346|Experimental|Test First|Topiramate Capsules 25 mg
9487970|NCT00905346|Active Comparator|Reference First|Topamax® 25 mg Capsule
9487971|NCT00905164|Experimental|Test First|Topiramate Capsules, 25 mg
9487972|NCT00905164|Active Comparator|Reference First|Topamax® Capsules, 25 mg
9487973|NCT00904943|Experimental|Test First|Topiramate Capsules, 25 mg
9487974|NCT00904943|Active Comparator|Reference First|Topamax® Capsules, 25 mg
9487975|NCT00904683|Experimental|LY2062430|
9487976|NCT00904683|Placebo Comparator|Placebo|
9487977|NCT00903552|Experimental|Low Dose|
9487978|NCT00903552|Placebo Comparator|PBS|
9487979|NCT00903552|Experimental|High Dose|
9487980|NCT00902928|Experimental|1. YM150, Dose X, twice daily|
9487981|NCT00902928|Experimental|2, YM150, Dose X, once daily|
9487982|NCT00902928|Experimental|3. YM150, Dose Y, twice daily|
9487983|NCT00902928|Experimental|4. YM150, Dose Y, once daily|
9487984|NCT00902928|Active Comparator|5. Enoxaparin|
9487985|NCT00902291|Active Comparator|1. Gemcitabine monotherapy|
9487986|NCT00902291|Experimental|2. Gemcitabine plus AGS-1C4D4|
9487987|NCT00902200|Placebo Comparator|Vehicle|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
9487988|NCT00902200|Experimental|AR-12286 0.05%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
9487989|NCT00902200|Experimental|AR-12286 0.1%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
9487990|NCT00902200|Experimental|AR-12286 0.25%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
9487991|NCT00901979|Experimental|LCQ908 Dose 1|
9487992|NCT00901979|Experimental|LCQ908 Dose 2|
9487993|NCT00901979|Experimental|LCQ908 Dose 3|
9487994|NCT00901979|Experimental|LCQ908 Dose 4|
9487995|NCT00901979|Experimental|LCQ908 Dose 5|
9487996|NCT00901979|Placebo Comparator|Placebo|
9487997|NCT00901979|Active Comparator|Sitagliptin|
9487998|NCT00901693|Experimental|AL-46383A|AL-46383A Ophthalmic Solution, 1 drop in each eye, 8 times a day for 10 days
9487999|NCT00901693|Placebo Comparator|Vehicle|AL-46383A Ophthalmic Solution Vehicle, 1 drop in each eye, 8 times a day, for 10 days
9488000|NCT00900900|Experimental|Dehydroepiandrosterone (DHEA)|
9488001|NCT00900900|Experimental|Pregnenolone|
9488002|NCT00900900|Placebo Comparator|Placebo|
9488003|NCT00900783|Experimental|2|FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days
9488004|NCT00900783|Active Comparator|3|Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days
9488005|NCT00900783|Experimental|1|FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days
9488006|NCT00899977|Placebo Comparator|Placebo|Subjects may receive a single, oral dose of placebo (capsule) in one of 4 crossover periods. Also, subjects may receive placebo orally, twice daily for 14 days in the last phase of the study.
9488007|NCT00899977|Experimental|1 mg TC-5214|Subjects may receive a single, oral capsule of 1 mg TC-5214 in one of 4 crossover periods.
9488008|NCT00899977|Experimental|2 mg TC-5214|Subjects may receive a single, oral capsule of 2 mg TC-5214 in one of 4 crossover periods.
9488009|NCT00899977|Experimental|4 mg TC-5214|Subjects may receive a single, oral capsule of 4 mg TC-5214 in one of 4 crossover periods. Also, subjects may receive 4 mg TC-5214 orally, twice daily for 14 days in the last phase of the study.
9488010|NCT00899977|Experimental|8 mg TC-5214|Subjects may receive a single, oral capsule of 8 mg TC-5214 in one of 4 crossover periods.
9488011|NCT00894868|Experimental|Vildagliptin|
9488012|NCT00894868|Placebo Comparator|Placebo|
9488013|NCT00894530|Experimental|1|
9488014|NCT00894530|Placebo Comparator|2|
9488015|NCT00893139|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
9488016|NCT00893139|Experimental|AL-38583 0.10%|AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
9488017|NCT00893139|Placebo Comparator|AL-38583 vehicle|Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
9488018|NCT00892970|Experimental|1|
9488019|NCT00892970|Placebo Comparator|2|
9488020|NCT00892762|Experimental|Travoprost APS|Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
9488021|NCT00892762|Active Comparator|XALATAN|Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
9488022|NCT00892203|Experimental|Active|
9488023|NCT00892203|Active Comparator|Comparator|
9488024|NCT00892203|Placebo Comparator|Placebo|
9488025|NCT00890968|Experimental|Triamcinolone Acetonide (TAC) DuraPeel|
9488026|NCT00890968|Placebo Comparator|Placebo|
9488027|NCT00890890|Experimental|Avagacestat (50 mg)|
9488028|NCT00890890|Placebo Comparator|Placebo|
9488029|NCT00890591|Experimental|Treatment|
9488030|NCT00890409|No Intervention|Normothermia|Rectal temperature was maintained at 36.0-37.5 degree C.
9488031|NCT00890409|Experimental|Hypothermia|The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
9488032|NCT00890305|Experimental|CT-011 in combination with FOLFOX|"CT-011 (3 mg/kg) administered intravenously every 4 weeks for 4 weeks and every 12 weeks thereafter until disease progression or maximum tolerance.~FOLFOX (FOLFOX4 or mFOLFOX6) administered 7 days after the first administration of CT-011 and repeated every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation."
9488033|NCT00890305|Active Comparator|FOLFOX|FOLFOX (FOLFOX-4 or mFOLFOX6) administered every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.
9488034|NCT00890149|Experimental|Ondansetron|Ondansetron + BASICS Plus
9488035|NCT00890149|Placebo Comparator|Placebo|Placebo + BASICS Plus
9488036|NCT00889967|Experimental|1|Ciprofloxacin for Inhalation 100 mg/day by inhalation
9488037|NCT00889967|Experimental|2|Ciprofloxacin for inhalation 150 mg/day by inhalation
9488038|NCT00889967|Placebo Comparator|Placebo|Placebo by inhalation
9488039|NCT00889889|Experimental|1|
9488040|NCT00889889|Placebo Comparator|2|
9488041|NCT00889486|Placebo Comparator|Placebo|Four placebo capsules taken orally once per day for 28 days
9488042|NCT00889486|Experimental|10 mg TZP-102|One 10 mg TZP-102 Capsule and three placebo capsules taken orally once per day for 28 days
9488043|NCT00889486|Experimental|20 mg TZP-102|Two 10 mg TZP-102 Capsules and two placebo capsules taken orally once per day for 28 days
9488044|NCT00889486|Experimental|40 mg TZP-102|Four 10 mg TZP-102 Capsules taken orally once per day for 28 days
9488045|NCT00889473|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
9488046|NCT00889473|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
9488047|NCT00889382|Experimental|Phase 1 Arm A|Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)
9488048|NCT00889382|Experimental|Phase 1 Arm B1|Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)
9488049|NCT00889382|Experimental|Phase 1 Arm B2|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)
9488050|NCT00889382|Experimental|Phase 1 Arm B3|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)
9488051|NCT00889382|Experimental|Phase 2 Arm A|Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15
9488052|NCT00889382|Experimental|Phase 2 Arm B|Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15
9488053|NCT00889382|Experimental|Phase 2 Arm C|Paclitaxel on Days 1, 8, and 15
9488054|NCT00889382|Experimental|Phase 2 Arm C Roll-over|Continuous OSI-906 BID from Day 1 onwards
9488055|NCT00888914|Active Comparator|Dose A|RT001 Dose A; Active Comparator
9488056|NCT00888914|Active Comparator|Dose B|RT001 Dose B; Active Comparator
9488057|NCT00888914|Active Comparator|Dose C|RT001 Dose C; Active Comparator
9488058|NCT00888914|Active Comparator|Dose D|RT001 Dose D; Active Comparator
9488059|NCT00888914|Placebo Comparator|Dose E|RT001 Dose E; Vehicle Comparator
9488060|NCT00888355|Placebo Comparator|1|Placebo
9488061|NCT00888355|Experimental|2|Losartan 50 q.a.m.
9488062|NCT00888355|Experimental|3|Losartan 25 b.i.d.
9488063|NCT00888355|Experimental|4|Losartan 25 q.a.m.
9488064|NCT00887250|Placebo Comparator|1|Placebo
9488065|NCT00887250|Experimental|2|Losartan 50 mg for 12 weeks
9488066|NCT00887250|Experimental|3|Losartan 50 mg titrated to 100 mg after 6 weeks
9488067|NCT00886782|Experimental|Cdc7-inhibitor|
9488068|NCT00886600|Placebo Comparator|1|Placebo
9488069|NCT00886600|Experimental|2|losartan 50 mg q.d.
9488070|NCT00886600|Experimental|3|losartan 100 mg q.d.
9488071|NCT00886600|Experimental|4|losartan 50 mg b.i.d.
9488072|NCT00886470|Experimental|ST266 1|Topical treatment every other day
9488073|NCT00886470|Experimental|ST266 2|Topical treatment every 4th day
9488074|NCT00886470|Experimental|ST266 3|Topical treatment every 7th day
9488075|NCT00885196|Experimental|AEB071 200 mg BID|
9488076|NCT00885196|Experimental|AEB071 400 mg OD|
9488077|NCT00885196|Experimental|AEB071 300 mg BID|
9488078|NCT00885196|Placebo Comparator|Placebo BID|
9488079|NCT00884715|Experimental|1 implant|117 mg Octreotide implant
9488080|NCT00884715|Experimental|2 implants|234 mg Octreotide implant
9488081|NCT00884507|Placebo Comparator|Placebo|
9488082|NCT00884507|Experimental|RO5313534 15mg|
9488083|NCT00884507|Experimental|RO5313534 1mg|
9488084|NCT00884507|Experimental|RO5313534 5mg|
9488085|NCT00884234|Experimental|1|RT001 (Botulinum Toxin Type A Topical Gel)
9488086|NCT00884234|Placebo Comparator|2|Vehicle Control
9488087|NCT00883896|Placebo Comparator|Arm 1|Part 1: Placebo
9488088|NCT00883896|Experimental|Arm 2|Part 1: 100 mg ILV-094 SC Q4W
9488089|NCT00883896|Experimental|Arm 3|Part 1: 100 mg ILV-094 SC Q2W
9488090|NCT00883896|Placebo Comparator|Arm 4|
9488091|NCT00883896|Experimental|Arm 5|Part 2: 200 mg ILV-094 SC Q2W
9488092|NCT00882440|Placebo Comparator|1|Placebo
9488093|NCT00882440|Experimental|2|Losartan 10 mg
9488094|NCT00882440|Experimental|3|Losartan 25 mg
9488095|NCT00882440|Experimental|4|Losartan 50 mg
9488096|NCT00882440|Experimental|5|Losartan 100 mg
9488097|NCT00882440|Experimental|6|Losartan 150 mg
9488098|NCT00882440|Active Comparator|7|Enalapril 20 mg
9488099|NCT00881452|Active Comparator|CM-AT|CM-AT (Luminenz-AT)- 900mg CM-AT, pancreatic enzyme concentrate (720mg)
9488100|NCT00881452|Placebo Comparator|Placebo|Placebo 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)
9488101|NCT00881023|Active Comparator|1|Randomized to Microfracture
9488102|NCT00881023|Experimental|2|Randomized to Device
9488103|NCT00881023|Experimental|3|Non-randomized with lesion greater than 6cmˆ2
9488104|NCT00880490|Experimental|1|Inhaled PT005 2.4 mcg
9488105|NCT00880490|Experimental|2|Inhaled PT005 4.8 mcg
9488106|NCT00880490|Experimental|3|Inhaled PT005 9.6 mcg
9488107|NCT00880490|Placebo Comparator|4|Inhaled Placebo
9488108|NCT00880490|Active Comparator|5|Formoterol Fumarate 12 mcg (Foradil Aerolizer)
9488109|NCT00880217|Experimental|001|JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
9488110|NCT00880217|Experimental|002|JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
9488111|NCT00880217|Experimental|003|JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
9488112|NCT00880217|Active Comparator|004|Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
9488113|NCT00880217|Active Comparator|005|OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
9488114|NCT00880217|Placebo Comparator|006|Placebo capsule once daily for 42 days
9488115|NCT00879762|Experimental|Group A: High Dose|Single high dose of IMVAMUNE® (5x10^8 TCID50, consisting of two 0.5 mL injections) vaccine on Day 0 and a single saline placebo dose (single 0.5 mL injection) on Day 28 to match the two dose regimen of Group B.
9488116|NCT00879762|Active Comparator|Group B: Standard Dose|Standard two dose regimen of IMVAMUNE® (1x10^8 TCID50) vaccine on Day 0 (consisting of 0.5 mL injection of vaccine and 0.5 mL injection of saline placebo) and Day 28 (single 0.5 mL injection of vaccine).
9488117|NCT00879606|Experimental|1|Participants will be randomized to receive ALT-836.
9488118|NCT00879606|Placebo Comparator|2|Patients will be randomized to receive placebo.
9488119|NCT00879138|Placebo Comparator|Sugar pill|
9488120|NCT00879138|Experimental|VA106483 2 mg|
9488121|NCT00879138|Experimental|VA106483 4 mg|
9488122|NCT00879138|Experimental|VA106483 8 mg|
9488123|NCT00877903|Experimental|Prochymal®|Participants will receive Prochymal® single intravenous (IV) infusion at a dose of 200 x 10^6 human mesenchymal stem cells (hMSC), reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.
9488124|NCT00877903|Placebo Comparator|Placebo|Participants will receive Prochymal® placebo-matching single IV infusion at a dose of of 200 x 10^6 hMSC, reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.
9488125|NCT00877279|Experimental|Belotero® Soft|Comparator will be given into the opposite side of the face that Belotero® Soft was administered for facial wrinkles, such as nasolabial folds.
9488126|NCT00877279|Active Comparator|CosmoDerm1|
9488127|NCT00876863|Experimental|CERE-110|CERE-110: Adeno-Associated Virus Delivery of NGF
9488128|NCT00876863|Sham Comparator|Placebo|Placebo Surgery
9488129|NCT00876798|Experimental|1|Lixivaptan
9488130|NCT00876798|Placebo Comparator|2|Placebo
9488131|NCT00875459|Experimental|VIAject™|Single injection
9488132|NCT00875160|Experimental|AT2101|
9488133|NCT00875108|Experimental|VIAject™|Single injection
9488134|NCT00874796|Experimental|GS-9450 10 mg/day|GS-9450 taken as one 10 mg capsule by mouth once daily
9488135|NCT00874796|Experimental|GS-9450 40 mg/day|GS-9450 taken as one 40 mg capsule by mouth once daily
9488136|NCT00874796|Placebo Comparator|Placebo|Placebo taken as one placebo capsule by mouth once daily
9488137|NCT00872885|Experimental|A|Dose 1
9488138|NCT00872885|Experimental|B|Dose 2
9488139|NCT00872885|Experimental|C|Dose 3
9488140|NCT00872885|Active Comparator|D|Morphine
9488141|NCT00872885|Placebo Comparator|E|Placebo
9488142|NCT00872430|Active Comparator|Placebo/Laxative tea crossover|This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
9488143|NCT00872430|Active Comparator|Laxative tea/Placebo crossover|This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).
9488144|NCT00872300|Experimental|1|
9488145|NCT00872196|Other|1 - Follow-up Study|This is a follow-up study with no treatment and only samples being collected.
9488146|NCT00872014|Experimental|15mg/ kg cohort|AMG 386 15mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
9488147|NCT00872014|Experimental|10 mg/kg cohort|AMG 386 10mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
9488148|NCT00871936|Experimental|1|SLx-4090 in combination with Metformin
9488149|NCT00871936|Other|2|Placebo
9488150|NCT00871481|Experimental|Treatment (laboratory-treated T cells and ipilimumab)|Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
9488151|NCT00871325|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
9488152|NCT00871325|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
9488153|NCT00871325|Placebo Comparator|Placebo|Placebo TID
9488154|NCT00871182|Experimental|PT001 18 mcg|Inhaled PT001 18 mcg
9488155|NCT00871182|Experimental|PT001 36 mcg|Inhaled PT001 36 mcg
9488156|NCT00871182|Experimental|PT001 72 mcg|Inhaled PT001 72 mcg
9488157|NCT00871182|Experimental|PT001 144 mcg|Inhaled PT001 144 mcg
9488158|NCT00871182|Placebo Comparator|Inhaled Placebo|Inhaled Placebo
9488159|NCT00871182|Active Comparator|Tiotropium Handihaler|Tiotropium 18 mcg administered via Handihaler
9488160|NCT00870818|Experimental|1 Active|"Protege had 4 study arms, 3 were dosed with different doses of teplizumab, and 1 was a control group given placebo. This Extension study will continue to assess the subjects from these 4 arms.~In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses"
9488161|NCT00870818|Experimental|2 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
9488162|NCT00870818|Experimental|3 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
9488163|NCT00870818|Placebo Comparator|1 controlled|In Protege: Placebo Comparator: IV dosing daily for 14 days times 2 courses
9488164|NCT00870688||1|epilepsy patients
9488165|NCT00870454|Experimental|001|Carisbamate 800 mg/d 200 mg/d twice daily titrated up to 400 mg twice daily as tolerated by Week 3
9488166|NCT00870454|Experimental|002|Carisbamate 1 200 mg/d 200 mg/d twice daily titrated up to 600 mg twice daily as tolerated by Week 3
9488167|NCT00870454|Active Comparator|003|Pregabalin 300 mg/d 75 mg/d twice daily for Week 1 followed by 150 mg twice daily for the remainder
9488168|NCT00870454|Placebo Comparator|004|Placebo Placebo capsules twice daily
9488169|NCT00870155|Experimental|Dirucotide|
9488170|NCT00869986|Experimental|Dirucotide|
9488171|NCT00869986|Placebo Comparator|Placebo|
9488172|NCT00869726|Experimental|Dirucotide|
9488173|NCT00869726|Placebo Comparator|Placebo|
9488174|NCT00869661|Experimental|Group 1|RO5024048 500 mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
9488175|NCT00869661|Experimental|Group 2|RO5024048 1000mg bid + Pegasys + Copegus for 8 weeks, followed by SOC for 16 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
9488176|NCT00869661|Experimental|Group 3|RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
9488177|NCT00869661|Experimental|Group 4|Group 4 will receive RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 36 weeks
9488178|NCT00869661|Active Comparator|Group 5|Group 5 will receive SOC for 48 weeks
9488179|NCT00869661|Experimental|Group 6|Group 6 provides retreatment on an open-label basis for patients of Group 5 who failed treatment. Patients will receive RO5024048 1000mg bid + Pegasys + Copegus for 24 weeks, followed by SOC for 24 weeks.
9488180|NCT00869336|Experimental|Luliconazole Cream 1% - 2 wks|Daily treatment with Luliconazole Cream 1% for 2 weeks
9488181|NCT00869336|Experimental|Luliconazole Cream 1% - 4 wks|Daily treatment with Luliconazole Cream 1% for 4 weeks
9488182|NCT00869336|Placebo Comparator|Placebo Comparator - 2 wks|Daily treatment with Vehicle Cream for 2 weeks
9488183|NCT00869336|Placebo Comparator|Placebo Comparator - 4 wks|Daily treatment with Vehicle Cream for 4 weeks
9488184|NCT00869128|Other|Placebo First|Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).
9488185|NCT00869128|Other|Circadin first|Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.
9488186|NCT00867698|Experimental|AST-120 (6g)|2 grams TID
9488187|NCT00867698|Placebo Comparator|Placebo A|2 grams TID
9488188|NCT00867698|Experimental|AST-120 (12g)|4 grams TID
9488189|NCT00867698|Placebo Comparator|Placebo B|4 grams TID
9488190|NCT00866476|Experimental|Vaccine-recipients|
9488191|NCT00866476|Placebo Comparator|Placebo|
9488192|NCT00866242|Experimental|Challenge-recipients|
9488193|NCT00864175|Experimental|Treatment A - INCB007839 and Trastuzumab|"INCB007839 100 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
9488194|NCT00864175|Experimental|Treatment B - INCB007839 and Trastuzumab|"INCB007839 200 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
9488195|NCT00864175|Experimental|Treatment C - INCB007839 and Trastuzumab|"INCB007839 300 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
9488196|NCT00864175|Experimental|Treatment D - INCB007839 and Docetaxel|INCB007839 300mg BID with docetaxel
9488197|NCT00863369|Experimental|Treatment (bortezomib, gemcitabine hydrochloride, rituximab)|Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
9488198|NCT00862524|Experimental|ARRY-334543 + gemcitabine|
9488199|NCT00861809|Experimental|Cohort 1 Period 1|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
9488200|NCT00861809|Experimental|Cohort 1 Period 2|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
9488201|NCT00861809|Experimental|Cohort 1 Period 3|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
9488202|NCT00861705|Active Comparator|Arm I (paclitaxel, doxorubicin, cyclophosphamide)|Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.
9488203|NCT00861705|Experimental|Arm II (paclitaxel, ddAC, bevacizumab)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.
9488204|NCT00861705|Experimental|Arm III (paclitaxel, ddAC, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.
9488205|NCT00861705|Experimental|Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.
9488206|NCT00861211|Experimental|Active treatment arm|
9488207|NCT00861211|Placebo Comparator|Placebo|
9488208|NCT00861185|Experimental|Senicapoc|
9488209|NCT00861185|Placebo Comparator|Placebo|
9488210|NCT00860288|Experimental|Vildagliptin Dose 1|
9488211|NCT00860288|Experimental|Vildagliptin Dose 2|
9488212|NCT00860288|Placebo Comparator|Placebo|
9488213|NCT00860288|Active Comparator|Sitagliptin|
9488214|NCT00859521|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
9488215|NCT00859521|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
9488216|NCT00859430|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
9488217|NCT00859430|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
9498133|NCT03468842|Active Comparator|Probiotic|Composition: Streptococcus dentisani: 2,5E+09CFUs, 2% (p/v) Guam Guar and 6% (p/v) Hidroxietilcelulosa. Dose of 2.5E+09 cfu/vial considering one administration every 48 hours, it will be equivalent to a dose of 1.0E+10 cfu/week Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
9498134|NCT03468829|Experimental|ALX-0171 Dose 1|
9498135|NCT03468829|Experimental|ALX-0171 Dose 2|
9498136|NCT03468829|Placebo Comparator|Placebo|
9498137|NCT03468803|Experimental|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
9498138|NCT03468790|Experimental|CMAB007 + Seretide/Symbicort + Ventolin|CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.
9498139|NCT03468790|Placebo Comparator|Placebo + Seretide/Symbicort + Ventolin|Placebo is without active components of the study drug and used as same as the study drug.
9498140|NCT03468777|Experimental|Part 1: Treatment Sequence (ABC)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 1 then Treatment B as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment C (optional Part 2) as a single dose of 150 mg ranitidine administered after 2 hours of single dose of 1000 mg lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9621736|NCT02521714|Experimental|Treatment A: 25mg capsule -under fasted condition|Single oral dose of 25mg lenalidomide (reference formulation, 1 x 25mg capsule) under fasted condition.
9488218|NCT00858871|Active Comparator|Brivanib|
9488219|NCT00858871|Active Comparator|Sorafenib|
9488220|NCT00858702|Experimental|1|olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks
9488221|NCT00858702|Experimental|2|olmesartan medoxomil and a diuretic tablet (of the thiazide class)
9488222|NCT00858052|Experimental|breast augmentation|breast implant
9488223|NCT00857285|Experimental|1|olmesartan medoxomil
9488224|NCT00857285|Active Comparator|2|losartan potassium
9488225|NCT00857090|Experimental|1|Drug
9488226|NCT00857090|Placebo Comparator|2|Vehicle
9488227|NCT00856934|No Intervention|Control|Wounds covered with standard dressings: three layers of paraffin gauze, standard bandages, elastic bandage.
9488228|NCT00856934|Experimental|PRP|PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
9488229|NCT00856934|Experimental|PRP+K|Keratinocytes suspended in PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
9488230|NCT00855764|Experimental|Paclitaxel|
9488231|NCT00855712|Experimental|Organ Care System|
9488232|NCT00855712|Active Comparator|Cold cardioplegia solution|
9488233|NCT00855179|Active Comparator|Antistax film-coated tablets 360 mg|Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
9488234|NCT00855179|Placebo Comparator|Placebo|Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
9488235|NCT00854945|Experimental|ON 01910.Na|1800 mg/day of ON 01910.Na administered as a 24-hour continuous intravenous infusion on days 1, 2 and 3 of 14-day cycle.
9488236|NCT00852839|Experimental|552-02|
9488237|NCT00852839|Placebo Comparator|Placebo|
9488238|NCT00851045|Active Comparator|Arm 1|Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322
9488239|NCT00851045|Active Comparator|Arm 2|Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution)
9488240|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/CT-322|
9488241|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/Bevacizumab/Placebo|
9488242|NCT00850174|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
9488243|NCT00850174|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
9488244|NCT00849862|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra 750 mg Tablet (reference) dosed in second period
9488245|NCT00849862|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
9488246|NCT00849797|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
9488247|NCT00849797|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
9488248|NCT00849667|Active Comparator|1|Carboplatin and taxane with MORAb-003 1.25 mg/kg
9488249|NCT00849667|Active Comparator|2|Carboplatin and taxane with MORAb-003 2.5 mg/kg
9488250|NCT00849667|Placebo Comparator|3|Carboplatin and taxane with Placebo
9488251|NCT00849576|Active Comparator|Regular Human Insulin|Single Injection
9488252|NCT00849576|Active Comparator|Inuslin Lispro (90%)|Single Injection
9488253|NCT00849576|Experimental|Insulin VIAject™ (75%)|Single Injection
9488254|NCT00849576|Experimental|Insulin VIAject™ (90%)|Single injection
9488255|NCT00849485|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra® 750 mg Tablet (reference) dosed in second period
9488256|NCT00849485|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
9488257|NCT00847405|Experimental|1|
9488258|NCT00847405|Active Comparator|2|
9488259|NCT00847366|Experimental|Perifosine 201|"Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer.~Perifosine dosage:~Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week."
9488260|NCT00847366|Experimental|Perifosine 206|"Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab.~Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle."
9488261|NCT00847366|Experimental|Perifosine 207|Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food.
9488262|NCT00847366|Experimental|Perifosine 208|Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
9488263|NCT00847366|Experimental|Perifosine 209|Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval).
9488264|NCT00846989|Experimental|1|
9488265|NCT00846989|Experimental|2|
9488266|NCT00846989|Active Comparator|3|
9488267|NCT00846885|Experimental|1|
9488268|NCT00846885|Active Comparator|2|
9488269|NCT00846781|Experimental|Denufosol tetrasodium Inhalation Solution|
9488270|NCT00845923|Other|Civamide Patch 0.015%|All subjects in study will receive the Civamide Patch 0.015%
9488271|NCT00845299|Experimental|1|Latanoprost punctal plug and use of artificial tears containing Benzalkonium Chloride
9545734|NCT03065296|Experimental|Musculoskeletal (MSK) Exercise Prescription|"Phase I: Residents will be surveyed as to their knowledge and confidence in both diagnosing specific musculoskeletal (MSK) issues and prescribing the correct home rehabilitation regimen.~In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.~Phase II: Residents will be surveyed again in May 2017 with the same multiple choice questions and Likert style confidence scales from phase 1~The survey will consist of multiple choice and short essay questions, focused on the most common musculoskeletal (MSK) injuries seen in the primary care setting."
9545735|NCT03065010|Other|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
9545736|NCT03064997|Active Comparator|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
9545737|NCT03064997|Placebo Comparator|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
9545738|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
9545739|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
9545740|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
9545741|NCT03065114||PGSno.|blastocysts from patients underwent preimplantational genetic screen (PGS) prtocols. only euploid embryos were selected to transfer.
9545742|NCT03065036|Experimental|Hydrus Aqueous Implant|Hydrus implanted into Schlemm's Canal.
9545743|NCT03065036|Other|IOL placement and Hydrus implant|Cataract Extraction with IOL placement and Hydrus implant into Schlemm's canal
9545744|NCT03064971|Experimental|Standard care + PTF DVD|The intervention will include the standard care, with the addition of the PTF DVD. Participants randomized to this condition will receive Pathways to Freedom: Leading the Way to a Smoke-Free Community© (PTF). The content of the intervention parallels the types of education, advice, and cessation/relapse prevention strategies that are delivered in clinic and quitline contexts, except for the focus on the specific needs of the Black community. The 60- minute DVD consists of 7 sections. The cultural adaptations (e.g., focus on menthol, focus on religion/spirituality, Black images and music) were infused throughout the DVD. The PTF DVD is useable at varying levels along the readiness to quit smoking continuum, as viewers are empowered to view sections that match their interests and goals. Quit Coaches will be trained to refer participants to appropriate sections for additional help.
9545745|NCT03064971|Active Comparator|Standard care + standard smoking cessation DVD|"This arm includes standard care, plus a standard smoking cessation DVD. The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies. Narrated by a physician, it describes the process of quitting and strategies for increasing physical activity and healthy nutrition. It includes testimonials from former smokers and dialogue among smokers in a group counseling setting. The information is presented in a standard format, intended for the general population of smokers."
9545746|NCT03064971|Active Comparator|Standard care only|Following the first counseling session, participants may receive up to 3 additional proactive counseling calls. Follow-up calls focus on challenges that may have occurred on the quit date or with the use of medication. Quit Coaches® review and modify the person's quit plan, and provide support as appropriate. Participants also receive standard self-help materials by mail, which is often referred to by Quit Coaches. For individuals who have successfully quit, the Coach will focus on relapse prevention strategies. Quit Coaches provide medication education to all participants eligible and interested in using cessation medications. This study will provide starter NRT kits (2 weeks supply) to all participants. Coaches provide decision support using a database-supported algorithm based on current scientific evidence and the product manufacturer use instructions for each drug.
9545747|NCT03064932|Active Comparator|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (<1g/day for all diets).~Post prandial test meal will be contain minimal amounts of spice."
9545748|NCT03064932|Experimental|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (~3g/day in the 2100kcal diet).~Post prandial test meal will be contain a moderate amount of spice."
9545749|NCT03064932|Experimental|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).~Post prandial test meal will be contain a culinary amount of spice."
9545750|NCT03065166|Experimental|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
9545751|NCT03065166|Other|Bagel Control|One 95g whole wheat bagel.
9545752|NCT03065127|Experimental|Cognitive Training|"Participants will independently complete cognitive exercises on the Smartbrain Pro computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks."
9545753|NCT03065127|Experimental|Cognitive Behavioural Therapy|Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety. Participants will complete a total of eight one-hour sessions over 4 weeks.
9545754|NCT03065127|Experimental|Proprioceptive Training|Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs. For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets. They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on. The blindfold will then be removed allowing participants to view their performance relative to the target. This task will be repeated for the remaining targets on both sides and for both upper and lower limbs. Participants will complete a total of eight one-hour sessions over 4 weeks.
9621737|NCT02521714|Experimental|Treatment B: 25mg oral suspension - under fasted condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fasted condition.
9488272|NCT00845299|Experimental|2|Latanoprost punctal plug only
9488273|NCT00845026|Experimental|LY2140023|
9488274|NCT00845026|Active Comparator|aripiprazole|
9488275|NCT00845026|Active Comparator|olanzapine|
9488276|NCT00845026|Active Comparator|risperidone|
9488279|NCT00842088|Experimental|Active|
9488280|NCT00842088|Placebo Comparator|Placebo|
9488281|NCT00841815|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
9488282|NCT00841815|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
9488283|NCT00841698|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
9488284|NCT00841698|Active Comparator|Paxil®|Paxil 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
9488285|NCT00841659|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
9488286|NCT00841659|Active Comparator|Paxil®|Paxil® 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
9488287|NCT00841542|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
9488288|NCT00841542|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
9488289|NCT00840879|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
9488290|NCT00840879|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
9488291|NCT00840866|Experimental|1|
9488292|NCT00840866|Active Comparator|2|
9488293|NCT00840840|Experimental|1|
9488294|NCT00840840|Active Comparator|2|
9488295|NCT00840632|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
9488296|NCT00840632|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
9488297|NCT00840476|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
9488298|NCT00840476|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
9488299|NCT00840411|Experimental|Clarithromycin (test) First|
9488300|NCT00840411|Active Comparator|Biaxin® XL (reference) First|
9488301|NCT00840281|Experimental|1|
9488302|NCT00840281|Active Comparator|2|
9488303|NCT00840268|Experimental|HPGG 0.25%|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
9488304|NCT00840268|Placebo Comparator|HPGG Vehicle|Hydroxypropyl Guar Galactomannan Vehicle, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
9488305|NCT00840216|Experimental|1|
9488306|NCT00840216|Active Comparator|2|
9488307|NCT00840203|Experimental|Mesalamine|Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
9488308|NCT00840203|Active Comparator|Rowasa®|Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
9488309|NCT00840099|Experimental|1|
9488310|NCT00840099|Active Comparator|2|
9488311|NCT00840073|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
9488312|NCT00840073|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
9488313|NCT00839930|Experimental|Cilostazol (test)|Cilostazol 50 mg Tablet (test) dosed in first period followed by Pletal® 50 mg Tablet (reference) dosed in second period
9488314|NCT00839930|Active Comparator|Pletal® (reference)|Pletal® 50 mg Tablet (reference) dosed in first period followed by Cilostazol 50 mg Tablet (test) dosed in second period.
9488315|NCT00838890|Active Comparator|Cdc7-inhibitor (A)|
9488316|NCT00838890|Active Comparator|Cdc7-inhibitor (B)|
9488317|NCT00838799|Experimental|1|
9488318|NCT00838799|Experimental|2|
9488319|NCT00838799|Experimental|3|
9488320|NCT00838799|Active Comparator|4|
9488321|NCT00838799|Placebo Comparator|5|
9488322|NCT00838630|Experimental|1|
9488323|NCT00838630|Active Comparator|2|
9488324|NCT00838591|Experimental|1|MN-221 given i.v. 1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min [600 μg] + 13.3 μg/min for 45 min [600 μg]) as an adjunct to the standard of care for acute exacerbation of asthma.
9488325|NCT00838591|Placebo Comparator|Placebo|Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v. 1-hour infusion with a regimen as described for MN-221.
9488326|NCT00838383|Experimental|sitaxsentan (1.0 mg/kg)|
9488327|NCT00838383|Experimental|sitaxsentan (2.0 mg/kg)|
9488328|NCT00838383|Placebo Comparator|Placebo|
9488329|NCT00838279|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
9488330|NCT00838279|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
9545755|NCT03065088|Experimental|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
9545756|NCT03065088|Experimental|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
9545757|NCT03065088|Active Comparator|control|The control group follows the World Health Organization's recommendations of physical activity.
9545758|NCT03064919|Experimental|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
9545759|NCT03064984|Active Comparator|CBS eyedrops|Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
9545760|NCT03064984|Active Comparator|PBS eyedrops|Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
9545761|NCT03064945|Sham Comparator|Shame device|
9545762|NCT03064945|Experimental|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
9545763|NCT03065231|Active Comparator|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
9545764|NCT03065231|Active Comparator|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
9545765|NCT03064958|Active Comparator|Control|Consumption of a high fat meal (1000kcal, 45g fat)
9545766|NCT03064958|Experimental|Spice 2g|Consumption of a high fat meal (1000kcal, 45g fat) with 2g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
9545767|NCT03064958|Experimental|Spice 6g|Consumption of a high fat meal (1000kcal, 45g fat) with 6g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
9545768|NCT03065101|Other|Trigen Intertan|"Unique integrated interlocking screw and trapezoidal nail shape~Resistance to femoral head rotation and cut-out~Active compression through linear motion without rotation~Single subtrochanteric lag screw option for stable fractures below lesser trochanter~Preloaded cannulated set screw converts construct to fixed angle device~Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon~Clothespin tip for stress modulation in femoral shaft~Potential for improved patient mobility and recovery~Manufactured by Smith & Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
9545769|NCT03065101|Other|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.~Participating sites may use whichever brand of SHS is currently in use.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
9545770|NCT03064906|Other|Meal Performance and/or Exercise|"This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.~Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions."
9545771|NCT03064893|Active Comparator|Dermacell|Device for immediate implant based breast reconstruction
9545772|NCT03064893|Active Comparator|Alloderm|Device for immediate implant based breast reconstruction
9545773|NCT03064880|Active Comparator|SV maximization|Dynamic fluid responsiveness parameters, such as stroke volume (SV) response to fluid therapy, are precise fluid indicators that specifically determine patient volume status and are helpful for clinicians to determine the appropriate time for fluid bolus. For SV maximization, the investigators maximize SV after anesthetic induction by fluid therapy up to achieve maximized SV maintained.
9545774|NCT03064880|No Intervention|SV normalization|NO active fluid therapy.
9545775|NCT03064815|Experimental|Spondylarthropathies with GI symptoms|Subjects in this arm will have spondylarthropathies and gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
9545776|NCT03064815|Experimental|Spondylarthropathies without GI symptoms|Subjects in this arm will have spondylarthropathies without gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
9545777|NCT03064802||BioBurst Fluid, Burst Allograft|Spinal Fusion with BioBurst Fluid or Burst Allograft
9545778|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
9545779|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
9545780|NCT03064529|Experimental|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
9545781|NCT03064828|Active Comparator|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kilovolts peak (kVp), 100-200mA
10040684|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
10040685|NCT01855906|Active Comparator|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
10040686|NCT01855906|Active Comparator|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
10040687|NCT01855932|Experimental|Technology Supported|
9488331|NCT00838136|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
9488332|NCT00838136|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
9488333|NCT00837265|Experimental|Neugranin Dose Level 1|
9488334|NCT00837265|Experimental|Neugranin Dose Level 2|
9488335|NCT00837265|Active Comparator|Pegfilgrastim|
9488336|NCT00836901|Experimental|Amoxicillin Calvulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 40-57 mg Chewable Tablet (reference) dosed in second period
9488337|NCT00836901|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (test) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (reference) dosed in second period
9488338|NCT00836706|Experimental|Clarithromycin (test)|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
9488339|NCT00836706|Active Comparator|Biaxin®|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
9488340|NCT00836472|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
9488341|NCT00836472|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
9488342|NCT00836069|Experimental|PD 0332334-α2δ ligand (450mg)|PD 0332334, 450mg/day, for 8 weeks and then 2 weeks of dose tapering.
9488343|NCT00836069|Experimental|PD 0332334-α2δ ligand (600mg)|PD 0332334, 600mg/day, for 8 weeks and then 2 weeks of dose tapering.
9488344|NCT00836069|Active Comparator|Paroxetine|Paroxetine, 20mg/daym for 8 weeks and then 2 weeks of dose tapering.
9488345|NCT00836069|Placebo Comparator|Placebo|Inactive Substance (placebo) for 10 weeks.
9488346|NCT00836056|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
9488347|NCT00836056|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
9488348|NCT00836004|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
9488349|NCT00836004|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
9488350|NCT00835991|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
9488351|NCT00835991|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
9488352|NCT00835796|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
9488353|NCT00835796|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
9488354|NCT00835718|Experimental|Stage I, Arm 1|MK0594 5 mg/day
9488355|NCT00835718|Placebo Comparator|Stage I, Arm 2|Placebo
9488356|NCT00835718|Experimental|Stage II, Arm 2|MK0594 1 mg/day
9488357|NCT00835718|Experimental|Stage II, Arm 3|MK0594 1 mg/week
9488358|NCT00835718|Placebo Comparator|Stage II, Arm 4|Placebo
9488359|NCT00835705|Experimental|Amoxicillin Clavulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 400-57 mg Chewable Tablet (reference) dosed in second period
9488360|NCT00835705|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (reference) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in second period
9488361|NCT00835692|Experimental|Clarithromycin Tablets|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
9488362|NCT00835692|Active Comparator|Biaxin® Tablets|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
9488363|NCT00835666|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
9488364|NCT00835666|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
9488365|NCT00835640|Experimental|1|
9488366|NCT00835640|Active Comparator|2|
9488367|NCT00835614|Experimental|1|
9488368|NCT00835614|Active Comparator|2|
9545782|NCT03064828|Experimental|CT colonoscopy(low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
9545783|NCT03064594||cornuostomy|cornuostomy
9545784|NCT03064594||wedge resection|wedge resection
9545785|NCT03064646|Experimental|Organ Preservation|The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer
9545786|NCT03064464||CA-MRSA infection|None intervention
9545787|NCT03064464||HA-MRSA infection|None intervention
9545788|NCT03064464||CA-MSSA infection|None intervention
9545789|NCT03064737|Other|This study is a non-drug one arm study|Skin biopsy for genetic analyze
9545790|NCT03064724|Experimental|Smoking Cessation Group|Patients received the interactive mobile doctor (iMD) intervention.
9545791|NCT03064672|Experimental|induction by transcervical Balloon Catheters insertion|
9545792|NCT03064672|No Intervention|induction without transcervical Balloon Catheters|
9545793|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
9545794|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
9545795|NCT03064581|Experimental|Intervention|Gender-specific culturally tailored social-support informed educational intervention session.
9545796|NCT03064581|No Intervention|Control|Usual care with delayed intervention at the end of study.
9545797|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
9545798|NCT03064555||Healthy participants|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
9545799|NCT03064477|Experimental|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
9545800|NCT03064477|Active Comparator|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
9545801|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
9545802|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
9545803|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
9545804|NCT03064776|Experimental|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to~Continuously capture multidimensional behaviour as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.~Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision support system (CDSS) and Recommender operation.~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient-initiated (i.e. on-demand) real-time assessments, to the participants and in their own environment."
9545805|NCT03064776|Experimental|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
9545806|NCT03064516|Experimental|Endocrown|Restorations with ceramic endocrown in endodontically treated teeth
9545807|NCT03064516|Active Comparator|Onlay and fiber pin|Restorations with onlay ceramic and glass fiber pin in endodontically treated teeth
9545808|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
9545809|NCT03064633|Active Comparator|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
9621738|NCT02521714|Experimental|Treatment C: 25mg oral suspension -under fed condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fed condition.
9488369|NCT00835588|Experimental|Pantoprazole|Pantoprazole Sodium 40 mg DR Tablet (test) dosed in first period followed by Protonix® 40 mg DR Tablet (reference) dosed in second period
9488370|NCT00835588|Active Comparator|Protonix®|Protonix 40 mg DR Tablet (reference) dosed in first period followed by Pantoprazole Sodium 40 mg DR Tablet (test) dosed in second period
9488371|NCT00835575|Experimental|1|
9488372|NCT00835575|Active Comparator|2|
9488373|NCT00835549|Experimental|1|
9488374|NCT00835549|Active Comparator|2|
9488375|NCT00835536|Experimental|1|
9488376|NCT00835536|Active Comparator|2|
9488377|NCT00835497|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip® 5/500 mg Tablet (reference) dosed in second period
9488378|NCT00835497|Active Comparator|Metaglip®|Metaglip® 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
9488379|NCT00835484|Experimental|1|
9488380|NCT00835484|Active Comparator|2|
9488381|NCT00835406|Experimental|Alendronate Sodium First|70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period
9488382|NCT00835406|Active Comparator|Fosamax® First|70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.
9488383|NCT00835367|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
9488384|NCT00835367|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period
9488385|NCT00835354|Experimental|1|
9488386|NCT00835354|Active Comparator|2|
9488387|NCT00835276|Experimental|1|
9488388|NCT00835276|Active Comparator|2|
9488389|NCT00835263|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
9488390|NCT00835263|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
9488391|NCT00835211|Experimental|1|
9488392|NCT00835211|Active Comparator|2|
9488393|NCT00835172|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
9488394|NCT00835172|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
9488395|NCT00835146|Experimental|1|
9488396|NCT00835146|Active Comparator|2|
9488397|NCT00835081|Experimental|1|
9488398|NCT00835081|Active Comparator|2|
9488399|NCT00835042|Experimental|1|
9488400|NCT00835042|Active Comparator|2|
9488401|NCT00834990|Experimental|1|
9488402|NCT00834990|Active Comparator|2|
9488403|NCT00834977|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
9488404|NCT00834977|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period
9488405|NCT00834964|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
9488406|NCT00834964|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
9488407|NCT00834873|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
9488408|NCT00834873|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
9488409|NCT00834795|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
9488410|NCT00834795|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
9488411|NCT00834756|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
9488412|NCT00834756|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
9488413|NCT00834743|Experimental|1|
9488414|NCT00834743|Active Comparator|2|
9488415|NCT00834717|Experimental|Granisetron|Granisetron 1 mg Tablet (test) dosed in first period followed by Kytril® 1 mg Tablet (reference) dosed in second period
9488416|NCT00834717|Active Comparator|Kytril®|Kytril 1 mg Tablet (reference) dosed in first period followed by Granisetron 1 mg Tablet (test) dosed in second period
9488417|NCT00834639|Experimental|1|
9488418|NCT00834639|Active Comparator|2|
9488419|NCT00834613|Experimental|1|
9488420|NCT00834613|Active Comparator|2|
9488421|NCT00834587|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip™ 5/500 mg Tablet (reference) dosed in second period
9621739|NCT02521753|Active Comparator|Metformin|Metformin 850mg twice a day for six months
10040688|NCT01855971|Active Comparator|Fragile X syndrome experimental group|"Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).~Dosage form: capsules of 200mg Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Treatment period: 3 months (from month 1 to month 4)~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
9488422|NCT00834587|Active Comparator|Metaglip™|Metaglip™ 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
9488423|NCT00834574|Experimental|1|
9488424|NCT00834574|Active Comparator|2|
9488425|NCT00834561|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
9488426|NCT00834561|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
9488427|NCT00834535|Experimental|1|
9488428|NCT00834535|Active Comparator|2|
9498141|NCT03468777|Experimental|Part 1: Treatment Sequence (BAC)|Participants will receive Treatment B on Days 1 to 5 of period 1 then Treatment A on Day 1 of period 2 followed by Treatment C (optional Part 2) on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9498142|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DEF)|Participants will receive Treatment D as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 1 then Treatment E as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment F as a single oral dose of 150 mg ranitidine administered after 2 hours after a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9498143|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EFD)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment F on Day 1 of period 2 followed by Treatment D on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9498144|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FDE)|Participants will receive Treatment F on Days 1 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9498145|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FED)|Participants will receive Treatment F on Day 1 of period 1 then Treatment E on Days 1 to 5 of period 2 followed by Treatment D on Days 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9498146|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EDF)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment F on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9498147|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DFE)|Participants will receive Treatment D on Day 1 period 1 then Treatment F on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
9498148|NCT03468751|Experimental|HLX10, Dose Finding Cohort|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.3, 1.0, 3.0, and 10 mg/kg, starting from 0.3 mg/kg.
9498149|NCT03468751|Experimental|HLX10, Dose Expansion Cohort (200 mg )|Each cycle of treatment consists of 4 weeks. Patients who enroll into this expansion cohort will receive an infusion of assigned dose of HLX10 at 200 mg once every two weeks.
9498150|NCT03468725|Experimental|XPF-008|Single oral dose
9498151|NCT03468725|Active Comparator|Placebo|Single oral dose
9498152|NCT03468712|Experimental|Experimental group|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
9498153|NCT03468699|Experimental|Autologous BMMC transplantation|Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward
9498154|NCT03468686|Active Comparator|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
9498155|NCT03468686|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
9498156|NCT03468686|Active Comparator|Unilateral rTMS|Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)
9498157|NCT03468647|Experimental|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
9498158|NCT03468634|Experimental|Adenocarcinoma|patients diagnosed with adenocarcinoma
9498159|NCT03468634|Experimental|Squamous cell cancer|patients diagnosed with squamous cell cancer
9498160|NCT03468634|Experimental|Other|patients diagnosed with another condition
9498161|NCT03468634|Experimental|Barrett's oesophagus|patients diagnosed with Barrett's oesophagus
9498162|NCT03468634|Experimental|Low-grade dysplasia|patients diagnosed with low-grade dysplasia
9498163|NCT03468634|Experimental|High-grade dysplasia|patients diagnosed with high-grade dysplasia
9498164|NCT03468634|Experimental|Indefinite for dysplasia|patients where the diagnosis is unclear
9498165|NCT03468634|Experimental|no dysplasia|patients not diagnosed with any cancer
9498166|NCT03468621|Other|Intradermal wound closure|Intradermal wound closure of the groin wound
9498167|NCT03468621|Other|Transdermal wound closure|Wound closure of the groin wound with metal staples
9498168|NCT03468595|Experimental|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
9545810|NCT03064633|Active Comparator|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
9545811|NCT03064386|Experimental|plate group|internal fixation with the plate
9545812|NCT03064386|Experimental|screw group|internal fixation with the screw
9545813|NCT03064399|Experimental|lateral ligament repairment|
9545814|NCT03064399|Experimental|without lateral ligament repairment|
9545815|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
9545816|NCT03064568|Experimental|Misoprostol 100Mcg Tab|Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.
9545817|NCT03064568|Placebo Comparator|Placebo|Patients will receive identical inert tablets per rectum 30 minutes preoperatively.
9545818|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.~QoL questionnaire SF-12 and and a screening questionnaire were requested"
9545819|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
9545820|NCT03064282|Placebo Comparator|Placebo|Drug free base as placebo
9545821|NCT03064282|Experimental|group two- papaverine arm|papaverine in a suitable base
9545822|NCT03064334||one medium of focus groups|"The present study aims to understand patient experiences and outcomes post- Total Knee Arthroplasty(TKA). Therefore, a qualitative approach will be most appropriate to facilitate the collection of in-depth experiences and perceptions of patients post-TKA.~The medium of focus groups (with 8-10 patients) is preferred to allow a group of patients to share their perceptions and experiences post-surgery, with sufficient quantity and diversity of views while balancing the facilitator's ability to manage all patients' participation for 90-120 minutes (Bloor, 2006)."
9545823|NCT03064347|Active Comparator|Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder in enteric coating as single dose
9545824|NCT03064347|Placebo Comparator|Non Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder with separate enteric coating materials as single dose
9545825|NCT03064347|Active Comparator|Enteric Coated Sucrose|200kcal sucrose in enteric coating as single dose
9545826|NCT03064347|Placebo Comparator|Non-Enteric Coated Sucrose|200kcal sucrose with separate enteric coating materials as single dose
9545827|NCT03064347|Active Comparator|Enteric Coated Whey Protein|200kcal whey protein in enteric coating as single dose
9545828|NCT03064347|Placebo Comparator|Non-Enteric Coated Whey Protein|200kcal whey protein with separate enteric coating materials as single dose
9545829|NCT03064347|Active Comparator|Enteric Coated Pea Protein|200kcal pea protein in enteric coating as single dose
9545830|NCT03064347|Placebo Comparator|Non-Enteric Coated Pea Protein|200kcal pea protein with separate enteric coating materials as single dose
9545831|NCT03064139|Experimental|MCG - Mindful Walking|Participants will be trained in mindful walking technique
9545832|NCT03064139|Active Comparator|SCG - Education and Self-Care|Participants will receive education in self-management of knee OA
9545833|NCT03064191|Active Comparator|calcium hydroxide chlorhexidine|intervention: calcium hydroxide chlorhexidine combination an intra-canal medication composed of calcium hydroxide powder and chlorhexidine solution as a combination to be administered as intra-canal paste for decreasing postoperative symptoms
9545834|NCT03064191|Active Comparator|calcium hydroxide|intervention: calcium hydroxide an intra-canal medicament composed of calcium hydroxide paste for decreasing postoperative symptoms and signs .
9545835|NCT03064100||Specimens that meet inclusion criteria|
9545836|NCT03064256|Experimental|Physical training program|"Intervention participants are submitted to supervised aerobic physical training at the predetermined intensity, which is composed of three weekly sessions, lasting one hour, over a period of 12 weeks.~All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise."
9545837|NCT03064256|No Intervention|Control Group|Control participants receive routine outpatient care for a 12-week period.
9545838|NCT03064321|Experimental|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
9545839|NCT03064321|Other|Information Control|General health information website
9545840|NCT03064061|Sham Comparator|Virtual Reality Neutral|neutral VR session before oocytes retrieval
9545841|NCT03064061|Active Comparator|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
9545842|NCT03064165|Experimental|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
9545843|NCT03064165|Placebo Comparator|Sham block|Postoperative sham-block with normal saline.
9545844|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
9545845|NCT03064048|Active Comparator|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
9621740|NCT02521753|Experimental|Magnesium|Magnesium chloride 250mg daily for six months
9545846|NCT03064048|Placebo Comparator|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
9803794|NCT03328078|Experimental|Emavusertib (CA-4948) and ibrutinib dose escalation|Part A2: Evaluate escalating dose levels of oral emavusertib in combination with 560 mg daily (QD) of oral ibrutinib (or 420 mg QD for WM/LPL and CLL/SLL). Separate escalation of emavusertib will be performed for each of these ibrutinib doses. The starting dose of emavusertib to be used in combination will be 200 mg twice a day (BID). It is anticipated that 12 to 18 patients will be required to establish optimal combination dosing.
10040689|NCT01855971|Placebo Comparator|Fragile X syndrome control group|"Placebo administration. Placebo consists in capsules containing rice flour. Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
9545847|NCT03063996|Other|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
9545848|NCT03063996|Active Comparator|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
9545849|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
9545850|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
9545851|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
9545852|NCT03064269|Experimental|Arm 1|CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
9545853|NCT03064308|No Intervention|Control|Participants will receive standard NHS care with no intervention.
9545854|NCT03064308|Other|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
9545855|NCT03064243|Experimental|apatinib group|apatinib 500mg po qd
9545856|NCT03064022||Size < the 3rd or 10th percentiles|Infant size smaller than the 3rd or 10th percentiles relative to the Fenton growth chart for weight or head circumference at discharge from neonatal intensive care
9545857|NCT03064022||Rapid early growth|Rapid early growth will be defined as exceeding birthweight in the first week of life
9545858|NCT03064022||Growth velocity calculation methods|We will compare a variety of growth velocity calculation methods used in clinical care and research to compare and assess growth velocity calculation methods
9545859|NCT03064022||Size for gestational age|Small size for gestational age
9545860|NCT03063957||Microscopic Colitis|Patients with confirmed microscopic colitis
9545861|NCT03063957||Control|Patients that are not diagnosed with microscopic colitis
9545862|NCT03064360||Biomarker Testing, PROs, PRIs|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (Tnl), symptom and quality of life questionnaires, and patient metrics (activity, sleep, heart rate, heart rate variability).
9545863|NCT03063970|Experimental|Experimental Group|Wear of the tailor made Dynamic Lycra Orthosis for up to eight hours every day for eight weeks Usual rehabilitation
9545864|NCT03063970|Active Comparator|Comparison Group|Usual rehabilitation
9545865|NCT03063983|Experimental|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
9545866|NCT03063983|No Intervention|Control|31 weeks of MAP
9545867|NCT03063931|Experimental|magnesium|
9545868|NCT03063931|Placebo Comparator|placebo|
9545869|NCT03064035|Experimental|Fixed dose 4FPCC|"Incorporating a fixed dose of 1500 IU.~If the patient receiving the 1500 IU fixed dose remains in a bleeding state and the INR remains above goal, an additional 500 IU may be administered at the physician's discretion to minimize bleeding and attempt to achieve hemostasis."
9545870|NCT03064035|Active Comparator|Variable dose 4FPCC|"The FDA-approved variable dosing algorithm is as follows:~initial INR 2-3.9: 25 IU/kg (maximum dose 2500 IU), initial INR 4-6: 35 IU/kg (maximum dose 3500 IU), and initial INR >6: 50 IU/kg (maximum dose 5000 IU). The patient weight will be obtained using a scale and documented by the treating registered nurse"
9545871|NCT03063762|Experimental|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
9545872|NCT03063762|Experimental|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
9545873|NCT03063762|Experimental|Extension Part (Arm A): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
9621741|NCT02521753|Experimental|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
9621742|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
9545874|NCT03063762|Experimental|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
9545875|NCT03063762|Experimental|Extension Part (Arm C): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
9545876|NCT03063762|Experimental|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: Arm D is closed for future enrollment"
9545877|NCT03063892|Placebo Comparator|Control Arm|Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
9545878|NCT03063892|Experimental|Experimental Arm|Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.
9545879|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
9545880|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
9545881|NCT03063736|Experimental|Td vaccine with entolimod|Td vaccine (4 ug) + Entolimod (1 ug) (n=25)
9545882|NCT03063736|Placebo Comparator|Td vaccine only|Td vaccine (4 ug) (n=15)
9545883|NCT03063801||Cardiac surgery|All adult patients having undergone surgery between January 2006 and December 2016 within the CHU Brugmann hospital.
9545884|NCT03063775|Active Comparator|1. Mucograft® Seal + Bio-Oss®|
9545885|NCT03063775|Active Comparator|2. FGG + Bio-Oss®|
9545886|NCT03063775|Active Comparator|3. FGG + Gelatine sponge (Spongostan®)|
9545887|NCT03063775|Active Comparator|4. Spongostan®+ Mucograft® Seal|
9545888|NCT03063775|No Intervention|5. Spongostan®|
9545889|NCT03063814|Experimental|APP|In the APP group, a video sequence of each exercise, supported by short written descriptions (in accordance to 'Get set - Train smarter', (9) on how to perform the exercise correctly, was shown to the participants on an iPad. The video-recorded exercises were performed by the same physiotherapist who supervised PHY participants. If required, the participants in the APP group were allowed to watch the video and description several times between trials of the same exercise. The participants approved their own trials when they believed that the exercises had been performed as described.
9545890|NCT03063814|Active Comparator|PHY|In PHY, a physiotherapist demonstrated and explained the focus areas of each of the five exercises before the participant performed the exercises. If needed, verbal feedback was given between trials to correct the performance of the exercise. The physiotherapist approved trials that were performed with proper technique.
9545891|NCT03063645|Experimental|Group ABC|AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)
9545892|NCT03063645|Experimental|Group BCA|AC-SD-01 (50g), AC-SD-01 (75g), AC-1202
9545893|NCT03063645|Experimental|Group CAB|AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)
9545894|NCT03063879|Experimental|Sovodak|Sofosbuvir 400 mg and daclatasvir 60 mg
9545895|NCT03063580|Experimental|SAR439954 with or without rifampicin|Period 1: single oral dose of 400 mg sotagliflozinon Day 1 morning Period 2: once-daily oral doses of 600 mg rifampicin from Days 1 to 10 and a single oral dose of 400 mg sotagliflozin
10040690|NCT01855984|Experimental|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
9545896|NCT03063567|Other|one month trial of Nasal Mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
9545897|NCT03063567|Other|One month trial of Oronasal mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
9545898|NCT03063567|Other|One month trial of Nasal pillows|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
9545899|NCT03063840|Experimental|Microwave ablation (MWA)|Microwave ablation (MWA)
9545900|NCT03063541|Experimental|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
9545901|NCT03063541|No Intervention|standard care|blood pressure management according to guidelines
9545902|NCT03063723||CHC patients|15 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir orDaclatasvir-Sofosbuvir.
9545903|NCT03063723||Healthy controls|10 Healthy controls without any treatment
9545904|NCT03063671|Active Comparator|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
10040691|NCT01855984|Placebo Comparator|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
9621743|NCT02521740||controls|someone who lives with an healthy elderly
9545905|NCT03063671|Active Comparator|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
9545906|NCT03063671|Active Comparator|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
9545907|NCT03063671|Active Comparator|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
9545908|NCT03063632|Experimental|Group I (pembrolizumab, interferon gamma-1b)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.
9545909|NCT03063632|Experimental|Group II (pembrolizumab, interferon gamma-1b)|Patients pembrolizumab IV over 30 minutes on day 1 and interferon gamma-1b SC once a week. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity.
9545910|NCT03063788|Experimental|HIV uninfected|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 2 HIV uninfected individuals
9545911|NCT03063788|Experimental|HIV infected viremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with viremia who are not receiving antiretroviral therapy
9545912|NCT03063788|Experimental|HIV infected aviremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with undetectable HIV viral load who are receiving antiretroviral therapy
9616780|NCT02539381|Other|Gold Standard Assessments|"Formal perimetry (Goldman or Octopus visual field)~Albert's visual inattention test~Star cancellation visual inattention test~line bisection test~These are performed as part of the routine assessment in the visual stroke orthoptic clinic and neuro-ophthalmology clinics.~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
9616781|NCT02539381|Other|Usual Clinical Screening Practice|"Visual field assessment to confrontation~Visual inattention assessment to bilateral stimuli~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
9616782|NCT02539381|Other|Stroke Vision App|"Digital tumbling E visual accuity assessment~Digital visual field assessment~Digital line crossing assessment~Digital shape cancellation assessment~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
9616783|NCT02539524|Active Comparator|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
9616784|NCT02539524|Experimental|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
10040692|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
9616785|NCT02539186|Experimental|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
9616786|NCT02539186|Active Comparator|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
9616787|NCT02539212|Active Comparator|microwave ablation|microwave ablation
9616788|NCT02539212|Active Comparator|radiofrequency ablation|radiofrequency ablation
9616789|NCT02539173|Experimental|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
9616790|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
9616791|NCT02539316|Active Comparator|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
9616792|NCT02539316|Experimental|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
9616793|NCT02539329||patient|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
9616794|NCT02539329||control|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies
9616795|NCT02539290|Experimental|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
9616796|NCT02539290|Sham Comparator|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
10040693|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
9545913|NCT03063853|Other|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
9545914|NCT03063853|Other|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
9545915|NCT03063658|Active Comparator|Paracetamol|Paracetamol (Paracerol) 1 gram will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
9545916|NCT03063658|Active Comparator|Ibuprofen|Ibuprofen (Intrafen) 800 mg will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
9545917|NCT03063619|Placebo Comparator|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
9545918|NCT03063619|Experimental|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
9545919|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
9545920|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
9545921|NCT03063866|Active Comparator|M group|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg
9545922|NCT03063866|Active Comparator|P Group|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v
9545923|NCT03063697||patients who check the safety data after taking Dilatrend SR|
9545924|NCT03063528|Experimental|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.~12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
9545925|NCT03063528|Experimental|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.~12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
9545926|NCT03063515|No Intervention|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
9545927|NCT03063515|Active Comparator|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
9545928|NCT03063554|Active Comparator|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement. EUS via either stomach or duodenum.
10040694|NCT01856023|Active Comparator|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
9545929|NCT03063554|Placebo Comparator|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement only.
9545930|NCT03063684|Experimental|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
9545931|NCT03063684|Experimental|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
9545932|NCT03063489|Experimental|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
9545933|NCT03063463||Pneumatic Dilation|Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation
9545934|NCT03063463||Surgical Myotomy|Subject with achalasia undergoing routine care EGD with surgical myotomy
9545935|NCT03063320|Active Comparator|Low Spice|The test meal (~1200kcal and 44g fat) will contain ~0.6g of spice blend
9545936|NCT03063320|Experimental|Moderate Spice|The test meal (~1200kcal and 44g fat) will contain ~3.7g of spice blend
9545937|NCT03063320|Experimental|Culinary Spice|The test meal (~1200kcal and 44g fat) will contain ~7.4g of spice blend
9545938|NCT03063307|Active Comparator|Atraumatic Restorative Treatment|
9545939|NCT03063307|Experimental|Silver Diamine Fluoride|
9545940|NCT03063346|Experimental|Protein hydrolysate high dose|
10040695|NCT01856023|Active Comparator|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
9545941|NCT03063346|Experimental|Protein hydrolysate low dose|
9545942|NCT03063346|Placebo Comparator|Placebo|
9545943|NCT03063268|Experimental|Trust-Enhanced Messaged with Interactive Features on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
9545944|NCT03063268|Experimental|Interactive Features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
9545945|NCT03063268|Active Comparator|Standard E-Consent|Standardized text currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
9545946|NCT03063411|Experimental|Executive function intervention|The intervention comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks requiring working memory and inhibitory control. These tasks are child friendly and are based on established measures of executive function. The working memory tasks involve maintaining information in mind and processing information (for example, finding items hiding in different locations that move around) and suppressing a dominant but incorrect response (for example, a game where children try to catch fish but not sharks). Children receive feedback on their responses. If children score 75% or more correct in a session the difficulty level increases in the following session.
9545947|NCT03063411|Active Comparator|Visual search and simple decision making|The control task program, like the intervention, comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks not requiring executive function skills. Instead, they require simple attention and decision making skills and visual search skills. For example, finding an item among distractors (e.g., a spaceship), or deciding which of two animals can fly (out of a bird and a fish). Children receive feedback on their responses.
9545948|NCT03063372|Experimental|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
9545949|NCT03063372|Placebo Comparator|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
9545950|NCT03063424|Other|Healthy subjects|
9545951|NCT03063424|Other|Asthmatics with EIB|
9545952|NCT03063359|Experimental|Intranasal fentanyl + Oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
9545953|NCT03063359|Active Comparator|Oral morphine + Intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
9545954|NCT03063333|Experimental|Coping-oriented hypnosis|
9545955|NCT03063333|Placebo Comparator|Neutral hypnosis|
9545956|NCT03063333|No Intervention|current treatment only|
9545957|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
9545958|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
9545959|NCT03063190|Placebo Comparator|Hyperparathyroidism_0|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
9545960|NCT03063190|Active Comparator|Hyperparathyroidism_1|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
9545961|NCT03063190|Placebo Comparator|Adynamic_0|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
9545962|NCT03063190|Active Comparator|Adynamic_1|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
9545963|NCT03063229|Active Comparator|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
9545964|NCT03063229|Active Comparator|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
9545965|NCT03063229|Other|Healthy Volunteers|Participants with no Diabetes.
9545966|NCT03063177|Experimental|1840Newtons/s(N/s);125ms;250 Newtons(N)|Participants will receive a spinal manipulative therapy of 20 Newtons (N) preload leading to a peak force of 250N over 125ms (rate of force application of 1840N/s).
9545967|NCT03063177|Experimental|920N/s;125ms;135N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 135N over 125ms (rate of force application of 920N/s).
9545968|NCT03063177|Experimental|920N/s;250ms;250N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 250N over 250ms (rate of force application of 920N/s).
9545969|NCT03063177|No Intervention|control|Spinal stiffness will be assessed at each sesssion, however, participants won't receive any spinal manipulative therapy.
9545970|NCT03063242|Experimental|Project I: Healthy participants|5 healthy participants will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Blood samples will be drawn and analyzed for mDC levels.
9545971|NCT03063242|Experimental|Project II: Patients with CKD stage IV/V|5 Patients with CKD stage IV/V who are cytomegalovirus (CMV) seropositive with mean blood mDC levels <1.0x104/mL will receive sargramostim treatment once all 5 healthy participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
9545972|NCT03063242|Experimental|Project III: kidney transplant patients|5 Kidney transplant recipients who are CMV seropositive with neutropenia (defined as absolute neutrophil count <1.0 x103/mm3) and/or CMV viremia will receive sargramostim treatment once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
9545973|NCT03062943|Experimental|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
9545974|NCT03062852|Experimental|Medication safety vest|During administration rounds, nurses will wear the medication safety vest.
9545975|NCT03062852|No Intervention|Control|During administration rounds, nurses will be dressed as usual without a safety vest.
9545976|NCT03062839|Experimental|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
9545977|NCT03062839|Placebo Comparator|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
9545978|NCT03062956|Experimental|Single oral dose of MYK-491|single-dose, oral suspension
9545979|NCT03062956|Placebo Comparator|Single oral dose of placebo|single-dose, oral suspension
9545980|NCT03062800|Experimental|P+Cisplatin/Carboplatin+T|"Induction therapy (Platinum based chemotherapy combined with antiangiogenic therapy 4-6 cycles):~Pemetrexed + Platinum + Thalidomide [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle, ivgtt +thalidomide 100-200mg/d ,oral, qn ]~Continue maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Thalidomide 100mg/d ,oral, qn, until either disease progression or unacceptable toxicity."
9545981|NCT03062800|Experimental|P+Cisplatin/Carboplatin|"Induction therapy ( Platinum based chemotherapy 4-6 cycles):~Pemetrexed + Platinum [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle,ivgtt ]~Maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Pemetrexed (500mg/m^2) on day 1 of 21-days cycle, ivgtt.until either disease progression or unacceptable toxicity"
9545982|NCT03063008|Other|Lumbar fusion with PEEK cage|Control arm
9545983|NCT03063008|Other|Lumbar fusion with TiPEEK cage|Study arm
9545984|NCT03062813|Experimental|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
9545985|NCT03062813|Active Comparator|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
9545986|NCT03062904|Experimental|drug|
9545987|NCT03063099|Experimental|ReNu™ Injection|ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
9545988|NCT03062787|Experimental|Cingal®|Single 4 ml intra-articular injection of Hyaluronic Acid plus Triamcinolone Hexacetonide
9545989|NCT03062787|Active Comparator|Monovisc®|Single 4 ml intra-articular injection of Sodium Hyaluronate
9545990|NCT03063073|Placebo Comparator|Group I (Bupivacaine group)|ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
9545991|NCT03063073|Active Comparator|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
9545992|NCT03063112|Active Comparator|Group 1( radiofrequency group )|Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion
10040696|NCT01856036|Experimental|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
9545993|NCT03063112|Placebo Comparator|Group 2 ( alcohol group )|Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.
9545994|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
9545995|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
9545996|NCT03063034|Active Comparator|PD21864AA, PD21864AB|Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.
9545997|NCT03063034|Active Comparator|PD21864AB, PD21864AA|Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.
9545998|NCT03062930|Active Comparator|Track 1|Training of non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks followed by sham condition (playing board games/computer games) for 3 weeks
9545999|NCT03062930|Sham Comparator|Track 2|Sham condition (playing board games/computer games) for 3 weeks followed by training of the non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks
9546000|NCT03062774|Experimental|PB-119|intervention: PB-119 injection
9546001|NCT03062761|Experimental|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
9546002|NCT03062761|Active Comparator|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
9546003|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
9546004|NCT03062657|Experimental|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
9546005|NCT03063047|Active Comparator|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
9546006|NCT03063047|Active Comparator|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
9546007|NCT03062982|Experimental|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
9546008|NCT03062982|Experimental|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
9546009|NCT03062644|Experimental|MR308 100 mg bid|Tramadol/Celecoxib)
9546010|NCT03062644|Experimental|MR308 150 mg bid|Tramadol/Celecoxib
9546011|NCT03062644|Experimental|MR308 200 mg bid|Tramadol/Celecoxib
9546012|NCT03062644|Active Comparator|Tramadol 100 mg qid|Tramadol
9546013|NCT03062644|Active Comparator|Celecoxib 100 mg bid|Celecoxib
9546014|NCT03062644|Placebo Comparator|Placebo|Placebo
9546015|NCT03062722|Experimental|keyhole approach|open minimally invasive approach
9488429|NCT00834522|Experimental|Granisetron|Granisetron 2 x 1 mg Tablet (test) dosed in first period followed by Kytril® 2 x 1 mg Tablet (reference) dosed in second period
9488430|NCT00834522|Active Comparator|Kytril®|Kytril® 2 x 1 mg Tablet (reference) dosed in first period followed by Granisetron 2 x 1 mg Tablet (test) dosed in second period
9488431|NCT00834444|Experimental|1|
9488432|NCT00834444|Active Comparator|2|
9488433|NCT00834431|Experimental|1|
9488434|NCT00834431|Active Comparator|2|
9488435|NCT00834418|Experimental|Leflunomide|Leflunomide 20 mg Tablet
9488436|NCT00834418|Active Comparator|Arava™|Arava™ 20 mg Tablet
9488437|NCT00834405|Experimental|Leflunomide|Leflunomide 20 mg Tablet
9488438|NCT00834405|Active Comparator|Arava®|Arava® 20 mg Tablet
9488439|NCT00834340|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
9488440|NCT00834340|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
9488441|NCT00834275|Experimental|1|
9488442|NCT00834275|Active Comparator|2|
9488443|NCT00834249|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
9488444|NCT00834249|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
9488445|NCT00834197|Experimental|1|
9488446|NCT00834197|Active Comparator|2|
9488447|NCT00834132|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
9488448|NCT00834132|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
9488449|NCT00834067|Experimental|1|
9488450|NCT00834067|Active Comparator|2|
9488451|NCT00833937|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
9488452|NCT00833937|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
9488453|NCT00833664|Experimental|Terbinafine|Terbinafine 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
9488454|NCT00833664|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
9488455|NCT00833586|Experimental|Terbinafine|Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
9488456|NCT00833586|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
9488457|NCT00833521|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
9488458|NCT00833521|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
9488459|NCT00833495|Experimental|1|FOV1101-00 concentration 1 and Prednisolone Acetate 0.12% (Pred Mild®)
9488460|NCT00833495|Experimental|2|FOV1101-00 concentration 2 and Prednisolone Acetate 0.12% (Pred Mild®)
9488461|NCT00833495|Experimental|3|Vehicle of FOV1101-00 and Prednisolone Acetate 1% (Pred Forte®)
9488462|NCT00833495|Placebo Comparator|4|Vehicle of FOV1101-00 and vehicle of FOV1101-00
9488463|NCT00832507|Experimental|Cicletanine 150 mg QD|Cicletanine 150 mg administered once daily (QD)
9488464|NCT00832507|Experimental|Cicletanine 150 mg BID|Cicletanine 150 mg administered twice daily (BID)
9488465|NCT00832507|Experimental|Cicletanine 300 mg QD|Cicletanine 300 mg administered once daily (QD)
9488466|NCT00832507|Placebo Comparator|Placebo|Placebo to match cicletanine administered once daily
9488467|NCT00831662|Placebo Comparator|Arm 2|
9488468|NCT00831662|Experimental|Arm 1|
9488469|NCT00831532|Experimental|Normal|Healthy Volunteers
9488470|NCT00831532|Experimental|Mild Hepatic Impairment|Mild hepatic impairment patients
9488471|NCT00831532|Experimental|Moderate hepatic Impairment|Moderate Hepatic Impairment Patients
9488472|NCT00831532|Experimental|Severe Hepatic Impairment|Severe Hepatic Impairment Patients
9488473|NCT00831051|Experimental|Q8003 12mg/8mg|Combination
9488474|NCT00831051|Active Comparator|Morphine sulfate 12 mg|Single component
9488475|NCT00831051|Active Comparator|Oxycodone HCl 8mg|Single component
9488476|NCT00831051|Experimental|Q8003 6mg/4mg|Combination
9488477|NCT00831051|Active Comparator|Morphine sulfate 6mg|Single component
9488478|NCT00831051|Active Comparator|Oxycodone HCl 4mg|Single component
9488479|NCT00830336|Experimental|Azithromycin (test)|Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
9488480|NCT00830336|Active Comparator|Zithromax® (reference)|Zithromax® for Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in second period
9488481|NCT00830258|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
9488482|NCT00830258|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
9488483|NCT00830219|Experimental|1|
9488484|NCT00830219|Active Comparator|2|
9546016|NCT03063151|Experimental|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
9546017|NCT03063151|Experimental|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
9546018|NCT03062436|Experimental|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
9546019|NCT03062735|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
9546020|NCT03062735|Sham Comparator|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
9546021|NCT03062696|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
9546022|NCT03062384|Experimental|AT-001|Yeast-selenium supplement
9546023|NCT03062384|Placebo Comparator|Placebo|Yeast supplement devoid of selenium
9546024|NCT03062397|Experimental|Low-dose group|JPI-289 Low dose or placebo
9546025|NCT03062397|Experimental|High-dose group|JPI-289 High dose or placebo
9546026|NCT03062397|Placebo Comparator|Placebo group|Same dosage of JPI-289 low and high dose
9546027|NCT03062709|Experimental|All Participants|Breathe Easy Coalition written materials provided to parent/guardian, plus Maine Tobacco Helpline referral provided to smoking adult in the home, plus testing of the child's urine cotinine and results reported to parent/guardian
9546028|NCT03062553|Experimental|MCT + Neuromodulation (MCT-N)|"Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~The Metacognitive Training (MCT) group intervention will consist of an 8-module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
9546029|NCT03062553|Experimental|Sham/MCT group (MCT- S)|"Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT.~MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8-module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
9546030|NCT03062553|Experimental|Neuromodulation/Treatment as Usual TAU-N|"Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~TAU is a four week waitlist control group."
9546031|NCT03062475|Experimental|lifestyle intervention group|Pregnant women allocated to this group receive lifestyle intervention. With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
9546032|NCT03062475|No Intervention|control group|Pregnant women allocated to this group receive standard prenatal care.
9546033|NCT03062514|Experimental|Experimental|Subjects'Vagus Nerve stimulator is on always
9546034|NCT03062514|Sham Comparator|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
9546035|NCT03062423|Experimental|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
9546036|NCT03062423|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
9546037|NCT03062423|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
9616797|NCT02539303|Experimental|Intervention|Infusion of Yamani-15/5 chemical solution.
9616798|NCT02539082|Placebo Comparator|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
9616799|NCT02539082|Experimental|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
9616800|NCT02539069|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect through arthroscopy
9616801|NCT02539238|Active Comparator|control|Annual BLS training
9616802|NCT02539238|Experimental|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
9546038|NCT03062371|Experimental|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
9546039|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
9546040|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
9546041|NCT03062670|Experimental|Retreat|A full day off-site training session
9546042|NCT03062670|No Intervention|Control|Care teams normal process
9546043|NCT03062618|Experimental|Part A: Single Dose|Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)
9546044|NCT03062618|Placebo Comparator|Part A: Single Dose (Placebo)|Two escalating sequences of matching placebo oral tablets, in 3 periods
9546045|NCT03062618|Experimental|Part B: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
9546046|NCT03062618|Placebo Comparator|Part B: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
9546047|NCT03062618|Experimental|Part C: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
9546048|NCT03062618|Placebo Comparator|Part C: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
9546049|NCT03062501|No Intervention|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
9546050|NCT03062501|Experimental|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
9546051|NCT03062579|Experimental|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
9546052|NCT03062462|Active Comparator|clopidogrel|To observe double standard-dose clopidogrel on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
9546053|NCT03062462|Experimental|ticagrelor|To observe low-dose of ticagrelor on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
9546054|NCT03062410|Other|Electronic PRO|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
9546055|NCT03062527|Experimental|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.~Interventions:~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
9546056|NCT03062527|Experimental|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)~Interventions:~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
9546057|NCT03062566||Severe TBI patients|GCS 3-8
9546058|NCT03062332||Bipolar disorder,mania|The group includes subjects who are diagnosed to mania episode of bipolar disorder.
9546059|NCT03062332||Bipolar disorder,depressive|The group includes subjects who are diagnosed to depression episode of bipolar disorder.
9546060|NCT03062332||Bipolar disorder,mixed|The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
9546061|NCT03062332||First episode major depression|The group includes subjects who are diagnosed to first episode of major depression.
9546062|NCT03062332||major depression，recurrent|The group includes subjects who are diagnosed to recurrent episode of major depression.
9546063|NCT03062332||Healthy control|The group includes subjects who are Healthy control.
9546064|NCT03062293|Experimental|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
9546065|NCT03062345|Experimental|Single-User Mode first, Multi-User Mode second|
9546066|NCT03062345|Experimental|Multi-User Mode first, Single-User Mode second|
9546067|NCT03062592|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
9546068|NCT03062592|Experimental|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil
9546069|NCT03062592|Experimental|hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
9546070|NCT03062319|Active Comparator|Dual-therapy group|Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
9621744|NCT02521935|Active Comparator|Complete traditional dentures|Complete maxillary/mandible dentures made in the traditional manner.
9546071|NCT03062319|Active Comparator|Single-therapy group|Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
9546072|NCT03062202|Experimental|Depression group|SilverCloud iCBT for depression.
9546073|NCT03062202|Experimental|Anxiety group|SilverCloud iCBT anxiety disorders.
9546074|NCT03062202|Experimental|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
9546075|NCT03062215|Experimental|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
9546076|NCT03062215|No Intervention|Control Group|Waiting list
9546077|NCT03062176|Experimental|Active Treatment|Anakinra (Kineret)
9546078|NCT03062098|Experimental|IVF patients|IVF patients before embryo transfer. Before performing embryo transfer in the routine manner, ten patients will be asked to participate in the study. After signing informed consent, participants will undergo the experimental procedure: Speculum will be placed to visualize the cervix. The thin ultrasound probe will be places posterior to the cervix. While viewing the image on the ultrasound screen, the probe will be moved manually to obtain the best imaging of the cervical canal. An empty embryo transfer catheter will be introduced to the cervical canal and will be advanced under ultrasound imaging up to the internal os. The catheter will be withdrawn, and routine embryo transfer will follow.
9546079|NCT03061968|Experimental|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
9546080|NCT03061968|No Intervention|control group|The control group only receive routine care in sick baby room unite.
9546081|NCT03062241|Experimental|Cryoablation|The pulmonary vein (PV) isolation in patients randomized to intervention group.
9546082|NCT03062241|No Intervention|Conventional treatment|Pharmacological treatment according to 2016 ESC (European Society of Cardiology) guidelines for the diagnosis and treatment of acute and chronic heart failure and to 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS).
9546083|NCT03061786||AKI|
9546084|NCT03061786||non-AKI|
9546085|NCT03061929||Undernourised|Mother's with BMI less than 18.5
9546086|NCT03061929||Normally Nourished|Mother's with BMI greater than or equal to 18.5 to less than or equal to 25.
9546087|NCT03061929||Overnourished|Mother's with BMI over 25 to less than or equal to 35.
9546088|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
9546089|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
9546090|NCT03061994||Cardiomyopathy|"Children(older than 18 years old) are diagnosed as cardiomyopathy by three cardiologists and recruited in pediatric heart center,Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.~Adults are diagnosed as cardiomyopathy by three cardiologists and recruited in the department of cardiology ,Beijing Anzhen Hospital."
9546091|NCT03061994||Control|Healthy children and adults are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
9546092|NCT03061799|Experimental|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).~*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
9546093|NCT03061799|Placebo Comparator|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
9546094|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
9546095|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
9546096|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
9546097|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
9546098|NCT03062046|Experimental|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
9546099|NCT03062085||High myopic cataract group|Cataract patients with high myopia.
9546100|NCT03062085||Age-related cataract group|Age-related cataract patients.
9546101|NCT03062085||Ametropic cataract group|Cataract patients with ametropia.
9546102|NCT03061851|Experimental|conventional treatment|given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
9546103|NCT03061851|Experimental|conventional treatment + maltose app|the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.
9546104|NCT03061942|Active Comparator|Conventional|Arthroscopic rotator cuff repair without synovectomy
9546105|NCT03061942|Experimental|Synovectomy|Arthroscopic rotator cuff repair with synovectomy
9616803|NCT02539095|Experimental|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
9616804|NCT02539095|Placebo Comparator|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
10040697|NCT01856049|Other|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
10040698|NCT01856062|Experimental|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
10040699|NCT01856062|Placebo Comparator|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
10040700|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
10040701|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:~Class 1a/1c antiarrhythmics~Sotalol~Amiodarone"
9488485|NCT00830206|Experimental|Azithromycin (test)|Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
9488486|NCT00830206|Active Comparator|Zithromax® (reference)|Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in second period
9488487|NCT00830154|Experimental|1|0.30 mg pagoclone BID
10040702|NCT01856088|Experimental|Inspiron Stent|Stent Inspiron with Sirolimus
10040703|NCT01856088|Active Comparator|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
10040704|NCT01856101|Experimental|BEZ235, powder|"Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.~Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
10040705|NCT01856127|Experimental|Vilazodone|Vilazodone
10040706|NCT01856127|Active Comparator|Sertraline|Sertraline
9488488|NCT00830154|Experimental|2|0.60 mg pagoclone BID
9488489|NCT00830154|Placebo Comparator|3|placebo
10040707|NCT01856153|Other|Before meal|Strawberry-Placebo-Placebo
10040708|NCT01856153|Other|With Meal|Placebo-Strawberry-Placebo
10040709|NCT01856153|Other|After Meal|Placebo-Placebo-Strawberry
10040710|NCT01856166|Active Comparator|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
10040711|NCT01856166|Experimental|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
10040712|NCT01856179|Experimental|Echium oil young|"BMI<25,~age 20-30"
10040713|NCT01856179|Experimental|Echium oil older|age 40-70 BMI <25
10040714|NCT01856179|Experimental|Echium oil older, overweight|age 40-70 BMI >25
9488490|NCT00830102|Active Comparator|1|"Period 1 Treatment Regimen A: FlutiForm 100/10 ug~Period 2 Treatment Regimen B: FlutiForm 250/10 ug~Period 3 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 4 Treatment Regimen D: Flixotide Evohaler 250 ug"
9488491|NCT00830102|Active Comparator|2|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 3 Treatment Regimen B: FlutiForm 250/10 ug~Period 4 Treatment Regimen A: FlutiForm 100/10 ug"
9488492|NCT00830102|Active Comparator|3|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug~Period 2 Treatment Regimen A: FlutiForm 100/10 ug~Period 3 Treatment Regimen F: Placebo~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug"
9488493|NCT00830102|Active Comparator|4|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 2 Treatment Regimen F: Placebo~Period 3 Treatment Regimen A: FlutiForm 100/10 ug~Period 4 Treatment Regimen B: FlutiForm 250/10 ug"
9488494|NCT00830102|Active Comparator|5|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 4 Treatment Regimen F: Placebo"
9488495|NCT00830102|Active Comparator|6|"Period 1 Treatment Regimen F: Placebo~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug"
9488496|NCT00830024|Experimental|Alprazolam (test)|Alprazolam 3 mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
9488497|NCT00830024|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (test) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
9488498|NCT00829998|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
9488499|NCT00829998|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
9488500|NCT00829868|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
9488501|NCT00829868|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
9488502|NCT00829790|Experimental|1|Doxycycline Monohydrate
9488503|NCT00829790|Active Comparator|2|Vibramycin Monohydrate®
9488504|NCT00829764|Experimental|1|Doxycycline Monohydrate
9488505|NCT00829764|Active Comparator|2|Vibramycin Monohydrate®
9488506|NCT00829712|Experimental|1|
9488507|NCT00829712|Active Comparator|2|Focalin®
9488508|NCT00829686|No Intervention|No intervention|No antibiotic
9488509|NCT00829686|Active Comparator|Septra DS|Septra DS (800/160) two pills PO BID x 7 days
9488510|NCT00829673|Experimental|1|
9488511|NCT00829673|Active Comparator|2|Focalin®
9488512|NCT00829530|Experimental|1|
9488513|NCT00829530|Active Comparator|2|
9488514|NCT00829504|Experimental|1|
9488515|NCT00829504|Active Comparator|2|
9488516|NCT00829452|Experimental|1|
9546106|NCT03061877||Anxiety or depression|
9488517|NCT00829452|Active Comparator|2|
9488518|NCT00829426|Experimental|Alprazolam|Alprazolam 3mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
9488519|NCT00829426|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (reference) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
9488520|NCT00829374|Experimental|1|Dimebon, 5 mg orally three times daily
9488521|NCT00829374|Experimental|2|Dimebon, 20 mg orally three times daily
9488522|NCT00829374|Placebo Comparator|3|Placebo orally three times daily
9488523|NCT00829309|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
9488524|NCT00829309|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
9488525|NCT00828321|Experimental|1|
9488526|NCT00828321|Active Comparator|2|
9488527|NCT00827008|Experimental|1, verum|
9488528|NCT00826059|Active Comparator|Active Stimulation|"Implantation/ISS Stimulation during 5 consecutive days & Standard of Care (SoC).~Day 1: First stimulation initiated within 24 hours from stroke onset, following implantation completion. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: ISS Stimulation treatment sessions repeated daily. Each treatment will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last ISS Stimulation treatment session, imaging performed for assessing Injectable Neuro Stimulator (INS) positioning and/or lesion. Implant removal procedure will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
9488529|NCT00826059|Sham Comparator|Sham Stimulation|"Sham Implantation and Sham Stimulation during 5 consecutive days & Standard of Care (SoC).~Day 1: First Sham stimulation initiated within 24 hours from stroke onset, following Sham implantation procedure. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: Sham Stimulation sessions repeated daily. Each Sham Stimulation will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last Sham Stimulation session, imaging performed for lesion assessment. Sham Implant removal will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
9488530|NCT00825955|Experimental|Brivanib|
9488531|NCT00825955|Placebo Comparator|Placebo|
9488532|NCT00825539|Placebo Comparator|Placebo|
9488533|NCT00825539|Experimental|AQW051|
9488534|NCT00825513|Experimental|Akreos Toric|Akreos Toric Intraocular Lens
9488535|NCT00825513|Active Comparator|Akreos Advanced|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
9488536|NCT00823992|Placebo Comparator|placebo|
9488537|NCT00823992|Experimental|taspoglutide|
9488538|NCT00823680|Placebo Comparator|Placebo|
9488539|NCT00823680|Experimental|RO5027838 200mg|
9488540|NCT00823680|Experimental|RO5027838 50mg|
9488541|NCT00823680|Experimental|RO5093151 10mg|
9488542|NCT00823680|Experimental|RO5093151 400mg|
9488543|NCT00821977|Experimental|Vildagliptin Dose 1|
9488544|NCT00821977|Experimental|Vildagliptin Dose 2|
9488545|NCT00821977|Placebo Comparator|Placebo|
9488546|NCT00821249|Experimental|ARRY-520|
9488547|NCT00821249|Experimental|ARRY-520 + G-CSF support|
9488548|NCT00821249|Experimental|ARRY-520 + dexamethasone + G-CSF support|
9488549|NCT00821002|Experimental|Plug placement|
9488550|NCT00820924|Experimental|LAPATINIB|LAPATINIB 1500MG ORAL ONCE DAILY
9488551|NCT00820846|Experimental|Part A, Group 1|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
9488552|NCT00820846|Placebo Comparator|Part A, Group 2|Participants will receive four placebo injections
9488553|NCT00820846|Experimental|Part B, Group 3|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
9488554|NCT00820846|Experimental|Part B, Group 4|Participants will receive three injections of the MVA/HIV62 vaccine and one injection of the placebo
9488555|NCT00820846|Placebo Comparator|Part B, Group 5|Participants will receive four placebo injections
9488556|NCT00820300|Experimental|Punctal plug|
9488557|NCT00819169|Experimental|Part 1 Cohort 3|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)
9488558|NCT00819169|Experimental|Part 1 Cohort 1|AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)
9488559|NCT00819169|Experimental|Part 1 Cohort 2|AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)
9488560|NCT00819169|Experimental|Part 2|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg Q3W, or the MTD, as determined in Part 1 of the study
9488561|NCT00818844|Experimental|Nepafenac|Nepafenac 0.1% dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
9488562|NCT00818844|Placebo Comparator|BSS|BSS dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
9488563|NCT00818571|Experimental|Vildagliptin 25 mg qd in Renal Impaired (RI) patients|
9488564|NCT00818571|Experimental|Vildagliptin 50 mg qd in RI Patients|
9488565|NCT00818571|Experimental|Vildagliptin 25 mg qd in matched Healthy Volunteer (HV)|
9488566|NCT00818571|Experimental|Vildagliptin 50 mg qd in matched HV|
9488567|NCT00818493|Experimental|1|Q8003, flexible ascending dose
9488568|NCT00818493|Experimental|2|Low dose Q8003
9488569|NCT00818493|Active Comparator|3|Percocet (oxycodone and acetaminophen)
9488570|NCT00818480|Experimental|1. YM155|
9488571|NCT00817986|Experimental|Arbaclofen placarbil 20 mg|Arbaclofen placarbil 20 mg, BID, for 14 days including the taper period.
9803795|NCT03328078|Experimental|Emavusertib (CA-4948) and ibrutinib dose expansion|"In expansion phase, the emavusertib recommended Phase 2 dose (RP2D) in combination with ibrutinib will be administered in Non-Hodgkin Lymphoma (NHL) disease-specific cohorts. Approximately 131 NHL patients will be enrolled in 4 NHL disease specific cohorts:~Cohort 1 - Marginal zone lymphoma (MZL)~Cohort 2 - ABC diffuse large B-cell lymphoma (DLBCL) or extranodal subtypes: Leg-, testicular-, or NOS-type~Cohort 3 - Primary central nervous system lymphoma (PCNSL)~Cohort 4 - Patients receiving ibrutinib monotherapy who have developed adaptive, secondary resistance. Indications include:~Mantle Cell Lymphoma (MCL), MZL, CLL/SLL, or WM/LPL~Indications for which ibrutinib is National Comprehensive Cancer Network (NCCN)-listed (e.g., PCNSL)~Patients with NHL and known myddosome mutations~Patients may be candidates for maintaining ibrutinib while emavusertib will be added for resistance reversal. A brief gap of ibrutinib therapy of <3 weeks is acceptable."
9488572|NCT00817986|Placebo Comparator|Placebo for Arbaclofen placarbil|Placebo for 14 days
9488573|NCT00817986|Experimental|Arbaclofen placarbil 30 mg|Arbaclofen placarbil 30 mg, BID, for 14 days including the taper period.
9488574|NCT00817986|Experimental|Arbaclofen placarbil 40 mg|Arbaclofen placarbil 40 mg, BID, for 14 days including the taper period.
9488575|NCT00817362|Experimental|IPI-504 and Trastuzumab|"IPI-504 IV infusion 300 mg/m2 once weekly in combination with trastuzumab infusion every 3 weeks. (Continuous schedule)~Three week cycle with IPI-504 twice per week for 2 weeks and trastuzumab once per cycle followed by one week without treatment.~Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.~IPI-504 and trastuzumab will be administered for all cycles. Until progression or unacceptable toxicity develops."
9488576|NCT00814372|Experimental|MBX-102 400|
9488577|NCT00814372|Experimental|MBX-102 600|
9488578|NCT00814372|Placebo Comparator|Placebo|
9488579|NCT00814372|Active Comparator|Actos|30-45 mg
9488580|NCT00814294|Placebo Comparator|1; Placebo|Patients receive a sugar pill.
9488581|NCT00814294|Experimental|2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Patients receive Oral HDV-Insulin (U-5).
9488582|NCT00814294|Experimental|3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Patients receive Oral HDV-Insulin (U-15).
9488583|NCT00814073|Experimental|Masitinib & BSC|Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
9488584|NCT00814073|Placebo Comparator|Placebo & BSC|Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
9488585|NCT00813956|Experimental|1|standard chemotherapy plus BSI-201
9488586|NCT00813605|Experimental|Arm A|AMG 655 10 mg/kg plus AMG 479 placebo in combination with FOLFIRI every 14 days
9488587|NCT00813605|Active Comparator|Arm C|AMG 479 Placebo plus AMG 655 Placebo in combination with FOLFIRI every 14 days
9488588|NCT00813605|Experimental|Arm B|AMG 479 12 mg/kg plus AMG 655 placebo in combination with FOLFIRI every 14 days
9488589|NCT00813163|Experimental|PEP02|Liposome Irinotecan
9488590|NCT00812383|Experimental|Bivalirudin|
9488591|NCT00812383|Active Comparator|Heparin|
9488592|NCT00812305|Experimental|Low dose in healthy patients|
9488593|NCT00812305|Experimental|Low dose in hepatically impaired patients|
9488594|NCT00812240|Experimental|Masitinib (7.5)|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
9488595|NCT00812240|Experimental|Masitinib (6.0)|Participants receive masitinib (6.0 mg/kg/day), given orally twice daily
9488596|NCT00812240|Active Comparator|Active Comparator (7.5)|Participants receive imatinib at 400 or 600 mg per day
9488597|NCT00812240|Active Comparator|Active Comparator (6.0)|Participants receive imatinib at 400 or 600 mg per day
9488598|NCT00811902|Experimental|Nerispirdine 50mg|Nerispirdine 50mg once daily for 14 weeks
9488599|NCT00811902|Experimental|Nerispirdine 100mg|Nerispirdine 100mg once daily for 14 weeks
9488600|NCT00811902|Experimental|Nerispirdine 200mg|Nerispirdine 200mg once daily for 14 weeks
9488601|NCT00811902|Placebo Comparator|Placebo|Placebo for Nerispirdine once daily for 14 weeks
9488602|NCT00811889|Placebo Comparator|Placebo|
9488603|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 75mg|
9488604|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 150mg|
9488605|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 25mg|
9488606|NCT00811499|Experimental|ARRY-371797 (Schedule 1)|
9488607|NCT00811499|Experimental|ARRY-371797 (Schedule 2)|
9488608|NCT00811499|Placebo Comparator|Placebo|
9488609|NCT00810979|Experimental|1|SLx-4090 dose #1 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
9488610|NCT00810979|Experimental|2|SLx-4090 dose #2 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
9488611|NCT00810979|Other|3|Placebo in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
9488612|NCT00810732|Experimental|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
9488613|NCT00810732|Active Comparator|Nifedipine|Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
9488614|NCT00810732|Placebo Comparator|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
9488615|NCT00810147|Active Comparator|A1|
9488616|NCT00810147|Active Comparator|A2|
9488617|NCT00810147|Active Comparator|A3|
9488618|NCT00810147|Active Comparator|A4|
9488619|NCT00810147|Placebo Comparator|A5|
9488620|NCT00809679|Experimental|T-62 100 mg bid|
9488621|NCT00809679|Experimental|T-62 200 mg bid|
9488622|NCT00809679|Placebo Comparator|Placebo|
9488623|NCT00809562|Experimental|1|
9488624|NCT00809562|Placebo Comparator|2|
9546107|NCT03061877||Non-anxiety or depression|
9488625|NCT00809510|Experimental|1|
9488626|NCT00808288|Experimental|PF-00610355|
9488627|NCT00808288|Experimental|PF- 00610355|
9488628|NCT00808288|Experimental|PF - 00610355|
9488629|NCT00808288|Placebo Comparator|Placebo|
9488630|NCT00808288|Active Comparator|Salmeterol|
9488631|NCT00807612|Experimental|Part 1 Cohort 1|AMG 479 at 18 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 18 mg/kg monotherapy for 24 months from study day 1
9488632|NCT00807612|Experimental|Part 1 Cohort 2|AMG 479 at 12 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 12 mg/kg monotherapy for 24 months from study day 1
9488633|NCT00807612|Experimental|Part 2|"AMG 479 in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 monotherapy for 24 months from study day 1~(AMG 479 dose in Part 2 will be the final AMG 479 dose from Part 1)"
9488634|NCT00806806|Placebo Comparator|Placebo|
9488635|NCT00806806|Experimental|SKY0402|
9488636|NCT00806403|Active Comparator|thrombolysis|
9488637|NCT00806403|Active Comparator|invasive|
9488638|NCT00805818|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1 mg/kg/h (Cohort 1, n=20), 3 mg/kg/h (Cohort 2, n=20) or 6 mg/kg/h (Cohort 3, n=133) intravenous infusion for a total of 72 consecutive hours.
9488639|NCT00805818|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion (Cohort 1, n=10), (Cohort 2, n=10) or (Cohort 3, n=67) intravenous infusion for a total of 72 consecutive hours.
9488640|NCT00805805|Experimental|1|Tetrathiomolybdate with ursodiol
9488641|NCT00805805|Placebo Comparator|2|Placebo with ursodiol
9488642|NCT00805350|Experimental|Eplivanserin|Eplivanserin 5 mg/day
9488643|NCT00805350|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg/day
9488644|NCT00803517||Photodynamic therapy (PDT)|
9488645|NCT00803517||Focal laser photocoagulation (focal)|
9488646|NCT00803413|Other|Back School|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
9488647|NCT00803413|Other|Supervised Walking|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group
9488648|NCT00803413|Other|Back School and Walking|Participants received weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening); 30 minutes of on-place supervised walking in group
9488649|NCT00803413|Other|Control Group|Participants received weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
9488650|NCT00803114|Experimental|Epidural Morphine|2.5 mg dose of epidural morphine given within one hour following vaginal delivery
9488651|NCT00803114|Placebo Comparator|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
9488652|NCT00802425|Experimental|2|AM-111 low dose
9488653|NCT00802425|Placebo Comparator|1|
9488654|NCT00802425|Experimental|3|AM-111 high dose
9488655|NCT00802347|Experimental|I5NP|
9488656|NCT00802347|Placebo Comparator|Saline|
9488657|NCT00801060|Experimental|Treatment Group A|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
9488658|NCT00801060|Active Comparator|Treatment Group B|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
9488659|NCT00800605|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
9488660|NCT00800605|Placebo Comparator|2|Phosphate-buffered saline
9488661|NCT00799552|Placebo Comparator|Placebo|
9488662|NCT00799552|Experimental|RX-10045|
9488663|NCT00799292|No Intervention|No injection|Patients did not receive an injection at cervix prior to beginning the procedure
9488664|NCT00799292|Experimental|Injection of vasopressin|Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy
9488665|NCT00796523|Experimental|Happiest Baby videotape|videotape describing the Happiest Baby on the Block technique
9488666|NCT00796523|Placebo Comparator|control videotape|videotape with normal newborn instruction
9488667|NCT00796289|Experimental|GnRH High Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
9488668|NCT00796289|Experimental|GnRH Medium Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
9546108|NCT03062111|Active Comparator|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
9546109|NCT03062111|Active Comparator|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
9546110|NCT03061838|Active Comparator|MabThera®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
9546111|NCT03061838|Experimental|Ritumax®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
9546112|NCT03062020|Experimental|Intervention group: QUIPP tool arm|In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
9546113|NCT03062020|No Intervention|Control group: no QUIPP tool arm|Women will be managed according to current clinical practice.
9546114|NCT03061981|Active Comparator|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
9546115|NCT03061981|Placebo Comparator|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
9546116|NCT03061981|Other|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
9546117|NCT03061981|Other|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
9546118|NCT03062007|Experimental|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
9546119|NCT03062254|Experimental|Radium-223|
9546120|NCT03062163|Experimental|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
9546121|NCT03062163|Experimental|Placebo|normal saline was loaded on transdermal patch
9546122|NCT03061773|Experimental|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
9546123|NCT03061773|Active Comparator|Group did not exercise|Group did not exercise: conventional hospital treatment
9546124|NCT03061734|Experimental|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
9546125|NCT03061734|Experimental|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
9546126|NCT03061734|Active Comparator|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
9546127|NCT03061734|Active Comparator|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
9546128|NCT03061734|Placebo Comparator|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
9488669|NCT00796289|Experimental|GnRH Low Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
9488670|NCT00796289|Active Comparator|Clomiphene Citrate|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
9488671|NCT00796289|Placebo Comparator|Placebo|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
9488672|NCT00795418|Experimental|CAD106|
9488673|NCT00795418|Placebo Comparator|Placebo|
9488674|NCT00794924|Experimental|Probiotics, VSL#3|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received commercially available probiotics (VSL#3) for 45 days.
9488675|NCT00794924|Placebo Comparator|Placebo|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received placebo sachets for 45 days.
9488676|NCT00794677|Placebo Comparator|Sugar Pill|Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
9488677|NCT00794677|Experimental|ezetimibe|10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
9488678|NCT00794586|Experimental|FTI 80mg/20mg BID|Fosfomycin/Tobramycin combination 80mg/20 mg inhaled twice daily
9488679|NCT00794586|Experimental|FTI 160mg/40mg BID|Fosfomycin/Tobramycin combination 160 mg/40 mg inhaled twice daily
9488680|NCT00794586|Placebo Comparator|Placebo A BID|Placebo A inhaled twice daily
10040715|NCT01856205|Placebo Comparator|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
9488681|NCT00794586|Placebo Comparator|Placebo B BID|Placebo B inhaled twice daily
9488682|NCT00794430|Experimental|V3381|V3381: titrated from 100 mg bid to maximum 400 mg bid over 4 weeks followed by maintenance phase at highest tolerated dose. Total duration of treatment 13 weeks.
9488683|NCT00794430|Placebo Comparator|Placebo|Placebo to match V3381, 100 mg, given according to the same regimen.
9488684|NCT00792727|Experimental|Ketoprofen Patch|Treatment with experimental drug
9488685|NCT00792727|Placebo Comparator|Placebo Patch|Treatment with placebo drug
9488686|NCT00792116|Experimental|Gum Chewing|
9488687|NCT00792116|No Intervention|Non-gum chewing|
9488688|NCT00791154|Active Comparator|ARM B|Blinded AMG 102 study drug and carboplatin or cisplatin and etoposide
9488689|NCT00791154|Placebo Comparator|ARM C|Blinded placebo and carboplatin or cisplatin and etoposide
9488690|NCT00791154|Active Comparator|ARM A|Blinded AMG 479 study drug and carboplatin or cisplatin and etoposide
9488691|NCT00790660|Experimental|ASP1941 Lowest Dose|Oral
9488692|NCT00790660|Experimental|ASP1941 Low Dose|Oral
9488693|NCT00790660|Experimental|ASP1941 Medium Dose|Oral
9488694|NCT00790660|Experimental|ASP1941 High Dose|Oral
9488695|NCT00790660|Placebo Comparator|Placebo|Oral
9488696|NCT00790426|Experimental|FGFR3 wild type|
9488697|NCT00790426|Experimental|FGFR3 mutant|
9488698|NCT00790127|Placebo Comparator|Placebo|Placebo
9488699|NCT00790127|Experimental|HQK-1001|HQK-1001
9488700|NCT00789633|Experimental|Masitinib & gemcitabine|Participants receive masitinib (9 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
9488701|NCT00789633|Placebo Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
9488702|NCT00788541|Experimental|3 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 6 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
9488703|NCT00788541|Experimental|3 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 3.75 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
9488704|NCT00788541|Experimental|48 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 96 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
9488705|NCT00788541|Experimental|48 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
9488706|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, low volume|Anecortave Acetate Vehicle, one injection of 0.5 mL in the study eye monthly for 6 months.
9488707|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, high volume|Anecortave Acetate Vehicle, one injection of 0.8 mL in the study eye monthly for 6 months.
9488708|NCT00788528|Experimental|Arm A|1600 mg S-2367 (velneperit)
9488709|NCT00787059|Experimental|Ad5.hAC6|Will receive intracoronary adenovirus encoding human adenylyl cyclase type 6
9488710|NCT00787059|Placebo Comparator|sucrose solution|Will receive intracoronary sucrose solution
9488711|NCT00786201|Placebo Comparator|Placebo|
9488712|NCT00786201|Experimental|CNTO 888 1 mg/kg|
9488713|NCT00786201|Experimental|CNTO 888 5 mg/kg|
9488714|NCT00786201|Experimental|CNTO 888 15 mg/kg|
9488715|NCT00785954|Experimental|A1: KAI-9803|
9488716|NCT00785954|Experimental|A2: KAI-9803|
9488717|NCT00785954|Experimental|A3: KAI-9803|
9488718|NCT00785954|Placebo Comparator|A4: Placebo|
9488719|NCT00785226|Experimental|RDEA119 with Sorafenib|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day and sorafenib from 400 mg/day to 800 mg/day.
9488720|NCT00783406|Experimental|PF- 00610355|
9488721|NCT00783406|Experimental|PF-00610355|
9488722|NCT00783406|Experimental|PF -00610355|
9488723|NCT00783406|Placebo Comparator|Placebo|
9488724|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 4mg|inserted daily and replaced every 4 weeks
10040716|NCT01856205|Placebo Comparator|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
10040717|NCT01856231|Experimental|8 week group|Lifestyle physical activity self-efficacy
9488725|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 6mg|inserted daily and replaced every 4 weeks
9488726|NCT00782535|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
9488727|NCT00782535|Experimental|Treatment B|Single therapeutic dose of CHF 4226 pMDI
9488728|NCT00782535|Experimental|Treatment C|Single supratherapeutic dose of CHF 4226 pMDI
9488729|NCT00782535|Experimental|Treatment D|Single supratherapeutic dose of CHF 4226 pMDI
9488730|NCT00782535|Placebo Comparator|Treatment E|Single dose of placebo
9488731|NCT00782431|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
9488732|NCT00782431|Active Comparator|2|Licensed egg-derived, trivalent seasonal influenza vaccine
9488733|NCT00781742|Experimental|1|100 mg iv once per dosing day
9488734|NCT00781742|Experimental|2|150 mg iv once per dosing day
9488735|NCT00781742|Placebo Comparator|3|
9488736|NCT00781443|Experimental|A|
9488737|NCT00781443|Placebo Comparator|B|
9488738|NCT00781339|Experimental|Active|
9488739|NCT00781118|Experimental|Treatment|The Treatment arm has alerting enabled in their device during the 6-month randomization period. Treatment arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Treatment arm was re-defined as an ALARMS_ON group which included A) Control patients after the randomization period and until database lock (4/1/2014); and, b) Treatment patients both during the randomization period and after the randomization period until database lock (4/1/2014).
9488740|NCT00781118|Other|Control|The Control arm has alerting disabled in their device during the 6-month randomization period. Control arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Control arm was re-defined as an ALARMS_OFF group which included A) Control patients during the randomization period when the Guardian did not have alarms enabled.
9488741|NCT00780000|Experimental|A1|
9488742|NCT00779519|Placebo Comparator|Placebo|
9488743|NCT00779519|Experimental|TTP435|
9488744|NCT00779428|Experimental|A1|
9488745|NCT00777309|Experimental|1|Erlotinib (150 mg) once daily plus ARQ 197 (360 mg) twice daily.
9488746|NCT00777309|Active Comparator|2|Erlotinib (150 mg) once daily plus ARQ 197 placebo twice daily
9488747|NCT00777231|Experimental|Sickle Cell Disease|Recipients treated with an enriched hematopoetic stem cell infusion
9488748|NCT00777231|Experimental|Non-Malignant Disorders|Recipients treated with an enriched hematopoetic stem cell infusion
9488749|NCT00777231|Experimental|Aplastic Anemia|Recipients treated with an enriched hematopoetic stem cell infusion
9488750|NCT00777231|Experimental|Sickle Cell Disease : Extended Protocol|Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning
9488751|NCT00776373|Experimental|Arm 1|Rapamycin in combination with High Dose Etoposide and Cytarabine (HiVAC)
9488752|NCT00774761|Experimental|1|
9488753|NCT00774761|Experimental|2|
9488754|NCT00774761|Active Comparator|3|
9488755|NCT00774761|Active Comparator|4|
9488756|NCT00774761|Active Comparator|5|
9488757|NCT00773344|Experimental|A1|
9488758|NCT00772785|Experimental|Probuphine|buprenorphine implant
9488759|NCT00772525|Experimental|Sequence 1|"placebo,1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
9488760|NCT00772525|Experimental|Sequence 2|"placebo,1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
9488761|NCT00772525|Experimental|Sequence 3|"50 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
9488762|NCT00772525|Experimental|Sequence 4|"50 mg Nerispirdine, 1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
9488763|NCT00772525|Experimental|Sequence 5|"400 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
9488764|NCT00772525|Experimental|Sequence 6|"400 mg Nerispirdine, 1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
9488765|NCT00772343|Placebo Comparator|Placebo Vaccine|0.9% Normal saline
9488766|NCT00772343|Experimental|Low dose|Low dose vaccine with adjuvant
9488767|NCT00772343|Experimental|High dose 1|High-dose vaccine with adjuvant
9488768|NCT00772343|Experimental|High dose 2|High-dose vaccine without adjuvant
9488769|NCT00771446|Experimental|ELAD (plus Standard of Care)|Treatment with ELAD in addition to standard of care therapy Standard of care therapy defines uniform treatment for ascites, esophageal varices, dietary recommendations, etc.
9488770|NCT00771446|Other|Standard of Care (Control)|Standard of care treatment Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
9488771|NCT00771134|Experimental|Lu AA39959|
9488772|NCT00771134|Placebo Comparator|Placebo|
9488773|NCT00771134|Active Comparator|Quetiapine|
9488774|NCT00770848|Other|Phase 1b - AMG 102|Phase 1b is an open-label study with AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed, will be administered by IV Q3W in combination with MP.
9488775|NCT00770848|Experimental|Phase 2 Arm A - AMG 102 + MP|AMG 102 safe dose level in phase 1b in combination with MP, will be administered by IV Q3W.
10040718|NCT01856244|Experimental|sensorimotor treadmill training|specific treadmill control using oscillating platform
10040719|NCT01856244|Active Comparator|conventional treadmill training|conventional treadmill control
10040720|NCT01856283|Experimental|Nilotinib|study of nilotinib 300 mg BID
10040721|NCT01856296|Experimental|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
10040722|NCT01856296|Experimental|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
10040723|NCT01856348|Experimental|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
10040724|NCT01856374|Active Comparator|Cypher group|
10040725|NCT01856374|Experimental|Xience group|
10040726|NCT01856374|Active Comparator|Pravastatin group|
10040727|NCT01856374|Experimental|Atorvastatin group|
9488776|NCT00770848|Placebo Comparator|Phase 2 Arm C- PLACEBO|Placebo in combination with MP, will be administered by IV Q3W.
9488777|NCT00770848|Experimental|Phase 2 Arm B - AMG 102 + MP|Safe dose level in phase 1b of AMG 102 + MP will be administered by Q3W
9488778|NCT00770081|Experimental|1|50mg qd vildagliptin
9488779|NCT00770081|Active Comparator|2|sitagliptin (25mg qd)
9488780|NCT00769795|Experimental|Experimental|Bicalutamide 50 mg daily for 12 weeks Goserelin 10.8 mg SC once IMC-A12 10 mg/kg IV every three weeks for 12 weeks
9488781|NCT00768482|Experimental|Probuphine|Patients are first inducted on SL BPN, and then switched to 4 Probuphine implants
9488782|NCT00768274|Experimental|Arm A|Low-dose apabetalone (RVX000222) or placebo
9488783|NCT00768274|Experimental|Arm B|apabetalone (RVX000222) Dose-escalation or placebo
9488784|NCT00768274|Experimental|Arm C|high-dose apabetalone (RVX000222) or placebo
9488785|NCT00767416|Experimental|Cohort 1 MEDI-559|MEDI-559
9488786|NCT00767416|Placebo Comparator|Cohort 1 Placebo|Placebo
9488787|NCT00767299|Experimental|1|
9488788|NCT00767299|Placebo Comparator|2|
9488789|NCT00766688|Experimental|25 mg/day AVE5530|
9488790|NCT00766688|Experimental|50 mg/day AVE5530|
9488791|NCT00766688|Placebo Comparator|Placebo|
9488792|NCT00766324|Experimental|A|
9488793|NCT00766324|Experimental|B|
9488794|NCT00765830|Experimental|1|50mg qd vildagliptin
9488795|NCT00765830|Placebo Comparator|2|Placebo
9488796|NCT00765804|Active Comparator|Low Dose: DP 7.5 mA-min at 2.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA
9488797|NCT00765804|Active Comparator|High Dose: DP 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA
9488798|NCT00765804|Placebo Comparator|Placebo: 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)
9488799|NCT00765700|Active Comparator|Ketoprofen 10% Cream|"Topical Ketoprofen 10% Cream~1gram three times daily for 7 days"
9488800|NCT00765700|Placebo Comparator|Placebo|"Topical placebo cream~1gram three times daily for 7 days"
9488801|NCT00765518|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
9488802|NCT00765518|Other|Standard of Care|Standard of care therapy only.
9488803|NCT00765323|Active Comparator|1|84 mg octreotide implant for 6 months
9488804|NCT00765323|Active Comparator|2|Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks
9488805|NCT00764634|Placebo Comparator|1 Placebo|
9488806|NCT00764634|Active Comparator|2 rBV A/B Vaccine|
9488807|NCT00764634|Placebo Comparator|3 Placebo|
9488808|NCT00764634|Active Comparator|4 rBV A/B Vaccine|
9488809|NCT00763555|Experimental|1|CD 2027, 3 ug/g Oily Spray, twice a day for 8 weeks
9488810|NCT00763555|Placebo Comparator|2|
9488811|NCT00763503|Experimental|CD 2027|
9488812|NCT00761709|Experimental|AL-39256|AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
9488813|NCT00761709|Active Comparator|XALATAN|Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks.
9488814|NCT00761709|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
9488815|NCT00760955|Experimental|TAK-583 5 mg QD|
9488816|NCT00760955|Experimental|TAK-583 50 mg QD|
9488817|NCT00760955|Experimental|TAK-583 100 mg QD|
9488818|NCT00760955|Placebo Comparator|Placebo QD|
9488819|NCT00760539|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
9488820|NCT00760539|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
9488821|NCT00760344|Experimental|SYR-472 3.125 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
9488822|NCT00760344|Experimental|SYR-472 12.5 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
9488823|NCT00760344|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
9488824|NCT00760344|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
10040728|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
10040729|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
10040730|NCT01856413|Experimental|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
10040731|NCT01856426|Experimental|1- EDP239|EDP239 given once a day.
10040732|NCT01856426|Placebo Comparator|Placebo|1 treatment arm will be placebo, dose given once a day.
9488825|NCT00760344|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin stable dose therapy)
10040733|NCT01856426|Experimental|2- EDP239|EDP239 given once a day.
10040734|NCT01856426|Experimental|3-EDP239|EDP239 given once a day.
10040735|NCT01856426|Experimental|4-EDP239|EDP239 given once a day.
10040736|NCT01856439|Other|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
10040737|NCT01856452|Active Comparator|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
10040738|NCT01856452|Experimental|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
9488826|NCT00760344|Active Comparator|Sitagliptin 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
9488827|NCT00759135|Experimental|1|Single therapeutic dose of 2.5 mg NX-1207
9488828|NCT00759135|Experimental|2|Single low dose of 0.125 mg NX-1207 for dose-response evaluation
9488829|NCT00759135|Active Comparator|3|5.0 mg finasteride q.d.
9488830|NCT00758966|Experimental|NF (Naltrexone+Fluoxetine)|Naltrexone SR 32 mg and fluoxetine 60 mg
9488831|NCT00758966|Active Comparator|Fluoxetine|Fluoxetine 60 mg
9488832|NCT00758966|Active Comparator|Naltrexone|Naltrexone SR 32 mg
9488833|NCT00758953|Experimental|1|
9488834|NCT00758953|Experimental|2|
9488835|NCT00758953|Placebo Comparator|3|
9488836|NCT00758953|Placebo Comparator|4|
9488837|NCT00758563|Placebo Comparator|A|
9488838|NCT00758563|Active Comparator|B|
9488839|NCT00758303|Active Comparator|1|Low Dose TRIA-662
9488840|NCT00758303|Active Comparator|2|High Dose TRIA-662
9488841|NCT00758303|Placebo Comparator|3|Matching Placebo for TRIA-662
9488842|NCT00758290|Active Comparator|A|
9488843|NCT00758290|Experimental|B|
9488844|NCT00757757|Experimental|MCS110|
9488845|NCT00756574|Active Comparator|1. Surgical|surgical mask
9488846|NCT00756574|Active Comparator|2. N95 Respirator|N95 respirator
9488847|NCT00755287|Active Comparator|insulin glargine|insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
9488848|NCT00755287|Experimental|taspoglutide 10 mg|taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
9488849|NCT00755287|Experimental|taspoglutide 10 mg/20 mg|taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment
9488850|NCT00754988|Placebo Comparator|Placebo|Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
9488851|NCT00754988|Active Comparator|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
9488852|NCT00754988|Experimental|Taspoglutide 10 mg|Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
9488853|NCT00754988|Experimental|Taspoglutide up-titrated to 20 mg|Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
9488854|NCT00754455|Experimental|Low dose|
9488855|NCT00754455|Experimental|Mid dose|
9488856|NCT00754455|Experimental|High dose|
9488857|NCT00754455|Placebo Comparator|Placebo|
9488858|NCT00754221|Experimental|1|
9488859|NCT00753285|Experimental|Renal Denervation|
9488860|NCT00752570|Placebo Comparator|2|AMG 386 placebo QW, FOLFIRI Q2W
9488861|NCT00752570|Active Comparator|1|Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W
9488862|NCT00752505|Experimental|A|
9488863|NCT00752505|Experimental|B|
9488864|NCT00752297|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A
9488865|NCT00752297|Placebo Comparator|2|Preservative-free Saline
9488866|NCT00752258|Experimental|1|Mentor Purified Toxin Botulinum Toxin Type A
9488867|NCT00752050|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
9488868|NCT00752050|Placebo Comparator|2|Preservative-free Saline - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
9488869|NCT00751803|Experimental|BI 44370 TA Low Dose|
9488870|NCT00751803|Experimental|BI 44370 TA Medium Dose|
9488871|NCT00751803|Experimental|BI 44370 TA High Dose|
9488872|NCT00751803|Placebo Comparator|Placebo|
9488873|NCT00751803|Active Comparator|Eletriptan|
9488874|NCT00751231|Active Comparator|Arm 1|300mg or 600mg loading dose of Clopidogrel followed by once daily dosing of 75 mg Clopidogrel for up to 120 days.
9488875|NCT00751231|Experimental|Arm 2|IV bolus of PRT060128 prior to PCI and twice daily administration of 50 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
9488876|NCT00751231|Experimental|Arm 3|IV bolus of PRT060128 prior to PCI and twice daily administration of 100 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
9488877|NCT00751231|Experimental|Arm 4|IV bolus of PRT060128 prior to PCI and twice daily administration of 150 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
9546129|NCT03061760||1. OAB (-) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
9546130|NCT03061760||2. OAB (-) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
9546131|NCT03061760||3. OAB (+) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
9546132|NCT03061760||4.OAB (+) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
10040739|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
10040740|NCT01856504||CCTA Patient|"Consenting adult patients ≥18 years of age;~Suspected but without known prior history of CAD~Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)~Glomerular filtration rate >60 ml/min~CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
9546133|NCT03061760||5.Control group|Healthy volunteer individuals aged 20-40. 'Initial evaluation' made only once.
9546134|NCT03062150|Placebo Comparator|Placebo+Placebo|Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
9546135|NCT03062150|Active Comparator|Fludrocortisone+Placebo|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH."
9546136|NCT03062150|Active Comparator|Placebo+D-Cycloserine|"Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
9546137|NCT03062150|Active Comparator|Fludrocortison+D-Cycloserine|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
9546138|NCT03061656|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
9546139|NCT03061916|Experimental|Cinnamon|20% cinnamon will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving cinnamon 20%
9546140|NCT03061916|Experimental|Ginger|20% ginger will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving ginger 20%
9546141|NCT03061916|Active Comparator|Chlorhexidine|Chlorhexidine gluconate 0.2%,will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving chlorhexidine.
9546142|NCT03061864|No Intervention|Standard Counseling|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology.
9546143|NCT03061864|Experimental|Periviable Birth Plan|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan.
9546144|NCT03061604|Experimental|Hemospray|"All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
9546145|NCT03061604|Active Comparator|Non Hemospray|"All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
9546146|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.~Subjects in the non-dry eye criteria must meet all of the following criteria:~Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes~OSDI questionnaire score <13.~Fluorescein TBUT > 7 s in both eyes.~CFS of 0 in all areas in both eyes.~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
9546147|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
9546148|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
9546149|NCT03061721|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
9546150|NCT03061721|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
9546151|NCT03061721|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
9546152|NCT03061721|Placebo Comparator|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
9546153|NCT03061682|Experimental|Add on lens|
9546154|NCT03061591|Active Comparator|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.~Pukka's Wholistic Turmeric"
9546155|NCT03061591|Placebo Comparator|Placebo|Identical placebo capsules
9546156|NCT03061448|Experimental|Inhibitory learning based treatment|The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.
10040741|NCT01856517|Placebo Comparator|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
10040742|NCT01856517|Active Comparator|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
10040743|NCT01856556|Experimental|NRX-1074, 1 mg|1 mg IV
9546157|NCT03061448|Active Comparator|Habituation based treatment|The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).
9546158|NCT03061708|Experimental|AZD2014 50mg BD continuous schedule of a 28 day cycle|AZD2014 50mg BD continuous schedule of a 28 day cycle
9546159|NCT03061396|Experimental|Electroacupuncture Single point|Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)
9546160|NCT03061396|Experimental|Electroacupuncture Matching points|There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)
9546161|NCT03061422|Experimental|xylitol chewing gum|intervention
9546162|NCT03061422|Experimental|xylitol with bicarbonate chewing gum|intervention
9546163|NCT03061422|Active Comparator|Paraffin pellet|comparator
9546164|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
9546165|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
9546166|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
9546167|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
9546168|NCT03061409|Experimental|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
9546169|NCT03061409|Placebo Comparator|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
9546170|NCT03061435|Other|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
9546171|NCT03061435|Other|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
9546172|NCT03061435|Other|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
9546173|NCT03061383|Active Comparator|8% Arginine based toothpaste|The procedure will be performed after scaling in group D1 using 8% arginine based toothpaste (Colgate Pro-relief) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
9546174|NCT03061383|Active Comparator|8% Strontium acetate based toothpaste|The procedure will be performed after scaling in group D2 using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
9546175|NCT03061383|Placebo Comparator|tooth past without active ingredient|The procedure will be performed after scaling in group D3 control group using placebo . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
9546176|NCT03061461|Active Comparator|rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the EvoBlue handpiece as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.07 mJ/mm^2 (i.e., setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the radial shock waves set at 15 Hz."
10040744|NCT01856556|Placebo Comparator|Placebo|Saline
10040745|NCT01856556|Experimental|NRX-1074, 5 mg|5 mg IV
9621745|NCT02521935|Active Comparator|Complete CADCAM dentures|Complete maxillary/mandible dentures made with CADCAM (computer-aided design/computer-aided manufacturing) technology
9621746|NCT02521805|Sham Comparator|PA|Animal protein and no fiber (control)
10040746|NCT01856556|Experimental|NRX-1074, 10 mg IV|10 mg
10040747|NCT01856556|Experimental|NRX-1074, 50 mg IV|50 mg
10040748|NCT01856556|Experimental|NRX-1074, 25 mg PO|25 mg
10040749|NCT01856556|Experimental|NRX-1074, 125 mg PO|125 mg
10040750|NCT01856621|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
10040751|NCT01856621|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
9546177|NCT03061461|Sham Comparator|Sham rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the placebo EvoBlue handpiece of the Swiss DolorClast (that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves) as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 sham radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.00 mJ/mm^2 (setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the sham radial shock waves set at 15 Hz."
9546178|NCT03061617|Other|volume controlled ventilation (VCV)|VCV mode, tide volume 6ml/kg, f 12-14, set fixed tide volume for each breath
9546179|NCT03061617|Experimental|pressure controlled ventilation (PCV)|PCV mode, pressure is adjusted to achieve tide volume 6ml/kg, f 12-14
9546180|NCT03061344|Experimental|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
9546181|NCT03061292|Experimental|Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation with pectoral nerve block
9546182|NCT03061292|Sham Comparator|Without Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation without pectoral nerve block
9546183|NCT03061357|Experimental|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
9546184|NCT03061357|No Intervention|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
9546185|NCT03061266|Experimental|E-health education group|E-health education group will be received the shared care program using e-health education.
9546186|NCT03061266|Other|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
9546187|NCT03061253|Experimental|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
9546188|NCT03061253|Experimental|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
9546189|NCT03061253|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
9546190|NCT03061110|Active Comparator|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
9546191|NCT03061110|Experimental|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
9546192|NCT03060993|Placebo Comparator|Placebo|35 mg of tetrahydrocannabinol/cannabidiol (LT1.0/LT1.0 %) in vaporized form. Placebo will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
9546193|NCT03060993|Active Comparator|Cannabis|35 mg of cannabis (tetrahydrocannabinol/cannabidiol; 18.0/LT1.0 %) in vaporized form. THC/CBD will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
9546194|NCT03061162|Experimental|Study Arm|Gastric cancer patients with peritoneal metastasis undergo pulsed low dose rate 3-dimensional conformal radiation therapy, QD, 5 days a week for 25 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
9546195|NCT03061058|Experimental|Individualized Group|"mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels.~Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w)."
9546196|NCT03061058|Active Comparator|Control Group|"mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients.~Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w)."
9546197|NCT03061019|Active Comparator|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
9621747|NCT02521805|Experimental|PAF|Animal protein added fiber
9621748|NCT02521805|Experimental|PVF|Vegetable protein naturally containing dietary fiber
9621749|NCT02521805|Experimental|PAVM|Animal protein and dietary fiber in meal
9621750|NCT02521883|Active Comparator|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
9546198|NCT03061019|Experimental|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
9546199|NCT03061019|No Intervention|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
9546200|NCT03061006|Experimental|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
9546201|NCT03061006|Active Comparator|Warfarin|Dose-adjusted warfarin (INR: 2.0-3.0)
9546202|NCT03061149|Experimental|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).~Additionally, nerve and gliding exercises were administered."
9546203|NCT03061149|Active Comparator|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
9546204|NCT03061071|Experimental|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
9546205|NCT03061071|Experimental|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
9546206|NCT03061227|Active Comparator|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
9546207|NCT03061227|Placebo Comparator|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
9546208|NCT03060928|Active Comparator|Control|Arthroscopic Rotator Cuff Repair with standard treatment
9546209|NCT03060928|Experimental|Experimental 1|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with micro-perforations
9546210|NCT03060928|Experimental|Experimental 2|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with the combination of micro-perforations and use of Artelon® Tissue Reinforcement
9546211|NCT03061136|Placebo Comparator|Placebo|Placebo administered orally
9546212|NCT03061136|Experimental|Clonazepam 0.1mg|0.1mg clonazepam administered orally
9546213|NCT03061136|Experimental|Clonazepam 0.2mg|0.2mg clonazepam administered orally
9546214|NCT03061136|Experimental|Clonazepam 0.3mg|0.3mg clonazepam administered orally
9546215|NCT03061240|Experimental|Postoperative patients|We recruit postoperative patients who undergo open surgery and are not receiving local anesthesia. We install a smart pain assessment tool on patient's skin to capture different type of data.
9546216|NCT03061045|Experimental|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
9546217|NCT03060915|Other|Polysomnography and actigraphy|Polysomnography and actigraphy
9546218|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
9546219|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
9546220|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
9546221|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
9546222|NCT03060967|Experimental|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
9546223|NCT03060967|Experimental|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
9546224|NCT03060889|Active Comparator|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
9546225|NCT03060889|No Intervention|Controls|Control group will not receive Tranexamic acid
9546226|NCT03060902|Experimental|Dialectical Behavior Therapy Skills|Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
9546227|NCT03060902|No Intervention|Family Services as Usual|Mothers will continue with services they are receiving in the community
9546228|NCT03060954|Experimental|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
9546229|NCT03060954|Other|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
9546230|NCT03060941|Experimental|Group 1|Physical activity education
9546231|NCT03060941|Experimental|Group 2|Physical activity education and facility access
9546232|NCT03060941|Experimental|Group 3|Physical activity education and supervised exercise sessions
9546233|NCT03060941|Experimental|Group 4|Physical activity education and self-monitoring (Fitbit)
9546234|NCT03060941|Experimental|Group 5|Physical activity education and active living counseling
9546235|NCT03060941|Experimental|Group 6|Physical activity education, facility access, and supervised exercise sessions
9546236|NCT03060941|Experimental|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
9546237|NCT03060941|Experimental|Group 8|Physical activity education, facility access, and active living counseling
9546238|NCT03060941|Experimental|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
9546239|NCT03060941|Experimental|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
9546240|NCT03060941|Experimental|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
9546241|NCT03060941|Experimental|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
9546242|NCT03060941|Experimental|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
9546243|NCT03060941|Experimental|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
9546244|NCT03060941|Experimental|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
9546245|NCT03060941|Experimental|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
9546246|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
9546247|NCT03060642||Controls|Non-BE endoscopic controls
9546248|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
9546249|NCT03060707|Experimental|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
9546250|NCT03060707|Active Comparator|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
9546251|NCT03060863|No Intervention|1. Comparison|Families in this group will not receive any of the interventions.
9546252|NCT03060863|Experimental|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
9546253|NCT03060863|Experimental|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
9546254|NCT03060863|Experimental|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
9546255|NCT03060863|Experimental|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
9546256|NCT03060681|Experimental|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
9546257|NCT03060681|No Intervention|C group|
9546258|NCT03060694||Diabetes group|Patients in this group are recruited from both departments of endocrinology and gastroenterology. The diagnosis of diabetes is confirmed by medical history, using anti-diabetic medicines or laboratory tests.
9546259|NCT03060694||Non-diabetes group|Patients in this group are recruited from department of gastroenterology. The exclusion of diabetes is confirmed by medical history or laboratory tests.
9546260|NCT03060850|Experimental|AC0010MA|This is dose escalation study. Patients will receive AC0010MA 200mg bid,300mg bid,400mg bid or 500mg bid by mouth (the dose escalation whether ended depends on DLT and occupancy) everyday until intolerable toxicity or disease progression
9546261|NCT03060564|Experimental|AC repair with tendon graft|acromioclavicular repair with tendon graft.
9546262|NCT03060564|Active Comparator|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
9546263|NCT03060837|Active Comparator|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
9546264|NCT03060837|Active Comparator|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
9546265|NCT03060824||CABG with the aid of CPB.|Cardiac surgical patients subjected to coronary artery bypass grafting with the aid of Cardiopulmonary Bypass. Perioperative measurements of osmolality in plasma.
9546266|NCT03060538|Experimental|Multiple Ascending Dose BFKB8488A|Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
9546267|NCT03060538|Placebo Comparator|Placebo|Participants will receive BFKB8488A-matching placebo.
9546268|NCT03060785|Experimental|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
9546269|NCT03060785|Active Comparator|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
9546270|NCT03060655|Placebo Comparator|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
9546271|NCT03060655|Placebo Comparator|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
9546272|NCT03060525|Experimental|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
9546273|NCT03060525|Experimental|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
9546274|NCT03060525|Other|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
9546275|NCT03060525|Other|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
9546276|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
9546277|NCT03060356|Active Comparator|Melanoma|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
9546278|NCT03060356|Active Comparator|Breast|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
9546279|NCT03060226|Other|Control group|
9546280|NCT03060226|Other|radiosensibility group|
9546281|NCT03060200|Experimental|Active intervention|Self-administered online CBT plus therapist check in. Moderately depressed participants will be testing a depression app, employing a self administered plus therapist check in, online CBT intervention, for 6 weeks.
9546282|NCT03060200|No Intervention|Waiting list|Moderately depressed participants will be put on a wait list for 6 weeks, after which access to the depression app will be given.
9546283|NCT03060200|Placebo Comparator|Placebo|Sham self-administered online CBT plus therapist check in. Moderately depressed participants will be using a depression app - the same platform and largely in the same format as the tested app, employing a self administered plus therapist check in, online sham intervention, for 6 weeks. The intervention will include the same sections and features as the original app, except for the complete exercises and behavioral activation sections. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense information on psychological well being.
9546284|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP > 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine >0.3 mg/dL or by 50%), oliguria (<0.5 mL/kg/h for >6h) , or hepatic injury (ALT, AST, or total bilirubin >2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
9546285|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP > 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
9546286|NCT03060343|Experimental|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
9546287|NCT03060278|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), an 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
9546288|NCT03060278|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
9546289|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
9546290|NCT03060395|Sham Comparator|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
9546291|NCT03060395|Active Comparator|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.~Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
9546292|NCT03060434|Active Comparator|Control|Ibuprofen
9546293|NCT03060434|Experimental|Pentoxifylline|Pentoxifylline oral tablets
9546294|NCT03060460|Experimental|Ultrasound arm - Randomized group|Ultrasound guided sheath insertion
9546295|NCT03060460|No Intervention|Conventional arm - Randomized group|Conventional arm during randomized phase
9546296|NCT03060460|No Intervention|Historical control group|Conventional arm, non-randomization phase
9546297|NCT03060382|Experimental|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into tibia.
9546298|NCT03060382|Placebo Comparator|total knee arthroplasty|For the patients of control group, total knee arthroplasty was conducted.
9546299|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
9616805|NCT02539121|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
9616806|NCT02539121|Placebo Comparator|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
9616807|NCT02539199|Active Comparator|Misoprostol modified-release pessary|
9616808|NCT02539199|Active Comparator|Misoprostol, per-oral tablets|
9616809|NCT02539030|Active Comparator|microfracture|simple microfracture for cartilage defect of knee
9616810|NCT02539030|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
9616811|NCT02539043|Active Comparator|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
9616812|NCT02539043|Active Comparator|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
9616813|NCT02539056|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
9616814|NCT02539017|Experimental|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
9616815|NCT02539017|Active Comparator|Chemo|Control group: Chemo Therapy group
9616816|NCT02538991|Experimental|Bulkamid|
9616817|NCT02538991|Active Comparator|Tension-free Vaginal Tape|
9616818|NCT02539394|Experimental|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
9616819|NCT02539394|Placebo Comparator|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
9616820|NCT02539277|Experimental|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
9616821|NCT02539277|Active Comparator|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
9616822|NCT02539147||patients with severe sepsis|blood samples from patients with severe sepsis
9616823|NCT02539498|Active Comparator|Control|Control post menopausal women without PHPT
9616824|NCT02539498|Experimental|Experimental|Post menopausal women with PHPT followed for one year
9616825|NCT02538978|Experimental|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
9616826|NCT02538978|Placebo Comparator|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
9616827|NCT02538731|Other|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
9616828|NCT02538731|Other|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
9616829|NCT02538887||Radio Frequency Surgical Detection|
9616830|NCT02538952|Experimental|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
9621751|NCT02521883|Placebo Comparator|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
9621752|NCT02521779|Experimental|Test Meal Saturated Fat|Saturated-fat Treatment Meal
9621753|NCT02521779|Experimental|Test Meal N-6 Fat|N-6 fat Treatment Meal.
9621754|NCT02521779|Experimental|Test Meal N-3 Fat|N-3 fat Treatment Meal.
9621755|NCT02521779|Experimental|Test Meal Low-fat|Low-fat Treatment Meal.
9546300|NCT03060408||Open|Patients underwent open distal pancreatectomy
9546301|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
9546302|NCT03060304|Experimental|study group|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
9546303|NCT03060304|Active Comparator|control group|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If endometrial thickness <7mm and E2<100pg/ml, the dose of estradiol valerate can increase or combine other estradiol. Endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before endometrium transformation. The embryo transfer day is decided according embryo development. Serum levels of E2, P are tested on the day before embryo transfer.
9546304|NCT03060291|Experimental|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
9546305|NCT03060291|Active Comparator|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
9546306|NCT03060291|No Intervention|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
9546307|NCT03060317||Validation group DOC|Examination with neurological scales.
9546308|NCT03060148|Active Comparator|Spinal cord stimulation|Medtronic neurostimulation system for spinal cord stimulation
9546309|NCT03060148|No Intervention|Control|No implantation of Medtronic neurostimulation system
9546310|NCT03060135|No Intervention|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
9546311|NCT03060135|Active Comparator|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
9546312|NCT03060135|Experimental|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
9546313|NCT03060161|Experimental|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
9546314|NCT03060239|Experimental|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
9546315|NCT03060122|No Intervention|Standard Care|Patient's randomized to this arm will receive standard post operative/post immobilization physical therapy or occupational therapy rehabilitation care without the use of NIN or CES.
9546316|NCT03060122|Experimental|NIN (InterX) and CES (Alpha-Stim)|"The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area. Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
9546317|NCT03060122|Active Comparator|NIN (InterX) and sham CES|"The Alpha-Stim Cranial Electrical Stimulation device intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level that serves as a sham treatment.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
9546318|NCT03060265|Active Comparator|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
9546319|NCT03060265|Placebo Comparator|Placebo|100ml normal saline, one dose IV
9546320|NCT03060109||Suspected traumatic brain injury|
9546321|NCT03060083|Experimental|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
9662997|NCT04122079||Clinical (outpatients)|Patients receiving mental health treatment at the three psychotherapeutic centers; two university clinics and a family mental health clinic
10040752|NCT01856621|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
9488878|NCT00750685|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
9488879|NCT00750633|Experimental|Moxidex|Moxidex otic solution
9488880|NCT00750633|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
9488881|NCT00750633|Active Comparator|Dexamethasone|Dexamethasone phosphate otic solution
9488882|NCT00750295|Experimental|1|
9488883|NCT00750295|Experimental|2|
9488884|NCT00750295|Experimental|3|
9488885|NCT00750295|Experimental|4|
9488886|NCT00750295|Experimental|5|
9488887|NCT00750295|Experimental|6|
9488888|NCT00750295|Experimental|7|
9488889|NCT00750243|Experimental|A|
9488890|NCT00750243|Active Comparator|B|
9488891|NCT00749788|Experimental|1|JTT-302, 200 mg
9488892|NCT00749788|Experimental|2|JTT-302, 400 mg
9488893|NCT00749788|Placebo Comparator|3|Matching placebo tablets
9488894|NCT00749632|Active Comparator|1|
9488895|NCT00749632|Active Comparator|2|
9488896|NCT00749632|Active Comparator|3|
9488897|NCT00749216|Experimental|QW|IV infusion of 400mg once each week for 2 months
9488898|NCT00749216|Experimental|Q4W|IV infusion of 400mg once every four weeks for 2 months
9488899|NCT00749216|Experimental|Q8W|IV infusion of 400mg once every eight weeks for 2 months
9488900|NCT00748852|Experimental|1|JTT-302, 400 mg
9488901|NCT00748605|Placebo Comparator|Placebo|S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
9488902|NCT00748605|Experimental|S-2367 1600 mg q.d. 54 weeks|S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
9488903|NCT00748605|Experimental|S-2367 1600 mg q.d. 60 weeks|S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
9488904|NCT00748501|Active Comparator|Cohort 1|SB-509 drug administration via IM injection of neck, arms, and legs
9488905|NCT00748501|Active Comparator|Cohort 2|SB-509 drug administration via IM injection of legs
9488906|NCT00748124|Experimental|PleuraSeal Sealant Device|
9488907|NCT00748124|Other|Control|
9488908|NCT00747929|Placebo Comparator|S-2367 Placebo|Placebo + reduced calorie diet
9488909|NCT00747929|Experimental|S-2367 800 mg|S-2367 800 mg q.d. + reduced calorie diet
9488910|NCT00747929|Experimental|S-2367 1600 mg|S-2367 1600 mg q.d. + reduced calorie diet
9488911|NCT00747318|Experimental|1|
9488912|NCT00747123|Placebo Comparator|Placebo|Subcutaneous injection on days 1, 29, 57 and 85.
9488913|NCT00747123|Experimental|ACE-011 0.1 mg/kg|Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
9488914|NCT00747123|Experimental|ACE-011 0.3 mg/kg|Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
9488915|NCT00747123|Experimental|ACE-011 0.5 mg/kg|Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
9488916|NCT00746616|Experimental|1|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
9488917|NCT00745316|Experimental|1|oral Dose 1
9488918|NCT00745316|Experimental|2|oral Dose 2
9488919|NCT00745316|Experimental|3|oral Dose 3
9488920|NCT00745316|Experimental|4|oral Dose 4
9488921|NCT00745316|Experimental|5|oral Dose 5
9488922|NCT00745316|Placebo Comparator|6|Placebo - 2 capsules bid
9488923|NCT00744926|Placebo Comparator|placebo|
9488924|NCT00744926|Experimental|taspoglutide 10mg sc|
9488925|NCT00744926|Experimental|taspoglutide 10mg/20mg sc|
9488926|NCT00744731|Experimental|001|placebo placebo for 1 week
9488927|NCT00744731|Experimental|002|carisbamate 400 mg/day to 1,200 mg per day
9488928|NCT00744367|Placebo Comparator|Placebo|Placebo in addition to continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly.
9488929|NCT00744367|Experimental|Taspoglutide 10mg|Taspoglutide 10mg once weekly in addition to continued stable metformin plus pioglitazone treatment
9488930|NCT00744367|Experimental|Taspoglutide 10mg/20mg|Taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued stable metformin plus pioglitazone treatment.
9488931|NCT00744276|Active Comparator|1|
9488932|NCT00744276|Active Comparator|2|
9488933|NCT00744276|Active Comparator|3|
9488934|NCT00744276|Placebo Comparator|4|
9488935|NCT00744276|Placebo Comparator|5|
9488936|NCT00744276|Placebo Comparator|6|
9488937|NCT00743938|Experimental|A1|
9488938|NCT00743938|Active Comparator|B2|
9498169|NCT03468595|Experimental|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson & Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
9498170|NCT03468595|Active Comparator|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
9498171|NCT03468582|Experimental|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
9498172|NCT03468569|Experimental|Functional Movement Screen|Movement Analysis for injury risk
9498173|NCT03468569|Experimental|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
9803796|NCT03315377|Active Comparator|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
9488939|NCT00743925|Active Comparator|1|A-002 (500 mg QD) plus Atorvastatin (80 mg QD)
9488940|NCT00743925|Placebo Comparator|2|Matching Placebo tablets plus Atorvastatin (80 mg QD)
9488941|NCT00743795|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 48 weeks + 24 weeks treatment-free follow-up (n = 50)
9488942|NCT00743795|Experimental|2|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up (n = 100)
9488943|NCT00743795|Experimental|3|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up. However, subjects who achieve RVR (HCV RNA undetectable at Week 4) and maintain that response through Week 24 will stop all study drugs at Week 24 and be followed for an additional 48 weeks (n = 50).
9488944|NCT00743184|Placebo Comparator|Placebo + Placebo|Participants will receive Placebo + Placebo on Days 0 and 14 of each 6-month course.
9488945|NCT00743184|Experimental|15 mg Ozarelix + 15 mg Ozarelix|Participants will receive 15 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
9488946|NCT00743184|Experimental|30 mg Ozarelix + 15 mg Ozarelix|Participants will receive 30 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
9488947|NCT00743002|Experimental|TT223 with Metformin and/or TZD|TT223 as a treatment for Type 2 diabetes is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
9488948|NCT00743002|Placebo Comparator|Placebo with Metformin and/or TZD|Placebo as a comparator is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
9488949|NCT00742716|Experimental|CTA018 Injection low dose|Low dose IV 3 times a week for 4 weeks
9488950|NCT00742716|Experimental|CTA018 Injection low to mid dose|low to mid dose IV 3 times a week for 4 weeks
9488951|NCT00742716|Experimental|CTA018 Injection mid to high dose|mid to high dose IV 3 times a week for 4 weeks
9488952|NCT00742716|Experimental|CTA018 Injection high dose|high dose IV 3 times a week for 4 weeks
9488953|NCT00741715|Placebo Comparator|1|
9488954|NCT00741715|Experimental|2|AVE5530 25mg
9488955|NCT00741715|Experimental|3|AVE5530 50mg
9488956|NCT00741715|Active Comparator|4|atorvastatin 10mg
9488957|NCT00741715|Experimental|5|atorvastatin 10mg + AVE5530 25mg
9488958|NCT00741715|Experimental|6|atorvastatin 10mg + AVE5530 50mg
9488959|NCT00741715|Active Comparator|7|atorvastatin 20mg
9488960|NCT00741715|Experimental|8|atorvastatin 20mg + AVE5530 25mg
9488961|NCT00741715|Experimental|9|atorvastatin 20mg + AVE5530 50mg
9488962|NCT00741715|Active Comparator|10|atorvastatin 40mg
9488963|NCT00741715|Experimental|11|atorvastatin 40mg + AVE5530 25mg
9488964|NCT00741715|Experimental|12|atorvastatin 40mg + AVE5530 50mg
9488965|NCT00741715|Active Comparator|13|atorvastatin 80mg
9488966|NCT00741715|Experimental|14|atorvastatin 80mg + AVE5530 25mg
9488967|NCT00741715|Experimental|15|atorvastatin 80mg + AVE5530 50mg
9488968|NCT00741442|Experimental|1|RDEA806 400 mg qd
9488969|NCT00741442|Experimental|3|RDEA806 400 mg bid
9488970|NCT00741442|Placebo Comparator|2|Placebo QD
9488971|NCT00741442|Placebo Comparator|4|Placebo BID
9488972|NCT00740727|Experimental|EASI|Subjects will undergo placement of EASI catheters. All subjects in whom EASI catheters are placed, will receive Human Recombinant Hyaluronidase (HRH) as part of the EASI placement. (No subject will receive HRH, other than as part of EASI catheter placement.)
9488973|NCT00740623|Experimental|001|Carisbamate 800 mg/day for 14 weeks
9488974|NCT00740623|Experimental|002|Carisbamate 1,200 mg/day for 14 weeks
9488975|NCT00740623|Placebo Comparator|003|placebo for 14 weeks
9488976|NCT00740610|Experimental|Cohort 1|22 subjects to receive 1 mg GS-9450 for 4 weeks
9488977|NCT00740610|Experimental|Cohort 2|22 subjects to receive 5 mg GS-9450 for 4 weeks
9488978|NCT00740610|Experimental|Cohort 3|22 subjects to receive 10 mg GS-9450 for 4 weeks
9488979|NCT00740610|Experimental|Cohort 4|22 subjects to receive 40 mg GS-9450 for 4 weeks
9488980|NCT00740610|Placebo Comparator|Cohort 5|22 subjects to receive placebo to match GS-9450 for 4 weeks
9488981|NCT00740480||Surgical|Adult population (ages 18-65) with clinically significant nasal septum deviation.
9488982|NCT00739739|Experimental|PD 0299685 15mg|
9488983|NCT00739739|Experimental|PD 0299685 30mg|
9488984|NCT00739739|Placebo Comparator|Placebo|
9488985|NCT00739349|Experimental|1|Cyclosporine 0.05%
9488986|NCT00739349|Experimental|2|Cyclosporine 0.1%
9488987|NCT00739349|Placebo Comparator|3|vehicle/placebo
9488988|NCT00738582|Experimental|Open Label|Pemetrexed, Cisplatin and MORAb-009 (Amatuximab)
9488989|NCT00738387|Experimental|ASA404 + docetaxel|"1800 mg/m2 of ASA404 intravenous (IV) on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
9488990|NCT00738387|Placebo Comparator|Placebo + docetaxel|"Placebo i.v. on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
9488991|NCT00737516|Experimental|single arm|HPC, Cord Blood
9488992|NCT00735085|Experimental|SLV334|
9488993|NCT00735085|Placebo Comparator|Placebo|
9488994|NCT00734461|Placebo Comparator|Placebo|Placebo, single dose
9488995|NCT00734461|Active Comparator|Oxycodone 20 mg|Oxycodone 20 mg single dose tablet
9488996|NCT00734461|Active Comparator|Oxycodone 40 mg|Oxycodone 40 mg single dose tablet
9488997|NCT00734461|Experimental|PTI-801 20/.001 mg|Oxycodone 20 mg / Naltrexone 0.001 mg
10040753|NCT01856621|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
9488998|NCT00734461|Experimental|PTI-801 40/.001 mg|Oxycodone 40 mg / Naltrexone 0.001 mg
9488999|NCT00734461|Experimental|PTI-801 20/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
9489000|NCT00734461|Experimental|PTI-801 40/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
9489001|NCT00734435|Active Comparator|1|Zonisamide SR 360 mg and olanzapine 10-20 mg daily
9489002|NCT00734435|Placebo Comparator|2|Placebo and olanzapine 10-20 mg daily
9489003|NCT00734292|Placebo Comparator|I|"Period 1 Treatment Regimen A: FlutiForm 250/10 ug~Period 2 Treatment Regimen B: FlutiForm 100/10 ug~Period 3 Treatment Regimen C: placebo"
9489004|NCT00734292|Placebo Comparator|II|"Period 1 Treatment Regimen B: FlutiForm 100/10 ug~Period 2 Treatment Regimen C: placebo~Period 3 Treatment Regimen A: FlutiForm 250/10 ug"
9489005|NCT00734292|Placebo Comparator|III|"Period 1 Treatment Regimen C: placebo~Period 2 Treatment Regimen A: FlutiForm 250/10 ug~Period 3 Treatment Regimen B: FlutiForm 100/10 ug"
9489006|NCT00734253|Experimental|1|Pyridorin 150 mg bid
9489007|NCT00734253|Experimental|2|Pyridorin 300 mg bid
9489008|NCT00734253|Placebo Comparator|3|Placebo bid
9489009|NCT00730665|Experimental|100ug|
9489010|NCT00730665|Experimental|300ug|
9489011|NCT00730665|Experimental|1mg|
9489012|NCT00730665|Experimental|3mg|
9489013|NCT00730665|Placebo Comparator|Placebo|
9489014|NCT00729027|Experimental|25 mg/day AVE5530|
9489015|NCT00729027|Experimental|50 mg/day AVE5530|
9489016|NCT00729027|Placebo Comparator|Placebo|
9489017|NCT00728351|Experimental|vildagliptin + metformin|
9489018|NCT00728351|Active Comparator|metformin|
9489019|NCT00728091|Experimental|Satavaptan Dose 1|Fixed Low dose up to day 4, followed by optional titration up to day 30
9489020|NCT00728091|Experimental|Satavaptan Dose 2|Fixed High dose up to day 4, followed by optional titration up to day 30
9489021|NCT00728091|Placebo Comparator|Placebo|
9489022|NCT00726648|Experimental|1|
9489023|NCT00726648|Experimental|2|
9489024|NCT00726648|Experimental|3|
9489025|NCT00726648|Experimental|4|
9489026|NCT00726648|Placebo Comparator|5|
9489027|NCT00725881|Experimental|1|.25 mg/kg TSC
9489028|NCT00725881|Experimental|2|.5 mg/kg TSC
9489029|NCT00725881|Experimental|3|.75 mg/kg TSC
9489030|NCT00725881|Experimental|4|1.0 mg/kg TSC
9489031|NCT00725881|Experimental|5|1.25 mg/kg TSC
9489032|NCT00725881|Experimental|6|1.5 mg/kg TSC
9489033|NCT00725881|Experimental|7|1.75 mg/kg TSC
9489034|NCT00725881|Experimental|8|2.0 mg/kg TSC
9489035|NCT00725881|Placebo Comparator|9|5.0 mL 0.9% normal saline
9489036|NCT00725803|Experimental|Cohort 1|Subjects randomized 3:1 (active:placebo) to receive GS-9450 10 mg/day or placebo.
9489037|NCT00725803|Experimental|Cohort 2|Subjects randomized 3:1 (active:placebo) to receive GS-9450 40 mg/day or placebo.
9489038|NCT00725803|Experimental|Cohort 3|Subjects randomized 3:1 (active:placebo) to receive GS-9450 80 mg/day or placebo.
9489039|NCT00725803|Experimental|Cohort 4|Subjects randomized 3:1 (active:placebo) to receive GS-9450 5 mg/day or placebo. Cohort may or may not be conducted pending blinded review of previous cohorts.
9489040|NCT00724841|Experimental|1|40 mg/m2 GMX1777 with Temozolomide
9489041|NCT00724841|Experimental|2|50 mg/m2 GMX1777 with Temozolomide
9489042|NCT00724841|Experimental|3|62 mg/m2 GMX1777 with Temozolomide
9489043|NCT00724841|Experimental|4|80 mg/m2 GMX1777 with Temozolomide
9489044|NCT00724841|Experimental|5|100 mg/m2 GMX1777 with Temozolomide
9489045|NCT00724841|Experimental|6|125 mg/m2 GMX1777 with Temozolomide
9489046|NCT00724698||Group|Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria
9489047|NCT00724334|Experimental|1|
9489048|NCT00724048|Experimental|ACR16 10 mg|"Participants receive one ACR16 10mg twice daily:~First four weeks - ACR16 10mg qd - one active 10mg capsule daily. After four weeks - ACR16 10mg bid - two active 10mg capsules taken as two separate doses (20mg ACR16 per day)."
9489049|NCT00724048|Experimental|ACR16 22.5 mg|"Participants receive one ACR16 22.5mg capsule twice daily:~First four weeks - ACR16 22.5mg qd - one active 22.5mg capsule daily. After four weeks - ACR16 22.5mg bid - two active 22.5mg capsules taken as two separate doses (45mg ACR16 per day)."
9489050|NCT00724048|Experimental|ACR16 45 mg|"Participants receive one ACR16 45mg capsule twice daily:~First four weeks - ACR16 45mg qd - one active 45mg capsule daily. After four weeks - ACR16 45mg bid - two active 45mg capsule taken as two separate doses (90mg ACR16 per day)."
9489051|NCT00724048|Placebo Comparator|Placebo|"Weeks 1-4, Participants receive a one placebo capsule once daily for four weeks.~Weeks 5-26, Participants receive a one placebo capsule taken twice daily as two separate doses."
9489052|NCT00722917|Experimental|TAK-379 25 mg QD|
9489053|NCT00722917|Experimental|TAK-379 100 mg QD|
9489054|NCT00722917|Experimental|TAK-379 200 mg QD|
9489055|NCT00722917|Active Comparator|Pioglitazone 30 mg QD|
9489056|NCT00722917|Placebo Comparator|Placebo|
9489057|NCT00722592|Experimental|Vintafolide + PLD|Participants receive vintafolide 2.5 mg intravenous (IV) bolus on Days 1, 3, 5, 15, 17, and 19 and Pegylated Liposomal Doxorubicin (PLD) weight-based dose, IV on Day 1 of each 4-week cycle.
9489058|NCT00722592|Active Comparator|PLD Alone|Participants receive PLD on Day 1 of each 4-week cycle.
9489059|NCT00722358|Active Comparator|BMS-650032|
9489060|NCT00722358|Placebo Comparator|Placebo|
9489061|NCT00722046|Experimental|PF-04360365 0.1 mg/kg|
9489062|NCT00722046|Experimental|PF-04360365 0.5 mg/kg|
9489063|NCT00722046|Experimental|PF-04360365 1 mg/kg|
9489064|NCT00722046|Placebo Comparator|Placebo|
9489065|NCT00722046|Experimental|PF-04360365 3 mg/kg|
9489066|NCT00722046|Experimental|PF-04360365 8.5 mg/kg|
9498174|NCT03468569|Experimental|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
9546322|NCT03060083|Experimental|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
9546323|NCT03060070|Placebo Comparator|control group,|saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
9546324|NCT03060070|Active Comparator|ketamine group,|ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
9546325|NCT03060070|Active Comparator|dexmedetomidine group|dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
9546326|NCT03059888|Experimental|Abatacept|125mg abatacept in 1ml solution administered once per week by subcutaneous injection
9546327|NCT03059927|Active Comparator|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
9546328|NCT03059927|Active Comparator|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
9546329|NCT03059927|Active Comparator|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
9546330|NCT03059992|Experimental|Ibrexafungerp (SCY-078)|Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.
9546331|NCT03059849|Active Comparator|Temporary increase in adalimumab|
9546332|NCT03059849|No Intervention|Continued monitoring as per standard of care|
9546333|NCT03059966|Experimental|Enamel Matrix Derivative|Microsurgery for root coverage associated with Enamel Matrix Derivative
9546334|NCT03059966|Placebo Comparator|Placebo|Microsurgery for root coverage associated with a Placebo comparator
9546335|NCT03060018|Experimental|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
9546336|NCT03059979|Active Comparator|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
9546337|NCT03059979|Placebo Comparator|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
9546338|NCT03059680|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
9546339|NCT03059680|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake
9546340|NCT03059875|Other|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
9546341|NCT03059875|Other|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
9546342|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler|single dose of Salmeterol/fluticasone Easyhaler
9546343|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
9546344|NCT03060044|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
9546345|NCT03060044|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration
9546346|NCT03059771|Experimental|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
9546347|NCT03059771|Active Comparator|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
9546348|NCT03059693|Experimental|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
9546349|NCT03059693|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
9546350|NCT03059784|Experimental|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
9546351|NCT03059784|No Intervention|control|usual care without APP
9546352|NCT03059732||Thailand|Thai patients who diagnosed gastric cancer
9546353|NCT03059732||Japan|Japanese patients who diagnosed gastric cancer
9546354|NCT03059797|Experimental|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
9546355|NCT03059797|Placebo Comparator|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
9546356|NCT03059836|Experimental|n3 PUFA|Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
9546357|NCT03059836|Placebo Comparator|Placebo|Intervention: Organic Sunflower Oil 5000mg per day
9546358|NCT03059914|Experimental|InterOss|Maxillary sinus augmentation using ABBM Inteross ( Xenograft)
9546359|NCT03059914|Active Comparator|Bio-oss|Maxillary sinus augmentation using ABBM Bio-oss ( Xenograft)
9803797|NCT03315377|Active Comparator|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
9546360|NCT03059719|Experimental|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
9546361|NCT03059719|Active Comparator|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
9546362|NCT03059706|Experimental|RegenoGel-OSP™|
9546363|NCT03059706|Placebo Comparator|Placebo|
9803798|NCT03301896|Experimental|LHC165 single agent|LHC165 intratumoral injection given alone
9498175|NCT03468569|Experimental|Illinois Agility Test|Agility measurement, Functional Movement Screen
9498176|NCT03468569|No Intervention|Injury History|Athletes injury history for last year was recorded as injury count.
9498177|NCT03468517|No Intervention|Control group|Standard preoperative evaluation process will continue without any intervention.
9498178|NCT03468517|Active Comparator|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
9498179|NCT03468504|Experimental|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
9498180|NCT03468504|Placebo Comparator|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
9498181|NCT03468491|Experimental|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
9498182|NCT03468491|Active Comparator|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
9498183|NCT03468478|Experimental|sirolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
9498184|NCT03468478|Experimental|everolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
9498185|NCT03468478|Active Comparator|mycophenolate +tacrolimus|Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).
9498186|NCT03468465|Experimental|Medical device: Transcutaneous electrical neurostimulation|Medical device 4 weeks with daily sessions of 30 minutes
9498187|NCT03468465|Active Comparator|Solifenacin|10 mg tablet daily during 75 days maximum
9498188|NCT03468452||Early extubation|The endotracheal tube is removed in the operation room, and no suction support is required after surgery.
9498189|NCT03468452||late extubation|"Take the tracheal tube back to the ward for respiratory support or removal of air.~The catheter is inserted again within 48h."
9498190|NCT03468439|Other|femoral nerve block|
9498191|NCT03468413|Experimental|Single ascending dose, CP1050 or Placebo|
9498192|NCT03468413|Experimental|Multiple ascending dose, CP1050 or Placebo|
9498193|NCT03468387|Active Comparator|Primary realignment|
9498194|NCT03468387|Active Comparator|Suprapubic cystostomy|
9498195|NCT03468374|Active Comparator|Lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
9498196|NCT03468374|Active Comparator|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
9498197|NCT03468361|Placebo Comparator|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
9498198|NCT03468361|Experimental|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
9498199|NCT03468348|Placebo Comparator|placebo group|
9498200|NCT03468348|Active Comparator|duloxetine 30|
9498201|NCT03468348|Active Comparator|duloxetine 60|
9498202|NCT03468348|Active Comparator|duloxetine 90|
9498203|NCT03468335|Other|Single Arm|"Cancer treatment for PDAC:~Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
9498204|NCT03468322|Experimental|AC-203 1% ointment|AC-203 1% ointment, QD
9498205|NCT03468322|Placebo Comparator|Vehicle ointment|Vehicle ointment, QD
9498206|NCT03468296|Experimental|Continued Q2 Week Treatment|Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
9498207|NCT03468296|Active Comparator|Treat-And-Extend Treatment|Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
9498208|NCT03468283|Experimental|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
9498209|NCT03468283|No Intervention|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
9498210|NCT03468257|Active Comparator|Progressive Muscle Relaxation only|Condition 1: 7-dose control - Progressive Muscle Relaxation only
9498211|NCT03468257|Experimental|Pairs Progressive Muscle Relaxation with fruit|Condition 2: 5-dose - Pairs Progressive Muscle Relaxation with fruit 5 consecutive days; Condition 3: 7-dose - Pairs Progressive Muscle Relaxation with fruit 7 consecutive days; Condition 4: 9-dose - Pairs Progressive Muscle Relaxation with fruit 9 consecutive days
9498212|NCT03468244|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
9546364|NCT03059758|Experimental|Brain activity during reasoning and measure of math skill|Brain activity during reasoning and measure of math skill
9546365|NCT03059654|Active Comparator|Ultrasound PCT|Ultrasound guide Percutaneous tracheostomy
10040754|NCT01856634|Experimental|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
9489067|NCT00721760|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
9489068|NCT00721760|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
9489069|NCT00721695|Experimental|1|OMS302 Irrigation Solution
9489070|NCT00721695|Active Comparator|2|OMS302-PE HCl Irrigation Solution
9489071|NCT00721695|Placebo Comparator|3|Standard topical mydriatics and BSS Irrigation Solution
9489072|NCT00719550|Placebo Comparator|Phase 2 Arm C|AMG 102 placebo plus ECX
9489073|NCT00719550|Other|Phase 1b|Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.
9489074|NCT00719550|Active Comparator|Phase 2 Arm B|AMG 102 at 7.5mg/kg plus ECX
9489075|NCT00719550|Active Comparator|Phase 2 Arm A|AMG 102 at 15mg/kg plus ECX
9489076|NCT00718965|Experimental|25 mg/day AVE5530|
9489077|NCT00718965|Experimental|50 mg/day AVE5530|
9489078|NCT00718965|Placebo Comparator|Placebo|
9489079|NCT00718692|Experimental|1|Patients treated with Sym001
9489080|NCT00718224|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~To maintain the blind, placebo for Enoxaparin sodium:~12 and 24 hours after surgery, then once daily if no SRI~12 hours after surgery only if SRI"
9489081|NCT00718224|Active Comparator|Enoxaparin|"Enoxaparin sodium 30 mg twice daily (20 mg once daily if Severe Renal Impairment [SRI]) for 7-10 days with an initial dose given 12 hours after surgery~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
9489082|NCT00717457|Active Comparator|exenatide|
9489083|NCT00717457|Experimental|taspoglutide 10mg|
9489084|NCT00717457|Experimental|taspoglutide 10mg/20mg|
9489085|NCT00716534|Experimental|A|12.5 mg ABT-869 + Carboplatin/Paclitaxel
9489086|NCT00716534|Experimental|B|7.5 mg ABT-869 + Carboplatin/Paclitaxel
9489087|NCT00716534|Placebo Comparator|C|Placebo (7.5 mg or 12.5 mg) + Carboplatin/Paclitaxel
9489088|NCT00714597|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
9489089|NCT00714597|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
9489090|NCT00713518|Active Comparator|Arm 1 ranibizumab|0.5 mg ranibizumab intravitreal injection given every 4 weeks from baseline to Week 12
9489091|NCT00713518|Experimental|Arm 2 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
9489092|NCT00713518|Experimental|Arm 3 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
9489093|NCT00713518|Experimental|Arm 4 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12
9489094|NCT00713518|Experimental|Arm 5 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
9489095|NCT00713401|Experimental|Cohort A|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion
9489096|NCT00713401|Experimental|Cohort B|Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion
9489097|NCT00713401|Experimental|Cohort C|Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion
9489098|NCT00713401|Experimental|Cohort D|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion
9489099|NCT00713401|Experimental|Cohort E|Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion
9489100|NCT00712699|Experimental|Sequence 1: XR-MAS then placebo|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 1 first receive treatment with XR-MAR for 3 weeks and then placebo for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period otherwise occurs (XR-MAS is not clinically suspected to have lingering effects beyond initial dosing/day of administration), including the crossover week to PBO.
9498213|NCT03468231|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
9498214|NCT03468231|Experimental|Sorafenbi plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
10040755|NCT01856634|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
10040756|NCT01856634|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
9498217|NCT03468192|Experimental|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
9498218|NCT03468192|No Intervention|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
9498219|NCT03468166||Chronic stroke|The data for motor function and gait pattern analysis was obtained.
9498220|NCT03468153|Experimental|CAR-T cell therapy|Patient-derived dual specificity CD19 and CD22 CAR-T
9498221|NCT03468140|Experimental|Current end stage liver disease patients|Eculizumab
9498222|NCT03468140|Other|Historical controls|The Ochsner database will be used to obtain 5 historical matches for each study participant. Matching criteria for each patient will include: 1) gender; 2) (MELD) Score ± 5; 3) age ± 5 years; 4) body mass index (BMI) ± 5 kg/m2; 5) donor macrosteatosis ± 5%; and 6) CIT± 3 hours.
9498223|NCT03468114|Experimental|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
9498224|NCT03468114|Active Comparator|Control|Participant households will receive 4 visits by health extension workers delivering standard care
9498225|NCT03468101||Dairy farmers COPD|
9498226|NCT03468101||Non farmers COPD|
9498227|NCT03468088|Experimental|Hand grip strengthening|This group will receive handgrip strengthening exercises.
9498228|NCT03468088|Active Comparator|Conventional treatment|This group will receive conventional exercises.
9498229|NCT03468062|Experimental|Dexmedetomidine|0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.
9498230|NCT03468062|Placebo Comparator|Placebo|Only normal saline 100mL is administered for 5 minutes after anesthetic induction.
9498231|NCT03468049|Experimental|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
9498232|NCT03468049|Experimental|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
9498233|NCT03468049|Experimental|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
9498234|NCT03468049|Active Comparator|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
9498235|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
9498236|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
9498237|NCT03468023|Experimental|Short arm cast|Patient treated with below-elbow cast
9498238|NCT03468023|Active Comparator|Long arm cast|Patients treated with above-elbow cast
9498239|NCT03468010|Active Comparator|The control group (Group A)|In Group A, observation is given after chemoradiation
9498240|NCT03468010|Experimental|The experiment group (Group B)|in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.
9498241|NCT03467997|No Intervention|Filtered Air|Subjects sit in a room for two hours breathing in filtered air which resembles levels of air pollution found in the ambient environment
9498242|NCT03467997|Active Comparator|Diesel Exhaust|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed.
9498243|NCT03467997|Active Comparator|TSST/Stress only|Subjects undergo a mental stress test, known as the Trier Social Stress Test (TSST), which involves a public speaking and math task.
9498244|NCT03467997|Active Comparator|Diesel Exhaust and stress|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed and are subject to a mental stress test (TSST) which involves a public speaking and math task.
9498245|NCT03467984|Experimental|LBVE|Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age
9498246|NCT03467984|Active Comparator|Prevnar13|Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age
9498247|NCT03467932|Active Comparator|Cohort A: ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
9546366|NCT03059654|Active Comparator|Surgical tracheostomy|Surgical tracheostomy
9546367|NCT03059628|Experimental|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
9546368|NCT03059628|Other|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
9546369|NCT03059862|Experimental|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
9546370|NCT03059862|Placebo Comparator|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
9546371|NCT03060031|Experimental|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
9546372|NCT03060031|Placebo Comparator|Placebo|Each participant will undergo pain tasks after self-administration of placebo
9546373|NCT03060005|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
9546374|NCT03060005|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
9546375|NCT03060005|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
9546376|NCT03060005|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
9546377|NCT03059940|Experimental|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
9546378|NCT03059940|Experimental|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~LDCT provider and patient discuss options for pharmacotherapy.~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
9546379|NCT03059940|Experimental|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
9546380|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
9546381|NCT03059667|Active Comparator|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:~topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)~or re-induction by carboplatin - etoposide chemotherapy."
9546382|NCT03059667|Experimental|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
9546383|NCT03059602||Knee group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total knee arthroplasty.
9546384|NCT03059602||Hip group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total hip arthroplasty.
9546385|NCT03059602||Spine group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing Cervical/Thoracic Lumbar Spine Surgery (Discectomy, Foraminotomy, Laminectomy, Fusion, Nerve Root Decompression)
9662998|NCT04122079||Clinical (self-reported)|Students and community nonstudent participants who were receiving psychological or psychiatric treatment
9662999|NCT04122079||Non-clinical (Community)|Members of the community
10040757|NCT01856634|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:~Patient's > 10 kg will receive DPF 10 mg BID + OBR~Patient's > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
10040758|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
10040759|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
10040760|NCT01856647||psoriatic lean|9 psoriatic lean
10040761|NCT01856647||psoriatic obese|9 psoriatic obese
10040762|NCT01856660|Experimental|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
10040763|NCT01856660|Experimental|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
10040764|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
9546386|NCT03059563|Experimental|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
9546387|NCT03059563|Placebo Comparator|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
9498248|NCT03467932|Active Comparator|Cohort A: ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
9498249|NCT03467932|Active Comparator|Cohort A: ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
9498250|NCT03467932|Placebo Comparator|Cohort A: Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
9546388|NCT03059615|Experimental|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
9546389|NCT03059615|Experimental|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
9546390|NCT03059615|Experimental|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
9546391|NCT03059615|Experimental|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
9546392|NCT03059290|Active Comparator|protaper next file|the PROTAPER NEXT™ X1 (017/04) file, in one or more passes until the working length is reached. Use PROTAPER NEXT X2 (025/06), exactly as described for PROTAPER NEXT X1 file, until the working length is passively reached. Gauge the foramen with a size 025 hand file and, if this file binds at length, the canal is shaped and ready for disinfection. If the size 025 hand file is loose at length, then continue shaping with the PROTAPER NEXT X3 (30/07) and, when necessary, the PROTAPER NEXT X4 (040/06) or PROTAPER NEXT X5 (050/06), gauging after each instrument with the 030, 040 or 050 hand files, respectively. During canal shaping, irrigate, recapitulate with a small-sized hand file after each sequential PROTAPER NEXT instrument, then re-irrigate. in an endodontic motor according to the manufacturer instructions (X-Smart, Dentsply Maillefer, USA.), with torque 2.0 N.cm and speed 300 rpm.
9546393|NCT03059277|Experimental|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
9546394|NCT03059316|Active Comparator|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
9546395|NCT03059316|Active Comparator|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
9546396|NCT03059303|Experimental|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
9546397|NCT03059303|Experimental|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
9546398|NCT03059303|Experimental|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
9546399|NCT03059303|Experimental|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
9546400|NCT03059303|Experimental|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
9546401|NCT03059303|Experimental|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9546402|NCT03059303|Experimental|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9546403|NCT03059303|Experimental|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9498251|NCT03467932|Placebo Comparator|Cohort A: Excipient-Matched Placebo three times daily-TID|Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
9498252|NCT03467932|Active Comparator|Cohort B:ORMD-0801, 8 mg once daily - QHS:|ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
9498253|NCT03467932|Active Comparator|Cohort B: ORMD-0801 8 mg twice daily - BID|ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
9546404|NCT03059303|Experimental|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9546405|NCT03059303|Experimental|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9546406|NCT03059303|Experimental|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9546407|NCT03059303|Experimental|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9546408|NCT03059303|Experimental|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
9546409|NCT03059212|Experimental|High frequency rTMS|Real rTMS, one session per day, for 10 days
9546410|NCT03059212|Experimental|High frequency rTMS with cognitive training|Real rTMS and cognitive training, one session per day, for 10 days
9546411|NCT03059212|Sham Comparator|Sham rTMS|Sham rTMS, one session per day, for 10 days
9546412|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
9546413|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
9546414|NCT03059225|Experimental|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention of contralesional 1Hz-rTMS for 10 daily sessions.
9546415|NCT03059225|Sham Comparator|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program.
9546416|NCT03059225|Experimental|High frequency rTMS|High-frequency rTMS to ipsilesional region for 10 daily sessions.
9546417|NCT03059537|Experimental|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
9546418|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
9546419|NCT03059524||patients with multiple organ failure|
9546420|NCT03059524||patients without multiple organ failure|
9546421|NCT03059524||normal subjects|
9546422|NCT03059368|Experimental|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
9546423|NCT03059238|Experimental|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
9546424|NCT03059238|Experimental|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
9546425|NCT03059238|Experimental|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
9546426|NCT03059186|Experimental|Intervention|Online daily gratitude journal.
10040765|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
9546427|NCT03059186|No Intervention|Control|
9546428|NCT03059199|Experimental|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
9546429|NCT03059160|Experimental|open label|
9546430|NCT03059134|Experimental|Mirabegron 25mg for 12 weeks|Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks
9546431|NCT03059134|Active Comparator|Mirabegron 25mg followed by 50mg|Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks
9546432|NCT03059134|Active Comparator|Mirabegron 25mg followed by solifenacin|Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks
9546433|NCT03059134|Active Comparator|Mirabegron 25mg add-on solifenacin|Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,
9546434|NCT03059147|Experimental|SF1126 + Nivolumab|SF1126 900-1100 mg/m2 IV twice weekly + Nivolumab 240 mg IV every 2 weeks
9546435|NCT03059108|Experimental|Early Loading|Implant early loading: prosthesis delivery 4 weeks after implant placement
9546436|NCT03059108|Active Comparator|Conventional Loading|Implant conventional loading: prosthesis delivery 8 weeks after implant placement
9546437|NCT03059095|Experimental|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
9546438|NCT03059082|Other|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
9546439|NCT03059082|Other|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
10040766|NCT01856725|Active Comparator|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing~Hemodynamic measurements for CRT device programming"
9546440|NCT03059082|Other|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
9546441|NCT03059069|Experimental|Glitamin|800mg/day
9546442|NCT03059069|Placebo Comparator|Placebo|same shape, color, size tablet as Glitamin
9546443|NCT03058848|Experimental|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
9546444|NCT03058809|Experimental|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
9546445|NCT03058939|Experimental|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
9546446|NCT03058939|Other|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
9546447|NCT03058939|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
9546448|NCT03058939|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
9546449|NCT03058939|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
9546450|NCT03058939|Other|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
9546451|NCT03059004|Experimental|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
9546452|NCT03059004|Experimental|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
9546453|NCT03059004|Experimental|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
9546454|NCT03059004|Experimental|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
9546455|NCT03058926||Chronic Pancreatitis|
9546456|NCT03058926||Diabetes|
9546457|NCT03058926||Pancreatic Cancer|
9546458|NCT03058900|Experimental|Fecal microbiota transplantation (FMT)|
9546459|NCT03058900|Sham Comparator|Placebo (saline)|
9546460|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
9546461|NCT03058731||Control|Other biological mesh
9546462|NCT03058822|Experimental|Prefilled Syringe Upper Arm|Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699
9546463|NCT03058822|Experimental|Prefilled Syringe Thigh|Single subcutaneous dose from prefilled syringe into thigh of BMS-931699
9546464|NCT03058822|Experimental|Prefilled Syringe Abdomen|Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699
9546465|NCT03058822|Experimental|Drug in Vial Upper Arm|Single subcutaneous dose from drug in vial into upper arm of BMS-931699
9546466|NCT03058822|Experimental|Drug in Vial Thigh|Single subcutaneous dose from drug in vial into thigh of BMS-931699
9546467|NCT03058822|Experimental|Drug in Vial Abdomen|Single subcutaneous dose from drug in vial into abdomen of BMS-931699
9546468|NCT03058770|Experimental|sensorimotor retraining program|Fifteen 40-minute sensorimotor retraining sessions will be provided over a 5-week period.
10040767|NCT01856725|Experimental|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing~CRT device programming without hemodynamics"
10040768|NCT01856738|Placebo Comparator|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
9546469|NCT03058770|Active Comparator|Relaxation technique|Subjects will perform fifteen 40-minute relaxation sessions over a 5-week period.
9546470|NCT03058835|Experimental|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
9546471|NCT03059017|Experimental|Niosomal salbutamol sulphate inhalers|Niosomes
9546472|NCT03059017|Placebo Comparator|salbutamol sulphate inhalers|control testing
9546473|NCT03058965|Experimental|[18F]MNI-958|To evaluate [18F]MNI-958, a tau targeted PET radioligand.
9663000|NCT04122079||Non-clinical (Students)|University undergraduate students
10040769|NCT01856738|Experimental|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
10040770|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
10040771|NCT01856777|Other|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
10040772|NCT01856777|Other|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
9546474|NCT03059043|Experimental|viscoelastic-free system|Eyes in this group will use viscoelastic-free implantation system during the surgery
9546475|NCT03059043|Active Comparator|viscoelastic-assisted system|Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
9546476|NCT03058744|Experimental|IDP-118 Lotion|8 Weeks
9546477|NCT03058744|Experimental|HP Monad Lotion|8 Weeks
9546478|NCT03058744|Active Comparator|Ultravate Cream|2 Weeks
9546479|NCT03058744|Active Comparator|Tazorac Cream|4 Weeks
9546480|NCT03058887|Experimental|Arm cranking|exercising for 3 months twice per week.
9546481|NCT03058887|Experimental|Cycling|exercising for 3 months twice per week.
9546482|NCT03058887|No Intervention|Control group|No exercise intervention.
9546483|NCT03058874|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
9546484|NCT03058874|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
9546485|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
9546486|NCT03059056|Experimental|pharmacokinetic evaluation|Empagliflozin 25 mg
9546487|NCT03058718|Experimental|Procalcitonin-guided antibiotic treatment group|"Patients were divided into 2 subgroups:~No infection group (including patients with procalcitonin<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics.~Infection group (including patients with procalcitonin>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below <0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent."
9546488|NCT03058718|Active Comparator|Standard antibiotic therapy group|The application of antibiotics is given to patiens according to the doctor's experience.
9546489|NCT03058861|Experimental|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
9546490|NCT03058861|No Intervention|Control Group|Routine primary care will be provided.
9546491|NCT03058666|Experimental|Aerosolized Calfactant|"NICU Patients with a clinical diagnosis of RDS~Inspired oxygen ≥21% to maintain adequate oxygen saturation~Not Intubated~Requiring Nasal continuous positive airway pressure"
9546492|NCT03058666|No Intervention|Usual Care|There will be no protocol driven interventions in the usual care group.
9546493|NCT03058653|Experimental|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
9546494|NCT03058640|Experimental|Karate Intervention|Participants will be enrolled into PKSA karate classes which includes at least two, standardized 1-hour classes per week for 12 weeks. Participants must attend at LEAST 20/24 classes. Attendance sheets will be signed by parents at each site. Practice at home will also be encouraged. Log sheets will be provided to participants to log their practice
9546495|NCT03058640|No Intervention|Standard Care|Participants will have no initial intervention. Investigators will request that participants do not enroll in a structured martial arts class during the one-year period. Participants will, however, be given the option of receiving the structured karate program at 6 months, once measurements are completed
9546496|NCT03058614|Active Comparator|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
9546497|NCT03058614|Active Comparator|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
9546498|NCT03058510||Stable CAD Patients|Stable CAD patients with calcified bifurcation lesion
10040773|NCT01856803|Active Comparator|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
9616831|NCT02538952|Active Comparator|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
9616832|NCT02538952|No Intervention|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
9803799|NCT03301896|Experimental|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
10040774|NCT01856803|Experimental|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
10040775|NCT01856816|Experimental|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
10040776|NCT01856816|Experimental|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
9489101|NCT00712699|Experimental|Sequence 2 Placebo then XR-MAS|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 2 will first receive treatment with PBO for 3 weeks and then XR-MAS for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period (stimulants are not clinically suspected to have lingering effects beyond initial dosing/day of administration)otherwise occurs, including the crossover week to XR-MAS.
9489102|NCT00712426|Active Comparator|A|Randomized to receive creatine monohydrate (up to 40 grams daily)
9489103|NCT00712426|Placebo Comparator|B|Randomized to receive placebo (up to 40 grams daily)
9489104|NCT00711555|Experimental|Single arm study with Emend|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day."
9489105|NCT00711035|Experimental|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line.
9489106|NCT00710580|Experimental|A|
9489107|NCT00710580|Active Comparator|B|
10040777|NCT01856816|Other|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
10040778|NCT01856829|Placebo Comparator|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
10040779|NCT01856829|Experimental|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
10040780|NCT01856842|Active Comparator|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
10040781|NCT01856842|Active Comparator|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
10040782|NCT01856881|Active Comparator|AMG 876|
10040783|NCT01856881|Placebo Comparator|Placebo|
10040784|NCT01856920|Experimental|A|GI-6207 for 1 year
10040785|NCT01856920|Experimental|B|6 months of surveillance followed by GI-6207 for 1 year
10040786|NCT01856946|Experimental|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
10040787|NCT01856959|Experimental|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
10040788|NCT01856959|Experimental|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg & albuterol 2.5mg and consisted about 5 min,which used only once
9489108|NCT00710580|Placebo Comparator|C|
9489109|NCT00710567|Other|Historical Data|"DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients"
9489110|NCT00709904|Experimental|Semuloparin extension treatment|Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
9489111|NCT00709904|Placebo Comparator|Placebo extension treatment|Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days
9489112|NCT00709865|Experimental|1|.03 mg/kg
9489113|NCT00709865|Experimental|2|.15 mg/kg
9489114|NCT00709865|Experimental|3|.3 mg/kg
9489115|NCT00709865|Placebo Comparator|4|Placebo
9489116|NCT00709371|Placebo Comparator|Placebo|Combination tablet containing Zonisamide SR placebo plus bupropion SR placebo SR = Sustained Release
9489117|NCT00709371|Active Comparator|Bupropion 360|Combination tablet containing Zonisamide SR placebo plus bupropion SR 360 mg/day; SR = Sustained Release
9489118|NCT00709371|Active Comparator|Zonisamide 120|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR placebo; SR = Sustained Release
9489119|NCT00709371|Active Comparator|Zonisamide 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR placebo; SR = Sustained Release
9489120|NCT00709371|Experimental|Zonisamide 120/Bupropion 360|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
9489121|NCT00709371|Experimental|Zonisamide 360/Bupropion 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
9489122|NCT00708292|Experimental|Single Agent AUY922|
9489123|NCT00708292|Experimental|AUY922 + Bortezomib|
9489124|NCT00708292|Experimental|AUY922 + Bortezomib + Dexamethasone|
9489125|NCT00708084|Experimental|A|CL184 combined with rabies vaccination
9489126|NCT00708084|Active Comparator|B|HRIG combined with rabies vaccination
9489127|NCT00707889|Active Comparator|A|Open-label to Bevacizumab plus mFOLFOX6
9489128|NCT00707889|Active Comparator|B|Open-label to High-dose ABT-869 arm plus mFOLFOX6
9489129|NCT00707889|Active Comparator|C|Open-label to low-dose ABT-869 arm plus mFOLFOX6
9546499|NCT03058354||Group TIVA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
10040789|NCT01856959|Active Comparator|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
10040790|NCT01856972|Experimental|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
9546500|NCT03058354||Group GA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
9546501|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
9546502|NCT03058523||Pregnant|30 pregnant women
9546503|NCT03058302|Experimental|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
9546504|NCT03058302|Experimental|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
9546505|NCT03058302|No Intervention|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
9546506|NCT03058432|Experimental|Intensity-modulated Radiotherapy|Radiotherapy alone was given.
9546507|NCT03058432|Active Comparator|Concurrent chemoradiotherapy|Concurrent cisplatin-based radiotherapy was given.
9546508|NCT03058419|Experimental|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam [2 milligram (mg)], warfarin [10 mg], caffeine [50 mg], dextromethorphan [30 mg], bupropion [150 mg] and omeprazole [20 mg]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
9546509|NCT03058367|Experimental|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
9546510|NCT03058367|Experimental|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
9546511|NCT03058367|Placebo Comparator|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
9546512|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
9546513|NCT03058536|Active Comparator|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
9546514|NCT03058536|Active Comparator|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone~400 mg micronized vaginal progesterone daily from randomization to 36 weeks~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
9546515|NCT03058536|Active Comparator|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
9546516|NCT03058536|No Intervention|No intervention|Expectant management
10040791|NCT01856972|Experimental|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
10040792|NCT01856972|Active Comparator|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
10040793|NCT01856985|Experimental|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
9546517|NCT03058341|Sham Comparator|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
9546518|NCT03058341|Experimental|Group P|Patients will be anaesthetized using total intravenous propofol.
9546519|NCT03058484|No Intervention|Control|Standard of care, i.e. regular clinic services are provided prior to the study.
9546520|NCT03058484|Experimental|Community Health Worker Intervention|This arm is a four-part behavioral intervention that includes: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
9546521|NCT03058549|Experimental|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
9546522|NCT03058549|No Intervention|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
9546523|NCT03058575|Experimental|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
9546524|NCT03058575|Other|Control|No Intervention
9546525|NCT03058289|Experimental|Cohort A|"INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.~Closed to enrollment"
9546526|NCT03058289|Experimental|Cohort B1|"INT230-6 injections every 28 days for 5 sessions into deep tumors, low starting dose, low drug concentration per tumor~Closed to enrollment"
10040794|NCT01856998|Active Comparator|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
10040795|NCT01856998|Experimental|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
10040796|NCT01857011|Experimental|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
10040797|NCT01857011|Active Comparator|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
10040798|NCT01857037|Other|Single arm|Single arm
10040799|NCT01857076|Active Comparator|Clinical|Subject submitted to clinical obesity treatment
9489130|NCT00707304|Experimental|1|Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
9489131|NCT00707304|Placebo Comparator|2|Placebo contains the same phosphate-based buffer used as the diluent for the talactoferrin solution. In addition, the placebo will contain FD&C/EU grade dyes suitable for oral use to mimic the color of the vialed drug product.
9489132|NCT00706537|Experimental|CP-945598 20 mg|
10040800|NCT01857076|Active Comparator|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
10040801|NCT01857076|Active Comparator|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
10040802|NCT01857089|Experimental|Pressure Measurement|
10040803|NCT01857128|Experimental|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
10040804|NCT01857128|Active Comparator|Negative Pressure Wound Therapy|Usual care including vacuum and canister
9489133|NCT00706537|Placebo Comparator|Placebo|
9489134|NCT00706147|Placebo Comparator|1|
9489135|NCT00706147|Active Comparator|2|
9489136|NCT00704782|Experimental|Dimebon|20 mg by mouth 3 times a day
9489137|NCT00704483|Experimental|1|1g tid
9489138|NCT00704483|Active Comparator|2|Sevelamer HCl
9489139|NCT00704483|Experimental|3|SBR759 1.5 g tid
9489140|NCT00704483|Active Comparator|4|Sevelamer HCl
9489141|NCT00703573|Experimental|Group A|S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
9489142|NCT00703573|Experimental|Group B|S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)
9489143|NCT00703573|Placebo Comparator|Group C|Placebo BID (four tablets of placebo BID)
9489144|NCT00702741|Experimental|A|Chondrogen (low dose)
9489145|NCT00702741|Experimental|B|Chondrogen (high dose)
10040805|NCT01857141|Experimental|dexmedetomidine|
10040806|NCT01857141|Placebo Comparator|normal saline|
10040807|NCT01857154|Active Comparator|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
10040808|NCT01857154|Active Comparator|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
10040809|NCT01857154|Active Comparator|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
10040810|NCT01857154|Active Comparator|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
10040811|NCT01857167|Experimental|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
10040812|NCT01857167|Experimental|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
10040813|NCT01857167|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
10040814|NCT01857180|Experimental|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
10040815|NCT01857180|No Intervention|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
9489146|NCT00702741|Placebo Comparator|C|Hyaluronan
9489147|NCT00701883|Placebo Comparator|Placebo/Placebo|
9489148|NCT00701883|Experimental|MBX-8025 50 mg/Placebo|
9489149|NCT00701883|Experimental|MBX-8025 100 mg/Placebo|
9489150|NCT00701883|Active Comparator|Placebo/Atorvastatin 20 mg|
9489151|NCT00701883|Experimental|MBX-8025 50 mg/Atorvastatin 20 mg|
9489152|NCT00701883|Experimental|MBX-8025 100 mg/Atorvastatin 20 mg|
9489153|NCT00701181|Active Comparator|Laser|This is a procedure - not a drug intervention.
9489154|NCT00701181|Experimental|PF-04523655 (High)|
9489155|NCT00701181|Experimental|PF-04523655 middle|
9489156|NCT00701181|Experimental|PF-04523655 low|
9489157|NCT00699790|Experimental|A1|
9489158|NCT00699790|Placebo Comparator|A2|
9489159|NCT00699517|Experimental|1|
9489160|NCT00699517|Placebo Comparator|2|
9489161|NCT00698789|Experimental|Treatment A|5 mg of INCB019602 in AM with placebo administration in PM
9489162|NCT00698789|Experimental|Treatment B|20 mg of INCB019602 in AM with placebo administration in PM
9489163|NCT00698789|Experimental|Treatment C|5 mg of INCB019602 in PM with placebo administration in AM
9489164|NCT00698789|Experimental|Treatment D|20 mg of INCB019602 in PM with placebo administration in AM
9489165|NCT00698789|Experimental|Treatment E|7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
9489166|NCT00698789|Placebo Comparator|Treatment F|Placebo BID
9489167|NCT00698230|Experimental|Treatment A - INCB013739 & Metformin|INCB013739 5 mg QD and Metformin
9489168|NCT00698230|Experimental|Treatment B - INCB013739 & Metformin|INCB013739 15 mg QD and Metformin
9489169|NCT00698230|Experimental|Treatment C - INCB013739 & Metformin|INCB013739 50 mg QD and Metformin
9489170|NCT00698230|Experimental|Treatment D - INCB013739 & Metformin|INCB013739 100 mg QD and Metformin
9489171|NCT00698230|Experimental|Treatment E - INCB013739 & Metformin|INCB013739 200 mg QD and Metformin
9489172|NCT00698230|Placebo Comparator|Treatment F - Placebo|Matching placebo
9489173|NCT00697918|Experimental|001|RWJ-333369100 mg to 400 mg twice daily
9489174|NCT00697762|Placebo Comparator|003|Placebo tablet twice daily for 12 weeks
9489175|NCT00697762|Experimental|002|RWJ-333369 200 mg tablet twice daily for 12 weeks
9489176|NCT00697762|Experimental|001|RWJ-333369 100 mg tablet twice daily for 12 weeks
9489177|NCT00697710|Experimental|Cohort A|50 mg S-777469 or Placebo, BID
9489178|NCT00697710|Experimental|Cohort B|200 mg S-777469 or Placebo, BID
9489179|NCT00697710|Experimental|Cohort C|800 mg S-777469 or Placebo, BID
9489180|NCT00697099|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
10040816|NCT01857193|Experimental|L-R-E arm|Participants who took ribociclib (LEE011), everolimus (RAD001) and exemestane triple combination
10040817|NCT01857193|Experimental|L-E arm|Participants who ribociclib (LEE011) and exemestane double combination
10040818|NCT01857219|Experimental|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
10040819|NCT01857245|Experimental|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
9546527|NCT03058289|Experimental|Cohort EA|"INT230-6 injections every 2 weeks for 5 sessions into superficial tumors, medium starting dose, low drug concentration per tumor~Closed to enrollment"
10040820|NCT01857245|Experimental|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
10040821|NCT01857245|Active Comparator|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
9546528|NCT03058289|Experimental|Cohort EC|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor~Closed to enrollment"
9546529|NCT03058289|Experimental|Cohort EC2|INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC
9546530|NCT03058289|Experimental|Cohort DEC: Safety with INT230-6|"INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody Keytruda (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.~Closed to enrollment"
9546531|NCT03058289|Experimental|EC3: INT230-6 monotherapy fixed maximal dose|INT230-6 injections every 2 weeks for 5 sessions at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.
9546532|NCT03058289|Experimental|DEC2: INT230-6 combined with pembrolizumab|INT230-6 per the dosing of cohort EC3 combined with Keytruda (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.
9546533|NCT03058289|Experimental|FEC: INT230-6 combined with ipilimumab|INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.
9546534|NCT03058497|Active Comparator|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
9546535|NCT03058497|Placebo Comparator|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
9546536|NCT03058406||Eribulin mesylate|
9546537|NCT03058445|Experimental|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
9546538|NCT03058055|Placebo Comparator|Placebo|Usual lifestyle activities
9546539|NCT03058055|Experimental|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
10040822|NCT01857284|Experimental|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
10040823|NCT01857284|Active Comparator|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
10040824|NCT01857336|Experimental|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
9546540|NCT03058055|Experimental|Reading|Daily reading (out loud into a voice recorder) for one hour
9546541|NCT03058458|Experimental|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
9546542|NCT03058458|Experimental|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
9546543|NCT03058458|Experimental|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
9546544|NCT03058458|Experimental|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
10040825|NCT01857349|Active Comparator|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
10040826|NCT01857349|Active Comparator|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
10040827|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
10040828|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
10040829|NCT01857388|Experimental|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
9546545|NCT03058471|Active Comparator|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
9546546|NCT03058471|Active Comparator|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
9546547|NCT03058263|Experimental|partial dose of neostigmine|Those who received partial dose of neostigmine as rocuronium reversal
9546548|NCT03058263|Experimental|TOF ratio-based dose of neostigmine|Those who received TOF ratio-based dose of neostigmine as rocuronium reversal
9546549|NCT03058120|No Intervention|Stress testing|Patient with chest pain, low risk by modified HEART score, undergoes whatever admission and stress testing plan is determined by ED and inheriting decision unit physicians.
9546550|NCT03058120|Active Comparator|Early discharge|Patient with chest pain, low risk by modified HEART score, is discharged from the emergency room without admission nor stress testing.
9546551|NCT03058068|Experimental|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
9546552|NCT03058068|Experimental|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
9546553|NCT03058068|Experimental|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.
9546554|NCT03058068|Experimental|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.
9546555|NCT03058068|Placebo Comparator|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
9546556|NCT03058042|Experimental|Home pelvic floor muscle training|Patients will perform strength training of the pelvic floor muscles daily at home. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will return for consultation, in which the MAP evaluation and training progression will be performed.
9546557|NCT03058042|Sham Comparator|Outpatient pelvic floor muscle training|The patients will perform 24 outpatient sessions of pelvic floor muscle strength training and home training. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will perform the evaluation of the MAP and progression of the training.
9546558|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
9546559|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
9546560|NCT03058224|Experimental|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
9546561|NCT03058224|Placebo Comparator|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
9546562|NCT03058172|Other|Odors (food and non-food)|Odorants diluted in mineral oil.
9546563|NCT03058172|Other|Pictures (food and non-food)|Pictures of objects or scenes.
9546564|NCT03058250|No Intervention|Control|Standard of care, no intervention
9546565|NCT03058250|Active Comparator|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
9546566|NCT03058029|Experimental|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)
9546567|NCT03058029|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)
9546568|NCT03058159|Other|Subjects with a high dream recall frequency|
9546569|NCT03058159|Other|Subjects with a law dream recall frequency|
9546570|NCT03058198|Experimental|High Grade Glioma|"We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from thehot-spot on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies."
9546571|NCT03058237|Experimental|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
9546572|NCT03058237|Experimental|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
9546573|NCT03058237|Active Comparator|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
9546574|NCT03058237|Experimental|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
9546575|NCT03058237|Experimental|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
9546576|NCT03058237|Experimental|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
9546577|NCT03058237|Active Comparator|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
9546578|NCT03058237|Experimental|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
9546579|NCT03058237|Experimental|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
9546580|NCT03058237|Experimental|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
9546581|NCT03058237|Experimental|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
9546582|NCT03058237|Experimental|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
9546583|NCT03058237|Experimental|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
9546584|NCT03058237|Experimental|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
9546585|NCT03058393|Experimental|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
9546586|NCT03058562|Experimental|Crossover Sequence A|"Each in the fasting state:~Period 1: Single-dose matching placebo~Period 2: Single-dose ABX-1431"
9546587|NCT03058562|Experimental|Crossover Sequence B|"Each in the fasting state:~Period 1: Single-dose ABX-1431~Period 2: Single-dose matching placebo"
9546588|NCT03058562|Experimental|Crossover Sequence C|"Each with a standard high fat meal:~Period 3: Single-dose matching placebo~Period 4: Single-dose ABX-1431"
9546589|NCT03058562|Experimental|Crossover Sequence D|"Each with a standard high fat meal:~Period 3: Single-dose ABX-1431~Period 4: Single-dose matching placebo"
9546590|NCT03058016|Experimental|Personalized recommendations for diet|"After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built.~Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month."
9546591|NCT03058133|Other|fMRI study|
9546592|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
9546593|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
9546594|NCT03057938|Experimental|18F-Florbetaben (FBB)|18F-Florbetaben
9546595|NCT03058081|Experimental|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
9546596|NCT03058081|No Intervention|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
9546597|NCT03058094|Experimental|AC0010|AC0010, 300mg, orally, BID with a 21-day cycle
9546598|NCT03058094|Active Comparator|Chemotherapy|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.
9546599|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
9546600|NCT03058276|Experimental|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
9546601|NCT03058276|Active Comparator|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
9546602|NCT03058276|Experimental|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
9546603|NCT03058276|Sham Comparator|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
9546604|NCT03057990|Experimental|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
9546605|NCT03058146|Experimental|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
9546606|NCT03058146|Active Comparator|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
9546607|NCT03057925|Experimental|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
9546608|NCT03057925|No Intervention|Group B|untreated no treatment; regular ultrasonic image follow-up
9546609|NCT03057912|Experimental|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
9546610|NCT03057912|Experimental|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
9546611|NCT03057912|No Intervention|Control group|Observation
9546612|NCT03057951|Experimental|Empagliflozin|
9546613|NCT03057951|Placebo Comparator|Placebo|
10040830|NCT01857388|No Intervention|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
10040831|NCT01857401||Observational study|Blood draw only, observational study
9546614|NCT03057847|Experimental|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
9546615|NCT03057769|Experimental|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
9546616|NCT03057769|Placebo Comparator|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
9546617|NCT03057899|Experimental|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
9546618|NCT03057899|Placebo Comparator|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
9546619|NCT03057834|Active Comparator|Functionally impaired|Women with urinary incontinence and short physical performance battery score of <9
9546620|NCT03057834|Placebo Comparator|Functionally normal|Women with urinary incontinence and short physical performance battery score of > 10
10040832|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
10040833|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
10040834|NCT01857453|Experimental|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
10040835|NCT01857466|Experimental|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
9546621|NCT03057782||Group A|"Plan for major surgery anticipated to cause pain and agitation (i.e. esophageal atresia treatment);~Patients who are anticipated to receive prolonged post-surgical neuromuscular blockade (NMB)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. These subjects will also receive EMG monitoring. Subjects in this group will also have video recordings that may be used for novel analysis such as subdermal blood flow or micro-movement."
9546622|NCT03057782||Group B|"Plan for major surgery anticipated to cause pain and agitation (i.e. bowel surgery);~Patients who are not anticipated to receive acute post-surgical NMB~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
9546623|NCT03057782||Group C|"Plan for minor surgery anticipated to cause pain and agitation (i.e. hernia repair)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
9546624|NCT03057782||Group D|"No plan for surgery~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
9546625|NCT03057808|Experimental|Gestational weight gain intervention (GWG-only)|The GWG intervention will begin upon randomization to the GWG-only or the GWG+PPWL arm, and continue until the birth of the participant's child.
9546626|NCT03057808|Experimental|Postpartum weight loss intervention (PPWL-only)|The PPWL intervention will begin at 6-weeks postpartum (when most women will be approved for weight loss and exercise by their obstetrician) for those participants randomized to the PPWL only or the GWG+PPWL arms, and will continue until 6-months postpartum.
9546627|NCT03057808|Experimental|Combined|During the gestational phase participants will receive the same intervention as the GWG only group. During the postpartum phase participants will receive the the same intervention as the PPWL group.
9546628|NCT03057886||Compare the Spot On with others consecrated thermometers|This study intends to compare the accuracy of the new device(SPOT ON thermometer) with the oral and esophageal in participants submitted to general and spinal anesthesia, in different types of population (pediatric and adult)
9546629|NCT03057821|No Intervention|Control|The control group will not receive any hydrogen peroxide skin preparation
9546630|NCT03057821|Experimental|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
9546631|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
9546632|NCT03057873|Experimental|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
9546633|NCT03057873|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
9546634|NCT03057691||No depression/anxiety|patients suffered from ACS who have undergone PCI without depression or anxiety
9546635|NCT03057691||Depression|patients suffered from post-ACS depression who have undergone PCI
9546636|NCT03057691||Anxiety|patients suffered from post-ACS anxiety who have undergone PCI
9546637|NCT03057691||Depression with anxiety|patients suffered from post-ACS depression with anxiety who have undergone PCI
9546638|NCT03057730|Experimental|Group 1: Thin Biotype|"Gingival thickness < 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
9546639|NCT03057730|Experimental|Group 2: Thick Biotype|"Gingival thickness ≥ 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
9546640|NCT03057717|Other|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
9546641|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
9546642|NCT03057548|Active Comparator|Pulmonary Vein Isolation (PVI)|"Cryoablation only of Pulmonary Veins~or~Radiofrequency ablation only of Pulmonary Veins~Pulmonary Vein Isolation (PVI) alone."
9546643|NCT03057548|Experimental|PVI & Posterior Left Atrial Ablation|"Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~or~Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)"
9546644|NCT03057509|Experimental|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.~Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.~Standard LAR Octreotide will be administered.~Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.~Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
9546645|NCT03057418|Experimental|Aurixim|"Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.~Mode of administration: intravenous."
9546646|NCT03057522|Experimental|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
9546647|NCT03057522|No Intervention|Control Group|This group will not receive any intervention.
9546648|NCT03057379|No Intervention|Control arm|Usual source of care
9546649|NCT03057379|Experimental|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
9546650|NCT03057379|Experimental|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
9546651|NCT03057379|Experimental|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
9546652|NCT03057327|Active Comparator|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
9546653|NCT03057327|Experimental|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
9546654|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
9546655|NCT03057236|No Intervention|Standard of Care|This arm does not receive the behavioral intervention. Participants will complete HCV treatment per standard of care.
10040836|NCT01857466|Active Comparator|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
9803800|NCT03301012|Active Comparator|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
9489181|NCT00697099|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
9489182|NCT00696332|Experimental|Talampanel 50mg|50mg Talampanel 3 times per day
9489183|NCT00696332|Experimental|Talampanel 25mg|25mg Talampanel 3 times per day
9489184|NCT00696332|Placebo Comparator|Placebo|placebo 3 times per day
9489185|NCT00695305|Placebo Comparator|placebo|placebo to match
9489186|NCT00695305|Active Comparator|rilapladib|250 mg/day
9489187|NCT00694928|Experimental|1|clindamycin phosphate/butoconazole nitrate
9489188|NCT00694928|Active Comparator|2|butoconazole nitrate
9489189|NCT00694382|Experimental|Semuloparin|Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
9489190|NCT00694382|Placebo Comparator|Placebo|Placebo (for semuloparin) once daily until change in chemotherapy regimen
9489191|NCT00694135|Active Comparator|EGP-437 1.6 mA-min at 0.4 mA|Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA
9489192|NCT00694135|Active Comparator|EGP-437 4.8 mA-min at 1.2 mA|Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA
9489193|NCT00694135|Active Comparator|EGP-437 10.0 mA-min at 2.5 mA|Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA
9489194|NCT00694135|Active Comparator|EGP-437 14.0 mA-min at 3.5 mA|Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA
9489195|NCT00692484|Experimental|1|Chlorhexidine gluconate 2%
9489196|NCT00692484|Active Comparator|2|Povidone iodine scrub and paint
9489197|NCT00692445|Active Comparator|citalopram + TC-5214|
9489198|NCT00692445|Placebo Comparator|citalopram + placebo|
9489199|NCT00691964|Experimental|A|
9489200|NCT00691964|Active Comparator|B|
9489201|NCT00691964|Placebo Comparator|C|
9489202|NCT00691717|Experimental|24 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye
9489203|NCT00691717|Experimental|48 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye
9489204|NCT00691717|Experimental|60 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye
9489205|NCT00691717|Placebo Comparator|Anecortave Acetate Vehicle|Single depot administration of 0.8 mL in the study eye
9489206|NCT00690716|Experimental|1|Nasal CO2
9489207|NCT00690716|Placebo Comparator|2|Inactive Placebo
9489208|NCT00690456|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
9489209|NCT00690456|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily on top of metformin
9489210|NCT00690066|Experimental|Prochymal|PROCHYMAL®
9489211|NCT00690066|Placebo Comparator|Placebo|Placebo
9489212|NCT00688766|Experimental|IPI-504|retaspimycin hydrochloride (IPI-504) plus best supportive care
9489213|NCT00688766|Placebo Comparator|Placebo|Placebo plus best supportive care
9489214|NCT00688441|Experimental|Active|CO2 Gas
9489215|NCT00688441|Placebo Comparator|Placebo|Inactive Placebo Gas
9489216|NCT00687882|Experimental|Intervention: A|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
9489217|NCT00687882|Active Comparator|B|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
9489218|NCT00687882|Other|Parallel Cohort: Persistent Occlusive Thrombosis|Patients with completely occlusive thrombosis at 6 weeks.
9489219|NCT00687882|Other|Parallel Cohort: Persistent Antiphospholipid Antibody|Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.
9489220|NCT00687687|Experimental|Pacitaxel/Carboplatin/Iniparib|Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy.
9489221|NCT00686933|Experimental|1|
9489222|NCT00685113|Experimental|1|
9489223|NCT00685113|Experimental|2|
9489224|NCT00685113|Placebo Comparator|3|
9498254|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg once daily - QHS:|ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
9498255|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg twice daily - BID|ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
9498256|NCT03467932|Placebo Comparator|Excipient matched placebo once daily - QHS|Excipient matched placebo once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
9498257|NCT03467919|Experimental|MFAT(Micro Fragmented Adipose Tissue)|Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.
9498258|NCT03467919|Active Comparator|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg).
9498259|NCT03467880||Healthy subjects|Healthy subjects.
9498260|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
9498261|NCT03467880||Asthma|Patience with asthma.
9498262|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
9498263|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
9498264|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
9489225|NCT00684944|Active Comparator|1|30mg tid TRx0014
9489226|NCT00684944|Active Comparator|2|60mg tid TRx0014
9489227|NCT00684918|Experimental|Experimental|In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
9489228|NCT00683722|Experimental|Prochymal™|Participants received Prochymal™ a total of 400×10^6 cells, intravenous (IV) infusions on Days 0, 30, 60, and 90.
9489229|NCT00683722|Placebo Comparator|Placebo|Participants received placebo-matching IV infusions on Days 0, 30, 60 and 90.
9489230|NCT00683423|Experimental|A|
9489231|NCT00683423|Placebo Comparator|B|
9489232|NCT00682981|Experimental|Phase I A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
9489233|NCT00682981|Experimental|Phase I B|Obatoclax for 24 hours for 3 days with carboplatin/etoposide.
9489234|NCT00682981|Experimental|Phase II A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
9489235|NCT00682981|Active Comparator|Phase II B|Carboplatin/etoposide without continued study treatment
9489236|NCT00680784|Experimental|HKT-500 Ketoprofen Topical Patch|Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
9489237|NCT00680784|Placebo Comparator|Placebo Patch|Treatment with placebo patch
9489238|NCT00680472|Active Comparator|A,1 HKT-500 Ketoprofen Topical Patch|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain
9489239|NCT00680472|Placebo Comparator|A,2 Placebo Patch|Treatment with placebo patch
9489240|NCT00680342|Placebo Comparator|1|Placebo (lactose pill)
9489241|NCT00680342|Experimental|2|700mg of Legalon (silymarin) three times daily
9489242|NCT00680342|Experimental|3|420mg Legalon (silymarin) three times daily
9489243|NCT00680069|Experimental|High Dose Group|Volunteers will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart
9489244|NCT00680069|Experimental|Low Dose Group|Volunteers will receive 15 mcg intramuscularly (IM). Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart.
9489245|NCT00679991|Active Comparator|PRT-201|
9489246|NCT00679991|Placebo Comparator|2|
9489247|NCT00679731|Experimental|A|ABT-874
9489248|NCT00679731|Active Comparator|B|Methotrexate
9489249|NCT00679588|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery (placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind)
9489250|NCT00679588|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium (placebo for Semuloparin sodium 8 hours after surgery to maintain the blind)
9489251|NCT00678171|Experimental|OP-1 Putty|Patients randomized to the OP-1 Putty Spinal System arm will receive OP-1 Putty with AVS™TL PEEK Spacer System and XIA® Spinal System.
9489252|NCT00678171|Active Comparator|Autograft|Patients randomized to the Autograft Spinal System arm will receive iliac crest autograft with AVS™TL PEEK Spacer System and XIA® Spinal System.
9489253|NCT00678119|Experimental|1: AGS-003+sunitinib|Single arm study AGS-003 plus sunitinib
9489254|NCT00677313|Experimental|1|
9489255|NCT00677079|Experimental|Iniparib|Iniparib, twice weekly on Days 1 and 4 of each week during 8-week cycles
9489256|NCT00677053|Experimental|TAK-442 10 mg BID|Added with standard care for recurrent ischemic events.
9489257|NCT00677053|Experimental|TAK-442 20 mg BID|Added with standard care for recurrent ischemic events
9489258|NCT00677053|Experimental|TAK-442 40 mg QD|Added with standard care for recurrent ischemic events
9489259|NCT00677053|Experimental|TAK-442 40 mg BID|Added with standard care for recurrent ischemic events
9489260|NCT00677053|Experimental|TAK-442 80 mg QD|Added with standard care for recurrent ischemic events
9489261|NCT00677053|Experimental|TAK-442 80 mg BID|Added with standard care for recurrent ischemic events
9489262|NCT00677053|Experimental|TAK-442 160 mg QD|Added with standard care for recurrent ischemic events
9489263|NCT00677053|Experimental|TAK-442 120 mg BID|Added with standard care for recurrent ischemic events
9489264|NCT00677053|Placebo Comparator|Placebo|Added with standard care for recurrent ischemic events
9489265|NCT00676832|Placebo Comparator|Group 1|
9489266|NCT00676832|Experimental|Group 2|
9489267|NCT00676832|Experimental|Group 3|
9489268|NCT00676832|Experimental|Group 4|
9489269|NCT00676832|Experimental|Group 5|
9489270|NCT00675844|Experimental|elvucitabine|Subjects currently receiving elvucitabine will continue elvucitabine as part of their ART regimen for an additional 48 months.
9489271|NCT00675623|Experimental|A|Dimebon, 5 mg orally three times daily
9489272|NCT00675623|Experimental|B|Dimebon 20 mg orally three times daily
9489273|NCT00675623|Placebo Comparator|C|Placebo orally three times daily for six months
9489274|NCT00674635|Placebo Comparator|Placebo|matching placebo
9489275|NCT00674635|Active Comparator|GSK315234A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
9489276|NCT00674440|Experimental|1|Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and will be scheduled for surgery. Eligible children in this arm will PET imaging with F-DOPA prior to surgery.
9489277|NCT00674440|Experimental|3|Children diagnosed with hyperinsulinism who have had partial pancreas removal but still display signs of hyperinsulinism. Eligible children in this arm may have PET imaging with F-DOPA.
9489278|NCT00674440|Experimental|2|Children diagnosed with hyperinsulinism who are successfully managed with diazoxide, octreotide, other medications,and/or tube feedings. Eligible children in this arm will PET imaging with F-DOPA.
9489279|NCT00673062|Experimental|SCH 900538|
9498265|NCT03467828|Experimental|Study Group|Infants diagnosed with BPD.
10040837|NCT01857479|Active Comparator|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]
9489280|NCT00673062|Active Comparator|Encapsulated pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
9489281|NCT00673062|Placebo Comparator|Placebo Capsules|
9489282|NCT00672997|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
9489283|NCT00672997|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
9489284|NCT00672412|Experimental|1|Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
9489285|NCT00672412|Experimental|2|Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
9489286|NCT00672386|Experimental|001|JNJ16269110 5 mg twice daily for 12 weeks
9489287|NCT00672386|Experimental|002|JNJ16269110 10 mg twice daily for 12 weeks
9489288|NCT00672386|Experimental|003|JNJ16269110 15 mg twice daily for 12 weeks
9489289|NCT00672386|Placebo Comparator|004|Placebo twice daily for 12 weeks
9489290|NCT00672191|Experimental|1|
9489291|NCT00672074|Active Comparator|1 Ipamorelin|
9489292|NCT00672074|Placebo Comparator|2 Placebo|
9489293|NCT00672009|Experimental|One|
9489294|NCT00671073|Active Comparator|1|Oglemilast low dose, oral administration once daily for 12 weeks
9489295|NCT00671073|Active Comparator|2|Oglemilast middle dose, oral administration, once daily for 12 weeks
9489296|NCT00671073|Active Comparator|3|Oglemilast high dose, oral administration, once daily for 12 weeks.
9489297|NCT00671073|Placebo Comparator|4|Placebo
9489298|NCT00670592|Other|HCD122|
9489299|NCT00670033|Experimental|Travoprost new formulation|Travoprost ophthalmic solution (new formulation), 1 of 3 dose levels, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
9489300|NCT00670033|Active Comparator|TRAVATAN|Travoprost ophthalmic solution 0.004%, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
9489301|NCT00670033|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
9489302|NCT00668772|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
9489303|NCT00668772|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
9489304|NCT00668772|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
9489305|NCT00668772|Active Comparator|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
9489306|NCT00668772|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
9489307|NCT00668187||Gangliosidosis Diseases Study Population|This study observes one cohort: 42 infantile or juvenile Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis affected subjects; and 10 late-onset gangliosidosis disease affected subjects.
9489308|NCT00667953|Experimental|Arm A:|
9489309|NCT00667654|Experimental|100-200 µg CNTX-4975|single dose
9489310|NCT00667654|Experimental|300-425 µg CNTX-4975|Total dose delivered as two separate lower doses
9489311|NCT00667654|Experimental|600-700 µg CNTX-4975|Total dose delivered as two separate lower doses
9489312|NCT00667654|Experimental|800 µg CNTX-4975|Total dose delivered as two separate lower doses
9489313|NCT00667654|Experimental|900-1000 µg CNTX-4975|Total dose delivered as two separate lower doses
9489314|NCT00667173|Experimental|1|
9489315|NCT00667173|Placebo Comparator|2|
9489316|NCT00667173|Placebo Comparator|3|
9489317|NCT00666900|Experimental|1|
9489318|NCT00666900|Experimental|2|
9489319|NCT00666900|Placebo Comparator|3|
9489320|NCT00666497|Experimental|A|Azacitidine
9489321|NCT00666497|Experimental|B|MGCD0103
9489322|NCT00666497|Experimental|C|Azacitidine + MGCD0103
9489323|NCT00665223|Experimental|ACR16 - once daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, ACR16 45 mg capsule and one placebo capsule were taken as two separate doses.
9489324|NCT00665223|Experimental|ACR16 - twice daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, an ACR16 45 mg capsule was taken twice daily as two separate doses (total dose: 90 mg).
9489325|NCT00665223|Placebo Comparator|Placebo|Participant received a placebo capsule once daily for four weeks. Weeks 5-26, a placebo capsule was taken twice daily as two separate doses.
9489326|NCT00665145|Experimental|1|Cohort 1
9489327|NCT00665145|Experimental|2|Cohort 2
9489328|NCT00665145|Placebo Comparator|3|Cohort 3
9489329|NCT00665145|Experimental|4|Cohort 4
9489330|NCT00664716|Placebo Comparator|Placebo|subcutaneous administration of placebo given for 12 weeks
9489331|NCT00664716|Experimental|One Dose|BG9924 - dosage level administered as per Biogen Idec protocol
9489332|NCT00664716|Experimental|Second Dose|BG9924 - dosage level administered as per Biogen Idec protocol
9489333|NCT00664716|Experimental|Third Dose|BG9924 - dosage level administered as per Biogen Idec protocol
9489334|NCT00664716|Experimental|Fourth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
9489335|NCT00664716|Experimental|Fifth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
9489336|NCT00664664|Experimental|1|APD125 20 mg
9489337|NCT00664664|Experimental|2|APD125 40 mg
9489338|NCT00664664|Placebo Comparator|3|Matching Placebo
9489339|NCT00664625|Experimental|1|"BMS-791325 (100 mg)~or~placebo match for (100 mg)"
9489340|NCT00664625|Experimental|2|"BMS-791325 (300 mg)~or~placebo match for (300 mg)"
9489341|NCT00664625|Experimental|3|"BMS-791325 (900 mg)~or~placebo match for (900 mg)"
9489342|NCT00664625|Experimental|4|"BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)"
9489343|NCT00664573|Experimental|Group 2|Drug: BG9924 - dose administered as per Biogen-Idec protocol
9489344|NCT00664573|Experimental|Group 1|Drug: BG9924 - dose administered as per Biogen-Idec protocol
9489345|NCT00664573|Experimental|Group 3|Drug: BG9924 - dose administered as per Biogen-Idec protocol
9489346|NCT00664573|Experimental|Group 4|Drug: BG9924 - dose administered as per Biogen-Idec protocol
9489347|NCT00664482|Experimental|1|AGS-006
9489348|NCT00664378|Experimental|I|CYT997
9489349|NCT00664027|Experimental|25 mg|25 mg RTA 402 (Bardoxolone methyl)/Stratum 1
9489350|NCT00664027|Experimental|75 mg|75 mg RTA 402 (Bardoxolone methyl)/Stratum 1
9489351|NCT00664027|Experimental|150 mg|150 mg RTA 402 (Bardoxolone methyl)/Stratum 1
9489352|NCT00664027|Experimental|25/75 mg|25 mg -> 75 mg RTA 402 (Bardoxolone methyl)/Stratum 2
9489353|NCT00663936|Experimental|1|T-817MA once daily
9489354|NCT00663936|Placebo Comparator|2|Placebo once daily
9489355|NCT00663767|Placebo Comparator|Placebo|
9489356|NCT00663767|Experimental|Placebo, ARRY-371797|
9489357|NCT00663767|Experimental|ARRY-371797, Placebo|
9489358|NCT00663767|Experimental|ARRY-371797|
9489359|NCT00663767|Active Comparator|Celecoxib, Placebo|
9489360|NCT00663767|Experimental|Celecoxib, ARRY-371797|
9489361|NCT00662740|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
9489362|NCT00662740|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
9489363|NCT00662740|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
9489364|NCT00662740|Active Comparator|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
9489365|NCT00662740|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
9489366|NCT00662597|Experimental|ASA404|
9489367|NCT00662597|Placebo Comparator|ASA40 Placebo|
9489368|NCT00662506|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy, IMRT)|See Detailed Description
9489369|NCT00662389|Experimental|A|
9489370|NCT00660959|Experimental|Active Comparator|lixivaptan
9489371|NCT00660959|Placebo Comparator|Placebo|placebo
9489372|NCT00660881|Experimental|EMAB|1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
9489373|NCT00659061|Active Comparator|Intervention|Multiple micronutrient fortificant (Sprinkles) and nutrition education given by LHWs.
9489374|NCT00659061|No Intervention|Control|Routine public health massages by Lady Health Workers (LHWs) during their community visits.
9489375|NCT00658762|Experimental|PD 0332334 225 mg BID|
9489376|NCT00658762|Experimental|PD 0332334 300 mg BID|
9489377|NCT00658762|Active Comparator|Paroxetine 20 mg q am|
9489378|NCT00658762|Placebo Comparator|Placebo BID|
9489379|NCT00658372|Experimental|PD 0332334 225 mg BID|
9489380|NCT00658372|Experimental|PD 0332334 300 mg BID|
9489381|NCT00658372|Active Comparator|Paroxetine 20 mg QD|
9489382|NCT00658372|Placebo Comparator|Placebo BID|
9489383|NCT00658086|Active Comparator|1|ALN-RSV01
9489384|NCT00658086|Placebo Comparator|2|Normal saline
9489385|NCT00658047|Experimental|0.25 mg CH-1504|0.25 mg CH-1504
9489386|NCT00658047|Experimental|0.5 mg CH-1504|0.5 mg CH-1504
9489387|NCT00658047|Experimental|1.0 mg CH-1504|1.0 mg CH-1504
9489388|NCT00658047|Active Comparator|Methotrexate|Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks
9489389|NCT00658008|Experimental|PD 0332334 175 mg BID|
9489390|NCT00658008|Experimental|PD 0332334 225 mg BID|
9489391|NCT00658008|Experimental|PD 0332334 75 mg BID|
9489392|NCT00658008|Active Comparator|Paroxetine 20 mg QD|
9489393|NCT00658008|Placebo Comparator|Placebo BID|
9489394|NCT00657826|Experimental|19mm arotic valve implant|Single arm study for patients who require a smaller valve size of the ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm.
9489395|NCT00657501|Experimental|testosterone gel|1% testosterone transdermal gel
9489396|NCT00657501|Placebo Comparator|Placebo gel|placebo transdermal gel
9489397|NCT00657189|Experimental|1|MEDI-545
9489398|NCT00657189|Experimental|2|MEDI-545
9489399|NCT00657189|Experimental|3|MEDI-545
9489400|NCT00657189|Experimental|4|MEDI-545
9489401|NCT00657189|Placebo Comparator|5|Placebo
9489402|NCT00656890|Placebo Comparator|2|sterile saline for injection
9489403|NCT00656890|Experimental|1|MDX-1100 for injection
9489404|NCT00656539|Experimental|1|AzaSite®
9489405|NCT00656539|No Intervention|2|
9489406|NCT00656357|Placebo Comparator|A|SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo
9489407|NCT00656357|Experimental|B|Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo
9489408|NCT00656097|Experimental|A|CL184 combined with rabies vaccination
9489409|NCT00656097|Active Comparator|B|HRIG combined with rabies vaccination
9489410|NCT00656097|Placebo Comparator|C|Placebo combined with rabies vaccination
9489411|NCT00655369|Experimental|15 mg|
9489412|NCT00655369|Experimental|25 mg|
9546656|NCT03057236|Experimental|Cognitive Behavior Coping Skills|The CBCS intervention is a structured module-based group intervention involving 9, 2-hour sessions. Participants will participate in 4 weekly sessions before HCV treatment to learn and practice new cognitive behavioral skills, and 5 sessions during HCV treatment at weeks 2, 4, 6, 8, and 12.
10040838|NCT01857479|Experimental|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
9489413|NCT00655369|Experimental|35 mg|
9489414|NCT00655369|Experimental|5 mg|
9489415|NCT00655369|Experimental|50 mg|
9489416|NCT00655369|Placebo Comparator|Placebo|
9489417|NCT00654992|Active Comparator|EPO group|
9489418|NCT00654992|Placebo Comparator|Placebo group|
9489419|NCT00654706|Experimental|Sertindole|
9489420|NCT00654706|Active Comparator|Quetiapine|
9489421|NCT00653185|Experimental|SYR-472 25 mg QD|(with lifestyle modification and/or metformin therapy)
9489422|NCT00653185|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin therapy)
9489423|NCT00653185|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin therapy)
9489424|NCT00653185|Experimental|SYR-472 200 mg QD|(with lifestyle modification and/or metformin therapy)
9489425|NCT00653185|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin therapy)
9489426|NCT00651508|Experimental|Single Arm 25mg/m2|KOS-1584 25mg/m2
9489427|NCT00650949|Experimental|CYT997|
9489428|NCT00650702|Experimental|1|Low Latanoprost-PPDS
9489429|NCT00650702|Experimental|2|Medium Latanoprost-PPDS
9489430|NCT00650702|Experimental|3|High Latanoprost-PPDS
9489431|NCT00649025|Experimental|1|FlutiForm 250/10ug
9489432|NCT00649025|Active Comparator|2|SKP Fluticasone 250ug
9489433|NCT00649025|Active Comparator|3|Flovent Fluticasone HFA
9489434|NCT00647231|Experimental|A, 2, II, HKT-500 Topical Patch|A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
9489435|NCT00647231|Placebo Comparator|Placebo Patch|Treatment with placebo patch
9489436|NCT00646542|Experimental|1|
9489437|NCT00646542|Placebo Comparator|2|
9489438|NCT00645177|Active Comparator|A|"In study, this arm is a randomized (blinded) to ABT-869 arm plus paclitaxel.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
9498266|NCT03467828|No Intervention|Control Group|Infants born in similar gestational week and birth weight but not diagnosed with BPD.
9498267|NCT03467776||healthy|healthy control, 5 months to 3 years
9498268|NCT03467776||wheezing with atopy|suspected asthma with wheezing (>3 episodes per year) and atopy
9498269|NCT03467776||wheezing without atopy|wheezing without atopy
9498270|NCT03467750|Experimental|Ketorolac|Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved
9498271|NCT03467750|Active Comparator|Standard of Care|Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure.
9498272|NCT03467737|Experimental|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
9498273|NCT03467737|Experimental|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
9498274|NCT03467737|Experimental|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
9498275|NCT03467737|Experimental|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
9498276|NCT03467737|Experimental|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
9498277|NCT03467737|Experimental|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
9498280|NCT03467698|Experimental|Active tDCS|active HD-tDCS will be administered
9498281|NCT03467698|Sham Comparator|Sham tDCS|sham HD-tDCS will be administered
9498282|NCT03467672||Infected patients|
9498283|NCT03467672||Control group|
9498284|NCT03467659|Experimental|Cracked whole wheat porridge|Large particle whole wheat porridge
9498285|NCT03467659|Experimental|Semolina wheat porridge|Large particle refined wheat porridge
9498286|NCT03467659|Experimental|Whole wheat flour porridge|Small particle whole wheat porridge
9498287|NCT03467659|Experimental|Refined wheat flour porridge|Small particle refined wheat porridge
9498288|NCT03467659|Experimental|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
9498289|NCT03467659|Experimental|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
9498290|NCT03467646|Active Comparator|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
9498291|NCT03467646|Active Comparator|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
9498292|NCT03467646|Experimental|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
9546657|NCT03057262||Study group|Study group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the study group was used the typical acrylic anterior repositioning splint fabricated in tete-a-tete (incisal) jaws position, covered the lower teeth arch to recapture a displaced disc(s) and decrease the intensity of pain. The anterior repositioning splint was recommended to 20 - hour use for a period of four months.
9546658|NCT03057262||Control group|Control group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the control group the investigators used the biostymulation laser (Terapus 2, Accuro, Poland), wave length 808 nm, power 32 J in the form of 12 session (duration of a single session was 3 min 45 s), performed every second day, on the area of the both temporomandibular joints (distance to the skin was 1 cm) with opened mouth and systematic performing of muscles self-exercises with a dominant protrusive position of mandible.
9546659|NCT03057392|Experimental|immersion and them sham procedure|"hemodialysis patients will do a 3 hours dialysis session while sitting in a bath and then have a dry session outside the bath"
9546660|NCT03057392|Sham Comparator|sham session and then immersion|dialysis patients will have a 3 hour dialysis session (dry session) and then immersion
9546661|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
9546662|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
9546663|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
9546664|NCT03057483||Post partum women|Women who have given birth < 45 days seasonal influenza vaccine
9546665|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
9546666|NCT03057340|Experimental|DRibble vaccine|Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.
9546667|NCT03057535|Experimental|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
9546668|NCT03057535|Placebo Comparator|Sodium Chloride|Ingestion of sodium chloride (4 g)
9546669|NCT03057457||Kidney Injury|
9546670|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
9546671|NCT03057652|Experimental|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
9546672|NCT03057652|Experimental|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
9546673|NCT03057652|Experimental|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
9546674|NCT03057652|Experimental|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
9546675|NCT03057652|Experimental|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
9546676|NCT03057652|Experimental|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
9546677|NCT03057444|Experimental|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
9546678|NCT03057405||intra-operative CBCT|
9546679|NCT03057405||3D virtual planning + intra-operative navigation|
9546680|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
9546681|NCT03057184|Experimental|Intervention group|behavioral intervention program
9546682|NCT03057184|No Intervention|Usual care|Usual care
9546683|NCT03057288|Experimental|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
9546684|NCT03057197|No Intervention|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
9546685|NCT03057197|Experimental|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
9546686|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
9546687|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
9546688|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
9546689|NCT03057171||health individuals|patients who will undergo screening EGD
9546690|NCT03057223|Experimental|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
9546691|NCT03057210|No Intervention|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
9546692|NCT03057210|Experimental|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
9546693|NCT03057210|Experimental|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
9546694|NCT03057210|Experimental|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
9546695|NCT03057210|Experimental|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
9546696|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
9546697|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
9546698|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
9546699|NCT03057470|Active Comparator|0% Bolus Insulin Correction|0% Bolus Insulin Correction
9546700|NCT03057470|Active Comparator|50% Bolus Insulin Correction|50% Bolus Insulin Correction
9546701|NCT03057470|Active Comparator|100% Bolus Insulin Correction|100% Bolus Insulin Correction
9546702|NCT03057470|Active Comparator|150% Bolus Insulin Correction|150% Bolus Insulin Correction
9546703|NCT03057314|Experimental|Amorphous calcium carbonate|"The investigation product will include:~ACC tablets, containing 200 mg elemental calcium~1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
9546704|NCT03057574|Experimental|Treatment|Follitropin Alfa (Gonapure)
9546705|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using Dotarem contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Dotarem
9546706|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using a Gadovist contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Gadovist
9546707|NCT03057080|Other|PTA procedure|Percutaneous transluminal angioplasty (PTA) in patients with ischemic leg ulcer
9546708|NCT03057158||1|Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
9546709|NCT03057158||2|Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
9546710|NCT03057158||3|Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
9546711|NCT03057158||4|Healthy Volunteers
9546712|NCT03057093||TIII>TI|Subjects with TIII>TI in initial ECG
9546713|NCT03057093||Non TIII>TI|Subjects without TIII>TI in initial ECG
9546714|NCT03057145|Experimental|Prexasertib Combine with Olaparib|"Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.~Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
9616833|NCT02538913|Experimental|Exercise training|Patients randomized to the exercise training group will be individually instructed in correct pelvic floor muscle contractions and intensive pelvic floor muscle training to perform daily. In addition they will be encouraged to exercise regularly ≥3 days/week. The exercise program will be individualized and consisting of both aerobic and strength exercise training.
9616834|NCT02538913|Active Comparator|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
9616835|NCT02538926|Experimental|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
9616836|NCT02538939|Experimental|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
9616837|NCT02538705|Experimental|Neovasculgen|
9546715|NCT03056781|Experimental|social interaction|Participants will engage in a social interaction with another person
9546716|NCT03056781|Experimental|food consumption|Participants will be offered food stuffs to eat/drink
9546717|NCT03056989|Experimental|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
9546718|NCT03056989|Experimental|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
9546719|NCT03056989|Experimental|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
9546720|NCT03056820|Active Comparator|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
9546721|NCT03056820|Active Comparator|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
9546722|NCT03057041|Experimental|Fentanyl|
9546723|NCT03057041|Placebo Comparator|Placebo|
9546724|NCT03056807|Active Comparator|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
9546725|NCT03056807|Active Comparator|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
9546726|NCT03056885|Experimental|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
9546727|NCT03056885|Experimental|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
9546728|NCT03057067|Experimental|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
9546729|NCT03056846|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
9546730|NCT03056846|Experimental|Probiotic Combination|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
9546731|NCT03056846|Experimental|Bifidobacterium bifidum|A commercially available probiotic strain (Bifidobacterium bifidum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
9546732|NCT03056846|Experimental|Bifidobacterium longum|A commercially available probiotic strain (Bifidobacterium longum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
9546737|NCT03056768|Active Comparator|active control|Health promotion provided by local health bureau.
9546738|NCT03056768|Experimental|multidomain intervention|1-year multidomain health promotion (physical activities, cognitive training, nutritional sessions)
9546739|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
9546740|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
9546741|NCT03056963|Experimental|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
9546742|NCT03056963|Placebo Comparator|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
9546743|NCT03056950|No Intervention|non-oclusion training group|The control (non-occlusion training) group will follow the standard s/p distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
9546744|NCT03056950|Active Comparator|occlusion traingn with tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being used. Intervention: Occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
9546745|NCT03056937||Obese with metabolic syndrome|bariatric surgery
9546746|NCT03056937||Obese without metabolic syndrome|bariatric surgery
9546747|NCT03056937||Healthy|Control
9546748|NCT03057015|Experimental|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
9546749|NCT03057015|Placebo Comparator|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
9546750|NCT03056924||Vedolizumab monotherapy|IBD patients on vedolizumab monotherapy, all patients will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
9546751|NCT03056924||vedolizumab + immunomodulator|IBD patients receiving combination treatment with vedolizumab and concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine), will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and/or receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
9546752|NCT03056924||biologic + immunomodulator|IBD patients on other biologic therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab) with concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine) and receivePneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
9546753|NCT03056924||non-immunosuppressive therapy|IBD patients not taking any immunosuppressive therapy (these patients may be taking oral or topical 5-aminosalicylates) and recive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
9616838|NCT02538848|Experimental|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
9546754|NCT03056833|Experimental|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
9546755|NCT03057028|Experimental|anakinra|Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
9546756|NCT03056976|Experimental|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
9546757|NCT03056976|Experimental|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
9546758|NCT03056976|Experimental|Fixed mandibular denture|A fixed four-implant mandibular denture
9546759|NCT03056729|Experimental|Cohort HV1|
9546760|NCT03056729|Experimental|Cohort HV2|
9546761|NCT03056729|Experimental|Cohort HV3|
9546762|NCT03056729|Experimental|Cohort HV4|
9546763|NCT03056729|Experimental|Cohort HV5|
9546764|NCT03056729|Experimental|Cohort AD1|
9546765|NCT03056742|Experimental|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
9546766|NCT03056716|Experimental|Silastic drain|Placement of 19FR silastic drain as basal drain
9546767|NCT03056716|Active Comparator|Conventional drain|Placement of 32FR conventional drain as basal drain
9546768|NCT03056612||Group 1|Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
9546769|NCT03056612||Group 2|Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
9546770|NCT03056612||ACLF|ACLF-patients were specified the patients who were admitted at hospital with ACLF,
9546771|NCT03056521|Experimental|Info|"In this arm the patients are counseled preoperatively about post operative pain.~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
9546772|NCT03056521|No Intervention|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
9546773|NCT03056495|Experimental|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
9546774|NCT03056560|Experimental|Video Bystander Program|TakeCARE video
9546775|NCT03056560|No Intervention|Control Video|Study Skills Video
9546776|NCT03056586|Experimental|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.~Follow-up will be after 3, 6, and 12 month period."
9546777|NCT03056586|No Intervention|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
9546778|NCT03056664|Experimental|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
9546779|NCT03056664|Experimental|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
9546780|NCT03056664|Experimental|Ctrl|Patient in this arm will receive routine surgery and local NS injection
9546781|NCT03056677|Experimental|Control|No Whey Protein
9546782|NCT03056677|Experimental|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
9546783|NCT03056677|Experimental|Modified Whey|Modified whey protein will be given
9546784|NCT03056625|Experimental|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
9546785|NCT03056625|Placebo Comparator|Control|Participant will be given normal rice 1 meal/day
9546786|NCT03056508|Experimental|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
9546787|NCT03056508|Active Comparator|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
9546788|NCT03056547|Experimental|Induced dyspnea|
9546789|NCT03056703|Experimental|Acetylsalicylic acid [1000mg]|
9546790|NCT03056703|Active Comparator|Acetylsalicylic acid [500mg]|
9546791|NCT03056482|Active Comparator|Ondansetron 8mg|8mg Ondansetron prepared in a 100mL normal saline mini-bag
9546792|NCT03056482|Experimental|Haloperidol 0.05mg/kg|0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
9546793|NCT03056482|Experimental|Haloperidol 0.1mg/kg|0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
9546794|NCT03056599|Experimental|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
9546795|NCT03056430|Experimental|Training Group 1|Slackline training
9546796|NCT03056430|Experimental|Training Group 2|Slackline training
9546797|NCT03056391|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
9546798|NCT03056391|No Intervention|No Paracetamol|"No Paracetamol plus IV artesunate or oral artemether/lumefantrine.~If temperature >39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives."
9616839|NCT02538848|Experimental|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
9546799|NCT03056443|Experimental|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
9546800|NCT03056443|No Intervention|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
9546801|NCT03056404|Experimental|control subject|additional blood sample and 15 control subjects will be seen in consultations in the service of pneumology. The visit will include an auscultation, a respiratory functional exploration and a blood test (2 tubes of 7 ml of total blood). A questionnaire of exhibition will be realized to collect the species of birds and the times of exhibition.
10040839|NCT01857492|Sham Comparator|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability [29] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study [30]. Subjects will also meditate while receiving stimulation
9546802|NCT03056651|Other|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
9546803|NCT03056469|Active Comparator|Care providers do have access to PROs|Participants complete patient-reported outcome (PRO) questionnaires. Care providers do have access to the PROs and use them in clinical decision making.
9546804|NCT03056469|Active Comparator|Care providers do not have access to PROs|The participants complete patient-reported outcome (PRO) questionnaires. Care providers do not have access to the PROs.
9546805|NCT03056469|No Intervention|Control group|Standard follow-up. The participants do not complete PRO questionnaires.
9546806|NCT03056378|Experimental|Pooled RBCs|Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated
9546807|NCT03056378|Active Comparator|Standard RBCs|Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)
9546808|NCT03056365|Experimental|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
9546809|NCT03056365|Active Comparator|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
9546810|NCT03056326|Experimental|CHF6333 Active|
9546811|NCT03056326|Placebo Comparator|Placebo|
9546812|NCT03056417|Experimental|Intervention|Participants in the Complete Health Improvement Program.
9546813|NCT03056417|No Intervention|No Change to Treatment|Participants who choose not to participate in the Complete Health Improvement Program.
9546814|NCT03056287|Experimental|Aerobic Exercise|Treadmill aerobic exercise
9546815|NCT03056287|Experimental|rTMS|repetitive transcranial magnetic stimulation
9546816|NCT03056287|Experimental|AET+rTMS|Combined aerobic exercise and rTMS
9546817|NCT03056287|Sham Comparator|Sham|Sham rTMS
9546818|NCT03056170|Active Comparator|Active tDCS|The anode is placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode is placed over the left temporo-parietal cortex (TPJ) In active stimulation with a Transcranial Direct Current Stimulation, the device will deliver a charge of 1 mA for 30 minutes.
9546819|NCT03056170|Sham Comparator|Sham tDCS|In sham stimulation, with a Transcranial Direct Current Stimulation, no current will be delivered from one electrode to the other except one 30 s ramp up and down at the beginning and one at the end of the sham stimulation duration (30 min) Same electrode montage than in the active group.
9546820|NCT03056183|Experimental|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
9546821|NCT03056183|No Intervention|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
9546822|NCT03056274|Active Comparator|Metformin arm|Metformin
9546823|NCT03056274|Active Comparator|Ursodeoxycholic acid|Ursodeoxycholic acid
9546824|NCT03056131|Experimental|Diacutaneous Fibrolysis Treatment|
9546825|NCT03056131|No Intervention|Control Group|
9546826|NCT03056118|Experimental|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
9546827|NCT03056118|Active Comparator|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
9546828|NCT03056118|Active Comparator|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
9546829|NCT03056118|Active Comparator|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
9546830|NCT03056209|Experimental|KL1333 25mg|Group 1
9546831|NCT03056209|Experimental|KL1333 50mg|Group 2
9546832|NCT03056209|Experimental|KL1333 100mg|Group 3
9546833|NCT03056209|Experimental|KL1333 200mg|Group 4
9546834|NCT03056209|Experimental|KL1333 400mg|Group 5
9546835|NCT03056209|Experimental|KL1333 600mg|Group 6
9546836|NCT03056209|Experimental|KL1333 800mg|Group 7
9546837|NCT03056079|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
10040840|NCT01857492|Active Comparator|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS [5]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
10040841|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
10040842|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
9546838|NCT03056053|Other|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
9546839|NCT03056261|Experimental|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
9546840|NCT03056261|Placebo Comparator|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
9546841|NCT03056092|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
9546842|NCT03056248|Active Comparator|Lithium|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
9546843|NCT03056248|Placebo Comparator|Placebo|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
9546844|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
9546845|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
9546846|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
9546847|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
9546848|NCT03055962|Experimental|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
9546849|NCT03055962|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 days.
9546850|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
9546851|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
9546852|NCT03055949|No Intervention|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
9546853|NCT03055949|Experimental|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
9546854|NCT03056235|Experimental|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
9546855|NCT03056235|Placebo Comparator|Saline control|Saline
9546856|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
9546857|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
9546858|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
9546859|NCT03055663|Experimental|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
9546860|NCT03055663|Active Comparator|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
9546861|NCT03055702|Experimental|SMS group|receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
9546862|NCT03055702|No Intervention|Usual care group|Usual care, either telephone reminder or no reminder
9616840|NCT02538848|Experimental|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
9546863|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
10040843|NCT01857518|Other|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
9546864|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
9546865|NCT03055559||Globifer Forte|
9546866|NCT03055637|Active Comparator|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
9546867|NCT03055637|Active Comparator|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
9546868|NCT03055741|Experimental|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
9546869|NCT03055741|Experimental|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
9546870|NCT03055741|Placebo Comparator|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
9546871|NCT03055689|Experimental|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
9546872|NCT03055689|Active Comparator|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
9546873|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
9546874|NCT03055780||CT-FFR. CTA. FFR|59 patients with suspected CAD that have been scheduled for an interventional FFR study
9546875|NCT03055767|Other|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
9546876|NCT03055767|Other|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
9546877|NCT03055754|Experimental|Argon randomized arm|Endoscopic procedure with a full inventory, measurement of the anastomosis diameter, and an argon plasma coagulation. Followup of all patients by a multidisciplinary team (life, food orientations).
9546878|NCT03055754|Active Comparator|Control arm|Full inventory and measurement of the anastomosis diameter, without any intervention. Followup of all patients by a multidisciplinary team (life, food orientations).
9546879|NCT03055819|Experimental|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
9546880|NCT03055845|Experimental|STA363 dose 1|
9546881|NCT03055845|Experimental|STA363 dose 2|
9546882|NCT03055845|Experimental|STA363 dose 3|
9546883|NCT03055845|Placebo Comparator|Placebo|
9546884|NCT03055533|Experimental|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment. Participation may be in clinic or via telehealth.
9546885|NCT03055533|No Intervention|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks). Participation may be in clinic or via telehealth.
9546886|NCT03055572|Experimental|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
9546887|NCT03055572|Active Comparator|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
9546888|NCT03055572|No Intervention|Control Group|The control group will continue the medical therapy prescribed by their provider.
9546889|NCT03055546|Experimental|Oxytocin|intranasal administration of oxytocin
9546890|NCT03055546|Placebo Comparator|Placebo|intranasal administration of placebo
9546891|NCT03055676|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 166)
9546892|NCT03055676|Active Comparator|Late drain removal|Removing drain(s) on postoperative day 5 or later (n = 166)
10040844|NCT01857518|Other|Healthy adolescent control Group|Healthy adolescents recruited from general population
9546893|NCT03055585|Experimental|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
9546894|NCT03055585|Other|Comparison arm|Standard practice dengue control activities
9546895|NCT03055598|Experimental|Ferric Citrate|Ferric Citrate (Auryxia) will be dosed initially at 2 tablets three times a day (with meals).
9546896|NCT03055429|Experimental|Full Scale Unit|Testing of 6 modules
9546897|NCT03055520|Experimental|arithmetic training (Kumon method)|
9546898|NCT03055520|Placebo Comparator|nonspecific recreation|
9546899|NCT03055455||Sepsis|Children with severe sepsis or septic shock
9546900|NCT03055507|Active Comparator|Control|Standard pain regimen of acetaminophen 650 mg q6hrs while awake until cessation of need for scheduled pain medication with the addition of oxycodone 5 mg q3 hrs PRN pain.
9546901|NCT03055507|Experimental|Ibuprofen|Alternating every 3 hours acetaminophen 650 mg and ibuprofen 400 mg while awake until cessation of need for schedule pain medication with the addition of oxycodone 5 mg q3hr PRN pain.
10040845|NCT01857544|Experimental|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
10040846|NCT01857557|Experimental|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
10040847|NCT01857557|No Intervention|Control Group|Patients receiving usual headache care but no exercise program
9546902|NCT03055481|Active Comparator|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
9546903|NCT03055481|Experimental|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
10040848|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
10040849|NCT01857596|Experimental|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
9546904|NCT03055208|Experimental|Radiosurgery|"Following intraoperative confirmation of glioblastoma (frozen section):~Early (24-72h post surgery) stereotactic ablation (gamma knife radiosurgery) of residual tumor (defined in early postoperative T1-weighted MRI scanning with and without contrast), followed by standard-of-care therapy (chemo-radiotherapy with 60 Gy external beam radiation therapy (EBRT) and 75 mg/m2/d temozolomide, followed by adjuvant chemotherapy with 150-200 mg/m2/d/cycle temozolomide in a 5/28 days schedule)."
9546905|NCT03055234|Experimental|Oral Treprostinil|Extended-release oral tablet for three times daily (TID) administration
9546906|NCT03055234|Placebo Comparator|Placebo|Placebo (sugar pill) for TID administration
9546907|NCT03055312|Active Comparator|TPC chemotherapy|"Conventional chemotherapy(choose a):~TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)"
9546908|NCT03055312|Experimental|Bicalutamide|Bicalutamide 150mg/day every 28 days
9546909|NCT03055351|No Intervention|Control group|Participants will complete the outcome measures but will not receive any intervention.
9546910|NCT03055351|Experimental|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
9546911|NCT03055468|Experimental|Peer Support|Participants in this group will receive peer support as well as antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
9546912|NCT03055468|Active Comparator|No Peer support|Participants will only receive antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
9616841|NCT02538848|Experimental|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
9616842|NCT02538796|Experimental|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
9616843|NCT02538796|Experimental|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
9616844|NCT02538796|Experimental|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
9616845|NCT02538796|Experimental|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
9616846|NCT02538796|Active Comparator|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
9616847|NCT02538796|Active Comparator|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
9616848|NCT02538796|Active Comparator|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
9616849|NCT02538796|Active Comparator|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
9616850|NCT02538692|Experimental|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
9616851|NCT02538692|Placebo Comparator|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
9616852|NCT02538770|Experimental|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
10040850|NCT01857609|Experimental|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
10040851|NCT01857609|Experimental|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
9616853|NCT02538770|Active Comparator|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
10040852|NCT01857609|Experimental|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
9616856|NCT02538718|Active Comparator|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
9616857|NCT02538718|Experimental|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
9616858|NCT02538835|Experimental|Metacognitive Therapy|
9616859|NCT02538835|Active Comparator|Mindfulness based cognitive therapy|
9616860|NCT02538835|Placebo Comparator|Support groups|
9616861|NCT02538640|Experimental|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
9616862|NCT02538640|Active Comparator|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
9616863|NCT02538601|Experimental|CBT-A|An 8-session, CBT-based group smoking cessation program (CBT-A) enhanced with transdiagnostic skills for the management of anxiety and fear-based avoidance behaviors.
9616864|NCT02538601|Active Comparator|CBT-S|An 8-session, CBT-based, traditional group CBT based smoking cessation program.
9616865|NCT02538627|Experimental|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
9546913|NCT03055247|Experimental|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
9546914|NCT03055117|Experimental|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
9546915|NCT03055117|Active Comparator|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
9546916|NCT03055117|Active Comparator|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
9546917|NCT03055169||intensive care patients|patients with a least one organ dysfunction
9546918|NCT03055442||Follicular Fluids|Follicular fluids obtained by 8 oocyte donors
9546919|NCT03055377|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
9546920|NCT03055377|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
9546921|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
9546922|NCT03055143|Experimental|SPARC-08-038|2 mg/ml
9546923|NCT03055143|Active Comparator|Ref-08-038|
9546924|NCT03055299|Experimental|COMEX|Patients receive comprehensive exercise intervention
9546925|NCT03055130||Case group|Female IBD patients who had sexual life between 21-60 years-old were recruited.
9546926|NCT03055130||control group|Female people who perform physical examination in our hospital between 21-60 years-old were recruited as control during the study period.
9546927|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI<13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
9546928|NCT03055273|Experimental|SOCIABLE IMMEDIATE|Receive services now
9546929|NCT03055273|Active Comparator|SOCIABLE wait list|Receive services four months post-enrollment
9546930|NCT03055182|Experimental|Low back pain patients|Subjects included in physical rehabilitation program.
9546931|NCT03055182|No Intervention|Control subjects|No intervention administered
9546932|NCT03055091|Experimental|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
9546933|NCT03055091|Placebo Comparator|Placebo|Participants in the placebo arm will receive sorbitol syrup.
9546934|NCT03055078|Experimental|mesenchymal stem cells|According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion.
9546935|NCT03054896|Experimental|VR-EPOCH|"Standard chemotherapy regimen, DA-EPOCH-R, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~Chemotherapy cycles will be administered approximately every 3 weeks~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
9546936|NCT03054896|Experimental|VR-CHOP|"Standard chemotherapy regimen, R-CHOP, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~Chemotherapy cycles will be administered approximately every 3 weeks~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
9546937|NCT03055052|Active Comparator|Control Formula|Standard formula for preterm infants.
9546938|NCT03055052|Experimental|Experimental formula|Formula with higher protein and new fat blend for preterm infants.
9546939|NCT03054948|Experimental|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
9546940|NCT03054948|Active Comparator|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
9546941|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI >150 active; CDAI < 150 quiescent)
9546942|NCT03054727||Villalta phone score > or = to 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call
9546943|NCT03054727||Villalta phone score < 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call
9546944|NCT03054987|Active Comparator|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
9546945|NCT03054987|Active Comparator|ERCP|At ERCP, the common bile duct will be selectively cannulated using a sphincterotome and guide wire technique. Once biliary access is obtained a stent will be deployed to facilitate biliary drainage.
9546946|NCT03054831|Active Comparator|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
9546947|NCT03054831|Active Comparator|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
9546948|NCT03054831|Active Comparator|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
9546949|NCT03054831|Active Comparator|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
9546950|NCT03054974|Experimental|Modern rehabilitation treatment|Modern rehabilitation treatment
9546951|NCT03054974|Experimental|Modern rehabilitation &TCM|Modern rehabilitation treatment and traditional Chinese medicine
9546952|NCT03054974|Experimental|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment and Baimai Ruangao
9546953|NCT03054974|Experimental|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine treatment
9546954|NCT03054766|Experimental|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Sham macular laser"
9546955|NCT03054766|Experimental|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
9546956|NCT03054753|Other|Abduction brace wearing time analysis|The abduction brace wearing time analysis is performed in patients, who undergo a rotator cuff repair with postoperative abduction brace treatment
9546957|NCT03054701|Experimental|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
9546958|NCT03054701|Active Comparator|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
9546959|NCT03054714|Active Comparator|group A|exchange of the infected catheter with a new one over a guidewire
9546960|NCT03054714|Active Comparator|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
9546961|NCT03054779|Experimental|Canola oil|regular canola oil
9546962|NCT03054779|Experimental|High oleic acid canola oil|high stability/high oleic canola oil
9546963|NCT03054779|Active Comparator|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
9546964|NCT03054688|Experimental|Somnotouch NIBP|Blood pressure measurement with Somnotouch-NIBP device in addition to standard cuff based device
9546965|NCT03054675||Pneumonia|"Patients suffering from postoperative pneumonia including all three of the following:~Clinical signs of a pulmonary infection (i.e. fever ≥ 38°C combined with productive cough and/or dyspnea)~A new rise of inflammatory markers (i.e. WBC count ≥ 10.5 x 109 and elevated CRP)~New radiographic infiltrates on chest x-ray without another explanation. Patients with pneumonia undergo spirometry before and on every second day after lung surgery"
9546966|NCT03054675||No Pneumonia|Patients without pneumonia undergo spirometry before and on every second day after lung surgery
9546967|NCT03054675||Open (no pneumonia)|"Patients undergoing open anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
9546968|NCT03054675||Minimally invasive (no pneumonia)|"Patients undergoing minimally invasive anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
10040853|NCT01857648|Experimental|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
10040854|NCT01857648|No Intervention|Control|Control group.
9546969|NCT03054662|Experimental|Patients with Haemophilia|Male patients with severe and moderate haemophilia A and B in Ivory Coast
9546970|NCT03054662|Experimental|Carriers for Haemophilia|Carriers for severe and moderate haemophilia A and B in Ivory Coast
9546971|NCT03054623||DRIL procedure|Adult (>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
9546972|NCT03054610|Active Comparator|Control|5 ml of local anesthetic (ropivacaine 7.5%)
9546973|NCT03054610|Active Comparator|Steroid|1ml of steroid Betamethason Sodium Phosphate (Celestone®) and local anesthetic (ropivacaine 7.5%)
9546974|NCT03054610|Experimental|BTX-A|200U Botulinum Toxins, Type A
9546975|NCT03054597|Experimental|Adults|"The arm consisted of adult participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks Peripheral Light Motion exercises: 4 times over 2 weeks"
9616866|NCT02538627|Experimental|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
10040855|NCT01857661|Other|control|hearing aid without an integrated sound generator
10040856|NCT01857661|Experimental|sound generator|hearing aid with an integrated sound generator
10040857|NCT01857687||patients with coronary artery stenosis|
9546976|NCT03054597|Experimental|Children|"The arm consisted of child participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks"
9546977|NCT03054415|Other|Healthy Subjects|
9546978|NCT03054545|Experimental|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
9546979|NCT03054311|Experimental|Lifestyle Matters intervention|
9546980|NCT03054532|Experimental|Durvalumab and lenalidomide|"Open-label use of 2 drugs:~Durvalumab 1500 mg intravenously on day 1 of a 28-day cycle until progressive disease or intolerance.~Lenalidomide orally on days 1 through 21 of each 28-day cycle for 6 cycles."
9546981|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
9546982|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
9546983|NCT03054441||Experimental group|Children, Adolescents and Young with hemiplegia
9546984|NCT03054441||Control group|Children, Adolescents and Young with typical development
9546985|NCT03054454|Active Comparator|intervention|This group will receive Podiatry treatment and care from the MDT which is the intervention group.
9546986|NCT03054454|No Intervention|comparator|This group will receive usual care
9546987|NCT03054480|Experimental|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
9546988|NCT03054480|Active Comparator|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
9546989|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
9546990|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
9546991|NCT03054402|Experimental|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
9546992|NCT03054402|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
9546993|NCT03054207|Experimental|HIV clopidogrel|clopidogrel 300 mg single dose oral route
9546994|NCT03054207|Experimental|HIV prasugrel|prasugrel 60 mg single dose oral route
9546995|NCT03054207|Active Comparator|Control clopidogrel|clopidogrel 300 mg single dose oral route
9546996|NCT03054207|Active Comparator|Control prasugrel|prasugrel 60 mg single dose oral route
9546997|NCT03054285|No Intervention|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
9546998|NCT03054285|Experimental|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
9546999|NCT03054467|Active Comparator|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
9547000|NCT03054467|Active Comparator|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
9547001|NCT03054168|Experimental|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
9547002|NCT03054168|Placebo Comparator|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
9547003|NCT03054168|Experimental|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
9547004|NCT03054168|Placebo Comparator|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
9547005|NCT03054220|Experimental|CYP2D6 gene score 1|carriers of 1 fully functional and 1non functional CYP2D6 alleles
9547006|NCT03054220|Experimental|CYP2D6 gene score 2|carriers of 2 fully functional CYP2D6 alleles
9547007|NCT03054233|Experimental|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
9547008|NCT03054233|Experimental|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
9547009|NCT03054259|Experimental|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
9547010|NCT03054259|Placebo Comparator|Control|2 x 100mg methylprednisolone plus placebo
9547011|NCT03054246|Other|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
9547012|NCT03054272||Residents|Anesthesia residents from University of Montreal Anesthesia Department who were watching the video
9547013|NCT03054272||Attending Physicians|Attending physicians from University of Montreal Anesthesia Department who were watching the video
9547014|NCT03054194|Experimental|Cohort 1: Dose 1 E2730|Participants will receive Dose 1 of oral E2730 on Day 1.
9547015|NCT03054194|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive matching oral placebo on Day 1.
9547016|NCT03054194|Experimental|Cohort 2: Dose 2 E2730|Participants will receive Dose 2 of oral E2730 on Day 1.
9547017|NCT03054194|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive oral matching placebo on Day 1.
9547018|NCT03054194|Experimental|Cohort 3: Dose 3 E2730|Participants will receive Dose 3 of oral E2730 on Day 1.
9547019|NCT03054194|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive oral matching placebo on Day 1.
9547020|NCT03054129|Experimental|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program. Balance training will be non-supervised program."
9547021|NCT03054129|Active Comparator|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program."
9547022|NCT03054012||CAS group|computer-assisted surgery group
9547023|NCT03054025|Experimental|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
9547024|NCT03053921|Placebo Comparator|recession coverage|30 recession defects treated with Zucchelli's technique.
9547025|NCT03053921|Active Comparator|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
9547026|NCT03053908|Experimental|Elderly Patients|
9547027|NCT03054142||AKI|
9547028|NCT03054142||non-AKI|
9547029|NCT03053765|Active Comparator|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
9547030|NCT03053765|Experimental|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
9547031|NCT03053765|Experimental|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
9547032|NCT03053765|No Intervention|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
9547033|NCT03053739|Active Comparator|Combination arm A-Sildenafil and Bosentan|"Combination Arm A -Intervention- Drug~Tab Sildenafil 20 mg - three times a day for 6 months,and~Tab Bosentan 62.5mg - twice a day for 6 months"
9547034|NCT03053739|Placebo Comparator|Monotherapy arm-Sildenafil and Placebo|Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
9547035|NCT03053726|Experimental|Variable Frequency Stimulation|Subjects in this group received variable frequency stimulation of deep brain stimulation
9547036|NCT03053726|Sham Comparator|Constant Frequency Stimulation|Subjects in this group received constant frequency stimulation of deep brain
9547037|NCT03053752|Experimental|Transcutaneous Electric Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
9547038|NCT03054090|Other|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
9547039|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
9547040|NCT03053934|Active Comparator|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
9547041|NCT03053934|Experimental|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
9547042|NCT03053986|Active Comparator|Apple polyphenols|White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)
9547043|NCT03053986|Placebo Comparator|Placebo|Indistinguishable capsules with similar dimension, colour, odour and taste
9547044|NCT03053856|Experimental|Pembrolizumab arm|Adjuvant Pembrolizumab
9547045|NCT03053843|Experimental|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
9547046|NCT03053843|No Intervention|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
9547047|NCT03053882|Active Comparator|green tea and peppermint|
9547048|NCT03053882|Active Comparator|peppermint and green tea|
9547049|NCT03053817|Experimental|Exercise group|The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
9547050|NCT03053817|No Intervention|Control|No treatment
9547051|NCT03053973|Experimental|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
9547052|NCT03053973|Other|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
9547053|NCT03053791|Experimental|Intervention group|Single-armed study. All patients will receive treatment.
9547054|NCT03053869|Experimental|Benzodiazepine - Limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
9547055|NCT03053869|Active Comparator|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
9547056|NCT03053947|Other|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
9547057|NCT03053895|Experimental|CSDH Bedside twist drill technique|For patients randomized to bedside drainage of Chronic Subdural Hematoma, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic.
9547058|NCT03053895|Active Comparator|CSDH Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
9547059|NCT03053830|Experimental|Intervention Group|Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.
9547060|NCT03053804|Experimental|MR/PET|hypothesize that MR/PET can have better information than current CT image study
9547061|NCT03053778|Experimental|Intervention|Early follow-up after discharge
9547062|NCT03053713|Active Comparator|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
9547063|NCT03053713|Placebo Comparator|Habitual Diet|Habitual diet (control) x 12 weeks.
9547064|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
9547065|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
9547066|NCT03053674|Experimental|Explanation|Explanation to parents on importance of post-partum influenza vaccination on health of their newborn infant with a follow-up questionnaire to determine rate of vaccination
9547067|NCT03053674|Active Comparator|No explanation|No explanation will be given to parents but they will be followed-up with a questionnaire to determine rate of vaccination
9547068|NCT03053661||primary surgery + adj. C)RT|treatment naive patients to be treated by conventional primary surgery followed by adjuvant (chemo-)radiotherapy with curative intent
9547069|NCT03053661||primary chemoradiation|treatment naive patients to be treated by conventional primary chemoradiotherapy with curative intent
9547070|NCT03053453|Active Comparator|Standard of Care Spinal Surgery|Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
9616867|NCT02538627|Experimental|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
10040858|NCT01857700|Experimental|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
10040859|NCT01857700|Placebo Comparator|Standard of Care|
10040860|NCT01857726|Experimental|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
10040861|NCT01857726|Active Comparator|The TACE-only group|Transarterial chemoembolization with doxorubicin
10040862|NCT01857752|Experimental|temozolomide|
10040863|NCT01857765|Active Comparator|Standard of Care|
10040864|NCT01857765|Experimental|Rehabilitation|
10040865|NCT01857778||Lactating Women|
9616868|NCT02538627|Experimental|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
9616869|NCT02538627|Experimental|Colorectal cancer Expansion|Doses established in part 1 of the study
9616870|NCT02538627|Experimental|Head and neck Expansion|Doses established in part 1 of the study
9616871|NCT02538653|Experimental|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
9616872|NCT02538653|Active Comparator|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
10040866|NCT01857791|Experimental|multidisciplinary, behavior modification|
10040867|NCT01857804|Experimental|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
10040868|NCT01857804|Experimental|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
10040869|NCT01857804|Experimental|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
10040870|NCT01857804|Placebo Comparator|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
10040871|NCT01857817|Experimental|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
10040872|NCT01857817|Placebo Comparator|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
9489439|NCT00645177|Placebo Comparator|B|"In study, this arm is a randomized (blinded) to placebo for ABT-869 plus paclitaxel arm.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
9489440|NCT00645021|Experimental|Mild hepatic function|
9489441|NCT00645021|Experimental|Moderate hepatic function|
9489442|NCT00645021|Experimental|Normal hepatic function|
9489443|NCT00644839|Experimental|CP-945,598|
9489444|NCT00643669|Experimental|AL-3789|AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye
9489445|NCT00643669|No Intervention|No treatment|Fellow eye, as randomized
9489446|NCT00643383|Active Comparator|1|
9489447|NCT00643383|Placebo Comparator|2|
9489448|NCT00642148|Active Comparator|Seretide|
9489449|NCT00642148|Placebo Comparator|Placebo|Placebo tablet
9489450|NCT00642148|Experimental|GW856553|
9489451|NCT00641732|Experimental|TAK-442 40 mg QD|
9489452|NCT00641732|Experimental|TAK-442 80 mg QD|
9489453|NCT00641732|Experimental|TAK-442 10 mg BID|
9489454|NCT00641732|Experimental|TAK-442 20 mg BID|
9489455|NCT00641732|Experimental|TAK-442 40 mg BID|
9489456|NCT00641732|Experimental|TAK-442 80 mg BID|
9489457|NCT00641732|Active Comparator|Enoxaparin 30 mg BID|
9489458|NCT00640484|Experimental|A|CHF 4226 (carmoterol) 2 μg once a day, in the morning
9489459|NCT00640484|Experimental|B|CHF 4226 (carmoterol) 4 μg once a day, in the morning
9489460|NCT00640484|Placebo Comparator|C|placebo once a day, in the morning
9489461|NCT00640484|Active Comparator|D|salmeterol 50 μg twice daily, in the morning and in the evening
9489462|NCT00640419|Experimental|1|
9489463|NCT00640419|Experimental|2|
9489464|NCT00640419|Placebo Comparator|3|
9489465|NCT00640185|Placebo Comparator|1|
9489466|NCT00640185|Experimental|2|
9489467|NCT00640185|Experimental|3|
9489468|NCT00638755|Experimental|1|The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
9489469|NCT00638755|Experimental|2|The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
9489470|NCT00638755|Experimental|3|The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
9489471|NCT00638755|Experimental|4|The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
9489472|NCT00638703|Experimental|I|Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes
9489473|NCT00638703|Placebo Comparator|II|Size 2 enteric coated capsule containg placebo
9489474|NCT00637130|Experimental|Travoprost 0.0008%|Travoprost ophthalmic solution, 0.0008%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
9489475|NCT00637130|Experimental|Travoprost 0.001%|Travoprost ophthalmic solution, 0.001%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
9489476|NCT00637130|Experimental|Travoprost 0.0012%|Travoprost ophthalmic solution, 0.0012%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
9489477|NCT00637130|Active Comparator|TRAVATAN + Vehicle|TRAVATAN, one drop in study eye(s) once daily (8 PM), and Vehicle, one drop in study eye(s) once daily (8 AM), for two weeks
9489478|NCT00637130|Placebo Comparator|Vehicle|Vehicle, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
9498293|NCT03467633|Experimental|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
9498294|NCT03467633|No Intervention|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
9498295|NCT03467620|Experimental|Cannabidiol oral capsule|25-mg capsule of Cannabidiol (CBD) per day taken daily for a duration of 12 weeks.
9498296|NCT03467620|Placebo Comparator|Placebo oral capsule|One placebo capsule per day for a duration of 12 weeks
9498297|NCT03467607|Active Comparator|3ml/kg|15 patients ventilated with 3ml/kg ideal body weight while on one lung ventilation
9498298|NCT03467607|Active Comparator|4ml/kg|15 patients ventilated with 4ml/kg ideal body weight while on one lung ventilation
9498299|NCT03467607|Active Comparator|control|15 patients ventilated using the anaesthetists usual ventilation strategy
9498300|NCT03467594|Experimental|Intervention arm|"8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.~Outcome measures assessed at baseline and follow-up (8 weeks)"
9498301|NCT03467594|No Intervention|Control|Outcome measures only at baseline at follow-up (8 weeks)
9498302|NCT03467568|Active Comparator|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
9498303|NCT03467568|Active Comparator|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
9498304|NCT03467568|Active Comparator|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
9547071|NCT03053453|Experimental|Sensor Guided Spinal Surgery|The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery. The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data. The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
9547072|NCT03053466|Experimental|Single-Arm|APL-501
9547073|NCT03053479|Experimental|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
9547074|NCT03053479|Experimental|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
9547075|NCT03053479|Experimental|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
9547076|NCT03053648|Experimental|Self-acupressure Group|Subjects in this group will attend two weekly 120-minute self-acupressure training sessions in a classroom at the School of Nursing, the Hong Kong Polytechnic University. The subjects will be instructed on how to perform the self-acupressure treatment by a trained instructor. To enhance interaction and ensure the quality of teaching, each course will be conducted in a small group of 6 participants. Subjects will perform self-acupressure daily for 4 consecutive weeks.
9547077|NCT03053648|Active Comparator|Sleep Hygiene Education Group|To control the contact time with professional person in the treatment group, participants in this group will receive two sessions of 120-minute sleep hygiene training session. The participants will be asked to follow the health hygiene instructions daily for 4 consecutive weeks.
9547078|NCT03053388|Experimental|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
9547079|NCT03053388|Active Comparator|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
9547080|NCT03053544|Experimental|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
9547081|NCT03053323|Experimental|Lifestyle Intervention|
9616873|NCT02538822|Experimental|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
9616874|NCT02538874|Experimental|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
9616875|NCT02538874|Experimental|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
9616876|NCT02538874|Experimental|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
9616877|NCT02538575|Experimental|6-minute walk test|
9616878|NCT02538588|Experimental|Nebulizer 1|Nebulization with akita nebulizer
9616879|NCT02538588|Active Comparator|Nebulizer 2|Nebulization with eFlow nebulizer
9616880|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
9616881|NCT02538549|Active Comparator|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
9616882|NCT02538549|No Intervention|TAU Only|This group will receive only the treatment as usual.
9616883|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
9616884|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
9616885|NCT02538484|Active Comparator|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
9616886|NCT02538484|Active Comparator|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
9616887|NCT02538484|Active Comparator|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
9616888|NCT02538497|Experimental|NBO plus routine care|The Newborn Behavioral Observation
9616889|NCT02538497|Other|Routine care|
9616890|NCT02538536|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
9616891|NCT02538263|Experimental|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
9616892|NCT02538263|No Intervention|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
9616893|NCT02538289|Other|Patients admitted before talks|Patients admitted to Cardiology or Respiratory Medicine Departments before the interventional teaching talks.
10040873|NCT01857830|Experimental|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
10040874|NCT01857830|Active Comparator|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
10040875|NCT01857843|Experimental|ZES group|
10040876|NCT01857843|Active Comparator|EES group|
10040877|NCT01857843|Experimental|Vytorin group|
10040878|NCT01857843|Active Comparator|Mevalotin group|
10040879|NCT01857856|No Intervention|No treatment|no medical treatment
10040880|NCT01857856|Active Comparator|Eplerenone|Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily
10040881|NCT01857895|Experimental|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
9489479|NCT00637052|Experimental|ARRY-520|
9489480|NCT00636480|Experimental|CHG 2%-26 ml|Chlorhexidine gluconate in an aqueous base, 26 ml applicator
9489481|NCT00636480|Active Comparator|ChloraPrep 26 ml|ChloraPrep One-Step 26 ml Active drug contains chlorhexidine gluconate and alcohol
9489482|NCT00636480|Placebo Comparator|Sterile Saline|Sterile salt water administered topically.
9489483|NCT00635934|Experimental|A-MAV™disc|
9489484|NCT00635505|Experimental|T|albuterol HFA 180 mcg QID
9489485|NCT00635505|Active Comparator|R|180 mcg QID 12 weeks
9489486|NCT00635505|Placebo Comparator|P|2 actuations QID 12 weeks or until use of rescue drug
9489487|NCT00635193|Other|Cohort 1|Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk
9489488|NCT00635193|Other|Cohort 2|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk
9489489|NCT00635193|Other|Group A|liposomal doxorubicin, 40 mg/m2 q4wk
9489490|NCT00635193|Other|Group B|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)
9489491|NCT00635193|Other|Group C|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)
9489492|NCT00634829|Experimental|T|Armstrong Albuterol HFA Inhalation Aerosol
9489493|NCT00634829|Active Comparator|R|2 inhalations Proventil-HFA Albuterol Sulfate, 108 mcg, prior to exercise
9489494|NCT00634829|Placebo Comparator|P|Placebo-HFA
9489495|NCT00634517|Experimental|T|Armstrong Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
9489496|NCT00634517|Active Comparator|R|Proventil-HFA, Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
9489497|NCT00633997|Experimental|1|Healthy volunteers
9489498|NCT00633997|Experimental|2|Type II diabetics
9489499|NCT00633789|Experimental|1|
9489500|NCT00633789|Placebo Comparator|2|
9489501|NCT00631111|Experimental|1|
9489502|NCT00631111|Active Comparator|2|
9489503|NCT00631111|Active Comparator|3|
9489504|NCT00631111|Placebo Comparator|4|
9489505|NCT00630799|Experimental|1|leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)
9489506|NCT00630656|Experimental|1|Talactoferrin alfa
9489507|NCT00630656|Placebo Comparator|2|Placebo
9489508|NCT00630552|Placebo Comparator|Placebo + Gemcitabine|
9489509|NCT00630552|Experimental|AMG 655 + Gemcitabine|
9489510|NCT00630552|Experimental|AMG 479 + Gemcitabine|
9489511|NCT00630201|Experimental|Probuphine|buprenorphine implant
9489512|NCT00629980|Experimental|1|
9489513|NCT00629980|No Intervention|2|
9489514|NCT00629941|Experimental|1|
9489515|NCT00629590|Experimental|1|
9489516|NCT00629590|No Intervention|2|
9489517|NCT00629551|Experimental|Saredutant 100mg and Paroxetine 20 mg|combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks
9489518|NCT00629551|Experimental|Saredutant 30mg and Paroxetine 20mg|combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks
9489519|NCT00629551|Active Comparator|Paroxetine 20 mg and saredutant placebo|paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks
9489520|NCT00629551|Placebo Comparator|Placebo|Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase
9489521|NCT00627419|Experimental|1|IPI-504
9489522|NCT00626704|Experimental|Arm 1|AMG 655 + Doxorubicin
9489523|NCT00626704|Placebo Comparator|Arm 2|Placebo + Doxorubicin
9489524|NCT00626236|Experimental|Treatment 1|
9489525|NCT00626236|Experimental|Treatment 2|
9489526|NCT00626236|Experimental|Treatment 3|
9489527|NCT00626236|Experimental|Treatment 4|
9489528|NCT00626106|Placebo Comparator|Placebo|
9489529|NCT00626106|Active Comparator|Investigational Product|
9489530|NCT00626106|Other|Roll-over|
9489531|NCT00626002|Experimental|1|
9489532|NCT00625833|Placebo Comparator|Placebo|
9489533|NCT00625833|Experimental|2|
9489534|NCT00625664|Experimental|1|
9489535|NCT00625664|Active Comparator|2|
9489536|NCT00625651|Experimental|AMG 655 Low Dose|AMG 655 (low dose) + mFOLFOX6 + Bevacizumab
9489537|NCT00625651|Placebo Comparator|Placebo|Placebo + mFOLFOX6 + Bevacizumab
9489538|NCT00625651|Experimental|AMG 655 High Dose|AMG 655 (high dose) + mFOLFOX6 + Bevacizumab
9489539|NCT00625612|Placebo Comparator|2|
9489540|NCT00625612|Experimental|1|Denufosol Tetrasodium (INS37217) Inhalation Solution
9489541|NCT00625326|Experimental|75 µg/g COL-121 Ointment|75 µg/g COL-121 Ointment
9489542|NCT00625326|Experimental|150 µg/g COL-121 Ointment|150 µg/g COL-121 Ointment
9489543|NCT00625326|Experimental|300 µg/g COL-121 Ointment|300 µg/g COL-121 Ointment
9489544|NCT00625326|Active Comparator|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment (active control)
9489545|NCT00625326|Placebo Comparator|Placebo Ointment|Placebo Ointment
9489546|NCT00624858|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/ day
10040882|NCT01857895|Experimental|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
10040883|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
10040884|NCT01857921|Active Comparator|Pravastatin group|
10040885|NCT01857921|Experimental|Combination of Atorvastatin and trimetazidine group|
10040886|NCT01857947|No Intervention|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
10040887|NCT01857960||Adolescents|Acne survey among Mexican adolescents
10040888|NCT01857999|Experimental|Losartan|Losartan 50 mg bid orally
10040889|NCT01857999|Placebo Comparator|Placebo|Placebo 1 pill bid orally
10040890|NCT01858012||HCV infection|patients with hepatitis C infection
10040891|NCT01858012||non-HCV infection|healthy controls
10040892|NCT01858025|Experimental|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
9489547|NCT00624845|Experimental|Drug|
9489548|NCT00624845|Placebo Comparator|Vehicle|
9489549|NCT00624390|Experimental|Sepraspray|Sepraspray applied directly to both sides of the uterus, Fallopian tubes, and ovaries (or opposing sites if not possible to apply directly). Sepraspray was applied via a sterile cannula at a tissue concentration of approximately 5 mg/cm^2.
9489550|NCT00624390|No Intervention|Control|No anti-adhesion treatment was used.
9489551|NCT00624351|Placebo Comparator|Placebo|Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
9489552|NCT00624351|Experimental|EMAB 600mg|600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
9489553|NCT00624351|Experimental|EMAB 100mg|100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
9489554|NCT00624351|Experimental|EMAB 400mg|400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
9489555|NCT00624351|Experimental|EMAB 1200mg|1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
9489556|NCT00624351|Experimental|EMAB 1800mg|1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
9489557|NCT00622765|Experimental|001|R256918 5 mg capsule twice daily
9489558|NCT00622765|Experimental|002|R256918 10 mg capsule twice daily
9489559|NCT00622765|Experimental|003|R256918 15 mg capsule twice daily
9489560|NCT00622765|Placebo Comparator|004|placebo Placebo capsule twice daily
9489561|NCT00622193|Experimental|1 Active 50 mg|
9489562|NCT00622193|Experimental|2 Active 100 mg|
9489563|NCT00622193|Placebo Comparator|3 Placebo|
9489564|NCT00621894|Experimental|LGD4665|LGD-4665: Experimental Thrombopoietin mimetic
9489565|NCT00621894|Placebo Comparator|Placebo|Placebo
9489566|NCT00620685|Placebo Comparator|1|
9489567|NCT00620685|Experimental|2|
9489568|NCT00620685|Experimental|3|
9489569|NCT00620451|Experimental|Larazotide acetate 4 mg|larazotide acetate capsules 4 mg TID
9489570|NCT00620451|Experimental|Larazotide acetate 8 mg|Larazotide acetate capsules 8 mg TID
9489571|NCT00620451|Placebo Comparator|Placebo|Placebo capsules
9489572|NCT00620256|Experimental|AL-37807|AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
9489573|NCT00620256|Active Comparator|Timolol|Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
9489574|NCT00620256|Placebo Comparator|AL-37807 vehicle|AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
9489575|NCT00618319|Experimental|1|BIIB021
9489576|NCT00618098|Experimental|Octaplex (human prothrombin complex concentrate)|Participants to receive1 or more Octaplex infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
9489577|NCT00618098|Active Comparator|Fresh frozen plasma|Participants to receive1 or more fresh frozen plasma infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
9489578|NCT00618007|Experimental|30 mg QD|
9489579|NCT00618007|Experimental|20 mg QD|
9489580|NCT00618007|Placebo Comparator|Placebo|
9489581|NCT00617552|Placebo Comparator|1|
9489582|NCT00617552|Experimental|2|
9489583|NCT00617552|Experimental|3|
9489584|NCT00617552|Experimental|4|
9489585|NCT00617552|Experimental|5|
9489586|NCT00617552|Experimental|6|
9489587|NCT00617552|Experimental|7|
9489588|NCT00617552|Experimental|8|
9489589|NCT00617526|Experimental|RDEA806 400 mg|Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
9489590|NCT00617526|Experimental|RDEA806 600 mg|Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
9489591|NCT00617526|Experimental|RDEA806 800 mg|Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
9489592|NCT00617526|Experimental|RDEA806 1000 mg|Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.
9489593|NCT00617331|Experimental|Dose 7.5 mcg|7.5 micrograms of vaccine administered on Day 0 and Day 28.
9489594|NCT00617331|Experimental|Dose 30 mcg|30 micrograms of vaccine administered on Day 0 and Day 28.
9489595|NCT00616811|Experimental|Vildagliptin|
10040893|NCT01858038|No Intervention|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
9616894|NCT02538289|Other|Patients admitted after talks|Patients admitted to Cardiology or Respiratory Medicine Departments after the interventional teaching talks.
9616895|NCT02538367|Experimental|YH12852 IR 0.05mg|Once daily
9616896|NCT02538367|Experimental|YH12852 IR 0.1mg|Once daily
9616897|NCT02538367|Experimental|YH12852 IR 0.3mg|Once daily
10040894|NCT01858038|Experimental|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
9616898|NCT02538367|Experimental|YH12852 IR 0.5mg|Once daily
9616899|NCT02538367|Experimental|YH12852 IR 1mg|Once daily
9616900|NCT02538367|Experimental|YH12852 IR 2mg|Once daily
10040895|NCT01858051|Active Comparator|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
9489596|NCT00616811|Active Comparator|Sitagliptin|
9489597|NCT00616798|Experimental|3|
9489598|NCT00616798|Placebo Comparator|4|
9489599|NCT00616798|Experimental|1|
9489600|NCT00616798|Experimental|2|
9489601|NCT00616330|Experimental|1|clindamycin phosphate/butoconazole nitrate
9489602|NCT00616330|Active Comparator|2|clindamycin phosphate
9489603|NCT00616330|Active Comparator|3|butoconazole nitrate
9489604|NCT00616148|Placebo Comparator|Placebo|
9489605|NCT00616148|Experimental|YKP3089|
9489606|NCT00615966|Experimental|1|
9489607|NCT00615966|Experimental|2|
9489608|NCT00615966|Placebo Comparator|3|
9489609|NCT00615940|Experimental|1|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with WX-671 once daily by mouth, Days 1-21 inclusive.
9489610|NCT00615940|Experimental|2|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with placebo once daily by mouth, Days 1-21 inclusive.
9489611|NCT00615693|Experimental|1|
9489612|NCT00615251|Experimental|1|
9489613|NCT00615251|Active Comparator|2|
9489614|NCT00614705|Experimental|1|
9489615|NCT00614705|Placebo Comparator|2|
9489616|NCT00614601|Experimental|1|Vaccine + chemo + chemoradiation therapy
9489617|NCT00614601|Experimental|2|Vaccine Only
9489618|NCT00613002|Experimental|testosterone gel|1% testosterone transdermal gel
9489619|NCT00613002|Placebo Comparator|placebo gel|placebo transdermal gel
9489620|NCT00612742|Experimental|testosterone gel|1% testosterone transdermal gel
9489621|NCT00612742|Placebo Comparator|placebo gel|placebo transdermal gel
9489622|NCT00612664|Active Comparator|Arm 1|0.1 mg/kg every 3 weeks
9489623|NCT00612664|Active Comparator|Arm 2|1 mg/kg every 3 weeks
9489624|NCT00612664|Active Comparator|Arm 3|1 mg/kg every 6 weeks
9489625|NCT00612664|Active Comparator|Arm 4|5 mg/kg every 3 weeks
9489626|NCT00612170|Experimental|3|
9489627|NCT00612170|Sham Comparator|4|
9489628|NCT00612170|Experimental|1|
9489629|NCT00612170|Experimental|2|
9489630|NCT00612014|Placebo Comparator|1|
9489631|NCT00612014|Experimental|2|40 micrograms/kg
9489632|NCT00612014|Experimental|3|80 micrograms/kg
9489633|NCT00612014|Experimental|4|160 micrograms/kg
9489634|NCT00612014|Experimental|5|320 microgram/kg
9489635|NCT00612014|Experimental|6|600 microgram/kg
9489636|NCT00609323|Experimental|1|
9489637|NCT00609323|Placebo Comparator|2|
9489638|NCT00607256|Experimental|Open Label|
9489639|NCT00606697|Active Comparator|Overall study|Male and female subjects, 18-64 years of age (inclusive), with a primary diagnosis of primary insomnia
9489640|NCT00606476|Active Comparator|1|0.15 mg/kg active bapineuzumab
9489641|NCT00606476|Active Comparator|2|0.5 mg/kg active bapineuzumab
9489642|NCT00606476|Active Comparator|3|1.0 mg/kg active bapineuzmab
9489643|NCT00605735|Experimental|A1|
9489644|NCT00605735|Placebo Comparator|P1|
9489645|NCT00605553|Experimental|1|Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
9489646|NCT00605553|Placebo Comparator|2|Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control
9489647|NCT00604123|Experimental|JNJ-17166864|
9489648|NCT00604123|Placebo Comparator|Placebo|
9489649|NCT00603863|Experimental|multiple dose levels|1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine.
9489650|NCT00603668|Experimental|milatuzumab|different doses of hLL1
9489651|NCT00603616|Placebo Comparator|1|Placebo pills
9489652|NCT00603616|Active Comparator|2|Rifaximin
9489653|NCT00603577|Placebo Comparator|Placebo|
9489654|NCT00603577|Experimental|Xaliproden|
9489655|NCT00602745|Active Comparator|5-Fluorouracil|
9489656|NCT00602745|Experimental|S-1|
9547082|NCT03053531|Experimental|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
9547083|NCT03053336|Experimental|App-technology group|"Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which steps are automatically measured and laboratory values from blood sampling within primary care will be shown.~Intervention: App-technology to increase physical activity"
9547084|NCT03053336|No Intervention|Control group|The control group will receive standard care
9547085|NCT03053570|Experimental|Cryoballoon|
9547086|NCT03053570|Experimental|Radiofrequency Energy(Contact Force)|
9547087|NCT03053622|Experimental|Mirikizumab Test Subcutaneous (SC) 1|Mirikizumab test formulation given as a single injection under the skin in healthy participants
9547088|NCT03053622|Experimental|Mirikizumab Test SC 2|Mirikizumab test formulation given as two injections under the skin in healthy participants
9547089|NCT03053622|Experimental|Mirikizumab Test Intravenous (IV)|Mirikizumab test formulation given as an infusion into the vein in healthy participants
9547090|NCT03053622|Active Comparator|Mirikizumab Reference|Mirikizumab reference formulation given as three injections under the skin in healthy participants
9547091|NCT03053583|Active Comparator|Miller Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Miller blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
9547092|NCT03053583|Active Comparator|Wis-Hipple Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Wis- Hipple blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
9547093|NCT03053583|Active Comparator|C-Mac Laryngoscope blade|An image of the best glottic view will be saved on C-MAC monitor's SD card during laryngoscopy using C-MAC straight blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
9547094|NCT03053375|Experimental|Acute/subacute; active device|MDCure active device
9547095|NCT03053375|Placebo Comparator|Acute/subacute; sham|MDCure sham device
9547096|NCT03053375|Experimental|Chronic; active device|MDCure active device
9547097|NCT03053375|Placebo Comparator|Chronic; sham|MDCure sham device
9547098|NCT03053557|Experimental|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
9547099|NCT03053557|No Intervention|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
9547100|NCT03053414|Active Comparator|Treatment Arm # 1|50,000 IU oral vitamin D2 per week for 12 weeks + Dietary counseling
9547101|NCT03053414|Active Comparator|Treatment Arm # 2|50,000 IU oral vitamin D2 per week x 12 weeks then 800 IU/day oral vitamin D3 for 6 months + Dietary counseling
9547102|NCT03053414|Active Comparator|Treatment Arm # 3|50,000 IU oral vitamin D2 per week x 12 weeks then 5,000 IU/day oral vitamin D3 for 6 months+ Dietary counseling
9547103|NCT03053414|Active Comparator|Treatment Arm # 4|5,000 IU oral daily vitamin D3 for 9 months + Dietary counseling
10040896|NCT01858051|Active Comparator|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
9547104|NCT03053635|Experimental|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm^2) will be used."
9547105|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
9547106|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
9547107|NCT03053505|Experimental|Recurrent CDI FMT|"Non-randomized group (R) for treatment of recurrent CDI with FMT"
9547108|NCT03053505|Active Comparator|Primary CDI antibiotic|"Randomized group (F AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)"
9547109|NCT03053505|Experimental|Primary CDI FMT|"Randomized group (F FMT) for the treatment of primary CDI with FMT"
9547110|NCT03053284|Placebo Comparator|Placebo|Normal saline s.c. injection once
9547111|NCT03053284|Experimental|Pasireotide|Pasireotide 0.6mg s.c. once
9547112|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
9547113|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
9547114|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
9547115|NCT03053219|Experimental|AC0010|each participant will be given AC0010 300mg bid
9547116|NCT03053258||Diagnostic Breath Analysis: VAP|Collection of exhaled breath samples
9616901|NCT02538367|Experimental|YH12852 IR 3mg|Once daily
9616902|NCT02538367|Experimental|YH12852 DR1 0.5mg|Once daily
10040897|NCT01858051|Placebo Comparator|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
10040898|NCT01858064|Experimental|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
9547117|NCT03053024||Cohort 1: Relapse/refractory MCL (rrMCL ) Participants|Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma [rrMCL]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
9547118|NCT03053024||Cohort 2: Newly Diagnosed MCL Participants|Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
9547119|NCT03053128|Experimental|CSWT group|Patients in CSWT group will receive cardiac shock wave therapy for three moths, every first week of the month.
9547120|NCT03053128|Sham Comparator|Sham CSWT group|Patients in sham CSWT group will receive sham cardiac shock wave, which segregated by an air-cushion.
9547121|NCT03053115|Experimental|CASES|treatment with levothyroxine and liothyronine
9547122|NCT03053115|Active Comparator|CONTROLS|treatment with levothyroxine and placebo
9547123|NCT03053206|Experimental|ADE arm|"ADE arm~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
9547124|NCT03053011|Experimental|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
9547125|NCT03053089|Experimental|Stage 1 (adult)|AGT-181
9547126|NCT03053089|Experimental|Stage 2 (children)|AGT-181
9547127|NCT03053232|Experimental|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
9547128|NCT03053232|Active Comparator|Endoclips|Use of endoclips to close gastrointestinal perforation.
9547129|NCT03052998|Active Comparator|Ivermectin|Ivermectin and anti-epileptic treatment
9547130|NCT03052998|No Intervention|no treatment|only anti-epileptic treatment
9547131|NCT03053076|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
9547132|NCT03053076|Experimental|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
9547133|NCT03053167|Experimental|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
9547134|NCT03052946|Active Comparator|Bulking agent|Bulking agent in fecal incontinence
9547135|NCT03052946|Placebo Comparator|Endoanal electrostimulation|Endoanal electrostimulation in fecal incontinence
9547136|NCT03052933|Experimental|Copanlisib/gemcitabine|
9547137|NCT03052868|Other|Data Collection|The study visit will be scheduled for three to six months after completing adjuvant chemotherapy treatment. At the study visit, informed consent will be obtained and neurocognitive attention testing will be performed. The assessments chosen were carefully selected based on breadth, psychometric properties, standardized broad clinical use, good external validity and time efficiency. The testing time for the battery of neuropsychological tests is approximately 45-60 minutes. Participants will also be asked to complete a packet of several questionnaires including several self-rated measures of mood and quality of life, in addition to a brief questionnaire to obtain information about exercise, sleep, and education and employment backgrounds. It is estimated that questionnaire completion will require no more than 30 minutes. Participants will be seen on only one occasion, and may receive, upon request, written feedback about the results of the evaluation.
9547138|NCT03052790|Active Comparator|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
9547139|NCT03052790|Experimental|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
9547140|NCT03052829|Experimental|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
9547141|NCT03052829|Placebo Comparator|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
9547142|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Patients undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
9547143|NCT03052595||Control|Age, sex, Body Mass Index (BMI) matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Healthy controls undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
9616903|NCT02538367|Experimental|YH12852 DR1 1mg|Once daily
9616904|NCT02538367|Experimental|YH12852 DR1 2mg|Once daily
9616905|NCT02538367|Experimental|YH12852 DR1 4mg|Once daily
9616906|NCT02538367|Experimental|YH12852 DR2 8mg|Once daily
9616907|NCT02538367|Active Comparator|Prucalopride 2mg|Once daily
9616908|NCT02538367|Placebo Comparator|Placebo|Once daily
9616909|NCT02538458|Active Comparator|Test group|3 % hypertonic saline up to 72H.
9616910|NCT02538458|Placebo Comparator|Placebo control group|"3 % hypertonic saline up to 24H.~Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
9547144|NCT03052907|Other|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
10040899|NCT01858077|Active Comparator|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
9547145|NCT03052647|Active Comparator|Subcuticular arm|closure technique that the Adhesive Latch arem (dermaclip) arm is being compared to
9547146|NCT03052647|Active Comparator|Adhesive Latch Arm (Demaclip arm)|This is the arm which the adhesive latch system is used and it is being compared to the arm of subcuticular
9547147|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
9547148|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
9547149|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
9547150|NCT03052894|Experimental|Hydraulic Monitoring Device|Monitoring device to be compared to electromyographic (EMG) device in the same patient; measures depth of neuromuscular blockade during general anesthesia based on the pressure exerted by the muscles of the thumb.
9547151|NCT03052894|Active Comparator|Standard EMG Monitoring Device|Currently used standard monitoring device; measures depth of neuromuscular blockade during general anesthesia based on the action potential of the muscles of the thumb.
9547152|NCT03052673|Active Comparator|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
9547153|NCT03052673|Active Comparator|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
9547154|NCT03052582|Active Comparator|Team 1: skimmed/whole|Milktype: 3 weeks with skimmed milk followed by 3 weeks with whole milk
9547155|NCT03052582|Active Comparator|Team 2: whole/skimmed|Milktype: 3 weeks with whole milk followed by 3 weeks with skimmed milk
9547156|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
9547157|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
9547158|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
9547159|NCT03052777|Experimental|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
9547160|NCT03052777|No Intervention|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
9547161|NCT03052712|Active Comparator|Patients|battery of tests of social cognition
9547162|NCT03052712|Active Comparator|Control|battery of tests of social cognition
9547163|NCT03052660|Experimental|Midazolam|Midazolam, 3.75 mg , oral, once, 30-45 minutes before surgery
9547164|NCT03052660|Placebo Comparator|Placebo|Placebo, oral, once, 30-45 minutes before surgery
9547165|NCT03052881|Experimental|Robot assisted surgery|To investigate use of an intraocular robotic system to assist the surgeon in performing one of two operation: i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage.
10040900|NCT01858077|Active Comparator|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
10040901|NCT01858090|Placebo Comparator|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
9547166|NCT03052881|No Intervention|Control|A control group of patients underwent either i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage without the use of a robot i.e. the surgery was done in the standard manner.
9547167|NCT03052556|Other|Cohort of women with cystic fibrosis|Includable patients are adult women, transplanted or not, followed at Lyon CRCM (Centre de Ressources et de Compétences de la Mucoviscidose).
9547168|NCT03052491|Experimental|Stem Cell 100+ Intervention|Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks
9547169|NCT03052504||Cx prospective|Cystectomy patients followed with prospective registration of complications
9547170|NCT03052504||Cx retrospective|Cystectomy patients followed with retrospective registration of complications
9547171|NCT03052504||Nx prospective|Nephrectomy patients followed with prospective registration of complications
9547172|NCT03052504||Nx retrospective|Nephrectomy patients followed with retrospective registration of complications
9547173|NCT03052270|Experimental|Vaginal progesterone and Pessary|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care plus Arabin pessary"
10040902|NCT01858090|Active Comparator|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
9547174|NCT03052270|Active Comparator|Vaginal progesterone only|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care"
9547175|NCT03052348|Active Comparator|Group R|Polyethylene glycol hexadecyl ether & betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
9547176|NCT03052348|Experimental|Group A|Fusidic acid & Polyethylene glycol hexadecyl ether,& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
9547177|NCT03052387|Placebo Comparator|control|"Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.~Buccal& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.~Decortication of the bone bed to increase the blood supply to the onlay graft.~The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.~Periosteal incisions are usually needed to allow tension free sutures.~Vicryl 3/0 sutures for closer.~augmentin 1g twice daily for 5 days.~catflam 50g twice daily for 3 days"
9547178|NCT03052387|Active Comparator|Comparator|"Crestal incision with labial flap reflected leaving the palatal tissues without elevation.~Marking of the 3 bony cuts ( 2 vertical cuts & 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.~Drilling of pilot drill and first drill only.~3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.~splitting osteotomes are used and mallet to complete the splitting of the bony segment.~After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.~The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.~Drilling through the bony segment and the block graft.~Immediate implant placement~chin graft block dental implants"
9547179|NCT03052205|Experimental|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
9547180|NCT03052400|Experimental|Mifepristone 600 mg daily|Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks
9547181|NCT03052400|Placebo Comparator|Placebo|Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks
9547182|NCT03052465|Experimental|Feeding|Test soup meal feeding intervention
9547183|NCT03052478|Experimental|vismodegib arm|. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
9547184|NCT03052439|Active Comparator|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
9547185|NCT03052439|Active Comparator|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
10040903|NCT01858090|Active Comparator|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
10058492|NCT02018679|Experimental|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
9547186|NCT03052439|Active Comparator|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
10058493|NCT02018679|Active Comparator|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
10058494|NCT02018692|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
10058495|NCT02018692|Placebo Comparator|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
10058496|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
10058497|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
10058498|NCT02018718|Other|Marathoners|
10058499|NCT02018731|Experimental|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
10058500|NCT02018731|Experimental|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
10058501|NCT02018757|Experimental|As2O3|Subjects will be treated with TACE containing As2O3
10058502|NCT02018757|Placebo Comparator|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
10058503|NCT02018770|Experimental|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
9547187|NCT03052439|Active Comparator|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
9547188|NCT03052439|Active Comparator|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
9547189|NCT03052361|Experimental|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
9498305|NCT03467568|Placebo Comparator|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
9498306|NCT03467555|Experimental|distalization group|Class II correction using zygomatic miniplates
9547190|NCT03052361|Placebo Comparator|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
9547191|NCT03052231|Active Comparator|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
9547192|NCT03052231|No Intervention|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
9547193|NCT03052413|Active Comparator|Active|
9547194|NCT03052413|Placebo Comparator|Placebo|
9547195|NCT03052374|No Intervention|Control Group|Mothers will receive standard care such as referral to psychotherapy (intervention mothers will have the same access) over the same length of time.
9547196|NCT03052374|Experimental|VID-KIDS Intervention Program Group|RN review photos of infant engagement/disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
9547197|NCT03052335|Experimental|Pillcam® COLON 2 Capsule and colonoscopy|Persons with positive immunochemical fecal occult blood tests will be examined by second generation colon capsule endoscopy (CCE2) and optical colonoscopy afterwards.
9547198|NCT03052218|Experimental|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
9547199|NCT03052244|Experimental|intervention tDCS+VI|The anode will be placed over C3-C4 (EEG 10/20 system) to target M1 and the cathode over the contralateral supraorbital area. The stimulation will apply to the hemisphere which contralateral to the more painful hemi body. 2mA will be delivered over 20 min via neuroConn DC stimulator combined with video presenting walking legs. A total of 10 sessions (5 per week) will be administrated at the same manner.
9547200|NCT03052244|Sham Comparator|tDCS Sham+VI Sham|The stimulation will be turned on for only short duration (up to 30 sec), the video film will contains graphical illustrations or nature movie without human movement.
9547201|NCT03052179|Active Comparator|VSL#3|VSL#3 poly-biotic 450 billion in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
9547202|NCT03052179|Placebo Comparator|Placebo|Maltose in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
9547203|NCT03052192||FAM group (n=98)|"≥65 years. Acutely admitted medical patients.~Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup.~Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.~If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician.~Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size."
9547204|NCT03052192||Control group 1 (n=54)|"≥65 years. No hospital admissions within the past two years.~Matched individually with patients in the FAM group by age, sex, and municipality.~Examined at inclusion and 52 weeks after inclusion.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality."
9547205|NCT03052192||Control group 2 (n=60)|"20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)~Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples."
9547206|NCT03052140|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
9547207|NCT03052140|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
9547208|NCT03051932|Active Comparator|Ofiramev®( IV Acetaminophen)|Patients randomized to the treatment arm will receive 1 g (100 mL) intravenous acetaminophen infused over 15-minutes every 6 hours for 4 doses total.
9547209|NCT03051932|Placebo Comparator|Placebo IV administration|Patients randomized to the placebo arm will receive 100 mL of normal saline infused over 15 minutes every 6 hours for 4 doses total
9547210|NCT03051958|Experimental|Internet mindfulness&exposure treatment|A 12-week treatment where the main treatment components are mindfulness, exposure and response prevention, a form of cognitive behavior therapy. The treatment entails methods to increase acceptance and non-reactivity to aversive thoughts and emotions associated with AD. The treatment is delivered via the Internet and comprises 10 modules, each with a specific theme. Throughout treatment, the patient is given structured exercises to work with on a daily basis.
9547211|NCT03051958|Active Comparator|Treatment as usual|"Participants receive information about moisturizer and anti-inflammatory lotion treatment which is treatment as usual.~After 12 weeks, patients in this arm are crossed over to treatment."
9547212|NCT03052166||Cohort A|The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
9547213|NCT03052166||Cohort B|The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
9547214|NCT03052166||Cohort C|The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.
9547215|NCT03052023|Experimental|group A (dual approach lap hernioplasty)|dual approach laparoscopic inguinal hernioplasty by combination of TAPP (group B) and pneumo-dissection preperitoneal instead of sharp dissection
9547216|NCT03052023|Active Comparator|group B (TAPP)|trans-abdominal preperitoneal hernioplasty (TAPP) after induction of pneumoperitoneum through peritoneal approach peritoneal incision and preperitoneal dissection then mesh fixation done
9547217|NCT03052023|Active Comparator|group C (Lichtenstein hernioplasty)|open inguinal hernioplasty (lichtenstein) repair through inguinal incision and dissection of the sac anteriorly , excision of the sac and then mesh fixation in the posterior wall of inguinal canal
9547218|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
9547219|NCT03051945|Experimental|Ketamine|Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
9547220|NCT03051945|Placebo Comparator|Placebo|Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
9547221|NCT03051984|Experimental|NMES|Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
9547222|NCT03051984|No Intervention|Control|No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
9547223|NCT03052062|Experimental|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
9547224|NCT03051906|Experimental|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
9547225|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
9547226|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
9547227|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
9547228|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
9547229|NCT03051880|Experimental|Repair Control EGF®|EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.
9547230|NCT03051880|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.
9547231|NCT03051997|Experimental|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
9547232|NCT03051997|Active Comparator|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
9547233|NCT03052114||Stroke|Electrical Impedance Tomography with scalp electrodes
9547234|NCT03052114||Head Injury|Electrical Impedance Tomography with scalp electrodes
9547235|NCT03051867||Third-trimester pregnant women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
9547236|NCT03051867||Nonpregnant control women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
9547237|NCT03051854|Experimental|ICC-T|Intervention: Interaction Competencies with children - for teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
9547238|NCT03051854|No Intervention|Control schools|The control school do not receive any intervention.
9547239|NCT03051841|Experimental|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
10040904|NCT01858116|Experimental|[68Ga]ABY-025|
10040905|NCT01858129|Experimental|Inhaled steroids (Budicort)|Inhaled Budicort
9547240|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
9547241|NCT03051893|Experimental|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
9547242|NCT03051893|Experimental|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
10040906|NCT01858129|Placebo Comparator|Control|Inhaled NS 0.9%
9547243|NCT03051893|Experimental|Part B|The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
9547244|NCT03051724|Experimental|Intervention group|"These OSA patient's are not familiarized with the use of internet and mobile technologies and with CPAP prescription. They follow the intervetion follow up that consists in an adaptation session where the tecnitian delivers them an automatic CPAP machine. Patient's are titrated with this automatic device in 5-7 days and are treated with the automatic device during 3 months.~The other part of the follow up consists on a voicemail where the patient can contact us 24h a day and on an , with an internet-connected tablet with a special app where the patient's answer a questionnaire once two weeks."
9547245|NCT03051724|No Intervention|Control group|These patient's are patient's that follow the process that all patient's take during CPAP treatment. During the three months of study, the follow up will be the usual.
9547246|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
9547247|NCT03051685|Experimental|DFN-15 Dose 1|
9547248|NCT03051685|Experimental|DFN-15 Dose 2|
9547249|NCT03051685|Experimental|DFN-15 Dose 3|
9547250|NCT03051685|Active Comparator|Active Comparator|
9547251|NCT03051542|Experimental|NK/T-cell lymphoma patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
9616911|NCT02538380|Experimental|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
9616912|NCT02538328|Active Comparator|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
9616913|NCT02538328|Placebo Comparator|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
9616914|NCT02538393|Experimental|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
9616915|NCT02538393|Experimental|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
9616916|NCT02538393|Experimental|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
10040907|NCT01858142|Experimental|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
10040908|NCT01858142|Placebo Comparator|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
10040909|NCT01858155|Experimental|Melatonin|
10040910|NCT01858168|Experimental|One|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Ewing sarcoma
9489659|NCT00602602|Experimental|GemOx and Bev, then chemoradiation, then surgery|"Gemcitabine 1000 mg/m2 over 100 min on day 1 every 2 weeks~Oxaliplatin 85 mg/m2 over 2 hours on day 2 every 2 weeks~Bevacizumab 10 mg/kg over 90 minutes on day 1 every 2 weeks. Infusion duration may be shortened in subsequent courses if tolerated.~One cycle is 2 weeks. Chemoradiation to begin prior to 4 weeks from last dose of Gem. Between 4 and 6 weeks following chemoradiotherapy, patients will undergo re-staging with CT or MRI and CA 19-9. If there is no evidence of disease progression, the patient will be referred to the surgeon for re-evaluation and consideration of surgical intervention"
10040911|NCT01858168|Experimental|Two|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle Irinotecan, given by IV once per day on days 1-7 of each cycle
10040912|NCT01858168|Experimental|Three|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Rhabdomyosarcoma
9489660|NCT00602576|Experimental|Arm A|Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
9489661|NCT00602576|Experimental|Arm B|Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33.
9489662|NCT00602576|Experimental|Arm C|Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
9489663|NCT00602576|Experimental|Arm D|Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33.
9489664|NCT00602329|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
9489665|NCT00602329|Experimental|Arm II|Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
9489666|NCT00602329|Active Comparator|FOLFOX alone (control)|Patients receive FOLFOX as in arm I.
9489667|NCT00600782|Experimental|Group A|These subjects were further stratified into 3 groups according to the size of their PPD skin test reactions
9489668|NCT00600288|Experimental|1|
9489669|NCT00600288|Placebo Comparator|2|
9489670|NCT00600275|Experimental|BGT226|
9489671|NCT00599989|Experimental|APBI|
9489672|NCT00595699|Placebo Comparator|2|Double-blind
9489673|NCT00595699|Experimental|1|escitalopram group
9489674|NCT00595426|Experimental|1. YM150 Dose X, twice daily|
9489675|NCT00595426|Experimental|2. YM150 Dose Y, once daily|
9489676|NCT00595426|Experimental|3. YM150 Dose Y, twice daily|
9489677|NCT00595426|Experimental|4. YM150 Dose Z, once daily|
9489678|NCT00595426|Active Comparator|5. Warfarin|various doses
9489679|NCT00594984|Active Comparator|Arm 1 - Phase 1|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
9489680|NCT00594984|Placebo Comparator|Arm 2 - Phase 2|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
9489681|NCT00592995|Placebo Comparator|1|
9489682|NCT00592995|Active Comparator|2|
9489683|NCT00591799|Experimental|Jarvik 2000 Ventricular Assist System|Jarvik 2000 Ventricular Assist System
9489684|NCT00589875|Experimental|Single arm|This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.
9489685|NCT00589823|Active Comparator|1|Immediate Release Morphine sulphate capsules taken at start of relevant BTCP episode. Each episode treated with either this medication OR the experimental comparator.
9489686|NCT00589823|Experimental|2|Nasalfent spray taken at start of relevant BTCP episode. Each episode to be treated with either this medication OR the active comparator (IRMS)
9489687|NCT00587275|Experimental|1|AST-120, 2 gram sachets
9489688|NCT00587275|Placebo Comparator|2|Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.
9489689|NCT00586651|Experimental|lestaurtinib|
9489690|NCT00584974|Experimental|0.5 mg SEP-225289|0.5 mg SEP-225289
9489691|NCT00584974|Experimental|2.0 mg of SEP-225289|2.0 mg of SEP-225289
9489692|NCT00584974|Active Comparator|Venlafaxine|150 mg Venlafaxine
9489693|NCT00584974|Placebo Comparator|Placebo|placebo
9489694|NCT00583830|Active Comparator|A|Paclitaxel and carboplatin
9489695|NCT00583830|Experimental|B|Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
9489696|NCT00583830|Experimental|C|Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
9489697|NCT00583674|Experimental|B|
9489698|NCT00583674|Experimental|A|
9489699|NCT00583674|Active Comparator|C|
9489700|NCT00583609|Experimental|1|PEG3350
9489701|NCT00583531|Experimental|I|Active treatment with AST-120
9489702|NCT00583154|Experimental|1|BLI-801 Dose 1
9489703|NCT00583154|Experimental|2|BLI-801 Dose 2
9489704|NCT00583154|Experimental|3|BLI-801 Dose 3
9489705|NCT00583154|Experimental|4|BLI-801 Dose 4
9489706|NCT00583128|Experimental|1|AST-120, 2 gram sachets
9489707|NCT00583128|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
9498308|NCT03467503|No Intervention|Prenatal Care/Nutrition Education|Participants were given nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
9498309|NCT03467503|Experimental|Dietary Intervention|Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
9547252|NCT03051555|Experimental|18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
9547253|NCT03051789|Experimental|Menstrual Cup|One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
9547254|NCT03051789|Experimental|Cash Transfer|Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
9547255|NCT03051789|Experimental|Cups and Cash|A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
9547256|NCT03051789|No Intervention|Control|'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
9547257|NCT03051711|Experimental|GBT440 Dose 1|Dose 1
9547258|NCT03051711|Experimental|GBT440 Dose 2|Dose 2
9547259|NCT03051568|Experimental|PTCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
9547260|NCT03051581|Experimental|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
9547261|NCT03051776|Experimental|Kinesio Taping|It was done a four week phase with Kinesio Taping in the arm affected with lymphedema.
9547262|NCT03051776|Active Comparator|Compression garment|It was done a four week phase with Compression garment in the arm affected with lymphedema.
9547263|NCT03051594|Active Comparator|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
9547264|NCT03051594|Active Comparator|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
9547265|NCT03051594|Experimental|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
9547266|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
9547267|NCT03051698|Experimental|C1-inhibitor|One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
9547268|NCT03051698|Placebo Comparator|Saline|One gift of intravenous administration of 0.9% NaCl during one hour.
9547269|NCT03051698|Experimental|Antibiotics|broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).
9547270|NCT03051503|Active Comparator|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
9547271|NCT03051503|Placebo Comparator|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
9547272|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
9547273|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
10040913|NCT01858181|Experimental|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
9547274|NCT03051451|Placebo Comparator|Placebo Oral Tablet|Placebo
9547275|NCT03051750|Active Comparator|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
9547276|NCT03051750|Experimental|Kinesio Taping|Kinesio Taping during three weeks
9547277|NCT03051438|Other|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
9547278|NCT03051438|Other|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
9547279|NCT03051490|Experimental|Liprotamase|Individually-optimized dose to be administered orally
9547280|NCT03051490|Active Comparator|porcine PERT|Individually-optimized dose to be administered orally
9547281|NCT03051425|Experimental|Test group|Probiotic yogurt supplementation
10040914|NCT01858181|Experimental|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
9547282|NCT03051425|Placebo Comparator|Placebo group|Placebo supplementation
9547283|NCT03051412||Current Patellofemoral Pain|This group has current patellofemoral pain
10040915|NCT01858181|Experimental|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
10040916|NCT01858207|Active Comparator|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
10040917|NCT01858207|Active Comparator|RFA|Recent advances in local ablation are aimed to expand the ablation size (> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
10040918|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
9547284|NCT03051412||Recovered|This group has a previous history of patellofemoral pain, but currently self reports as recovered.
9547285|NCT03051412||Control|This is a control group with no history of knee pain.
10040919|NCT01858233|Experimental|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
9547286|NCT03051399|Placebo Comparator|Placebo|Maltodextrin, 500 mg/day, single serving
10040920|NCT01858233|No Intervention|Routine care|standard dietary counseling
9547287|NCT03051399|Active Comparator|EpiCor|EpiCor, 500 mg/day, single serving
9547288|NCT03051347|Other|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
9547289|NCT03051347|Other|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
9547290|NCT03051347|Other|Validation Questionnaire and Interview-Moderate to Severe|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
9547291|NCT03051347|Other|Validation Questionnaire and Interview-Mild|For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.
9547292|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
9547293|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
9547294|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
9547295|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
9547296|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
9547297|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
9547298|NCT03051074|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for up to 90 minutes on three separate occasions
9547299|NCT03051074|Active Comparator|Comparison condition|The participant will watch a relaxing 90 minute film as a comparison condition
9547300|NCT03051230||Studied group|Women exposed to ovarian hyperstimulation for In Vitro fertilisation
9547301|NCT03051295|Active Comparator|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
9547302|NCT03051295|Experimental|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
9547303|NCT03051295|Active Comparator|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
9547304|NCT03051295|Experimental|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
9547305|NCT03051386|Experimental|VEE Vaccine|0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
9547306|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
9547307|NCT03051373|Experimental|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
9547308|NCT03051373|Active Comparator|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
9547309|NCT03051308|Experimental|First Application in Hour 0|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group
9547310|NCT03051308|Experimental|First Application in Hour 6|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 6' cold ischemic tissue group
9547311|NCT03051308|Experimental|First Application in Hour 12|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 12' cold ischemic tissue group
10040921|NCT01858246|Active Comparator|Bonebridge|Implantation with a Bonebridge
10040922|NCT01858246|Active Comparator|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
10040923|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
10040924|NCT01858259||azathioprine|Patients receiving azathioprine
9547312|NCT03051308|Experimental|First Application in Hour 18|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 18' cold ischemic tissue group
9547313|NCT03051308|Experimental|First Application in Hour 24|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group
9547314|NCT03051321|Experimental|Wellness toileting system|Subjects given SchwabCare Wellness Toileting system
9547315|NCT03051334||BiAV|Bicuspid aortic valve
9547316|NCT03051334||TAV|Tricuspid aortic valve
9547317|NCT03051087|Experimental|Ganilever (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
9547318|NCT03051087|Active Comparator|Orgalutran (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
9547319|NCT03051152|Experimental|Elderly with CCS>5 - D1 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with limited lymphadenectomy
9547320|NCT03051152|Experimental|Elderly with CCS>5 - D2 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with extended lymphadenectomy
9547321|NCT03051139|Experimental|ICU A and ICU B|This is the intervention group.
9547322|NCT03051139|No Intervention|ICU C and ICU D|This is the usual care group.
9547323|NCT03051269|Experimental|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
9547324|NCT03051243|Active Comparator|Linagliptin and Basal Insulin|linagliptin (trajenta) 5mg once daily combined with basal insulin (glargine Lantus; sanofi) 0.15-0.3 units/kg TDD before bed time.
9547325|NCT03051243|Active Comparator|Basal Insulin and Bolus Insulin|Basal Insulin (Glargine Lantus; Sanofi) based therapy once daily before bedtime and glulisine (Apidra; sanofi) before meals. insulin dose will be 0.5 units/kg divided half as insulin glargine once daily and half as insulin glulisine before meals.
9547326|NCT03051360|Active Comparator|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
9547327|NCT03051360|Placebo Comparator|Placebo|Patients will receive bi-weekly placebo.
9547328|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
9547329|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
9547330|NCT03051035|Experimental|KO-947|
9547331|NCT03050866|Other|Treatment|Treatment intervention with Cabazitaxel with premedication as necessary (antihistamine, corticosteroid, H2 antagonist, antiemetic prophylaxis)
9547332|NCT03050905|Experimental|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
9547333|NCT03050879|Experimental|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
9547334|NCT03050879|Active Comparator|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
9547335|NCT03050827|Active Comparator|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
9547336|NCT03050827|Placebo Comparator|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
9547337|NCT03050853|Experimental|E-Cigarette|The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
9547338|NCT03050853|No Intervention|Assessments only|The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
9547339|NCT03050931||Epilepsy with intracranial electrodes|Electrical Impedance Tomography with depth electrodes or intracranial electrode mats
9547340|NCT03050931||Epilepsy with scalp electrodes|Electrical Impedance Tomography with scalp electrodes
9547341|NCT03050957|Experimental|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
9547342|NCT03050957|Experimental|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
9547343|NCT03050944||Cases|Lifestyle behaviour and dietary habits assessment in couples achieving pregnancy after in vitro fertilization process.
9547344|NCT03050944||Controls|Lifestyle behaviour and dietary habits assessment in couples failed to achieve pregnancy after in vitro fertilization process.
9547345|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previous on 25 μg)|Subjects received 25 μg in trial 000129.
9547346|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previously on placebo)|Subjects received placebo in trial 000129
9547347|NCT03051009|Experimental|Desmopressin ODT 25 μg (female)|New female subjects
9547348|NCT03051009|Experimental|Desmopressin ODT 25 μg (male previous on 25 μg)|Subjects received 25 μg in trial 000130
9547349|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on 50 μg)|Subjects received 50 μg in trial 000130
9547350|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on placebo)|Subjects received placebo in trial 000130
9547351|NCT03051009|Experimental|Desmopressin ODT 25 μg (male)|Subjects received placebo in trial 000130
9547352|NCT03051009|Experimental|Desmopressin ODT 50 μg (male)|New male subjects
9547353|NCT03050996||robotic radical prostatectomy patients|Patient scheduled to undergo robotic assisted radical prostatectomy
10040925|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
9489708|NCT00583076|Experimental|1|AST-120, 2grams, three times daily
9489709|NCT00581997|Experimental|1|QAX576
9489710|NCT00581997|Placebo Comparator|2|Placebo
9489711|NCT00581906||pts undergoing surgery or chemo-radiation treatment|
9489712|NCT00581477|Experimental|Droxidopa|Patients with known or suspected Dopamine beta-Hydroxylase Deficiency were administered Droxidopa doses of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg or 300 mg up to three times daily. Supine and upright blood pressures were subsequently measured 60 to 240 minutes post-dose.
9489713|NCT00580216|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 7 weeks followed a maintenance dosing adjusted according to the age and to the renal function for a minimum total treatment duration of 6 months.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or overdosage)."
9489714|NCT00580216|Active Comparator|Warfarin|Warfarin, INR-adjusted dose, for a minimum total treatment duration of 6 months.
9489715|NCT00580125|Experimental|A2|
9489716|NCT00580125|Placebo Comparator|A5|
9489717|NCT00580125|Active Comparator|A4|
9489718|NCT00580125|Experimental|A3|
9489719|NCT00580125|Experimental|A1|
9489720|NCT00579384|Experimental|001|
9489721|NCT00579189|Experimental|Moxidex|Moxidex otic solution
9489722|NCT00579189|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
9489723|NCT00579020|Experimental|Moxidex|Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
9489724|NCT00579020|Active Comparator|Moxifloxacin|Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
9489725|NCT00579020|Active Comparator|Dexamethasone|Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
9489726|NCT00578955|Experimental|1|
9489727|NCT00578955|Active Comparator|2|
9489728|NCT00578955|Active Comparator|3|
9489729|NCT00578773|Experimental|Moxidex|Moxidex otic solution
9489730|NCT00578773|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
9489731|NCT00578773|Other|TT only|Tympanostomy tubes only
9489732|NCT00578695|Experimental|Active|Lixivaptan
9489733|NCT00578695|Placebo Comparator|Placebo|Placebo
9489734|NCT00578474|Experimental|Moxidex|Moxidex otic solution
9489735|NCT00578474|Active Comparator|FLOXIN|Ofloxacin otic solution
9489736|NCT00577148|Experimental|Rimonabant|Rimonabant 20 mg once daily.
9489737|NCT00577148|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
9489738|NCT00576667|Experimental|Rimonabant|Rimonabant 20 mg once daily.
9489739|NCT00576667|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
9489740|NCT00576537|Experimental|Dendritic Cell Immunotherapy|Patients who consent to participate in the study and receive the Dendritic Cell vaccine manufactured from their own tumor cells.
9489741|NCT00576342|Other|AL-3862+timolol, then COSOPT|AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
9489742|NCT00576342|Other|COSOPT, then AL-3862+timolol|Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
9489743|NCT00575055|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
9489744|NCT00575055|Placebo Comparator|Placebo Dose|infusion every 13 weeks for a total of 6 infusions.
9489745|NCT00575055|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
9489746|NCT00574860|Experimental|EN3285 (NAC ProGelz)|The EN3285 arm is the product under development
9489747|NCT00574860|Placebo Comparator|No active ingredients (placebo)|This will be an oral product that contains no active ingredient
9489748|NCT00574860|Other|Standard of Care|This arm will reflect the typical standard of care for the patient
9489749|NCT00574132|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
9489750|NCT00574132|Placebo Comparator|Placebo Control|infusion every 13 weeks for a total of 6 infusions.
9489751|NCT00574132|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
9489752|NCT00572585|Experimental|AEB071|
9489753|NCT00572585|Placebo Comparator|Placebo|
9489754|NCT00570986|Placebo Comparator|1|Arm #1 is used for entire study. At week 12, arm is rerandomized.
9489755|NCT00570986|Active Comparator|2|Arm #2 is used for entire study. At week 12, arm is rerandomized.
9489756|NCT00570986|Active Comparator|3|Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
9489757|NCT00570752|Active Comparator|Placebo + background low to moderate dose statin|Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks
9489758|NCT00570752|Experimental|BMS-582949 + Background low to moderate dose statin|BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks
9489759|NCT00570752|Active Comparator|Atorvastatin|Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks
9489760|NCT00570635|Experimental|A|
9489761|NCT00570635|Experimental|B|
9489762|NCT00570336|Experimental|2.5 milligram (mg) CTS-1027|2.5 mg CTS-1027
9489763|NCT00570336|Experimental|5 mg CTS-1027|5 mg CTS-1027
9489764|NCT00570336|Experimental|10 mg CTS-1027|10 mg CTS-1027
9489765|NCT00570336|Experimental|30 mg CTS-1027|30 mg CTS-1027
9489766|NCT00570336|Placebo Comparator|Placebo|Placebo
9489767|NCT00569972|Experimental|15 mg PD 0200390|
9489768|NCT00569972|Experimental|30 mg PD 0200390|
9489769|NCT00569972|Experimental|45 mg PD 0200390|
9489770|NCT00569972|Experimental|60 mg PD 0200390|
9489771|NCT00569972|Experimental|Placebo PD 0200390|
9489772|NCT00569387|Experimental|Vaccine group|
9489773|NCT00569153|Experimental|Arm 1 (TAK-700)|
9547354|NCT03050840|Other|Self-monitoring|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage (SSB) consumption via text messaging. The Way to Health platform will record data.
9547355|NCT03050840|Experimental|Self-monitoring plus gamification|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage consumption via text messaging. Participants will be awarded medals and points based on meeting step per day and SSB consumption goals The Way to Health platform will be used to record data.
9547356|NCT03051022|Active Comparator|Dexamethasone 8 mg|Bupivacaine 0,125% 12,5 mg combined with dexamethasone 8 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
9547357|NCT03051022|Active Comparator|Morphine 2 mg|Bupivacaine 0,125% 12,5 mg combined with morphine 2 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
9547358|NCT03050749|Other|Princess® VOLUME|
9547359|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
9547360|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
9547361|NCT03050762||Endocrine Disease Group|"Information from the medical record recorded and entered into a research database.~Starting about 2-3 years after testing and/or diagnosis and/or treatment and continuing for up to 15 years after surgery, research team will contact participant by phone to follow up."
9547362|NCT03050788|Experimental|Smartphone confocal microscopy imaging|Subject's skin lesion will be imaged with the smartphone confocal microscopy.
9547363|NCT03050710|Other|Princess® VOLUME Lidocaine|
9547364|NCT03050723|Other|Princess® FILLER|
9547365|NCT03050684|Active Comparator|vaginal lavage group|We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule
9547366|NCT03050684|Placebo Comparator|Control group|We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.
9547367|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
9547368|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
9547369|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
9547370|NCT03050437|Experimental|Pem/Cis|Pem/Cis IV every 3 weeks
9547371|NCT03050437|Active Comparator|Pem alone|Pem IV alone every 3 weeks
9547372|NCT03050671|Active Comparator|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
9547373|NCT03050671|Active Comparator|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
9547374|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction > 50% on transthoracic echocardiography
9547375|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction < 40% on transthoracic echocardiography
9547376|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
9547377|NCT03050476|Experimental|bRESCAP|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion of 9000 IU over the next 24 hours.
9547378|NCT03050476|Placebo Comparator|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24 hours.
9547379|NCT03050632|Experimental|Working Memory Intervention (N-back)|Participants will complete the working memory priming task either for the first 3 days of the intervention or the last 3 days of the intervention, with order counterbalanced across participants. The working memory prime is the N-back test, a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back) (Jaeggi et al., 2010).
9547380|NCT03050632|Placebo Comparator|"White Bear Task"|Participants will complete this non-working-memory control task either for the first 3 days of the intervention or the last 3 days of the intervention, depending on counterbalanced order. The task consists of a procedure developed by Wegner and colleagues (1987) in a study of thought suppression, which instructs participants to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
9547381|NCT03050411|Experimental|Apatinib|Apatinib in combination with EGFR-TKIs
9547382|NCT03050515|Experimental|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
9547383|NCT03050528|Experimental|Combined Exercise and ACT treatment|Participants will attend a weekly group-based multidisciplinary pain programme for a period of eight weeks. The programme will combine exercise with the psychological approach acceptance and commitment therapy (ACT).
9547384|NCT03050528|Active Comparator|Standalone supervised exercise|Participants will attend a weekly group-based supervised exercise class for a period of eight weeks.
9547385|NCT03050554|Experimental|SBRT+Avelumab|"SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)~Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles"
10040926|NCT01858259||methotrexate|Patients receiving methotrexate
10040927|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
9489774|NCT00569153|Experimental|Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)|
9489775|NCT00569153|Experimental|Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)|
9489776|NCT00569153|Experimental|Arm 4 (TAK-700 at 600 mg)|
9489777|NCT00569062|Experimental|Arm 1|GW856553X 7.5mg BID for 6 weeks
9489778|NCT00569062|Placebo Comparator|Placebo|Placebo to match, BID, 6 weeks
9489779|NCT00568594|Experimental|1|
9489780|NCT00568594|Placebo Comparator|2|
9489781|NCT00566657|Experimental|Riferminogene pecaplasmid|4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals
9489782|NCT00566657|Placebo Comparator|Placebo|4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals
9489783|NCT00566449|Experimental|001|JNJ-31001074 10 mg daily for 4 weeks
9489784|NCT00566449|Placebo Comparator|003|Placebo one dose daily for 4 weeks
9489785|NCT00566449|Experimental|002|JNJ-31001074 30 mg daily for 4 weeks
9489786|NCT00566397|Experimental|1|
9489787|NCT00566397|Experimental|2|
9489788|NCT00566397|Placebo Comparator|3|
9489789|NCT00566345|Experimental|1|Vero-cell derived influenza vaccine
9489790|NCT00566345|Placebo Comparator|2|Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)
9489791|NCT00566202|Experimental|JNJ-18038683|
9489792|NCT00566202|Placebo Comparator|Placebo|
9489793|NCT00566202|Active Comparator|Escitalopram|
9489794|NCT00565760|Experimental|1|
9489795|NCT00565760|Placebo Comparator|2|
9489796|NCT00564928|Experimental|IPI-504: Group A|No Prior treatment for prostate cancer with cytotoxic chemotherapy (adjuvant or neoadjuvant chemotherapy is acceptable if completed >2 years prior to study)
9489797|NCT00564928|Experimental|IPI-504: Group B|"Must have evidence of radiographic metastatic disease~Must have been treated with a docetaxel-based chemotherapy regimen for HRPC with a minimum of 2 cycles with either PSA or RECIST defined radiographic progression during or witin 60 days of completeing docetaxel based chemotheraph or be intolerant of docetaxel-based chemotherapy~No more than three prior chemotherapies regimens for HRPC"
9489798|NCT00564421|Experimental|Epinastine low concentration:low dose volume|
9489799|NCT00564421|Experimental|Epinastine low concentration:high dose volume|
9489800|NCT00564421|Experimental|Epinastine high concentration:low dose volume|
9489801|NCT00564421|Experimental|Epinastine high concentration:high dose volume|
9489802|NCT00564421|Placebo Comparator|Placebo nasal spray|
9489803|NCT00564226|Experimental|SSR240600C Dose Level 1|
9489804|NCT00564226|Experimental|SSR240600C Dose Level 2|
9489805|NCT00564226|Experimental|SSR240600C Dose Level 3|dose level 3
9489806|NCT00564226|Active Comparator|Tolterodine|
9489807|NCT00564226|Placebo Comparator|Placebo|
9489808|NCT00563680|Experimental|Exploratory Cohort|If a total of two or more responses (partial and complete) in EFTs/DSRCTs are documented in this or the ongoing phase 1 study (20050118), then the study will allow enrollment of up to 10 additional EFT/DSRCT subjects who have been exposed to prior anti-IGF-1R targeting therapy.
9489809|NCT00563680|Experimental|Main Cohort|Subjects with relapsed Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have not received prior anti-IGF-1R therapy will receive AMG 479 at 12mg/kg.
9489810|NCT00563563|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg daily subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
9489811|NCT00563459|Experimental|001|carisbamate 400-1200 mg/day for 12 months
9489812|NCT00563459|Active Comparator|002|topiramate 200-400mg/day for 12 months
9489813|NCT00563459|Active Comparator|003|levetiracetam 1000-3000mg/day for 12 months
9489814|NCT00562887|Placebo Comparator|1|
9489815|NCT00562887|Experimental|400 mg|
9489816|NCT00562887|Experimental|700mg|
9489817|NCT00562575|Experimental|1|SLx-4090
9489818|NCT00562575|Placebo Comparator|2|Matching Placebo Dose
9489819|NCT00562497|Placebo Comparator|Placebo|Participants will receive 6 infusions of placebo-matching Prochymal® intravenously (IV) during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.
9489820|NCT00562497|Active Comparator|Prochymal® 2x10^6 hMSC/kg|Participants will receive 6 infusions of Prochymal® 2x10^6 human mesenchymal stem cells (hMSC)/kg IV during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.
9489821|NCT00560482|Active Comparator|A|
9489822|NCT00560482|Placebo Comparator|B|
9489823|NCT00560183|Experimental|1|
9489824|NCT00560183|Placebo Comparator|2|
9489825|NCT00559650|Placebo Comparator|Arm 1|
9489826|NCT00559650|Experimental|Arm 2|
9489827|NCT00559247|Experimental|or Placebo - Dose Panel 1|Oral Suspension, 10 mg
9489828|NCT00559247|Experimental|or Placebo - Dose Panel 2|Oral Suspension 50 mg
9489829|NCT00559247|Experimental|or Placebo - Dose Panel 3|Oral Suspension, 200 mg
9489830|NCT00559247|Experimental|or Placebo - Dose Panel 4|Oral Suspension or Solution, 2.5 to 600 mg
9489831|NCT00558311|Experimental|Clazosentan|A continuous intravenous infusion of clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
9489832|NCT00558311|Placebo Comparator|Placebo|A continuous intravenous infusion of placebo-matching clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
9489833|NCT00558207|Experimental|1|ARQ 197
10040928|NCT01858272|Experimental|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
10040929|NCT01858285||Epilepsy, genetics|
10040930|NCT01858298|Experimental|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
10040931|NCT01858298|Experimental|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
10040932|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
10040933|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
10040934|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
10040935|NCT01858324|Experimental|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
9489834|NCT00558207|Active Comparator|2|Gemcitabine
9489835|NCT00558038|Active Comparator|1|
9489836|NCT00558038|Experimental|2|
9489837|NCT00557973|Experimental|XP19986 SR1 10 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 10 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
9489838|NCT00557973|Experimental|XP19986 SR1 20 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 20 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
9489839|NCT00557973|Experimental|XP19986 SR1 30 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 30 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
9489840|NCT00557401|Experimental|XP19986 SR3, 20 mg QD|XP19986, 20 mg QD for approximately 32 days
9489841|NCT00557401|Experimental|XP19986 SR3, 40 mg QD|XP19986, 40 mg QD for approximately 32 days
9489842|NCT00557401|Experimental|XP19986 SR3, 60 mg QD|XP19986, 60 mg QD for approximately 32 days
9489843|NCT00557401|Experimental|XP19986 SR3, 30 mg BID|XP19986, 30 mg BID for approximately 32 days
9489844|NCT00557401|Placebo Comparator|Placebo|Placebo for approximately 32 days
9489845|NCT00555789|Active Comparator|1|mycophenolic and tacrolimus
9489846|NCT00555789|Experimental|2|mycophenolic and tacrolimus
9489847|NCT00555204|Experimental|A|
9489848|NCT00555204|Experimental|B|
9489849|NCT00555204|Experimental|C|
9489850|NCT00555204|Experimental|D|
9489851|NCT00555204|Experimental|E|
9489852|NCT00555204|Experimental|F|
9489853|NCT00555204|Placebo Comparator|G|
9489854|NCT00554385|Experimental|1|
9489855|NCT00554294|No Intervention|Control group|Control schools had school curriculum as usual and did not receive environmental intervention.
9489856|NCT00554294|Experimental|Intervention group|Intervention schools received water dispensers, drinking bottles and lessons as intervention.
9489857|NCT00554190|Experimental|1|AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
9489858|NCT00554190|Active Comparator|2|Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
9489859|NCT00553306|Experimental|Arm I|Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
9489860|NCT00552474|Placebo Comparator|Group B|Implanted but no active stimulation
9489861|NCT00552474|Experimental|Group A|Active Stimulation
9489862|NCT00551148|Experimental|15 mg|
9489863|NCT00551148|Experimental|30 mg|
9489864|NCT00551148|Experimental|5 mg|
9489865|NCT00551148|Experimental|60 mg|
9489866|NCT00551148|Placebo Comparator|Placebo|
9489867|NCT00550017|Experimental|1|
9489868|NCT00549679|Experimental|25 mcg|25 microgram inhaled once daily
9489869|NCT00549679|Experimental|87.5 mcg|87.5 microgram inhaled once daily
9489870|NCT00549679|Placebo Comparator|Placebo|Placebo inhaled once daily
9489871|NCT00548925|Experimental|1|
9489872|NCT00548925|Placebo Comparator|2|
9489873|NCT00548587|Active Comparator|1|Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.
9489874|NCT00548587|Active Comparator|2|Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.
9489875|NCT00548587|Active Comparator|3|Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.
9489876|NCT00548587|Placebo Comparator|4|Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.
9489877|NCT00548119|Experimental|NeoCart|
9489878|NCT00548119|Active Comparator|microfracture|
9547386|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
9547387|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of >30%. This will include patients scheduled for carotid endarterectomy (>50% for men and >70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
9547388|NCT03050606|Experimental|Pilates|"This group will perform a modified Pilates exercise program, which will be performed using mat, accessories and studio apparatus, in individual sessions, twice a week, lasting 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
9547389|NCT03050606|Active Comparator|Aerobic|"This group will perform aerobic exercise, performed on the treadmill or stationary bike according to the choice of the patient. The training will be performed controlling the heart rate of training. The exercises will be performed individually, twice a week and each session will last 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
9547390|NCT03050645||previous GDM|Women with previous GDM
9547391|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
9547392|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
9547393|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
9547394|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
9547395|NCT03050580|Experimental|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
9547396|NCT03050580|Active Comparator|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
9547397|NCT03050385|Active Comparator|active stimulation during cognitive rehabilitation|"active transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA(milliampere)~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
9547398|NCT03050385|Sham Comparator|sham stimulation during cognitive rehabilitation|"sham transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
9547399|NCT03050424|Experimental|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
9547400|NCT03050424|Placebo Comparator|Placebo|Sodium Chloride 0.9%
9547401|NCT03050281|Experimental|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
9547402|NCT03050281|Placebo Comparator|Didactic Workshop|Lectures
9547403|NCT03050255|Experimental|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)"
9547404|NCT03050255|Experimental|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)"
9547405|NCT03050255|Experimental|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Medical air (MA)~Oxygen (4 Liter/min)"
9547406|NCT03050255|Experimental|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)~Medical air (MA)"
9547407|NCT03050255|Experimental|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Medical air (MA)~Oxygen (2 Liter/min)"
9547408|NCT03050255|Experimental|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)~Medical air (MA)"
9547409|NCT03050346||CAD patients|Consecutive patients scheduled for a coronary angiography on the basis of cardiac symptoms and a test positive for inducible coronary ischemia, who are affected by one-vessel or two-vessel CAD at the time of the OS-CMR with breathing maneuvers (HVBH).
9547410|NCT03050346||Healthy subjects|Subjects without current or pre-existing cardiovascular and lung disease and absence of medication with cardiovascular effects.
9547411|NCT03050502|Active Comparator|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
9547412|NCT03050502|Sham Comparator|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
9547413|NCT03050047|Experimental|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
9547414|NCT03050047|Experimental|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
9547415|NCT03050047|Experimental|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
9547416|NCT03050047|Experimental|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
9547417|NCT03050034|Experimental|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
10040936|NCT01858324|No Intervention|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
9547418|NCT03050034|Active Comparator|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
9547419|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
9547420|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
9547421|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
9547422|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' > 14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet velocity >2.8 m/sec and septal e' velocity < 7 cm/s. A sample size of about 250 patients is required.
9547423|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
9547424|NCT03049995||SEO: SE in Outdoor in Extreme conditions|SE can also be performed outdoors, with pocket size or portable instruments, in a setting of ecological stress entirely different from standard indoor testing. The diagnostic target is the early subclinical identification of pulmonary edema. Subjects involved in extreme sporting events (competitive triathlon, marathon, apnea diving etc) or ordinary exercise in extreme environments (trekking at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70).
9547425|NCT03049995||SETOF: SE in operated Tetralogy of Fallot|Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age > 10 years, height > 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
9547426|NCT03049995||DOSPAH: Doppler SE in Pulmonary Arterial Hypertension|Patients at risk, borderline, or early established pulmonary hypertension capable of exercising will be recruited by regional reference centers, a physical stress will be performed and the hemodynamic assessment will include the assessment of pulmonary hemodynamics. The primary positivity criteria are the increase in systolic pulmonary artery pressure (> 40 mmHg) and the flow-adjusted variation in pulmonary vascular resistances. A sample size of about 250 patients is required to detect a significant stress-induced hemodynamic changes with a 3 -year follow-up.
10040937|NCT01858337|Experimental|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
10040938|NCT01858337|Experimental|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
10040939|NCT01858337|Active Comparator|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
10040940|NCT01858337|Active Comparator|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
10040941|NCT01858350|Other|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
10040942|NCT01858350|Other|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
10040943|NCT01858350|No Intervention|No intervention|
10040944|NCT01858350|Other|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
10040945|NCT01858402|Active Comparator|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
10040946|NCT01858402|Active Comparator|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
9489879|NCT00547651|Experimental|Amrubicin|Amrubicin
9489880|NCT00547651|Active Comparator|Topotecan|Topotecan
9489881|NCT00547066|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously.
9489882|NCT00546793|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.
9489883|NCT00546780|Active Comparator|Arm A|Tanespimycin + Bortezomib
9489884|NCT00546780|Active Comparator|Arm B|Bortezomib
9489885|NCT00546585|Experimental|90 mcg of Influenza A/H7N7|25 subjects to receive 90 mcg of Influenza A/H7N7.
9489886|NCT00546585|Experimental|15 mcg of Influenza A/H7N7|25 subjects to receive 15 mcg of Influenza A/H7N7.
9489887|NCT00546585|Experimental|7.5 mcg of Influenza A/H7N7|25 subjects to receive 7.5 mcg of Influenza A/H7N7.
9489888|NCT00546585|Experimental|45 mcg of Influenza A/H7N7|25 subjects to receive 45 mcg of Influenza A/H7N7.
9489889|NCT00546585|Placebo Comparator|Saline placebo|25 subjects to receive placebo.
9489890|NCT00546273|Experimental|RUTI 5 micrograms of FCMtb|RUTI dose: 5 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
9489891|NCT00546273|Experimental|RUTI 25 micrograms of FCMtb|RUTI dose: 25 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
9489892|NCT00546273|Experimental|RUTI 100 micrograms of FCMtb|RUTI dose: 100 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
9489893|NCT00546273|Experimental|RUTI 200 micrograms of FCMtb|RUTI 200 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
9489894|NCT00546273|Placebo Comparator|placebo|placebo of the vaccine RUTI (total n=8, n=2 for each period)
9489895|NCT00546247|Experimental|1|
9489896|NCT00545454|Experimental|SSR150106 QD|90 micro grams oral solution once daily (QD)
9489897|NCT00545454|Experimental|SSR150106 OEQD|90 micro grams oral solution once every other day (OEQD)
9489898|NCT00545454|Placebo Comparator|Placebo|oral solution QD or OEQD
9489899|NCT00544960|Experimental|1|AT-101 and docetaxel
9489900|NCT00544960|Placebo Comparator|2|placebo and docetaxel
9489901|NCT00544466|Experimental|Treatment (enzyme inhibitor, radiation therapy, transplant)|PREPARATIVE REGIMEN*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: *Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
9489902|NCT00544297|Experimental|PEP005 gel administration|0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand
9489903|NCT00544115|Active Comparator|Regimen I|Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
9489904|NCT00544115|Active Comparator|Regimen II|Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
9489905|NCT00544115|Active Comparator|Regimen III|Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
9489906|NCT00544115|Active Comparator|Regimen IV|Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
9489907|NCT00544115|Active Comparator|Regimen V|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
9489908|NCT00544115|Active Comparator|Regimen VI|Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
9489909|NCT00543582|Experimental|1|
9489910|NCT00543374|Placebo Comparator|Placebo|Placebo
9489911|NCT00543374|Active Comparator|PROCHYMAL Low dose|Low dose (total of 600 million cells)
9489912|NCT00543374|Active Comparator|PROCHYMAL High dose|High dose (total of 1200 cells)
9489913|NCT00542724|Experimental|A|VIAject™
9489914|NCT00542724|Active Comparator|B|Regular Human Insulin
9489915|NCT00542685|Experimental|PD 0332334 300 mg BID|
9489916|NCT00542685|Placebo Comparator|Placebo BID|
9489917|NCT00542685|Experimental|PD 0332334 225 mg BID|
9489918|NCT00542685|Experimental|PD 0332334 175 mg BID|
9489919|NCT00542633|Experimental|A|VIAject™
9489920|NCT00542633|Active Comparator|B|Regular Human Insulin
9489921|NCT00542035|Experimental|ARRY-371797|
9489922|NCT00542035|Experimental|Placebo, ARRY-371797|
9489923|NCT00542035|Placebo Comparator|Placebo|
9489924|NCT00542009|Experimental|CE-326,597 100 mg QD|
9489925|NCT00542009|Experimental|CE-326,597 50 mg QD|
9489926|NCT00542009|Experimental|CE-326,597 25 mg QD|
9489927|NCT00542009|Placebo Comparator|Placebo|
9489928|NCT00542009|Experimental|CE-326,597 5mg QD|
9489929|NCT00540358|Active Comparator|Arm G/C|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
9489930|NCT00540358|Experimental|Arm G/C/I|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
9489931|NCT00539929|Experimental|E6201 0.005% BID|Participants applied E6201 0.005% cream to a pre-identified marker lesion twice a day (BID) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
9489932|NCT00539929|Experimental|E6201 0.01% BID|Participants applied E6201 0.01% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
9547427|NCT03049995||DITSE: Diagnosis of CAD by imaging SE|"A clear step-up in diagnostic sensitivity (with a modest loss in specificity) and risk stratification capability is obtained with assessment of coronary flow velocity reserve in the left anterior descending coronary artery,left ventricular contractile reserve through changes in left ventricular elastance, and B-lines. Allcomers referred to the SE lab with suspected CAD will be evaluated with standard regional wall motion analysis and also - whenever feasible - with left ventricular coronary flow reserve and left ventricular elastance reserve and - when possible- B-lines (quadruple imaging).A sample size of about 5,000 patients will be required."
9547428|NCT03049995||GENES: Genetic Stress echocardiography|The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
9489933|NCT00539929|Experimental|E6201 0.03% BID|Participants applied E6201 0.03% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
9547429|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
9547430|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound
9547431|NCT03050099||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
9547432|NCT03050099||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
9547433|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
9547434|NCT03050086|Experimental|BPX-04 1% Minocycline Topical Gel|once daily topical administration of 1% minocycline gel to the face
9547435|NCT03050086|Experimental|BPX-04 2% Minocycline Topical Gel|once daily topical administration of 2% minocycline gel to the face
9547436|NCT03050086|Placebo Comparator|BPX-01 Vehicle Topical Gel|once daily topical administration of vehicle gel to the face
9547437|NCT03050242|Experimental|Glycopyrrolate|Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
9547438|NCT03050242|No Intervention|Control|No injection is conducted in this group.
9547439|NCT03050112|Experimental|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
9547440|NCT03050125|Experimental|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
9547441|NCT03050125|Experimental|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
9547442|NCT03050125|Experimental|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
9547443|NCT03050190|Experimental|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
9547444|NCT03050138||Dabigatran|In the RE-COVER- and RE-COVER II studies, one group of DVT and/or PE patients were randomized to receive 6 months of treatment with dabigatran (150 mg twice daily). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
9547445|NCT03050138||Warfarin|In the RE-COVER- and RE-COVER II studies, the other group of DVT and/or PE patients were randomized to receive 6 months of treatment with warfarin (once daily to maintain international normalized ratio (INR) 2.0-3.0). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
9547446|NCT03050177|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
9547447|NCT03050177|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
9547448|NCT03050229|Experimental|Empagliflozin|Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
9547449|NCT03050229|Placebo Comparator|Placebo|Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
9547450|NCT03050151|Experimental|1 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by auto-injector device
9547451|NCT03050151|Experimental|2 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by prefilled syringe
9547452|NCT03050151|Experimental|3 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by auto-injector device
9547453|NCT03050151|Experimental|4 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by prefilled syringe
9547454|NCT03050164|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
9547455|NCT03050164|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
10040947|NCT01858415|Experimental|Single arm|
10040948|NCT01858441|Other|Abiraterone Acetate|
10040949|NCT01858454|Experimental|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
10040950|NCT01858454|Active Comparator|Open myomectomy|Open surgery for myomectomy
9489934|NCT00539929|Experimental|E6201 0.03% QD|Participants applied E6201 0.03% cream to a pre-identified marker lesion once a day (QD) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
9547456|NCT03049982|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
9547457|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
10040951|NCT01858467|Experimental|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
9489935|NCT00539721|Experimental|Rolapitant Dose 1|
9489936|NCT00539721|Experimental|Rolapitant Dose 2|
9489937|NCT00539721|Experimental|Rolapitant Dose 3|
9489938|NCT00539721|Experimental|Rolapitant Dose 4|
9489939|NCT00539721|Active Comparator|Ondansetron|
9489940|NCT00539721|Placebo Comparator|Placebo|
9489941|NCT00538343|Experimental|RTA 744|
9489942|NCT00535366|Experimental|Tiotropium+salmeterol+fluticasone|
9489943|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide low|
9489944|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide high|
9489945|NCT00535366|Placebo Comparator|Placebo|
9489946|NCT00534027|Experimental|Arm 2|Low Dose AMG 655 with paclitaxel/carboplatin
9489947|NCT00534027|Placebo Comparator|Arm 3|Placebo with paclitaxel/carboplatin
9489948|NCT00534027|Experimental|Arm 1|AMG 655 High doseplus paclitaxel/carboplatin
9489949|NCT00533377|Experimental|CP-533,536 Dose Level 2|
9489950|NCT00533377|Placebo Comparator|Placebo|
9489951|NCT00533377|Other|Standard of Care|
9489952|NCT00533377|Experimental|CP-533,536 Dose Level 1|
9489953|NCT00533377|Experimental|CP-533,536 Dose Level 3|
9489954|NCT00533377|Experimental|CP-533.536 Dose Level 4|
9489955|NCT00532311|Experimental|Lapaquistat Acetate 50 mg QD|(and stable statin therapy)
9489956|NCT00532311|Active Comparator|Stable statin therapy|
9489957|NCT00532233|Experimental|1|QAX576
9489958|NCT00531622|Experimental|Saredudant/Escitalopram|Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks
9489959|NCT00531622|Active Comparator|Placebo and Escitalopram|Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks
9489960|NCT00531622|Placebo Comparator|Placebo|Placebo for saredutant and Placebo for Escitalopram once daily for one week during the screening phase and for a maximum of 8 weeks during the active phase
9489961|NCT00530166|Experimental|002|sham comparator 3(100 mg) tablets once daily for 12 weeks
9489962|NCT00530166|Experimental|001|JNJ-18054478 3(100 mg) tablets once daily for 12 weeks
9489963|NCT00530114|Placebo Comparator|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
9489964|NCT00530114|Experimental|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
9489965|NCT00530062|Active Comparator|Albuterol HFA-BAI|Albuterol Hydrofluoroalkane (HFA) Breath-Actuated Inhaler (BAI)
9489966|NCT00530062|Active Comparator|Albuterol HFA-MDI|Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
9489967|NCT00529503|Experimental|1|SGN-40, rituximab, etoposide, carboplatin, ifosfamide
9489968|NCT00529503|Placebo Comparator|2|placebo, rituximab, etoposide, carboplatin, ifosfamide
9489969|NCT00529152|Other|A|Ferriprox Oral Solution single treatment
9489970|NCT00528697|Experimental|1|Lowest ABT-089 dose
9489971|NCT00528697|Experimental|2|Low-medium ABT-089 dose
9489972|NCT00528697|Experimental|3|Medium-high ABT-089 dose
9489973|NCT00528697|Experimental|4|Highest ABT-089 dose
9489974|NCT00528697|Active Comparator|5|atomoxetine
9489975|NCT00528697|Placebo Comparator|6|placebo
9489976|NCT00528333|Experimental|1|Lintuzumab plus low dose cytarabine
9489977|NCT00528333|Active Comparator|2|Placebo plus low dose cytarabine
9489978|NCT00528242|Experimental|1|SLx-2101
9489979|NCT00528242|Placebo Comparator|2|Matching Placebo Dose
9489980|NCT00526227|Experimental|Secura ICD implant|Secura ICD device implanted
9489981|NCT00526045|Experimental|Escalation|
9489982|NCT00526045|Experimental|HER2 Positive|
9489983|NCT00526045|Experimental|ER+ breast cancer|
9489984|NCT00525330|Experimental|KRP-104 120 mg QD|
9489985|NCT00525330|Experimental|KRP-104 60 mg BID|
9489986|NCT00525330|Placebo Comparator|Placebo|
9489987|NCT00524277|Experimental|Arm I|HLA-A2-positive patients receive GP2 peptide + GM-CSF vaccine intradermally (ID) every 3-4 weeks for a total of up to 6 inoculations.
9489988|NCT00524277|Active Comparator|Arm II|HLA-A2-positive patients receive GM-CSF ID every 3-4 weeks for a total of up to 6 inoculations.
9489989|NCT00524277|Experimental|Arm III|HLA-A2-negative patients receive AE37 peptide/GM-CSF vaccine ID every 3-4 weeks for a total of up to 6 inoculations.
9489990|NCT00524277|Active Comparator|Arm IV|HLA-A2-negative patients receive GM-CSF ID ID every 3-4 weeks for a total of up to 6 inoculations
9489991|NCT00524056|Experimental|001|Carisbamate two 100 mg tablets twice per day
9489992|NCT00524056|Placebo Comparator|002|Placebo two placebo tablets twice per day
9489993|NCT00523328|Experimental|BG9924|dosage administered as per Biogen-idec protocol
9489994|NCT00523250|Experimental|AR-102 0.003% Ophthalmic Solution|q.d. ocular
9489995|NCT00523250|Experimental|AR-102 0.005% Ophthalmic Solution|q.d. ocular
9489996|NCT00523250|Experimental|AR-102 0.01% Ophthalmic Solution|q.d. ocular
9489997|NCT00523250|Experimental|AR-102 0.03% Ophthalmic Solution|q.d. ocular
9489998|NCT00523250|Experimental|AR-102 Vehicle Ophthalmic Solution|q.d. ocular
9489999|NCT00523042|Experimental|A|
9490000|NCT00523042|Active Comparator|B|
9490001|NCT00522990|Experimental|1|Refractory Hematological Malignancies
9490002|NCT00522834|Active Comparator|1|Elesclomol (STA-4783) in Combination With Paclitaxel
9490003|NCT00522834|Other|2|Paclitaxel alone
9490004|NCT00522145|Experimental|Group 1|
9490005|NCT00520923|Experimental|1|160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.
9547458|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
10040952|NCT01858467|Active Comparator|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
9490006|NCT00520923|Experimental|2|80mg of LY2140023, taken orally as 40mg twice daily, for up to 4 weeks.
9490007|NCT00520923|Experimental|3|40mg of LY2140023, taken orally as 20mg twice daily, for up to 4 weeks.
9490008|NCT00520923|Experimental|4|10mg of LY2140023, taken orally as 5mg twice daily, for up to 4 weeks.
9490009|NCT00520923|Placebo Comparator|5|Placebo of LY2140023, taken orally twice daily, for up to 4 weeks.
9490010|NCT00520923|Active Comparator|6|Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.
9490011|NCT00519389|Experimental|Low dose H5N1 VLP Vaccine|
9490012|NCT00519389|Experimental|Mid dose H5N1 VLP Vaccine|
9490013|NCT00519389|Experimental|High dose H5N1 VLP Vaccine|
9490014|NCT00519389|Placebo Comparator|Placebo|
9490015|NCT00519142|Placebo Comparator|1|metformin + placebo for mitiglinide
9490016|NCT00519142|Experimental|2|metformin + mitiglinide three times a day with meals
9490017|NCT00519142|Experimental|3|metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal
9490018|NCT00517920|Experimental|ABT-869|
9490019|NCT00517868|Other|Crossover|Placebo Treatment on Visit 1 followed by URG101 Treatment on Visit 2
9490020|NCT00517868|Other|Crossover 2|URG101 Treatment on Visit 1 followed by Placebo Treatment on Visit 2
9490021|NCT00517790|Experimental|ABT-869 0.25 mg/kg|Approximately half of the subjects were randomized to receive the high dose
9490022|NCT00517790|Experimental|ABT-869 0.10 mg/kg|Approximately half of the subjects were randomized to receive the Low Dose
9490023|NCT00517439|Experimental|Group 1|Group 1 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
9490024|NCT00517439|Experimental|Group 2|Group 2 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
9490025|NCT00517439|Experimental|Group 3|Group 3 will receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd for 24 weeks; after 24 weeks, those achieving a rapid virological response (RVR) will stop all medication, and non-RVR patients will remain on triple combination for an additional 24 weeks.
9490026|NCT00517439|Experimental|Group 4|Group 4 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
9490027|NCT00517439|Experimental|Group 5|Group 5 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
9490028|NCT00517439|Experimental|Group 6|Group 6 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
9490029|NCT00517439|Active Comparator|Group 7|Standard of care (SOC)
9490030|NCT00517153|Experimental|1|OGT-918 - Zavesca (miglustat)
9490031|NCT00517153|No Intervention|2|Standard treatment
9490032|NCT00517049|Experimental|1|
9490033|NCT00514865|Experimental|E1|1-2 mg of ONO-2333
9490034|NCT00514865|Experimental|E2|5-10 mg of ONO-2333
9490035|NCT00514865|Placebo Comparator|P|placebo comparator
9490036|NCT00514371|Experimental|tanespimycin and bortezomib|A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
9490037|NCT00514371|Experimental|bortezomib and tanespimycin|A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
9490038|NCT00514371|Experimental|bortezomib tanespimycin|A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.
9490039|NCT00514267|Experimental|1. HRPC|
9490040|NCT00514267|Experimental|2. Solid Tumors|
9490041|NCT00513617|Active Comparator|Low Dose|0.05 g/kg/day Arginine
9490042|NCT00513617|Active Comparator|High Dose|0.10 g/kg/day Arginine
9490043|NCT00513617|Placebo Comparator|Placebo|No Arginine
9490044|NCT00512317|Experimental|ganaxolone|active experimental drug
9490045|NCT00511485|Experimental|Etarfolatide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
9490046|NCT00511459|Experimental|A|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW
9490047|NCT00511459|Experimental|D|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW
9490048|NCT00511459|Experimental|B|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW
9490049|NCT00511459|Active Comparator|C|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW
9547459|NCT03049956|Experimental|Patients with clinical suspicion of ocular myasthenia gravis|
9547460|NCT03049722|Experimental|AVOPT Patient|
10040953|NCT01858480|Active Comparator|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
10040954|NCT01858480|Placebo Comparator|Placebo|Placebo dosage form designed to mock active.
9547461|NCT03049930|Experimental|Ketamine|Participants randomized to this arm will receive ketamine (1 mg/ml solution) infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
9547462|NCT03049930|Placebo Comparator|Placebo|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
9547463|NCT03049527|Experimental|Education, Incentives and Feedback|Education, Incentives and Feedback are all directed to all study participants.
9547464|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
9547465|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
9547466|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
9547467|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
9547468|NCT03049605|Experimental|Magnetic Therapy|Twenty five patient were exposed to low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss for 30 minutes / session for 2 times per week for 3 months .
9547469|NCT03049605|Experimental|Laser Therapy|Twenty five patients were treated with 24 sessions of laser therapy at a rate of two sessions / week for three months. Each patient will be exposed to Helium neon infrared laser (850 nano-meter continuous wave mode from a comfortable prone lying position.
9547470|NCT03049605|Experimental|Medical therapy|Fifteen patients were received only medical treatment .
9490050|NCT00511043|Experimental|All pts|PTK787
9490051|NCT00510133|Experimental|GRNVAC1|Autologous dendritic cell vaccine
9547471|NCT03049787|Experimental|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
9547472|NCT03049787|Active Comparator|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
9547473|NCT03049943|Active Comparator|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
9547474|NCT03049943|Experimental|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
9547475|NCT03049826|Experimental|Stem cell transplantation (SCT)|Children undergoing stem cell transplantation (SCT)
9490052|NCT00508989|Experimental|1|
9490053|NCT00508989|Placebo Comparator|2|
9490054|NCT00508625|Other|C|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
9490055|NCT00508625|Experimental|E|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
10040955|NCT01858493|Experimental|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
10040956|NCT01858493|Sham Comparator|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
10040957|NCT01858506|Experimental|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
9547476|NCT03049826|No Intervention|Home parenteral nutrition (HPN)|Children receiving home parenteral nutrition
10040958|NCT01858506|Active Comparator|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
10040959|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
9547477|NCT03049826|No Intervention|Healthy reference group|Healthy children
9490056|NCT00508625|Experimental|B|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.
9490057|NCT00508625|Other|A|40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only
9490058|NCT00508625|Experimental|D|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
9490059|NCT00508066|Experimental|Arm 1|Subjects in arm 1 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse 0.25 - 0.5% (according to patient's weight) Bupivacaine at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
9490060|NCT00508066|Placebo Comparator|Arm 2|Subjects in arm 2 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse normal saline at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
9490061|NCT00507936|Experimental|A|ABT-894 1 mg BID
9490062|NCT00507936|Experimental|B|ABT-894 2 mg BID
9490063|NCT00507936|Experimental|C|ABT-894 4 mg BID
9490064|NCT00507936|Placebo Comparator|D|
9490065|NCT00507936|Active Comparator|E|Duloxetine 60 mg QD
9490066|NCT00507741|Experimental|Ertafolide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg ertafolide labeled with 20 to 25 mCi of technetium-99m Part A: Induction phase of treatment: Two 4-week cycles; if stable disease or better at week 8 computed tomography (CT), participant may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit. Part B: 4-week cycles with CT every 8 weeks. Participants continue until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
9490067|NCT00506792|Experimental|1|QAU145
9490068|NCT00506792|Placebo Comparator|2|Placebo
9490069|NCT00505219|Experimental|Ixmyelocel-T|Core decompression & treatment with Tissue Repair Cells (TRCs), demineralized bone matrix bound in autologous plasma
9490070|NCT00505219|Active Comparator|Standard of Care Only|Core decompression, demineralized bone matrix bound in autologous plasma, without any TRCs.
9490071|NCT00504270|Placebo Comparator|Placebo|po daily
9490072|NCT00504270|Experimental|RG3421 120mg|120mg po daily
9490073|NCT00504270|Experimental|RG3421 20mg|20mg po daily
9490074|NCT00502710|Experimental|RO4876904 1|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
9490075|NCT00502710|Experimental|RO4876904 2|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
9490076|NCT00502710|Experimental|RO4876904 3|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
9490077|NCT00502710|Experimental|RO4876904 4|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
9490078|NCT00502710|Placebo Comparator|Placebo|Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
9490079|NCT00502515|Experimental|25 mg SSR180575|orally once daily for 24 weeks
9490080|NCT00502515|Experimental|100 mg SSR180575|orally once daily for 24 weeks
9490081|NCT00502515|Placebo Comparator|Placebo|orally once daily for 24 weeks
9490082|NCT00501709|Experimental|Treatment|Allogenic pancreatic islet transplant using belatacept and raptiva
9490083|NCT00501202|Placebo Comparator|002|placebo twice daily for 4 weeks
9490084|NCT00501202|Experimental|001|RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks
9490085|NCT00500812|Experimental|0.3 mg|Subjects Receiving 0.3 mg Cethrin
9490086|NCT00500812|Experimental|1 mg|Subjects receiving 1 mg Cethrin
9490087|NCT00500812|Experimental|3 mg|Subjects receiving 3 mg Cethrin
9490088|NCT00500812|Experimental|6 mg|Subjects receiving 6 mg Cethrin
9490089|NCT00500812|Experimental|9 mg|Subjects receiving 9 mg Cethrin
9490090|NCT00500084|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months
9490091|NCT00499239|Experimental|GS-9219|Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m^2) until determination of the maximum tolerated dose (MTD)
9490092|NCT00498966|Experimental|Group A|Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor.Intervention: Perifosine.
9490093|NCT00498966|Experimental|Group B|Patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Intervention: Perifosine.
9490094|NCT00498914|Experimental|1|
9547478|NCT03049696|No Intervention|Control Group (Standard of Care)|All patients will receive the Centre for Metabolic and Bariatric Surgery (CMBS) standard of care including two to four multidisciplinary visits over six months, exercise counseling (kinesiologist), completion of a the CMBS behavior modification program (Craving ChangeTM), and achievement of lifestyle and dietary modification goals in order to be scheduled for surgery. The standard of care will be used as the control group (n=24). Matched historical controls (1:1) will be selected (based on age, gender, and body mass index) from the existing CMBS database.
9547479|NCT03049696|Experimental|Intervention Group-ENCOURAGEING START|Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
9547480|NCT03049592|Experimental|HIBISCUS counseling|Subject receives a third trimester prenatal appointment with a family planning specialist for contraceptive counseling (utilizing the Contraceptive CHOICE counseling script emphasizing the WHO birth-to-pregnancy recommendation of 18 months) and a follow up postpartum contraception visit with a family planning specialist.
9547481|NCT03049592|No Intervention|Standard counseling|Subect receives standard high-risk prenatal care and postpartum contraception provision by the referring community clinic. The community clinic offer standard family planning counseling that does not emphasize utilizing of long-acting reversible contraception to promote birth-to-pregnancy spacing of 18 months. This scenario is current the standard practice at the institutions.
9547482|NCT03049579|Experimental|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
10040960|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
10040961|NCT01858571|Experimental|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
9547483|NCT03049579|Placebo Comparator|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
9547484|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
9547485|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
9547486|NCT03049904|No Intervention|Wait List Control|Participants wait 3 weeks before receiving the intervention.
9547487|NCT03049904|Experimental|Experimental Vr2L 2Spirit|Participants immediately begin their participation in the virtual world.
9547488|NCT03049878|Active Comparator|analgesic group|preoperative oral dose of paracetamol-codeine
9547489|NCT03049878|Placebo Comparator|placebo group|preoperative placebo (starch)
9547490|NCT03049839|Experimental|Intervention_ structured|One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)
9547491|NCT03049839|Experimental|Intervention_ Informative|"Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).~There is a single group session where they receive information to prevent cardiomatabolic risk factors"
9547492|NCT03049839|Experimental|Intervention_ Communitarian|"One year, Intervention program at Community level. People with a FINDRISC less than 12 points.~Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors"
9547493|NCT03049800||FEP - Treatment as Usual|First Episode Psychosis patients who receive treatment as usual while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
9547494|NCT03049800||FEP - Targeted Cognitive Training|First Episode Psychosis patients who receive targeted cognitive training exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
9547495|NCT03049800||FEP - General Cognitive Exercises|First Episode Psychosis patients who receive general cognitive exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
9547496|NCT03049800||Healthy Controls|Age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
9547497|NCT03049683||Normal subjects|Thirty healthy volunteers without a previous history of vertigo or neuro-otologic diseases will be enrolled in this study. The subjects will be also screened with a full history on vestibular disorders, with pure tone audiogram, and head-impulse tests to exclude the possibility of previous vestibular disorders or migraine which may cause abnormal VEMPs.
10040962|NCT01858571|Placebo Comparator|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)~Capsules of same size and color as used in metronomic therapy Best supportive care~Management of pain as per WHO standard for pain management"
9665312|NCT05105763|Other|feedback training on single joint first|Participants in Subgroup 1 will first undergo Condition B in the first visit and then Condition A in the second visit.
9490095|NCT00498212|Experimental|1018 ISS-HBsAg-Single|Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
10040963|NCT01858584|Experimental|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
10040964|NCT01858584|Active Comparator|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
9665313|NCT05105763|Other|sequential feedback training on multi-joint first|Participants in Subgroup 2 will start with Condition A in the first visit and then undergo Condition B in the second visit.
10040965|NCT01858584|No Intervention|control group|
9490096|NCT00498212|Experimental|1018 ISS-HBsAg-Double|Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)
9490097|NCT00497757|Experimental|Cardiac Failure Patients|Recipients treated with an enriched hematopoetic stem cell infusion from the heart donor's bone marrow
9490098|NCT00497159|Placebo Comparator|1|Placebo
9490099|NCT00497159|Experimental|2|Dimebon
9490100|NCT00496132|Experimental|1|
9490101|NCT00495885|Experimental|Volinanserin|Volinanserin 2 mg for a maximum of 87 days
9490102|NCT00495885|Placebo Comparator|Placebo|Placebo for volinanserin for a maximum of 106 days
9490103|NCT00495222|Experimental|Tissue plication|The Endoscopic Suturing System (ESS) is used for tissue apposition and reduction of the size of a dilated GJ anastomosis in subjects who are regaining weight after successful weight loss following gastric bypass
9490104|NCT00495131|Active Comparator|Peginterfron and ribavirin (24 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
9490105|NCT00495131|Active Comparator|Peginterferon and ribavirin (48 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
9490106|NCT00493441|Experimental|Treatment|
9490107|NCT00492960|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
9490108|NCT00492960|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
9490109|NCT00492960|Experimental|Larazotide acetate 8 mg|larazotide acetate 8 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
9490110|NCT00492960|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
9490111|NCT00492596|Experimental|device|insertion of balloon system
9490112|NCT00492596|Sham Comparator|sham|cystoscopy with sham system
9490113|NCT00492323|Placebo Comparator|002|placebo twice daily for 4 weeks
9490114|NCT00492323|Experimental|001|carisbamate 200 mg tablet twice daily for 4 weeks
9490115|NCT00491738|Experimental|1|
9490116|NCT00491738|Placebo Comparator|2|
9490117|NCT00489203|Experimental|Arm I|Patients receive oral beclomethasone dipropionate 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
9490118|NCT00489203|Active Comparator|Arm II|Patients receive oral placebo 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
9490119|NCT00488839|Other|IPX056 20 mg - OLE|A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
9490120|NCT00488839|Other|IPX056 40 mg - OLE|A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
9490121|NCT00488839|Other|Baclofen 20 mg - OLE|A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
9490122|NCT00488839|Other|Placebo - OLE|A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
9490123|NCT00488748|Experimental|MST|Magnetic Seizure Therapy (MST)
9490124|NCT00488748|Active Comparator|ECT|Electroconvulsive Therapy (ECT)
9490125|NCT00488267|Experimental|Thermoprofen|ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery [CHADD™] patch)
9490126|NCT00488267|Placebo Comparator|Placebo Matrix|Placebo matrix with CHADD patch.
9490127|NCT00488267|Placebo Comparator|Ketoprofen matrix/placebo CHADD|Ketoprofen matrix with placebo CHADD patch (no heat)
9490128|NCT00487656|Experimental|ART-123|6 mg/ml ampule solution for injection
9490129|NCT00487656|Placebo Comparator|Placebo|6 mg/mlampule of solution for injection
9490130|NCT00487305|Experimental|Biological/Vaccine|"Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.~--------------------------------------------------------------------------------"
9490131|NCT00486538|Experimental|Single arm|One oral dose daily
9547498|NCT03049683||Acute unilateral vestibular neuritis|The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score > 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
9547499|NCT03049670||latent available chlorine (LAC)|applying LAC on infected wounds
9547500|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
9547501|NCT03049761|Active Comparator|Water Flosser|Power interdental Cleaning Device
9547502|NCT03049761|Active Comparator|String floss|Manual interdental cleaning device
9547503|NCT03049761|Active Comparator|Manual Toothbrush|ADA standard manual toothbrush
9547504|NCT03049631|Active Comparator|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
9547505|NCT03049631|Experimental|Raspberry|Red raspberries (1 cup equivalent)
9547506|NCT03049553|Other|HPV-test|Cobas HPV-DNA test is performed on the cervical sample in addition to the routine cytology
9547507|NCT03049553|No Intervention|Routine|Screening with cytology as usual in the cervical screening program
9547508|NCT03049657|Active Comparator|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
9547509|NCT03049657|Active Comparator|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
9547510|NCT03049410|Active Comparator|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
9547511|NCT03049410|Active Comparator|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
9547512|NCT03049319|Experimental|Laser|All six interventions will be applied to patient's back.
9547513|NCT03049332|Experimental|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
9547514|NCT03049163|Other|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
9547515|NCT03049163|Experimental|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
9547516|NCT03049202||Never-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
9547517|NCT03049202||Ex-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that stopped smoking. Definition of smoking: > 10 pack years. Definition of ex-smoker: > 2 years since smoke cessation.
9547518|NCT03049202||Current-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that are currently smoking. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
9547519|NCT03049202||Current-smoker healthy controls|Current-smokers that are otherwise healthy, with normal lung function. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
9547520|NCT03049202||Never-smoker healthy controls|Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
9547521|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
9547522|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
9547523|NCT03049371|Other|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
9547524|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
9547525|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
9547526|NCT03049059|Experimental|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
9547527|NCT03049059|Active Comparator|4% hydroquinone cream alone|
9547528|NCT03049137|Experimental|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
9547529|NCT03049137|Active Comparator|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
9547530|NCT03049124|Experimental|Exercise|Participants will be asked to complete a 12-week exercise intervention and all study assessments.
9547531|NCT03049293|No Intervention|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
9547532|NCT03049293|Experimental|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
9547533|NCT03049358|Experimental|Arm I (olfactory training)|Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.
9665314|NCT05104892|Experimental|Rilzabrutinib|Rilzabrutinib and ICS/LABA
9547534|NCT03049358|Sham Comparator|Arm II (sham training)|Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks.
10040966|NCT01858597||gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
9547535|NCT03049384|Active Comparator|Traditional Exercise|A classical exercise intervention based on current guidelines for cancer survivors.
9547536|NCT03049384|Experimental|Tailored Exercise|A tailored and individualized exercise intervention based on the results of pre-intervention testing.
10040967|NCT01858597||control|Those healthy pregnant women
10040968|NCT01858610|Other|Irbesartan alone|Irbesartan 300 mg alone
9547537|NCT03049111|Experimental|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
9547538|NCT03049267|Experimental|Apremilast|N=15
9547539|NCT03049267|Placebo Comparator|Placebo Oral Tablet|N=5
9547542|NCT03049046|Active Comparator|CC100 250 mg|CC100 250 mg once daily by mouth for 7 days
9547543|NCT03049046|Active Comparator|CC100 500 mg|CC100 500 mg once daily by mouth for 7 days
9547544|NCT03049046|Active Comparator|CC100 1000 mg|CC100 1000 mg once daily by mouth for 7 days
9547545|NCT03049046|Placebo Comparator|Placebo|Placebo once daily by mouth for 7 days
9547546|NCT03049241||knee extensors|
9547547|NCT03049241||ankle plantar|
9547548|NCT03049228||Type 2 Diabetic Patients|"Obese (BMI > 27 kg/m2 < 35 kg/m2)~Non-insulin dependent; they must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months~They should have a (moderately) well-controlled diabetes (defined by a HbA1c<8%)"
9547549|NCT03049228||Obese Subjects|"A similar BMI as T2DM patients (BMI > 27 kg/m2< 35)~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
9547550|NCT03049228||Lean subjects|"BMI between 20-25 kg/m2~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
9547551|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
9547552|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
9547553|NCT03049436||Patients with program of adapted physical activity|
9547554|NCT03049085|Active Comparator|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
9547555|NCT03049085|Placebo Comparator|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
9547556|NCT03049345|Experimental|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
9547557|NCT03048786|Active Comparator|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
9547558|NCT03048786|Experimental|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
9547559|NCT03048851|Experimental|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
9547560|NCT03048851|Experimental|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
10040969|NCT01858610|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
10040970|NCT01858610|Other|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
10040971|NCT01858623|Other|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
10040972|NCT01858623|Other|Losartan 100 mg|Losartan 100 mg alone
10040973|NCT01858623|Other|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
9547561|NCT03048851|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
9547562|NCT03048851|Experimental|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
9547563|NCT03048851|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
9547564|NCT03048903|Experimental|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
9547565|NCT03048903|Placebo Comparator|Starch Corn|Medical Starch is harmless to people
9665315|NCT05104892|Placebo Comparator|Placebo|Placebo and ICS/LABA
10040974|NCT01858649|Active Comparator|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
10040975|NCT01858649|Active Comparator|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
10040976|NCT01858662|Active Comparator|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
10040977|NCT01858662|Active Comparator|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
9547566|NCT03048760|Experimental|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan & 1 after approx. 2 weeks of radiotherapy treatment.
9547567|NCT03048812|Experimental|O'Ring attachment (A)|One arm of our research will receive O'Ring attachment for 3 months and after this period they will recieve the second attachment Equator for more 3 months
9547568|NCT03048812|Experimental|Equator attachment (B)|The second arm of our research will receive Equator attachment for 3 months and after this period they will recieve the second attachement O Ring for more 3 months
9547569|NCT03048773|Experimental|shockwave therapy|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
9547570|NCT03048773|Placebo Comparator|placebo|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
9547571|NCT03048890||Patients with PAD|Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.
9547572|NCT03048890||Patients without PAD|Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.
9547573|NCT03048838|Experimental|Risk reduction behavioral intervention|"Couples randomized to the risk reduction behavioral intervention (Conectando Latinos en Pareja) will participate in four weekly sessions with a facilitator. Each session will last 2 hours. Participants will receive information and complete activities, participate in games and discussions to improve their relationship and improve health."
9547574|NCT03048838|Active Comparator|Wellness Promotion Intervention|Couples randomized to the wellness promotion control group will receive the same number of hours of attention as the active experimental group but will not receive the risk reduction intervention. Information presented will consist of topics related to general health.
9547575|NCT03048877|Experimental|Apatinib|Apatinib Mesylate Tablets
9547576|NCT03048877|Placebo Comparator|Placebo|Placebo Tablets
9547577|NCT03048825|Experimental|Colchicine + Spironolactone +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
9547578|NCT03048825|Experimental|Spironolactone +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
9547579|NCT03048825|Experimental|Colchicine +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
9547580|NCT03048825|Placebo Comparator|Placebo +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
9547581|NCT03048929|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
9547582|NCT03048929|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
9547583|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
9547584|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
9547585|NCT03048955|Active Comparator|Indirect Decompression System|Superion® IDS surgical procedure
9547586|NCT03048955|Active Comparator|Direct decompression Surgery|Open, direct decompression surgical procedure
9547587|NCT03048942|Experimental|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
9547588|NCT03048942|Active Comparator|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
9547589|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
9547590|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
9547591|NCT03048669|Experimental|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
9547592|NCT03048669|No Intervention|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
9547593|NCT03048643|No Intervention|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
9547594|NCT03048643|Experimental|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
9547595|NCT03048994|Placebo Comparator|Placebo|Placebo
9547596|NCT03048994|Active Comparator|Glutamine|Glutamine
9547597|NCT03048734||Group (1): Men with Nocturia ≥2.|
9547598|NCT03048734||Group (2): Men with no nocturia (0-1).|
10040978|NCT01858675|Experimental|Biomarkers, total blood volume|
10040979|NCT01858688|Experimental|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
9547599|NCT03048721|Experimental|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
9547600|NCT03048721|Experimental|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
9547601|NCT03048682|Experimental|Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #2, 3, or 4"
9547602|NCT03048682|Active Comparator|Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #7 or after. This is our current practice."
9547603|NCT03048708|Experimental|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
9547604|NCT03048708|No Intervention|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
9547605|NCT03048981|Experimental|Fish oil intake|Healthy volunteers given maximum dose of fish oil for 10 days.
9547606|NCT03048370|Experimental|Left body temperature VS|Left body temperature (37°C) vestibular stimulation
9547607|NCT03048370|Experimental|Right body temperature VS|Right body temperature (37°C) vestibular stimulation
9547608|NCT03048370|Experimental|Left warm CVS|Left warm (44°C) caloric vestibular stimulation
9547609|NCT03048370|Experimental|Right warm CVS|Right warm (44°C) caloric vestibular stimulation
9547610|NCT03048370|Experimental|Left cold CVS|Left cold (30°C) caloric vestibular stimulation
9547611|NCT03048370|Experimental|Right cold CVS|Right cold (30°C) caloric vestibular stimulation
9547612|NCT03048474|Experimental|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
9547613|NCT03048318|Experimental|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
9547614|NCT03048318|Active Comparator|Portal Flushing only of Graft|Back table flush of portal vein only
9547615|NCT03048565|No Intervention|Usual care|No intervention
9547616|NCT03048565|Experimental|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
9547617|NCT03048357|Active Comparator|Freedom Bed|Freedom Bed Continuous Lateral Rotation Therapy System
9547618|NCT03048357|Other|Standard Hospital Bed & Protocol|Standard Hospital Bed with manual caregiver re-positioning every 2 hours
9547619|NCT03048409||Enteral tube fed adults|Enteral formula
10040980|NCT01858714|Active Comparator|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
9547620|NCT03048968|Experimental|study group1: elderly adults|Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS
9547621|NCT03048968|Experimental|study group2: stroke patients|Sit-to-stand movement and treadmill gait with GEMS and without GEMS
9547622|NCT03048344|Experimental|Part 1|Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
9547623|NCT03048344|Experimental|Part 2|Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
9547624|NCT03048526|Experimental|NovaTears®|
9547625|NCT03048526|Active Comparator|Hydrabak®|Unpreserved sodium chloride (0.9%) eye drops in ABAK® system
9547626|NCT03048656|Experimental|Individuals with leg-length discrepancy|Patients of Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences diagnosed with leg-length discrepancy. The examination of participants included a measurement of the length of lower limbs and the weight distribution as well as performing the static posturography.
9547627|NCT03048656|Active Comparator|control group|The group with healthy individuals; without leg-length discrepancy. The examination of participants included a measurement of the weight distribution as well as performing the static posturography.
9547628|NCT03048435||Cervical Cancer Patients|Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
10040981|NCT01858714|Experimental|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
9547629|NCT03048435||Oncologist|Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
9547630|NCT03048396|Experimental|Uterus transplantation|
9547631|NCT03048695|Experimental|Goal Management Training|Cognitive rehabilitation
9547632|NCT03048695|No Intervention|Waiting list|
9547633|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
9547634|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
9547635|NCT03048916|Other|general swallowing therapy|"including:~oral exercises~tactile stimulation~compensatory techniques~swallowing maneuvers"
9547636|NCT03048916|Experimental|the NMES therapy with VitalStim therapeutic device|The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS
9547637|NCT03048916|Active Comparator|: the combined NMES and general swallowing therapies|
9547638|NCT03048630|Experimental|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
9547639|NCT03048630|Other|Delayed intervention|Delayed knowledge and behavioral intervention
9547640|NCT03048552|No Intervention|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
9547641|NCT03048552|Experimental|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
9547642|NCT03048448|Experimental|Fevipiprant 450mg|450mg Film Coated Tablet
9547643|NCT03048591|Experimental|Electroacupuncture group|
9547644|NCT03048591|No Intervention|control group|
9616917|NCT02538393|Experimental|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
9616918|NCT02538224|Active Comparator|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
9616919|NCT02538224|Sham Comparator|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
9616920|NCT02538211|Placebo Comparator|Control|"Control group - subjects will receive no antibiotics~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
9616921|NCT02538211|Active Comparator|Broad-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~Ciprofloxacin 500mg 2dd1~Vancomycin 250mg 3dd2~Metronidazole 500mg 3dd1~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
9616922|NCT02538211|Active Comparator|Narrow-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~• Vancomycine 250mg 3dd2~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
9616923|NCT02538302|Experimental|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
9616924|NCT02538302|Active Comparator|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
9616925|NCT02538432|Experimental|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
9616926|NCT02538432|Active Comparator|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
9616927|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
9616928|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
10040982|NCT01858714|Experimental|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
9616929|NCT02538445|Experimental|Patients group 1|Memorization of the verbs by miming the action
9616930|NCT02538445|Experimental|Patients group 2|Memorization of the verbs by imagining the action
9616931|NCT02538445|Experimental|Patients group 3|Memorization of the action verbs by means of another word
9616932|NCT02538445|Experimental|Patients group 4|Simple memorization of the verbs
9616933|NCT02538445|Active Comparator|Healthy volonteers group 1|Memorization of the verbs by miming the action
9616934|NCT02538445|Active Comparator|Healthy volonteers group 2|Memorization of the verbs by imagining the action
9616935|NCT02538445|Active Comparator|Healthy volonteers group 3|Memorization of the action verbs by means of another word
9616936|NCT02538445|Active Comparator|Healthy volonteers group 4|Simple memorization of the verbs
9616937|NCT02538250|Experimental|1 Nutricomp Drink Plus|Nutricomp Drink Plus
9616938|NCT02538237|Experimental|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
10040983|NCT01858727|Active Comparator|forced air warming group|30 minutes before the preoperative will use forced air warming.
9616939|NCT02538237|Sham Comparator|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
9616940|NCT02538198|Experimental|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
9616941|NCT02538185|Placebo Comparator|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with vaccine (0.1mL);~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
9616942|NCT02538185|Active Comparator|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
9665316|NCT05104307||Cardiac Performance System (NSR)|Subjects will wear Cardiac Performance System (CPS) non-invasive device during their standard echocardiogram
9547645|NCT03048240|Experimental|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
9547646|NCT03048604|Experimental|Genio(TM) system therapy|
9547647|NCT03048188|Experimental|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
9547648|NCT03048162|Active Comparator|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
9547649|NCT03048162|Active Comparator|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
9547650|NCT03048162|Active Comparator|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
9547651|NCT03048175|Experimental|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
9547652|NCT03048175|No Intervention|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
9547653|NCT03048214|Sham Comparator|General Anaesthesia|Patients would receive routine general anaesthesia for their distal radial fracture surgery
9547654|NCT03048214|Experimental|Regional Anaesthesia|Patients would receive routine infraclavicular nerve block for their distal radial fracture surgery
9547655|NCT03047915|No Intervention|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
9547656|NCT03047915|Experimental|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
9547657|NCT03048292||Mobilized Neurointervention Team|Patients undergoing endovascular stroke interventions.
9547658|NCT03048292||Mobilized Patient|
9547659|NCT03048292||Core Comprehensive Stroke Center Treatment|
9547660|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
9547661|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
9547662|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
9547663|NCT03047850||Study Group|All patients included in this study.
9547664|NCT03048123|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
9547665|NCT03048123|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
9547666|NCT03048110|Experimental|ODM-201|All subjects will receive a single dose of BAY1841788 (ODM-201) (600 mg) in the first treatment period of the study, then all subjects will receive twice daily 200 mg itraconazole on 1 day and once daily 200 mg itraconazole for the following 6 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the second treatment period, then all subjects will receive once a day 600 mg rifampicin for 10 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the third treatment period
9547667|NCT03047941||All patients|All patients included in the present study
9547668|NCT03047876||All neonates and infants undergoing aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
9547669|NCT03048097|Experimental|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
9547670|NCT03047902|Active Comparator|Parent Present|"The adolescents in group 1 (Parent Present) will be aware that their parents will be able to share the information on the questionnaire, but they will be assured of the confidentiality of the CO test. This will also be explained to the parent.~Intervention: Parents will be present for the questionnaire but not for the CO test."
9547671|NCT03047902|Active Comparator|Parent Absent|"The adolescents in group 2 (parents not present) will be assured of the confidentiality of the questionnaire and CO test. The confidentiality of the test will also be explained to the parent.~Intervention: Parents will not be present for the questionnaire or the CO test"
9547672|NCT03047837|Placebo Comparator|Arm A|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID)
9547673|NCT03047837|Experimental|Arm B|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
9547674|NCT03047837|Experimental|Arm C|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID)
9547675|NCT03047837|Experimental|Arm D|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
9547676|NCT03048084|Active Comparator|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
9616943|NCT02538185|Placebo Comparator|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
9616944|NCT02538172|Experimental|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
9547677|NCT03048084|Active Comparator|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
9547678|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
9547679|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
9547680|NCT03047798|Experimental|aqueous single-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in aqueous single-phase form.
9547681|NCT03047798|Experimental|oil-water two-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in oil-water two-phase form.
9547682|NCT03047798|Placebo Comparator|Control|The control mouthrinse only contained sodium fluoride
9547683|NCT03047811|Experimental|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
9547684|NCT03048136|Experimental|Flat-Dose|Nivolumab flat dose + Ipilimumab
9547685|NCT03048136|Experimental|Weight-Based Dose|Nivolumab weight-based dose + Ipilimumab
9547686|NCT03047824|Other|Continuous monitoring-guided therapy|Healthcare providers were allowed to use the blood glucose values displayed on the intravascular continuous monitoring to adapt insulin therapy
9547687|NCT03047824|Other|Standard of care|Healthcare providers used the usual intermittent method to adapt insulin therapy; the blood glucose values measured by the intravascular continuous monitoring were not displayed but recorded. Usual care involves the adjustment of insulin infusion based on BG values measured with a blood gas analyser 4-6 times per day.
9547688|NCT03047967|Experimental|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
9547689|NCT03047967|Experimental|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
9547690|NCT03047954|Experimental|Broncho-Vaxom|1 capsule (3.5 mg) per day, administered over 9 months
9547691|NCT03047954|Placebo Comparator|Placebo|Matching placebo capsule
9547692|NCT03047863|Experimental|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
9547693|NCT03047863|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
9547694|NCT03048019||Tirofiban Therapy|
9547695|NCT03048019||Cangrelor Therapy|
9547696|NCT03047772|Placebo Comparator|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
9547697|NCT03047772|Experimental|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
9547698|NCT03047772|Experimental|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
9547699|NCT03047772|Experimental|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
9547700|NCT03047772|Placebo Comparator|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
9547701|NCT03047772|Active Comparator|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
9547702|NCT03047772|Placebo Comparator|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
9547703|NCT03047772|Experimental|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
9547704|NCT03048032||Acute heart failure patients|Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
9547705|NCT03048032||Control group|Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.
9547706|NCT03048266||MEN1 Patients Who Have Developed Aggressive PNETs-Cases|
9547707|NCT03048266||MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls|
9547708|NCT03047525|No Intervention|control group|patients will just regularly chemotherapy
9547709|NCT03047525|Experimental|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
9547710|NCT03047694|Experimental|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
9547711|NCT03047694|Active Comparator|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
9547712|NCT03047538|Active Comparator|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
9616945|NCT02538172|Other|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
9616946|NCT02538159|Experimental|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
10040984|NCT01858727|No Intervention|control group|do not active heating group
9547713|NCT03047538|Active Comparator|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
9547714|NCT03047629|Experimental|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
9547715|NCT03047629|Placebo Comparator|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
9547716|NCT03047473|Experimental|Newly diagnosed GBM|single arm, open label Addition of Avelumab to standard treatment
9547717|NCT03047499||Scar Length|
9547718|NCT03047499||Vancouver scar scale|
9547719|NCT03047499||Scar width|
9547720|NCT03047668|Active Comparator|low-carb with PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), amplified with walnuts and walnut-sunflower muffins
9547721|NCT03047668|Active Comparator|low-carb without PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), without walnuts / walnut-sunflower muffins
9547722|NCT03047668|Active Comparator|low-fat with PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), amplified with walnuts and walnut-sunflower muffins
9547723|NCT03047668|Active Comparator|low-fat without PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), without walnuts / walnut-sunflower muffins
9547724|NCT03047408|Experimental|patients with PD-RBD|"patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study RBHP 2013 DURIF  at least three years ago."
9547725|NCT03047564|Experimental|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
9547726|NCT03047564|Active Comparator|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
9547727|NCT03047382|Active Comparator|Worthing Hospital site|AKI Care bundle instituted at Worthing site
9547728|NCT03047382|No Intervention|Chichester Hospital site|Continues standard care
9547729|NCT03047642||Malawi febrile patients|Children and adults with fever presenting at the outpatient department
9547730|NCT03047642||Brazil febrile patients|Children and adults with fever presenting at the outpatient department
9547731|NCT03047642||Gabon febrile patients|Children with fever or with a recent history of fever presenting at the outpatient department
9547732|NCT03047759|Active Comparator|Intervention A|water flosser
9547733|NCT03047759|Active Comparator|Intervention B|air floss
9547734|NCT03047733|Active Comparator|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
9547735|NCT03047733|Experimental|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
9547736|NCT03047707|Experimental|S-Shearwave and TE|
9547737|NCT03047655|Active Comparator|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
9547738|NCT03047655|Active Comparator|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
9547739|NCT03047460||healthy|"healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses~Intervention: multimodal evoked potentials"
10040985|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
9547740|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:~Aged 18 to 58 years old, inclusive, at the time of informed consent.~Expanded Disability Status Scale (EDSS) 0.0 to 6.5.~Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb~Have no comorbid condition (ie neuropathy) that could affect testing.~Intervention: multimodal evoked potentials"
9547741|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF with trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) with trilineage aplasia excluding Fanconi Anemia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
9547742|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/o trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) without trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
9547743|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/ Fanconi Anemia|Patients with acquired or inherited bone marrow failure (iBMF) with Fanconi Anemia and related DNA Repair Disorders will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
9547744|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
9547745|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
10040986|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
10040987|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
10058504|NCT02018770|Placebo Comparator|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
9490132|NCT00486512|Experimental|Active Treatment (calcitriol+ASA+CaCO3)|Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). The daily dose was administered as 1 capsule containing 0.5 mg calcitriol (Rocaltrol; Roche) and 2 tablets containing a 37.5-mg ASA core with a 625-mg calcium carbonate shell (tablet-in-tablet) that was made expressly for this study. Patients should take 1 capsule and 2 tablets daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
9490133|NCT00486512|Placebo Comparator|Placebo to calcitriol+ASA+CaCO3|Daily dose of matching placebo to 0.5 mg calcitriol, 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). Patients should take 1 capsule and 2 tablets of placebo daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
9490134|NCT00486200|Active Comparator|1|Oral administration of active comparator
9490135|NCT00486200|Placebo Comparator|2|Oral administration of placebo
9490136|NCT00486200|Experimental|3|Dosing regimen 1
9490137|NCT00486200|Experimental|4|Dosing regimen 2
9490138|NCT00486200|Experimental|5|Dosing regimen 3
9490139|NCT00486200|Experimental|6|Dosing regimen 4
9490140|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 1|
9490141|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 2|
9490142|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 3|
9490143|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 4|
9490144|NCT00484536|Experimental|CDP323 1000 mg/day|
9490145|NCT00484536|Experimental|CDP323 500 mg/day|
9490146|NCT00484536|Placebo Comparator|Placebo|
9490147|NCT00484419|Experimental|colesevelam|colesevelam tablets 625 mg
9490148|NCT00484419|Active Comparator|rosiglitazone|rosiglitazone maleate 4mg
9490149|NCT00484419|Active Comparator|sitagliptin|sitagliptin phosphate tablets
9498310|NCT03467490|Experimental|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
9498311|NCT03467490|No Intervention|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
9498312|NCT03467464|Experimental|Intervention|EMDR treatment
9498313|NCT03467438|Experimental|A|Zinc-l-carnosine, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
9498314|NCT03467438|Placebo Comparator|B|Placebo, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
9498315|NCT03467399|Experimental|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
9498316|NCT03467347|Experimental|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
9498317|NCT03467347|Experimental|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
9498318|NCT03467334|Experimental|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
9498319|NCT03467334|Experimental|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
9498320|NCT03467334|Active Comparator|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
9498321|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
9498322|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
10058505|NCT02018783|Experimental|Sensodyne|Digital application for 60 seconds.
9547746|NCT03047356|Experimental|"First-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the first person (if I...then I...). Ifs are critical situations, thens are appropriate responses."
9547747|NCT03047356|Experimental|"Second-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the second person (if you...then you...). Ifs are critical situations, thens are appropriate responses."
9547748|NCT03047356|Placebo Comparator|Control|"Participants are presented with ifs (critical situations) and thens but are not asked to form if-then plans."
9547749|NCT03047577|No Intervention|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
9547750|NCT03047577|Other|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
9547751|NCT03047590|Experimental|Choice-No Affect|These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
9547752|NCT03047590|Experimental|Choice-Affect|These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
9547753|NCT03047590|Experimental|No Choice-Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). Meanwhile, these participants are instructed to focus on the good feelings that come with exercise. this is heart rate-based exercise intensity with a focus on positive affect."
9547754|NCT03047590|Active Comparator|No Choice-No Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). This is heart rate-based exercise intensity with no focus on positive affect."
9547755|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
9547756|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
9547757|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
9547758|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
9547759|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
9547760|NCT03047512|Experimental|Internet-based program|The internet based program includes the following modules: (1) information and psychoeducational material, (2) symptom monitoring with personalized automatic feedback, (3) forum (peer support moderated by mental health professionals) and (4) chat (individualized support by mental health professionals). It also considers (5) the referral to face-to-face treatment of cases with symptoms that require it. (6) In addition to the web page in the institutions, there will be a monthly health promotion booth during breaks.
9547761|NCT03047512|No Intervention|Control Group|The control group will receive two psychoeducational workshops / conferences. In addition, the adolescents in the control group can participate in the monthly health promotion booths offered by the program.
9547762|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
9547763|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
9547764|NCT03047278|Active Comparator|Control Group|Adult patients (18 - 59 years old) with neuropathic pain of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting (phase I). To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10). In phase II, after 15 days (wash-out) from phase I, cetirizine hydrochloride (10 mg) was administered orally, twice a day, as pills, for five days. On the last day of cetirizine treatment, an oral single dose of gabapentin (300 mg), as capsule, was administered. Serial blood and urine samples were collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling.
9547765|NCT03047278|Experimental|Controlled Diabetes Group|Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≤ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
9547766|NCT03047278|Experimental|Uncontrolled Diabetes Group|Adult patients (18 - 59 years old) with uncontrolled type 2 diabetes (glycated hemoglobin ≥ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
10058506|NCT02018783|Experimental|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
10058507|NCT02018783|Experimental|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
10040988|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
9547767|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
10040989|NCT01858818||healthy 18 year old males|
9547768|NCT03047252|Experimental|Experimental group|"Home-based rehabilitation sessions performed with the novel digital biofeedback system.~Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol."
9547769|NCT03047252|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
9547770|NCT03047096|Experimental|HA & CS group|hyaluronic acid and corticosteroids
9547771|NCT03047096|Experimental|HA group|hyaluronic acid
9547772|NCT03047291|Placebo Comparator|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
9547773|NCT03047291|Experimental|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
9547774|NCT03047044|Active Comparator|Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
9547775|NCT03047044|Experimental|Optimizing B.I (New) PCA mode|(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
9547776|NCT03047018|Experimental|CHANGE Program|Participants with ASD will complete the The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) program.
9547777|NCT03046953|Experimental|Avleumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
9547778|NCT03046979|Experimental|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
9547779|NCT03046940|No Intervention|Control group|No communication with a doctor
9547780|NCT03046940|Experimental|Patient-centered|Participants communicate with a doctor that uses a patient-centered style of communication
9547781|NCT03046940|Experimental|Doctor-centered|Participants communicate with a doctor that uses a doctor-centered style of communication
9547782|NCT03047304|Other|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
9547783|NCT03047057|Experimental|Lidocaine|IV Lidocaine infusion
9547784|NCT03047057|Placebo Comparator|Control|IV normal saline infusion
9547785|NCT03047317|Experimental|MABp1|
9547786|NCT03047109|Active Comparator|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
9547787|NCT03047109|Active Comparator|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
9547788|NCT03047239|Experimental|Open angle glaucoma|SENSIMED Triggerfish
9547789|NCT03047265|Experimental|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
9547790|NCT03047265|Active Comparator|Cisplatin|Cisplatin combine with IMRT
9547791|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
9547792|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
9547793|NCT03046992|Experimental|YH25448|"Dose Escalation Phase: Consists of 7 Cohorts~Dose Expansion Phase: Consists of 5 Cohorts~Dose Extension Phase: Consists of 2 Cohorts"
9547794|NCT03046914|Experimental|HLA-B*5801 screen test|An arm in which a participant takes HLA-B*5801 test before administration of allopurinol
9547795|NCT03046901|Experimental|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
9547796|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
9547797|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
9547798|NCT03046836|Experimental|Oxytocin|Each participant will self-administer 40 IU intranasal Oxytocin
9547799|NCT03046836|Placebo Comparator|Control|Each participant will self-administer matching saline placebo
10040990|NCT01858831|Experimental|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
10040991|NCT01858831|Active Comparator|Atovaquone 750 mg|Atovaquone 750 mg
10040992|NCT01858831|Active Comparator|Atovaquone 1500 mg|Atovaquone 1500 mg
10040993|NCT01858844|Active Comparator|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
10058508|NCT02018783|Placebo Comparator|Cocorico|Digital application for 60 seconds
9547800|NCT03046628|Experimental|Patients with diabetic feet ulcers|Each patient will be examined twice, first with TcPO2 (TCM400, Radiometer Medical ApS, Denmark) and then with a green laser (harmonic of continuous neodymium-doped yttrium aluminium garnet laser 532-nm wavelength and fast camera (PixelLink PLE531) system.
9547801|NCT03046693|Experimental|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
9547802|NCT03046693|Placebo Comparator|Group B|Subjects in group B get placebo for 60 days.
9547803|NCT03046758|Experimental|Participants|
9616947|NCT02538159|Experimental|Experimental PICC|PICC insertion Peripherally inserted catheter
9616948|NCT02538133|Experimental|99mTc-Exametazime (HMPAO)-labeled leucocytes|
9547804|NCT03046888|Experimental|PCNL|Percutant nephrolithotomy is a standard procedure for stones treatment over 2 cm.The puncture will be performed with an 18-G nephrostomy needle. The access thus gained guaranteed the transpapillary route of the percutaneous tract, a basic condition for the prevention of bleeding. Subsequently, following withdrawal of the puncture needle and urine drainage, a flexible guidewire will be inserted and advanced to the upper calyx or ureter.
9547805|NCT03046888|Experimental|Robot assisted pyelolithotomy|Robot assisted pyelolithotomy, is a new technique to remove stones of more than 2 cm. A 12-mm camera port is placed at the level of the umbilicus and lateral. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
9547806|NCT03046875|Experimental|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
9547807|NCT03046875|Sham Comparator|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
9547808|NCT03046498|Experimental|Program participants|Patients enrolled in the DSMP and DPP who provide consent.
9547809|NCT03046485|Experimental|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
9547810|NCT03046485|No Intervention|Wait list control|Wait list control
9547811|NCT03046667|Experimental|Test drink|Test drink: Barley β-glucan
9547812|NCT03046667|Placebo Comparator|Control drink|Control drink: barley beverage
9547813|NCT03046563|Experimental|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
9547814|NCT03046563|Sham Comparator|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
9616949|NCT02538003|Experimental|Group 1(RT):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)~Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
9616950|NCT02538003|Experimental|Group 2(TR):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)~Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
9616951|NCT02537977|Experimental|CAR-T cells|Autologous 2nd generation CD19-directed CAR-T cells
9616952|NCT02538146|Experimental|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
9616953|NCT02538068|Experimental|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
9616954|NCT02538068|Active Comparator|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
9616955|NCT02538120|Active Comparator|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
9616956|NCT02538120|Active Comparator|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
9616957|NCT02538055|Placebo Comparator|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
9616958|NCT02538055|Experimental|Living Healthy Program|Participants in this arm worked with a Community Health Worker (CHW) who provided the Living Healthy Program. The Living Healthy Program was a cognitive-behavioral therapy based lifestyle modification program. Participants and CHW interacted by telephone 8 times over 3 months.
9616959|NCT02537964|Experimental|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
9616960|NCT02537964|No Intervention|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
9616961|NCT02538081|Active Comparator|Risperidone plus placebo|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus placebo
9616962|NCT02538081|Active Comparator|Risperidone plus DMXB-A|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus DMXB-A
9616963|NCT02537860|Experimental|Three PVB injections|Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
9616964|NCT02537860|Experimental|Five PVB injections|Patients will receive five PVB injections between T11 and L3.
9616965|NCT02537912|Active Comparator|Sugarlock®|Subjects ingested 2 capsules Sugarlock® (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
9616966|NCT02537912|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
9616967|NCT02537886||Evaluation Group|Researchers will conduct a focus group to evaluate VIC after it has been developed and used by patients. Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC. We will use this information to enhance the generalizability of the VIC approach.
9616968|NCT02537847|Experimental|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
9616969|NCT02537847|Active Comparator|control group|Intervention was prescribed ertapenem for patients.
9616970|NCT02537925|Active Comparator|concurrent_radiochemotherapy|Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
9547815|NCT03046706|Active Comparator|standard voice rest|This group maintains postoperative voice rest. Namely, absolute voice rest for a week, followed by a week of relative voice rest sound (talking is allowed for 20 minutes a day). post operative voice rest
9547816|NCT03046706|Experimental|no voice rest|This group has no limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions.
9547817|NCT03046771|Experimental|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
9547818|NCT03046771|No Intervention|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
9547819|NCT03046654|Experimental|Cervical cerclage|Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.
9547820|NCT03046589|Experimental|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
9547821|NCT03046589|Experimental|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
9547822|NCT03046589|Experimental|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
9547823|NCT03046589|Experimental|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
9547824|NCT03046589|Experimental|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
9547825|NCT03046589|Experimental|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
9547826|NCT03046511|Experimental|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
9547827|NCT03046511|Active Comparator|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
9547828|NCT03046719|Active Comparator|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
9547829|NCT03046719|Placebo Comparator|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
9547830|NCT03046797|Experimental|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
9547831|NCT03046797|Active Comparator|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
9547832|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
9547833|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
9547834|NCT03046784||Pregnant women in third trimester|"Non-labouring pregnant women hospitalised during their third trimester of pregnancy has an haemodynamic evaluation with Nexfin technology and transthoracic cardiac ultrasonography.~Evaluation is performed in two positions : dorsal decubitus and left lateral decubitus."
9547835|NCT03046641|Experimental|continuous training group|With the continuous training program
9547836|NCT03046641|Experimental|interval training group|With the interval training program
9547837|NCT03046732|Experimental|Explore Transplant Ontario|"Intervention 'Implementing Explore Transplant Education'"
9547838|NCT03046732|No Intervention|Control|The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.
9547839|NCT03046537|Active Comparator|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
9547840|NCT03046537|Active Comparator|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
9547841|NCT03046615||EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
9547842|NCT03046615||Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
9547843|NCT03046550|Experimental|Cohort A|Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
9547844|NCT03046550|Experimental|Cohort B|Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
9547845|NCT03046550|Experimental|Cohort C|Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
9547846|NCT03046680|Experimental|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
9547847|NCT03046680|Active Comparator|Multiprofessional Team|Physician, nurse, nutrionist usual care.
9547848|NCT03046459|Experimental|BNZ132-1-40|a range of IV doses
9547849|NCT03046810|Experimental|Wellness toileting system|This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
9547850|NCT03046407|Experimental|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
9547851|NCT03046394|Active Comparator|C-SACH|All the interventions will be administered to the patient in this single-subject trial, each 6 times
9547852|NCT03046394|Active Comparator|B-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
9490150|NCT00484029|Experimental|1|Nasal Carbon Dioxide
9490151|NCT00484029|Placebo Comparator|2|Air
9490152|NCT00483977|Active Comparator|Oxycodone|
9490153|NCT00483977|Placebo Comparator|Placebo|
9490154|NCT00483977|Experimental|PF-00592379|
9490155|NCT00483171|Placebo Comparator|Placebo|
9490156|NCT00483171|Other|Non-pharmacological weight loss program (NPP)|
9490157|NCT00483171|Other|Low Calorie Diet|
9490158|NCT00482664|Experimental|1 mg|
9490159|NCT00482664|Experimental|10 mg|
9490160|NCT00482664|Experimental|3 mg|
9490161|NCT00482664|Placebo Comparator|Placebo|
9490162|NCT00482092|Placebo Comparator|Placebo|Participants will receive matching placebo administered as intravenous (IV) infusions.
9490163|NCT00482092|Active Comparator|Prochymal® - Low dose|Participants will receive a total dose of Prochymal® 600 x 10^6 cells, IV infusion, on four days, once daily.
9490164|NCT00482092|Active Comparator|Prochymal® - High dose|Participants will receive a total dose of Prochymal® 1200 x 10^6 cells, IV infusion, on four days, once daily.
9490165|NCT00481520|Experimental|1|
9490166|NCT00481520|Placebo Comparator|2|
9490167|NCT00481325|Experimental|A1|
9490168|NCT00481325|Active Comparator|A2|
9490169|NCT00481325|Placebo Comparator|A3|
9490170|NCT00480831|Experimental|1|
9490171|NCT00480831|Placebo Comparator|2|
9490172|NCT00480701|Experimental|[123I]-IBVM|To assess [123I] IBVM and SPECT imaging
9490173|NCT00479817|Experimental|Arm A|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 10 mg/kg IV QW
9490174|NCT00479817|Experimental|Arm B|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 3 mg/kg IV QW
9490175|NCT00479817|Active Comparator|Arm C|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 placebo
9490176|NCT00479635|Experimental|TPI 287|
9490177|NCT00479505|Experimental|Active|
9490178|NCT00479505|Placebo Comparator|Placebo|
9490179|NCT00479492|Experimental|1|
9490180|NCT00479492|Experimental|2|
9490181|NCT00479492|Experimental|3|
9490182|NCT00479492|Placebo Comparator|4|
9490183|NCT00479427|Experimental|Overall study|overall study population
9490184|NCT00479258|Experimental|Inhaled insulin (Exubera)|
9490185|NCT00479258|Active Comparator|Subcutaneous Insulin (subject's prescribed)|
9490186|NCT00478972|Experimental|Rimonabant|Rimonabant 20 mg once daily in addition to diet and exercise
9490187|NCT00478972|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily in addition to diet and exercise
9490188|NCT00478738|Other|GSK961081|GSK961081
9490189|NCT00478595|Experimental|Rimonabant|Rimonabant 20 mg once daily
9490190|NCT00478595|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily
9490191|NCT00478088|Experimental|1|NeoDisc
9490192|NCT00478088|Active Comparator|2|ACDF
9490193|NCT00477529|Experimental|ABI-008|
9490194|NCT00476931|Experimental|1|SB-509
9490195|NCT00476931|Placebo Comparator|2|
9490196|NCT00474188|Experimental|Single Arm|
9490197|NCT00473525|Placebo Comparator|Placebo|
9490198|NCT00473525|Experimental|PF-00734200 10 mg QD|
9490199|NCT00473525|Experimental|PF-00734200 20 mg QD|
9490200|NCT00473525|Experimental|PF-00734200 5 mg QD|
9490201|NCT00473525|Experimental|PF-00734200 2 mg QD|
9490202|NCT00472836|Experimental|Normal renal function|
9490203|NCT00472836|Experimental|Severe renal impairment|
9490204|NCT00472693|Experimental|Bevacizumab and ABI-007 (Abraxane)|Bevacizumab and ABI-007 (Abraxane)
9490205|NCT00468442|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplants and maintenance immunosuppressive therapy.
9490206|NCT00468403|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplantations and continuous immunosuppressive therapy including belatacept
9490207|NCT00468273|Experimental|Intravenous Immune Globulin|Subjects with primary humoral immunodeficiency
9490208|NCT00468117|Experimental|Islet transplantation|Up to three separate islet transplants will occur and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG) and etanercept throughout study.
9490209|NCT00468039|Experimental|vildagliptin + metformin|
9490210|NCT00468000|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
9490211|NCT00468000|Placebo Comparator|Placebo|The control arm of the study will receive placebo injections.
9490212|NCT00467402|Experimental|1|
9490213|NCT00467402|Experimental|2|
9490214|NCT00467402|Placebo Comparator|3|
9490215|NCT00467025|Experimental|Arm A|
9490216|NCT00467025|Experimental|Arm B|
9490217|NCT00467025|Active Comparator|Arm C|
9490218|NCT00466765|Experimental|Single Arm|Use Brava system for pre-expansion of breast prior to fat grafting
9490219|NCT00465959|Experimental|400 mg TrIP|
9490220|NCT00465959|Experimental|800 mg TrIP|
9490221|NCT00465959|Placebo Comparator|Placebo|
9490222|NCT00465803|Other|DuoTrav|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
9490223|NCT00465803|Other|Travatan/Timolol|One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
9490224|NCT00465517|Experimental|ganaxolone|active study drug
9490225|NCT00465517|Placebo Comparator|non-active drug|placebo
9490226|NCT00464633|Experimental|Alvocidib|Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles
9490227|NCT00464555|Experimental|Islet Transfusion and LSF|Participants assigned to this group will receive an islet transfusion and an immunosuppressive medication regimen containing LSF.
9490228|NCT00464243|Experimental|Volinanserin|2 mg volinanserin tablets orally once daily
9490229|NCT00464243|Placebo Comparator|Placebo|tablets orally once daily
9490230|NCT00464061|Experimental|Volinanserin|
9490231|NCT00464061|Placebo Comparator|Placebo|
9490232|NCT00463242|Experimental|Agomelatine|Dosing for each subject in this extension study began with the same dose (25 mg or 50 mg of agomelatine orally once daily) the subject was receiving at the end of Week 8, the week before this study began.
9490233|NCT00463242|Active Comparator|2|
9490234|NCT00463242|Placebo Comparator|3|
9490235|NCT00462202|Experimental|Sulodexide|Open label extension to original trial
9490236|NCT00461006|Experimental|Aleglitazar|
9490237|NCT00461006|Active Comparator|Actos|
9490238|NCT00460941|Placebo Comparator|Placebo|sc weekly
9490239|NCT00460941|Experimental|Taspoglutide 20mg|sc weekly
9490240|NCT00460941|Experimental|Taspoglutide 20mg-30mg|sc weekly
9490241|NCT00460941|Experimental|Taspoglutide 20mg-40mg|sc weekly
9490242|NCT00460317|Placebo Comparator|Arm B|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
9490243|NCT00460317|Active Comparator|Arm A|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
9490244|NCT00459745|Active Comparator|Pravastatin|Pravastatin 40 mg
9490245|NCT00459745|Active Comparator|Fenofibrate|Fenofibrate 160 mg
9490246|NCT00459745|Experimental|Pravafen (Parvastatin and Fenofibrate)|Combined Therapy of Pravastatin 40 mg and Fenofibrate 160 mg.
9490247|NCT00459277|Experimental|Nasalfent, Fentanyl Citrate Nasal Spray|
9490248|NCT00459277|Placebo Comparator|Placebo Spray|
9490249|NCT00458978|Experimental|Treatment (enzyme inhibitor)|Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
9490250|NCT00458861|Experimental|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
9490251|NCT00458861|Placebo Comparator|Placebo|Subcutaneous administration of placebo given every other week for 12 weeks
9490252|NCT00458601|Experimental|CDX-110 with GM-CSF|
9490253|NCT00458276|Experimental|1|Tezosentan
9490254|NCT00458276|Placebo Comparator|2|Placebo
9490255|NCT00457457|Active Comparator|Comparator|Tamsulosin 0.4 mg prolonged release
9490256|NCT00457457|Experimental|Treatment Arm|There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg & 100mg), UK-369,003 IR (40mg),
9490257|NCT00456378|Experimental|DIAM™ spinal stabilization system|Implantation of the DIAM Spinal Stabilization System
9490258|NCT00456378|Active Comparator|Conservative care|Conservative Care
9490259|NCT00455559|Experimental|Perifosine 100 mg/d + imatinib mesylate|Perifosine 100 mg/d x 28 days Oral daily dose of perifosine 100 mg and oral daily dose of imatinib mesylate (current dose at time of progression of disease [PD] without interruption). Both drugs will be taken on a continuous basis and should be taken with food. Each cycle will be defined as 28 days.
9490260|NCT00455559|Experimental|Perifosine 900 mg/d + imatinib mesylate|Perifosine 900 mg/d (300 mg tid), 1 x weekly Oral once-weekly dose of perifosine 900 mg (300 mg tid) + oral daily dose of imatinib mesylate (current dose at time of PD without interruption). Perifosine will be taken on days 1, 8, 15, and 22 of a 28-day cycle. Both medications should be taken with food.
9490261|NCT00455156|Experimental|150/15 NES/EE CVR|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
9490262|NCT00454220|Placebo Comparator|Placebo|
9490263|NCT00454220|Experimental|0.01 mg MRrhTSH + 131-I arm|
9490264|NCT00454220|Experimental|0.03 mg MRrhTSH + 131-I arm|
9490265|NCT00453531|Experimental|Healthy Volunteers|
9490266|NCT00453271|Experimental|NB-002 0.25% BID|
9490267|NCT00453271|Experimental|NB-002 0.5% QD|
9490268|NCT00453271|Experimental|NB-002 0.5% BID|
9490269|NCT00453271|Sham Comparator|Vehicle control|
9490270|NCT00452127|Experimental|1|
9490271|NCT00451152|Experimental|Anecortave Acetate Depot|
9490272|NCT00451152|Placebo Comparator|Anecortave Acetate Vehicle|
9490273|NCT00450970|Experimental|1|Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of platinum (IV) compounds that are absorbed by the oral route. The lipophilic properties of these compounds, and hence their absorption, are largely determined by the nature of the axial acetate ligands.
9490274|NCT00450970|Experimental|2|Prednisone (17 alpha, 21-dihydroxypregna-1, 4-diene-3, 11, 20-trione) is commercially formulated as the acetate salt (prednisone 21-acetate). It is a biologically inert glucocorticoid, which is converted to active prednisolone in the liver.
9490275|NCT00449904|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months.
9490276|NCT00449878|Experimental|Liprotamase|"Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units).~Open Label Period: Liprotamase administered orally with each of three meals and two snacks daily for 21 days.~Double Blind Treatment Period: Administered orally with each of three meals and two snacks daily for 6 days.~Second Open Label Period: Administered orally with each of three meals and two snacks daily for 7 days."
9490277|NCT00449878|Placebo Comparator|Placebo|Double Blind Treatment Period: Placebo (microcrystalline cellulose) administered orally with each of three meals and two snacks daily for 6 days.
9490278|NCT00449605|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
9490279|NCT00449605|Active Comparator|Glimepiride|Glimepiride from 1 mg up to 6 mg once daily on top of metformin
9490280|NCT00448890|Experimental|GSK729327|Dose escalation from 1.0mg to 6 mg.
9490281|NCT00448890|Placebo Comparator|Placebo|
9490282|NCT00448721|Experimental|Perifosine|Perifosine will be administered orally at 100mg PO daily with food. One treatment cycle will consist of 42 days (6 weeks).
9490283|NCT00448422|Experimental|1|Tablet
9490284|NCT00448422|Placebo Comparator|2|Tablet
9490285|NCT00448058|Experimental|GSK372475|flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day
9490286|NCT00448058|Active Comparator|Venlafaxine|Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day
9490287|NCT00448058|Placebo Comparator|placebo|
9490288|NCT00447993|Experimental|1 NT-501|High Dose Implant
9490289|NCT00447993|Experimental|2 NT-501|Low Dose Implant
9490290|NCT00447980|Experimental|1 NT-501 implant|High Dose
9490291|NCT00447980|Experimental|2 NT-501 implant|Low Dose
9490292|NCT00447954|Experimental|1 high dose NT-501 implant|
9490293|NCT00447954|Experimental|2 low dose NT-501 implant|
9490294|NCT00447954|Sham Comparator|3 sham procedure|No implant
9490295|NCT00447564|Active Comparator|Group A|
9490296|NCT00447564|Placebo Comparator|Group B|
9490297|NCT00445198|Experimental|Phase 1 and Phase 2a|
9490298|NCT00443391|Experimental|1|
9490299|NCT00443326|Experimental|AMG 714|AMG 714 will be given as a multiple dose regimen
9490300|NCT00443287|Placebo Comparator|1|
9490301|NCT00443287|Experimental|2|dose level 1
9490302|NCT00443287|Experimental|3|dose level 2
9490303|NCT00443287|Experimental|4|dose level 3
9490304|NCT00443287|Active Comparator|5|
9490305|NCT00442104|Experimental|ganaxolone|
9490306|NCT00442039|Experimental|Lithium dosing 1|The starting dose of lithium was 300 mg for patients weighing < 20 kg [no patients were enrolled that weighed less than 20 kg] and 600 mg for patients weighing ≥ 20 kg.
9490307|NCT00442039|Experimental|Lithium dosing 2|"The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability."
9490308|NCT00442039|Experimental|Lithium dosing 3|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
9490309|NCT00442039|Placebo Comparator|Placebo|
9490310|NCT00441896|Experimental|ganaxolone|ganaxolone
9490311|NCT00441896|Placebo Comparator|non-active drug|placebo
9490312|NCT00440531|Active Comparator|1|RECOMBIVAX HB™
9490313|NCT00440531|Experimental|2|Modified Process Hepatitis B Vaccine
9490314|NCT00440531|Active Comparator|3|ENGERIX-B™
9490315|NCT00439738|Experimental|valsartan/HCTZ|
9490316|NCT00439738|Active Comparator|HCTZ +Amlodipine|
9490317|NCT00439634|Placebo Comparator|Placebo|
9490318|NCT00439634|Experimental|AVE1625 dose level 1|
9490319|NCT00439634|Experimental|AVE1625 dose level 2|
9490320|NCT00439634|Experimental|AVE1625 dose level 3|
9490321|NCT00437112|Experimental|1|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with insulin glargine and OAM continuation followed by 24 week treatment period with HIIP and OAM continuation~8 week follow up period"
9490322|NCT00437112|Experimental|2|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with HIIP and OAM continuation followed by 24 week treatment period with insulin glargine and OAM continuation~8 week follow up period"
9490323|NCT00437021|Active Comparator|Group C|Dryvax® vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
9490324|NCT00437021|Experimental|Group D|Standard dose IMVAMUNE® vaccine or placebo on Day 0 and Dryvax® vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
9490325|NCT00437021|Experimental|Group E|Dryvax® vaccine and standard dose IMVAMUNE® vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
9490326|NCT00437021|Experimental|Group F|Standard dose IMVAMUNE® vaccine or placebo on Day 0.
9490327|NCT00437021|Experimental|Group B|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 28.
9490328|NCT00437021|Experimental|Group A|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 7.
9490329|NCT00436683|Experimental|1|Dose titration on active
9490330|NCT00436683|Active Comparator|2|Dose titration
9490331|NCT00436670|Experimental|AMG 317 75 mg|75 subjects
9490332|NCT00436670|Placebo Comparator|Placebo Arm|75 subjects
9490333|NCT00436670|Experimental|AMG 317 300 mg|75 subjects
9490334|NCT00436670|Experimental|AMG 317 150 mg|75 subjects
9490335|NCT00435916|Experimental|1|
9490336|NCT00434850|Experimental|Allogeneic Pancreatic Islet Cells|Participants in this study can receive up to three separate islet transplants. They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant. Participants will continue taking sirolimus for the duration of the study. On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus. The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant. Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant. Etanercept will also be administered on Days 3, 7, and 10 post-transplant. Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
9490337|NCT00434811|Experimental|Islet Transplantation|Participants will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG), sirolimus, and low-dose tacrolimus.
9490338|NCT00434473|Placebo Comparator|Placebo|
9490339|NCT00434473|Experimental|A-001|
9490340|NCT00434226|Experimental|Bevacizumab + Carboplatin/Paclitaxel + Sunitinib|
9490341|NCT00434226|Placebo Comparator|Bevacizumab + Carboplatin/Paclitaxel|
9498323|NCT03467308||Colorectal cancer patients|50 Patients confirmed histopathologically to have early stages of colorectal cancer.
9547853|NCT03046394|Active Comparator|A-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
9547854|NCT03046381|Other|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
10040994|NCT01858844|Experimental|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
10040995|NCT01858857||Geriatric psychiatric in patients|
9547855|NCT03046355|Experimental|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
9547856|NCT03046355|Active Comparator|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
9547857|NCT03046368|No Intervention|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
9547858|NCT03046368|Experimental|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
9547859|NCT03046368|Experimental|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
9547860|NCT03046368|Experimental|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
9547861|NCT03046368|Experimental|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
9547862|NCT03046368|Experimental|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
9547863|NCT03046368|Experimental|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
9547864|NCT03046368|Experimental|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
9547865|NCT03046368|Experimental|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
9547866|NCT03046368|Experimental|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
9547867|NCT03046368|Experimental|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
9547868|NCT03046316|Other|local consolidative treatment|Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.
9547869|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
9547870|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
9547871|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
9547872|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
9547873|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
9547874|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
9547875|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
9547876|NCT03046030|Experimental|Healthy Volunteers|In this experiment, we will apply a crossover design in healthy subjects. Each subject will receive four treatments in four separate sessions: 1) VGAIT, 2) VGAIT control condition, 3) real acupuncture, and 4) sham acupuncture. Each session will be separated by at least 7 days. Subjects will participate in five experimental sessions: a training and familiarity behavioral session and four fMRI sessions during which the subject will receive one of the four treatments.
9547877|NCT03046173|Experimental|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
9547878|NCT03046173|Experimental|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
9547879|NCT03046160|Experimental|experimental group|"where treatment will involve conventional and Manual therapy (Mobilization with movement)+ tape (postural correction of scapular anterior tilt)~The Manual therapy (Mobilization with movement)intervention was of grade III mobilizations with movement performed in sitting for 6-10 repetitions for 3 sets~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
9547880|NCT03046160|Active Comparator|control group|"treatment will consist of the conventional approach+ tape (postural correction of scapular anterior tilt)~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
9547881|NCT03046199|No Intervention|Control|
9547882|NCT03046199|Experimental|Questionnaire|
9547883|NCT03046199|Experimental|Coordination|
9547884|NCT03046199|Experimental|Questionnaire + coordination|
9547885|NCT03046095|Experimental|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
9547886|NCT03046095|Experimental|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
9547887|NCT03045991|Experimental|sequential training group (SEQ)|"The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
9547888|NCT03045991|Active Comparator|control intervention group (CI)|"The control intervention group (CI) will receive a control training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
9547889|NCT03046303|Experimental|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
9547890|NCT03046303|No Intervention|conventional pathway group|The conventional pathway group received conventional care.
9547891|NCT03046186||Gastric sleeve operated subjects|12 patients who have undergone gastric sleeve operation >12 month prior to inclution.
9547892|NCT03046186||Control Subjects|12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age
9547893|NCT03046186||Gastric bypass operated subjects|12 patients, who have undergone Roux-en-Y gastric bypass >12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.
9547894|NCT03046004|Experimental|Decision aid|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
9547895|NCT03046004|Active Comparator|Control|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
9547896|NCT03046017|Active Comparator|real tDCS|In this group, the tDCS stimulates areas of the brain being examined in this study to increase their activity.
9547897|NCT03046017|Sham Comparator|sham tDCS|In this group, sham tDCS does not provide real stimulation though participants will not know this until the debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
10040996|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
10040997|NCT01858909|Placebo Comparator|Control|saline every 12 hours for 28 days
9547898|NCT03046017|Other|control group|In this group, participants will receive tDCS but will only receive a cream on their lower back.
9547899|NCT03046251|Other|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
9547900|NCT03046251|No Intervention|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
10040998|NCT01858909|Experimental|Melatonin|Oral 30mg/12hours melatonin 28 days
10040999|NCT01858935|Experimental|ND-L02-s0201 Injection 0.03 mg/kg|
10041000|NCT01858935|Experimental|ND-L02-s0201 Injection 0.1 mg/kg|
10041001|NCT01858935|Experimental|ND-L02-s0201 Injection 0.2 mg/kg|
10041002|NCT01858935|Experimental|ND-L02-s0201 Injection 0.4 mg/kg|
10041003|NCT01858935|Experimental|ND-L02-s0201 Injection 0.5 mg/kg|
10041004|NCT01858935|Experimental|ND-L02-s0201 Injection 0.6 mg/kg|
10041005|NCT01858935|Experimental|ND-L02-s0201 Injection 0.8 mg/kg|
10041006|NCT01858935|Placebo Comparator|Placebo|
10041007|NCT01858948|Experimental|Quitiapine plus Omega|Patients will be randomized to EPA+DHA supplements (OmegaRx) for 24 weeks
10041008|NCT01858948|Placebo Comparator|Quetiapine plus Placebo|Patients will be randomized to similar in shape an color placebo supplements (corn oil)
10041009|NCT01858961|Experimental|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
10041010|NCT01858961|Experimental|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
10041011|NCT01858987|Active Comparator|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
10041012|NCT01858987|Experimental|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
10058509|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
10058510|NCT02018835|Other|patients of an insufficiency organic severe surgical mitrale|
9547901|NCT03046264||coronary angiography|patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure
9547902|NCT03046277||Patients undergoing LTx|Retrospective analysis of clinical data
9547903|NCT03046277||Patients with pretransplant renal functional reserve testing|Prospective analysis of clinical data
10041013|NCT01859000|Experimental|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
10041014|NCT01859000|Other|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron & Kaminer, 2004) as well as trauma (La Greca & Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
9547906|NCT03046108|Active Comparator|blind injection of Morton neuroma|"Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.~Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
9547907|NCT03046108|Active Comparator|blind injection of Mepivacaine|"1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
9547908|NCT03046108|Active Comparator|blind injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
9547909|NCT03046108|Experimental|ultrasound guided injection|US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.
9547910|NCT03046108|Experimental|guided injection of mepivacaine|"2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
9547911|NCT03046108|Experimental|guided injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
9547912|NCT03046043|Experimental|Low-Voltage & CFAE guided ablation|"Pulmonary isolation will be performed~Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation~CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™~Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.~CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage & CFAE guided ablation)"
9547913|NCT03046043|Active Comparator|PV Isolation Only|"Pulmonary vein isolation will be performed.~Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
9547914|NCT03046290|Active Comparator|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
9547915|NCT03046290|Active Comparator|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
9547916|NCT03045952|Experimental|microwave ablation|Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
9547917|NCT03045939|Other|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
9547918|NCT03045939|Active Comparator|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
9547919|NCT03046238|Active Comparator|dexmetedomedine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
9547920|NCT03046238|Placebo Comparator|control|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
9547921|NCT03045900|Active Comparator|Translucent bulk-fill resin composite|*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
9616971|NCT02537925|Experimental|celecoxib_radiochemotherapy|Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
10041015|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
10041016|NCT01859052|Other|Obese migraineurs|Low carbohydrate diet
9547922|NCT03045900|Experimental|Shaded bulk-fill resin composite|*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
9547923|NCT03045874||30 parent-child dyads|Stratified purposive sampling will assure representation proportional to the minority representation in the community and will include equal subsamples (15 families each) of families with children 6-18 months of age and children aged 19-36 months.
9547924|NCT03045874||30 primary care providers|"Investigators will purposively recruit 30 primary care providers to assure proportional representation of physicians and NPs with a snowball method. The sample sizes should be sufficient to achieve saturation of the data for qualitative analyses, but we will recruit more participants if saturation is not obtained with the planned sample."
9547925|NCT03045874||focus groups|The investigators will hold separate focus groups for parents of the two age groups and clinicians. We anticipate conducting approximately 6 focus groups with 8-10 participants in each to review and refine the sleep program.
9547926|NCT03045874||22 parent-child dyads|The investigators will conduct feasibility testing of a 3 week sleep health promotion intervention. The intervention will be delivered to parents of children ages 12-36 months enrolled in one childcare center.
9547927|NCT03045874||5 childcare teachers|Teachers will be trained to deliver a brief sleep health intervention
9547928|NCT03045848||Biofreedom drug-coated stent|Subject implanted Biofreedom DCS for coronary artery disease
9547929|NCT03045796||Maintenance Hemodialysis Patients|Following the initial recruitment, all individuals who are willing to participate and sign the informed consent document will be provided with a medical history form to complete. In addition, we will ask them to sign a HIPAA authorization form in order to look into their medical records for monthly blood work (blood chemistry), anthropometric data (height and weight), interdialytic weight gain (weight gain since last treatment) history, and current medications.
9547930|NCT03045822|Experimental|Patients with cardiac implantable electronic devices|
9547931|NCT03045783|Experimental|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
9547932|NCT03045783|No Intervention|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
10041017|NCT01859052|Other|low-fat diet|Obese Migraineurs
10041018|NCT01859052|Other|Controls|Controls receiving AHA diet recommendations
10041019|NCT01859065|Placebo Comparator|Control|Mothers receive routine anticipatory guidance
10041020|NCT01859065|Experimental|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
10041021|NCT01859091|Experimental|Fat Reduction|
10041022|NCT01859104|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
10041023|NCT01859117|Experimental|3 x 10^6 cells|3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
9547933|NCT03045835|Experimental|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
9547934|NCT03045835|Active Comparator|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
9547935|NCT03045770|Experimental|mFOLFOX|The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
10041024|NCT01859117|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
10041025|NCT01859117|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
10041026|NCT01859117|Experimental|100 x 10^6 cells|100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
9547936|NCT03045770|Experimental|mFOLFIRI|The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
9665317|NCT05103839|Experimental|Yoga for Caregivers and Persons With Dementia|Persons With Dementia and their caregivers will participate in up to 20 group yoga classes.
10041027|NCT01859156||Carbon Monoxide Exposure|
10041028|NCT01859169||Control Group|Group that be administrated biliary drainage only
10041029|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
10041030|NCT01859182|Experimental|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
10041031|NCT01859234|Experimental|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
10041032|NCT01859260|No Intervention|Control|
10041033|NCT01859260|Experimental|Intervention|CPAP/autopap
10041034|NCT01859273|No Intervention|Standard Care|Standard Care after kidney transplantation
10041035|NCT01859273|Experimental|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
10041036|NCT01859286||regular sign out process|
10041037|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
10041038|NCT01859351|Experimental|WX-037|PI3K inhibitor
10041039|NCT01859351|Experimental|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
10041040|NCT01859377|Other|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
10041041|NCT01859377|Other|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
10041042|NCT01859416|Experimental|Oral nutritional supplement|2 * 125 mL low volume, energy and nutrient dense ONS per day (2 * 300 kcal) in addition to usual nutritional care
9547937|NCT03045770|Experimental|FOLFPTX|The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
9547938|NCT03045757||Healthy Newborn|Healthy Newborn
9547939|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
9547940|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
9547941|NCT03045692|Active Comparator|Control group|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
9547942|NCT03045692|Experimental|Study group|4 hour creatinine clearance is used to decide colistin maintenance dosage.
9547943|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
9547944|NCT03045705|Active Comparator|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
9547945|NCT03045705|Active Comparator|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
9547946|NCT03045666|Experimental|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
9547947|NCT03045666|No Intervention|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
9547948|NCT03045627|Active Comparator|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
9547949|NCT03045627|Active Comparator|Active comparator|"Ara-C, Aclarubicin Combined G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .~One course includes 28 days."
9547950|NCT03045640|Experimental|FSI ECD|"Vulnerable Households (ubudehe 1 or 2) in the Government of Rwanda's poverty classification system, when categories ranged from 1 to 6; the system has since been restructured to have four categories only. Often a way to identify households for public works opportunities or other government assistance programs. For this arm, families had to be Ubudehe 1 or 2 and have a child aged 0-3 years. Households meeting these criteria in the catchment area(s) received the FSI ECD home-based parenting intervention from bachelor-level interventionists/coaches."
9547951|NCT03045718|Experimental|Horticultural Therapy|Horticultural Therapy will consists of 1 hour sessions, weekly for 9 months, to engage subjects in gardening-based activities.
9547952|NCT03045718|Other|Waitlist Control|The control group will be placed on a waiting list and only be contacted for assessments. They will receive the same Horticultural Therapy intervention after the active treatment group at a later date.
9547953|NCT03045601|Experimental|CT-FFR|Analyse With New CT-FFR Method
9547954|NCT03045601|Active Comparator|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
9547955|NCT03045458|Active Comparator|Tissue level dental implant|Tissue level dental implants (Straumann AG, Waldenburg, Switzerland) were inserted in patients group I (n=20).
9547956|NCT03045458|Active Comparator|Bone level dental implant|Bone level dental implants (Straumann AG, Waldenburg, Switzerland ) were inserted in patients group II (n=20).
9547957|NCT03045484|Experimental|The moderate group|Patient who was suffering from moderate pain in the mouth, pharynx, or larynx during the treatment of chemoradiotherapy consented to take controlled-release oxycodone, oxycodone was begun at the level of mild pain. We called this the moderate group. Controlled-release oxycodone was used to relieve oral mucositis pain induced by chemoradiotherapy in this group.
9547958|NCT03045484|Experimental|The severe group|Patients who did not ask for controlled-release oxycodone until the pain reached a moderate level during the treatment of chemoradiotherapywere called the severe group. Controlled-release oxycodone was also used to relieve oral mucositis pain induced by chemoradiotherapy in this group..
9547959|NCT03045471||R-EPOCH|
9547960|NCT03045471||R-CHOP|
9547961|NCT03045588|Experimental|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
9547962|NCT03045588|Active Comparator|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
9547963|NCT03045562|Placebo Comparator|Control group|Patients will be assigned to receive 100ml of normal saline
10041043|NCT01859416|No Intervention|Control|Usual nutritional care
9547964|NCT03045562|Experimental|Experimental group|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline
9547965|NCT03045523|Experimental|GLPG2222 Dose 1|
9547966|NCT03045523|Experimental|GLPG2222 Dose 2|
9547967|NCT03045523|Placebo Comparator|Placebo|
9547968|NCT03045315|Experimental|women included in a IVF program|
9547969|NCT03045536||Patients with TFR|Patients treated with TFR for oncologic or non-oncologic reason
9547970|NCT03045510|Experimental|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
9547971|NCT03045406|Experimental|Apixaban|orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
9547972|NCT03045406|Active Comparator|Dalteparin|subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
9547973|NCT03045185|Experimental|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
10041044|NCT01859429|Experimental|Stepped Care|Structured stepped requirement of psychosocial support
10041045|NCT01859429|No Intervention|Care as usual|Unstructured requirement of psychosocial support
10041046|NCT01859442|Active Comparator|Exercise group|6 week structured responsive interval exercise training programme
10041047|NCT01859442|Sham Comparator|Control group|Negative, unsupervised, out of hospital control group
10041048|NCT01859455|Experimental|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
10041049|NCT01859455|Experimental|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
10041050|NCT01859455|Experimental|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
10041051|NCT01859455|Placebo Comparator|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
10041052|NCT01859455|Placebo Comparator|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
10041053|NCT01859468|Experimental|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
10041054|NCT01859468|Placebo Comparator|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
9490345|NCT00432185|Active Comparator|1|One day treatment
9490346|NCT00432185|Active Comparator|2|Two day treatment
9498324|NCT03467308||Risky group|20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
9498325|NCT03467295||Surgically treated group|Surgical removal of intracerebral CMs by craniotomy with or without following stereotactic radiosurgery.
9498326|NCT03467295||Conservatively treated group|Observation with the best medicine administration and supportive treatment are performed.
9498327|NCT03467282|Experimental|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
9498328|NCT03467282|Placebo Comparator|Placebo|1g polydextrose/maltodextrin - twice day
9498329|NCT03467256|Experimental|experimental|Patients will receive fludarabine 120 mg/m2 (totally) intravenously (IV) over 30 minutes on days -5 to -2 and cyclophosphamide 750 mg/m2 IV over 60 minutes on day -2. One hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.
9498330|NCT03467243|Experimental|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
9498331|NCT03467243|Experimental|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
9498332|NCT03467243|Other|Treatment as usual|Veterans receive treatment as usual
9498333|NCT03467230||NoL Index|All patients will be monitored by PMD-200 device
9498334|NCT03467178|Experimental|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
9498335|NCT03467178|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
9498336|NCT03467165|Experimental|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
9498337|NCT03467165|Experimental|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
9498338|NCT03467139|Experimental|Study Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. Then, abdominal breathing exercise training was given 3 times a week as 30 sets of 3 sets a week and the patients were treated for 8 weeks
9498339|NCT03467139|No Intervention|Control Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion.
9498340|NCT03467100|Experimental|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
9498341|NCT03467100|Placebo Comparator|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
9498342|NCT03467087|Experimental|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
10041055|NCT01859481|Placebo Comparator|Placebo|
10041056|NCT01859481|Experimental|Eletriptan HBr 40 mg|
10041057|NCT01859481|Experimental|Eletriptan HBr 80 mg|
10058511|NCT02018835|Other|insufficiency organic mitrale moderated in severe asymptomatic|
9547974|NCT03045679|Experimental|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
9547975|NCT03045679|Experimental|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
9547976|NCT03045198|Experimental|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
9547977|NCT03045211|Experimental|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
9547978|NCT03045211|No Intervention|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
9547979|NCT03045549|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
9547980|NCT03045549|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
9547981|NCT03045497|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
9547982|NCT03045341|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
9547983|NCT03045341|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
9547984|NCT03045341|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
9547985|NCT03045341|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
9547986|NCT03045380|Experimental|Game based rehabilitation|Game based rehabilitation will be administered once a week for 8 weeks.
9547987|NCT03045380|Active Comparator|Conventional rehabilitation|Conventional physiotherapy program will be administered once a week for 8 weeks.
9547988|NCT03045380|No Intervention|No intervention|Waitlist
9547989|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
10041058|NCT01859520|Experimental|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
10041059|NCT01859533|Experimental|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
10041060|NCT01859533|No Intervention|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
9547990|NCT03045159|Experimental|Strong Families|parenting program
9547991|NCT03045159|Active Comparator|Strong Parents|self-care program
9547992|NCT03045419||Patients group|"with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or > 20mm) and high-risk group of HCC~scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
9547993|NCT03045419||Living liver donor candidates|"living liver donor candidates without history of liver disease~schedule for gadoxetic acid-enhanced liver MRI as preoperative workup~only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
9547994|NCT03045432|Experimental|video-teaching materials|"regular passive ROM exercise~regular rehabilitation programe~alternative video-teaching materials"
9547995|NCT03045432|Other|control group|"regular passive ROM exercise~regular rehabilitation programe~regular oral-teaching materials"
9547996|NCT03045146||Multimodal brain imaging|Consecutive patients experiencing an acute ischemic stroke treated by thrombectomy according to the current recommendations. Clinical outcome will be compared according to the baseline imaging profile processed after patient treatment.
9547997|NCT03045354|Experimental|Mashed potatoes|Eggs with a side of mashed potatoes
9547998|NCT03045354|Experimental|French fries|Eggs with a side of French fries
9547999|NCT03045354|Experimental|Beans|Eggs with a side of beans
9548000|NCT03045354|Experimental|Traditional breakfast|Cereal, milk, toast and jam
9548001|NCT03045354|Experimental|Breakfast skipping|No breakfast
10041061|NCT01859546|No Intervention|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
10041062|NCT01859546|Experimental|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
10041063|NCT01859559|Experimental|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
9548002|NCT03045237|Experimental|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
9548003|NCT03045237|No Intervention|Control Group|The control group has the basic information through health professionals.
9548004|NCT03045172|Active Comparator|Group 1|20 subjects with Platelet Rich Plasma injections
9548005|NCT03045172|Placebo Comparator|Group 2|10 subjects with placebo injections
9548006|NCT03045445|Experimental|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
9548007|NCT03045445|Active Comparator|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
9548008|NCT03045263|Active Comparator|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
9548009|NCT03045263|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
9616972|NCT02537769|Experimental|LVAD+TVR|In addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
9616973|NCT02537769|Active Comparator|LVAD only|LVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
9616974|NCT02537834|Experimental|Tofogliflozin ＋GLP-1 analogue|Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.
9616975|NCT02538315||Surgery plus PET/CT imaging|Dopaminergic stem cell transplant and [18F]FDOPA PET/CT
9616976|NCT02537938|Experimental|NGP 555|NGP 555 given once a day for 14 days as a capsule; 100 mg, 200 mg, or 400 mg
9616977|NCT02537938|No Intervention|Placebo|Placebo comparator given once a day for 14 days as a capsule.
9616978|NCT02537665|Other|incidence of bleeding|the effect of the epidural catheter filled with heated or normal saline before inserting into epidural on the incidence of bleeding.
9616979|NCT02537665|Placebo Comparator|inserting time of catheter|record the time from beginning of catheter inserting to completing the placement of the catheter.
9616980|NCT02537756|Experimental|1- Verbalize, Choice|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics they choose
9616981|NCT02537756|Experimental|2- Listen, Choice|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics they choose
9616982|NCT02537756|Experimental|3- Verbalize, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics assigned to them
9616983|NCT02537756|Experimental|4- Listen, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics assigned to them
9616984|NCT02537795||Deep Brain Stimulation Patients|Patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
9616985|NCT02537795||Deep Brain Stimulation Family Members|Family members of patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
9616986|NCT02537795||Anterior Capsulotomy Patients|Patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
9616987|NCT02537795||Anterior Capsulotomy Family Members|Family members of patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
9616988|NCT02537587|Active Comparator|Control 1|67g of Control energy bar containing 4g protein, 15g fat, 42g carbohydrate, 2g fiber, and 24g sugar.
9616989|NCT02537587|Active Comparator|Control 2|86g of Control energy bar containing 5g protein, 20g fat, 55g carbohydrate, 3g fiber and 30g sugar
9616990|NCT02537587|Experimental|15/0|Experimental bar with 15% added resistant starch and 0% added protein; 66g portion containing 3g protein, 7g fat, 50g carbohydrate, 10g fiber and 16g sugar
9616991|NCT02537587|Experimental|15/0-LS|Experimental bar with 15% added resistant starch and 0% added protein with reduced sugar; 84g portion containing 4g protein, 8g fat, 55g carbohydrate, 15g fiber and 15g sugar
9616992|NCT02537587|Experimental|15/5|Experimental bar with 15% added resistant starch and 5% added protein; 75g portion containing 9g protein, 7g fat, 52g carbohydrate, 12g fiber and 17g sugar
9616993|NCT02537587|Experimental|10/5|Experimental bar with 10% added resistant starch and 5% added protein; 72g portion containing 10g protein, 8g fat, 49g carbohydrate, 9g fiber and 19g sugar
9616994|NCT02537587|Experimental|10/10|Experimental bar with 10% added resistant starch and 10% added protein; 80g portion containing 17g protein, 7g fat, 49g carbohydrate, 9g fiber and 18g sugar
9616995|NCT02537639||Control group|Control group. Standard teaching in transesophageal echocardiography.
9616996|NCT02537639||Intervention group|Intervention group. Additional teaching with a transesophageal echocardiography simulator.
9616997|NCT02537782|Other|Cardiac resynchronisation therapy implantation|Patients with current guideline-based indication for CRT implantation.
9616998|NCT02537652||Major Stroke|Patients diagnosed with major stroke who will undergo blood pressure assessment
9616999|NCT02537652||Minor stroke|Patients diagnosed with minor stroke who will undergo blood pressure assessment
9617000|NCT02537509|Active Comparator|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
9617001|NCT02537509|Placebo Comparator|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
10058512|NCT02018835|Other|patients of an aortic bicuspidie|
10058513|NCT02018835|Other|patients of a syndrome of Marfan|
9548010|NCT03045393|Experimental|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
9548011|NCT03045120||dasatinib cohort|Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
9548012|NCT03045120||imatinib cohort|Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
9548013|NCT03045120||nilotinib cohort|Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
9548014|NCT03045120||bosutinib cohort|Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
9548015|NCT03045133|Active Comparator|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
9548016|NCT03045133|Active Comparator|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
9548017|NCT03045250|Active Comparator|Type 1 Diabetes|Subjects with known Type 1 diabetes
9548018|NCT03045250|Placebo Comparator|Healthy Controls|Healthy controls
9548019|NCT03045107|Experimental|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
9548020|NCT03045107|Active Comparator|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
9548021|NCT03045068|Experimental|Study Group|"Platelet Transfusion Management~Pre-Termination of CPB- Platelet Transfusion 10ml/kg to be administered to the patient via central venous access when the patient has been rewarmed to 35*C, (the Sano or BT shunt clip is still on in children with SV physiology)~Post CPB- Platelet transfusion 10ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
9548022|NCT03045068|Active Comparator|Control Group|"Platelet Transfusion Management~Pre-Termination of CPB- No intervention~Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
9548023|NCT03045016|Experimental|Prazosin, ALPRESS® LP 2,5 et 5 mg|Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
9548024|NCT03044925|Experimental|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
9548025|NCT03044925|Active Comparator|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
9548026|NCT03045003|Other|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
9548027|NCT03045003|Other|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
9548028|NCT03044899||Adult surgical patients|All surgeries in adult patients
9548029|NCT03045055|Experimental|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
9548030|NCT03045055|Sham Comparator|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
9548031|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
9548032|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
9548033|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
9548034|NCT03044912|Experimental|treatment group|Mirabegron 50 mg for comparison
9548035|NCT03044912|Active Comparator|Comparative group|Patient take Mirabegron 25 mg
9548036|NCT03044678|Experimental|Experimental: REACH for Success|Experimental: Exposure-based, cognitive and behavioral, social skills training intervention 6-weeks - 6 session -20-30 min each
9548037|NCT03044678|Active Comparator|Active Comparator: Self-study|"Active Comparator: Books What to do when you are scared and worried?How to do homework without throwing-up? How to get organized without losing it? Reading at home"
9548038|NCT03044964|Active Comparator|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
9548039|NCT03044964|Placebo Comparator|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
9548040|NCT03044652|Experimental|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
9548041|NCT03044652|Active Comparator|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
9548042|NCT03044873|Experimental|BMS 986165 and Rosuvastatin|
9548043|NCT03044756|Experimental|-ve arm|The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
9548044|NCT03044756|No Intervention|+ve arm|The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
9548045|NCT03044860|Experimental|Type 2 diabetes|Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
9548046|NCT03044860|Experimental|Healthy|Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
9617002|NCT02537496|Experimental|Alzheimer's disease rTMS|The intervention procedure done in this group is repetitive Transcranial Magnetic Stimulation.
9548047|NCT03044626|Experimental|study group A|"Patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
9548048|NCT03044626|Other|study group B|"Patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w)."
9548049|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio < 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
9548050|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
9548051|NCT03044743|Experimental|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
9548052|NCT03044600||Young MEN1 Negative Group|Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
9548053|NCT03044834||Pleuropulmonary Blastoma|"Patients born between 01/01/2000 and 01/01/2016 ;~Followed up for PPB~Treated in a French department of paediatric oncology or paediatric surgery~Study agreement"
9548054|NCT03044951|Experimental|cryoballoon ablation|patients who accept cryoballoon ablation
9548055|NCT03044951|Active Comparator|radiofrequency ablation|patients who accept radiofrequency ablation
9548056|NCT03044795|Experimental|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
9548057|NCT03044795|Experimental|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
9548058|NCT03044665|Active Comparator|High-intensity statin monotherapy|Statin monotherapy
9548059|NCT03044665|Experimental|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
9548060|NCT03044769||Patient with CLA with surgery|
9548061|NCT03044769||Patient with CLA without surgery|
9548062|NCT03044587|Experimental|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
9548063|NCT03044587|Other|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
9548064|NCT03044821|Experimental|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
9548065|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.~This group will also complete a 3-hour nutrition module prior to study completion."
9548066|NCT03044808|Experimental|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
9548067|NCT03044808|Placebo Comparator|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
9548068|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
9548069|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 10 years post-implant). Participants in this group must already have an MCS device in place.
9548070|NCT03044561|Experimental|Sildenafil citrate|
9548071|NCT03044561|Placebo Comparator|placebo|
9548072|NCT03044548|Experimental|Experimental|Supportive supervision
9548073|NCT03044548|No Intervention|Control|No intervention
9548074|NCT03044522|No Intervention|No Nurse Education|Subjects who are enrolled into study arm with no Nurse Pain Educator will be monitored every month to assess their use of their medication, quality of life, physical and mental well-being. No intervention will be conducted with these subjects beyond that of standard of care at the facility.
9548075|NCT03044522|Other|Nurse Education|Subject enrolled into the Nurse Pain Educator arm will be educated (Opioid Education) on different opioid pain management topics with a focus on safe and appropriate use and consumption of opioid analgesics.
9548076|NCT03044509||TB exposure|
9548077|NCT03044509||TB infection (latent TB)|
9548078|NCT03044509||TB disease (active TB)|
9548079|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
10058514|NCT02018835|Other|Healthy volunteers|
9617003|NCT02537496|Sham Comparator|Alzheimer's disease rTMS Sham|The intervention procedure done in this group is Repetitive Transcranial Magnetic Stimulation - Sham
10041064|NCT01859559|Experimental|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
9490347|NCT00431873|Experimental|1|MGCD0103 administered orally three times per week.
9490348|NCT00430950|Experimental|1|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ) 40/25 mg + OM/HCTZ 20/25 mg matching placebo
9490349|NCT00430950|Experimental|2|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ)20/25 mg + OM/HCTZ 40/25 matching placebo
9490350|NCT00430508|Experimental|4|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
9490351|NCT00430508|Experimental|1|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
9490352|NCT00430508|Experimental|3|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
9490353|NCT00430508|Experimental|2|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
9490354|NCT00430092|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days
9490355|NCT00430092|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days
9490356|NCT00430092|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
9490357|NCT00429923|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days.
9490358|NCT00429923|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days.
9490359|NCT00429923|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
9490360|NCT00429429|Experimental|Peanut protein solution|Subjects receiving the peanut sublingual peanut protein drops. Sublingual Immunotherapy.
9490361|NCT00427856|Experimental|Obatoclax mesylate 40mg|40 mg over 3 hrs q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
9490362|NCT00427856|Experimental|Obatoclax mesylate 60mg|60 mg obatoclax mesylate over 24 hours, q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
9490363|NCT00427440|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
9490364|NCT00427440|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
9490365|NCT00427219|Experimental|Ozarelix|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received ozarelix on Day 0 and Day 14.
9490366|NCT00427219|Placebo Comparator|Placebo|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received placebo Day 0 and Day 14.
9490367|NCT00427154|Active Comparator|A|
9490368|NCT00427154|Active Comparator|B|
9490369|NCT00425464|Experimental|Synchrony® Dual Optic Intraocular Lens|
9490370|NCT00425464|Active Comparator|Standard Monofocal Intraocular Lens|
9490371|NCT00425321|Experimental|RWJ-445380 100 mg|
9490372|NCT00425321|Experimental|RWJ-445380 200 mg|
9490373|NCT00425321|Experimental|RWJ-445380 300 mg|
9490374|NCT00425321|Placebo Comparator|Placebo|
9490375|NCT00425100|Experimental|Open Label-fesoterodine|Single treatment study arm.
9490376|NCT00422981|Active Comparator|AL-108 5 mg|5 mg QD
9490377|NCT00422981|Active Comparator|AL-108 15 mg|15 mg BID
9490378|NCT00422981|Placebo Comparator|Placebo|Placebo
9490379|NCT00422019|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
9490380|NCT00422019|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.
9490381|NCT00421525|Other|Multiple Doses|Multiple Dose levels
9490382|NCT00420888|Experimental|Safety group|6-12 patients
9490383|NCT00420888|Experimental|1|
9490384|NCT00420888|Other|2|Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
9490385|NCT00420732|Experimental|Vaccine Group|
9490386|NCT00417287|Active Comparator|High dose|128 mg/m2
9490387|NCT00417287|Active Comparator|Low dose|54 mg/m2
9490388|NCT00417209|Experimental|Larotaxel (XRP9881)|
9490389|NCT00417209|Active Comparator|5-Fluorouracil or capecitabine|Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
9490390|NCT00417118|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
9490391|NCT00417118|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily in the morning for a maximum of 8 weeks
9490392|NCT00417118|Placebo Comparator|Placebo|Placebo for one week during the run in period and for a maximum of 8 weeks during the active period
9490393|NCT00415623|Active Comparator|Amlodipine 5mg|
9490394|NCT00415623|Experimental|Amlodipine 10mg|
9490395|NCT00415142|Experimental|Saredutant 100 mg|Saredudant100 mg once daily for a maximum of 32 weeks
9490396|NCT00415142|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily for a maximum of 32 weeks
9490397|NCT00415142|Placebo Comparator|Placebo|Placebo once daily for one week during screening phase and a maximum of 8 weeks during the acute phase
10041065|NCT01859559|Experimental|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
10041066|NCT01859585|Experimental|Parecoxib|Parecoxib
9490398|NCT00413725|Experimental|1|Three doses of MRKAd5 HIV-1 gag/pol/nef vaccine
9490399|NCT00413725|Placebo Comparator|2|Placebo
9490400|NCT00413205|Placebo Comparator|Placebo|po daily
9490401|NCT00413205|Experimental|RAR Gamma|5mg po daily
9490402|NCT00413114|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 30mg
9490403|NCT00411892|Experimental|A|
9490404|NCT00411892|Active Comparator|B|
9490405|NCT00411801|Experimental|Uniplas|Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
9490406|NCT00411801|Active Comparator|Cryosupernatant plasma|Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
9490407|NCT00411528|Experimental|1: 8 mg/m2 study drug + prednisone|Patupilone 8 mg/m2 + prednisone 5 mg bid daily
9490408|NCT00411528|Experimental|2: study drug + prednisone days 1 -8|Patupilone 10 mg/m2 + prednisone days 1 -8 at 25 mg bid, day 9 at 20 mg bid, day 10 at 15 mg bid, day 11 at 10 mg bid, day 12 - 21 at 5 mg bid
9490409|NCT00411528|Experimental|3: Study drug + prednisone days 1 - 4|Patupilone 10 mg/m2 + prednisone days 1 - 4 at 5 mg bid, days 5 -12 at 25 mg bid, day 13 at 20 mg bid, day 14 at 15 mg bid, day 15 at 10 mg bid, day 16 - 21 at 5 mg bid
9490410|NCT00411528|Active Comparator|4: Docetaxel 75 mg/m2 + prednisone 5 mg bid daily|Docetaxel 75 mg/m2 once every 3 weeks + prednisone 5 mg bid daily
9490411|NCT00411385|Experimental|1|900 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
9490412|NCT00411385|Experimental|2|1200 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
9490413|NCT00411385|Active Comparator|3|180 mcg PEG-IFNx2a every 1 week (24 doses)+ Ribavirin 800 micrograms per day
9490414|NCT00411242|Experimental|1|
9490415|NCT00411242|Experimental|2|
9490416|NCT00411242|Placebo Comparator|3|
9490417|NCT00411099|Experimental|1|
9490418|NCT00411099|Experimental|2|
9490419|NCT00411099|Placebo Comparator|3|
9490420|NCT00408954|Placebo Comparator|Placebo|
9490421|NCT00408954|Active Comparator|UK-369,003|
9490422|NCT00407914|Experimental|1|Aquamid
9490423|NCT00407914|Active Comparator|2|Restylane
9490424|NCT00407303|Experimental|1|30mg obatoclax, 1.0mg/m2 bortezomib
9490425|NCT00407303|Experimental|2|obatoclax 30 mg, bortezomib 1.3 mg/m2
9490426|NCT00407303|Experimental|3|Obatoclax 45 mg, Bortezomib 1.3 mg/m2
9490427|NCT00406809|Experimental|Phase 1a and 1b|Relapsed or refractory lymphoid malignancies
9490428|NCT00406809|Experimental|Arm A (Phase 2a)|Relapsed or refractory follicular lymphoma
9490429|NCT00406809|Experimental|Arm B (Phase 2a)|Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
9490430|NCT00406809|Experimental|Extension Study|Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
9490431|NCT00406588|Experimental|1|
9490432|NCT00406588|Placebo Comparator|2|
9490433|NCT00406458|Experimental|SB-509|60 mg SB-509 injected IM into lower limbs every 2 months
9490434|NCT00406458|Placebo Comparator|Normal Saline|Normal saline injected IM into lower limbs every 2 months
9490435|NCT00406068|Experimental|Mycobacterial cell wall-DNA complex|Mycobacterial cell wall-DNA complex
9490436|NCT00405951|Experimental|Obatoclax Mesylate + Docetaxel|Obatoclax Mesylate 250mL in combination with Docetaxel
9490437|NCT00405743|Experimental|Arm A|CP4055, 2 and 4 hour IV infusion
9490438|NCT00405743|Experimental|Arm B|CP-4055, Continuous IV infusion
9490439|NCT00405327|Experimental|DC vaccine therapy|Tumor lysate-pulsed dendritic cell (DC) vaccine following HSCT
9490440|NCT00404014|Active Comparator|AL-208|1 dose of 300 mg
9490441|NCT00404014|Placebo Comparator|Placebo|
9490442|NCT00403416|Active Comparator|Mycophenolic Acid / tacrolimus|
9490443|NCT00403416|Experimental|AEB071 / tacrolimus arm 1|
9490444|NCT00403416|Experimental|AEB071 / tacrolimus arm 2|
9490445|NCT00403169|Experimental|Lenalidomide for Advanced RCC|25 mg/day Lenalidomide for 21 days per cycle.
9490446|NCT00402428|Active Comparator|1|180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
9490447|NCT00402428|Experimental|2|900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
9490448|NCT00402428|Experimental|3|1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
9490449|NCT00401570|Experimental|Cohort 1|Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine
9490450|NCT00401570|Experimental|Cohort 2|Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine
9490451|NCT00401388|Experimental|Group A: chondrosarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
9498343|NCT03467061|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 14 days
9498344|NCT03467061|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 14 days
9548080|NCT03044405|Other|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
9548081|NCT03044938|Experimental|Salbutamol|Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
9548082|NCT03044938|Placebo Comparator|Placebo|Inoculant treatment through a substance that does not have an inherent power to produce an effect that is desired or expected. Four placebo puffs will be offered through a device similar to the salbutamol intervention device.
9548083|NCT03044639|Experimental|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
9548084|NCT03044639|Experimental|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
9548085|NCT03044639|Experimental|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
9548086|NCT03044639|Experimental|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
9548087|NCT03044366||Characteristics of Anesthesia management|Evaluate the average value of these data.
9548088|NCT03044366||Comorbidities|Evaluate the average value of these data.
9548089|NCT03044379|Active Comparator|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
9548090|NCT03044379|Placebo Comparator|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
9548091|NCT03044392|Active Comparator|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
9548092|NCT03044392|Active Comparator|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
9548093|NCT03044392|Active Comparator|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
9548094|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
9548095|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
9548096|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
9548097|NCT03044340|Experimental|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
9548098|NCT03044119|Active Comparator|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
9548099|NCT03044119|Experimental|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
9548100|NCT03044171|Experimental|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
9548101|NCT03044171|Experimental|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
9548102|NCT03044444|Experimental|high dose citrus extract|this group will receive a high dose (500mg/day) of the citrus extract for 8 weeks
9548103|NCT03044444|Experimental|low dose citrus extract|this group will receive a low dose (400mg/day) of the citrus extract for 8 weeks
9548104|NCT03044444|Placebo Comparator|placebo|this group will receive a placebo (500mg maltodextrin per day) for 8 weeks
9548105|NCT03044184|Active Comparator|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
9548106|NCT03044184|No Intervention|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
9548107|NCT03044067|Experimental|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
9548108|NCT03044067|Active Comparator|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
9548109|NCT03044301|Other|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
9548110|NCT03044301|Other|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
9548111|NCT03044301|Other|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
9548112|NCT03044301|Other|No special BMI|Subcutaneous low ZENEO® injection
10041067|NCT01859585|Experimental|Ketorolac|Ketorolac
10041068|NCT01859585|No Intervention|No medication|No medication
10041069|NCT01859624|Experimental|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
10041070|NCT01859650||NSCLC patients undergoing RT|
10041071|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
10041072|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
10041073|NCT01859663||Women with a history of irregular menstrual cycles|We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
9498345|NCT03467061|Other|Antibacterial mouthwash|2 x 10mL antibacterial mouthwash per day for 14 days
9498346|NCT03467035||desaturation|"ΔSpO2 >10% or lowest SpO2<90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
9498347|NCT03467035||non-desaturation|"ΔSpO2 <10% and lowest SpO2>90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
9498348|NCT03467009|Experimental|iPACT Intervention|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.~Eight-week longitudinal tailored CBT-based text-message program."
9498349|NCT03467009|Active Comparator|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
9498350|NCT03467009|Experimental|iPACT Intervention- App|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the message portion of the intervention delivered via app.~Eight-week longitudinal tailored CBT-based message program delivered via app."
9498351|NCT03466983|Experimental|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
9498352|NCT03466983|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
9498353|NCT03466970||IgG4 patient|20 samples of IgG4 patients
9498354|NCT03466970||healthy donors|20 healthy donors
9498355|NCT03466957|Experimental|3D printed applicator|individually designed applicator for BT
9498356|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
9498357|NCT03466931|Experimental|Dietary intervention|Meals containing Milk and Milk
9498358|NCT03466931|No Intervention|Historical cohort|Standard care
9498359|NCT03466905|Active Comparator|Intervention|Assessment of Ambulance Medical Service
9498360|NCT03466905|No Intervention|Control|Local treatment guidelines
9498361|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
9498362|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
9498363|NCT03466840|Experimental|The Coronally Advanced Lingual Flap|"On the lingual side of mandible, a full-thickness muco-periosteal flap is elevated until reaching mylohyoid line. Using a blunt instrument, a connective tissue band is localized continuing with the epimysium of the mylohyoid muscle and is inserted into the inner part of the lingual flap . The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe the amount of advancement is measured."
9498364|NCT03466840|Active Comparator|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured"
9498365|NCT03466814||JIA participants|
9498366|NCT03466788|Other|Patients treated with chemotherapy|
9498367|NCT03466788|Other|Patients not treated with chemotherapy|
9498368|NCT03466749|Experimental|Intervention group|Paclitaxel Eluting Balloon Catheter treatment
9498369|NCT03466736||cognitively intact older adults|Each subject will receive an amyloid PET scan with [18F]flutemetamol
9498370|NCT03466736||Mild Cognitive Impairment|Each subject will receive an amyloid PET scan with [18F]flutemetamol
9498371|NCT03466736||Alzheimer's disease|Each subject will receive an amyloid PET scan with [18F]flutemetamol
9498372|NCT03466710|Active Comparator|Colposcopy arm|Patients received colposcopy as per standard of care
9498373|NCT03466710|Experimental|Pap arm|Patients received a Pap test only
9498374|NCT03466710|Experimental|HPV arm|Patients received an HPV test only
9500335|NCT05321524|Experimental|SD (1.5mg adult-equivalent dose of OCA) + MD High dose (10mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Medium Dose Cohort, 8 (±1) eligible subjects will be assigned to the High Dose Cohort and will receive a 10 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart."
10041074|NCT01859689|Experimental|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
10041075|NCT01859728|Experimental|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
10041076|NCT01859728|Active Comparator|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
10041077|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
9500336|NCT05321511|Active Comparator|a-GnRH|Administration of triptorelin acetate 0.2 mg for final oocyte maturation.
9500337|NCT05321511|Active Comparator|hCG|Administration of coriogonadotropine alfa 250 mcg for final oocyte maturation.
9500338|NCT05321511|Experimental|a-GnRH + hCG|Administration of triptorelin acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation.
9500339|NCT05321498|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
9500340|NCT05321498|Placebo Comparator|1.0 mg/kg Placebo|1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 12 weeks.
9500341|NCT05321485|Experimental|MedicijnWijs|All participants will undergo the same intervention of using MedicijnWijs, and they will serve as their own control.
9500342|NCT05321459||Comatose patients in intensive care unit|Patient admitted in the intensive care unit (ICU) for post cardiac arrest (CA) coma, persistent for at least 3 days after CA.
9500343|NCT05321446|Experimental|GoHand Feedback Group|"Both groups will receive a standardized home practice program, the GRASP (Graded Repetitive Arm Supplementary Program). This is a program that has a standard set of arm and hand movements to be practiced 45 minutes per day over a one month period. The person manipulates objects to practice different hand movements. These are everyday objects and each person will be given a set of these to take home and to keep.~For the Experimental Group, the person will be taught the GRASP program and how to move the wrist and hand optimally to activate the GoHand sensor to hear the sound."
9500344|NCT05321446|Sham Comparator|GoHand Measurement Group|For Group 2, the person will be taught GRASP program and how to wear the sensor so it measures movement but does not emit a sound.
9500345|NCT05321420|Placebo Comparator|Placebo|Placebo oral administration
9500346|NCT05321420|Active Comparator|pirfenidone 801 mg TID|pirfenidone 801 mg TID oral administration
9500347|NCT05321420|Experimental|LYT-100 550 mg TID|LYT-100 (Deupirfenidone) 550 mg TID oral administration
9500348|NCT05321420|Experimental|LYT-100 825 mg TID|LYT-100 (Deupirfenidone) 825 mg TID oral administration
9500349|NCT05321407||X-linked agammaglobulinemia (XLA)|This study is a non-randomized observational cohort study of participants with XLA who have either received, as standard care, the Pfizer BioNTech BNT162b2 mRNA vaccine or the Moderna mRNA-1273 vaccine. In this protocol, vaccination is entirely voluntary and vaccines are not provided by the study.
9500350|NCT05321381|Active Comparator|RISE Early|RISE peer support program available early, launched study year 1
9500351|NCT05321381|Active Comparator|RISE Late|RISE peer support program available later, launched study year 2
9500352|NCT05321368|Experimental|LINKED-HEARTS Program|"Patients in the LINKED-HEARTS Program will be trained to measure their blood pressure with an Omron 10 series device using the Sphygmo telemonitoring app. The physician, pharmacist and Community Health Worker will have access to transmit data.~Community Health Workers will provide education on managing blood pressure; reinforce positive blood pressure self-management behaviors; deliver knowledge and skills to promote healthy chronic conditions; assist with linking clinical and administrative services; and link participants with community resources.~The study pharmacist will conduct telehealth visits, optimize pharmacologic therapy. The pharmacists will assess and address medication adherence to improve hypertension and diabetes control."
9500353|NCT05321368|No Intervention|Enhanced Usual Care|Patients in the Enhanced Usual Care Arm, will receive care as usual from their primary care provider and will be trained to measure their blood pressure with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
9500354|NCT05321342|Experimental|Intervention group|This group will receive Professional Development and Coaching (CCU)
9500355|NCT05321342|No Intervention|Control group|Business as usual
9500356|NCT05321329|Experimental|Single Arm|Capecitabine will be taken orally at dose of 1250 mg/m2 PO BID on days 1→14 every 3 weeks Cycles are to be repeated every 21 days for a total of 8 cycles
9500357|NCT05321316|Experimental|68Ga-N188|Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-N188 PET/CT scan.
9500361|NCT05321277|Active Comparator|Walnut diet|Participants will consume 56 g of walnuts each day at home for 3 weeks.
9500362|NCT05321277|Active Comparator|No-nut diet|Participants will follow a no-nut diet for 3 weeks.
9500363|NCT05321264|Experimental|Intervention|The intervention is defined as educational support (improving the knowledge of the disease, identification of risks and consequences), behavioral support (promoting skills related to personal, home, and environmental self-care) and attitudinal support (reflecting on benefits and risks).
9500364|NCT05321264|No Intervention|Control|Control group will receive the usual strategy of a health service provider institution.
9548113|NCT03044210|Other|Cockayne patients|"Interventions performed:~blood sample~urinary collection~metabolic evaluation~clinical evaluation"
9490452|NCT00401388|Experimental|Group B: alveolar soft part sarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of alveolar soft part sarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
9548114|NCT03044210|Other|Control subjects|"Interventions performed:~urinary collection~metabolic evaluation~clinical evaluation"
9490453|NCT00401388|Experimental|Group C: extra-skeletal myxoid|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of extra-skeletal myxoid chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
9490454|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib|All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
9490455|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib + Dexa|If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
9490456|NCT00401011|Experimental|Phase I: Dose 1: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
9490457|NCT00401011|Experimental|Phase I: Dose 2: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
9490458|NCT00401011|Experimental|Phase I: Dose 3: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
9490459|NCT00401011|Experimental|Phase I: Dose 4: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
9490460|NCT00399906|Active Comparator|A1|10 mg
9490461|NCT00399906|Active Comparator|A2|30 mg
9490462|NCT00399906|Active Comparator|A3|100 mg
9490463|NCT00399906|Placebo Comparator|P1|10 or 100 mg
9490464|NCT00399789|Active Comparator|Perifosine 150 mg qd|A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg to be given in one dose at bedtime.
9490465|NCT00399789|Active Comparator|Perifosine 900 mg per week|A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 1,200 mg divided into four doses of 300 mg.
9490466|NCT00399789|Active Comparator|Perifosine 50 mg tid|A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg.
9490467|NCT00398879|Experimental|Arm 1: Perifosine + Capecitabine|Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
9490468|NCT00398879|Placebo Comparator|Arm 2: Perifosine Placebo + Capecitabine|Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
9490469|NCT00398710|Experimental|Perifosine|Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.
9490470|NCT00397696|Experimental|[123I] 5-IA|To assess [123I] 5IA and SPECT imaging
9490471|NCT00397345|Experimental|Trovax|
9490472|NCT00397345|Placebo Comparator|Placebo|
9490473|NCT00397254|Active Comparator|Clinical Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a clinical limit of study medication received Rizatriptan 10mg ODT: 27 tablets per month."
9490474|NCT00397254|Active Comparator|Formulary Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a formulary limit of study medication received Rizatriptan 10mg ODT: 9 tablets per month."
9490475|NCT00397228|Experimental|ALTROPANE®|ALTROPANE® dosing
9490476|NCT00396448|Experimental|CP-945,598 Treatment B|
9490477|NCT00396448|Experimental|CP-945,598 Treatment A|
9490478|NCT00396448|Placebo Comparator|Placebo|
9490479|NCT00396357|Experimental|vildagliptin + metformin|
9490480|NCT00396357|Active Comparator|Metformin|
9490481|NCT00395317|Placebo Comparator|Arm 1|placebo (4 tablets)
9490482|NCT00395317|Experimental|Arm 2|SB-683699 150 mg bid (1 x 150mg + 3 placebo tablets)
9490483|NCT00395317|Experimental|Arm 3|SB-683699 600 mg bid (2 x 300mg + 2 placebo tablets)
9490484|NCT00395317|Experimental|Arm 4|SB-683699 900 mg bid (3 x 300 mg + 1 placebo tablet)
9490485|NCT00395317|Experimental|Arm 5|SB-683699 1200 mg bid, male subjects only (4 x 300 mg tablets)
9490486|NCT00394563|Experimental|1|monoclonal antibody
9490487|NCT00394563|Experimental|2|
9490488|NCT00394563|Experimental|3|
9490489|NCT00394563|Experimental|4|
9490490|NCT00394563|Experimental|5|
9490491|NCT00394563|Placebo Comparator|placebo|
9490492|NCT00394199|Experimental|1|FlutiForm 100/10ug
9490493|NCT00394199|Experimental|2|Fluticasone 100
9490494|NCT00394199|Active Comparator|3|Formoterol 10
9490495|NCT00393991|Experimental|1|FlutiForm 100/10 μg
9490496|NCT00393991|Active Comparator|2|Fluticasone 100 μg
9490497|NCT00393991|Active Comparator|3|Formoterol 10 μg
9490498|NCT00393991|Placebo Comparator|4|Placebo
9490499|NCT00393952|Experimental|1|FlutiForm 250/10
9490500|NCT00393952|Active Comparator|2|FlutiForm 100/10
9490501|NCT00393952|Active Comparator|3|Fluticasone 250
9490502|NCT00393952|Active Comparator|4|Formoterol 10
9490503|NCT00393952|Placebo Comparator|5|Placebo
9490504|NCT00393120|Experimental|Treatment A - INCB009471 100mg IR|INCB009471, 100 mg IR orally once daily
9490505|NCT00393120|Experimental|Treatment B - INCB009471 300mg SR|INCB009471, 300 mg SR orally once daily
9490506|NCT00393120|Placebo Comparator|Treatment C - Placebo|Placebo matching INCB009471
10041078|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
9548115|NCT03044236|Experimental|Novel Stretching Technique|Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
9548116|NCT03044236|Active Comparator|Traditional Stretching Technique|Participants will perform the modified sleeper stretch in a side-lying position on the side of the throwing shoulder with the throwing shoulder and elbow flexed to 90° . The participants will be instructed to allow the throwing shoulder to naturally fall into internal rotation to the end ROM where resistance will be felt . The participants will be then instructed to use the non-throwing hand to push the throwing shoulder into further internal rotation to the point of mild discomfort by applying pressure at the area of the wrist joint.
9548117|NCT03044470|Experimental|Cold saline|Saline stored at 4 degrees centigrade
9548118|NCT03044470|Experimental|Normal Saline|Saline stored at room temperature
10041079|NCT01859767|Experimental|[123I]MNI-672 SPECT|[123I]MNI-672 single photon emission tomography (SPECT)imaging
10041080|NCT01859780|Experimental|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
10041081|NCT01859806|Active Comparator|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
10041082|NCT01859806|Active Comparator|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
10041083|NCT01859819|Experimental|Group B|"De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH <2 X ULN.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine"
10041084|NCT01859819|Experimental|Group C, CNS negative|"De-novo Mature CD 20 + B-ALL (> 25% Bone marrow blasts) without CNS involvement.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine"
10041085|NCT01859819|Experimental|Group C, CNS Positive|"De-novo Mature CD 20 + B-NHL with CNS involvement:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,"
9548119|NCT03044275|Experimental|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.~New adhesive strip Standard adhesive strip"
9548120|NCT03044132|Experimental|DermACELL AWM|Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.
10041086|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
10041087|NCT01859845|No Intervention|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
9548121|NCT03044041|Experimental|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
9548122|NCT03044041|Active Comparator|High dose|Single dose of intra-articular Tranexamic acid 3 grams
9548123|NCT03044093|Active Comparator|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
9548124|NCT03044093|Experimental|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.~Mifepristone"
9548125|NCT03044327|Other|LPS challenge|LPS inhalation and bronchial instillation
9548126|NCT03044457|Experimental|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
9548127|NCT03044457|Active Comparator|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
10041088|NCT01859845|Experimental|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
10041089|NCT01859858|Experimental|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
9548128|NCT03044262|Experimental|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
9548129|NCT03044288|Experimental|Cohort 9|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin.~Standard adhesive strip and a strip with a newly developed adhesive (new adhesive strip)"
9548130|NCT03044080|Active Comparator|IncobotulinumtoxinA|Injection of 200-300 units of IncobotulinumtoxinA (Xeomin ®)
9548131|NCT03044080|Active Comparator|OnabotulinumtoxinA|Injection of 200-300 units of onabotulinumtoxiA (Botox®)
9548132|NCT03044015|Experimental|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
9548133|NCT03044015|Active Comparator|Control|Intervention as usual
9548134|NCT03044002||4French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
9548135|NCT03044002||6French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
9548136|NCT03043846||Tight control and Treat to Target arm|For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
9548137|NCT03043846||Usual care arm|For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
9548138|NCT03043833|Experimental|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
9548139|NCT03043833|No Intervention|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
9548140|NCT03043859|Experimental|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
9548141|NCT03043859|No Intervention|Wait Listed Control|Participants in the control arm will not receive any intervention.
9548142|NCT03043677||Non-inflamed|
9548143|NCT03043677||Inflamed ulcerative colitis|
9548144|NCT03043677||inflamed Crohn´s disease|
9548145|NCT03043742|Experimental|Phase I Open Label|"open label bone marrow derived autologous CD133+ selected stem cell application in patients receiving trans-myocardial laser revascularization to improve regional myocardial function as detailed below:~Drug: CD133+ selected stem cells Dosage: Single injection of 0.1-0.2 ml around each laser channel Frequency: 10-20 channels Duration: Trans-Myocardial Revascularization"
9548146|NCT03043898||Part A(i) Healthy Volunteers|50 healthy volunteers. Intervention: Lung sound recording for part A(i) of the study.
9548147|NCT03043898||Part A(ii) Patients|100 patients with wheezing and/or crackles due to respiratory disease. Intervention: Lung sound recording for part A(ii) of the study.
9548148|NCT03043898||Part B(i) 'normal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having a 'normal' lung structure.~Intervention: Lung sound transmission measurement for part B(i) of the study."
9548149|NCT03043898||Part B(ii) 'abnormal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having an 'abnormal' lung structure.~Intervention: Lung sound transmission measurement for part B(ii) of the study."
9548150|NCT03043820|Active Comparator|Raloxifene|Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.
9548151|NCT03043820|Placebo Comparator|Placebo|Placebo 2 tablets daily for 12 weeks.
9548152|NCT03043989|Active Comparator|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
9548153|NCT03043989|Active Comparator|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
9548154|NCT03043976|Active Comparator|feedback and goal-setting group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
10041090|NCT01859858|Experimental|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
9548155|NCT03043976|Active Comparator|Control group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'WT and will undertake a blood sample (BNP). After a run-in period (1 week) with an Actigraph GT9X Link device disabled from showing the number of steps, patients will wear an Actigraph GT9X Link device which still only displays time and battery level and will upload data via the Study Admin Mobile application for smartphones/tablets without receiving any feedback. After 8 weeks, patients will be assessed (SF36, 6'WT, BNP) and will start to wear a new device enabled to display the daily step count. Patients will be asked to aim for an average specified number of steps/day, receiving a weekly summary of the previous week with targets to achieve week by week. After 8 weeks, patients will be assessed (6'WT, SF36, BNP) and will carry on wearing the device and receiving feedbacks and targets for a further 8 week period, after that patients will be finally assessed (SF36, 6'WT, BNP)
9548156|NCT03043976|Placebo Comparator|newly diagnosed patients|"In the week leading up to their inpatient admission for diagnostic investigations, patients who are treatment-naïve will be given the Actigraph GT9X Link device which will only display the time and the charge level of the battery. Patients will be asked, as well, to fill a questionnaire about their quality of life, to perform a 6MWT and a blood sample (BNP). As soon as patients start the drug therapy, patients will wear a second Actigraph GT9X Link device still disabled from showing real time data about the number of daily steps. Participants will not receive any feedback during the whole period and will be asked, as well, to upload the data collected through the remote mobile system. At their first clinical assessment (after about 4 or 5 weeks), 6'WT, BNP and questionnaire about quality of life will be reassessed.~If patients are not being started on drug therapy then they will be withdrawn from the study"
9548157|NCT03043781|Experimental|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
9548158|NCT03043781|Active Comparator|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
9548159|NCT03043937||cardiac patients WHO class 1,2|
9548160|NCT03043937||cardiac patients WHO class 3,4|
9548161|NCT03043664|Experimental|Arm 1|Keytruda (pembrolizumab) 200 mg intravenous (IV) every 3 weeks and Somatuline Depot (lanreotide depot) 90mg subcutaneous (SQ) every 3 weeks
9548162|NCT03043690||Ammonium succinate|Patients in main pooled study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
9548163|NCT03043690||Placebo|Patients in placebo study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
9548166|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr [H&Y] scores 1-2) aged 35 to 80 years
9548167|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
9548168|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
9548169|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
10058515|NCT02018848|Placebo Comparator|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.~Thus, the placebo training sessions are identical to the bias assessment sessions."
9548170|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
9548171|NCT03043703|Experimental|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
9548172|NCT03043638|Experimental|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
9548173|NCT03043638|Active Comparator|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
9548174|NCT03043625|Experimental|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
9548175|NCT03043625|Placebo Comparator|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
9548176|NCT03043963|Active Comparator|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
9548177|NCT03043963|Experimental|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
9548178|NCT03044054|Experimental|ECHOPULSE|ECHOPULSE HIFU
9548179|NCT03043612|Experimental|Ureteral Study Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent that is coextruded with an alpha-blocker medication
9548180|NCT03043612|Active Comparator|Ureteral Control Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent
9548181|NCT03044145|Experimental|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
9548182|NCT03044145|Experimental|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
9548183|NCT03044145|Active Comparator|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
10041091|NCT01859871|No Intervention|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
10041092|NCT01859871|Experimental|Website Intervention|Navigate website plus standard of care
9548184|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
9548185|NCT03043521|Experimental|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
10041093|NCT01859884|Experimental|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
9548186|NCT03043521|Experimental|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
9548187|NCT03043521|Experimental|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
9548188|NCT03043521|Active Comparator|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
9617004|NCT02537496|No Intervention|Healthy Control|Healthy control group will only participate in baseline assessments which include baseline neuropsychological testing and baseline measurement of neuroplasticity. This will be used to standardize neuropsychological test scores and to compare the baseline neuroplasticity between healthy participants and Alzheimer's disease (AD) participants. Healthy control group will not get rTMS intervention.
9617005|NCT02537704|Experimental|Group Lifestyle Balance Program|"Participants will be assigned to an adaptation of the Group Lifestyle Balance Program, a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.~Additionally, participants will attend at least one monthly visit with a nutritionist (individually).~The lifestyle objectives for participants will be as follows:~To lose 5-10% of initial weight through healthy eating.~To do 150 minutes of physical activity each week."
9617006|NCT02537691|Other|Inhaled Corticosteroids (ICS) + Controller Medications|Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of >/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.
9617007|NCT02537899|Other|Treatment|NeuroAiD
9617008|NCT02537457|Experimental|BAY59-7939 Rivaroxaban granule|
9617009|NCT02537457|Active Comparator|BAY59-7939 Rivaroxaban tablet|
9617010|NCT02537548|Experimental|Treatment (RPLND)|Patients undergo RPLND.
9617011|NCT02537353|Placebo Comparator|Group 1|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application of metal clips. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
9617012|NCT02537353|Active Comparator|Group 2|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application adsorption powder, marketed under the name Hemospray. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
9617013|NCT02537470|Other|Arm 1|Placebo
9617014|NCT02537470|Experimental|Arm 2|Biphasic remogliflozin etabonate
9617015|NCT02537561|Experimental|Arm 1: Cisplatin, Gemcitabine, Talazoparib Solid Tumors|"Dose levels of the drugs will be dependent on which dose level the participants is enrolled.~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
9617016|NCT02537561|Experimental|Arm 2: Cisplatin, Gemcitabine, Talazoparib NSCLC|"Dose levels of the drugs will depend on what the MTD is in the dose escalation portion of the study~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
9617017|NCT02537626|Active Comparator|Erchonia ALS Laser|The Erchonia ALS Laser is a mains powered variable hertz laser device made up of five independent red laser diodes mounted in scanner devices and positioned equidistant from each other. Each scanner emits 7.5 milliwatts (mW) ± 1.0 mW 640 nanometers (nm) with a tolerance of ±10 nm of red laser light.
9617018|NCT02537626|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia ALS Laser but does not emit any therapeutic light.
10041094|NCT01859884|No Intervention|Control Standard of Care|This group receives standard of care with a post test.
10041095|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
9548189|NCT03043547|Experimental|Nal-IRI + 5-FU + leucovorin (Arm A)|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion), 5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
9548190|NCT03043547|Other|5-FU + leucovorin (Arm B)|Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
9548191|NCT03043352|Experimental|Group A (intervention)|'Management of SAM at home' LHWs will identify and treat all cases of severe acute malnutrition (SAM) as per the study eligibility criteria (MUAC < 11.5 cm) and manage all cases of SAM without complications at home with 'Standard CMAM program'. The LHWs will also identify SAM with complications for further assessment to the BHU Doctor and subsequent referral to the stabilization center . They will also provide one to one health and Infant and Young Child Feeding (IYCF) counselling to care takers of children in their catchment area.
9548192|NCT03043352|Active Comparator|Group B (Control)|'Management of SAM at facility' LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
9548193|NCT03043261|Experimental|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
9548194|NCT03043404|Experimental|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
9548195|NCT03043430|Experimental|Ketamine|Ketamine 100 mg/mL concentration administered in a single 1.0 mg/kg dose with a maximum of 50mg intranasal via mucosal atomization device.
9548196|NCT03043430|Active Comparator|Midazolam|Midazolam 5 mg/mL concentration administered in a single administered in a single 0.3 mg/kg dose with a maximum of 5mg intranasal via mucosal atomization device.
9548197|NCT03043391|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
9548198|NCT03043417|Experimental|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
9548199|NCT03043417|No Intervention|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
9548200|NCT03043248|Experimental|Cohort A|TRK-700 + Digoxin
9548201|NCT03043248|Experimental|Cohort B|TRK-700 + Midazolam
9548202|NCT03043508||Participants With Confirmed MEN1 With PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
9548203|NCT03043508||Participants With Confirmed MEN1 Without PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
9548204|NCT03043300||US Travelers to South or Southeast Asia|"Adult individuals who are planning a short term trip to South or Southeast Asia and meet all eligibility criteria will complete the questionnaires and/or provide stool specimens at the following time points:~No greater than 4 weeks prior to travel departure: Screening Criteria Review~One week prior to travel departure: Pre-Travel Questionnaire and Pre-Travel Stool Specimen Collection~Two weeks after return from travel: Short-Term Post-Travel Questionnaire and Short-Term Post-Travel Stool Specimen Collection~14 weeks after return from travel: Long-Term Post-Travel Questionnaire and Long-Term Post-Travel Stool Specimen Collection"
9548205|NCT03043482|Experimental|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
9548206|NCT03043482|Experimental|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
9548207|NCT03043482|Experimental|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
9548208|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
9548209|NCT03043443|Placebo Comparator|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
9548210|NCT03043443|Active Comparator|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
9548211|NCT03043456|Active Comparator|Thermoplastic Resin group|Thermoplastic complete denture placement is done (Thermoplastic Comfort Systems, inc.)
9548212|NCT03043456|Placebo Comparator|conventional acrylic resin group|Conventional acrylic resin complete denture placement is done. (Acrostone, inc.)
9548213|NCT03043469||Healthy participants|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
9548214|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
9617019|NCT02537600|Experimental|Cobimetinib + Vemurafenib combination|"Every patients will be treated with :~Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm."
9548215|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
9548216|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
9548217|NCT03043235||African American Females|No intervention
9548218|NCT03043235||African American Males|No intervention
9548219|NCT03043235||Caucasian Females|No intervention
9548220|NCT03043235||Caucasian Males|No intervention
9548221|NCT03043495|Active Comparator|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
9548222|NCT03043495|Active Comparator|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
9548223|NCT03043495|Active Comparator|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
9548224|NCT03043495|Active Comparator|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
9548225|NCT03043222|Experimental|PAE-Prostate Arterial Embolization|PAE-Prostate Arterial Embolization
9548226|NCT03043222|Active Comparator|PUL- Prostatic urethral lift|PUL- Prostatic urethral lift
9548227|NCT03043157|Other|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
9548228|NCT03043196|Active Comparator|Rosuvastatin Group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
9548229|NCT03043196|Placebo Comparator|Placebo Group|Oral prophylaxis followed by placebo gel placement in intrabony defects
9548230|NCT03043144||End stage renal disease|Observational study, no intervention
9548231|NCT03043131|Active Comparator|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
9548232|NCT03043131|Experimental|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
9548233|NCT03043183|Experimental|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，<9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
9548234|NCT03043183|No Intervention|Conventional group|PG-SGA ≥2，<9
9548235|NCT03042936|Experimental|Arm 1|Insulin Superheroes Club Curriculum
9548236|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
9548237|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
9548238|NCT03043053|Experimental|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
9548239|NCT03043053|Placebo Comparator|placebo|placebo nasal spray (4 times per day for 8 weeks)
9548240|NCT03042949|Experimental|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
9548241|NCT03042897|Experimental|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
9548242|NCT03042832|Experimental|LOCI|Leadership development with coaching and organizational change support
9548243|NCT03042832|Active Comparator|Internet Based Training|Internet based Webinar leadership training
9548244|NCT03043001|Other|add-on memantine therapy|add-on memantine treatment
9548245|NCT03043027|Experimental|Liposomal bupivicaine|
9548246|NCT03043027|Active Comparator|bupivicaine|
9548247|NCT03043027|Placebo Comparator|saline|
9548248|NCT03042806|Other|experimental group|COPD patients will be asked to fill in the Maugeri Physical Activity Questionnaire (MaPAct) to assess self perceived physical activity.
9548249|NCT03043040|Experimental|Telephone follow up|"Patients discharged from hospital A and B after a suicide attempt receive a protocolized telephone follow which is added to their usual treatment (TAU). Calls are made by nurses at weeks 1,2,4,12 and 24 after the index suicide attempt.~TAU: Includes whatever treatment the doctor decides to offer to that patient (psychopharmacology, psychotherapy etc)."
9548250|NCT03043040|Active Comparator|Control|Patients discharged from hospital C after a suicide attempt receive treatment as usual (whatever treatment the doctor decides to offer to that patient: psychopharmacology, psychotherapy etc).
9548251|NCT03043066|Placebo Comparator|Group A -control group|15 subjects underwent scaling and root planing
9548252|NCT03043066|Active Comparator|Group B-Interventional group|15 subjects underwent scaling and root planing along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
9548253|NCT03043118|Experimental|Variety|Children receive three servings of vegetables each prepared with a different herb and spice blend.
9548254|NCT03043118|No Intervention|No Variety - Control|Children receive three servings of vegetables each prepared with the same herb and spice blend.
9548255|NCT03042741|Experimental|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
9548256|NCT03042741|Placebo Comparator|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
9548257|NCT03042884|Experimental|Wearable Exercise Trackers - Inpatient Group|"Questionnaires completed at baseline and within 24 hours of discharge.~Participant given a wearable exercise tracker to be worn 24 hours a day while in the acute inpatient rehabilitation unit."
9548258|NCT03042884|Experimental|Wearable Exercise Trackers - Outpatient Group|"Questionnaires completed at baseline and again in 14 days.~Participant given a wearable exercise tracker to be worn 24 hours a day for 14 days."
9548259|NCT03042845|Active Comparator|Judkins L3.5/R4 cardiac catheters|
9548260|NCT03042845|Experimental|Tiger cardiac catheter|
9548261|NCT03042793|Experimental|Vaccination|Vaccine: PD-L1 peptide.
9548262|NCT03043014|Experimental|Mifépristone group|
9548263|NCT03043014|Active Comparator|misoprostol group|
9548264|NCT03042871|Active Comparator|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
9548265|NCT03042871|Active Comparator|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
9548266|NCT03042650|Experimental|Intensive Referral Intervention Group|Intensive Referral Intervention will by done by trained probation officers
9548267|NCT03042650|Active Comparator|Standard Practice Facilitated Group|Standard Current Practice will be provided by untrained probation officers
9548268|NCT03042728|Active Comparator|Dog interaction|Dog interaction will be received by patients in addition to usual care of fibromyalgia.
9548269|NCT03042728|Active Comparator|Human Interaction|Human interaction will be received by patients in addition to usual care of fibromyalgia.
9548270|NCT03042520||IFN-based therapy historical controls|Patients who had ever participated the parent studies, GS-US-334-0115 or GS-US-337-0131, will be invited to participate the current study in outpatient clinic. For the patients who have participated study will be invited to participate the current study as matched historical control n our outpatient clinic,
9548271|NCT03042520||Sofosbuvir-based therapy observational group|"Patients ≥ 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643)~Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies.~Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response:~Patients ≥ 20 of years who had received peginterferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response~Patients who have ever participated study will be collected as historical control."
9548272|NCT03042442||Patients with pancreatic cancer|Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
9548273|NCT03042442||health patients (controls)|Health patients
9548274|NCT03042546|Active Comparator|Calcium Sulphate|
9548275|NCT03042546|Active Comparator|PMMA|
9548276|NCT03042546|Active Comparator|Nothing|
9548277|NCT03042533|Active Comparator|Conventional Compression|Nail will be seated using conventional compression technique
9548278|NCT03042533|Active Comparator|Standard Backslapping|Nail will be seated using standard backslapping technique
9548279|NCT03042533|Active Comparator|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
9548280|NCT03042572|Experimental|Allogeneic Mesenchymal Stromal Cell|Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection
9548281|NCT03042572|Placebo Comparator|Placebo|Intramuscular placebo injection
9548282|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
9548283|NCT03042429|Experimental|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
9548284|NCT03042429|Active Comparator|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
9548285|NCT03042676||ATLG group|ATLG treatment for GVHD prophylaxis.
9548286|NCT03042676||no ATLG group|No ATLG treatment.
9548287|NCT03042689|Experimental|Regorafenib|
9548288|NCT03042494|Placebo Comparator|Control|Isocaloric food without the test prebiotic.
9548289|NCT03042494|Experimental|Prebiotic|Prebiotic consumed as one daily serving of 7 g in Group 1 and consumed as one daily serving of 2.5-3 g in Group 2.
9548290|NCT03042377|Active Comparator|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
9548291|NCT03042377|Active Comparator|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
9548292|NCT03042377|Active Comparator|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
9548293|NCT03042377|Active Comparator|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
9548294|NCT03042364|No Intervention|No intervention|Standard treatment
9548295|NCT03042364|Experimental|Intervention|Endometrial scratching before standard treatment
9548296|NCT03042598|Experimental|Biphasic Cuirass Ventilation|Patients requiring emergent intubation in the Emergency Department will be provided ventilation during the apnic phase of intubation via the use of BCV.
9548297|NCT03042624|Experimental|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
9548298|NCT03042624|Placebo Comparator|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
9548299|NCT03042338|Experimental|Central Executive Training1|Training tasks targeting working memory
9548300|NCT03042338|Active Comparator|Central Executive Training2|Training tasks targeting inhibitory control and response speed
9548301|NCT03042585|Experimental|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
9548302|NCT03042585|Experimental|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
9548303|NCT03042585|Experimental|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
9548304|NCT03042585|Experimental|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
9548305|NCT03042611|Experimental|Apatinib|
9548306|NCT03042611|Experimental|Placebo|
9548307|NCT03042663|Experimental|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
9548308|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
9548309|NCT03042325|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance [CrCl].
9548310|NCT03042507|Other|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
9548311|NCT03042247||Hodgkin lymphoma patients|Hodgkin lymphoma patients with confirmed histological diagnosis
9548312|NCT03042247||DLBC non Hodgkin lymphoma patients|DLBC non Hodgkin lymphoma patients with confirmed histological diagnosis
9548313|NCT03042260|Experimental|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Trimethoprim-Sulfamethoxazole 180mg/800mg oral tablet, 3 times a week, for 6 months. Subjects may remain on the drug longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months.
9548314|NCT03042260|Placebo Comparator|Placebo|"Tablets that look exactly the same as the experimental drug, 3 times a week, for 6 months.~Subjects may remain on the placebo longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months."
9548315|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
9548316|NCT03042208|Experimental|Intervention|Access to Weight Watchers in-person meetings and online tools.
9548317|NCT03042208|Other|Self-Guided Control Group|Received handout with basic weight management advice.
9548318|NCT03042234|Experimental|Group Insulin-resistant|Insulin-resistant obese adolescents
9548319|NCT03042234|Experimental|Group Insulin-sensitive|Insulin-sensitive obese adolescents
9548320|NCT03042130|Experimental|Iron Carboxymaltose|"standard of care + double dose of IV iron ferinject~the medicine will be given twice within one week."
9548321|NCT03042130|Other|control|standard of care
9548322|NCT03042195|Active Comparator|Intervention group|Supplementary parenteral nutrition
9548323|NCT03042195|No Intervention|Control group|The control group will receive standard nutritional care
9548324|NCT03042351|Other|Unique arm|Magic Kegel app
9548325|NCT03042455|Experimental|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
9548326|NCT03042455|Experimental|Robot|Robot-Assisted upper arm training group(intervention group2)
9548327|NCT03042455|Active Comparator|Conventional|Conventional training group(control group)
9617020|NCT02537275|Experimental|wearing contact lense group|normal subjects after wearing tinted/normal contact lenses
10041096|NCT01859910|Experimental|compression|compression and scrub of lid margin for 5 circles before cataract surgery
10041097|NCT01859910|Active Comparator|control|no compression or scrub of lid margin
9490507|NCT00393068|Experimental|Treatment|"Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).~Surgery will be performed approximately 12-14 weeks after beginning this combined treatment."
10041098|NCT01859936|Experimental|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
9490508|NCT00392574|Experimental|1|Prulifloxacin
9490509|NCT00392574|Placebo Comparator|2|Placebo
9490510|NCT00391560|Experimental|Group 1 on Perifosine|"Patients with AML, MDS, CML-BP non-lymphoid, CMML, or Agnogenic Myeloid Metaplasia (AMM).~After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
9490511|NCT00391560|Experimental|Group 2 on Perifosine|"Patients with CLL, ALL, or CML-BP lymphoid. After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
9490512|NCT00391209|Experimental|1|
9490513|NCT00391209|Experimental|2|
10041099|NCT01859936|No Intervention|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
9490514|NCT00391196|Placebo Comparator|Placebo|
9490515|NCT00391196|Experimental|CP-945,598|
9490516|NCT00391196|Experimental|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
9490517|NCT00391066|Active Comparator|1|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
9490518|NCT00391066|Experimental|2|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
9490519|NCT00390845|Experimental|SB681323|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
9490520|NCT00390845|Experimental|Placebo|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
9490521|NCT00390533|Experimental|Saredutant 30 mg|Saredutant 30 mg once daily for a maximum of 8 weeks
9490522|NCT00390533|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily for a maximum of 8 weeks
10058516|NCT02018848|Experimental|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
10058517|NCT02018861|Experimental|Parsaclisib|escalating doses given every day (QD)
10058518|NCT02018861|Experimental|Parsaclisib in combination with itacitinib (INCB039110)|Starting dose of parsaclisib determined in Part 1 of the study in combination with itacitinib (INCB039110)given QD
10058519|NCT02018861|Experimental|Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide|Starting dose of parsaclisib determined in Part 1 given in combination with: rituximab on Days 1 and 2 of Cycle 1, and Day 1 of Cycles 2 and 3; ifosfamide and carboplatin given on Day 3 of each Cycle; and etoposide given on Days 3 to 5 of each Cycle.
10058520|NCT02018874|Experimental|LY2780301|
10058521|NCT02018900|Placebo Comparator|Placebo|Placebo
10058522|NCT02018900|Experimental|Ecologic 825/scFOS|Ecologic 825/scFOS
10058523|NCT02018939|Experimental|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
10058524|NCT02018939|Experimental|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
9490523|NCT00390533|Placebo Comparator|Placebo|Placebo for saredutant once daily for one week during the screening phase and for a maximum of 8 weeks during the acute phase
10041100|NCT01860014|Active Comparator|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
9490524|NCT00390143|Experimental|Group A|Subjects previously primed with meningococcal vaccine 134612.
9490525|NCT00390143|Active Comparator|Group B|Subjects previously primed with Mencevax™ ACWY.
9490526|NCT00389779|Experimental|Darusentan|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks
9490527|NCT00389779|Active Comparator|Guanfacine|Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks
9490528|NCT00389779|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
9490529|NCT00389675|Experimental|Darusentan|Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
9490530|NCT00389675|Active Comparator|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
9490531|NCT00389155|Experimental|vinflunine and gemcitabine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
9490532|NCT00389155|Placebo Comparator|placebo and gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
9490533|NCT00389077|Experimental|Perifosine Daily Dose|Daily dose perifosine 50 mg.
9490534|NCT00389077|Experimental|Perifosine Twice Daily Dose|Twice daily dose perifosine 50 mg.
9490535|NCT00388960|Experimental|Amrubicin|Amrubicin 45mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
9490536|NCT00388960|Experimental|Amrubicin plus Cisplatin|Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> IV day 1 of each 21-day cycle until disease progression.
9490537|NCT00388960|Active Comparator|Cisplatin plus etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 each 21-day cycle until disease progression.
9490538|NCT00388609|Experimental|T|5 mg (ST) to 50 mg (LT)
9490539|NCT00388609|Experimental|U|10 mg (ST) to 50 mg (LT)
9490540|NCT00388609|Experimental|V|25 mg (ST) to 50 mg (LT)
9490541|NCT00388609|Experimental|W|50 mg (ST and LT)
9490542|NCT00388609|Experimental|X|25 mg/d (X1 wk), 5 mg/d (X11 wks) (ST) to 50 mg (LT)
9490543|NCT00388609|Experimental|Z|"Open label: 50 mg/d (X 4 wks) 100 mg/wk (X8 wks) (ST) to 50 mg (LT)~Once daily (x 4 weeks), once daily (x 8 weeks)"
9490544|NCT00388609|Placebo Comparator|Y|0 mg (ST and LT)
9490545|NCT00388518|Active Comparator|Actos|
9490546|NCT00388518|Experimental|Aleglitazar 1|
9490547|NCT00388518|Experimental|Aleglitazar 2|
9490548|NCT00388518|Experimental|Aleglitazar 3|
9490549|NCT00388518|Experimental|Aleglitazar 4|
9490550|NCT00388518|Placebo Comparator|Placebo|
9490551|NCT00387907|Experimental|Larotaxel + Trastuzumab|
9490552|NCT00387686|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
9490553|NCT00387686|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
9490554|NCT00387686|Active Comparator|C|Buffer/CPM + surgical fixation Intervention
9490555|NCT00387686|Other|D|Standard of Care: Surgical fixation intervention
9490556|NCT00385697|Experimental|1|
9490557|NCT00385697|Experimental|2|
9490558|NCT00385697|Experimental|3|
9490559|NCT00385697|Placebo Comparator|4|
9490560|NCT00385515|Experimental|1|SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days
9490561|NCT00385515|Placebo Comparator|2|placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days
9490562|NCT00384904|No Intervention|A1|
9490563|NCT00384904|Experimental|A2|
9490564|NCT00384904|Experimental|A3|
9490565|NCT00384904|No Intervention|B1|
9490566|NCT00384904|Experimental|B2|
9490567|NCT00384904|Experimental|B3|
9490568|NCT00384852|Experimental|A|1.0 mg/mL rhBMP-2/CPM + SOC
9490569|NCT00384852|Experimental|B|2.0 mg/mL rhBMP-2/CPM + SOC
9490570|NCT00384852|Active Comparator|C|Buffer/CPM + SOC
9490571|NCT00384852|Other|D|Standard of Care Alone (SOC)
9490572|NCT00384358|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
9490573|NCT00384358|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
9490574|NCT00384358|Other|C|Control: Surgical fixation
9490575|NCT00383578|Experimental|Vildagliptin|
9490576|NCT00383578|Active Comparator|Metformin|
9498375|NCT03466684|Experimental|BIA-directed fluid resuscitation|After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL > 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.
9498376|NCT03466684|Active Comparator|Traditional fluid resuscitation|A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.
9498377|NCT03466671|Other|Low dose once per day and placebo|"Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
10041101|NCT01860014|Active Comparator|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
10041102|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
10041103|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
10041104|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
10041105|NCT01860053|Experimental|behavioral intervention|
10041106|NCT01860053|No Intervention|no treatment control|
10041107|NCT01860066|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
10041108|NCT01860066|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
10041109|NCT01860105|Active Comparator|75mg MDCO-157|iv
9490577|NCT00383513|Experimental|Epratuzumab|
9490578|NCT00383422|Experimental|1|
9490579|NCT00383422|Active Comparator|2|
9490580|NCT00382811|Experimental|1|Daily Phenoxodiol + weekly carboplatin
9490581|NCT00382811|Active Comparator|2|Daily phenoxodiol placebo + weekly carboplatin
9490582|NCT00382096|Experimental|Vildagliptin + Metformin Dose 1|
9490583|NCT00382096|Experimental|Vildagliptin + Metformin Dose 2|
9490584|NCT00382096|Active Comparator|Vildagliptin|
9490585|NCT00382096|Active Comparator|Metformin|
9490586|NCT00379990|Experimental|GW274150 60 mg once daily for 28 days|60 mg GW274150 taken once daily for 28 days
9490587|NCT00379990|Active Comparator|Prednisolone 7.5 mg once daily for 28 days|7.5 mg prednisolone taken once daily for 28 days
9490588|NCT00379990|Placebo Comparator|Placebo once daily for 28 days|Placebo taken once daily for 28 days
9490589|NCT00379938|Experimental|1|25 micrograms + MF59 (n=26)
9490590|NCT00379938|Experimental|3|2.5 micrograms + MF59 (n=26)
9490591|NCT00379938|Placebo Comparator|4|saline (n=11)
9490592|NCT00379938|Experimental|2|25 micrograms alone (n=26)
9490593|NCT00377182|Active Comparator|PEGASYS with COPEGUS|
9490594|NCT00377182|Experimental|RO5024048 1500mg in combination with PEGASYS|
9490595|NCT00377182|Experimental|RO5024048 3000mg in combination with PEGASYS|
9490596|NCT00377182|Experimental|RO5024048 in combination with PEGASYS and COPEGUS|
9490597|NCT00375791|Experimental|Perifosine daily|Patients will take three 50 mg tablets of perifosine daily at bedtime with food. Patients will be examined every three weeks. If patients have no progression it is allowed to receive 8 cycles of perifosine
9490598|NCT00375791|Experimental|Perifosine daily + Dexa twice per week|Patients will take three 50 mg tablets of perifosine daily at bedtime with food until progression. If progressive disease is confirmed by a second measurement at least one week later the patient will receive a combination of 20 mg twice per week dexamethasone (dexa) and 150 mg perifosine daily at bedtime.
9490599|NCT00375401|Experimental|CP-945,598 Treatment A|
9490600|NCT00375401|Experimental|CP-945,598 Treatment B|
9490601|NCT00375401|Placebo Compa